PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Dahl, ME; Dabbagh, K; Liggitt, D; Kim, S; Lewis, DB				Dahl, ME; Dabbagh, K; Liggitt, D; Kim, S; Lewis, DB			Viral-induced T helper type 1 responses enhance allergic disease by effects on lung dendritic cells	NATURE IMMUNOLOGY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; EOSINOPHILIC AIRWAY INFLAMMATION; TH2 IMMUNE-RESPONSES; INFLUENZA-VIRUS; INTERFERON-GAMMA; ANTIGEN EXPOSURE; INFECTION; MICE; ASTHMA; SENSITIZATION	It is widely accepted that T helper type 1 (T(H)1) cytokines such as interferon-gamma(IFN-gamma) antagonize allergic diseases mediated by T(H)2 cytokines. The 'hygiene hypothesis' has also proposed that decreased childhood exposure to pathogen-derived T(H)1 cytokines may underlie the recent increased prevalence of asthma, a T(H)2-mediated disease. We show here that influenza A viral infection, which induces large amounts of intrapulmonary IFN-gamma production, unexpectedly enhanced later allergen-specific asthma and promoted dual allergen-specific T(H)1 and T(H)2 responses. Pulmonary dendritic cells obtained from the lung after viral clearance and resolution of acute inflammation conferred enhanced allergic disease and concurrent T(H)1 and T(H)2 immune responses, and these effects were dependent on IFN-gamma secreted during the acute viral infection. Thus, respiratory viral infection and the acute T(H)1 response can positively regulate T(H)2-dependent allergic pulmonary disease in vivo, at least in part, by altering pulmonary dendritic cell function.	Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Program Immunol, Stanford, CA 94305 USA; Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA	Lewis, DB (reprint author), Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA.	dblewis@stanford.edu			NIAID NIH HHS [R01 AI 44699]		Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; CHERWINSKI HM, 1987, J EXP MED, V166, P1229, DOI 10.1084/jem.166.5.1229; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Dabbagh K, 2002, J IMMUNOL, V168, P4524; Dabbagh K, 2000, J IMMUNOL, V165, P3418; Doherty PC, 1997, IMMUNOL REV, V159, P105, DOI 10.1111/j.1600-065X.1997.tb01010.x; Doyle AG, 1999, J EXP MED, V190, P1081, DOI 10.1084/jem.190.8.1081; EICHELBERGER MC, 1991, J GEN VIROL, V72, P1695, DOI 10.1099/0022-1317-72-7-1695; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; FINKELMAN FD, 1990, ANNU REV IMMUNOL, V8, P303, DOI 10.1146/annurev.immunol.8.1.303; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; GRAHAM MB, 1993, J EXP MED, V178, P1725, DOI 10.1084/jem.178.5.1725; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Holgate ST, 1999, NATURE, V402, P2, DOI 10.1038/35037000; HUANG S, 1993, SCIENCE, V259, P1742, DOI 10.1126/science.8456301; Hussell T, 1996, J GEN VIROL, V77, P2447, DOI 10.1099/0022-1317-77-10-2447; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kamath AT, 2002, BLOOD, V100, P1734; KOLOPPSARDA MN, 1994, ANAT REC, V239, P150, DOI 10.1002/ar.1092390205; Krug N, 1996, AM J RESP CELL MOL, V14, P319; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lewis DB, 2002, CURR OPIN IMMUNOL, V14, P644, DOI 10.1016/S0952-7915(02)00388-6; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; Lyons AB, 2001, METHOD CELL BIOL, V63, P375; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790; MARRACK P, 1983, J EXP MED, V158, P1635, DOI 10.1084/jem.158.5.1635; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; MO XY, 1995, J VIROL, V69, P1288; Morel PA, 1998, CRIT REV IMMUNOL, V18, P275; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; SARAWAR SR, 1994, J IMMUNOL, V153, P1246; Schwarze J, 1999, J IMMUNOL, V163, P5729; Schwarze J, 1999, J IMMUNOL, V162, P4207; Schwarze J, 2002, EUR RESPIR J, V19, P341, DOI 10.1183/09031936.02.00254302; Schwarze J, 1999, J IMMUNOL, V162, P2997; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; ten Hacken NHT, 1998, EUR RESPIR J, V11, P312, DOI 10.1183/09031936.98.11020312; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Tsitoura DC, 2000, J IMMUNOL, V165, P3484; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wohlleben G, 2003, J IMMUNOL, V170, P4601; Yamamoto N, 2000, EUR J IMMUNOL, V30, P316, DOI 10.1002/1521-4141(200001)30:1<316::AID-IMMU316>3.0.CO;2-0; Yamamoto N, 2001, J VIROL, V75, P499, DOI 10.1128/JVI.75.1.499-505.2001	49	152	158	0	0	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	MAR	2004	5	3					337	343		10.1038/ni1041		7	Immunology	Immunology	779ZV	WOS:000189344600017	14973436	
J	Tulic, MK; Fiset, PO; Christodoulopoulos, P; Vaillancourt, P; Desrosiers, M; Lavigne, F; Eiden, J; Hamid, Q				Tulic, MK; Fiset, PO; Christodoulopoulos, P; Vaillancourt, P; Desrosiers, M; Lavigne, F; Eiden, J; Hamid, Q			Amb a 1-immunostimulatory oligodeoxynucleotide conjugate immunotherapy decreases the nasal inflammatory response	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						amb a 1-immunostimulatory phosphorothioate; oligonucleotide conjugate; immunotherapy; rhinitis; ragweed	GRASS-POLLEN IMMUNOTHERAPY; MESSENGER-RNA; EOSINOPHILS; LYMPHOCYTES; EXPRESSION; ASTHMA; INCREASES; MUCOSA; DNA	Background: Amb a 1-immunostimulatory phosphorothioate oligonucleotide conjugate (AIC) is a novel immunotherapeutic compound consisting of purified Amb a 1 from short ragweed proteins covalently linked to an immunostimulatory phosphorothioate oligodeoxyribonucleotide. In sensitized animals AIC can stimulate an Amb a 1-specific T(H)1 response and decrease pulmonary reactivity to ragweed challenge. Clinical trials have documented reduced allergic response to AIC in comparison with licensed ragweed extract. Objectives: We sought to determine the in vivo effect,of shortcourse immunotherapy with AIC on eosinophilia and cytokine mRNA expression in the nasal mucosa of ragweed-sensitive patients. Methods: Ragweed-sensitive patients with allergic rhinitis were treated with 6 escalating doses of AIC (0.06-12 mug, n 28) or placebo (n = 29) at weekly intervals immediately before the 2001 ragweed season. Symptom scores and medication use were recorded for the 2001 and 2002 ragweed seasons for all patients. A subset of patients (12 receiving AIC and 7 receiving placebo) consented to have nasal biopsy specimens taken before immunization and before and after the first ragweed season. The preseason and postseason biopsy specimens were taken 24 hours after ragweed allergen challenge and compared with the initial unchallenged biopsy specimen to assess cytokine and inflammatory cell responses by using immunocytochemistry and in situ hybridization. Results: AIC was safe and well tolerated by all patients. There was no difference between the AIC and placebo groups in the number of allergen-induced major basic protein-, IL-4-, IL-5-, or IFN-gamma-positive cells in the mucosa in the first weeksafter AIC immunization. On rechallenge and rebiopsy after the end of the 2001 ragweed season, however, AIC-treated patients had a significantly reduced increase in eosinophils and IL-4 mRNA-positive cells and an increased number of IFN-gamma mRNA-positive cells compared with placebo-treated patients. No difference between treatment groups was observed in symptom scores or medication use during the first ragweed season. During the second ragweed season, however, there was a significant decrease in chest symptoms and a trend toward reduced nasal symptoms in the AIC-treated group. Conclusion: Short-course immunotherapy with AIC can modify the response of nasal mucosa to allergen challenge by increasing T(H)1 cytokine production and decreasing T(H)2 cytokine production and eosinophilia. This modification was not immediate but was observed 4 to 5 months after completion of immunotherapy and seasonal ragweed-pollen exposure. The T-cell subset shift after immunization and seasonal exposure was followed by evidence of clinical efficacy in the second ragweed season without additional AIC immunizations.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Univ Montreal, Ctr Hosp, Montreal, PQ, Canada; Dynavax Technol Corp, Berkeley, CA USA	Hamid, Q (reprint author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.		Tulic, Meri/P-6613-2016				CHRISTODOULOPOU.P, 2002, J ALLERGY CLIN IMMUN, V109, P973; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90645-6; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282; DURHAM SR, 1997, ARB P EHRLICH I BUND, V91, P33; FREW AJ, 1988, J IMMUNOL, V141, P4158; HAMID Q, 1987, P NATL ACAD SCI USA, V84, P6760, DOI 10.1073/pnas.84.19.6760; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170	15	152	170	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					235	241		10.1016/j.jaci.2003.11.001		7	Allergy; Immunology	Allergy; Immunology	773EX	WOS:000188885700008	14767435	
J	Papadopoulos, NG; Stanciu, LA; Papi, A; Holgate, ST; Johnston, SL				Papadopoulos, NG; Stanciu, LA; Papi, A; Holgate, ST; Johnston, SL			A defective type 1 response to rhinovirus in atopic asthma	THORAX			English	Article							RESPIRATORY SYNCYTIAL VIRUS; COMMON COLD VIRUS; VIRAL-INFECTIONS; AIRWAYS INFLAMMATION; GAMMA PRODUCTION; NATURAL-KILLER; MESSENGER-RNA; OLD CHILDREN; T-CELLS; CYTOKINE	Background: Rhinoviruses (RVs) are the most frequent precipitants of the common cold and asthma exacerbations, but little is known about the immune response to these viruses and its potential implications in the pathogenesis of asthma. Methods: Peripheral blood mononuclear cells (PBMC) from patients with atopic asthma and normal subjects were exposed to live or inactivated RV preparations. Levels of interferon (IFN)gamma and interleukins IL-12, IL-10, IL-4, IL-5 and IL-13 were evaluated in the culture supernatants with specific immunoassays. Results: Exposure of PBMC to RVs induced the production of IFNgamma, IL-12, IL-10, and IL-13. Cells from asthmatic subjects produced significantly lower levels of IFNgamma and IL-12 and higher levels of IL-10 than normal subjects. IL-4 was induced only in the asthmatic group, while the IFNgamma/IL-4 ratio was more than three times lower in the asthmatic group. Conclusions: This evidence suggests that the immune response to RVs is not uniquely of a type 1 phenotype, as previously suggested. The type 1 response is defective in atopic asthmatic individuals, with a shift towards a type 2 phenotype in a way similar, but not identical, to their aberrant response to allergens. A defective type 1 immune response to RVs may be implicated in the pathogenesis of virus induced exacerbations of asthma.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, Fac Med, London W2 1PG, England; Univ Southampton, Southampton Gen Hosp, Southampton SO16 6YD, Hants, England	Johnston, SL (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, Fac Med, London W2 1PG, England.		Johnston, Sebastian/I-2423-2012; Papadopoulos, Nikolaos/L-8670-2013	Papadopoulos, Nikolaos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-2508-3872; PAPI, ALBERTO/0000-0002-6924-4500			ALWAN WH, 1994, J EXP MED, V179, P81, DOI 10.1084/jem.179.1.81; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Cousens LP, 1999, J EXP MED, V189, P1315, DOI 10.1084/jem.189.8.1315; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; CRUMP CE, 1994, ANTIMICROB AGENTS CH, V38, P1425; Fischer JE, 1997, J VIROL, V71, P8672; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 1996, J IMMUNOL, V157, P1605; Gern JE, 1996, J IMMUNOL, V156, P621; Gern JE, 2000, AM J RESP CRIT CARE, V162, P2226; Grunberg K, 1999, CLIN EXP ALLERGY, V29, P65; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HSIA J, 1990, J INFECT DIS, V162, P591; Hussell T, 1996, J GEN VIROL, V77, P2447, DOI 10.1099/0022-1317-77-10-2447; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Johnston SL, 1997, J INFECT DIS, V175, P323; JOHNSTON SL, 1995, AM J RESP CRIT CARE, V152, P546; Johnston SL, 1995, DIAGNOSTIC PROCEDURE, P553; Kaur B, 1998, BRIT MED J, V316, P118; LEVANDOWSKI RA, 1986, J INFECT DIS, V153, P743; LEVANDOWSKI RA, 1991, J MED VIROL, V35, P116, DOI 10.1002/jmv.1890350208; Marone G, 1998, IMMUNOL TODAY, V19, P5, DOI 10.1016/S0167-5699(97)01187-0; McInnes E, 1998, RES VET SCI, V64, P163, DOI 10.1016/S0034-5288(98)90013-3; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Orange JS, 1996, J IMMUNOL, V156, P1138; PANUSKA JR, 1995, J CLIN INVEST, V96, P2445, DOI 10.1172/JCI118302; Papadopoulos NG, 1999, J MED VIROL, V58, P100, DOI 10.1002/(SICI)1096-9071(199905)58:1<100::AID-JMV16>3.0.CO;2-D; PAPADOPOULOS NG, 1999, DIFFICULT ASTHMA, P183; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Ramshaw IA, 1997, IMMUNOL REV, V159, P119, DOI 10.1111/j.1600-065X.1997.tb01011.x; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; SCOTT P, 1993, SCIENCE, V260, P496, DOI 10.1126/science.8097337; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wimalasundera SS, 1997, J INFECT DIS, V176, P755; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	39	152	164	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	APR	2002	57	4					328	332		10.1136/thorax.57.4.328		5	Respiratory System	Respiratory System	541JJ	WOS:000174981200009	11923551	
J	McDuffie, HH; Pahwa, P; McLaughlin, JR; Spinelli, JJ; Fincham, S; Dosman, JA; Robson, D; Skinnider, LF; Choi, NW				McDuffie, HH; Pahwa, P; McLaughlin, JR; Spinelli, JJ; Fincham, S; Dosman, JA; Robson, D; Skinnider, LF; Choi, NW			Non-Hodgkin's lymphoma and specific pesticide exposures in men: Cross-Canada study of pesticides and health	CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION			English	Article							SOFT-TISSUE SARCOMA; MULTIPLE-MYELOMA; MALIGNANT-LYMPHOMA; CIGARETTE-SMOKING; CANCER MORTALITY; RISK-FACTORS; FARMERS; OCCUPATIONS; HERBICIDES; APPLIERS	Our objective in the study was to investigate the putative associations of specific pesticides with non-Hodgkin's Lymphoma [NHL; International Classification of Diseases, version 9 (ICD-9) 200, 202]. We conducted a Canadian multicenter population-based incident, case (n = 517)-control (n = 1506) study among men in a diversity of occupations using an initial postal questionnaire followed by a telephone interview for those reporting pesticide exposure of 10 h/year or more, and a 15% random sample of the remainder. Adjusted odds ratios (ORs) were computed using conditional logistic regression stratified by the matching variables of age and province of residence, and subsequently adjusted for statistically significant medical variables (history of measles, mumps, cancer, allergy desensitization treatment, and a positive history of cancer in first-degree relatives). We found that among major chemical classes of herbicides, the risk of NHL was statistically significantly increased by exposure to phenoxyherbicides [OR, 1.38; 95% confidence interval (CI), 1.06-1.81] and to dicamba (OR, 1.88; 95% Cl, 1.32-2.68). Exposure to carbamate (OR, 1.92; 95% CI, 1.22-3.04) and to organophosphorus insecticides (OR, 1.73; 95% Cl, 1.27-2.36), amide fungicides, and the fumigant carbon tetrachloride (OR, 2.42; 95% Cl, 1.19-5.14) statistically significantly increased risk. Among individual compounds, in multivariate analyses, the risk of NHL was statistically significantly increased by exposure to the herbicides 2,4-dichlorophenoxyacetic acid (2,4-D; OR, 1.32; 95% CL 1.01-1.73), mecoprop (OR, 2.33; 95% CI, 1.58-3.44), and dicamba (OR, 1.68; 95% CI, 1.00-2.81); to the insecticides malathion (OR, 1.83; 95% Cl, 1.31-2.55), 1,1,1-trichloro-2,2-bis (4-chlorophenyl) ethane (DDT), carbaryl (OR, 2.11; 95% CI, 1.21-3.69), aldrin, and lindane; and to the fungicides captan and sulfur compounds. In additional multivariate models, which included exposure to other major chemical classes or individual pesticides, personal antecedent cancer, a history of cancer among first-degree relatives, and exposure to mixtures containing dicamba (OR, 1.96; 95% CL 1.40-2.75) or to mecoprop (OR, 2.22; 95% CL 1.49-3.29) and to aldrin (OR, 3.42; 95% Cl, 1.18-9.95) were significant independent predictors of an increased risk for NHL, whereas a personal history of measles and of allergy desensitization treatments lowered the risk. We concluded that NHL was associated with specific pesticides after adjustment for other independent predictors.	Univ Saskatchewan, Ctr Agr Med, Saskatoon, SK S7N 0W8, Canada; Univ Toronto, Natl Canc Inst, Epidemiol Unit, Toronto, ON M5S 1A8, Canada; St Pauls Hosp, Ctr Hlth Evaluat & Outcome Sci, Vancouver, BC V6Z 1Y6, Canada; Alberta Canc Board, Div Epidemiol Prevent & Screening, Edmonton, AB T6G 1Z2, Canada; Allan Blair mem Ctr, Saskatchewan Canc Agcy, Regina, SK S4T 7TA, Canada; Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 0W8, Canada; Manitoba Canc Treatment & Res Fdn, Winnipeg, MB R3E 0V9, Canada	McDuffie, HH (reprint author), Royal Univ Hosp, Ctr Agr Med, 103 Hosp Dr,POB 120, Saskatoon, SK S7N 0W8, Canada.		Spinelli, John/B-6210-2013; McLaughlin, John/E-4577-2013				ALAVANJA MCR, 1989, ARCH ENVIRON HEALTH, V44, P94; BANKS PM, 1992, CANCER RES, V52, pS5453; BERSTEIN R, 1992, CANC RES S, V52, pS5510; BLAIR A, 1990, RECENT RES CANCER, V120, P132; BLAIR A, 1990, AM J IND MED, V18, P285, DOI 10.1002/ajim.4700180308; BLAIR A, 1994, AGR HLTH SAFETY WORK, P111; BOND GG, 1989, FUND APPL TOXICOL, V12, P172, DOI 10.1016/0272-0590(89)90073-0; Breslow NE, 1980, STATISTICAL METHODS, P32; BROWN LM, 1992, CANCER CAUSE CONTROL, V3, P49, DOI 10.1007/BF00051912; BROWN LM, 1991, AM J EPIDEMIOL, V134, P348; BUESCHING DP, 1984, J NATL CANCER I, V72, P503; BURMEISTER LF, 1983, AM J EPIDEMIOL, V118, P72; CANTOR KP, 1992, CANCER RES, V52, P2447; CANTOR KP, 1982, INT J CANCER, V29, P239, DOI 10.1002/ijc.2910290303; Cerhan JR, 1997, J NATL CANCER I, V89, P314; DELZELL E, 1985, AM J EPIDEMIOL, V121, P391; DEVESA SS, 1992, CANCER RES, V52, pS5432; DOSMAN JA, 1990, 60081223 U SASK; Gallagher R P, 1985, Natl Cancer Inst Monogr, V69, P163; Garry VF, 1996, CANCER EPIDEM BIOMAR, V5, P11; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; HARDELL L, 1981, BRIT J CANCER, V43, P169, DOI 10.1038/bjc.1981.25; Herrinton LJ, 1998, CANCER EPIDEM BIOMAR, V7, P25; HOAR SK, 1986, JAMA-J AM MED ASSOC, V256, P1141, DOI 10.1001/jama.256.9.1141; HOLFORD TR, 1992, CANCER RES, V52, pS5443; *IARC, 1986, MON EV CARC RISK CHE, V41; IARC, 1987, OV EV CARC UPD IARC, V1; IARC, 1991, MON EV CARC RISKS HU, V53; KOEPSELL TD, 1987, AM J EPIDEMIOL, V126, P1051; Kross BC, 1996, AM J IND MED, V29, P501; LINET MS, 1992, LEUKEMIA RES, V16, P621, DOI 10.1016/0145-2126(92)90011-U; LINET MS, 1992, CANC RES S, V52, pS5465; MCDUFFIE HH, 1988, CHEST, V93, P241, DOI 10.1378/chest.93.2.241; MILLS PK, 1992, AM J EPIDEMIOL, V136, P287; MOODY RP, 1992, AM IND HYG ASSOC J, V53, P436; PEARCE NE, 1985, AM J EPIDEMIOL, V121, P225; SAFTLAS AF, 1987, AM J IND MED, V11, P119, DOI 10.1002/ajim.4700110202; SCHERR PA, 1992, CANCER RES, V52, pS5503; SCHUMACHER MC, 1985, J OCCUP ENVIRON MED, V27, P580, DOI 10.1097/00043764-198508000-00016; SEVERSON RK, 1989, J CLIN EPIDEMIOL, V42, P995, DOI 10.1016/0895-4356(89)90165-0; TOMATIS L, 1980, CANCER RES, V40, P1; VENA JE, 1985, AM J EPIDEMIOL, V122, P66; WIGLE DT, 1990, J NATL CANCER I, V82, P575, DOI 10.1093/jnci/82.7.575; WIKLUND K, 1987, BRIT J CANCER, V56, P505, DOI 10.1038/bjc.1987.234; WIKLUND K, 1986, J NATL CANCER I, V77, P657; WOODS JS, 1987, J NATL CANCER I, V78, P899; Zahm S H, 1990, Epidemiology, V1, P349, DOI 10.1097/00001648-199009000-00004	47	152	156	0	25	AMER ASSOC CANCER RESEARCH	BIRMINGHAM	PO BOX 11806, BIRMINGHAM, AL 35202 USA	1055-9965			CANCER EPIDEM BIOMAR	Cancer Epidemiol. Biomarkers Prev.	NOV	2001	10	11					1155	1163				9	Oncology; Public, Environmental & Occupational Health	Oncology; Public, Environmental & Occupational Health	492DX	WOS:000172154100007	11700263	
J	Wu, PS; Dupont, WD; Griffin, MR; Carroll, KN; Mitchel, EF; Gebretsadik, T; Hartert, TV				Wu, Pingsheng; Dupont, William D.; Griffin, Marie R.; Carroll, Kecia N.; Mitchel, Edward F.; Gebretsadik, Tebeb; Hartert, Tina V.			Evidence of a Causal Role of Winter Virus Infection during Infancy in Early Childhood Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; respiratory winter virus infection; timing of birth	RESPIRATORY-SYNCYTIAL-VIRUS; VIRAL-INFECTIONS; LUNG-DISEASE; RISK-FACTORS; BRONCHIOLITIS; AGE; CHILDREN; ALLERGY; BIRTH; PATHOGENESIS	Rationale: Bronchiolitis during infancy is associated with an increased risk of childhood asthma. Whether winter viral infections cause asthma or are a manifestation of a predisposition to asthma development is unknown. Objectives: To study the relationship of winter virus infection during infancy and the development of childhood asthma. Methods: We studied over 95,000 infants born between 1995 and 2000 and followed through 2005 who were enrolled in the Tennessee Medicaid program from birth through early childhood to determine whether infant birth in relationship to the wintervirus peak alters the risk of developing early childhood asthma. Measurements and Main Results: Among 95,310 children studied during five winter virus seasons from birth through early childhood, the risk of developing asthma tracked with the timing of infant birth in relationship to the winter virus peak. Infant birth approximately 4 months before the winter virus peak carried the highest risk, with a 29% increase in odds of developing asthma compared with birth 12 months before the peak (adjusted odds ratio, 1.29; 95% confidence interval, 1.19-1.40). Infant age at the winter virus peak was comparable to or greater than other known risk factors for asthma. Conclusions: Timing of birth in relationship to winter virus season confers a differential and definable risk of developing early childhood asthma, establishing winter virus seasonality as a causal factor in asthma development. Delay of exposure or prevention of winter viral infection during early infancy could prevent asthma.	[Wu, Pingsheng; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Nashville, TN 37232 USA; [Wu, Pingsheng; Griffin, Marie R.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; [Wu, Pingsheng; Dupont, William D.; Gebretsadik, Tebeb] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; [Griffin, Marie R.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Ctr Hlth Serv Res, Nashville, TN 37232 USA; [Griffin, Marie R.; Hartert, Tina V.] Vanderbilt Univ, Sch Med, Inst Med & Publ Hlth, Nashville, TN 37232 USA; [Dupont, William D.; Griffin, Marie R.; Mitchel, Edward F.] Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37232 USA; [Carroll, Kecia N.] Vanderbilt Univ, Sch Med, Dept Pediat, Nashville, TN 37232 USA	Hartert, TV (reprint author), Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, 6107 Med Ctr E, Nashville, TN 37232 USA.	tina.hartert@vanderbilt.edu	Dupont, William/I-4430-2012		NIH [U01 HL 072,471, F32 HL 086,048]; Thrasher Research Fund	Supported by research grants from NIH U01 HL 072,471 (T.V.H.), Thrasher Research Fund (P.W., T.V.H.), and NIH F32 HL 086,048 (P.W., T.V.H.).	ABERG N, 1989, CLIN EXP ALLERGY, V19, P643, DOI 10.1111/j.1365-2222.1989.tb02761.x; BOYCE RG, 2000, J PEDIATR, V137, P865; BUCKLEY RH, 1996, NELSON TXB PEDIAT, P561; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Carroll KN, 2007, PEDIATRICS, V119, P1104, DOI 10.1542/peds.2006-2837; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; DE AA, 2001, J PEDIATR, V138, P311; de Francisco A, 1998, VACCINE, V16, P564, DOI 10.1016/S0264-410X(97)00245-4; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543; Hall CB, 1998, TXB PEDIAT INFECT DI, P2084; Harrell F. E., 2001, REGRESSION MODELING; Hartert TV, 2000, J AM GERIATR SOC, V48, P651; Hartert TV, 2003, AM J OBSTET GYNECOL, V189, P1705, DOI 10.1016/S0002-9378(03)00857-3; Hartter HK, 2000, PEDIATR INFECT DIS J, V19, P635, DOI 10.1097/00006454-200007000-00010; Henderson J, 2005, PEDIATR ALLERGY IMMU, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; Matthews SP, 2005, J VIROL, V79, P2050, DOI 10.1128/JVI.79.4.2050-2057.2005; Noble V, 1997, ARCH DIS CHILD, V76, P315; Openshaw PJM, 2004, J ALLERGY CLIN IMMUN, V114, P1275, DOI 10.1016/j.jaci.2004.08.024; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Robertson SE, 2004, B WORLD HEALTH ORGAN, V82, P914; Saijo Masayuki, 1994, Acta Paediatrica Japonica, V36, P371; Shay DK, 2001, J INFECT DIS, V183, P16, DOI 10.1086/317655; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Talbot TR, 2005, AM J MED, V118, P285, DOI 10.1016/j.ajm.2004.09.016; van Rijt LS, 2005, J CLIN VIROL, V34, P161, DOI 10.1016/j.jcv.2005.07.002; Wakefield DB, 2006, PEDIATR PULM, V41, P962, DOI 10.1002/ppul.20476; WELLIVER RC, 1981, NEW ENGL J MED, V305, P841, DOI 10.1056/NEJM198110083051501; WELLIVER RC, 1986, J PEDIATR-US, V109, P776, DOI 10.1016/S0022-3476(86)80692-8; *WHOSIS, ASTHM FACT WHO STAT; WJST M, 1992, CLIN EXP ALLERGY, V22, P1026, DOI 10.1111/j.1365-2222.1992.tb03032.x; WU P, 2007, P AM THORAC SOC, V4, pA80; WU P, 2006, JOINT STAT M AUG 6 1	43	151	155	1	12	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2008	178	11					1123	1129		10.1164/rccm.200804-579OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	378GO	WOS:000261309400005	18776151	
J	Bollinger, ME; Dahlquist, LM; Mudd, K; Sonntag, C; Dillinger, L; McKenna, K				Bollinger, ME; Dahlquist, LM; Mudd, K; Sonntag, C; Dillinger, L; McKenna, K			The impact of food allergy on the daily activities of children and their families	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							QUALITY-OF-LIFE; PEANUT ALLERGY; POPULATION; PARENTS	Background: Food allergy affects a significant number of children, and its management requires considerable time and vigilance. Objective: To determine the impact of food allergy on the daily activities of food allergic children and their families. Methods: Caregivers of food allergic children from a university-based allergy practice completed a questionnaire that evaluated their perception of the impact of their child's food allergy on family activities. Results: Of the 87 families who completed the study, more than 60% of caregivers reported that food allergy significantly affected meal preparation and 49% or more indicated that food allergy affected family social activities. Forty-one percent of parents reported a significant impact on their stress levels and 34% reported that food allergy had an impact on school attendance, with 10% choosing to home school their children because of food allergy. The number of food allergies had a significant impact on activity scores, but the existence of comorbid conditions such as asthma and atopic dermatitis did not significantly affect the results. Conclusions: Food allergy has a significant effect on activities of families of food allergic children. Further study is needed to determine more detailed effects of food allergy on parent-child interactions and development.	Univ Maryland, Sch Med, Div Pediat Pulmonol Allergy, Baltimore, MD 21201 USA; Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA	Bollinger, ME (reprint author), Univ Maryland, Sch Med, Div Pediat Pulmonol Allergy, Baltimore, MD 21201 USA.	mbolling@peds.umaryland.edu					Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; AVERY NJ, 2003, PEDIATR ALLERGY IMMU, V12, P378; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; CRNIC KA, 1990, CHILD DEV, V61, P1628, DOI 10.1111/j.1467-8624.1990.tb02889.x; DeVellis R. F., 2003, SCALE DEV THEORY APP; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163; Landgraf JM, 1996, CHILD HLTH QUESTIONA; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790; Nunnally J. C., 1994, PSYCHOMETRIC THEORY; Parker JG, 1995, DEV PSYCHOPATHOL, V2, P96; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Sampson HA, 1996, ANNU REV NUTR, V16, P161, DOI 10.1146/annurev.nutr.16.1.161; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461; Stein REK, 2003, J DEV BEHAV PEDIATR, V24, P9; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wood RA, 2003, PEDIATRICS, V111, P1631; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	20	151	151	1	30	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	MAR	2006	96	3					415	421				7	Allergy; Immunology	Allergy; Immunology	026XU	WOS:000236377400009	16597075	
J	Werfel, T; Breuer, K; Rueff, F; Przybilla, B; Worm, M; Grewe, M; Ruzicka, T; Brehler, R; Wolf, H; Schnitker, J; Kapp, A				Werfel, T; Breuer, K; Rueff, F; Przybilla, B; Worm, M; Grewe, M; Ruzicka, T; Brehler, R; Wolf, H; Schnitker, J; Kapp, A			Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study	ALLERGY			English	Article						atopic dermatitis; eczema; house dust mite; hyposensitization; specific immunotherapy	PATCH TEST; T-CELLS; HYPOSENSITIZATION; SKIN	Background: The effect of specific immunotherapy (SIT) on eczema in atopic dermatitis is not known. Therefore, a multi-centre, randomized dose-response trial, double-blind with respect to the efficacy of a biologically standardized depot house dust mite preparation was performed. Methods: Eighty-nine adults with a chronic course of atopic dermatitis, SCORAD >= 40 and allergic sensitization to house dust mites [CAP-FEIA >= 3] were included, of whom 51 completed the study. Subcutaneous SIT with a house dust mite preparation (Dermatophagoides pteronyssinus/D. farinae) applying maintenance doses of 20, 2000 and 20 000 SQ-U in weekly intervals for 1 year. The main outcome measures addressed the change of the SCORAD as average of the values after 9 and 12 months of SIT in comparison with the value at baseline. Results: The SCORAD declined in the three dose groups in a dose-dependent manner (P = 0.0368, Jonckheere-Terpstra test) and was significantly lower in the two high-dose groups (2000, 20000 SQ-U) compared with the low-dose group of 20 SQ-U (P = 0.0379, U-test) after 1 year of SIT. The use of topical corticosteroids was significantly reduced with higher doses (P = 0.0007, Mantel-Haenszel chi-square test). Conclusions: Allergen-SIT for 1 year with a house dust mite preparation is able to improve the eczema in patients with atopic dermatitis who are sensitized to house dust mite allergens and reduces the need for topical corticosteroids. SIT may be valuable in the treatment of this chronic skin disease.	Hannover Med Sch, Dept Dermatol & Allergol, D-30449 Hannover, Germany; Univ Munich, Clin & Polyclin Dermatol & Allergol, Munich, Germany; Humboldt Univ, Dept Dermatol & Allergol, Berlin, Germany; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany; Univ Hosp, Dept Dermatol, Munster, Germany; ALK SCHERAX Arzneimittel GmbH, Clin Res, Hamburg, Germany; Inst Angew Stat GmbH, Bielefeld, Germany	Werfel, T (reprint author), Hannover Med Sch, Dept Dermatol & Allergol, Ricklinger Str, D-30449 Hannover, Germany.						Di Prisco de Fuenmayor MC, 1979, BRIT J DERMATOL, V101, P697; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; Mastrandrea F, 2001, EXPERT OPIN INV DRUG, V10, P49, DOI 10.1517/13543784.10.1.49; MITCHELL EB, 1982, LANCET, V1, P127; Pacor Maria Luisa, 1994, Recenti Progressi in Medicina, V85, P273; RING J, 1982, BRIT J DERMATOL, V107, P597, DOI 10.1111/j.1365-2133.1982.tb00412.x; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SEIDENARI S, 1986, DERMATOLOGICA, V172, P229; STALDER JF, 1993, DERMATOLOGY, V186, P23; Trofimowicz A, 1995, Rocz Akad Med Bialymst, V40, P414; Werfel T, 1998, ALLERGY, V53, P731; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Zachariae H, 1985, Acta Derm Venereol Suppl (Stockh), V114, P48	15	151	158	0	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	FEB	2006	61	2					202	205		10.1111/j.1398-9995.2006.00974.x		4	Allergy; Immunology	Allergy; Immunology	001XJ	WOS:000234575700009	16409197	
J	Ricciardolo, FLM				Ricciardolo, FLM			Multiple roles of nitric oxide in the airways	THORAX			English	Review							GUINEA-PIG TRACHEA; OBSTRUCTIVE PULMONARY-DISEASE; VASOACTIVE-INTESTINAL-PEPTIDE; VASCULAR SMOOTH-MUSCLE; EXHALED AIR; IN-VITRO; L-ARGININE; ASTHMATIC-PATIENTS; RELAXING FACTOR; MILD ASTHMA	Nitric oxide is endogenously released in the airways by nitric oxide synthase. Functionally, two isoforms of this enzyme exist: constitutive and inducible. The former seems to protect airways from excessive bronchoconstriction while the latter has a modulatory role in inflammatory disorders of the airways such as asthma. This review explores the physiological and pathophysiological role of endogenous nitric oxide in the airways, and the clinical aspects of monitoring nitric oxide in exhaled air of patients with respiratory disease.	Osped Riuniti Bergamo, Dept Resp Dis, I-24100 Bergamo, Italy	Ricciardolo, FLM (reprint author), Osped Riuniti Bergamo, Dept Resp Dis, Largo Barozzi 1, I-24100 Bergamo, Italy.						ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ADLER KB, 1995, AM J RESP CELL MOL, V13, P526; ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; Agusti AGN, 1999, EUR RESPIR J, V14, P523, DOI 10.1034/j.1399-3003.1999.14c08.x; Ali S, 1997, AM J PHYSIOL-LUNG C, V273, pL581; ALVING K, 1993, BRIT J PHARMACOL, V110, P739; ALVING K, 1993, EUR RESPIR J, V6, P1368; ARCHER S, 1993, FASEB J, V7, P349; Baile EM, 1998, J APPL PHYSIOL, V84, P809; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; BELVISI MG, 1991, EUR J PHARMACOL, V198, P219, DOI 10.1016/0014-2999(91)90626-2; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; Black PN, 1998, LANCET, V351, P449, DOI 10.1016/S0140-6736(05)78399-9; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chang RH, 1997, IMMUNOLOGY, V90, P364, DOI 10.1111/j.1365-2567.1997.00364.x; Charan NB, 1997, J APPL PHYSIOL, V82, P686; Clini E, 1998, THORAX, V53, P881; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Corradi M, 1999, THORAX, V54, P572; CREMONA G, 1991, LUNG, V169, P185, DOI 10.1007/BF02714154; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; deBoer J, 1996, BRIT J PHARMACOL, V119, P1109; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; Duszyk M, 2001, AM J PHYSIOL-LUNG C, V281, pL450; Duszyk R, 2000, FREE RADICAL RES, V33, P449; ELLIS JL, 1992, AM REV RESPIR DIS, V146, P1543; Emanueli C, 1998, BRIT J PHARMACOL, V125, P963, DOI 10.1038/sj.bjp.0702174; Figini M, 1996, BRIT J PHARMACOL, V117, P1270; Figini M, 1996, AM J RESP CRIT CARE, V153, P918; FILEP JG, 1993, BRIT J PHARMACOL, V109, P637; FISCHER A, 1993, NEUROSCI LETT, V149, P157, DOI 10.1016/0304-3940(93)90760-I; Fischer A, 1996, J AUTONOM NERV SYST, V56, P157, DOI 10.1016/0165-1838(95)00085-2; FOLKERTS G, 1995, J CLIN INVEST, V95, P26, DOI 10.1172/JCI117649; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gibson PG, 2000, EUR RESPIR J, V16, P1008; Grasemann H, 1997, PEDIATR PULM, V24, P173, DOI 10.1002/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; GREEN SJ, 1990, J IMMUNOL, V144, P278; GRUETTER CA, 1989, AM REV RESPIR DIS, V139, P1192; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Hamad AM, 1999, AM J PHYSIOL-LUNG C, V277, pL910; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; HENRY Y, 1991, EUR BIOPHYS J, V20, P1; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HOBBS AJ, 1997, NITRIC OXIDE LUNG, P1; HOGMAN M, 1993, EUR RESPIR J, V6, P177; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; IGNARRO LJ, 1993, P NATL ACAD SCI USA, V90, P8103, DOI 10.1073/pnas.90.17.8103; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1989, CIRC RES, V65, P1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; JAIN B, 1995, AM J PHYSIOL-LUNG C, V268, pL911; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; JANSEN A, 1992, J PHARMACOL EXP THER, V261, P154; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64; Jatakanon A, 1998, THORAX, V53, P91; JORENS PG, 1993, EUR RESPIR J, V6, P258; Kageyama N, 1997, EUR RESPIR J, V10, P13, DOI 10.1183/09031936.97.10010013; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, pA799; Kubes P, 1997, EUR RESPIR J, V10, P4; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; Lamas S., 1997, NITRIC OXIDE LUNG, P59; Lee YC, 2000, ALLERGY, V55, P959, DOI 10.1034/j.1398-9995.2000.00724.x; LEI YH, 1993, BRIT J PHARMACOL, V108, P228; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V201, P883, DOI 10.1006/bbrc.1994.1784; Li C G, 1991, Br J Pharmacol, V102, P91; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; Ludviksdottir D, 1999, RESP MED, V93, P552, DOI 10.1016/S0954-6111(99)90154-3; Malerba M, 2001, RESP MED, V95, P520, DOI 10.1053/rmed.2001.1082; MALINSKI T, 1996, METHODS NITRIC OXIDE, P319; Marietta MA, 1993, J BIOL CHEM, V17, P12231; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Mehta S, 1997, AM J PHYSIOL-LUNG C, V272, pL124; Mehta S, 1997, AM J PHYSIOL-LUNG C, V273, pL656; Meurs H, 1999, BRIT J PHARMACOL, V126, P559, DOI 10.1038/sj.bjp.0702372; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Mills CD, 2000, J IMMUNOL, V164, P6166; Miura M, 1997, AM J RESP CRIT CARE, V156, P217; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NAGAKI M, 1995, RESP PHYSIOL, V102, P89, DOI 10.1016/0034-5687(95)00042-C; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727; Ninomiya H, 1996, BRIT J PHARMACOL, V119, P1341; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Ozaki M, 2001, HYPERTENSION, V37, P322; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Patel HJ, 1999, FASEB J, V13, P1810; PERSSON MG, 1990, ACTA PHYSIOL SCAND, V140, P449, DOI 10.1111/j.1748-1716.1990.tb09021.x; PERSSON MG, 1995, BRIT J PHARMACOL, V116, P2957; PERSSON MG, 1993, EUR J PHARMACOL, V249, P7; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; Ricciardolo FLM, 2000, BRIT J PHARMACOL, V129, P915, DOI 10.1038/sj.bjp.0703135; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Ricciardolo FLM, 2001, J ALLERGY CLIN IMMUN, V108, P198, DOI 10.1067/mai.2001.116572; Ricciardolo FLM, 2000, AM J RESP CELL MOL, V22, P97; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672; RICCIARDOLO FLM, 1994, BRIT J PHARMACOL, V113, P1147; Ricciardolo FLM, 1997, LANCET, V350, P1297, DOI 10.1016/S0140-6736(05)62474-9; Riley MS, 1997, CHEST, V111, P44, DOI 10.1378/chest.111.1.44; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rutgers SR, 1999, THORAX, V54, P576; Saleh D, 1998, FASEB J, V12, P929; SASAKI F, 1995, J APPL PHYSIOL, V78, P539; SCHILING M, 1998, BRIT J PHARMACOL, V123, P1450; Schuiling M, 1998, AM J RESP CRIT CARE, V158, P1442; Silkoff PE, 1998, AM J RESP CRIT CARE, V157, P1822; Silvestri M, 1999, EUR RESPIR J, V13, P321, DOI 10.1034/j.1399-3003.1999.13b17.x; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; Sterk PJ, 1999, THORAX, V54, P565; Stirling RG, 1998, THORAX, V53, P1030; STRETTON D, 1991, CLIN EXP PHARMACOL P, V18, P675, DOI 10.1111/j.1440-1681.1991.tb01380.x; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99; Taylor DA, 1998, THORAX, V53, P483; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; Toward TJ, 2000, BRIT J PHARMACOL, V131, P271, DOI 10.1038/sj.bjp.0703589; van Rensen ELJ, 1999, THORAX, V54, P403; WARD JK, 1995, AM J RESP CELL MOL, V13, P175; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Xiong YL, 1999, J IMMUNOL, V162, P445; ZAFIRIOU OC, 1980, ANAL CHEM, V52, P1662, DOI 10.1021/ac50061a029	153	151	162	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	FEB	2003	58	2					175	182		10.1136/thorax.58.2.175		8	Respiratory System	Respiratory System	644TB	WOS:000180934500017	12554905	
J	Kharitonov, SA; Barnes, PJ				Kharitonov, Sergei A.; Barnes, Peter J.			Exhaled biomarkers	CHEST			English	Article						asthma; COPD; exhaled breath condensate; exhaled nitric oxide	NITRIC-OXIDE MEASUREMENTS; OBSTRUCTIVE PULMONARY-DISEASE; BREATH CONDENSATE; ASTHMA; COPD; LUNG; MARKERS; PROSTAGLANDINS; LEUKOTRIENES; AIR	Assessing airway and lung inflammation is important for investigating the underlying mechanisms of asthma and COPD. Yet these cannot be measured directly in clinical research and practice because of the difficulties in monitoring inflammation. Noninvasive monitoring may assist in early recognition of asthma and COPD, assessment of its severity, and response to treatment, especially during disease exacerbations. There is increasing evidence that breath analysis may have an important place in clinical management of asthma and COPD. The article reviews the role of current noninvasive measurements of exhaled gases, such as nitric oxide (NO), inflammatory markers in exhaled breath condensate (EBC), and exhaled breath temperature, as wen as novel methods in monitoring and management of asthma and COPD.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Royal Brompton & Natl Heart Hosp, London SW3 6LY, England	Kharitonov, SA (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Airway Dis, Dovehouse St, London SW3 6LY, England.	s.kharitonov@imperial.ac.uk					ATS Workshop Proceedings, 2006, P AM THORAC SOC, V3, P131; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P6, DOI 10.1164/rccm.200510-1659PP; Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294; Brindicci C, 2005, EUR RESPIR J, V26, P52, DOI 10.1183/09031936.05.00125304; de Jongste J C, 2000, Paediatr Respir Rev, V1, P354; Dupont LJ, 2003, CHEST, V123, P751, DOI 10.1378/chest.123.3.751; Effros RM, 2003, AM J RESP CRIT CARE, V167, P91; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 2003, CURR ALLERGY ASTHM R, V3, P121, DOI 10.1007/s11882-003-0024-7; Kharitonov SA, 2004, SWISS MED WKLY, V134, P175; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, pA799; Leung TF, 2005, THORAX, V60, P822, DOI 10.1136/thx.2004.039321; McCulloch M, 2006, INTEGR CANCER THER, V5, P30, DOI 10.1177/1534735405285096; Montuschi P, 2005, CLIN CHIM ACTA, V356, P22, DOI 10.1016/j.cccn.2005.01.012; Montuschi P, 2003, THORAX, V58, P585, DOI 10.1136/thorax.58.7.585; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; Montuschi P, 2005, THORAX, V60, P827, DOI 10.1136/thx.2004.035592; Paredi P, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-15; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107; van Straaten JFM, 1998, MODERN PATHOL, V11, P648	27	150	156	1	20	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2006	130	5					1541	1546		10.1378/chest.130.5.1541		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	106OH	WOS:000242109800038	17099035	
J	Lai, CKW; de Guia, TS; Kim, YY; Kuo, SH; Mukhopadhyay, A; Soriano, JB; Trung, PL; Zhong, NS; Zainudin, N; Zainudin, BMZ				Lai, CKW; de Guia, TS; Kim, YY; Kuo, SH; Mukhopadhyay, A; Soriano, JB; Trung, PL; Zhong, NS; Zainudin, N; Zainudin, BMZ		Asthma Insights Reality Asia Pacif	Asthma control in the Asia-Pacific region: The asthma insights and reality in Asia-Pacific study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asia; asthma epidemiology; asthma control; asthma management; inhaled corticosteroids	HONG-KONG; PREVALENCE; GUIDELINES; MANAGEMENT; EPIDEMIOLOGY; POPULATION; ISAAC	Background: Few data on asthma management are available for the Asia-Pacific region. Objective: This study examined asthma symptoms, health care use, and management in the Asia-Pacific region. Methods: We performed a cross-sectional survey, followed by administration of a questionnaire in a face-to-face setting in the respondents' homes in their language of choice. Urban centers in 8 areas were surveyed: China, Hong Kong, Korea, Malaysia, The Philippines, Singapore, Taiwan, and Vietnam. Results: A population sample of 3207 respondents with physician-diagnosed asthma was identified by screening 108,360 households. Daytime asthma symptoms were reported by 51.4% of respondents, and 44.3% reported sleep disturbance caused by asthma in the preceding 4 weeks. At least 2 in every 5 respondents (43.6%) had been hospitalized, attended a hospital emergency department, or made unscheduled emergency visits to other health care facilities for treatment of asthma during the previous 12 months. Overall, 15.3% of respondents reported that they had required admission to the hospital for asthma treatment. Asthma severity correlated with the frequencies of hospitalizations and emergency visits for asthma in the past year. Even in those patients with severe persistent asthma, 34.3% regarded their disease as being well or completely controlled. Current use of an inhaled corticosteroid was reported by only 13.6% of respondents, and 56.3% used quick-relief bronchodilators. Absence from school and work in the past year was reported by 36.5 % of children and 26.5 % of adults. Conclusion: As reported for other regions, current levels of asthma control in the Asia-Pacific region fall markedly short of goals specified in international guidelines for asthma management. (J Allergy Clin Immunol 2003; 111:263-8.).	Chinese Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; Philippine Heart Ctr, Quezon City, Philippines; Seoul Natl Univ Hosp, Seoul 110744, South Korea; Natl Taiwan Univ Hosp, Taipei, Taiwan; Natl Univ Singapore Hosp, Singapore 117548, Singapore; GlaxoSmithKline Res & Dev Ltd, Worldwide Epidemiol, Greenford, Middx, England; Univ Med & Pharm, Ho Chi Minh City, Vietnam; Guangzhou Inst Resp Dis, Guangzhou, Peoples R China; Paediat Inst Hosp, Kuala Lumpur, Malaysia; Damansara Specialist Hosp, Petaling Jaya, Malaysia	Lai, CKW (reprint author), Room 1403,Tak Shing House,20 Voeux Rd Ctr, Hong Kong, Hong Kong, Peoples R China.			Soriano, Joan B/0000-0001-9740-2994			Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R., 2000, J ALLERGY CLIN IMMUN, V105, P466; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P514, DOI 10.1016/S0091-6749(96)70084-2; Choy DKL, 1999, CLIN EXP ALLERGY, V29, P84; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; HE WQ, 2001, CHIN J TUBERC RESP D, V24, P444; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Kim YY, 1997, CLIN EXP ALLERGY, V27, P761, DOI 10.1046/j.1365-2222.1997.710839.x; Kish L, 1965, SURVEY SAMPLING; Lai CKW, 1996, CLIN EXP ALLERGY, V26, P5, DOI 10.1111/j.1365-2222.1996.tb00050.x; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; National Institutes of Health, 1995, NIH PUBL, V95-2754; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Reid D, 2000, Respirology, V5, P281, DOI 10.1046/j.1440-1843.2000.00265.x; Taylor DM, 1999, CHEST, V116, P1638, DOI 10.1378/chest.116.6.1638; Woolcock A, 1998, Respirology, V3, P63, DOI 10.1111/j.1440-1843.1998.tb00098.x	20	150	180	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					263	268		10.1067/mai.2003.30		6	Allergy; Immunology	Allergy; Immunology	644WF	WOS:000180942700007	12589343	
J	von Klot, S; Wolke, G; Tuch, T; Heinrich, J; Dockery, DW; Schwartz, J; Kreyling, WG; Wichmann, HE; Peters, A				von Klot, S; Wolke, G; Tuch, T; Heinrich, J; Dockery, DW; Schwartz, J; Kreyling, WG; Wichmann, HE; Peters, A			Increased asthma medication use in association with ambient fine and ultrafine particles	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma symptoms; inhaled beta(2)-agonists; inhaled corticosteroids; particulate air pollution; wheezing	PARTICULATE AIR-POLLUTION; PEAK EXPIRATORY FLOW; CHRONIC RESPIRATORY SYMPTOMS; TIME-SERIES; URBAN AIR; LONGITUDINAL DATA; PM10 POLLUTION; HEALTH; CHILDREN; MODELS	The association between particulate air pollution and asthma medication use and symptoms was assessed in a panel study of 53 adult asthmatics in Erfurt, Germany in winter 1996/1997. Number concentrations of ultrafine particles, 0.01-0.1 mum in diameter (NC0.01-0.1), mean 17,300.cm(-3), and mass concentrations of fine particles 0.01-2.5 mum in diameter (MC0.01-2.5), mean 30.3 mug.m(-3), were measured concurrently. They were not highly correlated (r=0.45). The associations between ambient particle concentrations and the prevalence of inhaled beta(2)-agonist, corticosteroid use and asthma symptoms, were analysed separately with logistic regression models, adjusting for trend, temperature, weekend, holidays, and first order autocorrelation of the error. Cumulative exposures over 14 days of ultrafine and fine particles were associated with corticosteroid use. beta(2)-agonist use was associated with 5-day mean NC0.01-0.1 and MC0.01-2.5. The prevalence of asthma symptoms was associated with ambient particle concentrations. The results suggest that reported asthma medication use and symptoms increase in association with particulate air pollution and gaseous pollutants such as nitrogen dioxide.	GSF, Natl Res Ctr Environm Hlth, Inst Epidemiol, D-85758 Neuherberg, Germany; Univ Munich, Inst Med Informat Biometry & Epidemiol, Chair Epidemiol, Munich, Germany; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; GSF, Natl Res Ctr Environm Hlth, Inst Inhalat Biol, D-85758 Neuherberg, Germany	von Klot, S (reprint author), GSF, Natl Res Ctr Environm Hlth, Inst Epidemiol, POB 1129, D-85758 Neuherberg, Germany.		Peters, Annette/A-6117-2011	Kreyling, Wolfgang/0000-0002-0702-6567			Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Brumback BA, 2000, J AM STAT ASSOC, V95, P16; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DUSSELDORP A, 1995, AM J RESP CRIT CARE, V152, P1932; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; Janssen NAH, 2000, J AIR WASTE MANAGE, V50, P1133; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Neukirch F, 1998, ARCH ENVIRON HEALTH, V53, P320; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; POPE A, 1999, AIR POLLUTION HLTH, P673; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; POPE CA, 1996, AM J RESP CRIT CARE, V154, P229; Richter K, 1999, ALLERGOLOGIE, V22, P14; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; Roemer W, 2000, EUR RESPIR J, V15, P553, DOI 10.1034/j.1399-3003.2000.15.21.x; Roemer W, 2000, CLIN EXP ALLERGY, V30, P1067; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; SCHWARTZ J, 1991, ENVIRON HEALTH PERSP, V90, P181, DOI 10.2307/3430866; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SEGALA C, 1998, EUR RESPIR J, V11, P577; SILVERMAN F, 1992, ARCH ENVIRON HEALTH, V47, P51; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; Tuch T, 2000, ATMOS ENVIRON, V34, P139, DOI 10.1016/S1352-2310(99)00248-4; Tuch T, 1997, ATMOS ENVIRON, V31, P4193, DOI 10.1016/S1352-2310(97)00260-4; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; van der Zee SC, 2000, EUR RESPIR J, V15, P700, DOI 10.1034/j.1399-3003.2000.15d13.x; Wichmann HE, 2000, PHILOS T ROY SOC A, V358, P2751; Tuch T, 2000, RES REP HLTH EFF I, V98, P5; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	42	150	151	0	13	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2002	20	3					691	702		10.1183/09031936.02.01402001		12	Respiratory System	Respiratory System	596VL	WOS:000178187100030	12358349	
J	DeMeo, MT; Mutlu, EA; Keshavarzian, A; Tobin, MC				DeMeo, MT; Mutlu, EA; Keshavarzian, A; Tobin, MC			Intestinal permeation and gastrointestinal disease	JOURNAL OF CLINICAL GASTROENTEROLOGY			English	Review						intestinal permeation; gastrointestinal disease; gastrointestinal tract	INFLAMMATORY-BOWEL-DISEASE; MULTIPLE ORGAN FAILURE; SEVERE ACUTE-PANCREATITIS; FIRST-DEGREE RELATIVES; 1ST DEGREE RELATIVES; COWS MILK ALLERGY; CROHNS-DISEASE; BACTERIAL TRANSLOCATION; CELIAC-DISEASE; INCREASED PERMEABILITY	The gastrointestinal tract constitutes one of the largest sites of exposure to the outside environment. The function of the gastrointestinal tract in monitoring and sealing the host interior from intruders is called the gut barrier. A variety of specific and nonspecific mechanisms are in operation to establish the host barrier: these include luminal mechanisms and digestive enzymes, the epithelial cells together with tight junctions in between them, and the gut immune system. Disruptions in the gut barrier follow injury from various causes including nonsteroidal anti-inflammatory drugs and oxidant stress, and involve mechanisms such as adenosine triphosphate depletion and damage to epithelial cell cytoskeletons that regulate tight junctions. Ample evidence links gut barrier dysfunction to multiorgan system failure in sepsis and immune dysregulation. Additionally, contribution of gut barrier dysfunction to gastrointestinal disease is an evolving concept and is the focus of this review. An overview of the evidence for the role of gut barrier dysfunction in disorders such as Crohn's disease, celiac disease. food allergy, acute pancreatitis, non-alcoholic fatty liver disease., and alcoholic liver disease is provided, together with critical insight into the implications of this evidence as a primary disease mechanism.	Rush Univ, Rush Presbyterian St Lukes Med Ctr, Div Gastroenterol & Nutr, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, Div Allergy & Immunol, Chicago, IL 60612 USA	DeMeo, MT (reprint author), Rush Univ, Rush Presbyterian St Lukes Med Ctr, Div Gastroenterol & Nutr, Profess Bldg,1725 W Harrison,Suite 206, Chicago, IL 60612 USA.						ADENIS A, 1992, GUT, V33, P678, DOI 10.1136/gut.33.5.678; AINSWORTH M, 1989, SCAND J GASTROENTERO, V24, P993, DOI 10.3109/00365528909089246; ALVERDY JC, 1988, SURGERY, V104, P185; ANDRE C, 1987, ANN ALLERGY, V59, P127; ANDRE F, 1988, GUT, V29, P511, DOI 10.1136/gut.29.4.511; Banan A, 2001, AM J PHYSIOL-GASTR L, V280, pG1234; BARAU E, 1990, J PEDIATR GASTR NUTR, V11, P72, DOI 10.1097/00005176-199007000-00015; BARBA A, 1989, BRIT J DERMATOL, V120, P71, DOI 10.1111/j.1365-2133.1989.tb07767.x; Bevins CL, 1999, GUT, V45, P911; BIGATELLO LM, 1987, AM J GASTROENTEROL, V82, P11; BJARNASON I, 1983, GASTROENTEROLOGY, V85, P318; BJARNASON I, 1994, GUT, V35, pS18, DOI 10.1136/gut.35.1_Suppl.S18; BJARNASON I, 1985, BRIT J DERMATOL, V112, P291, DOI 10.1111/j.1365-2133.1985.tb04856.x; BJARNASON I, 1987, Gut, V28, P1057, DOI 10.1136/gut.28.9.1057; BJARNASON I, 1993, GASTROENTEROLOGY, V104, P1832; BJARNASON I, 1995, GASTROENTEROLOGY, V108, P1566, DOI 10.1016/0016-5085(95)90708-4; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087; D'Inca R, 1999, AM J GASTROENTEROL, V94, P2956; DEITCH EA, 1992, ANN SURG, V216, P117, DOI 10.1097/00000658-199208000-00002; DINCA R, 1995, DIGEST DIS SCI, V40, P1388, DOI 10.1007/BF02065556; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444; DUMONT GCL, 1984, CLIN ALLERGY, V14, P55; DUPONT C, 1989, J PEDIATR GASTR NUTR, V8, P459, DOI 10.1097/00005176-198905000-00007; FALTHMAGNUSSON K, 1988, J ALLERGY CLIN IMMUN, V81, P743, DOI 10.1016/0091-6749(88)91048-2; FALTHMAGNUSSON K, 1986, CLIN ALLERGY, V16, P543, DOI 10.1111/j.1365-2222.1986.tb01993.x; FERRY DM, 1989, GASTROENTEROLOGY, V97, P61; Fihn BM, 2000, GASTROENTEROLOGY, V119, P1029, DOI 10.1053/gast.2000.18148; Gabe SM, 1998, GASTROENTEROLOGY, V115, P67, DOI 10.1016/S0016-5085(98)70366-X; GIANOTTI L, 1993, PANCREAS, V8, P551, DOI 10.1097/00006676-199309000-00004; GIANOTTI L, 1994, CRIT CARE MED, V22, P265, DOI 10.1097/00003246-199402000-00018; HALL EJ, 1991, GUT, V32, P749, DOI 10.1136/gut.32.7.749; HAMILTON I, 1987, J PEDIATR GASTR NUTR, V6, P697, DOI 10.1097/00005176-198709000-00006; HAWKER PC, 1980, GASTROENTEROLOGY, V79, P508; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514; Heyman M, 2000, ANN NY ACAD SCI, V915, P304; Hilsden RJ, 1996, GASTROENTEROLOGY, V110, P1395, DOI 10.1053/gast.1996.v110.pm8613043; HOLLANDER D, 1992, SCAND J GASTROENTERO, V27, P721, DOI 10.3109/00365529209011172; HOLLANDER D, 1986, ANN INTERN MED, V105, P883; Irvine EJ, 2000, GASTROENTEROLOGY, V119, P1740, DOI 10.1053/gast.2000.20231; JACKSON PG, 1981, LANCET, V1, P1285; JALONEN T, 1991, J ALLERGY CLIN IMMUN, V88, P737, DOI 10.1016/0091-6749(91)90180-V; JUBY LD, 1989, GUT, V30, P476, DOI 10.1136/gut.30.4.476; Juvonen PO, 2000, SCAND J GASTROENTERO, V35, P1314; KAGNOFF M, 1998, SLEISENGER FORDTRANS, P19; Kalfarentzos F, 1997, BRIT J SURG, V84, P1665; KATZ KD, 1989, GASTROENTEROLOGY, V97, P927; Kennedy M, 1998, GASTROENTEROLOGY, V114, P510, DOI 10.1016/S0016-5085(98)70534-7; Kennedy RJ, 2000, BRIT J SURG, V87, P1346, DOI 10.1046/j.1365-2168.2000.01615.x; Keshavarzian A, 1999, AM J GASTROENTEROL, V94, P200; Kotani J, 1999, ARCH SURG-CHICAGO, V134, P287, DOI 10.1001/archsurg.134.3.287; LAUDAT A, 1994, W INDIAN MED J, V43, P87; Lemaire LCJM, 1997, BRIT J SURG, V84, P1340; Liu Q, 1997, J SURG RES, V69, P171, DOI 10.1006/jsre.1997.5069; Luiten EJT, 1997, CLIN INFECT DIS, V25, P811, DOI 10.1086/515545; MARIN ML, 1983, AM J GASTROENTEROL, V78, P537; MARSH MN, 1990, GUT, V31, P32, DOI 10.1136/gut.31.1.32; Mathurin P, 2000, HEPATOLOGY, V32, P1008, DOI 10.1053/jhep.2000.19621; MAY GR, 1993, GASTROENTEROLOGY, V104, P1627; McClave SA, 1997, JPEN-PARENTER ENTER, V21, P14, DOI 10.1177/014860719702100114; McKay DM, 1999, GUT, V44, P283; MEDDINGS JB, 1993, GASTROENTEROLOGY, V104, P1619; MOORE FA, 1989, J TRAUMA, V29, P916, DOI 10.1097/00005373-198907000-00003; MOORE FA, 1995, SURG CLIN N AM, V75, P257; MUNKHOLM P, 1994, GUT, V35, P68, DOI 10.1136/gut.35.1.68; NANJI AA, 1994, P SOC EXP BIOL MED, V205, P243; Nathens AB, 1997, CLIN INFECT DIS, V25, P817, DOI 10.1086/515547; Nicoletti C, 2000, GUT, V47, P735, DOI 10.1136/gut.47.5.735; O'Boyle CJ, 1998, GUT, V42, P29; Ouellette AJ, 1997, GASTROENTEROLOGY, V113, P1779, DOI 10.1053/gast.1997.v113.pm9352884; PAGANELLI R, 1990, ANN ALLERGY, V64, P377; Peeters M, 1997, GASTROENTEROLOGY, V113, P802, DOI 10.1016/S0016-5085(97)70174-4; PEETERS M, 1994, DIGEST DIS SCI, V39, P2170, DOI 10.1007/BF02090367; Puspok A, 1998, EUR J CLIN INVEST, V28, P67; RAMAGE JK, 1988, GASTROENTEROLOGY, V94, P1368; REINHARDT MC, 1984, ANN ALLERGY, V53, P597; ROBERTS SA, 1977, LANCET, V2, P1131; RYAN CM, 1993, GASTROENTEROLOGY, V104, P890; SARKER SA, 1992, GUT, V33, P987, DOI 10.1136/gut.33.7.987; SCADDING G, 1989, DIGESTION, V42, P104; Schmid SW, 1999, GUT, V45, P311; SCHRANDER JJP, 1990, J PEDIATR GASTR NUTR, V10, P189, DOI 10.1097/00005176-199002000-00008; SEDMAN PC, 1994, GASTROENTEROLOGY, V107, P643; Smecuol E, 1997, GASTROENTEROLOGY, V112, P1129, DOI 10.1016/S0016-5085(97)70123-9; Soderholm JD, 1999, GUT, V44, P96; Somasundaram S, 1997, GUT, V41, P344; SUTHERLAND LR, 1994, LANCET, V343, P998; Swank GM, 1996, WORLD J SURG, V20, P411; TEAHON K, 1992, GUT, V33, P320, DOI 10.1136/gut.33.3.320; Tibble JA, 2000, GASTROENTEROLOGY, V119, P15, DOI 10.1053/gast.2000.8523; UKABAM SO, 1983, DIGESTION, V27, P70; Unno N, 1997, AM J PHYSIOL-GASTR L, V272, pG923; Van Elburg R M, 1993, Pediatr Allergy Immunol, V4, P79; VANELBURG RM, 1993, GUT, V34, P354, DOI 10.1136/gut.34.3.354; VANLEEUWEN PAM, 1994, GUT, V35, pS28, DOI 10.1136/gut.35.1_Suppl.S28; Ventura A, 1999, GASTROENTEROLOGY, V117, P297, DOI 10.1053/gast.1999.0029900297; VOGELSANG H, 1995, AM J GASTROENTEROL, V90, P1838; Wallace JL, 2000, GASTROENTEROLOGY, V119, P512, DOI 10.1053/gast.2000.9304; Wang X, 1996, WORLD J SURG, V20, P307; Wang XD, 1996, WORLD J SURG, V20, P299; WEAVER LT, 1988, T ROY SOC TROP MED H, V82, P784, DOI 10.1016/0035-9203(88)90236-2; Wigg AJ, 2001, GUT, V48, P206, DOI 10.1136/gut.48.2.206; Windsor ACJ, 1998, GUT, V42, P431; WYATT J, 1993, LANCET, V341, P1437, DOI 10.1016/0140-6736(93)90882-H; Wyatt J, 1997, AM J GASTROENTEROL, V92, P1891; YACYSHYN BR, 1995, GASTROENTEROLOGY, V108, P132, DOI 10.1016/0016-5085(95)90017-9; Yang SQ, 1997, P NATL ACAD SCI USA, V94, P2557, DOI 10.1073/pnas.94.6.2557	108	150	160	5	14	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0192-0790			J CLIN GASTROENTEROL	J. Clin. Gastroenterol.	APR	2002	34	4					385	396		10.1097/00004836-200204000-00003		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	536RR	WOS:000174716100003	11907349	
J	Nafstad, P; Magnus, P; Gaarder, PI; Jaakkola, JJK				Nafstad, P; Magnus, P; Gaarder, PI; Jaakkola, JJK			Exposure to pets and atopy-related diseases in the first 4 years of life	ALLERGY			English	Article						allergic rhinitis; asthma; atopy; children; epidemiology; pets	RISK-FACTORS; RESPIRATORY HEALTH; FURRED PETS; HAY-FEVER; SENSITIZATION; ASTHMA; CHILDREN; ALLERGY; CAT; ENVIRONMENT	Background: It is still unclear how early-life exposure to pets is related to children's risk of developing atopy-related diseases. We estimated associations between early-life exposure to pets and atopy-related diseases at 0-4 years of life in a cohort of Norwegian children. Methods: A population-based cohort of 2531 children born in Oslo, Norway, was followed from birth to the age of 4 years. Information on early-life exposure to pets, a number of possible confounders, and atopy-related diseases was mainly collected by questionnaire. Results: In logistic regression analysis adjusting for potential confounders, the odds ratio for being exposed to pets in early life (reference category: not exposed) was, for bronchial obstruction at 0-2 years of life, 1.2 (95% confidence interval 0.9, 1.8); for asthma at the age of 4 years, 0.7 (0.5, 1.1); for allergic rhinitis at the age of 4 years, 0.6 (0.4, 1.0); and for atopic eczema at 0-6 months of life, 0.7 (0.5, 0.9). Conclusions: The results indicate that early-life exposure to pets or lifestyle factors associated with, exposure to pets reduce the risk of developing atopy-related diseases in early childhood. However, these findings might also be explained by selection for keeping pets.	Natl Publ Hlth Inst, Epidemiol Sect, Dept Populat Hlth Sci, N-0403 Oslo, Norway; Ulleval Univ Hosp, Dept Immunol & Transfus Med, Oslo, Norway; Nord Sch Publ Hlth, Gothenburg, Sweden	Nafstad, P (reprint author), Natl Publ Hlth Inst, Epidemiol Sect, Dept Populat Hlth Sci, POB 4404 Torshov, N-0403 Oslo, Norway.		Jaakkola, Jouni/G-4314-2012				ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Egmar AC, 1998, PEDIATR ALLERGY IMMU, V9, P31, DOI 10.1111/j.1399-3038.1998.tb00297.x; Frosh AC, 1999, CLIN EXP ALLERGY, V29, P457; Gordon S, 1997, CLIN EXP ALLERGY, V27, P479, DOI 10.1046/j.1365-2222.1997.d01-537.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HONG CY, 1994, Q J MED, V87, P639; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kleinert S, 2000, LANCET, V355, P1795, DOI 10.1016/S0140-6736(05)73062-2; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; NAFSAD P, 1998, AM J RESP CRIT CARE, V157, P401; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; POPP W, 1990, ALLERGY, V45, P75, DOI 10.1111/j.1398-9995.1990.tb01087.x; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; STRACHAN DP, 1995, BRIT MED J, V311, P1053; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	25	150	155	0	10	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	APR	2001	56	4					307	312		10.1034/j.1398-9995.2001.00881.x		6	Allergy; Immunology	Allergy; Immunology	415DR	WOS:000167706000007	11284797	
J	Tolbert, PE; Mulholland, JA; MacIntosh, DL; Xu, F; Daniels, D; Devine, OJ; Carlin, BP; Klein, M; Dorley, J; Butler, AJ; Nordenberg, DF; Frumkin, H; Ryan, PB; White, MC				Tolbert, PE; Mulholland, JA; MacIntosh, DL; Xu, F; Daniels, D; Devine, OJ; Carlin, BP; Klein, M; Dorley, J; Butler, AJ; Nordenberg, DF; Frumkin, H; Ryan, PB; White, MC			Air quality and pediatric emergency room visits for asthma in Atlanta, Georgia	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						air pollution; asthma; child; emergency service, hospital; ozone	HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; CHILDHOOD ASTHMA; MEXICO-CITY; POLLUTION; OZONE	Pediatric emergency room visits for asthma were studied in relation to air quality indices in a spatio-temporal investigation of approximately 130,000 visits (similar to 6,000 for asthma) to the major emergency care centers in Atlanta, Georgia, during the summers of 1993-1995, Generalized estimating equations, logistic regression, and Bayesian models were fitted to the data. in logistic regression models comparing estimated exposures of asthma cases with those of the nonasthma patients, controlling for temporal and demographic covariates and using residential zip code to link patients to spatially resolved ozone levels, the estimated relative risk per 20 parts per billion (ppb) increase in the maximum 8-hour ozone level was 1.04 (p < 0.05). The estimated relative risk for particulate matter less than or equal to 10 mu m in aerodynamic diameter (PM10) was 1.04 per 15 mu g/m(3) (p < 0.05). Exposure-response trends (p < 0.01) were observed for ozone (>100 ppb vs. <50 ppb: odds ratio = 1.23, p = 0.003) and PM10 (>60 mu g/m(3) vs. <20 mu g/m(3): odds ratio = 1.26, p = 0.004). In models with ozone and PM10, both terms became nonsignificant because of collinearity of the variables (r = 0.75), The other analytical approaches yielded consistent findings. This study supports accumulating evidence regarding the relation of air pollution to childhood asthma exacerbation.	Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA; Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Cincinnati, OH USA; Emory Univ, Sch Med, Atlanta, GA USA	Tolbert, PE (reprint author), Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA.		Ryan, P. Barry/A-7662-2009; White, Mary /C-9242-2012; Tolbert, Paige/A-5676-2015	White, Mary /0000-0002-9826-3962; Frumkin, Howard/0000-0001-7079-3534			Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BESAG J, 1974, J ROY STAT SOC B MET, V36, P192; CARLIN BP, 1998, CASE STUDIES BAYESIA, V4, P303; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; CRESSIE N. A. C., 1991, STAT SPATIAL DATA; Gilks WR, 1996, MARKOV CHAIN MONTE C; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LINN W, 1994, AM J RESP CRIT CARE, V127, P51; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MULHOLLAND JA, 1998, J AIR WASTE MANAGE, V48, P174; Ponka A, 1996, J EPIDEMIOL COMMUN H, V50, pS59, DOI 10.1136/jech.50.Suppl_1.s59; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; SAS Institute Inc., 1989, SAS STAT US GUID VER, V2; Schouten JP, 1996, J EPIDEMIOL COMMUN H, V50, pS22, DOI 10.1136/jech.50.Suppl_1.s22; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; WEISEL CP, 1995, ENVIRON HEALTH PERSP, V103, P97, DOI 10.2307/3432456; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; *WHO, 1977, INT CLASS DIS MAN IN; 1993, MMWR MORB MORTAL WKL, V42, P301	26	150	152	0	11	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	APR 15	2000	151	8					798	810				13	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	303UR	WOS:000086443700009	10965977	
J	Grootendorst, DC; Gauw, SA; Verhoosel, RM; Sterk, PJ; Hospers, JJ; Bredenbroker, D; Bethke, TD; Hiemstra, PS; Rabe, KF				Grootendorst, Diana C.; Gauw, Stefanie A.; Verhoosel, Renate M.; Sterk, Peter J.; Hospers, Jeannette J.; Bredenbroeker, Dirk; Bethke, Thomas D.; Hiemstra, Pieter S.; Rabe, Klaus F.			Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD	THORAX			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW LIMITATION; PHOSPHODIESTERASE-4 INHIBITOR; LUNG-FUNCTION; SYSTEMIC INFLAMMATION; ASTHMA; METAANALYSIS; FLUTICASONE; PROPIONATE; MODULATION	Background: Roflumilast is a targeted oral once-daily administered phosphodiesterase 4 (PDE4) inhibitor with clinical efficacy in chronic obstructive pulmonary disease (COPD). Results from in vitro studies with roflumilast indicate that it has anti-inflammatory properties that may be applicable for the treatment of COPD. Methods: In a crossover study, 38 patients with COPD (mean (SD) age 63.1 (7.0) years, post-bronchodilator forced expiratory volume in 1 s (FEV1) 61.0 (12.6)% predicted) received 500 mu g roflumilast or placebo once daily for 4 weeks. Induced sputum samples were collected before and after 2 and 4 weeks of treatment. Differential and absolute cell counts were determined in whole sputum samples. Markers of inflammation were determined in sputum supernatants and blood. Spirometry was performed weekly. Results: Roflumilast significantly reduced the absolute number of neutrophils and eosinophils/g sputum compared with placebo by 35.5% (95% CI 15.6% to 50.7%; p = 0.002) and 50.0% (95% CI 26.8% to 65.8%; p<0.001), respectively. The relative proportion of sputum neutrophils and eosinophils was not affected by treatment (p>0.05). Levels of soluble interleukin-8, neutrophil elastase, eosinophil cationic protein and alpha(2)-macroglobulin in sputum and the release of tumour necrosis factor alpha from blood cells were significantly reduced by roflumilast compared with placebo treatment (p<0.05 for all). Post-bronchodilator FEV1 improved significantly during roflumilast compared with placebo treatment with a mean difference between treatments of 68.7 ml (95% CI 12.9 to 124.5; p = 0.018). Conclusion: PDE4 inhibition by roflumilast treatment for 4 weeks reduced the number of neutrophils and eosinophils, as well as soluble markers of neutrophilic and eosinophilic inflammatory activity in induced sputum samples of patients with COPD. This anti-inflammatory effect may in part explain the concomitant improvement in post-bronchodilator FEV1.	Leiden Univ, Med Ctr, Dept Pulmonol C3 P, NL-2300 RC Leiden, Netherlands; ALTANA Pharma AG, Constance, Germany	Grootendorst, DC (reprint author), Leiden Univ, Med Ctr, Dept Pulmonol C3 P, POB 9600, NL-2300 RC Leiden, Netherlands.	d.c.Grootendorst@lumc.nl					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Barnes NC, 2006, AM J RESP CRIT CARE, V173, P736, DOI 10.1164/rccm.200508-1321OC; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Celli B, 2006, CHEST, V129, P5, DOI 10.1378/chest.129.1.5; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277; Di Stefano A, 2001, CLIN EXP ALLERGY, V31, P893, DOI 10.1046/j.1365-2222.2001.01098.x; Donaldson GC, 2005, CHEST, V128, P1995, DOI 10.1378/chest.128.4.1995; Essayan DM, 2001, J ALLERGY CLIN IMMUN, V108, P671; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; Fujimoto K, 1999, CHEST, V115, P697, DOI 10.1378/chest.115.3.697; Gamble E, 2003, AM J RESP CRIT CARE, V168, P976, DOI 10.1164/rccm.200212-1490OC; Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588; Gizycki MJ, 2002, THORAX, V57, P799, DOI 10.1136/thorax.57.9.799; Grootendorst DC, 2003, PULM PHARMACOL THER, V16, P115, DOI 10.1016/S1094-5539(02)00172-4; Grootendorst DC, 2003, PULM PHARMACOL THER, V16, P341, DOI 10.1016/S1094-5539(03)00090-7; Grootendorst DC, 1999, EUR RESPIR J, V13, P647, DOI 10.1183/09031936.99.13364799; GROOTENDORST DC, 2004, EUR RESP J S48, V24, pS306; Grootendorst Diana C, 2002, Curr Opin Allergy Clin Immunol, V2, P61, DOI 10.1097/00130832-200202000-00010; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; In 'T Veen J. C. C. M., 1996, European Respiratory Journal, V9, P2441, DOI 10.1183/09031936.96.09122441; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL203; QUANJER PH, 1993, EUR RESPIR J, V6, P5; Rabe KF, 2005, LANCET, V366, P563, DOI 10.1016/S0140-6736(05)67100-0; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; RIISE GC, 1994, EUR RESPIR J, V7, P1673, DOI 10.1183/09031936.94.07091673; Romano Suzanne J, 2005, Treat Respir Med, V4, P85, DOI 10.2165/00151829-200504020-00002; SCHOONBROOD DFM, 1994, AM J RESP CRIT CARE, V150, P1519; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Smits HH, 1998, CLIN EXP IMMUNOL, V111, P463; Sutherland ER, 2003, THORAX, V58, P937, DOI 10.1136/thorax.58.11.937; Suttorp N, 1996, LUNG, V174, P181; Van Rensen ELJ, 2002, AM J RESP CRIT CARE, V165, P1275, DOI 10.1164/rccm.2110092; Wollin L, 2006, PULM PHARMACOL THER, V19, P343, DOI 10.1016/j.pupt.2005.09.002; Wouters EF, 2002, CHEST, V121, P127	39	149	154	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	DEC	2007	62	12					1081	1087		10.1136/thx.2006.075937		7	Respiratory System	Respiratory System	235QV	WOS:000251250300019	17573446	
J	Alfven, T; Braun-Fahrlander, C; Brunekreef, B; von Mutius, E; Riedler, J; Scheynius, A; van Hage, M; Wickman, M; Benz, MR; Budde, J; Michels, KB; Schram, D; Ublagger, E; Waser, M; Pershagen, G				Alfven, T; Braun-Fahrlander, C; Brunekreef, B; von Mutius, E; Riedler, J; Scheynius, A; van Hage, M; Wickman, M; Benz, MR; Budde, J; Michels, KB; Schram, D; Ublagger, E; Waser, M; Pershagen, G		PARSIFAL Study Grp	Allergic diseases and atopic sensitization in children related to farming and anthroposophic lifestyle - the PARSIFAL study	ALLERGY			English	Article						asthma; environment; epidemiology; paediatrics; rhinitis	HOUSE-DUST ENDOTOXIN; HAY-FEVER; FARMERS CHILDREN; BIRTH COHORT; ASTHMA; EXPOSURE; PREVALENCE; CHILDHOOD; SCHOOLCHILDREN; SYMPTOMS	Background: The prevalence of allergic diseases has increased rapidly in recent decades, particularly in children. For adequate prevention it is important not only to identify risk factors, but also possible protective factors. The aim of this study was to compare the prevalence of allergic diseases and sensitization between farm children, children in anthroposophic families, and reference children, with the aim to identify factors that may protect against allergic disease. Methods: The study was of cross-sectional design and included 14 893 children, aged 5-13 years, from farm families, anthroposophic families (recruited from Steiner schools) and reference children in Austria, Germany, the Netherlands, Sweden and Switzerland. A detailed questionnaire was completed and allergen-specific IgE was measured in blood. Results: Growing up on a farm was found to have a protective effect against all outcomes studied, both self-reported, such as rhinoconjunctivitis, wheezing, atopic eczema and asthma and sensitization (allergen specific IgE >= 0.35 kU/l). The adjusted odds ratio (OR) for current rhinoconjunctivitis symptoms was 0.50 (95% confidence interval (CI) 0.38-0.65) and for atopic sensitization 0.53 (95% CI 0.42-0.67) for the farm children compared to their references. The prevalence of allergic symptoms and sensitization was also lower among Steiner school children compared to reference children, but the difference was less pronounced and not as consistent between countries, adjusted OR for current rhinoconjunctivitis symptoms was 0.69 (95% CI 0.56-0.86) and for atopic sensitization 0.73 (95% CI 0.58-0.92). Conclusions: This study indicates that growing up on a farm, and to a lesser extent leading an anthroposophic life style may confer protection from both sensitization and allergic diseases in childhood.	Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Dr Von Haunersche Kinderklin, Munich, Germany; Kinderspital Schwarzach, Schwarzach, Austria; Karolinska Hosp & Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden; Karolinska Univ Hosp, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Karolinska Hosp, Unit Environm Med, S-10401 Stockholm, Sweden; Harvard Univ, Brigham & Womens Hosp, Sch Med,Dept Epidemiol,Sch Publ Hlth, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Childrens Hosp, Dept Paediat Pulmonol & Allergol, Salzburg, Austria	Alfven, T (reprint author), Karolinska Inst, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Pershagen, Goran/0000-0002-9701-1130; brunekreef, bert/0000-0001-9908-0060; Alfven, Tobias/0000-0002-2328-3512			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2003, CLIN EXP ALLERGY, V33, P409, DOI 10.1046/j.1365-2222.2003.01650.x; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Toelle BG, 2004, BRIT MED J, V328, P386, DOI 10.1136/bmj.328.7436.386; [Anonymous], 1997, EUR ALL WHIT PAP; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x	25	149	153	3	23	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	APR	2006	61	4					414	421		10.1111/j.1398-9995.2005.00939.x		8	Allergy; Immunology	Allergy; Immunology	016BC	WOS:000235594500004	16512802	
J	Silva, GE; Sherrill, DL; Guerra, S; Barbee, RA				Silva, GE; Sherrill, DL; Guerra, S; Barbee, RA			Asthma as a risk factor for COPD in a longitudinal study	CHEST			English	Article						asthma; chronic bronchitis; COPD; pulmonary emphysema	MONOXIDE DIFFUSING-CAPACITY; AIR-FLOW OBSTRUCTION; SKIN-TEST REACTIVITY; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; BRONCHIAL RESPONSIVENESS; POPULATION SAMPLE; LUNG-FUNCTION; SERUM IGE; FOLLOW-UP	Background: For several years, asthma and COPD have been regarded as distinct entities, with distinct clinical courses. However, despite distinctive physiologic features at the time of diagnosis, and different risk factors, the two diseases over time may develop features that are quite similar. Study objective: To evaluate the association between physician-diagnosed asthma and the subsequent development of COPD in a cohort of 3,099 adult subjects from Tucson, AZ. Design and methods: A prospective observational study. Participants completed up to 12 standard respiratory questionnaires and 11 spirometry lung function measurements over a period of 20 years. Survival curves (with time to development of COPD as the dependent variable) were compared between subjects with asthma and subjects without asthma at the initial survey. Results: Subjects with active asthma (n = 192) had significantly higher hazard ratios than inactive (n = 156) or nonasthmatic subjects (n = 2751) for acquiring COPD. As compared with nonasthmatics, active asthmatics had a 10-times-higher risk for acquiring symptoms of chronic bronchitis (95% confidence interval [CI], 4.94 to 20.25), 17-times-higher risk of receiving a diagnosis of emphysema (95% CI, 8.31 to 34.83), and 12.5-times-higher risk of fulfilling COPD criteria (95% CI, 6.84 to 22.84), even after adjusting for smoking history and other potential confounders. Conclusions: Physician-diagnosed asthma is significantly associated with an increased risk for CB, emphysema, and COPD.	Univ Arizona, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA	Sherrill, DL (reprint author), Univ Arizona, Arizona Resp Ctr, Coll Med, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	duane@resp-sci.arizona.edu			NHLBI NIH HHS [HL10506-02]		American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; BARBEE RA, 1976, ANN INTERN MED, V84, P129; BARBEE RA, 1997, EPIDEMIOLOGY NATURAL; Barnes PJ, 2000, CHEST, V117, P10; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P185; DEGOOIJER A, 1993, EUR RESPIR J, V6, P848; FANTA CH, 1989, J ASTHMA, V26, P87, DOI 10.3109/02770908909073237; Fletcher C, 1976, NATURAL HIST CHRONIC; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; KNUDSON RJ, 1987, AM REV RESPIR DIS, V135, P805; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LIEBERMA.J, 1969, NEW ENGL J MED, V281, P279, DOI 10.1056/NEJM196908072810601; Mannino DM, 2002, CHEST, V121, p121S, DOI 10.1378/chest.121.5_suppl.121S; National Asthma Education and Prevention Program, 1997, NIH PUBL, V97-4051; OCONNOR GT, 1995, AM J RESP CRIT CARE, V152, P87; Orie NGM, 1961, BRONCH INT S ASS NET; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; RENZETTI AD, 1986, AM REV RESPIR DIS, V133, P1205; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377; Sherrill D, 2003, EUR RESPIR J, V21, P95, DOI 10.1183/09031936.03.00017103; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; VILLAR MTA, 1995, AM J RESP CRIT CARE, V151, P656; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; World Health Organization, GOLD GLOB STRAT MAN; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1; 1979, ANN REV RESP DIS, V119, P831	34	149	160	0	9	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUL	2004	126	1					59	65		10.1378/chest.126.1.59		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	841XP	WOS:000222965900013	15249443	
J	Berges-Gimeno, MP; Simon, RA; Stevenson, DD				Berges-Gimeno, MP; Simon, RA; Stevenson, DD			Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						aspirin; asthma; rhinitis; desensitization; nonsteroidal anti-inflammatory drugs; aspirin desensitization treatment	RHINOSINUSITIS-ASTHMA; CHALLENGES	Background: Aspirin desensitization treatment is an option to decrease disease activity and reduce the need for systemic corticosteroids in patients with aspirin-exacerbated respiratory disease (AERD). Objective: This study was designed to determine whether the clinical courses of patients with AERD improved as early as 6 months after starting aspirin desensitization and to compare this with follow-up evaluations after at least a year. Methods: Between 1995 and 2000, 172 patients with AERD were admitted to our General Clinical Research Center, were desensitized to and treated with aspirin, were discharged to their home communities, and participated in follow-up interviews and written assessments of their clinical courses. Results: By the first 6 months of aspirin treatment, there were significant reductions in sinus infections and numbers of short courses of prednisone and improvements in sense of smell and general assessment of nasal-sinus and asthma symptoms (P <.0001). These results persisted for I to 5 years (P <.0001). Mean prednisone doses decreased from 10.8 mg/d to 8.1 and 3.6 mg/d at 6 months and greater than 1 year, respectively. Of the 172 patients, 24 (14%) discontinued aspirin treatment because of side effects, and 115 (67%) responded to aspirin treatment. After eliminating those who discontinued aspirin treatment because of side effects, the improvement rate was 115 (78%) of 148 patients. Of the 126 patients who completed a year or more of aspirin treatment, 110 (87%) experienced improvement. Conclusion: Aspirin desensitization followed by daily aspirin is efficacious by at least the first 6 months of treatment and continues to be effective for up to 5 years of follow-up.	Scripps Clin, La Jolla, CA 92037 USA; Scripps Res Inst, La Jolla, CA USA	Stevenson, DD (reprint author), Scripps Clin, 10666 N Torrey Rd, La Jolla, CA 92037 USA.				NCRR NIH HHS [M01RR00833]		CHIU JT, 1983, J ALLERGY CLIN IMMUN, V71, P560, DOI 10.1016/0091-6749(83)90437-2; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9; Kennedy D W, 1992, Laryngoscope, V102, P1; Mastalerz L, 1997, ALLERGY, V52, P895, DOI 10.1111/j.1398-9995.1997.tb01248.x; McFadden EA, 1997, AM J RHINOL, V11, P263, DOI 10.2500/105065897781446702; Nakamura H, 1999, ACTA OTO-LARYNGOL, V119, P592; STEVENSON DD, 1988, NEW ENGL REG ALLERGY, V9, P135; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V73, P500, DOI 10.1016/0091-6749(84)90361-0; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177; Stevenson DD, 1998, ALLERGY PRINCIPLES P, V2, P1225; Sweet JA, 1990, J ALLERGY CLIN IMMUN, V86, P59; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Widal MF, 1922, PRESSE MED, V30, P189; ZEISS CR, 1976, J ALLERGY CLIN IMMUN, V57, P440, DOI 10.1016/0091-6749(76)90059-2; 1997, NIH PUBLICATION, V4051	18	149	153	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					180	186		10.1067/mai.2003.7		7	Allergy; Immunology	Allergy; Immunology	636PR	WOS:000180465500028	12532116	
J	Bucchieri, F; Puddicombe, SM; Lordan, JL; Richter, A; Buchanan, D; Wilson, SJ; Ward, J; Zummo, G; Howarth, PH; Djukanovic, R; Holgate, ST; Davies, DE				Bucchieri, F; Puddicombe, SM; Lordan, JL; Richter, A; Buchanan, D; Wilson, SJ; Ward, J; Zummo, G; Howarth, PH; Djukanovic, R; Holgate, ST; Davies, DE			Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							NONASTHMATIC SUBJECTS; FACTOR RECEPTOR; CELLS; AIRWAY; EXPRESSION; HYPERREACTIVITY; PROLIFERATION; ANTIOXIDANTS; INFLAMMATION; BIOPSIES	Abnormal apoptotic mechanisms are associated with disease pathogenesis. Because the asthmatic bronchial epithelium is characteristically damaged with loss of columnar epithelial cells, we postulated that this is due to unscheduled apoptosis. Using an antibody directed toward the caspase cleavage product of poly(ADP-ribose) polymerase, immunohistochemistry applied to endobronchial biopsies showed higher levels of staining in the bronchial epithelium of subjects with asthma as compared with normal control subjects (% epithelial staining [median (range) = 10.5 (1.4-24.5) versus 0.4 (0.0-9.7)]; P < 0.001). Because we were unable to determine whether this difference was due to ongoing inflammation in vivo, cultures of normal and asthmatic bronchial epithelial cells were used to study apoptosis in vitro. In complete growth medium, these cells showed no difference in their rate of proliferation or viability. However, cells from subjects with asthma were more susceptible to the apoptotic effects of H2O2 than cells from normal control subjects (% apoptotic cells = 32.2 [8.8-54.9] versus 14.3 [6.4-24.7]; P < 0.05), even though both were similarly affected by treatment with actinomycin D. These data indicate that the susceptibility of asthmatic bronchial epithelium to oxidants is greater than normal. This susceptibility may contribute to the rising trends in asthma associated with air pollution and diets low in antioxidants.	Southampton Gen Hosp, Brooke Labs, Sch Med, Southampton SO9 6YD, Hants, England; Univ Palermo, Human Anat Sect, Palermo, Italy	Davies, DE (reprint author), Southampton Gen Hosp, Brooke Labs, Sch Med, Level F,Mailpoint 888, Southampton SO9 6YD, Hants, England.		Bucchieri, Fabio/F-8877-2012; Davies, Donna/H-2993-2012	BUCCHIERI, Fabio/0000-0002-0209-8668			Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; CHAGANI T, 2001, AM J RESP CRIT CARE, V163, pA739; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148; Devalia JL, 1999, INT ARCH ALLERGY IMM, V118, P437, DOI 10.1159/000024157; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074; HATCH GE, 1995, AM J CLIN NUTR, V61, p625S; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; Holgate ST, 1999, NATURE, V402, pB2; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; ILOWITE JS, 1989, AM REV RESPIR DIS, V139, P1139; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Knaapen M., 1999, PROMEGA NOTES, V72, P7; Martinez FD, 1999, LANCET S2, V354, pSII12; McDonald PP, 1999, J IMMUNOL, V163, P6164; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; Morcillo EJ, 1999, PHARMACOL RES, V40, P393, DOI 10.1006/phrs.1999.0549; *NAT I HLTH NAT HE, 1995, NIH PUBL; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; POSTMA DS, 1988, AM REV RESPIR DIS, V137, P57; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; SCHRAUFSTATTER I, 1988, J CLIN INVEST, V82, P1040, DOI 10.1172/JCI113660; Schutte B, 2000, Prog Cell Cycle Res, V4, P207; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Uhal BD, 1998, AM J PHYSIOL-LUNG C, V275, pL1192; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; Wark P A, 2000, Respirology, V5, P51, DOI 10.1046/j.1440-1843.2000.00226.x; Wellington CL, 2000, CLIN GENET, V57, P1, DOI 10.1034/j.1399-0004.2000.570101.x; White SR, 2001, AM J RESP CELL MOL, V24, P282; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237	38	149	155	1	9	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	AUG	2002	27	2					179	185				7	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	580XN	WOS:000177262200009	12151309	
J	Julia, V; Hessel, EM; Malherbe, L; Glaichenhaus, N; O'Garra, A; Coffman, RL				Julia, V; Hessel, EM; Malherbe, L; Glaichenhaus, N; O'Garra, A; Coffman, RL			A restricted subset of dendritic cells captures airborne antigens and remains able to activate specific T cells long after antigen exposure	IMMUNITY			English	Article							IN-VIVO; AIRWAY HYPERRESPONSIVENESS; IMMUNOLOGICAL-TOLERANCE; INHALED ANTIGEN; ATOPIC ASTHMA; MURINE MODEL; LYMPH-NODES; EXPRESSION; INDUCTION; LUNG	Mice sensitized for a Th2 response to Leishmania LACK antigen developed allergic airway inflammation upon exposure to LACK aerosol. Using multimers of I-A(d) molecules bound to a LACK peptide as probes, we tracked the migration of LACK-specific Th2 cells to the airways. Elevated numbers of LACK-specific Th2 cells remained in the airways for 5 weeks after the last aerosol. Substantial numbers of DC presenting LACK peptides were found in the airways, but not in other compartments, for up to 8 weeks after antigen exposure. These LACK-presenting airway DC expressed CD11c and CD11b as well as high levels of surface molecules involved in uptake and costimulation. Taken together, our results may explain the chronic Th2 airway inflammation characteristic of allergic asthma.	DNAX Res Inst Mol & Cellular Biol Inc, Res Inst, Dept Immunol, Palo Alto, CA 94304 USA; Univ Nice Sophia Antipolis, CNRS, Inst Pharmacol Mol & Cellulaire, F-06560 Valbonne, France	Julia, V (reprint author), DNAX Res Inst Mol & Cellular Biol Inc, Res Inst, Dept Immunol, 901 Calif Ave, Palo Alto, CA 94304 USA.	julia@ipmc.cnrs.fr; rcoffman@dvax.com		O'Garra, Anne/0000-0001-9845-6134			Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; Doherty PC, 1998, CURR OPIN MICROBIOL, V1, P419, DOI 10.1016/S1369-5274(98)80059-3; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Hermans IF, 2000, J IMMUNOL, V164, P3095; HOLT PG, 1994, J IMMUNOL, V153, P256; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Hurst SD, 2001, J IMMUNOL, V166, P4922; INABA K, 1995, CELL IMMUNOL, V163, P148, DOI 10.1006/cimm.1995.1109; Inaba K, 1998, J EXP MED, V188, P2163, DOI 10.1084/jem.188.11.2163; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Julia V, 1996, SCIENCE, V274, P421, DOI 10.1126/science.274.5286.421; Kim SK, 2000, J IMMUNOL, V165, P7285; Knight SC, 1998, EUR J IMMUNOL, V28, P1636; Kronin V, 2000, INT IMMUNOL, V12, P731, DOI 10.1093/intimm/12.5.731; Leenen PJM, 1998, J IMMUNOL, V160, P2166; Liu CP, 2000, P NATL ACAD SCI USA, V97, P14596, DOI 10.1073/pnas.250390997; Malhotra V, 2000, J AM SOC ECHOCARDIOG, V13, P771, DOI 10.1067/mje.2000.106078; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; McSorley SJ, 1997, IMMUNITY, V7, P401, DOI 10.1016/S1074-7613(00)80361-1; MOUGNEAU E, 1995, SCIENCE, V268, P563, DOI 10.1126/science.7725103; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Rees W, 1999, P NATL ACAD SCI USA, V96, P9781, DOI 10.1073/pnas.96.17.9781; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SEDGWICK JD, 1985, IMMUNOLOGY, V56, P635; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Smith AL, 1999, J EXP MED, V189, P593, DOI 10.1084/jem.189.3.593; TAYLOR FGR, 1985, INT ARCH ALLER A IMM, V76, P243; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Vermaelen KY, 2001, J EXP MED, V193, P51; Wang J, 2000, BLOOD, V95, P2337; White DW, 1999, J IMMUNOL, V162, P980; WILLOUGHBY JB, 1977, J IMMUNOL, V119, P2137; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275; Yamaguchi E, 1999, EUR RESPIR J, V13, P814, DOI 10.1034/j.1399-3003.1999.13d20.x	45	149	155	1	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613			IMMUNITY	Immunity	FEB	2002	16	2					271	283		10.1016/S1074-7613(02)00276-5		13	Immunology	Immunology	524YC	WOS:000174039600010	11869687	
J	Patel, AM; Ryu, JH; Reed, CE				Patel, AM; Ryu, JH; Reed, CE			Hypersensitivity pneumonitis: Current concepts and future questions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						hypersensitivity pneumonitis; immunopathogenesis; lymphocytes; antibody; cytokines; chemokines; adhesion molecules; causative agents; diagnosis; prognosis; high-resolution computed tomography; bronchoalveolar lavage; pathology	EXTRINSIC ALLERGIC ALVEOLITIS; BRONCHOALVEOLAR LAVAGE FLUID; PIGEON-BREEDERS DISEASE; IMMUNOLOGICAL LUNG-DISEASE; BIRD FANCIERS LUNG; MAST-CELL TRYPTASE; HIGH-RESOLUTION CT; ACUTE FARMERS LUNG; PULMONARY FIBROSIS; AIRWAY LESIONS	Hypersensitivity pneumonitis (extrinsic allergic alveolitis) caused by inhaled allergens can progress to disabling or even fatal end-stage lung disease. The only truly effective treatment is early recognition and control of exposure. Although patients produce antibody exuberantly, the immunopathogenesis involves cellular immunity-notably, CD8(+) cytotoxic lymphocytes, multinucleate giant cell granulomas, and ultimately interstitial fibrosis. Many causative agents have been recognized in occupational dusts or mists, but most current new cases arise from residential exposure to pet birds (pigeons and parakeets), contaminated humidifiers, and indoor molds. The symptoms and physical findings are nonspecific. Serum IgG containing high titers of specific antibody to the offending antigen is elevated, Pulmonary function tests show restrictive and diffusion defects with hypoxemia, especially after exercise. Occasionally, small airways disease causes obstruction. Radiographic changes vary according to the stage of the disease and are best evaluated by means of high-resolution computed tomography. In typical cases, the history of a known exposure and the presence of a characteristic interstitial lung disease with serologic confirmation of IgG antibody to the offending antigen suffice for diagnosis. In more obscure cases, observation of changes after a natural environmental exposure, bronchoalveolar lavage, and lung biopsy might be indicated. Among the many questions that remain are the following: What is the prevalence of hypersensitivity pneumonitis and how often is it the cause of chronic interstitial fibrosis? What is the long-term prognosis? Why do most individuals exposed to these antigens develop a vigorous antibody response whereas only a few develop the disease? How does exposure to endotoxin and cigarette smoking affect the disease? To answer these questions, standardized and validated clinical laboratory immunochemical tests are needed, in addition to a systematic approach to diagnosis, classification of disease severity, risk assessment, and management. This review is limited to the disease caused by airborne allergens and focuses on its immunopathogenesis, eliciting agents, clinical manifestations, diagnosis, management, and prognosis.	Mayo Clin, Dept Internal Med, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA	Patel, AM (reprint author), Mayo Clin, Dept Internal Med, Div Pulm & Crit Care Med, Mayo Bldg E 18,200 1st St SW, Rochester, MN 55905 USA.						Adawi A, 1998, CLIN IMMUNOL IMMUNOP, V89, P222, DOI 10.1006/clin.1998.4606; ADLER BD, 1992, RADIOLOGY, V185, P91; AGOSTINI C, 1987, J CLIN IMMUNOL, V7, P64, DOI 10.1007/BF00915427; Agostini C, 1996, AM J RESP CRIT CARE, V153, P1359; ANDO M, 1991, J ALLERGY CLIN IMMUN, V87, P1002, DOI 10.1016/0091-6749(91)90423-L; ANDO M, 1991, AM REV RESPIR DIS, V144, P765; Baldwin CI, 1999, CLIN EXP IMMUNOL, V117, P230; BARBEE RA, 1968, AM REV RESPIR DIS, V97, P223; BJERMER L, 1988, ARCH INTERN MED, V148, P1362, DOI 10.1001/archinte.148.6.1362; Blackwell TS, 2001, AM J RESP CRIT CARE, V163, P1516; BOST TW, 1994, AM J RESP CRIT CARE, V10, P596; BOUCHARD S, 1995, AM J RESP CRIT CARE, V152, P997; BRAUN SR, 1979, AM REV RESPIR DIS, V119, P185; CAMPBELL AR, 1989, AM REV RESPIR DIS, V140, P317; Cormier Y, 2000, EUR RESPIR J, V16, P56, DOI 10.1034/j.1399-3003.2000.16a10.x; CORMIER Y, 1985, CHEST, V87, P796, DOI 10.1378/chest.87.6.796; COSTABEL U, 1988, EUR RESPIR J, V1, P5; Dai H, 1999, CLIN EXP ALLERGY, V29, P1209; DENIS M, 1995, AM J RESP CRIT CARE, V151, P164; DENIS M, 1995, INFLAMMATION, V19, P157, DOI 10.1007/BF01534459; Drent M, 1997, SARCOIDOSIS VASC DIF, V14, P31; DRENT M, 1993, EUR RESPIR J, V6, P1276; Erkinjuntti-Pekkanen R, 1998, AM J RESP CRIT CARE, V158, P662; FINK JN, 1986, CHEST, V89, pS193; FINK JN, 1992, CLIN CHEST MED, V13, P303; FINK JN, 1972, CHEST, V62, P277, DOI 10.1378/chest.62.3.277; FINK JN, 1987, MONOGR ALLERGY, V21, P59; FLAHERTY DK, 1980, AM REV RESPIR DIS, V122, P437; FOURNIER E, 1985, CHEST, V88, P563, DOI 10.1378/chest.88.4.563; Garcia JEL, 1999, MEDIAT INFLAMM, V8, P43; GRAMMER LC, 1987, ANN ALLERGY, V58, P151; GRANT IWB, 1972, BRIT MED J, V1, P530; Gudmundsson G, 1997, J CLIN INVEST, V99, P2386, DOI 10.1172/JCI119420; Gudmundsson G, 1999, EXP LUNG RES, V25, P217; GURNEY JW, 1992, RADIOL CLIN N AM, V30, P1219; HALEY PJ, 1991, INT ARCH ALLER A IMM, V96, P168; Hansell DM, 1996, RADIOLOGY, V199, P123; Hisauchi-Kojima K, 1999, J ALLERGY CLIN IMMUN, V103, P1158, DOI 10.1016/S0091-6749(99)70193-4; HUNT LW, 1992, MAYO CLIN PROC, V67, P941; Israel-Assayag E, 1999, J IMMUNOL, V163, P6794; Israel-Assayag E, 1999, AM J RESP CRIT CARE, V159, P1830; KALTREIDER HB, 1993, WESTERN J MED, V159, P570; KANE GC, 1993, CHEST, V104, P627, DOI 10.1378/chest.104.2.627; Khalil N, 1996, AM J RESP CELL MOL, V14, P131; KOKKARINEN J, 1994, CHEST, V106, P509, DOI 10.1378/chest.106.2.509; KURUP VP, 1987, MYCOPATHOLOGIA, V98, P91, DOI 10.1007/BF00437294; Kuwano K, 1999, J CLIN INVEST, V104, P13, DOI 10.1172/JCI5628; LOPEZ M, 1987, MONOGR ALLERGY, V21, P70; MALMBERG P, 1990, AM J IND MED, V17, P7; MARX JJ, 1990, AM J IND MED, V18, P263, DOI 10.1002/ajim.4700180304; McSharry C, 2000, CLIN EXP ALLERGY, V30, P1221; Miyagawa T, 2000, AM J RESP CRIT CARE, V161, P961; MORELL F, 1986, THORAX, V41, P538, DOI 10.1136/thx.41.7.538; Mori S, 1998, OCCUP MED-OXFORD, V48, P465, DOI 10.1093/occmed/48.7.465; Ohtani Y, 1999, INTERNAL MED, V38, P896, DOI 10.2169/internalmedicine.38.896; Oshima M, 1999, LUNG, V177, P229, DOI 10.1007/PL00007643; Pan LH, 2000, AM J RESP CRIT CARE, V161, P1689; Pardo A, 2000, AM J RESP CRIT CARE, V161, P1698; Patel RA, 2000, J COMPUT ASSIST TOMO, V24, P965, DOI 10.1097/00004728-200011000-00025; Patterson R, 1998, CHEST, V114, P931, DOI 10.1378/chest.114.3.931; PATTERSON R, 1978, J ALLERGY CLIN IMMUN, V62, P103, DOI 10.1016/0091-6749(78)90086-6; PATTERSON R, 1979, AM REV RESPIR DIS, V120, P1113; PerezPadilla R, 1996, CHEST, V110, P371, DOI 10.1378/chest.110.2.371; PEREZPADILLA R, 1993, AM REV RESPIR DIS, V148, P49; PESCI A, 1991, CHEST, V100, P1197, DOI 10.1378/chest.100.5.1197; Ramirez-Venegas A, 1998, AM J RESP CRIT CARE, V158, P862; REED CE, 1983, J OCCUP ENVIRON MED, V25, P207, DOI 10.1097/00043764-198303000-00014; REIJULA K, 1986, PATHOL RES PRACT, V181, P418; REMYJARDIN M, 1993, RADIOLOGY, V189, P111; RICHERSON HB, 1989, J ALLERGY CLIN IMMUN, V84, P839, DOI 10.1016/0091-6749(89)90349-7; Rodrigo MJ, 2000, OCCUP ENVIRON MED, V57, P159, DOI 10.1136/oem.57.3.159; Schaaf BM, 2001, AM J RESP CRIT CARE, V163, P379; Schuyler M, 2000, J LAB CLIN MED, V136, P29, DOI 10.1067/mlc.2000.107694; Schuyler M, 1997, CHEST, V111, P534, DOI 10.1378/chest.111.3.534; SELMANLAMA M, 1993, CLIN CHEST MED, V14, P699; Shanley TP, 1996, J CLIN INVEST, V97, P963, DOI 10.1172/JCI118520; Sharma O P, 1995, Semin Respir Infect, V10, P96; Shigematsu M, 1998, SARCOIDOSIS VASC DIF, V15, P173; SHIJUBO N, 1995, CLIN EXP IMMUNOL, V102, P91; SOLER P, 1987, THORAX, V42, P565, DOI 10.1136/thx.42.8.565; STRICKER WE, 1986, J ALLERGY CLIN IMMUN, V78, P411, DOI 10.1016/0091-6749(86)90026-6; Suga M, 1997, SARCOIDOSIS VASC DIF, V14, P131; SUGIYAMA Y, 1995, EUR RESPIR J, V8, P1084, DOI 10.1183/09031936.95.08071084; TAKIZAWA H, 1989, J IMMUNOL, V143, P1982; TESCHLER H, 1993, EUR RESPIR J, V6, P709; TRENTIN L, 1990, J IMMUNOL, V145, P2147; Wahlstrom J, 1997, EUR RESPIR J, V10, P772; WALLS AF, 1991, CLIN SCI, V81, P183; WALLS AF, 1990, INT ARCH ALLER A IMM, V92, P233; Yamasaki H, 1999, J IMMUNOL, V163, P3516; Yoshizawa Y, 1999, J ALLERGY CLIN IMMUN, V103, P315, DOI 10.1016/S0091-6749(99)70507-5	91	149	162	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					661	670				10	Allergy; Immunology	Allergy; Immunology	498RG	WOS:000172523800001	11692086	
J	Ip, S; Chung, M; Raman, G; Trikalinos, TA; Lau, J				Ip, Stanley; Chung, Mei; Raman, Gowri; Trikalinos, Thomas A.; Lau, Joseph			A Summary of the Agency for Healthcare Research and Quality's Evidence Report on Breastfeeding in Developed Countries	BREASTFEEDING MEDICINE			English	Article; Proceedings Paper	1st Annual Summit on Breastfeeding	JUN 11-12, 2009	Washington, DC				EPITHELIAL OVARIAN-CANCER; INFANT-DEATH-SYNDROME; ENVIRONMENTAL RISK-FACTORS; PROSPECTIVE BIRTH COHORT; ACUTE OTITIS-MEDIA; COGNITIVE-DEVELOPMENT; DIABETES-MELLITUS; REPRODUCTIVE FACTORS; CHILDHOOD LEUKEMIA; HIP FRACTURE	Objectives: This article summarizes the Agency for Healthcare Research and Quality's evidence report on the effects of breastfeeding on term infant and maternal health outcomes in developed countries. Evidence Report Data Sources: Medline, CINAHL, Cochrane Library, bibliographies of selected reviews, and suggestions from domain experts were surveyed. Searches were limited to English-language publications. Evidence Report Review Methods: Eligible comparisons examined the association between differential exposure to breastfeeding and health outcomes. We assessed 15 infant and six maternal outcomes. For four outcomes, we also updated previously published systematic reviews. For the rest of the outcomes, we either summarized previous systematic reviews or conducted new systematic reviews; randomized and non-randomized comparative trials, prospective cohorts, and case-control studies were included. Adjusted estimates were extracted from non-experimental designs. The studies were graded for methodological quality. We did not draw conclusions from poor quality studies. Evidence Report Results: We screened over 9,000 abstracts. Thirty-two primary studies on term infant health outcomes, 43 primary studies on maternal health outcomes, and 28 systematic reviews or meta-analyses that covered approximately 400 individual studies were included in this review. A history of breastfeeding was associated with a reduction in the risk of acute otitis media, nonspecific gastroenteritis, severe lower respiratory tract infections, atopic dermatitis, asthma (young children), obesity, type 1 and 2 diabetes, childhood leukemia, and sudden infant death syndrome. There was no relationship between breastfeeding in term infants and cognitive performance. There were insufficient good quality data to address the relationship between breastfeeding and cardiovascular diseases and infant mortality. For maternal outcomes, a history of lactation was associated with a reduced risk of type 2 diabetes, breast, and ovarian cancer. Early cessation of breastfeeding or no breastfeeding was associated with an increased risk of maternal postpartum depression. There was no relationship between a history of lactation and the risk of osteoporosis. The effect of breastfeeding in mothers on return-to-prepregnancy weight was negligible, and the effect of breastfeeding on postpartum weight loss was unclear. Evidence Report Conclusions: A history of breastfeeding is associated with a reduced risk of many diseases in infants and mothers. Future research would benefit from clearer selection criteria, definitions of breastfeeding exposure, and adjustment for potential confounders. Matched designs such as sibling analysis may provide a method to control for hereditary and household factors that are important in certain outcomes.	[Ip, Stanley; Chung, Mei; Raman, Gowri; Trikalinos, Thomas A.; Lau, Joseph] Tufts Med Ctr, Evidence Based Practice Ctr, Inst Clin Res & Hlth Policy Studies, Boston, MA 02111 USA	Ip, S (reprint author), Tufts Med Ctr, Evidence Based Practice Ctr, Inst Clin Res & Hlth Policy Studies, 800 Washington St, Boston, MA 02111 USA.	SIp@tuftsmedicalcenter.org	panduru, mihaela/H-2411-2011				Agostoni C, 2001, ADV EXP MED BIOL, V501, P137; ALDERMAN BW, 1986, AM J EPIDEMIOL, V124, P262; Alho OP, 1996, AM J EPIDEMIOL, V143, P1149; Alho OP, 1996, J CLIN EPIDEMIOL, V49, P9, DOI 10.1016/0895-4356(95)00538-2; Anderson JW, 1999, AM J CLIN NUTR, V70, P525; Angelsen NK, 2001, ARCH DIS CHILD, V85, P183, DOI 10.1136/adc.85.3.183; Arenz S, 2004, INT J OBESITY, V28, P1247, DOI 10.1038/sj.ijo.0802758; Bachrach VRG, 2003, ARCH PEDIAT ADOL MED, V157, P237; Beral V, 2002, LANCET, V360, P187; Beral V, 2001, BRIT J CANCER, V85, P1685; Bernier MO, 2000, HUM REPROD UPDATE, V6, P374, DOI 10.1093/humupd/6.4.374; Bland RM, 2003, ARCH DIS CHILD, V88, P778, DOI 10.1136/adc.88.9.778; Brooke H, 1997, BRIT MED J, V314, P1516; Burgess SW, 2006, PEDIATRICS, V117, pE787, DOI 10.1542/peds.2005-1753; Chan HHL, 1996, OSTEOPOROSIS INT, V6, P228, DOI 10.1007/BF01622739; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; Chaudron LH, 2001, J PSYCHOSOM OBST GYN, V22, P103, DOI 10.3109/01674820109049960; Chen A, 2004, PEDIATRICS, V113, P435; Chiaffarino F, 2005, GYNECOL ONCOL, V98, P304, DOI 10.1016/j.ygyno.2005.05.006; Chien PFW, 2001, ADV NUTR RES, V10, P69; CHUA S, 1994, BRIT J OBSTET GYNAEC, V101, P804, DOI 10.1111/j.1471-0528.1994.tb11950.x; CHUNG M, 2008, ANN INTERN MED, V49, P565; COOPER PJ, 1993, J PSYCHOSOM RES, V37, P171, DOI 10.1016/0022-3999(93)90084-S; CRAMER DW, 1983, J NATL CANCER I, V71, P711; CUMMING RG, 1993, INT J EPIDEMIOL, V22, P962; CUMMING RG, 1993, INT J EPIDEMIOL, V22, P684, DOI 10.1093/ije/22.4.684; Dahlquist G, 2002, DIABETES CARE, V25, P1755; Der G, 2006, BRIT MED J, V333, P945, DOI 10.1136/bmj.38978.699583.55; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEWEY KG, 1993, AM J CLIN NUTR, V58, P162; Dockerty JD, 1999, BRIT J CANCER, V80, P1483, DOI 10.1038/sj.bjc.6690548; Drane DL, 2000, PAEDIATR PERINAT EP, V14, P349, DOI 10.1046/j.1365-3016.2000.00301.x; Duffy LC, 1997, PEDIATRICS, V100, part. no., DOI 10.1542/peds.100.4.e7; DUNCAN B, 1993, PEDIATRICS, V91, P867; FALL CHD, 1995, BRIT MED J, V310, P428; Fleming PJ, 1996, BRIT MED J, V313, P191; Gammon MD, 2002, BREAST CANCER RES TR, V74, P235, DOI 10.1023/A:1016387020854; Gartner LM, 2005, PEDIATRICS, V115, P496, DOI 10.1542/peds.2004-2491; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; GERSTEIN HC, 1994, DIABETES CARE, V17, P13, DOI 10.2337/diacare.17.1.13; Gillman MW, 2001, JAMA-J AM MED ASSOC, V285, P2461, DOI 10.1001/jama.285.19.2461; Gomez-Sanchiz M, 2004, CLIN PEDIATR, V43, P753, DOI 10.1177/000992280404300811; Greggi S, 2000, GYNECOL ONCOL, V79, P50, DOI 10.1006/gyno.2000.5909; GROSS SJ, 1983, NEW ENGL J MED, V308, P237, DOI 10.1056/NEJM198302033080501; Grummer-Strawn Laurence M, 2004, Pediatrics, V113, pe81, DOI 10.1542/peds.113.2.e81; Guise JM, 2005, PEDIATRICS, V116, pE724, DOI 10.1542/peds.2005-0636; GWINN ML, 1990, J CLIN EPIDEMIOL, V43, P559, DOI 10.1016/0895-4356(90)90160-Q; HANNAH P, 1992, BRIT J PSYCHIAT, V160, P777, DOI 10.1192/bjp.160.6.777; Harder T, 2005, AM J EPIDEMIOL, V162, P397, DOI 10.1093/aje/kwi222; HARTGE P, 1989, AM J OBSTET GYNECOL, V161, P10; Henderson J, 2004, BIRTH-ISS PERINAT C, V31, P76; HIGGINS JPT, 2003, BRIT MED J, V327, P560; HOFFMAN S, 1993, OSTEOPOROSIS INT, V3, P171, DOI 10.1007/BF01623672; HOWIE PW, 1990, BRIT MED J, V300, P11; Ip S, 2007, 153 AG HEALTHC RES Q; Jain A, 2002, PEDIATRICS, V109, P1044, DOI 10.1542/peds.109.6.1044; Janney CA, 1997, AM J CLIN NUTR, V66, P1116; Jernstrom H, 2004, J NATL CANCER I, V96, P1094, DOI 10.1093/jnci/djh211; Jones ME, 1998, INT J EPIDEMIOL, V27, P444, DOI 10.1093/ije/27.3.444; Kleinman RE, 2004, PEDIAT NUTR HDB; KREIGER N, 1982, AM J EPIDEMIOL, V116, P141; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kwan ML, 2004, PUBLIC HEALTH REP, V119, P521, DOI 10.1016/j.phr.2004.09.002; Lawlor DA, 2006, PAEDIATR PERINAT EP, V20, P148, DOI 10.1111/j.1365-3016.2006.00704.x; Lee SY, 2003, INT J CANCER, V105, P390, DOI 10.1002/ijc.11078; Li RW, 2005, PEDIATRICS, V115, pE31, DOI 10.1542/peds.2004-0481; Lipworth L, 2000, J NATL CANCER I, V92, P302, DOI 10.1093/jnci/92.4.302; Martin RM, 2005, AM J EPIDEMIOL, V161, P15, DOI 10.1093/aje/kwh338; Martin RM, 2004, EUR HEART J, V25, P778, DOI 10.1016/j.ehj.2004.02.006; McKinney PA, 1999, DIABETES CARE, V22, P928, DOI 10.2337/diacare.22.6.928; Meloni T, 1997, DIABETES CARE, V20, P340, DOI 10.2337/diacare.20.3.340; Michaelsson K, 2001, AM J EPIDEMIOL, V153, P1166, DOI 10.1093/aje/153.12.1166; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; Mitchell EA, 1997, PEDIATRICS, V100, P835, DOI 10.1542/peds.100.5.835; Modugno F, 2001, ANN EPIDEMIOL, V11, P568, DOI 10.1016/S1047-2797(01)00213-7; Mortensen EL, 2002, JAMA-J AM MED ASSOC, V287, P2365, DOI 10.1001/jama.287.18.2365; Mortensen EL, 2002, JAMA-J AM MED ASSOC, V287, P2946; *NAT IMM SURV, BREASTF PRACT RES NA; Ness RB, 2000, EPIDEMIOLOGY, V11, P111, DOI 10.1097/00001648-200003000-00006; NEWCOMB PA, 1994, NEW ENGL J MED, V330, P81, DOI 10.1056/NEJM199401133300201; Norris JM, 1996, EPIDEMIOLOGY, V7, P87, DOI 10.1097/00001648-199601000-00015; Oddy WH, 1999, BRIT MED J, V319, P815; Oddy WH, 2003, PAEDIATR PERINAT EP, V17, P81, DOI 10.1046/j.1365-3016.2003.00464.x; Olson CM, 2003, INT J OBESITY, V27, P117, DOI 10.1038/sj.ijo.0802156; Owen CG, 2005, PEDIATRICS, V115, P1367, DOI 10.1542/peds.2004-1176; Owen CG, 2003, BRIT MED J, V327, P1189, DOI 10.1136/bmj.327.7425.1189; Owen CG, 2006, AM J CLIN NUTR, V84, P1043; PETTITT DJ, 1995, DIABETES, V44, pA6; Quinn PJ, 2001, J PAEDIATR CHILD H, V37, P465, DOI 10.1046/j.1440-1754.2001.00702.x; Riman T, 2002, AM J EPIDEMIOL, V156, P363, DOI 10.1093/aje/kwf048; RISCH HA, 1983, AM J EPIDEMIOL, V117, P128; RISCH HA, 1994, AM J EPIDEMIOL, V140, P585; Rosenbaum PF, 2000, AM J EPIDEMIOL, V152, P1136, DOI 10.1093/aje/152.12.1136; ROSENBLATT KA, 1993, INT J EPIDEMIOL, V22, P192, DOI 10.1093/ije/22.2.192; SCARIATI PD, 1997, PEDIATRICS, V99, P5; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Seimyr L, 2004, J PSYCHOSOM OBST GYN, V25, P23, DOI 10.1080/01674820410001737414; Shu XO, 1999, J NATL CANCER I, V91, P1765, DOI 10.1093/jnci/91.20.1765; Sichieri R, 2003, INT J OBESITY, V27, P815, DOI 10.1038/sj.ijo.0802285; Siskind V, 1997, EPIDEMIOLOGY, V8, P188, DOI 10.1097/00001648-199703000-00011; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Stuebe AM, 2005, JAMA-J AM MED ASSOC, V294, P2601, DOI 10.1001/jama.294.20.2601; Tai TY, 1998, DIABETES RES CLIN PR, V42, P197, DOI 10.1016/S0168-8227(98)00105-3; TEELE DW, 1989, J INFECT DIS, V160, P83; Titus-Ernstoff L, 2001, BRIT J CANCER, V84, P714, DOI 10.1054/bjoc.2000.1596; Tung KH, 2005, AM J EPIDEMIOL, V161, P321, DOI 10.1093/aje/kwi046; Tung KH, 2003, AM J EPIDEMIOL, V158, P629, DOI 10.1093/aje/kwg177; TYSON JE, 1983, J PEDIATR-US, V103, P95; Vennemann MMT, 2005, ACTA PAEDIATR, V94, P655, DOI 10.1080/08035250410024231; Vernacchio L, 2004, INT J PEDIATR OTORHI, V68, P795, DOI 10.1016/j.ijporl.2004.01.012; Visalli N, 2003, ARCH DIS CHILD, V88, P695, DOI 10.1136/adc.88.8.695; Warner R, 1996, BRIT J PSYCHIAT, V168, P607, DOI 10.1192/bjp.168.5.607; Wennergren G, 1997, ACTA PAEDIATR, V86, P963, DOI 10.1111/j.1651-2227.1997.tb15180.x; WEST RO, 1966, CANCER, V19, P1001, DOI 10.1002/1097-0142(196607)19:7<1001::AID-CNCR2820190714>3.0.CO;2-S; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; WYNDER EL, 1969, CANCER, V23, P352, DOI 10.1002/1097-0142(196902)23:2<352::AID-CNCR2820230212>3.0.CO;2-4; Yen ML, 2003, GYNECOL ONCOL, V89, P318, DOI 10.1016/S0090-8258(03)00088-X; Young TK, 2002, ARCH PEDIAT ADOL MED, V156, P651	119	148	154	7	41	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1556-8253			BREASTFEED MED	Breastfeed. Med.	OCT	2009	4			1			S17	S30		10.1089/bfm.2009.0050		14	Obstetrics & Gynecology; Pediatrics	Obstetrics & Gynecology; Pediatrics	585AW	WOS:000276797700007	19827919	
J	Jerrett, M; Shankardas, K; Berhane, K; Gauderman, WJ; Kunzli, N; Avol, E; Gilliland, F; Lurmann, F; Molitor, JN; Molitor, JT; Thomas, DC; Peters, J; McConnell, R				Jerrett, Michael; Shankardas, Ketan; Berhane, Kiros; Gauderman, W. James; Kunzli, Nino; Avol, Edward; Gilliland, Frank; Lurmann, Fred; Molitor, Jassy N.; Molitor, John T.; Thomas, Duncan C.; Peters, John; McConnell, Rob			Traffic-related air pollution and asthma onset in children: A prospective cohort study with individual exposure measurement	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma onset; children; nitrogen dioxide; traffic	CHRONIC RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; ALLERGIC RHINITIS; SCHOOL CHILDREN; PREVALENCE; HEALTH; QUESTIONNAIRE; COMMUNITY; AGE; EPIDEMIOLOGY	BACKGROUND: The question of whether air pollution contributes to asthma onset remains unresolved. OBJECTIVES: In this study, we assessed the association between asthma onset in children and traffic-related air pollution. METHODS: We selected a sample of 217 children from participants in the Southern California Children's Health Study, a prospective cohort designed to investigate associations between air pollution and respiratory health in children 10-18 years of age. Individual covariates and new asthma incidence (30 cases) were reported annually through questionnaires during 8 years of follow-up. Children had nitrogen dioxide monitors placed outside their home for 2 weeks in the summer and 2 weeks in the fall-winter season as a marker of traffic-related air pollution. We used multilevel Cox models to test the associations between asthma and air pollution. RESULTS: In models controlling for confounders, incident asthma was positively associated with traffic Pollution, with a hazard ratio (HR) of 1.29 [95% confidence interval (CI), 1.07-1.56] across the average within-community interquartille range of 6.2 ppb in annual residential NO(2). Using the total interquartile range for all measurements of 28.9 ppb increased the HR to 3.25 (95% CI, 1.35-7.85). CONCLUSIONS: In this cohort, markers of traffic-related air pollution were associated with the onset of asthma. The risks observed suggest that air pollution exposure contributes to new-onset asthma.	[Jerrett, Michael] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA; [Shankardas, Ketan; Berhane, Kiros; Gauderman, W. James; Avol, Edward; Gilliland, Frank; Thomas, Duncan C.; Peters, John; McConnell, Rob] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA; [Kunzli, Nino] Ctr Res Environm Epidemiol CREAL, IMIM, Barcelona, Spain; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA; [Molitor, Jassy N.; Molitor, John T.] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England	Jerrett, M (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, 140 Warren Hall, Berkeley, CA 94720 USA.	jerrett@berkeley.edu	Kunzli, Nino/F-7195-2014; Osborne, Nicholas/N-4915-2015	Kunzli, Nino/0000-0001-8360-080X; Osborne, Nicholas/0000-0002-6700-2284	National Institute of Environmental Health Sciences [5P30ES007048, 5P01ES011627, 5P01ES009581, 1R03ES014046]; U.S. Environmental Protection Agency [RD831861, R826708, R831845]; California Air Resources Board [94-331]; Hastings Foundation	This work was funded by the National Institute of Environmental Health Sciences (grants 5P30ES007048, 5P01ES011627, 5P01ES009581, and 1R03ES014046), the U.S. Environmental Protection Agency (grants RD831861, R826708, and R831845), California Air Resources Board contract 94-331, and the Hastings Foundation.	Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; HAAN M, 1987, AM J EPIDEMIOL, V125, P989; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; JIN RL, 1994, HLTH IMPACT UNEMPLOY; Juhn YJ, 2005, SOC SCI MED, V60, P2453, DOI 10.1016/j.socscimed.2004.11.034; Kelly FJ, 2004, LANCET, V363, P95, DOI 10.1016/S0140-6736(03)15308-1; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059; Livingstone AE, 1996, BRIT MED J, V312, P676; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 2002, EPIDEMIOLOGY, V13, P288, DOI 10.1097/00001648-200205000-00009; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Migliaretti Giuseppe, 2004, Pediatr Pulmonol, V38, P198, DOI 10.1002/ppul.20057; Molitor J, 2006, AM J EPIDEMIOL, V164, P69, DOI 10.1093/aje/kwj150; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; PEAT JK, 1992, CHEST, V102, P153, DOI 10.1378/chest.102.1.153; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; SORENSEN G, 1987, ANNU REV PUBL HEALTH, V8, P235, DOI 10.1146/annurev.publhealth.8.1.235; Tabachnick B. G., 1985, USING MULTIVARIATE S; TATALOVICH T, 2006, INT J HEALTH GEOGR, V7, P55; *US BUR CENS, 1992, 1990 SUMM TAP FIL 3; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilkinson P, 1999, THORAX, V54, P1070; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WJST M, 1993, BRIT MED J, V307, P596; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	53	148	155	4	36	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2008	116	10					1433	1438		10.1289/ehp.10968		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	355TA	WOS:000259730100042	18941591	
J	Kull, I; Bergstrom, A; Lilja, G; Pershagen, G; Wickman, M				Kull, I.; Bergstrom, A.; Lilja, G.; Pershagen, G.; Wickman, M.			Fish consumption during the first year of life and development of allergic diseases during childhood	ALLERGY			English	Article						asthma; BAMSE; children; fish; sensitization	OIL SUPPLEMENTATION; BIRTH COHORT; FATTY-ACIDS; FOOD ALLERGY; ASTHMA RISK; CHILDREN; ATOPY; INFANTS; OMEGA-3-FATTY-ACIDS; PREVENTION	Background: Fish consumption during infancy has been regarded as a risk factor for allergic disease but later evidence suggests a protective role. However, methodological limitations in the studies make conclusions uncertain. The aim of this study was to assess the association between fish consumption during the first year of life and development of allergic diseases by age 4. Methods: A prospective birth cohort of 4089 new-born infants was followed for 4 years using parental questionnaires at ages 2 months, 1, 2 and 4 years to collect information on exposure and health effects. The response rate at 4 years was 90%. A clinical investigation was performed at age 4 years, which included blood sampling for analysis of specific IgE to common food and airborne allergens. Results: Parental allergic disease and onset of eczema or wheeze during the first year of life delayed introduction of fish in the child's diet. After exclusion of such children to avoid disease-related modification of exposure, regular fish consumption during the first year of life was associated with a reduced risk for allergic disease by age 4, ORadj 0.76 (95% CI 0.61-0.94) and sensitization, ORadj 0.76 (0.58-1.0). The reduced risk appeared most pronounced for multiple disease, ORadj 0.56 (0.35-0.89). IgE-sensitization to fish was only present among 18 of the 2614 children. Conclusion: Regular fish consumption before age 1 appears to be associated with a reduced risk of allergic disease and sensitization to food and inhalant allergens during the first 4 years of life.	Stockholm Cty Council, Stockholm, Sweden; Karolinska Inst, Natl Inst Environm Med, S-10401 Stockholm, Sweden; Childrens Hosp, Inst Sodersjukhuset, Karolinska Inst, Stockholm, Sweden	Kull, I (reprint author), Dept Occupat & Environm Med, Norrbacka 3rd Level, SE-17176 Stockholm, Sweden.			Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771			Barden AE, 2004, FREE RADICAL RES, V38, P233, DOI 10.1080/10715760310001656722; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bohme M, 2003, CLIN EXP ALLERGY, V33, P1226, DOI 10.1046/j.1365-2222.2003.01749.x; Calder PC, 2003, CLIN EXP ALLERGY, V33, P412, DOI 10.1046/j.1365-2222.2003.01633.x; Denburg JA, 2005, PEDIATR RES, V57, P276, DOI 10.1203/01.PDR.0000148279.72611.1D; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; FOUCARD T, 1995, ALLERGI OCH ASTMA BA; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kalantar-Zadeh K, 2004, MED HYPOTHESES, V62, P280, DOI 10.1016/j.mehy.2003.10.001; Kompauer I, 2004, EUR J MED RES, V9, P378; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; Oddy WH, 2004, J ASTHMA, V41, P319, DOI 10.1081/JAS-120026089; PEAT JK, 1992, EUR RESPIR J, V5, P921; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Roehr CC, 2004, CLIN EXP ALLERGY, V34, P1534, DOI 10.1111/j.1365-2222.2004.02080.x; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495; Simopoulos AP, 1999, AM J CLIN NUTR, V70, p560S; THIEN FCK, 1993, AM REV RESPIR DIS, V147, P1138; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wickman M, 2004, ALLERGY, V59, P30, DOI 10.1111/j.1398-9995.2004.00572.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2005.00764.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Woods RK, 2004, THORAX, V59, P105, DOI 10.1136/thorax.2003.009498; Zeiger RS, 2003, PEDIATRICS, V111, P1662	31	148	154	0	14	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	AUG	2006	61	8					1009	1015		10.1111/j.1398-9995.2006.01115.x		7	Allergy; Immunology	Allergy; Immunology	061NZ	WOS:000238880600017	16867056	
J	Groskreutz, DJ; Monick, MM; Powers, LS; Yarovinsky, TO; Look, DC; Hunninghake, GW				Groskreutz, DJ; Monick, MM; Powers, LS; Yarovinsky, TO; Look, DC; Hunninghake, GW			Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells	JOURNAL OF IMMUNOLOGY			English	Article							NF-KAPPA-B; TOLL-LIKE RECEPTOR-3; DENDRITIC CELLS; ACTIVATION; PKR; EXPRESSION; LOCALIZATION; TRAFFICKING; RECOGNITION; CYTOKINES	Respiratory syncytial virus (RSV) preferentially infects airway epithelial cells, causing bronchiolitis, upper respiratory infections, asthma exacerbations, chronic obstructive pulmonary disease exacerbations, and pneumonia in immunocompromised hosts. A replication intermediate of RSV is dsRNA. This is an important ligand for both the innate immune receptor, TLR3, and protein kinase R (PKR). One known effect of RSV infection is the increased responsiveness of airway epithelial cells to subsequent bacterial ligands (i.e., LPS). In this study, we examined a possible role for RSV infection in increasing amounts and responsiveness of another TLR, TLR3. These studies demonstrate that RSV infection of A549 and human tracheobronchial epithelial cells increases the amounts of TLR3 and PKR in a time-dependent manner. This leads to increased NF-kappa B activity and production of the inflammatory cytokine IL-8 following a later exposure to dsRNA. Importantly, TLR3 was not detected on the cell surface at baseline but was detected on the cell surface after RSV infection. The data demonstrate that RSV, via an effect on TLR3 and PKR, sensitizes airway epithelial cells to subsequent dsRNA exposure. These findings are consistent with the hypothesis that RSV infection sensitizes the airway epithelium to subsequent viral and bacterial exposures by up-regulating TLRs and increasing their membrane localization.	Univ Iowa, Div Pulm Crit Care & Occupat Med, Roy J & Lucille A Carver Coll Med, Iowa City, IA 52242 USA; Univ Iowa, Div Pulm Crit Care & Occupat Med, Vet Adm Med Ctr, Iowa City, IA 52242 USA	Groskreutz, DJ (reprint author), Univ Iowa, Div Pulm Crit Care & Occupat Med, Roy J & Lucille A Carver Coll Med, 100 Eckstein Med Res Bldg, Iowa City, IA 52242 USA.	dayna-groskreutz@uiowa.edu			NCRR NIH HHS [RR00059]; NHLBI NIH HHS [HL-077431, HL-60316, K08 HL089392, R01 HL079901, R01 HL079901-05]		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Akira S, 2001, ADV IMMUNOL, V78, P1, DOI 10.1016/S0065-2776(01)78001-7; Aksoy E, 2005, J BIOL CHEM, V280, P277, DOI 10.1074/jbc.M411223200; Aldallal N, 2002, AM J RESP CRIT CARE, V166, P1248, DOI 10.1164/rccm.200206-627OC; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Deb A, 2001, J IMMUNOL, V166, P6170; Demarchi F, 1999, J VIROL, V73, P7080; Ernst S, 2004, CELL MOL LIFE SCI, V61, P1684, DOI 10.1007/s00018-004-4116-x; Flaherty DM, 2002, J IMMUNOL, V168, P5675; FOTI M, 2004, NOVART FDN SYMP, V262, P141; Foti M, 2004, NOVART FDN SYMP, V262, P265; Foti Michelangelo, 2004, Novartis Found Symp, V262, P125; Funami K, 2004, INT IMMUNOL, V16, P1143, DOI 10.1093/intimm/dxh115; Gao ZH, 2003, J PHARMACOL EXP THER, V307, P870, DOI 10.1124/jpet.103.055525; Gil J, 2001, ONCOGENE, V20, P385, DOI 10.1038/sj.onc.1204109; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Hewson CA, 2005, J VIROL, V79, P12273, DOI 10.1128/JVI.79.19.12273-12279.2005; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; KINGSBURY D W, 1990, P945; KUMAR A, 1994, P NATL ACAD SCI USA, V91, P6288, DOI 10.1073/pnas.91.14.6288; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Martinez I, 2002, J GEN VIROL, V83, P1445, DOI 10.1099/vir.0.18337-0; Mastronarde JG, 1996, J INFECT DIS, V174, P262; Matsumoto M, 2002, BIOCHEM BIOPH RES CO, V293, P1364, DOI 10.1016/S0006-291X(02)00380-7; Matsumoto M, 2003, J IMMUNOL, V171, P3154; Ramaswamy M, 2004, AM J RESP CELL MOL, V30, P893, DOI 10.1165/rcmb.2003-0410OC; Rudd BD, 2005, J VIROL, V79, P3350, DOI 10.1128/JVI.79.6.3350-3357.2005; RUECKERT RR, 1990, VIROLOGY, V2, P507; Sarntinoranont M, 2003, J PHARM SCI, V92, P232, DOI 10.1002/jps.10280; Silva AM, 2004, J BIOL CHEM, V279, P37670, DOI 10.1074/jbc.M406554200; Spann KM, 2005, J VIROL, V79, P5353, DOI 10.1128/JVI.79.9.5353-5362.2005; Taddeo B, 2003, P NATL ACAD SCI USA, V100, P12408, DOI 10.1073/pnas.2034952100; Taylor DR, 1996, MOL CELL BIOL, V16, P6295; Tissari J, 2005, J IMMUNOL, V174, P4289; Ueta M, 2005, BIOCHEM BIOPH RES CO, V331, P285, DOI 10.1016/j.bbrc.2005.02.196; Vijay-Kumar M, 2005, J IMMUNOL, V174, P6322; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127	37	148	161	0	5	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 1	2006	176	3					1733	1740				8	Immunology	Immunology	004QF	WOS:000234766600052	16424203	
J	Robinson, DS; Campbell, DA; Durharm, SR; Pfeffer, J; Barnes, PJ; Chung, KF				Robinson, DS; Campbell, DA; Durharm, SR; Pfeffer, J; Barnes, PJ; Chung, KF		Asthma Allergy Research Grp of the	Systematic assessment of difficult-to-treat asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						adherence; diagnosis; psychiatry; severe asthma	AIR-FLOW LIMITATION; CLINICAL CHARACTERISTICS; RESISTANT ASTHMA; BRITTLE ASTHMA; MANAGEMENT; TRIAL	Five per cent of asthmatics remain symptomatic despite high-dose treatment. The aim of the study was to investigate how often such difficult-to-treat asthma is due to intractable asthma, misdiagnosis, non-adherence with therapy, or psychiatric problems. Difficult asthma was defined as persistence of symptoms despite treatment at step 4 of British guidelines or requirement for long-term oral glucocorticoids (step 5). One-hundred patients with a respiratory physician diagnosis of asthma were investigated in a single tertiary respiratory unit in an open and descriptive study. Twelve of the patients studied did not have asthma and a further seven had additional diagnoses. Of the remainder, 55 had an asthma diagnosis confirmed by demonstration of reversible airflow narrowing or peak flow variability, whilst 20 did not. Noncompliance with prednisolone therapy was more frequent in the 55 with confirmed asthma (nine of 18 prescribed oral prednisolone at a dose of greater than or equal to 15 mg(.)day(-1)) and was not detected in the "unconfirmed asthma" group. There were no other significant differences between these groups. A major psychiatric component was detected in 10 patients. Systematic evaluation of difficult asthma is useful as it can identify alternative or additional diagnoses, psychiatric illness or nonconcordance with therapy in a substantial proportion of cases (32% in the present series).	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Upper Resp Med, Fac Med, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Fac Med, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Allergy, Fac Med, London SW3 6LY, England; Royal Brompton & Harefield NHS Trust, London, England	Robinson, DS (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Allergy & Clin Immunol, Fac Med, Dovehouse St, London SW3 6LY, England.			Adcock, Ian/0000-0003-2101-8843; Chung, Kian Fan/0000-0001-7101-1426			ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Ayres JG, 1998, THORAX, V53, P315; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, p1s; British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; Carr DH, 1998, RESP MED, V92, P448, DOI 10.1016/S0954-6111(98)90290-6; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594; Chung KF, 1999, EUR RESPIR J, V13, P1198; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016; Fireman P, 2000, ALLERGY ASTHMA PROC, V21, P45, DOI 10.2500/108854100778248935; GOLDBERG DP, 1976, BRIT J PSYCHIAT, V129, P61, DOI 10.1192/bjp.129.1.61; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; Miles JF, 1997, CLIN EXP ALLERGY, V27, P1151; Payne DNR, 2001, THORAX, V56, P345, DOI 10.1136/thorax.56.5.345; SHINER RJ, 1990, LANCET, V336, P137, DOI 10.1016/0140-6736(90)91659-X; Szefler SJ, 1997, EUR RESPIR J, V10, P1640, DOI 10.1183/09031936.97.10071640; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; WAREHAM NJ, 1993, THORAX, V48, P1117, DOI 10.1136/thx.48.11.1117; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; [Anonymous], 2001, AM J RESP CRIT CARE, V162, P2341	23	148	154	0	2	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2003	22	3					478	483		10.1183/09031936.03.00017003		6	Respiratory System	Respiratory System	721VP	WOS:000185339400016	14516138	
J	Kharitonov, SA; Barnes, PJ				Kharitonov, SA; Barnes, PJ			Clinical aspects of exhaled nitric oxide	EUROPEAN RESPIRATORY JOURNAL			English	Editorial Material						asthma; exhaled breath; isoprostanes; nitric oxide; noninvasive markers of airway; inflammation; S-nitrosothiols	OBSTRUCTIVE PULMONARY-DISEASE; LUNG-TRANSPLANT RECIPIENTS; CYSTIC-FIBROSIS; ASTHMATIC-PATIENTS; MILD ASTHMA; INDUCED SPUTUM; AIRWAY INFLAMMATION; OXIDATIVE STRESS; YOUNG-CHILDREN; OBLITERATIVE BRONCHIOLITIS	There has been intense research into the role nitric oxide (NO) plays in physiological and pathological mechanisms and its clinical significance in respiratory medicine, Elevated levels of exhaled levels of exhaled NO in asthma and other inflammatory lung diseases lead to many studies examining NO as potential markers of airway inflammation, enabling repeated noninvasive and standardized monitoring of airway inflammation. In airway inflammation, NO is not merely a marker but may have antiinflammatory and pro-inflammatory effects, Significant correlation has been found between exhaled NO and skin test scores in steroid naive asthmatic patients, allowing to discriminate patients with and without airway responsiveness. Exhaled NO is significantly elevated in acute asthma, or steroid-resistant severe asthma, or when the maintenance dose of inhaled steroids is reduced, and quickly reduced down to the levels in patients with stable asthma after steroid treatment. Exhaled NO has been successfully used to monitor anti-inflammatory treatment with inhaled corticosteroids in asthma, Exhaled NO is extremely sensitive and rapid marker of the dose-dependent effect of steroid treatment, or asthma deterioration, which is increased to any changes in lung function, provocative concentration causing a 20% fall in forced expiratory volume, sputum eosinophilia or asthma symptoms. Exhaled NO is not increased in stable chronic obstructive pulmonary disease (COPD), but patients with unstable COPD, or bronchiectasis have high NO levels. Exhaled and nasal NO are diagnostically low in cystic fibrosis and primary pulmonary dyskinesia. Analysis of exhaled air, including nitric oxide, is feasible and could provide a noninvasive method for use in monitoring and management of lung diseases.	Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll Sch Med, London SW3 6LY, England	Barnes, PJ (reprint author), Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll Sch Med, Dovehouse St, London SW3 6LY, England.						Adisesh LA, 1998, CLIN EXP ALLERGY, V28, P876; Aizawa H, 1998, PROSTAG LEUKOTR ESS, V59, P185, DOI 10.1016/S0952-3278(98)90061-8; ALVING K, 1993, EUR RESPIR J, V6, P1368; ANSARIN K, 1998, EUR RESP J S28, V12, pS432; Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197; Artlich A, 1999, EUR RESPIR J, V13, P1396, DOI 10.1183/09031936.99.13614029; BalfourLynn IM, 1996, ARCH DIS CHILD, V75, P319; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262; Baraldi E, 1997, J PEDIATR-US, V131, P381, DOI 10.1016/S0022-3476(97)80062-5; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Beghetti M, 1998, ANN THORAC SURG, V66, P532, DOI 10.1016/S0003-4975(98)00447-0; Behr J, 1997, AM J RESP CRIT CARE, V156, P1897; Bellofiore S., 1998, European Respiratory Journal, V12, p430S; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; Black SM, 1998, AM J PHYSIOL-HEART C, V275, pH1643; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; BROWN RK, 1995, FREE RADICAL BIO MED, V18, P801, DOI 10.1016/0891-5849(94)00172-G; BROWN RK, 1994, PEDIATR RES, V36, P487, DOI 10.1203/00006450-199410000-00013; Brown RK, 1996, EUR RESPIR J, V9, P334, DOI 10.1183/09031936.96.09020334; Castagnaro A, 1999, CHEST, V116, P941, DOI 10.1378/chest.116.4.941; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810; Corradi M, 1999, THORAX, V54, P572; delPozo V, 1997, J IMMUNOL, V158, P859; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894; Elmer HL, 1999, AM J PHYSIOL-LUNG C, V276, pL466; Everett AD, 1998, AM J PHYSIOL-LUNG C, V274, pL1058; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032; Fuglsang G, 1998, PEDIATR PULM, V25, P314, DOI 10.1002/(SICI)1099-0496(199805)25:5<314::AID-PPUL5>3.0.CO;2-I; Gabbay E, 1999, AM J RESP CRIT CARE, V160, P2093; Garnier P, 1996, EUR RESPIR J, V9, P1134, DOI 10.1183/09031936.96.09061134; Gershman NH, 1999, J ALLERGY CLIN IMMUN, V104, P322, DOI 10.1016/S0091-6749(99)70374-X; Giaid A, 1998, CHEST, V114, p208S, DOI 10.1378/chest.114.3_Supplement.208S; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; Grasemann H, 1997, PEDIATR PULM, V24, P173, DOI 10.1002/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O; Gratziou C., 1998, European Respiratory Journal, V12, p127S; GRATZIOU C, 1998, EUR RESPIR J, V28, pS364; GRATZIOU C, 1998, AM J RESP CRIT CAR S, V157, pA611; Gribbe O, 1999, ANN PLAS SURG, V42, P180; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMPL V, 1993, J APPL PHYSIOL, V75, P1748; Hanazawa T., 2000, AM J RESP CRIT CARE, V161, pA919; Hargreave FE, 1999, AM J RESP CRIT CARE, V160, pS53; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Hislop AA, 1997, ARCH DIS CHILD, V77, pF16; Ho LP, 1998, EUR RESPIR J, V12, P1290, DOI 10.1183/09031936.98.12061290; HO LP, 1998, AM J RESP CRIT CARE, V157, pA608; Holz O, 1998, CLIN EXP ALLERGY, V28, P284; Holz O, 1998, THORAX, V53, P83; HOLZ O, 1998, AM J RESP CRIT CARE, V157, pA612; Hull J, 1997, THORAX, V52, P557; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jatakanon A, 1998, EUR RESPIR J, V12, P1084, DOI 10.1183/09031936.98.12051084; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 1998, THORAX, V53, P91; Jeffery PK, 1998, THORAX, V53, P129; Jones KL, 1998, AM J PHYSIOL-LUNG C, V275, pL1120; Kanazawa H, 1996, CHEST, V110, P927, DOI 10.1378/chest.110.4.927; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, CLIN SCI, V88, P135; Kharitonov SA, 1999, EUR RESPIR J, V14, P1023, DOI 10.1183/09031936.99.14510239; Kharitonov SA, 1998, AM J RESP CRIT CARE, V158, P1374; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kharitonov SA, 1997, THORAX, V52, P1051; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, pA799; Kharitinov SA, 2000, AM J RESP CRIT CARE, V161, pA186; KIPS JC, 1998, EUR RESP J S26, V11, P95; Kobayashi H, 1999, JPN J PHYSIOL, V49, P541, DOI 10.2170/jjphysiol.49.541; Lanz MJ, 1997, PEDIATR PULM, V24, P305; Lanz MJ, 1999, ANN ALLERG ASTHMA IM, V82, P161, DOI 10.1016/S1081-1206(10)62591-4; LEONE AM, 1994, BIOCHEM BIOPH RES CO, V201, P883, DOI 10.1006/bbrc.1994.1784; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; Linnane SJ, 1998, AM J RESP CRIT CARE, V158, P207; Loukides S, 1998, LANCET, V352, P371, DOI 10.1016/S0140-6736(05)60471-0; Lundberg JON, 1996, ARCH DIS CHILD, V75, P323; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; Marshall HE, 1999, AM J RESP CELL MOL, V21, P296; Mason NA, 1998, J PATHOL, V185, P313, DOI 10.1002/(SICI)1096-9896(199807)185:3<313::AID-PATH93>3.0.CO;2-8; Mason NA, 1998, J HEART LUNG TRANSPL, V17, P710; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; McDermott CD, 1997, TRANSPLANTATION, V64, P270, DOI 10.1097/00007890-199707270-00016; McFadden ER, 1999, J ALLERGY CLIN IMMUN, V104, P46, DOI 10.1016/S0091-6749(99)70112-0; Meng QH, 1998, J PATHOL, V184, P323, DOI 10.1002/(SICI)1096-9896(199803)184:3<323::AID-PATH2>3.0.CO;2-2; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Montuschi P, 1999, AM J RESP CRIT CARE, V159, pA798; NARANG I, 2000, AM J RESP CRIT CARE, V161, pA223; Nightingale JA, 1998, THORAX, V53, P87; ODonnell DM, 1997, AM J RESP CRIT CARE, V156, P1892; Olin Anna-Carin, 1998, Rhinology (Utrecht), V36, P117; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Parameswaran K., 1998, European Respiratory Journal, V12, p248S; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905; Pedoto A, 1999, AM J RESP CRIT CARE, V159, P397; Petruzzelli S, 1997, AM J RESP CRIT CARE, V156, P1902; Piacentini G. L., 1998, European Respiratory Journal, V12, p142S; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323; PRIOR WA, 1995, AM J PHYSIOL, V268, pL699; Riley MS, 1997, CHEST, V111, P44, DOI 10.1378/chest.111.1.44; Robbins RA, 1996, AM J RESP CRIT CARE, V153, P1631; Robbins RA, 1997, CHEST, V112, P313, DOI 10.1378/chest.112.2.313; Roger N, 1997, AM J RESP CRIT CARE, V156, P800; Rutgers SR, 1999, THORAX, V54, P576; SAETTA M, 1997, MON ARCH CHEST DIS, V52, P6; Saleh D, 1998, FASEB J, V12, P929; Sartori C, 1999, AM J RESP CRIT CARE, V160, P879; Sato K, 1996, INTERNAL MED, V35, P356, DOI 10.2169/internalmedicine.35.356; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Silvestri M, 1999, EUR RESPIR J, V13, P321, DOI 10.1034/j.1399-3003.1999.13b17.x; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Stirling RG, 1998, THORAX, V53, P1030; Su YC, 1998, AM J RESP CELL MOL, V19, P819; TARODO DIF, 1999, RESP MED, V93, P183; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237; Tomita K, 1999, N-S ARCH PHARMACOL, V359, P249, DOI 10.1007/PL00005349; Tyler RC, 1999, AM J PHYSIOL-LUNG C, V276, pL297; VAN RE, 1999, THORAX, V54, P403; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317; WITKOSARSAT V, 1995, AM J RESP CRIT CARE, V152, P1910; XUE C, 1995, NEW ENGL J MED, V333, P1642; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; Yates DH, 1997, EUR RESPIR J, V10, P1483, DOI 10.1183/09031936.97.10071483; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247; YERMILOV V, 1995, FEBS LETT, V376, P207, DOI 10.1016/0014-5793(95)01281-6	140	148	155	0	2	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2000	16	4					781	792		10.1183/09031936.00.16478100		12	Respiratory System	Respiratory System	374ET	WOS:000165332000032	11106225	
J	Fisk, WJ				Fisk, WJ			Health and productivity gains from better indoor environments and their relationship with building energy efficiency	ANNUAL REVIEW OF ENERGY AND THE ENVIRONMENT			English	Review						economics; health; productivity	RESPIRATORY-TRACT INFECTIONS; OFFICE WORKERS; UNITED-STATES; TASK-PERFORMANCE; ALLERGIC DISEASE; ECONOMIC COSTS; ASTHMA; CHILDREN; SYMPTOMS; SATISFACTION	Theoretical considerations and empirical data suggest that existing technologies and procedures can improve indoor environments in a manner that significantly increases productivity and health. The existing literature contains moderate to strong evidence that characteristics of buildings and indoor environments significantly influence rates of communicable respiratory illness, allergy and asthma symptoms, sick building symptoms, and worker performance. Whereas there is considerable uncertainty in the estimates of the magnitudes of productivity gains that may be obtained by providing better indoor environments, the projected gains are very large. For the United States, the estimated potential annual savings and productivity gains are $6 to $14 billion from reduced respiratory disease, $1 to $4 billion from reduced allergies and asthma, $10 to $30 billion from reduced sick building syndrome symptoms, and $20 to $160 billion from direct improvements in worker performance that are unrelated to health. Productivity gains that are quantified and demonstrated could serve as a strong stimulus for energy efficiency measures that simultaneously improve the indoor environment.	Lawrence Berkeley Natl Lab, Indoor Environm Dept, Environm Energy Technol Div, Berkeley, CA 94720 USA	Fisk, WJ (reprint author), Lawrence Berkeley Natl Lab, Indoor Environm Dept, Environm Energy Technol Div, Berkeley, CA 94720 USA.						ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BERMAN SM, 1993, J ILLUM ENG SOC, V22, P150; BERMAN SM, 1994, J ILLUM ENG SOC, V23, P123; BORAY PF, 1989, J ENVIRON PSYCHOL, V9, P297, DOI 10.1016/S0272-4944(89)80011-8; Brightman HS, 1997, P HLTH BUILD IAQ 97, V2, P453; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; *COMM ASS ASTHM IN, 1999, CLEAR AIR ASTHM IND; Dales R, 1998, ARCH ENVIRON HEALTH, V53, P190; *DIV RESP DIS STUD, 1984, MMWR-MORBID MORTAL W, V33, P506; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; Drinka PJ, 1996, J AM GERIATR SOC, V44, P910; *EN INF ADM, 1998, DOEEIA062595; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; Fireman P, 1997, ALLERGY ASTHMA PROC, V18, P63, DOI 10.2500/108854197778605482; Fisk WJ, 1997, INDOOR AIR, V7, P158, DOI 10.1111/j.1600-0668.1997.t01-1-00002.x; Fisk WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; Fisk WJ, 2000, INDOOR AIR QUALITY H, P41; GARIBALDI RA, 1985, AM J MED, V78, P32, DOI 10.1016/0002-9343(85)90361-4; HALL JD, 1998, P IAQ 98 US ASHRAE S; HARVING H, 1991, ALLERGY, V46, P33, DOI 10.1111/j.1398-9995.1991.tb00647.x; HEDGE A, 1995, ERGONOMICS, V38, P260, DOI 10.1080/00140139508925103; Heschong Mahone Group, 1999, DAYL SCH INV REL DAY; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; HUSMAN T, 1993, P 6 INT C IND AIR QU, V1, P171; INGRAM JM, 1993, IMMUNOL ALLERGY CLIN, V13, P785; *IPMVP IEQ COMM, 1999, IND ENV QUAL INTRO L; JAAKKOLA JJK, 1995, OCCUP ENVIRON MED, V52, P709; JAAKKOLA JJK, 1995, EUR J EPIDEMIOL, V11, P213, DOI 10.1007/BF01719490; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; KATZEV R, 1992, ENVIRON BEHAV, V24, P759, DOI 10.1177/0013916592246004; KOSKINEN O, 1995, INDOOR AIR, V5, P3, DOI 10.1111/j.1600-0668.1995.t01-3-00002.x; Koskinen OM, 1997, INDOOR AIR, V7, P262, DOI 10.1111/j.1600-0668.1997.00005.x; KRONER WM, 1992, P IND ENV PROD JUN 2; LANGMUIR AD, 1948, AM J HYG, V48, P240; MCMENAMIN P, 1995, CHRONIC AIRWAY DIS C; Mendell MJ, 1993, INDOOR AIR, V3, P227, DOI 10.1111/j.1600-0668.1993.00003.x; Menzies D, 1997, ARCH ENVIRON HEALTH, V52, P360; Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107; Menzies D, 1998, J ALLERGY CLIN IMMUN, V101, P38, DOI 10.1016/S0091-6749(98)70191-5; MILTON DK, 2000, IN PRESS INDOOR AIR, V10; Myhrvold A., 1997, P HLTH BUILD IAQ 199, V1, P81; Myhrvold A. N., 1996, P IND AIR 96 7 INT C, P369; *NATL EL MAN ASS, 1989, LIGHT HUM PERF REV; NELSON NA, 1995, SCAND J WORK ENV HEA, V21, P51; *NEW YORK STAT COM, 1923, VENTILATION REPORT N, pCH23; NUNES F, 1993, P 6 INT C IND AIR QU, V1, P53; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1994, ANN ALLERGY, V72, P381; POLLART SM, 1987, PRIMARY CARE, V14, P591; Pope A. M., 1993, INDOOR ALLERGENS ASS; PRELLER L, 1990, P IND AIR 90 OTT CAN, V1, P227; RAPPAPORT S, 1998, MMWR-MORBID MORTAL W, V47, P1022; RAW GJ, 1990, P 5 INT C IND AIR QU, V1, P231; RICHARDS AL, 1993, AM J PUBLIC HEALTH, V83, P1326, DOI 10.2105/AJPH.83.9.1326; Romm J. J., 1994, LEAN CLEAN MANAGEMEN; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; SIEBER WK, 1996, P IND AIR 96 7 INT C, V2, P901; SMITH AP, 1990, PHILOS T ROY SOC B, V327, P519, DOI 10.1098/rstb.1990.0095; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; SMITH JL, 1982, J THEOR SOC BEHAV, V12, P29, DOI 10.1111/j.1468-5914.1982.tb00436.x; SMITH MD, 1997, BUS HLTH         OCT, P47; [Anonymous], 1979, J ILLUMINATING ENG S; SUNDELL J, 1994, INDOOR AIR S, V2, P1; TINKER MA, 1952, AM J PSYCHOL, V65, P600, DOI 10.2307/1418042; TRAYNOR GW, 1993, P IND AIR 93 HELS 6, V3, P595; US Bureau of the Census, 1997, STAT ABSTR US 1997; *US DEP HHS, 1994, DHHS PUB; US Environmental Protection Agency (EPA), 1989, EPA400189001C; Veitch JA, 1998, J ILLUM ENG SOC, V27, P107; VEITCH JA, 1991, J ENVIRON PSYCHOL, V11, P87, DOI 10.1016/S0272-4944(05)80007-6; VEITCH JA, 1990, J ENVIRON PSYCHOL, V10, P209, DOI 10.1016/S0272-4944(05)80096-9; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARGOCKI P, 1998, 9803 TU DENM CENT IN; WARSHAUER DM, 1989, AM J EPIDEMIOL, V129, P319; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WOODS JE, 1989, OCCUP MED, V4, P753; WOODS JE, 1987, 4TH P INT C IND AIR, V2, P464; WYON DP, 1979, SCAND J WORK ENV HEA, V5, P352; Wyon DP, 1996, P IND AIR 96 I PUBL, V1, P1067; Wyon D., 1996, P IAQ 96 PATHS BETT, P5; Wyon D, 1993, P INDOOR AIR 93, V6, P3	84	148	153	4	56	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	1056-3466			ANNU REV ENERG ENV	Annu. Rev. Energ. Environ.		2000	25						537	566		10.1146/annurev.energy.25.1.537		30	Energy & Fuels; Engineering, Environmental	Energy & Fuels; Engineering	396EZ	WOS:000166624500016		
J	Willart, MAM; Deswarte, K; Pouliot, P; Braun, H; Beyaert, R; Lambrecht, BN; Hammad, H				Willart, Monique A. M.; Deswarte, Kim; Pouliot, Philippe; Braun, Harald; Beyaert, Rudi; Lambrecht, Bart N.; Hammad, Hamida			Interleukin-1 alpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							THYMIC STROMAL LYMPHOPOIETIN; ADAPTIVE IMMUNE-RESPONSES; DENDRITIC CELL MATURATION; NF-KAPPA-B; T-CELLS; AIRWAY INFLAMMATION; TH2 RESPONSES; SEVERE ASTHMA; IN-VIVO; MICE	House dust mite (HDM) is one of the most common allergens worldwide. In this study, we have addressed the involvement of IL-1 in the interaction between HDM and the innate immune response driven by lung epithelial cells (ECs) and dendritic cells (DCs) that leads to asthma. Mice lacking IL-1R on radioresistant cells, but not hematopoietic cells, failed to mount a Th2 immune response and did not develop asthma to HDM. Experiments performed in vivo and in isolated air-liquid interface cultures of bronchial ECs showed that TLR4 signals induced the release of IL-1 alpha, which then acted in an autocrine manner to trigger the release of DC-attracting chemokines, GM-CSF, and IL-33. Consequently, allergic sensitization to HDM was abolished in vivo when IL-1 alpha, GM-CSF, or IL-33 was neutralized. Thymic stromal lymphopoietin (TSLP) became important only when high doses of allergen were administered. These findings put IL-1 alpha upstream in the cytokine cascade leading to epithelial and DC activation in response to inhaled HDM allergen.	[Willart, Monique A. M.; Deswarte, Kim; Pouliot, Philippe; Lambrecht, Bart N.; Hammad, Hamida] Univ Ghent VIB, Dept Mol Biomed Res, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium; [Braun, Harald; Beyaert, Rudi] Univ Ghent VIB, Dept Mol Biomed Res, Unit Mol Signal Transduct Inflammat, B-9000 Ghent, Belgium; [Willart, Monique A. M.; Deswarte, Kim; Pouliot, Philippe; Lambrecht, Bart N.; Hammad, Hamida] Univ Ghent, Dept Resp Med, B-9000 Ghent, Belgium; [Braun, Harald; Beyaert, Rudi] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, NL-3015 GE Rotterdam, Netherlands	Hammad, H (reprint author), Univ Ghent VIB, Dept Mol Biomed Res, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium.	hamida.hammad@ugent.be	Beyaert, Rudi/B-2589-2009; Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834	Flemish Organization for Scientific Research (FWO); European Research Council; Ghent University; National Institutes of Health [5R21AI083690-02]; FWO	B.N. Lambrecht is a recipient of an Odysseus Grant of the Flemish Organization for Scientific Research (FWO) and a recipient of a European Research Council Consolidator grant and a Ghent University Multidisciplinary Research Partnership grant (Group-ID). H. Hammad and B.N. Lambrecht are supported by National Institutes of Health grant number 5R21AI083690-02. H. Hammad is a recipient of an FWO program grant. B.N. Lambrecht is a recipient of a GOA Concerted Research Initiative from Ghent University.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barrett NA, 2009, J IMMUNOL, V182, P1119; Ben-Sasson SZ, 2009, P NATL ACAD SCI USA, V106, P7119, DOI 10.1073/pnas.0902745106; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Bleck B, 2006, J IMMUNOL, V176, P7431; Botelho FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028457; Cates EC, 2004, J IMMUNOL, V173, P6384; Caucig P, 2010, INT ARCH ALLERGY IMM, V152, P303, DOI 10.1159/000288283; Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603; Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612; Eiwegger T, 2011, EUR J IMMUNOL, V41, P1535, DOI 10.1002/eji.201141668; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Headley MB, 2009, J IMMUNOL, V182, P1641; Hurst SD, 2002, J IMMUNOL, V169, P443; Joosten LAB, 2009, ARTHRITIS RHEUM, V60, P3651, DOI 10.1002/art.25006; Kashyap M, 2011, J IMMUNOL, V187, P1207, DOI 10.4049/jimmunol.1100355; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Kool M, 2011, IMMUNITY, V34, P627, DOI 10.1016/j.immuni.2011.04.012; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lee HC, 2008, J IMMUNOL, V181, P5189; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Lei LY, 2011, J IMMUNOL, V186, P2254, DOI 10.4049/jimmunol.1002503; Lewkowich IP, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-122; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; MARINI M, 1991, AM J RESP CELL MOL, V4, P519; MATTOLI S, 1990, AM J PHYSIOL, V259, pL320; Mayer AK, 2008, EUR J IMMUNOL, V38, P1689, DOI 10.1002/eji.200737936; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; STANLEY E, 1994, P NATL ACAD SCI USA, V91, P5592, DOI 10.1073/pnas.91.12.5592; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Wills-Karp M, 2010, CURR OPIN IMMUNOL, V22, P777, DOI 10.1016/j.coi.2010.10.011; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	52	147	147	2	24	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	JUL 30	2012	209	8					1505	1517		10.1084/jem.20112691		13	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	982BK	WOS:000307016500013	22802353	
J	Mackay, D; Haw, S; Ayres, JG; Fischbacher, C; Pell, JP				Mackay, Daniel; Haw, Sally; Ayres, Jon G.; Fischbacher, Colin; Pell, Jill P.			Smoke-free Legislation and Hospitalizations for Childhood Asthma.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CROSS-SECTIONAL SURVEY; SECONDHAND SMOKE; 2ND-HAND SMOKE; EXPOSURE; SCOTLAND; IMPLEMENTATION; CHILDREN; HEALTH	Background: Previous studies have shown that after the adoption of comprehensive smoke-free legislation, there is a reduction in respiratory symptoms among workers in bars. However, it is not known whether respiratory disease is also reduced among people who do not have occupational exposure to environmental tobacco smoke. The aim of our study was to determine whether the ban on smoking in public places in Scotland, which was initiated in March 2006, influenced the rate of hospital admissions for childhood asthma. Methods: Routine hospital administrative data were used to identify all hospital admissions for asthma in Scotland from January 2000 through October 2009 among children younger than 15 years of age. A negative binomial regression model was fitted, with adjustment for age group, sex, quintile of socioeconomic status, urban or rural residence, month, and year. Tests for interactions were also performed. Results: Before the legislation was implemented, admissions for asthma were increasing at a mean rate of 5.2% per year (95% confidence interval [CI], 3.9 to 6.6). After implementation of the legislation, there was a mean reduction in the rate of admissions of 18.2% per year relative to the rate on March 26, 2006 (95% CI, 14.7 to 21.8; P<0.001). The reduction was apparent among both preschool and school-age children. There were no significant interactions between hospital admissions for asthma and age group, sex, urban or rural residence, region, or quintile of socioeconomic status. Conclusions: In Scotland, passage of smoke-free legislation in 2006 was associated with a subsequent reduction in the rate of respiratory disease in populations other than those with occupational exposure to environmental tobacco smoke. (Funded by NHS Health Scotland.) N Engl J Med 2010;363:1139-45.	[Mackay, Daniel; Pell, Jill P.] Univ Glasgow, Sect Publ Hlth, Glasgow G12 8RZ, Lanark, Scotland; [Haw, Sally] Scottish Collaborat Publ Hlth Res Policy, Edinburgh, Midlothian, Scotland; [Ayres, Jon G.] Univ Birmingham, Inst Occupat & Environm Med, Birmingham, W Midlands, England; [Fischbacher, Colin] NHS Natl Serv, Informat Serv Div, Edinburgh, Midlothian, Scotland	Pell, JP (reprint author), Univ Glasgow, Sect Publ Hlth, Rm 305,1 Lilybank Gardens, Glasgow G12 8RZ, Lanark, Scotland.	j.pell@clinmed.gla.ac.uk			NHS Health Scotland	Supported by a project grant from NHS Health Scotland.	Akhtar PC, 2009, TOB CONTROL, V18, P409, DOI 10.1136/tc.2009.030627; Akhtar PC, 2007, BRIT MED J, V335, P545, DOI 10.1136/bmj.39311.550197.AE; Akhtar PC, 2010, J EPIDEMIOL COMMUN H, V64, P341, DOI 10.1136/jech.2008.084178; Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; Ashley MJ, 1998, TOB CONTROL, V7, P61; Ayres JG, 2009, OCCUP ENVIRON MED, V66, P339, DOI 10.1136/oem.2008.040311; Baena-Cagnani CE, 2009, CURR OPIN ALLERGY CL, V9, P136, DOI 10.1097/ACI.0b013e3283294038; Black C., 2009, SCOTTISH SCH ADOLESC; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Haw SJ, 2007, BRIT MED J, V335, P549, DOI 10.1136/bmj.39315.670208.47; HERMAN PM, 2010, AM J PUBLIC HLT 0513; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1902, DOI 10.1016/j.jacc.2009.10.004; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; Office of Environmental Health Hazard Assessment, 2005, HLTH EFF EXP ENV TOB; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; Scottish Government, 2009, SCOTL PEOPL ANN REP; Semple S, 2007, ANN OCCUP HYG, V51, P571, DOI 10.1093/annhyg/mem044; Semple S, 2007, TOB CONTROL, V16, P127, DOI 10.1136/tc.2006.018119; Vork KL, 2007, ENVIRON HEALTH PERSP, V115, P1394, DOI 10.1289/ehp.10155	20	147	155	0	13	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 16	2010	363	12					1139	1145		10.1056/NEJMoa1002861		7	Medicine, General & Internal	General & Internal Medicine	649TD	WOS:000281795800008	20843248	
J	Hackett, TL; Warner, SM; Stefanowicz, D; Shaheen, F; Pechkovsky, DV; Murray, LA; Argentieri, R; Kicic, A; Stick, SM; Bai, TR; Knight, DA				Hackett, Tillie-Louise; Warner, Stephanie Mary; Stefanowicz, Dorota; Shaheen, Furquan; Pechkovsky, Dmitri V.; Murray, Lynne A.; Argentieri, Rochelle; Kicic, Anthony; Stick, Stephen M.; Bai, Tony R.; Knight, Darryl A.			Induction of Epithelial-Mesenchymal Transition in Primary Airway Epithelial Cells from Patients with Asthma by Transforming Growth Factor-beta 1	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; epithelial-mesenchymal transition; transforming growth factor-beta 1; epithelium	GROWTH-FACTOR-BETA; RETICULAR BASEMENT-MEMBRANE; ACTIVATED PROTEIN-KINASE; PULMONARY-FIBROSIS; EXPRESSION; MOUSE; LUNG; SMAD; TRANSDIFFERENTIATION; TGF-BETA-1	Rationale Airway remodeling in asthma is associated with the accumulation of fibroblasts, the primary cell responsible for synthesis and secretion of extracellular matrix proteins. The process by which the number of fibroblasts increases in asthma is poorly understood, but epithelial-mesenchymal transition (EMT) may play a significant role. Objectives: To evaluate whether EMT occurs in primary airway epithelial cells (AECs), the mechanisms involved, and if this process is altered in asthmatic AECs. Methods: AECs were obtained from subjects with asthma (n = 8) and normal subjects without asthma (n = 10). Monolayer and air-liquid interface-AEC (ALI-AEC) cultures were treated with transforming growth factor (TGF)-beta 1 (10 ng/ml) for 72 hours and assayed for mesenchymal and epithelial markers using quantitative polymerase chain reaction, confocal microscopy, and immunoblot. The involvement of BMP-7, Smad3, and MAPK-mediated signaling were also evaluated. Measurements and Main Results: TGF-beta 1-induced EMT in AEC monolayers derived from subjects with asthma and normal donors. EMT was characterized by changes in cell morphology, increased expression of mesenchymal markers EDA-fibronectin, vimentin, alpha-smooth muscle actin, and collagen-1, and loss of epithelial markers E-cadherin and zonular occludin-1. Inhibition of TGF-beta 1-induced signaling with Smad3-inhibiting siRNA or TGF-beta 1-neutralizing antibodies prevented and reversed EMT, respectively, whereas BMP-7 had no effect. In ALI-AEC cultures derived from normal subjects, EMT was confined to basally situated cells, whereas in asthmatic ALI-AEC cultures EMT was widespread throughout the epithelium. Conclusions: TGF-beta 1 induces EMT in a Smad3-dependent manner in primary AECs. However, in asthmatic-derived ALI-AEC cultures, the number of cells undergoing EMT is greater. These findings support the hypothesis that epithelial repair in asthmatic airways is dysregulated.	[Hackett, Tillie-Louise; Warner, Stephanie Mary; Stefanowicz, Dorota; Shaheen, Furquan; Pechkovsky, Dmitri V.; Bai, Tony R.; Knight, Darryl A.] St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada; [Hackett, Tillie-Louise; Pechkovsky, Dmitri V.; Knight, Darryl A.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Murray, Lynne A.; Argentieri, Rochelle] Centocor Ltd, Dept Immunobiol, Radnor, PA USA; [Kicic, Anthony; Stick, Stephen M.] Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia; [Kicic, Anthony; Stick, Stephen M.] Univ Western Australia, Sch Pediat & Child Hlth, Nedlands, WA 6009, Australia; [Stick, Stephen M.] Telethon Inst Child Hlth Res, Subiaco, WA, Australia	Hackett, TL (reprint author), St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Dis, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	thackett@mrl.ubc.ca	Stick, Stephen/O-5683-2014	Pechkovsky, Dmitri/0000-0001-8908-3444	Thomas Abraham at The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research; Departments of Pathology and Laboratory Medicine; The University of British Columbia-St. Paul's Hospital, Vancouver, British Columbia, Canada	Images were generated with the help of Thomas Abraham at The James Hogg iCAPTURE Centre for Cardiovascular and Pulmonary Research, Departments of Pathology and Laboratory Medicine, The University of British Columbia-St. Paul's Hospital, Vancouver, British Columbia, Canada. The imaging facility is CFI funded.	Ando S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-31; Bai TR, 2005, CLIN SCI, V108, P463; Bakin AV, 2002, J CELL SCI, V115, P3193; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bates RC, 2003, MOL BIOL CELL, V14, P1790, DOI 10.1091/mbc.E02-09-0583; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Daniely Y, 2004, AM J PHYSIOL-CELL PH, V287, pC171, DOI 10.1152/ajpcell.00226.2003; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Ellenrieder V, 2001, CANCER RES, V61, P4222; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Forino M, 2006, INT J EXP PATHOL, V87, P197, DOI 10.1111/j.1365-2613.2006.00479.x; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Greiling D, 1997, J CELL SCI, V110, P861; Hackett TL, 2008, STEM CELLS, V26, P2576, DOI 10.1634/stemcells.2008-0171; HACKETT TL, 2008, AM J RESP CRIT CARE, V177, pA97; Hajj R, 2007, J Pathol, V211, P340, DOI 10.1002/path.2118; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Huebener P, 2008, J IMMUNOL, V180, P2625; Kaimori A, 2007, J BIOL CHEM, V282, P22089, DOI 10.1074/jbc.M700998200; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; KNOX P, 1986, J CELL BIOL, V102, P2318, DOI 10.1083/jcb.102.6.2318; Kojima T, 2008, LIVER INT, V28, P534, DOI 10.1111/j.1478-3231.2007.01631.x; Leir SH, 2000, AM J PHYSIOL-LUNG C, V278, pL1129; Liu YH, 2004, J AM SOC NEPHROL, V15, P1, DOI 10.1097/01.ASN.0000106015.29070.E7; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; McDowell N, 2001, INT J DEV BIOL, V45, P199; Molloy EL, 2008, GROWTH FACTORS, V26, P12, DOI 10.1080/08977190801987166; Murray LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004039; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pechkovsky DV, 2008, J BIOL CHEM, V283, P12898, DOI 10.1074/jbc.M708226200; Ross KR, 2007, CELL SIGNAL, V19, P923, DOI 10.1016/j.cellsig.2006.11.008; Saika S, 2004, AM J PATHOL, V164, P651, DOI 10.1016/S0002-9440(10)63153-7; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Sato M, 2003, J CLIN INVEST, V112, P1486, DOI 10.1172/JCI200319270; Schramek H, 2003, AM J PHYSIOL-CELL PH, V285, pC652, DOI 10.1152/ajpcell.00463.2002; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; TURLEY EA, 1992, CANCER METAST REV, V11, P21, DOI 10.1007/BF00047600; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.E04-08-0658; Ward C, 2005, THORAX, V60, P865, DOI 10.1136/thx.2005.043026; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Woods AJ, 2004, EMBO J, V23, P2531, DOI 10.1038/sj.emboj.7600267; Wu Z, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-1; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zavadil J, 2001, P NATL ACAD SCI USA, V98, P6686, DOI 10.1073/pnas.111614398; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zeisberg M, 2003, AM J PHYSIOL-RENAL, V285, pF1060, DOI 10.1152/ajprenal.00191.2002; Zeisberg M, 2003, NAT MED, V9, P964, DOI 10.1038/nm888	57	147	156	0	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2009	180	2					122	133		10.1164/rccm.200811-1730OC		12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	472EP	WOS:000268112500006	19406982	
J	Murcray, CE; Lewinger, JP; Gauderman, WJ				Murcray, Cassandra E.; Lewinger, Juan Pablo; Gauderman, W. James			Gene-Environment Interaction in Genome-Wide Association Studies	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article							BREAST-CANCER; AIR-POLLUTION; SUSCEPTIBILITY; RISK; ASTHMA; LOCI; REPLICATION; CHILDREN; SMOKING	It is a commonly held belief that most complex diseases (e.g., diabetes, asthma, cancer) are affected in part by interactions between genes and environmental factors. However, investigators conducting genome-wide association studies typically test for only the marginal effects of each genetic marker on disease. In this paper, the authors propose an efficient and easily implemented 2-step analysis of genome-wide association study data aimed at identifying genes involved in a gene-environment interaction. The procedure complements screening for marginal genetic effects and thus has the potential to uncover new genetic signals that have not been identified previously.	[Murcray, Cassandra E.; Lewinger, Juan Pablo; Gauderman, W. James] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA	Murcray, CE (reprint author), Univ So Calif, Dept Prevent Med, 1540 Alcazar St,CHP 222F, Los Angeles, CA 90089 USA.	murcray@usc.edu			NHGRI NIH HHS [P50 HG 002790-02, P50 HG002790]; NHLBI NIH HHS [5R01HL087680, 5R01HL61768, 5R01HL76647, R01 HL061768, R01 HL076647, R01 HL087680]; NIEHS NIH HHS [P01 ES009581, 5P01ES009581, 5P01ES011627, 5P30ES007048, 5R01ES014447, 5R01ES014708, P01 ES011627, P30 ES007048, R01 ES014447, R01 ES014708, T32 ES013678]; ORD VA [RD831861]; PHS HHS [R826708]		BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Browning BL, 2007, GENET EPIDEMIOL, V31, P365, DOI 10.1002/gepi.20216; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Easton DF, 2007, NATURE, V447, P1087, DOI 10.1038/nature05887; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J EPIDEMIOL, V155, P478, DOI 10.1093/aje/155.5.478; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Hunter DJ, 2007, NAT GENET, V39, P870, DOI 10.1038/ng2075; Ito H, 2004, CARCINOGENESIS, V25, P1395, DOI 10.1093/carcin/bgh153; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; Kraft P, 2007, HUM HERED, V63, P111, DOI 10.1159/000099183; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Millstein J, 2006, AM J HUM GENET, V78, P15, DOI 10.1086/498850; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; RISCH N, 1996, SCIENCE, V273, P1517; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Stern MC, 2002, CANCER EPIDEM BIOMAR, V11, P1004; Van Steen K, 2005, NAT GENET, V37, P683, DOI 10.1038/ng1582; van der Vaart A. W., 1998, ASYMPTOTIC STAT; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364; Zhao JY, 2006, GENETICS, V174, P1529, DOI 10.1534/genetics.106.060491	24	147	154	2	12	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JAN 15	2009	169	2					219	226		10.1093/aje/kwn353		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	395IQ	WOS:000262518200013	19022827	
J	D'Amato, G; Liccardi, G; D'Amato, M; Holgate, S				D'Amato, G; Liccardi, G; D'Amato, M; Holgate, S			Environmental risk factors and allergic bronchial asthma	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review						air pollution; bronchial asthma; pollen allergy; respiratory allergy; thunderstorm-associated asthma; urban air pollution	OUTDOOR AIR-POLLUTION; THUNDERSTORM-ASSOCIATED ASTHMA; RESPIRATORY HEALTH SURVEY; DIESEL EXHAUST PARTICLES; FINE-PARTICULATE MATTER; GRASS-POLLEN ALLERGEN; PPM NITROGEN-DIOXIDE; OZONE EXPOSURE; PULMONARY-FUNCTION; SULFUR-DIOXIDE	The prevalence of allergic respiratory diseases such as bronchial asthma has increased in recent years, especially in industrialized countries. A change in the genetic predisposition is an unlikely cause of the increase in allergic diseases because genetic changes in a population require several generations. Consequently, this increase may be explained by changes in environmental factors, including indoor and outdoor air pollution. Over the past two decades, there has been increasing interest in studies of air pollution and its effects on human health. Although the role played by outdoor pollutants in allergic sensitization of the airways has yet to be clarified, a body of evidence suggests that urbanization, with its high levels of vehicle emissions, and a westernized lifestyle are linked to the rising frequency of respiratory allergic diseases observed in most industrialized countries, and there is considerable evidence that asthmatic persons are at increased risk of developing asthma exacerbations with exposure to ozone, nitrogen dioxide, sulphur dioxide and inhalable particulate matter. However, it is not easy to evaluate the impact of air pollution on the timing of asthma exacerbations and on the prevalence of asthma in general. As concentrations of airborne allergens and air pollutants are frequently increased contemporaneously, an enhanced IgE-mediated response to aeroallergens and enhanced airway inflammation could account for the increasing frequency of allergic respiratory allergy and bronchial asthma. Pollinosis is frequently used to study the interrelationship between air pollution and respiratory allergy. Climatic factors (temperature, wind speed, humidity, thunderstorms, etc) can affect both components (biological and chemical) of this interaction. By attaching to the surface of pollen grains and of plant-derived particles of paucimicronic size, pollutants could modify not only the morphology of these antigen-carrying agents but also their allergenic potential. In addition, by inducing airway inflammation, which increases airway permeability, pollutants overcome the mucosal barrier and could be able to 'prime' allergen-induced responses. There are also observations that a thunderstorm occurring during pollen season can induce severe asthma attacks in pollinosis patients. After rupture by thunderstorm, pollen grains may release part of their cytoplasmic content, including inhalable, allergen-carrying paucimicronic particles.	High Special Hosp A Cardarelli, Div Pneumol Allergol, Dept Chest Dis, I-80121 Naples, Italy; Southampton Gen Hosp, Resp Cell & Mol Biol Res Div, Southampton SO9 4XY, Hants, England	D'Amato, G (reprint author), High Special Hosp A Cardarelli, Div Pneumol Allergol, Dept Chest Dis, Via Rione Sirignano 10, I-80121 Naples, Italy.	gdamato@qubisoft.it	D'Amato, Maria/H-3074-2012	D'Amato, Maria/0000-0002-5906-5701			ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; ADAMS WC, 1983, J APPL PHYSIOL, V55, P805; *AM THOR SOC, 1996, HLTH EFFECTS OUTDO 2, V153, P477; *AMB IT, 2001, RAPP STAT PAES; Anderson M, 1994, J AEROSOL SCI, V25, P567; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; BALMES JR, 1987, AM REV RESPIR DIS, V136, P1117; BALMES JR, 1993, ENVIRON HEALTH PERSP, V101, P219, DOI 10.2307/3431683; Balmes J. R., 1997, RES REP HLTH EFF I, V78, P1; BARRY CC, 1994, ENVIRONMENT, V36, P5; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; BATES DV, 1983, CAN J PUBLIC HEALTH, V74, P117; BAUER MA, 1986, AM REV RESPIR DIS, V134, P1203; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BECKETT WS, 1985, J APPL PHYSIOL, V59, P1879; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Bernard SM, 2001, ENVIRON HEALTH PERSP, V109, P199, DOI 10.2307/3435010; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Brunekreef B, 2000, LANCET, V355, P1517, DOI 10.1016/S0140-6736(00)02168-1; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Cacciola RR, 2002, ALLERGY, V57, P281, DOI 10.1034/j.1398-9995.2002.1r3315.x; Celenza A, 1996, BRIT MED J, V312, P604; CHAPMAN MD, 1998, ENCY IMMUNOLOGY, P64; CHEN LL, 1995, AM J RESP CRIT CARE, V151, pA27; CHRISTIAN DL, 1996, AM J RESP CRIT CARE, V153, pA699; Churg A, 1997, AM J RESP CRIT CARE, V155, P2109; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; COLERIDGE JCG, 1993, J APPL PHYSIOL, V74, P2345; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; COSTA DL, 1998, AM J RESP CRIT CARE, V157, pA880; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2002, EUR RESPIR J, V20, P763, DOI 10.1183/09031936.02.00401402; D'Amato G, 2002, CLIN EXP ALLERGY, V32, P1391, DOI 10.1046/j.1365-2745.2002.01519.x; D'AMATO G, 1981, Zeitschrift fuer Erkrankungen der Atmungsorgane, V157, P281; D'Amato G, 2001, ALLERGY, V56, P1109, DOI 10.1034/j.1398-9995.2001.00317.x; D'Amato G, 1998, PULM PHARMACOL THER, V11, P369, DOI 10.1006/pupt.1999.0159; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P566, DOI 10.1111/j.1365-2222.1994.tb00954.x; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; D'Amato G, 2000, MONALDI ARCH CHEST D, V6, P471; D'Amato G, 2004, DIET HUMAN IMMUNE FU, P397; DAMATO G, 2002, MONOGR EUR RESP SOC, V21, P7; D'Amato G, 2001, POLLENOSIS 2000 GLOB; DAMATO G, BMJ; Davidson AC, 1996, BRIT MED J, V312, P601; DAVIS GL, 1967, AUSTR J SCI, V30, P235; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; DEVLIN RB, 1993, AM REV RESPIR DIS, V147, pA71; DEVLIN VJ, 1991, J SPINAL DISORD, V4, P1; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; *DIES WORK GROUP, 1995, DIES EXH CRIT AN EM; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 1997, ENVIRON HEALTH PERSP, V105, P1285, DOI 10.2307/3433548; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Emberlin J., 1998, EUR RESPIR REV, V53, P164; FARRELL BP, 1979, AM REV RESPIR DIS, V119, P725; FERNANDEZCALDAS E, 1989, GRANA, V28, P205; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98; FOLINSBEE LJ, 1984, J APPL PHYSIOL, V57, P984; FOLINSBEE LJ, 1980, AM REV RESPIR DIS, V121, P431; FOXCROFT WJ, 1986, J APPL PHYSIOL, V61, P960; Frenguelli G., 1998, AEROBIOLOGIA, V14, P39, DOI 10.1007/BF02694593; GarciaOrtega P, 1997, MED CLIN-BARCELONA, V108, P677; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; GHIO AJ, 1993, AM J RESP CELL MOL, V8, P403; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; HACKNEY JD, 1977, J APPL PHYSIOL, V43, P82; HAZUCHA MJ, 1983, J APPL PHYSIOL, V54, P730; HERNANDO L, 1989, LANCET, V1, P502; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; HOLGUIN AH, 1985, EVALUATION SCI BASIS, P262; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HORSTMAN D, 1986, Toxicology and Industrial Health, V2, P289; Horstman DH, 1995, TOXICOL IND HEALTH, V11, P369; HORVATH SM, 1981, AM REV RESPIR DIS, V123, P496; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JENSEN J, 1989, ALLERGY, V44, P52, DOI 10.1111/j.1398-9995.1989.tb00446.x; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KREIT JW, 1989, J APPL PHYSIOL, V66, P217; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; LINN WS, 1987, AM REV RESPIR DIS, V136, P1127; LINN WS, 1986, ARCH ENVIRON HEALTH, V41, P292; Loddenkemper R, 2003, EUROPEAN LUNG WHITE; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MIKIHIROSIGE H, 1994, SEX PLANT REPROD, V7, P95; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOSHENIN V, 1987, J TOXICOL ENV HLTH, V22, P371; MURRAY V, 1994, BRIT MED J, V309, P131; NAUSS KM, DIESEL EXHAUST CRITI, V199, P13; Pacini E, 1993, PLANT SYST EVOL S, V7, P1, DOI DOI 10.1007/978-3-7091-6661-1_; PACKE GE, 1985, LANCET, V2, P199; PEDEN D, 1996, AM J RESP CRIT CARE, V153, pA700; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Pekkanen J, 2002, CIRCULATION, V106, P933, DOI 10.1161/01.CIR.0000027561.41736.3C; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; REIDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; ROGER LJ, 1990, TOXICOL IND HEALTH, V6, P155; ROSSI OVJ, 1993, THORAX, V30, P2; Rudell B, 1990, J AEROSOL SCI     S1, V21, P411; RUSZNAK C, 1996, THORAX, V344, P1668; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1187; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; SCHELEGLE ES, 1986, MED SCI SPORT EXER, V18, P408; SCHLESINGER RB, 1987, J TOXICOL ENV HEALTH, V20, P125; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHUMWAY RH, 1988, ENVIRON RES, V45, P224, DOI 10.1016/S0013-9351(88)80049-5; Smith KR, 1997, CHEM RES TOXICOL, V10, P828, DOI 10.1021/tx960164m; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; STOKINGER H E, 1956, AMA Arch Ind Health, V14, P158; Sullivan J, 2005, EPIDEMIOLOGY, V16, P41, DOI 10.1097/01.ede.0000147116.34813.56; Sullivan J, 2003, AM J EPIDEMIOL, V157, P501, DOI 10.1093/aje/kwg015; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Taylor PE, 2004, CLIN EXP ALLERGY, V34, P1591, DOI 10.1111/j.1365-2222.2004.02078.x; THURSTON GD, 1997, AM J RESP CRIT CARE, V155, pA426; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; VAGAGGINI B, 2002, AM J RESP CRIT CARE, V16, P1073; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; VIEGI G, 2002, EUR RESP MON, V7, P1; Vinckier S, 2001, ALLERGY, V56, P1129, DOI 10.1034/j.1398-9995.2001.00172.x; Wallis D. N., 1995, European Respiratory Journal, V8, p500S; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; WJST M, 1993, BRIT MED J, V307, P596; Wong GWK, 2004, CURR OPIN PULM MED, V10, P62, DOI 10.1097/00063198-200401000-00011; YANAI M, 1990, J APPL PHYSIOL, V68, P2267	162	147	153	3	37	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2005	35	9					1113	1124		10.1111/j.1365-2222.2005.02328.x		12	Allergy; Immunology	Allergy; Immunology	964SX	WOS:000231901900001	16164436	
J	van Strien, RT; Engel, R; Holst, O; Bufe, A; Eder, W; Waser, M; Braun-Fahrlander, C; Riedler, J; Nowak, D; von Mutius, E				van Strien, RT; Engel, R; Holst, O; Bufe, A; Eder, W; Waser, M; Braun-Fahrlander, C; Riedler, J; Nowak, D; von Mutius, E		ALEX Study Team	Microbial exposure of rural school children, as assessed by levels of N-acetyl-muramic acid in mattress dust, and its association with respiratory health	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						farming; allergy; asthma; peptidoglycan; muramic acid; microbial exposure; hygiene hypothesis	TANDEM MASS-SPECTROMETRY; ALLERGIC SENSITIZATION; ENDOTOXIN LEVELS; HAY-FEVER; FARMERS CHILDREN; ASTHMA; ENVIRONMENTS; AGE; DETERMINANTS; COMMUNITY	Background: Endotoxin exposure has been shown to be associated with a decreased prevalence of atopic sensitization and symptoms. Yet endotoxin represents only a part of the indoor microbial exposure. Muramic acid, a constituent of peptidoglycan, is present in gram-negative and gram-positive bacteria in the environment and may therefore serve as an additional marker of microbial exposure. Objective: To study the factors determining the level of indoor exposure to muramic acid/peptidoglycan, as well as its potential association with respiratory health. Methods: In 553 farm and nonfarm school children from Austria, Switzerland, and Germany, mattress dust muramic acid concentrations were determined, and health was assessed by using IgE measurements and questionnaire information. Results: The muramic acid concentration was found to be significantly higher in dust from farm children's mattresses than in dust from nonfarm children's mattresses (157 vs 131 ng/mg). Children with higher mattress dust muramic acid concentrations had a significantly lower prevalence of wheezing (odds ratio of highest vs lowest tertile of muramic acid concentration, 0.3; 95 % CI, 0.1-0.9), regardless of farming status and endotoxin exposure. The association for asthma was similar, and no association was found with atopic sensitization. Conclusion: Next to endotoxin, muramic acid provides us with an independent marker of microbial exposure. Unlike endotoxin, muramic acid was inversely associated with wheezing rather than with atopic sensitization.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Res Ctr Borstel, Div Struct Biochem, Leibniz Ctr Med & Biol Sci, Borstel, Germany; Ruhr Univ Bochum, Dept Expt Pneumol, D-4630 Bochum, Germany; Arizona Resp Ctr, Tucson, AZ USA; Inst Social & Prevent Med, Basel, Switzerland; Childrens Hosp, Salzburg, Austria; Inst Occupat & Environm Med, Munich, Germany	von Mutius, E (reprint author), Von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	erika.von.mutius@med.uni-muenchen.de					BLACK GE, 1994, ANAL CHEM, V66, P4171, DOI 10.1021/ac00095a010; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HEUMANN D, 1994, INFECT IMMUN, V62, P2715; Krahmer M, 1998, AM IND HYG ASSOC J, V59, P524, DOI 10.1202/0002-8894(1998)059<0524:TAVABL>2.0.CO;2; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Laitinen S, 2001, ANN AGR ENV MED, V8, P213; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Liu LJS, 2000, J AIR WASTE MANAGE, V50, P1957, DOI 10.1080/10473289.2000.10464225; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; MIELNICZUK Z, 1995, J CHROMATOGR B, V670, P167, DOI 10.1016/0378-4347(95)00152-9; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Saraf A, 1999, INDOOR AIR, V9, P219, DOI 10.1111/j.1600-0668.1999.00002.x; Sebastian A, 2003, APPL ENVIRON MICROB, V69, P3103, DOI 10.1128/AEM.69.6.3103-3109.2003; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, THORAX S1, V55, pS2; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; WEIDEMANN B, 1994, INFECT IMMUN, V62, P4709; Wickens K, 2003, INDOOR AIR, V13, P128, DOI 10.1034/j.1600-0668.2003.00187.x; Zhiping Wang, 1996, American Journal of Respiratory and Critical Care Medicine, V154, P1261	30	147	149	2	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					860	867		10.1016/j.jaci.2004.01.078		8	Allergy; Immunology	Allergy; Immunology	818UC	WOS:000221269000007	15131567	
J	Bernard, A; Carbonnelle, S; Michel, O; Higuet, S; de Burbure, C; Buchet, JP; Hermans, C; Dumont, X; Doyle, I				Bernard, A; Carbonnelle, S; Michel, O; Higuet, S; de Burbure, C; Buchet, JP; Hermans, C; Dumont, X; Doyle, I			Lung hyperpermeability and asthma prevalence in schoolchildren: unexpected associations with the attendance at indoor chlorinated swimming pools	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							CLARA CELL PROTEIN; RESPIRATORY SYMPTOMS; BRONCHIAL RESPONSIVENESS; NITROGEN TRICHLORIDE; SERUM; CHILDREN; CC16; DISINFECTANT; SWIMMERS; SMOKERS	Aims: To study whether exposure to nitrogen trichloride in indoor chlorinated pools may affect the respiratory epithelium of children and increase the risk of some lung diseases such as asthma. Methods: In 226 healthy children, serum surfactant associated proteins A and B (SP-A and SP-B), 16 kDa Clara cell protein (CC 16), and IgE were measured. Lung specific proteins were measured in the serum of 16 children and 13 adults before and after exposure to NCl3, in an indoor chlorinated pool. Relations between pool attendance and asthma prevalence were studied in 1881 children. Asthma was screened with the exercise induced bronchoconstriction test (EIB). Results: Pool attendance was the most consistent predictor of lung epithelium permeability. A positive dose-effect relation was found with cumulated pool attendance and serum SP-A and SP-B. Serum IgE. was unrelated to pool attendance, but correlated positively with lung hyperpermeability as assessed by serum SP-B. Changes in serum levels of lung proteins were reproduced in children and adults attending an indoor pool. Serum SP-A and SP-B were already significantly increased after one hour on the pool side without swimming. Positive EIB and total asthma prevalence were significantly correlated with cumulated pool attendance indices. Conclusions: Regular attendance at chlorinated pools by Young children is associated with an exposure dependent increase in lung epithelium permeability and increase in the risk of developing asthma especially in association with other risk factors. We therefore postulate that the increasing exposure of children to chlorination products in indoor pools might be an important cause of the rising incidence of childhood asthma and allergic diseases in industrialised countries. Further epidemiological studies should be undertaken to test this hypothesis.	Univ Catholique Louvain, Fac Med, Ind Toxicol Unit, B-1200 Brussels, Belgium; Free Univ Brussels, St Pierre Univ Hosp, Clin Allergol & Resp Dis, B-1000 Brussels, Belgium; Flinders Univ S Australia, Dept Human Physiol, Sch Med, Adelaide, SA 5001, Australia; Flinders Univ S Australia, Dept Crit Care Med, Sch Med, Adelaide, SA 5001, Australia	Bernard, A (reprint author), Univ Catholique Louvain, Toxicol Unit, 30-54 Clos Chapelle Aux Champs, B-1200 Brussels, Belgium.		BERNARD, Alfred/A-6511-2010	BERNARD, Alfred/0000-0003-3171-3743; michel, olivier/0000-0002-1528-1277			BARBEE SJ, 1983, AM IND HYG ASSOC J, V44, P145, DOI 10.1202/0002-8894(1983)044<0145:AITONT>2.3.CO;2; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P243, DOI 10.2307/3432380; Belsley D., 1980, REGRESSION DIAGNOSTI; BERNARD A, 1992, LANCET, V339, P1620, DOI 10.1016/0140-6736(92)91891-B; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Broeckaert F, 1999, LANCET, V353, P900, DOI 10.1016/S0140-6736(99)00540-1; Broeckaert F, 2000, CLIN EXP ALLERGY, V30, P469; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; DESCHAMPS D, 1994, CHEST, V105, P1895, DOI 10.1378/chest.105.6.1895; DOYLE IR, 1995, AM J RESP CRIT CARE, V152, P307; Doyle IR, 1997, AM J RESP CRIT CARE, V156, P1217; *EPA, 1994, CHLOR; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570; Fjellbirkeland Lars, 1995, Tidsskrift for den Norske Laegeforening, V115, P2051; GAGNAIRE F, 1994, J APPL TOXICOL, V14, P405, DOI 10.1002/jat.2550140604; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hermans C, 1998, CLIN CHIM ACTA, V272, P101, DOI 10.1016/S0009-8981(98)00006-0; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; HERY M, 1995, ANN OCCUP HYG, V39, P437; JESSEN HJ, 1988, Z GESAMTE HYG, V34, P248; JONES A, 1994, THORAX, V49, P757, DOI 10.1136/thx.49.8.757; Karnak I, 1996, CLIN PEDIATR, V35, P471, DOI 10.1177/000992289603500908; Laing IA, 2000, AM J RESP CRIT CARE, V161, P124; MARTINEZ TT, 1995, J TOXICOL-CLIN TOXIC, V33, P349; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; MUSTCHIN CP, 1979, THORAX, V34, P682, DOI 10.1136/thx.34.5.682; NAKAMURA TY, 1995, J CELL BIOL, V131, P509, DOI 10.1083/jcb.131.2.509; Nelson H S, 1998, Clin Cornerstone, V1, P57; Newman D J, 1994, Kidney Int Suppl, V47, pS20; PENNY PT, 1983, BRIT MED J, V287, P461; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; Priftanji A, 2001, LANCET, V358, P1426, DOI 10.1016/S0140-6736(01)06521-7; Ring PC, 2000, CLIN EXP ALLERGY, V30, P1085; Robin M, 2002, EUR RESPIR J, V20, P1152, DOI 10.1183/09031936.02.02042001; SCHRAUFSTATTER IU, 1990, J CLIN INVEST, V85, P554, DOI 10.1172/JCI114472; SCHULLERLEVIS G, 1994, ADV EXP MED BIOL, V35, P931; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Stewart G A, 1993, Pediatr Allergy Immunol, V4, P163, DOI 10.1111/j.1399-3038.1993.tb00087.x; Tanen DA, 1999, NEW ENGL J MED, V341, P848, DOI 10.1056/NEJM199909093411115; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597; WATT SJ, 1991, UNDERSEA BIOMED RES, V18, P347; WHO, 2000, GUID SAF RECR WAT EN, V2	45	147	152	1	16	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUN	2003	60	6					385	394		10.1136/oem.60.6.385		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	683LJ	WOS:000183149900002	12771389	
J	Leigh, R; Ellis, R; Wattie, J; Southam, DS; de Hoogh, M; Gauldie, J; O'Byrne, PM; Inman, MD				Leigh, R; Ellis, R; Wattie, J; Southam, DS; de Hoogh, M; Gauldie, J; O'Byrne, PM; Inman, MD			Dysfunction and remodeling of the mouse airway persist after resolution of acute allergen-induced airway inflammation	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; MILD ASTHMA; SUBEPITHELIAL FIBROSIS; INDUCED INCREASE; MURINE MODEL; HYPERRESPONSIVENESS; RESPONSIVENESS; HYPERREACTIVITY; METHACHOLINE; EOSINOPHILIA	The mechanisms underlying airway hyperresponsiveness remain unclear, although airway inflammation and remodeling are likely important contributing factors. We hypothesized that airway physiology would differ between mice subjected to brief or chronic allergen exposure, and that these differences would be associated with characteristic inflammatory markers and indices of airway remodeling. BALB/c mice were sensitized to ovalbumin and studied at several time points following brief or chronic allergen challenge protocols. By measuring airway responses to methacholine, we demonstrated increases in maximal inducible bronchoconstriction that persisted for 8 wk following either brief or chronic allergen challenge; we also observed increases in airway reactivity, although it was only in chronically challenged mice that these changes persisted beyond the resolution of allergen-induced inflammation. Using airway morphometry, we further demonstrated that increases in maximal bronchoconstriction were associated with increases in airway contractile tissue in both models, and that chronic, but not brief, allergen challenge resulted in subepithelial fibrosis. Our observations that different aspects of sustained airway dysfunction and remodeling persist beyond the resolution of acute inflammatory events support the concept that remodeling occurs as a consequence of allergic airway inflammation, and that these structural changes contribute independently to the persistence of airway hyperresponsiveness.	Firestone Inst Resp Hlth, St Josephs Healthcare, Dept Med, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Ctr Gene Therapeut, Dept Pathol, Hamilton, ON L8N 4A6, Canada	Inman, MD (reprint author), Firestone Inst Resp Hlth, St Josephs Healthcare, Dept Med, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.			O'Byrne, Paul/0000-0003-0979-281X			Boulet L P, 1998, Can Respir J, V5, P16; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROWN RH, 1995, J APPL PHYSIOL, V79, P1242; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; Busse WW, 2001, NEW ENGL J MED, V344, P350; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cockcroft DW, 1997, ASTHMA, P1253; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hogan SP, 1998, J IMMUNOL, V161, P1501; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lotvall J, 1998, THORAX, V53, P419; Ohno I, 1997, AM J RESP CELL MOL, V16, P212; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; ROCHE WR, 1989, LANCET, V1, P520; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Temelkovski J, 1998, THORAX, V53, P849; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Volgyesi GA, 2000, J APPL PHYSIOL, V89, P413; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Webb DC, 2000, J IMMUNOL, V165, P108; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; [Anonymous], NIH PUBLICATION	45	147	161	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	NOV	2002	27	5					526	535		10.1165/rcmb.2002-0048OC		10	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	614KW	WOS:000179189000002	12397011	
J	Bergmann, RL; Diepgen, TL; Kuss, O; Bergmann, KE; Kujat, J; Dudenhausen, JW; Wahn, U				Bergmann, RL; Diepgen, TL; Kuss, O; Bergmann, KE; Kujat, J; Dudenhausen, JW; Wahn, U		MAS-Study Grp	Breastfeeding duration is a risk factor for atopic eczema	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopic eczema; children; breastfeeding	COWS MILK ALLERGY; BREAST-FED INFANTS; DISEASE; CHILDHOOD; PROTEINS; EXPOSURE; IGE; AGE	Background The results of numerous studies on the influence of breastfeeding in the prevention of atopic disorders are often contradictory. One of the most important problems is confounding by other lifestyle factors. Objective The aim of the present study was to analyse the effect of any breastfeeding duration on the prevalence of atopic eczema in the first seven years of life taking into account other risk factors. Methods In an observational birth cohort study 1314 infants born in 1990 were followed-up for seven years. At 3, 6, 12, 18, 24 months and every year thereafter, parents were interviewed and filled in questionnaires, children were examined and blood was taken for in vitro allergy tests. Generalized Estimation Equations (GEE)-models were used to model risk factors for the prevalence of atopic eczema and for confounder adjustment Results Breastfeeding was carried out for longer if at least one parent had eczema, the mother was older, did not smoke in pregnancy, and the family had a high social status. The prevalence of atopic eczema in the first seven years increased with each year of age (OR 1.05; 95% CI 1.01-1.09 for each year), with each additional month of breastfeeding (1.03; 1.00-1.06 for each additional month), with a history of parental atopic eczema (2.06; 1.38-3.08), and if other atopic signs and symptoms appeared, especially specific sensitization (1.53; 1.25-1.88), and asthma (1.41; 1.07-1.85). Although breastfeeding should be recommended for all infants, it does not prevent eczema in children with a genetic risk. Conclusion Parental eczema is the major risk factor for eczema. But in this study, each month of breastfeeding also increased the risk.	Univ Hosp Rudolf Virchow, Charite, Dept Obstet, D-13353 Berlin, Germany; Univ Hosp Rudolf Virchow, Charite, Dept Pediat, D-13353 Berlin, Germany; Univ Heidelberg, Dept Clin Soc Med, D-6900 Heidelberg, Germany; Robert Koch Inst, D-1000 Berlin, Germany	Bergmann, RL (reprint author), Univ Hosp Rudolf Virchow, Charite, Dept Obstet, Augustenburger Pl 1, D-13353 Berlin, Germany.			Kuss, Oliver/0000-0003-3301-5869			Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann R L, 1993, Pediatr Allergy Immunol, V4, P130, DOI 10.1111/j.1399-3038.1993.tb00081.x; Bergmann RL, 2000, CLIN EXP ALLERGY, V30, P1740, DOI 10.1046/j.1365-2222.2000.00927.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BERGMANN RL, 1994, MONATSSCHR KINDERH, V142, P412; BJORKSTEN B, 1999, ALLERGY CLIN IMMUNOL, V104, P119; Bottcher MF, 2000, PEDIATR RES, V47, P157; Cantisani A, 1997, FEBS LETT, V412, P515, DOI 10.1016/S0014-5793(97)00828-4; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; deBoissieu D, 1997, ACTA PAEDIATR, V86, P1042; Duchen K, 1998, PEDIATR RES, V44, P478, DOI 10.1203/00006450-199810000-00003; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; Grulee CG, 1936, J PEDIATR-US, V9, P223, DOI 10.1016/S0022-3476(36)80058-4; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; HOWIE PW, 1990, BRIT MED J, V300, P11; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; JACOBSSON I, 1991, EUR J CLIN NUTR S1, V45, P29; Jarvinen KM, 2000, PEDIATR RES, V48, P457; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8; KOLETZKO B, 1999, PADIATRISCHE ALLERGO, P148; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; Ziegler A, 1998, BIOMETRICAL J, V40, P115, DOI 10.1002/(SICI)1521-4036(199806)40:2<115::AID-BIMJ115>3.0.CO;2-6	32	147	152	2	11	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2002	32	2					205	209		10.1046/j.1365-2222.2002.01274.x		5	Allergy; Immunology	Allergy; Immunology	537PM	WOS:000174767800011	11929483	
J	Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA				Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA		Natl Cooperative Inner City Asthma	Mouse allergen. II. The relationship of mouse allergen exposure to mouse sensitization and asthma morbidity in inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; indoor allergens; inner-city asthma; sensitization; asthma morbidity	DER-P-I; MITE; RISK; CHILDHOOD; CAT	Background: Although mouse allergen is known to cause occupational asthma in laboratory workers, its potential significance in home environments has never been studied. Objective: This study was designed to define the prevalence of mouse sensitivity and its relationship to mouse allergen exposure and disease activity in inner-city children with asthma, Methods: A subset Of 499 subjects from the National Cooperative Inner-City Asthma Study had dust samples adequate for mouse allergen analysis, as well as valid puncture skin test (PST) results, Data were analyzed to relate mouse allergen exposure and other risk factors to mouse sensitization and asthma morbidity, Results: Eighty-nine (18%) of the 499 children had a positive mouse skin test response, Children whose homes had mouse allergen levels above the median (1.60 mug/g) in the kitchen had a significantly higher rate of mouse sensitization (23% vs 11%, P = .007). Atopy was also significantly related to mouse sensitization, with 40% of those with more than 4 positive PST responses having mouse sensitivity compared with 4% of those with no other positive PST responses (P < .0001). When atopy and exposure were considered together, 53% of those with more than 4 positive PST responses and allergen levels above the median had a positive PST response to mouse allergen compared with 22% of those with more than 4 positive PST responses and allergen levels below the median (P < .0001). The relationship among mouse allergen exposure, sensitization, and any measures of asthma morbidity was not statistically significant, Conclusions: Mouse allergen may be an important indoor allergen in inner-city children with asthma, with exposure and atopy contributing to mouse sensitization.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat,Div Allergy & Immunol, Boston, MA USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD USA; New England Res Inst, Watertown, MA 02172 USA; Albert Einstein Sch Med, Bronx, NY USA; Childrens Mem Hosp, Chicago, IL 60614 USA; Cook Cty Hosp, Chicago, IL 60612 USA; Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Henry Ford Hosp, Detroit, MI 48202 USA; Wayne State Univ, Med Ctr, Detroit, MI 48202 USA; Mt Sinai Sch Med, New York, NY USA; Washington Univ, Sch Med, St Louis, MO USA; St Louis Univ, Sch Med, St Louis, MO USA; Howard Univ, Washington, DC 20059 USA; NIAID, Program Off, Bethesda, MD 20892 USA; Ctr Occupat Environm Hlth, Irvine, CA USA; New England Res Inst, Watertown, MA 02172 USA	Wood, RA (reprint author), Johns Hopkins Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007]; NIEHS NIH HHS [ES09606]		AUNYER J, 1997, EUR RESPIR J, V10, P2490; BERKOWITZ RB, 1992, J ALLERGY CLIN IMMUN, V90, P979, DOI 10.1016/0091-6749(92)90471-D; BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KUHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; Mitchell H, 1997, PEDIATR PULM, V24, P237; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Phipatanakul W, 1999, J ALLERGY CLIN IMMUN, V103, pS235; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; POLLART S, 1995, J ALLERGY CLIN IMMUN, V87, P505; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L	23	147	148	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1075	1080				6	Allergy; Immunology	Allergy; Immunology	384ER	WOS:000165930300008	11112889	
J	Friedberg, MW; Schneider, EC; Rosenthal, MB; Volpp, KG; Werner, RM				Friedberg, Mark W.; Schneider, Eric C.; Rosenthal, Meredith B.; Volpp, Kevin G.; Werner, Rachel M.			Association Between Participation in a Multipayer Medical Home Intervention and Changes in Quality, Utilization, and Costs of Care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LONGITUDINAL DATA-ANALYSIS; STRUCTURAL CAPABILITIES; TRANSFORMATION; EFFICIENCY; MODELS; TRIAL; WILL	IMPORTANCE Interventions to transform primary care practices into medical homes are increasingly common, but their effectiveness in improving quality and containing costs is unclear. OBJECTIVE To measure associations between participation in the Southeastern Pennsylvania Chronic Care Initiative, one of the earliest and largest multipayer medical home pilots conducted in the United States, and changes in the quality, utilization, and costs of care. DESIGN, SETTING, AND PARTICIPANTS Thirty-two volunteering primary care practices participated in the pilot (conducted from June 1, 2008, to May 31, 2011). We surveyed pilot practices to compare their structural capabilities at the pilot's beginning and end. Using claims data from 4 participating health plans, we compared changes (in each year, relative to before the intervention) in the quality, utilization, and costs of care delivered to 64 243 patients who were attributed to pilot practices and 55 959 patients attributed to 29 comparison practices (selected for size, specialty, and location similar to pilot practices) using a difference-in-differences design. EXPOSURES Pilot practices received disease registries and technical assistance and could earn bonus payments for achieving patient-centered medical home recognition by the National Committee for Quality Assurance (NCQA). MAIN OUTCOMES AND MEASURES Practice structural capabilities; performance on 11 quality measures for diabetes, asthma, and preventive care; utilization of hospital, emergency department, and ambulatory care; standardized costs of care. RESULTS Pilot practices successfully achieved NCQA recognition and adopted new structural capabilities such as registries to identify patients overdue for chronic disease services. Pilot participation was associated with statistically significantly greater performance improvement, relative to comparison practices, on 1 of 11 investigated quality measures: nephropathy screening in diabetes (adjusted performance of 82.7% vs 71.7% by year 3, P<.001). Pilot participation was not associated with statistically significant changes in utilization or costs of care. Pilot practices accumulated average bonuses of $92 000 per primary care physician during the 3-year intervention. CONCLUSIONS AND RELEVANCE A multipayer medical home pilot, in which participating practices adopted new structural capabilities and received NCQA certification, was associated with limited improvements in quality and was not associated with reductions in utilization of hospital, emergency department, or ambulatory care services or total costs over 3 years. These findings suggest that medical home interventions may need further refinement.	[Friedberg, Mark W.; Schneider, Eric C.] RAND Corp, Boston, MA USA; [Friedberg, Mark W.; Schneider, Eric C.] Brigham & Womens Hosp, Div Gen Internal Med, Boston, MA 02115 USA; [Friedberg, Mark W.; Schneider, Eric C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Schneider, Eric C.; Rosenthal, Meredith B.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; [Volpp, Kevin G.; Werner, Rachel M.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA; [Volpp, Kevin G.] Univ Penn, Perelman Sch Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA; [Volpp, Kevin G.; Werner, Rachel M.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA; [Volpp, Kevin G.] Wharton Business Sch, Dept Hlth Care Management, Philadelphia, PA USA; [Volpp, Kevin G.] Penn Med Ctr Hlth Care Innovat, Philadelphia, PA USA	Friedberg, MW (reprint author), 20 Pk Plaza,Ste 920, Boston, MA 02116 USA.	mfriedbe@rand.org		Rosenthal, Meredith/0000-0003-3410-0184; Schneider, Eric/0000-0002-1132-5084	Commonwealth Fund; Aetna	This study was sponsored by the Commonwealth Fund and Aetna.	[Anonymous], PATIENT CENTERED MED; [Anonymous], 2007, JOINT PRINCIPLES OF; [Anonymous], IMPROVING PERFORMANC; Bitton A, 2010, J GEN INTERN MED, V25, P584, DOI 10.1007/s11606-010-1262-8; Boult C, 2011, ARCH INTERN MED, V171, P460, DOI 10.1001/archinternmed.2010.540; Buntin MB, 2004, J HEALTH ECON, V23, P525, DOI 10.1016/j.jhealeco.2003.10.005; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Clarke RMA, 2012, HEALTH AFFAIR, V31, P627, DOI 10.1377/hlthaff.2011.0908; Crabtree Benjamin F, 2010, Ann Fam Med, V8 Suppl 1, pS80, DOI 10.1370/afm.1107; Diedhiou A, 2010, MED CARE RES REV, V67, P450, DOI 10.1177/1077558710367735; Fifield J, 2013, J GEN INTERN MED, V28, P778, DOI 10.1007/s11606-013-2386-4; Flottemesch TJ, 2012, AM J MANAG CARE, V18, P677; Friedberg Mark W, 2009, Am J Manag Care, V15, pS291; Friedberg MW, 2009, ANN INTERN MED, V151, P456; Friedberg MW, 2009, J GEN INTERN MED, V24, P162, DOI 10.1007/s11606-008-0856-x; Gabbay RA, 2013, ANN FAM MED, V11, pS99, DOI 10.1370/afm.1473; Gabbay Robert A, 2011, Jt Comm J Qual Patient Saf, V37, P265; Gilfillan RJ, 2010, AM J MANAG CARE, V16, P607; Graubard BI, 1999, BIOMETRICS, V55, P652, DOI 10.1111/j.0006-341X.1999.00652.x; Hoff T, 2012, MED CARE RES REV, V69, P619, DOI 10.1177/1077558712447688; [Anonymous], THE BREAKTHROUGH SER; Jackson GL, 2013, ANN INTERN MED, V158, P169, DOI 10.7326/0003-4819-158-3-201302050-00579; Jaen Carlos Roberto, 2010, Ann Fam Med, V8 Suppl 1, pS57, DOI 10.1370/afm.1121; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McWilliams JM, 2013, HEALTH SERV RES, V48, P1526, DOI 10.1111/1475-6773.12032; National Committee for Quality Assurance, 2008, STANDARDS AND GUIDEL; Nutting PA, 2009, ANN FAM MED, V7, P254, DOI 10.1370/afm.1002; [Anonymous], OPTUM NORMALIZED PRI; [Anonymous], STATEMENTS OF SUPPOR; Peikes D, BUILDING THE EVIDENC; Peikes D, 2012, AM J MANAG CARE, V18, P105; Reid RJ, 2010, HEALTH AFFAIR, V29, P835, DOI 10.1377/hlthaff.2010.0158; Reid RJ, 2009, AM J MANAG CARE, V15, pE71; Roby DH, 2010, MED CARE RES REV, V67, P412, DOI 10.1177/1077558710368682; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Rosenthal MB, RECOMMENDED CORE MEA; Rosenthal MB, 2013, JAMA INTERN MED, V173, P1907, DOI 10.1001/jamainternmed.2013.10063; Rosenthal MB, 2010, MED CARE RES REV, V67, P476, DOI 10.1177/1077558710368412; Setodji Claude Messan, 2012, Health Serv Outcomes Res Methodol, V12, P62; Song Z, 2011, NEW ENGL J MED, V365, P909, DOI 10.1056/NEJMsa1101416; Werner RM, 2013, MED CARE, V51, P487, DOI 10.1097/MLR.0b013e31828d4d29; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	42	146	146	6	35	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 26	2014	311	8					815	825		10.1001/jama.2014.353		11	Medicine, General & Internal	General & Internal Medicine	AB4XQ	WOS:000331793700021	24570245	
J	Pulendran, B; Artis, D				Pulendran, Bali; Artis, David			New Paradigms in Type 2 Immunity	SCIENCE			English	Review							T-HELPER-CELL; THYMIC STROMAL LYMPHOPOIETIN; ANTIGEN-PRESENTING CELLS; DUST MITE ALLERGEN; RESPONSES IN-VIVO; DENDRITIC CELLS; EPITHELIAL-CELLS; INNATE IMMUNITY; IL-4 PRODUCTION; LYMPHOID-CELLS	Nearly half of the world's population harbors helminth infections or suffers from allergic disorders. A common feature of this population is the so-called "type 2 immune response," which confers protection against helminths, but also promotes pathologic responses associated with allergic inflammation. However, the mechanisms that initiate and control type 2 responses remain enigmatic. Recent advances have revealed a role for the innate immune system in orchestrating type 2 responses against a bewildering array of stimuli, from nanometer-sized allergens to 20-meter-long helminth parasites. Here, we review these advances and suggest that the human immune system has evolved multiple mechanisms of sensing such stimuli, from recognition of molecular patterns via innate immune receptors to detecting metabolic changes and tissue damage caused by these stimuli.	[Pulendran, Bali] Yerkes Natl Primate Res Ctr, Emory Vaccine Ctr, Dept Pathol, Atlanta, GA 30329 USA; [Artis, David] Univ Penn, Perelman Sch Med, Dept Microbiol, Philadelphia, PA 19104 USA; [Artis, David] Univ Penn, Perelman Sch Med, Inst Immunol, Philadelphia, PA 19104 USA	Pulendran, B (reprint author), Yerkes Natl Primate Res Ctr, Emory Vaccine Ctr, Dept Pathol, 954 Gatewood Rd, Atlanta, GA 30329 USA.	bpulend@emory.edu; dartis@mail.med.upenn.edu			NIH [U19AI090023, HHSN266200700006C, U54AI057157, R37AI48638, R37DK057665, U19AI057266, N01 AI50025, AI061570, AI087990, AI074878, AI083480, AI095466, AI095608]; Bill and Melinda Gates Foundation; Burroughs Wellcome Fund in Pathogenesis of Infectious Disease Award	Research in the Pulendran lab is supported by the NIH (grants U19AI090023, HHSN266200700006C, U54AI057157, R37AI48638, R37DK057665, U19AI057266, and N01 AI50025 to B.P.) and the Bill and Melinda Gates Foundation. Research in the Artis lab is supported by the NIH (grants AI061570, AI087990, AI074878, AI083480, AI095466, and AI095608 to D.A.) and the Burroughs Wellcome Fund Investigator in Pathogenesis of Infectious Disease Award (D.A.). We sincerely apologize to our colleagues that, owing to limitations of space, we were unable to cite many relevant references.	Agrawal S, 2003, J IMMUNOL, V171, P4984; Allen JE, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002003; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Chen F, 2012, NAT MED, V18, P260, DOI 10.1038/nm.2628; Coffman RL, 2010, IMMUNITY, V33, P492, DOI 10.1016/j.immuni.2010.10.002; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460; Fritz JH, 2007, IMMUNITY, V26, P445, DOI 10.1016/j.immuni.2007.03.009; Godefroy E, 2011, CANCER CELL, V19, P333, DOI 10.1016/j.ccr.2011.01.037; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Hotez PJ, 2007, NEW ENGL J MED, V357, P1018, DOI 10.1056/NEJMra064142; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kaiser F, 2009, J EXP MED, V206, P1863, DOI 10.1084/jem.20091059; Karasuyama H, 2011, ANNU REV IMMUNOL, V29, P45, DOI 10.1146/annurev-immunol-031210-101257; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kelso A, 1999, INT IMMUNOL, V11, P617, DOI 10.1093/intimm/11.4.617; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Klechevsky E, 2008, IMMUNITY, V29, P497, DOI 10.1016/j.immuni.2008.07.013; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Marichal T, 2011, NAT MED, V17, P996, DOI 10.1038/nm.2403; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pawankar R, 2012, CURR OPIN ALLERGY CL, V12, P39, DOI 10.1097/ACI.0b013e32834ec13b; Pedroza-Gonzalez A, 2011, J EXP MED, V208, P479, DOI 10.1084/jem.20102131; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Poulsen LK, 2009, CLIN EXP ALLERGY, V39, P623, DOI 10.1111/j.1365-2222.2009.03245.x; Pulendran B, 2001, J IMMUNOL, V167, P5067; Pulendran B, 2010, NAT IMMUNOL, V11, P647, DOI 10.1038/ni.1894; Querec TD, 2008, NAT IMMUNOL, V10, P116, DOI DOI 10.1038/NI.1688; Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Ronald PC, 2010, SCIENCE, V330, P1061, DOI 10.1126/science.1189468; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Shreffler WG, 2006, J IMMUNOL, V177, P3677; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Steinfelder S, 2009, J EXP MED, V206, P1681, DOI 10.1084/jem.20082462; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Voehringer D, 2011, CURR OPIN IMMUNOL, V23, P789, DOI 10.1016/j.coi.2011.09.005; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wenink MH, 2009, J IMMUNOL, V183, P6960, DOI 10.4049/jimmunol.0900713; Whelan M, 2000, J IMMUNOL, V164, P6453; Yang D, 2012, J EXP MED, V209, P157, DOI 10.1084/jem.20101354; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	72	146	149	2	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2012	337	6093					431	435		10.1126/science.1221064		5	Multidisciplinary Sciences	Science & Technology - Other Topics	979FS	WOS:000306802300033	22837519	
J	Nordling, E; Berglind, N; Melen, E; Emenius, G; Hallberg, J; Nyberg, F; Pershagen, G; Svartengren, M; Wickman, M; Bellander, T				Nordling, Emma; Berglind, Niklas; Melen, Erik; Emenius, Gunnel; Hallberg, Jenny; Nyberg, Fredrik; Pershagen, Goeran; Svartengren, Magnus; Wickman, Magnus; Bellander, Tom			Traffic-related air pollution and childhood respiratory symptoms, function and allergies	EPIDEMIOLOGY			English	Article							LONG-TERM EXPOSURE; LUNG-FUNCTION GROWTH; 3 EUROPEAN AREAS; NITROGEN-DIOXIDE; PULMONARY-FUNCTION; BIRTH COHORT; CHILDREN; HEALTH; ASTHMA; SCHOOLCHILDREN	Background: Urban air pollution can trigger asthma symptoms in children, but there is conflicting evidence on effects of long-term exposure on lung function, onset of airway disease and allergic sensitization. Methods: The spatial distribution of nitrogen oxides from traffic (traffic-NOx) and inhalable particulate matter from traffic (traffic-PM10) in the study area was assessed with emission databases and dispersion modeling. Estimated levels were used to assign first-year exposure levels for children in a prospective birth cohort (n = 4089), by linking to geocoded home addresses. Parents in 4 Swedish municipalities provided questionnaire data on symptoms and exposures when the children were 2 months and 1, 2, and 4-year-old. At 4 years, 73% of the children underwent clinical examination including peak expiratory flow and specific IgE measurements. Results: Exposure to air pollution from traffic during the first year of life was associated with an excess risk of persistent wheezing (odds ratio [OR] for 44 mu g/m(3) [5th-95th percentile] difference in traffic-NO, = 1.60; 95% confidence interval [Cl] = 1.09-2.36). Similar results were found for sensitization (measured as specific IgE) to inhalant allergens, especially pollen (OR for traffic-NO, = 1.67; 95% CI = 1.10-2.53), at the age of 4 years. Traffic-related air pollution exposure during the first year of life was also associated with lower lung function at 4 years of age. Results were similar using traffic-NOx and traffic-PM10 as indicators. Conclusions: Exposure to moderate levels of locally emitted air pollution from traffic early in life appears to influence the development of airway disease and sensitization in preschool children.	[Bellander, Tom] Karolinska Hosp, Stockholm Cty Council, Dept Environm & Occupat Hlth, SE-17176 Stockholm, Sweden; [Berglind, Niklas; Melen, Erik; Nyberg, Fredrik; Pershagen, Goeran; Wickman, Magnus; Bellander, Tom] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Melen, Erik; Hallberg, Jenny; Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Hallberg, Jenny; Svartengren, Magnus] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Nyberg, Fredrik] AstraZeneca R&D, Molndal, Sweden	Bellander, T (reprint author), Karolinska Hosp, Stockholm Cty Council, Dept Environm & Occupat Hlth, Norrbacka 3rd Floor, SE-17176 Stockholm, Sweden.	tom.bellander@sll.se					Baldi I, 1999, EUR RESPIR J, V14, P132, DOI 10.1034/j.1399-3003.1999.14a22.x; Bellander T, 2001, ENVIRON HEALTH PERSP, V109, P633, DOI 10.2307/3455039; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Emenius G, 2003, OCCUP ENVIRON MED, V60, P876, DOI 10.1136/oem.60.11.876; Franze T, 2005, ENVIRON SCI TECHNOL, V39, P1673, DOI 10.1021/es0488737; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gidhagen L, 2004, ATMOS ENVIRON, V38, P2029, DOI 10.1016/j.atmosenv.2004.02.014; Hallberg J, 2006, ACTA PAEDIATR, V95, P1191, DOI 10.1080/08035250600584794; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; JOHANSSON C, 1999, PUBLICATION, V41; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lannero E, 2002, PEDIATR ALLERGY IMMU, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; LANTMATERIVERKE, 1996, IATORT 2000; Lewne M, 2004, SCI TOTAL ENVIRON, V332, P217, DOI 10.1016/j.scitotenv.2004.04.014; Llewellin P, 2002, RESPIROLOGY, V7, P333, DOI 10.1046/j.1440-1843.2002.00417.x; Magnus P, 1998, INT J EPIDEMIOL, V27, P995, DOI 10.1093/ije/27.6.995; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Melen E, 2004, CLIN EXP ALLERGY, V34, P839, DOI 10.1111/j.1365-2222.2004.01957.x; Miyabara Y, 1998, INT ARCH ALLERGY IMM, V116, P124, DOI 10.1159/000023935; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; *NAT, 2005, 5519 SWED ENV PROT A; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; Rosenlund M, 2006, EPIDEMIOLOGY, V17, P383, DOI 10.1097/01.ede.0000219722.25569.0f; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; Shima M, 2003, J EPIDEMIOL, V13, P108; *SLB AN, 2007, AIR STOCKH ANN REP 2; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; 1989, OCCUPATIONS POPULATI	42	146	150	5	41	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	MAY	2008	19	3					401	408		10.1097/EDE.0b013e31816alce3		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	293DF	WOS:000255314400010	18379426	
J	Williams, H; Flohr, C				Williams, Hywel; Flohr, Carsten			How epidemiology has challenged 3 prevailing concepts about atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; atopic march; eczema; hygiene	ECZEMA; SENSITIZATION; CHILDREN; ALLERGY; ASTHMA; ASSOCIATION; PREVALENCE; DISEASES; SCHOOLCHILDREN; RHINITIS	We challenge 3 prevailing concepts in understanding atopic dermatitis using data from epidemiologic studies. First, we show that although atopy is associated with atopic dermatitis to some degree, its importance is not likely to be a simple cause-and-effect relationship, especially at a population level. Our epidemiologic data do not exclude a contributory role for IgE-mediated immunologic processes, especially in those with existing and severe disease. Second, evidence is presented that does not support a straightforward inverse relationship between infections and atopic dermatitis risk. A link, if present, is likely to be more complex, depending critically on the timing and type of infectious exposure. Third, recent evidence suggests that the risk of subsequent childhood asthma is not increased in children with early atopic dermatitis who are not also early wheezers, suggesting a comanifestation of phenotypes rather than a progressive atopic march. Collectively, these observations underline the importance of epidemiologic studies conducted at a population level to gain a more balanced understanding of the enigma of atopic dermatitis.	Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2NR, England	Williams, H (reprint author), Univ Nottingham, Ctr Evidence Based Dermatol, Kings Meadow Campus,Room A103,Lenton Lane, Nottingham NG7 2NR, England.	hywel.williams@nottingham.ac.uk					Arshad SH, 2002, CLIN EXP ALLERGY, V32, P843, DOI 10.1046/j.1365-2222.2002.01378.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BIEBER T, 2005, J ALLERGY CLIN IMMUN, V117, P378; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V117, pS475, DOI 10.1016/j.jaci.2005.10.018; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cooper PJ, 2004, PARASITE IMMUNOL, V26, P455, DOI 10.1111/j.0141-9838.2004.00728.x; Flohr C, 2005, Br J Dermatol, V152, P202, DOI 10.1111/j.1365-2133.2004.06436.x; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; FLOHR C, 2005, J ALLERGY CLIN IMMUN, V117, P378; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; Mohrenschlager M, 2006, BRIT J DERMATOL, V154, P505, DOI 10.1111/j.1365-2133.2005.07042.x; Mortz CG, 2003, ACTA DERM-VENEREOL, V83, P194, DOI 10.1080/00015550310007201; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Perkin MR, 2004, PEDIATR ALLERGY IMMU, V15, P221, DOI 10.1111/j.1399-3038.2004.00160.x; Ring J, 2001, J AM ACAD DERMATOL, V45, P49; Ronmark E, 2003, PEDIATR ALLERGY IMMU, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Schafer T, 2000, BRIT J DERMATOL, V143, P992, DOI 10.1046/j.1365-2133.2000.03832.x; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; STRACHAN DP, 1989, BRIT MED J, V299, P1259; STRACHAN DP, 2000, ATOPIC DERMATITIS EP, P221, DOI 10.1017/CBO9780511545771.019; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Williams HC, 2005, J ALLERGY CLIN IMMUN, V116, P1064, DOI 10.1016/j.jaci.2005.08.026; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams HC, 2000, ATOPIC DERMATITIS EP, P41, DOI 10.1017/CBO9780511545771.005; Williams HC, 2000, ATOPIC DERMATITIS EP, V1st, P3, DOI 10.1017/CBO9780511545771.003; WILLIAMS HC, 2006, IN PRESS ARCH DERMAT; Yemaneberhan H, 2004, CLIN EXP ALLERGY, V34, P779, DOI 10.1111/j.1365-2222.2004.01946.x	38	146	156	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					209	213		10.1016/j.jaci.2006.04.043		5	Allergy; Immunology	Allergy; Immunology	065UH	WOS:000239184800025	16815157	
J	Ono, SJ; Nakamura, T; Miyazaki, D; Ohbayashi, M; Dawson, M; Toda, M				Ono, SJ; Nakamura, T; Miyazaki, D; Ohbayashi, M; Dawson, M; Toda, M			Chemokines: Roles in leukocyte development, trafficking, and effector function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						chemokines; receptors; allergy; asthma; signal transduction	HUMAN MAST-CELLS; MACROPHAGE INFLAMMATORY PROTEIN-1-ALPHA; EOTAXIN RECEPTOR CCR3; CD4(+) T-CELLS; FC-EPSILON-RI; LATE-PHASE; DENDRITIC CELLS; IN-VIVO; ALLERGIC CONJUNCTIVITIS; NEUTROPHIL MIGRATION	Chemokines, representing a large superfamily of 8- to 15-kd proteins, were originally discovered through their ability to recruit various cell types into sites of inflammation. It is now clear that these molecules play a much wider role in immune homeostasis, playing key roles in driving the maturation, homing, and activation of leukocytes. In this review we analyze the roles chemokines play in the development, recruitment, and activation of leukocytes. Because signaling from the receptors drives these processes, signal transduction from chemokine receptors will also be reviewed. Taken together, we highlight the various points at which chemokines contribute to allergic inflammation and at which their targeting might contribute to new therapies for type I hypersensitivity reactions.	UCL, Univ London, Inst Ophthalmol, Dept Immunol, London EC1V 9EL, England; UCL, Univ London, Inst Child Hlth, Dept Immunol, London EC1V 9EL, England; Moorfields Eye Hosp, London, England	Ono, SJ (reprint author), UCL, Univ London, Inst Ophthalmol, Dept Immunol, 11-43 Bath St, London EC1V 9EL, England.						AGRAWAL L, 2003, EXPERT OPIN INV DRUG, V12, P185; Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; Alexander JM, 2002, CELL, V111, P343, DOI 10.1016/S0092-8674(02)01007-3; Anders HJ, 2002, J CLIN INVEST, V109, P251, DOI 10.1172/JCI14040; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; Barnes PJ, 2001, NOVART FDN SYMP, V234, P255; BAYCE JA, 2003, J ALLERGY CLIN IMMUN, V111, P24; Beil WJ, 2000, HISTOL HISTOPATHOL, V15, P937; Bertrand CP, 2000, EXPERT OPIN INV DRUG, V9, P43, DOI 10.1517/13543784.9.1.43; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Borish LC, 2003, J ALLERGY CLIN IMMUN, V111, P460, DOI 10.1067/mai.2003.108; Brown V, 2003, THORAX, V58, P311, DOI 10.1136/thorax.58.4.311; Campbell JD, 2002, INT IMMUNOL, V14, P1255, DOI 10.1093/intimm/dxf098; Carollo M, 2001, BRIT J PHARMACOL, V134, P1166, DOI 10.1038/sj.bjp.0704371; CHAPOVAL SP, 2001, J ALLERGY CLIN IMMUN, V168, P245; Clemetson KJ, 2000, BLOOD, V96, P4046; Combadiere C, 2003, CIRCULATION, V107, P1009, DOI 10.1161/01.CIR.0000057548.68243.42; Cosmi L, 2001, INT ARCH ALLERGY IMM, V125, P273, DOI 10.1159/000053827; Coward WR, 2002, J IMMUNOL, V169, P5287; Curnock AP, 2003, J IMMUNOL METHODS, V273, P29, DOI 10.1016/S0022-1759(02)00416-7; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Paulis A, 2000, J IMMUNOL, V165, P7171; Dombrowicz D, 2000, J IMMUNOL, V165, P1266; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Fan J, 2003, NAT MED, V9, P315, DOI 10.1038/nm832; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Fernandis AZ, 2003, J BIOL CHEM, V278, P9536, DOI 10.1074/jbc.M211803200; Flower RJ, 2003, NAT REV DRUG DISCOV, V2, P179, DOI 10.1038/nrd.1034; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Furue M, 2003, BRIT J DERMATOL, V148, P128, DOI 10.1046/j.1365-2133.2003.04934.x; Ghildyal N, 1996, J EXP MED, V184, P1061, DOI 10.1084/jem.184.3.1061; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gomez-Mouton C, 2001, P NATL ACAD SCI USA, V98, P9642, DOI 10.1073/pnas.171160298; GORDON S, 2003, NAT REV IMMUNOL, V3, P36; Guo J, 2003, ARTERIOSCL THROM VAS, V23, P447, DOI 10.1161/01.ATV.0000058431.78833.F5; Gurish MF, 2002, J IMMUNOL, V168, P5730; Hageman GS, 2001, PROG RETIN EYE RES, V20, P705, DOI 10.1016/S1350-9462(01)00010-6; Han KH, 1999, J BIOL CHEM, V274, P32055, DOI 10.1074/jbc.274.45.32055; HANDY RLC, 2002, P INT S OC IMM INFL, P18; Hirata H, 2003, J CLIN IMMUNOL, V23, P34, DOI 10.1023/A:1021948214742; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Huang CF, 1997, J BIOL CHEM, V272, P31885, DOI 10.1074/jbc.272.50.31885; Huang CF, 1998, J IMMUNOL, V160, P1910; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Inamura H, 2002, INT ARCH ALLERGY IMM, V128, P142, DOI 10.1159/000059405; Janeway CA, 2002, IMMUNOBIOLOGY; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; JUREMALM M, 2001, J ALLERGY CLIN IMMUN, V50, P168; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kawasaki S, 2001, J IMMUNOL, V166, P2055; Khan IA, 2001, J IMMUNOL, V166, P1930; Kim Y, 2001, J IMMUNOL, V166, P5183; KITAMURA Y, 1989, ANNU REV IMMUNOL, V7, P59, DOI 10.1146/annurev.immunol.7.1.59; Lahn M, 2002, P NATL ACAD SCI USA, V99, P8850, DOI 10.1073/pnas.132519299; Lang K, 2003, SCAND J IMMUNOL, V57, P350, DOI 10.1046/j.1365-3083.2003.01247.x; Langenkamp A, 2003, EUR J IMMUNOL, V33, P474, DOI 10.1002/immu.200310023; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; LEPIDI H, 1995, J CELL SCI, V108, P1771; Lesnik P, 2003, J CLIN INVEST, V111, P333, DOI 10.1172/JCI200315555; Levesque JP, 2003, J CLIN INVEST, V111, P187, DOI 10.1172/JCI200315994; Lewis DB, 2002, CURR OPIN IMMUNOL, V14, P644, DOI 10.1016/S0952-7915(02)00388-6; Li Y, 2001, BLOOD, V97, P3484, DOI 10.1182/blood.V97.11.3484; Lippert U, 1998, J IMMUNOL, V161, P2600; Liu ZJ, 2001, P NATL ACAD SCI USA, V98, P7289, DOI 10.1073/pnas.121171998; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; MAGUIRE JE, 1995, J EXP MED, V182, P2079, DOI 10.1084/jem.182.6.2079; Makino Y, 2002, CLIN IMMUNOL, V102, P302, DOI 10.1006/clim.2001.5178; Mancardi S, 2003, IMMUNOLOGY, V108, P523, DOI 10.1046/j.1365-2567.2003.01613.x; Mariani M, 2003, J IMMUNOL METHODS, V273, P103, DOI 10.1016/S0022-1759(02)00503-3; Marone G, 2001, INT ARCH ALLERGY IMM, V125, P89, DOI 10.1159/000053802; Menzies-Gow A, 2002, J IMMUNOL, V169, P2712; Miyazaki D, 2000, INVEST OPHTH VIS SCI, V41, P3850; Miyazaki D, 1999, INVEST OPHTH VIS SCI, V40, pS687; Monteclaro FS, 1996, J BIOL CHEM, V271, P19084; Nakajima T, 2002, BLOOD, V100, P3861, DOI 10.1182/blood-2002-02-0602; Nardelli B, 1999, J IMMUNOL, V162, P435; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; Ohkubo Kimihiro, 1998, Rhinology (Utrecht), V36, P156; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Oliveira SHP, 2001, INFLAMM RES, V50, P168, DOI 10.1007/s000110050741; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; Ono SJ, 2003, CLIN EXP ALLERGY, V33, P279, DOI 10.1046/j.1365-2745.2003.01616.x; Osbourn JK, 1998, NAT BIOTECHNOL, V16, P778, DOI 10.1038/nbt0898-778; PARFREY NA, 1989, CRIT REV IMMUNOL, V9, P45; Pinco KA, 2002, MOL BIOL CELL, V13, P3203, DOI 10.1091/mbc.02-05-0086; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295; Pribila JT, 2003, IMMUNOL RES, V27, P107, DOI 10.1385/IR:27:1:107; Price KS, 2003, AM J RESP CELL MOL, V28, P420, DOI 10.1165/rcmb.2002-0155OC; Proudfoot AEI, 2003, SEMIN IMMUNOL, V15, P57, DOI 10.1016/S1044-5323(02)00128-8; Rochdi MD, 2003, J BIOL CHEM, V278, P17827, DOI 10.1074/jbc.M210319200; Rodriguez-Frade JM, 2001, TRENDS IMMUNOL, V22, P612, DOI 10.1016/S1471-4906(01)02036-1; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Root Allen W., 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P27, DOI 10.2174/1568008024606293; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; Sachdev P, 2002, J BIOL CHEM, V277, P17638, DOI 10.1074/jbc.M111575200; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Salazar-Mather TP, 2002, J CLIN INVEST, V110, P321, DOI 10.1172/JCI200215376; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Savinov AY, 2003, J EXP MED, V197, P643, DOI 10.1084/jem.20021378; SAYAMA K, 2002, BMC IMMUNOL, V3, P1; Sayama Koichi, 2002, BMC Immunol, V3, P5, DOI 10.1186/1471-2172-3-5; Schier AF, 2003, CURR BIOL, V13, pR192, DOI 10.1016/S0960-9822(03)00122-2; Schuh JM, 2002, J IMMUNOL, V168, P1447; Schultz Armin, 2003, Curr Opin Allergy Clin Immunol, V3, P21, DOI 10.1097/00130832-200302000-00004; Senechal S, 2002, LAB INVEST, V82, P929, DOI 10.1097/01.LAB.0000020417.13757.05; Shapiro SD, 2003, NATURE, V421, P223, DOI 10.1038/421223a; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; Suzuki Y, 2001, J IMMUNOL, V167, P3064; Tenscher K, 1996, BLOOD, V88, P3195; Toda M., 2003, Journal of Allergy and Clinical Immunology, V111, pS117, DOI 10.1016/S0091-6749(03)80352-4; Toda M, 2002, IMMUNOLOGY, V106, P1, DOI 10.1046/j.1365-2567.2002.01407.x; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; von Herrath MG, 2003, NAT REV IMMUNOL, V3, P223, DOI 10.1038/nri1029; Vulcano M, 2003, J IMMUNOL, V170, P3843; Wakahara S, 2001, CYTOKINE, V16, P143, DOI 10.1006/cyto.2001.0958; WOLPE SD, 1989, FASEB J, V3, P2565; Wong MM, 2003, SEMIN IMMUNOL, V15, P5, DOI 10.1016/S1044-5323(02)00123-9; Woo CH, 2002, BIOCHEM BIOPH RES CO, V298, P392, DOI 10.1016/S0006-291X(02)02432-4; Wuyts A, 2003, LAB INVEST, V83, P23, DOI 10.1097/01.LAB.0000048719.53282.00; Yano K, 1997, LAB INVEST, V77, P185; Ying S, 2001, CLIN EXP ALLERGY, V31, P1724, DOI 10.1046/j.1365-2222.2001.01232.x; Youn BS, 2001, BIOCHEM BIOPH RES CO, V281, P627, DOI 10.1006/bbrc.2001.4393; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139; Zingoni A, 1998, J IMMUNOL, V161, P547	129	146	149	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1185	1199		10.1067/mai.2003.1594		15	Allergy; Immunology	Allergy; Immunology	688FZ	WOS:000183424700002	12789214	
J	Reed, CE; Milton, DK				Reed, CE; Milton, DK			Endotoxin-stimulated innate immunity: A contributing factor for asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						airway inflammation; asthma; cell biology; chronic obstructive pulmonary disease; endotoxin; eosinophils; environmental exposure neutrophils; tolerance	TUMOR-NECROSIS-FACTOR; ACUTE LUNG INJURY; NF-KAPPA-B; CAUSES BRONCHIAL HYPERRESPONSIVENESS; RESOLUTION COMPUTED-TOMOGRAPHY; DOSE-RESPONSE RELATIONSHIPS; PLATELET-ACTIVATING-FACTOR; PROTEIN-TYROSINE KINASE; COTTON TEXTILE WORKERS; TNF-ALPHA PRODUCTION	Exposure to airborne endotoxin in infancy may protect against asthma by promoting enhanced T(H)1 response and tolerance to allergens. On the other hand, later in life, it adversely affects patients with asthma. Endotoxin binding to receptors on macrophages and other cells generates IL-12, which inhibits IgE responses. It also generates cytokines like IL-1, TNF-alpha, and IL-8, which cause inflammation. These signal transduction pathways resemble those leading to the generation of cytokines, such as IL-4, IL-13, and IL-5, which are responsible for the inflammation of IgE-mediated allergic disease. The main difference seems to be that endotoxin recruits neutrophils, but IgE recruits eosinophils, and the details of the tissue injury from these granulocytes differ. Sources of airborne endotoxin include many agricultural dusts, aerosols from contaminated water in many industrial plants, contaminated heating and air-conditioning systems, mist-generating humidifiers, and damp or water-damaged homes. Acute inhalation of high concentrations of endotoxin can cause fever, cough, and dyspnea. Chronic inhalation of lesser amounts causes chronic bronchitis and emphysema and is associated with airway hyperresponsiveness. Airborne endotoxin adversely affects patients with asthma in 3 ways: (1) by increasing the severity of the airway inflammation; (2) by increasing the susceptibility to rhinovirus-induced colds; and (3) by causing chronic bronchitis and emphysema with development of irreversible airway obstruction after chronic exposure of adults. The most effective management is mitigating exposure. The potential of drug treatments requires further clinical investigation.	Mayo Clin, Allerg Dis Res Lab, Rochester, MN USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Reed, CE (reprint author), POB 158, Boulder Jct, WI 54512 USA.		Milton, Donald/G-3286-2010	Milton, Donald/0000-0002-0550-7834			Abrams L, 2000, Appl Occup Environ Hyg, V15, P492; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Anderson K, 1996, OCCUP ENVIRON MED, V53, P106; BACHWICH PR, 1986, AM J PATHOL, V125, P421; Baykal A, 1999, SURGERY, V125, P403, DOI 10.1016/S0039-6060(99)70008-5; Bellanti JA, 2000, ANN ALLERG ASTHMA IM, V84, P249, DOI 10.1016/S1081-1206(10)62762-7; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; Boichot E, 1999, PULM PHARMACOL THER, V12, P285, DOI 10.1006/pupt.1999.0212; Borovikova LV, 2000, NATURE, V405, P458; Boulet L P, 1998, Can Respir J, V5, P270; Brauer RB, 2000, INFECT IMMUN, V68, P1626, DOI 10.1128/IAI.68.3.1626-1632.2000; BURRELL R, 1994, CIRC SHOCK, V43, P137; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Chanez P, 1996, INT ARCH ALLERGY IMM, V111, P83; CHRISTIANI DC, 1993, AM J IND MED, V23, P333, DOI 10.1002/ajim.4700230210; Christiani DC, 1999, AM J IND MED, V35, P321, DOI 10.1002/(SICI)1097-0274(199904)35:4<321::AID-AJIM1>3.0.CO;2-L; CHRISTIANI DC, 1994, CHEST, V105, P1713, DOI 10.1378/chest.105.6.1713; CLEMENTSEN P, 1990, ALLERGY, V45, P402, DOI 10.1111/j.1398-9995.1990.tb01090.x; CLEMENTSEN P, 1990, ALLERGY, V45, P10, DOI 10.1111/j.1398-9995.1990.tb01078.x; Cowan DB, 2000, AM J PHYSIOL-HEART C, V279, pH619; Delgado M, 1999, J IMMUNOL, V162, P2358; Dentener MA, 2000, AM J RESP CELL MOL, V23, P146; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; DONHAM K, 1989, BRIT J IND MED, V46, P31; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; EDEN E, 1986, IMMUNOPHARMACOLOGY, V12, P81, DOI 10.1016/0162-3109(86)90033-0; Eldridge MW, 2000, J TOXICOL ENV HEAL A, V61, P27, DOI 10.1080/00984100050116762; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Eppihimer MJ, 1999, SHOCK, V11, P93, DOI 10.1097/00024382-199902000-00004; Ertel W, 1996, ARCH SURG-CHICAGO, V131, P51; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Feng WG, 2000, BIOCHEM BIOPH RES CO, V269, P570, DOI 10.1006/bbrc.2000.2341; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; FLAHERTY DK, 1984, INFECT IMMUN, V43, P213; FOLKERTS G, 1988, AM REV RESPIR DIS, V137, P1441; FORTEZA R, 1994, AM J RESP CRIT CARE, V149, P687; Galea E, 1999, FASEB J, V13, P2125; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Ghofrani HA, 1996, AM J PHYSIOL-LUNG C, V270, pL62; Grenier P, 1996, EUR RADIOL, V6, P199; Hakki A, 2000, INT J IMMUNOPHARMACO, V22, P403, DOI 10.1016/S0192-0561(00)00005-9; HARKEMA JR, 1992, AM J PATHOL, V141, P307; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hasko G, 2000, J IMMUNOL, V164, P1013; Hines CJ, 2000, INDOOR AIR, V10, P2, DOI 10.1034/j.1600-0668.2000.010001002.x; HOFFMANN H, 1991, AM REV RESPIR DIS, V143, P289; HOLLANDER A, 1994, OCCUP ENVIRON MED, V51, P73; Hsuan SL, 1999, MICROB PATHOGENESIS, V26, P263, DOI 10.1006/mpat.1998.0271; HUANG ZB, 1990, CHEST, V98, P576, DOI 10.1378/chest.98.3.576; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471; Ingalls RR, 1999, INFECT DIS CLIN N AM, V13, P341, DOI 10.1016/S0891-5520(05)70078-7; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Jeffery PK, 1997, EUR RESPIR J, V10, P1655, DOI 10.1183/09031936.97.10071655; JORNA THJM, 1994, CHEST, V106, P1050, DOI 10.1378/chest.106.4.1050; Joyce DA, 1997, IMMUNOL CELL BIOL, V75, P345, DOI 10.1038/icb.1997.53; Kamochi M, 1999, AM J PHYSIOL-LUNG C, V277, pL310; Karres I, 1996, ARCH SURG-CHICAGO, V131, P1310; Keicho N, 1999, AM J PHYSIOL-LUNG C, V277, pL523; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; Kimata M, 1998, PHARMACOLOGY, V56, P230, DOI 10.1159/000028202; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332; KIPS JC, 1993, CLIN EXP ALLERGY, V23, P518, DOI 10.1111/j.1365-2222.1993.tb03240.x; Kirychuk S, 1998, Can Respir J, V5, P472; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; KONNO S, 1994, INT ARCH ALLERGY IMM, V105, P308; KUDLACZ EM, 1993, LAB ANIM SCI, V43, P445; Kullman GJ, 1998, AM IND HYG ASSOC J, V59, P403, DOI 10.1202/0002-8894(1998)059<0403:ODEFWI>2.0.CO;2; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lahti A, 2000, J PHARMACOL EXP THER, V294, P1188; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394; Larsson BM, 1997, THORAX, V52, P638; Lauw FN, 2000, INFECT IMMUN, V68, P1014, DOI 10.1128/IAI.68.3.1014-1018.2000; Lefort J, 1998, J IMMUNOL, V161, P474; LI D, 1995, OCCUP ENVIRON MED, V52, P328; Li LW, 2000, J BIOL CHEM, V275, P23340, DOI 10.1074/jbc.M001950200; Madjdpour C, 2000, AM J PHYSIOL-LUNG C, V278, pL572; Mahar S, 1999, AM IND HYG ASSOC J, V60, P679, DOI 10.1080/00028899908984491; MALMBERG P, 1993, EUR RESPIR J, V6, P400; MAMOLEN M, 1993, AM J IND MED, V23, P483, DOI 10.1002/ajim.4700230311; Mariano F, 1999, NEPHROL DIAL TRANSPL, V14, P1150, DOI 10.1093/ndt/14.5.1150; Martinez FD, 1999, LANCET, V354, pSII12; Medvedev AE, 2000, J IMMUNOL, V164, P5564; Medzhitov R, 2000, NEW ENGL J MED, V343, P338; MICHEL O, 1995, INT ARCH ALLERGY IMM, V108, P298; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; MICHEL O, 1991, ANN ALLERGY, V66, P39; Milanowski J, 1998, J TOXICOL ENV HEAL A, V53, P5, DOI 10.1080/009841098159439; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Milton DK, 1996, AM IND HYG ASSOC J, V57, P889, DOI 10.1202/0002-8894(1996)057<0889:WETEPC>2.0.CO;2; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; MILTON DK, 1990, AM REV RESPIR DIS, V142, P184; Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.0.CO;2-V; MILTON DK, 1995, AM J IND MED, V28, P469, DOI 10.1002/ajim.4700280404; Miyanohara T, 2000, LARYNGOSCOPE, V110, P126, DOI 10.1097/00005537-200001000-00023; Mochizuki T, 1997, CHEST, V112, P1522, DOI 10.1378/chest.112.6.1522; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Nakamura A, 1999, KIDNEY INT, V56, P839, DOI 10.1046/j.1523-1755.1999.00630.x; Nathens AB, 1998, J IMMUNOL, V160, P2959; Neely CF, 1997, AM J PHYSIOL-LUNG C, V272, pL353; Nelson ME, 1999, CHEST, V115, P151, DOI 10.1378/chest.115.1.151; Nicolai T, 1998, THORAX, V53, P1035; Nightingale JA, 1998, THORAX, V53, P563; Ning YY, 2000, J TOXICOL ENV HEAL A, V59, P165, DOI 10.1080/009841000156952; Niven RM, 1997, THORAX, V52, P22; Nolan B, 1999, SURGERY, V126, P406, DOI 10.1016/S0039-6060(99)70185-6; NOM S, 1987, AGENTS ACTIONS, V20, P29; Nonaka M, 1999, INT ARCH ALLERGY IMM, V119, P314, DOI 10.1159/000024209; OLSON NC, 1990, AM J PHYSIOL, V258, pH1674; OLSON NC, 1990, J APPL PHYSIOL, V69, P1315; OZESMI M, 1987, BRIT J IND MED, V44, P479; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084; Pal TM, 1997, AM J IND MED, V31, P682; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; PARK JH, 2001, IN PRESS ENV HLTH PE; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Pauwels R, 1990, Agents Actions Suppl, V31, P11; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Prados M, 1995, Allergol Immunopathol (Madr), V23, P24; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; ROSENTHAL GJ, 1992, TOXICOL APPL PHARM, V112, P222, DOI 10.1016/0041-008X(92)90191-T; Ruetten H, 1999, MEDIAT INFLAMM, V8, P77; RYLANDER R, 1993, ANN OCCUP HYG, V37, P57, DOI 10.1093/annhyg/37.1.57; RYLANDER R, 1986, ENVIRON HEALTH PERSP, V66, P83, DOI 10.2307/3430218; RYLANDER R, 1984, CLIN ALLERGY, V14, P109, DOI 10.1111/j.1365-2222.1984.tb02197.x; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981; Rylander R, 1999, EUR RESPIR J, V13, P1151, DOI 10.1034/j.1399-3003.1999.13e35.x; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Senthilselvan A, 1997, AM J RESP CRIT CARE, V156, P410; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204; Shimizu T, 1996, AM J RESP CRIT CARE, V153, P1412; SIGSGAARD T, 1994, PHARMACOGENETICS, V4, P135, DOI 10.1097/00008571-199406000-00004; SIGSGAARD T, 1992, AM J IND MED, V22, P163, DOI 10.1002/ajim.4700220204; Silva JRL, 2000, TOXICOLOGY, V152, P31; Simpson JCG, 1998, OCCUP ENVIRON MED, V55, P668; Simpson JCG, 1999, ANN OCCUP HYG, V43, P107, DOI 10.1016/S0003-4878(98)00083-0; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; Skerrett SJ, 1999, AM J PHYSIOL-LUNG C, V276, pL715; SMID T, 1994, AM J IND MED, V25, P877, DOI 10.1002/ajim.4700250611; Spittler A, 1999, FASEB J, V13, P563; Steer JH, 1998, ANN RHEUM DIS, V57, P732, DOI 10.1136/ard.57.12.732; STEIGER D, 1995, AM J RESP CELL MOL, V12, P307; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715; SUR S, 1993, AM REV RESPIR DIS, V148, P713; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; TANIZAKI Y, 1993, J ASTHMA, V30, P309, DOI 10.3109/02770909309054531; TAZI A, 1991, AM J RESP CELL MOL, V4, P140; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; Thorne PS, 1997, AM IND HYG ASSOC J, V58, P792, DOI 10.1202/0002-8894(1997)058<0792:FEOEAS>2.0.CO;2; Trapp JF, 1998, CHEST, V113, P505, DOI 10.1378/chest.113.2.505; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; van der Bruggen T, 1999, INFECT IMMUN, V67, P3824; VANNIER E, 1991, J CLIN INVEST, V87, P1936, DOI 10.1172/JCI115219; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Vogelzang PFJ, 2000, CHEST, V117, P1488, DOI 10.1378/chest.117.5.1488; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Wang D, 1999, J BIOMED SCI, V6, P28, DOI 10.1007/BF02256421; Wang Z, 1998, RESP MED, V92, P1022, DOI 10.1016/S0954-6111(98)90349-3; Wang Z, 1999, CLIN EXP IMMUNOL, V115, P6; Wang Z, 1997, EUR RESPIR J, V10, P381, DOI 10.1183/09031936.97.10020381; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; WARREN CPW, 1986, ENVIRON HEALTH PERSP, V66, P55; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; Wheeler MD, 1999, AM J PHYSIOL-LUNG C, V277, pL952; White JE, 2000, J CELL PHYSIOL, V182, P381; Wolk K, 2000, BLOOD, V96, P218; Woskie SR, 1996, AM IND HYG ASSOC J, V57, P1154, DOI 10.1202/0002-8894(1996)057<1154:EAFAFI>2.0.CO;2; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Xing Z, 1998, J CLIN INVEST, V101, P311, DOI 10.1172/JCI1368; Yamamoto C, 1997, CHEST, V112, P505, DOI 10.1378/chest.112.2.505; Yokota Y, 2000, ARCH BIOCHEM BIOPHYS, V379, P7, DOI 10.1006/abbi.2000.1849; Zhang HB, 1999, AM J RESP CRIT CARE, V160, P1703; Zock JP, 1999, AM J RESP CRIT CARE, V159, P137	185	146	147	2	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2001	108	2					157	166		10.1067/mai.2001.116862		10	Allergy; Immunology	Allergy; Immunology	465HY	WOS:000170584600001	11496229	
J	Bernard, SM; Samet, JM; Grambsch, A; Ebi, KL; Romieu, I				Bernard, SM; Samet, JM; Grambsch, A; Ebi, KL; Romieu, I			The potential impacts of climate variability and change on air pollution-related health effects in the United States	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; climate change; criteria air pollutants; global warming; ozone; particulate matter	SOUTHERN CALIFORNIA COMMUNITIES; OBSTRUCTIVE PULMONARY-DISEASE; 0.12 PPM OZONE; HOSPITAL ADMISSIONS; NITROGEN-DIOXIDE; RESPIRATORY MORBIDITY; EXERCISING CHILDREN; CHRONIC EXPOSURE; DIFFERING LEVELS; UCLA POPULATION	Climate change may affect exposures to air pollutants by affecting weather, anthropogenic emissions, and biogenic emissions and by changing the distribution and types of airborne allergens. Local temperature, precipitation, clouds, atmospheric water vapor. wind speed, and wind direction influence atmospheric chemical processes, and interactions occur between local and global-scale environments. If the climate becomes warmer and more variable, air quality is likely to be affected. However, the specific types of change (i.e., local, regional, or global), the direction of change in a particular location (i.e., positive or negative), and the magnitude of change in air quality that may be attributable to climate change are a matter of speculation, based on extrapolating present understanding to future scenarios. There is already extensive evidence on the health effects of air pollution. Ground-level ozone can exacerbate chronic respiratory diseases and cause short-term reductions in lung function. Exposure to particulate matter can aggravate chronic respiratory and cardiovascular diseases, alter host defenses, damage lung tissue, lead to premature death, and possibly contribute to cancer. Health effects of exposures to carbon monoxide, sulfur dioxide, and nitrogen dioxide can include reduced work capacity, aggravation of existing cardiovascular diseases, effects on pulmonary function, respiratory illnesses, lung irritation, and alterations in the lung's defense systems. Adaptations to climate change should include ensuring responsiveness of air quality protection programs to changing pollution levels. Research needs include basic atmospheric science work on the association between weather and air pollutants; improving air pollution models and their linkage with climate change scenarios; and closing gaps in the understanding of exposure patterns and health effects.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; US EPA, Off Res & Dev, Washington, DC 20460 USA; EPRI, Palo Alto, CA USA; US Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA	Bernard, SM (reprint author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, 615 N Wolfe St,Room 7041, Baltimore, MD 21205 USA.						Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; ATS, 2000, AM J RESP CRIT CARE, V161, P665; AVOL EL, 1984, JAPCA J AIR WASTE MA, V34, P804; AVOL EL, 1987, JAPCA J AIR WASTE MA, V37, P158; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BEARD RR, 1967, AM J PUBLIC HEALTH N, V57, P2012, DOI 10.2105/AJPH.57.11.2012; BENIGNUS VA, 1977, PERCEPT MOTOR SKILL, V45, P1007; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Davis DL, 1997, LANCET, V350, P1341, DOI 10.1016/S0140-6736(97)10209-4; DETELS R, 1991, AM J PUBLIC HEALTH, V81, P350, DOI 10.2105/AJPH.81.3.350; DETELS R, 1987, CHEST, V92, P594, DOI 10.1378/chest.92.4.594; DIAZ IAC, 1989, MYCOPATHOLOGIA, V108, P113; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Durry E, 1997, J MED VET MYCOL, V35, P321; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Epton MJ, 1997, THORAX, V52, P528; FOLINSBEE LJ, 1988, JAPCA J AIR WASTE MA, V38, P28; FOLINSBEE LJ, 1984, J APPL PHYSIOL, V57, P984; GARDNER DE, 1984, J TOXICOL ENV HEALTH, V13, P423; GERY MW, 1987, EPA600387047; GOINGS SAJ, 1989, AM REV RESPIR DIS, V139, P1075; GOLDSTEIN E, 1980, NITROGEN OXIDES THEI, P143; HALES J, 1988, SENSITIVITY URBAN RE; HARLOS DP, 1988, ACUTE EXPOSURE NITRO; HATAKEYAMA S, 1991, J GEOPHYS RES-ATMOS, V96, P947, DOI 10.1029/90JD02341; Holgate ST, 1999, AIR POLLUTION HLTH; HORVATH SM, 1971, ARCH ENVIRON HEALTH, V23, P343; KAMENS RM, 1982, EPA600382014; KEHRL HR, 1985, AM REV RESPIR DIS, V131, P719; Kirkland TN, 1996, EMERG INFECT DIS, V2, P192; KOENIG JQ, 1987, AM REV RESPIR DIS, V136, P1152; Kunzli N, 1997, ENVIRON HEALTH PERSP, V105, P1078, DOI 10.2307/3433849; LAMB BK, 1984, EPA600384001; Lambert W.E., 1998, ENV OCCUPATIONAL MED, P1501; LAWTHER PJ, 1970, THORAX, V25, P525, DOI 10.1136/thx.25.5.525; LINN WS, 1983, ARCH ENVIRON HEALTH, V38, P278; LOWRY T, 1956, JAMA-J AM MED ASSOC, V162, P153; LYNCH JA, 1996, TRENDS PRECIPITATION, P100; MARTIN HC, 1989, GLOBAL CLIMATE CHANG; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; MCDONNELL WF, 1983, J APPL PHYSIOL, V54, P1345; MCDONNELL WF, 1985, AM REV RESPIR DIS, V132, P875; MCFARLAND RA, 1973, ARCH ENVIRON HEALTH, V27, P355; MILLER FJ, 1982, AIR POLLUTION NITROG; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MORRIS RE, 1995, P 88 AIR WAST MAN AS; Morris R.E., 1989, POTENTIAL EFFECTS GL; MORRIS RE, 1991, P SPEC C TROP OZ ENV, V2, P5; MORROW PE, 1984, J TOXICOL ENV HEALTH, V13, P205; MUSTAFA MG, 1978, AM REV RESPIR DIS, V118, P1061; *NRC, 1998, RES PRIOR AIRB PART, P195; *NRC, 1991, RETH OZ PROBL URB RE, P524; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; PENNER JE, 1989, POTENTIAL EFFECTS GL; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; ROBINSON P, 1989, GLOBAL CLIMATE CHANG; ROMIEU I, 1998, URBAN TRAFFIC POLLUT, P10; Samet J., 2000, 94 HLTH EFF I; SAMSON P, UNPUB; Schneider E, 1997, JAMA-J AM MED ASSOC, V277, P904, DOI 10.1001/jama.277.11.904; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; SCHWARTZ J, 1989, 8992 AIR WAST MAN AS; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SPENGLER JD, 1990, P 1 INT S TOT EXP AS, P66; Thurston GD, 1999, AIR POLLUTION HLTH, P485, DOI 10.1016/B978-012352335-8/50097-1; *US EPA, 1996, AIR QUAL CRIT PART M, V3; *US EPA, 1989, POT EFF GLOB CLIM CH; *US EPA, 1996, AIR QUAL CRIT OZ REL, V3; *US EPA, 1996, NAT AIR QUAL EM TREN; U. S. EPA, 1997, NAT AIR POLL EM TREN; [Anonymous], 1986, AIR QUAL CRIT LEAD; [Anonymous], 1998, NAT AIR QUAL EM TREN; USEPA, 1997, FED REG, V62, P138	81	146	152	9	78	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2001	109			2			199	209		10.2307/3435010		11	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	434PF	WOS:000168824500005	11359687	
J	Kool, M; Willart, MAM; van Nimwegen, M; Bergen, I; Pouliot, P; Virchow, JC; Rogers, N; Osorio, F; Reis e Sousa, C; Hammad, H; Lambrecht, BN				Kool, Mirjam; Willart, Monique A. M.; van Nimwegen, Menno; Bergen, Ingrid; Pouliot, Philippe; Virchow, J. Christian; Rogers, Neil; Osorio, Fabiola; Reis e Sousa, Caetano; Hammad, Hamida; Lambrecht, Bart N.			An Unexpected Role for Uric Acid as an Inducer of T Helper 2 Cell Immunity to Inhaled Antigens and Inflammatory Mediator of Allergic Asthma	IMMUNITY			English	Article							HOUSE-DUST MITE; INDUCED NEUTROPHIL ACTIVATION; MONOSODIUM URATE CRYSTALS; HELPER TYPE-2 RESPONSE; CD4(+) T-CELLS; DENDRITIC CELLS; AIRWAY INFLAMMATION; NALP3 INFLAMMASOME; XANTHINE-OXIDASE; ADAPTIVE IMMUNITY	Although deposition of uric acid (UA) crystals is known as the cause of gout, it is unclear whether UA plays a role in other inflammatory diseases. We here have shown that UA is released in the airways of allergen-challenged asthmatic patients and mice, where it was necessary for mounting T helper 2 (Th2) cell immunity, airway eosinophilia, and bronchial hyperreactivity to inhaled harmless proteins and clinically relevant house dust mite allergen. Conversely, administration of UA crystals together with protein antigen was sufficient to promote Th2 cell immunity and features of asthma. The adjuvant effects of UA did not require the inflammasome (NIrp3, Pycard) or the interleukin-1 (Myd88, IL-1r) axis. UA crystals promoted Th2 cell immunity by activating dendritic cells through spleen tyrosine kinase and PI3-kinase delta signaling. These findings provide further molecular insight into Th2 cell development and identify UA as an essential initiator and amplifier of allergic inflammation.	[Kool, Mirjam; Willart, Monique A. M.; Pouliot, Philippe; Lambrecht, Bart N.] Univ Ghent, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium; [Hammad, Hamida] Univ Ghent, Dynam Imaging Unit, B-9000 Ghent, Belgium; [Kool, Mirjam; van Nimwegen, Menno; Bergen, Ingrid; Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, NL-3015 Rotterdam, Netherlands; [Kool, Mirjam] VIB, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Virchow, J. Christian] Univ Hosp Rostock, Dept Pulm Med, D-18057 Rostock, Germany; [Rogers, Neil; Osorio, Fabiola; Reis e Sousa, Caetano] Canc Res UK, Immunobiol Lab, London Res Inst, Lincolns Inn Fields Labs, London WC2A 3LY, England	Hammad, H (reprint author), Univ Ghent, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium.	hamida.hammad@ugent.be; bartiambrecht@ugent.be	Osorio, Fabiola/H-4529-2014; Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Osorio, Fabiola/0000-0001-5306-7856; Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834; Reis e Sousa, Caetano/0000-0001-7392-2119	Marie-Curie Intereuropean Fellowship; Flemish Organization for Scientific Research (FWO); European Research Council; Ghent University; NIH [R21]	M.K. is a recipient of a Marie-Curie Intereuropean Fellowship. B.N.L. is a recipient of an Odysseus Grant of the Flemish Organization for Scientific Research (FWO), a European Research Council starting grant, a Concerted Research Initiative Grant (GOA) of Ghent University, and a Multidisciplinary Research Platform (MRP) Grant of Ghent University. H.H. and B.N.L. are the recipients of an NIH grant (R21) and a University of Ghent 4-year project grant. We thank B. Ryffel, B. Vanhaesebroeck, T. De Smedt, and J. Tschopp for provision of mice.	AKAIKE T, 1990, J CLIN INVEST, V85, P739, DOI 10.1172/JCI114499; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Chen CJ, 2006, J CLIN INVEST, V116, P2262, DOI 10.1172/JCI28075; Desaulniers P, 2001, J LEUKOCYTE BIOL, V70, P659; Dodge IL, 2003, J IMMUNOL, V170, P4457; Ebeling C, 2007, J IMMUNOL, V179, P2910; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; Franchi L, 2007, J BIOL CHEM, V282, P18810, DOI 10.1074/jbc.M610762200; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hassoun PM, 1998, AM J RESP CRIT CARE, V158, P299; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Imanaka T, 1999, J BIOL CHEM, V274, P11968, DOI 10.1074/jbc.274.17.11968; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kobayashi T, 2010, J IMMUNOL, V184, P6350, DOI 10.4049/jimmunol.0902673; Kool M, 2008, J IMMUNOL, V181, P3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kuipers H, 2004, J LEUKOCYTE BIOL, V76, P1028, DOI 10.1189/jlb.0604325; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Li HF, 2008, J IMMUNOL, V181, P17; Li HF, 2007, J IMMUNOL, V178, P5271; Lommatzsch M, 2006, J ALLERGY CLIN IMMUN, V118, P91, DOI 10.1016/j.jaci.2006.02.034; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Marrack P, 2009, NAT REV IMMUNOL, V9, P287, DOI 10.1038/nri2510; Matsubara S, 2006, AM J RESP CELL MOL, V34, P426, DOI 10.1165/rcmb.2005-0298OC; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Mckee AS, 2009, J IMMUNOL, V183, P4403, DOI 10.4049/jimmunol.0900164; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Ng G, 2008, IMMUNITY, V29, P807, DOI 10.1016/j.immuni.2008.09.013; Papi A, 2008, J BIOL CHEM, V283, P28595, DOI 10.1074/jbc.M805766200; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Popa-Nita O, 2007, J LEUKOCYTE BIOL, V82, P763, DOI 10.1189/jlb.0307174; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Santos CXC, 2009, ANTIOXID REDOX SIGN, V11, P2409, DOI 10.1089/ARS.2009.2625; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Vorbach C, 2003, TRENDS IMMUNOL, V24, P512, DOI 10.1016/S1471-4906(03)00237-0; Williams A, 2010, CURR OPIN IMMUNOL, V22, P34, DOI 10.1016/j.coi.2010.01.004; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	55	145	148	1	18	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613			IMMUNITY	Immunity	APR 22	2011	34	4					527	540		10.1016/j.immuni.2011.03.015		14	Immunology	Immunology	761AQ	WOS:000290367300012	21474346	
J	Gibson, PG; McDonald, VM; Marks, GB				Gibson, Peter G.; McDonald, Vanessa M.; Marks, Guy B.			Asthma in older adults	LANCET			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIALS; AIR-FLOW OBSTRUCTION; DRY POWDER INHALERS; QUALITY-OF-CARE; SMOKING-CESSATION; ELDERLY-PATIENTS; GERIATRIC ASSESSMENT; COMORBID CONDITIONS; PRACTICE GUIDELINES	Asthma in older people is common and is characterised by underdiagnosis and undertreatment. Ageing is associated with unique issues that modify expression, recognition, and treatment of the disease. In particular, asthma and chronic obstructive pulmonary disease (COPD) both overlap and converge in older people. This concurrence, together with absence of precise diagnostic methods, makes diagnosis complex. A multidimensional assessment that addresses airway problems, comorbidities, risk factors, and management skills will draw attention to key needs for intervention. Increased attention to the complications of asthma and obstructive airway disease in older people is needed, specifically to develop effective systems of care, appropriate clinical practice guidelines, and a research agenda that delivers improved health outcomes.	[Gibson, Peter G.; McDonald, Vanessa M.; Marks, Guy B.] Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [McDonald, Vanessa M.] Univ Newcastle, Fac Hlth, Sch Nursing & Midwifery, Callaghan, NSW 2308, Australia; [Gibson, Peter G.; McDonald, Vanessa M.] John Hunter Hosp, Hunter Med Res Inst, Dept Resp & Sleep Med, New Lambton, NSW, Australia; [Gibson, Peter G.; Marks, Guy B.] Woolcock Inst Med Res, Sydney, NSW, Australia; [Marks, Guy B.] Liverpool Hosp, Dept Resp Med, Sydney, NSW, Australia; [Marks, Guy B.] Univ New S Wales, S Western Sydney Clin Sch, Sydney, NSW, Australia	Gibson, PG (reprint author), Univ Newcastle, Fac Hlth, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia.	peter.gibson@newcastle.edu.au			NHMRC; AstraZeneca; Boehringer Ingelheim; GlaxoSmithKline; Novartis; Pharmaxis; National Health and Medical Research Council (NHMRC) Centre for Respiratory and Sleep Medicine; Australian Department of Health and Ageing through the Australian Institute of Health and Welfare	PGG holds an NHMRC Practitioner Fellowship. He has participated in educational symposia funded by AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline and Novartis, and has participated in studies funded by Pharmaxis and GlaxoSmithKline. VMM is supported by the National Health and Medical Research Council (NHMRC) Centre for Respiratory and Sleep Medicine. She has also received honorariums for participation in educational meetings from AstraZeneca and Novartis. G BM is on an advisory board for Novartis and has given lectures at educational seminars sponsored by AstraZeneca and Boehringer Ingelheim. He has undertaken contract research for GlaxoSmithKline. The Australian Centre for Asthma Monitoring, of which he is Director, is funded by the Australian Department of Health and Ageing through the Australian Institute of Health and Welfare. He is the recipient of a Practitioner Fellowship from the Australian National Health and Medical Research Council.	Abdullah Abu Saleh M, 2008, BMC Geriatr, V8, P25, DOI 10.1186/1471-2318-8-25; Allen SC, 2009, INT J CLIN PRACT, V63, P1150, DOI 10.1111/j.1742-1241.2009.02060.x; Allen SC, 2009, AGE AGEING, V38, P548, DOI 10.1093/ageing/afp110; Andrews KL, 2009, HEALTH PROMOT J AUST, V20, P146; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Australian Centre for Asthma Monitoring, 2008, ASTHM AUSTR 2008; Australian Centre for Asthma Monitoring, 2005, HLTH CAR EXP BURD DI; Australian Centre for Asthma Monitoring, 2009, BURD DIS DUE ASTHM A; Bahadori K, 2009, BMC PULM MED, V19, P24; Banerji A, 2006, J AM GERIATR SOC, V54, P48, DOI 10.1111/j.1532-5415.2005.00563.x; Barnard Amanda, 2005, Med J Aust, V183, pS41; Barua P, 2005, DRUG AGING, V22, P1029, DOI 10.2165/00002512-200522120-00004; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; Beasley R, 2009, LANCET, V374, P670, DOI 10.1016/S0140-6736(09)61541-5; Bellia V, 2004, AM J RESP CRIT CARE, V170, P100; Bellia V, 2003, EUR RESPIR J, V21, p21S, DOI 10.1183/09031936.03.00402303; Bellia V, 2003, CHEST, V123, P1066, DOI 10.1378/chest.123.4.1066; BELLIA V, 2009, EUR RESP MONOGR, V43, P56; Bellia V, 2007, CHEST, V132, P1175, DOI 10.1378/chest.06-2824; Berend Norbert, 2005, Med J Aust, V183, pS28; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Board M, 2006, INT J CLIN PRACT, V60, P510, DOI 10.1111/j.1368-5031.2006.00933.x; Borrelli B, 2010, ADDICTION, V105, P1100, DOI 10.1111/j.1360-0443.2010.02900.x; Boulet LP, 2009, EUR RESPIR J, V33, P897, DOI 10.1183/09031936.00121308; Boulet LP, 2003, RESP MED, V97, P739, DOI 10.1053/rmed.2003.1491; Boyd CM, 2005, JAMA-J AM MED ASSOC, V294, P716, DOI 10.1001/jama.294.6.716; Bozek A, 2010, J ASTHMA, V47, P162, DOI 10.3109/02770900903497204; Brown DW, 2004, AM J PREV MED, V26, P112, DOI 10.1016/j.amepre.2003.10.004; Buist A Sonia, 2006, Am J Respir Crit Care Med, V174, P1077, DOI 10.1164/rccm.200510-1606OC; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Cassino C, 2000, AM J RESP CRIT CARE, V162, P1423; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; Chotirmall SH, 2009, J AM GERIATR SOC, V57, P901, DOI 10.1111/j.1532-5415.2009.02216.x; COSIO BG, 2009, EUR RESP MON, V43, P205; Cote CG, 2008, EUR RESPIR J, V31, P571, DOI 10.1183/09031936.00104507; Craig BM, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-144; De Martinis M, 2005, FEBS LETT, V579, P2035, DOI 10.1016/j.febslet.2005.02.055; Doll R, 2004, BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gadoury MA, 2005, EUR RESPIR J, V26, P853, DOI 10.1183/09031936.05.00093204; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; GIBSON PG, 1995, CHEST, V107, P1003, DOI 10.1378/chest.107.4.1003; Godtfredsen NS, 2008, EUR RESPIR J, V32, P844, DOI 10.1183/09031936.00160007; Goeman DP, 2007, DRUG AGING, V24, P381, DOI 10.2165/00002512-200724050-00003; Goeman Dianne P, 2005, Med J Aust, V183, pS26; Goeman DP, 2009, MED J AUSTRALIA, V191, P113; Harding SM, 2000, AM J RESP CRIT CARE, V162, P34; Hargreave FE, 2009, CLIN EXP ALLERGY, V39, P1652, DOI 10.1111/j.1365-2222.2009.03321.x; HARGREAVE FE, 2006, CLIN EXP ALLERGY, V68, P1415; Harrington JJ, 2007, CLIN CHEST MED, V28, P673, DOI 10.1016/j.ccm.2007.07.002; Hewitt J, 2005, THORAX, V60, P331, DOI 10.1136/thx.2004.029579; Horne R., 2006, CHEST, V130; Huang TT, 2009, J ADV NURS, V65, P348, DOI 10.1111/j.1365-2648.2008.04874.x; Incalzi RA, 2009, EUR RESPIR MONOGR, P35; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jorgensen NR, 2007, RESP MED, V101, P177, DOI 10.1016/j.rmed.2006.03.029; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kerr S, 2006, HEALTH SOC CARE COMM, V14, P572, DOI 10.1111/j.1365-2524.2006.00659.x; Lavorini F, 2008, RESP MED, V102, P593, DOI 10.1016/j.rmed.2007.11.003; Lehmann S, 2004, RESP MED, V98, P1071, DOI 10.1016/j.rmed.2004.03.019; LUKS VP, 2010, EUR RESPIR J, V36, P225; Marks GB, 2009, MED J AUSTRALIA, V191, P197; Marsh SE, 2008, THORAX, V63, P761, DOI 10.1136/thx.2007.089193; McDonald VM, 2009, ALLERGY FRONTIERS: DIAGNOSIS AND HEALTH ECONOMICS, VOL 4, P475, DOI 10.1007/978-4-431-98349-1_26; McDonald VM, 2005, MED J AUSTRALIA, V182, P250; MCDONALD VM, AGE AGEING IN PRESS; Meyer KC, 1998, MECH AGEING DEV, V104, P169, DOI 10.1016/S0047-6374(98)00065-7; Molander L, 2001, CLIN PHARMACOL THER, V69, P57, DOI 10.1067/mcp.2001.113181; Morgan R, 1997, BRIT J GEN PRACT, V47, P427; Navaratnam P, 2008, J AM GERIATR SOC, V56, P1312, DOI 10.1111/j.1532-5415.2008.01767.x; Oreopoulos A, 2009, CLIN GERIATR MED, V24, P643; Orimo H, 2006, GERIATR GERONTOL INT, V6, P149, DOI DOI 10.1111/J.1447-0594.2006.00341.X; Patel R, 2009, J ASTHMA, V46, P30, DOI 10.1080/02770900802460563; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Plaza V, 2000, RESPIRATION, V67, P65, DOI 10.1159/000029465; QUINET P, 2009, ANN PHYS REHABIL MED, V53, P69; Rabell-Santacana V, 2008, ARCH BRONCONEUMOL, V44, P519, DOI 10.1016/S1579-2129(08)60097-X; ROEBUCK J, 1979, J SOC HIST, V12, P416; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Savale L, 2009, AM J RESP CRIT CARE, V179, P566, DOI 10.1164/rccm.200809-1398OC; Schneider A, 2006, PATIENT EDUC COUNS, V61, P292, DOI 10.1016/j.pec.2005.04.008; Sharma G, 2006, CLIN INTERV AGING, V1, P253, DOI 10.2147/ciia.2006.1.3.253; Shirtcliffe P, 2012, INTERN MED J, V42, P83, DOI 10.1111/j.1445-5994.2010.02238.x; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; STUCK AE, 1993, LANCET, V342, P1032, DOI 10.1016/0140-6736(93)92884-V; Terry DF, 2008, J GERONTOL A-BIOL, V63, P809; Thomas M, 2001, BRIT MED J, V322, P1098, DOI 10.1136/bmj.322.7294.1098; Thomson NC, 2005, CURR OPIN ALLERGY CL, V5, P57, DOI 10.1097/00130832-200502000-00011; Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; UN, 2002, REP 2 WORLD ASS AG; Vitry AI, 2008, MED J AUSTRALIA, V189, P360; Walters JA, 2008, THORAX, V63, P408, DOI 10.1136/thx.2007.082859; Wang JJ, 2009, OPHTHALMOLOGY, V116, P652, DOI 10.1016/j.ophtha.2008.12.001; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; Whitson HE, 2006, J AM GERIATR SOC, V54, P466, DOI 10.1111/j.1532-5415.2005.00641.x; Wieshammer S, 2008, RESPIRATION, V75, P18, DOI 10.1159/000109374; Wilper AP, 2008, ANN INTERN MED, V149, P170; Wood LG, 2009, PHARMACOL THERAPEUT, V123, P37, DOI 10.1016/j.pharmthera.2009.03.015; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	105	145	148	2	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	2010	376	9743					803	813		10.1016/S0140-6736(10)61087-2		11	Medicine, General & Internal	General & Internal Medicine	650EC	WOS:000281831000032	20816547	
J	Katz, Y; Rajuan, N; Goldberg, MR; Eisenberg, E; Heyman, E; Cohen, A; Leshno, M				Katz, Yitzhak; Rajuan, Nelly; Goldberg, Michael R.; Eisenberg, Eli; Heyman, Eli; Cohen, Adi; Leshno, Moshe			Early exposure to cow's milk protein is protective against IgE-mediated cow's milk protein allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE-mediated cow's milk allergy; soy allergy; breast-feeding; skin prick test; oral challenge	KOALA BIRTH COHORT; FOOD CHALLENGES; PEANUT ALLERGY; INFANTS; IMMEDIATE; CHILDREN; AGE; HYPERSENSITIVITY; CONSUMPTION; CHILDHOOD	Background: The diversity in the perceived prevalence, recovery, and risk factors for cow's milk allergy (CMA) necessitated a large-scale, population-based prospective study. Objective: We sought to determine the prevalence, cross-reactivity with soy allergy, and risk factors for the development of CMA. Methods: In a prospective study the feeding history of 13,019 infants was obtained by means of telephone interview (95.8%) or questionnaire (4.2%). Infants with probable adverse reactions to milk were examined, skin prick tested, and challenged orally. Results: Ninety-eight percent of the cohort participated in the study. The cumulative incidence for IgE-mediated CMA was 0.5% (66/13,019 patients). The mean age of cow's milk protein (CMP) introduction was significantly different (P<.001) between the healthy infants (61.6 +/- 92.5 days) and those with IgE-mediated CMA (116.1 +/- 64.9 days). Only 0.05% of the infants who were started on regular CMP formula within the first 14 days versus 1.75% who were started on formula between the ages of 105 and 194 days had IgE-mediated CMA (P<.001). The odds ratio was 19.3 (95% CI, 6.0-62.1) for development of IgE-mediated CMA among infants with exposure to CMP at the age of 15 days or more (P<.001). Sixty-four patients with IgE-mediated CMA tolerated soy, and none had a proved allergy to soy. Conclusions: IgE-mediated CMA is much less common than generally reported. Early exposure to CMP as a supplement to breast-feeding might promote tolerance. Finally, soy is a reasonable feeding alternative in patients with IgE-mediated CMA. (J Allergy Clin Immunol 2010;126:77-82.)	[Katz, Yitzhak; Goldberg, Michael R.; Cohen, Adi] Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel; [Heyman, Eli] Assaf Harofeh Med Ctr, Dept Neonatol, IL-70300 Zerifin, Israel; [Katz, Yitzhak; Rajuan, Nelly] Tel Aviv Univ, Sackler Fac Med, Dept Pediat, IL-69978 Tel Aviv, Israel; [Eisenberg, Eli] Tel Aviv Univ, Raymond & Beverly Sackler Sch Phys & Astron, IL-69978 Tel Aviv, Israel; [Leshno, Moshe] Tel Aviv Univ, Fac Management, IL-69978 Tel Aviv, Israel	Katz, Y (reprint author), Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel.	ykatz49@gmail.com	Eisenberg, Eli/D-2587-2009	Eisenberg, Eli/0000-0001-8681-3202	Israel Dairy Board	Supported by the Israel Dairy Board.	BACHMAN KD, 1957, PEDIATRICS, V20, P393; Bhatia J, 2008, PEDIATRICS, V121, P1062, DOI 10.1542/peds.2008-0564; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; El Mouzan MI, 2009, ANN SAUDI MED, V29, P20; Elizur A, 2007, ANN ALLERG ASTHMA IM, V98, P540; FORD RPK, 1983, ARCH DIS CHILD, V58, P856; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; HOST A, 2002, ANN ALLERGY ASTHAM S, V89, pS33; JAKOBSSON I, 1979, ACTA PAEDIATR SCAND, V68, P853; Jarret EE, 1984, LANCET, V6, P797; Jarvinen KM, 2009, J ALLERGY CLIN IMMUN, V124, P1267, DOI 10.1016/j.jaci.2009.10.006; Klemola T, 2002, J PEDIATR-US, V140, P219, DOI 10.1067/mpd.2002.121935; Kummeling I, 2005, PEDIATR ALLERGY IMMU, V16, P679, DOI 10.1111/j.1399-3038.2005.00333.x; Kvenshagen B, 2008, ACTA PAEDIATR, V97, P196, DOI 10.1111/j.1651-2227.2007.00599.x; Martorell Antonio, 2006, Allergol Immunopathol (Madr), V34, P46, DOI 10.1157/13086746; Mikkelsen Andrea, 2007, J Pediatr Health Care, V21, P238, DOI 10.1016/j.pedhc.2006.05.007; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Prescott SL, 2009, NESTLE NUTR WORKS SE, V64, P185, DOI 10.1159/000235791; Rassin M, 2009, INT NURS REV, V56, P123, DOI 10.1111/j.1466-7657.2008.00681.x; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; Sampson Hugh A., 2003, Journal of Allergy and Clinical Immunology, V111, pS540; Sanchez-Valverde F, 2009, ALLERGY, V64, P884, DOI 10.1111/j.1398-9995.2008.01931.x; Sanz Ortega J, 2001, An Esp Pediatr, V54, P536; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Wood RA, 2003, PEDIATRICS, V111, P1631; Zeiger RS, 1999, J PEDIATR-US, V134, P614, DOI 10.1016/S0022-3476(99)70249-0	36	145	149	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2010	126	1					77	82		10.1016/j.jaci.2010.04.020		6	Allergy; Immunology	Allergy; Immunology	627SE	WOS:000280061800014	20541249	
J	Chen, G; Korfhagen, TR; Xu, Y; Kitzmiller, J; Wert, SE; Maeda, Y; Gregorieff, A; Clevers, H; Whitsett, JA				Chen, Gang; Korfhagen, Thomas R.; Xu, Yan; Kitzmiller, Joseph; Wert, Susan E.; Maeda, Yutaka; Gregorieff, Alexander; Clevers, Hans; Whitsett, Jeffrey A.			SPDEF is required for mouse pulmonary goblet cell differentiation and regulates a network of genes associated with mucus production	JOURNAL OF CLINICAL INVESTIGATION			English	Article							BRONCHIAL EPITHELIAL-CELLS; TRANSCRIPTION FACTOR; HUMAN AIRWAY; LUNG MORPHOGENESIS; MUCIN BIOSYNTHESIS; EXPRESSION; RECEPTOR; ASTHMA; GROWTH; IL-13	Various acute and chronic inflammatory stimuli increase the number and activity of pulmonary mucus-producing goblet cells, and goblet cell hyperplasia and excess mucus production are central to the pathogenesis of chronic pulmonary diseases. However, little is known about the transcriptional programs that regulate goblet cell differentiation. Here, we show that SAM-pointed domain-containing Ets-like factor (SPDEF) controls a transcriptional program critical for pulmonary goblet cell differentiation in mice. Initial cell-lineage-tracing analysis identified nonciliated secretory epithelial cells, known as Clara cells, as the progenitors of goblet cells induced by pulmonary allergen exposure in vivo. Furthermore, in vivo expression of SPDEF in Clara cells caused rapid and reversible goblet cell differentiation in the absence of cell proliferation. This was associated with enhanced expression of genes regulating goblet cell differentiation and protein glycosylation, including forkhead box A3 (Foxa3), anterior gradient 2 (Agr2), and glucosaminyl. (N-acetyl) transferase 3, mucin type (Gcnt3). Consistent with these findings, levels of SPDEF and FOXA3 were increased in mouse goblet cells after sensitization with pulmonary allergen, and the proteins were colocalized in goblet cells lining the airways of patients with chronic lung diseases. Deletion of the mouse Spdef gene resulted in the absence of goblet cells in tracheal/laryngeal submucosal glands and in the conducting airway epithelium after pulmonary allergen exposure in vivo. These data show that SPDEF plays a critical role in regulating a transcriptional network mediating the goblet cell differentiation and mucus hyperproduction associated with chronic pulmonary disorders.	[Chen, Gang; Korfhagen, Thomas R.; Xu, Yan; Kitzmiller, Joseph; Wert, Susan E.; Maeda, Yutaka; Whitsett, Jeffrey A.] Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Perinatal Inst, Cincinnati, OH 45229 USA; [Chen, Gang; Korfhagen, Thomas R.; Xu, Yan; Kitzmiller, Joseph; Wert, Susan E.; Maeda, Yutaka; Whitsett, Jeffrey A.] Univ Cincinnati, Sch Med, Cincinnati, OH USA; [Gregorieff, Alexander; Clevers, Hans] Netherlands Inst Dev Biol, Utrecht, Netherlands	Whitsett, JA (reprint author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Perinatal Inst, MLC 7029,3333 Burner Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org			NIH [HL090156, HL095580]	The authors acknowledge support from Ann Maher for preparation of the manuscript; the Morphology Core in the Division of Pulmonary Biology at Cincinnati Children's Hospital Medical Center; Michael Mucenski, Michael Bruno, and Angela Keiser for technical support; and Johannes C.M. van der Loo, Punam Malik, and Anusha Sridharan for assistance with lentiviral vectors. Grant support was provided by the NIH to J.A. Whitsett (HL090156 and HL095580) and T.R. Korfhagen (HL095580).	Betsuyaku T, 2004, MICRON, V35, P229, DOI 10.1016/j.micron.2003.11.015; Beum PV, 2005, AM J PHYSIOL-LUNG C, V288, pL116, DOI 10.1152/ajplung.00370.2003; Beum PV, 2001, ADV EXP MED BIOL, V491, P279; Chen H, 2005, J CELL BIOCHEM, V94, P168, DOI 10.1002/jcb.20297; Davies JR, 2007, INT J BIOCHEM CELL B, V39, P1943, DOI 10.1016/j.biocel.2007.05.013; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; Di Valentin E, 2009, AM J PHYSIOL-LUNG C, V296, pL185, DOI 10.1152/ajplung.90367.2008; Feldman RJ, 2003, CANCER RES, V63, P4626; Finkelman FD, 2005, J IMMUNOL, V174, P4630; Fulkerson PC, 2006, AM J RESP CELL MOL, V35, P337, DOI 10.1165/rcmb.2005-0474OC; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; GREGORIEFF A, 2006, THESIS U UTRECHT UTR; Guseh JS, 2009, DEVELOPMENT, V136, P1751, DOI 10.1242/dev.029249; Hattori R, 2008, ANN OTO RHINOL LARYN, V117, P51; Hiemisch H, 1997, EMBO J, V16, P3995, DOI 10.1093/emboj/16.13.3995; Holzinger A, 1996, HYBRIDOMA, V15, P49, DOI 10.1089/hyb.1996.15.49; HSU JC, 1981, ANN STAT, V9, P1026, DOI 10.1214/aos/1176345582; Huang J, 1999, AM J RESP CRIT CARE, V160, P725; Ishibashi Y, 2005, GLYCOCONJUGATE J, V22, P53, DOI 10.1007/s10719-005-0292-7; ISHIKAWA N, 1994, IMMUNOLOGY, V81, P480; Katz JP, 2002, DEVELOPMENT, V129, P2619; Kazanjian A, 2004, CANCER RES, V64, P6874, DOI 10.1158/0008-5472.CAN-04-0633; Komiya T, 1999, BBA-GENE STRUCT EXPR, V1444, P434, DOI 10.1016/S0167-4781(99)00010-X; Kunikata T, 2005, NAT IMMUNOL, V6, P524, DOI 10.1038/ni1188; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Maeda Y, 2007, PHYSIOL REV, V87, P219, DOI 10.1152/physrev.00028.2006; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; Matsumoto T, 1998, J ANTI-AGING MED, V1, P131, DOI 10.1089/rej.1.1998.1.131; Murata T, 1996, J IMMUNOL, V156, P2972; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AK, 2009, AM J RESP CELL MOL, V40, P1, DOI 10.1165/rcmb.2008-0011ED; Persson S, 2005, MOL PHYLOGENET EVOL, V36, P734, DOI 10.1016/j.ympev.2005.04.002; Ramirez RD, 2004, CANCER RES, V64, P9027, DOI 10.1158/0008-5472.CAN-04-3703; ROGERS DF, 1994, EUR RESPIR J, V7, P1690; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Ross AJ, 2007, AM J RESP CELL MOL, V37, P169, DOI 10.1165/rcmb.2006-0466OC; Salathe M, 2002, NOVART FDN SYMP, V248, P20; Schambach A, 2006, MOL THER, V13, P391, DOI 10.1016/j.ymthe.2005.08.012; Shatos MA, 2001, INVEST OPHTH VIS SCI, V42, P1455; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Tan SH, 2007, AM J RESP CELL MOL, V36, P737, DOI 10.1165/rcmb.2006-0334OC; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; van Es JH, 2005, NATURE, V435, P959, DOI 10.1038/nature03659; Vaughan MB, 2006, DIFFERENTIATION, V74, P141, DOI 10.1111/j.1432-0436.2006.00069.x; Wan HJ, 2004, P NATL ACAD SCI USA, V101, P14449, DOI 10.1073/pnas.0404424101; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wright GW, 2003, BIOINFORMATICS, V19, P2448, DOI 10.1093/bioinformatics/btg345; Xu Y, 2006, J BIOL CHEM, V281, P11279, DOI 10.1074/jbc.M512072200; Xu Y, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-455; Yang Q, 2001, SCIENCE, V294, P2155, DOI 10.1126/science.1065718; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; You YJ, 2002, AM J PHYSIOL-LUNG C, V283, pL1315, DOI 10.1152/ajplung.00169.2002; Zecchini V, 2005, GENE DEV, V19, P1686, DOI 10.1101/gad.341705; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC; ZEITLMANN L, 2006, Patent No. 2006061414; ZEITLMANN L, 2005, Patent No. 2005056604	60	145	146	0	11	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	OCT	2009	119	10					2914	2924		10.1172/JCI39731		11	Medicine, Research & Experimental	Research & Experimental Medicine	503HA	WOS:000270523100027	19759516	
J	Brackbill, RM; Hadler, JL; DiGrande, L; Ekenga, CC; Farfel, MR; Friedman, S; Perlman, SE; Stellman, SD; Walker, DJ; Wu, D; Yu, SC; Thorpe, LE				Brackbill, Robert M.; Hadler, James L.; DiGrande, Laura; Ekenga, Christine C.; Farfel, Mark R.; Friedman, Stephen; Perlman, Sharon E.; Stellman, Steven D.; Walker, Deborah J.; Wu, David; Yu, Shengchao; Thorpe, Lorna E.			Asthma and Posttraumatic Stress Symptoms 5 to 6 Years Following Exposure to the World Trade Center Terrorist Attack	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-CITY; CENTER HEALTH REGISTRY; DISASTER VICTIMS SPEAK; 11 SEPTEMBER 2001; PSYCHOMETRIC PROPERTIES; RESPIRATORY SYMPTOMS; RECOVERY WORKERS; PTSD CHECKLIST; RISK-FACTORS; CENTER SITE	Context The World Trade Center Health Registry provides a unique opportunity to examine long-term health effects of a large-scale disaster. Objective To examine risk factors for new asthma diagnoses and event-related post-traumatic stress (PTS) symptoms among exposed adults 5 to 6 years following exposure to the September 11, 2001, World Trade Center (WTC) terrorist attack. Design, Setting, and Participants Longitudinal cohort study with wave 1 (W1) enrollment of 71 437 adults in 2003-2004, including rescue/recovery worker, lower Manhattan resident, lower Manhattan office worker, and passersby eligibility groups; 46 322 adults (68%) completed the wave 2 (W2) survey in 2006-2007. Main Outcome Measures Self-reported diagnosed asthma following September 11; event-related current PTS symptoms indicative of probable posttraumatic stress disorder (PTSD), assessed using the PTSD Checklist (cutoff score >= 44). Results Of W2 participants with no stated asthma history, 10.2% (95% confidence interval [CI], 9.9%-10.5%) reported new asthma diagnoses postevent. Intense dust cloud exposure on September 11 was a major contributor to new asthma diagnoses for all eligibility groups: for example, 19.1% vs 9.6% in those without exposure among rescue/recovery workers (adjusted odds ratio, 1.5 [ 95% CI, 1.4-1.7]). Asthma risk was highest among rescue/recovery workers on the WTC pile on September 11 (20.5% [ 95% CI, 19.0%-22.0%]). Persistent risks included working longer at the WTC site, not evacuating homes, and experiencing a heavy layer of dust in home or office. Of participants with no PTSD history, 23.8% ( 95% CI, 23.4%-24.2%) reported PTS symptoms at either W1(14.3%) or W2 (19.1%). Nearly 10% ( 9.6% [ 95% CI, 9.3%-9.8%]) had PTS symptoms at both surveys, 4.7% ( 95% CI, 4.5%-4.9%) had PTS symptoms at W1 only, and 9.5% ( 95% CI, 9.3%-9.8%) had PTS symptoms at W2 only. At W2, passersby had the highest rate of PTS symptoms (23.2% [ 95% CI, 21.4%-25.0%]). Event-related loss of spouse or job was associated with PTS symptoms at W2. Conclusion Acute and prolonged exposures were both associated with a large burden of asthma and PTS symptoms 5 to 6 years after the September 11 WTC attack. JAMA. 2009;302(5):502-516 www.jama.com	[Hadler, James L.; DiGrande, Laura; Ekenga, Christine C.; Farfel, Mark R.; Friedman, Stephen; Perlman, Sharon E.; Stellman, Steven D.; Walker, Deborah J.; Wu, David; Yu, Shengchao; Thorpe, Lorna E.] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA; [Brackbill, Robert M.] Ctr Dis Control & Prevent, Agcy Tox Subst & Dis Registry, Atlanta, GA USA; [Stellman, Steven D.] Columbia Univ, Dept Epidemiol, Mailman Sch Publ Hlth, New York, NY USA	Thorpe, LE (reprint author), New York City Dept Hlth & Mental Hyg, 125 Worth St,Room 315, New York, NY 10013 USA.	lthorpe@health.nyc.gov			Agency for Toxic Substances and Disease Registry (ATSDR) of the Centers for Disease Control and Prevention (CDC) [U50/ATU272750]; National Center for Environmental Health (NCEH); New York City Department of Health and Mental Hygiene (NYCDOHMH)	This study was supported by Cooperative Agreement U50/ATU272750 from the Agency for Toxic Substances and Disease Registry (ATSDR) of the Centers for Disease Control and Prevention (CDC), which included support from the National Center for Environmental Health (NCEH), and by the New York City Department of Health and Mental Hygiene (NYCDOHMH).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrews B, 2007, AM J PSYCHIAT, V164, P1319, DOI 10.1176/appi.apj.2007.06091491; Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; Banauch GI, 2006, AM J RESP CRIT CARE, V174, P312, DOI 10.1164/rccm.200511-1736OC; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bonanno GA, 2004, AM PSYCHOL, V59, P20, DOI 10.1037/0003-066X.59.1.20; Brackbill Robert M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Brewin CR, 2008, J TRAUMA STRESS, V21, P3, DOI 10.1002/jts.20310; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Buyantseva LV, 2007, J OCCUP ENVIRON MED, V49, P310, DOI 10.1097/JOM.ob013e318032256e; Daly ES, 2008, J TRAUMA STRESS, V21, P227, DOI 10.1002/jts.20311; de la Hoz RE, 2008, INT ARCH OCC ENV HEA, V81, P479, DOI 10.1007/s00420-007-0240-x; DiGrande L, 2008, J TRAUMA STRESS, V21, P264, DOI 10.1002/jts.20345; Fagan J, 2003, PSYCHOSOM MED, V65, P993, DOI 10.1097/01.PSY.0000097334.48556.5F; Farfel M, 2008, J URBAN HEALTH, V85, P880, DOI 10.1007/s11524-008-9317-4; FRIEDMAN S, 2008, CITY HLTH INFORM, V27, P41; Galea S, 2003, AM J EPIDEMIOL, V158, P514, DOI 10.1093/aje/kwg187; Galea S, 2008, EPIDEMIOLOGY, V19, P47, DOI 10.1097/EDE.0b013e31815cIdbf; GAUTRIN D, 2006, ASTHMA WORKPLACE REL; HENNESSY CH, 1994, PUBLIC HEALTH REP, V109, P665; Herbert R, 2006, ENVIRON HEALTH PERSP, V114, P1853, DOI 10.1289/ehp.9592; Herbstman JB, 2005, ENVIRON RES, V99, P85, DOI 10.1016/j.envres.2004.08.010; Hobfoll SE, 2006, J TRAUMA STRESS, V19, P867, DOI 10.1002/jts.20166; Izbicki G, 2007, CHEST, V131, P1414, DOI 10.1378/chest.06-2114; King LA, 1998, J PERS SOC PSYCHOL, V74, P420, DOI 10.1037/0022-3514.74.2.420; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lin S, 2007, J ASTHMA, V44, P325, DOI 10.1080/02770900701344181; Linley PA, 2004, J TRAUMA STRESS, V17, P11, DOI 10.1023/B:JOTS.0000014671.27856.7e; Lioy PJ, 2006, ENVIRON SCI TECHNOL, V40, P6876, DOI 10.1021/es062980e; Lioy PJ, 2006, ANN NY ACAD SCI, V1076, P54, DOI 10.1196/annals.1371.002; Lombardo LJ, 2000, ENVIRON HEALTH PERSP, V108, P697, DOI 10.2307/3454406; Murphy J, 2007, STAT MED, V26, P1688, DOI 10.1002/sim.2806; Nandi A, 2004, J OCCUP ENVIRON MED, V46, P1057, DOI 10.1097/01.jom.0000141663.22902.0a; Norris FH, 2002, PSYCHIATRY, V65, P207, DOI 10.1521/psyc.65.3.207.20173; Norris FH, 2002, PSYCHIATRY, V65, P240, DOI 10.1521/psyc.65.3.240.20169; North Carol S, 2004, Ann Clin Psychiatry, V16, P209, DOI 10.1080/10401230490522034; North CS, 2002, J URBAN HEALTH, V79, P383, DOI 10.1093/jurban/79.3.383; Perrin MA, 2007, AM J PSYCHIAT, V164, P1385, DOI 10.1176/appi.apj.2007.06101645; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Reibman J, 2009, J OCCUP ENVIRON MED, V51, P534, DOI 10.1097/JOM.0b013e3181a0365b; Rodriguez JJ, 2008, CURR OPIN PSYCHIATR, V21, P370, DOI 10.1097/YCO.0b013e328304d984; Rudd RA, 2007, J ASTHMA, V44, P65, DOI 10.1080/02770900601125896; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Skloot GS, 2009, CHEST, V135, P492, DOI 10.1378/chest.08-1391; Thomas PA, 2008, ENVIRON HEALTH PERSP, V116, P1383, DOI 10.1289/ehp.11205; Ventureyra VAG, 2002, PSYCHOTHER PSYCHOSOM, V71, P47, DOI 10.1159/000049343; Verger P, 2004, AM J PSYCHIAT, V161, P1384, DOI 10.1176/appi.ajp.161.8.1384; Wagner VL, 2005, J URBAN HEALTH, V82, P76, DOI 10.1093/jurban/jti010; Weathers FW, 1993, ANN CONV INT SOC TRA; Webber MP, 2009, ENVIRON HEALTH PERSP, V117, P975, DOI 10.1289/ehp.0800291; Wheeler K, 2007, ENVIRON HEALTH PERSP, V115, P1584, DOI 10.1289/ehp.10248; *WORLD TRAD CTR HL, 2006, SAMPL BUILD DEN EST	52	145	145	2	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 5	2009	302	5					502	516				15	Medicine, General & Internal	General & Internal Medicine	479DS	WOS:000268640500015	19654385	
J	Morgenstern, V; Zutavern, A; Cyrys, J; Brockow, I; Gehring, U; Koletzko, S; Bauer, CP; Reinhardt, D; Wichmann, HE; Heinrich, J				Morgenstern, V.; Zutavern, A.; Cyrys, J.; Brockow, I.; Gehring, U.; Koletzko, S.; Bauer, C. P.; Reinhardt, D.; Wichmann, H-Erich; Heinrich, J.			Respiratory health and individual estimated exposure to traffic-related air pollutants in a cohort of young children	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							PARTICULATE MATTER; PRESCHOOL-CHILDREN; ATOPIC-DERMATITIS; NITROGEN-DIOXIDE; BIRTH COHORT; POLLUTION; ASTHMA; SYMPTOMS; ASSOCIATION; GIS	Objectives: To estimate long-term exposure to traffic-related air pollutants on an individual basis and to assess adverse health effects using a combination of air pollution measurement data, data from geographical information systems (GIS) and questionnaire data. Methods: 40 measurement sites in the city of Munich, Germany were selected at which to collect particulate matter with a 50% cut-off aerodynamic diameter of 2.5 mm (PM2.5) and to measure PM2.5 absorbance and nitrogen dioxide (NO2). A pool of GIS variables (information about street length, household and population density and land use) was collected for the Munich metropolitan area and was used in multiple linear regression models to predict traffic-related air pollutants. These models were also applied to the birth addresses of two birth cohorts (German Infant Nutritional Intervention Study (GINI) and Influence of Life-style factors on the development of the Immune System and Allergies in East and West Germany (LISA)) in the Munich metropolitan area. Associations between air pollution concentrations at birth address and 1-year and 2-year incidences of respiratory symptoms were analysed. Results: The following means for the estimated exposures to PM2.5, PM2.5 absorbance and NO2 were obtained: 12.8 mu g/m(3), 1.7 x 10(-5) m(-1) and 35.3 mu g/m(3), respectively. Adjusted odds ratios (ORs) for wheezing, cough without infection, dry cough at night, bronchial asthma, bronchitis and respiratory infections indicated positive associations with traffic-related air pollutants. After controlling for individual confounders, significant associations were found between the pollutant PM2.5 and sneezing, runny/stuffed nose during the first year of life (OR 1.16, 95% confidence interval 1.01 to 1.34) Similar effects were observed for the second year of life. These findings are similar to those from our previous analysis that were restricted to a subcohort in Munich city. The extended study also showed significant effects for sneezing, running/stuffed nose. Additionally, significant associations were found between NO2 and dry cough at night (or bronchitis) during the first year of life. The variable "living close to major roads'' (< 50 m), which was not analysed for the previous inner city cohort with birth addresses in the city of Munich, turned out to increase the risk of wheezing and asthmatic/spastic/obstructive bronchitis. Conclusions: Effects on asthma and hay fever are subject to confirmation at older ages, when these outcomes can be more validly assessed.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; Kinderklin & Kinderpoliklin Dr Haunerschen Kinder, Munich, Germany; Univ Augsburg, WZU, Ctr Environm Sci, D-8900 Augsburg, Germany; Tech Univ Munich, Kinderklin & Poliklin, D-8000 Munich, Germany; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands	Heinrich, J (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	joachim.heinrich@gsf.de	Mavoa, Suzanne/B-5372-2010; Cyrys, Josef/B-5359-2014; Wang, Linden/M-6617-2014	Cyrys, Josef/0000-0002-2105-8696; Gehring, Ulrike/0000-0003-3612-5780			Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Cyrys J, 2005, ENVIRON HEALTH PERSP, V113, P987, DOI 10.1289/ehp.7662; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gordian ME, 2006, J EXPO SCI ENV EPID, V16, P49, DOI 10.1038/sj.jea.7500436; Han KS, 2004, REMOTE SENS ENVIRON, V92, P52, DOI 10.1016/j.rse.2004.05.005; Heinrich J, 2005, OCCUP ENVIRON MED, V62, P517, DOI 10.1136/oem.2004.016766; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hochadel M, 2006, ATMOS ENVIRON, V40, P542, DOI 10.1016/j.atmosenv.2005.09.067; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Kuehni CE, 2006, INT J EPIDEMIOL, V35, P779, DOI 10.1093/ije/dyl022; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; *LAND MUNCH, 2006, STAT AMT; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Livingstone AE, 1996, BRIT MED J, V312, P676; Masson V, 2003, J CLIMATE, V16, P1261, DOI 10.1175/1520-0442-16.9.1261; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Monn C, 2001, ATMOS ENVIRON, V35, P1, DOI 10.1016/S1352-2310(00)00330-7; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WHO, 2005, WHO AIR QUAL GUID GL; Wilkinson P, 1999, THORAX, V54, P1070; WJST M, 1993, BRIT MED J, V307, P596; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	39	145	149	6	40	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JAN	2007	64	1					8	16		10.1136/oem.2006.028241		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	119VT	WOS:000243043100006	16912084	
J	Cates, EC; Fattouh, R; Wattie, J; Inman, MD; Goncharova, S; Coyle, AJ; Gutierrez-Ramos, JC; Jordana, M				Cates, EC; Fattouh, R; Wattie, J; Inman, MD; Goncharova, S; Coyle, AJ; Gutierrez-Ramos, JC; Jordana, M			Intranasal exposure of mice to house dust mite elicits allergic airway inflammation via a GM-CSF-mediated mechanism	JOURNAL OF IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; EPITHELIAL-CELLS; INHALED ANTIGEN; T-CELL; SENSITIZED MICE; IGE RESPONSES; MODEL; HYPERRESPONSIVENESS; EOSINOPHILIA; OVALBUMIN	It is now well established that passive exposure to inhaled OVA leads to a state of immunological tolerance. Therefore, to elicit allergic sensitization, researchers have been compelled to devise alternative strategies, such as the systemic delivery of OVA in the context of powerful adjuvants, which are alien to the way humans are exposed and sensitized to allergens. The objectives of these studies were to investigate immune-inflammatory responses to intranasal delivery of a purified house dust mite (HDM) extract and to evaluate the role of GM-CSF in this process. HDM was delivered to BALB/c mice daily for 10 days. After the last exposure, mice were killed, bronchoalveolar lavage was performed, and samples were obtained. Expression/production of Th2-associated molecules in the lymph nodes, lung, and spleen were evaluated by real-time quantitative PCR and ELISA, respectively. Using this exposure protocol, exposure to HDM alone generated Th2 sensitization based on the expression/production of Th2 effector molecules and airway eosinophilic inflammation. Flow cytometric analysis demonstrated expansion and activation of APCs in the lung and an influx of activated Th2 effector cells. Moreover, this inflammation was accompanied by airways hyper-responsiveness and a robust memory-driven immune response. Finally, administration of anti-GM-CSF-neutralizing Abs markedly reduced immune-inflammatory responses in both lung and spleen. Thus, intranasal delivery of HDM results in Th2 sensitization and airway eosinophilic inflammation that appear to be mediated, at least in part, by endogenous GM-CSF production.	McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, Div Resp Dis & Allergy, W Hamilton, ON L8S 3Z5, Canada; St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON, Canada; Millennium Pharmaceut, Cambridge, MA 02139 USA	Jordana, M (reprint author), McMaster Univ, Dept Pathol & Mol Med, Ctr Gene Therapeut, Div Resp Dis & Allergy, HSC-4H21,1200 Main St, W Hamilton, ON L8S 3Z5, Canada.	jordanam@mcmaster.ca					Asokananthan N, 2002, J IMMUNOL, V169, P4572; Duez C, 1996, EUR J IMMUNOL, V26, P1088, DOI 10.1002/eji.1830260520; Gajewska BU, 2001, J CLIN INVEST, V108, P577, DOI 10.1172/JCI12627; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; Hewitt CRA, 1998, ALLERGY, V53, P60; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Hoyne GF, 2000, AM J RESP CRIT CARE, V162, pS169; Hsiue TR, 1997, INT ARCH ALLERGY IMM, V112, P295; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; King C, 1998, J IMMUNOL, V161, P3645; Lee YL, 2001, HUM GENE THER, V12, P2065, DOI 10.1089/10430340152677412; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; Neeno T, 1996, J IMMUNOL, V156, P3191; OBrien RM, 1996, IMMUNOL CELL BIOL, V74, P174, DOI 10.1038/icb.1996.24; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; Ritz SA, 2002, AM J RESP CELL MOL, V27, P428, DOI 10.1165/rcmb.4824; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Sun G, 2001, J IMMUNOL, V167, P1014; Swirski FK, 2002, CLIN EXP ALLERGY, V32, P411, DOI 10.1046/j.1365-2222.2002.01291.x; Swirski FK, 2002, J IMMUNOL, V169, P3499; Tategaki A, 2002, INT ARCH ALLERGY IMM, V129, P204, DOI 10.1159/000066774; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Volgyesi GA, 2000, J APPL PHYSIOL, V89, P413	30	145	153	0	12	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	NOV 15	2004	173	10					6384	6392				9	Immunology	Immunology	869QL	WOS:000224999000058	15528378	
J	Vander Leek, TK; Liu, AH; Stefanski, K; Blacker, B; Bock, SA				Vander Leek, TK; Liu, AH; Stefanski, K; Blacker, B; Bock, SA			The natural history of peanut allergy in young children and its association with serum peanut-specific IgE	JOURNAL OF PEDIATRICS			English	Article							COW MILK ALLERGY; FOOD CHALLENGES; CLINICAL COURSE; DOUBLE-BLIND; NUT ALLERGY; SKIN-TESTS; HYPERSENSITIVITY; ANAPHYLAXIS; ADOLESCENTS; INFANTS	Objectives: To observe the nature and frequency of adverse reactions caused by accidental peanut exposure in young children with clinical peanut hypersensitivity and to determine the value of serum peanut-specific IgE levels during follow-up. Study design: Eighty-three children with clinical peanut hypersensitivity diagnosed before their fourth birthdays were contacted yearly to track adverse peanut reactions. Serum peanut-specific IgE levels were determined in 51 of 83 subjects. Results: Fifty-eight percent (31/53) of subjects followed up for 5 years experienced adverse reactions from accidental peanut exposure, Regardless of the nature of their initial reaction, the majority with subsequent reactions (52%, 31/60) experienced potentially life-threatening symptoms. The group with isolated skin symptoms (11/51, 22%) had lower serum peanut-specific IgE levels than the group with respiratory and/or gastrointestinal symptoms (40/51, 78%) (median: 1.25 kU(A)/L vs 11.65 kU(A)/L, P = .004, Wilcoxon rank sums test). Despite this, there was no threshold level below which only skin symptoms appeared to occur. Four selected subjects had negative double-blind placebo-controlled food challenge responses to peanuts during follow-up. Conclusions: The majority of children with clinical peanut hypersensitivity followed up for 5 years will have adverse reactions from accidental peanut exposure. Symptoms experienced during subsequent adverse peanut reactions may not be consistent with symptoms reported during initial reactions. Therefore proper education regarding peanut avoidance land treatment of adverse reactions is necessary in all cases of clinical peanut hypersensitivity. Young children who are allergic to peanuts can lose clinical hypersensitivity.	Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Bock, SA (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,Rm J211, Denver, CO 80206 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NCRR NIH HHS [M 01 RR00051]		BECK MS, 1990, MEAS SCI TECHNOL, V1, P561, DOI 10.1088/0957-0233/1/7/004; BISHOP JM, 1990, J PEDIATR-US, V116, P862, DOI 10.1016/S0022-3476(05)80641-9; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOCK SA, 1978, CLIN ALLERGY, V8, P559, DOI 10.1111/j.1365-2222.1978.tb01509.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; Eigenmann PA, 1998, PEDIATR ALLERGY IMMU, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Ewan PW, 1996, BRIT MED J, V312, P1074; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Hourihane JO, 1996, BRIT MED J, V313, P518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Hourihane JO, 1998, BRIT MED J, V316, P1271; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1046/j.1365-2222.1996.d01-297.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; SAMPSON HA, 1985, J PEDIATR-US, V107, P669, DOI 10.1016/S0022-3476(85)80390-5; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sicherer S.H., 1998, PEDIATRICS, V102, P6; Tariq SM, 1996, BRIT MED J, V313, P514; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	23	145	147	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	DEC	2000	137	6					749	755		10.1067/mpd.2000.109376		7	Pediatrics	Pediatrics	383HD	WOS:000165876300005	11113829	
J	Douwes, J; Zuidhof, A; Doekes, G; van der Zee, S; Wouters, I; Boezen, HM; Brunekreef, B				Douwes, J; Zuidhof, A; Doekes, G; van der Zee, S; Wouters, I; Boezen, HM; Brunekreef, B			(1 -> 3)-beta-D-glucan and endotoxin in house dust and peak flow variability in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							RESPIRATORY SYMPTOMS; HOME DAMPNESS; AIRWAYS INFLAMMATION; ASTHMATIC SYMPTOMS; CHILDHOOD ASTHMA; MITE ALLERGEN; EXPOSURE; HEALTH; MOLDS; ENVIRONMENTS	House dust-associated bacterial endotoxins have been shown to be associated with asthma severity, and a similar role has been suggested for fungal (1-->3)-beta-D-glucans. In this study the relation between these agents and peak expiratory flow (PEF) variability was investigated in 148 children 7 to 11 yr of age of whom 50% had self- or parent-reported chronic respiratory symptoms. All children self-monitored twice daily their PEF for a period of 16 wk. Dust samples were collected from mattresses and from living room and bedroom floors, and endotoxin and (1-->3)-beta-D-glucan were measured in dust extracts. The relations with mean daily PEF variability (Ampl%mean) were investigated by linear regression analysis, adjusting for dust mite allergen levels, presence of pets, and type of floor cover. In unadjusted analyses the levels of both endotoxin and (1-->3)-beta-D-glucan per square meter of living room floor were significantly associated with PEF-variability (but not when expressed per gram of sampled dust), particularly in atopic children with asthma symptoms. Adjusted analyses showed the same association for (1-->3)-beta-D-glucan but not for endotoxin. Although no associations were found with microbial agent levels in bedroom floor or mattress dust, high levels of (1-->3)-beta-D-glucan in living room floor dust apparently increase PEF variability in asthmatic children.	Univ Wageningen & Res Ctr, Environm & Occupat Hlth Grp, NL-6700 AE Wageningen, Netherlands; Univ Groningen, Dept Epidemiol, Groningen, Netherlands; Wellington Sch Med, Wellington Asthma Res Grp, Wellington, New Zealand	Doekes, G (reprint author), Univ Wageningen & Res Ctr, Environm & Occupat Hlth Grp, POB 238, NL-6700 AE Wageningen, Netherlands.			brunekreef, bert/0000-0001-9908-0060; Douwes, Jeroen/0000-0003-3599-4036			Andriessen JW, 1998, CLIN EXP ALLERGY, V28, P1191; *BIBLE, LEVITICUS, V14; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BLACKLEY CH, 1873, HAY FEVER EXPT RES C; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; COLOFF MJ, 1992, CLIN EXP ALLERGY   S, V22, P1; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; FLOYER SJ, 1726, TREATISE ASTHMA; FOGELMARK B, 1994, INT J EXP PATHOL, V75, P85; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Jalaludin B, 1998, J ALLERGY CLIN IMMUN, V102, P382, DOI 10.1016/S0091-6749(98)70124-1; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; ROEMER W, 1998, EUR RESPIR REV, V8, P4; Rylander R, 1997, MEDIAT INFLAMM, V6, P275, DOI 10.1080/09629359791613; SMID T, 1992, AM REV RESPIR DIS, V146, P1474; Stone BA, 1992, CHEM BIOL 1 3 BETA G; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; STRACHAN DP, 1988, BRIT MED J, V297, P1223; Thorn J, 1998, AM J IND MED, V33, P463; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; Ulmer AJ, 1997, INT J OCCUP ENV HEAL, V3, pS8; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; ZOCK JP, 1994, EUR RESPIR J, V7, P1254, DOI 10.1183/09031936.94.07071254; 1850, NATURE, V2, P199	38	145	146	2	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT	2000	162	4					1348	1354				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	364RD	WOS:000089905900027	11029343	
J	Kerstjens, HAM; Disse, B; Schroder-Babo, W; Bantje, TA; Gahlemann, M; Sigmund, R; Engel, M; van Noord, JA				Kerstjens, Huib A. M.; Disse, Bernd; Schroeder-Babo, Winfried; Bantje, Theo A.; Gahlemann, Martina; Sigmund, Ralf; Engel, Michael; van Noord, Jan A.			Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; severe uncontrolled asthma; randomized controlled trial; anticholinergics; tiotropium	OBSTRUCTIVE PULMONARY-DISEASE; COPD PATIENTS; BROMIDE; ADULTS; EFFICACY	Background: Some patients with severe asthma remain symptomatic and obstructed despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic agent, might be an effective bronchodilator in such patients. Objective: We sought to compare the efficacy and safety of 2 doses of tiotropium (5 and 10 mu g daily) administered through the Respimat inhaler with placebo as add-on therapy in patients with uncontrolled severe asthma (Asthma Control Questionnaire score, >= 1.5; postbronchodilator FEV(1), <= 80% of predicted value) despite maintenance treatment with at least a high-dose inhaled corticosteroid plus a long-acting beta(2)-agonist. Methods: This was a randomized, double-blind, crossover study with three 8-week treatment periods. The primary end point was peak FEV(1) at the end of each treatment period. Results: Of 107 randomized patients (54% female patients; mean, 55 years of age; postbronchodilator FEV(1), 65% of predicted value), 100 completed all periods. Peak FEV(1) was significantly higher with 5 mu g (difference, 139 mL; 95% CI, 96181 mL) and 10 mu g (difference, 170 mL; 95% CI, 128-213 mL) of tiotropium than with placebo (both P < .0001). There was no significant difference between the active doses. Trough FEV(1) at the end of the dosing interval was higher with tiotropium (5 mg: 86 mL [95% CI, 41-132 mL]; 10 mg: 113 mL [95% CI, 67-159 mL]; both P < .0004). Daily home peak expiratory flow measurements were higher with both tiotropium doses. There were no significant differences in asthma-related health status or symptoms. Adverse events were balanced across groups except for dry mouth, which was more common on 10 mu g of tiotropium. Conclusion: The addition of once-daily tiotropium to asthma treatment, including a high-dose inhaled corticosteroid plus a long-acting beta(2)-agonist, significantly improves lung function over 24 hours in patients with inadequately controlled, severe, persistent asthma. (J Allergy Clin Immunol 2011;128:308-14.)	[Kerstjens, Huib A. M.] Univ Groningen, Dept Pulmonol, Univ Med Ctr Groningen, NL-9700 RB Groningen, Netherlands; [Disse, Bernd; Gahlemann, Martina; Sigmund, Ralf; Engel, Michael] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany; [Schroeder-Babo, Winfried] Krankenhaus Gelnhausen, Gelnhausen, Germany; [Bantje, Theo A.] Amphia Ziekenhuis, Dept Pulmonol, Breda, Netherlands; [van Noord, Jan A.] Atrium Med Ctr, Dept Pulmonol, Heerlen, Netherlands	Kerstjens, HAM (reprint author), Univ Groningen, Dept Pulmonol, Univ Med Ctr Groningen, Postbox 30-001, NL-9700 RB Groningen, Netherlands.	h.a.m.kerstjens@long.umcg.nl			Boehringer Ingelheim; Pfizer; Chiesi; Novartis; GlaxoSmithKline	H. A. M. Kerstjens receives research support from Boehringer Ingelheim and Pfizer and has consulted with Boehringer Ingelheim. J. A. van Noord receives research support from Boehringer Ingelheim, Chiesi, Novartis, and GlaxoSmithKline. The rest of the authors have declared that they have no conflict of interest.	Bateman ED, 2010, RESP MED, V104, P1460, DOI 10.1016/j.rmed.2010.06.004; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bateman ED, 2011, J ALLERGY CLIN IMMUN, V128, P315, DOI 10.1016/j.jaci.2011.06.004; BOS ST, 2007, EUR RESPIR J, V30, P653; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Disse B, 1999, LIFE SCI, V64, P457, DOI 10.1016/S0024-3205(98)00588-8; Fardon T, 2007, RESP MED, V101, P1218, DOI 10.1016/j.rmed.2006.11.001; Global Initiative for Asthma - GINA, 2009, GLOB STRAT ASTHM MAN; Gosens R, 2005, AM J RESP CRIT CARE, V171, P1096, DOI 10.1164/rccm.200409-1249OC; Gross NJ, 2006, EUR J PHARMACOL, V533, P36, DOI 10.1016/j.ejphar.2005.12.072; Iwamoto H, 2008, EUR RESPIR J, V31, P1379, DOI 10.1183/09031936.00014108; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Kapoor AS, 2009, CAN RESPIR J, V16, P99; Littner MR, 2000, AM J RESP CRIT CARE, V161, P1136; Magnussen H, 2008, RESP MED, V102, P50, DOI 10.1016/j.rmed.2007.08.003; Park HW, 2009, ALLERGY, V64, P778, DOI 10.1111/j.1398-9995.2008.01876.x; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; QUANJER PH, 1993, EUR RESPIR J, V6, P5; Rodrigo G, 1999, AM J MED, V107, P363, DOI 10.1016/S0002-9343(99)00243-0; ROISIN RR, GLOB IN CHRON OBSTR; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; van Noord JA, 2009, RESP MED, V103, P22, DOI 10.1016/j.rmed.2008.10.002; van Noord JA, 2005, EUR RESPIR J, V26, P214, DOI 10.1183/09031936.05.00140404; Westby M, 2004, COCHRANE DB SYST REV	26	144	149	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2011	128	2					308	314		10.1016/j.jaci.2011.04.039		7	Allergy; Immunology	Allergy; Immunology	799IQ	WOS:000293280800009	21636120	
J	Fens, N; Zwinderman, AH; van der Schee, MP; de Nijs, SB; Dijkers, E; Roldaan, AC; Cheung, D; Bel, EH; Sterk, PJ				Fens, Niki; Zwinderman, Aeilko H.; van der Schee, Marc P.; de Nijs, Selma B.; Dijkers, Erica; Roldaan, Albert C.; Cheung, David; Bel, Elisabeth H.; Sterk, Peter J.			Exhaled Breath Profiling Enables Discrimination of Chronic Obstructive Pulmonary Disease and Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						biomarkers; diagnosis; electronic nose; exhaled breath; volatile organic compounds	ELECTRONIC NOSE; LUNG-CANCER; SYSTEMIC INFLAMMATION; GLOBAL STRATEGY; COPD; AIR; SIMILARITIES; BIOMARKERS; PROTEOMICS; MECHANISMS	Rationale Chronic obstructive pulmonary disease (COPD) and asthma can exhibit overlapping clinical features. Exhaled air contains volatile organic compounds (VOCs) that may qualify as noninvasive biomarkers. VOC profiles can be assessed using integrative analysis by electronic nose, resulting in exhaled molecular fingerprints (breathprints). Objectives: We hypothesized that breathprints by electronic nose can discriminate patients with COPD and asthma. Methods: Ninety subjects participated in a cross-sectional study: 30 patients with COPD (age, 61.6+/-9.3 years; FEV1, 1.72+/-0.69 L), 20 patients with asthma (age, 35.4+/-15.1 years; FEV1, 3.32+/-0.86 L), 20 nonsmoking control subjects (age, 56.7+/-9.3 years; FEV1, 3.44+/-0.76 L), and 20 smoking control subjects (age, 56.1+/-5.9 years; FEV1, 3.58+/-0.78). After 5 minutes of tidal breathing through an inspiratory VOC filter, an expiratory vital capacity was collected in a Tedlar bag and sampled by electronic nose. Breathprints were analyzed by discriminant analysis on principal component reduction resulting in cross-validated accuracy values (accuracy). Repeatability and reproducibility were assessed by measuring samples in duplicate by two devices. Measurements and Main Results: Breathprints from patients with asthma were separated from patients with COPD (accuracy 96%; P < 0.001), from nonsmoking control subjects (accuracy, 95%; P < 0.001), and from smoking control subjects (accuracy, 92.5%; P < 0.001). Exhaled breath profiles of patients with COPD partially overlapped with those of asymptomatic smokers (accuracy, 66%; P = 0.006). Measurements were repeatable and reproducible. Conclusions: Molecular profiling of exhaled air can distinguish patients with COPD and asthma and control subjects. Our data demonstrate a potential of electronic noses in the differential diagnosis of obstructive airway diseases and in the risk assessment in asymptomatic smokers. Clinical trial registered with www.trialregister.nI (NTR 1282).	[Fens, Niki; van der Schee, Marc P.; de Nijs, Selma B.; Dijkers, Erica; Bel, Elisabeth H.; Sterk, Peter J.] Univ Amsterdam, Dept Resp Med, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; [Roldaan, Albert C.] Haga Teaching Hosp Leyweg, Dept Pulm Dis, The Hague, Netherlands; [Cheung, David] Albert Schweitzer Hosp, Dept Resp Med, Dordrecht, Netherlands	Fens, N (reprint author), Univ Amsterdam, Dept Resp Med, Acad Med Ctr, F5-260,POB 22700, NL-1100 DE Amsterdam, Netherlands.	N.Fens@amc.nl			Netherlands Asthma Foundation [3.2.06.17]	Supported by Netherlands Asthma Foundation grant no. 3.2.06.17.	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bateman ED, 2008, GLOBAL INITIATIVE AS; Bhattacharya S, 2009, AM J RESP CELL MOL, V40, P359, DOI 10.1165/rcmb.2008-0114OC; Bossuyt PM, 2003, ANN INTERN MED, V138, pW1, DOI DOI 10.7326/0003-4819-138-1-200301070-00010; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Buszewski B, 2007, BIOMED CHROMATOGR, V21, P553, DOI 10.1002/bmc.835; Carraro S, 2007, AM J RESP CRIT CARE, V175, P986, DOI 10.1164/rccm.200606-769OC; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Crameri R, 2005, ALLERGY, V60, P1227, DOI 10.1111/j.1398-9995.2005.00873.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Laurentiis G, 2008, EUR RESPIR J, V32, P1175, DOI 10.1183/09031936.00072408; Decramer M, 2005, INT J CLIN PRACT, V59, P385, DOI 10.1111/j.1368-5031.2005.00509.x; Dragonieri S, 2007, J ALLERGY CLIN IMMUN, V120, P856, DOI 10.1016/j.jaci.2007.05.043; Dragonieri S, 2009, LUNG CANCER, V64, P166, DOI 10.1016/j.lungcan.2008.08.008; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Fens N, 2009, AM J RESP CRIT CARE, V179; FENS N, 2009, AM J RESP CRIT CARE, V179, pA4324; Friedrich MJ, 2009, JAMA-J AM MED ASSOC, V301, P585, DOI 10.1001/jama.2009.90; Gaspar EM, 2009, J CHROMATOGR A, V1216, P2749, DOI 10.1016/j.chroma.2008.10.125; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Gluud C, 2005, BRIT MED J, V330, P724, DOI 10.1136/bmj.330.7493.724; Guerra S, 2005, CURR OPIN PULM MED, V11, P7; HIGASHIMOTO Y, RESP MED IN PRESS; Higashimoto Y, 2008, RESPIROLOGY, V13, P128, DOI 10.1111/j.1440-1843.2007.01170.x; Jousilahti P, 2002, ANN ALLERG ASTHMA IM, V89, P381; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; Knottnerus JA, 2003, J CLIN EPIDEMIOL, V56, P1118, DOI 10.1016/S0895-4356(03)00206-3; Lewis NS, 2004, ACCOUNTS CHEM RES, V37, P663, DOI 10.1021/ar030120m; Machado RF, 2005, AM J RESP CRIT CARE, V171, P1286, DOI 10.1164/rccm.200409-1184OC; Mauad T, 2008, CURR OPIN PULM MED, V14, P31, DOI 10.1097/MCP.0b013e3282f19846; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Morrison D, 1999, AM J RESP CRIT CARE, V159, P473; Moser B, 2005, RESP PHYSIOL NEUROBI, V145, P295, DOI 10.1016/j.resp.2004.02.002; Paredi P, 2000, AM J RESP CRIT CARE, V162, P1450; PAULING L, 1971, P NATL ACAD SCI USA, V68, P2374, DOI 10.1073/pnas.68.10.2374; Phillips M, 2008, CLIN CHIM ACTA, V393, P76, DOI 10.1016/j.cca.2008.02.021; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Scott SM, 2006, MICROCHIM ACTA, V156, P183, DOI 10.1007/s00604-006-0623-9; Sepper R, 2004, J PROTEOME RES, V3, P277, DOI 10.1021/pr049955x; Shaham O, 2005, SENSOR ACTUAT B-CHEM, V106, P76, DOI 10.1016/j.snb.2004.05.039; Van Berkel JJBN, 2008, J CHROMATOGR B, V861, P101, DOI 10.1016/j.jchromb.2007.11.008; Weston AD, 2004, J PROTEOME RES, V3, P179, DOI 10.1021/pr0499693; Wouters EFM, 2002, THORAX, V57, P1067, DOI 10.1136/thorax.57.12.1067	45	144	148	6	22	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2009	180	11					1076	1082		10.1164/rccm.200906-0939OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	523WA	WOS:000272104100008	19713445	
J	Scadding, GK; Durlham, SR; Mirakian, R; Jones, NS; Leech, SC; Farooque, S; Ryan, D; Walker, SM; Clark, AT; Dixon, TA; Jolles, SRA; Siddique, N; Cullinan, P; Howarth, PH; Nasser, SM				Scadding, G. K.; Durlham, S. R.; Mirakian, R.; Jones, N. S.; Leech, S. C.; Farooque, S.; Ryan, D.; Walker, S. M.; Clark, A. T.; Dixon, T. A.; Jolles, S. R. A.; Siddique, N.; Cullinan, P.; Howarth, P. H.; Nasser, S. M.			BSACI guidelines for the management of allergic and non-allergic rhinitis	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review						allergen; allergy; antihistamine; anti-leukotriene; aspirin; asthma; BSACI; cat allergen; child; corticosteroid; cromoglicate; decongestant; guideline; house dust mite; IgE; immunotherapy; ipratropium bromide; lactation; nitric oxide; occupational; pregnancy; rhinitis; rhinosinusitis; sinusitis; skin prick test; sublingual immunotherapy; surgery	AQUEOUS NASAL SPRAY; LEUKOTRIENE RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED-TRIAL; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; PLACEBO-CONTROLLED EVALUATION; GRASS-POLLEN IMMUNOTHERAPY; CONTROLLED CLINICAL-TRIAL; HEALTH-CARE WORKERS; QUALITY-OF-LIFE; DOUBLE-BLIND	This guidance for the management of patients with allergic and non-allergic rhinitis has been prepared by the Standards of Care Committee (SOCC) of the British Society for Allergy and Clinical Immunology (BSACI). The guideline is based on evidence as well as on expert opinion and is for use by both adult physicians and paediatricians practicing in allergy. The recommendations are evidence graded. During the development of these guidelines, all BSACI members were included in the consultation process using a web-based system. Their comments and suggestions were carefully considered by the SOCC. Where evidence was lacking, consensus was reached by the experts on the committee. Included in this guideline are clinical classification of rhinitis, aetiology, diagnosis, investigations and management including subcutaneous and sublingual immunotherapy. There are also special sections for children, co-morbid associations and pregnancy. Finally, we have made recommendations for potential areas of future research.	[Mirakian, R.; Clark, A. T.; Nasser, S. M.] Univ Cambridge, NHS Fdn Trust, Allergy Clin, Cambridge, England; [Scadding, G. K.] Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England; [Durlham, S. R.] Imperial Coll NHLI, Dept Upper Resp Med, London, England; [Jones, N. S.] Queens Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Nottingham NG7 2UH, England; [Leech, S. C.] Kings Coll Hosp London, Dept Child Hlth, London, England; [Farooque, S.] Guys Hosp, Dept Asthma Allergy & Resp Med, London SE1 9RT, England; [Ryan, D.] Univ Aberdeen, Dept Gen Practice & Primary Care, Aberdeen, Scotland; [Walker, S. M.] The Athenaeum, Educ Hlth, Warwick, England; [Dixon, T. A.] Royal Liverpool & Broadgreen Univ Hosp, NHS Trust, Liverpool, Merseyside, England; [Jolles, S. R. A.] Univ Wales Hosp, Cardiff, Wales; [Siddique, N.] Southampton Gen Hosp, Dept Resp Med, Southampton SO9 4XY, Hants, England; [Cullinan, P.] Univ London Imperial Coll Sci Technol & Med, Dept Occupat & Environm Med, London, England	Nasser, SM (reprint author), Univ Cambridge, NHS Fdn Trust, Allergy Clin 2A, Cambridge CB2 0QQ, England.	shuaib.nasser@addenbrookes.nhs.uk	Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258; Jolles, Stephen/0000-0002-7394-6804	Medical Research Council [G0501746]		ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407; Allen DB, 2000, J ALLERGY CLIN IMM S, V106, P179; ALVAREZCUESTA O, 2006, ALLERGY S82, V61, P1; AUBIER M, 1991, AM REV RESPIR DIS, V143, P346; Bachert C, 2004, IMMUNOL ALLERGY CLIN, V24, P19, DOI 10.1016/S0889-8561(03)00104-8; Bachert C, 2004, ALLERGY, V59, P11, DOI 10.1111/j.0108-1675.2004.00389.x; Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Barry B, 2000, Rev Prat, V50, P1548; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Blaiss MS, 2004, CURR MED RES OPIN, V20, P1937, DOI 10.1185/030079904X13266; Blaiss MS, 2000, ALLERGY ASTHMA PROC, V21, P7, DOI 10.2500/108854100778248953; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Bonadonna P, 2001, AM J RHINOL, V15, P297; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858; British Thoracic Society, 2003, THORAX S1, V58, pi1; BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6; Bui CM, 2005, J ALLERGY CLIN IMMUN, V116, P1042, DOI 10.1016/j.jaci.2005.07.031; Canonica GW, 2007, ALLERGY, V62, P359, DOI 10.1111/j.1398-9995.2006.01277.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; Ciprandi G, 2004, CLIN EXP ALLERGY, V34, P958, DOI 10.1111/j.1365-2222.2004.01960.x; Ciprandi G, 2001, ALLERGY, V56, P1068, DOI 10.1034/j.1398-9995.2001.00191.x; Ciprandi G, 1997, J ALLERGY CLIN IMMUN, V99, P301, DOI 10.1016/S0091-6749(97)70046-0; Clement P A, 1984, Rhinology, V22, P151; Clement PAR, 1999, INT J PEDIATR OTORHI, V49, pS95, DOI 10.1016/S0165-5876(99)00141-X; Cockburn IM, 1999, J OCCUP ENVIRON MED, V41, P948, DOI 10.1097/00043764-199911000-00005; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Corren J, 2007, CURR OPIN PULM MED, V13, P13, DOI 10.1097/MCP.0b013e328010d0db; Cortona G, 2001, G Ital Med Lav Ergon, V23, P64; Cottin V, 2003, Rev Pneumol Clin, V59, P17; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187; de Blic J, 2005, PEDIATR ALLERGY IMMU, V16, P267, DOI 10.1111/j.1399-3038.2005.00216.x; Demoly P, 2003, DRUGS, V63, P1813, DOI 10.2165/00003495-200363170-00004; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; Diav-Citrin O, 2003, J ALLERGY CLIN IMMUN, V111, P1239, DOI 10.1067/mai.2003.1499; Didier A, 2006, J ALLERGY CLIN IMMUN, V117, P721, DOI 10.1016/j.jaci.2006.01.022; DOTY RL, 1984, LARYNGOSCOPE, V94, P176, DOI 10.1288/00005537-198402000-00004; Doyle William J, 2002, Curr Opin Allergy Clin Immunol, V2, P21, DOI 10.1097/00130832-200202000-00004; Drake-Lee A, 2002, J LARYNGOL OTOL, V116, P580; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Dykewicz MS, 2003, ANN ALLERG ASTHMA IM, V91, P44; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518; Ellegard EK, 2001, CLIN OTOLARYNGOL, V26, P394, DOI 10.1046/j.1365-2273.2001.00491.x; Ellegard Eva K, 2003, Am J Respir Med, V2, P469; Fergie N, 1999, J LARYNGOL OTOL, V113, P893; FERGUSON JL, 1990, OTOLARYNG HEAD NECK, V102, P207; Filon FL, 2006, OCCUP ENVIRON MED, V63, P121, DOI 10.1136/oem.2003.011460; Flanagan P, 1997, ACTA OTO-LARYNGOL, V117, P590, DOI 10.3109/00016489709113443; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Fokkens WJ, 1998, AM J RHINOL, V12, P21, DOI 10.2500/105065898782102990; Fowler PD, 2002, CLIN OTOLARYNGOL, V27, P489, DOI 10.1046/j.1365-2273.2002.00627.x; Fowler SJ, 2002, EUR J CLIN PHARMACOL, V58, P187, DOI 10.1007/s00228-002-0458-1; FREW AJ, 1993, BRIT MED J, V307, P919; Gani F, 2001, ALLERGY, V56, P65, DOI 10.1034/j.1398-9995.2001.00794.x; GANI F, 2003, ALLERG IMMUNOL, V35, P306; Garavello W, 2005, INT ARCH ALLERGY IMM, V137, P310, DOI 10.1159/000086462; Garavello W, 2003, PEDIATR ALLERGY IMMU, V14, P140, DOI 10.1034/j.1399-3038.2003.00021.x; Garay R, 2004, ALLERGY, V59, P4, DOI 10.1111/j.0108-1675.2004.00388.x; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899; GERBLICH AA, 1986, J ALLERGY CLIN IMMUN, V77, P676, DOI 10.1016/0091-6749(86)90408-2; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Gleeson M, 1996, CLIN EXP ALLERGY, V26, P697, DOI 10.1111/j.1365-2222.1996.tb00596.x; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Grammer LC, 2002, J OCCUP ENVIRON MED, V44, P1179, DOI 10.1097/01.jom.0000044121.59147.44; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; GROSSMAN J, 1995, J ALLERGY CLIN IMMUN, V95, P1123, DOI 10.1016/S0091-6749(95)70216-4; Gwaltney J M Jr, 1999, Can Respir J, V6 Suppl A, p46A; Gwaltney JM, 2002, AM J MED, V112, p13S; Hadley JA, 2003, OTOLARYNG CLIN N AM, V36, P825, DOI 10.1016/S0030-6665(03)00054-9; HALL SK, 1994, ANN EMERG MED, V23, P884, DOI 10.1016/S0196-0644(94)70329-9; Hamano N, 1998, ALLERGY ASTHMA PROC, V19, P263, DOI 10.2500/108854198778557773; Hansen Inga, 2004, Curr Opin Allergy Clin Immunol, V4, P159, DOI 10.1097/00130832-200406000-00004; Hemery ML, 2004, ALLERGY, V59, P1013, DOI 10.1111/j.1398-9995.2004.00484.x; Hilberg O, 2000, Rhinol Suppl, V16, P3; Hindmarch I, 2002, CLIN EXP ALLERGY, V32, P133, DOI 10.1046/j.0022-0477.2001.01245.x; Homer JJ, 1999, BRIT MED J, V318, P1355; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927; Hughes RGM, 1998, CLIN OTOLARYNGOL, V23, P224; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; Hurst JR, 2005, EUR RESPIR J, V26, P846, DOI 10.1183/09031936.05.00043405; Incaudo GA, 2004, CLIN REV ALLERG IMMU, V27, P159, DOI 10.1385/CRIAI:27:2:159; James IGV, 2003, CURR MED RES OPIN, V19, P313, DOI 10.1185/030079903125001785; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; Jennings C. R., 1998, Rhinology (Utrecht), V36, P188; Johnson SR, 2006, J PEDIATR-US, V148, P386, DOI 10.1016/j.jpeds.2005.11.034; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Joss J D, 1999, J Am Osteopath Assoc, V99, pS13; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; Kaiser HB, 1998, ALLERGY ASTHMA PROC, V19, P23, DOI 10.2500/108854198778557962; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P7; Karjalainen A, 2003, CHEST, V123, P283, DOI 10.1378/chest.123.1.283; Kayarkar R, 2002, CLIN OTOLARYNGOL, V27, P18, DOI 10.1046/j.1365-2273.2002.00515.x; Keles N, 2004, AM J RHINOL, V18, P23; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kronqvist M, 1999, ALLERGY, V54, P1142, DOI 10.1034/j.1398-9995.1999.00115.x; Krzeski A, 2002, AM J RHINOL, V16, P155; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Laforest L, 2005, INT ARCH ALLERGY IMM, V136, P281, DOI 10.1159/000083955; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Leone C, 1997, J ALLERGY CLIN IMMUN, V100, P775, DOI 10.1016/S0091-6749(97)70273-2; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; MALLING HJ, 1994, CLIN EXP ALLERGY, V24, P515, DOI 10.1111/j.1365-2222.1994.tb00948.x; MALM L, 1994, ACTA OTO-LARYNGOL, P53; Marshall AH, 2001, BRIT J NEUROSURG, V15, P8; Mastalerz L, 2002, EUR J CLIN INVEST, V32, P949, DOI 10.1046/j.1365-2362.2002.01088.x; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Mazzotta P, 1999, DRUG SAFETY, V20, P361, DOI 10.2165/00002018-199920040-00005; McMahon C, 1997, CLIN OTOLARYNGOL, V22, P318, DOI 10.1046/j.1365-2273.1997.00042.x; McNeely W, 1998, DRUGS, V56, P91, DOI 10.2165/00003495-199856010-00011; *MED CONTR AG COMM, 1994, CURR PROBL PHARMACOV, V20, P5; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2002, CLIN THER, V24, P942, DOI 10.1016/S0149-2918(02)80009-1; Meltzer EO, 1997, ANN ALLERG ASTHMA IM, V78, P485; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; Moller C, 2003, CLIN EXP ALLERGY, V33, P816, DOI 10.1046/j.1365-2222.2003.01689.x; Moore EJ, 2001, AM J RHINOL, V15, P355; Moretti ME, 2003, J ALLERGY CLIN IMMUN, V111, P479, DOI 10.1067/mai.2003.130; Naclerio RM, 1998, CLIN EXP ALLERGY, V28, P54; Nasser SMS, 2001, BRIT MED J, V322, P1589, DOI 10.1136/bmj.322.7302.1589; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592; Nayak AS, 2001, ALLERGY, V56, P1077, DOI 10.1034/j.1398-9995.2001.00082.x; Nelson Harold S., 2003, Journal of Allergy and Clinical Immunology, V112, pS96, DOI 10.1016/S0091-6749(03)01883-9; NEUKIRCH F, 1995, RESP MED, V89, P685, DOI 10.1016/0954-6111(95)90136-1; O'Meara TJ, 2005, ALLERGY, V60, P529, DOI 10.1111/j.1398-9995.2005.00741.x; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; Ostberg Birgitte, 1997, Rhinology (Utrecht), V35, P58; Ottaviano G, 2006, RHINOLOGY, V44, P32; Owen CG, 2004, BRIT J GEN PRACT, V54, P451; Park YJ, 2002, CL ALLER IM, V16, P275; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P177, DOI 10.1097/00130832-200406000-00007; Passali D, 2003, ANN OTO RHINOL LARYN, V112, P683; Patou J, 2006, CLIN EXP ALLERGY, V36, P972, DOI 10.1111/j.1365-2222.2006.02544.x; Pawankar R., 2003, Clinical and Experimental Allergy Reviews, V3, P74, DOI 10.1046/j.1472-9725.2003.00017.x; Peden D B, 2001, Curr Allergy Asthma Rep, V1, P242, DOI 10.1007/s11882-001-0011-9; Perry RJ, 2002, ARCH DIS CHILD, V87, P45, DOI 10.1136/adc.87.1.45; Petrick MM, 2003, IMMUNOL ALLERGY CLIN, V23, P193, DOI 10.1016/S0889-8561(02)00082-6; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Philpott CM, 2004, CLIN OTOLARYNGOL, V29, P138, DOI 10.1111/j.1365-2273.2004.00801.x; Portnoy JM, 2004, CURR ALLERGY ASTHM R, V4, P439, DOI 10.1007/s11882-004-0009-1; Portnoy JM, 2004, EXPERT OPIN PHARMACO, V5, P125, DOI 10.1517/eoph.5.1.125.25497; Powell RJ, 2007, CLIN EXP ALLERGY, V37, P631, DOI 10.1111/j.1365-2222.2007.02678.x; PRAS E, 1991, DICP ANN PHARMAC, V25, P939; Prieto JL, 1996, CLIN EXP ALLERGY, V26, P61, DOI 10.1111/j.1365-2222.1996.tb00057.x; PRIETO L, 1994, EUR RESPIR J, V7, P1845, DOI 10.1183/09031936.94.07101845; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Ramadan Hassan H, 2005, J Otolaryngol, V34 Suppl 1, pS14; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; Rasmussen N, 2001, CURR OPIN RHEUMATOL, V13, P3, DOI 10.1097/00002281-200101000-00002; Ratner PH, 2003, ANN ALLERG ASTHMA IM, V90, P536; Ratner PH, 1998, J FAM PRACTICE, V47, P118; Ratner PH, 2002, MAYO CLIN PROC, V77, P350; Recer GM, 2004, CLIN EXP ALLERGY, V34, P268, DOI 10.1111/j.1365-2222.2004.01863.x; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Romero Jose Narvas, 1992, Rhinology (Utrecht), V30, P169; Salib RJ, 2003, DRUG SAFETY, V26, P863, DOI 10.2165/00002018-200326120-00003; SAMPSON AP, 2000, THORAX, V55, P28; Scadding G K, 2001, Curr Opin Allergy Clin Immunol, V1, P15, DOI 10.1097/00130832-200102000-00004; SCADDING GK, 1995, CLIN EXP ALLERGY, V25, P391, DOI 10.1111/j.1365-2222.1995.tb01068.x; Schenkel EJ, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e22; Schwarzer G., 2004, COCHRANE DB SYST REV; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sehmi R., 2003, Current Drug Targets - Inflammation and Allergy, V2, P271, DOI 10.2174/1568010033484007; Serra HA, 1998, BRIT J CLIN PHARMACO, V45, P147, DOI 10.1046/j.1365-2125.1998.00657.x; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; Sheikh A, 2007, CLIN EXP ALLERGY, V37, P90, DOI 10.1111/j.1365-2222.2006.02619.x; SHEIKH A, 2005, J ALLERGY CLIN IMM S, V115, pS42, DOI 10.1016/j.jaci.2004.12.184; SHEIKH A, 2000, COCHRANE DB SYST REV; Shusterman D, 2003, CURR ALLERGY ASTHM R, V3, P258, DOI 10.1007/s11882-003-0048-z; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SIMPSON RJ, 1994, ANN ALLERGY, V73, P497; Siracusa A, 2000, CLIN EXP ALLERGY, V30, P1519, DOI 10.1046/j.1365-2222.2000.00946.x; Skoner D, 2000, PEDIATRICS, V105, P23; Skov M, 2002, EUR RESPIR J, V20, P127, DOI 10.1183/09031936.02.00248002; SLAVIN RG, 1998, J ALLERGY CLIN IMMUN, V101, P357; Smurthwaite Lyn, 2002, Curr Allergy Asthma Rep, V2, P231, DOI 10.1007/s11882-002-0024-z; SOTOMAYOR H, 1984, AM REV RESPIR DIS, V130, P56; Starling-Schwanz R, 2005, ALLERGY, V60, P795, DOI 10.1111/j.1398-9995.2005.00779.x; STERK PJ, 1993, EUR RESPIR J, V6, P894; Storms WW, 2004, J ALLERGY CLIN IMMUN, V114, pS146, DOI 10.1016/j.jaci.2004.08.045; TabordaBarata L, 1996, CLIN EXP ALLERGY, V26, P68, DOI 10.1111/j.1365-2222.1996.tb00058.x; TAN R, 1995, DRUG AGING, V7, P168, DOI 10.2165/00002512-199507030-00002; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tomooka LT, 2000, LARYNGOSCOPE, V110, P1189, DOI 10.1097/00005537-200007000-00023; TOWNLEY R G, 1975, Journal of Allergy and Clinical Immunology, V56, P429, DOI 10.1016/0091-6749(75)90061-5; VAN ARSDEL P P Jr, 1959, Acta Genet Stat Med, V9, P101; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Van Rijswijk JB, 2003, ALLERGY, V58, P754, DOI 10.1034/j.1398-9995.2003.00203.x; van Rijswijk JB, 2006, CURR ALLERGY ASTHM R, V6, P132; VAN SJ, 2002, ALLERGY, V57, P346; VERDIANI P, 1990, J ALLERGY CLIN IMMUN, V86, P576, DOI 10.1016/S0091-6749(05)80215-5; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Weiner JM, 1998, BRIT MED J, V317, P1624; WERNFORS M, 1986, INT ARCH ALLER A IMM, V79, P77; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P616, DOI 10.1046/j.1365-2222.2001.01088.x; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P126, DOI 10.1046/j.0022-0477.2001.01252.x; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; WOOD CC, 1995, J ALLERGY CLIN IMMUN, V95, P1111, DOI 10.1016/S0091-6749(95)70214-8; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Yanez A, 2002, ANN ALLERG ASTHMA IM, V89, P479; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7; Yewell J, 2002, ANN OTO RHINOL LARYN, V111, P174; YOULTEN LJF, 1995, CLIN EXP ALLERGY, V25, P159, DOI 10.1111/j.1365-2222.1995.tb01021.x; Yssel H, 1998, CLIN EXP ALLERGY, V28, P104; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305; 1999, DRUG THER B, V37, P17	234	144	155	1	11	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2008	38	1					19	42		10.1111/j.1365-2222.2007.02888.x		24	Allergy; Immunology	Allergy; Immunology	253QS	WOS:000252533300003	18081563	
J	Poole, JA; Barriga, K; Leung, DYM; Hoffman, M; Eisenbarth, GS; Rewers, M; Norris, JM				Poole, JA; Barriga, K; Leung, DYM; Hoffman, M; Eisenbarth, GS; Rewers, M; Norris, JM			Timing of initial exposure to cereal grains and the risk of wheat allergy	PEDIATRICS			English	Article						food allergy; wheat; solid-food exposure and introduction (timing); infant diet	FOOD ALLERGY; ATOPIC SENSITIZATION; MUCOSAL IMMUNITY; CELIAC-DISEASE; FOLLOW-UP; AUTOIMMUNITY; PREVENTION; CHILDREN; ASTHMA; HYPERSENSITIVITY	OBJECTIVE. Early exposure to solid foods in infancy has been associated with the development of allergy. The aim of this study was to examine the association between cereal-grain exposures (wheat, barley, rye, oats) in the infant diet and development of wheat allergy. METHODS. A total of 1612 children were enrolled at birth and followed to the mean age of 4.7 years. Questionnaire data and dietary exposures were obtained at 3, 6, 9, 15, and 24 months and annually thereafter. The main outcome measure was parent report of wheat allergy. Children with celiac disease autoimmunity detected by tissue transglutaminase autoantibodies were excluded. Wheat-specific immunoglobulin E levels on children reported to have wheat allergy were obtained. RESULTS. Sixteen children (1%) reported wheat allergy. Children who were first exposed to cereals after 6 months of age had an increased risk of wheat allergy compared with children first exposed to cereals before 6 months of age ( after controlling for confounders including a family history of allergic disorders and history of food allergy before 6 months of age). All 4 children with detectable wheat-specific immunoglobulin E were first exposed to cereal grains after 6 months. A first-degree relative with asthma, eczema, or hives was also independently associated with an increased risk of wheat-allergy development. CONCLUSIONS. Delaying initial exposure to cereal grains until after 6 months may increase the risk of developing wheat allergy. These results do not support delaying introduction of cereal grains for the protection of food allergy.	Univ Colorado, Dept Prevent Med & Biometr, Denver, CO 80262 USA; Univ Colorado, Dept Biometr, Denver, CO 80262 USA; Univ Colorado, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA; Hlth Sci Ctr, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Med, Div Clin Immunol & Allergy, Denver, CO USA; Natl Jewish Med & Res Ctr, Dept Pediat, Div Clin Immunol & Allergy, Denver, CO USA	Norris, JM (reprint author), Univ Colorado, Dept Prevent Med & Biometr, 4200 E 9th Ave,Box B119, Denver, CO 80262 USA.	jill.norris@uchsc.edu			NCRR NIH HHS [M01RR00069]; NIDDK NIH HHS [DK32493, DK50979, P30 DK 57516, R01-DK49654]		Baker SS, 2000, PEDIATRICS, V106, P346; Bjorksten B, 2005, CURR OPIN ALLERGY CL, V5, P249; Bjorksten B, 2004, CLIN REV ALLERG IMMU, V26, P129, DOI 10.1385/CRIAI:26:3:129; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gartner LM, 2005, PEDIATRICS, V115, P496, DOI 10.1542/peds.2004-2491; Host A, 1999, ARCH DIS CHILD, V81, P80; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914; Jarvinen KM, 2003, CLIN EXP ALLERGY, V33, P1060, DOI 10.1046/j.1365-2222.2003.01741.x; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; KLEINMAN RE, 2004, PEDIAT NUTR HDB, P103; Mayer L, 2003, PEDIATRICS, V111, P1595; Norris JM, 2005, JAMA-J AM MED ASSOC, V293, P2343, DOI 10.1001/jama.293.19.2343; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; Rewers M, 1996, DIABETOLOGIA, V39, P807, DOI 10.1007/s001250050514; ROEHR CC, 2001, J ALLERGY CLIN IMMUN, V10, P7548; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P139, DOI 10.1016/j.jaci.2004.11.003; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; Sudo N, 1997, J IMMUNOL, V159, P1739; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	27	144	154	0	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2006	117	6					2175	2182		10.1542/peds.2005-1803		8	Pediatrics	Pediatrics	048XE	WOS:000237979000038	16740862	
J	Jaakkola, JJK; Gissler, M				Jaakkola, JJK; Gissler, M			Maternal smoking in pregnancy, fetal development, and childhood asthma	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; LOW-BIRTH-WEIGHT; FAMILY HISTORY; LUNG-FUNCTION; RESPIRATORY-FUNCTION; PARENTAL SMOKING; CHILDREN; INFANTS; HEALTH; LIFE	Objectives. We examined the relationships among maternal smoking in pregnancy, fetal development, and the risk of asthma in childhood. Methods. We conducted a population-based cohort study, where all 58841 singleton births were followed for 7 years using nationwide registries. Results. Maternal smoking increased the risk of asthma (adjusted odds ratio = 1.35; 95% confidence interval = 1.13, 1.62 for high exposure). Low birthweight and preterm delivery increased the risk of asthma at the age of 7, whereas being small for gestational age did not. Conclusions. Maternal smoking in pregnancy increases the risk of asthma during the first 7 years of life, and only a small fraction of the effect seems to be mediated through fetal growth. (Am J Public Health. 2004;94:136-140).	Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Natl Res & Dev Ctr Welf & Hlth, Helsinki, Finland	Jaakkola, JJK (reprint author), Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England.	j.jaakkola@bham.ac.uk	Jaakkola, Jouni/G-4314-2012				Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gissler M, 1998, PAEDIATR PERINAT EP, V12, P437; GISSLER M, 1995, SCAND J SOC MED, V23, P75; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Hoo AF, 1998, AM J RESP CRIT CARE, V158, P700; Infante-Rivard C, 1999, AM J EPIDEMIOL, V150, P528; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Milner AD, 1999, ARCH DIS CHILD, V80, pF8; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; Pihkala J, 1989, Duodecim, V105, P1540; Steffensen FH, 2000, EPIDEMIOLOGY, V11, P185, DOI 10.1097/00001648-200003000-00018; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P204; World Health Organization, 1980, INT CLASS DIS; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	19	144	147	0	10	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	JAN	2004	94	1					136	140		10.2105/AJPH.94.1.136		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	762CL	WOS:000187952700035	14713711	
J	Fusco, D; Forastiere, F; Michelozzi, P; Spadea, T; Ostro, B; Arca, M; Perucci, CA				Fusco, D; Forastiere, F; Michelozzi, P; Spadea, T; Ostro, B; Arca, M; Perucci, CA			Air pollution and hospital admissions for respiratory conditions in Rome, Italy	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; hospital admissions; respiratory disease; time-series	OBSTRUCTIVE PULMONARY-DISEASE; MINNEAPOLIS ST-PAUL; URBAN AIR; EUROPEAN CITIES; APHEA PROJECT; TIME-SERIES; ASTHMA; ASSOCIATION; EMERGENCY; LONDON	Most of the evidence regarding the association between particulate air pollution and emergency room visits or hospital admissions for respiratory conditions and asthma comes from the USA. European time-series analyses have suggested that gaseous air pollutants are important determinants of acute hospitalization for respiratory conditions, at least as important as particulate mass. The association between daily mean levels of suspended particles and gaseous pollutants (sulphur dioxide, nitrogen dioxide, carbon monoxide, ozone) was examined. The daily emergency hospital admissions for respiratory conditions in the metropolitan area of Rome during 1995 - 1997,were also recorded. Daily counts of hospital admissions for total respiratory conditions (43 admissions .day(-1)), acute respiratory infections including pneumonia (18.day(-1)), chronic obstructive pulmonary disease (COPD) (13.day(-1)), and asthma (4.5.day(-1)) among residents of all ages and among children (0-14 yrs) were analysed, The generalized additive models included spline smooth functions of the day of study, mean temperature, mean humidity, influenza epidemics, and indicator variables for day of the week and holidays, Total respiratory admissions were significantly associated with same-da, level of NO2 (2.5%, increase per interquartile range (IQR) change, 22.3 mug.m(-3)) and CO (2.8% increase per IQR, 1.5 mg.m(-3)). No effect was found for particulate matter and SO2, whereas O-3 was associated with admissions only among children (lag 1, 5.5%, increase per IQR, 23.9 mug.m(3)). The effect of NO2 was stronger on acute respirator!, infections (lag 0, 4.0% increase) and on asthma among children (lag 1, 10.7% increase). The admissions for all ages for asthma and CORD were associated only with same-day level of CO (5.5% and 4.3% increase, respectively). Multipollutant models confirmed the role of CO on all respiratory admissions, including asthma and COPD, and that of NO2 on acute respiratory infections, Among children, O-3 remained a strong indicator of acute respiratory infections, Carbon monoxide and photochetnical pollutants (nitrogen dioxide, ozone) appear to he determinants of acute respiratory conditions in Rome, Since carbon monoxide and nitrogen dioxide are good indicators of combustion products from traffic related sources, the detected effect may be due to unmeasured fine and ultrafine particles.	Agcy Publ Hlth, I-00198 Rome, Italy; Calif Environm Protect Agcy, Oakland, CA USA	Forastiere, F (reprint author), Agcy Publ Hlth, Lazio Reg,Via Santa Costanza 53, I-00198 Rome, Italy.		Michelozzi, Paola/J-8608-2016; Forastiere, Francesco/J-9067-2016; Fusco, Danilo/K-1383-2016; Spadea, Teresa/K-4991-2016	Michelozzi, Paola/0000-0002-1646-2555; Forastiere, Francesco/0000-0002-9162-5684; Fusco, Danilo/0000-0003-1759-5621; Spadea, Teresa/0000-0002-0771-0545			Anderson HR, 1998, THORAX, V53, P842; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Becker S, 1999, J TOXICOL ENV HEAL A, V57, P445, DOI 10.1080/009841099157539; Brook JR, 1997, J AIR WASTE MANAGE, V47, P2; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Burnett RT, 1997, ENVIRON RES, V72, P24, DOI 10.1006/enrs.1996.3685; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; Chauhan A. J., 1998, Reviews on Environmental Health, V13, P73; CHAUHAN AJ, 1992, AM J RESP CRIT CARE, V159, pA699; D'Innocenzio F, 1998, ANN CHIM-ROME, V88, P281; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; EPA (Environmental Protection Agency), 1996, EPA600P95001; Hagen JA, 2000, EPIDEMIOLOGY, V11, P136, DOI 10.1097/00001648-200003000-00009; Hajat S, 1999, THORAX, V54, P597; Hastie T, 1990, GEN ADDITIVE MODELS; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; Michelozzi P, 1998, OCCUP ENVIRON MED, V55, P605; Moolgavkar SH, 1997, EPIDEMIOLOGY, V8, P364, DOI 10.1097/00001648-199707000-00003; Morgan G, 1998, AM J PUBLIC HEALTH, V88, P1761, DOI 10.2105/AJPH.88.12.1761; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pitard A, 1997, STAT MED, V16, P527, DOI 10.1002/(SICI)1097-0258(19970315)16:5<527::AID-SIM429>3.0.CO;2-C; Poloniecki JD, 1997, OCCUP ENVIRON MED, V54, P535; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; Sunyer J, 1997, THORAX, V52, P760; SUNYER J, 1991, AM J EPIDEMIOL, V134, P277; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541; Thom SR, 1997, CHEM RES TOXICOL, V10, P1023, DOI 10.1021/tx970041h	39	144	146	0	24	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUN	2001	17	6					1143	1150		10.1183/09031936.01.00005501		8	Respiratory System	Respiratory System	454HT	WOS:000169967700015	11491157	
J	Harding, SM; Guzzo, MR; Richter, JE				Harding, SM; Guzzo, MR; Richter, JE			The prevalence of gastroesophageal reflux in asthma patients without reflux symptoms	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	Digestive Disease Week / 98th American-Gastroenterology-Association Meeting	MAY 11-14, 1997	WASHINGTON, D.C.	Amer Gastroenterol Assoc			PLACEBO-CONTROLLED CROSSOVER; LOWER ESOPHAGEAL SPHINCTER; CHRONIC COUGH; DOUBLE-BLIND; OMEPRAZOLE; THERAPY; DISEASE; DIAGNOSIS; PRESSURE	Gastroesophageal reflux is a potential trigger of asthma that may be clinically silent. This study examines the prevalence of gastroesophageal reflux in asthma patients without reflux symptoms. This prospective cohort study evaluated 26 patients with stable asthma without reflux symptoms using esophageal manometry and 24-h esophageal pH testing. Gastroesophageal reflux was considered present if esophageal acid contact times were abnormal. Demographic variables were analyzed to determine if they predicted the presence of gastroesophageal reflux, Asthma patients with asymptomatic gastroesophageal reflux were compared with 30 age-matched asthma patients with symptomatic gastroesophageal reflux. The prevalence of abnormal 24-h esophageal pH tests in asthma patients without reflux symptoms was 62% (16 of 26), Demographic variables did not predict abnormal 24-h esophageal pH tests in asthma patients with asymptomatic gastroesophageal reflux. Asthma patients with asymptomatic gastroesophageal reflux had higher amounts of proximal esophageal acid exposure (p < 0.05) compared with asthma patients with symptomatic gastroesophageal reflux. Because demographic variables do not predict abnormal 24-h esophageal pH tests in asthma patients without reflux symptoms, 24-h esophageal pH testing is required. This study suggests that gastroesophageal reflux is present in asthma patients, even in the absence of esophageal symptoms.	Univ Alabama, Div Pulm Allergy & Crit Care Med, Dept Med, Birmingham, AL 35294 USA; Cleveland Clin Fdn, Dept Gastroenterol, Cleveland, OH 44195 USA	Harding, SM (reprint author), Univ Alabama, Div Pulm Allergy & Crit Care Med, Dept Med, 215 Tinsley Harrison Tower,1900 Univ Blvd, Birmingham, AL 35294 USA.				NHLBI NIH HHS [HL03633]		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Boeree MJ, 1998, EUR RESPIR J, V11, P1070, DOI 10.1183/09031936.98.11051070; DALTON CB, 1987, ESOPHAGEAL MOTILITY, P35; DEVAULT KR, 1995, ARCH INTERN MED, V155, P2165; Field SK, 1996, CHEST, V109, P316, DOI 10.1378/chest.109.2.316; Field SK, 1999, CHEST, V116, P766, DOI 10.1378/chest.116.3.766; Field SK, 1998, CHEST, V114, P275, DOI 10.1378/chest.114.1.275; GARCIAPULIDO J, 1990, CHEST, V98, P806, DOI 10.1378/chest.98.4.806; Hamamoto J, 1997, J APPL PHYSIOL, V82, P738; Harding SM, 1996, AM J MED, V100, P395, DOI 10.1016/S0002-9343(97)89514-9; Harding SM, 1999, J ALLERGY CLIN IMMUN, V104, P251, DOI 10.1016/S0091-6749(99)70360-X; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; Harding SM, 1999, CHEST, V115, P654, DOI 10.1378/chest.115.3.654; HOLMES PW, 1978, THORAX, V33, P394, DOI 10.1136/thx.33.3.394; IRWIN RS, 1993, CHEST, V103, P1662, DOI 10.1378/chest.103.6.1662; JAMIESON JR, 1992, AM J GASTROENTEROL, V87, P1102; Kahrilas PJ, 1996, GASTROENTEROLOGY, V110, P1982, DOI 10.1053/gast.1996.1101982; Kiljander TO, 1999, CHEST, V116, P1257, DOI 10.1378/chest.116.5.1257; LAM HGT, 1994, DIGEST DIS SCI, V39, P402, DOI 10.1007/BF02090215; LARRAIN A, 1991, CHEST, V99, P1330, DOI 10.1378/chest.99.6.1330; Matthews DE, 1996, USING UNDERSTANDING; MEIER JH, 1994, DIGEST DIS SCI, V39, P2127, DOI 10.1007/BF02090360; MITTAL RK, 1988, J CLIN INVEST, V81, P1182, DOI 10.1172/JCI113433; Mittal RK, 1997, NEW ENGL J MED, V336, P924; RICHTER JE, 1992, DIGEST DIS SCI, V37, P849, DOI 10.1007/BF01300382; ROUSSOS C, 1982, NEW ENGL J MED, V307, P786, DOI 10.1056/NEJM198209233071304; SCHNATZ PF, 1996, AM J GASTROENTEROL, V91, P715; SHEFFER LA, 1991, US DEP HHS PUBLICATI; SINCLAIR JW, 1991, AMBULATORY ESOPHAGEA, P23; SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613; STEIN MR, 1980, ANN ALLERGY, V45, P238; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301; Teichtahl H, 1996, AUST NZ J MED, V26, P671, DOI 10.1111/j.1445-5994.1996.tb02938.x; Vaezi MF, 1997, SOUTHERN MED J, V90, P305, DOI 10.1097/00007611-199703000-00008	35	144	148	0	2	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL	2000	162	1					34	39				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	333JH	WOS:000088126800007	10903216	
J	Akdis, M; Akdis, CA				Akdis, Muebeccel; Akdis, Cezmi A.			Mechanisms of allergen-specific immunotherapy: Multiple suppressor factors at work in immune tolerance to allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Regulatory T cells; immunotherapy; IgE; T cells; IL-10; TGF-beta; allergen immunotherapy; T helper cells; immune tolerance; IgE; IgG; T cells; B cells; mast cells; basophils; eosinophils	REGULATORY T-CELLS; IMMUNOLOGY/PRACTALL CONSENSUS REPORT; EOSINOPHIL CATIONIC PROTEIN; GRASS-POLLEN IMMUNOTHERAPY; TRANSCRIPTION FACTOR FOXP3; TOLL-LIKE RECEPTORS; HOUSE-DUST MITES; SUBLINGUAL IMMUNOTHERAPY; TGF-BETA; ASTHMATIC-CHILDREN	Allergen-specific immunotherapy (AIT) has been used for more than 100 years as a desensitizing therapy for IgE-mediated allergic diseases and represents a potentially curative way of treatment. The mechanisms of action of AIT include the induction of very early desensitization of mast cells and basophils; generation of regulatory T and regulatory B (Breg) cell responses; regulation of IgE and IgG(4); decreases in numbers and activity of eosinophils and mast cells in mucosal allergic tissues; and decreases in the activity of basophils in circulation. Skewing of allergen-specific effector T and effector B cells to a regulatory phenotype appears as a key event in the course of AIT and normal immune response to allergens. Recently, inducible IL-10-secreting Breg cells were also demonstrated to contribute to allergen tolerance through suppression of effector T cells and selective induction of IgG4 isotype antibodies. Allergen-specific regulatory T and Breg cells orchestrate a general immunoregulatory activity, which can be summarized as suppression of cytokines from inflammatory dendritic cells; suppression of effector T(H)1, T(H)2, and T(H)17 cells; suppression of allergen-specific IgE and induction of IgG(4); and suppression of migration of mast cells, basophils, eosinophils, and effector T cells to tissues. A detailed knowledge of the mechanisms of AIT is not only important in designing the prevention and treatment of allergic diseases but might also find applications in the treatment of autoimmune diseases, organ transplantation, chronic infection, and cancer.	[Akdis, Muebeccel; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-8006 Zurich, Switzerland	Akdis, M (reprint author), Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.uzh.ch; akdisac@siaf.uzh.ch			Swiss National Foundation [320030_140772, 320030_132899]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); European 7th frame work project MeDALL: Mechanisms of the Development of Allergy [261357]; European 7th frame work project PREDICTA: Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases [260895]	The authors' laboratories are supported by the Swiss National Foundation grants 320030_140772 and 320030_132899 and the Christine Kuhne Center for Allergy Research and Education (CK-CARE), European 7th frame work projects MeDALL: Mechanisms of the Development of Allergy (no. 261357), and PREDICTA: Post-Infectious Immune Reprogramming and Its Association with Persistence and Chronicity of Respiratory Allergic Diseases (no. 260895).	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2006, CURR OPIN IMMUNOL, V18, P718, DOI 10.1016/j.coi.2006.09.016; Akdis CA, 2013, J ALLERGY CLIN IMMUN, V131, P1479, DOI 10.1016/j.jaci.2013.02.036; Akdis CA, 2012, NAT MED, V18, P736, DOI 10.1038/nm.2754; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2013, MIDDLETONS ALLERGY P; Akdis M, 2012, J ALLERGY CLIN IMMUN, V129, P1438, DOI 10.1016/j.jaci.2012.05.003; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Akdis M, 2009, NAT REV DRUG DISCOV, V8, P645, DOI 10.1038/nrd2653; Bae JM, 2013, J ALLERGY CLIN IMMUN, V132, P110, DOI 10.1016/j.jaci.2013.02.044; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bennett CL, 2001, NAT GENET, V27, P20; Berin MC, 2013, J ALLERGY CLIN IMMUN, V131, P14, DOI 10.1016/j.jaci.2012.10.058; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; Branton MH, 1999, MICROBES INFECT, V1, P1349, DOI 10.1016/S1286-4579(99)00250-6; Burks AW, 2013, J ALLERGY CLIN IMMUN, V131, P1288, DOI 10.1016/j.jaci.2013.01.049; Calderon MA, 2013, ALLERGY, V68, P825, DOI 10.1111/all.12180; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen W, 2008, J IMMUNOL, V181, P5396; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CHEN WY, 1995, J ASTHMA, V32, P29, DOI 10.3109/02770909509089497; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DelValle J, 1997, AM J PHYSIOL-GASTR L, V273, pG987; Deniz G, 2013, J ALLERGY CLIN IMMUN, V132, P527, DOI 10.1016/j.jaci.2013.07.030; Durham SR., 2010, J ALLERGY CLIN IMMUN, V125, pe1; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; EBERLEINKONIG B, 1995, CLIN EXP ALLERGY, V25, P704, DOI 10.1111/j.1365-2222.1995.tb00007.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; GERSHON RK, 1975, TRANSPLANT REV, V26, P170; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; Hakansson L, 1997, J ALLERGY CLIN IMMUN, V99, P551, DOI 10.1016/S0091-6749(97)70084-8; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; James LK, 2011, J ALLERGY CLIN IMMUN, V127, pe1; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Joss A, 2000, EUR J IMMUNOL, V30, P1683, DOI 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Jutel M, 1995, J IMMUNOL, V154, P4178; Jutel M, 2013, ALLERGOL INT, V62, P425, DOI 10.2332/allergolint.13-RAI-0608; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Kucuksezer UC, 2013, J ALLERGY CLIN IMMUN, V131, P875, DOI 10.1016/j.jaci.2012.10.051; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Lin SY, 2013, JAMA-J AM MED ASSOC, V309, P1278, DOI 10.1001/jama.2013.2049; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Marcucci F, 2001, ALLERGY, V56, P231; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mauri C, 2012, ANNU REV IMMUNOL, V30, P221, DOI 10.1146/annurev-immunol-020711-074934; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novak N, 2012, J ALLERGY CLIN IMMUN, V130, P1153, DOI 10.1016/j.jaci.2012.04.039; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; O'Mahony L, 2011, J ALLERGY CLIN IMMUN, V128, P1153, DOI 10.1016/j.jaci.2011.06.051; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; Oral HB, 2006, EUR J IMMUNOL, V36, P380, DOI 10.1002/eji.200425523; Orihara K, 2007, J ALLERGY CLIN IMMUN, V120, P960, DOI 10.1016/j.jaci.2007.05.036; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Palomares O, 2012, J ALLERGY CLIN IMMUN, V129, P510, DOI 10.1016/j.jaci.2011.09.031; Platts-Mills TAE, 2011, IMMUNOL REV, V242, P51, DOI 10.1111/j.1600-065X.2011.01021.x; Plewako H, 2006, INT ARCH ALLERGY IMM, V141, P346, DOI 10.1159/000095461; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Romano A, 2011, J ALLERGY CLIN IMMUN, V127, pS67, DOI 10.1016/j.jaci.2010.11.047; Sackesen C, 2013, ALLERGY, V68, P593, DOI 10.1111/all.12133; Sakaguchi S, 2003, J CLIN INVEST, V112, P1310, DOI 10.1172/JCI200320274; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2013, NAT REV IMMUNOL, V13, P461, DOI 10.1038/nri3464; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Shim YK, 2003, CLIN EXP ALLERGY, V33, P52; Smarr CB, 2013, CRIT REV IMMUNOL, V33, P389; Strober S, 1996, IMMUNOL REV, V149, P217, DOI 10.1111/j.1600-065X.1996.tb00906.x; Taylor A, 2007, J ALLERGY CLIN IMMUN, V120, P76, DOI 10.1016/j.jaci.2007.04.004; Taylor A, 2009, MOL IMMUNOL, V46, P622, DOI 10.1016/j.molimm.2008.07.031; Treter S, 2000, CELL IMMUNOL, V206, P116, DOI 10.1006/cimm.2000.1739; Urry Z, 2006, CURR ALLERGY ASTHM R, V6, P363, DOI 10.1007/s11882-996-0005-8; van de Veen W, 2013, J ALLERGY CLIN IMMUN, V131, P1204, DOI 10.1016/j.jaci.2013.01.014; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Wachholz Petra A, 2004, Curr Opin Allergy Clin Immunol, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; WALKER C, 1991, J IMMUNOL, V146, P1829; Walker SM, 2011, CLIN EXP ALLERGY, V41, P1177, DOI 10.1111/j.1365-2222.2011.03794.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zhang LJ, 2007, J CELL PHYSIOL, V211, P590, DOI 10.1002/jcp.21001; Zimmer A, 2012, J ALLERGY CLIN IMMUN, V129, P1020, DOI 10.1016/j.jaci.2012.02.014	110	143	147	6	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					621	631		10.1016/j.jaci.2013.12.1088		11	Allergy; Immunology	Allergy; Immunology	AC3EK	WOS:000332397600002	24581429	
J	Wolterink, RGJK; KleinJan, A; van Nimwegen, M; Bergen, I; de Bruijn, M; Levani, Y; Hendriks, RW				Wolterink, Roel G. J. Klein; KleinJan, Alex; van Nimwegen, Menno; Bergen, Ingrid; de Bruijn, Marjolein; Levani, Yelvi; Hendriks, Rudi W.			Pulmonary innate lymphoid cells are major producers of IL-5 and IL-13 in murine models of allergic asthma	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						Asthma; Cytokines; House dust mite; Innate immunity; Innate lymphoid cells	ROR-GAMMA-T; AIRWAY HYPERREACTIVITY; ADAPTIVE IMMUNITY; IN-VIVO; DENDRITIC CELLS; TYPE-2 IMMUNITY; NKP46(+) CELLS; LUNG; INFLAMMATION; CYTOKINE	Allergic asthma is characterized by chronic airway inflammation and hyperreactivity and is thought to be mediated by an adaptive T helper-2 (Th2) cell-type immune response. Here, we demonstrate that type 2 pulmonary innate lymphoid cells (ILC2s) significantly contribute to production of the key cytokines IL-5 and IL-13 in experimental asthma. In naive mice, lineage-marker negative ILC2s expressing IL-7Ra, CD25, Sca-1, and T1/ST2(IL-33R) were present in lungs and mediastinal lymph nodes (MedLNs), but not in broncho-alveolar lavage (BAL) fluid. Upon intranasal administration of IL-25 or IL-33, an asthma phenotype was induced, whereby ILC2s accumulated in lungs, MedLNs, and BAL fluid. After IL-25 and IL-33 administration, ILC2s constituted similar to 50 and similar to 80% of IL-5+/IL-13+ cells in lung and BAL, respectively. Also in house dust mite-induced or ovalbumin-induced allergic asthma, the ILC2 population in lung and BAL fluid increased significantly in size and ILC2s were a major source of IL-5 or IL-13. Particularly in OVA-induced asthma, the contribution of ILC2s to the total population of intracellular IL-5+ and IL-13+ cells in the lung was in the same range as found for Th2 cells. We conclude that both ILC2s and Th2 cells produce large amounts of IL-5 and IL-13 that contribute to allergic airway inflammation.	[Wolterink, Roel G. J. Klein; KleinJan, Alex; van Nimwegen, Menno; Bergen, Ingrid; de Bruijn, Marjolein; Levani, Yelvi; Hendriks, Rudi W.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands; [Wolterink, Roel G. J. Klein] Inst Pasteur, Dept Immunol, Innate Immun Unit, F-75724 Paris, France; [Wolterink, Roel G. J. Klein] Inst Pasteur, INSERM U668, Paris, France; [Wolterink, Roel G. J. Klein] Univ Paris Diderot, Paris, France	Hendriks, RW (reprint author), Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands.	r.hendriks@erasmusmc.nl		Levani, Yelvi/0000-0002-8291-6842	Ligue Nationale Contre le Cancer (LNCC), France	We thank Bart Lambrecht, Mirjam Kool, Tom Cupedo and Ferry Cornelissen (Erasmus MC Rotterdam) and James Di Santo (Institut Pasteur, Paris) for valuable discussions regarding this research. We thank Bjorn Clausen, Christian Wohn, Tom Cupedo, Ferry Cornelissen, Kim van der Weerd, Odilia Corneth and Erik Lubberts for providing various mouse strains. RKW is supported by a scholarship from the Ligue Nationale Contre le Cancer (LNCC), France.	Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; de Almeida CR, 2009, J IMMUNOL, V182, P999; Dolgachev V, 2009, J IMMUNOL, V183, P5705, DOI 10.4049/jimmunol.0901666; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Hurst SD, 2002, J IMMUNOL, V169, P443; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Kim HY, 2012, J ALLERGY CLIN IMMUN, V129, P216, DOI 10.1016/j.jaci.2011.10.036; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kroeger KM, 2009, J LEUKOCYTE BIOL, V86, P769, DOI 10.1189/jlb.0708452; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Luci C, 2009, NAT IMMUNOL, V10, P75, DOI 10.1038/ni.1681; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Reinhardt RL, 2009, NAT IMMUNOL, V10, P385, DOI 10.1038/ni.1715; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Sanos SL, 2009, NAT IMMUNOL, V10, P83, DOI 10.1038/ni.1684; Satoh-Takayama N, 2008, IMMUNITY, V29, P958, DOI 10.1016/j.immuni.2008.11.001; Satoh-Takayama N, 2010, J EXP MED, V207, P273, DOI 10.1084/jem.20092029; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sharkhuu T, 2006, CLIN EXP ALLERGY, V36, P1575, DOI 10.1111/j.1365-2222.2006.02595.x; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Yang Q, 2011, J IMMUNOL, V187, P5505, DOI 10.4049/jimmunol.1102039; Yokota Y, 1999, NATURE, V397, P702, DOI 10.1038/17812; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	43	143	144	4	26	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	MAY	2012	42	5					1106	1116		10.1002/eji.201142018		11	Immunology	Immunology	932VD	WOS:000303317700008	22539286	
J	Commins, SP; James, HR; Kelly, LA; Pochan, SL; Workman, LJ; Perzanowski, MS; Kocan, KM; Fahy, JV; Nganga, LW; Ronmark, E; Cooper, PJ; Platts-Mills, TAE				Commins, Scott P.; James, Hayley R.; Kelly, Libby A.; Pochan, Shawna L.; Workman, Lisa J.; Perzanowski, Matthew S.; Kocan, Katherine M.; Fahy, John V.; Nganga, Lucy W.; Ronmark, Eva; Cooper, Philip J.; Platts-Mills, Thomas A. E.			The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-alpha-1,3-galactose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ticks; anaphylaxis; oligosaccharide; alpha-gal; IgE antibody to CCD	AMBLYOMMA-AMERICANUM ACARI; UNITED-STATES; COLORECTAL-CANCER; INDOOR ALLERGEN; ACUTE ASTHMA; CETUXIMAB; ANAPHYLAXIS; HUMANS; RISK; SENSITIZATION	Background: In 2009, we reported a novel form of delayed anaphylaxis to red meat that is related to serum IgE antibodies to the oligosaccharide galactose-alpha-1,3-galactose (alpha-gal). Most of these patients had tolerated meat for many years previously. The implication is that some exposure in adult life had stimulated the production of these IgE antibodies. Objectives: We sought to investigate possible causes of this IgE antibody response, focusing on evidence related to tick bites, which are common in the region where these reactions occur. Methods: Serum assays were carried out with biotinylated proteins and extracts bound to a streptavidin ImmunoCAP. Results: Prospective studies on IgE antibodies in 3 subjects after tick bites showed an increase in levels of IgE to alpha-gal of 20fold or greater. Other evidence included (1) a strong correlation between histories of tick bites and levels of IgE to alpha-gal (chi(2) = 26.8, P < .001), (2) evidence that these IgE antibodies are common in areas where the tick Amblyomma americanum is common, and (3) a significant correlation between IgE antibodies to alpha-gal and IgE antibodies to proteins derived from A americanum (r(s) = 0.75, P < .001). Conclusion: The results presented here provide evidence that tick bites are a cause, possibly the only cause, of IgE specific for alpha-gal in this area of the United States. Both the number of subjects becoming sensitized and the titer of IgE antibodies to alpha-gal are striking. Here we report the first example of a response to an ectoparasite giving rise to an important form of food allergy. (J Allergy Clin Immunol 2011;127:1286-93.)	[Commins, Scott P.; James, Hayley R.; Kelly, Libby A.; Pochan, Shawna L.; Workman, Lisa J.; Platts-Mills, Thomas A. E.] Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Perzanowski, Matthew S.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; [Kocan, Katherine M.] Oklahoma State Univ, Ctr Vet Hlth Sci, Stillwater, OK 74078 USA; [Fahy, John V.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Nganga, Lucy W.] Kenya Med Res Inst KEMRI, Ctr Resp Dis, Nairobi, Kenya; [Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden; [Cooper, Philip J.] Univ San Francisco Quito, Cumbaya, Quito, Ecuador; [Cooper, Philip J.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England	Platts-Mills, TAE (reprint author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu			National Institutes of Health [RO1 AI-20565, AI-AADCRC-U19-070364, K08 AI085190, R21 AI087985]; Wellcome Trust [072405/Z/03/Z]; Phadia; NIH	Supported by National Institutes of Health grant RO1 AI-20565, AI-AADCRC-U19-070364, K08 AI085190, R21 AI087985, and the Wellcome Trust 072405/Z/03/Z (to P. J. C.).; Disclosure of potential conflict of interest: S. P. Commins is a volunteer committee member for the American Association of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma & Immunology and is an author for Up to Date. M. S. Perzanowski receives research support from the National Institutes of Health (NIH) and is a member of the AAAAI. J. V. Fahy receives research support from the NIH. P. J. Cooper receives research support from Wellcome Trust. T. A. E. Platts-Mills receives research support from Phadia and the NIH and has a patent on an assay. The rest of the authors have declared that they have no conflict of interest.	Apperson CS, 2008, VECTOR-BORNE ZOONOT, V8, P597, DOI 10.1089/vbz.2007.0271; Beaudouin E, 1997, ANN ALLERG ASTHMA IM, V79, P43; Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422; BROWN SJ, 1986, EXP PARASITOL, V62, P40, DOI 10.1016/0014-4894(86)90006-8; BURKE G, 2005, EMERG INFECT DIS; Centers for Disease Control and Prevention, 2010, ROCK MOUNT SPOTT FEV; *CDCP, 2010, EHRL QUEST ANSW; Childs JE, 2003, ANNU REV ENTOMOL, V48, P307, DOI 10.1146/annurev.ento.48.091801.112728; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Commins SP, 2009, J ALLERGY CLIN IMMUN, V124, P652, DOI 10.1016/j.jaci.2009.08.026; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Erwin EA, 2009, J ALLERGY CLIN IMMUN, V123, P706, DOI 10.1016/j.jaci.2008.11.042; Foley KA, 2010, ANN ONCOL, V21, P1455, DOI 10.1093/annonc/mdp535; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; GAUCI M, 1989, CLIN EXP ALLERGY, V19, P279, DOI 10.1111/j.1365-2222.1989.tb02384.x; Ginsberg HS, 2002, J VECTOR ECOL, V27, P215; Gronlund H, 2009, J ALLERGY CLIN IMMUN, V123, P1189, DOI 10.1016/j.jaci.2009.03.011; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; Hotez PJ, 2008, PLOS NEGLECT TROP D, V2, DOI 10.1371/journal.pntd.0000256; Kleine-Tebbe J, 2006, J ALLERGY CLIN IMMUN, V117, P190, DOI 10.1016/j.jaci.2005.08.056; Koike C, 2007, P NATL ACAD SCI USA, V104, P559, DOI 10.1073/pnas.0610012104; Kotsyfakis M, 2008, J IMMUNOL, V181, P5209; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/rccm.2103044; Merten HA, 2000, J VECTOR ECOL, V25, P102; Mixson TR, 2006, J MED ENTOMOL, V43, P1261, DOI 10.1603/0022-2585(2006)43[1261:POEBAR]2.0.CO;2; Nakazawa T, 2007, J ALLERGY CLIN IMMUN, V119, P421, DOI 10.1016/j.jaci.2006.11.633; *OH STAT U ENT, 2010, CHIGG FACT SHEET; O'Neil BH, 2007, J CLIN ONCOL, V25, P2644; Paddock CD, 2007, CURR TOP MICROBIOL, V315, P289; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Peters E, 1999, INT ARCH ALLERGY IMM, V118, P372, DOI 10.1159/000024140; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Ronmark E, 2009, J ALLERGY CLIN IMMUN, V124, P357, DOI 10.1016/j.jaci.2009.05.011; Stjernberg L, 2002, SCAND J INFECT DIS, V34, P840, DOI 10.1080/0036554021000026955; Van Nunen SA, 2009, MED J AUSTRALIA, V190, P510; VANWYE JE, 1991, NEW ENGL J MED, V324, P777; Wikel SK, 1996, ANNU REV ENTOMOL, V41, P1	42	143	145	8	27	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1286	U310		10.1016/j.jaci.2011.02.019		14	Allergy; Immunology	Allergy; Immunology	756NG	WOS:000290018600025	21453959	
J	Lamprecht, B; McBurnie, MA; Vollmer, WM; Gudmundsson, G; Welte, T; Nizankowska-Mogilnicka, E; Studnicka, M; Bateman, E; Anto, JM; Burney, P; Mannino, DM; Buist, SA				Lamprecht, Bernd; McBurnie, Mary Ann; Vollmer, William M.; Gudmundsson, Gunnar; Welte, Tobias; Nizankowska-Mogilnicka, Ewa; Studnicka, Michael; Bateman, Eric; Anto, Josep M.; Burney, Peter; Mannino, David M.; Buist, Sonia A.		BOLD Collaborative Res Grp	COPD in Never Smokers Results From the Population-Based Burden of Obstructive Lung Disease Study	CHEST			English	Article							NUTRITION EXAMINATION SURVEY; ENVIRONMENTAL TOBACCO-SMOKE; AIR-FLOW OBSTRUCTION; 3RD NATIONAL-HEALTH; PULMONARY-DISEASE; GRAIN DUST; GENDER-DIFFERENCES; PASSIVE SMOKING; BIOMASS SMOKE; US POPULATION	Background: Never smokers comprise a substantial proportion of patients with COPD. Their characteristics and possible risk factors in this population are not yet well defined. Methods: We analyzed data from 14 countries that participated in the international, population-based Burden of Obstructive Lung Disease (BOLD) study. Participants were aged >= 40 years and completed postbronchodilator spirometry testing plus questionnaires about respiratory symptoms, health status, and exposure to COPD risk factors. A diagnosis of COPD was based on the postbronchodilator FEV1/FVC ratio, according to current GOLD (Global Initiative for Obstructive Lung Disease) guidelines. In addition to this, the lower limit of normal (LLN) was evaluated as an alternative threshold for the FEV1/FVC ratio. Results: Among 4,291 never smokers, 6.6% met criteria for mild (GOLD stage I) COPD, and 5.6% met criteria for moderate to very severe (GOLD stage II+) COPD. Although never smokers were less likely to have COPD and had less severe COPD than ever smokers, never smokers nonetheless comprised 23.3% (240/1,031) of those classified with GOLD stage II+ COPD. This proportion was similar, 20.5% (171/832), even when the LLN was used as a threshold for the FEV1/FVC ratio. Predictors of COPD in never smokers include age, education, occupational exposure, childhood respiratory diseases, and BMI alterations. Conclusion: This multicenter international study confirms previous evidence that never smokers comprise a substantial proportion of individuals with COPD. Our data suggest that, in addition to increased age, a prior diagnosis of asthma and, among women, lower education levels are associated with an increased risk for COPD among never smokers. CHEST 2011; 139(4):752-763	[Lamprecht, Bernd; Studnicka, Michael] Paracelsus Med Univ, Dept Pulm Med, A-5020 Salzburg, Austria; [Buist, Sonia A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA; [McBurnie, Mary Ann; Vollmer, William M.] Kaiser Permanente Ctr Hlth Res, Portland, OR USA; [Gudmundsson, Gunnar] Landspitali Univ Hosp, Dept Resp Med Allergy & Sleep, Reykjavik, Iceland; [Welte, Tobias] Hannover Med Sch, Dept Resp Med, Hannover, Germany; [Nizankowska-Mogilnicka, Ewa] Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland; [Bateman, Eric] Univ Cape Town, ZA-7925 Cape Town, South Africa; [Anto, Josep M.] Ctr Res Environm Epidemiol, Barcelona, Spain; [Burney, Peter] Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; [Mannino, David M.] Univ Kentucky, Lexington, KY USA	Lamprecht, B (reprint author), Paracelsus Med Univ, Dept Pulm Med, Mullner Hauptstr 48, A-5020 Salzburg, Austria.	b.lamprecht@salk.at	Gudmundsson, Gunnar/F-1974-2013; Anto, J/H-2676-2014	Gudmundsson, Gunnar/0000-0002-7251-8322; Anto, J/0000-0002-4736-8529; Mannino, David/0000-0003-3646-7828	ALTANA; Aventis; AstraZeneca; Boehringer-Ingleheim; Chiesi; GlaxoSmithKline; Merck; Novartis; Pfizer Inc; Schering-Plough; Sunovion Pharmaceuticals Inc; University of Kentucky; Schering Plough; Sepracor; AstraZeneca, Spain	The BOLD initiative was funded in part by unrestricted educational grants to the operations center from ALTANA. Aventis, AstraZeneca, Boehringer-Ingleheim, Chiesi, GlaxoSmithKline, Merck, Novartis, Pfizer Inc, Schering-Plough, Sunovion Pharmaceuticals Inc, and the University of Kentucky.; The authors have reported to CHEST the following conflicts of interest: Dr McBurnie received funding for the BOLD study operations center and/or other research from unrestricted educational grants from GlaxoSmithKline, Pfizer, Boehringer Ingelheim, AstraZeneca, ALTANA, Novartis, Merck, Chiesi, Schering Plough, and Sepracor. Dr Vollmer has served on ad hoc advisory boards for Merck and Co; has participated in COPD workshops funded by Merck and GlaxoSmithKline; mid is director of the Burden of Obstructive Lung Disease (BOLD) Operations Center, for which funding includes unrestricted educational grants to the Kaiser Permanente Center for Health Research from Boehringer Ingelheim, Pfizer, ALTANA, GlaxoSmithKline, AstraZeneca, Novartis, Chiesi, and Merck. Dr Auto has received an educational grant from AstraZeneca, Spain. Dr Mannino has received research funding from GlaxoSmithKline, Pfizer, and Novartis. He has served as a speaker, advisor, or consultant for AstraZeneca, MAP Dey, Seprecor, Boehringer-Ingelheim, GlaxoSmithKline, Pfizer, and Novartis. He has also served as an expert witness in active and passive smoking cases. Dr Buist is a member of Advisory Boards for AstraZeneca, GlaxoSmithKline, Merck, and Novartis and has received unrestricted educational grants to the BOLD Operations Center from Chiesi, Boehringer Ingelheim, Pfizer, Novartis, GlaxoSmithKline, Sepracor, and Merck. Drs Lamprecht, Gudmundsson, Welte, Nizankowska-Mogilnicka, Studnicka, Bateman, and Burney have reported to CHEST that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BARKER DJP, 1991, BRIT MED J, V303, P671; Behrendt CE, 2005, CHEST, V128, P1239, DOI 10.1378/chest.128.3.1239; Bridevaux PO, 2010, EUR RESPIR J, V36, P1259, DOI 10.1183/09031936.00004110; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Buist A Sonia, 2005, COPD, V2, P277, DOI 10.1081/COPD-200057610; Celli BR, 2005, AM J MED, V118, P1364, DOI 10.1016/j.amjmed.2005.06.041; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Chan-Yeung M, 2004, INT J TUBERC LUNG D, V8, P2; Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752; Curtis Jeffrey L, 2007, Proc Am Thorac Soc, V4, P512, DOI 10.1513/pats.200701-002FM; DOPICO GA, 1982, J ALLERGY CLIN IMMUN, V69, P435, DOI 10.1016/0091-6749(82)90118-X; Dransfield MT, 2006, RESP MED, V100, P1110, DOI 10.1016/j.rmed.2005.09.019; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Ekici A, 2005, ENVIRON RES, V99, P93, DOI 10.1016/j.envres.2005.01.004; Ezzati M, 2005, LANCET, V366, P104, DOI 10.1016/S0140-6736(05)66845-6; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hardie JA, 2002, EUR RESPIR J, V20, P1117, DOI 10.1183/09031936.02.00023202; Hnizdo E, 2002, AM J EPIDEMIOL, V156, P738, DOI 10.1093/aje/kwf105; Hnizdo E, 2000, THORAX, V55, P32, DOI 10.1136/thorax.55.1.32; Iribarren C, 2001, J EPIDEMIOL COMMUN H, V55, P721, DOI 10.1136/jech.55.10.721; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; KRISHNA K, 1977, American Review of Respiratory Disease, V115, P402; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Lamprecht B, 2008, RESP MED, V102, P1833, DOI 10.1016/j.rmed.2008.07.007; Larsson ML, 2003, EUR RESPIR J, V21, P672, DOI 10.1183/09031936.03.00033702; Lundback B, 2003, RESP MED, V97, P115, DOI 10.1053/rmed.2003.1446; McKeever TM, 2010, AM J CLIN NUTR, V92, P408, DOI 10.3945/ajcn.2009.29021; Miravitlles M, 2005, RESP MED, V99, P985, DOI 10.1016/j.rmed.2005.01.012; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nizankowska-Mogilnicka Ewa, 2007, Pol Arch Med Wewn, V117, P402; Oroczo-Levi M, 2006, EUR RESPIR J, V27, P542; Prescott E, 1999, EUR RESPIR J, V13, P1109, DOI 10.1034/j.1399-3003.1999.13e28.x; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Ramirez-Venegas A, 2006, AM J RESP CRIT CARE, V173, P393, DOI 10.1164/rccm.200504-568OC; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616; Silverman EK, 2000, AM J RESP CRIT CARE, V162, P2152; Simoni M, 2007, RESP MED, V101, P531, DOI 10.1016/j.rmed.2006.06.021; Smith KR, 2000, P NATL ACAD SCI USA, V97, P13286, DOI 10.1073/pnas.97.24.13286; TABONA M, 1984, CHEST, V85, P782, DOI 10.1378/chest.85.6.782; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; Varraso R, 2007, THORAX, V62, P786, DOI 10.1136/thx.2006.074534; VONESSEN SG, 1988, AM REV RESPIR DIS, V138, P921; Williams RL, 2000, BIOMETRICS, V56, P645, DOI 10.1111/j.0006-341X.2000.00645.x; XU X, 1994, EUR RESPIR J, V7, P1056; Yin P, 2007, LANCET, V370, P751, DOI 10.1016/S0140-6736(07)61378-6; Zhou Y, 2009, EUR RESPIR J, V33, P509, DOI 10.1183/09031936.00084408	49	143	144	6	28	AMER COLL CHEST PHYSICIANS	GLENVIEW	2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA	0012-3692			CHEST	Chest	APR	2011	139	4					752	763		10.1378/chest.10-1253		12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	750HZ	WOS:000289538500007	20884729	
J	Poon, AH; Laprise, C; Lemire, M; Montpetit, A; Sinnett, D; Schurr, E; Hudson, TJ				Poon, AH; Laprise, C; Lemire, M; Montpetit, A; Sinnett, D; Schurr, E; Hudson, TJ			Association of vitamin D receptor genetic variants with susceptibility to asthma and atopy	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						genetic predisposition; polymorphism; vitamin D receptor	FAMILY-BASED TESTS; 1,25-DIHYDROXYVITAMIN D-3; CHEMOKINE RECEPTOR; ONSET ASTHMA; BONE-DENSITY; POLYMORPHISM; TUBERCULOSIS; ALLELES; DISEASE; PROGRESSION	Genome scans for asthma have identified suggestive or significant linkages on 17 different chromosomes, including chromosome 12, region q13-23, housing the vitamin D receptor (VDR) gene. Through interaction with VDR, 1,25-dihydroxyvitamin D3 mediates numerous biological activities, such as regulation of helper T-cell development and subsequent cytokine secretion profiles. Variants of the VDR have been found to be associated with immune-mediated diseases that are characterized by an imbalance in helper T-cell development, such as Crohn's disease and tuberculosis. The VDR, hence, is a good candidate to be investigated for association with asthma, which is characterized by enhanced helper T-cell type 2 activity. Here, we examined VDR genetic variants in an asthma family-based cohort from Quebec. We report six variants to be strongly associated with asthma and four with atopy (0.0005 less than or equal to p less than or equal to 0.05). Analysis of the linkage disequilibrium pattern and haplotypes also revealed significant association with both phenotypes (0.0004 less than or equal to p less than or equal to 0.01). The findings have been replicated by another research team in a second but not in a third cohort. These results identify VDR variants as genetic risk factors for asthma/atopy and implicate a non-human leukocyte antigen immunoregulatory molecule in the pathogenesis of asthma and atopy.	McGill Univ, Montreal, PQ H3A 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; McGill Univ, Ctr Hlth, McGill Ctr Study Host Resistance, Inst Res, Montreal, PQ, Canada; Univ Quebec, Chicoutimi, PQ, Canada; Univ Montreal, Chicoutimi Hosp, Community Genom Med Ctr, Chicoutimi, PQ, Canada	Hudson, TJ (reprint author), McGill Univ, 740 Penfield Ave,Room 7105, Montreal, PQ H3A 1A4, Canada.	tom.hudson@mcgill.ca	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; ALROY I, 1995, MOL CELL BIOL, V15, P5789; Barber Y, 2001, J INFECT DIS, V184, P1279, DOI 10.1086/324000; Becker Y, 2004, VIRUS GENES, V28, P5, DOI 10.1023/B:VIRU.0000012260.32578.72; Bell PA, 2002, BIOTECHNIQUES, P70; Bell PA, 2002, BIOTECHNIQUES S, P74; Bell PA, 2002, BIOTECHNIQUES S, P76; BELL PA, 2002, BIOTECHNIQUES S, P77; Bellamy R, 1999, J INFECT DIS, V179, P721, DOI 10.1086/314614; Boonstra A, 2001, J IMMUNOL, V167, P4974; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Cantorna MT, 2000, ARCH BIOCHEM BIOPHYS, V377, P135, DOI 10.1006/abbi.2000.1765; Cantorna MT, 1998, J IMMUNOL, V160, P5314; Carling T, 1998, J CLIN ENDOCR METAB, V83, P2255, DOI 10.1210/jc.83.7.2255; Chang TJ, 2000, CLIN ENDOCRINOL, V52, P575, DOI 10.1046/j.1365-2265.2000.00985.x; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Crofts LA, 1998, P NATL ACAD SCI USA, V95, P10529, DOI 10.1073/pnas.95.18.10529; Engert JC, 2002, DIABETES, V51, P1629, DOI 10.2337/diabetes.51.5.1629; Fassbender WJ, 2002, HORM METAB RES, V34, P330, DOI 10.1055/s-2002-33262; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HAUSSLER MR, 1997, J ENDOCRINOL, V154, P57; Hizawa N, 2002, AM J RESP CRIT CARE, V166, P686, DOI 10.1164/rccm.2002020090OC; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Horvath S, 2004, GENET EPIDEMIOL, V26, P61, DOI 10.1002/gepi.10295; Hudson TJ, 2003, NAT GENET, V33, P439, DOI 10.1038/ng0403-439; Ioannidis JPA, 2003, TRENDS MOL MED, V9, P135, DOI 10.1016/S1471-4914(03)00030-3; Kraichely Dennis M., 1998, Frontiers in Bioscience, V3, pD821; Laird NM, 2000, GENET EPIDEMIOL, V19, P36; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; LEMIRE JM, 1995, J NUTR, V125, pS1704; LEMIRE JM, 1995, J STEROID BIOCHEM, V53, P599, DOI 10.1016/0960-0760(95)00106-A; LEWONTIN RC, 1988, GENETICS, V120, P849; Liu Wei, 2003, Zhonghua Liu Xing Bing Xue Za Zhi, V24, P389; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; Lorentzon M, 2000, J CLIN ENDOCR METAB, V85, P1666, DOI 10.1210/jc.85.4.1666; McDermott MF, 1997, DIABETOLOGIA, V40, P971, DOI 10.1007/s001250050776; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; MORRISON NA, 1992, P NATL ACAD SCI USA, V89, P6665, DOI 10.1073/pnas.89.15.6665; Motohashi Y, 2003, J CLIN ENDOCR METAB, V88, P3137, DOI 10.1210/jc.2002-021881; Noguchi E, 2002, AM J RESP CRIT CARE, V166, P43, DOI 10.1164/rccm.2110052; Ofori H, 2004, SCAND J INFECT DIS, V36, P46, DOI 10.1080/00365540310017087; Pani MA, 2000, DIABETES, V49, P504, DOI 10.2337/diabetes.49.3.504; POON A, 2003, AM J HUM GENET, V73, pS385; RABY BA, IN PRESS AM J RESP C; Roy S, 1999, J INFECT DIS, V179, P187, DOI 10.1086/314536; Sainz J, 1997, NEW ENGL J MED, V337, P77, DOI 10.1056/NEJM199707103370202; Selvaraj P, 2000, INDIAN J MED RES, V111, P172; Simmons JD, 2000, GUT, V47, P211, DOI 10.1136/gut.47.2.211; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Taylor JA, 1996, CANCER RES, V56, P4108; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Verbeek W, 1997, BIOCHEM BIOPH RES CO, V238, P77, DOI 10.1006/bbrc.1997.7239; Wilkinson RJ, 2000, LANCET, V355, P618, DOI 10.1016/S0140-6736(99)02301-6; Wong HL, 2003, CARCINOGENESIS, V24, P1091, DOI 10.1093/carcin/bgg059; [Anonymous], 1987, AM REV RESP DIS, V136, P225	57	143	151	11	28	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 1	2004	170	9					967	973		10.1164/rccm.200403-412oc		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	865YJ	WOS:000224739800010	15282199	
J	Aaron, SD; Fergusson, D; Dent, R; Chen, Y; Vandemheen, KL; Dales, RE				Aaron, SD; Fergusson, D; Dent, R; Chen, Y; Vandemheen, KL; Dales, RE			Effect of weight reduction on respiratory function and airway reactivity in obese women	CHEST			English	Article						asthma; obesity; pulmonary function	ASTHMA; HEALTH	Background: Population-based studies have documented an association between obesity and an increased prevalence of asthma in women. Methods: We prospectively studied 58 obese women with a body mass index of > 30 kg/m(2), 24 of whom had asthma, who were enrolled in an intensive 6-month weight loss program to determine whether loss of body mass would be correlated with improvements in bronchial reactivity, lung function, and disease-specific health status. Results: Patients lost air average of 20 kg over the 6-month period. For every 10% relative loss of weight, the FVC improved by 92 mL (p = 0.05) and the FEV1 improved by 73 mL (p = 0.04), however, bronchial reactivity did not significantly change with weight loss (p = 0.23). Patients who lost > 13% of their pretreatment weight experienced improvements in FEV1 (p = 0.01), FVC (p = 0.02), and total lung capacity (p = 0.05) compared to patients in the lowest quartile who failed to lose significant amounts of weight. Neither group experienced any significant change in methacholine responsiveness (p = 0.57). Patients who completed the 6-month weight loss program experienced improvements in respiratory health status, irrespective of weight loss. Conclusion: We concluded that weight loss can improve lung function in obese women, however, the improvements appear to be independent of changes in airway reactivity.	Univ Ottawa, Dept Med, Ottawa, ON, Canada; Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON, Canada	Aaron, SD (reprint author), Ottawa Gen Hosp, Div Resp Med, Gen Campus,Room 1812F,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.	saaron@ottawahospital.on.ca		Aaron, Shawn/0000-0002-4762-3542			BARR RG, 2001, CHEST, V120, P1434; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; Chen Y, 2001, RESP MED, V95, P13, DOI 10.1053/rmed.2000.0961; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Dent RM, 2002, OBES RES, V10, P651, DOI 10.1038/oby.2002.88; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283; Lau DCW, 1999, CAN MED ASSOC J, V160, P503; NAIMARK A, 1960, J APPL PHYSIOL, V15, P377; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Shaheen SO, 1999, THORAX, V54, P396; SHARP JT, 1980, CLIN CHEST MED, V1, P103; SHARP JT, 1964, J CLIN INVEST, V43, P728, DOI 10.1172/JCI104957; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827	17	143	153	1	7	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2004	125	6					2046	2052		10.1378/chest.125.6.2046		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	832FQ	WOS:000222253100017	15189920	
J	Dahlen, I; Janson, C				Dahlen, I; Janson, C			Anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease	CHEST			English	Article						anxiety; asthma; COPD; depression; emergency treatment; relapse	AIR-FLOW OBSTRUCTION; NEAR-FATAL ASTHMA; HOSPITAL ANXIETY; RISK-FACTORS; LUNG-DISEASE; SCALE; MORBIDITY; SYMPTOMS; LIFE; BREATHLESSNESS	Study objectives: To investigate whether psychological factors predict outcome after emergency treatment for obstructive pulmonary disease. Setting: Emergency department at a university hospital. Patients: Forty-three patients presenting with exacerbation of asthma or COPD. Intervention: The patients received emergency treatment and were followed up for 4 weeks. Measurement: Spirometry, blood sampling, pulse oximetry, breathing rate, pulse rate, and dyspnea score was measured before and during emergency treatment. The psychological status was assessed using the hospital anxiety and depression (HAD) scale questionnaire at the end of the follow-up period. Results: Anxiety and/or depression was found in 17 patients (40%). Of these patients, nine patients (53%) were admitted to hospital or had a relapse within 1 month, compared with five patients (19%) in the group without anxiety and/or depression (p < 0.05). Among patients who relapsed within 1 month (n = 14), the HAD total score was 12.4 +/- 5.9 compared with 8.6 +/- 5.1 (mean +/- SD) among the patients without a relapse (p < 0.05). After making adjustments for age, gender, atopic status, treatment, and pack-years, the significant association between treatment failure and anxiety and/or depression still remained. Conclusion: Our study indicates that anxiety and depression are related to the outcome of emergency treatment in patients with obstructive pulmonary disease. Further studies should be conducted evaluating the effect of treatment of anxiety and depression in patients with recurrent exacerbations of asthma and COPD.	Univ Uppsala Hosp, Dept Med Sci Resp Med & Allergol, SE-75185 Uppsala, Sweden	Dahlen, I (reprint author), Univ Uppsala Hosp, Dept Lung Med & Allergol, SE-75185 Uppsala, Sweden.						BENJAMIN S, 1977, J PSYCHOSOM RES, V21, P463, DOI 10.1016/0022-3999(77)90069-1; BURDON JGW, 1982, AM REV RESPIR DIS, V126, P825; CAMPBELL DA, 1995, THORAX, V50, P254, DOI 10.1136/thx.50.3.254; Centanni S, 2000, RESP MED, V94, P742, DOI 10.1053/rmed.1999.0766; Chetta A, 1998, AM J RESP CRIT CARE, V157, P116; Dahlen I, 1999, RESP MED, V93, P744, DOI 10.1016/S0954-6111(99)90043-4; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; DEAL EC, 1979, J APPL PHYSIOL, V46, P476; EMERMAN CL, 1995, ANN EMERG MED, V26, P6, DOI 10.1016/S0196-0644(95)70230-X; *EUR COMM COAL STE, 1983, CLIN RESPIR PHYSL, V19, pS22; GUYATT GH, 1987, BRIT J DIS CHEST, V81, P45, DOI 10.1016/0007-0971(87)90107-0; Harrison BDW, 1998, THORAX, V53, P519; Innes NJ, 1998, J ROY COLL PHYS LOND, V32, P430; ISOAHO R, 1995, PSYCHOL REP, V76, P287; JANSON C, 1994, AM J RESP CRIT CARE, V149, P930; Joseph KS, 1996, BMJ-BRIT MED J, V312, P79; KELLNER R, 1987, J PSYCHOSOM RES, V31, P575, DOI 10.1016/0022-3999(87)90036-5; LEWIN B, 1992, LANCET, V339, P1036, DOI 10.1016/0140-6736(92)90547-G; Lisspers J, 1997, ACTA PSYCHIAT SCAND, V96, P281, DOI 10.1111/j.1600-0447.1997.tb10164.x; MAHLER DA, 1987, AM REV RESPIR DIS, V135, P1229; MASUDA M, 1966, J PSYCHOSOM RES, V10, P255, DOI 10.1016/0022-3999(66)90092-4; Miles JF, 1997, CLIN EXP ALLERGY, V27, P1151; MOOREY S, 1991, BRIT J PSYCHIAT, V158, P255, DOI 10.1192/bjp.158.2.255; MURATA GH, 1989, ANN EMERG MED, V18, P501, DOI 10.1016/S0196-0644(89)80833-9; PEACH H, 1981, THORAX, V36, P585, DOI 10.1136/thx.36.8.585; PICADO C, 1989, J ASTHMA, V26, P231, DOI 10.3109/02770908909073254; RYAN G, 1991, AUST NZ J MED, V21, P681, DOI 10.1111/j.1445-5994.1991.tb01370.x; Schmaling KB, 1998, J ASTHMA, V35, P631, DOI 10.3109/02770909809048965; SILVERMAN M, 1988, AM REV RESPIR DIS, V137, P206; STEHR DE, 1991, ANN EMERG MED, V20, P1113, DOI 10.1016/S0196-0644(05)81386-1; TAL A, 1976, PSYCHOSOM MED, V38, P190; WAREHAM NJ, 1993, THORAX, V48, P1117, DOI 10.1136/thx.48.11.1117; WILKINSON MJB, 1988, J ROY COLL GEN PRACT, V38, P311; WOLKOVE N, 1989, CHEST, V96, P1247, DOI 10.1378/chest.96.6.1247; YAMAMOTO H, 1987, RESPIRATION, V52, P42; YELLOWLEES PM, 1987, MED J AUSTRALIA, V146, P305; YELLOWLEES PM, 1989, CHEST, V95, P1298, DOI 10.1378/chest.95.6.1298; Yohannes AM, 2000, INT J GERIATR PSYCH, V15, P1090, DOI 10.1002/1099-1166(200012)15:12<1090::AID-GPS249>3.0.CO;2-L; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	39	143	153	0	6	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2002	122	5					1633	1637		10.1378/chest.122.5.1633		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	617TH	WOS:000179376600026	12426264	
J	Lordan, JL; Bucchieri, F; Richter, A; Konstantinidis, A; Holloway, JW; Thornber, M; Puddicombe, SM; Buchanan, D; Wilson, SJ; Djukanovic, R; Holgate, ST; Davies, DE				Lordan, JL; Bucchieri, F; Richter, A; Konstantinidis, A; Holloway, JW; Thornber, M; Puddicombe, SM; Buchanan, D; Wilson, SJ; Djukanovic, R; Holgate, ST; Davies, DE			Cooperative effects of Th2 cytokines and allergen on normal and asthmatic bronchial epithelial cells	JOURNAL OF IMMUNOLOGY			English	Article							DIESEL EXHAUST PARTICLES; IN-VITRO; INFLAMMATORY CYTOKINE; NONASTHMATIC SUBJECTS; GENETIC-VARIANTS; ILE50VAL VARIANT; IL-4 RECEPTOR; SOCS PROTEINS; IGE SYNTHESIS; EXPRESSION	In sensitized individuals, exposure to allergens such as Dermatophagoides pteronyssinus (Der p) causes Th2 polarization and release of cytokines, including IL-4 and IL-13. Because Der p extracts also have direct effects on epithelial cells, we hypothesized that allergen augments the effects of Th2 cytokines by promoting mediator release from the bronchial epithelium in allergic asthma. To test our hypothesis, primary bronchial epithelial cultures were grown from bronchial brushings of normal and atopic asthmatic subjects. RT-PCR showed that each culture expressed IL-4Ralpha, common gamma-chain, and IL-13Ralpha(1), as well as IL-13Ralpha(2), which negatively regulates IL-13 signaling; FACS analysis confirmed IL-13Ralpha(2) protein expression. Exposure of epithelial cultures to either Der p extracts, TNF-alpha, IL-4, or IL-13 enhanced GM-CSF and IL-8 release, and this was partially suppressible by corticosteroids. Simultaneous exposure of the epithelial cultures to IL-4 or IL-13 together with Der p resulted in a further increase in cytokine release, which was at least additive. Release of TGF-alpha was also increased by TNF-a and combinations of IL-4, IL-13, and Der p; however, this stimulation was only significant in the asthma-derived cultures. These data suggest that, in an allergic environment, Th2 cytokines and allergen have the potential to sustain airway inflammation through a cooperative effect on cytokine release by the bronchial epithelium. Our novel finding that IL-4, IL-13, and allergen enhance release of TGF-a, a ligand for the epidermal growth factor receptor that stimulates fibroblast proliferation and goblet cell differentiation, provides a potential link between allergen exposure, Th2 cytokines, and airway remodelling in asthma.	Southampton Gen Hosp, Resp Cell & Mol Biol Div 810, Sch Med, Southampton SO16 6YD, Hants, England	Davies, DE (reprint author), Southampton Gen Hosp, Resp Cell & Mol Biol Div 810, Sch Med, Southampton SO16 6YD, Hants, England.		Bucchieri, Fabio/F-8877-2012; Holloway, John/B-5424-2009; Davies, Donna/H-2993-2012	Holloway, John/0000-0001-9998-0464; BUCCHIERI, Fabio/0000-0002-0209-8668			BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; BOOTH B, 2001, CHEST, V120, P158; BUCCHIERI F, 2000, AM J RESP CRIT CARE, V161, pA153; Dabbagh K, 1999, J IMMUNOL, V162, P6233; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Devalia JL, 1999, INT ARCH ALLERGY IMM, V118, P437, DOI 10.1159/000024157; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Gallucci RM, 2000, J IMMUNOL, V164, P872; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kile BT, 2001, INT J HEMATOL, V73, P292, DOI 10.1007/BF02981953; King C, 1998, J IMMUNOL, V161, P3645; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Merlos-Suarez A, 1998, J BIOL CHEM, V273, P24955, DOI 10.1074/jbc.273.38.24955; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832; Nakamura Y, 1996, AM J RESP CELL MOL, V15, P680; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nicola NA, 1999, COLD SPRING HARB SYM, V64, P397, DOI 10.1101/sqb.1999.64.397; Nicola NA, 2000, EXP HEMATOL, V28, P1105, DOI 10.1016/S0301-472X(00)00525-7; Richter A, 2001, AM J RESP CELL MOL, V25, P385; SANDFORD AJ, 2000, J ALLERGY CLIN IMMUN, V106, P1350; SEHMI R, 1993, CLIN EXP ALLERGY, V23, P1027, DOI 10.1111/j.1365-2222.1993.tb00295.x; SHARMA S, 2001, AM J RESP CRIT CARE, V163, pA862; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; STEMPEL DA, 1980, J PEDIATR-US, V97, P185, DOI 10.1016/S0022-3476(80)80471-9; Takeyama K, 2000, J IMMUNOL, V164, P1546; Teran LM, 1996, AM J RESP CRIT CARE, V154, P469; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; van der Velden VHJ, 1998, CYTOKINE, V10, P803, DOI 10.1006/cyto.1998.0365; Wang J, 2000, BLOOD, V95, P2337; *WHO NHLBI, 1995, WHO NHLBI WORKSH REP; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Xing Z, 1996, J LEUKOCYTE BIOL, V59, P481; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	50	143	148	2	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUL 1	2002	169	1					407	414				8	Immunology	Immunology	565GA	WOS:000176360400052	12077271	
J	Strickland, I; Kisich, K; Hauk, PJ; Vottero, A; Chrousos, GP; Klemm, DJ; Leung, DYM				Strickland, I; Kisich, K; Hauk, PJ; Vottero, A; Chrousos, GP; Klemm, DJ; Leung, DYM			High constitutive glucocorticoid receptor beta in human neutrophils enables them to reduce their spontaneous rate of cell death in response to corticosteroids	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						neutrophils; glucocorticoid insensitivity; glucocorticoid receptor; interleukin 8; inflammation	STREPTOLYSIN-O; APOPTOSIS; ISOFORM; EXPRESSION; BINDING; DEXAMETHASONE; INFLAMMATION; SPECIFICITY; ASTHMA	Neutrophils are markedly less sensitive to glucocorticoids than T cells, making it difficult to control inflammation in neutrophil-mediated diseases. Development of new antiinflammatory strategies for such diseases would be aided by an understanding of mechanisms underlying differential steroid responsiveness. Two protein isoforms of the human glucocorticoid receptor (GR) exist, GR alpha and GR beta, which arise from alternative splicing of the GR pre-mRNA primary transcripts. GR beta does not bind glucocorticoids and is an inhibitor of GR alpha activity. Relative amounts of these two GRs can therefore determine the level of glucocorticoid sensitivity. In this study, human neutrophils and peripheral blood mononuclear cells (PBMCs) were studied to determine the relative amounts of each GR isoform. The mean fluorescence intensity (MFI) using immunofluorescence analysis for GR alpha was 475 +/- 62 and 985 +/- 107 for PBMCs and neutrophils, respectively. For GR beta, the MFI was 350 +/- 60 and 1,389 +/- 143 for PBMCs and neutrophils, respectively (P < 0.05). After interleukin (IL)-8 stimulation of neutrophils, there was a statistically significant increase in intensity of GR<beta> staining to 2,497 +/- 140 (P < 0.05). No change in GR<alpha> expression was observed. This inversion of the GR alpha /GR beta ratio in human neutrophils compared with PBMCs was confirmed by quantitative Western analysis. Increased GR beta mRNA expression in neutrophils at baseline, and after IL-8 exposure, was observed using RNA dot blot analysis. Increased levels of GR alpha /GR beta heterodimers were found in neutrophils as compared with PBMCs using coimmunoprecipitation/Western analysis. Transfection of mouse neutrophils, which do not contain GR beta, resulted in a significant reduction in the rate of cell death when treated with dexamethasone. We conclude that high constitutive expression of GR beta by human neutrophils may provide a mechanism by which these cells escape glucocorticoid-induced cell death. Moreover, upregulation of this GR by proinflammatory cytokines such as IL-8 further enhances their survival in the presence of glucocorticoids during inflammation.	Natl Jewish Med Res Ctr, Dept Pediat, Denver, CO 80206 USA; Natl Jewish Med Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; NICHD, Pediat & Reprod Endocrinol Branch, NIH, Bethesda, MD 20892 USA	Leung, DYM (reprint author), Natl Jewish Med Res Ctr, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.				NCRR NIH HHS [M01 RR000051, MO1 RR00051]; NHLBI NIH HHS [HL34303, HL36577, HL37260, P01 HL034303, P01 HL036577, R37 HL037260]; NIAMS NIH HHS [AR41256, R01 AR041256]		BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BLOOM JW, 1999, IMMUNOLOGY ALLERGY C, P653; Brogan IJ, 1999, MOL CELL ENDOCRINOL, V157, P95, DOI 10.1016/S0303-7207(99)00156-2; Broughton CM, 1997, LEUKEMIA, V11, P1435, DOI 10.1038/sj.leu.2400774; CHU P, 1994, ARCH DERMATOL, V130, P1278, DOI 10.1001/archderm.130.10.1278; COBLE BI, 1988, INT ARCH ALLER A IMM, V55, P398; Cox G, 1997, J LEUKOCYTE BIOL, V61, P224; deCastro M, 1996, MOL MED, V2, P597; deLange P, 1997, MOL ENDOCRINOL, V11, P1156, DOI 10.1210/me.11.8.1156; Di Baldassarre A, 2000, CELL MOL BIOL, V46, P153; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Kato T, 1995, NAT IMMUN, V14, P198; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Liles WC, 1996, J EXP MED, V184, P429, DOI 10.1084/jem.184.2.429; MEIER F, 1989, Skin Pharmacology, V2, P61; Modarress KJ, 1997, J BIOL CHEM, V272, P23986, DOI 10.1074/jbc.272.38.23986; Negoescu A, 1998, BIOMED PHARMACOTHER, V52, P252, DOI 10.1016/S0753-3322(98)80010-3; Oakley RH, 1996, J BIOL CHEM, V271, P9550; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; Otto C, 1997, J BIOL CHEM, V272, P26665, DOI 10.1074/jbc.272.42.26665; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Sala A, 1999, J BIOL CHEM, V274, P28264, DOI 10.1074/jbc.274.40.28264; Schleimer RP, 1990, AM REV RESPIR DIS S, V141, pS59; SPILLER DG, 1995, ANTISENSE RES DEV, V5, P13; Starkebaum G, 1997, Curr Opin Hematol, V4, P196; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737	29	143	149	2	2	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	MAR 5	2001	193	5					585	593		10.1084/jem.193.5.585		9	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	411WN	WOS:000167522500005	11238589	
J	Fagan, KA; McMurtry, IF; Rodman, DM				Fagan, KA; McMurtry, IF; Rodman, DM			Role of endothelin-1 in lung disease	RESPIRATORY RESEARCH			English	Review						asthma; endothelin; fibrosis; inflammation; pulmonary hypertension	BRONCHOALVEOLAR LAVAGE FLUID; OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-DISTRESS-SYNDROME; BRONCHIAL EPITHELIAL-CELLS; PERFUSED RAT LUNGS; COLLAGEN GEL CONTRACTION; GUINEA-PIG PULMONARY; AIR-FLOW OBSTRUCTION; SMOOTH-MUSCLE CELLS; PLASMA ENDOTHELIN-1	Endothelin-1 (ET-1) is a 21 amino acid peptide with diverse biological activity that has been implicated in numerous diseases. ET-1 is a potent mitogen regulator of smooth muscle tone, and inflammatory mediator that may play a key role in diseases of the airways, pulmonary circulation, and inflammatory lung diseases, both acute and chronic. This review will focus on the biology of ET-1 and its role in lung disease.	Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Cardiovasc Pulm Res Lab, Denver, CO 80262 USA	Fagan, KA (reprint author), Univ Colorado, Hlth Sci Ctr, Div Pulm Sci & Crit Care Med, Cardiovasc Pulm Res Lab, 4200 E 9th Ave,B-133, Denver, CO 80262 USA.	karen.fagan@uchsc.edu					Aarnio P, 1996, SCAND J THORAC CARD, V30, P113, DOI 10.3109/14017439609107255; ABRAHAM DJ, 1997, AM J PATHOL, V151, P81; ACKERMAN V, 1995, J ALLERGY CLIN IMMUN, V96, P618, DOI 10.1016/S0091-6749(95)70260-1; Aguirre JI, 2000, AM J PHYSIOL-LUNG C, V278, pL981; Ahmed SI, 2000, AM J RESP CELL MOL, V22, P422; Alanen K, 2000, HISTOPATHOLOGY, V36, P161; ALBERTINE KH, 1999, CHEST, V116, P1015; Ali H, 2000, GUT, V47, P685, DOI 10.1136/gut.47.5.685; ALLISON RC, 1990, J APPL PHYSIOL, V69, P597; AOKI T, 1994, ANN ALLERGY, V73, P365; ARAI H, 1990, NATURE, V348, P730, DOI 10.1038/348730a0; ARINAMI T, 1991, AM J HUM GENET, V48, P990; ASAKURA H, 1992, AM J HEMATOL, V41, P71, DOI 10.1002/ajh.2830410202; Aversa CR, 1997, AM J PHYSIOL-LUNG C, V273, pL848; Battistini B, 1998, PULM PHARMACOL THER, V11, P79, DOI 10.1006/pupt.1998.0148; BELL KM, 1998, J CARDIOVASC PHAR S3, V33, pS537; BLADE PN, 1989, FEBS LETT, V255, P129; BONVALLET ST, 1994, AM J PHYSIOL, V266, pH1327; Cacoub P, 1997, CARDIOVASC RES, V33, P196, DOI 10.1016/S0008-6363(96)00189-7; CALE ARJ, 1994, CIRCULATION, V90, P952; CAMBREY AD, 1994, AM J RESP CELL MOL, V11, P439; CANDENAS ML, 1992, EUR J PHARMACOL, V210, P291, DOI 10.1016/0014-2999(92)90418-4; Cases E, 1996, BRIT J PHARMACOL, V119, P1337; Celik G, 1998, RESPIRATION, V65, P289, DOI 10.1159/000029278; Chalmers GW, 1999, EUR RESPIR J, V13, P1288, DOI 10.1183/09031936.99.13612939; Chalmers GW, 1997, AM J RESP CRIT CARE, V156, P382; Chalmers GW, 1999, CLIN EXP ALLERGY, V29, P1526; CHEN WY, 1995, J ASTHMA, V32, P29, DOI 10.3109/02770909509089497; Cohen AJ, 1997, FASEB J, V11, P3221; COHEN AJ, 1997, LUNG CANCER S, V18, P574; Dawas K, 1999, ANN ROY COLL SURG, V81, P306; DENUCCI G, 1988, P NATL ACAD SCI USA, V85, P9797; DICARLO VS, 1995, AM J PHYSIOL-LUNG C, V269, pL690; Doi S, 2000, J APPL PHYSIOL, V88, P210; Drimal J, 2000, EUR J PHARMACOL, V396, P19, DOI 10.1016/S0014-2999(00)00198-9; DRUML W, 1993, AM REV RESPIR DIS, V148, P1169; Dubin D, 1989, J VASC MED BIOL, V1, P150; Dupuis J, 1996, CIRCULATION, V94, P1578; Eberl LP, 2000, INT J CANCER, V86, P182, DOI 10.1002/(SICI)1097-0215(20000415)86:2<182::AID-IJC6>3.0.CO;2-G; FILEP JG, 1993, BRIT J PHARMACOL, V110, P1213; Finsnes F, 1997, AM J RESP CRIT CARE, V155, P1404; Finsnes F, 1998, AM J RESP CRIT CARE, V158, P1600; Finsnes F, 2000, EUR RESPIR J, V15, P743, DOI 10.1034/j.1399-3003.2000.15d19.x; Frasch HF, 1999, AM J PHYSIOL-LUNG C, V276, pL304; Fujii T, 1999, RESPIRATION, V66, P212, DOI 10.1159/000029380; Fujitani Y, 1997, AM J RESP CRIT CARE, V155, P1890; FUKURODA T, 1994, J APPL PHYSIOL, V76, P1976; GIAID A, 1990, J PATHOL, V162, P15, DOI 10.1002/path.1711620105; GIAID A, 1991, AM J RESP CELL MOL, V4, P50; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; GIAID A, 1993, LANCET, V341, P1550; GILLESPIE MN, 1986, J PHARMACOL EXP THER, V236, P339; GLASSBERG MK, 1994, AM J RESP CELL MOL, V10, P316; GOLDEN CL, 1995, AM J RESP CELL MOL, V12, P503; GOLDIE RG, 1995, AM J RESP CRIT CARE, V152, P1653; Goldie RG, 1999, PULM PHARMACOL THER, V12, P79, DOI 10.1006/pupt.1999.0190; GOMEZGARRE D, 1992, EUR J PHARMACOL, V224, P167, DOI 10.1016/0014-2999(92)90801-A; GUARDA E, 1993, CARDIOVASC RES, V27, P2130, DOI 10.1093/cvr/27.12.2130; GUIDRY C, 1991, J CELL BIOL, V115, P873, DOI 10.1083/jcb.115.3.873; HAAK T, 1994, METABOLISM, V43, P267, DOI 10.1016/0026-0495(94)90091-4; HALIM A, 1995, THROMB RES, V77, P321, DOI 10.1016/0049-3848(95)93835-N; HARRISON VJ, 1993, J CARDIOVASC PHARM, V22, pS57, DOI 10.1097/00005344-199322008-00017; HARRISON VJ, 1995, P NATL ACAD SCI USA, V92, P6344, DOI 10.1073/pnas.92.14.6344; HASSOUN PM, 1992, P SOC EXP BIOL MED, V199, P165; HASUNUMA K, 1990, AM J PHYSIOL, V259, pH48; HATAKEYAMA H, 1994, BIOCHEM MOL BIOL INT, V34, P127; HAY DWP, 1993, BRIT J PHARMACOL, V110, P392; HAY DWP, 1993, BRIT J PHARMACOL, V110, P1175; Helset E, 1996, AM J PHYSIOL-LUNG C, V271, pL538; HELSET E, 1993, CIRC SHOCK, V39, P15; HELSET E, 1994, CIRC SHOCK, V44, P201; Henry PJ, 1999, CLIN EXP PHARMACOL P, V26, P162, DOI 10.1046/j.1440-1681.1999.03010.x; HICKEY KA, 1985, AM J PHYSIOL, V248, P550; Hill NS, 1997, J APPL PHYSIOL, V83, P1209; Hocher B, 2000, AM J RESP CELL MOL, V23, P19; Hocher B, 1997, J CLIN INVEST, V99, P1380, DOI 10.1172/JCI119297; HURIBAL M, 1995, J AM COLL SURGEONS, V180, P318; INOUE A, 1989, J BIOL CHEM, V264, P14954; ISHIDA K, 1990, BIOCHEM BIOPH RES CO, V173, P496, DOI 10.1016/S0006-291X(05)80061-0; IWASAKI S, 1995, J BIOL CHEM, V270, P6997; Jeppsson A, 1998, TRANSPLANTATION, V66, P806, DOI 10.1097/00007890-199809270-00018; KHALIL N, 1989, J EXP MED, V170, P727, DOI 10.1084/jem.170.3.727; KIMURA S, 1989, J CARDIOVASC PHARM, V13, pS5, DOI 10.1097/00005344-198900135-00003; KIOWSKI W, 1994, CIRCULATION, V90, P27; KOUREMBANAS S, 1993, J CLIN INVEST, V92, P99, DOI 10.1172/JCI116604; KRAFT M, 1994, AM J RESP CRIT CARE, V149, P947; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Langleben D, 1999, CIRCULATION, V99, P3266; LANGLEBEN D, 1993, AM REV RESPIR DIS, V148, P1646; Lee SD, 1998, J CLIN INVEST, V101, P927, DOI 10.1172/JCI1910; LEHOUX S, 1992, BRIT J PHARMACOL, V107, P996; LI H, 1994, AM J PHYSIOL, V266, P553; LI HB, 1994, J APPL PHYSIOL, V77, P1451; LIPPTON HL, 1993, J APPL PHYSIOL, V75, P38; MANSOOR AM, 1995, BIOCHEM BIOPH RES CO, V215, P981, DOI 10.1006/bbrc.1995.2560; Marini M, 1996, BIOCHEM BIOPH RES CO, V220, P896, DOI 10.1006/bbrc.1996.0502; MARKEWITZ BA, 1995, AM J PHYSIOL-LUNG C, V269, pL215; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; MCLEAN MR, 1994, J CARDIOVASC PHARM, V23, P838; MCMILLEN MA, 1995, J AM COLL SURGEONS, V180, P621; Michael JR, 1997, AM J PHYSIOL-LUNG C, V273, pL768; Michael JR, 1996, AM J RESP CRIT CARE, V154, P555; MITAKA C, 1993, CHEST, V104, P476, DOI 10.1378/chest.104.2.476; MIYAUCHI T, 1993, CIRC RES, V73, P887; Moller S, 1999, EUR J PHARMACOL, V365, pR1, DOI 10.1016/S0014-2999(98)00864-4; MORELLI S, 1995, AM J MED, V99, P255, DOI 10.1016/S0002-9343(99)80157-0; Muramatsu M, 1997, AM J PHYSIOL-LUNG C, V272, pL807; Muramatsu M, 1999, AM J PHYSIOL-LUNG C, V276, pL358; MURLAS CG, 1995, BIOCHEM BIOPH RES CO, V212, P953, DOI 10.1006/bbrc.1995.2062; MUSTAERS SE, 1998, AM J RESP CELL MOL B, V18, P611; Mutsaers SE, 1998, PULM PHARMACOL THER, V11, P221, DOI 10.1006/pupt.1998.0142; Nagase T, 1999, J APPL PHYSIOL, V87, P2020; Nagase T, 1998, AM J RESP CRIT CARE, V157, P560; NAKAMURA S, 1990, HISTOCHEMISTRY, V94, P475, DOI 10.1007/BF00272609; Nakanishi K, 1999, LAB INVEST, V79, P1347; Nelson JB, 1996, CANCER RES, V56, P663; NOGUCHI K, 1995, J APPL PHYSIOL, V79, P700; NOGUCHI Y, 1995, BIOCHEM BIOPH RES CO, V210, P302, DOI 10.1006/bbrc.1995.1661; OBRIEN RF, 1987, J CELL PHYSIOL, V132, P263, DOI 10.1002/jcp.1041320210; Odoux C, 1997, AM J RESP CRIT CARE, V156, P1429; ONG ACM, 1995, KIDNEY INT, V48, P390, DOI 10.1038/ki.1995.307; OPARIL S, 1995, AM J PHYSIOL-LUNG C, V268, pL95; PARADIS I, 1993, CLIN CHEST MED, V14, P751; Park SH, 1997, AM J RESP CRIT CARE, V156, P600; PEACOCK AJ, 1992, AM J RESP CELL MOL, V7, P492; Pedram A, 1997, J BIOL CHEM, V272, P17097, DOI 10.1074/jbc.272.27.17097; PIGUET PF, 1989, J EXP MED, V170, P655, DOI 10.1084/jem.170.3.655; POWER RF, 1989, J CARDIOVASC PHARM, V13, pS50, DOI 10.1097/00005344-198900135-00013; PRINS BA, 1994, J BIOL CHEM, V269, P11938; REDINGTON AE, 1995, AM J RESP CRIT CARE, V151, P1034; RODMAN DM, 1992, J CARDIOVASC PHARM, V20, P658, DOI 10.1097/00005344-199210000-00021; ROZENGURT N, 1990, J PATHOL, V160, P5, DOI 10.1002/path.1711600104; SAKURAI T, 1990, NATURE, V348, P732, DOI 10.1038/348732a0; Sanai L, 1996, INTENS CARE MED, V22, P52, DOI 10.1007/BF01728331; Sato K, 2000, AM J PHYSIOL-LUNG C, V278, pL434; SATO K, 1999, AM J PHYSIOL, V270, pL511; SATOH M, 1992, RESPIRATION, V59, P145; Schersten H, 1996, J THORAC CARDIOV SUR, V111, P253, DOI 10.1016/S0022-5223(96)70423-3; SCHERSTEN H, 1994, TRANSPLANTATION, V57, P159, DOI 10.1097/00007890-199401000-00027; Schmeck J, 1999, J APPL PHYSIOL, V87, P2284; Schmeck J, 2000, CRIT CARE MED, V28, P2851, DOI 10.1097/00003246-200008000-00028; SCOTT JP, 1991, TRANSPLANTATION, V51, P813, DOI 10.1097/00007890-199104000-00015; Shahar I, 1999, INT J IMMUNOPHARMACO, V21, P759, DOI 10.1016/S0192-0561(99)00056-9; Shennib H, 1998, AM J RESP CRIT CARE, V157, P1975; SHENNIB H, 1995, J CARDIOVASC PHARM, V26, pS516; SHENNIB H, TRANSPLANTATION, V59, P994; SIMMET T, 1992, EUR J PHARMACOL, V211, P319, DOI 10.1016/0014-2999(92)90387-J; SIROIS MG, 1992, EUR J PHARMACOL, V214, P119, DOI 10.1016/0014-2999(92)90108-G; SOFIA M, 1993, RESPIRATION, V60, P89; SOFIA M, 1994, RESPIRATION, V61, P263; Soma S, 1999, AM J RESP CELL MOL, V20, P620; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; STELZNER TJ, 1992, AM J PHYSIOL, V262, P614; STEWART DJ, 1991, ANN INTERN MED, V114, P464; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; Sunose Y, 2000, J HEART LUNG TRANSPL, V19, P298, DOI 10.1016/S1053-2498(99)00140-0; Takeda S, 1997, ANN THORAC SURG, V63, P1562, DOI 10.1016/S0003-4975(97)00367-6; TAMAOKI J, 1991, AM J RESP CELL MOL, V4, P426; Teder P, 2000, AM J RESP CELL MOL, V23, P7; UCHIDA Y, 1992, BIOCHEM BIOPH RES CO, V189, P1196, DOI 10.1016/0006-291X(92)92331-Q; UGUCCIONI M, 1995, J CLIN PATHOL, V48, P330, DOI 10.1136/jcp.48.4.330; VANCHEESWARAN R, 1994, J RHEUMATOL, V21, P1838; VEMULAPALLI S, 1992, J PHARMACOL EXP THER, V262, P1062; VILLASCHI S, 1994, LAB INVEST, V71, P291; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320; WAGNER OF, 1992, J BIOL CHEM, V267, P16066; WEIBKE JL, 1992, BIOCHIM BIOPHYS ACTA, V1134, P105; YANAGISAWA M, 1988, NATURE, V332, P411, DOI 10.1038/332411a0; YOSHIZUMI M, 1989, BIOCHEM BIOPH RES CO, V161, P859, DOI 10.1016/0006-291X(89)92679-X; Zamora MR, 1996, AM J PHYSIOL-LUNG C, V270, pL101; ZHAO YD, 1995, J CARDIOVASC PHARM, V26, pS336; ZHAO YD, 1995, J CARDIOVASC PHAR S3, V261, pS341; Zheng L, 2000, EUR RESPIR J, V16, P146, DOI 10.1034/j.1399-3003.2000.16a26.x	174	143	158	0	6	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1465-993X			RESP RES	Respir. Res.		2001	2	2					90	101		10.1186/rr44		12	Respiratory System	Respiratory System	443UZ	WOS:000169361200007	11686871	
J	Chapman, MD; Pomes, A; Breiteneder, H; Ferreira, F				Chapman, Martin D.; Pomes, Anna; Breiteneder, Heimo; Ferreira, Fatima			Nomenclature and structural biology of allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; nomenclature; IgE; asthma; protein families; allergic disease; protein structure; biologic function	BIRCH POLLEN ALLERGEN; DUST-MITE ALLERGENS; SEED STORAGE PROTEINS; PLANT FOOD ALLERGENS; CRYSTAL-STRUCTURE; CROSS-REACTIVITY; CAT ALLERGEN; BINDING; COCKROACH; IMMUNOTHERAPY	Purified allergens are named using the systematic nomenclature of the Allergen Nomenclature Sub-Committee of the World Health Organization and International Union of Immunological Societies. The system uses abbreviated Linnean genus and species names and an Arabic number to indicate the chronology of allergen purification. Most major allergens from mites, animal dander, pollens, insects, and foods have been cloned, and more than 40 three-dimensional allergen structures are in the Protein Database. Allergens are derived from proteins with a variety of biologic functions, including proteases, ligand-binding proteins, structural proteins, pathogenesis-related proteins, lipid transfer proteins, profilins, and calcium-binding proteins. Biologic function, such as the proteolytic enzyme allergens of dust mites, might directly influence the development of IgE responses and might initiate inflammatory responses in the lung that are associated with asthma. Intrinsic structural or biologic properties might also influence the extent to which allergens persist in indoor and outdoor environments or retain their allergenicity in the digestive tract. Analyses of the protein family database suggest that the universe of allergens comprises more than 120 distinct protein families. Structural biology and proteomics define recombinant allergen targets for diagnostic and therapeutic purposes and identify motifs, patterns, and structures of immunologic significance.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA; Med Univ Vienna, Vienna, Austria; Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria	Chapman, MD (reprint author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	mdc@inbio.com	Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335; Pomes, Anna/0000-0002-8729-1829			Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; Asokananthan N, 2002, J IMMUNOL, V169, P4572; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI 10.1016/j.jaci.2004.01.079; BREITENEDER H, 2006, DETECTING ALLERGENS, P37; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409; CHAPMAN MD, 2003, ALLERGENS ALLERGEN I, P51; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Czerwinski EW, 2005, J BIOL CHEM, V280, P3740, DOI 10.1074/jbc.M409655200; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Dunwell JM, 2000, MICROBIOL MOL BIOL R, V64, P153, DOI 10.1128/MMBR.64.1.153-179.2000; Fan Y, 2005, INSECT MOL BIOL, V14, P45, DOI 10.1111/j.1365-2583.2004.00530.x; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Ferreira F, 2004, ADV IMMUNOL, V84, P79, DOI 10.1016/S0065-2776(04)84003-3; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Gadermaier G, 2004, CURR ALLERGY ASTHM R, V4, P391, DOI 10.1007/s11882-004-0090-5; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; Ivanciuc O, 2003, NUCLEIC ACIDS RES, V31, P359, DOI 10.1093/nar/gkg010; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224; KING TP, 1994, B WORLD HEALTH ORGAN, V72, P797; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KREIS M, 1985, J MOL BIOL, V183, P499, DOI 10.1016/0022-2836(85)90017-8; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; MARSH DG, 1986, B WORLD HEALTH ORGAN, V64, P767; Marsh D, 1975, ANTIGENS, V3, P271; Meno K, 2005, J IMMUNOL, V175, P3835; Piboonpocanun S, 2006, CLIN EXP ALLERGY, V36, P510, DOI 10.1111/j.1365-2222.2006.02464.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Schenk MF, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-168; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Smith AM, 2001, J ALLERGY CLIN IMMUN, V107, P977, DOI 10.1067/mai.2001.115629; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Tinghino R, 2002, J ALLERGY CLIN IMMUN, V109, P314, DOI 10.1067/mai.2002.121528; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wopfner N, 2005, INT ARCH ALLERGY IMM, V138, P337, DOI 10.1159/000089188; Wunschmann S, 2005, J ALLERGY CLIN IMMUN, V116, P140, DOI 10.1016/j.jaci.2005.04.024	44	142	150	0	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					414	420		10.1016/j.jaci.2006.11.001		7	Allergy; Immunology	Allergy; Immunology	137YB	WOS:000244327900020	17166572	
J	Jackson, LE				Jackson, LE			The relationship of urban design to human health and condition	LANDSCAPE AND URBAN PLANNING			English	Article						ecological design; public health; social capital	LYME-DISEASE; RISK; ENVIRONMENT; COMMUNITY; PEOPLE; HOME	The population of the United States of America is currently experiencing increased illness from dispersed and synergistic causes. Many of the acute insults of the past have receded due to centralized health care and regulatory action. However, chronic ailments including asthma and allergies, animal-transmitted diseases, obesity, diabetes, heart disease, and depression are on the rise. These diverse illnesses join with forest fragmentation, stream degradation, wetlands destruction, and the concomitant loss of native species to suggest detrimental contributions from the built environment. This paper surveys the state of the science on the impacts of urban design on human health and well-being. Drawing primarily on recent peer-reviewed literature in a broad array of health, planning, and environmental fields, it outlines the influence of design at three spatial scales on aspects of physical and mental health, and social and cultural vibrancy. Selected ecological effects are also discussed to illustrate shared associations with urbanization. While causal chains are generally complex and not always completely understood, sufficient evidence exists to reveal urban design as a powerful tool for improving human condition. Solutions are discussed at the personal and professional level, emphasizing cross-disciplinary collaboration in urban planning and design, and the participation of residents in shaping their living environment. At the parcel scale, greenery and access to it visually and physically are the principal keys to health. These elements must be incorporated into relatively high-density neighborhood designs that include public buildings, open space, mixed land use, and pedestrian walkways to increase physical exercise and enhance civic life. Finally, neighborhoods must be embedded in existing urban infrastructure to provide larger cultural and business opportunities and reduce reliance on the automobile. Further research is recommended to strengthen the associations between design and health. Increased communication on this subject is also necessary between design and health practitioners and their clients and colleagues. (C) 2002 Elsevier Science B.V. All rights reserved.	US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA	Jackson, LE (reprint author), US EPA, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA.		Marra, Giulia/L-8303-2014				ADAMS RE, 1992, J COMMUNITY PSYCHOL, V20, P353, DOI 10.1002/1520-6629(199210)20:4<353::AID-JCOP2290200409>3.0.CO;2-Z; Andersen RE, 1999, JAMA-J AM MED ASSOC, V281, P335, DOI 10.1001/jama.281.4.335; Arnold CL, 1996, J AM PLANN ASSOC, V62, P243, DOI 10.1080/01944369608975688; Balfour JL, 2002, AM J EPIDEMIOL, V155, P507, DOI 10.1093/aje/155.6.507; Berleant A., 1992, AESTHETICS ENV; Berman M.A., 1996, J PLAN LIT, V10, P347, DOI 10.1177/088541229601000401; Booth DB, 1993, P WAT 93 NAT C WAT M, P545; BOWARD DM, 1999, 903R99023 EPA MAR DE; Brown A, 2001, LANDSCAPE ARCHIT, V91, P12; CDC, 1998, MMWR-MORBID MORTAL W, V47, P1097; CDC: Lyme disease. United States, 2001, MMWR-MORBID MORTAL W, V50, P181; Cervero R, 1996, TRANSPORT RES A-POL, V30, P361, DOI 10.1016/0965-8564(95)00033-X; CHEN D, 2001, P PRES BEH SMART GRO; COSTA G, 1988, INT ARCH OCC ENV HEA, V60, P371, DOI 10.1007/BF00405673; Cromley EK, 1998, AM J EPIDEMIOL, V147, P472; DISTER SW, 1993, P GIS 93 7 ANN S GEO, P1149; Evans GW, 2000, J CONSULT CLIN PSYCH, V68, P526, DOI 10.1037/0022-006X.68.3.526; Frumkin P, 2001, AM J PREV MED, V20, P234; GLASS GE, 1995, AM J PUBLIC HEALTH, V85, P944, DOI 10.2105/AJPH.85.7.944; Hill K, 2002, ECOLOGY AND DESIGN: FRAMEWORKS FOR LEARNING, P203; JACKSON RJ, 2001, WHAT OLMSTEAD SIC KN; JACKSON RJ, 2001, CRETING HLTH ENV IMP; Jacobs J., 1961, DEATH LIFE GREAT AM; KAPLAN R, 1973, ENVIRON BEHAV, V5, P145, DOI 10.1177/001391657300500202; Kaplan R., 1998, PEOPLE MIND DESIGN M; Kaplan R., 1989, EXPERIENCE NATURE PS; KREYLING F, 2001, PLANNING        0604; Kunstler James Howard, 1996, HOME NOWHERE REMAKIN; Kuo FE, 1998, AM J COMMUN PSYCHOL, V26, P823, DOI 10.1023/A:1022294028903; LINDHEIM R, 1983, ANNU REV PUBL HEALTH, V4, P335, DOI 10.1146/annurev.pu.04.050183.002003; Lyle J.T., 1994, REGENERATIVE DESIGN; LYMAN F, 2000, MSNBC REPORT    0523; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Nassauer Joan Iverson, 1997, P65; POLAKOVIC G, 2002, LOS ANGELES TIM 0201; Putnam R., 2000, BOWLING ALONE COLLAP; Ritz B, 2002, AM J EPIDEMIOL, V155, P17, DOI 10.1093/aje/155.1.17; Schueler T.R, 1992, WATERSHED RESTORATIO; SCHULTE F, 1994, T 2 INT HIGH TEMP EL, V1, P3; SMITH CJ, 1977, GEOGRAPHY MENTAL HLT; Steingraber S, 2002, ECOLOGY AND DESIGN: FRAMEWORKS FOR LEARNING, P192; *STPP, 1999, AGGR DRIV AR YOU RIS; STRADLING R, 2002, NEWS OBSERVER   0116; Sullivan W. C., 1996, URBAN COMMUNITY FORE, V4; Ulrich R. S., 1979, Landscape Research, V4, P17; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402; Ulrich R. S., 1983, HUMAN BEHAVIOR ENV A, V6, P85, DOI DOI 10.1007/978-1-4613-3539-9_; *USDA SOIL CONS SE, 1979, URB HYDR SMALL WAT U; Wells NM, 2000, ENVIRON BEHAV, V32, P775, DOI 10.1177/00139160021972793; 2000, MAKING BIODIVERSITY	50	142	148	21	158	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-2046			LANDSCAPE URBAN PLAN	Landsc. Urban Plan.	AUG 15	2003	64	4					191	200	PII S0169-2046(02)00230-X	10.1016/S0169-2046(02)00230-X		10	Ecology; Environmental Studies; Geography; Geography, Physical; Urban Studies	Environmental Sciences & Ecology; Geography; Physical Geography; Urban Studies	700LN	WOS:000184113600001		
J	McKeever, TM; Lewis, SA; Smith, C; Hubbard, R				McKeever, TM; Lewis, SA; Smith, C; Hubbard, R			The importance of prenatal exposures on the development of allergic disease - A birth cohort study using the West Midlands General Practice Database	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; epidemiology; hay fever; eczema; perinatal exposures	CORD BLOOD; HAY-FEVER; ATOPIC DISORDERS; ASTHMATIC WOMEN; EARLY-CHILDHOOD; FAMILY-SIZE; NEW-ZEALAND; IN-UTERO; RISK; INFECTIONS	The etiology of allergic disease is not understood, but a decreased exposure to infection may play an important role. There are few published data on the impact of change in microbial exposure during pregnancy on the child's risk of developing allergic disease. Using a birth cohort of 24,690 children, derived from the West Midlands General Practice Research Database, we investigated a number of perinatal exposures on the incidence of asthma, eczema, and hay fever. Our findings suggest that exposure to antibiotics in utero is associated with an increased risk of asthma in a dose-related manner (more than two courses of antibiotics compared wit ne adjusted hazard ratio [HR] 1.68; 95% confidence interval [CI], 1.51-1.87), and similar associations are present for eczema (adjust HR 1.17; 95% CI, 1.06-1.29) and hay fever (adjusted HR 1.56; 95% CI, 1.22-2.01). Exposure to a range of infections in utero was also associated with a small increased risk of developing allergic disease. Strong protective effects of older siblings on the incidence of allergy are present within this cohort, but previous pregnancies that did not result in a live birth were not protective. Our findings suggest that exposure to antibiotics and to infections in utero is a potentially important risk factor in the development of allergic disease.	Univ Nottingham, Div Resp Med, Nottingham NG7 2RD, England	McKeever, TM (reprint author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.		Research Datalink, Clinical Practice/H-2477-2013; CPRD, CPRD/B-9594-2017	McKeever, Tricia/0000-0003-0914-0416			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BELL IR, 1991, PSYCHOTHER PSYCHOSOM, V55, P24; Bodner C, 1998, THORAX, V53, P28; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Gustafsson P A, 1997, Pediatr Pulmonol Suppl, V16, P262; *JOINT FORM COMM, 2001, BRIT NAT FORM; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Liu SL, 2001, AM J OBSTET GYNECOL, V184, P90, DOI 10.1067/mob.2001.108073; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; MCKEEVER TM, 2001, THORAX, V56, P458; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; NASR S, 1981, J AFFECT DISORDERS, V3, P291, DOI 10.1016/0165-0327(81)90030-6; OSSOFSKY HJ, 1976, COMPR PSYCHIAT, V17, P335, DOI 10.1016/0010-440X(76)90008-0; Pekkanen J, 1999, ACTA PAEDIATR, V88, P710; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Strachan DP, 2000, THORAX S1, V55, pS2; SUGERMAN AA, 1982, ANN ALLERGY, V48, P166; Sunyer J, 2001, CLIN EXP ALLERGY, V31, P1352, DOI 10.1046/j.1365-2222.2001.01187.x; Timonen M, 2001, AM J MED GENET, V105, P216, DOI 10.1002/ajmg.1199; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wamboldt MZ, 1996, J AM ACAD CHILD PSY, V35, P1042, DOI 10.1097/00004583-199608000-00015; Wamboldt MZ, 2000, AM J MED GENET, V96, P146, DOI 10.1002/(SICI)1096-8628(20000403)96:2<146::AID-AJMG4>3.0.CO;2-J; Wen SW, 2001, ANN EPIDEMIOL, V11, P7, DOI 10.1016/S1047-2797(00)00077-6; Wickens K, 1999, J ALLERGY CLIN IMMUN, V104, P554, DOI 10.1016/S0091-6749(99)70323-4; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; Wright RJ, 1999, AM J RESP CRIT CARE, V159, pA103; Xu B, 1999, ALLERGY, V54, P829, DOI 10.1034/j.1398-9995.1999.00117.x; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723	37	142	145	6	12	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 15	2002	166	6					827	832		10.1164/rccm.200202-158OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	594AU	WOS:000178027300011	12231492	
J	Pedotti, R; Mitchell, D; Wedemeyer, J; Karpuj, M; Chabas, D; Hattab, EM; Tsai, M; Galli, SJ; Steinman, L				Pedotti, R; Mitchell, D; Wedemeyer, J; Karpuj, M; Chabas, D; Hattab, EM; Tsai, M; Galli, SJ; Steinman, L			An unexpected version of horror autotoxicus: anaphylactic shock to a self peptide	NATURE IMMUNOLOGY			English	Article							MYELIN BASIC-PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; MAST-CELL DEGRANULATION; CENTRAL-NERVOUS-SYSTEM; TUMOR-NECROSIS-FACTOR; FC-GAMMA-RIII; MULTIPLE-SCLEROSIS; T-CELLS; PROTEOLIPID PROTEIN	EAE can refer either to experimental autoimmune encephalomyelitis or experimental allergic encephalomyelitis. Although EAE is classically a prototypicT helper I (THI) cell-mediated autoimmune disease, it can also be induced by T(H)2 cells. Characteristically, the most severe manifestation of allergy, anaphylaxis, is associated with exposure to a foreign antigen that is often derived from medication, insect venom or food. We report here that, after self-tolerance to myelin is destroyed, anaphylaxis may be triggered by a self-antigen, in this case a myelin peptide. "Horror autotoxicus", which was initially described by Ehrlich, may not only include autoimmunity to self, it may also encompass immediate hypersensitivity to self, which leads to shock and rapid death.	Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA; Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA; Univ Milan, IRCCS Osped Maggiore Policlin, Inst Clin Neurol, Milan, Italy	Steinman, L (reprint author), Stanford Univ, Med Ctr, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.		Messier, Claude/A-2322-2008; Hattab, Eyas/E-9342-2016	Messier, Claude/0000-0002-4791-1763; Hattab, Eyas/0000-0002-3660-6261			Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Anderson AC, 2000, J EXP MED, V191, P761, DOI 10.1084/jem.191.5.761; Bebo BF, 1996, IMMUNOL CELL BIOL, V74, P225, DOI 10.1038/icb.1996.41; Begolka WS, 1998, J IMMUNOL, V161, P4437; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785; BOVE JR, 1988, TRANSFUSION, V28, P603, DOI 10.1046/j.1537-2995.1988.28689059042.x; BRENNER T, 1994, J NEUROL SCI, V122, P210, DOI 10.1016/0022-510X(94)90300-X; BROSNAN CF, 1988, J NEUROIMMUNOL, V18, P87, DOI 10.1016/0165-5728(88)90137-3; DAVIS HM, 1990, THROMB HAEMOSTASIS, V63, P386; DIETSCH GN, 1989, J IMMUNOL, V142, P1476; Dines KC, 1997, J NEUROPATH EXP NEUR, V56, P627; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Encinas JA, 1996, J NEUROSCI RES, V45, P655; Faquim-Mauro EL, 1999, J IMMUNOL, V163, P3572; Galli S, 1999, FUNDAMENTAL IMMUNOLO, P1137; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; HURTENBACH U, 1993, J EXP MED, V177, P1499, DOI 10.1084/jem.177.5.1499; ISHIZAKA T, 1984, PROG ALLERGY, V34, P188; Jensen MA, 1999, J AUTOIMMUN, V12, P73, DOI 10.1006/jaut.1998.0263; JOHNSON D, 1988, BRAIN RES, V444, P195, DOI 10.1016/0006-8993(88)90929-8; Kappos L, 2000, NAT MED, V6, P1176; Kim R, 1993, Del Med J, V65, P17; Klein L, 2000, NAT MED, V6, P56; KRUGER PG, 1990, ACTA NEUROL SCAND, V81, P31; KUCHROO VK, 1994, J IMMUNOL, V153, P3326; Lafaille JJ, 1997, J EXP MED, V186, P307, DOI 10.1084/jem.186.2.307; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; LINTHICUM DS, 1982, J EXP MED, V156, P31, DOI 10.1084/jem.156.1.31; LINTHICUM DS, 1982, CELL IMMUNOL, V73, P299, DOI 10.1016/0008-8749(82)90457-9; LINTHICUM DS, 1982, IMMUNOBIOLOGY, V162, P211; LIU GY, 1995, IMMUNITY, V3, P407, DOI 10.1016/1074-7613(95)90170-1; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOTA I, 1969, LIFE SCI PT 1 PHYSI, V8, P813, DOI 10.1016/0024-3205(69)90099-X; OLSSON Y, 1974, ACTA NEUROL SCAND, V50, P611; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; PRIBYL TM, 1993, P NATL ACAD SCI USA, V90, P10695, DOI 10.1073/pnas.90.22.10695; Radu CG, 2000, INT IMMUNOL, V12, P1553, DOI 10.1093/intimm/12.11.1553; Ruiz PJ, 1999, J IMMUNOL, V162, P3336; SCHERNTHANER G, 1993, DIABETES CARE, V16, P155; Schwartz M, 2000, IMMUNOL TODAY, V21, P265, DOI 10.1016/S0167-5699(00)01633-9; Secor VH, 2000, J EXP MED, V191, P813, DOI 10.1084/jem.191.5.813; Shopnick RI, 1996, TRANSFUSION, V36, P358, DOI 10.1046/j.1537-2995.1996.36496226153.x; SOLOWAY P, 1991, J EXP MED, V174, P847, DOI 10.1084/jem.174.4.847; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Steinman L, 2000, NAT MED, V6, P15, DOI 10.1038/71466; STEINMAN L, 1982, NATURE, V299, P738, DOI 10.1038/299738a0; TOMS R, 1990, J NEUROIMMUNOL, V30, P169, DOI 10.1016/0165-5728(90)90101-R; TUOHY VK, 1989, J IMMUNOL, V142, P1523; VANDENBARK AA, 1985, J IMMUNOL, V135, P229; Waisman A, 1996, NAT MED, V2, P899, DOI 10.1038/nm0896-899; WERSHIL BK, 1988, J IMMUNOL, V140, P2356; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; ZAMVIL S, 1985, NATURE, V317, P355, DOI 10.1038/317355a0; ZAMVIL SS, 1986, NATURE, V324, P258, DOI 10.1038/324258a0; ZELENIKA D, 1993, J NEUROCHEM, V60, P1574, DOI 10.1111/j.1471-4159.1993.tb03325.x	55	142	143	2	5	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	MAR	2001	2	3					216	222		10.1038/85266		7	Immunology	Immunology	409YT	WOS:000167413800013	11224520	
J	Bitton, A; Martin, C; Landon, BE				Bitton, Asaf; Martin, Carina; Landon, Bruce E.			A Nationwide Survey of Patient Centered Medical Home Demonstration Projects	JOURNAL OF GENERAL INTERNAL MEDICINE			English	Article						primary care; physician payment; health reform	CHRONIC CARE MODEL; COMMUNITY-HEALTH CENTERS; QUALITY IMPROVEMENT; INTERNAL-MEDICINE; OUTCOMES; DISEASE; ASTHMA	The patient centered medical home has received considerable attention as a potential way to improve primary care quality and limit cost growth. Little information exists that systematically compares PCMH pilot projects across the country. Cross-sectional key-informant interviews. Leaders from existing PCMH demonstration projects with external payment reform. We used a semi-structured interview tool with the following domains: project history, organization and participants, practice requirements and selection process, medical home recognition, payment structure, practice transformation, and evaluation design. A total of 26 demonstrations in 18 states were interviewed. Current demonstrations include over 14,000 physicians caring for nearly 5 million patients. A majority of demonstrations are single payer, and most utilize a three component payment model (traditional fee for service, per person per month fixed payments, and bonus performance payments). The median incremental revenue per physician per year was $22,834 (range $720 to $91,146). Two major practice transformation models were identified-consultative and implementation of the chronic care model. A majority of demonstrations did not have well-developed evaluation plans. Current PCMH demonstration projects with external payment reform include large numbers of patients and physicians as well as a wide spectrum of implementation models. Key questions exist around the adequacy of current payment mechanisms and evaluation plans as public and policy interest in the PCMH model grows.	[Bitton, Asaf; Martin, Carina; Landon, Bruce E.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; [Bitton, Asaf] Brigham & Womens Hosp, Div Gen Med, Boston, MA 02115 USA; [Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA	Landon, BE (reprint author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	landon@hcp.med.harvard.edu			Agency for Health Care Research and Quality; Commonwealth Fund; The American Board of Internal Medicine Foundation; Health Resources and Services Administration of the Department of Health and Human Services [T32HP10251]	The authors would like to thank all of the survey respondents for their willingness to participate in the study. This study was funded in part by grants from the Agency for Health Care Research and Quality, the Commonwealth Fund, and The American Board of Internal Medicine Foundation. Dr. Bitton is supported by grant number T32HP10251 from the Health Resources and Services Administration of the Department of Health and Human Services to support the Harvard Medical School Fellowship in General Medicine and Primary Care. The study contents are solely the responsibility of the authors and do not necessarily represent the official views of the Department of Health and Human Services.	American Academy of Family Physicians (AAFP) American Academy of Pediatrics American College of Physicians & Medical American Osteopathic Association, 2007, JOINT PRINC PAT CTR; *ACP, 2009, PAT CTR MED HOM; Berenson RA, 2008, HEALTH AFFAIR, V27, P1219, DOI 10.1377/hlthaff.27.5.1219; Bodenheimer T, 2009, NEW ENGL J MED, V360, P2693, DOI 10.1056/NEJMp0902909; Chin MH, 2007, MED CARE, V45, P1135; Coleman K, 2009, HEALTH AFFAIR, V28, P75, DOI 10.1377/hlthaff.28.1.75; Fisher ES, 2008, NEW ENGL J MED, V359, P1202, DOI 10.1056/NEJMp0806233; Ginsburg JA, 2008, ANN INTERN MED, V148, P55; Hauer KE, 2008, JAMA-J AM MED ASSOC, V300, P1154, DOI 10.1001/jama.300.10.1154; Homer CJ, 2005, ARCH PEDIAT ADOL MED, V159, P464, DOI 10.1001/archpedi.159.5.464; Hroscikoski MC, 2006, ANN FAM MED, V4, P317, DOI 10.1370/afm.570; Kuzel AJ, 2009, ANN FAM MED, V7, P85, DOI 10.1370/afm.956; Landon BE, 2007, NEW ENGL J MED, V356, P921, DOI 10.1056/NEJMsa062860; Lipner RS, 2006, ANN INTERN MED, V144, P29; Mangione-Smith R, 2005, AMBUL PEDIATR, V5, P75, DOI 10.1367/A04-106R.1; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; Nutting PA, 2009, ANN FAM MED, V7, P254, DOI 10.1370/afm.1002; Paulus RA, 2008, HEALTH AFFAIR, V27, P1235, DOI 10.1377/hlthaff.27.5.1235; *PCPCC, 2009, PAT CTR MED HOM BUIL; REID R, 2009, AM J MANAG CARE, V9, pE71; Rittenhouse DR, 2009, JAMA-J AM MED ASSOC, V301, P2038, DOI 10.1001/jama.2009.691; Rosenthal TC, 2008, J AM BOARD FAM MED, V21, P427, DOI 10.3122/jabfm.2008.05.070287; Solberg LI, 2006, ANN FAM MED, V4, P109, DOI 10.1370/afm.424; Steiner BD, 2008, ANN FAM MED, V6, P361, DOI 10.1370/afm.866; Vargas RB, 2007, J GEN INTERN MED, V22, P215, DOI 10.1007/s11606-006-0072-5	25	141	141	1	22	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0884-8734			J GEN INTERN MED	J. Gen. Intern. Med.	JUN	2010	25	6					584	592		10.1007/s11606-010-1262-8		9	Health Care Sciences & Services; Medicine, General & Internal	Health Care Sciences & Services; General & Internal Medicine	596UY	WOS:000277712200020	20467907	
J	Rothenberg, ME				Rothenberg, Marc E.			Biology and Treatment of Eosinophilic Esophagitis	GASTROENTEROLOGY			English	Review							GASTROESOPHAGEAL-REFLUX DISEASE; ANTI-IL-5 MEPOLIZUMAB THERAPY; MAJOR BASIC-PROTEIN; CELIAC-DISEASE; FOOD ALLERGY; SKIN PRICK; CLINICAL-FEATURES; CATIONIC PROTEIN; PATCH TESTS; T-CELLS	Eosinophilic esophagitis is a recently recognized but expanding disorder characterized by antigen-driven eosinophil accumulation in the esophagus. Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are distinct in their histopathology, gene expression signature, response to therapy, hereditary risk, and association with allergies. The pathogenesis of eosinophilic esophagitis involves environmental and genetic factors, particularly food antigens and expression level of the eosinophil chemoattractant eotaxin-3, respectively. Analyses of gene expression signatures and animal models have indicated the importance of adaptive T-cell immunity that involves interleukin-5 and interleukin-13-induced esophageal epithelial cell responses. Symptoms, dysregulation of esophageal gene expression, and pathology are largely reversible following reduced exposure to specific food antigens as well as anti-inflammatory therapy, but chronic treatment is necessary to prevent relapse. Therefore, eosinophilic esophagitis is a disease with unique features that include chronic esophagitis, atopy, immune sensitization to oral antigens, reversibility, and familial association.	Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp, Dept Pediat,Med Ctr,Coll Med, Cincinnati, OH 45229 USA	Rothenberg, ME (reprint author), Univ Cincinnati, Div Allergy & Immunol, Cincinnati Childrens Hosp, Dept Pediat,Med Ctr,Coll Med, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org			NIAID NIH HHS [U19 AI070235, R01 AI045898, R01 AI05780, R01 AI057803, R01 AI080581, R01 AI45898]; NIDDK NIH HHS [P30 DK078392, R01 DK067255, R01 DK076893]		Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Aceves SS, 2005, J ALLERGY CLIN IMMUN, V116, P705, DOI 10.1016/j.jaci.2005.05.011; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Almansa C, 2009, AM J GASTROENTEROL, V104, P828, DOI 10.1038/ajg.2008.169; Assa'ad A, 2005, ANN ALLERG ASTHMA IM, V95, P309; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Attwood SEA, 2003, GUT, V52, P181, DOI 10.1136/gut.52.2.181; Balatsinou C, 2008, DIGEST LIVER DIS, V40, P145, DOI 10.1016/j.dld.2007.01.017; BASSETT J, 2009, DIS ESOPHAGUS, V6, P543; Bhattacharya B, 2007, HUM PATHOL, V38, P1744, DOI 10.1016/j.humpath.2007.05.008; Bischoff S, 2005, GASTROENTEROLOGY, V128, P1089, DOI 10.1053/j.gastro.2004.08.015; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; Blanchard C, 2005, CLIN EXP ALLERGY, V35, P1096, DOI 10.1111/j.1365-2222.2005.02299.x; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Blanchard C, 2007, J ALLERGY CLIN IMMUN, V120, P204; Blanchard C, 2006, J ALLERGY CLIN IMMUN, V118, P1054, DOI 10.1016/j.jaci.2006.07.038; Bousvaros A, 2008, DIGEST LIVER DIS, V40, P32, DOI 10.1016/j.dld.2007.07.168; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Caillat-Zucman S, 2006, HUM IMMUNOL, V67, P204, DOI 10.1016/j.humimm.2006.02.013; Cantu P, 2005, DIGEST LIVER DIS, V37, P129, DOI 10.1016/j.dld.2004.04.008; Catassi C, 2008, CURR OPIN GASTROEN, V24, P687, DOI 10.1097/MOG.0b013e32830edc1e; Cherian S, 2006, ARCH DIS CHILD, V91, P1000, DOI 10.1136/adc.2006.100974; Collins MH, 2008, CLIN GASTROENTEROL H, V6, P621, DOI 10.1016/j.cgh.2008.01.004; Collins Margaret H, 2008, Gastrointest Endosc Clin N Am, V18, P59, DOI 10.1016/j.giec.2007.09.014; Croese J, 2003, GASTROINTEST ENDOSC, V58, P516, DOI 10.1067/S0016-5107(03)01870-4; Cury EK, 2004, J PEDIATR SURG, V39, DOI 10.1016/j.jpedsurg.2003.10.028; Dahshan A, 2000, J CLIN GASTROENTEROL, V31, P213, DOI 10.1097/00004836-200010000-00005; Desai TK, 2005, GASTROINTEST ENDOSC, V61, P795, DOI 10.1016/S0016-5107(05)00313-5; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fox VL, 2002, GASTROINTEST ENDOSC, V56, P260, DOI 10.1067/mge.2002.126390; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Fujiwara H, 2002, ANN ALLERG ASTHMA IM, V89, P429; Furuta GT, 2007, GASTROENTEROLOGY, V133, P1342, DOI 10.1053/j.gastro.2007.08.017; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gharaee-Kermani M, 1998, INT J MOL MED, V1, P43; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Heine RG, 2008, J GASTROEN HEPATOL, V23, P993, DOI 10.1111/j.1440-1746.2008.05514.x; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Hue S, 2004, IMMUNITY, V21, P367, DOI 10.1016/j.immuni.2004.06.018; Hunt KA, 2008, NAT GENET, V40, P395, DOI 10.1038/ng.102; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Justinich CJ, 1997, J PEDIATR GASTR NUTR, V25, P194, DOI 10.1097/00005176-199708000-00011; Kagalwalla AF, 2007, J PEDIATR GASTR NUTR, V44, P386, DOI 10.1097/01.mpg.0000243430.32087.5c; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kapel RC, 2008, GASTROENTEROLOGY, V134, P1316, DOI 10.1053/j.gastro.2008.02.016; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Koning F, 2005, SPRINGER SEMIN IMMUN, V27, P217, DOI 10.1007/s00281-005-0203-9; Korsapati H, 2009, GUT, V58, P1056, DOI 10.1136/gut.2008.168146; Lack G, 2008, NEW ENGL J MED, V359, P1252, DOI 10.1056/NEJMcp0800871; Lee GSC, 2007, DYSPHAGIA, V22, P55, DOI 10.1007/s00455-006-9043-6; Lewis CJ, 2009, DIS ESOPHAGUS, V22, P249, DOI 10.1111/j.1442-2050.2008.00896.x; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Lucendo AJ, 2007, EUR J GASTROEN HEPAT, V19, P417, DOI 10.1097/MEG.0b013e328010bd69; Lucendo AJ, 2007, AM J SURG PATHOL, V31, P598, DOI 10.1097/01.pas.0000213392.49698.8c; Mackenzie SH, 2008, ALIMENT PHARM THER, V28, P1140, DOI 10.1111/j.1365-2036.2008.03795.x; Malerba G, 2000, AM J RESP CRIT CARE, V162, P1587; Markowitz JE, 2003, GASTROENTEROL CLIN N, V32, P949, DOI 10.1016/S0889-8553(03)00047-5; Milner JD, 2007, P NATL ACAD SCI USA, V104, P576, DOI 10.1073/pnas.0610289104; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1053/S0016-5085(03)01352-0; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Mishra A, 2008, GASTROENTEROLOGY, V134, P204, DOI 10.1053/j.gastro.2007.10.002; Mishra A, 2007, J LEUKOCYTE BIOL, V81, P916, DOI 10.1189/jlb.1106653; Molina-Infante J, 2009, J CHIN MED ASSOC, V72, P166, DOI 10.1016/S1726-4901(09)70046-2; Mueller S, 2006, J CLIN PATHOL, V59, P1175, DOI 10.1136/jcp.2005.031922; Mulder DJ, 2009, GUT, V58, P166, DOI 10.1136/gut.2008.157628; Munitiz V, 2003, DIS ESOPHAGUS, V16, P165, DOI 10.1046/j.1442-2050.2003.00319.x; Netzer P, 2007, EUR J GASTROEN HEPAT, V19, P865; Nizet V, 2008, NAT MED, V14, P910, DOI 10.1038/nm0908-910; Noble A, 2007, J PEDIATR GASTR NUTR, V44, P498, DOI 10.1097/MPG.0b013e31802c41cd; NOBLE C, 2008, PEDIAT TRANSPLA 1101; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1053/S1542-3565(04)00240-X; Noel RJ, 2005, CURR OPIN PEDIATR, V17, P690, DOI 10.1097/01.mop.0000184291.34654.be; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Nurko Samuel, 2008, Gastrointest Endosc Clin N Am, V18, P73, DOI 10.1016/j.giec.2007.09.006; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ober C, 2005, J ALLERGY CLIN IMMUN, V116, P274, DOI 10.1016/j.jaci.2005.04.039; Onbasi K, 2005, CLIN EXP ALLERGY, V35, P1423, DOI 10.1111/j.1365-2222.2005.02351.x; Ooi CY, 2008, J GASTROEN HEPATOL, V23, P1144, DOI 10.1111/j.1440-1746.2007.05239.x; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Parfitt JR, 2006, MODERN PATHOL, V19, P90, DOI 10.1038/modpathol.3800498; Patel SM, 2005, GASTROINTEST ENDOSC, V61, P165, DOI 10.1016/S0016-5107(04)02459-9; PENROSE L, 1953, ACTA GENET STAT MED, P257; Phipps S, 2002, J IMMUNOL, V169, P4604; Protheroe C, 2009, CLIN GASTROENTEROL H, V7, P749, DOI 10.1016/j.cgh.2009.03.022; Quaglietta L, 2007, ALIMENT PHARM THERAP, V26, P487, DOI 10.1111/j.1365-2036.2007.03388.x; Ronkainen J, 2006, GASTROENTEROLOGY, V130, pA575; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876; Rothenberg MA, 2001, J ALLERGY CLIN IMMUN, V108, P891, DOI 10.1067/mai.2001.120095; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Roy-Ghanta S, 2008, CLIN GASTROENTEROL H, V6, P531, DOI 10.1016/j.cgh.2007.12.045; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Schaefer ET, 2008, CLIN GASTROENTEROL H, V6, P165, DOI 10.1016/j.cgh.2007.11.008; Shah AA, 2009, AM J GASTROENTEROL, V104, P716, DOI 10.1038/ajg.2008.117; Shitrit ABG, 2006, ISRAEL MED ASSOC J, V8, P587; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 2007, CURR OPIN ALLERGY CL, V7, P274, DOI 10.1097/ACI.0b013e32813aee4a; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Spergel JM, 2009, J PEDIATR GASTR NUTR, V48, P30, DOI 10.1097/MPG.0b013e3181788282; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stein ML, 2008, J ALLERGY CLIN IMMUN, V121, P1473, DOI 10.1016/j.jaci.2008.02.033; Steiner SJ, 2006, J PEDIATR GASTR NUTR, V42, P506, DOI 10.1097/01.mpg.0000221906.06899.1b; Stepniak D, 2006, HUM IMMUNOL, V67, P460, DOI 10.1016/j.humimm.2006.03.011; Stone KD, 2008, CLIN EXP ALLERGY, V38, P1858, DOI 10.1111/j.1365-2222.2008.03122.x; Straumann A, 2008, J ALLERGY CLIN IMMUN, V121, pS44, DOI 10.1016/j.jaci.2007.12.179; Straumann A, 2004, DIGESTION, V70, P109, DOI 10.1159/000080934; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Straumann A, 2008, J ALLERGY CLIN IMMUN, V122, P425, DOI 10.1016/j.jaci.2008.06.012; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; van Heel DA, 2006, GUT, V55, P444, DOI 10.1136/gut.2005.079335; van Heel DA, 2007, NAT GENET, V39, P827, DOI 10.1038/ng2058; Veerappan GR, 2009, CLIN GASTROENTEROL H, V7, P420, DOI 10.1016/j.cgh.2008.10.009; Verzegnassi F, 2007, GUT, V56, P1029, DOI 10.1136/gut.2006.117986; VICARIO M, 2009, GUT             0614; Villarin AJL, 2005, REV ESP ENFERM DIG, V97, P229; Walsh ER, 2008, J EXP MED, V205, P1285, DOI 10.1084/jem.20071836; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; WHITNEYMILLER CL, 2004, AM J CLIN PATHOL, V131, P788; Yamazaki K, 2006, DIGEST DIS SCI, V51, P1934, DOI 10.1007/s10620-005-9048-2; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0; Yousefi S, 2008, NAT MED, V14, P949, DOI 10.1038/nm.1855; Zink DA, 2007, GASTROINTEST ENDOSC, V65, P330, DOI 10.1016/j.gie.2006.07.021	134	141	147	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085			GASTROENTEROLOGY	Gastroenterology	OCT	2009	137	4					1238	1249		10.1053/j.gastro.2009.07.007		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	499VT	WOS:000270255200017	19596009	
J	Zanation, AM; Carrau, RL; Snyderman, CH; Germanwala, AV; Gardner, PA; Prevedello, DM; Kassam, AB				Zanation, Adam M.; Carrau, Ricardo L.; Snyderman, Carl H.; Germanwala, Anand V.; Gardner, Paul A.; Prevedello, Daniel M.; Kassam, Amin B.			Nasoseptal flap reconstruction of high flow intraoperative cerebral spinal fluid leaks during endoscopic skull base surgery	AMERICAN JOURNAL OF RHINOLOGY & ALLERGY			English	Article						CSF leak; endoscopic; meningioma; nasoseptal flap; prognosis; reconstruction; sinonasal tumor; skull base; vascularized flap		Background: Over the past 10 years, significant anatomic, technical, and instrumentation advances have facilitated the exposure and resection of intradural lesions via a fully endoscopic expanded endonasal approach (EEA). The vascularized nasoseptal flap (based on the posterior nasoseptal artery) has become our primary endoscopic reconstructive technique. The goals of this study are to prospectively evaluate the nasoseptal flap and high-risk cerebral spinal fluid (CSF) leak variables. Methods: Prospective evaluation was performed of EEA patients with intraoperative high-flow leaks (either a cistern or ventricle open to nasal cavity during tumor dissection) who underwent nasoseptal flap reconstruction. Results: Seventy consecutive nasoseptal flaps for high-flow intraoperative leaks were evaluated prospectively by the primary author. Twelve risk factors were then graded at the time of the operations and correlated to CSF leak outcomes. The overall postoperative CSF leak rate was 5.7% (4/70). All four postoperative leaks were successfully managed with endoscopic repair and CSF diversion. A multivariate analysis of all 12 risk factors is detailed. Pediatric patients, large dural defects, and radiation therapy were noted to be factors in reconstructive failure. One flap death occurred in a patient with prior surgery and proton therapy, this leak was managed with a temporoparietal flap and endonasal repair. Conclusion: The nasoseptal flap is an excellent anterior skull base reconstructive technique. Patients with high-flow intraoperative CSF leaks had a 94% successful reconstruction rate. Patients with skull base proton radiation therapy are at higher risk for flap failure and preparation for nonradiated tissue reconstruction should be discussed with the patient. (Am J Rhinol Allergy 23, 518-521, 2009; doi: 10.2500/ajra.2009.23.3378)	[Zanation, Adam M.] Univ N Carolina, Dept Otolaryngol Head & Neck Surg, Chapel Hill, NC 27599 USA; [Germanwala, Anand V.] Univ N Carolina, Dept Neurol Surg, Chapel Hill, NC 27599 USA; [Carrau, Ricardo L.; Snyderman, Carl H.] Univ Pittsburgh, Med Ctr, Dept Otolaryngol Head & Neck Surg, Pittsburgh, PA USA; [Carrau, Ricardo L.; Snyderman, Carl H.; Gardner, Paul A.; Prevedello, Daniel M.; Kassam, Amin B.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Pittsburgh, PA USA	Zanation, AM (reprint author), Univ N Carolina, Dept Otolaryngol Head & Neck Surg, CB 7070,Phys Off Bldg,Manning Dr, Chapel Hill, NC 27599 USA.	azanatio@med.unc.edu					Fortes FSG, 2007, LARYNGOSCOPE, V117, P1329, DOI 10.1097/mlg.0b013e318062111f; Fortes FSG, 2007, LARYNGOSCOPE, V117, P970, DOI 10.1097/MLG.0b013e3180471482; Hadad G, 2006, LARYNGOSCOPE, V116, P1882, DOI 10.1097/01.mlg.0000234933.37779.c4; Harvey RJ, 2008, AM J RHINOL, V22, P516, DOI 10.2500/ajr.2008.22.3223; Kassam Amin, 2005, Neurosurg Focus, V19, pE4; Kassam Amin, 2005, Neurosurg Focus, V19, pE3; Kassam AB, 2008, NEUROSURGERY, V63, P44, DOI 10.1227/01.NEU.0000297074.13423.F5; Nicolai P, 2008, AM J RHINOL, V22, P308, DOI 10.2500/ajr.2008.22.3170; Pinheiro-Neto CD, 2007, LARYNGOSCOPE, V117, P1560, DOI 10.1097/MLG.0b013e31806db514; Shah RN, 2009, LARYNGOSCOPE, V119, P1067, DOI 10.1002/lary.20216; Zanation AM, 2009, LARYNGOSCOPE, V119, P13, DOI 10.1002/lary.20022	11	141	149	0	3	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1945-8924			AMJ RHINOL ALLERGY	Am. J. Rhinol. Allergy	SEP-OCT	2009	23	5					518	521		10.2500/ajra.2009.23.3378		4	Otorhinolaryngology	Otorhinolaryngology	503KS	WOS:000270533800013	19807986	
J	Simons, FER; Frew, AJ; Ansotegui, IJ; Bochner, BS; Golden, DBK; Finkelman, FD; Leung, DYM; Lotvall, J; Marone, G; Metcalfe, DD; Muller, U; Rosenwasser, LJ; Sampson, HA; Schwartz, LB; van Hage, M; Walls, AF				Simons, F. Estelle R.; Frew, Anthony J.; Ansotegui, Ignacio J.; Bochner, Bruce S.; Golden, David B. K.; Finkelman, Fred D.; Leung, Donald Y. M.; Lotvall, Jan; Marone, Gianni; Metcalfe, Dean D.; Mueller, Ulrich; Rosenwasser, Lanny J.; Sampson, Hugh A.; Schwartz, Lawrence B.; van Hage, Marianne; Walls, Andrew F.			Risk assessment in anaphylaxis: Current and future approaches	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						anaphylaxis; mast cell; basophil; IgE; Fc epsilon RI; histamine; tryptase; most cell carboxypeptidase; allergens; insect venom allergy; food allergy	HYMENOPTERA VENOM ALLERGY; INSECT-STING CHALLENGE; HUMAN MAST-CELLS; FC-EPSILON-RI; BASOPHIL ACTIVATION TEST; PEANUT ALLERGY; FOOD ALLERGY; IN-VITRO; SKIN PRICK; FATAL REACTIONS	Risk assessment of individuals with anaphylaxis is currently hampered by lack of (1) an optimal and readily available laboratory test to confirm the clinical diagnosis of an anaphylaxis episode and (2) an optimal method of distinguishing allergen-sensitized individuals who are clinically tolerant from those at risk for anaphylaxis episodes after exposure to the relevant allergen. Our objectives were to review the effector mechanisms involved in the pathophysiology of anaphylaxis; to explore the possibility of developing an optimal laboratory test to confirm the diagnosis of an anaphylaxis episode, and the possibility of improving methods to distinguish allergen sensitization from clinical reactivity; and to develop a research agenda for risk assessment in anaphylaxis. Researchers from the American Academy of Allergy, Asthma & Immunology and the European Academy of Allergology and Clinical Immunology held a PRACTALL (Practical Allergy) meeting to discuss these objectives. New approaches being investigated to support the clinical diagnosis of anaphylaxis include serial measurements of total tryptase in serum during an anaphylaxis episode, and measurement of baseline total tryptase levels after the episode. Greater availability of the test for mature beta-tryptase, a more specific mast cell activation marker for anaphylaxis than total tryptase, is needed. Measurement of chymase, mast cell carboxypeptidase A3, platelet-activating factor, and other mast cell products may prove to be useful. Consideration should be given to measuring a panel of mediators from mast cells and basophils. New approaches being investigated to help distinguish sensitized individuals at minimum or no risk from those at increased risk of developing anaphylaxis include measurement of the ratio of allergen-specific IgE to total IgE, determination of IgE directed at specific allergenic epitopes, measurement of basophil activation markers by using flow cytometry, and assessment of allergen-specific cytokine responses. Algorithms have been developed for risk assessment of individuals with anaphylaxis, along with a research agenda for studies that could lead to an improved ability to confirm the clinical diagnosis of anaphylaxis and to identify allergen-sensitized individuals who are at increased risk of anaphylaxis.	Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Winnipeg, MB R3T 2N2, Canada; Brighton Gen Hosp, Dept Resp Med, Brighton, E Sussex, England; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Royal Hosp, Belfast, Antrim, North Ireland; Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45221 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Dept Resp Med & Allergol, Gothenburg, Sweden; Univ Naples Federico 2, Div Clin Immunol & Allergy, Naples, Italy; NIAID, Lab Allerg Dis, NIH, Bethesda, MD 20892 USA; Univ Bern, Inselspital, Med Klin, CH-3010 Bern, Switzerland; Childrens Mercy Hosp & Clin, Dept Pediat, Kansas City, MO 64108 USA; Mt Sinai Sch Med, Dept Pediat & Biomed Sci, New York, NY 10029 USA; Virginia Commonwealth Univ, Div Rheumatol Allergy & Immunol, Richmond, VA 23284 USA; Karolinska Inst & Univ Hosp, Dept Med Clin Immunol & Allergy, Stockholm, Sweden; Southampton Gen Hosp, Immunopharmacol Grp, Southampton, Hants, England	Simons, FER (reprint author), 820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	Imcniven@hsc.mb.ca	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596	Department of Health [H039]; Intramural NIH HHS; Medical Research Council [G0500729]		Aalto-Korte K, 2001, ALLERGY, V56, P461, DOI 10.1034/j.1398-9995.2001.056005461.x; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akin C., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80711-X; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown RH, 2005, ANESTHESIOLOGY, V102, P496, DOI 10.1097/00000542-200503000-00004; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; Buckley MG, 2006, J ALLERGY CLIN IMMUN, V117, pS69, DOI 10.1016/j.jaci.2005.12.278; Carr WW, 2005, J ALLERGY CLIN IMMUN, V116, P341, DOI 10.1016/j.jaci.2005.03.035; Caughey GH, 2006, J ALLERGY CLIN IMMUN, V117, P1411, DOI 10.1016/j.jaci.2006.02.026; Chang TW, 2006, J ALLERGY CLIN IMMUN, V117, P1203, DOI 10.1016/j.jaci.2006.04.005; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Crameri R, 2006, IMMUNOL ALLERGY CLIN, V26, P179, DOI 10.1016/j.iac.2006.02.003; Daschner A, 2000, J ALLERGY CLIN IMMUN, V105, P176, DOI 10.1016/S0091-6749(00)90194-5; de Weck AL, 2004, J INVEST ALLERG CLIN, V14, P253; Dominguez-Ortega J, 2001, INT ARCH ALLERGY IMM, V125, P86, DOI 10.1159/000053801; Eberlein-Konig B, 2006, ALLERGY, V61, P1084, DOI 10.1111/j.1398-9995.2006.01122.x; Ebo DG, 2006, ALLERGY, V61, P1028, DOI 10.1111/j.1398-9995.2006.01039.x; Ebo DG, 2006, ALLERGY, V61, P211, DOI 10.1111/j.1398-9995.2006.00982.x; Ebo DG, 2005, CYTOM PART B-CLIN CY, V64B, P28, DOI 10.1002/cyto.b.20042; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Edston E, 1998, FORENSIC SCI INT, V93, P135, DOI 10.1016/S0379-0738(98)00040-1; Erdmann SM, 2004, ALLERGY, V59, P1102, DOI 10.1111/j.1398-9995.2004.00624.x; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Finkelman FD, 2005, J ALLERGY CLIN IMMUN, V115, P449, DOI 10.1016/j.jaci.2004.12.1125; Fregonese L, 2005, J ALLERGY CLIN IMMUN, V115, P1148, DOI 10.1016/j.jaci.2005.01.068; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Gamboa P, 2004, CLIN EXP ALLERGY, V34, P1448, DOI 10.1111/j.1365-2222.2004.02050.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Genovese A, 2000, INFECT IMMUN, V68, P5517, DOI 10.1128/IAI.68.10.5517-5524.2000; Golden DBK, 2006, J ALLERGY CLIN IMMUN, V117, P670, DOI 10.1016/j.jaci.2005.12.1313; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI 10.1067/mai.2003.1606; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Grammer LC, 2000, ANN ALLERG ASTHMA IM, V85, P368; Gruchalla RS, 2006, NEW ENGL J MED, V354, P601, DOI 10.1056/NEJMcp043986; Grunwald T, 2006, J ALLERGY CLIN IMMUN, V117, P848, DOI 10.1016/j.jaci.2005.12.1331; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; Hand S, 2004, CLIN EXP ALLERGY, V34, P720, DOI [10.1111/j.1365-2222.2004.1932.x, 10.1111/j.1365-2222.2004.01932.x]; Harboe T, 2006, ACTA ANAESTH SCAND, V50, P324, DOI 10.1111/j.1399-6576.2005.00962.x; Harboe T, 2005, ANESTHESIOLOGY, V102, P897, DOI 10.1097/00000542-200505000-00006; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hennersdorf F, 2005, CELL RES, V15, P325, DOI 10.1038/sj.cr.7290301; Hershko AY, 2001, SCAND J CLIN LAB INV, V61, P449; Hilger C, 2005, J ALLERGY CLIN IMMUN, V115, P617, DOI 10.1016/j.jaci.2004.11.052; Hoffman DR, 2003, ALLERGY ASTHMA PROC, V24, P123; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Hundley TR, 2004, BLOOD, V104, P2410, DOI 10.1182/blood-2004-02-0631; Jappe U, 2006, ALLERGY, V61, P1220, DOI 10.1111/j.1398-9995.2006.01232.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2005, ALLERGY, V60, P1312, DOI 10.1111/j.1398-9995.2005.00896.x; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Joint Task Force on Practice Practice Parameters; American Academy of Allergy Asthma and Immunology; American College of Allergy Asthma and Immunology, 2005, J ALLERGY CLIN IMMUN, V115, pS483; JUTEL M, 1995, J IMMUNOL, V154, P4187; KALINER M, 1981, J ALLERGY CLIN IMMUN, V68, P365, DOI 10.1016/0091-6749(81)90134-2; Katz HR, 2002, CURR OPIN IMMUNOL, V14, P698, DOI 10.1016/S0952-7915(02)00400-4; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kemp SF, 2002, J ALLERGY CLIN IMMUN, V110, P341, DOI 10.1067/mai.2002.126811; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Ko J, 2006, ANN ALLERG ASTHMA IM, V97, P365; Kounis NG, 2006, INT J CARDIOL, V110, P7, DOI 10.1016/j.ijcard.2005.08.007; Kulka M, 2005, BLOOD, V105, P592, DOI 10.1182/blood-2004-07-2838; Le TH, 2006, J CLIN INVEST, V116, P866, DOI 10.1172/JCI28312; Lebel B, 2001, ALLERGY, V56, P688, DOI 10.1034/j.1398-9995.2001.00103.x; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; Ludolph-Hauser D, 2001, LANCET, V357, P361, DOI 10.1016/S0140-6736(00)03647-3; MARONE G, 2000, MAST CELLS BASOPHILS, P454; Marone Gianni, 2004, Novartis Found Symp, V257, P133; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; McEuen AR, 2001, FOOD ALLERGY INTOLER, V2, P105; Messaad D, 2004, ANN INTERN MED, V140, P1001; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Min HK, 2004, J ALLERGY CLIN IMMUN, V114, P48, DOI 10.1016/j.jaci.2004.04.008; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; MULLER U, 2006, ALLERGOL, V26, P45; Muller UR, 2005, CURR OPIN ALLERGY CL, V5, P343; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jsci.2004.11.012, 10.1016/j.jaci.2004.11.012]; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; Nishio H, 2005, INT J LEGAL MED, V119, P331, DOI 10.1007/s00414-005-0524-1; Nopp A, 2006, ALLERGY, V61, P1366, DOI 10.1111/j.1398-9995.2006.01211.x; Oskeritzian CA, 2005, J ALLERGY CLIN IMMUN, V115, P1162, DOI 10.1016/j.jaci.2005.02.022; PATELLA V, 1995, J IMMUNOL, V154, P2855; Peng DJ, 2004, J HAZARD MATER, V114, P1, DOI 10.1016/j.jhazmat.2004.08.029; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Radcliffe M, 2005, LANCET, V365, P1360, DOI 10.1016/S0140-6736(05)61036-7; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Saini S, 2004, J ALLERGY CLIN IMMUN, V114, P768, DOI 10.1016/j.jaci.2004.06.015; Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI [10.1016/j.jaci.2005.01.008, 10.1016/j.jaci.2005.01.009]; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Saxon Andrew, 2004, Curr Opin Allergy Clin Immunol, V4, P563, DOI 10.1097/00130832-200412000-00015; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Schwartz LB, 1995, J CLIN INVEST, V96, P2702, DOI 10.1172/JCI118337; Schwartz LB, 2003, J IMMUNOL, V170, P5667; SCHWARTZ LB, 1989, J CLIN INVEST, V83, P1551, DOI 10.1172/JCI114051; Shanmugam G, 2006, J ALLERGY CLIN IMMUN, V117, P950, DOI 10.1016/j.jaci.2005.12.1356; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Shreffler WG, 2006, ANN ALLERG ASTHMA IM, V96, P865; Shreffler WG, 2006, CURR OPIN ALLERGY CL, V6, P226, DOI 10.1097/01.all.0000225165.83144.2f; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; STELLATO C, 1991, BRIT J ANAESTH, V67, P751, DOI 10.1093/bja/67.6.751; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Strait RT, 2003, J IMMUNOL, V170, P3835; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Stumpf JL, 2006, ANN PHARMACOTHER, V40, P699, DOI 10.1345/aph.1G295; Sturm GJ, 2004, ALLERGY, V59, P1110, DOI 10.1111/j.1398-9995.2004.00400.x; Sudheer PS, 2005, ANAESTHESIA, V60, P251, DOI 10.1111/j.1365-2044.2004.04086.x; Taylor ML, 2004, J MOL DIAGN, V6, P335, DOI 10.1016/S1525-1578(10)60529-6; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; Thong BYH, 2004, ANN ALLERG ASTHMA IM, V92, P619; Thottingal TB, 2006, J ALLERGY CLIN IMMUN, V118, P905, DOI 10.1016/j.jaci.2006.06.016; Tkaczyk C, 2004, BLOOD, V104, P207, DOI 10.1182/blood-2000-08-2769; Turner H, 1999, NATURE, V402, pB24; Vadas P., 2003, Journal of Allergy and Clinical Immunology, V111, pS206, DOI 10.1016/S0091-6749(03)80712-1; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; VANDERLINDEN PWG, 1992, J ALLERGY CLIN IMMUN, V90, P110, DOI 10.1016/S0091-6749(06)80017-5; VANDERLINDEN PWG, 1990, LANCET, V336, P904, DOI 10.1016/0140-6736(90)92272-J; VANDERLINDEN PWG, 1993, BLOOD, V82, P1740; VANDERLINDEN PWG, 1994, J ALLERGY CLIN IMMUN, V94, P151, DOI 10.1016/0091-6749(94)90034-5; VANDERLINDEN PWG, 1993, BLOOD, V82, P1732; VANDERLINDEN PWG, 1993, ANN INTERN MED, V118, P161; Vigorito C, 1997, INT J CLIN LAB RES, V27, P178, DOI 10.1007/BF02912454; Walls AF, 2000, ASTHMA RHINITIS, P968; Wang J, 2006, J ALLERGY CLIN IMMUN, V117, pS39, DOI 10.1016/j.jaci.2005.12.161; Wickman M, 2005, ALLERGY, V60, P650, DOI 10.1111/j.1398-9995.2005.00764.x; Yokoi H, 2006, ALLERGY, V61, P769, DOI 10.1111/j.1398-9995.2006.01133.x; Zhao W, 2006, J IMMUNOL, V177, P694; Zhou X, 2006, J ALLERGY CLIN IMMUN, V117, pS85, DOI 10.1016/j.jaci.2005.12.342	150	141	144	0	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1		S			S2	S24		10.1016/j.jaci.2007.05.001		23	Allergy; Immunology	Allergy; Immunology	193KY	WOS:000248274100002	17602945	
J	Kohl, J; Baelder, R; Lewkowich, IP; Pandey, MK; Hawlisch, H; Wang, LH; Best, J; Herman, NS; Sproles, AA; Zwirner, J; Whitsett, JA; Gerard, C; Sfyroera, G; Lambris, JD; Wills-Karp, M				Kohl, J; Baelder, R; Lewkowich, IP; Pandey, MK; Hawlisch, H; Wang, LH; Best, J; Herman, NS; Sproles, AA; Zwirner, J; Whitsett, JA; Gerard, C; Sfyroera, G; Lambris, JD; Wills-Karp, M			A regulatory role for the C5a anaphylatoxin in, type 2 immunity in asthma	JOURNAL OF CLINICAL INVESTIGATION			English	Article							INDUCED AIRWAY HYPERRESPONSIVENESS; PLASMACYTOID DENDRITIC CELLS; ISCHEMIA-REPERFUSION INJURY; TH2 EFFECTOR FUNCTIONS; GENOME-WIDE SEARCH; ALLERGIC-ASTHMA; INHALED ANTIGEN; CUTTING EDGE; IN-VIVO; C3A ANAPHYLATOXIN	Complement component 5 (CS) has been described as either promoting or protecting against airway hyper-responsiveness (AHR):in experimental allergic asthma, suggesting pleomorphic effects of C5. Here we report that local pharmacological targeting of the C5a receptor (C5aR) prior to initial allergen sensitization in murine models of inhalation tolerance or allergic asthma resulted in either induction or marked enhancement of Th2-polarized immune responses, airway inflammation, and AHR. Importantly, C5aR-deficient mice exhibited a similar, increased allergic phenotype. Pulmonary allergen exposure in CSaR-targeted mice resulted in increased sensitization and accumulation of CD4(+)CD69(+) T cells associated with a marked increase in pulmonary myeloid, but not plasmacytoid, DC numbers. Pulmonary DCs from C5aR-targeted mice produced large amounts of CC chemokine ligand 17 (CCL17) and CCL22 ex vivo, suggesting a negative impact of C5aR signaling on pulmonary homing of Th2 cells. In contrast, C5aR targeting in sensitized mice led to suppressed airway inflammation and AHR but was still associated with enhanced production of Th2 effector cytokines. These data suggest a dual role for C5a in allergic asthma, i.e., protection from the development of maladaptive type 2 immune responses during allergen sensitization at the DC/T cell interface but enhancement of airway inflammation and AHR in an established inflammatory environment.	Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Univ Gottingen, Dept Immunol, D-3400 Gottingen, Germany; Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA; Harvard Univ, Childrens Hosp, Sch Med, Ina Sue Perlmutter Lab, Boston, MA 02115 USA; Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	Kohl, J (reprint author), Childrens Hosp Res Fdn, Div Mol Immunol, MLC 7021, Cincinnati, OH 45229 USA.	joerg.koehl@chmcc.org	Koehl, Joerg/C-8531-2011	Koehl, Joerg/0000-0003-1121-3178; Lambris, John/0000-0002-9370-5776	NHLBI NIH HHS [R01 HL067736, R01-HL67736]; NIAID NIH HHS [R01 AI057839, R01-AI057839]		Abe K, 2001, KIDNEY INT, V60, P137, DOI 10.1046/j.1523-1755.2001.00780.x; Abe M, 2001, J IMMUNOL, V167, P4651; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Baelder R, 2005, J IMMUNOL, V174, P783; Bautsch W, 2000, J IMMUNOL, V165, P5401; BITO LZ, 1977, SCIENCE, V196, P83, DOI 10.1126/science.557238; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Cates EC, 2004, J IMMUNOL, V173, P6384; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Colten H. R, 1993, COMPLEMENT HLTH DIS, P127; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Vries B, 2003, J IMMUNOL, V170, P3883; Drouin SM, 2002, J IMMUNOL, V169, P5926; Drouin SM, 2001, J IMMUNOL, V167, P4141; Drouin SM, 2001, J IMMUNOL, V166, P2025; Eglite S, 2000, J IMMUNOL, V165, P2183; Ember JA, 1998, HUMAN COMPLEMENT SYS, P241; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gerard NP, 2002, CURR OPIN IMMUNOL, V14, P705, DOI 10.1016/S0952-7915(02)00410-7; Godau J, 2004, J IMMUNOL, V173, P3437; Guo RF, 2005, ANNU REV IMMUNOL, V23, P821, DOI 10.1146/annurev.immunol.23.021704.115835; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Hasegawa K, 2004, HUM GENET, V115, P295, DOI 10.1007/s00439-004-1157-z; Hawlisch H, 2006, MOL IMMUNOL, V43, P13, DOI 10.1016/j.molimm.2005.06.028; Hawlisch H, 2005, IMMUNITY, V22, P415, DOI 10.1016/j.immuni.2005.02.006; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Heller T, 1999, J IMMUNOL, V163, P985; Hopken UE, 1996, NATURE, V383, P86, DOI 10.1038/383086a0; Huber-Lang M, 2002, AM J PATHOL, V161, P1849, DOI 10.1016/S0002-9440(10)64461-6; Humbles AA, 2000, NATURE, V406, P998; Kao J, 1999, AM J PHYSIOL-LUNG C, V277, pL264; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Keane-Myers A, 1998, J IMMUNOL, V161, P919; KHIRWADKAR K, 1993, INT ARCH ALLERGY IMM, V100, P35; Kim AHJ, 2004, J IMMUNOL, V173, P2524; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Krug N, 2001, AM J RESP CRIT CARE, V164, P1841; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Liu JN, 2005, J EXP MED, V201, P567, DOI 10.1084/jem.20040863; Lloyd CM, 2003, CURR OPIN PHARMACOL, V3, P443, DOI 10.1016/S1471-4892(03)00069-9; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Marsh DG, 1997, NAT GENET, V15, P389; Maruo K, 1997, J ALLERGY CLIN IMMUN, V100, P253, DOI 10.1016/S0091-6749(97)70233-1; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MIHAN E, 2004, P R HLTH SCI J, V23, P47; Oriss TB, 2005, J IMMUNOL, V174, P854; Otto M, 2004, J BIOL CHEM, V279, P142, DOI 10.1074/jbc.M310078200; Peng T, 2005, J CLIN INVEST, V115, P1590, DOI 10.1172/JCI22906; Penna G, 2002, J IMMUNOL, V169, P6673; Perl AKT, 2002, TRANSGENIC RES, V11, P21; Riese RJ, 2004, NAT IMMUNOL, V5, P243, DOI 10.1038/ni0304-243; Soruri A, 2003, IMMUNOL LETT, V88, P47, DOI 10.1016/S0165-2478(03)00052-X; STIMLER NP, 1981, J IMMUNOL, V126, P2258; STIMLER NP, 1980, AM J PATHOL, V100, P327; STIMLER NP, 1982, J IMMUNOL, V128, P2247; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Wills-Karp M, 2004, NAT REV GENET, V5, P376, DOI 10.1038/nrg1326; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Zimmermann T, 1989, Prog Clin Biol Res, V308, P291	64	141	146	0	3	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	MAR	2006	116	3					783	796		10.1172/JCI26582		14	Medicine, Research & Experimental	Research & Experimental Medicine	019RL	WOS:000235854300030	16511606	
J	Kumar, RK; Foster, PS				Kumar, RK; Foster, PS			Modeling allergic asthma in mice - Pitfalls and opportunities	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Review							INDUCED AIRWAY HYPERREACTIVITY; ANTIGEN-INDUCED EOSINOPHIL; GOBLET CELL HYPERPLASIA; MURINE MODEL; MOUSE MODELS; BRONCHIAL HYPERRESPONSIVENESS; TRANSGENIC MICE; LUNG DAMAGE; T-CELLS; IMMUNOLOGICAL-TOLERANCE	Studies in murine experimental models have contributed greatly to understanding the mechanisms of allergic inflammation underlying asthma. However, models involving short-term high-level exposure of sensitized animals to antigen have significant limitations for investigating the pathogenesis of the lesions of chronic asthma. Modeling chronic asthma is problematic, because long-term antigenic challenge often triggers widespread pulmonary parenchymal inflammation or leads to eventual downregulation of inflammation and airway hyperreactivity. We have developed an improved murine model in which animals are exposed to low mass concentrations of aerosolized antigen for 6-8 wk. The mice exhibit airway-specific acute-on-chronic inflammation and changes of airway wall remodeling as seen in human asthma, together with hyperreactivity to a cholinergic agonist which can be specifically attributed to airway disease. This more realistic model of asthma offers a number of opportunities for investigation of pathogenetic mechanisms and novel therapeutic agents.	Univ New S Wales, Dept Pathol, Sydney, NSW 2052, Australia; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 2601, Australia	Kumar, RK (reprint author), Univ New S Wales, Dept Pathol, Sydney, NSW 2052, Australia.		Kumar, Rakesh/J-6124-2012; Foster, Paul/G-5057-2013	Kumar, Rakesh/0000-0002-9531-8411; 			Aharony D, 1998, AM J RESP CRIT CARE, V157, pS214; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Campbell EM, 1998, J IMMUNOL, V161, P7047; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910; Cohn L, 2001, AM J RESP CELL MOL, V24, P509; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; CORRIGAN CJ, 1996, SEVERE ASTHMA PATHOG, P103; DiGirolamo N, 1997, J LEUKOCYTE BIOL, V61, P667; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Foster PS, 2000, LAB INVEST, V80, P655; Foster PS, 2002, LAB INVEST, V82, P455; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fujitani Y, 1997, AM J RESP CRIT CARE, V155, P1890; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Hertz M, 2001, J IMMUNOL, V167, P3792; Hisada T, 1999, AM J RESP CRIT CARE, V160, P571; Hisada T, 1999, AM J RESP CELL MOL, V20, P992; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Jungsuwadee P, 2002, CLIN IMMUNOL, V102, P145, DOI 10.1006/clim.2001.5157; Kaminuma O, 1997, AM J RESP CELL MOL, V16, P448; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173; KIPS JC, 1992, AM REV RESPIR DIS, V145, P1306; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Kumar RK, 2000, CLIN EXP ALLERGY, V30, P1486, DOI 10.1046/j.1365-2222.2000.00911.x; Kumar RK, 2002, LAB INVEST, V82, P495; Kumar RK, 2001, IMMUNOL CELL BIOL, V79, P141, DOI 10.1046/j.1440-1711.2001.00981.x; KUMAR RK, 2002, IN PRESS CLIN EXP AL; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Leong KP, 2001, ANN ALLERG ASTHMA IM, V87, P96; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; MacKenzie JR, 2001, J IMMUNOL, V167, P3146; MacLean JA, 1996, J EXP MED, V184, P1461, DOI 10.1084/jem.184.4.1461; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2001, J IMMUNOL, V167, P1683; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; NAGAI H, 1993, LIFE SCI, V53, pPL243; NAGASE T, 1994, AM J RESP CRIT CARE, V150, P218; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; Oh SW, 2002, J IMMUNOL, V168, P1992; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; Pauwels RA, 1997, AM J RESP CRIT CARE, V156, pS78; RAEBURN D, 1992, J PHARMACOL TOXICOL, V27, P143, DOI 10.1016/1056-8719(92)90035-Y; Sakai K, 2001, INT ARCH ALLERGY IMM, V126, P126, DOI 10.1159/000049503; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Stelts D, 1998, AM J RESP CELL MOL, V18, P463; Tanaka H, 2001, INFLAMM RES, V50, P616, DOI 10.1007/PL00000243; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temelkovski J, 1998, THORAX, V53, P849; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; VELAN GM, 1993, PATHOLOGY, V25, P282; Webb DC, 2000, J IMMUNOL, V165, P108; Wilder JA, 1999, AM J RESP CELL MOL, V20, P1326; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2000, IMMUNOPHARMACOLOGY, V48, P263, DOI 10.1016/S0162-3109(00)00223-X; Wolyniec WW, 1998, AM J RESP CELL MOL, V18, P777; Yiamouyiannis CA, 1999, AM J PATHOL, V154, P1911, DOI 10.1016/S0002-9440(10)65449-1; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	77	141	148	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	SEP	2002	27	3					267	272		10.1165/rcmb.F248		6	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	590EZ	WOS:000177806500001	12204888	
J	Vahter, M; Berglund, M; Akesson, A; Liden, C				Vahter, M; Berglund, M; Akesson, A; Liden, C			Metals and women's health	ENVIRONMENTAL RESEARCH			English	Review							BLOOD LEAD LEVELS; ENVIRONMENTAL CADMIUM EXPOSURE; JAPANESE GENERAL-POPULATION; NUTRIENT-SUFFICIENT DIET; DRINKING-WATER; COGNITIVE FUNCTION; POSTMENOPAUSAL WOMEN; CONTACT-DERMATITIS; OSTEOBLASTIC CELLS; MERCURY EXPOSURE	There is a lack of information concerning whether environmental-related health effects are more or less prevalent or manifested differently in women compared to men. Previously, most research in the area of toxicology and environmental and occupational health involved male subjects. The present work aims at reviewing exposure and health effects of cadmium, nickel, lead, mercury, and arsenic manifested differently in women than in men. The gender difference in exposure to nickel results in a much higher prevalence of nickel allergy and hand eczema in women than in men. The internal cadmium dose is generally higher in women than in men, due to a higher gastrointestinal absorption at low iron stores. This was probably one major reason why Itai-itai disease was mainly a woman's disease. Yet, data are sparse regarding the risk for women relative to men to develop cadmium-induced kidney damage in populations exposed to low levels of cadmium. Lead is accumulated mainly in bone and increased endogenous lead exposure has been demonstrated in women during periods of increased bone turnover, e.g., menopause. Both lead and mercury exposure in pregnant women has to be kept low in order to prevent neurodevelopment effects in the developing fetus and child. Limited data indicate that women are more affected than men following exposure to methylmercury at adult age, while males seem to be more sensitive to exposure during early development. Regarding arsenic, some data indicate gender differences in the biotransformation by methylation, possibly also in susceptibility to certain arsenic-related cancers. Obviously, gender-related differences in exposure and health effects caused by metals are highly neglected research areas, which need considerable focus in the future. (C) 2002 Elsevier Science (USA).	Karolinska Inst, Inst Environm Med, Div Met & Hlth, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Med, Stockholm, Sweden; Stockholm Cty Council, Stockholm, Sweden	Vahter, M (reprint author), Karolinska Inst, Inst Environm Med, Div Met & Hlth, Box 210, SE-17177 Stockholm, Sweden.			Liden, Carola/0000-0001-9951-5896; Berglund, Marika/0000-0003-4241-4706			AHMAD AS, 2001, ENV HLTH PERSPECT, V109, P629; Akesson A, 2000, ENVIRON HEALTH PERSP, V108, P289, DOI 10.2307/3454345; AKESSON A, 2002, AM J PUBLIC HEALTH, V321, P177; Alfven T, 2000, J BONE MINER RES, V15, P1579, DOI 10.1359/jbmr.2000.15.8.1579; Arisawa K, 2001, INT ARCH OCC ENV HEA, V74, P255, DOI 10.1007/s004200000225; Baecklund M, 1999, ENVIRON RES, V80, P222; Ballew C, 1999, J PEDIATR-US, V134, P623, DOI 10.1016/S0022-3476(99)70250-7; Barregard L, 1999, ENVIRON HEALTH PERSP, V107, P867, DOI 10.2307/3454473; BERGLUND M, 1994, ENVIRON HEALTH PERSP, V102, P1058, DOI 10.2307/3431993; BHATTACHARYYA MH, 1988, TOXICOLOGY, V50, P193, DOI 10.1016/0300-483X(88)90091-1; BHATTACHARYYA MH, 1988, TOXICOLOGY, V50, P205, DOI 10.1016/0300-483X(88)90092-3; Bjorkman L, 2000, ENVIRON HEALTH PERSP, V108, P719, DOI 10.2307/3434724; BLASCHKO A, 1989, DEUT MED WOCHENSCHR, V15, P925; Burger J, 2000, ENVIRON RES, V83, P140, DOI 10.1006/enrs.2000.4060; Center for Disease Control, 1991, PREV LEAD POIS YOUNG; *CDC, 2001, JAMA-J AM MED ASSOC, V285, P1436; CHAN HM, 1993, TOXICOL APPL PHARM, V120, P308, DOI 10.1006/taap.1993.1116; Concha G, 1998, TOXICOL SCI, V44, P185, DOI 10.1093/toxsci/44.2.185; Concha G, 1998, INT ARCH OCC ENV HEA, V71, P42, DOI 10.1007/s004200050248; DeSesso JM, 1998, REPROD TOXICOL, V12, P385, DOI 10.1016/S0890-6238(98)00021-5; Egeland GM, 1997, SCIENCE, V278, P1904, DOI 10.1126/science.278.5345.1904; *EU, 1994, OFFICIAL J EUROPEAN, pL188; Flint GN, 1998, CONTACT DERMATITIS, V39, P213, DOI 10.1111/j.1600-0536.1998.tb05912.x; Fredriksson A, 1996, NEUROTOXICOL TERATOL, V18, P129, DOI 10.1016/0892-0362(95)02059-4; GIMENEZLLORT E, 2001, ENVIRON TOXICOL PHAR, V9, P61; Golub MS, 1998, J TOXICOL ENV HEAL B, V1, P199; Goyer RA, 1997, ANNU REV NUTR, V17, P37, DOI 10.1146/annurev.nutr.17.1.37; Grandjean P, 1998, ENVIRON RES, V77, P165, DOI 10.1006/enrs.1997.3804; Gulson BL, 1998, J LAB CLIN MED, V131, P324, DOI 10.1016/S0022-2143(98)90182-2; GULSON BL, 1995, J LAB CLIN MED, V125, P703; Gulson BL, 1997, J LAB CLIN MED, V130, P51, DOI 10.1016/S0022-2143(97)90058-5; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HALLEN IP, 1995, SCI TOTAL ENVIRON, V166, P149, DOI 10.1016/0048-9697(95)04523-4; Hellstrom L, 2001, AM J KIDNEY DIS, V38, P1001, DOI 10.1053/ajkd.2001.28589; Hernandez-Avila M, 2000, ARCH ENVIRON HEALTH, V55, P355; HernandezAvila M, 1997, ENVIRON RES, V74, P116, DOI 10.1006/enrs.1997.3756; Hopenhayn-Rich C, 2000, ENVIRON HEALTH PERSP, V108, P667, DOI 10.2307/3434889; HopenhaynRich C, 1996, ENVIRON HEALTH PERSP, V104, P620, DOI 10.2307/3433091; Hotz P, 1999, LANCET, V354, P1508, DOI 10.1016/S0140-6736(99)91145-5; Houston DK, 1999, NUTR REV, V57, P277; Hsu KH, 1997, ARSENIC EXPOSURE HLT, P190; Hu H, 1996, JAMA-J AM MED ASSOC, V275, P1171, DOI 10.1001/jama.275.15.1171; Hultman P, 2001, J AUTOIMMUN, V17, P27, DOI 10.1006/jaut.2001.0521; Ikeda M, 2000, INT ARCH OCC ENV HEA, V73, P15, DOI 10.1007/PL00007933; Ishihara T, 2001, TOXICOLOGY, V163, P23, DOI 10.1016/S0300-483X(01)00367-5; IWAMI K, 1993, ARCH TOXICOL, V67, P352, DOI 10.1007/BF01973707; Jarup L, 2000, OCCUP ENVIRON MED, V57, P668, DOI 10.1136/oem.57.10.668; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; KIDO T, 1991, ARCH ENVIRON HEALTH, V46, P43; Kjellstrom T., 1986, CADMIUM HLTH TOXICOL, V2, P257; Kobayashi E, 2002, TOXICOL LETT, V129, P85, DOI 10.1016/S0378-4274(01)00520-3; Korrick SA, 1999, AM J PUBLIC HEALTH, V89, P330, DOI 10.2105/AJPH.89.3.330; Kurttio P, 1998, ARCH ENVIRON CON TOX, V34, P297, DOI 10.1007/s002449900321; Li AM, 2000, ARCH DIS CHILD, V83, P174, DOI 10.1136/adc.83.2.174; Liden C, 1996, BRIT J DERMATOL, V134, P193; Liden C, 2001, CONTACT DERMATITIS, V44, P65, DOI 10.1034/j.1600-0536.2001.440201.x; Liden C, 2001, CONTACT DERMATITIS, V44, P7, DOI 10.1034/j.1600-0536.2001.440102.x; Liden C., 1995, METAL TOXICOLOGY, P447; LIDEN C, 2000, HDB OCCUPATIONAL DER, P524; Liden C, 2001, TXB CONTACT DERMATIT, P935; MAGOS L, 1981, ARCH TOXICOL, V48, P11, DOI 10.1007/BF00297071; MCKEOWNEYSSEN GE, 1983, AM J EPIDEMIOL, V118, P470; McRill C, 2000, J OCCUP ENVIRON MED, V42, P4, DOI 10.1097/00043764-200001000-00004; Meding B, 2000, CONTACT DERMATITIS, V43, P65, DOI 10.1034/j.1600-0536.2000.043002065.x; Meding B, 2001, CONTACT DERMATITIS, V45, P341, DOI 10.1034/j.1600-0536.2001.450604.x; Miyahara T, 2001, CALCIFIED TISSUE INT, V68, P185, DOI 10.1007/s002230001216; Muldoon SB, 1996, NEUROEPIDEMIOLOGY, V15, P62, DOI 10.1159/000109891; *NBHW, 2001, ENV HLTH REP 2001; Needleman HL, 2000, ENVIRON RES, V84, P20, DOI 10.1006/enrs.2000.4069; NEWBOLD R, 1995, ENVIRON HEALTH PERSP, V103, P83, DOI 10.2307/3432514; Newland MC, 1996, TOXICOL APPL PHARM, V139, P374, DOI 10.1006/taap.1996.0178; NIELSEN JB, 1991, PHARMACOL TOXICOL, V68, P208; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; NILSSON U, 1991, PHARMACOL TOXICOL, V68, P477; Nishijo M, 1999, TOXICOL LETT, V108, P321, DOI 10.1016/S0378-4274(99)00105-8; Noonan CW, 2002, ENVIRON HEALTH PERSP, V110, P151; *NRC, 1999, ARSENIC DRINKING WAT; National Research Council (NRC), 2001, ARS DRINK WAT; NRC, 2000, TOX EFF METH; Onalaja AO, 2000, ENVIRON HEALTH PERSP, V108, P23, DOI 10.2307/3454630; Oo YK, 2000, ARCH ENVIRON HEALTH, V55, P98; Osman K, 1998, CLIN BIOCHEM, V31, P657, DOI 10.1016/S0009-9120(98)00071-X; Osman K, 2000, CLIN BIOCHEM, V33, P131, DOI 10.1016/S0009-9120(00)00052-7; Payton M, 1998, NEUROTOXICOL TERATOL, V20, P19, DOI 10.1016/S0892-0362(97)00075-5; Petrick JS, 2000, TOXICOL APPL PHARM, V163, P203, DOI 10.1006/taap.1999.8872; POUNDS JG, 1991, ENVIRON HEALTH PERSP, V91, P17, DOI 10.2307/3430978; ROBERTS JS, 1995, MT SINAI J MED, V62, P343; Sakamoto M, 2001, ENVIRON RES, V87, P92, DOI 10.1006/enrs.2001.4293; Schwartz BS, 2000, NEUROLOGY, V55, P1144; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; Setlow VP, 1998, GENDER DIFFERENCES S; SILBERGELD EK, 1988, ENVIRON RES, V47, P79, DOI 10.1016/S0013-9351(88)80023-9; Silbergeld EK, 1999, J WOMENS HEALTH, V8, P227, DOI 10.1089/jwh.1999.8.227; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; Staessen JA, 1999, LANCET, V353, P1140, DOI 10.1016/S0140-6736(98)09356-8; STAESSEN JA, 1992, ENVIRON RES, V58, P25, DOI 10.1016/S0013-9351(05)80202-6; Styblo M, 2000, ARCH TOXICOL, V74, P289, DOI 10.1007/s002040000134; SYMANSKI E, 1995, AM J EPIDEMIOL, V141, P1047; Thomas VM, 1999, ENVIRON SCI TECHNOL, V33, P3942, DOI 10.1021/es990231+; TSURITANI I, 1992, J TOXICOL ENV HEALTH, V37, P519; TSURITANI I, 1994, TOXICOL LETT, V71, P209; Uriu K, 2000, TOXICOL APPL PHARM, V164, P264, DOI 10.1006/taap.2000.8908; VAHTER M, 1994, TOXICOL APPL PHARM, V124, P221, DOI 10.1006/taap.1994.1026; Vahter M, 2000, ENVIRON RES, V84, P186, DOI 10.1006/enrs.2000.4098; Vahter M, 1997, INT ARCH OCC ENV HEA, V70, P282, DOI 10.1007/s004200050220; Vahter Marie, 1999, Science Progress, V82, P69; WANG CH, 1993, TOXICOL APPL PHARM, V120, P228, DOI 10.1006/taap.1993.1107; Weyermann M, 1998, ENVIRON RES, V76, P19, DOI 10.1006/enrs.1997.3780; World Health Organization, 1991, ENV HLTH CRIT, V118; WHO (World Health Organization), 1995, ENV HLTH CRIT, V165; [Anonymous], 1996, GUID DRINK WAT QUAL, V2; Wilson AK, 1996, TOXICOL APPL PHARM, V140, P451, DOI 10.1006/taap.1996.0242; Yamanaka O, 1998, ENVIRON RES, V77, P1, DOI 10.1006/enrs.1998.3839; Yang JM, 1997, ANN CLIN LAB SCI, V27, P135	115	141	154	1	29	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	MAR	2002	88	3					145	155		10.1006/enrs.2002.4338		11	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	552NM	WOS:000175626500002	12051792	
J	Ring, J; Kramer, U; Schafer, T; Behrendt, H				Ring, J; Kramer, U; Schafer, T; Behrendt, H			Why are allergies increasing?	CURRENT OPINION IN IMMUNOLOGY			English	Review							HOUSE-DUST MITE; IMMUNOGLOBULIN-E; AIR-POLLUTION; ATOPIC ECZEMA; HAY-FEVER; LIFE-STYLE; CHILDREN; ASTHMA; PREVALENCE; CHILDHOOD	The incidence of atopic allergy is increasing in certain 'Western' countries but this remains unexplained. Various hypotheses with differing amounts of evidence and/or relevance have been assessed, including increased awareness of the diseases, improved diagnostics, genetic susceptibility, psycho-social influences, allergen exposure, decreased immune-system stimulation, underlying disease, anti-allergic therapy and pollution.	Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; Med Inst Umwelthyg, D-40225 Dusseldorf, Germany; Neuherberg Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, D-80802 Munich, Germany	Ring, J (reprint author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Behrendt H, 1995, PROG ALLER CLIN IMM, V3, P83; Behrendt H, 1993, ALLERGO J, V3, P31; BEHRENDT H, 2000, NATL COUNCIL ENV ISS; BEHRENDT H, 2001, ALLERGY CLIN IMMUNOL, V13, P127; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Blumenthal M, 1997, GENETICS ALLERGY AST; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BURR ML, 1993, EPIDEMIOLOGY ALLERGI; Coca AF, 1923, J IMMUNOL, V8, P163; COOKSON WOCM, 1989, LANCET, V1, P1292; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164; DiazSanchez D, 1997, ALLERGY, V52, P52; Diepgen T, 2000, ATOPIC DERMATITIS EP, P96, DOI 10.1017/CBO9780511545771.009; GASSNERBACHMANN M, 2000, DEUT MED WOCHENSCHR, V125, P923; Heinrich J, 1999, Eur J Med Res, V4, P107; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Holgate ST, 1999, NATURE, V402, pB2; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; ILLI S, 2001, ALLERGY CLIN IMMUNOL, V13, P99, DOI 10.1027/0838-1925.13.3.99; JUTEL M, 2001, IN PRESS NATURE; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Kramer U, 1999, INT J EPIDEMIOL, V28, P865, DOI 10.1093/ije/28.5.865; KRAMER U, 1997, AIR POLLUTION EPIDEM, V8; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; LESOUEF P, 2000, ACI INT S, V1, P43; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Olesen AB, 2001, LANCET, V357, P1749, DOI 10.1016/S0140-6736(00)04896-0; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; RING J, 1985, HAUTARZT, V36, P470; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P7; Schafer T, 1996, ALLERGY, V51, P532; Schafer T, 1997, J AM ACAD DERMATOL, V36, P550, DOI 10.1016/S0190-9622(97)70242-1; SCHNYDER U. W., 1960, ACTA GENET ET STATIST MED, V10, P1; Schultz Larsen F, 1993, Monogr Allergy, V31, P9; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIGURS N, 1995, PEDIATRICS, V95, P500; Simons E, 1994, ANCESTORS ALLERGY; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, BRIT MED J, V299, P1259; SUZUKI KK, 2001, INT ARCH ALLERGY IMM, V124, P113; TAYLOR B, 1984, LANCET, V2, P1255; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Wahn U, 2000, SPECIAL REPORT ALLER; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Wichmann H, 1995, ALLERGOL J, V6, P315; WICKMAN M, 1994, CLIN EXP ALLERGY, V24, P109, DOI 10.1111/j.1365-2222.1994.tb00205.x; Williams HC, 2000, ATOPIC DERMATITIS EP; WOOLCOCK AJ, 2000, ACI INT S, V1, P53; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3; 1997, EUROPEAN ALLERGY WHI	64	141	148	2	23	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2001	13	6					701	708		10.1016/S0952-7915(01)00282-5		8	Immunology	Immunology	486BB	WOS:000171797600012	11677093	
J	Chapman, MD; Smith, AM; Vailes, LD; Arruda, LK; Dhanaraj, V; Pomes, A				Chapman, MD; Smith, AM; Vailes, LD; Arruda, LK; Dhanaraj, V; Pomes, A			Recombinant allergens for diagnosis and therapy of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						recombinant allergens; mites; animal allergens; allergy diagnostics; allergy therapeutics; asthma; allergy vaccines; allergen immunotherapy	HOUSE-DUST-MITE; DER-P-I; CROSS-REACTIVE ALLERGEN; HIGH-LEVEL EXPRESSION; IGE-BINDING; PICHIA-PASTORIS; MOLECULAR-CLONING; MAJOR ALLERGEN; X-RAY; DERMATOPHAGOIDES-PTERONYSSINUS	Many of the problems associated with using natural allergenic products for allergy diagnosis and treatment can be overcome with use of genetically engineered recombinant allergens. Over the past 10 years, the most important allergens from mites, pollens, animal dander, insects, and foods have been cloned, sequenced, and expressed. In many cases the three-dimensional allergen structure has been determined and B-cell and T-cell epitopes have been mapped. These studies show that allergens have diverse biologic functions (they may be enzymes, enzyme inhibitors, lipocalins, or structural proteins) and that as a rule the allergen function is unrelated to its ability to cause IgE antibody responses, High-level expression systems have been developed to produce recombinant allergens in bacteria, yeast, or insect cells. Recombinant allergens show comparable IgE antibody binding to their natural counterparts (where available) and show excellent reactivity on skin testing and in in vitro diagnostic tests. Cocktails of recombinant allergens can be formulated with predetermined and uniform allergen levels, which could replace natural allergens and result in the development of innovative, patient-based tests for allergy diagnosis. Recombinant allergens also offer the exciting possibility of developing new forms of allergen immunotherapy, including the use of hypoallergens, allergens coupled to IgE suppressive adjuvants, and peptide-based therapies. The production of recombinant allergens as defined molecular entities makes it feasible to consider the possibility of developing prophylactic allergen vaccines. The introduction of recombinant allergens in research and in clinical trials should lead to significant improvements in allergy diagnosis and treatment.	Univ Virginia, Asthma & Allerg Dis Ctr, Dept Internal Med, Charlottesville, VA 22908 USA; USP, Fac Med Ribeirao Preto, Dept Microbiol Immunol & Parasitol, Ribeirao Preto, Brazil; Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England	Chapman, MD (reprint author), Univ Virginia, Asthma & Allerg Dis Ctr, Dept Internal Med, Box 801355, Charlottesville, VA 22908 USA.		Arruda, L. Karla /D-5845-2013; Osborne, Nicholas/N-4915-2015	Arruda, L. Karla /0000-0002-7505-210X; Osborne, Nicholas/0000-0002-6700-2284; Pomes, Anna/0000-0002-8729-1829	NIAID NIH HHS [AI 34607, AI 32557]		AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; American Academy of Allergy Asthma and Immunology (AAAAI), 1997, J ALLERGY CLIN IMMUN, V99, P583; Arruda LK, 1995, J BIOL CHEM, V270, P31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563; ARRUDA LK, 1999, ALLERGY CLIN IMMUNOL, V11, P167, DOI 10.1027/0838-1925.11.5.167; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Benson DA, 2000, NUCLEIC ACIDS RES, V28, P15, DOI 10.1093/nar/28.1.15; Best EA, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90940-0; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Burks AW, 1999, INT ARCH ALLERGY IMM, V118, P313, DOI 10.1159/000024114; Burks W, 1999, INT ARCH ALLERGY IMM, V119, P165, DOI 10.1159/000024191; CHAPMAN MD, 1991, J ALLERGY CLIN IMMUN, V88, P300, DOI 10.1016/0091-6749(91)90091-2; Chapman MD, 1997, ALLERGY, V52, P374, DOI 10.1111/j.1398-9995.1997.tb01014.x; COOPER JB, 1990, J MOL BIOL, V214, P199, DOI 10.1016/0022-2836(90)90156-G; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385; EBNER C, 1997, ACI INT, V9, P69; ESCH RE, 1992, ARB PEI GSH, V85, P171; Ferrari E, 1997, FEBS LETT, V401, P73, DOI 10.1016/S0014-5793(96)01436-6; Flower DR, 1996, BIOCHEM J, V318, P1; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Hansen G, 2000, J IMMUNOL, V164, P223; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holt PG, 1998, ALLERGY, V53, P72; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; Ichikawa K, 1999, J ALLERGY CLIN IMMUN, V103, pS184; ICHIKAWA K, 2000, IN PRESS INT ARCH AL; Jacquet A, 2000, CLIN EXP ALLERGY, V30, P677, DOI 10.1046/j.1365-2222.2000.00823.x; Jorge PPO, 2000, J ALLERGY CLIN IMMUN, V105, pS169, DOI 10.1016/S0091-6749(00)90943-6; KEATING KM, 1993, MOL IMMUNOL, V30, P559; King C, 1998, J IMMUNOL, V161, P3645; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; KOSHTE VL, 1992, INT ARCH ALLERGY IMM, V97, P17; LARCHE M, 2000, IN PRESS INT ARCH AL; Lascombe MB, 2000, J BIOL CHEM, V275, P21572, DOI 10.1074/jbc.M002854200; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; LITWIN A, 1991, CLIN EXP ALLERGY, V21, P457, DOI 10.1111/j.1365-2222.1991.tb01686.x; Maecker HT, 1999, FASEB J, V13, pA319; Maleki SJ, 2000, J IMMUNOL, V164, P5844; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90938-2; POMES A, 2001, IN PRESS ALLERGY CLI; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; Schramm G, 1999, J IMMUNOL, V162, P2406; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Shakib F, 2000, CLIN EXP ALLERGY, V30, P751, DOI 10.1046/j.1365-2222.2000.00865.x; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Shoji H, 1997, BIOSCI BIOTECH BIOCH, V61, P1668; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH AM, 1999, IMMUNOTHERAPY ASTHMA, P99; SMITH AM, 2000, IN PRESS INT ARCH AL; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Sporik R, 1999, THORAX, V54, P675; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902; vanderVeen MJ, 1996, J ALLERGY CLIN IMMUN, V98, P1028, DOI 10.1016/S0091-6749(96)80187-4; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; vanRee R, 1996, ALLERGY, V51, P387; van Ree R, 1999, ALLERGY CLIN IMMUNOL, V11, P55, DOI 10.1027/0838-1925.11.2.55; vantHof W, 1997, J BIOL CHEM, V272, P1837; VAUGHAN W, 2000, J ALLERGY CLIN IMMUN, V105, pS363; Virtanen T, 1999, IMMUNOL TODAY, V20, P398, DOI 10.1016/S0167-5699(99)01515-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Waterham HR, 1997, GENE, V186, P37, DOI 10.1016/S0378-1119(96)00675-0; WILLSKARP M, 1998, ALLERGY, V53, P111; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56; Wu SY, 1999, J BIOL CHEM, V274, P170, DOI 10.1074/jbc.274.1.170	91	141	153	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					409	418				10	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900001	10984358	
J	Yokouchi, Y; Nukaga, Y; Shibasaki, M; Noguchi, E; Kimura, K; Ito, S; Nishihara, M; Yamakawa-Kobayashi, K; Takeda, K; Imoto, N; Ichikawa, K; Matsui, A; Hamaguchi, H; Arinami, T				Yokouchi, Y; Nukaga, Y; Shibasaki, M; Noguchi, E; Kimura, K; Ito, S; Nishihara, M; Yamakawa-Kobayashi, K; Takeda, K; Imoto, N; Ichikawa, K; Matsui, A; Hamaguchi, H; Arinami, T			Significant evidence for linkage of mite-sensitive childhood asthma to chromosome 5q31-q33 near the interleukin 12 B locus by a genome-wide search in Japanese families	GENOMICS			English	Article							TOTAL SERUM IGE; IL-4 GENE-EXPRESSION; BRONCHIAL HYPERRESPONSIVENESS; UNDERLYING ASTHMA; ALLERGIC-ASTHMA; RELATIVE RISKS; MAJOR GENE; NF-Y; MARKERS; RESPONSIVENESS	Childhood-onset asthma is frequently found in association with atopy. Although asthmatic children may develop IgE antibodies against variety of allergens, asthma is associated primarily with allergy to house-dust mites, molds, or other allergens. In this study, me conducted a genome-wide linkage search in 47 Japanese families (197 members) with more than two mite-sensitive atopic asthmatics (65 affected sib-pairs) using 398 markers. Multipoint linkage analysis was carried out for atopic asthma as a qualitative trait using the MAPMAKER/SIB program. We observed signficant evidence for linkage with maximum lod scores (MLS) of 4.8 near the interleukin 12 B gene locus on chromosome 5q31-q33. In addition, suggestive evidence on 4q35 with MLS = 2.7 and on 13q11 with MLS = 2.4 was obtained. The other possible linkage regions included 6p22-p21.3 (MLS = 2.1), 12q21-q23 (MILS = 1.9), and 13q14.1-q14.3 (MLS = 2.0). Many of the linkage loci suggested in this study were at or close to those suggested by genome-wide studies for asthma in Caucasian populations. The present study suggests the contribution of the interleukin 12 B gene or nearby gene(s) to mite-sensitive atopic asthma and a considerable number of genetic variants common across Caucasians and Japanese populations contributing to asthma, although the relative importance of various variants may differ between the groups. (C) 2000 Academic Press.	Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Pediat, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Dermatol, Tsukuba, Ibaraki 3058575, Japan	Arinami, T (reprint author), Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan.		Yamakawa-Kobayashi, Kimiko/C-1698-2013				Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BLEECKER ER, 1995, CLIN EXP ALLERGY, V25, P84, DOI 10.1111/j.1365-2222.1995.tb00430.x; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; CARABALLO LR, 1990, TISSUE ANTIGENS, V35, P182, DOI 10.1111/j.1399-0039.1990.tb01777.x; COOKSON WOCM, 1991, CLIN EXP ALLERGY, V21, P473, DOI 10.1111/j.1365-2222.1991.tb01688.x; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DIZIER MH, 1995, GENET EPIDEMIOL, V12, P93, DOI 10.1002/gepi.1370120109; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; Grimbacher B, 1999, AM J HUM GENET, V65, P735, DOI 10.1086/302547; Halushka MK, 1999, NAT GENET, V22, P239; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P449, DOI 10.1016/S0091-6749(98)70134-4; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P443, DOI 10.1016/S0091-6749(98)70133-2; Holroyd KJ, 1998, GENOMICS, V52, P233, DOI 10.1006/geno.1998.5445; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535; Kraan TCTMV, 1997, J IMMUNOL, V158, P5560; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LARSEN GL, 1992, NEW ENGL J MED, V326, P1540; Lee YL, 1999, SCAND J IMMUNOL, V49, P229; LIWEBER M, 1994, J IMMUNOL, V153, P4122; LIWEBER M, 1995, IMMUNOBIOLOGY, V193, P263; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Moffatt M. F., 1994, Lancet (North American Edition), V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845; *NAT HEART LUNG BL, 1997, 974051 NAT HEART LUN; Noguchi E, 1998, GENOMICS, V47, P121, DOI 10.1006/geno.1997.5054; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Okano Y, 1998, INT ARCH ALLERGY IMM, V115, P83, DOI 10.1159/000023834; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHIBASAKI M, 1988, J ALLERGY CLIN IMMUN, V82, P86, DOI 10.1016/0091-6749(88)90056-5; SIEBURTH D, 1992, GENOMICS, V14, P59, DOI 10.1016/S0888-7543(05)80283-6; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; Taniguchi T, 1998, EUR CYTOKINE NETW, V9, P43; Vaughan PS, 1997, J MOL MED-JMM, V75, P348, DOI 10.1007/s001090050120; WARRINGTON JA, 1994, GENOMICS, V24, P395, DOI 10.1006/geno.1994.1636; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; XU J, 1995, AM J HUM GENET, V57, P425	47	141	150	0	15	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0888-7543			GENOMICS	Genomics	JUN 1	2000	66	2					152	160		10.1006/geno.2000.6201		9	Biotechnology & Applied Microbiology; Genetics & Heredity	Biotechnology & Applied Microbiology; Genetics & Heredity	327PG	WOS:000087801500004	10860660	
J	Martinez, FD; Vercelli, D				Martinez, Fernando D.; Vercelli, Donata			Asthma	LANCET			English	Article							INNATE LYMPHOID-CELLS; MILD PERSISTENT ASTHMA; REGULATORY T-CELLS; INTERMITTENT INHALED CORTICOSTEROIDS; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; GENOME-WIDE ASSOCIATION; ACTING BETA-AGONISTS; STEP-UP THERAPY; CHILDHOOD ASTHMA	Asthma is a heterogeneous group of conditions that result in recurrent, reversible bronchial obstruction. Although the disease can start at any age, the first symptoms occur during childhood in most cases. Asthma has a strong genetic component, and genome-wide association studies have identified variations in several genes that slightly increase the risk of disease. Asthma is often associated with increased susceptibility to infection with rhinoviruses and with changes in the composition of microbial communities colonising the airways, but whether these changes are a cause or consequence of the disease is unknown. There is currently no proven prevention strategy; however, the finding that exposure to microbial products in early life, particularly in farming environments, seems to be protective against asthma offers hope that surrogates of such exposure could be used to prevent the disease. Genetic and immunological studies point to defective responses of lung resident cells, especially those associated with the mucosal epithelium, as crucial elements in the pathogenesis of asthma. Inhaled corticosteroids continue to be the mainstay for the treatment of mild and moderate asthma, but limited adherence to daily inhaled medication is a major obstacle to the success of such therapy. Severe asthma that is refractory to usual treatment continues to be a challenge, but new biological therapies, such as humanised antibodies against IgE, interleukin 5, and interleukin 13, off er hope to improve the quality of life and long-term prognosis of severe asthmatics with specific molecular phenotypes.	[Martinez, Fernando D.; Vercelli, Donata] Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Martinez, Fernando D.; Vercelli, Donata] Univ Arizona, Inst BIO5, Tucson, AZ 85724 USA	Martinez, FD (reprint author), Univ Arizona, Arizona Resp Ctr, 1501 N Campbell, Tucson, AZ 85724 USA.	fernando@arc.arizona.edu			US National Heart, Lung, and Blood Institute; US National Institute of Allergy and Infectious Diseases	The authors were funded by grants from the US National Heart, Lung, and Blood Institute and the US National Institute of Allergy and Infectious Diseases.	Akinbami L, 2012, TRENDS ASTHMA PREVAL; Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; Anees W, 2006, THORAX, V61, P751, DOI 10.1136/thx.2005.054080; Apter AJ, 2011, J ALLERGY CLIN IMMUN, V128, P516, DOI 10.1016/j.jaci.2011.05.010; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Barnes PJ, 2013, J ALLERGY CLIN IMMUN, V131, P636, DOI 10.1016/j.jaci.2012.12.1564; Beasley R, 2009, EUR RESPIR J, V33, P3, DOI 10.1183/09031936.00163408; Bedouch P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050949; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; Bisgaard H, 2006, LANCET, V367, P286, DOI 10.1016/S0140-6736(06)68051-3; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; Boitano S, 2011, AM J PHYSIOL-LUNG C, V300, pL605, DOI 10.1152/ajplung.00359.2010; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1995, AM J RESP CRIT CARE, V152, P1497; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Charlson ES, 2011, AM J RESP CRIT CARE, V184, P957, DOI 10.1164/rccm.201104-0655OC; Chowdhury B., 2010, LONG ACTING BETA AGO; Chu EK, 2005, AM J RESP CELL MOL, V32, P373, DOI 10.1165/rcmb.2004-02660C; Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corren J, 2011, NEW ENGL J MED, V365, P1089; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Custovic A, 2011, J ALLERGY CLIN IMMUN, V127, P390, DOI 10.1016/j.jaci.2010.10.050; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Drazen JM, 2009, NEW ENGL J MED, V360, P1671, DOI 10.1056/NEJMe0902057; Ducharme FM, 2012, THORAX, V67, P102, DOI 10.1136/thoraxjnl-2011-200961; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fahy JV, 2011, AM J RESP CRIT CARE, V184, P390, DOI 10.1164/rccm.201107-1258ED; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Gauvreau GM, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-140; Gehring U, 2012, ALLERGY, V67, P248, DOI 10.1111/j.1398-9995.2011.02739.x; Gerald LB, 2009, PEDIATRICS, V123, P466, DOI 10.1542/peds.2008-0499; Gowers AM, 2012, RESPIROLOGY, V17, P887, DOI 10.1111/j.1440-1843.2012.02195.x; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Hilty M, 2010, PLOS ONE, V5, pe8578; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; Holberg CJ, 1996, AM J RESP CRIT CARE, V154, P144; Holgate ST, 2011, J ALLERGY CLIN IMMUN, V128, P495, DOI 10.1016/j.jaci.2011.06.052; Holt PG, 2012, NAT MED, V18, P726, DOI 10.1038/nm.2768; Horne Rob, 2007, BMC Pulm Med, V7, P8, DOI 10.1186/1471-2466-7-8; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jarjour NN, 2012, AM J RESP CRIT CARE, V185, P356, DOI 10.1164/rccm.201107-1317PP; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kubo S, 2012, INT IMMUNOPHARMACOL, V12, P59, DOI 10.1016/j.intimp.2011.10.011; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Maier RM, 2010, APPL ENVIRON MICROB, V76, P2663, DOI 10.1128/AEM.01665-09; Mallol J, 2008, THORAX, V63, P167, DOI 10.1136/thx.2006.063180; Marinho Susana, 2006, Prim Care Respir J, V15, P152, DOI 10.1016/j.pcrj.2006.02.005; Marri PR, 2013, J ALLERGY CLIN IMMUN, V131, P346, DOI 10.1016/j.jaci.2012.11.013; Martinez FD, 2011, J ALLERGY CLIN IMMUN, V128, P939, DOI 10.1016/j.jaci.2011.09.020; Martinez FD, 2011, LANCET, V377, P650, DOI 10.1016/S0140-6736(10)62145-9; Masuoka M, 2012, J CLIN INVEST, V122, P2590, DOI 10.1172/JCI58978; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Mjosberg J, 2012, EUR J IMMUNOL, V42, P1093, DOI 10.1002/eji.201242549; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Ni Chroinin M, 2009, COCHRANE DB SYST REV, V2009; Nikander K, 2011, ARCH DIS CHILD, V96, P168, DOI 10.1136/adc.2010.187724; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ostergaard MS, 2012, PRIM CARE RESP J, V21, P214, DOI 10.4104/pcrj.2012.00038; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rachiotis G, 2007, THORAX, V62, P147, DOI 10.1136/thx.2006.061952; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Rodriguez A, 2011, THORAX, V66, P1043, DOI 10.1136/thoraxjnl-2011-200225; Round JL, 2011, SCIENCE, V332, P974, DOI 10.1126/science.1206095; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Savenije OE, 2011, J ALLERGY CLIN IMMUN, V127, P1505, DOI 10.1016/j.jaci.2011.02.002; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Siroux V, 2011, EUR RESPIR J, V38, P310, DOI 10.1183/09031936.00120810; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Solis-Cohen S, 1900, JAMA-J AM MED ASSOC, V34, P1164; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Strunk RC, 2006, J ALLERGY CLIN IMMUN, V118, P1040, DOI 10.1016/j.jaci.2006.07.053; Sullivan PW, 2011, J ALLERGY CLIN IMMUN, V127, P363, DOI 10.1016/j.jaci.2010.10.042; Sykes A, 2012, J ALLERGY CLIN IMMUN, V129, P1506, DOI 10.1016/j.jaci.2012.03.044; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Tattersfield AE, 2002, LANCET, V360, P1313, DOI 10.1016/S0140-6736(02)11312-2; Tennessen JA, 2012, SCIENCE, V337, P64, DOI 10.1126/science.1219240; Thamrin C, 2011, J ALLERGY CLIN IMMUN, V127, P1494, DOI 10.1016/j.jaci.2011.01.018; Thamrin C, 2010, THORAX, V65, P403, DOI 10.1136/thx.2009.129668; Toelle BG, 2010, J ALLERGY CLIN IMMUN, V126, P388, DOI 10.1016/j.jaci.2010.04.031; Torgerson DG, 2012, AM J HUM GENET, V90, P273, DOI 10.1016/j.ajhg.2012.01.008; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tschumperlin DJ, 2006, ANNU REV PHYSIOL, V68, P563, DOI 10.1146/annurev.physiol.68.072304.113102; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Turpeinen M, 2012, THORAX, V67, P100, DOI 10.1136/thoraxjnl-2011-200246; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Van Dyken SJ, 2011, J IMMUNOL, V187, P2261, DOI 10.4049/jimmunol.1100972; van Oosterhout AJM, 2005, EUR RESPIR J, V26, P918, DOI 10.1183/09031936.05.00011205; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Wadsworth SJ, 2013, CURR ALLERGY ASTHM R, V13, P118, DOI 10.1007/s11882-012-0325-9; Wahidi MM, 2012, AM J RESP CRIT CARE, V185, P709, DOI 10.1164/rccm.201105-0883CI; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Williams LK, 2011, J ALLERGY CLIN IMMUN, V128, P1185, DOI 10.1016/j.jaci.2011.09.011; Wlasiuk G, 2012, CURR OPIN ALLERGY CL, V12, P461, DOI 10.1097/ACI.0b013e328357a3bc; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Zar HJ, 2012, PEDIATR DRUGS, V14, P353, DOI 10.2165/11597420-000000000-00000; Zhang YM, 2012, CURR OPIN PULM MED, V18, P6, DOI 10.1097/MCP.0b013e32834dc532	159	140	151	9	98	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 19	2013	382	9901					1360	1372		10.1016/S0140-6736(13)61536-6		13	Medicine, General & Internal	General & Internal Medicine	238UG	WOS:000325975700026	24041942	
J	Meijboom, WB; Mollet, NR; Van Mieghem, CAG; Kluin, J; Weustink, AC; Pugliese, F; Vourvouri, E; Cademartiri, F; Bogers, AJJC; Krestin, GP; de Feyter, PJ				Meijboom, Willem B.; Mollet, Nico R.; Van Mieghem, Carlos A. G.; Kluin, Jolanda; Weustink, Annick C.; Pugliese, Francesca; Vourvouri, Eleni; Cademartiri, Filippo; Bogers, Ad J. J. C.; Krestin, Gabriel P.; de Feyter, Pim J.			Pre-operative computed tomography coronary anglography to detect significant coronary artery disease in patients referred for cardiac valve surgery	JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY			English	Article							VALVULAR HEART-DISEASE; PRACTICE GUIDELINES COMMITTEE; ASSOCIATION TASK-FORCE; AORTIC-STENOSIS; RADIATION-EXPOSURE; ANGINA-PECTORIS; ANGIOGRAPHY; ACCURACY; CT; QUANTIFICATION	OBJECTIVES We studied the diagnostic performance of 64-slice computed tomography coronary angiography (CTCA) to rule out or detect significant coronary stenosis in patients referred for valve surgery. BACKGROUND Invasive conventional coronary angiography (CCA) is recommended in most patients scheduled for valve surgery. METHODS During a 6-month period, 145 patients were prospectively identified from a consecutive patient population scheduled for valve surgery. Thirty-five patients were excluded because of CTCA criteria: irregular heart rhythm (n = 26), impaired renal function (n = 5), and known contrast allergy (n = 4). General exclusion criteria were: hospitalization in community hospital (n = 4), no need for CCA (n = 4), previous coronary artery bypass surgery (n = 1), or percutaneous coronary intervention (n = 4). Of the remaining 97 patients, 27 denied written informed consent. Thus, the study population comprised 70 patients (49 male, 21 female;, mean age 63 +/- 11 years). RESULTS Prevalence of significant coronary artery disease, defined as having at least 1 >= 50% stenosis per patient, was 25.7%. Beta-blockers were administered in 71%, and 64% received lorazepam. The mean heart rate dropped from 72.5 +/- 12.4 to 59.5 +/- 7.5 beats/min. The mean scan time was 12.8 +/- 1.3 s. On a per-patient analysis, the sensitivity, specificity, and positive and negative predictive values were: 100% (18 of 18; 95% confidence interval [CI] 78 to 100), 92% (48 of 52; 95% CI 81 to 98), 82% (18 of 22; 95% CI 59 to 94), and 100% (48 of 48; 95% CI 91 to 100), respectively. CONCLUSIONS The diagnostic accuracy of 64-slice CTCA for ruling out the presence of significant coronary stenoses in patients undergoing valve surgery is excellent and allows CTCA implementation as a gatekeeper for invasive CCA in these patients.	Erasmus Med Ctr, Dept Cardiol, Thoraxctr, NL-3015 GD Rotterdam, Netherlands; Erasmus Med Ctr, Dept Radiol, Thoraxctr, NL-3015 GD Rotterdam, Netherlands; Erasmus Med Ctr, Dept Cardiothorac Surg, Thoraxctr, NL-3015 GD Rotterdam, Netherlands	de Feyter, PJ (reprint author), Erasmus Med Ctr, Dept Cardiol & Radiol, Thoraxctr, Room BA 589,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	p.j.defeyter@erasmusmc.nl	Cademartiri, Filippo/H-7336-2015	Cademartiri, Filippo/0000-0002-0579-3279			Achenbach S, 2006, EUR J RADIOL, V57, P331, DOI 10.1016/j.ejrad.2005.12.017; AGATSTON AS, 1990, J AM COLL CARDIOL, V15, P827; ALEXOPOULOS D, 1993, ANGIOLOGY, V44, P707, DOI 10.1177/000331979304400906; Austen WG, 1975, CIRCULATION S4, V51, P5; Bonow RO, 1998, CIRCULATION, V98, P1949; Coles DR, 2006, J AM COLL CARDIOL, V47, P1840, DOI 10.1016/j.jacc.2005.11.078; Flohr TG, 2006, EUR RADIOL, V16, P256, DOI 10.1007/s00330-005-2919-2; Gilard M, 2006, J AM COLL CARDIOL, V47, P2020, DOI 10.1016/j.jacc.2005.11.085; GREEN SJ, 1985, AM J CARDIOL, V55, P1063, DOI 10.1016/0002-9149(85)90747-7; Hausleiter J, 2006, CIRCULATION, V113, P1305, DOI 10.1161/CIRCULATIONAHA.105.602490; Jakobs TF, 2002, EUR RADIOL, V12, P1081, DOI 10.1007/s00330-001-1278-x; KETTUNEN R, 1992, AM J CARDIOL, V69, P1442, DOI 10.1016/0002-9149(92)90898-9; KUPARI M, 1992, AM J CARDIOL, V70, P635, DOI 10.1016/0002-9149(92)90204-C; Leber AW, 2005, J AM COLL CARDIOL, V46, P147, DOI 10.1016/j.jacc.2005.03.071; Leschka S, 2005, EUR HEART J, V26, P1482, DOI 10.1093/eurheartj/ehi261; LUND O, 1990, J THORAC CARDIOV SUR, V100, P327; Lung B, 1993, J HEART VALVE DIS, V2, P430; LYTLE B W, 1991, Cardiology Clinics, V9, P301; Mollet NR, 2005, CIRCULATION, V112, P2318, DOI 10.1161/CIRCULATIONAHA.105.533471; MULLANY CJ, 1987, J AM COLL CARDIOL, V10, P66; OLOFSSON BO, 1985, ACTA MED SCAND, V218, P365; Raff GL, 2005, J AM COLL CARDIOL, V46, P552, DOI 10.1016/j.jacc.2005.05.056; RAMSDALE DR, 1984, EUR HEART J, V5, P716; RASK P, 1994, J NUCL MED, V35, P983; SAMUELS B, 1995, J AM COLL CARDIOL, V25, P99, DOI 10.1016/0735-1097(94)00317-J; Scanlon PJ, 1999, J AM COLL CARDIOL, V33, P1756, DOI 10.1016/S0735-1097(99)00126-6; Trabold T, 2003, ROFO-FORTSCHR RONTG, V175, P1051; VANDEPLAS A, 1988, AM J CARDIOL, V62, P117, DOI 10.1016/0002-9149(88)91375-6; Vogl TJ, 2002, RADIOLOGY, V223, P212, DOI 10.1148/radiol.2231010515	29	140	144	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0735-1097			J AM COLL CARDIOL	J. Am. Coll. Cardiol.	OCT 17	2006	48	8					1658	1665		10.1016/j.jacc.2006.06.054		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	096ZC	WOS:000241414600022	17045904	
J	Schaumann, F; Borm, PJA; Herbrich, A; Knoch, J; Pitz, M; Schins, RPF; Luettig, B; Hohlfeld, JM; Heinrich, J; Krug, N				Schaumann, F; Borm, PJA; Herbrich, A; Knoch, J; Pitz, M; Schins, RPF; Luettig, B; Hohlfeld, JM; Heinrich, J; Krug, N			Metal-rich ambient particles (Particulate Matter(2.5)) cause airway inflammation in healthy subjects	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollution; bronchoscopy; monocytes; oxidants	RESPIRATORY SYMPTOMS; EAST-GERMANY; POLLUTION; LUNG; CHILDREN; DISEASE; PM2.5; INSTILLATION; PHENOTYPE; ENDOTOXIN	Epidemiologic studies have shown an increased prevalence of allergic asthma in children living in a German smelter area (Hettstedt) compared with a cohort who live in a nonindustrialized area (Zerbst). However, it is not known whether ambient particles (particulate matter(2.5) [PM2.5]) from these areas induce distinct lung inflammation, which might be an explanation for this difference. Therefore, 100 mug of PM2.5 suspensions, collected simultaneously in the two areas, were instilled through a bronchoscope into contralateral lung segments of 12 healthy volunteers. PM2.5 from both Hettstedt and Zerbst increased the number of leukocytes in the bronchoalveolar lavage performed 24 hours later. PM2.5 from Hettstedt, but not Zerbst, induced a significant influx of monocytes (Hettstedt: 7.0% vs. Zerbst: 4.3%) without influencing the expression of surface activation markers on monocytes and alveolar macrophages. Oxidant radical generation of bronchoalveolar lavage cells and cytokine concentration (interieukin-6 and tumor necrosis factor-alpha) in bronchoalveolar lavage fluid was significantly increased after instillation of Hettstedt PM2.5. We conclude that environmentally relevant concentrations of PM2.5 from the smelter area induced distinct airway inflammation in healthy subjects with a selective influx of monocytes and increased generation of oxidant radicals. The higher concentration of transition metals in PM2.5 from Hettstedt might be responsible for this increased inflammation.	Fraunhofer Inst Toxicol & Expt Med, D-30625 Hannover, Germany; Inst Umweltmed Forsch, Dusseldorf, Germany; GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany	Krug, N (reprint author), Fraunhofer Inst Toxicol & Expt Med, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	krug@item.fraunhofer.de					Adamson IYR, 2000, TOXICOL APPL PHARM, V166, P111, DOI 10.1006/taap.2000.8955; Erpenbeck VJ, 2004, AM J RESP CRIT CARE, V169, P578, DOI 10.1164/rccm.200301-104OC; Frye C, 2003, ENVIRON HEALTH PERSP, V111, P383, DOI 10.1289/ehp.5355; GAIL DB, 1991, AM REV RESPIR DIS, V144, P1414; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P1471, DOI 10.1289/ehp.6300; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704; Gong H, 2003, INHAL TOXICOL, V15, P305, DOI 10.1080/08958370390168300; Harder SD, 2001, ENVIRON HEALTH PERSP, V109, P599, DOI 10.2307/3454676; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Heinrich J, 2003, ATMOS ENVIRON, V37, P3659, DOI 10.1016/S1352-2310(03)00467-9; Heinrich J, 2002, EPIDEMIOLOGY, V13, P394, DOI 10.1097/01.EDE.00000016977.59359.B6; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; Krombach F, 1996, EUR RESPIR J, V9, P984, DOI 10.1183/09031936.96.09050984; Lensmar C, 1999, CLIN EXP ALLERGY, V29, P1632, DOI 10.1046/j.1365-2222.1999.00757.x; Maus U, 2001, AM J PHYSIOL-LUNG C, V280, pL58; Meyer I, 2003, INT J HYG ENVIR HEAL, V206, P181, DOI 10.1078/1438-4639-00207; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; SCHAUMANN F, 2000, AM J RESP CRIT CARE, V169, pA278; Shi TM, 2003, J ENVIRON MONITOR, V5, P550, DOI 10.1039/b303928p	22	140	151	2	27	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2004	170	8					898	903		10.1164/rccm.200403-423OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	861GT	WOS:000224404800014	15229099	
J	Peat, JK; Mihrshahi, S; Kemp, AS; Marks, GB; Tovey, ER; Webb, K; Mellis, CM; Leeder, SR				Peat, JK; Mihrshahi, S; Kemp, AS; Marks, GB; Tovey, ER; Webb, K; Mellis, CM; Leeder, SR		Childhood Asthma Study Team	Three-year outcomes of dietary fatty acid modification and house dust mite reduction in the Childhood Asthma Prevention Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; allergy; asthma; atopy; omega-3 fatty acids; house dust mite; primary prevention	RESPIRATORY SYMPTOMS; RANDOMIZED TRIAL; HIGH-RISK; FISH-OIL; ATOPY; COUGH; INTERVENTION; AVOIDANCE; PREGNANCY; INFANTS	Background: Two factors thought to influence the risk of asthma are the promoting effect of sensitization to house dust mites and the preventive effect of increased omega-3 fatty acids. Although house dust mite allergen avoidance has been used as a preventive strategy in several trials, the effect of omega-3 fatty acid supplementation in the primary prevention of asthma and allergic disease is not known. Objective: To measure the effects of dietary supplementation with omega-3 fatty acids and house dust mite allergen avoidance in children with a family history of asthma. Methods: A total of 616 children at high risk of asthma were enrolled antenatally in a randomized controlled trial, and 526 children remained in the trial at age 3 years. The outcomes were symptoms of allergic disease and allergen sensitization. Results: There was a significant 10.0% (95% CI, 3.7-16.4) reduction in the prevalence of cough in atopic children in the active diet group (P = .003; number needed to treat, 10) but a negligible 1.1 % (95 % CI, -7.1 to 9.5) reduction cough among nonatopic children. There was a 7.2% (95% CI, 10.11-14.3) reduction in sensitization to house dust mite in the active allergen avoidance group (P = .05; number needed to treat, 14). No significant differences in wheeze were found with either intervention. Conclusion: These results suggest that our interventions, designed to be used in simple public health campaigns, may have a role in preventing the development of allergic sensitization and airways disease in early childhood. This offers the prospect of reducing allergic disease in later life.	Univ Sydney, Discipline Paediat & Child Hlth, Childrens Hosp, Westmead Clin Sch, Sydney, NSW 2006, Australia; Childrens Hosp, Clin Epidemiol Unit, Westmead, NSW 2145, Australia; Woolcock Inst Med Res, Camperdown, NSW, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW, Australia; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	Mihrshahi, S (reprint author), Childrens Hosp, Clin Epidemiol Unit, Locked Bag 4001, Westmead, NSW 2145, Australia.	seemann@chw.edu.au	Mihrshahi, Seema/A-9877-2009; Osborne, Nicholas/N-4915-2015; Tovey, Euan/G-8604-2017	Mihrshahi, Seema/0000-0001-6567-9884; Osborne, Nicholas/0000-0002-6700-2284; Tovey, Euan/0000-0002-1802-7266			Arntzen KJ, 1998, PROSTAG OTH LIPID M, V56, P183, DOI 10.1016/S0090-6980(98)00048-3; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; CALDER PC, 1908, CLIN EXP ALLERG, V33, P412; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; Chang AB, 1999, ARCH DIS CHILD, V80, P211; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Ewart HS, 2002, J NUTR, V132, P1149; Faniran AO, 1998, ARCH DIS CHILD, V79, P411; Gore Claudia, 2003, Paediatr Respir Rev, V4, P213, DOI 10.1016/S1526-0542(03)00055-1; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; HALMERBAUER G, 2002, PEDIAT ALLERGY I S15, V3, P47; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Mantzioris E, 2000, AM J CLIN NUTR, V72, P42; Martinez FD, 1999, ALLERGY, V54, P24, DOI 10.1111/j.1398-9995.1999.tb04384.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2003, ALLERGY, V58, P784, DOI 10.1034/j.1398-9995.2003.00194.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; National Asthma Council Australia, 2002, ASTHM MAN HDB; Oddy WH, 2004, J ASTHMA, V41, P319, DOI 10.1081/JAS-120026089; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Ponsonby AL, 2002, J CLIN EPIDEMIOL, V55, P556, DOI 10.1016/S0895-4356(01)00519-4; Raatz SK, 2001, J NUTR, V131, P231; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; SCHWARTZ J, 2000, AM J CLIN NUTR S, V71, P393; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SHAHAR E, 1994, NEW ENGL J MED, V331, P228, DOI 10.1056/NEJM199407283310403; STONE R, 1992, J APPL PHYSIOL, V73, P649; Warner JO, 1998, PEDIATR PULM, V25, P1	31	140	147	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					807	813		10.1016/j.jaci.2004.06.057		7	Allergy; Immunology	Allergy; Immunology	861SO	WOS:000224439100013	15480319	
J	Ferreira, F; Hawranek, T; Gruber, P; Wopfner, N; Mari, A				Ferreira, F; Hawranek, T; Gruber, P; Wopfner, N; Mari, A			Allergic cross-reactivity: from gene to the clinic	ALLERGY			English	Review						allergen structure; allergenicity; arthropod allergens; cross-reactive carbohydrate determinant; cross-reactivity; food allergens; immunoglobulin E antibodies; insect venom allergens; latex allergens; pollen allergens	IGE-BINDING EPITOPES; GRASS-POLLEN ALLERGEN; HOUSE-DUST MITE; BET V 1; CONTROLLED FOOD CHALLENGE; MAJOR CHERRY ALLERGEN; LATEX-FRUIT SYNDROME; COWS MILK ALLERGY; BIRD-EGG SYNDROME; PEANUT ALLERGY	A large number of allergenic proteins have now their complete cDNA sequences determined and in some cases also the 3D structures. It turned out that most allergens could be grouped into a small number of structural protein families, regardless of their biological source. Structural similarity among proteins from diverse sources is the molecular basis of allergic cross-reactivity. The clinical relevance of immunoglobulin E (IgE) cross-reactivity seems to be influenced by a number of factors including the immune response against the allergen, exposure and the allergen. As individuals are exposed to a variable number of allergenic sources bearing homologous molecules, the exact nature of the antigenic structure inducing the primary IgE immune response cannot be easily defined. In general, the 'cross-reactivity' term should be limited to defined clinical manifestations showing reactivity to a source without previous exposure. 'Co-recognition', including by definition 'cross-reactivity', could be used to describe the large majority of the IgE reactivity where co-exposure to a number of sources bearing homologous molecules do not allow unequivocal identification of the sensitizing molecule. The analysis of reactivity clusters in diagnosis allows the interpretation of the patient's reactivity profile as a result of the sensitization process, which often begins with exposure to a single allergenic molecule.	Salzburg Univ, Inst Genet & Allgemeine Biol, Dept Genet & Gen Biol, A-5020 Salzburg, Austria; Landeskliniken Salzburg, Dept Dermatol, Salzburg, Austria; Natl Hlth Serv, Allergy Unit, Rome, Italy	Ferreira, F (reprint author), Salzburg Univ, Inst Genet & Allgemeine Biol, Dept Genet & Gen Biol, Hellbrunnerstr 34, A-5020 Salzburg, Austria.		Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335			Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Anibarro B, 2000, J ALLERGY CLIN IMMUN, V105, P834, DOI 10.1067/mai.2000.104547; Anibarro B, 1997, J ALLERGY CLIN IMMUN, V100, P734, DOI 10.1016/S0091-6749(97)70266-5; Arena A, 2000, Allergol Immunopathol (Madr), V28, P287; Armentia A, 2001, CLIN EXP ALLERGY, V31, P1250, DOI 10.1046/j.1365-2222.2001.01142.x; Asero R, 1998, CLIN EXP ALLERGY, V28, P1368, DOI 10.1046/j.1365-2222.1998.00399.x; Asero R, 2000, ANN ALLERG ASTHMA IM, V84, P460; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Asero R, 2001, J ALLERGY CLIN IMMUN, V108, P309, DOI 10.1067/mai.2001.116983; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201; Ball T, 1999, INT ARCH ALLERGY IMM, V118, P208, DOI 10.1159/000024070; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Barkholt V, 1998, ALLERGY, V53, P106; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Bauer A, 1999, ALLERGY, V54, P894, DOI 10.1034/j.1398-9995.1999.00228.x; Bausela BA, 1997, ANN ALLERG ASTHMA IM, V78, P213; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; Bellioni-Businco B, 1999, J ALLERGY CLIN IMMUN, V103, P1191, DOI 10.1016/S0091-6749(99)70198-3; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Bousquet J, 1998, ALLERGY, V53, P3; Boyano Martinez T., 2001, Clinical and Experimental Allergy, V31, P1464, DOI 10.1046/j.1365-2222.2001.01175.x; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Brusic V, 2003, TRENDS IMMUNOL, V24, P225, DOI 10.1061/S1471-4906(03)00075-9; BUBLIN M, 2003, FASEB J; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Businco L, 2000, J ALLERGY CLIN IMMUN, V105, P1031, DOI 10.1067/mai.2000.106377; Cadot P, 2001, ALLERGY, V56, P192, DOI 10.1034/j.1398-9995.2001.056002192.x; Cahen YD, 1998, CLIN EXP ALLERGY, V28, P1026, DOI 10.1046/j.1365-2222.1998.00356.x; Cambra O, 1996, IMMUNOL LETT, V50, P173, DOI 10.1016/0165-2478(96)02539-4; Carlsen KCL, 2002, ALLERGY, V57, P529, DOI 10.1034/j.1398-9995.2002.13305.x; Chang CY, 2002, J BIOMED SCI, V9, P645, DOI 10.1159/000067279; Cheong N, 2003, ALLERGY, V58, P352, DOI 10.1034/j.1398-9995.2003.00033.x; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; Colombo P, 1998, J IMMUNOL, V160, P2780; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Dauby PAL, 2002, ANN ALLERG ASTHMA IM, V89, P319; De Swert LFA, 2002, J ALLERGY CLIN IMMUN, V110, P524, DOI 10.1067/mai.2002.127435; DEGROOT H, 1990, J ALLERGY CLIN IMMUN, V86, P107; DEMAATBLEEKER F, 1995, ALLERGY, V50, P438; DEMAATBLEEKER F, 1985, ANN ALLERGY, V54, P245; Diez-Gomez ML, 1998, ANN ALLERG ASTHMA IM, V80, P24; DOMON C, 1990, PLANT MOL BIOL, V15, P643, DOI 10.1007/BF00017838; Drouet M, 1996, MONOGR ALLERGY, V32, P164; ERBEN AM, 1993, J ALLERGY CLIN IMMUN, V92, P846, DOI 10.1016/0091-6749(93)90062-K; Fanta C, 1998, ALLERGY, V53, P539, DOI 10.1111/j.1398-9995.1998.tb04095.x; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Fernandez-Rivas M, 1999, CLIN EXP ALLERGY, V29, P1239, DOI 10.1046/j.1365-2222.1999.00628.x; Ferreira F, 1998, FASEB J, V12, P231; Ferreira F, 2000, J ALLERGY CLIN IMMUN, V105, pS137, DOI 10.1016/S0091-6749(00)90842-X; Ferreira F, 2002, INT ARCH ALLERGY IMM, V128, P171, DOI 10.1159/000064249; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Fiocchi A, 1998, ALLERGY, V53, P798; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Flicker S, 2000, J IMMUNOL, V165, P3849; Fluckiger S, 2002, INT ARCH ALLERGY IMM, V128, P292, DOI 10.1159/000063862; Foetisch K, 2003, J ALLERGY CLIN IMMUN, V111, P889, DOI 10.1067/mai.2003.173; Furmonaviciene R, 2001, J CLIN PATHOL-MOL PA, V54, P155, DOI 10.1136/mp.54.3.155; GALL H, 1994, J ALLERGY CLIN IMMUN, V94, P70, DOI 10.1016/0091-6749(94)90073-6; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P63, DOI 10.1016/S1043-4526(08)60093-5; Gendel SM, 2002, ANN NY ACAD SCI, V964, P87; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171; Gold MS, 2003, J PAEDIATR CHILD H, V39, P376, DOI 10.1046/j.1440-1754.2003.00156.x; Gonzalez EM, 2002, MOL IMMUNOL, V39, P93, DOI 10.1016/S0161-5890(02)00044-5; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Gupta N, 1996, J ALLERGY CLIN IMMUN, V98, P903, DOI 10.1016/S0091-6749(96)80006-6; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; Hanninen AR, 1999, J ALLERGY CLIN IMMUN, V104, P194, DOI 10.1016/S0091-6749(99)70135-1; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; HENZGEN M, 1991, ALLERGOLOGIE, V14, P90; Herrera I, 2002, ALLERGY, V57, P261, DOI 10.1034/j.1398-9995.2002.1n3547.x; HERRMANN D, 1995, J INVEST ALLERG CLIN, V5, P259; Hileman RE, 2002, INT ARCH ALLERGY IMM, V128, P280, DOI 10.1159/000063861; HIMLY M, 2002, FASEB J, V17, P106; HOFFMAN DR, 1986, J ALLERGY CLIN IMMUN, V78, P337, DOI 10.1016/S0091-6749(86)80086-0; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Hoffmann-Sommergruber K, 2002, BIOCHEM SOC T, V30, P930, DOI 10.1042/BST0300930; Hourihane J, 2001, Arch Dis Child, V85, P510; Iacovacci P, 2001, CLIN EXP ALLERGY, V31, P458, DOI 10.1046/j.1365-2222.2001.01019.x; IBANEZ MD, 1999, ALLERGY, V54, P1209; Ivanciuc O, 2003, NUCLEIC ACIDS RES, V31, P359, DOI 10.1093/nar/gkg010; Ivanciuc O, 2002, BIOINFORMATICS, V18, P1358, DOI 10.1093/bioinformatics/18.10.1358; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Karisola P, 2002, J BIOL CHEM, V277, P22656, DOI 10.1074/jbc.M201076200; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; KELSO JM, 1995, ANN ALLERG ASTHMA IM, V74, P391; Kelso JM, 1999, J ALLERGY CLIN IMMUN, V104, P202, DOI 10.1016/S0091-6749(99)70136-3; Kemp AS, 2003, J PAEDIATR CHILD H, V39, P372, DOI 10.1046/j.1440-1754.2003.00157.x; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; Kleter Gijs A, 2002, BMC Struct Biol, V2, P8, DOI 10.1186/1472-6807-2-8; Krebitz M, 2003, J MOL BIOL, V329, P721, DOI 10.1016/S0022-2836(03)00403-0; Lai HY, 2002, INT ARCH ALLERGY IMM, V127, P181, DOI 10.1159/000053862; LANGELAND T, 1983, ALLERGY, V38, P399; Lepp U, 2002, ALLERGY, V57, P864, DOI 10.1034/j.1398-9995.2002.23575_7.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Lombardero M, 2002, ALLERGY, V57, P29, DOI 10.1034/j.1398-9995.2002.057s71029.x; Lombardi C, 2000, ALLERGY, V55, P677, DOI 10.1034/j.1398-9995.2000.00687.x; LOVELESS MH, 1950, J ALLERGY, V21, P500, DOI 10.1016/0021-8707(50)90098-0; LU G, 1995, J BIOL CHEM, V270, P4457; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; Maglio O, 2002, PROTEIN ENG, V15, P635, DOI 10.1093/protein/15.8.635; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; MANDALLAZ MM, 1988, INT ARCH ALLER A IMM, V87, P143; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Mari A, 2003, CLIN EXP ALLERGY, V33, P1419, DOI 10.1046/j.1365-2222.2003.01773.x; Mari A, 2003, CLIN EXP ALLERGY, V33, P1429, DOI 10.1046/j.1365-2222.2003.01783.x; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Matsumoto T, 2002, ALLERGY, V57, P926, DOI 10.1034/j.1398-9995.2002.23606.x; Matsumoto T, 2001, ALLERGY, V56, P247, DOI 10.1034/j.1398-9995.2001.056003247.x; Meglio P, 2002, ALLERGY, V57, P868, DOI 10.1034/j.1398-9995.2002.23575_12.x; Mellon MB, 2002, J IMMUNOL, V168, P290; Mempel M, 2003, J ALLERGY CLIN IMMUN, V111, P1406, DOI 10.1067/mai.2003.1497; Midoro-Horiuti T, 2001, ANN ALLERG ASTHMA IM, V87, P261; Mirza O, 2000, J IMMUNOL, V165, P331; Modrzynski Marek, 2002, Przegl Lek, V59, P1007; Mogensen JE, 2002, J BIOL CHEM, V277, P23684, DOI 10.1074/jbc.M202065200; MOLLER C, 1989, ANN ALLERGY, V62, P343; Moneret-Vautrin DA, 2001, ALLERGY, V56, P1071, DOI 10.1034/j.1398-9995.2001.00047.x; Monti G, 2002, CLIN EXP ALLERGY, V32, P1515, DOI 10.1046/j.1365-2745.2002.01454.x; MRAIHI ML, 1989, REV FR ALLERGOL, V29, P187, DOI 10.1016/S0335-7457(89)80017-6; Muller UR, 2002, ALLERGY, V57, P570, DOI 10.1034/j.1398-9995.2002.02157.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Neudecker P, 2001, J BIOL CHEM, V276, P22756, DOI 10.1074/jbc.M101657200; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; ORTOLANI C, 1993, ANN ALLERGY, V71, P470; Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V101, P531, DOI 10.1016/S0091-6749(98)70360-4; Patriarca G, 1998, HEPATO-GASTROENTEROL, V45, P52; Perez-Calderon R, 2002, ALLERGY, V57, P752, DOI 10.1034/j.1398-9995.2002.23787.x; Perez-Pimiento AJ, 1999, ALLERGY, V54, P626, DOI 10.1034/j.1398-9995.1999.00806.x; Peroni DG, 2000, PEDIATR ALLERGY IMMU, V11, P260, DOI 10.1034/j.1399-3038.2000.00001.x; Pires G, 2002, ALLERGY, V57, P957, DOI 10.1034/j.1398-9995.2002.23832_2.x; Poulsen LK, 2001, ALLERGY, V56, P39, DOI 10.1034/j.1398-9995.2001.00912.x; Pumphrey RSH, 2000, LANCET, V355, P1099, DOI 10.1016/S0140-6736(05)72220-0; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Restani P, 1999, CLIN EXP ALLERGY, V29, P997, DOI 10.1046/j.1365-2222.1999.00563.x; Rihs HP, 1999, J ALLERGY CLIN IMMUN, V104, P1293; Robotham JM, 2002, J ALLERGY CLIN IMMUN, V109, P143, DOI 10.1067/mai.2002.120558; Rueff F, 2001, ALLERGY, V56, P82, DOI 10.1034/j.1398-9995.2001.00936.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, PEDIATR ALLERGY IMMU, V12, P91, DOI 10.1034/j.1399-3038.2001.121420.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sanchez-Hernandez MC, 2000, ALLERGY, V55, P297, DOI 10.1034/j.1398-9995.2000.00460.x; Scheurer S, 2000, CLIN EXP ALLERGY, V30, P962, DOI 10.1046/j.1365-2222.2000.00821.x; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Schramm G, 1999, J IMMUNOL, V162, P2406; Sicherer SH, 2000, ALLERGY, V55, P515, DOI 10.1034/j.1398-9995.2000.00119.x; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Sidenius KE, 2001, ALLERGY, V56, P723, DOI 10.1034/j.1398-9995.2001.056008723.x; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Spuergin P, 1997, ALLERGY, V52, P293, DOI 10.1111/j.1398-9995.1997.tb00993.x; Stadler MB, 2003, FASEB J, V17, P1141, DOI 10.1096/fj.02-1052fje; Steinman HA, 1996, J ALLERGY CLIN IMMUN, V98, P241, DOI 10.1016/S0091-6749(96)70146-X; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; Suphioglu C, 1998, MOL IMMUNOL, V35, P293, DOI 10.1016/S0161-5890(98)00050-9; SUSSMAN GL, 2002, J ALLERGY CLIN IMMUN, V110, DOI UNSP S033-S039; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; Swoboda I, 2002, J IMMUNOL, V168, P4576; SZEPFALUSI Z, 1993, INT ARCH ALLERGY IMM, V102, P288; SZEPFALUSI Z, 1994, J ALLERGY CLIN IMMUN, V93, P932, DOI 10.1016/0091-6749(94)90388-3; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; TEE RD, 1993, CLIN EXP ALLERGY, V23, P257, DOI 10.1111/j.1365-2222.1993.tb00319.x; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Tinghino R, 2002, J ALLERGY CLIN IMMUN, V109, P314, DOI 10.1067/mai.2002.121528; Unsworth DJ, 2001, ARCH DIS CHILD, V84, P410, DOI 10.1136/adc.84.5.410; Vadas P, 2003, J ALLERGY CLIN IMMUN, V112, P175, DOI 10.1067/mai.2003.1480; VALDIVIESO R, 1994, J ALLERGY CLIN IMMUN, V94, P928, DOI 10.1016/0091-6749(94)90161-9; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Van Durme P, 2003, J ALLERGY CLIN IMMUN, V112, P452, DOI 10.1067/mai.2003.1613; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; van Ree R, 2002, BIOCHEM SOC T, V30, P910; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; vanRee R, 1996, ALLERGY, V51, P108; Verma J, 2003, INT ARCH ALLERGY IMM, V130, P193, DOI 10.1159/000069518; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wagner S, 2002, BIOCHEM SOC T, V30, P935, DOI 10.1042/BST0300935; Wagner S, 2001, INT ARCH ALLERGY IMM, V125, P120, DOI 10.1159/000053805; Wagner S, 2000, EUR J BIOCHEM, V267, P7006, DOI 10.1046/j.1432-1327.2000.01801.x; Wal JM, 2002, ANN ALLERG ASTHMA IM, V89, P3; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Warner JO, 2002, PEDIATR ALLERGY IMMU, V13, P149, DOI 10.1034/j.1399-3038.2002.00059.x; Weber RW, 2003, J ALLERGY CLIN IMMUN, V112, P229, DOI 10.1067/mai.2003.1683; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Werfel SJ, 1997, J ALLERGY CLIN IMMUN, V99, P293, DOI 10.1016/S0091-6749(97)70045-9; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P1401; WYSS M, 1996, NAHRUNGSMITTEL ALLER, P218; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379; Yagami T, 2002, INT ARCH ALLERGY IMM, V128, P271, DOI 10.1159/000063859; ZORZET A, 2002, IN SILICO BIOL, V2	219	140	150	3	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	MAR	2004	59	3					243	267		10.1046/j.1398-9995.2003.00407.x		25	Allergy; Immunology	Allergy; Immunology	774NA	WOS:000188988300001	14982506	
J	Mcmillan, SJ; Lloyd, CM				Mcmillan, SJ; Lloyd, CM			Prolonged allergen challenge in mice leads to persistent airway remodelling	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						airway remodelling; allergic airway inflammation; asthma; eosinophils; Th2 cytokines	BRONCHIAL EPITHELIAL-CELLS; MOUSE ASTHMA MODEL; GROWTH-FACTOR-BETA; MURINE MODEL; SUBEPITHELIAL FIBROSIS; INTERFERON-GAMMA; TRANSFORMING GROWTH-FACTOR-BETA-1; GENE-EXPRESSION; ATOPIC ASTHMA; IN-VITRO	Background Inflammatory infiltrates, airway hyper-responsiveness, goblet cell hyperplasia and subepithelial thickening are characteristic of chronic asthma. Current animal models of allergen-induced airway inflammation generally concentrate on the acute inflammation following allergen exposure and fail to mimic all of these features. Objective The aim of this study was to use a murine model of prolonged allergen-induced airway inflammation in order to characterize the cells and molecules involved in the ensuing airway remodelling. Moreover, we investigated whether remodelling persists in the absence of continued allergen challenge. Methods Acute pulmonary eosinophilia and airways hyper-reactivity were induced after six serial allergen challenges in sensitized mice (acute phase). Mice were subsequently challenged three times a week with ovalbumin (OVA) (chronic phase) up to day 55. To investigate the persistence of pathology, one group of mice were left for another 4 weeks without further allergen challenge (day 80). Results The extended OVA challenge protocol caused significant airway remodelling, which was absent in the acute phase. Specifically, remodelling was characterized by deposition of collagen as well as airway smooth muscle and goblet cell hyperplasia. Importantly, these airway changes, together with tissue eosinophilia were sustained in the absence of further allergen challenge. Examination of cytokines revealed a dramatic up-regulation of IL-4 and tumour growth factor-beta1 during the chronic phase. Interestingly, while IL-4 levels were significantly increased during the chronic phase, levels of IL-13 fell. Levels of the Th1-associated cytokine IFN-gamma also increased during the chronic phase. Conclusion In conclusion, we have demonstrated that prolonged allergen challenge results in persistent airway wall remodelling.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Leukocyte Biol Sect, Div Biomed Sci, London SW7 2AZ, England	Lloyd, CM (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Leukocyte Biol Sect, Div Biomed Sci, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk			Wellcome Trust [087618, 057704]		Blyth DI, 2000, AM J RESP CELL MOL, V23, P241; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291; CHAKIR J, 2003, ALLERGY CLIN IMMUNOL, V111, P1293; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Dunhill M, 1969, THORAX, V24, P176; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gharaee-Kermani M, 2001, CYTOKINE, V15, P138, DOI 10.1006/cyto.2001.0903; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; HARTNELL A, 1993, IMMUNOLOGY, V80, P281; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Hoshino M, 1998, THORAX, V53, P21; Huaux F, 2003, J IMMUNOL, V170, P2083; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Lloyd CM, 2001, J IMMUNOL, V166, P2033; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; Magnan A, 1997, CLIN EXP ALLERGY, V27, P389; McKenzie ANJ, 2000, PHARMACOL THERAPEUT, V88, P143, DOI 10.1016/S0163-7258(00)00088-7; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; Moir LM, 2003, AM J PHYSIOL-LUNG C, V284, pL148, DOI 10.1152/ajplung.00105.2002; Ohno I, 1996, AM J RESP CELL MOL, V15, P404; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Richter A, 2001, AM J RESP CELL MOL, V25, P385; ROCHE WR, 1989, LANCET, V1, P520; Sempowski GD, 1996, J CELL PHYSIOL, V167, P290, DOI 10.1002/(SICI)1097-4652(199605)167:2<290::AID-JCP13>3.0.CO;2-C; Tanaka H, 2001, INFLAMM RES, V50, P616, DOI 10.1007/PL00000243; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temelkovski J, 1998, THORAX, V53, P849; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; WANNER A, 1990, CHEST S, V97, P11; Wen FQ, 2002, AM J RESP CELL MOL, V26, P484; Wenzel SE, 2002, J IMMUNOL, V169, P4613; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang SL, 1999, LAB INVEST, V79, P395; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	49	140	151	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2004	34	3					497	507		10.1111/j.1365-2222.2004.01895.x		11	Allergy; Immunology	Allergy; Immunology	801LY	WOS:000220098600025	15005746	
J	Pronovost, P; Weast, B; Schwarz, M; Wyskiel, RM; Prow, D; Milanovich, SN; Berenholtz, S; Dorman, T; Lipsett, P				Pronovost, P; Weast, B; Schwarz, M; Wyskiel, RM; Prow, D; Milanovich, SN; Berenholtz, S; Dorman, T; Lipsett, P			Medication reconciliation: A practical tool to reduce the risk of medication errors	JOURNAL OF CRITICAL CARE			English	Article							ACUTE MYOCARDIAL-INFARCTION; HOSPITALIZED-PATIENTS; EVENTS; DISEASE	Preventable adverse drug events are associated with one out of five injuries or deaths. Estimates reveal that 46% of medication errors occur on admission or discharge from a clinical unit/hospital when patient orders are written. This study was performed to reduce medication errors in patient's discharge orders through a reconciliation process in an adult surgical intensive care unit (ICU). A discharge survey was implemented as part of the medication reconciliation process. The admitting nurse initiated the survey within 24 hours of ICU admission and the charge nurse completed the survey on discharge. Baseline data were obtained through a random sampling of 10% of discharges in first 2 weeks of the study (July 2001-May 2002). Medical and anesthesia records were reviewed, allergies and home medications verified with patient/family and findings compared with orders at time of ICU discharge. Baseline data revealed that 31 of 33 (94%) patients had orders changed. By week 24, nearly all medication errors in discharge orders were eliminated. In conclusion, use of the discharge survey in this medication reconciliation process resulted in a dramatic drop in medications errors for patients discharged from an ICU. The survey is now a part of our electronic medical record and used in 4 adult ICUs and 2 medicine floors. (C) 2003 Elsevier Inc. All rights reserved.	Johns Hopkins Univ, Dept Anesthesiol & Crit Care Med Surg, Baltimore, MD USA	Pronovost, P (reprint author), 901 S Bond St,Suite 318, Baltimore, MD 21231 USA.						*AHA, 2003, HEART STROK FACTS 20; Agency for Healthcare Research and Quality (AHRQ), 2002, TRANSL RES PRACT RED; Bates DW, 1997, JAMA-J AM MED ASSOC, V277, P307, DOI 10.1001/jama.277.4.307; Boersma E, 2001, JAMA-J AM MED ASSOC, V285, P1865, DOI 10.1001/jama.285.14.1865; Braunstein J B, 2001, Cardiol Rev, V9, P96, DOI 10.1097/00045415-200103000-00008; FROLKIS J, 1999, CIRCULATION, V95, P851; KOHN L, 1999, MTO ERR IS HUMAN BUI; Langley G, 1996, IMPROVEMENT GUIDE PR; LEAPE LL, 1991, NEW ENGL J MED, V324, P377, DOI 10.1056/NEJM199102073240605; MANGANO D, 1997, NEW ENGL J MED, V335, P1713; Newby LK, 2000, NEW ENGL J MED, V342, P749, DOI 10.1056/NEJM200003163421101; *NTSB, 2002, WE ARE ALL SAF NTSB; PILOTE L, 1995, NEW ENGL J MED, V333, P565, DOI 10.1056/NEJM199508313330907; Reason J, 2000, BRIT MED J, V320, P786; SEXTON JB, 2001, P 11 INT S AV PSYCH; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Sueta CA, 1999, AM J CARDIOL, V83, P1303, DOI 10.1016/S0002-9149(99)00117-4	17	140	145	5	22	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0883-9441			J CRIT CARE	J. Crit. Care	DEC	2003	18	4					201	205		10.1016/S0883-9441(03)00108-4		5	Critical Care Medicine	General & Internal Medicine	759BG	WOS:000187717500001	14691892	
J	Utell, MJ; Frampton, MW				Utell, MJ; Frampton, MW			Acute health effects of ambient air pollution: The ultrafine particle hypothesis	JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG			English	Article; Proceedings Paper	12th International Congress of the Internatioanl-Society-for-Aerosols-in-Medicine (ISAM)	JUN 12-16, 1999	VIENNA, AUSTRIA	Int Soc Aerosols Med		air pollution; particulate matter; ultrafine particles	MORTALITY	A strong and consistent association has been observed between adjusted mortality rates and ambient particle concentration. The strongest associations are seen for respiratory and cardiac deaths, particularly among the elderly. Particulate air pollution is also associated with asthma exacerbations, increased respiratory symptoms, decreased lung function, increased medication use, and increased hospital admissions. The U.S. Environmental Protection Agency (EPA) has recently promulgated a new national ambient air quality standard for fine particles, and yet the mechanisms for health effects at such low particle mass concentrations remain unclear. Hypotheses to identify the responsible particles have focused on particle acidity, particle content of transition metals, bioaerosols, and ultrafine particles. Because ultrafine particles are efficiently deposited in the respiratory tract and may be important in initiating airway inflammation, we have initiated clinical studies with ultrafine carbon particles in healthy subjects. These studies examine the role of ultrafines in: (1) the induction of airway inflammation; (2) expression of leukocyte and endothelial adhesion molecules in blood; (3) the alteration of blood coagulability; and (4) alteration in cardiac electrical activity. These events could lead to exacerbation of underlying cardiorespiratory disease. For example, airway inflammation may activate endothelium and circulating leukocytes, and induce a systemic acute phase response with transient hypercoagulability; this could explain the epidemiologic linkages between pollutant exposures and cardiovascular events. These approaches should be useful in identifying mechanisms for pollutant-induced respiratory and systemic effects, and in providing data for determining appropriate air quality standards.	Univ Rochester, Med Ctr, Dept Med, Pulm Unit, Rochester, NY 14642 USA	Utell, MJ (reprint author), Univ Rochester, Med Ctr, Dept Med, Pulm Unit, Box 692,601 Elmwood Ave, Rochester, NY 14642 USA.						Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BOSCIA JA, 2000, AM J RESP CRIT CARE, V161, pA239; BRAND P, 1991, ATMOS ENVIRON A-GEN, V25, P581, DOI 10.1016/0960-1686(91)90055-C; BRAND P, 1992, ATMOS ENVIRON A-GEN, V26, P2541; CAMPEN MJ, 1997, AM J RESP CRIT CARE, V155, pA247; COLOME SD, 1992, ATMOS ENVIRON A-GEN, V26, P2173, DOI 10.1016/0960-1686(92)90405-A; FRAMPTON MW, 2000, PARTICLE LUNG INTERA, P653; FRAMPTON MW, 2000, AM J RESP CRIT CARE, V161, pA257; Godleski J. J., 2000, 91 HLTH EFF I; International Committee on Radiological Protection, 1994, HUM RESP TRACT MOD R; Lioy PJ, 1999, J AIR WASTE MANAGE, V49, P200, DOI 10.1080/10473289.1999.10463789; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; Mauderly J, 1998, ATMOSPHERIC OBSERVATIONS: HELPING BUILD THE SCIENTIFIC BASIS FOR DECISIONS RELATED TO AIRBORNE PARTICULATE MATTER, P9; *NAT RES COUNC, 1998, RES PRIOR AIRB PART, V1, P44; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Oberdorster G, 1994, ANN OCCUP HYG     S1, V38, P295; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; PETERS A, 1998, AM J RESP CRIT CARE, V157, P880; Petersen LJ, 1997, NEPHROL DIAL TRANSPL, V12, P1376, DOI 10.1093/ndt/12.7.1376; Riesenfeld E, 2000, INHAL TOXICOL, V12, P83, DOI 10.1080/08958378.2000.11463201; Salmi M, 1997, ADV IMMUNOL, V64, P139, DOI 10.1016/S0065-2776(08)60889-5; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6	22	140	145	2	29	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0894-2684			J AEROSOL MED	J. Aerosol Med.-Depos. Clear. Eff. Lung	WIN	2000	13	4					355	359		10.1089/jam.2000.13.355		5	Public, Environmental & Occupational Health; Respiratory System	Public, Environmental & Occupational Health; Respiratory System	395UH	WOS:000166599300005	11262441	
J	Hofmann, AM; Scurlock, AM; Jones, SM; Palmer, KP; Lokhnygina, Y; Steele, PH; Kamilaris, J; Burks, AW				Hofmann, Alison M.; Scurlock, Amy M.; Jones, Stacie M.; Palmer, Kricia P.; Lokhnygina, Yuliya; Steele, Pamela H.; Kamilaris, Janet; Burks, A. Wesley			Safety of a peanut oral immunotherapy protocol in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut; food allergy; oral immunotherapy	TREE NUT ALLERGY; ANAPHYLACTIC REACTIONS; TOLERANCE INDUCTION; EGG ALLERGY; FOOD; DESENSITIZATION	Background: Oral immunotherapy (OIT) offers a promising therapeutic option for peanut allergy. Given that during OIT an allergic patient ingests an allergen that could potentially cause a serious reaction, the safety of OIT is of particular concern. Objective: The purpose of this study was to examine safety during the initial escalation day, buildup phase, and home dosing phase in subjects enrolled in a peanut OIT study. Methods: Skin, upper respiratory tract, chest, and abdominal symptoms were recorded with initial escalation day and buildup phase dosings. Subjects also maintained daily diaries detailing symptoms after each home dosing. A statistical analysis of these data was performed. Results: Twenty of 28 patients completed all phases of the study. During the initial escalation day, upper respiratory tract (79%) and abdominal (68%) symptoms were the most likely symptoms experienced. The risk of mild wheezing during the initial escalation day was 18%. The probability of having any symptoms after a buildup phase dose was 46%, with a risk of 29% for upper respiratory tract symptoms and 24% for skin symptoms. The risk of reaction with any home dose was 3.5%. Upper respiratory tract (1.2%) and skin (1.1%) symptoms were the most likely after home doses. Treatment was given with 0.7% of home doses. Two subjects received epinephrine after I home dose each. Conclusions: Subjects were more likely to have significant allergic symptoms during the initial escalation day when they were in a closely monitored setting than during other phases of the study. Allergic reactions with home doses were rare. (J Allergy Clin Immunol 2009;124:286-91.)	[Hofmann, Alison M.; Steele, Pamela H.; Kamilaris, Janet; Burks, A. Wesley] Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA; [Scurlock, Amy M.; Jones, Stacie M.; Palmer, Kricia P.] Univ Arkansas, Dept Pediat, Div Allergy & Immunol, Little Rock, AR 72204 USA; [Lokhnygina, Yuliya] Duke Univ, Dept Biostat & Bioinformat, Durham, NC 27706 USA	Burks, AW (reprint author), Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Box 2644, Durham, NC 27710 USA.	wesley.burks@duke.edu			Food Allergy and Anaphylaxis Network; Gerber Foundation; Food Allergy Project; Dorothy and Frank Robins Family Foundation; National Center for Research Resources (NCRR) [1 UL 1 RR024128-01]; National Institutes of Health (NIH); NIH Roadmap for Medical Research	Supported by the Food Allergy and Anaphylaxis Network, the Gerber Foundation, the Food Allergy Project, and the Dorothy and Frank Robins Family Foundation. The project described was supported by grant no. 1 UL 1 RR024128-01 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) and NIH Roadmap for Medical Research, and its contents are solely the responsibility of the authors and do not necessarily represent the official view of NCRR or NIH.	Allen CW, 2007, J PAEDIATR CHILD H, V43, P214, DOI 10.1111/j.1440-1754.2007.00996.x; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Fleischer DM, 2007, CURR ALLERGY ASTHM R, V7, P175, DOI 10.1007/s11882-007-0018-y; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; *INT TREE NUT COUN, NUTR 1 OUNC TREE NUT; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; King N, 2005, MOL NUTR FOOD RES, V49, P963, DOI 10.1002/mnfr.200500073; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Mansfield L, 2006, ANN ALLERG ASTHMA IM, V97, P266; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; Patriarca G, 2006, DIGEST DIS SCI, V51, P471, DOI 10.1007/s10620-006-3157-4; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	21	139	139	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2009	124	2					286	291		10.1016/j.jaci.2009.03.045		6	Allergy; Immunology	Allergy; Immunology	482CD	WOS:000268860400015	19477496	
J	Joubert, E; Gelderblom, WCA; Louw, A; de Beer, D				Joubert, E.; Gelderblom, W. C. A.; Louw, A.; de Beer, D.			South African herbal teas: Aspalathus linearis, Cyclopia spp. and Athrixia phylicoides-A review	JOURNAL OF ETHNOPHARMACOLOGY			English	Review						Anticarcinogenic; Antioxidant; Bush tea; Chemical composition; Honeybush; Phyto-oestrogenic; Polyphenols; Rooibos	CAMELLIA-SINENSIS TEAS; ANTIOXIDANT ACTIVITY RELATIONSHIPS; BATCH EXTRACTION CONDITIONS; MAJOR PHENOLIC-COMPOUNDS; FIXED-BED EXTRACTION; ROOIBOS TEA; HONEYBUSH TEA; AQUEOUS EXTRACTS; BUSH TEA; IN-VITRO	Rooibos (Aspalathus linearis (Brum.f) Dahlg.) and honeybush (Cyclopia Vent. species) are popular indigenous South African herbal teas enjoyed for their taste and aroma. Traditional medicinal uses of rooibos in South Africa include alleviation of infantile colic, allergies, asthma and dermatological problems, while a decoction of honeybush was used as a restorative and as an expectorant in chronic catarrh and pulmonary tuberculosis. Traditional medicinal uses of Athrixia phylicoides DC., or bush tea, another indigenous South African plant with very limited localised use as herbal tea, include treatment of boils, acne, infected wounds and infected throats. Currently rooibos and honeybush are produced for the herbal tea market, while bush tea has potential for commercialisation. A summary of the historical and modern uses, botany, distribution, industry and chemical composition of these herbal teas is presented. A comprehensive discussion of in vitro, ex vivo and in vivo biological properties, required to expand their applications as nutraceutical and cosmeceutical products, is included, with the main emphasis on rooibos. Future research needs include more comprehensive chemical characterisation of extracts, identification of marker compounds for extract standardisation and quality control, bioavailability and identification of bio-markers of dietary exposure, investigation of possible herb-drug interactions and plant improvement with regards to composition and bioactivity. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Joubert, E.; de Beer, D.] ARC Infruitec Nietvoorbij, Post Harvest & Wine Technol Div, ZA-7599 Stellenbosch, South Africa; [Joubert, E.] Univ Stellenbosch, Dept Food Sci, ZA-7602 Matieland, South Africa; [Gelderblom, W. C. A.] MRC, PROMEC Unit, ZA-7505 Bellville, South Africa; [Gelderblom, W. C. A.; Louw, A.] Univ Stellenbosch, Dept Biochem, ZA-7602 Matieland, South Africa	Joubert, E (reprint author), ARC Infruitec Nietvoorbij, Post Harvest & Wine Technol Div, Private Bag X5026, ZA-7599 Stellenbosch, South Africa.	joubertL@arc.agric.za	Louw, Ann/A-7620-2012	Louw, Ann/0000-0002-1021-6732; De Beer, Dalene/0000-0002-3680-142X; Joubert, Elizabeth/0000-0002-9717-9769			Adlercreutz H, 1997, ANN MED, V29, P95; AKAIKE T, 1995, J AGR FOOD CHEM, V43, P1864, DOI 10.1021/jf00055a021; Almajano MP, 2008, FOOD CHEM, V108, P55, DOI 10.1016/j.foodchem.2007.10.040; AMIN A, 2007, RECENT PAT ANTI-CANC, V2, P1; Araya H. T., 2005, THESIS U PRETORIA PR; Baranska M, 2006, ANAL CHEM, V78, P7716, DOI 10.1021/ac061123q; Blommaert K.L.J., 1978, AGROPLANTAE, V10, P49; BOHLMANN F, 1982, PHYTOCHEMISTRY, V21, P1806, DOI 10.1016/0031-9422(82)85073-5; BOHLMANN F, 1977, PHYTOCHEMISTRY, V16, P1773, DOI 10.1016/0031-9422(71)85087-2; BOND P, 1984, PLANTS CAPE FLORA DE, P285; BOTHA M, 2005, THESIS STELLENBOSCH; Bowie J, 1830, S A Q J, Vi, P27; Bramati L, 2003, J AGR FOOD CHEM, V51, P7472, DOI 10.1021/jf0347721; Bramati L, 2002, J AGR FOOD CHEM, V50, P5513, DOI 10.1021/jf025697h; Breet P, 2005, NUTR RES, V25, P983, DOI 10.1016/j.nutres.2005.08.010; Cassidy A, 2000, J SCI FOOD AGR, V80, P1044, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1044::AID-JSFA586>3.3.CO;2-E; CHELLAN N, 2007, PHARM TOX C MAR S AF, P42; CHENEY RALPH H., 1963, ECON BOT, V17, P186, DOI 10.1007/BF02859435; Coetzee G, 2008, S AFR J ENOL VITIC, V29, P33; Coetzee W.H.K., 1953, BOERDERY SUID AFRIKA, V28, P95; Cornwell T, 2004, PHYTOCHEMISTRY, V65, P995, DOI 10.1016/j.phytochem.2004.03.005; DAHLGREN R, 1968, BOT NOTISER, V121, P165; Dahlgren R., 1988, FLORA SO AFRICA, V16, P84; DAHLGREN ROLF, 1964, BOT NOTISER, V117, P188; De Nysschen AM, 1996, BIOCHEM SYST ECOL, V24, P243, DOI 10.1016/0305-1978(95)00100-X; de Beer D, 2007, INDIGENOUS PLANT USE, P30; Dixon RA, 2004, ANNU REV PLANT BIOL, V55, P225, DOI 10.1146/annurev.arplant.55.031903.141729; Dos A, 2005, J SENS STUD, V20, P228, DOI 10.1111/j.1745-459X.2005.00020.x; Du Toit J, 1999, J FOOD QUALITY, V22, P241; du Toit J, 1998, J FOOD PROCESS PRES, V22, P493; Du Toit J, 1999, J SCI FOOD AGR, V79, P2040; du Toit J, 1998, J SCI FOOD AGR, V76, P537; du Toit J, 1998, J SUSTAIN AGR, V12, P67, DOI 10.1300/J064v12n02_06; du Toit R, 2001, TOXICOLOGY, V166, P63, DOI 10.1016/S0300-483X(01)00446-2; Edenharder R, 2002, MUTAT RES-GEN TOX EN, V521, P57, DOI 10.1016/S1383-5718(02)00212-7; Ferreira D, 1998, J AGR FOOD CHEM, V46, P3406, DOI 10.1021/jf980258x; Ferreira D, 1995, P REC DEV TECHN FUND, P73; Fouche G., 2006, PHARMACOLOGYONLINE, V3, P494; Fox F.W., 1982, FOOD VELD EDIBLE WIL, P119; Garg A, 2001, PHYTOTHER RES, V15, P655, DOI 10.1002/ptr.1074; Gilani AH, 2006, BASIC CLIN PHARMACOL, V99, P365, DOI 10.1111/j.1742-7843.2006.pto_507.x; Greenish H., 1881, PHARM J T, V11, P549; Gruner S., 2003, 1 INT C POL HLTH 18, P14; GUARDIA T, 2003, PHARMACOLOGY, V56, P683; HABU T, 1985, J AGR FOOD CHEM, V33, P249, DOI 10.1021/jf00062a024; HESSELING PB, 1979, S AFR MED J, V55, P631; HESSELING PB, 1982, S AFR MED J, V62, P1037; HILLIS WE, 1967, PHYTOCHEMISTRY, V6, P59, DOI 10.1016/0031-9422(67)85008-8; Hitomi E, 1999, J JPN SOC FOOD SCI, V46, P779; HITOMI E, 2004, ITE LETT BATTER NEW, V5, P64; HOFMEYR J, 1922, BOTHALIA, V1, P105; HOLMES DJ, 1995, J GERONTOL A-BIOL, V50, pB59; HUANG M, 2008, PHYTOTHER RES, V22, P669; Hubbe ME, 2000, ROY SOC CH, P242, DOI 10.1533/9781845698188.5.242; HUBBE MH, 2000, THESIS STELLENBOSCH; Hutchings A., 1996, ZULU MED PLANTS INVE; Ichiyama K, 2007, BIOSCIENCE BIOTECHNO, V71, P589; INANAMI O, 1995, NEUROSCI LETT, V196, P85, DOI 10.1016/0304-3940(95)11853-O; ITO A, 1991, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON TEA SCIENCE, P381; Ivanova D, 2005, J ETHNOPHARMACOL, V96, P145, DOI 10.1016/j.jep.2004.08.033; Jaganyi D, 2003, FOOD CHEM, V83, P121, DOI 10.1016/S0308-8146(03)00065-7; Jang EH, 2004, FOOD CHEM TOXICOL, V42, P1749, DOI 10.1016/j.fct.2004.07.001; Joubert E, 1998, J FOOD PROCESS PRES, V22, P405, DOI 10.1111/j.1745-4549.1998.tb00359.x; JOUBERT E, 1990, INT J FOOD SCI TECH, V25, P344; JOUBERT E, 1990, LEBENSM WISS TECHNOL, V23, P178; JOUBERT E, 1990, LEBENSM WISS TECHNOL, V23, P181; Joubert E, 2004, FOOD RES INT, V37, P133, DOI 10.1016/j.foodres.2003.09.011; Joubert E, 2005, J AGR FOOD CHEM, V53, P10260, DOI 10.1021/jf051355a; JOUBERT E, 1990, INT J FOOD SCI TECH, V25, P339; Joubert E, 2003, EUR FOOD RES TECHNOL, V216, P270, DOI 10.1007/s00217-002-0644-5; Joubert E, 1995, INT J FOOD SCI TECH, V30, P783; JOUBERT E, 1988, INT J FOOD SCI TECH, V23, P43; Joubert E, 1996, FOOD CHEM, V55, P403, DOI 10.1016/0308-8146(95)00166-2; Joubert E, 1997, INT J FOOD SCI TECH, V32, P127, DOI 10.1046/j.1365-2621.1997.00388.x; Joubert E, 1984, THESIS STELLENBOSCH; JOUBERT E, 1997, J FOOD SCI TECHNOLOG, V32, P135; Joubert E, 1994, THESIS STELLENBOSCH; Joubert E., 2006, POLYPHENOLS COMMUNIC, P505; JOUBERT E, 1988, J FOOD SCI TECHNOLOG, V23, P203; Joubert E, 2008, J AGR FOOD CHEM, V56, P954, DOI 10.1021/jf072904a; Joubert E, 2008, PHYTOCHEM ANALYSIS, V19, P169, DOI 10.1002/pca.1033; Joubert E, 2006, J APPL BOT FOOD QUAL, V80, P138; Joubert E, 2006, J AGR FOOD CHEM, V54, P5279, DOI 10.1021/jf060617l; Jurani M, 2008, BRIT POULTRY SCI, V49, P55, DOI 10.1080/00071660701816949; Kamara BI, 2004, J AGR FOOD CHEM, V52, P5391, DOI 10.1021/jf040097z; Kamara BI, 2003, J AGR FOOD CHEM, V51, P3874, DOI 10.1021/jf0210730; KAWAKAMI M, 1993, J AGR FOOD CHEM, V41, P633, DOI 10.1021/jf00028a023; Kazuno S, 2005, ANAL BIOCHEM, V347, P182, DOI 10.1016/j.ab.2005.09.020; KELLY KM, 1985, J PLANT PHYSIOL, V121, P37; Khan A, 2006, EUR J NUTR, V45, P463, DOI 10.1007/s00394-006-0620-0; KIES P., 1951, BOTHALIA, V6, P161; KINAE N, 1994, ACS SYM SER, V547, P68; KOBERT R, 1906, LEHRBUCH INTOXIKATIO, V2, P748; KOEPPEN B., 1965, TETRAHEDRON LETT, V39, P3497; KOEPPEN BH, 1962, BIOCHEM J, V83, P507; KOEPPEN BH, 1965, BIOCHEM J, V97, P444; KOEPPEN BH, 1966, BIOCHEM J, V99, P604; KOMATSU K, 1994, CANCER LETT, V77, P33, DOI 10.1016/0304-3835(94)90344-1; Krafczyk N, 2008, J AGR FOOD CHEM, V56, P3368, DOI 10.1021/jf703701n; Kucharska J, 2004, PHYSIOL RES, V53, P515; Kunishiro K, 2001, BIOSCI BIOTECH BIOCH, V65, P2137, DOI 10.1271/bbb.65.2137; Kurzer MS, 1997, ANNU REV NUTR, V17, P353, DOI 10.1146/annurev.nutr.17.1.353; Lamosova D, 1997, COMP BIOCHEM PHYS C, V116, P39, DOI 10.1016/S0742-8413(96)00138-7; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; Le Roux A, 2008, S AFR J BOT, V74, P139, DOI 10.1016/j.sajb.2007.08.006; Lee EJ, 2004, BIOFACTORS, V21, P285; Leiro JM, 2003, BIOCHEM PHARMACOL, V65, P1361, DOI 10.1016/S0006-2952(03)00041-8; Leistner O. A., 2000, STRELITZIA, V10, P125; Lindsey KL, 2002, J FOOD SCI, V67, P2129, DOI 10.1111/j.1365-2621.2002.tb09514.x; Magee PJ, 2004, BRIT J NUTR, V91, P513, DOI 10.1079/BJN20031075; Maicu MC, 2008, THESIS STELLENBOSCH; Mak P, 2006, NEOPLASIA, V8, P896, DOI 10.1593/neo.06538; Manach C, 2004, AM J CLIN NUTR, V79, P727; Manley M, 2006, J NEAR INFRARED SPEC, V14, P213; Marais C, 1996, TETRAHEDRON LETT, V37, P5763, DOI 10.1016/0040-4039(96)01178-1; Marais C, 2000, PHYTOCHEMISTRY, V55, P43, DOI 10.1016/S0031-9422(00)00182-5; Marais SS, 1998, 3 TANN C BEND OR PHY, P129; MARKAVERICH BM, 1993, STEROIDS, V58, P268, DOI 10.1016/0039-128X(93)90071-T; Marloth R, 1913, CHEM S AFRICAN PLANT, P9; Marloth R, 1909, AGR J, V35, P634; Marloth R, 1925, FLORA S AFRICA SYNOP, P69; Marnewick J, 2005, CANCER LETT, V224, P193, DOI 10.1016/j.canlet.2004.11.014; Marnewick JL, 2000, MUTAT RES-GEN TOX EN, V471, P157, DOI 10.1016/S1383-5718(00)00128-5; Marnewick JL, 2004, MUTAT RES-GEN TOX EN, V558, P145, DOI 10.1016/j.mrgentox.2003.12.003; Marnewick JL, 2003, J AGR FOOD CHEM, V51, P8113, DOI 10.1021/jf0344643; MARNEWICK JL, 2004, THESIS U STELLENBOSC; Mashimbye MJ, 2006, S AFR J CHEM-S-AFR T, V59, P1; Matsuda K, 2007, J PHARMACOL SCI, V103, P214, DOI 10.1254/jphs.FP0061311; McGaw LJ, 2007, J ETHNOPHARMACOL, V110, P16, DOI 10.1016/j.jep.2006.08.029; Mertens-Talcott SU, 2006, J CLIN PHARMACOL, V46, P1390, DOI 10.1177/0091270006294277; MFENYANA C, 2008, THESIS STELLENBOSCH; Mokgalaka NS, 2004, J ANAL ATOM SPECTROM, V19, P1375, DOI 10.1039/b407416e; MORTON JF, 1983, ECON BOT, V37, P164, DOI 10.1007/BF02858780; Mudau FN, 2006, S AFR J BOT, V72, P398, DOI 10.1016/j.sajb.2005.10.007; Mudau NF, 2005, HORTSCIENCE, V40, P1898; Na HK, 2004, BIOFACTORS, V21, P149; Nakamura S, 1997, J INFECT CHEMOTHER, V3, P128, DOI 10.1007/BF02491502; Nakano M, 1997, BIOSCI BIOTECH BIOCH, V61, P267; NEETHLING HS, 1988, S AFR J SCI, V84, P278; Nikolova V., 2007, TOXICOL LETT, V172, P120; Nunez-Selles AJ, 2005, J BRAZIL CHEM SOC, V16, P699, DOI 10.1590/S0103-50532005000500004; Oh SM, 2004, LIFE SCI, V74, P1325, DOI 10.1016/j.lfs.2003.06.045; Otto F., 2003, EURO COSMETICS, P20; OTTO F, 2003, 1 INT C POL HLTH 1 S, P13; Pengilly M, 2008, J AGR FOOD CHEM, V56, P4047, DOI 10.1021/jf073095y; Persson IAL, 2006, J PHARM PHARMACOL, V58, P1139, DOI 10.1211/jpp.58.8.0016; Piccinelli AL, 2004, J AGR FOOD CHEM, V52, P5863, DOI 10.1021/jf040100e; RABE C, 1994, PHYTOCHEMISTRY, V35, P1559, DOI 10.1016/S0031-9422(00)86894-6; Rampedi I., 2005, ACTA ACAD, V37, P165; REYNECKE J, 1949, FARMING S AFRICA, V24, P409; REYNECKE J, 1949, FARMING S AFRICA, V24, P412; REYNEKE J., 1949, Farming in South Africa, V24, P397; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; RICHFIELD D, 2008, THESIS STELLENBOSCH; ROOD B, 1994, UIT VELDAPTEEK, P51; Rotelli AE, 2003, PHARMACOL RES, V48, P601, DOI 10.1016/S1043-6618(03)00225-1; Rukachaisirikul V, 2006, TETRAHEDRON, V62, P8578, DOI 10.1016/j.tet.2006.06.059; SASAKI YF, 1993, MUTAT RES, V286, P221, DOI 10.1016/0027-5107(93)90187-K; Sauter W., 2004, THESIS TU MUNCHEN WE; Scheepers S, 2001, THESIS STELLENBOSCH; Schulz H, 2003, EUR FOOD RES TECHNOL, V216, P539, DOI 10.1007/s00217-003-0696-1; SCHUTTE AL, 1995, PLANT SYST EVOL, V195, P243, DOI 10.1007/BF00989299; Schutte A.L., 1995, THESIS RAND AFRIKAAN; Shimamura N, 2006, BIOL PHARM BULL, V29, P1271, DOI 10.1248/bpb.29.1271; Shimoi K, 1996, MUTAT RES-FUND MOL M, V350, P153, DOI 10.1016/0027-5107(95)00116-6; SHIMOI K, 1994, ACS SYM SER, V547, P106; SHINDO Y, 1991, PROCEEDINGS OF THE INTERNATIONAL SYMPOSIUM ON TEA SCIENCE, P385; Silva MM, 2002, FREE RADICAL RES, V36, P1219, DOI 10.1080/1071576021000016472; Simon M, 2000, GEN PHYSIOL BIOPHYS, V19, P365; SISSING, 2008, THESIS U W CAPE BELL; SMITH CA, 1966, BOT SURVEY MEMOIR, V35, P247; SNIJMAN P, 2003, 1 INT C POL HLTH, P358; SNIJMAN PW, 2007, THESIS U W CAPE BELL; SNIJMAN PW, 2007, MUTAT RES, V613, P111; SNYCKERS FO, 1974, J S AFR CHEM I, V27, P5; Standley L, 2001, J AGR FOOD CHEM, V49, P114, DOI 10.1021/jf000802d; Steenkamp V, 2004, S AFR J BOT, V70, P660; Terblanche S.E, 1982, REPORT HONEYBUSH TEA; TIEDTKE J, 2002, EURO COSMETICS  0616; Vieira MDT, 2008, PHYTOMEDICINE, V15, P31, DOI 10.1016/j.phymed.2007.06.006; Touyz L Z, 1982, J Dent Assoc S Afr, V37, P737; Toyoda M, 1997, J AGR FOOD CHEM, V45, P2561, DOI 10.1021/jf970024y; Ulicna O, 2006, PHYSIOL RES, V55, P157; Ulicna O, 2003, PHYSIOL RES, V52, P461; Usui T, 2006, ENDOCR J, V53, P7, DOI 10.1507/endocrj.53.7; van der Merwe JD, 2006, MUTAT RES-GEN TOX EN, V611, P42, DOI 10.1016/j.megentox.2006.06.030; van Heerden FR, 2003, BIOCHEM SYST ECOL, V31, P885, DOI 10.1016/S0305-1978(03)00084-X; VANDERBANK M, 1995, BIOCHEM SYST ECOL, V23, P257, DOI 10.1016/0305-1978(95)00016-N; VANDERMERWE JD, 2004, THESIS STELLENBOSCH; VANWYK BE, 1989, S AFR J BOT, V55, P520; Van Wyk B. E., 1997, MED PLANTS S AFRICA, P290; Van Wyk B.E., 2000, PEOPLES PLANTS GUIDE, P102; Verhoog NJD, 2007, S AFR J SCI, V103, P13; Verhoog NJD, 2007, J AGR FOOD CHEM, V55, P4371, DOI 10.1021/jf063588n; vonGadow A, 1997, FOOD CHEM, V60, P73, DOI 10.1016/S0308-8146(96)00312-3; vonGadow A, 1997, J AGR FOOD CHEM, V45, P632, DOI 10.1021/jf960281n; vonGadow A, 1997, J AGR FOOD CHEM, V45, P1370, DOI 10.1021/jf960280v; Watt JM, 1962, MED POISONOUS PLANTS; Watt J. M., 1932, MED POISONOUS PLANTS, P70; Whelan AM, 2006, ANN PHARMACOTHER, V40, P836, DOI 10.1345/aph.1G226; Winterton P., 1999, THESIS STELLENBOSCH; Yoo KM, 2008, FOOD CHEM, V106, P929, DOI 10.1016/j.foodchem.2007.07.006; YOSHIKAWA T, 1990, EXP MED BIOL, V264, P171; 2005, S AFRICAN FOOD REV, V32, P21; De Beer S. W., 2002, SA Patent, Patent No. [2002/2802, 20022802]; 2006, S AFRICAN FOOD REV, V33, P24; 2005, FOODNAVIGATOR E 1201; 1991, ROOIBOS TEA BOARD AN; 2008, ATHRIXIA; 1994, ROOIBOS, P4; 1967, ROOIBOS TEA BOARD AN	211	139	146	3	29	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	OCT 28	2008	119	3					376	412		10.1016/j.jep.2008.06.014		37	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	372LU	WOS:000260903900006	18621121	
J	Kolarik, B; Naydenov, K; Larsson, M; Bornehag, CG; Sundell, J				Kolarik, Barbara; Naydenov, Kiril; Larsson, Malin; Bornehag, Carl-Gustaf; Sundell, Jan			The association between phthalates in dust and allergic diseases among Bulgarian children	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						allergy; asthma; children; DEHP; phthalates	IN-HOUSE DUST; INTERIOR SURFACE MATERIALS; DI(2-ETHYLHEXYL) PHTHALATE; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; INDOOR AIR; ASTHMA; SYMPTOMS; EXPOSURE; POPULATION	BACKGROUND: Recent studies have identified associations between the concentration of phthalates in indoor dust and allergic symptoms in the airways, nose, and skin. OBJECTIVES: Our goal was to investigate the associations between allergic symptoms in children and the concentration of phthalate esters in settled dust collected from children's homes in Sofia and Burgas, Bulgaria. METHODS: Dust samples from the child's bedroom were collected. A total of 102 children (2-7 Years of age) had symptoms of wheezing, rhinitis, and/or eczema in preceding 12 months (cases), and 82 were nonsymptomatic (controls). The dust samples were analyzed for their content of dimethyl phthalate (DMP), diethyl phthalate (DEP), di-n-butyl phthalate (DnBP), butyl benzyl phthalate (BBzP), di(2-ethylhexyl) phthalate (DEHP), and di-n-octyl phthalate (DnOP). RESULTS: A higher concentration of DEHP was found in homes of case children than in those of controls (1.24 vs. 0.86 mg/g dust). The concentration of DEHP was significantly associated with wheezing in the preceding 12 months (p = 0.035) as reported by parents. We found a dose-response relationship between DEHP concentration and case status and between DEHP concentration and wheezing in the preceding 12 months. CONCLUSIONS: This study shows an association between concentration of DEHP in indoor dust and wheezing among preschool children in Bulgaria.	[Kolarik, Barbara] Silesian Tech Univ, Fac Environm Engn & Energy, ISE, OWiTO, PL-44100 Gliwice, Poland; [Kolarik, Barbara] Tech Univ Denmark, Dept Mech Engn, Int Ctr Indoor Environm & Energy, DK-2800 Lyngby, Denmark; [Naydenov, Kiril] Birch & Krogboe AS, Virum, Denmark; [Bornehag, Carl-Gustaf] SP Tech Res Inst Sweden, Boras, Sweden	Kolarik, B (reprint author), Silesian Tech Univ, Fac Environm Engn & Energy, ISE, OWiTO, Konarskiego 18, PL-44100 Gliwice, Poland.	bf@mek.dtu.dk	Sundell, Jan/B-2857-2012				Adibi JJ, 2003, ENVIRON HEALTH PERSP, V111, P1719, DOI 10.1289/ehp.6235; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 2006, LANCET, V368, P783; Becker K, 2004, INT J HYG ENVIR HEAL, V207, P409, DOI 10.1078/1438-4639-00309; Blount BC, 2000, ENVIRON HEALTH PERSP, V108, P979, DOI 10.1289/ehp.00108979; Bornehag CG, 2006, SCAND J PUBLIC HEALT, V34, P534, DOI 10.1080/14034940600607467; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Brasche S, 2005, INT J HYG ENVIR HEAL, V208, P247, DOI 10.1016/j.ijheh.2005.03.003; Butte W, 2001, GEFAHRST REINHALT L, V61, P19; CALAFAT A, 2004, PEDIATRICS, V113, P429; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Clausen PA, 2003, J CHROMATOGR A, V986, P179, DOI 10.1016/S0021-9673(02)02007-1; Fromme H, 2004, INDOOR AIR, V14, P188, DOI 10.1046/j.1600-0668.2003.00223.x; Glue C, 2005, BASIC CLIN PHARMACOL, V96, P140, DOI 10.1111/j.1742-7843.2005.pto960208.x; Green R, 2005, ENVIRON HEALTH PERSP, V113, P1222, DOI 10.1289/chp.7932; *ISAAC, 1998, ISAAC PHAS 2; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2006, AM J EPIDEMIOL, V164, P742, DOI 10.1093/aje/kwj249; KERSTEN W, 2003, REINHALTUNG LUFT, V63, P85; Koch HM, 2005, INT ARCH OCC ENV HEA, V78, P223, DOI 10.1007/s00420-004-0570-x; Koch HM, 2003, INT J HYG ENVIR HEAL, V206, P77, DOI 10.1078/1438-4639-00205; Larsen ST, 2007, TOXICOLOGY, V235, P119, DOI 10.1016/j.tox.2007.03.010; Lee MH, 2004, INT ARCH ALLERGY IMM, V134, P213, DOI 10.1159/000078768; Naydenov K., 2005, P 10 INT C IND ARI Q, P3574; Naydenov K G, 2007, THESIS TU DENMARK LY; Nielsen GD, 2007, INDOOR AIR, V17, P236, DOI 10.1111/j.1600-0668.2006.00468.x; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; POHNER A, 1997, UMWELT GESUNDHEIT, V2, P1; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; STRACHAN DP, 1989, BRIT MED J, V299, P1259; World Health Organization (WHO), 2003, CHILDR RISK MAIN HLT; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x	36	139	150	4	61	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2008	116	1					98	103		10.1289/ehp.10498		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	248GZ	WOS:000252142100031	18197306	
J	Brugge, D; Durant, JL; Rioux, C				Brugge, Doug; Durant, John L.; Rioux, Christine			Near-highway pollutants in motor vehicle exhaust: A review of epidemiologic evidence of cardiac and pulmonary health risks	ENVIRONMENTAL HEALTH			English	Review							PARTICULATE AIR-POLLUTION; HEART-RATE-VARIABILITY; LONG-TERM EXPOSURE; CHRONIC RESPIRATORY SYMPTOMS; LUNG-CANCER; ULTRAFINE PARTICLES; SUBMICROMETER PARTICLES; CHILDHOOD ASTHMA; SCHOOL-CHILDREN; URBAN AIR	There is growing evidence of a distinct set of freshly-emitted air pollutants downwind from major highways, motorways, and freeways that include elevated levels of ultrafine particulates (UFP), black carbon (BC), oxides of nitrogen (NOx), and carbon monoxide (CO). People living or otherwise spending substantial time within about 200 m of highways are exposed to these pollutants more so than persons living at a greater distance, even compared to living on busy urban streets. Evidence of the health hazards of these pollutants arises from studies that assess proximity to highways, actual exposure to the pollutants, or both. Taken as a whole, the health studies show elevated risk for development of asthma and reduced lung function in children who live near major highways. Studies of particulate matter (PM) that show associations with cardiac and pulmonary mortality also appear to indicate increasing risk as smaller geographic areas are studied, suggesting localized sources that likely include major highways. Although less work has tested the association between lung cancer and highways, the existing studies suggest an association as well. While the evidence is substantial for a link between near-highway exposures and adverse health outcomes, considerable work remains to understand the exact nature and magnitude of the risks.			dbrugge@aol.com; john.durant@tufts.edu; Christine.rioux@tufts.edu	Durant, John/F-2424-2017	Durant, John/0000-0002-7016-1622	NIEHS NIH HHS [R01 ES015462]		Adar SD, 2007, EPIDEMIOLOGY, V18, P95, DOI 10.1097/01.ede.0000249409.81050.46; *AM HOUS SURV US, 2003, H15003 AM HOUS SURV; Beeson WL, 1998, ENVIRON HEALTH PERSP, V106, P813, DOI 10.1289/ehp.98106813; Biggeri A, 1996, ENVIRON HEALTH PERSP, V104, P750, DOI 10.2307/3433221; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Chambers L A, 1976, AIR POLLUTION, V1; Chan CC, 2004, ENVIRON HEALTH PERSP, V112, P1063, DOI 10.1289/chp.6897; Choi KS, 1997, ARCH ENVIRON HEALTH, V52, P160; Chuang KJ, 2005, ENVIRON HEALTH PERSP, V113, P1693, DOI 10.1289/ehp.8145; Delfino RJ, 2005, ENVIRON HEALTH PERSP, V113, P934, DOI 10.1289/ehp.7938; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Finkelstein MM, 2005, J EPIDEMIOL COMMUN H, V59, P481, DOI 10.1136/jech.2004.026203; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Graedel T. E., 1986, ATMOSPHERIC CHEM COM; Heinrich J, 2005, ENVIRON RES, V98, P240, DOI 10.1016/j.envres.2004.08.004; Hitchins J, 2000, ATMOS ENVIRON, V34, P51, DOI 10.1016/S1352-2310(99)00304-0; Health Effects Institute, 2000, REAN HARV 6 CIT STUD; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hoffmann B, 2006, EUR HEART J, V27, P2696, DOI 10.1093/eurheartj/ehl278; Hong YC, 2005, INT ARCH OCC ENV HEA, V78, P132, DOI 10.1007/s00420-004-0554-x; Hwang BF, 2005, THORAX, V60, P467, DOI 10.1136/thx.2004.033977; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jerrett M, 2005, J TOXICOL ENV HEAL A, V68, P1207, DOI 10.1080/15287390590936085; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Kim JH, 2005, J KOREAN MED SCI, V20, P42; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Laden F, 2006, AM J RESP CRIT CARE, V173, P667, DOI 10.1164/rccm.200503-443OC; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059; Lipfert FW, 2006, ATMOS ENVIRON, V40, P154, DOI 10.1016/j.atmosenv.2005.09.027; LWEGUGAMUKASA JS, 2005, J ASTHMA, V42, P337; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; MERKUS PJF, 2005, NEW ENGL J MED, V351, P2652; Migliaretti G, 2005, INT ARCH OCC ENV HEA, V78, P164, DOI 10.1007/s00420-004-0569-3; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; Morawska L, 1999, ATMOS ENVIRON, V33, P1261, DOI 10.1016/S1352-2310(98)00266-0; Nafstad P, 2003, THORAX, V58, P1071, DOI 10.1136/thorax.58.12.1071; *NAT RES COUN COMM, 2004, RES PRIOR AIRB PART; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; OBERDORSTER G, 2001, INT ARCH OCCUPATIONA, V65, P1531; Ong P, 2006, AM J PUBLIC HEALTH, V96, P499, DOI 10.2105/AJPH.2005.071373; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; PETERS A, 2004, NEW ENGL J MED, V351, P1861; Peters Annette, 2005, Toxicol Appl Pharmacol, V207, P477, DOI 10.1016/j.taap.2005.04.030; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Riediker M, 2004, AM J RESP CRIT CARE, V169, P934, DOI 10.1164/rccm.200310-1463OC; ROGGE WF, 1993, ENVIRON SCI TECHNOL, V27, P636, DOI 10.1021/es00041a007; ROORDAKNAPPE MC, 1998, ATMOS ENVIRON, V32, P921; Ruckerl R, 2007, ENVIRON HEALTH PERSP, V115, P1072, DOI 10.1289/ehp.10021; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Sandhu RS, 2005, INHAL TOXICOL, V17, P409, DOI 10.1080/08958370590929538; Schwartz J, 2005, THORAX, V60, P455, DOI 10.1136/thx.2004.024836; Shi JP, 1999, SCI TOTAL ENVIRON, V235, P51, DOI 10.1016/S0048-9697(99)00189-8; Sioutas C, 2005, ENVIRON HEALTH PERSP, V113, P947, DOI 10.1289/ehp.7939; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Tonne C, 2007, ENVIRON HEALTH PERSP, V115, P53, DOI 10.1289/ehp.9587; U. S. Environmental Protection Agency, 2004, AIR QUAL CRIT PART M; U. S. Environmental Protection Agency, 2002, HLTH ASS DOC DIES EN; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2005, OCCUP ENVIRON MED, V62, P376, DOI 10.1136/oem.2004.017228; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Vineis P, 2006, INT J CANCER, V119, P169, DOI 10.1002/ijc.21801; Vinzents PS, 2005, ENVIRON HEALTH PERSP, V113, P1485, DOI 10.1289/ehp.7562; Visser O, 2004, CANCER CAUSE CONTROL, V15, P331, DOI 10.1023/B:CACO.0000027480.32494.a3; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; Wheeler A, 2006, ENVIRON HEALTH PERSP, V114, P560, DOI 10.1289/ehp.8337; WJST M, 1993, BRIT MED J, V307, P596; Zhang KM, 2004, ATMOS ENVIRON, V38, P6655, DOI 10.1016/j.atmosenv.2004.06.044; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zhu YF, 2002, ATMOS ENVIRON, V36, P4323, DOI 10.1016/S1352-2310(02)00354-0	91	139	144	6	68	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1476-069X			ENVIRON HEALTH-GLOB	Environ. Health	AUG 9	2007	6								23	10.1186/1476-069X-6-23		12	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	208EA	WOS:000249301400001	17688699	
J	Clougherty, JE; Levy, JI; Kubzansky, LD; Ryan, PB; Suglia, SF; Canner, MJ; Wright, RJ				Clougherty, Jane E.; Levy, Jonathan I.; Kubzansky, Laura D.; Ryan, P. Barry; Suglia, Shakira Franco; Canner, Marina Jacobson; Wright, Rosalind J.			Synergistic effects of traffic-related air pollution and exposure to violence on urban asthma etiology	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						childhood asthma; exposure to violence (ETV); geographic information systems (GIS); intraurban variability; nitrogen dioxide (NO2); social-environmental synergy; stress	COMMUNITY VIOLENCE; ENVIRONMENTAL JUSTICE; HEALTH DISPARITIES; STRESS REACTIVITY; CHILDHOOD ASTHMA; LUNG-FUNCTION; BIRTH-COHORT; CHILDREN; ASSOCIATION; SYMPTOMS	BACKGROUND: Disproportionate-life stress and consequent physiologic alteration (i.e., immune dysregulation) has been proposed as a major pathway linking socioeconomic position, environmental exposures, and health disparities. Asthma, for example, disproportionately affects lower-income urban communities, where air pollution and social stressors may be elevated. OBJECTIVES: We aimed to examine the role of exposure to violence (ETV), as a chronic stressor, in altering susceptibility to traffic-related air pollution in asthma etiology. METHODS: We developed geographic information systems (GIS)-based models to retrospectively estimate residential exposures to traffic-related pollution for 413 children in a community-based pregnancy cohort, recruited in East Boston, Massachusetts, between 1987 and 1993, using monthly nitrogen dioxide measurements for 13 sites over 18 years. We merged pollution estimates with questionnaire data on lifetime ETV and examined the effects of both on childhood asthma etiology. RESULTS: Correcting for potential confounders, we found an elevated risk of asthma with a 1-SD (4.3 ppb) increase in NO2 exposure solely among children with above-median ETV [odds ratio (OR) = 1.63; 95% confidence interval (0), 1.14-2-33)]. Among children always living in the same community, with lesser exposure measurement error, this association was magnified (OR = 2.40; 95% Cl, 1.48-3.88). Of multiple exposure periods, year-of-diagnosis NO2 was most predictive of asthma, outcomes. CONCLUSIONS: We found an association between traffic-related air pollution and asthma solely among urban children exposed to violence. Future studies should consider socially patterned susceptibility, common spatial distributions of social and physical environmental factors, and potential synergies among these. Prospective assessment of physical and social exposures may help determine causal pathways and critical exposure periods.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02215 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	Clougherty, JE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr Room 404,POB 15677, Boston, MA 02215 USA.	jcloughe@hsph.harvard.edu	Levy, Jonathan/A-9102-2008; Ryan, P. Barry/A-7662-2009; Levy, Jon/B-4542-2011	Levy, Jon/0000-0002-1116-4006	NHLBI NIH HHS [K08 HL04187]; NICHD NIH HHS [F31 HD049317, F31 HD049317-01A1]; NIEHS NIH HHS [R03 ES013988, T32 ES007142]		Augustyn M, 2002, ARCH PEDIAT ADOL MED, V156, P800; AYRES MM, 2006, THESIS EMORY U ATLAN; BAXTER LK, 2006, J EXPOS SCI ENV 1018; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brulle RJ, 2006, ANNU REV PUBL HEALTH, V27, P103, DOI 10.1146/annurev.publhealth.27.021405.102124; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; Ferris BG, 1978, AM REV RESPIR DIS, V118, P55; FUGISAWA T, 2005, DRUG TARGETS INFLAMM, V4, P505, DOI DOI 10.2174/1568010054526304; Gee GC, 2004, ENVIRON HEALTH PERSP, V112, P1645, DOI 10.1289/ehp.7074; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Gordian ME, 2006, J EXPO SCI ENV EPID, V16, P49, DOI 10.1038/sj.jea.7500436; Gordon M.T., 1991, FEMALE FEAR SOCIAL C; GRAVES P, 1988, LAND ECON, V64, P220, DOI 10.2307/3146246; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Hellhammer DH, 1997, PSYCHONEUROENDOCRINO, V22, P643, DOI 10.1016/S0306-4530(97)00063-2; Hochadel M, 2006, ATMOS ENVIRON, V40, P542, DOI 10.1016/j.atmosenv.2005.09.067; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Jerrett M, 2004, J EPIDEMIOL COMMUN H, V58, P31, DOI 10.1136/jech.58.1.31; KATZ C, 1991, ANN ASSOC AM GEOGR, V81, P488, DOI 10.1111/j.1467-8306.1991.tb01706.x; Kindlon DJ, 1996, INT J METHOD PSYCH, V6, P187, DOI 10.1002/(SICI)1234-988X(199612)6:4<187::AID-MPR161>3.3.CO;2-A; Krewski D, 2000, REANALYSIS HARVARD 6; Levy Jonathan I, 2004, Environ Health, V3, P13, DOI 10.1186/1476-069X-3-13; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Liu Y, 2005, ENVIRON SCI TECHNOL, V39, P3269, DOI 10.1021/es049352rn; Maantay J, 2007, HEALTH PLACE, V13, P32, DOI 10.1016/j.healthplace.2005.09.009; MARTINEZ P, 1993, PSYCHIATRY, V56, P22; Martins MCH, 2004, J EPIDEMIOL COMMUN H, V58, P41, DOI 10.1136/jech.58.1.41; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Morello-Frosch R, 2006, ENVIRON HEALTH PERSP, V114, P1150, DOI 10.1289/ehp.8930; NIEUWENHUIJSEN MJ, 2000, SPATIAL EPIDEMIOLOGY; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; OCKENFELS MC, 1995, PSYCHOSOM MED, V57, P460; Oh YM, 2004, RESPIROLOGY, V9, P363, DOI 10.1111/j.1440-1843.2004.00609.x; Overstreet S, 2000, AM J ORTHOPSYCHIAT, V70, P263, DOI 10.1037/h0087828; RICHTERS JE, 1990, CHECKLIST CHILDRENS; SAHSUVAROGLU T, 2004, MODELING INTRAURBAN; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Selner-O'Hagan MB, 1998, J CHILD PSYCHOL PSYC, V39, P215, DOI 10.1017/S002196309700187X; SPENGLER JD, 1983, ENVIRON SCI TECHNOL, V17, P164, DOI 10.1021/es00109a008; SUGLIA SF, 2006, THESIS HARVARD SCH P; Thomson CC, 2002, ARCH PEDIAT ADOL MED, V156, P818; Tsaih SW, 2004, ENVIRON HEALTH PERSP, V112, P1178, DOI 10.1289/ehp.7024; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; *US CENS BUR GEOGR, 2001, TIGER LIN FIL; Weiss B, 2006, ENVIRON HEALTH PERSP, V114, P1479, DOI 10.1289/ehp.9101; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; Wright RJ, 2006, CLIN CHEST MED, V27, P413, DOI 10.1016/j.ccm.2006.04.003; Zanobetti A, 2000, J OCCUP ENVIRON MED, V42, P469, DOI 10.1097/00043764-200005000-00002; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	57	139	142	7	34	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2007	115	8					1140	1146		10.1289/ehp.9863		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	197CO	WOS:000248531400026	17687439	
J	Saxon, A; Diaz-Sanchez, D				Saxon, A; Diaz-Sanchez, D			Air pollution and allergy: you are what you breathe	NATURE IMMUNOLOGY			English	Editorial Material							S-TRANSFERASE M1; OZONE EXPOSURE; POLYMORPHISMS; CHALLENGE; RESPONSES; CHILDREN; ASTHMA; CELLS	How does air pollution affect asthma and allergic rhinitis? Particulate and gaseous pollution drive proallergic inflammation through the generation of oxidative stress, which is regulated by individual genetic susceptibility.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA 90095 USA	Saxon, A (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA 90095 USA.	ddiazsa@mednet.ucla.edu					Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Chen LL, 2004, CHEST, V125, P2328, DOI 10.1378/chest.125.6.2328; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fahy O, 2002, J IMMUNOL, V168, P5912; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620; LONDON SJ, 1995, J NATL CANCER I, V87, P1246, DOI 10.1093/jnci/87.16.1246; Romieu I, 2004, THORAX, V59, P8; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Takizawa Hajime, 2004, Curr Opin Allergy Clin Immunol, V4, P355, DOI 10.1097/00130832-200410000-00005; Todokoro M, 2004, INFLAMMATION, V28, P105, DOI 10.1023/B:IFLA.0000033026.91221.ed; U. S. EPA, 1997, NAT AIR POLL EM TREN; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; YANG IA, 2004, AM J RESP CRIT CARE, V171, P171	20	139	145	1	13	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	MAR	2005	6	3					223	226		10.1038/ni0305-223		4	Immunology	Immunology	899AN	WOS:000227117400002	15716966	
J	Arshad, SH; Kurukulaaratchy, RJ; Fenn, M; Matthews, S				Arshad, SH; Kurukulaaratchy, RJ; Fenn, M; Matthews, S			Early life risk factors for current wheeze, asthma, and bronchial hyperresponsiveness at 10 years of age	CHEST			English	Article						atopy; bronchial hyperresponsiveness; childhood asthma; risk factors; wheezing	AUSTRALIAN SCHOOLCHILDREN; ENVIRONMENTAL-FACTORS; RESPIRATORY SYMPTOMS; ALLERGIC DISORDERS; PARENTAL SMOKING; 2 POPULATIONS; BIRTH COHORT; NEW-ZEALAND; CHILDREN; PREVALENCE	Study objectives: We sought to identify early life factors (ie, first 4 years) associated with wheeze, asthma, and bronchial hyperresponsiveness (BHR) at age 10 years, comparing their relative influence for these conditions. Methods: Children were seen at birth, and at 1, 2, 4, and 10 years of age in a whole-population birth cohort study (1,456 subjects). Information was collected prospectively on genetic and environmental risk factors. Skin-prick testing was performed at 4 years of age. Current wheeze (in the last 12 months) and currently diagnosed asthma (CDA) [ie, current wheeze and ever-diagnosed asthmatic subject] were recorded at 10 years of age when BHR was measured at bronchial challenge. Independent significant risk factors for these outcomes were identified by logistic regression. Results: Independent significance for current wheeze occurred with maternal asthma (odds ratio [OR], 2.08; 95% confidence interval [CI], 1.27 to 3.41) and paternal asthma (OR,. 2.12; 95% CI 1.29 to 3.51), recurrent chest infections at 2 years (OR, 3.98; 95% CI, 2.36 to 6.70), atopy at 4 years of age (OR, 3.69; 95% CI, 2.36 to 5.76), eczema at 4 years of age (OR, 2.15; 95% CI, 1.24 to 3.73), and parental smoking at 4 years of age (OR, 2.18; 95% CI, 1.25 to 3.81). For CDA, significant factors were maternal asthma (OR, 2.26; 95% CI, 1.24 to 3.73), paternal asthma (OR, 2.30; 95% CI, 1.17 to 4.52), and sibling asthma (OR, 2.00; 95% CI, 1.16 to 3.43), recurrent chest infections at I year of age (OR, 2.67; 95% CI, 1.12 to 6.40) and 2 years of age (OR, 4.11; 95% CI, 2.06 to S. IS), atopy at 4 years of age (OR, 7.22; 95% CI, 4.13 to 12.62), parental smoking at I year of age (OR, 1.99; 95% CI, 1.15 to 3.45), and male gender (OR, 1.72; 95% CI, 1.01 to 2.95). For BHR, atopy at 4 years of age (OR, 5.38; 95% CI, 3.06 to 9.47) and high social class at birth (OR, 2.03; 95% CI, 1.16 to 3.53) proved to be significant. Conclusions: Asthmatic heredity, predisposition to early life atopy, plus early passive smoke exposure and recurrent chest infections are important influences for the occurrence of wheeze and asthma at 10 years of age. BHR at 10 years of age has a narrower risk profile, suggesting that factors influencing wheezing symptom expression may differ from those predisposing the patient to BHR.	St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England	Arshad, SH (reprint author), Univ Hosp N Staffordshire, Dept Resp Med, Newcastle Rd, Stoke On Trent ST4 6QG, Staffs, England.	sha@soton.ac.uk					Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66; CRANE J, 1989, J ALLERGY CLIN IMMUN, V84, P768, DOI 10.1016/0091-6749(89)90307-2; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DUFF AL, 1994, AM J RESP CRIT CARE, V149, P365; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365; Halken Susanne, 2003, Paediatr Respir Rev, V4, P128, DOI 10.1016/S1526-0542(03)00026-5; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hide DW, 1996, PEDIATR ALLERGY IMMU, V7, P117, DOI 10.1111/j.1399-3038.1996.tb00410.x; Kurukulaaratchy RJ, 2003, J ALLERGY CLIN IMMUN, V112, P311, DOI 10.1067/mai.2003.1623; KURUKULAARATCHY RJ, 2002, RESP MED, V96, P162; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; LEE DA, 1983, BRIT MED J, V286, P1256; Lemanske RF, 2003, J PEDIATR-US, V142, pS3, DOI 10.1067/mpd.2003.19; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Oddy WH, 1999, BRIT MED J, V319, P815; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; PEAT JK, 1994, BRIT MED J, V308, P1591; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; Sarafino EP, 2000, PEDIATR ALLERGY IMMU, V11, P80, DOI 10.1034/j.1399-3038.2000.00065.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Sears MR, 1996, ARCH DIS CHILD, V75, P392; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Van Asperen P P, 1994, Pediatr Allergy Immunol, V5, P178; vonMutius E, 1996, AM J RESP CRIT CARE, V153, P1266; VONMUTIUS E, 2000, AM J RESP CRIT CARE, V161, P1563	39	139	147	0	9	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	FEB	2005	127	2					502	508		10.1378/chest.127.2.502		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	898LV	WOS:000227079200018	15705988	
J	Dannenberg, AL; Jackson, RJ; Frumkin, H; Schieber, RA; Pratt, M; Kochtitzky, C; Tilson, HH				Dannenberg, AL; Jackson, RJ; Frumkin, H; Schieber, RA; Pratt, M; Kochtitzky, C; Tilson, HH			The impact of community design and land-use choices on public health: A scientific research agenda	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							OUTDOOR AIR-POLLUTION; PHYSICAL-ACTIVITY; BUILT ENVIRONMENT; CHILDREN; TRENDS; SPRAWL; ASTHMA	The design of a community's built environment influences the physical and mental health of its residents. Because few studies have investigated this relationship, the Centers for Disease Control and Prevention hosted a workshop in May 2002 to help develop a scientific research agenda on these issues. Workshop participants' areas of expertise included physical activity, injury prevention, air pollution, water quality, urban planning, transportation, architecture, epidemiology, land use, mental health, social capital, housing, and social marketing. This report describes the 37 questions in the resulting research agenda. The next steps are to define priorities and obtain resources. The proposed research will help identify the best practices for designing new communities and revitalizing old ones in ways that promote physical and mental health.	CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA; CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA; CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA; CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC 27515 USA	Dannenberg, AL (reprint author), CDC, Div Emergency & Environm Hlth Serv, Natl Ctr Environm Hlth, 4770 Buford Hwy,Mail Stop F-30, Atlanta, GA 30341 USA.						Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Briss PA, 2000, AM J PREV MED, V18, P35, DOI 10.1016/S0749-3797(99)00119-1; Brownson R, 1998, APPL EPIDEMIOLOGY TH; Bullard R. B., 1997, JUST TRANSPORTATION; Carter SP, 2003, AM J PUBLIC HEALTH, V93, P1442, DOI 10.2105/AJPH.93.9.1442; Center for Disease Control and Prevention, 2001, MMWR-MORBID MORTAL W, V50, P166; Centers for Disease Control and Prevention, SPOTL SYND; Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P701; *CTR OUTC MEAS BRA, 2001, CRAIG HOSP INV ENV F; *DUAN PLAT ZYB CO, SMART COD; Elvik R, 2001, ACCIDENT ANAL PREV, V33, P327, DOI 10.1016/S0001-4575(00)00046-4; EVANS GW, IN PRESS J URBAN HLT; Ewing R, 2002, MEASURING SPRAWL ITS; Frank LD, 2000, TRANSPORT RES D-TR E, V5, P173, DOI 10.1016/S1361-9209(99)00032-2; Frank LD, 2001, J PLAN LIT, V16, P202, DOI 10.1177/08854120122093339; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Frumkin H, 2002, PUBLIC HEALTH REP, V117, P201, DOI 10.1016/S0033-3549(04)50155-3; *GEORG I TECHN, STRAT METR ATL REG T; Handy SL, 2002, AM J PREV MED, V23, P64, DOI 10.1016/S0749-3797(02)00475-0; Hawe P, 2000, SOC SCI MED, V51, P871, DOI 10.1016/S0277-9536(00)00067-8; Holtzclaw J, 2002, TRANSPORT PLAN TECHN, V25, P1, DOI 10.1080/03081060290032033; *I MED BOARD HLTH, 2003, WHO WILL KEEP PUBL H; *INT PHYS ACT QUES, 2002, INT PHYS ACT QUEST; Kahn EB, 2002, AM J PREV MED, V22, P73, DOI 10.1016/S0749-3797(02)00434-8; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Kouri C, 1999, WAIT BUS LOWCOUNTRY; Kuo FE, 2001, ENVIRON BEHAV, V33, P343, DOI 10.1177/00139160121973025; *LOC GOV COMM, 2003, 2 ANN NEW PARTN SMAR; Lopez R, 2003, URBAN AFF REV, V38, P325, DOI 10.1177/1078087402238805; Maibach EW, 2003, AM J HEALTH PROMOT, V18, P114; Mair JS, 2003, ANNU REV PUBL HEALTH, V24, P209, DOI 10.1146/annurev.publhealth.24.100901.140826; *MAR COUNT BIC COA, SAF ROUT SCH; Matte TD, 2000, J URBAN HEALTH, V77, P7, DOI 10.1007/BF02350959; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MICHAEL S, INT CLEARINGHOUSE CR; *NAT HIGHW TRAFF S, NAT SURV SPEED OTH U, V2; [Treatment of O National Task Force on the P], 2000, ARCH INTERN MED, V160, P898, DOI DOI 10.1001/ARCHINTE.160.7.898; *NAT TRUST HIST PR, 2000, HIST NEIGHB SCH AG S; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.2012.40; Pikora TJ, 2002, AM J PREV MED, V23, P187, DOI 10.1016/S0749-3797(02)00498-1; POLLAK PB, 1999, LIVEABLE COMMUNITIES; Pucher J, 2003, AM J PUBLIC HEALTH, V93, P1509, DOI 10.2105/AJPH.93.9.1509; Putnam R., 2000, BOWLING COLLAPSE REV; *RW JOHNS FDN, 2002, ACT LIV NEWT C; *RW JOHNS FDN, ACT LIV POL ENV STUD; Sallis J. F., 1997, HLTH BEHAV HLTH ED T, P403; *SMART GROWTH NETW, 2002, SMART GROWTH; Taylor AF, 2001, ENVIRON BEHAV, V33, P54, DOI 10.1177/00139160121972864; Taylor Ralph B., 1996, PHYSICAL ENV CRIME; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; *US DEP JUST, 1994, 28 CFR 26; *US GREEN BUILD CO, 2003, LEAD EN ENV DES GREE; *WHO, 1948, WHO DEF HLTH NEW YOR; World Health Organization (WHO), INT CLASS FUNCT DIS; Yin RK, 1994, CASE STUDY RES DESIG	56	139	139	8	42	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	SEP	2003	93	9					1500	1508		10.2105/AJPH.93.9.1500		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	716KL	WOS:000185027300033	12948970	
J	Pearce, N; Douwes, J; Beasley, R				Pearce, N; Douwes, J; Beasley, R			Is allergen exposure the major primary cause of asthma?	THORAX			English	Review						asthma; allergen; childhood exposure; atopy	DUST MITE ALLERGEN; PAPUA-NEW-GUINEA; INNER-CITY CHILDREN; DER-P-I; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; RISK-FACTORS; LOS-ALAMOS; NEW-MEXICO; PREVALENCE	In recent decades a number of authors have argued that allergen exposure is the major primary cause of asthma, and that the global increases in asthma prevalence are due to increases in exposure to aeroallergens. We have assessed the epidemiological evidence in support of this hypothesis. No longitudinal studies were identified in which allergen exposure during infancy in a random population sample has been related to asthma risk after the age of six years. Two studies have been conducted in selected populations chosen on the basis of a family history of asthma or allergy; one study found a nonstatistically significant association whereas the other study found no association. Many of the identified prevalence studies in children showed negative associations between allergen exposure and current asthma, and the weighted averages of the population attributable risks in children were 4% for Der p 1, 11% for Fel d 1, -4% for Bla g 2, and 6% for Can f 1. There was little change in these estimates in studies in which children whose parents had adopted allergen avoidance measures were excluded. Furthermore, evidence from population studies is equivocal and provides little consistent evidence that allergen exposure is associated with the prevalence of asthma at the population level. Population-based cohort studies are clearly required, but currently available evidence does not indicate that allergen exposure is a major risk factor for the primary causation of asthma in children.	Wellington Sch Med, Wellington Asthma Res Grp, Wellington, New Zealand	Pearce, N (reprint author), Wellington Sch Med, Wellington Asthma Res Grp, POB 7343, Wellington, New Zealand.			Douwes, Jeroen/0000-0003-3599-4036; Beasley, Richard/0000-0003-0337-406X			ANTO JM, 1998, EUR RESPIR REV, V8, P159; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; Burge PS, 1995, RESP MED, P1262; Burney P, 1996, EUR RESPIR J, V9, P687; BURR ML, 1993, ARCH DIS CHILD, V68, P724; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; CULLINAN P, 1999, DIFFICULT ASTHMA, P113; Custovic A, 1998, THORAX, V53, P63; Custovic A., 1998, EUR RESPIR REV, V8, P155; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hirsch T, 1998, CLIN EXP ALLERGY, V28, P956; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Martin YC, 1998, PERSPECT DRUG DISCOV, V12, P3, DOI 10.1023/A:1017037831628; Martinez FD, 1997, AM J RESP CRIT CARE, V156, pS117; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Pearce N, 2000, THORAX, V55, P352, DOI 10.1136/thorax.55.5.352; Pearce N, 1999, THORAX, V54, P268; Pearce N, 1998, ASTHMA EPIDEMIOLOGY; PEAT JK, 1994, BRIT MED J, V308, P1591; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; TURNER KJ, 1988, CLIN ALLERGY, V18, P331, DOI 10.1111/j.1365-2222.1988.tb02880.x; vanStrien RT, 1996, EUR RESPIR J, V9, P926, DOI 10.1183/09031936.96.09050926; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wickens K, 1999, PEDIATR ALLERGY IMMU, V10, P199, DOI 10.1034/j.1399-3038.1999.00033.x; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460; WOOLCOCK AJ, 1989, EUR RESPIR J, V2, P822; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571	50	139	144	2	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY	2000	55	5					424	431		10.1136/thorax.55.5.424		8	Respiratory System	Respiratory System	310GD	WOS:000086817400015	10770825	
J	Guilliams, M; Bruhns, P; Saeys, Y; Hammad, H; Lambrecht, BN				Guilliams, Martin; Bruhns, Pierre; Saeys, Yvan; Hammad, Hamida; Lambrecht, Bart N.			The function of Fc gamma receptors in dendritic cells and macrophages	NATURE REVIEWS IMMUNOLOGY			English	Review							CYTOPLASMIC DOMAIN HETEROGENEITY; ANTIBODY-DEPENDENT ENHANCEMENT; DENGUE HEMORRHAGIC-FEVER; IGG IMMUNE-COMPLEXES; RII-MEDIATED UPTAKE; DUST MITE ALLERGEN; CD8(+) T-CELLS; ANTIGEN PRESENTATION; IN-VIVO; CROSS-PRESENTATION	Dendritic cells (DCs) and macrophages use various receptors to recognize foreign antigens and to receive feedback control from adaptive immune cells. Although it was long believed that all immunoglobutin Fc receptors are universally expressed by phagocytes, recent findings indicate that only monocyte-derived DCs and macrophages express high levels of activating Fc receptors for IgG (Fc gamma Rs), whereas conventional and plasmacytoid DCs express the inhibitory Fc gamma R. In this Review, we discuss how the uptake, processing and presentation of antigens by DCs and macrophages is influenced by Fc gamma R recognition of innmunoglobulins and immune complexes in the steady state and during inflammation.	[Guilliams, Martin; Saeys, Yvan; Hammad, Hamida; Lambrecht, Bart N.] VIB Inflammat Res Ctr, Immunoregulat Lab, B-9052 Ghent, Belgium; [Guilliams, Martin; Saeys, Yvan; Hammad, Hamida; Lambrecht, Bart N.] Univ Ghent, Dept Resp Med, B-9000 Ghent, Belgium; [Bruhns, Pierre] Inst Pasteur, Dept Immunol, Lab Anticorps Therapie & Pathol, F-75015 Paris, France; [Bruhns, Pierre] Inst Natl Sante & Rech Med, U760, F-75015 Paris, France; [Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, Rotterdam, Netherlands	Guilliams, M (reprint author), VIB Inflammat Res Ctr, Immunoregulat Lab, B-9052 Ghent, Belgium.	martin.guilliams@irc.vib-ugent.be; bart.lambrecht@irc.vib-ugent.be	Bruhns, Pierre/F-5567-2013; Saeys, Yvan/C-1311-2009; Lambrecht, Bart/K-2484-2014	Bruhns, Pierre/0000-0002-4709-8936; Saeys, Yvan/0000-0002-0415-1506; Lambrecht, Bart/0000-0003-4376-6834			Akilesh S, 2004, J CLIN INVEST, V113, P1328, DOI 10.1172/JCI200418838; Akiyama K, 2003, J IMMUNOL, V170, P1641; Amigorena S, 1999, IMMUNOL REV, V172, P279, DOI 10.1111/j.1600-065X.1999.tb01372.x; AMIGORENA S, 1992, NATURE, V358, P337, DOI 10.1038/358337a0; AMIGORENA S, 1992, SCIENCE, V256, P1808, DOI 10.1126/science.1535455; Anthony RM, 2011, NATURE, V475, P110, DOI 10.1038/nature10134; Baker K, 2011, P NATL ACAD SCI USA, V108, P9927, DOI 10.1073/pnas.1019037108; Bandukwala HS, 2007, J EXP MED, V204, P1875, DOI 10.1084/jem.20061134; Bayry J, 2003, BLOOD, V101, P758, DOI 10.1182/blood-2002-05-1447; Benitez-Ribas D, 2008, J IMMUNOL, V181, P5219; Benitez-Ribas D, 2006, J EXP MED, V203, P1629, DOI 10.1084/jem.20052364; Bergtold A, 2005, IMMUNITY, V23, P503, DOI 10.1016/j.immuni.2005.09.013; Biburger M, 2011, IMMUNITY, V35, P932, DOI 10.1016/j.immuni.2011.11.009; Bjorck P, 2008, J IMMUNOL, V181, P3811; Blank U, 2009, IMMUNOL REV, V232, P59, DOI 10.1111/j.1600-065X.2009.00832.x; Blink SE, 2010, CELL IMMUNOL, V264, P54, DOI 10.1016/j.cellimm.2010.04.011; Bonnerot C, 1998, EMBO J, V17, P4606, DOI 10.1093/emboj/17.16.4606; Boruchov AM, 2005, J CLIN INVEST, V115, P2914, DOI 10.1172/JCI24772; Boule MW, 2004, J EXP MED, V199, P1631, DOI 10.1084/jem.20031942; Braun DA, 2013, J BIOL CHEM, V288, P2986, DOI 10.1074/jbc.M112.386573; Brownlie RJ, 2008, J EXP MED, V205, P883, DOI 10.1084/jem.20072565; Bruhns P, 2003, IMMUNITY, V18, P573, DOI 10.1016/S1074-7613(03)00080-3; Bruhns P, 2012, BLOOD, V119, P5640, DOI 10.1182/blood-2012-01-380121; CELIS E, 1984, SCIENCE, V224, P297, DOI 10.1126/science.6231724; Clatworthy MR, 2004, J EXP MED, V199, P717, DOI 10.1084/jem.20032197; Clynes R, 1999, J EXP MED, V189, P179, DOI 10.1084/jem.189.1.179; Clynes RA, 2000, NAT MED, V6, P443; Crow AR, 2003, BLOOD, V102, P558, DOI 10.1182/blood-2003-01-0023; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Daeron M, 2008, IMMUNOL REV, V224, P11, DOI 10.1111/j.1600-065X.2008.00666.x; Dai XL, 2009, BLOOD, V114, P318, DOI 10.1182/blood-2008-10-184457; de Jong JMH, 2006, MOL IMMUNOL, V43, P2045, DOI 10.1016/j.molimm.2006.01.002; den Haan JMM, 2002, J EXP MED, V196, P817, DOI 10.1084/jem.20020295; Denkers EY, 2005, TRENDS PARASITOL, V21, P35, DOI 10.1016/j.pt.2004.10.004; Desai DD, 2007, J IMMUNOL, V178, P6217; Dhodapkar KM, 2007, J EXP MED, V204, P1359, DOI 10.1084/jem.20062545; Dhodapkar KM, 2005, P NATL ACAD SCI USA, V102, P2910, DOI 10.1073/pnas.0500014102; Dobel T, 2013, BLOOD, V121, P3609, DOI 10.1182/blood-2012-08-447045; Edberg JC, 1999, J BIOL CHEM, V274, P30328, DOI 10.1074/jbc.274.42.30328; Flinsenberg TWH, 2012, BLOOD, V120, P5163, DOI 10.1182/blood-2012-06-434498; Flores M, 2009, J IMMUNOL, V183, P7129, DOI 10.4049/jimmunol.0901169; Gatto D, 2013, NAT IMMUNOL, V14, P446, DOI 10.1038/ni.2555; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Gilliet M, 2008, NAT REV IMMUNOL, V8, P594, DOI 10.1038/nri2358; Gonzalez D, 2005, INT J INFECT DIS, V9, P280, DOI 10.1016/j.ijid.2004.07.012; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Guilliams M, 2013, J EXP MED, V210, P1977, DOI 10.1084/jem.20131199; Guriec N, 2006, J LEUKOCYTE BIOL, V79, P59, DOI 10.1189/jlb.0305155; Guzman MG, 2010, VIRUSES-BASEL, V2, P2649, DOI 10.3390/v2122649; Halstead SB, 2010, LANCET INFECT DIS, V10, P712, DOI 10.1016/S1473-3099(10)70166-3; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Haniffa M, 2012, IMMUNITY, V37, P60, DOI 10.1016/j.immuni.2012.04.012; Hartwig C, 2010, EUR J IMMUNOL, V40, P1284, DOI 10.1002/eji.200939900; Hashimoto D, 2013, IMMUNITY, V38, P792, DOI 10.1016/j.immuni.2013.04.004; Heijnen IAFM, 1996, J CLIN INVEST, V97, P331, DOI 10.1172/JCI118420; Henault J, 2012, IMMUNITY, V37, P986, DOI 10.1016/j.immuni.2012.09.014; Hernandez M, 2002, CIRC RES, V90, P38, DOI 10.1161/hh0102.102978; Hoffmann E, 2012, P NATL ACAD SCI USA, V109, P14556, DOI 10.1073/pnas.1203912109; Hubber A, 2010, ANNU REV CELL DEV BI, V26, P261, DOI 10.1146/annurev-cellbio-100109-104034; Hunter CA, 2012, NAT REV MICROBIOL, V10, P766, DOI 10.1038/nrmicro2858; Iijima N, 2011, P NATL ACAD SCI USA, V108, P284, DOI 10.1073/pnas.1005201108; Ioan-Facsinay A, 2002, IMMUNITY, V16, P391, DOI 10.1016/S1074-7613(02)00294-7; James LC, 2007, P NATL ACAD SCI USA, V104, P6200, DOI 10.1073/pnas.0609174104; Jonsson F, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00016; Joller N, 2011, EUR J IMMUNOL, V41, P889, DOI 10.1002/eji.201041340; Joller N, 2010, P NATL ACAD SCI USA, V107, P20441, DOI 10.1073/pnas.1013827107; Kalergis AM, 2002, J EXP MED, V195, P1653, DOI 10.1084/jem.20020338; Kaneko Y, 2006, J EXP MED, V203, P789, DOI 10.1084/jem.20051900; Karsten CM, 2012, IMMUNOBIOLOGY, V217, P1067, DOI 10.1016/j.imbio.2012.07.015; Kima PE, 2000, J EXP MED, V191, P1063, DOI 10.1084/jem.191.6.1063; Kitamura K, 2007, J IMMUNOL, V178, P480; KLIKS SC, 1988, AM J TROP MED HYG, V38, P411; Kool M, 2011, J LEUKOCYTE BIOL, V90, P1177, DOI 10.1189/jlb.0610342; Laborde EA, 2007, J IMMUNOL, V179, P673; Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744; Lee SMY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008072; Li FB, 2012, CELL CYCLE, V11, P3343, DOI [10.4161/cc.21842, 10.1073/pnas.1208698109]; Li X, 2009, GENES IMMUN, V10, P380, DOI 10.1038/gene.2009.35; Liu SG, 2006, AM J PHYSIOL-CELL PH, V290, pC990, DOI 10.1152/ajpcell.00308.2005; Liu Y, 2006, J IMMUNOL, V177, P8440; Maglione PJ, 2008, J IMMUNOL, V180, P3329; Mallery DL, 2010, P NATL ACAD SCI USA, V107, P19985, DOI 10.1073/pnas.1014074107; Mancardi DA, 2008, J CLIN INVEST, V118, P3738, DOI 10.1172/JCI36452; Mancardi DA, 2013, BLOOD, V121, P1563, DOI 10.1182/blood-2012-07-442541; Mancardi DA, 2011, J IMMUNOL, V186, P1899, DOI 10.4049/jimmunol.1003642; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Martinez FO, 2013, BLOOD, V121, pE57, DOI 10.1182/blood-2012-06-436212; McEwan WA, 2013, NAT IMMUNOL, V14, P327, DOI 10.1038/ni.2548; McEwan WA, 2011, BIOESSAYS, V33, P803, DOI 10.1002/bies.201100093; McGaha TL, 2008, J IMMUNOL, V180, P5670; McLachlan JB, 2009, IMMUNITY, V30, P277, DOI 10.1016/j.immuni.2008.11.013; Means TK, 2005, J CLIN INVEST, V115, P407, DOI 10.1172/JCI200523025; Merad M, 2013, ANNU REV IMMUNOL, V31, P563, DOI 10.1146/annurev-immunol-020711-074950; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470; Miller JC, 2012, NAT IMMUNOL, V13, P888, DOI 10.1038/ni.2370; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; Nimmerjahn F, 2006, IMMUNITY, V24, P19, DOI 10.1016/j.immuni.2005.11.010; Nimmerjahn F, 2005, IMMUNITY, V23, P41, DOI 10.1016/j.immuni.2005.05.010; Nimmerjahn F, 2008, NAT REV IMMUNOL, V8, P34, DOI 10.1038/nri2206; Nimmerjahn Falk, 2012, Cancer Immun, V12, P13; ODIN JA, 1991, SCIENCE, V254, P1785, DOI 10.1126/science.1837175; Ono M, 1996, NATURE, V383, P263, DOI 10.1038/383263a0; Padigel UM, 2005, J IMMUNOL, V174, P6340; Painter MW, 2011, J IMMUNOL, V186, P3047, DOI 10.4049/jimmunol.1002695; Parcina M, 2008, J IMMUNOL, V181, P3823; Persson EK, 2013, IMMUNITY, V38, P958, DOI 10.1016/j.immuni.2013.03.009; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Pricop L, 2001, J IMMUNOL, V166, P531; Qiao SW, 2008, P NATL ACAD SCI USA, V105, P9337, DOI 10.1073/pnas.0801717105; Rafiq K, 2002, J CLIN INVEST, V110, P71, DOI 10.1172/JCI200215640; Regnault A, 1999, J EXP MED, V189, P371, DOI 10.1084/jem.189.2.371; Robbins SH, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-1-r17; Roopenian DC, 2007, NAT REV IMMUNOL, V7, P715, DOI 10.1038/nri2155; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Samsom JN, 2005, J IMMUNOL, V174, P5279; Samuelsson A, 2001, SCIENCE, V291, P484, DOI 10.1126/science.291.5503.484; Saylor CA, 2010, J IMMUNOL, V184, P336, DOI 10.4049/jimmunol.0902752; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Schulz C, 2012, SCIENCE, V336, P86, DOI 10.1126/science.1219179; Schuurhuis DH, 2002, J IMMUNOL, V168, P2240; Schwab I, 2013, NAT REV IMMUNOL, V13, P176, DOI 10.1038/nri3401; Seeling M, 2013, P NATL ACAD SCI USA, V110, P10729, DOI 10.1073/pnas.1301001110; Segura E, 2013, IMMUNITY, V38, P336, DOI 10.1016/j.immuni.2012.10.018; Segura E, 2012, J EXP MED, V209, P653, DOI 10.1084/jem.20111457; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Siragam V, 2006, NAT MED, V12, P688, DOI 10.1038/nm1416; Smith KGC, 2010, NAT REV IMMUNOL, V10, P328, DOI 10.1038/nri2762; Steinman R. M., 1974, IN VITRO, V139, P380; Stetson DB, 2006, IMMUNITY, V24, P93, DOI 10.1016/j.immuni.2005.12.003; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Tamoutounour S, 2013, IMMUNITY, V39, P925, DOI 10.1016/j.immuni.2013.10.004; Tamoutounour S, 2012, EUR J IMMUNOL, V42, P3150, DOI 10.1002/eji.201242847; Te Velde Anje A., 1992, Journal of Immunology, V149, P4048; Tel J, 2013, BLOOD, V121, P459, DOI 10.1182/blood-2012-06-435644; Tel J, 2012, IMMUNOBIOLOGY, V217, P1017, DOI 10.1016/j.imbio.2012.01.016; Tian J, 2007, NAT IMMUNOL, V8, P487, DOI 10.1038/ni1457; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Tobar JA, 2004, J IMMUNOL, V173, P4058; Tridandapani S, 2003, J IMMUNOL, V170, P4572; Tridandapani S, 2002, J BIOL CHEM, V277, P5082, DOI 10.1074/jbc.M110277200; van der Poel CE, 2011, J IMMUNOL, V186, P2699, DOI 10.4049/jimmunol.1003526; van Montfoort N, 2012, J IMMUNOL, V189, P92, DOI 10.4049/jimmunol.1103703; Vidarsson G, 2006, BLOOD, V108, P3573, DOI 10.1182/blood-2006-05-024539; Wenink MH, 2009, J IMMUNOL, V183, P4509, DOI [10.4049/jimmunol.0900153, 10.1049/jimmunol.0900153]; Woelbing F, 2006, J EXP MED, V203, P177, DOI 10.1084/jem.20052288; Yada A, 2003, CELL IMMUNOL, V225, P21, DOI 10.1016/j.cellimm.2003.09.008; Yang ZY, 2007, J IMMUNOL, V178, P1077; Yona S, 2013, IMMUNITY, V38, P79, DOI 10.1016/j.immuni.2012.12.001; Yuasa T, 1999, J EXP MED, V189, P187, DOI 10.1084/jem.189.1.187; Zhu XP, 2001, J IMMUNOL, V166, P3266; Zigmond E, 2012, IMMUNITY, V37, P1076, DOI 10.1016/j.immuni.2012.08.026	152	138	140	18	72	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733	1474-1741		NAT REV IMMUNOL	Nat. Rev. Immunol.	FEB	2014	14	2					94	108		10.1038/nri3582		15	Immunology	Immunology	AA3VI	WOS:000331022400012	24445665	
J	Caliskan, M; Bochkov, YA; Kreiner-Moller, E; Bonnelykke, K; Stein, MM; Du, GX; Bisgaard, H; Jackson, DJ; Gern, JE; Lemanske, RF; Nicolae, DL; Ober, C				Caliskan, Minal; Bochkov, Yury A.; Kreiner-Moller, Eskil; Bonnelykke, Klaus; Stein, Michelle M.; Du, Gaixin; Bisgaard, Hans; Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.; Nicolae, Dan L.; Ober, Carole			Rhinovirus Wheezing Illness and Genetic Risk of Childhood-Onset Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GASDERMIN-LIKE GSDML; 17Q21 VARIANTS; SMOKE EXPOSURE; EXPRESSION; ORMDL3; ASSOCIATION; EXACERBATIONS; INFECTIONS; CHILDREN; DISEASE	BACKGROUND Both genetic variation at the 17q21 locus and virus-induced respiratory wheezing illnesses are associated with the development of asthma. Our aim was to determine the effects of these two factors on the risk of asthma in the Childhood Origins of Asthma (COAST) and the Copenhagen Prospective Study on Asthma in Childhood (COPSAC) birth cohorts. METHODS We tested genotypes at the 17q21 locus for associations with asthma and with human rhinovirus (HRV) and respiratory syncytial virus (RSV) wheezing illnesses and tested for interactions between 17q21 genotypes and HRV and RSV wheezing illnesses with respect to the risk of asthma. Finally, we examined genotype-specific expression of 17q21 genes in unstimulated and HRV-stimulated peripheral-blood mononuclear cells (PBMCs). RESULTS The 17q21 variants were associated with HRV wheezing illnesses in early life, but not with RSV wheezing illnesses. The associations of 17q21 variants with asthma were restricted to children who had had HRV wheezing illnesses, resulting in a significant interaction effect with respect to the risk of asthma. Moreover, the expression levels of ORMDL3 and of GSDMB were significantly increased in HRV-stimulated PBMCs, as compared with unstimulated PBMCs. The expression of these genes was associated with 17q21 variants in both conditions, although the increase with exposure to HRV was not genotype-specific. CONCLUSIONS Variants at the 17q21 locus were associated with asthma in children who had had HRV wheezing illnesses and with expression of two genes at this locus. The expression levels of both genes increased in response to HRV stimulation, although the relative increase was not associated with the 17q21 genotypes. (Funded by the National Institutes of Health.)	[Caliskan, Minal; Stein, Michelle M.; Du, Gaixin; Nicolae, Dan L.; Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Med, Chicago, IL 60637 USA; [Nicolae, Dan L.] Univ Chicago, Dept Stat, Chicago, IL 60637 USA; [Ober, Carole] Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; [Bochkov, Yury A.; Jackson, Daniel J.; Gern, James E.; Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Pediat, Madison, WI USA; [Lemanske, Robert F., Jr.] Univ Wisconsin, Dept Med, Madison, WI USA; [Kreiner-Moller, Eskil; Bonnelykke, Klaus; Bisgaard, Hans] Univ Copenhagen, Fac Hlth Sci, Gentofte, Denmark; [Kreiner-Moller, Eskil; Bonnelykke, Klaus; Bisgaard, Hans] Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Gentofte, Denmark	Caliskan, M (reprint author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.	caliskan@uchicago.edu; c-ober@genetics.uchicago.edu	Du, Gaixin/M-9901-2014; Bisgaard, Hans/N-4761-2016	Du, Gaixin/0000-0002-4616-7725; Bisgaard, Hans/0000-0003-4131-7592; Bochkov, Yury/0000-0003-2618-4496; Kreiner, Eskil/0000-0003-1204-2438	National Institutes of Health [HL070831, AI070503]; KL2 from the National Institutes of Health [UL1TR00042]; Lundbeck Foundation; Danish Council for Strategic Research; Danish Pediatric Asthma Center	Funded by the National Institutes of Health.; Supported by grants (HL070831 and AI070503) from the National Institutes of Health. Dr. Jackson was supported by KL2 grant UL1TR000427 from the National Institutes of Health. The Lundbeck Foundation, Danish Council for Strategic Research, and Danish Pediatric Asthma Center provided the core funding for the COPSAC research unit.	Akhabir L, 2011, RESPIROLOGY, V16, P396, DOI 10.1111/j.1440-1843.2011.01939.x; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127; Bisgaard H, 2010, BRIT MED J, V341, pc4978; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Carl-Mcgrath S, 2008, PATHOLOGY, V40, P13, DOI 10.1080/00313020701716250; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Flory JH, 2009, J ALLERGY CLIN IMMUN, V124, P605, DOI 10.1016/j.jaci.2009.05.047; Halapi E, 2010, EUR J HUM GENET, V18, P902, DOI 10.1038/ejhg.2010.38; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hyvarinen MK, 2005, PEDIATR PULM, V40, P316, DOI 10.1002/ppul.20273; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Miller M, 2012, P NATL ACAD SCI USA, V109, P16648, DOI 10.1073/pnas.1204151109; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murphy A, 2010, HUM MOL GENET, V19, P4745, DOI 10.1093/hmg/ddq392; Ober C, 2011, IMMUNOL REV, V242, P10, DOI 10.1111/j.1600-065X.2011.01029.x; Ober C, 2011, TRENDS GENET, V27, P107, DOI 10.1016/j.tig.2010.12.004; Saeki N, 2009, GENE CHROMOSOME CANC, V48, P261, DOI 10.1002/gcc.20636; Smit LAM, 2010, EUR RESPIR J, V36, P57, DOI 10.1183/09031936.00154509; Sykes A, 2008, J ALLERGY CLIN IMMUN, V122, P685, DOI 10.1016/j.jaci.2008.08.017; Trujillo-Alonso V, 2011, J VIROL, V85, P12594, DOI 10.1128/JVI.05620-11; van der Valk RJP, 2012, ALLERGY, V67, P767, DOI 10.1111/j.1398-9995.2012.02819.x; Verlaan DJ, 2009, GENOME RES, V19, P118, DOI 10.1101/gr.084798.108; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x	29	138	142	3	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 11	2013	368	15					1398	1407		10.1056/NEJMoa1211592		10	Medicine, General & Internal	General & Internal Medicine	122QT	WOS:000317333600007	23534543	
S	Lambrecht, BN; Hammad, H		Paul, WE		Lambrecht, Bart N.; Hammad, Hamida			Lung Dendritic Cells in Respiratory Viral Infection and Asthma: From Protection to Immunopathology	ANNUAL REVIEW OF IMMUNOLOGY, VOL 30	Annual Review of Immunology		English	Review; Book Chapter						dendritic cells; virus; asthma; allergy	ALLERGIC AIRWAY INFLAMMATION; HOUSE-DUST MITE; CD8(+) T-CELL; THYMIC STROMAL LYMPHOPOIETIN; INFLUENZA-VIRUS INFECTION; AMBIENT PARTICULATE MATTER; HELPER TYPE-2 RESPONSE; BLOOD MONOCYTE SUBSETS; BRONCHIAL LYMPH-NODE; EPITHELIAL-CELLS	Lung dendritic cells (DCs) bridge innate and adaptive immunity, and depending on context, they also induce a Th1, Th2, or Th17 response to optimally clear infectious threats. Conversely, lung DCs can also mount maladaptive Th2 immune responses to harmless allergens and, in this way, contribute to immunopathology. It is now clear that the various aspects of DC biology can be understood only if we take into account the functional specializations of different DC subsets that are present in the lung in homeostasis or are attracted to the lung as part of the inflammatory response to inhaled noxious stimuli. Lung DCs are heavily influenced by the nearby epithelial cells, and a model is emerging whereby direct communication between DCs and epithelial cells determines the outcome of the pulmonary immuneresponse. Here, we have approached DC biology from the perspective of viral infection and allergy to illustrate these emerging concepts.	[Lambrecht, Bart N.; Hammad, Hamida] Univ Ghent VIB, Lab Immunoregulat & Mucosal Immunol, Dept Mol Biomed Res, B-9052 Ghent, Belgium; [Lambrecht, Bart N.] Ghent Univ Hosp, Dept Resp Med, B-9000 Ghent, Belgium; [Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, NL-3015 CE Rotterdam, Netherlands	Lambrecht, BN (reprint author), Univ Ghent VIB, Lab Immunoregulat & Mucosal Immunol, Dept Mol Biomed Res, B-9052 Ghent, Belgium.	bart.lambrecht@ugent.be; hamida.hammad@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Ballesteros-Tato A, 2010, NAT IMMUNOL, V11, P216, DOI 10.1038/ni.1838; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barrett NA, 2009, J IMMUNOL, V182, P1119; Beaty SR, 2007, J IMMUNOL, V178, P1882; Beauchamp NM, 2010, J VIROL, V84, P10191, DOI 10.1128/JVI.00892-10; Belz GT, 2007, NAT IMMUNOL, V8, P1060, DOI 10.1038/ni1505; Belz GT, 2007, P NATL ACAD SCI USA, V104, P6341, DOI 10.1073/pnas.0609990104; Belz GT, 2004, P NATL ACAD SCI USA, V101, P8670, DOI 10.1073/pnas.0402644101; Belz GT, 2006, EUR J IMMUNOL, V36, P327, DOI 10.1002/eji.200535432; Blank F, 2011, IMMUNOBIOLOGY, V216, P86, DOI 10.1016/j.imbio.2010.02.006; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Burgdorf S, 2007, SCIENCE, V316, P612, DOI 10.1126/science.1137971; Chen L, 2006, J IMMUNOL, V177, P2373; Cheong C, 2010, CELL, V143, P416, DOI 10.1016/j.cell.2010.09.039; Cheung DS, 2010, J IMMUNOL, V185, P4983, DOI 10.4049/jimmunol.1002456; Crowe SR, 2003, J EXP MED, V198, P399, DOI 10.1084/jem.20022151; Davidson S, 2011, J IMMUNOL, V186, P5938, DOI 10.4049/jimmunol.1002635; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; del Rio ML, 2007, J IMMUNOL, V178, P6861; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Demedts IK, 2006, AM J RESP CELL MOL, V35, P387, DOI 10.1165/rcmb.2005-0382OC; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; Diao J, 2006, J IMMUNOL, V176, P7196; Dodge IL, 2003, J IMMUNOL, V170, P4457; Dudziak D, 2007, SCIENCE, V315, P107, DOI 10.1126/science.1136080; Edelson BT, 2010, J EXP MED, V207, P823, DOI 10.1084/jem.20091627; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Eiwegger T, 2011, EUR J IMMUNOL, V41, P1535, DOI 10.1002/eji.201141668; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; GeurtsvanKessel CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007187; GeurtsvanKessel CH, 2009, J EXP MED, V206, P2339, DOI 10.1084/jem.20090410; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Hahn I, 2011, AM J RESP CELL MOL, V45, P534, DOI 10.1165/rcmb.2010-0279OC; Halle S, 2009, J EXP MED, V206, P2593, DOI 10.1084/jem.20091472; HAMILTONEASTON A, 1995, J VIROL, V69, P6359; Hammad H, 2003, J IMMUNOL, V171, P3936; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; HAVENITH CEG, 1994, CLIN EXP IMMUNOL, V96, P339; Hildner K, 2008, SCIENCE, V322, P1097, DOI 10.1126/science.1164206; Hintzen G, 2006, J IMMUNOL, V177, P7346; Hoeffel G, 2007, IMMUNITY, V27, P481, DOI 10.1016/j.immuni.2007.07.021; Hollingsworth JW, 2010, J ALLERGY CLIN IMMUN, V125, P1167, DOI 10.1016/j.jaci.2010.03.001; Hufford MM, 2011, J EXP MED, V208, P167, DOI 10.1084/jem.20101850; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Jahnsen FL, 2006, J IMMUNOL, V177, P5861; Jakubzick C, 2008, J IMMUNOL METHODS, V337, P121, DOI 10.1016/j.jim.2008.07.005; Jakubzick C, 2008, J IMMUNOL, V180, P3019; Jakubzick C, 2006, J IMMUNOL, V176, P3578; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Jelley-Gibbs DM, 2005, J EXP MED, V202, P697, DOI 10.1084/jem.20050227; Kallal LE, 2010, EUR J IMMUNOL, V40, P1042, DOI 10.1002/eji.200939778; Kim TS, 2010, J EXP MED, V207, P1161, DOI 10.1084/jem.20092017; Kim TS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004204; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; KRADIN RL, 1993, AM J PATHOL, V142, P811; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kuipers H, 2003, J IMMUNOL, V171, P3645; Kuroda E, 2011, IMMUNITY, V34, P514, DOI 10.1016/j.immuni.2011.03.019; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; Landsman L, 2007, J IMMUNOL, V178, P2000; Legge KL, 2003, IMMUNITY, V18, P265, DOI 10.1016/S1074-7613(03)00023-2; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Lin KL, 2008, J IMMUNOL, V180, P2562; Liu K, 2007, NAT IMMUNOL, V8, P578, DOI 10.1038/ni1462; Liu K, 2009, SCIENCE, V324, P392, DOI [10.1126/science.1170540, 10.1126/science.1171243]; Marichal T, 2010, J ALLERGY CLIN IMMUN, V126, P836, DOI 10.1016/j.jaci.2010.06.009; Marsolais D, 2011, MOL PHARMACOL, V79, P61, DOI 10.1124/mol.110.066811; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McComb JG, 2008, AM J PATHOL, V173, P949, DOI 10.2353/ajpath.2008.071034; McGill J, 2008, J EXP MED, V205, P1635, DOI 10.1084/jem.20080314; McGill J, 2010, J EXP MED, V207, P521, DOI 10.1084/jem.20091711; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Medoff BD, 2009, J IMMUNOL, V182, P623; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Naik SH, 2006, NAT IMMUNOL, V7, P663, DOI 10.1038/ni1340; Naito T, 2008, AM J RESP CELL MOL, V38, P161, DOI 10.1165/rcmb.2007-0237OC; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Okunishi K, 2004, J IMMUNOL, V173, P6393; Oriss TB, 2005, J IMMUNOL, V174, P854; Osterholzer JJ, 2005, J IMMUNOL, V175, P874; Otero K, 2010, BLOOD, V116, P2942, DOI 10.1182/blood-2009-12-259903; Page K, 2009, J IMMUNOL, V183, P3400, DOI 10.4049/jimmunol.0900838; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Plantinga M, 2010, EUR J IMMUNOL, V40, P2112, DOI 10.1002/eji.201040562; POLLARD AM, 1990, J EXP MED, V172, P159, DOI 10.1084/jem.172.1.159; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Randolph GJ, 1999, IMMUNITY, V11, P753, DOI 10.1016/S1074-7613(00)80149-1; Rangasamy T, 2010, AM J RESP CELL MOL, V43, P276, DOI 10.1165/rcmb.2008-0438OC; Raymond M, 2011, J ALLERGY CLIN IMMUN, V128, P192, DOI 10.1016/j.jaci.2011.04.029; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Robays LJ, 2007, J IMMUNOL, V178, P5305; Robinson RT, 2010, J EXP MED, V207, P591, DOI 10.1084/jem.20091085; Sallmann E, 2011, J IMMUNOL, V187, P164, DOI 10.4049/jimmunol.1003392; Sammani S, 2011, AM J RESP C IN PRESS; Serbina NV, 2003, IMMUNITY, V19, P59, DOI 10.1016/S1074-7613(03)00171-7; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; Shen CH, 2010, P NATL ACAD SCI USA, V107, P22587, DOI 10.1073/pnas.1016350108; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Smits HH, 2009, MUCOSAL IMMUNOL, V2, P331, DOI 10.1038/mi.2009.16; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Stumbles PA, 2001, J IMMUNOL, V167, P228; Suarez-Ramirez JE, 2011, EUR J IMMUN IN PRESS; Sung SSJ, 2001, J IMMUNOL, V166, P1261; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Takagi T, 2011, AM J RESP CRIT CARE, V183, P31, DOI 10.1164/rccm.201001-0107OC; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1111/j.1365-2222.1996.tb00591.x; Van Pottelberge GR, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-35; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2011, AM J RESP CRIT CARE, V184, P303, DOI 10.1164/rccm.201101-0019OC; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; VANHAARST JMW, 1994, AM J RESP CELL MOL, V11, P344; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Vermaelen KY, 2001, J EXP MED, V193, P51; von Garnier C, 2005, J IMMUNOL, V175, P1609; von Garnier C, 2007, J IMMUNOL, V179, P5748; Walter MJ, 2001, J EXP MED, V193, P339, DOI 10.1084/jem.193.3.339; Walzer T, 2005, J ALLERGY CLIN IMMUN, V115, P192, DOI 10.1016/j.jaci.2004.08.046; Wang HW, 2006, J IMMUNOL, V177, P6263; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Waskow C, 2008, NAT IMMUNOL, V9, P676, DOI 10.1038/ni.1615; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Willart MAM, 2009, J EXP MED, V206, P2823, DOI 10.1084/jem.20082401; Williams MA, 2008, J IMMUNOL, V181, P4545; Wills-Karp M, 2010, CURR OPIN IMMUNOL, V22, P777, DOI 10.1016/j.coi.2010.10.011; Wolf AI, 2009, J IMMUNOL, V182, P871; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Ye YL, 2011, AM J PHYSIOL-LUNG C, V300, pL216, DOI 10.1152/ajplung.00165.2010; Yoo JK, 2010, J EXP MED, V207, P1435, DOI 10.1084/jem.20091373; Zammit DJ, 2005, IMMUNITY, V22, P561, DOI 10.1016/j.immuni.2005.03.005; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	162	138	140	2	40	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	0732-0582		978-0-8243-3030-9	ANNU REV IMMUNOL	Annu. Rev. Immunol.		2012	30						243	270		10.1146/annurev-immunol-020711-075021		28	Immunology	Immunology	BAH94	WOS:000304198100011	22224777	
J	Carlsen, KH; Anderson, SD; Bjermer, L; Bonini, S; Brusasco, V; Canonica, W; Cummiskey, J; Delgado, L; Del Giacco, SR; Drobnic, F; Haahtela, T; Larsson, K; Palange, P; Popov, T; van Cauwenberge, P				Carlsen, K. H.; Anderson, S. D.; Bjermer, L.; Bonini, S.; Brusasco, V.; Canonica, W.; Cummiskey, J.; Delgado, L.; Del Giacco, S. R.; Drobnic, F.; Haahtela, T.; Larsson, K.; Palange, P.; Popov, T.; van Cauwenberge, P.			Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: Part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA(2)LEN	ALLERGY			English	Review						asthma; allergy; bronchial responsiveness; sports; exercise-induced asthma	CROSS-COUNTRY SKIERS; HYPERVENTILATION-INDUCED ASTHMA; ICE HOCKEY PLAYERS; BRONCHIAL RESPONSIVENESS; INDUCED BRONCHOSPASM; INDUCED BRONCHOCONSTRICTION; AIRWAY INFLAMMATION; INDUCED ANAPHYLAXIS; COLD-AIR; INDUCED HYPOXEMIA	Aims: To analyze the changes in the prevalence of asthma, bronchial hyperresponsiveness (BHR) and allergies in elite athletes over the past years, to review the specific pathogenetic features of these conditions and to make recommendations for their diagnosis. Mehtods: The Task Force reviewed present literature by searching Medline up to November 2006 for relevant papers by the search words: asthma, bronchial responsiveness, EIB, athletes and sports. Sign criteria were used to assess level of evidence and grades of recommendation. Results: The problems of sports-related asthma and allergy are outlined. Epidemiological evidence for an increased prevalence of asthma and BHR among competitive athletes, especially in endurance sports, is provided. The mechanisms for development of asthma and bronchial hyperresponsiveness in athletes are outlined. Criteria are given for the diagnosis of asthma and exercise induced asthma in the athlete. Conclusions: The prevalence of asthma and bronchial hyperresponsiveness is markedly increased in athletes, especially within endurance sports. Environmental factors often contribute. Recommendations for the diagnosis of asthma in athletes are outlined.	[Carlsen, K. H.] Univ Oslo, Rikshosp, Fac Med, Dept Paediat,Med Ctr, NO-0791 Oslo, Norway; [Carlsen, K. H.] Norwegian Sch Sport Sci, Oslo, Norway; [Anderson, S. D.] Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; [Bjermer, L.] Univ Lund Hosp, Dept Resp Med & Allergol, S-22185 Lund, Sweden; [Bonini, S.] CNR, Inst Neurobiol & Mol Med, Rome, Italy; [Bonini, S.] Univ Naples 2, Naples, Italy; [Brusasco, V.] Univ Genoa, Dipartimento Med Interna, Genoa, Italy; [Canonica, W.] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; [Cummiskey, J.] Blackrock Clin, Dublin, Ireland; [Delgado, L.] Univ Porto, Serv & Lab Imunol, Fac Med, Hosp S Joao, P-4100 Oporto, Portugal; [Del Giacco, S. R.] Policlin Univ Cagliari, Cagliari, Italy; [Drobnic, F.] Olymp Training Ctr CAR, Sports & Physiol Dept, Barcelona, Spain; [Haahtela, T.] Univ Helsinki, Cent Hosp, Dept Allergy, Skin Allergy Hosp, Helsinki, Finland; [Palange, P.] Dipartimento Med Clin, Rome, Italy; [Popov, T.] Med Univ 1, Clin Ctr Allergol, Sofia, Bulgaria; [van Cauwenberge, P.] Univ Ghent, Dept Otorhinolaryngol, B-9000 Ghent, Belgium	Carlsen, KH (reprint author), Univ Oslo, Rikshosp, Fac Med, Dept Paediat,Med Ctr, Ullveien 14, NO-0791 Oslo, Norway.		FMUP, CINTESIS/C-6631-2014; Delgado, Luis/L-8035-2013	FMUP, CINTESIS/0000-0001-7248-2086; Delgado, Luis/0000-0003-2375-9071			Adir Y, 2004, CHEST, V126, P394, DOI 10.1378/chest.126.2.394; AMIRAV I, 1986, S AFR MED J, V69, P227; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Anderson SD, 2003, J ALLERGY CLIN IMMUN, V111, P45, DOI 10.1067/mai.2003.1; ANDERSON SD, 1971, BMJ-BRIT MED J, V4, P814; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; AVITAL A, 1995, THORAX, V50, P511, DOI 10.1136/thx.50.5.511; BARNES PJ, 1981, THORAX, V36, P435, DOI 10.1136/thx.36.6.435; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; BJERMER L, 2005, DIAGNOSIS PREVENTION, P19; Bonadonna P, 2001, AM J RHINOL, V15, P297; Bonini S, 2004, ALLERGY, V59, P33, DOI 10.1046/j.1398-9995.2003.00355.x; Bonsignore MR, 2001, AM J PHYSIOL-LUNG C, V281, pL668; Bonsignore MR, 2003, MED SCI SPORT EXER, V35, P1146, DOI 10.1249/01.MSS.0000074581.08023.25; Boulet LP, 2005, CLIN INVEST MED, V28, P15; BOULET LP, 1987, THORAX, V42, P953, DOI 10.1136/thx.42.12.953; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; BRUSASCO V, 1989, J APPL PHYSIOL, V66, P1190; BUCHBINDER EM, 1983, JAMA-J AM MED ASSOC, V250, P2973, DOI 10.1001/jama.250.21.2973; Carlsen KH, 1999, AM J RESP CRIT CARE, V159, pA412; Carlsen KH, 1998, RESP MED, V92, P308, DOI 10.1016/S0954-6111(98)90114-7; Carlsen KH, 1997, SCAND J MED SCI SPOR, V7, P160; Carlsen KH, 2000, RESP MED, V94, P750, DOI 10.1053/rmed.2000.0809; Carlsen KH, 1989, CHILDREN EXERCISE, VXIII, P351; Chimenti L, 2007, AM J RESP CRIT CARE, V175, P442, DOI 10.1164/rccm.200608-1086OC; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; Cockcroft DW, 2005, CHEST, V127, P839, DOI 10.1378/chest.127.3.839; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crimi E, 2002, J APPL PHYSIOL, V92, P2353, DOI 10.1152/japplphysiol.01248.2001; Dahlen B, 2001, EUR RESPIR J, V17, P581, DOI 10.1183/09031936.01.17405810; DEAL EC, 1979, J APPL PHYSIOL, V46, P467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476; DEMPSEY JA, 1990, CHEST, V97, pS81, DOI 10.1378/chest.97.3_Supplement.81S-a; Dickinson JW, 2006, BRIT J SPORT MED, V40, P179, DOI 10.1136/bjsm.2005.022764; Dickinson JW, 2005, THORAX, V60, P629, DOI 10.1136/thx.2004.037499; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; DROBNIC F, 2005, DIAGNOSIS PREVENTION, P35; Durand F, 2000, MED SCI SPORT EXER, V32, P926; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; FARLEY RD, 1988, THORAX, V43, P289, DOI 10.1136/thx.43.4.289; Feinstein RA, 1996, CLIN J SPORT MED, V6, P119; Fitch KD, 2006, CLIN REV ALLERG IMMU, V31, P259, DOI 10.1385/CRIAI:31:2:259; FREED AN, 1987, AM REV RESPIR DIS, V136, P595; FREED AN, 1994, AM J RESP CELL MOL, V11, P724; Gall H, 2000, ALLERGY, V55, P1096, DOI 10.1034/j.1398-9995.2000.00812.x; GILBERT IA, 1992, J CLIN INVEST, V90, P699, DOI 10.1172/JCI115940; GODFREY S, 1991, THORAX, V46, P488, DOI 10.1136/thx.46.7.488; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Heir T., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P94; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P128; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P134; Heir T., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P152; HELBLING A, 1990, SCHWEIZ MED WSCHR, V120, P231; Helenius I, 2004, ALLERGY, V59, P39, DOI 10.1046/j.1398-9995.2003.00353.x; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Helenius IJ, 1997, THORAX, V52, P157; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; HENRIKSEN JM, 1986, ALLERGY, V41, P225, DOI 10.1111/j.1398-9995.1986.tb00304.x; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; JONES NL, 1988, THORAX LUNG BIOL HLT, P627; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086; Katelaris CH, 2000, J ALLERGY CLIN IMMUN, V106, P260; KATZ RM, 1984, J ALLERGY CLIN IMMUN, V73, P708, DOI 10.1016/0091-6749(84)90311-7; KIDD JM, 1983, J ALLERGY CLIN IMMUN, V71, P407, DOI 10.1016/0091-6749(83)90070-2; Koskela HO, 2003, CHEST, V124, P1341, DOI 10.1378/chest.124.4.1341; Kotaru C, 2005, J APPL PHYSIOL, V98, P1028, DOI 10.1152/japplphysiol.01186.2003; Lagerkvist BJ, 2004, ENVIRON HEALTH PERSP, V112, P1768, DOI 10.1289/ehp.7027; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; LARSSON K, 1993, BRIT MED J, V307, P1326; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1985, THORAX, V40, P481, DOI 10.1136/thx.40.7.481; Lumme A, 2003, EUR RESPIR J, V22, P113, DOI 10.1183/09031936.03.00112403; Maiolo C, 2004, INT J SPORTS MED, V25, P139; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564; McFadden ER, 1996, AM J RESP CRIT CARE, V153, P942; Morici G, 2004, MED SCI SPORT EXER, V36, P1723, DOI 10.1249/01.MSS.0000142411.27685.72; Nielsen KG, 2005, AM J RESP CRIT CARE, V171, P238, DOI 10.1164/rccm.200404-528OC; NIEMINEN MM, 1988, THORAX, V43, P896, DOI 10.1136/thx.43.11.896; Nystad W, 2000, MED SCI SPORT EXER, V32, P266, DOI 10.1097/00005768-200002000-00003; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; OMORI C, 1995, J APPL PHYSIOL, V78, P1043; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; PIERSON WE, 1986, MED SCI SPORT EXER, V18, P322, DOI 10.1249/00005768-198606000-00012; POWERS SK, 1992, EUR J APPL PHYSIOL O, V65, P37, DOI 10.1007/BF01466272; POWERS SK, 1988, EUR J APPL PHYSIOL O, V58, P298, DOI 10.1007/BF00417266; POWERS SK, 1987, SPORTS MED, V4, P46, DOI 10.2165/00007256-198704010-00005; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Reiss TF, 1997, THORAX, V52, P1030; Ronsen O., 1995, European Respiratory Journal, V8, p473S; Ross RG, 2000, MED SCI SPORT EXER, V32, P1985, DOI 10.1097/00005768-200012000-00003; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2003, INHAL TOXICOL, V15, P237, DOI 10.1080/08958370390168256; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SAMARANCH JA, 1988, OLYMPIC BOOK SPORTS, pR6; Schoene RB, 1997, CLIN J SPORT MED, V7, P257, DOI 10.1097/00042752-199710000-00003; Shadick NA, 1999, J ALLERGY CLIN IMMUN, V104, P123, DOI 10.1016/S0091-6749(99)70123-5; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882; Slieker M G, 2003, Monaldi Arch Chest Dis, V59, P155; SODAL A, 1997, BRONCHIAL HYPERREACT; Stensrud T, 2004, AM J RESP CRIT CARE, V169, pA694; Stensrud T, 2007, MED SCI SPORT EXER, V39, P1681, DOI 10.1249/mss.0b013e31813738ac; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; Sue-Chu M, 2000, RESPIRATION, V67, P417, DOI 10.1159/000029541; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; Turcotte H, 2003, J ASTHMA, V40, P71, DOI 10.1081/JAS-120017209; Varraso R, 2002, TOXICOL IND HEALTH, V18, P269, DOI 10.1191/0748233702th150oa; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; WILLIAMS JH, 1986, MED SCI SPORT EXER, V18, P168; Wubbel C, 2004, CHEST, V125, P453, DOI 10.1378/chest.125.2.453; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZACH MS, 1987, J ALLERGY CLIN IMMUN, V80, P9, DOI 10.1016/S0091-6749(87)80184-7; ZWICK H, 1990, LUNG, V168, P111; [Anonymous], 2006, GLOBAL STRATEGY ASTH	144	138	138	1	20	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	APR	2008	63	4					387	403		10.1111/j.1398-9995.2008.01662.x		17	Allergy; Immunology	Allergy; Immunology	270FF	WOS:000253705300002	18315727	
J	Thompson, C; Powrie, F				Thompson, C; Powrie, F			Regulatory T cells	CURRENT OPINION IN PHARMACOLOGY			English	Review							TRANSCRIPTION FACTOR FOXP3; IN-VIVO; TGF-BETA; CUTTING EDGE; DENDRITIC CELLS; DEPENDENT MECHANISMS; SUPPRESSOR FUNCTION; IMMUNE PATHOLOGY; CD4(+)CD25(+); CD25(+)	Regulatory T (T-R) cells are a subset of T cells that function to control immune responses. Different populations of T-R cells have been described, including thymically derived CD4(+)CD25(+) T-R cells and TO cells induced in the periphery through exposure to antigen. A transcription factor, Foxp3, has been identified that is essential for CD4(+)CD25(+) T-R cell development and function. There is now evidence that transforming growth factor-beta might play a role in this pathway. CD4(+)CD25(+) T-R cells proliferate extensively in vivo in an antigen-specific manner, and can respond to both self and foreign peptides. By suppressing excessive immune responses, T-R cells play a key role in the maintenance of self-tolerance, thus preventing autoimmune disease, as well as inhibiting harmful inflammatory diseases such as asthma and inflammatory bowel disease.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England	Powrie, F (reprint author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.	fiona.powrie@pathology.oxford.ac.uk					Aluvihare VR, 2004, NAT IMMUNOL, V5, P266, DOI 10.1038/ni1037; Annacker O, 2001, J IMMUNOL, V166, P3008; Belghith M, 2003, NAT MED, V9, P1202, DOI 10.1038/nm924; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bruder D, 2004, EUR J IMMUNOL, V34, P623, DOI 10.1002/eji.200324799; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cobbold SP, 2004, J IMMUNOL, V172, P6003; Cong YZ, 2002, J IMMUNOL, V169, P6112; Cozzo C, 2003, J IMMUNOL, V171, P5678; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fantini MC, 2004, J IMMUNOL, V172, P5149; Fisson S, 2003, J EXP MED, V198, P737, DOI 10.1084/jem.20030686; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Foussat A, 2003, J IMMUNOL, V171, P5018; Gavin M, 2003, CURR OPIN IMMUNOL, V15, P690, DOI 10.1016/j.coi.2003.09.011; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Graca L, 2002, J EXP MED, V195, P1641, DOI 10.1084/jem.20012097; Green EA, 2003, P NATL ACAD SCI USA, V100, P10878, DOI 10.1073/pnas.1834400100; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Hesse M, 2004, J IMMUNOL, V172, P3157; Higgins SC, 2003, J IMMUNOL, V171, P3119; Hisaeda H, 2004, NAT MED, V10, P29, DOI 10.1038/nm975; Hori S, 2002, EUR J IMMUNOL, V32, P1282, DOI 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huehn J, 2004, J EXP MED, V199, P303, DOI 10.1084/jem.20031562; Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Kriegel MA, 2004, J EXP MED, V199, P1285, DOI 10.1084/jem.20032158; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Lin CH, 2003, EUR J IMMUNOL, V33, P626, DOI 10.1002/eji.200323570; Liu HY, 2003, J IMMUNOL, V171, P5012; Malek TR, 2003, J LEUKOCYTE BIOL, V74, P961, DOI 10.1189/jlb.0603272; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Mamura M, 2004, BLOOD, V103, P4594, DOI 10.1182/blood-2003-08-2897; Mills KHG, 2004, SEMIN IMMUNOL, V16, P107, DOI 10.1016/j.smim.2003.12.006; Mottet C, 2003, J IMMUNOL, V170, P3939; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nakamura K, 2004, J IMMUNOL, V172, P834; Oldenhove G, 2003, J EXP MED, V198, P259, DOI 10.1084/jem.20030654; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Piccirillo CA, 2004, SEMIN IMMUNOL, V16, P81, DOI 10.1016/j.smim.2003.12.003; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Piccirillo CA, 2001, J IMMUNOL, V167, P1137; Ramsdell F, 2003, CURR OPIN IMMUNOL, V15, P718, DOI 10.1016/j.coli.2003.09.008; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Seddon B, 2000, IMMUNOL TODAY, V21, P95, DOI 10.1016/S0167-5699(99)01559-5; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Suvas S, 2003, J EXP MED, V198, P889, DOI 10.1084/jem.20030171; Tang QZ, 2003, J IMMUNOL, V171, P3348; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Uraushihara K, 2003, J IMMUNOL, V171, P708; Vieira PL, 2004, J IMMUNOL, V172, P5986; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Yamazaki S, 2003, J EXP MED, V198, P235, DOI 10.1081/jem.20030422; Zheng SG, 2004, J IMMUNOL, V172, P5213	66	138	156	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4892			CURR OPIN PHARMACOL	Curr. Opin. Pharmacol.	AUG	2004	4	4					408	414		10.1016/j.coph.2004.05.001		7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	846LC	WOS:000223316000017	15251137	
J	de Marco, R; Accordini, S; Cerveri, I; Corsico, A; Sunyer, J; Neukirch, F; Kunzli, N; Leynaert, B; Janson, C; Gislason, T; Vermeire, P; Svanes, C; Anto, JM; Burney, P				de Marco, R; Accordini, S; Cerveri, I; Corsico, A; Sunyer, J; Neukirch, F; Kunzli, N; Leynaert, B; Janson, C; Gislason, T; Vermeire, P; Svanes, C; Anto, JM; Burney, P		European Community Resp Hlth Surve	An international survey of chronic obstructive pulmonary disease in young adults according to GOLD stages	THORAX			English	Article							RESPIRATORY-HEALTH-SURVEY; AIR-FLOW OBSTRUCTION; GENDER-DIFFERENCES; SMOKING-HABITS; UNITED-STATES; COPD; MORTALITY; ASTHMA	Background: The recently published GOLD guidelines provide a new system for staging chronic obstructive pulmonary disease (COPD) from mild (stage I) to very severe (stage IV) and introduce a stage 0 (chronic cough and phlegm without airflow obstruction) that includes subjects "at risk" of developing the disease. Methods: In order to assess the prevalence of GOLD stages of COPD in high income countries and to evaluate their association with the known risk factors for airflow obstruction, data from the European Community Respiratory Health Survey on more than 18 000 young adults (20-44 years) were analysed. Results: The overall prevalence was 11.8% (95% CI 11.3 to 12.3) for stage 0, 2.5% (95% CI 2.2 to 2.7) for stage I, and 1.1% (95% CI 1.0 to 1.3) for stages II-III. Moderate to heavy smoking (greater than or equal to15 pack years) was significantly associated with both stage 0 (relative risk ratio (RRR) = 4.15; 95% CI 3.55 to 4.84) and stages I+ (RRR = 4.09; 95% CI 3.17 to 5.26), while subjects with stages I+ COPD had a higher likelihood of giving up smoking (RRR = 1.39; 95% CI 1.04 to 1.86) than those with GOLD stage 0 (RRR = 1.05; 95% CI 0.86 to 1.27). Environmental tobacco smoke had the same degree of positive association in both groups. Respiratory infections in childhood and low socioeconomic class were significantly and homogeneously associated with both groups, whereas occupational exposure was significantly associated only with stage 0. All the GOLD stages showed a significantly higher percentage of healthcare resource users than healthy subjects (p < 0.001), with no difference between stage 0 and COPD. Conclusions: A considerable percentage of young adults already suffered from COPD. GOLD stage 0 was characterised by the presence of the same risk factors as COPD and by the same high demand for medical assistance.	Univ Verona, Ist Biol 2, Dipartimento Med & Sanita Pubbl, Sez Epidemiol & Stat Med,Unit Epidemiol & Med Sta, I-37134 Verona, Italy; Univ Pavia, IRCCS Policlin S Matteo, Div Resp Dis, I-27100 Pavia, Italy; Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; INSERM, U408, Paris, France; Univ So Calif, Keck Sch Med, Div Occupat & Eniviron Hlth, Los Angeles, CA USA; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; Univ Hosp, Dept Allergy & Resp Med, Reykjavik, Iceland; Univ Antwerp, Dept Resp Med, B-2020 Antwerp, Belgium; Univ Bergen, Dept Thorac Med, Bergen, Norway; Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain; Univ London Kings Coll, Dept Publ Hlth Sci, London WC2R 2LS, England	de Marco, R (reprint author), Univ Verona, Ist Biol 2, Dipartimento Med & Sanita Pubbl, Sez Epidemiol & Stat Med,Unit Epidemiol & Med Sta, Str Grazie 8, I-37134 Verona, Italy.	roberto.demarco@univr.it	de Marco, Roberto/A-5470-2008; SESM, SESM/C-1440-2008; bucca, caterina/C-9886-2009; Kunzli, Nino/F-7195-2014; Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	bucca, caterina/0000-0002-9941-9236; Kunzli, Nino/0000-0001-8360-080X; Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110; Corsico, Angelo Guido/0000-0002-8716-4694			Becklake MR, 2000, THORAX, V55, P629; BUIST AS, 1994, TXB RESP MED, P1959; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Calverley PMA, 2000, CHEST, V117, p365S, DOI 10.1378/chest.117.5_suppl_2.365S; Cerveri I, 2003, EUR RESPIR J, V22, P413, DOI 10.1183/09031936.03.00121103; Cerveri I, 2001, EUR RESPIR J, V18, P85, DOI 10.1183/09031936.01.00087101; CERVERII, 2003, AM J RESP CRIT CARE, V167, P936; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; FEINLEIB M, 1989, AM REV RESPIR DIS, V140, pS9; Hosmer W.D., 1989, APPL LOGISTIC REGRES; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Medical Research Council, 1976, RESP SYMPT QUEST; *NHLBI, 2003, NHLBI WHO WORKSH APR; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; RENNARD S, 2002, EUR RESPIR J, V20, P793; Snider GL, 2003, AM J RESP CRIT CARE, V167, P678, DOI 10.1164/rccm.200203-204PP; Sobradillo Pena Victor, 2000, Chest, V118, P981; THOM TJ, 1989, AM REV RESPIR DIS, V140, pS27; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; XU X, 1994, EUR RESPIR J, V7, P1056	24	138	138	1	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	FEB 1	2004	59	2					120	125		10.1136/thorax.2003.011163		6	Respiratory System	Respiratory System	770UY	WOS:000188750200010	14760151	
J	Heinrich, J; Bolte, G; Holscher, B; Douwes, J; Lehmann, I; Fahlbusch, B; Bischof, W; Weiss, M; Borte, M; Wichmann, HE				Heinrich, J; Bolte, G; Holscher, B; Douwes, J; Lehmann, I; Fahlbusch, B; Bischof, W; Weiss, M; Borte, M; Wichmann, HE		LISA study grp	Allergens and endotoxin on mothers' mattresses and total immunoglobulin E in cord blood of neonates	EUROPEAN RESPIRATORY JOURNAL			English	Article						cat allergen; cord blood immunoglobulin E; endotoxin; house dust; mite allergen; prenatal exposures	HOUSE-DUST ENDOTOXIN; HUMAN IMMUNE-SYSTEM; EARLY-LIFE; ENVIRONMENTAL ALLERGENS; PRENATAL SENSITIZATION; ASTHMA; EXPOSURE; RESPONSES; PREGNANCY; GESTATION	The current authors examined whether mite and cat allergen and bacterial endotoxin levels in dust of the mothers' mattresses were associated with cord blood immunoglobulin (Ig)E (CB-IgE) levels in newborns. Data from 1,332 term and normal weight neonates, from an ongoing birth cohort study, Influences of life-style related factors on the immune system and the development of allergies in childhood (LISA), with complete information on exposure to biocontaminants in mattress dust and CB-IgE were analysed. Two thirds of CB-IgE were undetectable (<0.35 kU(.)L(-1)). Thus, 0.35 and 0.45 kU(.)L(-1) (4th quartile) were chosen as cut-offs. Nonparametric smoothing (generalised additive models) showed statistically significant confounder-adjusted associations between elevated CB-IgE levels (greater than or equal to0.45 kU(.)L(-1)) and log-transformed exposures to cat (linear), mite (inverse u-shaped), and endotoxin (u-shaped). After adjustment for covariables, elevated CB-IgE levels (logistic regression using the 1st-4th quartiles of exposure) were positively associated with high cat-allergen exposure and medium exposure to mite allergen, but were inversely associated with exposure to endotoxin. The associations were similar, but somewhat weaker, when 0.35 kU(.)L(-1) was used as cut-off. These results, showing an association between prenatal allergen and endotoxin exposures and immunoglobulin E production, suggest that the development of foetal immune responses may be affected.	GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, D-85764 Neuherberg, Germany; Univ Utrecht, Div Environm & Occupat Hlth, IRAS, Utrecht, Netherlands; Leipzig Halle Ltd, Dept Human Exposure Res & Epidemiol, UFZ, Leipzig, Germany; Univ Jena, Inst Clin Immunol, D-6900 Jena, Germany; Univ Jena, Dept Indoor Climatol Ark, Erfurt, Germany; Univ Munich, Dr Von Haunersches Kinderspital, Munich, Germany; Univ Leipzig, Dept Paediat, Leipzig, Germany	Heinrich, J (reprint author), GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, Inglostaeder Landstr 1, D-85764 Neuherberg, Germany.	Joachim.Heinrich@gsf.de		Douwes, Jeroen/0000-0003-3599-4036			Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Fahlbusch B, 1999, ALLERGY, V54, P1215, DOI 10.1034/j.1398-9995.1999.00196.x; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Hastie T, 1990, GEN ADDITIVE MODELS; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Herz U, 2000, AM J RESP CRIT CARE, V162, pS62; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; King CL, 1998, J IMMUNOL, V160, P3578; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Martinez FD, 1999, LANCET, V354, pSII12; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Palfi M, 1998, AM J REPROD IMMUNOL, V39, P24; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 2000, ALLERGY, V55, P470; Prescott SL, 1998, J IMMUNOL, V160, P4730; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sacks G, 1999, IMMUNOL TODAY, V20, P114, DOI 10.1016/S0167-5699(98)01393-0; Szepfalusi Z, 2000, PEDIATR RES, V48, P404; Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Warner JA, 1998, CLIN EXP ALLERGY, V28, P35; Warner JA, 1996, PEDIATR ALLERGY IMMU, V7, P98, DOI 10.1111/j.1399-3038.1996.tb00406.x	32	138	138	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2002	20	3					617	623		10.1183/09031936.02.02322001		7	Respiratory System	Respiratory System	596VL	WOS:000178187100018	12358337	
J	Vernooy, JHJ; Dentener, MA; van Suylen, RJ; Buurman, WA; Wouters, EFM				Vernooy, JHJ; Dentener, MA; van Suylen, RJ; Buurman, WA; Wouters, EFM			Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; TRANSGENIC MICE; AIRWAY INFLAMMATION; CELL HYPERPLASIA; CIGARETTE-SMOKE; COTTON DUST; GRAIN DUST; ENDOTOXIN; EXPRESSION; EMPHYSEMA	Lipopolysaccharide (LPS), a major proinflammatory glycolipid component of the gram-negative bacterial cell wall, is one of the agents ubiquitously present as contaminant on airborne particles, including air pollution, organic dusts, and cigarette smoke. Chronic exposure to significant levels of LPS is reported to be associated with the development and/or progression of many types of lung diseases, including asthma, chronic bronchitis, and progressive irreversible airflow obstruction, that are all characterized by chronic inflammatory processes in the lung. In the present study, pathologic effects of long-term LPS exposure to the lung were investigated in detail. To this end, a murine model in which mice were exposed to repeated intratracheal instillation of Escherichia coli LPS was developed. We show that long-term LPS instillation in mice results in persistent chronic pulmonary inflammation, characterized by peribronchial and perivascular lymphocytic aggregates (CD4(+), CD8(+), and CD19(+)), parenchymal accumulation of macrophages and CD8+ T cells, and altered cytokine expression. Furthermore, airway and alveolar alterations such as mucus cell metaplasia, airway wall thickening, and irreversible alveolar enlargement accompanied the chronic inflammatory response. Interestingly, the observed inflammatory and pathologic changes mimic changes observed in human subjects with chronic inflammatory lung diseases, especially chronic obstructive pulmonary disease (COPD), suggesting that this murine model could be applicable to dissect the role of inflammation in the pathogenesis of these disease conditions.	Univ Hosp Maastricht, Dept Pulmonol, Dept Pathol, NL-6202 AZ Maastricht, Netherlands; Maastricht Univ, Nutr & Toxicol Res Inst Maastricht, Dept Pulmonol, Maastricht, Netherlands; Maastricht Univ, Nutr & Toxicol Res Inst Maastricht, Dept Gen Surg, Maastricht, Netherlands	Vernooy, JHJ (reprint author), Univ Hosp Maastricht, Dept Pulmonol, Dept Pathol, POB 5800, NL-6202 AZ Maastricht, Netherlands.						Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; CAVAGNA G, 1969, BRIT J IND MED, V26, P314; Daemen MARC, 1999, J IMMUNOL, V162, P5506; Daemen MARC, 1999, TRANSPLANTATION, V67, P792, DOI 10.1097/00007890-199903270-00003; DEL A, 1984, AM IND HYG ASSOC J, V45, P336; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; Fujita M, 2001, AM J PHYSIOL-LUNG C, V280, pL39; George CLS, 2001, AM J PHYSIOL-LUNG C, V280, pL203; HARKEMA JR, 1993, TOXICOL LETT, V68, P251, DOI 10.1016/0378-4274(93)90136-L; Hartung J, 1999, DEUT TIERARZTL WOCH, V106, P522; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; KOLOPPSARDA MN, 1994, ANAT REC, V239, P150, DOI 10.1002/ar.1092390205; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289; Lutgens E, 1999, CIRCULATION, V99, P276; Michaelis AR, 2000, INTERDISCIPL SCI REV, V25, P73; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; MILTON DK, 1990, AM REV RESPIR DIS, V142, P184; Ofulue AF, 1998, AM J PHYSIOL-LUNG C, V275, pL1134; Otten LA, 1998, EUR J IMMUNOL, V28, P473, DOI 10.1002/(SICI)1521-4141(199802)28:02<473::AID-IMMU473>3.0.CO;2-E; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; SCHINDLER R, 1990, BLOOD, V75, P40; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; SMID T, 1994, AM J IND MED, V25, P877, DOI 10.1002/ajim.4700250611; STARCHER B, 1989, EXP LUNG RES, V15, P785, DOI 10.3109/01902148909062861; STOLK J, 1992, J PATHOL, V167, P349, DOI 10.1002/path.1711670314; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; ULICH TR, 1991, AM J PATHOL, V138, P1097; Vernooy JHJ, 2001, AM J RESP CELL MOL, V24, P569; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; YANIGIHARA K, 2001, AM J RESP CELL MOL B, V24, P66	37	138	151	1	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	JAN	2002	26	1					152	159				8	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	510YX	WOS:000173236100020	11751215	
J	Gereda, JE; Klinnert, MD; Price, MR; Leung, DYM; Liu, AH				Gereda, JE; Klinnert, MD; Price, MR; Leung, DYM; Liu, AH			Metropolitan home living conditions associated with indoor endotoxin levels	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; prevention; infants; endotoxin; house dust; allergen; animal; cat; dog; air conditioning	IN-HOUSE DUST; HAY-FEVER; ENVIRONMENTAL ENDOTOXIN; BACTERIAL-ENDOTOXIN; INHALED ENDOTOXIN; COTTON DUST; ASTHMA; EXPOSURE; CHILDREN; ALLERGEN	Background: Household endotoxin exposure in allergy and asthma has been gaining attention for its dual potential to exacerbate these conditions in individuals with established disease and to abrogate atopy before disease onset. Objective: We sought to better understand the home environmental and Lifestyle factors influencing house dust endotoxin levels, Methods: From the homes of 86 infants with wheeze in metropolitan Denver, Colorado, house dust endotoxin (detected with a standardized Limulus Amebocyte Lysate assay) and common indoor allergen (Fel d 1, Can f 1, Her p 1, Her f 1, and Bla g 1) contents were quantified. Comprehensive home environment and lifestyle questionnaires were completed during home visits by trained study staff and parents. Results: House dust endotoxin levels were associated with only 2 home environmental features: animals in the home and the presence of central air conditioning. The strongest positive associations were found with animals in the home, Interestingly,the homes without cats or other animals revealed a negative correlation between house dust Fel d 1 and endotoxin (P = .03), Central air conditioning, especially during months of typical use, was associated with lower house dust endotoxin levels, No significant associations between house dust endotoxin levels and home dampness, number of household inhabitants or young children, cleaning frequency, or presence of tobacco smokers in the home were found, Conclusions: Indoor endotoxin exposure can be increased by the presence of animals in the home and decreased with central air conditioning, In some homes without animals, where allergen exposure adequate for sensitization still occurs, there are lower levels of house dust endotoxin, Therefore in homes without animals, factors that influence allergen and endotoxin levels in house dust probably differ, Households with detectable allergen levels but low endotoxin levels may provide a predisposing environment for animal allergen sensitization.	Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Div Pediat Behav Hlth, Denver, CO USA	Liu, AH (reprint author), Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NCRR NIH HHS [M01-RR00051]; NHLBI NIH HHS [HL-36577]; NIAID NIH HHS [R18AI41137]		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Andriessen JW, 1998, CLIN EXP ALLERGY, V28, P1191; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; Chun D T, 2000, Appl Occup Environ Hyg, V15, P152; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DONHAM K, 1989, BRIT J IND MED, V46, P31; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; Duchaine C, 1999, AM IND HYG ASSOC J, V60, P89, DOI 10.1080/00028899908984426; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; LE JM, 1986, J IMMUNOL, V136, P4525; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; MICHEL O, 1991, ANN ALLERGY, V66, P39; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Mitchell H, 1997, PEDIATR PULM, V24, P237; Nicolai T, 1998, THORAX, V53, P1035; OLENCHOCK SA, 1992, SCAND J WORK ENV HEA, V18, P58; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; PLATT SD, 1989, BRIT MED J, V298, P1673; Ponsonby AL, 1999, THORAX, V54, P664; Quinn PJ, 1994, CLIN VET MICROBIOLOG; REIIJONEN TM, 2000, PEDIATRICS, V106, P1406; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; WEISS K, 1992, CHEST, V6, pS362; Wickens K, 1999, J ALLERGY CLIN IMMUN, V104, P554, DOI 10.1016/S0091-6749(99)70323-4	43	138	139	2	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					790	796				7	Allergy; Immunology	Allergy; Immunology	434JX	WOS:000168812300005	11344344	
J	Arruda, LK; Vailes, LD; Ferriani, VPL; Santos, BR; Pomes, A; Chapman, MD				Arruda, LK; Vailes, LD; Ferriani, VPL; Santos, BR; Pomes, A; Chapman, MD			Cockroach allergens and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Allergy-Asthma-and-Immunology	MAR, 2000	SAN DIEGO, CALIFORNIA	Amer Acad Allergy Asthma & Immunol		cockroach; asthma; indoor allergens; public health; risk factors; environment	HOUSE-DUST MITE; IMMUNOSTIMULATORY DNA-SEQUENCES; INNER-CITY CHILDREN; HIGH-LEVEL EXPRESSION; AMERICAN COCKROACH; RISK-FACTORS; AIRWAY HYPERRESPONSIVENESS; BLATTELLA-GERMANICA; INHALANT ALLERGENS; SHRIMP ALLERGEN	Asthma and allergy are the most common diseases associated with cockroach infestation of houses in the United States and other parts of the world. Sensitization and exposure to cockroach allergens is associated with increased asthma morbidity in the United States, especially among lower socioeconomic groups, including African American and Hispanic populations. Exposure to cockroach allergens in the first 3 months of life has been associated with repeated wheezing and asthma. The principal domestic cockroach species are Blattella germanica and Periplaneta americana. Both species produce several potent allergens, including Bla g 2 (inactive aspartic proteinase), Bla g 4 (calycin), Bla g 5 (glutathione-S-transferase), the group 1 cross-reactive allergens Bla g 1 and Per a 1, and tropomyosin. Structural homology between tropomyosins from cockroaches, mites, and shrimp may explain clinical cases of the oral allergy syndrome. The 3-dimensional structures of several cockroach allergens are known, and biologically active recombinant allergens have been produced in high-level expression vectors. The use of recombinant cockroach allergens should allow mechanisms of cockroach-induced asthma to be investigated and may lead to the development of new approaches to asthma treatment. Environmental allergen measurements of Bla g 1 and Bla g 2 have allowed exposure levels that cause allergic sensitization to be established. Abatement studies have shown that a sustained decrease in cockroach allergen levels is difficult but can be accomplished by professional application of insecticides, together with rigorous household cleaning. Cockroach asthma is an important public health problem that affects patients who are the least likely to be compliant with treatment with asthma medications or environmental control. Patient education, improvements in the housing stock, and improvements in environmental and immunologic treatment strategies are likely to be the most successful approaches to reduce the prevalence of cockroach-induced asthma.	Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Pediat, BR-14049 Ribeirao Preto, Brazil; Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Cell & Mol Biol, BR-14049 Ribeirao Preto, Brazil; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Chapman, MD (reprint author), UVA Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.		Arruda, L. Karla /D-5845-2013; Ferriani, Virginia/E-2209-2012	Arruda, L. Karla /0000-0002-7505-210X; Pomes, Anna/0000-0002-8729-1829	NIAID NIH HHS [AI32557, AI34607]		AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; ARRUDA LK, 1995, J BIOL CHEM, V270, P3116; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; Broide D, 1998, J IMMUNOL, V161, P7054; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Camara AA, 2000, J ALLERGY CLIN IMMUN, V105, pS80, DOI 10.1016/S0091-6749(00)91578-1; Campbell EM, 1998, J IMMUNOL, V161, P7047; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409; Chapman MD, 1998, REV FR ALLERGOL, V38, P842, DOI 10.1016/S0335-7457(98)80153-6; Chapman MD, 1996, ALLERGY ALLERGIC DIS, P942; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; Creticos P. S., 1997, Journal of Allergy and Clinical Immunology, V99, pS401; Creticos PS, 2000, J ALLERGY CLIN IMMUN, V105, pS559, DOI 10.1016/S0091-6749(00)90060-5; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)81051-2; DUFF AL, 1993, PEDIATRICS, V92, P535; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; GARCIA DP, 1994, ANN ALLERGY, V72, P203; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; Henderson CE, 2000, J REPROD MED, V45, P341; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG BC, 1988, J ASTHMA, V25, P205; KANG BC, 1992, ANN ALLERGY, V68, P23744; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Lima RC, 1999, J ALLERGY CLIN IMMUN, V103, pS29; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; McGill KA, 1998, PEDIATRICS, V102, P77, DOI 10.1542/peds.102.1.77; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; MENDOZA J, 1970, ANN ALLERGY, V28, P159; Mollet JA, 1997, J MED ENTOMOL, V34, P307; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; O'Connor G T, 1999, Environ Health Perspect, V107, P243; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90938-2; Prescott SL, 1998, J IMMUNOL, V160, P4730; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Santos ABR, 2000, J ALLERGY CLIN IMMUN, V105, pS325, DOI 10.1016/S0091-6749(00)91383-6; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHULANER FA, 1970, PEDIATRICS, V45, P465; SHANTI KN, 1993, J IMMUNOL, V151, P5354; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; SMITH AM, 1998, IMMUNOTHERAPY ASTHMA; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902; vanRee R, 1996, ALLERGY, V51, P108; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wu CH, 1996, J BIOL CHEM, V271, P17937; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4; Zhou DH, 1998, J ALLERGY CLIN IMMUN, V101, P653	79	138	152	3	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					419	428		10.1067/mai.2001.112854		10	Allergy; Immunology	Allergy; Immunology	416RE	WOS:000167793300001	11240940	
J	Boulet, LP; Turcotte, H; Laviolette, M; Naud, F; Bernier, MC; Martel, S; Chakir, J				Boulet, LP; Turcotte, H; Laviolette, M; Naud, F; Bernier, MC; Martel, S; Chakir, J			Airway hyperresponsiveness, inflammation, and subepithelial collagen deposition in recently diagnosed versus long-standing mild asthma - Influence of inhaled corticosteroids	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							NONASTHMATIC SUBJECTS; OCCUPATIONAL ASTHMA; ALLERGIC RHINITIS; TERM TREATMENT; BUDESONIDE; METHACHOLINE; EXPRESSION; CESSATION; STEROIDS; EXPOSURE	This study aimed at documenting airway inflammation and subepithelial collagen deposition in patients using only inhaled beta(2)-agonists with either recently diagnosed asthma (RDA: less than or equal to 2 yr, n = 16) or long-standing asthma (LSA: greater than or equal to 13 yr, n = 16) and at the influence of an intense inhaled corticosteroid (ICS) treatment on these parameters, in relation to changes in airway responsiveness. Patients had a methacholine inhalation test and a bronchoscopy with bronchial biopsies before and after an 8-wk treatment with inhaled fluticasone propionate (FP), 1,000 mu g/day. Baseline FEV1 (mean +/- SEM) was normal and similar in both groups (RDA: 98.1 +/- 2.7, LSA: 94.5 +/- 4.6%). Geometric mean methacholine PC20 was lower in LSA than in RDA (0.44 versus 3.37 mg/ml) at baseline and improved similarly by 1.85 and 1.86 double concentrations with FP treatment. PC20 normalized (greater than or equal to 16 mg/ml) in five patients with RDA and two patients with LSA. Baseline mean bronchial cell counts (per mm(2) connective tissue surface) for CD3(+), CD4(+), CD8(+), CD25(+), EG1(+), CD45ro(+), and AA1(+) cells were similar in both groups. With FP, EG1(+) (p < 0.001), EG2(+) (p = 0.018), and AA1(+) counts (p = 0.009) decreased significantly in both groups while CD45ro(+) (p = 0.02) counts decreased only in LSA. Baseline type 1 and type 3 collagen deposition underneath the basement membrane was similar in RDA and LSA and did not change significantly after FP. This study shows that recent compared to long-standing mild asthma is associated with a similar degree of airway inflammation and subepithelial fibrosis, and a similar improvement in airway hyperresponsiveness after 8 wk on high-dose ICS. It also indicates that once asthma becomes symptomatic, airway responsiveness cannot normalize in most subjects over such a time period, even with a high dose of ICS.	Univ Laval, Hop Laval, Inst Cardiol & Pneumol, St Foy, PQ G1V 4G5, Canada	Boulet, LP (reprint author), Univ Laval, Hop Laval, Inst Cardiol & Pneumol, 2725 Chemin St Foy, St Foy, PQ G1V 4G5, Canada.						American Thoracic Society, 1979, AM REV RESPIR DIS, V119, P831; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; BLEECKER ER, 1991, CLIN EXP ALLERGY, V21, P233; Boulet L P, 1998, Can Respir J, V5, P68; Boulet L P, 1998, Can Respir J, V5, P16; BOULET LP, 1995, EUR RESPIR J, V8, P913; BOULET LP, 1994, EUR RESPIR J, V7, P1567, DOI 10.1183/09031936.94.07091567; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Chakir J, 1996, LAB INVEST, V75, P735; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hoshino M, 1998, THORAX, V53, P21; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832; Juniper EF, 1991, HISTAMINE METHACHOLI; KAY AB, 1991, J ALLERGY CLIN IMMUN, V87, P893, DOI 10.1016/0091-6749(91)90408-G; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V98, pS3, DOI 10.1016/S0091-6749(96)80122-9; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, pS33; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; LUNDGREN R, 1977, Scandinavian Journal of Respiratory Diseases Supplementum, V101, P179; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953; NEWTER J, 1985, APPL LINEAR STAT MOD, P636; Pedersen S, 1997, CLIN EXP ALLERGY, V27, P995, DOI 10.1111/j.1365-2222.1997.tb01247.x; Saetta M, 1998, Eur Respir J Suppl, V26, p20S; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; 1992, CLIN EXP ALLERGY S, V1, P1	36	138	144	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT	2000	162	4					1308	1313				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	364RD	WOS:000089905900020	11029336	
J	Mauroy, B; Filoche, M; Weibel, ER; Sapoval, B				Mauroy, B; Filoche, M; Weibel, ER; Sapoval, B			An optimal bronchial tree may be dangerous	NATURE			English	Article							MODEL	The geometry and dimensions of branched structures such as blood vessels or airways are important factors in determining the efficiency of physiological processes. It has been shown that fractal trees can be space filling(1) and can ensure minimal dissipation(2-4). The bronchial tree of most mammalian lungs is a good example of an efficient distribution system with an approximate fractal structure(5,6). Here we present a study of the compatibility between physical optimization and physiological robustness in the design of the human bronchial tree. We show that this physical optimization is critical in the sense that small variations in the geometry can induce very large variations in the net air flux. Maximum physical efficiency therefore cannot be a sufficient criterion for the physiological design of bronchial trees. Rather, the design of bronchial trees must be provided with a safety factor and the capacity for regulating airway calibre. Paradoxically, our results suggest that bronchial malfunction related to asthma is a necessary consequence of the optimized efficiency of the tree structure.	Ecole Normale Super, Ctr Math & Leurs Applicat, F-94235 Cachan, France; Ecole Polytech, CNRS, Phys Mat Condensee Lab, F-91128 Palaiseau, France; Univ Bern, Dept Anat, CH-3000 Bern, Switzerland	Ecole Normale Super, Ctr Math & Leurs Applicat, F-94235 Cachan, France.	Bernard.Sapoval@polytechnique.fr		FILOCHE, Marcel/0000-0001-8637-3016			Bejan A., 2000, SHAPE STRUCTURE ENG; Brown J.H., 2000, SCALING BIOL; Hess WR, 1914, ARCH ANAT PHYSL, P1; Hoppeler H, 2003, MED SCI SPORT EXER, V35, P95, DOI 10.1249/01.MSS.0000043292.99104.12; Kitaoka H, 1999, J APPL PHYSIOL, V87, P2207; Mandelbrot B. B., 1982, FRACTAL GEOMETRY NAT; Mauroy B, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.148101; Murray CD, 1926, P NATL ACAD SCI USA, V12, P207, DOI 10.1073/pnas.12.3.207; NELSON TR, 1988, IEEE T MED IMAGING, V7, P321, DOI 10.1109/42.14515; Que CL, 2001, J APPL PHYSIOL, V91, P1131; Sapoval B, 2002, P NATL ACAD SCI USA, V99, P10411, DOI 10.1073/pnas.122352499; Sapoval B., 1997, UNIVERSALITES FRACTA; Weibel E, 1963, MORPHOMETRY HUMAN LU; Weibel ER, 2000, SYMMORPHOSIS; Weibel E. R., 1984, PATHWAY OXYGEN; Weibel E. R., 1997, LUNG SCI FDN, V1, P1061; WEST BJ, 1986, J APPL PHYSIOL, V60, P1089; West GB, 1997, SCIENCE, V276, P122, DOI 10.1126/science.276.5309.122; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003	19	137	145	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	FEB 12	2004	427	6975					633	636		10.1038/nature02287		4	Multidisciplinary Sciences	Science & Technology - Other Topics	773AJ	WOS:000188875300041	14961120	
J	Prather, M; Gauss, M; Berntsen, T; Isaksen, I; Sundet, J; Bey, I; Brasseur, G; Dentener, F; Derwent, R; Stevenson, D; Grenfell, L; Hauglustaine, D; Horowitz, L; Jacob, D; Mickley, L; Lawrence, M; von Kuhlmann, R; Muller, JF; Pitari, G; Rogers, H; Johnson, M; Pyle, J; Law, K; van Weele, M; Wild, O				Prather, M; Gauss, M; Berntsen, T; Isaksen, I; Sundet, J; Bey, I; Brasseur, G; Dentener, F; Derwent, R; Stevenson, D; Grenfell, L; Hauglustaine, D; Horowitz, L; Jacob, D; Mickley, L; Lawrence, M; von Kuhlmann, R; Muller, JF; Pitari, G; Rogers, H; Johnson, M; Pyle, J; Law, K; van Weele, M; Wild, O			Fresh air in the 21st century?	GEOPHYSICAL RESEARCH LETTERS			English	Article							TROPOSPHERIC OZONE; INTERCONTINENTAL TRANSPORT; POLLUTION; ASTHMA; POLLUTANTS; EXPOSURE; HEALTH	Ozone is an air quality problem today for much of the world's population. Regions can exceed the ozone air quality standards (AQS) through a combination of local emissions, meteorology favoring pollution episodes, and the clean-air baseline levels of ozone upon which pollution builds. The IPCC 2001 assessment studied a range of global emission scenarios and found that all but one projects increases in global tropospheric ozone during the 21st century. By 2030, near-surface increases over much of the northern hemisphere are estimated to be about 5 ppb (+2 to +7 ppb over the range of scenarios). By 2100 the two more extreme scenarios project baseline ozone increases of >20 ppb, while the other four scenarios give changes of -4 to +10 ppb. Even modest increases in the background abundance of tropospheric ozone might defeat current AQS strategies. The larger increases, however, would gravely threaten both urban and rural air quality over most of the northern hemisphere.	Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA; Univ Oslo, Inst Geofys, N-0315 Oslo, Norway; Swiss Fed Inst Technol, CH-1015 Lausanne, Switzerland; Max Planck Inst Meteorol, D-20146 Hamburg, Germany; Commiss European Communities, Joint Res Ctr, Inst Environm, I-21020 Ispra, Italy; Hadley Ctr, UK Met Off, Bracknell, Berks, England; CEA, CNRS, Inst Pierre Simon Laplace, F-91198 Gif Sur Yvette, France; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ USA; Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MD USA; Max Planck Inst Chem, D-55128 Mainz, Germany; Inst Aeron Spatiale Belgique, B-1180 Brussels, Belgium; Univ Aquila, Dipartimento Fis, I-67010 Laquila, Italy; Univ Cambridge, Ctr Atmospher Sci, Cambridge CB2 1EW, England; Royal Netherlands Meteorol Inst, NL-3730 AE De Bilt, Netherlands; Frontier Res Syst Global Change, Yokohama, Kanagawa, Japan	Prather, M (reprint author), Univ Calif Irvine, Dept Earth Syst Sci, Irvine, CA 92697 USA.		Wild, Oliver/A-4909-2009; Stevenson, David/C-8089-2012; Mickley, Loretta/D-2021-2012; Pfister, Gabriele/A-9349-2008; Horowitz, Larry/D-8048-2014	Wild, Oliver/0000-0002-6227-7035; Stevenson, David/0000-0002-4745-5673; Mickley, Loretta/0000-0002-7859-3470; Horowitz, Larry/0000-0002-5886-3314; Pitari, Giovanni/0000-0001-7051-9578			Brasseur GP, 1998, GEOPHYS RES LETT, V25, P3807, DOI 10.1029/1998GL900013; Desqueyroux H, 2002, ENVIRON RES, V89, P29, DOI 10.1006/enrs.2002.4357; *EEA, 2002, 9 EEA, P73; Emberson LD, 2001, WATER AIR SOIL POLL, V130, P107, DOI 10.1023/A:1012251503358; Fiore AM, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015601; Gupta ML, 1998, GEOPHYS RES LETT, V25, P3931, DOI 10.1029/1998GL900099; HAAGENSMIT AJ, 1952, IND ENG CHEM, V44, P1342, DOI 10.1021/ie50510a045; Jensen SS, 2001, INT J VEHICLE DES, V27, P195, DOI 10.1504/IJVD.2001.001964; Johnson CE, 2001, GEOPHYS RES LETT, V28, P1723, DOI 10.1029/2000GL011996; Li Q., 2002, J GEOPHYS RES, V107, DOI [10.1029/2001JD001422, DOI 10.1029/2001JD001422]; Mauzerall DL, 2001, ANNU REV ENERG ENV, V26, P237, DOI 10.1146/annurev.energy.26.1.237; Morrison GC, 2002, ENVIRON SCI TECHNOL, V36, P2185, DOI 10.1021/es0113089; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Nakicenovic N. J., 2000, SPECIAL REPORT EMISS; Oksanen E, 2001, ATMOS ENVIRON, V35, P5245, DOI 10.1016/S1352-2310(01)00346-6; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; Penner J. E., 2001, CLIMATE CHANGE 2001, P289; Prather M, 2001, CLIMATE CHANGE 2001, P239; Tarrason L, 1998, TELLUS B, V50, P331, DOI 10.1034/j.1600-0889.1998.t01-3-00002.x; Taylor GE, 2001, HUM ECOL RISK ASSESS, V7, P1183, DOI 10.1080/20018091094934; Wild O, 2001, J GEOPHYS RES-ATMOS, V106, P27729, DOI 10.1029/2000JD000123	21	137	146	1	15	AMER GEOPHYSICAL UNION	WASHINGTON	2000 FLORIDA AVE NW, WASHINGTON, DC 20009 USA	0094-8276			GEOPHYS RES LETT	Geophys. Res. Lett.	JAN 31	2003	30	2							1100	10.1029/2002GL016285		4	Geosciences, Multidisciplinary	Geology	678YB	WOS:000182893300006		
J	Celedon, JC; Litonjua, AA; Ryan, L; Platts-Mills, T; Weiss, ST; Gold, DR				Celedon, JC; Litonjua, AA; Ryan, L; Platts-Mills, T; Weiss, ST; Gold, DR			Exposure to cat allergen, maternal history of asthma, and wheezing in first 5 years of life	LANCET			English	Article							CHILDREN; ATOPY	We looked for an association between early exposure to pets and asthma and wheezing in children whose mothers or fathers did or did not have a history of asthma. We followed up 448 children, who had at least one parent with a history of atopy, from birth to 5 years. Among children whose mothers had no history of asthma, exposure to a cat or a Fel d 1 concentration of at least 8 mug/g at the age of 2-3 months was associated with a reduced risk of wheezing between the ages of 1 and 5 years. However, among children whose mothers did have a history of asthma, such exposures were associated with an increased risk of wheezing at or after the age of 3 years. There was no association between wheezing and exposure to dog or dog allergen, and the father's allergy status had no effect on the relation between childhood wheezing and cat exposure.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Univ Virginia, Dept Med, Ctr Asthma & Allergy, Charlottesville, VA USA; Harvard Sch Publ Hlth, Boston, MA 02115 USA	Celedon, JC (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA.		Ryan, Louise/A-4562-2009	Ryan, Louise/0000-0001-5957-2490	NHLBI NIH HHS [KO1 HL04370-01A1]; NIEHS NIH HHS [ES35786]		Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; THERNEAU TM, 2000, MODELING SURVIVAL DA, P185	5	137	142	2	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 7	2002	360	9335					781	782		10.1016/S0140-6736(02)09906-3		2	Medicine, General & Internal	General & Internal Medicine	592HX	WOS:000177933000022	12241839	
J	Antczak, A; Montuschi, P; Kharitonov, S; Gorski, P; Barnes, PJ				Antczak, A; Montuschi, P; Kharitonov, S; Gorski, P; Barnes, PJ			Increased exhaled cysteinyl-leukotrienes and 8-isoprostane in aspirin-induced asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						aspirin-induced asthma; cysteinyl-leukotrienes; exhaled breath condensate; 8-isoprostane; prostaglandin E-2	SENSITIVE ASTHMATICS; OXIDATIVE STRESS; URINARY LEUKOTRIENE-E4; BRONCHIAL PROVOCATION; INTOLERANT ASTHMA; EPITHELIAL-CELLS; ARACHIDONIC-ACID; C-4 SYNTHASE; IN-VIVO; CONDENSATE	The pathogenesis of aspirin-induced asthma (AIA) has not yet been clearly elucidated, although eicosanoid metabolites appear to play an important role. We hypothesized that levels of eicosanolds in exhaled air condensate are abnormal in patients with AIA and that they change in patients receiving steroid therapy. We measured cysteinyl-leukotrienes (cys-LTs), prostaglandin E-2 (PGE(2)), and leukotriene B-4 (LTB4), and also 8-isoprostane as a marker of oxidative stress, by enzyme immunoassay in exhaled breath condensate from patients with AIA (17 steroid naive; mean age, 41 +/- 23 years; FEV1, 63%pred), 26 patients with aspirin-tolerant asthma (ATA) (11 steroid naive; mean age, 47 +/- 18 years; FEV1, 69%pred), and 16 healthy subjects (mean age, 45 +/- 17 years; FEV1, 93%pred). Cys-LTs were significantly higher in steroid-naive patients with Al compared with steroid-naive patients with ATA and healthy subjects (152.3 +/- 30.4 and 36.6 +/- 7.1 versus 19.4 +/- 2.8 pg/ml; p < 0.05 and p < 0.05, respectively). Steroid-naive patients with AIA also had higher levels of 8-isoprostane than normal subjects (131.8 +/- 31.0 versus 21.9 +/- 4.5 pg/ml; p < 0.05). There were significantly lower levels of both cys-LTs and 8-isoprostanes in steroid-treated patients with AIA. There was no difference in either the PGE(2) or LTB4 level between the patient groups. This is the first study to show that cys-LTs and 8-isoprostanes are elevated in expired breath condensate of steroid-naive patients with AIA, and that cys-LTs are decreased in steroid-treated patients. Exhaled PGE(2) levels are not reduced, so that it is unlikely that a deficiency of PGE(2) is an important mechanism, whereas exhaled LT84 levels are unchanged, indicating an abnormality beyond 5-lipoxygenase.	Med Univ Lodz, Dept Pneumol & Allergol, PL-50153 Lodz, Poland; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England	Antczak, A (reprint author), Med Univ Lodz, Dept Pneumol & Allergol, Kopcinskiego Str 22, PL-50153 Lodz, Poland.			MONTUSCHI, Paolo/0000-0001-5589-1750			Aksoy MO, 1999, J ALLERGY CLIN IMMUN, V103, P1081, DOI 10.1016/S0091-6749(99)70183-1; Antczak A, 2000, RESP MED, V94, P416, DOI 10.1053/rmed.1999.0801; Antczak A, 1997, EUR RESPIR J, V10, P1231; Bochenek G, 1996, ALLERGY, V51, P16, DOI 10.1111/j.1398-9995.1996.tb04544.x; BOZEMAN PM, 1990, J IMMUNOL METHODS, V126, P125, DOI 10.1016/0022-1759(90)90020-V; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025; CHRISTIE PE, 1991, AM REV RESPIR DIS, V49, P749; COCKCROFT DW, 1985, ANN ALLERGY, V55, P527; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Crocker IC, 1997, ANN ALLERG ASTHMA IM, V78, P497; DAHLEN B, 1993, EUR RESPIR J, V6, P1018; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; Dworski R, 1999, AM J RESP CRIT CARE, V160, P1947; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953; HAM EA, 1983, P NATL ACAD SCI-BIOL, V80, P4349, DOI 10.1073/pnas.80.14.4349; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96; Lindsay MA, 1998, J IMMUNOL, V160, P4526; Montuschi P, 2000, THORAX, V55, P205, DOI 10.1136/thorax.55.3.205; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175; MURRAY JJ, 1998, AM J RESP CRITICA S3, V157, pA872; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472; Picado C, 1999, AM J RESP CRIT CARE, V160, P291; PICADO C, 1992, AM REV RESPIR DIS, V145, P65; Pratico D, 1996, J BIOL CHEM, V271, P8919; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; SAMTER M, 1968, ANN INTERN MED, V68, P975; Sanak M, 2000, AM J RESP CELL MOL, V23, P290; Schafer D, 1999, EUR RESPIR J, V13, P638, DOI 10.1183/09031936.99.13363899; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; SEDGWICK JB, 1990, AM REV RESPIR DIS, V142, P120; SERHAN CN, 1982, BIOCHEM BIOPH RES CO, V107, P1006, DOI 10.1016/0006-291X(82)90622-2; Sestini P, 1996, AM J RESP CRIT CARE, V153, P572; SHINDO K, 1994, CHEST, V105, P1038, DOI 10.1378/chest.105.4.1038; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940; SMITH CM, 1992, EUR RESPIR J, V5, P693; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Szczeklik A., 1992, P548; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608; SZCZEKLIK A, 1988, CLIN ALLERGY, V18, P15, DOI 10.1111/j.1365-2222.1988.tb02838.x; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Takagi A, 1996, J BIOCHEM-TOKYO, V119, P979	47	137	142	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2002	166	3					301	306		10.1164/rccm.2101021		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	580QV	WOS:000177246000011	12153961	
J	Wickman, M; Kull, I; Pershagen, G; Nordvall, SL				Wickman, M; Kull, I; Pershagen, G; Nordvall, SL			The BAMSE Project: presentation of a prospective longitudinal birth cohort study	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article; Proceedings Paper	Congress of the European-Academy-of-Allergy-and-Clinical-Immunology	JUN, 2001	BERLIN, GERMANY	European Acad Allergy & Clin Immunol				The aims of this prospective and longitudinal project are to establish crucial risk factors for asthma and other allergic diseases in childhood, and to study factors of importance for prognosis at already established allergic disease. Socio-economic factors, such as inequality in health, are also to be addressed. The project started in February 1994. To reach sufficient power, 4,000 children had to be included. In November 1996, this number was reached (4,093). Inclusion in the study was made at 3-4 months of age. At that time, and before induction of allergic disease/asthma of the child, a questionnaire focused on exposure, genetics and socio-economic factors was answered. Settled dust was sampled for later analysis of furred animal and mite allergens. When the children were aged both 1 and 2 years, their parents were asked to fill in new questionnaires focusing on respiratory and allergic (skin, gastrointestinal) symptoms, but also key variables of exposure. Cases with asthma are identified and, for every case, two matched controls drawn. During the following winter, the homes of cases and controls were investigated and the temperature, indoor humidity, air change rate and NO2 measured. Two hundred cases (5%) were expected to be identified during the first 2 years of the children's lives. Some 479 homes have now been investigated and 97.7% of the original 4,093 children still remain in the cohort. The 2-year symptom follow-up ended in November 1998. The 4-year follow-up started on 1 September 1998 and was planned to be finished in June 2000. Questionnaires (allergic and respiratory symptoms, key variables of exposure at home and day care) are sent out to all 4,093 families. All children are invited for examination, lung function tests (PEF, flow-volume, MVV and oxygen clearance) and physical performance. Blood is taken from all children (20 ml). Allergy screening is performed and specific IgE examined. Blood cells will be frozen to allow for later DNA extraction. In subsets (children with any allergic and/or respiratory manifestation and controls), markers of inflammation in blood and urine will be examined, as well as eosinophils in nasal smear. Interviews are carried out to assess the severity of asthma, type/periodicity of health care given, asthma medication and parental sick leave when appropriate. As a separate project, financed by the EU, outdoor pollution as risk factors for asthma and allergies are to be studied within the BAMSE cohort. A follow-up of 8-9 years is underway.	Stockholm Cty Council, Dept Environm Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Karolinska Inst, Sachs Childrens Hosp, Inst Sodersjukhuset, Stockholm, Sweden; Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Wickman, M (reprint author), Karolinska Hosp, Dept Environm Hlth, Norrbacka Bldg,Level 3, SE-17176 Stockholm, Sweden.							0	137	137	1	16	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.		2002	13			15			11	13		10.1034/j.1399-3038.13.s.15.10.x		3	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	638KW	WOS:000180571000003	12688617	
J	Leynaert, B; Neukirch, C; Jarvis, D; Chinn, S; Burney, P; Neukirch, F				Leynaert, B; Neukirch, C; Jarvis, D; Chinn, S; Burney, P; Neukirch, F		European Comm Resp Hlth Survey	Does living on a farm during childhood protect against asthma, allergic rhinitis, and atopy in adulthood?	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; allergic rhinitis; immunologic sensitization; farm; epidemiologic studies	RESPIRATORY-HEALTH-SURVEY; HAY-FEVER; INTESTINAL MICROFLORA; FAMILY-SIZE; CHILDREN; SENSITIZATION; PREVALENCE; COMMUNITY; EXPOSURE; RISK	Recent studies of children suggest that factors encountered in a farm environment might protect against the development of allergy. However, it remains uncertain whether living on a farm in childhood is associated with a decreased risk of atopic diseases in adulthood. We analyzed data from 6,251 randomly selected adults 20 to 44 yr of age participating in the European Community Respiratory Health Survey (ECRHS). Subjects answered a detailed questionnaire and underwent specific IgE measurements to five allergens. After adjustment for potential confounders, including pet exposure in childhood, number of siblings, severe respiratory infection in childhood, and parental history of allergy, living on a farm in childhood was associated with a reduced risk of atopic sensitization in adulthood (OR = 0.76, Cl 95% = 0.60-0.97). Compared with other adults, those who had lived on a farm as a child were less frequently sensitized to cat (OR = 0.63, Cl 95% = 0.41-0.96) and to Timothy grass (OR = 0.68, Cl 95% = 0.50-0.94), and were at lower risk of having nasal symptoms in the presence of pollen (OR = 0.80, Cl 95% = 0.64-1.02). The protective effect of farming environment in childhood observed in this population-based sample of young adults provides evidence in favor of the hypothesis that environmental factors encountered in childhood may have a lifelong protective effect against the development of allergy.	Univ Paris 07, INSERM U408, F-75870 Paris 18, France; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England	Leynaert, B (reprint author), Univ Paris 07, INSERM U408, BP 416, F-75870 Paris 18, France.	leynaert@bichat.inserm.fr	Jarvis, Deborah/E-6494-2011; bucca, caterina/C-9886-2009	bucca, caterina/0000-0002-9941-9236	NCRR NIH HHS [2 S07 RR05521-28]		Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bodner C, 1998, THORAX, V53, P28; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gassner-Bachmann M, 2000, DEUT MED WOCHENSCHR, V125, P924, DOI 10.1055/s-2000-6778; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Heinrich J, 1998, ALLERGY, V53, P89, DOI 10.1111/j.1398-9995.1998.tb03779.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Pearce N, 1999, THORAX, V54, P268; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Upton MN, 2000, BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, BRIT MED J, V308, P692	37	137	140	0	12	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2001	164	10					1829	1834				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	502TK	WOS:000172758700017	11734431	
J	Herrick, CA; MacLeod, H; Glusac, E; Tigelaar, RE; Bottomly, K				Herrick, CA; MacLeod, H; Glusac, E; Tigelaar, RE; Bottomly, K			Th2 responses induced by epicutaneous or inhalational protein exposure are differentially dependent on IL-4	JOURNAL OF CLINICAL INVESTIGATION			English	Article							CD4+ T-CELLS; INTERLEUKIN-4-DEFICIENT MICE; NIPPOSTRONGYLUS-BRASILIENSIS; EOSINOPHILIC INFLAMMATION; IL-4-DEFICIENT MICE; AIRWAY INFLAMMATION; AEROSOLIZED ANTIGEN; CYTOKINE RESPONSES; ATOPIC-DERMATITIS; TRANSGENIC MICE	Atopic individuals are predisposed to mounting vigorous Th2-type immune responses to environmental allergens. To determine the factors responsible, animal models that closely mimic natural modes of allergen exposure should prove most informative. Therefore, we investigated the role of IL-4, a known Th2-promoting cytokine, in generation of Th2 responses after exposure of either the skin or airway to soluble protein. Compared with wild-type (WT) mice, IL-4-deficient (IL-4(-/-)) mice showed markedly impaired Th2 activation after primary exposure to inhaled ovalbumin (OVA), with decreased OVA-specific IgG1 and IgE, and significantly fewer eosinophils in bronchoalveolar lavage (BAL) fluid after airway challenge. In contrast, IL-4(-/-) mice initially exposed to epicutaneous (e.c.) OVA mounted Th2 responses equivalent to responses in WT mice, with high numbers of eosinophils in BAL fluid. Because Th2 responses were not induced by e.c. OVA exposure in Stat6(-/-) mice (mice lacking signal transducer and activator of transcription 6), the role of IL-13 was tested. In vivo depletion of IL-13 prevented Th2 responses induced by e.c. OVA exposure in IL-4(-/-) mice. These data demonstrate a marked difference in the IL-4 dependence of Th2 responses generated at two anatomic sites of natural allergen encounter and identify the skin as a particularly potent site for Th2 sensitization.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA	Herrick, CA (reprint author), Yale Univ, Sch Med, Dept Dermatol, 333 Cedar St,POB 208059, New Haven, CT 06520 USA.				NHLBI NIH HHS [R01 HL054450, R01-HL-54450]; NIAMS NIH HHS [T32 AR007016, T32-AR-07016, P30-AR4192]		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Chensue SW, 1997, J IMMUNOL, V159, P3565; Chensue SW, 1999, J IMMUNOL, V162, P3106; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; DOHERTY TM, 1993, J IMMUNOL, V151, P7151; Donaldson DD, 1998, J IMMUNOL, V161, P2317; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HUANG SK, 1995, J IMMUNOL, V155, P2688; Kaplan MH, 1998, J LEUKOCYTE BIOL, V64, P2; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lawrence RA, 1996, EXP PARASITOL, V84, P65, DOI 10.1006/expr.1996.0090; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LIN JX, 1995, IMMUNITY, V2, P1; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; NAKAJIMA H, 1994, J EXP MED, V179, P1145, DOI 10.1084/jem.179.4.1145; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SMERZBERTLING C, 1995, J BIOL CHEM, V270, P966; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; THORNHILL MH, 1991, J IMMUNOL, V146, P592; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; VAJDY M, 1995, J EXP MED, V181, P41, DOI 10.1084/jem.181.1.41; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; VONDERWEID T, 1994, EUR J IMMUNOL, V24, P2285, DOI 10.1002/eji.1830241004; Wang L F, 1996, J Immunol, V156, P4077; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yokota K, 1996, J IMMUNOL, V157, P1529; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869	59	137	137	1	3	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	MAR	2000	105	6					765	775		10.1172/JCI8624		11	Medicine, Research & Experimental	Research & Experimental Medicine	295NJ	WOS:000085974500012	10727445	
J	Zwiener, C; Richardson, SD; De Marini, DM; Grummt, T; Glauner, T; Frimmel, FH				Zwiener, Christian; Richardson, Susan D.; De Marini, David M.; Grummt, Tamara; Glauner, Thomas; Frimmel, Fritz H.			Drowning in disinfection byproducts? Assessing swimming pool water	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Review							DRINKING-WATER; MUTATION SPECTRA; BIRTH-WEIGHT; TRIHALOMETHANE CONCENTRATIONS; LIQUID-CHROMATOGRAPHY; RESPIRATORY SYMPTOMS; NITROGEN TRICHLORIDE; CHEMICAL-IONIZATION; MASS-SPECTROMETRY; SALMONELLA TA100	Disinfection is mandatory for swimming pools: public pools are usually disinfected by gaseous chlorine or sodium hypochlorite and cartridge filters; home pools typically use stabilized chlorine. These methods produce a variety of disinfection byproducts (DBPs), such as trihalomethanes (THMs), which are regulated carcinogenic DBPs in drinking water that have been detected in the blood and breath of swimmers and of nonswimmers at indoor pools. Also produced are halogenated acetic acids (HAAs) and haloketones, which irritate the eyes, skin, and mucous membranes; trichloramine, which is linked with swimming-pool-associated asthma; and halogenated derivatives of UV sun screens, some of which show endocrine effects. Precursors of DBPs include human body substances, chemicals used in cosmetics and sun screens, and natural organic matter. Analytical research has focused also on the identification of an additional portion of unknown DBPs using gas chromatography (GC)/mass spectrometry (MS) and liquid chromatography (LC)/MS/MS with derivatization. Children swimmers have an increased risk of developing asthma and infections of the respiratory tract and ear. A 1.6-2.0-fold increased risk for bladder cancer has been associated with swimming or showering/bathing with chlorinated water. Bladder cancer risk from THM exposure (all routes combined) was greatest among those with the GSTT1-1 gene. This suggests a mechanism involving distribution of THMs to the bladder by dermal/inhalation exposure and activation there by GSTT1-1 to mutagens. DBPs may be reduced by engineering and behavioral means, such as applying new oxidation and filtration methods, reducing bromide and iodide in the source water, increasing air circulation in indoor pools, and assuring the cleanliness of swimmers. The positive health effects gained by swimming can be increased by reducing the potential adverse health risks.	Univ Karlsruhe, Engler Bunte Inst, D-7500 Karlsruhe, Germany; US EPA, Natl Exposure Res Lab, Athens, GA 30613 USA; US EPA, Div Environm Carcinogenesis, Res Triangle Pk, NC 27711 USA; Fed Environm Agcy, Bad Elster, Germany	Zwiener, C (reprint author), Univ Karlsruhe, Engler Bunte Inst, D-7500 Karlsruhe, Germany.	christian.zwiener@ciw.uni-karlsruhe.de					AGGAZZOTTI G, 1986, WATER RES, V20, P959, DOI 10.1016/0043-1354(86)90036-9; AGGAZZOTTI G, 1990, ARCH ENVIRON HEALTH, V45, P175; AGGAZZOTTI G, 1993, ARCH ENVIRON HEALTH, V48, P250; Aggazzotti G, 1998, SCI TOTAL ENVIRON, V217, P155, DOI 10.1016/S0048-9697(98)00174-0; AGGAZZOTTI G, 2004, J WATER HEALTH, P1; Backer LC, 2000, J EXPO ANAL ENV EPID, V10, P321, DOI 10.1038/sj.jea.7500098; BEECH JA, 1980, AM J PUBLIC HEALTH, V70, P79, DOI 10.2105/AJPH.70.1.79; Bernard A, 2005, TOXICOL APPL PHARM, V206, P185, DOI 10.1016/j.taap.2004.10.022; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; CANTOR KP, 2006, EPIDEMIOLOGY SS150, V17; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; *CDCP, HLTH SWIMM; Chu H, 2002, OCCUP ENVIRON MED, V59, P243, DOI 10.1136/oem.59.4.243; *CRANF U, 2002, 3 INT C POOL WAT QUA; DEMARINI DM, 1994, MUTAGENESIS, V9, P429, DOI 10.1093/mutage/9.5.429; DeMarini DM, 1995, ENVIRON MOL MUTAGEN, V26, P270, DOI 10.1002/em.2850260403; DeMarini DM, 1997, ENVIRON MOL MUTAGEN, V30, P440, DOI 10.1002/(SICI)1098-2280(1997)30:4<440::AID-EM9>3.0.CO;2-M; *DIN, 2000, 19643 DIN; ERDINGER L, 1990, FORUM STADTE HYG, V41, P185; Fantuzzi G, 2001, SCI TOTAL ENVIRON, V264, P257, DOI 10.1016/S0048-9697(00)00722-1; Frimmel F. H., 2004, AB ARCH BADEW, V57, P586; FUNG K, 1981, ANAL CHEM, V53, P168, DOI 10.1021/ac00225a009; Glauner T, 2005, ACTA HYDROCH HYDROB, V33, P585, DOI 10.1002/aheh.200400605; Glauner T, 2005, WATER RES, V39, P4494, DOI 10.1016/j.watres.2005.09.005; Glauner T., 2004, GWF WASSER ABWASSER, V145, P706; Grosjean E, 1999, ANAL CHEM, V71, P1851, DOI 10.1021/ac981022v; GRUMMT T, 2003, WORKSH POOL WAT CHEM; HAGEN K, 2003, WORKSH POOL WAT CHEM; Hinckley AF, 2005, ENVIRON HEALTH PERSP, V113, P1808, DOI 10.1289/ehp.8282; [Anonymous], 2004, IARC MON EV CARC RIS, V84, P512; *INT AG RES CANC, 1991, IARC MON EV CARC RIS, V52, P544; Judd SJ, 2000, WATER RES, V34, P1611, DOI 10.1016/S0043-1354(99)00316-4; JUDD SJ, 1995, WATER RES, V29, P1203, DOI 10.1016/0043-1354(94)00230-5; Kim H, 2002, CHEMOSPHERE, V46, P123, DOI 10.1016/S0045-6535(00)00581-6; King BS, 2006, AM J IND MED, V49, P119, DOI 10.1002/ajim.20259; Klotz JB, 1999, EPIDEMIOLOGY, V10, P383, DOI 10.1097/00001648-199907000-00008; Kolliker S, 1998, ANAL CHEM, V70, P1979, DOI 10.1021/ac9709458; Krasner SW, 2006, ENVIRON SCI TECHNOL, V40, P7175, DOI 10.1021/es060353j; Kundu B, 2004, MUTAT RES-GEN TOX EN, V562, P39, DOI 10.1016/j.mrgentox.2004.05.007; Kundu B, 2004, MUTAT RES-FUND MOL M, V554, P335, DOI 10.1016/j.mrfmmm.2004.05.015; Lagerkvist BJ, 2004, ENVIRON HEALTH PERSP, V112, P1768, DOI 10.1289/ehp.7027; Landi S, 2000, MUTAT RES-REV MUTAT, V463, P247, DOI 10.1016/S1383-5742(00)00050-8; Levesque B, 2000, J TOXICOL ENV HEAL A, V61, P225, DOI 10.1080/00984100050136553; Levesque B, 2006, INT ARCH OCC ENV HEA, V80, P32, DOI 10.1007/s00420-006-0100-0; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; Nickmilder M, 2007, OCCUP ENVIRON MED, V64, P37, DOI 10.1136/oem.2005.025452; Nieuwenhuijsen MJ, 2002, EPIDEMIOLOGY, V13, P725, DOI 10.1097/01.EDE.0000030722.16351.91; Nieuwenhuijsen MJ, 2000, OCCUP ENVIRON MED, V57, P73, DOI 10.1136/oem.57.2.73; Nystad W, 2003, ACTA PAEDIATR, V92, P905, DOI 10.1080/08035250310003587; Pegram RA, 1997, TOXICOL APPL PHARM, V144, P183, DOI 10.1006/taap.1997.8123; Plewa MJ, 2004, ENVIRON SCI TECHNOL, V38, P62, DOI 10.1021/es030477l; Richardson SD, 2003, ENVIRON SCI TECHNOL, V37, P3782, DOI 10.1021/es030339w; Richardson SD, 2000, OZONE-SCI ENG, V22, P653; Richardson SD, 1999, ENVIRON SCI TECHNOL, V33, P3378, DOI 10.1021/es9900297; Richardson S. D., 1998, ENCY ENV ANAL REMEDI, V3, P1398; RICHARDSON SD, 2003, WORKSH POOL WAT CHEM; ROOK JJ, 1977, ENVIRON SCI TECHNOL, V11, P478, DOI 10.1021/es60128a014; Rook J.J., 1974, WAT TREAT EXAM, V23, P351; Ross MK, 2004, TOXICOL APPL PHARM, V195, P166, DOI 10.1016/i.taap.2003.11.019; Schlumpf Margret, 2001, Environmental Health Perspectives, V109, P239, DOI 10.2307/3434691; SINGER PC, 1994, J ENVIRON ENG-ASCE, V120, P727, DOI 10.1061/(ASCE)0733-9372(1994)120:4(727); Stav D, 2005, NEW ENGL J MED, V353, P1635, DOI 10.1056/NEJMc050955; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; Toledano MB, 2005, ENVIRON HEALTH PERSP, V113, P225, DOI 10.1289/ehp.7111; *U KARLSR, 2003, WORKSH POOL WAT CHEM; *US EPA, 1979, DISTSS12 US EPA; Villanueva CM, 2004, EPIDEMIOLOGY, V15, P357, DOI 10.1097/01.ede.0000121380.02594.fc; Villanueva Cristina M, 2007, Am J Epidemiol, V165, P148, DOI 10.1093/aje/kwj364; Waller K, 1998, EPIDEMIOLOGY, V9, P134, DOI 10.1097/00001648-199803000-00006; Weil L., 1980, Z WASS ABWASS FORSCH, V13, P165; Weinberg H. S., 2002, OCCURRENCE DISINFECT; Weisel C. P., 1994, WATER CONTAMINATION, P135; Whitaker HJ, 2003, ENVIRON HEALTH PERSP, V111, P688, DOI 10.1289/eph.5963; WHO, 2006, GUID SAF RECR WAT EN, V2; WILDSOET CF, 1989, WATER SCI TECHNOL, V21, P241; Wright JM, 2004, ENVIRON HEALTH PERSP, V112, P920, DOI 10.1289/ehp.6779; Xu X, 2005, J EXPO ANAL ENV EPID, V15, P289, DOI 10.1038/sj.jea.7500404; Xu X, 2002, TOXICOL APPL PHARM, V184, P19, DOI 10.1006/taap.2002.9494; Zwiener C, 2005, TRAC-TREND ANAL CHEM, V24, P613, DOI 10.1016/j.trac.2005.03.014; Zwiener C, 2004, ANAL BIOANAL CHEM, V378, P862, DOI 10.1007/s00216-003-2412-1; Zwiener C, 2003, WA SCI TECHNOL, V3, P321; Zwiener C, 2003, ACS SYM SER, V850, P356; Zwiener C., 2002, Analytical and Bioanalytical Chemistry, V372, P615; ZWIENER C, 2003, WATER CHINA, P59; ZWIENER C, 2003, WORKSH POOL WAT CHEM; 2000, BUDESGESETZESBLATT 1, P1045; 2003, POOLS SPA MARKETING; 1979, FED REG, V44, P624	88	136	139	14	139	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X	1520-5851		ENVIRON SCI TECHNOL	Environ. Sci. Technol.	JAN 15	2007	41	2					363	372		10.1021/es062367v		10	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	124RS	WOS:000243388200010	17310693	
J	Calder, PC; Krauss-Etschmann, S; de Jong, EC; Dupont, C; Frick, JS; Frokiaer, H; Heinrich, J; Garn, H; Koletzko, S; Lack, G; Mattelio, G; Renz, H; Sangild, PT; Schrezenmeir, J; Stulnig, TM; Thymann, T; Wold, AE; Koletzko, B				Calder, Philip C.; Krauss-Etschmann, Susanne; de Jong, Esther C.; Dupont, Christophe; Frick, Julia-Stefanie; Frokiaer, Hanne; Heinrich, Joachim; Garn, Holger; Koletzko, Sibylle; Lack, Gideon; Mattelio, Gianluca; Renz, Harald; Sangild, Per T.; Schrezenmeir, Juergen; Stulnig, Thomas M.; Thymann, Thomas; Wold, Agnes E.; Koletzko, Berthold			Early nutrition and immunity - progress and perspectives	BRITISH JOURNAL OF NUTRITION			English	Review						immunity; infection; allergy; asthma; atopic disease; lymphocyte; dendritic cell; cytokine; inflammation; probiotic; polyunsaturated fatty acid	POLYUNSATURATED FATTY-ACIDS; FISH-OIL SUPPLEMENTATION; CHILDHOOD ASTHMA PREVENTION; GUT EPITHELIAL MONOLAYERS; PLACEBO-CONTROLLED TRIAL; REGULATORY T-CELLS; ATOPIC DISEASE; ALLERGIC SENSITIZATION; DENDRITIC CELLS; DOUBLE-BLIND	The immune system exists to protect the host against pathogenic organisms and highly complex pathways of recognition, response, elimination and memory have evolved in order to fulfil this role. The immune system also acts to ensure tolerance to 'self', to food and other environmental components, and to commensal bacteria. A breakdown in the tolerogenic pathways can also lead to inflammatory diseases. The prevalence of inflammatory diseases, including atopic disorders, has increased over the last 60 years. The development of tolerance is the result of active immune mechanisms and both development and maintenance of tolerance are lifelong processes which start very early in life, even prenatally. Profound immunologic changes occur during pregnancy, involving a polarization of T helper (Th) cells towards a dominance of Th2 and regulatory T cell effector responses in both mother and fetus. This situation is important to maintain pregnancy through avoidance of the rejection of the immunologically incompatible fetus. During the third trimester of human pregnancy, fetal T cells are able to mount antigen-specific responses to environmental and food-derived antigens and antigen-specific T cells are detectable in cord blood in virtually all newborns indicating in utero sensitization. If the neonatal immune system is not able to down-regulate the pre-existing Th2 dominance effectively then an allergic phenotype may develop. Changes occur at, and soon after, birth in order that the immune system of the neonate becomes competent and functional and that the gut becomes colonized with bacteria. Exposure to bacteria during birth and from the mother's skin and the provision of immunologic factors in breast milk are amongst the key events that promote maturation of the infant's gut and gut-associated and systemic immune systems. The introduction of formula and of solid foods exposes the infant to novel food antigens and also affects the gut flora. Nutrition may be the source of antigens to which the immune system must become tolerant, provide factors, including nutrients, that themselves might modulate immune maturation and responses, and provide factors that influence intestinal flora, which in turn will affect antigen exposure, immune maturation and immune responses. Through these mechanisms it is possible that nutrition early in life might affect later immune competence, the ability to mount an appropriate immune response upon infection, the ability to develop a tolerogenic response to 'self' and to benign environmental antigens, and the development of immunologic disorders. A Workshop held in February 2006 considered recent findings in the areas of oral tolerance, routes of sensitization to allergens and factors affecting the development of atopic disease; factors influencing the maturation of dendritic cells and the development of regulatory T cells; the influence of gut microflora on immunity, allergic sensitization and infectious disease; the role of nutrition in preventing necrotizing enterocolitis in an animal model of preterm birth; and the role of PUFA of different classes in influencing immune responses and in shaping the development of atopic disease. This report summarizes the content of the lectures and the subsequent discussions.	Univ Southampton, Sch Med, Inst Human Nutr, Southampton SO16 7PX, Hants, England; Univ Munich, Dr Von Haunerschen Kinderspital, Clin Cooperat Grp Pediat Immune Regulat, D-80337 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Univ Amsterdam, Dept Cell Biol & Histol, NL-1105 AZ Amsterdam, Netherlands; Univ Paris 05, Hop St Vincent de Paul, Dept Pediat Gastroenterol, F-75014 Paris, France; Univ Paris 05, Hop St Vincent de Paul, Nutr Unit, F-75014 Paris, France; Univ Tubingen, Dept Med Microbiol & Hyg, D-72076 Tubingen, Germany; Tech Univ Denmark, Bioctr, DK-2800 Lyngby, Denmark; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85758 Neuherberg, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, Cent Lab, D-35043 Marburg, Germany; Univ Munich, Dr Von Haunerschen Kinderspital, Div Gastroenterol, D-80337 Munich, Germany; Univ London Imperial Coll Sci Technol & Med, St Marys Hosp, London W2 1NY, England; European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy; Royal Vet & Agr Univ, Dept Human Nutr, DK-1958 Frederiksberg, Denmark; Fed Res Ctr Nutr & Food, Inst Physiol & Biochem Nutr, D-24103 Kiel, Germany; Univ Vienna, Dept Internal Med 3, Clin Div Endocrinol & Metab, A-1090 Vienna, Austria; Gothenburg Univ, Sahlgrenska Acad, Dept Clin Bacteriol, S-41346 Gothenburg, Sweden; Univ Munich, Dr Von Haunerschen Kinderspital, Div Metab Dis & Nutr Med, D-80337 Munich, Germany	Calder, PC (reprint author), Univ Southampton, Sch Med, Inst Human Nutr, Bassett Crescent E, Southampton SO16 7PX, Hants, England.	pcc@soton.ac.uk	Perez , Claudio Alejandro/F-8310-2010; Wold, Agnes/M-6310-2013; Calder, Philip/E-9739-2013; Wilkinson, Stuart/C-2802-2013; Osborne, Nicholas/N-4915-2015	Perez , Claudio Alejandro/0000-0001-9688-184X; Calder, Philip/0000-0002-6038-710X; Osborne, Nicholas/0000-0002-6700-2284; Wold, Agnes/0000-0001-9196-5040			ADLERBERTH I, 2005, PEDIATR RES, V59, P96; Ahrne S, 2005, MICROBES INFECT, V7, P1256, DOI 10.1016/j.micinf.2005.04.011; Akerblom H K, 1985, Acta Paediatr Scand Suppl, V318, P49; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Autenrieth IB, 1997, GUT, V41, P793; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bagga D, 2003, P NATL ACAD SCI USA, V100, P1751, DOI 10.1073/pnas.0334211100; Barnes KC, 2006, J ALLERGY CLIN IMMUN, V117, P243, DOI 10.1016/j.jaci.2005.11.030; Bergonzelli GE, 2005, DIGESTION, V72, P57, DOI 10.1159/000087638; Bjerke T, 1994, Pediatr Allergy Immunol, V5, P88, DOI 10.1111/j.1399-3038.1994.tb00223.x; Bjornvad CR, 2005, AM J PHYSIOL-REG I, V289, pR1212, DOI 10.1152/ajpregu.00776.2004; Black FT, 1989, TRAVEL MED, V7, P333; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bolte G, 2005, ANN EPIDEMIOL, V15, P207, DOI 10.1016/j.annepidem.2004.04.004; Bolte G, 2001, AM J RESP CRIT CARE, V163, P277; Borchers AT, 2005, J ASTHMA, V42, P225, DOI 10.1081/JAS-200051302; Braback L, 2001, PEDIATR ALLERGY IMMU, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Braun-Fahrlander C, 2000, PEDIATR ALLERGY IMMU, V11, P19, DOI 10.1034/j.1399-3038.2000.00505.x; Broughton KS, 1997, AM J CLIN NUTR, V65, P1011; Calder P C, 1992, Mediators Inflamm, V1, P107, DOI 10.1155/S0962935192000188; CALDER PC, 1994, BIOCHEM J, V300, P509; CALDER PC, 1992, CLIN SCI, V82, P695; CALDER PC, 1991, INT J BIOCHEM, V23, P579; Calder PC, 2006, AM J CLIN NUTR, V83, p1505S; Calder PC, 2000, PEDIATR ALLERGY IMMU, V11, P29, DOI 10.1034/j.1399-3038.2000.00508.x; Calder PC, 2003, CLIN EXP ALLERGY, V33, P412, DOI 10.1046/j.1365-2222.2003.01633.x; Calder PC, 2002, BRIT J NUTR, V87, pS31, DOI [10.1079/BJN2001455, 10.1079/BJN2001482]; Calder PC, 2001, NUTR RES, V21, P309, DOI 10.1016/S0271-5317(00)00287-6; Calder P. C., 2003, LIPIDS, V38, P342; Cunard R, 2002, J IMMUNOL, V168, P2795; de Jong EC, 2002, J IMMUNOL, V168, P1704; de Urquiza AM, 2000, SCIENCE, V290, P2140; de Vrese M, 2005, CLIN NUTR, V24, P481, DOI 10.1016/j.clnu.2005.02.006; DEBOISSIEU D, 2006, IN PRESS ALLERGY; Decsi T, 2005, ADV EXP MED BIOL, V569, P109; *DEP HLTH, 1997, COMM TOX CHEM FOOD C; Duchen K, 1998, PEDIATR RES, V44, P478, DOI 10.1203/00006450-199810000-00003; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fan YY, 2004, J IMMUNOL, V173, P6151; Fan YY, 2003, J NUTR, V133, P1913; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; GALLAI V, 1995, J NEUROIMMUNOL, V56, P143, DOI 10.1016/0165-5728(94)00140-J; Gionchetti P, 2000, GASTROENTEROLOGY, V119, P305, DOI 10.1053/gast.2000.9370; GOLDMAN DW, 1983, BIOCHEM BIOPH RES CO, V117, P282, DOI 10.1016/0006-291X(83)91572-3; Hatakka K, 2001, BRIT MED J, V322, P1327, DOI 10.1136/bmj.322.7298.1327; Herz U, 2001, INT ARCH ALLERGY IMM, V124, P193, DOI 10.1159/000053708; Hilton E, 1997, J TRAVEL MED, V4, P41, DOI 10.1111/j.1708-8305.1997.tb00772.x; Hodge L, 1996, MED J AUSTRALIA, V164, P137; HODGE L, 1994, AUST NZ J MED, V24, P727, DOI 10.1111/j.1445-5994.1994.tb01793.x; Huang JS, 2002, DIGEST DIS SCI, V47, P2625, DOI 10.1023/A:1020501202369; Isolauri E, 2004, CURR ALLERGY ASTHM R, V4, P270, DOI 10.1007/s11882-004-0070-9; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Jones CA, 2002, PEDIAT ALLERG IMM-UK, V13, P19, DOI 10.1034/j.1399-3038.13.s.15.6.x; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Jones CA, 1998, LANCET, V351, P1859, DOI 10.1016/S0140-6736(05)78805-X; Kabesch M, 1999, EUR RESPIR J, V13, P577, DOI 10.1183/09031936.99.13357799; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; KONDO N, 1992, ARCH DIS CHILD, V67, P1003; Kramer MS, 2003, COCHRANE DB SYST REV; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; LAUBEREAU B, 2005, CHILD CARE HLTH DEV, V31, P124; Lauritzen L, 2005, LIPIDS, V40, P669, DOI 10.1007/s11745-005-1429-6; LEE TH, 1984, J BIOL CHEM, V259, P2383; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Marteau PR, 2001, AM J CLIN NUTR, V73, p430S; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; MEYDANI SN, 1991, J NUTR, V121, P547; Michaelsson J, 2006, J IMMUNOL, V176, P5741; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2004, PEDIATR ALLERGY IMMU, V15, P517, DOI 10.1111/j.1399-3038.2004.00187.x; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; Ogden NS, 2005, CURR OPIN ALLERGY CL, V5, P179, DOI 10.1097/01.all.0000162312.64308.fc; OKSANEN PJ, 1990, ANN MED, V22, P53, DOI 10.3109/07853899009147242; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Pedone CA, 2000, INT J CLIN PRACT, V54, P568; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; POWELL JD, 2006, IN PRESS CLIN IMMUNO; POYSA L, 1991, ALLERGY, V46, P161, DOI 10.1111/j.1398-9995.1991.tb00564.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 2004, CURR OPIN CLIN NUTR, V7, P123, DOI 10.1097/00075197-200403000-00004; Prescott SL, 1998, J IMMUNOL, V160, P4730; Raghupathy R, 2001, SEMIN IMMUNOL, V13, P219, DOI 10.1006/smim.2001.0316; Reinhard G, 1998, BIOCHEM BIOPH RES CO, V245, P933, DOI 10.1006/bbrc.1998.8549; Renz H, 2006, CHEM IMMUNOL ALLERGY, V91, P30; Rescigno M, 2001, IMMUNOBIOLOGY, V204, P572, DOI 10.1078/0171-2985-00094; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rimoldi M, 2005, BLOOD, V106, P2818, DOI 10.1182/blood-2004-11-4321; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Sanderson P, 1998, BBA-LIPID LIPID MET, V1392, P300, DOI 10.1016/S0005-2760(98)00044-7; Sanderson Peter, 1995, Journal of Nutritional and Environmental Medicine (Abingdon), V5, P119, DOI 10.3109/13590849509000211; Sangild P T, 2003, Acta Vet Scand Suppl, V98, P105; Sangild PT, 2002, J NUTR, V132, P2673; SANGILD PT, 2006, GASTROENTEROLOGY, V130, P2776; Sausenthaler S, 2006, PEDIAT ALLERG IMM-UK, V17, P85, DOI 10.1111/j.1399-3038.2005.00366.x; Schachter H., 2004, AHRQ PUBLICATION, V04-E013-2; Schaeffer L, 2006, HUM MOL GENET, V15, P1745, DOI 10.1093/hmg/ddl117; Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7; Serhan CN, 2005, CURR OPIN CLIN NUTR, V8, P115, DOI 10.1097/00075197-200503000-00003; Shah Shilpa, 2006, Indian J Med Sci, V60, P13; Sigal LH, 2005, JCR-J CLIN RHEUMATOL, V11, P113, DOI 10.1097/01.rhu.0000158529.32452.01; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Stulnig TM, 2003, INT ARCH ALLERGY IMM, V132, P310, DOI 10.1159/000074898; Stulnig TM, 1998, J CELL BIOL, V143, P637, DOI 10.1083/jcb.143.3.637; Stulnig TM, 2004, LIPIDS, V39, P1171, DOI 10.1007/s11745-004-1344-x; Stulnig TM, 2001, J BIOL CHEM, V276, P37335, DOI 10.1074/jbc.M106193200; Szepfalusi Z, 2000, PEDIATR RES, V48, P404; Tariq SM, 1996, BRIT MED J, V313, P514; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Thien F.C.K., 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001283; THILAGANATHAN B, 1992, FETAL DIAGN THER, V7, P53; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI13416; Trak-Fellermeier MA, 2004, EUR RESPIR J, V23, P575, DOI 10.1183/09031936.04.00074404; Trebble TM, 2003, AM J CLIN NUTR, V78, P376; Tubelius Py, 2005, Environ Health, V4, P25, DOI 10.1186/1476-069X-4-25; Turchet P, 2003, J Nutr Health Aging, V7, P75; Valledor AF, 2004, BIOCHEM PHARMACOL, V67, P201, DOI 10.1016/j.bcp.2003.10.016; Van Niel CW, 2002, PEDIATRICS, V109, P678, DOI 10.1542/peds.109.4.678; Vazquez-Torres A, 1999, NATURE, V401, P804, DOI 10.1038/44593; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Waidmann M, 2003, GASTROENTEROLOGY, V125, P162, DOI 10.1016/S0016-5085(03)00672-3; Wallace FA, 2001, J LEUKOCYTE BIOL, V69, P449; Warner JA, 1996, PEDIATR ALLERGY IMMU, V7, P98, DOI 10.1111/j.1399-3038.1996.tb00406.x; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P493; Wegmann M, 2005, CLIN EXP ALLERGY, V35, P1263, DOI 10.1111/j.1365-2222.2005.02306.x; Weizman Z, 2005, PEDIATRICS, V115, P5, DOI 10.1542/peds.2004-1815; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261; YAQOOB P, 1994, IMMUNOLOGY, V82, P603; Yaqoob P, 2000, EUR J CLIN INVEST, V30, P260, DOI 10.1046/j.1365-2362.2000.00623.x; Yu G, 1998, EUR J PEDIATR, V157, P298, DOI 10.1007/s004310050815; Yu G, 1996, ACTA PAEDIATR, V85, P679, DOI 10.1111/j.1651-2227.1996.tb14124.x; ZAJEWSKA H, 2001, J PEDIAT GASTROEN S2, V33, pS17; Zeyda M, 2006, PROG LIPID RES, V45, P187, DOI 10.1016/j.plipres.2006.01.002; Zeyda M, 2002, J BIOL CHEM, V277, P28418, DOI 10.1074/jbc.M203343200; Zeyda M, 2003, J IMMUNOL, V170, P6033; Zirngibl A, 2002, PEDIATR ALLERGY IMMU, V13, P394, DOI 10.1034/j.1399-3038.2002.01110.x	144	136	144	4	55	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 2RU CAMBRIDGE, ENGLAND	0007-1145			BRIT J NUTR	Br. J. Nutr.	OCT	2006	96	4					774	790		10.1079/BJN20061917		17	Nutrition & Dietetics	Nutrition & Dietetics	089GB	WOS:000240867300022	17010239	
J	Belanger, K; Beckett, W; Triche, E; Bracken, MB; Holford, T; Ren, P; McSharry, JE; Gold, DR; Platts-Mills, TAE; Leaderer, BP				Belanger, K; Beckett, W; Triche, E; Bracken, MB; Holford, T; Ren, P; McSharry, JE; Gold, DR; Platts-Mills, TAE; Leaderer, BP			Symptoms of wheeze and persistent cough in the first year of life: Associations with indoor allergens, air contaminants, and maternal history of asthma	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						allergens; cockroaches; cough; dust; fungi; infant; nitrogen dioxide; respiratory sounds	INFANT RESPIRATORY SYMPTOMS; HOUSE-DUST MITE; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE; PARENTAL SMOKING; UNITED-STATES; CHILDREN; EXPOSURE; RISK; PREDICTORS	In a cohort of 849 infants with an asthmatic sibling, the authors examined the relations of exposure to allergens (dust mite, cockroach, cat, and dog), nitrogen dioxide, and mold with symptoms of wheeze and persistent cough in the first year of life (1998-2000). Among infants whose mothers had physician-diagnosed asthma, neither dust mite allergen nor dog allergen was associated with either symptom. Exposure to cockroach allergen (Bla g 1 at greater than or equal to2 U/g) modestly increased the risk for wheeze (odds ratio (OR)=1.87, 95% confidence interval (CI): 0.94, 3.71), and exposure to cat allergen modestly decreased the risk (OR=0.60, 95% CI: 0.35, 1.03). Among infants of mothers with no asthma history, exposure to gas stoves (OR=1.50, 95% CI: 1.05, 2.15) and wood-burning stoves (OR=2.09, 95% CI: 1.12, 3.91) increased the risk of persistent cough. Similarly, measured nitrogen dioxide concentration was associated with persistent cough (OR=1.21, 95% CI: 1.05, 1.40). Persistent mold affected both infants of mothers with asthma (for wheeze, OR=2.27, 95% CI: 1.27, 4.07; for cough, OR=1.83, 95% CI: 1.04, 3.22) and infants of mothers without asthma (for cough, OR=1.55, 95% CI: 1.04, 2.31). Reported exposure was confirmed by an association of measured fungi with wheeze (OR=1.23, 95% CI: 1.01, 1.49). This appears to have been the first study to measure all of these home exposures (indoor allergens, nitrogen dioxide, fungi) and to prospectively measure the frequency of infant wheeze and persistent cough.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Occupat Med Div, Rochester, NY USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Pulm, Boston, MA USA; Univ Virginia, Med Ctr, Dept Med, Div Allergy & Immunol, Charlottesville, VA USA	Belanger, K (reprint author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.		Triche, Elizabeth/I-4986-2014; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIEHS NIH HHS [ES05410, ES07456]		BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; Bosken CH, 2000, AM J RESP CRIT CARE, V161, P1810; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURR ML, 1993, ARCH DIS CHILD, V68, P724; *COMM ASTHM IND AI, 2000, CLEAN AIR ASTHM IND; Csonka P, 2000, PEDIATR ALLERGY IMMU, V11, P225, DOI 10.1034/j.1399-3038.2000.00088.x; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leaderer BP, 1997, J PHARM PHARMACOL, V49, P39; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Ortega AN, 2001, ANN ALLERG ASTHMA IM, V86, P405; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; PLATTSMILLS TA, 1997, J ALLERGY CLIN IMMUN, V97, P1079; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Samet J M, 1993, Res Rep Health Eff Inst, P1; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; Sears MR, 1996, ARCH DIS CHILD, V75, P392; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Strachan DP, 1998, THORAX, V53, P204; Tager IB, 1998, AM J RESP CRIT CARE, V158, P349; Triche EW, 2002, AM J RESP CRIT CARE, V166, P1105, DOI 10.1164/rccm.2202014; vanStrien RT, 1996, EUR RESPIR J, V9, P926, DOI 10.1183/09031936.96.09050926; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; ZEIGER RS, 1985, J ALLERGY CLIN IMMUN, V75, P633, DOI 10.1016/0091-6749(85)90086-7	41	136	139	2	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	AUG 1	2003	158	3					195	202		10.1093/aje/kwg148		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	707RF	WOS:000184523100001	12882940	
J	Mihrshahi, S; Peat, JK; Marks, GB; Mellis, CM; Tovey, ER; Webb, K; Britton, WJ; Leeder, SR				Mihrshahi, S; Peat, JK; Marks, GB; Mellis, CM; Tovey, ER; Webb, K; Britton, WJ; Leeder, SR		CAPS Team	Eighteen-month outcomes of house dust mite avoidance and dietary fatty acid modification in the Childhood Asthma Prevention Study (CAPS)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; asthma; atopy; fatty acids; house dust mite; primary prevention	RANDOMIZED TRIAL; EARLY-LIFE; PREGNANCY; INFANCY	Background: Observational studies have linked house dust mite (HDM) exposure and dietary fatty acid intake with asthma in childhood. However, definitive evidence of their role in the etiology of asthma requires a randomized controlled trial. Objective: We hypothesized that the incidence of asthma and allergy in high-risk children would be reduced by avoidance of HDM allergens, supplementation with omega-3 fatty acids, or the combination of these strategies. We present the results of an interim analysis reporting outcomes assessed at 18 months. Methods: A total of 616 pregnant women were randomized to an HDM avoidance intervention, comprising the use of impermeable mattress covers and an acaricide or control and the use of an oil supplement, margarines, and cooking oils containing high levels of omega-3 fatty acids or control. Atopic status was measured by skin prick testing. Symptoms, diagnoses, and medication histories were elicited by means of parental interviews. Results: The diet intervention resulted in a 9.8% absolute reduction (95% CI, 1.5-18.1; P =.02) in the prevalence of any wheeze and a 7.8% absolute reduction (95% CI, 0.5-15.1, P =.04) in prevalence of wheeze of >1 week, but it had no effect on serum IgE, atopy, or doctors' diagnosis of asthma. The HDM avoidance intervention did not affect these outcomes but was associated with a lower use of oral steroids. Conclusion: Increasing dietary omega-3 fatty acids might have a beneficial effect on the prevalence of wheeze during the first 18 months of life. Follow-up to age 5 years, when the effect of the interventions on asthma risk will be assessed, is underway.	Childrens Hosp, Clin Epidemiol Unit, Westmead, NSW 2145, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Univ Sydney, Centenary Inst Canc Med & Cell Biol, Sydney, NSW 2006, Australia; Univ Sydney, Dept Biochem, Sydney, NSW 2006, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW, Australia; Univ Sydney, Woolcock Inst Med Res, Sydney, NSW 2006, Australia; Univ Sydney, Dept Child Hlth & Paediat, Sydney, NSW 2006, Australia	Mihrshahi, S (reprint author), Childrens Hosp, Clin Epidemiol Unit, Locked Bag 4001, Westmead, NSW 2145, Australia.		Mihrshahi, Seema/A-9877-2009; Tovey, Euan/G-8604-2017	Mihrshahi, Seema/0000-0001-6567-9884; Tovey, Euan/0000-0002-1802-7266			ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mihrshahi S, 2002, RESPIROLOGY, V7, P147, DOI 10.1046/j.1440-1843.2002.00384.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; MIHRSHAHI S, 2003, IN PRESS ALLERGY; PEAT JK, 1992, EUR RESPIR J, V5, P921; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	16	136	142	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					162	168		10.1067/mai.2003.36		7	Allergy; Immunology	Allergy; Immunology	636PR	WOS:000180465500025	12532113	
J	Zock, JP; Jarvis, D; Luczynska, C; Sunyer, J; Burney, P				Zock, JP; Jarvis, D; Luczynska, C; Sunyer, J; Burney, P		European Community Resp Hlth Surv	Housing characteristics, reported mold exposure, and asthma in the European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; housing; dampness; mold; carpeting; European Community Respiratory Health Survey	HOME DAMPNESS; DUST MITES; FUNGAL PROPAGULES; INDOOR AIR; SYMPTOMS; ADULTS; CHILDREN; (1->3)-BETA-D-GLUCAN; INFECTIONS; ALLERGENS	Background: The effects of home dampness and mold exposure on adult asthma are not clear. Objective: We aimed to investigate the associations between housing characteristics related to dampness, mold exposure, and house dust mite levels and adult asthma in 38 study centers from the European Community Respiratory Health Survey. Methods: Data about the present home, heating and ventilation systems, double glazing, floor covers, recent water damage, and mold exposure were obtained by means of an interviewer-led questionnaire. The associations between these factors and asthma, as defined on the basis of symptoms in the last year, and of bronchial responsiveness, as determined with methacholine challenge, were evaluated. Odds ratios (ORs) were obtained by using random-effects meta-analyses adjusted within study centers for sex, age group, and smoking status. Results: Fitted carpets and rugs in the bedroom were related to fewer asthma symptoms and bronchial responsiveness (OR range, 0.69-0.91). This effect was consistent across centers and more pronounced among house dust mite-sensitized individuals. Reported mold exposure in the last year was associated with asthma symptoms and bronchial responsiveness (OR range, 1.14-1.44). This effect was homogeneous among centers and stronger in subjects sensitized to Cladosporium species. In centers with a higher prevalence of asthma, the prevalence of reported indoor mold exposure was also high. This association was observed for reported mold exposure by asthmatic subjects (Spearman r(s) = 0.46), as well as reported mold exposure by nonasthmatic subjects (r(s) = 0.54). Reported mold exposure was highest in older houses with recent water damage. Conclusion: We conclude that indoor mold growth has an adverse effect on adult asthma.	Municipal Inst Med Res, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England	Zock, JP (reprint author), Municipal Inst Med Res, Resp & Environm Hlth Res Unit, Dr Aiguader 80, E-08003 Barcelona, Spain.		Jarvis, Deborah/E-6494-2011; Sanchez-Ramos, Jose Luis/G-1259-2011; Sunyer, J/G-6909-2014	Sanchez-Ramos, Jose Luis/0000-0001-7187-9989; Sunyer, J/0000-0002-2602-4110; ROMANO, Canzio/0000-0001-5294-9793; Abramson, Michael/0000-0002-9954-0538; Soriano, Joan B/0000-0001-9740-2994	NCRR NIH HHS [2SO7 RR 05521-28]		ARMSTRONG BG, 1990, AM J EPIDEMIOL, V132, P1176; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Evans J, 2000, J EPIDEMIOL COMMUN H, V54, P677, DOI 10.1136/jech.54.9.677; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; PLATT SD, 1989, BRIT MED J, V298, P1673; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; Rylander R, 1997, MEDIAT INFLAMM, V6, P275, DOI 10.1080/09629359791613; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; Williamson IJ, 1997, THORAX, V52, P229	31	136	138	0	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					285	292	UNSP 1/81/126383	10.1067/mai.2002.126383		8	Allergy; Immunology	Allergy; Immunology	585DY	WOS:000177509800014	12170270	
J	Koppelman, GH; Stine, OC; Xu, JF; Howard, TD; Zheng, SQL; Kauffman, HF; Bleecker, ER; Meyers, DA; Postma, DS				Koppelman, GH; Stine, OC; Xu, JF; Howard, TD; Zheng, SQL; Kauffman, HF; Bleecker, ER; Meyers, DA; Postma, DS			Genome-wide search for atopy susceptibility genes in Dutch families with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						genetics of atopy; asthma; specific IgE; eosinophils; genoine-wide search	LINKAGE ANALYSIS; CHROMOSOME 5Q31-Q33; MITE SENSITIZATION; FOUNDER POPULATION; UNDERLYING ASTHMA; ALLERGY; MARKERS; SCREEN; LOCUS; HYPERRESPONSIVENESS	Background: Atopy is a phenotype associated with asthma that has a heritable component. However, the role of atopy-susceptibility genes in the development and expression of asthma and allergic disorders is not understood. Objective: We sought to study the familial aggregation and co-occurrence of atopic phenotypes within family members of patients with asthma and to identify chromosomal regions that may contain genes that regulate different atopic phenotypes. Methods: In 200 families (n = 1174) ascertained through a proband with asthma, genome-wide screen and linkage analysis was performed for the following atopic phenotypes: (1) specific IgE to common aeroallergens (Phadiatop assay); (2) specific IgE to Der p 1; (3) positive skin test responses to house dust mite; (4) positive skin test responses to 1 or more of 16 allergens; and (5) peripheral blood eosinophils. Results were compared with the linkage results for total serum IgE levels. Results: There was clear familial aggregation of atopy. A high total serum IgE level in combination with a positive Phadiatop result or a normal total IgE level in combination with a negative Phadiatop result was found in 56.1% of the probands and 66.9% of the offspring. Several chromosomal regions that showed evidence for linkage to an atopic phenotype (ie, 2q, 6p, 7q, and 13q) also showed evidence of linkage with total serum IgE (Xu et al. Am J Hum Genet 2000;67:1163-73). Specific regions of interest for atopic traits were also detected on chromosomes 11q, 17q, and 22q. Conclusions: Atopic phenotypes show familial aggregation, although family members may differ in expression of atopy. Specific chromosomal regions appear to be important in susceptibility to different phenotypes of atopic responsiveness.	Beatrixoord, Dept Pulm Rehabil, Haren, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Wake Forest Univ, Sch Med, Ctr Human Genomics, Winston Salem, NC 27109 USA	Postma, DS (reprint author), Univ Groningen, Dept Pulmonol, POB 30-001, NL-9700 RB Groningen, Netherlands.				NCRR NIH HHS [1 P41 RR03655]; NHLBI NIH HHS [R01HL48341, R01HL66393]		Almasy L, 1998, AM J HUM GENET, V62, P1198, DOI 10.1086/301844; Amelung PJ, 1998, CLIN EXP ALLERGY, V28, P397; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Burney PGJ, 1997, ASTHMA, P35; Clarke JR, 2000, AM J RESP CRIT CARE, V162, P2188; COOKSON WOCM, 1989, LANCET, V1, P1292; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812; Fryer AA, 2000, GENES IMMUN, V1, P509, DOI 10.1038/sj.gene.6363717; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kjellman NIM, 1999, PEDIATR ALLERGY IMMU, V10, P11; Kong A, 1997, AM J HUM GENET, V61, P1179, DOI 10.1086/301592; KOPPELMAN GH, 2000, ASTHMA, P146; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; Kurz T, 2000, J ALLERGY CLIN IMMUN, V106, P925, DOI 10.1067/mai.2000.110557; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; MARSHALL E, 1994, SCIENCE, V264, P1524, DOI 10.1126/science.8202702; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739; Nickel RG, 2000, J IMMUNOL, V164, P1612; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Strauch K, 2000, AM J HUM GENET, V66, P1945, DOI 10.1086/302911; VANCAMP G, 1997, TRENDS GENET, V13, P82; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	34	136	143	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					498	506		10.1067/mai.2002.122235		9	Allergy; Immunology	Allergy; Immunology	534KW	WOS:000174586400018	11897998	
J	Haby, MM; Peat, JK; Marks, GB; Woolcock, AJ; Leeder, SR				Haby, MM; Peat, JK; Marks, GB; Woolcock, AJ; Leeder, SR			Asthma in preschool children: prevalence and risk factors	THORAX			English	Article						asthma; prevalence; risk factors; preschool children	HOUSE-DUST MITE; CHILDHOOD ASTHMA; ATOPIC DISEASE; ALLERGEN AVOIDANCE; FAMILY-SIZE; HAY-FEVER; ASSOCIATION; AGE; SENSITIVITY; SEVERITY	Background-The prevalence of asthma in children has increased in many countries over recent years. To plan effective interventions to reverse this trend we need a better understanding of the risk factors for asthma in early life. This study was undertaken to measure the prevalence of, and risk factors for, asthma in preschool children. Methods-Parents of children aged 3-5 years living in two cities (Lismore, n=383; Wagga Wagga, n=591) in New South Wales, Australia were surveyed by questionnaire to ascertain the presence of asthma and various proposed risk factors for asthma in their children. Recent asthma was defined as ever having been diagnosed with asthma and having cough or wheeze in the last 12 months and having used an asthma medication in the last 12 months. Atopy was measured by skin prick tests to six common allergens. Results-The prevalence of recent asthma was 22% in Lismore and 18% in Wagga Wagga. Factors which increased the risk of recent asthma were: atopy (odds ratio (OR) 2.35, 95% CI 1.49 to 3.72), having a parent with a history of asthma (OR 2.05, 95% CI 1.34 to 3.16), having had a serious respiratory infection in the first 2 years of life (OR 1.93, 95% CI 1.25 to 2.99), and a high dietary intake of polyunsaturated fats (OR 2.03, 95% CI 1.15 to 3.60). Breast feeding (OR 0.41, 95% CI 0.22 to 0.74) and having three or more older siblings (OR 0.16, 95% CI 0.04 to 0.71) decreased the risk of recent asthma. Conclusions-Of the factors tested, those that have the greatest potential to be modified to reduce the risk of asthma are breast feeding and consumption of polyunsaturated fats.	Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia; Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia	Haby, MM (reprint author), Royal Childrens Hosp, Ctr Community Child Hlth, Flemington Rd, Parkville, Vic 3052, Australia.						Altman DG, 1992, PRACTICAL STAT MED R; Armitage P., 1994, STAT METHODS MED RES; *AUSTR BUR STAT, 1991, 43640 AUSTR BUR STAT; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; CHINN S, 1991, THORAX, V46, P454, DOI 10.1136/thx.46.6.454; Haby MM, 2000, PEDIATR PULM, V30, P377, DOI 10.1002/1099-0496(200011)30:5<377::AID-PPUL3>3.0.CO;2-3; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HODGE L, 1994, AUST NZ J MED, V24, P727, DOI 10.1111/j.1445-5994.1994.tb01793.x; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; KIRSHNER B, 1990, J CLIN EPIDEMIOL, V43, P765, DOI 10.1016/0895-4356(90)90236-I; Kleinbaum D, 1982, EPIDEMIOLOGICAL RES; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; LUCAS A, 1990, BRIT MED J, V300, P837; LUYT DK, 1993, BRIT MED J, V306, P1386; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MERRETT TG, 1988, ANN ALLERGY, V61, P13; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Oddy WH, 1999, BRIT MED J, V319, P815; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1994, BRIT MED J, V308, P1591; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Pepys J., 1975, BRIT J HOSP MED, V14, P412; Ponsonby AL, 1998, ARCH DIS CHILD, V79, P328; ROBERTSON CF, 1991, BRIT MED J, V302, P116; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; VONMUTIUS E, 1994, BRIT MED J, V308, P692; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	34	136	139	3	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	AUG	2001	56	8					589	595		10.1136/thorax.56.8.589		7	Respiratory System	Respiratory System	456XF	WOS:000170107500003	11462059	
J	Marrie, TJ				Marrie, TJ			Community-acquired pneumonia in the elderly	CLINICAL INFECTIOUS DISEASES			English	Review							RESISTANT STREPTOCOCCUS-PNEUMONIAE; INITIAL ANTIMICROBIAL THERAPY; RESPIRATORY-TRACT INFECTIONS; NURSING-HOME RESIDENTS; TERM-CARE FACILITIES; RISK-FACTORS; HOSPITALIZED-PATIENTS; PENICILLIN-RESISTANT; RANDOMIZED TRIAL; REQUIRING HOSPITALIZATION	Pneumonia in the elderly is a common and serious problem with a clinical presentation that can differ from that in younger patients. Older patients with pneumonia complain of significantly fewer symptoms than do younger patients, and delirium commonly occurs. Indeed, delirium may be the only manifestation of pneumonia in this group of patients. Alcoholism, asthma, immunosuppression, and age >70 years are risk factors for community-acquired pneumonia in the elderly. Among nursing home residents, the following are risk factors for pneumonia: advanced age, male sex, difficulty in swallowing, inability to take oral medications, profound disability, bedridden state, and urinary incontinence. Streptococcus pneumoniae is the most common cause of pneumonia among the elderly Aspiration pneumonia is underdiagnosed in this group of patients, and tuberculosis always should be considered. In this population an etiologic diagnosis is rarely available when antimicrobial therapy must be instituted. Use of the guidelines for treatment of pneumonia issued by the Infectious Diseases Society of America, with modification for treatment in the nursing home setting, is recommended.	Univ Alberta, Dept Med, Edmonton, AB, Canada	Marrie, TJ (reprint author), 2F130 WMC,8440 112 St, Edmonton, AB T6G 2B7, Canada.						ALBAUM MN, 1996, CHEST, V110, P345; Amsden GW, 1999, J ANTIMICROB CHEMOTH, V44, P1, DOI 10.1093/jac/44.1.1; Atlas SJ, 1998, ARCH INTERN MED, V158, P1350, DOI 10.1001/archinte.158.12.1350; BARTLETT CLR, 1992, RESP MED, V86, P7; Bartlett JG, 1998, CLIN INFECT DIS, V26, P811, DOI 10.1086/513953; BERENDT RF, 1975, J INFECT DIS, V132, P689; BERK SL, 1993, J AM GERIATR SOC, V42, P683; BERNTSSON E, 1986, EUR J CLIN MICROBIOL, V5, P446, DOI 10.1007/BF02075702; BOHTE R, 1995, THORAX, V50, P543, DOI 10.1136/thx.50.5.543; BRANCATI FL, 1993, LANCET, V342, P30, DOI 10.1016/0140-6736(93)91887-R; The British Thoracic Society and the Public Health Laboratory Service, 1987, Q J MED, V62, P195; BURMAN LA, 1991, J INFECT DIS, V163, P1087; Butler JC, 1996, J INFECT DIS, V174, P986; Campbell GD, 1998, CLIN INFECT DIS, V26, P1188; Choi EH, 1998, CLIN INFECT DIS, V26, P1346, DOI 10.1086/516340; CHOW CW, 1994, CAN J INFECT DIS SC, V5, pC20; ClavoSanchez AJ, 1997, CLIN INFECT DIS, V24, P1052; Conte HA, 1999, AM J MED, V106, P20, DOI 10.1016/S0002-9343(98)00369-6; Croghan John E., 1994, Dysphagia, V9, P141, DOI 10.1007/BF00341256; Dean NC, 2000, CHEST, V117, P393, DOI 10.1378/chest.117.2.393; DEGELAU J, 1995, J AM GERIATR SOC, V43, P245; Detsky AS, 1987, J PATENTER ENTERAL N, V1, P8; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; Dominguez JA, 1998, J CLIN MICROBIOL, V36, P2718; DORFF GJ, 1973, AM J MED SCI, V266, P349, DOI 10.1097/00000441-197311000-00002; DRINKA PJ, 1994, J GEN INTERN MED, V9, P650, DOI 10.1007/BF02600312; Einarsson S, 1998, SCAND J INFECT DIS, V30, P253; EVARD PH, 1991, INT C ANT AG CHEM WA, V108, pA56; Ewig S, 1999, EUR RESPIR J, V14, P370, DOI 10.1034/j.1399-3003.1999.14b22.x; Ewig S, 1998, AM J RESP CRIT CARE, V158, P1102; FANG GD, 1990, MEDICINE, V69, P307; Feagan BG, 2000, CAN MED ASSOC J, V162, P1415; Fine MJ, 1999, ARCH INTERN MED, V159, P970, DOI 10.1001/archinte.159.9.970; FINE MJ, 1994, ARCH INTERN MED, V154, P2666; Fine MJ, 1997, NEW ENGL J MED, V336, P243, DOI 10.1056/NEJM199701233360402; FLOURNOY D J, 1983, Ecology of Disease, V2, P157; Forward K R, 1999, Semin Respir Infect, V14, P243; GARB JL, 1978, JAMA-J AM MED ASSOC, V240, P2169; Gleason PP, 1999, ARCH INTERN MED, V159, P2562, DOI 10.1001/archinte.159.21.2562; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P145; GROSS PA, 1995, ANN INTERN MED, V123, P518; Halm EA, 1998, JAMA-J AM MED ASSOC, V279, P1452, DOI 10.1001/jama.279.18.1452; HEDLUND J, 1995, SCAND J INFECT DIS, V27, P32, DOI 10.3109/00365549509018970; HEDLUND JU, 1993, THORAX, V48, P785, DOI 10.1136/thx.48.8.785; HORNER J, 1994, ALZ DIS ASSOC DIS, V8, P177; HORNER J, 1988, NEUROLOGY, V38, P1359; INOUYE SK, 1993, J GEN INTERN MED, V8, P645, DOI 10.1007/BF02598279; Intrator O, 1999, MED CARE, V37, P228, DOI 10.1097/00005650-199903000-00003; JAY SJ, 1975, NEW ENGL J MED, V293, P798, DOI 10.1056/NEJM197510162931604; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977; KAUPPINEN MT, 1995, J INFECT DIS, V172, P1330; KIKUCHI R, 1994, AM J RESP CRIT CARE, V150, P251; KLUDT P, 1997, MMWR-MORBID MORTAL W, V46, P60; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; Koivula I, 1999, ARCH INTERN MED, V159, P1550, DOI 10.1001/archinte.159.14.1550; Koivula I, 1997, AM J MED, V103, P281, DOI 10.1016/S0002-9343(97)00149-6; LANDEFELD CS, 1995, NEW ENGL J MED, V332, P1338, DOI 10.1056/NEJM199505183322006; Langille D, 1993, Can J Infect Dis, V4, P328; LEIKIN DR, 2000, AM J PUBLIC HEALTH, V90, P223; LEVY M, 1988, CHEST, V92, P43; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; Loeb M, 1999, ARCH INTERN MED, V159, P2058, DOI 10.1001/archinte.159.17.2058; Loeb M, 2000, CAN MED ASSOC J, V162, P1133; MACKNIGHT C, 1995, AGE AGEING, V24, P126, DOI 10.1093/ageing/24.2.126; MacKnight C, 1996, POSTGRAD MED, V99, P269; Marrie T J, 1990, Semin Respir Infect, V5, P260; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; Marrie TJ, 1997, J AM GERIATR SOC, V45, P50; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Marrie TJ, 2000, JAMA-J AM MED ASSOC, V283, P749, DOI 10.1001/jama.283.6.749; MARSTON BJ, 1994, ARCH INTERN MED, V154, P2417, DOI 10.1001/archinte.154.21.2417; Marston BJ, 1997, ARCH INTERN MED, V157, P1709; Medina-Walpole AM, 1999, J AM GERIATR SOC, V47, P1005; Meehan TP, 1997, JAMA-J AM MED ASSOC, V278, P2080, DOI 10.1001/jama.278.23.2080; MENDANI SN, 2000, NUTR IMMUNOLOGY PRIN, P403; Metlay JP, 2000, CLIN INFECT DIS, V30, P520, DOI 10.1086/313716; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; MORENO S, 1995, CLIN INFECT DIS, V20, P1195; MORLEY JE, 1986, AM J MED, V81, P679, DOI 10.1016/0002-9343(86)90557-7; Muder RR, 1998, AM J MED, V105, P319, DOI 10.1016/S0002-9343(98)00262-9; MUNDY LM, 1995, AM J RESP CRIT CARE, V152, P1309; Mylotte JM, 1998, J AM GERIATR SOC, V46, P1538; NARAIN JP, 1985, J AM GERIATR SOC, V33, P258; National Centre for Health Statistics, 1992, VITAL HLTH STAT, V13, P1; Naughton BJ, 2000, J AM GERIATR SOC, V48, P82; NAVA JM, 1994, CLIN INFECT DIS, V19, P884; *NCCLS, 1999, M100S9; Nichol KL, 1999, ARCH INTERN MED, V159, P2437, DOI 10.1001/archinte.159.20.2437; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; Niederman MS, 1998, CLIN THER, V20, P820, DOI 10.1016/S0149-2918(98)80144-6; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Orr PH, 1996, CLIN INFECT DIS, V23, P1240; Ortqvist A, 1998, LANCET, V351, P399, DOI 10.1016/S0140-6736(97)07358-3; PALMER RM, 1995, CLEV CLIN J MED, V62, P117; PATRIARCA PA, 1986, AM J EPIDEMIOL, V124, P114; PERRY BC, 1982, J AM GERIATR SOC, V30, P367; PHILLIPS SL, 1993, J AM GERIATR SOC, V41, P1071; PLOUFFE JF, 1995, CLIN INFECT DIS, V20, P1286; Plouffe JF, 1996, JAMA-J AM MED ASSOC, V275, P194, DOI 10.1001/jama.275.3.194; Porath A, 1997, J INFECTION, V34, P41, DOI 10.1016/S0163-4453(97)80008-4; Potter J, 1997, J INFECT DIS, V175, P1; RAMIREZ JA, 1995, ARCH INTERN MED, V155, P1273, DOI 10.1001/archinte.155.12.1273; Ramirez JA, 1995, CLIN PULM MED, V2, P327, DOI 10.1097/00045413-199511000-00002; RAMIREZ JA, 1997, INFECT MED, V14, P319; Rello J, 1996, CLIN INFECT DIS, V23, P723; REUBEN DB, 1995, NEW ENGL J MED, V332, P1345, DOI 10.1056/NEJM199505183322007; Riquelme R, 1997, AM J RESP CRIT CARE, V156, P1908; Riquelme R, 1996, AM J RESP CRIT CARE, V154, P1450; ROCKWOOD K, 1994, CAN MED ASSOC J, V150, P489; Ruiz M, 1999, AM J RESP CRIT CARE, V160, P397; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SORVILLO FJ, 1984, J INFECTION, V9, P252, DOI 10.1016/S0163-4453(84)90530-9; STEAD WW, 1985, NEW ENGL J MED, V312, P1483, DOI 10.1056/NEJM198506063122304; STEEN B, 1986, TRIANGLE, V25, P33; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; Syrjala H, 1998, CLIN INFECT DIS, V27, P358, DOI 10.1086/514675; TERPENNING MS, 1994, J AM GERIATR SOC, V42, P1062; Torres A, 1996, AM J RESP CRIT CARE, V154, P1456; TREANOR JJ, 1992, ANN INTERN MED, V117, P625; Troy CJ, 1997, JAMA-J AM MED ASSOC, V277, P1214, DOI 10.1001/jama.277.15.1214; *US DOE, 1995, HUM RAD EXP DEP EN R, P1; VALENTI WM, 1978, NEW ENGL J MED, V298, P1108, DOI 10.1056/NEJM197805182982002; WENGER NS, 1995, ARCH INTERN MED, V155, P2056, DOI 10.1001/archinte.155.19.2056; WOODHEAD M, 1994, J ANTIMICROB CHEMOTH, V34, P85; Yee AMF, 2000, CLIN INFECT DIS, V30, P25, DOI 10.1086/313588	126	136	147	1	7	UNIV CHICAGO PRESS	CHICAGO	5720 SOUTH WOODLAWN AVE, CHICAGO, IL 60637-1603 USA	1058-4838			CLIN INFECT DIS	Clin. Infect. Dis.	OCT	2000	31	4					1066	1078		10.1086/318124		13	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	375EU	WOS:000165387200031	11049791	
J	Ostrom, QT; Bauchet, L; Davis, FG; Deltour, I; Fisher, JL; Langer, CE; Pekmezci, M; Schwartzbaum, JA; Turner, MC; Walsh, KM; Wrensch, MR; Barnholtz-Sloan, JS				Ostrom, Quinn T.; Bauchet, Luc; Davis, Faith G.; Deltour, Isabelle; Fisher, James L.; Langer, Chelsea Eastman; Pekmezci, Melike; Schwartzbaum, Judith A.; Turner, Michelle C.; Walsh, Kyle M.; Wrensch, Margaret R.; Barnholtz-Sloan, Jill S.			The epidemiology of glioma in adults: a "state of the science" review	NEURO-ONCOLOGY			English	Article						brain tumors; epidemiology; genome-wide association studies; glioma; risk factors	CENTRAL-NERVOUS-SYSTEM; UPPER MIDWEST HEALTH; MAGNETIC-FIELD EXPOSURE; HIGH-GRADE GLIOMA; MOBILE PHONE USE; SINGLE-NUCLEOTIDE POLYMORPHISMS; INTEGRATED GENOMIC ANALYSIS; CHILDHOOD-CANCER SURVIVOR; OCCUPATIONAL RISK-FACTORS; POPULATION-BASED ANALYSIS	Gliomas are the most common primary intracranial tumor, representing 81% of malignant brain tumors. Although relatively rare, they cause significant mortality and morbidity. Glioblastoma, the most common glioma histology (similar to 45% of all gliomas), has a 5-year relative survival of similar to 5%. A small portion of these tumors are caused by Mendelian disorders, including neurofibromatosis, tuberous sclerosis, and Li-Fraumeni syndrome. Genomic analyses of glioma have also produced new evidence about risk and prognosis. Recently discovered biomarkers that indicate improved survival include O-6-methylguanine-DNA methyltransferase methylation, isocitrate dehydrogenase mutation, and a glioma cytosine-phosphate-guanine island methylator phenotype. Genome-wide association studies have identified heritable risk alleles within 7 genes that are associated with increased risk of glioma. Many risk factors have been examined as potential contributors to glioma risk. Most significantly, these include an increase in risk by exposure to ionizing radiation and a decrease in risk by history of allergies or atopic disease(s). The potential influence of occupational exposures and cellular phones has also been examined, with inconclusive results. We provide a "state of the science" review of current research into causes and risk factors for gliomas in adults.	[Ostrom, Quinn T.; Barnholtz-Sloan, Jill S.] Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA; [Bauchet, Luc] CHU Montpellier, Montpellier 5, France; [Bauchet, Luc] INSERM, Montpellier 5, France; [Davis, Faith G.] Univ Alberta, Sch Publ Hlth, Edmonton Clin Hlth Acad 3 300, Edmonton, AB, Canada; [Deltour, Isabelle] Int Agcy Res Canc, F-69372 Lyon 8, France; [Fisher, James L.] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA; [Fisher, James L.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA; [Langer, Chelsea Eastman; Turner, Michelle C.] Ctr Res Environm Epidemiol, Barcelona, Spain; [Langer, Chelsea Eastman; Turner, Michelle C.] Univ Pompeu Fabra, Barcelona, Spain; [Langer, Chelsea Eastman; Turner, Michelle C.] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Pekmezci, Melike] Univ Calif San Francisco, Sch Med, Dept Pathol, San Francisco, CA 94143 USA; [Schwartzbaum, Judith A.] Ohio State Univ, Coll Publ Hlth, Dept Epidemiol, Columbus, OH 43210 USA; [Turner, Michelle C.] Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada; [Walsh, Kyle M.; Wrensch, Margaret R.] Univ Calif San Francisco, Sch Med, Dept Neurol Surg, San Francisco, CA USA	Barnholtz-Sloan, JS (reprint author), Case Western Reserve Univ, Case Comprehens Canc Ctr, Sch Med, 11100 Euclid Ave,Wearn 152, Cleveland, OH 44106 USA.	jsb42@case.edu	Fisher, James/F-4996-2012; Schwartzbaum, Judith/A-9022-2016		NCI NIH HHS [P50 CA097257, P30 CA043703]		Amirian E, 2010, NEURO-ONCOLOGY, V12, P444, DOI 10.1093/neuonc/nop057; Amirian ES, 2013, CANCER EPIDEMIOL, V37, P908, DOI 10.1016/j.canep.2013.08.004; Arita H, 2013, ACTA NEUROPATHOL, V126, P267, DOI 10.1007/s00401-013-1141-6; Arora RS, 2010, EUR J CANCER, V46, P1607, DOI 10.1016/j.ejca.2010.02.007; Arora RS, 2009, NEURO-ONCOLOGY, V11, P403, DOI 10.1215/15228517-2008-097; Arrigo RT, 2012, J NEURO-ONCOL, V106, P627, DOI 10.1007/s11060-011-0702-6; Baan R, 2011, LANCET ONCOL, V12, P624, DOI 10.1016/S1470-2045(11)70147-4; Backes DM, 2013, J NEURO-ONCOL, V113, P229, DOI 10.1007/s11060-013-1122-6; Baldi I, 2011, INT J CANCER, V129, P1477, DOI 10.1002/ijc.25765; Barchana M, 2012, ASIAN PAC J CANCER P, V13, P5857, DOI 10.7314/APJCP.2012.13.11.5857; Bauchet L, 2010, NEURO-ONCOLOGY, V12, P725, DOI 10.1093/neuonc/noq030; Benson VS, 2014, INT J EPIDEMIOL, V43, P275, DOI 10.1093/ije/dyt186; Benson VS, 2013, INT J EPIDEMIOL, V42, P792, DOI 10.1093/ije/dyt072; Berg-Beckhoff G, 2009, EUR J EPIDEMIOL, V24, P433, DOI 10.1007/s10654-009-9355-6; Bethke L, 2008, CANCER EPIDEM BIOMAR, V17, P1195, DOI 10.1158/1055-9965.EPI-07-2733; Bettegowda C, 2011, SCIENCE, V333, P1453, DOI 10.1126/science.1210557; Bondy ML, 2008, CANCER-AM CANCER SOC, V113, P1953, DOI 10.1002/cncr.23741; Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034; Brenner AV, 2007, CARCINOGENESIS, V28, P2543, DOI 10.1093/carcin/bgm210; Bucchi L, 2004, J OCCUP ENVIRON MED, V46, P249, DOI 10.1097/01.jom.0000116804.10496.fc; Calboli FCF, 2011, J NATL CANCER I, V103, P1588, DOI 10.1093/jnci/djr361; Carreon T, 2005, ENVIRON HEALTH PERSP, V113, P546, DOI 10.1289/ehp.7456; Chen HY, 2011, AM J EPIDEMIOL, V173, P915, DOI 10.1093/aje/kwq457; Chen Y, 2013, ARCH MED RES, V44, P281, DOI 10.1016/j.arcmed.2013.04.004; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Coble JB, 2009, NEURO-ONCOLOGY, V11, P242, DOI 10.1215/15228517-2009-002; Crocetti E, 2012, EUR J CANCER, V48, P1532, DOI 10.1016/j.ejca.2011.12.013; Darefsky AS, 2012, CANCER-AM CANCER SOC, V118, P2163, DOI 10.1002/cncr.26494; Davis F, 2011, RADIAT RES, V175, P790, DOI 10.1667/RR2186.1; de Andrade M, 2001, GENET EPIDEMIOL, V20, P258, DOI 10.1002/1098-2272(200102)20:2<258::AID-GEPI8>3.0.CO;2-N; De Roos AJ, 2003, CANCER CAUSE CONTROL, V14, P139, DOI 10.1023/A:1023053916689; Deltour I, 2012, EPIDEMIOLOGY, V23, P301, DOI 10.1097/EDE.0b013e3182448295; Di Stefano AL, 2013, NEURO-ONCOLOGY, V15, P542, DOI 10.1093/neuonc/nos284; Dobes Martin, 2011, Surg Neurol Int, V2, P176, DOI 10.4103/2152-7806.90696; Dubrow R, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-325; Egan KM, 2012, J MED GENET, V49, P420, DOI 10.1136/jmedgenet-2012-100941; Enciso-Mora V, 2013, BRIT J CANCER, V108, P2178, DOI 10.1038/bjc.2013.155; Enciso-Mora V, 2013, HUM MOL GENET, V22, P2293, DOI 10.1093/hmg/ddt063; Esteller M, 2000, NEW ENGL J MED, V343, P1350, DOI 10.1056/NEJM200011093431901; Felini MJ, 2007, NEUROEPIDEMIOLOGY, V29, P55, DOI 10.1159/000108919; Feychting M, 1997, EPIDEMIOLOGY, V8, P384, DOI 10.1097/00001648-199707000-00006; FLODERUS B, 1993, CANCER CAUSE CONTROL, V4, P465, DOI 10.1007/BF00050866; Frei P, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d6387; Gigineishvili D, 2013, J NEURO-ONCOL, V112, P241, DOI 10.1007/s11060-013-1054-1; Goodenberger ML, 2012, CANCER GENET-NY, V205, P613, DOI 10.1016/j.cancergen.2012.10.009; Gousias K, 2009, NEUROEPIDEMIOLOGY, V33, P89, DOI 10.1159/000222090; Hakansson N, 2002, OCCUP ENVIRON MED, V59, P481, DOI 10.1136/oem.59.7.481; Hardell L, 2013, INT J ONCOL, V43, P1833, DOI 10.3892/ijo.2013.2111; Hartmann C, 2010, ACTA NEUROPATHOL, V120, P707, DOI 10.1007/s00401-010-0781-z; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; [Anonymous], 2002, IARC WORK GROUP EV C; Il'yasova D, 2009, CANCER EPIDEM BIOMAR, V18, P1232, DOI 10.1158/1055-9965.EPI-08-0995; Jakola AS, 2012, JAMA-J AM MED ASSOC, V308, P1881, DOI 10.1001/jama.2012.12807; Jenkins RB, 2012, NAT GENET, V44, P1122, DOI 10.1038/ng.2388; Jenkins RB, 2011, CANCER GENET-NY, V204, P13, DOI 10.1016/j.cancergencyto.2010.10.002; Jiao YC, 2012, ONCOTARGET, V3, P709; Johansen C, 2007, OCCUP ENVIRON MED, V64, P782, DOI 10.1136/oem.2006.029116; Johnson DR, 2012, CANCER-AM CANCER SOC, V118, P5608, DOI 10.1002/cncr.27590; Jung KW, 2012, J NEURO-ONCOL, V109, P301, DOI 10.1007/s11060-012-0893-5; Kannan K, 2012, ONCOTARGET, V3, P1194; Karipidis KK, 2007, OCCUP MED-OXFORD, V57, P518, DOI 10.1093/occmed/kqm078; Karipidis KK, 2007, CANCER CAUSE CONTROL, V18, P305, DOI 10.1007/s10552-006-0106-7; Kheifets L, 2008, J OCCUP ENVIRON MED, V50, P677, DOI 10.1097/JOM.0b013e3181757a27; Kheifets LI., 2001, BIOELECTROMAGNETICS, V22, pS120; Khuder SA, 1998, AM J IND MED, V34, P252, DOI 10.1002/(SICI)1097-0274(199809)34:3<252::AID-AJIM7>3.0.CO;2-X; Killela PJ, 2013, P NATL ACAD SCI USA, V110, P6021, DOI 10.1073/pnas.1303607110; Koeman T, 2014, CANCER CAUSE CONTROL, V25, P203, DOI 10.1007/s10552-013-0322-x; Komohara Y, 2012, CANCER SCI, V103, P2165, DOI 10.1111/cas.12015; Koshy M, 2012, J NEURO-ONCOL, V107, P207, DOI 10.1007/s11060-011-0738-7; Labussiere M, 2010, NEUROLOGY, V74, P1886, DOI 10.1212/WNL.0b013e3181e1cf3a; Lachance DH, 2011, AM J EPIDEMIOL, V174, P574, DOI 10.1093/aje/kwr124; Lacroix M, 2001, J NEUROSURG, V95, P190, DOI 10.3171/jns.2001.95.2.0190; Larjavaara S, 2007, NEURO-ONCOLOGY, V9, P319, DOI 10.1215/15228517-2007-016; Lee CH, 2010, J KOREAN NEUROSURG S, V48, P145, DOI 10.3340/jkns.2010.48.2.145; Lee ST, 2014, INT J CANCER, V134, P2199, DOI 10.1002/ijc.28535; Linet MS, 2012, CA-CANCER J CLIN, V62, P75, DOI 10.3322/caac.21132; Linos E, 2007, J NATL CANCER I, V99, P1544, DOI 10.1093/jnci/djm170; Little MP, 2012, BMJ-BRIT MED J, V344, pe1147; Liu XY, 2012, ACTA NEUROPATHOL, V124, P615, DOI 10.1007/s00401-012-1031-3; Liu YH, 2007, CARCINOGENESIS, V28, P1906, DOI 10.1093/carcin/bgm073; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Mathews JD, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f2360; McCarthy BJ, 2011, CANCER EPIDEM BIOMAR, V20, P370, DOI 10.1158/1055-9965.EPI-10-0948; McCarthy BJ, 2011, NEURO-ONCOLOGY, V13, P242, DOI 10.1093/neuonc/noq173; MCLAUGHLIN JK, 1987, J NATL CANCER I, V78, P253; Menegoz F, 2002, EUR J CANCER, V38, P696, DOI 10.1016/S0959-8049(01)00423-3; Mocellin S, 2012, JNCI-J NATL CANCER I, V104, P840, DOI 10.1093/jnci/djs222; Mur P, 2013, ACTA NEUROPATHOL, V126, P277, DOI 10.1007/s00401-013-1130-9; Navas-Acien A, 2002, CANCER EPIDEM BIOMAR, V11, P1678; Neglia JP, 2006, J NATL CANCER I, V98, P1528, DOI 10.1093/jnci/djj411; Nielsen MS, 2009, NEURO-ONCOLOGY, V11, P311, DOI 10.1215/15228517-2008-105; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Ohgaki Hiroko, 2009, V472, P323, DOI 10.1007/978-1-60327-492-0_14; Ostrom QT, 2013, NEURO-ONCOLOGY, V15, P1, DOI 10.1093/neuonc/not151; Pan SY, 2005, J OCCUP ENVIRON MED, V47, P704, DOI 10.1097/01.jom.0000165747.95801.c5; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Picano E, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-157; Preston DL, 2007, RADIAT RES, V168, P1, DOI 10.1667/RR0763.1; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; Provost D, 2007, OCCUP ENVIRON MED, V64, P509, DOI 10.1136/oem.2006.028100; Pukkala E, 2009, ACTA ONCOL, V48, P646, DOI 10.1080/02841860902913546; Rajaraman P, 2012, HUM GENET, V131, P1877, DOI 10.1007/s00439-012-1212-0; Rice T, 2013, NEURO-ONCOLOGY, V15, P535, DOI 10.1093/neuonc/nos324; Roosli M, 2007, OCCUP ENVIRON MED, V64, P553, DOI 10.1136/oem.2006.030270; Ruan Zhenchao, 2011, Front Biosci (Elite Ed), V3, P33, DOI 10.2741/e217; Ruder AM, 2013, OCCUP ENVIRON MED, V70, P73, DOI 10.1136/oemed-2011-100588; Ruder AM, 2012, AM J IND MED, V55, P747, DOI 10.1002/ajim.22085; Sadetzki S, 2005, RADIAT RES, V163, P424, DOI 10.1667/RR3329; Sadones J, 2009, EUR J CANCER, V45, P146, DOI 10.1016/j.ejca.2008.09.002; Samanic CM, 2008, AM J EPIDEMIOL, V167, P976, DOI 10.1093/aje/kwm401; Sanson M, 2011, HUM MOL GENET, V20, P2897, DOI 10.1093/hmg/ddr192; Sant M, 2012, INT J CANCER, V131, P173, DOI 10.1002/ijc.26335; Savitz DA, 2000, AM J IND MED, V38, P417; Scheurer ME, 2008, CANCER EPIDEM BIOMAR, V17, P1277, DOI 10.1158/1055-9965.EPI-07-2621; Scheurer ME, 2011, INT J CANCER, V129, P2290, DOI 10.1002/ijc.25883; Schlehofer B, 2011, ALLERGY, V66, P1434, DOI 10.1111/j.1398-9995.2011.02670.x; Schoemaker MJ, 2006, INT J CANCER, V119, P2165, DOI 10.1002/ijc.22091; Schoemaker MJ, 2010, AM J EPIDEMIOL, V171, P1165, DOI 10.1093/aje/kwq075; Schwartzbaum J, 2012, J NATL CANCER I, V104, P1251, DOI 10.1093/jnci/djs315; Schwartzbaum JA, 2010, CARCINOGENESIS, V31, P1770, DOI 10.1093/carcin/bgq152; Schwartzbaum JA, 2010, NEURO-ONCOLOGY, V12, P320, DOI 10.1093/neuonc/nop035; Shete S, 2011, CANCER RES, V71, P7568, DOI 10.1158/0008-5472.CAN-11-0013; Shete S, 2009, NAT GENET, V41, P899, DOI 10.1038/ng.407; Smith JS, 2000, J CLIN ONCOL, V18, P636; Sorahan T, 2001, OCCUP ENVIRON MED, V58, P626, DOI 10.1136/oem.58.10.626; Stacey SN, 2011, NAT GENET, V43, P1098, DOI 10.1038/ng.926; Stupp R, 2005, NEW ENGL J MED, V352, P987, DOI 10.1056/NEJMoa043330; Stupp R, 2007, J CLIN ONCOL, V25, P4127, DOI 10.1200/JCO.2007.11.8554; Sun G, 2013, CANCER EPIDEMIOL, V37, P306, DOI 10.1016/j.canep.2013.01.003; Sun XQ, 2012, CANCER EPIDEM BIOMAR, V21, P2242, DOI 10.1158/1055-9965.EPI-12-0703; Taylor AJ, 2010, J CLIN ONCOL, V28, P5287, DOI 10.1200/JCO.2009.27.0090; THERIAULT G, 1994, AM J EPIDEMIOL, V139, P550; TORNQVIST S, 1991, British Journal of Industrial Medicine, V48, P597; Tseng MY, 2006, J NEUROSURG, V105, P297; Turner MBJ, 2013, 2013 C INT SOC ENV E; Turner MC, 2013, CANCER CAUSE CONTROL, V24, P949, DOI 10.1007/s10552-013-0171-7; Turner MC, 2012, CANCER IMMUNOL IMMUN, V61, P1493, DOI 10.1007/s00262-011-1180-6; TYNES T, 1992, AM J EPIDEMIOL, V136, P81; van den Bent MJ, 2011, CLIN CANCER RES, V17, P7148, DOI 10.1158/1078-0432.CCR-11-1274; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Viel JF, 1998, ARCH ENVIRON HEALTH, V53, P65; Villeneuve PJ, 2002, INT J EPIDEMIOL, V31, P210, DOI 10.1093/ije/31.1.210; Walsh KM, 2013, NEURO-ONCOLOGY, V15, P1041, DOI 10.1093/neuonc/not051; Walsh KM, 2013, GENET EPIDEMIOL, V37, P222, DOI 10.1002/gepi.21707; World Health Organization (WHO), 2007, ENV HLTH CRIT; Wick W, 2009, J CLIN ONCOL, V27, P5874, DOI 10.1200/JCO.2009.23.6497; Wiemels JL, 2007, CANCER EPIDEM BIOMAR, V16, P1229, DOI 10.1158/1055-9965.EPI-07-0041; Wiemels JL, 2009, INT J CANCER, V125, P680, DOI 10.1002/ijc.24369; Wiestler B, 2013, ACTA NEUROPATHOL, V126, P443, DOI 10.1007/s00401-013-1156-z; Wigertz A, 2007, AM J EPIDEMIOL, V166, P941, DOI 10.1093/aje/kwm203; Wohrer A, 2009, J NEURO-ONCOL, V95, P401, DOI 10.1007/s11060-009-9938-9; Wrensch M, 2009, NAT GENET, V41, P905, DOI 10.1038/ng.408; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yiin JH, 2012, ENVIRON HEALTH-GLOB, V11, DOI 10.1186/1476-069X-11-39; Zheng TZ, 2001, J OCCUP ENVIRON MED, V43, P317, DOI 10.1097/00043764-200104000-00005	157	135	142	10	46	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1522-8517	1523-5866		NEURO-ONCOLOGY	Neuro-Oncology	JUL	2014	16	7					896	913		10.1093/neuonc/nou087		18	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	AK0SR	WOS:000338126100002	24842956	
J	Tatham, AS; Shewry, PR				Tatham, A. S.; Shewry, P. R.			Allergens in wheat and related cereals	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review						allergy; cereals; wheat	EXERCISE-INDUCED ANAPHYLAXIS; ALPHA-AMYLASE-INHIBITOR; LIPID TRANSFER PROTEIN; CONTROLLED FOOD CHALLENGE; IGE-BINDING EPITOPE; ASPERGILLUS-DERIVED ENZYMES; BAKERS ASTHMA DISEASE; LOW-MOLECULAR-WEIGHT; MAJOR ALLERGEN; OMEGA-5 GLIADIN	Wheat is one of the major crops grown, processed and consumed by humankind and is associated with both intolerances (notably coeliac disease) and allergies. Two types of allergy are particularly well characterized. The first is bakers' asthma, which results from the inhalation of flour and dust during grain processing. Although a number of wheat proteins have been shown to bind IgE from patients with bakers' asthma, there is no doubt a well-characterized group of inhibitors of alpha-amylase (also called chloroform methanol soluble, or CM, proteins) are the major components responsible for this syndrome. The second well-characterized form of allergy to wheat proteins is wheat-dependent exercise-induced anaphylaxis (WDEIA), with the omega(5)-gliadins (part of the gluten protein fraction) being the major group of proteins which are responsible. Other forms of food allergy have also been reported, with the proteins responsible including gluten proteins, CM proteins and non-specific lipid transfer proteins. Processing of wheat and of related cereals (barley and rye, which may contain related allergens) may lead to decreased allergenicity while genetic engineering technology offers opportunities to eliminate allergens by suppressing gene expression.	[Tatham, A. S.] Univ Wales Coll Cardiff, Inst Cardiff, Cardiff Sch Hlth Sci, Cardiff CF5 2YB, S Glam, Wales; [Shewry, P. R.] Ctr Crop Genet Improvement, Harpenden AL5 2JQ, Herts, England	Tatham, AS (reprint author), Univ Wales Coll Cardiff, Inst Cardiff, Cardiff Sch Hlth Sci, Western Ave, Cardiff CF5 2YB, S Glam, Wales.	atatham@uwic.ac.uk			Biotechnology and Biological Sciences Research Council of the UK	Rothamsted Research receives grant-aided support from the Biotechnology and Biological Sciences Research Council of the UK. The authors thank Dr Bill Hurkman (USDA, ARS, WRRC, Albany, CA) for providing Fig. 2.	Aihara M, 2002, BRIT J DERMATOL, V146, P466, DOI 10.1046/j.1365-2133.2002.04601.x; Akagawa M, 2007, J AGR FOOD CHEM, V55, P6863, DOI 10.1021/jf070843a; Amano M, 1998, BIOCHEM J, V330, P1229; ARMENTIA A, 1993, CLIN EXP ALLERGY, V23, P410, DOI 10.1111/j.1365-2222.1993.tb00347.x; ARMENTIA A, 1990, ANN ALLERGY, V65, P149; Asero R, 2001, ANN ALLERG ASTHMA IM, V87, P65; Baldo B. A., 1984, Advances in Cereal Science and Technology, V6, P289; BALDO BA, 1982, PROG ALLERGY, V30, P1; BALDO BA, 1978, CLIN ALLERGY, V8, P109, DOI 10.1111/j.1365-2222.1978.tb00456.x; Ballmer-Weber BK, 2002, ALLERGY, V57, P873, DOI 10.1034/j.1398-9995.2002.23541.x; BARBER D, 1989, FEBS LETT, V248, P119, DOI 10.1016/0014-5793(89)80444-2; Battais F, 2005, J CEREAL SCI, V42, P109, DOI 10.1016/j.jcs.2005.01.004; Battais F, 2005, ALLERGY, V60, P815, DOI 10.1111/j.1398-9995.2005.00795.x; Battais F, 2003, CLIN EXP ALLERGY, V33, P962, DOI 10.1046/j.1365-2222.2003.01592.x; Baur X, 1998, CLIN EXP ALLERGY, V28, P1591; Baur X, 1996, ALLERGY, V51, P326, DOI 10.1111/j.1398-9995.1996.tb04617.x; Baur X, 1998, ALLERGY, V53, P562, DOI 10.1111/j.1398-9995.1998.tb03931.x; Bhalla PL, 1999, P NATL ACAD SCI USA, V96, P11676, DOI 10.1073/pnas.96.20.11676; Bhalla PL, 2001, INT ARCH ALLERGY IMM, V124, P51, DOI 10.1159/000053666; BLANDS J, 1976, INT ARCH ALLER A IMM, V52, P392; BRISMAN J, 1991, BRIT J IND MED, V48, P604; Carbonero P, 1999, SEED PROTEINS, P617; Codina R, 1997, CLIN EXP ALLERGY, V27, P424, DOI 10.1046/j.1365-2222.1997.d01-514.x; Cristaudo A, 2004, CONTACT DERMATITIS, V51, P84, DOI 10.1111/j.0105-1873.2004.00410.x; De Zotti R, 1994, Med Lav, V85, P142; DeMasi JM, 2006, J ASTHMA, V43, P333, DOI 10.1080/02770900600701358; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; Elms J, 2006, ANN OCCUP HYG, V50, P379, DOI 10.1093/annhyg/mei080; Escudero C, 2002, J ALLERGY CLIN IMMUN, V109, pS282, DOI 10.1016/S0091-6749(02)81996-0; Feldman M., 1995, EVOLUTION CROP PLANT, P184; Fernandez-Anaya S, 1999, J ALLERGY CLIN IMMUN, V103, P959, DOI 10.1016/S0091-6749(99)70449-5; FRANKEN J, 1994, INT ARCH ALLERGY IMM, V104, P171; Garcia-Casado G, 2001, J ALLERGY CLIN IMMUN, V108, P647, DOI 10.1067/mai.2001.118793; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; GARCIACASADO G, 1995, FEBS LETT, V364, P36, DOI 10.1016/0014-5793(95)00355-D; GarciaCasado G, 1996, CLIN EXP ALLERGY, V26, P428, DOI 10.1046/j.1365-2222.1996.d01-326.x; Gijzen M, 2003, J ALLERGY CLIN IMMUN, V112, P803, DOI 10.1016/S0091-6749(03)01884-0; Gilissen LJWJ, 2005, J ALLERGY CLIN IMMUN, V115, P364, DOI 10.1016/j.jaci.2004.10.014; GOMEZ L, 1990, FEBS LETT, V261, P85, DOI 10.1016/0014-5793(90)80642-V; Grimshaw KEC, 2003, CLIN EXP ALLERGY, V33, P1581, DOI 10.1046/j.1365-2222.2003.01795.x; Guinnepain MT, 1996, ANN ALLERG ASTHMA IM, V77, P491; Harada S, 2001, BRIT J DERMATOL, V145, P336, DOI 10.1046/j.1365-2133.2001.04329.x; Herman EM, 2003, PLANT PHYSIOL, V132, P36, DOI 10.1104/pp.103.021865; Herman EM, 2003, J EXP BOT, V54, P1317, DOI 10.1093/jxb/erg164; Herzinger T, 2004, ANN ALLERG ASTHMA IM, V92, P673; Hischenhuber C, 2006, ALIMENT PHARM THERAP, V23, P559, DOI 10.1111/j.1365-2036.2006.02768.x; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6<529::AID-AJIM1>3.0.CO;2-I; James JM, 1997, J ALLERGY CLIN IMMUN, V99, P239, DOI 10.1016/S0091-6749(97)70103-9; Jegou S, 2001, J AGR FOOD CHEM, V49, P4942, DOI 10.1021/jf010487a; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Kent N. L., 1994, TECHNOLOGY CEREALS; Kimoto M., 1998, ANN REPORT INTERDISC, V17, P53; KREIS M, 1985, J MOL BIOL, V183, P499, DOI 10.1016/0022-2836(85)90017-8; Kusaba-Nakayama M, 2000, FOOD CHEM TOXICOL, V38, P179, DOI 10.1016/S0278-6915(99)00143-X; KUSHIMOTO H, 1985, ARCH DERMATOL, V121, P355, DOI 10.1001/archderm.121.3.355; Lauriere M, 2006, CONTACT DERMATITIS, V54, P283, DOI 10.1111/j.0105-1873.2006.00830.x; LAVAUD F, 1994, ALLERGY, V49, P159, DOI 10.1111/j.1398-9995.1994.tb00819.x; Leduc V, 2003, J ALLERGY CLIN IMMUN, V111, P897, DOI 10.1067/mai.2003.1345; Lehto M, 2003, CLIN EXP ALLERGY, V33, P90, DOI 10.1046/j.1365-2222.2003.01568.x; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Marion D., 2004, PLANT FOOD ALLERGENS, P57; Maruyama N, 1998, EUR J BIOCHEM, V255, P739, DOI 10.1046/j.1432-1327.1998.2550739.x; Matsuo H, 2005, J IMMUNOL, V175, P8116; Matsuo H, 2005, FEBS J, V272, P4431, DOI 10.1111/j.1742-4658.2005.04858.x; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; Matsuo H, 2004, J BIOL CHEM, V279, P12135, DOI 10.1074/jbc.M311340200; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; MENA M, 1992, PLANT MOL BIOL, V20, P451, DOI 10.1007/BF00040604; Mesa-del-Castillo M, 2004, ALLERGY, V59, P1229, DOI 10.1111/j.1398-9995.2004.00447.x; Mittag D, 2004, MOL NUTR FOOD RES, V48, P380, DOI 10.1002/mnfr.200400016; Monsalve R. I., 2004, PLANT FOOD ALLERGENS, P42; Morita E, 2000, BRIT J DERMATOL, V143, P1059, DOI 10.1046/j.1365-2133.2000.03844.x; Morita E, 2003, J DERMATOL SCI, V33, P99, DOI 10.1016/S0923-1811(03)00156-7; Morita E, 2001, BRIT J DERMATOL, V145, P182, DOI 10.1046/j.1365-2133.2001.04314.x; Morita E, 2007, J DERMATOL SCI, V47, P109, DOI 10.1016/j.jdermsci.2007.03.004; MORREN MA, 1993, J AM ACAD DERMATOL, V29, P723; MUNDY J, 1984, FEBS LETT, V167, P210, DOI 10.1016/0014-5793(84)80128-3; Nakase M, 1996, J AGR FOOD CHEM, V44, P2624, DOI 10.1021/jf9508099; Oda S, 1997, J CEREAL SCI, V26, P29, DOI 10.1006/jcrs.1996.0113; Okuzaki A, 2004, PLANT CELL REP, V22, P509, DOI 10.1007/s00299-003-0698-2; Osborne T.B., 1924, VEGETABLE PROTEINS, P154; Palacin A, 2007, ALLERGY, V62, P26; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Palosuo K, 2001, CLIN EXP ALLERGY, V31, P466, DOI 10.1046/j.1365-2222.2001.01023.x; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V106, P744, DOI 10.1067/mai.2000.108712; Pastorello EA, 2007, INT ARCH ALLERGY IMM, V144, P10, DOI 10.1159/000102609; Petrovska N, 2004, MOL BREEDING, V14, P489, DOI 10.1007/s11032-004-1011-y; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; POSCH A, 1995, ELECTROPHORESIS, V16, P1115, DOI 10.1002/elps.11501601188; Quirce S, 2000, CLIN EXP ALLERGY, V30, P839; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; Quirce S, 2002, ANN ALLERG ASTHMA IM, V89, P197; RAMAZZINI B, MORBIS ARTIFICIUM DI; RODRIGUEZLOPERENA MA, 1975, PHYTOCHEMISTRY, V14, P1219, DOI 10.1016/S0031-9422(00)98598-4; SALCEDO G, 1978, PHYTOCHEMISTRY, V17, P1491, DOI 10.1016/S0031-9422(00)94627-2; Salcedo G., 2004, PLANT FOOD ALLERGENS, P70; SANCHEZMONGE G, 1997, CLIN EXP ALLERGY, V27, P1130; SANCHEZMONGE R, 1992, BIOCHEM J, V281, P401; Sander I, 1998, J ALLERGY CLIN IMMUN, V102, P256; Sander I, 2000, CLIN EXP ALLERGY, V30, P560, DOI 10.1046/j.1365-2222.2000.00746.x; Sander I, 2001, J ALLERGY CLIN IMMUN, V107, P907, DOI 10.1067/mai.2001.113761; SANDIFORD CP, 1994, CLIN EXP ALLERGY, V24, P549, DOI 10.1111/j.1365-2222.1994.tb00952.x; Sandiford CP, 1997, CLIN EXP ALLERGY, V27, P1120, DOI 10.1046/j.1365-2222.1997.1310936.x; SANDIFORD CP, 1995, CLIN EXP ALLERGY, V25, P340, DOI 10.1111/j.1365-2222.1995.tb01052.x; SHEFFER AL, 1980, J ALLERGY CLIN IMMUN, V66, P106, DOI 10.1016/0091-6749(80)90056-1; Shewry PR, 2007, WOODHEAD PUBL FOOD S, P147, DOI 10.1533/9781845692278.2.147; Shewry PR, 2003, ADV GENET, V49, P111, DOI 10.1016/S0065-2660(03)01003-4; Shewry P. R., 2004, PLANT FOOD ALLERGENS, P24; SHEWRY PR, 1997, ADV BOT RES, V26, P136; Simonato B, 2001, CLIN EXP ALLERGY, V31, P1771, DOI 10.1046/j.1365-2222.2001.01200.x; Simonato B, 2001, J AGR FOOD CHEM, V49, P5668, DOI 10.1021/jf0104984; Skylas D, 2005, J CEREAL SCI, V41, P165, DOI 10.1016/j.jcs.2004.08.010; SUTTON R, 1982, J IMMUNOL METHODS, V52, P183, DOI 10.1016/0022-1759(82)90044-8; SUTTON R, 1984, CLIN ALLERGY, V14, P93, DOI 10.1111/j.1365-2222.1984.tb02196.x; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; Tanabe S, 1996, BIOCHEM BIOPH RES CO, V219, P290, DOI 10.1006/bbrc.1996.0225; Tanabe S, 1996, BIOSCI BIOTECH BIOCH, V60, P1269; TARVAINEN K, 1991, CLIN EXP ALLERGY, V21, P609, DOI 10.1111/j.1365-2222.1991.tb00854.x; Terada R, 2002, NAT BIOTECHNOL, V20, P1030, DOI 10.1038/nbt737; VALDIVIESO R, 1994, ANN ALLERGY, V73, P337; Varjonen E, 1996, CLIN EXP ALLERGY, V26, P436, DOI 10.1046/j.1365-2222.1996.d01-328.x; VARJONEN E, 1997, CLIN EXP ALLERGY, V55, P386; Vensel WH, 2005, PROTEOMICS, V5, P1594, DOI 10.1002/pmic.200401034; WALSH BJ, 1989, J IMMUNOL METHODS, V121, P275, DOI 10.1016/0022-1759(89)90171-3; Walusiak J, 2004, ALLERGY, V59, P442, DOI 10.1111/j.1398-9995.2003.00418.x; WATANABE M, 1995, BIOSCI BIOTECH BIOCH, V59, P1596; Watanabe M, 2000, BIOSCI BIOTECH BIOCH, V64, P2663, DOI 10.1271/bbb.64.2663; WATANABE M, 1994, BIOSCI BIOTECH BIOCH, V58, P388; Weichel M, 2006, J ALLERGY CLIN IMMUN, V117, P676, DOI 10.1016/j.jaci.2005.11.040; Weichel M, 2006, ALLERGY, V61, P128, DOI 10.1111/j.1398-9995.2006.00999.x; WEISS W, 1993, ELECTROPHORESIS, V14, P805, DOI 10.1002/elps.11501401126; Weiss W, 1997, ELECTROPHORESIS, V18, P826, DOI 10.1002/elps.1150180529; Williams T., 1998, TECHNOLOGY BREADMAKI, P45; Yamashita H, 2002, BIOSCI BIOTECH BIOCH, V66, P2487, DOI 10.1271/bbb.66.2487; Zapatero L, 2003, ALLERGY, V58, P956, DOI 10.1034/j.1398-9995.2003.00158.x; Zhu T, 1999, P NATL ACAD SCI USA, V96, P8768, DOI 10.1073/pnas.96.15.8768	139	135	140	4	59	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-7894	1365-2222		CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2008	38	11					1712	1726		10.1111/j.1365-2222.2008.03101.x		15	Allergy; Immunology	Allergy; Immunology	364KH	WOS:000260334100005	18823308	
J	Mosen, DM; Schatz, M; Magid, DJ; Carnargo, CA				Mosen, David M.; Schatz, Michael; Magid, David J.; Carnargo, Carlos A., Jr.			The relationship between obesity and asthma severity and control in adults	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; quality of life; obesity; hospitalization; inhaled; corticosleroids	BODY-MASS INDEX; QUALITY-OF-LIFE; HEALTH-CARE UTILIZATION; WEIGHT-REDUCTION; ASSOCIATION; PREVALENCE; OVERWEIGHT; TRENDS; WOMEN	Background: The association of obesity with asthma outcomes is not well understood. Objective: The objective of this study was to examine the association of obesity, as represented by a body mass index (BMI) of greater than 30 kg/m(2), with quality-of-life scores, asthma control problems, and asthma-related hospitalizations. Methods: The study followed a cross-sectional design. Questionnaires were completed at home by a random sample of 1113 members of a large integrated health care organization who were 35 years of age or older with health care use suggestive of active asthma. Outcomes included the mini-Asthma Quality of Life Questionnaire, the Asthma Therapy Assessment Questionnaire, and self-reported asthma-related hospitalization. Several other factors known to influence asthma outcomes also were collected: demographics, smoking status, oral corticosteroid use in the past month, evidence of gastroesophageal reflux disease, and inhaled corticosteroid use in the past month. Multiple logistic regression models were used to measure the association of BMI status with outcomes. Results: Even after adjusting for demographics, smoking status, oral corticosteroid use, evidence of gastroesophageal reflux disease, and inhaled corticosteroid use, obese adults were more likely than those with normal BMIs (<25 k g/m(2)) to report poor asthma-specific quality of life (odds ratio [OR], 2.8; 95% Cl, 1.6-4.9), poor asthma control (OR, 2.7; 95% Cl, 1.7-4.3), and a history of asthma-related hospitalizations (OR, 4.6; 95% Cl, 1.4-14.4). Conclusions: Our findings suggest that obesity is associated with worse asthma outcomes, especially an increased risk of asthma related hospitalizations.	[Schatz, Michael] Kaiser Permanente, Dept Allergy, San Diego, CA USA; [Magid, David J.] Kaiser Permanente, Clin Res Unit, Denver, CO USA; [Carnargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA; [Mosen, David M.] Kaiser Permanente, Ctr Hlth Res, Portland, OR USA	Mosen, DM (reprint author), Kaiser Permanente NW, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR USA.	david.m.mosen@kpchr.org			National Institutes of Health; Research Foundations; AstraZeneca; Critical Therapeutics; GlaxoSmithKline; Merck; Novartis; Respironics	M. Schatz has consulting arrangements with GlaxoSmithKline and has received research support from GlaxoSmithKline and Merck. C. A. Camargo has consulting arrangements with AstraZeneca, Novartis, and Critical Therapeutics; is on the advisory board for Dey, Genentech. GlaxoSmithKline. Merck, Novartis, and Schering-Plough: is on the speakers bureau for AstraZeneca, GlaxoSmithKline, and Merck: and has received research support from the National Institutes of Health, Research Foundations. AstraZeneca. Critical Therapeutics. GlaxoSmithKline. Merck. Novartis. and Respironics. The rest of the authors have declared that they have no conflict of interest.	Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Juniper EF, 2004, EUR RESPIR J, V23, P287, DOI 10.1183/09031936.04.00064204; Juniper EF, 1999, EUR RESPIR J, V5, P35; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; MACGREGOR AMC, 1993, OBES SURG, V3, P15, DOI 10.1381/096089293765559700; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Mosen David M, 2007, J Ambul Care Manage, V30, P21; Nyholm M, 2007, OBESITY, V15, P197, DOI 10.1038/oby.2007.536; Peters SP, 2003, AM J MED, V115, p49S, DOI 10.1016/S0002-9343(03)00193-1; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Schatz M, 2007, J ASTHMA, V44, P341, DOI 10.1080/02770900701344421; Schatz M, 2007, QUAL LIFE RES, V16, P345, DOI 10.1007/s11136-006-9103-2; SCHILLER JS, 2004, VITAL HLTH STAT 10, V220, P1; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Van Den Eeden SK, 2003, AM J EPIDEMIOL, V157, P1015, DOI 10.1093/aie/kwg068; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647; Vollmer WM, 2002, AM J RESP CRIT CARE, V165, P195; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835	27	135	140	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					507	511		10.1016/j.jaci.2008.06.024		5	Allergy; Immunology	Allergy; Immunology	348TW	WOS:000259234000010	18774387	
J	Shea, KM; Truckner, RT; Weber, RW; Peden, DB				Shea, Katherine M.; Truckner, Robert T.; Weber, Richard W.; Peden, David B.			Climate change and allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						climate change; global warming; pollen; air pollution; ozone; allergic rhinitis; asthma; mitigation; adaptation; prevention	RAGWEED AMBROSIA-ARTEMISIIFOLIA; PARTICULATE AIR-POLLUTION; ELEVATED ATMOSPHERIC CO2; DIESEL EXHAUST PARTICLES; ASTHMATIC-CHILDREN; MEXICO-CITY; NITROGEN-DIOXIDE; CHILDHOOD ASTHMA; OZONE EXPOSURE; AMBIENT OZONE	Climate change is potentially the largest global threat to human health ever encountered. The earth is warming, the warming is accelerating, and human actions are largely responsible. If current emissions and land use trends continue unchecked, the next generations will face more injury, disease, and death related to natural disasters and heat waves, higher rates of climate-related infections, and wide-spread malnutrition, as well as more allergic and air pollution-related morbidity and mortality. This review highlights links between global climate change and anticipated increases in prevalence and severity of asthma and related allergic disease mediated through worsening ambient air pollution and altered local and regional pollen production. The pattern of change will vary regionally depending on latitude, altitude, rainfall and storms, land-use patterns, urbanization, transportation, and energy production. The magnitude of climate change and related increases in allergic disease will be affected by how aggressively greenhouse gas mitigation strategies are pursued, but at best an average warming of I to 2 degrees C is certain this century. Thus, anticipation of a higher allergic disease burden will affect clinical practice as well as public health planning. A number of practical primary and secondary prevention strategies are suggested at the end of the review to assist in meeting this unprecedented public health challenge.	[Shea, Katherine M.] Univ N Carolina, Inst Environm, Sch Publ Hlth, Dept Mat & Child Health, Chapel Hill, NC 27599 USA; [Peden, David B.] Univ N Carolina, Dept Pediat, Chapel Hill, NC 27599 USA; [Truckner, Robert T.] US Environm Protect Agcy, Natl Hlth & Environm Effects Lab, NHEERL Human Res Protocol Off, Res Triangle Pk, NC USA; [Weber, Richard W.] Univ Colorado, Natl Jewish Med & Res Ctr, Dept Med, Hlth Sci Ctr, Boulder, CO 80309 USA	Shea, KM (reprint author), Univ N Carolina, Inst Environm, Sch Publ Hlth, Dept Mat & Child Health, 111 Miller Hall,Campus Box 1105, Chapel Hill, NC 27599 USA.	kshea@email.unc.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			*AQI, 2007, AQI ED TOOLK WEATH; Aw J, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002688; Barck C, 2005, ENVIRON RES, V97, P58, DOI 10.1016/j.envres.2004.02.009; BARNES PJ, 1994, POSTGRAD MED J, V70, P319; Bates DV, 2005, EPIDEMIOLOGY, V16, P427, DOI 10.1097/01.ede.0000165793.71278.ec; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Bell ML, 2007, CLIMATIC CHANGE, V82, P61, DOI 10.1007/s10584-006-9166-7; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Breton MC, 2006, SCI TOTAL ENVIRON, V370, P39, DOI 10.1016/j.scitotenv.2006.05.022; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Charron A, 2007, ATMOS ENVIRON, V41, P1960, DOI 10.1016/j.atmosenv.2006.10.041; Chen KS, 2004, J AIR WASTE MANAGE, V54, P36; Cheng L, 1998, ATMOS ENVIRON, V32, P673, DOI 10.1016/S1352-2310(97)00319-1; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Dennis A, 2002, ATMOS ENVIRON, V36, P3779, DOI 10.1016/S1352-2310(02)00219-4; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; [Anonymous], 2008, INT EN OUTL; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Fraser MP, 2003, ATMOS ENVIRON, V37, P2117, DOI 10.1016/S1352-2310(03)00075-X; Frei T, 1998, GRANA, V37, P172; Galan C, 2005, INT J BIOMETEOROL, V49, P184, DOI 10.1007/s00484-004-0223-5; Garcia-Mozo H, 2006, ANN AGR ENV MED, V13, P209; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Ghio AJ, 2004, J AEROSOL MED, V17, P157, DOI 10.1089/0894268041457200; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Hansen J, 2007, ATMOS CHEM PHYS, V7, P2287; Hegerl GC, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P663; Holz O, 2002, CLIN EXP ALLERGY, V32, P681, DOI 10.1046/j.1365-2222.2002.01358.x; Jaffe D, 2003, ATMOS ENVIRON, V37, P391, DOI 10.1016/S1352-2310(02)00862-2; Jaffe D, 2007, ATMOS ENVIRON, V41, P5452, DOI 10.1016/j.atmosenv.2007.02.34; Jauregui E, 1997, ATMOS ENVIRON, V31, P3821, DOI 10.1016/S1352-2310(97)00136-2; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kan HD, 2005, BIOMED ENVIRON SCI, V18, P159; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; Kinney PL, 2002, ENVIRON HEALTH PERSP, V110, P539; Kishikawa R, 2001, Arerugi, V50, P369; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; Kunii O, 2002, ARCH ENVIRON HEALTH, V57, P16; Lamarque JF, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023419; LEE BK, ENV MONITOR ASSESS, V136, P21; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; Lenton TM, 2008, P NATL ACAD SCI USA, V105, P1786, DOI 10.1073/pnas.0705414105; LEVIN L, URBANIZATION ENERGY; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Matthews HD, 2008, GEOPHYS RES LETT, V35, DOI 10.1029/2007GL032388; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; Menetrez MY, 2007, ATMOS ENVIRON, V41, P8264, DOI 10.1016/j.atmosenv.2007.06.021; Mohan JE, 2006, P NATL ACAD SCI USA, V103, P9086, DOI 10.1073/pnas.0602392103; Moore D, 2006, CAN J PUBLIC HEALTH, V97, P105; Moorman JE, 2007, MMWR-MORBID MORTAL W, V56, P18; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Mott JA, 2005, INT J HYG ENVIR HEAL, V208, P75, DOI 10.1016/j.ijheh.2005.01.018; Newson R, 1997, THORAX, V52, P680; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; *NRDC, 1999, SCORCH EARTH IMP IMP; Parry Martin, 2007, CLIMATE CHANGE 2007, P7; Parry ML, 2007, CLIMATE CHANGE 2007, P23; Peden DB, 1997, ALLERGY, V52, P37; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peden DB, 2003, MIDDLETONS ALLERGY P, P515; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1996, AM J EPIDEMIOL, V144, P570; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Phuleria HC, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD004626; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Purves DW, 2004, GLOBAL CHANGE BIOL, V10, P1737, DOI 10.1111/j.1365-2486.2004.00844.x; RADKE LF, 1995, ATMOS RES, V38, P315, DOI 10.1016/0169-8095(95)00003-A; Rasmussen Alix, 2002, Aerobiologia, V18, P253, DOI 10.1023/A:1021321615254; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Rodriguez-Rajo FJ, 2004, ANN AGR ENV MED, V11, P35; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Salvador P, 2008, SCI TOTAL ENVIRON, V390, P495, DOI 10.1016/j.scitotenv.2007.10.052; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Shariat SF, 2008, CURR OPIN UROL, V18, P1; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SILLMAN S, 1995, J GEOPHYS RES-ATMOS, V100, P11497, DOI 10.1029/94JD02146; SOLOMON AM, 1971, BULL NJ ACAD SCI, V16, P30; Solomon S, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P19; SPIEKSMA FTM, 1995, GRANA, V34, P51; Stach A, 2007, J INVEST ALLERG CLIN, V17, P39; Statheropoulos M, 2007, J ANAL APPL PYROL, V78, P430, DOI 10.1016/j.jaap.2006.10.011; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Swiston JR, 2008, EUR RESPIR J, V32, P129, DOI 10.1183/09031936.00097707; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Tzedakis PC, 2004, SCIENCE, V306, P2231, DOI 10.1126/science.1102398; *US EPA, SO2 WHAT IS IT DOES; *US EPA, NOX WHAT IS IT DOES; WANG JH, 1995, J ALLERGY CLIN IMMUN, V96, P669, DOI 10.1016/S0091-6749(95)70266-0; Watson JG, 2001, ATMOS ENVIRON, V35, P1567, DOI 10.1016/S1352-2310(00)00461-1; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Weber RW, 2003, IMMUNOL ALLERGY CLIN, V23, P357, DOI 10.1016/S0889-8561(03)00029-8; Weber RW, 2002, ANN ALLERG ASTHMA IM, V88, P251; Weng CY, 2007, PHILOS T R SOC B, V362, P253, DOI 10.1098/rstb.2006.1985; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; *WHO, 2008, MESS WHO DIR GEN MAR; Wojas B, 2007, ATMOS ENVIRON, V41, P9064, DOI 10.1016/j.atmosenv.2007.08.010; Wu HWY, 2001, ENVIRON INT, V26, P213, DOI 10.1016/S0160-4120(00)00108-2; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	120	135	144	5	63	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					443	453		10.1016/j.jaci.2008.06.032		11	Allergy; Immunology	Allergy; Immunology	348TW	WOS:000259234000001	18774380	
J	Soar, J; Pumphrey, R; Cant, A; Clarke, S; Corbett, A; Dawson, P; Ewan, P; Foex, B; Gabbott, D; Griffiths, M; Hall, J; Harper, N; Jewkes, F; Maconochie, I; Mitchell, S; Nasser, S; Nolan, J; Rylance, G; Sheikh, A; Unsworth, DJ; Warrell, D				Soar, Jasmeet; Pumphrey, Richard; Cant, Andrew; Clarke, Sue; Corbett, Allison; Dawson, Peter; Ewan, Pamela; Foex, Bernard; Gabbott, David; Griffiths, Matt; Hall, Judith; Harper, Nigel; Jewkes, Fiona; Maconochie, Ian; Mitchell, Sarah; Nasser, Shuaib; Nolan, Jerry; Rylance, George; Sheikh, Aziz; Unsworth, David Joseph; Warrell, David		Working Grp Resuscitat Council UK	Emergency treatment of anaphylactic reactions - Guidelines for healthcare providers	RESUSCITATION			English	Article						anaphylactic reactions; treatment	RESUSCITATION-COUNCIL GUIDELINES; EPINEPHRINE ABSORPTION; ALLERGIC REACTIONS; LIFE-SUPPORT; MANAGEMENT; CHILDREN; SHOCK; ADRENALINE; EPIDEMIOLOGY; VASOPRESSIN	The UK incidence of anaphylactic reactions is increasing. Patients who have an anaphylactic reaction have life-threatening airway and, or breathing and, or circulation problems usually associated with skin or mucosal changes. Patients having an anaphylactic reaction should be treated using the Airway, Breathing, Circulation, Disability, Exposure (ABCDE) approach. Anaphylactic reactions are not easy to study with randomised controlled trials. There are, however, systematic reviews of the available evidence and a wealth of clinical experience to help formulate guidelines. The exact treatment will depend on the patient's location, the equipment and drugs available, and the skills of those treating the anaphylactic reaction. Early treatment with intramuscular adrenaline is the treatment of choice for patients having an anaphylactic reaction. Despite previous guidelines, there is still confusion about the indications, dose and route of adrenaline. Intravenous adrenaline must only be used in certain specialist settings and only by those skilled and experienced in its use. All those who are suspected of having had an anaphylactic reaction should be referred to a specialist in allergy. Individuals who are at high risk of an anaphylactic reaction should carry an adrenaline auto-injector and receive training and support in its use. There is a need for further research about the diagnosis, treatment and prevention of anaphylactic reactions. (C) 2008 Resuscitation Council (UK). Published by Elsevier Ireland Ltd.	[Soar, Jasmeet; Unsworth, David Joseph] Southmead Gen Hosp, N Bristol NHS Trust, Bristol BS10 5NB, Avon, England; [Pumphrey, Richard] Cent Manchester & Manchester Childrens Hosp, Manchester M13 9WL, Lancs, England; [Cant, Andrew] Newcastle Gen Hosp, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England; [Clarke, Sue] Community Hlth Clin, Royston SG8 6HH, Herts, England; [Corbett, Allison] Royal Pharmaceut Soc GB, British Natl Formulary, London SE1 7JN, England; [Ewan, Pamela] Univ Cambridge, NHS Fdn Trust, Cambridge CB2 0QQ, England; [Foex, Bernard] Manchester Royal Infirm, Manchester M13 9WL, Lancs, England; [Gabbott, David] Gloucestershire Royal Hosp, Gloucester GL1 3NN, England; [Griffiths, Matt] Royal Coll Nursing UK, London W1G 0RN, England; [Hall, Judith] Cardiff Univ, Dept Anaesthet & Intens Care Med, Cardiff CF14 4XN, S Glam, Wales; [Harper, Nigel] Manchester Royal Infirm, Anaesthet React Clin, Manchester M13 9WL, Lancs, England; [Jewkes, Fiona] Ambulance Serv Assoc, London SE1 8RT, England; [Maconochie, Ian] St Marys Hosp NHS Trust, London W2 1NY, England; [Nasser, Shuaib] Univ Cambridge, NHS Fdn Trust, Cambridge CB2 0QQ, England; [Nolan, Jerry] Royal United Hosp, Bath BA1 3NG, Avon, England; [Rylance, George] Royal Victoria Infirm, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; [Sheikh, Aziz] Univ Edinburgh, Gen Practice Sect Div Community Hlth Sci, Edinburgh EH8 9DX, Midlothian, Scotland; [Warrell, David] John Radcliffe Hosp, Oxford OX3 9DU, England	Soar, J (reprint author), Southmead Gen Hosp, N Bristol NHS Trust, Bristol BS10 5NB, Avon, England.	Jasmeet.soar@nbt.nhs.uk	Sheikh, Aziz /D-2818-2009	Sheikh, Aziz /0000-0001-7022-3056; Nolan, Jerry/0000-0003-3141-3812	Chief Scientist Office [CZG/2/296]		Alves B, 2001, Arch Dis Child, V85, P348; Baolin Liu, 2005, Planta Med, V71, P424, DOI 10.1055/s-2005-864137; Bautista E, 2002, INT ARCH ALLERGY IMM, V128, P151, DOI 10.1159/000059406; Biarent D, 2005, RESUSCITATION, V67, pS97, DOI 10.1016/j.resuscitation.2005.10.010; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown AFT, 1998, J ACCID EMERG MED, V15, P89; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Brown SGA, 2005, CURR OPIN ALLERGY CL, V5, P359, DOI 10.1097/01.all.0000174158.78626.35; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; Brown SGA, 2004, EMERG MED J, V21, P149, DOI 10.1136/emj.2003.009449; Brown Simon G A, 2004, Emerg Med Australas, V16, P120, DOI 10.1111/j.1742-6723.2004.00562.x; Chamberlain D, 1999, RESUSCITATION, V41, P93; CHONG LK, 1995, AM J RESP CELL MOL, V13, P540; Choo K, 2007, CLIN EXP ALLERGY, V37, P1090, DOI 10.1111/j.1365-2222.2007.02711.x; *DEP HLTH, 2006, DEP HLTH E REV SERV; Dewachter P, 2007, ANESTHESIOLOGY, V106, P977, DOI 10.1097/01.anes.0000265157.09438.1f; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Ewan P W, 2001, Anaesthesia, V56, P771, DOI 10.1046/j.1365-2044.2001.01916-3.x; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Ewan PW, 1998, BRIT MED J, V316, P1442; Gikas Aristofanis, 2005, BMC Cardiovasc Disord, V5, P6, DOI 10.1186/1471-2261-5-6; GLAESER PW, 1993, ANN EMERG MED, V22, P1119, DOI 10.1016/S0196-0644(05)80975-8; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171; Gompels LL, 2002, POSTGRAD MED J, V78, P416, DOI 10.1136/pmj.78.921.416; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Haymore BR, 2005, ALLERGY ASTHMA PROC, V26, P361; Heytman M, 2004, ANAESTHESIA, V59, P1210, DOI 10.1111/j.1365-2044.2004.03968.x; Higgins DJ, 1999, ANAESTHESIA, V54, P1126, DOI 10.1046/j.1365-2044.1999.01197.x; Health Protection Agency, 2005, NAT MIN STAND IMM TR; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Johnston SL, 2003, BRIT MED J, V326, P589, DOI 10.1136/bmj.326.7389.589; Jose R, 2007, POSTGRAD MED J, V83, DOI 10.1136/pgmj.2007.059097; Kay LJ, 2005, CHEM IMMUNOL ALLERGY, V87, P145; Kill C, 2004, INT ARCH ALLERGY IMM, V134, P260, DOI 10.1159/000078775; Laxenaire MC, 1999, ANN FR ANESTH, V18, P796, DOI 10.1016/S0750-7658(00)88460-9; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217; Lieberman P., 2005, ANN ALLERG ASTHMA IM, V95, P258, DOI DOI 10.1016/S1081-1206(10)61217-3; Lieberman P., 2005, ANN ALLERG ASTHMA IM, V95, P226, DOI DOI 10.1016/S1081-1206(10)61217-3; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596; Lin RY, 2000, ANN EMERG MED, V36, P462, DOI 10.1067/mem.2000.109445; Manser R, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001740; McLean-Tooke APC, 2003, BRIT MED J, V327, P1332, DOI 10.1136/bmj.327.7427.1332; Mullins RJ, 2003, CLIN EXP ALLERGY, V33, P1033, DOI 10.1046/j.1365-2222.2003.01671.x; Muraro A, 2007, ALLERGY, V62, P857, DOI 10.1111/j.1398-9995.2007.01421.x; Nolan JP, 2005, RESUSCITATION, V67, pS39, DOI 10.1016/j.resuscitation.2005.10.009; Poon M, 2004, EMERG MED J, V21, P76; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pumphrey Richard S H, 2004, Novartis Found Symp, V257, P116; Pumphrey RS, 2004, NOVART FDN SYMP, V257, P276; Pumphrey RS, 2004, NOVART FDN SYMP, V7, P128; Pumphrey RS, 2004, NOVART FDN SYMP, V257, P157; Pumphrey RSH, 2003, J ALLERGY CLIN IMMUN, V112, P451, DOI 10.1067/mai.2003.1614; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Rowe BH, 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002178; Sampson HA, 2006, ANN EMERG MED, V47, P373, DOI 10.1016/j.annemergmed.2006.01.018; SchmidtTraub S, 1997, BRIT J CLIN PSYCHOL, V36, P51; Schummer W, 2004, ANESTHESIOLOGY, V101, P1025, DOI 10.1097/00000542-200410000-00032; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; SHEIKH AHC, 2008, IN PRESS J R SOC MED; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Simons FER, 2007, ALLERGY, V62, P827, DOI 10.1111/j.1398-9995.2007.01433.x; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Smith M, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002886; Soar J, 2005, RESUSCITATION, V67, pS135, DOI 10.1016/j.resuscitation.2005.10.004; Song TT, 2005, ANN ALLERG ASTHMA IM, V94, P539; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859; Thomas M, 2005, EMERG MED J, V22, P272, DOI 10.1136/emj.2005.023507; Tole JW, 2007, IMMUNOL ALLERGY CLIN, V27, P309, DOI 10.1016/j.jac.2007.03.011; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898; Visscher PK, 1996, LANCET, V348, P301, DOI 10.1016/S0140-6736(96)01367-0; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; ZULL DN, 1995, ALLERGY PROC, V16, P113, DOI 10.2500/108854195778690345	77	135	139	2	21	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	MAY	2008	77	2					157	169		10.1016/j.resuscitation.2008.02.001		13	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	299BL	WOS:000255730700003	18358585	
J	Samet, J; Krewski, D				Samet, Jonathan; Krewski, Daniel			Health effects associated with exposure to ambient air pollution	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES			English	Article; Proceedings Paper	Conference on Strategies for Clean Air and Health	NOV 05-07, 2003	Rome, ITALY	NERAM			LONG-TERM EXPOSURE; AMERICAN-CANCER-SOCIETY; ALL-CAUSE MORTALITY; HARVARD 6 CITIES; PARTICULATE MATTER; TIME-SERIES; RESPIRATORY-DISEASES; CANADIAN CITIES; CASE-CROSSOVER; ASTHMA HOSPITALIZATION	The World Health Organization has identified ambient air pollution as a high public health priority, based on estimates of air pollution related death and disability-adjusted life years derived in its Global Burden of Disease initiative. The NERAM Colloquium Series on Health and Air Quality was initiated to strengthen the linkage between scientists, policymakers, and other stakeholders by reviewing the current state of science, identifying policy-relevant gaps and uncertainties in the scientific evidence, and proposing a path forward for research and policy to improve air quality and public health. The objective of this paper is to review the current state of science addressing the impacts of air pollution on human health. The paper is one of four background papers prepared for the 2003 NERAM/AirNet Conference on Strategies for Clean Air and Health, the third meeting in the international Colloquium Series. The review is based on the framework and findings of the U. S. National Research Committee (NRC) on Research Priorities for Airborne Particulate Matter and addresses key questions underlying air quality risk management policy decisions.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada	Samet, J (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, 615 N Wolfe St,Suite W6041, Baltimore, MD 21205 USA.	jsamet@jhsph.edu					Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; Anderson HR, 2003, EUR RESPIR J, V21, p39S, DOI 10.1183/09031936.03.00402203; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; Brunekreef B, 2003, J TOXICOL ENV HEAL A, V66, P1723, DOI 10.1080/15287390390211720; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, ENVIRON RES, V72, P24, DOI 10.1006/enrs.1996.3685; Burnett RT, 1997, EPIDEMIOLOGY, V8, P162, DOI 10.1097/00001648-199703000-00007; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; Burnett RT, 2000, INHAL TOXICOL, V12, P15, DOI 10.1080/089583700750019495; Cakmak S, 2003, J TOXICOL ENV HEAL A, V66, P1811, DOI 10.1080/15287390390212053; Calderon-Garciduenas L, 2003, PEDIATR PULM, V36, P148, DOI 10.1002/ppul.10338; *CAN WID STAND DEV, 1999, COMP BEN INF; Chang LT, 2003, J TOXICOL ENV HEAL A, V66, P1825, DOI 10.1080/15287390390212099; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; Cohen A. J., 2003, J TOXICOL ENV HEAL A, V66, P1489; Devlin RB, 2003, EUR RESPIR J, V21, p76S, DOI 10.1183/09031936.03.00402403; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dominici F, 2003, AM J EPIDEMIOL, V157, P1055, DOI 10.1093/aje/kwg087; Dominici F, 2000, BIOSTATISTICS, V1, P157, DOI DOI 10.1093/BI0STATISTICS/1.2.157; DOMINICI F, 2003, HLTH EFFECTS I; Frampton MW, 2001, ENVIRON HEALTH PERSP, V109, P529, DOI 10.2307/3454664; Fung K, 2005, J TOXICOL ENV HEAL A, V68, P1137, DOI 10.1080/15287390590936003; Fung KY, 2003, INT J EPIDEMIOL, V32, P1064, DOI 10.1093/ije/dyg246; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Goldberg MS, 2005, J TOXICOL ENV HEAL A, V68, P1111, DOI 10.1080/15287390590935950; Greenbaum Daniel S., 2001, American Journal of Epidemiology, V154, pS78, DOI 10.1093/aje/154.12.S78; Greenbaum DS, 2003, J TOXICOL ENV HEAL A, V66, P1493, DOI 10.1080/15287390390211397; Hedley AJ, 2002, LANCET, V360, P1646; *HLTH EFF I, 2003, REV AN TIM SER STUD; Health Effects Institute, 2003, ASS HLTH IMP AIR QUA; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hoover BK, 2003, J TOXICOL ENV HEAL A, V66, P1553, DOI 10.1080/15287390390211496; Jang AS, 2003, ALLERGY, V58, P585, DOI 10.1034/j.1398-9995.2003.00205.x; Jerrett M, 2003, J TOXICOL ENV HEAL A, V66, P1735, DOI 10.1080/15287390390211766; Jerrett M, 2003, J TOXICOL ENV HEAL A, V66, P1783, DOI 10.1080/15287390390212017; Karakatsani A, 2003, EUR J EPIDEMIOL, V18, P45; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; KATSOUYANNI K, 2002, 1 ANN AIRN C DEC 11; KATSOUYANNI K, 2003, HLTH EFFECTS I; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Krewski D, 2003, J TOXICOL ENV HEAL A, V66, P1507, DOI 10.1080/15287390390211487; KREWSKI D, 2004, J TOXICOL ENV HEAL A, V68, P1093; Krewski D, 2000, REANALYSIS HARVARD 6; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; LIN M, 2003, AM J EPIDEMIOL, V159, P294; Linn WS, 2000, ENVIRON HEALTH PERSP, V108, P427, DOI 10.2307/3454383; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; Mallick R, 2002, J Cancer Epidemiol Prev, V7, P155; Maynard R, 2003, J TOXICOL ENV HEAL A, V66, P1891, DOI 10.1080/15287390390212477; Maynard R, 2003, J TOXICOL ENV HEAL A, V66, P1499, DOI 10.1080/15287390390211469; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; [Anonymous], 1998, COMM RES PRIOR AIRB; NRC (National Research Council), 2003, AC EXP GUID LEV SEL, V3; *NRC, 2001, COMM RES PRIOR AIRB; *NRC, 2000, AC EXP GUID LEV SEL, V1; *NRC, 1999, COMM RES PRIOR AIRB; National Research Council (NRC), 2004, AIR QUAL MAN US; NRC (National Research Council), 2002, AC EXP GUID LEV SEL, V2; Oftedal B, 2003, EUR J EPIDEMIOL, V18, P671; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters J, 1996, INT J EPIDEMIOL, V25, P821, DOI 10.1093/ije/25.4.821; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pope CA, 1996, J EXPO ANAL ENV EPID, V6, P23; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Pope C., 2003, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Raizenne M, 2003, J TOXICOL ENV HEAL A, V66, P1503, DOI 10.1080/15287390390211478; Ramsay T, 2003, ENVIRON HEALTH PERSP, V111, P1283, DOI 10.1289/ehp.6047; Ramsay TO, 2003, EPIDEMIOLOGY, V14, P18, DOI 10.1097/00001648-200301000-00009; Salehi F, 2003, TOXICOL APPL PHARM, V191, P264, DOI 10.1016/S0041-008X(03)00238-2; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schwartz J, 2000, AM J EPIDEMIOL, V151, P440; SCHWARTZ J, 1999, EPIDEMIOLOGY, V10, P1; Stieb DM, 2002, J AIR WASTE MANAGE, V52, P470; Stieb DM, 2002, ENVIRON RES, V89, P210, DOI 10.1006/enrs.2002.4373; Sunyer J, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.8.e2; *UK DEP HLTH, 2001, STAT REP LONG TERM E; *US EP A, 1997, EPA410R97002; *US EP A, 1999, EPA410R99001; Utell MJ, 2002, INHAL TOXICOL, V14, P1231, DOI 10.1080/08958370290084881; Villeneuve PJ, 2003, J EXPO ANAL ENV EPID, V13, P427, DOI 10.1038/sj.jea.7500292; Villeneuve PJ, 2002, ANN EPIDEMIOL, V12, P568, DOI 10.1016/S1047-2797(01)00292-7; Vincent R, 2001, AM J RESP CRIT CARE, V163, pA313; White WH, 2003, J TOXICOL ENV HEAL A, V66, P1879, DOI 10.1080/15287390390212323; WHO, 2002, WORLD HLTH REP; WIGLE DT, 2003, CHILDRENS HLTH ENV; Willis A, 2003, J TOXICOL ENV HEAL A, V66, P1605, DOI 10.1080/15287390390211559; Yang Q, 2003, INHAL TOXICOL, V15, P101; Zanobetti A, 2002, EPIDEMIOLOGY, V13, P588, DOI 10.1097/01.EDE.0000020321.67963.7B; Zanobetti A, 2000, Biostatistics, V1, P279, DOI 10.1093/biostatistics/1.3.279; Zeger SL, 1999, EPIDEMIOLOGY, V10, P171, DOI 10.1097/00001648-199903000-00015	97	135	137	9	28	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1528-7394			J TOXICOL ENV HEAL A	J. Toxicol. Env. Health Part A	FEB 1	2007	70	3-4					227	242		10.1080/15287390600884644		16	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	141FC	WOS:000244562800007	17365585	
J	Zimmermann, G				Zimmermann, Gisbert			Review on safety of the entomopathogenic fungus Metarhizium anisopliae	BIOCONTROL SCIENCE AND TECHNOLOGY			English	Review						Metarhizium anisopliae; occurrence; host range; toxins; environmental fate; safety; side-effects	VAR. ACRIDUM DEUTEROMYCOTINA; GROUND-DWELLING ARTHROPODS; BEETLE MELIGETHES-AENEUS; INSECT PATHOGENIC FUNGI; MYCOTOXIN DESTRUXIN-E; LEGUME FLOWER THRIPS; VIRUS-LIKE PARTICLES; BEAUVERIA-BASSIANA; ENTOMOGENOUS FUNGI; METARRHIZIUM-ANISOPLIAE	The entomopathogenic fungus Metarhizium anisopliae (Metschn.) Sorokin is widely used for biocontrol of pest insects, and many commercial products are on the market or under development. The aim of this review is to summarise all relevant safety data of this fungus, which are necessary for the commercialisation and registration process. The review contains the following sections: (1) identity, (2) biological properties (history, natural occurrence and geographical distribution, host range, mode of action, production of metabolites/toxins, effect of environmental factors), (3) methods to determine and quantify residues, (4) fate and behaviour in the environment (mobility and persistence in air, water and soil), (5) effects on non-target organisms (microorganisms, plants, soil organisms, aquatic organisms, predators, parasitoids, honey bees, earth worms, etc.), (6) effects on vertebrates (fish, amphibia, reptiles, and birds), and (7) effects on mammals and human health (allergy, pathogenicity/toxicity). On the basis of the presented knowledge, M. anisopliae is considered to be safe with minimal risks to vertebrates, humans and the environment.	Inst Biol Control, Fed Biol Res Ctr Agr & Forestry, D-64287 Darmstadt, Germany	Zimmermann, G (reprint author), Inst Biol Control, Fed Biol Res Ctr Agr & Forestry, Heinrichstr 243, D-64287 Darmstadt, Germany.	gisbert.zimmermanng@gmx.net					Alves RT, 1998, CROP PROT, V17, P675, DOI 10.1016/S0261-2194(98)00074-X; Alves SB, 1996, J APPL ENTOMOL, V120, P559; ALVES SB, 1984, J APPL ENTOMOL, V97, P127; Amiri B, 1999, BIOCONTROL SCI TECHN, V9, P487, DOI 10.1080/09583159929451; Amiri-Besheli B, 2000, MYCOL RES, V104, P447, DOI 10.1017/S095375629900146X; Arthurs S, 2003, BIOL CONTROL, V26, P333, DOI 10.1016/S1049-9644(02)00166-4; Asensio L., 2003, Spanish Journal of Agricultural Research, V1, P37; Peveling R., 1999, IOBC WPRS B, V22, P2; Austwick PKC., 1980, ECOLOGICAL B STOCKHO, V31, P91; BAATH E, 1991, MYCOL RES, V95, P1140; Barbieri RT, 2005, J INVEST ALLERG CLIN, V15, P131; Barker CW, 1998, NEW ZEAL J ECOL, V22, P189; BATEMAN RP, 1993, ANN APPL BIOL, V122, P145, DOI 10.1111/j.1744-7348.1993.tb04022.x; BEILHARZ VC, 1982, T BRIT MYCOL SOC, V79, P507; BIDOCHKA MJ, 1994, CURR GENET, V25, P107, DOI 10.1007/BF00309534; Bidochka MJ, 2000, MYCOL RES, V104, P1094, DOI 10.1017/S0953756299002403; Bidochka MJ, 1998, CAN J BOT, V76, P1198; BIDOCHKA MJ, 2005, INSECT FUNGAL ASS, P3; Bischoff JF, 2006, MYCOLOGIA, V98, P737, DOI 10.3852/mycologia.98.5.737; Bogo MR, 1996, MYCOL RES, V100, P1468; BOUCIAS DG, 1998, PRINCIPLES INSECT PA, P568; Braga GUL, 2001, J INVERTEBR PATHOL, V78, P98, DOI 10.1006/jipa.2001.5048; Braga GUL, 2001, MYCOL RES, V105, P874, DOI 10.1017/S0953756201004270; Braga GUL, 2001, PHOTOCHEM PHOTOBIOL, V74, P734, DOI 10.1562/0031-8655(2001)074<0734:BSUAUR>2.0.CO;2; Broza M, 2001, PEDOBIOLOGIA, V45, P523, DOI 10.1078/0031-4056-00104; BUCHWALDT L, 1992, PLANT PATHOL, V41, P55, DOI 10.1111/j.1365-3059.1992.tb02316.x; BUDAVARI S, 1996, MERCK INDEX, P472; Burges HD, 1981, MICROBIAL CONTROL PE, P737; Burgner D, 1998, J CLIN MICROBIOL, V36, P1146; Butt T. M., 2001, Fungi as biocontrol agents: progress, problems and potential, P1, DOI 10.1079/9780851993560.0001; BUTT TM, 1994, BIOCONTROL SCI TECHN, V4, P207, DOI 10.1080/09583159409355328; Butt TM, 1998, BIOCONTROL SCI TECHN, V8, P533, DOI 10.1080/09583159830045; *CABI, 2007, CABI BIOSC CBS LANDC; CHASE AR, 1986, FLA ENTOMOL, V69, P285, DOI 10.2307/3494930; Che Y, 2001, J NAT PROD, V64, P555, DOI 10.1021/np000547r; CLERK G. C., 1965, TRANS BRIT MYCOL SOC, V48, P193; COLEGATE SM, 1979, AUST J CHEM, V32, P2257; Cook J, 1996, BIOL CONTROL, V7, P333, DOI 10.1006/bcon.1996.0102; Copping L. G., 2004, MANUAL BIOCONTROL AG, P702; CURRAN J, 1994, MYCOL RES, V98, P547; Danfa A, 1999, BIOCONTROL SCI TECHN, V9, P187; De Croos JNA, 2001, MYCOL RES, V105, P868, DOI 10.1017/S0953756201004099; De Croos JNA, 1999, CAN J MICROBIOL, V45, P1055, DOI 10.1139/cjm-45-12-1055; de la Rosa W, 2000, ENVIRON ENTOMOL, V29, P126, DOI 10.1603/0046-225X-29.1.126; DeGarcia MCC, 1997, J MED VET MYCOL, V35, P361; DHOJ GY, 2003, MITTEILUNGEN SCHWEIZ, V76, P249; Dimbi S, 2004, BIOCONTROL, V49, P83, DOI 10.1023/B:BICO.0000009397.84153.79; DOBERSKI JW, 1980, T BRIT MYCOL SOC, V74, P95; DOMSCH KH, 1980, COMPENDIUM SOIL FUNG, P413; DONOVANPELUSO M, 1980, APPL ENTOMOL ZOOL, V15, P498; Driver F, 2000, MYCOL RES, V104, P134, DOI 10.1017/S0953756299001756; Dromph KM, 2003, PEDOBIOLOGIA, V47, P245, DOI 10.1078/0031-4056-00188; Dromph KM, 2002, APPL SOIL ECOL, V21, P197, DOI 10.1016/S0929-1393(02)00092-6; Dumas C, 1996, J INVERTEBR PATHOL, V67, P137, DOI 10.1006/jipa.1996.0021; Ekesi S, 1999, MYCOPATHOLOGIA, V148, P131, DOI 10.1023/A:1007122622650; Ekesi S, 2000, BIOCONTROL, V45, P79, DOI 10.1023/A:1009927302916; Ekesi S, 2003, J INVERTEBR PATHOL, V83, P157, DOI 10.1016/S0022-2011(03)00069-7; Ekesi S, 1998, J APPL ENTOMOL, V122, P629; Ekesi S, 1999, BIOCONTROL SCI TECHN, V9, P177; Ekesi S, 1999, ENVIRON ENTOMOL, V28, P1154; ELKADI MK, 1983, ENVIRON ENTOMOL, V12, P37; Fan M. Z., 1990, Proceedings and abstracts, Vth International Colloquium on Invertebrate Pathology and Microbial Control, Adelaide, Australia, 20-24 August 1990., P172; FARGUES J, 1985, AGRONOMIE, V5, P73, DOI 10.1051/agro:19850111; Fargues J, 1996, MYCOPATHOLOGIA, V135, P171, DOI 10.1007/BF00632339; FARGUES J, 1985, ENTOMOPHAGA, V30, P353, DOI 10.1007/BF02372341; FEGAN M, 1993, J GEN MICROBIOL, V139, P2075; FERRON P, 1972, Entomophaga, V17, P165, DOI 10.1007/BF02371127; FERRON P., 1981, MICROBIAL CONTROL PE, P465; FRIEDRICHS K., 1913, Tropenpflanzer, V17, P660; FRIEDRICHS K., 1913, Tropenpflanzer, V17, P603; FRIEDRICHS K., 1913, Tropenpflanzer, V17, P538; FUXA JR, 1995, ACS SYM SER, V595, P42; GAMS W, 1973, ACTA BOT NEERL, V22, P518; GEMMA JN, 1984, MYCOLOGIA, V76, P256, DOI 10.2307/3793101; GENTHNER FJ, 1995, DIS AQUAT ORGAN, V22, P163, DOI 10.3354/dao022163; Genthner FJ, 1997, J INVERTEBR PATHOL, V69, P157, DOI 10.1006/jipa.1996.4653; Genthner FJ, 1998, ARCH ENVIRON CON TOX, V35, P317; Ginsberg HS, 2002, ENVIRON ENTOMOL, V31, P1191, DOI 10.1603/0046-225X-31.6.1191; Glare T.R., 1991, P547; Goettel M. S., 2001, Fungi as biocontrol agents: progress, problems and potential, P347, DOI 10.1079/9780851993560.0347; Goettel MS, 1990, SAFETY MICROBIAL INS, P209; GOETTEL MS, 1997, MEMOIRS ENTOMOLOGICA, V171, P83; Guo H.-l., 1986, Acta Mycologica Sinica, V5, P177; Hageskal G, 2006, APPL ENVIRON MICROB, V72, P7586, DOI 10.1128/AEM.01628-06; HAJEK AE, 1994, ANNU REV ENTOMOL, V39, P293, DOI 10.1146/annurev.en.39.010194.001453; HALL RA, 1982, ENTOMOPHAGA, V27, P121, DOI 10.1007/BF02375218; Hallsworth JE, 1999, J INVERTEBR PATHOL, V74, P261, DOI 10.1006/jipa.1999.4883; HARRIS CM, 1988, J AM CHEM SOC, V110, P940, DOI 10.1021/ja00211a039; Hartwig J., 1992, Pflanzenschutz-Nachrichten Bayer, V45, P159; Heimpel A. M., 1971, MICROBIAL CONTROL IN, P469; Hokkanen HMT, 2003, PROG BIOL CONTROL, V1, P63; Hong TD, 1999, BIOCONTROL SCI TECHN, V9, P165; Hozzank A., 2003, IOBC-WPRS Bulletin, V26, P31; Hu G, 2002, APPL ENVIRON MICROB, V68, P6383, DOI 10.1128/AEM.68.12.6383-6387.2002; Hughes WOH, 2004, J INVERTEBR PATHOL, V85, P46, DOI 10.1016/j.jip.2003.12.005; Humber Richard A., 1997, P153, DOI 10.1016/B978-012432555-5/50011-7; HUNT TR, 1994, ENTOMOPHAGA, V39, P313, DOI 10.1007/BF02373036; Husberg GB, 2001, BIOCONTROL, V46, P261, DOI 10.1023/A:1011479616787; HYWELJONES NL, 1990, MYCOL RES, V94, P389; IGNOFFO CM, 1992, ENVIRON ENTOMOL, V21, P913; IGNOFFO CM, 1973, ANN NY ACAD SCI, V217, P141, DOI 10.1111/j.1749-6632.1973.tb32756.x; Instanes C, 2006, TOXICOL LETT, V161, P219, DOI 10.1016/j.toxlet.2005.09.006; Inyang EN, 1999, MYCOL RES, V103, P419, DOI 10.1017/S0953756298007333; Inyang EN, 1999, MYCOL RES, V103, P974, DOI 10.1017/S0953756298007989; Inyang EN, 2000, MYCOL RES, V104, P653, DOI 10.1017/S0953756200002641; Ivie MA, 2002, J ECON ENTOMOL, V95, P651, DOI 10.1603/0022-0493-95.4.651; Jani BR, 2001, CORNEA, V20, P765, DOI 10.1097/00003226-200110000-00020; Jaronski ST, 2003, PROG BIOL CONTROL, V1, P237; Jevanand H. R., 1995, Journal of Ecotoxicology & Environmental Monitoring, V5, P51; JOHNPULLE A. L., 1938, TROP AGRIC [CEYLON], V90, P80; Johnson DL, 2002, J TOXICOL ENV HEAL A, V65, P2145, DOI 10.1080/00984100290071847; Kaakeh W, 1996, J ENTOMOL SCI, V31, P378; KABALUK T, 2005, AGR AGR FOOD CANADA, P242; Kanga LHB, 2003, J ECON ENTOMOL, V96, P1091, DOI 10.1603/0022-0493-96.4.1091; Keller S., 2001, Agrarforschung, V8, P248; Keller S, 2003, BIOCONTROL, V48, P307, DOI 10.1023/A:1023646207455; Keller S., 1989, P239; Kershaw MJ, 1999, J INVERTEBR PATHOL, V74, P213, DOI 10.1006/jipa.1999.4884; KHACHATOURIANS GG, 1996, MYCOTA, V6, P331; Kim HS, 2002, J ANTIBIOT, V55, P598; Kleespies R., 1989, Gesunde Pflanzen, V41, P350; Klein MG, 1999, BIOCONTROL SCI TECHN, V9, P151; Klingen I, 2002, AGR ECOSYST ENVIRON, V91, P191, DOI 10.1016/S0167-8809(01)00227-4; Klingen I, 2002, BIOCONTROL, V47, P411, DOI 10.1023/A:1015653910648; KODAIRA YOSHINORI, 1961, JOUR FAC TEXTILE SCI AND TECHNOL SHINSHU UNIV SER E AGRIC AND SERICULT, V5, P1; Krasnoff SB, 1996, J NAT PROD, V59, P485, DOI 10.1021/np9601216; Krasnoff SB, 2006, J AGR FOOD CHEM, V54, P7083, DOI 10.1021/jf061405r; Krauss U, 2004, BIOCONTROL SCI TECHN, V14, P331, DOI 10.1080/09583150410001665196; Laird M., 1990, Safety of microbial insecticides.; Landa Z., 2002, ISTRO C BRNO SESS 2, P195; LATCH G C M, 1976, Entomophaga, V21, P31, DOI 10.1007/BF02372013; Lazzarini GMJ, 2006, MYCOL RES, V110, P485, DOI 10.1016/j.mycres.2005.12.001; LEAL SCM, 1994, BIOCONTROL SCI TECHN, V4, P89, DOI 10.1080/09583159409355316; LEATHERDALE D, 1970, Entomophaga, V15, P419, DOI 10.1007/BF02370311; Liang Z. Q., 1991, Acta Mycologica Sinica, V10, P257; LIN KJ, 1986, J INVERTEBR PATHOL, V47, P120; Liu BL, 1999, BIOTECHNOL LETT, V21, P657, DOI 10.1023/A:1005562632616; Liu CM, 2004, J CHROMATOGR SCI, V42, P140; Liu ZY, 2001, J INVERTEBR PATHOL, V78, P178, DOI 10.1006/jipa.2001.5039; Liu ZY, 2002, MYCOL RES, V106, P1100, DOI 10.1017/S0953756202006378; LIU ZY, 1993, J INVERTEBR PATHOL, V62, P248, DOI 10.1006/jipa.1993.1107; Maniania NK, 2002, BIOCONTROL SCI TECHN, V12, P59, DOI 10.1080/09583150120110662; MARSHALL KC, 1980, ADSORPTION MICROORGA, P1; Martin PAW, 2000, BIOCONTROL SCI TECHN, V10, P315, DOI 10.1080/09583150050044583; Mavridou A, 1998, MYCOL RES, V102, P1233, DOI 10.1017/S0953756298006339; METSCHNIKOFF E, 1879, ZAPISKI IMPERATORSKO, P21; Mietkiewski R., 1996, Roczniki Nauk Rolniczych. Seria E, Ochrona Roslin, V25, P47; MIETKIEWSKI R, 1994, ROCZNIKI NAUK ROLN E, V24, P33; MIETKIEWSKI R, 1995, P C ACT POT US BIOL, P94; Milner RJ, 1997, J INVERTEBR PATHOL, V69, P64, DOI 10.1006/jipa.1996.4636; Milner RJ, 2003, BIOCONTROL SCI TECHN, V13, P507, DOI 10.1080/0958315031000140965; Milner RJ, 2003, BIOCONTROL, V48, P335, DOI 10.1023/A:1023630319127; Milner RJ, 2002, PEST MANAG SCI, V58, P718, DOI 10.1002/ps.517; Milner RJ, 2002, AUST J ENTOMOL, V41, P82, DOI 10.1046/j.1440-6055.2002.00262.x; MOHAN KS, 1982, T BRIT MYCOL SOC, V78, P181; Moore D, 1996, BIOCONTROL SCI TECHN, V6, P63, DOI 10.1080/09583159650039539; MOORE D, 1993, ANN APPL BIOL, V122, P605, DOI 10.1111/j.1744-7348.1993.tb04061.x; Moore D, 1996, BIOCONTROL SCI TECHN, V6, P51, DOI 10.1080/09583159650039520; Muir D, 1998, MED MYCOL, V36, P51, DOI 10.1080/02681219880000091; MULLERKOGLER E, 1980, ENTOMOPHAGA, V25, P301, DOI 10.1007/BF02371929; Muller-Kogler E., 1976, Z PFLANZENKRANKHEITE, V83, P96; MULLERKOGLER E, 1965, ANWENDUNG BIOL SCHAD, P444; Nielsen C, 2005, ENVIRON ENTOMOL, V34, P133; NUUTINEN V, 1991, J INVERTEBR PATHOL, V58, P147, DOI 10.1016/0022-2011(91)90173-N; Osorio S, 2007, J CLIN MICROBIOL, V45, P651, DOI 10.1128/JCM.01502-06; Ouedraogo A, 1997, MYCOPATHOLOGIA, V137, P37, DOI 10.1023/A:1006882621776; Ouedraogo RM, 2003, J INVERTEBR PATHOL, V82, P103, DOI 10.1016/S0022-2011(02)00185-4; PAIS M, 1981, PHYTOCHEMISTRY, V20, P715, DOI 10.1016/0031-9422(81)85160-6; PATRICK M, 1993, BIOTECHNOL LETT, V15, P997, DOI 10.1007/BF00129924; Pedras MSC, 2002, PHYTOCHEMISTRY, V59, P579, DOI 10.1016/S0031-9422(02)00016-X; Pedras MSC, 2003, PHYTOCHEMISTRY, V64, P957, DOI 10.1016/S0031-9422(03)00444-8; PEREIRA JCR, 1979, T BRIT MYCOL SOC, V72, P495; Peveling R, 2003, ENVIRON TOXICOL CHEM, V22, P1437, DOI 10.1897/1551-5028(2003)22<1437:TAPOMA>2.0.CO;2; Peveling R, 1999, CROP PROT, V18, P323, DOI 10.1016/S0261-2194(99)00032-0; POPRAWSKI TJ, 1994, J APPL ENTOMOL, V117, P135; Quesada-Moraga E, 2004, J INVERTEBR PATHOL, V87, P51, DOI 10.1016/j.jip.2004.07.002; Rangel DEN, 2005, J INVERTEBR PATHOL, V88, P116, DOI 10.1016/j.jip.2004.11.007; Rangel DEN, 2004, J INVERTEBR PATHOL, V87, P77, DOI 10.1016/j.jip.2004.06.007; RATH AC, 1995, J INVERTEBR PATHOL, V65, P186, DOI 10.1006/jipa.1995.1027; Rath AC, 1995, BIOCONTROL SCI TECHN, V5, P439, DOI 10.1080/09583159550039639; RATH AC, 1995, J INVERTEBR PATHOL, V65, P152, DOI 10.1006/jipa.1995.1023; REINECKE P, 1990, BRIGHT CROP PROT C P, V2, P49; Revankar SG, 1999, J CLIN MICROBIOL, V37, P195; ROBERT P, 1989, MYCOPATHOLOGIA, V108, P179, DOI 10.1007/BF00436223; ROBERTI R, 1993, J PLANT DIS PROTECT, V100, P203; ROBERTS D W, 1977, Miscellaneous Publications of the Entomological Society of America, V10, P19; ROBERTS DW, 1976, US DHEW PUBLICATION, P85; Roberts DW, 1981, MICROBIAL CONTROL PE, P441; Roddam LF, 1997, J INVERTEBR PATHOL, V69, P285, DOI 10.1006/jipa.1996.4644; ROMBACH MC, 1987, T BRIT MYCOL SOC, V88, P451; ROMBACH MC, 1986, MYCOTAXON, V27, P87; Ryan MJ, 2003, WORLD J MICROB BIOT, V19, P839, DOI 10.1023/A:1026008416131; Saik JE, 1990, SAFETY MICROBIAL INS, P115; SAMUELS RI, 1988, MYCOPATHOLOGIA, V104, P51, DOI 10.1007/BF00437924; SAPIEHAWASZKIEW.A, 2003, IOBC WPRS B, V26, P113; SCHABEL HG, 1982, J INVERTEBR PATHOL, V39, P410, DOI 10.1016/0022-2011(82)90069-6; SCHAERFFENBERG B, 1968, ENTOMOPHAGA, V13, P175, DOI 10.1007/BF02371788; SHADDUCK JA, 1982, ENVIRON ENTOMOL, V11, P189; Shah PA, 1998, BIOCONTROL SCI TECHN, V8, P357; Shapiro-Ilan DI, 2003, ENVIRON ENTOMOL, V32, P187, DOI 10.1603/0046-225X-32.1.187; Siegel JP, 1990, SAFETY MICROBIAL INS, P101; Sim KL, 1997, GLYCOCONJUGATE J, V14, P661, DOI 10.1023/A:1018505130422; SIM KL, 1995, MYCOL RES, V99, P1078; Skrobek A, 2005, FEMS MICROBIOL LETT, V251, P23, DOI 10.1016/j.femsle.2005.07.029; Smits JE, 1999, J WILDLIFE DIS, V35, P194; SNEH B, 1991, J INVERTEBR PATHOL, V58, P269, DOI 10.1016/0022-2011(91)90071-W; SOROKIN N, 1883, RASTITELNYE PARAZITY, V2, P268; St Leger Raymond, 1993, P211; St. Leger Raymond J., 1996, P443; Steinhaus E. A., 1949, Principles of insect pathology; STEINHAUS EA, 1957, J ECON ENTOMOL, V50, P715; Stenzel K., 1992, Pflanzenschutz-Nachrichten Bayer, V45, P143; Stolz I, 2002, BIOCONTROL SCI TECHN, V12, P349, DOI 10.1080/09583150220128130; Strasser H, 2000, BIOCONTROL SCI TECHN, V10, P717, DOI 10.1080/09583150020011690; Strasser H, 1996, P 3 INT WORKSH MICR, P125; SUZUKI A, 1971, AGR BIOL CHEM TOKYO, V35, P1641; Tamerler C, 1999, BIOTECHNOL LETT, V21, P501, DOI 10.1023/A:1005596205335; Tamerler C, 1998, FEMS MICROBIOL LETT, V168, P17, DOI 10.1111/j.1574-6968.1998.tb13249.x; TamerlerYildir C, 1997, BIOTECHNOL LETT, V19, P919, DOI 10.1023/A:1018358208768; Tarasco E., 1997, Entomologica (Bari), V31, P157; Thomsen L, 2000, ENVIRON ENTOMOL, V29, P1041, DOI 10.1603/0046-225X-29.5.1041; TIGANOMILANI MS, 1995, J INVERTEBR PATHOL, V65, P206, DOI 10.1006/jipa.1995.1031; Tkaczuk C., 1996, ROCZNIKI NAUK ROLN E, V25, P41; Toriello C, 2006, ECOTOX ENVIRON SAFE, V65, P278, DOI 10.1016/j.ecoenv.2005.07.016; TULLOCH M, 1976, T BRIT MYCOL SOC, V66, P407; Tyni-Juslin J., 1990, Proceedings and abstracts. Vth International Colloquium on Invertebrate Pathology and Microbial Control, Adelaide, Australia, 20-24 August 1990., P156; Uchida R, 2005, J ANTIBIOT, V58, P804; VALDEZBARILLAS JR, 2006, ECOLOGICAL IMPORTANC; Vanninen I, 2000, BIOCONTROL, V45, P201, DOI 10.1023/A:1009998919531; Vanninen I, 1996, MYCOL RES, V100, P93; VEEN KH, 1966, J INVERTEBR PATHOL, V8, P268, DOI 10.1016/0022-2011(66)90145-5; Veen K. H., 1968, MEDED LANDBOUWHOGESC, V68, P1; Ventura M.A., 2001, Journal of Neuropterology, V3, P33; Vestergaard S, 2003, PROG BIOL CONTROL, V1, P35; Vey A., 2001, Fungi as biocontrol agents: progress, problems and potential, P311, DOI 10.1079/9780851993560.0311; Vey A, 2002, J INVERTEBR PATHOL, V80, P177, DOI 10.1016/S0022-2011(02)00104-0; Vilcinskas A, 1999, ADV PARASIT, V43, P267, DOI 10.1016/S0065-308X(08)60244-4; WALSTAD JD, 1970, J INVERTEBR PATHOL, V16, P221, DOI 10.1016/0022-2011(70)90063-7; Wang CS, 2004, J INVERTEBR PATHOL, V85, P168, DOI 10.1016/j.jip.2004.02.008; Wang CS, 2003, FEMS MICROBIOL LETT, V226, P373, DOI 10.1016/S0378-1097(03)00640-2; Ward MDW, 1998, TOXICOL SCI, V45, P195, DOI 10.1093/toxsci/45.2.195; Ward MDW, 2000, TOXICOLOGY, V143, P141, DOI 10.1016/S0300-483X(99)00166-3; Ward MDW, 2000, TOXICOLOGY, V147, P133, DOI 10.1016/S0300-483X(00)00191-8; WASTI SS, 1980, PARASITOLOGY, V80, P419; WELLING M, 1994, ENTOMOPHAGA, V39, P351, DOI 10.1007/BF02373040; Wernicke K, 1995, MITT DGAAE, V10, P207; Wraight S. P., 2001, Fungi as biocontrol agents: progress, problems and potential, P253, DOI 10.1079/9780851993560.0253; Zimmermann G, 1998, IOBC WPRS B, V21, P289; Zimmermann G., 1981, Nachrichtenblatt des Deutschen Pflanzenschutzdienstes (Stuttgart), V33, P103; ZIMMERMANN G, 1993, PESTIC SCI, V37, P375, DOI 10.1002/ps.2780370410; ZIMMERMANN G, 1983, PEDOBIOLOGIA, V25, P65; Zimmermann G., 1992, Nachrichtenblatt des Deutschen Pflanzenschutzdienstes, V44, P19; Zimmermann G., 1984, Nachrichtenblatt des Deutschen Pflanzenschutzdienstes, V36, P55; ZIMMERMANN G, 1982, J INVERTEBR PATHOL, V40, P36, DOI 10.1016/0022-2011(82)90034-9; ZIMMERMANN G, 1986, J APPL ENTOMOL, V102, P213; Zimmermann G, 2005, NATURLICHE SCHADLING, P87; Zimmermann G, 2007, BIOCONTROL SCI TECHN, V17, P553, DOI 10.1080/09583150701309006	257	135	144	11	86	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0958-3157	1360-0478		BIOCONTROL SCI TECHN	Biocontrol Sci. Technol.		2007	17	9-10					879	920		10.1080/09583150701593963		42	Biotechnology & Applied Microbiology; Entomology	Biotechnology & Applied Microbiology; Entomology	249ST	WOS:000252250700001		
J	Montagnoli, C; Fallarino, F; Gaziano, R; Bozza, S; Bellocchio, S; Zelante, T; Kurup, WP; Pitzurra, L; Puccetti, P; Romani, L				Montagnoli, C; Fallarino, F; Gaziano, R; Bozza, S; Bellocchio, S; Zelante, T; Kurup, WP; Pitzurra, L; Puccetti, P; Romani, L			Immunity and tolerance to Aspergillus involve functionally distinct regulatory T cells and tryptophan catabolism	JOURNAL OF IMMUNOLOGY			English	Article							INDUCED AIRWAY HYPERREACTIVITY; DENDRITIC CELLS; INDOLEAMINE 2,3-DIOXYGENASE; EXPERIMENTAL ASTHMA; CANDIDA-ALBICANS; INHALED ANTIGEN; MURINE MODEL; TGF-BETA; IN-VIVO; FUMIGATUS	The inherent resistance to diseases caused by Aspergillus fumigatus suggests the occurrence of regulatory mechanisms that provide the host with adequate defense without necessarily eliminating the fungus or causing unacceptable levels of host damage. In this study, we show that a division of labor occurs between functionally distinct regulatory T cells (Treg) that are coordinately activated by a CD28/B-7-dependent costimulatory pathway after exposure of mice to Aspergillus conidia. Early in infection, inflammation is controlled by the expansion, activation and local recruitment of CD4(+)CD25(+) Treg capable of suppressing neutrophils through the combined actions of IL-10 and CTLA-4 on indoleamine 2,3-dioxygenase. The levels of IFN-gamma produced in this early phase set the subsequent adaptive stage by conditioning the indoleamine 2,3-dioxygenase-dependent tolerogenic program of dendritic cells and the subsequent activation and expansion of tolerogenic Treg, which produce IL-10 and TGF-beta, inhibit Th2 cells, and prevent allergy to the fungus. The coordinate activation of Treg may, however, be subverted by the fungus, as germinating conidia are capable of interfering with anti-inflammatory and tolerogenic Treg programs. Thus, regulation is an essential component of the host response in infection and allergy to the fungus, and its manipulation may allow the pathogen to overcome host resistance and promote disease.	Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, I-06126 Perugia, Italy; Vet Affairs Med Ctr, Med Coll Wisconsin, Milwaukee, WI 53285 USA	Romani, L (reprint author), Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, Via Giochetto, I-06126 Perugia, Italy.	lromani@unipg.it	Fallarino, Francesca/O-3358-2013; zelante, teresa/F-7933-2017	Fallarino, Francesca/0000-0002-8501-2136; zelante, teresa/0000-0002-7071-0302; Pitzurra, Lucia/0000-0002-6866-7982; Puccetti, Paolo/0000-0001-6674-2128			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Alyanakian MA, 2003, P NATL ACAD SCI USA, V100, P15806, DOI 10.1073/pnas.2636971100; Arora S, 2005, J IMMUNOL, V174, P6346; Banerjee B, 2004, INFECT IMMUN, V72, P6087, DOI 10.1128/IAI.72.10.6087-6094.2004; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Bozza S, 2005, J IMMUNOL, V174, P2910; Bozza S, 2002, J IMMUNOL, V168, P1362; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Casaulta C, 2003, PEDIATR RES, V53, P313, DOI 10.1203/01.PDR.0000047528.79014.CF; Cenci E, 1998, RES IMMUNOL, V149, P445, DOI 10.1016/S0923-2494(98)80768-2; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Ermann J, 2005, BLOOD, V105, P2220, DOI 10.1182/blood-2004-05-2044; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Hagendorens MM, 2003, CLIN EXP ALLERGY, V33, P633, DOI 10.1046/j.1365-2222.2003.01649.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hori S, 2002, EUR J IMMUNOL, V32, P1282, DOI 10.1002/1521-4141(200205)32:5<1282::AID-IMMU1282>3.0.CO;2-#; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Kurup V P, 2000, Indian J Chest Dis Allied Sci, V42, P225; LEVITZ SM, 1985, J INFECT DIS, V152, P33; Liang S, 2005, J EXP MED, V201, P127, DOI 10.1084/jem.20041201; Lohr J, 2003, NAT IMMUNOL, V4, P664, DOI 10.1038/ni939; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Marr KA, 2002, INFECT DIS CLIN N AM, V16, P875, DOI 10.1016/S0891-5520(02)00035-1; McMillan SJ, 2005, J IMMUNOL, V174, P5774; Mencacci A, 2002, J IMMUNOL, V169, P3180; Montagnoli C, 2002, J IMMUNOL, V169, P6298; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909; Orabona C, 2004, NAT IMMUNOL, V5, P1134, DOI 10.1038/ni1124; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Paust S, 2004, P NATL ACAD SCI USA, V101, P10398, DOI 10.1073/pnas.0403342101; Roilides E, 1997, J IMMUNOL, V158, P322; Romani L, 2004, BLOOD, V103, P4232, DOI 10.1182/blood-2003-11-4036; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Tai XG, 2005, NAT IMMUNOL, V6, P152, DOI 10.1038/ni1160; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180; von Bubnoff D, 2004, CLIN EXP ALLERGY, V34, P1056, DOI 10.1111/j.1365-2222.2004.01984.x; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	52	135	149	0	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 1	2006	176	3					1712	1723				12	Immunology	Immunology	004QF	WOS:000234766600050	16424201	
J	Ek, KH; Morrison, GM; Rauch, S				Ek, KH; Morrison, GM; Rauch, S			Environmental routes for platinum group elements to biological materials - a review	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article; Proceedings Paper	7th International Symposium on Highway and Urban Pollution	MAY, 2002	Inst Quimic Sarria, Barcelona, SPAIN		Inst Quimic Sarria	platinum; palladium; rhodium; PGE; biological material; transformation; mobility; speciation; bioavailability; uptake	PLASMA-MASS SPECTROMETRY; AUTOMOBILE CATALYTIC-CONVERTERS; MAGNETIC-SECTOR FIELD; AIRBORNE PARTICULATE MATTER; SIZE-EXCLUSION CHROMATOGRAPHY; URBAN ROAD DUST; GROUP-METALS; ICP-MS; CONTACT-DERMATITIS; PRECIOUS METALS	The increased use of platinum group elements (PGE) in automobile catalysts has led to concern over potential environmental and biological accumulation. Platinum (Pt), palladium (Pd) and rhodium (Rh) concentrations have increased in the environment since the introduction of automobile catalysts. This review summarises current knowledge concerning the environmental mobility, speciation and bioavailability of Pt, Pd and Rh. The greater proportion of PGE emissions is from automobile catalysts, in the form of nanometer-sized catalyst particles, which deposit on roadside surfaces, as evidenced in samples of road dust, grass and soil. In soil, PGE can be transformed into more mobile species through complexation with organic matter and can be solubilised in low pH rainwater. There are indications that environmentally formed Pd species are more soluble and hence more mobile in the environment than Rh and Pt. PGE can reach waterbodies through stormwater transport and deposition in sediments. Besides external contamination of grass close to roads, internal PGE uptake has been observed for plants growing on soil contaminated with automobile catalyst PGE. Fine particles of PGE were also detected on the surface of feathers sampled from passerines and raptors in their natural habitat, and internal organs of these birds also contained PGE. Uptake has been observed in sediment-dwelling invertebrates, and laboratory studies have shown an uptake of PGE in eel and fish exposed to water containing road dust. The available evidence indicates that the PGE, especially Pd, are transported to biological materials through deposition in roots by binding to sulphur-rich low molecular weight species in plants. PGE uptake to exposed animals have uptake rates in the following order: Pd>Pt>Rh. The liver and kidney accumulate the highest levels of PGE, especially Pd. Urinary Pd and Rh, but not Pt, levels are correlated with traffic intensity. Dental alloys may lead to elevated urinary Pt levels. Platinum is a well-known allergen and Pd also shows a strong sensitisation potential. (C) 2004 Elsevier B.V. All rights reserved.	Chalmers Univ Technol, Water Environm Transport, SE-41296 Gothenburg, Sweden; MIT, RM Parsons Lab 48 108, Cambridge, MA 02139 USA	Ek, KH (reprint author), Chalmers Univ Technol, Water Environm Transport, SE-41296 Gothenburg, Sweden.	kristine.ek@wet.chalmers.se		Rauch, Sebastien/0000-0003-3636-0684			ALT F, 1993, FRESEN J ANAL CHEM, V346, P693, DOI 10.1007/BF00321274; Alt F, 2002, ANAL LETT, V35, P1349, DOI [10.1081/AL-120006671, 10.1081/AL-12000671]; Artelt S, 1999, SCI TOTAL ENVIRON, V228, P219, DOI 10.1016/S0048-9697(99)00049-2; Barany E, 2002, SCI TOTAL ENVIRON, V286, P129, DOI 10.1016/S0048-9697(01)00970-6; Barany E, 2002, TOXICOL LETT, V134, P177, DOI 10.1016/S0378-4274(02)00187-X; Barbante C, 2001, ENVIRON SCI TECHNOL, V35, P835, DOI 10.1021/es000146y; Barefoot RR, 1997, ENVIRON SCI TECHNOL, V31, P309, DOI 10.1021/es960712i; Becker JS, 2000, FRESEN J ANAL CHEM, V368, P490, DOI 10.1007/s002160000539; BEDELLO PG, 1987, CONTACT DERMATITIS, V17, P111, DOI 10.1111/j.1600-0536.1987.tb02674.x; Begerow J, 1996, J ANAL ATOM SPECTROM, V11, P303, DOI 10.1039/ja9961100303; Begerow J, 1997, FRESEN J ANAL CHEM, V359, P427, DOI 10.1007/s002160050603; Begerow J, 1999, BIOMARKERS, V4, P27, DOI 10.1080/135475099230976; Begerow J, 1997, J ANAL ATOM SPECTROM, V12, P1095, DOI 10.1039/a701094j; Begerow J, 1999, ZBL HYG UMWELTMED, V202, P411; Boch K, 2002, ANAL CHIM ACTA, V459, P257, DOI 10.1016/S0003-2670(02)00123-X; Caroli S, 2001, SPECTROCHIM ACTA B, V56, P1241, DOI 10.1016/S0584-8547(01)00203-8; Cinti D, 2002, SCI TOTAL ENVIRON, V293, P47, DOI 10.1016/S0048-9697(01)01137-8; DELACUADRA J, 1991, CONTACT DERMATITIS, V25, P182, DOI 10.1111/j.1600-0536.1991.tb01825.x; Dongarra G, 2003, APPL GEOCHEM, V18, P109, DOI 10.1016/S0883-2927(02)00051-3; Einhauser TJ, 1996, J ANAL ATOM SPECTROM, V11, P747, DOI 10.1039/ja9961100747; EK KH, 2003, IN PRESS SCI TOTAL E; EK KH, 2003, IN PRESS ARCH ENV CO; Ely JC, 2001, ENVIRON SCI TECHNOL, V35, P3816, DOI 10.1021/es001989s; FANCHIANG YT, 1979, J AM CHEM SOC, V101, P1442, DOI 10.1021/ja00500a013; Farago ME, 1998, ANALYST, V123, P451, DOI 10.1039/a705920e; Farago ME, 1996, FRESEN J ANAL CHEM, V354, P660; FARAGO ME, 1983, INORG CHIM ACTA, V79, P233; Gomez B, 2001, SCI TOTAL ENVIRON, V269, P131, DOI 10.1016/S0048-9697(00)00826-3; HABASHI F, 1997, PRECIOUS METALS REFA; Helmers E, 1998, FRESEN J ANAL CHEM, V362, P522, DOI 10.1007/s002160051118; HOLBROOK D J JR, 1975, Environmental Health Perspectives, V10, P95, DOI 10.2307/3428413; Jappe U, 1999, CONTACT DERMATITIS, V40, P111, DOI 10.1111/j.1600-0536.1999.tb06003.x; Jarvis KE, 2001, ENVIRON SCI TECHNOL, V35, P1031, DOI 10.1021/es0001512; Jensen KH, 2002, ARCH ENVIRON CON TOX, V42, P338, DOI 10.1007/s00244-001-0024-3; Kanitsar K, 2003, J ANAL ATOM SPECTROM, V18, P239, DOI 10.1039/b212218a; Kielhorn J, 2002, INT J HYG ENVIR HEAL, V205, P417, DOI 10.1078/1438-4639-00180; Klueppel D, 1998, J ANAL ATOM SPECTROM, V13, P255, DOI 10.1039/a708999f; Kovacheva P, 2002, ANAL CHIM ACTA, V464, P7, DOI 10.1016/S0003-2670(02)00428-2; Krachler M, 1998, ANAL CHIM ACTA, V363, P1, DOI 10.1016/S0003-2670(98)00052-X; Kummerer K, 1999, SCI TOTAL ENVIRON, V225, P155, DOI 10.1016/S0048-9697(98)00341-6; Kylander ME, 2003, J ENVIRON MONITOR, V5, P91, DOI 10.1039/b211736c; Laschka D, 1997, CHEMOSPHERE, V34, P1803, DOI 10.1016/S0045-6535(97)00036-2; LEE DS, 1983, NATURE, V305, P47, DOI 10.1038/305047a0; Leopold I, 1997, FRESEN J ANAL CHEM, V359, P364, DOI 10.1007/s002160050588; LINDELL B, 1997, DECOS NEB BASIS OCCU; Lustig S, 1996, SCI TOTAL ENVIRON, V188, P195, DOI 10.1016/0048-9697(96)05172-8; Lustig S, 1997, FRESEN J ANAL CHEM, V357, P1157, DOI 10.1007/s002160050323; Lustig S, 1998, MIKROCHIM ACTA, V129, P189, DOI 10.1007/BF01244740; Lustig S, 1997, ENVIRON SCI POLLUT R, V4, P141, DOI 10.1007/BF02986321; Ma R, 2001, J ANAL ATOM SPECTROM, V16, P1070, DOI 10.1039/b102940c; Melber C, 2002, PALLADIUM ENV HLTH C; Menzel CM, 2001, GEOSTANDARD NEWSLETT, V25, P239, DOI 10.1111/j.1751-908X.2001.tb00599.x; MESSERSCHMIDT J, 1994, ANAL CHIM ACTA, V291, P161, DOI 10.1016/0003-2670(94)85139-5; Messerschmidt J, 2000, ANALYST, V125, P397, DOI 10.1039/b000471p; MESSERSCHMIDT J, 1995, ELECTROPHORESIS, V16, P800, DOI 10.1002/elps.11501601131; Moldovan M, 2002, SCI TOTAL ENVIRON, V296, P199, DOI 10.1016/S0048-9697(02)00087-6; Moldovan M, 1999, J ANAL ATOM SPECTROM, V14, P1163, DOI 10.1039/a901516g; Moldovan M, 2003, SURF INTERFACE ANAL, V35, P354, DOI 10.1002/sia.1541; Moldovan M, 2001, WATER RES, V35, P4175, DOI 10.1016/S0043-1354(01)00136-1; MOORE W, 1974, ENVIRON RES, V8, P234, DOI 10.1016/0013-9351(74)90055-3; MOORE W, 1975, Environmental Health Perspectives, V10, P63, DOI 10.2307/3428410; Muller M, 2000, FRESEN J ANAL CHEM, V368, P109, DOI 10.1007/s002160000494; Nachtigall D, 1997, J CHROMATOGR A, V775, P197, DOI 10.1016/S0021-9673(97)00278-1; Nachtigall D, 1996, FRESEN J ANAL CHEM, V354, P742; Palacios M, 2000, SCI TOTAL ENVIRON, V257, P1, DOI 10.1016/S0048-9697(00)00464-2; PALACIOS MA, 2000, ANTHROP PLATINUM GRO, P1; PETERSON PJ, 1985, INTERDISCIPL SCI REV, V10, P159; Philippeit G, 2001, J CHROMATOGR B, V760, P237, DOI 10.1016/S0378-4347(01)00271-7; PLATINUM JM, 2002, INTERIM REV; PLATINUM JM, 1996, YB J M; Rauch S, 2000, J ANAL ATOM SPECTROM, V15, P329, DOI 10.1039/a909100i; Rauch S, 2003, ENVIRON SCI TECHNOL, V37, P3283, DOI 10.1021/es034162h; Rauch S, 2001, TRACE ELEMENT SPECIATION FOR ENVIRONMENT, FOOD AND HEALTH, P176, DOI 10.1039/9781847552204-00176; Rauch S, 2001, ENVIRON SCI TECHNOL, V35, P595, DOI 10.1021/es000048c; Rauch S, 2002, SCI TOTAL ENVIRON, V286, P243, DOI 10.1016/S0048-9697(01)00988-3; Rauch S, 1999, SCI TOTAL ENVIRON, V235, P261, DOI 10.1016/S0048-9697(99)00203-X; Rauch S., 1999, P 8 INT C URB STORM, V1, P202; RAUCH S, 2001, ENV RELEVANCE PLATIN; RAUCH S, 2000, ANTHROP PLATINUM GRO; Ravindra K, 2004, SCI TOTAL ENVIRON, V318, P1, DOI 10.1016/S0048-9697(03)00372-3; Rodushkin I, 1999, FRESEN J ANAL CHEM, V364, P338, DOI 10.1007/s002160051346; Santucci B, 2000, CONTACT DERMATITIS, V43, P333, DOI 10.1034/j.1600-0536.2000.043006333.x; Schafer J, 1998, J GEOCHEM EXPLOR, V64, P307, DOI 10.1016/S0375-6742(98)00040-5; Schafer J, 1998, SCI TOTAL ENVIRON, V215, P59, DOI 10.1016/S0048-9697(98)00115-6; Schafer J, 1999, ENVIRON SCI TECHNOL, V33, P3166, DOI 10.1021/es990033i; Schierl R, 2001, ARCH ENVIRON HEALTH, V56, P283; Sures B, 2003, ENVIRON POLLUT, V122, P401, DOI 10.1016/S0269-7491(02)00306-8; Sures B, 2002, ECOTOXICOLOGY, V11, P385, DOI 10.1023/A:1020517624371; Sures B, 2001, ENVIRON POLLUT, V113, P341, DOI 10.1016/S0269-7491(00)00185-8; TONG SSC, 1975, ARCH ENVIRON HEALTH, V30, P329; Tuit CB, 2000, ENVIRON SCI TECHNOL, V34, P927, DOI 10.1021/es990666x; Van de Velde K, 2000, ATMOS ENVIRON, V34, P3117, DOI 10.1016/S1352-2310(99)00434-3; VAUGHAN GT, 1992, SCI TOTAL ENVIRON, V111, P47, DOI 10.1016/0048-9697(92)90044-S; Verstraete D, 1998, SCI TOTAL ENVIRON, V218, P153, DOI 10.1016/S0048-9697(98)00204-6; Wataha JC, 1996, J ORAL REHABIL, V23, P309, DOI 10.1111/j.1365-2842.1996.tb00858.x; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217; Wei Chen, 1994, Science of the Total Environment, V146-147, P169, DOI 10.1016/0048-9697(94)90234-8; Yong P, 2002, J CHEM TECHNOL BIOT, V77, P593, DOI 10.1002/jctb.606; ZELAZOWSKI AJ, 1984, ARCH BIOCHEM BIOPHYS, V229, P246; Zereini F, 1997, SCI TOTAL ENVIRON, V206, P137, DOI 10.1016/S0048-9697(97)00219-2; Zereini F, 2001, ENVIRON SCI TECHNOL, V35, P1996, DOI 10.1021/es001126z; ZEREINI F, 1999, ANTHROP PLATINUM GRO, P73; Zhang BL, 1997, J INORG BIOCHEM, V65, P295, DOI 10.1016/0162-0134(93)00001-D; Zhang Q, 1998, J INORG BIOCHEM, V72, P195, DOI 10.1016/S0162-0134(98)10080-6; Zhong WQ, 1997, J INORG BIOCHEM, V66, P179, DOI 10.1016/S0162-0134(96)00201-2	105	135	142	6	64	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697			SCI TOTAL ENVIRON	Sci. Total Environ.	DEC 1	2004	334				SI		21	38		10.1016/j.scitotenv.2004.04.027		18	Environmental Sciences	Environmental Sciences & Ecology	873QN	WOS:000225295900005	15504490	
J	Cyrys, J; Heinrich, J; Hoek, G; Meliefste, K; Lewne, M; Gehring, U; Bellander, T; Fischer, P; Van Vliet, P; Brauer, M; Wichmann, HE; Brunekreef, B				Cyrys, J; Heinrich, J; Hoek, G; Meliefste, K; Lewne, M; Gehring, U; Bellander, T; Fischer, P; Van Vliet, P; Brauer, M; Wichmann, HE; Brunekreef, B			Comparison between different traffic-related particle indicators: Elemental. carbon (EC), PM2.5 mass, and absorbance	JOURNAL OF EXPOSURE ANALYSIS AND ENVIRONMENTAL EPIDEMIOLOGY			English	Article						traffic-related pollutants; particles; PM10; PM2.5; absorbance; EC	CHRONIC RESPIRATORY SYMPTOMS; DIESEL EXHAUST PARTICLES; PARTICULATE MATTER; AIR-POLLUTION; SPATIAL VARIABILITY; DAILY MORTALITY; CHILDREN; HEALTH; SMOKE; PM10	Here we compare PM2.5 (particles with aerodynamic diameter less than 2.5 mum) mass and filter absorbance measurements with elemental carbon (EC) concentrations measured in parallel at the same site as well as collocated PM2.5 and PM10 (particles with aerodynamic diameter less than 10 mum) mass and absorbance measurements. The data were collected within the Traffic-Related Air Pollution on Childhood Asthma (TRAPCA) study in Germany, The Netherlands and Sweden. The study was designed to assess the health impact of spatial contrasts in long-term average concentrations. The measurement sites were distributed between background and traffic locations. Annual EC and PM2.5 absorbance measurements were at traffic sites on average 43-84% and 26-76% higher, respectively, compared to urban background sites. The contrast for PM2.5 mass measurements was lower (8-35%). The smaller contrast observed for PM2.5 mass in comparison with PM2.5 absorbance and EC documents that PM2.5 mass underestimates exposure contrasts related to motorized traffic emissions. The correlation between PM10 and PM2.5 was high, documenting that most of the spatial variation of PM10 was because of PM2.5. The measurement of PM2.5 absorbance was highly correlated with EC measurements and suggests that absorbance can be used as a simple, inexpensive and non-destructive method. to estimate motorized traffic-related particulate air pollution. The EC/absorbance relation differed between countries and site type (background/traffic), supporting the need for site-specific calibrations of the simple absorbance method. While the ratio between PM2.5 and PM10 mass ranged from 0.54 to 0.68, the ratio of PM2.5 absorbance and PM10 absorbance was 0.96-0.97, indicating that PM2.5 absorbance captures nearly all of the particle absorbance.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Chair Epidemiol, Munich, Germany; Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Unit, Utrecht, Netherlands; Stockholm Cty Council, Dept Environm Hlth, Stockholm, Sweden; Natl Inst Publ Hlth & Environm, Lab Exposure Assessment & Environm Epidemiol, Bilthoven, Netherlands; Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V5Z 1M9, Canada	Cyrys, J (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Cyrys, Josef/B-5359-2014; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; brunekreef, bert/0000-0001-9908-0060; Cyrys, Josef/0000-0002-2105-8696; Gehring, Ulrike/0000-0003-3612-5780; Brauer, Michael/0000-0002-9103-9343			BAYRAM H, 1998, J RESP CELL MOL BIOL, V18, P441; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; CHOW JC, 1995, J AIR WASTE MANAGE, V45, P320; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; COUNTANT B, EPA454R01008 OFF AIR; Cyrys J, 1998, J EXPO ANAL ENV EPID, V8, P447; DELUMYEA RG, 1980, ATMOS ENVIRON, V14, P647, DOI 10.1016/0004-6981(80)90047-5; DiazSanchez D, 1997, ALLERGY, V52, P52; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; FISCHER A, 1997, SCHRIFTENREIHE UMWEL, V80; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gray HA, 1998, ATMOS ENVIRON, V32, P3805; HAMILTON RS, 1991, ATMOS ENVIRON A-GEN, V25, P715, DOI 10.1016/0960-1686(91)90070-N; Hies T, 2000, ATMOS ENVIRON, V34, P3495, DOI 10.1016/S1352-2310(00)00146-1; Hoek G, 1997, ATMOS ENVIRON, V31, P3609, DOI 10.1016/S1352-2310(97)00158-1; Hoek G, 1997, ATMOS ENVIRON, V31, P3341, DOI 10.1016/S1352-2310(97)00150-7; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; HORVATH H, 1993, ATMOS ENVIRON A-GEN, V27, P293, DOI 10.1016/0960-1686(93)90104-7; *ISO, 1993, 98351993 ISO INT ORG; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Janssen NAH, 1997, ATMOS ENVIRON, V31, P1185, DOI 10.1016/S1352-2310(96)00291-9; KEEBER G, 1990, ATMOSPHERIC ENV A, V24, P2795; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; MARPLE VA, 1987, JAPCA J AIR WASTE MA, V37, P1303; Monn C, 1997, ATMOS ENVIRON, V31, P2243, DOI 10.1016/S1352-2310(97)00030-7; NAKAI S, 1995, J EXPO ANAL ENV EPID, V5, P125; Nielsen T, 1996, ATMOS ENVIRON, V30, P3481, DOI 10.1016/1352-2310(96)00096-9; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; OECD, 1964, METH MEAS AIR POLL; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Penttinen P, 2000, ATMOS ENVIRON, V34, P2581, DOI 10.1016/S1352-2310(99)00491-4; Schmid H, 2001, ATMOS ENVIRON, V35, P2111, DOI 10.1016/S1352-2310(00)00493-3; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Tolocka MP, 2001, AEROSOL SCI TECH, V34, P88; Ulrich E., 1992, J AEROSOL SCI S23, V1, pS925; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; *VDI, 1996, VER DTSCH ING 1, V2465; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596; WOLFF GT, 1985, ATMOS ENVIRON, V19, P305, DOI 10.1016/0004-6981(85)90098-8	43	135	136	3	41	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1053-4245			J EXPO ANAL ENV EPID	J. Expo. Anal. Environ. Epidemiol.	MAR	2003	13	2					134	143		10.1038/sj.jea.7500262		10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	676HD	WOS:000182744500005	12679793	
J	Cataldo, D; Munaut, C; Noel, A; Frankenne, F; Bartsch, P; Foidart, JM; Louis, R				Cataldo, D; Munaut, C; Noel, A; Frankenne, F; Bartsch, P; Foidart, JM; Louis, R			MMP-2-and MMP-9-linked gelatinolytic activity in the sputum from patients with asthma and chronic obstructive pulmonary disease	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						asthma; COPD; matrix metalloproteinases; MMP-9; TIMP-1	BRONCHOALVEOLAR LAVAGE FLUID; AIR-FLOW OBSTRUCTION; TISSUE INHIBITOR; IV COLLAGENASE; MATRIX METALLOPROTEINASES; ALVEOLAR MACROPHAGES; CHRONIC-BRONCHITIS; PROGELATINASE-A; SMOOTH-MUSCLE; INFLAMMATION	Background: The course of asthma and chronic obstructive pulmonary disease (COPD) is associated with bronchial morphological changes. Metalloproteinases are thought to play a role in these structural changes. Methods: We studied the gelatinolytic activity present in the induced sputum from 20 patients with asthma, 20 with COPD and 19 healthy controls. The assessment of gelatinolytic activity was performed by quantitative zymography, and gelatinolytic species were identified by Western blot analysis. Tissue inhibitor of metalloproteinase-l (TIMP-1) was detected by reverse zymography and ELISA. Results: From zymography, we found significantly higher gelatinolytic activity linked to pro-matrix metalloproteinase-9 (pro-MMP-9) in the sputum from asthmatics (p < 0.0001) and COPD patients (p < 0.0001) compared to the control group. Furthermore, the activated form of MMP-9 (85 kD) was found in the sputum from 60% of asthmatics and 85% of COPD patients, but was absent in that of control subjects (p < 0.0001). Importantly, although less frequently detectable than pro-MMP-9, pro-MMP-2 (72 kD) was found more frequently in asthmatics (50%) than in control subjects (5%) (p < 0.005). We also described two unusual gelatinolytic species of 45 and 120 kD and showed that they derived from MMP-9 according to their ability to bind gelatin and anti-MMP-9 antibody. Levels of TIMP-1 were higher in asthmatics (p < 0.05) and COPD patients (p < 0.05) than in controls. Conclusion: Asthmatics and COPD patients display an increased gelatinolytic activity linked to MMP-2 and MMP-9 and higher levels of TIMP-1 in their sputum. Copyright (C) 2000 S. Karger AG, Basel.	Univ Liege, Dept Pneumol, Liege, Belgium; Univ Liege, Dept Biol Tumor & Dev, Liege, Belgium	Cataldo, D (reprint author), CHU Sart Tilman, Dept Pneumol, B-4000 Liege, Belgium.			Noel, Agnes/0000-0002-7670-6179; Cataldo, Didier/0000-0002-3079-7941			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Bigg HF, 1997, J BIOL CHEM, V272, P15496, DOI 10.1074/jbc.272.24.15496; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; CATALDO D, 1998, AM J RESP CRIT CARE, V157, pA502; COLLIER IE, 1992, J BIOL CHEM, V267, P6776; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635; Dahlen B, 1999, THORAX, V54, P590; Devy L, 1997, BIOCHEM BIOPH RES CO, V238, P842, DOI 10.1006/bbrc.1997.7398; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Finlay GA, 1997, AM J RESP CRIT CARE, V156, P240; FLETCHER C, 1977, BRIT MED J, V1, P1645; GOLDBERG GI, 1992, J BIOL CHEM, V267, P4583; HEUSSEN C, 1980, ANAL BIOCHEM, V102, P196, DOI 10.1016/0003-2697(80)90338-3; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; HUHTALA P, 1991, J BIOL CHEM, V266, P16485; JEFFERY PK, 1994, AM J RESP CRIT CARE, V150, pS6; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109; Kips JC, 1998, EUR RESPIR J, V11, p9S; Kumagai K, 1999, J IMMUNOL, V162, P4212; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324; Mautino G, 1997, AM J RESP CELL MOL, V17, P583; Nagase H, 1997, BIOL CHEM, V378, P151; Naureckas ET, 1999, AM J RESP CRIT CARE, V160, P2062; Noel A, 1997, INVAS METAST, V17, P221; REMACLE AG, 1995, PROTEIN EXPRES PURIF, V6, P417, DOI 10.1006/prep.1995.1056; Shapiro SD, 1998, CURR OPIN CELL BIOL, V10, P602, DOI 10.1016/S0955-0674(98)80035-5; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945	36	135	145	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	NOV	2000	123	3					259	267		10.1159/000024452		9	Allergy; Immunology	Allergy; Immunology	379VF	WOS:000165663000010	11112863	
J	Johansen, JD; Menne, T; Christophersen, J; Kaaber, K; Veien, N				Johansen, JD; Menne, T; Christophersen, J; Kaaber, K; Veien, N			Changes in the pattern of sensitization to common contact allergens in Denmark between 1985-86 and 1997-98, with a special view to the effect of preventive strategies	BRITISH JOURNAL OF DERMATOLOGY			English	Article						chromate; contact allergy; Denmark; fragrance mix; nickel; patch testing	PATCH TEST; DERMATITIS; CEMENT	The objective of the present study is to describe any changes in the prevalence of sensitization to common contact allergens in patch-tested patients over a 12-year period, Attention is given to possible effects of preventive strategics introduced in Denmark regarding nickel and chromate sensitization during that period, and particular areas of concern are identified. Members of the Danish Contact Dermatitis Group collected patch-test results from consecutive eczema patients as well as information about exposures and demographic variables over a 6-month period in 1985-86. The investigation was repeated in 1997-98 in the same clinics, at the same time of year, using identical methods and patch-test substances, including nickel sulphate 5%, potassium dichromate 0.5% and fragrance mix 8%. Nickel was the most common contact allergen in both study periods, followed by the fragrance mix. In children 0-18 years of age, the frequency of nickel allergy decreased from 24.8% in the first study period to 9.2% in the second study period (P < 0.0008), Fragrance mix allergy doubled in frequency from 4.1% in 1985-86 to 9.9% in 1997-98, an increase that affected all age groups. Contact allergy to potassium dichromate decreased significantly from 3.0% in the first period to 1.2% in the second period (P = 0.001). The decrease was seen in both sexes and was most pronounced among those of working age, No other significant changes were found in the frequency of sensitization to common allergens over the 12-year observation period.	Univ Copenhagen, Gentofte Hosp, Dept Dermatol, DK-2900 Copenhagen, Denmark; Dermatol Clin, DK-2830 Virum, Denmark; Dermatol Clin, DK-7400 Herning, Denmark; Dermatol Clin, Aalborg, Denmark	Johansen, JD (reprint author), Univ Copenhagen, Gentofte Hosp, Dept Dermatol, DK-2900 Copenhagen, Denmark.						Andersen K. E., 1995, TXB CONTACT DERMATIT, P421; AVNSTORP C, 1992, ACTA DERM-VENER    S, V179, P2; BUCKLEY DA, IN PRESS BR J DERMAT; BUTLER H, 1993, POUCHERS PERFUMES CO, V3, P639; CHRISTOPHERSEN J, 1989, CONTACT DERMATITIS, V21, P291, DOI 10.1111/j.1600-0536.1989.tb04746.x; *DAN MIN ENV SAT O, 1991, 854 DAN MIN ENV STAT; *DAN WORK ENV SERV, 1983, 661 DAN WORK ENV SER; *INT FRAGR ASS, 1974, COD PRACT GUID PER B; IRVINE C, 1994, OCCUP MED-OXFORD, V44, P17, DOI 10.1093/occmed/44.1.17; Johansen JD, 1997, ACTA DERM-VENEREOL, V77, P149; Johansen JD, 1996, BRIT J DERMATOL, V135, P419, DOI 10.1111/j.1365-2133.1996.tb01506.x; LIM JTE, 1992, CONTACT DERMATITIS, V26, P321; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; Menne T, 1996, ANN CLIN LAB SCI, V26, P133; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Olsavszky R, 1998, CONTACT DERMATITIS, V38, P329, DOI 10.1111/j.1600-0536.1998.tb05768.x; ROTHENBORG HW, 1968, ARCH DERMATOL, V97, P417, DOI 10.1001/archderm.97.4.417; Somogyi LP, 1996, CHEM IND-LONDON, P170; Uter W, 1998, EUR J DERMATOL, V8, P36; WILKINSON DS, 1970, ACTA DERM-VENEREOL, V50, P287; Zachariae COC, 1996, CONTACT DERMATITIS, V35, P83, DOI 10.1111/j.1600-0536.1996.tb02295.x	21	135	137	1	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	MAR	2000	142	3					490	495		10.1046/j.1365-2133.2000.03362.x		6	Dermatology	Dermatology	296GP	WOS:000086016300016	10735956	
J	Jackson, DJ; Sykes, A; Mallia, P; Johnston, SL				Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.			Asthma exacerbations: Origin, effect, and prevention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; asthma exacerbations; viral infection; virus; allergy; allergen; pollutant; bacteria	BRONCHIAL EPITHELIAL-CELLS; VIRUS-INDUCED ASTHMA; BUDESONIDE/FORMOTEROL COMBINATION THERAPY; PLACEBO-CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; INDOOR NITROGEN-DIOXIDE; SEVERE ALLERGIC-ASTHMA; NECROSIS-FACTOR-ALPHA; INNER-CITY CHILDREN; HUMAN RHINOVIRUS C	Asthma is the most common chronic respiratory disease, affecting up to 10% of adults and 30% of children in the Western world. Despite advances in asthma management, acute exacerbations continue to occur and impose considerable morbidity on patients and constitute a major burden on health care resources. Respiratory tract viruses have emerged as the most frequent triggers for exacerbations in both children and adults; however, the mechanisms underlying these remain poorly understood. More recently, it has become increasingly clear that interactions might exist between viruses and other triggers, increasing the likelihood of an exacerbation. In this article we begin with an overview of the health, economic, and social burden that exacerbations of asthma carry with them. This is followed by a review of the pathogenesis of asthma exacerbations, highlighting the various triggers responsible and multiple interactions that exist between them. The final section first addresses what preventative measures are currently available for asthma exacerbations and subsequently examines which of the new treatments in development might lessen the burden of exacerbations in the future. (J Allergy Clin Immunol 2011;128:1165-74.)	[Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, London W2 1PG, England; [Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.] Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mech Asthma, London W2 1PG, England; [Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.] Ctr Resp Infect, London, England; [Jackson, David J.; Sykes, Annemarie; Mallia, Patrick; Johnston, Sebastian L.] Imperial Coll Healthcare NHS Trust, London, England	Johnston, SL (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, Wright Fleming Inst Infect & Immun, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Johnston, Sebastian/I-2423-2012		MRC [G0601236]; MRC Centre [G1000758]; Predicta FP7 Collaborative Project [260895]; Wellcome Trust; ERC [233015]; National Institutes of Health Research; Asthma UK	Supported in part by MRC project grant G0601236, MRC Centre grant G1000758, the Predicta FP7 Collaborative Project grant 260895, and the Wellcome Trust-sponsored Centre for Respiratory Infection (CRI). D.J.J. is supported by ERC FP7 Advanced grant 233015 (to S.L.J.), A.S. is supported by an MRC Clinical Training Fellowship, A.S. and P.M. are National Institutes of Health Research Clinical Lecturers, and S.L.J. holds the Asthma UK Clinical Chair (CH1155).; S.L. Johnston is a consultant for AstraZeneca, Centocor, and Sanofi-Pasteur; is a consultant for and shareholder in Synairgen; has received research support from the European Research Council, Medical Research Council Clinical Training Fellowship, National Institutes of Health Research, Asthma UK, Medical Research Council, Predicta FP7 Collaborative Project, and the Wellcome Trust-sponsored Centre for Respiratory Infection. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami LJ, 2011, NATL HLTH STAT REPOR, V12, P1; ALLEGRA L, 1994, EUR RESPIR J, V7, P2165, DOI 10.1183/09031936.94.07122165; *AM LUNG ASS, TRENDS ASTHM MORB; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barnes NC, 2000, THORAX, V55, P478, DOI 10.1136/thorax.55.6.478; Barnes PJ, 2010, TRENDS PHARMACOL SCI, V31, P335, DOI 10.1016/j.tips.2010.04.009; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; BERKOVICH S, 1970, ANN ALLERGY, V28, P43; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2010, BRIT MED J, V341, pc4978; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Bueving HJ, 2005, CURR OPIN ALLERGY CL, V5, P65, DOI 10.1097/00130832-200502000-00012; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2011, J ALLERGY CLIN IMMUN, V127, P130, DOI 10.1016/j.jaci.2010.11.014; Castro M, 2010, AM J RESP CRIT CARE, V181, P116, DOI 10.1164/rccm.200903-0354OC; Cates CJ, 2004, COCHRANE DB SYST REV; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Christy C, 2004, ARCH DIS CHILD, V89, P734, DOI 10.1136/adc.2003.030999; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Cosentini R, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-48; Covar RA, 2008, J ALLERGY CLIN IMMUN, V122, P741, DOI 10.1016/j.jaci.2008.08.021; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; CUSTOVIC A, 2007, ALLERGY CLIN IMMU S2, P270; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Edwards MR, 2011, EMBO MOL MED, V3, P306, DOI 10.1002/emmm.201100143; Edwards MR, 2006, AM J RESP CELL MOL, V34, P616, DOI 10.1165/rcmb.2005-0385OC; Falsey AR, 2005, NEW ENGL J MED, V352, P1749, DOI 10.1056/NEJMoa043951; Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Gibson PG, 2004, THORAX, V59, P94, DOI 10.1136/thorax.2003.011858; Gibson PG, 2002, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001117, DOI 10.1002/14651858.CD001117]; Gielen V, 2010, EUR RESPIR J, V36, P646, DOI 10.1183/09031936.00095809; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grant E N, 1999, Curr Opin Pulm Med, V5, P27, DOI 10.1097/00063198-199901000-00005; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Grissell TV, 2005, AM J RESP CRIT CARE, V172, P433, DOI 10.1164/rccm.200412-1621OC; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Guevara JP, 2003, BRIT MED J, V326, P1308, DOI 10.1136/bmj.326.7402.1308; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2011, ANN INTERN MED, V154, P573, DOI 10.7326/0003-4819-154-9-201105030-00002; Hansel NN, 2008, ENVIRON HEALTH PERSP, V116, P1428, DOI 10.1289/ehp.11349; Hartert TV, 2002, ANN ALLERG ASTHMA IM, V89, P467; He R, 2010, ANN NY ACAD SCI, V1183, P13, DOI 10.1111/j.1749-6632.2009.05128.x; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jang YJ, 2006, EUR RESPIR J, V27, P12, DOI 10.1183/09031936.06.00008005; Johnston NW, 2007, PEDIATRICS, V120, pE702, DOI 10.1542/peds.2006-3317; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; Johnston SL, 2006, J ALLERGY CLIN IMMUN, V117, P1233, DOI 10.1016/j.jaci.2006.03.035; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kattan M, 2007, J ALLERGY CLIN IMMUN, V120, P618, DOI 10.1016/j.jaci.2007.05.014; Kaufman EH, 2011, J ALLERGY CLIN IMMUN, V127, P462, DOI 10.1016/j.jaci.2010.10.029; Khetsuriani N, 2007, J ALLERGY CLIN IMMUN, V119, P314, DOI 10.1016/j.jaci.2006.08.041; Kolbe J, 2002, THORAX, V57, P317, DOI 10.1136/thorax.57.4.317; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Kramarz P, 2001, J PEDIATR-US, V138, P306, DOI 10.1067/mpd.2001.112168; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; LAMBERT HP, 1972, BRIT MED J, V3, P323; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lau SKP, 2009, J INFECT DIS, V200, P1096, DOI 10.1086/605697; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Legg JP, 2005, PEDIATR INFECT DIS J, V24, P611, DOI 10.1097/01.inf.0000168747.94999.aa; Libster R, 2010, NEW ENGL J MED, V362, P45, DOI 10.1056/NEJMoa0907673; Lieberman D, 2003, AM J RESP CRIT CARE, V167, P406, DOI 10.1164/rccm.200209-996OC; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Mallia P, 2011, AM J RESP CRIT CARE, V183, pA3728; Mann JK, 2010, ENVIRON HEALTH PERSP, V118, P1497, DOI 10.1289/ehp.0901292; Massanari M, 2009, CLIN PEDIATR, V48, P859, DOI 10.1177/0009922809339054; Meltzer EO, 2011, J ALLERGY CLIN IMMUN, V127, P167, DOI 10.1016/j.jaci.2010.08.042; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller EK, 2009, J CLIN VIROL, V46, P85, DOI 10.1016/j.jcv.2009.06.007; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller MK, 2007, RESP MED, V101, P481, DOI 10.1016/j.rmed.2006.07.005; MILLER TP, 1992, CHEST, V102, P515, DOI 10.1378/chest.102.2.515; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Namazy JA, 2005, CURR OPIN PULM MED, V11, P56, DOI 10.1097/01.mcp.0000148568.20273.f5; NICHOLSON KG, 1993, BRIT MED J, V307, P982; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; O'Riordan S, 2010, CAN MED ASSOC J, V182, P39, DOI 10.1503/cmaj.091724; Office of Environmental Health Hazard Assessment, 2005, HLTH EFF EXP ENV TOB; Ohta K, 2009, RESPIROLOGY, V14, P1156, DOI 10.1111/j.1440-1843.2009.01633.x; Oliver BGG, 2008, THORAX, V63, P519, DOI 10.1136/thx.2007.081752; Papi A, 2007, EUR RESPIR J, V29, P682, DOI 10.1183/09031936.00095906; Papi A, 2011, EUR RESPIR J, V37, P5, DOI 10.1183/09031936.00145710; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pavord ID, 2007, AM J RESP CRIT CARE, V176, P1185, DOI 10.1164/rccm.200704-571OC; Peters SP, 2007, J ALLERGY CLIN IMMUN, V119, P1454, DOI 10.1016/j.jaci.2007.03.022; Plessa E, 2010, CLIN PEDIATR, V49, P777, DOI 10.1177/0009922810368558; Prescott E, 1997, THORAX, V52, P287; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Ramsay CF, 2011, THORAX, V66, P7, DOI 10.1136/thx.2010.135038; Rees P John, 2007, Arch Dis Child Educ Pract Ed, V92, pep127; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schmaling KB, 2002, J ASTHMA, V39, P501, DOI 10.1081/JAS-120004916; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Skevaki CL, 2009, CLIN EXP ALLERGY, V39, P1700, DOI 10.1111/j.1365-2222.2009.03307.x; Stanford RH, 2008, CURR MED RES OPIN, V24, P3141, DOI 10.1185/03007990802462990 ; Stokes JR, 1998, EUR RESPIR J, V11, P324, DOI 10.1183/09031936.98.11020324; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Strunk RC, 2008, J ALLERGY CLIN IMMUN, V122, P1138, DOI 10.1016/j.jaci.2008.09.028; Tahan F, 2007, EUR RESPIR J, V29, P91, DOI 10.1183/09031936.00029206; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002; Weiss KB, 2010, ANN ALLERG ASTHMA IM, V105, P174, DOI 10.1016/j.anai.2010.04.018; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; [Anonymous], ASTHMA INSIGHT MANAG	136	134	141	4	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1165	1174		10.1016/j.jaci.2011.10.024		10	Allergy; Immunology	Allergy; Immunology	865WX	WOS:000298342700003	22133317	
J	Zosky, GR; Sly, PD				Zosky, G. R.; Sly, P. D.			Animal models of asthma	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review						animal; asthma; model	ALLERGEN-INDUCED AIRWAY; HOUSE-DUST MITE; ANTIGEN-INDUCED BRONCHOCONSTRICTION; LATE-PHASE BRONCHOCONSTRICTION; RESPIRATORY SYSTEM MECHANICS; BROWN-NORWAY RAT; MOUSE MODEL; T-CELLS; BRONCHIAL RESPONSIVENESS; LUNG INFLAMMATION	Animal models of asthma are a tool that allows studies to be conducted in the setting of an intact immune and respiratory system. These models have highlighted the importance of T-helper type 2 driven allergic responses in the progression of asthma and have been useful in the identification of potential drug targets for interventions involving allergic pathways. However, a number of drugs that have been shown to have some efficacy in animal models of asthma have shown little clinical benefit in human asthmatics. This may be due to a number of factors including the species of animal chosen and the methods used to induce an asthmatic phenotype in animals that do not normally develop a disease that could be characterized as asthma. The range of animal models available is vast, with the most popular models being rodents (inbred mice and rats) and guinea-pigs, which have the benefit of being easy to handle and being relatively cost effective compared with other models that are available. The recent advances in transgenic technology and the development of species-specific probes, particularly in mice, have allowed detailed mechanistic studies to be conducted. Despite these advances in technology, there are a number of issues with current animal models of asthma that must be recognized including the disparity in immunology and anatomy between these species and humans, the requirement for adjuvant during senitization in most models, the acute nature of the allergic response that is induced and the use of adult animals as the primary disease model. Some larger animal models using sheep and dogs have been developed that may address some of these issues but they also have different biology from humans in many ways and are extremely costly, with very few probes available for characterizing allergic responses in the airway in these species. As research in this area continues to expand, the relative merits and limitations of each model must be defined and understood in order to evaluate the information that is obtained from these models and to extrapolate these findings to humans so that effective drug therapies can be developed. Despite these issues, animal models have been, and will continue to be, vital in understanding the mechanisms that are involved in the development and progression of asthma.	Telethon Inst Child Hlth Res, Div Clin Sci, Subiaco, WA 6008, Australia; Univ Western Australia, Ctr Child Hlth Res, Crawley, WA, Australia	Zosky, GR (reprint author), Telethon Inst Child Hlth Res, Div Clin Sci, 100 Roberts Rd, Subiaco, WA 6008, Australia.	graemez@ichr.uwa.edu.au	Sly, Peter/F-1486-2010; Zosky, Graeme/B-2048-2014	Sly, Peter/0000-0001-6305-2201; Zosky, Graeme/0000-0001-9039-0302			ABRAHAM W M, 1989, Pulmonary Pharmacology, V2, P33, DOI 10.1016/S0952-0600(89)80007-9; ABRAHAM WM, 1988, AM REV RESPIR DIS, V138, P1565; ABRAHAM WM, 1983, AM REV RESPIR DIS, V128, P839; ABRAHAM WM, 1995, EUR RESPIR REV, V5, P211; Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Anderson GG, 1998, ARCH DIS CHILD, V78, P488; ANDREW DK, 1984, INT ARCH ALLER A IMM, V75, P208; Aoshiba K, 2004, CLIN REV ALLERG IMMU, V27, P35, DOI 10.1385/CRIAI:27:1:035; Babu KS, 2001, CLIN EXP ALLERGY, V31, P182, DOI 10.1046/j.1365-2222.2001.01058.x; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Bates J, 2004, AM J RESP CELL MOL, V31, P373; Bates JHT, 2003, J APPL PHYSIOL, V94, P1297, DOI 10.1152/japplphysiol.00706.2002; BATES JHT, 1993, J APPL PHYSIOL, V75, P2493; Bettinelli D, 2002, J APPL PHYSIOL, V93, P2044, DOI 10.1152/japplphysiol.00492.2002; Bettinelli D, 2002, J APPL PHYSIOL, V92, P709; BLYTHE SA, 1988, PEDIATR PULM, V4, P173, DOI 10.1002/ppul.1950040310; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Brewer JM, 1999, J IMMUNOL, V163, P6448; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150; Brusasco V, 2003, J APPL PHYSIOL, V95, P1305, DOI 10.1152/japplphysiol.00001.2003; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254; Burgess JK, 2006, AM J PHYSIOL-LUNG C, V290, pL153, DOI 10.1152/ajplung.00287.2005; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Collie DDS, 1997, AM J VET RES, V58, P34; Collins RA, 2003, RESP PHYSIOL NEUROBI, V139, P51, DOI 10.1016/j.resp.2003.09.003; Daser A, 2000, IMMUNOGENETICS, V51, P632, DOI 10.1007/s002510000206; de Bie JJ, 2000, EXP LUNG RES, V26, P491; De Sanctis GT, 2001, J ALLERGY CLIN IMMUN, V108, P11, DOI 10.1067/ami.2001.116429; deWeck AL, 1997, INT ARCH ALLERGY IMM, V113, P55; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Eriksson U, 2005, J IMMUNOL, V175, P2715; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074; EWART S, 1995, J APPL PHYSIOL, V79, P560; Fan M, 2006, INT IMMUNOPHARMACOL, V6, P36, DOI 10.1016/j.intimp.2005.07.008; Fan T, 1997, AM J RESP CELL MOL, V17, P156; Farraj AK, 2003, TOXICOL PATHOL, V31, P432, DOI 10.1080/01926230390213766; Fattouh R, 2005, AM J RESP CRIT CARE, V172, P314, DOI 10.1164/rccm.200502-198OC; Fish SC, 2005, J IMMUNOL, V174, P7716; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fulkerson PC, 2005, CLIN EXP ALLERGY, V35, P1251, DOI 10.1111/j.1365-2222.2005.02354.x; Gelfand EW, 2002, AM J RESP CRIT CARE, V166, P5, DOI 10.1164/rccm.2204023; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Gomes RFM, 2000, J APPL PHYSIOL, V89, P908; Gomez FP, 2000, BIODRUGS, V14, P21, DOI 10.2165/00063030-200014010-00003; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hantos Z, 2003, J APPL PHYSIOL, V95, P1695, DOI 10.1152/japplphysiol.00104.2003; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; HERZBERG B, 2006, J ALLERGY CLIN IMMUN, V118, P382; HESSEL EM, 1995, J APPL PHYSIOL, V79, P1711; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; HOLT PG, 1981, INT ARCH ALLER A IMM, V65, P42; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Holt PG, 2002, J EXP MED, V196, P1271, DOI 10.1084/jem.20021572; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; Howat WJ, 2002, AM J PHYSIOL-LUNG C, V282, pL115; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Huovinen E, 2003, RESP MED, V97, P273, DOI 10.1053/rmed.2003.1419; HUTSON PA, 1988, AM REV RESPIR DIS, V138, P1157; Hylkema MN, 2002, CLIN EXP IMMUNOL, V129, P390, DOI 10.1046/j.1365-2249.2002.01938.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; ITABASHI S, 1993, INT ARCH ALLERGY IMM, V101, P215; James A, 2005, CLIN EXP ALLERGY, V35, P703, DOI 10.1111/j.1365-2222.2005.02270.x; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; JONES TR, 1995, CAN J PHYSIOL PHARM, V73, P191; KAROL MH, 1994, EUR RESPIR J, V7, P555, DOI 10.1183/09031936.94.07030555; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Kurucz I, 2006, CURR PHARM DESIGN, V12, P3175, DOI 10.2174/138161206778194169; LAGENBACK EG, 1990, J APPL PHYSIOL, V68, P1427; LANES S, 1986, J APPL PHYSIOL, V61, P864; Lee SC, 1999, J IMMUNOL, V162, P6867; Liu S, 2005, INFLAMM RES, V54, P221, DOI 10.1007/s00011-005-1346-9; Lobb RR, 1996, EUR RESPIR J, V9, pS104; Lordan JL, 2002, J IMMUNOL, V169, P407; Lundy SK, 2003, AM J PATHOL, V163, P1961, DOI 10.1016/S0002-9440(10)63554-7; Machida I, 2005, CLIN EXP ALLERGY, V35, P884, DOI 10.1111/j.1365-2222.2005.02262.x; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Melkild I, 2002, CLIN EXP ALLERGY, V32, P1370, DOI 10.1046/j.1365-2745.2002.01458.x; MISAWA M, 1987, JPN J PHARMACOL, V45, P63, DOI 10.1254/jjp.45.63; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUCCITELLI RM, 1987, J PHARMACOL EXP THER, V243, P467; MULLER KM, 1993, J IMMUNOL, V150, P5576; Mullins LJ, 1996, J CLIN INVEST, V97, P1557, DOI 10.1172/JCI118579; Nakagome K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-46; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Pabst R, 2002, PATHOBIOLOGY, V70, P252, DOI 10.1159/000070737; Padrid P, 1992, Probl Vet Med, V4, P320; Pauwels RA, 1997, AM J RESP CRIT CARE, V156, pS78; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; Persson CGA, 2002, AM J RESP CRIT CARE, V166, P6, DOI 10.1164/rccm.2204001; PHELAN RF, 1983, AM REV RESPIR DIS, V128, pS1; Pillow JJ, 2001, J APPL PHYSIOL, V91, P2730; PLOPPER CG, 1983, AM REV RESPIR DIS, V128, pS4; Pretolani M, 1996, ANN NY ACAD SCI, V796, P72, DOI 10.1111/j.1749-6632.1996.tb32568.x; PRETOLANI M, 1993, BIOCHEM PHARMACOL, V45, P791, DOI 10.1016/0006-2952(93)90161-O; Redman TK, 2001, EXP LUNG RES, V27, P433, DOI 10.1080/019021401300317143; Ressmeyer AR, 2006, EUR RESPIR J, V28, P603, DOI 10.1183/09031936.06.00004206; Richards IM, 1996, CLIN EXP ALLERGY, V26, P618, DOI 10.1111/j.1365-2222.1996.tb00586.x; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; SASAKI H, 1987, AM REV RESPIR DIS, V136, P1459; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; SCHLESINGER RB, 1981, ANAT REC, V199, P99, DOI 10.1002/ar.1091990110; Schneider T, 1997, AM J RESP CELL MOL, V17, P702; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; SELIG W, 1999, IN VIVO MODELS INFLA, P111; Shardonofsky FR, 1999, J ALLERGY CLIN IMMUN, V104, P215, DOI 10.1016/S0091-6749(99)70138-7; Shichijo M, 1998, CLIN EXP ALLERGY, V28, P1228; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Singh P, 2003, AM J PHYSIOL-LUNG C, V284, pL588, DOI 10.1152/ajplung.00287.2002; Sly P. D., 2004, DRUG DISCOV TODAY DI, V1, P337, DOI 10.1016/j.ddmod.2004.11.016; Smith N, 2005, CLIN EXP ALLERGY, V35, P522, DOI 10.1111/j.1365-2222.2005.02211.x; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Sundstrom E, 2003, J PHARMACOL EXP THER, V307, P408, DOI 10.1124/jpet.103.053546; Szelenyi I, 2000, INFLAMM RES, V49, P639, DOI 10.1007/s000110050642; TAGARI P, 1990, J APPL PHYSIOL, V68, P1321; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; TAKEDA K, 2001, AM J PHYSIOL-LUNG C, V281, P394; Tang MLK, 2006, PHARMACOL THERAPEUT, V112, P474, DOI 10.1016/j.pharmthera.2006.05.001; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Temelkovski J, 1998, THORAX, V53, P849; TOMIOKA K, 1989, EUR J PHARMACOL, V170, P209, DOI 10.1016/0014-2999(89)90541-4; Trifilieff A, 2000, BRIT J PHARMACOL, V130, P1581, DOI 10.1038/sj.bjp.0703501; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; Turner DJ, 1996, AM J RESP CRIT CARE, V153, P545; Varner AE, 2000, ASTHMA RHINITIS, P1172, DOI 10.1002/9780470694923.ch5; Virchow JC, 2006, RESP MED, V100, P1952, DOI 10.1016/j.rmed.2006.02.026; Walker C, 1998, J IMMUNOL, V161, P1962; Webb DC, 2003, EUR J IMMUNOL, V33, P3377, DOI 10.1002/eji.200324178; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; WHITEHEAD GS, 2003, AM J PHYSIOL-LUNG C, V285, P32; WillsKarp M, 1997, AM J RESP CRIT CARE, V156, pS89; Wise JT, 1999, J IMMUNOL, V162, P5592; YEH HC, 1976, ENVIRON HEALTH PERSP, V15, P147, DOI 10.2307/3428398; Young HWJ, 2006, AM J RESP CELL MOL, V35, P549, DOI 10.1165/rcmb.2006-00600C; Zosky GR, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-15; Sly P. D., 2006, ALLERGY CLIN IMMUNOL, V18, P76, DOI 10.1027/0838-1925.18.2.76	154	134	138	1	23	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUL	2007	37	7					973	988		10.1111/j.1365-2222.2007.02740.x		16	Allergy; Immunology	Allergy; Immunology	180WQ	WOS:000247398300004	17581191	
J	de Lange, EE; Altes, TA; Patrie, JT; Gaare, JD; Knake, JJ; Mugler, JP; Platts-Mills, TA				de lange, Eduard E.; Altes, Talissa A.; Patrie, James T.; Gaare, John D.; Knake, Jeffrey J.; Mugler, John P., III; Platts-Mills, Thomas A.			Evaluation of asthma with hyperpolarized helium-3 MRI - Correlation with clinical severity and spirometry	CHEST			English	Article						airflow obstruction; airway; asthma; bronchial activity; hyperpolarized gases; hyperpolarized helium-3; MRI; pulmonary function test; spirometry; ventilation defect	LUNG-TRANSPLANT RECIPIENTS; PULMONARY-FUNCTION TESTS; MAGNETIC-RESONANCE; CYSTIC-FIBROSIS; SMALL AIRWAYS; AIR SPACES; GAS; ABNORMALITIES; VENTILATION; VOLUMES	Background: Accurate characterization of asthma severity is difficult due to the variability of symptoms. Hyperpolarized helium-3 MRI ((HHeMR)-He-3) is a new technique in which the airspaces are visualized, depicting regions with airflow obstruction as "ventilation defects." The objective of this study was to compare the extent of (HHeMR)-He-3 ventilation defects with measures of asthma severity and spirometry. Methods: Patients with a physician diagnosis of asthma and normal control subjects underwent (HHeMR)-He-3. For each person, the number and size of ventilation defects were scored and the average number of ventilation defects per slice (VDS) was calculated. The correlations of the imaging findings with measures of asthma severity and spirometry were determined. Results: There were 58 patients with asthma (mild-intermittent, n = 13; mild-persistent, n = 13; moderate-persistent, n = 20; and severe-persistent, n = 12) and 18 control subjects. Mean +/- SE VDS for asthmatics was significantly greater than for control subjects (0.99 +/- 0.15 vs; 0.26 +/- 0.22, p = 0.004). Among asthmatics, VDS was significantly higher for the group with moderate-persistent and severe-persistent disease than for the group with mild-intermittent and mild-persistent disease (1.37 +/- 0.24 vs 0.53 +/- 0.12, p < 0.001). VDS correlated significantly with FEV1/FVC (r = -0.51, p = 0.002), forced expiratory flow between 25% and 75% from the beginning of FVC (FEF25-75%) percentage of predicted for height, sex, and race (%predicted) [r = -0.50, p = 0.001], and FEV1 %predicted (r = -0.40, p = 0.002), but not with FVC %predicted (r = -0.26, p = 0.057) and peak expiratory flow %predicted (r = -0.16, p = 0.231). Many asthmatics had an elevated VDS, but their spirometric indexes, except FEF25%-75%, were normal. Most ventilation defects were < 3 cm in size for all asthmatics. In the group of patients with moderate-to-severe persistant asthma, there were more defects >= 3 cm than in the group with mild-intermittent and mild-persistent disease (p = 0.021). Conclusions: Regional changes of airflow obstruction in asthmatics depicted by (HHeMR)-He-3 correlate with measures of asthma severity and spirometry.	Univ Virginia, Dept Radiol, Charlottesville, VA USA; Univ Virginia, Dept Hlth Evaluat Sci, Charlottesville, VA USA; Univ Virginia, Dept Internal Med, Div Asthma Allergy & Immunol, Charlottesville, VA USA	de Lange, EE (reprint author), Univ Virginia Hlth Sci Syst, Dept Radiol, HSC 800170, Charlottesville, VA 22908 USA.	delange@virginia.edu	Mugler, John/B-9432-2013	Mugler, John/0000-0002-4140-308X	NHLBI NIH HHS [HL66479]		AGNEW JE, 1984, CLIN SCI, V66, P525; Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; ALTES TA, 2002, P RSNA 88 M, P347; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; BATTISTON JJ, 2005, P RSNA 91 M, P241; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; de Lange EE, 1999, RADIOLOGY, V210, P851; DELANGE EE, 2003, P 89 SCI ASS ANN M R, P525; Donnelly LF, 1999, RADIOLOGY, V212, P885; Fonseca-Guedes CHF, 2003, PEDIATR PULM, V36, P49, DOI 10.1002/ppul.10309; GAARE J, 2004, P 90 SCI ASS ANN M R, P514; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Guenther D, 2000, NMR BIOMED, V13, P182, DOI 10.1002/1099-1492(200006)13:4<182::AID-NBM642>3.0.CO;2-N; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; HODSON ME, 1974, THORAX, V29, P296, DOI 10.1136/thx.29.3.296; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Kauczor HU, 1996, RADIOLOGY, V201, P564; Kavuru MS, 1999, CLIN CHEST MED, V20, P153, DOI 10.1016/S0272-5231(05)70133-7; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; MacFall JR, 1996, RADIOLOGY, V200, P553; McAdams HP, 1999, AM J ROENTGENOL, V173, P955; Mentore K, 2005, ACAD RADIOL, V12, P1423, DOI 10.1016/j.acra.2005.07.008; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; Miller LA, 2005, CLIN EXP ALLERGY, V35, P894, DOI 10.1111/j.1365-2222.2005.02271.x; Mitsunobu F, 2003, EUR RESPIR J, V22, P106, DOI 10.1183/09031936.03.00081702; MITSUNOBU F, 2002, THORAX, V57, P851; Mugler JP, 1997, MAGNET RESON MED, V37, P809, DOI 10.1002/mrm.1910370602; National Asthma Education and Prevention Program, 1997, PUBL NAT ASTHM ED PR; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; PETHERAM IS, 1981, CLIN RADIOL, V32, P281, DOI 10.1016/S0009-9260(81)80039-6; Petty TL, 2001, CLIN CHEST MED, V22, P845, DOI 10.1016/S0272-5231(05)70070-8; Salerno M, 2002, RADIOLOGY, V222, P252; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Swift AJ, 2005, EUR J RADIOL, V54, P352, DOI 10.1016/j.ejrad.2004.08.002; van Beek EJR, 2004, J MAGN RESON IMAGING, V20, P540, DOI 10.1002/jmri.20154; VERNON P, 1986, EUR J NUCL MED, V12, P16, DOI 10.1007/BF00638789; Woodhouse N, 2005, J MAGN RESON IMAGING, V21, P365, DOI 10.1002/jmri.20290; Zaporozhan J, 2004, CHEST, V125, P173, DOI 10.1378/chest.125.1.173	40	134	137	2	7	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	OCT	2006	130	4					1055	1062		10.1378/chest.130.4.1055		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	094UX	WOS:000241265700022	17035438	
J	Gurney, JG; McPheeters, ML; Davis, MM				Gurney, James G.; McPheeters, Melissa L.; Davis, Matthew M.			Parental report of health conditions and health care use among children with and without autism - National Survey of Children's Health	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							SPECTRUM DISORDERS; GASTROINTESTINAL DISORDERS; TUBEROUS SCLEROSIS; MEDICAL CONDITIONS; PREVALENCE TRENDS; ASPERGER-SYNDROME; ABNORMALITIES; EPILEPSY; DISABILITIES; INDIVIDUALS	Objective: To compare parent-reported prevalence of health conditions and health care use between children with and without autism. Design: Cross-sectional analysis of the 2003 to 2004 National Survey of Children's Health. Setting: Population-based sample across the United States. Participants: More than 100 000 parents. The main exposure was "autism" (not further defined), from response to the question: "Has a doctor or health professional ever told you that your child has autism?" Main Outcome Measures: Medical and mental health conditions and measures of health care use. Results: Autism prevalence among children aged 3 to 17 years was 53 per 10 000 (95% confidence interval, 45-61 per 10 000), equating to a national estimate of 324 000 children (95% confidence interval, 274 000-375 000 children). Children with autism had a significantly (P <.001) higher prevalence of depression or anxiety problems (38.9% vs 4.2%) and behavioral or conduct problems (58.9% vs 5.2%) than children without autism. Respiratory, food, and skin allergies were reported by parents more often for children with autism, with food allergies having the strongest relative difference between the groups (odds ratio, 4.5; 95% confidence interval, 3.0-7.0). Children with autism had significantly (P <.001) higher mean physician visits over 12 months for preventive care, nonemergency care, and hospital emergency care, and were far more likely than children without autism to receive physical, occupational, or speech therapy (76.0% vs 6.3%), to need treatment or counseling for an emotional, developmental, or behavioral problem (75.4% vs 7.0%), and, among those taking a prescribed medication, to be using a medication long-term (51.4% vs 14.5%). Conclusion: We found markedly higher reports of concurrent conditions and health care use associated with childhood autism in this study.	Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit, Ann Arbor, MI 48109 USA; Univ Michigan, Gerald R Ford Sch Publ Policy, Div Gen Internal Med, Ann Arbor, MI 48109 USA	Gurney, JG (reprint author), Univ Michigan, Dept Pediat, Child Hlth Evaluat & Res Unit, 300 N Ingalls St,Room 6E02, Ann Arbor, MI 48109 USA.	jamegurn@umich.edu					*AM AC PED, 2002, PEDIATRICS, V7, P1221; *AM AC PED COUNC C, 2005, PEDIATRICS, V116, P1268; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Baker P, 1998, J AUTISM DEV DISORD, V28, P279, DOI 10.1023/A:1026004501631; Barton M, 1998, J AUTISM DEV DISORD, V28, P273, DOI 10.1023/A:1026052417561; Black C, 2002, BRIT MED J, V325, P419, DOI 10.1136/bmj.325.7361.419; Canitano R, 2005, J CHILD NEUROL, V20, P27, DOI 10.1177/08830738050200010401; Castillo M, 2005, ACAD RADIOL, V12, P533, DOI 10.1016/j.acra.2005.02.012; Cooley WC, 2004, CURR OPIN PEDIATR, V16, P689, DOI 10.1097/01.mop.0000146440.79293.5b; Danielsson S, 2005, EPILEPSIA, V46, P918, DOI 10.1111/j.1528-1167.2005.57504.x; Duan N, 1983, J EC BUSINESS STATIS, V1, P115; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Ghaziuddin M, 1998, J INTELL DISABIL RES, V42, P279; Ghaziuddin M, 2002, J AUTISM DEV DISORD, V32, P299, DOI 10.1023/A:1016330802348; GHAZLUDDIN M, 2005, MENTAL HLTH ASPECTS, P109; Gillberg C, 2000, ACTA PSYCHIAT SCAND, V102, P321, DOI 10.1034/j.1600-0447.2000.102005321.x; Gillberg C, 1996, DEV MED CHILD NEUROL, V38, P191; GILLBERG IC, 1994, DEV MED CHILD NEUROL, V36, P50; Goldstein S, 2004, J AUTISM DEV DISORD, V34, P329, DOI 10.1023/B:JADD.0000029554.46570.68; Gurney JG, 2003, ARCH PEDIAT ADOL MED, V157, P622, DOI 10.1001/archpedi.157.7.622; Harrison J, 2004, J AUTISM DEV DISORD, V34, P727, DOI 10.1007/s10803-004-5293-z; Hastings RP, 2005, RES DEV DISABIL, V26, P456, DOI 10.1016/j.ridd.2004.10.003; Horvath K, 2002, CURR OPIN PEDIATR, V14, P583, DOI 10.1097/01.MOP.0000030221.71203.46; Kielinen M, 2004, AUTISM, V8, P49, DOI 10.1177/1362361304040638; Kuddo T, 2003, CURR OPIN PEDIATR, V15, P339, DOI 10.1097/00008480-200306000-00020; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Malow BA, 2004, MENT RETARD DEV D R, V10, P122, DOI 10.1002/mrdd.20023; Molloy CA, 2003, AUTISM, V7, P165, DOI 10.1177/1362361303007002004; *NCHS, 2004, HLTH US 2004 CHARTB; Newschaffer CJ, 2005, PEDIATRICS, V115, pE277, DOI 10.1542/peds.2004-1958; ONeill M, 1997, J AUTISM DEV DISORD, V27, P283, DOI 10.1023/A:1025850431170; RUTTER M, 1994, J CHILD PSYCHOL PSYC, V35, P311, DOI 10.1111/j.1469-7610.1994.tb01164.x; RUTTER M, 1983, J CHILD PSYCHOL PSYC, V24, P513, DOI 10.1111/j.1469-7610.1983.tb00129.x; Sturm H, 2004, DEV MED CHILD NEUROL, V46, P444, DOI 10.1017/S0012162204000738; Yeargin-Allsopp M, 2003, JAMA-J AM MED ASSOC, V289, P49, DOI 10.1001/jama.289.1.49	35	134	134	2	21	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	AUG	2006	160	8					825	830		10.1001/archpedi.160.8.825		6	Pediatrics	Pediatrics	071BX	WOS:000239573400010	16894082	
J	Greinacher, A; Lubenow, N; Eichler, P				Greinacher, A; Lubenow, N; Eichler, P			Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia	CIRCULATION			English	Article						hirudin; antibodies; anticoagulants; shock, anaphylactic	RECOMBINANT HIRUDIN; ANTIHIRUDIN ANTIBODIES; CLINICAL-RELEVANCE; R-HIRUDIN; ANTICOAGULATION; IGE	Background - Lepirudin (Refludan) is a hirudin derivative. It is a direct thrombin inhibitor obtained by recombinant technology from the medicinal leech and is approved for treatment of heparin-induced thrombocytopenia complicated by thrombosis. Because 3 cases of fatal anaphylaxis possibly associated with use of lepirudin have been reported, we initiated an investigation of putative lepirudin-associated anaphylaxis. Methods and Results - Aided by the manufacturer (Schering AG, Berlin, Germany), we used the lepirudin study databases to identify all patients in whom possible anaphylaxis/severe allergy was recorded from 1994 to September 2002. The 26 possible cases identified were reviewed independently by 2 investigators. After excluding patients with mild skin reactions, reactions likely caused by concomitant medications, poorly documented cases, and reactions that did not correspond temporally with lepirudin use, there remained 9 patients judged to have had severe anaphylaxis in close temporal association with lepirudin. All reactions occurred within minutes of intravenous lepirudin administration, with 4 fatal outcomes (3 acute cardiorespiratory arrests, 1 hypotension-induced myocardial infarction). In these 4 cases, a previous uneventful treatment course with lepirudin was identified (1 to 12 weeks earlier). We recorded high-titer IgG-anti-lepirudin antibodies in an additional patient with anaphylaxis. Because lepirudin has been used in approximate to35 000 patients, the risk of anaphylaxis is approximate to0.015% (5 of 32 500) on first exposure and 0.16% (4 of 2500) in reexposed patients (7.5% estimated reexposures). Conclusion - Lepirudin can cause fatal anaphylaxis, particularly in patients who are treated within 3 months of a previous exposure. The overall risk/benefit assessment of lepirudin as a treatment for heparin-induced thrombocytopenia remains favorable.	Univ Greifswald, Inst Immunol & Transfus Med, D-17489 Greifswald, Germany; Berlex Inc, Wayne, NJ 07470 USA	Greinacher, A (reprint author), Univ Greifswald, Inst Immunol & Transfus Med, Klinikum Sauerbruchstr, D-17489 Greifswald, Germany.						Bircher AJ, 1996, J ALLERGY CLIN IMMUN, V98, P994, DOI 10.1016/S0091-6749(96)80018-2; CLOSE P, 1994, CORONARY ARTERY DIS, V5, P943; Eichler P, 2000, BLOOD, V96, P2373; Greinacher A, 2003, BLOOD, V101, P2617, DOI 10.1182/blood-2002-04-1055; Greinacher A, 1999, CIRCULATION, V100, P587; Greinacher A, 1999, CIRCULATION, V99, P73; Greinacher A, 2001, CIRCULATION, V103, P1479; Harenberg J, 2000, BRIT J HAEMATOL, V108, P528; Huhle G, 1999, BRIT J HAEMATOL, V106, P195; KRAFT D, 1982, ALLERGY, V37, P481, DOI 10.1111/j.1398-9995.1982.tb02331.x; PROEBSTLE TM, 1995, J ALLERGY CLIN IMMUN, V95, P1059, DOI 10.1016/S0091-6749(95)70111-7; Song XH, 1999, CIRCULATION, V100, P1528; Warkentin TE, 1998, THROMB HAEMOSTASIS, V79, P1; WEISS ME, 1989, NEW ENGL J MED, V320, P886, DOI 10.1056/NEJM198904063201402	14	134	138	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0009-7322			CIRCULATION	Circulation	OCT 28	2003	108	17					2062	2065		10.1161/01.CIR.0000096056.37269.14		4	Cardiac & Cardiovascular Systems; Peripheral Vascular Disease	Cardiovascular System & Cardiology	736TT	WOS:000186189800006	14568897	
J	Skoner, DP; Rachelefsky, GS; Meltzer, EO; Chervinsky, P; Morris, RM; Seltzer, JM; Storms, WW; Wood, RA				Skoner, DP; Rachelefsky, GS; Meltzer, EO; Chervinsky, P; Morris, RM; Seltzer, JM; Storms, WW; Wood, RA			Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate	PEDIATRICS			English	Article						beclomethasone dipropionate; intranasal corticosteroids; growth; allergic rhinitis; pediatric	ADRENAL AXIS SUPPRESSION; ALLERGIC RHINITIS; THERAPEUTIC EFFICACY; PREPUBERTAL CHILDREN; ASTHMATIC-CHILDREN; SHORT-TERM; BUDESONIDE; GLUCOCORTICOSTEROIDS; CORTICOSTEROIDS; PLACEBO	Objective. Intranasal beclomethasone dipropionate (BDP) has generally been considered to have no systemic activity at recommended doses, but the potential for long-term effects on growth has not previously been evaluated. This study was undertaken to assess the effects of 1 year of treatment with intranasal BDP on growth in children. Study Design. In this double-blind, randomized, parallel- group study, 100 prepubertal children 6 to 9 years old with perennial allergic rhinitis were treated with aqueous BDP 168 mu g twice daily (n = 51) or placebo (n = 49) for 1 year. Subjects' baseline heights were required to be between the 5th and 95th percentile, and skeletal age as determined by left wrist radiograph was required to be within 2 years of chronological age. Washout periods for medications known to affect growth, including other forms of corticosteroids, were established, and these medications were prohibited during the study. However, short courses of oral prednisolone lasting no more than 7 days, and short courses of dermatologic corticosteroids lasting no more than 10 days, were allowed. Height was measured with a stadiometer after 1, 2, 4, 6, 8, 10, and 12 months of treatment. The hypothalamic-pituitary-adrenocortical axis was assessed by measurements of 8 AM basal cortisol concentrations and response to .25 mg cosyntropin stimulation. The primary safety parameter was the rate of change in standing height. Statistical analyses were based on all randomized subjects who received at least 1 dose of medication (intent-to-treat principle). The rate of change in standing height was analyzed for all subjects who entered the study and for those completing the full 12 months of treatment (n = 80). The rate of change in standing height over the 1-year study was calculated as the slope of a linear regression line fitted to each subject's height measurements over time. Because there was a statistically significant between-group difference in standing height at baseline, an analysis of covariance was performed for all analyses of standing height data. Results. Of the 100 subjects enrolled, 90 completed the study. The 2 treatment groups were generally comparable at baseline; however, at baseline, mean age and mean height were significantly greater in the BDP treatment group that the in placebo treatment group. In both analyses, overall growth rate was significantly slower in BDP-treated subjects than placebo-treated subjects. The mean change in standing height after 1 year was 5.0 cm in the BDP-treated subjects compared with 5.9 cm in the placebo-treated subjects. The difference in growth rates was evident as early as the 1-month treatment visit, suggesting that the effect on growth occurred initially. The growth-suppressive effect of BDP remained consistent across all age and gender subgroups, and among subjects with and without a previous history of corticosteroid use. Use of additional exogenous corticosteroids during the study was similar in both groups and did not affect the results. Because there was a baseline imbalance in height, a supplemental analysis of the differences in prestudy growth rates was performed. This analysis found no baseline imbalance in prestudy growth rates. To determine whether the difference in growth rates during the study could be attributed to preexisting growth rates, a z score analysis was performed. The heights of both groups were normalized at baseline and at the end of the study using the US National Center for Health Statistics data for mean and standard deviations of height. This analysis confirmed that the difference in growth rates between the 2 groups was primarily attributable to the treatment rather than to any preexisting difference in growth. Additional analyses confirmed that the results were not influenced by outlier values. No significant between-group difference were found in the hypothalamic-pituitary-adrenocortical axis assessments. No unusual adverse events were observed. No evidence of other systemic effects of BDP was found, including analysis for fluid and electrolyte imbalances; alterations in protein, lipid, or carbohydrate metabolism; alterations in formed elements in blood; and alterations in differential white blood cell counts, including eosinophils. Conclusions. Additional study is warranted to define the clinical relevance of these findings. This study suggests, however, that intranasal BDP may slow growth rate in children without suppressing basal 6 AM cortisol concentrations or the response to cosyntropin stimulation, which are commonly used clinically to test for adrenal suppression. The effect on final height is unknown. Alterative explantations for the finding of drug-induced growth suppression, including the possibility that the results were affected by either differences in height and age at baseline between the 2 groups or by outlier values, were discounted upon additional analysis. The results of this study were considered by the Food and Drug Administration in the development of recently proposed new class labeling for all inhaled and intranasal corticosteroids, which states that these agents may cause a reduction in growth velocity in pediatric patients (see reference 21). However, both the Food and Drug Administration and several professional bodies in the United States concur that, depending on disease severity, the benefits of intranasal corticosteroid therapy may outweigh the risks (see reference 22). Because the effect, if any, on final height in not known, the height of children receiving long-term therapy should be monitored periodically during treatment, and should be plotted on a growth or growth-velocity chart to monitor for growth suppression. To minimize the risks of systemic corticosteroid exposure, including growth suppresson, dose-reduction strategies should be considered. For patients who concomitantly receive exogenous corticosteroids via other routes for other conditions, such as inhaled corticosteroids for asthma, clinicians should consider the total corticosteroid exposure and titrate each patient to the lowest effective dose. Clinicians should also consider each medication's potential for systemic effects when selecting among the various available corticosteroids.	Childrens Hosp, Pittsburgh, PA 15231 USA; Allergy Res Fdn, Los Angeles, CA USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; New England Res Ctr, N Dartmouth, MA USA; Park Nicollet Med Ctr, Minneapolis, MN USA; Clin Res Inst, San Diego, CA USA; Asthma & Allergy Associates, Colorado Springs, CO USA; Pediat Consultants, Lutherville Timonium, MD USA	Skoner, DP (reprint author), Childrens Hosp, 3705 5th Ave, Pittsburgh, PA 15231 USA.						BALFOURLYNN L, 1986, ARCH DIS CHILD, V61, P1049; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; Chervinsky P, 1996, CLIN THER, V18, P790, DOI 10.1016/S0149-2918(96)80039-7; Chrousos GP, 1998, NEUROIMMUNOMODULAT, V5, P288, DOI 10.1159/000026349; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Edwards TB, 1995, CLIN THER, V17, P1032, DOI 10.1016/0149-2918(95)80082-4; KARLBERG J, 1993, ACTA PAEDIATR, V82, P631, DOI 10.1111/j.1651-2227.1993.tb18029.x; Lipworth BJ, 1997, THORAX, V52, P476; Meltzer EO, 1998, CLIN PEDIATR, V37, P1, DOI 10.1177/000992289803700101; Montgomery SM, 1997, ARCH DIS CHILD, V77, P326; OBERGER E, 1990, ACTA PAEDIATR SCAND, V79, P77, DOI 10.1111/j.1651-2227.1990.tb11335.x; Patel L, 1998, ARCH DIS CHILD, V79, P169; RACHELEFSKY GS, 1998, J ALLERGY CLIN IMMUN, P101; Saha MT, 1997, ACTA PAEDIATR, V86, P138, DOI 10.1111/j.1651-2227.1997.tb08854.x; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; TANNER JM, 1985, J PEDIATR-US, V107, P317, DOI 10.1016/S0022-3476(85)80501-1; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688; Wihl JA, 1997, ALLERGY, V52, P620, DOI 10.1111/j.1398-9995.1997.tb01040.x; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V101, P470, DOI 10.1016/S0091-6749(98)70354-9; WOLTHERS OD, 1992, ACTA PAEDIATR, V81, P902, DOI 10.1111/j.1651-2227.1992.tb12132.x; WOLTHERS OD, 1994, ALLERGY, V49, P96, DOI 10.1111/j.1398-9995.1994.tb00807.x; WOLTHERS OD, 1993, ACTA PAEDIATR, V82, P635, DOI 10.1111/j.1651-2227.1993.tb18030.x; 1998, ACAAI MEMBER AL 1116; 1998, FDA TALK PAPER  1109	27	134	142	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2000	105	2					art. no.	e23		10.1542/peds.105.2.e23		7	Pediatrics	Pediatrics	280ML	WOS:000085106500006	10654983	
J	Sorkness, RL; Bleecker, ER; Busse, WW; Calhoun, WJ; Castro, M; Chung, KF; Curran-Everett, D; Erzurum, SC; Gaston, BM; Israel, E; Jarjour, NN; Moore, WC; Peters, SP; Teague, WG; Wenzel, SE				Sorkness, Ronald L.; Bleecker, Eugene R.; Busse, William W.; Calhoun, William J.; Castro, Mario; Chung, Kian Fan; Curran-Everett, Douglas; Erzurum, Serpil C.; Gaston, Benjamin M.; Israel, Elliot; Jarjour, Nizar N.; Moore, Wendy C.; Peters, Stephen P.; Teague, W. Gerald; Wenzel, Sally E.		Natl Heart Lung Blood Inst Severe	Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						airway closure; difficult asthma; fixed obstruction	CHRONIC PERSISTENT ASTHMA; ELASTIC RECOIL; NOCTURNAL ASTHMA; FLOW OBSTRUCTION; RESEARCH-PROGRAM; REFERENCE VALUES; RESIDUAL VOLUME; EXPIRATORY FLOW; SMOOTH-MUSCLE; DISTAL LUNG	Five to ten percent of asthma cases are poorly controlled chronically and refractory to treatment, and these severe cases account for disproportionate asthma-associated morbidity, mortality, and health care utilization. While persons with severe asthma tend to have more airway obstruction, it is not known whether they represent the severe tail of a unimodal asthma population, or a severe asthma phenotype. We hypothesized that severe asthma has a characteristic physiology of airway obstruction, and we evaluated spirometry, lung volumes, and reversibility during a stable interval in 287 severe and 382 nonsevere asthma subjects from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. We partitioned airway obstruction into components of air trapping [indicated by forced vital capacity (FVC)] and airflow limitation [indicated by forced expiratory volume in 1 s (FEV1)/FVC]. Severe asthma had prominent air trapping, evident as reduced FVC over the entire range of FEV1/FVC. This pattern was confirmed with measures of residual lung volume/total lung capacity (TLC) in a subgroup. In contrast, nonsevere asthma did not exhibit prominent air trapping, even at FEV1/FVC <75% predicted. Air trapping also was associated with increases in TLC and functional reserve capacity. After maximal bronchodilation, FEV1 reversed similarly from baseline in severe and nonsevere asthma, but the severe asthma classification was an independent predictor of residual reduction in FEV1 after maximal bronchodilation. An increase in FVC accounted for most of the reversal of FEV1 when baseline FEV1 was <60% predicted. We conclude that air trapping is a characteristic feature of the severe asthma population, suggesting that there is a pathological process associated with severe asthma that makes airways more vulnerable to this component.	[Sorkness, Ronald L.; Busse, William W.; Jarjour, Nizar N.] Univ Wisconsin, Madison, WI 53705 USA; [Bleecker, Eugene R.; Moore, Wendy C.; Peters, Stephen P.] Wake Forest Univ, Winston Salem, NC 27109 USA; [Calhoun, William J.] Univ Pittsburgh, Pittsburgh, PA USA; [Calhoun, William J.] Univ Texas Galveston, Med Branch, Galveston, TX 77550 USA; [Castro, Mario] Washington Univ, St Louis, MO USA; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, London, England; [Curran-Everett, Douglas; Wenzel, Sally E.] Natl Jewish Med & Res Ctr, Denver, CO USA; [Erzurum, Serpil C.] Cleveland Clin, Cleveland, OH 44106 USA; [Gaston, Benjamin M.] Univ Virginia, Charlottesville, VA USA; [Israel, Elliot] Brigham & Womens Hosp, Boston, MA 02115 USA; [Teague, W. Gerald] Emory Univ, Atlanta, GA 30322 USA	Sorkness, RL (reprint author), Univ Wisconsin, 777 Highland Ave, Madison, WI 53705 USA.	rlsorkne@wisc.edu		Chung, Kian Fan/0000-0001-7101-1426	NCATS NIH HHS [UL1 TR000005]; NCRR NIH HHS [M01-RR-007122-14, M01-RR-018390, M01-RR-03186]; NHLBI NIH HHS [HL-69116, HL-69130, HL-69149, HL-69155, HL-69167, HL-69170, HL-69174, HL-69349]		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Brown RH, 2006, J APPL PHYSIOL, V101, P30, DOI 10.1152/japplphysiol.01190.2005; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Cassino C, 2000, AM J RESP CRIT CARE, V162, P1423; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V117, P1244, DOI 10.1016/j.jaci.2006.02.038; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778; Gelb AF, 2002, CHEST, V121, P715, DOI 10.1378/chest.121.3.715; Gibbons WJ, 1996, AM J RESP CRIT CARE, V153, P582; GOLD WM, 1967, J APPL PHYSIOL, V23, P433; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hill MJ, 1997, J APPL PHYSIOL, V82, P233; In't Veen CCM, 2000, AM J RESP CRIT CARE, V161, P1902; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50; Jarjour NN, 1999, AM J RESP CRIT CARE, V160, P336; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179; KAMM RD, 1989, RESP PHYSIOL, V75, P141, DOI 10.1016/0034-5687(89)90059-5; King GG, 1998, AM J RESP CRIT CARE, V158, P1900; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551; LEITH DE, 1967, J APPL PHYSIOL, V23, P221; Lutchen KR, 2001, AM J RESP CRIT CARE, V164, P207; Mackay LG, 2003, ACCREDIT QUAL ASSUR, V8, P191, DOI 10.1007/s00769-003-0622-z; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; MCCARTHY DS, 1980, THORAX, V35, P298, DOI 10.1136/thx.35.4.298; MEAD J, 1967, J APPL PHYSIOL, V22, P95; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; PRIDE NB, 1967, J APPL PHYSIOL, V23, P646; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; STOCKS J, 1995, EUR RESPIR J, V8, P492, DOI 10.1183/09031936.95.08030492; STREK ME, 2001, AM J RESP CRIT CARE, V164, P744; Verbanck S, 2003, J APPL PHYSIOL, V94, P1380, DOI 10.1152/japplphysiol.00588.2002; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; Wagers SS, 2004, J CLIN INVEST, V114, P104, DOI 10.1172/JC1200419569; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; WEMPE JB, 1992, J ALLERGY CLIN IMMUN, V89, P679, DOI 10.1016/0091-6749(92)90374-B; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788	51	133	137	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	FEB	2008	104	2					394	403		10.1152/japplphysiol.00329.2007		10	Physiology; Sport Sciences	Physiology; Sport Sciences	260PO	WOS:000253022500010	17991792	
J	Camargo, CA; Clark, S; Kaplan, MS; Lieberman, P; Wood, RA				Camargo, Carlos A., Jr.; Clark, Sunday; Kaplan, Michael S.; Lieberman, Philip; Wood, Robert A.			Regional differences in EpiPen prescriptions in the United States: The potential role of vitamin D	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; epidemiology; EpiPen; vitamin D	REGULATORY T-CELLS; SUN EXPOSURE; ANAPHYLAXIS; EPIDEMIOLOGY; POPULATION; ALLERGY; MELANOMA; CHILDREN; RISK; D-3	Background: The epidemiology of anaphylaxis is uncertain, especially its geographic distribution. Objective: To address this deficit, we examined regional rates of EpiPen prescriptions in the United States. Methods: EpiPen prescriptions in 2004 were obtained for all 50 states and Washington, DC, from NDCHealth, Pharmaceutical Audit Suite (Alpharetta, Ga). Data included the number of total filled prescriptions, including refills, and the actual number of EpiPens prescribed. Several data sets were used to obtain state-specific populations, as well as multiple demographic, health, and weather characteristics. State population was used to calculate the average number of prescriptions written per person. Results: Overall, there were 1,511,534 EpiPen prescriptions filled during 2004. These prescriptions accounted for 2,495,188 EpiPens. On average, there were 5.71 EpiPens prescribed per 1000 persons. Massachusetts had the highest number of prescriptions per 1000 persons (11.8), whereas Hawaii had the lowest (2.7). In addition to state-to-state variation, there was an obvious regional difference: New England (Connecticut, Rhode Island, Massachusetts, Vermont, New Hampshire, Maine) had the highest values, with 8 to 12 EpiPen prescriptions per 1000 persons, whereas the southern states (between and including California and Mississippi) had only 3 prescriptions per 1000 persons. The New England finding persisted even when controlling for all available factors (eg, population demographic characteristics, number of health care providers, prescriptions for other medications). Conclusion: A strong north-south gradient was observed for the prescription of EpiPens in the United States, with the highest rates found in New England. Clinical implications: The regional differences in EpiPen prescribing may provide important etiologic clues (vitamin D status) and merit further investigation.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr D Receptor Activat Res, Boston, MA 02114 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Kaiser Permanente, Dept Allergy, Los Angeles, CA USA; Univ Tennessee, Coll Med, Memphis, TN 38163 USA; Johns Hopkins Med Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD USA	Camargo, CA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr D Receptor Activat Res, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Annesi-Maesano I, 2002, PEDIATR RES, V52, P3, DOI 10.1023/01.PDR/0000017228.29635.EF; Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown SJ, 2006, ANN PHARMACOTHER, V40, P1158, DOI 10.1345/aph.1G513; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S; Centers for Disease Control and Prevention, 2006, BEH RISK FACT SURV S; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hernan MA, 1999, NEUROLOGY, V53, P1711; Hollis BW, 2005, J NUTR, V135, P317; Ivry GB, 2006, DERMATOL SURG, V32, P481, DOI 10.1111/j.1524-4725.2006.32101.x; Jemal A, 2004, CA-CANCER J CLIN, V54, P8; Lieberman P, 2006, ANN ALLERG ASTHMA IM, V97, P596; Lin R, 2004, BIOESSAYS, V26, P21, DOI 10.1002/bies.10368; MEEHAN MA, 1992, CELL IMMUNOL, V140, P400, DOI 10.1016/0008-8749(92)90206-5; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; Oliveria SA, 2006, ARCH DIS CHILD, V91, P131, DOI 10.1136/adc.2005.086918; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1023/01.PDR.0000017267.23950.48; Feldman D, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P1; Schwartz RH, 2005, NAT IMMUNOL, V6, P327, DOI 10.1038/ni1184; Simons FER, 2002, J ALLERGY CLIN IMMUN, V110, P647, DOI 10.1067/mai.2002.127860; Thomas MK, 1998, NEW ENGL J MED, V338, P777, DOI 10.1056/NEJM199803193381201; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; 2006, US CENSUS BUREAU WEB; 2006, NOAA WEB SITE	29	133	135	1	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					131	136		10.1016/j.jaci.2007.03.049		6	Allergy; Immunology	Allergy; Immunology	190NS	WOS:000248066400019	17559916	
J	Kozyrskyj, AL; Ernst, P; Becker, AB				Kozyrskyj, Anita L.; Ernst, Pierre; Becker, Allan B.			Increased risk of childhood asthma from antibiotic use in early life	CHEST			English	Article						antibacterial agents; asthma; child; infant	INTESTINAL MICROFLORA; ATOPIC-DERMATITIS; 1ST YEAR; ALLERGIC DISEASE; ORAL ANTIBIOTICS; SWEDISH INFANTS; BIRTH COHORT; SCHOOL-AGE; CHILDREN; EXPOSURE	Background: To address the major methodological issues of reverse causation and selection bias in epidemiologic studies of antibiotic use in early life and the development of asthma, we undertook a cohort study of this association in a complete population of children. Methods: Using the health-care and prescription databases of Manitoba, Canada, this longitudinal study assessed the association between antibiotic prescription use during the first year of life and asthma at age 7 years in a 1995 birth cohort of 13,116 children. Results: Independent of well-known asthma risk factors, asthma was significantly more likely to develop in children who had received antibiotics in the first year of life at age 7 years. The association with asthma was observed for antibiotic use in non-respiratory tract infections (adjusted odds ratio [OR], 1.86; 95% confidence interval [CI], 1.02 to 3.37). The risk of asthma was highest in children receiving more than four courses of antibiotics (adjusted OR, 1.46; 95% CI, 1.14 to 1.88), especially among rural children, and in the absence of maternal asthma or a dog in the birth year. Broad-spectrum (BS) cephalosporin use was more common in these sub-populations of children. Conclusions: Antibiotic use in early life was associated with the development of childhood asthma, a risk that may be reduced by avoiding the use of BS cephalosporins.	Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; Royal Victoria Hosp, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB, Canada	Kozyrskyj, AL (reprint author), 210 Pharm Bldg, Winnipeg, MB R3T 2N2, Canada.	kozyrsk@cc.umanitoba.ca					Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bennet R, 2002, INFECTION, V30, P158, DOI 10.1007/s15010-002-2140-z; BENNET R, 1991, SCAND J INFECT DIS, V23, P63, DOI 10.3109/00365549109023376; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Bonnemaison E, 2003, BIOL NEONATE, V84, P304, DOI 10.1159/000073639; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Edlund C, 2000, J ANTIMICROB CHEMOTH, V46, P41, DOI 10.1093/jac/46.suppl_1.41; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Farooqi IS, 1998, THORAX, V53, P927; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kozyrskyj AL, 2004, CAN MED ASSOC J, V171, P133, DOI 10.1503/cmaj.1031630; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; KOZYRSKYJ AL, 2005, J ALLERGY CLIN IMMUN, V115, P173; KOZYRSKYJ AL, 2005, ALLERGY ASTHMA CLIN, V1, P108; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; MARTINEZ F, 1999, LANCET S2, V354, P112; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mattes J, 1999, CLIN EXP ALLERGY, V29, P729; McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Noverr MC, 2005, CLIN EXP ALLERGY, V35, P1511, DOI 10.1111/j.1365-2222.2005.02379.x; Noverr MC, 2005, INFECT IMMUN, V73, P30, DOI 10.1128/IAI.73.1.30-38.2005; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Robinson JR, 1997, MED CARE, V35, P932, DOI 10.1097/00005650-199709000-00006; Schumann A, 2005, PHYSIOL GENOMICS, V23, P235, DOI 10.1152/physiolgenomics.00057.2005; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Thomas M, 2006, PEDIATR ALLERGY IMMU, V17, P184, DOI 10.1111/j.1399-3038.2006.00389.x; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Voor T, 2005, CLIN EXP ALLERGY, V35, P153, DOI 10.1111/j.1365-2222.2005.02157.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766	50	133	152	2	19	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2007	131	6					1753	1759		10.1378/chest.06-3008		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	180CD	WOS:000247336600023	17413050	
J	von Mutius, E				von Mutius, Erika			Allergies, infections and the hygiene hypothesis - The epidemiological evidence	IMMUNOBIOLOGY			English	Article						hygiene hypothesis; epidemiology; allergy; infection	EARLY BCG VACCINATION; SCHOOL-AGE-CHILDREN; DAY-CARE ATTENDANCE; ATOPIC DISEASE; BIRTH COHORT; EARLY-LIFE; FARMERS CHILDREN; EARLY-CHILDHOOD; HAY-FEVER; 1ST YEAR	The 'hygiene hypothesis' was first proposed by Strachan in 1989 suggesting that infections and unhygienic contact with older siblings or through other exposures may confer protection from the development of allergic illnesses. This hypothesis has evolved in various ways exploring the role of overt viral and bacterial infections, the significance of environmental exposure to microbial compounds, and their effect on underlying responses of innate and adaptive immunity. So far a truly unifying concept is still lacking, but various pieces of a complex interplay between a host's immune response, characteristics of the invading microorganism, the level and variety of the environmental exposure, and the interactions between a genetic background and a range of exposures become apparent. All these pieces eventually assemble to the clinical presentation of a complex syndrome namely of asthma and allergic illnesses. Even if today practical implications cannot directly be deduced from these findings, there is great potential for the development of novel preventive and therapeutic strategies in the future based on the concepts of the 'hygiene hypothesis'. (C) 2007 Elsevier GmbH. All rights reserved.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany	von Mutius, E (reprint author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Erika.Von.Mutius@med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515			Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BAUER S, 2007, IMMUNOBIOLOGY, V212; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Calvani M, 2002, EUR RESPIR J, V20, P391, DOI 10.1183/09031936.02.00274502; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241; Cullinan P, 2003, EUR RESPIR J, V22, P956, DOI 10.1183/09031936.03.00039102; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Elliott L, 2004, EUR RESPIR J, V24, P938, DOI 10.1183/09031936.04.0006404; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; GARN H, 2007, IMMUNOBIOLOGY, V212; Gruber C, 2002, PEDIATR ALLERGY IMMU, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Henderson J, 2005, PEDIATR ALLERGY IMMU, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jarvis D, 2004, ALLERGY, V59, P1063, DOI 10.1111/j.1398-9995.2004.00539.x; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999; Nja F, 2003, ARCH DIS CHILD, V88, P566, DOI 10.1136/adc.88.7.566; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2004, AM J IND MED, V46, P349, DOI 10.1002/ajim.20000; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Rennie Donna C, 2002, Can Respir J, V9, P313; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; VANRIET E, 2007, IMMUNOBIOLOGY, V212; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x	48	133	134	4	44	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0171-2985			IMMUNOBIOLOGY	Immunobiology		2007	212	6					433	439		10.1016/j.imbio.2007.03.002		7	Immunology	Immunology	185VM	WOS:000247738500002	17544828	
J	Eduard, W; Douwes, J; Omenaas, E; Heederik, D				Eduard, W; Douwes, J; Omenaas, E; Heederik, D			Do farming exposures cause or prevent asthma? Results from a study of adult Norwegian farmers	THORAX			English	Article							RESPIRATORY SYMPTOMS; DANISH FARMERS; HAY-FEVER; ALLERGIC SENSITIZATION; OCCUPATIONAL EXPOSURE; CHRONIC-BRONCHITIS; CHILDREN; PREVALENCE; ENDOTOXIN; DUST	Background: A protective effect of endotoxin exposure on atopy and asthma in farmers' children has been postulated. Studies of adult farmers have shown conflicting results but often lack exposure data. The prevalence of asthma in farmers with different exposure levels to microbial agents and irritant gases was compared. Methods: Atopy was defined as a positive response to multiple radioallergosorbent tests (RAST) with a panel of 10 common respiratory allergens, and asthma was ascertained by a questionnaire using a stratified sample (n = 2169) of a farming population from south-eastern Norway. Exposure of farmers to total dust, fungal spores, bacteria, endotoxins, and ammonia was assessed by exposure measurements. Results: The prevalence of asthma was 3.7% for physician diagnosed asthma and 2.7% for current asthma. The prevalence of atopy was 14%, but most asthmatic subjects were non-atopic (80%). Compared with farmers without livestock, ( 1) asthma was significantly higher in cattle farmers (ORadj 1.8, 95% CI 1.1 to 2.8) and pig farmers (ORadj 1.6, 95% CI 1.0 to 2.5), (2) non-atopic asthma was significantly higher in pig farmers (ORadj 2.0, 95% CI 1.2 to 3.3) and in farmers with two or more types of livestock (ORadj 1.9, 95% CI 1.1 to 3.3), and ( 3) atopic asthma was less common in farmers with two or more types of livestock (ORadj 0.32, 95% CI 0.11 to 0.97). Exposure to endotoxins, fungal spores, and ammonia was positively associated with non-atopic asthma and negatively associated with atopic asthma. No associations were found with atopy. Conclusions: Exposure to endotoxins and fungal spores appears to have a protective effect on atopic asthma but may induce non-atopic asthma in farmers.	Natl Inst Occupat Hlth, N-0033 Oslo, Norway; Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Univ Bergen, Inst Med, N-5020 Bergen, Norway	Eduard, W (reprint author), Natl Inst Occupat Hlth, POB 8149, N-0033 Oslo, Norway.	wijnand.eduard@stami.no		Douwes, Jeroen/0000-0003-3599-4036			BAKKE P, 1990, SCAND J WORK ENV HEA, V16, P195; BAKKE P, 1991, EUR RESPIR J, V4, P273; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Court CS, 2002, THORAX, V57, P951, DOI 10.1136/thorax.57.11.951; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Eduard W, 2001, OCCUP ENVIRON MED, V58, P113, DOI 10.1136/oem.58.2.113; Eduard W, 1988, ANN OCCUP HYG, V32, P447; EDUARD W, 1999, NOR J EPIDEMIOL, V142, P43; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; HAMSTEN MV, 1987, CLIN EXP ALLERGY, V17, P417; Heldal K, 1996, ANN OCCUP HYG, V40, P437, DOI 10.1016/0003-4878(95)00089-5; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; IVERSEN M, 1990, ALLERGY, V45, P347, DOI 10.1111/j.1398-9995.1990.tb00510.x; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Martinez FD, 1999, LANCET S2, V354, pSII12; Melbostad E, 1997, SCAND J WORK ENV HEA, V23, P271; Melbostad E, 2001, AM J IND MED, V39, P209, DOI 10.1002/1097-0274(200102)39:2<209::AID-AJIM1008>3.0.CO;2-5; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Preller L, 1995, SCAND J WORK ENV HEA, V21, P504; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Steenland K, 2000, SCAND J WORK ENV HEA, V26, P37; Toren K, 1996, OCCUP ENVIRON MED, V53, P757; TOREN K, 1991, BRIT J IND MED, V48, P323; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4	33	133	135	0	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY 1	2004	59	5					381	386		10.1136/thx.2004.013326		6	Respiratory System	Respiratory System	815WQ	WOS:000221072800007	15115863	
J	Ryu, JH; Myers, J; Swenson, SJ				Ryu, JH; Myers, J; Swenson, SJ			Bronchiolar disorders	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review						bronchiolitis; bronchiolitis obliterans; organizing pneumonia	INTERSTITIAL LUNG-DISEASE; OBLITERANS ORGANIZING PNEUMONIA; HIGH-RESOLUTION CT; LANGERHANS-CELL HISTIOCYTOSIS; IDIOPATHIC PULMONARY FIBROSIS; RESPIRATORY SYNCYTIAL VIRUS; SMALL AIRWAYS DISEASES; AIR-FLOW OBSTRUCTION; THIN-SECTION CT; DIFFUSE PANBRONCHIOLITIS	Bronchiolar abnormalities are relatively common and occur in a variety of clinical settings. Various histopathologic patterns of bronchiolar injury have been described and have led to confusing nomenclature with redundant and overlapping terms. Some histopathologic patterns of bronchiolar disease may be relatively unique to a specific clinical context but others are nonspecific with respect to either etiology or pathogenesis. Herein, we present a scheme separating (1) those disorders in which the bronchiolar disease is the predominant abnormality (primary bronchiolar disorders) from (2) parenchymal disorders with prominent bronchiolar involvement and (3) bronchiolar involvement in large airway diseases. Primary bronchiolar disorders include constrictive bronchiolitis (obliterative bronchiolitis, bronchiolitis obliterans), acute bronchiolitis, diffuse panbronchiolitis, respiratory bronchiolitis, mineral dust airway disease, follicular bronchiolitis, and a few other rare variants. Prominent bronchiolar involvement may be seen in several interstitial lung diseases, including hypersensitivity pneumonitis, respiratory bronchiolitis-associated interstitial lung disease, cryptogenic organizing pneumonia (idiopathic bronchiolitis obliterans organizing pneumonia), and pulmonary Langerhans' cell histiocytosis. Large airway diseases that commonly involve bronchioles include bronchiectasis, asthma, and chronic obstructive pulmonary disease. The clinical relevance of a bronchiolar lesion is best determined by identifying the underlying histopathologic pattern and assessing the correlative clinico-physiologic-radiologic context.	Mayo Clin, Div Pulm & Crit Care Med, Rochester, MN 55905 USA; Mayo Clin, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Mayo Clin, Dept Radiol, Rochester, MN 55905 USA	Ryu, JH (reprint author), Mayo Clin, Div Pulm & Crit Care Med, Desk E 18,200 1st St SW, Rochester, MN 55905 USA.						AGUAYO SM, 1992, NEW ENGL J MED, V327, P1285, DOI 10.1056/NEJM199210293271806; AKIRA M, 1989, RADIOLOGY, V171, P117; American Thoracic Society European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias, 2002, AM J RESP CRIT CARE, V165, P277; *AM THOR SOC STAT, 1909, AM J RESP CRIT CARE, V158, pS1; Andersen P, 1998, THORAX, V53, P302; Arcasoy SM, 1999, NEW ENGL J MED, V340, P1081, DOI 10.1056/NEJM199904083401406; Aubry MC, 2000, CLIN CHEST MED, V21, P11, DOI 10.1016/S0272-5231(05)70005-8; BAZ MA, 1995, AM J RESP CRIT CARE, V151, P895; Belperio JA, 2002, J IMMUNOL, V169, P1037; Boag AH, 1999, AM J SURG PATHOL, V23, P1539, DOI 10.1097/00000478-199912000-00012; Boehler A, 1996, EUR RESPIR J, V9, P1317, DOI 10.1183/09031936.96.09061317; BOSWELL RT, 1995, J OCCUP ENVIRON MED, V37, P850, DOI 10.1097/00043764-199507000-00015; BREATNACH E, 1982, CLIN RADIOL, V33, P657, DOI 10.1016/S0009-9260(82)80395-4; Brown MJ, 1997, AM J ROENTGENOL, V168, P1561; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; CHANDLER PW, 1986, AM J ROENTGENOL, V147, P899; Chang AB, 1998, PEDIATR RADIOL, V28, P23, DOI 10.1007/s002470050286; CHURG A, 1985, AM REV RESPIR DIS, V131, P139; CHURG A, 1994, DIS BRONCHIOLES, P27; COHEN AJ, 1994, AM J RESP CRIT CARE, V149, P1670; Colby TV, 1998, AM J CLIN PATHOL, V109, P101; Collins J, 1998, AM J ROENTGENOL, V171, P365; COOPER JD, 1993, J HEART LUNG TRANSPL, V12, P714; Cordier JF, 2000, THORAX, V55, P318, DOI 10.1136/thorax.55.4.318; CORRIN B, 1992, CHEST, V102, pS7, DOI 10.1378/chest.102.1_Supplement.7S; CRAWFORD SW, 1993, CLIN CHEST MED, V14, P741; Davies CWH, 2000, CLIN RADIOL, V55, P217, DOI 10.1053/crad.1999.0366; DAVISON AG, 1983, Q J MED, V52, P382; Desai SR, 1997, CLIN RADIOL, V52, P332, DOI 10.1016/S0009-9260(97)80126-2; Elkin SL, 2001, SEM RESP CRIT CARE M, V22, P387, DOI 10.1055/s-2001-17382; EPLER GR, 1983, CHEST, V83, P161, DOI 10.1378/chest.83.2.161; EPLER GR, 1979, JAMA-J AM MED ASSOC, V242, P528, DOI 10.1001/jama.242.6.528; EPLER GR, 1985, NEW ENGL J MED, V312, P152, DOI 10.1056/NEJM198501173120304; EPLER GR, 1992, CHEST S, V102, P2; EPLER GR, 1994, DIS BRONCHIOLES, P27; Estenne M, 2002, AM J RESP CRIT CARE, V166, P440, DOI 10.1164/rccm.200201-003PP; Estenne M, 2002, J HEART LUNG TRANSPL, V21, P297, DOI 10.1016/S1053-2498(02)00398-4; Fitzgerald JE, 1996, AM J RESP CRIT CARE, V154, P497; Forlani S, 2002, SARCOIDOSIS VASC DIF, V19, P47; FORTOUL TI, 1985, LUNG, V163, P305, DOI 10.1007/BF02713828; Fraig M, 2002, AM J SURG PATHOL, V26, P647, DOI 10.1097/00000478-200205000-00011; Franquet T, 1999, EUR RADIOL, V9, P1290, DOI 10.1007/s003300050836; FUJII T, 1995, THORAX, V50, P1246, DOI 10.1136/thx.50.12.1246; FULMER JD, 1977, J CLIN INVEST, V60, P595, DOI 10.1172/JCI108811; GARDINER K, 1993, BRIT J IND MED, V50, P1082; GARG K, 1994, AM J ROENTGENOL, V162, P803; GEDDES DM, 1977, Q J MED, V46, P427; GOSINK BB, 1973, AM J ROENTGENOL, V117, P816; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Hansell DM, 1998, RADIOLOGY, V209, P697; HANSELL DM, 1994, RADIOLOGY, V193, P369; Hansell DM, 1996, RADIOLOGY, V199, P123; Hansell DM, 2001, SEMIN ROENTGENOL, V36, P51, DOI 10.1053/sroe.2001.20463; Harrison AM, 1999, AM J RESP CRIT CARE, V159, P1918; Hartman TE, 1997, RADIOGRAPHICS, V17, P377; Hartman TE, 1996, CHEST, V110, P378, DOI 10.1378/chest.110.2.378; Hayakawa H, 1996, AM J RESP CRIT CARE, V154, P1531; HERZOG CA, 1981, AM REV RESPIR DIS, V124, P636; Heyneman LE, 1999, AM J ROENTGENOL, V173, P1617; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOGG JC, 1993, CLIN CHEST MED, V14, P733; HOLT RM, 1993, J COMPUT ASSIST TOMO, V17, P46; Homma S, 1998, EUR RESPIR J, V12, P444, DOI 10.1183/09031936.98.12020444; Howling SJ, 1999, RADIOLOGY, V212, P637; Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736; IWATA M, 1994, HUM PATHOL, V25, P357, DOI 10.1016/0046-8177(94)90143-0; JENSEN SP, 2002, RADIOLOGY, V57, P1078; Johkoh T, 1999, J COMPUT ASSIST TOMO, V23, P174, DOI 10.1097/00004728-199903000-00003; Johnson BA, 2003, AM J RESP CRIT CARE, V167, P1271, DOI 10.1164/rccm.200205-410OC; Kadota J, 2001, CHEST, V120, P602, DOI 10.1378/chest.120.2.602; Kambouchner M, 2002, AM J RESP CRIT CARE, V166, P1483, DOI 10.1164/rrcm.2201050; KATZENSTEIN ALA, 1986, AM J SURG PATHOL, V10, P373, DOI 10.1097/00000478-198606000-00002; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301; Kelly K, 1997, CLIN CHEST MED, V18, P319, DOI 10.1016/S0272-5231(05)70382-8; Kim CK, 2001, CHEST, V120, P1101, DOI 10.1378/chest.120.4.1101; KINANE BT, 1993, CHEST, V104, P1183, DOI 10.1378/chest.104.4.1183; KINDT GC, 1989, AM REV RESPIR DIS, V140, P483; KING TE, 1992, CHEST, V102, pS8, DOI 10.1378/chest.102.1_Supplement.8S; KING TE, 1993, CLIN CHEST MED, V14, P693; KING TE, 1993, CLIN CHEST MED, V14, P607; KINOSHITA M, 1992, INTERNAL MED, V31, P674, DOI 10.2169/internalmedicine.31.674; KOSS MN, 1995, SEMIN DIAGN PATHOL, V12, P158; KRAFT M, 1993, AM REV RESPIR DIS, V148, P1093; Kreiss K, 2002, NEW ENGL J MED, V347, P330, DOI 10.1056/NEJMoa020300; Krishnan P, 2002, CHEST, V121, P659, DOI 10.1378/chest.121.2.659; Kudoh S, 1998, Curr Opin Pulm Med, V4, P116, DOI 10.1097/00063198-199803000-00010; Kudoh S, 1998, AM J RESP CRIT CARE, V157, P1829; Kuhn JP, 2002, RADIOL CLIN N AM, V40, P89, DOI 10.1016/S0033-8389(03)00111-8; Lange W, 1901, DEUTSCH ARCH KLIN ME, V70, P342; Lappi-Blanco E, 2002, J PATHOL, V196, P220, DOI 10.1002/path.1038; Lazor R, 2000, AM J RESP CRIT CARE, V162, P571; Liebow AA, 1969, FRONTIERS PULMONARY, P102; Lohr RH, 1997, ARCH INTERN MED, V157, P1323, DOI 10.1001/archinte.157.12.1323; Lucaya J, 1998, J COMPUT ASSIST TOMO, V22, P592, DOI 10.1097/00004728-199807000-00015; LYNCH DA, 1990, RADIOLOGY, V176, P243; LYNCH DA, 1993, CLIN CHEST MED, V14, P623; LYNCH DA, 2002, RADIOL CLIN N AM, V39, P1153; Mahadeva R, 2000, EUR RESPIR J, V15, P41, DOI 10.1183/09031936.00.15104100; Majeski EI, 2003, AM J RESP CELL MOL, V28, P208, DOI 10.1165/rcmb.4891; Markopoulou KD, 2002, EUR RESPIR J, V19, P20, DOI 10.1183/09031936.02.00282001; Masuda T, 2002, PEDIATR PATHOL MOL M, V21, P41, DOI 10.1080/15227950252774156; Matsuse T, 1996, CHEST, V110, P1289, DOI 10.1378/chest.110.5.1289; McGuinness G, 2002, RADIOL CLIN N AM, V40, P1, DOI 10.1016/S0033-8389(03)00105-2; McLoud Theresa C., 1994, P27; McNamara PS, 2002, BRIT MED BULL, V61, P13, DOI 10.1093/bmb/61.1.13; Miller AL, 2003, J IMMUNOL, V170, P3348; MILLER RR, 1995, AM J SURG PATHOL, V19, P653, DOI 10.1097/00000478-199506000-00005; Moon J, 1999, THORAX, V54, P1009; MULLER NL, 1987, RADIOLOGY, V162, P151; MULLER NL, 1995, RADIOLOGY, V196, P3; Muller NL, 2001, EUR RESPIR J, V18, P867, DOI 10.1183/09031936.01.00266901; Myers JL, 2002, AM J RESP CRIT CARE, V166, P1419, DOI 10.1164/rrcm.2209005; MYERS JL, 1987, AM REV RESPIR DIS, V135, P880; MYERS JL, 1993, CLIN CHEST MED, V14, P611; NAGAI A, 1985, AM REV RESPIR DIS, V132, P937; Nagai S, 2000, Curr Opin Pulm Med, V6, P415, DOI 10.1097/00063198-200009000-00005; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; Nousari HC, 1999, NEW ENGL J MED, V340, P1406, DOI 10.1056/NEJM199905063401805; ODA H, 1994, CHEST, V106, P1116, DOI 10.1378/chest.106.4.1116; Oh YW, 1999, AM J ROENTGENOL, V172, P745; Panitch HB, 2001, CURR OPIN PEDIATR, V13, P256, DOI 10.1097/00008480-200106000-00008; PARADIS I, 1993, CLIN CHEST MED, V14, P731; PARK CS, 1995, RADIOLOGY, V203, P361; Park JS, 2002, J COMPUT ASSIST TOMO, V26, P13, DOI 10.1097/00004728-200201000-00003; PARK JS, 2002, J COMPUT ASSIST TOMO, V126, P13; Patel AM, 2001, J ALLERGY CLIN IMMUN, V108, P661; PENN CC, 1993, CLIN CHEST MED, V14, P645; Perez T, 1998, AM J RESP CRIT CARE, V157, P1658; PerezPadilla R, 1996, CHEST, V110, P371, DOI 10.1378/chest.110.2.371; Purcell IF, 1997, RESP MED, V91, P175, DOI 10.1016/S0954-6111(97)90055-X; REMYJARDIN M, 1993, RADIOLOGY, V186, P107; REYES CN, 1982, CHEST, V81, P142, DOI 10.1378/chest.81.2.142; Reynaud-Gaubert M, 2002, J HEART LUNG TRANSPL, V21, P721, DOI 10.1016/S1053-2498(02)00392-3; Ryu JH, 2001, EUR RESPIR J, V17, P122, DOI 10.1183/09031936.01.17101220; Ryu JH, 1998, MAYO CLIN PROC, V73, P1085; Ryu JH, 2001, MAYO CLIN PROC, V76, P1144; Sadikot RT, 2000, CHEST, V117, P282, DOI 10.1378/chest.117.1.282; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Sato A, 1996, AM J RESP CRIT CARE, V154, P1903; Schlesinger C, 2002, CURR OPIN PULM MED, V8, P112, DOI 10.1097/00063198-200203000-00006; Schwartzman KJ, 1995, EUR RESPIR J, V8, P2191, DOI 10.1183/09031936.95.08122191; Selman M, 1998, Curr Opin Pulm Med, V4, P9, DOI 10.1097/00063198-199801000-00003; SELMANLAMA M, 1993, CLIN CHEST MED, V14, P699; Shaw RJ, 2002, RESP MED, V96, P67, DOI 10.1053/rmed.2001.1216; SHEERIN N, 1995, THORAX, V50, P207, DOI 10.1136/thx.50.2.207; Stern EJ, 1995, J THORAC IMAG, V10, P294, DOI 10.1097/00005382-199501040-00007; SUGIYAMA Y, 1993, CLIN CHEST MED, V14, P765; Takizawa H, 1997, AM J RESP CRIT CARE, V156, P266; THURLBECK WM, 1980, AM REV RESPIR DIS, V122, P183; Todate A, 2000, AM J RESP CRIT CARE, V162, P148; Turato G, 2002, AM J RESP CRIT CARE, V166, P105, DOI 10.1164/rccm.2111084; Vassallo R, 2000, NEW ENGL J MED, V342, P1969, DOI 10.1056/NEJM200006293422607; Wang JS, 2000, HISTOPATHOLOGY, V37, P402, DOI 10.1046/j.1365-2559.2000.00990.x; WELLS AU, 1993, CLIN CHEST MED, V14, P655; Wells AU, 2001, SEM RESP CRIT CARE M, V22, P449, DOI 10.1055/s-2001-17387; WILCOX P, 1987, CHEST, V92, P18, DOI 10.1378/chest.92.1.18; WRIGHT JL, 1992, AM REV RESPIR DIS, V146, P240; WRIGHT JL, 1993, CLIN CHEST MED, V14, P635; Yanagihara K, 2001, INT J ANTIMICROB AG, V18, pS83; Yousem SA, 1997, MODERN PATHOL, V10, P864; YOUSEM SA, 1985, HUM PATHOL, V16, P700, DOI 10.1016/S0046-8177(85)80155-6; Yousem SA, 2002, MODERN PATHOL, V15, P1148, DOI 10.1097/01.MP.0000037309.04985.B4; YOUSEM SA, 1989, MAYO CLIN PROC, V64, P1373; YOUSEM SA, 1989, TRANSPLANTATION, V47, P893, DOI 10.1097/00007890-198905000-00030	164	133	156	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2003	168	11					1277	1292		10.1164/rccm.200301.053SO		16	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	747KU	WOS:000186804300008	14644923	
J	Gilbert, NL; Woodhouse, S; Stieb, DM; Brook, JR				Gilbert, NL; Woodhouse, S; Stieb, DM; Brook, JR			Ambient nitrogen dioxide and distance from a major highway	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						air pollution; nitrogen dioxide; NO2; passive monitoring; traffic	AIR-POLLUTION; ASTHMA; MOTORWAYS	The primary objective of this pilot study was to measure the variation of ambient nitrogen dioxide (NO2) concentration with increasing distance from a major highway in Montreal, Canada, in order to assess the validity of distance from the roadways as a surrogate for exposure to traffic-related air pollution in epidemiologic studies. A total of 31 two-sided Ogawa(TM) passive samplers (using triethanolamine-impregnated filters as an absorbent) were installed for 7 days in groups of two or three along an axis perpendicular to a major highway where traffic density exceeds 100 000 vehicles/day. Distances ranged from 0 to 1310 m from the highway. Concentrations of NO2 ranged from 11.9 to 29.3 ppb, and decreased significantly with increasing logarithmic distance from the highway (P < 0.0001). Concentrations of NO2 were also significantly lower upwind than downwind relative to the highway (P= 0.0012). These findings indicate that distance from highways may be a valid surrogate for traffic-related air pollution. (C) 2003 Elsevier Science B.V. All rights reserved.	Hlth Canada, Air Hlth Effects Div, Ottawa, ON K1A 0L2, Canada; Environm Canada, Ctr Atmospher Res Expt, Egbert, ON, Canada; Environm Canada, Meteorol Serv Canada, Toronto, ON, Canada	Gilbert, NL (reprint author), Hlth Canada, Air Hlth Effects Div, 7th Floor,275 Slater St,PL 3807B, Ottawa, ON K1A 0L2, Canada.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Gilbert, Nicolas/0000-0001-6985-8046			Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; *GOV QUEB, 1996, DEB CIRC JOURN MOYEN; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; LIARD R, 1999, ENVIRON RES, V81, P331; Livingstone AE, 1996, BRIT MED J, V312, P676; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; RODES CE, 1981, ATMOS ENVIRON, V15, P243, DOI 10.1016/0004-6981(81)90024-X; Roorda-Knape MC, 1999, SCI TOTAL ENVIRON, V235, P339, DOI 10.1016/S0048-9697(99)00217-X; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; World Health Organization, 1997, ENV HLTH CRIT, V188; Wilkinson P, 1999, THORAX, V54, P1070	14	133	136	3	14	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697			SCI TOTAL ENVIRON	Sci. Total Environ.	AUG 1	2003	312	1-3					43	46		10.1016/S0048-9697(03)00228-6		4	Environmental Sciences	Environmental Sciences & Ecology	708TH	WOS:000184585100005	12873397	
J	Hoek, G; Meliefste, K; Cyrys, J; Lewne, M; Bellander, T; Brauer, M; Fischer, P; Gehring, U; Heinrich, J; van Vliet, P; Brunekreef, B				Hoek, G; Meliefste, K; Cyrys, J; Lewne, M; Bellander, T; Brauer, M; Fischer, P; Gehring, U; Heinrich, J; van Vliet, P; Brunekreef, B			Spatial variability of fine particle concentrations in three European areas	ATMOSPHERIC ENVIRONMENT			English	Article						PM2.5; diesel; soot; traffic; exposure	URBAN AIR-POLLUTION; PARTICULATE MATTER; NITROGEN-DIOXIDE; BLACK SMOKE; RURAL SITES; EXPOSURE; CHILDREN; INDOOR; PM10; NETHERLANDS	Epidemiological studies of long-term air pollution effects have been hampered by difficulties in characterizing the spatial variation in air pollution. We conducted a study to assess the risk of long-term exposure to traffic-related air pollution for the development of inhalant allergy and asthma in children in Stockholm county, Munich and the Netherlands. Exposure to traffic-related air pollution was assessed through a 1-year monitoring program and regression modeling using exposure indicators. This paper documents the performance of the exposure monitoring strategy and the spatial variation of ambient particle concentrations. We measured the ambient concentration of PM2.5 and the reflectance of PM2.5 filters ('soot') at 40-42 sites representative of different exposure conditions of the three study populations. Each site was measured during four 14-day average sampling periods spread over one year (spring 1999 to summer 2000). In each study area, a continuous measurement site was operated to remove potential bias due to temporal variation. The selected approach was an efficient method to characterize spatial differences in annual average concentration between a large number of sites in each study area. Adjustment with data from the continuous measurement site improved the precision of the calculated annual averages, especially for PM2.5. Annual average PM2.5 concentrations ranged from 11 to 20 mug/m(3) in Munich, from 8 to 16 mug/m(3) in Stockholm and from 14 to 26 mug/m(3) in the Netherlands. Larger spatial contrasts were found for the absorption coefficient of PM2.5. PM2.5 concentrations were on average 17-18% higher at traffic sites than at urban background sites, but PM2.5 absorption coefficients at traffic sites were between 31% and 55% increased above background. This suggests that spatial variation of traffic-related air pollution may be underestimated if PM2.5 only is measured. (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Unit, NL-3508 TD Utrecht, Netherlands; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Stockholm Cty Council, Dept Environm Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Stockholm, Sweden; Natl Inst Publ Hlth & Environm, Lab Exposure Assessment & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands	Hoek, G (reprint author), Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Unit, POB 80-176, NL-3508 TD Utrecht, Netherlands.		Cyrys, Josef/B-5359-2014	brunekreef, bert/0000-0001-9908-0060; Gehring, Ulrike/0000-0003-3612-5780; Cyrys, Josef/0000-0002-2105-8696; Brauer, Michael/0000-0002-9103-9343			Bellander T, 2001, ENVIRON HEALTH PERSP, V109, P633, DOI 10.2307/3455039; Bernard NL, 1997, J EXPO ANAL ENV EPID, V7, P165; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Burton RM, 1996, ENVIRON SCI TECHNOL, V30, P400, DOI 10.1021/es950030f; Cyrys J, 1998, J EXPO ANAL ENV EPID, V8, P447; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Hering S, 1999, J AIR WASTE MANAGE, V49, P725, DOI 10.1080/10473289.1999.10463843; Hoek G, 1997, ATMOS ENVIRON, V31, P3609, DOI 10.1016/S1352-2310(97)00158-1; Hoek G, 2000, J AIR WASTE MANAGE, V50, P1380, DOI 10.1080/10473289.2000.10464182; Hoek G., 2001, RISK ASSESSMENT EXPO; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Janssen NAH, 1997, ATMOS ENVIRON, V31, P1185, DOI 10.1016/S1352-2310(96)00291-9; Janssen NAH, 2000, J AIR WASTE MANAGE, V50, P1133; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; Lebret E, 2000, ATMOS ENVIRON, V34, P177, DOI 10.1016/S1352-2310(99)00292-7; MARPLE VA, 1987, JAPCA J AIR WASTE MA, V37, P1303; MONN C, 1995, ATMOS ENVIRON, V29, P2565, DOI 10.1016/1352-2310(95)94999-U; Monn C, 2001, ATMOS ENVIRON, V35, P1, DOI 10.1016/S1352-2310(00)00330-7; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Raaschou-Nielsen O, 2000, J EXPO ANAL ENV EPID, V10, P4, DOI 10.1038/sj.jea.7500070; Roemer WH, 2001, ENVIRON HEALTH PERSP, V109, P151, DOI 10.2307/3434768; Roosli M, 2000, J AIR WASTE MANAGE, V50, P1115, DOI 10.1080/10473289.2000.10464161; Roosli M, 2001, ATMOS ENVIRON, V35, P3701, DOI 10.1016/S1352-2310(00)00511-2; Van der Zee SC, 1998, ATMOS ENVIRON, V32, P3717, DOI 10.1016/S1352-2310(98)00094-6; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596	28	133	133	4	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	SEP	2002	36	25					4077	4088	PII S1352-2310(02)00297-2	10.1016/S1352-2310(02)00297-2		12	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	601XB	WOS:000178473100007		
J	Pandya, RJ; Solomon, G; Kinner, A; Balmes, JR				Pandya, RJ; Solomon, G; Kinner, A; Balmes, JR			Diesel exhaust and asthma: Hypotheses and molecular mechanisms of action	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						air pollution; allergy; asthma; diesel exhaust; immunology; irritant; particulate matter; respiratory	BRONCHIAL EPITHELIAL-CELLS; PARTICULATE AIR-POLLUTION; IGE ANTIBODY-PRODUCTION; EMERGENCY ROOM VISITS; SHORT-TERM EXPOSURE; ACTIVITY IN-VITRO; ADJUVANT ACTIVITY; CYTOKINE PRODUCTION; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE	Several components of air pollution have been linked to asthma. In addition to the well-studied critera air pollutants, such as nitrogen dioxide, sulfur dioxide, and ozone, diesel exhaust and diesel exhaust particles (DEPs) also appear to play a role in respiratory and allergic diseases. Diesel exhaust is composed of vapors, gases, and fine particles emitted by diesel-fueled compression-ignition engines. DEPs can act as nonspecific airway irritants at relatively high levels. At lower levels, DEPs promote release of specific cytokines, chemokines, immunoglobulins, and oxidants in the upper and lower airway. Release of these mediators of the allergic and inflammatory response initiates a cascade that can culminate in airway inflammation, mucus secretion, serum leakage into the air-ways, and bronchial smooth muscle contraction. DEPs also may promote expression of the T(H)2 immunologic response phenotype that has been associated with asthma and allergic disease. DEPs appear to have greater immunologic effects in the presence of environmental allergens than they do a-lone. This immunologic evidence may help explain the epidemiologic studies indicating that children living along major trucking thoroughfares are at increased risk for asthmatic and allergic symptoms and a-re more likely to have objective evidence of respiratory dysfunction.	Univ Calif San Francisco, Div Occupat & Environm Med, San Francisco, CA 94143 USA; San Francisco Gen Hosp, San Francisco, CA 94110 USA; Natl Resources Def Council, San Francisco, CA USA	Balmes, JR (reprint author), Univ Calif San Francisco, Div Occupat & Environm Med, POB 0843, San Francisco, CA 94143 USA.				ODCDC CDC HHS [T42/CCT 910427]		Abe S, 2000, AM J RESP CELL MOL, V22, P296; *AIR RES BOARD, 1998, MOT VEH FACTS FIG 19, P78; *AIR RES BOARD, 1998, PROP ID DIES EXH TOX; AZZAWI M, 1992, AM REV RESPIR DIS, V145, P1477; BALMES JR, 1987, AM REV RESPIR DIS, V136, P1117; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; Blomberg A., 1996, European Respiratory Journal Supplement, V9, p447S; Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604; Boland S, 2000, AM J PHYSIOL-LUNG C, V278, pL25; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Buchdahl R, 1996, BRIT MED J, V312, P661; Busse WW, 2001, NEW ENGL J MED, V344, P350; Calmes D, 1998, PEDIATRICS, V101, P845, DOI 10.1542/peds.101.5.845; Casillas AM, 1999, ANN ALLERG ASTHMA IM, V83, P624, DOI 10.1016/S1081-1206(10)62884-0; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Clark NM, 1999, ENVIRON HEALTH PERSP, V107, P421; D'Amato G, 1999, Monaldi Arch Chest Dis, V54, P470; Davies RJ, 1998, CLIN EXP ALLERGY, V28, P8; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; Devalia JL, 1999, INT ARCH ALLERGY IMM, V118, P437, DOI 10.1159/000024157; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EGGLESTON PA, 1999, ENV HLTH PERSPECT, V107, P1; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; GROSS M, 1996, NAT TRANSPORTATION S; Hajat S, 1999, THORAX, V54, P597; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280; HEINRICH J, 1999, ENV HLTH PERSPECT, V107, P1; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hiura TS, 1999, J IMMUNOL, V163, P5582; HUANG JL, 1991, ARCH ENVIRON HEALTH, V46, P296; Ichinose T, 1998, TOXICOL SCI, V44, P70, DOI 10.1093/toxsci/44.1.70; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; JORRES R, 1990, EUR RESPIR J, V3, P132; Kakinoki Y, 2000, SCAND J IMMUNOL, V51, P202; Kemeny DM, 2000, TOXICOLOGY, V152, P3, DOI 10.1016/S0300-483X(00)00286-9; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Kobayashi T, 1997, FUND APPL TOXICOL, V38, P166, DOI 10.1006/faat.1997.2347; KRANKENHAUS G, 1990, EUR RESPIR J, V3, P1322; KUMAGAI Y, 1995, FREE RADICAL BIO MED, V18, P365, DOI 10.1016/0891-5849(94)00125-4; Lee AH, 2000, BIOCHEM J, V350, P131, DOI 10.1042/0264-6021:3500131; Lezcano-Meza D, 1999, CLIN EXP ALLERGY, V29, P1301; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Maejima K, 1997, J TOXICOL ENV HEALTH, V52, P231, DOI 10.1080/009841097159674; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MCCONNELL R, 1999, ENV HLTH PERSPECT, V107, P1; Millar W J, 1998, Health Rep, V10, P9; Miyabara Y, 1998, EUR RESPIR J, V11, P291, DOI 10.1183/09031936.98.11020291; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; MIYABARA Y, 1998, AM J RESP CRIT CARE, V157, P1; Mori Y, 1996, J TOXICOL ENV HEALTH, V47, P125, DOI 10.1080/009841096161834; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Muto E, 1996, LIFE SCI, V59, P1563, DOI 10.1016/0024-3205(96)00487-0; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nicolai T, 1999, Monaldi Arch Chest Dis, V54, P475; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Passalacqua G, 2000, THORAX, V55, pS26, DOI 10.1136/thorax.55.suppl_2.S26; PEDEN BB, 2000, ENVIRON HEALTH PER S, V108, P475; Peden DB, 1997, ALLERGY, V52, P37; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; RUSZNAK C, 1994, ALLERGY, V49, P21, DOI 10.1111/j.1398-9995.1994.tb04234.x; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Sampson AP, 2000, CLIN EXP ALLERGY, V30, P22; Schierhorn K, 1999, AM J RESP CELL MOL, V20, P1013; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Steerenberg PA, 1999, INHAL TOXICOL, V11, P1109; Steinsvik TE, 1998, TOXICOLOGY, V128, P219, DOI 10.1016/S0300-483X(98)00075-4; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; STREENBERG PA, 1999, INHAL TOXICOL, V11, P1109; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Suzuki T, 1996, J CLIN LAB IMMUNOL, V48, P187; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Takano H, 1999, TOXICOLOGY, V139, P19, DOI 10.1016/S0300-483X(99)00104-3; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 1999, J IMMUNOL, V162, P4705; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167; Trenga CA, 1999, OCCUP ENVIRON MED, V56, P544; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; U. S. EPA, 1997, NAT AIR POLL EM TREN; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; WADE JF, 1993, J OCCUP ENVIRON MED, V35, P149, DOI 10.1097/00043764-199302000-00015; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; Yang HM, 1999, J TOXICOL ENV HEAL A, V58, P261, DOI 10.1080/009841099157232; Yoshino S, 1999, CELL IMMUNOL, V192, P72, DOI 10.1006/cimm.1998.1427	117	133	138	4	20	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	FEB	2002	110			1			103	112				10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	538BV	WOS:000174794900011	11834468	
J	Radulovic, S; Wilson, D; Calderon, M; Durham, S				Radulovic, S.; Wilson, D.; Calderon, M.; Durham, S.			Systematic reviews of sublingual immunotherapy (SLIT)	ALLERGY			English	Review						allergic rhinitis; immunotherapy; systematic review	PLACEBO-CONTROLLED TRIAL; GRASS ALLERGEN TABLETS; RANDOMIZED CONTROLLED-TRIAL; HOUSE-DUST-MITE; STANDARDIZED 5-GRASS-POLLEN EXTRACT; PARIETARIA-JUDAICA EXTRACT; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; POLLEN EXTRACT; CLINICAL-EFFICACY	P>Allergic rhinitis is common worldwide, with significant morbidity and impact on quality of life. In patients who don't respond adequately to anti-allergic drugs. Subcutaneous allergen immunotherapy is effective although requires specialist administration. Sublingual immunotherapy may represent an effective and safer alternative. This Cochrane systematic review is an update of one published in 2003. We searched Cochrane ENT Group Trials Register, Central, PubMed, EMBASE, CINAHL, Web of Science, Biosis Previews, Cambridge Scientific Abstarcts, mRCT and additional sources. We included randomised, double-blind, placebo- controlled trials of sublingual immunotherapy in adults and children. Two authors selected studies and assessed them for quality. Data were put into RevMan 5.0 for a statistical analysis. We used standardised mean difference (SMD), with a random effect model to combine data. Sixty studies were included, with 49 suitable for meta-analysis. We found significant reductions in symptoms (SMD -0.49; 95%CI (-0.64 to -0.34, P < 0.00001)) and medication requirements (SMD -0.32; 95%CI (-0.43 to -0.21, P < 0.00001)) compared with placebo. None of the trials reported severe systemic reactions, anaphylaxis or use of Adrenaline. This updated review reinforces the conclusion of the original 2003 Cochrane Review that sublingual immunotherapy is effective for allergic rhinitis and appears a safe route of administration.	[Durham, S.] Royal Brompton Hosp, Imperial Coll NHLI, Dept Allergy & Resp Med, London SW3 6LY, England; [Radulovic, S.] Kings Coll London, London WC2R 2LS, England; [Wilson, D.] Univ Hosp Birmingham NHS Trust, Selly Oak Hosp, Birmingham, W Midlands, England	Durham, S (reprint author), Royal Brompton Hosp, Imperial Coll NHLI, Dept Allergy & Resp Med, London SW3 6LY, England.	s.durham@imperial.ac.uk			ALK Abello; Horsholm Denmark	SR Durham has received lecture and consultancy fees and research funding via Imperial College from ALK Abello, Horsholm Denmark, a manufacturer of allergy vaccines. Moises Calderon has received lecture fees from ALK Abello, Horsholm Denmark, a manufacturer of allergy vaccines.	Abramson MJ, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001186.pub2; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; Calderon M, 2010, ALLERGY, V65, P420, DOI 10.1111/j.1398-9995.2009.02292.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2008, DRUG TODAY, V44, P31; Cao Lan-Fang, 2007, Zhonghua Er Ke Za Zhi, V45, P736; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; CLARKE M, COCHRANE REV HDB, V4; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; The Cochrane Collaboration, 2008, REV MAN REVMAN COMP; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; DEBLAY F, 2003, 22 C EUR AC ALL CLIN, P780; Di Rienzo V., 2006, Clinical and Experimental Allergy Reviews, V6, P67, DOI 10.1111/j.1472-9725.2006.00102.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Drachenberg KJ, 2001, ALLERGOLOGIE, V24, P525; DUBAKIENE R, 2003, 22 C EUR AC ALL CLIN; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; DURHAM SR, 2010, J ALLERGY CLIN IMMUN, V125; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Higgins J, 2008, COCHRANE HDB SYSTEMA; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ibanez MD, 2007, PEDIATR ALLERGY IMMU, V18, P516, DOI 10.1111/j.1399-3038.2007.00556.x; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Malling HJ, 2006, J INVEST ALLERG CLIN, V16, P162; Marcucci F, 2005, PEDIATR ALLERGY IMMU, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; NIETO A, 2009, J ALLERGY CLIN IMMUN, V124; Ott H, 2009, ALLERGY, V64, P179, DOI 10.1111/j.1398-9995.2008.01875.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; Palma-Carlos A G, 2006, Allergol Immunopathol (Madr), V34, P194, DOI 10.1157/13094026; Panzner P, 2008, RESP MED, V102, P1296, DOI 10.1016/j.rmed.2008.03.024; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1395-9995.2006.01098.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PETER R, 2009, ALLERGY, V90, P352; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Tari M G, 1994, Allergol Immunopathol (Madr), V22, P209; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; Vervloet D, 2007, INT ARCH ALLERGY IMM, V142, P239, DOI 10.1159/000097026; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wessner D. B., 2001, Allergy (Copenhagen), V56, P88; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2003, COCHRANE DB SYST REV, DOI [10.1016/S1081-1206(10)60004-X, DOI 10.1002/14651858.CD002893]; Wutrich B, 2003, J INVESTIG ALLERGOL, V13, P145	89	132	138	0	11	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	JUN	2011	66	6					740	752		10.1111/j.1398-9995.2011.02583.x		13	Allergy; Immunology	Allergy; Immunology	754ZP	WOS:000289896700005	21443635	
J	Bedoret, D; Wallemacq, H; Marichal, T; Desmet, C; Calvo, FQ; Henry, E; Closset, R; Dewals, B; Thielen, C; Gustin, P; de Leval, L; Van Rooijen, N; Le Moine, A; Vanderplasschen, A; Cataldo, D; Drion, PV; Moser, M; Lekeux, P; Bureau, F				Bedoret, Denis; Wallemacq, Hugues; Marichal, Thomas; Desmet, Christophe; Calvo, Florence Quesada; Henry, Emmanuelle; Closset, Rodrigue; Dewals, Benjamin; Thielen, Caroline; Gustin, Pascal; de Leval, Laurence; Van Rooijen, Nico; Le Moine, Alain; Vanderplasschen, Alain; Cataldo, Didier; Drion, Pierre-Vincent; Moser, Muriel; Lekeux, Pierre; Bureau, Fabrice			Lung interstitial macrophages alter dendritic cell functions to prevent airway allergy in mice	JOURNAL OF CLINICAL INVESTIGATION			English	Article							RESPIRATORY SYNCYTIAL VIRUS; COLONY-STIMULATING FACTOR; HOUSE-DUST ENDOTOXIN; ALVEOLAR MACROPHAGES; IN-VIVO; INHALED ANTIGEN; IMMUNE-RESPONSES; PERITONEAL-MACROPHAGES; CYTOKINE PRODUCTION; IL-12 PRODUCTION	The respiratory tract is continuously exposed to both innocuous airborne antigens and immunostimulatory molecules of microbial origin, such as LPS. At low concentrations, airborne LPS can induce a lung DC-driven Th2 cell response to harmless inhaled antigens, thereby promoting allergic asthma. However, only a small fraction of people exposed to environmental LIPS develop allergic asthma. What prevents most people from mounting a lung DC-driven Th2 response upon exposure to LPS is not understood. Here we have shown that lung interstitial macrophages (IMs), a cell population with no previously described in vivo function, prevent induction of a Th2 response in mice challenged with LPS and an experimental harmless airborne antigen. IMs, but not alveolar macrophages, were found to produce high levels of IL-10 and to inhibit LPS-induced maturation and migration of DCs loaded with the experimental harmless airborne antigen in an IL-10-dependent manner. We further demonstrated that specific in vivo elimination of IMs led to overt asthmatic reactions to innocuous airborne antigens inhaled with low doses of LPS. This study has revealed a crucial role for IMs in maintaining immune homeostasis in the respiratory tract and provides an explanation for the paradox that although airborne LPS has the ability to promote the induction of Th2 responses by lung DCs, it does not provoke airway allergy under normal conditions.	[Bedoret, Denis; Wallemacq, Hugues; Marichal, Thomas; Desmet, Christophe; Closset, Rodrigue; Lekeux, Pierre; Bureau, Fabrice] Univ Liege, Lab Cellular & Mol Physiol, GIGA Res, B-4000 Liege, Belgium; [Calvo, Florence Quesada; Cataldo, Didier] CHU Liege, Lab Biol Tumors & Dev, GIGA Res, Liege, Belgium; [Henry, Emmanuelle; Moser, Muriel] Univ Libre Bruxelles, Inst Mol Biol & Med, Physiol Anim Lab, Gosselies, Belgium; [Dewals, Benjamin; Vanderplasschen, Alain] Univ Liege, Fac Vet Med, Lab Immunol & Vaccinol, B-4000 Liege, Belgium; [Thielen, Caroline; de Leval, Laurence] CHU Liege, Pathol Lab, GIGA Res, Liege, Belgium; [Gustin, Pascal] Univ Liege, Fac Vet Med, Dept Funct Sci, B-4000 Liege, Belgium; [Van Rooijen, Nico] Vrije Univ Amsterdam, Med Ctr, Fac Med, Dept Mol Cell Biol, Amsterdam, Netherlands; [Le Moine, Alain] Univ Libre Bruxelles, Inst Med Immunol, Gosselies, Belgium; [Drion, Pierre-Vincent] Univ Liege, Anim Facil B23, B-4000 Liege, Belgium	Bureau, F (reprint author), Univ Liege, Lab Cellular & Mol Physiol, GIGA Res, Ave Hop,Batiment B34, B-4000 Liege, Belgium.	fabrice.bureau@ulg.ac.be		Cataldo, Didier/0000-0002-3079-7941	Fonds National de la Recherche Scientifique (FNRS; Belgium; Mandat d'Impulsion Scientifique); Fonds de la Recherche Scientifique Medicale (FRSM; Belgium); Belgian Programme on Interuniversity Attraction Poles (IUAP)	We thank Kris Thielemans for providing recombinant murine GM-CSF; Sandrine Florquin for providing Tlr4<SUP>-/-</SUP> mice; Sandra Ormenese and the Cell Imaging and Flow Cytometry GIGA Technological Platform for FACS analysis; and Ilham Sbai, Cedric Francois, and Fabrice Jaspar for excellent technical and secretarial assistance. Clodronate (Cl<INF>2</INF>MDP) was a gift of Roche Diagnostics GmbH. The Laboratory of Cellular and Molecular Physiology is supported by grants from the Fonds National de la Recherche Scientifique (FNRS; Belgium; Mandat d'Impulsion Scientifique), by the Fonds de la Recherche Scientifique Medicale (FRSM; Belgium), by the Belgian Programme on Interuniversity Attraction Poles (IUAP; FEDIMMUNE) initiated by the Belgian State (Belgian Science Policy), and by an Action de Recherche Concertee de la Communaute Francaise de Belgique. D. Bedoret and T. Marichal are research fellows, C. Desmet is a postdoctoral researcher, and M. Moser is a research director at the FNRS.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; ALBLAS ABV, 1981, J EXP MED, V154, P235; Alexis NE, 2005, J ALLERGY CLIN IMMUN, V115, P345, DOI 10.1016/j.jaci.2004.11.040; Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Apte RS, 2006, PLOS MED, V3, P1371, DOI 10.1371/journal.pmed.0030310; AUSTYN JM, 1981, EUR J IMMUNOL, V11, P805, DOI 10.1002/eji.1830111013; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JC1200216109; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Demangel C, 2002, EUR J IMMUNOL, V32, P994, DOI 10.1002/1521-4141(200204)32:4<994::AID-IMMU994>3.3.CO;2-Y; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Erwig LP, 2007, AM J PATHOL, V171, P2, DOI 10.2353/ajpath.2007.070135; FrankeUllmann G, 1996, J IMMUNOL, V157, P3097; Geissmann F, 1999, J IMMUNOL, V162, P4567; Gerber JS, 2001, J IMMUNOL, V166, P6861; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gueders MM, 2008, BIOCHEM PHARMACOL, V75, P514, DOI 10.1016/j.bcp.2007.09.012; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hasko G, 2007, PHARMACOL THERAPEUT, V113, P264, DOI 10.1016/j.pharmthera.2006.08.003; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kalinski P, 1997, J IMMUNOL, V159, P28; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; Lagranderie M, 2003, IMMUNOLOGY, V108, P352, DOI 10.1046/j.1365-2567.2003.01609.x; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Martinez FO, 2008, FRONT BIOSCI-LANDMRK, V13, P453, DOI 10.2741/2692; Meyts I, 2006, J IMMUNOL, V177, P6460; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; PANUSKA JR, 1990, J CLIN INVEST, V86, P113, DOI 10.1172/JCI114672; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Salez L, 2000, J LEUKOCYTE BIOL, V67, P545; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Smit LAM, 2008, EUR RESPIR J, V31, P1241, DOI 10.1183/09031936.00090607; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; STEINMAN RM, 1978, P NATL ACAD SCI USA, V75, P5132, DOI 10.1073/pnas.75.10.5132; Sternberg EM, 2006, NAT REV IMMUNOL, V6, P318, DOI 10.1038/nri1810; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; THEPEN T, 1991, EUR J IMMUNOL, V21, P2845, DOI 10.1002/eji.1830211128; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Tidball JG, 2007, J PHYSIOL-LONDON, V578, P327, DOI 10.1113/jphysiol.2006.118265; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wang SH, 2001, J IMMUNOL, V166, P2741	67	132	135	0	17	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	DEC	2009	119	12					3723	3738		10.1172/JCI39717		16	Medicine, Research & Experimental	Research & Experimental Medicine	527SI	WOS:000272386400021	19907079	
J	Brockow, K; Romano, A; Aberer, W; Bircher, AJ; Barbaud, A; Bonadonna, P; Faria, E; Kanny, G; Lerch, M; Pichler, WJ; Ring, J; Cernadas, JR; Tomaz, E; Demoly, P; Christiansen, C				Brockow, K.; Romano, A.; Aberer, W.; Bircher, A. J.; Barbaud, A.; Bonadonna, P.; Faria, E.; Kanny, G.; Lerch, M.; Pichler, W. J.; Ring, J.; Cernadas, J. Rodrigues; Tomaz, E.; Demoly, P.; Christiansen, C.		European Network Drug Allergy; EAACI Interest Grp Drug	Skin testing in patients with hypersensitivity reactions to iodinated contrast media - a European multicenter study	ALLERGY			English	Article						contrast media; hypersensitivity; skin tests	DRUG HYPERSENSITIVITY; ANAPHYLAXIS; IMMEDIATE; ALLERGY; GUIDELINES; PROTOCOL; RISK	Iodinated contrast media cause both immediate and nonimmediate hypersensitivity reactions. The aim of this prospective study was to determine the specificity and sensitivity of skin tests in patients who have experienced such reactions. Skin prick, intradermal and patch tests with a series of contrast media were conducted in 220 patients with either immediate or nonimmediate reaction. Positive skin tests were defined according to internationally accepted guidelines. Seventy-one never-exposed subjects and 11 subjects who had tolerated contrast medium exposure, served as negative controls. Skin test specificity was 96-100%. For tests conducted within the time period from 2 to 6 months after the reaction, up to 50% of immediate reactors and up to 47% of nonimmediate reactors were skin test positive. For immediate reactors, the intradermal tests were the most sensitive, whereas delayed intradermal tests in combination with patch tests were needed for optimal sensitivity in nonimmediate reactors. Contrast medium cross-reactivity was more common in the nonimmediate than in the immediate group. Interestingly, 49% of immediate and 52% of nonimmediate symptoms occurred in previously unexposed patients. Many of these patients were skin test positive, indicating that they were already sensitized at the time of first contrast medium exposure. These data suggest that at least 50% of hypersensitivity reactions to contrast media are caused by an immunological mechanism. Skin testing appears to be a useful tool for diagnosis of contrast medium allergy and may play an important role in selection of a safe product in previous reactors.	[Brockow, K.; Ring, J.] Tech Univ Munich, Dept Dermatol & Allergol Biederstein, Div Environm Dermatol & Allergol, Helmholtz Zentrum Munchen, D-80802 Munich, Germany; [Aberer, W.] Med Univ Graz, Dept Dermatol, Graz, Austria; [Bircher, A. J.] Univ Basel Hosp, Dept Dermatol, Allergy Unit, CH-4031 Basel, Switzerland; [Romano, A.] CI Columbus, Allergy Unit, Rome, Italy; [Romano, A.] IRCCS Oasi Maria SS, Troina, Italy; [Barbaud, A.] Univ Hosp, Dept Dermatol, Fournier Hosp, Nancy, France; [Bonadonna, P.] Verona Hosp, Allergy Unit, Verona, Italy; [Faria, E.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal; [Kanny, G.] Univ Hosp, Dept Internal Med Clin Immunol & Allergy, Cent Hosp, Nancy, France; [Lerch, M.; Pichler, W. J.] Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland; [Cernadas, J. Rodrigues] Univ Hosp S Joao, Dept Allergy & Clin Immunol, Oporto, Portugal; [Tomaz, E.] Hosp S Bernardo, Setubal, Portugal; [Demoly, P.] Univ Hosp Montpellier, Hop Arnaud de Villeneuve, INSERM, Montpellier, France; [Christiansen, C.] GE Healthcare, Res & Dev, Oslo, Norway	Brockow, K (reprint author), Tech Univ Munich, Dept Dermatol & Allergol Biederstein, Div Environm Dermatol & Allergol, Helmholtz Zentrum Munchen, Biedersteiner Str 29, D-80802 Munich, Germany.			Romano, Antonino/0000-0001-9742-9898			Arnold AW, 2007, DERMATOLOGY, V214, P89, DOI 10.1159/000069620; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Blanca M, 1999, J ALLERGY CLIN IMMUN, V103, P918, DOI 10.1016/S0091-6749(99)70439-2; Bohm I, 2006, EUR RADIOL, V16, P1570, DOI 10.1007/s00330-006-0202-9; Brockow K, 2005, TOXICOLOGY, V209, P189, DOI 10.1016/j.tox.2004.12.032; Brockow K, 2005, ALLERGY, V60, P150, DOI 10.1111/j.1398-9995.2005.00745.x; Brockow K, 1999, Allerg Immunol (Paris), V31, P49; Christiansen C, 2005, TOXICOLOGY, V209, P185, DOI 10.1016/j.tox.2004.12.020; Christiansen C., 2007, DRUG HYPERSENSITIVIT, P140; Christiansen C, 2002, EUR RADIOL, V12, pS94, DOI 10.1007/s00330-002-1620-y; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; Dewachter P, 2001, ALLERGY, V56, P250, DOI 10.1034/j.1398-9995.2001.056003250.x; GOMES ER, 2005, ALLERGY CLIN IMMUNOL, V17, P1; Hosoya T, 2000, Radiat Med, V18, P39; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kanny G, 1993, Allerg Immunol (Paris), V25, P425; Kanny G, 2005, J ALLERGY CLIN IMMUN, V115, P179, DOI 10.1016/j.jaci.2004.09.012; KATAYAMA H, 1990, RADIOLOGY, V175, P621; Kvedariene V, 2006, CLIN EXP ALLERGY, V36, P1072, DOI 10.1111/j.1365-2222.2006.02532.x; Laporte JR, 2003, PHARMACOEPIDEM DR S, V12, P195, DOI 10.1002/pds.822; Laroche D, 1998, RADIOLOGY, V209, P183; LAROCHE D, 2006, CONTRAST MED MOL IMA, V1, P81, DOI 10.1002/cmmi.63; Lerch M, 2007, J ALLERGY CLIN IMMUN, V119, P1529, DOI 10.1016/j.jaci.2007.02.007; Mertes PM, 2005, J INVEST ALLERG CLIN, V15, P91; Messaad D, 2004, ANN INTERN MED, V140, P1001; Mita H, 1998, ALLERGY, V53, P1133, DOI 10.1111/j.1398-9995.1998.tb03832.x; RING J, 1977, LANCET, V1, P466; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; Romano A, 2002, RADIOLOGY, V225, P466, DOI 10.1148/radiol.2251011654; TOLEDO JG, 2000, REV ALERG MEX, V47, P22; Trcka J, 2008, AM J ROENTGENOL, V190, P666, DOI 10.2214/AJR.07.2872; Valfrey J, 2002, REV FR ALLERGOL, V42, P157, DOI 10.1016/S0335-7457(01)00130-7; Vernassiere C, 2004, CONTACT DERMATITIS, V50, P359, DOI 10.1111/j.0105-1873.2004.00367.x; Wyatt JP, 1996, J ACCID EMERG MED, V13, P114	34	132	135	0	5	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	FEB	2009	64	2					234	241		10.1111/j.1398-9995.2008.01832.x		8	Allergy; Immunology	Allergy; Immunology	397AK	WOS:000262634000008	19178403	
J	Terashima, A; Watarai, H; Inoue, S; Sekine, E; Nakagawa, R; Hase, K; Iwamura, C; Nakajima, H; Nakayama, T; Taniguchi, M				Terashima, Asuka; Watarai, Hiroshi; Inoue, Sayo; Sekine, Etsuko; Nakagawa, Ryusuke; Hase, Koji; Iwamura, Chiaki; Nakajima, Hiroshi; Nakayama, Toshinori; Taniguchi, Masaru			A novel subset of mouse NKT cells bearing the IL-17 receptor B responds to IL-25 and contributes to airway hyperreactivity	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							KILLER T-CELLS; IN-VIVO; ALLERGIC-ASTHMA; TH2 RESPONSES; ACTIVATION; IDENTIFICATION; POPULATION; EXPRESSION; LUNG; HYPERRESPONSIVENESS	Airway hypersensitive reaction (AHR) is an animal model for asthma, which is caused or enhanced by environmental factors such as allergen exposure. However, the precise mechanisms that drive AHR remain unclear. We identified a novel subset of natural killer T (NKT) cells that expresses the interleukin 17 receptor B (IL-17RB) for IL-25 (also known as IL-17E) and is essential for the induction of AHR. IL-17RB is preferentially expressed on a fraction of CD4(+) NKT cells but not on other splenic leukocyte populations tested. IL-17RB(+) CD4(+) NKT cells produce predominantly IL-13 and Th2 chemokines upon stimulation with IL-25 in vitro. IL-17RB(+) NKT cells were detected in the lung, and depletion of IL-17RB(+) NKT cells by IL-17RB(-)specific monoclonal antibodies or NKT cell deficient J alpha 18(-/-) mice failed to develop IL-25-dependent AHR. Cell transfer of IL-17RB(+) but not IL-17RB(-) NKT cells into J alpha 18(-/-) mice also successfully reconstituted AHR induction. These results strongly suggest that IL-17RB(+) CD4(+) NKT cells play a crucial role in the pathogenesis of asthma.	[Terashima, Asuka; Watarai, Hiroshi; Inoue, Sayo; Sekine, Etsuko; Nakagawa, Ryusuke; Taniguchi, Masaru] RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Tsurumi Ku, Kanagawa 2300045, Japan; [Hase, Koji] RIKEN, Res Ctr Allergy & Immunol, Lab Epithelial Immunobiol, Tsurumi Ku, Kanagawa 2300045, Japan; [Iwamura, Chiaki; Nakayama, Toshinori] Chiba Univ, Dept Immunol, Chuo Ku, Chiba 2608670, Japan; [Nakajima, Hiroshi] Chiba Univ, Dept Mol Genet, Grad Sch Med, Chuo Ku, Chiba 2608670, Japan	Watarai, H (reprint author), RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Tsurumi Ku, Kanagawa 2300045, Japan.	hwatarai@rcai.riken.jp	Watarai, Hiroshi/G-9894-2012; Taniguchi, Masaru/N-7932-2015; Nakayama, Toshinori/E-1067-2017	Watarai, Hiroshi/0000-0003-1511-2593; Taniguchi, Masaru/0000-0001-7821-7179; Nakayama, Toshinori/0000-0002-1434-2007			Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Brigl M, 2003, NAT IMMUNOL, V4, P1230, DOI 10.1038/ni1002; Coquet JM, 2008, P NATL ACAD SCI USA, V105, P11287, DOI 10.1073/pnas.0801631105; Crowe NY, 2005, J EXP MED, V202, P1279, DOI 10.1084/jem.20050953; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Harada M, 2006, J EXP MED, V203, P2929, DOI 10.1084/jem.20062206; Hizawa N, 2006, CLIN EXP ALLERGY, V36, P1109, DOI 10.1111/j.1365-2222.2006.02550.x; Hurst SD, 2002, J IMMUNOL, V169, P443; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Jamieson AM, 2002, IMMUNITY, V17, P19, DOI 10.1016/S1074-7613(02)00333-3; Johnston B, 2003, J IMMUNOL, V171, P2960; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Letuve S, 2006, J ALLERGY CLIN IMMUN, V117, P590, DOI 10.1016/j.jaci.2005.10.025; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Meyer EH, 2007, J IMMUNOL, V179, P4661; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Moseley TA, 2003, CYTOKINE GROWTH F R, V14, P155, DOI 10.1016/S1359-6101(03)00002-9; Pan GH, 2001, J IMMUNOL, V167, P6559; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Rachitskaya AV, 2008, J IMMUNOL, V180, P5167; Rahman MS, 2006, J IMMUNOL, V177, P4064; Tamachi T, 2006, J ALLERGY CLIN IMMUN, V118, P606, DOI 10.1016/j.jaci.2006.04.051; Taniguchi M, 2003, ANNU REV IMMUNOL, V21, P483, DOI 10.1146/annurev.ummunol.21.120601.141057; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; Watarai H, 2008, NAT PROTOC, V3, P70, DOI 10.1038/nprot.2007.515; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	31	132	137	1	5	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	NOV 24	2008	205	12					2727	U29		10.1084/jem.20080698		10	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	378BE	WOS:000261295300007	19015310	
J	Sundell, J				Sundell, J			On the history of indoor air quality and health	INDOOR AIR			English	Article						IAQ; health; allergy; indoor environments; dampness; ventilation	SYNDROME SBS SYMPTOMS; SCIENTIFIC EVIDENCE; ENVIRONMENTS; VENTILATION; BUILDINGS; EXPOSURE; PRODUCTIVITY; ASSOCIATIONS; DAMPNESS; OFFICE	Indoor air is a dominant exposure for humans. More that half of the body's intake during a lifetime is air inhaled in the home. Thus, most illnesses related to environmental exposures stem from indoor air exposure. Indoor air was believed to be a major environmental factor for more than a hundred years, from the start of the hygienic revolution, around 1850, until outdoor environmental issues entered the scene, and became dominant around 1960. Main environmental issues today are outdoor air quality, energy use, and sustainable buildings, but not indoor air quality (IAQ). But, there is mounting evidence that exposure to IAQ is the cause of excessive morbidity and mortality. In developing regions indoor unvented burning of biomass for cooking is the cause of at least 2,000,000 deaths a year (mainly women and children), and in the developed world IAQ is a main cause of allergies, other hypersensitivity reactions, airway infections, and cancers. Cancer of the lungs is related to indoor radon and ETS exposure. Allergies, airway infections and sick building syndrome are associated with, e.g., "dampness", a low ventilation rate, and plasticizers. In the future more emphasis must be given to IAQ and health issues.	Tech Univ Denmark, Int Ctr Indoor Environm & Energy, DK-2800 Lyngby, Denmark	Sundell, J (reprint author), Tech Univ Denmark, Int Ctr Indoor Environm & Energy, Niels Koppels Alle,Bldg 402, DK-2800 Lyngby, Denmark.	jas@mek.dtu.dk	Sundell, Jan/B-2857-2012				Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, INDOOR AIR, V14, P59, DOI 10.1111/j.1600-0668.2004.00274.x; BORNEHAG CG, 2004, IN PRESS INDOOR AIR; Carnelly D, 1887, PHILOS T R SOC B, V178, P61; Fang L, 1999, INDOOR AIR, V9, P193, DOI 10.1111/j.1600-0668.1999.t01-1-00006.x; FANGER PO, 1988, ENERG BUILDINGS, V12, P7, DOI 10.1016/0378-7788(88)90052-7; FANGER PO, 1988, ENERG BUILDINGS, V12, P1, DOI 10.1016/0378-7788(88)90051-5; FANGER PO, 1992, EURO CH ENV, V4, P59; Schneider T, 2003, INDOOR AIR, V13, P38, DOI 10.1034/j.1600-0668.2003.02025.x; SMITH KR, 2003, P HLTH BUILDINGS, V1, P118; SUNDELL J, 1995, ALLERGY, V50, P106; Sundell J., 1993, INDOOR AIR, V3, P82, DOI 10.1111/j.1600-0668.1993.t01-2-00003.x; SUNDELL J, 1994, INDOOR AIR S, V2; Sundell J., 1999, INDOOR ENV HLTH; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x; Wargocki P, 1999, INDOOR AIR, V9, P165, DOI 10.1111/j.1600-0668.1999.t01-1-00003.x; Weschler CJ, 2000, INDOOR AIR, V10, P92, DOI 10.1034/j.1600-0668.2000.010002092.x; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x	22	132	148	6	64	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0905-6947			INDOOR AIR	Indoor Air	AUG	2004	14			7			51	58		10.1111/j.1600-0668.2004.00273.x		8	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	850DF	WOS:000223590700007	15330772	
J	McParland, BE; Macklem, PT; Pare, PD				McParland, BE; Macklem, PT; Pare, PD			Airway wall remodeling: friend or foe?	JOURNAL OF APPLIED PHYSIOLOGY			English	Review						asthma; pathophysiology; smooth muscle	SMOOTH-MUSCLE CELLS; OBSTRUCTIVE PULMONARY-DISEASE; BRONCHIAL BASEMENT-MEMBRANE; DOSE-RESPONSE CURVE; FATAL ASTHMA; SUBEPITHELIAL FIBROSIS; DEEP INSPIRATION; MILD ASTHMA; INDUCED BRONCHOCONSTRICTION; LENGTH OSCILLATION	Airway wall remodeling is well documented for asthmatic airways and is believed to result from chronic and/or short-term exposure to inflammatory stimuli. Airway wall remodeling can contribute to airway narrowing as well as to the airway hyperresponsiveness, which is a characteristic abnormality in asthma. However, the potential for airway narrowing could be much worse if it were not for some of the protective effects of remodeling that may help to limit airway narrowing in asthmatic patients. This minireview discusses the evidence for airway wall remodeling and its effects, friend and/or foe, on airway narrowing in asthmatic patients.	Univ British Columbia, McDonald Res Labs, iCAPTURE Ctr, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; McGill Univ, Div Resp, Montreal, PQ H2X 2P2, Canada; McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada	Pare, PD (reprint author), Univ British Columbia, McDonald Res Labs, iCAPTURE Ctr, St Pauls Hosp, Burrard Bldg,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.		McParland, Brent/A-2841-2012				ARMOUR CL, 1988, J PHARMACOL EXP THER, V245, P687; Bai TR, 2000, AM J RESP CRIT CARE, V162, P663; BAI TR, 1990, AM REV RESPIR DIS, V141, P552; BAI TR, 1991, AM REV RESPIR DIS, V143, P441; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648; BRAMLEY AM, 1995, AM J RESP CRIT CARE, V152, P1513; BRAMLEY AM, 1994, EUR RESPIR J, V7, P337, DOI 10.1183/09031936.94.07020337; BRAMLEY AM, 1998, AM J RESP CRIT CARE, V157, pA518; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Brown RH, 1998, J APPL PHYSIOL, V85, P2012; Brown RH, 2001, AM J RESP CRIT CARE, V163, P994; BURNS CB, 1985, J APPL PHYSIOL, V59, P1590; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Carroll NG, 2000, AM J RESP CRIT CARE, V161, P244; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689; CERRINA J, 1989, PROSTAGLANDINS, V37, P457, DOI 10.1016/0090-6980(89)90095-6; CERRINA J, 1986, AM REV RESPIR DIS, V134, P57; DAWSON SV, 1977, J APPL PHYSIOL, V43, P498; DEJONGSTE JC, 1987, EUR J RESPIR DIS, V71, P23; DEPEE S, 1991, EUR RESPIR J, V4, P421; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; EBINA M, 1990, AM REV RESPIR DIS, V141, P1327; FINUCANE KE, 1969, J APPL PHYSIOL, V26, P330; FISH JE, 1977, J ALLERGY CLIN IMMUN, V60, P41, DOI 10.1016/0091-6749(77)90081-1; Fredberg JJ, 2000, J ALLERGY CLIN IMMUN, V106, P615, DOI 10.1067/mai.2000.109429; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752; Fredberg JJ, 1996, J APPL PHYSIOL, V81, P2703; FROEB HF, 1968, J APPL PHYSIOL, V25, P244; Gabbrielli S., 1994, Pathologica (Genoa), V86, P157; Gelb AF, 2002, CHEST, V121, P715, DOI 10.1378/chest.121.3.715; GILLIS JM, 1988, J MUSCLE RES CELL M, V9, P18, DOI 10.1007/BF01682145; GOLD WM, 1967, J APPL PHYSIOL, V23, P433; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669; GUNST SJ, 1990, J APPL PHYSIOL, V68, P2223; GUNST SJ, 1988, J APPL PHYSIOL, V65, P2490; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; Herrera AM, 2002, AM J PHYSIOL-CELL PH, V282, pC310; HILLMAN DR, 1983, RESP PHYSIOL, V54, P295, DOI 10.1016/0034-5687(83)90073-7; HOGG JC, 1984, CLIN CHEST MED, V5, P567; Holgate ST, 2000, RESP MED, V94, pS3; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P295, DOI 10.1067/mai.2001.111928; HOSSAIN S, 1973, AM REV RESPIR DIS, V107, P99; Huang J, 1999, AM J RESP CRIT CARE, V160, P725; Huber HL, 1922, ARCH INTERN MED, V30, P689; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50; Jackson AC, 1999, AM J RESP CRIT CARE, V159, pA468; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JAMES AL, 1988, AM REV RESPIR DIS, V138, P136; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JIANG H, 1992, J APPL PHYSIOL, V72, P39; Johnson PRA, 2000, AM J RESP CRIT CARE, V162, P2145; King GG, 1998, AM J RESP CRIT CARE, V158, P1900; Kuo KH, 2001, J APPL PHYSIOL, V90, P1811; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Lambert RK, 1997, J APPL PHYSIOL, V83, P140; LAMBERT RK, 1991, J APPL PHYSIOL, V71, P666; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Li X, 1997, AM J RESP CRIT CARE, V156, P229; LIM TK, 1987, AM REV RESPIR DIS, V135, P591; MACKLEM PT, 1990, ANN ALLERGY, V64, P113; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; MACKLEM PT, 1987, CHEST, V91, pS189, DOI 10.1378/chest.91.6.189S; Mandelbrot BB, 1999, SCI AM, V280, P70; Mauad Thais, 1999, American Journal of Respiratory and Critical Care Medicine, V160, P968; MCPARLAND BE, 1998, AM J RESP CRIT CARE, V157, pA517; MCPARLAND BE, 2001, AM J RESP CRIT CARE, V163, pA415; MCPARLAND BE, IN PRESS AM J RESP C; MEAD J, 1970, J APPL PHYSIOL, V28, P596; Meiss RA, 1999, J APPL PHYSIOL, V86, P5; Milanese M, 2001, J APPL PHYSIOL, V91, P1035; MOMOSE K, 1981, J PHARMACOBIO-DYNAM, V4, P670; Moore BJ, 1997, AM J RESP CRIT CARE, V156, P1278; Moore BJ, 1996, AM J RESP CRIT CARE, V154, P642; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Oliver J. P. J., 1992, SOCIAL WORK SOCIAL S, V3, P5; OMARI TI, 1993, BRIT J CLIN PHARMACO, V35, P357; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Orsida BE, 1999, THORAX, V54, P289; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; PARE PD, 1991, AM REV RESPIR DIS, V143, P1189; PARE PD, 1995, THORAX, V50, P328, DOI 10.1136/thx.50.4.328; PARHAM WM, 1983, AM REV RESPIR DIS, V128, P240; Pedersen OF, 1997, J APPL PHYSIOL, V83, P1721; PERESS L, 1976, AM J MED, V61, P165, DOI 10.1016/0002-9343(76)90165-0; Persson CGA, 1996, CLIN EXP ALLERGY, V26, P746, DOI 10.1111/j.1365-2222.1996.tb00604.x; PLISS LB, 1989, J APPL PHYSIOL, V66, P2298; PRATUSEVICH VR, 1995, J GEN PHYSIOL, V105, P73, DOI 10.1085/jgp.105.1.73; Qi D, 2002, AM J PHYSIOL-CELL PH, V282, pC1298, DOI 10.1152/ajpcell.00554.2001; Que CL, 2001, J APPL PHYSIOL, V91, P1131; ROBERTS JA, 1984, THORAX, V39, P837, DOI 10.1136/thx.39.11.837; ROCHE WR, 1989, LANCET, V1, P520; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138; SCHELLENBERG RR, 1984, INT ARCH ALLER A IMM, V75, P237; Shen X, 1997, J APPL PHYSIOL, V83, P731; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; SOBONYA RE, 1984, AM REV RESPIR DIS, V130, P289; Solway J, 1997, AM J RESP CELL MOL, V17, P144; STERK PJ, 1985, AM REV RESPIR DIS, V132, P272; TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749; Vanacker NJ, 2002, CLIN EXP ALLERGY, V32, P914, DOI 10.1046/j.1365-2222.2002.01394.x; Wang L, 2000, J APPL PHYSIOL, V88, P2246; Wang L, 2002, J APPL PHYSIOL, V92, P1865, DOI 10.1152/japplphysiol.01155.2001; Wang L, 2001, J APPL PHYSIOL, V90, P734; Whicker S D, 1988, Pulm Pharmacol, V1, P25, DOI 10.1016/0952-0600(88)90007-5; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788; WOOLCOCK AJ, 1984, AM REV RESPIR DIS, V130, P71; Xu JQ, 1997, J MUSCLE RES CELL M, V18, P381, DOI 10.1023/A:1018634412117; Zhu YK, 2001, J ALLERGY CLIN IMMUN, V108, P989, DOI 10.1067/mai.2001.120193	120	132	137	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	JUL	2003	95	1					426	434		10.1152/japplphysiol.00159.2003		9	Physiology; Sport Sciences	Physiology; Sport Sciences	687AY	WOS:000183354700052	12794101	
J	Centeno, JA; Mullick, FG; Martinez, L; Page, NP; Gibb, H; Longfellow, D; Thompson, C; Ladich, ER				Centeno, JA; Mullick, FG; Martinez, L; Page, NP; Gibb, H; Longfellow, D; Thompson, C; Ladich, ER			Pathology related to chronic arsenic exposure	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article; Proceedings Paper	3rd International Meeting on the Molecular Mechanisms of Metal Toxicity and Carcinogenicity	SEP 02-06, 2001	STINTINO, ITALY			angiosarcoma; arsenic; Bowen disease; hepatocellular carcinoma; hepatoportal sclerosis; hyperkeratosis; liver; noncirrhotic portal fibrosis; squamous cell carcinoma	IDIOPATHIC PORTAL-HYPERTENSION; DRINKING-WATER; WELL WATER; MORTALITY; ANGIOSARCOMA; PREVALENCE; ARGENTINA; DISEASES	Millions now suffer the effects of chronic arseniasis related to environmental arsenic exposure. The biological mechanisms responsible for arsenic-induced toxicity and especially chronic effects, including cancer, are not well known. The U.S. Armed Forces Institute of Pathology (AFIP) is participating in an international research effort to improve this understanding by the development of the International Tissue and Tumor Repository for Chronic Arsenosis (ITTRCA). The ITTRCA obtains, archives, and makes available for research purposes, tissues from subjects exposed to arsenic. We provide here a short overview of arsenic-induced pathology, briefly describe arsenic-induced lesions in the skin and liver, and present five case reports from the ITTRCA. Arsenic-induced skin pathology includes hyperkeratosis, pigmentation changes, Bowen disease, squamous cell carcinoma, and basal cell carcinomas. A unique spectrum of skin lesions, known as arsenical keratosis, is rather characteristic of chronic arseniasis. Bowen disease, or squamous cell carcinoma in situ of the skin, has been well documented as a consequence of arsenical exposure. A spectrum of liver lesions has also been attributed to chronic arseniasis. Of these, hepatocellular carcinoma, angiosarcoma, cirrhosis, and hepatoportal sclerosis have been associated with arsenic exposure. We present case reports that relate to these health conditions, namely, squamous cell carcinoma, basal cell carcinoma, and Bowen disease of the skin and hepatocellular carcinoma and angiosarcoma of the liver. Four patients had been treated with arsenical medications for such conditions as asthma, psoriasis, and syphilis, and one case occurred in a boy chronically exposed to arsenic in drinking water.	Armed Forces Inst Pathol, Div Biophys Toxicol, Washington, DC 20306 USA; US EPA, Washington, DC 20460 USA; Natl Canc Inst, Bethesda, MD USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Centeno, JA (reprint author), Armed Forces Inst Pathol, Div Biophys Toxicol, Washington, DC 20306 USA.						Biggs ML, 1998, SCIENCE, V281, P785; Centeno J.A., 2000, ARSENIC INDUCED LESI, P46; Chen Chien-Jen, 1994, V27, P109; CHEN CJ, 1990, CANCER RES, V50, P5470; CHEN CJ, 1995, HYPERTENSION, V25, P53; Chen CJ, 1996, ARTERIOSCL THROM VAS, V16, P504; DATTA DV, 1979, GUT, V20, P378, DOI 10.1136/gut.20.5.378; Duenas C, 1998, J CLIN GASTROENTEROL, V26, P303, DOI 10.1097/00004836-199806000-00019; Falk H, 1981, Am J Ind Med, V2, P43, DOI 10.1002/ajim.4700020108; HOOD RD, 1977, ENVIRON HEALTH PERSP, V19, P219; Hopenhayn-Rich C, 1998, INT J EPIDEMIOL, V27, P561, DOI 10.1093/ije/27.4.561; HopenhaynRich C, 1996, EPIDEMIOLOGY, V7, P117, DOI 10.1097/00001648-199603000-00003; LAI MS, 1994, AM J EPIDEMIOL, V139, P484; LEONARD A, 1980, MUTAT RES, V75, P49, DOI 10.1016/0165-1110(80)90027-5; Maloney ME, 1996, DERMATOL SURG, V22, P301; Mazumder DNG, 1999, ARSENIC EXPOSURE AND HEALTH EFFECTS, P335, DOI 10.1016/B978-008043648-7/50037-6; National Research Council, 2001, ARS DRINK WAT 2001 U; NESHIWAT LF, 1992, AM J MED, V93, P219, DOI 10.1016/0002-9343(92)90054-F; NEVENS F, 1990, J HEPATOL, V11, P80, DOI 10.1016/0168-8278(90)90276-W; NORDSTROM S, 1978, HEREDITAS, V88, P51; OKUDA K, 1989, ADV LIVER DIS, P79; PAGE NP, 2000, METALS BIOL MED, V6, P759; REGELSON W, 1968, CANCER, V21, P514, DOI 10.1002/1097-0142(196803)21:3<514::AID-CNCR2820210323>3.0.CO;2-Z; Roth F., 1957, GERMAN MED MONTHLY, V2, P172; Tsai SM, 1999, ARCH ENVIRON HEALTH, V54, P186; WU MM, 1989, AM J EPIDEMIOL, V130, P1123	26	132	137	4	9	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2002	110			5			883	886				4	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	612FQ	WOS:000179064200042	12426152	
J	Anderson, SD; Argyros, GJ; Magnussen, H; Holzer, K				Anderson, SD; Argyros, GJ; Magnussen, H; Holzer, K			Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						hyperpnoea; bronchial provocation; exercise	THERMALLY-INDUCED ASTHMA; COLD-AIR; BRONCHOPROVOCATION TECHNIQUE; INDUCED BRONCHOSPASM; DRY AIR; HYPERVENTILATION; CHALLENGE; RESPONSIVENESS; REACTIVITY; CHILDREN	The International Olympic Committee Medical Commission (IOC-MC) requires notification for use of a beta (2) agonist at the Winter Olympic Games in Salt Lake City. This notification will be required seven days before the event and must be accompanied by objective evidence that justifies the need to use one. The IOC-MC has expressed the viewpoint that, at present, eucapnic voluntary hyperpnoea (EVH) is the optimal laboratory challenge to confirm that an athlete has exercise induced bronchoconstriction (EIB). The EVH test recommended was specifically designed to identify EIB. EVH has been performed in thousands of subjects in both the laboratory and the field. The test requires the subject to hyperventilate dry air containing 5% carbon dioxide at room temperature for six minutes at a target ventilation of 30 times the subject's forced expiratory volume in one second (FEV1). The test conditions can be modified to simulate the conditions that give the athlete their symptoms with exercise. A reduction in FEV1 of 10% or more of the value before the test is considered positive.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Krankenhaus Grosshansdorf, Ctr Pneumol & Thorac Surg, D-22927 Grosshansdorf, Germany; Walter Reed Hlth Care Syst, Walter Reed Army Med Ctr, Washington, DC 20307 USA; Alfred Hosp, Dept Immunol & Asthma, Prahran, Vic 3052, Australia	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, Level 9 Page Chest Pavil, Camperdown, NSW 2050, Australia.			Anderson, Sandra/0000-0002-6308-8770			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; ANDERSON SD, 2001, RESPIROLOGY, V6, pA10; ARGYROS GJ, 1995, CHEST, V108, P419, DOI 10.1378/chest.108.2.419; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; ASSOUFI BK, 1986, B EUR PHYSIOPATH RES, V22, P349; BANNER AS, 1984, NEW ENGL J MED, V311, P883, DOI 10.1056/NEJM198410043111404; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P476; Dwyer TM, 1997, AM J PHYSIOL-LUNG C, V272, pL1121; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; FINNERTY JP, 1992, EUR RESPIR J, V5, P323; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565; NOWAK D, 1992, EUR J CLIN PHARMACOL, V43, P591, DOI 10.1007/BF02284956; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; ROACH JM, 1994, CHEST, V105, P667, DOI 10.1378/chest.105.3.667; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; WILBER RL, 2000, IN PRESS MED SCI SPO; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016	30	132	135	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	OCT	2001	35	5					344	347		10.1136/bjsm.35.5.344		4	Sport Sciences	Sport Sciences	479FR	WOS:000171394800019	11579071	
J	Karjalainen, A; Kurppa, K; Martikainen, R; Klaukka, T; Karjalainen, J				Karjalainen, A; Kurppa, K; Martikainen, R; Klaukka, T; Karjalainen, J			Work is related to a substantial portion of adult-onset asthma incidence in the Finnish population	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; occupational medicine; risk; incidence; population	OCCUPATIONAL ASTHMA; BRONCHIAL-ASTHMA; SMOKING; EXPOSURES; RISK; FINLAND	There are no population-based follow-up studies to estimate the fraction of asthma incidence that is attributable to work. In Finland, individuals with clinically well-established persistent asthma are registered for reimbursement of medication from the national health insurance scheme. We combined, at an individual level, these data with the population census data of 1985, 1990, and 1995 to estimate the attributable fraction of work in adult-onset persistent asthma. Our follow-up study covered the entire 25- to 59-yr-old employed population of Finland in 1986-1998. Relative risks (RR) for occupational categories were estimated in comparison to those employed in administrative work. There were 49,575 incident cases of asthma. The attributable fraction of occupation was 29% (95% CI 25-33%) for men and 17% (95% CI 15-19%) for women. The risk was increased especially in agricultural work, manufacturing work, and service work. In addition to already established risk occupations of occupational asthma, such as food and beverage work, the analysis identified a large number of occupations with significant excess of asthma incidence. The results indicate that the impact of occupational factors in the inception of adult-onset persistent asthma, and consequently the potential for prevention, is much larger and more widely spread than generally assumed.	Finnish Inst Occupat Hlth, Dept Epidemiol & Biostat, FIN-00250 Helsinki, Finland; Social Insurance Inst, SF-00381 Helsinki, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland	Karjalainen, A (reprint author), Finnish Inst Occupat Hlth, Dept Epidemiol & Biostat, Topeliuksenkatu 41 aA, FIN-00250 Helsinki, Finland.						Arinen S, 1998, MAIN FINDINGS FINNIS, P5; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; Flodin U, 1996, SCAND J WORK ENV HEA, V22, P451; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; Haahtela T, 1998, THORAX, V53, P1005; HELAKORPI S, 1999, PUBLICATION NATL PUB, pB19; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058; Karjalainen A., 1998, European Respiratory Journal, V12, p76s; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262; Meredith S, 1996, THORAX, V51, P435, DOI 10.1136/thx.51.4.435; Milton DK, 1998, AM J IND MED, V33, P1, DOI 10.1002/(SICI)1097-0274(199801)33:1<1::AID-AJIM1>3.0.CO;2-2; NG TP, 1994, AM J IND MED, V25, P709, DOI 10.1002/ajim.4700250510; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Reijula K, 1996, CHEST, V110, P58, DOI 10.1378/chest.110.1.58; ROTHMAN KJ, 1997, MODER EPIDEMIOLOGY; Sears MR, 1997, LANCET, V350, P1; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; Toren K, 1999, EUR RESPIR J, V13, P496, DOI 10.1183/09031936.99.13349699; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534; XU XP, 1993, CHEST, V104, P1364, DOI 10.1378/chest.104.5.1364	25	132	134	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2001	164	4					565	568				4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	469LL	WOS:000170816900011	11520716	
J	Ostro, B; Lipsett, M; Mann, J; Braxton-Owens, H; White, M				Ostro, B; Lipsett, M; Mann, J; Braxton-Owens, H; White, M			Air pollution and exacerbation of asthma in African-American children in Los Angeles	EPIDEMIOLOGY			English	Article						air pollution; asthma; children; race; particulate matter; fungi; pollens; environmental exposure	EMERGENCY ROOM VISITS; RESPIRATORY HEALTH; CHILDHOOD ASTHMA; OZONE EXPOSURE; PM10 POLLUTION; ACID AEROSOLS; SYMPTOMS; SEVERITY; ADMISSIONS; CALIFORNIA	Significant increases in asthma morbidity and mortality in the United States have occurred since the 1970s, particularly among African-Americans. Exposure to various environmental factors, including air pollutants and allergens, has been suggested as a partial explanation of these trends. To examine relations between several air pollutants and asthma exacerbation in African Americans, we recruited a panel of 138 children in central Los Angeles. We recorded daily data on respiratory symptoms and medication use for 13 weeks and examined these data in conjunction with data on ozone (O-3) nitrogen dioxide (NO2), particulate matter (PM10 and PM2.5), meteorological variables, pollens, and molds. Using generalized estimating equations, we found associations between respiratory symptom occurrence and several environmental factors. For example, new episodes of cough were associated with exposure to PM10 (OR = 1.25; 95% CI = 1.12-1.39; interquartile range [IQR] = 17 mug/m(3), 24-hour average), PM2.5 (OR = 1.10; 95% CI = 1.03-1.18; IQR = 30 mug/m(3), 12-hour average), NO2, and the molds Cladosporium and Alternaria, but not with exposure to O-3 or pollen. The factors PM10 and O-3 were associated with the use of extra asthma medication. For this population several bioaerosols and air pollutants had effects that may be clinically significant.	Calif Off Environm Hlth Hazard Assessment, Air Pollut Epidemiol Unit, Oakland, CA 94612 USA; Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Calif Publ Hlth Inst, Berkeley, CA USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Air Pollut Resp Hlth Branch, Atlanta, GA USA	Ostro, B (reprint author), Calif Off Environm Hlth Hazard Assessment, Air Pollut Epidemiol Unit, 1515 Clay St,16th Floor, Oakland, CA 94612 USA.		White, Mary /C-9242-2012	White, Mary /0000-0002-9826-3962	PHS HHS [U60/CCU908048-03-1]		BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Gong H, 1997, ARCH ENVIRON HEALTH, V52, P34; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Hallaren MT, 1991, NEW ENGL J MED, V324, P359; OSTRO BD, 1991, AM J PUBLIC HEALTH, V81, P694, DOI 10.2105/AJPH.81.6.694; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; SLY RM, 1988, ANN ALLERGY, V60, P433; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	28	132	140	1	25	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	MAR	2001	12	2					200	208		10.1097/00001648-200103000-00012		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	405CJ	WOS:000167139400012	11246581	
J	Custovic, A; Simpson, BM; Simpson, A; Hallam, C; Craven, M; Brutsche, M; Woodcock, A				Custovic, A; Simpson, BM; Simpson, A; Hallam, C; Craven, M; Brutsche, M; Woodcock, A			Manchester Asthma and Allergy Study: Low-allergen environment can be achieved and maintained during pregnancy and in early life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						primary prevention; dust mite; avoidance; atopy; asthma	HOUSE-DUST MITE; RISK FACTOR; P-I; SENSITIZATION; AVOIDANCE; CHILDHOOD; EXPOSURE; INFANCY; POPULATION; DISORDERS	Background: Early exposure to dust mite allergens may be critical for primary sensitization. Reducing exposure may offer a realistic chance for primary prevention of sensitization and asthma, but it is essential to implement measures that can achieve and maintain the low-allergen environment. Objective: Our purpose was to assess the effectiveness of mite allergen avoidance measures in achieving and maintaining a low-allergen environment during pregnancy and in the first year of life. Methods: The Manchester Asthma and Allergy Study is a prospective, prenatally randomized study that follows the development of asthma and atopy in a cohort of infants at high risk (both parents atopic) who are randomly allocated to full mite allergen avoidance or to a normal regimen. Avoidance measures comprise (1) mite-proof covers (mattress, pillow, and quilt) for parental bed, (2) high-filtration vacuum cleaner, (3) vinyl flooring in infant's bedroom, (4) new crib and portable crib mattresses encased in mite-proof material, (5) benzyl benzoate (Acarosan) applied on carpets and soft furniture, (6) bed linens washed in hot water weekly, and (7) washable soft toys. Dust samples from the parental bed, bedroom floor, living room floor, infant's mattress, and nursery floor were collected between the 10th and 14th weeks of pregnancy, immediately after birth, and then at age 6 months and 1 year, and Der p 1 levels were determined by mAb-based ELISA. Results: Recovered Der p 1 from maternal mattress was reduced by 97.25% (95% confidence interval [CI] 95.25%-98.41%) during the second and third trimesters of pregnancy, with the effect persisting for 6 months (98% reduction, 95% CI 97.258-99.1%) and 12 months (97.6% reduction, 95% CI 95.7%-98.6%) after the birth (active vs control, P <.000001). Total Der p 1 from bedroom floor in the active group was reduced by 53.7% (95 % CI 25.7%-71.2%) in samples collected within 4 weeks of the child's birth, with the percentage reduction being 62.8% (95 % CI 39.3%-77.2%) at 6 months and 26.5% (95% CI-24% to 57.1%) at 1 year (active compared vs control, P <.007). Der p 1 levels in crib mattress and nursery floor in the active group were extremely low (crib mattresses geometric mean [95% CI] 2.3 ng [1.6-3.4] at birth, 6.8 ng [4.5-10] at age 6 months, and 15.6 ng [9.8-24.8] at age 1 year [active vs control, P =.001]; nursery 1 ng [0.9-1.1] at birth, 1.7 ng [1.2-2.5] at age 6 months, and 2 ng [1.3-3.5] at age 1 year [active vs control, P <.00001]). The total amount of allergen recovered at age 1 year was 29-fold (95% CI 15.1- to 56.7-fold) higher in the control group than in the active group. Conclusions: The avoidance measures used in this study achieved and maintained a low mite allergen environment during pregnancy and in the first year of life in homes of infants at risk of atopy.	Wythenshawe Hosp, North West Lung Ctr, Manchester M23 9LT, Lancs, England	Custovic, A (reprint author), Wythenshawe Hosp, North West Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666			ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Asher MI, 1998, EUR RESPIR J, V12, P315; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P581; BROWN T, 1994, IRISH UNIV REV, V24, P38; Custovic A, 1998, THORAX, V53, P63; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Holt PG, 1997, THORAX, V52, P1; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; *NAT ASTHM CAMP, 1999, NAT ASTHM AUD 1999 2; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; [Anonymous], 1997, EUR ALL WHIT PAP; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	27	132	136	0	5	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				252	258		10.1016/S0091-6749(00)90073-3		7	Allergy; Immunology	Allergy; Immunology	285RQ	WOS:000085402200008	10669844	
J	Bel, EH; Sousa, A; Fleming, L; Bush, A; Chung, KF; Versnel, J; Wagener, AH; Wagers, SS; Sterk, PJ; Compton, CH				Bel, Elisabeth H.; Sousa, Ana; Fleming, Louise; Bush, Andrew; Chung, K. Fan; Versnel, Jennifer; Wagener, Ariane H.; Wagers, Scott S.; Sterk, Peter J.; Compton, Chris H.		Unbiased Biomarkers Prediction	Diagnosis and definition of severe refractory asthma: an international consensus statement from the Innovative Medicine Initiative (IMI)	THORAX			English	Review							TO-TREAT ASTHMA; RANDOMIZED CONTROLLED-TRIAL; AIR-FLOW LIMITATION; LUNG-FUNCTION; SPUTUM EOSINOPHILIA; RESEARCH-PROGRAM; CLINICAL CHARACTERISTICS; INHALED CORTICOSTEROIDS; GASTROESOPHAGEAL-REFLUX; OCCUPATIONAL ASTHMA	Patients with severe refractory asthma pose a major healthcare problem. Over the last decade it has become increasingly clear that, for the development of new targeted therapies, there is an urgent need for further characterisation and classification of these patients. The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U-BIOPRED) consortium is a pan-European public-private collaboration funded by the European Commission Innovative Medicines Initiative of the European Union. U-BIOPRED aims to subphenotype patients with severe refractory asthma by using an innovative systems biology approach. This paper presents the U-BIOPRED international consensus on the definition and diagnosis of severe asthma, aligning the latest concepts in adults as well as in children. The consensus is based on existing recommendations up to 2010 and will be used for the selection of patients for the upcoming U-BIOPRED study. It includes the differentiation between 'problematic', 'difficult' and 'severe refractory' asthma, and provides a systematic algorithmic approach to the evaluation of patients presenting with chronic severe asthma symptoms for use in clinical research and specialised care.	[Bel, Elisabeth H.; Wagener, Ariane H.; Sterk, Peter J.] Univ Amsterdam, Dept Resp Med, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Sousa, Ana] GlaxoSmithKline Inc, Stevenage, Herts, England; [Fleming, Louise] Univ London Imperial Coll Sci Technol & Med, Clin Trials & Evaluat Unit, London, England; [Bush, Andrew] Royal Brompton Hosp, Dept Paediat Resp Med, London SW3 6LY, England; [Chung, K. Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Versnel, Jennifer] Asthma UK, London, England; [Wagers, Scott S.] BioSci Consulting, Maasmechelen, Belgium; [Compton, Chris H.] EFPIA Headquarters, EFPIA, Brussels, Belgium	Bel, EH (reprint author), Univ Amsterdam, Dept Resp Med, Acad Med Ctr, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	e.h.bel@amc.uva.nl	Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; Chung, Kian Fan/0000-0001-7101-1426; Djukanovic, Ratko/0000-0001-6039-5612	European Commission Innovative Medicine Initiative [IMI_Call_2008_1_12]	This report was supported by grants from the European Commission Innovative Medicine Initiative Understanding Severe Asthma, IMI_Call_2008_1_12; final protocol available at http://www.imi.europa.eu/.	Adcock IM, 2008, LANCET, V372, P1073, DOI 10.1016/S0140-6736(08)61449-X; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694; Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Bel Elisabeth, 2005, Treat Respir Med, V4, P365, DOI 10.2165/00151829-200504060-00002; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Bush Andrew, 2009, Proc Am Thorac Soc, V6, P712, DOI 10.1513/pats.200906-046DP; Castro M, 2009, AM J RESP CRIT CARE, V181, P116; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Chung KF, 1999, EUR RESPIR J, V13, P1198; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-11740C; Denning DW, 2009, AM J RESP CRIT CARE, V179, P11, DOI 10.1164/rccm.200805-737OC; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; Ehnhage A, 2009, ALLERGY, V64, P762, DOI 10.1111/j.1398-9995.2008.01870.x; FitzGerald JM, 2006, THORAX, V61, P992, DOI 10.1136/thx.2005.045195; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harding SM, 2000, AM J RESP CRIT CARE, V162, P34; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Hedlin G, 2010, EUR RESPIR J, V36, P196, DOI 10.1183/09031936.00104809; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; Horne R, 2006, CHEST, V130, p65S, DOI 10.1378/chest.130.1_suppl.65S; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Juniper EF, 2006, RESP MED, V100, P616, DOI 10.1016/j.rmed.2005.08.012; Kiljander TO, 2010, AM J RESP CRIT CARE, V181, P1042, DOI 10.1164/rccm.200910-1537OC; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; LUNDE H, 1994, BRIT MED J, V308, P18; MACGREGOR AMC, 1993, ARCH SURG-CHICAGO, V128, P1153; Maclennan C, 2006, PEDIATR PULM, V41, P577, DOI 10.1002/ppul.20415; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; [Anonymous], NAT ASTHM ED PREV PR; National Institutes of Health National Heart Lung and Blood Institute Global Initiative for Asthma, 2008, GLOB STRAT ASTHM MAN; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Rayens MK, 2008, J ALLERGY CLIN IMMUN, V122, P537, DOI 10.1016/j.jaci.2008.06.029; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Reddy RC, 2011, OBES SURG, V21, P200, DOI 10.1007/s11695-010-0155-6; Ricciardolo FLM, 2004, AM J RESP CRIT CARE, V169, P1252; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Rothenberg SS, 2008, J ALLERGY CLIN IMMUN, V121, P1069, DOI 10.1016/j.jaci.2008.02.027; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Salpeter S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003566.pub2; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Strunk RC, 2006, NEW ENGL J MED, V354, P2689, DOI 10.1056/NEJMct055184; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; The ENFUMOSA cross-sectional European multicentre study of the clinical phenotype of chronic severe asthma, 2003, EUR RESP J, V22, P470; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; van Veen IH, 2009, J ALLERGY CLIN IMMUN, V124, P615, DOI 10.1016/j.jaci.2009.06.029; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Williams LK, 2007, J ALLERGY CLIN IMMUN, V120, P1153, DOI 10.1016/j.jaci.2007.08.020; Williams LK, 2004, J ALLERGY CLIN IMMUN, V114, P1288, DOI 10.1016/j.jaci.2004.09.028; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341	82	131	135	3	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	OCT	2011	66	10					910	917		10.1136/thx.2010.153643		8	Respiratory System	Respiratory System	822EO	WOS:000295026900013	21106547	
J	Reilly, JJ; Kelly, J				Reilly, J. J.; Kelly, J.			Long-term impact of overweight and obesity in childhood and adolescence on morbidity and premature mortality in adulthood: systematic review	INTERNATIONAL JOURNAL OF OBESITY			English	Review						overweight; child; BMI; morbidity	BODY-MASS INDEX; CORONARY-HEART-DISEASE; CARDIOVASCULAR RISK-FACTORS; YOUNG ADULTHOOD; FOLLOW-UP; BLOOD-PRESSURE; BREAST-CANCER; LIFE-COURSE; MIDDLE-AGE; SUBSEQUENT MORTALITY	Background and objective: The last systematic review on the health consequences of child and adolescent obesity found little evidence on consequences for adult health. The present study aimed to summarize evidence on the long-term impact of child and adolescent obesity for premature mortality and physical morbidity in adulthood. Methods: Systematic review with evidence searched from January 2002 to June 2010. Studies were included if they contained a measure of overweight and/or obesity between birth and 18 years (exposure measure) and premature mortality and physical morbidity (outcome) in adulthood. Results: Five eligible studies examined associations between overweight and/or obesity, and premature mortality: 4/5 found significantly increased risk of premature mortality with child and adolescent overweight or obesity. All 11 studies with cardiometabolic morbidity as outcomes reported that overweight and obesity were associated with significantly increased risk of later cardiometabolic morbidity (diabetes, hypertension, ischaemic heart disease, and stroke) in adult life, with hazard ratios ranging from 1.1-5.1. Nine studies examined associations of child or adolescent overweight and obesity with other adult morbidity: studies of cancer morbidity were inconsistent; child and adolescent overweight and obesity were associated with significantly increased risk of later disability pension, asthma, and polycystic ovary syndrome symptoms. Conclusions: A relatively large and fairly consistent body of evidence now demonstrates that overweight and obesity in childhood and adolescence have adverse consequences on premature mortality and physical morbidity in adulthood. International Journal of Obesity (2011) 35, 891-898; doi: 10.1038/ijo.2010.222; published online 26 October 2010	[Reilly, J. J.] Univ Glasgow, Yorkhill Hosp, Fac Med, Glasgow G3 8SJ, Lanark, Scotland; [Kelly, J.] NHS QIS, Scottish Intercollegiate Guidelines Network, Glasgow, Lanark, Scotland	Reilly, JJ (reprint author), Univ Glasgow, Yorkhill Hosp, Fac Med, Glasgow G3 8SJ, Lanark, Scotland.	jjr2y@clinmed.gla.ac.uk	Sriwisit, Sukhumaphorn/G-1405-2011		Scottish Funding Council	This work was funded by Scottish Funding Council.	Adair LS, 2009, AM J CLIN NUTR, V89, P1383, DOI 10.3945/ajcn.2008.27139; Baer HJ, 2005, BREAST CANCER RES, V7, pR314, DOI 10.1186/bcr998; Baker JL, 2007, NEW ENGL J MED, V357, P2329, DOI 10.1056/NEJMoa072515; Bardia A, 2009, CANCER EPIDEM BIOMAR, V17, P374; Barlow SE, 2007, PEDIATRICS, V120, pS164, DOI 10.1542/peds.2007-2329C; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Bibbins-Domingo K, 2007, NEW ENGL J MED, V357, P2371, DOI 10.1056/NEJMsa073166; Bjorge T, 2008, AM J EPIDEMIOL, V157, P517; Bjorge T, 2008, AM J EPIDEMIOL, V168, P30, DOI 10.1093/aje/kwn096; Daniels SR, 2009, INT J OBESITY, V33, pS60, DOI 10.1038/ijo.2009.20; Daviglus Martha L, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P125, DOI 10.1586/14737167.5.2.125; Engeland A, 2003, AM J EPIDEMIOL, V157, P517, DOI 10.1093/aje/kwf219; Engeland A, 2004, EPIDEMIOLOGY, V15, P79, DOI 10.1097/01.ede.0000100148.40711.59; Falkstedt D, 2007, INT J OBESITY, V31, P777, DOI 10.1038/sj.ijo.0803480; Ferraro KF, 2003, J GERONTOL B-PSYCHOL, V58, pS110; Field AE, 2005, OBES RES, V13, P163, DOI 10.1038/oby.2005.21; Ford CA, 2008, J ADOLESCENT HEALTH, V43, P576, DOI 10.1016/j.jadohealth.2008.06.010; Franks PW, 2010, NEW ENGL J MED, V362, P485, DOI 10.1056/NEJMoa0904130; Freedman DS, 2008, INT J OBESITY, V32, P749, DOI 10.1038/sj.ijo.0803798; Freedman DS, 2007, J PEDIATR-US, V150, P12, DOI 10.1016/j.jpeds.2006.08.042; Gordon-Larsen P, 2007, OBESITY, V15, P2790, DOI 10.1038/oby.2007.331; Gunnell DJ, 1998, AM J CLIN NUTR, V67, P1111; Han JC, 2010, LANCET, V375, P1737, DOI 10.1016/S0140-6736(10)60171-7; Hill AJ, 2011, OBESITY EPI IN PRESS; HOFFMANS MDAF, 1988, J CLIN EPIDEMIOL, V41, P749, DOI 10.1016/0895-4356(88)90161-8; Hypponen E, 2003, DIABETES CARE, V26, P2512, DOI 10.2337/diacare.26.9.2512; Jeffreys M, 2004, INT J CANCER, V112, P348, DOI 10.1002/ijc.20423; Jeffreys M, 2003, INT J OBESITY, V27, P1391, DOI 10.1038/sj.ijo.0802414; Karnehed N, 2007, SCAND J PUBLIC HEALT, V35, P48, DOI 10.1080/14034940600858524; Laitinen J, 2003, INT J OBESITY, V27, P710, DOI 10.1038/sj.ijo.0802301; Lammi N, 2009, DIABETOLOGIA, V52, P403; Law CM, 2002, CIRCULATION, V105, P1088, DOI 10.1161/hc0902.104677; Lawlor DA, 2006, DIABETOLOGIA, V49, P2614, DOI 10.1007/s00125-006-0408-z; Lawlor DA, 2005, CIRCULATION, V111, P1891, DOI 10.1161/01.CIR.0000161798.45728.4D; Lawlor DA, 2006, AM J CLIN NUTR, V83, P767; Lee JM, 2010, INT J OBESITY, V34, P614, DOI 10.1038/ijo.2009.235; Leeners B, 2006, EARLY HUM DEV, V82, P663, DOI 10.1016/j.earlhumdev.2005.12.012; Li L, 2007, J HYPERTENS, V25, P1215, DOI 10.1097/HJH.0b013e3280f3c01a; Li S, 2003, JAMA-J AM MED ASSOC, V290, P2071; Lobstein T, 2006, INT J PEDIAR OBES, V1, P26; Mamun AA, 2009, OBESITY, V17, P1255; MUST A, 1992, NEW ENGL J MED, V327, P1350, DOI 10.1056/NEJM199211053271904; Must A, 2006, INT J OBESITY, V30, P590, DOI 10.1038/sj.ijo.0803300; Narayan KMV, 2007, DIABETES CARE, V30, P1562, DOI 10.2337/dc06-2544; Neovius M, 2008, INT J OBESITY, V32, P1319, DOI 10.1038/ijo.2008.70; Neovius M, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b496; Nguyen QM, 2010, DIABETES CARE, V33, P670, DOI 10.2337/dc09-1635; Okasha M, 2002, J EPIDEMIOL COMMUN H, V56, P780, DOI 10.1136/jech.56.10.780; Owen CG, 2009, INT J OBESITY, V33, P866, DOI 10.1038/ijo.2009.102; Raghuveer G, 2010, AM J CLIN NUTR, V91, p1514S, DOI 10.3945/ajcn.2010.28701D; Reilly JJ, 2003, ARCH DIS CHILD, V88, P748, DOI 10.1136/adc.88.9.748; Reilly JJ, 2006, INT J OBESITY, V30, P595, DOI 10.1038/sj.ijo.0803301; Reilly JJ, 2011, OBESITY EPI IN PRESS; Sachdev HPS, 2009, ARCH DIS CHILD, V94, P768, DOI 10.1136/adc.2008.140905; Sanderson M, 2002, BRIT J CANCER, V86, P84, DOI 10.1038/sj/bjc.6600009; Schubert CM, 2009, J PEDIAT, V155; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Singh AS, 2008, OBES REV, V9, P474, DOI 10.1111/j.1467-789X.2008.00475.x; Srinivasan SR, 2003, METABOLISM, V52, P443, DOI 10.1053/meta.2003.50065; Sun SS, 2008, J PEDIATR, V152, P191, DOI 10.1016/j.jpeds.2007.07.055; Swerdlow AJ, 2002, J NATL CANCER I, V94, P1238; van Dam RM, 2006, ANN INTERN MED, V145, P91; Viner RM, 2005, BRIT MED J, V330, P1339; Wang LY, 2010, J ADOLESCENT HEALTH, V46, P467, DOI 10.1016/j.jadohealth.2009.11.204; Xanthakos SA, 2007, J PEDIATR-US, V150, P3, DOI 10.1016/j.jpeds.2006.11.040; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166	66	131	140	6	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0307-0565			INT J OBESITY	Int. J. Obes.	JUL	2011	35	7					891	898		10.1038/ijo.2010.222		8	Endocrinology & Metabolism; Nutrition & Dietetics	Endocrinology & Metabolism; Nutrition & Dietetics	791DB	WOS:000292641300002		
J	Vocanson, M; Hennino, A; Rozieres, A; Poyet, G; Nicolas, JF				Vocanson, M.; Hennino, A.; Rozieres, A.; Poyet, G.; Nicolas, J. -F.			Effector and regulatory mechanisms in allergic contact dermatitis	ALLERGY			English	Review						allergic contact dermatitis; CD4+regulatory T cells; CD8+effector T cells; haptens; mast cells	CD8(+) T-CELLS; DELAYED-TYPE HYPERSENSITIVITY; LANGERIN(+) DENDRITIC CELLS; EPIDERMAL LANGERHANS CELLS; MAJOR HISTOCOMPATIBILITY COMPLEX; CUTANEOUS LYMPHOCYTE ANTIGEN; IN-VIVO; IMMUNE-RESPONSES; INFLAMMATORY RESPONSES; SKIN SENSITIZATION	Allergic contact dermatitis (ACD), one of the commonest occupational diseases, is a T-cell-mediated skin inflammation caused by repeated skin exposure to contact allergens, i.e. nonprotein chemicals called haptens. Allergic contact dermatitis, also referred to as contact hypersensitivity, is mediated by CD8+ T cells, which are primed in lymphoid organs during the sensitization phase and are recruited in the skin upon re-exposure to the hapten. Subsets of CD4+ T cells endowed with suppressive activity are responsible for both the down-regulation of eczema in allergic patients and the prevention of priming to haptens in nonallergic individuals. Therefore, ACD should be considered as a breakdown of the skin immune tolerance to haptens. Recent advances in the pathophysiology of ACD have demonstrated the important role of skin innate immunity in the sensitization process and have revisited the dogma that Langerhans cells are mandatory for CD8+ T-cell priming. They have also introduced mast cells as a pivotal actor in the magnitude of the inflammatory reaction. Finally, the most recent studies address the nature, the mode and the site of action of the regulatory T cells that control the skin inflammation with the aim of developing new strategies of tolerance induction in allergic patients.	[Vocanson, M.] INSERM, IFR BioSci Lyon Gerland 128, U851, F-69365 Lyon, France; [Vocanson, M.; Hennino, A.; Rozieres, A.; Poyet, G.; Nicolas, J. -F.] Univ Lyon 1, Fac Med Lyon Sud, F-69365 Lyon, France; [Vocanson, M.; Hennino, A.; Rozieres, A.; Poyet, G.; Nicolas, J. -F.] Univ Lyon, IFR128, Lyon, France; [Nicolas, J. -F.] Hosp Civils Lyon, Lyon, France	Vocanson, M (reprint author), INSERM, IFR BioSci Lyon Gerland 128, U851, 21 Av Tony Garnier, F-69365 Lyon, France.		ROZIERES, Aurore/M-4447-2014; Marc, VOCANSON/G-5431-2017				Aiba S., 2007, ALLERGOL INT, V56, P201, DOI 10.2332/allergolint.R-07-147; Akiba H, 2002, J IMMUNOL, V168, P3079; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; Albanesi C, 2001, J LEUKOCYTE BIOL, V70, P617; Allan RS, 2006, IMMUNITY, V25, P153, DOI 10.1016/j.immuni.2006.04.017; ASANO Y, 2008, EUR J DERMATOL, V19, P166; ASKENASE PW, 1980, J EXP MED, V152, P1358, DOI 10.1084/jem.152.5.1358; Avenel-Audran M, 1999, Allerg Immunol (Paris), V31, P217; Belsito DV, 2000, J ALLERGY CLIN IMMUN, V105, P409, DOI 10.1067/mai.2000.104937; Benezra C, 1987, Acta Derm Venereol Suppl (Stockh), V134, P62; Bennett CL, 2005, J CELL BIOL, V169, P569, DOI 10.1083/jcb.200501071; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Biedermann T, 2000, J EXP MED, V192, P1441, DOI 10.1084/jem.192.10.1441; Biedermann T, 2001, EUR J IMMUNOL, V31, P1582, DOI 10.1002/1521-4141(200105)31:5<1582::AID-IMMU1582>3.0.CO;2-M; Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560; Bonneville M, 2007, J INVEST DERMATOL, V127, P1430, DOI 10.1038/sj.jid.5700726; Bouloc A, 1998, J INVEST DERMATOL, V111, P44, DOI 10.1046/j.1523-1747.1998.00236.x; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Buckley DA, 2002, OCCUP MED-OXFORD, V52, P13, DOI 10.1093/occmed/52.1.13; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Campos RA, 2006, IMMUNOLOGY, V117, P536, DOI 10.1111/j.1365-2567.2006.02330.x; Campos RA, 2006, J IMMUNOL, V177, P3686; Cattani F, 2006, EUR CYTOKINE NETW, V17, P42; Cavani A, 2003, J IMMUNOL, V171, P5760; Cavani A, 2001, TRENDS IMMUNOL, V22, P118, DOI 10.1016/S1471-4906(00)01815-9; CAVANI A, 1995, J IMMUNOL, V154, P1232; Cavani A, 2007, CURR OPIN ALLERGY CL, V7, P404; Cavani Andrea, 2003, Curr Opin Allergy Clin Immunol, V3, P243, DOI 10.1097/00130832-200308000-00002; Chen AI, 1999, IMMUNITY, V11, P689, DOI 10.1016/S1074-7613(00)80143-0; CHER DJ, 1987, J IMMUNOL, V138, P3688; Coenraads P-J, 2007, Eur J Dermatol, V17, P564; Cumberbatch M, 2003, APMIS, V111, P797, DOI 10.1034/j.1600-0463.2003.11107811.x; Divkovic M, 2005, CONTACT DERMATITIS, V53, P189, DOI 10.1111/j.0105-1873.2005.00683.x; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Dubois B, 2003, EUR J DERMATOL, V13, P111; Dudda JC, 2004, J IMMUNOL, V172, P857; Engeman T, 2004, J LEUKOCYTE BIOL, V76, P941, DOI 10.1189/jlb.0304193; ENK AH, 1995, J INVEST DERMATOL, V105, pS80, DOI 10.1111/1523-1747.ep12316112; Erdmann I, 2002, J IMMUNOL, V168, P2139; Fukunaga A, 2008, J IMMUNOL, V180, P3057; Furio L, 2008, EUR J DERMATOL, V18, P141, DOI 10.1684/ejd.2008.0351; Gainers ME, 2007, J IMMUNOL, V179, P8509; Gamerdinger K, 2003, J EXP MED, V197, P1345, DOI 10.1084/jem.20030121; GAWKRODGER DJ, 1986, CONTACT DERMATITIS, V15, P132, DOI 10.1111/j.1600-0536.1986.tb01312.x; Ginhoux F, 2007, J EXP MED, V204, P3133, DOI 10.1084/jem.20071733; Girardi M, 2002, J EXP MED, V195, P855, DOI 10.1084/jem.20012000; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; GOCINSKI BL, 1990, J IMMUNOL, V144, P4121; Gorbachev AV, 2001, CRIT REV IMMUNOL, V21, P451; Gorbachev AV, 2001, J IMMUNOL, V167, P156; GRABBE S, 1995, J IMMUNOL, V155, P4207; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Griem P, 1998, IMMUNOL TODAY, V19, P133, DOI 10.1016/S0167-5699(97)01219-X; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Hagvall L, 2007, CHEM RES TOXICOL, V20, P807, DOI 10.1021/tx700017v; He DG, 2006, J IMMUNOL, V177, P6852; Herrick CA, 2003, J ALLERGY CLIN IMMUN, V111, P1087, DOI 10.1067/mai.2003.1413; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; Jakob T, 2001, J ALLERGY CLIN IMMUN, V108, P688; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; KALISH RS, 1994, J CLIN INVEST, V93, P2039, DOI 10.1172/JCI117198; Kaplan DH, 2008, EUR J IMMUNOL, V38, P2369, DOI 10.1002/eji.200838397; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Karlberg AT, 2008, CHEM RES TOXICOL, V21, P53, DOI 10.1021/tx7002239; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331; Kerfoot SM, 2008, J IMMUNOL, V181, P1717; Kim HK, 2006, J LEUKOCYTE BIOL, V79, P686, DOI 10.1189/jlb.0805436; Kish DD, 2005, J LEUKOCYTE BIOL, V78, P725, DOI 10.1189/jlb.0205069; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kissenpfennig A, 2006, TRENDS IMMUNOL, V27, P132, DOI 10.1016/j.it.2006.01.003; Kohler J, 1997, J IMMUNOL, V158, P591; Kolesaric A, 1997, J INVEST DERMATOL, V109, P580, DOI 10.1111/1523-1747.ep12337508; Kondo S, 1996, J IMMUNOL, V157, P4822; Krasteva M, 1998, J IMMUNOL, V160, P1181; Krasteva M, 1999, EUR J DERMATOL, V9, P65; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; LARSEN JM, 2008, J ALLERGY CLIN IMMUN, V123, P486; Le Borgne M, 2006, IMMUNITY, V24, P191, DOI 10.1016/j.immuni.2006.01.005; Lebbink RJ, 2007, MOL IMMUNOL, V44, P2153, DOI 10.1016/j.molimm.2006.11.014; Lepoittevin JP, 2006, CONTACT DERMATITIS, V54, P73, DOI 10.1111/j.0105-1873.2006.00795.x; Lepoittevin JP, 1997, EUR J DERMATOL, V7, P151; Li L, 1997, J IMMUNOL, V158, P4152; Lopez CB, 1998, INT ARCH ALLERGY IMM, V117, P194, DOI 10.1159/000024010; Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518; LYNCH DH, 1981, J IMMUNOL, V126, P1892; Maeda A, 2008, J IMMUNOL, V180, P3065; Mahnke K, 2007, EUR J IMMUNOL, V37, P2117, DOI 10.1002/eji.200636841; Martin S, 2003, EXP DERMATOL, V12, P78, DOI 10.1034/j.1600-0625.2003.120110.x; MARTIN S, 1993, J IMMUNOL, V151, P678; MARTIN S, 1992, J IMMUNOL, V149, P2569; Martin S, 2000, J INVEST DERMATOL, V115, P260, DOI 10.1046/j.1523-1747.2000.00038.x; Martin SF, 2004, J IMMUNOL, V173, P3178; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Martin SF, 2008, CURR OPIN ALLERGY CL, V8, P289, DOI 10.1097/ACI.0b013e3283088cf9; Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Maurer M, 2003, J CLIN INVEST, V112, P432, DOI 10.1172/JCI200318106; MCMINN PC, 1990, IMMUNOLOGY, V71, P46; Melrose J, 1998, J IMMUNOL, V161, P2457; Meng XM, 1998, J CLIN INVEST, V101, P1462, DOI 10.1172/JCI1031; Merk HF, 2007, TOXICOL APPL PHARM, V224, P313, DOI 10.1016/j.taap.2007.01.004; Mora JR, 2006, TRENDS IMMUNOL, V27, P235, DOI 10.1016/j.it.2006.03.007; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nicolas JF, 2008, ANN DERMATOL VENER, V135, P733, DOI 10.1016/j.annder.2008.07.047; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; O'Garra A, 2007, NAT REV IMMUNOL, V7, P425, DOI 10.1038/nri2097; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; Pichler Werner J, 2006, Allergol Int, V55, P17, DOI 10.2332/allergolint.55.17; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724; PTAK W, 1980, J EXP MED, V151, P362, DOI 10.1084/jem.151.2.362; Reiser H, 1996, EUR J IMMUNOL, V26, P880, DOI 10.1002/eji.1830260424; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Riemann H, 2005, J IMMUNOL, V175, P5866; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Ruckert R, 2002, J INVEST DERMATOL, V119, P370, DOI 10.1046/j.1523-1747.2002.01849.x; Sabatte J, 2007, CYTOKINE GROWTH F R, V18, P5, DOI 10.1016/j.cytogfr.2007.01.002; Saint-Mezard P, 2004, EUR J DERMATOL, V14, P284; Saint-Mezard P, 2004, EUR J DERMATOL, V14, P131; Saint-Mezard P, 2003, J INVEST DERMATOL, V120, P641, DOI 10.1046/j.1523-1747.2003.12093.x; Sakaguchi S, 2006, IMMUNOL REV, V212, P8, DOI 10.1111/j.0105-2896.2006.00427.x; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359; Santamaria-Babi LF, 2004, EUR J DERMATOL, V14, P13; Shevach EM, 2006, IMMUNITY, V25, P195, DOI 10.1016/j.immuni.2006.08.003; Skold M, 2004, CHEM RES TOXICOL, V17, P1697, DOI 10.1021/tx049831z; Suzuki K, 2007, NATURE, V446, P680, DOI 10.1038/nature05652; SYMINGTON FW, 1993, J IMMUNOL, V150, P1286; Takeshita K, 2004, INT IMMUNOL, V16, P685, DOI 10.1093/intimm/dxh073; Tamagawa-Mineoka R, 2007, AM J PATHOL, V170, P2019, DOI 10.2353/ajpath.2007.060881; TAMAKI K, 1981, J INVEST DERMATOL, V77, P225, DOI 10.1111/1523-1747.ep12480043; Traidl C, 2000, J IMMUNOL, V165, P3058; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839; Tsuji RF, 2002, J EXP MED, V196, P1277, DOI 10.1084/jem.20020649; Tsuji RF, 2000, J IMMUNOL, V165, P1588; Tsushima F, 2003, EUR J IMMUNOL, V33, P2773, DOI 10.1002/eji.200324084; Van Och FMM, 2002, TOXICOL APPL PHARM, V184, P46, DOI 10.1006/taap.2002.9473; Villadangos JA, 2005, SEMIN IMMUNOL, V17, P262, DOI 10.1016/j.smim.2005.05.015; Villadangos JA, 2007, IMMUNITY, V26, P390, DOI 10.1016/j.immuni.2007.04.006; Vocanson M, 2006, M S-MED SCI, V22, P158, DOI 10.1051/medsci/2006222158; Vocanson M, 2006, J INVEST DERMATOL, V126, P815, DOI 10.1038/sj.jid.5700174; VONBONIN A, 1992, INT IMMUNOL, V4, P869, DOI 10.1093/intimm/4.8.869; Wakabayashi T, 2005, IMMUNOL CELL BIOL, V83, P18, DOI 10.1111/j.1440-1711.2005.01310.x; Walzer T, 2003, J IMMUNOL, V170, P1615; Wang LC, 2008, J IMMUNOL, V180, P4722; Wang YH, 2007, J CLIN INVEST, V117, P3655, DOI 10.1172/JCI34182; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; Wulferink M, 2002, EUR J IMMUNOL, V32, P1338, DOI 10.1002/1521-4141(200205)32:5<1338::AID-IMMU1338>3.0.CO;2-4; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Xu H, 1997, J IMMUNOL, V158, P4721; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; Yang JP, 2006, P NATL ACAD SCI USA, V103, P147, DOI 10.1073/pnas.0509054103; Yokozeki H, 2001, CLIN EXP IMMUNOL, V125, P351, DOI 10.1046/j.1365-2249.2001.01570.x; Zaba LC, 2009, J INVEST DERMATOL, V129, P302, DOI 10.1038/jid.2008.225; Zhang Y, 2002, J BIOL INORG CHEM, V7, P327, DOI 10.1007/s00775-001-0302-6	159	131	137	1	22	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	DEC	2009	64	12					1699	1714		10.1111/j.1398-9995.2009.02082.x		16	Allergy; Immunology	Allergy; Immunology	516CT	WOS:000271520000001	19839974	
J	Burks, AW; Laubach, S; Jones, SM				Burks, A. Wesley; Laubach, Susan; Jones, Stacie M.			Oral tolerance, food allergy, and immunotherapy: Implications for future treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immune tolerance; immunotherapy; food allergy; food hypersensitivity; T cells; TGF-beta; clonal anergy; forkhead box P3 protein; sublingual immunotherapy; oral immunotherapy	REGULATORY T-CELLS; COWS MILK ALLERGY; GROWTH-FACTOR-BETA; QUALITY-OF-LIFE; PEANUT ALLERGY; TGF-BETA; ACTIVE SUPPRESSION; IMMUNE-RESPONSES; SMALL-INTESTINE; MURINE MODEL	The lumen of the gastrointestinal tract is exposed daily to an array of dietary proteins. The vast majority of proteins are tolerated through suppression of cellular or Immoral responses, a process known as oral tolerance. However, in approximately 6% of children and 4% of adults in the United States, tolerance to a given dietary antigen either is not established or breaks down, resulting in food hypersensitivity. Although food allergies can result in sudden and life-threatening symptoms, their prevalence is remarkably low considering the complexities of the gut-associated mucosal system. Suppression involves signaling by an array of nonprofessional antigen-presenting cells, dendritic cells, and regulatory T cells, as well as lymphocyte anergy or deletion. Several factors, including antigen properties, route of exposure, and genetics and age of the host, contribute to the development of oral tolerance. Although the current standard of care for patients with food allergies is based on avoidance of the trigger, increased understanding of the mechanisms involved in tolerance has shifted focus of treatment and prevention toward inducing tolerance. Data from early-phase clinical trials suggest both sublingual and oral immunotherapy are effective in reducing sensitivity to allergens. In this article we review the mechanisms of tolerance, discuss aberrations in oral tolerance, and provide information on novel prevention and treatment paradigms for food allergy.	[Burks, A. Wesley; Laubach, Susan] Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA; [Jones, Stacie M.] Univ Arkansas Med Sci, Div Allergy & Immunol, Dept Pediat, Little Rock, AR 72205 USA; [Jones, Stacie M.] Arkansas Childrens Hosp, Little Rock, AR USA	Burks, AW (reprint author), Duke Univ, Med Ctr, Div Allergy & Immunol, Dept Pediat, Durham, NC 27710 USA.	wesley.burks@duke.edu					Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Barone KS, 2000, CELL IMMUNOL, V199, P65, DOI 10.1006/cimm.1999.1603; BARONE KS, 1995, CELL IMMUNOL, V163, P19, DOI 10.1006/cimm.1995.1094; Bennett CL, 2001, NAT GENET, V27, P20; Beyer K, 2005, J ALLERGY CLIN IMMUN, V116, P704, DOI 10.1016/j.jaci.2005.05.007; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; BLAND PW, 1986, IMMUNOLOGY, V58, P9; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; Chatchatee P, 2001, CLIN EXP ALLERGY, V31, P1256, DOI 10.1046/j.1365-2222.2001.01167.x; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; CHEN YH, 1995, J IMMUNOL, V155, P910; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Dakin R, 1929, AM J MED SCI, V4, P98; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Freire-de-Lima CG, 2000, NATURE, V403, P199, DOI 10.1038/35003208; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; GARSIDE P, 1995, INT IMMUNOL, V7, P501, DOI 10.1093/intimm/7.3.501; *IMM TOL NETW, LEAP STUD; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kawai T, 2006, CELL DEATH DIFFER, V13, P816, DOI 10.1038/sj.cdd.4401850; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kopper RA, 2005, INT ARCH ALLERGY IMM, V136, P16, DOI 10.1159/000082580; Kraehenbuhl J P, 1992, Trends Cell Biol, V2, P170, DOI 10.1016/0962-8924(92)90036-M; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Levy Y, 2003, ALLERGY, V58, P1206, DOI 10.1046/j.1398-9995.2003.00307.x; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Marth T, 1998, ANN NY ACAD SCI, V859, P290, DOI 10.1111/j.1749-6632.1998.tb11148.x; MASON DW, 1981, NATURE, V293, P150, DOI 10.1038/293150a0; Medzhitov R, 1997, NATURE, V388, P394; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Menezes JD, 2003, INT IMMUNOL, V15, P447, DOI 10.1093/intimm/dxg043; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; SCOTT H, 1980, SCAND J IMMUNOL, V12, P77, DOI 10.1111/j.1365-3083.1980.tb00043.x; Shreffler WG, 2006, J IMMUNOL, V177, P3677; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; Torgerson TR, 2007, GASTROENTEROLOGY, V132, P1705, DOI 10.1053/j.gastro.2007.02.044; Wells HG, 1911, J INFECT DIS, V9, P147; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	61	131	140	4	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1344	1350		10.1016/j.jaci.2008.02.037		7	Allergy; Immunology	Allergy; Immunology	313WW	WOS:000256771700007	18410959	
J	Jansen, KL; Larson, TV; Koenig, JQ; Mar, TF; Fields, C; Stewart, J; Lippmann, M				Jansen, KL; Larson, TV; Koenig, JQ; Mar, TF; Fields, C; Stewart, J; Lippmann, M			Associations between health effects and particulate matter and black carbon in subjects with respiratory disease	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; black carbon; chronic obstructive pulmonary disease; fractional exhaled nitric oxide; panel study; particulate matter	EXHALED NITRIC-OXIDE; OBSTRUCTIVE PULMONARY-DISEASE; AMBIENT AIR-POLLUTION; SHORT-TERM EXPOSURE; SOURCE APPORTIONMENT; ULTRAFINE PARTICLES; ASTHMATIC-CHILDREN; OXYGEN-SATURATION; FINE PARTICLES; LUNG-FUNCTION	We measured fractional exhaled nitric oxide (FENO), spirometry, blood pressure, oxygen saturation of the blood (SaO(2)), and pulse rate in 16 older subjects with asthma or chronic obstructive pulmonary disease (COPD) in Seattle, Washington. Data were collected daily for 12 days. We simultaneously collected PM10 and PM2.5 (particulate matter <= 10 mu m or <= 2.5 mu m, respectively) filter samples at a central outdoor site, as well as outside and inside the subjects' homes. Personal PM10 filter samples were also collected. All filters were analyzed for mass and light absorbance. We analyzed within-subject associations between health outcomes and air pollution metrics using a linear mixed-effects model with random intercept, controlling for age, ambient relative humidity, and ambient temperature. For the 7 subjects with asthma, a 10 mu g/m(3) increase in 24-hr average outdoor PM10 and PM2.5 was associated with a 5.9 [95% confidence interval (CI), 2.9-8.9] and 4.2 ppb (95% CI, 1.3-7.1) increase in FENO, respectively. A 1 mu g/m(3) increase in outdoor, indoor, and personal black carbon (BC) was associated with increases in FENO of 2.3 ppb (95% Cl, 1.1-3.6), 4.0 ppb (95% CI, 2.0-5.9), and 1.2 ppb (95% Cl, 0.2-2.2), respectively. No significant association was found between PM or BC measures and changes in spirometry, blood pressure, pulse rate, or SaO(2) in these subjects. Results from this study indicate that FENO may be a more sensitive market of PM exposure than traditional health outcomes and that particle-associated BC is useful for examining associations between primary combustion constituents of PM and health outcomes.	Univ Washington, Sch Publ Hlth & Community Med, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; NYU, Sch Med, Tuxedo Pk, NY USA	Koenig, JQ (reprint author), Univ Washington, Sch Publ Hlth & Community Med, Dept Environm & Occupat Hlth Sci, Box 357234, Seattle, WA 98195 USA.	jkoenig@u.washington.edu			NIEHS NIH HHS [ES 07033, P30 ES007033]		Adamkiewicz G, 2004, THORAX, V59, P204, DOI 10.1136/thorax.2003.006445; ALLEN R, 2001, J AIR WASTE MANAGE, V51, P1651; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Brauer M, 2001, J EXPO ANAL ENV EPID, V11, P490, DOI 10.1038/sj.jea.7500195; Brunekreef B., 2005, RES REP HLTH EFF I, V127, P1; CONNY JM, 2002, J GEOPHYS RES, P107; Crapo RO, 1995, AM J RESP CRIT CARE, V152, P1107; DeMeo DL, 2004, AM J RESP CRIT CARE, V170, P383, DOI 10.1164/rccm.200402-244OC; Deykin A, 1998, AM J RESP CRIT CARE, V157, P769; Dockery DW, 2001, ENVIRON HEALTH PERSP, V109, P483, DOI 10.2307/3454657; Fischer PH, 2002, INT ARCH OCC ENV HEA, V75, P348, DOI 10.1007/s00420-002-0320-x; Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Gold DR, 2005, ENVIRON HEALTH PERSP, V113, P883, DOI 10.1289/ehp.7737; Gong Jr H, 2003, RES REP HLTH EFF I, V118; Hobbs PV, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002352; Ibald-Mulli A, 2001, AM J PUBLIC HEALTH, V91, P571, DOI 10.2105/AJPH.91.4.571; Jobsis Q, 1999, EUR RESPIR J, V13, P1406; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Koenig JQ, 2003, ENVIRON HEALTH PERSP, V111, P1625, DOI 10.1289/ehp.6160; Larson T, 2004, J AIR WASTE MANAGE, V54, P1175; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; LIN C, 1973, APPL OPTICS, V12, P1356, DOI 10.1364/AO.12.001356; Linn WS, 1999, J AIR WASTE MANAGE, V49, P108; Liu LJS, 2003, ENVIRON HEALTH PERSP, V111, P909, DOI 10.1289/ehp.6011; Liu LJS, 2002, ENVIRON SCI TECHNOL, V36, P2977, DOI 10.1021/es0112644; Mar TF, 2005, EPIDEMIOLOGY, V16, P681, DOI 10.1097/01.ede.0000173037.83211.d6; Martin LD, 1997, ENVIRON HEALTH PERSP, V105, P1301, DOI 10.2307/3433551; Maykut NN, 2003, ENVIRON SCI TECHNOL, V37, P5135, DOI 10.1021/es030370y; Mayol-Bracero OL, 2002, J GEOPHYS RES-ATMOS, V107, DOI 10.1029/2001JD000522; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Newson EJ, 2000, J OCCUP ENVIRON MED, V42, P270, DOI 10.1097/00043764-200003000-00007; Nightingale JA, 1999, THORAX, V54, P1061; O'Neill MS, 2005, CIRCULATION, V111, P2913, DOI 10.1161/CIRCULATIONAHA.104.517110; Olin AC, 2001, RESP MED, V95, P491, DOI 10.1053/rmed.2001.1076; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Peters A, 1999, AM J EPIDEMIOL, V150, P1094; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Piacentini GL, 2002, PEDIATR ALLERGY IMMU, V13, P137, DOI 10.1034/j.1399-3038.2002.00072.x; Pietropaoli AP, 2004, INHAL TOXICOL, V16, P59, DOI 10.1080/08958370490443079; Pope CA, 1999, AM J RESP CRIT CARE, V159, P365; POPE CA, 1999, ENVIRON HEALTH PERSP, V107, P567, DOI 10.2307/3434399; Posfai M, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004169; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Shepherd MD, 1999, DIFFER GEOM APPL, V10, P1, DOI 10.1016/S0926-2245(98)00025-4; SLAUGHTER JC, 2004, J EXPO ANAL ENV EPID, V9, P1; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Steerenberg PA, 1999, EUR RESPIR J, V13, P334, DOI 10.1034/j.1399-3003.1999.13b19.x; Tunnicliffe WS, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.11.e15; U.S. EPA, 2004, 600P99002ABF US EPA; Van Amsterdam JGC, 1999, ARCH ENVIRON HEALTH, V54, P331; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835	59	131	139	2	56	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	DEC	2005	113	12					1741	1746		10.1289/ehp.8153		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	989ZP	WOS:000233713200046	16330357	
J	Kabesch, M; Hoefler, C; Carr, D; Leupold, W; Weiland, SK; von Mutius, E				Kabesch, M; Hoefler, C; Carr, D; Leupold, W; Weiland, SK; von Mutius, E			Glutathione S transferase deficiency and passive smoking increase childhood asthma	THORAX			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; PARENTAL SMOKING; SPIROMETRIC INDEXES; LUNG-FUNCTION; CHILDREN; POLYMORPHISMS; M1; PREVALENCE; GENOTYPES; GENE	Background: It has been suggested that the genetically determined deficiency of glutathione S transferase (GST) enzymes involved in the detoxification of environmental tobacco smoke (ETS) components may contribute to the development of asthma. Methods: A large population of German schoolchildren (n = 3054) was genotyped for deficiencies of the GST isoforms M1 and T1. The association between GSTM1 and GSTT1 genotypes and asthma as well as atopy was investigated with respect to current and in utero ETS exposure. Results: In children lacking the GSTM1 allele who were exposed to current ETS the risk for current asthma (OR 5.5, 95% CI 1.6 to 18.6) and asthma symptoms such as wheeze ever (OR 2.8, 95% CI 1.3 to 6.0), current wheezing (OR 4.7, 95% CI 1.8 to 12.6) and shortness of breath (OR 8.9, 95% CI 2.1 to 38.4) was higher than in GSTM1 positive individuals without ETS exposure. Hints of an interaction between ETS exposure and GSTM1 deficiency were identified. In utero smoke exposure in GSTT1 deficient children was associated with significant decrements in lung function compared with GSTT1 positive children not exposed to ETS. Conclusions: GSTM1 and GSTT1 deficiency may increase the adverse health effects of in utero and current smoke exposure.	Univ Munich, Childrens Univ Hosp, D-80337 Munich, Germany; Univ Childrens Hosp Dresden, Dresden, Germany; Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany	Kabesch, M (reprint author), Univ Munich, Childrens Univ Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Kabesch@med.uni-muenchen.de	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Alexandrov K, 2002, CARCINOGENESIS, V23, P1969, DOI 10.1093/carcin/23.12.1969; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Botto LD, 2001, AM J EPIDEMIOL, V153, P1016, DOI 10.1093/aje/153.10.1016; Chen CL, 1996, PHARMACOGENETICS, V6, P187, DOI 10.1097/00008571-199604000-00005; COOK DG, 1993, THORAX, V48, P14, DOI 10.1136/thx.48.1.14; Cook DG, 1999, THORAX, V54, P357; Cook DG, 1997, THORAX, V52, P1081; Cook DG, 1998, THORAX, V53, P884; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Ivaschenko TE, 2002, J MOL MED-JMM, V80, P39, DOI 10.1007/s001090100274; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; LOFROTH G, 1989, MUTAT RES, V222, P73, DOI 10.1016/0165-1218(89)90021-9; Menegon A, 1998, LANCET, V352, P1344, DOI 10.1016/S0140-6736(98)03453-9; Oddoze C, 1999, CLIN CHEM, V45, P505; Ollikainen T, 1998, ENVIRON MOL MUTAGEN, V31, P311, DOI 10.1002/(SICI)1098-2280(1998)31:4<311::AID-EM2>3.0.CO;2-L; Reiner A, 2003, BIOINFORMATICS, V19, P368, DOI 10.1093/bioinformatics/btf877; Ryberg D, 1997, CARCINOGENESIS, V18, P1285, DOI 10.1093/carcin/18.7.1285; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; VANPOPPEL G, 1992, CARCINOGENESIS, V13, P303, DOI 10.1093/carcin/13.2.303; von Ehrenstein OS, 2002, EUR RESPIR J, V19, P1099, DOI 10.1183/09031936.02.00104302; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x	25	131	133	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUL	2004	59	7					569	573		10.1136/thx.2003.016667		5	Respiratory System	Respiratory System	833IC	WOS:000222329600007	15223862	
J	Bachrach, VRG; Schwarz, E; Bachrach, LR				Bachrach, VRG; Schwarz, E; Bachrach, LR			Breastfeeding and the risk of hospitalization for respiratory disease in infancy - A meta-analysis	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							SYNCYTIAL VIRUS-INFECTION; BREAST-FEEDING DEFINITIONS; PARENTAL SMOKING; PASSIVE SMOKING; ATOPIC DISEASE; ASTHMA; CHILDREN; BRONCHIOLITIS; ILLNESS; ASSOCIATION	Objective: To examine breastfeeding and the risk of hospitalization for lower respiratory tract disease in healthy full-term infants with access to modern medical care. Data Sources: MEDLINE, personal communication with researchers, the OVID databases, Dissertation Abstracts Online, and BIOSIS. Study Selection: The titles, abstracts, and text of studies from developed countries were explored for breastfeeding exposure measures and lower respiratory tract disease hospitalization rates. For summary statistics, we required 3 inclusion criteria: (1) a feeding contrast of a minimum of 2 months of exclusive breastfeeding (no formula supplementation) vs no breastfeeding and (2) study populations that excluded sick, low birth weight or premature infants and (3) reflected affluent regions; 27% of studies met these criteria. Data Extraction: We abstracted data from all relevant reports. Data Synthesis: Data from all primary material (33 studies) indicated a protective association between breastfeeding and the risk of respiratory disease hospitalization. Nine studies met all inclusion criteria, and 7 cohort studies were pooled. The feeding contrasts in these 7 studies were 4 or more months of exclusive breastfeeding vs no breastfeeding. The summary relative risk (95% confidence interval) was 0.28 (0.14-0.54), using a random-effects model. This effect remained stable and statistically significant after adjusting for the effects of smoking or socioeconomic status. Conclusion: Among generally healthy infants in developed nations, more than a tripling in severe respiratory tract illnesses resulting in hospitalizations was noted for infants who were not breastfed compared with those who were exclusively breastfed for 4 months.	Univ Calif San Francisco, Div Gen Internal Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Bachrach, VRG (reprint author), Oak Hill Ave, Palo Alto, CA 94306 USA.			Schwarz, Eleanor Bimla/0000-0002-9912-8236			*ABB LAB ROSS PROD, ROSS MOTH SURV; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; AVERY ME, 1994, PEDIAT MED, P286; Ball TM, 1999, PEDIATRICS, V103, P870; BAUCHNER H, 1986, JAMA-J AM MED ASSOC, V256, P887, DOI 10.1001/jama.256.7.887; BEAUDRY M, 1995, J PEDIATR-US, V126, P191, DOI 10.1016/S0022-3476(95)70544-9; Beck Laurie F, 2002, MMWR Surveill Summ, V51, P1; Lopez Bravo IM, 1997, REV PANAM SALUD PUBL, V1, P9; Bulkow LR, 2002, PEDIATRICS, V109, P210, DOI 10.1542/peds.109.2.210; Busse W W, 1999, Can Respir J, V6, P97; Busse WW, 2001, NEW ENGL J MED, V344, P350; CARLSEN KH, 1987, PEDIATR PULM, V3, P153, DOI 10.1002/ppul.1950030308; Cesar JA, 1999, BRIT MED J, V318, P1316; CHEN Y, 1989, CHEST, V95, P1004, DOI 10.1378/chest.95.5.1004; CHEN Y, 1988, PEDIATRICS, V81, P58; Coffin CJ, 1997, CONTRACEPTION, V55, P323, DOI 10.1016/S0010-7824(97)00039-5; COOK RJ, 1995, BRIT MED J, V310, P452; CULLINAN TR, 1983, ARCH DIS CHILD, V58, P423; CUNNINGHAM AS, 1979, J PEDIATR-US, V95, P685, DOI 10.1016/S0022-3476(79)80711-8; Dell S, 2001, ARCH PEDIAT ADOL MED, V155, P1261; *DEP HLTH HUM SERV, 2001, DHHS PUBL, P211; DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0; DOWNHAM MAPS, 1976, BRIT MED J, V2, P274; ELLESTADSAYED J, 1979, CAN MED ASSOC J, V120, P295; ELLIS AA, 1991, WHY ARE PRESCHOOL CH, P14; *EUR LONG STUD PRE, 1989, PAEDIATR PERINAT EP, V3, P460; FALLOT ME, 1980, PEDIATRICS, V65, P1121; FERGUSSON DM, 1981, AUST PAEDIATR J, V17, P191; FRANK AL, 1982, PEDIATRICS, V70, P239; Gartner LM, 1997, PEDIATRICS, V100, P1035; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201; Golding J, 1997, EARLY HUM DEV, V49, pS105, DOI 10.1016/S0378-3782(97)00056-X; Goldman AS, 1997, CURR TOP MICROBIOL, V222, P205; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; HALL CB, 1984, J PEDIATR-US, V105, P358, DOI 10.1016/S0022-3476(84)80005-0; Hanson LA, 2000, ACTA PAEDIATR, V89, P252, DOI 10.1080/080352500750028339; Hawkes JS, 1999, PEDIATR RES, V45, P648, DOI 10.1203/00006450-199905010-00006; HEILMAN CA, 1990, J INFECT DIS, V161, P402; Henderson L, 2000, BRIT MED J, V321, P1196, DOI 10.1136/bmj.321.7270.1196; Hoey C, 1997, AM J MANAG C, V3, P861; Howard TS, 2000, J PEDIATR-US, V137, P227, DOI 10.1067/mpd.2000.107525; HOWIE PW, 1990, BRIT MED J, V300, P11; *I MED, 1985, NEW VACC DEV EST PRI, V2; JIN C, 1993, J PEDIATR-US, V123, P553, DOI 10.1016/S0022-3476(05)80949-7; KAUFMAN HS, 1976, ANN ALLERGY, V37, P410; KOVAR MG, 1984, PEDIATRICS, V74, P615; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LABBOK M, 1990, STUD FAMILY PLANN, V21, P226, DOI 10.2307/1966617; LEVENTHAL JM, 1986, PEDIATRICS, V78, P896; MOK JYQ, 1982, BRIT MED J, V285, P333; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Oddy WH, 1999, BRIT MED J, V319, P815; *OFF WOM HLTH, 2000, BREASTF HHS BLUEPR A; OGSTON SA, 1987, J EPIDEMIOL COMMUN H, V41, P21, DOI 10.1136/jech.41.1.21; Pabst HF, 1997, ACTA PAEDIATR, V86, P1291, DOI 10.1111/j.1651-2227.1997.tb14900.x; Perlstein PH, 2000, ARCH PEDIAT ADOL MED, V154, P1001; PETITTI DB, 2000, MONOGRAPHS EPIDEMIOL, P101; PISACANE A, 1994, ACTA PAEDIATR, V83, P714, DOI 10.1111/j.1651-2227.1994.tb13125.x; PULLAN CR, 1980, BRIT MED J, V281, P1034; RYLANDER E, 1995, EPIDEMIOLOGY, V6, P289, DOI 10.1097/00001648-199505000-00017; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; SLY R, 2000, NELSON TXB PEDIAT, P666; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Spencer N, 1996, ARCH DIS CHILD, V74, P50; *STAT CORP, 1999, STAT TECHN B REPR, V8; TAYLOR B, 1982, LANCET, V1, P1227; Weiss KB, 1992, CHEST, V101, P362; [Anonymous], 1994, LANCET, V344, P1239	72	131	142	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	2003	157	3					237	243				7	Pediatrics	Pediatrics	653KX	WOS:000181435300007	12622672	
J	Janson, C; Chinn, S; Jarvis, D; Zock, JP; Toren, K; Burney, P				Janson, C; Chinn, S; Jarvis, D; Zock, JP; Toren, K; Burney, P		European Community Resp Hlth Surv	Effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey: a cross-sectional study	LANCET			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; PULMONARY-FUNCTION; PARENTAL SMOKING; ASTHMA; EXPOSURE; ADULTS; SENSITIZATION; POPULATION; WOMEN; HYPERRESPONSIVENESS	Background Passive smoking is widespread, and environmental tobacco smoke contains many potent respiratory irritants. This analysis aimed to estimate the effect of passive smoking on respiratory symptoms, bronchial responsiveness, lung function, and total serum IgE in the European Community Respiratory Health Survey. Methods This analysis included data from 7882 adults (age 20-48 years) who had never smoked, from 36 centres in.16 countries. Information on passive smoking, respiratory symptoms, asthma, and allergic rhinitis was gathered through a structured interview. Spirometry and methacholine challenge were carried out, and total and specific IgE were measured. The effect of passive smoking was estimated by means of logistic and multiple linear regression for each country and combined across countries by random-effects meta-analysis. Findings In 12 of the 36 centres, more than half the participants were regularly involuntarily exposed to tobacco smoke. The prevalence of passive smoking in the workplace varied from 2.5% in Uppsala, Sweden, to 53.8% in Galdalkao, Spain. Passive smoking was significantly associated with nocturnal chest tightness (odds ratio 1.28 [95% CI 1.02 to 1.60]), nocturnal breathlessness (1.30 [1.01 to 1.67]), breathlessness after activity (1.25 [1.07 to 1.47]), and increased bronchial responsiveness (effect -0.18 [-0.30 to -0.05]). Passive smoking in the workplace was significantly associated with all types of respiratory symptoms and current asthma (odds ratio 1.90 [95% CI 0.90 to 2.88]). No significant association was found between passive smoking and total serum IgE. Interpretation Passive smoking is common but the prevalence varies widely between different countries, Passive smoking increased the likelihood of experiencing respiratory symptoms and was associated with increased bronchial responsiveness. Decreasing involuntary exposure to tobacco smoke in the community, especially in workplaces, is likely to improve respiratory health.	Uppsala Univ, Akad Sjukhuset, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; Univ London Kings Coll, Dept Publ Hlth Sci, London WC2R 2LS, England; IMIM, Resp & Environm Hlth Res Unit, Barcelona, Spain; Sahlgrens Univ Hosp, Sect Occupat & Environm Hlth, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Sect Allergol, S-41345 Gothenburg, Sweden	Janson, C (reprint author), Akad Sjukhuset, Dept Resp Med, SE-75185 Uppsala, Sweden.		Jarvis, Deborah/E-6494-2011; Jarvis, Martin/B-1034-2008	Jarvis, Martin/0000-0001-9238-8038			Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; CARREY IM, 1999, EPIDEMIOLOGY, V10, P319; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Cook DG, 1999, THORAX, V54, P357; Corrao M, 2000, TOBACCO CONTROL COUN; Coultas DB, 1998, THORAX, V53, P381; DELFINO RJ, 1993, EUR RESPIR J, V6, P1104; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; European Community for Coal and Steel, 1983, CLIN RESP PHYS S5, V19, P22; Frette C, 1996, AM J EPIDEMIOL, V143, P757; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413; MASJEDI MR, 1990, THORAX, V45, P27, DOI 10.1136/thx.45.1.27; MENON P, 1992, J ALLERGY CLIN IMMUN, V89, P560, DOI 10.1016/0091-6749(92)90323-T; OLIVIERI M, IN PRESS ARCH ENV HL; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241; Piitulainen E, 1998, THORAX, V53, P939; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; RANDO RJ, 1992, AM IND HYG ASSOC J, V53, P699, DOI 10.1202/0002-8894(1992)053<0699:AOMMOE>2.0.CO;2; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; ROBBINS AS, 1993, INT J EPIDEMIOL, V22, P809, DOI 10.1093/ije/22.5.809; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; Sapigni T, 1998, EUR RESPIR J, V11, P278, DOI 10.1183/09031936.98.11020278; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V82, P331, DOI 10.1016/0091-6749(88)90003-6; Strachan DP, 1998, THORAX, V53, P117; Sunyer J, 1997, THORAX, V52, P235; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; XU XP, 1995, AM J RESP CRIT CARE, V151, P41	34	131	132	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 22	2001	358	9299					2103	2109		10.1016/S0140-6736(01)07214-2		7	Medicine, General & Internal	General & Internal Medicine	505GV	WOS:000172905800007	11784622	
J	Dennekamp, M; Howarth, S; Dick, CAJ; Cherrie, JW; Donaldson, K; Seaton, A				Dennekamp, M; Howarth, S; Dick, CAJ; Cherrie, JW; Donaldson, K; Seaton, A			Ultrafine particles and nitrogen oxides generated by gas and electric cooking	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article						cooking fuels; nitrogen oxides; ultrafine particles	PARTICULATE AIR-POLLUTION; PERSONAL EXPOSURE; RESPIRATORY SYMPTOMS; DIOXIDE EXPOSURE; LUNG-CANCER; PULMONARY TOXICITY; INHALED ALLERGEN; PM10 POLLUTION; CHILDREN; HEALTH	Objectives - To measure the concentrations of particles less than 100 nm diameter and of oxides of nitrogen generated by cooking with gas and electricity, to comment on possible hazards to health in poorly ventilated kitchens. Methods - Experiments with gas and electric rings, grills, and ovens were used to compare different cooking procedures. Nitrogen oxides (NO,) were measured by a chemiluminescent ML9841A NO, analyser. A TSI 3934 scanning mobility particle sizer was used to measure average number concentration and size distribution of aerosols in the size range 10-500 nm. Results-High concentrations of particles are generated by gas combustion, by frying, and by cooking of fatty foods. Electric rings and grills may also generate particles from their surfaces. In experiments where gas burning was the most important source of particles, most particles were in the size range 15-40 nm. When bacon was fried on the gas or electric rings the particles were of larger diameter, in the size range 50-100 nm. The smaller particles generated during experiments grew in size with time because of coagulation. Substantial concentrations of NO, were generated during cooking on gas; four rings for 15 minutes produced 5 minute peaks of about 1000 ppb nitrogen dioxide and about 2000 ppb nitric oxide. Conclusions - Cooking in a poorly ventilated kitchen may give rise to potentially toxic concentrations of numbers of particles. Very high concentrations of oxides of nitrogen may also be generated by gas cooking, and with no extraction and poor ventilation, may reach concentrations at which adverse health effects may be expected. Although respiratory effects of exposure to NO, might be anticipated, recent epidemiology suggests that cardiac effects cannot be excluded, and further investigation of this is desirable.	Univ Aberdeen, Sch Med, Dept Environm & Occupat Med, Aberdeen AB25 2ZD, Scotland; Napier Univ, Sch Life Sci, Edinburgh EH10 5DT, Midlothian, Scotland	Seaton, A (reprint author), Univ Aberdeen, Sch Med, Dept Environm & Occupat Med, Foresterhill, Aberdeen AB25 2ZD, Scotland.		Cherrie, John/A-4879-2008	Cherrie, John/0000-0001-8901-6890			Abt E, 2000, ENVIRON HEALTH PERSP, V108, P35, DOI 10.2307/3454293; Anderson HR, 1998, THORAX, V53, P842; Berry RW, 1996, INDOOR AIR QUALITY 1; Chao CYH, 2000, BUILD ENVIRON, V35, P545, DOI 10.1016/S0360-1323(99)00040-2; Chiang TA, 1999, ENVIRON RES, V81, P18, DOI 10.1006/enrs.1998.3876; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; Dick CAJ, 2001, OCCUP ENVIRON MED, V58, P208, DOI 10.1136/oem.58.3.208; Dimitroulopoulou C, 2001, ATMOS ENVIRON, V35, P269, DOI 10.1016/S1352-2310(00)00176-X; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DONALDSON K, 1998, MECH LUNG INJURY CAU, V10, P21; Farrow A, 1997, ARCH ENVIRON HEALTH, V52, P189; FERIN J, 1990, J AEROSOL SCI, V21, P381, DOI 10.1016/0021-8502(90)90064-5; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891; Hajat S, 1999, THORAX, V54, P597; Jarvis D, 1998, EUR RESPIR J, V11, P651; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Ko YC, 1997, INT J EPIDEMIOL, V26, P24, DOI 10.1093/ije/26.1.24; Ko YC, 2000, AM J EPIDEMIOL, V151, P140; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Li S, 1994, Arch Environ Health, V49, P119; MELIA RJW, 1977, BRIT MED J, V2, P149; OSUNSANYA T, 2000, OCCUP ENVIRON MED, V58, P154; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pilotto LS, 1997, INT J EPIDEMIOL, V26, P788, DOI 10.1093/ije/26.4.788; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; QUACKENBOSS JJ, 1986, ENVIRON SCI TECHNOL, V20, P775, DOI 10.1021/es00150a003; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Siegmann K., 1996, J AEROSOL SCI, V27, pS493, DOI DOI 10.1016/0021-8502(96)00319-9; SPEIZER FE, 1980, AM REV RESPIR DIS, V121, P3; SPENGLER J, 1994, J AIR WASTE MANAGE, V44, P39; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; Wallace L, 2000, Appl Occup Environ Hyg, V15, P39, DOI 10.1080/104732200301836; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WARHEIT DB, 1990, EXP MOL PATHOL, V52, P309, DOI 10.1016/0014-4800(90)90072-L; Willeke K., 1993, AEROSOL MEASUREMENT; Wu PF, 1999, ENVIRON RES, V80, P122, DOI 10.1006/enrs.1997.3798	46	131	136	9	31	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	AUG	2001	58	8					511	516		10.1136/oem.58.8.511		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	454ZY	WOS:000170002900004	11452045	
J	Kroes, R; Galli, C; Munro, I; Schilter, B; Tran, LA; Walker, R; Wurtzen, G				Kroes, R; Galli, C; Munro, I; Schilter, B; Tran, LA; Walker, R; Wurtzen, G			Threshold of toxicological concern for chemical substances present in the diet: A practical tool for assessing the need for toxicity testing	FOOD AND CHEMICAL TOXICOLOGY			English	Review						threshold; toxicological endpoints; structural alerts; NOEL	DEVELOPMENTAL NEUROTOXICITY EVALUATION; CARCINOGENIC POTENCY DATABASE; ACOUSTIC STARTLE RESPONSE; NONCANCER RISK ASSESSMENT; ESTROGEN-RECEPTOR-BETA; PERINATAL PCB EXPOSURE; BREAST-CANCER CELLS; SPRAGUE-DAWLEY RATS; FEMALE B6C3F1 MICE; PRENATAL EXPOSURE	The de,minimis concept acknowledges a human exposure threshold value for chemicals below which there is no significant risk to human health. It is the underlying principle for the US Food and Drug Administration (FDA) regulation on substances used in food-contact articles. Further to this, the principle of Threshold of Toxicological Concern (TTC) has been developed and is now used by the joint FAO/WHO Expert Committee on Food Additives (JECFA) in their evaluations. Establishing an accepted TTC would benefit consumers, industry and regulators, since it would preclude extensive toxicity evaluations when Lumen intakes are below such threshold, and direct considerable time and cost resources towards testing substances with the highest potential risk to human health. It was questioned, however, whether specific endpoints that may potentially give rise to low-dose effects would be covered by such threshold. In this review., the possibility of defining a TTC for chemical substances present in the diet was examined for general toxicity endpoints (including carcinogenicity), as well as for specific endpoints, namely neurotoxicity and developmental neurotoxicity, immunotoxicity and developmental toxicity. For each of these endpoints, a database of specific no-observed-effect levels (NOELs) was compiled by screening oral toxicity studies. The substances recorded in each specific database were selected on the basis of their demonstrated adverse effects. For the neurotoxicity and developmental neurotoxicity databases, it was intended to cover all classes of compounds reported to hare tither a demonstrated neurotoxic or developmentally neurotoxic effect, or at least, on a biochemical or pharmacological basis were considered to have a potential for displaying such effects. For the immunotoxicity endpoint, it was ensured that only immunotoxicants were included in the database by selecting most of the substances from the Luster er al. database, provided that they satisfied the criteria for immunotoxicity defined by Luster. For the developmental toxicity database, substances were selected from the Munro ct nl. database that contained the lowest NOELs retrieved from the literature for more than 600 compounds. After screening these, substances shelving any effect which could point to developmental toxicity as broadly defined by the US EPA (1986) were recorded in the database. Additionally., endocrine toxicity and allergenicity, were addressed as two separate cases, using different approaches and methodology. The distributions of NOELs for the neurotoxicity, developmental neurotoxicity and developmental toxicity endpoints were compared with the distribution of NOELs for non-specific carcinogenic endpoints. As the immunotoxicity database was too limited to draw such a distribution of immune NOELs, the immunotoxicity endpoint,vas evaluated by comparing immune NOELs (or LOELs-lowest-observed-effect levels-when NOELs were not available),vith non-immune NOELs (or LOELs), in order to compare the sensitivity of this endpoint with non-specific endpoints. A different methodology was adopted for the evaluation of the endocrine toxicity endpoint since data currently available do not permit the establishment of a clear causal link between endocrine active chemicals and adverse effects in humans. Therefore, this endpoint was analysed by estimating the human exposure to oestrogenic environmental chemicals and evaluating their potential impact on human health, based on their contribution to the overall exposure, and their estrogenic potency relative to endogenous hormones. The allergenicity endpoint was not analysed as such. It was addressed in a separate section because this issue is not relevant to the overall population but rather to subsets of susceptible individuals, and allergic risks are usually controlled by other means (i.e, labelling) than the Threshold of Toxicological Concern approach. However, as several researchers are currently examining the existence of a threshold in allergy, the possibility of determining threshold doses for food allergens was put into perspective, and the likelihood for chemical substances to induce allergy at dietary relevant doses was discussed. The analysis indicated that, within the limitation of the databases, developmental neurotoxicity and developmental toxicity were not more sensitive than other non-specific endpoints. Although the cumulative distribution of NOELs for neurotoxic compounds was significantly loner than those for other non-cancer endpoints, these substances were accommodated within the TTC of 1.5 mu g/person/day. Furthermore, the analysis demonstrated that none of the specific non-cancer endpoints evaluated in the present study was more sensitive than cancer and, that a TTC of 1.5 mu g/person/day based on cancer endpoints provides an adequate margin of safety. Analysis of the immunotoxicity database should that for the group of immunotoxicants examined here, the specific immunotoxic endpoint was not more sensitive than other endpoints. In other words, the distribution of immunotoxic NOELs for these compounds did not appear to differ from the distribution of nonspecific endpoints NOELs for the same compounds. The dietary intakes of environmental oestrogenic chemicals were estimated and their oestrogenic potencies were compared with that of endogenous hormones, in order to assess their impact on human health. The results are in line with scientific data obtained so far, suggesting that estrogenic compounds of anthropogenic origin, in comparison with endogenous hormones, possess only little hormonal activity lilts phytoestrogens. Results of animal studies do not suggest that hormonal effects are to be expected from the rather lon concentrations found in foods. More data are necessary to determine threshold doses for food allergens. However, provided that numerous criteria need to be satisfied before sensitization occurs, it is unlikely that small molecules used in little amounts in foods would induce such reactions. On the basis of the present analysis, which was conducted using conservative assumptions at each step of the procedure (i.e. in data compilation and data analysis), and continually adopting a "worst case" perspective, it can be concluded that a Threshold of Toxicological Concern of 1.5 mu g/person/day provides adequate safety assurance. Chemical substances present in the diet that are consumed at levels below this threshold pose no appreciable risk. Moreover, for compounds which do not possess structural alerts for genotoxicity and carcinogenicity, further analysis mag indicate that a higher Threshold of Toxicological Concern mag he appropriate. (C) 2000 Elsevier in Science Ltd. All rights reserved.	ILSI Europe, B-1200 Brussels, Belgium; Univ Utrecht, Fac Vet Med, RITOX, NL-3508 TD Utrecht, Netherlands; Univ Milan, Inst Pharmacol Sci, I-20133 Milan, Italy; CanTox Inc, Mississauga, ON L5N 2XN, Canada; Nestec Ltd, Nestle Res Ctr, CH-1000 Lausanne, Switzerland; Univ Surrey, Sch Biol Sci, Guildford GU2 5XH, Surrey, England; Coca Cola, Nord & No Eurasia Div, DK-2600 Glostrup, Denmark	Tran, LA (reprint author), ILSI Europe, Ave E Mounier 83,Box 6, B-1200 Brussels, Belgium.						Abekawa T, 1997, BRAIN RES, V767, P34, DOI 10.1016/S0006-8993(97)00542-8; AHLBOM J, 1994, BRAIN RES, V645, P318, DOI 10.1016/0006-8993(94)91666-7; ALI SF, 1986, NEUROTOXICOLOGY, V7, P365; ANTHONY DC, 1990, GASSARETT DOULLS TOX, P407; ARNOLD DL, 1985, FOOD CHEM TOXICOL, V23, P779, DOI 10.1016/0278-6915(85)90278-9; ASHBY J, 1988, MUTAT RES, V204, P17, DOI 10.1016/0165-1218(88)90114-0; BARANSKI B, 1983, ARCH TOXICOL, V54, P297, DOI 10.1007/BF01234482; Barkhem T, 1998, MOL PHARMACOL, V54, P105; BARNARD RC, 1994, REGUL TOXICOL PHARM, V19, P211, DOI 10.1006/rtph.1994.1019; BARONCELLI S, 1995, J TOXICOL ENV HEALTH, V46, P355; Becci P J, 1982, J Appl Toxicol, V2, P201, DOI 10.1002/jat.2550020406; Becci P J, 1981, J Appl Toxicol, V1, P256, DOI 10.1002/jat.2550010504; BECK BD, 1993, FUND APPL TOXICOL, V20, P1, DOI 10.1006/faat.1993.1001; BECK BD, 1989, PRINCIPLES METHODS T, P1; BIEGEL LB, 1995, FUND APPL TOXICOL, V27, P185, DOI 10.1006/faat.1995.1123; BILKEIGORZO A, 1993, FOOD CHEM TOXICOL, V31, P357, DOI 10.1016/0278-6915(93)90191-Z; BLACKER AM, 1993, FUND APPL TOXICOL, V21, P420, DOI 10.1006/faat.1993.1117; BOUSQUET J, 1999, ALLERGY, V53, P1; BOUSQUET J, 1994, DOSSIER SCI I FRANC, V4; BOUTEMY, 1980, WHO FOOD ADDITIVES S, V25; Breslin WJ, 1996, FUND APPL TOXICOL, V29, P119, DOI 10.1006/faat.1996.0013; BRUNNER R, 1978, PSYCHOTOXICITY SELEC; BUELKESAM J, 1984, NEUROBEH TOXICOL TER, V6, P171; BUELKESAM J, 1991, NEUROTOXICOL TERATOL, V13, P297, DOI 10.1016/0892-0362(91)90075-8; BUI QQ, 1986, TOXICOLOGY, V42, P195, DOI 10.1016/0300-483X(86)90009-0; BUREK JD, 1980, J ENVIRON PATHOL TOX, V4, P157; BURNS LA, 1994, DRUG CHEM TOXICOL, V17, P317, DOI 10.3109/01480549409017863; BUSTER JE, 1978, J CLIN ENDOCR METAB, V46, P907; Calabrese EJ, 1997, REGUL TOXICOL PHARM, V26, P36, DOI 10.1006/rtph.1997.1115; CAO W, 1990, TOXICOL APPL PHARM, V105, P492, DOI 10.1016/0041-008X(90)90152-K; CARLSON JN, 1987, PSYCHOPHARMACOLOGY, V91, P122, DOI 10.1007/BF00690940; Chappell J, 1996, MOL BREEDING, V2, P1; CHAUBE S, 1966, CANCER RES, V26, P1448; CHAUBE S, 1973, CANCER RES, V33, P2231; CHERNOFF N, 1982, J TOXICOL ENV HEALTH, V10, P541; CHERNOFF N, 1990, TERATOLOGY, V42, P651, DOI 10.1002/tera.1420420610; COLBORN T, 1995, ENVIRON HEALTH PERSP, V103, P135, DOI 10.2307/3432522; COLE J, BEHAV EFFECTS SMOKEL; COLLINS TFX, 1975, TOXICOLOGY, V3, P129, DOI 10.1016/0300-483X(75)90014-1; CORYSLECHTA DA, 1985, TOXICOL APPL PHARM, V78, P291, DOI 10.1016/0041-008X(85)90292-3; COX GE, 1975, TOXICITY STUDIES RAT; CRAMER GM, 1978, FOOD COSMET TOXICOL, V16, P255, DOI 10.1016/S0015-6264(76)80522-6; CROFTON KM, 1989, TOXICOL APPL PHARM, V97, P113, DOI 10.1016/0041-008X(89)90060-4; Crofton KM, 1996, TOXICOL LETT, V84, P155, DOI 10.1016/0378-4274(95)03618-0; CROFTON KM, 1988, FUND APPL TOXICOL, V10, P624, DOI 10.1016/0272-0590(88)90189-3; CROFTON KM, 1984, TOXICOL APPL PHARM, V75, P318, DOI 10.1016/0041-008X(84)90214-X; *CSTEE, 1999, CSTEE OP HUM WILDL H; Dale M.J., 1976, WHO FOOD ADDITIVES S; DAVIS GJ, 1978, TERATOLOGY, V17, pA33; DEAN JH, 1990, CASSARETT DOULLS TOX, P282; DESI I, 1983, NEUROBEH TOXICOL TER, V5, P503; DEWDNEY JM, 1991, FOOD CHEM TOXICOL, V29, P477, DOI 10.1016/0278-6915(91)90095-O; *DFG, 1998, HORM AKT STOFF LEB; DIETER MP, 1988, J TOXICOL ENV HEALTH, V24, P357; Dorgan JF, 1997, ENVIRON HEALTH PERSP, V105, P583, DOI 10.2307/3433374; DOULL, 1960, UNPUB; Dourson ML, 1996, REGUL TOXICOL PHARM, V24, P108, DOI 10.1006/rtph.1996.0116; DOWEDWARDS D, 1989, PHARMACOL BIOCHEM BE, V33, P167, DOI 10.1016/0091-3057(89)90446-2; *DUTCH HLTH COUNC, 1991, IMM STOFF; EC, 1996, EUR WORKSH IMP END D; EIBEN R, 1983, 11969 AG I TOX; EMA M, 1991, NEUROTOXICOL TERATOL, V13, P489, DOI 10.1016/0892-0362(91)90054-Z; *EPA, 1998, FIN REP US EPA; *EPA, 1986, FED REGISTER, V51, P34027; Environmental Protection Agency (EPA), 1997, EPA630R96012; ERIKSSON P, 1991, TOXICOL APPL PHARM, V108, P78, DOI 10.1016/0041-008X(91)90270-O; Eubanks M W, 1997, Environ Health Perspect, V105, P482; EXON JH, 1982, ENVIRON HEALTH PERSP, V46, P137, DOI 10.2307/3429430; Exon J.H., 1985, WATER CHLORINATION C, V5; FAO, 1995, REP FAO TECHN CONS F; *FDA, 1982, TOX PRIMC SAF ASS DI; FELDMAN D, 1986, ENDOCR REV, V7, P409; FOKKEMA GN, 1994, SBTR95027 SHELL RES; Frawley J P, 1967, Food Cosmet Toxicol, V5, P293, DOI 10.1016/S0015-6264(67)83055-4; FULLERTON FR, 1987, J TOXICOL ENV HEALTH, V22, P175; GOEBEL R, 1974, J CLIN ENDOCR METAB, V39, P969; GOLD LS, 1984, ENVIRON HEALTH PERSP, V58, P9, DOI 10.2307/3429857; GOLD LS, 1989, ENVIRON HEALTH PERSP, V79, P259, DOI 10.2307/3430559; GOLDEY ES, 1995, NEUROTOXICOL TERATOL, V17, P313, DOI 10.1016/0892-0362(94)00073-M; GRALLA EJ, 1969, TOXICOL APPL PHARM, V15, P604, DOI 10.1016/0041-008X(69)90062-3; GRAY LE, 1986, NEUROTOXICOLOGY, V7, P449; HALES BF, 1992, TERATOLOGY, V45, P671, DOI 10.1002/tera.1420450612; HAMMOND B, 1979, P NATL ACAD SCI USA, V76, P6641, DOI 10.1073/pnas.76.12.6641; HANNUKSELA M, 1987, ALLERGY, V42, P561, DOI 10.1111/j.1398-9995.1987.tb00386.x; HAYES JR, 1986, CASSARETT DOULLS TOX, P774; HENCK JW, 1994, NEUROTOXICOL TERATOL, V16, P391, DOI 10.1016/0892-0362(94)90028-0; HOOS PC, 1983, BIOL REPROD, V29, P833, DOI 10.1095/biolreprod29.4.833; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; HSIEH GC, 1990, ARCH TOXICOL, V64, P320, DOI 10.1007/BF01972993; *HUNT RES CTR, 1966, UNPUB; HUTCHINGS DE, 1989, NEUROTOXICOL TERATOL, V11, P65, DOI 10.1016/0892-0362(89)90087-1; HUTCHINGS DE, 1979, J PHARMACOL EXP THER, V208, P106; HUTCHINGS DE, 1989, NEUROTOXICOL TERATOL, V11, P353, DOI 10.1016/0892-0362(89)90006-8; IBRAHIM HS, 1990, NUTR RES, V10, P315, DOI 10.1016/S0271-5317(05)80273-8; *IPCS, 1994, WHO ENV HLTH CRIT, V170; Ishida N, 1997, NEUROSCIENCE, V81, P1183, DOI 10.1016/S0306-4522(97)00220-0; JANSSEN I, 1997, PHYTOESTROGENS HORMO; *JMPR, 1993, FENPR, P233; JOHNSON HE, 1966, TEMIK TECHNICAL GRAD; KABAT K, 1985, NEUROBEH TOXICOL TER, V7, P519; KAGI MK, 1994, LANCET, V344, P60, DOI 10.1016/S0140-6736(94)91083-9; KANEDA M, 1993, FOOD CHEM TOXICOL, V31, P533, DOI 10.1016/0278-6915(93)90202-A; KATAGIRI H, 1976, AM J OBSTET GYNECOL, V124, P272; KAVLOCK, 1996, ENV HLTH PERSPECT S4, V104, P715; KAWASAKI H, 1991, FOLIA PHARMACOL JPN, V98, P345, DOI 10.1254/fpj.98.5_345; Kawashima Kunio, 1995, Journal of Toxicological Sciences, V20, P15; KIHARA T, 1984, TERATOLOGY SA, V30, P10; KIMMERLE, 1974, ARCH TOXICOL, V33, P1; Kodsi MH, 1997, NEUROSCI LETT, V231, P103, DOI 10.1016/S0304-3940(97)00482-5; KOSTAS J, 1981, NEUROBEH TOXICOL TER, V3, P467; KREWSKI D, 1990, REGUL TOXICOL PHARM, V12, P13, DOI 10.1016/S0273-2300(05)80043-1; Kuhnau J, 1976, World Rev Nutr Diet, V24, P117; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/endo.139.10.6216; Kwon OS, 1997, NEUROTOXICOLOGY, V18, P571; LANDGREN BM, 1980, ACTA ENDOCRINOL-COP, V94, P89; LANE RW, 1982, TOXICOL APPL PHARM, V63, P409, DOI 10.1016/0041-008X(82)90270-8; LANKAS GR, 1995, WHO FOOD ADDITIVES S, V39; LEHOTZKY K, 1989, NEUROTOXICOL TERATOL, V11, P321, DOI 10.1016/0892-0362(89)90076-7; LENTON EA, 1978, CLIN ENDOCRINOL, V9, P37, DOI 10.1111/j.1365-2265.1978.tb03570.x; LESSOF MH, 1994, ILSI EUROPE CONCISE; LEWIS SC, 1990, REGUL TOXICOL PHARM, V11, P314, DOI 10.1016/0273-2300(90)90030-F; LITTLEFIELD NA, 1983, J TOXICOL ENV HEALTH, V12, P671; Llorens J, 1997, NEUROTOXICOL TERATOL, V19, P117, DOI 10.1016/S0892-0362(96)00216-4; LU FC, 1990, TOXICOLOGIE DONNEES, P145; LUSTER MI, 1981, TOXICOL APPL PHARM, V58, P252, DOI 10.1016/0041-008X(81)90430-0; LUSTER MI, 1992, FUND APPL TOXICOL, V18, P200, DOI 10.1016/0272-0590(92)90047-L; LUSTER MI, 1993, FUND APPL TOXICOL, V21, P71, DOI 10.1006/faat.1993.1074; LUSTER MI, 1989, TOXICOL APPL PHARM, V101, P328, DOI 10.1016/0041-008X(89)90281-0; LUTHRA YK, 1980, J IMMUNOPHARMACOL, V2, P245; MADSEN C, 1995, ALLERGENIC HYPERSENS, P301; MAKELA S, 1994, ENVIRON HEALTH PERSP, V102, P572; MARKAVERICH BM, 1988, J STEROID BIOCHEM, V30, P71, DOI 10.1016/0022-4731(88)90078-7; MATSUDA M, 1990, TERATOLOGY, V41, P147, DOI 10.1002/tera.1420410204; Mattsson JL, 1996, FOOD CHEM TOXICOL, V34, P393, DOI 10.1016/0278-6915(96)00121-4; MAYURA K, 1993, TOXICOLOGY, V77, P123, DOI 10.1016/0300-483X(93)90143-G; MCCLAIN RM, 1979, TOXICOL APPL PHARM, V48, pA32; MCCOLLISTER, 1959, J AGR FOOD CHEM, V7, P689; MCCOLLISTER, 1968, FOOD COSMETICS TOXIC, V6, P185; MCLACHLAN JA, 1977, J TOXICOL ENV HEALTH, V2, P527; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165; MIKSICEK RJ, 1993, MOL PHARMACOL, V44, P37; MILLER WR, 1996, MED INTELLIGENCE UNI; MOOLENAAR RJ, 1994, REGUL TOXICOL PHARM, V20, P302, DOI 10.1006/rtph.1994.1078; MOORE RW, 1991, TOXICOL APPL PHARM, V109, P85, DOI 10.1016/0041-008X(91)90193-I; MORING SE, 1990, APPLIED BIOSYSTEMS R, V2, P2; MORRISSEY RE, 1990, FUND APPL TOXICOL, V15, P350, DOI 10.1016/0272-0590(90)90060-W; MULLER G, 1990, TERATOLOGY, V42, P253, DOI 10.1002/tera.1420420309; MUNRO C S, 1990, Drug Investigation, V2, P1; Munro IC, 1996, FOOD CHEM TOXICOL, V34, P829, DOI 10.1016/S0278-6915(96)00049-X; MUNRO IC, 1980, J ENVIRON PATHOL TOX, V3, P437; Munro IC, 1999, FOOD CHEM TOXICOL, V37, P207, DOI 10.1016/S0278-6915(98)00112-4; MUNRO IC, 1998, WHO FOOD ADDITIVES S, V40; MURRAY FJ, 1979, TOXICOL APPL PHARM, V50, P241, DOI 10.1016/0041-008X(79)90149-2; NAGASAWA H, 1980, P SOC EXP BIOL MED, V165, P394; NELSON BK, 1989, NEUROTOXICOL TERATOL, V11, P273, DOI 10.1016/0892-0362(89)90070-6; Neubert D, 1997, REGUL TOXICOL PHARM, V26, P9, DOI 10.1006/rtph.1997.1149; NOLEN GA, 1987, FOOD CHEM TOXICOL, V25, P1, DOI 10.1016/0278-6915(87)90300-0; NOLEN GA, 1986, NEUROTOXICOL TERATOL, V8, P643; NRC, 1996, CARC ANT HUM DIET; *NTP, 1994, NTP TECHN REP SER, V435; *NTP, 1989, NTP TECHN REP PER TO; *NTP, 1986, NTP TECHN REP SER, V316; *NTP, 1992, NTP TOC REP SER, V23; *NTP, 1989, NTP TECHNI REP SER, V358; OConnor JC, 1996, FUND APPL TOXICOL, V33, P182, DOI 10.1006/faat.1996.0156; Odum J, 1998, TOXICOL IN VITRO, V12, P273, DOI 10.1016/S0887-2333(97)00115-X; Ohmori H, 1997, NEUROTOXICOL TERATOL, V19, P205, DOI 10.1016/S0892-0362(97)00014-7; OLSEN P, 1986, FOOD CHEM TOXICOL, V24, P1, DOI 10.1016/0278-6915(86)90256-5; OSER BL, 1976, TOXICOLOGY, V6, P47, DOI 10.1016/0300-483X(76)90007-X; OVERMANN SR, 1987, ENVIRON RES, V44, P56, DOI 10.1016/S0013-9351(87)80086-5; PALERMONETO J, 1994, NEUROTOXICOL TERATOL, V16, P65, DOI 10.1016/0892-0362(94)90010-8; Phillips KE, 1997, DRUG CHEM TOXICOL, V20, P189, DOI 10.3109/01480549709003878; POUL JM, 1988, NEUROTOXICOL TERATOL, V10, P267, DOI 10.1016/0892-0362(88)90027-X; Ramamoorthy K, 1997, ENDOCRINOLOGY, V138, P1520, DOI 10.1210/en.138.4.1520; RECK G, 1979, ACTA ENDOCRINOL-COP, V90, P519; REED MJ, 1983, HORM BLOOD, V4, P318; Reel JR, 1996, FUND APPL TOXICOL, V34, P288, DOI 10.1006/faat.1996.0198; RENWICK AG, 1993, FOOD ADDIT CONTAM, V10, P275; RICE DC, 1992, NEUROTOXICOLOGY, V13, P443; Roberts DW, 1981, DEV TOXICOLOGY, P167; ROBERTSON RT, 1980, TOXICOL APPL PHARM, V53, P541, DOI 10.1016/0041-008X(80)90367-1; ROBINSON EC, 1991, J TOXICOL ENV HEALTH, V32, P345; ROBINSON EC, 1992, FUND APPL TOXICOL, V18, P549, DOI 10.1016/0272-0590(92)90114-W; Robinson M., 1981, OCEANOGRAPHIC MONTHL, P2; ROITT I, 1993, IMMUNOLOGIE; Rosso SB, 1997, BRAIN RES, V769, P163, DOI 10.1016/S0006-8993(97)00823-8; ROUSSEAUX CG, 1986, J APPL TOXICOL, V6, P179, DOI 10.1002/jat.2550060308; Rudel R, 1997, ENVIRON HEALTH PERSP, V105, P655, DOI 10.2307/3433385; Rulis A.M., 1986, FOOD PROTECTION TECH, P29; RULIS AM, 1989, RISK ASSESSMENT SETT, V7, P271; RUPPERT PH, 1982, NEUROBEH TOXICOL TER, V4, P135; SAFE SH, 1995, ENVIRON HEALTH PERSP, V103, P346, DOI 10.2307/3432287; SANDERS VM, 1982, TOXICOL APPL PHARM, V62, P358, DOI 10.1016/0041-008X(82)90138-7; Sasser LB, 1996, REPROD TOXICOL, V10, P311, DOI 10.1016/0890-6238(96)00060-3; Saunders PTK, 1997, J ENDOCRINOL, V154, pR13, DOI 10.1677/joe.0.154R013; SCF (Scientic Committee for Food), 1996, OP RESP REQ COMM SCF; SCHANTZ SL, 1991, ENVIRON TOXICOL CHEM, V10, P747, DOI 10.1897/1552-8618(1991)10[747:LNEOPP]2.0.CO;2; SCHANTZ SL, 1989, NEUROTOXICOL TERATOL, V11, P243, DOI 10.1016/0892-0362(89)90066-4; SCHEPERS GW, 1964, ARCH ENVIRON HEALTH, V8, P277; SCHWETZ BA, 1978, PENTACHLOROPHENOL CH, P301; SCOTT JR, 1977, AM J OBSTET GYNECOL, V128, P668; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Shelby MD, 1996, ENVIRON HEALTH PERSP, V104, P1296, DOI 10.2307/3432965; SHORE CO, 1983, NEUROBEH TOXICOL TER, V5, P565; SIEBER SM, 1978, TERATOLOGY, V18, P31, DOI 10.1002/tera.1420180107; SMIALOWICZ RJ, 1989, TOXICOLOGY, V56, P197, DOI 10.1016/0300-483X(89)90133-9; SONG ZY, 1997, APMIS, V105, P435; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; SOTO AM, 1994, ENVIRON HEALTH PERSP, V102, P380, DOI 10.2307/3431626; SPENCE SG, 1995, TERATOLOGY, V51, P383, DOI 10.1002/tera.1420510604; SPYKER JM, 1977, J TOXICOL ENV HEALTH, V3, P989; SQUIBB RE, 1980, TOXICOL APPL PHARM, V55, P188, DOI 10.1016/0041-008X(80)90235-5; STANWORTH DR, 1987, IMMUNOTOXICOLOGY, P426; Stevens JT, 1997, J TOXICOL ENV HEALTH, V50, P415, DOI 10.1080/00984109708983999; STOMER VEV, 1990, NEUROTOXICOL TERATOL, V12, P85, DOI 10.1016/0892-0362(90)90117-U; TAKAHASHI RN, 1991, NEUROTOXICOL TERATOL, V13, P21, DOI 10.1016/0892-0362(91)90023-P; TANAKA T, 1993, TOXICOL IND HEALTH, V9, P1027; TAYLOR DH, 1985, SCI TOTAL ENVIRON, V47, P415, DOI 10.1016/0048-9697(85)90345-6; TAYLOR SL, 1987, ANN ALLERGY, V59, P93; Taylor SL, 1998, ADV FOOD NUTR RES, V42, P1, DOI 10.1016/S1043-4526(08)60091-1; TENNANT RW, 1991, MUTAT RES, V257, P209, DOI 10.1016/0165-1110(91)90002-D; TERAMOTO S, 1980, MUTAT RES, V77, P71, DOI 10.1016/0165-1218(80)90122-6; THOMAS PT, 1978, TOXICOL APPL PHARM, V44, P41, DOI 10.1016/0041-008X(78)90282-X; Thomson D., 1980, ICLARM NEWSLETTER, V3, P3; THYSEN B, 1985, J TOXICOL ENV HEALTH, V16, P763; TRIZIO D, 1988, FOOD CHEM TOXICOL, V26, P527, DOI 10.1016/0278-6915(88)90006-3; TUSING TW, 1962, TOXICOL APPL PHARM, V4, P402, DOI 10.1016/0041-008X(62)90050-9; Ulbrich B, 1996, ENVIRON HEALTH PERSP, V104, P407, DOI 10.2307/3432662; UNNERUS HA, 1979, ACTA ENDOCR-COP    S, V91, P266; Vanden Bossche H, 1985, Curr Top Med Mycol, V1, P313; VERDEAL K, 1979, J FOOD PROTECT, V42, P577; VOMSAAL FS, 1995, TOXICOL LETT, V77, P343, DOI 10.1016/0378-4274(95)03316-5; VORHEES CV, 1985, NEUROBEH TOXICOL TER, V7, P471; VORHEES CV, 1987, NEUROTOXICOL TERATOL, V9, P445, DOI 10.1016/0892-0362(87)90056-0; VORHEES CV, 1983, TERATOLOGY, V28, P309, DOI 10.1002/tera.1420280302; VORHEES CV, 1984, FOOD CHEM TOXICOL, V22, P1, DOI 10.1016/0278-6915(84)90044-9; VORHEES CV, 1994, FUND APPL TOXICOL, V23, P194, DOI 10.1006/faat.1994.1098; VORHEES CV, 1979, SCIENCE, V205, P1220, DOI 10.1126/science.472738; VORHEES CV, 1983, J PHARM EXPT THERAPY, V227, P106; VOS JG, 1990, TOXICOL APPL PHARM, V105, P144, DOI 10.1016/0041-008X(90)90366-3; VOS JG, 1984, TOXICOLOGY, V29, P325, DOI 10.1016/0300-483X(84)90164-1; WALKENSBERENDSE.DH, 1996, REGULATORY TOXICOLOG, V24, pS237; WANG B X, 1990, Yaoxue Xuebao, V25, P401; WATSON ES, 1983, TOXICOL APPL PHARM, V71, P1, DOI 10.1016/0041-008X(83)90040-6; WEIL CS, 1963, J AGR FOOD CHEM, V11, P486, DOI 10.1021/jf60130a015; WeinandHarer A, 1997, ENVIRON TOXICOL PHAR, V3, P97, DOI 10.1016/S1382-6689(96)00145-7; WELSCH F, 1985, ARCH TOXICOL, V57, P104, DOI 10.1007/BF00343119; WESTER PW, 1988, UNPUB 2 YEAR FEEDING; World Health Organization, 1987, ENV HLTH CRIT, V70; WINTER CK, 1992, REV ENVIRON CONTAM T, V127, P23; WISE LD, 1995, NEUROTOXICOL TERATOL, V17, P189, DOI 10.1016/0892-0362(94)00071-K; Wise LD, 1997, NEUROTOXICOL TERATOL, V19, P315, DOI 10.1016/S0892-0362(97)00002-0; WISE LD, 1994, FOOD CHEM TOXICOL, V32, P239, DOI 10.1016/0278-6915(94)90196-1; WOLFF MS, 1993, J NATL CANCER I, V85, P648, DOI 10.1093/jnci/85.8.648; WUTHRICH B, 1995, P 16 EUR C ALL CLIN, P859; YANG RSH, 1984, FUND APPL TOXICOL, V4, P539, DOI 10.1016/0272-0590(84)90043-5; Yu TX, 1997, BRAIN RES, V747, P195, DOI 10.1016/S0006-8993(96)01181-X; Ziegler J, 1997, J NATL CANCER I, V89, P1186; 1968, EVALUATION CARCINOGE, V2; 1986, TOXICOLOGY APPL PHAR, V82, P19; 1991, NEUROTOXICITY 83; 1986, AM CYANAMID; 1984, TOXICOLOGIST, V4, P179; 1991, NEUROTOXICITY 81; 1968, EVALUATION CARCINOGE, V1; 1980, AM CYANAMID; 1991, NEUROTOXICITY 82	267	131	140	2	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915			FOOD CHEM TOXICOL	Food Chem. Toxicol.	FEB-MAR	2000	38	2-3					255	312		10.1016/S0278-6915(99)00120-9		58	Food Science & Technology; Toxicology	Food Science & Technology; Toxicology	308BC	WOS:000086687800012	10717364	
J	Palmans, E; Kips, JC; Pauwels, RA				Palmans, E; Kips, JC; Pauwels, RA			Prolonged allergen exposure induces structural airway changes in sensitized rats	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; BROWN-NORWAY RATS; CHRONIC-BRONCHITIS; ANTIGEN CHALLENGE; ASTHMA; EXPRESSION; FIBRONECTIN; RESPONSIVENESS; PROLIFERATION; METHACHOLINE	The pathogenesis and functional consequences of airway remodeling in asthma remain to be fully established. In the present study we evaluated the effect of prolonged allergen exposure on airway function and structure in rats. Sensitized Brown Norway rats were repeatedly exposed for periods of 2 4, or 12 wk to aerosolized ovalbumin (OA) or phosphate-buffered saline (PBS). OA exposure induced a persistent increase in OA-specific serum IgE and in the number of peribronchial eosinophils. After 2 wk of OA exposure, airway histology revealed goblet-cell hyperplasia, an increase in bromodeoxyuridine-positive cells in airway epithelium, increased fibronectin deposition, and a thickening of the airway inner wall area. This coincided with airway hyperresponsiveness (AHR) to aerosolized carbachol. After OA exposure for 12 wk, increased fibronectin (p < 0.05 versus PBS) and collagen deposition (p < 0.05 versus PBS) were observed in the submucosa. After 12 wk of exposure, neither total nor inner wall area or airway responsiveness to carbachol were any longer significantly different from those of PBS-exposed animals. In conclusion, prolonged OA exposure in rats induces structural airway changes that bear similarities to airway remodeling in asthma. The study data further indicate that depending on the extent and distribution of remodeling, changes in the extracellular matrix can enhance or protect against AHR.	State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Palmans, E (reprint author), State Univ Ghent Hosp, Dept Resp Dis, De Pintelaan 185, B-9000 Ghent, Belgium.						BAI A, 1994, J APPL PHYSIOL, V77, P1011; BELLOFIORE S, 1988, J APPL PHYSIOL, V65, P1642; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; BRAMLEY AM, 1995, AM J RESP CRIT CARE, V152, P1513; Cairns JA, 1996, J IMMUNOL, V156, P275; CASSCELLS W, 1990, AM J PATHOL, V137, P801; Cohen MD, 1997, AM J RESP CELL MOL, V16, P85; COHEN P, 1995, AM J PHYSIOL-LUNG C, V269, pL151; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; ELWOOD W, 1991, J ALLERGY CLIN IMMUN, V88, P951, DOI 10.1016/0091-6749(91)90253-K; GILLERY P, 1986, EXP CELL RES, V167, P29, DOI 10.1016/0014-4827(86)90201-6; GLASSBERG MK, 1994, AM J RESP CELL MOL, V10, P316; HACKZU A, 1994, AM J RESP CRIT CARE, V150, P23; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; KIPS JC, 1992, AM REV RESPIR DIS, V145, P1306; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; LAMBERT RK, 1994, J APPL PHYSIOL, V77, P1206; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Li X, 1997, AM J RESP CRIT CARE, V156, P229; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; McKay S, 1998, AM J RESP CELL MOL, V18, P823; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365; Panettieri Reynold Jr., 1998, American Journal of Physiology, V274, pL417; RAGHOW R, 1994, FASEB J, V8, P823; ROCHE WR, 1989, LANCET, V1, P520; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423; STEWART AG, 1995, AM J RESP CELL MOL, V12, P110; TAKIZAWA T, 1971, AM REV RESPIR DIS, V104, P331; Temelkovski J, 1998, THORAX, V53, P849; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; WELCH MP, 1990, J CELL BIOL, V110, P133, DOI 10.1083/jcb.110.1.133; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	36	131	170	0	3	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB	2000	161	2					627	635				9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	285ED	WOS:000085376000046	10673209	
J	Wootton, R				Wootton, Richard			Twenty years of telemedicine in chronic disease management - an evidence synthesis	JOURNAL OF TELEMEDICINE AND TELECARE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; CONGESTIVE-HEART-FAILURE; OF-THE-LITERATURE; HOME TELEHEALTH; DIABETES MANAGEMENT; METAANALYSIS; CARE; INTERVENTIONS; SUPPORT; BURDEN	A literature review was conducted to obtain a high-level view of the value of telemedicine in the management of five common chronic diseases (asthma, COPD, diabetes, heart failure, hypertension). A total of 141 randomised controlled trials (RCTs) was identified, in which 148 telemedicine interventions of various kinds had been tested in a total of 37,695 patients. The value of each intervention was categorised in terms of the outcomes specified by the investigators in that trial, i.e. no attempt was made to extract a common outcome from all studies, as would be required for a conventional meta-analysis. Summarizing the value of these interventions shows, first, that most studies have reported positive effects (n = 108), and almost none have reported negative effects (n = 2). This suggests publication bias. Second, there were no significant differences between the chronic diseases, i.e. telemedicine seems equally effective (or ineffective) in the diseases studied. Third, most studies have been relatively short-term (median duration 6 months). It seems unlikely that in a chronic disease, any intervention can have much effect unless applied for a long period. Finally, there have been very few studies of cost-effectiveness. Thus the evidence base for the value of telemedicine in managing chronic diseases is on the whole weak and contradictory.	Univ Hosp N Norway, Norwegian Ctr Integrated Care & Telemed, N-9038 Tromso, Norway	Wootton, R (reprint author), Univ Hosp N Norway, Norwegian Ctr Integrated Care & Telemed, POB 6060, N-9038 Tromso, Norway.	r_wootton@pobox.com	Wootton, Richard/F-7609-2014	Wootton, Richard/0000-0002-2666-3596			AbuDagga A, 2010, TELEMED J E-HEALTH, V16, P830, DOI 10.1089/tmj.2010.0015; Bartoli L, 2009, TELEMED J E-HEALTH, V15, P877, DOI 10.1089/tmj.2009.0044; Bolton C.E., 2010, J EVAL CLIN PRACT, V17, P1216; Chaudhry SI, 2007, J CARD FAIL, V13, P56, DOI 10.1016/j.cardfail.2006.09.001; Chaudhry SI, 2010, NEW ENGL J MED, V363, P2301, DOI 10.1056/NEJMoa1010029; Clark RA, 2007, BRIT MED J, V334, P942, DOI 10.1136/bmj.39156.536968.55; Clarke M, 2011, J TELEMED TELECARE, V17, P7, DOI 10.1258/jtt.2010.100113; Costa BM, 2009, BMC FAM PRACT, V10, DOI 10.1186/1471-2296-10-72; Dang S, 2009, TELEMED J E-HEALTH, V15, P783, DOI 10.1089/tmj.2009.0028; Darkins A, 2008, TELEMED J E-HEALTH, V14, P1118, DOI 10.1089/tmj.2008.0021; Druss BG, 2001, HEALTH AFFAIR, V20, P233, DOI 10.1377/hlthaff.20.6.233; Farmer A, 2005, DIABETIC MED, V22, P1372, DOI 10.1111/j.1464-5491.2005.01627.x; Freidlin B, 2008, CLIN CANCER RES, V14, P4368, DOI 10.1158/1078-0432.CCR-08-0325; Hebert PL, 2008, ANN INTERN MED, V149, P540; Inglis SC, 2010, COCHRANE DB SYST REV, V8; Jaana M, 2009, AM J MANAG CARE, V15, P313; Koehler F, 2011, CIRCULATION, V123, P1873, DOI 10.1161/CIRCULATIONAHA.111.018473; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Louis AA, 2003, EUR J HEART FAIL, V5, P583, DOI 10.1016/S1388-9842(03)00160-0; Martinez A, 2006, J TELEMED TELECARE, V12, P234, DOI 10.1258/135763306777889109; McLEan S., 2010, COCHRANE DB SYST REV, V10; McLean S, 2011, COCHRANE DB SYST REV, V7, P1; Ouwens M, 2005, INT J QUAL HEALTH C, V17, P141, DOI 10.1093/intqhc/mzi016; Polisena J, 2009, DIABETES OBES METAB, V11, P913, DOI 10.1111/j.1463-1326.2009.01057.x; Polisena J, 2010, J TELEMED TELECARE, V16, P120, DOI 10.1258/jtt.2009.090812; Polisena J, 2010, J TELEMED TELECARE, V16, P68, DOI 10.1258/jtt.2009.090406; Seto E, 2008, TELEMED J E-HEALTH, V14, P679, DOI 10.1089/tmj.2007.0114; Shea S, 2009, J AM MED INFORM ASSN, V16, P446, DOI 10.1197/jamia.M3157; Shulman RM, 2010, INT J PEDIAT ENDOCRI; Sterne JAC, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d4002; Sutherland D, 2009, J CLIN NURS, V18, P2978, DOI 10.1111/j.1365-2702.2009.02900.x; Verhoeven Fenne, 2010, J Diabetes Sci Technol, V4, P666; Verhoeven F, 2007, J MED INTERNET RES, V9, DOI 10.2196/jmir.9.5.e37; Wootton R, 2003, BEST PRACTICES BEHAV, VII, P1	34	130	131	3	41	ROYAL SOC MEDICINE PRESS LTD	LONDON	1 WIMPOLE STREET, LONDON W1G 0AE, ENGLAND	1357-633X			J TELEMED TELECARE	J. Telemed. Telecare		2012	18	4					211	220		10.1258/jtt.2012.120219		10	Health Care Sciences & Services	Health Care Sciences & Services	969HK	WOS:000306046100007	22674020	
J	Liu, L; Poon, R; Chen, L; Frescura, AM; Montuschi, P; Ciabattoni, G; Wheeler, A; Dales, R				Liu, Ling; Poon, Raymond; Chen, Li; Frescura, Anna-Maria; Montuschi, Paolo; Ciabattoni, Giovanni; Wheeler, Amanda; Dales, Robert			Acute Effects of Air Pollution on Pulmonary Function, Airway Inflammation, and Oxidative Stress in Asthmatic Children	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; children; exhaled breath condensate; inflammation; oxidative stress; pulmonary function	EXHALED BREATH CONDENSATE; NITRIC-OXIDE; THIOBARBITURIC-ACID; LIPID-PEROXIDATION; PARTICULATE MATTER; RESPIRATORY HEALTH; EPITHELIAL INJURY; IN-VIVO; EXPOSURE; 8-ISOPROSTANE	BACKGROUND: Air pollution is associated with respiratory symptoms, lung function decrements, and hospitalizations. However, there is little information about the influence of air pollution on lung injury. OBJECTIVE: In this study we investigated acute effects of air pollution on pulmonary function and airway oxidative stress and inflammation in asthmatic children. METHODS: We studied 182 children with asthma, 9-14 years of age, for 4 weeks. Daily ambient concentrations of sulfur dioxide, nitrogen dioxide, ozone, and particulate matter <= 2.5 mu m in aerodynamic diameter (PM(2.5)) were monitored from two stations. Once a week we measured spirometry and fractional exhaled nitric oxide (Fe(NO)), and determined thiobarbituric acid reactive substances (TBARS) and 8-isoprostane-two oxidative stress markers-and interieukin-6 (IL-6) in breath condensate. We tested associations using mixed-effects regression models, adjusting for confounding variables. RESULTS: Interquartile-range increases in 3-day average SO(2) (5.4 ppb), NO(2) (6.8 ppb), and PM(2.5) (5.4 mu g/m(3)) were associated with decreases in forced expiratory flow between 25% and 75% of forced vital capacity, with changes being -3.1% [95% confidence interval (CI), -5.8 to -0.3), -2.8% (95% CI, -4.8 to -0.8), and -3.0% (95% CI, -4.7 to -1.2), respectively. SO(2), NO(2), and PM(2.5) were associated with increases in TBARS, with changes being 36.2% (95% CI, 15.7 to 57.2), 21.8% (95% CI, 8.2 to 36.0), and 24.8% (95% CI, 10.8 to 39.4), respectively. Risk estimates appear to be larger in children not taking corticosteroids than in children taking corticosteroids. O(3) (5.3 ppb) was not associated with health end points. Fe(NO), 8-isoprostane, and IL-6 were not associated with air pollutants. CONCLUSION: Air pollution may increase airway oxidative stress and decrease small airway function of asthmatic children. Inhaled corticosteroids may reduce oxidative stress and improve airway function.	[Liu, Ling; Poon, Raymond; Chen, Li; Frescura, Anna-Maria; Wheeler, Amanda; Dales, Robert] Hlth Canada, Healthy Environm & Consumer Safety Branch, Ottawa, ON K1A 0K9, Canada; [Montuschi, Paolo; Ciabattoni, Giovanni] Univ Cattolica Sacro Cuore, Fac Med, Dept Pharmacol, I-00168 Rome, Italy	Liu, L (reprint author), Hlth Canada, Healthy Environm & Consumer Safety Branch, AL 4903B,269 Laurier Ave, Ottawa, ON K1A 0K9, Canada.	ling_liu@hc-sc.gc.ca		MONTUSCHI, Paolo/0000-0001-5589-1750; Wheeler, Amanda/0000-0001-9288-8163	Canada-the United States Border Air Quality Strategy	This study was funded by the Canada-the United States Border Air Quality Strategy.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Balint B, 2001, THORAX, V56, P456, DOI 10.1136/thorax.56.6.456; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904; Baraldi E, 2003, THORAX, V58, P505, DOI 10.1136/thorax.58.6.505; Barregard L, 2008, OCCUP ENVIRON MED, V65, P319, DOI 10.1136/oem.2006.032458; Brand H S, 2006, Int J Dent Hyg, V4, P160, DOI 10.1111/j.1601-5037.2006.00171.x; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Caglieri A, 2006, ENVIRON HEALTH PERSP, V114, P542, DOI 10.1289/ehp.8506; Canadian Institute for Health information, 2001, RESP DIS CAN; Carpagnano GE, 2003, EUR RESPIR J, V21, P589, DOI 10.1183/09031936.03.00022203; Chuang KJ, 2007, AM J RESP CRIT CARE, V176, P370, DOI 10.1164/rccm.200611-1627OC; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P550, DOI 10.1289/ehp.10911; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Dye JA, 1997, AM J RESP CELL MOL, V17, P625; Epton MJ, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-16; Frampton MW, 1997, RES REP HLTH EFF I, V78, P73; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Goldoni M, 2004, ENVIRON HEALTH PERSP, V112, P1293, DOI 10.1289/ehp.7108; HALLIWELL B, 1981, FEBS LETT, V128, P347, DOI 10.1016/0014-5793(81)80114-7; Halliwell B., 1989, FREE RADICAL BIO MED, P188; Halliwell Barry, 1993, American Journal of Clinical Nutrition, V57, p715S; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519; JANERO DR, 1990, FREE RADICAL BIO MED, V9, P515, DOI 10.1016/0891-5849(90)90131-2; Khor YH, 2007, CLIN EXP ALLERGY, V37, P1189, DOI 10.1111/j.1365-2222.2007.02762.x; Kodavanti UP, 2000, TOXICOL APPL PHARM, V164, P250, DOI 10.1006/taap.2000.8899; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; LEBECQUE P, 1993, PEDIATR PULM, V16, P19, DOI 10.1002/ppul.1950160105; Lehtonen H, 2007, THORAX, V62, P602, DOI 10.1136/thx.2006.067868; Mar TF, 2005, ENVIRON HEALTH PERSP, V113, P1791, DOI 10.1289/ehp.7883; Meng ZQ, 2003, ENVIRON RES, V93, P285, DOI 10.1016/S0013-9351(03)00045-8; Montuschi P, 2003, INFLAMM RES, V52, P502, DOI 10.1007/s00011-003-1212-6; Montuschi P, 2002, FREE RADICAL BIO MED, V33, P1403, DOI 10.1016/S0891-5849(02)01084-5; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175; Montuschi P, 2005, NEW PERSPECTIVES MON; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; PELCLOVA D, 2007, IND HLTH, V49, P766; Persinger RL, 2002, MOL CELL BIOCHEM, V234, P71, DOI 10.1023/A:1015973530559; Rhoden CR, 2004, TOXICOL SCI, V79, P296, DOI 10.1093/toxsci/kfh122; ROMIEU I, 2008, J ALLERGY CLIN IMMUN, V121, P930; Stieb DM, 2000, J EXPO ANAL ENV EPID, V10, P461, DOI 10.1038/sj.jea.7500112; Sunyer J, 1997, THORAX, V52, P760; Vichit-Vadakan N, 2001, ENVIRON HEALTH PERSP, V109, P381, DOI 10.2307/3434785; Villar M, 2007, MOL CELL PROTEOMICS, V6, P40; Walter MF, 2004, J AM COLL CARDIOL, V44, P1996, DOI 10.1016/j.jacc.2004.08.029; Wong CM, 2002, ENVIRON HEALTH PERSP, V110, P67; Yagi K., 1982, LIPID PEROXIDE BIOL, P232	51	130	139	7	58	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2009	117	4					668	674		10.1289/ehp11813		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	426JQ	WOS:000264704500044	19440509	
J	Beckerman, B; Jerrett, M; Brook, JR; Verma, DK; Arain, MA; Finkelstein, MM				Beckerman, Bernardo; Jerrett, Michael; Brook, Jeffrey R.; Verma, Dave K.; Arain, Muhammad A.; Finkelstein, Murray M.			Correlation of nitrogen dioxide with other traffic pollutants near a major expressway	ATMOSPHERIC ENVIRONMENT			English	Article						traffic; air pollution; NO2; VOC; fine particulate matter; ultrafine particles; Toronto; distance decay	AIR-POLLUTION; ULTRAFINE PARTICLES; PM2.5 CONCENTRATIONS; HIGHWAY; INDOOR; ROAD; EXPOSURE; CHILDREN; OUTDOOR; ASTHMA	Objectives: This study addresses three objectives: (1) to assess the correlation of NO2 to other ambient pollutants measured with passive samplers; (2) to explore peak traffic particulate matter air pollution correlations with passively measured NO2; and (3) to pilot an advanced mobile air pollution laboratory to supply supplementary information on correlations between NO2 and other air pollutants. Methods: Active and passive monitoring was conducted at two transects perpendicular to an expressway with nearly 400,000 vehicles per day. NO2, NOx, O-3, VOCs, fine-particles and ultrafine particles were measured at increasing distance away from the expressway. The measurement equipment included Ogawa, TraceAir and 3 M organic vapor monitors (OVM-3500) passive samplers, and an array of active measurement equipment: Dust-Trak and P-Trak monitors, chemoluminescent analyzer, aethalometer, tapered element oscillating microbalance, Grimm condensation particle counter, and an lonicon analytik proton transfer reaction mass spectrometer. Results: Levels of NO2 were observed to decay with increasing distance from the expressway, declining to background levels by 300 m. Moderate to high correlations were observed between passive NO2 measurements and passive NOx, O-3 (r similar to 0.60-0.86). The correlations with active PM measurements made with Dust-Trak and P-Trak monitors were in the range 0.64-0.78; correlations between NO2 and VOCs were more variable. Active measurements of NO2 and PM2.5, ultrafine particles, O-3 and black carbon, had high correlations (r similar to 0.7-0.96). Discussion: The variability of many traffic-related pollutants around an expressway is characterized well by passive measurements of NO2. Further research is needed to assess whether these relationships hold in different traffic and land-use environments. (c) 2007 Elsevier Ltd. All rights reserved.	[Beckerman, Bernardo] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA; [Jerrett, Michael] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Jerrett, Michael] Univ So Calif, Los Angeles, CA 90089 USA; [Verma, Dave K.; Arain, Muhammad A.; Finkelstein, Murray M.] McMaster Univ, Hamilton, ON L8S 4L8, Canada	Beckerman, B (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, 140 Warren Hall 7360, Berkeley, CA 94720 USA.	beckerman@berkeley.edu		Arain, M. Altaf/0000-0002-1433-5173			Atkinson R, 2000, ATMOS ENVIRON, V34, P2063, DOI 10.1016/S1352-2310(99)00460-4; BROOK RD, 2007, IN PRESS J OCCUPATIO; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Finkelstein MM, 2007, ENVIRON RES, V104, P420, DOI 10.1016/j.envres.2007.03.002; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Hitchins J, 2000, ATMOS ENVIRON, V34, P51, DOI 10.1016/S1352-2310(99)00304-0; HODGES L, 1977, ENV POLLUTION HOLT; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Jerrett M, 2007, J TOXICOL ENV HEAL A, V70, P200, DOI 10.1080/15287390600883018; Jo WK, 2005, CHEMOSPHERE, V59, P1557, DOI 10.1016/j.chemosphere.2004.12.021; JOHNSON WB, 1973, JAPCA J AIR WASTE MA, V23, P490; Kanaroglou PS, 2005, ATMOS ENVIRON, V39, P2399, DOI 10.1016/j.atmosenv.2004.06.049; LEBRET E, 2000, ATMOS ENVIRON, V34, P117; McConnell R, 2006, SCI TOTAL ENVIRON, V363, P166, DOI 10.1016/j.scitotenv.2005.06.028; *MTO, 2006, PROV HIGHW TRAFF VOL; Ramachandran G, 2000, J AIR WASTE MANAGE, V50, P1157; Reponen T, 2003, J ENVIRON MONITOR, V5, P557, DOI 10.1039/b303557c; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Sahsuvaroglu T, 2006, J AIR WASTE MANAGE, V56, P1059; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; Sillman S, 1999, ATMOS ENVIRON, V33, P1821, DOI 10.1016/S1352-2310(98)00345-8; Tiitta P, 2002, ATMOS ENVIRON, V36, P4057, DOI 10.1016/S1352-2310(02)00309-6; Weisel CP, 2005, J EXPO ANAL ENV EPID, V15, P123, DOI 10.1038/sj.jea.7500379; Yanosky JD, 2002, ATMOS ENVIRON, V36, P107, DOI 10.1016/S1352-2310(01)00422-8; Zhang KM, 2005, ATMOS ENVIRON, V39, P4155, DOI 10.1016/j.atmosenv.2005.04.003; Zhou Y, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-89; Zhu YF, 2006, ENVIRON SCI TECHNOL, V40, P2531, DOI 10.1021/es0516514; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zhu YF, 2002, ATMOS ENVIRON, V36, P4323, DOI 10.1016/S1352-2310(02)00354-0	30	130	132	5	64	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	JAN	2008	42	2					275	290		10.1016/j.atmosenv.2007.09.042		16	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	261OD	WOS:000253088300006		
J	Cruz, AA; Popov, T; Pawankar, R; Annesi-Maesano, I; Fokkens, W; Kemp, J; Ohta, K; Price, D; Bousquet, J				Cruz, A. A.; Popov, T.; Pawankar, R.; Annesi-Maesano, I.; Fokkens, W.; Kemp, J.; Ohta, K.; Price, D.; Bousquet, J.		ARIA Initiative Sci Comm	Common characteristics of upper and lower airways in rhinitis and asthma: ARIA update, in collaboration with GA(2)LEN	ALLERGY			English	Review						allergy; asthma; atopy; review; rhinitis	SEASONAL ALLERGIC RHINITIS; EXHALED NITRIC-OXIDE; INDEPENDENT RISK-FACTOR; PRIMARY-SCHOOL CHILDREN; ADULT-ONSET ASTHMA; QUALITY-OF-LIFE; IN-HOUSE DUST; HAY-FEVER; BRONCHIAL HYPERRESPONSIVENESS; ATOPIC ECZEMA	This update aimed to review the new evidence available to support or refute prior Allergic Rhinitis and its Impact on Asthma (ARIA) statements. A Medline search of publications between 2000 and 2005 was conducted, with articles selected by experts. New evidence supports previous ARIA statements, such as: (i) allergic rhinitis (AR) is a risk factor for asthma; (ii) patients with persistent rhinitis should be evaluated for asthma; (iii) most patients with asthma have rhinitis; (iv) a combined strategy should be used to treat the airways and (v) in low- to middle-income countries, a different strategy may be needed. The increased risk of asthma has also been found among sufferers from non-AR. Recent reports show AR is a global problem. Many studies demonstrated parallel increasing prevalence of asthma and rhinitis, but in regions of highest prevalence, it may be reaching a plateau. Factors associated with a reduced risk of asthma and AR have been identified, confirming previous findings of protection related to exposure to infections. Treatment of rhinitis with intranasal glucocorticosteroids, antihistamines, leukotriene antagonists or immunotherapy may reduce morbidity because of asthma. To take advantage of the paradigm of unified airways, there is a need to rationalize diagnosis and treatment to optimize management.	Univ Fed Bahia, Sch Med, CNPq, Programme Control Asthma & Allerg Rhinitis, Salvador, BA, Brazil; Med Univ Sofia, Clin Ctr Allergol, Sofia, Bulgaria; Nippon Med Coll, Dept Otolaryngol, Div Rhinol & Allergy, Tokyo 113, Japan; INSERM, Paris, France; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; Univ Calif San Diego, Sch Med, Dept Pediat, San Diego, CA 92103 USA; Univ Tokyo, Dept Otolaryngol, Tokyo 113, Japan; Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen, Scotland; Univ Hosp, INSERM, Montpellier, France	Cruz, AA (reprint author), Univ Fed Bahia, Sch Med, CNPq, Programme Control Asthma & Allerg Rhinitis, Salvador, BA, Brazil.		Annesi-Maesano, Isabella/D-9173-2016; Cruz, Alvaro/I-1676-2012	Cruz, Alvaro/0000-0002-7403-3871			Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Al Frayh AR, 2001, ANN ALLERG ASTHMA IM, V86, P292; Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; Annesi-Maesano I, 2004, CLIN EXP ALLERGY, V34, P1017, DOI 10.1111/j.1365-2222.2004.02002.x; Annus T, 2005, PEDIATR ALLERGY IMMU, V16, P315, DOI 10.1111/j.1399-3038.2005.00276.x; Arnedo-Pena A, 2005, An Pediatr (Barc), V62, P229, DOI 10.1157/13071837; Aronsson D, 2005, CLIN EXP ALLERGY, V35, P1457, DOI 10.1111/j.1365-2222.2005.02363.x; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Aubier M, 2001, ALLERGY, V56, P35, DOI 10.1034/j.1398-9995.2001.00629.x; Bachert C, 2002, Allergy, V57, P841; Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; Bager P, 2003, CLIN EXP ALLERGY, V33, P1512, DOI 10.1046/j.1365-2222.2003.01796.x; Baiardini I, 2003, ALLERGY, V58, P289, DOI 10.1034/j.1398-9995.2003.00079.x; Banac S, 2004, CROAT MED J, V45, P721; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Bavbek S, 2003, J INVEST ALLERG CLIN, V13, P252; Bayram I, 2004, TURKISH J PEDIATR, V46, P221; Berger WE, 2002, ANN ALLERG ASTHMA IM, V89, P485; Bolte G, 2005, ANN EPIDEMIOL, V15, P207, DOI 10.1016/j.annepidem.2004.04.004; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Boulay ME, 2002, CLIN EXP ALLERGY, V32, P1441, DOI 10.1046/j.1365-2745.2002.01508.x; Bousquet J, 2006, ALLERGY, V61, P1086, DOI 10.1111/j.1398-9995.2006.01144.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P723, DOI 10.1111/j.1365-2222.2005.02251.x; Bousquet J, 2004, CLIN EXP ALLERGY, V34, P897, DOI 10.1111/j.1365-2222.2004.01969.x; Bousquet J, 2004, J ALLERGY CLIN IMMUN, V113, P43, DOI 10.1016/j.jaci.2003.09.047; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Braback L, 2005, EUR RESPIR J, V26, P1064, DOI 10.1183/09031936.05.00022105; Braback L, 2005, RESP MED, V99, P1010, DOI 10.1016/j.rmed.2005.02.004; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; BRAZIL MS, 2004, ASMA RINITE; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Bugiani M, 2005, ALLERGY, V60, P165, DOI 10.1111/j.1398-9995.2005.00659.x; Burr ML, 2003, CLIN EXP ALLERGY, V33, P1675, DOI 10.1111/j.1365-2222.2003.01816.x; Camargos PAM, 2004, PEDIATR PULM, V38, P186, DOI 10.1002/ppul.20084; Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Chang J, 2001, YONSEI MED J, V42, P106; Chatkin Moema N., 2005, J. Pediatr. (Rio J.), V81, P411, DOI 10.1590/S0021-75572005000600013; Chatzi L, 2005, CHEST, V127, P372, DOI 10.1378/chest.127.1.372; Chen JT, 2002, ENVIRON HEALTH PERSP, V110, P211; Cibella F, 2004, ALLERGY, V59, P1074, DOI 10.1111/j.1398-9995.2004.00559.x; Ciprandi G, 2005, RESP MED, V99, P1606, DOI 10.1016/j.rmed.2005.03.030; Ciprandi G, 2005, INT ARCH ALLERGY IMM, V136, P266, DOI 10.1159/000083953; Cirillo Ignazio, 2003, Eur Ann Allergy Clin Immunol, V35, P204; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; Corren J, 2005, J ALLERGY CLIN IMMUN, V115, P202, DOI 10.1016/j.jaci.2004.09.035; Crimi E, 2001, J APPL PHYSIOL, V91, P1029; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; da Cunha SS, 2004, ALLERGY, V59, P857; Dahl R, 2005, ALLERGY, V60, P875, DOI 10.1111/j.1398-9995.2005.00819.x; de Meer G, 2005, ALLERGY, V60, P619, DOI 10.1111/j.1398-9995.2005.00746.x; Demir AU, 2004, PEDIATR ALLERGY IMMU, V15, P531, DOI 10.1111/j.1399-3038.2004.00202.x; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Dennis R, 2004, ANN ALLERG ASTHMA IM, V93, P568; Devenny A, 2004, BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; Dhong HJ, 2005, ACTA OTO-LARYNGOL, V125, P169, DOI 10.1080/00016480410015767; Di Lorenzo G, 2005, INT J IMMUNOPATH PH, V18, P715; Dizier MH, 2005, GENES IMMUN, V6, P95, DOI 10.1038/sj.gene.6364163; Dotterud LK, 2000, J EUR ACAD DERMATOL, V14, P107, DOI 10.1046/j.1468-3083.2000.00027.x; Downs SH, 2001, MED J AUSTRALIA, V175, P10; Falade AG, 2004, MED PRIN PRACT, V13, P20, DOI 10.1159/000074046; Filipiak B, 2001, EUR J EPIDEMIOL, V17, P77, DOI 10.1023/A:1010979522339; Foliaki S, 2004, INT J EPIDEMIOL, V33, P558, DOI 10.1093/ije/dyh031; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; Gruber C, 2002, PEDIATR ALLERGY IMMU, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Guerra S, 2005, ALLERGY, V60, P343, DOI 10.1111/j.1398-9995.2005.00717.x; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Hailu S, 2003, PEDIATR PULM, V35, P427, DOI 10.1002/ppul.10215; Halpern MT, 2004, J ASTHMA, V41, P117, DOI 10.1081/JAS-120026069; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; Huang SL, 2002, CLIN EXP ALLERGY, V32, P1029, DOI 10.1046/j.1365-2745.2002.01424.x; Huurre TM, 2004, J ASTHMA, V41, P311, DOI 10.1081/JAS-120026088; Jan IS, 2004, J FORMOS MED ASSOC, V103, P259; Jarvis D, 2004, ALLERGY, V59, P1063, DOI 10.1111/j.1398-9995.2004.00539.x; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Kabir M L, 2005, Mymensingh Med J, V14, P41; Kanani AS, 2005, ANN ALLERG ASTHMA IM, V94, P341; Kaukiainen A, 2005, INT ARCH OCC ENV HEA, V78, P452, DOI 10.1007/s00420-004-0600-8; Kelly EAB, 2003, J ALLERGY CLIN IMMUN, V111, P79, DOI 10.1067/mai.2003.28; Kircher S, 2002, ANN ALLERG ASTHMA IM, V89, P463; Kivity S, 2001, PEDIATR PULM, V32, P217, DOI 10.1002/ppul.1111; Kocevar VS, 2005, ALLERGY, V60, P338, DOI 10.1111/j.1398-9995.2005.00712.x; Koh YI, 2002, INT ARCH ALLERGY IMM, V129, P341, DOI 10.1159/000067593; Kurz T, 2005, ALLERGY, V60, P192, DOI 10.1111/j.1398-9995.2005.00646.x; Laforest L, 2005, ANN ALLERG ASTHMA IM, V95, P26; Latvala J, 2005, BRIT MED J, V330, P1186, DOI 10.1136/bmj.38448.603921.AF; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; Lee SL, 2004, PEDIATR ALLERGY IMMU, V15, P72, DOI 10.1046/j.0905-6157.2003.00109.x; Levesque Benoit, 2004, Can Respir J, V11, P343; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Leynaert Benedicte, 2004, Journal of Allergy and Clinical Immunology, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Lis Grzegorz, 2004, Otolaryngol Pol, V58, P1103; Lombardi C, 2001, RESP MED, V95, P9, DOI 10.1053/rmed.2000.0945; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; Martignon G, 2005, PEDIATR ALLERGY IMMU, V16, P193, DOI 10.1111/j.1399-3038.2005.00254.x; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Mavale-Manuel S, 2004, ALLERGY, V59, P388, DOI 10.1046/j.1398-9995.2003.00333.x; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Mete N, 2004, ANN ALLERG ASTHMA IM, V93, P193; Milanese M, 2001, J APPL PHYSIOL, V91, P1035; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Monteil MA, 2004, REV PANAM SALUD PUBL, V16, P193, DOI 10.1590/S1020-49892004000900006; Montnemery P, 2001, EUR RESPIR J, V17, P596, DOI 10.1183/09031936.01.17405960; Moscato G, 2005, CHEST, V128, P3590, DOI 10.1378/chest.128.5.3590; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nga NN, 2003, PEDIATR ALLERGY IMMU, V14, P272, DOI 10.1034/j.1399-3038.2003.00043.x; Nickel R, 2002, CLIN EXP ALLERGY, V32, P1274, DOI 10.1046/j.1365-2745.2002.01482.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Olin AC, 2004, CLIN EXP ALLERGY, V34, P221, DOI 10.1111/j.1365-2222.2004.01888.x; Palczynski C, 2001, ALLERGY, V56, P1186, DOI 10.1034/j.1398-9995.2001.00236.x; Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960; Passalacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P1054, DOI 10.1016/j.jaci.2005.12.1308; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Peroni DG, 2003, CLIN EXP ALLERGY, V33, P1349, DOI 10.1046/j.1365-2222.2003.01766.x; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2003, CLIN EXP ALLERGY, V33, P873, DOI 10.1046/j.1365-2222.2003.01676.x; Ponikau JU, 2003, J ALLERGY CLIN IMMUN, V112, P877, DOI 10.1067/mai.2003.1790; Porsbjerg C, 2005, ANN ALLERG ASTHMA IM, V95, P137; Price D, 2005, CLIN EXP ALLERGY, V35, P282, DOI 10.1111/j.1365-2222.2005.02182.x; Reinartz SM, 2005, ALLERGY, V60, P1301, DOI 10.1111/j.1398-9995.2005.00911.x; Remes ST, 2005, CLIN EXP ALLERGY, V35, P160, DOI 10.1111/j.1365-2222.2005.02172.x; Riccio AN, 2002, CLIN EXP ALLERGY, V32, P422, DOI 10.1046/j.1365-2222.2002.01315.x; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Robertson CF, 2004, MED J AUSTRALIA, V180, P273; Ronmark E, 2003, PEDIATR ALLERGY IMMU, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Sackesen C, 2004, ANN RHEUM DIS, V63, P187, DOI 10.1136/ard.2003.007013; Saini S, 2004, J ALLERGY CLIN IMMUN, V114, P768, DOI 10.1016/j.jaci.2004.06.015; Salib RJ, 2004, J ALLERGY CLIN IMMUN, V114, P799, DOI 10.1016/j.jaci.2004.07.010; Salib RJ, 2003, CLIN EXP ALLERGY, V33, P1629, DOI 10.1111/j.1365-2222.2003.01828.x; Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64; Scadding GK, 2000, CLIN OTOLARYNGOL, V25, P551, DOI 10.1046/j.1365-2273.2000.00417.x; Schmidt SM, 2005, PEDIATR ALLERGY IMMU, V16, P137, DOI 10.1111/j.1399-3038.2005.00229.x; Schramm B, 2003, EUR RESPIR J, V21, P116, DOI 10.1183/09031936.03.00019502; Selnes A, 2005, ALLERGY, V60, P894, DOI 10.1111/j.1398-9995.2005.00797.x; Shamssain MH, 2001, ANN ALLERG ASTHMA IM, V86, P428; Shekelle PG, 1999, BRIT MED J, V318, P593; Sherrill DL, 2005, RESP MED, V99, P1377, DOI 10.1016/j.rmed.2005.03.025; Sichletidis L, 2004, Allergol Immunopathol (Madr), V32, P59, DOI 10.1157/13059845; Simoes SD, 2005, CLIN EXP ALLERGY, V35, P602, DOI 10.1111/j.1365-2222.2005.02235.x; Sole D, 2004, Allergol Immunopathol (Madr), V32, P7, DOI 10.1157/13057763; Sole D, 2005, PEDIATR ALLERGY IMMU, V16, P121, DOI 10.1111/j.1399-3038.2005.00227.x; Souza-Machado A, 2005, ALLERGY, V60, P379, DOI 10.1111/j.1398-9995.2005.00709.x; Stelmach R, 2005, CHEST, V128, P3140, DOI 10.1378/chest.128.5.3140; Svanes C, 2005, THORAX, V60, P445, DOI 10.1136/thx.2004.032615; Svanes C, 2002, THORAX, V57, P945, DOI 10.1136/thorax.57.11.945; Taramarcaz P, 2003, COCHRANE DB SYST REV, V4; Teeratakulpisarn J, 2004, ASIAN PAC J ALLERGY, V22, P175; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Terreehorst I, 2002, CLIN EXP ALLERGY, V32, P1160, DOI 10.1046/j.1365-2745.2002.01461.x; Thio BJ, 2000, THORAX, V55, P826, DOI 10.1136/thorax.55.10.826; Thomas M, 2005, PEDIATRICS, V115, P129, DOI 10.1542/peds.2004-0067; Toren K, 2002, RESP MED, V96, P635, DOI 10.1053/rmed.2002.1319; Tutluoglu B, 2002, CLIN EXP ALLERGY, V32, P1170, DOI 10.1046/j.1365-2745.2002.01439.x; Upton MN, 2000, BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; Valero A, 2005, ALLERGY, V60, P1126, DOI 10.1111/j.1398-9995.2005.00835.x; Vellinga A, 2005, ACTA CLIN BELG, V60, P219; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P1660; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Walusiak J, 2004, ALLERGY, V59, P1294, DOI 10.1111/j.1398-9995.2004.00560.x; Walusiak J, 2004, ALLERGY, V59, P442, DOI 10.1111/j.1398-9995.2003.00418.x; Walusiak Jolanta, 2004, Int J Occup Med Environ Health, V17, P433; Wang XS, 2004, ARCH DIS CHILD, V89, P423, DOI 10.1136/adc.2003.031112; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; Watelet JB, 2004, AM J RHINOL, V18, P267; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P616, DOI 10.1046/j.1365-2222.2001.01088.x; Wilson AM, 2005, CLIN EXP ALLERGY, V35, P39, DOI 10.1111/j.1365-2222.2004.02072.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wong TW, 2004, ARCH DIS CHILD, V89, P631, DOI 10.1136/adc.2003.030601; Woszczek G, 2002, EUR RESPIR J, V20, P79, DOI 10.1183/09031936.02.01002001; Yan DC, 2005, ANN ALLERG ASTHMA IM, V95, P579; Yu Jui-Huan, 2005, Journal of Microbiology Immunology and Infection, V38, P123; Zanolin ME, 2004, ALLERGY, V59, P306, DOI 10.1046/j.1398-9995.2003.00391.x	196	130	138	0	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	NOV	2007	62			84			1	41		10.1111/j.1398-9995.2007.01551.x		41	Allergy; Immunology	Allergy; Immunology	218VL	WOS:000250043200001	17924930	
J	Chan-Yeung, M; Ferguson, A; Watson, W; Dimich-Ward, H; Rousseau, R; Lilley, M; DyBuncio, A; Becker, A				Chan-Yeung, M; Ferguson, A; Watson, W; Dimich-Ward, H; Rousseau, R; Lilley, M; DyBuncio, A; Becker, A			The Canadian childhood asthma primary prevention study: Outcomes at 7 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						asthma; primary prevention	FATTY-ACID MODIFICATION; ALLERGEN AVOIDANCE; BRONCHIAL HYPERRESPONSIVENESS; HOUSE-DUST; INFANCY; CHILDREN; REACTIVITY; SYMPTOMS; ATOPY	Background: Avoidance of any one of the individual risk factors associated with childhood asthma has not been successful in preventing its development. Objective: The purpose of this study is to determine the effectiveness of a multifaceted intervention program for the primary prevention of asthma in high-risk infants at 7 years of age. Methods: Five hundred forty-five high-risk infants with an immediate family history of asthma and allergies were prospectively randomized into intervention or control groups prenatally. Intervention measures introduced before birth and during the first year of life included avoidance of house dust, pets, and environmental tobacco smoke and encouragement of breast-feeding with delayed introduction of solid foods. Assessment of outcomes at 7 years consisted of examination by pediatric allergists, methacboline inhalation tests, and allergy skin tests. Results: At 7 years, 469 of the 545 children were contacted, and 380 returned for further assessment. The prevalence of pediatric allergist-diagnosed asthma was significantly lower in the intervention group than in the control group (14.9% vs 23.0%; adjusted risk ratio, 0.44; 95% CI, 0.25-0.79). The prevalence of allergic rhinitis, atopic dermatitis, atopy (defined as positive skin test reactions to any common allergen), and bronchial hyperresponsiveness (defined as the provocative concentration of methacholine that induced a 20% decrease in FEV1 from a postsaline value of less than 7.8 mg/mL) were not significantly different between the 2 groups. The prevalence of asthma (defined as wheeze without colds and the presence of bronchial hyperresponsiveness) was also significantly lower in the intervention group compared with the control group (12.9% vs 25.0%; adjusted risk ratio, 0.39; 95% CI, 0.22-0.71).	Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 3J5, Canada; Univ British Columbia, Dept Pediat, Div Allergy, Vancouver, BC V5Z 3J5, Canada; Univ Manitoba, Manitoba Inst Child Hlth, Sect Allergy & Clin Immunol, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada	Chan-Yeung, M (reprint author), Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, 2775 Heather St, Vancouver, BC V5Z 3J5, Canada.	myeung@interchange.ubc.ca					ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Chan-Yeung M, 2002, ANN ALLERG ASTHMA IM, V88, P52; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; *ISAAC COORD COMM, 1992, MAN INT STUD ASTHM A; Kurukulaaratchy RJ, 2003, J ALLERGY CLIN IMMUN, V112, P311, DOI 10.1067/mai.2003.1623; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057	17	130	135	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					49	55		10.1016/j.jaci.2005.03.029		7	Allergy; Immunology	Allergy; Immunology	017IC	WOS:000235686300007	15990772	
J	Cenci, E; Mencacci, A; Bacci, A; Bistoni, F; Kurup, VP; Romani, L				Cenci, E; Mencacci, A; Bacci, A; Bistoni, F; Kurup, VP; Romani, L			T cell vaccination in mice with invasive pulmonary aspergillosis	JOURNAL OF IMMUNOLOGY			English	Article							ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; CHRONIC GRANULOMATOUS-DISEASE; HUMAN-IMMUNODEFICIENCY-VIRUS; CANDIDA-ALBICANS INFECTION; LUNG DENDRITIC CELLS; HOST-DEFENSE; MURINE ASPERGILLOSIS; ANTIFUNGAL ACTIVITY; MUCOSAL IMMUNITY; MAJOR ALLERGEN	Aspergillus fumigatus, an opportunistic fungal pathogen, is responsible for multiple airway diseases of an allergic and a nonallergic nature. In a murine model of invasive pulmonary aspergillosis, resistance is associated with a decreased lung inflammatory pathology and the occurrence of an IL-12-dependent Th1-type reactivity that are both impaired by IL-4, In the present study we assess the ability of Aspergillus crude culture filtrate Ags and the recombinant allergen Asp f 2 to induce protective antifungal responses in mice with invasive pulmonary aspergillosis, Similar to what occurred upon nasal exposure to viable A. fumigatus conidia, treatment of immunocompetent mice with Aspergillus crude culture filtrate Ags resulted in the development of local and peripheral protective Th1 memory responses, mediated by Ag-specific CD4(+) T cells producing IFN-gamma and IL-2 capable of conferring protection upon adoptive transfer to naive recipients. Protective Th1 responses could not be observed in mice deficient of IFN-gamma or IL-12 and did not occur in response to Asp f 2, which, on the contrary, elicited high level production of inhibitory IL-4. The results show that Ags of Aspergillus exist with the ability to induce both Th1- and Th2-type reactivity during infection, a finding that suggests a possible mechanism through which potentially protective immune responses are inhibited in mice with the infection. However, the occurrence of Th1-mediated resistance upon vaccination with Aspergillus crude culture filtrate Ags, suggests the existence of fungal Ags useful as a candidate vaccine against invasive pulmonary aspergillosis.	Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, I-06122 Perugia, Italy; Med Coll Wisconsin, Div Allergy Immunol, Milwaukee, WI 53295 USA; Vet Affairs Med Ctr, Milwaukee, WI 53295 USA	Romani, L (reprint author), Univ Perugia, Dept Expt Med & Biochem Sci, Microbiol Sect, Via Giochetto, I-06122 Perugia, Italy.				NIAID NIH HHS [AI42349]		Aarvak T, 1999, J IMMUNOL, V162, P1246; ANAISSIE E, 1992, CLIN INFECT DIS, V14, pS43; Banerjee B, 1998, INFECT IMMUN, V66, P5175; Banerjee B, 1999, INFECT IMMUN, V67, P2284; BEYER J, 1994, ANTIMICROB AGENTS CH, V38, P911; Cenci E, 1998, J INFECT DIS, V178, P1750, DOI 10.1086/314493; Cenci E, 1998, J IMMUNOL, V161, P3543; Cenci E, 1998, RES IMMUNOL, V149, P445, DOI 10.1016/S0923-2494(98)80768-2; Cenci E, 1999, J INFECT DIS, V180, P1957, DOI 10.1086/315142; Cenci E, 1997, INFECT IMMUN, V65, P564; Chauhan B, 1997, J IMMUNOL, V159, P4072; CLERICI M, 1994, J CLIN INVEST, V93, P768, DOI 10.1172/JCI117031; COHEN MS, 1981, AM J MED, V71, P59, DOI 10.1016/0002-9343(81)90259-X; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Del Sero G, 1999, MICROBES INFECT, V1, P1169, DOI 10.1016/S1286-4579(99)00245-2; DENNING DW, 1991, NEW ENGL J MED, V324, P654, DOI 10.1056/NEJM199103073241003; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; DEREPENTIGNY L, 1993, INFECT IMMUN, V61, P3791; DIXON DM, 1989, INFECT IMMUN, V57, P1452; GERSON SL, 1984, ANN INTERN MED, V100, P345; Grazziutti ML, 1997, J INFECT DIS, V176, P1579; Groll AH, 1998, CLIN INFECT DIS, V27, P437, DOI 10.1086/514717; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; Holt PG, 1999, J LEUKOCYTE BIOL, V66, P272; KNUTSEN AP, 1994, J ALLERGY CLIN IMMUN, V94, P215, DOI 10.1016/0091-6749(94)90043-4; KOLLS JK, 1993, AM J MED SCI, V306, P330, DOI 10.1097/00000441-199311000-00012; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P176; KURUP VP, 1992, J IMMUNOL, V148, P3783; KURUP VP, 1990, INT ARCH ALLER A IMM, V91, P145; Kurup VP, 1996, PEPTIDES, V17, P183, DOI 10.1016/0196-9781(95)02104-3; Kurup VP, 1999, ALLERGY, V54, P420, DOI 10.1034/j.1398-9995.1999.00944.x; LAAN M, 1999, J IMMUNOL, V162, P347; LANGERMANN S, 1994, NATURE, V372, P552, DOI 10.1038/372552a0; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310; Lin JY, 1996, INT IMMUNOL, V8, P499, DOI 10.1093/intimm/8.4.499; Masten BJ, 1999, J IMMUNOL, V162, P1310; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; McGuirk P, 1998, EUR J IMMUNOL, V28, P153, DOI 10.1002/(SICI)1521-4141(199801)28:01<153::AID-IMMU153>3.0.CO;2-#; Mehrad B, 1999, J IMMUNOL, V162, P1633; Mencacci A, 1998, J IMMUNOL, V161, P6228; MILLIKEN ST, 1990, REV INFECT DIS, V12, pS374; Morgenstern DE, 1997, J EXP MED, V185, P207, DOI 10.1084/jem.185.2.207; Novak N, 1999, ALLERGY, V54, P792, DOI 10.1034/j.1398-9995.1999.00101.x; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; PALMER LB, 1991, THORAX, V46, P15, DOI 10.1136/thx.46.1.15; POLLARD AM, 1990, J EXP MED, V172, P159, DOI 10.1084/jem.172.1.159; Powderly WG, 1998, JAMA-J AM MED ASSOC, V280, P72, DOI 10.1001/jama.280.1.72; RHODES JC, 1993, FUNGAL INFECT IMMUNE, P359; Roilides E, 1997, J IMMUNOL, V158, P322; ROILIDES E, 1993, J INFECT DIS, V167, P905; Roilides E, 1998, RES IMMUNOL, V149, P454, DOI 10.1016/S0923-2494(98)80769-4; Romani L, 1997, CURR OPIN IMMUNOL, V9, P484, DOI 10.1016/S0952-7915(97)80099-4; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; SCHAFFNER A, 1985, J CLIN INVEST, V76, P1755, DOI 10.1172/JCI112166; Schelenz S, 1999, MED MYCOL, V37, P183, DOI 10.1046/j.1365-280X.1999.00219.x; SHAH A, 1990, ANN ALLERGY, V64, P507; Shi FD, 1999, J IMMUNOL, V162, P5757; SHI FD, 1998, J NEUROL SCI, V58, P51; SMITH JA, 1994, J LEUKOCYTE BIOL, V56, P672; Tian JD, 1996, J EXP MED, V183, P1561, DOI 10.1084/jem.183.4.1561; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; VADOLAS J, 1995, EUR J IMMUNOL, V25, P969, DOI 10.1002/eji.1830250417; VANCOTT JL, 1997, BEHRING I MITT, V98, P44; WALDORF AR, 1984, J INFECT DIS, V150, P752; WEINBERGER M, 1992, MEDICINE, V71, P24; Wise JT, 1999, J IMMUNOL, V162, P5592; Wolach B, 1998, CLIN INFECT DIS, V26, P204, DOI 10.1086/516254; WYCLIFFE WL, 1997, INFECT DIS CLIN N AM, V11, P411; YELDANDI V, 1995, J HEART LUNG TRANSPL, V14, P883	72	130	138	0	0	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUL 1	2000	165	1					381	388				8	Immunology	Immunology	327WH	WOS:000087816800050	10861075	
J	Hansen, G; Jin, SLC; Umetsu, DT; Conti, M				Hansen, G; Jin, SLC; Umetsu, DT; Conti, M			Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							BETA(2)-ADRENERGIC RECEPTOR; SELECTIVE-INHIBITION; ATOPIC-DERMATITIS; SMOOTH-MUSCLE; RAT-BRAIN; T-CELLS; AMP; IDENTIFICATION; ACTIVATION; ASTHMA	Muscarinic cholinergic signaling plays an essential role in the control of the normal airway functions and in the development of pulmonary pathologies including asthma. In this paper we demonstrate that the airways of mice deficient in a cAMP-specific phosphodiesterase (PDE4D) are no longer responsive to cholinergic stimulation. Airway hyperreactivity that follows exposure to antigen was also abolished in PDE4D(-/-) mice, despite an apparently normal lung inflammatory infiltration. The loss of cholinergic responsiveness was specific to the airway, not observed in the heart, and was associated with a loss of signaling through muscarinic receptors with an inability to decrease cAMP accumulation. These findings demonstrate that the PDE4D gene plays an essential role in cAMP homeostasis and cholinergic stimulation of the airway, and in the development of hyperreactivity. In view of the therapeutic potentials of PDE4 inhibitors, our findings provide the rationale for novel strategies that target a single PDE isoenzyme.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pediat, Div Immunol & Transplantat Biol, Stanford, CA 94305 USA	Conti, M (reprint author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.				NIAID NIH HHS [R01 AI026322, R01 AI26322]; NICHD NIH HHS [R01 HD020788, R01 HD20788]		BARNES PJ, 1995, EUR RESPIR J, V8, P457, DOI 10.1183/09031936.95.08030457; BEAVO JA, 1995, PHYSIOL REV, V75, P725; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; BUXTON ILO, 1985, J BIOL CHEM, V260, P6733; CHAN SC, 1993, J ALLERGY CLIN IMMUN, V91, P1179, DOI 10.1016/0091-6749(93)90321-6; CLAYBERGER C, 1983, J EXP MED, V157, P1906, DOI 10.1084/jem.157.6.1906; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1982, ENDOCRINOLOGY, V110, P1189; Conti M, 1999, Prog Nucleic Acid Res Mol Biol, V63, P1; Costello RW, 1998, THORAX, V53, P613; Eglen RM, 1996, PHARMACOL TOXICOL, V78, P59; ENGELS P, 1994, FEBS LETT, V350, P291, DOI 10.1016/0014-5793(94)00788-8; ERNEUX C, 1985, MOL CELL ENDOCRINOL, V43, P123, DOI 10.1016/0303-7207(85)90075-9; Fuhrmann M, 1999, AM J RESP CELL MOL, V20, P292; Gantner F, 1997, J ALLERGY CLIN IMMUN, V100, P527; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; HANIFIN JM, 1995, J INVEST DERMATOL, V105, pS84, DOI 10.1111/1523-1747.ep12316116; HARDEN TK, 1985, ADV CYCLIC NUCL PROT, V19, P207; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARPER JF, 1975, J CYCLIC NUCL PROT, V1, P207; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; HULME EC, 1990, ANNU REV PHARMACOL, V30, P633, DOI 10.1146/annurev.pa.30.040190.003221; Iona S, 1998, MOL PHARMACOL, V53, P23; Jin SLC, 1998, J BIOL CHEM, V273, P19672, DOI 10.1074/jbc.273.31.19672; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; LEVITT RC, 1989, J APPL PHYSIOL, V67, P1125; Lim J, 1999, J BIOL CHEM, V274, P19677, DOI 10.1074/jbc.274.28.19677; Macaulay AE, 1998, J IMMUNOL, V160, P1694; MAEDA A, 1988, FEBS LETT, V239, P339, DOI 10.1016/0014-5793(88)80947-5; Nagase T, 1998, AM J RESP CRIT CARE, V157, P560; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stengel PW, 2000, J PHARMACOL EXP THER, V292, P877; Takahashi M, 1999, J NEUROSCI, V19, P610; TANNER LI, 1986, MOL PHARMACOL, V29, P455; TENOR H, 1999, ANTIINFLAMMATORY DRU, P87; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; TOMLINSON PR, 1995, BIOCHEM PHARMACOL, V49, P1809, DOI 10.1016/0006-2952(94)00532-Q; TORPHY TJ, 1990, MOL PHARMACOL, V37, P206; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69; Zaagsma J, 1997, LIFE SCI, V60, P1061, DOI 10.1016/S0024-3205(97)00048-9	44	130	133	0	1	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 6	2000	97	12					6751	6756		10.1073/pnas.97.12.6751		6	Multidisciplinary Sciences	Science & Technology - Other Topics	322UA	WOS:000087526300093	10841571	
J	Karlberg, AT; Bergstrom, MA; Borje, A; Luthman, K; Nilsson, JLG				Karlberg, Ann-Therese; Bergstrom, Moa Andresen; Borje, Anna; Luthman, Kristina; Nilsson, J. Lars G.			Allergic contact dermatitis-formation, structural requirements, and reactivity of skin sensitizers	CHEMICAL RESEARCH IN TOXICOLOGY			English	Review							LYMPH-NODE ASSAY; OXIDIZED D-LIMONENE; MECHANISTIC APPLICABILITY DOMAINS; HEPATIC CYTOCHROME-P450 ENZYMES; HUMAN DENDRITIC CELLS; IN-VITRO; GUINEA-PIG; 15-HYDROPEROXYABIETIC ACID; OXIDATION-PRODUCTS; P-PHENYLENEDIAMINE	Contact allergy is caused by a wide range of chemicals after skin contact. Its clinical manifestation, allergic contact dermatitis (ACD), is developed upon repeated contact with the allergen. This perspective focuses on two areas that have yielded new useful information during the last 20 years: (i) structure-activity relationship (SAR) studies of contact allergy based on the concept of hapten-protein binding and (ii) mechanistic investigations regarding activation of nonsensitizing compounds to contact allergens by air oxidation or skin metabolism. The second area is more thoroughly reviewed since the full Picture has previously not been published. Prediction of the sensitizing capacity of a chemical is important to avoid outbreaks of ACD in the population. Much research has been devoted to the development of in vitro and in silico predictive testing methods. Today, no method exists that is sensitive enough to detect weak allergens and that is robust enough to be used for routine screening. To cause sensitization, a chemical C, must bind to macromolecules (proteins) in the skin, Expert systems containing information about the relationship between the chemical structure and the ability of chemicals to haptenate proteins are available. However, few designed SAR studies based on mechanistic investigations of prohaptens have been published. Many compounds are not allergenic themselves but are activated in the skin (e.g., metabolically) or before skin contact (e.g., via air oxidation) to form skin sensitizers. Thus, more basic research is needed on the chemical reactions involved in the antigen formation and the immunological mechanisms. The clinical importance of air oxidation to activate nonallergenic compounds has been demonstrated. Oxidized fragrance terpenes, in contrast to the pure terpenes, gave positive patch test reactions in consecutive dermatitis patients as frequently as the most common standard allergens. This shows the importance of using compounds to which people are exposed when screening for ACD in dermatology clinics.	[Karlberg, Ann-Therese; Bergstrom, Moa Andresen; Borje, Anna; Luthman, Kristina; Nilsson, J. Lars G.] Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden	Karlberg, AT (reprint author), Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden.	karlberg@chem.gu.se	Borje, Anna/A-7581-2010; Luthman, Kristina/A-7600-2010; Karlberg, Ann-Therese/A-7706-2010	Luthman, Kristina/0000-0003-4344-8609; 			Aeby P, 2004, J INVEST DERMATOL, V122, P1154, DOI 10.1111/j.0022-202X.2004.22402.x; Ahlfors SR, 2003, SKIN PHARMACOL APPL, V16, P59, DOI 10.1159/000068288; Alvarez-Sanchez R, 2003, CHEM RES TOXICOL, V16, P627, DOI 10.1021/tx0256634; ANDERSEN KE, 1985, CONTACT ALLERGY PRED, V14; ANDERSON C, 1995, J IMMUNOL, V155, P3530; Aptula AO, 2006, TOXICOL IN VITRO, V20, P239, DOI 10.1016/j.tiv.2005.07.003; Aptula AO, 2005, CHEM RES TOXICOL, V18, P1420, DOI 10.1021/tx050075m; Arnau EG, 2002, TETRAHEDRON, V58, P5535; Ashby J, 1995, TOXICOLOGY, V103, P177, DOI 10.1016/0300-483X(95)03132-Y; Backtorp C, 2006, J PHYS CHEM A, V110, P12204, DOI 10.1021/jp0603278; BAER H, 1966, IMMUNOCHEMISTRY, V3, P479, DOI 10.1016/0019-2791(66)90133-9; BARRATT MD, 1994, TOXICOL IN VITRO, V8, P823, DOI 10.1016/0887-2333(94)90077-9; BARRATT MD, 1994, TOXICOL IN VITRO, V8, P1053, DOI 10.1016/0887-2333(94)90244-5; BARRATT MD, 1998, ALLERGIC CONTACT DER, P129; BASKETTER DA, 1992, CONTACT DERMATITIS, V27, P90, DOI 10.1111/j.1600-0536.1992.tb05216.x; BASKETTER DA, 1988, CONTACT DERMATITIS, V19, P248, DOI 10.1111/j.1600-0536.1988.tb02921.x; Basketter DA, 1999, J APPL TOXICOL, V19, P261, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<261::AID-JAT572>3.0.CO;2-5; BASKETTER DA, 1992, CONTACT DERMATITIS, V27, P137, DOI 10.1111/j.1600-0536.1992.tb05241.x; BASKETTER DA, 1992, ACTA DERM-VENEREOL, V72, P264; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bergh M, 1998, J PHARM SCI, V87, P276, DOI 10.1021/js9704036; Bergh M, 1997, CONTACT DERMATITIS, V37, P9, DOI 10.1111/j.1600-0536.1997.tb00368.x; Bergh M, 1998, CONTACT DERMATITIS, V39, P14, DOI 10.1111/j.1600-0536.1998.tb05805.x; Bergh M, 1999, J PHARM SCI, V88, P483, DOI 10.1021/js980210y; Bergstrom MA, 2006, CHEM RES TOXICOL, V19, P760, DOI 10.1021/tx060006n; Bergstrom MA, 2007, CHEM RES TOXICOL, V20, P927, DOI 10.1021/tx7000114; Bergstrom MA, 2007, J INVEST DERMATOL, V127, P1145, DOI 10.1038/sj.jid.5700638; Bertrand F, 1997, CHEM RES TOXICOL, V10, P335, DOI 10.1021/tx960087v; Bezard M, 1997, CHEM RES TOXICOL, V10, P987, DOI 10.1021/tx970014r; Bezard M, 2005, BIOORGAN MED CHEM, V13, P3977, DOI 10.1016/j.bmc.2005.04.004; Bodin A, 2003, CHEM RES TOXICOL, V16, P575, DOI 10.1021/tx025609n; Bodin A, 2001, CONTACT DERMATITIS, V44, P207, DOI 10.1034/j.1600-0536.2001.044004207.x; Bodin A, 2000, CONTACT DERMATITIS, V43, P82, DOI 10.1034/j.1600-0536.2000.043002082.x; Brared Christensson Johanna, 2006, Contact Dermatitis, V55, P230, DOI 10.1111/j.1600-0536.2006.00913.x; Cheung C, 2003, J DERMATOL SCI, V31, P9, DOI 10.1016/S0923-1811(02)00139-1; Coulter EM, 2007, J PHARMACOL EXP THER, V320, P885, DOI 10.1124/jpet.106.113803; Crum-Brown A., 1868, T R SOC EDINBURGH, V25, P151; Cruz MT, 2005, ARCH DERMATOL RES, V297, P43, DOI 10.1007/s00403-005-0574-8; De Groot A.C., 1994, PATCH TESTING TEST C; Dimitrov S, 2005, J CHEM INF MODEL, V45, P839, DOI 10.1021/ci0500381; Dimitrov SD, 2005, INT J TOXICOL, V24, P189, DOI 10.1080/10915810591000631; Divkovic M, 2005, CONTACT DERMATITIS, V53, P189, DOI 10.1111/j.0105-1873.2005.00683.x; DONBROW M, 1987, NONIONIC SURFACTANTS, P1011; DUPUIS G, 1982, ALLGERIC CONTACT DER; EILSTEIN J, 2006, CONTACT DERMATITIS, V55, P9; Eilstein J, 2006, CHEM RES TOXICOL, V19, P1248, DOI 10.1021/tx0601408; Elahi EN, 2004, CHEM RES TOXICOL, V17, P301, DOI 10.1021/tx0341456; Enslein K, 1997, FOOD CHEM TOXICOL, V35, P1091, DOI 10.1016/S0278-6915(97)87277-8; Estrada E, 2003, CHEM RES TOXICOL, V16, P1226, DOI 10.1021/tx034093k; Estrada E, 2004, J CHEM INF COMP SCI, V44, P688, DOI 10.1021/ci0342425; Fedorowicz A, 2005, CHEM RES TOXICOL, V18, P954, DOI 10.1021/tx0497806; Fedorowicz A, 2004, INT J MOL SCI, V5, P56, DOI 10.3390/i5020056; FOSSEREAU J, 1982, OCCUPATIONAL CONTACT; FRANOT C, 1994, CHEM RES TOXICOL, V7, P307, DOI 10.1021/tx00039a006; Fregert S, 1969, CONTACT DERMATITIS N, V5, P85; FROSCH PJ, 1995, CONTACT DERMATITIS, V33, P333, DOI 10.1111/j.1600-0536.1995.tb02048.x; GAFVERT E, 1994, CHEM RES TOXICOL, V7, P260, DOI 10.1021/tx00038a020; Gerberick GF, 2007, METHODS, V41, P54, DOI 10.1016/j.ymeth.2006.07.006; Gerberick GF, 2004, TOXICOL SCI, V81, P332, DOI 10.1093/toxsci/kfh213; Gerberick GF, 2004, CONTACT DERMATITIS, V50, P274, DOI 10.1111/j.0105-1873.2004.00290.x; Gildea LA, 2006, J INVEST DERMATOL, V126, P1813, DOI 10.1038/sj.jid.5700319; Goetz G, 1999, BIOORG MED CHEM LETT, V9, P1141, DOI 10.1016/S0960-894X(99)00151-1; Graham C, 1996, QUANT STRUCT-ACT REL, V15, P224, DOI 10.1002/qsar.19960150307; Greene N, 1999, SAR QSAR ENVIRON RES, V10, P299, DOI 10.1080/10629369908039182; Greene N, 2002, ADV DRUG DELIVER REV, V54, P417, DOI 10.1016/S0169-409X(02)00012-1; Hagvall L, 2007, CHEM RES TOXICOL, V20, P807, DOI 10.1021/tx700017v; HALL LH, 1991, J CHEM INF COMP SCI, V31, P76, DOI 10.1021/ci00001a012; HANSSON C, 1995, ACTA DERM-VENEREOL, V75, P34; HELLERSTROM S, 1955, J INVEST DERMATOL, V24, P217; HELLERSTROM S, 1939, ACTA DERM-VENEREOL, V20, P657; Isaksson M, 2000, ACTA DERM-VENEREOL, V80, P33, DOI 10.1080/000155500750012496; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; Kalgutkar AS, 2005, CURR DRUG METAB, V6, P161, DOI 10.2174/1389200054021799; Karlberg AT, 2007, CONTACT DERMATITIS, V56, P355, DOI 10.1111/j.1600-0536.2006.01037.x; KARLBERG AT, 1994, ARCH DERMATOL RES, V286, P97, DOI 10.1007/BF00370734; KARLBERG AT, 1994, ANN OCCUP HYG, V38, P199, DOI 10.1093/annhyg/38.2.199; KARLBERG AT, 1985, CONTACT DERMATITIS, V13, P209, DOI 10.1111/j.1600-0536.1985.tb02552.x; KARLBERG AT, 1988, J PHARM PHARMACOL, V40, P42; KARLBERG AT, 1992, CONTACT DERMATITIS, V26, P332, DOI 10.1111/j.1600-0536.1992.tb00129.x; Karlberg AT, 1996, CONTACT DERMATITIS, V35, P201, DOI 10.1111/j.1600-0536.1996.tb02358.x; KARLBERG AT, 1991, ANN OCCUP HYG, V35, P419, DOI 10.1093/annhyg/35.4.419; Karlberg AT, 1997, CONTACT DERMATITIS, V36, P201, DOI 10.1111/j.1600-0536.1997.tb00270.x; Karlberg A-T, 1993, CRITERIA DOCUMENTS N, P207; KARLBERG AT, 2000, HDB OCCUPATIONAL DER, P509; KAROL MH, 1999, COMMENTS TOXICOL, V7, P59; Kato Hiroshi, 2003, J Toxicol Sci, V28, P19, DOI 10.2131/jts.28.19; Kimber I, 1998, J TOXICOL ENV HEAL A, V53, P563; KIMBER I, 1991, FOOD CHEM TOXICOL, V29, P125, DOI 10.1016/0278-6915(91)90167-6; KIMBER I, 1995, TOXICOLOGY, V103, P6373; Andersen KE, 1985, CONTACT ALLERGY PRED, V14, P152; KLOPMAN G, 1992, QUANT STRUCT-ACT REL, V11, P176, DOI 10.1002/qsar.19920110208; KOHL C, 1992, CARCINOGENESIS, V13, P1091, DOI 10.1093/carcin/13.7.1091; LANDSTEINER K, 1936, STUDIES SENSITIZATIO, P625; Langton K, 2006, CONTACT DERMATITIS, V55, P342, DOI 10.1111/j.1600-0536.2006.00969.x; Lash LH, 2000, ENVIRON HEALTH PERSP, V108, P177; Lepoittevin JP, 1999, CELL BIOL TOXICOL, V15, P47, DOI 10.1023/A:1007502723275; LEVINE WG, 1991, DRUG METAB REV, V23, P253, DOI 10.3109/03602539109029761; Li Y, 2007, CHEM RES TOXICOL, V20, P114, DOI 10.1021/tx6002535; Lisi P, 1998, CONTACT DERMATITIS, V39, P304, DOI 10.1111/j.1600-0536.1998.tb05945.x; Lovell CR, 1993, PLANTS AND THE SKIN; Marques MM, 1997, CARCINOGENESIS, V18, P1949, DOI 10.1093/carcin/18.10.1949; Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x; Matura M, 2004, CONTACT DERMATITIS, V51, P180, DOI 10.1111/j.0105-1873.2004.00436.x; Matura M, 2002, J AM ACAD DERMATOL, V47, P709, DOI 10.1067/mjd.2002.124817; Matura M, 2006, CONTACT DERMATITIS, V55, P274, DOI 10.1111/j.1600-0536.2006.00939.x; MAYER RL, 1954, PROG ALLERGY, V4, P79, DOI 10.1159/000313666; Meschkat E, 2001, CHEM RES TOXICOL, V14, P110, DOI 10.1021/tx000225n; Miller MD, 2005, J CHEM INF MODEL, V45, P924, DOI 10.1021/ci050018z; MONTELIUS J, 1994, ACTA DERM-VENEREOL, V74, P22; Moulon C, 1995, EUR J IMMUNOL, V25, P3308, DOI 10.1002/eji.1830251216; Mutterer V, 2000, CHEM RES TOXICOL, V13, P1028, DOI 10.1021/tx9901433; Naisbitt DJ, 2004, TOXICOLOGY, V194, P179, DOI 10.1016/j.tox.2003.09.004; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; Nilsson AM, 2005, FOOD CHEM TOXICOL, V43, P1627, DOI 10.1016/j.fct.2005.05.004; Nilsson AM, 2005, CHEM RES TOXICOL, V18, P308, DOI 10.1021/tx049758c; Nilsson U, 1996, CHROMATOGRAPHIA, V42, P199, DOI 10.1007/BF02269653; PARMAR D, 1991, DRUG METAB DISPOS, V19, P1101; Patlewicz G, 2007, SAR QSAR ENVIRON RES, V18, P515, DOI 10.1080/10629360701427872; Patlewicz G., 2003, QSAR COMB SCI, V22, P196, DOI 10.1002/qsar.200390012; Patlewicz G, 2007, REGUL TOXICOL PHARM, V48, P225, DOI 10.1016/j.yrtph.2007.03.003; Patlewicz GY, 2004, CONTACT DERMATITIS, V50, P91, DOI 10.1111/j.0105-1873.2004.00322.x; PAYNE MP, 1994, J CHEM INF COMP SCI, V34, P154, DOI 10.1021/ci00017a019; Pease CKS, 2003, TOXICOLOGY, V192, P1, DOI 10.1016/S0300-483X(03)00246-4; PICARDO M, 1990, DERMATOLOGICA, V181, P104; PONTOPPIDAN J, 2005, CONTACT DERMATITIS, P185; Ridings JE, 1996, TOXICOLOGY, V106, P267, DOI 10.1016/0300-483X(95)03190-Q; Roberts DW, 2007, SAR QSAR ENVIRON RES, V18, P343, DOI 10.1080/10629360701306118; Roberts DW, 2007, CHEM RES TOXICOL, V20, P44, DOI 10.1021/tx060121y; Roberts DW, 2007, CHEM RES TOXICOL, V20, P61, DOI 10.1021/tx600330u; Roberts DW, 2006, CHEM RES TOXICOL, V19, P1228, DOI 10.1021/tx060102o; ROBERTS DW, 1995, CHEM RES TOXICOL, V8, P545, DOI 10.1021/tx00046a008; Roberts DW, 2002, SAR QSAR ENVIRON RES, V13, P145, DOI 10.1080/10629360290002244; Roberts DW, 1999, CONTACT DERMATITIS, V41, P14, DOI 10.1111/j.1600-0536.1999.tb06201.x; ROBERTS DW, 1982, J THEOR BIOL, V99, P807, DOI 10.1016/0022-5193(82)90199-0; ROBERTS DW, 1990, CONTACT DERMATITIS, V23, P331, DOI 10.1111/j.1600-0536.1990.tb05167.x; Roberts DW, 1997, CONTACT DERMATITIS, V37, P107, DOI 10.1111/j.1600-0536.1997.tb00313.x; Roberts DW, 2000, CONTACT DERMATITIS, V42, P154, DOI 10.1034/j.1600-0536.2000.042003154.x; ROBERTS DW, 1993, CONTACT DERMATITIS, V29, P78, DOI 10.1111/j.1600-0536.1993.tb03487.x; ROBERTS DW, 1991, ARCH DERMATOL RES, V283, P387, DOI 10.1007/BF00371821; ROMAGNOLI P, 1991, EMBO J, V10, P1303; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; Rosenkranz HS, 1999, SAR QSAR ENVIRON RES, V10, P263, DOI 10.1080/10629369908039180; Rosenkranz HS, 1999, SAR QSAR ENVIRON RES, V10, P277, DOI 10.1080/10629369908039181; Rustemeyer T., 2006, CONTACT DERMATITIS, P11, DOI 10.1007/3-540-31301-X_2; Ryan CA, 2005, TOXICOL SCI, V88, P4, DOI 10.1093/toxsci/kfi245; Ryan CA, 2001, TOXICOL IN VITRO, V15, P43, DOI 10.1016/S0887-2333(00)00059-X; RYAN TJ, 1987, DERM PRACTICE, V5, P8; SANTUCCI B, 1987, CONTACT DERMATITIS, V16, P93, DOI 10.1111/j.1600-0536.1987.tb01386.x; SCHMIDT RJ, 1990, ARCH DERMATOL RES, V282, P56, DOI 10.1007/BF00505646; Schnuch A, 2004, CONTACT DERMATITIS, V50, P65, DOI 10.1111/j.0105-1873.2004.00302.x; Seidenari S, 1997, CONTACT DERMATITIS, V36, P91, DOI 10.1111/j.1600-0536.1997.tb00420.x; SERUPHANSEN N, 2004, 929 EPA MIN ENV; SJOBORG S, 1984, CONTACT DERMATITIS, V10, P94, DOI 10.1111/j.1600-0536.1984.tb00342.x; Skold M, 2006, FOOD CHEM TOXICOL, V44, P538, DOI 10.1016/j.fct.2005.08.028; Skold M, 2004, CHEM RES TOXICOL, V17, P1697, DOI 10.1021/tx049831z; Skold M, 2002, CONTACT DERMATITIS, V46, P267, DOI 10.1034/j.1600-0536.2002.460504.x; Smith CK, 2001, J CHROMATOGR B, V758, P249, DOI 10.1016/S0378-4347(01)00184-0; Smith CK, 2000, TOXICOL APPL PHARM, V168, P189, DOI 10.1006/taap.2000.9025; Smith CK, 2001, ALLERGIC CONTACT DER, P119; Smith C. K., 2001, ALLERGIC CONTACT DER, P89; Sosted H, 2004, CONTACT DERMATITIS, V51, P241, DOI 10.1111/j.0105-1873.2004.00440.x; Stanley LA, 2005, TOXICOLOGY, V210, P147, DOI 10.1016/j.tox.2005.01.019; Tang XJ, 2002, BIOMED ENVIRON SCI, V15, P113; Testa B, 2005, CHEM BIODIVERS, V2, P872, DOI 10.1002/cbdv.200590064; Van den Broeke LT, 1999, IMMUNOLOGY, V96, P578; Vandebriel Rob J, 2005, Toxicol Appl Pharmacol, V207, P142, DOI 10.1016/j.taap.2005.01.054; Vohr H-W, 2005, ARCH TOXICOL, V79, P721, DOI 10.1007/s00204-005-0005-9; Volkel W, 1999, TOXICOL SCI, V47, P144, DOI 10.1093/toxsci/47.2.144; Wahlberg JE, 2006, CONTACT DERMATITIS, P366; Wallenhammar LM, 2004, J INVEST DERMATOL, V122, P1381, DOI 10.1111/j.0022-202X.2004.22604.x; White IR, 2006, CLIN EXP DERMATOL, V31, P724, DOI 10.1111/j.1365-2230.2006.02226.x; White JML, 2006, CLIN EXP ALLERGY, V36, P1289, DOI 10.1111/j.1365-2222.2006.02561.x; WIDMARK G, 1975, SVENSK KEM TIDSKR, V69, P175; Wright Z. M., 2001, International Journal of Cosmetic Science, V23, P75, DOI 10.1046/j.1467-2494.2001.00066.x	175	129	132	1	23	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0893-228X			CHEM RES TOXICOL	Chem. Res. Toxicol.	JAN	2008	21	1					53	69		10.1021/tx7002239		17	Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology	Pharmacology & Pharmacy; Chemistry; Toxicology	254KJ	WOS:000252585200006	18052130	
J	Bai, TR; Vonk, JM; Postma, DS; Boezen, HM				Bai, T. R.; Vonk, J. M.; Postma, D. S.; Boezen, H. M.			Severe exacerbations predict excess lung function decline in asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						airways remodelling; exacerbations; prognosis; treatment of asthma	AIR-FLOW OBSTRUCTION; FOLLOW-UP; GENERAL-POPULATION; CORTICOSTEROIDS; POLYMORPHISMS; LIMITATION; DISEASE; ADULTS	Severe asthma exacerbations are periods of intense airway inflammation that have been hypothesised to contribute to structural changes in the airways. If so, accelerated lung function decline over time should be more prevalent in adult patients with asthma who have frequent exacerbations than those without, but to date this has not been demonstrated. A cohort study was performed in order to investigate the effect of severe exacerbations on the progression of airway obstruction in 93 nonsmoking asthmatics with moderate-to-severe disease prior to treatment with inhaled corticosteroids. Subjects were followed for >= 5 yrs (median follow-up 11 yrs). In total, 56 (60.2%) subjects experienced at least one severe exacerbation (median rate 0.10.yr(-1)). Oral corticosteroid use and more severe airway obstruction at baseline were associated with a higher exacerbation rate. Independent of these variables, asthma patients with frequent exacerbations had a significantly larger annual decline in forced expiratory volume in one second (FEV1; median difference (95% confidence interval) 16.9 (1.5-32.2) mL.yr(-1)). Exacerbation rate significantly predicted an excess decline in FEV1, such that one severe exacerbation per year was associated with a 30.2 mL greater annual decline in FEV1. These data support the hypothesis that exacerbations, indicating intermittent periods of worsening airway inflammation, are associated with excess lung function decline in asthma.	Univ British Columbia, St Pauls Hosp, Div Resp, James Hogg Capture Ctr, Vancouver, BC V6Z 1Y6, Canada; Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, Groningen, Netherlands	Bai, TR (reprint author), Univ British Columbia, St Pauls Hosp, Div Resp, James Hogg Capture Ctr, Rm 166,1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	tbai@mrl.ubc.ca					Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Bai TR, 2005, CLIN SCI, V108, P463; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; *GINA, NAT I HLTH PUBL; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.01938.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Oshita Y, 2003, THORAX, V58, P757, DOI 10.1136/thorax.58.9.757; Panizza JA, 2006, INTERN MED J, V36, P773, DOI 10.1111/j.1445-5994.2006.01214.x; Pauwels Romain A, 2004, Proc Am Thorac Soc, V1, P73, DOI 10.1513/pats.2306024; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Prescott E, 1997, THORAX, V52, P287; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reddel HK, 2005, THORAX, V60, P164, DOI 10.1136/thx.2004.030437; Shute JK, 1997, INT ARCH ALLERGY IMM, V113, P366; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322	22	129	132	0	2	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2007	30	3					452	456		10.1183/09031936.00165106		5	Respiratory System	Respiratory System	211FM	WOS:000249509700010	17537763	
J	Delfino, RJ; Quintana, PJE; Floro, J; Gastanaga, VM; Samimi, BS; Kleinman, MT; Liu, LJS; Bufalino, C; Wu, CF; McLaren, CE				Delfino, RJ; Quintana, PJE; Floro, J; Gastanaga, VM; Samimi, BS; Kleinman, MT; Liu, LJS; Bufalino, C; Wu, CF; McLaren, CE			Association of FEV1 in asthmatic children with personal and microenvironmental exposure to airborne particulate matter	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; epidemiology; forced expiratory volume; longitudinal data analysis; nitrogen dioxide; ozone; panel study; particulate air pollution	ANTIINFLAMMATORY MEDICATION USE; AMBIENT AIR-POLLUTION; INNER-CITY CHILDREN; RESPIRATORY HEALTH; SYMPTOM SEVERITY; PARTICLES; INDOOR; TIME; CALIFORNIA; POLLUTANTS	Exposure to particulate matter (PM) air pollution has been shown to exacerbate children's asthma, but the exposure sources and temporal characteristics are still under study. Children's exposure to PM is likely to involve both combustion-related ambient PM and PM related to a child's activity in various indoor and outdoor microenvironments. Among 19 children with asthma, 9-17 years of age, we examined the relationship of temporal changes in percent predicted forced expiratory volume in 1 sec (FEV1) to personal continuous PM exposure and to 24-hr average gravimetric PM mass measured at home and central sites. Subjects were followed for 2 weeks during either the fall of 1999 or the spring of 2000, in a southern California region affected by transported air pollution. FEV1 was measured by subjects in the morning, afternoon, and evening. Exposure measurements included continuous PM using a passive nephelometer carried by subjects; indoor, outdoor home, and central-site 24-hr gravimetric PM2.5 (PM of aerodynamic diameter < 2.5 mum) and PM10; and central-site hourly PM10, nitrogen dioxide, and ozone. Data were analyzed with linear mixed models controlling for within-subject autocorrelation, FEV1 maneuver time, and exposure period. We found inverse associations of FEV1 with increasing PM exposure during the 24 hr before the FEV1 maneuver and with increasing multiday PM averages. Deficits in percent predicted FEV1 (95% confidence interval) for given PM interquartile ranges measured during the preceding 24-hr were as follows: 128 mug/m(3) 1-hr maximum personal PM, -6.0% (-10.5 to -1.4); 30 mug/m(3) 24-hr average personal PM, -5.9% (-10.8 to -1.0); 6.7 mug/m(3) indoor home PM2.5, -1.6% (-2.8 to -0.4); 16 mug/m(3) indoor home PM10, -2.1% (-3.7 to -0.4); 7.1 mug/m(3) outdoor home PM2.5, -1-1% (-2.4 to 0.1); and 7.5 mug/m(3) central-site P-M2.5, -0.7% (-1.9 to 0.4). Stronger associations were found for multiday moving averages of PM for both personal and stationary-site PM. Stronger associations with personal PM were found in boys allergic to indoor allergens. FEV1 was weakly associated with NO2 but not with O-3. Results suggest mixed respiratory effects of PM in asthmatic children from both ambient background exposures and personal exposures in various microenvironments.	Univ Calif Irvine, Coll Med, Dept Med, Div Epidemiol, Irvine, CA 92697 USA; San Diego State Univ, Grad Sch Publ Hlth, Div Occupat & Environm Hlth, San Diego, CA 92182 USA; Univ Calif Irvine, Coll Med, Dept Community & Environm Med, Irvine, CA 92717 USA; Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA	Delfino, RJ (reprint author), Univ Calif Irvine, Coll Med, Dept Med, Div Epidemiol, 224 Irvine Hall, Irvine, CA 92697 USA.	rdelfino@uci.edu		Wu, Chang-fu/0000-0003-2244-1934	NIEHS NIH HHS [ES 06214]		Allen G, 1997, J AIR WASTE MANAGE, V47, P682; Allen R, 2003, ENVIRON SCI TECHNOL, V37, P3484, DOI 10.1021/es021007e; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; Custovic A, 1999, PEDIATR ALLERGY IMMU, V10, P258, DOI 10.1034/j.1399-3038.1999.00050.x; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Diggle P, 2002, ANAL LONGITUDINAL DA; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; HERING S, 1997, ATMOS ENVIRON, V3, P1; Hopke PK, 2003, ATMOS ENVIRON, V37, P3289, DOI 10.1016/S1352-2310(03)00331-5; Howard-Reed C, 2000, J AIR WASTE MANAGE, V50, P1125; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; Koenig JQ, 2003, ENVIRON HEALTH PERSP, V111, P1625, DOI 10.1289/ehp.6160; LARSON T, IN PRESS J AIR WASTE; Lee K, 1999, J AIR WASTE MANAGE, V49, P1238, DOI 10.1080/10473289.1999.10463913; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; Lipfert FW, 1999, J AIR WASTE MANAGE, V49, P182; Littell R., 1996, SAS SYSTEM MIXED MOD; Liu LJS, 1997, ENVIRON HEALTH PERSP, V105, P58, DOI 10.1289/ehp.9710558; Liu LJS, 2003, ENVIRON HEALTH PERSP, V111, P909, DOI 10.1289/ehp.6011; Liu LJS, 2002, ENVIRON SCI TECHNOL, V36, P2977, DOI 10.1021/es0112644; McBride SJ, 1999, J EXPO ANAL ENV EPID, V9, P602, DOI 10.1038/sj.jea.7500057; Morawska L, 1999, ATMOS ENVIRON, V33, P4401, DOI 10.1016/S1352-2310(99)00217-4; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; National Research Council, 1998, RES PRIOR AIRB PART; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 1997, EUR RESPIR J, V10, P872; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Quintana PJE, 2000, J EXPO ANAL ENV EPID, V10, P437, DOI 10.1038/sj.jea.7500105; Quintana PJE, 2001, ENVIRON RES, V87, P199, DOI 10.1006/enrs.2001.4304; Richards LW, 1999, ATMOS ENVIRON, V33, P4787, DOI 10.1016/S1352-2310(99)00267-8; Roemer W, 1999, OCCUP ENVIRON MED, V56, P86; Roemer W, 2000, CLIN EXP ALLERGY, V30, P1067; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Segala C, 1998, EUR RESPIR J, V11, P677; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346; THOMAS A, 1994, ATMOS ENVIRON, V28, P935, DOI 10.1016/1352-2310(94)90251-8; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; *US EPA, 1990, NAT AIR QUAL EM TREN; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; WU CF, IN PESS J EXPO ANAL; YAKOVLEVA E, 1999, ENVIRON SCI TECHNOL, V33, P3845; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835	51	129	135	2	19	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2004	112	8					932	941		10.1289/ehp.6815		10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	829BO	WOS:000222018200046	15175185	
J	Ameille, J; Pauli, G; Calastreng-Crinquand, A; Vervloet, D; Iwatsubo, Y; Popin, E; Bayeux-Dunglas, MC; Kopferschmitt-Kubler, MC; Arnaud, G; Bergeret, A; Blaumeiser, M; de Blay, F; Boitel, L; Bonnin, C; Brochard, P; Brun, J; Cabal, C; Cador, B; Caillaud, D; Cantineau, A; Chazenfus, J; Choudat, D; Conso, F; Costes, S; Couot, M; Curtes, JP; Dalphin, JC; Danaud, D; Danjou, P; Delemott, B; Deschamps, F; Dewitte, JD; Didier, A; Dhivert-Donnadieu, H; Doutrellot-Philippon, C; Dufresne-Benetti, F; Dumont, D; Dupas, D; Faucon, D; Fumery, JL; Gabrillargues, D; Garnier, R; Godard, P; Grudzien, F; Hemery, JM; Javelaud, B; Lasfargues, G; Leleu, B; Letourneux, M; Libert, B; Loriot, J; Martin, F; Michel, MP; Nisse, C; Paris, C; Pairon, JC; Penneau-Fontbonne, D; Perdrix, A; Petiet, G; de Santi, PP; Robin, H; Saadjian, M; Smolik, HJ; Soulat, JM; Tarin, C; Terracol, D; Tessier-Cotte, C; de Lara, JMT				Ameille, J; Pauli, G; Calastreng-Crinquand, A; Vervloet, D; Iwatsubo, Y; Popin, E; Bayeux-Dunglas, MC; Kopferschmitt-Kubler, MC; Arnaud, G; Bergeret, A; Blaumeiser, M; de Blay, F; Boitel, L; Bonnin, C; Brochard, P; Brun, J; Cabal, C; Cador, B; Caillaud, D; Cantineau, A; Chazenfus, J; Choudat, D; Conso, F; Costes, S; Couot, M; Curtes, JP; Dalphin, JC; Danaud, D; Danjou, P; Delemott, B; Deschamps, F; Dewitte, JD; Didier, A; Dhivert-Donnadieu, H; Doutrellot-Philippon, C; Dufresne-Benetti, F; Dumont, D; Dupas, D; Faucon, D; Fumery, JL; Gabrillargues, D; Garnier, R; Godard, P; Grudzien, F; Hemery, JM; Javelaud, B; Lasfargues, G; Leleu, B; Letourneux, M; Libert, B; Loriot, J; Martin, F; Michel, MP; Nisse, C; Paris, C; Pairon, JC; Penneau-Fontbonne, D; Perdrix, A; Petiet, G; de Santi, PP; Robin, H; Saadjian, M; Smolik, HJ; Soulat, JM; Tarin, C; Terracol, D; Tessier-Cotte, C; de Lara, JMT			Reported incidence of occupational asthma in France, 1996-99: the ONAP programme	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							WORK-RELATED ASTHMA; RESPIRATORY-DISEASES; UNITED-KINGDOM; SURVEILLANCE SYSTEM; POPULATION; RISK; EXPOSURES; FINLAND; CANADA	Aims: To estimate the general and specific incidence of occupational asthma in France in 1996-99; and to describe the distribution of cases by age, sex, suspected causal agents, and occupation. Methods: New cases of occupational asthma were collected by a national surveillance programme, based on voluntary reporting, named Observatoire National des Asthmes Professionnels (ONAP), involving a network of occupational and chest physicians. For each case, the reporting form included information on age, sex, location of workplace, occupation, suspected causal agent, and methods of diagnosis. Estimates of the working population, used to calculate incidence rates by age, sex, region, and occupation, were obtained from the Institut National de la Statistique et des Etudes Economiques (INSEE) and from the French Securite Sociale statistics. Results: In 1996-99, 2178 cases of occupational asthma were reported to the ONAP, giving a mean annual rate of 24/million. Rates in men were higher than rates in women (27/million versus 19/million). The highest rate was observed in the 15-29 years age group (30/million). The most frequently incriminated agents were flour (20.3%), isocyanates (14.1%), latex (7.2%), aldehyde (5.9%), persulphate salts (5.8%), and wood dusts (3.7%). The highest risks of occupational asthma were found in bakers and pastry makers (683/million), car painters (326/million), hairdressers (308/million), and Wood workers (218/million). Conclusion: Despite likely underreporting, the number of cases of occupational asthma reported to the ONAP was approximately twice the number of compensated cases over the same period. The relevance of the programme is confirmed by the reproducibility of the results year after year, and its consistency with other surveillance programmes. The ONAP programme is useful for the identification of targets for primary prevention.	Inst Interuniv Med Travail Paris Ile France, F-75270 Paris 06, France; Soc Pneumol Langue Francaise, F-75006 Paris, France	Ameille, J (reprint author), Hop Ray Poincare, Unite Pathol Profess & Sante Travail, 104 Bd Raymond Poincare, F-92380 Garches, France.		Paris, Christophe/A-8515-2013				Ameille J, 1997, EUR RESPIR J, V10, P55, DOI 10.1183/09031936.97.10010055; BENA A, 1999, MED LAV, V40, P556; BLAINEY AD, 1986, THORAX, V41, P42, DOI 10.1136/thx.41.1.42; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Chan-Yeung M., 1999, ASTHMA WORKPLACE, P129; CONTRERAS GR, 1994, OCCUP ENVIRON MED, V51, P710; GANNON PFG, 1993, BRIT J IND MED, V50, P791; GARDNER MJ, 1989, STAT CONFIDENCE, P116; Henneberger P K, 1999, Int J Occup Environ Health, V5, P1; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; *INSEE, 2000, ANNUAIRE STAT FRANC; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; KESKINEN H, 1978, CLIN ALLERGY, V8, P569, DOI 10.1111/j.1365-2222.1978.tb01511.x; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kopferschmitt-Kubler MC, 2002, EUR RESPIR J, V19, P84, DOI 10.1183/09031936.02.00102202; Leino T, 1997, J OCCUP ENVIRON MED, V39, P534, DOI 10.1097/00043764-199706000-00008; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; MATTE TD, 1990, CHEST, V98, pS173, DOI 10.1378/chest.98.5_Supplement.173S; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; Meredith S, 1996, THORAX, V51, P435, DOI 10.1136/thx.51.4.435; MEREDITH SK, 1989, BR J IND MED, V48, P292; PAULI G, 1999, ASTHME PROFESSIONNEL, P523; Provencher S, 1997, OCCUP ENVIRON MED, V54, P272; Reinisch F, 2001, AM J IND MED, V39, P72; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; Ross DJ, 1998, OCCUP MED-OXFORD, V48, P481, DOI 10.1093/occmed/48.8.481; Toren K, 1996, OCCUP ENVIRON MED, V53, P757; Toren K, 1999, EUR RESPIR J, V13, P496, DOI 10.1183/09031936.99.13349699; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	34	129	131	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	FEB	2003	60	2					136	141		10.1136/oem.60.2.136		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	641MF	WOS:000180748000011	12554842	
J	Lehtimaki, L; Kankaanranta, H; Saarelainen, S; Hahtola, P; Jarvenpaa, R; Koivula, T; Turjanmaa, V; Moilanen, E				Lehtimaki, L; Kankaanranta, H; Saarelainen, S; Hahtola, P; Jarvenpaa, R; Koivula, T; Turjanmaa, V; Moilanen, E			Extended exhaled NO measurement differentiates between alveolar and bronchial inflammation	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							POTENT OXIDANT PEROXYNITRITE; NITRIC-OXIDE; ASTHMATIC-PATIENTS; PULMONARY-FUNCTION; LOWER AIRWAYS; METHACHOLINE; INDUCTION; FIBROSIS; SYNTHASE; AIR	Lower respiratory tract inflammation can be detected by measuring exhaled nitric oxide (NO) concentration at a single exhalation flow rate, but this does not differentiate between alveolar and bronchial NO production. We assessed alveolar NO concentration and bronchial NO flux with an extended method of measuring exhaled NO at several exhalation flow rates in 40 patients with asthma, 17 patients with alveolitis, and 57 healthy control subjects. Bronchial NO flux was higher in asthma (2.5 +/- 0.3 nl/s, p < 0.001) than in alveolitis (0.7 +/- 0.1 nl/s) and healthy control subjects (0.7 + 0.1 nl/s). Alveolar NO concentration was higher in alveolitis (4.1 +/- 0.3 ppb, p < 0.001) than in asthma (1.1 +/- 0.2 ppb) and healthy control subjects (1.1 +/- 0.1 ppb). In asthma, bronchial NO flux correlated with serum level of eosinophil protein X (EPX) (r = 0.60, p < 0.001) and bronchial hyperresponsiveness (r = 0.55, p < 0.001). In alveolitis, alveolar NO concentration correlated inversely with pulmonary diffusing capacity (r = -0.55, p = 0.022) and pulmonary restriction. Glucocorticoid treatment or allergen avoidance normalized bronchial NO flux in asthma and decreased alveolar NO concentration toward normal in alveolitis. In conclusion, extended exhaled NO measurement can be used to separately assess alveolar and bronchial inflammation and to assess disease activity/severity in asthma and alveolitis.	Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Tampere Univ Hosp, Dept Radiol, Tampere, Finland; Tampere Univ Hosp, Dept Clin Physiol, Tampere, Finland	Moilanen, E (reprint author), Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33014 Tampere, Finland.			Kankaanranta, Hannu/0000-0001-5258-0906			Altman DG, 1991, PRACTICAL STAT MED R; ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P646; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P2185; BORLAND CDR, 1989, EUR RESPIR J, V2, P56; CHINET T, 1990, THORAX, V45, P675, DOI 10.1136/thx.45.9.675; Gabbay E, 1999, AM J RESP CRIT CARE, V160, P2093; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hogman M, 2000, RESP MED, V94, P985, DOI 10.1053/rmed.2000.0872; Hogman M, 1999, AM J RESP CRIT CARE, V159, pA862; HOGMAN M, 2000, EUR RESPIR J, V16, pS443; Hyde RW, 1997, J APPL PHYSIOL, V82, P1290; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Koller DY, 1999, CLIN EXP ALLERGY, V29, P786; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; Lehtimaki L, 2000, ANN MED, V32, P417, DOI 10.3109/07853890008995949; Moilanen E, 1999, INFLAMMATION BASIC P, P787; NIEMINEN MM, 1992, CHEST, V102, P1537, DOI 10.1378/chest.102.5.1537; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Saleh D, 1998, FASEB J, V12, P929; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Silkoff PE, 2000, CLIN CHEST MED, V21, P345, DOI 10.1016/S0272-5231(05)70271-9; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; TERHO EO, 1986, AM J IND MED, V10, P329, DOI 10.1002/ajim.4700100333; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; Viljanen A A, 1982, Scand J Clin Lab Invest Suppl, V159, P21	29	129	130	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN	2001	163	7					1557	1561				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	443JE	WOS:000169337400013	11401873	
J	Ren, P; Jankun, TM; Belanger, K; Bracken, MB; Leaderer, BP				Ren, P; Jankun, TM; Belanger, K; Bracken, MB; Leaderer, BP			The relation between fungal propagules in indoor air and home characteristics	ALLERGY			English	Article						fungal propagules; house characteristics; indoor air; seasonal variation	MOLDS; PREVALENCE; DAMPNESS; DUST	Background: Questionnaires are commonly used in epidemiologic studies to obtain information about house characteristics in order to predict the household aeroallergen exposure levels. However, the reliability of the predictions made with the questionnaires has not been evaluated. To address this issue, we compared objectively measured fungal propagules including the most frequently isolated mold genera (i.e., Alternaria, Aspergillus, Cladosporium, Penicillium, etc.) in a large sample of homes and compared these measured values to the questionnaire-determined household characteristics. Methods: As part of a prospective cohort study on the relation between residential allergen exposure and development of asthma in neonates, fungal air samples were collected from infant bedrooms and main living areas in 1000 homes in the Northeast USA, from December 1996 to January 1999. A Burkard portable air sampler was used in combination with DG-18 and MEA agars. A questionnaire was used to obtain information on host and house characteristics that may have an impact on the presence of fungal propagules in the air. This included information on observation of moisture problems (e.g., water leakage or damage, and mold or mildew growth), ventilation and heating facilities, building age and type, number of occupants, annual household income, presence of pets and pests, cleaning regimens, etc. Results: The number of CFU/m(3) air collected on MEA was significantly higher than on DG-18 (means, respectively, 1033.5 and 846.0 CFU/m(3)) (P < 0.0005). However, there was no significant difference between the numbers of CFU/m(3) air collected from the main living area and from the infant bedroom. There was only a very weak relationship between the house characteristics, as described by questionnaire, and the presence of fungal propagules in indoor air. Only the temperature, relative humidity, season, and cats inside homes had a statistically significant impact on the presence of fungal propagules in indoor air. Conclusions: The presence of fungal propagules in indoor air cannot be reliably predicted by home characteristics. Actual measurements are required for fungal exposure assessment, and the use of only;one medium to collect samples in one location in a home might be adequate to represent residential levels of fungi in indoor air.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Div Environm Hlth Sci, New Haven, CT 06510 USA	Ren, P (reprint author), NYSDOH, Wadsworth Ctr Labs & Res, David Axelrod Inst, 120 New Scotland Ave, Albany, NY 12208 USA.				NIEHS NIH HHS [ES/07456]		Blackley CH, 1873, EXPT RES CAUSES NATU; *COMM EUR COMM, 1994, 12 CEC; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; Feinberg S, 1935, WISC MED J, V34, P254; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; PLATT SD, 1989, BRIT MED J, V298, P1673; PRINCE H, 1934, TEX J MED, V30, P340; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; RUSSELL C, 1999, INDOOR AIR S, V4, P934; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; VERHOEFF AP, 1994, AIR QUAL MG, V2, P129; VONDERWERFF P, 1958, MOLD FUNGI BRONCHIAL	14	129	135	0	12	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	MAY	2001	56	5					419	424		10.1034/j.1398-9995.2001.056005419.x		6	Allergy; Immunology	Allergy; Immunology	437BW	WOS:000168971200008	11350305	
J	Campbell, JJ; Brightling, CE; Symon, FA; Qin, S; Murphy, KE; Hodge, M; Andrew, DP; Wu, LJ; Butcher, EC; Wardlaw, AJ				Campbell, JJ; Brightling, CE; Symon, FA; Qin, S; Murphy, KE; Hodge, M; Andrew, DP; Wu, LJ; Butcher, EC; Wardlaw, AJ			Expression of chemokine receptors by lung T cells from normal and asthmatic subjects	JOURNAL OF IMMUNOLOGY			English	Article							CHEMOATTRACTANT RECEPTORS; DIFFERENTIAL EXPRESSION; ATOPIC ASTHMA; LYMPHOCYTES; RECOGNITION; PULMONARY; BIOLOGY	The lung is an important tertiary lymphoid organ with constant trafficking of T cells through the lung in both health and disease. T cell migration is controlled by a combination of adhesion receptors and chemokines expressed on vascular endothelium and in the tissue, often in an organ-specific manner. This leads to selective accumulation of different T cell subsets, a process called lymphocyte homing. There is evidence for a distinct lung-homing pathway, but no specific lung-homing receptors have been described. We analyzed the chemokine receptor profile of lung T cells to determine the extent to which lung T cells shared homing pathways with other organs such as the gut and skin. In addition, we compared expression of receptors in normal and asthmatic individuals to determine whether different pathways were used in health and disease, We observed that lung T cells expressed a profile of chemokine and adhesion receptors distinct from that of gut- and skin-homing T cells although no chemokine receptor specific for the lung was found. In particular, lung T cells expressed CCR5 and CXCR3, but not CeR9 or cutaneous lymphocyte Ag, and only low levels of CCR4 and alpha (4)beta (7). No differences were observed between lung T cells from normal vs asthmatic subjects. This study provides added support far the concept of a lung-homing pathway separate from other mucosal organs such as the gut and suggests that the chemokine pathways that control T cell migration in normal homeostasis and Th2-type inflammatory responses are similar.	Univ Leicester, Sch Med, Inst Lung Hlth, Leicester, Leics, England; Univ Leicester, Sch Med, Div Resp Med, Leicester, Leics, England; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Div Transfus Med, Boston, MA 02115 USA; Stanford Univ, Sch Med, Dept Pathol, Lab Immunol & Vasc Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Ctr Digest Dis, Stanford, CA 94305 USA; Vet Affairs Palo Alto Healthcare Syst, Ctr Mol Biol & Med, Palo Alto, CA 94304 USA; Millenium Pharmaceut, Cambridge, MA 02142 USA	Wardlaw, AJ (reprint author), Glenfield Gen Hosp, Groby Rd, Leicester LE3 9QP, Leics, England.				NIAID NIH HHS [AI46784, AI47822]; NIGMS NIH HHS [GM37734]		Abitorabi MA, 1996, J IMMUNOL, V156, P3111; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; Brandtzaeg P, 1999, MUCOSAL IMMUNOLOGY, P439; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 1996, J CELL BIOL, V134, P255, DOI 10.1083/jcb.134.1.255; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; CURTIS JL, 1995, AM J RESP CELL MOL, V12, P520; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; ERLE DJ, 1994, AM J RESP CELL MOL, V10, P237; Homey B, 2000, J IMMUNOL, V164, P3465; Jarmin DI, 2000, J IMMUNOL, V164, P3460; Krug N, 1996, AM J RESP CELL MOL, V14, P319; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Luster AD, 1998, NEW ENGL J MED, V338, P436; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sauty A, 1999, J IMMUNOL, V162, P3549; Teraki Y, 1997, J IMMUNOL, V159, P6018; WANG W, 2000, J BIOL CHEM; Zabel BA, 1999, J EXP MED, V190, P1241, DOI 10.1084/jem.190.9.1241; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	30	129	134	3	5	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 15	2001	166	4					2842	2848				7	Immunology	Immunology	400QA	WOS:000166882000086	11160352	
J	Ahmed, SR				Ahmed, SR			The immune system as a potential target for environmental estrogens (endocrine disrupters): a new emerging field	TOXICOLOGY			English	Review						immune; autoimmune; estrogens; environmental estrogens; endocrine disrupters; allergies	ADULT MALE-RATS; LUPUS-ERYTHEMATOSUS; SEX-HORMONES; AUTOIMMUNE-DISEASES; POLYCHLORINATED-BIPHENYLS; ORGANOCHLORINE COMPOUNDS; AUTOANTIBODY PRODUCTION; CYTOKINE PRODUCTION; MURINE SPLENOCYTES; GONADAL-STEROIDS	It is now well known that natural (17 beta-estradiol) and synthetic (e.g. diethylstilbestrol) estrogens not only affect the reproductive system, but also markedly influence the immune system. Recently, a new class of estrogens that is abundant in the environment (in industrial chemicals, pesticides, and surfactants) has been recognized. Some of these estrogenic chemicals (which are a large subgroup of endocrine disrupters) have also been shown to influence the immune system. This review assimilates growing evidence in wildlife, laboratory animals and to a limited extent in humans, which suggests that environmental chemicals may also affect the immune system. Further studies are needed to ascertain the immunological consequences of exposure to environmental estrogens, especially in humans. At the present time, it is not known whether the human immune system responds to a low dose of environmental estrogens or if environmental estrogens influence certain subsets of human populations, rather than the general population. Conceivably, an alteration of the immune system by environmental estrogens could affect the individuals' ability to mount well-regulated immune responses to microbial and vaccine antigens, allergens, self and tumor antigens. Possible changes in the immune system must be investigated routinely in toxicity studies. A comprehensive mechanistic understanding of potential immunomodulatory chemicals is needed. In this regard, relevant laboratory animals may be especially useful in identifying susceptible periods of life, whether both genders are equally affected, in analysis of changes in target lymphoid organs, and to determine the immunological effects of mixtures of chemicals. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Ctr Mol Med & Infect Dis, Blacksburg, VA 24060 USA	Ahmed, SR (reprint author), Virginia Polytech Inst & State Univ, Virginia Maryland Reg Coll Vet Med, Dept Biomed Sci & Pathobiol, Ctr Mol Med & Infect Dis, 1410 Prices Fork Rd, Blacksburg, VA 24060 USA.				NIEHS NIH HHS [R01-ES08043]		AHMED S A, 1988, P289; Ahmed S. Ansar, 1993, P148; AHMED SA, 1985, AM J PATHOL, V121, P531; AHMED SA, 1993, J AUTOIMMUN, V6, P265, DOI 10.1006/jaut.1993.1023; Ahmed SA, 1999, ENVIRON HEALTH PERSP, V107, P681, DOI 10.2307/3434327; AHMED SA, 1998, DECADE AUTOIMMUNITY, P325; AHMED SA, UNPUB IMMUNOL TODAY; AHMED SA, 1989, AUTOIMMUNITY TOXICOL, P415; Alvarez L, 2000, J APPL TOXICOL, V20, P81, DOI 10.1002/(SICI)1099-1263(200001/02)20:1<81::AID-JAT629>3.0.CO;2-Z; Ansar A. S., 1989, J IMMUNOL, V142, P2647; Arcaro KF, 1999, J CELL BIOCHEM, V72, P94, DOI 10.1002/(SICI)1097-4644(19990101)72:1<94::AID-JCB10>3.0.CO;2-Y; ATKINSON HAC, 1984, TOXICOL LETT, V23, P215, DOI 10.1016/0378-4274(84)90129-2; Banerjee BD, 1997, ENVIRON RES, V74, P43, DOI 10.1006/enrs.1997.3749; BARNETT JB, 1987, TOXICOL LETT, V39, P263, DOI 10.1016/0378-4274(87)90242-6; Barnett J., 1994, IMMUNOTOXICOLOGY IMM, P191; Blake CA, 1997, ENDOCRINE, V6, P243, DOI 10.1007/BF02820499; BLYLER G, 1994, FUND APPL TOXICOL, V23, P188, DOI 10.1006/faat.1994.1097; Boockfor FR, 1997, BIOL REPROD, V57, P267, DOI 10.1095/biolreprod57.2.267; Bruder MC, 1999, TOXICOL PATHOL, V27, P171, DOI 10.1177/019262339902700204; BURRELL R, 1993, MOL ASPECTS MED, V14, P1, DOI 10.1016/0098-2997(93)90019-A; CARLSTEN H, 1990, CLIN EXP IMMUNOL, V80, P467; Carpenter D O, 1998, Int J Occup Med Environ Health, V11, P291; Chapin RE, 1997, FUND APPL TOXICOL, V40, P138, DOI 10.1006/faat.1997.2381; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Collins P, 1999, NAT MED, V5, P1130, DOI 10.1038/13453; Colosio C, 1999, TOXICOL LETT, V108, P285, DOI 10.1016/S0378-4274(99)00100-9; COSTA MCL, 1977, ACTA PHARMACOL TOX, V41, P249; CUMMINGS AM, 1989, TOXICOL APPL PHARM, V97, P454, DOI 10.1016/0041-008X(89)90250-0; Das SK, 1997, P NATL ACAD SCI USA, V94, P12786, DOI 10.1073/pnas.94.24.12786; Dayan M, 1997, IMMUNOLOGY, V90, P101, DOI 10.1046/j.1365-2567.1997.00122.x; De Guise S, 1998, J TOXICOL ENV HEAL A, V55, P479, DOI 10.1080/009841098158287; de Jager C, 1999, ANDROLOGIA, V31, P99, DOI 10.1046/j.1439-0272.1999.00245.x; DESCOTES J, 1995, CLIN CHEM, V41, P1870; Descotes J, 1996, ARCH TOX S, V18, P29; Donner KJ, 1999, CYTOMETRY, V35, P80, DOI 10.1002/(SICI)1097-0320(19990101)35:1<80::AID-CYTO11>3.0.CO;2-8; EROSCHENKO VP, 1995, REPROD TOXICOL, V9, P379, DOI 10.1016/0890-6238(95)00025-6; FACEMIRE CF, 1995, ENVIRON HEALTH PERSP, V103, P79, DOI 10.2307/3432416; FIORE MC, 1986, ENVIRON RES, V41, P633, DOI 10.1016/S0013-9351(86)80157-8; FOX HS, 1991, J IMMUNOL, V146, P4362; Fox LL, 1999, J TOXICOL ENV HEAL A, V58, P233, DOI 10.1080/009841099157313; FrazierJessen MR, 1996, J IMMUNOL, V156, P3036; FRY DM, 1981, SCIENCE, V213, P922, DOI 10.1126/science.7256288; GAVALCHIN J, 1998, LINKING ENV AGENTS A; GRASMAN KA, 1995, ARCH ENVIRON CON TOX, V28, P161; Grasman KA, 1996, ENVIRON HEALTH PERSP, V104, P829, DOI 10.2307/3432714; GROSSMAN CJ, 1984, ENDOCR REV, V5, P435; Haas C, 1998, J IMMUNOL, V160, P3713; HAHN BH, 1999, DUBOIS LUPUS ERYTHEM, P339; HATTORI M, 1979, J ENDOCRINOL, V83, P101, DOI 10.1677/joe.0.0830101; HERBST AL, 1971, NEW ENGL J MED, V284, P878, DOI 10.1056/NEJM197104222841604; HERMANOWICZ A, 1982, INT ARCH OCC ENV HEA, V50, P329, DOI 10.1007/BF00377829; Holladay SD, 1999, ENVIRON HEALTH PERSP, V107, P687, DOI 10.2307/3434328; HOMODELARCHE F, 1991, J STEROID BIOCHEM, V40, P619, DOI 10.1016/0960-0760(91)90285-D; Huber SA, 1999, LUPUS, V8, P384, DOI 10.1177/096120339900800511; Inadera H, 2000, ENDOCRINOLOGY, V141, P50, DOI 10.1210/endo.141.1.7233; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; JONTELL M, 1995, J DENT RES, V74, P1162; KANNAN K, 1993, ARCH ENVIRON CON TOX, V25, P227; Karpinski EC, 1999, EMIGRE FEMINISM: TRANSNATIONAL PERSPECTIVES, P17; Kehlen A, 1999, J NEUROIMMUNOL, V101, P1, DOI 10.1016/S0165-5728(99)00111-3; KEITH LH, 1997, HDB PROPERTY DATA, P1; KLINMAN DM, 1995, IMMUNOL REV, V144, P157; Kohen F, 1998, Dev Immunol, V5, P277, DOI 10.1155/1998/62380; LAHITA RG, 1999, SYSTEMIC LUPUS ERYTH, P129; LAHITA RG, 1987, SYSTEMIC LUPUS ERYTH, P523; LAHVIS GP, 1995, ENVIRON HEALTH PERSP, V103, P67, DOI 10.2307/3432414; LI ZG, 1993, CLIN EXP RHEUMATOL, V11, P157; LUSTER MI, 1988, FUND APPL TOXICOL, V10, P2, DOI 10.1016/0272-0590(88)90247-3; LUSTER MI, 1993, ENVIRON HEALTH PERSP, V100, P219, DOI 10.2307/3431528; MACHOLD KP, 1990, J RHEUMATOL, V17, P831; Marin ML, 1996, J TOXICOL ENV HEALTH, V48, P379, DOI 10.1080/009841096161267; MCCONNACHIE PR, 1992, ARCH ENVIRON HEALTH, V47, P295; MENCONI S, 1988, ARCH ENVIRON HEALTH, V43, P349; Michielsen CCPPC, 1999, ENVIRON HEALTH PERSP, V107, P783, DOI 10.2307/3434341; Michielsen CPPC, 1997, TOXICOL APPL PHARM, V144, P12, DOI 10.1006/taap.1997.8104; Munkittrick K.R., 1991, CAN J FISH AQUAT SCI, V48, P1; Nair-Menon JU, 1999, LIFE SCI, V65, P1125, DOI 10.1016/S0024-3205(99)00346-X; NairMenon JU, 1996, TOXICOL APPL PHARM, V139, P437, DOI 10.1006/taap.1996.0185; Nieto M, 1999, BLOOD, V94, P2767; NOLLER KL, 1988, FERTIL STERIL, V49, P1080; Norman JC, 1998, IMMUNOLOGY, V94, P48; Olsen NJ, 1996, ENDOCR REV, V17, P369, DOI 10.1210/er.17.4.369; POLISCHUK SC, 1995, SCI TOTAL ENVIRON, V160-61, P465, DOI 10.1016/0048-9697(95)04380-J; Reichrtova E, 1999, ENVIRON HEALTH PERSP, V107, P895, DOI 10.2307/3454477; Rosenberg AM, 1999, J TOXICOL ENV HEAL A, V57, P225, DOI 10.1080/009841099157674; ROUBINIAN JR, 1978, J EXP MED, V147, P1568, DOI 10.1084/jem.147.6.1568; Ruh MF, 1998, ENDOCRINE, V9, P207, DOI 10.1385/ENDO:9:2:207; SCHOEPF T, 1998, P 46 INT REL C OAK B, P7; Schwarting A, 1998, J IMMUNOL, V161, P494; Segura JJ, 1999, J ENDODONT, V25, P341, DOI 10.1016/S0099-2399(06)81168-4; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884; Skobeloff EM, 1996, ARCH INTERN MED, V156, P1837; SMITHSON G, 1995, J IMMUNOL, V155, P3409; SOTO AM, 1995, ENVIRON HEALTH PERSP, V103, P113, DOI 10.2307/3432519; Staples JE, 1998, TOXICOL APPL PHARM, V151, P200, DOI 10.1006/taap.1998.8446; Stewart JJ, 1998, IMMUNOL TODAY, V19, P352, DOI 10.1016/S0167-5699(98)01298-5; Stiller-Winkler R, 1999, TOXICOL LETT, V107, P219, DOI 10.1016/S0378-4274(99)00050-8; Straube E, 1999, TOXICOL LETT, V107, P225, DOI 10.1016/S0378-4274(99)00051-X; Stubner UP, 1999, ALLERGY, V54, P865, DOI 10.1034/j.1398-9995.1999.00961.x; Sullivan DA, 1997, J RHEUMATOL, V24, P17; SVENSSON BG, 1994, INT ARCH OCC ENV HEA, V65, P351, DOI 10.1007/BF00383243; Tabata N, 1997, ARCH DERMATOL RES, V289, P410, DOI 10.1007/s004030050213; Tryphonas H, 1998, CAN J PUBLIC HEALTH, V89, pS49; TUNG KSK, 1987, AM J PATHOL, V126, P293; van Zandbergen G, 1999, J IMMUNOL, V163, P5806; Verthelyi D, 1997, J AUTOIMMUN, V10, P115, DOI 10.1006/jaut.1996.0121; VERTHELYI D, 1994, ENDOCRINOLOGY, V135, P2615, DOI 10.1210/en.135.6.2615; Verthelyi DI, 1998, CELL IMMUNOL, V189, P125, DOI 10.1006/cimm.1998.1372; Vial T, 1996, J TOXICOL ENV HEALTH, V48, P215, DOI 10.1080/009841096161294; Vom Saal FS, 1998, TOXICOL IND HEALTH, V14, P239; VOS JG, 1977, CRC CR REV TOXICOL, V5, P67, DOI 10.3109/10408447709101342; Walker C, 1999, ENVIRON HEALTH PERSP, V107, P619; WALKER SE, 1994, J LAB CLIN MED, V124, P401; WALKER SE, 1999, DUBOIS LUPUS ERYTHEM, P311; WINGARD DL, 1988, WESTERN J MED, V149, P551; WIRA CR, 1987, J IMMUNOL, V138, P4159	116	129	138	1	20	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-483X			TOXICOLOGY	Toxicology	SEP 7	2000	150	1-3					191	206				16	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	358GA	WOS:000089549200016	10996675	
J	Masopust, D; Schenkel, JM				Masopust, David; Schenkel, Jason M.			The integration of T cell migration, differentiation and function	NATURE REVIEWS IMMUNOLOGY			English	Review							CHEMOKINE RECEPTOR CCR7; CD103(+) DENDRITIC CELLS; LYMPH-NODES; CUTTING EDGE; IN-VIVO; RESIDENT MEMORY; ANTIGEN PRESENTATION; PERIPHERAL-TISSUES; HOMING RECEPTOR; L-SELECTIN	T cells function locally. Accordingly, T cells' recognition of antigen, their subsequent activation and differentiation, and their role in the processes of infection control, tumour eradication, autoimmunity, allergy and alloreactivity are intrinsically coupled with migration. Recent discoveries revise our understanding of the regulation and patterns of T cell trafficking and reveal limitations in current paradigms. Here, we review classic and emerging concepts, highlight the challenge of integrating new observations with existing T cell classification schemes and summarize the heuristic framework provided by viewing T cell differentiation and function first through the prism of migration.	[Masopust, David; Schenkel, Jason M.] Univ Minnesota, Sch Med, Dept Microbiol, Ctr Immunol, Minneapolis, MN 55455 USA	Masopust, D (reprint author), Univ Minnesota, Sch Med, Dept Microbiol, Ctr Immunol, Minneapolis, MN 55455 USA.	masopust@umn.edu			US National Institutes of Health (NIH) [R01AI084913-01]; NIH [T32AI007313]; Office Of The Director, NIH [DP2OD006467]	The authors thank V. Vezys and S. Jameson (University of Minnesota) for helpful discussion. This study was supported by US National Institutes of Health (NIH) grant R01AI084913-01 (to D.M.), NIH grant T32AI007313 (to J.M.S.) and the Office Of The Director, NIH, under Award Number DP2OD006467 (to D.M.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.	ABERNETHY NJ, 1991, IMMUNOLOGY, V72, P239; Abitorabi MA, 1996, J IMMUNOL, V156, P3111; Agrewala JN, 2007, J BIOL CHEM, V282, P6106, DOI 10.1074/jbc.M608266200; Anderson KG, 2012, J IMMUNOL, V189, P2702, DOI 10.4049/jimmunol.1201682; Ariotti S, 2012, P NATL ACAD SCI USA, V109, P19739, DOI 10.1073/pnas.1208927109; Arnon TI, 2011, SCIENCE, V333, P1898, DOI 10.1126/science.1208248; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Bao XF, 2010, IMMUNITY, V33, P817, DOI 10.1016/j.immuni.2010.10.018; Bardi G, 2001, EUR J IMMUNOL, V31, P3291, DOI 10.1002/1521-4141(200111)31:11<3291::AID-IMMU3291>3.0.CO;2-Z; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; Belyakov IM, 2004, J CLIN INVEST, V113, P998, DOI 10.1172/JCI200420261; Boissonnas A, 2007, J EXP MED, V204, P345, DOI 10.1084/jem.20061890; Bousso P, 2003, NAT IMMUNOL, V4, P579, DOI 10.1038/ni928; Brandtzaeg P, 2008, MUCOSAL IMMUNOL, V1, P31, DOI 10.1038/mi.2007.9; Braun A, 2011, NAT IMMUNOL, V12, P879, DOI 10.1038/ni.2085; Bromley SK, 2013, J IMMUNOL, V190, P970, DOI 10.4049/jimmunol.1202805; Bromley SK, 2005, NAT IMMUNOL, V6, P895, DOI 10.1038/ni1240; Budhu S, 2010, J EXP MED, V207, P223, DOI 10.1084/jem.20091279; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CAHILL RNP, 1976, J EXP MED, V143, P870, DOI 10.1084/jem.143.4.870; Campanella GSV, 2008, J IMMUNOL METHODS, V331, P127, DOI 10.1016/j.jim.2007.12.002; Campbell DJ, 2002, J EXP MED, V195, P135, DOI 10.1084/jem.20011502; Casey KA, 2012, J IMMUNOL, V188, P4866, DOI 10.4049/jimmunol.1200402; Castellino F, 2006, NATURE, V440, P890, DOI 10.1038/nature04651; Coombes JL, 2010, NAT REV IMMUNOL, V10, P353, DOI 10.1038/nri2746; Cyster JG, 2012, ANNU REV IMMUNOL, V30, P69, DOI 10.1146/annurev-immunol-020711-075011; Debes GF, 2005, NAT IMMUNOL, V6, P889, DOI 10.1038/ni1238; Egen JG, 2011, IMMUNITY, V34, P807, DOI 10.1016/j.immuni.2011.03.022; El-Asady R, 2005, J EXP MED, V201, P1647, DOI 10.1084/jem.20041044; Ely KH, 2003, J IMMUNOL, V170, P1423; Fife BT, 2009, NAT IMMUNOL, V10, P1185, DOI 10.1038/ni.1790; GALLATIN WM, 1983, NATURE, V304, P30, DOI 10.1038/304030a0; Gebhardt T, 2013, TRENDS IMMUNOL, V34, P27, DOI 10.1016/j.it.2012.08.008; Gebhardt T, 2011, NATURE, V477, P216, DOI 10.1038/nature10339; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Geissmann F, 2005, PLOS BIOL, V3, P650, DOI 10.1371/journal.pbio.0030113; Gerner MY, 2012, IMMUNITY, V37, P364, DOI 10.1016/j.immuni.2012.07.011; GOWANS JL, 1957, BRIT J EXP PATHOL, V38, P67; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; GOWANS JL, 1959, J PHYSIOL-LONDON, V146, P54; Groom JR, 2012, IMMUNITY, V37, P1091, DOI 10.1016/j.immuni.2012.08.016; Guarda G, 2007, NAT IMMUNOL, V8, P743, DOI 10.1038/ni1469; Hammerschmidt SI, 2008, J EXP MED, V205, P2483, DOI 10.1084/jem.20080039; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; Harris TH, 2012, NATURE, V486, P545, DOI 10.1038/nature11098; HAY JB, 1977, J EXP MED, V145, P31, DOI 10.1084/jem.145.1.31; Hickman HD, 2011, J EXP MED, V208, P2511, DOI 10.1084/jem.20102545; Hikono H, 2007, J EXP MED, V204, P1625, DOI 10.1084/jem.20070322; Hofmann M, 2011, P NATL ACAD SCI USA, V108, P16741, DOI 10.1073/pnas.1107200108; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Jameson SC, 2009, IMMUNITY, V31, P859, DOI 10.1016/j.immuni.2009.11.007; Janatpour MJ, 2001, J EXP MED, V194, P1375, DOI 10.1084/jem.194.9.1375; Jiang XD, 2012, NATURE, V483, P227, DOI 10.1038/nature10851; Johansson-Lindbom B, 2005, J EXP MED, V202, P1063, DOI 10.1084/jem.20051100; Johansson-Lindbom B, 2007, IMMUNOL REV, V215, P226, DOI 10.1111/j.1600-065X.2006.00482.x; Kaiser A, 2005, J IMMUNOL, V175, P2349; Kang SS, 2011, J EXP MED, V208, P747, DOI 10.1084/jem.20101295; Kaufman DR, 2008, J IMMUNOL, V181, P4188; Klonowski KD, 2004, IMMUNITY, V20, P551, DOI 10.1016/S1074-7613(04)00103-7; Kohlmeier JE, 2007, J IMMUNOL, V178, P4721; Kohout TA, 2004, J BIOL CHEM, V279, P23214, DOI 10.1074/jbc.M402125200; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Ledgerwood LG, 2008, NAT IMMUNOL, V9, P42, DOI 10.1038/ni1534; Lee YT, 2011, J VIROL, V85, P4085, DOI 10.1128/JVI.02493-10; Lefrancois L, 2006, ANNU REV IMMUNOL, V24, P681, DOI 10.1146/annurev.immunol.24.021605.090650; Leon B, 2012, NAT IMMUNOL, V13, P681, DOI 10.1038/ni.2309; Li HL, 2011, J VIROL, V85, P11007, DOI 10.1128/JVI.05346-11; Li WJ, 2012, J CLIN INVEST, V122, P2499, DOI 10.1172/JCI62970; Liu LZ, 2006, IMMUNITY, V25, P511, DOI 10.1016/j.immuni.2006.06.019; Lo CG, 2005, J EXP MED, V201, P291, DOI 10.1084/jem.20041509; Looney M.R., 2010, NAT METHODS, V8, P91; Ma CS, 2012, J EXP MED, V209, P1241, DOI 10.1084/jem.20120994; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; Mackay LK, 2012, P NATL ACAD SCI USA, V109, P7037, DOI 10.1073/pnas.1202288109; Mandl J. N., 2012, P NATL ACAD SCI USA, V38, P263; Marshall DR, 2001, P NATL ACAD SCI USA, V98, P6313, DOI 10.1073/pnas.101132698; Masopust D, 2006, J IMMUNOL, V176, P2079; Masopust D, 2004, J IMMUNOL, V172, P4875; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Masopust D, 2012, J IMMUNOL, V188, P5811, DOI 10.4049/jimmunol.1102695; Masopust D, 2010, J EXP MED, V207, P553, DOI 10.1084/jem.20090858; McCully ML, 2012, BLOOD, V120, P4591, DOI 10.1182/blood-2012-05-433037; McDole JR, 2012, NATURE, V483, P345, DOI 10.1038/nature10863; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Mescher MF, 2006, IMMUNOL REV, V211, P81, DOI 10.1111/j.0105-2896.2006.00382.x; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Moon JJ, 2007, IMMUNITY, V27, P203, DOI 10.1016/j.immuni.2007.07.007; Muller AJ, 2012, IMMUNITY, V37, P147, DOI 10.1016/j.immuni.2012.05.015; Obar Joshua J, 2008, Immunity, V28, P859, DOI 10.1016/j.immuni.2008.04.010; Okada T, 2002, J EXP MED, V196, P65, DOI 10.1084/jem.20020201; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; PICKER LJ, 1993, J IMMUNOL, V150, P1122; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; Rocha B, 2006, IMMUNOL REV, V211, P182, DOI 10.1111/j.0105-2896.2006.00378.x; Roman E, 2002, J EXP MED, V196, P957, DOI 10.1084/jem.20021052; Rosen H, 2007, TRENDS IMMUNOL, V28, P102, DOI 10.1016/j.it.2007.01.007; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annure.immunol.21.090501.080131; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Salmi M, 2005, IMMUNOL REV, V206, P100, DOI 10.1111/j.0105-2896.2005.00285.x; Sathaliyawala T., 2012, IMMUNITY, V38, P1; Scanlon ST, 2011, J EXP MED, V208, P2113, DOI 10.1084/jem.20110522; Scimone ML, 2004, J EXP MED, V199, P1113, DOI 10.1084/jem.20031645; SEGEL GB, 1981, BLOOD, V57, P894; Shin HN, 2012, NATURE, V491, P463, DOI 10.1038/nature11522; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Sigmundsdottir H, 2008, NAT IMMUNOL, V9, P981, DOI 10.1038/ni.f.208; Sigmundsdottir H, 2007, NAT IMMUNOL, V8, P285, DOI 10.1038/ni1433; Soderberg KA, 2005, P NATL ACAD SCI USA, V102, P16315, DOI 10.1073/pnas.0506190102; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stagg AJ, 2002, EUR J IMMUNOL, V32, P1445, DOI 10.1002/1521-4141(200205)32:5<1445::AID-IMMU1445>3.0.CO;2-E; STEEBER DA, 1987, SCANNING MICROSCOPY, V1, P831; Stenstad H, 2007, P NATL ACAD SCI USA, V104, P10122, DOI 10.1073/pnas.0700269104; Stevceva L, 2002, J VIROL, V76, P11659, DOI 10.1128/JVI.76.22.11659-11676.2002; Strutt TM, 2010, NAT MED, V16, P558, DOI 10.1038/nm.2142; Svensson M, 2008, MUCOSAL IMMUNOL, V1, P38, DOI 10.1038/mi.2007.4; Teijaro JR, 2011, J IMMUNOL, V187, P5510, DOI 10.4049/jimmunol.1102243; Thomas SY, 2011, J EXP MED, V208, P1179, DOI 10.1084/jem.20102630; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020; Wakim LM, 2008, J IMMUNOL, V181, P5837; Wakim LM, 2010, P NATL ACAD SCI USA, V107, P17872, DOI 10.1073/pnas.1010201107; Wakim LM, 2012, J IMMUNOL, V189, P3267; Webster B, 2006, J EXP MED, V203, P1903, DOI 10.1084/jem.20052272; WHALER B C, 1956, J Physiol, V132, P41; Woodland DL, 2009, NAT REV IMMUNOL, V9, P153, DOI 10.1038/nri2496; Zehn D, 2009, NATURE, V458, P211, DOI 10.1038/nature07657; Zidar DA, 2009, P NATL ACAD SCI USA, V106, P9649, DOI 10.1073/pnas.0904361106	129	128	131	9	82	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	MAY	2013	13	5					309	320		10.1038/nri3442		12	Immunology	Immunology	132MK	WOS:000318072400008	23598650	
J	Nygaard, UC; Hansen, JS; Samuelsen, M; Alberg, T; Marioara, CD; Lovik, M				Nygaard, Unni C.; Hansen, Jitka S.; Samuelsen, Mari; Alberg, Torunn; Marioara, Calin D.; Lovik, Martinus			Single-Walled and Multi-Walled Carbon Nanotubes Promote Allergic Immune Responses in Mice	TOXICOLOGICAL SCIENCES			English	Article						carbon nanotubes; adjuvant effect; airway inflammation; allergy; mice; IgE	DIESEL EXHAUST PARTICLES; AIRWAY INFLAMMATION; ADJUVANT ACTIVITY; ULTRAFINE PARTICLES; RESPIRATORY HEALTH; FINE PARTICLES; IGE PRODUCTION; SENSITIZATION; TOXICITY; ANTIGEN	The adjuvant effect of particles on allergic immune responses has been shown to increase with decreasing particle size and increasing particle surface area. Like ultrafine particles, carbon nanotubes (CNTs) have nano-sized dimensions and a large relative surface area and might thus increase allergic responses. Therefore, we examined whether single-walled (sw) and multi-walled (mw) CNTs have the capacity to promote allergic responses in mice, first in an sc injection model and thereafter in an intranasal model. Balb/cA mice were exposed to three doses of swCNT, mwCNT, as well as ultrafine carbon black particles (ufCBPs, Printex90) during sensitization with the allergen ovalbumin (OVA). Five days after an OVA booster, OVA-specific IgE, IgG1, and IgG2a antibodies in serum and the numbers of inflammatory cells and cytokine levels in bronchoalveolar lavage fluid (BALF) were determined. Furthermore, ex vivo OVA-induced cytokine release from mediastinal lymph node (MLN) cells was measured. In separate experiments, differential cell counts were determined in BALF 24 h after a single intranasal exposure to the particles in the absence of allergen. We demonstrate that both swCNT and mwCNT together with OVA strongly increased serum levels of OVA-specific IgE, the number of eosinophils in BALF, and the secretion of Th2-associated cytokines in the MLN. On the other hand, only mwCNT and ufCBP with OVA increased IgG2a levels, neutrophil cell numbers, and tumor necrosis factor-alpha and monocyte chemoattractant protein-1 levels in BALF, as well as the acute influx of neutrophils after exposure to the particles alone. This study demonstrates that CNTs promote allergic responses in mice.	[Nygaard, Unni C.; Hansen, Jitka S.; Samuelsen, Mari; Alberg, Torunn; Lovik, Martinus] Norwegian Inst Publ Hlth, Div Environm Med, NO-0403 Oslo, Norway; [Hansen, Jitka S.] Natl Res Ctr Working Environm, DK-2100 Copenhagen, Denmark; [Marioara, Calin D.] SINTEF Mat & Chem, NO-7465 Trondheim, Norway; [Lovik, Martinus] Norwegian Univ Sci & Technol, Fac Med, Dept Canc Res & Mol Med, NO-7489 Trondheim, Norway	Nygaard, UC (reprint author), Norwegian Inst Publ Hlth, Div Environm Med, POB 4404 Nydalen,Lovisenbergata 8, NO-0403 Oslo, Norway.	unni.cecilie.nygaard@fhi.no					Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; Bang JJ, 2004, J NANOSCI NANOTECHNO, V4, P716, DOI 10.1166/jnn.2004.095; Brunauer S, 1938, J AM CHEM SOC, V60, P309, DOI 10.1021/ja01269a023; Buford Mary C, 2007, Part Fibre Toxicol, V4, P6, DOI 10.1186/1743-8977-4-6; de Haar C, 2006, CLIN EXP ALLERGY, V36, P1469, DOI 10.1111/j.1365-2222.2006.02586.x; de Haar C, 2005, TOXICOL SCI, V87, P409, DOI 10.1093/toxsci/kfi255; DEHAAR C, 2008, J ALLERGY CLIN IMMUN, V101, P1246; Dutta D, 2007, TOXICOL SCI, V100, P303, DOI 10.1093/toxsci/kfm217; Granum B, 2002, TOXICOL SCI, V65, P7, DOI 10.1093/toxsci/65.1.7; Granum B, 2000, INHAL TOXICOL, V12, P365, DOI 10.1080/08958378.2000.11463247; Hansen SF, 2008, ECOTOXICOLOGY, V17, P438, DOI [10.1007/s10646-008-0210-4, 10.1007/s00787-008-0686-8]; Inoue K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-106; Kagan VE, 2006, TOXICOL LETT, V165, P88, DOI 10.1016/j.toxlet.2006.02.001; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Lovik M, 2007, METHODS, V41, P72, DOI 10.1016/j.ymeth.2006.07.014; Mercer RR, 2008, AM J PHYSIOL-LUNG C, V294, pL87, DOI 10.1152/ajplung.00186.2007; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008; Muller J, 2008, CHEM RES TOXICOL, V21, P1698, DOI 10.1021/tx800101p; Murr L E, 2006, Int J Environ Res Public Health, V3, P48, DOI 10.3390/ijerph2006030007; Nygaard UC, 2004, TOXICOL SCI, V82, P515, DOI 10.1093/toxsci/kfh287; Ormstad H, 1998, TOXICOLOGY, V129, P227, DOI 10.1016/S0300-483X(98)00079-1; Parnia S, 2002, ALLERGY, V57, P1111, DOI 10.1034/j.1398-9995.2002.02167.x; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Powers KW, 2007, NANOTOXICOLOGY, V1, P42, DOI 10.1080/17435390701314902; Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227; Ryman-Rasmussen JP, 2009, AM J RESP CELL MOL, V40, P349, DOI 10.1165/rcmb.2008-0276OC; Salvador-Morales C, 2006, MOL IMMUNOL, V43, P193, DOI 10.1016/j.molimm.2005.02.006; SAMUELSEN M, SCAND J IMM IN PRESS; Sato Y, 2005, MOL BIOSYST, V1, P176, DOI 10.1039/b502429c; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Service RF, 2004, SCIENCE, V304, P1732, DOI 10.1126/science.304.5678.1732; Shvedova AA, 2008, AM J PHYSIOL-LUNG C, V295, pL552, DOI 10.1152/ajplung.90287.2008; Stern ST, 2008, TOXICOL SCI, V101, P4, DOI 10.1093/toxsci/kfm169; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Van den Broeck W, 2006, J IMMUNOL METHODS, V312, P12, DOI 10.1016/j.jim.2006.01.022; Wan JX, 2007, INHAL TOXICOL, V19, P177, DOI 10.1080/08958370701496145; Wick P, 2007, TOXICOL LETT, V168, P121, DOI 10.1016/j.toxlet.2006.08.019	41	128	134	2	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080			TOXICOL SCI	Toxicol. Sci.	MAY	2009	109	1					113	123		10.1093/toxsci/kfp057		11	Toxicology	Toxicology	441AQ	WOS:000265742100014	19293371	
J	Sjogren, YM; Jenmalm, MC; Bottcher, MF; Bjorksten, B; Sverremark-Ekstrom, E				Sjogren, Y. M.; Jenmalm, M. C.; Bottcher, M. F.; Bjorksten, B.; Sverremark-Ekstrom, E.			Altered early infant gut microbiota in children developing allergy up to 5 years of age	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; bifidobacteria; Clostridium difficile; endotoxin; Fel d 1; gut microbiota; infant; lactobacilli; siblings	PLACEBO-CONTROLLED TRIAL; SPECIES-SPECIFIC PRIMERS; REAL-TIME PCR; SWEDISH INFANTS; ATOPIC ECZEMA; INTESTINAL BIFIDOBACTERIA; FECAL MICROBIOTA; ENDOTOXIN LEVELS; RIBOSOMAL-RNA; HOUSE-DUST	Early colonization with bifidobacteria and lactobacilli is postulated to protect children from allergy, while Clostridium (C.) difficile colonization might be associated with allergic disease. Previous studies of infant gut microbiota in relation to subsequent allergy development have mostly employed culture-dependent techniques, studied genera of bacteria and the follow-up period was limited to 2 years. To relate gut microbiota in early infancy, notably bifidobacteria and lactobacilli at species level, to allergy development during the first 5 years of life and study if environmental factors influence the early infant gut microbiota. Fecal samples were collected at 1 week, 1 month and 2 months after birth from 47 Swedish infants, followed prospectively to 5 years of age. Bacterial DNA was analysed with real-time PCR and related to allergy development, family size as well as endotoxin and Fel d 1 levels in house dust samples. Primers binding to C. difficile, four species of bifidobacteria, two lactobacilli groups and Bacteroides fragilis were used. Children regarded as allergic manifested allergic symptoms and were skin prick test positive during their first 5 years while non-allergic children were neither. Children who developed allergy were significantly less often colonized with lactobacilli group I (Lactobacillus (L.) rhamnosus, L. casei, L. paracasei), Bifidobacterium adolescentis and C. difficile during their first 2 months. Infants colonized with several Bifidobacterium species had been exposed to higher amounts of endotoxin and grew up in larger families than infants harbouring few species. A more diverse gut microbiota early in life might prevent allergy development and may be related to the previously suggested inverse relationship between allergy, family size and endotoxin exposure. Cite this as: Y. M. Sjogren, M. C. Jenmalm, M. F. Bottcher, B. BjorkstEn and E. Sverremark-Ekstrom, Clinical & Experimental Allergy, 2009 (39) 518-526.	[Sjogren, Y. M.] Stockholm Univ, Wenner Gren Inst, Dept Immunol, Arrhenius Lab Nat Sci F5, S-10691 Stockholm, Sweden; [Jenmalm, M. C.; Bottcher, M. F.] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Paediat, Linkoping, Sweden; [Bjorksten, B.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Sjogren, YM (reprint author), Stockholm Univ, Wenner Gren Inst, Dept Immunol, Arrhenius Lab Nat Sci F5, Svante Arrhenius Vag 16-18, S-10691 Stockholm, Sweden.	ylva.sjogren@imun.su.se	Jenmalm, Maria/C-9679-2009; Sverremark-Ekstrom, Eva/A-2305-2016	Jenmalm, Maria/0000-0002-2117-5366; Sverremark-Ekstrom, Eva/0000-0001-6271-8681	Ekhaga foundation; Cancer and Allergy foundation; Mjolkdroppen; Magnus Bergvall foundation,; Swedish Research Council [57X-15160-05-2, 74X-20146-01-2]; National Swedish Association against Allergic Diseases; National Heart and Lung Association; Swedish Foundation for Health Care Sciences and Allergy Research	This work was supported by the Ekhaga foundation, the Cancer and Allergy foundation, Mjolkdroppen, the Magnus Bergvall foundation, the Swedish Research Council (57X-15160-05-2 and 74X-20146-01-2), the National Swedish Association against Allergic Diseases, the National Heart and Lung Association, and the Swedish Foundation for Health Care Sciences and Allergy Research.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Adlerberth I, 2006, PEDIATR RES, V59, P96, DOI 10.1203/01.pdr.0000191137.12774.b2; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Ahrne S, 2005, MICROBES INFECT, V7, P1256, DOI 10.1016/j.micinf.2005.04.011; BENNET R, 1991, SCAND J INFECT DIS, V23, P63, DOI 10.3109/00365549109023376; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061; Gronlund MM, 2007, CLIN EXP ALLERGY, V37, P1764, DOI 10.1111/j.1365-2222.2007.02849.x; Haarman M, 2005, APPL ENVIRON MICROB, V71, P2318, DOI 10.1128/AEM.71.5.2318-2324.2005; He F, 2002, MICROBIOL IMMUNOL, V46, P781; He F, 2001, FEMS IMMUNOL MED MIC, V30, P43, DOI 10.1016/S0928-8244(00)00232-7; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Klein G, 2006, INT J SYST EVOL MICR, V56, P2501, DOI 10.1099/ijs.0.64656-0; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Mackie R I, 1999, Am J Clin Nutr, V69, p1035S; Matsuki T, 2004, APPL ENVIRON MICROB, V70, P167, DOI 10.1128/AEM.70.1.167-173.2004; Matsuki Takahiro, 2003, Curr Issues Intest Microbiol, V4, P61; Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956; MIDTVEDT T, 1987, APPL ENVIRON MICROB, V53, P2866; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rinttila T, 2004, J APPL MICROBIOL, V97, P1166, DOI 10.1111/j.1365-2672.2004.02409.x; Sakata S, 2005, FEMS MICROBIOL LETT, V243, P417, DOI 10.1016/j.femsle.2005.01.002; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Song YL, 2000, FEMS MICROBIOL LETT, V187, P167, DOI 10.1016/S0378-1097(00)00196-8; Sonnenburg JL, 2004, NAT IMMUNOL, V5, P569, DOI 10.1038/ni1079; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Stsepetove J, 2007, FEMS IMMUNOL MED MIC, V51, P260, DOI 10.1111/j.1574-695X.2007.00306.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Suzuki S, 2007, CLIN EXP ALLERGY, V37, P506, DOI 10.1111/j.1365-2222.2007.02676.x; Voor T, 2005, CLIN EXP ALLERGY, V35, P153, DOI 10.1111/j.1365-2222.2005.02157.x; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Young SL, 2004, CLIN DIAGN LAB IMMUN, V11, P686, DOI 10.1128/CDLI.11.4.686-690.2004	41	128	135	0	16	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2009	39	4					518	526		10.1111/j.1365-2222.2008.03156.x		9	Allergy; Immunology	Allergy; Immunology	418YA	WOS:000264184800010	19220322	
J	de Jongste, JC; Carraro, S; Hop, WC; Baraldi, E				de Jongste, Johan C.; Carraro, Silvia; Hop, Wim C.; Baraldi, Eugenio		CHARISM Study Grp	Daily Telemonitoring of Exhaled Nitric Oxide and Symptoms in the Treatment of Childhood Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway inflammation; inhaled corticosteroid; symptom-free days; lung function; telemedicine	RANDOMIZED CONTROLLED-TRIAL; CHILDREN; EXACERBATIONS; GUIDE; MANAGEMENT	Rationale Asthma treatment might improve when inhaled steroids are titrated on airway inflammation. Fractional exhaled nitric oxide (FE(NO0.05)), a marker of eosinophilic airway inflammation, can be measured at home. Objectives: We assessed daily FE(NO0.05) telemonitoring in the management of childhood asthma. Methods: Children with atopic asthma (n = 151) were randomly assigned to two groups: FE(NO0.05) Plus symptom monitoring, or monitoring of symptoms only. All patients scored asthma symptoms in an electronic diary over 30 weeks; 77 received a portable nitric oxide (NO) analyzer. Data were transmitted daily to the coordinating centers. Patients were phoned every 3 weeks and their steroid dose was adapted according to FE(NO0.05) and symptoms, or according to symptoms. Children were seen at 3, 12, 21, and 30 weeks for examination and lung function testing. The primary end point was the proportion of symptom-free days in the last 12 study weeks. Measurements and Main Results: Telemonitoring was feasible with reliable FE(NO0.05) data for 86% of days, and valid diary entries for 79% of days. Both groups showed an increase in symptom-free days, improvement of FEV(1) and quality of life, and a reduction in steroid dose. None of the changes from baseline differed between groups. The difference in symptom-free days over the last 12 weeks was 0.3% (P = 0.95; 95% confidence interval, -10 to 11%). There was a trend for fewer exacerbations in the FE(NO0.05) group. Conclusions: Thirty weeks of daily FENO(0.05) and symptom telemonitoring was associated with improved asthma control and a lower steroid dose. We found no added value of daily FENO(0.05) monitoring compared with daily symptom monitoring only.	[de Jongste, Johan C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Div Pediat Resp Med,Dept Pediat, NL-3000 CB Rotterdam, Netherlands; [Carraro, Silvia; Baraldi, Eugenio] Univ Padua, Dept Pediat, Unit Allergy & Resp Med, Padua, Italy; [Hop, Wim C.] Erasmus Univ, Med Ctr, Dept Biostat, NL-3000 CB Rotterdam, Netherlands	de Jongste, JC (reprint author), Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Div Pediat Resp Med,Dept Pediat, POB 2060, NL-3000 CB Rotterdam, Netherlands.	j.c.dejongste@erasmusmc.nl		BARALDI, EUGENIO/0000-0002-1829-3652; MARSEGLIA, GIAN LUIGI/0000-0003-3662-0159			American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST.PUBMED:15817806; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; de Jongste JC, 2005, EUR RESPIR J, V26, P379, DOI 10.1183/09031936.05.00080705; DEJONGSTE JC, 2008, AM J RESP CRIT CARE, V177, pA992; Fritsch M, 2006, PEDIATR PULM, V41, P855, DOI 10.1002/ppul.20455; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Pijnenburg MW, 2006, PEDIATR ALLERGY IMMU, V17, P189, DOI 10.1111/j.1399-3038.2006.00394.x; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-14270C; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	20	128	130	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 15	2009	179	2					93	97		10.1164/rccm.200807-1010OC		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	394PC	WOS:000262458000005	18931330	
J	Gunthorpe, MJ; Szallasi, A				Gunthorpe, Martin J.; Szallasi, Arpad			Peripheral TRPV1 receptors as targets for drug development: New molecules and mechanisms	CURRENT PHARMACEUTICAL DESIGN			English	Review							GENE-RELATED PEPTIDE; SENSORY NERVE DESENSITIZATION; HUMAN EPIDERMAL-KERATINOCYTES; ACID-INDUCED COLITIS; OBESE ZUCKER RATS; VANILLOID RECEPTOR-1; CAPSAICIN RECEPTOR; POTENTIAL VANILLOID-1; EPITHELIAL-CELLS; SUBSTANCE-P	Based on the painful effects of exposure to capsaicin, TRPV1 ( transient receptor potential vanilloid subfamily member 1) localization is most readily associated with peripheral sensory neurons, however, TRPV1 is now known to be expressed, albeit at lower levels, in the spinal cord, brain and a wide-range of non-neuronal cells. The latter includes epithelial cells ( e. g. keratinocytes, urothelium, gastric epithelial cells, enterocytes, and pneumocytes) through vascular endothelium and cells of the immune system ( e. g. T-cells and mast cells) to smooth muscle, fibroblasts and hepatocytes. Despite extensive research, the physiological function of TRPV1 in the brain and in non-neuronal tissues remains elusive. The preliminary results are exciting, but many are unconfirmed and/ or contradictory. As yet, studies with TRPV1 knock-out mice have proven unhelpful in clarifying such biological roles. Now that a range of potent and selective TRPV1 antagonists are available in this rapidly expanding research field, further understanding of the biological roles of TRPV1 throughout the body is within reach. In this article, we will summarize the known roles of peripheral TRPV1 receptors in physiology and disease and review the current perspectives for the therapeutic potential of TRPV1 agonists and antagonists in the treatment of a wide range of conditions such as pain, cancer, migraine, chronic cough, asthma, rectal hypersensitivity, inflammatory bowel disease, obesity, overactive bladder and diabetes. New applications of targeting central TRPV1 receptors are reviewed in the accompanying article by Starowicz et al. ( in this issue).	[Szallasi, Arpad] Monmouth Med Ctr, Dept Pathol, Long Branch, NJ 07740 USA; [Gunthorpe, Martin J.] GlaxoSmithKline Inc, Neurol Ctr Excellence Drug Discovery, Harlow CM19 5AW, Essex, England; [Szallasi, Arpad] Drexel Univ, Coll Med, Dept Pathol, Philadelphia, PA 19104 USA	Szallasi, A (reprint author), Monmouth Med Ctr, Dept Pathol, Long Branch, NJ 07740 USA.	aszallasi@sbhcs.com					Ahern GP, 2003, J BIOL CHEM, V278, P30429, DOI 10.1074/jbc.M305051200; Akerman S, 2004, BRIT J PHARMACOL, V142, P1354, DOI 10.1038/sj.bjp.0705896; AKIBA Y, 2004, BIOCHEM BIOPH RES CO, V321, P25; Amadesi S, 2004, J NEUROSCI, V24, P4300, DOI 10.1523/JNEUROSCI.5679-03.2004; BELZA A, 2001, INT J OBESITY, V31, P121; Bhattacharya A, 2007, J PHARMACOL EXP THER, V323, P665, DOI 10.1124/jpet.107.127258; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Birder LA, 2001, P NATL ACAD SCI USA, V98, P13396, DOI 10.1073/pnas.231243698; Bodo E, 2005, AM J PATHOL, V166, P985, DOI 10.1016/S0002-9440(10)62320-6; BUIATTI E, 1989, INT J CANCER, V44, P611, DOI 10.1002/ijc.2910440409; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816; Chan CLH, 2003, LANCET, V361, P385, DOI 10.1016/S0140-6736(03)12392-6; CHANDRAN P, 2006, NEUR M PLANN ATL GA; Chizh BA, 2007, PAIN, V132, P132, DOI 10.1016/j.pain.2007.06.006; Contassot E, 2004, GYNECOL ONCOL, V93, P182, DOI 10.1016/j.ygyno.2003.12.040; CRUZ F, 2007, NEUROPEPTIDES; CUI JY, 1992, AM J PHYSIOL, V262, pR568; Cui M, 2006, J NEUROSCI, V26, P9385, DOI 10.1523/JNEUROSCI.1246-06.2006; Cuypers E, 2006, FEBS LETT, V580, P5728, DOI 10.1016/j.febslet.2006.09.030; Dasgupta P, 1998, EUR UROL, V33, P28, DOI 10.1159/000019531; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; DAVIS JB, 2006, NEUR M PLANN ATL GA; Denda M, 2001, BIOCHEM BIOPH RES CO, V285, P1250, DOI 10.1006/bbrc.2001.5299; ELLIS CN, 1993, J AM ACAD DERMATOL, V29, P438; Gatti R, 2006, J APPL PHYSIOL, V101, P506, DOI 10.1152/japplphysiol.01558.2005; Gavva NR, 2007, J PHARMACOL EXP THER, V323, P128, DOI 10.1124/jpet.107.125674; Gavva NR, 2007, J NEUROSCI, V27, P3366, DOI 10.1523/JNEUROSCI.4833-06.2007; Gavva NR, 2005, J PHARMACOL EXP THER, V313, P474, DOI 10.1124/jpet.104.079855; Geppetti P, 2006, EUR J PHARMACOL, V533, P207, DOI 10.1016/j.ejphar.2005.12.063; Geppetti Pierangelo, 2005, J Headache Pain, V6, P61, DOI 10.1007/s10194-005-0153-6; Ghilardi JR, 2005, J NEUROSCI, V25, P3126, DOI 10.1523/JNEUROSCI.3815-04.2005; Goadsby Peter J, 2004, Curr Pain Headache Rep, V8, P393, DOI 10.1007/s11916-996-0013-3; Gram DX, 2007, EUR J NEUROSCI, V25, P213, DOI 10.1111/j.1460-9568.2006.05261.x; Gram DX, 2005, EUR J ENDOCRINOL, V153, P963, DOI 10.1530/eje.1.02046; Gram DX, 2005, EUR J PHARMACOL, V509, P211, DOI 10.1016/j.ejphar.2004.12.039; GRAM DX, 2007, NEUROPEPTIDES; Guillot E, 1996, LIFE SCI, V59, P969, DOI 10.1016/0024-3205(96)00403-1; Gunthorpe MJ, 2007, J PHARMACOL EXP THER, V321, P1183, DOI 10.1124/jpet.106.116657; Harada N, 2007, GROWTH HORM IGF RES, V17, P408, DOI 10.1016/j.ghir.2007.04.009; Hartel M, 2006, GUT, V55, P519, DOI 10.1136/gut.2005.073205; Hashimoto K, 2006, CURR PHARM DESIGN, V12, P3857, DOI 10.2174/138161206778559614; Herman RM, 2007, INT J OBESITY, V31, P226, DOI 10.1038/sj.ijo.0803418; HOCH-LIGETI C, 1951, Acta Unio Int Contra Cancrum, V7, P606; Holzer P, 2004, EUR J PHARMACOL, V500, P231, DOI 10.1016/j.ejphar.2004.07.028; Honore P, 2005, J PHARMACOL EXP THER, V314, P410, DOI 10.1124/jpet.105.083915; Hsu CL, 2007, J AGR FOOD CHEM, V55, P1730, DOI 10.1021/jf062912b; Hutter MM, 2005, PANCREAS, V30, P260, DOI 10.1097/01.mpa.0000153616.63384.24; Inoue K, 2002, BIOCHEM BIOPH RES CO, V291, P124, DOI 10.1006/bbrc.2002.6393; Ito K, 2004, CANCER RES, V64, P1071, DOI 10.1158/0008-5472.CAN-03-1670; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Jia YL, 2005, DRUG NEWS PERSPECT, V18, P165, DOI 10.1358/dnp.2005.18.3.892761; JUN HS, 2007, FOOD CHEM TOXICOL, V55, P1730; Jung MY, 2001, CANCER LETT, V165, P139, DOI 10.1016/S0304-3835(01)00426-8; Kang HJ, 2003, INT J CANCER, V103, P475, DOI 10.1002/ijc.10855; Kim CS, 2004, J MED FOOD, V7, P267, DOI 10.1089/1096620041938713; Kimball ES, 2004, NEUROGASTROENT MOTIL, V16, P811, DOI 10.1111/j.1365-2982.2004.00549.x; KNOTKOVA H, 2007, IN PRESS CLIN J PAIN; Lappin SC, 2006, EUR J PHARMACOL, V540, P73, DOI 10.1016/j.ejphar.2006.04.046; Lazzeri M, 2005, EUR UROL, V48, P691, DOI 10.1016/j.eururo.2005.05.018; Lazzeri M, 2004, EUR UROL, V46, P792, DOI 10.1016/j.eururo.2004.08.007; Lee H, 2005, PFLUG ARCH EUR J PHY, V451, P160, DOI 10.1007/s00424-005-1438-y; Lee YS, 2000, CANCER LETT, V161, P121, DOI 10.1016/S0304-3835(00)00608-X; Li WH, 2007, J INVEST DERMATOL, V127, P2328, DOI 10.1038/sj.jid.5700880; LOPEZCARRILLO L, 1994, AM J EPIDEMIOL, V139, P263; MAGGI CA, 1987, N-S ARCH PHARMACOL, V336, P538; Massa F, 2006, J MOL MED-JMM, V84, P142, DOI 10.1007/s00109-005-0016-2; Matthews PJ, 2004, EUR J GASTROEN HEPAT, V16, P897, DOI 10.1097/00042737-200409000-00014; MCLEOD RL, 2006, PULM PHARMACOL THER, V20, P750; McLeod Robbie L, 2006, Cough, V2, P10, DOI 10.1186/1745-9974-2-10; MELNYK A, 1995, OBES RES, V3, P337; Moesgaard SG, 2005, AM J PHYSIOL-ENDOC M, V288, pE1137, DOI 10.1152/ajpendo.00356.2004; Moss AC, 2007, CLIN GASTROENTEROL H, V5, P642, DOI 10.1016/j.cgh.2007.03.002; Nelson MT, 2006, CURR PHARM DESIGN, V12, P2189, DOI 10.2174/138161206777585184; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Noble MD, 2006, AM J PHYSIOL-GASTR L, V291, pG128, DOI 10.1152/ajpgi.00442.2005; NOTANI P N, 1987, Nutrition and Cancer, V10, P103; Pare M, 2007, J COMP NEUROL, V501, P543, DOI 10.1002/cne.21262; PAUS R, 1995, ARCH DERMATOL RES, V287, P500, DOI 10.1007/BF00373436; PETTERSSON M, 1986, ENDOCRINOLOGY, V119, P865; Pomonis JD, 2003, J PHARMACOL EXP THER, V306, P387, DOI 10.1124/jpet.102.046268; Rami HK, 2004, DRUG DISCOV TODAY, V1, P97, DOI 10.1016/j.ddstr.2004.08.020; Razavi R, 2006, CELL, V127, P1123, DOI 10.1016/j.cell.2006.10.038; Rong WF, 2004, J PHYSIOL-LONDON, V560, P867, DOI 10.1113/jphysiol.2004.071746; Salh B, 2003, AM J PHYSIOL-GASTR L, V285, pG235, DOI 10.1152/ajpgi.00449.2002; Sanchez AM, 2006, APOPTOSIS, V11, P89, DOI 10.1007/s10495-005-3275-z; Sanchez MG, 2005, EUR J PHARMACOL, V515, P20, DOI 10.1016/j.ejphar.2005.04.010; Siemens J, 2006, NATURE, V444, P208, DOI 10.1038/nature05285; Silva C, 2001, BJU INT, V88, P355, DOI 10.1046/j.1464-410X.2001.02339.x; SMITH PG, 2002, CELL TISSUE RES, V51, P121; Southall MD, 2003, J PHARMACOL EXP THER, V304, P217, DOI 10.1124/jpet.102.040675; Stander S, 2004, EXP DERMATOL, V13, P129, DOI 10.1111/j.0906-6705.2004.0178.x; Staud R, 2006, CURR PHARM DESIGN, V12, P23, DOI 10.2174/138161206775193235; Storr M, 2007, NEUROGASTROENT MOTIL, V19, P625, DOI 10.1111/j.1365-2982.2007.00946.x; Sugimoto K, 2002, GASTROENTEROLOGY, V123, P1912, DOI 10.1053/gast.2002.37050; SUHR YJ, LIFE SCI, V56, P1845; Surh YJ, 2002, J NATL CANCER I, V94, P1263; SURI A, 2007, IN PRESS TRENDS PHAR; SZALLASI A, 1990, CARCINOGENESIS, V11, P583, DOI 10.1093/carcin/11.4.583; Szallasi A, 2005, TRENDS PHARMACOL SCI, V26, P437, DOI 10.1016/j.tips.2005.07.001; Szallasi A, 1996, J Peripher Nerv Syst, V1, P6; Szallasi A, 1999, PHARMACOL REV, V51, P159; SZALLASI A, 1989, CANCER RES, V49, P6052; Szallasi A, 2007, NAT REV DRUG DISCOV, V6, P357, DOI 10.1038/nrd2280; TANAKA T, 1988, J INVEST DERMATOL, V90, P399, DOI 10.1111/1523-1747.ep12456487; Trevisani M, 2004, THORAX, V59, P769, DOI 10.1136/thx.2003.012930; VANBUREN JJ, 2005, MOL PAIN, V1, P16; Vanmolkot FHM, 2006, CLIN PHARMACOL THER, V79, P263, DOI 10.1016/j.clpt.2005.11.005; Wahlqvist ML, 2001, LANCET, V358, P348, DOI 10.1016/S0140-6736(01)05586-6; Wang HL, 2007, J MED CHEM, V50, P3528, DOI 10.1021/jm070191h; Wang XB, 2005, J PHYSIOL-LONDON, V564, P541, DOI 10.1113/jphysiol.2004.081844; Westerterp-Plantenga MS, 2005, INT J OBESITY, V29, P682, DOI 10.1038/sj.ijo.0802862; Wick EC, 2006, AM J PHYSIOL-GASTR L, V290, pG959, DOI 10.1152/ajpgi.00154.2005; Winston J, 2007, GASTROENTEROLOGY, V132, P615, DOI 10.1053/j.gastro.2006.11.014; Yiangou Y, 2001, LANCET, V357, P1338, DOI 10.1016/S0140-6736(00)04503-7; Zhang J, 2003, LEUKEMIA RES, V27, P275, DOI 10.1016/S0145-2126(02)00164-9; Zhang ZM, 2007, J NEUROSCI, V27, P2693, DOI 10.1523/JNEUROSCI.4542-06.2007	117	128	135	3	21	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y26, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128			CURR PHARM DESIGN	Curr. Pharm. Design	JAN	2008	14	1					32	41				10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	274XT	WOS:000254036800004	18220816	
J	Bachert, C; Bousquet, J; Canonica, GW; Durham, SR; Klimek, L; Mullol, J; Van Cauwenberge, PB; Van Hammee, G				Bachert, C; Bousquet, J; Canonica, GW; Durham, SR; Klimek, L; Mullol, J; Van Cauwenberge, PB; Van Hammee, G		XPERT Study Grp	Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ARIA; persistent allergic rhinitis; health-related quality of life; levocetirizine; long-term therapy; pharmacoeconomics	HISTAMINE-INDUCED WHEAL; HEALTH-STATUS; DOUBLE-BLIND; CETIRIZINE; ASTHMA; RHINOCONJUNCTIVITIS; QUESTIONNAIRE; EPIDEMIOLOGY; LORATADINE; VOLUNTEERS	Background: Allergic Rhinitis and its Impact on Asthma in collaboration with the World Health Organization initiative reclassified allergic rhinitis, like asthma, by duration and severity. The Xyzal in Persistent Rhinitis Trial is the first large, long-term clinical trial studying patients with persistent rhinitis as defined by Allergic Rhinitis and its Impact on Asthma. Objectives: Two primary objectives were defined: comparison of the Rhinoconjunctivitis Quality of Life Questionnaire overall score and Total 5 Symptoms Score (rhinorrhea, sneezing, nasal congestion, and nasal and ocular pruritus) over a period of 4 weeks between levocetirizine 5 mg and placebo. Secondary endpoints included similar evaluations at 1 week and 3, 4.5, and 6 months, summary scores for a general health status questionnaire (Medical Outcomes Survey Short Form 36), a pharmacoeconomic assessment, comorbidities, and a safety evaluation. Methods: The Xyzal in Persistent Rhinitis Trial was a 6-month double-blind, placebo-controlled, multicenter, multinational trial in 551 patients. Adults with persistent rhinitis sensitized to both grass pollen and house dust mite were randomized to receive levocetirizine 5 mg/d or placebo. Results: A total of 421 patients completed the full study. Levocetirizine significantly improved both the Rhinoconjunctivitis Quality of Life Questionnaire overall score and the Total 5 Symptoms Score from week 1 to 6 months (all P values < .001). Medical Outcomes Survey Short Form 36 summary scores were also improved in the levocetirizine group compared with the placebo group. Treatment cessation because of lack of effect, comorbidities, and overall costs of disease, and comorbidities per working patient per month (E160.27 vs E108.18) were lower in the levocetirizine group. Conclusion: Levocetirizine was shown to improve quality of life and symptoms and to decrease the overall costs of the disease over the 6-month treatment period.	State Univ Ghent Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium	Bachert, C (reprint author), State Univ Ghent Hosp, Dept Otorhinolaryngol, Pintelaan 185, B-9000 Ghent, Belgium.	Claus.Bachert@ugent.be					Barber JA, 2000, STAT MED, V19, P3219, DOI 10.1002/1097-0258(20001215)19:23<3219::AID-SIM623>3.0.CO;2-P; Bellanti JA, 2000, ALLERGY ASTHMA PROC, V21, P367, DOI 10.2500/108854100778249088; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Ciprandi G, 2001, ANN ALLERG ASTHMA IM, V87, P222; Clough GF, 2001, ALLERGY, V56, P985, DOI 10.1034/j.1398-9995.2001.00204.x; Devalia JL, 2001, ALLERGY, V56, P50, DOI 10.1034/j.1398-9995.2001.00726.x; Fireman P, 1997, AM J RHINOL, V11, P95, DOI 10.2500/105065897782537142; Gandon JM, 2002, BRIT J CLIN PHARMACO, V54, P51, DOI 10.1046/j.1365-2125.2002.01611.x; Grant JA, 2002, ANN ALLERG ASTHMA IM, V88, P190; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Juniper E. F., 1998, J ALLERGY CLIN IMM 2, V101, P386; Kremer B, 2001, ALLERGY, V56, P957, DOI 10.1034/j.1398-9995.2001.00919.x; Leynadier F, 2001, Acta Otorhinolaryngol Belg, V55, P305; Leynaert B., 2000, J ALLERGY CLIN IMMUN, V106, P201; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Majani G, 2001, ALLERGY, V56, P313, DOI 10.1034/j.1398-9995.2001.00852.x; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Simons FER, 1996, ALLERGY ASTHMA PROC, V17, P185, DOI 10.2500/108854196778996895; Spector S. L., 1997, J ALLERGY CLIN IMMUN, V99, P773; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338; THOMPSON M, 2002, CLIN EXP ALLERGY, V32, P1; Tripathi A, 2001, PHARMACOECONOMICS, V19, P891, DOI 10.2165/00019053-200119090-00001; Ware J. E., 1993, SF 36 HLTH SURVEY MA	29	128	143	1	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					838	844		10.1016/j.jaci.2004.05.070		7	Allergy; Immunology	Allergy; Immunology	861SO	WOS:000224439100018	15480324	
J	Noakes, PS; Holt, PG; Prescott, SL				Noakes, PS; Holt, PG; Prescott, SL			Maternal smoking in pregnancy alters neonatal cytokine responses	ALLERGY			English	Article						allergens; cord blood; cytokines; pregnancy; smoking	BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA PRODUCTION; CORD-BLOOD; PARENTAL SMOKING; ALLERGIC SENSITIZATION; SERUM IGE; BRONCHIAL RESPONSIVENESS; SUBSEQUENT DEVELOPMENT; RESPIRATORY-FUNCTION; 9-YEAR-OLD CHILDREN	Background: Maternal cigarette smoking in pregnancy is an important, common and avoidable exposure that has been linked with elevated cord blood ( CB) immunoglobulin E levels and subsequent asthma and allergic disease in childhood. Despite this, there is still very little information about the immunological effects of maternal smoking on the fetus. Methods: This aim of this study was to compare cord blood mononuclear cell (CBMC) cytokine responses to allergens [ ovalbumin ( OVA) or house dust mite (HDM)] and mitogens [ concanavalin A ( ConA) or phytohemaglutinen (PHA)] in neonates whose mothers smoked throughout pregnancy ( n = 17) with responses of neonates whose mothers never smoked ( n = 40). Cell cultures were stimulated for 24 h and supernatants collected for cytokine detection by enzyme-linked immunosorbent assay [ interleukin (IL)-13, IL-6, interferon (IFN) gamma and IL-10]. Cell pellets were also collected for cytokine mRNA detection (IL-5, IL-9, IFNgamma). Results: Maternal smoking in pregnancy was associated with significantly higher neonatal T helper type 2 (IL-13 protein) responses to both HDM ( P = 0.01) and OVA ( P = 0.035). These effects remained statistically significant after allowing for confounding factors, including the effects of maternal atopy. Similar trends were also seen for IL-9mRNA, IL-5mRNA and IL-6 responses, although these were not statistically significant. Although IFNgamma mRNA responses to PHA ( P = 0.015) and ConA ( P = 0.025) were lower if mothers smoked in pregnancy, there were no differences in neonatal (Th1) IFNgamma protein responses to allergens or mitogens. Conclusions: These findings indicate that maternal cigarette smoking can modify aspects of fetal immune function and highlight the need for further studies in this area.	Univ Western Australia, Princess Margaret Hosp Children, Sch Paediat & Child Hlth, Perth, WA 6840, Australia; Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA, Australia	Prescott, SL (reprint author), Univ Western Australia, Princess Margaret Hosp Children, Sch Paediat & Child Hlth, GPO Box D184, Perth, WA 6840, Australia.		Holt, Patrick/H-1548-2011; Prescott, Susan/H-5665-2014; Osborne, Nicholas/N-4915-2015	Holt, Patrick/0000-0003-1193-0935; Osborne, Nicholas/0000-0002-6700-2284			ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Ausiello CM, 1999, INFECT IMMUN, V67, P4064; BROWN RW, 1995, PEDIATR PULM, V19, P23, DOI 10.1002/ppul.1950190105; BYRON KA, 1994, CLIN EXP IMMUNOL, V95, P333; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; ElNawawy A, 1996, J TROP PEDIATRICS, V42, P166, DOI 10.1093/tropej/42.3.166; Gabrielsson S, 2001, CLIN EXP IMMUNOL, V126, P390, DOI 10.1046/j.1365-2249.2001.01703.x; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Higgins S, 2002, CURR OPIN OBSTET GYN, V14, P145, DOI 10.1097/00001703-200204000-00007; Hoo AF, 1998, AM J RESP CRIT CARE, V158, P700; KONDO N, 1992, ARCH DIS CHILD, V67, P1003; Kopp MV, 2001, CLIN EXP ALLERGY, V31, P1536, DOI 10.1046/j.1365-2222.2001.01198.x; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Matsuoka T, 2001, PEDIATR INT, V43, P453, DOI 10.1046/j.1442-200X.2001.01445.x; Ohshima Y, 2002, PEDIATR RES, V51, P195, DOI 10.1203/00006450-200202000-00012; OWNBY DR, 1988, J ALLERGY CLIN IMMUN, V82, P634, DOI 10.1016/0091-6749(88)90976-1; Power LL, 2002, J REPROD IMMUNOL, V56, P19, DOI 10.1016/S0165-0378(01)00146-2; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 2001, CLIN EXP ALLERGY, V31, P1653, DOI 10.1046/j.1365-2222.2001.01258.x; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; RONCHETTI R, 1992, ARCH DIS CHILD, V67, P496; RONCHETTI R, 1990, J ALLERGY CLIN IMMUN, V86, P400, DOI 10.1016/S0091-6749(05)80104-6; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; Spinozzi F, 2001, PEDIATR ALLERGY IMMU, V12, P231; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P117; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573; WJST M, 1994, ALLERGY, V49, P766, DOI 10.1111/j.1398-9995.1994.tb02100.x	44	128	134	1	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	OCT	2003	58	10					1053	1058		10.1034/j.1398-9995.2003.00290.x		6	Allergy; Immunology	Allergy; Immunology	723RQ	WOS:000185445700014	14510725	
J	Kips, JC; Anderson, GP; Fredberg, JJ; Herz, U; Inman, MD; Jordana, M; Kemeny, DM; Lotvall, J; Pauwels, RA; Plopper, CG; Schmidt, D; Sterk, PJ; Van Oosterhout, AJM; Vargaftig, BB; Chung, KF				Kips, JC; Anderson, GP; Fredberg, JJ; Herz, U; Inman, MD; Jordana, M; Kemeny, DM; Lotvall, J; Pauwels, RA; Plopper, CG; Schmidt, D; Sterk, PJ; Van Oosterhout, AJM; Vargaftig, BB; Chung, KF			Murine models of asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						airway reactivity; asthma; in vivo models; murine	AIRWAY SMOOTH-MUSCLE; CD4(+) T-CELLS; PASSIVE SENSITIZATION; IGE RESPONSES; ALLERGEN; MICE; RESPONSIVENESS; EXPOSURE; MOUSE; INFLAMMATION	In vivo animal models can offer valuable information on several aspects of asthma pathogenesis and treatment. The mouse is increasingly used in these models, mainly because this species allows for the application in vivo of a broad range of immunological tools, including gene deletion technology. Mice, therefore, seem particularly useful to further elucidate factors influencing the response to inhaled allergens. Examples include: the role of immunoregulatory mechanisms that protect against T-helper cell type 2 cell development; the trafficking of T-cells; and the contribution of the innate immunity. However, as for other animal species, murine models also have limitations. Mice do not spontaneously develop asthma and no model mimics the entire asthma phenotype. Instead, mice should be used to model specific traits of the human disease. The present task force report draws attention to specific aspects of lung structure and function that need to be borne in mind when developing such models and interpreting the results. In particular, efforts should be made to develop models that mimic the lung function changes characteristic of asthma as closely as possible. A large section of this report is therefore devoted to an overview of airway function and its measurement in mice.	State Univ Ghent Hosp, Dept Med Genet, B-9000 Ghent, Belgium	Kips, JC (reprint author), State Univ Ghent Hosp, Dept Med Genet, De Pintelaan 185, B-9000 Ghent, Belgium.		Vargaftig, Bernardo Boris/C-3323-2013	Lotvall, Jan/0000-0001-9195-9249; Chung, Kian Fan/0000-0001-7101-1426			Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241; BRUSASCO V, 1989, J APPL PHYSIOL, V66, P1190; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Duez C, 2000, AM J RESP CRIT CARE, V161, P200; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; Evans MJ, 1999, AM J RESP CELL MOL, V21, P655; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Goldmann WH, 1998, EXP CELL RES, V239, P235, DOI 10.1006/excr.1997.3915; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Held HD, 1999, BRIT J PHARMACOL, V126, P1191, DOI 10.1038/sj.bjp.0702394; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Holmes BJ, 1997, EUR J IMMUNOL, V27, P2657, DOI 10.1002/eji.1830271027; HOLT PG, 1981, IMMUNOLOGY, V42, P409; in 't Veen Johannes C. C. M., 2000, American Journal of Respiratory and Critical Care Medicine, V161, P1902; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; Kapsali T, 2000, J APPL PHYSIOL, V89, P711; Kips JC, 2001, EUR RESPIR J, V17, P499, DOI 10.1183/09031936.01.17304990; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; Lai YL, 2000, J APPL PHYSIOL, V88, P939; LAPORTE JD, 1999, AM J PHYSIOL, V277, P943; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lefort J, 2001, AM J RESP CELL MOL, V24, P345; Lefort J, 1998, J IMMUNOL, V161, P474; London CA, 2000, J IMMUNOL, V164, P265; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; Maksym GN, 2000, J APPL PHYSIOL, V89, P1619; MANZINI S, 1992, BRIT J PHARMACOL, V105, P968; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318; Nagase T, 1996, J APPL PHYSIOL, V81, P2373; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510; PINKERTON KE, 1997, COMPREHENSIVE TOXICO, P23; Plopper CG, 1996, RESP SYSTEM, P135; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schmidt D, 1999, EUR RESPIR J, V14, P315, DOI 10.1034/j.1399-3003.1999.14b13.x; SEDER RA, 1994, J EXP MED, V179, P299, DOI 10.1084/jem.179.1.299; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; STERK PJ, 1986, AM REV RESPIR DIS, V134, P714; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temelkovski J, 1998, THORAX, V53, P849; Tomaki M, 2000, J IMMUNOL, V165, P4040; TOURNOY KG, 2001, J IMMUNOL, V166, P6985; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Van Winkle LS, 1999, AM J RESP CELL MOL, V21, P44; Volgyesi GA, 2000, J APPL PHYSIOL, V89, P413; VUKMANOVICSTEJI.M, 2001, IMMUNOLOGY, V102, P112; Walter DM, 2001, J IMMUNOL, V167, P4668; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; Wang N, 1995, BIOCHEM CELL BIOL, V73, P327; Watson N, 1998, CLIN EXP ALLERGY, V28, P679; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; West JAA, 2000, AM J RESP CELL MOL, V23, P27; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	55	128	139	0	8	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	AUG	2003	22	2					374	382		10.1183/09031936.03.00026403		9	Respiratory System	Respiratory System	713NU	WOS:000184865400033	12952276	
J	Werler, MM; Sheehan, JE; Mitchell, AA				Werler, MM; Sheehan, JE; Mitchell, AA			Maternal medication use and risks of gastroschisis and small intestinal atresia	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						gastroschisis; intestinal atresia; medicine; pregnancy	VASCULAR DISRUPTION; EXPOSURE; DEFECTS	Gastroschisis and small intestinal atresia (SIA) are birth defects that are thought to arise from vascular disruption of fetal mesenteric vessels. Previous studies of gastroschisis have suggested that risk is increased for maternal use of vasoactive over-the-counter medications, including specific analgesics and decongestants. This retrospective study evaluated the relation between maternal use of cough/cold/analgesic medications and risks of gastroschisis and SIA. From 1995 to 1999, the mothers of 206 gastroschisis cases, 126 SIA cases, and 798 controls in the United States and Canada were interviewed about medication use and illnesses. Risks of gastroschisis were elevated for use of aspirin (odds ratio = 2.7, 95% confidence interval: 1.2, 5.9), pseudoephedrine (odds ratio = 1.8, 95% confidence interval: 1.0, 3.2), acetaminophen (odds ratio = 1.5, 95% confidence interval: 1.1, 2.2), and pseudoephedrine combined with acetaminophen (odds ratio = 4.2, 95% confidence interval: 1.9, 9.2). Risks of SIA were increased for any use of pseudoephedrine (odds ratio = 2.0, 95% confidence interval: 1.0, 4.0) and for use of pseudoephedrine in combination with acetaminophen (odds ratio = 3.0, 95% confidence interval: 1.1, 8.0). Reported fever, upper respiratory infection, and allergy were not associated with risks of either defect. These findings add more evidence that aspirin use in early pregnancy increases risk of gastroschisis. Although pseudoephedrine has previously been shown to increase gastroschisis risk, findings of this study raise questions about interactions between medications and possible confounding by underlying illness.	Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, Brookline, MA 02446 USA	Werler, MM (reprint author), Boston Univ, Sch Publ Hlth, Slone Epidemiol Unit, 1371 Beacon St, Brookline, MA 02446 USA.						DRONGOWSKI R A, 1991, Fetal Diagnosis and Therapy, V6, P14; GOLDBAUM G, 1990, TERATOLOGY, V42, P397, DOI 10.1002/tera.1420420408; GOODMAN GA, 1996, PHRM BASIS THERAPEUT; HOYME HE, 1990, PEDIATRICS, V85, P743; HOYME HE, 1981, J PEDIATR-US, V98, P228, DOI 10.1016/S0022-3476(81)80640-3; LOUW JH, 1955, LANCET, V2, P1065; Lynberg M, 1992, TERATOLOGY, V45, P453; MARTIN ML, 1992, TERATOLOGY, V45, P647, DOI 10.1002/tera.1420450609; MartinezFrias ML, 1997, TERATOLOGY, V56, P241, DOI 10.1002/(SICI)1096-9926(199710)56:4<241::AID-TERA2>3.0.CO;2-1; Penman DG, 1998, BRIT J OBSTET GYNAEC, V105, P328, DOI 10.1111/j.1471-0528.1998.tb10095.x; Szabo KT, 1989, CONGENITAL MALFORMAT; Torfs CP, 1996, TERATOLOGY, V54, P84, DOI 10.1002/(SICI)1096-9926(199606)54:2<84::AID-TERA4>3.0.CO;2-4; VANALLEN MI, 1981, PEDIATR ANN, V10, P219; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407	14	128	136	1	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JAN 1	2002	155	1					26	31		10.1093/aje/155.1.26		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	509GC	WOS:000173137100005	11772781	
J	von Berg, A; Filipiak-Pittroff, B; Kraemer, U; Link, E; Bollrath, C; Brockow, I; Koletzko, S; Armin, G; Heinrich, J; Wichmann, HE; Bauer, CP; Reinhardt, D; Berdel, D				von Berg, Andrea; Filipiak-Pittroff, Birgit; Kraemer, Ursula; Link, Elke; Bollrath, Christina; Brockow, Inken; Koletzko, Sibylle; Gruebl, Armin; Heinrich, Joachim; Wichmann, H. -Erich; Bauer, Carl-P.; Reinhardt, Dietrich; Berdel, Dietrich		GINIplus study grp	Preventive effect of hydrolyzed infant formulas persists until age 6 years: Long-term results from the German Infant Nutritional Intervention Study (GINI)	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						birth cohort; long-term allergy prevention; hydrolysates; double-blind randomized trial	FOOD-ALLERGEN AVOIDANCE; DIETARY PREVENTION; CHILDHOOD ASTHMA; SMALL CHILDREN; RECOMMENDATIONS; DISEASE; ATOPY; PROPHYLAXIS; COMMITTEE; EXPOSURE	Background: The long-term effect of nutritional intervention with hydrolyzed infant formulas on allergy development has not been sufficiently evaluated. Objective: We performed a follow-up of the German Infant Nutritional Intervention study until 6 years of life to investigate the long-term allergy-preventive effect of 3 hydrolyzed infant formulas compared with cow's milk formula (CMF) in a randomized, double-blind trial. Methods: Between 1995 and 1998, 2252 newborns with atopic heredity were randomly assigned at birth to receive one of 4 blinded formulas: partially or extensively hydrolyzed whey formula, extensively hydrolyzed casein formula, or CMF as milk substitute for the first 4 months when breast-feeding was insufficient. The cohort was followed from birth until 6 years of age with yearly questionnaires. Outcomes were physician-diagnosed allergic diseases (atopic dermatitis, food allergy, allergic urticaria, asthma, and hay fever/allergic rhinitis). Log-binomial regression modeled with generalized estimation equations was used for the statistical analysis. Results: In the intent-to-treat analysis the relative risk of a physician's diagnosis of allergic manifestation (AM) compared with CMF was 0.82 (95% CI, 0.70-0.96) for partially hydrolyzed whey formula, 0.90 (95% CI, 0.78-1.04) for extensively hydrolyzed whey formula, and 0.80 (95% CI, 0.69-0.93) for extensively hydrolyzed casein formula. The corresponding figures for atopic eczema were 0.79 (95% CI, 0.64-0.97), 0.92 (95% CI, 0.76-1.11), and 0.71 (95% CI, 0.58-0.88), respectively. In the per-protocol analysis all effects were stronger and significant. No significant effect on other AMs was found. Conclusion: The data confirm a long-term allergy-preventive effect of hydrolyzed infant formulas on AM and atopic eczema until 6 years of age.	[von Berg, Andrea; Filipiak-Pittroff, Birgit; Bollrath, Christina; Berdel, Dietrich] Marien Hosp, Dept Pediat, Wesel, Germany; [Kraemer, Ursula; Link, Elke] Univ Dusseldorf, Inst Umweltmed Forschung, Dusseldorf, Germany; [Brockow, Inken; Heinrich, Joachim; Wichmann, H. -Erich] German Res Ctr Environm Hlth GmbH, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Koletzko, Sibylle; Reinhardt, Dietrich] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Brockow, Inken; Gruebl, Armin; Bauer, Carl-P.] Tech Univ Munich, Dept Pediat, D-8000 Munich, Germany; [Bauer, Carl-P.] LVA Oberbayern, Munich, Germany; [Wichmann, H. -Erich] Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany	von Berg, A (reprint author), Marien Hosp, Dept Pediat, Pastor Janssen Str 8-38, Wesel, Germany.	vonberg@marien-hospital-wesel.de					American Academy of Pediatrics Committee on Nutrition, 2000, PEDIATRICS, V106, P236; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Brand PLP, 2007, PEDIAT ALLERG IMM-UK, V18, P475, DOI 10.1111/j.1399-3038.200700541.x; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Diggle P, 2002, ANAL LONGITUDINAL DA; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.01; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Host A, 1999, ARCH DIS CHILD, V81, P80; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; Osborn D. A., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003664; Schoetzau A, 2002, ARCH DIS CHILD, V86, P180, DOI 10.1136/adc.86.3.180; Schoetzau A, 2001, EUR J PEDIATR, V160, P323, DOI 10.1007/PL00008442; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Zeiger RS, 2003, PEDIATRICS, V111, P1662; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	28	127	135	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1442	1447		10.1016/j.jaci.2008.04.021		6	Allergy; Immunology	Allergy; Immunology	313WW	WOS:000256771700021	18539195	
J	Chen, E; Miller, GE				Chen, Edith; Miller, Gregory E.			Stress and inflammation in exacerbations of asthma	BRAIN BEHAVIOR AND IMMUNITY			English	Review						stress; asthma; cytokines; glucocorticoids; autonomic nervous system	PSYCHOLOGICAL STRESS; CHILDHOOD ASTHMA; SOCIOECONOMIC-STATUS; CYTOKINE PROFILES; COMMON COLD; EXPRESSION; CHILDREN; ATOPY; SUSCEPTIBILITY; ADOLESCENTS	In this mini-review, we outline a model depicting the immunologic mechanisms by which psychological stress can exacerbate clinical symptoms in patients with asthma. This model highlights the importance of both social and physical exposures in the exacerbation of asthma symptoms. The basic premise of the model is that psychological stress operates by altering the magnitude of the airway inflammatory response that irritants, allergens, and infections bring about in persons with asthma. The biological pathways for how stress amplifies the immune response to asthma triggers include the hypothalamic-pituitary-adrenal (HPA) axis, the sympathetic-adrenal-medullary (SAM) axis, and the sympathetic (SNS) and parasympathetic (PNS) arms of the autonomic nervous system. Empirical evidence for this model is reviewed, and conclusions and future research directions are discussed. (C) 2007 Elsevier Inc. All rights reserved.	Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	Chen, E (reprint author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	echen@psych.ubc.ca	Osborne, Nicholas/N-4915-2015; Vollrath, Margarete/G-1297-2011	Osborne, Nicholas/0000-0002-6700-2284; 	NHLBI NIH HHS [HL073975, R01 HL073975, R01 HL073975-01A2, R01 HL073975-02, R01 HL073975-03]		Andrulis DP, 1998, ANN INTERN MED, V129, P412; Busse WW, 2001, NEW ENGL J MED, V344, P350; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Cohen S, 1999, PSYCHOSOM MED, V61, P175; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037//0278-6133.17.3.214; Cohen S, 1995, MEASURING STRESS GUI, P3; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; Holtzman MJ, 2002, PHYSIOL REV, V82, P19; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Kang DH, 2001, RES NURS HEALTH, V24, P245, DOI 10.1002/nur.1027; Kang DH, 1997, J INTERF CYTOK RES, V17, P481, DOI 10.1089/jir.1997.17.481; LAZARUS RS, 1984, STRES APPRAISAL COPI; LEHRER PM, 1993, J ASTHMA, V30, P5, DOI 10.3109/02770909309066375; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/rccm.2109065; Marshall GD, 2000, ALLERGY ASTHMA PROC, V21, P241, DOI 10.2500/108854100778248917; MILLER BD, 1994, J AM ACAD CHILD PSY, V33, P1236, DOI 10.1097/00004583-199411000-00004; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Segerstrom SC, 2004, PSYCHOL BULL, V130, P601, DOI 10.1037/0033-2909.130.4.601; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Smith A, 2001, PSYCHONEUROENDOCRINO, V26, P411, DOI 10.1016/S0306-4530(00)00063-9; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; WRIGHT RJ, 2005, J ALLERGY CLIN IMMUN, V116, P130	31	127	132	4	14	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591			BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2007	21	8					993	999		10.1016/j.bbi.2007.03.009		7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	227NV	WOS:000250664300001	17493786	
J	Strickland, DH; Stumbles, PA; Zosky, GR; Subrata, LS; Thomas, JA; Turner, DJ; Sly, PD; Holt, PG				Strickland, Deborah H.; Stumbles, Philip A.; Zosky, Graeme R.; Subrata, Lily S.; Thomas, Jenny A.; Turner, Debra J.; Sly, Peter D.; Holt, Patrick G.			Reversal of airway hyperresponsiveness by induction of airway mucosal CD4(+) CD25(+) regulatory T cells	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							DENDRITIC CELLS; INHALED ANTIGEN; RESPIRATORY-TRACT; ASTHMATIC REACTIONS; IGE RESPONSES; IN-VIVO; ALLERGEN; HYPERREACTIVITY; INFLAMMATION; SUPPRESSION	An important feature of atopic asthma is the T cell-driven late phase reaction involving transient bronchoconstriction followed by development of airways hyperresponsiveness (AHR). Using a unique rat asthma model we recently showed that the onset and duration of the aeroallergen-induced airway mucosal T cell activation response in sensitized rats is determined by the kinetics of functional maturation of resident airway mucosal dendritic cells (AMDCs) mediated by cognate interactions with CD4(+) T helper memory cells. The study below extends these investigations to chronic aeroallergen exposure. We demonstrate that prevention of ensuing cycles of T cell activation and resultant AHR during chronic exposure of sensitized rats to allergen aerosols is mediated by CD4(+) CD25(+) Foxp3(+) LAG3(+) CTLA(+) CD45RC(+) T cells which appear in the airway mucosa and regional lymph nodes within 24 h of initiation of exposure, and inhibit subsequent Th-mediated upregulation of AMDC functions. These cells exhibit potent regulatory T (T reg) cell activity in both in vivo and ex vivo assay systems. The maintenance of protective T reg activity is absolutely dependent on continuing allergen stimulation, as interruption of exposure leads to waning of T reg activity and reemergence of sensitivity to aeroallergen exposure manifesting as AMDC/T cell upregulation and resurgence of T helper 2 cytokine expression, airways eosinophilia, and AHR.	Univ Western Australia, Telethon Inst Child Hlth, Fac Med & Dent, Perth, WA 6008, Australia; Univ Western Australia, Ctr Child Hlth Res, Fac Med & Dent, Perth, WA 6008, Australia	Holt, PG (reprint author), Univ Western Australia, Telethon Inst Child Hlth, Fac Med & Dent, Perth, WA 6008, Australia.	patrick@ichr.uwa.edu.au	Sly, Peter/F-1486-2010; Holt, Patrick/H-1548-2011; Zosky, Graeme/B-2048-2014	Sly, Peter/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935; Zosky, Graeme/0000-0001-9039-0302			Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P597, DOI 10.1111/j.1365-2222.1989.tb02752.x; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Mannie MD, 2004, CELL IMMUNOL, V230, P33, DOI 10.1016/j.cellimm.2004.08.005; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Petak F, 1997, J APPL PHYSIOL, V82, P1479; PLATTSMILLS TAE, 1995, PROGR ALLERGY CLIN I, P90; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Tadokoro CE, 2006, J EXP MED, V203, P505, DOI 10.1084/jem.20050783; Tang QJY, 2005, NAT IMMUNOL, V7, P83; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Van Rijt LS, 2005, CLIN EXP ALLERGY, V35, P1125, DOI 10.1111/j.1365-2222.2005.02321.x; vanHalteren AG, 1997, J IMMUNOL, V159, P3009; von Garnier C, 2005, J IMMUNOL, V175, P1609; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	34	127	140	0	6	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	NOV 27	2006	203	12					2649	2660		10.1084/jem.20060155		12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	109WG	WOS:000242339700008	17088431	
J	Wagers, S; Lundblad, LKA; Ekman, M; Irvin, CG; Bates, JHT				Wagers, S; Lundblad, LKA; Ekman, M; Irvin, CG; Bates, JHT			The allergic mouse model of asthma: normal smooth muscle in an abnormal lung?	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						inflammation; lung impedance; resistance; elastance; mucosal thickening	RESPIRATORY SYSTEM MECHANICS; ACUTE PULMONARY RESPONSE; INTRAVENOUS HISTAMINE; FORCED-OSCILLATIONS; AIRWAY-CLOSURE; VENTILATION DISTRIBUTION; FREQUENCY-DEPENDENCE; ASYMPTOMATIC ASTHMA; TEMPORAL DYNAMICS; TISSUE MECHANICS	Mice with allergically inflamed airways are widely used as animal models of asthma, but their relevance for human asthma is not understood. We, therefore, examined the time course of changes in respiratory input impedance during induced bronchoconstriction in BALB/c mice sensitized and challenged with ovalbumin. Our results indicate that bronchoconstriction in mice is accompanied by complete closure of substantial regions of the lung and that closure increases markedly when the lungs are allergically inflamed. With the aid of an anatomically accurate computational model of the mouse lung, we show that the hyperresponsiveness of mice with allergically inflamed airways can be explained entirely by a thickening of the airway mucosa and an increased propensity of the airways to close, without the involvement of any increase in the degree of airway smooth muscle shortening. This has implications for the pathophysiology of asthma and suggests that at least some types of asthma may benefit from therapies aimed at manipulating surface tension at the air-liquid interface in the lungs.	Univ Vermont, Dept Med, Vermont Lung Ctr, Burlington, VT 05405 USA; Lund Univ, Dept Physiol Sci, SE-22184 Lund, Sweden	Bates, JHT (reprint author), HSRF 228,149 Beaumont Ave, Burlington, VT 05405 USA.	jason.h.bates@uvm.edu			NCRR NIH HHS [P20 RR-15557]; NHLBI NIH HHS [R01 HL-67273]		BALASSY Z, 1995, J APPL PHYSIOL, V78, P875; BATES JHT, 1993, J APPL PHYSIOL, V75, P405; BATES JHT, 1990, J APPL PHYSIOL, V69, P995; BATES JHT, 1994, J APPL PHYSIOL, V76, P616; Bates JHT, 1997, J APPL PHYSIOL, V82, P55; Black LD, 2003, J APPL PHYSIOL, V95, P511, DOI 10.1152/japplphysiol.01114.2002; Brusasco V, 2003, J APPL PHYSIOL, V95, P1305, DOI 10.1152/japplphysiol.00001.2003; CHEN B, 2003, AM J RESP CRIT CARE, V167, pA882; Evans KLJ, 2003, J APPL PHYSIOL, V94, P245, DOI 10.1152/japplphysiol.00593.2002; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752; Fredberg JJ, 1996, J APPL PHYSIOL, V81, P2703; FREDBERG JJ, 1993, J APPL PHYSIOL, V74, P1387; GAVER DP, 1990, J APPL PHYSIOL, V69, P74; Gillis HL, 1999, ANN BIOMED ENG, V27, P14, DOI 10.1114/1.161; Gillis HL, 1999, J APPL PHYSIOL, V86, P2001; Gomes RFM, 2000, J APPL PHYSIOL, V89, P908; Gomes RFM, 2002, RESP PHYSIOL NEUROBI, V130, P317, DOI 10.1016/S0034-5687(02)00017-8; Gunst SJ, 2001, J APPL PHYSIOL, V90, P741; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; HORSFIELD K, 1982, J APPL PHYSIOL, V52, P21; Jensen A, 2001, J APPL PHYSIOL, V91, P506; KAMINSKY DA, 1995, AM J RESP CRIT CARE, V152, P1784; Kaminsky DA, 2003, CHEST, V123, p363S, DOI 10.1378/chest.123.3_suppl.363S; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179; King GG, 1998, AM J RESP CRIT CARE, V158, P1900; Kraft M, 2001, AM J RESP CRIT CARE, V163, P1551; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Lauzon AM, 2000, J APPL PHYSIOL, V89, P2023; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; LUDWIG MS, 1994, J APPL PHYSIOL, V77, P2029; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; Lutchen KR, 1996, J APPL PHYSIOL, V80, P1841; Lutchen KR, 1996, J APPL PHYSIOL, V80, P1696; Lutchen KR, 1997, J APPL PHYSIOL, V83, P1192; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; MACKLEM PT, 1987, CHEST, V91, pS189, DOI 10.1378/chest.91.6.189S; MCCARTHY D, 1973, AM REV RESPIR DIS, V107, P559; MISHIMA M, 1994, J APPL PHYSIOL, V77, P2140; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORENO RH, 1993, J APPL PHYSIOL, V75, P738; NAURECKAS ET, 1994, J APPL PHYSIOL, V76, P1372; OKAZAWA M, 1995, J APPL PHYSIOL, V78, P608; OTIS DR, 1993, J APPL PHYSIOL, V75, P1323; PERUN ML, 1995, J APPL PHYSIOL, V79, P1717; Petak F, 1997, J APPL PHYSIOL, V82, P1479; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; SIEGLER D, 1976, AM REV RESPIR DIS, V114, P123; SIMILOWSKI T, 1991, EUR RESPIR J, V4, P353; Thorpe CW, 1997, J APPL PHYSIOL, V82, P1616; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849	52	127	131	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	JUN	2004	96	6					2019	2027		10.1152/japplphysiol.00924.2003		9	Physiology; Sport Sciences	Physiology; Sport Sciences	819EJ	WOS:000221296600002	14660507	
J	Mapp, CE; Fryer, AA; De Marzo, N; Pozzato, V; Padoan, M; Boschetto, P; Strange, RC; Hemmingsen, A; Spiteri, MA				Mapp, CE; Fryer, AA; De Marzo, N; Pozzato, V; Padoan, M; Boschetto, P; Strange, RC; Hemmingsen, A; Spiteri, MA			Glutathione S-transferase GSTP1 is a susceptibility gene for occupational asthma induced by isocyanates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						isocyanates; occupational asthma; airway hyperresponsiveness; genetic markers	TOLUENE DIISOCYANATE TDI; SENSITIZED SUBJECTS; OXIDATIVE STRESS; INFLAMMATION; ASSOCIATION; HYPERRESPONSIVENESS; IDENTIFICATION; LOCALIZATION; POLYMORPHISM; RESPONSES	Background: Polymorphism at the pi class glutathione-S-transferase locus (GSTP1) is associated with allergen-induced asthma and related phenotypes. Objective: We sought to determine whether GSTP1 polymorphism influences susceptibility to asthma induced by toluene diisocyanate (TDI). Methods: The role of GSTP1 was assessed in 131 workers exposed to TDI, 92 with TDI-induced asthma and 39 asymptomatic subjects. The phenotype of the disease was characterized by using detailed clinical history, lung volumes, airway responsiveness to methacholine, and airway responsiveness to TDI. GST genotypes were determined by using PCR-based assays. Results: In patients exposed to TDI for 10 or more years, the frequency of the GSTP1 Val/Val genotype was lower in subjects who had asthma (odds ratio, 0.23; 95% confidence interval, 0.05-1.13; P = .074). Similarly, the frequency of this genotype was significantly lower in subjects with evidence of moderate-to-severe airway hyperresponsiveness to methacholine compared with the frequency in subjects with normal or mild hyperresponsiveness (P = .033). Conclusion: These data suggest that homozygosity for the GSTP1*Val allele confers protection against TDI-induced asthma and airway hyperresponsiveness. This view is supported by the finding that the protective effect increases in proportion to the duration of exposure to TDI.	Univ Ferrara, Dept Clin & Expt Med, Sect Occupat Med, I-44100 Ferrara, Italy; N Staffordshire Hosp Trust, Stoke On Trent, Staffs, England; Keele Univ, Stoke On Trent, Staffs, England; Univ Padua, Dept Environm Med & Publ Hlth, Sect Occupat Med, Padua, Italy	Mapp, CE (reprint author), Dipartimento Med Clin & Sperimentale, Sez Igiene & Med Lavoro, Via Fossato Mortara 64-B, I-44100 Ferrara, Italy.			Fryer, Anthony/0000-0001-8678-0404			ANTTILA S, 1993, CANCER RES, V53, P5643; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; *COMM COMM EUR, 1971, TABL REF EX SPIR; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hemmingsen A, 2001, RESPIR RES, V2, P250; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P438; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MAPP CE, 1986, EUR J RESPIR DIS, V69, P276; Mapp CE, 1997, AM J RESP CRIT CARE, V156, pS139; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; MAPP CE, 1988, EUR RESPIR J, V1, P273; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; MAPP CE, 1999, EUROPEAN RESP MONOGR, V11, P255; Mattey DL, 1999, ANN RHEUM DIS, V58, P164, DOI 10.1136/ard.58.3.164; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Postma DS, 2000, AM J RESP CRIT CARE, V162, pS118; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; ROWE D, 1997, BIOCHEM J, V235, P481; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; ZOCCA E, 1990, J APPL PHYSIOL, V68, P1576	29	127	133	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					867	872		10.1067/mai.2002.123234		6	Allergy; Immunology	Allergy; Immunology	553QW	WOS:000175687800019	11994713	
J	von Mutius, E; Pearce, N; Beasley, R; Cheng, S; von Ehrenstein, O; Bjorksten, B; Weiland, S				von Mutius, E; Pearce, N; Beasley, R; Cheng, S; von Ehrenstein, O; Bjorksten, B; Weiland, S		ISAAC Steering Comm	International patterns of tuberculosis and the prevalence of symptoms of asthma, rhinitis, and eczema	THORAX			English	Article						tuberculosis; atopy; asthma	CHILDHOOD ISAAC; IMMUNE-RESPONSE; CHILDREN; ALLERGIES; INFECTION; ASSOCIATION; WORLDWIDE; ATOPY; MICE	Background-An ecological analysis was conducted of the relationship between tuberculosis notification rates and the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema in 85 centres from 23 countries in which standardised data are available. These essentially comprised countries in Europe as well as the USA, Canada, Australia, and New Zealand. Methods-Tuberculosis notification rates were obtained from the World Health Organization. Data on the prevalence of symptoms of asthma, rhinitis, and eczema in 235 477 children aged 13-14 years were based on the responses to the written and video questionnaires from the International Study of Asthma and Allergies in Childhood (ISAAC). The analysis was adjusted for gross national product (GNP) as an estimate of the level of affluence. Results-Tuberculosis notification rates were significantly inversely associated with the lifetime prevalence of wheeze and asthma and the 12 month period prevalence of wheeze at rest as assessed by the video questionnaire. An increase in the tuberculosis notification rates of 25 per 100 000 was associated with an absolute decrease in the prevalence of wheeze ever of 4.7%. Symptoms of allergic rhinoconjunctivitis in the past 12 months were inversely associated with tuberculosis notification rates, but there were no other significant associations with other ISAAC questions on allergic rhinoconjunctivitis or atopic eczema. Conclusions-These findings are consistent with recent experimental evidence which suggests that exposure to Mycobacterium tuberculosis may reduce the risk of developing asthma.	Univ Munich, Childrens Hosp, Klinikum Innenstadt, D-8000 Munich, Germany; Univ Otago, Wellington Sch Med, Wellington, New Zealand; Linkoping Univ Hosp, S-58185 Linkoping, Sweden; Univ Munster, Inst Epidemiol & Social Med, D-4400 Munster, Germany	von Mutius, E (reprint author), Klinikum Innenstadt, Haunersche Kinderklin, Linwurmstr 4, D-80337 Munich, Germany.		Clayton, Tadd/B-7914-2009; Ellwood, Philippa/G-7555-2015	Ellwood, Philippa/0000-0002-1994-4023; Beasley, Richard/0000-0003-0337-406X			Anderson HR, 1997, CIBA F SYMP, V206, P190; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Cauthen G. M., 1988, ANN RISK TUBERCULOUS; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; COPELAND KT, 1977, AM J EPIDEMIOL, V105, P488; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; HILMAN BC, 1993, PEDIAT RESP DIS DIAN, P311; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Morgenstern H, 1998, MODERN EPIDEMIOLOGY, P459; NOVMARK A, 1975, ACTA DERM-VENEREOL, V55, P181; ORME IM, 1993, J INFECT DIS, V167, P1481; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, V2nd, P115; Schluger NW, 1998, AM J RESP CRIT CARE, V157, P679; SHAW R, 1995, INT J EPIDEMIOL, V24, P597, DOI 10.1093/ije/24.3.597; SHAW RA, 1992, CLIN EXP ALLERGY, V22, P562; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; STYBLO K, 1981, Bulletin of the International Union Against Tuberculosis, V56, P118; United Nations Development Programme, 1994, HUM DEV REP; Wang CC, 1998, IMMUNOLOGY, V93, P307; World Health Organization, 1996, TUB GLOB EM CAS NOT; WILLIAMS H, 2000, IN PRESS J ALLERGY C; Woolcock AJ, 1997, CIBA F SYMP, V206, P122	31	127	130	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2000	55	6					449	453		10.1136/thorax.55.6.449		5	Respiratory System	Respiratory System	319WP	WOS:000087367100004	10817790	
J	Thorburn, AN; Macia, L; Mackay, CR				Thorburn, Alison N.; Macia, Laurence; Mackay, Charles R.			Diet, Metabolites, and "Western-Lifestyle" Inflammatory Diseases	IMMUNITY			English	Review							CHAIN FATTY-ACIDS; REGULATORY T-CELLS; PROTEIN-COUPLED RECEPTOR; GERMINATED BARLEY FOODSTUFF; GUT MICROBIOTA; ULCERATIVE-COLITIS; IMMUNE-RESPONSES; BOWEL-DISEASE; DEACETYLASE INHIBITION; AIRWAY INFLAMMATION	One explanation for the increased incidence of allergies, asthma, and even some autoimmune diseases has been the hygiene hypothesis. However, recent studies also highlight an important role for diet and bacterial metabolites in controlling various immune pathways, including gut and immune homeostasis, regulatory T cell biology, and inflammation. Dietary-related metabolites engage "metabolite-sensing'' G-protein-coupled receptors, such as GPR43, GPR41, GPR109A, GPR120, and GPR35. These receptors are expressed on immune cells and some gut epithelial cells and generally mediate a direct anti-inflammatory effect. Insufficient intake of "healthy foodstuffs'' adversely affects the production of bacterial metabolites. These metabolites and those derived directly from food drive beneficial downstream effects on immune pathways. We propose that insufficient exposure to dietary and bacterial metabolites might underlie the development of inflammatory disorders in Western countries. This review highlights what is currently known about diet, metabolites, and their associated immune pathways in relation to the development of inflammatory disease.	[Thorburn, Alison N.; Macia, Laurence; Mackay, Charles R.] Monash Univ, Dept Immunol, Clayton, Vic 3800, Australia	Mackay, CR (reprint author), Monash Univ, Dept Immunol, Clayton, Vic 3800, Australia.	charles.mackay@monash.edu	Mackay, Charles/A-9673-2008	Mackay, Charles/0000-0002-6338-7340	Australian National Health and Medical Research Council; Australian Research Council; CRC for Asthma and Airways	We have been supported by Australian National Health and Medical Research Council, the Australian Research Council, and the CRC for Asthma and Airways.	Aagaard K., 2014, SCI TRANSL MED, V6, DOI [10.1126/scitranslmed.3008599, DOI 10.1126/SCITRANSLMED.3008599]; Ahern PP, 2014, IMMUNITY, V40, P815, DOI 10.1016/j.immuni.2014.05.012; Alenghat T, 2013, NATURE, V504, P153, DOI 10.1038/nature12687; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Berthon BS, 2013, RESPIROLOGY, V18, P447, DOI 10.1111/resp.12015; Boulet LP, 2013, CLIN EXP ALLERGY, V43, P8, DOI 10.1111/j.1365-2222.2012.04040.x; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Chang PV, 2014, P NATL ACAD SCI USA, V111, P2247, DOI 10.1073/pnas.1322269111; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Clemente JC, 2012, CELL, V148, P1258, DOI 10.1016/j.cell.2012.01.035; Devereux G, 2006, NAT REV IMMUNOL, V6, P869, DOI 10.1038/nri1958; Digby JE, 2012, ARTERIOSCL THROM VAS, V32, P669, DOI 10.1161/ATVBAHA.111.241836; Digby JE, 2010, ATHEROSCLEROSIS, V209, P89, DOI 10.1016/j.atherosclerosis.2009.08.045; Dixon Anne E, 2010, Proc Am Thorac Soc, V7, P325, DOI 10.1513/pats.200903-013ST; Dorrestein PC, 2014, IMMUNITY, V40, P824, DOI 10.1016/j.immuni.2014.05.015; Dupaul-Chicoine J, 2010, IMMUNITY, V32, P367, DOI 10.1016/j.immuni.2010.02.012; DYERBERG J, 1979, LANCET, V2, P433; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Elinav E, 2011, CELL, V145, P745, DOI 10.1016/j.cell.2011.04.022; Estruch R, 2013, NEW ENGL J MED, V368, P1279, DOI 10.1056/NEJMoa1200303; Fujita T, 2011, J INVEST DERMATOL, V131, P1660, DOI 10.1038/jid.2011.123; Fukuda S, 2011, NATURE, V469, P543, DOI 10.1038/nature09646; Furusawa Y, 2013, NATURE, V504, P446, DOI 10.1038/nature12721; Gambhir D, 2012, INVEST OPHTH VIS SCI, V53, P2208, DOI 10.1167/iovs.11-8447; Gao H, 2004, MOL CELL, V14, P303, DOI 10.1016/S1097-2765(04)00216-3; Geuking MB, 2011, IMMUNITY, V34, P794, DOI 10.1016/j.immuni.2011.03.021; GEUKING MB, 2013, TREG CELL RES, V23, P1339; HARIG JM, 1989, NEW ENGL J MED, V320, P23, DOI 10.1056/NEJM198901053200105; Hashimoto T, 2012, NATURE, V487, P477, DOI 10.1038/nature11228; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Huttenhower C, 2014, IMMUNITY, V40, P843, DOI 10.1016/j.immuni.2014.05.013; Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798; Ishikawa T, 2009, BIOSCI BIOTECH BIOCH, V73, P677, DOI 10.1271/bbb.80733; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jensen ME, 2012, CURR OPIN ALLERGY CL, V12, P186, DOI 10.1097/ACI.0b013e3283508df5; Jostins L, 2012, NATURE, V491, P119, DOI 10.1038/nature11582; Kanauchi O, 2002, J GASTROENTEROL, V37, P67; Kanauchi O, 2001, J GASTROEN HEPATOL, V16, P160, DOI 10.1046/j.1440-1746.2001.02427.x; Kau AL, 2011, NATURE, V474, P327, DOI 10.1038/nature10213; Kimura I, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2852; King DE, 2012, J ACAD NUTR DIET, V112, P642, DOI 10.1016/j.jand.2012.01.019; King NJC, 2007, INT J BIOCHEM CELL B, V39, P2167, DOI 10.1016/j.biocel.2007.01.004; Le Chatelier E, 2013, NATURE, V500, P541, DOI 10.1038/nature12506; Lepage P, 2011, GASTROENTEROLOGY, V141, P227, DOI 10.1053/j.gastro.2011.04.011; Li Ying, 2011, Cell, V147, P629, DOI 10.1016/j.cell.2011.09.025; Lukasova M, 2011, J CLIN INVEST, V121, P1163, DOI 10.1172/JCI41651; Macia L, 2012, IMMUNOL REV, V245, P164, DOI 10.1111/j.1600-065X.2011.01080.x; Manichanh C, 2006, GUT, V55, P205, DOI 10.1136/gut.2005.073817; Maslowski KM, 2011, NAT IMMUNOL, V12, P5, DOI 10.1038/ni0111-5; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Munoz-Planillo R, 2013, IMMUNITY, V38, P1142, DOI 10.1016/j.immuni.2013.05.016; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Normand S, 2011, P NATL ACAD SCI USA, V108, P9601, DOI 10.1073/pnas.1100981108; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Ou JH, 2013, AM J CLIN NUTR, V98, P111, DOI 10.3945/ajcn.112.056689; Park Y, 2011, ARCH INTERN MED, V171, P1061, DOI 10.1001/archinternmed.2011.18; Peterson DA, 2007, CELL HOST MICROBE, V2, P328, DOI 10.1016/j.chom.2007.09.013; Rook Graham A W, 2003, Curr Opin Allergy Clin Immunol, V3, P337, DOI 10.1097/00130832-200310000-00003; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Sapieha P, 2008, NAT MED, V14, P1067, DOI 10.1038/nm.1873; Scheppach W, 1996, DIGEST DIS SCI, V41, P2254, DOI 10.1007/BF02071409; Shan MM, 2013, SCIENCE, V342, P447, DOI 10.1126/science.1237910; Simopoulos AP, 2002, J AM COLL NUTR, V21, P495; Sin DD, 2008, THORAX, V63, P1018, DOI 10.1136/thx.2007.086819; Singh N, 2014, IMMUNITY, V40, P128, DOI 10.1016/j.immuni.2013.12.007; Smith PM, 2013, SCIENCE, V341, P569, DOI 10.1126/science.1241165; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, THORAX S1, V55, pS2; Suzuki M, 2013, J BIOL CHEM, V288, P10684, DOI 10.1074/jbc.M112.420042; Tan J, 2014, ADV IMMUNOL, V121, P91, DOI 10.1016/B978-0-12-800100-4.00003-9; Tao R, 2007, NAT MED, V13, P1299, DOI 10.1038/nm1652; Thangaraju M, 2009, CANCER RES, V69, P2826, DOI 10.1158/0008-5472.CAN-08-4466; Toma I, 2008, J CLIN INVEST, V118, P2526, DOI 10.1172/JCI33293; Topping DL, 2001, PHYSIOL REV, V81, P1031; TREEM WR, 1994, J PEDIATR GASTR NUTR, V18, P159, DOI 10.1097/00005176-199402000-00007; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Vaarala O, 2008, DIABETES, V57, P2555, DOI 10.2337/db08-0331; Veldhoen M, 2012, NAT REV IMMUNOL, V12, P696, DOI 10.1038/nri3299; Vinolo MAR, 2011, NUTRIENTS, V3, P858, DOI 10.3390/nu3100858; Vogt MC, 2014, CELL, V156, P495, DOI 10.1016/j.cell.2014.01.008; Wang LQ, 2009, NAT REV DRUG DISCOV, V8, P969, DOI 10.1038/nrd3031; Willemsen LEM, 2003, GUT, V52, P1442, DOI 10.1136/gut.52.10.1442; Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026; Wood LG, 2012, AM J CLIN NUTR, V96, P534, DOI 10.3945/ajcn.111.032623; Wood LG, 2011, J ALLERGY CLIN IMMUN, V127, P1133, DOI 10.1016/j.jaci.2011.01.036; Wrzosek L, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-61; Xiong YM, 2004, P NATL ACAD SCI USA, V101, P1045, DOI 10.1073/pnas.2637002100; Yan YQ, 2013, IMMUNITY, V38, P1154, DOI 10.1016/j.immuni.2013.05.015; Zaki MH, 2010, IMMUNITY, V32, P379, DOI 10.1016/j.immuni.2010.03.003; Zandi-Nejad K, 2013, FASEB J, V27, P4366, DOI 10.1096/fj.12-223933; Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003	97	126	128	13	86	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613	1097-4180		IMMUNITY	Immunity	JUN 19	2014	40	6					833	842		10.1016/j.immuni.2014.05.014		10	Immunology	Immunology	AO6DT	WOS:000341440200003	24950203	
J	Edwards, TM; Myers, JP				Edwards, Thea M.; Myers, John Peterson			Environmental exposures and gene regulation in disease etiology	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						chemicals; disease risk; DNA methylation; drug resistance; endocrine disruption; environment; fetal origins of adult disease; gene expression; gene regulation; susceptibility	DIESEL EXHAUST PARTICLES; ACTIVATOR MESSENGER-RNA; AIRWAY EPITHELIAL-CELLS; PRIMORDIAL GERM-CELLS; SMOOTH-MUSCLE-CELLS; PARKINSONS-DISEASE; PROSTATE-CANCER; ALPHA-SYNUCLEIN; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; ESCHERICHIA-COLI	OBJECTIVE: Health or disease is shaped for all individuals by interactions between their genes and environment. Exactly how the environment changes gene expression and how this can lead to disease are being explored in a fruitful new approach to environmental health research, representative studies of which are reviewed here. DATA SOURCES: We searched Web of Science and references of relevant publications to understand the diversity of gene regulatory mechanisms affected by environmental exposures with disease implications. DATA SYNTHESIS: Pharmaceuticals, pesticides, air pollutants, industrial chemicals, heavy metals, hormones, nutrition, and behavior can change gene expression through a broad array of gene regulatory mechanisms. Mechanisms include regulation of gene translocation, histone modifications, DNA methylation, DNA repair, transcription, RNA stability, alternative RNA splicing, protein degradation, gene copy number, and transposon activation. Furthermore, chemically induced changes in gene regulation are associated with serious and complex human diseases, including cancer, diabetes and obesity, infertility, respiratory diseases, allergies, and neurodegenerative disorders such as Parkinson and Alzheimer diseases. One of the best-studied areas of gene regulation is epigenetics, especially DNA methylation. Our examples of environmentally induced changes in DNA methylation are presented in the context of early development, when methylation patterns are initially laid down. This approach highlights the potential role for altered DNA methylation in fetal origins of adult disease and inheritance of acquired genetic change. CONCLUSIONS: The reviewed studies indicate that genetic predisposition for disease is best predicted in the context of environmental exposures. Second, the genetic mechanisms investigated in these studies offer new avenues for risk assessment research. Finally, we are likely to witness dramatic improvements in human health, and reductions in medical costs, if environmental pollution is decreased.	Univ Florida, Dept Zool, Gainesville, FL 32611 USA; Environm Hlth Sci, Charlottesville, VA USA	Edwards, TM (reprint author), Univ Florida, Dept Zool, Gainesville, FL 32611 USA.	tedwards@zoo.ufl.edu		Edwards, Thea/0000-0002-6176-2872			Akesson AA, 2005, ENVIRON HEALTH PERSP, V113, P1627, DOI 10.1289/ehp.8033; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Baba M, 1998, AM J PATHOL, V152, P879; Baccarelli A, 2006, CARCINOGENESIS, V27, P2001, DOI 10.1093/carcin/bgl011; Bao BY, 2006, CARCINOGENESIS, V27, P32, DOI 10.1093/carcin/bgi170; BENJAMIN RC, 1980, J BIOL CHEM, V255, P502; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Boland S, 2000, AM J PHYSIOL-LUNG C, V278, pL25; Bolognesi C, 2003, MUTAT RES-REV MUTAT, V543, P251, DOI 10.1016/S1383-5742(03)00015-2; BROOKMAN JJ, 1992, DEVELOPMENT, V116, P1185; BROWN AWA, 1986, J AM MOSQUITO CONTR, V2, P123; CAIRNS J, 1991, GENETICS, V128, P695; *CDCP, 2005, 050570 NAT CTR ENV H; CervantesLaurean D, 1996, J BIOL CHEM, V271, P10461; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Cheng RYS, 2004, MOL CARCINOGEN, V40, P1, DOI 10.1002/mc.20022; Cheng RYS, 2002, ENVIRON HEALTH PERSP, V110, P801; COPUR S, 1995, BIOCHEM PHARMACOL, V49, P1419, DOI 10.1016/0006-2952(95)00067-A; Day JK, 2002, J NUTR, V132, p2419S; De Petro G, 1998, CANCER RES, V58, P2234; Diefenbach J, 2005, CELL MOL LIFE SCI, V62, P721, DOI 10.1007/s00018-004-4503-3; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; Dolinoy DC, 2006, ENVIRON HEALTH PERSP, V114, P567, DOI 10.1289/ehp.8700; Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3; Edwards TM, 2007, ENVIRON HEALTH PERSP, V115, P1264, DOI 10.1289/ehp.9951; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; El-Sawy M, 2005, J MOL BIOL, V354, P246, DOI 10.1016/j.jmb.2005.09.050; Etoh T, 2004, AM J PATHOL, V164, P689, DOI 10.1016/S0002-9440(10)63156-2; FLEMING L, 1994, ANN NEUROL, V36, P100, DOI 10.1002/ana.410360119; FOSTER PL, 1994, GENETICS, V138, P253; GAIDO KW, 1995, TOXICOL APPL PHARM, V133, P34, DOI 10.1006/taap.1995.1124; Gao Z, 2003, J DRUG TARGET, V11, P87, DOI 10.1080/1061186031000138623; Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598; Guerrero-Bosagna C, 2005, EVOL DEV, V7, P341, DOI 10.1111/j.1525-142X.2005.05033.x; GUGLIUCCI A, 1995, BIOCHEM BIOPH RES CO, V212, P56, DOI 10.1006/bbrc.1995.1935; Hajkova P, 2002, MECH DEVELOP, V117, P15, DOI 10.1016/S0925-4773(02)00181-8; Hastings PJ, 2004, PLOS BIOL, V2, P2220, DOI 10.1371/journal.pbio.0020399; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HENRY WM, 1980, ENVIRON SCI TECHNOL, V14, P450, DOI 10.1021/es60164a010; Hersh MN, 2004, RES MICROBIOL, V155, P352, DOI 10.1016/j.resmic.2004.01.020; Jirajaroenrat K, 2001, INSECT BIOCHEM MOLEC, V31, P867, DOI 10.1016/S0965-1748(01)00032-7; Jordan IK, 2003, TRENDS GENET, V19, P68, DOI 10.1016/S0168-9525(02)00006-9; Kim HT, 1998, AM J MED GENET, V80, P391, DOI 10.1002/(SICI)1096-8628(19981204)80:4<391::AID-AJMG16>3.0.CO;2-H; Koivisto P, 1997, CANCER RES, V57, P314; Kraunz KS, 2006, INT J CANCER, V119, P1553, DOI 10.1002/ijc.22013; Kurata Y, 2003, JPN J VET RES, V50, P175; Lee MH, 2004, TOXICOL APPL PHARM, V197, P19, DOI 10.1016/j.taap.2004.02.003; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Li SF, 1997, CANCER RES, V57, P4356; LI SF, 2003, EPIGENETICS CANC PRE, P191; Lilienthal H, 2000, TOXICOL SCI, V57, P292, DOI 10.1093/toxsci/57.2.292; Lu KP, 2000, MUTAT RES-FUND MOL M, V454, P35, DOI 10.1016/S0027-5107(00)00095-6; Lu KP, 1998, BIOCHEM BIOPH RES CO, V253, P828, DOI 10.1006/bbrc.1998.9866; Marano F, 2002, CELL BIOL TOXICOL, V18, P315, DOI 10.1023/A:1019548517877; Meredith GE, 2004, PARKINSONISM RELAT D, V10, P191, DOI 10.1016/j.parkreldis.2004.01.001; Minegishi T, 2003, MOL CELL ENDOCRINOL, V202, P123, DOI 10.1016/S0303-7207(03)00073-X; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Morales JF, 2002, MUTAGENESIS, V17, P193, DOI 10.1093/mutage/17.3.193; Mytilineou C, 2004, J NEURAL TRANSM, V111, P1237, DOI 10.1007/s00702-004-0167-2; Newbold RR, 2000, CARCINOGENESIS, V21, P1355, DOI 10.1093/carcin/21.7.1355; Newbold RR, 1998, CARCINOGENESIS, V19, P1655, DOI 10.1093/carcin/19.9.1655; Palus J, 2003, MUTAT RES-GEN TOX EN, V540, P19, DOI 10.1016/S1383-5718(03)00167-0; PENTECOST BT, 1987, J BIOL CHEM, V262, P10134; Pogribny IP, 2004, MUTAT RES-FUND MOL M, V548, P53, DOI 10.1016/j.mrfmmm.2003.12.014; PRODY CA, 1989, P NATL ACAD SCI USA, V86, P690, DOI 10.1073/pnas.86.2.690; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Richardson B, 2003, AGEING RES REV, V2, P245, DOI 10.1016/S1568-1637(03)00010-2; Ritchie JM, 2005, ENVIRON RES, V98, P104, DOI 10.1016/j.envres.2004.05.013; Ritchie JM, 2003, J OCCUP ENVIRON MED, V45, P692, DOI 10.1097/01.jom.0000071510.96740.0b; Roling JA, 2004, MAR ENVIRON RES, V57, P377, DOI 10.1016/j.marenvres.2003.11.001; Rouleau M, 2004, J CELL SCI, V117, P815, DOI 10.1242/jcs.01080; Roulland S, 2004, CANCER RES, V64, P2264, DOI 10.1158/0008-5472.CAN-03-3604; Ruden DM, 2005, HUM MOL GENET, V14, pR149, DOI 10.1093/hmg/ddi103; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Samet JM, 2002, ENVIRON HEALTH PERSP, V110, P985; SCHIFF R, 1991, GENE DEV, V5, P521, DOI 10.1101/gad.5.4.521; Schroeder JC, 2001, EPIDEMIOLOGY, V12, P701, DOI 10.1097/00001648-200111000-00020; Schwartz GG, 2003, DIABETES CARE, V26, P468, DOI 10.2337/diacare.26.2.468; Shiao YH, 2005, TOXICOL APPL PHARM, V205, P290, DOI 10.1016/j.taap.2004.10.017; Shimba S, 2000, BIOCHEM BIOPH RES CO, V272, P441, DOI 10.1006/bbrc.2000.2789; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Sinibaldi-Vallebona P, 2006, GENE CHROMOSOME CANC, V45, P1, DOI 10.1002/gcc.20266; Smith FM, 2006, CYTOGENET GENOME RES, V113, P279, DOI 10.1159/000090843; Smith MT, 2005, TOXICOL APPL PHARM, V206, P237, DOI 10.1016/j.taap.2004.11.026; Stribinskis V, 2006, CANCER RES, V66, P2616, DOI 10.1158/0008-5472.CAN-05-3478; Sun F, 2005, J PHARMACOL EXP THER, V315, P69, DOI 10.1124/jpet.105.084632; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; TAM PPL, 1994, DEVELOPMENT, V120, P2925; TAN SS, 1993, NAT GENET, V3, P170, DOI 10.1038/ng0293-170; TANIGUCHI T, 1995, P NATL ACAD SCI USA, V92, P2159, DOI 10.1073/pnas.92.6.2159; TRELOGAN SA, 1995, P NATL ACAD SCI USA, V92, P1520, DOI 10.1073/pnas.92.5.1520; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; TURUSOV VS, 1992, INT J CANCER, V50, P131, DOI 10.1002/ijc.2910500126; VANGURP RJHLM, 1994, JNCI-J NATL CANCER I, V86, P1070, DOI 10.1093/jnci/86.14.1070; Verschure PJ, 2004, BIOL CELL, V96, P569, DOI 10.1016/j.biolcel.2004.07.001; Virag L, 2002, PHARMACOL REV, V54, P375, DOI 10.1124/pr.54.3.375; Vivacqua A, 2003, ENDOCRINE, V22, P275, DOI 10.1385/ENDO:22:3:275; Walker BE, 1997, CARCINOGENESIS, V18, P791, DOI 10.1093/carcin/18.4.791; Weaver ICG, 2005, J NEUROSCI, V25, P11045, DOI 10.1523/JNEUROSCI.3652-05.2005; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; WILKS A, 1984, NUCLEIC ACIDS RES, V12, P1163, DOI 10.1093/nar/12.2.1163; Wu GY, 2004, J NUTR, V134, P2169; Wu Q, 2004, BIOL REPROD, V70, P1790, DOI 10.1095/biolreprod.103.025387; Xu Q, 2005, PEST MANAG SCI, V61, P1096, DOI 10.1002/ps.1090; Yang JM, 2003, REPROD TOXICOL, V17, P553, DOI 10.1016/S0890-6238(03)00100-X; Yu W, 1999, TOXICOL APPL PHARM, V158, P161, DOI 10.1006/taap.1999.8692	110	126	134	3	57	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2007	115	9					1264	1270		10.1289/ehp.9951		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	206RM	WOS:000249200600020	17805414	
J	Ege, MJ; Frei, R; Bieli, C; Schram-Bijkerk, D; Waser, M; Benz, MR; Weiss, G; Nyberg, F; van Hage, M; Pershagen, G; Brunekreef, B; Riedler, J; Lauener, R; Braun-Fahrlander, C; von Mutius, E				Ege, Markus Johannes; Frei, Remo; Bieli, Christian; Schram-Bijkerk, Dieneke; Waser, Marco; Benz, Marcus R.; Weiss, Gertraud; Nyberg, Fredrik; van Hage, Marianne; Pershagen, Goeran; Brunekreef, Bert; Riedler, Josef; Lauener, Roger; Braun-Fahrlaender, Charlotte; von Mutius, Erika		PARSIFAL Study team	Not all farming environments protect against the development of asthma and wheeze in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheeze; atopic sensitization; farming; microbial components	SCHOOL-AGE-CHILDREN; ALLERGIC DISEASES; FARMERS CHILDREN; HAY-FEVER; ATOPIC SENSITIZATION; LIFE-STYLE; HOUSE DUST; PREVALENCE; EXPOSURE; DEOXYNIVALENOL	Background: In recent years, studies have shown a protective effect of being raised in a farm environment on the development of hay fever and atopic sensitization. Inconsistent data on the relation of farming to asthma and wheeze have raised some doubt about a true protective effect. Objective: We sought to study the differential effects of farm-associated exposures on specific asthma-related health outcomes. Methods: The cross-sectional Prevention of Allergy Risk Factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle study included 8263 school-age children from rural areas in 5 European countries. Information on farm-related exposures and health outcomes was obtained by using questionnaires. In subsamples allergen-specific IgE and RNA expression of CD14 and Toll-like receptor genes were measured, and dust from children's mattresses was evaluated for microbial components. Results: Inverse relations with a diagnosis of asthma were found for pig keeping (odds ratio [OR], 0.57; 95% CI, 0.38-0.86), farm milk consumption (OR, 0.77; 95% CI, 0.60-0.99), frequent stay in animal sheds (OR, 0.71; 95% CI, 0.54-0.95), child's involvement in haying (OR, 0.56; 95% CI, 0.38-0.81), and use of silage (OR, 0.55; 95% CI, 0.31-0.98; for nonatopic asthma) and in Germany for agriculture (OR, 0.34; 95% CI, 0.22-0.53). Protective factors were related with higher expression levels of genes of the innate immunity. Potential risk factors for asthma and wheeze were also identified in the farm milieu. Levels of endotoxin and extracellular polysaccharides were related to the health outcomes independently of the farm exposures. Conclusions: The protective effect of being raised in a farm environment was ascribed to distinct exposures. Clinical implications: The development of atopic sensitization and atopic and nonatopic asthma is most likely determined by different environmental factors, possibly reflecting distinct pathomechanisms.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Utrecht, Med Ctr, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, NL-3508 TC Utrecht, Netherlands; Childrens Hosp, Salzburg, Austria; AstraZeneca R&D, Molndal, Sweden; Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Childrens Hosp, Stockholm, Sweden	Ege, MJ (reprint author), Univ Munich, Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-803371 Munich, Germany.	markus.ege@med.uni-muenchen.de	Osborne, Nicholas/N-4915-2015; Lauener, Roger/O-8612-2016; van Hage, Marianne/A-9678-2017	Osborne, Nicholas/0000-0002-6700-2284; Lauener, Roger/0000-0002-8412-606X; van Hage, Marianne/0000-0003-3091-1596; Pershagen, Goran/0000-0002-9701-1130; brunekreef, bert/0000-0001-9908-0060; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515			Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Bondy GS, 2000, J TOXICOL ENV HEAL B, V3, P109, DOI 10.1080/109374000281113; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; Chew GL, 2001, INDOOR AIR, V11, P171, DOI 10.1034/j.1600-0668.2001.011003171.x; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Pestka J, 2006, TOXICOL SCI, V92, P445, DOI 10.1093/toxsci/kfl012; Pestka JJ, 2005, J TOXICOL ENV HEAL B, V8, P39, DOI 10.1080/10937400590889458; Pestka JJ, 2004, TOXICOL LETT, V153, P61, DOI 10.1016/j.toxlet.2004.04.023; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2003, OCCUP ENVIRON MED, V60, P770, DOI 10.1136/oem.60.10.770; Remes ST, 2005, CLIN EXP ALLERGY, V35, P160, DOI 10.1111/j.1365-2222.2005.02172.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Roussel S, 2005, ANN AGR ENV MED, V12, P217; Roussel S, 2004, OCCUP ENVIRON MED, V61; Schneweis I, 2000, APPL ENVIRON MICROB, V66, P3639, DOI 10.1128/AEM.66.8.3639-3641.2000; Schollenberger M, 2006, MYCOPATHOLOGIA, V161, P43, DOI 10.1007/s11046-005-0199-7; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wagner M, 2005, J VET MED B, V52, P278, DOI 10.1111/j.1439-0450.2005.00866.x; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; WASER M, 2007, IN PRESS ALLERGY; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Yeung VP, 1998, J IMMUNOL, V161, P4146	41	126	127	4	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1140	1147		10.1016/j.jaci.2007.01.037		8	Allergy; Immunology	Allergy; Immunology	167CB	WOS:000246427200014	17349684	
J	Sampson, MA; Munoz-Furlong, A; Sicherer, SH				Sampson, MA; Munoz-Furlong, A; Sicherer, SH			Risk-taking and coping strategies of adolescents and young adults with food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; adolescent; risk taking	DIAL TELEPHONE SURVEY; TREE NUT ALLERGY; ANAPHYLACTIC REACTIONS; PREVALENCE; CHILDREN; PEANUT	Background: Fatal food-allergic reactions are most common among adolescents and young adults. Objective: To gain insight toward devising interventions, we queried risk-taking behaviors and coping strategies of persons age 13 to 21 years with food allergy. Methods: We used an Internet-based anonymous questionnaire devised on the basis of data from focus groups. Results: Participants (174 subjects; 49% male; mean age, 16 years) reported the following: 75% had peanut allergy, 75% had 2 or more food allergies, and 87% had been prescribed self-injectable epinephrine. Regarding risk taking, 61% reported that they "always" carry self-injectable epinephrine, but frequencies varied according to activities: traveling (94%), restaurants (81%), friends' homes (67%), school dance (61%), wearing tight clothes (53%), and sports (43%). Fifty-four percent indicated purposefully ingesting a potentially unsafe food. Willingness to eat a food labeled "may contain" an allergen was reported by 42%. Twenty-nine participants were designated at high risk because they did not always carry epinephrine and ate foods that "may contain" allergens. The high-risk group, compared with the rest of the participants (P < .05), felt less "concern" about and "different" because of their allergy and had more recent reactions. The high-risk group was not distinguishable (P = not significant) by age, sex, or number or severity of reactions. Participants variably (60%) tell their friends about their allergy, but 68% believe education of their friends would make living with food allergy easier. Conclusions: A significant number of teens with food allergy admit to risk taking that varies by social circumstances and perceived risks. The results imply that education of teenagers and, importantly, those around them during social activities might reduce risk taking and its consequences. Clinical implications: Our survey of adolescents and young adults with food allergy revealed risk-taking behaviors that vary by social circumstances and perceived risks, indicating that education of teenagers and their peers might reduce risk taking and its consequences.	Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immuonl, Dept Pediat, New York, NY USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA	Sicherer, SH (reprint author), Mt Sinai Hosp, Div Allergy Immunol, Jaffe Food Allergy Inst, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu					Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Kim JS, 2005, J ALLERGY CLIN IMMUN, V116, P164, DOI 10.1016/j.jaci.2005.03.039; Noone S. A., 2003, Journal of Allergy and Clinical Immunology, V111, pS133, DOI 10.1016/S0091-6749(03)80417-7; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Rolison MR, 2002, ADOLESCENCE, V37, P585; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P575, DOI 10.1016/j.jaci.2004.12.1122; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	13	126	126	0	22	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1440	1445		10.1016/j.jaci.2006.03.009		6	Allergy; Immunology	Allergy; Immunology	053UX	WOS:000238332300037	16751011	
J	Baker, BS				Baker, BS			The role of microorganisms in atopic dermatitis	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Review							STAPHYLOCOCCAL-ENTEROTOXIN-B; LYMPHOCYTE-ASSOCIATED ANTIGEN; T-CELLS; ANTIMICROBIAL PEPTIDES; HYGIENE HYPOTHESIS; PITYROSPORUM-OVALE; CROHNS-DISEASE; BACTERIAL SUPERANTIGENS; MALASSEZIA-FURFUR; STRATUM-CORNEUM	Atopic dermatitis (AD) is a common, fluctuating skin disease that is often associated with atopic conditions such as asthma and IgE-mediated food allergy and whose skin lesions are characterized by a Th-2 cell-mediated response to environmental antigens. The increasing prevalence and severity of atopic diseases including AD over the last three decades has been attributed to decreased exposure to microorganisms during early life, which may result in an altered Th-1/Th-2-balance and/or reduced T cell regulation of the immune response. Patients with AD exhibit defects in innate and acquired immune responses resulting in a heightened susceptibility to bacterial, fungal and viral infections, most notably colonization by S. aureus. Toxins produced by S. aureus exacerbate disease activity by both the induction of toxin-specific IgE and the activation of various cell types including Th-2 cells, eosinophils and keratinocytes. Allergens expressed by the yeast Malazessia furfur, a component of normal skin flora, have also been implicated in disease pathogenesis in a subset of AD patients. Microorganisms play an influential role in AD pathogenesis, interacting with disease susceptibility genes to cause initiation and/or exacerbation of disease activity.			drbsbaker@aol.com					Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; ALMOHANA F, 1993, J ALLERGY CLIN IMMUN, V92, P575; Arikawa J, 2002, J INVEST DERMATOL, V119, P433, DOI 10.1046/j.1523-1747.2002.01846.x; Aspres Nicholas, 2004, Australas J Dermatol, V45, P199, DOI 10.1111/j.1440-0960.2004.00097.x; BELEW PW, 1980, MYCOPATHOLOGIA, V70, P187, DOI 10.1007/BF00443030; BIRAGYN A, 2002, SCIENCE, V298, P10255; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; BREDIUS RGM, 1993, J IMMUNOL, V151, P1463; BROBERG A, 1992, ACTA DERM-VENEREOL, V72, P187; Buentke E, 2003, APMIS, V111, P789, DOI 10.1034/j.1600-0463.2003.11107810.x; Cho SH, 2001, J INVEST DERMATOL, V116, P658, DOI 10.1046/j.0022-202x.2001.01331.x; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Davison S, 2000, CLIN EXP IMMUNOL, V121, P181, DOI 10.1046/j.1365-2249.2000.01270.x; Devos SA, 2000, ALLERGY, V55, P1056, DOI 10.1034/j.1398-9995.2000.00782.x; Ezepchuk YV, 1996, J INVEST DERMATOL, V107, P603, DOI 10.1111/1523-1747.ep12583377; Flohr C, 2005, Br J Dermatol, V152, P202, DOI 10.1111/j.1365-2133.2004.06436.x; Gallo RL, 2002, J ALLERGY CLIN IMMUN, V110, P823, DOI 10.1067/mai.2002.129801; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; GOODMAN RE, 1994, J IMMUNOL, V152, P5189; Guzik TJ, 2005, CLIN EXP ALLERGY, V35, P448, DOI 10.1111/j.1365-2222.2005.02210.x; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; IMAYAMA S, 1994, J ALLERGY CLIN IMMUN, V94, P195, DOI 10.1016/0091-6749(94)90040-X; Johansson C, 2002, J INVEST DERMATOL, V118, P1044, DOI 10.1046/j.1523-1747.2002.01758.x; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Kim TY, 1999, CLIN EXP DERMATOL, V24, P226, DOI 10.1046/j.1365-2230.1999.00460.x; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Leung Ting-fan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P169, DOI 10.2174/1568010053586336; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lin YT, 2003, J IMMUNOL, V171, P1102; Linder MT, 1996, CLIN EXP ALLERGY, V26, P1286, DOI 10.1111/j.1365-2222.1996.tb00526.x; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lubbe J, 2003, AM J CLIN DERMATOL, V4, P641; MAEDA K, 1992, Journal of Dermatological Science, V3, P151, DOI 10.1016/0923-1811(92)90029-B; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; Matsubara M, 2004, FEBS LETT, V566, P195, DOI 10.1016/j.febslet.2004.04.028; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; Morishita Y, 1999, CLIN EXP ALLERGY, V29, P1110; Mrabet-Dahbi S, 2005, CLIN EXP ALLERGY, V35, P274, DOI 10.1111/j.1365-2222.2005.02192.x; Nickel RG, 2000, J IMMUNOL, V164, P1612; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; Nishio Y, 2001, J HUM GENET, V46, P664, DOI 10.1007/s100380170018; Nissen D, 1997, ANN ALLERG ASTHMA IM, V79, P403; Nissen D, 1998, ANN ALLERG ASTHMA IM, V81, P247; Nomura I, 2003, J IMMUNOL, V171, P3262; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Pivarcsi A, 2005, CURR IMMUNOL REV, V1, P29, DOI 10.2174/1573395052952941; Proft T, 2003, CLIN EXP IMMUNOL, V133, P299, DOI 10.1046/j.1365-2249.2003.02203.x; Rieg S, 2005, J IMMUNOL, V174, P8003; RING J, 1992, ALLERGY, V47, P265, DOI 10.1111/j.1398-9995.1992.tb02051.x; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Stern U M, 2000, J Dermatol, V27, P491; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Travers JB, 2001, J INVEST DERM SYMP P, V6, P225, DOI 10.1046/j.0022-202x.2001.00045.x; WAKITA H, 1995, J INVEST DERMATOL, V105, P536, DOI 10.1111/1523-1747.ep12323426; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; WATNABE S, 2001, J INVEST DERMATOL, V116, P769; Wedi B, 2002, J ALLERGY CLIN IMMUN, V109, P477, DOI 10.1067/mai.2002.121702; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zanetti M, 2004, J LEUKOCYTE BIOL, V75, P39, DOI 10.1189/jlb.0403147	85	126	135	0	11	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0009-9104			CLIN EXP IMMUNOL	Clin. Exp. Immunol.	APR	2006	144	1					1	9		10.1111/j.1365-2249.2005.02980.x		9	Immunology	Immunology	021YT	WOS:000236022500001	16542358	
J	Shaheen, SO; Newson, RB; Henderson, AJ; Headley, JE; Stratton, FD; Jones, RW; Strachan, DP				Shaheen, SO; Newson, RB; Henderson, AJ; Headley, JE; Stratton, FD; Jones, RW; Strachan, DP		ALSPAC Study Team	Prenatal paracetamol exposure and risk of asthma and elevated immunoglobulin E in childhood	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; birth cohort; fetal; IgE; paracetamol (acetaminophen); pregnancy; prenatal; wheezing	GLUTATHIONE-S-TRANSFERASE; NORMAL-CHILDREN; HUMAN-FETAL; ACETAMINOPHEN; PREGNANCY; RAT; MOUSE; CELLS; LUNG; COMPLICATIONS	Background We recently found that paracetamol (acetaminophen) use in late pregnancy was associated with an increased risk of early wheezing in the offspring. Objective To see whether use of paracetamol in late pregnancy is associated with an increased risk of asthma, wheezing and other atopic outcomes in the child at school age. Methods In the population-based Avon Longitudinal Study of Parents and Children, we measured associations of paracetamol and aspirin use in late pregnancy (20-32 weeks) with asthma, hayfever, eczema (n=8511) and wheezing (8381) in the offspring at 69-81 months, and with atopy (positive skin prick test to Dermatophagoides pteronyssinus, cat or grass, n=6527) and blood total IgE (n=5148) at 7 years. We used logistic and linear regression to analyse binary outcomes and log-transformed IgE, respectively, controlling for potential confounders. Results Use of paracetamol, but not aspirin, in late pregnancy was positively associated with asthma (odds ratios (ORs), comparing children whose mothers took paracetamol 'sometimes' and 'most days/daily' with those whose mothers never took it, 1.22 (95% confidence interval (CI): 1.06-1.41) and 1.62 (95% CI: 0.86-3.04), respectively; P trend=0.0037), wheezing (ORs 1.20 (95% CI: 1.02-1.40) and 1.86 (95% CI: 0.98-3.55), respectively; P trend=0.011), and total IgE (geometric mean ratios 1.14 (95% CI: 1.03-1.26) and 1.52 (95% CI: 0.98-2.38), respectively; P trend=0.0034), but not hayfever, eczema or skin test positivity. The proportion of asthma attributable to paracetamol use in late pregnancy, assuming a causal relation, was 7%. Conclusion: Paracetamol exposure in late gestation may cause asthma, wheezing and elevated IgE in children of school age.	Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England; Univ London St Georges Hosp, Sch Med, Dept Community Hlth Sci, London SW17 0RE, England	Shaheen, SO (reprint author), Univ London Kings Coll, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, Capital House ,42 Weston St, London SE1 3QD, England.	seif.shaheen@kcl.ac.uk		Henderson, Alexander John/0000-0001-9650-231X			Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227; CHEN TS, 1990, DRUG METAB DISPOS, V18, P882; COSSAR D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P221, DOI 10.1016/0167-4838(90)90171-B; Dimova S, 2000, BIOCHEM PHARMACOL, V59, P1467, DOI 10.1016/S0006-2952(00)00257-4; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; HART SGE, 1995, FUND APPL TOXICOL, V24, P260, DOI 10.1006/faat.1995.1029; JEFFERY EH, 1988, TOXICOL APPL PHARM, V93, P452, DOI 10.1016/0041-008X(88)90048-8; Leadbitter P, 1999, THORAX, V54, P905; LEVY G, 1975, PEDIATRICS, V55, P895; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; MICHELI L, 1994, ENVIRON HEALTH PERSP, V102, P63; Mumford SE, 1999, ARCH DIS CHILD, V81, pF228; Mumford SE, 1999, ARCH DIS CHILD, V81, pF146; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; PLACKE ME, 1987, TOXICOL PATHOL, V15, P381; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; ROLLINS DE, 1979, SCIENCE, V205, P1414, DOI 10.1126/science.38505; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; StataCorp, 2003, STAT STAT SOFTW REL; Strachan DP, 1996, BRIT MED J, V312, P1195; Terwindt GM, 2000, NEUROLOGY, V55, P624; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; Wu Z, 2004, CLIN EXP IMMUNOL, V135, P194, DOI 10.1111/j.1365-2249.2004.02372.x; Wu Z, 2001, INT IMMUNOL, V13, P297, DOI 10.1093/intimm/13.3.297; Xu B, 1999, ALLERGY, V54, P829, DOI 10.1034/j.1398-9995.1999.00117.x; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723	35	126	129	2	14	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2005	35	1					18	25		10.1111/j.1365-2222.2005.02151.x		8	Allergy; Immunology	Allergy; Immunology	887ZH	WOS:000226343500004	15649261	
J	Gern, JE; Reardon, CL; Hoffjan, S; Nicolae, D; Li, ZH; Roberg, KA; Neaville, WA; Carlson-Dakes, K; Adler, K; Hamilton, R; Anderson, E; Gilbertson-White, S; Tisler, C; DaSilva, D; Anklam, K; Mikus, LD; Rosenthal, LA; Ober, C; Gangnon, R; Lemanske, RF				Gern, JE; Reardon, CL; Hoffjan, S; Nicolae, D; Li, ZH; Roberg, KA; Neaville, WA; Carlson-Dakes, K; Adler, K; Hamilton, R; Anderson, E; Gilbertson-White, S; Tisler, C; DaSilva, D; Anklam, K; Mikus, LD; Rosenthal, LA; Ober, C; Gangnon, R; Lemanske, RF			Effects of dog ownership and genotype on immune development and atopy in infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Interleukin-10; hypersensitivity; dogs; cats; children; Interleukin-13; allergy; cytokines; CD14; atopic dermatitis	MODIFIED TH2 RESPONSE; ALLERGIC SENSITIZATION; DENDRITIC CELLS; EARLY EXPOSURE; CAT ALLERGEN; RISK-FACTORS; SCHOOL-AGE; EARLY-LIFE; 1ST YEAR; ASTHMA	Background: Exposure to furred pets might confer protection against the development of allergic sensitization through a mechanism that is incompletely understood. Objective: The objective of this study was to determine the effects of pet exposure and genotype on immunologic development and the incidence of atopic markers and diseases in the first year of life. Methods: Pet exposure in the home was compared with cytokine secretion patterns (mitogen-stimulated mononuclear cells at birth and age 1 year) and indicators of atopy (allergen-specific and total IgE, eosinophilia, food allergy, atopic dermatitis) in 285 infants. Interactions with genotype at the CD14 locus were also evaluated in the data analyses. Results: Exposure to dogs was associated with reduced allergen sensitization (19% vs 33%, P =.020) and atopic dermatitis (30% vs 51%, P < .001). The risk for atopic dermatitis was further influenced by genotype at the CD14 locus (P =.006), even after adjusting for exposure to dogs (P =.003). Furthermore, infants with the genotype -159TT were less likely to develop atopic dermatitis if they were exposed to a dog (5% vs 43%, P =.04). Last, dog exposure was associated with increased IL-10 (117 vs 79 pg/mL, P =.002) and IL-13 (280 vs 226 pg/mL, P =.013) responses at age 1 year. Conclusions: Having a dog in infancy is associated with higher IL-10 and IL-13 cytokine secretion profiles and reduced allergic sensitization and atopic dermatitis. These findings suggest that postnatal exposure to dogs can influence immune development in a genotype-specific fashion and thereby attenuate the development of atopy in at-risk children.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA	Gern, JE (reprint author), K4-918 CSC,600 Highland Ave, Madison, WI 53792 USA.		Rosenthal, Louis/A-8868-2008		NCRR NIH HHS [2 M01 RR03186-16]; NHLBI NIH HHS [P01 HL70831-01, 1R01HL61879-01]		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P938, DOI 10.1067/mai.2003.1417; ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Blahnik MJ, 2001, PEDIATR RES, V50, P726, DOI 10.1203/00006450-200112000-00016; Braback L, 2001, PEDIATR ALLERGY IMMU, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DESJARDINS A, 1993, J ALLERGY CLIN IMMUN, V91, P979, DOI 10.1016/0091-6749(93)90210-7; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; Freund RJ, 1997, STAT METHODS; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jeannin P, 1998, J IMMUNOL, V160, P3555; KUEHR J, 1992, J ALLERGY CLIN IMMUN, V90, P358, DOI 10.1016/S0091-6749(05)80015-6; Langrish CL, 2002, CLIN EXP IMMUNOL, V128, P118, DOI 10.1046/j.1365-2249.2002.01817.x; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; Mirel DB, 2002, DIABETES, V51, P3336, DOI 10.2337/diabetes.51.11.3336; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1067/mai.2003.1716; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pagano M., 2000, PRINCIPLES BIOSTATIS; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	37	126	126	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					307	314		10.1016/j.jaci.2003.11.017		8	Allergy; Immunology	Allergy; Immunology	773EX	WOS:000188885700020	14767447	
J	D'Amato, G; Liccardi, G; D'Amato, M; Cazzola, M				D'Amato, G; Liccardi, G; D'Amato, M; Cazzola, M			Outdoor air pollution, climatic changes and allergic bronchial asthma	EUROPEAN RESPIRATORY JOURNAL			English	Review						air pollution; bronchial asthma; pollen allergy; respiratory allergy; urban air pollution	THUNDERSTORM-ASSOCIATED ASTHMA; DIESEL EXHAUST PARTICLES; PPM NITROGEN-DIOXIDE; OZONE EXPOSURE; PULMONARY-FUNCTION; GRASS-POLLEN; PARTICULATE MATTER; SULFUR-DIOXIDE; RESPIRATORY RESPONSES; NONASTHMATIC SUBJECTS	Both the prevalence and severity of respiratory allergic diseases such as bronchial asthma have increased in recent years. Among the factors implicated in this "epidemic" are indoor and outdoor airborne pollutants. Urbanisation with its high levels of vehicle emissions and Westernised lifestyle parallels the increase in respiratory allergy in most industrialised countries, and people who live in urban areas tend to be more affected by the disease than those of rural areas. In atopic subjects, exposure to air pollution increases airway responsiveness to aeroallergens. Pollen is a good model with which to study the interrelationship between air pollution and respiratory allergic diseases. Biological aerosols carrying antigenic proteins, such as pollen grains or plant-derived paucimicronic components, can produce allergic symptoms. By adhering to the surface of these airborne allergenic agents, air pollutants could modify their antigenic properties. Several factors influence this interaction, i.e., type of air pollutant, plant species, nutrient balance, climatic factors, degree of airway sensitisation and hyperresponsiveness of exposed subjects. However, the airway mucosal damage and the impaired mucociliary clearance induced by air pollution may facilitate the penetration and the access of inhaled allergens to the cells of the immune system, and so promote airway sensitisation. As a consequence, an enhanced immunoglobulin E-mediated response to aeroallergens and enhanced airway inflammation favoured by air pollution could account for the increasing prevalence of allergic respiratory diseases in urban areas.	Azienda Osped Alta Specialita A Cardarelli, Div Pneumol & Allergol, Naples, Italy; Azienda Osped Alta Specialita A Cardarelli, Dept Chest Dis, Naples, Italy	D'Amato, G (reprint author), Hosp A Cardarelli, Div Pneumol & Allergol, Via Rione Sirignano 10, I-80121 Naples, Italy.		Cazzola, Mario/G-9397-2012; D'Amato, Maria/H-3074-2012	D'Amato, Maria/0000-0002-5906-5701			Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; ADAMS WC, 1983, J APPL PHYSIOL, V55, P805; Anderson HR, 1998, THORAX, V53, P842; Anderson M, 1994, J AEROSOL SCI, V25, P567; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; BALMES JR, 1987, AM REV RESPIR DIS, V136, P1117; BALMES JR, 1993, ENVIRON HEALTH PERSP, V101, P219, DOI 10.2307/3431683; Balmes J. R., 1997, RES REP HLTH EFF I, V78, P1; BARRY CC, 1994, ENVIRONMENT, V36, P5; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; BATES DV, 1983, CAN J PUBLIC HEALTH, V74, P117; BAUER MA, 1986, AM REV RESPIR DIS, V134, P1203; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BECKETT WS, 1985, J APPL PHYSIOL, V59, P1879; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Brunekreef B, 2000, LANCET, V355, P1517, DOI 10.1016/S0140-6736(00)02168-1; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; Celenza A, 1996, BRIT MED J, V312, P604; CHAPMAN MD, 1998, ENCY IMMUNOLOGY, P64; CHEN LL, 1995, AM J RESP CRIT CARE, V151, pA27; CHRISTIAN DL, 1996, AM J RESP CRIT CARE, V153, pA699; Churg A, 1997, AM J RESP CRIT CARE, V155, P2109; COLERIDGE HM, 1976, NATURE, V264, P451, DOI 10.1038/264451a0; COLERIDGE JCG, 1993, J APPL PHYSIOL, V74, P2345; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; COSTA DL, 1998, AM J RESP CRIT CARE, V157, pA880; D'Amato G, 1994, Monaldi Arch Chest Dis, V49, P406; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'AMATO G, 1981, Zeitschrift fuer Erkrankungen der Atmungsorgane, V157, P281; D'Amato G, 2001, ALLERGY, V56, P1109, DOI 10.1034/j.1398-9995.2001.00317.x; D'Amato G, 1998, PULM PHARMACOL THER, V11, P369, DOI 10.1006/pupt.1999.0159; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; DAmato G, 1996, ANN ALLERG ASTHMA IM, V77, P147; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P566, DOI 10.1111/j.1365-2222.1994.tb00954.x; DAMATO G, 1991, ANN ALLERGY, V67, P421; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; D'Amato G, 2000, MONALDI ARCH CHEST D, V6, P471; D'Amato G, 2001, POLLENOSIS 2000 GLOB; Davidson AC, 1996, BRIT MED J, V312, P601; DAVIS GL, 1967, AUSTR J SCI, V30, P235; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; DEVLIN RB, 1993, AM REV RESPIR DIS, V147, pA71; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; *DIES WORK GROUP, 1995, DIES EXH CRIT AN EM; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 1997, ENVIRON HEALTH PERSP, V105, P1285, DOI 10.2307/3433548; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Emberlin J., 1998, EUR RESPIR REV, V53, P164; FARRELL BP, 1979, AM REV RESPIR DIS, V119, P725; FERNANDEZCALDAS E, 1989, GRANA, V28, P205; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98; FOLINSBEE LJ, 1984, J APPL PHYSIOL, V57, P984; FOLINSBEE LJ, 1980, AM REV RESPIR DIS, V121, P431; FOXCROFT WJ, 1986, J APPL PHYSIOL, V61, P960; Frenguelli G., 1998, AEROBIOLOGIA, V14, P39, DOI 10.1007/BF02694593; GarciaOrtega P, 1997, MED CLIN-BARCELONA, V108, P677; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; GHIO AJ, 1993, AM J RESP CELL MOL, V8, P403; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; GOLDSTEIN IF, 1988, ARCH ENVIRON HEALTH, V43, P138; HACKNEY JD, 1977, J APPL PHYSIOL, V43, P82; HAZUCHA MJ, 1983, J APPL PHYSIOL, V54, P730; HERNANDO L, 1989, LANCET, V1, P502; Holgate ST, 1999, AIR POLLUTION HLTH; HOLGUIN AH, 1985, EVALUATION SCI BASIS, P262; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HORSTMAN D, 1986, Toxicology and Industrial Health, V2, P289; Horstman DH, 1995, TOXICOL IND HEALTH, V11, P369; HORVATH SM, 1981, AM REV RESPIR DIS, V123, P496; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; JENSEN J, 1989, ALLERGY, V44, P52, DOI 10.1111/j.1398-9995.1989.tb00446.x; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KREIT JW, 1989, J APPL PHYSIOL, V66, P217; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Lebowitz MD, 1996, EUR RESPIR J, V9, P1029, DOI 10.1183/09031936.96.09051029; LEBOWITZ MD, 1985, JAPCA J AIR WASTE MA, V35, P1154; LINN WS, 1987, AM REV RESPIR DIS, V136, P1127; LINN WS, 1986, ARCH ENVIRON HEALTH, V41, P292; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCDONNELL WF, 1987, TOXICOL IND HEALTH, V3, P507; MIKIHIROSIGE H, 1994, SEX PLANT REPROD, V7, P95; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOSHENIN V, 1987, J TOXICOL ENV HLTH, V22, P371; MURRAY V, 1994, BRIT MED J, V309, P131; Nauss K.M., 1995, CRITICAL ANAL EMISSI, P13; Osterlee A., 1996, OCCUP ENVIRON MED, V53, P241; Pacini E, 1993, PLANT SYST EVOL S, V7, P1, DOI DOI 10.1007/978-3-7091-6661-1_; PACKE GE, 1985, LANCET, V2, P199; PACKE GE, 1986, LANCET, V1, P850; PEDEN D, 1996, AM J RESP CRIT CARE, V153, pA700; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; PLINIUS YOUNGER, COMMUNICATION; Pope CA, 1999, ENVIRON HEALTH PERSP, V107, P613, DOI 10.2307/3434450; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; REIDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; ROGER LJ, 1990, TOXICOL IND HEALTH, V6, P155; ROSSI OVJ, 1993, THORAX, V30, P2; RUDELL B, 1990, J AEROSOL SCI, V21, pS411; RUSZNAK C, 1996, THORAX, V344, P1668; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1187; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; SCHELEGLE ES, 1986, MED SCI SPORT EXER, V18, P408; SCHENKER M, 1993, NEW ENGL J MED, V329, P1807, DOI 10.1056/NEJM199312093292410; SCHLESINGER RB, 1987, J TOXICOL ENV HEALTH, V20, P125; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHUMWAY RH, 1988, ENVIRON RES, V45, P224, DOI 10.1016/S0013-9351(88)80049-5; Smith KR, 1997, CHEM RES TOXICOL, V10, P828, DOI 10.1021/tx960164m; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STOKINGER H E, 1956, AMA Arch Ind Health, V14, P158; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; THURSTON GD, 1997, AM J RESP CRIT CARE, V155, pA426; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Viegi G, 1998, INT J TUBERC LUNG D, V2, P947; Vinckier S, 2001, ALLERGY, V56, P1129, DOI 10.1034/j.1398-9995.2001.00172.x; Wallis D. N., 1995, European Respiratory Journal, V8, p500S; White MC, 1997, AM J EPIDEMIOL, V145, P432; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; WJST M, 1993, BRIT MED J, V307, P596; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; YANAI M, 1990, J APPL PHYSIOL, V68, P2267; 2001, AMBIENTE ITALIA 2000	162	126	130	5	22	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2002	20	3					763	776		10.1183/09031936.02.00401402		14	Respiratory System	Respiratory System	596VL	WOS:000178187100038	12358357	
J	Almqvist, C; Wickman, M; Perfetti, L; Berglind, N; Renstrom, A; Hedren, M; Larsson, K; Hedlin, G; Malmberg, P				Almqvist, C; Wickman, M; Perfetti, L; Berglind, N; Renstrom, A; Hedren, M; Larsson, K; Hedlin, G; Malmberg, P			Worsening of asthma in children allergic to cats, after indirect exposure to cat at school	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							PEAK EXPIRATORY FLOW; DAY-CARE-CENTERS; DOG CAN-F-1; SYMPTOMS; SENSITIZATION; FEL-D-1; DUST; MITE; HYPERRESPONSIVENESS; ENVIRONMENT	Exposure to cat allergen at school might exacerbate symptoms in asthmatic children with cat allergy. To study this, we identified 410 children, 6-12 yr of age, who were being treated for asthma (inhaled steroids and beta -agonists), were allergic to cats, and had no Eat at home. Peak expiratory flow (PEF), asthma symptoms, medication, fever and/or sore throat, and contact with furred pets were recorded twice daily during the last week of summer holidays and the second and third weeks of school. The number of cat owners in each class was recorded. Ninety-two children with asthma reported no contact with furred pets. Among these, children who attended classes with > 18% (median value) cat owners reported significantly decreased PEF, more days with asthma symptoms, and increased use of medication after school started. Those in classes with less than or equal to 18% cat owners reported no change. Children in classes with many cat owners ran a 9-fold increased risk of exacerbated asthma after school start compared with children in classes with few cat owners, after adjusting for age, sex, and fever and/or sore throat. Thus, asthma symptoms, PEF, and the use of asthma medication in children with cat allergy may be affected by indirect cat exposure at school.	Karolinska Hosp, Dept Environm Hlth, S-17176 Stockholm, Sweden; Fdn Salvatore Maugeri, Ist Sci Pavia, Clin Lavoro & Riabilitazione, IRCCS, Pavia, Italy; Natl Inst Working Life, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Stockholm, Sweden; Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; Karolinska Inst, Dept Woman & Child Hlth, Astrid Lindgren Childrens Hosp, Stockholm, Sweden	Almqvist, C (reprint author), Karolinska Hosp, Dept Environm Hlth, Norrbacka Bldg,3rd Floor, S-17176 Stockholm, Sweden.						Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Brand PLP, 1997, EUR RESPIR J, V10, P1242, DOI 10.1183/09031936.97.10061242; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; *COLL STAT, 1999, STAT US GUID REL 6, P256; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1046/j.1365-2222.1996.d01-278.x; Dreborg S, 1989, ALLERGY S10, V44, P1; ENBERG RN, 1993, ANN ALLERGY, V70, P471; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588; Hollander A, 1998, EUR RESPIR J, V11, P929, DOI 10.1183/09031936.98.11040929; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Plaschke P, 1999, ALLERGY, V54, P843, DOI 10.1034/j.1398-9995.1999.00162.x; Quanjer PH, 1997, PEDIATR PULM, V24, P2, DOI 10.1002/(SICI)1099-0496(199707)24:1<2::AID-PPUL2>3.3.CO;2-U; Reddel HK, 1998, EUR RESPIR J, V12, P309, DOI 10.1183/09031936.98.12020309; ROEMER W, 1998, EUR RESPIR REV, V8, P4; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Sporik R, 1999, THORAX, V54, P675; Sterk PJ, 1999, EUR RESPIR J, V14, P1435, DOI 10.1183/09031936.99.14614359; STORR J, 1989, ARCH DIS CHILD, V64, P103; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Warner JO, 1998, PEDIATR PULM, V25, P1; Wickman M, 1999, CLIN EXP ALLERGY, V29, P626	29	126	127	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR	2001	163	3					694	698				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	419HW	WOS:000167944100021	11254526	
J	Arkwright, PD; David, TJ				Arkwright, PD; David, TJ			Intradermal administration of a killed Mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mycobacterium vaccae; atopic dermatitis; atopy; T(H)2	ALLERGIC DISEASE; BCG VACCINATION; DENDRITIC CELLS; INFECTION; IMMUNOTHERAPY; TUBERCULOSIS; LYMPHOCYTES; OVALBUMIN; ASTHMA; TRIAL	Background: Although a doubling in the prevalence of atopic disease, including atopic dermatitis, in the Western world over the last few generations has been paralleled by a marked reduction in infectious diseases, especially tuberculosis, it is unclear whether this increase in atopy is causally related to reduced exposure to mycobacteria. Objectives: The aim of this study was to determine whether administration of mycobacterial antigens to atopic individuals might ameliorate their disease. Methods: Forty-one children aged 5 to 18 years with moderate-to-severe atopic dermatitis were enrolled in a randomized, double-blind, placebo-controlled trial, where they were given either one intradermal injection of killed Mycobacterium vaccae (SRL 172) or buffer solution (placebo). Changes in skin surface area affected by dermatitis and dermatitis severity score were assessed before treatment and at 1 and 3 months after treatment. Results: Children treated with SRL 172 showed a mean 48% (95% CI, 32%-65%) reduction in surface area affected by dermatitis compared with a mean 4% (95% CI, -29% to 22%) reduction for the placebo group (P < .001) and a median 68% (interquartile range, 46%-85%) reduction in dermatitis severity score compared with 18% (interquartile range, -2% to 34%) for the placebo group (P < .01) at 3 months after treatment. There were no untoward effects of the treatment, apart from a local reaction in 13 of the 21 children, which occurred 1 month after SRL 172 administration and settled spontaneously. Conclusion: SRL 172 was associated with an improvement in the severity of the dermatitis in children with moderate-to-severe disease.	Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Manchester M9 7AA, Lancs, England	Arkwright, PD (reprint author), Univ Manchester, Booth Hall Childrens Hosp, Acad Unit Child Hlth, Charlestown Rd, Manchester M9 7AA, Lancs, England.		Arkwright, Peter/C-5149-2012				Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; DAVID TJ, 1984, BRIT J DERMATOL, V111, P597, DOI 10.1111/j.1365-2133.1984.tb06630.x; Hart DNJ, 1997, BLOOD, V90, P3245; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hrouda D, 1998, BRIT J UROL, V82, P568; Johnson D, 1999, VACCINE, V17, P2583, DOI 10.1016/S0264-410X(99)00055-9; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Maraveyas A, 1999, ANN ONCOL, V10, P817, DOI 10.1023/A:1008307821189; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Schaible UE, 2000, J IMMUNOL, V164, P4843; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stead WW, 1997, CLIN CHEST MED, V18, P65, DOI 10.1016/S0272-5231(05)70356-7; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Tocque K, 1998, AM J RESP CRIT CARE, V158, P484; Tukenmez F, 1999, PEDIATR ALLERGY IMMU, V10, P107, DOI 10.1034/j.1399-3038.1999.00029.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wang CC, 1998, IMMUNOLOGY, V93, P307	20	126	127	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					531	534		10.1067/mai.20001.113081		4	Allergy; Immunology	Allergy; Immunology	416RE	WOS:000167793300017	11240956	
J	Van Schoor, J; Joos, GF; Pauwels, RA				Van Schoor, J; Joos, GF; Pauwels, RA			Indirect bronchial hyperresponsiveness in asthma: mechanisms pharmacology and implications for clinical research	EUROPEAN RESPIRATORY JOURNAL			English	Review						adenosine challenge; airway inflammation; asthma; bronchial challenges; bronchial hyperresponsiveness; exercise challenge	EXERCISE-INDUCED ASTHMA; NEBULIZED DISTILLED WATER; METABISULFITE-INDUCED BRONCHOCONSTRICTION; BRADYKININ-INDUCED BRONCHOCONSTRICTION; SALINE-INDUCED BRONCHOCONSTRICTION; PROPRANOLOL-INDUCED BRONCHOCONSTRICTION; NEUTRAL ENDOPEPTIDASE INHIBITOR; A-INDUCED BRONCHOCONSTRICTION; METHACHOLINE-INDUCED BRONCHOCONSTRICTION; ADENOSINE-INDUCED BRONCHOCONSTRICTION	Bronchial hyperresponsiveness (BHR), an abnormal increase in airflow limitation following the exposure to a stimulus, is an important pathophysiological characteristic of bronchial asthma. Because of heterogeneity of the airway response to different stimuli, the latter have been divided into direct and indirect stimuli. Direct stimuli cause airflow limitation by a direct action on the effector cells involved in the airflow limitation, while indirect stimuli exert their action essentially on inflammatory and neuronal cells that act as an intermediary between the stimulus and the effector cells. This manuscript reviews the clinical and experimental studies on the mechanisms involved in indirect BHR in patients with asthma. Pharmacological stimuli (adenosine, tachykinins, bradykinin, sodium metabisulphite/sulphur dioxide, and propranolol) as well as physical stimuli (exercise, nonisotonic aerosols, and isocapnic hyperventilation) are discussed. The results of the different direct and indirect bronchial challenge tests are only weakly correlated and are therefore not mutually interchangeable. Limited available data (studies on the effects of allergen avoidance and inhaled corticosteroids) suggest that indirectly acting bronchial stimuli (especially adenosine) might better reflect the degree of airway inflammation than directly acting stimuli. It remains to be established whether monitoring of indirect BHR as a surrogate marker of inflammation tin addition to symptoms and lung function) is of clinical relevance to the long-term management of asthmatic patients. This seems to be the case for the direct stimulus methacholine. More work needs to be performed to find out whether, indirect stimuli are more suitable in asthma monitoring than direct ones. Recommendations on the application of indirect challenges in clinical practice and research will shortly be available from the European Respiratory Society Task Force.	State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Joos, GF (reprint author), State Univ Ghent Hosp, Dept Resp Dis, 7K12 IE,De Pintelaan 185, B-9000 Ghent, Belgium.						AALBERS R, 1991, AM REV RESPIR DIS, V144, P352; ADVENIER C, 1992, AM REV RESPIR DIS, V146, P1177; Ahmed T, 1999, AM J RESP CRIT CARE, V160, P576; ALBAZZAZ MK, 1989, THORAX, V44, P816, DOI 10.1136/thx.44.10.816; ALI H, 1986, INT ARCH ALLER A IMM, V79, P413; ALLEGRA L, 1980, EUR J RESPIR DIS S, V106, P41; ALTOUNYAN REC, 1986, EUR J RESPIR DIS, V69, P277; Anderson S D, 1996, Respirology, V1, P175, DOI 10.1111/j.1440-1843.1996.tb00029.x; ANDERSON SD, 1994, CHEST, V105, P673, DOI 10.1378/chest.105.3.673; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; Anderson SD, 1993, ALLERGY PRINCIPLES P, P1343; ARAKI H, 1989, J ALLERGY CLIN IMMUN, V84, P99, DOI 10.1016/0091-6749(89)90183-8; ARGYROS GJ, 1995, CHEST, V108, P419, DOI 10.1378/chest.108.2.419; BADIER M, 1988, J ALLERGY CLIN IMMUN, V81, P437, DOI 10.1016/0091-6749(88)90913-X; BARNES PJ, 1996, NEUROGENIC INFLAMMAT, P169; BARYISHAY E, 1983, AM REV RESPIR DIS, V127, P572; BASCOM R, 1986, AM REV RESPIR DIS, V134, P248; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822; BELCHER NG, 1989, EUR RESPIR J, V2, P44; BELLINGAN GJ, 1992, BRIT J CLIN PHARMACO, V34, P71; BELLOFIORE S, 1994, AM J RESP CRIT CARE, V150, P853; Belvisi M, 1996, CLIN EXP ALLERGY, V26, P1343; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; Berman AR, 1996, AM J RESP CRIT CARE, V154, P418; Bianco S, 1980, Eur J Respir Dis Suppl, V106, P81; BIANCO S, 1992, J ALLERGY CLIN IMMUN, V90, P833, DOI 10.1016/0091-6749(92)90109-F; BIANCO S, 1988, LANCET, V2, P252; Bianco S, 1983, Eur J Respir Dis Suppl, V128 (Pt 1), P213; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; BLACK JL, 1985, THORAX, V40, P427, DOI 10.1136/thx.40.6.427; BLACK JL, 1987, J ALLERGY CLIN IMMUN, V80, P39, DOI 10.1016/S0091-6749(87)80188-4; BLACKIE SP, 1990, AM REV RESPIR DIS, V142, P1133; BOOTSMA GP, 1995, THORAX, V50, P1044, DOI 10.1136/thx.50.10.1044; BOULET LP, 1989, J ALLERGY CLIN IMMUN, V83, P882, DOI 10.1016/0091-6749(89)90101-2; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Brusasco V, 1998, THORAX, V53, P992; CARPENTIERE G, 1991, CURR THER RES CLIN E, V49, P507; CARPENTIERE G, 1990, CHEST, V98, P263, DOI 10.1378/chest.98.2.263; Ceyhan BB, 1997, INT J CLIN PHARM TH, V35, P208; CHAN W, 1986, CLIN SCI, V70, pP65; CHEUNG D, 1992, AM REV RESPIR DIS, V145, P1275; CHEUNG D, 1993, AM REV RESPIR DIS, V148, P1467; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRIMI N, 1988, CLIN ALLERGY, V18, P367, DOI 10.1111/j.1365-2222.1988.tb02884.x; Crimi N, 1997, THORAX, V52, P775; CRIMI N, 1995, THORAX, V50, P505, DOI 10.1136/thx.50.5.505; Crimi N, 1996, EUR RESPIR J, V9, P1139, DOI 10.1183/09031936.96.09061139; CRIMI N, 1993, J ALLERGY CLIN IMMUN, V91, P1096, DOI 10.1016/0091-6749(93)90225-5; CRIMI N, 1990, ANN ALLERGY, V65, P115; CRIMI N, 1989, J ALLERGY CLIN IMMUN, V83, P921, DOI 10.1016/0091-6749(89)90106-1; CRIMI N, 1994, CLIN EXP ALLERGY, V24, P115, DOI 10.1111/j.1365-2222.1994.tb00206.x; CRIMI N, 1992, EUR RESPIR J, V5, P560; CRIMI N, 1988, CLIN ALLERGY, V18, P375, DOI 10.1111/j.1365-2222.1988.tb02885.x; CRIMI N, 1995, EUR RESPIR J, V8, P905; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161; DAXUN Z, 1989, J ALLERGY CLIN IMMUN, V83, P152, DOI 10.1016/0091-6749(89)90490-9; de la Fuente PT, 1998, AM J RESP CRIT CARE, V157, P1127; de Vries K, 1968, Bronches, V18, P439; DEBENEDICTIS FM, 1995, J ALLERGY CLIN IMMUN, V96, P510, DOI 10.1016/S0091-6749(95)70295-4; DECRAMER M, 1984, B EUR PHYSIOPATH RES, V20, P237; Dekhuijzen PNR, 1997, EUR RESPIR J, V10, P2749, DOI 10.1183/09031936.97.10122749; DELBONO L, 1986, EUR J RESPIR DIS, V69, P268; DELBUFALO C, 1989, RESPIRATION, V55, P181; DENT G, 1996, PULMONARY CRITICAL C, P173; Di Maria GU, 1998, EUR RESPIR J, V12, P1454, DOI 10.1183/09031936.98.12061454; DIXON C M S, 1988, American Review of Respiratory Disease, V137, P238; DIXON CMS, 1989, BRIT J CLIN PHARMACO, V27, P831; DIXON CMS, 1990, BRIT J CLIN PHARMACO, V30, P371; DIXON M, 1980, BRIT J PHARMACOL, V70, P11; DORWARD AJ, 1982, CLIN ALLERGY, V12, P355, DOI 10.1111/j.1365-2222.1982.tb02539.x; Doull IJM, 1997, PEDIATR PULM, V23, P404, DOI 10.1002/(SICI)1099-0496(199706)23:6<404::AID-PPUL2>3.0.CO;2-I; DRIVER AG, 1991, AM REV RESPIR DIS, V143, P1002; duToit JI, 1997, ALLERGY ASTHMA PROC, V18, P7, DOI 10.2500/108854197778612817; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EICHLER I, 1992, CHEST, V102, P753, DOI 10.1378/chest.102.3.753; ELLIS JL, 1993, J PHARMACOL EXP THER, V267, P95; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V130, P363; ESCHENBACHER WL, 1984, AM REV RESPIR DIS, V129, P211; FABBRI LM, 1984, ANN ALLERGY, V53, P172; FABBRI LM, 1983, J ALLERGY CLIN IMMUN, V71, P468, DOI 10.1016/0091-6749(83)90463-3; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P879; Feoktistov I, 1998, TRENDS PHARMACOL SCI, V19, P148, DOI 10.1016/S0165-6147(98)01179-1; Field PI, 1996, THORAX, V51, P159, DOI 10.1136/thx.51.2.159; FINE JM, 1987, AM REV RESPIR DIS, V136, P1122; FINNERTY JP, 1991, THORAX, V46, P190, DOI 10.1136/thx.46.3.190; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593; FINNERTY JP, 1990, J ALLERGY CLIN IMMUN, V86, P353, DOI 10.1016/S0091-6749(05)80098-3; FINNERTY JP, 1992, EUR RESPIR J, V5, P323; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746; FINNEY MJB, 1990, AM REV RESPIR DIS, V141, P1151; Fiocchi A, 1997, ANN ALLERG ASTHMA IM, V79, P503; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203; Fischer AR, 1997, THORAX, V52, P1074; FORESI A, 1986, CHEST, V90, P822, DOI 10.1378/chest.90.6.822; FORESI A, 1987, CHEST, V92, P455, DOI 10.1378/chest.92.3.455; FORESI A, 1993, EUR RESPIR J, V6, P181; FORESI A, 1993, ANN ALLERGY, V70, P159; FRANK NR, 1962, J APPL PHYSIOL, V17, P252; Fredholm BB, 1996, DRUG DEVELOP RES, V39, P262, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<262::AID-DDR5>3.0.CO;2-P; Fujimura M, 1998, CLIN EXP ALLERGY, V28, P893; Fujimura M, 1999, AM J RESP CRIT CARE, V160, P2100; FULLER RW, 1991, CHEST, V100, P670, DOI 10.1378/chest.100.3.670; FULLER RW, 1987, AM REV RESPIR DIS, V135, P176; GALDESSEBALDT M, 1985, J PEDIATR-US, V107, P526, DOI 10.1016/S0022-3476(85)80009-3; GEPPETTI P, 1993, REGUL PEPTIDES, V47, P1, DOI 10.1016/0167-0115(93)90268-D; GERRITSEN J, 1988, THORAX, V43, P451, DOI 10.1136/thx.43.6.451; GRAVELYN TR, 1988, AM REV RESPIR DIS, V137, P641; GROOT CAR, 1992, EUR RESPIR J, V5, P1075; GROOT CAR, 1994, PULM PHARMACOL, V7, P59, DOI 10.1006/pulp.1994.1006; GRUBBE RE, 1990, J ALLERGY CLIN IMMUN, V85, P881, DOI 10.1016/0091-6749(90)90072-C; Hamad AM, 1999, EUR RESPIR J, V14, P702, DOI 10.1034/j.1399-3003.1999.14c34.x; HARRIES MG, 1981, LANCET, V1, P5; HAWKSWORTH RJ, 1992, EUR RESPIR J, V5, P963; HEANEY LG, 1995, CLIN EXP ALLERGY, V25, P179, DOI 10.1111/j.1365-2222.1995.tb01024.x; HEATON RW, 1983, THORAX, V38, P506, DOI 10.1136/thx.38.7.506; HENRIKSEN JM, 1985, BRIT MED J, V291, P248; HERXHEIMER H, 1948, LANCET, V1, P83; HERXHEIMER H, 1961, J PHYSIOL-LONDON, V158, P38; Ho WZ, 1997, J IMMUNOL, V159, P5654; HOPP RJ, 1988, ANN ALLERGY, V60, P129; HOPP RJ, 1988, ANN ALLERGY, V61, P13; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P3847, DOI 10.1016/0006-2952(84)90050-9; HULSMANN AR, 1994, AM J RESP CRIT CARE, V150, P1012; ICHINOSE M, 1990, J PHARMACOL EXP THER, V253, P594; Ichinose M, 1996, AM J RESP CRIT CARE, V153, P936; ICHINOSE M, 1992, LANCET, V340, P1248, DOI 10.1016/0140-6736(92)92948-F; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; IND P W, 1984, American Review of Respiratory Disease, V129, pA10; IND PW, 1989, AM REV RESPIR DIS, V139, P1390; IND PW, 1985, THORAX, V40, P903, DOI 10.1136/thx.40.12.903; ISHII Y, 1990, PROSTAGLANDINS, V39, P685, DOI 10.1016/0090-6980(90)90028-T; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; JONGEJAN RC, 1991, BRIT J PHARMACOL, V102, P931; Joos G, 1988, Pulm Pharmacol, V1, P41, DOI 10.1016/0952-0600(88)90009-9; JOOS G, 1987, THORAX, V42, P779, DOI 10.1136/thx.42.10.779; Joos GF, 1996, DRUG DEVELOP RES, V39, P330, DOI 10.1002/(SICI)1098-2299(199611/12)39:3/4<330::AID-DDR13>3.0.CO;2-5; JOOS GF, 1989, J ALLERGY CLIN IMMUN, V83, P663, DOI 10.1016/0091-6749(89)90080-8; JOOS GF, 1994, EUR RESPIR J, V7, P1161; Joos GF, 1996, AM J RESP CRIT CARE, V153, P1781; JUNIPER EF, 1987, CLIN ALLERGY, V17, P523, DOI 10.1111/j.1365-2222.1987.tb02048.x; KIVITY S, 1995, EUR RESPIR J, V8, P253, DOI 10.1183/09031936.95.08020253; KOETER GH, 1984, EUR J CLIN PHARMACOL, V26, P435, DOI 10.1007/BF00542137; KOETER GH, 1982, ALLERGY, V37, P587, DOI 10.1111/j.1398-9995.1982.tb02344.x; KONIG P, 1987, J ALLERGY CLIN IMMUN, V79, P64, DOI 10.1016/S0091-6749(87)80018-0; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440; Lazarus SC, 1997, AM J RESP CRIT CARE, V156, P1725; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lehnigk B, 1998, EUR RESPIR J, V11, P617; LEMIRE TS, 1989, CHEST, V95, P958, DOI 10.1378/chest.95.5.958; MAGGI CA, 1993, EUR RESPIR J, V6, P735; Maggi CA, 1997, REGUL PEPTIDES, V70, P75, DOI 10.1016/S0167-0115(97)00029-3; MAGNUSSEN H, 1992, J ALLERGY CLIN IMMUN, V89, P1119, DOI 10.1016/0091-6749(92)90295-D; MAKKER HK, 1993, J ALLERGY CLIN IMMUN, V92, P82, DOI 10.1016/0091-6749(93)90041-D; MAKKER HK, 1994, AM J RESP CRIT CARE, V149, P1012; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; MARGOLSKEE DJ, 1988, AM REV RESPIR DIS, V137, P842; MATTOLI S, 1987, J ALLERGY CLIN IMMUN, V79, P678, DOI 10.1016/S0091-6749(87)80165-3; MATTOLI S, 1986, CHEST, V90, P726, DOI 10.1378/chest.90.5.726; MATTOLI S, 1987, ANN ALLERGY, V58, P134; MCFADDEN ER, 1990, LANCET, V335, P880; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931; MOLIMARD M, 1995, EUR J PHARMACOL, V278, P253, DOI 10.1016/0014-2999(95)00159-I; MOLIMARD M, 1995, EUR J PHARMACOL, V278, P49, DOI 10.1016/0014-2999(95)00103-R; MOLIMARD M, 1994, AM J RESP CRIT CARE, V149, P123; MORTON AR, 1992, ANN ALLERGY, V68, P143; MYERS DJ, 1986, AM REV RESPIR DIS, V133, P1154; Myers JD, 1997, THORAX, V52, P861; NADEL JA, 1965, J APPL PHYSIOL, V20, P164; Nadel J.A., 1996, NEUROGENIC INFLAMMAT, P115; NAKAI S, 1991, ANN ALLERGY, V66, P155; Naline E, 1996, AM J PHYSIOL-LUNG C, V271, pL763; NALINE E, 1989, AM REV RESPIR DIS, V140, P679; Nannini LJ, 1997, CHEST, V111, P858, DOI 10.1378/chest.111.4.858; NICHOL GM, 1989, THORAX, V44, P1009, DOI 10.1136/thx.44.12.1009; NICHOL GM, 1992, EUR J CLIN PHARMACOL, V42, P491, DOI 10.1007/BF00314856; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576; Norris AA, 1996, CLIN EXP ALLERGY, V26, P250; OBATA T, 1994, ANN ALLERGY, V72, P167; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875; OCONNOR BJ, 1994, THORAX, V49, P307, DOI 10.1136/thx.49.4.307; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560; OHICKEY SP, 1989, THORAX, V44, P650, DOI 10.1136/thx.44.8.650; OHICKEY SP, 1989, EUR RESPIR J, V2, P923; OKAYAMA M, 1987, J ALLERGY CLIN IMMUN, V80, P291, DOI 10.1016/0091-6749(87)90034-0; OOSTERHOFF Y, 1995, THORAX, V50, P937, DOI 10.1136/thx.50.9.937; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132; PATEL KR, 1984, BRIT MED J, V288, P1496; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; PAUWELS R, 1997, ALLERGY ALLERGIC DIS, P682; PAVORD I, 1994, THORAX, V49, P245, DOI 10.1136/thx.49.3.245; Pavord I, 1996, EUR RESPIR J, V9, P217, DOI 10.1183/09031936.96.09020217; PAVORD ID, 1994, EUR RESPIR J, V7, P50, DOI 10.1183/09031936.94.07010050; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PAVORD ID, 1992, THORAX, V47, P797, DOI 10.1136/thx.47.10.797; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143; Pennings HJ, 1997, EUR RESPIR J, V10, P665; PERONI DG, 1995, CLIN EXP ALLERGY, V25, P680, DOI 10.1111/j.1365-2222.1995.tb00003.x; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1989, AM REV RESPIR DIS, V139, P463; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9; PIERSON WE, 1989, ANN ALLERGY, V63, P461; PISARRI TE, 1992, J APPL PHYSIOL, V73, P2305; POLOSA R, 1990, EUR RESPIR J, V3, P914; POLOSA R, 1990, ALLERGY, V45, P174, DOI 10.1111/j.1398-9995.1990.tb00480.x; POLOSA R, 1993, EUR RESPIR J, V6, P687; POLOSA R, 1990, EUR RESPIR J, V3, P665; Polosa R, 1997, EUR RESPIR J, V10, P2460, DOI 10.1183/09031936.97.10112460; POLOSA R, 1991, J ALLERGY CLIN IMMUN, V87, P939, DOI 10.1016/0091-6749(91)90415-K; Polosa R, 1997, EUR RESPIR J, V10, P866; Polosa R, 1997, J ALLERGY CLIN IMMUN, V99, P338, DOI 10.1016/S0091-6749(97)70051-4; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; Polosa R, 1997, THORAX, V52, P919; Polosa R, 1998, EUR RESPIR J, V12, P551, DOI 10.1183/09031936.98.12030551; POLOSA R, 1990, AM REV RESPIR DIS, V142, P1367; PROUD D, 1997, LUNG, P89; PYE S, 1995, AM J RESP CRIT CARE, V151, P337; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369; Rajakulasingam K, 1996, J APPL PHYSIOL, V80, P1973; RAJAKULASINGAM K, 1995, J ALLERGY CLIN IMMUN, V96, P502, DOI 10.1016/S0091-6749(95)70294-6; RAJAKULASINGAM K, 1993, J ALLERGY CLIN IMMUN, V92, P140, DOI 10.1016/0091-6749(93)90049-L; RAJAKULASINGAM K, 1994, THORAX, V49, P485, DOI 10.1136/thx.49.5.485; Reiss TF, 1997, THORAX, V52, P1030; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RICHARDS R, 1989, CLIN EXP ALLERGY, V19, P285, DOI 10.1111/j.1365-2222.1989.tb02385.x; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; RIMMER J, 1986, CLIN ALLERGY, V16, P221, DOI 10.1111/j.1365-2222.1986.tb00769.x; ROBUSCHI M, 1989, Pulmonary Pharmacology, V1, P187, DOI 10.1016/S0952-0600(89)80016-X; ROBUSCHI M, 1988, Respiration, V54, P100; ROBUSCHI M, 1987, CLIN ALLERGY, V17, P69, DOI 10.1111/j.1365-2222.1987.tb02321.x; ROBUSCHI M, 1992, AM REV RESPIR DIS, V145, P1285; RODWELL LT, 1992, EUR RESPIR J, V5, P953; RODWELL LT, 1993, THORAX, V48, P208, DOI 10.1136/thx.48.3.208; RODWELL LT, 1993, EUR RESPIR J, V6, P855; RODWELL LT, 1991, EUR RESPIR J, V4, P1126; Rodwell LT, 1997, THORAX, V52, P59; RODWELL LT, 1992, AM REV RESPIR DIS, V146, P1149; RODWELL LT, 1993, EUR J RESP DIS S17, V6, pS200; ROGERS DF, 1993, THORAX, V48, P1095, DOI 10.1136/thx.48.11.1095; ROSENTHAL RR, 1990, AM REV RESPIR DIS, V141, P368; SAETTA M, 1995, J ALLERGY CLIN IMMUN, V95, P1285, DOI 10.1016/S0091-6749(95)70088-9; SAKAMOTO T, 1994, AM J RESP CRIT CARE, V149, P387; SARIA A, 1988, AM REV RESPIR DIS, V137, P1330; Schmidt D, 1996, EUR J CLIN PHARMACOL, V50, P269, DOI 10.1007/s002280050106; Schmidt D, 1996, Pneumologie, V50, P779; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285; SCHWARTZ HJ, 1984, J ALLERGY CLIN IMMUN, V74, P511, DOI 10.1016/0091-6749(84)90387-7; SEIDENBERG J, 1992, ARCH DIS CHILD, V67, P214; SHEPPARD D, 1982, J APPL PHYSIOL, V53, P169; SHEPPARD D, 1983, ENVIRON RES, V30, P412, DOI 10.1016/0013-9351(83)90227-X; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; SHEPPARD D, 1983, AM REV RESPIR DIS, V127, P691; Shimizu T, 1997, AM J RESP CRIT CARE, V155, P170; Siffredi M, 1997, ANN ALLERG ASTHMA IM, V78, P238; SIMONSSON BG, 1973, RESPIRATION, V30, P378; SMITH CM, 1990, EUR RESPIR J, V3, P144; SMITH CM, 1987, J ALLERGY CLIN IMMUN, V79, P85, DOI 10.1016/S0091-6749(87)80021-0; SMITH CM, 1989, EUR RESPIR J, V2, P36; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SOLWAY J, 1993, J CLIN INVEST, V92, P315, DOI 10.1172/JCI116569; SOLWAY J, 1991, J APPL PHYSIOL, V71, P2077; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TAL A, 1984, J PEDIATR-US, V104, P516, DOI 10.1016/S0022-3476(84)80539-9; Taylor DA, 1998, THORAX, V53, P483; THOMSON NC, 1978, THORAX, V33, P694, DOI 10.1136/thx.33.6.694; TRANFA CME, 1995, EUR RESPIR J, V8, P600; TULLETT WM, 1985, THORAX, V40, P41, DOI 10.1136/thx.40.1.41; TULLETT WM, 1982, THORAX, V37, P737, DOI 10.1136/thx.37.10.737; Van Schoor J, 1999, AM J RESP CRIT CARE, V159, pA880; Van Schoor J, 1998, EUR RESPIR J, V12, P17, DOI 10.1183/09031936.98.12010017; VanSchoor J, 1997, AM J RESP CRIT CARE, V155, P875; VARONIER HS, 1968, INT ARCH ALLER A IMM, V34, P293; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Wang M, 1996, THORAX, V51, P799, DOI 10.1136/thx.51.8.799; WIEBICKE W, 1990, J ALLERGY CLIN IMMUN, V86, P915, DOI 10.1016/S0091-6749(05)80155-1; WIEBICKE W, 1988, PEDIATR PULM, V4, P225, DOI 10.1002/ppul.1950040407; WILKENS JH, 1990, BRIT J CLIN PHARMACO, V29, P85; WILSON N, 1984, THORAX, V39, P588, DOI 10.1136/thx.39.8.588; WILSON NM, 1982, THORAX, V37, P657, DOI 10.1136/thx.37.9.657; Wojnarowski C, 1996, EUR RESPIR J, V9, P1896, DOI 10.1183/09031936.96.09091896; WOLFSDORF J, 1969, PEDIATRICS, V43, P799; WOOLCOCK AJ, 1991, AM REV RESPIR DIS, V143, P1438; WRIGHT W, 1990, AM REV RESPIR DIS, V141, P1400; ZEBALLOS RJ, 1978, AM REV RESPIR DIS, V118, P877	293	126	130	1	5	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2000	16	3					514	533		10.1034/j.1399-3003.2000.016003514.x		20	Respiratory System	Respiratory System	359RH	WOS:000089625500026	11028670	
J	Rundell, KW; Wilber, RL; Szmedra, L; Jenkinson, DM; Mayers, LB; Im, J				Rundell, KW; Wilber, RL; Szmedra, L; Jenkinson, DM; Mayers, LB; Im, J			Exercise-induced asthma screening of elite athletes: field versus laboratory exercise challenge	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						bronchospasm; athlete; exercise; cold; pulmonary function test	CROSS-COUNTRY SKIERS; INDUCED BRONCHOSPASM; COLD-AIR; FIGURE SKATERS; RESPONSIVENESS; INHALATION; HYPERPNEA; DIAGNOSIS; EXPOSURE; SEVERITY	Purpose: The purpose of this study was to compare a laboratory based exercise challenge (LBC) to a field based exercise challenge (FBC) for pulmonary function test (PFT) exercise-induced asthma (EIA) screening of elite athletes. Methods: Twenty-three elite cold weather athletes (14 men, 9 women) PFT positive for EIA (FBC screened) served as subjects. Twenty-three gender and sport matched Controls (nonasthmatics) were randomly selected to establish PFT reference values for normal elite athletes. Before FBC, athletes completed a medical history questionnaire for EIA symptoms. FBC evaluations consisted of baseline spirometry, actual or simulated competition, and 5, 10, and 15 min postexercise spirometry. PFT positive athletes were evaluated in the laboratory using an exercise challenge simulating race intensity (ambient conditions: 21 degrees C, 60% relative humidity). PFT procedures were identical to FBC. Results: 91%, of PFT positive and 48% of PFT normal athletes reported at least one symptom of EIA, with postrace cough most frequent. Baseline spirometry was the same for PFT positives and normal controls. Lower limit reference range (MN - 2 SD) of FEV1 for controls suggests that postexercise decrements of greater than similar to-7% indicate abnormal airway response in this population. Exercise time duration did not effect bronchial reactivity; 78% of FBC PFT positives; were PFT normal post-LBC. Conclusion: Self-reported symptoms by elite athletes are not reliable in identifying EIA. Reference range criterion for FEV1 decrement in the elite athlete postexercise contrasts current recommended guidelines. Moreover, a large number of false negatives may occur in this population if EIA screening is performed with inadequate exercise and environmental stress.	United States Olymp Comm Lake Placid, Sport Sci & Technol Div, Lake Placid, NY 12946 USA	Rundell, KW (reprint author), United States Olymp Comm Lake Placid, Sport Sci & Technol Div, Lake Placid, NY 12946 USA.						American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; BECK KC, 1994, AM J RESP CRIT CARE, V149, P352; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; EGGLESTON PA, 1986, MED SCI SPORT EXER, V18, P318, DOI 10.1249/00005768-198606000-00011; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; Giesbrecht G G, 1995, Can J Appl Physiol, V20, P300; GODFREY S, 1975, PEDIATRICS, V56, P893; HAAS F, 1986, J APPL PHYSIOL, V61, P210; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P128; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P134; Helenius IJ, 1996, THORAX, V51, P628, DOI 10.1136/thx.51.6.628; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; KATZ RM, 1986, MED SCI SPORT EXER, V18, P331, DOI 10.1249/00005768-198606000-00014; KONIG P, 1989, ALLERGY PROC, V10, P345, DOI 10.2500/108854189778959830; Larsson L., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P124; LEE KY, 1994, J SPORT SCI, V12, P279, DOI 10.1080/02640419408732173; MAHLER DA, 1993, MED SCI SPORT EXER, V25, P554; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCKENZIE DC, 1994, MED SCI SPORT EXER, V26, P951; MCLAUGHLIN FJ, 1983, PEDIATRICS, V72, P503; NOVISKI N, 1987, AM REV RESPIR DIS, V136, P592; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; RICE SG, 1985, ANN ALLERGY, V55, P790; RUNDELL KW, IN PRESS MED SCI SPO; RUPP NT, 1992, AM J DIS CHILD, V146, P941; Rupp NT, 1996, PHYSICIAN SPORTSMED, V24, P77, DOI 10.3810/psm.1996.01.1213; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; Tan RA, 1998, SPORTS MED, V25, P1, DOI 10.2165/00007256-199825010-00001; Tikkanen H. O., 1999, Medicine and Science in Sports and Exercise, V31, pS99, DOI 10.1097/00005768-199905001-00335; Tikkanen Heikki Iikka Helenius, 1996, Medicine and Science in Sports and Exercise, V28, pS90; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; WARREN JB, 1984, CLIN SCI, V66, P79; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WILBER RL, IN PRESS MED SCI SPO	38	126	129	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2000	32	2					309	316		10.1097/00005768-200002000-00010		8	Sport Sciences	Sport Sciences	283TG	WOS:000085291400010	10694112	
J	Paunio, M; Heinonen, OP; Virtanen, M; Leinikki, P; Patja, A; Peltola, H				Paunio, M; Heinonen, OP; Virtanen, M; Leinikki, P; Patja, A; Peltola, H			Measles history and atopic diseases - A population-based cross-sectional study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							VACCINATION PROGRAM; ASTHMA; INFECTIONS; CHILDHOOD; RUBELLA; FINLAND; MUMPS; CHILDREN; SIZE	Context Many recent cross-sectional studies have suggested that lack of early exposure to communicable diseases, including measles, in affluent countries may have increased rates of atopic disease. Objective To study the association between natural measles infection and atopy, Design and Setting Cross-sectional nationwide study in Finland using data gathered between November 1, 1982, and June 30, 1986. Subjects A total of 547 910 individuals aged 14 months to 19 years who at the time of measles-mumps-rubella (MMR) vaccination had relevant information collected on the occurrence of measles and allergic rhinitis, eczema, and asthma. Main Outcome Measures Lifetime occurrence of atopic manifestations in subjects who had had measles compared with those who had not, expressed as age-specific and age-adjusted prevalence ratios. Results The age-adjusted prevalence ratio of atopic manifestations among those who had had measles (n = 20 690) compared with those who had not (n = 527 220) was 1.32 (95% confidence interval [CI], 1.27-1.36) for eczema, 1.41 (95% CI, 1.33-1.49) for rhinitis, and 1.67 (95% CI, 1.54-1.79) for asthma. The positive association between measles and atopy was evident at all ages, in both urban and rural dwellers, and among subjects with many or few contacts at home or in day care. Conclusions Based on our data, measles and atopy occur more frequently together than expected, which does not support the hypothesis that experiencing natural measles infection offers protection against atopic disease.	Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Assoc Local & Reg Author, Dept Hosp Serv, Helsinki, Finland; Natl Publ Hlth Inst, Dept Infect Dis, Helsinki, Finland; Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland	Paunio, M (reprint author), Minist Social Affairs & Hlth, POB 267, Helsinki 00171, Finland.						Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; Bodner C, 1998, THORAX, V53, P28; Campbell DE, 1996, LANCET, V348, P825, DOI 10.1016/S0140-6736(05)65244-0; *CENTR STAT OFF FI, 1987, STAT YB FINL 1987; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; FOX JP, 1971, AM J EPIDEMIOL, V94, P179; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; Hayney M S, 1998, Int J Infect Dis, V2, P143, DOI 10.1016/S1201-9712(98)90116-3; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1997, BRIT MED J, V314, P999; PAUNIO M, 1991, AM J EPIDEMIOL, V133, P1152; PELTOLA H, 1994, NEW ENGL J MED, V331, P1397, DOI 10.1056/NEJM199411243312101; PELTOLA H, 1986, LANCET, V1, P137; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Soothill JF, 1996, LANCET, V348, P825, DOI 10.1016/S0140-6736(05)65245-2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; VONMUTIUS E, 1994, BRIT MED J, V308, P692	22	126	130	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	2000	283	3					343	346		10.1001/jama.283.3.343		4	Medicine, General & Internal	General & Internal Medicine	273WM	WOS:000084732400025	10647796	
J	Ryman-Rasmussen, JP; Tewksbury, EW; Moss, OR; Cesta, MF; Wong, BA; Bonner, JC				Ryman-Rasmussen, Jessica P.; Tewksbury, Earl W.; Moss, Owen R.; Cesta, Mark F.; Wong, Brian A.; Bonner, James C.			Inhaled Multiwalled Carbon Nanotubes Potentiate Airway Fibrosis in Murine Allergic Asthma	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						carbon nanotubes; asthma; fibrosis; lung	INTRATRACHEAL INSTILLATION; PULMONARY TOXICITY; MICE; PARTICLES; INTERLEUKIN-13; FIBROBLASTS; DEPOSITION; RESPONSES; EXPOSURE	Carbon nanotubes are gaining increasing attention due to possible health risks from occupational or environmental exposures. This study tested the hypothesis that inhaled multiwalled carbon nanotubes (MWCNT) would increase airway fibrosis in mice with allergic asthma. Normal and ovalbumin-sensitized mice were exposed to a MWCNT aerosol (100 mg/m(3)) or saline aerosol for 6 hours. Lung injury, inflammation, and fibrosis were examined by histopathology, clinical chemistry, ELISA, or RT-PCR for cytokines/chemokines, growth factors, and Collagen at 1 and 14 days after inhalation. Inhaled MWCNT were distributed throughout the lung and found in macrophages by light microscopy, but were also evident in epithelial cells by electron microscopy. Quantitative morphometry showed significant airway fibrosis at 14 days in mice that received a combination of ovalbumin and MWCNT, but not in mice that received ovalbumin or MWCNT only. Ovalbumin-sensitized mice that did not inhale MWCNT had elevated levels IL-13 and transforming growth factor (TGF)-beta 1 in lung lavage fluid, but not platelet-derived growth factor (PDGF)-AA. In contrast, unsensitized mice that inhaled MWCNT had elevated PDGF-AA, but not increased levels of TGF-beta 1 and IL-13. This suggested that airway fibrosis resulting from combined ovalbumin sensitization and MWCNT inhalation requires PDGF, a potent fibroblast mitogen, and TGF-beta 1, which stimulates Collagen production. Combined ovalbumin sensitization and MWCNT inhalation also synergistically increased IL-5 mRNA levels, which could further contribute to airway fibrosis. These data indicate that inhaled MWCNT require pre-existing inflammation to cause airway fibrosis. Our findings suggest that individuals with pre-existing allergic inflammation may be susceptible to airway fibrosis from inhaled MWCNT.	[Ryman-Rasmussen, Jessica P.; Cesta, Mark F.; Bonner, James C.] N Carolina State Univ, Dept Environm & Mol Toxicol, Raleigh, NC 27695 USA; [Ryman-Rasmussen, Jessica P.; Tewksbury, Earl W.; Moss, Owen R.; Cesta, Mark F.; Wong, Brian A.; Bonner, James C.] Hamner Inst Hlth Sci, Res Triangle Pk, NC USA; [Cesta, Mark F.] Natl Inst Environm Hlth Sci, Cellular & Mol Pathol Branch, Res Triangle Pk, NC USA	Bonner, JC (reprint author), N Carolina State Univ, Dept Environm & Mol Toxicol, Box 7633, Raleigh, NC 27695 USA.	james_bonner@ncsu.edu			The American Chemistry Council's Long Range Research Initiative; The Intramural Research Program of the National Institutes of Health; National Institute of the Environmental Health Sciences; North Carolina State University's College of Agricultural and Life Sciences	This study was funded by The American Chemistry Council's Long Range Research Initiative provided to The Hamner Institutes for Health Sciences, The Intramural Research Program of the National Institutes of Health, National Institute of the Environmental Health Sciences, and North Carolina State University's College of Agricultural and Life Sciences.	Bianco A, 2005, CURR OPIN CHEM BIOL, V9, P674, DOI 10.1016/j.cbpa.2005.10.006; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Card JW, 2007, AM J RESP CELL MOL, V37, P300, DOI 10.1165/rcmb.2007-00570C; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Doherty T, 2007, CURR OPIN IMMUNOL, V19, P676, DOI 10.1016/j.coi.2007.07.017; Donaldson K, 2006, TOXICOL SCI, V92, P5, DOI 10.1093/toxsci/kfj130; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Gavett SH, 2001, INT ARCH ALLERGY IMM, V124, P109, DOI 10.1159/000053685; Ingram JL, 2006, J IMMUNOL, V177, P4141; Inoue K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-106; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lewis CC, 2005, J ALLERGY CLIN IMMUN, V115, P534, DOI 10.1016/j.jaci.2004.11.051; Li JG, 2007, ENVIRON TOXICOL, V22, P415, DOI 10.1002/tox.20270; Lison D, 2008, TOXICOL SCI, V101, P179, DOI 10.1093/toxsci/kfm249; Mangum James B, 2006, Part Fibre Toxicol, V3, P15, DOI 10.1186/1743-8977-3-15; Matsumoto A, 2006, CLIN IMMUNOL, V121, P227, DOI 10.1016/j.clim.2006.08.003; Maynard AD, 2004, J TOXICOL ENV HEAL A, V67, P87, DOI 10.1080/15287390490253688; Melechko AV, 2005, J APPL PHYS, V97, P1; Mercer RR, 2008, AM J PHYSIOL-LUNG C, V294, pL87, DOI 10.1152/ajplung.00186.2007; Miller FJ, 2000, INHAL TOXICOL, V12, P19, DOI 10.1080/089583700196536; Mitchell LA, 2007, TOXICOL SCI, V100, P203, DOI 10.1093/toxsci/kfm196; Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008; National Institute for Occupational Safety and Health (NIOSH), 2005, NIOSH POCK GUID CHEM; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111; Samuelsen M, 2008, TOXICOLOGY, V246, P124, DOI 10.1016/j.tox.2008.01.001; Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005; Voltz JW, 2008, AM J RESP CELL MOL, V39, P45, DOI 10.1165/rcmb.2007-0340OC; Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wynn TA, 2008, J PATHOL, V214, P199, DOI 10.1002/path.2277	33	125	126	1	9	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAR	2009	40	3					349	358		10.1165/rcmb.2008-0276OC		10	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	412PC	WOS:000263735700012	18787175	
J	Busacker, A; Newell, JD; Keefe, T; Hoffman, EA; Granroth, JC; Castro, M; Fain, S; Wenzel, S				Busacker, Ashley; Newell, John D., Jr.; Keefe, Thomas; Hoffman, Eric A.; Granroth, Janice Cook; Castro, Mario; Fain, Sean; Wenzel, Sally			A Multivariate Analysis of Risk Factors for the Air-Trapping Asthmatic Phenotype as Measured by Quantitative CT Analysis	CHEST			English	Article						air trapping; asthma; atopy; neutrophils; quantitative CT	OBSTRUCTIVE PULMONARY-DISEASE; VOLUME REDUCTION SURGERY; COMPUTED-TOMOGRAPHY; OBJECTIVE QUANTIFICATION; LUNG DENSITOMETRY; HUMAN NEUTROPHILS; FLOW OBSTRUCTION; ALLERGIC-ASTHMA; EMPHYSEMA; DENSITY	Background: Patients with severe asthma have increased physiologically measured air trapping; however, a study using CT measures of air trapping has not been performed. This study was designed to address two hypotheses: (1) air trapping measured by multidetector CT (MDCT) quantitative methodology would be a predictor of a more severe asthma phenotype; and (2) historical, clinical, allergic, or inflammatory risk factors could be identified via multivariate analysis. Methods: MDCT scanning of a subset of Severe Asthma Research Program subjects ,vas performed at functional residual capacity. Air trapping was defined as >= 9.66% of the lung tissue < - 850 Hounsfield units (HU). Subjects classified as having air trapping were then compared to subjects without air trapping on clinical and demographic factors using both univariate and multivariate statistical analyses. Results: Subjects with air trapping were significantly more likely to have a history of asthma-related hospitalizations, ICU visits, and/or mechanical ventilation.. Duration of asthma a (odds ratio [OR], 1.42; 95% confidence interval [CI], 1.08 to 1.87), history pneumonia (OR, 8.55; 95% CI, 2.07 to 35.26), high levels of airway neutrophils (OR, 8.67; 95% CI, 2.05 to 36.57), airflow obstruction (FEN(1)/FVC) OR, 1.61; 95% CI, 1.21 to 2.14], and atopy (OR, 11.54; 95% CI, 1.97 to 67.70) were identified as independent risk factors associated with the air-trapping phenotype. Conclusions: Quantitative CT-determined air trapping in asthmatic subjects identifies a group of individuals it high risk for severe disease. Several independent risk factors for the presence of this phenotype were identified: perhaps most interestingly, history of Pneumonia, neutrophilic inflammation, and atopy. (CHEST 2009; 135:48-56)	[Busacker, Ashley; Keefe, Thomas] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA; [Newell, John D., Jr.] Natl Jewish Med & Res Ctr, Div Radiol, Denver, CO USA; [Hoffman, Eric A.; Granroth, Janice Cook] Univ Iowa, Dept Radiol, Carver Coll Med, Iowa City, IA 52242 USA; [Castro, Mario] Washington Univ, Sch Med, Div Pulm & Crit Care Med, St Louis, MO USA; [Fain, Sean] Univ Wisconsin, Madison, WI USA; [Wenzel, Sally] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA USA	Busacker, A (reprint author), Colorado State Univ, Dept Environm & Radiol Hlth Sci, Campus Delivery 1681, Ft Collins, CO 80523 USA.	Ashley.Busacker@colostate.edu	Fain, Sean/K-4260-2016	Fain, Sean/0000-0001-5461-0646	National Institutes of Health [HL69149, HL64368, HL69349, HL69170, HL-69155, HL69174, HL69130, HL69167, HL69116, HL69174-05]	Grant support was provided by National Institutes of Health HL69149, HL64368, HL69349, HL69170, HL-69155, HL69174, HL69130. HL69167, HL69116, and HL69174-05.	Bakker ME, 2005, INVEST RADIOL, V40, P777, DOI 10.1097/01.rli.0000186418.31139.21; Bankier AA, 1999, RADIOLOGY, V211, P851; Bankier Alexander A, 2002, Crit Rev Comput Tomogr, V43, P399; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; Brown LG, 2006, ABEL SYMP, V1, P1, DOI 10.1007/978-3-540-34197-0_1; Brown RH, 2003, EUR RESPIR J, V22, P57, DOI 10.1183/09031936.03.00090403; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; COX G, 1995, J IMMUNOL, V154, P4719; Coxson HO, 1999, AM J RESP CRIT CARE, V159, P851; COXSON HO, 1995, J APPL PHYSIOL, V79, P1525; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4; Ernst P, 2007, AM J RESP CRIT CARE, V176, P162, DOI 10.1164/rccm.200611-1630OC; Gevenois PA, 1996, RADIOLOGY, V199, P825; Gierada DS, 1997, RADIOLOGY, V205, P235; Gierada DS, 2001, RADIOLOGY, V220, P448; Gierada DS, 2000, CHEST, V117, P991, DOI 10.1378/chest.117.4.991; GOULD GA, 1988, AM REV RESPIR DIS, V137, P380; Hoffman EA, 2004, ACAD RADIOL, V11, P1370, DOI 10.1016/j.acra.2004.09.005; HOFFMAN EA, 1985, J APPL PHYSIOL, V59, P468; Hoffman EA, 2003, ACAD RADIOL, V10, P1104, DOI 10.1016/S1076-6332(03)00330-1; HOFFMAN EA, 1983, J APPL PHYSIOL, V54, P1414; Hosmer D. W., 2000, APPL LOGISTIC REGRES; Hu SY, 2001, IEEE T MED IMAGING, V20, P490, DOI 10.1109/42.929615; Huda W, 2007, AM J ROENTGENOL, V188, P540, DOI 10.2214/AJR.06.0101; Jain N, 2005, PEDIATR PULM, V40, P211, DOI 10.1002/ppul.20215; Johnson JL, 1998, RADIOLOGY, V206, P95; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; LILES WC, 1995, BLOOD, V86, P3181; Madani A, 2006, RADIOLOGY, V238, P1036, DOI 10.1148/radiol.2382042196; Martinez FJ, 2006, AM J RESP CRIT CARE, V173, P1326, DOI 10.1164/rccm.200510-1677OC; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Mauad Thais, 1999, American Journal of Respiratory and Critical Care Medicine, V160, P968; Mergo PJ, 1998, AM J ROENTGENOL, V170, P1355; MINIATI M, 1995, AM J RESP CRIT CARE, V151, P1359; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Mitsunobu F, 2001, THORAX, V56, P851, DOI 10.1136/thorax.56.11.851; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Newell J D Jr, 2004, Eur Respir J, V23, P769, DOI 10.1183/09031936.04.00026504; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; Pham DN, 2003, ANN ALLERG ASTHMA IM, V90, P72; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; van Beek EJR, 2008, CLIN CHEST MED, V29, P195, DOI 10.1016/j.ccm.2007.12.003; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604; Walamies MA, 1998, CLIN PHYSIOL, V18, P49; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel S, 2000, AM J RESP CRIT CARE, V162, P2341	51	125	130	0	2	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JAN	2009	135	1					48	56		10.1378/chest.08-0049		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	392LN	WOS:000262304300011	18689585	
J	Prescott, SL; Smith, P; Tang, M; Palmer, DJ; Sinn, J; Huntley, SJ; Cormack, B; Heine, RG; Gibson, RA; Makrides, M				Prescott, Susan L.; Smith, Peter; Tang, Mimi; Palmer, Debra J.; Sinn, John; Huntley, Sophie J.; Cormack, Barbara; Heine, Ralf G.; Gibson, Robert A.; Makrides, Maria			The importance of early complementary feeding in the development of oral tolerance: Concerns and controversies	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						infant feeding; weaning practices; allergy prevention; growth and development	BREAST-FED INFANTS; PROSPECTIVE BIRTH COHORT; SOLID FOOD INTRODUCTION; ALLERGIC DISEASE; CHILDHOOD ECZEMA; CELIAC-DISEASE; NEW-ZEALAND; FOLLOW-UP; PREVENTION; RISK	Rising rates of food allergies in early childhood reflect increasing failure of early immune tolerance mechanisms. There is mounting concern that the current recommended practice of delaying complementary foods until 6 months of age may increase, rather than decrease, the risk of immune disorders. Tolerance to food allergens appears to be driven by regular, early exposure to these proteins during a 'critical early window' of development. Although the timing of this window is not clear in humans, current evidence suggests that this is most likely to be between 4 and 6 months of life and that delayed exposure beyond this period may increase the risk of food allergy, coeliac disease and islet cell autoimmunity. There is also evidence that other factors such as favourable colonization and continued breastfeeding promote tolerance and have protective effects during this period when complementary feeding is initiated. This discussion paper explores the basis for concern over the current recommendation to delay complementary foods as an approach to preventing allergic disease. It will also examine the growing case for introducing complementary foods from around 4 months of age and maintaining breastfeeding during this early feeding period, for at least 6 months if possible.	[Prescott, Susan L.] Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth Res, Perth, WA 6001, Australia; [Smith, Peter] Bond Univ, Sch Med, Gold Coast, Qld, Australia; [Tang, Mimi] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Palmer, Debra J.; Makrides, Maria] Womens & Childrens Hlth Res Inst, Children Youth & Womens Hlth Serv, Adelaide, SA, Australia; [Sinn, John] Royal N Shore Hosp, Dept Neonatol, St Leonards, NSW 2065, Australia; [Huntley, Sophie J.] Flinders Univ S Australia, Dept Nutr & Dietet, Adelaide, SA, Australia; [Cormack, Barbara] Auckland City Hosp, Nutr Serv, Auckland, New Zealand; [Heine, Ralf G.] Royal Childrens Hosp, Dept Gastroenterol & Clin Nutr, Parkville, Vic 3052, Australia; [Gibson, Robert A.] Univ Adelaide, Sch Agr Food & Wine, Adelaide, SA, Australia	Prescott, SL (reprint author), Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth Res, POB D184, Perth, WA 6001, Australia.	sprescott@meddent.uwa.edu.au	Palmer, Debra /L-8554-2013; Makrides, Maria/B-6392-2014; Prescott, Susan/H-5665-2014	Makrides, Maria/0000-0003-3832-541X; Cormack, Barbara/0000-0003-2329-8287; Gibson, Robert/0000-0002-8750-525X			Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Baker SS, 2000, PEDIATRICS, V106, P346; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chantry CJ, 2007, BREASTFEED MED, V2, P63, DOI 10.1089/bfm.2007.0002; Exl BM, 2000, EUR J NUTR, V39, P145, DOI 10.1007/s003940070018; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1982, J EPIDEMIOL COMMUN H, V36, P118, DOI 10.1136/jech.36.2.118; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.01; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10; FORSYTH JS, 1993, BRIT MED J, V306, P1572; Halken S, 1996, PEDIATR ALLERGY IMMU, V7, P102, DOI 10.1111/j.1399-3038.1996.tb00407.x; Host A, 1999, ARCH DIS CHILD, V81, P80; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; Kajosaari M, 1991, Adv Exp Med Biol, V310, P453; Kramer MS, 2004, ADV EXP MED BIOL, V554, P63; Kramer MS, 2000, ADV EXP MED BIOL, V478, P327; Lanigan JA, 2001, EUR J CLIN NUTR, V55, P309, DOI 10.1038/sj.ejcn.1601168; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Munns C, 2006, MED J AUSTRALIA, V185, P268; Norris JM, 2005, JAMA-J AM MED ASSOC, V293, P2343, DOI 10.1001/jama.293.19.2343; Norris JM, 2003, JAMA-J AM MED ASSOC, V290, P1713, DOI 10.1001/jama.290.13.1713; POLOUS LM, 2007, J ALLERGY CLIN IMMUN, V120, P878; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Prescott SL, 2005, MED J AUSTRALIA, V182, P464; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Skeaff SA, 2005, NUTRITION, V21, P325, DOI 10.1016/j.nut.2004.07.004; Sudo N, 1997, J IMMUNOL, V159, P1739; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; WALRAVENS PA, 1992, LANCET, V340, P683, DOI 10.1016/0140-6736(92)92229-9; *WHO DEP NUTR HLTH, 2001, OPT DUR EXCL BREASTF; ZEIGER R, 1995, J ALLERGY CLIN IMMUN, V96, P1179; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	34	125	132	5	21	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0905-6157			PEDIAT ALLERG IMM-UK	Pediatr. Allergy Immunol.	AUG	2008	19	5					375	380		10.1111/j.1399-3038.2008.00718.x		6	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	325EI	WOS:000257570900001	18266825	
J	Liu, J; Ballaney, M; Al-Alem, U; Quan, C; Jin, X; Perera, F; Chen, LC; Miller, RL				Liu, Jinming; Ballaney, Manisha; Al-Alem, Umaima; Quan, Chunli; Jin, Ximei; Perera, Frederica; Chen, Lung-Chi; Miller, Rachel L.			Combined inhaled diesel exhaust particles and allergen exposure alter methylation of T helper genes and IgE production In vivo	TOXICOLOGICAL SCIENCES			English	Article						environmental exposure; respiratory sensitization; cytokines; inhalation toxicology; epigenetic modification.	IFN-GAMMA GENE; CELL DIFFERENTIATION; TH2 DIFFERENTIATION; AIR-POLLUTION; EXPRESSION; PROMOTER; CPG; DEMETHYLATION; TRANSCRIPTION; ENVIRONMENT	Changes in methylation of CpG sites at the interleukin (IL)-4 and interferon (IFN)-gamma promoters are associated with T helper (Th) 2 polarization in vitro. No previous studies have examined whether air pollution or allergen exposure alters methylation of these two genes in vivo. We hypothesized that diesel exhaust particles (DEP) would induce hypermethylation of the IFN-gamma promoter and hypomethylation of IL-4 in CD4(+) T cells among mice sensitized to the fungus allergen Aspergillus fumigatus. We also hypothesized that DEP-induced methylation changes would affect immunoglobulin (Ig) E regulation. BALB/c mice were exposed to a 3-week course of inhaled DEP exposure while undergoing intranasal sensitization to A. fumigatus. Purified DNA from splenic CD4(+) cells underwent bisulfite treatment, PCR amplification, and pyrosequencing. Sera IgE levels were compared with methylation levels at several CpG sites in the IL-4 and IFN-gamma promoter. Total IgE production was increased following intranasal sensitization A. fumigatus. IgE production was augmented further following combined exposure to A. fumigatus and DEP exposure. Inhaled DEP exposure and intranasal A. fumigatus induced hypermethylation at CpG(-45), CpG(-53), CpG(-205) sites of the IFN-gamma promoter and hypomethylation at CpG(-408) of the IL-4 promoter. Altered methylation of promoters of both genes was correlated significantly with changes in IgE levels. This study is the first to demonstrate that inhaled environmental exposures influence methylation of Th genes in vivo, supporting a new paradigm in asthma pathogenesis.	[Liu, Jinming; Ballaney, Manisha; Al-Alem, Umaima; Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA; [Quan, Chunli; Jin, Ximei; Chen, Lung-Chi] NYU, Tuxedo Pk, NY 10987 USA; [Perera, Frederica] Columbia Univ, Joseph L Mailman Sch Publ Hlth, New York, NY 10032 USA	Miller, RL (reprint author), Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, PH8C,630 W 168th St, New York, NY 10032 USA.	rlm14@columbia.edu	Cjem, Lung-Chi/H-5030-2012	Chen, Lung Chi/0000-0003-1154-2107	NIEHS NIH HHS [P30 ES000260, 1R21ES013063, ES00260, P01 ES009600, P01ES09600, R01 ES015495, R01ES015495, R21 ES013063, R21 ES013063-01, R21 ES013063-02, R21 ES013063-03]		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Belinsky SA, 2002, CARCINOGENESIS, V23, P335, DOI 10.1093/carcin/23.2.335; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; COMB M, 1990, NUCLEIC ACIDS RES, V18, P3975, DOI 10.1093/nar/18.13.3975; Dupont JM, 2004, ANAL BIOCHEM, V333, P119, DOI 10.1016/j.ab.2004.05.007; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gilmour P.S., 2003, AM J PHYSIOL-LUNG C, V284, P533; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kersh EN, 2006, J IMMUNOL, V176, P4083; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; McDonald JD, 2004, AEROSOL SCI TECH, V38, P62, DOI 10.1080/02786820490247623; Miller RL, 1999, AM J PUBLIC HEALTH, V89, P819, DOI 10.2105/AJPH.89.6.819; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Padilla J, 2005, J IMMUNOL, V174, P8097; Thompson SL, 2001, TOXICOL LETT, V120, P143, DOI 10.1016/S0378-4274(01)00292-2; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tykocinski LO, 2005, J BIOL CHEM, V280, P28177, DOI 10.1074/jbc.M502038200; VENN AJ, 2001, AM J RESP CRIT CARE, V164, P2217; Vickaryous N, 2005, REPROD FERT DEVELOP, V17, P335, DOI 10.1071/RD04133; White GP, 2002, J IMMUNOL, V168, P2820; White GP, 2006, PEDIATR ALLERGY IMMU, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Yano S, 2003, J IMMUNOL, V171, P2510; YE JP, 1994, J BIOL CHEM, V269, P25728; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	32	125	135	0	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080			TOXICOL SCI	Toxicol. Sci.	MAR	2008	102	1					76	81		10.1093/toxsci/kfm290		6	Toxicology	Toxicology	260PY	WOS:000253023600007	18042818	
J	Celedon, JC; Milton, DK; Ramsey, CD; Litonjua, AA; Ryan, L; Platts-Mills, TAE; Gold, DR				Celedon, Juan C.; Milton, Donald K.; Ramsey, Clare D.; Litonjua, Augusto A.; Ryan, Louise; Platts-Mills, Thomas A. E.; Gold, Diane R.			Exposure to dust mite allergen and endotoxin in early life and asthma and atopy in childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; dust mite; wheeze; atopy; asthma	DAY-CARE ATTENDANCE; HOUSE-DUST; 1ST YEAR; LIMULUS ASSAY; P-I; CHILDREN; WHEEZE; RISK; HISTORY; INFANCY	Background: There has been no longitudinal study of the relation between concurrent exposure to dust mite allergen and endotoxin in early life and asthma and atopy at school age. Objectives: To examine the relation between exposure to dust mite allergen and endotoxin at age 2 to 3 months and asthma, wheeze, and atopy in high-risk children. Methods: Birth cohort study of 440 children with parental history of atopy in the Boston metropolitan area. Results: In multivariate analyses, early exposure to high levels of dust mite allergen (>= 10 mu g/g) was associated with increased risks of asthma at age 7 years (odds ratio [OR], 3.0; 95% CI, 1.1-7.9) and late-onset wheeze (OR, 5.0; 95% Cl, 1.5-16.4). Exposure to endotoxin levels above the lowest quartile at age 2 to 3 months was associated with reduced odds of atopy at school age (OR, 0.5; 95% CI, 0.2-0.9). In contrast with its inverse association with atopy, endotoxin exposure in early life was associated with an increased risk of any wheeze between ages I and 7 years that did not change significantly with time (hazard ratio for each quartile increment in endotoxin levels, 1.23; 95% CI, 1.07-1.43). Conclusion: Among children at risk of atopy, early exposure to high levels of dust mite allergen is associated with increased risks of asthma and late-onset wheeze. In these children, endotoxin exposure is associated with a reduced risk of atopy but an increased risk of wheeze. Clinical implications: Early endotoxin exposure may be a protective factor against atopy but a risk factor for wheeze in high-risk children.	Channing Labs, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Univ Massachusetts, Sch Hlth & Environm, Dept Work Environm, Lowell, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Virginia, Dept Med, Asthma & Allergy Ctr, Charlottesville, VA 22903 USA	Celedon, JC (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Ryan, Louise/A-4562-2009; Milton, Donald/G-3286-2010; Mac Sharry, John/B-5509-2011	Ryan, Louise/0000-0001-5957-2490; Milton, Donald/0000-0002-0550-7834; Mac Sharry, John/0000-0002-9528-6261; Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [R01 HL073373, HL04370, HL073373, HL079966, K01 HL004370, R01 HL079966]; NIAID NIH HHS [R01 AI035786, R01 AI035786-10]; NIEHS NIH HHS [ES07036, ES35786, R01 ES007036, R56 ES007036]		Abraham JH, 2005, J ALLERGY CLIN IMMUN, V116, P431, DOI 10.1016/j.jaci.2005.05.015; Andersen P.K., 1982, ANN STAT, V10, P1110; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.6.e77; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LE JM, 1986, J IMMUNOL, V136, P4525; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michel O, 2003, J ENDOTOXIN RES, V9, P293, DOI 10.1179/096805103225002539; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Raby BA, 2004, PEDIATRICS, V114, pE327, DOI 10.1542/peds.2003-0838-L; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; THERNEAU TM, 2000, MODELING SURVIVAL DA, P185; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Wahl SM, 2004, CURR OPIN IMMUNOL, V16, P768, DOI 10.1016/j.coi.2004.09.006	38	125	131	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					144	149		10.1016/j.jaci.2007.03.037		6	Allergy; Immunology	Allergy; Immunology	190NS	WOS:000248066400021	17507083	
J	Izbicki, G; Chavko, R; Banauch, GI; Weiden, MD; Berger, KI; Aldrich, TK; Hall, C; Kelly, KJ; Prezant, DJ				Izbicki, Gabriel; Chavko, Robert; Banauch, Gisela I.; Weiden, Michael D.; Berger, Kenneth I.; Aldrich, Thomas K.; Hall, Charles; Kelly, Kerry J.; Prezant, David J.			World Trade Center "sarcoid-like" granulomatous pulmonary disease in New York city fire department rescue workers	CHEST			English	Article						airway hyperreactivity; asthma; emergency medical services workers; firefighters; granulomatous pneumonitis; sarcoidosis; World Trade Center	BRONCHIAL HYPERREACTIVITY; AIRWAY HYPERREACTIVITY; CENTER COLLAPSE; RISK-FACTORS; CENTER SITE; FIREFIGHTERS; EXPOSURE; PNEUMONITIS; ASSOCIATION; INVOLVEMENT	Background: Previous reports suggest that sarcoidosis occurs with abnormally high frequency in firefighters. We sought to determine whether exposure to World Trade Center (WTC) "dust" during the collapse and rescue/recovery effort increased the incidence of sarcoidosis or "sarcoid-like" granulomatous pulmonary disease (SLGPD). Methods: During the 5 years after the WTC disaster, enrollees in the Fire Department of New York (FDNY) WTC monitoring and treatment programs who had chest radiograph findings suggestive of sarcoidosis underwent evaluation, including the following: chest CT imaging, pulmonary function, provocative challenge, and biopsy. Annual incidence rates were compared to the 15 years before the WTC disaster. Results: After WTC dust exposure, pathologic evidence consistent with new-onset sarcoidosis was found in 26 patients: all 26 patients had intrathoracic adenopathy, and 6 patients (23%) had extrathoracic disease. Thirteen patients were identified during the first year after WTC dust exposure (incidence rate, 86/100,000), and 13 patients were identified during the next 4 years (average annual incidence rate, 22/100,000; as compared to 15/100,000 during the 15 years before the WTC disaster). Eighteen of 26 patients (69%) had findings consistent with asthma. Eight of 21 patients (38%) agreeing to challenge testing had airway hyperreactivity (AHR), findings not seen in FDNY sarcoidosis patients before the WTC disaster. Conclusion: After the WTC disaster, the incidence of sarcoidosis or SLGPD was increased among FDNY rescue workers. This new information about the early onset of WTC-SLGPD and its association with asthma/AHR has important public health consequences for disease prevention, early detection, and treatment following environmental/occupational exposures.	New York City Fire Dept, Off Med Affairs, Brooklyn, NY 11201 USA; Montefiore Med Ctr, Albert Einstein Coll Med, Div Pulm, Bronx, NY 10467 USA; Shaare Zedek Med Ctr, Pulm Inst, IL-91000 Jerusalem, Israel; Ben Gurion Univ Negev, IL-84105 Beer Sheva, Israel; NYU, Coll Med, Div Pulm, New York, NY USA; Albert Einstein Coll Med, Bronx, NY 10467 USA	Prezant, DJ (reprint author), New York City Fire Dept, Off Med Affairs, Room 4w-1, Brooklyn, NY 11201 USA.	prezand@fdny.nyc.gov		Berger, Kenneth/0000-0003-4879-6071			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1299, DOI 10.1164/ajrccm/136.5.1299; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; Armbruster C, 1996, LANCET, V348, P690, DOI 10.1016/S0140-6736(05)65119-7; Banauch GI, 2005, CURR OPIN PULM MED, V11, P160, DOI 10.1097/01.mcp.0000151716.96241.0a; Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; Banauch GI, 2006, AM J RESP CRIT CARE, V174, P312, DOI 10.1164/rccm.200511-1736OC; Barnard J, 2005, J OCCUP ENVIRON MED, V47, P226, DOI 10.1097/01.jom.0000155711.88781.91; Baughman RP, 2001, AM J RESP CRIT CARE, V164, P1885; BECHTEL JJ, 1981, AM REV RESPIR DIS, V124, P759; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; DEPALMA A, 2006, NY TIMES        1026; Drent M, 2000, RESP MED, V94, P815, DOI 10.1053/rmed.2000.0827; Duval-Morin G, 2001, Rev Pneumol Clin, V57, P28; EDMONSTONE WM, 1998, THORAX, V43, P342; Gorham ED, 2004, CHEST, V126, P1431, DOI 10.1378/chest.126.5.1431; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Herbert R, 2006, ENVIRON HEALTH PERSP, V114, P1853, DOI 10.1289/ehp.9592; Hunninghake GW, 1999, AM J RESP CRIT CARE, V160, P736; Judson MA, 1999, SARCOIDOSIS VASC DIF, V16, P75; Kajdasz DK, 2001, ANN EPIDEMIOL, V11, P111, DOI 10.1016/S1047-2797(00)00179-4; KERN DG, 1993, AM REV RESPIR DIS, V148, P974; Klimczak A, 2000, Pneumonol Alergol Pol, V68, P273; Kreider ME, 2005, CHEST, V128, P207, DOI 10.1378/chest.128.1.207; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; MACEIRA JMP, 1984, AM J CLIN PATHOL, V81, P563; Mann JM, 2005, AM J IND MED, V48, P225, DOI 10.1002/ajim.20196; MARCIAS S, 1994, SARCOIDOSIS, V11, P118; Meloni M, 1988, Recenti Prog Med, V79, P179; *NAT I OCC SAF HLT, 1997, MMWR-MORBID MORTAL W, V46, P539; Newman L S, 1998, Semin Respir Infect, V13, P212; Newman LS, 2004, AM J RESP CRIT CARE, V170, P1324, DOI 10.1164/rccm.200402-2490C; Nowak D, 1990, Pneumologie, V44 Suppl 1, P572; OHRN MB, 1995, RESPIRATION, V62, P136; OLAFSSON M, 1985, THORAX, V40, P51, DOI 10.1136/thx.40.1.51; PRESAS FM, 1986, ANN NY ACAD SCI, V465, P523, DOI 10.1111/j.1749-6632.1986.tb18529.x; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Prezant DJ, 1999, CHEST, V116, P1183, DOI 10.1378/chest.116.5.1183; Rafnsson V, 1998, OCCUP ENVIRON MED, V55, P657; Rom WN, 2002, AM J RESP CRIT CARE, V166, P797, DOI 10.1164/rccm.200206-576OC; Safirstein BH, 2003, CHEST, V123, P301, DOI 10.1378/chest.123.1.301; SCADDING JG, 1961, BRIT MED J, V4, P1165; SHAPIRO GG, 1989, PROVOCATIVE CHALLENG, P405; Shorr AF, 2001, CHEST, V120, P881, DOI 10.1378/chest.120.3.881; Williams W J, 1989, Sarcoidosis, V6, P111; WINTERBAUER RH, 1973, ANN INTERN MED, V78, P65	46	125	130	0	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2007	131	5					1414	1423		10.1378/chest.06-2114		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	168SQ	WOS:000246544700024	17400664	
J	Eder, W; Klimecki, W; Yu, LZ; von Mutius, E; Riedler, J; Braun-Fahrlander, C; Nowak, D; Martinez, FD				Eder, W; Klimecki, W; Yu, LZ; von Mutius, E; Riedler, J; Braun-Fahrlander, C; Nowak, D; Martinez, FD		ALEX Study Team	Opposite effects of CD14/-260 on serum IgE levels in children raised in different environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						serium IgE; CD14/-260; microbial exposure; gene-environment interaction	PROMOTER POLYMORPHISM; CD14 PROMOTER; C-159T POLYMORPHISM; ENDOTOXIN LEVELS; MATTRESS DUST; SOLUBLE CD14; ASTHMA; GENE; ASSOCIATION; EXPOSURE	Background: Most complex diseases are the result of interactions between polymorphisms in the genome and environmental exposures. Objective: We sought to investigate the previously reported association between a polymorphism in the promoter region of CD14 (CD14/-260C -> T) and serum IgE levels in relation to the environment to which children are exposed. Methods: In 624 children living in 2 rural communities in Europe, we compared total and specific serum IgE levels between the genotypes of CD14/-260 in relation to exposure to animals and in relation to house dust endotoxin. Results: We found that the C allele of CD14/-260 was associated with higher levels of both total and specific serum IgE to aeroallergens in children with regular contact with pets, whereas an association in the opposite direction was found in children with regular contact with stable animals. This modifying effect of animal exposure was not explained by levels of house dust endotoxin. However, in children with high levels of house dust endotoxin, the C allele was associated with less specific IgE, independently from animal exposure. Conclusion: Because CD14 is a pattern recognition receptor for microbial molecules, the results suggest that the type and concentrations of such molecules present in the environment strongly determine the direction of the association between CD14/-260 and serum markers of atopy.	Univ Arizona, Arizona Resp Ctr, Innate Immun Program Genom Applicat, Tucson, AZ 85724 USA; Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; Childrens Hosp, Salzburg, Austria; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Univ Munich, Inst & Outpatient Clin Occupat & Environm Med, Munich, Germany	Martinez, FD (reprint author), Univ Arizona, Arizona Resp Ctr, Innate Immun Program Genom Applicat, 1501 N Campbell Ave,POB 245030, Tucson, AZ 85724 USA.	fernando@arc.arizona.edu		von Mutius, Erika/0000-0002-8893-4515	NHLBI NIH HHS [HL66800, HL67672]		AMELUNG PJ, 2000, AM J RESP CRIT CARE, V161, pA927; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gao PS, 1999, CLIN GENET, V56, P164; Gehring U, 2004, INDOOR AIR, V14, P284, DOI 10.1111/j.1600-0668.2004.00244.x; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Heumann D, 2002, CLIN CHIM ACTA, V323, P59, DOI 10.1016/S0009-8981(02)00180-8; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Karhukorpi J, 2002, CLIN EXP IMMUNOL, V128, P326, DOI 10.1046/j.1365-2249.2002.01837.x; Kedda MA, 2005, THORAX, V60, P211, DOI 10.1136/thx.2004.028449; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838; LEWONTIN RC, 1994, AM J HUM GENET, V26, P400; Lotz S, 2004, J LEUKOCYTE BIOL, V75, P467, DOI 10.1189/jlb.0803360; Obana N, 2002, SCAND J GASTROENTERO, V37, P699, DOI 10.1080/00365520212504; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Remold SK, 2004, NAT GENET, V36, P423, DOI 10.1038/ng1324; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; SCHLICHTING CD, 1998, PHENOTYPIC EVOLUTION, P51; Schmitz G, 2002, CURR OPIN LIPIDOL, V13, P513, DOI 10.1097/00041433-200210000-00007; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; 2003, LANCET, V361, P357	30	125	126	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					601	607		10.1016/j.jaci.2005.05.003		7	Allergy; Immunology	Allergy; Immunology	017IE	WOS:000235686500020	16159630	
J	Leigh, R; Ellis, R; Wattlie, JN; Hirota, JA; Matthaei, KI; Foster, PS; O'Byrne, PM; Inman, MD				Leigh, R; Ellis, R; Wattlie, JN; Hirota, JA; Matthaei, KI; Foster, PS; O'Byrne, PM; Inman, MD			Type 2 cytokines in the pathogenesis of sustained airway dysfunction and airway remodeling in mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						allergic disease; asthma; interleukin-4; interleukin-5; interleukin-13	OBSTRUCTIVE PULMONARY-DISEASE; ALLERGEN-INDUCED INCREASE; MURINE MODEL; CHRONIC ASTHMA; MILD ASTHMA; DEFICIENT MICE; LUNG DAMAGE; MOUSE MODEL; INFLAMMATION; HYPERREACTIVITY	The mechanisms underlying airway hyperresponsiveness remain unclear, although airway inflammation and remodeling likely play important roles. We have observed sustained airway hyperreactivity and airway remodeling occurring in mice after chronic allergen exposure and persisting beyond resolution of allergen-induced inflammation. The aim of this study was to delineate mechanisms involved in allergen-induced airway hyperreactivity and airway remodeling and to examine evidence for a causal association between airway remodeling and sustained airway hyperreactivity. Wild-type (WT) and interleukin (IL)-4-, IL-5-, and IL-13-deficient (-/-) mice were sensitized and studied 4 weeks after chronic allergen exposure. By measuring airway responsiveness and airway morphometry, we demonstrated that WT mice developed sustained airway hyperreactivity and aspects of airway remodeling after chronic allergen exposure. Both IL-4(-/-) and IL-13(-/-) mice were protected from developing sustained airway hyperreactivity and aspects of airway remodeling. In contrast, IL-5(-/-) mice developed sustained airway hyperreactivity and aspects of airway remodeling similar to that seen in WT mice. Our results confirm that IL-4 and IL-13, but not IL-5, are critical for the development of sustained airway hyperreactivity and airway remodeling after allergen exposure.	McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON L8S 4L8, Canada; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia	Inman, MD (reprint author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	inmanma@mcmaster.ca	Klaus, Matthaei/D-8691-2011; Foster, Paul/G-5057-2013	O'Byrne, Paul/0000-0003-0979-281X			Boulet L P, 1998, Can Respir J, V5, P16; Boulet L P, 2000, Can Respir J, V7, P239; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; Bradford-Hill A., 1965, P ROY SOC MED, P295; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; Busse WW, 2001, NEW ENGL J MED, V344, P350; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Cockcroft DW, 1997, ASTHMA, P1253; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Ellis R, 2003, LAB INVEST, V83, P1285, DOI 10.1097/01.LAB.0000087586.25982.B5; Foster PS, 2000, LAB INVEST, V80, P655; Foster PS, 2002, LAB INVEST, V82, P455; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674; HEGELE RG, 1995, AM J RESP CRIT CARE, V151, P1659; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; Kopf M, 1996, IMMUNITY, V4, P15, DOI 10.1016/S1074-7613(00)80294-0; Kumar RK, 2002, CLIN EXP ALLERGY, V32, P1104, DOI 10.1046/j.1365-2222.2002.01420.x; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; LEIGH R, 2003, AM J RESP CRIT CARE, V167, pA494; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; Persson CGA, 2002, AM J RESP CRIT CARE, V166, P6, DOI 10.1164/rccm.2204001; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; ROCHE WR, 1989, LANCET, V1, P520; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Tanaka H, 2001, INFLAMM RES, V50, P616, DOI 10.1007/PL00000243; Temelkovski J, 1998, THORAX, V53, P849; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Volgyesi GA, 2000, J APPL PHYSIOL, V89, P413; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Webb DC, 2000, J IMMUNOL, V165, P108; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang M, 2001, AM J RESP CELL MOL, V25, P522; Zhu Z, 2002, J IMMUNOL, V168, P2953; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	56	125	133	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2004	169	7					860	867		10.1164/rccm.200305-706OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	807IB	WOS:000220494100019	14701709	
J	Zhang, JF; Smith, KR				Zhang, JF; Smith, KR			Indoor air pollution: a global health concern	BRITISH MEDICAL BULLETIN			English	Article							VOLATILE ORGANIC-COMPOUNDS; ENVIRONMENTAL TOBACCO-SMOKE; SICK BUILDING SYNDROME; DEVELOPING-COUNTRIES; PASSIVE SMOKING; PARENTAL SMOKING; LUNG-CANCER; EXPOSURE; CHILDREN; OZONE	Indoor air pollution is ubiquitous, and takes many forms, ranging from smoke emitted from solid fuel combustion, especially in households in developing countries, to complex mixtures of volatile and semi-volatile organic compounds present in modern buildings. This paper reviews sources of, and health risks associated with, various indoor chemical pollutants, from a historical and global perspective. Health effects are presented for individual compounds or pollutant mixtures based on real-world exposure situations. Health risks from indoor air pollution are likely to be greatest in cities in developing countries, especially where risks associated with solid fuel combustion coincide with risk associated with modern buildings. Everyday exposure to multiple chemicals, most of which are present indoors, may contribute to increasing prevalence of asthma, autism, childhood cancer, medically unexplained symptoms, and perhaps other illnesses. Given that tobacco consumption and synthetic chemical usage will not be declining at least in the near future, concerns about indoor air pollution may be expected to remain.	Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ 08854 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Zhang, JF (reprint author), Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	jjzhang@eohsi.rutgers.edu					Alcaide J, 1996, TUBERCLE LUNG DIS, V77, P112, DOI 10.1016/S0962-8479(96)90024-6; Altet MN, 1996, TUBERCLE LUNG DIS, V77, P537, DOI 10.1016/S0962-8479(96)90052-0; Anderson HR, 1997, THORAX, V52, P1003; Apte MG, 2000, INDOOR AIR, V10, P246, DOI 10.1034/j.1600-0668.2000.010004246.x; Basu R., 1999, J ENV MED, V1, P173, DOI DOI 10.1002/JEM.28; Bennett DH, 2002, ENVIRON SCI TECHNOL, V36, p206A, DOI 10.1021/es0222770; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; *CALEPA, 1997, SMOK TOB CONTR MON, V10; Centers of Disease Control (CDC), 1990, MMWR-MORBID MORTAL W, V39, pviii; DARBY SC, 1995, J NATL CANCER I, V87, P378, DOI 10.1093/jnci/87.5.378; Fan ZH, 2003, ENVIRON SCI TECHNOL, V37, P1811, DOI 10.1021/es026231i; FIEDLER N, 2002, P IND AIR; Finkelman RB, 1999, P NATL ACAD SCI USA, V96, P3427, DOI 10.1073/pnas.96.7.3427; Fisk W. J., 2001, INDOOR AIR QUALITY H; Ge S, 2001, J AIR WASTE MANAGE, V51, P524, DOI 10.1080/10473289.2001.10464293; Girman JR, 1998, WESTERN J MED, V168, P158; Godish T, 2000, INDOOR ENV QUALITY, P95; Goldemberg J, 2000, WORLD ENERGY ASSESSM, P367; Gurunathan S, 1998, ENVIRON HEALTH PERSP, V106, P9, DOI 10.1289/ehp.981069; Hackshaw AK, 1997, BRIT MED J, V315, P980; HUDNELL HK, 1992, ARCH ENVIRON HEALTH, V47, P31; Jha P, 1999, CURBING EPIDEMIC GOV; Khuder SA, 2000, EUR J EPIDEMIOL, V16, P1117, DOI 10.1023/A:1010967513957; Kipen HM, 2002, ENVIRON HEALTH PERSP, V110, P591; KJAERGAARD SK, 1991, ATMOS ENVIRON A-GEN, V25, P1417; KOREN HS, 1992, ANN NY ACAD SCI, V641, P215, DOI 10.1111/j.1749-6632.1992.tb16545.x; LI SH, 2002, ENVIRON SCI TECHNOL, V36, P3295; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; Murray CJL, 1996, GLOBAL BURDEN DIS CO; Ott WR, 1998, SCI AM, V278, P86; Prah JD, 1998, ENVIRON HEALTH PERSP, V106, P739, DOI 10.1289/ehp.98106739; RYAN CM, 1992, J CONSULT CLIN PSYCH, V60, P220, DOI 10.1037//0022-006X.60.2.220; Smith KR, 2002, INDOOR AIR, V12, P198, DOI 10.1034/j.1600-0668.2002.01137.x; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; Smith KR, 2002, J EXPO ANAL ENV EPID, V12, P167, DOI 10.1038/sj/jea/7500219; Smith KR, 2002, SCIENCE, V298, P1847, DOI 10.1126/science.298.5600.1847; SMITH KR, 1993, ANNU REV ENERG ENV, V18, P529, DOI 10.1146/annurev.energy.18.1.529; Smith K., 1988, ENVIRONMENT, V30, P28; Smith K.R., 1988, ENVIRONMENT, V30, P10; Smith KR, 1994, EPIDEMIOLOGY LUNG CA, P151; Smith K. R., 1988, ENVIRONMENT, V30, P16; SMITH KR, 2003, IN PRESS COMP QUANTI; Smith KR, 1997, INT PERSPECTIVES ENV, P51; Strachan DP, 1998, THORAX, V53, P50; Strachan DP, 1997, THORAX, V52, P905; Strachan DP, 1998, THORAX, V53, P204; Thun M, 1999, ENVIRON HEALTH PERSP, V107, P841, DOI 10.2307/3434563; TSIA SM, 2003, ENVIRON SCI TECHNOL, V37, P2689; U.S. Environmental Protection Agency, 1992, EPA600690006F; *US NAT AC SCI COM, 1999, HLTH EFF EXP RAD; VALLARINO J, 2001, INDOOR AIR QUALITY H; Venners SA, 2001, AM J RESP CRIT CARE, V164, P973; Wainman T, 2000, ENVIRON HEALTH PERSP, V108, P1139, DOI 10.2307/3434825; WALLACE L, 1993, RISK ANAL, V13, P135, DOI 10.1111/j.1539-6924.1993.tb01059.x; Weschler C J, 2001, ScientificWorldJournal, V1, P443; Weschler CJ, 1996, ENVIRON SCI TECHNOL, V30, P3250, DOI 10.1021/es960032f; WESCHLER CJ, 1992, ENVIRON SCI TECHNOL, V26, P179, DOI 10.1021/es00025a022; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x; World Health Organization, 2002, WORLD HLTH REP RED R; World Health Organization, 2001, WORLD HLTH REP MENT, P2001; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35; Wolkoff P, 2000, INDOOR AIR, V10, P82, DOI 10.1034/j.1600-0668.2000.010002082.x; Zhang J, 2000, ATMOS ENVIRON, V34, P4537, DOI 10.1016/S1352-2310(99)00450-1; Zhang JF, 1999, ENVIRON SCI TECHNOL, V33, P2311, DOI 10.1021/es9812406; Zhang JF, 2002, ENVIRON HEALTH PERSP, V110, P961; Zhang JF, 1996, J EXPO ANAL ENV EPID, V6, P147	66	125	132	5	30	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0007-1420			BRIT MED BULL	Br. Med. Bull.		2003	68						209	225		10.1093/bmb/ldg029		17	Medicine, General & Internal	General & Internal Medicine	771NG	WOS:000188791900013	14757719	
J	van Ree, R				van Ree, R			Carbohydrate epitopes and their relevance for the diagnosis and treatment of allergic diseases	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Review						IgE; carbohydrate epitopes; recombinant allergens; diagnostic tests; immunotherapy	YEAST PICHIA-PASTORIS; BASOPHIL HISTAMINE-RELEASE; AEGYPTI SALIVARY ALLERGEN; O-GLYCOSYLATION CODES; IGE CROSS-REACTIVITY; DUST MITE ALLERGEN; RECOMBINANT ALLERGENS; ESCHERICHIA-COLI; BIRCH POLLEN; DENDRITIC CELLS	Allergenicity of plant and invertebrate N-glycans has been shown to be caused by the presence of two typical nonmammalian substitutions: an alpha(1,3)-fucose linked to the proximal N-acetylglucosamine and a beta(1,2)-xylose linked to the core mannose. IgE antibodies against these carbohydrate structures are induced upon exposure to pollen or after insect stings, and result in extensive cross-reactivity to plant and invertebrate foods. These cross-reactive IgE antibodies have been shown to possess variable degrees of biological activity, but have never been convincingly shown to induce clinical food allergy. The most likely explanation for this lack of clinical relevance has to be sought in a combination of epitope valency and antibody affinity. In diagnostic tests, these antibodies are at the basis of many false-positive test results for food allergy. Recombinant technologies offer the possibility to produce allergens that do not carry IgE-binding glycans. Whether their absence or presence is of importance for the application of recombinant allergens in immunotherapy is still largely unknown. Copyright (C) 2002 S. Karger AG, Basel.	Sanquin Res, CLB, Dept Immunopathol, NL-1006 AD Amsterdam, Netherlands	van Ree, R (reprint author), Sanquin Res, CLB, Dept Immunopathol, POB 9190, NL-1006 AD Amsterdam, Netherlands.						AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Aalberse RC, 1996, MONOGR ALLERGY, V32, P78; Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Afferni C, 1999, CLIN EXP ALLERGY, V29, P1087, DOI 10.1046/j.1365-2222.1999.00590.x; Akdis CA, 2001, INT ARCH ALLERGY IMM, V124, P180, DOI 10.1159/000053704; Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Almeida IC, 2001, J LEUKOCYTE BIOL, V70, P467; Altmann F, 1998, GLYCOCONJUGATE J, V15, P79, DOI 10.1023/A:1006947701714; Altmann F, 1999, GLYCOCONJUGATE J, V16, P109, DOI 10.1023/A:1026488408951; Apweiler R, 1999, BBA-GEN SUBJECTS, V1473, P4, DOI 10.1016/S0304-4165(99)00165-8; Asero R, 2000, INT ARCH ALLERGY IMM, V122, P20, DOI 10.1159/000024355; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Balbas P, 2001, MOL BIOTECHNOL, V19, P251, DOI 10.1385/MB:19:3:251; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Bendelac A, 2002, J EXP MED, V195, pF19, DOI 10.1084/jem.20020073; BERGER EG, 1982, EXPERIENTIA, V38, P1129, DOI 10.1007/BF01959725; Best EA, 2000, PROTEIN EXPRES PURIF, V20, P462, DOI 10.1006/prep.2000.1327; Breiteneder H, 1999, INT ARCH ALLERGY IMM, V118, P309, DOI 10.1159/000024112; Breiteneder H, 2001, INT ARCH ALLERGY IMM, V124, P48, DOI 10.1159/000053665; BREITENEDER H, 1989, EMBO J, V8, P1935; Bretthauer RK, 1999, BIOTECHNOL APPL BIOC, V30, P193; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CARRAWAY KL, 1989, BIOESSAYS, V10, P117, DOI 10.1002/bies.950100406; Cereghino JL, 2000, FEMS MICROBIOL REV, V24, P45, DOI 10.1111/j.1574-6976.2000.tb00532.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124; Cramer CL, 1996, ANN NY ACAD SCI, V792, P62, DOI 10.1111/j.1749-6632.1996.tb32492.x; de Jong EC, 2002, J IMMUNOL, V168, P1704; DERWENDA U, 2002, J MOL BIOL, V318, P189; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P448, DOI 10.1046/j.1365-2222.2002.01306.x; DUBUSKE LM, 1993, ALLERGY PROC, V14, P243, DOI 10.2500/108854193778811955; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; DURHAM SR, 1995, EUR ARCH OTO-RHINO-L, V252, pS64, DOI 10.1007/BF02484438; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Fahlbusch B, 1998, J INVEST ALLERG CLIN, V8, P325; FAYE L, 1993, ANAL BIOCHEM, V209, P104, DOI 10.1006/abio.1993.1088; FAYE L, 1988, GLYCOCONJUGATE J, V5, P245, DOI 10.1007/BF01049085; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; FUREDER W, 1994, ALLERGY, V49, P861, DOI 10.1111/j.1398-9995.1994.tb00788.x; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; Gonzalez E, 2001, CLIN EXP ALLERGY, V31, P313, DOI 10.1046/j.1365-2222.2001.00980.x; Grabenhorst E, 1999, GLYCOCONJUGATE J, V16, P81, DOI 10.1023/A:1026466408042; HANSEN MY, 1994, ALLERGY, V49, P235, DOI 10.1111/j.1398-9995.1994.tb02655.x; HAYASHI M, 1990, EUR J BIOCHEM, V191, P287, DOI 10.1111/j.1432-1033.1990.tb19122.x; Hiemori M, 2000, INT ARCH ALLERGY IMM, V122, P238, DOI 10.1159/000024404; Hilkens CMU, 1997, BLOOD, V90, P1920; Hounsell EF, 1996, GLYCOCONJUGATE J, V13, P19, DOI 10.1007/BF01049675; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; Jacquet A, 2002, CLIN EXP ALLERGY, V32, P1048, DOI 10.1046/j.1365-2222.2002.01437.x; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jankiewicz A, 1996, INT ARCH ALLERGY IMM, V111, P268; Jensen-Jarolim E, 2002, ALLERGY, V57, P805, DOI 10.1034/j.1398-9995.2002.23686.x; Jensen-Jarolim E, 1999, CLIN EXP ALLERGY, V29, P1075, DOI 10.1046/j.1365-2222.1999.00592.x; Jung E, 1997, BIOTECHNOL APPL BIOC, V25, P3; KALADAS PM, 1983, MOL IMMUNOL, V20, P727, DOI 10.1016/0161-5890(83)90050-0; Kalinski P, 1997, ADV EXP MED BIOL, V417, P363; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kieliszewski MJ, 2001, PHYTOCHEMISTRY, V57, P319, DOI 10.1016/S0031-9422(01)00029-2; King TP, 2001, J IMMUNOL, V166, P6057; Kraft D, 1999, INT ARCH ALLERGY IMM, V118, P171, DOI 10.1159/000024058; Kraft D, 1998, ALLERGY, V53, P62; Krebitz M, 2000, FASEB J, V14, P1279, DOI 10.1096/fj.14.10.1279; Kwaasi AAA, 2002, ALLERGY, V57, P508, DOI 10.1034/j.1398-9995.2002.23308.x; LAINE AC, 1988, ELECTROPHORESIS, V9, P841, DOI 10.1002/elps.1150091210; Lerouge P., 2000, Current Pharmaceutical Biotechnology, V1, P347, DOI 10.2174/1389201003378843; Lerouge P, 1998, PLANT MOL BIOL, V38, P31, DOI 10.1023/A:1006012005654; Liu YJ, 2000, CURR TOP MICROBIOL, V251, P149; LOMMERSE JPM, 1995, BIOCHEMISTRY-US, V34, P8196, DOI 10.1021/bi00025a027; Lorenzo S, 2000, CLIN EXP ALLERGY, V30, P551, DOI 10.1046/j.1365-2222.2000.00758.x; Luttkopf D, 2002, MOL IMMUNOL, V38, P515, DOI 10.1016/S0161-5890(01)00087-6; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; Maldonado-Lopez R, 2001, J IMMUNOL, V167, P4345; Maras M, 1999, GLYCOCONJUGATE J, V16, P99, DOI 10.1023/A:1026436424881; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; McDermott MJ, 2000, MOL IMMUNOL, V37, P361, DOI 10.1016/S0161-5890(00)00061-4; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Monsalve R I, 1999, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P181; MOSER M, 1992, J IMMUNOL, V149, P454; MUCCI N, 1992, ALLERGY, V47, P424, DOI 10.1111/j.1398-9995.1992.tb02083.x; NOLTE H, 1993, ALLERGY PROC, V14, P251, DOI 10.2500/108854193778812017; O'Riordain G, 2002, CLIN EXP ALLERGY, V32, P455, DOI 10.1046/j.1365-2222.2002.01312.x; Ogawa H, 1996, GLYCOCONJUGATE J, V13, P555, DOI 10.1007/BF00731443; Ohsuga H, 1996, J BIOL CHEM, V271, P26653; OHTA M, 1989, ARCH BIOCHEM BIOPHYS, V275, P151, DOI 10.1016/0003-9861(89)90359-7; Palomares O, 2002, EUR J BIOCHEM, V269, P2538, DOI 10.1046/j.1432-1033.2002.02920.x; Peng ZK, 2001, INT IMMUNOL, V13, P1445, DOI 10.1093/intimm/13.12.1445; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; Pierson-Mullany LK, 2002, CLIN EXP ALLERGY, V32, P107, DOI 10.1046/j.0022-0477.2001.01244.x; Pomes A, 2002, EUR J BIOCHEM, V269, P3086, DOI 10.1046/j.1432-1033.2002.02990.x; PRENNER C, 1992, BIOCHEM J, V284, P377; RAFNAR T, 1992, J BIOL CHEM, V267, P21119; Ramos JDA, 2001, INT ARCH ALLERGY IMM, V126, P286, DOI 10.1159/000049525; Rautiainen J, 1998, BIOCHEM BIOPH RES CO, V247, P746, DOI 10.1006/bbrc.1998.8851; Reindl J, 2000, J ALLERGY CLIN IMMUN, V106, P379, DOI 10.1067/mai.2000.107602; ROGERS BL, 1991, J IMMUNOL, V147, P2547; SAVOLAINEN J, 1990, ALLERGY, V45, P54, DOI 10.1111/j.1398-9995.1990.tb01084.x; Schachter H, 2000, GLYCOCONJUGATE J, V17, P465; Schmidt M, 1996, J ALLERGY CLIN IMMUN, V98, P82, DOI 10.1016/S0091-6749(96)70229-4; SHIBASAKI M, 1992, INT ARCH ALLERGY IMM, V98, P18; Shoji H, 1996, BIOSCI BIOTECH BIOCH, V60, P621; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Shpak E, 1999, P NATL ACAD SCI USA, V96, P14736, DOI 10.1073/pnas.96.26.14736; Smith PM, 1996, J ALLERGY CLIN IMMUN, V98, P331, DOI 10.1016/S0091-6749(96)70158-6; Soldatova L N, 1999, Arb Paul Ehrlich Inst Bundesamt Sera Impfstoffe Frankf A M, P189; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; Sowka S, 1998, EUR J BIOCHEM, V255, P213, DOI 10.1046/j.1432-1327.1998.2550213.x; Sten E, 2002, ALLERGY, V57, P398, DOI 10.1034/j.1398-9995.2002.13423.x; Swoboda I, 2002, J IMMUNOL, V168, P4576; TOMALSKI MD, 1993, ARCH INSECT BIOCHEM, V22, P303, DOI 10.1002/arch.940220302; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259; Triantafilou M, 2002, TRENDS IMMUNOL, V23, P301, DOI 10.1016/S1471-4906(02)02233-0; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; van Die I, 1999, FEBS LETT, V463, P189, DOI 10.1016/S0014-5793(99)01508-2; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; van Oort E, 2001, INT ARCH ALLERGY IMM, V126, P196, DOI 10.1159/000049514; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANREE R, 1995, INT ARCH ALLERGY IMM, V106, P146; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1999, IMMUNOTHERAPY ASTHMA, P399; van Ree R, 2000, ALLERGY CLIN IMMUNOL, V12, P7, DOI 10.1027/0838-1925.12.1.7; Vieira PL, 2000, J IMMUNOL, V164, P4507; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Vieths S, 1997, ENVIRON TOXICOL PHAR, V4, P61, DOI 10.1016/S1382-6689(97)10043-6; Vieths S, 2002, ALLERGY, V57, P100, DOI 10.1034/j.1398-9995.57.s72.20.x; WAN LL, 1994, PHYTOCHEMISTRY, V37, P933; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WEBER A, 1986, COMP BIOCHEM PHYS B, V83, P321, DOI 10.1016/0305-0491(86)90374-3; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Xu WZ, 1998, INT ARCH ALLERGY IMM, V115, P245, DOI 10.1159/000023907; YASUDA Y, 1970, BIOCHEMISTRY-US, V9, P25, DOI 10.1021/bi00803a004; Yasuhara T, 2001, BIOSCI BIOTECH BIOCH, V65, P563, DOI 10.1271/bbb.65.563; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoshida A, 1997, J BIOL CHEM, V272, P16884, DOI 10.1074/jbc.272.27.16884; YUUKI T, 1991, AGR BIOL CHEM TOKYO, V55, P1233	154	125	129	0	8	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	NOV	2002	129	3					189	197		10.1159/000066770		9	Allergy; Immunology	Allergy; Immunology	625EC	WOS:000179803100002	12444315	
J	Gilliland, FD; Gauderman, WJ; Vora, H; Rappaport, E; Dubeau, L				Gilliland, FD; Gauderman, WJ; Vora, H; Rappaport, E; Dubeau, L			Effects of Glutathione-S-Transferase M1, T1, and P1 on childhood lung function growth	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						glutathione-S-transferase; FEV; children; polymorphism; growth	OBSTRUCTIVE PULMONARY-DISEASE; SOUTHERN CALIFORNIA COMMUNITIES; OXIDATIVE STRESS; AIR-POLLUTION; RESPIRATORY SYMPTOMS; MATERNAL SMOKING; SUPERGENE FAMILY; DIFFERING LEVELS; BIRTH-WEIGHT; CHILDREN	The effects of glutathione-S-transferase (GST) M1, GSTT1, and GSTP1 genotypes on lung function growth were investigated in 1,940 children enrolled in the Children's Health Study as fourth graders (aged 8-11 years) in two cohorts during 1993 and 1996 and were followed annually over a 4-year period. Genotypes for GSTM1 and GSTT1 and GSTP1 codon 105variants (ile105 and val105)were determined using DNA from buccal cell specimens. We used two-level regression models to estimate the effects of GSTM1, GSTT1, and GSTP1 genotypes on the adjusted annual average lung function growth. GSTM1 null was associated with deficits in annual growth rates for FVC (-0.21%; 95% confidence interval [Cl], -0.40, 0.03) and FEV1, (-0.27%; 95% Cl, -0.50, -0.04). Children who were homozygous for the GSTP1 val105 allele had slower lung function growth (FVC -0.35%; 95% Cl, -0.62, -0.07; and FEV1 -0.34%; 95% Cl, -0.68, 0.00) than children with one or more ile105 alleles. Children with asthma who were homozygous for the GSTP1 val105 allele had substantially larger deficits in FVC, IFEVI, and maximal mid-expiratory flow than children without asthma. The deficits in FVC and FEV1 growth associated with both GSTM1 null and the GSTP1 val105 allele were largest and were statistically significant in non-Hispanic white children. We conclude that GSTM1 and GSTP1 genotypes are associated with lung function growth in school children.	Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA; Univ So Calif, Dept Pathol, Keck Sch Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Dept Prevent Med, Keck Sch Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.				NHLBI NIH HHS [5 R01HL61768]; NIEHS NIH HHS [2P30ES07048, 1P50ES09581]		American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; Baranova H, 1997, HUM GENET, V99, P822, DOI 10.1007/s004390050455; BARKER DJP, 1991, BRIT MED J, V303, P671; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Berhane K, 2000, AM J RESP CRIT CARE, V162, P1723; BURROWS B, 1980, AM REV RESPIR DIS, V122, P813; Chen Y, 1999, THORAX, V54, P818; Chen Y, 1999, GENET EPIDEMIOL, V16, P95, DOI 10.1002/(SICI)1098-2272(1999)16:1<95::AID-GEPI8>3.3.CO;2-Y; Cook DG, 1998, THORAX, V53, P884; Dezateux C, 1997, BRIT MED BULL, V53, P40; EBIKRYSTON KL, 1988, J CLIN EPIDEMIOL, V41, P251, DOI 10.1016/0895-4356(88)90129-1; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; GOLD DR, 1989, AM REV RESPIR DIS, V140, P877; Greene LS, 1999, NUTRITION, V15, P899, DOI 10.1016/S0899-9007(99)00209-9; Harrison DJ, 1997, HUM EXP TOXICOL, V16, P356; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hemmingsen A, 2001, Respir Res, V2, P255, DOI 10.1186/rr64; Hole DJ, 1996, BRIT MED J, V313, P711; Ishii T, 1999, THORAX, V54, P693; KAUFFMANN F, 1989, AM J EPIDEMIOL, V129, P1289; Koyama H, 1998, THORAX, V53, pS10; MacNee W, 2000, CHEST, V117, p303S, DOI 10.1378/chest.117.5_suppl_1.303S-a; Peterhans E, 1997, J NUTR, V127, pS962; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Sandford AJ, 2001, AM J RESP CRIT CARE, V163, P469; Sandford AJ, 2000, CLIN CHEST MED, V21, P633, DOI 10.1016/S0272-5231(05)70173-8; SAS Institute, 2001, SAS STAT US GUID VER; Schunemann HJ, 1997, AM J EPIDEMIOL, V146, P939; Schwarz KB, 1996, FREE RADICAL BIO MED, V21, P641, DOI 10.1016/0891-5849(96)00131-1; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616; SHAHEEN SO, 1995, AM J RESP CRIT CARE, V151, P1649; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17; SILVERMAN EK, 2001, FOUND S, V234, P45; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; Wjst M, 1998, PEDIATR ALLERGY IMMU, V9, P80, DOI 10.1111/j.1399-3038.1998.tb00308.x; WOODHOUSE G, 1995, MLN USERS GUIDE	48	125	127	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2002	166	5					710	716		10.1164/rccm.2112065		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	588ZZ	WOS:000177734100018	12204870	
J	Mannino, DM; Homa, DM; Redd, SC				Mannino, DM; Homa, DM; Redd, SC			Involuntary smoking and asthma severity in children - Data from the Third National Health and Nutrition Examination Survey	CHEST			English	Article						asthma; children; tobacco smoke pollution	ENVIRONMENTAL TOBACCO-SMOKE; PASSIVE SMOKING; PARENTAL SMOKING; RESPIRATORY HEALTH; CHILDHOOD ASTHMA; UNITED-STATES; US POPULATION; EXPOSURE; COTININE	Study objectives: We sought to determine the indicators of asthma severity among children in the United States with high and low levels of tobacco smoke exposure. Design: Cross-sectional study. Setting: Nationally representative survey of participants in the Third National Health and Nutrition Examination Survey (from 1988 to 1994). Participants. Five hundred twenty-three children with physician-diagnosed asthma. Measurements and results: We stratified the study participants into tertiles on the basis of serum levels of cotinine (a metabolite of nicotine that indicates tobacco smoke exposure). We used logistic and linear regression modeling, adjusting for known covariates, to determine the effect of high environmental tobacco smoke exposure on the following outcomes: asthma severity (determined using reported symptom and respiratory illness frequency); lung function; physician P visits; and school absence. Among our study sample, 78.6% of children had mild asthma, 6.8% of children bad moderate asthma, and 14.6% of children had severe asthma. Asthmatic children with high levels of smoke exposure, compared with those with low levels of exposure, were more likely to have moderate or severe asthma (odds ratio, 2.7 95% confidence interval [CI], 1.1 to 6.8) and decreased lung function, with a mean FEV1 decrement of 213 mL or 8.1% (95% CI, -14.7 to - 3.5). Conclusions: Involuntary smoke exposure is associated with increased asthma severity and worsened lung function in a nationally representative group of US children with asthma.	CDCP, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, Atlanta, GA 30333 USA	Mannino, DM (reprint author), CDCP, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Air Pollut & Resp Hlth Branch, 1600 Clifton Rd,MS E-17, Atlanta, GA 30333 USA.			Mannino, David/0000-0003-3646-7828			Abulhosn RS, 1997, ARCH PEDIAT ADOL MED, V151, P135; AZIZI BHO, 1990, PEDIATR PULM, V9, P24, DOI 10.1002/ppul.1950090106; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cook DG, 1999, THORAX, V54, P357; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Eggleston PA, 1998, PEDIATRICS, V101, P349, DOI 10.1542/peds.101.3.349; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; Fielder HMP, 1999, ARCH DIS CHILD, V80, P253; FORASTIERE F, 1992, INT J EPIDEMIOL, V21, P66, DOI 10.1093/ije/21.1.66; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Halterman JS, 2000, PEDIATRICS, V105, P272; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; Kohler E, 1999, HUM EXP TOXICOL, V18, P212, DOI 10.1191/096032799678839932; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; MURRAY AB, 1988, CHEST, V94, P701, DOI 10.1378/chest.94.4.701; National Center for Health Statistics, 1994, VITAL HLTH STAT, V1, P1; Oddoze C, 1999, CLIN CHEM, V45, P505; Osborne ML, 1999, CHEST, V115, P85, DOI 10.1378/chest.115.1.85; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; *SAS I, 1990, SAS VERS 6; SCHULMAN R, 2002, BUCUVALAS RES ASTHMA; Shah B., 1996, SUDAAN USERS MANUAL; SHEFFER AL, 1993, MED CARE, V31, pMS20; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136; Strachan DP, 1998, THORAX, V53, P204; [Anonymous], 1987, AM REV RESP DIS, V136, P1285	29	125	127	0	1	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	AUG	2002	122	2					409	415		10.1378/chest.122.2.409		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	584CJ	WOS:000177449400009	12171810	
J	Zanobetti, A; Schwartz, J; Gold, D				Zanobetti, A; Schwartz, J; Gold, D			Are there sensitive subgroups for the effects of airborne particles?	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						effect modification; hospital admissions; particulate air pollution	PARTICULATE AIR-POLLUTION; CLINICAL COMORBIDITY INDEX; EMERGENCY ROOM VISITS; FLY-ASH PARTICLES; HOSPITAL ADMISSIONS; TIME-SERIES; RESPIRATORY-DISEASE; ADMINISTRATIVE DATA; EUROPEAN CITIES; APHEA PROJECT	Recent studies have shown that particulate air pollution is a risk factor for hospitalization for heart and lung disease; however, little is known about what subpopulations are most sensitive to this pollutant. We analyzed Medicare hospital admissions for heart disease, chronic obstructive pulmonary disorders (COPD) and pneumonia in Chicago, Cook County, Illinois, between 1985 and 1994. We examined whether previous admissions or secondary diagnoses for selected conditions predisposed persons to having a greater risk from air pollution. We also considered effect modification by age, sex, and race. We found that the air-pollution-associated increase in hospital admissions for cardiovascular diseases was almost doubled in subjects with concurrent respiratory infections. The risk was also increased by a previous admission for conduction disorders. For COPD and pneumonia admissions, diagnosis of conduction disorders or dysrhythmias increased the risk of particulate matter < 10 mu m in aerodynamic diameter (PM10)-associated admissions. Persons with asthma had twice the risk of a PM10-associated pneumonia admission and persons with heart failure had twice the risk of PM10-induced COPD admissions. The PM10 effect did not vary by sex, age, and race. These results suggest that patients with acute respiratory infections or defects in the electrical control of the heart are a risk group for particulate matter effects.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Zanobetti, A (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, 665 Huntington Ave, Boston, MA 02115 USA.				NIEHS NIH HHS [ES07937]		Akaike H, 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Brumback BA, 2000, J AM STAT ASSOC, V95, P16; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; CLARKE RW, 1997, AM J RESP CRIT CARE, V155, pA245; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; DAILEY LA, 1998, AM J RESP CRIT CARE, V157, pA598; Delfino RJ, 1998, ENVIRON RES, V76, P67, DOI 10.1006/enrs.1997.3794; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; DOMINICI F, IN PRESS R STAT SO A; GILMOUR MI, 1997, AM J RESP CRIT CARE, V155, pA244; Godleski J. J., 2000, 91 HLTH EFF I; Gold DR, 2000, CIRCULATION, V101, P1267; GOLESKI JJ, 1996, AM J RESP CRIT CARE, V153, pA15; Gordon T, 1998, TOXICOL LETT, V96-7, P285, DOI 10.1016/S0378-4274(98)00084-8; Hallstrom AP, 1996, CIRCULATION, V93, P2019; HAMADA K, 1999, AM J RESP CRIT CAR A, V28; Hastie T, 1990, GEN ADDITIVE MODELS; Hoek G, 1999, EPIDEMIOLOGY, V10, pS177; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; KODAVENTI UP, 1998, AM J RESP CRIT CARE, V157, pA260; Lambert AL, 1999, AM J RESP CRIT CARE, V159, pA26; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; Librero J, 1999, J CLIN EPIDEMIOL, V52, P171, DOI 10.1016/S0895-4356(98)00160-7; MALENKA DJ, 1994, J CLIN EPIDEMIOL, V47, P1027, DOI 10.1016/0895-4356(94)90118-X; Matsui K, 1996, J GEN INTERN MED, V11, P262, DOI 10.1007/BF02598265; MONANE M, 1996, ARCH NEUROL-CHICAGO, V53, P848; National Research Council, 1998, RES PRIOR AIRB PART; NEHLS GJ, 1973, JAPCA J AIR WASTE MA, V23, P180; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Peters A, 1999, EPIDEMIOLOGY, V10, pS177; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; ROMANO PS, 1993, J CLIN EPIDEMIOL, V46, P1075, DOI 10.1016/0895-4356(93)90103-8; Rossi G, 1999, ARCH ENVIRON HEALTH, V54, P158; SALDIVA PHN, 1995, ARCH ENVIRON HEALTH, V50, P159; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Samet J. M., 1995, PARTICULATE AIR POLL; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; SCHWARTZ J, 1995, THORAX, V50, P531, DOI 10.1136/thx.50.5.531; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; SCHWARTZ J, 1994, INT BIOM SOC 17 INT, P55; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; TAN WC, 1997, AM J RESP CRIT CARE, V155, P1441; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Watkinson WP, 1998, TOXICOL SCI, V41, P209, DOI 10.1093/toxsci/41.2.209; WATKINSON WP, 1998, AM J RESP CRIT CARE, V157, pA150; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382; ZELIKOFF JT, 1999, P 3 C PART AIR POLL	64	125	138	3	12	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2000	108	9					841	845		10.1289/ehp.00108841		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	360BW	WOS:000089647400021	11017888	
J	Kankaanranta, H; Lindsay, MA; Giembycz, MA; Zhang, XZ; Moilanen, E; Barnes, PJ				Kankaanranta, H; Lindsay, MA; Giembycz, MA; Zhang, XZ; Moilanen, E; Barnes, PJ			Delayed eosinophil apoptosis in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						albuterol; apoptosis; asthma; eosinophil; fenoterol; GM-CSF; IL-5; salmeterol	HUMAN-BLOOD EOSINOPHILS; PROGRAMMED CELL-DEATH; IN-VITRO; GM-CSF; SURVIVAL; MACROPHAGES; ALBUTEROL; AGONISTS; PROLONG; IL-5	Background: Eosinophilic inflammation of the airways is a key characteristic of asthma, A defect in apoptosis might contribute to the chronic tissue eosinophilia associated with asthma. Objective: Our purpose was to examine whether the rate of apoptosis differs between peripheral blood eosinophils from asthmatic patients and healthy volunteers, Methods: Peripheral blood was obtained from volunteers with asthma and from control volunteers. Eosinophils were isolated by CD16-negative selection to >99% purity and were cultured for 48 hours, The number of apoptotic eosinophils in the culture was assessed by flow cytometric analysis of relative DNA content in propidium iodide-stained cells. Eosinophil apoptosis is expressed as apoptosis index (number of apoptotic cells/total number of cells). Results: Eosinophils From asthmatic patients not taking steroid medication survived longer (apoptosis index 0.25) than those of healthy control subjects (apoptosis index 0.40, P < .05). In contrast, the rate of apoptosis in eosinophils from patients concurrently taking steroids (apoptosis index 0.46) is higher than that of those not using steroids (P < .01) and not different from that of healthy subjects. To assess whether endogenous IL-3, IL-5, and CM-CSF production contributes to the delayed eosinophil apoptosis, the effects of the corresponding neutralizing antibodies were studied on eosinophil longevity. Neutralization of GM-CSF, but not of IL-3 or IL-5, increased slightly but significantly (P < .01) the rate of apoptosis in eosinophils obtained from patients with asthma, To assess whether beta(2)-agonist medication could contribute to the observed differences, we determined the in vitro effects of albuterol, Fenoterol, and salmeterol on eosinophil apoptosis, All beta(2)-agonists inhibited eosinophil apoptosis by 12% to 19%, A possibility existed that a prior in vivo exposure to IL-5, GM-CSF, or beta(2)-agonists would explain the observed difference. To study this, eosinophils were incubated with GM-CSF, IL-5, and albuterol for 2 to 3 hours, followed by washout of the added compounds, and were subsequently cultured for 48 hours. However, an exposure to GM-CSF (7 pmol/L) or IL-5 (10 pmol/L) for 15 to 180 minutes was not a sufficient signal to prevent eosinophil apoptosis, In contrast, exposure to albuterol (100 nmol/L) for 120 minutes was sufficient to induce a significant (P < .05) decrease in eosinophil apoptosis, Conclusions: The results suggest that eosinophil apoptosis is delayed in asthma, This delay may be partly explained by production of GM-CSF, The in vitro effects of beta(2)-agonists suggest that beta(2)-agonist use might contribute to the prolonged eosinophil survival through inhibition of apoptosis and thus may worsen eosinophilia in asthmatic patients, Use of inhaled glucocorticoids seems to totally reverse the delayed eosinophil apoptosis in asthma.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England; Tampere Univ, Sch Med, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Kankaanranta, Hannu/0000-0001-5258-0906			Adkins JC, 1997, DRUGS, V54, P331, DOI 10.2165/00003495-199754020-00011; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747; Evans DJ, 1996, EUR RESPIR J, V9, P703, DOI 10.1183/09031936.96.09040703; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738; Giembycz MA, 1999, PHARMACOL REV, V51, P213; Hallsworth MP, 1996, BRIT J PHARMACOL, V117, P79; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Haslett C, 1997, BRIT MED BULL, V53, P669; HOCHHAUS G, 1992, INT J CLIN PHARM TH, V30, P342; JONKMAN JHG, 1986, ARZNEIMITTEL-FORSCH, V36-2, P1133; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; KANKAANRANTA H, IN PRESS METHODS MOL; MURPHY S, 1997, NIH PUBL; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Nielson CP, 1998, AM J RESP CRIT CARE, V157, P184; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; POWELL ML, 1986, J CLIN PHARMACOL, V26, P643; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Simon HU, 1997, J IMMUNOL, V158, P3902; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SPRY CJF, 1993, IMMUNOPHARMACOLOGY E, P1; STERN M, 1992, J IMMUNOL, V148, P3543; TAI PC, 1991, CLIN EXP IMMUNOL, V85, P312; Vignola AM, 1999, J ALLERGY CLIN IMMUN, V103, P563, DOI 10.1016/S0091-6749(99)70225-3; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1046/j.1365-2222.1997.d01-532.x; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	28	125	140	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2000	106	1	1				77	83				7	Allergy; Immunology	Allergy; Immunology	337ZH	WOS:000088393300011	10887309	
J	Kurup, VP; Shen, HD; Banerjee, B				Kurup, VP; Shen, HD; Banerjee, B			Respiratory fungal allergy	MICROBES AND INFECTION			English	Review						fungal allergens; IgE antibody; recombinant allergens; ELISA; Western blot	ASPERGILLUS-FUMIGATUS ALLERGENS; ALKALINE SERINE PROTEINASE; MAJOR ALLERGEN; BRONCHOPULMONARY ASPERGILLOSIS; CLADOSPORIUM-HERBARUM; MOLD ALLERGY; ALTERNARIA-ALTERNATA; PENICILLIUM-CITRINUM; ASTHMATIC-PATIENTS; IMMUNE-RESPONSES	Fungal allergy including allergic rhinitis, conjunctivitis, bronchial asthma, and allergic bronchopulmonary mycoses results from exposure to spores. In this review are have dealt with the common allergenic fungi and allergens, immunopathogenesis, diagnostic assays, and the possible control of allergy in the future based on epitope-specific immunotherapy and vaccination. (C) 2000 Editions scientifiques et medicales Elsevier SAS.	Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA; Vet Affairs Med Ctr, Milwaukee, WI USA; Vet Gen Hosp Taipei, Dept Med Res & Educ, Taipei 11217, Taiwan	Kurup, VP (reprint author), Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NIAID NIH HHS [AI42349]		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P375; Bacharier LB, 1998, INT ARCH ALLERGY IMM, V115, P257, DOI 10.1159/000069456; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201; Banerjee B, 1998, INFECT IMMUN, V66, P5175; BAUR X, 1994, CLIN EXP ALLERGY, V24, P465, DOI 10.1111/j.1365-2222.1994.tb00935.x; BEAUMONT F, 1985, ANN ALLERGY, V55, P740; BEAUMONT F, 1984, ANN ALLERGY, V53, P486; Becker AB, 1996, J ALLERGY CLIN IMMUN, V97, P151; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114; BURGE HA, 1985, CLIN REV ALLERG, V3, P319, DOI 10.1007/BF02992998; BURGE HA, 1989, IMMUNOL ALLERGY CLIN, V9, P307; Bush RK, 1997, ANN ALLERG ASTHMA IM, V78, P287; Chou H, 1999, INT ARCH ALLERGY IMM, V119, P282, DOI 10.1159/000024205; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; DELPRETE G, 1994, LAB INVEST, V70, P299; Garrett M, 1997, AEROBIOLOGIA, V13, P121, DOI DOI 10.1007/BF; GRAVESEN S, 1985, Allergy (Copenhagen), V40, P21, DOI 10.1111/j.1398-9995.1985.tb04292.x; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.3.CO;2-Y; Hemmann S, 1998, CLIN EXP ALLERGY, V28, P860; Horner WE, 1998, ALLERGY, V53, P1114, DOI 10.1111/j.1398-9995.1998.tb03830.x; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; ISHIGURO A, 1992, INFECT IMMUN, V60, P1550; ITKIN IH, 1966, J ALLERGY, V37, P187, DOI 10.1016/0021-8707(66)90113-4; KARLSSONBORGA A, 1989, ANN ALLERGY, V63, P521; KEENEY EL, 1951, ANN INTERN MED, V34, P223; KIM SJ, 1978, AM REV RESPIR DIS, V118, P547; KOIVIKKO A, 1991, ALLERGY, V46, P85, DOI 10.1111/j.1398-9995.1991.tb00549.x; KOZAK PP, 1979, ANN ALLERGY, V43, P88; KURUP VP, 1989, IMMUNOL ALLERGY CLIN, V9, P285; KURUP VP, 1977, MICROBIOS, V19, P191; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439; KURUP VP, 1994, J LAB CLIN MED, V123, P749; KURUP VP, 1986, ZBL BAKT-INT J MED M, V261, P509; KURUP VP, 1993, FUNGAL INFECT IMMUNE, P393; KURUVILLA S, 1993, RES PRACTICE HUMAN R, V1, P1; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; MILLER JD, 1992, ATMOS ENVIRON A-GEN, V26, P2163, DOI 10.1016/0960-1686(92)90404-9; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P143; PARIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902, DOI 10.1016/0091-6749(91)90247-L; PORTNOY J, 1987, ANN ALLERGY, V59, P39; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; Sander I, 1998, J ALLERGY CLIN IMMUN, V102, P256; Shen HD, 1997, CLIN EXP ALLERGY, V27, P79; Shen HD, 1998, INT ARCH ALLERGY IMM, V116, P29, DOI 10.1159/000023921; Shen HD, 1999, CLIN EXP ALLERGY, V29, P642; SHEN HD, 1999, ALLERGY, V54, P120; SWARDNORDMO M, 1989, INT ARCH ALLER A IMM, V90, P155; SWARDNORDMO M, 1985, INT ARCH ALLER A IMM, V78, P249; TURNER KJ, 1980, CLIN ALLERGY, V10, P441, DOI 10.1111/j.1365-2222.1980.tb02127.x; VERMA J, 1994, INT ARCH ALLERGY IMM, V104, P175; Weber R W, 1989, J Allergy Clin Immunol, V84, P1093, DOI 10.1016/0091-6749(89)90160-7; WISDOM GB, 1976, CLIN CHEM, V22, P1243; Wuethrich B, 1989, INT ARCH ALLER A IMM, V90, P3; Yu CJ, 1999, BIOCHEM BIOPH RES CO, V261, P669, DOI 10.1006/bbrc.1999.1093; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V58, P405, DOI 10.1016/0091-6749(76)90121-4	59	125	132	0	4	EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS CEDEX 15	23 RUE LINOIS, 75724 PARIS CEDEX 15, FRANCE	1286-4579			MICROBES INFECT	Microbes Infect.	JUL	2000	2	9					1101	1110		10.1016/S1286-4579(00)01264-8		10	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	353PG	WOS:000089284200013	10967290	
J	Bisgaard, H; Simpson, A; Palmer, CNA; Bonnelykke, K; Mclean, I; Mukhopadhyay, S; Pipper, CB; Halkjaer, LB; Lipworth, B; Hankinson, J; Woodcock, A; Custovic, A				Bisgaard, Hans; Simpson, Angela; Palmer, Colin N. A.; Bonnelykke, Klaus; Mclean, Irwin; Mukhopadhyay, Somnath; Pipper, Christian B.; Halkjaer, Liselotte B.; Lipworth, Brian; Hankinson, Jenny; Woodcock, Ashley; Custovic, Adnan			Gene-environment interaction in the onset of eczema in infancy: Filaggrin loss-of-function mutations enhanced by neonatal cat exposure	PLOS MEDICINE			English	Article							ATOPIC-DERMATITIS; ICHTHYOSIS VULGARIS; CHILDHOOD ASTHMA; BIRTH COHORT; RISK; LIFE; SENSITIZATION; PREDISPOSE; DIAGNOSIS; ALLERGENS	Background Loss-of-function variants in the gene encoding filaggrin (FLG) are major determinants of eczema. We hypothesized that weakening of the physical barrier in FLG-deficient individuals may potentiate the effect of environmental exposures. Therefore, we investigated whether there is an interaction between FLG loss-of-function mutations with environmental exposures ( pets and dust mites) in relation to the development of eczema. Methods and Findings We used data obtained in early life in a high-risk birth cohort in Denmark and replicated the findings in an unselected birth cohort in the United Kingdom. Primary outcome was age of onset of eczema; environmental exposures included pet ownership and mite and pet allergen levels. In Copenhagen (n = 379), FLG mutation increased the risk of eczema during the first year of life ( hazard ratio [HR] 2.26, 95% confidence interval [CI] 1.27-4.00, p = 0.005), with a further increase in risk related to cat exposure at birth amongst children with FLG mutation (HR 11.11, 95% CI 3.79-32.60, p < 0.0001); dog exposure was moderately protective (HR 0.49, 95% CI 0.24-1.01, p = 0.05), but not related to FLG genotype. In Manchester ( n 503) an independent and significant association of the development of eczema by age 12 mo with FLG genotype was confirmed (HR 1.95, 95% CI 1.13-3.36, p = 0.02). In addition, the risk increased because of the interaction of cat ownership at birth and FLG genotype (HR 3.82, 95% CI 1.35-10.81, p = 0.01), with no significant effect of the interaction with dog ownership (HR 0.59, 95% CI 0.16-2.20, p = 0.43). Mite-allergen had no effects in either cohort. The observed effects were independent of sensitisation. Conclusions We have demonstrated a significant interaction between FLG loss-of-function main mutations (501x and 2282del4) and cat ownership at birth on the development of early-life eczema in two independent birth cohorts. Our data suggest that cat but not dog ownership substantially increases the risk of eczema within the first year of life in children with FLG loss-of-function variants, but not amongst those without. FLG-deficient individuals may need to avoid cats but not dogs in early life.	[Bisgaard, Hans; Bonnelykke, Klaus; Pipper, Christian B.; Halkjaer, Liselotte B.] Univ Hosp Gentofte, Danish Paediat Asthma Ctr, Copenhagen, Denmark; [Simpson, Angela; Hankinson, Jenny; Woodcock, Ashley; Custovic, Adnan] Univ S Manchester Hosp, Natl Hlth Serv Fdn Trust, Sch Translat Med, Manchester M20 8LR, Lancs, England; [Palmer, Colin N. A.; Mclean, Irwin] Univ Dundee, Populat Pharmacogenet Grp, Biomed Res Ctr, Ninewells Hosp, Dundee, Scotland; [Palmer, Colin N. A.; Mclean, Irwin] Univ Dundee, Sch Med, Dundee, Scotland; [Mukhopadhyay, Somnath] Royal Alexandra Hosp Children, Brighton, E Sussex, England; [Mukhopadhyay, Somnath] Sussex Med Sch, Brighton, E Sussex, England; [Lipworth, Brian] Univ Dundee, Asthma & Allergy Res Grp, Div Med & Therapeut, Ninewells Hosp, Dundee DD1 4HN, Scotland; [Lipworth, Brian] Univ Dundee, Sch Med, Dundee DD1 4HN, Scotland	Bisgaard, H (reprint author), Univ Hosp Gentofte, Danish Paediat Asthma Ctr, Copenhagen, Denmark.	bisgaard@copsac.com	Palmer, Colin/C-7053-2008; Kronow, Joern/B-1054-2011; Custovic, Adnan/A-2435-2012; Bisgaard, Hans/N-4761-2016	Palmer, Colin/0000-0002-6415-6560; Custovic, Adnan/0000-0001-5218-7071; Bisgaard, Hans/0000-0003-4131-7592; McLean, William Henry Irwin/0000-0001-5539-5757; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666; Pipper, Christian Bressen/0000-0003-0261-616X			Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Custovic A, 2002, PEDIATR ALLERGY IMMU, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic Adnan, 2004, Pediatr Pulmonol Suppl, V26, P12; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Paganelli R, 1998, ALLERGY, V53, P763; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x	20	124	125	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1549-1676			PLOS MED	PLos Med.	JUN	2008	5	6							e131	10.1371/journal.pmed.0050131		6	Medicine, General & Internal	General & Internal Medicine	318QB	WOS:000257105600018	18578563	
J	Krishnamoorthy, N; Oriss, TB; Paglia, M; Fei, MJ; Yarlagadda, M; Vanhaesebroeck, B; Ray, A; Ray, P				Krishnamoorthy, Nandini; Oriss, Timothy B.; Paglia, Melissa; Fei, Mingjian; Yarlagadda, Manohar; Vanhaesebroeck, Bart; Ray, Anuradha; Ray, Prabir			Activation of c-Kit in dendritic cells regulates T helper cell differentiation and allergic asthma	NATURE MEDICINE			English	Article							TRANSCRIPTION FACTOR GATA-3; BOUND TGF-BETA; AIRWAY INFLAMMATION; MAST-CELLS; PROTO-ONCOGENE; CHOLERA-TOXIN; GROWTH-FACTOR; W-LOCUS; EXPRESSION; RESPONSES	Dendritic cells ( DCs) are integral to the differentiation of T helper cells into T helper type 1 T(H)1, T(H)2 and T(H)17 subsets. Interleukin-6 ( IL-6) plays an important part in regulating these three arms of the immune response by limiting the T(H)1 response and promoting the T(H)2 and T(H)17 responses. In this study, we investigated pathways in DCs that promote IL-6 production. We show that the allergen house dust mite ( HDM) or the mucosal adjuvant cholera toxin promotes cell surface expression of c-Kit and its ligand, stem cell factor ( SCF), on DCs. This dual upregulation of c-Kit and SCF results in sustained signaling downstream of c-Kit, promoting IL-6 secretion. Intranasal administration of antigen into c-Kit-mutant mice or neutralization of IL-6 in cultures established from the lung-draining lymph nodes of immunized wild-type mice blunted the T(H)2 and T(H)17 responses. DCs lacking functional c-Kit or those unable to express membrane-bound SCF secreted lower amounts of IL- 6 in response to HDM or cholera toxin. DCs expressing nonfunctional c-Kit were unable to induce a robust T(H)2 or T(H)17 response and elicited diminished allergic airway inflammation when adoptively transferred into mice. Expression of the Notch ligand Jagged-2, which has been associated with T(H)2 differentiation, was blunted in DCs from c-Kit-mutant mice. c-Kit upregulation was specifically induced by T(H)2- and T(H)17-skewing stimuli, as the T(H)1-inducing adjuvant, CpG oligodeoxynucleotide, did not promote either c-Kit or Jagged-2 expression. DCs generated from mice expressing a catalytically inactive form of the p110 delta subunit of phosphatidylinositol-3 ( PI3) kinase ( p110(D910A)) secreted lower amounts of IL-6 upon stimulation with cholera toxin. Collectively, these results highlight the importance of the c-Kit-PI3 kinase-IL-6 signaling axis in DCs in regulating T cell responses.	[Krishnamoorthy, Nandini; Oriss, Timothy B.; Paglia, Melissa; Fei, Mingjian; Yarlagadda, Manohar; Ray, Anuradha; Ray, Prabir] Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, Pittsburgh, PA 15213 USA; [Krishnamoorthy, Nandini; Ray, Anuradha; Ray, Prabir] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA 15213 USA; [Vanhaesebroeck, Bart] Queen Mary Univ London, Ctr Cell Signalling, Inst Canc, Barts & London Queen Marys Sch Med & Dent, London EC1M 6BQ, England	Ray, A (reprint author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Dept Med, 3459 5th Ave, Pittsburgh, PA 15213 USA.	raya@pitt.edu; rayp@pitt.edu			NHLBI NIH HHS [HL 060207, HL 069810, HL 077430, HL 084932, P50 HL084932, R01 HL060207, R01 HL069810, R01 HL077430]; NIAID NIH HHS [AI 048927, R01 AI048927]		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Amsen D, 2007, IMMUNITY, V27, P89, DOI 10.1016/j.immuni.2007.05.021; Arora M, 2006, P NATL ACAD SCI USA, V103, P7777, DOI 10.1073/pnas.0508492103; Bagley KC, 2002, INFECT IMMUN, V70, P5533, DOI 10.1128/IAI.70.10.5533-5539.2002; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Borg C, 2004, J CLIN INVEST, V114, P379, DOI 10.1172/jci20041102; BRANNAN CI, 1991, P NATL ACAD SCI USA, V88, P4671, DOI 10.1073/pnas.88.11.4671; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; Cates EC, 2004, J IMMUNOL, V173, P6384; CHABOT B, 1988, NATURE, V335, P88, DOI 10.1038/335088a0; Chatterjea D, 2005, IMMUNOL LETT, V99, P122, DOI 10.1016/j.imlet.2005.02.015; Chen L, 2006, J IMMUNOL, V177, P2373; Crackower MA, 2002, CELL, V110, P737, DOI 10.1016/S0092-8674(02)00969-8; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Dodge IL, 2003, J IMMUNOL, V170, P4457; Fang TC, 2007, IMMUNITY, V27, P100, DOI 10.1016/j.immuni.2007.04.018; FLANAGAN JG, 1991, CELL, V64, P1025, DOI 10.1016/0092-8674(91)90326-T; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; GEISSLER EN, 1988, CELL, V55, P185, DOI 10.1016/0092-8674(88)90020-7; Happel KI, 2005, J EXP MED, V202, P761, DOI 10.1084/jem.20050193; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Houde C, 2004, BLOOD, V104, P3697, DOI 10.1182/blood-2003-12-4114; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Kalesnikoff J, 2006, P NATL ACAD SCI USA, V103, P2659, DOI 10.1073/pnas.0511191103; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Lukacs NW, 1996, J IMMUNOL, V156, P3945; Luty WH, 2007, J IMMUNOL, V179, P819; MIYAZAWA K, 1995, BLOOD, V85, P641; Okkenhaug K, 2002, SCIENCE, V297, P1031; Oriss TB, 2005, J IMMUNOL, V174, P854; Ostroukhova M, 2006, J CLIN INVEST, V116, P996, DOI 10.1127/JCI26490; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; QIU F, 1988, EMBO J, V7, P1003; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; SERVE H, 1995, EMBO J, V14, P473; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Veldhoen M, 2006, IMMUNITY, V24, P179, DOI 10.1016/j.immuni.2006.01.001; YEE NS, 1993, J BIOL CHEM, V268, P14189; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	49	124	127	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2008	14	5					565	573		10.1038/nm1766		9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	298IQ	WOS:000255681800038	18454155	
J	Bousquet, J; Annesi-Maesano, I; Carat, F; Leger, D; Rugina, M; Pribil, C; El Hasnaoui, A; Chanal, I				Bousquet, J; Annesi-Maesano, I; Carat, F; Leger, D; Rugina, M; Pribil, C; El Hasnaoui, A; Chanal, I			Characteristics of intermittent and persistent allergic rhinitis: DREAMS study group	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; ARIA; asthma; rhinitis	SKIN PRICK TESTS; PERENNIAL RHINITIS; ASTHMA; POPULATION; POLLEN; VALIDATION; ADULTS; ATOPY; QUESTIONNAIRE; HETEROGENEITY	Background In the Allergic Rhinitis and its Impact on Asthma ( ARIA) classification, intermittent and persistent rhinitis were proposed to replace seasonal and perennial allergic rhinitis (AR). Aim To better understand the ARIA classification of rhinitis. Methods A cross-sectional study was carried out in 591 patients consulting ENT or allergy specialists for AR and 502 control subjects. The diagnosis of AR was based on a score for allergic rhinitis (SFAR) >= 7. Patients were classified according to the four ARIA classes ( mild intermittent, mild persistent, moderate/severe intermittent and moderate/severe persistent). Allergen sensitization (skin prick tests (SPTs) or specific IgE) and co- morbidities were examined according to the ARIA classes. Results Ten percent of patients had mild intermittent rhinitis, 14% mild persistent rhinitis, 17% moderate/severe intermittent rhinitis and 59% moderate/severe persistent rhinitis. Most patients with intermittent rhinitis had a pollen sensitivity, but 5% had a single house dust mite (HDM) sensitization. Over 50% of patients with persistent rhinitis were allergic to pollens or HDM. Asthma was present in 24% of rhinitis patients and in only 2% of the control population ( P < 0.0001). Patients with moderate/severe persistent rhinitis had the highest asthma prevalence (33%). Discussion Intermittent and persistent rhinitis are not synonymous of seasonal and perennial rhinitis. Most patients consulting specialists have severe rhinitis. Asthma prevalence increases with duration and severity of rhinitis supporting the ARIA major recommendation that patients with persistent rhinitis should be evaluated for asthma.	CHU Montpellier, Clin Malad Resp, Hop Arnaud de Villeneuve, F-34295 Montpellier, France; INSERM U454, Montpellier, France; INSERM U472, Villejuif, France; Hop Cochin, F-75674 Paris, France; Hop Hotel Dieu, Paris, France; Hop Intercommunal Creteil, Creteil, France; GSK, Marly Le Roi, France	Bousquet, J (reprint author), CHU Montpellier, Clin Malad Resp, Hop Arnaud de Villeneuve, F-34295 Montpellier, France.	jean.bousquet@wanadoo.fr	Annesi-Maesano, Isabella/D-9173-2016				Annesi-Maesano I, 2002, ALLERGY, V57, P107, DOI 10.1034/j.1398-9995.2002.1o3170.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BOUSQUET J, 2002, ALLERGY, V58, P841; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; BUCHOLTZ GA, 1991, ANN ALLERGY, V67, P534; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; International Consensus Report on Diagnosis and Management of Rhinitis, 1994, ALLERGY S, V49, P1; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Lagier B, 1995, J ALLERGY CLIN IMMUN, V96, P932, DOI 10.1016/S0091-6749(95)70231-8; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413; Leynaert N, 2004, J ALLERGY CLIN IMMUN, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; Pariente PD, 1997, PHARMACOECONOMICS, V12, P585; PENE J, 1994, IMMUNOLOGY, V81, P58; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PEPYS J, 1994, ALLERGY, V49, P397, DOI 10.1111/j.1398-9995.1994.tb00830.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Ricca V, 2000, J ALLERGY CLIN IMMUN, V105, P54, DOI 10.1016/S0091-6749(00)90177-5; Rudin A, 2001, ALLERGY, V56, P1042, DOI 10.1034/j.1398-9995.2001.00991.x; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7	30	124	125	1	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2005	35	6					728	732		10.1111/j.1365-2222.2005.02274.x		5	Allergy; Immunology	Allergy; Immunology	937WG	WOS:000229956100009	15969662	
J	Douwes, J				Douwes, J			(1 -> 3)-beta-D-glucans and respiratory health: a review of the scientific evidence	INDOOR AIR			English	Article						(1 -> 3)-beta-D-glucan; review; respiratory health; fungi; damp; epidemiology	UPPER AIRWAY INFLAMMATION; IN-HOUSE DUST; WORK-RELATED SYMPTOMS; MOLD EXPOSURE; PULMONARY INFLAMMATION; PERSONAL EXPOSURES; ALLERGIC RESPONSE; WASTE COLLECTORS; CYTOKINE RELEASE; SOLUBLE GLUCAN	(1 -> 3)-beta-D-glucan are non-allergenic structural cell wall components of most fungi that have been suggested to play a causal role in the development of respiratory symptoms associated with indoor fungal exposure. This review describes the currently available epidemiological literature on health effects of (1 -> 3)-beta-D-glucan, focusing on atopy, airway inflammation and symptoms, asthma, and lung function. In addition to population studies, studies in human volunteers experimentally exposed to (1 -> 3)-beta-D-glucan are described as well as relevant animal studies. Furthermore, the review discusses exposure assessment methods, the potential for exposure control and it concludes with identifying research needs. The observational and experimental studies reviewed suggested some association between (1 -> 3)-beta-D-glucan exposure, airway inflammation and symptoms, however, results were mixed and specific symptoms and potential underlying inflammatory mechanisms associated with exposure could not be identified. Large observational studies using well validated exposure assessment methods are needed to further our knowledge regarding the potential health effects of indoor (1 -> 3)-beta-D-glucan exposure.	Massey Univ, Ctr Publ Hlth Res, Palmerston North, New Zealand	Douwes, J (reprint author), Private Box 756, Wellington, New Zealand.	j.douwes@massey.ac.nz		Douwes, Jeroen/0000-0003-3599-4036			ADACHI Y, 1994, BIOL PHARM BULL, V17, P1554; AKETAGAWA J, 1993, J BIOCHEM-TOKYO, V113, P683; Beijer L, 2003, EUR RESPIR J, V21, P317, DOI 10.1183/09031936.03.00283603; Beijer L, 2002, MEDIAT INFLAMM, V11, P149, DOI 10.1080/09622935020138181; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Bonlokke JH, 2004, INT ARCH OCC ENV HEA, V77, P136, DOI 10.1007/s00420-003-0479-9; BOWERS GJ, 1986, INT J IMMUNOPHARMACO, V8, P313, DOI 10.1016/0192-0561(86)90113-X; COOK JA, 1980, CIRC SHOCK, V7, P225; DILUZIO NR, 1979, J RETICULOENDOTH SOC, V26, P67; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032; Douwes J, 2000, AM J IND MED, V37, P459, DOI 10.1002/(SICI)1097-0274(200005)37:5<459::AID-AJIM2>3.0.CO;2-J; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Eduard W, 2001, OCCUP ENVIRON MED, V58, P113, DOI 10.1136/oem.58.2.113; FOGELMARK B, 1992, AGENTS ACTIONS, V35, P50, DOI 10.1007/BF01990951; FOGELMARK B, 1994, INT J EXP PATHOL, V75, P85; Fogelmark B, 2001, MEDIAT INFLAMM, V10, P13, DOI 10.1080/09629350151073748; Fogelmark B, 1997, INDOOR BUILT ENVIRON, V6, P291, DOI 10.1177/1420326X9700600506; Foto M, 2004, ANAL BIOANAL CHEM, V379, P156, DOI 10.1007/s00216-004-2583-4; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; Gladding T, 2003, AM J IND MED, V43, P584, DOI 10.1002/ajim.10220; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Heldal KK, 2003, EUR RESPIR J, V21, P641, DOI 10.1183/09031936.03.00059702; Heldal KK, 2003, OCCUP ENVIRON MED, V60, P444, DOI 10.1136/oem.60.6.444; Institute of Medicine (US) Committee on Damp Indoor Spaces and Health, 2004, DAMP IND SPAC HLTH; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; Instanes C, 2004, CLIN EXP ALLERGY, V34, P1634, DOI 10.1111/j.1365-2222.2004.02076.x; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; Korpi A, 2003, MEDIAT INFLAMM, V12, P139, DOI 10.1080/0962935031000134851; Kruger T, 2004, CYTOKINE, V25, P73, DOI 10.1016/j.cyto.2003.10.001; Lebron F, 2003, J BIOL CHEM, V278, P25001, DOI 10.1074/jbc.M301426200; Mandryk J, 1999, AM J IND MED, V35, P481, DOI 10.1002/(SICI)1097-0274(199905)35:5<481::AID-AJIM5>3.0.CO;2-N; Mandryk J, 2000, ANN OCCUP HYG, V44, P281; Milton DK, 2001, APPL ENVIRON MICROB, V67, P5420, DOI 10.1128/AEM.67.12.5420-5424.2001; Ormstad H, 2000, J TOXICOL ENV HEAL A, V61, P55, DOI 10.1080/00984100050116780; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; RAMANI M, 1988, CLIN IMMUNOL, V81, P696; Rylander R, 1997, ARCH ENVIRON HEALTH, V52, P281; Rylander R, 1998, MEDIAT INFLAMM, V7, P105; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; Rylander R, 2000, TOXICOLOGY, V152, P47, DOI 10.1016/S0300-483X(00)00291-2; Rylander R, 1999, EUR RESPIR J, V13, P1151, DOI 10.1034/j.1399-3003.1999.13e35.x; RYLANDER R, 1996, INDOOR BUILT ENVIRON, V5, P106, DOI 10.1177/1420326X9600500206; [Anonymous], 1994, INDOOR ENVIRON, DOI DOI 10.1177/1420326X9400300311; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; SAITO K, 1992, CHEM PHARM BULL, V40, P1227; Sigsgaard T, 2000, EUR RESPIR J, V16, P140, DOI 10.1034/j.1399-3003.2000.16a25.x; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Thorn J, 1998, AM J IND MED, V33, P463; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; Thorn J, 2001, MEDIAT INFLAMM, V10, P173; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Williams DL, 1997, MEDIAT INFLAMM, V6, P247, DOI 10.1080/09629359791550; Wouters IM, 2002, OCCUP ENVIRON MED, V59, P106, DOI 10.1136/oem.59.2.106; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Young SH, 2003, J TOXICOL ENV HEAL A, V66, P551, DOI 10.1080/15287390390156281; Young SH, 2003, J TOXICOL ENV HEAL A, V66, P25, DOI 10.1080/152873903901557232; Young SH, 2002, TOXICOL APPL PHARM, V178, P172, DOI 10.1006/taap.2001.9332; Young SH, 2001, J TOXICOL ENV HEAL A, V64, P311, DOI 10.1080/152873901316981303; ZHANG K, 1994, J CELL BIOCHEM, V56, P225, DOI 10.1002/jcb.240560217; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	64	124	131	2	15	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0905-6947			INDOOR AIR	Indoor Air	JUN	2005	15	3					160	169		10.1111/j.1600-0668.2005.00333.x		10	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	921GF	WOS:000228751500003	15865616	
J	Banauch, GI; Alleyne, D; Sanchez, R; Olender, K; Cohen, HW; Weiden, M; Kelly, KJ; Prezant, DJ				Banauch, GI; Alleyne, D; Sanchez, R; Olender, K; Cohen, HW; Weiden, M; Kelly, KJ; Prezant, DJ			Persistent hyperreactivity and reactive airway dysfunction in firefighters at the World Trade Center	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						inorganic particulate matter; nonspecific bronchial hyperreactivity; reactive airways dysfunction syndrome; firefighters; World Trade Center collapse	DOSE-RESPONSE CURVES; BRONCHIAL RESPONSIVENESS; OCCUPATIONAL ASTHMA; FOLLOW-UP; HEALTH CONSEQUENCES; POPULATION-SAMPLE; SMOKE-INHALATION; SYNDROME RADS; LUNG-FUNCTION; EXPOSURE	New York City Fire Department rescue workers experienced massive exposure to airborne particulates at the World Trade Center site. Aims of this longitudinal study were to (1) determine if bronchial hyperreactivity was present, persistent, and independently associated with exposure intensity, (2) identify objective measures shortly after the collapse that would predict persistent hyperreactivity and a diagnosis of reactive airways dysfunction 6 months post-collapse. A representative sample of 179 rescue workers stratified by exposure intensity (high, moderate, and control) without current smoking or prior respiratory disease was enrolled. Highly exposed workers arrived within 2 hours of collapse, moderately exposed workers arrived later on Days 1-2; control subjects were not exposed. Hyperreactivity at 1, 3, and 6 months post-collapse was associated with exposure intensity, independent of ex-smoking and airflow obstruction. Six months post-collapse, highly exposed workers were 6.8 times more likely than moderately exposed workers and control subjects to be hyperreactive (95% confidence interval, 1.8-25.2; p = 0.004), and hyperreactivity persisted in 55% of those hyperreactive at I and/or 3 months. In highly exposed subjects, hyperreactivity 1 or 3 months post-collapse was the sole predictor for reactive airways dysfunction (p = 0.021). In conclusion, development and persistence of hyperreactivity and reactive airways dysfunction were strongly and independently associated with exposure intensity. Hyperreactivity shortly post-collapse predicted reactive airways dysfunction at 6 months in highly exposed workers; this has important implications for disaster management.	Montefiore Med Ctr, Div Pulm, Bronx, NY 10467 USA; Albert Einstein Coll Med, Dept Epidemiol & Social Med, Bronx, NY 10467 USA; New York City Fire Dept, Bur Hlth Sci, Brooklyn, NY USA; NYU, Sch Med, Div Pulm, New York, NY USA	Prezant, DJ (reprint author), Montefiore Med Ctr, Div Pulm, Centennial 423, Bronx, NY 10467 USA.			Cohen, Hillel/0000-0002-4524-0898	NIOSH CDC HHS [R01-OH07350]; ODCDC CDC HHS [U1Q/CCU221158-01]		Abul AT, 2001, ANN ALLERG ASTHMA IM, V86, P465; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Bardana EJ, 1999, ANN ALLERG ASTHMA IM, V83, P583, DOI 10.1016/S1081-1206(10)62876-1; BAXTER PJ, 1983, ARCH ENVIRON HEALTH, V38, P138; BECKETT WS, 1997, BRIT MED J, V314, P338; BLANC PD, 1993, CHEST, V103, P1699, DOI 10.1378/chest.103.6.1699; Bourbeau J, 1996, EUR RESPIR J, V9, P1470, DOI 10.1183/09031936.96.09071470; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Chen LC, 2002, LANCET, V360, pS37, DOI 10.1016/S0140-6736(02)11814-9; CHIA KS, 1990, BRIT J IND MED, V47, P524; CONE JE, 1994, CHEST, V106, P500, DOI 10.1378/chest.106.2.500; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; ERNST P, 1989, THORAX, V44, P116, DOI 10.1136/thx.44.2.116; Fagan J, 2002, MMWR-MORBID MORTAL W, V51, P781; FIREMAN E, IN PRESS AM J RESP C; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704; Ghio AJ, 2000, AM J RESP CRIT CARE, V162, P981; Hodgins P, 1998, AM J RESP CRIT CARE, V157, P1390; HUGEL DW, 1998, J LAB CLIN MED, V111, P684; KERN DG, 1991, AM REV RESPIR DIS, V144, P1058; KINSELLA J, 1991, LANCET, V337, P595, DOI 10.1016/0140-6736(91)91650-J; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KREMER AM, 1994, AM J IND MED, V26, P655, DOI 10.1002/ajim.4700260508; Laprise C, 1997, AM J RESP CRIT CARE, V156, P403; Lemiere C, 1996, MED CLIN N AM, V80, P749, DOI 10.1016/S0025-7125(05)70466-1; Leroyer C, 1998, OCCUP ENVIRON MED, V55, P356; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; MALO JL, 1988, AM REV RESPIR DIS, V138, P807; McKinney K, 2002, MMWR-MORBID MORTAL W, V51, P453; Mochizuki H, 2000, PEDIATRICS, V106, P1442, DOI 10.1542/peds.106.6.1442; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; Piirila PL, 1996, SCAND J WORK ENV HEA, V22, P191; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; PROMISLOFF RA, 1990, CHEST, V98, P928, DOI 10.1378/chest.98.4.928; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62; RIJCKEN B, 1993, AM REV RESPIR DIS, V147, P1447; RIJCKEN B, 1993, EUR RESPIR J, V6, P617; Rom WN, 2002, AM J RESP CRIT CARE, V166, P797, DOI 10.1164/rccm.200206-576OC; SARIC M, 1991, BRIT J IND MED, V48, P653; SHERMAN CB, 1989, AM REV RESPIR DIS, V140, P185; Stephenson J, 2002, JAMA-J AM MED ASSOC, V288, P1219, DOI 10.1001/jama.288.10.1219; Tarlo SM, 2000, OCCUP MED, V15, P471; TATTERSFIELD AE, 1985, AIRWAY RESPONSIVENES, P94; Townsend MC, 2000, J OCCUP ENVIRON MED, V42, P228, DOI 10.1097/00043764-200003000-00003; Verlato G, 1996, EUR RESPIR J, V9, P506, DOI 10.1183/09031936.96.09030506; Vijayan VK, 1996, EUR RESPIR J, V9, P1977, DOI 10.1183/09031936.96.09101977	48	124	124	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 1	2003	168	1					54	62		10.1164/rccm.200211-1329OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	695HH	WOS:000183824700008	12615613	
J	Helenius, I; Rytila, P; Sarna, S; Lumme, A; Helenius, M; Remes, V; Haahtela, T				Helenius, I; Rytila, P; Sarna, S; Lumme, A; Helenius, M; Remes, V; Haahtela, T			Effect of continuing or finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma: A 5-year prospective follow-up study of 42 highly trained swimmers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; athletes; airway inflammation; bronchial hyperresponsiveness; swimming; sports medicine	CROSS-COUNTRY SKIERS; INDUCED SPUTUM; PREVALENCE; RESPONSIVENESS; EXPOSURE; RISK	Background: Mild eosinophilic airway inflammation and bronchial hyperresponsiveness-ie, mild asthma-have been shown to affect a high proportion of endurance athletes. The persistence of airway inflammation, bronchial hyperresponsiveness, and asthma in this population is not known, however, inasmuch as follow-up studies of athletes' asthma have not been performed. Objective: The purpose of this study was to investigate effect of finishing high-level sports on airway inflammation, bronchial hyperresponsiveness, and asthma. Methods: Forty-two elite competitive swimmers, most of them from the Finnish national team (37/42; 88%), were followed for 5 years in a prospective manner. All of the swimmers completed questionnaires and underwent resting spirometry, histamine challenge testing, and skin prick tests at baseline and at follow-up. Twenty-nine swimmers (69%) also gave induced sputum samples on both occasions. Sixteen (38%) of the swimmers had continued their competitive careers during follow-up (active swimmers), but 26 (62%) had stopped competing more than 3 months before the follow-up examination (past swimmers). Results: Bronchial responsiveness was increased in 7 (44%) of the 16 active swimmers at baseline and in 8 (50%) of the 16 active swimmers at follow-up; it was increased in 8 (31%) of the 26 past swimmers at baseline and in 3 (12%) of the 26 past swimmers at follow-up (McNemar test, P = .025). The difference in the change in bronchial hyperresponsiveness between the study groups was significant (likelihood ratio test, P = .023). Current asthma (defined as bronchial hyperresponsiveness and exercise-induced bronchial symptoms monthly) was observed in 5 (31%) of the active swimmers at baseline and in 7 (44%) of the active swimmers at follow-up; of the past swimmers, it occurred in 6 (23%) at baseline and in 1 (4%) at follow-up (McNemar test, P = .025). The difference in the change in current asthma between the study groups was significant (likelihood ratio test, P = .0040). The sputum differential cell counts of eosinophils and lymphocytes increased significantly during the follow-up period in the active swimmers (Wilcoxon signed rank sum test; P = .033 and P = .0029, respectively); in the past swimmers, the sputum differential cell counts of eosinophils tended to decrease during the follow-up period (P = .17), whereas the differential cell counts of lymphocytes did not change significantly. The changes in the sputum differential cell counts of eosinophils between the study groups differed significantly (Mann-Whitney U test, P = .019). Conclusion: In swimmers who had stopped high-level training, bronchial hyperresponsiveness and asthma attenuated or even disappeared. Mild eosinophilic airway inflammation was aggravated among highly trained swimmers who remained active during the 5-year follow-up. Our results suggest that athletes' asthma is partly reversible and that it may develop during and subside after an active sports career.	Univ Helsinki, Cent Hosp, Div Allergy, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland	Helenius, I (reprint author), Arhipanpolku 8 B A, FIN-00420 Helsinki, Finland.			Sarna, Seppo/0000-0003-3458-1627			AGGAZZOTTI G, 1993, ARCH ENVIRON HEALTH, V48, P250; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Belda J, 2000, AM J RESP CRIT CARE, V161, P475; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; *FINN MIN ED, 1998, WAT QUAL IND SWIMM P; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; HAAHTELA T, 1990, BRIT MED J, V301, P266; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Helenius IJ, 1997, THORAX, V52, P157; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086; Kujala UM, 1996, THORAX, V51, P288, DOI 10.1136/thx.51.3.288; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479; LARSSON K, 1993, BRIT MED J, V307, P1326; Metso T, 1996, ALLERGY, V51, P226; Peleman RA, 1999, EUR RESPIR J, V13, P839, DOI 10.1034/j.1399-3003.1999.13d24.x; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; Viljanen AA, 1982, SCAND J CLIN LA S159, V42, P1; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; ZWICK H, 1990, LUNG, V168, P111	28	124	127	0	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					962	968		10.1067/mai.2002.124769		7	Allergy; Immunology	Allergy; Immunology	566RU	WOS:000176442700011	12063525	
J	Chan, E; Zhan, CL; Homer, CJ				Chan, E; Zhan, CL; Homer, CJ			Health care use and costs for children with attention-deficit/hyperactivity disorder - National estimates front the Medical Expenditure Panel Survey	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the Academy-for-Health-Services-Research-and-Health-Policy	JUN   11, 2001	ATLANTA, GEORGIA	Acad Hlth Serv Res & Hlth Policy			DEFICIT HYPERACTIVITY DISORDER; COUNTY-WIDE SAMPLE; PSYCHOSOCIAL PROBLEMS; ASTHMA; IDENTIFICATION; ADOLESCENTS; MANAGEMENT; PATTERNS; CRITERIA	Context: Although attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent chronic condition of childhood, little is known about patterns of health care use and associated expenditures. Objective: To compare health care use and costs among children with ADHD, children with asthma, and the general pediatric population. Design and Setting: The 1996 Medical Expenditure Panel Survey, a nationally representative household survey. Participants: All 5439 children aged 5 to 20 years from the 1996 Medical Expenditure Panel Survey were included in this analysis. Children who had ADHD, asthma,d or neither (general population) were identified from Into-national Classification of Diseases, Ninth Revision, Clinical Modification codes and prescription records. Main Outcome Measures: Mean health care use (outpatient visits, emergency department visits, hospital stays, home health visit days, and prescriptions) and associated expenditures. Results: We identified 105 children with ADHD, 322 with asthma, and 4052 with neither diagnosis. Children with ADHD had significantly higher mean total health care costs ($1151) compared with children with asthma ($1091 P<.05) and the general population ($712 P<.001). After adjusting for age, Sex, race, household income, access to care, parent education, and martial Status, excess total costs were $479 for children with ADHD (P<.001) and $437 for children with asthma (P<.01). Conclusions: Overall costs of care for children with ADHD are comparable to costs for children with asthma and significantly greater than for the general pediatric Population, Specific types of health care use and the sources of expenditures differ between children with ADHD and children with asthma. Because much ADHD-related care occurs within school and mental health settings, these figures likely underestimate the true costs of caring for children with this condition.	Childrens Hosp, Hlth Serv Res, Div Gen Pediat, Boston, MA 02115 USA; Agcy Healthcare Res & Qual, Rockville, MD USA	Chan, E (reprint author), Childrens Hosp, Hlth Serv Res, Div Gen Pediat, 300 Longwood Ave,LO-240, Boston, MA 02115 USA.				BHP HRSA HHS [T32 PE10018]		BARKLEY RA, 1991, J AM ACAD CHILD PSY, V30, P752, DOI 10.1097/00004583-199109000-00009; Barkley RA, 1996, PEDIATRICS, V98, P1089; Camp BW, 1997, ARCH PEDIAT ADOL MED, V151, P78; Cohen J., 1997, DESIGN METHODS MED E; DiScala C, 1998, PEDIATRICS, V102, P1415, DOI 10.1542/peds.102.6.1415; Donahue JG, 1997, J ASTHMA, V34, P273, DOI 10.3109/02770909709067217; GOLDBERG ID, 1984, PEDIATRICS, V73, P278; Guevara J, 2001, PEDIATRICS, V108, P71, DOI 10.1542/peds.108.1.71; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; HORWITZ SM, 1992, PEDIATRICS, V89, P480; Jensen PS, 1999, ARCH GEN PSYCHIAT, V56, P1073; KELLEHER K, 2001, TEN ECON NEUROSCI, V3, P60; Kelleher KJ, 2000, PEDIATRICS, V105, P1313, DOI 10.1542/peds.105.6.1313; Korn EL, 1999, ANAL HLTH SURVEYS; Leibson CL, 2001, JAMA-J AM MED ASSOC, V285, P60, DOI 10.1001/jama.285.1.60; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957; OSBORNE ML, 1995, J CLIN EPIDEMIOL, V48, P1393, DOI 10.1016/0895-4356(95)00065-8; Safer DJ, 1996, PEDIATRICS, V98, P1084; Shah B. V., 1997, SUDAAN USERS MANUAL; SHARP L, 1992, PEDIATRICS, V89, P619; SZATMARI P, 1989, J CHILD PSYCHOL PSYC, V30, P205, DOI 10.1111/j.1469-7610.1989.tb00235.x; Szatmari P., 1992, CHILD ADOL PSYCH CL, P361; *US DHHS, 1988, INT CLASS DIS 9 REV; Wasserman RC, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e38; Wolraich ML, 1996, J AM ACAD CHILD PSY, V35, P319, DOI 10.1097/00004583-199603000-00013; Wolraich ML, 1998, J DEV BEHAV PEDIATR, V19, P162, DOI 10.1097/00004703-199806000-00003	27	124	125	2	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAY	2002	156	5					504	511				8	Pediatrics	Pediatrics	548RC	WOS:000175402100018	11980558	
J	Leaderer, BP; Belanger, K; Triche, E; Holford, T; Gold, DR; Kim, Y; Jankun, T; Ren, P; McSharry, JE; Plattsmills, TAE; Chapman, MD; Bracken, MB				Leaderer, BP; Belanger, K; Triche, E; Holford, T; Gold, DR; Kim, Y; Jankun, T; Ren, P; McSharry, JE; Plattsmills, TAE; Chapman, MD; Bracken, MB			Dust mite, cockroach, cat, and dog allergen concentrations in homes of asthmatic children in the northeastern United States: Impact of socioeconomic factors and population density	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						aeroallergens; asthma; cats; cockroaches; dogs; dust mites; indoor air; socioeconomic factors	INNER-CITY CHILDREN; MONOCLONAL-ANTIBODIES; INDOOR ALLERGENS; PUERTO-RICAN; RISK-FACTORS; EXPOSURE; PREVALENCE; MORTALITY; SENSITIZATION; MORBIDITY	Home exposures to aeroallergens are an important environmental factor in allergic sensitization and in the development and exacerbation of asthma. We assessed variations in home concentrations of dust Mite, cock-roach, cat, and dog allergens in dust collected in the main living areas of asthmatics' homes by family income, mother's education, dwelling type, population density, household population density, and ethnicity in Connecticut and south-central Massachusetts. Dust samples were collected at the time of home interview in 999 homes as part of an ongoing longitudinal birth cohort study of 1,002 infants and their asthmatic siblings. The analysis employed lower arid upper cut points for group 1 dust mite (greater than or equal to2.0 mug/g and greater than or equal to10 mug/g), cockroach (greater than or equal to1.0 U/g and greater than or equal to4.0 U/g), cat (greater than or equal to1.0 mug/g and greater than or equal to8.0 ug/g), and dog (greater than or equal to2.0 mug/g and 10.0 mug/g) allergens. Subject residences were geocoded to assess population density from the U.S. Census, and multiple logistic regression was used to control for confounding, The portion of homes at the lower cut point for dust mite, cockroach, cat, and dog allergens were 46.9%, 24.9%, 42.2%, and 35.6%, respectively; the upper cut point for each of the allergens was reached in 22.4%, 13.4%, 21.0%, and 22.9% of the homes, respectively. In all, 86.0% of the homes had at least one allergen at the lower cut point, and 58.0% had at least one allergen at the upper cut point. Forty-nine percent of the homes had two or more allergens at the lower cut point, and 19.7% had two or more allergens at the upper cut point. Higher education of the mother, higher household income, living in a single-family home in a less densely populated area with fewer people per room, and being a white household were associated with elevated dust mite, cat, and dog allergens and low cockroach allergen. In contrast, low income, living in a multifamily home in a high population density area with a higher occupancy rate per room, and being a Hispanic or black household were associated with elevated cockroach allergens and low concentrations of dust mite, cat, and dog allergens. Although the presence of an individual allergen is more likely associated with one or more socioeconomic or ethnic factors, most homes typically have multiple allergen burdens in excess of concentrations thought to be associated with sensitization and exacerbation of asthma. Mite and cockroach allergens have distinct and opposite associations with socioeconomic factors and population density.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06520 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Bostons Beth Israel Hosp, Div Pulm, Boston, MA 02115 USA; Univ Virginia, Med Ctr, Dept Med, Div Allergy & Immunol, Charlottesville, VA USA	Leaderer, BP (reprint author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, 60 Coll St,POB 208034, New Haven, CT 06520 USA.		Triche, Elizabeth/I-4986-2014		NIEHS NIH HHS [ES05410, ES07456]		Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; CAIL RS, 1992, J PEDIATR, V121, P862; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; COULTAS DB, 1994, AM J RESP CRIT CARE, V149, pS93; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EVANS R, 1992, CHEST, V101, pS368; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; *GEOL INC, 1990, CENS CD PLUS MAPS 19; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LUCZZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P277; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PERSKY VW, 1998, ANN ALLERG ASTHMA IM, V81, P226; PLATTSMILLS TA, 1997, J ALLERGY CLIN IMMUN, V97, P1079; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; RAPPAPORT S, 1998, MMWR-MORBID MORTAL W, V47, P1022; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SAS/STAT User's guide, 1990, SAS STAT US GUID, V1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; WEISS KB, 1990, CHEST, V98, pS179, DOI 10.1378/chest.98.5_Supplement.179S; WEISS ST, 1993, J ASTHMA, V30, P329, DOI 10.3109/02770909309056738; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189	37	124	128	1	5	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2002	110	4					419	425				7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	541GB	WOS:000174975900031	11940461	
J	Apelberg, BJ; Aoki, Y; Jaakkola, JJK				Apelberg, BJ; Aoki, Y; Jaakkola, JJK			Systematic review: Exposure to pets and risk of asthma and asthma-like symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						pets; asthma; wheeze; domestic animal; meta-analysis; selection bias	RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; HOME-ENVIRONMENT; ATOPIC SENSITIZATION; CHILDREN; PREVALENCE; ALLERGY; CAT; ASSOCIATION; MORBIDITY	Background: Studies of exposure to pets and risk of asthma have yielded conflicting results. Objectives: We performed a systematic review to synthesize the evidence of the effect of exposure to pets in the home on the risk of asthma and asthma-related symptoms. We also assessed differences between the studies as sources of heterogeneity of the results. Methods: We conducted a MEDLINE search (until the end of 1999) using the following boolean search command: (asthma[all] OR wheez*[all]) AND (domestic animal*[all] OR pets[all]). The outcome was limited to either diagnosis of asthma or the symptom of wheezing, The exposure of interest was domestic animals in the home, Appropriate temporal relationship was defined as present in studies with either pet keeping within the first 2 years of life, in the past, or exposure to pets preceding the outcome. Results: Thirty-two of the 217 retrieved articles fulfilled the eligibility criteria. Inappropriate time sequence of the exposure and outcome information was an important source of heterogeneity and an indication of potential selection bias. Therefore we analyzed studies focusing on early exposure or ensuring appropriate temporal sequence. The pooled risk estimates for both asthma (fixed-effects odds ratio, 1.11; 95% CI, 0.98-1.25; heterogeneity, P = .04; random-effects odds ratio, 1.09; 95% CI, 0.89-1.34) and wheezing (fixed-effects odds ratio, 1.19; 95% CI, 1.05-1.35; heterogeneity, P = .03; random-effects odds ratio, 1.17; 95% CI, 0.95-1.44) indicated a small effect, which was limited to studies with a median study population age of over 6 years (fixed-effects odds ratio, 1.19; 95% CI, 1.02-1.40; heterogeneity, P = .04; random-effects odds ratio, 1.15; 95% CI, 0.86-1.56; fixed-effects odds ratio, 1.29; 95% CI, 1.12-1.48; heterogeneity, P = .31). In younger children the harmful effect disappeared for wheezing (odds ratio, 0.80; 95% CI, 0.59-1.08; P = .38). Conclusion: Exposure to pets appears to increase the risk of asthma and wheezing in older children. The observed lower risk among exposed than among unexposed young children is consistent with a protective effect in this age, group but could also be explained by selection bias.	Johns Hopkins Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Jaakkola, JJK (reprint author), Nord Sch Publ Hlth, Environm Hlth Program, POB 12133, SE-40242 Gothenburg, Sweden.		Jaakkola, Jouni/G-4314-2012				ABDULRAZZAQ YM, 1995, J ASTHMA, V32, P117, DOI 10.3109/02770909509083232; Abuekteish F, 1996, ANN TROP PAEDIATR, V16, P227; Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; al Frayh A R, 1989, Allerg Immunol (Paris), V21, P389; ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Austin JB, 1997, ARCH DIS CHILD, V76, P22; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Bener A., 1993, Indian Journal of Pediatrics, V60, P791, DOI 10.1007/BF02751050; Bener A, 1995, Allerg Immunol (Paris), V27, P190; Bener A, 1996, HUM BIOL, V68, P405; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Burr ML, 1999, THORAX, V54, P27; DAIGLER GE, 1991, LARYNGOSCOPE, V101, P293; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15; GREENLAND S, 1987, EPIDEMIOL REV, V9, P1; HALKEN S, 1991, ALLERGY, V46, P507, DOI 10.1111/j.1398-9995.1991.tb00613.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; KALYONCU AF, 1994, ALLERGY, V49, P485, DOI 10.1111/j.1398-9995.1994.tb00846.x; Kane MP, 1999, J ASTHMA, V36, P371, DOI 10.3109/02770909909068230; LEEN MG, 1994, IRISH MED J, V87, P142; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; Nriagu J, 1999, EUR J EPIDEMIOL, V15, P747, DOI 10.1023/A:1007653709188; ONTEFORT S, 1998, CLIN EXP ALLERGY, V38, P1089; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills T A, 1996, Curr Opin Pulm Med, V2, P29; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Poole C, 1999, AM J EPIDEMIOL, V150, P469; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sears MR, 1998, CLIN EXP ALLERGY, V28, P82; Sharp S.J., 1998, STAT TECHNICAL B REP, V7, P106; Sharp S, 1998, STATA TECH B, V42, P16; SHAW R, 1994, NEW ZEAL MED J, V107, P387; Siracusa A, 1997, Monaldi Arch Chest Dis, V52, P434; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; *STAT, 1999, STAT STAT SOFTW REL; STEICHEN T, 1998, STAT TECHNICAL B REP, V8, P84; STRACHAN DP, 1995, BRIT MED J, V311, P1053; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352; Zacharasiewicz A, 1999, WIEN KLIN WOCHENSCHR, V111, P882	48	124	127	4	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					455	460		10.1067/mai.2001.113240		6	Allergy; Immunology	Allergy; Immunology	416RE	WOS:000167793300006	11240945	
J	Mannino, DM; Moorman, JE; Kingsley, B; Rose, D; Repace, J				Mannino, DM; Moorman, JE; Kingsley, B; Rose, D; Repace, J			Health effects related to environmental tobacco smoke exposure in children in the United States - Data from the Third National Health and Nutrition Examination Survey	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							PARENTAL SMOKING; PASSIVE SMOKING; COTININE; PARTICULATE; POLLUTION; WORKPLACE; CHILDHOOD; ASTHMA	Objective: To determine the effects of prenatal. and postnatal smoke exposure on the respiratory health of children in the United States. Design: Nationally representative cross-sectional survey, including questionnaire information, measurements of serum cotinine (a metabolite of nicotine), and pulmonary function measurement, of 5400 US children. Setting and Participants: Children aged 4 to 16 years in the Third National Health and Nutrition Examination Survey, October 25, 1988, to October 15, 1994. Methods: We stratified the study participants into tertiles, on the basis of serum cotinine levels, and used logistic and linear regression modeling, adjusting for known covariates, to determine the effect of high environmental tobacco smoke (ETS) exposure (on the basis of a high cotinine level) on outcomes such as the prevalence of current asthma, the prevalence of frequent wheezing, school absence, and lung function. For children aged 4 to 11 years, we also determined the effect of prenatal maternal smoking on these outcomes. Results: We observed effects of ETS exposure in all age groups, although the effects varied between age groups. Among all children significant effects associated with high cotinine levels were for wheezing apart from cold in the past year (odds ratio [OR], 1.8; 95% confidence interval [CI], 1.1-2.8); 6 or more days of school absence in the past year (OR, 2.0; 95% CI, 1.4-2.8); and lung function decrements in the forced expiratory volume in 1 second (mean change, -1.8%; 95% CI, -3.2% to -0.4%) and the maximal midexpiratory flow (mean change, -5.9%; 95% CI, -8.1% to -3.4%). Although current and ever asthma were not significantly associated with high cotinine levels in the overall group (OR, 1.5; 95% CI, 0.8-2.7, and OR, 1.3; 95% CI, 0.8-2.2, respectively), they were increased significantly among 4- to 6-year-old children (OR, 5.3; 95% CI, 2.2-12.7, and OR, 2.3; 95% CI, 1.1-5.1, respectively). Conclusions: We investigated recent ETS exposures as important predictors of respiratory health outcomes in children 4 years and older. Environmental tobacco smoke exposure affects children of all ages, although the exact effects may vary between age groups.	Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Ctr Dis Control, Ctr Chron Dis Prevent & Hlth Promot, Epidemiol Branch, Off Smoking & Hlth, Atlanta, GA 30333 USA; Ctr Dis Control & Prevent, Off Vital & Hlth Stat, Natl Ctr Hlth Stat, Washington, DC USA; Repace Associates, Bowie, MD USA	Mannino, DM (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 1600 Clifton Rd,MS E-17, Atlanta, GA 30333 USA.			Mannino, David/0000-0003-3646-7828			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188; California Environmental Protection Agency, 1997, TOB CONTROL, V6, P346; Caraballo RS, 1998, JAMA-J AM MED ASSOC, V280, P135, DOI 10.1001/jama.280.2.135; Cook DG, 1999, THORAX, V54, P357; Cook DG, 1997, THORAX, V52, P1081; Cook DG, 1998, THORAX, V53, P884; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Klepeis NE, 1999, J EXPO ANAL ENV EPID, V9, P622, DOI 10.1038/sj.jea.7500065; Mannino D M, 1996, Tob Control, V5, P13, DOI 10.1136/tc.5.1.13; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Repace JL, 1998, RISK ANAL, V18, P71, DOI 10.1111/j.1539-6924.1998.tb00917.x; REPACE JL, 1993, RISK ANAL, V13, P463, DOI 10.1111/j.1539-6924.1993.tb00747.x; SAS Institute Inc, 1990, SAS LANG REF VERS 6; Shah B. V., 1997, SUDAAN USERS MANUAL; Strachan DP, 1997, THORAX, V52, P905; Strachan DP, 1998, THORAX, V53, P204; Theunissen NCM, 1998, QUAL LIFE RES, V7, P387, DOI 10.1023/A:1008801802877; [Anonymous], 1994, VITAL HLTH STAT 1, V1, P1	22	124	129	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JAN	2001	155	1					36	41				6	Pediatrics	Pediatrics	389RU	WOS:000166252200007	11177060	
J	Tournoy, KG; Kips, JC; Schou, C; Pauwels, RA				Tournoy, KG; Kips, JC; Schou, C; Pauwels, RA			Airway eosinophilia is not a requirement for allergen-induced airway hyperresponsiveness	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						airway hyperresponsiveness; Der p 1; eosinophil; house dust mite; immunoglobulin E	CELL-DEFICIENT MICE; DUST MITE ALLERGEN; DER-P-I; T-CELLS; DERMATOPHAGOIDES-PTERONYSSINUS; BRONCHIAL HYPERREACTIVITY; MURINE MODEL; GUINEA-PIGS; INFLAMMATION; ASTHMA	Background House dust mites (HDMs) are the major source of perennial allergens causing human allergic asthma. Animal models mimicking as closely as possible the allergic features observed in human asthma are therefore interesting tools for studying the immunological and pathophysiological mechanisms involved. Especially the role of eosinophils and allergen-specific immunoglobulin (Ig) E in the pathophysiology of airway hyperresponsiveness (AHR) remains a subject of intense debate. Objective To develop a mouse model of allergic airway inflammation and hyperresponsiveness based on the use of purified house dust mite allergen (Der p 1) as clinical relevant allergen. Furthermore, we studied the effects of low dose allergen exposure on the airway eosinophilia and AHR. Methods On day 0, C57B1/6 mice were immunized with purified Der p 1 intraperitoneally. From day 14-20, the mice were exposed daily to a 30-min aerosol of different concentrations of house dust mite extract. Results Mice, actively immunized with Der p 1 and subsequently exposed to HDM aerosols, developed AHR, eosinophil infiltration of the airways and allergen-specific IgE. Moreover, lowering the concentration of the HDM aerosol also induced AHR and IgE without apparent eosinophil influx into the airways. Der p 1-sensitized mice exposed to PBS produced IgE, but did not show AHR or eosinophil influx. Conclusion This in vivo model of HDM-induced allergic airway changes suggests that AHR is not related to either eosinophil influx or allergen-specific serum IgE, thereby reducing the importance of these factors as essential elements for allergic AHR.	State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium; ALK, Horsholm, Denmark	Tournoy, KG (reprint author), State Univ Ghent Hosp, Dept Resp Dis, Pintelaan 185,7 K12 IE, B-9000 Ghent, Belgium.						BUIJS J, 1995, AM J RESP CRIT CARE, V151, P873; CHUNG KF, 1995, EUR RESPIR REV, V5, P184; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Coyle AJ, 1998, EUR J IMMUNOL, V28, P2640, DOI 10.1002/(SICI)1521-4141(199809)28:09<2640::AID-IMMU2640>3.0.CO;2-X; CURTIS JL, 1991, J CLIN INVEST, V88, P1244, DOI 10.1172/JCI115428; DAVIS PB, 1995, AM J RESP CELL MOL, V12, P367; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Duez C, 1996, EUR J IMMUNOL, V26, P1088, DOI 10.1002/eji.1830260520; GARSSEN J, 1993, AM REV RESPIR DIS, V147, P307; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; Hsiue TR, 1997, INT ARCH ALLERGY IMM, V112, P295; ISHII A, 1989, INT ARCH ALLER A IMM, V89, P400; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535; KIPS JC, 1997, CLIN ASTHMA REV, V1, P45; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83; LACK C, 1995, AM J RESP CRIT CARE, V152, P1765; Lee YL, 1999, SCAND J IMMUNOL, V49, P229; Lefort J, 1996, J ALLERGY CLIN IMMUN, V97, P788, DOI 10.1016/S0091-6749(96)80157-6; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; Matsubara S, 1998, INT ARCH ALLERGY IMM, V116, P67, DOI 10.1159/000023927; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MILLS TAP, 1997, J ALLERGY CLIN IMMUN, V100, pS2; *NAT HEART LUNG BL, 1995, NHLBI PUBL; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; RENZ H, 1995, INT ARCH ALLERGY IMM, V106, P46; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1987, INT ARCH ALLER A IMM, V83, P44; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Yasue M, 1998, LAB ANIM SCI, V48, P346; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	38	124	133	2	5	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2000	30	1					79	85				7	Allergy; Immunology	Allergy; Immunology	286RN	WOS:000085459400012	10606934	
J	Lambrecht, BN; Hammad, H				Lambrecht, Bart N.; Hammad, Hamida			The role of dendritic and epithelial cells as master regulators of allergic airway inflammation	LANCET			English	Review							HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; RESPIRATORY SYNCYTIAL VIRUS; CD4(+) T-CELLS; IMMUNE-RESPONSES; INHALED ANTIGEN; CIGARETTE-SMOKE; LYMPH-NODES; IN-VIVO; EXPERIMENTAL ASTHMA	Lung dendritic cells bridge innate and adaptive immunity, integrating a variety of stimuli from allergens, microbial colonisation, environmental pollution, and innate immune cells into a signal for T lymphocytes of the adaptive immune system. Dendritic cells have a pivotal role in the activation of T helper (Th) 2 cells and allergic inflammation. Lung dendritic cells can also prevent harmful immune responses to innocuous inhaled antigens via induction of regulatory T cells or Th1 cells. In our Review, we discuss how understanding the biology of dendritic cells is crucial for understanding the interaction between allergens, the environment, and genetics, and focus on how dendritic cells conspire with airway epithelial cells and innate pro-Th2 cells to cause allergic sensitisation and asthma.	[Lambrecht, Bart N.; Hammad, Hamida] Ghent Univ Hosp, Dept Pulm Med, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium	Lambrecht, BN (reprint author), Ghent Univ Hosp, Dept Pulm Med, Lab Immunoregulat & Mucosal Immunol, De Pintelaan 185, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834			Adam E, 2010, EUR J IMMUNOL, V40, P1995, DOI 10.1002/eji.200939913; Bachem A, 2010, J EXP MED, V207, P1273, DOI 10.1084/jem.20100348; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Barrett NA, 2009, J IMMUNOL, V182, P1119; Beaty SR, 2007, J IMMUNOL, V178, P1882; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; de Haar C, 2008, J ALLERGY CLIN IMMUN, V121, P1246, DOI 10.1016/j.jaci.2008.01.010; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; Dodge IL, 2003, J IMMUNOL, V170, P4457; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; Fainaru O, 2004, EMBO J, V23, P969, DOI 10.1038/sj.emboj.7600085; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gangl K, 2009, ALLERGY, V64, P398, DOI 10.1111/j.1398-9995.2008.01861.x; GeurtsvanKessel C H, 2008, Mucosal Immunol, V1, P442, DOI 10.1038/mi.2008.39; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; GeurtsvanKessel CH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007187; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jakubzick C, 2006, J IMMUNOL, V176, P3578; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Keber MM, 2005, J ENDOTOXIN RES, V11, P186, DOI 10.1179/096805105X35206; Kobayashi T, 2009, J IMMUNOL, V182, P2502, DOI 10.4049/jimmunol.0802773; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Lagranderie M, 2010, J IMMUNOL, V184, P1062, DOI 10.4049/jimmunol.0901822; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; MacLean JA, 1996, AM J PATHOL, V148, P657; MacRedmond RE, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-84; Medoff BD, 2009, J IMMUNOL, V182, P623; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1046/j.1365-2222.1996.d01-337.x; Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Pace E, 2008, IMMUNOLOGY, V124, P401, DOI 10.1111/j.1365-2567.2007.02788.x; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Provoost S, 2010, J IMMUNOL, V184, P426, DOI 10.4049/jimmunol.0902564; Randolph GJ, 2005, NAT REV IMMUNOL, V5, P617, DOI 10.1038/nri1670; RANGASAMY T, 2009, AM J RESP CELL MOL B, DOI DOI 10.1165/RCMB.2008-04380C; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Robays LJ, 2009, J IMMUNOL, V183, P2758, DOI 10.4049/jimmunol.0802204; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Smits HH, 2009, MUCOSAL IMMUNOL, V2, P331, DOI 10.1038/mi.2009.16; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stoll S, 2002, SCIENCE, V296, P1873, DOI 10.1126/science.1071065; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; TAZI A, 1993, J CLIN INVEST, V91, P566, DOI 10.1172/JCI116236; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vermaelen KY, 2001, J EXP MED, V193, P51; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Yamamoto N, 2000, EUR J IMMUNOL, V30, P316, DOI 10.1002/1521-4141(200001)30:1<316::AID-IMMU316>3.0.CO;2-0; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	95	123	131	1	17	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 4	2010	376	9743					835	843		10.1016/S0140-6736(10)61226-3		9	Medicine, General & Internal	General & Internal Medicine	650EC	WOS:000281831000035	20816550	
J	Heinzerling, L; Frew, AJ; Bindslev-Jensen, C; Bonini, S; Bousquet, J; Bresciani, M; Carlsen, KH; Cauwenberge, P; Darsow, U; Fokkens, WJ; Haahtela, T; van Hoecke, H; Jessberger, B; Kowalski, ML; Kopp, T; Lahoz, CN; Lodrup Carlsen, KC; Papadopoulos, NG; Ring, J; Schmid-Grendelmeier, P; Vignola, AM; Wohrl, S; Zuberbier, T				Heinzerling, L; Frew, AJ; Bindslev-Jensen, C; Bonini, S; Bousquet, J; Bresciani, M; Carlsen, KH; Cauwenberge, P; Darsow, U; Fokkens, WJ; Haahtela, T; van Hoecke, H; Jessberger, B; Kowalski, ML; Kopp, T; Lahoz, CN; Lodrup Carlsen, KC; Papadopoulos, NG; Ring, J; Schmid-Grendelmeier, P; Vignola, AM; Wohrl, S; Zuberbier, T			Standard skin prick testing and sensitization to inhalant allergens across Europe - a survey from the GA(2)LEN network	ALLERGY			English	Article						European network; inhalant allergens; standard skin prick testing	RESPIRATORY-HEALTH-SURVEY; BRONCHIAL HYPERRESPONSIVENESS; INDIVIDUAL ALLERGENS; COPENHAGEN ALLERGY; COMMON ALLERGENS; SCHOOL-CHILDREN; TEST REACTIVITY; ATOPIC ECZEMA; YOUNG-ADULTS; HAY-FEVER	Skin prick testing (SPT) is the standard method for diagnosing allergic sensitization but is to some extent performed differently in clinical centres across Europe. There would be advantages in harmonizing the standard panels of allergens used in different European countries, both for clinical purposes and for research, especially with increasing mobility within Europe and current trends in botany and agriculture. As well as improving diagnostic accuracy, this would allow better comparison of research findings in European allergy centres. We have compared the different SPT procedures operating in 29 allergy centres within the Global Allergy and Asthma European Network (GA(2)LEN). Standard SPT is performed similarly in all centres, e.g. using commercial extracts, evaluation after 15-20 min exposure with positive results defined as a wheal > 3 mm diameter. The perennial allergens included in the standard SPT panel of inhalant allergens are largely similar (e.g. cat: pricked in all centres; dog: 26 of 29 centres and Dermatophagoides pteronyssinus: 28 of 29 centres) but the choice of pollen allergens vary considerably, reflecting different exposure and sensitization rates for regional inhalant allergens. This overview may serve as reference for the practising doctor and suggests a GA(2)LEN Pan-European core SPT panel.	Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergy Ctr Charite, D-10117 Berlin, Germany; Univ Southampton, Southampton Gen Hosp, Infect Inflammat & Repair Div, Southampton, Hants, England; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark; Odense Univ Hosp, Allergy Ctr, DK-5000 Odense, Denmark; CNR, Rome, Italy; INSERM, Paris, France; Univ Oslo, Natl Hosp, Voksentoppen BKL, Oslo, Norway; State Univ Ghent Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Div Environm Dermatol & Allergy GSF, D-8000 Munich, Germany; Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; Univ Helsinki, Cent Hosp, Helsinki, Finland; Med Univ Lodz, Dept Allergy & Clin Immunol, Lodz, Poland; Med Univ Vienna, Vienna, Austria; Univ Autonoma Madrid, Fdn Jimenez Diaz, ImmunoAllergy Dept, Madrid, Spain; Ullevaal Univ Hosp, Dept Pediat, Oslo, Norway; NKUA, Dept Allergy, Pediat Clin 2, Athens, Greece; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Univ Palermo, CNR, Inst Internal Med & Pneumol, Palermo, Italy; CNR, IBIM, Palermo, Italy	Zuberbier, T (reprint author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergy Ctr Charite, Schumannstr 20-21, D-10117 Berlin, Germany.		Bindslev-Jensen, Carsten/H-1877-2011; Wohrl, Stefan/B-6954-2013	Bindslev-Jensen, Carsten/0000-0002-8940-038X; Papadopoulos, Nikolaos/0000-0002-2508-3872; Wohrl, Stefan/0000-0002-6324-0007; Bonini, Sergio/0000-0003-0079-3031			AAS K, 1972, ACTA ALLERGOL, V27, P439; Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bjornsson E, 1996, ANN ALLERG ASTHMA IM, V77, P327; Bousquet J, 2004, ALLERGY, V59, P1, DOI 10.1111/j.1398-9995.2004.00425.x; Bousquet PJ, 2005, ALLERGY, V60, P407, DOI 10.1111/j.1398-9995.2004.00667.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Carlsen KCL, 2002, ALLERGY, V57, P529, DOI 10.1034/j.1398-9995.2002.13305.x; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Del Giacco SG, 2004, ALLERGY, V59, P575, DOI 10.1111/j.1398-9995.2004.00478.x; DREBORG S, 1989, J AM ACAD DERMATOL, V21, P820, DOI 10.1016/S0190-9622(89)70256-5; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; EAACI, 1993, ALLERGY, V48, P48; Gislason T, 2002, CHEST, V121, P158, DOI 10.1378/chest.121.1.158; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Krouse JH, 2003, OTOLARYNG HEAD NECK, V129, pS33, DOI 10.1016/S0194-5998(03)01398-6; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Linneberg A, 2001, CLIN EXP ALLERGY, V31, P1409, DOI 10.1046/j.1365-2222.2001.01178.x; Mortz CG, 2003, ACTA DERM-VENEREOL, V83, P194, DOI 10.1080/00015550310007201; Piette V, 2002, ALLERGY, V57, P940, DOI 10.1034/j.1398-9995.2002.23536.x; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Plaschke P, 1999, ALLERGY, V54, P843, DOI 10.1034/j.1398-9995.1999.00162.x; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb04652.x; Priftanji AV, 1999, ALLERGY, V54, P1042, DOI 10.1034/j.1398-9995.1999.00108.x; Rhodius R, 2002, ANN ALLERG ASTHMA IM, V88, P374; Ronchetti R, 2003, PEDIATR ALLERGY IMMU, V14, P201, DOI 10.1034/j.1399-3038.2003.00027.x; Saraclar Y, 1997, RESP MED, V91, P461; Sastre J, 1996, ALLERGY, V51, P582; Schafer T, 1996, ALLERGY, V51, P532; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; van Amsterdam JGC, 2003, CLIN EXP ALLERGY, V33, P187, DOI 10.1046/j.1365-2222.2003.01597.x; van Ree Ronald, 2004, Allergy, V59, P571; van Ree R, 2003, ARB P EHRLICH I BUND, V94, P70; Vartiainen E, 2002, J ALLERGY CLIN IMMUN, V109, P643, DOI 10.1067/mai.2002.123307; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Wieringa MH, 2001, CLIN EXP ALLERGY, V31, P1553, DOI 10.1046/j.1365-2222.2001.01188.x; Wuthrich B, 2001, Ther Umsch, V58, P253, DOI 10.1024/0040-5930.58.5.253; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	49	123	123	1	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	OCT	2005	60	10					1287	1300		10.1111/j.1398-9995.2005.00895.x		14	Allergy; Immunology	Allergy; Immunology	960BS	WOS:000231565800011	16134996	
J	Koenig, JQ; Mar, TF; Allen, RW; Jansen, K; Lumley, T; Sullivan, JH; Trenga, CA; Larson, TV; Liu, LJS				Koenig, JQ; Mar, TF; Allen, RW; Jansen, K; Lumley, T; Sullivan, JH; Trenga, CA; Larson, TV; Liu, LJS			Pulmonary effects of indoor- and outdoor-generated particles in children with asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						ambient air pollution; asthma; exhaled nitric oxide; infiltration; PM2.5	EXHALED NITRIC-OXIDE; ANTIINFLAMMATORY MEDICATION USE; PARTICULATE AIR-POLLUTION; HOSPITAL ADMISSIONS; RESPIRATORY SYMPTOMS; LUNG-FUNCTION; ASSOCIATION; EXPOSURE; MATTER; SEATTLE	Most particulate matter (PM) health effects studies use outdoor (ambient) PM as a surrogate for personal exposure. However, people spend most of their time indoors exposed to a combination of indoor-generated particles and ambient particles that have infiltrated. Thus, it is important to investigate the differential health effects of indoor- and ambient-generated particles. We combined our recently adapted recursive model and a predictive model for estimating infiltration efficiency to separate personal exposure (L) to PM2.5 (PM with aerodynamic diameter <= 2.5 pm) into its indoor-generated (E-ig) and ambient-generated (E-ag) components for 19 children with asthma. We then compared E-ig and E-ag to changes in exhaled nitric oxide (eNO), a marker of airway inflammation. Based on the recursive model with a sample size of eight children, E-ag was marginally associated with increases in eNO [5.6 ppb per 10-mu g/m(3) increase in PM2.5; 95% confidence interval (CI), -0.6 to 11.9; p = 0.08]. E-ig was not associated with eNO (-0.19 ppb change per 10 mu g/m(3)). Our predictive model allowed us to estimate E-ag and E-ig for all 19 children. For those combined estimates, only E-ag was significantly associated with an increase in eNO (E-ag: 5.0 ppb per 10-mu g/m(3) increase in PM2.5; 95% CI, 0.3 to 9.7; p = 0.04; E-ig: 3.3 ppb per 10-mu g/m(3) increase in PM2.5; 95% CI, -1.1 to 7.7; p = 0.15). Effects were seen only in children who were not using corticosteroid therapy. We conclude that the ambient-generated component of PM2.5 exposure is consistently associated with increases in eNO, and the indoor-generated component is less strongly associated with eNO.	Univ Washington, Dept Environm Hlth & Occupat Sci, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA	Koenig, JQ (reprint author), Univ Washington, Dept Environm Hlth, Box 357234,Room F5614,1705 NE Pacific, Seattle, WA 98195 USA.	Jkoenig@u.washington.edu			NIEHS NIH HHS [P30 ES07033]		Abt E, 2000, ENVIRON HEALTH PERSP, V108, P35, DOI 10.2307/3454293; Adamkiewicz G, 2004, THORAX, V59, P204, DOI 10.1136/thorax.2003.006445; Allen R, 2004, J AIR WASTE MANAGE, V54, P1197; Allen R., 2003, ENVIRON SCI TECHNOL, V37, P3485; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Anuszewski J, 1998, J EXPO ANAL ENV EPID, V8, P483; Brunekreef B, 1997, OCCUP ENVIRON MED, V54, P781; Dal Negro R, 2003, ALLERGY, V58, P1018; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Deykin A, 1998, AM J RESP CRIT CARE, V157, P769; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; EBELT ST, EPIDEMIOLOGY; JANSEN K, 2004, AM J RESP CRIT CARE, V169, pA282; Janssen NAH, 2002, ENVIRON HEALTH PERSP, V110, P43; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Koenig JQ, 2003, ENVIRON HEALTH PERSP, V111, P1625, DOI 10.1289/ehp.6160; Koenig J.Q, 2000, HLTH EFFECTS AMBIENT; Li AM, 2003, THORAX, V58, P974, DOI 10.1136/thorax.58.11.974; Liu LJS, 2003, ENVIRON HEALTH PERSP, V111, P909, DOI 10.1289/ehp.6011; Liu LJS, 2002, ENVIRON SCI TECHNOL, V36, P2977, DOI 10.1021/es0112644; Long CM, 2001, ENVIRON HEALTH PERSP, V109, P1019, DOI 10.2307/3454956; MAJID E, 2001, ENV HLTH PERSPECT, V109, P481; Nightingale JA, 1999, THORAX, V54, P1061; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; Sarnat JA, 2002, ENVIRON SCI TECHNOL, V36, P5305, DOI 10.1021/es025796b; Schwartz J, 2000, ENVIRON HEALTH PERSP, V108, P563, DOI 10.2307/3454620; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Simoni M, 2002, ARCH ENVIRON HEALTH, V57, P130; Smedbold HT, 2002, ARCH ENVIRON HEALTH, V57, P155; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167; Sunyer J, 2001, EUR RESPIR J, V17, P1024, DOI 10.1183/09031936.01.17510240; *US EPA, 2004, EPA600P99002ABF; Van Amsterdam JGC, 1999, ARCH ENVIRON HEALTH, V54, P331; Van Amsterdam JGC, 2000, ARCH ENVIRON HEALTH, V55, P418; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; WU CF, IN PRESS ATMOS ENV	39	123	127	2	23	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2005	113	4					499	503		10.1289/ehp.7511		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	913NO	WOS:000228158900052	15811822	
J	Brockow, K; Christiansen, C; Kanny, G; Clement, O; Barbaud, A; Bircher, A; DeWachter, P; Gueant, JL; Gueant, RMR; Mouton-Faivre, C; Ring, J; Romano, A; Sainte-Laudy, J; Demoly, P; Pichler, WJ				Brockow, K; Christiansen, C; Kanny, G; Clement, O; Barbaud, A; Bircher, A; DeWachter, P; Gueant, JL; Gueant, RMR; Mouton-Faivre, C; Ring, J; Romano, A; Sainte-Laudy, J; Demoly, P; Pichler, WJ		ENDA; EAACI Interest Grp Drug Hypersensi	Management of hypersensitivity reactions to iodinated contrast media	ALLERGY			English	Editorial Material						contrast media; diagnosis; immediate reaction; nonimmediate reaction; premedication; skin tests	DELAYED ADVERSE-REACTIONS; LATE-TYPE ALLERGY; ANAPHYLACTOID REACTION; RADIOCONTRAST MEDIUM; INVITRO HISTAMINE; DRUG-REACTIONS; SKIN-TESTS; AGENTS; PREMEDICATION; FREQUENCY	All iodinated contrast media (CM) are known to cause both immediate (less than or equal to1 h) and nonimmediate (>1 h) hypersensitivity reactions. Although for most immediate reactions an allergic hypersensitivity cannot be demonstrated, recent studies indicate that the severe immediate reactions may be IgE-mediated, while most of the nonimmediate exanthematous skin reactions, appear to be T-cell mediated. Patients who experience such hypersensitivity reactions are therefore advised to undergo an allergologic evaluation. Several investigators have found skin testing to be useful in confirming a CM allergy, especially in patients with nonimmediate skin eruptions. If a patient with confirmed allergy to a CM needs a new CM exposure, a skin test negative CM should be chosen and premedication may be tried. However, none of these precautional measures is a guarantee against a repeat reaction. More research focusing on pathomechanisms, diagnostic testing and premedication is therefore clearly needed in order to prevent CM-induced hypersensitivity reactions in the future.	Klin & Poliklin Dermatol & Allergol Biederstein, Munich, Germany; Amersham Hlth AS, Res & Dev, Oslo, Norway; Univ Hosp, Cent Hosp, Dept Internal Med Clin Immunol & Allergy, Nancy, France; Hosp Europeen G Pompidou, Serv Radiol, Paris, France; Fournier Hosp, Dept Dermatol, Nancy, France; Univ Hosp, Dept Dermatol, Allergy Unit, Basel, Switzerland; Cent Hosp, Dept Anesthesie Reanimat, Nancy, France; Fac Med Nancy, Lab Pathol Cellulaire & Mol Nutr, Nancy, France; UCSC, Allergy Unit, Dept Internal Med & Geriatr, Rome, Italy; IRCCS, Oasi Maria SS, Troina, Italy; Lab Immunol & Allergol, Paris, France; Hop Arnaud Villeneuve, INSERM, U454, Montpellier, France; Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, CH-3010 Bern, Switzerland	Brockow, K (reprint author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.		CLEMENT, Olivier/D-5221-2014	Romano, Antonino/0000-0001-9742-9898			Akiyama M, 1998, ACAD RADIOL, V5, pS159, DOI 10.1016/S1076-6332(98)80092-5; ALMEN T, 1994, INVEST RADIOL, V29, pS37; Alvarez-Fernandez JA, 2000, ALLERGY, V55, P581, DOI 10.1034/j.1398-9995.2000.00563.x; ANSELL G, 1980, INVEST RADIOL, V15, pS32, DOI 10.1097/00004424-198011001-00010; AOKI Y, 2002, JPN J RADIOL TECHNOL, V58, P1245; ASSEM ESK, 1983, BRIT J RADIOL, V56, P647; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Bettmann MA, 1997, RADIOLOGY, V203, P611; BOROFSKY HB, 1993, ADV XRAY CONTRAST, V1, P58; Brockow K, 1999, J ALLERGY CLIN IMMUN, V104, P1107; Brockow K, 1999, Allerg Immunol (Paris), V31, P49; Brockow K, 1999, J ALLERGY CLIN IMMUN, V104, P237, DOI 10.1016/S0091-6749(99)70141-7; CARO JJ, 1991, AM J ROENTGENOL, V156, P825; CHOYKE PL, 1992, RADIOLOGY, V183, P111; Christiansen C, 2000, EUR RADIOL, V10, P1965, DOI 10.1007/s003300000543; CHRISTIANSEN C, 2004, ALLERGOLOGIE, V27, P165; Christiansen C, 2002, EUR RADIOL, V12, pS94, DOI 10.1007/s00330-002-1620-y; COHAN RH, 1995, RADIOLOGY, V194, P357; Courvoisier S, 1998, ALLERGY, V53, P1221, DOI 10.1111/j.1398-9995.1998.tb03846.x; Demoly P, 1999, ALLERGY, V54, P999, DOI 10.1034/j.1398-9995.1999.00247.x; Dewachter P, 2001, ALLERGY, V56, P250, DOI 10.1034/j.1398-9995.2001.056003250.x; ERDMANN S, 2000, Z HAUTKRANKHEITEN, V75, P169; FISCHER HW, 1972, RADIOLOGY, V103, P497; Freed KS, 2001, AM J ROENTGENOL, V176, P1389; Gall H, 1999, CONTACT DERMATITIS, V40, P248, DOI 10.1111/j.1600-0536.1999.tb06058.x; GonzaloGarijo MA, 1997, ALLERGY, V52, P875, DOI 10.1111/j.1398-9995.1997.tb02164.x; GOODFELLOW T, 1986, BRIT J RADIOL, V59, P620; Hosoya T, 2000, Radiat Med, V18, P39; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kanny G, 1993, Allerg Immunol (Paris), V25, P425; Kanny G, 2001, EUR J DERMATOL, V11, P134; Kanzaki T, 1991, J Dermatol, V18, P528; KATAYAMA H, 1990, RADIOLOGY, V175, P621; Ketkar M, 2003, AM J NEURORADIOL, V24, P292; LANG DM, 1991, ANN INTERN MED, V115, P270; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; LAROCHE D, 1991, ANESTHESIOLOGY, V75, P945, DOI 10.1097/00000542-199112000-00004; Laroche D, 1998, RADIOLOGY, V209, P183; Laroche D, 1999, ALLERGY, V54, P13; LAROCHE D, 2004, ALLERGOLOGIE, V27, P165; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; Mita H, 1998, ALLERGY, V53, P1133, DOI 10.1111/j.1398-9995.1998.tb03832.x; MIYAMOTO Y, 1990, Nippon Acta Radiologica, V50, P295; Moneret-Vautrin DA, 2001, REV MED INTERNE, V22, P969, DOI 10.1016/S0248-8663(01)00455-6; Morcos SK, 2001, EUR RADIOL, V11, P1720, DOI 10.1007/s003300000778; Munechika H, 2003, EUR RADIOL, V13, P185, DOI 10.1007/s00330-002-1339-9; Otto K, 2003, ALLERGY, V58, P261, DOI 10.1034/j.1398-9995.2003.00062_3.x; PALMER F J, 1988, Australasian Radiology, V32, P426, DOI 10.1111/j.1440-1673.1988.tb02770.x; PATRIARCA G, 1978, ANN ALLERGY, V40, P200; Pichler Werner J, 2002, Am J Clin Dermatol, V3, P229, DOI 10.2165/00128071-200203040-00001; Pichler WJ, 2000, THORAX, V55, P561; RING J, 1977, LANCET, V1, P466; RING J, 1978, CLIN EXP IMMUNOL, V34, P302; RING J, 1978, CLIN EXP IMMUNOL, V32, P105; Roberts M, 1992, Australas Radiol, V36, P144, DOI 10.1111/j.1440-1673.1992.tb03103.x; Romano A, 2002, RADIOLOGY, V225, P466, DOI 10.1148/radiol.2251011654; Rosado A, 2001, AM J ROENTGENOL, V176, P262; Rydberg J, 1998, ACTA RADIOL, V39, P219; Sanchez-Perez J, 2003, CONTACT DERMATITIS, V48, P167, DOI 10.1034/j.1600-0536.2003.00051.x; SAVADER SJ, 1995, J INTERVENT RADIOL, V10, P115; SAVILL JS, 1908, POSTGRAD MED J, V64, P392; Schick E, 1996, CONTACT DERMATITIS, V35, P312, DOI 10.1111/j.1600-0536.1996.tb02403.x; Schild H., 1996, EUR RADIOL, V6, P9; Sedano E, 2001, ALLERGY, V56, P1015, DOI 10.1034/j.1398-9995.2001.00250.x; SIEGLE RL, 1980, INVEST RADIOL, V15, pS13, DOI 10.1097/00004424-198011001-00005; STOVSKY MD, 1995, J UROLOGY, V153, P1641, DOI 10.1016/S0022-5347(01)67487-1; Sutton AGC, 2001, AM HEART J, V141, P677, DOI 10.1067/mhj.2001.113570; SWEENEY MJ, 1983, J ALLERGY CLIN IMMUN, V71, P147, DOI 10.1016/0091-6749(83)90360-3; Vernassiere C, 2004, CONTACT DERMATITIS, V50, P359, DOI 10.1111/j.0105-1873.2004.00367.x; WAKKERSGARRITSEN BG, 1976, ANN ALLERGY, V36, P122; Watanabe H, 1999, DERMATOLOGY, V198, P291, DOI 10.1159/000018133; Webb JAW, 2003, EUR RADIOL, V13, P181, DOI 10.1007/s00330-002-1650-5; WITTEN DM, 1973, AM J ROENTGENOL, V119, P832; WOLF GL, 1991, INVEST RADIOL, V26, P404, DOI 10.1097/00004424-199105000-00003; WOLF GL, 1989, AM J ROENTGENOL, V152, P939; YAMAGUCHI K, 1991, RADIOLOGY, V178, P363; Yamauchi Ritsuko, 1997, Journal of Dermatology (Tokyo), V24, P243; Yasuda R, 1998, INVEST RADIOL, V33, P1, DOI 10.1097/00004424-199801000-00001; YOCUM MW, 1978, J ALLERGY CLIN IMMUN, V62, P309, DOI 10.1016/0091-6749(78)90163-X; YOSHIKAWA H, 1992, RADIOLOGY, V183, P737	80	123	130	0	7	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	FEB	2005	60	2					150	158		10.1111/j.1398-9995.2005.00745.x		9	Allergy; Immunology	Allergy; Immunology	887VF	WOS:000226332900004	15647034	
J	Copenhaver, CC; Gern, JE; Li, ZH; Shult, PA; Rosenthal, LA; Mikus, LD; Kirk, CJ; Roberg, KA; Anderson, EL; Tisler, CJ; DaSilva, DF; Hiemke, HJ; Gentile, K; Gangnon, RE; Lemanske, RF				Copenhaver, CC; Gern, JE; Li, ZH; Shult, PA; Rosenthal, LA; Mikus, LD; Kirk, CJ; Roberg, KA; Anderson, EL; Tisler, CJ; DaSilva, DF; Hiemke, HJ; Gentile, K; Gangnon, RE; Lemanske, RF			Cytokine response patterns, exposure to viruses, and respiratory infections in the first year of life	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						interferon-gamma; respiratory syncytial virus; daycare; sibling	DAY-CARE ATTENDANCE; INTERFERON-GAMMA; SYNCYTIAL VIRUS; AIRWAY INFLAMMATION; TRACT ILLNESS; ASTHMA; CHILDREN; RATS; BRONCHIOLITIS; INFANCY	Daycare attendance and siblings are associated with viral-induced wheezing in children. Preexisting immunologic factors may influence the expression of viral infections in infancy, and in turn, recurrent infections may influence the development of immune responses. A total of 285 children were enrolled in the Childhood Origins of Asthma Project at birth and followed for at least 1 year. Cord blood and 1-year mononuclear cells were stimulated with phytohemagglutinin, and cytokine-response profiles were measured by enzyme-linked immunosorbent assay. Nasal lavage was performed for moderate to severe respiratory illnesses. Daycare attendance and/or siblings significantly increased the likelihood of contracting respiratory syncytial virus (1.5-1.6-fold increase) and rhinovirus (1.8-2.1-fold increase), and increased the risk of rhinovirus-induced wheezing (14-18% vs. 2%, p = 0.011). Cord blood IFN-gamma responses were inversely related to the frequency of viral respiratory infections (r(s) = -0.11, p = 0.05), and more significant for subjects with high exposure to other children (r(s) = -0.27, p = 0.028). The interval change in infantile IFN-gamma responses correlated positively with the frequency of viral infections in infancy (r(s) = 0.12, p = 0.047). These data suggest that neonatal IFN-gamma responses may influence antiviral activity, or may represent a marker of antiviral immunity maturation. Conversely, the frequency of viral infections in infancy can influence IFN-gamma responses.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA	Copenhaver, CC (reprint author), Univ Wisconsin Hosp, K4-910,600 Highland Ave, Madison, WI 53792 USA.	cc.copenhaver@hosp.wisc.edu	Rosenthal, Louis/A-8868-2008		NHLBI NIH HHS [1R01HL61879-01, 1P01HL70831-01]		Aldous MB, 1996, AM J EPIDEMIOL, V143, P423; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; BONDESTAM M, 1984, ACTA PAEDIATR SCAND, V73, P197, DOI 10.1111/j.1651-2227.1984.tb09928.x; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Cho JY, 2001, J ALLERGY CLIN IMMUN, V108, P697, DOI 10.1067/mai.2001.119918; Choi EH, 2002, J INFECT DIS, V186, P1207, DOI 10.1086/344310; DaSilva D. F., 2003, Journal of Allergy and Clinical Immunology, V111, pS188, DOI 10.1016/S0091-6749(03)80639-5; Dorman SE, 1999, J PEDIATR-US, V135, P640, DOI 10.1016/S0022-3476(99)70064-8; Gern JE, 2002, PEDIATR ALLERGY IMMU, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Guerra S, 2004, AM J RESP CRIT CARE, V169, P70, DOI 10.1164/rccm.200304-499OC; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Hull J, 2003, J INFECT DIS, V188, P904, DOI 10.1086/377587; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; Kumar A, 1997, AM J RESP CRIT CARE, V155, P130; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2003, J PEDIATR-US, V142, pS3, DOI 10.1067/mpd.2003.19; Mikus LD, 2001, AM J RESP CELL MOL, V24, P74; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1067/mai.2003.1716; Nja F, 2003, ARCH DIS CHILD, V88, P566, DOI 10.1136/adc.88.7.566; Roberg K. A., 2003, Journal of Allergy and Clinical Immunology, V111, pS345, DOI 10.1016/S0091-6749(03)81270-8; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; Sorkness RL, 1999, AM J RESP CRIT CARE, V160, P705; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; TZONEVA M, 1988, CLIN GENET, V33, P454; Uhl EW, 1996, AM J RESP CRIT CARE, V154, P1834; VONMUTIUS E, 1994, BRIT MED J, V308, P692	29	123	126	1	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2004	170	2					175	180		10.1164/rccm.200312-1647OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	837NU	WOS:000222643000014	15087299	
J	Bumbacea, D; Campbell, D; Nguyen, L; Carr, D; Barnes, PJ; Robinson, D; Chung, KF				Bumbacea, D; Campbell, D; Nguyen, L; Carr, D; Barnes, PJ; Robinson, D; Chung, KF			Parameters associated with persistent airflow obstruction in chronic severe asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						airway remodelling; airway thickening; eosinophils; severe asthma	QUALITY-OF-LIFE; RESOLUTION COMPUTED-TOMOGRAPHY; HEALTH-STATUS; INHALED BUDESONIDE; DISEASE SEVERITY; WALL THICKNESS; NITRIC-OXIDE; MILD ASTHMA; INFLAMMATION; LUNGS	The significance of severe airflow obstruction in severe asthma is unclear. The current study determined whether severe airflow obstruction is related to inflammatory or structural changes in the airways. Patients with severe asthma from a tertiary referral clinic were divided into two groups according to their postbronchodilator forced expiratory volume in one second (FEV1): severe persistent airflow limitation (FEV1 <50% predicted; group S; n=37) and no obstruction (FEV1 >80% pred; group N; n=29). Smoking history, atopic status, lung function tests, exhaled NO, blood eosinophil count, quality of life scores using St George's Respiratory Questionnaire and high resolution computed tomography (HRCT) of the lungs were assessed. Patients from group S were older and had longer disease duration. There was no difference in smoking history, atopic status, hospital admissions, quality of life scores and amount of treatment with inhaled or oral corticosteroids. Exhaled NO and peripheral blood eosinophils were higher in group S (21.0+/-2.4 versus 12.8+/-2.3 ppb; 0.41+/-0.06 versus 0.15+/-0.03x10(9)cells(.)L(-1), respectively). HRCT scores for bronchial wall thickening and dilatation were higher in group S with no differences in air trapping. Peripheral blood eosinophilia and bronchial wall thickening on HRCT scan were the only parameters significantly and independently associated with persistent airflow obstruction. Patients with severe asthma and irreversible airflow obstruction had longer disease duration, a greater inflammatory process and more high resolution computed tomography airway abnormalities suggestive of airway remodelling, despite being on similar treatments and experiencing equivalent impairment in quality of life.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Univ Med Farm Carol Davila, Inst Natl Pneumol, Clin Pneumol, Bucharest, Romania	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk		Chung, Kian Fan/0000-0001-7101-1426			American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Ayres JG, 1998, THORAX, V53, P315; Barley EA, 1998, RESP MED, V92, P1207, DOI 10.1016/S0954-6111(98)90423-1; Barley EA, 1999, EUR RESPIR J, V14, P591, DOI 10.1034/j.1399-3003.1999.14c18.x; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; Carr DH, 1998, RESP MED, V92, P448, DOI 10.1016/S0954-6111(98)90290-6; Chung KF, 1999, EUR RESPIR J, V13, P1198; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; HIGGINS BG, 1989, AM REV RESPIR DIS, V140, P1368; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jatakanon A, 1999, THORAX, V54, P108; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; Juniper EF, 2001, EUR RESPIR J, V18, P38, DOI 10.1183/09031936.01.00088301; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; LYNCH DA, 1993, RADIOLOGY, V188, P829; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084; Park CS, 1997, RADIOLOGY, V203, P361; Quanjer P H, 1993, Eur Respir J Suppl, V16, P85; Redington AE, 1997, THORAX, V52, P310; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Stirling RG, 1998, THORAX, V53, P1030; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737	35	123	129	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUL	2004	24	1					122	128		10.1183/09031936.04.00077803		7	Respiratory System	Respiratory System	839FR	WOS:000222769400020	15293614	
J	Shinagawa, K; Kojima, M				Shinagawa, K; Kojima, M			Mouse model of airway remodeling - Strain differences	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; eosinophil; airway hyperresponsiveness; A/J mouse	SMOOTH-MUSCLE; CHRONIC EXPOSURE; MURINE MODEL; FATAL ASTHMA; INBRED MICE; INFLAMMATION; HYPERRESPONSIVENESS; EPITHELIUM; ANTIGEN; RESPONSIVENESS	We found that continuous eosinophilic inflammation after repeated antigen instillation into the nose was observed only in A/J mice, not in three other strains. Histologic analysis of tissues from A/J mice revealed features typical of airway remodeling, i.e., airway wall thickening and increased Collagen depositions were observed after 12 weeks' antigen exposure. Persistent airway hyperresponsiveness (AHR) was observed in chronically antigen-exposed A/J mice. Eosinophilic inflammation, Collagen deposition, and airway wall thickening were all less marked in BALB/c mice than in A/J mice, and no AHR was observed in the former strain. In C57BL/6 and C3H/HeJ mice, eosinophilic inflammation, airway wall thickening, and AHR were not observed at all, although slightly increase Collagen deposition was observed. Thus, we found that these changes were strain-dependent. On the other hand, in A/J mice inhalational antigen challenge after ovalbumin/alum immunization led only to a transient increase in eosinophils and to less airway wall thickening, indicating the importance of the protocol used. Use of A/J mice and giving antigen by instillation via the nose is to be recommended for studies of the mechanisms underlying asthma. In particular, useful qualitative and quantitative information relating to the structural and histologic changes in the lungs may be obtainable using this model.	Kissei Pharmaceut Co Ltd, Pharmacol Lab, Nagano 3998304, Japan	Shinagawa, K (reprint author), Kissei Pharmaceut Co Ltd, Pharmacol Lab, 4365-1 Kashiwabara, Nagano 3998304, Japan.						AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; BAI A, 1994, J APPL PHYSIOL, V77, P1011; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Bento AM, 1998, ALLERGY ASTHMA PROC, V19, P353, DOI 10.2500/108854198778612672; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; HIRANO T, 1988, INT ARCH ALLER A IMM, V85, P47; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; McDonald DM, 2001, AM J RESP CRIT CARE, V164, pS39; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; NAGATANI Y, 1986, YAKUGAKU ZASSHI, V106, P41; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117; Redington AE, 2000, CLIN EXP ALLERGY, V30, P42; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138; Shinagawa K, 2000, J IMMUNOL METHODS, V237, P65, DOI 10.1016/S0022-1759(00)00134-4; Shinagawa K, 2003, INT ARCH ALLERGY IMM, V130, P150, DOI 10.1159/000069005; Swirski FK, 2002, J IMMUNOL, V169, P3499; Temelkovski J, 1998, THORAX, V53, P849; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Yasue M, 1998, LAB ANIM SCI, V48, P346; Yiamouyiannis CA, 1999, AM J PATHOL, V154, P1911, DOI 10.1016/S0002-9440(10)65449-1	39	123	130	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2003	168	8					959	967		10.1164/rccm.200210-1188OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	731JY	WOS:000185881600009	12857720	
J	Jahn-Schmid, B; Harwanegg, C; Hiller, R; Bohle, B; Ebner, C; Scheiner, O; Mueller, MW				Jahn-Schmid, B; Harwanegg, C; Hiller, R; Bohle, B; Ebner, C; Scheiner, O; Mueller, MW			Allergen microarray: comparison of microarray using recombinant allergens with conventional diagnostic methods to detect allergen-specific serum immunoglobulin E	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						IgE; microarray technology; recombinant allergen; Type I allergy	GRASS PHLEUM-PRATENSE; POLLEN ALLERGEN; MAJOR ALLERGEN; PROTEIN MICROARRAYS; IGE; IMMUNOASSAYS; DISEASES; THERAPY; CLONING; GENE	Background The availability of recombinant allergens and recent advances in biochip technology led to the development of a novel test system for the detection of allergen-specific IgE. Objective To test the performance of this allergen microarray in a serological analytical study. Methods Standard allergens contained in grass pollen (Phl p 1, Phl p 2, Phl p 5 and Phl p 6) and tree pollen ( Bet v 1 and Bet v 2) were used as a model system. The detection of allergen-specific serum IgE using microarrays was compared with standard test systems: CAP/RAST and an in-house ELISA. In order to test the analytical sensitivity of the assays, geometric dilutions of a serum pool containing high levels of pollen-specific IgE from allergic individuals were tested in each system. To assess the analytical specificity, the sera of 51 patients with presumptive allergic symptoms were collected before diagnosis. Thereafter, the results for grass/tree-pollen-specific IgE were compared. Results The microarray has a good dynamic range similar to the CAP/RAST system. Microarray and ELISA showed comparable analytical sensitivity exceeding the CAP/RAST system. With respect to the analytical specificity, no significant cross-reactivity of the allergens was observed. For two of the allergens tested, weak positive signals were detected in the microarray test system, whereas they were not detectable by CAP/ RAST. Conclusion A good correlation of presently used methods to detect serum IgE and the novel microarray test system was observed. As a next step, a careful validation of this method for a multitude of allergens and a thorough clinical evaluation has to be provided. Microarray testing of allergen-specific IgE can be presumed to be the method of choice for a prospective component-resolved diagnosis of Type I allergy, and the basis for the design and monitoring of a patient-tailored specific immunotherapy in the future.	Univ Vienna, Inst Pathophysiol, A-1090 Vienna, Austria; VBC GENOMICS Biosci Res GmbH, Vienna, Austria	Scheiner, O (reprint author), Univ Vienna, Inst Pathophysiol, AKH-3Q,Wahringer Gurtel 18-20, A-1090 Vienna, Austria.						Avseenko NV, 2002, ANAL CHEM, V74, P927, DOI 10.1021/ac010970k; Breiteneder H, 2001, INT ARCH ALLERGY IMM, V124, P48, DOI 10.1159/000053665; BREITENEDER H, 1989, EMBO J, V8, P1935; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; Haab B., 2001, GENOME BIOL, V2; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Joos TO, 2002, CURR OPIN CHEM BIOL, V6, P76, DOI 10.1016/S1367-5931(01)00289-7; Joos TO, 2000, ELECTROPHORESIS, V21, P2641, DOI 10.1002/1522-2683(20000701)21:13<2641::AID-ELPS2641>3.3.CO;2-X; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Kim TE, 2002, EXP MOL MED, V34, P152; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; Lundberg M, 2001, ALLERGY, V56, P794, DOI 10.1034/j.1398-9995.2001.056008794.x; MacBeath G, 2000, SCIENCE, V289, P1760; Mezzasoma L, 2002, CLIN CHEM, V48, P121; Monzavi-Karbassi B, 2002, TRENDS BIOTECHNOL, V20, P207, DOI 10.1016/S0167-7799(02)01940-6; Robinson WH, 2002, NAT MED, V8, P295, DOI 10.1038/nm0302-295; SCHEINER O, 1995, ALLERGY, V50, P384, DOI 10.1111/j.1398-9995.1995.tb01167.x; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; Suck R, 2002, ALLERGY, V57, P821, DOI 10.1034/j.1398-9995.2002.23705.x; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1999, J IMMUNOL, V163, P5489	27	123	132	0	12	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2003	33	10					1443	1449		10.1046/j.1365-2222.2003.01784.x		7	Allergy; Immunology	Allergy; Immunology	727KN	WOS:000185657300019	14519153	
J	Kull, I; Wickman, M; Lilja, G; Nordvall, SL; Pershagen, G				Kull, I; Wickman, M; Lilja, G; Nordvall, SL; Pershagen, G			Breast feeding and allergic diseases in infants - a prospective birth cohort study	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							AGE 6; ASTHMA; CHILDREN; CHILDHOOD; EXPOSURE; SENSITIZATION; PREDICTORS; RISK; OLD	Aims: To investigate the effect of breast feeding on allergic disease in infants up to 2 years of age. Methods: A birth cohort of 4089 infants was followed prospectively in Stockholm, Sweden. Information about various exposures was obtained by parental questionnaires when the infants were 2 months old, and about allergic symptoms and feeding at 1 and 2 years of age. Duration of exclusive and partial breast feeding was assessed separately. Symptom related definitions of various allergic diseases were used. Odds ratios (OR) and 95% confidence intervals (CI) were estimated in a multiple logistic regression model. Adjustments were made for potential confounders. Results: Children exclusively breast fed during four months or more exhibited less asthma (7.7% v 12%, ORadj 0.7, 95% CI 0.5 to 0.8), less atopic dermatitis (24% v 27%, ORadj = 0.8, 95% CI 0.7 to 1.0), and less suspected allergic rhinitis (6.5% v 9%, ORadj = 0.7, 95% CI 0.5 to 1.0) by 2 years of age. There was a significant risk reduction for asthma related to partial breast feeding during six months or more (ORadj = 0.7, 95% CI 0.5 to 0.9). Three or more of five possible allergic disorders-asthma, suspected allergic rhinitis, atopic dermatitis, food allergy related symptoms, and suspected allergic respiratory symptoms after exposure to pets or pollen-were found in 6.5% of the children. Exclusive breast feeding prevented children from having multiple allergic disease (ORadj = 0.7, 95% CI 0.5 to 0.9) during the first two years of life. Conclusion: Exclusive breast feeding seems to have a preventive effect on the early development of allergic disease-that is, asthma, atopic dermatitis, and suspected allergic rhinitis, up to 2 years of age. This protective effect was also evident for multiple allergic disease.	Stockholm Cty Council, Dept Environm Hlth, Stockholm, Sweden; Karolinska Inst, Sachs Childrens Hosp, Inst Sodersjukhuset, Stockholm, Sweden; Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Wickman, M (reprint author), Karolinska Hosp, Dept Environm Hlth, Norrbacka Bldg,Level 3, SE-17176 Stockholm, Sweden.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BURR ML, 1993, ARCH DIS CHILD, V68, P724; Csonka P, 2000, PEDIATR ALLERGY IMMU, V11, P225, DOI 10.1034/j.1399-3038.2000.00088.x; Foucard T, 2000, ACTA PAEDIATR, V89, P71, DOI 10.1080/080352500750027439; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; KRAMER, 1988, J PEDIAT, V112, P81; Lannero E, 2002, PEDIATR ALLERGY IMMU, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; MCCONNOCHIE KM, 1986, PEDIATR PULM, V2, P260, DOI 10.1002/ppul.1950020503; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Oddy WH, 1999, BRIT MED J, V319, P815; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Peat JK, 1998, CLIN EXP ALLERGY, V28, P261; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAVILAHTI E, 1987, ARCH DIS CHILD, V62, P269; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; VANDENPLAS Y, 1997, ACTA PAEDIATR SCAND, V86, P283; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128, DOI 10.1111/j.1399-3038.1992.tb00036.x; WJST M, 1992, MONATSSCHR KINDERH, V140, P769; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	26	123	132	3	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	DEC	2002	87	6					478	481		10.1136/adc.87.6.478		4	Pediatrics	Pediatrics	622PJ	WOS:000179655200007	12456543	
J	Pochard, P; Gosset, P; Grangette, C; Andre, C; Tonnel, AB; Pestel, J; Mercenier, A				Pochard, P; Gosset, P; Grangette, C; Andre, C; Tonnel, AB; Pestel, J; Mercenier, A			Lactic acid bacteria inhibit T(H)2 cytokine production by mononuclear cells from allergic patients	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; type 2 cytokine; lactic acid bacteria; immunomodulation; superantigen; dust mite	INTERLEUKIN-12 IL-12; PROBIOTICS; LACTOBACILLI; CHILDHOOD; RESPONSES; MICE	Background: Among factors potentially involved in the increased prevalence of allergic diseases, modification of the intestinal bacteria flora or lack of bacterial stimulation during childhood has been proposed. Lactic acid bacteria (LAB) present in fermented foods or belonging to the natural intestinal microflora were shown to exert beneficial effects on human health. Recent reports have indicated their capacity to reduce allergic symptoms. Objective: The purpose of this investigation was to determine the effect of LAB on the production of type 2 cytokines, which characterize allergic diseases. Methods: PBMCs from patients allergic to house dust mite versus those from healthy donors were stimulated for 48 hours with the related Dermatophagoides pteronyssinus allergen or with a staphylococcal superantigen. The effect of LAB preincubation was assessed by measuring the type 2 cytokine production by means of specific ELISA. Results: The tested gram-positive LAB were shown to inhibit the secretion of T(H)2 cytokines (IL-4 and IL-5). This effect was dose dependent and was observed irrespective of the LAB strain used. No significant inhibition was induced by the control, gram-negative Escherichia coli TG1. Interestingly, LAB reduced the T(H)2 cytokine production from allergic PBMCs specifically restimulated with the related allergen. The inhibition mechanism was shown to be dependent on antigen-presenting cells (ie, monocytes) and on the involvement of IL-12 and IFN-gamma. Conclusion: The tested LAB strains were demonstrated to exhibit an anti-T(H)2 activity, and thus different, strains of this family might be useful in the prevention of allergic diseases.	Inst Pasteur, INSERM U 416, F-59019 Lille, France; Inst Biol, Lab Bacteriol Ecosyst, Lille, France; Stallergenes SA, Antony, France	Pestel, J (reprint author), Inst Pasteur, INSERM U 416, 1 Rue Prof Calmette,BP 425,IFR 17, F-59019 Lille, France.						Bengmark S, 2001, CURR OPIN CLIN NUTR, V4, P571, DOI 10.1097/00075197-200111000-00019; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bjorksten B, 1997, CLIN REV ALLERG IMMU, V15, P125, DOI 10.1007/BF02826583; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; Cameron SB, 2001, EUR CYTOKINE NETW, V12, P210; Drouault S, 2001, VET RES, V32, P101, DOI 10.1051/vetres:2001115; Fooks LJ, 1999, INT DAIRY J, V9, P53, DOI 10.1016/S0958-6946(99)00044-8; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Julge K, 1997, ACTA PAEDIATR, V86, P1188, DOI 10.1111/j.1651-2227.1997.tb14842.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kopp-Hoolihan L, 2001, J AM DIET ASSOC, V101, P229, DOI 10.1016/S0002-8223(01)00060-8; Lee YK, 2000, APPL ENVIRON MICROB, V66, P3692, DOI 10.1128/AEM.66.9.3692-3697.2000; Maassen CBM, 1998, VET QUART, V20, pS81; Marteau PR, 2001, AM J CLIN NUTR, V73, p430S; MARTINEZ FD, 1999, LANCET S2, V354; Matsuzaki T, 2000, IMMUNOL CELL BIOL, V78, P67, DOI 10.1046/j.1440-1711.2000.00887.x; Matsuzaki T, 1998, J DAIRY SCI, V81, P48; Miettinen M, 2000, J IMMUNOL, V164, P3733; Miettinen M, 1998, INFECT IMMUN, V66, P6058; Muller-Alouf H., 1999, Immunology Letters, V69, P33; Murch SH, 2001, LANCET, V357, P1057, DOI 10.1016/S0140-6736(00)04305-1; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Ouwehand AC, 1999, INT DAIRY J, V9, P43, DOI 10.1016/S0958-6946(99)00043-6; Robinson DS, 1996, CHEM IMMUNOL, V63, P187; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458	27	123	130	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					617	623		10.1067/mai.2002.128528		7	Allergy; Immunology	Allergy; Immunology	602JJ	WOS:000178501900013	12373271	
J	Rhodes, HL; Sporik, R; Thomas, P; Holgate, ST; Cogswell, JJ				Rhodes, HL; Sporik, R; Thomas, P; Holgate, ST; Cogswell, JJ			Early life risk factors for adult asthma: A birth cohort study of subjects at risk	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; bronchial hyperresponsiveness; food allergen; aeroallergen; risk factors	ALLERGIC AIRWAY DISEASE; DUST MITE ALLERGEN; SERUM IGE; CHILDHOOD ASTHMA; LUNG-FUNCTION; CHILDREN; ATOPY; EXPOSURE; AGE; RESPONSIVENESS	Background: Prediction of adult asthma is important, and early prevention strategies should be targeted at those most at risk. Identifying high-risk children at an early age, however, is currently difficult. Objective: We sought to determine those factors present in early life that predict an increased risk of adult asthma. Methods: A prospective cohort study of subjects at risk of asthma and atopy was undertaken in Poole, England. One hundred babies of atopic parents were recruited at birth. During the first 5 years of life, subjects were recalled annually, all respiratory events were reported, and skin prick tests and total serum IgE measurements were performed. At 11 and 22 years, bronchial hyperresponsiveness was also measured. Seventy-three subjects were followed up at 5 years, 67 at 11 years, and 63 at 22 years. Results: Twenty-three (37%) adult subjects reported wheezing within the previous 12 months. Fifteen (25%) of these subjects showed signs of bronchial hyperresponsiveness and were regarded as asthmatic. Wheezing before the age of 2 years occurred in 28% and was not significantly related to adult asthma (odds ratio, 0.3; 95% CI, 0.03-1.7; P =.19). A positive skin prick test response to hen's egg, cow's milk, or both in the first year was independently predictive of adult asthma (odds ratio, 10.7; 95% CI, 2.1-55.1; P =.001; sensitivity, 57%; specificity, 89%). Conclusion: Prediction of adult asthma remains difficult. In this study of subjects at risk of atopy, skin sensitivity to hen's egg or cow's milk in the first year was predictive of adult asthma.	Poole Hosp, Dept Paediat, Poole, Dorset, England; Bournemouth Univ, Poole Hosp, Dorset Res & Dev Support Unit, Bournemouth, Dorset, England; Dept Univ Med, Southampton, Hants, England	Rhodes, HL (reprint author), Southampton Gen Hosp, Room EG228,Mail Point 43,Tremona Rd, Southampton SO16 6YD, Hants, England.			Thomas, Peter/0000-0003-2478-4324			Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; BRITTEN N, 1987, BRIT MED J, V294, P1317; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Clough JB, 1999, AM J RESP CRIT CARE, V160, P1473; Cook DG, 1999, THORAX, V54, P357; *CYTEL SOFTW CORP, 1999, LOGX 4 WIND LOG REGR; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Leadbitter P, 1999, THORAX, V54, P905; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; NICKEL R, 1999, J ALLERGY CLIN IMMUN, V5, P613; Oddy WH, 1999, BRIT MED J, V319, P815; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; RONMARK E, 2000, EUR RESP J S31, V16, pS515; RONNA RJ, 1993, THORAX, V48, P21; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shaheen SO, 1999, THORAX, V54, P396; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STROPE GL, 1991, AM REV RESPIR DIS, V144, P655; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Warner JO, 1998, CLIN EXP ALLERGY, V28, P71; WILSON NM, 1992, ARCH DIS CHILD, V22, P325; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	38	123	126	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					720	725		10.1067/mai.2001.119151		6	Allergy; Immunology	Allergy; Immunology	498RG	WOS:000172523800010	11692095	
J	Klinnert, MD; Nelson, HS; Price, MR; Adinoff, AD; Leung, DYM; Mrazek, DA				Klinnert, MD; Nelson, HS; Price, MR; Adinoff, AD; Leung, DYM; Mrazek, DA			Onset and persistence of childhood asthma: Predictors from infancy	PEDIATRICS			English	Article						pediatric asthma; parenting; IgE allergy; psychosocial problems; risk; respiratory illness	RISK-FACTORS; NATURAL-HISTORY; CORD BLOOD; CHILDREN; STRESS; IGE; MOTHERS; HYPERRESPONSIVENESS; SENSITIZATION; RESPONSES	family history of asthma, asthma onset by 3 years of age was found previously to be positively associated with variables from the first year of life, including elevated total immunoglobulin E (IgE), frequent respiratory infections, and parenting difficulties. We followed this cohort of genetically at-risk children to investigate the relationship between factors assessed in infancy and asthma, allergy, and psychological status at school age. Methods. A cohort of 150 children who were at risk for developing asthma were identified prenatally on the basis of the mothers' having asthma. For 28 children, the father had asthma as well, putting them at bilateral genetic risk. Families primarily were middle and upper middle class Caucasians. Parents came to the clinic during the third trimester of pregnancy for assessments of medical and psychosocial functioning. A home visit took place when the infant was 3 weeks old, when parenting risk was assessed before the onset of any asthma symptoms. Parenting difficulties included problems with infant caregiving as well as components of maternal functioning, such as postpartum depression and inadequate marital support. Blood was drawn for serum IgE at 6 months of age. Parents and offspring subsequently came to the clinic multiple times, with the last clinic visit during the child's sixth year. Follow-up at age 6 involved a clinic visit for allergy and psychosocial evaluations, consisting of interviews and a behavior questionnaire. Seventy-seven children received the allergy and psychosocial evaluation, 26 received the psychosocial evaluation in the clinic, and 30 families received telephone interviews and mailed in questionnaires. Additional monitoring of families by telephone and mail was maintained over the next 2 years, until the children were 8, to ensure accurate characterization of the course of illness. Comprehensive medical records were obtained and reviewed for all health care contacts. Children were designated as having asthma when there was documentation in medical records of physician-diagnosed asthma, observed wheezing, and/or prescription of asthma medications during the time period when the child was between 6 and 8 years of age. Parental reports of the occurrence of asthma corroborated the medical record data. Results. Data regarding asthma status were available for 145 children through 8 years of age. Forty (28%) of the children manifested asthma between 6 and 8 years of age. Among variables previously reported to predict asthma onset by age 3, 3 proved to have significant univariate relationships with asthma between ages 6 and 8: elevated IgE levels measured when the children were 6 months of age, global ratings of parenting difficulties measured when infants were 3 weeks old, and higher numbers of respiratory infections in the first year of life. Among these offspring of mothers with asthma, paternal asthma showed a significant association with asthma between ages 6 and 8. Eczema in the first year was not significantly related to later asthma. Multiple logistic regression showed that the model that best predicted asthma at ages 6 to 8 from infancy variables included 2 main effects. The adjusted odds ratio for 6-month IgE was 2.15 (1.51, 3.05) and for parenting difficulties was 2.07 (1.15, 3.71). Although socioeconomic status (SES) was not associated with asthma at ages 6 to 8, families of lower SES were more likely to be rated as having parenting difficulties early in the child's life. The mothers of lower SES breastfed for a shorter period of time and were more likely to smoke during their infant's first year. There were more respiratory infections during the first year of life among infants whose mother was rated as having more parenting difficulties. Mothers who reported smoking breastfed their infants for a shorter length of time. Male gender was significantly associated with higher IgE levels when infants were 6 months of age. Laboratory testing was completed for 77 children at age 6. Total serum IgE levels were significantly higher for the children with asthma between ages 6 and 8. Skin-prick testing showed that the children with asthma had significantly more positive skin test reactions than did the children without asthma. Psychosocial interview data at 6 years of age were available for 103 families, and behavioral questionnaires were available for 133 families. On the basis of 6-year interviews, children with asthma were rated as being at greater psychological risk than were the children without asthma. Mothers' Child Behavior Checklist (CBCL) ratings of their children's behavior indicated higher internalizing scores for the children with asthma as compared with the children without asthma. Like the 6-month IgE, 6-year IgE was higher for boys. IgE levels measured at 6 months of age were significantly correlated with 6-year IgE levels. Parenting difficulties measured at 3 weeks were significantly correlated with 6-year measures of maternal depression, CBCL Internalizing score, and Child Psychological Risk (CPR) score. There also were significant correlations among the psychosocial variables assessed when the children were 6 years of age; maternal depression was significantly associated with child CBCL Internalizing score and CPR score, and the last 2 also were significantly correlated. Multiple logistic regression showed that 2 concurrently measured variables entered the model showing the strongest associations with asthma at ages 6 to 8. The adjusted odds ratio for CPR score was 3.21 (1.29-7.96) and for 6-year IgE was 1.71 (1.04-2.80). Conclusions. This study of the natural history of childhood asthma focused on the development of asthma into the school-age years in a genetically at-risk group of children. The relationships between biological and psychosocial variables in the first year and school-age asthma support the formulation of asthma as beginning early in life, with the developing immune system interacting with environmental influences. The data provide support for the possible contribution of psychosocial factors to asthma onset and persistence into childhood.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Colorado Allergy & Asthma Ctr, Littleton, CO USA; Mayo Clin, Rochester, MN USA	Klinnert, MD (reprint author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NCRR NIH HHS [M01 RR00051]; NHLBI NIH HHS [HL-36577, R01HL53584]		Achenbach TM, 1991, MANUAL CHILD BEHAV C; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Braun-Fahrlander C, 1998, PEDIATR PULM, V25, P159, DOI 10.1002/(SICI)1099-0496(199803)25:3<159::AID-PPUL5>3.0.CO;2-H; BUSSE WW, 1995, AM J RESP CRIT CARE, V151, P249; Chilcoat HD, 1997, J AM ACAD CHILD PSY, V36, P971, DOI 10.1097/00004583-199707000-00020; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; DeGarmo DS, 1999, CHILD DEV, V70, P1231, DOI 10.1111/1467-8624.00089; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GLEZEN WP, 1998, RSV ASTHMA IS THERE, P1; Gunnar MR, 1998, PREV MED, V27, P208, DOI 10.1006/pmed.1998.0276; GUNNAR MR, 1992, PEDIATRICS, V90, P491; GUNNAR MR, 1989, DEV PSYCHOL, V25, P355, DOI 10.1037//0012-1649.25.3.355; HERBERT TB, 1993, PSYCHOSOM MED, V55, P364; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; Hoek G, 1999, INT J EPIDEMIOL, V28, P293, DOI 10.1093/ije/28.2.293; Holgate ST, 1997, LANCET, V350, P5; Hollingshead A. B., 1975, 4 FACTOR INDEX SOCIA; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; Hosmer DW, 1989, APPL LOGISTIC REGRES, P307; JOHNSTONE DE, 1975, PEDIATRICS, V56, P398; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; Klinnert MD, 1997, J ASTHMA, V34, P77, DOI 10.3109/02770909709071206; KLINNERT MD, 1992, PSYCHIATRY, V55, P132; KLINNERT MD, 1994, PSYCHIATRY, V57, P51; LANDSTRA AM, 1999, EUR RESPIR J, V14, pS308; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Marshall GD, 2000, ALLERGY ASTHMA PROC, V21, P241, DOI 10.2500/108854100778248917; Marshall GD, 1998, BRAIN BEHAV IMMUN, V12, P297, DOI 10.1006/brbi.1998.0537; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MEYER RJ, 1962, PEDIATRICS, V29, P539; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; MRAZEK DA, 1991, J AM ACAD CHILD PSY, V30, P277, DOI 10.1097/00004583-199103000-00017; MRAZEK DA, 1995, J AM ACAD CHILD PSY, V34, P272, DOI 10.1097/00004583-199503000-00010; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Murray L, 1999, J CHILD PSYCHOL PSYC, V40, P1259, DOI 10.1111/1469-7610.00542; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; Peebles RS, 2000, CLIN EXP ALLERGY, V30, P1257; RADKEYARROW M, 1992, J AM ACAD CHILD PSY, V31, P68, DOI 10.1097/00004583-199201000-00011; SALK L, 1974, AM J DIS CHILD, V127, P30; SAMEROFF AJ, 1993, CHILD DEV, V64, P80, DOI 10.1111/j.1467-8624.1993.tb02896.x; Sears MR, 1996, ARCH DIS CHILD, V75, P392; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; SIGURS N, 1995, PEDIATRICS, V95, P500; SMITH JM, 1988, ALLERGY PRINCIPLES P, P891; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VANASPEREN PP, 1990, J ALLERGY CLIN IMMUN, V85, P790, DOI 10.1016/0091-6749(90)90200-N; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Wiesch DG, 1999, J ALLERGY CLIN IMMUN, V104, P895; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 1999, AM J RESP CRIT CARE, V159, pA103	54	123	123	1	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT	2001	108	4					art. no.	e69		10.1542/peds.108.4.e69		8	Pediatrics	Pediatrics	478AC	WOS:000171319600012	11581477	
J	Tang, CB; Inman, MD; van Rooijen, N; Yang, PC; Shen, HH; Matsumoto, K; O'Byrne, PM				Tang, CB; Inman, MD; van Rooijen, N; Yang, PC; Shen, HH; Matsumoto, K; O'Byrne, PM			Th type 1-stimulating activity of lung macrophages inhibits Th2-mediated allergic airway inflammation by an IFN-gamma-dependent mechanism	JOURNAL OF IMMUNOLOGY			English	Article							ANTIGEN-PRESENTING CELLS; DENDRITIC CELLS; ALVEOLAR MACROPHAGES; IMMUNE-RESPONSES; IL-12 PRODUCTION; INHALED ANTIGEN; DOWN-REGULATION; MICE; INDUCTION; ASTHMA	In the mucosal immune system, resident dendritic cells are specialized for priming Th2-polarized immunity, whereas the Ag-presenting activity of macrophages has been linked with the development of Th1 phenotype. As an immune switch toward Th1 can protect against Th2-mediated allergic response, this study investigated the capacity of lung macrophages to stimulate Th1 responses during the secondary exposure to inhaled allergen, thereby suppressing Th2-mediated allergic airway inflammation in a murine model of allergic asthma. Following airway macrophage depletion in OVA-sensitized mice, lung T cells defaulted to a phenotype that produced less Th1 (IFN-gamma) and more Th2 (IL-4 and IL-5) cytokines, leading to more severe airway hyperreactivity and inflammation after intranasal Ag challenge. After OVA pulsing and adoptive transfer, lung macrophages selectively promoted a Th1 response in Ag-sensitized recipients and did not induce pulmonary eosinophilia. By contrast, OVA pulsing and adoptive transfer of a lung cell preparation, consisting of dendritic cells, B cells, and macrophages, promoted a Th2 response with an associated inflammatory response that was suppressed when macrophages were present and pretreated with IFN-gamma, but exacerbated when macrophages were depleted before IFN-gamma treatment. In addition, Th1-promoting activity of lung macrophages was not related to the autocrine production of IL-12p40. These results suggest that the Th1-promoting APC activity may be an inherent property of the lung macrophage population, and may play an important role, upon stimulation by IFN-gamma, in antagonizing an ongoing Th2 immunity and Th2-dependent allergic responses.	McMaster Univ, Dept Med, Asthma Res Grp, Hamilton, ON, Canada; Vrije Univ Amsterdam, Fac Med, Dept Cell Biol & Immunol, Amsterdam, Netherlands	O'Byrne, PM (reprint author), St Josephs Hosp, Firestone Reg Chest & Allergy Clin, 50 Charlton Ave E, Hamilton, ON, Canada.			O'Byrne, Paul/0000-0003-0979-281X			Ahuja SS, 1998, J IMMUNOL, V161, P868; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; BREWER JM, 1994, CLIN EXP IMMUNOL, V97, P164; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254; Chattergoon MA, 1998, J IMMUNOL, V160, P5707; DeKruyff R, 1998, J IMMUNOL, V160, P2231; DEKRUYFF RH, 1995, J IMMUNOL, V154, P2578; Desmedt M, 1998, J IMMUNOL, V160, P5300; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; GAJEWSKI TF, 1991, J IMMUNOL, V146, P1750; GERMANN T, 1995, INT IMMUNOL, V7, P1649, DOI 10.1093/intimm/7.10.1649; Gracie JA, 1999, J CLIN INVEST, V104, P1393, DOI 10.1172/JCI7317; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Heufler C, 1996, EUR J IMMUNOL, V26, P659, DOI 10.1002/eji.1830260323; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Holtzman MJ, 1996, AM J RESP CELL MOL, V14, P316; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; Jun HS, 1999, J EXP MED, V189, P347, DOI 10.1084/jem.189.2.347; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lee JS, 1997, J FOOD DRUG ANAL, V5, P185; Lee SC, 1999, J IMMUNOL, V162, P6867; Li XM, 1998, J IMMUNOL, V160, P1378; Marinaro M, 1999, J IMMUNOL, V162, P114; MARSHALL JD, 1995, J IMMUNOL, V155, P111; Masten BJ, 1999, J IMMUNOL, V162, P1310; Masten BJ, 1997, AM J RESP CELL MOL, V16, P335; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Nabeshima S, 1999, INFECT IMMUN, V67, P3221; Salez L, 2000, J LEUKOCYTE BIOL, V67, P545; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Tang C, 1997, EUR RESPIR J, V10, P624; Tang CB, 1998, AM J RESP CRIT CARE, V157, P1120; Tang CB, 1998, J ALLERGY CLIN IMMUN, V102, P368, DOI 10.1016/S0091-6749(98)70122-8; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Underhill DM, 1999, J EXP MED, V190, P1909, DOI 10.1084/jem.190.12.1909; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; Wijburg OLC, 1997, J VIROL, V71, P9450; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WYNN TA, 1995, J IMMUNOL, V154, P3999	50	123	131	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 1	2001	166	3					1471	1481				11	Immunology	Immunology	396EE	WOS:000166622700008	11160186	
J	Halken, S; Hansen, KS; Jacobsen, HP; Estmann, A; Faelling, AE; Hansen, LG; Kier, SR; Lassen, K; Lintrup, M; Mortensen, S; Ibsen, KK; Osterballe, O; Host, A				Halken, S; Hansen, KS; Jacobsen, HP; Estmann, A; Faelling, AE; Hansen, LG; Kier, SR; Lassen, K; Lintrup, M; Mortensen, S; Ibsen, KK; Osterballe, O; Host, A			Comparison of a partially hydrolyzed infant formula with two extensively hydrolyzed formulas for allergy prevention: A prospective, randomized study	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						hypoallergenic infant formula; protein hydrolysates; allergy prevention; cow's milk allergy; pediatric	HIGH-RISK INFANTS; PARTIAL WHEY HYDROLYSATE; COW MILK FORMULAS; ATOPIC DISEASE; FOLLOW-UP; AVOIDANCE; PROPHYLAXIS; SOY; AGE; DISORDERS	The aim of this study was to compare the allergy-preventive effect of a partially hydrolyzed formula with two extensively hydrolyzed formulas, in infants with a high risk for development of allergic disease. High-risk infants from four Danish centres were included in the period from June 1994 to July 1995. Five-hundred and ninety-five high-risk infants were identified. Nigh-risk infants were defined as having biparental atopy, or a single atopic first-degree relative combined with cord blood immunoglobulin E (IgE) greater than or equal to 0.3 kU/l, At birth all infants were randomized to one of three different blinded formulas. All mothers had unrestricted diets during pregnancy and lactation and were encouraged to breast-feed exclusively. If breastfeeding was insufficient, one of the three formulas, according to randomization, was given during the first 4 months. It was recommended not to introduce cow's milk, cow's milk products, and solid foods until the age of 4 months. After the age of 4 months a normal unrestricted diet and conventional cow's milk-based formula were given when needed. All infants were followed-up prospectively with interview and physical examination at the age of 6, 12, and 18 months, and if any possible atopic symptoms were reported. If food allergy was suspected, controlled elimination/challenge procedures were performed in a hospital setting. Of 550 infants included in the study, 514 were seen at all visits and 36 were excluded owing to noncompliance. Of 478 infants who completed the study, 232 were exclusively breast-fed, 79 received an extensively hydrolyzed casein formula (Nutramigen), 82 an extensively hydrolyzed whey formula (Profylac), and 85 a partially hydrolyzed whey formula (Nan WA), during the first 4 months of life. These four groups were identical in regard to atopic predisposition, cord blood IgE, birthplace, and gender. Exclusively breastfed children were exposed less to tobacco smoke and pets at home and belonged to higher social classes, whereas the three formula groups were identical concerning environmental factors. The frequency of breast-feeding was high; only eight (2%) children were not breast-fed at all. The three formula groups were identical in regard to duration of breast-feeding: and age at introduction of formula and solid foods. No significant differences were found in the three groups of infants receiving formula milk regarding the cumulative incidence of atopic dermatitis or respiratory symptoms. The cumulative incidence of parental-reported cow's milk allergy was significantly higher in children fed partially hydrolyzed formula (Nan HA) compared with extensively hydrolyzed formula (Nutramigen or Profylac) at 12 and 18 months (NanHA, 7.1%; Nutramigen, 2.5%; Profylac, 0%; p = 0.033). The cumulative incidence of confirmed cow's milk allergy was 1.3% (three of 232) in exclusively breast-fed infants, 0.6% tone of 161) in infants fed extensively hydrolyzed formula (Nutramigen or Profylac), and 4.7% (four of 85) in infants fed partially hydrolyzed formula (Nan HA). Partially hydrolyzed formula was found to be less effective than extensively hydrolyzed formula in preventing cow's milk allergy, 0.6% vs. 4.7% (p = 0.05), but because of the small number of cases the results should be interpreted with caution. Compared with other similar studies the frequency of atopic symptoms was low, even though the dietetic intervention did not include either maternal diet during lactation or dietary restrictions to the children after the age of 3 months.	Sonderborg Hosp, Dept Paediat, DK-6400 Sonderborg, Denmark; Glostrup Univ Hosp, Glostrup, Denmark; Odense Univ Hosp, DK-5000 Odense, Denmark; Viborg Hosp, Viborg, Denmark	Halken, S (reprint author), Sonderborg Hosp, Dept Paediat, DK-6400 Sonderborg, Denmark.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Businco L, 1993, Pediatr Allergy Immunol, V4, P101, DOI 10.1111/j.1399-3038.1993.tb00077.x; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Halken S, 1995, ALLERGY S, V26, P49; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hollis S, 1999, BRIT MED J, V319, P670; HOST A, 1990, CLIN EXP ALLERGY, V45, P547; LUCAS A, 1990, BRIT MED J, V300, P837; MAKINENKILJUNEN S, 1993, CLIN EXP ALLERGY, V23, P287, DOI 10.1111/j.1365-2222.1993.tb00324.x; Marini A, 1996, ACTA PAEDIATR, V85, P1, DOI 10.1111/j.1651-2227.1996.tb14267.x; MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; OLDAEUS G, 1991, PEDIATR ALLERGY IMMU, V4, P156; RAGNO V, 1993, EUR J PEDIATR, V152, P760, DOI 10.1007/BF01953996; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; VANDENPLAS Y, 1988, EUR J PEDIATR, V148, P274, DOI 10.1007/BF00441420; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zeiger R, 1992, PEDIATR ALLERGY IMMU, V3, P110, DOI 10.1111/j.1399-3038.1992.tb00035.x	29	123	130	1	12	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	AUG	2000	11	3					149	161		10.1034/j.1399-3038.2000.00081.x		13	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	349UA	WOS:000089062900005	10981524	
J	Sanak, M; Levy, BD; Clish, CB; Chiang, N; Gronert, K; Mastalerz, L; Serhan, CN; Szczeklik, A				Sanak, M; Levy, BD; Clish, CB; Chiang, N; Gronert, K; Mastalerz, L; Serhan, CN; Szczeklik, A			Aspirin-tolerant asthmatics generate more lipoxins than aspirin-intolerant asthmatics	EUROPEAN RESPIRATORY JOURNAL			English	Article						anti-inflammatory mediators; aspirin-intolerant asthma; cysteinyl-leukotrienes; lipoxins	SENSITIVE ASTHMATICS; BRONCHIAL BIOPSIES; NASAL POLYPS; LEUKOTRIENE-E4; INHIBITION; RESPONSES; SYNTHASE; FLUIDS; ACID; ATL	Asthma is characterized by chronic airway inflammation resulting from overproduction of pro-inflammatory mediators, such as leukotrienes (LT), The authors questioned the biosynthetic capacity of asthmatic patients for lipoxins (LX) and 15-epimer lipoxins (15-epi-LX), endogenous regulators of inflammatory responses that inhibit pro-inflammatory events, Levels of LXA(4), 15-epi-LXA(4) and LTC4 were determined in 14 clinically characterized aspirin-intolerant asthmatics (AIA), 11 aspirin-tolerant asthmatics (ATh) and eight healthy volunteers using a stimulated whole blood protocol, Both LXA(4) and 15-epi-LXA(4) were generated in whole blood activated by the divalent cation ionophore, A23187, Higher levels of LXA(4) were produced in ATA than either AIA or healthy volunteers, Exposure of AIA whole blood to interleukin-3 prior to A23187 did not elevate their reduced capacity to generate LXA(4). Generation of a bronchoconstrictor, LTC4, was similar in both AIA and ATA, Consequently, the ratio of LXA(4):LTC4 quantitatively favoured the bronchoconstrictor for AIA and differed from both ATA and healthy subjects. In addition, the capacity for 15-epi-LXA(4) generation was also diminished in AIA, since whole blood stimulated in the presence of aspirin gave increased levels only in samples from ATA, The present results indicate that asthmatics possess the capacity to generate both lipoxins and 15-epimer-lipoxins, but aspirin-intolerant asthmatics display a lower biosynthetic capacity than aspirin-tolerant asthmatics for these potentially protective lipid mediators. This previously unappreciated, diminished capacity for lipoxin formation by aspirin-intolerant asthmatic patients may contribute to their more severe clinical phenotype, and represents a novel paradigm for the development of chronic inflammatory disorders.	Harvard Univ, Brigham & Womens Hosp, Sch Med,Ctr Expt Therapeut & Reperfus, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA; Jagiellonian Univ, Sch Med, Dept Med, Krakow, Poland	Serhan, CN (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med,Ctr Expt Therapeut & Reperfus, Dept Anesthesiol Perioperat & Pain Med, Thorn Bldg Med Res,Room 724,75 Francis St, Boston, MA 02115 USA.		Sanak, Marek/A-2115-2008	Sanak, Marek/0000-0001-7635-8103	NHLBI NIH HHS [HL56383, K08-HL03788]; NIGMS NIH HHS [GM-38765]		Chiang N, 1998, J PHARMACOL EXP THER, V287, P779; CHRISTIE PE, 1992, AM REV RESPIR DIS, V145, P1281; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187; DAHLEN SE, 1991, LIPOXYGENASES THEIR, P235; Drazen JM, 1999, NEW ENGL J MED, V340, P197; EDENIUS C, 1990, FEBS LETT, V272, P25, DOI 10.1016/0014-5793(90)80440-T; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447; KOWALSKI ML, 1993, J ALLERGY CLIN IMMUN, V91, P580, DOI 10.1016/0091-6749(93)90264-G; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LEE TH, 1991, BIOCHEM BIOPH RES CO, V180, P1416, DOI 10.1016/S0006-291X(05)81354-3; LEE TH, 1990, AM REV RESPIR DIS, V141, P1453; LEVY BD, 1993, LIPIDS, V28, P1047, DOI 10.1007/BF02537069; LEVY BD, 1999, LIPID 2 MESSENGERS, P83; Miura K, 1998, J ALLERGY CLIN IMMUN, V102, P512, DOI 10.1016/S0091-6749(98)70142-3; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90; ORTOLANI C, 1987, ANN ALLERGY, V59, P106; Picado C, 1999, AM J RESP CRIT CARE, V160, P291; SAMTER M, 1968, ANN INTERN MED, V68, P975; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Serhan CN, 1996, FASEB J, V10, P1147; Serhan CN, 1997, PROSTAGLANDINS, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; Szczeklik A, 1996, AM J RESP CRIT CARE, V154, P1608; Takano T, 1997, J EXP MED, V185, P1693, DOI 10.1084/jem.185.9.1693; Young JM, 1996, INFLAMM RES, V45, P246, DOI 10.1007/BF02259611	29	123	128	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUL	2000	16	1					44	49		10.1034/j.1399-3003.2000.16a08.x		6	Respiratory System	Respiratory System	335UE	WOS:000088262500008	10933083	
J	Lack, G				Lack, Gideon			Update on risk factors for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; risk factors; filaggrin; genetics; dual-allergen-exposure hypothesis	ORAL TOLERANCE INDUCTION; OF-FUNCTION MUTATIONS; PEANUT ALLERGY; ATOPIC-DERMATITIS; UNITED-STATES; GENE POLYMORPHISMS; FUNCTION VARIANTS; EARLY-CHILDHOOD; MATERNAL DIET; NUT ALLERGY	Despite efforts to prevent food allergy (FA) in children, IgE-mediated FAs are increasing in westernized countries. Previous preventive strategies, such as prolonged exclusive breast-feeding and delayed weaning onto solid foods, have recently been called into question. The present review considers possible risk factors and theories for the development of FA. An alternative hypothesis is proposed, suggesting that early cutaneous exposure to food protein through a disrupted skin barrier leads to allergic sensitization and that early oral exposure to food allergen induces tolerance. Novel interventional strategies to prevent the development of FA are also discussed. (J Allergy Clin Immunol 2012;129:1187-97.)	Kings Coll London, St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, MRC Asthma UK Ctr Allerg Mech Asthma,Childrens Al, London SE1 7EH, England	Lack, G (reprint author), Kings Coll London, St Thomas Hosp, Guys & St Thomas NHS Fdn Trust, MRC Asthma UK Ctr Allerg Mech Asthma,Childrens Al, Westminster Bridge Rd, London SE1 7EH, England.	gideon.lack@kcl.ac.uk	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	Medical Research Council [G1000758, MC_G1001205]		Alberto EJC, 2008, PEDIAT ALLERG IMM-UK, V19, P716, DOI 10.1111/j.1399-3038.2007.00709.x; Allan K, 2010, CLIN EXP ALLERGY, V40, P370, DOI 10.1111/j.1365-2222.2009.03413.x; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Anandan C, 2009, ALLERGY, V64, P840, DOI 10.1111/j.1398-9995.2009.02042.x; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Baker SS, 2000, PEDIATRICS, V106, P346; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Boussault P, 2007, ALLERGY, V62, P1251, DOI 10.1111/j.1398-9995.2007.01527.x; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Brown SJ, 2008, SEMIN CUTAN MED SURG, V27, P128, DOI 10.1016/j.sder.2008.04.001; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Camargo CA, 2006, J ALLERGY CLIN IMMUN, V117, pS139, DOI 10.1016/j.jaci.2005.12.554; Chan SMH, 2012, ALLERGY, V67, P336, DOI 10.1111/j.1398-9995.2011.02765.x; Committee on Toxicity of Chemicals in Food Consumer Products and the Environment, 1998, PEAN ALL; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Dotterud CK, 2010, BRIT J DERMATOL, V163, P616, DOI 10.1111/j.1365-2133.2010.09889.x; Dreskin SC, 2011, ANN ALLERG ASTHMA IM, V106, P170, DOI 10.1016/j.anai.2010.11.008; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Dubrac S, 2010, IMMUNOL CELL BIOL, V88, P400, DOI 10.1038/icb.2010.33; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Field CJ, 2005, J NUTR, V135, P1; Flohr C, 2010, BRIT J DERMATOL, V163, P1333, DOI 10.1111/j.1365-2133.2010.10068.x; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fox DE, 1998, LANCET, V352, P741, DOI 10.1016/S0140-6736(05)60863-X; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V114, P377, DOI 10.1016/j.jaci.2004.03.040; Goh DLM, 1999, ALLERGY, V54, P84, DOI 10.1034/j.1398-9995.1999.00925.x; Green R, 1997, S AFR MED J, V87, P878; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; Hill DJ, 1999, ANN MED, V31, P272, DOI 10.3109/07853899908995890; Hong XM, 2011, J ALLERGY CLIN IMMUN, V128, P374, DOI 10.1016/j.jaci.2011.05.007; Hourihane JO, 1996, BRIT MED J, V313, P518; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Kerosuo H, 1996, AM J ORTHOD DENTOFAC, V109, P148, DOI 10.1016/S0889-5406(96)70175-0; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kumar R, 2011, PEDIATRICS, V128, pE821, DOI 10.1542/peds.2011-0691; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lack G, 2007, NESTLE NUTR WORKS SE, V59, P63, DOI 10.1159/000098513; Lee Bee Wah, 2008, World Allergy Organ J, V1, P129, DOI 10.1097/WOX.0b013e31817b7431; Leung R, 1997, CLIN EXP ALLERGY, V27, P333, DOI 10.1046/j.1365-2222.1997.1310807.x; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Marth T, 1996, J IMMUNOL, V157, P2348; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Mortz CG, 2002, ACTA DERM-VENEREOL, V82, P359, DOI 10.1080/000155502320624096; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Namkung JH, 2010, J DERMATOL SCI, V57, P199, DOI 10.1016/j.jdermsci.2009.12.003; Nwaru BI, 2010, PEDIATR ALLERGY IMMU, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Rance F, 2000, ALLERGY, V55, P496, DOI 10.1034/j.1398-9995.2000.00383.x; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI 10.1067/mai.2000.108105; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200324843; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Sudo N, 1997, J IMMUNOL, V159, P1739; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P35, DOI 10.1016/0091-6749(77)90174-9; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V125, pAB217; Venter C, 2008, ALLERGY, V63, P354, DOI 10.1111/j.1398-9995.2007.01570.x; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Fifty-Fourth World Health Assembly, 2001, PROV AG IT 13 1 1 GL; Wjst Matthias, 2005, Clin Mol Allergy, V3, P7, DOI 10.1186/1476-7961-3-7; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	85	122	123	5	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2012	129	5					1187	1197		10.1016/j.jaci.2012.02.036		11	Allergy; Immunology	Allergy; Immunology	934CG	WOS:000303418000002	22464642	
J	Calderon, MA; Simons, FER; Malling, HJ; Lockey, RF; Moingeon, P; Demoly, P				Calderon, M. A.; Simons, F. E. R.; Malling, H. -J.; Lockey, R. F.; Moingeon, P.; Demoly, P.			Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile	ALLERGY			English	Review						allergen immunotherapy; mucosal; safety; subcutaneous; sublingual	SYSTEMIC REACTIONS; DOUBLE-DUMMY; DOUBLE-BLIND; ANAPHYLAXIS; RHINITIS; ORGANIZATION; ASTHMA; EFFICACY; INJECTIONS; FREQUENCY	Allergen immunotherapy reorients inappropriate immune responses in allergic patients. Sublingual allergen immunotherapy (SLIT) has been approved, notably in the European Union, as an effective alternative to subcutaneous allergen immunotherapy (SCIT) for allergic rhinitis patients. Compared with SCIT, SLIT has a better safety profile. This is possibly because oral antigen-presenting cells (mostly Langerhans and myeloid dendritic cells) exhibit a tolerogenic phenotype, despite constant exposure to danger signals from food and microbes. This reduces the induction of pro-inflammatory immune responses leading to systemic allergic reactions. Oral tissues contain relatively few mast cells and eosinophils (mostly located in submucosal areas) and, in comparison with subcutaneous tissue, are less likely to give rise to anaphylactic reactions. SLIT-associated immune responses include the induction of circulating, allergen-specific Th1 and regulatory CD4+ T cells, leading to clinical tolerance. Although 4075% of patients receiving SLIT experience mild, transient local reactions in the oral mucosa, these primary reactions rarely necessitate dose reduction or treatment interruption. We discuss 11 published case reports of anaphylaxis (all nonfatal) diagnosed according to the World Allergy Organization criteria and relate this figure to the approximately 1 billion SLIT doses administered worldwide since 2000. Anaphylaxis risk factors associated with SCIT and/or SLIT should be characterized further.	[Calderon, M. A.] Imperial College NHLI, Sect Allergy & Clin Immunol, Royal Brompton Hosp, London, England; [Simons, F. E. R.] Univ Manitoba, Dept Pediat & Child Hlth, Dept Immunol, Winnipeg, MB R3T 2N2, Canada; [Malling, H. -J.] Copenhagen Univ Hosp, Allergy Clin, Copenhagen, Denmark; [Lockey, R. F.] Univ S Florida, Coll Med, Div Allergy & Immunol, Tampa, FL USA; [Moingeon, P.] Stallergenes SA, Dept Res & Dev, Antony, France; [Demoly, P.] Univ Hosp Montpellier, Hop Arnaud Villeneuve, INSERM, Allergy Div,Pneumol Dept,U657, Montpellier, France	Calderon, MA (reprint author), Imperial College NHLI, Sect Allergy & Clin Immunol, Royal Brompton Hosp, Dovehouse St, London, England.	m.calderon@imperial.ac.uk			ALK-Abello; Stallergenes; Allergopharma	Moises Calderon has received consulting fees, honoraria for lectures and/or research funding from ALK-Abello and Stallergenes. F. Estelle R. Simons is on the Anaphylaxis Advisory Boards for ALK-Abello, Dey and Sanofi Aventis. Hans-Jorgen Malling has received consulting fees, honoraria for lectures and/or research funding from Allergopharma, ALK-Abello & Stallergenes. Richard F. Lockey consults with Merck-Schering, ALK and Dey. Philippe Moingeon is an employee of Stallergenes. Pascal Demoly is a consultant and a speaker for Stallergenes, ALK and Therabel and was a speaker for Schering-Plough-MSD, Astra Zeneca and GlaxoSmithKline.	Allam JP, 2008, ALLERGY, V63, P720, DOI 10.1111/j.1398-9995.2007.01611.x; Andre C, 2007, ALLERGY, V62, P1220, DOI 10.1111/j.1398-9995.2007.01512.x; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bernstein DI, 2010, ANN ALLERG ASTHMA IM, V104, P530, DOI 10.1016/j.anai.2010.04.008; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Buyukozturk S, 2010, ANN ALLERG ASTHMA IM, V104, P339, DOI 10.1016/j.anai.2010.01.014; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Cox L, 2008, CURR ALLERGY ASTHM R, V8, P102, DOI 10.1007/s11882-008-0019-5; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, p[131, e1], DOI [10.1016/j.jaci.2009.10.035, DOI 10.1016/J.JACI.2009.10.035]; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Herrscher R.F., 2006, ANN ALLERG ASTHMA IM, V96, P148; Incorvaia Cristoforo, 2008, Patient Prefer Adherence, V2, P247; Kaul S, 2011, ALLERGY, V66, P753, DOI 10.1111/j.1398-9995.2011.02552.x; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126; Lopez D. J. L., 2003, Journal of Allergy and Clinical Immunology, V111, pS72, DOI 10.1016/S0091-6749(03)80171-9; Malling HJ, 2009, CLIN EXP ALLERGY, V39, P387, DOI 10.1111/j.1365-2222.2008.03152.x; Mascarell L, 2009, CLIN EXP ALLERGY, V39, P1910, DOI 10.1111/j.1365-2222.2009.03337.x; Mascarell L, 2008, J ALLERGY CLIN IMMUN, V122, P603, DOI 10.1016/j.jaci.2008.06.034; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Novak N, 2011, ALLERGY, V66, P733, DOI 10.1111/j.1398-9995.2010.02535.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Radulovic S, 2011, ALLERGY, V66, P740, DOI 10.1111/j.1398-9995.2011.02583.x; Rodriguez-Perez N, 2008, ANN ALLERG ASTHMA IM, V101, P304; Roy SR, 2007, ANN ALLERG ASTHMA IM, V99, P82; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sieber J, 2011, CURR MED RES OPIN, V27, P855, DOI 10.1185/03007995.2011.559538; Simons FER, 2011, J ALLERGY CLIN IMMUN, V127, P587, DOI 10.1016/j.jaci.2011.01.038; Triggiani M, 2008, CLIN EXP IMMUNOL, V153, P7, DOI 10.1111/j.1365-2249.2008.03714.x; Valent P, 2011, INT ARCH ALLERGY IMM, V156, P119, DOI 10.1159/000323763	42	122	126	2	14	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538			ALLERGY	Allergy	MAR	2012	67	3					302	311		10.1111/j.1398-9995.2011.02761.x		10	Allergy; Immunology	Allergy; Immunology	894RX	WOS:000300445500003	22150126	
J	D'Amato, G; Cecchi, L; D'Amato, M; Liccardi, G				D'Amato, G.; Cecchi, L.; D'Amato, M.; Liccardi, G.			Urban Air Pollution and Climate Change as Environmental Risk Factors of Respiratory Allergy: An Update	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY			English	Review						Air pollution; Allergy; Allergic asthma; Bronchial asthma; Climate change; Environmental diseases; Airway hyperreactivity; Pollen allergy; Respiratory allergy; Urban air pollution; Hypersensitivity	LUNG-FUNCTION GROWTH; SOUTHERN CALIFORNIA CHILDREN; CASE-CROSSOVER ANALYSIS; HEAT-RELATED MORTALITY; PARTICULATE MATTER; CHILDHOOD ASTHMA; SCHOOL-CHILDREN; BRONCHIAL-ASTHMA; EUROPEAN CITIES; POLLEN ALLERGY	The incidence of allergic respiratory diseases and bronchial asthma appears to be increasing worldwide, and people living in urban areas more frequently experience these conditions than those living in rural areas. One of the several causes of the rise in morbidity associated with allergic respiratory diseases is the increased presence of outdoor air pollutants resulting from more intense energy consumption and exhaust emissions from cars and other vehicles. Urban air pollution is now a serious public health hazard. Laboratory studies confirm epidemiologic evidence that air pollution adversely affects lung function in asthmatics. Damage to airway mucous membranes and impaired mucociliary clearance caused by air pollution may facilitate access of inhaled allergens to the cells of the immune system, thus promoting sensitization of the airway. Consequently, a more severe immunoglobulin (Ig) E-mediated response to aeroallergens and airway inflammation could account for increasing prevalence of allergic respiratory diseases in polluted urban areas. The most abundant components of urban air pollution in urban areas with high levels of vehicle traffic are airborne particulate matter, nitrogen dioxide, and ozone. In addition, the earth's temperature is increasing, mainly as a result of anthropogenic factors (eg, fossil fuel combustion and greenhouse gas emissions from energy supply, transport, industry, and agriculture), and climate change alters the concentration and distribution of air pollutants and interferes with the seasonal presence of allergenic pollens in the atmosphere by prolonging these periods.	[D'Amato, G.; Liccardi, G.] High Specialty Hosp A Cardarelli, Dept Resp Dis, Div Pneumol & Allergol, I-80121 Naples, Italy; [Cecchi, L.] Allergy Clin, Florence, Italy; [Cecchi, L.] Univ Florence, Interdepartmental Ctr Bioclimatol, Florence, Italy; [D'Amato, M.] High Specialty Hosp V Monaldi, Dept Resp Dis, Div PheumoTisiol, Naples, Italy	D'Amato, G (reprint author), High Specialty Hosp A Cardarelli, Dept Resp Dis, Div Pneumol & Allergol, Via Rione Sirignano 10, I-80121 Naples, Italy.	gdamato@qubisoft.it	D'Amato, Maria/H-3074-2012; Osborne, Nicholas/N-4915-2015	D'Amato, Maria/0000-0002-5906-5701; Osborne, Nicholas/0000-0002-6700-2284			Andersen ZJ, 2008, THORAX, V63, P710, DOI 10.1136/thx.2007.085480; Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; ANTO JM, 2002, MONOGRAPH EUROPEAN R, P108; Asher MI, 1998, EUR RESPIR J, V12, P315; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Ayres JG, 2009, EUR RESPIR J, V34, P295, DOI 10.1183/09031936.00003409; Baccini M, 2008, EPIDEMIOLOGY, V19, P711, DOI 10.1097/EDE.0b013e318176bfcd; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BOUSQUET J, 1993, CLIN EXP ALLERGY, V23, P484; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Burney P, 1996, EUR RESPIR J, V9, P687; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Celenza A, 1996, BRIT MED J, V312, P604; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Curtis Luke, 2006, Environ Int, V32, P815, DOI 10.1016/j.envint.2006.03.012; D'Amato G, 2008, CLIN EXP ALLERGY, V38, P1264, DOI 10.1111/j.1365-2222.2008.03033.x; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; D'Amato G, 2002, EUR RESPIR J, V20, P763, DOI 10.1183/09031936.02.00401402; D'Amato G., 2008, Allergy and allergic diseases. Volume 2: allergic diseases, etiology, diagnosis and treatment, P1266, DOI 10.1002/9781444300918.ch60; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; D'Amato G, 2003, ALLERGY CLIN IMMUNOL, V15, P73, DOI 10.1027/0838-1925.15.2.73; DAMATO G, 2000, J INVEST ALLERG CLIN, V10, P33; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dockery DW, 2007, NEW ENGL J MED, V356, P511, DOI 10.1056/NEJMe068274; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Ebi KL, 2008, ENVIRON HEALTH PERSP, V116, P1449, DOI 10.1289/ehp.11463; EMBERLIN J, 1993, CLIN EXP ALLERGY, V23, P59; Epton M.J., 2008, ENV HLTH, V14, P7; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; *HLTH ENV ALL, CLIM CHANG; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Jacob DJ, 2009, ATMOS ENVIRON, V43, P51, DOI 10.1016/j.atmosenv.2008.09.051; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kim YK, 2001, ANN ALLERG ASTHMA IM, V86, P456; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; KOVATS S, 2008, 20012002 DEP HLTH; Lin S, 2008, ENVIRON HEALTH PERSP, V116, P1725, DOI 10.1289/ehp.11184; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McMichael AJ, 2006, LANCET, V367, P859, DOI 10.1016/S0140-6736(06)68079-3; Michelozzi P, 2009, AM J RESP CRIT CARE, V179, P383, DOI 10.1164/rccm.200802-217OC; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Mudway I. S., 2000, Molecular Aspects of Medicine, V21, P1, DOI 10.1016/S0098-2997(00)00003-0; MURRAY V, 1994, BRIT MED J, V309, P131; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; OFFEDAL B, 2007, CLIN EXP ALLERGY, V37, P1632; Pattenden S, 2006, OCCUP ENVIRON MED, V63, P828, DOI 10.1136/oem.2006.025213; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peden DB, 2008, MIDDLETONS ALLERGY P, P495; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; RIELD M, 2005, J ALLERGY CLIN IMMUN, V115, P221; ROM WN, 2007, AM J RESP CRIT CARE, V177, P1053; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; Salvi S, 2007, PAEDIATR RESPIR REV, V8, P275, DOI 10.1016/j.prrv.2007.08.008; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Schwartz J, 1992, PUBLIC HLTH REV, V19, P39; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; SHEA KM, 2008, J ALLERGY CLIN IMMUN, V122, P44353; Stafoggia M, 2008, J EPIDEMIOL COMMUN H, V62, P209, DOI 10.1136/jech.2007.060715; Stafoggia M, 2006, EPIDEMIOLOGY, V17, P315, DOI 10.1097/01.ede.0000208477.36665.34; Sugiri D, 2006, ENVIRON HEALTH PERSP, V114, P282, DOI 10.1289/ehp.8180; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Trenberth KE, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P235; Uysal N, 2003, CURR OPIN PULM MED, V9, P144, DOI 10.1097/00063198-200303000-00009; Van Roosbroeck S, 2008, EPIDEMIOLOGY, V19, P409, DOI 10.1097/EDE.0b013e3181673bab; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Verlato G, 2002, ARCH ENVIRON HEALTH, V57, P48; Wang Lei, 2007, Birth Defects Research, V81, P144, DOI 10.1002/bdrc.20097; WEILAND SK, 1994, ANN EPIDEMIOL, V4, P79; WJST M, 1993, BRIT MED J, V307, P596; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Wu F, 2007, ENVIRON HEALTH PERSP, V115, P971, DOI 10.1289/ehp.8989; Zanolin ME, 2004, ALLERGY, V59, P306, DOI 10.1046/j.1398-9995.2003.00391.x; Zhao ZH, 2008, ENVIRON HEALTH PERSP, V116, P90, DOI 10.1289/ehp.10576	98	122	125	9	78	ESMON PUBLICIDAD S A	BARCELONA	CALLE BALMES 209, 3 2, BARCELONA, 08006, SPAIN	1018-9068			J INVEST ALLERG CLIN	J. Invest. Allergol. Clin. Immunol.		2010	20	2					95	102				8	Allergy; Immunology	Allergy; Immunology	590SM	WOS:000277247900001	20461963	
J	Lin, S; Luo, M; Walker, RJ; Liu, X; Hwang, SA; Chinery, R				Lin, Shao; Luo, Ming; Walker, Randi J.; Liu, Xiu; Hwang, Syni-An; Chinery, Robert			Extreme High Temperatures and Hospital Admissions for Respiratory and Cardiovascular Diseases	EPIDEMIOLOGY			English	Article							HEAT-RELATED MORTALITY; AMBIENT-TEMPERATURE; AIR-POLLUTION; EUROPEAN CITIES; UNITED-STATES; TIME-SERIES; MORBIDITY; CITY; WAVE; HUMIDITY	Background: Although the association of high temperatures with mortality is well-documented, the association with morbidity has seldom been examined. We assessed the potential impact of hot weather on hospital admissions due to cardiovascular and respiratory diseases in New York City. We also explored whether the weather-disease relationship varies with socio-demographic variables. Method: We investigated effects of temperature and humidity on health by linking the daily cardiovascular and respiratory hospitalization counts with meteorologic conditions during summer, 1991-2004. We used daily mean temperature, mean apparent temperature, and 3-day moving average of apparent temperature as the exposure indicators. Threshold effects for health risks of meteorologic conditions were assessed by log-linear threshold models, after controlling for ozone, day of week, holidays, and long-term trend. Stratified analyses were used to evaluate temperature-demographic interactions. Results: For all 3 exposure indicators, each degree C above the threshold of the temperature-health effect curve (29 degrees C-36 degrees C) was associated with a 2.7%-3.1% increase in same-day hospitalizations due to respiratory diseases, and an increase of 1.4%-3.6% in lagged hospitalizations due to cardiovascular diseases. These increases for respiratory admissions were greater for Hispanic persons (6.1%/degrees C) and the elderly (4.7%/degrees C). At high temperatures, admission rates increased for chronic airway obstruction, asthma, ischemic heart disease, and cardiac dysrhythmias, but decreased for hypertension and heart failure. Conclusions: Extreme high temperature appears to increase hospital admissions for cardiovascular and respiratory disorders in New York City. Elderly and Hispanic residents may be particularly vulnerable to the temperature effects on respiratory illnesses.	[Lin, Shao] New York State Dept Hlth, Bur Environm & Occupat Epidemiol, Ctr Environm Hlth, Troy, NY 12180 USA; [Chinery, Robert] New York State Off Attorney Gen, Albany, NY USA	Lin, S (reprint author), New York State Dept Hlth, Bur Environm & Occupat Epidemiol, Ctr Environm Hlth, 547 River St,Room 200, Troy, NY 12180 USA.	sxl05@health.state.ny.us	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Lin, Shao/0000-0002-5535-7504	National Environmental Public Health Tracking Program, Centers for Disease Control and Prevention; National Science Foundation;  [5U38EH000184]	Supported in part by grants from the National Environmental Public Health Tracking Program, Centers for Disease Control and Prevention (5U38EH000184). The National Center for Atmospheric Research (NCAR) (see Acknowledgments) is supported by grants from the National Science Foundation.	Agarwal R, 2006, ENVIRON MONIT ASSESS, V114, P489, DOI 10.1007/s10661-006-4935-3; APPLEGATE WB, 1981, J AM GERIATR SOC, V29, P337; Armstrong B, 2006, EPIDEMIOLOGY, V17, P624, DOI 10.1097/01.ede.0000239732.50999.8f; Baccini M, 2008, EPIDEMIOLOGY, V19, P711, DOI 10.1097/EDE.0b013e318176bfcd; Barnett AG, 2007, BLOOD PRESS MONIT, V12, P195, DOI 10.1097/MBP.0b013e3280b083f4; Barnett AG, 2007, EPIDEMIOLOGY, V18, P369, DOI 10.1097/01.ede.0000257515.34445.a0; Basu R, 2002, EPIDEMIOL REV, V24, P190, DOI 10.1093/epirev/mxf007; Basu R, 2008, AM J EPIDEMIOL, V168, P632, DOI 10.1093/aje/kwn170; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; *DHHS, 1997, INT CLASS DIS; Donoghue ER, 1997, AM J FOREN MED PATH, V18, P11, DOI 10.1097/00000433-199703000-00002; Ebi KL, 2006, ENVIRON HEALTH PERSP, V114, P1318, DOI 10.1289/ehp.8880; Federal Register, 1999, FED REG, V64, P42530; Goncalves FLT, 2005, ENVIRON INT, V31, P343, DOI 10.1016/j.envint.2004.08.004; Hajat S, 2002, J EPIDEMIOL COMMUN H, V56, P367, DOI 10.1136/jech.56.5.367; HAJAT S, 2006, EPIDEMIOLOGY, V17, P638; Harlan SL, 2006, SOC SCI MED, V63, P2847, DOI 10.1016/j.socscimed.2006.07.030; Hastie T, 1989, GEN ADDITIVE MODELS; *IPCC N AM, 2007, N AM CLIM CHANG 2007, P617; Ishigami A, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-5; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Knowlton K, 2009, ENVIRON HEALTH PERSP, V117, P61, DOI 10.1289/ehp.11594; Knowlton K, 2007, AM J PUBLIC HEALTH, V97, P2028, DOI 10.2105/AJPH.2006.102947; Kovats RS, 2008, ANNU REV PUBL HEALTH, V29, P41, DOI 10.1146/annurev.publhealth.29.020907.090843; Kovats RS, 2004, OCCUP ENVIRON MED, V61, P893, DOI 10.1136/oem.2003.012047; Larrieu S, 2008, EUR J EPIDEMIOL, V23, P295, DOI 10.1007/s10654-008-9229-3; Leonard KJ, 2003, HEALTH POLICY, V63, P239, DOI 10.1016/S0168-8510(02)00082-9; Linares C, 2008, EUR J PUBLIC HEALTH, V18, P317, DOI 10.1093/eurpub/ckm108; Mastrangelo G, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-200; McMichael AJ, 2008, INT J EPIDEMIOL, V37, P1121, DOI 10.1093/ije/dyn086; Medina-Ramon M, 2006, ENVIRON HEALTH PERSP, V114, P1331, DOI 10.1289/ehp.9074; Misailidou M, 2006, EUR J CARDIOV PREV R, V13, P846, DOI 10.1097/01.hjr.0000221857.04168.06; Nitschke M, 2007, MED J AUSTRALIA, V187, P662; New York State Department of Health, 2002, 2002 ANN REP SPARCS; Rydman R J, 1999, J Med Syst, V23, P41, DOI 10.1023/A:1020871528086; Schwartz J, 2004, EPIDEMIOLOGY, V15, P755, DOI 10.1097/01.ede.0000134875.15919.0f; Semenza JC, 1999, AM J PREV MED, V16, P269, DOI 10.1016/S0749-3797(99)00025-2; STEADMAN RG, 1979, J APPL METEOROL, V18, P861, DOI 10.1175/1520-0450(1979)018<0861:TAOSPI>2.0.CO;2	38	122	128	3	26	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	SEP	2009	20	5					738	746		10.1097/EDE.0b013e3181ad5522		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	485EJ	WOS:000269103500021	19593155	
J	Marwick, JA; Caramori, G; Stevenson, CS; Casolari, P; Jazrawi, E; Barnes, PJ; Ito, K; Adcock, IM; Kirkham, PA; Papi, A				Marwick, John A.; Caramori, Gaetano; Stevenson, Christopher S.; Casolari, Paolo; Jazrawi, Elen; Barnes, Peter J.; Ito, Kazuhiro; Adcock, Ian M.; Kirkham, Paul A.; Papi, Alberto			Inhibition of PI3K delta Restores Glucocorticoid Function in Smoking-induced Airway Inflammation in Mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						inflammation; histone deacetylase; chromatin; oxidative stress	OBSTRUCTIVE PULMONARY-DISEASE; HISTONE DEACETYLASE ACTIVITY; PHOSPHOINOSITIDE 3-KINASE; GENE-EXPRESSION; RECEPTOR; ACTIVATION; ASTHMA; THEOPHYLLINE; P110-DELTA; PATHOGENESIS	Rationale. There is an increasing prevalence of reduced responsiveness to glucocorticoid therapy in severe asthma and chronic obstructive pulmonary disease (COPD). The molecular mechanism of this remains unknown. Recent studies have shown that histone deacetylase activity, which is critical to glucocorticoid function, is altered by oxidant stress and may be involved in the development of glucocorticoid insensitivity. Objectives: To determine the role of phosphoinositol-3-kinase (PI3K) in the development of cigarette smoke-induced glucocorticoid insensitivity. Methods: Wild-type, PI3K gamma knock-out and PI3K delta kinase dead knock-in transgenic mice were used in a model of cigarette smoke-induced glucocorticoid insensitivity. Peripheral lung tissue was obtained from six healthy nonsmokers, nine smokers with normal lung function, and eight patients with COPD. Measurements and Main Results: In vitro oxidative stress activates PI3K and induced a relative glucocorticoid resistance, which is restored by PI3K inhibition. In vivo, cigarette smoke exposure in mice increased tyrosine nitration of histone deacetylase 2 in the lung, correlating with reduced histone deacetylase 2 activity and reduced glucocorticoid function. Histone deacetylase 2 activity and the antiinflammatory effects of glucocorticoids were restored in PI3K delta kinase dead knock-in but not PI3K gamma knock-out smoke-exposed mice compared with wild type mice, correlating with reduced histone deacetylase 2 tyrosine nitration. Glucocorticoid receptor expression was significantly reduced in smoke-exposed mice, in smokers with normal lung function, and in patients with COPD. Conclusions: These data show that therapeutic inhibition of PI3K delta may restore glucocorticoid function in oxidative stress-induced glucocorticoid insensitivity.	[Marwick, John A.; Jazrawi, Elen; Barnes, Peter J.; Ito, Kazuhiro; Adcock, Ian M.; Kirkham, Paul A.] Univ London Imperial Coll Sci Technol & Med, Airways Dis Sect, Natl Heart & Lung Inst, London SW3 6LY, England; [Marwick, John A.; Stevenson, Christopher S.; Kirkham, Paul A.; Papi, Alberto] Novartis Inst Biomed Res, Resp Dis Area, Horsham, W Sussex, England; [Marwick, John A.; Caramori, Gaetano; Casolari, Paolo] Univ Ferrara, Ctr Ric Asma, I-44100 Ferrara, Italy; [Marwick, John A.; Caramori, Gaetano; Casolari, Paolo] Univ Ferrara, BPCO, I-44100 Ferrara, Italy	Marwick, JA (reprint author), Univ London Imperial Coll Sci Technol & Med, Airways Dis Sect, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	j.marwick@imperial.ac.uk		PAPI, ALBERTO/0000-0002-6924-4500	Novartis Institute for Biomedical Research	Supported by Novartis Institute for Biomedical Research	Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Bonneau O, 2006, AM J PHYSIOL-LUNG C, V290, pL1036, DOI 10.1152/ajplung.00422.2005; Ciencewicki J, 2008, J ALLERGY CLIN IMMUN, V122, P456, DOI 10.1016/j.jaci.2008.08.004; Condliffe AM, 2005, BLOOD, V106, P1432, DOI 10.1182/blood-2005-03-0944; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; Foukas LC, 2002, J BIOL CHEM, V277, P37124, DOI 10.1074/jbc.M202101200; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Glass CK, 2006, NAT REV IMMUNOL, V6, P44, DOI 10.1038/nri1748; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; GRUMMELLI SM, 2007, AM J RESP CRIT CARE, V175, pA684; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Ito K., 2001, FASEB Journal, V15, P1110; Leclerc O, 2006, EUR RESPIR J, V27, P1102, DOI 10.1183/09031936.06.00076905; Lee KS, 2006, FASEB J, V20, P455, DOI 10.1096/fj.05-5045com; MacNee W, 2007, CLIN CHEST MED, V28, P479, DOI 10.1016/j.ccm.2007.06.008; MARWICK J, 2007, AM J RESP CRIT CARE, V175, pA696; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; MARWICK JA, 2008, AM J RESP CRIT CARE, V177, pA333; Morris A, 2008, J PHARMACOL EXP THER, V327, P851, DOI 10.1124/jpet.108.140848; Mostefai HA, 2008, J IMMUNOL, V180, P5028; Okkenhaug K, 2003, NAT REV IMMUNOL, V3, P317, DOI 10.1038/nri1056; Okkenhaug K, 2002, SCIENCE, V297, P1031; Puri KD, 2004, BLOOD, V103, P3448, DOI 10.1182/blood-2003-05-1667; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rommel C, 2007, NAT REV IMMUNOL, V7, P191, DOI 10.1038/nri2036; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Stevenson CS, 2005, AM J PHYSIOL-LUNG C, V288, pL514, DOI 10.1152/ajplung.00317.2004; Varani K, 2006, AM J RESP CRIT CARE, V173, P398, DOI 10.1164/rccm.200506-869OC	35	122	133	12	19	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2009	179	7					542	548		10.1164/rccm.200810-1570OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	425UU	WOS:000264663700006	19164702	
J	Bateson, TF; Schwartz, J				Bateson, Thomas F.; Schwartz, Joel			Children's response to air pollutants	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; LOW-BIRTH-WEIGHT; POSTNEONATAL INFANT-MORTALITY; SOUTHERN CALIFORNIA CHILDREN; CHRONIC RESPIRATORY SYMPTOMS; DIESEL EXHAUST PARTICLES; CROSS-SECTIONAL AREA; PARTICULATE MATTER; LUNG-FUNCTION; AMERICAN CHILDREN	It is important to focus on children with respect to air pollution because (1) their lungs are not completely developed, (2) they can have greater exposures than adults, and (3) those exposures can deliver higher doses of different composition that may remain in the lung for greater duration. The undeveloped lung is more vulnerable to assault and less able to fully repair itself when injury disrupts morphogenesis. Children spend more time outside, where concentrations of combustion-generated air pollution are generally higher. Children have higher baseline ventilation rates and are more physically active than adults, thus exposing their lungs to more air pollution. Nasal breathing in adults reduces some pollution concentrations, but children are more typically mouth-breathers - suggesting that the composition of the exposure mixture at the alveolar level may be different. Finally, higher ventilation rates and mouth-breathing may pull air pollutants deeper into children's lungs, thereby making clearance slower and more difficult. Children also have immature immune systems, which plays a significant role in asthma. The observed consequences of early life exposure to adverse levels of air pollutants include diminished lung function and increased susceptibility to acute respiratory illness and asthma. Exposure to diesel exhaust, in particular, is an area of concern for multiple endpoints, and deserves further research.	[Bateson, Thomas F.] US EPA, NCEA, Off Res & Dev, Washington, DC 20460 USA; [Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Schwartz, Joel] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Schwartz, Joel] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA	Bateson, TF (reprint author), US EPA, NCEA, Off Res & Dev, 1200 Penn Ave NW,Mail Code 8623D, Washington, DC 20460 USA.	bateson.thomas@epa.gov					Ahluwalia IB, 1997, AM J EPIDEMIOL, V146, P42; ANDERSON H.R., 1999, AIR POLLUTION HLTH, P461, DOI 10.1016/B978-012352335-8/50096-X; Arcus-Arth A, 2007, RISK ANAL, V27, P97, DOI 10.1111/j.1539-6924.2006.00862.x; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Bayer-Oglesby L, 2005, ENVIRON HEALTH PERSP, V113, P1632, DOI 10.1289/ehp.8159; Bennett WD, 2003, J APPL PHYSIOL, V95, P497, DOI 10.1152/japplphysiol.00718.2002; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Bobak M, 2001, EPIDEMIOLOGY, V12, P358, DOI 10.1097/00001648-200105000-00018; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153; BURRI P., 1997, LUNG GROWTH DEV, P1; Chay KY, 2003, Q J ECON, V118, P1121, DOI 10.1162/00335530360698513; Dejin-Karlsson E, 1998, AM J PUBLIC HEALTH, V88, P1523, DOI 10.2105/AJPH.88.10.1523; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; Dejmek J, 2002, ENVIRON HEALTH PERSP, V110, P601; Diaz-Sanchez D, 2003, CURR ALLERGY ASTHM R, V3, P146, DOI 10.1007/s11882-003-0027-4; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; Ekelund U, 2004, AM J CLIN NUTR, V79, P851; Fanucchi MV, 2004, TOXICOL APPL PHARM, V201, P53, DOI 10.1016/j.taap.2004.05.002; Fanucchi MV, 1997, TOXICOL APPL PHARM, V144, P96, DOI 10.1006/taap.1997.8119; Fanucchi MV, 2000, AM J RESP CRIT CARE, V161, pA615; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Ginsberg GL, 2005, J TOXICOL ENV HEAL A, V68, P573, DOI 10.1080/15287390590921793; Ha EH, 2003, PEDIATRICS, V111, P284, DOI 10.1542/peds.111.2.284; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; *HER MAJ PUBLIC HL, 1954, 95 HER MAJ PUBLIC HL; Holt PG, 1998, ENVIRON HEALTH PERSP, V106, P795, DOI 10.2307/3434191; Hubal EAC, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454607; ILIFF ALBERTA, 1952, CHILD DEVELOPMENT, V23, P237, DOI 10.1111/j.1467-8624.1952.tb05735.x; Kharrazi M, 2004, EPIDEMIOLOGY, V15, P660, DOI 10.1097/01.ede.0000142137.39619.60; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; LAINE T, 1991, EUR J ORTHODONT, V13, P311; LANGSTON C, 1984, AM REV RESPIR DIS, V129, P607; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; LIN MC, 2001, J TOXICOL ENV HEAL A, V64, P37; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; Mar TF, 2004, INHAL TOXICOL, V16, P809, DOI 10.1080/08958370490506646; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Nikasinovic L, 2004, J TOXICOL ENV HEAL B, V7, P81, DOI 10.1080/10937400490241952; Nikasinovic L, 2003, J TOXICOL ENV HEAL B, V6, P521, DOI 10.1080/10937400306477; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Parker JD, 2005, PEDIATRICS, V115, P121, DOI 10.1542/peds.2004-0889; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; PLOPPER CG, 1994, J PHARMACOL EXP THER, V269, P867; POETS CF, 1993, PEDIATRICS, V92, P686; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Ritz B, 2006, PEDIATRICS, V118, P493, DOI 10.1542/peds.2006-0027; Sagiv SK, 2005, ENVIRON HEALTH PERSP, V113, P602, DOI 10.1289/ehp.7646; SALDIVA PHN, 1994, ENVIRON RES, V65, P218, DOI 10.1006/enrs.1994.1033; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Schwartz J., 1997, HLTH CROSSROADS TRAN, P61; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; SIGMUND E, EUR J PUBLI HLTH; Smiley-Jewell SM, 1998, AM J PHYSIOL-LUNG C, V274, pL485; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; WARREN DW, 1990, LARYNGOSCOPE, V100, P89; Wilhelm M, 2005, ENVIRON HEALTH PERSP, V113, P1212, DOI 10.1289/ehp.7751; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35; Woodruff TJ, 2006, ENVIRON HEALTH PERSP, V114, P786, DOI 10.1289/ehp.8484; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407	83	122	129	4	28	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1528-7394			J TOXICOL ENV HEAL A	J. Toxicol. Env. Health Part A		2008	71	3					238	243		10.1080/15287390701598234		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	251AA	WOS:000252341400008	18097949	
J	Douwes, J; van Strien, R; Doekes, G; Smit, J; Kerkhof, M; Gerritsen, J; Postma, D; Travier, N; Brunekreef, B				Douwes, J; van Strien, R; Doekes, G; Smit, J; Kerkhof, M; Gerritsen, J; Postma, D; Travier, N; Brunekreef, B			Does early indoor microbial exposure reduce the risk of asthma? The Prevention and Incidence of Asthma and Mite Allergy birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; endotoxin; (1 -> 3)-beta-D-glucan; hygiene hypothesis; infant cohort study	HOUSE-DUST ENDOTOXIN; CHILDREN; ATOPY; SENSITIZATION; INFANCY; LIFE; POLYMORPHISM; WHEEZE; AIRWAY; CD14	Background: Exposure to microbial agents might inhibit the development of atopy and asthma. Objective: We measured the association between microbial exposure assessed at 3 months and the development of atopic sensitization and doctor-diagnosed (DD) asthma and wheeze in the first 4 years in a birth cohort study of children with atopic mothers. Methods: Endotoxin, fungal (1 -> 3)-beta-D-glucans, extracellular polysaccharides from the genera Penicillium and Aspergillus (EPS-Pen/Asp), and dust on living room floors were measured at 3 months of age. Serum IgE levels against common allergens were determined at 1 and 4 years, and questionnaire information about respiratory morbidity was collected yearly. Results: Microbial levels in mattresses were low and not associated with serum IgE levels, DD asthma, and wheeze. Floor levels of biocontaminants and dust, on the other hand, were inversely associated with DD asthma, being most pronounced for endotoxin (odds ratio [OR], 0.40; 95% CI, 0.210.77) and EPS-Pen/Asp (OR, 0.42; 95% CI, 0.18-0.99). Mutual adjustment for other exposures did not significantly after the results for endotoxin and only moderately affected the results for EPS-Pen/Asp. Persistent wheeze was also consistently less common in the high-exposure group, being significant only for EPS-PenlAsp (OR, 0.37; 95% CI, 0.15-0.96). Transient wheeze and wheeze in the past 12 months were also reduced, but effects were smaller and not significant. Relationships with serum-specific IgE levels, which could only be assessed in 41% at age 4 years, were less pronounced and statistically significant only for EPS-Pen/Asp. Conclusions: Early exposure to common microbial contaminants, including fungal agents, might protect against asthma. Clinical implications: Microbial exposure in early life might protect against asthma and might constitute a novel target for prevention.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Municipal Hlth Serv, Dept Environm Med, Amsterdam, Netherlands; Natl Inst Publ Hlth & Environm, RIVM, Bilthoven, Netherlands; Univ Groningen, Beatrix Childrens Hosp, Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Epidemiol, Groningen, Netherlands; Univ Groningen, Med Ctr, Dept Pulm Med, Groningen, Netherlands; Erasmus Univ, Sophia Childrens Hosp, Dept Pediat, Rotterdam, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Brunekreef, B (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80178, NL-3508 TD Utrecht, Netherlands.	B.Brunekreef@iras.uu.nl	Kerkhof, Marjan/A-8846-2008	brunekreef, bert/0000-0001-9908-0060; Douwes, Jeroen/0000-0003-3599-4036			ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hastie T, 1990, GEN ADDITIVE MODELS; Institute of Medicine (US) Committee on Damp Indoor Spaces and Health, 2004, DAMP IND SPAC HLTH; Jain VV, 2004, EXPERT OPIN BIOL TH, V4, P1533, DOI 10.1517/14712598.4.9.1533; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Singh J, 2005, J ALLERGY CLIN IMMUN, V115, P330, DOI 10.1016/j.jaci.2004.11.021; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	30	122	124	2	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1067	1073		10.1016/j.jaci.2006.02.002		7	Allergy; Immunology	Allergy; Immunology	041EM	WOS:000237436300014	16675334	
J	Geppetti, P; Materazzi, S; Nicolettl, P				Geppetti, P; Materazzi, S; Nicolettl, P			The transient receptor potential vanilloid 1: Role in airway inflammation and disease	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Review						transient receptor potential vanilloid 1; cough; asthma exacerbation; acidic media	GENE-RELATED PEPTIDE; NERVE GROWTH-FACTOR; OBSTRUCTIVE PULMONARY-DISEASE; DEPENDENT PROTEIN-KINASE; SENSITIVE SENSORY NERVES; CAPSAICIN RECEPTOR; GUINEA-PIG; ACTIVATED RECEPTOR-2; EPITHELIAL-CELLS; URINARY-BLADDER	The transient receptor potential vanilloid 1 (TRPV1) is air excitatory cation channel, rather selectively expressed in a subpopulation of nociceptive, primary sensory neurons that promote neurogenic inflammation via neuropeptide release. TRPV1 is activated by noxious temperature, low extracellular pH and diverse lipid derivatives, and is uniquely sensitive to vanilloid molecules, including capsaicin. TRPV1 expression and sensitivity is highly regulated by diverse G protein-coupled and tyrosine kinase receptors. Other exogenous or endogenous chemical agents, including reactive oxygen species, ethanol and hydrogen sulphide sensitize/activate TRPV1. In the airways, TRPV1 agonists; cause cough, bronchoconstriction, microvascular leakage, hyperreactivity and hypersecretion. Patients with asthma and chronic obstructive pulmonary disease are more sensitive to the tussive effect of TRPV1 agonists and TRPV1 activation may contribute to respiratory symptoms caused by acidic media present in the airways during asthma exacerbation, gastroesophageal reflux induced asthma or in other conditions. TRPV1 antagonists may be useful in the treatment of these diseases. (c) 2005 Elsevier B.V. All rights reserved.	Univ Florence, Clin Pharmacol Unit, Dept Crit Care Med & Surg, I-50139 Florence, Italy; Univ Ferrara, Ctr Excellence Study Inflammat, I-44100 Ferrara, Italy	Geppetti, P (reprint author), Univ Florence, Clin Pharmacol Unit, Dept Crit Care Med & Surg, Viale Pieraccini 6, I-50139 Florence, Italy.	pierangelo.geppetti@unifi.it					Agopyan N, 2004, AM J PHYSIOL-LUNG C, V286, pL563, DOI 10.1152/ajplung.00299.2003; Agopyan N, 2003, TOXICOL APPL PHARM, V192, P21, DOI 10.1016/S0041-008X(03)00259-X; Amadesi S, 2004, J NEUROSCI, V24, P4300, DOI 10.1523/JNEUROSCI.5679-03.2004; Amadesi S, 2001, AM J RESP CRIT CARE, V163, P1206; Baluk P, 1996, EXP LUNG RES, V22, P409, DOI 10.3109/01902149609046032; BARNES PJ, 1986, LANCET, V1, P242; Basu S, 2005, P NATL ACAD SCI USA, V102, P5120, DOI 10.1073/pnas.0407780102; Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/0165-6147(96)10027-4; BEVAN S, 1995, J NEUROSCI, V15, P4918; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Bhave G, 2002, NEURON, V35, P721, DOI 10.1016/S0896-6273(02)00802-4; Birder LA, 2002, NAT NEUROSCI, V5, P856, DOI 10.1038/nn902; Birder LA, 2001, P NATL ACAD SCI USA, V98, P13396, DOI 10.1073/pnas.231243698; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Carr MJ, 2003, J PHARMACOL EXP THER, V304, P1275, DOI 10.1124/jpet.102.043422; Caterina MJ, 1997, NATURE, V389, P816; Chan CLH, 2003, LANCET, V361, P385, DOI 10.1016/S0140-6736(03)12392-6; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COSTELLO JF, 1985, BRIT J CLIN PHARMACO, V20, P355; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; De Petrocellis L, 2001, J NEUROCHEM, V77, P1660, DOI 10.1046/j.1471-4159.2001.00406.x; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; Doods H, 2000, BRIT J PHARMACOL, V129, P420, DOI 10.1038/sj.bjp.0703110; FAUSSONEPELLEGR.MS, 2005, HISTOCHEM CELL BIOL, P1; FRANCOCERECEDA A, 1991, BRIT J PHARMACOL, V102, P506; FUJIMURA M, 1994, J ASTHMA, V31, P463, DOI 10.3109/02770909409089488; Geppetti P, 2004, BRIT J PHARMACOL, V141, P1313, DOI 10.1038/sj.bjp.0705768; GEPPETTI P, 1992, REGUL PEPTIDES, V41, P83, DOI 10.1016/0167-0115(92)90516-W; GEPPETTI P, 1993, AM J PHYSIOL, V265, pL164; GEPPETTI P, 1991, NEUROSCIENCE, V41, P295, DOI 10.1016/0306-4522(91)90218-D; Geppetti P, 1996, NEUROGENIC INFLAMMAT; GOADSBY PJ, 1990, ANN NEUROL, V28, P183, DOI 10.1002/ana.410280213; Groneberg DA, 2004, AM J RESP CRIT CARE, V170, P1276, DOI 10.1164/rccm.200402-1740C; Hardie RC, 2003, ANNU REV PHYSIOL, V65, P735, DOI 10.1146/annurev.physiol.65.092101.142505; HARDING SM, 2003, AM J MED, V18, pS39; Harrison S, 2003, EUR J PHARMACOL, V475, P107, DOI 10.1016/S0014-2999(03)02114-9; Huang SM, 2002, P NATL ACAD SCI USA, V99, P8400, DOI 10.1073/pnas.122196999; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Inoue K, 2002, BIOCHEM BIOPH RES CO, V291, P124, DOI 10.1006/bbrc.2002.6393; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234; Ji RR, 2002, NEURON, V36, P57, DOI 10.1016/S0896-6273(02)00908-X; Joos Guy F., 2001, Current Opinion in Pharmacology, V1, P235, DOI 10.1016/S1471-4892(01)00042-X; Karai LJ, 2004, J BIOL CHEM, V279, P16377, DOI 10.1074/jbc.M310891200; Kido MA, 2003, J DENT RES, V82, P393; Kollarik M, 2002, J PHYSIOL-LONDON, V543, P591, DOI 10.1113/jphysiol.2002.022848; LALLOO UG, 1995, J APPL PHYSIOL, V79, P1082; Lee J, 2003, J MED CHEM, V46, P3116, DOI 10.1021/jm030089u; Lee MG, 2005, J PHYSIOL-LONDON, V566, P205, DOI 10.1113/jphysiol.2005.087577; Li L, 2005, FASEB J, V19, P1196, DOI 10.1096/fj.04-3583fje; LUNDBERG JM, 1983, NATURE, V302, P251, DOI 10.1038/302251a0; Mazzone SB, 2005, J PHYSIOL-LONDON, V569, P559, DOI 10.1113/jphysiol.2005.093153; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Mezey E, 2000, P NATL ACAD SCI USA, V97, P3655, DOI 10.1073/pnas.060496197; Millqvist E, 2005, ENVIRON HEALTH PERSP, V113, P849, DOI 10.1289/ehp.7657; Millqvist E, 2000, ALLERGY, V55, P546, DOI 10.1111/j.1398-9995.2000.all2513.x; Mitchell JE, 2005, EXP LUNG RES, V31, P295, DOI 10.1080/01902140590918803; Montell C, 1997, MOL PHARMACOL, V52, P755; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Myers AC, 2005, AM J RESP CRIT CARE, V171, P212, DOI 10.1164/rccm.200405-600OC; OCONNELL JP, 2005, FEBS LETT, V2, P2; Olesen J, 2004, NEW ENGL J MED, V350, P1104, DOI 10.1056/NEJMoa030505; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; PLEVKOVA J, 2004, J PHYSIOL PHARMACOL, V3, P101; Pomonis JD, 2003, J PHARMACOL EXP THER, V306, P387, DOI 10.1124/jpet.102.046268; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Prescott ED, 2003, SCIENCE, V300, P1284, DOI 10.1126/science.1083646; Ricciardolo FLM, 2004, J ALLERGY CLIN IMMUN, V113, P610, DOI 10.1016/j.jaci.2003.12.034; Rousseau E, 2005, AM J PHYSIOL-LUNG C, V288, pL460, DOI 10.1152/ajplung.00252.2004; Ruan T, 2005, J PHYSIOL-LONDON, V565, P563, DOI 10.1113/jphysiol.2005.086181; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Sanchez MG, 2005, EUR J PHARMACOL, V515, P20, DOI 10.1016/j.ejphar.2005.04.010; Schmidlin F, 2002, J IMMUNOL, V169, P5315; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Stander S, 2004, EXP DERMATOL, V13, P129, DOI 10.1111/j.0906-6705.2004.0178.x; Steinhoff M, 2000, NAT MED, V6, P151; Su X, 2005, J IMMUNOL, V175, P2598; Sugiura T, 2002, J NEUROPHYSIOL, V88, P544, DOI 10.1152/jn.00986.2001; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tognetto M, 2001, J NEUROSCI, V21, P1104; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Trevisani M, 2004, THORAX, V59, P769, DOI 10.1136/thx.2003.012930; Trevisani M, 2004, J PHARMACOL EXP THER, V309, P1167, DOI 10.1124/jpet.103.064162; Trevisani M, 2002, NAT NEUROSCI, V5, P546, DOI 10.1038/nn852; TREVISANI M, 2005, BRIT J PHARMACOL, V6, P6; Tucker RC, 2001, BRIT J PHARMACOL, V132, P1127, DOI 10.1038/sj.bjp.0703906; Undem BJ, 2002, PULM PHARMACOL THER, V15, P193, DOI 10.1006/pupt.2002.0362; Vally H, 2003, ADDICT BIOL, V8, P3, DOI 10.1080/1355621031000069828; van Hagen PM, 1999, ANN MED, V31, P15; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Veronesi B, 2000, TOXICOL APPL PHARM, V169, P66, DOI 10.1006/taap.2000.9040; Vriens J, 2004, CELL CALCIUM, V36, P19, DOI 10.1016/j.ceca.2003.11.006; Walker KM, 2003, J PHARMACOL EXP THER, V304, P56, DOI 10.1124/jpet.102.042010; Watanabe H, 2003, NATURE, V424, P434, DOI 10.1038/nature01807; Watanabe N, 2005, PULM PHARMACOL THER, V18, P187, DOI 10.1016/j.pupt.2004.12.002; Wong CH, 1999, THORAX, V54, P62; Zygmunt PM, 1999, NATURE, V400, P452	99	122	135	4	18	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 8	2006	533	1-3					207	214		10.1016/j.ejphar.2005.12.063		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	025KS	WOS:000236265400020	16464449	
J	Ryan, PH; LeMasters, G; Biagini, J; Bernstein, D; Grinshpun, SA; Shukla, R; Wilson, K; Villareal, M; Burkle, J; Lockey, J				Ryan, PH; LeMasters, G; Biagini, J; Bernstein, D; Grinshpun, SA; Shukla, R; Wilson, K; Villareal, M; Burkle, J; Lockey, J			Is it traffic type, volume, or distance? Wheezing in infants living near truck and bus traffic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						diesel; traffic; truck; bus; wheezing; geographic information system; infants	DIESEL EXHAUST PARTICLES; CHRONIC RESPIRATORY SYMPTOMS; AIR-POLLUTION; BRONCHIAL HYPERRESPONSIVENESS; PARTICULATE MATTER; CYTOKINE PRODUCTION; VEHICLE EMISSIONS; CHILDHOOD ASTHMA; FINE PARTICLES; URBAN AIR	Background: Previous studies of air pollution have not examined the association between exposure to varying types, distance, and amounts of traffic and wheezing in very young infants. Objective: We sought to determine the relationship between types of traffic, traffic volume, and distance and wheezing among infants less than 1 year of age. Methods: A geographic information system and a classification scheme were developed to categorize infants enrolled in the study as living near moving truck and bus traffic (highway > 50 miles per hour, > 1000 trucks daily, < 400 m), stop-and-go truck and bus traffic (< 50 miles per hour, < 100 m), or unexposed and not residing near either. Symptom data were based on health questionnaires administered to parents when the infants were 6 months of age and monthly health diaries. Results: Infants living very near (< 100 m) stop-and-go bus and truck traffic had a significantly increased prevalence of wheezing (adjusted odds ratio, 2.50; 95% CI, 1.15-5.42) when compared with unexposed infants. The prevalence of wheezing among nonwhite infants was at least twice that of white infants, regardless of exposure. Infants living less than 400 m from a high volume of moving traffic, however, did not have an increased prevalence of wheezing. Conclusion: These results suggest that the distance from and type of traffic exposures are more significant risk factors than traffic volume for wheezing in early infancy.	Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Div Immunol, Dept Internal Med, Cincinnati, OH 45267 USA	Ryan, PH (reprint author), Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA.	ryanph@email.uc.edu	Ryan, Patrick /L-7062-2015		NIEHS NIH HHS [ES11170, ES10957]		Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Brauer M, 2001, ENVIRON HEALTH PERSP, V109, P1039, DOI 10.2307/3454959; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; El-Sharif N, 2003, CLIN EXP ALLERGY, V33, P176, DOI 10.1046/j.1365-2222.2003.01598.x; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Jalaludin BB, 2004, ENVIRON RES, V95, P32, DOI 10.1016/S0013-9351(03)00038-0; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; LEMASTERS GK, 2003, AM THOR SOC INT C MA; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Pino P, 2004, EPIDEMIOLOGY, V15, P702, DOI 10.1097/01.ede.0000142153.28496.d0; Reponen T, 2003, J ENVIRON MONITOR, V5, P557, DOI 10.1039/b303557c; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Shima M, 2003, J EPIDEMIOL, V13, P108; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; SOLOMON G, 2001, COALITION CLEAN AIR; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Tong HY, 2000, J AIR WASTE MANAGE, V50, P543; Unal A, 2004, J AIR WASTE MANAGE, V54, P130; *US EPA, HLTH ASS DOC DIES EN; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Wilkinson P, 1999, THORAX, V54, P1070	45	122	123	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					279	284		10.1016/j.jaci.2005.014		6	Allergy; Immunology	Allergy; Immunology	017ID	WOS:000235686400006	16083780	
J	Weidinger, S; Klopp, N; Rummler, L; Wagenpfeil, S; Novak, N; Baurecht, HJ; Groer, W; Darsow, U; Heinrich, J; Gauger, A; Schafer, T; Jakob, T; Behrendt, H; Wichmann, HE; Ring, J; Illig, T				Weidinger, S; Klopp, N; Rummler, L; Wagenpfeil, S; Novak, N; Baurecht, HJ; Groer, W; Darsow, U; Heinrich, J; Gauger, A; Schafer, T; Jakob, T; Behrendt, H; Wichmann, HE; Ring, J; Illig, T			Association of NOD1 polymorphisms with atopic eczema and related phenotypes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic eczema; asthma; allergic rhinoconjunctivitis; IgE; CARD4; NOD1; SNP; haplotype; association	RESPIRATORY-HEALTH-SURVEY; HOUSE-DUST ENDOTOXIN; TOLL-LIKE RECEPTOR-2; CROHNS-DISEASE; LINKAGE DISEQUILIBRIUM; HYGIENE HYPOTHESIS; INNATE IMMUNITY; CELIAC-DISEASE; ASTHMA; CHILDREN	Background: Interactions with microbial pathogens are crucial for the maturation of the immune system. The nucleotide-binding oligomerization domain protein 1 (NOD1) is a cytosolic receptor sensing a muropeptide found mostly in gram-negative bacterial peptidoglycans. NOD1 is located on chromosome 7p14-p15, a region that has been linked with atopy. Recently, polymorphisms of the closely related NOD2 have been associated with atopy-related traits. Objectives: Within a large population-based cohort of German adults (n = 1417), a case-control population for atopic eczema (n = 454), and a large cohort of parent-offspring trios for atopic eczema (189 trios), we evaluated 11 NOD1 polymorphisms for associations with atopic phenotypes. Methods: Subjects were phenotyped by standardized questionnaires and interviews, skin examination, and serum IgE measurements. Genotyping was performed by using matrix-assisted laser desorption ionization-time of flight mass spectrometry. Results: Analyses revealed significant association of one NOD1 haplotype with atopic eczema in the population-based cohort (P = .004) and the case-control population (P = .003). Another NOD1 haplotype was associated with decreased total IgE (P = .008). In addition, significant associations with total serum IgE levels were observed for polymorphisms rs2907748 (P = .006), rs2907749 (P = .012), and rs2075822 (P = .018). These polymorphisms were significantly associated with atopic eczema and asthma in the family-based association analyses (P = .001-043). Seven polymorphisms showed significant transmission distortion for total IgE levels (P values < .0001-.029). Conclusion: These data indicate that genetic variants within NOD1 are important determinants of atopy susceptibility.	Tech Univ Munich, Dept Dermatol & Allergy, D-80802 Munich, Germany; GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; Tech Univ Munich, Inst Med Stat & Epidemiol, D-80802 Munich, Germany; Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; Med Univ Lubeck, Inst Social Med, Lubeck, Germany; Tech Univ Munich, Div Environm Dermatol & Allergy, GSF, D-80802 Munich, Germany; Tech Univ Munich, ZAUM Ctr Allergy & Environm, D-80802 Munich, Germany	Weidinger, S (reprint author), Tech Univ Munich, Dept Dermatol & Allergy, Biedersteiner St 29, D-80802 Munich, Germany.	weidinger@lrz.turn.de	Weidinger, Stephan/C-8461-2011; Jakob, Thilo/J-1621-2012; Baurecht, Hansjoerg/C-4035-2013				Abecasis GR, 2000, EUR J HUM GENET, V8, P545, DOI 10.1038/sj.ejhg.5200494; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Athman R, 2004, CURR OPIN MICROBIOL, V7, P25, DOI 10.1016/j.mib.2003.12.013; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bouchier-Hayes L, 2002, EMBO REP, V3, P616, DOI 10.1093/embo-reports/kvf1391; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Ciacci C, 2004, J ALLERGY CLIN IMMUN, V113, P1199, DOI 10.1016/j.jaci.2004.03.012; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder Waltraud, 2004, Curr Opin Allergy Clin Immunol, V4, P113, DOI 10.1097/00130832-200404000-00008; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hampe J, 2002, LANCET, V359, P1661, DOI 10.1016/S0140-6736(02)08590-2; Heine H, 2003, INT ARCH ALLERGY IMM, V130, P180, DOI 10.1159/000069517; Holt PG, 2002, EUR RESPIR J, V19, P538, DOI 10.1183/09031936.02.00229302; Homma T, 2004, AM J RESP CELL MOL, V31, P463, DOI 10.1165/rcmb.2004-0161OC; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Illig T, 2003, DIABETES, V52, P2861, DOI 10.2337/diabetes.52.11.2861; Inohara N, 2000, J BIOL CHEM, V275, P27823; INOHARA N, 2001, NAT REV IMMUNOL, V3, P371; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Leung DYM, 2003, CURR OPIN IMMUNOL, V15, P634, DOI 10.1016/j.coi.2003.09.009; Martinez FD, 1999, LANCET, V354, pSII12; Matsubara M, 2004, FEBS LETT, V566, P195, DOI 10.1016/j.febslet.2004.04.028; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836; Powrie F, 2003, SCIENCE, V299, P1030, DOI 10.1126/science.1082031; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Slatkin M, 1996, HEREDITY, V76, P377, DOI 10.1038/hdy.1996.55; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Wallin J, 1996, DEVELOPMENT, V122, P23; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yoo NJ, 2002, BIOCHEM BIOPH RES CO, V299, P652, DOI 10.1016/S0006-291X(02)02714-6	48	122	127	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2005	116	1					177	184		10.1016/j.jaci.2005.02.034		8	Allergy; Immunology	Allergy; Immunology	017IC	WOS:000235686300027	15990792	
J	Lowe, LA; Simpson, A; Woodcock, A; Morris, J; Murray, CS; Custovic, A				Lowe, LA; Simpson, A; Woodcock, A; Morris, J; Murray, CS; Custovic, A		NAC Manchester Asthma All	Wheeze phenotypes and lung function in preschool children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						dry air challenge; lung function; specific airway resistance; wheeze phenotypes	COLD-AIR CHALLENGE; RESPIRATORY SYMPTOMS; BRONCHIAL RESPONSIVENESS; MANCHESTER ASTHMA; HEALTHY-CHILDREN; YOUNG-CHILDREN; EARLY-LIFE; INFANTS; CHILDHOOD; ADULT	Distinct phenotypes can be identified in childhood wheezing illness. Within the context of a birth cohort study, we investigated the association between preschool lung function and phenotypes of wheeze. From parentally reported history of wheeze (interviewer-administered questionnaire, age 3 and 5 years), children were classified as never wheezers, transient early wheezers, late-onset wheezers, or persistent wheezers. Lung function (specific airway resistance [sRaw]; kPa/second) was assessed at age 3 (n = 463) and 5 years (n = 690). Persistent wheezers had markedly poorer lung function compared with other groups. In children who had wheezed by age 3, the risk of persistent wheeze increased with increased sRaw (odds ratio [OR] 5.2, 95% confidence interval [CI] 1.3-22.0; p = 0.02). In a multivariate model, increasing sRaw (OR 5.5, 95% CI 1.2-25.9; p = 0.03) and the child's sensitization (OR 2.8, 95% CI 1.3-5.8; p = 0.008) were significant independent predictors of persistent wheezing. We found no association between lung function at age 3 and late-onset wheeze in children who had not wheezed previously (OR 0.6, 95% CI 0.07-5.3; p = 0.64). In conclusion, poor lung function at age 3 predicted the subsequent persistence of symptoms in children who had wheezed within the first 3 years, but was not associated with the onset of wheeze after age 3 in children who had not wheezed previously.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Wythenshawe Hosp, Dept Med Stat, Manchester M23 9LT, Lancs, England	Custovic, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.	a.custovic@man.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666			BRUSSCE JE, 2004, AM J RESP CRIT CARE, V169, P1262; BUHR W, 1990, PEDIATR PULM, V8, P23, DOI 10.1002/ppul.1950080108; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; Clough JB, 1999, AM J RESP CRIT CARE, V160, P1473; Crenesse D, 2001, PEDIATR PULM, V32, P56, DOI 10.1002/ppul.1089; Custovic A, 2002, PEDIATR ALLERGY IMMU, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dab I, 1976, Pediatr Res, V10, P998; Delacourt C, 2001, AM J RESP CRIT CARE, V164, P1382; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Dezateux C, 1997, BRIT MED BULL, V53, P40; Dezateux C, 2001, THORAX, V56, P680, DOI 10.1136/thorax.56.9.680; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554; Nystad W, 2002, THORAX, V57, P1021, DOI 10.1136/thorax.57.12.1021; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Stick S, 2000, THORAX, V55, P587, DOI 10.1136/thorax.55.7.587; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Turner SW, 2002, AM J RESP CRIT CARE, V165, P1294, DOI 10.1164/rccm.200110-018OC; Vilozni D, 2001, AM J RESP CRIT CARE, V164, P2200, DOI 10.1164/rccm2101002; von Mutius E, 2001, THORAX, V56, P153, DOI 10.1136/thorax.56.2.153; WOODCOCK A, 2004, AM J RESP CRIT CARE, V170, P4333; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016	33	122	124	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 1	2005	171	3					231	237		10.1164/rccm.200406-695OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	891MY	WOS:000226586400007	15502115	
J	Helenius, I; Haahtela, T				Helenius, I; Haahtela, T			Allergy and asthma in elite summer sport athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; athletes; bronchial hyperresponsiveness; chlorine derivatives; maximal exercise capacity; sports medicine; summer events; swimming	EXERCISE-INDUCED BRONCHOSPASM; CROSS-COUNTRY SKIERS; COLD-AIR; INDUCED BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS; FIGURE SKATERS; MILD ASTHMA; CHILDREN; EXPOSURE; SWIMMERS	Exercise may increase ventilation up to 200 L/min for short periods of time in speed and power athletes, and for longer periods in endurance athletes, such as long-distance runners and swimmers. Therefore highly trained athletes are repeatedly and strongly exposed to cold air during winter training and to many pollen allergens in spring and summer. Competitive swimmers inhale and microaspirate large amounts of air that floats above the water surface, which means exposure to chlorine derivatives from swimming pool disinfectants. In the summer Olympic Games, 4% to 15% of the athletes showed evidence of asthma or used anti-asthmatic medication. Asthma is most commonly found in endurance events, such as cycling, swimming, or long-distance running. The risk of asthma is especially increased among competitive swimmers, of which 36% to 79% show bronchial hyperresponsiveness to methacholine or histamine. The risk of asthma is closely associated with atopy and its severity among athletes. A few studies have investigated occurrence of exercise-induced bronchospasm among highly trained athletes, The occurrences of exercise-induced bronchospasm vary from 3% to 35% and depend on testing environment, type of exercise used, and athlete population tested. Mild eosinophilic airway inflammation has been shown to affect elite swimmers and cross-country skiers. This eosinophilic inflammation correlates with clinical parameters (ie, exercise-induced bronchial symptoms and bronchial hyperresponsiveness). Athletes commonly use antiasthmatic medication to treat their exercise-induced bronchial symptoms. However, controlled studies on their long-term effects on bronchial hyperresponsiveness and airway inflammation in the athletes are lacking. Follow-up studies on asthma in athletes are also lacking. What will happen to bronchial hyperresponsiveness and airway inflammation after discontinuation of competitional career is unclear. In the future, follow-up studies on bronchial responsiveness and airway inflammation, as well as controlled studies on both short- and long-term effects of antiasthmatic drugs in the athletes are needed.	Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, Dept Allergol, Helsinki, Finland; Paijat Hame Cent Hosp, Lahti, Finland	Helenius, I (reprint author), Ohjaajantie 3A 4, Helsinki 00400, Finland.						AGGAZZOTTI G, 1993, ARCH ENVIRON HEALTH, V48, P250; ANDERSON SD, 1995, ASTHMA RHINITIS, P1178; Carlsen KH, 1998, PEDIATR ALLERGY IMMU, V9, P173, DOI 10.1111/j.1399-3038.1998.tb00369.x; Carlsen KH, 1989, CHILDREN EXERCISE, VXIII, P351; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; COCKCROFT DW, 1993, LANCET, V342, P833, DOI 10.1016/0140-6736(93)92695-P; de Benedictis FM, 1998, ANN ALLERG ASTHMA IM, V80, P352; DEAL EC, 1979, J APPL PHYSIOL, V46, P484; Dekhuijzen PNR, 1999, THORAX, V54, P1041; DOSMAN JA, 1991, AM REV RESPIR DIS, V144, P45; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; DROBNIC F, 1994, ARCH BRONCONEUMOL, V8, P419; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; Godfrey S., 1992, ASTHMA, P73; Griffin JW, 1997, LARYNGOSCOPE, V107, P1235, DOI 10.1097/00005537-199709000-00014; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Heir T., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P94; Helbling A, 1991, Schweiz Z Sportmed, V39, P77; Helenius IJ, 1996, THORAX, V51, P628, DOI 10.1136/thx.51.6.628; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; HELENIUS IJ, 1998, THESIS U HELSINKI HE; HENRIKSEN JM, 1986, ALLERGY, V41, P499, DOI 10.1111/j.1398-9995.1986.tb00335.x; Ienna TM, 1997, INT J SPORTS MED, V18, P142, DOI 10.1055/s-2007-972610; Karjalainen EM, 1999, EXERCISE-INDUCED ASTHMA AND SPORTS IN ASTHMA, P81; KOSKELA H, 1997, THESIS U KUOPIO KUOP; Kujala UM, 1996, THORAX, V51, P288, DOI 10.1136/thx.51.3.288; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; LARSSON K, 1993, BRIT MED J, V307, P1326; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564; MCKENZIE DC, 1994, MED SCI SPORT EXER, V26, P951; *MED COMM INT OL C, 1999, LIST CLASS PROH SUBS; Meltzer EO, 1996, J ALLERGY CLIN IMMUN, V97, P617, DOI 10.1016/S0091-6749(96)70307-X; *MIN SOC AFF HLTH, 1996, CLIN EXP ALLERGY S1, V26, pS1; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875; Oseid S., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P88; PAPALIA SM, 1996, ASPECTS INHALED BUDE; PAUL DW, 1993, INT J SPORTS MED, V14, P433, DOI 10.1055/s-2007-1021205; PEKKARINEN H, 1989, EUR J APPL PHYSIOL O, V58, P821, DOI 10.1007/BF02332213; PIERSON WE, 1989, ANN ALLERGY, V63, P461; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; RISSER WL, 1994, PEDIATRICS, V94, P129; Sandsund M, 1997, ANN NY ACAD SCI, V813, P751, DOI 10.1111/j.1749-6632.1997.tb51778.x; Schoene RB, 1997, CLIN J SPORT MED, V7, P257, DOI 10.1097/00042752-199710000-00003; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; SUZUKI S, 1985, ANN ALLERGY, V54, P136; TIKKANEN HO, 1994, BRIT MED J, V309, P1087; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; ZANCONATO S, 1990, PEDIATR PULM, V8, P240, DOI 10.1002/ppul.1950080406; ZWICK H, 1990, LUNG, V168, P111	63	122	124	0	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					444	452		10.1067/mai.2000.107749		9	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900005	10984362	
J	Arrieta, MC; Stiemsma, LT; Dimitriu, PA; Thorson, L; Russell, S; Yurist-Doutsch, S; Kuzeljevic, B; Gold, MJ; Britton, HM; Lefebvre, DL; Subbarao, P; Mandhane, P; Becker, A; McNagny, KM; Sears, MR; Kollmann, T; Mohn, WW; Turvey, SE; Finlay, BB				Arrieta, Marie-Claire; Stiemsma, Leah T.; Dimitriu, Pedro A.; Thorson, Lisa; Russell, Shannon; Yurist-Doutsch, Sophie; Kuzeljevic, Boris; Gold, Matthew J.; Britton, Heidi M.; Lefebvre, Diana L.; Subbarao, Padmaja; Mandhane, Piush; Becker, Allan; McNagny, Kelly M.; Sears, Malcolm R.; Kollmann, Tobias; Mohn, William W.; Turvey, Stuart E.; Finlay, B. Brett		CHILD Study Investigators	Early infancy microbial and metabolic alterations affect risk of childhood asthma	SCIENCE TRANSLATIONAL MEDICINE			English	Article							LONGITUDINAL DEVELOPMENT CHILD; NUCLEAR-MAGNETIC-RESONANCE; EARLY-LIFE; INTESTINAL MICROBIOTA; ANTIBIOTIC EXPOSURE; ALLERGIC-ASTHMA; GUT MICROBIOTA; YOUNG-CHILDREN; BIRTH COHORT; DISEASE	Asthma is the most prevalent pediatric chronic disease and affects more than 300 million people worldwide. Recent evidence in mice has identified a "critical window" early in life where gut microbial changes (dysbiosis) are most influential in experimental asthma. However, current research has yet to establish whether these changes precede or are involved in human asthma. We compared the gut microbiota of 319 subjects enrolled in the Canadian Healthy Infant Longitudinal Development (CHILD) Study, and show that infants at risk of asthma exhibited transient gut microbial dysbiosis during the first 100 days of life. The relative abundance of the bacterial genera Lachnospira, Veillonella, Faecalibacterium, and Rothia was significantly decreased in children at risk of asthma. This reduction in bacterial taxa was accompanied by reduced levels of fecal acetate and dysregulation of enterohepatic metabolites. Inoculation of germ-free mice with these four bacterial taxa ameliorated airway inflammation in their adult progeny, demonstrating a causal role of these bacterial taxa in averting asthma development. These results enhance the potential for future microbe-based diagnostics and therapies, potentially in the form of probiotics, to prevent the development of asthma and other related allergic diseases in children.	[Arrieta, Marie-Claire; Thorson, Lisa; Russell, Shannon; Yurist-Doutsch, Sophie; Britton, Heidi M.; Finlay, B. Brett] Univ British Columbia, Michael Smith Labs, Vancouver, BC V6T 1Z4, Canada; [Arrieta, Marie-Claire; Stiemsma, Leah T.; Dimitriu, Pedro A.; Russell, Shannon; Yurist-Doutsch, Sophie; Mohn, William W.; Finlay, B. Brett] Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; [Kuzeljevic, Boris; Kollmann, Tobias; Turvey, Stuart E.] Child & Family Res Inst, Vancouver, BC V4Z 4H4, Canada; [Kuzeljevic, Boris; Kollmann, Tobias; Turvey, Stuart E.] BC Childrens Hosp, Vancouver, BC V4Z 4H4, Canada; [Gold, Matthew J.; McNagny, Kelly M.] Univ British Columbia, Biomed Res Ctr, Vancouver, BC V6T 1Z3, Canada; [Lefebvre, Diana L.; Sears, Malcolm R.] McMaster Univ, Dept Med, Hamilton, ON L8S 4L8, Canada; [Subbarao, Padmaja] Univ Toronto, Dept Pediat, Toronto, ON M5S 2J7, Canada; [Subbarao, Padmaja] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Mandhane, Piush] Univ Alberta, Dept Pediat, Edmonton, AB T6G 2R3, Canada; [Mandhane, Piush] Univ Alberta, Sch Publ Hlth, Edmonton, AB T6G 2R3, Canada; [Becker, Allan] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Kollmann, Tobias; Turvey, Stuart E.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1Z4, Canada; [Finlay, B. Brett] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z4, Canada	Turvey, SE (reprint author), Child & Family Res Inst, Vancouver, BC V4Z 4H4, Canada.	sturvey@cw.bc.ca; bfinlay@mail.ubc.ca		Kuzeljevic, Boris/0000-0003-4712-9867; Tang, Patrick/0000-0003-1583-5484	Canadian Institutes of Health Research (CIHR) [CHM-94316, CMF 108029]; CIHR; Allergy, Genes and Environment (AllerGen) Network of the Centres of Excellence (NCE); Health Canada; Environment Canada; Canada Mortgage and Housing Corporation; Childhood Asthma Foundation; University of British Columbia; Tula Foundation; Aubrey J. Tingle Professorship in Pediatric Immunology	Funding: This research was supported by the Canadian Institutes of Health Research (CIHR; grants CHM-94316 and CMF 108029). The CIHR and the Allergy, Genes and Environment (AllerGen) Network of the Centres of Excellence (NCE) provided core funding for CHILD. Additional support for the CHILD Study has been provided by Health Canada, Environment Canada, Canada Mortgage and Housing Corporation, and the Childhood Asthma Foundation. L.T.S. is supported by the University of British Columbia Four Year Fellowship. A grant from the Tula Foundation to the Centre for Microbial Diversity and Evolution supported the work of P.A.D. S.E.T. holds the Aubrey J. Tingle Professorship in Pediatric Immunology and is a clinical scholar of the Michael Smith Foundation for Health Research.	Abrahamsson TR, 2014, CLIN EXP ALLERGY, V44, P842, DOI 10.1111/cea.12253; Arnold IC, 2011, J CLIN INVEST, V121, P3088, DOI 10.1172/JCI45041; Arpaia N, 2013, NATURE, V504, P451, DOI 10.1038/nature12726; Arrieta MC, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00427; Asher I, 2014, INT J TUBERC LUNG D, V18, P1269, DOI 10.5588/ijtld.14.0170; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Azad MB, 2013, CAN MED ASSOC J, V185, P385, DOI 10.1503/cmaj.121189; Bartram AK, 2011, APPL ENVIRON MICROB, V77, P3846, DOI 10.1128/AEM.02772-10; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Blanchet MR, 2007, BLOOD, V110, P2005, DOI 10.1182/blood-2006-12-062448; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; Campbell JM, 1997, J NUTR, V127, P130; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Castro-Rodriguez JA, 2011, J ALLERGY CLIN IMMUN, V127, P1082, DOI 10.1016/j.jaci.2011.01.024; Chassin C, 2010, CELL HOST MICROBE, V8, P358, DOI 10.1016/j.chom.2010.09.005; CORNICK NA, 1994, INT J SYST BACTERIOL, V44, P87; DeHaven CD, 2010, J CHEMINFORMATICS, V2, DOI 10.1186/1758-2946-2-9; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; DeSmedt T, 1996, J EXP MED, V184, P1413, DOI 10.1084/jem.184.4.1413; Evans AM, 2009, ANAL CHEM, V81, P6656, DOI 10.1021/ac901536h; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Forsythe P, 2007, AM J RESP CRIT CARE, V175, P561, DOI 10.1164/rccm.200606-821OC; Graham-Rowe D, 2011, NATURE, V479, pS2; Hartmann M, 2012, ISME J, V6, P2199, DOI 10.1038/ismej.2012.84; Holgate ST, 2012, NAT MED, V18, P673, DOI 10.1038/nm.2731; Holmes E, 2011, TRENDS MICROBIOL, V19, P349, DOI 10.1016/j.tim.2011.05.006; Hoskin-Parr L, 2013, PEDIAT ALLERG IMM-UK, V24, P762, DOI 10.1111/pai.12153; Hunt JRF, 2005, CLIN EXP ALLERGY, V35, P685, DOI 10.1111/j.1365-2222.2005.02239.x; Huttenhower C, 2012, NATURE, V486, P207, DOI 10.1038/nature11234; Jimenez E, 2014, MICROBIOLOGYOPEN, V3, P937, DOI 10.1002/mbo3.218; Langille MGI, 2013, NAT BIOTECHNOL, V31, P814, DOI 10.1038/nbt.2676; Lopez-Siles M, 2012, APPL ENVIRON MICROB, V78, P420, DOI 10.1128/AEM.06858-11; Love M. I., 2014, BIORXIV, V15, P550, DOI [10.1101/002832, DOI 10.1186/S13059-014-0550-8]; Manise M., 2014, PLOS ONE, V8; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; Martinez FD, 2013, LANCET, V382, P1360, DOI 10.1016/S0140-6736(13)61536-6; McMurdie PJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061217; Moraes TJ, 2015, PAEDIATR PERINAT EP, V29, P84, DOI 10.1111/ppe.12161; Neuwirth E, 2011, RCOLORBREWER COLORBR; Oksanen J., 2013, COMMUNITY ECOLOGY PA; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Parks DH, 2014, BIOINFORMATICS, V30, P3123, DOI 10.1093/bioinformatics/btu494; Ploner A., 2012, HEATPLUS HEATMAPS RO; Plummer M., 2006, R NEWS, V6, P7, DOI DOI 10.1159/000323281; Pollard K. S., 2005, BIOINFORMATICS COMPU; R Development Core Team, 2014, R LANG ENV STAT COMP; ROGOSA M, 1964, J BACTERIOL, V87, P162; Russell Shannon L, 2013, Gut Microbes, V4, P158, DOI 10.4161/gmic.23567; Russell SL, 2012, EMBO REP, V13, P440, DOI 10.1038/embor.2012.32; Samuel BS, 2008, P NATL ACAD SCI USA, V105, P16767, DOI 10.1073/pnas.0808567105; Sandin A, 2009, ACTA PAEDIATR, V98, P823, DOI 10.1111/j.1651-2227.2008.01215.x; Saude EJ, 2011, J ALLERGY CLIN IMMUN, V127, P757, DOI 10.1016/j.jaci.2010.12.1077; Saude EJ, 2009, AM J RESP CRIT CARE, V179, P25, DOI 10.1164/rccm.200711-1716OC; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Shreiner A, 2008, ADV EXP MED BIOL, V635, P113, DOI 10.1007/978-0-387-09550-9_10; Smith MI, 2013, SCIENCE, V339, P548, DOI 10.1126/science.1229000; Subbarao P, 2015, THORAX, V70, P998, DOI 10.1136/thoraxjnl-2015-207246; Takaro TK, 2015, J EXPO SCI ENV EPID, V25, P580, DOI 10.1038/jes.2015.7; Tanaka S, 2009, FEMS IMMUNOL MED MIC, V56, P80, DOI 10.1111/j.1574-695X.2009.00553.x; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Virchow Jr. J. C., 1996, J ALLERGY CLIN IMMUN, V98, pS27; WICKHAM H, 2011, J STAT SOFTW, V40, P1; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Xia JG, 2012, NUCLEIC ACIDS RES, V40, pW127, DOI 10.1093/nar/gks374; Xia JG, 2009, NUCLEIC ACIDS RES, V37, pW652, DOI 10.1093/nar/gkp356; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053; Zamar D, 2007, J STAT SOFTW, V21, P1	68	121	124	18	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	1946-6234	1946-6242		SCI TRANSL MED	Sci. Transl. Med.	SEP 30	2015	7	307							307ra152	10.1126/scitranslmed.aab2271		14	Cell Biology; Medicine, Research & Experimental	Cell Biology; Research & Experimental Medicine	CW8EY	WOS:000365233500005	26424567	
J	Oliphant, CJ; Hwang, YY; Walker, JA; Salimi, M; Wong, SH; Brewer, JM; Englezakis, A; Barlow, JL; Hams, E; Scanlon, ST; Ogg, GS; Fallon, PG; McKenzie, ANJ				Oliphant, Christopher J.; Hwang, You Yi; Walker, Jennifer A.; Salimi, Maryam; Wong, See Heng; Brewer, James M.; Englezakis, Alexandros; Barlow, Jillian L.; Hams, Emily; Scanlon, Seth T.; Ogg, Graham S.; Fallon, Padraic G.; McKenzie, Andrew N. J.			MHCII-Mediated Dialog between Group 2 Innate Lymphoid Cells and CD4(+) T Cells Potentiates Type 2 Immunity and Promotes Parasitic Helminth Expulsion	IMMUNITY			English	Article							ALLERGIC LUNG INFLAMMATION; DUST-MITE ALLERGEN; DENDRITIC CELLS; IN-VIVO; ADAPTIVE IMMUNITY; CYSTEINE PROTEASE; ANTIBODY-RESPONSE; TH2 RESPONSES; IL-4; EXPRESSION	Group 2 innate lymphoid cells (ILC2s) release interleukin-13 (IL-13) during protective immunity to helminth infection and detrimentally during allergy and asthma. Using two mouse models to deplete ILC2s in vivo, we demonstrate that T helper 2 (Th2) cell responses are impaired in the absence of ILC2s. We show that MHCII-expressing ILC2s interact with antigen-specific T cells to instigate a dialog in which IL-2 production from T cells promotes ILC2 proliferation and IL-13 production. Deletion of MHCII renders IL-13-expressing ILC2s incapable of efficiently inducing Nippostrongylus brasiliensis expulsion. Thus, during transition to adaptive T cell-mediated immunity, the ILC2 and T cell crosstalk contributes to their mutual maintenance, expansion and cytokine production. This interaction appears to augment dendritic-cell-induced T cell activation and identifies a previously unappreciated pathway in the regulation of type-2 immunity.	[Oliphant, Christopher J.; Hwang, You Yi; Walker, Jennifer A.; Wong, See Heng; Englezakis, Alexandros; Barlow, Jillian L.; Scanlon, Seth T.; McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England; [Salimi, Maryam; Ogg, Graham S.] Univ Oxford, John Radcliffe Hosp, NIHR Biomed Res Ctr, MRC Human Immunol Unit, Oxford OX3 9DS, England; [Hams, Emily; Fallon, Padraic G.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin 2, Ireland; [Fallon, Padraic G.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin 12, Ireland; [Fallon, Padraic G.] Trinity Coll Dublin, Inst Mol Med, Dublin 2, Ireland; [Brewer, James M.] Univ Pl, GRBC, Inst Infect Immun & Inflammat, Glasgow G12 8TA, Lanark, Scotland	McKenzie, ANJ (reprint author), MRC, Mol Biol Lab, Francis Crick Ave, Cambridge CB2 0QH, England.	anm@mrc-lmb.cam.ac.uk	Brewer, James/A-7186-2010	Brewer, James/0000-0001-7933-0915; Scanlon, Seth Thomas/0000-0002-1792-6382; Fallon, Padraic/0000-0002-8401-7293; Hams, Emily/0000-0002-9745-3246	American Asthma Foundation; UK-MRC; Wellcome Trust [100963/Z/13/Z]; A-STAR; Science Foundation Ireland; National Children's Research Centre; NIHR Biomedical Research Centre Programme; Janssen Research and Development	We thank the Ares staff for their technical assistance. We also thank A. Betz for providing MHCII-deficient mice. This work was supported by the American Asthma Foundation (A.N.J.M.), UK-MRC (A.N.J.M., G.S.O.), Wellcome Trust (grant number 100963/Z/13/Z) (A.N.J.M.), A-STAR (Y.Y.H.), Science Foundation Ireland and National Children's Research Centre (P.G.F.), and NIHR Biomedical Research Centre Programme (G.S.O.). A.N.J.M. and G.S.O. have research grant funding from Janssen Research and Development.	Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnden MJ, 1998, IMMUNOL CELL BIOL, V76, P34, DOI 10.1046/j.1440-1711.1998.00709.x; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Chan CW, 2006, NAT MED, V12, P207, DOI 10.1038/nm1352; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; COSGROVE D, 1991, CELL, V66, P1051, DOI 10.1016/0092-8674(91)90448-8; Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1; Forbes E, 2010, IMMUNOL CELL BIOL, V88, P240, DOI 10.1038/icb.2009.101; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hepworth MR, 2013, NATURE, V498, P113, DOI 10.1038/nature12240; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hu-Li J, 2001, IMMUNITY, V14, P1, DOI 10.1016/S1074-7613(01)00084-X; Jenkins SJ, 2008, J IMMUNOL, V180, P8083; Jun JE, 2003, IMMUNITY, V18, P751, DOI 10.1016/S1074-7613(03)00141-9; KAMATA I, 1995, CLIN EXP IMMUNOL, V102, P71; Liang HE, 2012, NAT IMMUNOL, V13, P58, DOI 10.1038/ni.2182; Mirchandani AS, 2014, J IMMUNOL, V192, P2442, DOI 10.4049/jimmunol.1300974; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Pape KA, 2007, IMMUNITY, V26, P491, DOI 10.1016/j.immuni.2007.02.011; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; RONCAROLO MG, 1991, J IMMUNOL, V147, P781; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Santambrogio L, 1999, P NATL ACAD SCI USA, V96, P15056, DOI 10.1073/pnas.96.26.15056; Schlenner SM, 2010, IMMUNITY, V32, P426, DOI 10.1016/j.immuni.2010.03.005; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; van Panhuys N, 2008, P NATL ACAD SCI USA, V105, P12423, DOI 10.1073/pnas.0806372105; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhu JF, 2003, IMMUNITY, V19, P739, DOI 10.1016/S1074-7613(03)00292-9	44	121	124	1	26	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613	1097-4180		IMMUNITY	Immunity	AUG 21	2014	41	2					283	295		10.1016/j.immuni.2014.06.016		13	Immunology	Immunology	AO6JA	WOS:000341455300015	25088770	
J	Hamilos, DL				Hamilos, Daniel L.			Chronic rhinosinusitis: Epidemiology and medical management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Rhinosinusitis; sinusitis; nasal polyposis; epidemiology; medical management; treatment	ENDOSCOPIC SINUS SURGERY; ALLERGIC FUNGAL RHINOSINUSITIS; PLACEBO-CONTROLLED TRIAL; CHRONIC HYPERPLASTIC SINUSITIS; MESSENGER-RNA EXPRESSION; AQUEOUS NASAL SPRAY; QUALITY-OF-LIFE; DOUBLE-BLIND; ASPIRIN DESENSITIZATION; MUCOCILIARY CLEARANCE	Chronic rhinosinusitis (CRS) affects 12.5% of the US population. On epidemiologic grounds, some association has been found between CRS prevalence and air pollution, active cigarette smoking, secondhand smoke exposure, perennial allergic rhinitis, and gastroesophageal reflux. The majority of pediatric and adult patients with CRS are immune competent. Data on genetic associations with CRS are still sparse. Current consensus definitions subclassify CRS into CRS without nasal polyposis (CRSsNP), CRS with nasal polyposis (CRSwNP), and allergic fungal rhinosinusitis (AFRS). Evaluation and medical management of CRS has been the subject of several recent consensus reports. The highest level of evidence for treatment for CRSsNP exists for saline lavage, intranasal steroids, and long-term macrolide antibiotics. The highest level of evidence for treatment of CRSwNP exists for intranasal steroids, systemic glucocorticoids, and topical steroid irrigations. Aspirin desensitization is beneficial for patients with aspirin-intolerant CRSwNP. Sinus surgery followed by use of systemic steroids is recommended for AFRS. Other modalities of treatment, such as antibiotics for patients with purulent infection and antifungal drugs for patients with AFRS, are potentially useful despite a lack of evidence from controlled treatment trials. The various modalities of medical treatment are reviewed in the context of recent consensus documents and the author's personal experience. (J Allergy Clin Immunol 2011; 128:693-707.)	Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA	Hamilos, DL (reprint author), Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol, 55 Fruit St,Bulfinch 422, Boston, MA 02114 USA.	dhamilos@partners.org					Aazami A, 2009, IRAN J ALLERGY ASTHM, V8, P199, DOI 08.04/ijaai.199203; Adams PF, 1999, VITAL HLTH STAT, V10, P1; Al-Qudah M, 2008, INT J PEDIATR OTORHI, V72, P817, DOI [10.1016/j.ijporl.2008.02.006, 10.1016/j.ijport.2008.02.006]; AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Alobid I, 2006, RHINOLOGY, V44, P8; Anand Vijay K, 2004, Ann Otol Rhinol Laryngol Suppl, V193, P3; Asero R, 2001, ANN ALLERG ASTHMA IM, V86, P283; Aukema AAC, 2005, J ALLERGY CLIN IMMUN, V115, P1017, DOI 10.1016/j.jaci.2004.12.1144; Bachert C, 2005, DRUGS, V65, P1537, DOI 10.2165/00003495-200565110-00006; Bachert C, 2010, CURR ALLERGY ASTHM R, V10, P194, DOI 10.1007/s11882-010-0096-0; Bassichis BA, 2001, OTOLARYNG HEAD NECK, V125, P487, DOI 10.1067/mhn.2001.119585; Benitez P, 2006, LARYNGOSCOPE, V116, P770, DOI 10.1097/01.mlg.0000205218.37514.0f; Benninger MS, 2003, OTOLARYNG HEAD NECK, V129, pS1, DOI 10.1016/S0194-5998(03)01397-4; Berrettini S, 1999, ALLERGY, V54, P242, DOI 10.1034/j.1398-9995.1999.00813.x; Bhattacharyya N, 2009, AMJ RHINOL ALLERGY, V23, P392, DOI 10.2500/ajra.2009.23.3355; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; Briggs RD, 2004, LARYNGOSCOPE, V114, P126, DOI 10.1097/00005537-200401000-00022; Cheng AG, 2009, OTOLARYNG HEAD NECK, V141, P86, DOI 10.1016/j.otohns.2009.03.020; Cherry WB, 2008, AM J MED, V121, P185, DOI 10.1016/j.amjmed.2007.09.022; Christian DL, 1998, AM J RESP CRIT CARE, V158, P532; Cryer J, 2004, ORL J OTO-RHINO-LARY, V66, P155, DOI 10.1159/000079994; Dahl M, 2004, J EXP MED, V199, P1391, DOI 10.1084/jem.20040111; Danese M, 1997, J RADIOL, V78, P651; DelGaudio JM, 2005, LARYNGOSCOPE, V115, P946, DOI 10.1097/01.MLG.0000163751.00885.63; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Donlan RM, 2002, CLIN MICROBIOL REV, V15, P167, DOI 10.1128/CMR.15.2.167-193.2002; Durmus R, 2010, ACTA OTO-LARYNGOL, V130, P1053, DOI 10.3109/00016481003621546; Ebbens FA, 2009, LARYNGOSCOPE, V119, P401, DOI 10.1002/lary.20064; Elliott KA, 2006, AM J RHINOL, V20, P1; Ferguson BJ, 2005, AM J RHINOL, V19, P452; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Fokkens W, 2007, RHINOL S, V20, P1; Ghegan MD, 2007, AM J RHINOL, V21, P560, DOI 10.2500/ajr.2007.21.3082; Gosepath J, 2001, ARCH OTOLARYNGOL, V127, P316; Gosepath J, 2008, ACTA OTO-LARYNGOL, V128, P778, DOI 10.1080/00016480701724896; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P1; Hamilos Daniel L, 2007, Clin Allergy Immunol, V20, P299; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HAMILOS DL, 2004, ANN OTOL RHINOL LA S, V193, P27; Harvey R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858; Hauptman G, 2007, OTOLARYNG HEAD NECK, V137, P815, DOI 10.1016/j.otohns.2007.07.034; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Hochstim CJ, 2010, OTOLARYNG HEAD NECK, V143, P697, DOI 10.1016/j.otohns.2010.07.017; Huang WH, 2006, LARYNGOSCOPE, V116, P288, DOI 10.1097/01.mlg.0000197316.36698.c4; Hutcheson PS, 2010, AM J RHINOL ALLERGY, V24, P405, DOI 10.2500/ajra.2010.24.3533; Ikram Mubasher, 2009, Ear Nose Throat J, V88, pE8; Javer AR, 2007, J OTOLARYNGOL, V36, P1, DOI 10.2310/7070.2006.0084; Jones NS, 1997, CLIN OTOLARYNGOL, V22, P47, DOI 10.1046/j.1365-2273.1997.00862.x; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Karaman M, 2009, AMJ RHINOL ALLERGY, V23, P2, DOI 10.2500/ajra.2009.23.3253; KATLE EJ, 2011, EUR ARCH OTORHINOLAR; Kennedy D W, 1992, Laryngoscope, V102, P1; Kennedy DW, 2005, LARYNGOSCOPE, V115, P1793, DOI 10.1097/01.mlg.0000175683.81260.26; Kienast K, 1996, Eur J Med Res, V1, P533; Koskinen OM, 1999, EUR RESPIR J, V14, P1363, DOI 10.1183/09031936.99.14613639; Landsberg R, 2007, OTOLARYNG HEAD NECK, V136, P252, DOI 10.1016/j.otohns.2006.09.010; Lavigne F, 2002, LARYNGOSCOPE, V112, P858, DOI 10.1097/00005537-200205000-00015; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; Li Y, 2008, ORL J OTO-RHINO-LARY, V70, P113, DOI 10.1159/000114534; Lieu JEC, 2000, ARCH OTOLARYNGOL, V126, P940; Lim M, 2008, AM J RHINOL, V22, P381, DOI 10.2500/ajr.2008.22.3189; Liou Aimee, 2003, Chest, V124, P1781, DOI 10.1378/chest.124.5.1781; Lotvall J, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-163; LUMRY WR, 1983, J ALLERGY CLIN IMMUN, V71, P580, DOI 10.1016/0091-6749(83)90440-2; Lund VJ, 2004, RHINOLOGY, V42, P57; Lusk RP, 1996, OTOLARYNG CLIN N AM, V29, P75; Mafee Mahmood F, 2007, Clin Allergy Immunol, V20, P185; Mainz JG, 2011, AURIS NASUS LARYNX, V38, P220, DOI 10.1016/j.anl.2010.09.001; MAJIMA Y, 2011, AURIS NASUS LARYNX; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; Micheletto C, 2004, ALLERGY, V59, P289, DOI 10.1046/j.1398-9995.2003.00351.x; Ozmen S, 2008, LARYNGOSCOPE, V118, P890, DOI 10.1097/MLG.0b013e318165e324; Parikh A, 2001, RHINOLOGY, V39, P75; Patiar S, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005232.pub2; Pauli C, 2007, LARYNGO RHINO OTOL, V86, P282, DOI 10.1055/s-2007-966094; Pearlman AN, 2009, AMJ RHINOL ALLERGY, V23, P145, DOI 10.2500/ajra.2009.23.3284; Pleis JR, 2009, VITAL HLTH STAT, V242, P1; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V115, P125, DOI 10.1016/j.jaci.2004.09.037; Ragab S, 2001, CLIN EXP ALLERGY, V31, P1385, DOI 10.1046/j.1365-2222.2001.01160.x; Ragab SM, 2004, LARYNGOSCOPE, V114, P923, DOI 10.1097/00005537-200405000-00027; Ramadan HH, 2002, OTOLARYNG HEAD NECK, V127, P546, DOI 10.1067/mhn.2002.129816; Reh DD, 2009, AMJ RHINOL ALLERGY, V23, P562, DOI 10.2500/ajra.2009.23.3377; Robinson S, 2006, AM J RHINOL, V20, P625, DOI 10.2500/ajr.2006.20.2907; Rollin M, 2009, RHINOLOGY, V47, P75; Rosenfeld RM, 2007, OTOLARYNG HEAD NECK, V137, pS1, DOI 10.1016/j.otohns.2007.06.726; Rozsasi A, 2008, ALLERGY, V63, P1228, DOI 10.1111/j.1398-9995.2008.01658.x; Sachanandani NS, 2009, ARCH OTOLARYNGOL, V135, P303, DOI 10.1001/archoto.2008.555; Sanclement JA, 2005, LARYNGOSCOPE, V115, P578, DOI 10.1097/01.mlg.0000161346.30752.18; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P260, DOI 10.1111/j.1365-2222.2007.02889.x; Schaefer D., 1999, Rhinology (Utrecht), V37, P56; Schapowal A. G., 1995, Acta Oto-Rhino-Laryngologica Belgica, V49, P235; Scheinberg Philip A, 2002, Ear Nose Throat J, V81, P648; Schubert Mark S, 2007, Clin Allergy Immunol, V20, P263; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P387, DOI 10.1016/S0091-6749(98)70125-3; Senior BA, 1999, OTOLARYNG HEAD NECK, V121, P66, DOI 10.1016/S0194-5998(99)70127-0; Senior BA, 1998, LARYNGOSCOPE, V108, P151, DOI 10.1097/00005537-199802000-00001; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; SHAPIRO GG, 1991, PEDIATRICS, V87, P311; Singhal D, 2010, AM J RHINOL ALLERGY, V24, P169, DOI 10.2500/ajra.2010.24.3462; Skorpinski EW, 2008, ANN ALLERG ASTHMA IM, V100, P529, DOI 10.1016/S1081-1206(10)60061-0; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Small CB, 2005, J ALLERGY CLIN IMMUN, V116, P1275, DOI 10.1016/j.jaci.2005.07.027; Sobol SE, 1998, J OTOLARYNGOL, V27, P252; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; SPEKTOR DM, 1989, ENVIRON HEALTH PERSP, V79, P167, DOI 10.2307/3430545; Stankiewicz JA, 2002, OTOLARYNG HEAD NECK, V126, P623, DOI 10.1067/mhn.2002.125602; Stewart RA, 2008, OTOLARYNG HEAD NECK, V139, P682, DOI 10.1016/j.otohns.2008.07.010; Stjarne P, 2009, ARCH OTOLARYNGOL, V135, P296, DOI 10.1001/archoto.2009.2; Subramanian HN, 2002, AM J RHINOL, V16, P303; Tammemagi CM, 2010, ARCH OTOLARYNGOL, V136, P327, DOI 10.1001/archoto.2010.43; Tichenor WS, 2008, J ALLERGY CLIN IMMUN, V121, P917, DOI 10.1016/j.jaci.2007.08.065; Uren B, 2008, LARYNGOSCOPE, V118, P1677, DOI 10.1097/MLG.0b013e31817aec47; Van Zele T, 2010, J ALLERGY CLIN IMMUN, V125, P1069, DOI 10.1016/j.jaci.2010.02.020; Vanlerberghe L, 2006, B-ENT, V2, P161; Vaughan WC, 2002, OTOLARYNG HEAD NECK, V127, P558, DOI 10.1067/mhn.2002.129738; WALD ER, 1995, J PEDIATR-US, V127, P339, DOI 10.1016/S0022-3476(95)70061-7; Wallwork B, 2006, LARYNGOSCOPE, V116, P189, DOI 10.1097/01.mlg.0000191560.53555.08; Wang XJ, 2000, JAMA-J AM MED ASSOC, V284, P1814, DOI 10.1001/jama.284.14.1814; Wang XJ, 2005, ARCH OTOLARYNGOL, V131, P237, DOI 10.1001/archotol.131.3.237; Whatley WS, 2006, AM J RHINOL, V20, P251, DOI 10.2500/ajr.2006.20.2855; WIGHT RG, 1992, CLIN OTOLARYNGOL, V17, P354, DOI 10.1111/j.1365-2273.1992.tb01012.x; Wise SK, 2008, OTOLARYNG HEAD NECK, V138, P38, DOI 10.1016/j.otohns.2007.10.020; Wise SK, 2006, AM J RHINOL, V20, P283, DOI 10.2500/ajr.2006.20.2849; WOLFF RK, 1986, ENVIRON HEALTH PERSP, V66, P223, DOI 10.2307/3430237	131	121	125	1	29	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					693	709		10.1016/j.jaci.2011.08.004		17	Allergy; Immunology	Allergy; Immunology	841UA	WOS:000296538100001	21890184	
J	Gregory, LG; Lloyd, CM				Gregory, Lisa G.; Lloyd, Clare M.			Orchestrating house dust mite-associated allergy in the lung	TRENDS IN IMMUNOLOGY			English	Review							PROTEASE-ACTIVATED RECEPTOR-2; THYMIC STROMAL LYMPHOPOIETIN; ADAPTIVE IMMUNE-RESPONSES; GROWTH-FACTOR RECEPTOR; DENDRITIC CELLS; AIRWAY INFLAMMATION; DERMATOPHAGOIDES-PTERONYSSINUS; T-CELL; STRUCTURAL BIOLOGY; NLRP3 INFLAMMASOME	House dust mites (HDM; Dermatophagoides sp.) are one of the commonest aeroallergens worldwide and up to 85% of asthmatics are typically HDM allergic. Allergenicity is associated both with the mites themselves and with ligands derived from mite-associated bacterial and fungal products. Murine models of allergic airways disease for asthma research have recently switched from the use of surrogate allergen ovalbumin together with adjuvant to use of the HDM extract. This has accelerated understanding of how adaptive and innate immunity generate downstream pathology. We review the myriad ways in which HDM allergic responses are orchestrated. Understanding the molecular pathways that elicit HDM-associated pathology is likely to reveal novel targets for therapeutic intervention.	[Gregory, Lisa G.; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England	Lloyd, CM (reprint author), Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, London SW7 2AZ, England.	c.1loyd@imperial.ac.uk		Lloyd, Clare/0000-0001-8977-6726	Medical Research Council [G1000758]; Wellcome Trust [087618]		Abramson MJ, 2010, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD001186.PUB2; Adams M.N., 2011, PHARMACOL THERAPEUT, V13, P248; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barrett NA, 2009, J IMMUNOL, V182, P1119; Bhure UN, 2009, ANN NUCL MED, V23, P549, DOI 10.1007/s12149-009-0275-z; Blumberga G, 2011, ALLERGY, V66, P178, DOI 10.1111/j.1398-9995.2010.02451.x; Burgel PR, 2008, EUR RESPIR J, V32, P1068, DOI 10.1183/09031936.00172007; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Carpenter S, 2009, BIOCHEM J, V422, P1, DOI 10.1042/BJ20090616; Casale TB, 2011, J ALLERGY CLIN IMMUN, V127, P8, DOI 10.1016/j.jaci.2010.10.034; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; CHAPMAN MD, 1980, INT ARCH ALLER A IMM, V61, P431; Chun J, 2009, J LEUKOCYTE BIOL, V86, P1135, DOI 10.1189/jlb.0209072; Chun J, 2009, CELL HOST MICROBE, V5, P47, DOI 10.1016/j.chom.2008.11.009; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Da Silva CA, 2010, AM J RESP CRIT CARE, V182, P1482, DOI 10.1164/rccm.200912-1877OC; Dai XJ, 2011, J ALLERGY CLIN IMMUN, V127, P806, DOI 10.1016/j.jaci.2010.12.006; Epton MJ, 2001, INT ARCH ALLERGY IMM, V124, P57, DOI 10.1159/000053668; Fahlbusch B, 2003, ALLERGY, V58, P150, DOI 10.1034/j.1398-9995.2003.00036.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Gavino ACP, 2008, DERMATITIS, V19, P121, DOI 10.2310/6620.2008.07068; Gregory LG, 2009, CLIN EXP ALLERGY, V39, P1597, DOI 10.1111/j.1365-2222.2009.03302.x; Gregory LG, 2010, AM J RESP CRIT CARE, V182, P143, DOI 10.1164/rccm.200905-0725OC; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hartl D, 2007, NAT MED, V13, P1423, DOI 10.1038/nm1690; Hauck R.W., 1999, AM J PHYSIOL, V277, pL222; HAY DB, 1992, EXP APPL ACAROL, V16, P37, DOI 10.1007/BF01201491; Hongjia Li, 2010, Cell Biochem Funct, V28, P597, DOI 10.1002/cbf.1697; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Jin C, 2011, J CLIN INVEST, V121, P941, DOI 10.1172/JCI43584; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019; Kemp AS, 2009, PAEDIATR RESPIR REV, V10, P63, DOI 10.1016/j.prrv.2009.02.002; Kidon MI, 2011, PEDIAT ALLERG IMM-UK, V22, P202, DOI 10.1111/j.1399-3038.2010.01094.x; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Koff J.L., 2008, AM J PHYSIOL-LUNG C, V294; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kroeger KM, 2009, J LEUKOCYTE BIOL, V86, P769, DOI 10.1189/jlb.0708452; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.011.041; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Larche Mark, 2007, Allergy Asthma Clin Immunol, V3, P53, DOI 10.1186/1710-1492-3-2-53; Le Cras TD, 2011, AM J PHYSIOL-LUNG C, V300, pL414, DOI 10.1152/ajplung.00346.2010; Lee CG, 2011, ANNU REV PHYSIOL, V73, P479, DOI 10.1146/annurev-physiol-012110-142250; Lee SE, 2010, YONSEI MED J, V51, P808, DOI 10.3349/ymj.2010.51.6.808; Letuve S, 2006, J ALLERGY CLIN IMMUN, V117, P590, DOI 10.1016/j.jaci.2005.10.025; Miglino N, 2011, EUR RESPIR J, V38, P50, DOI 10.1183/09031936.00068010; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mosges R, 2010, Acta Dermatovenerol Alp Pannonica Adriat, V19, P3; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; Muller T, 2010, ALLERGY, V65, P1545, DOI 10.1111/j.1398-9995.2010.02426.x; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; O'Neil SE, 2006, CLIN EXP ALLERGY, V36, P831, DOI 10.1111/j.1365-2222.2006.02497.x; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Pfaar O, 2010, AM J RHINOL ALLERGY, V24, P220, DOI 10.2500/ajra.2010.24.3437; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Pomes A, 2008, CURR ALLERGY ASTHM R, V8, P425, DOI 10.1007/s11882-008-0082-y; Post S, 2010, AM J RESP CRIT CARE, V181; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Ritter M, 2010, P NATL ACAD SCI USA, V107, P20459, DOI 10.1073/pnas.1010337107; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Senti G, 2009, CLIN EXP ALLERGY, V39, P562, DOI 10.1111/j.1365-2222.2008.03191.x; Shen HD, 1996, CLIN EXP ALLERGY, V26, P308; Simpson A, 2010, CLIN EXP ALLERGY, V40, P209, DOI 10.1111/j.1365-2222.2009.03391.x; Siracusa MC, 2010, IMMUNOL CELL BIOL, V88, P275, DOI 10.1038/icb.2010.1; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; STEWART GA, 1994, AM J IND MED, V25, P105, DOI 10.1002/ajim.4700250128; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; Thomas WR, 2007, IMMUNOL RES, V37, P187, DOI 10.1007/BF02697369; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P388, DOI 10.1007/s11882-005-0012-1; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Turi GJ, 2011, AM J PHYSIOL-LUNG C, V300, pL185, DOI 10.1152/ajplung.00271.2010; Valenta R, 2011, ALLERGY, V66, P775, DOI 10.1111/j.1398-9995.2011.02565.x; Valerio CR, 2005, J ALLERGY CLIN IMMUN, V116, P1296, DOI 10.1016/j.jaci.2005.09.046; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Ying S, 2005, J IMMUNOL, V174, P8183; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zhu Z, 2010, CLIN EXP ALLERGY, V40, P536, DOI 10.1111/j.1365-2222.2010.03477.x	104	121	122	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4906	1471-4981		TRENDS IMMUNOL	Trends Immunol.	SEP	2011	32	9					402	411		10.1016/j.it.2011.06.006		10	Immunology	Immunology	820XT	WOS:000294940100002	21783420	
J	Subrata, LS; Bizzintino, J; Mamessier, E; Bosco, A; McKenna, KL; Wikstrom, ME; Goldblatt, J; Sly, PD; Hales, BJ; Thomas, WR; Laing, IA; LeSouef, PN; Holt, PG				Subrata, Lily S.; Bizzintino, Joelene; Mamessier, Emilie; Bosco, Anthony; McKenna, Katherine L.; Wikstroem, Matthew E.; Goldblatt, Jack; Sly, Peter D.; Hales, Belinda J.; Thomas, Wayne R.; Laing, Ingrid A.; LeSouef, Peter N.; Holt, Patrick G.			Interactions between Innate Antiviral and Atopic Immunoinflammatory Pathways Precipitate and Sustain Asthma Exacerbations in Children	JOURNAL OF IMMUNOLOGY			English	Article							FC-EPSILON-RI; ALLERGIC AIRWAY INFLAMMATION; KILLER T-CELLS; DENDRITIC CELLS; RESPIRATORY-TRACT; VIRAL-INFECTION; HOSPITAL ADMISSIONS; IMMUNE-RESPONSE; VIRUS-INFECTION; EXPRESSION	Severe asthma exacerbations in children requiring hospitalization are typically associated with viral infection and occur almost exclusively among atopics, but the significance of these comorbidities is unknown. We hypothesized that underlying interactions between immunoinflammatory pathways related to responses to aeroallergen and virus are involved, and that evidence of these interactions is detectable in circulating cells during exacerbations. To address this hypothesis we used a genomics-based approach involving profiling of PBMC subpopulations collected during exacerbation vs convalescence by microarray and flow cytometry. We demonstrate that circulating T cells manifest the postactivated "exhausted" phenotype during exacerbations, whereas monocyte/dendritic cell populations display up-regulated CCR2 expression accompanied by phenotypic changes that have strong potential for enhancing local inflammation after their recruitment to the atopic lung. Notably, up-regulation of Fc epsilon R1, which is known to markedly amplify capacity for allergen uptake/presentation to Th2 effector cells via IgE-mediated allergen capture, and secondarily programming of IL-4/IL-13-dependent IL-13R(+) alternatively activated macrophages that have been demonstrated in experimental settings to be a potent source of autocrine IL-13 production. We additionally show that this disease-associated activation profile can be reproduced in vitro by cytokine exposure of atopic monocytes, and furthermore that IFN-alpha can exert both positive and negative roles in the process. Our findings suggest that respiratory viral infection in atopic children may initiate an atopy-dependent cascade that amplifies and sustains airway inflammation initiated by innate antiviral immunity via harnessing underlying atopy-associated mechanisms. These interactions may account for the unique susceptibility of atopics to severe viral-induced asthma exacerbations. The Journal of Immunology, 2009, 183: 2793-2800.	Telethon Inst Child Hlth Res, Perth, WA, Australia; Univ Western Australia, Fac Med & Dent, Ctr Child Hlth Res, Perth, WA 6009, Australia	Holt, PG (reprint author), Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Sly, Peter/F-1486-2010; Hales, Belinda/C-3858-2013; Laing, Ingrid/I-7092-2013; Bizzintino, Joelene/H-8840-2014; Bizzintino, Joelene/C-8665-2016; Holt, Patrick/H-1548-2011	Sly, Peter/0000-0001-6305-2201; Hales, Belinda/0000-0003-2193-3996; Laing, Ingrid/0000-0002-1641-9899; Holt, Patrick/0000-0003-1193-0935	National Health and Medical Research Council of Australia; The Australian Respiratory Council Ann Woolcock Research Fellowship	This work was funded by National Health and Medical Research Council of Australia. I.A.L. is supported by The Australian Respiratory Council Ann Woolcock Research Fellowship.	Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; ALBLAS ABV, 1981, J EXP MED, V154, P235; Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bolstad BM, 2004, INT REV NEUROBIOL, V60, P25; Bosco A, 2006, J IMMUNOL, V176, P4766; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Come JM, 2002, LANCET, V359, P831; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; Das J, 2006, NAT MED, V12, P1345, DOI 10.1038/nm1206-1345; Gill MA, 2005, J INFECT DIS, V191, P1105, DOI 10.1086/428589; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Holgate Stephen T, 2008, Allergol Int, V57, P1, DOI 10.2332/allergolint.R-07-154; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; HOLT PG, 1994, J IMMUNOL, V153, P256; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; HYYPIA T, 1989, J GEN VIROL, V70, P3261, DOI 10.1099/0022-1317-70-12-3261; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Kendziorski C, 2005, P NATL ACAD SCI USA, V102, P4252, DOI 10.1073/pnas.0500607102; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Maus UA, 2005, AM J PHYSIOL-LUNG C, V288, pL350, DOI 10.1152/ajplung.00061.2004; McWilliam AS, 1997, J VIROL, V71, P226; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; MYINT S, 1994, MOL CELL PROBE, V8, P357, DOI 10.1006/mcpr.1994.1052; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Qureshi F, 1998, NEW ENGL J MED, V339, P1030, DOI 10.1056/NEJM199810083391503; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Robays LJ, 2007, J IMMUNOL, V178, P5305; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Smyth GK, 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Thomas SY, 2007, J IMMUNOL, V179, P1901; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1111/j.1365-2222.1996.tb00591.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wherry EJ, 2007, IMMUNITY, V27, P670, DOI 10.1016/j.immuni.2007.09.006; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Xepapadaki P, 2007, IMMUNOBIOLOGY, V212, P453, DOI 10.1016/j.imbio.2007.03.008	56	121	125	0	5	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	AUG 15	2009	183	4					2793	2800		10.4049/jimmunol.0900695		8	Immunology	Immunology	482RN	WOS:000268906500068	19620293	
J	Garn, H; Renz, H				Garn, Holger; Renz, Harald			Epidemiological and immunological evidence for the hygiene hypothesis	IMMUNOBIOLOGY			English	Review						hygiene hypothesis; allergy; T cell responses; innate immunity	TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; PATTERN-RECOGNITION RECEPTOR; ALLERGIC AIRWAY DISEASE; INNATE IMMUNE-SYSTEM; LACTIC-ACID BACTERIA; DENDRITIC CELLS; MURINE MODEL; INTESTINAL MICROFLORA; ATOPIC-DERMATITIS	Allergic diseases are inflammatory disorders that develop on the basis of complex gene-environment interactions. The prevalence of allergies is steadily increasing and seems to be associated with modern lifestyle. Therefore, it was hypothesized that high living standards and hygienic conditions are correlated with an increased risk for the development of an allergic disease. This so-called "hygiene hypothesis" states that due to reduced exposure to microbial components, the proposed allergy-preventing potential of these factors is no more present in sufficient qualities and/or quantities, which leads to an imbalance of the immune system with a predisposition to the development of allergic disorders. Meanwhile, several epidemiological studies were conducted supporting this concept and generating novel ideas for the underlying mechanisms that were then followed up by use of well-defined animal models and human studies. The current view of cellular and molecular mechanisms responsible for these phenomena includes changes in the fine balancing of T helper cell 1 (Th1), Th2 and regulatory T cell (Treg) responses which are triggered by altered or missing innate immune cell activation. In fact, proper activation of cells of the innate immune system via their so-called pattern recognition receptors has been demonstrated to play a crucial role in early shaping of the immune system and suppression of the development of Th2-driven allergic immune responses. These processes start already in utero and prenatal as well as early postnatal developmental stages seem to represent a certain "window of opportunity" for allergy-preventing environmental influences. (C) 2007 Elsevier GmbH. All rights reserved.	Univ Marburg, Fac Med, Dept Clin Chem & Mol Diagnost, Biomed Res Ctr, D-35043 Marburg, Germany	Garn, H (reprint author), Univ Marburg, Fac Med, Dept Clin Chem & Mol Diagnost, Biomed Res Ctr, Hans Meerwein Str 2, D-35043 Marburg, Germany.	garn@staff.uni-marburg.de					Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Ahmad-Nejad P, 2004, J ALLERGY CLIN IMMUN, V113, P565, DOI 10.1016/j.jaci.2003.12.583; Akbari O, 2005, CURR ALLERGY ASTHM R, V5, P56, DOI 10.1007/s11882-005-0055-3; Alm JS, 1998, ALLERGY, V53, P537, DOI 10.1111/j.1398-9995.1998.tb04093.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Banerjee B, 2004, INFECT IMMUN, V72, P6087, DOI 10.1128/IAI.72.10.6087-6094.2004; Barlan IB, 2005, CURR OPIN ALLERGY CL, V5, P552, DOI 10.1097/01.all.0000191238.20632.e2; Bashir MEH, 2004, J IMMUNOL, V172, P6978; BENNET R, 1991, SCAND J INFECT DIS, V23, P63, DOI 10.3109/00365549109023376; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Blumenthal MN, 2005, CURR OPIN ALLERGY CL, V5, P141, DOI 10.1097/01.all.0000162306.12728.c2; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braga EG, 2003, IMMUNOL LETT, V88, P163, DOI 10.1016/S0165-2478(03)00079-8; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745; Busse William W., 2003, Journal of Allergy and Clinical Immunology, V111, pS799, DOI 10.1067/mai.2003.158; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Delayre-Orthez C, 2004, CLIN EXP ALLERGY, V34, P1789, DOI 10.1111/j.1365-2222.2004.02082.x; Eder Waltraud, 2004, Curr Opin Allergy Clin Immunol, V4, P113, DOI 10.1097/00130832-200404000-00008; Fageras B.M., 2004, J ALLERGY CLIN IMMUN, V114, P561; Farrar JD, 2002, J CLIN INVEST, V109, P431, DOI 10.1172/JC01200215093; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fujiwara D, 2004, INT ARCH ALLERGY IMM, V135, P205, DOI 10.1159/000081305; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Han XB, 2004, EUR J IMMUNOL, V34, P981, DOI 10.1002/eji.200324387; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Hoffjan S, 2005, J MOL MED-JMM, V83, P682, DOI 10.1007/s00109-005-0672-2; Holm TL, 2004, APMIS, V112, P629, DOI 10.1111/j.1600-0463.2004.apm1121001.x; Hopfenspirger MT, 2002, J IMMUNOL, V168, P2516; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kim YS, 2004, IMMUNOLOGY, V112, P624, DOI 10.1111/j.1365-2567.2004.01880.x; Komai-Koma M, 2004, P NATL ACAD SCI USA, V101, P3029, DOI 10.1073/pnas.0400171101; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Li XM, 2003, J IMMUNOL, V170, P3289; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Marks GB, 2006, CLIN EXP PHARMACOL P, V33, P285, DOI 10.1111/j.1440-1681.2006.04360.x; Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; OEHLING A, 1980, ALLERGOL IMMUNOPATH, V8, P177; Ozdemir C, 2003, CLIN EXP ALLERGY, V33, P266, DOI 10.1046/j.1365-2222.2003.01595.x; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Repa A, 2003, VACCINE, V22, P87, DOI 10.1016/S0264-410X(03)00528-0; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Sabroe I, 2003, J IMMUNOL, V171, P1630; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; Sayers I, 2004, J ALLERGY CLIN IMMUN, V114, P302, DOI 10.1016/j.jaci.2004.03.057; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Sobek V, 2004, ARTHRITIS RES THER, V6, P433; Stock P, 2006, CURR OPIN ALLERGY CL, V6, P12, DOI 10.1097/01.all.0000200502.69672.44; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tukenmez F, 1999, PEDIATR ALLERGY IMMU, V10, P107, DOI 10.1034/j.1399-3038.1999.00029.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vandenbulcke L, 2006, INT ARCH ALLERGY IMM, V139, P159, DOI 10.1159/000090393; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Wang YF, 2006, J ALLERGY CLIN IMMUN, V118, P143, DOI 10.1016/j.jaci.2006.03.020; Webber MP, 2002, PEDIATR PULM, V34, P105, DOI 10.1002/ppul.10146; Weigt H, 2004, J IMMUNOL, V172, P6080; XYSTRAKIS E, 2006, OPIN BIOL THER, V6, P121; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Yang IA, 2004, GENES IMMUN, V5, P41, DOI 10.1038/sj.gene.6364037	98	121	126	4	38	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0171-2985			IMMUNOBIOLOGY	Immunobiology		2007	212	6					441	452		10.1016/j.imbio.2007.03.006		12	Immunology	Immunology	185VM	WOS:000247738500003	17544829	
J	Hengge, UR; Currie, BJ; Jager, G; Lupi, O; Schwartz, RA				Hengge, Ulrich R.; Currie, Bart J.; Jaeger, Gerold; Lupi, Omar; Schwartz, Robert A.			Scabies: a ubiquitous neglected skin disease	LANCET INFECTIOUS DISEASES			English	Review							CRUSTED NORWEGIAN SCABIES; HOUSE-DUST MITE; TEA TREE OIL; SARCOPTES-SCABIEI; DERMATOPHAGOIDES-PTERONYSSINUS; ORAL IVERMECTIN; IN-VITRO; NOSOCOMIAL OUTBREAK; NORTHERN AUSTRALIA; EPIDEMIC SCABIES	Scabies has been a scourge among human beings for thousands of years. Its worldwide occurrence with epidemics during war, famine, and overcrowding is responsible for an estimated 300 million people currently infested. Scabies refers to the various skin lesions produced by female mites, and their eggs and scybala that are deposited in the epidermis, leading to delayed-type hypersensitivity reaction. Recent immunological findings such as cross-reactivity with house dust mite allergens and an altered T-helper-1/T-helper-2 pattern contribute to a better understanding of the pathomechanism. Furthermore, progress in molecular biology and cloning of relevant antigens could enable the development of a diagnostic ELISA system and candidate vaccines in the near future. Typical and atypical clinical presentations with pruritus as a hallmark of scabies occur in young, pregnant, immunocompromised, and elderly patients and include bullous and crusted (Norwegian) manifestations as well as those masked by steroid use (scabies incognito). This article reviews scabies management strategies in developed countries and resource-poor communities as well as typical complications, including the emergence of resistance and drug-related adverse events. Other problems such as post-scabies eczema and reinfestation, and newer treatments such as ivermectin are also discussed.	Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Charles Darwin Univ, Menzles Sch Hlth Res, Darwin, NT, Australia; Royal Darwin Hosp, No Terr Clin Sch, Darwin, NT, Australia; Ikonda HOsp, Njombe, Tanzania; Fed Univ State Rio de Janiero, Rio De Janeiro, Brazil; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Dermatol, Newark, NJ 07103 USA	Hengge, UR (reprint author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	ulrich.hengge@uni-duesseldorf.de					Adedayo O, 2003, POSTGRAD MED J, V79, P341, DOI 10.1136/pmj.79.932.341; Adjei O, 1997, E AFR MED J, V74, P729; ALEXANDER JO, 1984, ARTHROPODS HUMAN SKI, P227; Almeida Hiram Larangeira de Jr, 2005, J Am Acad Dermatol, V53, P357; Antony R, 1982, Indian J Public Health, V26, P108; Arlian LG, 2004, J MED ENTOMOL, V41, P74, DOI 10.1603/0022-2585-41.1.74; ARLIAN LG, 1995, AM J TROP MED HYG, V52, P539; ARLIAN LG, 1991, J INVEST DERMATOL, V96, P349, DOI 10.1111/1523-1747.ep12465257; AUBIN F, 1995, NEW ENGL J MED, V332, P612, DOI 10.1056/NEJM199503023320917; Austad Steven N., 1997, ILAR J, V38, P137; Badiaga S, 2005, EUR J DERMATOL, V15, P382; Barkwell R, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63020-6; Birrell G, 2000, LANCET, V356, P1084, DOI 10.1016/S0140-6736(00)02739-2; Blas M, 2005, AM J TROP MED HYG, V72, P855; Boix V, 1997, INFECT CONT HOSP EP, V18, P677; BOWEN R, 1951, South Med J, V44, P836; BURGESS I, 1994, ADV PARASIT, V33, P235, DOI 10.1016/S0065-308X(08)60414-5; BURKHART CG, 1983, ANN INTERN MED, V98, P498; CABRERA R, 1993, SEMIN DERMATOL, V12, P15; Cargill CF, 1997, VET PARASITOL, V70, P191, DOI 10.1016/S0304-4017(96)01137-5; Carson CF, 2006, CLIN MICROBIOL REV, V19, P50, DOI 10.1128/CMR.19.1.50-62.2006; Chosidow O, 2000, LANCET, V355, P819, DOI 10.1016/S0140-6736(99)09458-1; Chouela EN, 1999, ARCH DERMATOL, V135, P651, DOI 10.1001/archderm.135.6.651; CHRISTOPHERSEN J, 1978, ARCH DERMATOL, V114, P747, DOI 10.1001/archderm.114.5.747; Coleman CI, 2005, PHARMACOTHERAPY, V25, P448, DOI 10.1592/phco.25.3.448.61596; Corbett EL, 1996, GENITOURIN MED, V72, P115; COSKEY RJ, 1979, ARCH DERMATOL, V115, P109; Currie B, 1997, LANCET, V350, P1551, DOI 10.1016/S0140-6736(05)63983-9; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; Currie BJ, 2004, CLIN INFECT DIS, V39, pE8, DOI 10.1086/421776; CURRIE BJ, 1994, MED J AUSTRALIA, V161, P636; Davies J E, 1983, Arch Dermatol, V119, P142; del Giudice P, 1999, ARCH DERMATOL, V135, P705, DOI 10.1001/archderm.135.6.705; Dent JA, 1997, EMBO J, V16, P5867, DOI 10.1093/emboj/16.19.5867; Dougall A, 2005, AM J TROP MED HYG, V73, P977; Dourmishev A, 1998, J EUR ACAD DERMATOL, V11, P247, DOI 10.1016/S0926-9959(98)00075-0; Dourmishev AL, 2005, INT J DERMATOL, V44, P981, DOI 10.1111/j.1365-4632.2004.02253.x; Dourmishev AL, 1998, INT J DERMATOL, V37, P231; ESTES SA, 1993, SEMIN DERMATOL, V12, P26; ESTES SA, 1993, SEMIN DERMATOL, V12, P34; FAIN A, 1978, INT J DERMATOL, V17, P20, DOI 10.1111/j.1365-4362.1978.tb06040.x; FALK ES, 1981, ALLERGY, V36, P233, DOI 10.1111/j.1398-9995.1981.tb01568.x; FALK ES, 1980, BRIT J DERMATOL, V103, P283, DOI 10.1111/j.1365-2133.1980.tb07245.x; Fischer K, 2003, AM J TROP MED HYG, V68, P61; Gardon J, 1997, LANCET, V350, P18, DOI 10.1016/S0140-6736(96)11094-1; GEORGHIOU GP, 1990, ACS SYM SER, V421, P18; GLAZIOU P, 1993, TROP MED PARASITOL, V44, P331; GLOVER R, 1987, J AM ACAD DERMATOL, V16, P396, DOI 10.1016/S0190-9622(87)80145-7; HAAG ML, 1993, GERIATRICS, V48, P45; HENDERSON CA, 1992, TROP DOCT, V22, P165; Henderson CA, 1996, INT J DERMATOL, V35, P640, DOI 10.1111/j.1365-4362.1996.tb03688.x; HERNANDEZPEREZ E, 1983, J AM ACAD DERMATOL, V8, P121, DOI 10.1016/S0190-9622(83)80285-0; Heukelbach J, 2004, B WORLD HEALTH ORGAN, V82, P563; Heukelbach J, 2003, TROP MED INT HEALTH, V8, P368, DOI 10.1046/j.1365-3156.2003.01038.x; Heukelbach Jörg, 2003, Cad. Saúde Pública, V19, P1535, DOI 10.1590/S0102-311X2003000500032; HOLNESS DL, 1992, ARCH DERMATOL, V128, P1257, DOI 10.1001/archderm.128.9.1257; Holt DC, 2003, J INVEST DERMATOL, V121, P1419, DOI 10.1046/j.1523-1747.2003.12621.x; Huffam S E, 1998, Int J Infect Dis, V2, P152, DOI 10.1016/S1201-9712(98)90118-7; Jaramillo-Ayerbe F, 1998, ARCH DERMATOL, V134, P143, DOI 10.1001/archderm.134.2.143; KOLAR KA, 1991, AM FAM PHYSICIAN, V44, P1317; Landwehr D, 1998, INT J DERMATOL, V37, P588, DOI 10.1046/j.1365-4362.1998.00367.x; Lawrence G, 2005, B WORLD HEALTH ORGAN, V83, P34; Leekassa R, 2005, ETHIOPIAN MED J, V43, P189; Leppard B, 2000, BRIT J DERMATOL, V143, P520, DOI 10.1111/j.1365-2133.2000.03704.x; MARTY P, 1994, ANN TROP MED PARASIT, V88, P453; McCarthy JS, 2004, POSTGRAD MED J, V80, P382, DOI 10.1136/pgmj.2003.014563; MCKOY R, 1991, DERMATOLOGY, P189; MEINKING TL, 1995, NEW ENGL J MED, V333, P26, DOI 10.1056/NEJM199507063330105; Mellanby Kenneth, 1944, PARASITOLOGY, V35, P197; Menzano A, 2004, VET REC, V155, P568; Micali G, 1999, ACTA DERM-VENEREOL, V79, P396; Mimouni D, 2003, BRIT J DERMATOL, V149, P157, DOI 10.1046/j.1365-2133.2003.05329.x; Mitra M, 1995, J Indian Med Assoc, V93, P142; MONTESU MA, 1991, AM J DERMATOPATH, V13, P425; NAIR BKH, 1977, INDIAN J MED RES, V65, P513; ODONNELL BF, 1990, INT J DERMATOL, V29, P258, DOI 10.1111/j.1365-4362.1990.tb02557.x; Ogunbiyi AO, 2005, PEDIATR DERMATOL, V22, P6, DOI 10.1111/j.1525-1470.2005.22101.x; Oladimeji FA, 2000, J ETHNOPHARMACOL, V72, P305, DOI 10.1016/S0378-8741(00)00229-4; ORKIN M, 1995, CURR PROBL DERMATOL, V22, P105; Paasch U, 2000, INT J DERMATOL, V39, P463, DOI 10.1046/j.1365-4362.2000.00990.x; PACQUE M, 1990, LANCET, V335, P1377, DOI 10.1016/0140-6736(90)91253-7; Pannell RS, 2005, EPIDEMIOL INFECT, V133, P985, DOI 10.1017/S0950268805004425; Patel A, 1999, Australas J Dermatol, V40, P37, DOI 10.1046/j.1440-0960.1999.00314.x; Pence DB, 2002, REV SCI TECH OIE, V21, P385; Pettersson EU, 2005, INT J PARASITOL, V35, P39, DOI 10.1016/j.ijpara.2004.09.006; REID HFM, 1990, EPIDEMIOL INFECT, V105, P595; Roberts LJ, 2005, J INFECTION, V50, P375, DOI 10.1016/j.jinf.2004.08.033; Sachdev T R, 1982, J Indian Assoc Commun Dis, V5, P88; Savin JA, 2005, J ROY SOC MED, V98, P124, DOI 10.1258/jrsm.98.3.124; Shahab RKA, 2003, J AM ACAD DERMATOL, V49, P346, DOI 10.1067/S0190-9622(03)00876-4; Steen CJ, 2004, J AM ACAD DERMATOL, V50, P819, DOI 10.1016/j.jaad.2003.12.019; STERLING GB, 1992, AM FAM PHYSICIAN, V46, P1237; STEWART GA, 1992, IMMUNOLOGY, V75, P29; Stibich AS, 2001, CUTIS, V68, P89; Sullivan J R, 1997, Australas J Dermatol, V38, P137, DOI 10.1111/j.1440-0960.1997.tb01130.x; Sun G, 2001, J IMMUNOL, V167, P1014; SVARTMAN M, 1972, LANCET, V1, P249; Sweitzer SE, 1941, ARCH DERMATOL SYPH, V43, P678; TAPLIN D, 1991, LANCET, V337, P1016; TAPLIN D, 1990, PEDIATR DERMATOL, V7, P67, DOI 10.1111/j.1525-1470.1990.tb01078.x; Tarigan S, 2005, VET PARASITOL, V133, P101, DOI 10.1016/j.vetpar.2005.03.044; Terry BC, 2001, PUBLIC HEALTH, V115, P208, DOI 10.1016/S0033-3506(01)00445-0; Tomalik-Scharte D, 2005, EUR J CLIN PHARMACOL, V61, P399, DOI 10.1007/s00228-005-0932-7; Tsutsumi M, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-85; Usha V, 2000, J AM ACAD DERMATOL, V42, P236, DOI 10.1016/S0190-9622(00)90131-2; van der Heijden HMJF, 2000, VET PARASITOL, V89, P95, DOI 10.1016/S0304-4017(00)00197-7; Van Hee R, 2005, Rev Med Brux, V26, P475; Veraldi S, 1996, ACTA DERM-VENEREOL, V76, P167; Walker GJA, 2006, COCHRAN  DATABASE SY, V3; Walton SF, 1999, AM J TROP MED HYG, V61, P542; Walton SF, 2000, T ROY SOC TROP MED H, V94, P92, DOI 10.1016/S0035-9203(00)90454-1; Walton SF, 1999, CLIN INFECT DIS, V29, P1226, DOI 10.1086/313466; Walton SF, 2004, INT J PARASITOL, V34, P839, DOI 10.1016/j.ijpara.2004.04.002; Walton SF, 2004, ARCH DERMATOL, V140, P563, DOI 10.1001/archderm.140.5.563; WILCKE T, 2002, ACTA TROPICA S1, V83, pS100; WITKOWSKI JA, 1992, J AM ACAD DERMATOL, V27, P648, DOI 10.1016/S0190-9622(08)80213-7; Wong Li-Chuen, 2002, Australas J Dermatol, V43, P274, DOI 10.1046/j.1440-0960.2002.00626.x; WOODLEY D, 1981, J AM ACAD DERMATOL, V4, P715	118	121	128	0	21	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1473-3099			LANCET INFECT DIS	Lancet Infect. Dis.	DEC	2006	6	12					769	779		10.1016/S1473-3099(06)70654-5		11	Infectious Diseases	Infectious Diseases	110JV	WOS:000242375500019	17123897	
J	Rolinck-Werninghaus, C; Staden, U; Mehl, A; Hamelmann, E; Beyer, K; Niggemann, B				Rolinck-Werninghaus, C; Staden, U; Mehl, A; Hamelmann, E; Beyer, K; Niggemann, B			Specific oral tolerance induction with food in children: transient or persistent effect on food allergy?	ALLERGY			English	Article						children; food allergy; specific oral tolerance induction		Background: The standard treatment of food allergy is elimination of the incriminated food from the diet. Specific oral tolerance induction (SOTI) seems to be a promising approach for a causal treatment; however, it is unclear whether the tolerance achieved is transient or persistent. We report on a subset of three patients of a larger ongoing study who were treated successfully with SOTI treatment, but experienced a secondary loss of tolerance after a period of allergen avoidance. Methods: The patients suffered from IgE-mediated allergy either to cow's milk (CM) (patient A) or hen's egg (HE) (patients B and C), confirmed by double-blind, placebo-controlled food challenge (DBPCFC). SOTI treatment was performed at home on a daily basis until tolerance to a maximum of 250 ml CM or 4.5 g lyophilized HE protein was achieved. The daily maintenance dose was 100 ml CM or 2.5 g HE protein. Results: Patients A, B and C reached tolerance to the maximum dose after 37, 41 and 52 weeks, respectively. According to the protocol, patients A and B performed a strict secondary elimination diet for 2 months prior to a follow-up DBPCFC after a maintenance phase of 27 and 39 weeks, respectively. Patient C discontinued treatment for 2 days after 4 weeks on the maintenance dose. Despite previous tolerance, on re-exposure to the allergen all patients experienced moderate systemic allergic reactions. Conclusions: We conclude that SOTI can induce transient tolerance in food allergy, but does not necessarily lead to its permanent abrogation. Regular allergen intake seems necessary to maintain the established tolerance.	Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany	Niggemann, B (reprint author), Humboldt Univ, Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						Eigenmann PA, 2003, ALLERGY, V58, P1217, DOI 10.1046/j.1398-9995.2003.00303.x; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x	5	121	124	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	OCT	2005	60	10					1320	1322		10.1111/j.1398-9995.2005.00882.x		3	Allergy; Immunology	Allergy; Immunology	960BS	WOS:000231565800016	16135001	
J	Schmid-Grendelmeier, P; Fluckiger, S; Disch, R; Trautmann, A; Wuthrich, B; Blaser, K; Scheynius, A; Crameri, R				Schmid-Grendelmeier, P; Fluckiger, S; Disch, R; Trautmann, A; Wuthrich, B; Blaser, K; Scheynius, A; Crameri, R			IgE-mediated and T cell-mediated autoimmunity against manganese superoxide dismutase in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						autoallergy; Aspergillus fumigatus; atopic dermatitis; atopy; fungi; Malassezia sympodialis; intrinsic type; nonatopic eczema; recombinant allergens	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; FUMIGATUS ALLERGENS; PATCH TEST; MALASSEZIA; DISEASE; AUTOANTIBODIES; ITRACONAZOLE; REACTIVITY; RESPONSES; CLONING	Background: Autoreactivity of patients with atopic dermatitis (AD) to human proteins has been postulated as a decisive pathogenetic factor for AD. Objective: In this study, it was investigated whether the stress-inducible enzyme manganese superoxide dismutase (MnSOD) of human and fungal origin might act as an autoallergen in atopic dermatitis. Methods: Patients with AD (n = 69; mean SCORAD [SCORing Atopic Dermatitis], 27) and other inflammatory skin diseases as well as with inhalant allergies were investigated. The presence of specific IgE against recombinant MnSOD of fungal and human origin and the fungal extracts of Aspergillus fumigatus and Malassezia sympodialis was measured by CAP, ELISA, skin prick test, and in subset of patients also by atopy patch tests (APTs) and PBMC proliferation assays. Cross-reactivity between allergens was determined by CAP inhibition. The presence of MnSOD in human skin in various inflammatory skin conditions was investigated by immunohistochemistry. Results: Specific IgE antibodies against human MnSOD correlating with the disease activity were found in 29 out of 67 patients with AD. The human protein was able to induce in vitro T-cell reactivity and eczematous reactions in APT in MnSOD-sensitized patients with AD. MnSOD was upregulated in various inflammatory skin reactions and APT skin specimens. Cosensitization to structurally related and cross-reacting fungal MnSOD and the skin-colonizing yeast M sympodialis was observed in all patients sensitized against human MnSOD. Conclusion: Human MnSOD may play a role as an autoallergen in a subset of patients with AD, including nonatopic eczema. By molecular mimicry leading to cross-reactivity such sensitization might be induced primarily by exposure to environmental fungal MnSOD of M sympodialis.	Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; BioVisioN Schweiz AG, Davos, Switzerland; Alexanderhaus Klin, Davos, Switzerland; Karolinska Hosp & Inst, Dept Med, Unit Clin Allergy Res, Stockholm, Sweden	Schmid-Grendelmeier, P (reprint author), Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Gloriastr 31, CH-8091 Zurich, Switzerland.	peter.schmid@usz.ch					Andersson A, 2004, EUR J BIOCHEM, V271, P1885, DOI 10.1111/j.1432-1033.2004.04098.x; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Fluckiger S, 2002, J IMMUNOL, V168, P1267; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.3.CO;2-Y; Hemmann S, 1999, J ALLERGY CLIN IMMUN, V104, P601, DOI 10.1016/S0091-6749(99)70330-1; HIROSE K, 1993, FASEB J, V7, P361; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Ikezawa Z, 2004, EUR J DERMATOL, V14, P400; JANSSEN YMW, 1993, LAB INVEST, V69, P261; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kinaciyan T, 2002, J ALLERGY CLIN IMMUN, V109, P717, DOI 10.1067/mai.2002.123303; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Linder MT, 2000, CLIN EXP ALLERGY, V30, P122, DOI 10.1046/j.1365-2222.2000.00702.x; Lintu P, 2001, ALLERGY, V56, P512, DOI 10.1034/j.1398-9995.2001.056006512.x; MacMillan-Crow LA, 2001, FREE RADICAL RES, V34, P325, DOI 10.1080/10715760100300281; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; Mayer C, 1997, INT ARCH ALLERGY IMM, V113, P213; Nakabayashi A, 2000, MED MYCOL, V38, P337, DOI 10.1080/714030958; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Ochs RL, 2000, J ALLERGY CLIN IMMUN, V105, P1211, DOI 10.1067/mai.2000.107039; Omata N, 2001, LIFE SCI, V69, P223, DOI 10.1016/S0024-3205(01)01124-9; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Patterson R, 2000, CHEST, V118, P7, DOI 10.1378/chest.118.1.7; Poswig A, 1999, J INVEST DERMATOL, V112, P13, DOI 10.1046/j.1523-1747.1999.00465.x; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; SCHMIDGRENDELMEIER, 2001, INT ARCH ALLERGY IMM, V125, P96; Svejgaard EI, 2004, J EUR ACAD DERMATOL, V18, P445, DOI 10.1111/j.1468-3083.2004.00963.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, TRENDS IMMUNOL, V22, P530, DOI 10.1016/S1471-4906(01)02004-X; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Werfel T, 1998, ALLERGY, V53, P731; [Anonymous], 1992, ALLERGY, V47, P1; 1993, CONSENSUS REPORT EUR, V186, P23	38	121	128	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1068	1075		10.1016/j.jaci.2005.01.065		8	Allergy; Immunology	Allergy; Immunology	925LR	WOS:000229055100026	15867868	
J	Miller, RL; Garfinkel, R; Horton, M; Camann, D; Pereral, FP; Whyatt, RM; Kinney, PL				Miller, RL; Garfinkel, R; Horton, M; Camann, D; Pereral, FP; Whyatt, RM; Kinney, PL			Polycyclic aromatic hydrocarbons, environmental tobacco smoke, and respiratory symptoms in an inner-city birth cohort	CHEST			English	Article						asthma; environmental tobacco smoke; polycyclic aromatic hydrocarbons	DIESEL EXHAUST PARTICLES; CIGARETTE-SMOKE; LUNG-FUNCTION; AIR-POLLUTION; EXPOSURE; ALLERGEN; CHALLENGE; MICE; IGE; PARTICULATE	Study objectives: Several studies have found associations between diesel exposure, respiratory symptoms, and/or impaired pulmonary function. We hypothesized that prenatal exposure to airborne polycyclic aromatic hydrocarbons (PAH), important components of diesel exhaust and other combustion sources, may be associated with respiratory symptoms in young children. We also hypothesized that exposure to environmental tobacco smoke (ETS) may worsen symptoms beyond that observed to be associated with PAH alone. Design/participants: To test our hypotheses, we recruited 303 pregnant women from northern Manhattan believed to be at high risk for exposure to both PAH and ETS, collected 48-h personal PAH exposure measurements, and monitored their children prospectively. Results: By 12 months of age, more cough and wheeze were reported in children exposed to prenatal PAH in concert with ETS postnatally (PAH X ETS interaction odds ratios [ORs], 1.41 [p < 0.01] and 1.29 [p < 0.05], respectively). By 24 months, difficulty breathing and probable asthma were reported more frequently among children exposed to prenatal PAH and ETS postnatally (PAR X ETS ORs, 1.54 and 1.64, respectively [p < 0.05]). Conclusions: Our results suggest that early exposure to airborne PAH and ETS can lead to increased respiratory symptoms and probable asthma by age 12 to 24 months. Interventions to lower the risk of respiratory disease in young children living in the inner city may need to address the importance of multiple environmental exposures.	Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy Crit Care Med, New York, NY USA; Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY USA; SW Res Inst, Dept Analyt & Environm Chem, San Antonio, TX USA	Miller, RL (reprint author), 630 168th St, New York, NY 10032 USA.	rlm14@columbia.edu	Kinney, Patrick/H-7914-2012		NCRR NIH HHS [M01 RR000645, RR 00645]; NIEHS NIH HHS [R01 ES008977, 5R01 ES 08977, P01 ES009600, P01 ES009600-060005, P01 ES009600-070005, P01 ES009600-080005, P01 ES009600-090005, P30 ES 09089, P30 ES009089, P501 ES 09600, R01 ES 012468, R01 ES 11115 8, R01 ES012468]		BARKER DJP, 1989, LANCET, V2, P577; Bernert JT, 2000, J ANAL TOXICOL, V24, P333; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111; COULTAS DB, 1989, AM J EPIDEMIOL, V130, P338; Dempsey D, 2002, J PHARMACOL EXP THER, V301, P594, DOI 10.1124/jpet.301.2.594; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Georgiadis P, 2001, CARCINOGENESIS, V22, P1447, DOI 10.1093/carcin/22.9.1447; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Hamada K, 2003, J IMMUNOL, V170, P1683; HAMADA K, 2003, AM J RESP CRIT CARE, V167, pA942; Harrod KS, 2003, AM J RESP CELL MOL, V28, P451, DOI 10.1165/rcmb.2002-0100OC; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Kanoh T, 1996, J Clin Lab Immunol, V48, P133; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Lum S, 2001, AM J RESP CRIT CARE, V164, P2078; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; MENON P, 1992, J ALLERGY CLIN IMMUN, V89, P560, DOI 10.1016/0091-6749(92)90323-T; Northridge ME, 1999, AM J PUBLIC HEALTH, V89, P998, DOI 10.2105/AJPH.89.7.998; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perera FP, 1998, AM J EPIDEMIOL, V147, P309; Perera FP, 2002, ENVIRON HEALTH PERSP, V110, P197; RAUH V, 2002, ENV HLTH PERSPECT, V10, P323; ROMAGNANI, 1998, ALLERGY S, V46, P12; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; United Church of Christ. Commission for Racial Justice, 1987, TOX WAST RAC US NAT; WHITEKUS MJ, 2002, THE J IMMUNOL, V168, P2560; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yu M, 2002, TOXICOL SCI, V65, P99, DOI 10.1093/toxsci/65.1.99	38	121	129	6	18	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	OCT	2004	126	4					1071	1078		10.1378/chest.126.4.1071		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	864ZY	WOS:000224673100017	15486366	
J	Rana, JS; Mittleman, MA; Sheikh, J; Hu, FB; Manson, JE; Colditz, GA; Speizer, FE; Barr, RG; Camargo, CA				Rana, JS; Mittleman, MA; Sheikh, J; Hu, FB; Manson, JE; Colditz, GA; Speizer, FE; Barr, RG; Camargo, CA			Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women	DIABETES CARE			English	Article							TUMOR-NECROSIS-FACTOR; C-REACTIVE PROTEIN; INSULIN-RESISTANCE; OXIDATIVE STRESS; GENE-TRANSCRIPTION; LUNG-FUNCTION; TNF-ALPHA; MELLITUS; WEIGHT; COHORT	OBJECTIVE - Inflammation plays a key role in chronic obstructive pulmonary disease (COPD) and asthma. Increasing evidence points toward a role of inflammation in the pathogenesis of type 2 diabetes. We wanted to determine the relation of COPD and asthma with the development of type 2 diabetes. RESEARCH DESIGN AND METHODS - The Nurses' Health Study is a prospective cohort study. From 1988-1996, 103,614 female nurses were asked biennially about a physician diagnosis of emphysema, chronic bronchitis, asthma, and diabetes. RESULTS - During 8 years of follow-up, we documented a total of 2,959 new cases of type 2 diabetes. The risk of type 2 diabetes was significantly higher for patients with COPD than those without (multivariate relative risk 1.8, 95% CI 1.1-2.8). By contrast, the risk of type 2 diabetes among asthmatic patients was not increased (1.0, 0.8-1.2). The asthma results remained non-significant even when we evaluated diabetes risk by duration of asthma exposure. CONCLUSIONS - Our findings suggest that COPD may be a risk factor for developing type 2 diabetes. Differences in the inflammation and cytokine profile between COPD and asthma might explain why COPD, but not asthma, is associated with increased risk of type 2 diabetes.	Beth Israel Deaconess Med Ctr, Div Cardiol, Dept Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Allergy & Inflammat, Dept Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Brigham & Womens Hosp, Div Prevent Med, Dept Med,Med Sch, Boston, MA USA; Columbia Presbyterian Med Ctr, Dept Med, Div Gen Med, New York, NY USA; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA	Camargo, CA (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	ccamargo@partners.org	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NCI NIH HHS [R01 CA87969]; NHLBI NIH HHS [R01 HL63841, T32 HL07374, T32 HL07427]; NIDDK NIH HHS [R01 DK58845]		Anto JM, 2001, EUR RESPIR J, V17, P982, DOI 10.1183/09031936.01.17509820; Barnes Peter J., 2000, Chest, V117, p10S, DOI 10.1378/chest.117.2_suppl.10S; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Barr RG, 2002, AM J EPIDEMIOL, V155, P965, DOI 10.1093/aje/155.10.965; Blackburn D, 2002, J GEN INTERN MED, V17, P717, DOI 10.1046/j.1525-1497.2002.10649.x; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; Chung K. F., 2007, EUR RESPIR J, V34, p50s, DOI DOI 10.1183/09031936.01.00229701); Congleton J, 1999, P NUTR SOC, V58, P321, DOI 10.1017/S0029665199000439; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372; CREUTZBERG EC, 2004, EUR RESP J S46, V22, pS76; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; Eid AA, 2001, AM J RESP CRIT CARE, V164, P1414; Engstrom G, 2003, J INTERN MED, V253, P574, DOI 10.1046/j.1365-2796.2003.01138.x; Engstrom G, 2002, DIABETIC MED, V19, P167, DOI 10.1046/j.1464-5491.2002.00652.x; Festa A, 2002, DIABETES, V51, P1131, DOI 10.2337/diabetes.51.4.1131; Gavin JR, 1997, DIABETES CARE, V20, P1183; Grimble RF, 2002, CURR OPIN CLIN NUTR, V5, P551, DOI 10.1097/00075197-200209000-00015; GURWITZ JH, 1994, ARCH INTERN MED, V154, P97, DOI 10.1001/archinte.154.1.97; HARRIS M, 1979, DIABETES, V28, P1039; Hjalmarsen A, 1996, DIABETES METAB, V22, P37; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; Hu FB, 2004, DIABETES, V53, P693, DOI 10.2337/diabetes.53.3.693; Hu FB, 2001, NEW ENGL J MED, V345, P790, DOI 10.1056/NEJMoa010492; JAKOBSSON P, 1995, CLIN PHYSIOL, V15, P319, DOI 10.1111/j.1475-097X.1995.tb00522.x; JAKOBSSON P, 1995, CLIN PHYSIOL, V15, P547, DOI 10.1111/j.1475-097X.1995.tb00543.x; Lazarus R, 1998, EUR RESPIR J, V12, P641, DOI 10.1183/09031936.98.12030641; Mador MJ, 2002, AM J RESP CRIT CARE, V166, P787, DOI 10.1164/rccm.2206003; Majori M, 1999, J ALLERGY CLIN IMMUN, V103, P458, DOI 10.1016/S0091-6749(99)70471-9; Mannino DM, 2003, AM J MED, V114, P758, DOI 10.1016/S0002-9343(03)00185-2; MANSON JE, 1991, LANCET, V338, P774, DOI 10.1016/0140-6736(91)90664-B; Pauwels R A, 2001, Respir Care, V46, P798; Pitsiou G, 2002, RESP MED, V96, P594, DOI 10.1053/rmed.2002.1322; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; RIMM EB, 1993, AM J PUBLIC HEALTH, V83, P211, DOI 10.2105/AJPH.83.2.211; Rosen P, 2001, DIABETES METAB RES, V17, P189, DOI 10.1002/dmrr.196; Schols A M W J, 2003, Eur Respir J Suppl, V46, p81s; Schols AMWJ, 1996, THORAX, V51, P819, DOI 10.1136/thx.51.8.819; Spranger J, 2003, DIABETES, V52, P812, DOI 10.2337/diabetes.52.3.812; Takabatake N, 2000, AM J RESP CRIT CARE, V161, P1179; Thorand B, 2003, ARCH INTERN MED, V163, P93, DOI 10.1001/archinte.163.1.93; Vermeeren MAP, 1997, EUR RESPIR J, V10, P2264, DOI 10.1183/09031936.97.10102264; Wouters EFM, 2002, THORAX, V57, P1067, DOI 10.1136/thorax.57.12.1067	47	121	132	1	4	AMER DIABETES ASSOC	ALEXANDRIA	1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA	0149-5992			DIABETES CARE	Diabetes Care	OCT	2004	27	10					2478	2484		10.2337/diacare.27.10.2478		7	Endocrinology & Metabolism	Endocrinology & Metabolism	857KQ	WOS:000224115700030	15451919	
J	Wallace, LA; Mitchell, H; O'Connor, GT; Neas, L; Lippmann, M; Kattan, M; Koenig, J; Stout, JW; Vaughn, BJ; Wallace, D; Walter, M; Adams, K; Liu, LJS				Wallace, LA; Mitchell, H; O'Connor, GT; Neas, L; Lippmann, M; Kattan, M; Koenig, J; Stout, JW; Vaughn, BJ; Wallace, D; Walter, M; Adams, K; Liu, LJS			Particle concentrations in inner-city homes of children with asthma: The effect of smoking, cooking, and outdoor pollution	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						continuous monitors; environmental tobacco smoke; gravimetric measurements; indoor air; MIE pDR; optical scattering; PM10; PM2.5	PARTICULATE AIR-POLLUTION; PERSONAL EXPOSURE; FINE PARTICLES; HOSPITAL ADMISSIONS; AIRBORNE PARTICLES; INDOOR; SEATTLE; BALTIMORE; MATTER; EPIDEMIOLOGY	inner-city children have high rates of asthma. Exposures to particles, including allergens, may cause or exacerbate asthma symptoms. As part of an epidemiologic study of inner-city children with asthma, continuous (10-min average) measurements of particle concentrations were made for 2-week periods in 294 homes drawn from seven cities. Measurements were made using an optical scattering device that is most sensitive to fine particles. The concentrations recorded by these devices were corrected to agree with colocated outdoor gravimetric PM2.5 monitors. Indoor concentrations in the homes averaged 27.7 (standard deviation = 35.9) mug/m(3), compared with concurrent outdoor concentrations of 13.6 (7.5) mug/m(3). A multivariate model indicated that outdoor particles penetrated indoors with an efficiency of 0.48 and were therefore responsible for only 25% of the mean indoor concentration. The major indoor source was smoking, which elevated indoor concentrations by 37 mug/m(3) in the 10 1 homes with smokers. Other significant sources included frying, smoky cooking events, use of incense, and apartment housing, although the increases due to these events ranged only from 3 to 6 mug/m(3). The 10-min averaging time allowed calculation of an average diurnal variation, showing large increases in the evening due to smoking and smaller increases at meal times due to cooking. Most of the observed variance in indoor concentrations was day to day, with roughly similar contributions to the variance from visit to visit and home to home within a city and only a small contribution made by variance among cities. The small variation among cities and the similarity across cities of the observed indoor air particle distributions suggest that sources of indoor concentrations do not vary considerably from one city to the next, and thus that simple models can predict indoor air concentrations in cities having only outdoor measurements.	US EPA, Reston, VA 20191 USA; Rho Inc, Chapel Hill, NC USA; Boston Univ, Boston, MA 02215 USA; US EPA, Res Triangle Pk, NC 27711 USA; NYU, Sch Med, Tuxedo Pk, NY 10987 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA; Univ Washington, Seattle, WA 98195 USA; NIAID, Bethesda, MD 20892 USA	Wallace, LA (reprint author), US EPA, 11568 Woodhollow Ct, Reston, VA 20191 USA.		Neas, Lucas/J-9378-2012; Wallace, Lance/K-7264-2013	O'Connor, George/0000-0002-6476-3926; Wallace, Lance/0000-0002-6635-2303	NIAID NIH HHS [AI-39789, AI-39761, AI-39769, AI-39776, AI-39785, AI-39900, AI-39901, AI-39902]		BAHADORI T, IN PRESS J EXPO ANAL; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; DOCKERY DW, 1981, JAPCA J AIR WASTE MA, V31, P153; HIGHSMITH VR, 1988, ENVIRON SCI TECHNOL, V22, P1109, DOI 10.1021/es00174a019; Howard-Reed C, 2000, J AIR WASTE MANAGE, V50, P1125; Janssen NAH, 1999, ARCH ENVIRON HEALTH, V54, P95; Janssen NAH, 1998, AM J EPIDEMIOL, V147, P537; Janssen NAH, 1997, OCCUP ENVIRON MED, V54, P888; Jetter JJ, 2002, SCI TOTAL ENVIRON, V295, P51, DOI 10.1016/S0048-9697(02)00043-8; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KELLY TJ, 2001, 5083 GAS RES I; KLEPEIS N, 1995, 68017325 US EPA; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; LIOY PJ, 1990, ATMOS ENVIRON B-URB, V24, P57, DOI 10.1016/0957-1272(90)90010-R; Liu LJS, 2003, ENVIRON HEALTH PERSP, V111, P909, DOI 10.1289/ehp.6011; Liu LJS, 2002, ENVIRON SCI TECHNOL, V36, P2977, DOI 10.1021/es0112644; Long CM, 2001, ENVIRON HEALTH PERSP, V109, P1019, DOI 10.2307/3454956; *MIE, 1998, 8A MIE; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Ott W, 2000, J AIR WASTE MANAGE, V50, P1390; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; PELLIZZARI ED, 1993, PARTICLE TOTAL EXPOS, V1; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; Quintana PJE, 2001, ENVIRON RES, V87, P199, DOI 10.1006/enrs.2001.4304; ROJASBRACHO L, 2000, SCI TOTAL ENVIRON, V287, P249; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; SHELDON LS, 1989, 736CONBCS85 NEW YORK; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Sioutas C, 2000, ATMOS ENVIRON, V34, P4829, DOI 10.1016/S1352-2310(00)00244-2; SPENGLER JD, 1981, ATMOS ENVIRON, V15, P23, DOI 10.1016/0004-6981(81)90121-9; *US EPA, 2002, 600P99002AC2V EPA; *US EPA, 1996, 600P95001AFCF3V EPA; EPA U.S., 2001, NAT AIR QUAL EM TREN; WALLACE LA, 2002, J AIR WASTE MANAGE, V52, P174; WALLACE LA, 2000, APPL OCCUP ENV HYG, V15, P1; WALLACE LA, 2002, ANN M INT SOC EXP AN; Williams R, 2000, ATMOS ENVIRON, V34, P4193, DOI 10.1016/S1352-2310(00)00209-0; Wilson AL, 1996, J EXPO ANAL ENV EPID, V6, P311; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; 1997, FED REG, V62, P57	46	121	124	5	33	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2003	111	9					1265	1272		10.1289/ehp.6135		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	715VH	WOS:000184992700041	12842784	
J	Holzer, K; Anderson, SD; Douglass, J				Holzer, K; Anderson, SD; Douglass, J			Exercise in elite summer athletes: Challenges for diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eucapnic hyperpnea; elite athletes; methacholine challenge	EUCAPNIC VOLUNTARY HYPERVENTILATION; INDUCED ASTHMA; BRONCHIAL RESPONSIVENESS; INDUCED BRONCHOSPASM; HYPERTONIC SALINE; REACTIVITY; CHILDREN; METHACHOLINE; PROVOCATION; SALBUTAMOL	Background: There is a high prevalence of asthma and exercise-induced bronchoconstriction (EIB) in elite athletes when the diagnosis is based on symptoms and medication use. Objective measurements are now required by some sporting bodies to support a diagnosis of asthma or EIB to justify use of beta-agonists. Such measurements could include bronchial provocation with methacholine, with eucapnic voluntary hyperpnea (EVH) of dry air (a surrogate for exercise), or both. Objective: The aim of the study was to investigate the relationship between asthma symptoms and responses to methacholine and the EVH challenge in a group of unselected elite summer-sport athletes. The outcome would be to inform practitioners of a suitable objective approach to identifying those with asthma and EIB. Methods: Fifty elite summer-sport athletes with or without asthma were recruited from sporting teams and sports medicine centers throughout Melbourne, Australia. All subjects completed a respiratory questionnaire and, on separate days, underwent a bronchoprovocation challenge test with methacholine and EVH. Results: Forty-two subjects reported one or more respiratory symptoms in the past year, 9 had positive methacholine challenge results (mean PD20 of 1.69 +/- 2.05 mumol), and 25 had posit e EVH challenge results (mean fall in FEV1 of 25.4% +/- 15%). Although all subjects with positive methacholine challenge results had positive EVH challenge results, methacholine had a negative predictive value of only 61% and a sensitivity of 36% for identifying those responsive to EVH. Conclusion: These findings suggest that the pathogenesis of EIB in elite athletes might be different from that of asthma, and as such, neither symptoms nor the methacholine challenge test should be used exclusively for identifying EIB.	Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia; Monash Univ, Prahran, Vic, Australia; Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia	Holzer, K (reprint author), Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahran, Vic 3181, Australia.			Anderson, Sandra/0000-0002-6308-8770			ABRAMSON MJ, 1990, THORAX, V45, P924, DOI 10.1136/thx.45.12.924; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; ARGYROS GJ, 1995, CHEST, V108, P419, DOI 10.1378/chest.108.2.419; BACKER V, 1992, CLIN EXP ALLERGY, V22, P741, DOI 10.1111/j.1365-2222.1992.tb02813.x; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; Eliasson AH, 1999, CHEST, V115, P608, DOI 10.1378/chest.115.3.608; Gravetter F. J., 2000, STAT BEHAV SCI; HABY MM, 1995, EUR RESPIR J, V8, P729; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; *INT OL MED COMM, 2002, BER 2 ADR AG OL WINT; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; PIPER PJ, 1984, PHYSIOL REV, V64, P744; Quanjer PH, 1993, EUR RESPIR J, V6, P16; RICE SG, 1985, ANN ALLERGY, V55, P790; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; RUPP NT, 1992, AM J DIS CHILD, V146, P941; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SMITH CM, 1990, EUR RESPIR J, V3, P144; SMITH CM, 1989, EUR RESPIR J, V2, P36; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P369; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; van Baak MA, 2000, MED SCI SPORT EXER, V32, P1300, DOI 10.1097/00005768-200007000-00018; van Grunsven PM, 1999, THORAX, V54, P316; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	35	121	126	2	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					374	380		10.1067/mai.2002.127784		7	Allergy; Immunology	Allergy; Immunology	592KM	WOS:000177936900005	12209082	
J	Thickett, KM; McCoach, JS; Gerber, JM; Sadhra, S; Burge, PS				Thickett, KM; McCoach, JS; Gerber, JM; Sadhra, S; Burge, PS			Occupational asthma caused by chloramines in indoor swimming-pool air	EUROPEAN RESPIRATORY JOURNAL			English	Article						bronchial provocation test; nitrogen trichloride; occupational asthma; peak expiratory flow; swimming pool	BRONCHIAL RESPONSIVENESS; WORKERS	The first series of three workers who developed occupational asthma following exposure to airborne chloramines in indoor chlorinated swimming pools is reported. Health problems of swimmers in indoor pools have traditionally been attributed to the chlorine in the water. Chlorine reacts with bodily proteins to form chloramines; the most volatile and prevalent in the air above swimming pools is nitrogen trichloride. Two lifeguards and one swimming teacher with symptoms suggestive of occupational asthma kept 2-hourly measurements of peak expiratory flow at home and at work, analysed using the occupational asthma system (OASYS) plotter, and/or had specific bronchial challenge testing to nitrogen trichloride, or a workplace challenge. Air measurement in one of the pools showed the nitrogen trichloride levels to be 0.1-0.57 mg.m(-3), which was similar to other studies. Two workers had peak expiratory flow measurements showing occupational asthma (OASYS-2 scores 2.88 and 3.8), both had a positive specific challenge to nitrogen trichloride at 0.5 mg.m(-3) with negative challenges to chlorine released from sodium hypochlorite. The third worker had a positive workplace challenge. Swimming-pool asthma due to airborne nitrogen trichloride can occur in workers who do not enter the water because of this chloramine. The air above indoor swimming pools therefore needs to be assessed and managed as carefully as the water.	Birmingham Heartlands Hosp, Dept Resp Med, Occupat Lung Dis Unit, Birmingham B5 5SS, W Midlands, England; Inst Natl Rech & Secur, F-54501 Vandoeuvre Les Nancy, France; Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England	Thickett, KM (reprint author), Birmingham Heartlands Hosp, Dept Resp Med, Occupat Lung Dis Unit, Bordesley Green E, Birmingham B5 5SS, W Midlands, England.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			BURGE PS, 1982, EUR J RESPIR DIS, V63, P91; Gannon PFG, 1996, THORAX, V51, P484, DOI 10.1136/thx.51.5.484; Hailin G, 1990, ANAL CHIM ACTA, V237, P149; HERY M, 1995, ANN OCCUP HYG, V39, P427, DOI 10.1016/0003-4878(95)00013-5; HOLZWARTH G, 1984, WATER RES, V18, P1421, DOI 10.1016/0043-1354(84)90012-5; LAHL U, 1981, WATER RES, V15, P803, DOI 10.1016/0043-1354(81)90133-0; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; MCCOACH JS, 1999, INDOOR AIR, V4, P459; POTTS JE, 1994, THESIS U BRIT COLOMB; Quanjer P. H., 1993, EUR RESP J S16, V6, p5S; TCHOBANOGLOUS G, 1991, WASTEWATER ENG TREAT, P332; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	12	121	121	3	13	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAY	2002	19	5					827	832		10.1183/09031936.02.00232802		6	Respiratory System	Respiratory System	553AP	WOS:000175653600008	12030720	
J	Jeebhay, MF; Robins, TG; Lehrer, SB; Lopata, AL				Jeebhay, MF; Robins, TG; Lehrer, SB; Lopata, AL			Occupational seafood allergy: a review	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Review						occupational seafood allergy; occupational asthma; protein contact dermatitis	PROTEIN CONTACT-DERMATITIS; FISH PROCESSING-INDUSTRY; HUMAN EPIDERMAL KERATIN; HYPERSENSITIVITY REACTIONS; RESPIRATORY SYMPTOMS; URTICARIA SYNDROME; SKIN TEMPERATURE; MAJOR ALLERGEN; IGE; ASTHMA	Background-Recent years have seen increased levels of production and consumption of seafood, leading to more frequent reporting of allergic reactions in occupational and domestic settings. This review focuses on occupational allergy in the fishing and seafood processing industry. Review-Workers involved in either manual or automated processing of crabs' prawns, mussels, fish, and fishmeal production are commonly exposed to various constituents of seafood. Aerosolisation of seafood and cooking fluid during processing are potential occupational situations that could result in sensitisation through inhalation. There is great variability of aerosol exposure within and among various jobs with reported allergen concentrations ranging from 0.001 to 5.061(mug/m(3)). Occupational dermal exposure occurs as a result of unprotected handling of seafood and its byproducts. Occupational allergies have been reported in workers exposed to arthropods (crustaceans), molluscs, pisces (bony fish) and other agents derived from seafood. The prevalence of occupational asthma ranges from 7% to 36%, and for occupational protein contact dermatitis, from 3% to 11%. These health outcomes are mainly due to high molecular weight proteins in seafood causing an IgE mediated response. Cross reactivity between various species within a major seafood grouping also occurs. Limited evidence from dose-response relations indicate that development of symptoms is related to duration or intensity of exposure. The evidence for atopy as a risk factor for occupational sensitisation and asthma is supportive, whereas evidence for cigarette smoking is limited. Disruption of the intact skin barrier seems to be an important added risk factor for occupational protein contact dermatitis. Conclusion-The range of allergic disease associated with occupational exposure to crab is well characterised, whereas for other seafood agents the evidence is somewhat limited. There is a need for further epidemiological studies to better characterise this risk. More detailed characterisation of specific protein antigens in aerosols and associated establishment of dose-response relations for acute and chronic exposure to seafood; the respective roles of skin contact and inhalational exposure in allergic sensitisation and cross reactivity; and the contribution of host associated factors in the development of occupational seafood allergies are important areas for future research.	Univ Cape Town, Dept Publ Hlth, Occupat & Environm Hlth Res Unit, ZA-7925 Observatory, South Africa; Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; Tulane Univ, Med Ctr, Dept Med, New Orleans, LA USA; Groote Schuur Hosp, Dept Immunol, Allergol Unit, ZA-7925 Cape Town, South Africa	Jeebhay, MF (reprint author), Univ Cape Town, Dept Publ Hlth, Occupat & Environm Hlth Res Unit, Room 1111C,1st Floor,Anat Bldg,Anzio Rd, ZA-7925 Observatory, South Africa.		Lopata, Andreas/C-8160-2009; Lopata, Andreas/C-3831-2012	Lopata, Andreas/0000-0002-2940-9235	PHS HHS [R01 F002304]		Brostoff J., 1987, FOOD ALLERGY INTOLER, P356; Abeck D, 1990, Derm Beruf Umwelt, V38, P24; ALEXANDER AA, 1989, CUTIS, V42, P388; ALONSO MD, 1993, ALLERGY, V48, P349, DOI 10.1111/j.1398-9995.1993.tb02404.x; ARTIUNINA GP, 1992, GIGIENA TRUDA PROFES, V1, P34; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; AVILA R, 1971, Clinical Allergy, V1, P343, DOI 10.1111/j.1365-2222.1971.tb00784.x; BALDO BA, 1982, CLIN ALLERGY, V12, P179, DOI 10.1111/j.1365-2222.1982.tb01637.x; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BEAUDET N, 1994, APPL OCCUP ENV HYG, V9, P597; Beltrami V, 1989, Med Lav, V80, P425; BERNSTEIN DI, 1999, ASTHMA WORKPLACE, V24, P445; BJELLAND S, 1988, ARCH DERMATOL RES, V280, P119, DOI 10.1007/BF00417716; BJELLAND S, 1989, ARCH DERMATOL RES, V280, P469, DOI 10.1007/BF00427658; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; Carino M, 1985, Med Lav, V76, P471; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; Cartier A, 1999, J ALLERGY CLIN IMMUN, V103, pS179; CHAN-YEUNG M, 1986, American Review of Respiratory Disease, V133, P686; CLARKE PS, 1979, MED J AUSTRALIA, P623; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; CRONIN E, 1987, CONTACT DERMATITIS, V17, P265, DOI 10.1111/j.1600-0536.1987.tb01475.x; Cronin E, 1989, Adv Dermatol, V4, P113; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; de Besche A., 1937, ACTA MED SCAND, V42, P237; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; Dominguez C, 1996, ALLERGY ASTHMA PROC, V17, P83, DOI 10.2500/108854196778645092; Dorszscz W, 1981, INT ARCH OCC ENV HEA, V49, P13; Dory D, 1998, ALLERGY, V53, P42, DOI 10.1111/j.1398-9995.1998.tb03772.x; DOUGLAS JDM, 1995, LANCET, V346, P737, DOI 10.1016/S0140-6736(95)91505-2; Durborow RM, 1999, OCCUP MED-STATE ART, V14, P373; EDELMAN PA, 1994, US IND HYG C EXP; ELSAYED SM, 1970, INT ARCH ALLER A IMM, V38, P536; Fisher A A, 1988, Cutis, V42, P388; GADDIE J, 1980, LANCET, V2, P1350; GarciaAbujeta JL, 1997, CONTACT DERMATITIS, V36, P163, DOI 10.1111/j.1600-0536.1997.tb00404.x; Glass WI, 1998, AM J IND MED, V34, P163, DOI 10.1002/(SICI)1097-0274(199808)34:2<163::AID-AJIM9>3.0.CO;2-Y; GORANSSON K, 1981, CONTACT DERMATITIS, V7, P282; GRIFFIN P, 1994, ANN OCCUP HYG, V38, P923; Halkier-Sorensen L, 1996, Contact Dermatitis, V35, P1; HALKIER-SORENSEN L, 1991, Contact Dermatitis, V24, P94, DOI 10.1111/j.1600-0536.1991.tb01659.x; HALKIERSORENSEN L, 1988, CONTACT DERMATITIS, V19, P206, DOI 10.1111/j.1600-0536.1988.tb02896.x; HALKIERSORENSEN L, 1989, CONTACT DERMATITIS, V21, P172, DOI 10.1111/j.1600-0536.1989.tb04731.x; HALKIERSORENSEN L, 1989, CONTACT DERMATITIS, V21, P179, DOI 10.1111/j.1600-0536.1989.tb04732.x; Hansen TK, 1997, ANN ALLERG ASTHMA IM, V78, P187; Harvima RJ, 1999, SCAND J WORK ENV HEA, V25, P151; Hjorth N, 1976, Contact Dermatitis, V2, P28, DOI 10.1111/j.1600-0536.1976.tb02975.x; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; International Labour Organisation, 1999, SAF HLTH FISH IND; James JM, 1997, ANN ALLERG ASTHMA IM, V79, P131; JANSSENS V, 1995, BRIT J DERMATOL, V132, P1, DOI 10.1111/j.1365-2133.1995.tb08616.x; Jeebhay MF, 2000, OCCUP MED-OXFORD, V50, P406; Jyo T, 1980, OCCUPATIONAL ASTHMA, P209; KARLIN JM, 1979, J ALLERGY CLIN IMMUN, V63, P197; KAVLI G, 1987, CONTACT DERMATITIS, V17, P153, DOI 10.1111/j.1600-0536.1987.tb02696.x; KAVLI G, 1985, CONTACT DERMATITIS, V13, P69, DOI 10.1111/j.1600-0536.1985.tb02507.x; KIMURA K, 1994, FORENSIC SCI INT, V66, P111, DOI 10.1016/0379-0738(94)90335-2; KLAUSEN NK, 1986, Z LEBENSM UNTERS FOR, V182, P459, DOI 10.1007/BF01043268; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; LEHRER SB, 1993, CLIN REV ALLERG, V11, P155; LEHRER SB, 1990, ALLERGY PROC, V11, P67, DOI 10.2500/108854190778993290; Lehrer SB, 1996, CRIT REV FOOD SCI, V36, P553; LEHRER SB, 1990, ALLERGY PROC, V11, P197, DOI 10.2500/108854190778879846; LEHRER SB, 1992, FOOD TECHNOLOGY  MAY, P153; Lemiere C, 1996, ALLERGY, V51, P272, DOI 10.1111/j.1398-9995.1996.tb04606.x; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; Lindstrom CDV, 1996, SCAND J IMMUNOL, V44, P335, DOI 10.1046/j.1365-3083.1996.d01-314.x; Lopata AL, 1997, J ALLERGY CLIN IMMUN, V100, P642, DOI 10.1016/S0091-6749(97)70168-4; Lopata A. L., 2000, ALLERGY CLIN IMMUNOL, V12, P271, DOI 10.1027/0838-1925.12.6.271; LOPEZCRESPO R, 1998, EUROPEAN J ALLERGY C, V48, P90; MAIBACH HI, 1986, CONTACT DERMATITIS, V15, P100, DOI 10.1111/j.1600-0536.1986.tb01292.x; Malagie M., 1998, ENCY OCCUPATIONAL HL, V67, P2; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1988, AM REV RESPIR DIS, V138, P807; MALO JL, 1993, CLIN REV ALLERG, V11, P223; Malo JL, 1997, CLIN EXP ALLERGY, V27, P75, DOI 10.1046/j.1365-2222.1997.d01-421.x; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499; MEISTER W, 1978, Allergie und Immunologie (Leipzig), V24, P191; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; MOODY MW, 1993, CLIN REV ALLERG, V11, P159; MUSMAND JJ, 1993, CLIN EXP ALLERGY, V23, P722, DOI 10.1111/j.1365-2222.1993.tb00359.x; Nava C, 1983, Med Lav, V74, P302; *NIOSH, 1982, MMWR-MORBID MORTAL W, V31, P95; Olszanski R., 1997, EUROPEAN J CLIN IMMU, V37, P214; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; ONIZUKA R, 1990, ARERUGI JAPANESE J A, V36, P339; ORFORD RR, 1985, AM J IND MED, V7, P155, DOI 10.1002/ajim.4700070207; ORTEGA HG, 1999, 980069 NAT I OCC SAF; PASCUAL C, 1995, ALLERGY CLIN IMMUNOL, V7, P73; Pascual CY, 1996, MONOGR ALLERGY, V32, P174; PATEL PC, 1992, ANN ALLERGY, V68, P360; Peltonen L, 1985, Derm Beruf Umwelt, V33, P166; POTTER PC, 1997, CONTINUING MED ED, V15, P657; Purello-D'Ambrosio F, 2000, ANN ALLERG ASTHMA IM, V84, P439; Rodriguez J, 1997, ALLERGY, V52, P866, DOI 10.1111/j.1398-9995.1997.tb02159.x; SANCHEZ CD, 1994, CONTACT DERMATITIS, V31, P55, DOI 10.1111/j.1600-0536.1994.tb01913.x; SHERSON D, 1989, ALLERGY, V44, P336, DOI 10.1111/j.1398-9995.1989.tb00455.x; Smith D D, 1998, Int J Circumpolar Health, V57 Suppl 1, P601; TAS J, 1972, ISRAEL J MED SCI, V8, P630; Taylor AV, 2000, J ALLERGY CLIN IMMUN, V105, P166, DOI 10.1016/S0091-6749(00)90192-1; TOMASZUNAS S, 1988, LANCET, V1, P1116; TOSTI A, 1990, CONTACT DERMATITIS, V23, P215; Valsecchi R, 1996, CONTACT DERMATITIS, V35, P367; VONKROGH G, 1981, J AM ACAD DERMATOL, V5, P328, DOI 10.1016/S0190-9622(81)70099-9; WARPINSKI J R, 1990, Journal of Allergy and Clinical Immunology, V85, P170; Weytjens K, 1999, ALLERGY, V54, P892, DOI 10.1034/j.1398-9995.1999.00120.x	108	121	125	1	18	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	SEP	2001	58	9					553	562		10.1136/oem.58.9.553		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	464UQ	WOS:000170550500001	11511741	
J	Nordenhall, C; Pourazar, J; Ledin, MC; Levin, JO; Sandstrom, T; Adelroth, E				Nordenhall, C; Pourazar, J; Ledin, MC; Levin, JO; Sandstrom, T; Adelroth, E			Diesel exhaust enhances airway responsiveness in asthmatic subjects	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; airway responsiveness; diesel exhaust; induced sputum	EMERGENCY ROOM VISITS; INDUCED SPUTUM; NITROGEN-DIOXIDE; DAILY MORTALITY; POLLUTION; EXPOSURE; PARTICLES; INFLAMMATION; MICE; CHILDREN	Particulate matter (PM) pollution has been associated with negative health effects, including exacerbations of asthma following exposure to PM peaks. The aim of the present study was to investigate the effects of short-term exposure to diesel exhaust (DE) in asthmatics, by specifically addressing the effects on airway hyperresponsiveness, lung function and airway inflammation. Fourteen nonsmoking, atopic asthmatics with stable disease, on continuous treatment with inhaled corticosteroids, were included. All were hyperresponsive to methacholine. Each subject was exposed to DE (particles with a 50% cut-off aerodynamic diameter of 10 mum (PM10) 300 mug(.)m(-3)) and air during Ih on two separate occasions. Lung function was measured before and immediately after the exposures. Sputum induction was performed 6 h, and methacholine inhalation test 24 h, after each exposure. Exposure to DE was associated with a significant increase in the degree of hyperresponsiveness, as compared to after air, of 0.97 doubling concentrations at 24 h after exposure (p < 0.001). DE also induced a significant increase in airway resistance (p = 0.004) and in sputum levels of interleukin (IL)-6 (p = 0.048). No changes were detected in sputum levels of methyl-histamine, eosinophil cationic protein, myeloperoxidase and IL-8. This study indicated that short-term exposure to diesel exhaust, equal to high ambient levels of particulate matter, is associated with adverse effects in asthmatic airways, even in the presence of inhaled corticosteroid therapy. The increase in airway responsiveness may provide an important link to epidemiological findings exacerbations of asthma following exposure to particulate matter.	Umea Univ Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden; Inst Working Life, Dept Occupat Chem, Umea, Sweden	Adelroth, E (reprint author), Umea Univ Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden.						*AIRB PART EXP GRO, 1999, SOURC APP AIRB PART, P157; BARRY CC, 1994, ENVIRONMENT, V36, P5; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; JORRES R, 1991, LUNG, V169, P77, DOI 10.1007/BF02714145; JUNIPER EF, 1994, HISTAMINE METACHOLIN; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Miyabara Y, 1998, INT ARCH ALLERGY IMM, V116, P124, DOI 10.1159/000023935; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740; Peters A, 1997, EUR RESPIR J, V10, P872; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; ROGER LJ, 1990, TOXICOL IND HEALTH, V6, P155; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; RUDELL B, 1994, INT ARCH OCC ENV HEA, V66, P77, DOI 10.1007/BF00383361; Rudell B, 1999, OCCUP ENVIRON MED, V56, P527; Rudell B, 1990, J AEROSOL SCI     S1, V21, P411; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Steerenberg PA, 1998, EXP LUNG RES, V24, P85; Strand V, 1996, EUR RESPIR J, V9, P733, DOI 10.1183/09031936.96.09040733; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034	33	121	122	1	12	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAY	2001	17	5					909	915		10.1183/09031936.01.17509090		7	Respiratory System	Respiratory System	458RU	WOS:000170209000013	11488325	
J	Shukla, A; Timblin, C; BeruBe, K; Gordon, T; McKinney, W; Driscoll, K; Vacek, P; Mossman, BT				Shukla, A; Timblin, C; BeruBe, K; Gordon, T; McKinney, W; Driscoll, K; Vacek, P; Mossman, BT			Inhaled particulate matter causes expression of nuclear factor (NF)-kappa B-related genes and oxidant-dependent NF-kappa B activation in vitro	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							NECROSIS-FACTOR-ALPHA; TRACHEAL EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; AIR-POLLUTION; ALVEOLAR MACROPHAGES; RAT LUNG; C-JUN; ASBESTOS; ASTHMA; GENERATION	High levels of ambient air pollution are associated with exacerbation of asthma and respiratory morbidity, yet little is known concerning the mechanisms of inflammation and toxicity by components of inhaled particulate matter (PM), Brief inhalation of PM2.5 (particles of an aerodynamic diameter of <2.5 microns) (300 mu g/m(3) air for 6 h followed by a period of 24 h in clean air) by either C3H/HeJ or C57/BL6 mice caused significant (P less than or equal to 0.05) increases in steady-state messenger RNA (mRNA) levels of a number of nuclear factor (NF)-kappa B-associated and/or -regulated genes, including tumor necrosis factor-alpha and -beta, interleukin-6, interferon-gamma, and transforming growth factor-beta. Lung mRNA levels of lymphotoxin-beta and macrophage migration inhibitory factor were unchanged. In murine C10 alveolar cells and an NF-kappa B-luciferase reporter cell line, exposure to PM2.5 at noncytotoxic concentrations resulted in increases in transcriptional activation of NF-kappa B-dependent gene expression which were inhibited in the presence of catalase. Early and persistent increases in intracellular oxidants, as measured by flow cytometry and cell imaging using the oxidant probe 2'-7'-dichlorofluoroscin diacetate, were observed in epithelial cells exposed to PM2.5, and ultrafine carbon black particles. Studies here are the first to show NF-kappa B-related inflammatory and cytokine gene expression after inhalation of PM2.5 and oxidant-dependent induction of NF-kappa B activity by PM2.5 in pulmonary epithelial cells.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA; Univ Vermont, Dept Biostat, Burlington, VT 05405 USA; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF1 1XL, S Glam, Wales; NYU, Inst Environm Med, Sch Med, Tuxedo Park, NY 10987 USA; Procter & Gamble Co, Cardiovasc Res, Mason, OH USA	Mossman, BT (reprint author), Univ Vermont, Coll Med, Dept Pathol, Med Alumni BLdg, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL39469]; NIEHS NIH HHS [ES06499, R01ES/HL09213]		Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; CATALANO PB, 1999, AM J RESP CRIT CARE, V159, pA29; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291; Cheshire JL, 1997, MOL CELL BIOL, V17, P6746; Choi AMK, 1996, AM J PHYSIOL-LUNG C, V271, pL383; Cohen AJ, 1995, ENVIRON HEALTH PERSP, V103, P219, DOI 10.2307/3432314; Donaldson K, 1997, ENVIRON HEALTH PERSP, V105, P1285, DOI 10.2307/3433548; Donnelly SC, 1997, NAT MED, V3, P320, DOI 10.1038/nm0397-320; Gamble JF, 1998, ENVIRON HEALTH PERSP, V106, P535, DOI 10.1289/ehp.98106535; Gordon T, 1999, INHAL TOXICOL, V11, P71, DOI 10.1080/089583799197276; Grabowski GM, 1999, TOXICOL APPL PHARM, V156, P170, DOI 10.1006/taap.1999.8642; HALLSWORTH MP, 1994, EUR RESPIR J, V7, P1096; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; Janssen YMW, 1997, AM J PATHOL, V151, P389; Jimenez LA, 1997, AM J PHYSIOL-LUNG C, V273, pL1029; Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kennedy T, 1998, AM J RESP CELL MOL, V19, P366; KLEEBERGER SR, 1990, AM J PHYSIOL, V258, pL313; Ledbetter A, 1999, AM J RESP CRIT CARE, V159, pA29; Malkinson AM, 1997, TOXICOLOGY, V123, P53, DOI 10.1016/S0300-483X(97)00108-X; Mossman BT, 1998, AM J RESP CRIT CARE, V157, P1666; PHAN SH, 1992, J IMMUNOL, V149, P103; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; QUINLAN TR, 1994, AM J RESP CRIT CARE, V150, P200; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Smith KR, 1997, CHEM RES TOXICOL, V10, P828, DOI 10.1021/tx960164m; Timblin C, 1998, CANCER RES, V58, P4543; TIMBLIN CR, 1995, CANCER RES, V55, P2723	33	121	135	4	24	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	AUG	2000	23	2					182	187				6	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	344FW	WOS:000088749400011	10919984	
J	Chan-Yeung, M; Manfreda, J; Dimich-Ward, H; Ferguson, A; Watson, W; Becker, A				Chan-Yeung, M; Manfreda, J; Dimich-Ward, H; Ferguson, A; Watson, W; Becker, A			A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							ALLERGEN AVOIDANCE; FOLLOW-UP; AGE; MITE; DIET; LIFE	Background: The prevalence of asthma has increased in developed countries in the past 2 decades. The effectiveness of intervention measures on the primary prevention of asthma has not been well studied. Objective: To assess the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants (in this study, infants are defined as persons from birth to the age of 1 year). Design: Prospective, prenatally randomized, controlled study with follow-up through the age of 1 year. Setting: University hospital-based settings at 2 Canadian centers: Vancouver, British Columbia, and Winnipeg, Manitoba. Participants: A total of 545 high-risk infants (at least 1 first-degree relative with asthma or 2 first-degree relatives with other IgE-mediated allergic diseases) identified before birth. Interventions: Avoidance of house dust mite and pet allergens and environmental tobacco smoke, encouragement of breastfeeding, and supplementation with a partially hydrolyzed formula. Main Outcome Measures: Probable or possible asthma, rhinitis without apparent colds, and a prick skin test result positive for common inhalant allergens. Results: Thirty-eight (15.1%) of the 251 infants available for assessment in the intervention group and 49 (20.2%) of the 242 infants available for assessment in the control group fulfilled the criteria for possible or probable asthma (adjusted relative risk, 0.66; 90% confidence interval, 0.44-0.98). Also, 16.7% of the infants in the intervention group and 27.3% of the infants in the control group developed rhinitis without colds (adjusted relative risk, 0.51; 90% confidence interval, 0.35-0.74). The incidence of positive skin test results to 1 or more inhalant allergens was similar in both groups (4.4% in the intervention group and 4.6% in the control group). Conclusions: Our multifaceted intervention program resulted in a modest but significant (P = .04) reduction in the risk of possible or probable asthma and rhinitis without apparent colds at the age of 12 months in high-risk infants. In the absence of a validated definition of asthma at the age of 12 months, follow-up studies are needed to determine the effectiveness of the intervention program in the primary prevention of asthma in high-risk infants.	Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, Vancouver, BC, Canada; Univ British Columbia, Dept Paediat, Div Allergy, Vancouver, BC, Canada; Univ Manitoba, Dept Med, Winnipeg, MB, Canada; Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; Univ Manitoba, Dept Paediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB, Canada	Chan-Yeung, M (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Room 418,Professorial Block, Hong Kong, Hong Kong, Peoples R China.						ARSHAD SH, 1992, LANCET, V339, P1439; Burney P, 1996, EUR RESPIR J, V9, P687; Burney PGJ, 1997, ASTHMA, P35; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805; CHANYEUNG M, 1977, AM J RESP CRIT CARE, V155, pA73; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Marini A, 1996, Acta Paediatr Suppl, V414, P1; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *MIN IND, 1999, PROF CENS TRACTS ABB; MURRAY A, 1983, PEDIATRICS, V1, P418; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	24	121	124	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2000	154	7					657	663				7	Pediatrics	Pediatrics	332LE	WOS:000088075100003	10891016	
J	Martin, SF; Esser, PR; Weber, FC; Jakob, T; Freudenberg, MA; Schmidt, M; Goebeler, M				Martin, S. F.; Esser, P. R.; Weber, F. C.; Jakob, T.; Freudenberg, M. A.; Schmidt, M.; Goebeler, M.			Mechanisms of chemical-induced innate immunity in allergic contact dermatitis	ALLERGY			English	Review						contact dermatitis; inflammation; innate immunity; NOD-like receptor; Toll-like receptor	NF-KAPPA-B; TOLL-LIKE RECEPTORS; CELL-LINE THP-1; LYMPH-NODE ASSAY; CD8 T-CELLS; IN-VITRO; REACTIVE OXYGEN; DENDRITIC CELLS; SKIN SENSITIZERS; GENE-EXPRESSION	Allergic contact dermatitis (ACD) is one of the most prevalent occupational skin diseases and causes severe and long-lasting health problems in the case of chronification. It is initiated by an innate inflammatory immune response to skin contact with low molecular weight chemicals that results in the priming of chemical-specific, skin-homing CD8(+) Tc1/Tc17 and CD4(+) Th1/Th17 cells. Following this sensitization step, T lymphocytes infiltrate the inflamed skin upon challenge with the same chemical. The T cells then exert cytotoxic function and secrete inflammatory mediators to produce an eczematous skin reaction. The recent characterization of the mechanisms underlying the innate inflammatory response has revealed that contact allergens activate innate effector mechanisms and signalling pathways that are also involved in anti-infectious immunity. This emerging analogy implies infection as a potential trigger or amplifier of the sensitization to contact allergens. Moreover, new mechanistic insights into the induction of ACD identify potential targets for preventive and therapeutic intervention. We summarize here the latest findings in this area of research.	[Martin, S. F.; Esser, P. R.; Weber, F. C.; Jakob, T.] Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, D-79104 Freiburg, Germany; [Weber, F. C.] Univ Freiburg, Fac Biol, D-7800 Freiburg, Germany; [Freudenberg, M. A.] Max Planck Inst Immunbiol & Epigenet, Freiburg, Germany; [Schmidt, M.; Goebeler, M.] Univ Giessen, Dept Dermatol, Giessen, Germany	Martin, SF (reprint author), Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, Hauptstr 7, D-79104 Freiburg, Germany.	stefan.martin@uniklinik-freiburg.de	Esser, Philipp/F-6849-2011; Jakob, Thilo/J-1621-2012; Goebeler, Matthias/F-7118-2013; Schmidt, Marc/E-8821-2010	Schmidt, Marc/0000-0002-8643-1615			Ade N, 2009, TOXICOL SCI, V107, P451, DOI 10.1093/toxsci/kfn243; Aeby P, 2010, TOXICOL IN VITRO, V24, P1465, DOI 10.1016/j.tiv.2010.07.005; Antonopoulos C, 2001, J Immunol, V166, P3672; Antonopoulos C, 2008, J LEUKOCYTE BIOL, V83, P361, DOI 10.1189/jlb.0604352; Arthur JC, 2010, J IMMUNOL, V185, P4515, DOI 10.4049/jimmunol.1002227; Artik S, 1999, J IMMUNOL, V163, P1143; Ashikaga T, 2010, ATLA-ALTERN LAB ANIM, V38, P275; Babelova A, 2009, J BIOL CHEM, V284, P24035, DOI 10.1074/jbc.M109.014266; Basketter DA, 2007, CONTACT DERMATITIS, V57, P70, DOI 10.1111/j.1600-0536.2007.01141.x; Bergstrom MA, 2007, J INVEST DERMATOL, V127, P1145, DOI 10.1038/sj.jid.5700638; Bollyky PL, 2009, J LEUKOCYTE BIOL, V86, P567, DOI 10.1189/jlb.0109001; Bonneville M, 2007, J INVEST DERMATOL, V127, P1430, DOI 10.1038/sj.jid.5700726; Bruchhausen S, 2003, J INVEST DERMATOL, V121, P1039, DOI 10.1046/j.1523-1747.2003.12510.x; Burnstock G, 2007, CELL MOL LIFE SCI, V64, P1471, DOI 10.1007/s00018-007-6497-0; Chen G, 2009, ANNU REV PATHOL-MECH, V4, P365, DOI 10.1146/annurev.pathol.4.110807.092239; Copple IM, 2008, HEPATOLOGY, V48, P1292, DOI 10.1002/hep.22472; Copple IM, 2010, HDB EXP PHARM, V196, P233, DOI DOI 10.1007/978-3-642-00663-0_; D'Autreaux B, 2007, NAT REV MOL CELL BIO, V8, P813, DOI 10.1038/nrm2256; Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512; De Groot AC, 2008, PATCH TESTING TEST C; Di Nardo A, 2007, J IMMUNOL, V178, P1829; Dietz L, 2010, TOXICOL SCI, V117, P336, DOI 10.1093/toxsci/kfq209; Dinkova-Kostova AT, 2005, CHEM RES TOXICOL, V18, P1779, DOI 10.1021/tx050217c; Dudda JC, 2005, EUR J IMMUNOL, V35, P1056, DOI 10.1002/eji.200425817; Dudda JC, 2004, J IMMUNOL, V172, P857; Dwyer KM, 2007, PURINERG SIGNAL, V3, P171, DOI 10.1007/s11302-006-9050-y; Edele F, 2008, J IMMUNOL, V181, P3745; Emter R, 2010, TOXICOL APPL PHARM, V245, P281, DOI 10.1016/j.taap.2010.03.009; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; Freudenberg MA, 2009, GIORN ITAL DERMAT V, V144, P173; Friedmann PS, 2010, CONTACT DERMATITIS, V63, P237, DOI 10.1111/j.1600-0536.2010.01801.x; Fukata M, 2009, SEMIN IMMUNOL, V21, P242, DOI 10.1016/j.smim.2009.06.005; Galbiati V, 2010, TOXICOL IN VITRO, V25, P724; Gamerdinger K, 2003, J EXP MED, V197, P1345, DOI 10.1084/jem.20030121; Gao F, 2008, J BIOL CHEM, V283, P6058, DOI 10.1074/jbc.M709273200; Garcia-Pineres AJ, 2001, J BIOL CHEM, V276, P39713, DOI 10.1074/jbc.M101985200; Gariboldi S, 2008, J IMMUNOL, V181, P2103; Geier J, 2009, HAUTARZT, V60, P708, DOI 10.1007/s00105-008-1705-x; Gerberick GF, 2007, TOXICOL SCI, V97, P417, DOI 10.1093/toxsci/kfm064; Gerberick GF, 2004, TOXICOL SCI, V81, P332, DOI 10.1093/toxsci/kfh213; GOEBELER M, 1993, J INVEST DERMATOL, V100, P759, DOI 10.1111/1523-1747.ep12476328; GOEBELER M, 1995, J IMMUNOL, V155, P2459; Goebeler M, 2001, AM J PATHOL, V158, P431, DOI 10.1016/S0002-9440(10)63986-7; Goebeler M, 2001, BLOOD, V97, P46, DOI 10.1182/blood.V97.1.46; Grabbe S, 1996, J CLIN INVEST, V98, P1158, DOI 10.1172/JCI118899; Granstein RD, 2005, J IMMUNOL, V174, P7725; Grohmann U, 1998, IMMUNITY, V9, P315, DOI 10.1016/S1074-7613(00)80614-7; Heiss K, 2005, PROTEOMICS, V5, P3614, DOI 10.1002/pmic.200401215; Hirota M, 2010, J TOXICOL SCI, V35, P871, DOI 10.2131/jts.35.871; Hirota M, 2009, J TOXICOL SCI, V34, P139; Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang DH, 2011, PHYSIOL REV, V91, P221, DOI 10.1152/physrev.00052.2009; Jowsey IR, 2006, J APPL TOXICOL, V26, P341, DOI 10.1002/jat.1146; KAGATANI S, 2009, J INVEST DERMATOL, V130, P175; Karlberg AT, 2008, CHEM RES TOXICOL, V21, P53, DOI 10.1021/tx7002239; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kim D, 2009, IMMUNOL INVEST, V38, P132, DOI 10.1080/08820130802667499; Kimber I, 2011, TOXICOL SCI, V120, pS238, DOI 10.1093/toxsci/kfq346; Klekotka PA, 2010, J INVEST DERMATOL, V130, P184, DOI 10.1038/jid.2009.242; Lambeth JD, 2008, SEMIN IMMUNOPATHOL, V30, P339, DOI 10.1007/s00281-008-0123-6; Lass C, 2008, EXP DERMATOL, V17, P849, DOI 10.1111/j.1600-0625.2008.00717.x; Lass C, 2010, EXP DERMATOL, V19, P1007, DOI 10.1111/j.1600-0625.2010.01136.x; Lich JD, 2007, J IMMUNOL, V178, P1256; Lombardi C, 2004, ALLERGY, V59, P669, DOI 10.1111/j.1398-9995.2004.00408.x; Lu L, 2003, J EXP MED, V197, P567, DOI 10.1084/jem.20021762; Martin SF, 2006, MINI-REV MED CHEM, V6, P247, DOI 10.2174/138955706776073493; Martin SF, 2004, INT ARCH ALLERGY IMM, V134, P186, DOI 10.1159/000078765; Martin SF, 2011, ALLERGO J, V20, P81; MARTIN SF, 2011, ALLERGOLOGIE; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Martin SF, 2008, CURR OPIN ALLERGY CL, V8, P289, DOI 10.1097/ACI.0b013e3283088cf9; Martin SF, 2010, CELL MOL LIFE SCI, V67, P4171, DOI 10.1007/s00018-010-0495-3; Martinon F, 2009, ANNU REV IMMUNOL, V27, P229, DOI [10.1146/annurev.immunol.021908.132715, 10.1146/annurev.immunol.021908.132532]; Matsue H, 2003, J IMMUNOL, V171, P3010; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McKim JM, 2010, CUTAN OCUL TOXICOL, V29, P171, DOI 10.3109/15569527.2010.483869; Megherbi R, 2009, TOXICOL APPL PHARM, V238, P120, DOI 10.1016/j.taap.2009.05.001; Mehrotra P, 2005, TOXICOL MECH METHOD, V15, P343, DOI 10.1080/15376520500191490; Mizumoto N, 2002, NAT MED, V8, P358, DOI 10.1038/nm0402-358; Monzon ME, 2010, J BIOL CHEM, V285, P26126, DOI 10.1074/jbc.M110.135194; Morioka Y, 2008, J IMMUNOL, V181, P3915; Naik E, 2011, J EXP MED, V208, P417, DOI 10.1084/jem.20110367; Natsch A, 2008, TOXICOL SCI, V102, P110, DOI 10.1093/toxsci/kfm259; Natsch A, 2010, TOXICOL SCI, V113, P284, DOI 10.1093/toxsci/kfp228; Ott H, 2009, CHEM RES TOXICOL, V22, P399, DOI 10.1021/tx8003642; Ouwehand K, 2010, TOXICOL IN VITRO, V24, P578, DOI 10.1016/j.tiv.2009.10.014; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; Sato N, 2007, CLIN EXP ALLERGY, V37, P743, DOI 10.1111/j.1365-2222.2007.02705.x; Schaefer L, 2005, J CLIN INVEST, V115, P2223, DOI 10.1172/JC123755; Scheibner KA, 2006, J IMMUNOL, V177, P1272; Schmidt CS, 2002, J IMMUNOL, V168, P5521; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Schnuch A, 2011, CONTACT DERMATITIS, V64, P2, DOI 10.1111/j.1600-0536.2010.01800.x; Schram SE, 2007, DERMATITIS, V18, P125, DOI 10.2310/6620.2007.06007; Seidel-Guyenot W, 2006, J ALLERGY CLIN IMMUN, V117, P1170, DOI 10.1016/j.jaci.2006.01.014; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shornick LP, 1996, J EXP MED, V183, P1427, DOI 10.1084/jem.183.4.1427; Skazik C, 2011, ARCH BIOCHEM BIOPHYS, V508, P212, DOI 10.1016/j.abb.2011.01.013; Soltes L, 2006, BIOMACROMOLECULES, V7, P659, DOI 10.1021/bm050867v; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Spiewak Radoslaw, 2007, Expert Rev Clin Immunol, V3, P851, DOI 10.1586/1744666X.3.6.851; Stern R, 2007, BIOTECHNOL ADV, V25, P537, DOI 10.1016/j.biotechadv.2007.07.001; Surprenant A, 2009, ANNU REV PHYSIOL, V71, P333, DOI 10.1146/annurev.physiol.70.113006.100630; Sutterwala FS, 2006, IMMUNITY, V24, P317, DOI 10.1016/j.immuni.2006.02.004; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Thierse HJ, 2005, TOXICOLOGY, V209, P101, DOI 10.1016/j.tox.2004.12.015; Thyssen JP, 2010, BRIT J DERMATOL, V163, P115, DOI 10.1111/j.1365-2133.2010.09822.x; Thyssen JP, 2010, CONTACT DERMATITIS, V63, P63, DOI 10.1111/j.1600-0536.2010.01749.x; Thyssen JP, 2010, CHEM RES TOXICOL, V23, P309, DOI 10.1021/tx9002726; Uter W, 2003, CONTACT DERMATITIS, V48, P33, DOI 10.1034/j.1600-0536.46.s4.29_102.x; Valenzuela J, 2002, J IMMUNOL, V169, P6842; Vemula PK, 2011, NAT NANOTECHNOL, V6, P291, DOI [10.1038/nnano.2011.37, 10.1038/NNANO.2011.37]; Viemann D, 2007, J IMMUNOL, V178, P3198; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Vocanson M, 2008, J INVEST DERMATOL, V128, P2119, DOI 10.1038/jid.2008.15; Vroling AB, 2008, ALLERGY, V63, P1110, DOI 10.1111/j.1398-9995.2008.01785.x; Wang L, 2002, J BIOL CHEM, V277, P29874, DOI 10.1074/jbc.M203915200; Watanabe H, 2008, J IMMUNOL, V180, P5826; Watanabe H, 2007, J INVEST DERMATOL, V127, P1956, DOI 10.1038/sj.jid.5700819; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489	124	120	121	1	24	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	SEP	2011	66	9					1152	1163		10.1111/j.1398-9995.2011.02652.x		12	Allergy; Immunology	Allergy; Immunology	800EQ	WOS:000293343000004	21599706	
J	Po, JYT; FitzGerald, JM; Carlsten, C				Po, June Y. T.; FitzGerald, J. Mark; Carlsten, Chris			Respiratory disease associated with solid biomass fuel exposure in rural women and children: systematic review and meta-analysis	THORAX			English	Article							INDOOR AIR-POLLUTION; CHRONIC-BRONCHITIS; RISK-FACTORS; DEVELOPING-COUNTRIES; PULMONARY-DISEASE; INDIAN CHILDREN; LUNG-FUNCTION; HEALTH; SMOKE; INFECTIONS	Background Numerous studies with varying associations between domestic use of solid biomass fuels (wood, dung, crop residue, charcoal) and respiratory diseases have been reported. Objective To present the current data systematically associating use of biomass fuels with respiratory outcomes in rural women and children. Methods Systematic searches were conducted in 13 electronic databases. Data were abstracted from original articles that satisfied selection criteria for meta-analyses. Publication bias and heterogeneity of samples were tested. Studies with common diagnoses were analysed using random-effect models. Results A total of 2717 studies were identified. Fifty-one studies were selected for data extraction and 25 studies were suitable for meta-analysis. The overall pooled ORs indicate significant associations with acute respiratory infection in children (OR 3.53, 95% CI 1.94 to 6.43), chronic bronchitis in women (OR 2.52, 95% CI 1.88 to 3.38) and chronic obstructive pulmonary disease in women (OR 2.40, 95% CI 1.47 to 3.93). In contrast, no significant association with asthma in children or women was noted. Conclusion Biomass fuel exposure is associated with diverse respiratory diseases in rural populations. Concerted efforts in improving stove design and lowering exposure to smoke emission may reduce respiratory disease associated with biomass fuel exposure.	[Po, June Y. T.; FitzGerald, J. Mark; Carlsten, Chris] Univ British Columbia, Dept Med, Vancouver, BC V5Z 1M9, Canada	Carlsten, C (reprint author), Univ British Columbia, Vancouver Gen Hosp, Dept Med, 7th Floor,2775 Laurel St, Vancouver, BC V5Z 1M9, Canada.	chris.carlsten@vch.ca			Department of Medicine, University of British Columbia	Funding Department of Medicine, University of British Columbia.	Akhtar T, 2007, CHEST, V132, P1472, DOI 10.1378/chest.06-2529; ASHRAF A, 2009, GLOB HLTH ACTION, V2, DOI DOI 10.3402/GHA.V2I0.1999; Behera D, 2001, Indian J Chest Dis Allied Sci, V43, P27; Behera D, 1998, Indian J Chest Dis Allied Sci, V40, P89; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Campbell H, 1997, Health Bull (Edinb), V55, P20; COLLINGS DA, 1990, TROP DOCT, V20, P151; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; Egger M, 1997, BRIT MED J, V315, P629; Ehrlich RI, 2004, INT J TUBERC LUNG D, V8, P369; Ekici A, 2005, ENVIRON RES, V99, P93, DOI 10.1016/j.envres.2005.01.004; Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15; Fullerton DG, 2008, T ROY SOC TROP MED H, V102, P843, DOI 10.1016/j.trstmh.2008.05.028; Golshan M, 2002, RESP MED, V96, P382, DOI 10.1053/rmed.2002.1288; Hu GP, 2010, CHEST, V138, P20, DOI 10.1378/chest.08-2114; Kilabuko James H, 2007, Int J Environ Res Public Health, V4, P39, DOI 10.3390/ijerph2007010007; Kiraz K, 2003, CLIN INVEST MED, V26, P243; KITANGE HM, 1993, J EPIDEMIOL COMMUN H, V47, P303, DOI 10.1136/jech.47.4.303; Kurmi OP, 2010, THORAX, V65, P221, DOI 10.1136/thx.2009.124644; Liu BQ, 1998, BRIT MED J, V317, P1411; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Malik S K, 1985, Indian J Chest Dis Allied Sci, V27, P171; Masera OR, 2000, WORLD DEV, V28, P2083, DOI 10.1016/S0305-750X(00)00076-0; Mathers CD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P45; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Mishra V, 2003, ENVIRON HEALTH PERSP, V111, P71, DOI 10.1289/ehp.5559; Mishra V, 2005, POPUL ENVIRON, V26, P375, DOI 10.1007/s1111-005-0005-y; Mishra V, 2003, INT J EPIDEMIOL, V32, P847, DOI 10.1093/ije/dyg240; Mishra V. K., 1997, NATL FAM HLTH SURV B, V8, P1; MORRIS K, 1990, AM J DIS CHILD, V144, P105; Noonan CW, 2010, INHAL TOXICOL, V22, P108, DOI 10.3109/08958370903008888; Noorhassim I, 1995, Med J Malaysia, V50, P263; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Qureshi K A, 1994, Indian J Chest Dis Allied Sci, V36, P61; Regalado J, 2006, AM J RESP CRIT CARE, V174, P901, DOI 10.1164/rccm.200503-479OC; Savitha MR, 2007, INDIAN J PEDIATR, V74, P477, DOI 10.1007/s12098-007-0081-3; Sezer H, 2006, ANN EPIDEMIOL, V16, P59, DOI 10.1016/j.annepidem.2004.12.014; Shrestha IL, 2005, INT J OCCUP ENV HEAL, V11, P150; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; Smith K, 2004, COMP QUANTIFICATION, P1435; Smith-Sivertsen T, 2009, AM J EPIDEMIOL, V170, P211, DOI 10.1093/aje/kwp100; Song FJ, 2001, EVAL HEALTH PROF, V24, P126, DOI 10.1177/016327870102400203; Sterne JAC, 2001, BRIT MED J, V323, P101, DOI 10.1136/bmj.323.7304.101; Torres-Duque Carlos, 2008, Proc Am Thorac Soc, V5, P577, DOI 10.1513/pats.200707-100RP; Uzun Kursat, 2003, Environ Health Prev Med, V8, P13, DOI 10.1007/BF02897938	47	120	124	1	17	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2011	66	3					232	239		10.1136/thx.2010.147884		8	Respiratory System	Respiratory System	723AQ	WOS:000287478700013	21248322	
J	Thyssen, JP; Johansen, JD; Linneberg, A; Menne, T				Thyssen, Jacob P.; Johansen, Jeanne D.; Linneberg, Allan; Menne, Torkil			The epidemiology of hand eczema in the general population - prevalence and main findings	CONTACT DERMATITIS			English	Review						general population; hand eczema; hand dermatitis; nickel allergy; public health; regulation	IRRITANT CONTACT-DERMATITIS; ODENSE ADOLESCENCE COHORT; SECONDARY-SCHOOL PUPILS; 15-YEAR FOLLOW-UP; NICKEL ALLERGY; ATOPIC-DERMATITIS; INDUSTRIAL-CITY; SKIN EXPOSURE; FILAGGRIN MUTATIONS; SWEDISH POPULATION	Numerous studies have investigated the prevalence and risk factors of hand eczema in the general population. These studies are of high value as they tend to be less biased than studies using clinical populations and as they are important for healthcare decision makers when they allocate resources. This study aimed to review the epidemiology of hand eczema in the general population. Literature was examined using Pubmed-Medline, Biosis, Science Citation Index, and dermatology text books. On the basis of studies performed between 1964 and 2007, the point prevalence of hand eczema was around 4%, the 1-year prevalence nearly 10%, whereas the lifetime prevalence reached 15%. Based on seven studies, the median incidence rate of hand eczema was 5.5 cases/1000 person-years (women = 9.6 and men = 4.0). A high incidence rate was associated with female sex, contact allergy, atopic dermatitis, and wet work. Atopic dermatitis was the single most important risk factor for hand eczema. Hand eczema resulted in medical consultations in 70%, sick leave (> 7 days) in about 20%, and job change in about 10%. Mean sick time was longer among those with allergic hand eczema than those with atopic and irritant hand eczema. Moderate to severe extension of hand eczema was the strongest risk factor for persistence of hand eczema. Other risk factors included early onset of hand eczema and childhood eczema. The aetiology of hand eczema is multifactorial and includes environmental as well as genetic factors. Future studies should focus on unresolved areas of hand eczema, for example, genetic predisposition.	[Thyssen, Jacob P.; Johansen, Jeanne D.] Univ Copenhagen, Natl Allergy Res Ctr, Dept Dermatoloallergol, Gentofte Hosp, DK-2900 Hellerup, Denmark; [Linneberg, Allan] Univ Copenhagen, Glostrup Hosp, Res Ctr Prevent & Hlth, DK-2900 Hellerup, Denmark; [Menne, Torkil] Gentofte Univ Hosp, Dept Dermatoallergol, Gentofte, Denmark	Thyssen, JP (reprint author), Univ Copenhagen, Natl Allergy Res Ctr, Dept Dermatoloallergol, Gentofte Hosp, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	jacpth01@geh.regionh.dk			Horslev Foundation	The study was funded by the Horslev Foundation.	ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; AGNER T, 2006, CONTACT DERMATITIS, P127, DOI 10.1007/3-540-31301-X_9; Agrup G, 1969, ACTA DERM VENERE S61, V49, P1; Anveden B, 2009, BRIT J DERMATOL, V160, P616; Anveden I, 2006, CONTACT DERMATITIS, V54, P272, DOI 10.1111/j.0105-1873.2006.00823.x; Bhargava K, 2009, CONTACT DERMATITIS, V60, P222, DOI 10.1111/j.1600-0536.2008.01358.x; BJORNBERG A, 1975, ACTA DERM-VENEREOL, V55, P191; Bo K, 2008, DERMATOLOGY, V216, P40, DOI 10.1159/000109357; BONNEVIE P, 1939, ATIOLOGIE PATHOGENES; Brisman J, 1998, OCCUP ENVIRON MED, V55, P750; Brown SJ, 2008, BRIT J DERMATOL, V158, P1383, DOI 10.1111/j.1365-2133.2008.08551.x; Brown TP, 2007, CONTACT DERMATITIS, V56, P16, DOI 10.1111/j.1600-0536.2007.00979.x; Bryld LE, 2000, BRIT J DERMATOL, V142, P298, DOI 10.1046/j.1365-2133.2000.03301.x; Bryld LE, 2003, BRIT J DERMATOL, V149, P1214, DOI 10.1111/j.1365-2133.2003.05678.x; Dalgard F, 2004, BRIT J DERMATOL, V151, P452, DOI 10.1111/j.1365-2133.2004.06058.x; de Jongh CM, 2008, BRIT J DERMATOL, V159, P621, DOI 10.1111/j.1365-2133.2008.08730.x; Dotterud LK, 2007, CONTACT DERMATITIS, V56, P10, DOI 10.1111/j.1600-0536.2007.00980.x; DOTTERUD LK, 1995, ACTA PAEDIATR, V84, P402, DOI 10.1111/j.1651-2227.1995.tb13659.x; Fowler JF, 2006, CUTIS, V77, P385; Fung WK, 2000, PEDIATR DERMATOL, V17, P440, DOI 10.1046/j.1525-1470.2000.01841.x; Hald M, 2008, BRIT J DERMATOL, V158, P773, DOI 10.1111/j.1365-2133.2007.08431.x; Held E, 2002, OCCUP ENVIRON MED, V59, P556, DOI 10.1136/oem.59.8.556; HJORTH N, 1961, ECZEMATOUS ALLERGY B; Johansen JD, 2008, CONTACT DERMATITIS, V59, P48, DOI 10.1111/j.1600-0536.2008.01364.x; Johnson MT, 1978, SKIN CONDITIONS RELA, V212; Josefson A, 2009, BRIT J DERMATOL, V160, P828, DOI 10.1111/j.1365-2133.2008.09006.x; Josefson A, 2006, CONTACT DERMATITIS, V55, P286, DOI 10.1111/j.1600-0536.2006.00958.x; KAVLI G, 1984, CONTACT DERMATITIS, V10, P174, DOI 10.1111/j.1600-0536.1984.tb00027.x; Knudsen B, 2006, CONTACT DERMATITIS, V54, P170, DOI 10.1111/j.0105-1873.2005.0739c.x; Kutting B, 2009, BRIT J DERMATOL, V161, P390, DOI 10.1111/j.1365-2133.2009.09085.x; LANTINGA H, 1984, CONTACT DERMATITIS, V10, P135, DOI 10.1111/j.1600-0536.1984.tb00018.x; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Lerbaek A, 2007, BRIT J DERMATOL, V157, P1199, DOI 10.1111/j.1365-2133.2007.08252.x; Lerbaek A, 2007, BRIT J DERMATOL, V157, P552, DOI 10.1111/j.1365-2133.2007.08088.x; LERBAEK A, 2007, COMMUNICATION; Lerbaek A, 2008, CONTACT DERMATITIS, V58, P210, DOI 10.1111/j.1600-0536.2007.01305.x; Lerbaek A, 2007, J INVEST DERMATOL, V127, P1632, DOI 10.1038/sj.jid.5700750; Lind ML, 2007, OCCUP ENVIRON MED, V64, P191, DOI 10.1136/oem.2005.026211; Loffler H, 2006, CONTACT DERMATITIS, V54, P202, DOI 10.1111/j.0105-1873.2006.00825.x; Mattila L, 2001, CONTACT DERMATITIS, V44, P218, DOI 10.1034/j.1600-0536.2001.044004218.x; MEDING B, 1990, ACTA DERM-VENEREOL, P1; Meding B, 2000, CONTACT DERMATITIS, V43, P65, DOI 10.1034/j.1600-0536.2000.043002065.x; Meding B, 2006, SCAND J WORK ENV HEA, V32, P219; Meding B, 2005, BRIT J DERMATOL, V152, P975, DOI 10.1111/j.1365-2133.2005.06494.x; Meding B, 2005, J INVEST DERMATOL, V124, P893, DOI 10.1111/j.0022-202X.2005.23723.x; MEDING B, 1989, ACTA DERM-VENEREOL, V69, P227; Meding B, 2004, J INVEST DERMATOL, V122, P873, DOI 10.1111/j.0022-202X.2004.22406.x; Meding B, 2002, J INVEST DERMATOL, V118, P719, DOI 10.1046/j.1523-1747.2002.01718.x; MEDING B, 1990, CONTACT DERMATITIS, V23, P6, DOI 10.1111/j.1600-0536.1990.tb00076.x; Meding B, 2001, CONTACT DERMATITIS, V45, P341, DOI 10.1034/j.1600-0536.2001.450604.x; Meding B, 2009, BRIT J DERMATOL, V160, P514, DOI 10.1111/j.1365-2133.2008.08930.x; Meding B, 2001, CONTACT DERMATITIS, V45, P99, DOI 10.1034/j.1600-0536.2001.045002099.x; MEDING B, 1987, BRIT J DERMATOL, V116, P627, DOI 10.1111/j.1365-2133.1987.tb05895.x; MEDING B, 1990, CONTACT DERMATITIS, V23, P154, DOI 10.1111/j.1600-0536.1990.tb04776.x; MEDING B, 1990, CONTACT DERMATITIS, V22, P13, DOI 10.1111/j.1600-0536.1990.tb01499.x; Meding B, 2007, J INVEST DERMATOL, V127, P2147, DOI 10.1038/sj.jid.5700841; MEIJER C, 1995, CONTACT DERMATITIS, V32, P147, DOI 10.1111/j.1600-0536.1995.tb00804.x; MENNE T, 1982, ACTA DERM-VENEREOL, V62, P35; Menne T, 1978, Derm Beruf Umwelt, V26, P123; Moberg C, 2009, BRIT J DERMATOL, V161, P397, DOI 10.1111/j.1365-2133.2009.09099.x; Molin S, 2009, BRIT J DERMATOL, V161, P801, DOI 10.1111/j.1365-2133.2009.09245.x; Montnemery P, 2005, ACTA DERM-VENEREOL, V85, P429, DOI 10.1080/00015550510036658; Montnemery Peter, 2003, BMC Dermatol, V3, P4, DOI 10.1186/1471-5945-3-4; Mortz CG, 2002, ACTA DERM-VENEREOL, V82, P359, DOI 10.1080/000155502320624096; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; Nielsen NH, 1999, BRIT J DERMATOL, V141, P676; Nielsen NH, 2002, CONTACT DERMATITIS, V47, P71, DOI 10.1034/j.1600-0536.2002.470203.x; NINAN TK, 1992, BRIT MED J, V304, P873; Ogunbiyi AO, 2005, PEDIATR DERMATOL, V22, P6, DOI 10.1111/j.1525-1470.2005.22101.x; Ortengren U, 1999, EUR J ORAL SCI, V107, P496, DOI 10.1046/j.0909-8836.1999.eos107612.x; PELTONEN L, 1979, CONTACT DERMATITIS, V5, P27, DOI 10.1111/j.1600-0536.1979.tb05531.x; Popescu R, 1999, BRIT J DERMATOL, V140, P891, DOI 10.1046/j.1365-2133.1999.02821.x; Rasmussen K, 2006, AM J IND MED, V49, P767, DOI 10.1002/ajim.20350; REA JN, 1976, BRIT J PREV SOC MED, V30, P107; Schnuch A, 2003, CONTACT DERMATITIS, V49, P107, DOI 10.1111/j.0105-1873.2003.0128f.x; Schultz Larsen F, 1996, J Am Acad Dermatol, V34, P760; Skoet R, 2004, CONTACT DERMATITIS, V51, P159, DOI 10.1111/j.0105-1873.2004.00423.x; SMIT HA, 1993, INT J EPIDEMIOL, V22, P288, DOI 10.1093/ije/22.2.288; Svedman C, 2007, CONTACT DERMATITIS, V56, P338; Thyssen JP, 2009, BRIT J DERMATOL, V161, P1288, DOI 10.1111/j.1365-2133.2009.09405.x; Thyssen JP, 2009, BRIT J DERMATOL, V161, P1124, DOI 10.1111/j.1365-2133.2009.09325.x; Thyssen JP, 2008, CONTACT DERMATITIS, V59, P238, DOI 10.1111/j.1600-0536.2008.01418.x; Thyssen JP, 2007, CONTACT DERMATITIS, V57, P287, DOI 10.1111/j.1600-0536.2007.01220.x; Thyssen JP, 2009, CONTACT DERMATITIS, V61, P342, DOI 10.1111/j.1600-0536.2009.01625.x; Thyssen JP, 2009, J AM ACAD DERMATOL, V61, P799, DOI 10.1016/j.jaad.2009.03.030; Thyssen JP, 2008, DERMATITIS, V19, P303, DOI 10.2310/6620.2008.08022; Thyssen JP, 2009, NEW ENGL J MED, V360, P2259, DOI 10.1056/NEJMc0809293; THYSSEN JP, BRIT J DERMATOL; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Yngveson M, 1998, ACTA DERM-VENEREOL, V78, P371; Yngveson M, 1997, ACTA DERM-VENEREOL, V77, P455; Yngveson M, 2000, BRIT J DERMATOL, V142, P485, DOI 10.1046/j.1365-2133.2000.03361.x	92	120	121	3	20	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-1873			CONTACT DERMATITIS	Contact Dermatitis		2010	62	2					75	87				13	Allergy; Dermatology	Allergy; Dermatology	550XQ	WOS:000274167800002	20136890	
J	Condorelli, P; Shin, HW; Aledia, AS; Silkoff, PE; George, SC				Condorelli, Peter; Shin, Hye-Won; Aledia, Anna S.; Silkoff, Philip E.; George, Steven C.			A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						model; airway; alveolar	RESPIRATORY-TRACT; EXHALED AIR; BREATH-HOLD; ASTHMA; ALVEOLAR; IMPACT; DYNAMICS; HUMANS; LUNGS; NO	The most common technique employed to describe pulmonary gas exchange of nitric oxide (NO) combines multiple constant flow exhalations with a two-compartment model (2CM) that neglects 1) the trumpet shape (increasing surface area per unit volume) of the airway tree and 2) gas phase axial diffusion of NO. However, recent evidence suggests that these features of the lungs are important determinants of NO exchange. The goal of this study is to present an algorithm that characterizes NO exchange using multiple constant flow exhalations and a model that considers the trumpet shape of the airway tree and axial diffusion (model TMAD). Solution of the diffusion equation for the TMAD for exhalation flows > 100 ml/s can be reduced to the same linear relationship between the NO elimination rate and the flow; however, the interpretation of the slope and the intercept depend on the model. We tested the TMAD in healthy subjects (n = 8) using commonly used and easily performed exhalation flows (100, 150, 200, and 250 ml/s). Compared with the 2CM, estimates (mean +/- SD) from the TMAD for the maximum airway flux are statistically higher (J'aw(NO) = 770 +/- 470 compared with 440 +/- 270 pl/s), whereas estimates for the steady-state alveolar concentration are statistically lower (CA(NO) = 0.66 +/- 0.98 compared with 1.2 +/- 0.80 parts/billion). Furthermore, CANO from the TMAD is not different from zero. We conclude that proximal (airways) NO production is larger than previously predicted with the 2CM and that peripheral (respiratory bronchioles and alveoli) NO is near zero in healthy subjects.	Univ Calif Irvine, Dept Biomed Engn, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Chem Engn & Mat Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Dept Med, Div Pulm & Crit Care, Irvine, CA 92697 USA; Drexel Univ, Philadelphia, PA 19104 USA	George, SC (reprint author), Univ Calif Irvine, Dept Biomed Engn, 3120 Nat Sci 2, Irvine, CA 92697 USA.	scgeorge@uci.edu	George, Steven/K-9359-2015	George, Steven/0000-0003-2263-1914	NCRR NIH HHS [RR-00827]; NHLBI NIH HHS [HL-070645]		ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST.PUBMED:15817806; Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; Berkman N, 2005, THORAX, V60, P383, DOI 10.1136/thx.2004.031104; BOUHUYS A, 1987, AM PHYSL SOC, P699; Condorelli P, 2004, J APPL PHYSIOL, V96, P1832, DOI 10.1152/japplphysiol.01157.2003; Dupont LJ, 2003, CHEST, V123, P751, DOI 10.1378/chest.123.3.751; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; George SC, 2004, J APPL PHYSIOL, V96, P831, DOI 10.1152/japplphysiol.00950.2003; Girgis RE, 2002, AM J RESP CRIT CARE, V165, P1587, DOI 10.1164/rccm.2104003; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HANNA LM, 1986, J BIOMECH ENG-T ASME, V108, P12; Hogman M, 2000, RESP MED, V94, P985, DOI 10.1053/rmed.2000.0872; Hogman M, 1997, ACTA PHYSIOL SCAND, V159, P345, DOI 10.1046/j.1365-201X.1997.00101.x; Hogman M, 2002, RESP MED, V96, P24, DOI 10.1053/rmed.2001.1204; Lehtimaki L, 2000, ANN MED, V32, P417, DOI 10.3109/07853890008995949; Lehtimaki L, 2001, AM J RESP CRIT CARE, V163, P1557; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Rottier BL, 2005, J APPL PHYSIOL, V99, P378, DOI 10.1152/japplphysiol.00163.2005; Shin HW, 2006, J APPL PHYSIOL, V100, P623, DOI 10.1152/japplphysiol.00008.2005; Shin HW, 2005, J APPL PHYSIOL, V98, P1869, DOI 10.1152/japplphysiol.01002.2004; Shin HW, 2004, J APPL PHYSIOL, V97, P874, DOI 10.1152/japplphysiol.01297.2003; Shin HW, 2004, J APPL PHYSIOL, V96, P65, DOI 10.1152/japplphysiol.00575.2003; Shin HW, 2003, MED SCI SPORT EXER, V35, P995, DOI 10.1249/01.MSS.0000072247.46963.CD; Shin HW, 2002, J APPL PHYSIOL, V93, P2070, DOI 10.1152/japplphysiol.00129.2002; Shin HW, 2002, AM J RESP CRIT CARE, V165, P349; Shin HW, 2001, J APPL PHYSIOL, V91, P2173; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P642; Tsoukias NM, 2001, J APPL PHYSIOL, V91, P477; Van Muylem A, 2003, J APPL PHYSIOL, V94, P119, DOI 10.1152/japplphysiol.00044.2002; Weibel E, 1963, MORPHOMETRY HUMAN LU	36	120	121	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	JAN	2007	102	1					417	425		10.1152/japplphysiol.00533.2006		9	Physiology; Sport Sciences	Physiology; Sport Sciences	127QB	WOS:000243600300057	16888048	
J	Balali-Mood, M; Hefazi, M				Balali-Mood, Mahdi; Hefazi, Mehrdad			Comparison of early and late toxic effects of sulfur mustard in Iranian veterans	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Review							CHEMICAL WARFARE AGENTS; RESPIRATORY-TRACT; GAS INHALATION; COMPLICATIONS; EXPOSURE; INJURY; WEAPONS; WORKERS; CANCER	Sulfur mustard is an alkylating agent that reacts with ocular, respiratory, cutaneous, and bone marrow tissues, resulting in early and late toxic effects. We compare these effects based on the experience in Iranian veterans exposed to the agent during the Iran-Iraq conflict (1983-88). The first clinical manifestations of sulfur mustard poisoning occurred in the eyes with a sensation of grittiness, lacrimation, photophobia, blepharospasm, and corneal ulceration. Respiratory effects appeared as rhinorhea, laryngitis, tracheobronchitis, and dyspnoea. Skin lesions varied from erythema to bullous necrotization. Initial leukocytosis and lymphopenia returned to normal within four weeks in recovered patients, but marked cytopenia with bone marrow failure occurred in fatal cases. Late toxic effects of sulfur mustard were most commonly found in lungs, skin and eyes. Main respiratory complications were chronic obstructive pulmonary disease, bronchiectasis, asthma, large airway narrowing, and pulmonary fibrosis. Late skin lesions were hyperpigmentation, dry skin, atrophy, and hypopigmentation. Fifteen of the severely intoxicated patients were diagnosed with delayed keratitis, having corneal vascularization, thinning, and epithelial defect. Respiratory complications exacerbated over time, while cutaneous and ocular lesions decreased or remained constant. Both the severity and frequency of bronchiectatic lesions increased during long-term follow-up. The only deteriorating cutaneous complication was dry skin. The maximum incidence of delayed kaeratitis was observed 15 to 20 years after initial exposure. Being suggested as the main cause ofassociated with malignancies and recurrent infections, natural killer cells were significantly lower 16 to 20 years after intoxication.	Mashhad Univ Med Sci, Sch Med, Imam Reza Hosp, Med Toxicol Ctr, Mashhad 91735348, Iran	Balali-Mood, M (reprint author), Mashhad Univ Med Sci, Sch Med, Imam Reza Hosp, Med Toxicol Ctr, Mashhad 91735348, Iran.	mbalalimood@hotmail.com	Balali-Mood, Mahdi/Q-2600-2016	Balali-Mood, Mahdi/0000-0003-2543-7420			AFSHINNIAZ F, 1996, THESIS ISFAHAN U MED; Aghanouri R, 2004, AM J PHYSIOL-LUNG C, V287, P1160; ALEXANDER S F, 1947, Mil Surg, V101, P1; Anslow WP, 1946, CHEM WARFARE AGENTS, P440; Aslani J, 2000, PREVENTION TREATMENT, P76; Bagheri MH, 2003, ACTA RADIOL, V44, P241, DOI 10.1034/j.1600-0455.2003.00073.x; Balali-Mood M., 1984, P 1 WORLD C NEW COMP, P254; Balali M, 1986, P 2 WORLD C NEW COMP, P475; Balali M, 1992, P SEM LAT COMPL CHEM, P15; Balali-Mood M, 2005, FUND CLIN PHARMACOL, V19, P713, DOI 10.1111/j.1472-8206.2005.00364.x; Balali-Mood M., 1986, P 2 WORLD C NEW COMP, P489; Balali-Mood M, 1986, P 2 WORLD C NEW COMP, P464; BEEBE GW, 1960, J NATL CANCER I, V25, P1231; Bijani K, 2002, ECOTOX ENVIRON SAFE, V53, P422, DOI 10.1016/S0147-6513(02)00034-9; BLODI FC, 1971, INT OPHTHALMOL CLIN, V2, P1; CALLAWAY S, 1958, BRIT J PHARM CHEMOTH, V13, P395; CANELLI AF, 1918, RIV OSPEDALIERA ITAL, V8, P2; Chiesman W E, 1944, Br Med J, V2, P109; COLARDYN F, 1984, P 1 WORLD C NEW COMP, P254; Dacre JC, 1996, PHARMACOL REV, V48, P289; DAHL H, 1985, ACTA OPHTHALMOL    S, V173, pS30; DAYHIMI I, 1988, 1 INT MED C CHEM WAR; EASTON DF, 1988, BRIT J IND MED, V45, P652; Emad A, 1999, CHEST, V115, P1346, DOI 10.1378/chest.115.5.1346; Emad A, 1997, CHEST, V112, P734, DOI 10.1378/chest.112.3.734; Etezad-Razavi M, 2006, CLIN EXP OPHTHALMOL, V34, P342, DOI 10.1111/j.1442-9071.2006.1220.x; Fekri AR, 1992, P SEM LAT COMPL CHEM, P57; FOSTER J H, 1962, Am Surg, V28, P461; FREITAG L, 1991, CHEST, V100, P1436, DOI 10.1378/chest.100.5.1436; GEERAETS WJ, 1977, SOUTHERN MED J, V70, P348; Ghanei M, 2004, EUR J RADIOL, V52, P164, DOI 10.1016/j.ejrad.2004.03.018; Ghanei M, 2004, INHAL TOXICOL, V16, P491, DOI 10.1080/08958370490442421; Ghanei M, 2002, ENVIRON HEALTH PERSP, V110, P519; GHANEI M, 2003, AM J RES CRIT MED, V16, P845; Ghotbi L, 2002, INT IMMUNOPHARMACOL, V2, P981, DOI 10.1016/S1567-5769(02)00053-X; Hassan ZM, 2002, IMMUNOL LETT, V83, P151, DOI 10.1016/S0165-2478(02)00076-7; Hefazi M, 2005, INHAL TOXICOL, V17, P587, DOI 10.1080/08958370591000591; Hughes WF, 1942, ARCH OPHTHALMOL-CHIC, V27, P582; INADA I, 1978, J DERMATOL, V5, P49; Javadi MA, 2005, OPHTHALMOLOGY, V112, P617, DOI 10.1016/j.ophtha.2004.09.027; JAVADI MA, 2000, PREVENTION TREATMENT, P81; KHATERI S, 2003, J OCCUP ENVIRON MED, V452, P1136; Krumbhaar EB, 1919, J MED RES, V40, P497; KUMAR PVN, 1988, 1 INT MED C CHEM WAR; Mahmoudi M, 2005, INT IMMUNOPHARMACOL, V5, P1479, DOI 10.1016/j.intimp.2005.04.003; MANN I, 1948, MONOGRAPH S, V13; MANNING KP, 1981, CLIN OTOLARYNGOL, V6, P165, DOI 10.1111/j.1365-2273.1981.tb01527.x; MARS TC, 1996, CHEM WARFARE AGENTS; MAYNARD RL, 1991, LANCET, V337, P122; Maynard R. L., 1995, GEN APPL TOXICOLOGY, P1123; MCNAMARA BP, 1975, EBSP74030 US ARM ARM; MELLOR SG, 1991, BRIT J PLAST SURG, V44, P434; MOMENI AZ, 1992, ARCH DERMATOL, V128, P575; MORADI A, 2004, P 7 INT C DERM IR SO; MURRAY VSG, 1991, BRIT MED J, V302, P129; Nishimoto Y, 1987, Princess Takamatsu Symp, V18, P95; Papirmeister B., 1991, MED DEFENSE MUSTARD; Pickard H. L., 1919, AM J OPHTHALMOL, V3, P136; PIRIE A, 1947, BIOCHEM J, V41, P185; Pleyer U, 1999, AM J OPHTHALMOL, V128, P506, DOI 10.1016/S0002-9394(99)00178-6; RAZAVI SM, 1988, 1 INT MED C CHEM WAR; RENSHAW B, 1949, DIVISION 9 NATL DEFE; ROSENWASSER GOD, 1989, INT OPHTHALMOL CLIN, V29, P153, DOI 10.1097/00004397-198902930-00005; Sasser LB, 1996, REPROD TOXICOL, V10, P311, DOI 10.1016/0890-6238(96)00060-3; SHIRAZI SF, 1988, 1 INT MED C CHEM WAR; SIDELL FR, 1988, EMERGENCY TOXICOLOGY, P255; Sidell FR, 1990, USAARMICD TECHNICAL, P90; Smith HW, 1919, J PHARMACOL EXP THER, V13, P1; SMITH WJ, 1991, ARCH DERMATOL, V127, P1207, DOI 10.1001/archderm.127.8.1207; Solberg Y, 1997, SURV OPHTHALMOL, V41, P461, DOI 10.1016/S0039-6257(97)00021-0; TABARESTANI M, 1988, 1 INT MED C CHEM WAR; *UN SEC COUNC REP, 1988, S19823 UN SEC COUNC; Vedder E, 1925, MED ASPECTS CHEM WAR; WADA S, 1968, LANCET, V1, P1161; Warthin AS, 1918, J LAB CLIN MED, V4, P785; Willemss J, 1989, ANN MED MIL BELG, V3, ps1; ZANDIEH T, 1990, SCAND J IMMUNOL, V32, P423	77	120	124	1	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1742-7835			BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	OCT	2006	99	4					273	282		10.1111/j.1742-7843.2006.pto_429.x		10	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	094LB	WOS:000241239800001	17040211	
J	Shannon, MW; Best, D; Binns, HJ; Johnson, CL; Kim, JJ; Mazur, LJ; Reynolds, DW; Roberts, JR; Weil, WB; Balk, SJ; Miller, M; Shea, KM; Lipsett, M; Johnson, RH; Linet, M; Rogan, W; Spire, P				Shannon, MW; Best, D; Binns, HJ; Johnson, CL; Kim, JJ; Mazur, LJ; Reynolds, DW; Roberts, JR; Weil, WB; Balk, SJ; Miller, M; Shea, KM; Lipsett, M; Johnson, RH; Linet, M; Rogan, W; Spire, P		Comm Environm Hlth	Ambient air pollution: Health hazards to children	PEDIATRICS			English	Article						air pollution; adverse effects; children; asthma; environmental health	LOW-BIRTH-WEIGHT; SOUTHERN CALIFORNIA CHILDREN; RESPIRATORY HOSPITAL ADMISSIONS; AFRICAN-AMERICAN CHILDREN; DIESEL EXHAUST PARTICLES; MOTOR-VEHICLE EXHAUST; EMERGENCY-ROOM VISITS; LUNG-FUNCTION GROWTH; PULMONARY-FUNCTION; DAILY MORTALITY	Ambient (outdoor) air pollution is now recognized as an important problem, both nationally and worldwide. Our scientific understanding of the spectrum of health effects of air pollution has increased, and numerous studies are finding important health effects from air pollution at levels once considered safe. Children and infants are among the most susceptible to many of the air pollutants. In addition to associations between air pollution and respiratory symptoms, asthma exacerbations, and asthma hospitalizations, recent studies have found links between air pollution and preterm birth, infant mortality, deficits in lung growth, and possibly, development of asthma. This policy statement summarizes the recent literature linking ambient air pollution to adverse health outcomes in children and includes a perspective on the current regulatory process. The statement provides advice to pediatricians on how to integrate issues regarding air quality and health into patient education and children's environmental health advocacy and concludes with recommendations to the government on promotion of effective air-pollution policies to ensure protection of children's health.	Amer Acad Pediat, Comm Environm Hlth, Elk Grove Village, IL 60007 USA	Shannon, MW (reprint author), Amer Acad Pediat, Comm Environm Hlth, Elk Grove Village, IL 60007 USA.						*AM AC PED COMM EN, 1993, PEDIATRICS, V91, P12010; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432345; Bobak M, 1999, EPIDEMIOLOGY, V10, P666, DOI 10.1097/00001648-199911000-00004; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; *CA AIR RES BOARD, 2002, JUN 20 2002 BOARD M; CASTILLEJOS M, 1995, AM J RESP CRIT CARE, V152, P1501; Chen PC, 1999, ENVIRON HEALTH PERSP, V107, P921, DOI 10.2307/3454482; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Dejmek J, 2000, ENVIRON HEALTH PERSP, V108, P1159, DOI 10.2307/3434828; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Dockery DW, 2001, ENVIRON HEALTH PERSP, V109, P483, DOI 10.2307/3454657; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; ETZEL RA, 2003, PEDIAT ENV HLTH, P69; Feychting M, 1998, SCAND J WORK ENV HEA, V24, P8; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Frye C, 2003, ENVIRON HEALTH PERSP, V111, P383, DOI 10.1289/ehp.5355; Galizia A, 1999, ENVIRON HEALTH PERSP, V107, P675, DOI 10.2307/3434461; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Ghio AJ, 2002, ENVIRON HEALTH PERSP, V110, P89; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Goldman LR, 2001, PEDIATRICS, V108, P197, DOI 10.1542/peds.108.1.197; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Hajat S, 1999, THORAX, V54, P597; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; HWANG R, 2001, CLEAN GETAWAY SAFE E; *INT AG RES CANC, 1989, IARC MON EV CARC RIS, V46, P458; JACKSON RJ, CREATING HLTH ENV IM; Kinney PL, 1996, ENVIRON HEALTH PERSP, V104, P170, DOI 10.2307/3432785; Korrick SA, 1998, ENVIRON HEALTH PERSP, V106, P93, DOI 10.1289/ehp.9810693; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; Kyle AD, 2001, PUBLIC HEALTH REP, V116, P32, DOI 10.1016/S0033-3549(04)50020-1; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Leikauf GD, 2002, ENVIRON HEALTH PERSP, V110, P505; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Lipsett M, 1999, AM J PUBLIC HEALTH, V89, P1009, DOI 10.2105/AJPH.89.7.1009; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Morello-Frosch RA, 2000, RISK ANAL, V20, P273, DOI 10.1111/0272-4332.202026; National Research Council, 2002, EFF IMP CORP AV FUEL; NAZEMI MA, 2000, MULTIPLE AIR TOXICS; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Ostro BD, 2000, J EXPO ANAL ENV EPID, V10, P412, DOI 10.1038/sj.jea.7500094; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175; Pinkerton KE, 2000, ENVIRON HEALTH PERSP, V108, P457, DOI 10.2307/3454537; Plopper CG, 2000, ENVIRON HEALTH PERSP, V108, pA252, DOI 10.1289/ehp.108-a252; PLUNKETT LM, 1992, SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS : IMPLICATIONS FOR RISK ASSESSMENT, P79; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Pope CA, 1996, J EXPO ANAL ENV EPID, V6, P23; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schwartz J, 2001, ENVIRON HEALTH PERSP, V109, P405, DOI 10.2307/3434788; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; Solomon GM, 2001, NO BREATHING AISLES; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Suh HH, 2000, ENVIRON HEALTH PERSP, V108, P625, DOI 10.2307/3454398; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; *US EPA, 2002, EPA6008909057F NCFEA; *US EPA, SUPR COURT UPH EPA P; *US EPA, 2000, PUBL US EPA; *US EPA, AIR TOX HLTH EC EFF; *US EPA, 1996, PUBL US EPA; U.S. Environmental Protection Agency, 2001, PUBL US EPA; United States Environmental Protection Agency, 1993, EPA400K93001; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WILEY JA, 1991, PUBLICATION CALIFORN; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Woodruff TJ, 1998, ENVIRON HEALTH PERSP, V106, P245, DOI 10.1289/ehp.98106245; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032	98	120	128	7	22	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	DEC	2004	114	6					1699	1707		10.1542/peds.2004-2166		9	Pediatrics	Pediatrics	875WN	WOS:000225453000030		
J	Shore, SA; Rivera-Sanchez, YM; Schwartzman, IN; Johnston, RA				Shore, SA; Rivera-Sanchez, YM; Schwartzman, IN; Johnston, RA			Responses to ozone are increased in obese mice	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						inflammation; polymorphonuclear leukocytes; pulmonary mechanics; leptin	TUMOR-NECROSIS-FACTOR; BODY-MASS INDEX; INDUCED AIRWAY HYPERRESPONSIVENESS; EMERGENCY ROOM VISITS; INSULIN-RESISTANCE; WEIGHT-REDUCTION; OXIDATIVE STRESS; LEPTIN RECEPTOR; FACTOR-ALPHA; ASTHMA	Epidemiological data indicate an increased incidence of asthma in overweight adults and children. Ozone (O-3) is a common trigger for asthma. Accordingly, the purpose of this study was to compare O-3-induced airway hyperresponsiveness and airway inflammation in lean, wild-type (C57BL/6J) mice and mice that are obese as a consequence of a genetic defect in the gene encoding the satiety hormone leptin (ob/ob mice). The ob/ob mice eat excessively and weighed more than twice as much as age- and gender-matched wild-type mice. Airway responsiveness to intravenous methacholine was measured by forced oscillation. In air-exposed controls, baseline pulmonary resistance was greater, and the dose of methacholine required to double pulmonary resistance was lower in ob/ob than wild-type mice. Exposure to O-3 (2 parts/million for 3 h) caused AHR and airway inflammation in both groups of mice, but responses to O-3 were enhanced in ob/ob compared with wild-type mice. Administration of exogenous leptin did not reverse the enhanced inflammatory response observed in ob/ob mice, but augmented airway inflammation in wild-type mice. The inhaled dose of O-3 per gram of lung tissue was greater in ob/ob than wild-type mice. Our results indicate that O-3-induced airway responses are enhanced in ob/ob mice and suggest that inhaled O-3 dose may be one factor contributing to this difference, but other aspects of the obese phenotype may also contribute. Our results also indicate that the hormone leptin, which is increased in the obese, has the capacity to increase airway inflammation.	Harvard Univ, Sch Publ Hlth, Physiol Program, Boston, MA 02115 USA	Shore, SA (reprint author), Harvard Univ, Sch Publ Hlth, Physiol Program, 665 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL-33009, HL-66879]; NIEHS NIH HHS [ES-00002]		ARSALANE K, 1995, AM J RESP CELL MOL, V13, P60; Bergen HT, 2002, AM J RESP CELL MOL, V27, P71; BISHAI JM, 2003, AM J RESP CRIT CARE, V167, pA655; Bouloumie A, 1999, FASEB J, V13, P1231; Breslow MJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE443; Brusasco V, 1998, THORAX, V53, P992; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; DAVFIES DE, 2003, J ALLERGY CLIN IMMUN, V111, P215; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Fauroux B, 2000, PEDIATR PULM, V30, P41; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; Hazucha MJ, 1996, EUR J APPL PHYSIOL O, V73, P17, DOI 10.1007/BF00262805; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Ikejima K, 2001, HEPATOLOGY, V34, P288, DOI 10.1053/jhep.2001.26518; Ishii Y, 1998, AM J PHYSIOL-LUNG C, V274, pL171; Johnston CJ, 1999, EXP LUNG RES, V25, P81, DOI 10.1080/019021499270448; Kyzer S, 1999, OBES SURG, V9, P229, DOI 10.1381/096089299765553089; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Loffreda S, 1998, FASEB J, V12, P57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Matarese G, 2001, EUR J IMMUNOL, V31, P1324, DOI 10.1002/1521-4141(200105)31:5<1324::AID-IMMU1324>3.0.CO;2-Y; MAUTZ WJ, 1989, RESP PHYSIOL, V76, P69, DOI 10.1016/0034-5687(89)90018-2; Michalec L, 2002, J IMMUNOL, V168, P846; Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2; Noviski N, 1999, J APPL PHYSIOL, V86, P202; O'Donnell CP, 1999, AM J RESP CRIT CARE, V159, P1477; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; PENDINO KJ, 1994, AM J RESP CELL MOL, V11, P279; Pillow JJ, 2001, J APPL PHYSIOL, V91, P2730; Rosenbaum M, 1996, J CLIN ENDOCR METAB, V81, P3424, DOI 10.1210/jc.81.9.3424; SAMPSON MG, 1983, J APPL PHYSIOL, V55, P1269; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321; Shaheen SO, 1999, THORAX, V54, P396; Shore SA, 2002, J APPL PHYSIOL, V92, P1019, DOI 10.1152/japplphysiol.00381.2001; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tankersley CG, 1998, J APPL PHYSIOL, V85, P2261; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; Torday JS, 2002, AM J PHYSIOL-LUNG C, V282, pL405; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; Umemoto Y, 1997, BLOOD, V90, P3438; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Weister MJ, 1987, Toxicol. Appl. Pharmacol, V89, P429; YAP JCH, 1995, J APPL PHYSIOL, V79, P1199; ZERAH F, 1993, CHEST, V103, P1470, DOI 10.1378/chest.103.5.1470; ZHANG LY, 1995, EXP LUNG RES, V21, P503, DOI 10.3109/01902149509031755; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	61	120	125	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	SEP	2003	95	3					938	945		10.1152/japplphysiol.00336.2003		8	Physiology; Sport Sciences	Physiology; Sport Sciences	711HP	WOS:000184733800005	12794034	
J	Liu, LJS; Box, M; Kalman, D; Kaufman, J; Koenig, J; Larson, T; Lumley, T; Sheppard, L; Wallace, L				Liu, LJS; Box, M; Kalman, D; Kaufman, J; Koenig, J; Larson, T; Lumley, T; Sheppard, L; Wallace, L			Exposure assessment of particulate matter for susceptible populations in Seattle	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; CHD; COPD; infiltration efficiency; longitudinal correlation; personal cloud; PM2.5; wood smoke	OBSTRUCTIVE PULMONARY-DISEASE; PERSONAL EXPOSURE; AIR-POLLUTION; OUTDOOR CONCENTRATIONS; FINE PARTICLES; EPIDEMIOLOGY-EXPOSURE; COARSE PARTICLES; CASE-CROSSOVER; INDOOR; AMBIENT	In this article we present results from a 2-year comprehensive exposure assessment study that examined the particulate matter (PM) exposures and health effects in 108 individuals with and without chronic obstructive pulmonary disease (COPD), coronary heart disease (CHD), and asthma. The average personal exposures to PM with aerodynamic diameters < 2.5 mum (PM2.5) were similar to the average outdoor PM2.5 concentrations but significantly higher than the average indoor concentrations. Personal PM2.5 exposures in our study groups were lower than those reported in other panel studies of susceptible populations. Indoor and outdoor PM2.5, PM10 (PM with aerodynamic diameters < 10 mum), and the ratio of PM2.5 to PM10 were significantly higher during the heating season. The increase in outdoor PM10 in winter was primarily due to an increase in the PM2.5 fraction. A similar seasonal variation was found for personal PM2.5. The high-risk subjects in our study engaged in an equal amount of dust-generating activities compared with the healthy elderly subjects. The children in the study experienced the highest indoor PM2.5 and PM10 concentrations. Personal PM2.5 exposures varied by study group, with elderly healthy and CHD subjects having the lowest exposures and asthmatic children having the highest exposures. Within study groups, the PM2.5 exposure varied depending on residence because of different particle infiltration efficiencies. Although we found a wide range of longitudinal correlations between central-site and personal PM2.5 measurements, the longitudinal r is closely related to the particle infiltration efficiency. PM2.5 exposures among the COPD and CHD subjects can be predicted with relatively good power with a microenvironmental model composed of three microenvironments. The prediction power is the lowest for the asthmatic children.	Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; US EPA, Reston, VA USA	Liu, LJS (reprint author), Univ Washington, Dept Environm & Occupat Hlth Sci, Box 354695, Seattle, WA 98195 USA.		Kaufman, Joel/B-5761-2008	Kaufman, Joel/0000-0003-4174-9037; Wallace, Lance/0000-0002-6635-2303	NIEHS NIH HHS [P30 ES07033]		ALLEN R, 2001, J AIR WASTE MANAGE, V51, P1651; BAHADORI T, IN PRESS J EXPO ANAL; Brauer M, 1999, J EXPO ANAL ENV EPID, V9, P228, DOI 10.1038/sj.jea.7500040; CLAYTON CA, 1993, J EXPO ANAL ENV EPID, V3, P227; Demokritou P, 2001, AEROSOL SCI TECH, V35, P741, DOI 10.1080/02786820152546789; Ebelt ST, 2000, J AIR WASTE MANAGE, V50, P1081; EVANS G, 1999, J AIR WASTE MANAGE, V50, P1887; Goldberg MS, 2001, AM J EPIDEMIOL, V154, P817, DOI 10.1093/aje/154.9.817; Goswami E, 2002, J AIR WASTE MANAGE, V52, P324; Janssen NAH, 1999, ARCH ENVIRON HEALTH, V54, P95; Janssen NAH, 1998, AM J EPIDEMIOL, V147, P537; Janssen NAH, 1997, OCCUP ENVIRON MED, V54, P888; Janssen NAH, 2000, J AIR WASTE MANAGE, V50, P1133; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; KLEPEIS NE, 1996, EPA600R96074 NAT EXP; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; LARSON T, 1989, URBAN AIR TOXICS MIT; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; MARPLE VA, 1987, JAPCA J AIR WASTE MA, V37, P1303; MAYKUT N, 2001, P REG HAZ GLOB RAD B; MOOLGAVKAR S, 1997, EPIDEMIOLOGY, V8, P360; *NAT RES COUNC, 2001, RES PRIOR AIRB PART, V3; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; Rea AW, 2001, J AIR WASTE MANAGE, V51, P1271; REICHHARDT T, 1995, ENVIRON SCI TECHNOL, V29, pA360, DOI 10.1021/es00008a744; Rodes CE, 2001, J EXPO ANAL ENV EPID, V11, P103, DOI 10.1038/sj.jea.7500155; Rojas-Bracho L, 2000, J EXPO ANAL ENV EPID, V10, P294, DOI 10.1038/sj.jea.7500092; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Schwartz J, 2000, OCCUP ENVIRON MED, V57, P692, DOI 10.1136/oem.57.10.692; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P929; Sioutas C, 1999, J AEROSOL SCI, V30, P693, DOI 10.1016/S0021-8502(98)00758-7; Stieb D, 1998, APPL OCCUP ENV HYG, V13, P461; STYER P, 1995, ENVIRON HEALTH PERSP, V103, P490, DOI 10.2307/3432588; SUH HH, 1992, ENVIRON SCI TECHNOL, V26, P2507, DOI 10.1021/es00036a026; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; SWITZER P, 2001, 200122 STANF U; TSANG AM, 1996, EPA600R96148 OFF RES; *US EPA, 2001, 600P99002AB EPA OFF; Wallace L, 2000, AEROSOL SCI TECH, V32, P15, DOI 10.1080/027868200303894; Wallace L, 1996, J AIR WASTE MANAGE, V46, P98; Williams R, 2000, J EXPO ANAL ENV EPID, V10, P533, DOI 10.1038/sj.jea.7500108; Williams R, 2000, J EXPO ANAL ENV EPID, V10, P518, DOI 10.1038/sj.jea.7500107; Wilson WE, 1997, J AIR WASTE MANAGE, V47, P1238; Wilson WE, 2000, J AIR WASTE MANAGE, V50, P1167; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Zhang JF, 2002, ENVIRON HEALTH PERSP, V110, P961	48	120	123	6	50	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2003	111	7					909	918		10.1289/ehp.6011		10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	689ND	WOS:000183498900028	12782491	
J	Cataldo, DD; Tournoy, KG; Vermaelen, K; Munaut, C; Foidart, JM; Louis, R; Noel, A; Pauwels, RA				Cataldo, DD; Tournoy, KG; Vermaelen, K; Munaut, C; Foidart, JM; Louis, R; Noel, A; Pauwels, RA			Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation	AMERICAN JOURNAL OF PATHOLOGY			English	Article							BROWN-NORWAY RATS; GELATINASE-B; TISSUE INHIBITOR; BRONCHOALVEOLAR LAVAGE; ENDOTHELIAL-CELLS; HUMAN-NEUTROPHILS; MAST-CELLS; T-CELL; ASTHMA; ACTIVATION	We investigated the specific role of matrix metalloproteinase (MMP)-9 in allergic asthma using a murine model of allergen-induced airway inflammation and airway hyperresponsiveness in MMP-9(-/-) mice and their corresponding wild-type (WT) littermates. After a single intraperitoneal sensitization to ovalbumin, the mice were exposed daily either to ovalbumin (1%) or phosphate-buffered saline aerosols from days 14 to 21. Significantly less peribronchial mononuclear cell infiltration of the airways and less lymphocytes in the bronchoalveolar lavage fluid were detected in challenged MMP-9(-/-) as compared to WT mice. In contrast, comparable numbers of bronchoalveolar lavage fluid eosinophils; were observed in both genotypes. After allergen exposure, the WT mice developed a significant airway hyperresponsiveness to carbachol whereas the MMP-9(-/-) mice failed to do so. Allergen exposure induced an increase of MMP-9-related gelatinolytic activity in WT lung extracts. Quantitative reverse transcriptase-polymerase chain reaction showed increased mRNA levels of MMP-12, MMP-14, and urokinase-type plasminogen activator after allergen exposure in the lung extracts of WT mice but not in MMP-9-deficient mice. in contrast, the expression of tissue inhibitor of metalloproteinases-1 was enhanced after allergen exposure in both groups. We conclude that MMP-9 plays a key role in the development of airway inflammation after allergenexposure.	Univ Liege, Dept Resp Dis, Liege, Belgium; Univ Liege, Lab Biol Tumours & Dev, Liege, Belgium; State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Cataldo, DD (reprint author), CHU Sart Tilman, B-4000 Liege, Belgium.			Noel, Agnes/0000-0002-7670-6179; Cataldo, Didier/0000-0002-3079-7941			AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; Betsuyaku T, 1999, AM J RESP CELL MOL, V20, P1303; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRUSSELLE GJ, 1994, AM J RESP CELL MOL B, V12, P254; Cataldo D, 2001, ALLERGY, V56, P145, DOI 10.1034/j.1398-9995.2001.056002145.x; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Corry DB, 1998, MOL MED, V4, P344; Coyle AJ, 1998, EUR J IMMUNOL, V28, P2640, DOI 10.1002/(SICI)1521-4141(199809)28:09<2640::AID-IMMU2640>3.0.CO;2-X; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288; Devy L, 1997, BIOCHEM BIOPH RES CO, V238, P842, DOI 10.1006/bbrc.1997.7398; Edwards DR, 1996, INT J OBES RELAT MET, V20, P9; Esparza J, 1999, BLOOD, V94, P2754; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HACZKU A, 1995, IMMUNOLOGY, V85, P598; Haczku A, 1997, IMMUNOLOGY, V91, P176, DOI 10.1046/j.1365-2567.1997.d01-2221.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325; Ivanoff A, 1999, CLIN EXP METASTAS, V17, P695, DOI 10.1023/A:1006749304315; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Kips JC, 2000, AM J RESP CRIT CARE, V162, pS66; KJELDSEN L, 1994, BLOOD, V83, P1640; Kumagai K, 1999, J IMMUNOL, V162, P4212; Lambert CA, 2001, MATRIX BIOL, V20, P397, DOI 10.1016/S0945-053X(01)00156-1; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Lefort J, 1996, J ALLERGY CLIN IMMUN, V97, P788, DOI 10.1016/S0091-6749(96)80157-6; Legrand C, 1999, J CELL BIOL, V146, P517, DOI 10.1083/jcb.146.2.517; LEWALLE JM, 1995, J CELL PHYSIOL, V165, P475, DOI 10.1002/jcp.1041650305; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; Mackarel AJ, 1999, AM J RESP CELL MOL, V20, P1209; Matsubara S, 1998, INT ARCH ALLERGY IMM, V116, P67, DOI 10.1159/000023927; Mautino G, 1999, LAB INVEST, V79, P39; Mautino G, 1997, AM J RESP CELL MOL, V17, P583; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Nagase H, 1997, BIOL CHEM, V378, P151; Ohno I, 1997, AM J RESP CELL MOL, V16, P212; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; PEPPIN GJ, 1986, P NATL ACAD SCI USA, V83, P4322, DOI 10.1073/pnas.83.12.4322; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; Tournoy KG, 2001, J IMMUNOL, V166, P6982; Trocme C, 1998, J BIOL CHEM, V273, P20677, DOI 10.1074/jbc.273.32.20677; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; VISSERS MCM, 1988, BIOCHEM J, V249, P327; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yao PM, 1999, ANN NY ACAD SCI, V878, P512, DOI 10.1111/j.1749-6632.1999.tb07712.x; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	50	120	131	0	6	AMER SOC INVESTIGATIVE PATHOLOGY, INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3993 USA	0002-9440			AM J PATHOL	Am. J. Pathol.	AUG	2002	161	2					491	498		10.1016/S0002-9440(10)64205-8		8	Pathology	Pathology	582DQ	WOS:000177334800018	12163374	
J	Jensen, CS; Lisby, S; Baadsgaard, O; Volund, A; Menne, T				Jensen, CS; Lisby, S; Baadsgaard, O; Volund, A; Menne, T			Decrease in nickel sensitization in a Danish schoolgirl population with ears pierced after implementation of a nickel-exposure regulation	BRITISH JOURNAL OF DERMATOLOGY			English	Article						contact allergy; Denmark; exposure regulation; nickel; patch test	ORTHODONTIC TREATMENT; IMMUNE TOLERANCE; ALLERGY; CONTACT; INDUCTION; DENMARK; ATOPY	Background To reduce the skin nickel exposure of the population the Danish Ministry of Environment issued a regulation that was implemented in 1992, and the European Union countries have recently adopted an expanded regulation. Objectives The aim of our combined patch testing and questionnaire investigation of girls in public schools and high schools/production schools was to evaluate whether the regulation has had an impact on the prevalence of nickel sensitization. Methods To find a group of girls with cars pierced mainly after implementation of the nickel-exposure regulation in Denmark, girls were recruited from the fifth and sixth grade in 12 public schools (the public school group). After the public school level almost all girls from a public school population continue their education in high schools or other schools such as production schools or technical schools. Therefore, to find girls demographically similar to the public school girls but older, and with ears pierced before implementation of the regulation, girls from seven high schools and two production schools were recruited (the high school group). Four hundred and twenty-seven girls in the public school group (mean age 12.4 years, range 10-14) and 534 in the high school group (mean age 18.8 years, range 17-22) participated. All participants filled out a questionnaire concerning ear piercing, use of oral braces and former patch testing for nickel sensitivity. Three hundred and five girls (71.4%) in the public school group and 275 (51.5%) in the high school group were patch tested or had been tested previously and the results of these tests were included in the study. The relation between the frequency of nickel sensitization and the various factors that might influence the prevalence of nickel sensitization was evaluated by multivariate logistic regression analysis. The investigation was conducted from March 1999 to March 2000. Results The study showed that both increasing age and having ears pierced before 1992 enhanced the prevalence of nickel sensitization. We found that 17.1% of the girls in the high school group demonstrated a positive patch test reaction to nickel. In contrast, the prevalence of nickel sensitization in the public school group was only 3.9%. Comparing girls with and without pierced ears, the prevalence of nickel sensitization was significantly higher in girls with ears pierced before, but not after, 1992 (odds ratio 3.34 and 1.20, respectively). Only in the high school group was there a tendency that wearing oral braces before ear piercing had a protective effect on nickel sensitization, but this did not reach statistical significance. Conclusions As we found an effect of ear piercing before but not after 1992, this study strongly suggests that implementation of the nickel-exposure regulation in 1992 in Denmark has had the intended effect of protecting the female population from becoming allergic to nickel.	Univ Copenhagen, Gentofte Hosp, Dept Dermatol, DK-2900 Hellerup, Denmark; Novo Nordisk AS, Dept Biostat, DK-2880 Bagsvaerd, Denmark	Jensen, CS (reprint author), Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Niels Andersensvej 65, DK-2900 Hellerup, Denmark.						BOSS A, 1982, CONTACT DERMATITIS, V8, P211, DOI 10.1111/j.1600-0536.1982.tb04191.x; Danish Ministry of Environment, 1991, 854 DAN MIN ENV; *DAN MIN ENV EN, 2000, 24 DAN MIN ENV EN; Devos SA, 2001, CONTACT DERMATITIS, V44, P273, DOI 10.1034/j.1600-0536.2001.440503.x; DOTTERUD LK, 1994, CONTACT DERMATITIS, V31, P308, DOI 10.1111/j.1600-0536.1994.tb02025.x; EMMETT EA, 1988, J AM ACAD DERMATOL, V19, P314, DOI 10.1016/S0190-9622(88)70178-4; *INT CONT DERM RES, 1984, EUR STAND SER ICDRG, V11, P63; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; KANERVA L, 1988, CONTACT DERMATITIS, V18, P10, DOI 10.1111/j.1600-0536.1988.tb05482.x; Kerosuo H, 1996, AM J ORTHOD DENTOFAC, V109, P148, DOI 10.1016/S0889-5406(96)70175-0; LARSSONSTYMNE B, 1985, CONTACT DERMATITIS, V13, P289, DOI 10.1111/j.1600-0536.1985.tb02580.x; MCDONAGH AJG, 1992, BRIT J DERMATOL, V126, P16, DOI 10.1111/j.1365-2133.1992.tb08396.x; Menne T, 1996, ANN CLIN LAB SCI, V26, P133; MENNE T, 1990, CONTACT DERMATITIS, V23, P57, DOI 10.1111/j.1600-0536.1990.tb00093.x; Menne T., 1989, NICKEL SKIN IMMUNOLO, P109; MOERTZ CG, 1999, THESIS U SO DENMARK; NIELSEN NH, 1993, CONTACT DERMATITIS, V29, P16; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; STAERKJAER L, 1990, EUR J ORTHODONT, V12, P284; TODD DJ, 1989, ULSTER MED J, V58, P168; VANHOOGSTRATEN IMW, 1992, J INVEST DERMATOL, V99, P608, DOI 10.1111/1523-1747.ep12668010; VANHOOGSTRATEN IMW, 1993, J INVEST DERMATOL, V101, P26, DOI 10.1111/1523-1747.ep12358502; VANHOOGSTRATEN IMW, 1991, CLIN EXP IMMUNOL, V85, P441; VANHOOGSTRATEN IMW, 1994, J INVEST DERMATOL, V102, P80, DOI 10.1111/1523-1747.ep12371736; WAHLBERG JE, 2001, TXB CONTACT DERMATIT, P438	25	120	121	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	APR	2002	146	4					636	642		10.1046/j.1365-2133.2002.04666.x		7	Dermatology	Dermatology	559HG	WOS:000176020300014	11966696	
J	Mortimer, KM; Neas, LM; Dockery, DW; Redline, S; Tager, IB				Mortimer, KM; Neas, LM; Dockery, DW; Redline, S; Tager, IB			The effect of air pollution on inner-city children with asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; asthma; generalized estimating equations; inner-city; mixed linear models	RESPIRATORY-FUNCTION; AMBIENT OZONE; MEXICO-CITY; PARTICULATE; ASSOCIATION; REANALYSIS; RESPONSES; HEALTH	The effect of daily ambient air pollution was examined within a cohort of 846 asthmatic children residing in eight urban areas of the USA, using data from the National Cooperative Inner-City, Asthma Study. Daily air pollution concentrations were extracted from the Aerometric Information Retrieval System database from the Environment Protection Agency in the USA. Mixed linear models and generalized estimating equation models were used to evaluate the effects of several air pollutants (ozone, sulphur dioxide (SOD, nitrogen dioxide (NO2) and particles with a 50% cut-off aerodynamic diameter of 10 mum (PM10) on peak expiratory flow rate (PEFR) and symptoms in 846 children with a history of asthma (ages 4-9 yrs). None of the pollutants were associated with evening PEFR or symptom reports. Only ozone was associated with declines in morning %, PEFR (0.59% decline (95%, confidence interval (CI) 0.13-1.05%,) per interquartile range (IQR) increase in 5-day average ozone). In single pollutant models, each pollutant was associated with an increased incidence of morning symptoms: (odds ratio (OR)=1.16 (95%, Cl 1.02-1.30) per IQR increase in 4-day average ozone, OR=1.32 (95% CI 1.03-1.70) per IQR increase in 2-day average SO2, OR=1.48 (95% CI 1.02-2.16) per IQR increase in 6-day average NO2 and OR=1.26 (95% CI 1.0 1.59) per IQR increase in 2-day average PM10. This longitudinal analysis supports previous time-series findings that at levels below current USA air-quality standards, summer-air pollution is significantly related to symptoms and decreased pulmonary function among children with asthma.	Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; US EPA, Epidemiol & Biomarkers Branch, Natl Hlth & Environm Effects Res Lab, Human Studies Div, Chapel Hill, NC USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Environm Hlth, Boston, MA 02115 USA; Case Western Reserve Univ, Rainbow Babies & Childrens Hosp, Dept Pediat, Cleveland, OH 44106 USA; Univ Calif Berkeley, Dept Publ Hlth Biol & Epidemiol, Berkeley, CA 94720 USA	Mortimer, KM (reprint author), Univ Calif Berkeley, Sch Publ Hlth, 1918 Univ Ave, Berkeley, CA 94720 USA.		Neas, Lucas/J-9378-2012		NIAID NIH HHS [AI-15105, AI-30752, AI-30756, AI-30772, AI-30773, AI-30777, AI-30779, AI30780, U01 AI-30751]		AVOL EL, 1998, 82 HLTH EFF I; BALMES JR, 1993, ENVIRON HEALTH PERSP, V101, P219, DOI 10.2307/3431683; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Chatfield C., 1996, ANAL TIME SERIES; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Diggle P. J., 1994, ANAL LONGITUDINAL DA; FRISCHER TM, 1993, AM REV RESPIR DIS, V148, P961; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; Kimber Ian, 1998, Toxicology Letters (Shannon), V102-103, P301, DOI 10.1016/S0378-4274(98)00320-8; Kinney PL, 1996, ENVIRON HEALTH PERSP, V104, P170, DOI 10.2307/3432785; KINNEY PL, 1998, 98 HLTH EFF I; Littell R., 1996, SAS SYSTEM MIXED MOD; Mitchell H, 1997, PEDIATR PULM, V24, P237; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; National Heart Lung and Blood Institute, 1997, NIH PUB; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111; OSTRO BD, 1991, AM J PUBLIC HEALTH, V81, P694, DOI 10.2105/AJPH.81.6.694; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Redline S, 1996, PEDIATR PULM, V21, P203; Roemer W, 2000, CLIN EXP ALLERGY, V30, P1067; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; TAGER IB, 1998, 81 HLTH EFF I; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; [Anonymous], 1997, FED REG, V62	30	120	123	0	15	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	APR	2002	19	4					699	705		10.1183/09031936.02.00247102		7	Respiratory System	Respiratory System	541RB	WOS:000174996600018	11999000	
J	Rodriguez, MA; Winkleby, MA; Ahn, D; Sundquist, J; Kraemer, HC				Rodriguez, MA; Winkleby, MA; Ahn, D; Sundquist, J; Kraemer, HC			Identification of population subgroups of children and adolescents with high asthma prevalence - Findings from the Third National Health and Nutrition Examination Survey	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							BODY-MASS INDEX; CHILDHOOD ASTHMA; UNITED-STATES; RISK-FACTORS; RESPIRATORY ILLNESS; PARENTAL SMOKING; PUERTO-RICAN; ENVIRONMENTAL EXPOSURES; PASSIVE SMOKING; YOUNG-ADULTS	Objectives: To provide national estimates of asthma prevalence in African-American, Mexican American and white (non-Latino) children and adolescents using several common definitions; to evaluate familial, sociodemographic, and environmental risk factors that are independently associated with current asthma in children and to identify subgroups at particular risk for current asthma using 2 complementary data analytic approaches. Design: Cross-sectional study, using the Third National Health and Nutrition Examination Survey, 1988-1994. Setting: Eighty-nine mobile examination centers in the United States. Participants: Twelve thousand three hundred eighty-eight African American, Mexican American, and white (non-Latino) children and adolescents, aged 2 months through 16 years, selected from a systematic random, population-based, nationally representative sample. Main Outcome Measure: Current asthma, defined by caregivers who reported that their child currently had doctor-diagnosed asthma. Results: The overall prevalence of current asthma was 6.7% (95% confidence interval [CI], 5.6-7.8). Odds ratios for current asthma from the multiple regression analysis were 4.00 (95% CI, 2.90-5.52) for children with a parental history of asthma or hay fever, 1.94 (95% CI, 1.09-3.46) for children with body mass index (calculated as weight in kilograms divided by the square of height in meters) greater than or equal to the 85th percentile, and 1.64 (95% CI, 1.20-2.26) for children of African American ethnicity. African American and Mexican American children showed a consistent prevalence of current asthma across age while white children showed an increase in prevalence with age. The 2 highest-risk subgroups identified by the signal detection analysis were composed of children with a parental history of asthma or hay fever who were 10 years or older with a body mass index greater than or equal to the 85th percentile (31.0% current asthma), and children with a parental history who were 10 years or younger and of African American ethnicity (15.6% current asthma). Conclusions: The findings from this analysis show a strong independent association between obesity and current asthma in children and adolescents, and confirm previous reports of a parental history of asthma or hay fever and African American ethnicity as additional important risk factors.	Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Stanford Ctr Res Dis Prevent, Dept Med, Palo Alto, CA 94304 USA; Stanford Univ, Sch Med, Dept Psychiat, Palo Alto, CA 94304 USA	Rodriguez, MA (reprint author), Univ Calif Los Angeles, Sch Med, Dept Family Med, 924 Westwood Blvd,Suite 725, Los Angeles, CA 90024 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P609; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; CRAIN EF, 1994, PEDIATRICS, V94, P356; Dietz WH, 1998, J PEDIATR-US, V132, P191; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Gergen PJ, 1998, PEDIATRICS, V101, P1, DOI DOI 10.1542/PEDS.101.2.E8; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; GORTMAKER SL, 1982, AM J PUBLIC HEALTH, V72, P574, DOI 10.2105/AJPH.72.6.574; HALFON N, 1993, PEDIATRICS, V91, P56; Halterman JS, 2000, PEDIATRICS, V105, P272; Infante-Rivard C, 1999, AM J EPIDEMIOL, V150, P528; KRAEMER HC, 1992, SAGE PUBLICATIONS; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Lara M, 1999, WESTERN J MED, V170, P75; LEE DA, 1983, BRIT MED J, V286, P1256; Lieu TA, 1997, PEDIATRICS, V100, P334, DOI 10.1542/peds.100.3.334; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Martinez FD, 1999, LANCET S2, V354, pSII12; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; National Center for Health Statistics, 1994, VITAL HLTH STAT, V1, P1; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; PIKLE JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SHAH BV, 1991, SUDDAAN USERS MANUAL; Shaheen SO, 1999, THORAX, V54, P396; Siersted HC, 1998, BRIT MED J, V316, P651; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96; Strachan DP, 1997, THORAX, V52, P905; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174; Troiano RP, 1998, PEDIATRICS, V101, P497; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; Winkleby MA, 1999, JAMA-J AM MED ASSOC, V281, P1006, DOI 10.1001/jama.281.11.1006; WINKLEBY MA, 1994, AM J PUBLIC HEALTH, V84, P767, DOI 10.2105/AJPH.84.5.767; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777	52	120	125	1	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	MAR	2002	156	3					269	275				7	Pediatrics	Pediatrics	528XK	WOS:000174270000012	11876672	
J	Nielsen, KG; Bisgaard, H				Nielsen, KG; Bisgaard, H			Discriminative capacity of bronchodilator response measured with three different lung function techniques in asthmatic and healthy children aged 2 to 5 years	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						healthy children; preschool children; bronchodilator responsiveness; lung function tests	AIRWAY-RESISTANCE; INTERRUPTER TECHNIQUE; OSCILLATION TECHNIQUE; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; COLD-AIR; PLETHYSMOGRAPHY; REVERSIBILITY; CHALLENGE	The primary aim of this study was to quantify and compare bronchodilator responsiveness in healthy and asthmatic children aged 2 to 5 yr. The secondary aim of the study was to compare discriminative capacity (i.e., sensitivity, specificity, and predictive values of the reversibility test for the diagnosis of asthma) for each of the lung function tests applied in the study. Specific airway resistance (sRaw) as measured by whole-body plethysmography, respiratory resistance as measured with the interrupter technique (Rint), and respiratory resistance and reactance at 5 Hz (Rrs5, Xrs5, respectively) as measured with the impulse oscillation technique were assessed before and 20 min after inhalation of terbutaline from a pressurized metered-dose inhaler via a metal spacer by 92 children (37 healthy controls and 55 asthmatic subjects). The study of healthy children followed a randomized, double-blind, crossover design, whereas the study of asthmatic children was open. Baseline lung function was significantly decreased in asthmatic children as compared with healthy control subjects as reflected by all techniques used in the study. sRaw, Rint, and Rrs5, but not Xrs5, improved significantly with terbutaline as compared with placebo in healthy control subjects. Lung function Improved to a significantly greater extent in asthmatic children than in control subjects as reflected by all methods. sRaw provided the best discriminative power of such a bronchodilator response, with a sensitivity of 66% and specificity of 81% at the cutoff level of a 25% decrease in sRaw after bronchodilator administration. In conclusion, bronchodilator response measured by sRaw allows a separation of asthmatic from healthy young children. This may help define asthma in this clinically difficult-to-manage group of young wheezy children. The sensitivity and specificity of the other methods used in the study were less than those of sRaw.	Univ Copenhagen Hosp, Dept Pediat 5003, Rigshosp, DK-2100 Copenhagen, Denmark	Bisgaard, H (reprint author), Univ Copenhagen Hosp, Dept Pediat 5003, Rigshosp, DK-2100 Copenhagen, Denmark.		Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; BIBI H, 1991, PEDIATR PULM, V10, P244, DOI 10.1002/ppul.1950100404; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; BLAND JM, 1986, LANCET, V1, P307; Bridge PD, 1999, EUR RESPIR J, V13, P792, DOI 10.1034/j.1399-3003.1999.13d16.x; CASAN P, 1983, B EUR PHYSIOPATH RES, V19, P567; DALES RE, 1988, AM REV RESPIR DIS, V138, P317; DEMEDTS M, 1990, EUR RESPIR J, V3, P1084; EKWO EE, 1983, AM REV RESPIR DIS, V127, P108; Hellinckx J, 1998, EUR RESPIR J, V12, P438, DOI 10.1183/09031936.98.12020438; Klug B, 1998, PEDIATR PULM, V25, P322, DOI 10.1002/(SICI)1099-0496(199805)25:5<322::AID-PPUL6>3.0.CO;2-K; Klug B, 1999, EUR RESPIR J, V14, P1185, DOI 10.1183/09031936.99.14511859; Klug B, 1996, PEDIATR PULM, V21, P290; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; Nielsen KG, 2000, AM J RESP CRIT CARE, V162, P1500; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; VANNOORD JA, 1994, AM J RESP CRIT CARE, V150, P551; WAALKENS HJ, 1993, EUR RESPIR J, V6, P645; Warner JO, 1998, PEDIATR PULM, V25, P1	20	120	130	1	8	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2001	164	4					554	559				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	469LL	WOS:000170816900009	11520714	
J	Marogna, M; Spadolini, I; Massolo, A; Canonica, GW; Passalacqua, G				Marogna, Maurizio; Spadolini, Igino; Massolo, Alessandro; Canonica, Giorgio Walter; Passalacqua, Giovanni			Long-lasting effects of sublingual immunotherapy according to its duration: A 15-year prospective study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Sublingual immunotherapy; allergic rhinitis; long-lasting effect; house dust mite	GRASS-POLLEN IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; TERM CLINICAL-EFFICACY; HOUSE-DUST MITE; RESPIRATORY ALLERGY; IMMUNOGLOBULIN-E; POSITION PAPER; FOLLOW-UP; ASTHMA; CHILDREN	Background: Data on the long-term effects of sublingual immunotherapy (SLIT) are sparse, and the optimal duration of treatment is a matter of debate. Objective: We sought to prospectively evaluate the long-term effect of SLIT given for 3, 4, or 5 years and to compare the effect of those different durations. Methods: In this prospective open controlled study we followed up patients with respiratory allergy who were monosensitized to mites for 15 years. The subjects were divided in 4 groups receiving drug therapy alone or SLIT for 3, 4, or 5 years. Clinical scores, skin sensitizations, methacholine reactivity, and nasal eosinophil counts were evaluated every year during the winter months. The clinical effect was considered to persist until clinical scores remained at less than 50% of the baseline value, and then patients underwent another course of SLIT. Results: Seventy-eight patients were enrolled, and 59 completed the study. In the 12 control subjects no relevant change in clinical scores was seen throughout the study. In the patients receiving SLIT for 3 years, the clinical benefit persisted for 7 years. In those receiving immunotherapy for 4 or 5 years, the clinical benefit persisted for 8 years. New sensitizations occurred in all the control subjects over 15 years and in less than a quarter of the patients receiving SLIT (21%, 12%, and 11%, respectively). The second course of vaccination induced a benefit more rapidly than the first course. The behavior of bronchial hyperreactivity and nasal eosinophils paralleled the clinical score. Conclusion: Under the present conditions, it can be suggested that a 4-year duration of SLIT is the optimal choice because it induces a long-lasting clinical improvement similar to that seen with a 5-year course and greater than that of a 3-year vaccination. (J Allergy Clin Immunol 2010;126:969-75.)	[Marogna, Maurizio] Macchi Hosp Fdn, Pneumol Unit, Varese, Italy; [Spadolini, Igino] Anallergo, Dept Med, Florence, Italy; [Massolo, Alessandro] Univ Calgary, Fac Vet Med, Dept Ecosyst & Publ Hlth, Calgary, AB T2N 1N4, Canada; [Canonica, Giorgio Walter; Passalacqua, Giovanni] Univ Genoa, DIMI, I-16126 Genoa, Italy	Passalacqua, G (reprint author), Padiglione Maragliano, Dept Internal Med, Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	Massolo, Alessandro/I-3437-2012		ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche)	Supported in part by ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche).	Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 1998, ALLERGY S, V54, P1; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR., 2010, J ALLERGY CLIN IMMUN, V125, pe1; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Frew AJ, 2010, J ALLERGY CLIN IMMUN, V125, pS306, DOI 10.1016/j.jaci.2009.10.064; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2008, CLIN EXP ALLERGY, V38, P1074, DOI 10.1111/j.1365-2222.2008.02976.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2009, ANN ALLERG ASTHMA IM, V102, P69, DOI 10.1016/S1081-1206(10)60111-1; *NAT HEART LUNG BL, 1995, GLOB IN MAN ASTHM GI; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2009.02194.x, 10.1111/j.1398-9995.2008.01875.x]; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Scadding K, 1986, CLIN ALLERGY, V16, P483; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; Tahamiler R, 2007, LARYNGOSCOPE, V117, P965, DOI 10.1097/MLG.0b013e31804f8141	28	119	129	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2010	126	5					969	975		10.1016/j.jaci.2010.08.030		7	Allergy; Immunology	Allergy; Immunology	674HB	WOS:000283727100012	20934206	
J	Barrett, NA; Maekawa, A; Rahman, OM; Austen, KF; Kanaoka, Y				Barrett, Nora A.; Maekawa, Akiko; Rahman, Opu M.; Austen, K. Frank; Kanaoka, Yoshihide			Dectin-2 Recognition of House Dust Mite Triggers Cysteinyl Leukotriene Generation by Dendritic Cells	JOURNAL OF IMMUNOLOGY			English	Article							C-TYPE LECTIN; MANSONI EGG ANTIGENS; ALLERGIC AIRWAY INFLAMMATION; ARACHIDONIC-ACID CASCADE; RECEPTOR GAMMA-CHAIN; MOUSE BONE-MARROW; HUMAN MAST-CELLS; SCHISTOSOMA-MANSONI; DC-SIGN; PATTERN-RECOGNITION	House dust mites are a significant source of airborne allergen worldwide, but there is little understanding of how they so potently generate allergic inflammation. We found that extracts from the house dust mites Dermatophagoides farinae (Df) and Dermatophagoides pteronyssinus and from the mold Aspergillus fumigatus stimulated a rapid and robust production of cysteinyl leukotrienes (cys-LTs), proinflammatory lipid mediators, from mouse bone marrow-derived dendritic cells (BMDCs). Con A affinity chromatography of the Df extract revealed that the relevant ligand is a glycan(s), suggesting stimulation via a dendritic cell (DC) lectin receptor. Cys-LT production in BMDCs from wild-type mice was inhibited by spleen tyrosine kinase (Syk) inhibitors and was abolished in BMDCs from FcR gamma(-/-) mice, implicating either Dectin-2 or DC immunoactivating receptor. Transfection of each receptor in bone marrow-derived mast cells revealed that only Dectin-2 mediates cys-LT production by Df, Dermatophagoides pteronyssinus, and Aspergillus famigatus. Lentiviral knockdown of Dectin-2 in BMDCs attenuated Df extract-elicited cys-LT generation, thereby identifying Dectin-2 as the receptor. Lung CD11c(+) cells, but not peritoneal or alveolar macrophages, also generated cys-LTs in response to Df. These findings place Dectin-2 among the C-type lectin receptors that activate arachidonic acid metabolism and identify the Dectin-2/FcR gamma/Syk/cys-LT axis as a novel mechanism by which three potent indoor allergens may activate innate immune cells to promote allergic inflammation. The Journal of Immunology, 2009, 182: 1119-1128.	[Kanaoka, Yoshihide] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Kanaoka, Y (reprint author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Smith Bldg,Room 626C,1 Jimmy Fund Way, Boston, MA 02115 USA.	ykanaoka@rics.bwh.harvard.edu			National Institutes of Health [AI-07306, AI-31599, AI-52353, HL-36110, HL-82695]	This work was supported by National Institutes of Health Grants AI-07306, AI-31599, AI-52353, HL-36110, and HL-82695. N.A.B. is supported by an American Academy of Allergy, Asthma, and Immunology/Altana grant for advanced fellows-in-training and the Joycelyn C. Austen Fund for the Career Development of Women Physician Scientists.	Ago H, 2007, NATURE, V448, P609, DOI 10.1038/nature05936; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Austen KF, 2008, NAT IMMUNOL, V9, P113, DOI 10.1038/ni0208-113; Bonkobara M, 2001, J IMMUNOL, V167, P6893; Buczynski MW, 2007, J BIOL CHEM, V282, P22834, DOI 10.1074/jbc.M701831200; Cates EC, 2004, J IMMUNOL, V173, P6384; CLAESSON HE, 1985, BIOCHIM BIOPHYS ACTA, V836, P361, DOI 10.1016/0005-2760(85)90140-7; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; Deslee G, 2002, J ALLERGY CLIN IMMUN, V110, P763, DOI 10.1067/mai.2002.129121; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Ebeling C, 2007, J IMMUNOL, V179, P2910; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fattouh R, 2005, AM J RESP CRIT CARE, V172, P314, DOI 10.1164/rccm.200502-198OC; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Ichiyama T, 2005, CLIN EXP ALLERGY, V35, P1214, DOI 10.1111/j.1365-2222.2005.02323.x; Jiang YF, 2006, J IMMUNOL, V177, P2755; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Kanazawa N, 2003, J BIOL CHEM, V278, P32645, DOI 10.1074/jbc.M304226200; Kanazawa N, 2007, J DERMATOL SCI, V45, P77, DOI 10.1016/j.jdermsci.2006.09.001; Kim DC, 2006, J IMMUNOL, V176, P4440; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LEIER I, 1994, J BIOL CHEM, V269, P27807; LOBELL RB, 1993, J BIOL CHEM, V268, P1207; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Lynch KR, 1999, NATURE, V399, P789; Machida I, 2004, J IMMUNOL, V172, P1833; McCurdy JD, 2003, J IMMUNOL, V170, P1625; McGreal EP, 2006, GLYCOBIOLOGY, V16, P422, DOI 10.1093/glycob/cwj077; Meyer S, 2007, GLYCOBIOLOGY, V17, P1104, DOI 10.1093/glyco/cwm073; Molina DM, 2007, NATURE, V448, P613, DOI 10.1038/nature06009; Okano M, 2001, J IMMUNOL, V167, P442; Okano M, 1999, J IMMUNOL, V163, P6712; Olynych TJ, 2006, J ALLERGY CLIN IMMUN, V118, P837, DOI 10.1016/j.jaci.2006.06.008; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rius M, 2008, J PHARMACOL EXP THER, V324, P86, DOI 10.1124/jpet.107.131342; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; ROUZER CA, 1980, P NATL ACAD SCI-BIOL, V77, P4928, DOI 10.1073/pnas.77.8.4928; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Shreffler WG, 2006, J IMMUNOL, V177, P3677; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; Suram S, 2006, J BIOL CHEM, V281, P5506, DOI 10.1074/jbc.M509824200; Takai T, 2006, INT ARCH ALLERGY IMM, V139, P181, DOI 10.1159/000091163; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P194, DOI 10.1159/000086331; Taylor PR, 2005, EUR J IMMUNOL, V35, P2163, DOI 10.1002/eji.200425785; Thivierge M, 2006, J ALLERGY CLIN IMMUN, V117, P1155, DOI 10.1016/j.jaci.2005.12.1342; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Valera I, 2008, J IMMUNOL, V180, P5727; Valera I, 2007, J LEUKOCYTE BIOL, V81, P925, DOI 10.1189/jlb.0706451; van Die I, 2003, GLYCOBIOLOGY, V13, P471, DOI 10.1093/glycob/cwg052; van Vliet SJ, 2007, CURR OPIN IMMUNOL, V19, P435, DOI 10.1016/j.coi.2007.05.006; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; Woszczek G, 2008, J ALLERGY CLIN IMMUN, V121, P215, DOI 10.1016/j.jaci.2007.09.013; Yu CK, 2003, J IMMUNOL, V171, P3808	64	119	122	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JAN 15	2009	182	2					1119	1128				10	Immunology	Immunology	393RO	WOS:000262390600041	19124755	
J	Slama, R; Morgenstern, V; Cyrys, J; Zutavern, A; Herbarth, O; Wichmann, HE; Heinrich, J				Slama, Remy; Morgenstern, Verena; Cyrys, Josef; Zutavern, Anne; Herbarth, Olf; Wichmann, Heinz-Erich; Heinrich, Joachim		LISA Study Group	Traffic-related atmospheric pollutants levels during pregnancy and offspring's term birth weight: a study relying on a land-use regression exposure model	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						atmospheric pollution; birth weight; diesel soot; environment; geographic information system; intrauterine growth restriction; particulate matter; pregnancy; reproduction; road traffic; sensitivity analysis	PARTICULATE AIR-POLLUTION; POLYCYCLIC AROMATIC-HYDROCARBONS; LOS-ANGELES-COUNTY; FETAL-GROWTH; RESPIRATORY HEALTH; ORGANIC-COMPOUNDS; MATERNAL SMOKING; FINE PARTICLES; DNA-DAMAGE; OUTCOMES	BACKGROUND: Some studies have suggested that particulate matter (PM) levels during pregnancy may be associated with birth weight. Road traffic is a major source of fine PM (PM with aerodynamic diameter < 2.5 mu m; PM(2.5)). OBJECTIVE: We determined to characterize the influence of maternal exposure to atmospheric pollutants due to road traffic and urban activities on offspring term birth weight. METHODS: Women from a birth cohort [the LISA (Influences of Lifestyle Related Factors on the Human Immune System and Development of Allergies in Children) cohort] who delivered a non-premature baby with a birth weight > 2,500 g in Munich metropolitan area were included. We assessed PM(2.5), PM(2.5) absorbance (which depends on the blackness of PM(2.5), a marker of traffic-related air pollution), and nitrogen dioxide levels using a land-use regression model, taking into account the type and length of roads, population density, land coverage around the home address, and temporal variations in pollution during pregnancy. Using Poisson regression, we estimated prevalence ratios (PR) of birth weight < 3,000 g, adjusted for gestational duration, sex, maternal smoking, height, weight, and education. RESULTS: Exposure was defined for 1,0 16 births. Taking the lowest quartile of exposure during pregnancy as a reference, the PR of birth weight < 3,000 g associated with the highest quartile was 1.7 for PM(2.5) [95% confidence interval (CI), 1.2-2.7], 1.8 for PM(2.5) absorbance (95% Cl, 1.1-2.7), and 1.2 for NO(2) (95% Cl, 0.7-1.7). The PR associated with an increase of 1 mu g/m(3) in PM(2.5) levels was 1. 13 (95% Cl, 1.00-1.29). CONCLUSION: Increases in PM(2.5) levels and PM(2.5) absorbance were associated with decreases in term birth weight. Traffic-related air pollutants may have adverse effects on birth weight.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; INSERM, Inst Natl Sante Rech Med, UMR822, Le Kremlin Bicetre, France; INED, Inst Natl Etud Demog, Paris, France; Univ Paris Sud, F-94275 Le Kremlin Bicetre, France; Univ Augsburg, Ctr Environm Sci, WZU, Augsburg, Germany; Kinderklin & Kinderpoliklin Dr V Haunerschen Kind, Munich, Germany; UFZ Umwelt Forsch Zentrum, Leipzig, Germany; Univ Leipzig, Fac Med, Leipzig, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany	Slama, R (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany.	slama@vjf.inserm.fr	Cyrys, Josef/B-5359-2014; Slama, Remy/M-1755-2013	Slama, Remy/0000-0002-8980-8529; Cyrys, Josef/0000-0002-2105-8696			Albuquerque CA, 2004, EARLY HUM DEV, V80, P31, DOI 10.1016/j.earlhumdev.2004.05.004; Archibong AE, 2002, REPROD TOXICOL, V16, P801, DOI 10.1016/S0890-6238(02)00058-8; Basu R, 2004, J EXPO ANAL ENV EPID, V14, P391, DOI 10.1038/sj.jea.7500336; Bell ML, 2007, ENVIRON HEALTH PERSP, V115, P1118, DOI 10.1289/ehp.9759; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brook RD, 2005, CURR HYPERTENS REP, V7, P427, DOI 10.1007/s11906-005-0037-9; Brunekreef B., 2005, 127 HLTH EFF I; Choi H, 2006, ENVIRON HEALTH PERSP, V114, P1744, DOI 10.1289/ehp.8982; Council Directive, 1999, OFFICIAL J EUROPEA L, V163, P0041; Cyrys J, 2005, ENVIRON HEALTH PERSP, V113, P987, DOI 10.1289/ehp.7662; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; Dejmek J, 2000, ENVIRON HEALTH PERSP, V108, P1159, DOI 10.2307/3434828; Dubowsky SD, 2006, ENVIRON HEALTH PERSP, V114, P992, DOI 10.1289/ehp.8469; Efron B., 1993, INTRO BOOTSTRAP; Gehrig R, 2003, ATMOS ENVIRON, V37, P2571, DOI 10.1016/S1352-2310(03)00221-8; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Glinianaia SV, 2004, EPIDEMIOLOGY, V15, P36, DOI 10.1097/01.ede.0000101023.41844.ac; Gomiscek B, 2004, ATMOS ENVIRON, V38, P3917, DOI 10.1016/j.atmosenv.2004.03.056; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; HANSTEEN IL, 1998, J OCCUP ENV HLTH, V4, P63; Harrell F. E., 2001, REGRESSION MODELING; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Infante-Rivard C, 2006, EPIDEMIOLOGY, V17, P38, DOI 10.1097/01.ede.0000187669.34003.b1; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Jedrychowski W, 2004, ENVIRON HEALTH PERSP, V112, P1398, DOI 10.1289/ehp.7065; Kaaja RJ, 2005, JAMA-J AM MED ASSOC, V294, P2751, DOI 10.1001/jama.294.21.2751; Kanaka-Gantenbein C, 2003, ANN NY ACAD SCI, V997, P150, DOI 10.1196/annals.1290.017; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; KLEEMAN MJ, 1999, ENVIRON SCI TECHNOL, V33, P3518; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; Krzyzanowski M., 2005, HLTH EFFECTS TRANSPO; Lash TL, 2003, EPIDEMIOLOGY, V14, P451, DOI 10.1097/01.EDE.0000071419.41011.cf; Lewis C, 2006, AM J EPIDEMIOL, V163, P38, DOI 10.1093/aje/kwj009; Lloyd AC, 2001, J AIR WASTE MANAGE, V51, P809; Miozzo M, 2002, BIOL NEONATE, V81, P217, DOI 10.1159/000056752; MONN C, 1995, ATMOS ENVIRON, V29, P2565, DOI 10.1016/1352-2310(95)94999-U; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; National Center for Environmental Assessment, 2004, AIR QUAL CRIT PART M; Nieuwenhuijsen M, 2006, ENVIRON INT, V32, P996, DOI 10.1016/j.envint.2006.06.015; Parker JD, 2005, PEDIATRICS, V115, P121, DOI 10.1542/peds.2004-0889; Peduzzi P, 1996, J CLIN EPIDEMIOL, V49, P1373, DOI 10.1016/S0895-4356(96)00236-3; Perera FP, 2005, ENVIRON HEALTH PERSP, V113, P1062, DOI 10.1289/ehp.7908; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P1133, DOI 10.1289/ehp.6833; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P626, DOI 10.1289/ehp.6617; Perera FP, 1998, AM J EPIDEMIOL, V147, P309; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; *REG VON, 2004, LUFTR STADT MUNCH BA; Roemer WH, 2001, ENVIRON HEALTH PERSP, V109, P151, DOI 10.2307/3434768; Schauer JJ, 1999, ENVIRON SCI TECHNOL, V33, P1578, DOI 10.1021/es980081n; Schauer JJ, 2002, ENVIRON SCI TECHNOL, V36, P1169, DOI 10.1021/es0108077; Slama R, 2005, REV EPIDEMIOL SANTE, V53, p2S65; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Sram RJ, 2005, ENVIRON HEALTH PERSP, V113, P375, DOI 10.1289/ehp.6362; Takeda Y, 2004, J VIRAL HEPATITIS, V11, P33, DOI 10.1046/j.1365-2893.2003.00472.x; Tsukue N, 2002, INHAL TOXICOL, V14, P635, DOI 10.1080/08958370290084548; Vittinghoff E, 2007, AM J EPIDEMIOL, V165, P710, DOI 10.1093/aje/kwk052; Whyatt RM, 1998, ENVIRON HEALTH PERSP, V106, P821, DOI 10.2307/3434196; Wilhelm M, 2005, ENVIRON HEALTH PERSP, V113, P1212, DOI 10.1289/ehp.7751; Wilhelm M, 2003, ENVIRON HEALTH PERSP, V111, P207, DOI 10.1289/ehp.5688; Yoshida Seiichi, 2006, Environmental Sciences, V13, P139; Zdravkovic T, 2005, PLACENTA, V26, pS81, DOI 10.1016/j.placenta.2005.02.003	65	119	122	1	33	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2007	115	9					1283	1292		10.1289/ehp.10047		10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	206RM	WOS:000249200600023	17805417	
J	Litonjua, AA; Rifas-Shiman, SL; Ly, NP; Tantisira, KG; Rich-Edwards, JW; Camargo, CA; Weiss, ST; Gillman, MW; Gold, DR				Litonjua, Augusto A.; Rifas-Shiman, Sheryl L.; Ly, Ngoc P.; Tantisira, Kelan G.; Rich-Edwards, Janet W.; Camargo, Carlos A., Jr.; Weiss, Scott T.; Gillman, Matthew W.; Gold, Diane R.			Maternal antioxidant intake in pregnancy and wheezing illnesses in children at 2 y of age	AMERICAN JOURNAL OF CLINICAL NUTRITION			English	Article						asthma; diet; antioxidants; eczema; childhood; wheezing	ALLERGIC RHINITIS; CHILDHOOD ASTHMA; BLOOD-PRESSURE; HAY-FEVER; NATIONAL-HEALTH; DIETARY FACTORS; UNITED-STATES; LUNG-FUNCTION; T-CELLS; RISK	Background: Low intakes of dietary antioxidants may contribute to increases in asthma and allergy. Objective: We investigated the association of maternal total intakes (foods + supplements) of 10 antioxidant nutrients during pregnancy with wheezing and eczema in 2-y-old children. Design: Subjects were 1290 mother-child pairs in an ongoing cohort study. Maternal dietary and supplement intakes were assessed by using a validated food-frequency questionnaire administered in the first and second trimesters. Antioxidant nutrient intakes were calculated. and the mean for each nutrient was considered to be the exposure during pregnancy. The outcomes of interest were any wheezing by the child during either the first or second year of life, recurrent wheezing in both years, and eczema in either the first or second year. Results: No association was observed between maternal total intake of any antioxidant nutrient and eczema. In multivariate logistic regression models, the highest quartile compared with the lowest quartile of maternal total intakes of vitamin E [odds ratio (OR): 0.70; 95% Cl: 0.48,1.03] and zinc (OR: 0.59; 95% Cl: 0.41, 0.88) was inversely associated with any wheezing at 2 y of age (P for trend = 0.06 and 0.01 over quartiles of intake for vitamin E and zinc, respectively). Similar results were obtained for recurrent wheezing at 2 y of age with vitamin E (OR: 0.49; 95% Cl: 0.27, 0.90) and zinc (OR: 0.49; 95% Cl: 0.27. 0.87) (P for trend = 0.05 and 0.06 over quartiles of intake for vitamin E and zinc, respectively). Conclusion: Our results suggest that higher maternal total intakes of antioxidants during pregnancy may decrease the risks for wheezing illnesses in early childhood.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02215 USA; Massachusetts Gen Hosp, Div Pediat Pulm Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA 02115 USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Litonjua, AA (reprint author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu			NHLBI NIH HHS [HL61907, HL64925, K24 HL068041, K24 HL068041-03, R01 HL061907, R01 HL061907-03, R01 HL064925, R01 HL064925-03]; NIAID NIH HHS [AI35786, R01 AI035786, R56 AI035786]; NICHD NIH HHS [R37 HD034568, HD34568, R01 HD034568, R01 HD034568-03]		ACOG Committee on Practice Bulletins, 2003, OBSTET GYNECOL, V102, P203; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Carter ER, 2005, ANN ALLERG ASTHMA IM, V94, P634; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Cook DG, 1997, THORAX, V52, P628; Cunningham-Rundles S, 2005, J ALLERGY CLIN IMMUN, V115, P1119, DOI 10.1016/j.jaci.2005.04.036; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; DITORO R, 1987, ACTA PAEDIATR SCAND, V76, P612; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Fawzi WW, 2004, ANN EPIDEMIOL, V14, P754, DOI 10.1016/j.annepidem.2004.03.001; Forastiere F, 2000, THORAX, V55, P283, DOI 10.1136/thorax.55.4.283; Fowles ER, 2004, JOGNN-J OBST GYN NEO, V33, P809, DOI 10.1177/0884217504270599; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Gillman MW, 2004, CIRCULATION, V110, P1990, DOI 10.1161/01.CIR.0000143199.93495.96; Gillman MW, 2004, J PEDIATR-US, V144, P240, DOI 10.1016/j.jpeds.2003.10.064; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Ho E, 2004, J NUTR BIOCHEM, V15, P572, DOI 10.1016/j.jnutbio.2004.07.005; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Huh SY, 2005, INT J EPIDEMIOL, V34, P378, DOI 10.1093/ije/dyh373; *I MED FOOD NUTR B, 2000, PAN DIET ANT REL COM; *I MED FOOD NUTR B, 1990, COMM NUTR STAT DUR P; Kadrabova J, 1996, J TRACE ELEM MED BIO, V10, P50; King JC, 2000, AM J CLIN NUTR, V71, p1334S; Lara M, 2002, PEDIATRICS, V109, P919, DOI 10.1542/peds.109.5.919; Latvala J, 2005, BRIT MED J, V330, P1186, DOI 10.1136/bmj.38448.603921.AF; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Li-Weber M, 2002, EUR J IMMUNOL, V32, P2401, DOI 10.1002/1521-4141(200209)32:9<2401::AID-IMMU2401>3.0.CO;2-S; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Litonjua A. A., 2004, AM J RESP CRIT CARE, V169, pA501; Ly NP, 2006, PEDIATRICS, V117, pE1132, DOI 10.1542/peds.2005-2271; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; Nebeling LC, 1997, AM J PUBLIC HEALTH, V87, P268, DOI 10.2105/AJPH.87.2.268; Nja F, 2005, ACTA PAEDIATR, V94, P147, DOI 10.1080/08035250410023638; Oken E, 2004, AM J EPIDEMIOL, V160, P774, DOI 10.1093/aje/kwh282; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tan PH, 2005, J IMMUNOL, V174, P7633; Tantisira KG, 2001, THORAX, V56, P64; *USDA ARS, 2001, USDA NAT NUTR DAT ST; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; von Mutius E, 2001, THORAX, V56, P153, DOI 10.1136/thorax.56.2.153; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P493; Watt RG, 2001, PUBLIC HEALTH NUTR, V4, P1229, DOI 10.1079/PHN2001202; WILLETT WC, 1987, AM J CLIN NUTR, V45, P354; Wood LG, 2000, LIPIDS, V35, P967, DOI 10.1007/s11745-000-0607-x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; Zalewski PD, 2005, PHARMACOL THERAPEUT, V105, P127, DOI 10.1016/j.pharmthera.2004.09.004; 1992, MMWR MORB MORTAL W S, V41, P1	61	119	125	1	8	AMER SOC CLINICAL NUTRITION	BETHESDA	9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA	0002-9165			AM J CLIN NUTR	Am. J. Clin. Nutr.	OCT	2006	84	4					903	911				9	Nutrition & Dietetics	Nutrition & Dietetics	093AX	WOS:000241140700030	17023719	
J	Jowsey, IR; Basketter, DA; Westmoreland, C; Kimber, I				Jowsey, Ian R.; Basketter, David A.; Westmoreland, Carl; Kimber, Ian			A future approach to measuring relative skin sensitising potency: a proposal	JOURNAL OF APPLIED TOXICOLOGY			English	Article						skin; sensitisation; allergy; in vitro; in silico	LYMPH-NODE ASSAY; EPIDERMAL LANGERHANS CELLS; HUMAN DENDRITIC CELLS; NECROSIS-FACTOR-ALPHA; VITRO PRIMARY SENSITIZATION; SURFACE-MARKER EXPRESSION; MESSENGER-RNA EXPRESSION; IN-VITRO; CONTACT SENSITIZERS; ICCVAM EVALUATION	Current approaches to skin sensitisation risk assessment are dependent upon the availability of information regarding two fundamental parameters. Firstly, data relating to the relative skin sensitising potency of the chemical, and secondly, information regarding likely conditions of human exposure. During the past two decades, much has been achieved in terms of refining methods capable of informing these parameters. For example, the development of the local lymph node assay (LLNA) has made it possible to predict skin sensitising hazard, and to determine relative skin sensitising potency, in a way that was not possible previously. Taken together with accurate information about predicted exposure, such potency data can be used to facilitate the derivation of effective risk assessments. However, although the LLNA provides an integrated assessment of skin sensitising activity, it does require the use of experimental animals and there is growing enthusiasm for designing robust alternative approaches that will reduce or obviate that need. Progress is being made in defining alternative experimental strategies that avoid animal use, but it is clear that accurate characterisation of skin sensitisation hazards will require the effective integration of various sources of information. For this reason, we exemplify here one possible approach that, in theory, provides a framework for not only the identification of skin sensitising chemicals, but also the estimation of relative sensitising potency. This paradigm depends upon development of an understanding of the various biological, biochemical and chemical factors that impact on the allergenic properties of chemicals and the acquisition of skin sensitisation, and an ability to measure these in vitro. Copyright (c) 2006 John Wiley & Sons, Ltd.	Unilever Safety & Environm Assurance Ctr, Sharnbrook MK44 1LQ, Beds, England; Syngenta Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England	Jowsey, IR (reprint author), Unilever Safety & Environm Assurance Ctr, Colworth House, Sharnbrook MK44 1LQ, Beds, England.	ian.jowsey@unilever.com					Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Aiba S, 2000, IMMUNOLOGY, V101, P68, DOI 10.1046/j.1365-2567.2000.00087.x; Ashikaga T, 2002, TOXICOL IN VITRO, V16, P711, DOI 10.1016/S0887-2333(02)00060-7; AZAM P, 2005, IN PRESS TOXICOL APP; BARRATT MD, 1992, CONTACT DERMATITIS, V27, P98, DOI 10.1111/j.1600-0536.1992.tb05217.x; Basketter DA, 2000, CONTACT DERMATITIS, V42, P344, DOI 10.1034/j.1600-0536.2000.042006344.x; Basketter DA, 2002, FOOD CHEM TOXICOL, V40, P593, DOI 10.1016/S0278-6915(01)00130-2; Basketter DA, 2001, TRENDS PHARMACOL SCI, V22, P264, DOI 10.1016/S0165-6147(00)01704-1; BASKETTER DA, 1992, ACTA DERM-VENEREOL, V72, P264; Chapuis F, 1997, EUR J IMMUNOL, V27, P431, DOI 10.1002/eji.1830270213; Coutant KD, 1999, TOXICOL SCI, V48, P74, DOI 10.1093/toxsci/48.1.74; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Dean JH, 2001, REGUL TOXICOL PHARM, V34, P258, DOI 10.1006/rtph.2001.1497; Dearman RJ, 1998, J APPL TOXICOL, V18, P281, DOI 10.1002/(SICI)1099-1263(199807/08)18:4<281::AID-JAT506>3.0.CO;2-4; Degwert J, 1997, TOXICOL IN VITRO, V11, P613, DOI 10.1016/S0887-2333(97)00053-2; DUPUIS G, 1982, ALLERGIC CONTACT DER; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Felter SP, 2003, REGUL TOXICOL PHARM, V37, P1, DOI 10.1016/S0273-2300(02)00021-1; Gerberick G F, 2001, Am J Contact Dermat, V12, P156, DOI 10.1053/ajcd.2001.23926; Gerberick GF, 2004, TOXICOL SCI, V81, P332, DOI 10.1093/toxsci/kfh213; GERBERICK GF, 1992, FUND APPL TOXICOL, V19, P438, DOI 10.1016/0272-0590(92)90183-I; Haneke KE, 2001, REGUL TOXICOL PHARM, V34, P274, DOI 10.1006/rtph.2001.1498; HAUSER C, 1988, P NATL ACAD SCI USA, V85, P5625, DOI 10.1073/pnas.85.15.5625; Hulette BC, 2005, TOXICOL APPL PHARM, V209, P159, DOI 10.1016/j.taap.2005.03.019; Hulette BC, 2002, TOXICOL APPL PHARM, V182, P226, DOI 10.1006/taap.2002.9447; Kimber I, 2003, FOOD CHEM TOXICOL, V41, P1799, DOI 10.1016/S0278-6915(03)00223-0; Kimber I, 2002, CONTACT DERMATITIS, V47, P315, DOI 10.1034/j.1600-0536.2002.470601.x; Kimber I, 2001, TOXICOL IN VITRO, V15, P307, DOI 10.1016/S0887-2333(01)00027-3; KIMBER I, 1992, TOXICOL APPL PHARM, V117, P137, DOI 10.1016/0041-008X(92)90230-P; KIMBER I, 1992, FOOD CHEM TOXICOL, V30, P165, DOI 10.1016/0278-6915(92)90153-C; KIMBER I, 1991, FOOD CHEM TOXICOL, V29, P125, DOI 10.1016/0278-6915(91)90167-6; Kimber I, 1997, HUM ECOL RISK ASSESS, V3, P385; Krasteva M, 1996, CLIN EXP ALLERGY, V26, P563, DOI 10.1046/j.1365-2222.1996.d01-342.x; MAURER T, 1994, TOXICOLOGY, V93, P47, DOI 10.1016/0300-483X(94)90195-3; MOULON C, 1993, IMMUNOLOGY, V80, P373; Patlewicz G, 2001, CONTACT DERMATITIS, V44, P331, DOI 10.1034/j.1600-0536.2001.044006331.x; Patlewicz GY, 2004, CONTACT DERMATITIS, V50, P91, DOI 10.1111/j.0105-1873.2004.00322.x; Patlewicz GY, 2002, CONTACT DERMATITIS, V47, P219, DOI 10.1034/j.1600-0536.2002.470406.x; Pichowski JS, 2001, J APPL TOXICOL, V21, P115, DOI 10.1002/jat.742; Pichowski JS, 2000, TOXICOL IN VITRO, V14, P351, DOI 10.1016/S0887-2333(00)00030-8; POTTS RO, 1992, PHARMACEUT RES, V9, P663, DOI 10.1023/A:1015810312465; Reutter K, 1997, TOXICOL IN VITRO, V11, P619, DOI 10.1016/S0887-2333(97)00048-9; Roberts DW, 2000, CONTACT DERMATITIS, V42, P154, DOI 10.1034/j.1600-0536.2000.042003154.x; Rougier N, 2000, TOXICOLOGY, V145, P73, DOI 10.1016/S0300-483X(99)00222-X; Rustemeyer T, 2003, EXP DERMATOL, V12, P682, DOI 10.1034/j.1600-0625.2003.00077.x; Sailstad DM, 2001, REGUL TOXICOL PHARM, V34, P249, DOI 10.1006/rtph.2001.1496; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; SMITH CK, 2001, ALLERGIC CONTACT DER; Steiling W, 2001, FOOD CHEM TOXICOL, V39, P293, DOI 10.1016/S0278-6915(00)00147-2; Tuschl H, 2001, TOXICOL IN VITRO, V15, P327, DOI 10.1016/S0887-2333(01)00030-3; Warbrick EV, 1999, J APPL TOXICOL, V19, P255, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<255::AID-JAT573>3.0.CO;2-S; Yoshida Y, 2003, TOXICOL IN VITRO, V17, P221, DOI 10.1016/S0887-2333(03)00006-7	53	119	119	0	2	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	0260-437X			J APPL TOXICOL	J. Appl. Toxicol.	JUL-AUG	2006	26	4					341	350		10.1002/jat.1146		10	Toxicology	Toxicology	066KF	WOS:000239227600007	16773645	
J	Pitchford, SC; Momi, S; Giannini, S; Casali, L; Spina, D; Page, CP; Gresele, P				Pitchford, SC; Momi, S; Giannini, S; Casali, L; Spina, D; Page, CP; Gresele, P			Platelet P-selectin is required for pulmonary eosinophil and lymphocyte recruitment in a murine model of allergic inflammation	BLOOD			English	Article							PLATELET/POLYMORPHONUCLEAR LEUKOCYTE INTERACTION; ENDOTHELIUM IN-VIVO; GLYCOPROTEIN LIGAND-1; BRONCHIAL-ASTHMA; DEFICIENT MICE; WHOLE-BLOOD; CROSS-TALK; ADHESION; BETA(2)-INTEGRIN; CD11B/CD18	Platelets are necessary for lung leukocyte recruitment in a murine model of allergic inflammation, and platelet-leukocyte aggregates are formed in circulating blood of patients with asthma after allergen exposure. However, it is unknown how platelets induce pulmonary leukocyte recruitment in asthma. Here, we have investigated the importance of platelet adhesion molecule expression on pulmonary eosinophil and lymphocyte recruitment and on leukocyte CD11b and very late antigen (VLA)-4 expression in mice. Pulmonary leukocyte recruitment in platelet-depleted mice (sensitized and exposed to ovalbumin) transfused with fixed, unstimulated platelets (FUSPs) was abolished, whereas transfusion with platelets stimulated and fixed (FSPs), expressing P-selectin and P-selectin glycoprotein ligand-1 (PSGL-1), restored eosinophil and lymphocyte recruitment. Transfusion with platelets from P-selectin-deficient mice, or with FSPs stimulated in the presence of a blocking anti-P-selectin antibody, were unable to restore pulmonary leukocyte recruitment. Flow cytometric analysis revealed increased expression of CD11b and VLA-4 on leukocytes attached to platelets after allergen exposure, and CD11b expression on leukocytes was suppressed in thrombocytopenic mice but was restored with the transfusion of FSPs, but not FUSPs, a phenomenon concurrent with the formation of platelet-leukocyte complexes. P-selectin expression on the surfaces of platelets is a major requirement for pulmonary eosinophil and lymphocyte recruitment, allowing circulating platelets to bind to and stimulate leukocytes for endothelial attachment. (C) 2005 by The American Society of Hematology.	Univ Perugia, Dept Internal Med, Div Internal & Cardiovasc Med, I-06126 Perugia, Italy; Kings Coll London, Sackler Inst Pulm Pharmacol, GKT Sch Biomed Sci, London WC2R 2LS, England; Univ Perugia, Pneumatol Unit, Terni, Italy	Gresele, P (reprint author), Univ Perugia, Dept Internal Med, Div Internal & Cardiovasc Med, Via E dal Pozzo, I-06126 Perugia, Italy.	grespa@unipg.it	Gresele, Paolo/F-6775-2013	Gresele, Paolo/0000-0001-5365-8445; Spina, Domenico/0000-0002-6815-1564			BARNES PJ, 1992, J INTERN MED, V231, P453; BECK MR, 1980, BIORHEOLOGY, V17, P455; Blanks JE, 1998, EUR J IMMUNOL, V28, P433, DOI 10.1002/(SICI)1521-4141(199802)28:02<433::AID-IMMU433>3.0.CO;2-U; Broide DH, 1998, AM J RESP CELL MOL, V18, P218; BRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; Cerletti C, 1999, THROMB HAEMOSTASIS, V82, P787; DeSanctis GT, 1997, J APPL PHYSIOL, V83, P681; Diacovo TG, 1996, BLOOD, V88, P146; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; DONATI MB, 2002, PLATELETS THROMBOTIC, P824, DOI 409862349,12,1; Evangelista V, 1999, BLOOD, V93, P876; Evangelista V, 1996, BLOOD, V88, P4183; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; GOLDSMITH HL, 1981, BIORHEOLOGY, V18, P531; GRESELE P, 1982, NEW ENGL J MED, V306, P549; GRESELE P, 1993, J ALLERGY CLIN IMMUN, V91, P894, DOI 10.1016/0091-6749(93)90347-I; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; Jawien J, 2002, POL J PHARMACOL, V54, P157; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Jia GQ, 1999, INT IMMUNOL, V11, P1, DOI 10.1093/intimm/11.1.1; KARPATKIN S, 1981, ANN INTERN MED, V95, P636; Katayama T, 2000, CIRC RES, V86, P1031; Konstantopoulos K, 1998, CIRCULATION, V98, P873; LEY K, 1995, J EXP MED, V181, P669, DOI 10.1084/jem.181.2.669; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Moritani C, 1998, CHEST, V113, P452, DOI 10.1378/chest.113.2.452; Peters MJ, 1999, BRIT J HAEMATOL, V106, P391, DOI 10.1046/j.1365-2141.1999.01553.x; Pitchford SC, 2004, BLOOD, V103, P639, DOI 10.1182/blood-2003-05-1707; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; RINDER HM, 1991, BLOOD, V78, P1730; Schmidtke DW, 2000, J CELL BIOL, V149, P719, DOI 10.1083/jcb.149.3.719; Schober A, 2002, CIRCULATION, V106, P1523, DOI 10.1161/01.CIR.0000028590.02477.6F; Singbartl K, 2001, FASEB J, V15, P2337, DOI 10.1096/fj.01-0199com; Sullivan PJ, 2000, RESPIRATION, V67, P514, DOI 10.1159/000067466; TANGELDER GJ, 1982, MICROVASC RES, V23, P214, DOI 10.1016/0026-2862(82)90066-8; Teixeira MM, 1998, J IMMUNOL, V161, P2516; Theoret JF, 2001, J PHARMACOL EXP THER, V298, P658; Ulfman LH, 2003, AM J RESP CELL MOL, V28, P512, DOI 10.1165/rcmb.4806; YAMAMOTO H, 1993, J ALLERGY CLIN IMMUN, V91, P79, DOI 10.1016/0091-6749(93)90299-U	41	119	122	3	5	AMER SOC HEMATOLOGY	WASHINGTON	1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA	0006-4971			BLOOD	Blood	MAR 1	2005	105	5					2074	2081		10.1182/blood-2004-06-2282		8	Hematology	Hematology	901UU	WOS:000227308400042	15528309	
J	Noverr, MC; Noggle, RM; Toews, GB; Huffnagle, GB				Noverr, MC; Noggle, RM; Toews, GB; Huffnagle, GB			Role of antibiotics and fungal microbiota in driving pulmonary allergic responses	INFECTION AND IMMUNITY			English	Article							ORAL TOLERANCE INDUCTION; REGULATORY T-CELLS; BRONCHOPULMONARY ASPERGILLOSIS; CANDIDA-ALBICANS; MURINE MODEL; AIRWAY HYPERREACTIVITY; LYMPHOKINE PRODUCTION; PROSTAGLANDIN D-2; EARLY-CHILDHOOD; PEYERS-PATCHES	Over the past four decades, there has been a significant increase in allergy and asthma in westernized countries, which correlates with alterations in fecal microbiota (microflora) and widespread use of antibiotics (the "hygiene hypothesis"). Antibiotics also lead to overgrowth of the yeast Candida albicans, which can secrete potent prostaglandin-like immune response modulators. We have developed a mouse model of antibiotic-induced microbiota disruption that includes stable increases in gastrointestinal (GI) enteric bacteria and GI Candida levels with no introduction of microbes into the lungs. Mice are treated for 5 days with cefoperazone in the drinking water, followed by a single oral gavage of C albicans. This results in alterations of GI bacterial populations and increased yeast numbers in the GI microbiota for at least 2 to 3 weeks and can drive the development of a CD4 T-cell-mediated allergic airway response to subsequent mold spore (Aspergillus fumigatus) exposure in immunocompetent mice without previous systemic antigen priming. The allergic response in the lungs is characterized by increased levels of eosinophils, mast cells, interleukin-5 (IL-5), IL-13, gamma interferon, immunoglobulin E, and mucus-secreting cells. In the absence of antibiotics, mice exposed to Aspergillus spores do not develop an allergic response in the airways. This study provides the first experimental evidence to support a role for antibiotics and fungal microbiota in promoting the development of allergic airway disease. In addition, these studies also highlight the concept that events in distal mucosal sites such as the GI tract can play an important role in regulating immune responses in the lungs.	Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Huffnagle, GB (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.	ghuff@umich.edu			NHLBI NIH HHS [R01 HL065912, 2T32HL007749-11, R01-HL65912, T32 HL007749]; NIAID NIH HHS [R01 AI059201, R01-AI059201]		Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BETZ M, 1991, J IMMUNOL, V146, P108; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Blease K, 2001, J IMMUNOL, V166, P5219; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Calderone RA, 2001, CANDIDA CANDIDIASIS; Chung Y, 2002, IMMUNOBIOLOGY, V206, P408, DOI 10.1078/0171-2985-00190; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.3.CO;2-C; Cooper M D, 1974, Adv Exp Med Biol, V45, P13; Demetris A J, 1997, Ann Transplant, V2, P27; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Eyles JE, 2001, J PHARM PHARMACOL, V53, P601, DOI 10.1211/0022357011775929; Fidel PL, 1999, CLIN MICROBIOL REV, V12, P80; Fogelmark B, 2001, MEDIAT INFLAMM, V10, P13, DOI 10.1080/09629350151073748; Grunig G, 2003, FRONT BIOSCI, V8, pE157, DOI 10.2741/966; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Hall G, 2003, VACCINE, V21, P549, DOI 10.1016/S0264-410X(02)00394-8; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herve M, 2003, EUR J IMMUNOL, V33, P2764, DOI 10.1002/eji.200324143; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kankaanpaa P, 2001, ALLERGY, V56, P633, DOI 10.1034/j.1398-9995.2001.00965.x; Kauffman HF, 2003, FRONT BIOSCI, V8, pE190, DOI 10.2741/990; KENNEDY MJ, 1985, SABOURAUDIA, V23, P265; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Kurup VP, 2000, MICROBES INFECT, V2, P1101, DOI 10.1016/S1286-4579(00)01264-8; KURUP VP, 1992, J IMMUNOL, V148, P3783; Kurup VP, 2001, CLIN IMMUNOL, V98, P327, DOI 10.1006/clim.2000.4993; KURUP VP, 1990, INT ARCH ALLER A IMM, V91, P145; LARSON SE, 1980, J INFECT DIS, V142, P265; Maeda Y, 2001, IMMUNOBIOLOGY, V204, P442, DOI 10.1078/0171-2985-00054; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; MOREAU MC, 1995, ADV EXP MED BIOL, V371, P1229; Noverr MC, 2003, CLIN MICROBIOL REV, V16, P517, DOI 10.1128/CMR.16.3.517-533.2003; Noverr MC, 2002, INFECT IMMUN, V70, P400, DOI 10.1128/IAI.70.1.400-402.2002; Noverr MC, 2001, INFECT IMMUN, V69, P2957, DOI 10.1128/IAI.69.5.2957-2963.2001; Peters-Golden M, 2002, NAT MED, V8, P931, DOI 10.1038/nm0902-931; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P1035, DOI 10.1164/rccm.2202040; Pickett TE, 2000, INFECT IMMUN, V68, P205; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; ROUVEIX B, 1987, INT J IMMUNOPHARMACO, V9, P567, DOI 10.1016/0192-0561(87)90124-X; Russo M, 2001, AM J RESP CELL MOL, V24, P518; Russo M, 1998, IMMUNOL LETT, V61, P15, DOI 10.1016/S0165-2478(97)00155-7; SCHEFFER J, 1993, RESPIRATION, V60, P25; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Schuh JM, 2002, J IMMUNOL, V168, P1447; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; STRACHAN DP, 1989, BRIT MED J, V299, P1259; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Sudo N, 1997, J IMMUNOL, V159, P1739; Takabayashi K, 2003, J IMMUNOL, V170, P3898; Taube C, 2002, J IMMUNOL, V169, P6482; UETA E, 1992, INT J IMMUNOPHARMACO, V14, P877, DOI 10.1016/0192-0561(92)90087-2; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; VILLA ML, 1991, INT J IMMUNOPHARMACO, V13, P1099, DOI 10.1016/0192-0561(91)90161-Y; Whitacre CC, 1996, ANN NY ACAD SCI, V778, P217, DOI 10.1111/j.1749-6632.1996.tb21130.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wjst M, 2001, EUR J MED RES, V6, P263; Wu XM, 1998, EUR J IMMUNOL, V28, P134, DOI 10.1002/(SICI)1521-4141(199801)28:01<134::AID-IMMU134>3.0.CO;2-3; Yamanaka T, 2003, J IMMUNOL, V170, P816; Zhang XM, 2001, J IMMUNOL, V167, P4245	71	119	132	0	13	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567			INFECT IMMUN	Infect. Immun.	SEP	2004	72	9					4996	5003		10.1128/IAI.72.9.4996-5003.2004		8	Immunology; Infectious Diseases	Immunology; Infectious Diseases	849ZM	WOS:000223580400008	15321991	
J	Naisbitt, DJ; Farrell, J; Wong, G; Depta, JPH; Dodd, CC; Hopkins, JE; Gibney, CA; Chadwick, DW; Pickler, WJ; Pirmohamed, M; Park, BK				Naisbitt, DJ; Farrell, J; Wong, G; Depta, JPH; Dodd, CC; Hopkins, JE; Gibney, CA; Chadwick, DW; Pickler, WJ; Pirmohamed, M; Park, BK			Characterization of drug-specific T cells in lamotrigine hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						lamotrigine; anticonvulsant hypersensitivity; T cells; antigen processing; cytokines; chemokines; T-cell receptors	TOXIC EPIDERMAL NECROLYSIS; LYMPHOCYTE-TRANSFORMATION TEST; REACTIVE METABOLITES; COVALENT BINDING; IN-VITRO; CARBAMAZEPINE; RECOGNITION; SULFAMETHOXAZOLE; CLONES; SKIN	Background: Lamotrigine is associated with hypersensitivity reactions, which are most commonly characterized by skin rash. An immune etiology has been postulated, though the nature of this is unclear. Objectives: The aim of this study was to characterize the role of T cells in lamotrigine hypersensitivity. Methods: A lymphocyte transformation test was performed on 4 hypersensitive patients. Lymphocytes from 3 of 4 lamotrigine-hypersensitive patients proliferated when stimulated with lamotrigine. T-cell clones were generated from one patient to further characterize the nature of the T-cell involvement. Cells were characterized in terms of their phenotype, functionality, and mechanisms of antigen presentation and cytotoxicity. Results: Of the 44 drug-specific T-cell clones generated, most were CD4(+) with occasional CD8(+) cells. All clones expressed the up T-cell receptor; several Vbeta 5.1(+) or 9(+) T-cell clones were generated. All clones also expressed the skin-homing receptor cutaneous lymphocyte antigen. Lamotrigine-stimulated T cells were cytotoxic and secreted perforin, IFN-gamma, IL-5, and macrophage inflammatory protein la, macrophage inflammatory protein 1beta, RANTES, and I-309. Lamotrigine was present on HLA-DR and HLA-DQ by antigen-presenting cells in the absence of drug metabolism and processing. The T-cell receptor of certain clones could accommodate analogs of lamotrigine, but no cross-reactivity was seen with other anticonvulsants. Conclusions: Our data provide evidence that T cells are involved in the pathogenesis of some lamotrigine-hypersensitivity reactions. The identification of drug-specific cells that express cutaneous lymphocyte antigen and type 1 cytokines after T-cell receptor activation is consistent with the clinical symptoms. Furthermore, identification of large numbers of Vbeta 5.1(+) T cells suggests that polymorphisms within T-cell receptor genes might act as determinants of susceptibility. (J Allergy Clin Immunol 2003;111:1393-1403.).	Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3GE, Merseyside, England; Univ Liverpool, Dept Dermatol, Liverpool L69 3GE, Merseyside, England; Univ Bern, Inselspital, Clin Rheumatol & Clin Immunol Allergol, Bern, Switzerland; Univ Liverpool, Dept Neurol Sci, Liverpool L69 3BX, Merseyside, England	Naisbitt, DJ (reprint author), Univ Liverpool, Dept Pharmacol & Therapeut, Sherrington Bldg,Ashton St,POB 147, Liverpool L69 3GE, Merseyside, England.		Pirmohamed, Munir/H-6004-2011	Pirmohamed, Munir/0000-0002-7534-7266			Blanca M, 2000, ALLERGY, V55, P998, DOI 10.1034/j.1398-9995.2000.00628.x; Bocquet H, 1996, SEMIN CUTAN MED SURG, V15, P250, DOI 10.1016/S1085-5629(96)80038-1; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Brown KL, 1999, DEV MED CHILD NEUROL, V41, P267, DOI 10.1017/S0012162299000560; BRUNNER KT, 1968, IMMUNOLOGY, V14, P181; Dorner BG, 2002, P NATL ACAD SCI USA, V99, P6181, DOI 10.1073/pnas.092141999; FRIEDMANN PS, 1994, ARCH DERMATOL, V130, P598, DOI 10.1001/archderm.130.5.598; Gonzalez F. J., 1998, Clinical and Experimental Allergy, V28, P3; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Hashizume H, 2002, J IMMUNOL, V168, P5359; KAHN HD, 1984, ARCH INTERN MED, V144, P1677, DOI 10.1001/archinte.144.8.1677; Kalish RS, 1999, J ALLERGY CLIN IMMUN, V103, P192, DOI 10.1016/S0091-6749(99)70489-6; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Leeder JS, 1998, EPILEPSIA, V39, pS8, DOI 10.1111/j.1528-1157.1998.tb01679.x; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; Maggs JL, 2000, CHEM RES TOXICOL, V13, P1075, DOI 10.1021/tx0000825; MAURIHELLWEG D, 1995, J IMMUNOL, V155, P462; Naisbitt DJ, 2003, MOL PHARMACOL, V63, P732, DOI 10.1124/mol.63.3.732; Naisbitt DJ, 2002, MOL PHARMACOL, V62, P628, DOI 10.1124/mol.62.3.628; Naisbitt DJ, 2000, DRUG SAFETY, V23, P483, DOI 10.2165/00002018-200023060-00002; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175; Park BK, 2001, TOXICOLOGY, V158, P11, DOI 10.1016/S0300-483X(00)00397-8; Pichler Werner J, 2002, Am J Clin Dermatol, V3, P229, DOI 10.2165/00128071-200203040-00001; Pichler WJ, 1997, INT ARCH ALLERGY IMM, V113, P177; PICKER LJ, 1990, AM J PATHOL, V136, P1053; Pirmohamed M, 2001, NEUROLOGY, V56, P890; ROUJEAU JC, 1985, INT ARCH ALLER A IMM, V78, P22; Sachs B, 1997, DERMATOLOGY, V195, P60; Schaub N, 2000, ALLERGY, V55, P191, DOI 10.1034/j.1398-9995.2000.00467.x; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412; Schnyder B, 1997, J CLIN INVEST, V100, P136, DOI 10.1172/JCI119505; Schnyder B, 2000, J IMMUNOL, V164, P6647; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; Troger U, 2000, INT J CLIN PHARM TH, V38, P452; VanSnick J, 1996, J IMMUNOL, V157, P2570; von Greyerz S, 1999, J IMMUNOL, V162, P595; von Greyerz S, 2001, INT IMMUNOL, V13, P877, DOI 10.1093/intimm/13.7.877; Wolkenstein P, 1998, CHEM-BIOL INTERACT, V113, P39, DOI 10.1016/S0009-2797(98)00021-0; Wu LC, 2002, NATURE, V418, P552, DOI 10.1038/nature00920; Yawalkar N, 2000, J ALLERGY CLIN IMMUN, V106, P1171, DOI 10.1067/mai.2000.110922; ZAKRZEWSKA JM, 1988, J ALLERGY CLIN IMMUN, V82, P110, DOI 10.1016/0091-6749(88)90059-0; Zanni MP, 1998, J CLIN INVEST, V102, P1591, DOI 10.1172/JCI3544; Zanni MP, 1999, J INVEST DERMATOL, V112, P197, DOI 10.1046/j.1523-1747.1999.00484.x	44	119	136	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1393	1403		10.1067/mai.2003.1507		11	Allergy; Immunology	Allergy; Immunology	688FZ	WOS:000183424700032	12789244	
J	Vonk, JM; Jongepier, H; Panhuysen, CIM; Schouten, JP; Bleecker, ER; Postma, DS				Vonk, JM; Jongepier, H; Panhuysen, CIM; Schouten, JP; Bleecker, ER; Postma, DS			Risk factors associated with the presence of irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up	THORAX			English	Article							AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; RESPIRATORY SYMPTOMS; PULMONARY-FUNCTION; BRONCHIAL-ASTHMA; DECLINE; CHILDHOOD; ADULTS; HYPERRESPONSIVENESS; PERSISTENCE	Background: Childhood asthma is generally believed to be a disorder with a good prognosis. However, some asthmatics develop irreversible airway obstruction, probably as a result of airway remodelling. Methods: After 21-33 years, 228 adults (aged 13-44 years at baseline) with a history of asthma were re-examined to assess risk factors for the development of irreversible airway obstruction (IAO, forced expiratory volume in 1 second (FEV1) <80% predicted and reversibility <9% predicted) and a reduced postbronchodilator transfer coefficient (carbon monoxide transfer factor/alveolar volume, <80% predicted), both characteristics of COPD. Results: At follow up, 41% did not have airway obstruction (NAO), 43% had reversible airway obstruction (RAO), and 16% had IAO; 23% had a reduced transfer coefficient. Patients with RAO had asthma-like characteristics (wheezing, asthma attacks, bronchial hyperresponsiveness (BHR)) while patients with IAO had COPD-like symptoms (cough, phlegm, dyspnoea) at follow up. The development of IAO is determined by a lower FEV1, less reversibility of airway obstruction and, surprisingly, less severe BHR at initial screening. Eighty percent of the patients with asthma who used anti-inflammatory medication still had airway obstruction, but IAO developed less frequently. Smoking was associated with a reduced transfer coefficient but not with the development of IAO. Female sex was associated with a reduced transfer coefficient, whereas corticosteroid use was not. Conclusions: Although IAO and a low transfer coefficient are both characteristics of COPD, they represent distinct entities in adult asthmatics in terms of symptomatology, aetiology, and probably in therapeutic approaches and disease prevention.	Univ Groningen Hosp, Dept Pulmonol, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Dept Epidemiol & Stat, NL-9700 AB Groningen, Netherlands; Beatrixoord Hosp, Haren, Netherlands; Boston Univ, Sch Med, Boston, MA 02118 USA; Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA; Univ Maryland, Baltimore, MD 21201 USA	Postma, DS (reprint author), Univ Groningen Hosp, Dept Pulmonol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.						Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases American Thoracic Society, 1962, AM REV RESPIR DIS, V85, P762; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; BOOYNOORD H, 1957, INT ARCH ALLER A IMM, V10, P321; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; DEGOOIJER A, 1993, EUR RESPIR J, V6, P848; Elias JA, 2000, AM J RESP CRIT CARE, V161, pS168; FINUCANE KE, 1985, MED J AUSTRALIA, V142, P602; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LYNCH DA, 1993, RADIOLOGY, V188, P829; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; ROORDA RJ, 1993, AM REV RESPIR DIS, V148, P1490; ROORDA RJ, 2001, PEDIATR PULM, V18, P99; SAKAI F, 1987, J COMPUT ASSIST TOMO, V11, P963, DOI 10.1097/00004728-198711000-00007; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; VANBORK EL, 1978, THESIS RIJKSUNIVERSI; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; XU X, 1994, EUR RESPIR J, V7, P1056	26	119	127	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	APR	2003	58	4					322	327		10.1136/thorax.58.4.322		6	Respiratory System	Respiratory System	666BT	WOS:000182156300010	12668795	
J	Platts-Mills, TAE				Platts-Mills, TAE			The role of immunoglobulin E in allergy and asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						pathophysiology; asthma; allergy; IgE; allergic cascade	HOUSE-DUST MITE; SKIN-TEST REACTIVITY; FC-EPSILON-RI; MAST-CELLS; SERUM IGE; AIRWAY RESPONSIVENESS; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA; EARLY EXPOSURE; CHILDREN	it has been nearly a century since the first suggestion that a soluble factor in plasma or serum might be responsible for the symptoms of allergic disease and asthma, and more than 30 yr since immunoglobulin E (IgE) was identified as the key molecule in mediating what are now described as type 1 hypersensitivity reactions (allergic asthma, allergic rhinitis, food allergy, atopic dermatitis, some forms of drug allergy, and insect sting allergy). Since that time, many of the details of the inflammatory cascade underlying allergy and asthma have been elucidated, and IgE is now known to play a key upstream role. The goals of this report are to review the cellular and molecular events set in motion by IgE and to examine the evidence for its participation in both the immediate allergic response and the late-phase or chronic inflammatory response in the skin and lungs.	Univ Virginia, Med Ctr, Div Allergy & Immunol, Charlottesville, VA 22908 USA	Platts-Mills, TAE (reprint author), Univ Virginia, Med Ctr, Div Allergy & Immunol, Box 225, Charlottesville, VA 22908 USA.				NIAID NIH HHS [AI-20565, P01-AI50989]		Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BUSSE WW, 1995, AM J RESP CRIT CARE, V152, P388; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MITCHELL EB, 1986, BRIT J DERMATOL, V114, P65, DOI 10.1111/j.1365-2133.1986.tb02780.x; MITCHELL EB, 1984, J INVEST DERMATOL, V83, P290, DOI 10.1111/1523-1747.ep12340423; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Patalano F, 1999, ALLERGY, V54, P103; Pearlman DS, 1999, J ALLERGY CLIN IMMUN, V104, pS132; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PRESTA L, 1994, J BIOL CHEM, V269, P26368; Rajakulasingam K, 1997, J ALLERGY CLIN IMMUN, V100, P78; RAWLE FC, 1984, J IMMUNOL, V133, P195; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Smith AM, 1998, J ALLERGY CLIN IMMUN, V101, P423; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; Ward GW, 1999, J ALLERGY CLIN IMMUN, V104, P541, DOI 10.1016/S0091-6749(99)70321-0; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Woodfolk JA, 2000, J IMMUNOL, V165, P4379; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663	35	119	124	1	15	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2001	164	8		S			S1	S5				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	497DV	WOS:000172438200001	11704610	
J	Rastogi, SC; Heydorn, S; Johansen, JD; Basketter, DA				Rastogi, SC; Heydorn, S; Johansen, JD; Basketter, DA			Fragrance chemicals in domestic and occupational products	CONTACT DERMATITIS			English	Article						fragrance chemicals; domestic and occupational products; chemical analysis; fragrance mix (FM)	CONTACT ALLERGY; PATCH TEST; CONSTITUENTS; MIX; DERMATITIS; DEODORANTS; COSMETICS; PERFUMES	Epidemiological studies have described an increasing prevalence of fragrance allergy and indicated an association with hand eczema. 59 domestic and occupational products intended for hand exposure were subjected to gas chromatography-mass spectrometric (GC-MS) analyses to test the hypothesis that fragrance chemicals known to have the potential to cause contact allergy but not included in fragrance mix (FM) may be common ingredients in these products. A quantitative analysis of 19 selected fragrances was performed by GC-MS. Further analysis of GC-MS data revealed the presence of 43 other fragrance chemicals/groups of fragrance chemicals in the products investigated. Among the 19 target substances the most commonly detected were limonene in 78%, linalool in 61% and citronellol in 47% of the products investigated. The FM ingredients were present in these products with the following frequencies: oak moss (evernic acid methylester) 2%, cinnamic, alcohol 2%, cinnamic aldehyde (cinnamal) 3%, isoeugenol 5%, alpha -amylcinnamic aldehyde (amyl cinnamal) 8%, hydroxycitronellal 12%, eugenol 27%, and geraniol 41%. Thus, the chemical analyses of domestic and occupational products indicates that investigation of potential contact allergy related to these products types should consider fragrance allergens additional to those in the FM, since these may occur with high frequency. (C) Munksgaard, 2001.	Natl Environm Res Inst, Dept Environm Chem, DK-4000 Roskilde, Denmark; Univ Copenhagen, Gentofte Hosp, Dept Dermatol, DK-1168 Copenhagen, Denmark; Unilever Res, SEAC Toxicol, Sharnbrook, Beds, England	Rastogi, SC (reprint author), Natl Environm Res Inst, Dept Environm Chem, Frederiksborgvej 399,POB 358, DK-4000 Roskilde, Denmark.						Buckley DA, 2000, CONTACT DERMATITIS, V43, P304; CHRISTOPHERSEN J, 1989, CONTACT DERMATITIS, V21, P291, DOI 10.1111/j.1600-0536.1989.tb04746.x; EU Scientific Committee on Cosmetic and Non-Food Products Intended for Consumers, 1999, FRAGR ALL CONS REV P; FROSCH PJ, 1995, CONTACT DERMATITIS, V33, P333, DOI 10.1111/j.1600-0536.1995.tb02048.x; JOHANSEN JD, 1995, CONTACT DERMATITIS, V32, P18, DOI 10.1111/j.1600-0536.1995.tb00834.x; Johansen JD, 1997, ACTA DERM-VENEREOL, V77, P149; Johansen JD, 1996, BRIT J DERMATOL, V135, P419, DOI 10.1111/j.1365-2133.1996.tb01506.x; Johansen JD, 1996, CONTACT DERMATITIS, V34, P106, DOI 10.1111/j.1600-0536.1996.tb02139.x; KARLBERG AT, 1991, ANN OCCUP HYG, V35, P419, DOI 10.1093/annhyg/35.4.419; Opdyke DJL, 1975, FD COSMET TOXCOL S, V13, P825; Rastogi SC, 1998, CONTACT DERMATITIS, V39, P293, DOI 10.1111/j.1600-0536.1998.tb05944.x; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; RASTOGI SC, 1995, HRC-J HIGH RES CHROM, V18, P653; Rastogi SC, 1999, CONTACT DERMATITIS, V41, P84; SCHNUCH A, 1993, DERMATOS BER UMWELT, V41, P60	15	119	121	3	24	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	OCT	2001	45	4					221	225		10.1034/j.1600-0536.2001.450406.x		5	Allergy; Dermatology	Allergy; Dermatology	481WY	WOS:000171544500006	11683833	
J	Hammad, H; Charbonnier, AS; Duez, C; Jacquet, A; Stewart, GA; Tonnel, AB; Pestel, J				Hammad, H; Charbonnier, AS; Duez, C; Jacquet, A; Stewart, GA; Tonnel, AB; Pestel, J			Th2 polarization by Der p 1-pulsed monocyte-derived dendritic cells is due to the allergic status of the donors	BLOOD			English	Article							DUST MITE ALLERGEN; COSTIMULATORY MOLECULES; INTERLEUKIN (IL)-12; ATOPIC-DERMATITIS; LANGERHANS CELLS; DOWN-REGULATION; UP-REGULATION; IGE SYNTHESIS; CLASS-II; T-CELLS	The polarization of the immune response toward a Th2 or a Th1 profile can be mediated by dendritic cells (DCs) following antigen presentation and interaction with T cells. Costimulatory molecules such as CD80 and CD86 expressed by DCs, the polarizing cytokine environment during DC-T-cell interaction, and also the nature of the antigen are critical in the orientation of the immune response. In this study, the effect of the cysteine protease Der p 1, one of the major allergens of the house dust mite Dermatophagoides, pteronyssinus, on these different parameters was evaluated comparatively on monocyte-derived DCs obtained from healthy donors, from pollen-sensitive patients, or from patients sensitive to Dermatophagoides pteronyssinus. Results showed that Der p 1 induced an increase in CD86 expression only on DCs from house dust mite-sensitive patients. This was also associated with a higher capacity to induce T-cell proliferation, a rapid increase in the production of proinflammatory cytokines, tumor necrosis factor-alpha and interleukin (IL)-1 beta, and the type 2 cytokine IL-10. No changes in the release of IL-12 p70 were induced by Der p 1. Finally, purified T cells from house dust mite-sensitive patients stimulated by autologous Der p 1-pulsed DCs preferentially produced IL-4 rather than interferon-gamma. These effects were abolished ih the presence of the inactive precursor of Der p 1 (ProDer p 1). Taken together, these data suggest that DCs from house dust mite-sensitive patients, in contrast to DCs from healthy donors and from pollen-sensitive patients, exposed to Der p 1 play a pivotal role in the enhancement of the Th2 response associated with the allergic reaction developed in response to house dust mite exposure.	Inst Pasteur, INSERM, U416, F-59019 Lille, France; Free Univ Brussels, Dept Appl Genet, Gosselies, Belgium; Univ Western Australia, Dept Microbiol, Nedlands, WA 6009, Australia; CHRU Lille, Hop A Calmette, Dept Pneumol, Lille, France	Pestel, J (reprint author), Inst Pasteur, INSERM, U416, 1 Rue Professeur Calmette,BP-245, F-59019 Lille, France.		Hammad, Hamida/J-9391-2015	Hammad, Hamida/0000-0003-3762-8603			Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Alexander J, 1998, J IMMUNOL, V161, P6794; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Braun MC, 1999, J EXP MED, V189, P541, DOI 10.1084/jem.189.3.541; BUELENS C, 1995, EUR J IMMUNOL, V25, P2668, DOI 10.1002/eji.1830250940; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Comoy EE, 1998, J IMMUNOL, V160, P2456; Demangel C, 1999, EUR J IMMUNOL, V29, P1972, DOI 10.1002/(SICI)1521-4141(199906)29:06<1972::AID-IMMU1972>3.0.CO;2-1; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; Haczku A, 1999, AM J RESP CRIT CARE, V159, P1638; Henderson RA, 1997, J IMMUNOL, V159, P635; Hofer MF, 1998, J ALLERGY CLIN IMMUN, V101, P96, DOI 10.1016/S0091-6749(98)70199-X; Igietseme JU, 2000, J IMMUNOL, V164, P4212; Jacquet A, 2000, CLIN EXP ALLERGY, V30, P677, DOI 10.1046/j.1365-2222.2000.00823.x; Jaffar Z, 1999, AM J RESP CELL MOL, V20, P153; Jirapongsananuruk O, 1998, J IMMUNOL, V160, P4622; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1997, J IMMUNOL, V159, P28; Koch F, 1996, J EXP MED, V184, P741, DOI 10.1084/jem.184.2.741; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; LIFE P, 1995, EUR J IMMUNOL, V25, P333, DOI 10.1002/eji.1830250205; Lore K, 1998, J IMMUNOL METHODS, V214, P97, DOI 10.1016/S0022-1759(98)00040-4; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Marriott I, 1999, EUR J IMMUNOL, V29, P1107, DOI 10.1002/(SICI)1521-4141(199904)29:04<1107::AID-IMMU1107>3.0.CO;2-0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Ohki O, 1997, BRIT J DERMATOL, V136, P838, DOI 10.1111/j.1365-2133.1997.tb03922.x; Probst P, 1997, EUR J IMMUNOL, V27, P2634, DOI 10.1002/eji.1830271024; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROMAGNANI S, 1995, J CLIN IMMUNOL, V15, P121, DOI 10.1007/BF01543103; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; von Stebut E, 1998, J EXP MED, V188, P1547, DOI 10.1084/jem.188.8.1547; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	36	119	126	0	2	AMER SOC HEMATOLOGY	WASHINGTON	1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA	0006-4971			BLOOD	Blood	AUG 15	2001	98	4					1135	1141		10.1182/blood.V98.4.1135		7	Hematology	Hematology	461KU	WOS:000170364100034	11493462	
J	Gao, Y; Nish, SA; Jiang, RY; Hou, L; Licona-Limon, P; Weinstein, JS; Zhao, HY; Medzhitov, R				Gao, Yan; Nish, Simone A.; Jiang, Ruoyi; Hou, Lin; Licona-Limon, Paula; Weinstein, Jason S.; Zhao, Hongyu; Medzhitov, Ruslan			Control of T Helper 2 Responses by Transcription Factor IRF4-Dependent Dendritic Cells	IMMUNITY			English	Article							INTERFERON REGULATORY FACTOR-4; DUST MITE ALLERGEN; IN-VIVO; TYPE-2 IMMUNITY; CONTACT HYPERSENSITIVITY; LYMPH-NODES; T-CELLS; DIFFERENTIATION; EXPRESSION; SPECIFICATION	CD4(+) T cell differentiation is regulated by specialized antigen-presenting cells. Dendritic cells (DCs) produce cytokines that promote naive CD4(+) T cell differentiation into T helper 1 (Th1), Th17, and inducible T regulatory (iTreg) cells. However, the initiation of Th2 cell responses remains poorly understood, although it is likely that more than one mechanism might be involved. Here we have defined a specific DC subset that is involved in Th2 cell differentiation in vivo in response to a protease allergen, as well as infection with Nippostrongylus brasiliensis. We have demonstrated that this subset is controlled by the transcription factor interferon regulatory factor 4 (IRF4), which is required for their differentiation and Th2 cell-inducing function. IRF4 is known to control Th2 cell differentiation and Th2 cell-associated suppressing function in Treg cells. Our finding suggests that IRF4 also plays a role in DCs where it controls the initiation of Th2 cell responses.	[Gao, Yan; Nish, Simone A.; Licona-Limon, Paula; Weinstein, Jason S.; Medzhitov, Ruslan] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Gao, Yan] Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA; [Jiang, Ruoyi] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; [Hou, Lin] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT 06520 USA; [Medzhitov, Ruslan] Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA	Medzhitov, R (reprint author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.	ruslan.medzhitov@yale.edu			National Institutes of Health [RO1 AI08977, 5RO1 AI055502, R37 AI046688]; Howard Hughes Medical Institute	We would like to thank A. Iwasaki, Y. Kumamoto, U. Klein, B. Reizis, L. Chen, and A. Pernis for providing reagents. This study was supported by a grant from the National Institutes of Health (RO1 AI08977, 5RO1 AI055502, and R37 AI046688) and the Howard Hughes Medical Institute.	Bajana S, 2012, J IMMUNOL, V189, P3368, DOI 10.4049/jimmunol.1102613; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Borkowski TA, 1996, EUR J IMMUNOL, V26, P110, DOI 10.1002/eji.1830260117; Caton ML, 2007, J EXP MED, V204, P1653, DOI 10.1084/jem.20062648; Ciofani M, 2012, CELL, V151, P289, DOI 10.1016/j.cell.2012.09.016; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Glasmacher E, 2012, SCIENCE, V338, P975, DOI 10.1126/science.1228309; Haley K, 2012, J IMMUNOL, V188, P4334, DOI 10.4049/jimmunol.1102759; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hashimoto D, 2011, IMMUNITY, V35, P323, DOI 10.1016/j.immuni.2011.09.007; Henri S, 2001, J IMMUNOL, V167, P741; Henri S, 2010, IMMUNOL CELL BIOL, V88, P366, DOI 10.1038/icb.2010.34; Igyarto BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Ishiwata K, 2010, J IMMUNOL, V184, P2086, DOI 10.4049/jimmunol.0804051; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; King IL, 2010, J EXP MED, V207, P953, DOI 10.1084/jem.20091844; Klein U, 2006, NAT IMMUNOL, V7, P773, DOI 10.1038/ni1357; Kumamoto Y, 2013, IMMUNITY, V39, P733, DOI 10.1016/j.immuni.2013.08.029; Kumamoto Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005619; Leon B, 2012, NAT IMMUNOL, V13, P681, DOI 10.1038/ni.2309; Li P, 2012, NATURE, V490, P543, DOI 10.1038/nature11530; Lohoff M, 2002, P NATL ACAD SCI USA, V99, P11808, DOI 10.1073/pnas.182425099; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Nguyen LT, 2002, J EXP MED, V196, P1393, DOI 10.1084/jem.20021466; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; O'Shea JJ, 2010, SCIENCE, V327, P1098, DOI 10.1126/science.1178334; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Persson EK, 2013, IMMUNITY, V38, P958, DOI 10.1016/j.immuni.2013.03.009; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Satoh T, 2010, NAT IMMUNOL, V11, P936, DOI 10.1038/ni.1920; Schlitzer A, 2013, IMMUNITY, V38, P970, DOI 10.1016/j.immuni.2013.04.011; Sousa CRE, 2001, IMMUNITY, V14, P495; Steinfelder S, 2009, J EXP MED, V206, P1681, DOI 10.1084/jem.20082462; Suzuki S, 2004, P NATL ACAD SCI USA, V101, P8981, DOI 10.1073/pnas.0402139101; Tamura T, 2008, ANNU REV IMMUNOL, V26, P535, DOI 10.1146/annurev.immunol.26.021607.090400; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Tussiwand R, 2012, NATURE, V490, P502, DOI 10.1038/nature11531; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Zhou L, 2009, IMMUNITY, V30, P646, DOI 10.1016/j.immuni.2009.05.001	43	118	120	1	21	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613	1097-4180		IMMUNITY	Immunity	OCT 17	2013	39	4					722	732		10.1016/j.immuni.2013.08.028		11	Immunology	Immunology	AA2UP	WOS:000330950000013	24076050	
J	van Nimwegen, FA; Penders, J; Stobberingh, EE; Postma, DS; Koppelman, GH; Kerkhof, M; Reijmerink, NE; Dompeling, E; van den Brandt, PA; Ferreira, I; Mommers, M; Thijs, C				van Nimwegen, Frederika A.; Penders, John; Stobberingh, Ellen E.; Postma, Dirkje S.; Koppelman, Gerard H.; Kerkhof, Marjan; Reijmerink, Naomi E.; Dompeling, Edward; van den Brandt, Piet A.; Ferreira, Isabel; Mommers, Monique; Thijs, Carel			Mode and place of delivery, gastrointestinal microbiota, and their influence on asthma and atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Mode of delivery; cesarean section; hospital delivery; gastrointestinal microbiota composition; wheeze; eczema; asthma; atopy; mediation analysis; cohort study; KOALA study	KOALA BIRTH COHORT; INTESTINAL MICROFLORA; CESAREAN-SECTION; FECAL MICROFLORA; CHILDHOOD; ALLERGY; CHILDREN; INFANTS; RISK; GUT	Background: Both gastrointestinal microbiota composition and cesarean section have been linked to atopic manifestations. However, results are inconsistent, and the hypothesized intermediate role of the microbiota in the association between birth mode and atopic manifestations has not been studied yet. Objectives: We sought to investigate the relationship between microbiota composition, mode and place of delivery, and atopic manifestations. Methods: The Child, Parent and Health: Lifestyle and Genetic Constitution Birth Cohort Study included data on birth characteristics, lifestyle factors, and atopic manifestations collected through repeated questionnaires from birth until age 7 years. Fecal samples were collected at age 1 month (n = 1176) to determine microbiota composition, and blood samples were collected at ages 1 (n = 921), 2 (n = 822), and 6 to 7 (n = 384) years to determine specific IgE levels. Results: Colonization by Clostridium difficile at age 1 month was associated with wheeze and eczema throughout the first 6 to 7 years of life and with asthma at age 6 to 7 years. Vaginal home delivery compared with vaginal hospital delivery was associated with a decreased risk of eczema, sensitization to food allergens, and asthma. After stratification for parental history of atopy, the decreased risk of sensitization to food allergens (adjusted odds ratio, 0.52; 95% CI, 0.35-0.77) and asthma (adjusted odds ratio, 0.47; 95% CI, 0.29-0.77) among vaginally home-born infants was only found for children with atopic parents. Mediation analysis showed that the effects of mode and place of delivery on atopic outcomes were mediated by C difficile colonization. Conclusion: Mode and place of delivery affect the gastrointestinal microbiota composition, which subsequently influences the risk of atopic manifestations. (J Allergy Clin Immunol 2011;128:948-55.)	[van Nimwegen, Frederika A.; Penders, John; Mommers, Monique; Thijs, Carel] Maastricht Univ, Dept Epidemiol, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Penders, John; Stobberingh, Ellen E.] Maastricht Univ, Dept Med Microbiol, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Dompeling, Edward] Maastricht Univ, Dept Pediat Pulmonol, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Ferreira, Isabel] Maastricht Univ, Dept Clin Epidemiol & Med Technol Assessment, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Ferreira, Isabel] Maastricht Univ, Dept Internal Med, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, NL-6200 MD Maastricht, Netherlands; [Postma, Dirkje S.; Reijmerink, Naomi E.] Univ Groningen, Beatrix Childrens Hosp, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; [Koppelman, Gerard H.] Univ Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 AB Groningen, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands; [Reijmerink, Naomi E.] Univ Groningen, Univ Med Ctr Groningen, Beatrix Childrens Hosp, NL-9700 AB Groningen, Netherlands; [van den Brandt, Piet A.] Maastricht Univ, Dept Epidemiol, Sch Oncol & Dev Biol GROW, Med Ctr, NL-6200 MD Maastricht, Netherlands	Penders, J (reprint author), Maastricht Univ, Dept Epidemiol, CAPHRI Sch Publ Hlth & Primary Care, Med Ctr, POB 616, NL-6200 MD Maastricht, Netherlands.	j.penders@maastrichtuniversity.nl	Ferreira, Isabel/B-6033-2008	Ferreira, Isabel/0000-0003-1434-0607	Netherlands Asthma Foundation [3.2.07.022, 3.2.03.48]; Stichting Astma Bestrijding; Dutch Biobanking and Biomolecular Resources Infrastructure (BBMRI-NL); Topinstitute Pharma; GlaxoSmithKline; AstraZeneca	Supported by the Netherlands Asthma Foundation (grant no. 3.2.07.022&3.2.03.48), the Stichting Astma Bestrijding, and the Dutch Biobanking and Biomolecular Resources Infrastructure (BBMRI-NL).; Disclosure of potential conflict of interest: D. S. Postma has consultant arrangements with Nycomed and has received research support from Topinstitute Pharma and AstraZeneca. G. H. Koppelman has received honoraria and research support from GlaxoSmithKline. C. Thijs has received research support from the Netherlands Asthma Foundation. The rest of the authors have declared that they have no conflict of interest.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Akkerdaas JH, 2005, INT ARCH ALLERGY IMM, V138, P203, DOI 10.1159/000088720; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bastiaanssen JM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-1; Bernsen RMD, 2005, CLIN EXP ALLERGY, V35, P1135, DOI 10.1111/j.1365-2222.2005.02155.x; Bezirtzoglou E, 1997, ANAEROBE, V3, P173, DOI 10.1006/anae.1997.0102; Bindels P J E, 2008, Ned Tijdschr Geneeskd, V152, P550; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Fallani M, 2010, J PEDIATR GASTR NUTR, V51, P77, DOI 10.1097/MPG.0b013e3181d1b11e; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kummeling I, 2005, PEDIATR ALLERGY IMMU, V16, P679, DOI 10.1111/j.1399-3038.2005.00333.x; Leadbitter P, 1999, THORAX, V54, P905; MacKinnon DP, 2007, ANNU REV PSYCHOL, V58, P593, DOI 10.1146/annurev.psych.58.110405.085542; MacKinnon DP, 2008, INTRO STAT MEDIATION; Maitra A, 2004, CLIN EXP ALLERGY, V34, P1349, DOI 10.1111/j.1365-2222.2004.02048.x; Penders J, 2008, GUT, V57, P1025, DOI 10.1136/gut.2007.143214; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Roduit C, 2009, THORAX, V64, P107, DOI 10.1136/thx.2008.100875; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Rook GAW, 2005, GUT, V54, P317, DOI 10.1136/gut.2004.053785; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P9; Stapel SO, 2004, PEDIATR ALLERGY IMMU, V15, P230, DOI 10.1111/j.1399-3038.2004.00142.x; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Tofighi D., 2011, BEHAV RES METHODS; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105	32	118	125	11	55	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					948	U371		10.1016/j.jaci.2011.07.027		11	Allergy; Immunology	Allergy; Immunology	842FJ	WOS:000296578200005	21872915	
J	Ziska, L; Knowlton, K; Rogers, C; Dalan, D; Tierney, N; Elder, MA; Filley, W; Shropshire, J; Ford, LB; Hedberg, C; Fleetwood, P; Hovanky, KT; Kavanaugh, T; Fulford, G; Vrtis, RF; Patz, JA; Portnoy, J; Coates, F; Bielory, L; Frenz, D				Ziska, Lewis; Knowlton, Kim; Rogers, Christine; Dalan, Dan; Tierney, Nicole; Elder, Mary Ann; Filley, Warren; Shropshire, Jeanne; Ford, Linda B.; Hedberg, Curtis; Fleetwood, Pamela; Hovanky, Kim T.; Kavanaugh, Tony; Fulford, George; Vrtis, Rose F.; Patz, Jonathan A.; Portnoy, Jay; Coates, Frances; Bielory, Leonard; Frenz, David			Recent warming by latitude associated with increased length of ragweed pollen season in central North America	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						aerobiology; allergies; global warming	AMBROSIA-ARTEMISIIFOLIA L.; CLIMATE-CHANGE; COMMON RAGWEED; PUBLIC-HEALTH; UNITED-STATES; AEROALLERGENS; ALLERGY; URBANIZATION; TEMPERATURES; COUNTS	A fundamental aspect of climate change is the potential shifts in flowering phenology and pollen initiation associated with milder winters and warmer seasonal air temperature. Earlier floral anthesis has been suggested, in turn, to have a role in human disease by increasing time of exposure to pollen that causes allergic rhinitis and related asthma. However, earlier floral initiation does not necessarily alter the temporal duration of the pollen season, and, to date, no consistent continental trend in pollen season length has been demonstrated. Here we report that duration of the ragweed (Ambrosia spp.) pollen season has been increasing in recent decades as a function of latitude in North America. Latitudinal effects on increasing season length were associated primarily with a delay in first frost of the fall season and lengthening of the frost free period. Overall, these data indicate a significant increase in the length of the ragweed pollen season by as much as 13-27 d at latitudes above similar to 44 degrees N since 1995. This is consistent with recent Intergovernmental Panel on Climate Change projections regarding enhanced warming as a function of latitude. If similar warming trends accompany long-term climate change, greater exposure times to seasonal allergens may occur with subsequent effects on public health.	[Ziska, Lewis] ARS, Crop Syst & Global Change Lab, USDA, Beltsville, MD 20705 USA; [Knowlton, Kim] Columbia Univ, Mailman Sch Publ Hlth, Hlth & Environm Program, Nat Resources Def Council, New York, NY 10032 USA; [Knowlton, Kim] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; [Rogers, Christine] Univ Massachusetts, Amherst, MA 01003 USA; [Dalan, Dan] Allergy & Asthma Care Ctr, Fargo, ND 58103 USA; [Tierney, Nicole; Elder, Mary Ann] Allergy & Asthma Specialists, Minneapolis, MN 55402 USA; [Filley, Warren; Shropshire, Jeanne] Oklahoma Allergy & Asthma Clin, Oklahoma City, OK 73104 USA; [Ford, Linda B.] Ctr Asthma & Allergy, Omaha, NE 68123 USA; [Hedberg, Curtis; Fleetwood, Pamela] Hedberg Allergy & Asthma Ctr, Rogers, AR 72758 USA; [Hovanky, Kim T.] Allergy & Asthma Ctr Georgetown, Georgetown, TX 78628 USA; [Kavanaugh, Tony; Fulford, George] Allergy Associates, La Crosse, WI 54602 USA; [Vrtis, Rose F.; Patz, Jonathan A.] Univ Wisconsin, Nelson Inst Environm Studies, Madison, WI 53706 USA; [Vrtis, Rose F.; Patz, Jonathan A.] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53706 USA; [Portnoy, Jay] Univ Missouri, Sch Med, Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Coates, Frances] Aerobiol Res Labs, Nepean, ON K2E 7Y5, Canada; [Bielory, Leonard] Rutgers State Univ, Ctr Environm Predict, New Brunswick, NJ 08901 USA; [Frenz, David] HealthE Care Syst, St Paul, MN 55102 USA	Ziska, L (reprint author), ARS, Crop Syst & Global Change Lab, USDA, Beltsville, MD 20705 USA.	l.ziska@ars.usda.gov	Rogers, Christine/A-2189-2008; Knowlton, Kim/A-7159-2012; Osborne, Nicholas/N-4915-2015	Rogers, Christine/0000-0003-0887-9606; Osborne, Nicholas/0000-0002-6700-2284			[Anonymous], ASTHM IMM; *ARB DAY FDN, 2006, ZON CHANG USDA PLANT; Ariano R, 2010, ANN ALLERG ASTHMA IM, V104, P215, DOI 10.1016/j.anai.2009.12.005; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; *CDCP, 2005, ALL HAYF; CHAPMAN JA, 1986, GRANA, V25, P235; Cleland EE, 2007, TRENDS ECOL EVOL, V22, P357, DOI 10.1016/j.tree.2007.04.003; Clot Bernard, 2003, Aerobiologia, V19, P227, DOI 10.1023/B:AERO.0000006572.53105.17; Dahl A., 1996, AEROBIOLOGIA, V12, P97, DOI DOI 10.1007/BF02248133; Deen W, 1998, WEED SCI, V46, P561; Dvorin DJ, 2001, ANN ALLERG ASTHMA IM, V87, P394; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Emberlin J, 1997, GRANA, V36, P29; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; ENVIRONMENT CANADA, 2011, NAT CLIM DAT INF ARC; Frenz DA, 1999, ANN ALLERG ASTHMA IM, V83, P341, DOI 10.1016/S1081-1206(10)62828-1; Frenz DA, 2001, ANN ALLERG ASTHMA IM, V86, P150; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Hansen J, 2006, P NATL ACAD SCI USA, V103, P14288, DOI 10.1073/pnas.0606291103; *INT PAN CLIM CHAN, 2007, CLIM CHANG 2007 PHYS; Rodriguez-Rajo FJ, 2010, AEROBIOLOGIA, V26, P1, DOI 10.1007/s10453-009-9138-2; Kosisky SE, 1997, ANN ALLERG ASTHMA IM, V78, P381; Levetin E, 2008, CURR ALLERGY ASTHM R, V8, P418, DOI 10.1007/s11882-008-0081-z; Miller-Rushing AJ, 2008, TREE PHYSIOL, V28, P659; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; *US EPA, 2008, EPA600R06164F; Van Vliet AJH, 2002, INT J CLIMATOL, V22, P1757, DOI 10.1002/joc.820; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Wodehouse R, 1971, HAYFEVER PLANTS; Yang Y, 2010, COMPUT ELECTRON AGR, V71, P77, DOI 10.1016/j.compag.2009.12.006; Yli-Panula E, 2009, INT J ENV RES PUB HE, V6, P1706, DOI 10.3390/ijerph6061706; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	34	118	120	2	57	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAR 8	2011	108	10					4248	4251		10.1073/pnas.1014107108		4	Multidisciplinary Sciences	Science & Technology - Other Topics	731PA	WOS:000288120400079	21368130	
J	Barber, D; de la Torre, F; Feo, F; Florido, F; Guardia, P; Moreno, C; Quiralte, J; Lombardero, M; Villalba, M; Salcedo, G; Rodriguez, R				Barber, D.; de la Torre, F.; Feo, F.; Florido, F.; Guardia, P.; Moreno, C.; Quiralte, J.; Lombardero, M.; Villalba, M.; Salcedo, G.; Rodriguez, R.			Understanding patient sensitization profiles in complex pollen areas: a molecular epidemiological study	ALLERGY			English	Article						allergens; environment; epidemiology; food allergens; pollen	OLEA-EUROPAEA POLLEN; CROSS-REACTIVITY; RELEVANT ALLERGENS; MAJOR ALLERGENS; PURIFICATION; EXPRESSION; MARKER; NOMENCLATURE; PATTERNS; OLE-E-1	Background: Allergy diagnosis in patients exposed to multiple pollen species is complex and misdiagnosis is often a cause for unsuccessful specific immunotherapy. Objective: We studied the sensitization profile of individual allergens (major, minor and pan-allergens) in pollen-sensitized patients in a region with high exposure to olive pollen by investigating the influence of minor allergens on allergic disease and the association between pan- and minor allergen sensitizations. Methods: A panel of 13 purified allergens, which included the most relevant allergens in the area, as well as minor olive allergens and pan-allergens, were screened using a high-capacity technology (ADVIA-Centaur((R))) in 891 patients. Results: Olive allergy as measured by specific IgE to Ole e 1 was the leading pollinosis in the area. The minor olive allergens Ole e 7 and Ole e 9 were markers of more severe allergic illness. Profilin sensitization was associated mainly with grass allergy, the second most prevalent pollinosis. Salsola kali pollen allergy was the third most common cause of pollinosis in the area. The prevalence of sensitization to the peach allergen Pru p 3, a nonspecific lipid-transfer protein, was notable. Conclusion: Epidemiological analysis by component-resolved diagnosis is a new method, which elucidates the interaction between allergen exposure gradient and patient sensitization. High exposure leads to differential sensitization profiles some of which are associated with more severe allergic conditions. Profilin sensitization, related mainly to grass pollinosis, was a marker of more severe grass pollen sensitization.	[Barber, D.; Lombardero, M.] ALK Abello, Dept ID, E-28037 Madrid, Spain; [de la Torre, F.] ALK Abello, Med Mkt, E-28037 Madrid, Spain; [Feo, F.] Gen Hosp, Serv Alergia, Ciudad Real, Spain; [Florido, F.] Hosp Clin, Serv Alergia, Granada, Spain; [Guardia, P.] Hosp Virgen Macarena, Serv Alergia, Seville, Spain; [Moreno, C.] Hosp Reina Sofia, Serv Alergia, Cordoba, Spain; [Quiralte, J.] Hosp Ciudad Jaen, Serv Alergia, Jaen, Spain; [Villalba, M.; Rodriguez, R.] Univ Complutense, Dept Bioquim & Biol Mol, Fac Ciencias Quim, E-28040 Madrid, Spain; [Salcedo, G.] Univ Politecn Madrid, Unidad Bioquim, Dept Biotecnol, ETS Ingn Agron, Madrid, Spain	Barber, D (reprint author), ALK Abello, Dept ID, C Miguel Fleta 19, E-28037 Madrid, Spain.		IBIS, ALERGICAS/C-1733-2016; RODRIGUEZ, ROSALIA/K-4993-2014	RODRIGUEZ, ROSALIA/0000-0002-4280-3691	ALK-Abello. S. A (Madrid, Spain)	We thank the EXPO study group for their excellent work, and the participating investigators from the following hospitals and private allergy practices: Hospital Perpetuo Socorro ( Albacete), Dr M. Barcelo (Almeria), Hospital de Don Benito, Hospital Infanta Cristina and Hospital de Merida (Badajoz), Hospital de Caceres, Hospital de Coria and Hospital de Navalmoral de la Mata (Caceres), Hospital de Jerez, Dr D. Gutierrez and Clinica Dr Lobaton (Cadiz), Hospital General (Castellon), Hospital del Carmen and Dr P. Mur (Ciudad Real), Hospital Reina Sofia (Cordoba), Hospital Clinico and Clinica ALERGOMEDIC (Granada), Hospital Clinico Virgen de la Cinta and Dr Arias Irigoyen (Huelva), Hospital Ciudad Jaen (Jaen), Hospital Carlos Haya (Malaga), Hospital de Lorca, Hospital Morales Messeguer and Hospital Virgen Arrixaca (Murcia), Clinica Santa Isabel, Hospital El Tomillar, Hospital Virgen Macarena and Hospital Virgen del Rocio (Sevilla), Dr R. Guspi, Hospital San Pau i Sta. Tecla and Hospital Virgen de la Cinta (Tarragona), Hospital Talavera and Hospital Virgen del Valle (Toledo) and Hospital de Xativa (Valencia). We thank Ms Linda Puebla and K. Shashok for language revision of the manuscript, and Ms Carmen Barrio for expert secretarial assistance. This trial was supported by ALK-Abello. S. A (Madrid, Spain).	Aasmul-Olsen D, 1996, ADV EXP MED BIOL, V409, P261; Barber D, 2007, J INVEST ALLERG CLIN, V17, P11; Barber D, 2006, ARB P EHRLICH I BUND, V95, P128; Barderas R, 2007, CLIN EXP ALLERGY, V37, P1111, DOI 10.1111/j.1365-2222.2007.02744.x; Barderas R, 2004, BIOL CHEM, V385, P731, DOI 10.1515/BC.2004.089; Barderas R, 2004, J ALLERGY CLIN IMMUN, V113, P1192, DOI 10.1016/j.jaci.2003.12.587; Calabozo B, 2001, CLIN EXP ALLERGY, V31, P322, DOI 10.1046/j.1365-2222.2001.00985.x; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; De Linares C, 2007, CLIN EXP ALLERGY, V37, P125, DOI 10.1111/j.1365-2222.2006.02620.x; Diaz-Perales A, 2002, CLIN EXP ALLERGY, V32, P87, DOI 10.1046/j.0022-0477.2001.01257.x; Duffort O, 2006, INT ARCH ALLERGY IMM, V140, P131, DOI 10.1159/000092532; Florido JF, 1999, INT ARCH ALLERGY IMM, V119, P133, DOI 10.1159/000024188; Fromberg J, 2006, ALLERGY, V61, P1234, DOI 10.1111/j.1398-9995.2006.01222.x; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297; Jimeno L, 2004, ALLERGY, V59, P995, DOI 10.1111/j.1398-9995.2004.00464.x; KING TP, 1994, B WORLD HEALTH ORGAN, V72, P797; Ledesma A, 2006, ALLERGY, V61, P477, DOI 10.1111/j.1398-9995.2006.00969.x; Lopez JFF, 2002, ALLERGY, V57, P53; MATTHIESEN F, 1991, CLIN EXP ALLERGY, V21, P297, DOI 10.1111/j.1365-2222.1991.tb01661.x; MONSALVE R, 2003, 22 C EUR AC ALL CLIN, P91; Moreno-Grau S, 2006, ANN ALLERG ASTHMA IM, V96, P858; Palomares O, 2003, BIOCHEM J, V369, P593, DOI 10.1042/BJ20020423; Palomares O, 2005, CLIN EXP ALLERGY, V35, P345, DOI [10.1111/j.1365-2222.2004.02186.x, 10.1111/j.1365-2222.2005.02186.x]; POLO F, 1991, MOL IMMUNOL, V28, P169, DOI 10.1016/0161-5890(91)90101-O; Quiralte J, 2005, ALLERGY, V60, P360, DOI 10.1111/j.1398-9995.2005.00698.x; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Rodriguez R, 2007, BIOMED PHARMACOTHER, V61, P1, DOI 10.1016/j.biopha.2006.09.014; SALCEDO G, 2007, BIOCHIM BIOPHYS ACTA, V177, P781; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; SERRANO P, 2007, THESIS U CORDOBA COR; Tejera ML, 1999, J ALLERGY CLIN IMMUN, V104, P797; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x	35	118	120	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	NOV	2008	63	11					1550	1558		10.1111/j.1398-9995.2008.01807.x		9	Allergy; Immunology	Allergy; Immunology	359AH	WOS:000259958100019	18925892	
J	von Leupoldt, A; Sommer, T; Kegat, S; Baumann, HJ; Klose, H; Dahme, B; Buchel, C				von Leupoldt, Andreas; Sommer, Tobias; Kegat, Sarah; Baumann, Hans Joerg; Klose, Hans; Dahme, Bernhard; Buechel, Christian			The unpleasantness of perceived dyspnea is processed in the anterior insula and amygdala	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						brain; dyspnea; emotions; magnetic resonance imaging; perception	OBSTRUCTIVE PULMONARY-DISEASE; POSITRON-EMISSION-TOMOGRAPHY; AFFECTIVE DIMENSION; INTEROCEPTIVE AWARENESS; AIR HUNGER; BRAIN; PAIN; PERCEPTION; EXERCISE; ASTHMA	Rationale: The subjective perception of dyspnea, which is an impairing symptom in various cardiopulmonary diseases, consists of sensory (intensity) and affective aspects (unpleasantness). However, little is known about the cortical processing of the perception of dyspnea. Objectives: To investigate the cortical areas associated with the processing of the affective unpleasantness of perceived dyspnea. Methods: Brain imaging study using functional magnetic resonance imaging in 14 healthy volunteers. Measurements and Main Results: Dyspnea was induced by inspiratory resistive loaded breathing with concomitant positive and negative emotional stimulation by viewing standardized emotional picture series. The blood oxygen level-dependent contrast was measured as an index of local neuronal activity while respiration was continuously monitored. Negative emotional stimulation during loaded breathing was associated with higher unpleasantness of perceived dyspnea when compared with loaded breathing with concomitant positive emotional stimulation (P < 0.05). The levels of intensity of perceived dyspnea, respiratory responses, and load magnitude were similar between both conditions. Higher unpleasantness of dyspnea was associated with neuronal activations in the limbic system-that is, in the right anterior insula and in the right amygdala (respective Z values = 3.93 and 3.15; P < 0.05). Conclusions: The results of the present brain imaging study suggest that the unpleasantness of subjectively perceived dyspnea is processed in the right human anterior insula and amygdala.	[von Leupoldt, Andreas; Kegat, Sarah; Dahme, Bernhard] Univ Hamburg, Dept Psychol, D-20146 Hamburg, Germany; [von Leupoldt, Andreas; Sommer, Tobias; Buechel, Christian] Univ Med Ctr Hamburg Eppendorf, Dept Syst Neurosci Neuroimage Nord, Hamburg, Germany; [Baumann, Hans Joerg; Klose, Hans] Univ Med Ctr Hamburg Eppendorf, Dept Pneumol, Hamburg, Germany	von Leupoldt, A (reprint author), Univ Hamburg, Dept Psychol, Von Melle Pk 5, D-20146 Hamburg, Germany.	andreas.vonleupoldt@uni-hamburg.de	Frank, David/E-8213-2012				Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2; Banzett RB, 2000, NEUROREPORT, V11, P2117, DOI 10.1097/00001756-200007140-00012; Banzett RB, 2000, AM J RESP CRIT CARE, V162, P1178; Banzett RB, 2001, APS B, V11, P1; BERTHIER M, 1988, ANN NEUROL, V24, P41, DOI 10.1002/ana.410240109; Bingel U, 2002, PAIN, V99, P313, DOI 10.1016/S0304-3959(02)00157-4; Buchel C, 1998, NEURON, V20, P947, DOI 10.1016/S0896-6273(00)80476-6; CarrieriKohlman V, 1996, CHEST, V110, P1526, DOI 10.1378/chest.110.6.1526; CORFIELD DR, 1995, J PHYSIOL-LONDON, V488, P77; Craig AD, 2002, NAT REV NEUROSCI, V3, P655, DOI 10.1038/nrn894; Critchley HD, 2004, NAT NEUROSCI, V7, P189, DOI 10.1038/nn1176; Center for the Study of Emotion and Attention (CSEA-NIMH), 1999, INT AFF PICT SYST; Davenport PW, 1995, REGULATION BREATHING, P365; De Peuter S, 2004, CLIN PSYCHOL REV, V24, P557, DOI 10.1016/j.cpr.2004.05.001; De Peuter S, 2007, RESP MED, V101, P925, DOI 10.1016/j.rmed.2006.09.018; Evans KC, 2002, J NEUROPHYSIOL, V88, P1500, DOI 10.1152/jn.00957.2001; Farrell MJ, 2006, P NATL ACAD SCI USA, V103, P2416, DOI 10.1073/pnas.0511019103; Fink GR, 1996, J APPL PHYSIOL, V81, P1295; Friston K., 1995, HUMAN BRAIN MAPPING, P165, DOI DOI 10.1002/HBM.460030303; Giardino ND, 2007, COMPR PSYCHIAT, V48, P103, DOI 10.1016/j.comppsych.2006.11.001; Grant S, 1999, CHEST, V116, P1208, DOI 10.1378/chest.116.5.1208; Greenspan JD, 1999, PAIN, V81, P273, DOI 10.1016/S0304-3959(99)00021-4; Guz A, 1997, RESP PHYSIOL, V109, P197, DOI 10.1016/S0034-5687(97)00050-9; KILLIAN KJ, 1982, J APPL PHYSIOL, V52, P578; Lavietes MH, 2000, AM J RESP CRIT CARE, V161, P737; LEHRER PM, 1993, J PSYCHOSOM RES, V37, P515, DOI 10.1016/0022-3999(93)90007-3; Liotti M, 2001, P NATL ACAD SCI USA, V98, P2035, DOI 10.1073/pnas.98.4.2035; Meek PM, 2003, HEART LUNG, V32, P335, DOI 10.1016/S0147-9563(03)00100-6; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; MUZA SR, 1990, AM REV RESPIR DIS, V141, P909; O'Donnell Denis E, 2007, Proc Am Thorac Soc, V4, P145, DOI 10.1513/pats.200611-159CC; OGAWA S, 1990, MAGNET RESON MED, V14, P68, DOI 10.1002/mrm.1910140108; Peiffer C, 2001, AM J RESP CRIT CARE, V163, P951; Phan KL, 2002, NEUROIMAGE, V16, P331, DOI 10.1006/nimg.2002.1087; Pollatos O, 2005, COGNITIVE BRAIN RES, V25, P948, DOI 10.1016/j.cogbrainres.2005.09.019; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; SCANO G, 2006, CURR OPIN PULM MED, V12, P8; Schreckenberger M, 2005, NEUROLOGY, V64, P1175; Small DM, 2003, NEURON, V39, P701, DOI 10.1016/S0896-6273(03)00467-7; Tataranni PA, 1999, P NATL ACAD SCI USA, V96, P4569, DOI 10.1073/pnas.96.8.4569; Thornton JM, 2001, J PHYSIOL-LONDON, V533, P823, DOI 10.1111/j.1469-7793.2001.00823.x; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; von Leupoldt A, 2005, CHEST, V128, P3345, DOI 10.1378/chest.128.5.3345; von Leupoldt A, 2005, CHEST, V128, P345, DOI 10.1378/chest.128.1.345; von Leupoldt A, 2007, CHEST, V132, P1506, DOI 10.1378/chest.07-1245; von Leupoldt A, 2007, CHEST, V132, P141, DOI 10.1378/chest.07-0103; von Leupoldt A, 2007, RESP MED, V101, P839, DOI 10.1016/j.rmed.2006.06.033; von Leupoldt A, 2007, RESP MED, V101, P411, DOI 10.1016/j.rmed.2006.06.011; Von Leupoldt A, 2006, PSYCHOPHYSIOLOGY, V43, P641, DOI 10.1111/j.1469-8986.2006.00453.x; Von Leupoldt A, 2006, PSYCHOPHYSIOLOGY, V43, P382, DOI 10.1111/j.1469-8986.2006.00415.x; WILSON RC, 1991, CLIN SCI, V80, P65; WITTCHEN HU, 1997, SKID 1 STRUCTURED CL	53	118	120	2	9	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY 1	2008	177	9					1026	1032		10.1164/rccm.200712-18210C		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	295PJ	WOS:000255486100017	18263796	
J	Pajno, GB; Caminiti, L; Vita, D; Barberio, G; Salzano, G; Lombardo, F; Canonica, GW; Passalacqua, G				Pajno, Giovanni B.; Caminiti, Lucia; Vita, Daniela; Barberio, Giovanni; Salzano, Giuseppina; Lombardo, Fortunato; Canonica, Giorgio Walter; Passalacqua, Giovanni			Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; house dust mites; sublingual immunotherapy	ALLERGIC RHINITIS; CONSENSUS REPORT; EFFICACY; ASTHMA; STANDARDIZATION; MULTICENTER; TRIALS	Background: Atopic dermatitis often has an allergic component, and immunotherapy may therefore prove beneficial. Objective: To assess the effect of sublingual immunotherapy (SLIT) in children with atopic dermatitis. Methods: Children age 5 to 16 years with atopic dermatitis (Scoring Atopic Dermatitis [SCORAD] > 7) and sensitization to dust mites alone, without food allergy or chronic asthma, were enrolled in a randomized, double-blind, placebo-controlled study and stratified according to disease severity. SLIT or placebo was given for 18 months in addition to standard therapy. SCORAD, visual analog scale, and rescue medication consumption were recorded at 3-month intervals. Results: Fifty-six children were enrolled, and 28 were allocated to SLIT. Forty-eight completed the study, with 2 dropouts in the active and 6 in the placebo group. The difference from baseline in the SCORAD was significant (P = .025) between the 2 groups starting from month 9. Similarly, there was a significant reduction in the use of medications only in the active group. A trend toward significance was seen for the visual analog score only in the active group versus baseline (P = .07). A significant difference in the considered parameters was found only in patients with a mild-moderate disease, whereas severe patients had only a marginal benefit. SLIT had to be discontinued in 2 patients because of exacerbation of dermatitis. Conclusion: Sublingual immunotherapy to dust mite improves mild-moderate atopic dermatitis. Clinical implications: Sublingual immunotherapy may represent an additional therapeutic tool for the treatment of extrinsic atopic dermatitis in properly selected children.	Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Univ Messina, Dept Pediat, Allergy Unit, I-98100 Messina, Italy	Passalacqua, G (reprint author), Univ Genoa, Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it					Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Bindslev-Jensen C, 2001, ALLERGY, V56, P75, DOI 10.1034/j.1398-9995.2001.00922.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Fonacier L, 2006, ANN ALLERG ASTHMA IM, V97, P117; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; NOWAK N, 2003, J ALLERGY CLIN IM S6, V112, pS128; Pacor Maria Luisa, 1994, Recenti Progressi in Medicina, V85, P273; Pajno GB, 2003, PEDIATR ALLERGY IMMU, V14, P292, DOI 10.1034/j.1399-3038.2003.00060.x; Passalacqua G, 2006, CURR OPIN ALLERGY CL, V6, P449, DOI 10.1097/01.all.0000246617.41871.40; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Petrova S, 2001, Zh Mikrobiol Epidemiol Immunobiol, V1, P33; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Rienzo VD, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; STALDER JF, 1993, DERMATOLOGY, V186, P23; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Werfel T, 1998, ALLERGY, V53, P731	30	118	121	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2007	120	1					164	170		10.1016/j.jaci.2007.04.008		7	Allergy; Immunology	Allergy; Immunology	190NS	WOS:000248066400024	17543376	
J	Romieu, I; Torrent, M; Garcia-Esteban, R; Ferrer, C; Ribas-Fito, N; Anto, JM; Sunyer, J				Romieu, I.; Torrent, M.; Garcia-Esteban, R.; Ferrer, C.; Ribas-Fito, N.; Anto, J. M.; Sunyer, J.			Maternal fish intake during pregnancy and atopy and asthma in infancy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; atopy; children; fish intake; n-3 PUFA; pregnancy	POLYUNSATURATED FATTY-ACIDS; OIL SUPPLEMENTATION; ALLERGIC DISEASE; IMMUNOGLOBULIN-A; CONTROLLED-TRIAL; HIGH-RISK; CHILDHOOD; CONSUMPTION; RESPONSES; LIFE	Background: There is growing evidence that n-3 fatty acids have anti-inflammatory properties and may modulate immune response. Dietary intake of these nutrients during pregnancy could play a role in the risk of asthma and atopy in the offspring. Methods: Using data from a cohort of women (n=462) enrolled during pregnancy and whose offspring were followed up to 6 years, we evaluated the impact of fish consumption during pregnancy on the incidence of atopy and asthma. Dietary intake was assessed by food frequency questionnaire (42 items) applied by an interviewer. Results: Thirty-four percent of infants had a medical diagnosis of eczema at age 1 year, 14.3% of the children were atopic [based on skin prick test (SPT) at 6 years], and 5.7% had atopic wheeze at age 6 years. After adjusting for potential confounding factors, fish intake during pregnancy was protective against the risk of eczema at age 1 year, a positive SPT for house dust mite at age 6 years and atopic wheeze at age 6 years [odds ratio (OR)=0.73 95% confidence interval (CI) 0.55-0.98, OR=0.68, 95% CI 0.46-1.01 and OR=0.55, 95% CI 0.31-0.96, respectively]. For an increase in fish intake from once per week to 2.5 times per week, the risk of eczema at age 1 year decreased by 37%, and the risk of positive SPT at age 6 years by 35%. Stratification by breastfeeding showed that fish intake was significantly related to a decrease risk in persistent wheeze among non-breastfed children (P for interaction < 0.05). No protective effect was observed among breastfed children. Conclusion: Our data suggest a protective effect of fish intake during pregnancy on the risk of atopy-related outcomes.	Inst Nacl Salud Publ, Cuernavaca 62508, Morelos, Mexico; IB SALUT, Area Salud Menorca, Menorca, Spain; Inst Municipal Invest Med, CREAL, E-08003 Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain	Romieu, I (reprint author), Inst Nacl Salud Publ, 655 Avenida Univ, Col Santa Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.	iromieu@correo.insp.mx	Sunyer, J/G-6909-2014	Sunyer, J/0000-0002-2602-4110			Barden AE, 2004, FREE RADICAL RES, V38, P233, DOI 10.1080/10715760310001656722; Basagana X, 2002, PEDIATR ALLERGY IMMU, V13, P412, DOI 10.1034/j.1399-3038.2002.02081.x; Bingham SA, 2001, PUBLIC HEALTH NUTR, V4, P847, DOI 10.1079/PHN2000102; Calder PC, 2006, CURR OPIN CLIN NUTR, V9, P77, DOI 10.1097/01.mco.0000214562.14074.fa; Calder PC, 2006, CLIN EXP ALLERGY, V36, P138, DOI 10.1111/j.1365-2222.2006.02433.x; Calder PC, 2002, BRIT J NUTR, V87, pS31, DOI [10.1079/BJN2001455, 10.1079/BJN2001482]; Calder P, 2002, BR J NUTR, V88, P165; Calvani M, 2006, PEDIATR ALLERGY IMMU, V17, P94, DOI 10.1111/j.1399-3038.2005.00367.x; Duchen K, 2001, ALLERGY, V56, P587, DOI 10.1034/j.1398-9995.2001.00040.x; Duchen K, 2000, PEDIATR ALLERGY IMMU, V11, P29, DOI 10.1034/j.1399-3038.2000.00052.x; Dunstan JA, 2004, CLIN EXP ALLERGY, V34, P1237, DOI 10.1111/j.1365-2222.2004.02028.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Hastie T, 1990, GEN ADDITIVE MODELS; Hughes DA, 1997, CLIN EXP IMMUNOL, V110, P516, DOI 10.1046/j.1365-2249.1997.4351455.x; James M.J., 2000, AM J CLIN NUTR S, V71, P343; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Jones P. J. H., 2006, MODERN NUTR HLTH DIS, P92; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Laitinen K, 2006, CLIN EXP ALLERGY, V36, P166, DOI 10.1111/j.1365-2222.2006.02417.x; LIANG KY, 1986, BIOMETRIKA, V73, P132; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Prescott SL, 2004, CURR OPIN CLIN NUTR, V7, P123, DOI 10.1097/00075197-200403000-00004; Prescott SL, 1998, J IMMUNOL, V160, P4730; Salam MT, 2005, J ASTHMA, V42, P513, DOI 10.1081/JAS-200067619; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; Sunyer J, 2005, ENVIRON HEALTH PERSP, V113, P1787, DOI 10.1289/ehp.8127; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; TRICON S, 2006, CLIN EXP ALLERGY REV, V6, P11788; Yu G, 1998, EUR J PEDIATR, V157, P298, DOI 10.1007/s004310050815	33	118	123	1	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2007	37	4					518	525		10.1111/j.1365-2222.2007.02685.x		8	Allergy; Immunology	Allergy; Immunology	152XM	WOS:000245395600008	17430348	
J	Kitagaki, K; Businga, TR; Racila, D; Elliott, DE; Weinstock, JV; Kline, JN				Kitagaki, Kunihiko; Businga, Thomas R.; Racila, Doina; Elliott, David E.; Weinstock, Joel V.; Kline, Joel N.			Intestinal helminths protect in a murine model of asthma	JOURNAL OF IMMUNOLOGY			English	Article							REGULATORY T-CELLS; INDUCED AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; INTERLEUKIN-10-DEFICIENT MICE; CPG OLIGODEOXYNUCLEOTIDES; ALLERGIC SENSITIZATION; INVERSE ASSOCIATION; HYGIENE HYPOTHESIS; TH2 RESPONSES; HAY-FEVER	Underdeveloped nations are relatively protected from the worldwide asthma epidemic; the hygiene hypothesis suggests this is due to suppression of Th2-mediated inflammation by increased exposure to pathogens and their products. Although microbial exposures can promote Th2-suppressing Th1 responses, even Th2-skewing infections, such as helminths, appear to suppress atopy, suggesting an alternate explanation for these observations. To investigate whether induction of regulatory responses by helminths may counter allergic inflammation, we examined the effects of helminth infection in a murine model of atopic asthma. We chose Heligosomoides polygyrus, a gastrointestinal nematode, as the experimental helminth; this worm does not enter the lung in its life cycle. We found that H. polygyrus infection suppressed allergen-induced airway eosinophilia, bronchial hyperreactivity, and in vitro allergen-recall Th2 responses in an IL-10-dependent manner; total and OVA-specific IgE, however, were increased by worm infection. Finally, helminth-infected mice were protected against eosinophilic inflammation induced by adoptive transfer of OVA-stimulated CD4(+) cells, and transfer of cells from helminth-infected/OVA-exposed mice suppressed OVA-induced eosinophilic inflammation, suggesting a role for regulatory cells. Increased CD4(+)CD25(+)Foxp3(+) cells were found in thoracic lymph nodes of helminth-infected/OVA-exposed mice. Helminthic colonization appears to protect against asthma and atopic disorders; the regulatory cytokine, IL-10, may be a critical player.	Univ Iowa, Carver Coll Med, Dept Med, Iowa City, IA 52242 USA	Kline, JN (reprint author), Univ Iowa Hosp & Clin, C33GH,200 Hawkins Dr, Iowa City, IA 52242 USA.	joel-kline@uiowa.edu			NHLBI NIH HHS [HL079447, HL079448, HL59324]; NIEHS NIH HHS [ES05605]		Ameredes BT, 2005, J IMMUNOL, V175, P1206; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BATES JHT, 1992, J APPL PHYSIOL, V72, P46; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Edwards LJ, 2004, MULT SCLER, V10, P575, DOI 10.1191/1352458504ms1087oa; Elliott DE, 2004, EUR J IMMUNOL, V34, P2690, DOI 10.1002/eji.200324833; Elliott DE, 2000, FASEB J, V14, P1848, DOI 10.1096/fj.99-0885hyp; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fox JG, 2000, NAT MED, V6, P536, DOI 10.1038/75015; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; Groux H, 1997, NATURE, V389, P737; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Justice JP, 2001, AM J PHYSIOL-LUNG C, V280, pL363; Kay AB, 1996, ANN NY ACAD SCI, V796, P1, DOI 10.1111/j.1749-6632.1996.tb32561.x; Kitagaki K, 2002, CLIN DIAGN LAB IMMUN, V9, P1260, DOI 10.1128/CDLI.9.6.1260-1269.2002; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258; MacDonald AJ, 2002, J INFECT DIS, V185, P720, DOI 10.1086/339340; Makela MJ, 2002, AM J RESP CRIT CARE, V165, P824, DOI 10.1164/rccm.2105062; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MASTERS S, 1985, EPIDEMIOL REV, V7, P49; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; ROBINSON M, 1989, PARASITOLOGY, V98, P115; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Shi HN, 1998, J IMMUNOL, V160, P2449; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wilson MS, 2006, CHEM IMMUNOL ALLERGY, V90, P176; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Yang X, 2000, EUR J IMMUNOL, V30, P382, DOI 10.1002/1521-4141(200002)30:2<382::AID-IMMU382>3.3.CO;2-C; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	50	118	125	1	15	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2006	177	3					1628	1635				8	Immunology	Immunology	065DT	WOS:000239140300037	16849471	
J	Bel, EH				Bel, EH			Clinical phenotypes of asthma	CURRENT OPINION IN PULMONARY MEDICINE			English	Article						phenotypes; childhood asthma; adult-onset asthma; severe asthma	ASPIRIN-INDUCED ASTHMA; ADULT-ONSET ASTHMA; NEAR-FATAL ASTHMA; AIR-FLOW LIMITATION; CHLAMYDIA-PNEUMONIAE; OCCUPATIONAL ASTHMA; RISK-FACTORS; FOLLOW-UP; BRONCHIAL RESPONSIVENESS; ALLERGIC SENSITIZATION	Purpose of review Asthma is a phenotypically heterogeneous disorder and, over the years, many different clinical subtypes of asthma have been described. A precise definition of asthma phenotypes is now becoming more and more important, not only for a better understanding of pathophysiologic mechanisms, but in particular to ascertain the specific genes associated with these phenotypes. Recent findings In children, three asthma phenotypes are now well defined: transient infant wheezing, nonatopic wheezing of the toddler, and IgE-mediated wheezing/asthma. Recently, a fourth phenotype, late-onset childhood asthma has been added to this list. In adults, asthma persisting from childhood into adulthood should be distinguished from asthma starting in adulthood. The phenotypes of adult-onset asthma are still poorly defined. Until now, phenotypic classification has been based primarily on etiologic factors (eg, aspirin sensitivity, persistent respiratory infections, occupational factors, or toxic exposures) or clinical characteristics of the disease (eg, mild, severe, brittle, near fatal, with fixed airflow obstruction, steroid resistant). Novel noninvasive techniques to assess the type and severity of airway inflammation and dysfunction are increasingly used to identify better the different phenotypes. Summary The classic phenotype of IgE-mediated asthma starting in childhood is now clearly defined. However, many other phenotypes of asthma in childhood as well in adulthood are being recognized. In particular, asthma starting in adulthood and noneosinophilic asthma constitute an important part of the adult asthma population, and are,still poorly defined. A precise definition of these asthma phenotypes is urgently needed because they are likely to be associated with different genotypes, responses to treatment, and prognoses.	Leiden Univ, Ctr Med, Dept Pulm Dis, NL-2300 RC Leiden, Netherlands	Bel, EH (reprint author), Leiden Univ, Ctr Med, Dept Pulm Dis, POB 9600,C3P, NL-2300 RC Leiden, Netherlands.	e.h.d.bel@lumc.nl					Antczak A, 2002, AM J RESP CRIT CARE, V166, P301, DOI 10.1164/rccm.2101021; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BARDANA EJ, 2003, ALLERGY CLIN IMMU S2, V111, pS530; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338; BETSOU F, 2003, DIAGN LAB IMMUNOL, V10, P446; Bisgaard H, 2003, AM J RESP CRIT CARE, V167, P379, DOI 10.1164/rccm.200207-747OC; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Castro M, 2002, CHEST, V121, P1394, DOI 10.1378/chest.121.5.1394; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chan-Yeung Moira, 2003, Am J Respir Crit Care Med, V167, P450; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; de Meer G, 2003, CLIN EXP ALLERGY, V33, P789, DOI 10.1046/j.1365-2222.2003.01677.x; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; FABBRI LM, 2003, AM J RESP CRIT CARE, V187, P418; Falck C, 2002, CHEST, V122, P1587; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS824, DOI 10.1067/mai.2003.151; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Hahn DL, 2002, CHEST, V122, P1510, DOI 10.1378/chest.122.5.1510; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Hizawa N, 2002, AM J RESP CRIT CARE, V166, P686, DOI 10.1164/rccm.2002020090OC; Horak E, 2003, BRIT MED J, V326, P422, DOI 10.1136/bmj.326.7386.422; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Jorgensen IM, 2000, EUR RESPIR J, V15, P844, DOI 10.1034/j.1399-3003.2000.15e06.x; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Knox AJ, 2002, THORAX, V57, P565, DOI 10.1136/thorax.57.7.565; Konig P, 2002, PEDIATR PULM, V33, P307, DOI 10.1002/ppul.10090; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; LAUNG DY, 2003, J ALLERGY CLIN IMMUN, V111, P3; Lemanske RF, 2003, CHEST, V123, p385S, DOI 10.1378/chest.123.3_suppl.385S-a; Lemanske RF, 2002, J ALLERGY CLIN IMMUN, V109, pS521, DOI 10.1067/mai.2002.124564; Lewis CC, 2003, CHEST, V123, p428S, DOI 10.1378/chest.123.3_suppl.428S-a; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu Q, 2003, ANN ALLERG ASTHMA IM, V90, P35; Mallia P, 2002, ALLERGY, V57, P1118, DOI 10.1034/j.1398-9995.2002.02169.x; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Martin JG, 2003, AM J RESP CRIT CARE, V168, P568, DOI 10.1164/rccm.200201-021OC; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; Martinez FD, 2002, PEDIATRICS, V109, P362; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; Morahan G, 2002, LANCET, V360, P455, DOI 10.1016/S0140-6736(02)09676-9; Namazy JA, 2002, ANN ALLERG ASTHMA IM, V89, P542; NEWMANTAYLOR AJ, 2003, ANN ALLERG ASTHMA IM, V90, P24; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Picado C, 2003, ALLERGY, V58, P122, DOI 10.1034/j.1398-9995.2003.23792.x; Pierzchalska M, 2003, J ALLERGY CLIN IMMUN, V111, P1041, DOI 10.1067/mai.2003.1491; Platts-Mills TAE, 2002, JAMA-J AM MED ASSOC, V288, P1012, DOI 10.1001/jama.288.8.1012; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Strachan DP, 1996, BRIT MED J, V312, P1195; Szczeklik A, 2003, J ALLERGY CLIN IMMUN, V111, P913, DOI 10.1067/mai.2003.1487; Tarlo SA, 2003, ANN ALLERG ASTHMA IM, V90, P19; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; Toren K, 2002, RESP MED, V96, P635, DOI 10.1053/rmed.2002.1319; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303; Vignola AM, 2003, CHEST, V123, p417S, DOI 10.1378/chest.123.3_suppl.417S-a; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Wenzel S, 2003, CHEST, V123, p405S, DOI 10.1378/chest.123.3_suppl.405S-a; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Yao TC, 2003, J ALLERGY CLIN IMMUN, V111, P1285, DOI 10.1067/mai.2003.1506; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	76	118	129	3	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1070-5287			CURR OPIN PULM MED	Curr. Opin. Pulm. Med.	JAN	2004	10	1					44	50		10.1097/00063198-200401000-00008		7	Respiratory System	Respiratory System	773EY	WOS:000188885800007	14749605	
J	Delfino, RJ; Gong, H; Linn, WS; Pellizzari, ED; Hu, Y				Delfino, RJ; Gong, H; Linn, WS; Pellizzari, ED; Hu, Y			Asthma symptoms in Hispanic children and daily ambient exposures to toxic and criteria air pollutants	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						environmental air pollutants; hydrocarbons; longitudinal studies; nitrogen dioxide; ozone; statistical models; sulfur dioxide; vehicle emissions	PEAK EXPIRATORY FLOW; VOLATILE ORGANIC-COMPOUNDS; ANTIINFLAMMATORY MEDICATION USE; INNER-CITY CHILDREN; RESPIRATORY HEALTH; ULTRAFINE PARTICLES; FORMALDEHYDE EXPOSURE; FINE PARTICLES; LUNG-FUNCTION; LOS-ANGELES	Although acute adverse effects on asthma have been frequently found for the U.S. Environmental Protection Agency's principal criteria air pollutants, there is little epidemiologic information on specific hydrocarbons from toxic emission sources. We conducted a panel study of 22 Hispanic children with asthma who were 10-16 years old and living in a Los Angeles community with high traffic density. Subjects filled out symptom diaries daily for up to 3 months (November 1999 through January 2000). Pollutants included ambient hourly values of ozone, nitrogen dioxide, Sulfur dioxide, and carbon monoxide and 24-hr values of volatile organic compounds (VOCs), particulate matter with aerodynamic diameter <10 &mu;m (PM10), and elemental carbon (EC) and organic carbon (OC) PM10 fractions. Asthma symptom severity was regressed on pollutants using generalized estimating equations, and peak expiratory flow (PEF) was regressed on pollutants using mixed models. We found positive associations of symptoms with criteria air pollutants (O-3, NO2, SO2, PM10),, EC-OC, and VOCs (benzene, ethylbenzene, formaldehyde, acetaldehyde, acetone, 1,3-butadiene, tetrachloroethylene, toluene, m,p-xylene, and o-xylene). Selected adjusted odds ratios for bothersome or more severe asthma symptoms from interquartile range increases in pollutants were, for 1.4 ppb 8-hr NO2, 1.27 [95% confidence interval (Cl), 1.05-1-54]; 1.00 ppb benzene, 1.23 (95% Cl, 1.02-1.48); 3.16 ppb formaldehyde, 1.37 (95% CI, 1.04-1.80); 37 &mu;g/m(3) PM,0, 1.45 (95% Cl, 1.11-1.90); 2.91 &mu;g/m(3) EC, 1.85 (95% Cl, 1.11-3.08); and 4.64 &mu;g/m(3) OC, 1.88 (95% CI, 1.12-3.17). Two-pollutant models of EC or OC with PM10 showed little change in odds ratios for EC (to 1.83) or OC (to 1.89), but PM10 decreased from 1.45 to 1.0. There were no significant associations with PEF. Findings support the view that air toxics in the pollutant mix from traffic and industrial sources may have adverse effects on asthma in children.	Univ Calif Irvine, Coll Med, Dept Med, Div Epidemiol, Irvine, CA 92697 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA USA; Los Amigos Res & Educ Inst, Environm Hlth Serv, Downey, CA USA; Res Triangle Inst, Exposure Anal Res Program, Res Triangle Pk, NC 27709 USA	Delfino, RJ (reprint author), Univ Calif Irvine, Coll Med, Dept Med, Div Epidemiol, 224 Irvine Hall, Irvine, CA 92697 USA.				NIEHS NIH HHS [1P01ES09581-01]		Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Bernstein IL, 1999, ASTHMA WORKPLACE; Buchdahl R, 2000, OCCUP ENVIRON MED, V57, P86, DOI 10.1136/oem.57.2.86; CASS GR, 1995, DIESEL EXHAUST CRITI, P125; ChanYeung M, 1996, AM J RESP CRIT CARE, V154, P889; CHOW JC, 1993, ATMOS ENVIRON A-GEN, V27, P1185, DOI 10.1016/0960-1686(93)90245-T; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Eid N, 2000, PEDIATRICS, V105, P354, DOI 10.1542/peds.105.2.354; ENRIGHT PL, 1995, CHEST, V107, P657, DOI 10.1378/chest.107.3.657; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Goldberg S, 2001, CHEST, V120, P482, DOI 10.1378/chest.120.2.482; Hagen JA, 2000, EPIDEMIOLOGY, V11, P136, DOI 10.1097/00001648-200003000-00009; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; Kamps AWA, 2001, THORAX, V56, P180, DOI 10.1136/thorax.56.3.180; KIM, 2002, J AIR WASTE MANAGE A, V52, P297; Kinney PL, 2002, ENVIRON HEALTH PERSP, V110, P539; KOREN HS, 1992, ARCH ENVIRON HEALTH, V47, P39; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; Leikauf GD, 2002, ENVIRON HEALTH PERSP, V110, P505; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Littell R., 1996, SAS SYSTEM MIXED MOD; Malmberg LP, 2001, CHEST, V120, P1843, DOI 10.1378/chest.120.6.1843; MELTZER AA, 1989, CHEST, V96, P329, DOI 10.1378/chest.96.2.329; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; NHLBI, 1997, NIH PUBL, V98-4080; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Peden DB, 1997, ALLERGY, V52, P37; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Redline S, 1996, PEDIATR PULM, V21, P203; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184; SCAQMD, 2000, MULT AIR TOX EXP STU; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Segala C, 1998, EUR RESPIR J, V11, P677; Shingo S, 2001, EUR RESPIR J, V17, P220, DOI 10.1183/09031936.01.17202200; SLY PD, 1994, BRIT MED J, V308, P572; Thompson AJ, 2001, ARCH ENVIRON HEALTH, V56, P234; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; Tolbert PE, 2000, J EXPO ANAL ENV EPID, V10, P446, DOI 10.1038/sj.jea.7500106; ULRICH E, 1992, J AEROSOL SCI, V23, pS925; *US EPA, 1990, NAT AIR QUAL EM TREN; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Verschelden P, 1996, EUR RESPIR J, V9, P880, DOI 10.1183/09031936.96.09050880; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; Weisel CP, 2002, ENVIRON HEALTH PERSP, V110, P527; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835	66	118	122	3	28	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2003	111	4					647	656		10.1289/ehp.5992		10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	665WM	WOS:000182144300059	12676630	
J	Litonjua, AA; Milton, DK; Celedon, JC; Ryan, L; Weiss, ST; Gold, DR				Litonjua, AA; Milton, DK; Celedon, JC; Ryan, L; Weiss, ST; Gold, DR			A longitudinal analysis of wheezing in young children: The independent effects of early life exposure to house dust endotoxin, allergens, and pets	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; allergens; domestic animals; wheeze; asthma	HAY-FEVER; ASTHMA; RISK; SENSITIZATION; ATOPY; INHALATION; COMMUNITY; DECREASES; COCKROACH; RESPONSES	Background: It has been postulated that exposure to bacterial endotoxins and animals early in life might confer protection against the development of asthma and allergies. Objective: We investigated the longitudinal effects of exposure to house dust endotoxin (HDE), allergen levels, and the presence of a dog in the home on wheezing in young children over a 4-year period. Methods: Two hundred twenty-six children younger than 5 years were followed for 4 years. Endotoxin and allergen levels were measured from house dust collected at baseline. Longitudinal associations were investigated by using a proportional hazards technique that allowed for multiple outcomes per subject. Results: Exposure to high concentrations of HDE of greater than the median level was associated with an increased risk for wheezing over the period of observation (multivariate relative risk, 1.52; 95% CI, 1.07-2.14), but this risk rapidly decreased over time (P for trend = .005). Exposure to cockroach allergen was associated with increased risk for wheezing, whereas exposure to cat allergen and the presence of a dog in the home were both associated with decreased risk for wheezing. The risks associated with cockroach allergen, cat allergen, and dog did not change over the period of observation. Conclusion: The negative associations between exposures to dogs and cat allergen and wheeze appear to be independent of the effects of endotoxin and suggest that separate mechanisms might mediate the effects of HDE exposure and pet exposure on the developing immune system.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Litonjua, AA (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Milton, Donald/G-3286-2010; Ryan, Louise/A-4562-2009	Milton, Donald/0000-0002-0550-7834; Ryan, Louise/0000-0001-5957-2490; Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [K08 HL-03870]; NIAID NIH HHS [R01 AI/EHS-35786]; NIEHS NIH HHS [R01 ES-07036]		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Keman S, 1998, INT ARCH OCC ENV HEA, V71, P131, DOI 10.1007/s004200050260; LE JM, 1986, J IMMUNOL, V136, P4525; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1999, LANCET S2, V354, pSII12; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P443; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981; Silva JRL, 2000, TOXICOLOGY, V152, P31; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; THERNEAU TM, 2000, MODELING SURVIVAL DA, P185; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	33	118	118	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2002	110	5					736	742		10.1067/mai.2002.128948		7	Allergy; Immunology	Allergy; Immunology	612NN	WOS:000179082500008	12417882	
J	Takuma, K; Phuagphong, P; Lee, E; Mori, K; Baba, A; Matsuda, T				Takuma, K; Phuagphong, P; Lee, E; Mori, K; Baba, A; Matsuda, T			Anti-apoptotic effect of cGMP in cultured astrocytes - Inhibition by cGMP-dependent protein kinase of mitochondrial permeable transition pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; CYTOCHROME-C RELEASE; NITRIC-OXIDE; RAT ASTROCYTES; NA+-CA2+ EXCHANGER; REPERFUSION INJURY; CYCLOSPORINE-A; INNER MEMBRANE; PC12 CELLS; ACTIVATION	Reperfusion of cultured astrocytes with normal medium after exposure to H2O2-containing medium causes apoptosis. We have recently shown that ibudilast, which has been used for bronchial asthma and cerebrovascular disorders, attenuated the H2O2-induced apoptosis of astrocytes via the cGMP signaling pathway. This study examines the mechanism underlying the protective effect of cGMP. The membrane-permeable cGMP analog dibutyryl-cGMP attenuated the H2O2-induced decrease in cell viability, DNA ladder formation, nuclear condensation, reduction of the mitochondrial membrane potential, cytochrome c release from mitochondria, and caspase-3 activation in cultured astrocytes. These effects of dibutyryl-cGMP were almost completely inhibited by the cGMP-dependent protein kinase (PKG) inhibitor KT5823. In isolated rat brain mitochondria, cGMP in the presence of cytosolic extract from astrocytes inhibited the mitochondrial permeability transition pore (PTP) as determined by monitoring Ca2+-induced mitochondrial swelling. This ability of the cytosolic extract was inactivated by heat treatment and was mimicked by exogenous PKG. The effect of cGMP on the mitochondrial swelling was blocked by KT5823. The PTP inhibitors cyclosporin A and bongkrekic acid prevented the H2O2-induced decrease in cell viability and caspase-3 activation. These findings demonstrate that cGMP inhibits the mitochondrial PTP via the activation of PKG, and the prevention of mitochondrial dysfunction contributes to its anti-apoptotic effect.	Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Pharmaceut Sci, Lab Mol Neuropharmacol, Suita, Osaka 5650871, Japan; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Kobe, Hyogo 6512180, Japan; Kobe Gakuin Univ, Fac Pharmaceut Sci, Dept Pharmacol, Kobe, Hyogo 6512180, Japan; Kobe Gakuin Univ, High Technol Res Ctr, Kobe, Hyogo 6512180, Japan	Matsuda, T (reprint author), Osaka Univ, Grad Sch Pharmaceut Sci, Lab Med Pharmacol, 1-6 Yamadaoka, Suita, Osaka 5650871, Japan.						Adams JW, 2000, CIRC RES, V87, P1180; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BROEKEMEIER KM, 1989, J BIOL CHEM, V264, P7826; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; CHUN SY, 1995, ENDOCRINOLOGY, V136, P3120, DOI 10.1210/en.136.7.3120; CONNERN CP, 1994, BIOCHEM J, V302, P321; Custodio JBA, 1998, TOXICOL APPL PHARM, V152, P10, DOI 10.1006/taap.1998.8510; Estevez AG, 1998, J NEUROSCI, V18, P3708; Farinelli SE, 1996, J NEUROSCI, V16, P2325; FERRIS CD, 1992, ANNU REV PHYSIOL, V54, P469, DOI 10.1146/annurev.physiol.54.1.469; Friberg H, 1998, J NEUROSCI, V18, P5151; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1999, J NEUROSCI, V19, P6740; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; KRISTIAN T, 1994, BRAIN RES, V641, P295, DOI 10.1016/0006-8993(94)90158-9; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lemasters JJ, 1997, MOL CELL BIOCHEM, V174, P159, DOI 10.1023/A:1006827601337; Li JR, 2000, J BIOL CHEM, V275, P13026, DOI 10.1074/jbc.275.17.13026; Matsuda T, 1998, J NEUROCHEM, V70, P2004; Matsuda T, 1996, EUR J NEUROSCI, V8, P951, DOI 10.1111/j.1460-9568.1996.tb01582.x; Matsuda T, 1997, JPN J PHARMACOL, V74, P1, DOI 10.1254/jjp.74.1; Moriya R, 2000, FEBS LETT, V484, P253, DOI 10.1016/S0014-5793(00)02167-0; NIEMINEN AL, 1995, BIOCHEM J, V307, P99; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Schlossmann J, 2000, NATURE, V404, P197; Sciorati C, 1997, J BIOL CHEM, V272, P23211, DOI 10.1074/jbc.272.37.23211; SIEMKOWICZ E, 1981, STROKE, V12, P236; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; SILVER IA, 1992, J CEREBR BLOOD F MET, V12, P759; SIMS NR, 1991, J NEUROCHEM, V56, P1836, DOI 10.1111/j.1471-4159.1991.tb03438.x; Takuma K, 2000, EUR J PHARMACOL, V399, P1, DOI 10.1016/S0014-2999(00)00334-4; Takuma K, 1999, EUR J NEUROSCI, V11, P4204, DOI 10.1046/j.1460-9568.1999.00850.x; TAKUMA K, 1994, GLIA, V12, P336, DOI 10.1002/glia.440120410; Takuma K, 1996, BRAIN RES, V735, P265, DOI 10.1016/0006-8993(96)00588-4; TAKUMA K, 1995, J NEUROCHEM, V64, P1536; Takuma K, 2000, EUR J PHARMACOL, V406, P333, DOI 10.1016/S0014-2999(00)00701-9; Takuma K, 1996, J NEUROCHEM, V67, P1840; Takuma K, 2001, BRIT J PHARMACOL, V133, P841, DOI 10.1038/sj.bjp.0704146; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; TSOU K, 1993, P NATL ACAD SCI USA, V90, P3462, DOI 10.1073/pnas.90.8.3462; Yoon HS, 2000, BIOCHEM BIOPH RES CO, V276, P151, DOI 10.1006/bbrc.2000.3445; ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A	44	118	122	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 21	2001	276	51					48093	48099		10.1074/jbc.M108622200		7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	505QL	WOS:000172927000049	11677240	
J	Penttinen, P; Timonen, KL; Tiittanen, P; Mirme, A; Ruuskanen, J; Pekkanen, J				Penttinen, P; Timonen, KL; Tiittanen, P; Mirme, A; Ruuskanen, J; Pekkanen, J			Number concentration and size of particles in urban air: Effects on spirometric lung function in adult asthmatic subjects	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; FVC; FEV1; particles; particle size; peak expiratory flow rate; PEFR; spirometry	RESPIRATORY HEALTH; ULTRAFINE PARTICLES; CYTOKINE PRODUCTION; FINE PARTICLES; POLLUTION; CHILDREN; PM10; MORTALITY; ASSOCIATION; ATMOSPHERE	Daily variations in ambient particulate air pollution are associated with variations in respiratory lung Function. It has been suggested that the effects of particulate matter may be due to particles in the ultrafine (0.01-0.1 mum) size range. Be-cause previous studies on ultrafine particles only used self-monitored peak expiratory now rate (PEFR), we assessed the associations between particle mars and number concentrations in several size ranges measured at a central site and measured (biweekly) spirometric lung function among a group of 54 adult asthmatics (n = 495 measurements). We also compared results to daily morning, afternoon, and evening PEFR measurements done at home (n = 7,672-8,110 measurements), The median (maximum) 24 hr number concentrations were 14,500/cm(3) (46,500/cm(3)) ultrafine particles and 800/cm(3) (2,800/cm3) accumulation mode (0.1-1 mum) particles. The median (maximum) mass concentration of PM2.5 (particulate matter <2.5 <mu>m) and PM10 (particulate matter <10 <mu>m in aerodynamic diameter) were 8.4 mug/m(3) (38.3 mug/m(3)) and 13.5 mug/m(3) (73.7 mug/m(3)), respectively. The number of accumulation mode particles was consistently inversely associated with PEFR in spirometry. Inverse, but nonsignificant, associations were observed with ultrafine particles, and no associations were observed with large particles (PM10). Compared to the effect estimates for self-monitored PEFR, the effect estimates for spirometric PEFR tended to be larger. The standard errors were also larger, probably due to the lower number of spirometric measurements. The present results support the need to monitor the particle number and size distributions in urban air in addition to mass.	Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio 70701, Finland; Univ Tartu, Inst Environm Phys, EE-50090 Tartu, Estonia; Univ Kuopio, Dept Environm Sci, FIN-70211 Kuopio, Finland	Pekkanen, J (reprint author), Natl Publ Hlth Inst, Environm Epidemiol Unit, POB 95, Kuopio 70701, Finland.						Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DUSSELDORP A, 1995, AM J RESP CRIT CARE, V152, P1932; Harrison RM, 1999, ATMOS ENVIRON, V33, P309, DOI 10.1016/S1352-2310(98)00164-2; HOEK G, 1994, ENVIRON RES, V64, P136, DOI 10.1006/enrs.1994.1012; Hosiokangas J, 1999, ATMOS ENVIRON, V33, P3821, DOI 10.1016/S1352-2310(98)00400-2; Hughes LS, 1998, ENVIRON SCI TECHNOL, V32, P1153, DOI 10.1021/es970280r; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Neas LM, 1999, EPIDEMIOLOGY, V10, P550, DOI 10.1097/00001648-199909000-00015; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; PENTTINEN P, IN PRESS EUR RESP J; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; Roemer W, 2000, EUR RESPIR J, V15, P553, DOI 10.1034/j.1399-3003.2000.15.21.x; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; SCHLESINGER RB, 1994, ENVIRON RES, V65, P69, DOI 10.1006/enrs.1994.1022; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; TIMONEN KL, UNPUB; Vallius MJ, 2000, ENVIRON SCI TECHNOL, V34, P1919, DOI 10.1021/es990603e; VANDERZEE S, 1999, THESIS U WAGENINGEN; Vedal S, 1997, J AIR WASTE MANAGE, V47, P551; 1997, FINNISH POLLEN B, V22; [Anonymous], 1987, AM REV RESP DIS, V136, P1285	29	118	125	2	20	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2001	109	4					319	323		10.2307/3454889		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	427NZ	WOS:000168413600020	11335178	
J	Palmer, LJ; Rye, PJ; Gibson, NA; Burton, PR; Landau, LI; LeSouef, PN				Palmer, LJ; Rye, PJ; Gibson, NA; Burton, PR; Landau, LI; LeSouef, PN			Airway responsiveness in early infancy predicts asthma, lung function, and respiratory symptoms by school age	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							BRONCHIAL HYPERRESPONSIVENESS; SUBSEQUENT DEVELOPMENT; EARLY-CHILDHOOD; FAMILY HISTORY; RISK-FACTORS; CHILDREN; SMOKING; LIFE; POPULATION; INFLAMMATION	Asthma is the most common chronic childhood disease in developed nations. Little is known about the relationship between airway responsiveness in infancy and the development of asthma later in life. The relationship of airway responsiveness at 1 mo with asthma, atopy, lower respiratory symptoms, and lung function at 6 yr of age was investigated prospectively in 95 white children from a randomly ascertained birth cohort. Baseline spirometry, airway responsiveness to histamine, and skin reactivity to common allergens were assessed at the age of 1 mo and 6 yr. Total serum immunoglobulin E (IgE) was measured from cord blood and at 6 yr. Brood eosinophil counts were measured at 6 yr only. Family, symptom, and exposure histories at both time points were derived from questionnaire data. Independently of the other factors assessed, increased airway responsiveness at 1 mo was significantly associated with the following parameters measured at six yr: decreased FEV1 (p < 0.001); decreased FVC (p < 0.001); physician-diagnosed asthma (p < 0.001); and lower respiratory tract symptoms (p < 0.05). None of the other physiologic factors measured in infancy showed such consistent associations with important clinical and physiologic outcomes at age 6. These data suggest that airway responsiveness in early life defines a functional state that is associated with abnormal airway function, lower respiratory symptoms, and the emergence of asthma by 6 yr of age.	Univ Western Australia, Dept Paediat, Perth, WA 6009, Australia; TVW Telethon Inst Child Hlth Res, Div Populat Sci, Genet Epidemiol Unit, Perth, WA, Australia	Palmer, LJ (reprint author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Palmer, Lyle/K-3196-2014; Burton, Paul/H-7527-2016	Palmer, Lyle/0000-0002-1628-3055; 			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; BORRES MP, 1995, J ALLERGY CLIN IMMUN, V95, P694, DOI 10.1016/S0091-6749(95)70174-5; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Carlsen KH, 1997, PEDIATR ALLERGY IMMU, V8, P40; CLARKE JR, 1992, ARCH DIS CHILD, V67, P1454; Daly LE, 1991, INTERPRETATION USES; GELLER DE, 1988, PEDIATR PULM, V4, P90, DOI 10.1002/ppul.1950040206; HABY MM, 1994, PEDIATR PULM, V18, P323, DOI 10.1002/ppul.1950180510; The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee, 1998, LANCET, V351, P1125; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863; Ludviksdottir D, 2000, ALLERGY, V55, P259, DOI 10.1034/j.1398-9995.2000.00252.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; McCullagh P., 1989, GEN LINEAR MODELS; MONTGOMERY GL, 1990, AM REV RESPIR DIS, V142, P1372; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; PATTEMORE PK, 1993, CLIN EXP ALLERGY, V23, P886, DOI 10.1111/j.1365-2222.1993.tb00273.x; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749; SANTING RE, 1994, J ALLERGY CLIN IMMUN, V93, P1021, DOI 10.1016/S0091-6749(94)70051-6; SPEIGHT ANP, 1978, BRIT MED J, V2, P331; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; STICK SM, 1991, AM REV RESPIR DIS, V144, P1012; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TAGER IB, 1987, AM REV RESPIR DIS, V136, P1366; Warner JA, 1998, CLIN EXP ALLERGY, V28, P35; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P56, DOI 10.1111/j.1399-3038.1998.tb00304.x; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; Wright A L, 1998, Eur Respir J Suppl, V27, p17s; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	38	118	124	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN	2001	163	1					37	42				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	394TV	WOS:000166540100012	11208623	
J	Turner, MC; Krewski, D; Pope, CA; Chen, Y; Gapstur, SM; Thun, MJ				Turner, Michelle C.; Krewski, Daniel; Pope, C. Arden, III; Chen, Yue; Gapstur, Susan M.; Thun, Michael J.			Long-term Ambient Fine Particulate Matter Air Pollution and Lung Cancer in a Large Cohort of Never-Smokers	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						fine particulate matter air pollution; lung neoplasms; never-smokers; asthma; pulmonary disease, chronic obstructive	OBSTRUCTIVE PULMONARY-DISEASE; OXIDATIVE DAMAGE; HEALTH IMPACTS; NORWEGIAN MEN; FOLLOW-UP; MORTALITY; RISK; ASSOCIATION; EXPOSURE; INTERVENTIONS	Rationale: There is compelling evidence that acute and chronic exposure to ambient fine particulate matter (PM2.5) air pollution increases cardiopulmonary mortality. However, the role of PM2.5 in the etiology of lung cancer is less clear, particularly at concentrations that prevail in developed countries and in never-smokers. Objectives: This study examined the association between mean long-term ambient PM2.5 concentrations and lung cancer mortality among 188,699 lifelong never-smokers drawn from the nearly 1.2 million Cancer Prevention Study-II participants enrolled by the American Cancer Society in 1982 and followed prospectively through 2008. Methods: Mean metropolitan statistical area PM2.5 concentrations were determined for each participant based on central monitoring data. Cox proportional hazards regression models were used to estimate multivariate adjusted hazard ratios and 95% confidence intervals for lung cancer mortality in relation to PM2.5. Measurements and Main Results: A total of 1,100 lung cancer deaths were observed during the 26-year follow-up period. Each 10 mu g/m(3) increase in PM2.5 concentrations was associated with a 15-27% increase in lung cancer mortality. The association between PM2.5 and lung cancer mortality was similar in men and women and across categories of attained age and educational attainment, but was stronger in those with a normal body mass index and a history of chronic lung disease at enrollment (P < 0.05). Conclusions: The present findings strengthen the evidence that ambient concentrations of PM2.5 measured in recent decades are associated with small but measurable increases in lung cancer mortality.	[Turner, Michelle C.; Krewski, Daniel] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Inst Populat Hlth, Ottawa, ON K1N 6N5, Canada; [Turner, Michelle C.] Univ Ottawa, Fac Grad & Postdoctoral Studies, Ottawa, ON K1N 6N5, Canada; [Krewski, Daniel; Chen, Yue] Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada; [Pope, C. Arden, III] Brigham Young Univ, Dept Econ, Provo, UT 84602 USA; [Krewski, Daniel] Risk Sci Int, Ottawa, ON, Canada; [Gapstur, Susan M.; Thun, Michael J.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA	Turner, MC (reprint author), Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Inst Populat Hlth, 1 Stewart St,Room 313, Ottawa, ON K1N 6N5, Canada.	mturner@uottawa.ca			Canadian Institutes of Health Research	Supported by Canada Graduate Scholarship from the Canadian Institutes of Health Research (M. C. T.). D. K. is the Natural Sciences and Engineering Research Council Chair in Risk Science at the University of Ottawa.	Andre V, 2011, J APPL TOXICOL, V31, P131, DOI 10.1002/jat.1572; Beelen R, 2008, EPIDEMIOLOGY, V19, P702, DOI 10.1097/EDE.0b013e318181b3ca; Beelen R, 2008, ENVIRON HEALTH PERSP, V116, P196, DOI 10.1289/ehp.10767; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; CALLE EE, 1993, AM J EPIDEMIOL, V137, P235; Cohen AJ, 2003, THORAX, V58, P1010, DOI 10.1136/thorax.58.12.1010; Cohen A. J., 2004, COMP QUANTIFICATION, V2, P1353; Eisner MD, 2010, AM J RESP CRIT CARE, V182, P693, DOI 10.1164/rccm.200811-1757ST; Filleul L, 2005, OCCUP ENVIRON MED, V62, P453, DOI 10.1136/oem.2004.014746; Giles LV, 2011, ENVIRON HEALTH PERSP, V119, P29, DOI 10.1289/ehp.1002246; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; International for Research on Cancer, 1989, DIES GAS ENG EXH SOM; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Krewski D, 2009, RES REP HLTH EFF I, V140, P115; Krewski D, 2009, RES REP HLTH EFF I, V140, P5; Krewski D, 2000, REANALYSIS HARVARD 6; Laden F, 2006, AM J RESP CRIT CARE, V173, P667, DOI 10.1164/rccm.200503-443OC; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; Moller P, 2010, FREE RADICAL RES, V44, P1, DOI 10.3109/10715760903300691; Naess O, 2007, AM J EPIDEMIOL, V165, P435, DOI 10.1093/aje/kwk016; Nafstad P, 2003, THORAX, V58, P1071, DOI 10.1136/thorax.58.12.1071; Nafstad P, 2004, ENVIRON HEALTH PERSP, V112, P610, DOI 10.1289/ehp.6684; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Pope CA, 2011, ENVIRON HEALTH PERSP, V119, P1616, DOI 10.1289/ehp.1103639; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Price PN, PREDICTED GM OTHER P; Punturieri A, 2009, J NATL CANCER I, V101, P554, DOI 10.1093/jnci/djp023; Raaschou-Nielsen O, 2011, ENVIRON HEALTH PERSP, V119, P860, DOI 10.1289/ehp.1002353; Raaschou-Nielsen O, 2010, CANCER EPIDEM BIOMAR, V19, P1284, DOI 10.1158/1055-9965.EPI-10-0036; Ris CUS, 2007, INHAL TOXICOL, V19, P229; Sacks JD, 2011, ENVIRON HEALTH PERSP, V119, P446, DOI 10.1289/ehp.1002255; [Anonymous], 2008, SAS VERS 9 2; Siemiatycki J, 2003, J TOXICOL ENV HEAL A, V66, P1591, DOI 10.1080/15287390390211522; Sint T, 2008, INHAL TOXICOL, V20, P25, DOI 10.1080/08958370701758759 ; Turner MC, 2006, INT J CANCER, V118, P3124, DOI 10.1002/ijc.21752; Turner MC, 2007, AM J RESP CRIT CARE, V176, P285, DOI 10.1164/rccm.200612-17920C; Turner MC, 2011, CANCER EPIDEM BIOMAR, V20, P438, DOI 10.1158/1055-9965.EPI-10-1153; US Department of Commerce, 2008, CENS POP HOUS 1980 U; US Department of Commerce, 2004, CENS POP HOUS 2000 U; U.S. Department of Commerce Bureau of the Census, 1993, CENS POP HOUS 1990 U; Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538; van Donkelaar A, 2010, ENVIRON HEALTH PERSP, V118, P847, DOI 10.1289/ehp.0901623; Vineis P, 2006, INT J CANCER, V119, P169, DOI 10.1002/ijc.21801; WHO, 1992, ICD 10 INT STAT CLAS; World Health Organization, 1977, INT CLASS DIS MAN IN; Yorifuji T, 2010, OCCUP ENVIRON MED, V67, P111, DOI 10.1136/oem.2008.045542; Zhang JJ, 2007, ENVIRON HEALTH PERSP, V115, P848, DOI 10.1289/ehp.9479	49	117	127	12	89	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2011	184	12					1374	1381		10.1164/rccm.201106-1011OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	863AF	WOS:000298134500014	21980033	
J	Nohynek, GJ; Antignac, E; Re, T; Toutain, H				Nohynek, Gerhard J.; Antignac, Eric; Re, Thomas; Toutain, Herve			Safety assessment of personal care products/cosmetics and their ingredients	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Review						Safety assessment; Personal care products; Cosmetic ingredients; Hair dyes; Ultraviolet filters; Threshold of toxicological concern; Nanoparticles	PERMANENT HAIR-DYES; VITRO PERCUTANEOUS-ABSORPTION; TOXICOLOGICAL CONCERN TTC; NATURAL FLAVOR COMPLEXES; BLADDER-CANCER RISK; HUMAN HEALTH-RISK; PARA-PHENYLENEDIAMINE; IN-VITRO; AROMATIC-AMINES; STRATUM-CORNEUM	We attempt to review the safety assessment of personal care products (PCP) and ingredients that are representative and pose complex safety issues. PCP are generally applied to human skin and mainly produce local exposure, although skin penetration or use in the oral cavity, on the face, lips, eyes and mucosa may also produce human systemic exposure. In the EU, US and Japan, the safety of PCP is regulated under cosmetic and/or drug regulations. Oxidative hair dyes contain arylamines, the most chemically reactive ingredients of PCP. Although arylamines have an allergic potential, taking into account the high number of consumers exposed, the incidence and prevalence of hair dye allergy appears to be low and stable. A recent (2001) epidemiology study suggested an association of oxidative hair dye use and increased bladder cancer risk in consumers, although this was not confirmed by subsequent or previous epidemiologic investigations. The results of genetic toxicity, carcinogenicity and reproductive toxicity studies Suggest that modern hair dyes and their ingredients pose no genotoxic, carcinogenic or reproductive risk. Recent reports suggest that arylamines contained in oxidative hair dyes are N-acetylated in human or mammalian skin resulting in systemic exposure to traces of detoxified, i.e. non-genotoxic, metabolites, whereas human hepatocytes were unable to transform hair dye arylamines to potentially carcinogenic metabolites. An expert panel of the International Agency on Research of Cancer (IARC) concluded that there is no evidence for a causal association of hair dye exposure with an elevated cancer risk in consumers. Ultraviolet filters have important benefits by protecting the consumer against adverse effects of UV radiation; these substances undergo a stringent safety evaluation under current international regulations prior to their marketing. Concerns were also raised about the safety of solid nanoparticles in PCP, mainly TiO(2) and ZnO in Sunscreens. However, current evidence suggests that these particles are non-toxic, do not penetrate into or through normal or compromised human skin and, therefore, pose no risk to human health. The increasing use of natural plant ingredients in personal care products raised new safety issues that require novel approaches to their safety evaluation similar to those of plant-derived food ingredients. For example, the Threshold of Toxicological Concern (TTC) is a promising tool to assess the safety of substances present at trace levels as well as minor ingredients of plant-derived substances. The potential human systemic exposure to PCP ingredients is increasingly estimated on the basis of in vitro skin penetration data. However, new evidence suggests that the in vitro test may overestimate human systemic exposure to PCP ingredients due to the absence of metabolism in cadaver skin or misclassification of skin residues that, in vivo, remain in the stratum corneum or hair follicle openings, i.e. outside the living skin. Overall, today's safety assessment of PCP and their ingredients is not only based on science, but also on their respective regulatory status as well as other issues, such as the ethics of animal testing. Nevertheless, the record shows that today's PCP are safe and offer multiple benefits to quality of life and health of the consumer. In the interest of all stakeholders, consumers, regulatory bodies and producers, there is an urgent need for an international harmonization on the status and safety requirements of these products and their ingredients. (C) 2009 Elsevier Inc. Al rights reserved.	[Nohynek, Gerhard J.; Antignac, Eric; Toutain, Herve] LOREAL R&D, Global Safety Evaluat, F-92600 Asnieres, France; [Re, Thomas] LOreal USA, Res & Dev, Clark, NJ 07066 USA	Nohynek, GJ (reprint author), LOREAL R&D, Global Safety Evaluat, 25-29 Quai Aulagnier, F-92600 Asnieres, France.	gnohynec@rd.loreal.com					Aeby P, 2009, J INVEST DERMATOL, V129, P99, DOI 10.1038/jid.2008.209; Allemann IB, 2009, INT J DERMATOL, V48, P923, DOI 10.1111/j.1365-4632.2009.04081.x; AMES BN, 1975, P NATL ACAD SCI USA, V72, P2423, DOI 10.1073/pnas.72.6.2423; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; Axmon A, 2009, OCCUP ENVIRON MED, V66, P198, DOI 10.1136/oem.2008.039784; Baan R, 2008, LANCET ONCOL, V9, P322, DOI 10.1016/S1470-2045(08)70089-5; BABISH JG, 1991, J TOXICOL ENV HEALTH, V34, P197; BACHTHOMSEN M, 1993, PHOTODERMATOL PHOTO, V9, P242; Bando H, 1997, J PHARM SCI, V86, P759, DOI 10.1021/js960408n; Barlow SM, 2002, FOOD CHEM TOXICOL, V40, P145, DOI 10.1016/S0278-6915(01)00117-X; Benech-Kieffer F, 2003, SKIN PHARMACOL APPL, V16, P343, DOI 10.1159/000072929; BENNING V, 1994, MUTAGENESIS, V9, P199, DOI 10.1093/mutage/9.3.199; Bolt HM, 2007, CRIT REV TOXICOL, V37, P521, DOI 10.1080/10408440701385671; Bos JD, 2000, EXP DERMATOL, V9, P165, DOI 10.1034/j.1600-0625.2000.009003165.x; BURNETT C, 1980, J TOXICOL ENV HEALTH, V6, P247; Burnett C, 1981, Fundam Appl Toxicol, V1, P325, DOI 10.1016/S0272-0590(81)80040-1; BURNETT C, 1975, FOOD COSMET TOXICOL, V13, P353, DOI 10.1016/S0015-6264(75)80299-9; BURNETT CM, 1988, FOOD CHEM TOXICOL, V26, P467, DOI 10.1016/0278-6915(88)90059-2; BURNETT CM, 1987, FOOD CHEM TOXICOL, V25, P703, DOI 10.1016/0278-6915(87)90104-9; *CANT INC, 1997, ASS REPR RISKS POS U; Choi MJ, 2005, SKIN PHARMACOL PHYSI, V18, P209, DOI 10.1159/000086666; CIR Cosmetic Ingredient Review Expert Panel, 2008, INT J TOXICOL S4, V27, P1; COLDITZ GA, 1994, J NATL CANCER I, V86, P164, DOI 10.1093/jnci/86.3.164; Constable A, 2007, FOOD CHEM TOXICOL, V45, P2513, DOI 10.1016/j.fct.2007.05.028; Corbett JF, 1999, TOXICOLOGY, P899, DOI 10.1016/B978-012473270-4/50096-1; CORDLE F, 1981, REGULATORY TOXICOLOG, V1, P388, DOI 10.1016/0273-2300(81)90084-2; CRAMER GM, 1978, FOOD COSMET TOXICOL, V16, P255, DOI 10.1016/S0015-6264(76)80522-6; Czene K, 2003, INT J CANCER, V105, P108, DOI 10.1002/ijc.11040; De Groot AC, 1998, CLIN DERMATOL, V16, P167, DOI 10.1016/S0738-081X(97)00179-X; Deleo VA, 2006, DERMATITIS, V17, P53, DOI 10.2310/6620.2006.05054; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; Dressler WE, 2006, FOOD CHEM TOXICOL, V44, P371, DOI 10.1016/j.fct.2005.08.009; Dufour EK, 2006, MUTAT RES-GEN TOX EN, V607, P215, DOI 10.1016/j.mrgentox.2006.04.015; *EC, 1997, OFFICIAL J EURO 0916; *EC, 1997, OFFICIAL J EURO 0214; EDWARDS G, 2005, TOXICOL APPL PHARM, V207, pS623; EFSA, 2009, EFSA J, V7, P1249, DOI DOI 10.2093/J.EFSA.2009.124; *EFSA, 2004, PAN FOOD ADD FLAV PR; Eisenbrand G, 2002, FOOD CHEM TOXICOL, V40, P193, DOI 10.1016/S0278-6915(01)00118-1; El Maghraby G M, 2008, Eur J Pharm Sci, V34, P203, DOI 10.1016/j.ejps.2008.05.002; *EMEA, 2008, EMEAHMPC1013032008; *EMEA, 2005, EMEAHMPC1383812005; EMEA, 2006, EMEAHMPC321162005; Ernst E, 2002, ANN INTERN MED, V136, P42; *EU, 2006, OFF J EUR COMM L, V369, P1; Fabian E, 2008, ARCH TOXICOL, V82, P151, DOI 10.1007/s00204-007-0253-y; Filipe P, 2009, SKIN PHARMACOL PHYS, V22, P266, DOI 10.1159/000235554; Frawley J P, 1967, Food Cosmet Toxicol, V5, P293, DOI 10.1016/S0015-6264(67)83055-4; Freudenthal RI, 1999, INT J TOXICOL, V18, P353; Fu PP, 2009, J ENVIRON SCI HEAL C, V27, P91, DOI 10.1080/10590500902885676; Gago-Dominguez M, 2003, CARCINOGENESIS, V24, P483, DOI 10.1093/carcin/24.3.483; Gago-Dominguez M, 2001, INT J CANCER, V91, P575, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1092>3.0.CO;2-S; Gallicchio L, 2009, OBSTET GYNECOL, V113, P1018, DOI 10.1097/AOG.0b013e3181a1f906; Garrigue JL, 2006, MUTAT RES-GEN TOX EN, V608, P58, DOI 10.1016/j.mrgentox.2006.05.001; Goebel C, 2007, TOXICOL LETT, V172, pS31, DOI 10.1016/j.toxlet.2007.05.110; GOLD LS, 1992, RISK ANAL, V12, P579, DOI 10.1111/j.1539-6924.1992.tb00714.x; Golka K, 2002, TOXICOL LETT, V128, P229, DOI 10.1016/S0378-4274(01)00544-6; GOOSSENS A, 1997, ALLERG IMMUNOL, V24, P300; Gopee NV, 2007, TOXICOL SCI, V98, P249, DOI 10.1093/toxsci/kfm074; Gopee NV, 2009, TOXICOL SCI, V111, P37, DOI 10.1093/toxsci/kfp139; GOULET L, 1991, SCAND J WORK ENV HEA, V17, P25; Halliday-Bell JA, 2009, OCCUP MED-OXFORD, V59, P180, DOI 10.1093/occmed/kqp017; Hartung T, 2009, NATURE, V460, P208, DOI 10.1038/460208a; Herdt-Losavio ML, 2009, MATERN CHILD HLTH J, V13, P90, DOI 10.1007/s10995-008-0324-6; HORIO T, 1976, J INVEST DERMATOL, V67, P591, DOI 10.1111/1523-1747.ep12541692; Hueber-Becker F, 2004, FOOD CHEM TOXICOL, V42, P1227, DOI 10.1016/j.fct.2004.02.020; Hueber-Becker F, 2007, FOOD CHEM TOXICOL, V45, P160, DOI 10.1016/j.fct.2006.08.002; HUEBERBECKER F, 2009, FOOD CHEM UNPUB  OCT; International Agency for Research on Cancer (IARC), 1993, IARC MON EV CARC RIS, V57; ICH, 2009, INT C HARM TECHN REQ; *ILSI, 2003, ILSI EUR REP SER; Jacobi U, 2005, SKIN RES TECHNOL, V11, P91, DOI 10.1111/j.1600-0846.2005.00094.x; Joint FAO/WHO Expert Committee on Food Additives (JECFA), 1998, WHO FOOD ADD SER, V40; Jewell C, 2007, TOXICOL APPL PHARM, V225, P221, DOI 10.1016/j.taap.2007.08.002; Jonas DA, 1996, FOOD CHEM TOXICOL, V34, P931, DOI 10.1016/S0278-6915(96)00061-0; KADLUBAR FF, 1986, MAMMALIAN CYTOCHROME, V2, P81; Kawakubo Y, 2000, J PHARMACOL EXP THER, V292, P150; Kelsh MA, 2008, CANCER CAUSE CONTROL, V19, P549, DOI 10.1007/s10552-008-9123-z; Kersemaekers WM, 1997, EPIDEMIOLOGY, V8, P396, DOI 10.1097/00001648-199707000-00008; KERSEMAEKERS WM, 1995, SCAND J WORK ENV HEA, V21, P325; Kirkland D, 2007, MUTAT RES-GEN TOX EN, V628, P31, DOI 10.1016/j.mrgentox.2006.11.008; Kirkland D, 2006, MUTAT RES-GEN TOX EN, V608, P88, DOI 10.1016/j.mrgentox.2006.05.004; KIRKLAND DJ, 1992, MUTAT RES, V279, P181, DOI 10.1016/0165-1218(92)90065-8; KIRKLAND DJ, 1981, MUTAT RES, V90, P279, DOI 10.1016/0165-1218(81)90008-2; KIRKLAND DJ, 1978, LANCET          0715, P124; KLEINHANS D, 1976, DERMATOLOGICA, V152, P161; Kogevinas M, 2006, EUR J CANCER, V42, P1448, DOI 10.1016/j.ejca.2006.02.009; Krasteva M, 2005, EUR J DERMATOL, V15, P18; Krasteva M., 2010, EUR J DERMATOL, V20, P1; Krasteva M, 2009, DERMATITIS, V20, P123, DOI 10.2310/6620.2009.08089; Kroes R, 2007, FOOD CHEM TOXICOL, V45, P2533, DOI 10.1016/j.fct.2007.06.021; Kroes R, 2005, TOXICOL SCI, V86, P226, DOI 10.1093/toxsci/kfi169; Kroes R, 2004, TOXICOLOGY, V198, P213, DOI 10.1016/j.tox.2004.01.028; La Vecchia C, 2001, EUR J CANCER PREV, V10, P205, DOI 10.1097/00008469-200106000-00002; Lademann J, 2008, FOOD CHEM TOXICOL, V46, P2214, DOI 10.1016/j.fct.2008.02.018; Lalko J, 2006, FOOD CHEM TOXICOL, V44, P739, DOI 10.1016/j.fct.2005.10.006; LAVECCHIA C, 1999, IARC SCI PUBL, V147, P139; LEVECCHIA C, 1995, EUR J CANCER PREV, V4, P31; Lin J, 2006, CANCER EPIDEM BIOMAR, V15, P1746, DOI 10.1158/1055-9965.EPI-06-0156; MALKEY JP, 1993, VET HUM TOXICOL, V35, P445; Maouad M, 1999, J AM ACAD DERMATOL, V41, P573, DOI 10.1016/S0190-9622(99)70299-9; MARKS TA, 1981, TERATOLOGY, V24, P253, DOI 10.1002/tera.1420240303; MARZULLI FN, 1984, J SOC COSMET CHEM, V35, P95; Mavon A, 2007, SKIN PHARMACOL PHYS, V20, P10, DOI 10.1159/000096167; MCDONALD AD, 1988, BRIT J IND MED, V45, P56; Mendelsohn JB, 2009, CANCER SCI, V100, P1088, DOI 10.1111/j.1349-7006.2009.01149.x; MEULING WAJ, 2009, 7852 TNO; *MHLW, 2007, QUAS DRUGS; *MIN HLTH, 2009, REV APPR PROC HLTH R; Munro IC, 2008, TOXICOL LETT, V180, P151, DOI 10.1016/j.toxlet.2008.05.006; Munro IC, 2006, FOOD CHEM TOXICOL, V44, P758, DOI 10.1016/j.fct.2005.10.008; Munro IC, 1996, FOOD CHEM TOXICOL, V34, P829, DOI 10.1016/S0278-6915(96)00049-X; Munro IC, 2001, FOOD CHEM TOXICOL, V39, P331, DOI 10.1016/S0278-6915(00)00145-9; NEAL RA, 1995, FUND APPL TOXICOL, V24, P151, DOI 10.1006/faat.1995.1018; Nohynek GJ, 2008, SKIN PHARMACOL PHYS, V21, P136, DOI 10.1159/000131078; Nohynek GJ, 2007, CRIT REV TOXICOL, V37, P251, DOI 10.1080/10408440601177780; Nohynek GJ, 2005, TOXICOL LETT, V158, P196, DOI 10.1016/j.toxlet.2005.03.014; Nohynek GJ, 2004, FOOD CHEM TOXICOL, V42, P1885, DOI 10.1016/j.fct.2004.07.009; Nohynek GJ, 2004, FOOD CHEM TOXICOL, V42, P517, DOI 10.1016/j.fct.2003.11.003; Nohynek GJ, 2004, FOOD CHEM TOXICOL, V42, P93, DOI 10.1016/j.fct.2003.08.008; Nohynek GJ, 2001, REGUL TOXICOL PHARM, V33, P285, DOI 10.1006/rtph.2001.1476; NOHYNEK GJ, 2006, TOXICOL LETT, V63, P65; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; *NTP, 1978, TR84 NTP; OECD, 2007, ENVJMMONO200728 OECD; *PAP, 2005, 1 HYDR 4 AM UNPUB; Pauwels M, 2004, TOXICOL LETT, V151, P7, DOI 10.1016/j.toxlet.2004.01.026; Pauwels M, 2009, FOOD CHEM TOXICOL, V47, P898, DOI 10.1016/j.fct.2009.01.026; PAUWELS M, 2010, TOXICOL APPL PHARM, V243, P256; PEPELKO W E, 1985, Toxicology and Industrial Health, V1, P153; Pinheiro T, 2007, NUCL INSTRUM METH B, V260, P119, DOI 10.1016/j.nimb.2007.02.014; PRENTICE D, 2002, COMMUNICATION    APR; PRESTON RJ, 2009, MUTAGENESIS ELECT AD, DOI DOI 10.1093/MUTAGE/GEP044; Prusakiewicz JJ, 2006, PHARM RES, V23, P1517, DOI 10.1007/s11095-006-0273-y; Re TA, 2009, FOOD CHEM TOXICOL, V47, P1246, DOI 10.1016/j.fct.2009.02.016; Redlick F, 2007, CAN MED ASSOC J, V176, P445, DOI 10.1503/cmaj.061109; Renwick AG, 2004, TOXICOL LETT, V149, P223, DOI 10.1016/j.toxlet.2003.12.034; RHEN L, 1895, ARCH KLIN CHIR, V50, P588; ROJANAPO W, 1986, CARCINOGENESIS, V7, P1997, DOI 10.1093/carcin/7.12.1997; Rollison Dana E, 2006, J Toxicol Environ Health B Crit Rev, V9, P413, DOI 10.1080/10937400600681455; Ross JH, 2000, REGUL TOXICOL PHARM, V31, P53, DOI 10.1006/rtph.1999.1363; Rousseaux CG, 2003, BIRTH DEFECTS RES B, V68, P505, DOI 10.1002/bdrb.10053; RUTKOWSKI JV, 1982, TOXICOLOGY APPL PHAR, V63, P204; Rylander L, 2002, OCCUP ENVIRON MED, V59, P517, DOI 10.1136/oem.59.8.517; Sardas S, 1997, MUTAT RES-GEN TOX EN, V394, P153, DOI 10.1016/S1383-5718(97)00135-6; Sasaki YF, 1999, MUTAT RES-GEN TOX EN, V440, P1, DOI 10.1016/S1383-5718(99)00006-6; *SCC, 1991, OP EU SCI COMM COSM; *SCCNFP, 2002, SCCNFP 19 PLEN M 27; SCCNFP, 2003, SCI COMM COSM PROD N; *SCCP, 2006, SCI COMM SONC PROD O; *SCCP, 2009, POS STAT GEN MUT TES; *SCCP, 2006, SCCPPS NOT GUID TEST; *SCF, 1997, OP ASS FNOV FOOD S T; Schaefer H., 1996, SKIN BARRIER PRINCIP; Schauer UMD, 2006, TOXICOL APPL PHARM, V216, P339, DOI 10.1016/j.taap.2006.05.011; Schilter B, 2003, FOOD CHEM TOXICOL, V41, P1625, DOI 10.1016/S0278-6915(03)00221-7; Schnuch A, 2008, BRIT J DERMATOL, V159, P379, DOI 10.1111/j.1365-2133.2008.08644.x; Schnuch A, 1997, CONTACT DERMATITIS, V37, P200, DOI 10.1111/j.1600-0536.1997.tb02435.x; SCHNUCH A, 2009, DATA PRESENTED RECEN; SELKIRK, 1993, ENV HLTH PERSPECT S1, V101; SHELLEY WB, 1958, BRIT J DERMATOL, V70, P75, DOI 10.1111/j.1365-2133.1958.tb13297.x; SKATE JA, 2009, XENOBIOTICA IN PRESS; SKATE JA, 2007, TOXICOL LETT, V1725, pS31; Smith RL, 2005, FOOD CHEM TOXICOL, V43, P345, DOI 10.1016/j.fct.2004.11.007; Smith RL, 2004, TOXICOL LETT, V149, P197, DOI 10.1016/j.toxlet.2003.12.031; SPENGLER J, 1990, COSMET TOILETRIES, V105, P67; Stanley LA, 2005, TOXICOLOGY, V210, P147, DOI 10.1016/j.tox.2005.01.019; Stern ST, 2008, TOXICOL SCI, V101, P4, DOI 10.1093/toxsci/kfm169; Takkouche B, 2005, JAMA-J AM MED ASSOC, V293, P2516, DOI 10.1001/jama.293.20.2516; *TGA, 2009, THER GOOD ADM; Theogaraj E, 2007, MUTAT RES-GEN TOX EN, V634, P205, DOI 10.1016/j.mrgentox.2007.08.002; TREGEAR RT, 1962, J INVEST DERMATOL, V38, P375; Uter Wolfgang, 2007, J Dtsch Dermatol Ges, V5, P993, DOI 10.1111/j.1610-0387.2007.06511.x; Verdier-Sevrain Sylvie, 2007, J Cosmet Dermatol, V6, P75, DOI 10.1111/j.1473-2165.2007.00300.x; Volkel W, 2006, TOXICOL APPL PHARM, V216, P331, DOI 10.1016/j.taap.2006.05.012; World Health Organization (WHO), 1995, WHO WORKSH WHO GEN S; World Health Organization, 1987, PRINC SAF ASS FOOD A, V70; WILKES MF, 1993, INT ARCH OCC ENV HEA, V65, pS189, DOI 10.1007/BF00381338; WILKINSON JD, 2005, SCI HAIR CARE; Zeiger E, 1998, REGUL TOXICOL PHARM, V28, P85, DOI 10.1006/rtph.1998.1234; Zviak C., 2005, SCI HAIR CARE, P251; 2008, FED REG         0430, V73; 2008, FED REG         0430, V84; [Anonymous], 2004, FED REG, V69, P6787	184	117	127	16	166	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	MAR 1	2010	243	2			SI		239	259		10.1016/j.taap.2009.12.001		21	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	565NS	WOS:000275301400012	20005888	
J	Favrot, C; Steffan, J; Seewald, W; Picco, F				Favrot, Claude; Steffan, Jean; Seewald, Wolfgang; Picco, Federicca			A prospective study on the clinical features of chronic canine atopic dermatitis and its diagnosis	VETERINARY DERMATOLOGY			English	Article							ACVD TASK-FORCE; FOOD SENSITIVITY; CRITERIA; DOGS; ALLERGY; MANIFESTATIONS; POPULATION; PREVALENCE; VALIDATION; ETIOLOGY	Canine atopic dermatitis (CAD) is a multifaceted disease associated with exposure to various offending agents such as environmental and food allergens. The diagnosis of this condition is difficult because none of the typical signs are pathognomonic. Sets of criteria have been proposed but are mainly used to include dogs in clinical studies. The goals of the present study were to characterize the clinical features and signs of a large population of dogs with CAD, to identify which of these characteristics could be different in food-induced atopic dermatitis (FIAD) and non-food-induced atopic dermatitis (NFIAD) and to develop criteria for the diagnosis of this condition. Using simulated annealing, selected criteria were tested on a large and geographically widespread population of pruritic dogs. The study first described the signalment, history and clinical features of a large population of CAD dogs, compared FIAD and NFIAD dogs and confirmed that both conditions are clinically indistinguishable. Correlations of numerous clinical features with the diagnosis of CAD are subsequently calculated, and two sets of criteria associated with sensitivity and specificity ranging from 80% to 85% and from 79% to 85%, respectively, are proposed. It is finally demonstrated that these new sets of criteria provide better sensitivity and specificity, when compared to Willemse and Prelaud criteria. These criteria can be applied to both FIAD and NFIAD dogs.	[Favrot, Claude; Picco, Federicca] Univ Zurich, Clin Small Anim Internal Med, Vetsuisse Fac, Zurich, Switzerland; [Steffan, Jean; Seewald, Wolfgang] Novartis Anim Hlth, Basel, Switzerland	Favrot, C (reprint author), Univ Zurich, Clin Small Anim Internal Med, Vetsuisse Fac, Zurich, Switzerland.	cfavrot@vetclinics.unizh.ch			Novartis Animal Health, Basel, Switzerland	The study was funded by Novartis Animal Health, Basel, Switzerland.	Chesney CJ, 2002, J SMALL ANIM PRACT, V43, P203, DOI 10.1111/j.1748-5827.2002.tb00058.x; Chesney CJ, 2001, VET REC, V148, P445; DeBoer DJ, 2001, VET IMMUNOL IMMUNOP, V81, P271, DOI 10.1016/S0165-2427(01)00312-9; Denis Serge, 1994, Medecin Veterinaire du Quebec, V24, P11; Denis Serge, 1994, Medecin Veterinaire du Quebec, V24, P15; Fraser MA, 2008, J SMALL ANIM PRACT, V49, P128, DOI 10.1111/j.1748-5827.2007.00439.x; Griffin CE, 2001, VET IMMUNOL IMMUNOP, V81, P255, DOI 10.1016/S0165-2427(01)00346-4; HALLIWELL RE, 1971, VET REC, V89, P209; Halliwell R, 2006, VET IMMUNOL IMMUNOP, V114, P207, DOI 10.1016/j.vetimm.2006.08.013; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; KIRKPATRICK S, 1983, SCIENCE, V220, P671, DOI 10.1126/science.220.4598.671; Nesbitt GH, 2003, VET DERMATOL, V14, P67, DOI 10.1046/j.1365-3164.2003.00328.x; NESBITT GH, 1984, COMP CONT EDUC PRACT, V6, P73; NESBITT GH, 1978, J AM VET MED ASSOC, V172, P55; Nodtvedt A, 2006, VET REC, V159, P241; Olivry T, 2001, VET IMMUNOL IMMUNOP, V81, P219, DOI 10.1016/S0165-2427(01)00311-7; Olivry T, 2007, VET DERMATOL, V18, P390, DOI 10.1111/j.1365-3164.2007.00625.x; Picco F, 2008, VET DERMATOL, V19, P150, DOI 10.1111/j.1365-3164.2008.00669.x; Prelaud P, 1998, REV MED VET-TOULOUSE, V149, P1057; Saridomichelakis MN, 2007, VET DERMATOL, V18, P341, DOI 10.1111/j.1365-3164.2007.00619.x; SCOTT DW, 1981, J AM ANIM HOSP ASSOC, V17, P89; Sousa CA, 2001, VET IMMUNOL IMMUNOP, V81, P153, DOI 10.1016/S0165-2427(01)00297-5; Tarpataki N, 2006, ACTA VET HUNG, V54, P353, DOI 10.1556/AVet.54.2006.3.6; Verlinden A, 2006, CRIT REV FOOD SCI, V46, P259, DOI 10.1080/10408390591001117; WILLEMSE A, 1983, RES VET SCI, V34, P261; WILLEMSE T, 1986, J SMALL ANIM PRACT, V27, P771, DOI 10.1111/j.1748-5827.1986.tb02119.x; Williams HC, 1996, LANCET, V348, P1391, DOI 10.1016/S0140-6736(05)65466-9; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams HC, 1996, BRIT J DERMATOL, V135, P12; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Zur G, 2002, VET DERMATOL, V13, P89, DOI 10.1046/j.1365-3164.2002.00285.x	33	117	117	5	37	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0959-4493			VET DERMATOL	Vet. Dermatol.	FEB	2010	21	1					23	30		10.1111/j.1365-3164.2009.00758.x		8	Dermatology; Veterinary Sciences	Dermatology; Veterinary Sciences	551CR	WOS:000274183900003	20187911	
J	Moshammer, H; Hoek, G; Luttmann-Gibson, H; Neuberger, MA; Antova, T; Gehring, U; Hruba, F; Pattenclen, S; Rudnai, P; Slachtova, H; Zlotkowska, R; Fletcher, T				Moshammer, H; Hoek, G; Luttmann-Gibson, H; Neuberger, MA; Antova, T; Gehring, U; Hruba, F; Pattenclen, S; Rudnai, P; Slachtova, H; Zlotkowska, R; Fletcher, T			Parental smoking and lung function in children - An international study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						child; passive smoking; pregnancy; spirometry; tobacco	ENVIRONMENTAL TOBACCO-SMOKE; MATERNAL SMOKING; IN-UTERO; RESPIRATORY SYMPTOMS; AIR-POLLUTION; RISK-FACTORS; EXPOSURE; ASTHMA; CHILDHOOD; HEALTH	Rationale: Both prenatal and postnatal passive smoking have been linked with respiratory symptoms and asthma in childhood. Their differential contributions to lung function growth in the general children's population are less clear. Objective: To study the relative impact of pre- and postnatal exposure on respiratory functions of primary school children in a wide range of geographic settings, we analyzed flow and volume data of more than 20,000 children (aged 6-12 yr) from nine countries in Europe and North America. Methods: Exposure information had been obtained by comparable questionnaires, and spirometry followed a protocol of the American Thoracic Society/European Respiratory Society. Linear and logistic regressions were used, controlling for individual risk factors and study area. Heterogeneity between study-specific results and mean effects were estimated using meta-analytic tools. Main Results: Smoking during pregnancy was associated with decreases in lung function parameters between -1% (FEV1) and -6% maximal expiratory flow at 25% of vital capacity left (MEF25). A 4% lower maximal midexpiratory flow (MMEF) corresponded to a 40% increase in the risk of poor lung function (MMEF < 75% of expected). Associations with current passive smoking were weaker though still measurable, with effects ranging from -0.5% (FEV1) to -2% maximal expiratory flow (MEF50). Conclusions: Considering the high number of children exposed to maternal smoking in utero and the even higher number exposed to passive smoking after birth, this risk factor for reduced lung function growth remains a serious pediatric and public health issue.	Med Univ Vienna, Inst Environm Hlth, ZPH, Vienna, Austria; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Natl Ctr Publ Hlth Protect, Environm Hlth Unit, Sofia, Bulgaria; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; GSF, Natl Res ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Reg Author Publ Hlth, Dept Hlth Stat & Informat, Banska Bystrica, Slovakia; London Sch Hyg & Trop Med, Publ & Environm Hlth Res Unit, London WC1, England; Jozef Fodor Natl Ctr Publ Hlth, Natl Inst Environm Hlth, Budapest, Hungary; Inst Publ Hlth, Ostrava, Czech Republic; Inst Occupat Med & Environm Hlth, Dept Epidemiol, Sosnowiec, Poland	Neuberger, MA (reprint author), Kinderspitalgasse 15, A-1095 Vienna, Austria.	manfred.neuberger@univie.ac.at	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Neuberger, Manfred/0000-0002-8994-378X; Gehring, Ulrike/0000-0003-3612-5780			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1286; Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; Cook DG, 1998, THORAX, V53, P884; Corbo GM, 1996, AM J RESP CRIT CARE, V154, P695; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; European Respiratory Society, 1993, EUR RESPIR J, V16, P1; Gehring U, 2006, EUR RESPIR J, V27, P95, DOI 10.1183/09031936.06.00017205; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Kooi EMW, 2004, PEDIATR PULM, V38, P419, DOI 10.1002/ppul.20093; Kunzli N, 2000, EUR RESPIR J, V15, P131; Leonardi GS, 2002, EUR RESPIR J, V20, P890, DOI 10.1183/09031936.02.00260802; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Lodrup Carlsen K C, 1997, Eur Respir J, V10, P1774, DOI 10.1183/09031936.97.10081774; Luttmann H, 1997, Pneumologie, V51, P47; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; Morgan WJ, 1998, AM J RESP CRIT CARE, V158, P689; Moshammer H, 2004, INT J HYG ENVIR HEAL, V207, P337, DOI 10.1078/1438-4639-00299; Neuberger M, 2002, ATMOS ENVIRON, V36, P1733, DOI 10.1016/S1352-2310(02)00179-6; Neuberger M., 1994, PNEUMOLOGIE, V48, P175; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Rizzi M, 2004, CHEST, V125, P1387, DOI 10.1378/chest.125.4.1387; ROSE G, 1990, BRIT MED J, V301, P1031; Skorge TD, 2005, AM J RESP CRIT CARE, V172, P61, DOI 10.1164/rccm.200409-1158OC; Upton MN, 2004, AM J RESP CRIT CARE, V169, P479, DOI 10.1164/rccm.200211-1357OC; VONEHRENSTEIN OS, 2002, EUR RESPIR J, V12, P1099; Wenten M, 2005, AM J RESP CRIT CARE, V172, P1563, DOI 10.1164/rccm.200506-4900C; ZAPLETAL A, 1969, J APPL PHYSIOL, V26, P308; Zlotkowska R, 2005, EUR J EPIDEMIOL, V20, P719, DOI 10.1007/s10654-005-0033-z	34	117	126	0	9	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2006	173	11					1255	1263		10.1164/rccm.200510-1552OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	049BJ	WOS:000237990100014	16484675	
J	Taylor, SL; Hefle, SL; Bindslev-Jensen, C; Atkins, FM; Andre, C; Bruijnzeel-Koomen, C; Burks, AW; Bush, RK; Ebisawa, M; Eigenmann, PA; Host, A; Hourihane, JO; Isolauri, E; Hill, DJ; Knulst, A; Lack, G; Sampson, HA; Moneret-Vautrin, DA; Rance, F; Vadas, PA; Yunginger, JW; Zeiger, RS; Salminen, JW; Madsen, C; Abbott, P				Taylor, SL; Hefle, SL; Bindslev-Jensen, C; Atkins, FM; Andre, C; Bruijnzeel-Koomen, C; Burks, AW; Bush, RK; Ebisawa, M; Eigenmann, PA; Host, A; Hourihane, JO; Isolauri, E; Hill, DJ; Knulst, A; Lack, G; Sampson, HA; Moneret-Vautrin, DA; Rance, F; Vadas, PA; Yunginger, JW; Zeiger, RS; Salminen, JW; Madsen, C; Abbott, P			A consensus protocol for the determination of the threshold doses for allergenic foods: how much is too much?	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; clinical trial; DBPCFC; exposure; food; threshold; risk assessment	CASEIN HYDROLYSATE FORMULA; DOUBLE-BLIND; IGE CONCENTRATIONS; ATOPIC-DERMATITIS; PEANUT ALLERGY; EGG ALLERGY; COW MILK; CHALLENGES; HYPERSENSITIVITY; IDENTIFICATION	Background While the ingestion of small amounts of an offending food can elicit adverse reactions in individuals with IgE-mediated food allergies, little information is known regarding these threshold doses for specific allergenic foods. While low-dose challenge trials have been conducted on an appreciable number of allergic individuals, a variety of different clinical protocols were used making the estimation of the threshold dose very difficult. Objective A roundtable conference was convened to develop a consensus clinical protocol for low-dose challenge trials for the estimation of threshold doses for specific allergenic foods. Methods In May 2002, 20 clinical allergists and other interested parties were invited to participate in a roundtable conference to develop consensus of the key elements of a clinical protocol for low-dose challenge trials. Results A consensus protocol was developed. Patients with convincing histories of food allergies and supporting diagnostic evidence including past challenge trials or high CAP-RAST scores can be enrolled in low-dose challenge trials. Care must be taken with younger patients to assure that they have not outgrown their food allergy. An approach was developed for the medication status of patients entering such trials. Challenge materials must be standardized, for example, partially defatted peanut flour composed of equal amounts of the three major varieties of peanuts (Florunner, Virginia, Spanish). Challenge materials must be appropriately blinded with sensory evaluation used to confirm the adequacy of blinding. A double-blind, placebo-controlled design should be used for low-dose challenge trials. Low-dose challenge trials would begin at doses of 10 mug of the allergenic food and would continue with doses of 100 mug and 1 mg followed by specific higher doses up to 100 mg depending upon the expert judgement of the physician; even higher doses might be applied to assure that the patient is indeed reactive to the particular food. A 30-min time interval would be used between doses, and reactive doses would be expressed as both discrete and cumulative doses. The goal of each challenge would be to develop objective symptoms; trials should not be discontinued on the basis of subjective symptoms only. Statistically, a minimum of 29 patients would be enrolled in low-dose challenge trials for each allergenic food because 0 reactors out of 29 patients at a particular dose allow the conclusion that there is 95% certainty that 90% of allergic individuals will not react to that dose. Conclusion A consensus protocol was developed. Using this protocol, it will be possible to estimate threshold doses for allergenic foods, the lowest amount that elicits mild, objective symptoms in highly sensitive individuals.	Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE 68583 USA; Odense Univ Hosp, Dept Dermatol, DK-5000 Odense, Denmark; Natl Jewish Med & Res Ctr, Denver, CO USA; Stallergenes, Antony, France; Univ Med Ctr, Dept Dermatol Allergol, Utrecht, Netherlands; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Univ Wisconsin Hosp & Clin, William S Middleton Mem Vet Adm Hosp, Madison, WI 53792 USA; Natl Sagamihara Hosp, Kanagawa, Japan; Hop Enfants, Geneva, Switzerland; Odense Univ Hosp, Dept Pediat, DK-5000 Odense, Denmark; Univ Southampton, Southampton, Hants, England; Univ Turku, Dept Pediat, Turku, Finland; Royal Childrens Hosp, Parkville, Vic 3052, Australia; St Marys Hosp, London, England; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Univ Hosp, Dept Internal Med Clin Immunol & Allergol, Nancy, France; Hop Enfants, Dept Allergol, Toulouse, France; Wellesley Cent Hosp, Toronto, ON, Canada; Mayo Clin, Rochester, MN USA; Kaiser Permanente Med Ctr, San Diego, CA USA; Hlth Prod & Foods Branch, Chem Hlth Hazard Assessment Div, Ottawa, ON, Canada; Danish Vet & Food Adm, Soborg, Denmark; Food Stand Australia New Zealand, Canberra, ACT, Australia	Taylor, SL (reprint author), Univ Nebraska, Food Allergy Res & Resource Program, 143 Food Ind Bldg, Lincoln, NE 68583 USA.	staylor2@unl.edu	Bindslev-Jensen, Carsten/H-1877-2011; Osborne, Nicholas/N-4915-2015; Eigenmann, Philippe/A-6569-2017	Bindslev-Jensen, Carsten/0000-0002-8940-038X; Osborne, Nicholas/0000-0002-6700-2284; Eigenmann, Philippe/0000-0003-1738-1826			*AM AC PED SUBC NU, 1990, INF FORM ALL DIS REP; ANET J, 1985, INT ARCH ALLER A IMM, V77, P363; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Betschel S. D., 2003, Journal of Allergy and Clinical Immunology, V111, pS100, DOI 10.1016/S0091-6749(03)80279-8; Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; Bindslev-Jensen C, 2001, ALLERGY, V56, P75, DOI 10.1034/j.1398-9995.2001.00922.x; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P889, DOI 10.1016/0091-6749(92)90461-A; deBoissieu D, 1997, J PEDIATR-US, V131, P744, DOI 10.1016/S0022-3476(97)70104-5; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193; HOST A, 1988, ALLERGY, V43, P113, DOI 10.1111/j.1398-9995.1988.tb00404.x; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; Laoprasert N, 1998, J FOOD PROTECT, V61, P1522; LIFSCHITZ CH, 1988, J PEDIATR GASTR NUTR, V7, P141, DOI 10.1097/00005176-198801000-00026; MAHER TJ, 2002, FOOD ALLERGY INTOLER, P445; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Nilsson C, 1999, ALLERGY, V54, P1322, DOI 10.1034/j.1398-9995.1999.00236.x; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Romeira AM, 2003, ALLERGY, V58, P533, DOI 10.1034/j.1398-9995.2003.00154.x; ROSENTHAL E, 1991, ACTA PAEDIATR SCAND, V80, P958, DOI 10.1111/j.1651-2227.1991.tb11760.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; SAMPSON HA, 1983, J ALLERGY CLIN IMMUN, V71, P473, DOI 10.1016/0091-6749(83)90464-5; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAYLOR JD, 1991, J PEDIATR-US, V118, P71, DOI 10.1016/S0022-3476(05)81848-7; Stone H., 1992, SENSORY EVALUATION P; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Taylor S.L., 1996, CRIT REV FOOD SCI NU, V36, P91; TAYLOR SL, 1998, ADV FOOD NUTR RES, V44, P1; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	33	117	120	2	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2004	34	5					689	695		10.1111/j.1365-2222.2004.1886.x		7	Allergy; Immunology	Allergy; Immunology	820PN	WOS:000221401900005	15144458	
J	Ricciardolo, FLM; Gaston, B; Hunt, J				Ricciardolo, FLM; Gaston, B; Hunt, J			Acid stress in the pathology of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						airway pH; gastroesophageal reflux; tachykinins; capsaicin; exhaled breath condensate; acid; asthma; chronic obstructive pulmonary disease; cough; bronchoconstriction	EXHALED BREATH CONDENSATE; INDUCED AIRWAY HYPERRESPONSIVENESS; TACHYKININ RECEPTOR ANTAGONISTS; GUINEA-PIGS; CITRIC-ACID; INDUCED BRONCHOCONSTRICTION; NITRIC-OXIDE; GASTROESOPHAGEAL-REFLUX; CYSTIC-FIBROSIS; INDUCED COUGH	Although alteration of airway pH may serve an innate host defense capacity, it also is implicated in the pathophysiology of obstructive airway diseases. Acid-induced asthma appears in association with gastroesophageal reflux after accidental inhalation of acid (fog, pollution, and workplace exposure) and in the presence of altered airway pH homeostasis. Endogenous and exogenous exposures to acids evoke cough, bronchoconstriction, airway hyperreactivity, microvascular leakage, and heightened production of mucous, fluid, and nitric oxide. Abnormal acidity of the airways is reflected in exhaled breath assays. The intimate mechanisms of acid-induced airway obstruction are dependent on activation of capsaicin-sensitive sensory nerves. Protons activate these nerves with the subsequent release of tachykinins (major mediators of this pathway) that, in conjunction with kinins, nitric oxide, oxygen radicals, and proteases, modulate diverse aspects of airway dysfunction and inflammation. The recognition that acid stress might initiate or exacerbate airway obstructive symptomatology has prompted the consideration of new therapies targeting pH homeostasis.	Univ Virginia, Div Pediat Resp Med, Hlth Syst, Charlottesville, VA 22908 USA; G Gaslini Inst Children, Unit Resp Dis, Genoa, Italy	Hunt, J (reprint author), Univ Virginia, Div Pediat Resp Med, Hlth Syst, Box 800386, Charlottesville, VA 22908 USA.						ADLER K, 1972, AM REV RESPIR DIS, V106, P86; Antczak A, 2001, AM J RESP CRIT CARE, V163, p725A; BALDWIN SR, 1986, LANCET, V1, P11; BALMES J R, 1989, Environmental Health Perspectives, V79, P163, DOI 10.2307/3430544; BALMES JR, 1988, AM REV RESPIR DIS, V138, P35; Baud L, 1997, B ACAD NAT MED PARIS, V181, P247; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; Blaisdell CJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1248; BOYLE JT, 1985, AM REV RESPIR DIS, V131, pS16; Burvall K, 2002, LIFE SCI, V71, P299, DOI 10.1016/S0024-3205(02)01644-2; CAIN D, 2002, EUR RESPIR J, V20, pP3280; Canning BJ, 2001, J APPL PHYSIOL, V91, P2642; Caterina MJ, 1997, NATURE, V389, P816; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823; Curran DR, 2002, CURR OPIN PHARMACOL, V2, P243, DOI 10.1016/S1471-4892(02)00155-8; Daoui S, 1998, AM J RESP CRIT CARE, V158, P42; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; Di Franco A, 2001, PULM PHARMACOL THER, V14, P35, DOI 10.1006/pupt.2000.0264; Douidar SM, 1997, PEDIATR EMERG CARE, V13, P406, DOI 10.1097/00006565-199712000-00014; Dudeja PK, 1999, AM J PHYSIOL-LUNG C, V276, pL971; EFFROS RM, 1994, J APPL PHYSIOL, V77, P1460; FINE JM, 1987, AM REV RESPIR DIS, V136, P1122; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; FOLINSBEE LJ, 1989, ENVIRON HEALTH PERSP, V79, P195, DOI 10.2307/3430550; Forsberg K, 1988, Pulm Pharmacol, V1, P33, DOI 10.1016/0952-0600(88)90008-7; GATTO LA, 1985, LUNG, V163, P109, DOI 10.1007/BF02713812; GATTO LA, 1981, J APPL PHYSIOL, V50, P1224; GEFFNER JR, 1993, CLIN EXP IMMUNOL, V91, P164; Gessner C, 2003, RESP MED, V97, P1188, DOI 10.1016/S0954-6111(03)00225-7; Girard V, 1996, AM J RESP CRIT CARE, V153, P1496; GOLDMAN G, 1992, J APPL PHYSIOL, V73, P571; Hay DWP, 2002, J PHARMACOL EXP THER, V300, P314, DOI 10.1124/jpet.300.1.314; HERVE P, 1986, AM REV RESPIR DIS, V134, P986; HOLMA B, 1985, SCI TOTAL ENVIRON, V41, P101, DOI 10.1016/0048-9697(85)90181-0; HOLMA B, 1977, ARCH ENVIRON HEALTH, V32, P216; HOLZER P, 1991, PHARMACOL REV, V43, P143; Honma S, 2000, RESP MED, V94, P935, DOI 10.1053/rmed.2000.0816; HUGHES JH, 1974, J IMMUNOL, V112, P919; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101; Ishikawa T, 1999, J APPL PHYSIOL, V86, P1226; JACK CIA, 1994, RESP MED, V88, P441, DOI 10.1016/S0954-6111(05)80047-2; JACK CIA, 1995, THORAX, V50, P201, DOI 10.1136/thx.50.2.201; JACK CIA, 1991, THORAX, V46, pP751; Jacoby DB, 2001, J ALLERGY CLIN IMMUN, V107, P211, DOI 10.1067/mai.2001.112940; Jankowski W, 1969, Otolaryngol Pol, V23, P493; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; JENSEN PE, 1993, J IMMUNOL, V150, P3347; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; KARNAD DR, 1990, CRIT CARE MED, V18, P699, DOI 10.1097/00003246-199007000-00003; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; Kohrogi H, 2001, AM J MED, V111, P25, DOI 10.1016/S0002-9343(01)00859-2; KopferschmittKubler MC, 1996, REV MAL RESPIR, V13, P421; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Kruk-Zagajewska A, 1976, Otolaryngol Pol, V30, P479; Lai YL, 1999, BRIT J PHARMACOL, V126, P778, DOI 10.1038/sj.bjp.0702352; LALLOO UG, 1995, J APPL PHYSIOL, V79, P1082; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Leblebicioglu B, 1999, INFECT IMMUN, V67, P2019; Lee KH, 1998, CRIT CARE MED, V26, P2042, DOI 10.1097/00003246-199812000-00038; Lee LY, 2001, J APPL PHYSIOL, V91, P1318; Long R, 1999, ANTIMICROB AGENTS CH, V43, P403; Lopes FDTQS, 2002, J APPL PHYSIOL, V93, P842, DOI 10.1152/japplphysiol.00013.2002; Lopez DH, 1999, IMMUNOLOGY, V98, P450, DOI 10.1046/j.1365-2567.1999.00884.x; LOU YP, 1991, ACTA PHYSIOL SCAND, V142, P191, DOI 10.1111/j.1748-1716.1991.tb09147.x; MAGGI CA, 1995, PHYSIOL REV, V75, P277; Maggi CA, 1997, TRENDS PHARMACOL SCI, V18, P351, DOI 10.1016/S0165-6147(97)01107-3; MARTLING CR, 1988, ANESTHESIOLOGY, V68, P350, DOI 10.1097/00000542-198803000-00005; McShane D, 2003, EUR RESPIR J, V21, P37, DOI 10.1183/09031936.03.00027603; Metheny NA, 1999, NURS RES, V48, P189, DOI 10.1097/00006199-199907000-00001; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Nader-Djalal N, 1998, ANESTH ANALG, V87, P127, DOI 10.1097/00000539-199807000-00028; NAHAS GG, 1971, P SOC EXP BIOL MED, V138, P350; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111; NGAMTRAKULPANIT L, 2003, AM J RESP CRIT CARE, V167, pA446; NUUTINEN J, 1993, J OTOLARYNGOL, V22, P79; Ohrui T, 1997, CHEST, V111, P454, DOI 10.1378/chest.111.2.454; PALMER LB, 1986, AM REV RESPIR DIS, V133, P784; RABINOVITCH M, 1980, J RETICULOENDOTH SOC, V27, P189; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055; RATNER S, 1992, CELL IMMUNOL, V139, P399, DOI 10.1016/0008-8749(92)90081-Y; REGOLI D, 1994, PHARMACOL REV, V46, P551; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; ROTSTEIN OD, 1988, J SURG RES, V45, P298, DOI 10.1016/0022-4804(88)90079-0; SATOH H, 1993, EUR J PHARMACOL, V236, P367, DOI 10.1016/0014-2999(93)90473-U; Song YL, 2003, J GEN PHYSIOL, V122, P511, DOI 10.1085/jgp.200308866; Tate S, 2002, THORAX, V57, P926, DOI 10.1136/thorax.57.11.926; Teramoto S, 2003, CHEST, V123, P524, DOI 10.1378/chest.123.2.524; Trevani AS, 1999, J IMMUNOL, V162, P4849; Vaughan J, 2003, EUR RESPIR J, V22, P889, DOI 10.1183/09031936.03.00038803; Vincent D, 1997, EUR RESPIR J, V10, P2255, DOI 10.1183/09031936.97.10102255; Wadsworth SJ, 1997, AM J PHYSIOL-LUNG C, V273, pL427; Yasumitsu R, 1996, EUR J PHARMACOL, V300, P215, DOI 10.1016/0014-2999(95)00881-0; ZIGMOND SH, 1981, J IMMUNOL, V126, P478	98	117	122	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					610	619		10.1016/j.jaci.2003.12.034		10	Allergy; Immunology	Allergy; Immunology	814DY	WOS:000220956600005	15100663	
J	McConnell, R; Berhane, K; Gilliland, F; Molitor, J; Thomas, D; Lurmann, F; Avol, E; Gauderman, WJ; Peters, JM				McConnell, R; Berhane, K; Gilliland, F; Molitor, J; Thomas, D; Lurmann, F; Avol, E; Gauderman, WJ; Peters, JM			Prospective study of air pollution and bronchitic symptoms in children with asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; epidemiology; air pollution; child; particulate matter	SOUTHERN CALIFORNIA CHILDREN; DIESEL EXHAUST PARTICLES; LUNG-FUNCTION GROWTH; RESPIRATORY HEALTH; ORGANIC AEROSOL; INHALABLE PARTICLES; PERSONAL EXPOSURE; NITROGEN-DIOXIDE; ASSOCIATION; ADMISSIONS	The relationship of bronchitic symptoms to ambient particulate matter and to particulate elemental and organic carbon (OC), nitrogen dioxide (NO2), and other gaseous pollutants was examined in a cohort of children with asthma in 12 Southern California communities. Symptoms, assessed yearly by questionnaire from 1996 to 1999, were associated with the yearly variability of particulate matter with aerodynamic diameter less than 2.5 mum (odds ratio [OR] 1.09/mug/m(3); 95% confidence interval [CI] 1.01-1.17), OC (OR 1.41/mug/m(3); 95% CI 1.12-1.78), NO2 (OR 1.07/ppb; 95% CI 1.02-1.13), and ozone (OR 1.06/ppb; 95% Cl 1.00-1.12). The ORs associated with yearly within-community variability in air pollution were larger than the effect of the between-community 4-year average concentrations. In two pollutant models, the effects of yearly variation in OC and NO2 were only modestly reduced by adjusting for other pollutants, except in a model containing both OC and NO2; the effects of all other pollutants were reduced after adjusting for OC or NO2. We conclude that OC and NO2 deserve greater attention as potential causes of the chronic symptoms of bronchitis in children with asthma and that previous cross-sectional studies may have underestimated the risks associated with air pollution.	Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Sonoma Technol Inc, Petaluma, CA USA	McConnell, R (reprint author), Univ So Calif, Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.				NHLBI NIH HHS [5 R01 HL61768-04]; NIEHS NIH HHS [1 P01 ES11627-01, 5 P01 ES09581-05, 5 P30 ES07048-07]		Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P243, DOI 10.2307/3432380; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Casillas AM, 1999, ANN ALLERG ASTHMA IM, V83, P624, DOI 10.1016/S1081-1206(10)62884-0; Chauhan AJ, 1999, AM J RESP CRIT CARE, V159, pA699; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; DIGGLE PJ, 1994, ANAL LONGITUDIANAL D; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Hashimoto KI, 2001, AM J RESP CRIT CARE, V164, P1957; Heagerty PJ, 2000, STAT SCI, V15, P1; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hiura TS, 1999, J IMMUNOL, V163, P5582; Jedrychowski W, 1998, EUR RESPIR J, V11, P1312, DOI 10.1183/09031936.98.11061312; KOREN HS, 1995, ENVIRON HEALTH PERSP, V103, P235, DOI 10.2307/3432379; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Lierl MB, 2003, ANN ALLERG ASTHMA IM, V90, P28; Linaker CH, 2000, THORAX, V55, P930, DOI 10.1136/thorax.55.11.930; MANCHESTER JB, 2001, DETERMINATION ELEM B; McArdle W, 1996, EXERCISE PHYSL ENERG; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McConnell R, 2002, EPIDEMIOLOGY, V13, pS148; *NIOSH, 1999, NIOSH MAN AN METH; *NIOSH, 1996, EL CARB DIES EXH NIO; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; PETERS J, 1997, EPIDEMIOLOGIC INVEST; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; SALMON LG, 2000, ORGANIC ELEMENTAL CA; *SAS I INC, 1999, SAS STAT VERS 8 02 M; SCHAUER J, 1996, ATMOS ENVIRON, V22, P3837; Strader R, 1999, ATMOS ENVIRON, V33, P4849, DOI 10.1016/S1352-2310(99)00310-6; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; TURPIN BJ, 1991, ATMOS ENVIRON A-GEN, V25, P207, DOI 10.1016/0960-1686(91)90291-E; TURPIN BJ, 1995, ATMOS ENVIRON, V29, P3527, DOI 10.1016/1352-2310(94)00276-Q; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; VERHEIJ T, 1995, SCAND J PRIM HEALTH, V13, P8, DOI 10.3109/02813439508996728; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835	48	117	120	3	8	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2003	168	7					790	797		10.1164/rccm.200304-466OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	726QZ	WOS:000185611700010	12893648	
J	Hansel, TT; Kharitonov, SA; Donnelly, LE; Erin, EM; Currie, MG; Moore, WM; Manning, PT; Recker, DP; Barnes, PJ				Hansel, TT; Kharitonov, SA; Donnelly, LE; Erin, EM; Currie, MG; Moore, WM; Manning, PT; Recker, DP; Barnes, PJ			A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics	FASEB JOURNAL			English	Article						respiratory; pharmacology; tolerability	OBSTRUCTIVE PULMONARY-DISEASE; INOS INHIBITOR; AIRWAYS; LUNG; MICE; AIR; BRONCHODILATOR; NITROTYROSINE; PEROXYNITRITE; INFLAMMATION	The inducible isoenzyme of nitric oxide synthase (iNOS) generates nitric oxide (NO) in inflammatory diseases such as asthma. The prodrug L-N-6-(1-iminoethyl)lysine 5-tetrazole amide (SC-51) is rapidly converted in vivo to the active metabolite L-N-6-(1-iminoethyl)lysine (L-NIL). Initially, we performed in vitro experiments in human primary airway epithelial cells to demonstrate that L-NIL causes inhibition of iNOS. In a randomized double-blind placebo-controlled crossover trial, SC-51 was administered as a single oral dose (20 or 200 mg) in separate cohorts of healthy volunteers (two groups of n=12) and mild asthmatic patients (two groups of n=12). SC-51 (200 mg) reduced exhaled breath NO levels to <2 ppb in both healthy volunteers (P<0.001) and mild asthmatics (P<0.001) within 15 min, representing >90% inhibition of baseline levels of NO in asthmatic patients, with the effects lasting at least 72 h. There were no significant effects on blood pressure, pulse rate, or respiratory function (FEV1). This study demonstrates that an inhibitor of iNOS produces marked inhibition of exhaled breath NO in normal and asthmatic subjects without producing the side effects observed following the systemic administration of non-selective NOS inhibitors, and thus provides support for the potential use of iNOS inhibitors to treat a range of inflammatory clinical disorders.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Clin Studies Unit, London, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London, England; Pharmacia Corp, Skokie, IL USA; Pharmacia Corp, St Louis, MO USA	Hansel, TT (reprint author), Royal Brompton Hosp, NHLI Clin Studies Unit, London SW3 6HP, England.	t.hansel@imperial.ac.uk					Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALVING K, 1993, EUR RESPIR J, V6, P1368; Amin Ashok R., 1999, Current Opinion in Rheumatology, V11, P202, DOI 10.1097/00002281-199905000-00009; Ashina M, 1999, LANCET, V353, P287, DOI 10.1016/S0140-6736(98)01079-4; Ashutosh K, 2000, THORAX, V55, P109, DOI 10.1136/thorax.55.2.109; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BRYNE J, 2001, BR J CARDIOL, V8, P570; Clini E, 1998, THORAX, V53, P881; CONNOR JR, 1995, EUR J PHARMACOL, V273, P15, DOI 10.1016/0014-2999(94)00672-T; Corradi M, 1999, THORAX, V54, P572; Donnelly LE, 2001, AM J RESP CELL MOL, V24, P295; Dworski R, 2000, THORAX, V55, pS51, DOI 10.1136/thorax.55.suppl_2.S51; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; Hallinan EA, 2002, J MED CHEM, V45, P1686, DOI 10.1021/jm010420e; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; Hart CM, 1999, CHEST, V115, P1407, DOI 10.1378/chest.115.5.1407; Hickey MJ, 2001, CLIN SCI, V100, P1, DOI 10.1042/CS20000135; Hobbs AJ, 1999, ANNU REV PHARMACOL, V39, P191, DOI 10.1146/annurev.pharmtox.39.1.191; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; KUO HP, 1992, EUR J PHARMACOL, V221, P385; Leckie MJ, 2000, EXPERT OPIN INV DRUG, V9, P3; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; Lopez-Jaramillo P, 1998, LANCET, V351, P1176, DOI 10.1016/S0140-6736(05)79119-4; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; MISKO TP, 1993, ANAL BIOCHEM, V214, P1; MONCADA S, 1989, BIOCHEM PHARMACOL, V38, P1709, DOI 10.1016/0006-2952(89)90403-6; Moncada S, 1999, J ROY SOC MED, V92, P164; Moore WM, 1996, J MED CHEM, V39, P669, DOI 10.1021/jm950766n; Perner A, 1999, ALIMENT PHARM THERAP, V13, P135; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RITTER J, 2001, BR J CARDIOL, V8, P564; Rutgers SR, 1999, THORAX, V54, P576; Sadeghi-Hashjin G, 1998, CLIN EXP ALLERGY, V28, P1464; Saleh D, 1998, FASEB J, V12, P929; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829; SALVEMINI D, 1995, J CLIN INVEST, V96, P301, DOI 10.1172/JCI118035; Shah AM, 2000, PHARMACOL THERAPEUT, V86, P49, DOI 10.1016/S0163-7258(99)00072-8; Singh S, 1997, EUR RESPIR J, V10, P699; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Stirling RG, 1998, THORAX, V53, P1030; Szabo C, 1999, SHOCK, V12, P1, DOI 10.1097/00024382-199907000-00001; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99; Thomsen LL, 1998, CLIN NEUROSCI, V5, P28; Torreilles J, 2001, FRONT BIOSCI, V6, pD1161, DOI 10.2741/Torreill; Trifilieff A, 2000, J IMMUNOL, V165, P1526; Tulic MK, 2000, EUR RESPIR J, V15, P870, DOI 10.1183/09031936.00.15587000; VALLANCE P, 1989, LANCET, V2, P997; WARD JK, 1995, AM J RESP CELL MOL, V13, P175; Weinberger B, 1999, PHARMACOL THERAPEUT, V84, P401, DOI 10.1016/S0163-7258(99)00044-3; Xiong YL, 1999, J IMMUNOL, V162, P445; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247	59	117	122	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	MAY	2003	17	8					1298	+		10.1096/fj.02-0633fje		20	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	683TE	WOS:000183165000030	12738811	
J	Raby, BA; Klimecki, WT; Laprise, C; Renaud, Y; Faith, J; Lemire, M; Greenwood, C; Weiland, KM; Lange, C; Palmer, LJ; Lazarus, R; Vercelli, D; Kwiatkowski, DJ; Silverman, EK; Martinez, FD; Hudson, TJ; Weiss, ST				Raby, BA; Klimecki, WT; Laprise, C; Renaud, Y; Faith, J; Lemire, M; Greenwood, C; Weiland, KM; Lange, C; Palmer, LJ; Lazarus, R; Vercelli, D; Kwiatkowski, DJ; Silverman, EK; Martinez, FD; Hudson, TJ; Weiss, ST			Polymorphisms in toll-like receptor 4 are not associated with asthma or atopy-related phenotypes	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; genetics; polymorphism; toll-like receptor 4; genetic association	SINGLE-NUCLEOTIDE POLYMORPHISMS; HOUSE-DUST ENDOTOXIN; LINKAGE DISEQUILIBRIUM; BACTERIAL LIPOPOLYSACCHARIDE; HAPLOTYPE STRUCTURE; UNIFIED APPROACH; CD14 GENE; POPULATION; TLR4; MUTATIONS	Toll-like receptor 4 (TLR4) is the principal receptor for bacterial endotoxin recognition, and functional variants in the gene confer endotoxin-hyporesponsiveness in humans. Furthermore, there is evidence that endotoxin exposure during early life is protective against the development of atopy and asthma, although this relationship remains poorly understood. It is therefore possible that genetic variation in the TLR4 locus contributes to asthma susceptibility. In this study we characterize the genetic diversity in the TLR4 locus and test for association between the common genetic variants and asthma-related phenotypes. In a cohort of 90 ethnically diverse subjects, we resequenced the TLR4 locus and identified a total of 29 single nucleotide polymorphisms. We assessed five common polymorphisms for evidence of association with asthma in two large family-based cohorts: a heterogeneous North American cohort (589 families), and a more homogenous population from northeastern Quebec, Canada (167 families). Using the transmission-disequilibrum test, we found no evidence of association for any of the polymorphisms tested, including two functional variants. Furthermore, we found no evidence for association between the TLR4 variants and four quantitative intermediate asthma- and atopy-related phenotypes. Based on these results, we found no evidence that genetic variation in TLR4 contributes to asthma susceptibility.	Harvard Univ, Channing Lab, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA; Harvard Univ, Partners Ctr Genet & Genomics, Boston, MA 02115 USA; Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; Univ Montreal, Chicoutimi Hosp, Community Genomic Med Ctr, Montreal, PQ, Canada; Univ Quebec, Chicoutimi, PQ, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Dept Human Genet, Montreal, PQ H3A 2T5, Canada; McGill Univ, Ctr Hlth, Montreal Genome Ctr, Dept Med, Montreal, PQ H3A 2T5, Canada; McGill Univ, Ctr Hlth, Res Inst, Montreal, PQ H3A 2T5, Canada	Raby, BA (reprint author), Harvard Univ, Channing Lab, Brigham & Womens Hosp, Sch Med, 181 Longwood Ave, Boston, MA 02115 USA.	benjamin.raby@channing.harvard.edu	Palmer, Lyle/K-3196-2014	Palmer, Lyle/0000-0002-1628-3055; lazarus, ross/0000-0003-3939-1961	NHLBI NIH HHS [1 U01 HL66795-01, 2 T32 HL07427-22, N01HR-16049, P01 HL67664]		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; American thoracic society (ATS), 1979, AM REV RESPIR DIS, V119, P831; Arbour NC, 2000, NAT GENET, V25, P187; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Clark AG, 1998, AM J HUM GENET, V63, P595, DOI 10.1086/301977; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Ewing B, 1998, GENOME RES, V8, P175; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gordon D, 1998, GENOME RES, V8, P195; GUO SW, 1992, BIOMETRICS, V48, P361, DOI 10.2307/2532296; Hakonarson H, 2001, AM J RESP CRIT CARE, V164, P2036; HEYER E, 1995, AM J HUM GENET, V56, P970; HILL W G, 1968, Theoretical and Applied Genetics, V38, P226, DOI 10.1007/BF01245622; HILL WG, 1974, HEREDITY, V33, P229, DOI 10.1038/hdy.1974.89; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Hollox EJ, 2001, AM J HUM GENET, V68, P160, DOI 10.1086/316924; Juniper EF, 1994, HISTAMINE METHACHOLI; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Labuda M, 1996, AM J HUM GENET, V59, P633; Laird NM, 2000, GENET EPIDEMIOL, V19, pS36, DOI 10.1002/1098-2272(2000)19:1+<::AID-GEPI6>3.0.CO;2-M; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; Lange C, 2002, GENET EPIDEMIOL, V23, P165, DOI 10.1002/gepi.0209; Lazarus R, 2002, GENOMICS, V80, P223, DOI 10.1006/geno.2002.6820; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lindblad-Toh K, 2000, NAT GENET, V24, P381, DOI 10.1038/74215; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Nickerson DA, 2001, METH MOL B, V175, P29; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Schneider S, 2000, SOFTWARE POPULATION; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Smirnova I, 2001, GENETICS, V158, P1657; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; STEPHENS M, 2001, PHASE; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; von Mutius E, 2001, AM J RESP CRIT CARE, V164, P1106; VONMUTIUS E, 1999, PEDIAT ASTHMAED; Wjst M, 1998, BIOINFORMATICS, V14, P827, DOI 10.1093/bioinformatics/14.9.827; 1987, AM REV RESPIR DIS, V136, P225	54	117	125	0	4	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2002	166	11					1449	1456		10.1164/rrcm.200207-634OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	621LT	WOS:000179590900009	12406828	
J	Crain, EF; Walter, M; O'Connor, GT; Mitchell, H; Gruchalla, RS; Kattan, M; Malindzak, GS; Enright, P; Evans, R; Morgan, W; Stout, JW				Crain, EF; Walter, M; O'Connor, GT; Mitchell, H; Gruchalla, RS; Kattan, M; Malindzak, GS; Enright, P; Evans, R; Morgan, W; Stout, JW			Home and allergic characteristics of children with asthma in seven US urban communities and design of an environmental intervention: The Inner-City Asthma Study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						environmental intervention; home environmental characteristics; inner-city children; pediatric asthma	RISK-FACTORS; CHILDHOOD ASTHMA; PASSIVE SMOKING; VACUUM-CLEANERS; DOG ALLERGEN; EXPOSURE; SENSITIZATION; EFFICIENCY; MORBIDITY; HEALTH	Most published environmental remediation interventions have been directed at single allergens and have employed demanding strategies; few have been performed in the homes of inner-city children disproportionately burdened by asthma. Our objective was a) to describe the allergen sensitivities, environmental tobacco smoke (ETS) exposure, and home environmental characteristics of a national sample of inner-city children with moderate to severe asthma and b) to develop and implement a multifaceted, home-based comprehensive intervention to reduce home allergens and ETS, tailored to the specific sensitization and exposure profiles of those children. Allergen skin testing and a home evaluation were performed to determine the presence of ETS and factors known to be associated with increased indoor allergen levels. Based on published remediation techniques, a home environmental intervention, organized into modules, each addressing one of five specific allergen groups or ETS, was designed. Of 994 allergic children from seven U.S. urban communities, 937 successfully completed baseline interviews and home allergen surveys and were enrolled. More than 50% of children had positive skin tests to three or more allergen groups. Cockroaches were reported in 58% of homes, wall-to-wall carpeting in the child's bedroom in 55%, a smoker in 48%, mice or rats in 40%, and furry pets in 28%. More than 60% of enrolled families received four or more modules, and between 94% and 98% of all modules were completed. We conclude that most inner-city children with moderate to severe asthma are sensitized to multiple indoor allergens and that environmental factors known to be associated with asthma severity are commonly present in their homes. The intervention developed for the Inner-City Asthma Study employs accepted methods to address an array of allergens and ETS exposure while ensuring that the intervention is tailored to the specific sensitization profiles and home characteristics of these children.	Albert Einstein Coll Med, Jacobi Med Ctr, Dept Pediat Emergency Med, Bronx, NY 10467 USA; Rho Inc, Chapel Hill, NC USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Texas, SW Med Sch, Dept Med, Dallas, TX 75230 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; NIEHS, Res Triangle Pk, NC 27709 USA; Univ Arizona, Resp Sci Ctr, Tucson, AZ USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA	Crain, EF (reprint author), 1W20 Jacobi Hosp, 1400 Pelham Pkwy, Bronx, NY 10461 USA.			O'Connor, George/0000-0002-6476-3926	NIAID NIH HHS [AI-39900, AI-39761, AI-39769, AI-39776, AI-39901, AI-39902, AI39785, AI39789]		Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; BANDURA A, 1977, PSYCHOL REV, V84, P191, DOI 10.1037/0033-295X.84.2.191; BANDURA A, 1986, SOCIAL FDN THOUGHT A; Bandura A., 1986, SOCIAL LEARNING THEO; BUSH RK, 2001, J ALLERGY CLIN IMM S, V107, P403; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Clark NM, 1998, HDB HLTH BEHAV CHANG, P5; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EHRLICH R, 1992, AM REV RESPIR DIS, V145, P594; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Green R, 1999, ALLERGY, V54, P484, DOI 10.1034/j.1398-9995.1999.00029.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Horak F, 1995, Wien Med Wochenschr, V145, P1; *I MED CLEAR AIR, 2000, ASTHM IND EXP; Jones JA, 2001, PATIENT EDUC COUNS, V42, P67, DOI 10.1016/S0738-3991(00)00102-6; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Lioy PJ, 1999, J AIR WASTE MANAGE, V49, P200, DOI 10.1080/10473289.1999.10463789; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153; National Institutes of Health, 1997, NIH PUBL; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; Popplewell EJ, 2000, PEDIATR ALLERGY IMMU, V11, P142, DOI 10.1034/j.1399-3038.2000.00058.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Slezak JA, 1998, J ASTHMA, V35, P203, DOI 10.3109/02770909809068208; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strachan DP, 1998, THORAX, V53, P204; STRACHAN DP, 1988, BRIT MED J, V297, P1223; *US BUR CENS, 2000, CENS 2000 SUMM TAP F; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X	39	117	118	4	13	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2002	110	9					939	945				7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	591RJ	WOS:000177893800037	12204830	
J	Besnard, AG; Togbe, D; Guillou, N; Erard, F; Quesniaux, V; Ryffel, B				Besnard, Anne-Gaelle; Togbe, Dieudonnee; Guillou, Noelline; Erard, Francois; Quesniaux, Valerie; Ryffel, Bernhard			IL-33-activated dendritic cells are critical for allergic airway inflammation	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						Allergy; Cytokines; DC; IL-33; Lung inflammation	IL-1-LIKE CYTOKINE IL-33; T-CELLS; HUMAN EOSINOPHILS; HUMAN BASOPHILS; ST2 RECEPTOR; MURINE MODEL; MAST-CELLS; TH2 CELLS; IN-VIVO; ASTHMA	IL-33, a new member of the IL-1 family cytokine, is involved in Th2-type responses in a wide range of diseases and signals through the ST2 receptor expressed on many immune cells. Since the effects of IL-33 on DCs remain controversial, we investigated the ability of IL-33 to modulate DC functions in vitro and in vivo. Here, we report that IL-33 activates myeloid DCs to produce IL-6, IL-1 beta, TNF, CCL17 and to express high levels of CD40, CD80 OX40L and CCR7. Importantly, IL-33-activated DCs prime naive lymphocytes to produce the Th2 cytokines IL-5 and IL-13, but not IL-4. In vivo, IL-33 exposure induces DC recruitment and activation in the lung. Using an OVA-induced allergic lung inflammation model, we demonstrate that the reduced airway inflammation in ST2-deficient mice correlates with the failure in DC activation and migration to the draining LN. Finally, we show that adoptive transfer of IL-33-activated DCs exacerbates lung inflammation in a DC-driven model of allergic airway inflammation. These data demonstrate for the first time that IL-33 activates DCs during antigen presentation and thereby drives a Th2-type response in allergic lung inflammation.	[Besnard, Anne-Gaelle; Togbe, Dieudonnee; Guillou, Noelline; Erard, Francois; Quesniaux, Valerie; Ryffel, Bernhard] Univ Orleans, F-45071 Orleans 2, France; [Besnard, Anne-Gaelle; Togbe, Dieudonnee; Guillou, Noelline; Erard, Francois; Quesniaux, Valerie; Ryffel, Bernhard] CNRS, UMR 6218, F-45071 Orleans, France; [Togbe, Dieudonnee] Artimmune SAS, Ctr Innovat, Orleans, France	Ryffel, B (reprint author), Univ Orleans, 3B Rue Ferollerie, F-45071 Orleans 2, France.	bryffel@cnrs-orleans.fr			EFIS; "Agence Nationale pour la Recherche'' (ANR) [2007 MIME-103-02]; "Fondation pour la Recherche Medicale'' (FRM) [DAL 2007 0822007]; "Fond europeen de developpement regional'' (FEDER) [1575-32168]	We thank Professor Eddy Liew for critical reading and comments. We are grateful to the EFIS for financial support allowing a fruitful collaboration with Eddy Liew's group. This work was supported by the "Agence Nationale pour la Recherche'' (ANR 2007 MIME-103-02), the "Fondation pour la Recherche Medicale'' (FRM allergy DAL 2007 0822007), the "Fond europeen de developpement regional'' (FEDER Asthme 1575-32168).	Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Eigenbrod T, 2008, J IMMUNOL, V181, P8194; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Hamid Q, 2009, ANNU REV PHYSIOL, V71, P489, DOI 10.1146/annurev.physiol.010908.163200; Hammad H, 2002, J IMMUNOL, V169, P1524; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kazama H, 2008, IMMUNITY, V29, P21, DOI 10.1016/j.immuni.2008.05.013; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Komai-Koma M, 2007, EUR J IMMUNOL, V37, P2779, DOI 10.1002/eji.200737547; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Liu XJ, 2009, BIOCHEM BIOPH RES CO, V386, P181, DOI 10.1016/j.bbrc.2009.06.008; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Mangan NE, 2007, EUR J IMMUNOL, V37, P1302, DOI 10.1002/eji.200636520; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nakajima H, 2007, INT ARCH ALLERGY IMM, V142, P265, DOI 10.1159/000097357; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shum Bennett O. V., 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000707; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Smith DE, 2009, CLIN EXP ALLERGY, V40, P200; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Suzukawa M, 2008, LAB INVEST, V88, P1245, DOI 10.1038/labinvest.2008.82; Suzukawa M, 2008, J IMMUNOL, V181, P5981; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Turnquist HR, 2009, EUR J IMMUNOL, V39, P3292, DOI 10.1002/eji.200940026; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386; Woerly G, 2003, J EXP MED, V198, P411, DOI 10.1084/jem.20021384; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787	44	116	121	0	12	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	JUN	2011	41	6					1675	1686		10.1002/eji.201041033		12	Immunology	Immunology	776TB	WOS:000291559700018	21469105	
J	Vally, H; Misso, NLA; Madan, V				Vally, H.; Misso, N. L. A.; Madan, V.			Clinical effects of sulphite additives	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							METABISULFITE-INDUCED BRONCHOCONSTRICTION; DIOXIDE-INDUCED BRONCHOCONSTRICTION; ALLERGIC CONTACT-DERMATITIS; CHRONIC CHILDHOOD ASTHMA; SODIUM METABISULFITE; SULFUR-DIOXIDE; OCCUPATIONAL ASTHMA; BRONCHIAL HYPERREACTIVITY; BRONCHODILATOR SOLUTIONS; INHALED METABISULFITE	P>Sulphites are widely used as preservative and antioxidant additives in the food and pharmaceutical industries. Topical, oral or parenteral exposure to sulphites has been reported to induce a range of adverse clinical effects in sensitive individuals, ranging from dermatitis, urticaria, flushing, hypotension, abdominal pain and diarrhoea to life-threatening anaphylactic and asthmatic reactions. Exposure to the sulphites arises mainly from the consumption of foods and drinks that contain these additives; however, exposure may also occur through the use of pharmaceutical products, as well as in occupational settings. While contact sensitivity to sulphite additives in topical medications is increasingly being recognized, skin reactions also occur after ingestion of or parenteral exposure to sulphites. Most studies report a 3-10% prevalence of sulphite sensitivity among asthmatic subjects following ingestion of these additives. However, the severity of these reactions varies, and steroid-dependent asthmatics, those with marked airway hyperresponsiveness, and children with chronic asthma, appear to be at greater risk. In addition to episodic and acute symptoms, sulphites may also contribute to chronic skin and respiratory symptoms. To date, the mechanisms underlying sulphite sensitivity remain unclear, although a number of potential mechanisms have been proposed. Physicians should be aware of the range of clinical manifestations of sulphite sensitivity, as well as the potential sources of exposure. Minor modifications to diet or behaviour lead to excellent clinical outcomes for sulphite-sensitive individuals.	[Vally, H.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, ANU Coll Med & Hlth Sci, Canberra, ACT 0200, Australia; [Misso, N. L. A.] Univ Western Australia, Ctr Asthma Allergy & Resp Res, Lung Inst Western Australia Inc, Perth, WA 6009, Australia; [Madan, V.] Salford Royal NHS Fdn Trust, Dermatol Ctr, Manchester, Lancs, England	Vally, H (reprint author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, ANU Coll Med & Hlth Sci, GPO Box 4, Canberra, ACT 0200, Australia.	Hassan.Vally@anu.edu.au					Agard C, 1998, REV MAL RESPIR, V15, P537; Andersson E, 2006, EUR RESPIR J, V27, P720, DOI 10.1183/09031936.06.00034305; Andersson E, 1998, SCAND J WORK ENV HEA, V24, P12; ANIBARRO B, 1992, J ALLERGY CLIN IMMUN, V90, P103, DOI 10.1016/S0091-6749(06)80016-3; APETATO M, 1986, CONTACT DERMATITIS, V14, P194, DOI 10.1111/j.1600-0536.1986.tb01217.x; Asmus MJ, 1999, J ALLERGY CLIN IMMUN, V104, pS53, DOI 10.1016/S0091-6749(99)70274-5; ATKINSON DA, 1993, ANN ALLERGY, V71, P563; *AUSTR SOC CLIN IM, SULF ALL; BAKER GJ, 1981, MED J AUSTRALIA, V2, P614; BELLINGAN GJ, 1992, BRIT J CLIN PHARMACO, V34, P71; BETHEL RA, 1983, AM REV RESPIR DIS, V128, P592; BONER AL, 1990, J ALLERGY CLIN IMMUN, V85, P479, DOI 10.1016/0091-6749(90)90158-Z; BOUSHEY HA, 1982, J ALLERGY CLIN IMMUN, V69, P335, DOI 10.1016/0091-6749(82)90142-7; BUSH RK, 1986, J ALLERGY CLIN IMMUN, V78, P191, DOI 10.1016/0091-6749(86)90012-6; BUSH RK, 1990, CLIN REV ALLERG, V8, P159; CAMARASA JG, 1982, CONTACT DERMATITIS, V8, P268, DOI 10.1111/j.1600-0536.1982.tb04214.x; CHALLEN RG, 1990, MED J AUSTRALIA, V152, P196; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; Devalia JL, 1996, TOXICOL LETT, V86, P169, DOI 10.1016/0378-4274(96)03687-9; DIXON CM, 1988, THORAX, V43, P226; DIXON CMS, 1990, BRIT J CLIN PHARMACO, V30, P371; DOOMSGOOSSENS A, 1989, CONTACT DERMATITIS, V20, P124, DOI 10.1111/j.1600-0536.1989.tb03120.x; *ENV WORK GROUP, SKIN DEEP COSM SAF D; Epstein E, 1970, CONTACT DERMATITIS N, V7, P155; FIELD PI, 1994, THORAX, V49, P250, DOI 10.1136/thx.49.3.250; FINE JM, 1987, AM REV RESPIR DIS, V136, P1122; *FOOD DRUG ADM, 1986, FDA DRUG B, V16, P17; FREEDMAN BJ, 1977, CLIN ALLERGY, V7, P407, DOI 10.1111/j.1365-2222.1977.tb01471.x; FRIEDMAN ME, 1986, J ALLERGY CLIN IMMUN, V77, P159; GASTAMINZA G, 1995, CLIN EXP ALLERGY, V25, P698, DOI 10.1111/j.1365-2222.1995.tb00006.x; Gong H, 2001, CHEST, V119, P402, DOI 10.1378/chest.119.2.402; Green L. F., 1976, FOOD CHEM, V1, P103, DOI 10.1016/0308-8146(76)90003-0; GROTHEER G, 2005, FCS8787 U FLOR I FOO; GUNNISON AF, 1987, CRIT REV TOXICOL, V17, P185, DOI 10.3109/10408448709071208; Habenicht HA, 1983, IMMUNOL ALLERGY PRAC, V5, P243; Hamad AM, 1999, EUR RESPIR J, V14, P702, DOI 10.1034/j.1399-3003.1999.14c34.x; Hein H, 1996, Pneumologie, V50, P394; Hodge L, 1996, THORAX, V51, P805, DOI 10.1136/thx.51.8.805; HUANG AS, 1984, NEW ENGL J MED, V311, P542; JACOBS MC, 1995, CONTACT DERMATITIS, V33, P65, DOI 10.1111/j.1600-0536.1995.tb00463.x; Jimenez-Aranda G S, 1996, Rev Alerg Mex, V43, P152; KOCHEN J, 1973, PEDIATRICS, V52, P145; KOEPKE JW, 1984, JAMA-J AM MED ASSOC, V251, P2982, DOI 10.1001/jama.251.22.2982; KOEPKE JW, 1983, J ALLERGY CLIN IMMUN, V72, P504, DOI 10.1016/0091-6749(83)90588-2; Langevin PB, 1999, CHEST, V116, P1140, DOI 10.1378/chest.116.4.1140-a; Lazarus SC, 1997, AM J RESP CRIT CARE, V156, P1725; Lee A, 2001, CONTACT DERMATITIS, V44, P127, DOI 10.1034/j.1600-0536.2001.44020924.x; LESTER MR, 1995, J AM COLL NUTR, V14, P229; LINN WS, 1983, AM REV RESPIR DIS, V127, P278; Madan V, 2007, CONTACT DERMATITIS, V57, P173, DOI 10.1111/j.1600-0536.2007.01188.x; Malik Mohsin M, 2007, Contact Dermatitis, V56, P241, DOI 10.1111/j.1600-0536.2007.00972.x; MALO JL, 1995, THORAX, V50, P585, DOI 10.1136/thx.50.5.585; MCCLELLAN MD, 1990, CHEST, V97, P826, DOI 10.1378/chest.97.4.826; Merget R, 2005, EUR RESPIR J, V25, P386, DOI 10.1183/09031936.05.00024304; Nagayama Hirotoshi, 1997, Journal of Dermatology (Tokyo), V24, P675; NAGY SM, 1995, J FOOD PROTECT, V58, P95; NATER JP, 1968, DERMATOLOGICA, V136, P477; NOLAN AL, 1983, FOOD ENG, V84, P89; Nowak D, 1997, AM J RESP CRIT CARE, V156, P1151; OCONNOR BJ, 1994, THORAX, V49, P307, DOI 10.1136/thx.49.4.307; PAVORD ID, 1991, THORAX, V46, P633, DOI 10.1136/thx.46.9.633; PERONI DG, 1995, CLIN EXP ALLERGY, V25, P680, DOI 10.1111/j.1365-2222.1995.tb00003.x; PETERSEN CS, 1992, CONTACT DERMATITIS, V27, P344; PRENNER BM, 1976, ANN ALLERGY, V37, P180; PRIETO L, 1988, ALLERGOL IMMUNOPATH, V16, P393; RIGGS BS, 1986, ANN EMERG MED, V15, P77, DOI 10.1016/S0196-0644(86)80492-9; Roberts A. C., 1972, Journal of Food Technology, V7, P221, DOI 10.1080/10871200260293388; Roth JV, 2004, ANESTH ANALG, V98, P1499, DOI 10.1213/01.ANE.0000120092.39021.F2; Sanchez-Perez J, 2000, CONTACT DERMATITIS, V42, P176; SANZ J, 1992, J INVEST ALLERG CLIN, V2, P36; SCHORR WF, 1983, MULTIPLE INJURIES PE; SCHWARTZ HJ, 1984, J ALLERGY CLIN IMMUN, V74, P511, DOI 10.1016/0091-6749(84)90387-7; SCHWARTZ HJ, 1989, ANN ALLERGY, V62, P83; SCHWARTZ HJ, 1983, J ALLERGY CLIN IMMUN, V71, P487, DOI 10.1016/0091-6749(83)90466-9; SHEPPARD D, 1983, ENVIRON RES, V30, P412, DOI 10.1016/0013-9351(83)90227-X; SHEPPARD D, 1981, AM REV RESPIR DIS, V123, P486; SHER TH, 1985, ANN ALLERGY, V54, P224; Simon RA, 1998, ALLERGY, V53, P78; SIMON RA, 1989, ALLERGY PROC, V10, P357, DOI 10.2500/108854189778959858; SMOLINSKE SC, 1992, J TOXICOL-CLIN TOXIC, V30, P597; Steiner M, 2008, OCCUP MED-OXFORD, V58, P545, DOI 10.1093/occmed/kqn130; STEINMAN HA, 1993, S AFR MED J, V83, P387; STEVENSON DD, 1981, J ALLERGY CLIN IMMUN, V68, P26, DOI 10.1016/0091-6749(81)90119-6; STEVENSON DD, 1984, J ALLERGY CLIN IMMUN, V74, P469, DOI 10.1016/0091-6749(84)90380-4; Taylor S L, 1986, Adv Food Res, V30, P1, DOI 10.1016/S0065-2628(08)60347-X; Timbo B, 2004, J FOOD PROTECT, V67, P1806; TOWNS SJ, 1984, PEDIATRICS, V73, P631; TSEVAT J, 1987, ANN INTERN MED, V107, P263; TWAROG FJ, 1982, JAMA-J AM MED ASSOC, V248, P2030, DOI 10.1001/jama.248.16.2030; Valero A L, 1993, Allergol Immunopathol (Madr), V21, P221; Vally H, 2007, CLIN EXP ALLERGY, V37, P1062, DOI 10.1111/j.1365-2222.2007.02747.x; VANDENBOSSCHE LEG, 1993, PEDIATR PULM, V16, P236, DOI 10.1002/ppul.1950160405; VENA GA, 1994, CONTACT DERMATITIS, V31, P172, DOI 10.1111/j.1600-0536.1994.tb01959.x; Wang M, 1996, THORAX, V51, P799, DOI 10.1136/thx.51.8.799; WARNER CR, 2000, FOOD TESTING ANA AUG; WRIGHT W, 1990, AM REV RESPIR DIS, V141, P1400; WUTHRICH B, 1989, SCHWEIZ MED WSCHR, V119, P1177; WUTHRICH B, 1993, DERMATOLOGY, V187, P290; YANG WH, 1985, CAN MED ASSOC J, V133, P865; Yoshikawa T, 1990, Nihon Kyobu Shikkan Gakkai Zasshi, V28, P895	100	116	117	3	50	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2009	39	11					1643	1651		10.1111/j.1365-2222.2009.03362.x		9	Allergy; Immunology	Allergy; Immunology	509FY	WOS:000271001600005	19775253	
J	Nials, AT; Uddin, S				Nials, Anthony T.; Uddin, Sorif			Mouse models of allergic asthma: acute and chronic allergen challenge	DISEASE MODELS & MECHANISMS			English	Article							INHIBITS AIRWAY INFLAMMATION; SEVERE PERSISTENT ASTHMA; SOLUBLE IL-4 RECEPTOR; MURINE MODEL; BRONCHIAL HYPERRESPONSIVENESS; PULMONARY INFLAMMATION; MONOCLONAL-ANTIBODY; ATOPIC ASTHMA; PHOSPHODIESTERASE-4 INHIBITOR; CYSTEINYL-LEUKOTRIENES	Asthma is defined as a chronic inflammatory disease of the airways; however, the underlying physiological and immunological processes are not fully understood. Animal models have been used to elucidate asthma pathophysiology, and to identify and evaluate novel therapeutic targets. Several recent review articles (Epstein, 2004; Lloyd, 2007; Boyce and Austen, 2005; Zosky and Sly, 2007) have discussed the potential value of these models. Allergen challenge models reproduce many features of clinical asthma and have been widely used by investigators; however, the majority involve acute allergen challenge procedures. It is recognised that asthma is a chronic inflammatory disease resulting from continued or intermittent allergen exposure, usually via inhalation, and there has been a recent focus on developing chronic allergen exposure models, predominantly in mice. Here, we review the acute and chronic exposure mouse models, and consider their potential role and impact in the field of asthma research.	[Nials, Anthony T.; Uddin, Sorif] GlaxoSmithKline Med Res Ctr, Resp Ctr Excellence Drug Discovery, Stevenage SG1 2NY, Herts, England	Nials, AT (reprint author), GlaxoSmithKline Med Res Ctr, Resp Ctr Excellence Drug Discovery, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.	tony.t.nials@gsk.com					ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Boyce JA, 2005, J EXP MED, V201, P1869, DOI 10.1084/jem.20050584; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Choi IW, 2005, J ALLERGY CLIN IMMUN, V116, P537, DOI 10.1016/j.jaci.2005.05.034; Deveci F, 2008, RESPIROLOGY, V13, P488, DOI 10.1111/j.1440-1843.2008.01278.x; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Eum SY, 2003, AM J RESP CELL MOL, V28, P25, DOI 10.1165/rcmb.4532; Fernandez-Rodriguez S, 2008, INT IMMUNOPHARMACOL, V8, P756, DOI 10.1016/j.intimp.2008.01.025; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Foster PS, 2002, LAB INVEST, V82, P455; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAUVREAU GM, 2008, EUR RESP J IN PRESS; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Henderson WR, 2000, J IMMUNOL, V164, P1086; Henderson WR, 2000, J IMMUNOL, V164, P3360; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Herbert C, 2008, CLIN EXP ALLERGY, V38, P847, DOI 10.1111/j.1365-2222.2008.02950.x; HESSEL EM, 1995, J APPL PHYSIOL, V79, P1711; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; HOZAWA S, 1995, AM J RESP CRIT CARE, V152, P1198; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ITO K, 2008, AM J RESP C IN PRESS; Janssen EM, 2000, J IMMUNOL, V165, P7207; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; JUNGSUWADEE P, 2004, INT ARCH ALLERGY IMM, V133, P126; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173; Kanehiro A, 2000, AM J RESP CRIT CARE, V162, P1132; Kim CH, 2006, J ASTHMA, V43, P345, DOI 10.1080/02770900600701424; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P1796, DOI 10.1111/j.1365-2222.2004.02097.x; Kumar RK, 2004, AM J RESP CRIT CARE, V170, P1043, DOI 10.1164/rccm.200405-681OC; Kumar RK, 2003, J PHARMACOL EXP THER, V307, P349, DOI 10.1124/jpet.103.053819; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee SY, 2008, PULM PHARMACOL THER, V21, P14, DOI 10.1016/j.pupt.2006.10.009; Lee YC, 2006, INT IMMUNOPHARMACOL, V6, P703, DOI 10.1016/j.intimp.2005.10.007; Leigh R, 2004, J APPL PHYSIOL, V97, P2258, DOI 10.1152/japplphysiol.00597.2004; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-S09OC; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Lloyd CM, 2007, CURR ALLERGY ASTHM R, V7, P231; Lloyd CM, 2001, J IMMUNOL, V166, P2033; Louw C, 2007, RESPIRATION, V74, P411, DOI 10.1159/000095677; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; McMillan SJ, 2005, CLIN EXP ALLERGY, V35, P388, DOI 10.1111/j.1365-2222.2005.02193.x; Nagai H, 1996, ANN NY ACAD SCI, V796, P91, DOI 10.1111/j.1749-6632.1996.tb32570.x; Norris V, 2005, J ALLERGY CLIN IMMUN, V116, P761, DOI 10.1016/j.jaci.2005.04.045; Pearlman DS, 1997, ANN ALLERG ASTHMA IM, V78, P356; Ravensberg AJ, 2006, ALLERGY, V61, P1097, DOI 10.1111/j.1398-9995.2006.01146.x; Reiss TF, 1996, J ALLERGY CLIN IMMUN, V98, P528, DOI 10.1016/S0091-6749(96)70086-6; Richter M, 2007, PROSTAG LEUKOTR ESS, V76, P299, DOI 10.1016/j.plefa.2007.02.004; Riffo-Vasquez Y, 2002, PHARMACOL THERAPEUT, V94, P185, DOI 10.1016/S0163-7258(02)00217-6; Sarpong SB, 2003, INT ARCH ALLERGY IMM, V132, P346, DOI 10.1159/000074902; Shi H, 1998, EUR RESPIR J, V11, P624; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Siegle JS, 2006, AM J RESP CELL MOL, V35, P565, DOI 10.1165/rcmb.2006-01350C; STENTON SC, 1992, PULM PHARMACOL, V5, P199, DOI 10.1016/0952-0600(92)90041-E; Temelkovski J, 1998, THORAX, V53, P849; Tomkinson A, 2001, J IMMUNOL, V166, P5792; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; TOWNLEY RG, 1994, J LIPID MEDIAT CELL, V10, P345; Ulrich K, 2008, PULM PHARMACOL THER, V21, P637, DOI 10.1016/j.pupt.2008.02.006; van Schalkwyk E, 2005, J ALLERGY CLIN IMMUN, V116, P292, DOI 10.1016/j.jaci.2005.04.023; Wegmann Michael, 2008, J Occup Med Toxicol, V3 Suppl 1, pS4, DOI 10.1186/1745-6673-3-S1-S4; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel S, 2006, AM J RESP CRIT CARE, V174, P1173, DOI 10.1164/rccm.2609002; Yang GY, 2005, J PHARMACOL EXP THER, V313, P8, DOI 10.1124/jpet.104.076133; Zosky GR, 2007, CLIN EXP ALLERGY, V37, P973, DOI 10.1111/j.1365-2222.2007.02740.x	85	116	122	0	21	COMPANY OF BIOLOGISTS LTD	CAMBRIDGE	BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL, CAMBS, ENGLAND	1754-8403			DIS MODEL MECH	Dis. Model. Mech.	NOV-DEC	2008	1	4-5					213	220		10.1242/dmm.000323		8	Cell Biology; Pathology	Cell Biology; Pathology	474AK	WOS:000268254400010	19093027	
J	Arbes, SJ; Gergen, PJ; Vaughn, B; Zeldin, DC				Arbes, Samuel J., Jr.; Gergen, Peter J.; Vaughn, Ben; Zeldin, Darryl C.			Asthma cases attributable to atopy: Results from the third national health and nutrition examination survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; allergic sensitization; allergy skin test; asthma; atopy; epidemiology; NHANES III; skin prick test; survey	HOUSE-DUST MITE; COMMON ALLERGENS; CAT ALLERGEN; ASSOCIATION; SENSITIZATION; POPULATION; EXPOSURE; ADOLESCENTS; REACTIVITY; CHILDHOOD	Background: The percentage of asthma cases attributable to atopy is the subject of debate. Objectives: The objectives were to estimate the percentage of asthma cases in the US population attributable to atopy and to examine associations between allergen-specific skin tests and asthma. Methods: Data were obtained from the Third National Health and Nutrition Examination Survey, in which subjects age 6 to 59 years were skin tested with 10 allergens. Atopy was defined as at least 1 positive allergen-specific test. Doctor-diagnosed current asthma was assessed by questionnaire. Results: In the United States, 56.3% of the asthma cases were attributable to atopy, and that percentage was greater among males than females, among persons in the highest education category than in lower education categories, and among persons living in highly populated metropolitan areas than in all other areas. Each allergen-specific test was strongly associated with asthma before adjustment (odds ratios varied from 2.1 to 4.5); however, after adjustment by all the allergens, only tests to cat, Alternaria, white oak, and perennial rye were independently associated with asthma. Perennial rye was inversely associated with asthma. Of the 10 allergens, a positive response to cat accounted for the highest percentage of asthma cases (29.3%). Conclusion: About half of the current asthma cases in the US population represented by the Third National Health and Nutrition Examination Survey were attributable to atopy. Some allergen-specific skin tests were not independently associated with asthma. Clinical implications: If atopy could be prevented or reversed, or its effect on asthma blocked, then a large percentage of asthma cases in the US population could be prevented.	NIEHS, Lab Resp Biol, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; Rho Inc, Chapel Hill, NC USA	Zeldin, DC (reprint author), NIEHS, Lab Resp Biol, Div Intramural Res, NIH, POB 12233,MD D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov			Intramural NIH HHS [Z01 ES025041-10]		Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Jaakkola MS, 2006, J ALLERGY CLIN IMMUN, V117, P642, DOI 10.1016/j.jaci.2005.11.003; Judkins D. R., 1990, J OFF STAT, V6, P223; Lanphear BP, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e98; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325; *NAT CTR HLTH STA, 1986, PUBL US DAT TAP DOC; Pearce N, 1999, THORAX, V54, P268; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Rothman K., 1986, MODERN EPIDEMIOLOGY; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; VONMUTIUS E, 2007, P AM THORAC SOC, V4, P217	22	116	117	1	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1139	1145		10.1016/j.jaci.2007.07.056		7	Allergy; Immunology	Allergy; Immunology	231TZ	WOS:000250973400024	17889931	
J	Chan, PC; Xia, QS; Fu, PP				Chan, Po-Chuen; Xia, Qingsu; Fu, Peter P.			Ginkgo biloba leave extract: Biological, medicinal, and toxicological effects	JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS			English	Review						Gingko biloba leave extract; biological and toxicological effects; ginkgolidc; quercetin	HERB-DRUG INTERACTIONS; INDUCED NEURONAL DEATH; GLOBAL BRAIN ISCHEMIA; EGB 761 PROTECTS; DNA-DAMAGE; INDUCED NEPHROTOXICITY; INDUCED TOXICITY; NITRIC-OXIDE; IN-VITRO; CYTOCHROME-P450 PHENOTYPES	Ginkgo biloba leave extract is among the most widely sold herbal dietary supplements in the United States. Its purported biological effects include: scavenging free radical; lowering oxidative stress; reducing neural damages, reducing platelets aggregation; anti-inflammation; anti-tumor activities; and anti-aging. Clinically, it has been prescribed to treat CNS disorders such as Alzheimer's disease and cognitive deficits. It exerts allergy and changes in bleeding time. While its mutagenicity or carcinogenic activity has not been reported, its components, quercetin, kaempferol and rutin have been shown to be genotoxic. There are no standards or guidelines regulating the constituent components of Ginkgo biloba leave extract nor are exposure limits imposed. Safety evaluation of Ginkgo biloba leave extract is being conducted by the U.S. National Toxicology Program.	[Chan, Po-Chuen] NIEHS, Res Triangle Pk, NC 27709 USA; [Xia, Qingsu; Fu, Peter P.] Natl Ctr Toxicol Res, Jefferson, AR 72079 USA	Chan, PC (reprint author), NIEHS, Res Triangle Pk, Res Triangle Pk, NC 27709 USA.	chanp@niehs.nih.gov					Agha AM, 2001, J EXP CLIN CANC RES, V20, P39; Ahlemeyer B, 2003, PHARMACOPSYCHIATRY, V36, pS8; Al-Yahya AA, 2006, J ETHNOPHARMACOL, V107, P222, DOI 10.1016/j.jep.2006.03.014; AMBROSE AM, 1952, J AM PHARM ASSOC SCI, V41, P119; Antognoni F, 2004, ATLA-ALTERN LAB ANIM, V32, P79; Arenz A, 1996, PLANTA MED, V62, P548, DOI 10.1055/s-2006-957967; ATZORI C, 1993, ANTIMICROB AGENTS CH, V37, P1492; Bastianetto S, 2000, EUR J NEUROSCI, V12, P1882, DOI 10.1046/j.1460-9568.2000.00069.x; Bastianetto S, 2000, J NEUROCHEM, V74, P2268, DOI 10.1046/j.1471-4159.2000.0742268.x; Bastianetto S, 2002, NEUROBIOL AGING, V23, P891, DOI 10.1016/S0197-4580(02)00024-6; Bastianetto S, 2002, CELL MOL BIOL, V48, P693; Bent S, 2005, J GEN INTERN MED, V20, P657, DOI 10.1111/j.1525-1497.2005.0121.x; BENZI G, 1995, FREE RADICAL BIO MED, V19, P77, DOI 10.1016/0891-5849(94)00244-E; BHATTACHARYA RK, 1988, CANCER LETT, V39, P85, DOI 10.1016/0304-3835(88)90043-2; *BIOT U, 1998, PEG GINKG BIL; Boersma MG, 2000, CHEM RES TOXICOL, V13, P185, DOI 10.1021/tx990161k; Boots AW, 2005, BIOCHEM BIOPH RES CO, V338, P923, DOI 10.1016/j.bbrc.2005.10.031; Boots AW, 2005, FEBS LETT, V579, P677, DOI 10.1016/j.febslet.2004.12.044; BRAQUET P, 1991, J ETHNOPHARMACOL, V32, P135, DOI 10.1016/0378-8741(91)90111-P; BRAQUET P, 1987, Drugs of the Future, V12, P643; Bressler R, 2005, GERIATRICS, V60, P30; BROWN DJ, 1996, NARD J           MAY, P41; BROWN S, 1983, EXPERIENTIA, V39, P198, DOI 10.1007/BF01958898; CARIA H, 1995, MUTAT RES-GENET TOX, V343, P85, DOI 10.1016/0165-1218(95)90075-6; CARVER JH, 1983, MUTAT RES, V113, P45, DOI 10.1016/0165-1161(83)90240-6; Celik I, 2005, BASIC CLIN PHARMACOL, V97, P325, DOI 10.1111/j.1742-7843.2005.pto_153.x; Chandrasekaran K, 2003, PHARMACOPSYCHIATRY, V36, pS89; Chandrasekaran K, 2002, CELL MOL BIOL, V48, P663; Chermat R, 1997, PHARMACOL BIOCHEM BE, V56, P333, DOI 10.1016/S0091-3057(96)00298-5; Choi JY, 2005, ANALOG INTEGR CIRC S, V43, P5, DOI 10.1007/s10470-005-6566-y; Christen Y., 2000, AM J CLIN NUTR, V71, P621; Cohen-Salmon C, 1997, J PHYSIOLOGY-PARIS, V91, P291, DOI 10.1016/S0928-4257(97)82409-6; Coskun O, 2005, J APPL TOXICOL, V25, P8, DOI 10.1002/jat.1002; CREBELLI R, 1987, FOOD CHEM TOXICOL, V25, P9, DOI 10.1016/0278-6915(87)90301-2; CROOM EM, 1995, DRUG TOPICS      NOV, P84; da Silva J, 2002, FOOD CHEM TOXICOL, V40, P941, DOI 10.1016/S0278-6915(02)00015-7; Daba MH, 2002, PHARMACOL RES, V45, P461, DOI 10.1006/phrs.2002.0985; Dajas F, 2003, NEUROTOX RES, V5, P425; DeFeudis F. V., 1998, GINKGO BILOBA EXTRAC; *DIAL INF SERV, 1998, PIERS IMP US PORTS D; dos Santos-Neto LL, 2006, EVID-BASED COMPL ALT, V3, P441, DOI 10.1093/ecam/nel071; DroyLefaix MT, 1995, INT J TISSUE REACT, V17, P93; Dubey A-K, 2004, Kathmandu Univ Med J (KUMJ), V2, P225; DUCHE JC, 1989, INT J CLIN PHARM RES, V9, P165; Dugoua Jean-Jacques, 2006, Can J Clin Pharmacol, V13, pe277; DUNNICK JK, 1992, FUND APPL TOXICOL, V19, P423, DOI 10.1016/0272-0590(92)90181-G; Duthie SJ, 1997, MUTAT RES-GEN TOX EN, V390, P141, DOI 10.1016/S0165-1218(97)00010-4; Eckert A, 2003, PHARMACOPSYCHIATRY, V36, pS15; Eder E, 2000, ARCH TOXICOL, V74, P642, DOI 10.1007/s002040000170; Eder E., 1999, IARC SCI PUBL, V150, P219; Eliason B C, 1997, J Am Board Fam Pract, V10, P265; Ellison JM, 1998, J CLIN PSYCHIAT, V59, P199, DOI 10.4088/JCP.v59n0409f; EMERIT I, 1995, RADIAT RES, V144, P198, DOI 10.2307/3579259; Fitzpatrick AL, 2006, CONTEMP CLIN TRIALS, V27, P541, DOI 10.1016/j.cct.2006.06.007; Formica JV, 1995, FOOD CHEM TOXICOL, V33, P1061, DOI 10.1016/0278-6915(95)00077-1; GARDES-ALBERT M, 1990, Free Radical Biology and Medicine, V9, P190, DOI 10.1016/0891-5849(90)90850-I; Gilbert GJ, 1997, NEUROLOGY, V48, P1137; Golzer P, 1996, CHEM RES TOXICOL, V9, P1207, DOI 10.1021/tx9600107; Gong Qi-hai, 2006, Chin J Integr Med, V12, P37; Gulec M, 2006, TOXICOL IND HEALTH, V22, P125, DOI 10.1191/0748233705th255oa; Gurley BJ, 2004, CLIN PHARMACOL THER, V76, P428, DOI 10.1016/j.clpt.2004.07.007; Gurley BJ, 2005, DRUG AGING, V22, P525, DOI 10.2165/00002512-200522060-00006; Ha SW, 1996, RADIOTHER ONCOL, V41, P163, DOI 10.1016/S0167-8140(96)01808-7; HATCHER JF, 1983, FED PROC, V42, P786; Hauser D, 2002, TRANSPLANT INT, V15, P377, DOI 10.1007/s00147-002-0432-y; Hilton M, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003852.PUB2; HIRONO I, 1981, CANCER LETT, V13, P15, DOI 10.1016/0304-3835(81)90081-1; HIRONO I, 1992, JPN J CANCER RES, V83, P313; HOSAKA S, 1981, GANN, V72, P327; Houghton P, 1994, PHARM J, V253, P122; Hu ZP, 2005, DRUGS, V65, P1239, DOI 10.2165/00003495-200565090-00005; Huh H., 1992, Journal of Herbs, Spices & Medicinal Plants, V1, P91, DOI 10.1300/J044v01n01_10; ITO N, 1989, JPN J CANCER RES, V80, P317; ITOKAWA H, 1987, CHEM PHARM BULL, V35, P3016; ITOKAWA H, 1989, CHEM PHARM BULL, V37, P1619; Jaggy H, 1997, PHARMAZIE, V52, P735; JOYEUX M, 1995, PLANTA MED, V61, P126, DOI 10.1055/s-2006-958030; JURETZEK W, 1997, RECENT ADV GINKGO BI, P341; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; Kessler M, 2003, J PHARM PHARMACOL, V55, P131, DOI 10.1211/002235702559; Kim JD, 2006, J NUTR BIOCHEM, V17, P165, DOI 10.1016/j.jnutbio.2005.06.006; Kim SJ, 1997, SKIN PHARMACOL, V10, P200; KLEIJNEN J, 1992, BRIT J CLIN PHARMACO, V34, P352; KLEIJNEN J, 1992, LANCET, V340, P1136, DOI 10.1016/0140-6736(92)93158-J; Kohler S, 2004, BLOOD COAGUL FIBRIN, V15, P303, DOI 10.1097/01.mbc.0000114423.81125.8b; KRIEGLSTEIN J, 1995, EUR J PHARM SCI, V3, P39, DOI 10.1016/0928-0987(94)00073-9; KUBIAK R, 1990, ACTA BIOL HUNG, V41, P121; Kumar V, 2006, PHYTOTHER RES, V20, P1023, DOI 10.1002/ptr.1970; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LEE SJ, 1995, LIFE SCI, V57, P551, DOI 10.1016/0024-3205(95)00305-P; Lee SL, 1998, BIOCHEM PHARMACOL, V56, P527, DOI 10.1016/S0006-2952(98)00174-9; Li CL, 1997, PLANTA MED, V63, P563, DOI 10.1055/s-2006-957768; Lin SY, 1997, METHOD FIND EXP CLIN, V19, P367; Luo Y, 2002, P NATL ACAD SCI USA, V99, P12197, DOI 10.1073/pnas.182425199; Luo Y, 2006, LIFE SCI, V78, P2066, DOI 10.1016/j.lfs.2005.12.004; Marcilhac A, 1998, LIFE SCI, V62, P2329, DOI 10.1016/S0024-3205(98)00214-8; MARCOCCI L, 1994, BIOCHEM BIOPH RES CO, V201, P748, DOI 10.1006/bbrc.1994.1764; MARTIN CM, 1997, CONSULTANT PHARM, V12, P631; Massieu L, 2004, BRAIN RES, V1002, P76, DOI 10.1016/j.brainres.2003.12.018; MELTZ ML, 1981, MUTAT RES, V88, P317, DOI 10.1016/0165-1218(81)90043-4; MESSINA BA, 2006, J PERIANESTH NURS, V21, P279; Messina Barbara Ann M, 2006, J Perianesth Nurs, V21, P268, DOI 10.1016/j.jopan.2006.05.004; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; MOREAU JP, 1986, PRESSE MED, V15, P1458; MORINO K, 1982, CARCINOGENESIS, V3, P93, DOI 10.1093/carcin/3.1.93; Nadasi E, 2005, IN VIVO, V19, P559; Naidu M. U. R., 2002, Indian Journal of Experimental Biology, V40, P894; Naidu MUR, 2000, PHYTOMEDICINE, V7, P191; NAKAYASU M, 1986, MUTAT RES, V174, P79, DOI 10.1016/0165-7992(86)90081-3; *NTP, 1992, REP NR TECHN REP SER, V409; Okamoto T, 2005, INT J MOL MED, V16, P275; Oliver C., 1994, European Journal of Endocrinology, V130, P207; Ondrizek RR, 1999, FERTIL STERIL, V71, P517, DOI 10.1016/S0015-0282(98)00476-2; Ozturk G, 2004, TOXICOL APPL PHARM, V196, P169, DOI 10.1016/j.taap.2003.12.006; PACKER L, 1998, GINKGO BILOBA EXTRAC, P303; PAMUKCU AM, 1980, CANCER RES, V40, P3468; PIETTA PG, 1995, J CHROMATOGR B, V673, P75, DOI 10.1016/0378-4347(95)00252-E; Ponto Laura L Boles, 2003, Ann Clin Psychiatry, V15, P109, DOI 10.3109/10401230309085676; Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025; RAPIN JR, 1994, GEN PHARMACOL-VASC S, V25, P1009, DOI 10.1016/0306-3623(94)90111-2; Rosenblatt M, 1997, NEW ENGL J MED, V336, P1108, DOI 10.1056/NEJM199704103361518; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Rowin J, 1996, NEUROLOGY, V46, P1775; SAHU SC, 1994, CANCER LETT, V85, P159, DOI 10.1016/0304-3835(94)90269-0; Saito D, 1980, Teratog Carcinog Mutagen, V1, P213; Salvador R. L., 1995, CPJ RPC, V52, P39; Sasaki K, 1997, RES COMMUN MOL PATH, V96, P45; Sastre J, 1998, FREE RADICAL BIO MED, V24, P298, DOI 10.1016/S0891-5849(97)00228-1; Satyan KS, 1998, PSYCHOPHARMACOLOGY, V136, P148, DOI 10.1007/s002130050550; Scholtyssek H, 1997, CHEM-BIOL INTERACT, V106, P183, DOI 10.1016/S0009-2797(97)00067-7; Schuler D, 1999, CARCINOGENESIS, V20, P1345, DOI 10.1093/carcin/20.7.1345; Sener G, 2006, MOL CELL BIOCHEM, V283, P39, DOI 10.1007/s11010-006-2268-8; Sener G, 2007, FOOD CHEM TOXICOL, V45, P543, DOI 10.1016/j.fct.2006.07.024; SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771; Silva ID, 1997, MUTAGENESIS, V12, P383, DOI 10.1093/mutage/12.5.383; Smith PF, 1996, J ETHNOPHARMACOL, V50, P131, DOI 10.1016/0378-8741(96)01379-7; Soares VCG, 2006, FOOD CHEM TOXICOL, V44, P835, DOI 10.1016/j.fct.2005.11.006; SPRINGEN K, 1997, NEWSWEEK, P58; STICHER O, 1993, PLANTA MED, V59, P1; STOEWSAND GS, 1984, J TOXICOL ENV HEALTH, V14, P105; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Suzuki R, 2004, CANCER LETT, V210, P159, DOI 10.1016/j.canlet.2004.01.034; van Beek TA, 2005, BIOORGAN MED CHEM, V13, P5001, DOI 10.1016/j.bmc.2005.05.056; van Beek TA, 1998, FITOTERAPIA, V69, P195; van der Woude H, 2005, CHEM RES TOXICOL, V18, P1907, DOI 10.1021/tx050201m; VASSEUR M, 1994, GEN PHARMACOL, V25, P31, DOI 10.1016/0306-3623(94)90007-8; Walle T, 2003, BIOCHEM PHARMACOL, V65, P1603, DOI 10.1016/S0006-2952(03)00151-5; Wang Guo-xia, 2006, Chin J Integr Med, V12, P234; WATSON WAF, 1982, MUTAT RES, V103, P145, DOI 10.1016/0165-7992(82)90020-3; WEOERDENBAG HJ, 1997, GINKGO BILOBA, V3, P51; White HL, 1996, LIFE SCI, V58, P1315, DOI 10.1016/0024-3205(96)00097-5; Williamson Elizabeth M, 2005, Expert Opin Drug Saf, V4, P355, DOI 10.1517/14740338.4.2.355; WINTER E, 1991, PHARMACOL BIOCHEM BE, V38, P109, DOI 10.1016/0091-3057(91)90597-U; Winter JC, 1998, PHYSIOL BEHAV, V63, P425, DOI 10.1016/S0031-9384(97)00464-2; Wojcicki Jerzy, 1995, Materia Medica Polona, V27, P141; Wold RS, 2005, J AM DIET ASSOC, V105, P54, DOI 10.1016/j.jada.2004.11.002; Yamashita N, 2000, FREE RADICAL RES, V33, P623, DOI 10.1080/10715760000301141; Zhou W, 2004, CARDIOVASC DRUG REV, V22, P309; Zou L, 2002, LIFE SCI, V71, P1579, DOI 10.1016/S0024-3205(02)01913-6; 1998, GINKGO BILOBA HUPERI; 1992, HERBAL REMEDIES MARK	161	116	126	5	51	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1059-0501			J ENVIRON SCI HEAL C	J. Environ. Sci. Health Pt. C-Environ. Carcinog. Ecotoxicol. Rev.		2007	25	3					211	244		10.1080/10590500701569414		34	Oncology; Environmental Sciences; Toxicology	Oncology; Environmental Sciences & Ecology; Toxicology	264DD	WOS:000253264800002	17763047	
J	Delfino, RJ; Staimer, N; Gillen, D; Tjoa, T; Sioutas, C; Fung, K; George, SC; Kleinman, MT				Delfino, Ralph J.; Staimer, Norbert; Gillen, Dan; Tjoa, Thomas; Sioutas, Constantinos; Fung, Kochy; George, Steven C.; Kleinman, Michael T.			Personal and ambient air pollution is associated with increased exhaled nitric oxide in children with asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; epidemiology; exhaled nitric oxide; longitudinal data analysis; nitrogen dioxide; ozone; panel study; particulate air pollution	ANTIINFLAMMATORY MEDICATION USE; PARTICULATE-MATTER; NITROGEN-DIOXIDE; HEALTHY-SUBJECTS; EXPOSURE; SYMPTOMS; FLOW; PARTICLES; MONTELUKAST; POPULATION	BACKGROUND: Research has shown associations between pediatric asthma outcomes and airborne particulate matter (PM). The importance of particle components remains to be determined. METHODS: We followed a panel of 45 schoolchildren with persistent asthma living in Southern California. Subjects were monitored over 10 days with offline fractional exhaled nitric oxide (FENO), a biomarker of airway inflammation. Personal active sampler exposures included continuous particulate matter < 2.5 mu m in aerodynamic diameter (PM2.5), 24-hr PM2.5 elemental and organic carbon (EC, OC), and 24-hr nitrogen dioxide. Ambient exposures included PM2.5, PM2.5 EC and OC, and NO2. Data were analyzed with mixed models controlling for personal temperature, humidity and 10-day period. RESULTS: The strongest positive associations were between FENO and 2-day average pollutant concentrations. Per interquartile range pollutant increase, these were: for 24 mu g/m(3) personal PM2.5, 1.1 ppb F-ENO [95% confidence interval (CI), 0.1-1.9]; for 0.6 mu g/m(3) personal EC, 0.7 ppb FENO (95% CI, 0.3-1.1); for 17 ppb personal NO2, 1.6 ppb FENO (95% CI, 0.4-2.8). Larger associations were found for ambient EC and smaller associations for ambient NO2. Ambient PM2.5 and personal and ambient OC were significant only in subjects taking inhaled corticosteroids (ICS) alone. Subjects taking both ICS and antileukotrienes showed no significant associations. Distributed lag models showed personal PM2.5 in the preceding 5 hr was associated with F-ENO. In two-pollutant models, the most robust associations were for personal and ambient EC and NO2, and for personal but not ambient PM2.5. CONCLUSION: PM associations with airway inflammation in asthmatics may be missed using ambient particle mass, which may not sufficiently represent causal pollutant components from fossil fuel combustion.	Univ Calif Irvine, Sch Med, Dept Med, Div Epidemiol, Irvine, CA 92617 USA; Univ Calif Irvine, Dept Stat, Irvine, CA USA; Univ Calif Irvine, Dept Biomed Engn, Irvine, CA USA; Univ Calif Irvine, Sch Med, Dept Community & Environm Med, Irvine, CA 92717 USA; Univ So Calif, Dept Civil & Environm Engn, Sch Engn, Los Angeles, CA USA; AtmAA Inc, Calabasas, CA USA	Delfino, RJ (reprint author), Univ Calif Irvine, Sch Med, Dept Med, Div Epidemiol, 100 Theory,Suite 100, Irvine, CA 92617 USA.	rdelfino@uci.edu	Wang, Linden/M-6617-2014; George, Steven/K-9359-2015	George, Steven/0000-0003-2263-1914	NIEHS NIH HHS [ES11615, R01 ES011615]		Adamkiewicz G, 2004, THORAX, V59, P204, DOI 10.1136/thorax.2003.006445; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST.PUBMED:15817806; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Chakrabarti B, 2004, ATMOS ENVIRON, V38, P3329, DOI 10.1016/j.atmosenv.2004.03.007; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Diggle P, 2002, ANAL LONGITUDINAL DA; Ebelt ST, 2005, EPIDEMIOLOGY, V16, P396, DOI 10.1097/01.ede.0000158918.57071.3e; Fabbri LM, 1998, AM J RESP CRIT CARE, V157, pS195; Fine PM, 2004, ENVIRON SCI TECHNOL, V38, P1296, DOI 10.1021/es0348389; Fischer PH, 2002, INT ARCH OCC ENV HEA, V75, P348, DOI 10.1007/s00420-002-0320-x; Fung K, 2002, J AIR WASTE MANAGE, V52, P1333; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; GONG H, 2001, CHEST, V19, P402; Hamid Qutayba, 2003, Journal of Allergy and Clinical Immunology, V111, pS5, DOI 10.1067/mai.2003.22; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Jansen KL, 2005, ENVIRON HEALTH PERSP, V113, P1741, DOI 10.1289/ehp.8153; Jobsis Q, 2001, THORAX, V56, P285, DOI 10.1136/thorax.56.4.285; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; Koenig JQ, 2003, ENVIRON HEALTH PERSP, V111, P1625, DOI 10.1289/ehp.6160; Kroesbergen A, 1999, EUR RESPIR J, V14, P871, DOI 10.1034/j.1399-3003.1999.14d24.x; Lewis TC, 2005, ENVIRON HEALTH PERSP, V113, P1068, DOI 10.1289/ehp.7533; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Linn WS, 2004, ARCH ENVIRON HEALTH, V59, P385, DOI 10.3200/AEOH.59.8.385-391; Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9; Mar TF, 2005, ENVIRON HEALTH PERSP, V113, P1791, DOI 10.1289/ehp.7883; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; *NAT I OCC SAF HLH, 1994, DHHS PUBL; Persinger RL, 2002, MOL CELL BIOCHEM, V234, P71, DOI 10.1023/A:1015973530559; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Rabinovitch N, 2005, J ALLERGY CLIN IMMUN, V116, P1053, DOI 10.1016/j.jaci.2005.08.045; Roorda-Knape MC, 1999, SCI TOTAL ENVIRON, V235, P339, DOI 10.1016/S0048-9697(99)00217-X; Rundell KW, 2005, INHAL TOXICOL, V17, P99, DOI 10.1080/08958370590899479; Schauer JJ, 2002, ENVIRON SCI TECHNOL, V36, P1169, DOI 10.1021/es0108077; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Sheppard L, 2005, J EXPO ANAL ENV EPID, V15, P366, DOI 10.1038/sj.jea.7500413; Sioutas C, 2005, ENVIRON HEALTH PERSP, V113, P947, DOI 10.1289/ehp.7939; Staimer N, 2005, ANAL BIOANAL CHEM, V383, P955, DOI 10.1007/s00216-005-0086-6; Steerenberg PA, 2003, INT ARCH ALLERGY IMM, V131, P127, DOI 10.1159/000070928; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167; Van Amsterdam JGC, 1999, ARCH ENVIRON HEALTH, V54, P331; Molenberghs G, 2001, LINEAR MIXED MODELS; Zeidler MR, 2004, CURR OPIN PULM MED, V10, P31, DOI 10.1097/00063198-200401000-00006; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	49	116	117	3	52	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	NOV	2006	114	11					1736	1743		10.1289/ehp.9141		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	102OS	WOS:000241822300036	17107861	
J	Marra, F; Lynd, L; Coombes, M; Richardson, K; Legal, M; FitzGerald, JM; Marra, CA				Marra, F; Lynd, L; Coombes, M; Richardson, K; Legal, M; FitzGerald, JM; Marra, CA			Does antibiotic exposure during infancy lead to development of asthma? A systematic review and metaanalysis	CHEST			English	Review						antibiotics; childhood asthma; pediatrics	EARLY-CHILDHOOD; ALLERGIC DISEASE; BIRTH COHORT; INFECTIOUS-DISEASES; 1ST YEAR; RISK; PREVALENCE; LIFE; RHINITIS; DATABASE	Objectives: To determine the association between antibiotic exposure in the first year of life and the development of childhood asthma. Design: Metaanalysis of observational studies retrieved through systematic search of all available electronic data sources. Studies included in the metaanalyses were those with populations exposed to one or more courses of antibiotics during the first year of life, and asthma diagnosis was defined as diagnosis by a physician between the age of 1 to 18 years. Setting: Retrospective and prospective studies published in the English-language literature from 1966 to present. Results: Eight studies (four prospective and four retrospective) examined the association between exposure to at least one course of antibiotics and development of childhood asthma. The total number of subjects for the analysis comparing exposure to at least one antibiotic to no exposure in the first year of life was 12,082 children and 1,817 asthma cases. In the dose-response analysis, we included data from a total of 27,167 children and 3,392 asthma cases. The pooled odds ratio (OR) for the eight studies was 2.05 (95% confidence interval [CI], 1.41 to 2.99). The association was significantly stronger in the retrospective studies (OR, 2.82; 95% CI, 2.07 to 3.85) than the prospective studies (OR, 1.12; 95% CI, 0.88 to 1.42). Five of the eight studies examined whether the association was related to the number of courses of antibiotics taken in the first year of life. The overall OR for the dose-response analysis was 1.16 (95% CI, 1.05 to 1.28) for each additional course of antibiotics; however, this association was not significantly stronger in the retrospective studies (OR, 1.37; 95% CI, 1.18 to 1.60) relative to the prospective studies (OR, 1.07; 95% CI, 0.95 to 1.20). Conclusions: Exposure to at least one course of antibiotics in the first year of life appears to be a risk factor for the development of childhood asthma. Because of the limitations of the studies conducted to date, additional large-scale, prospective studies are needed to confirm this potential association.	Univ British Columbia, Hlth Econ Program, Ctr Clin Epidemiol & Evaluat, Vancouver Coastal Hlth Res Inst,Fac Pharmaceut Sc, Vancouver, BC V5Z 1L8, Canada; Univ British Columbia, Ctr Dis Control, Ctr Clin Epidemiol & Evaluat, Fac Med, Vancouver, BC V5Z 1L8, Canada	Marra, CA (reprint author), Univ British Columbia, Hlth Econ Program, Ctr Clin Epidemiol & Evaluat, Vancouver Coastal Hlth Res Inst,Fac Pharmaceut Sc, 828 W 10th Ave, Vancouver, BC V5Z 1L8, Canada.	carlo.marra@ubc.ca					Adams PF, 1999, VITAL HLTH STAT, V10, P1; ANDERSON HR, 1994, BRIT MED J, V308, P1600; BERLIN JA, 1993, EPIDEMIOLOGY, V4, P218, DOI 10.1097/00001648-199305000-00005; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Cullinan P, 2004, THORAX, V59, P11; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Farooqi IS, 1998, THORAX, V53, P927; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JOHNSON CC, 2003, EPIDEMIOLOGY, V15, pS88; LABBE KA, 1987, ANN INTERN MED, V107, P224; Light R. J., 1984, SUMMING SCI REVIEWIN; Martinez FD, 1999, LANCET S2, V354, pSII12; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; Schappert SM, 1992, ADV DATA, P1; Thomas M, 2003, THORAX, V58, P67; *US CENS BUR, 1997, WHOS MIND KIDS CHILD; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wjst M, 2001, EUR J MED RES, V6, P263; 1995, MMWR MORB MORTAL WKL, V44, P609	29	116	122	0	7	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAR	2006	129	3					610	618		10.1378/chest.129.3.610		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	027GY	WOS:000236404200018	16537858	
J	Boman, BC; Forsberg, AB; Jarvholm, BG				Boman, BC; Forsberg, AB; Jarvholm, BG			Adverse health effects from ambient air pollution in relation to residential wood combustion in modern society	SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH			English	Review						air pollution; asthma; biomass combustion; epidemiology; particulate matter; review; short-term exposure; wood smoke	FINE PARTICULATE MATTER; EMERGENCY ROOM VISITS; SANTA-CLARA COUNTY; SOURCE APPORTIONMENT; ORGANIC-COMPOUNDS; DAILY MORTALITY; ASTHMA; CHILDREN; PARTICLES; SEATTLE	This is a review of the adverse health effects of ambient air pollution in relation to residential wood combustion in modem society. From a literature search of PubMed, nine relevant studies were identified. All of them focused on the effects of short-term exposure such as asthma, respiratory symptoms, daily mortality, and lung function. Substantial quantitative information was only found for acute asthma in relation to particulate matter with an aerodynamic diameter of <10 mum. In comparison with the present general estimations for ambient particulate matter and adverse health effects, the relative risks were even stronger in the studies in which residential wood combustion was considered a major source of particulate matter. Thus there seems to be no reason to assume that the effects of particulate matter in areas polluted by wood smoke are weaker than elsewhere.	Umea Univ, SE-90187 Umea, Sweden	Boman, BC (reprint author), Umea Univ, SE-90187 Umea, Sweden.						Ackermann-Liebrich U., 1999, AIR POLLUTION HLTH, P559; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; BRUNNER T, 2001, P 1 WORLD C EXH BIOM, P1991; *CANT REG COUNC, 1997, CHRISTCH INV TOT EM; CHOW JC, 1995, J ENVIRON ENG-ASCE, V121, P378, DOI 10.1061/(ASCE)0733-9372(1995)121:5(378); CHRIESTENSEN KA, 1995, THESIS TU DENMARK; Cohen AJ, 1995, ENVIRON HEALTH PERSP, V103, P219, DOI 10.2307/3432314; COOPER JA, 1981, ENVIRON SCI TECHNOL, V15, P1045, DOI 10.1021/es00091a002; DAWSON KP, 1983, NEW ZEAL MED J, V96, P165; DEKONING HW, 1985, B WORLD HEALTH ORGAN, V63, P11; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; *EEA, 1998, 81997 EEA; FAIRLEY D, 1990, ENVIRON HEALTH PERSP, V89, P159, DOI 10.2307/3430912; Fischer A, 2001, CLIN REV ALLERG IMMU, V20, P3, DOI 10.1385/CRIAI:20:1:3; Ghio A.J., 1999, AIR POLLUTION HLTH, P635, DOI 10.1016/B978-012352335-8/50104-6; Hales S, 2000, AUST NZ J PUBL HEAL, V24, P89, DOI 10.1111/j.1467-842X.2000.tb00731.x; Harre ESM, 1997, THORAX, V52, P1040; Harrison RM, 2000, SCI TOTAL ENVIRON, V249, P85, DOI 10.1016/S0048-9697(99)00513-6; HAZUCHA MJ, 1999, AIR POLLUTION HLTH, P511, DOI 10.1016/B978-012352335-8/50098-3; HILDEMANN LM, 1994, ENVIRON SCI TECHNOL, V28, P1565, DOI 10.1021/es00058a006; Holgate ST, 1999, AIR POLLUTION HLTH; Hueglin C, 1997, ENVIRON SCI TECHNOL, V31, P3439, DOI 10.1021/es970139i; *INT EN AG, 2002, IEA PUBL; Katsouyanni K, 1997, CANCER CAUSE CONTROL, V8, P284, DOI 10.1023/A:1018492818416; Kleeman MJ, 1999, ENVIRON SCI TECHNOL, V33, P3516, DOI 10.1021/es981277q; KLOUDA GA, 1991, P 84 ANN M AIR WAST, V15, P1; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; LARSON TV, 1994, ANNU REV PUBL HEALTH, V15, P133; LARSON TV, 1992, P AIR WAST MAN ASS S, P39; LEWIS CW, 1991, P 84 ANN M AIR WAST, V15, P1; Lighty JS, 2000, J AIR WASTE MANAGE, V50, P1565; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; MacNee W, 1999, AIR POLLUTION HLTH, P653, DOI 10.1016/B978-012352335-8/50105-8; Maynard R. L, 1999, AIR POLLUTION HLTH, P749, DOI 10.1016/B978-012352335-8/50108-3; MUHLBAIERDASCH J, 1982, ENVIRON SCI TECHNOL, V16, P639; NORDIN A, 1998, ASHES PARTICULATE EM, P119; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Pope CA, 2000, AEROSOL SCI TECH, V32, P4, DOI 10.1080/027868200303885; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; Purvis CR, 2000, ENVIRON SCI TECHNOL, V34, P1653, DOI 10.1021/es981006f; RAMDAHL T, 1983, NATURE, V306, P580, DOI 10.1038/306580a0; RAU JA, 1989, AEROSOL SCI TECH, V10, P181, DOI 10.1080/02786828908959233; Reddy A., 1996, ENERGY RIO PROSPECTS; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schauer JJ, 2001, ENVIRON SCI TECHNOL, V35, P1716, DOI 10.1021/es001331e; Schauer JJ, 1996, ATMOS ENVIRON, V30, P3837, DOI 10.1016/1352-2310(96)00085-4; SCHLESINGER RB, 1999, AIR POLLUTION HLTH, P485; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; TORNQVIST M, 1994, ENVIRON HEALTH PERSP, V102, P173, DOI 10.2307/3431949; [Anonymous], 2000, 454R00002 USEPA; Valmari T, 1999, ENERG FUEL, V13, P390, DOI 10.1021/ef9800866; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; WHO, 2000, GUID AIR QUAL; WIESER U, 2001, P 1 WORLD C EXH BIOM, P805; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; Zelikoff JT, 2002, J TOXICOL ENV HEAL B, V5, P269, DOI 10.1080/10937400290070062	60	116	117	0	27	SCAND J WORK ENV HEALTH	HELSINKI	TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND	0355-3140			SCAND J WORK ENV HEA	Scand. J. Work Environ. Health	AUG	2003	29	4					251	260				10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	711XH	WOS:000184766000002	12934718	
J	Chew, GL; Rogers, C; Burge, HA; Muilenberg, ML; Gold, DR				Chew, GL; Rogers, C; Burge, HA; Muilenberg, ML; Gold, DR			Dustborne and airborne fungal propagules represent a different spectrum of fungi with differing relations to home characteristics	ALLERGY			English	Article						air sampling; dust sampling; fungi; home characteristics; mold	IN-HOUSE DUST; RESIDENTIAL CHARACTERISTICS; RESPIRATORY SYMPTOMS; INDOOR ENVIRONMENT; DOMESTIC INTERIORS; EXPOSURE; HEALTH; CHILDREN; ASTHMA; PREVALENCE	Background: Exposure to fungi is often assessed by culturing floor dust or air samples. Our objective was to evaluate the relationships between dustborne and airborne fungi and to identify factors that modify these relationships. Methods: From November 1994 to September 1996 sequential duplicate 45-l air samples were collected in bedrooms of 496 homes in the Boston area, using a Burkard culture plate sampler. After air sampling, bedroom floors were sampled with a vacuum cleaner that was modified to collect dust in a cellulose extraction thimble. Dust was sieved, and the fine dust was dilution-plated onto DG-18 media. Results: Concentrations of total culturable fungi per gram of bedroom-floor dust were correlated weakly, but significantly, with those of indoor air (r = 0.13, P < 0.05). Concentrations of some individual taxa in the dust and indoor air were also weakly associated. Adjusting for the concentrations of fungi in outdoor air, dustborne fungal concentrations were positively associated with those in indoor air for the taxa Cladosporium and Penicillium , but not for total fungi. The indoor air fungal levels were often predicted by different covariates to those predicting fungal levels in dust. The type of housing (house or apartment) and the presence of carpeting were often predictive factors for dust fungi. In contrast, outdoor fungal levels were often predictive of the indoor air fungal levels. Conclusions: Because our data do not indicate a strong overall relationship between culturable fungi in dust and indoor air, the results from these two methods (dust and air sampling) likely represent different types of potential fungal exposures to residents. It may be essential to collect both air and dust samples, as well as information on housing characteristics, as indicators for fungal exposure.	Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA	Chew, GL (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, 60 Haven Ave B-1, New York, NY 10032 USA.		Rogers, Christine/A-2189-2008	Rogers, Christine/0000-0003-0887-9606	NHLBI NIH HHS [HL-07427]; NIAID NIH HHS [AI-35786]		*AM C GOV IND HYG, 1998, BIOAER ASS CONTR; ANDERSEN AA, 1958, J BACTERIOL, V76, P471; *ASTM, 1990, E33784 ASTM; BEAUMONT F, 1984, ANN ALLERGY, V53, P486; Beguin H, 1996, AEROBIOLOGIA, V12, P113, DOI 10.1007/BF02248135; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BURGE H, 1990, J ALLERGY CLIN IMMUN, V86, P687, DOI 10.1016/S0091-6749(05)80170-8; BURGE HA, 1995, OCCUP MED, V10, P27; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Dillon HK, 1999, ENVIRON HEALTH PERSP, V107, P473; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; GRAVESEN S, 1978, ALLERGY, V33, P268, DOI 10.1111/j.1398-9995.1978.tb01547.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; *I MED DIV HLTH PR, 2000, CLEAR AIR ASTHM IND; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; Malloch DW., 1981, MOULDS THEIR ISOLATI; Miller JD, 1997, AM IND HYG ASSOC J, V58, P39; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PASANEN AL, 1991, ATMOS ENVIRON A-GEN, V25, P459, DOI 10.1016/0960-1686(91)90316-Y; PASANEN AL, 1992, ATMOS ENVIRON B-URB, V26, P121, DOI 10.1016/0957-1272(92)90044-S; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; SCHAEFFER N, 1953, J ALLERGY, V23, P348; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181; Su HJJ, 2001, ARCH ENVIRON HEALTH, V56, P144; SWAEBLY MA, 1953, J ALLERGY, V23, P370; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; von Arx J. A., 1970, GENERA FUNGI SPORULA	42	116	117	0	10	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JAN	2003	58	1					13	20		10.1034/j.1398-9995.2003.00013.x		8	Allergy; Immunology	Allergy; Immunology	643GJ	WOS:000180853300004	12580801	
J	Becker, S; Fenton, MJ; Soukup, JM				Becker, S; Fenton, MJ; Soukup, JM			Involvement of microbial components and toll-like receptors 2 and 4 in cytokine responses to air pollution particles	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							ALVEOLAR MACROPHAGE RESPONSES; EMERGENCY ROOM VISITS; TNF-ALPHA; RESPIRATORY ILLNESSES; INSOLUBLE COMPONENTS; SIGNAL-TRANSDUCTION; CUTTING EDGE; IN-VITRO; LIPOPOLYSACCHARIDE; ENDOTOXIN	Inhalation of particulate matter (PM) may result in exacerbation of inflammatory airways disease, including asthma. Results from this laboratory have shown that the coarse inhalable particle fraction (PM2.5-10) is responsible for most of the PM effects on human airway macrophages (AM), including induction of cytokine production. Endotoxins associated with these particles account for a large part of their potency, as activity of PM can be inhibited by polymixin B and an activating moiety bound by lipopolysaccharide (LPS)-binding protein (LBP). The hypothesis behind the present study was that not only particle-bound LPS, but also Gram-negative (Gram-) and Gram-positive (Gram+) bacteria are responsible for PM-induced stimulation of AM, and therefore that PM are likely to activate receptors involved in recognition of microbes. Low level contamination of model pollution particles with environmental Staphyloccocus, Streptococcus, and Pseudomonas species was found to confer cytokine-inducing activity on inactive particles. Only one Gram- bacterium was sufficient for significant stimulatation of 100 AM, whereas at least three times more Gram+ bacteria were required for a similar level of response. Cytokine responses induced by PM as well as Gram+ and Gram- bacteria were inhibited by anti-CD14 antibody and required the presence of LBP-containing serum. The involvement of Toll-like receptor (TLR) 2 and 4 in recognition of PMZ.,o was investigated in transfected Chinese hamster ovary cells expressing CD14 and TLR2 or TLR4. TLR4 was found to be involved in PM2.5-10 and Pseudomonas-induced activation, whereas TLR2 activation was induced by both Gram+ and Gram- bacteria and by PM. The synthetic lipid A analog E5531 fully inhibited the response to purified LPS and partially inhibited the response to PM and Pseudomonas. In contrast, E5531 had no effect on the response to Staphylococcus. Taken together, these results implicate microbial components as important players in AM-dependent inflammatory responses to PM.	US EPA, Natl Hlth & Environm Effect Res Lab, Res Triangle Pk, NC 27711 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA	Becker, S (reprint author), Human Studies Facil, EPA Bldg,104 Mason Farm Rd, Chapel Hill, NC 27599 USA.						Atkinson RW, 1999, ARCH ENVIRON HEALTH, V54, P398; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BOVALLIUS A, 1978, APPL ENVIRON MICROB, V35, P847; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Daniels AU, 2000, J BIOMED MATER RES, V49, P469, DOI 10.1002/(SICI)1097-4636(20000315)49:4<469::AID-JBM5>3.0.CO;2-A; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; Delude RL, 1998, J IMMUNOL, V161, P3001; Garcia JEL, 1999, MEDIAT INFLAMM, V8, P43; Ghio A. J. B. M., 1998, J BRONCHOL, V5, P185, DOI 10.1097/00128594-199807000-00003; HATCH GE, 1985, ENVIRON RES, V36, P67, DOI 10.1016/0013-9351(85)90008-8; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; Hirschfeld M, 2000, J IMMUNOL, V165, P618; Hodgson MJ, 2001, AM J IND MED, V39, P616, DOI 10.1002/ajim.1061; Ilabaca M, 1999, J AIR WASTE MANAGE, V49, P154; Imrich A, 2000, TOXICOL APPL PHARM, V167, P140, DOI 10.1006/taap.2000.9002; Kawata T, 1999, BRIT J PHARMACOL, V127, P853, DOI 10.1038/sj.bjp.0702596; Kim CS, 1996, J APPL PHYSIOL, V81, P2203; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Kitchens RL, 2000, CHEM IMMUNOL, V74, P61; Kooguchi K, 1998, INFECT IMMUN, V66, P3164; Landmann R, 2000, MICROBES INFECT, V2, P295, DOI 10.1016/S1286-4579(00)00298-7; Larsson BM, 1999, INFLAMMATION, V23, P217; Lentsch AB, 1999, AM J RESP CELL MOL, V20, P692; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 2001, J IMMUNOL, V166, P4074; MENTREZ MY, 2000, J AIR WASTE MANAGE, V51, P1436; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MONTON C, 1998, CHEST DIS, V53, P56; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; QUAY J, 1993, EXP LUNG RES, V19, P429, DOI 10.3109/01902149309064356; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Shoham S, 2001, J IMMUNOL, V166, P4620; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Su GL, 1995, CRIT REV IMMUNOL, V15, P201; Takeshita F, 2001, J IMMUNOL, V167, P3555	41	116	122	0	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	NOV	2002	27	5					611	618		10.1165/rcmb.4868		8	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	614KW	WOS:000179189000012	12397021	
J	Lin, S; Munsie, JP; Hwang, SA; Fitzgerald, E; Cayo, MR				Lin, S; Munsie, JP; Hwang, SA; Fitzgerald, E; Cayo, MR			Childhood asthma hospitalization and residential exposure to state route traffic	ENVIRONMENTAL RESEARCH			English	Article						asthma hospitalization; childhood asthma; traffic; automobile exhaust	RESPIRATORY HEALTH; AIR-POLLUTION; ADJUVANT ACTIVITY; CHILDREN; EXHAUST; ADMISSIONS; PARTICLES; ADULTS; ROADS; MICE	This study investigated whether pediatric hospitalization for asthma was related to living near a road with heavy traffic. In this case-control study, cases (N=417) consisted of white children aged 0-14 years who were admitted for asthma and who resided in Erie County, New York, excluding the city of Buffalo. Controls (N=461) were children in the same age range admitted during the same time period for nonrespiratory diseases. Subjects' residential addresses were linked to traffic information provided by the New York State Department of Transportation. After adjustments for age and poverty level were made, children hospitalized for asthma were more likely to live on roads with the highest tertile of vehicle miles traveled (VMT) (odds ratio (OR): 1.93, 95% confidence interval (CI): 1.13-3.29) within 200 m and were more likely to have trucks and trailers passing by within 200m of their residence (OR=1.43, 95% CI: 1.03-1.99) compared to controls. However, childhood asthma hospitalization was not significantly associated with residential distance from state roads, annual VMT within 500m, or whether trucks or trailers passed by within 500m. This study suggests that exposure to high volumes of traffic/trucks within 200m of homes contributes to childhood asthma hospitalizations. (C) 2002 Elsevier Science (USA).	New York State Dept Hlth, Bur Environm & Occupat Epidemiol, Troy, NY 12180 USA	Lin, S (reprint author), New York State Dept Hlth, Bur Environm & Occupat Epidemiol, Troy, NY 12180 USA.		Fitzgerald, Edward/F-4087-2010; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Lin, Shao/0000-0002-5535-7504			Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; COLLEY JRT, 1973, BRIT MED J, V3, P195; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; *GEOGR DAT TECHN I, 1995, MATCHM 2000 2 1 WIND; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; HILDEMANN LM, 1991, AEROSOL SCI TECH, V14, P138, DOI 10.1080/02786829108959478; Lin S, 1999, J ASTHMA, V36, P241; LINN W S, 1986, Toxicology and Industrial Health, V2, P99; LINN WS, 1983, AM REV RESPIR DIS, V289, P235; Livingstone AE, 1996, BRIT MED J, V312, P676; LUNN JE, 1967, BRIT J PREV SOC MED, V21, P7; *MAIL SOFTW, 1995, MAIL PLUS 4 US MAN; *MAP CORP, 1998, MAP PROF US GUID; MARTIN AE, 1964, P ROY SOC MED, V57, P969; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; *NY STAT DEP TRANS, 1994, HIGHW SUFF RAT; ONO M, 1989, J JAPAN SOC AIR POLL, V24, P90; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; OREHEK J, 1986, J CLIN INVEST, V56, P301; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; *US BUR CENS, 1993, 185 CURR POP REP P60; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; World Health Organization/United Nations Environment Programme, 1992, URB AIR POLL MEG WOR; WJST M, 1993, BRIT MED J, V307, P596	30	116	122	0	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	FEB	2002	88	2					73	81		10.1006/enrs.2001.4303		9	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	536LG	WOS:000174701100001	11908931	
J	Laumbach, RJ; Kipen, HM				Laumbach, Robert J.; Kipen, Howard M.			Respiratory health effects of air pollution: Update on biomass smoke and traffic pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Biomass; traffic; chronic obstructive pulmonary disease; asthma; air pollutants; particulate matter	OBSTRUCTIVE PULMONARY-DISEASE; DIESEL EXHAUST PARTICLES; ENVIRONMENTAL RISK-FACTORS; LONG-TERM EXPOSURE; AMBIENT AIR; LOS-ANGELES; SOLID-FUEL; STREPTOCOCCUS-PNEUMONIAE; DEVELOPING-COUNTRIES; ULTRAFINE PARTICLES	Mounting evidence suggests that air pollution contributes to the large global burden of respiratory and allergic diseases, including asthma, chronic obstructive pulmonary disease, pneumonia, and possibly tuberculosis. Although associations between air pollution and respiratory disease are complex, recent epidemiologic studies have led to an increased recognition of the emerging importance of traffic-related air pollution in both developed and less-developed countries, as well as the continued importance of emissions from domestic fires burning biomass fuels, primarily in the less-developed world. Emissions from these sources lead to personal exposures to complex mixtures of air pollutants that change rapidly in space and time because of varying emission rates, distances from source, ventilation rates, and other factors. Although the high degree of variability in personal exposure to pollutants from these sources remains a challenge, newer methods for measuring and modeling these exposures are beginning to unravel complex associations with asthma and other respiratory tract diseases. These studies indicate that air pollution from these sources is a major preventable cause of increased incidence and exacerbation of respiratory disease. Physicians can help to reduce the risk of adverse respiratory effects of exposure to biomass and traffic air pollutants by promoting awareness and supporting individual and community-level interventions. (J Allergy Clin Immunol 2012; 129: 3-11.)	[Kipen, Howard M.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, EOHSI, Piscataway, NJ 08854 USA; Rutgers State Univ, Piscataway, NJ USA	Kipen, HM (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, EOHSI, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	kipen@eohsi.rutgers.edu			National Institute of Environmental Health Sciences [P30 ES005022]; US Environmental Protection Agency STAR [RD 83457901]	Supported in part by National Institute of Environmental Health Sciences grant P30 ES005022 and US Environmental Protection Agency STAR Grant RD 83457901.	Andersen ZJ, 2011, AM J RESP CRIT CARE, V183, P455, DOI 10.1164/rccm.201006-0937OC; Armendariz C. R. E., 2008, INDOOR AIR, V18, P93; Balmes John R, 2010, Proc Am Thorac Soc, V7, P98, DOI 10.1513/pats.200907-081RM; Barry AC, 2010, J ASTHMA, V47, P735, DOI 10.3109/02770903.2010.485661; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behera D, 2001, Indian J Chest Dis Allied Sci, V43, P27; Behera D, 1998, Indian J Chest Dis Allied Sci, V40, P89; Behndig AF, 2011, THORAX, V66, P12, DOI 10.1136/thx.2010.140053; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brook RD, 2008, CLIN SCI, V115, P175, DOI 10.1042/CS20070444; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Bruce N, 2007, B WORLD HEALTH ORGAN, V85, P535, DOI 10.2471/BLT.06.035832; Cai H, 2011, SCI TOTAL ENVIRON, V409, P1935, DOI 10.1016/j.scitotenv.2011.01.025; Carlsten C, 2011, OCCUP ENVIRON MED, V68, P291, DOI 10.1136/oem.2010.055152; Ciencewicki J, 2007, INHAL TOXICOL, V19, P1135, DOI 10.1080/08958370701665434; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; D'Amato G, 2010, J INVEST ALLERG CLIN, V20, P95; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; DiazSanchez D, 1997, ALLERGY, V52, P52; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Eisner MD, 2010, AM J RESP CRIT CARE, V182, P693, DOI 10.1164/rccm.200811-1757ST; Ekici A, 2005, ENVIRON RES, V99, P93, DOI 10.1016/j.envres.2005.01.004; Ezzati M, 2002, ENVIRON HEALTH PERSP, V110, P1057; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15; Fruin SA, 2004, ATMOS ENVIRON, V38, P4123, DOI 10.1016/j.atmosenv.2004.04.026; Fullerton DG, 2008, T ROY SOC TROP MED H, V102, P843, DOI 10.1016/j.trstmh.2008.05.028; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Gilliland F, 2005, ENVIRON HEALTH PERSP, V113, P1447, DOI 10.1289/ehp.7673; Golshan M, 2002, RESP MED, V96, P382, DOI 10.1053/rmed.2002.1288; Health Effects Institute, 2010, 17 HLTH EFF I; Hu GP, 2010, CHEST, V138, P20, DOI 10.1378/chest.08-2114; Jaakkola MS, 2006, AM J RESP CRIT CARE, V174, P851, DOI 10.1164/rccm.2604004; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Kelly FJ, 2011, CLIN EXP ALLERGY, V41, P1059, DOI 10.1111/j.1365-2222.2011.03776.x; Kipen H, 2010, ANN NY ACAD SCI, V1203, P160, DOI 10.1111/j.1749-6632.2010.05638.x; Kipen HM, 2011, ENVIRON HEALTH PERSP, V119, P658, DOI 10.1289/ehp.1002784; Kunzli N, 2009, THORAX, V64, P664, DOI 10.1136/thx.2008.110031; Kurmi OP, 2010, THORAX, V65, P221, DOI 10.1136/thx.2009.124644; Li Y, 2010, SCI TOTAL ENVIRON, V408, P1226, DOI 10.1016/j.scitotenv.2009.11.035; Lin WW, 2011, ENVIRON HEALTH PERSP, V119, P1507, DOI 10.1289/ehp.1103461; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Mackay J, 2002, TOBACCO ATLAS; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Mishra V, 2003, ENVIRON HEALTH PERSP, V111, P71, DOI 10.1289/ehp.5559; Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875; Noorhassim I, 1995, Med J Malaysia, V50, P263; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; O'Brien KL, 2009, LANCET, V374, P893, DOI 10.1016/S0140-6736(09)61204-6; Orozco-Levi M, 2006, EUR RESPIR J, V27, P542, DOI 10.1183/09031936.06.00052705; Padhi BK, 2008, ANN NY ACAD SCI, V1140, P209, DOI 10.1196/annals.1454.015; Peden D, 2010, J ALLERGY CLIN IMMUN, V125, pS150, DOI 10.1016/j.jaci.2009.10.073; Peel Jennifer L, 2010, Res Rep Health Eff Inst, P3; Peel JL, 2010, RES REP HLTH EFF I, P25; Penard-Morand C, 2010, EUR RESPIR J, V36, P33, DOI 10.1183/09031936.00116109; Po JYT, 2011, THORAX, V66, P232, DOI 10.1136/thx.2010.147884; Pruss-Ustun A, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-7; Qureshi K A, 1994, Indian J Chest Dis Allied Sci, V36, P61; Reddy A., 1996, ENERGY RIO PROSPECTS; Regalado J, 2006, AM J RESP CRIT CARE, V174, P901, DOI 10.1164/rccm.200503-479OC; Rehfuess E, 2006, B WORLD HEALTH ORGAN, V84, P508, DOI 10.2471/BLT.06.032979; Romieu Isabelle, 2010, Proc Am Thorac Soc, V7, P116, DOI 10.1513/pats.200909-097RM; Romieu I, 2009, AM J RESP CRIT CARE, V180, P649, DOI 10.1164/rccm.200810-1556OC; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a; Sehlstedt M, 2010, INHAL TOXICOL, V22, P1144, DOI 10.3109/08958378.2010.529181; Shetty N, 2006, INT J TUBERC LUNG D, V10, P80; Slama K, 2010, INT J TUBERC LUNG D, V14, P6; Smith KR, 2011, LANCET, V378, P1717, DOI 10.1016/S0140-6736(11)60921-5; SMITH KR, 1993, ANNU REV ENERG ENV, V18, P529, DOI 10.1146/annurev.energy.18.1.529; Smith K, 2004, COMP QUANTIFICATION, P1435; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Torres-Duque Carlos, 2008, Proc Am Thorac Soc, V5, P577, DOI 10.1513/pats.200707-100RP; Trupin L, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-24; US Environmental Protection Agency, AIR QUAL CRIT PART M; Utell MJ, 2000, J AEROSOL MED, V13, P355, DOI 10.1089/jam.2000.13.355; Uzun Kursat, 2003, Environ Health Prev Med, V8, P13, DOI 10.1007/BF02897938; WEISEL CP, 1995, ENVIRON HEALTH PERSP, V103, P97, DOI 10.2307/3432456; Centre WM, 2011, WHO FACT SHEET 313; Yang HM, 2001, ENVIRON HEALTH PERSP, V109, P515, DOI 10.2307/3454711; Zhang JJ, 2007, ENVIRON HEALTH PERSP, V115, P848, DOI 10.1289/ehp.9479; Zhou HW, 2007, AM J RESP CELL MOL, V36, P460, DOI 10.1165/rcmb.2006-0293OC; Zhou Y, 2008, ATMOS ENVIRON, V42, P3087, DOI 10.1016/j.atmosenv.2007.12.037; Zhu YF, 2004, AEROSOL SCI TECH, V38, P5, DOI 10.1080/02786820390229156; Zhu YF, 2008, J AIR WASTE MANAGE, V58, P424, DOI 10.3155/1047-3289.58.3.424; Zuraimi MS, 2011, PEDIAT ALLERG IMM-UK, V22, pe112, DOI 10.1111/j.1399-3038.2010.00992.x; Zuurbier M, 2011, ENVIRON HEALTH PERSP, V119, P1384, DOI 10.1289/ehp.1003151; Zuurbier M, 2011, EPIDEMIOLOGY, V22, P219, DOI 10.1097/EDE.0b013e3182093693; Zuurbier M, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-48	92	115	118	6	77	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					3	13		10.1016/j.jaci.2011.11.021		11	Allergy; Immunology	Allergy; Immunology	869XT	WOS:000298634000002	22196520	
J	Gill, MA; Bajwa, G; George, TA; Dong, CC; Dougherty, II; Jiang, N; Gan, VN; Gruchalla, RS				Gill, Michelle A.; Bajwa, Gagan; George, Tiffany A.; Dong, Caroline C.; Dougherty, Irene I.; Jiang, Nan; Gan, Vanthaya N.; Gruchalla, Rebecca S.			Counterregulation between the Fc epsilon RI Pathway and Antiviral Responses in Human Plasmacytoid Dendritic Cells	JOURNAL OF IMMUNOLOGY			English	Article							INTERFERON-PRODUCING CELLS; ANTIGEN-PRESENTING CELLS; TOLL-LIKE RECEPTOR-9; ATOPIC-DERMATITIS; ASTHMA; VIRUS; EXPRESSION; IMMUNITY; ALPHA; IGE	Plasmacytoid dendritic cells (pDCs) play essential roles in directing immune responses. These cells may be particularly important in determining the nature of immune responses to viral infections in patients with allergic asthma as well those with other atopic diseases. The purposes of this study were 1) to compare the functional capacity of pDCs in patients with one type of allergic disorder, allergic asthma, and controls; 2) to determine whether IgE cross-linking affects antiviral responses of influenza-exposed pDCs; and 3) to determine whether evidence of counterregulation of Fc epsilon RIa and IFN-alpha pathways exists in these cells. pDC function was assessed in a subset of asthma patients and in controls by measuring IFN-alpha production after exposure of purified pDCs to influenza viruses. Fc epsilon RIa expression on pDCs was determined by flow cytometry in blood samples from patients with allergic asthma and controls. pDCs from patients with asthma secreted significantly less IFN-alpha upon exposure to influenza A (572 versus 2815; p = 0.03), and secretion was inversely correlated with serum IgE levels. Moreover, IgE cross-linking prior to viral challenge resulted in 1) abrogation of the influenza-induced pDC IFN-alpha response; 2) diminished influenza and gardiquimod-induced TLR-7 upregulation in pDCs; and 3) interruption of influenza-induced upregulation of pDC maturation/ costimulatory molecules. In addition, exposure to influenza and gardiquimod resulted in upregulation of TLR-7, with concomitant downregulation of Fc epsilon RIa expression in pDCs. These data suggest that counterregulation of Fc epsilon RI and TLR-7 pathways exists in pDCs, and that IgE cross-linking impairs pDC antiviral responses. The Journal of Immunology, 2010, 184: 5999-6006.	[Gill, Michelle A.; George, Tiffany A.; Dong, Caroline C.; Dougherty, Irene I.; Jiang, Nan; Gruchalla, Rebecca S.] Univ Texas SW Med Ctr Dallas, Div Allergy & Immunol, Dept Internal Med, Dallas, TX 75290 USA; [Gill, Michelle A.; Bajwa, Gagan] Univ Texas SW Med Ctr Dallas, Div Pediat Infect Dis, Dallas, TX 75290 USA; [Gill, Michelle A.; Bajwa, Gagan] Univ Texas SW Med Ctr Dallas, Div Pulm Vasc Biol, Dallas, TX 75290 USA; [Gan, Vanthaya N.] Univ Texas SW Med Ctr Dallas, Div Gen Pediat, Dept Pediat, Dallas, TX 75290 USA; Childrens Med Ctr Dallas, Dallas, TX 75290 USA	Gill, MA (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Room F3-202,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	michelle.gill@utsouthwestern.edu			Exxon Mobil Corporation; National Institutes of Health, National Institute of Allergy and Infectious Diseases [5 RO1 AI049570]	This work was supported by grants from Exxon Mobil Corporation (to M. G. and R. G.) and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (no. 5 RO1 AI049570, to R. G.).	Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bufe A, 2002, INT ARCH ALLERGY IMM, V127, P82, DOI 10.1159/000048173; Busse W.W., 2003, J ALLERGY CLIN IMMUN, V111, P799; Cao W, 2006, J EXP MED, V203, P1399, DOI 10.1084/jem.20052454; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Colonna M, 2004, NAT IMMUNOL, V5, P1219, DOI 10.1038/ni1141; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Friedlander Samuel L, 2005, Pediatr Infect Dis J, V24, pS170, DOI 10.1097/01.inf.0000187273.47390.01; Friedlander SL, 2005, PEDIATR INFECT DIS J, V24, pS174; Gehlhar K, 2006, CLIN EXP ALLERGY, V36, P331, DOI 10.1111/j.1365-2222.2006.02450.x; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; Gern JE, 2003, J PEDIATR-US, V142, pS9, DOI 10.1067/mpd.2003.20; Gern JE, 2003, J PEDIAT, V142, pS13; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hashizume H, 2005, J IMMUNOL, V174, P2396; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Jahnsen FL, 2000, J IMMUNOL, V165, P4062; Kadowaki N, 2002, HUM IMMUNOL, V63, P1126, DOI 10.1016/S0198-8859(02)00751-6; Liu YJ, 2005, ANNU REV IMMUNOL, V23, P275, DOI 10.1146/annurev.immunol.23.021704.115633; Lund JM, 2004, P NATL ACAD SCI USA, V101, P5598, DOI 10.1073/pnas.0400937101; Maurer D, 1998, J IMMUNOL, V161, P2731; Novak N, 2004, CURR ALLERGY ASTHM R, V4, P263, DOI 10.1007/s11882-004-0069-2; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Schroeder JT, 2008, J ALLERGY CLIN IMMUN, V121, P486, DOI 10.1016/j.jaci.2007.09.049; Schroeder JT, 2005, J IMMUNOL, V175, P5724; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; van Rijt LS, 2005, J CLIN VIROL, V34, P161, DOI 10.1016/j.jcv.2005.07.002; Van Rijt LS, 2005, CLIN EXP ALLERGY, V35, P1125, DOI 10.1111/j.1365-2222.2005.02321.x	32	115	117	0	6	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUN 1	2010	184	11					5999	6006		10.4049/jimmunol.0901194		8	Immunology	Immunology	606PP	WOS:000278439600011	20410486	
J	Renz-Polster, H; David, MR; Buist, AS; Vollmer, WM; O'Connor, EA; Frazier, EA; Wall, MA				Renz-Polster, H; David, MR; Buist, AS; Vollmer, WM; O'Connor, EA; Frazier, EA; Wall, MA			Caesarean section delivery and the risk of allergic disorders in childhood	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic rhinoconjunctivitis; asthma; atopic dermatitis; atopy; allergy; Caesarean section; intestinal flora; intestinal microbes; risk of allergic disorders	PLACEBO-CONTROLLED TRIAL; HAY-FEVER; ATOPIC DISEASE; BACTERIAL-FLORA; ASTHMA; CHILDREN; MODE; LIFE; INTERLEUKIN-10; COMPLICATIONS	Background The composition of the intestinal flora in young children, if unfavourable, may increase the susceptibility to allergic disorders. Beneficial intestinal microbes originate from the maternal vaginal tract and thus are more likely to be transferred during vaginal births than during Caesarean sections (C-sections). Objective To determine whether children born by C-section have a different risk of allergic disorders compared with those delivered vaginally. We also tested the hypothesis that the risk of allergic disorders is highest for children born after 'repeat C-sections'. Methods A retrospective cohort study of 8953 children aged 3-10 years. Children diagnosed with allergic rhinoconjunctivitis (AR), asthma, atopic dermatitis (AD), or food allergies were identified from the Kaiser Permanente Northwest Region electronic records. The children's sex, birth weight, birth order, postnatal exposure to antibiotics as well as the mothers' age, ethnicity, education, marital status, smoking status during pregnancy, and use of asthma or hayfever medications were identified through the mothers' medical records or through the Oregon Birth Registry. Results The risk of being diagnosed with AR was significantly higher in the children born by C-section than in those delivered vaginally: adjusted odds ratio (OR)=1.37%, 95% confidence interval (CI)=1.14-1.63. Delivery by C-section was also associated with the subsequent diagnosis of asthma (OR=1.24%, 95% CI=1.01-1.53); this association was gender specific, with a positive association restricted to girls (OR for asthma in girls: OR=1.53%, 95% CI=1.11-2.10; in boys: OR=1.08%, 95% CI=0.81-1.43). There was no significant association between mode of delivery and AD. If children born in a 'repeat C-section' were considered separately the risk of being diagnosed with AR increased further (OR=1.78%, 95% CI=1.34-2.37). The same increase was noted for asthma in girls (OR=1.83%, 95% CI=1.13-2.97) but not in boys. Conclusion Caesarean sections may be associated with an increased risk of developing AR in childhood.	Oregon Hlth Sci Univ, Portland, OR 97201 USA; Kaiser Permanente Ctr Hlth Res, Portland, OR USA	Renz-Polster, H (reprint author), Rohrmoos 10, D-88267 Vogt, Germany.	renzpoh@pol.net	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; ANNIBALE DJ, 1995, ARCH PEDIAT ADOL MED, V149, P862; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Butland BK, 1997, BRIT MED J, V315, P717; Chapman DJ, 1999, J AM DIET ASSOC, V99, P450, DOI 10.1016/S0002-8223(99)00109-1; Demissie K, 1998, AM J RESP CRIT CARE, V158, P1091; DiMatteo MR, 1996, HEALTH PSYCHOL, V15, P303; Gronlund MM, 1999, CLIN EXP IMMUNOL, V116, P521; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Hakansson S, 2003, CLIN EXP ALLERGY, V33, P757, DOI 10.1046/j.1365-2222.2003.01667.x; HALL MA, 1990, ARCH DIS CHILD, V65, P185; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; JENKINS MA, 1994, BRIT MED J, V309, P90; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Laubereau B, 2004, ARCH DIS CHILD, V89, P993, DOI 10.1136/adc.2003.043265; Leung GM, 2002, OBSTET GYNECOL, V99, P785, DOI 10.1016/S0029-7844(02)01940-3; Maitra A, 2004, CLIN EXP ALLERGY, V34, P1349, DOI 10.1111/j.1365-2222.2004.02048.x; Martinez F D, 1999, Lancet, V354 Suppl 2, pSII12, DOI 10.1016/S0140-6736(99)90437-3; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Negele K, 2004, PEDIAT ALLERG IMM-UK, V15, P48, DOI 10.1046/j.0905-6157.2003.00101.x; Pearce N, 1999, THORAX, V54, P268; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; ROTIMI VO, 1981, J MED MICROBIOL, V14, P51; Salminen S, 2004, GUT, V53, P1388, DOI 10.1136/gut.2004.041640; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Smith GCS, 2004, ARCH DIS CHILD, V89, P956, DOI 10.1136/adc.2003.045971; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Sudo N, 1997, J IMMUNOL, V159, P1739; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2000, J ASTHMA, V37, P589, DOI 10.3109/02770900009090814; [Anonymous], 1993, MMWR MORB MORTAL WKL, V42, P285	48	115	127	1	22	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2005	35	11					1466	1472		10.1111/j.1365-2222.2005.02356.x		7	Allergy; Immunology	Allergy; Immunology	982NR	WOS:000233169400009	16297144	
J	Sicherer, SH				Sicherer, SH			Food protein-induced enterocolitis syndrome: Case presentations and management lessons	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; food protein-induced enterocolitis syndrome	COWS MILK ALLERGY; EPITHELIAL BARRIER FUNCTION; NECROSIS-FACTOR-ALPHA; ATOPY PATCH TEST; GASTROINTESTINAL MANIFESTATIONS; CLINICAL-FEATURES; SKIN PRICK; TNF-ALPHA; INFANTS; SOY	Enterocolitis induced in infants by cow's milk and/or soy protein has been recognized for decades. Symptoms typically begin in the first month of life in association with failure to thrive and may progress to acidemia and shock. Symptoms resolve after the causal protein is removed from the diet but recur with a characteristic symptom pattern on re-exposure. Approximately 2 hours after reintroduction of the protein, vomiting ensues, followed by an elevation of the peripheral blood polymorphonuclear leukocyte count, diarrhea, and possibly lethargy and hypotension. The disorder is generally not associated with detectable food-specific IgE antibody. There are increasing reports of additional causal foods, prolonged clinical courses, and onset outside of early infancy, leading to description of a food protein-induced enterocolitis syndrome. The disorder poses numerous diagnostic and therapeutic challenges. The purpose of this report is to delineate the characteristic clinical features and review the possible pathophysiologic basis to frame a rational strategy toward management.	Mt Sinai Sch Med, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Div Allergy & Immunol, New York, NY USA	Sicherer, SH (reprint author), Mt Sinai Hosp, Jaffe Food Allergy Inst, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu					Benlounes N, 1996, J ALLERGY CLIN IMMUN, V98, P781, DOI 10.1016/S0091-6749(96)70127-6; Benlounes N, 1999, J ALLERGY CLIN IMMUN, V104, P863; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Burks A W, 1994, Pediatr Allergy Immunol, V5, P40, DOI 10.1111/j.1399-3038.1994.tb00217.x; Busse PJ, 2000, J ALLERGY CLIN IMMUN, V105, pS129, DOI 10.1016/S0091-6749(00)90815-7; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; COELLORAMIREZ P, 1984, J PEDIATR GASTR NUTR, V3, P215, DOI 10.1097/00005176-198403000-00008; de Boissieu D, 2003, J PEDIATR-US, V142, P203, DOI 10.1067/mpd.2003.92; FONTAINE JL, 1975, ARCH DIS CHILD, V50, P357; GOLDMAN H, 1986, AM J SURG PATHOL, V10, P75, DOI 10.1097/00000478-198602000-00001; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; HALPIN TC, 1977, J PEDIATR-US, V91, P404, DOI 10.1016/S0022-3476(77)81308-5; HEYMAN M, 1994, GASTROENTEROLOGY, V106, P1514; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; Hoffman KM, 1997, J ALLERGY CLIN IMMUN, V99, P360, DOI 10.1016/S0091-6749(97)70054-X; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Jarvinen KM, 1999, J PEDIATR-US, V135, P506, DOI 10.1016/S0022-3476(99)70175-7; JENKINS HR, 1984, ARCH DIS CHILD, V59, P326; Kapel N, 1999, CLIN CHEM LAB MED, V37, P29, DOI 10.1515/CCLM.1999.004; KELSO JM, 1993, J ALLERGY CLIN IMMUN, V92, P909, DOI 10.1016/0091-6749(93)90069-R; Levy Y, 2003, PEDIATR ALLERGY IMMU, V14, P325, DOI 10.1034/j.1399-3038.2003.00039.x; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; Majamaa H, 2001, CLIN EXP ALLERGY, V31, P590, DOI 10.1046/j.1365-2222.2001.01035.x; MCDONALD PJ, 1984, PEDIATR RES, V18, P751, DOI 10.1203/00006450-198408000-00016; MURRAY KF, 1993, J PEDIATR-US, V122, P90, DOI 10.1016/S0022-3476(05)83495-X; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Perackis K, 2003, J ALLERGY CLIN IMMUN, V112, P625, DOI 10.1067/mai.2003.1656; Planchon S, 1999, J CELL PHYSIOL, V181, P55, DOI 10.1002/(SICI)1097-4652(199910)181:1<55::AID-JCP6>3.0.CO;2-M; PLANCHON SM, 1994, J IMMUNOL, V153, P5730; POWELL G K, 1986, Comprehensive Therapy, V12, P28; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; POWELL GK, 1976, J PEDIATR-US, V88, P840, DOI 10.1016/S0022-3476(76)81128-6; Rubin MI, 1940, AM J MED SCI, V200, P385, DOI 10.1097/00000441-194009000-00014; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sampson Hugh A., 2003, Journal of Allergy and Clinical Immunology, V111, pS540; Sicherer SH., 2000, J PEDIAT GASTROENT S, V30, P45; Sicherer SH, 2003, PEDIATRICS, V111, P1609; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7; Sicherer SH, 1999, PEDIATR ALLERGY IMMU, V10, P226, DOI 10.1034/j.1399-3038.1999.00040.x; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI 10.1016/mai.2003.1681; VANDENPLAS Y, 1994, J PEDIATR GASTR NUTR, V19, P240, DOI 10.1097/00005176-199408000-00016; VANSICKLE GJ, 1985, GASTROENTEROLOGY, V88, P1915; VITORIA JC, 1982, ARCH DIS CHILD, V57, P44	44	115	120	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					149	156		10.1016/j.jaci.2004.09.033		8	Allergy; Immunology	Allergy; Immunology	886XS	WOS:000226267000022	15637562	
J	Terreehorst, I; Hak, E; Oosting, AJ; Tempels-Pavlica, Z; de Monchy, JGR; Bruijnzeel-Koomen, CAFM; Aalberse, RC; Gerth van Wijk, R				Terreehorst, I; Hak, E; Oosting, AJ; Tempels-Pavlica, Z; de Monchy, JGR; Bruijnzeel-Koomen, CAFM; Aalberse, RC; Gerth van Wijk, R			Evaluation of impermeable covers for bedding in patients with allergic rhinitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOUSE-DUST-MITE; PERENNIAL RHINITIS; INTRANASAL CAPSAICIN; MATTRESS ENCASINGS; ASTHMATIC-PATIENTS; AVOIDANCE MEASURES; ATOPIC-DERMATITIS; CUTOFF VALUES; DOUBLE-BLIND; CHILDREN	Background: Encasing bedding in impermeable covers reduces exposure to house-dust mites, but the clinical benefit of this intervention as part of mite-avoidance measures for patients with allergic rhinitis is not known. We performed a multicenter, randomized, placebo-controlled trial of one year of use of impermeable bedding covers in the bedrooms of patients with rhinitis who were sensitized to house-dust mites to determine the effects on the signs and symptoms of disease. Methods: Three participating university medical centers enrolled 279 patients with allergic rhinitis who were randomly assigned to receive impermeable or non-impermeable (control) covers for their mattress, pillow, and duvet or blanket. At the start of the study, all participants received information on general allergen-avoidance measures. The severity of rhinitis was measured on a rhinitis-specific visual-analogue scale and by means of a daily symptom score and nasal allergen provocation testing. We also measured the concentrations of Dermatophagoides pteronyssinus (Der p1) and D. farinae (Der f 1) in dust from patients' mattresses, bedroom floors, and living-room floors at base line and after 12 months as a measure of the efficacy of the intervention. Results: A total of 232 patients completed the study. There was a significant reduction in Der p1 and Der f 1 concentrations in the mattresses of the impermeable-cover group, whereas there was no significant reduction in the control group. However, there was no significant effect on the clinical outcome measures. Analyses of subgroups defined according to age, level of exposure, type and severity of sensitization, or characteristics of the patient's home had similar results. Conclusions: Mite-proof bedding covers, as part of a structured allergy-control program, reduced the level of exposure to mite allergens. Despite the success of the intervention, this single avoidance measure did not lead to a significant improvement of clinical symptoms in patients with allergic rhinitis.	Erasmus Med Ctr, Dept Allergol, NL-3015 GD Rotterdam, Netherlands; Albert Scheitzer Hosp, Dept Internal Med, Dordrecht, Netherlands; Univ Utrecht, Med Ctr, Dept Dermatol, Utrecht, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands; Sanquin Res, Dept Immunopathol, Amsterdam, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Gerth van Wijk, R (reprint author), Erasmus Med Ctr, Dept Allergol, Dr Molewaterplein 40, NL-3015 GD Rotterdam, Netherlands.			Terreehorst, Ingrid/0000-0002-3264-2740			Ad Hoc Working group on environmental allergens and asthma, 1999, J ALLERGY CLIN IMMUN, V103, P203; *AM AC ALL ASTHM I, 2001, ALL REP 2000; BEAUMONT F, 1985, ALLERGY, V40, P181, DOI 10.1111/j.1398-9995.1985.tb00214.x; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; de Graaf-in 't Veld T, 1995, Ann Allergy Asthma Immunol, V75, P261; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; deGraafintVeld C, 1997, THORAX, V52, P143; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Herman D, 1997, INT J PEDIATR OTORHI, V39, P1, DOI 10.1016/S0165-5876(96)01457-7; International Consensus Report on the diagnosis and management of rhinitis, 1994, ALLERGY S19, V49, P1; Koepke JW, 1999, ALLERGY ASTHMA PROC, V20, P337; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Malm L, 2000, RHINOLOGY, V38, P1; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; Moon JS, 1999, YONSEI MED J, V40, P238; NIEMEIJER NR, 1993, ALLERGY, V48, P491, DOI 10.1111/j.1398-9995.1993.tb01104.x; NIEMEIJER NR, 1993, ALLERGY, V48, P498, DOI 10.1111/j.1398-9995.1993.tb01105.x; Oosting AJ, 2002, J ALLERGY CLIN IMMUN, V110, P500, DOI 10.1067/mai.2002.126791; Sheikh A, 2001, COCHRANE DB SYST REV, V4; Terreehorst I, 2002, CLIN EXP ALLERGY, V32, P1160, DOI 10.1046/j.1365-2745.2002.01461.x; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693; Van Wijk RG, 2000, CLIN EXP ALLERGY, V30, P1792, DOI 10.1046/j.1365-2222.2000.00920.x; vanderHeide S, 1997, ALLERGY, V52, P921; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; VANREE R, 1994, ALLERGY, V49, P254; VARNEY VA, 1991, BRIT MED J, V302, P265; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262	34	115	122	0	7	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					237	246		10.1056/NEJMoa023171		10	Medicine, General & Internal	General & Internal Medicine	701KA	WOS:000184165700007	12867607	
J	Leikauf, GD				Leikauf, GD			Hazardous air pollutants and asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						acrolein; aldehydes; asthma; cadmium; chromium; formaldehyde; hazardous air pollutants; metals; nickel; ozone; particulate matter; urban air toxics	VOLATILE ORGANIC-COMPOUNDS; DIESEL EXHAUST PARTICLES; ENVIRONMENTAL TOBACCO-SMOKE; INDUCED OCCUPATIONAL ASTHMA; HYDROGEN-SULFIDE EXPOSURE; TOLUENE DIISOCYANATE TDI; MOLECULAR-WEIGHT AGENTS; QUANTITATIVE TRAIT LOCI; EMERGENCY ROOM VISITS; HUMAN-SERUM-ALBUMIN	Asthma has a high prevalence in the United States, and persons with asthma may be at added risk from the adverse effects of hazardous air pollutants (HAPs). Complex mixtures (fine particulate matter and tobacco smoke) have been associated with respiratory symptoms and hospital admissions for asthma. The toxic ingredients of these mixtures are HAPs, but whether ambient HAP exposures. can induce asthma remains unclear. Certain HAPs are occupational asthmagens, whereas others may act as adjuncts during sensitization. HAPs may exacerbate asthma because, once sensitized, individuals can respond to remarkably low concentrations, and irritants lower the bronchoconstrictive threshold to respiratory antigens. Adverse responses after ambient exposures to complex mixtures often occur at concentrations below those producing effects in controlled human exposures to a single compound. In addition, certain HAPs that have been associated with asthma in occupational settings may interact with criteria pollutants in ambient air to exacerbate asthma. Based on these observations and past experience with 188 HAPs, a list of 19 compounds that could have the highest impact on the induction or exacerbation of asthma was developed. Nine additional compounds were identified that might exacerbate asthma based on their irritancy, respirability, or ability to react with biological macromolecules. Although the ambient levels of these 28 compounds are largely unknown, estimated exposures from emissions inventories and limited air monitoring suggest that aldehydes (especially acrolein and formaldehyde) and metals (especially nickel and chromium compounds) may have possible health risk indices sufficient for additional attention. Recommendations for research are presented regarding exposure monitoring and evaluation of biologic mechanisms controlling how these substances induce and exacerbate asthma. Key words: acrolein, aldehydes, asthma, cadmium, chromium, formaldehyde, hazardous air pollutants, metals, nickel, ozone, particulate matter, urban air toxics.	Univ Cincinnati, Ctr Environm Genet, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Ctr Environm Genet, Dept Pulm & Crit Care Med, Cincinnati, OH 45267 USA	Leikauf, GD (reprint author), Univ Cincinnati, Ctr Environm Genet, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.				NHLBI NIH HHS [HL-65612, HL-65613]; NIEHS NIH HHS [ES06096, ES10562]		ABE Y, 1993, CLIN EXP ALLERGY, V23, P512, DOI 10.1111/j.1365-2222.1993.tb03239.x; *ACGIH, 2001, THR LIM VAL CHEM SUB; Adgate JL, 2000, J EXPO ANAL ENV EPID, V10, P650; AGIUS RM, 1994, OCCUP MED-OXFORD, V44, P34, DOI 10.1093/occmed/44.1.34; AGIUS RM, 1991, ANN OCCUP HYG, V35, P129, DOI 10.1093/annhyg/35.2.129; Agius RM, 2000, OCCUP MED, V15, P369; AkbarKhanzadeh F, 1997, OCCUP ENVIRON MED, V54, P296; ALBERT R E, 1975, Environmental Health Perspectives, V11, P209, DOI 10.2307/3428343; Alberts W M, 1996, Curr Opin Pulm Med, V2, P104, DOI 10.1097/00063198-199603000-00005; Albright JF, 1996, OTOLARYNG HEAD NECK, V114, P232, DOI 10.1016/S0194-5998(96)70173-0; ALEXANDERSSON R, 1982, INT ARCH OCC ENV HEA, V49, P275, DOI 10.1007/BF00377936; Altmuller J, 2001, AM J HUM GENET, V69, P936, DOI 10.1086/324069; ALTSHULLER AP, 1983, ATMOS ENVIRON, V17, P2131, DOI 10.1016/0004-6981(83)90211-1; ALTSHULLER AP, 1978, JAPCA J AIR WASTE MA, V28, P594; ALTSHULLER AP, 1993, ATMOS ENVIRON A-GEN, V27, P21, DOI 10.1016/0960-1686(93)90067-9; ALTSHULLER AP, 1965, PHOTOCHEM PHOTOBIOL, V4, P97, DOI 10.1111/j.1751-1097.1965.tb05731.x; *AM LUNG ASS, 1993, BREATH DANG, V2; AMDUR MO, 1983, AM IND HYG ASSOC J, V44, P7; ANDERSEN LI, 1986, CHEST, V90, P358, DOI 10.1378/chest.90.3.358; Anderson HR, 1996, BRIT MED J, V312, P665; ANDERSON LM, 1994, CARCINOGENESIS, V15, P2245, DOI 10.1093/carcin/15.10.2245; Anderson MJ, 2001, J EXPO ANAL ENV EPID, V11, P295, DOI 10.1038/sj.jea.7500168; ANDERSON MW, 1993, CARCINOGENESIS, V14, P787, DOI 10.1093/carcin/14.5.787; ANDREWS FJ, 1991, BRIT J DERMATOL, V124, P29, DOI 10.1111/j.1365-2133.1991.tb03278.x; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ARIS R, 1990, AM REV RESPIR DIS, V141, P546; Asano S, 2000, PATHOL INT, V50, P169, DOI 10.1046/j.1440-1827.2000.01032.x; ASHBY J, 1993, ENVIRON HEALTH PERSP, V101, P62, DOI 10.2307/3431573; ASHERSON GL, 1968, IMMUNOLOGY, V15, P405; Aylin P, 2001, THORAX, V56, P228, DOI 10.1136/thorax.56.3.228; BABIUK C, 1985, TOXICOL APPL PHARM, V79, P143, DOI 10.1016/0041-008X(85)90376-X; Baik Jae-Joong, 1995, Journal of Korean Medical Science, V10, P200; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P201; BARNES PJ, 1993, ANNU REV MED, V44, P229, DOI 10.1146/annurev.med.44.1.229; BARNES PJ, 1989, NEW ENGL J MED, V321, P1517; BARNES PJ, 1992, ASTHMA BASIC MECH CL; BARSELA S, 1992, ISRAEL J MED SCI, V28, P578; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BATES MN, 1992, AM J EPIDEMIOL, V135, P462; BAUER MA, 1986, AM REV RESPIR DIS, V134, P1203; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; Beach JR, 1997, EUR RESPIR J, V10, P563; Becklake Margaret R., 1993, P29; Bernstein DI, 1997, JAMA-J AM MED ASSOC, V278, P1907, DOI 10.1001/jama.278.22.1907; BERNSTEIN IL, 1989, J ALLERGY CLIN IMMUN, V83, P173; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; Bernstein IL, 1993, ASTHMA WORKPLACE; Bertazzi PA, 2001, AM J EPIDEMIOL, V153, P1031, DOI 10.1093/aje/153.11.1031; Blair A, 1997, CANCER CAUSE CONTROL, V8, P473, DOI 10.1023/A:1018417623867; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Bogdanffy MS, 1999, TOXICOL SCI, V51, P19, DOI 10.1093/toxsci/51.1.19; BOORMAN GA, 1987, ENVIRON HEALTH PERSP, V72, P63, DOI 10.2307/3430277; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V277, pL489; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; BOULET LP, 1988, CHEST, V94, P47; BOUSHEY HA, 1980, AM REV RESPIR DIS, V121, P389; BRAUN J, 1984, ARCH TOXICOL, V56, P50, DOI 10.1007/BF00316353; Bright P, 1997, THORAX, V52, P28; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Brooks Stuart M., 1993, P533; Buick JB, 2000, AM J IND MED, V37, P296, DOI 10.1002/(SICI)1097-0274(200003)37:3<296::AID-AJIM8>3.0.CO;2-2; Burg JR, 1998, TOXICOL IND HEALTH, V14, P367; BURGE PS, 1986, BRIT J IND MED, V43, P559; Burgess JL, 2001, J TOXICOL-CLIN TOXIC, V39, P165; BURNOUF T, 1994, ANIMAL CELL TECHNOLO, V6, P17; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P146, DOI 10.1016/0091-6749(79)90049-6; Butterworth BE, 1999, REGUL TOXICOL PHARM, V29, P23, DOI 10.1006/rtph.1998.1273; Byrd DM, 1996, INT ARCH OCC ENV HEA, V68, P484; *CA EPA, 2001, AIR TOX HOT SPOT P 3; *CAL AIR RES BOARD, 2001, ID PART EM DIES FUEL; CALABRESE EJ, 1991, AIR TOXICS TISK ASSE; *CALAIR, 1993, CALAIR AIR TOX HOT S; Cassee FR, 1996, ARCH TOXICOL, V70, P329, DOI 10.1007/s002040050282; CDC (Centers for Disease Control and Prevention), 2001, NAT REP HUM EXP ENV; CELLI B, 1976, NEW ENGL J MED, V295, P883, DOI 10.1056/NEJM197610142951609; CHARAN NB, 1979, AM REV RESPIR DIS, V119, P555; CHEN LC, 1992, J TOXICOL ENV HEALTH, V35, P165; CHESTNUT LG, 1991, ARCH ENVIRON HEALTH, V46, P135; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; CHOW JC, 1992, ATMOS ENVIRON A-GEN, V26, P3335, DOI 10.1016/0960-1686(92)90350-T; CHRISTIE D, 1992, MED J AUSTRALIA, V156, P841; CIRLA AM, 1994, SCI TOTAL ENVIRON, V150, P85, DOI 10.1016/0048-9697(94)90133-3; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; COHEN MA, 1991, ATMOS ENVIRON B-URB, V25, P79, DOI 10.1016/0957-1272(91)90042-D; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Colilla S, 2001, GENET EPIDEMIOL, V21, pS266; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; COOKSON WOCM, 1989, LANCET, V1, P1292; COOPER JA, 1980, JAPCA-INT J AIR POLL, V30, P116; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; Corhay JL, 1998, EUR RESPIR J, V11, P272, DOI 10.1183/09031936.98.11020272; COURTEAU JP, 1994, OCCUP ENVIRON MED, V51, P219; CREECH HJ, 1952, CANCER RES, V12, P557; Daisey JM, 1998, J EXPO ANAL ENV EPID, V8, P313; DAlessandro A, 1996, CHEST, V109, P331, DOI 10.1378/chest.109.2.331; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DAVIES JE, 1986, J SOC OCCUP MED, V36, P29; Dawson SV, 2001, RISK ANAL, V21, P1, DOI 10.1111/0272-4332.211085; De Raeve H, 1998, AM J IND MED, V34, P169, DOI 10.1002/(SICI)1097-0274(199808)34:2<169::AID-AJIM10>3.0.CO;2-T; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118; De Zotti R, 2000, OCCUP ENVIRON MED, V57, P837, DOI 10.1136/oem.57.12.837; Dearman RJ, 1996, FUND APPL TOXICOL, V33, P24, DOI 10.1006/faat.1996.0139; Dearman RJ, 2000, J APPL TOXICOL, V20, P221, DOI 10.1002/(SICI)1099-1263(200005/06)20:3<221::AID-JAT651>3.3.CO;2-R; DEFLORA S, 1987, CANCER RES, V47, P4740; DEKORT WL, 1988, VET HUM TOXICOL, V30, P9; delaHoz RE, 1997, AM J IND MED, V31, P195, DOI 10.1002/(SICI)1097-0274(199702)31:2<195::AID-AJIM9>3.0.CO;2-Z; DEMETER SL, 1992, CHEST, V102, P984; Demnati R, 1998, EUR RESPIR J, V11, P922, DOI 10.1183/09031936.98.11040922; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DESANCTIS GT, 2001, J ALLERGY CLIN IMMUN, V105, P11; DESCHAMPS D, 1994, CHEST, V105, P1895, DOI 10.1378/chest.105.6.1895; DESCHAMPS D, 1992, BRIT J IND MED, V49, P523; DESJARDINS R, 1992, J TOXICOL ENV HEALTH, V37, P351; Devalia JL, 1999, INT ARCH ALLERGY IMM, V118, P437, DOI 10.1159/000024157; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Dezateux C, 2001, THORAX, V56, P680, DOI 10.1136/thorax.56.9.680; Diamond ML, 2001, CHEMOSPHERE, V44, P1655, DOI 10.1016/S0045-6535(00)00509-9; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, ALLERGY, V52, P52; Diller W F, 1985, Toxicol Ind Health, V1, P7; DOAK SMA, 1976, TOXICOLOGY, V6, P139, DOI 10.1016/0300-483X(76)90016-0; DOCKERY DW, 1992, ENVIRON RES, V59, P362, DOI 10.1016/S0013-9351(05)80042-8; DOCKERY DW, 1982, JAPCA J AIR WASTE MA, V32, P937; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; DOCKERY DW, 1981, ATMOS ENVIRON, V15, P335, DOI 10.1016/0004-6981(81)90036-6; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dodge R, 1980, Am J Ind Med, V1, P359, DOI 10.1002/ajim.4700010312; DOE JE, 1995, TOXICOL IND HEALTH, V11, P13; Doelman C J, 1990, Agents Actions Suppl, V31, P81; DOLOVICH J, 1984, BRIT J IND MED, V41, P51; Dong WM, 1998, TOXICOL SCI, V44, P63, DOI 10.1093/toxsci/44.1.63; DOOMSGOOSSENS A, 1983, CONTACT DERMATITIS, V9, P247, DOI 10.1111/j.1600-0536.1983.tb04385.x; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Dye JA, 2001, ENVIRON HEALTH PERSP, V109, P395, DOI 10.2307/3434787; DYKEWICZ MS, 1991, J ALLERGY CLIN IMMUN, V87, P48, DOI 10.1016/0091-6749(91)90212-7; Englyst V, 2001, SCI TOTAL ENVIRON, V273, P77, DOI 10.1016/S0048-9697(00)00843-3; EULER GL, 1987, ARCH ENVIRON HEALTH, V42, P213; EVANS JS, 1984, ENVIRON INT, V10, P55, DOI 10.1016/0160-4120(84)90233-2; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537; Ewart SL, 1996, AM J RESP CELL MOL, V14, P487; FAIRLEY D, 1990, ENVIRON HEALTH PERSP, V89, P159, DOI 10.2307/3430912; FERGUSON JS, 1991, TOXICOL APPL PHARM, V107, P253, DOI 10.1016/0041-008X(91)90207-U; FERRIS BG, 1979, AM REV RESPIR DIS, V120, P767; FIALA ES, 1987, CARCINOGENESIS, V8, P1947, DOI 10.1093/carcin/8.12.1947; FINGERHUT MA, 1991, NEW ENGL J MED, V324, P212, DOI 10.1056/NEJM199101243240402; FINNEGAN MJ, 1989, THORAX, V44, P238, DOI 10.1136/thx.44.3.238; FLURY KE, 1983, MAYO CLIN PROC, V58, P389; FORSBERG B, 1993, EUR RESPIR J, V6, P1109; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Fujimaki H, 2001, SCI TOTAL ENVIRON, V270, P113, DOI 10.1016/S0048-9697(00)00789-0; Gavett SH, 2001, INT ARCH ALLERGY IMM, V124, P109, DOI 10.1159/000053685; Gebel T, 1997, CHEM-BIOL INTERACT, V107, P131, DOI 10.1016/S0009-2797(97)00087-2; Ghilarducci DP, 1995, REV ENVIRON CONTAM T, V144, P95; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; GODNIC-CVAR J, 1990, Arhiv za Higijenu Rada i Toksikologiju, V41, P257; GOLD DR, 1992, CLIN CHEST MED, V13, P215; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GOODMAN G, 1991, REGUL TOXICOL PHARM, V14, P118, DOI 10.1016/0273-2300(91)90002-D; Gram TE, 1997, PHARMACOL REV, V49, P297; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; GREEN FHY, 1991, J APPL PHYSIOL, V70, P1943; GREEN MA, 1983, RES COMMUN CHEM PATH, V40, P337; GROSJEAN D, 1984, JAPCA J AIR WASTE MA, V34, P537; GROTH DH, 1986, J TOXICOL ENV HEALTH, V18, P607; HALLEE TJ, 1969, AM REV RESPIR DIS, V99, P430; HALLIDAY GM, 1986, CELL IMMUNOL, V99, P220, DOI 10.1016/0008-8749(86)90230-3; HALLIDAY GM, 1990, IMMUNOLOGY, V69, P97; HANRAHAN J P, 1990, American Review of Respiratory Disease, V141, pA282; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; HARKONEN H, 1983, AM REV RESPIR DIS, V128, P840; HARVING H, 1991, AM REV RESPIR DIS, V143, P751; HASAN FM, 1983, ARCH ENVIRON HEALTH, V38, P76; Haseman JK, 1997, MUTAT RES-FUND MOL M, V380, P3, DOI 10.1016/S0027-5107(97)00121-8; HATCH GE, 1986, J TOXICOL ENV HEALTH, V19, P43; HAYES JP, 1992, AM REV RESPIR DIS, V146, P1311; HAYES JP, 1991, THORAX, V46, P396, DOI 10.1136/thx.46.5.396; HECHT SS, 1989, CARCINOGENESIS, V10, P1475, DOI 10.1093/carcin/10.8.1475; HENRY RL, 1991, PEDIATR PULM, V11, P127, DOI 10.1002/ppul.1950110209; Herrstrom P, 1997, INT ARCH OCC ENV HEA, V69, P339, DOI 10.1007/s004200050157; Hertwich EG, 2001, CHEMOSPHERE, V44, P843, DOI 10.1016/S0045-6535(00)00517-8; Hertwich EG, 2001, ENVIRON TOXICOL CHEM, V20, P928, DOI 10.1897/1551-5028(2001)020<0928:HTPFLC>2.0.CO;2; Hertwich EG, 2001, ENVIRON SCI TECHNOL, V35, P142, DOI 10.1021/es9911061; Hessel PA, 1997, AM J IND MED, V31, P554, DOI 10.1002/(SICI)1097-0274(199705)31:5<554::AID-AJIM9>3.0.CO;2-T; HEUSSEN GAH, 1993, J TOXICOL ENV HEALTH, V38, P419, DOI 10.1080/15287399309531729; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hobbesland A, 1997, SCAND J WORK ENV HEA, V23, P342; Holberg CJ, 2001, J ALLERGY CLIN IMMUN, V108, P772, DOI 10.1067/mai.2001.119158; Holder JW, 1999, TOXICOL IND HEALTH, V15, P445; Holder JW, 1999, TOXICOL IND HEALTH, V15, P458; Holz O, 1999, AM J RESP CRIT CARE, V159, P776; HONG CB, 1981, J TOXICOL ENV HEALTH, V7, P909; HOPPENBROUWERS T, 1990, LUNG, V168, P335, DOI 10.1007/BF02718150; HOWARD PH, 1991, HDB ENV DEGRADATION, P261; Hsu CH, 2000, FREE RADICAL BIO MED, V28, P636, DOI 10.1016/S0891-5849(99)00277-4; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; HUANG JL, 1991, ARCH ENVIRON HEALTH, V46, P296; Hyvelin JM, 2000, TOXICOL APPL PHARM, V164, P176, DOI 10.1006/taap.1999.8879; *IARC, 1999, IARC MON EV CARC RIS, V71, P1309; *IARC, 1999, IARC MON EV CARC RIS, V71, P1079; IARC, 1986, IARC MON EV CARC RIS, V40, P83; IARC, 1999, IARC MONOGR EVAL C 3, V71, P1465; *IARC, 1993, IARC MON EV CARC RIS, V57, P271; IP M, 1989, J OCCUP ENVIRON MED, V31, P141; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Johnson E S, 1991, Crit Rev Toxicol, V21, P451; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kafoury RM, 1999, AM J RESP CRIT CARE, V160, P1934; KAMAT SR, 1992, ENVIRON HEALTH PERSP, V97, P241, DOI 10.2307/3431360; KANERVA L, 1995, CLIN EXP ALLERGY, V25, P432, DOI 10.1111/j.1365-2222.1995.tb01074.x; KAUFMAN J, 1971, ARCH ENVIRON HEALTH, V23, P29; KELMAN GR, 1986, HUM TOXICOL, V5, P57; KENNEDY SM, 1991, AM REV RESPIR DIS, V143, P74; KESTEN S, 1995, ANN ALLERG ASTHMA IM, V74, P269; Kielhorn J, 2000, ENVIRON HEALTH PERSP, V108, P579, DOI 10.2307/3434875; Kim CW, 2001, YONSEI MED J, V42, P440; KINNEY PL, 1991, ENVIRON RES, V54, P99, DOI 10.1016/S0013-9351(05)80094-5; Kinoshita M, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P959; KLEEME JC, 1987, CANCER RES, V47, P6074; KLEINMAN MT, 1983, J TOXICOL ENV HEALTH, V12, P815; Klepeis NE, 2001, J EXPO ANAL ENV EPID, V11, P231, DOI 10.1038/sj.jea.7500165; KOENIG JQ, 1983, AM REV RESPIR DIS, V128, P221; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; KOREN HS, 1992, ANN NY ACAD SCI, V641, P215, DOI 10.1111/j.1749-6632.1992.tb16545.x; KOUTRAKIS P, 1988, ATMOS ENVIRON, V22, P157, DOI 10.1016/0004-6981(88)90308-3; Kriebel D, 2001, ARCH ENVIRON HEALTH, V56, P11; KRYZANOWSKI M, 1990, ENVIRON RES, V52, P117; Kyle AD, 2001, PUBLIC HEALTH REP, V116, P32, DOI 10.1016/S0033-3549(04)50020-1; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Langard S, 2000, OCCUP ENVIRON MED, V57, P65, DOI 10.1136/oem.57.1.65; LATENDRESSE JR, 1995, FUND APPL TOXICOL, V27, P33, DOI 10.1006/faat.1995.1106; Leaderer BP, 1997, J PHARM PHARMACOL, V49, P39; LEADERER BP, 1990, RISK ANAL, V10, P19, DOI 10.1111/j.1539-6924.1990.tb01016.x; LEBOWITZ MD, 1990, INT ARCH OCC ENV H S, V62, P147; LEE BM, 1993, IMMUNOL LETT, V36, P117, DOI 10.1016/0165-2478(93)90042-Z; LEE CC, 1977, ENVIRON HEALTH PERSP, V21, P25; LEE HS, 1991, BRIT J IND MED, V48, P283; Lee JS, 1997, J FOOD DRUG ANAL, V5, P185; LEE KP, 1982, J NATL CANCER I, V68, P157; Leffler CT, 1999, ENVIRON HEALTH PERSP, V107, P599, DOI 10.2307/3434404; Leggett RW, 2001, HEALTH PHYS, V81, P450, DOI 10.1097/00004032-200110000-00010; LEIKAUF GD, 1993, AM J RESP CELL MOL, V9, P594; LEIKAUF GD, 1989, J APPL PHYSIOL, V66, P171; LEIKAUF GD, 1995, ENVIRON HEALTH PERSP, V103, P253, DOI 10.2307/3432382; Leikauf GD, 2000, INHAL TOXICOL, V12, P59, DOI 10.1080/08958378.2000.11463231; LEIKAUF GD, 2000, HUM EXP THEIR HLTH E, P409; Lemus R., 1998, Reviews on Environmental Health, V13, P91; LEONG BKJ, 1987, FUND APPL TOXICOL, V9, P645, DOI 10.1016/0272-0590(87)90171-0; LERMAN S, 1988, AM FAM PHYSICIAN, V38, P135; Leroyer C, 1998, RESPIRATION, V65, P403, DOI 10.1159/000029303; Leroyer C, 1998, OCCUP ENVIRON MED, V55, P356; Leroyer C, 1999, OCCUP ENVIRON MED, V56, P334; LILIS R, 1981, ENVIRON HEALTH PERSP, V41, P167, DOI 10.2307/3429311; Lim Hong Euy, 1998, Korean Journal of Internal Medicine, V13, P127; Lim Sung-Chul, 1996, Korean Journal of Internal Medicine (English Edition), V11, P87; LIPPMANN M, 1989, JAPCA J AIR WASTE MA, V39, P672; Lippmann M., 2000, ENV TOXICANTS HUMAN, P771; Lipsett M, 1999, AM J PUBLIC HEALTH, V89, P1009, DOI 10.2105/AJPH.89.7.1009; LOGAN W P D, 1953, Lancet, V1, P336; Luebke RW, 2001, TOXICOL SCI, V62, P71, DOI 10.1093/toxsci/62.1.71; LUO JCJ, 1988, BR J IND MED, V47, P67; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; Mackay D., 1992, ILLUSTRATED HDB PHYS, P1; MADDALENA RL, 1995, CHEMOSPHERE, V30, P869, DOI 10.1016/0045-6535(94)00447-3; Malo JL, 1999, AM J RESP CRIT CARE, V159, P1879; MALO JL, 1982, J ALLERGY CLIN IMMUN, V69, P55, DOI 10.1016/0091-6749(82)90088-4; MALO JL, 1994, AM J RESP CRIT CARE, V150, P1142; Maltoni C, 1976, IARC SCI PUBL, V13, P127; Manfreda J, 2001, CAN MED ASSOC J, V164, P995; MAPP CE, 1988, EUR RESPIR J, V1, P273; Marsh DG, 1997, NAT GENET, V15, P389; Marth E, 2000, Cent Eur J Public Health, V8, P40; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; Mathison BH, 1995, FUND APPL TOXICOL, V28, P255, DOI 10.1006/faat.1995.1166; Mauderly JL, 1996, FUND APPL TOXICOL, V30, P233, DOI 10.1006/faat.1996.0061; MAUDERLY JL, 1994, ENVIRON HEALTH PERSP, V102, P165, DOI 10.2307/3431948; MAUDERLY JL, 1987, FUND APPL TOXICOL, V9, P208, DOI 10.1016/0272-0590(87)90044-3; MAUDERLY JL, 1990, J AEROSOL MED, V3, P169, DOI 10.1089/jam.1990.3.Suppl_1.S-169; MAUDERLY JL, 2001, TOXICOL SCI, V621, P6; MCCALLUM RI, 1983, BRIT J IND MED, V40, P384; McDowell SA, 2000, AM J RESP CELL MOL, V23, P466; McLane MP, 1998, AM J RESP CELL MOL, V19, P713; MERCHANT JA, 1990, CHEST, V98, pS145, DOI 10.1378/chest.98.5_Supplement.145S; Meredith SK, 2000, OCCUP ENVIRON MED, V57, P830, DOI 10.1136/oem.57.12.830; Meyers DA, 2001, GENET EPIDEMIOL, V21, pS4; MILLER FJ, 1979, JAPCA J AIR WASTE MA, V29, P610; Milo GE, 1996, P NATL ACAD SCI USA, V93, P5229, DOI 10.1073/pnas.93.11.5229; MIRVISH SS, 1991, J TOXICOL ENV HEALTH, V32, P59; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; Molhave L, 1991, J Expo Anal Environ Epidemiol, V1, P63; MOLHAVE L, 2000, ENV TOXICANTS HUMAN, P889; MOLHAVE L, 1986, PUBL ASHRAE, V2954, P306; Molhave L., 1982, ENVIRON INT, V8, P117, DOI 10.1016/0160-4120(82)90019-8; MOLLER DR, 1986, AM REV RESPIR DIS, V134, P175; MOOLGAVKAR SH, 1995, TOXICOLOGY, V102, P141, DOI 10.1016/0300-483X(95)03043-F; MOORE BB, 1991, CHEST, V100, P855, DOI 10.1378/chest.100.3.855; Morello-Frosch RA, 2000, RISK ANAL, V20, P273, DOI 10.1111/0272-4332.202026; MOSCATO G, 1987, J OCCUP ENVIRON MED, V29, P957; Moscato G, 1988, G Ital Med Lav, V10, P253; Muller H K, 1992, Semin Immunol, V4, P205; MULLER HK, 1985, BRIT J CANCER, V52, P81, DOI 10.1038/bjc.1985.152; MYOU S, 1993, AM REV RESPIR DIS, V148, P940; National Heart Lung and Blood Institute, 1991, J ALLERGY CLIN IMMUN, V88, P425; *NAT TOX PROGRY, 2001, 9 REP CARC; *NATL LIBR MED, 2001, SPEC INF SERV TOXN T; NEDDENRIEP D, 1990, American Review of Respiratory Disease, V141, pA282; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; NEMERY B, 1990, EUR RESPIR J, V3, P202; Nesnow S, 1985, Carcinog Compr Surv, V8, P257; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; NEWTON PE, 1994, FUND APPL TOXICOL, V22, P561, DOI 10.1006/faat.1994.1063; NIELSEN J, 1991, INT ARCH OCC ENV HEA, V63, P199, DOI 10.1007/BF00381569; Nikula KJ, 1997, FUND APPL TOXICOL, V37, P37, DOI 10.1006/faat.1997.2297; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V72, P407, DOI 10.1016/0091-6749(83)90507-9; NOVEY HS, 1969, J ALLERGY, V44, P315, DOI 10.1016/0021-8707(69)90036-7; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; OBERDORSTER G, 1986, SCAND J WORK ENV HEA, V12, P523; Obtulowicz K, 2000, Przegl Lek, V57, P446; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; OLAGUIBEL JM, 1989, ALLERGOL IMMUNOPATH, V17, P133; OLD LJ, 1963, NATURE, V198, P1215, DOI 10.1038/1981215a0; OREHEK J, 1976, J CLIN INVEST, V57, P301, DOI 10.1172/JCI108281; Orloff KG, 1998, ENVIRON HEALTH PERSP, V106, P665, DOI 10.2307/3434095; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; OSTRO B, 1993, ARCH ENVIRON HEALTH, V48, P336; OSTRO BD, 1991, AM J PUBLIC HEALTH, V81, P694, DOI 10.2105/AJPH.81.6.694; OSTRO BD, 1990, RISK ANAL, V10, P421, DOI 10.1111/j.1539-6924.1990.tb00525.x; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; Ott MG, 2000, OCCUP ENVIRON MED, V57, P43, DOI 10.1136/oem.57.1.43; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; OZKAYNAK H, 1985, ENVIRON HEALTH PERSP, V63, P45, DOI 10.2307/3430028; Palmer LJ, 1999, CLIN EXP ALLERGY, V29, P1555; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; PARK HS, 1994, CLIN EXP ALLERGY, V24, P676, DOI 10.1111/j.1365-2222.1994.tb00972.x; Pauluhn J, 2000, TOXICOL SCI, V56, P105, DOI 10.1093/toxsci/56.1.105; PAULUHN J, 1994, TOXICOLOGY, V92, P53, DOI 10.1016/0300-483X(94)90167-8; PEPELKO WE, 1993, REGUL TOXICOL PHARM, V17, P52, DOI 10.1006/rtph.1993.1006; Pepys J., 1993, P5; Pesatori AC, 1998, OCCUP ENVIRON MED, V55, P126; Peters A, 2001, CIRCULATION, V103, P2810; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Phillips ML, 2001, J EXPO ANAL ENV EPID, V11, P207, DOI 10.1038/sj.jea.7500161; PICKERING CAC, 1986, BRIT MED J, V292, P1362; Piipari R, 1998, CLIN EXP ALLERGY, V28, P358; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; POPE CA, 1993, AM REV RESPIR DIS, V147, P1136; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Prieto L, 2000, CLIN EXP ALLERGY, V30, P71; Prows DR, 2001, AM J RESP CELL MOL, V24, P740; PRYOR WA, 1992, FREE RADICAL BIO MED, V12, P83, DOI 10.1016/0891-5849(92)90060-T; QUEIROS M, 1990, ALLERGOL IMMUNOPATH, V18, P291; RAJAN KG, 1989, BRIT J IND MED, V46, P67; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; Rassokhin V M, 1968, Vrach Delo, V11, P125; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; Reinhold RW, 1998, TOXICOL SCI, V44, P197, DOI 10.1093/toxsci/44.2.197; RENNICK GJ, 1992, MED J AUSTRALIA, V156, P837; RICHARDS W, 1990, ANN ALLERGY, V65, P345; RICHARDSON DB, 1995, AM J IND MED, V28, P99, DOI 10.1002/ajim.4700280109; Rios-Blanco MN, 2000, CARCINOGENESIS, V21, P2011, DOI 10.1093/carcin/21.11.2011; Robertson GL, 1999, J EXPO ANAL ENV EPID, V9, P427, DOI 10.1038/sj.jea.7500053; ROBINSON JC, 1992, AM J IND MED, V21, P383, DOI 10.1002/ajim.4700210311; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Rosenbaum AS, 1999, J AIR WASTE MANAGE, V49, P1138, DOI 10.1080/10473289.1999.10463919; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; ROTHERY SP, 1991, BRIT J GEN PRACT, V41, P39; ROWENS B, 1991, CHEST, V99, P185, DOI 10.1378/chest.99.1.185; ROYCE S, 1993, CHEST, V103, P295, DOI 10.1378/chest.103.1.295; RUTISHAUSER M, 1990, LUNG, V168, P347, DOI 10.1007/BF02718151; SAAKADZE VP, 1977, GIG TR PROF, V6, P19; Sakano K, 2001, MUTAT RES-FUND MOL M, V479, P101, DOI 10.1016/S0027-5107(01)00158-0; Salnikow K, 2000, CANCER RES, V60, P3375; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Salome CM, 2000, EUR RESPIR J, V16, P38, DOI 10.1034/j.1399-3003.2000.16a07.x; SAMET JM, 1981, JAPCA J AIR WASTE MA, V31, P236; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SAMFIELD MM, 1992, A1A49 US EPA; SANTROCK J, 1992, CHEM RES TOXICOL, V5, P134, DOI 10.1021/tx00025a023; Sastre Joaquin, 2001, Journal of Allergy and Clinical Immunology, V108, P650; SAXENA AK, 1988, J EXP BIOL, V26, P195; Saxon A, 2000, IMMUNOPHARMACOLOGY, V48, P325, DOI 10.1016/S0162-3109(00)00234-4; SCHENKER MB, 1993, AM REV RESPIR DIS, V147, P1454; Schins RPF, 2000, EUR RESPIR J, V16, P626, DOI 10.1034/j.1399-3003.2000.16d10.x; Schneider P, 2001, SCI TOTAL ENVIRON, V267, P41, DOI 10.1016/S0048-9697(00)00766-X; Schneider P, 1999, J EXPO ANAL ENV EPID, V9, P282, DOI 10.1038/sj.jea.7500030; Schnitzer JE, 1996, AM J PHYSIOL, V270, P416; Schonhofer B, 1996, RESPIRATION, V63, P155; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12; SCHWARTZ J, 1991, ENVIRON RES, V56, P204, DOI 10.1016/S0013-9351(05)80009-X; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; Schwartz J, 1992, PUBLIC HLTH REV, V19, P39; Segerback D, 1998, CHEM-BIOL INTERACT, V115, P229, DOI 10.1016/S0009-2797(98)00076-3; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884; SETA JA, 1993, ASTHMA WORKPLACE, P627; Sheikh S, 1999, CHEST, V116, P52, DOI 10.1378/chest.116.1.52; SHEPPARD D, 1980, AM REV RESPIR DIS, V122, P873; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; SINGH HB, 1992, ATMOS ENVIRON A-GEN, V26, P2929, DOI 10.1016/0960-1686(92)90285-S; Smith JS, 1999, RISK ANAL, V19, P1223; SOYSETH V, 1992, BRIT J IND MED, V49, P125; SPEKTOR DM, 1985, ENVIRON RES, V37, P174, DOI 10.1016/0013-9351(85)90056-8; SPENGLER JD, 1981, ATMOS ENVIRON, V15, P23, DOI 10.1016/0004-6981(81)90121-9; SPENGLER JD, 1985, ENVIRON SCI TECHNOL, V19, P700, DOI 10.1021/es00138a008; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SRIVASTAVA RK, 1987, INDIAN J EXP BIOL, V25, P535; STAIN J P, 1983, Toxicological European Research, V5, P217; STAVERT DM, 1991, FUND APPL TOXICOL, V16, P636, DOI 10.1016/0272-0590(91)90152-T; Steenland K, 1998, AM J IND MED, V34, P220, DOI 10.1002/(SICI)1097-0274(199809)34:3<220::AID-AJIM3>3.0.CO;2-Z; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; STEPHENS EA, 1994, PHARMACOGENETICS, V4, P185, DOI 10.1097/00008571-199408000-00002; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1997, THORAX, V52, P905; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; SUH HH, 1992, ENVIRON SCI TECHNOL, V26, P2507, DOI 10.1021/es00036a026; SWAMINATHAN S, 1986, MUTAT RES, V172, P37, DOI 10.1016/0165-1218(86)90103-5; SWIECICHOWSKI AL, 1993, ENVIRON RES, V61, P185, DOI 10.1006/enrs.1993.1063; Symula DJ, 1999, NAT GENET, V23, P241; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Tan W, 2001, INT J CANCER, V95, P96, DOI 10.1002/1097-0215(20010320)95:2<96::AID-IJC1017>3.0.CO;2-2; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; TAUB SJ, 1970, EYE EAR NOSE THROAT, V49, P80; TAYLOR T R, 1991, South African Journal of Psychology, V21, P1; Teitelbaum D T, 1999, Int J Occup Environ Health, V5, P122; TERRACINI B, 1976, BRIT J CANCER, V33, P427, DOI 10.1038/bjc.1976.68; THEISS JC, 1977, CANCER RES, V37, P2717; Thompson AJ, 2001, ARCH ENVIRON HEALTH, V56, P234; TIMMER S, 1993, CHEST, V104, P816, DOI 10.1378/chest.104.3.816; Toren K, 1996, AM J IND MED, V29, P111, DOI 10.1002/(SICI)1097-0274(199602)29:2<111::AID-AJIM1>3.0.CO;2-V; TRIOLO AJ, 1982, J TOXICOL ENV HEALTH, V9, P637; TSENG RYM, 1990, ANN ALLERGY, V65, P379; Tuma S N, 1981, Arch Intern Med, V141, P1544; Turato G, 2000, OCCUP MED, V15, P445; TURK BH, 1987, INDOOR AIR QUALITY V, V1; *US DHHS, 1986, PUBL PHS; US-EPA, 1993, US EPA PUBL; *US EPA, 2001, US EPA TOX REL INV; *US EPA, 1991, COMM NAT LOC PERSP; UTELL MJ, 1984, JAPCA J AIR WASTE MA, V34, P931; Valberg PA, 1999, ENVIRON HEALTH PERSP, V107, P693, DOI 10.2307/3434652; VALLIERES M, 1977, AM REV RESPIR DIS, V115, P867; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; VANDENPLAS O, 1993, J ALLERGY CLIN IMMUN, V91, P850, DOI 10.1016/0091-6749(93)90342-D; VANDUUREN BL, 1979, J NATL CANCER I, V63, P1433; VERNOT EH, 1985, FUND APPL TOXICOL, V5, P1050, DOI 10.1016/0272-0590(85)90141-1; VERRAES S, 1995, LANCET, V346, P1434, DOI 10.1016/S0140-6736(95)92454-X; Vijayan VK, 1996, EUR RESPIR J, V9, P1977, DOI 10.1183/09031936.96.09101977; VILLAR RN, 1986, BRIT MED J, V292, P1597; WALLACE LA, 1987, ENVIRON RES, V43, P290, DOI 10.1016/S0013-9351(87)80030-0; WALSETH F, 1982, ARCH TOXICOL, V50, P1, DOI 10.1007/BF00569231; Wantke F, 1996, CLIN EXP ALLERGY, V26, P276; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WEISEL CP, 1995, ENVIRON HEALTH PERSP, V103, P97, DOI 10.2307/3432456; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; WEISS W, 1975, JAMA-J AM MED ASSOC, V234, P1139, DOI 10.1001/jama.234.11.1139; Weissman DN, 2000, OCCUP MED, V15, P385; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; WERNFORS M, 1986, INT ARCH ALLER A IMM, V79, P77; Wesselkamper SC, 2000, AM J PHYSIOL-LUNG C, V279, pL575; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITMORE RW, 1994, ARCH ENVIRON CON TOX, V26, P47, DOI 10.1007/BF00212793; Whitmore RW, 1999, J EXPO ANAL ENV EPID, V9, P369, DOI 10.1038/sj.jea.7500054; Wieslander G, 1999, INT ARCH OCC ENV HEA, V72, P507, DOI 10.1007/s004200050408; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Williams M D, 2001, Cancer Treat Res, V105, P31; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Windmill KF, 2000, TOXICOL SCI, V54, P19, DOI 10.1093/toxsci/54.1.19; WINSHIP KA, 1987, ADVERSE DRUG REACT, V2, P67; Wittczak Tomasz, 1996, Medycyna Pracy, V47, P259; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Woods GM, 1996, IMMUNOLOGY, V88, P134, DOI 10.1046/j.1365-2567.1996.d01-645.x; Woods GM, 2000, IMMUNOLOGY, V99, P16, DOI 10.1046/j.1365-2567.2000.00928.x; 1993, BR J INT MED, V50, P835; Woodruff TJ, 1998, ENVIRON HEALTH PERSP, V106, P245, DOI 10.1289/ehp.98106245; Wu CY, 2001, J AIR WASTE MANAGE, V51, P1129; Wu DN, 2000, CHEST, V118, P1553, DOI 10.1378/chest.118.6.1553; WU WA, 1989, J OCCUP ENVIRON MED, V31, P518, DOI 10.1097/00043764-198906000-00007; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; YARNELL JWG, 1979, BRIT J DIS CHEST, V73, P230, DOI 10.1016/S0007-0971(79)80144-8; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; Zhang YM, 1999, HUM MOL GENET, V8, P601, DOI 10.1093/hmg/8.4.601; Zhong BZ, 2000, TOXICOL SCI, V58, P102, DOI 10.1093/toxsci/58.1.102; Zhou DJ, 1998, CANCER RES, V58, P2182	511	115	124	5	42	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2002	110			4			505	526				22	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	586ER	WOS:000177572100003	12194881	
J	Lima, MT; Wilson, D; Pitkin, L; Roberts, A; Nouri-Aria, K; Jacobson, M; Walker, S; Durham, S				Lima, MT; Wilson, D; Pitkin, L; Roberts, A; Nouri-Aria, K; Jacobson, M; Walker, S; Durham, S			Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						antibodies; cytokines; hayfever; inummohistochemistry; immunotherapy; rhinoconjunctivitis; sublingual	PLACEBO-CONTROLLED TRIAL; STANDARDIZED 5-GRASS-POLLEN EXTRACT; PARIETARIA-JUDAICA EXTRACT; HOUSE-DUST-MITE; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; CLINICAL EFFICACY; INDUCED RHINITIS; DENDRITIC CELLS; ORAL-MUCOSA	Background Previous studies suggest that sublingual immunotherapy (SLIT) represents a safer alternative to injection immunotherapy but equivalent efficacy is yet to be confirmed. Objective To evaluate the efficacy and safety of SLIT in grass pollen-induced seasonal rhinoconjunctivitis. Methods A randomized, placebo-controlled trial in 56 adults over 18 months. Outcome measures included diary scores of seasonal symptoms and medication use, overall assessments, conjunctival and intradermal provocation tests and serum antibody measurements. To investigate possible mechanisms, sublingual biopsies were taken for measurement of local T cells, antigen-presenting cells and IL-12 mRNA expression. Results There were no significant differences between the mimunotherapy (IT) and placebo groups for diary symptom scores (P = 0.48) or rescue medication (P = 0.19). The patients' overall assessment of hayfever severity compared with previous years showed a highly significant improvement in favour of the IT group (P < 0.02). After treatment the late skin response was smaller (P = 0.003) and the ratio of serum allergen-specific IgG4/IgE was higher (P = 0.05) in the IT group. Both of these variables correlated with the clinical response to SLIT. There were no differences between groups in either the sublingual epithelium or lamina propria for numbers of CD3(+) cells (epithelium: P = 0.9. lamina propria: P = 0.2), CD1a(+) cells (P = 0.3, P = 0.25), CD68(+) cells (P = 0.9 P = 1.0) or IL-12 mRNA(+) cells (P = 0.6, P = 0.4). Local side-effects were minor and there were no serious treatment-related adverse events. Conclusion Grass pollen sublingual immunotherapy was well tolerated. Although there was no significant change in diary scores, the improvement in overall assessments, which correlated with inhibition of the late skin response and increases in serum IgG4: IgE ratio, indicates the need for larger, dose-ranging studies.	Natl Heart & Lung Inst, Imperial Coll Sci Technol & Med, Fac Med, Upper Resp Med, London SW3 6LY, England; Royal Brompton & Harefield Hosp NHS Trust, London, England	Durham, S (reprint author), Natl Heart & Lung Inst, Imperial Coll Sci Technol & Med, Fac Med, Upper Resp Med, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258			Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; CRUCHLEY AT, 1989, J ORAL PATHOL MED, V18, P510, DOI 10.1111/j.1600-0714.1989.tb01353.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Feliziani V, 1993, Allergol Immunopathol (Madr), V21, P173; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Malling HJ, 1996, CLIN EXP ALLERGY, V26, P1228, DOI 10.1111/j.1365-2222.1996.tb00517.x; MALLING HJ, 1993, ALLERGY, V48, P9; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170; VARNEY VA, 1991, BRIT MED J, V302, P265; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WOODHEAD JS, 1989, J BIOLUM CHEMILUM, V4, P611, DOI 10.1002/bio.1170040180	35	115	117	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2002	32	4					507	514		10.1046/j.0954-7894.2002.01327.x		8	Allergy; Immunology	Allergy; Immunology	546HX	WOS:000175269600005	11972594	
J	Van den Berge, M; Kerstjens, HAM; Meijer, RJ; De Reus, DM; Koeter, GH; Kauffman, HF; Postma, DS				Van den Berge, M; Kerstjens, HAM; Meijer, RJ; De Reus, DM; Koeter, GH; Kauffman, HF; Postma, DS			Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						adenosine 5 '-monophosphate; hyperresponsiveness; inflammation; asthma; sputum	BRONCHIAL BIOPSY SPECIMENS; NITRIC-OXIDE; INDUCED BRONCHOCONSTRICTION; INHALED BUDESONIDE; ASTHMATIC-PATIENTS; ATOPIC ASTHMA; EXHALED AIR; MILD ASTHMA; MAST-CELLS; HYPERRESPONSIVENESS	It has been suggested in cross-sectional studies that provocation with adenosine 5'-monophosphate (AMP) more closely reflects the inflammatory process in asthma than does provocation with methacholine or histamine. We investigated whether the steroid-induced improvement in the provocative concentration of AMP producing a 20% decline in FEV1 (PC20 AMP) is more closely associated with the concomitant reduction in airway inflammation than is the improvement in PC20 methacholine. In 120 asthmatic patients, we measured PC20 methacholine and PC20 AMP as well as sputum induction and nitric oxide (NO) in exhaled air before and after 2 weeks of treatment with corticosteroids. Improvement in PC20 AMP was solely related to reduction in airway inflammation (i.e., change in the number of sputum eosinophils, lymphocytes, epithelial cells, and concentration of NO in exhaled air). In contrast, improvement in PC20 methacholine was related to both reduction in airway inflammation (i.e., change in the number of sputum eosinophils and lymphocytes) and increase in FEV1 %predicted. The total explained variance of the improvement in bronchial hyperresponsiveness was greater for AMP than for methacholine (36% versus 22%, respectively). We conclude that PC20 AMP is more sensitive to changes in acute airway inflammation than is PC20 methacholine, further reinforcing the notion that PC20 AMP can be a useful tool for monitoring the effects of antilnflammatory therapy.	Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands	Postma, DS (reprint author), Univ Groningen Hosp, Dept Pulm Dis, Hanzeplein 1, NL-9700 RB Groningen, Netherlands.		van den berge, maarten/D-3990-2013				AALBERS R, 1993, EUR RESPIR J, V6, P840; Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; ALVING K, 1993, EUR RESPIR J, V6, P1368; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4; CRIMI N, 1992, EUR RESPIR J, V5, P560; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126; FINNEY MJB, 1985, BRIT J PHARMACOL, V85, P29; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473; GRATZIOU C, 1992, AM REV RESPIR DIS, V145, P1259; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Ichinose M, 2000, EUR RESPIR J, V15, P248, DOI 10.1034/j.1399-3003.2000.15b05.x; In 'T Veen J. C. C. M., 1996, European Respiratory Journal, V9, P2441, DOI 10.1183/09031936.96.09122441; Jeffery PK, 1996, EUR RESPIR J, V9, P1583, DOI 10.1183/09031936.96.09081583; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kidney JC, 1996, AM J RESP CRIT CARE, V153, P540; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, pS36; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; Meijer RJ, 1999, THORAX, V54, P894; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560; OOSTERHOFF Y, 1993, J ALLERGY CLIN IMMUN, V92, P773, DOI 10.1016/0091-6749(93)90023-9; PAUWELS RA, 1987, AM REV RESPIR DIS, V136, P374; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241	40	115	119	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2001	164	7					1127	1132				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	489VM	WOS:000172013200012	11673197	
J	Radon, K; Danuser, B; Iversen, M; Jorres, R; Monso, E; Opravil, U; Weber, C; Donham, KJ; Nowak, D				Radon, K; Danuser, B; Iversen, M; Jorres, R; Monso, E; Opravil, U; Weber, C; Donham, KJ; Nowak, D			Respiratory symptoms in European animal farmers	EUROPEAN RESPIRATORY JOURNAL			English	Article						animal confinement houses; ECRHS; pig farmers; poultry farmers	CHRONIC-BRONCHITIS; DAIRY FARMERS; LUNG-FUNCTION; HAY-FEVER; SENSITIZATION; ASTHMA; DUST; PREVALENCE; POPULATION; COMMUNITY	Farmers are known to be at high risk for the development of occupational airway disease. The aim of this European study was to determine which airway symptoms predominate in different types of animal farmers (cattle, pigs, poultry, sheep) and to compare the prevalence of symptoms to the general population. A total of 6,156 randomly selected animal farmers in Denmark, Germany (Schleswig-Holstein, Niedersachsen), Switzerland, and Spain completed a questionnaire on respiratory symptoms and farming characteristics in 1995-1997. The prevalence of general respiratory symptoms was compared to the results of the European Community Respiratory Health Survey (ECRHS) obtained in the same regions. Pig farmers were at highest risk for the development of work-related symptoms. A significant dose-response relationship between daily hours worked inside animal houses and symptoms was established for pig and poultry farmers. Additionally, self-reported nasal allergies (odds ratio (95% confidence interval): 3.92 (3.26-4.71)) and nasal irritation during work (3.98 (3.35-4.73)) were shown to be associated with the development of chronic phlegm. The prevalence of wheezing, shortness of breath, asthma and nasal allergies was significantly lower among all farmers in the age group 20-44 yrs than among the general population. However, the prevalence of usually bringing up phlegm in winter among farmers was significantly higher than in the general population (9.4 (8.3-10.5%) versus 7.5 (6.5-8.5%)). Individual factors have been shown to be related to the prevalence of chronic phlegm among farmers. Additionally, this study could support the hypothesis that farming could be negatively related to allergic diseases.	Univ Munich, Inst & Poliklin Arbeits & Umweltmed, Munich, Germany; ETH Zurich, Inst Hyg & Arbeitsphysiol, Zurich, Switzerland; Aarhus Kommune Hosp, DK-8000 Aarhus, Denmark; Zentrum Pneumol & Thoraxchirurg, Grosshansdorf, Germany; Hosp Germans Trias & Pujol, Badalona, Spain; Zentrum Arbeitsbedingte Erkankungen, Brunsbuttel, Germany; Univ Iowa, Coll Med, Dept Prevent Med & Environm Hlth, Iowa City, IA 52242 USA	Radon, K (reprint author), Univ Munich, Inst Occupat & Environm Med, Ziemssenstr 1, D-80336 Munich, Germany.						Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; DALPHIN JC, 1989, CHEST, V95, P1244, DOI 10.1378/chest.95.6.1244; DALPHIN JCH, 1993, CHEST, V103, P417, DOI 10.1378/chest.103.2.417; DUTKIEWICZ J, IN PRESS PREVENTION; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; Kimbell-Dunn M, 1999, AM J IND MED, V35, P51, DOI 10.1002/(SICI)1097-0274(199901)35:1<51::AID-AJIM7>3.0.CO;2-F; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Melbostad E, 1997, SCAND J WORK ENV HEA, V23, P271; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262; Monso E, 2000, AM J RESP CRIT CARE, V162, P1246; MULLER S, 1986, AM J IND MED, V10, P281, DOI 10.1002/ajim.4700100313; NOWAK D, 1994, ANN AGR ENV MED, V1, P81; PRELLER L, 1995, OCCUP ENVIRON MED, V52, P654; Radon K, 2000, ALLERGY, V55, P219, DOI 10.1034/j.1398-9995.2000.00461.x; RASKANDERSEN A, 1989, BRIT J IND MED, V46, P233; RYLANDER R, 1990, AM J IND MED, V17, P121; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; STELLMAN SD, 1988, AM J IND MED, V13, P43, DOI 10.1002/ajim.4700130104; Takai H, 1998, J AGR ENG RES, V70, P59, DOI 10.1006/jaer.1997.0280; Terho E O, 1987, Eur J Respir Dis Suppl, V152, P19; TERHO EO, 1990, AM J IND MED, V18, P269, DOI 10.1002/ajim.4700180305; VOHLONEN I, 1987, EUR J RESPIR DIS, V71, P175; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187	25	115	118	0	5	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	APR	2001	17	4					747	754		10.1183/09031936.01.17407470		8	Respiratory System	Respiratory System	438JT	WOS:000169050400027	11401073	
J	Paredi, P; Kharitonov, SA; Barnes, PJ				Paredi, P; Kharitonov, SA; Barnes, PJ			Elevation of exhaled ethane concentration in asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SMOOTH-MUSCLE CELLS; LIPID-PEROXIDATION; NITRIC-OXIDE; BRONCHIAL HYPERRESPONSIVENESS; OXIDATIVE STRESS; OXYGEN; GLUCOCORTICOIDS; EXHALATION; METHYLPREDNISOLONE; INFLAMMATION	Ethane is a product of lipid peroxidation as a result of oxidative stress and can be detected in the exhaled air. Oxidative stress plays a role in the pathogenesis of asthma. We measured exhaled ethane in 26 asthmatic subjects (mean age +/- SEM, 38 +/- 8 yr; 15 male, FEV1 60 +/- 4%) and compared it with exhaled nitric oxide (NO) measured by chemiluminescence, a noninvasive marker of oxidative stress and inflammation. Exhaled ethane was collected during a flow- and pressure-controlled exhalation into a reservoir discarding dead space air contaminated with ambient air. A sample of the expired air was analyzed by chromatography. Exhaled ethane levels were elevated in asthma patients not receiving steroid (n = 12, 2.06 +/- 0.30 ppb) compared with steroid-treated patients (n = 14, 0.79 +/- 0.70 ppb, p < 0.01) and to 14 nonsmoking control subjects (0.88 +/- 0.09 ppb, p < 0.05). In patients not receiving steroid treatment there was a positive correlation between exhaled ethane and NO (r = 0.55, p < 0.05) and air trapping assessed by the ratio of residual volume to total lung capacity (RV/TLC) (r = 0.60, p < 0.05). In addition, untreated patients with FEV1 < 60% predicted value had higher concentrations of ethane (2.86 +/- 0.37 ppb) compared with less obstructed patients (FEV1 > 60%, 1.26 +/- 0.12 ppb, p < 0.05). NO concentrations were higher in patients not on steroid treatment (14.7 +/- 1.7 ppb) than in steroid-treated patients (8.6 +/- 0.5 ppb, p < 0.05). Exhaled ethane is elevated in asthma, reduced in steroid-treated patients, and correlates with NO and airway obstruction. It may be a useful noninvasive marker of oxidative stress.	Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll Sch Sci Technol & Med, London SW3 6LY, England	Barnes, PJ (reprint author), Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll Sch Sci Technol & Med, Dovehouse St, London SW3 6LY, England.						Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; AULIK I. V., 1966, BYUL EKSP BIOL MED, V62, P115; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BARNES PJ, 1989, J ALLERGY CLIN IMMUN, V83, P1013, DOI 10.1016/0091-6749(89)90441-7; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; CHIARA O, 1991, CRIT CARE MED, V19, P260, DOI 10.1097/00003246-199102000-00023; Enright PL, 1994, AM J RESP CRIT CAR S, V149, P9; HABIB MP, 1989, J APPL PHYSIOL, V66, P1268; HABIB MP, 1995, AM J RESP CRIT CARE, V151, P1368; Inoue H, 1999, LUNG, V177, P53, DOI 10.1007/PL00007627; JEEJEEBHOY KN, 1991, FREE RADICAL BIO MED, V10, P191, DOI 10.1016/0891-5849(91)90075-E; JOSEPH BZ, 1993, INFLAMMATION, V17, P361, DOI 10.1007/BF00918997; Katsuyama K, 1999, ENDOCRINOLOGY, V140, P2183, DOI 10.1210/en.140.5.2183; KAZUI M, 1992, FREE RADICAL BIO MED, V13, P509, DOI 10.1016/0891-5849(92)90145-7; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KINNULA VL, 1995, LAB INVEST, V73, P3; KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127; KOUNO T, 1994, JPN J PHARMACOL, V64, P163, DOI 10.1254/jjp.64.163; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; LETTERON P, 1993, GUT, V34, P409, DOI 10.1136/gut.34.3.409; Marumo T, 1998, HYPERTENSION, V32, P1083; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Morrison D, 1999, AM J RESP CRIT CARE, V159, P473; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NEIJENS HJ, 1984, AM REV RESPIR DIS, V130, P744; Olopade CO, 1997, CHEST, V111, P862, DOI 10.1378/chest.111.4.862; Paredi P, 1998, THORAX, V53, P775; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055; STANBROOK MB, 1995, CHEST, V107, P992, DOI 10.1378/chest.107.4.992; TOSHNIWAL PK, 1992, NEUROCHEM RES, V17, P205, DOI 10.1007/BF00966801; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585; ZARLING EJ, 1987, CLIN CHEM, V33, P140; [Anonymous], 1987, AM REV RESP DIS, V136, P225	35	115	116	1	12	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT	2000	162	4					1450	1454				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	364RD	WOS:000089905900044	11029360	
J	Huby, RDJ; Dearman, RJ; Kimber, I				Huby, RDJ; Dearman, RJ; Kimber, I			Why are some proteins allergens?	TOXICOLOGICAL SCIENCES			English	Review						allergenicity; epitopes; proteins; simulated gastric fluid (SGF)	ALTERED PEPTIDE LIGANDS; HOUSE-DUST MITE; T-CELL CLONES; SITE-DIRECTED MUTAGENESIS; ANTIGEN-SPECIFIC IGE; NORWAY RAT MODEL; DER-P-I; DENDRITIC CELLS; MANNOSE RECEPTOR; MAJOR ALLERGEN	The ability of certain proteins to induce an allergic response in susceptible individuals is well established. Symptoms can range from mild erythema or rhinitis, to acute, and possibly fatal, anaphylactic shock. Because such allergic responses require complex interactions between the protein and the immune system, they are notoriously difficult to predict. Nevertheless, it is clear that some proteins are intrinsically more allergenic than others. The challenge for toxicologists is to identify those characteristics that confer on proteins the potential to induce allergic sensitization and allergic disease. Here, we first consider the potential contribution that individual epitopes may make to the allergenicity of a protein. These are the minimal peptide units within proteins that can be recognized by the immune system and are a fundamental requirement for all immune responses, including those resulting in allergic sensitization. It appears that allergens must necessarily contain B-cell epitopes to which immunoglobulin E (IgE) can bind, and T-cell epitopes capable of inducing a type 2 T-lymphocyte response. Nevertheless, it appears doubtful that the presence of appropriate epitopes alone is sufficient to endow a protein with allergenic potential. We therefore consider also the contribution that other features and characteristics of proteins may make to their overall allergenicity. In particular, we consider the effects that resistance to proteolysis, post-translational glycosylation, and enzymatic activity may have. It appears that relative stability in simulated gastric fluid (SGF) sometimes correlates with allergenic activity. However, this is not universally true, and it is known that there are protein allergens, such as some of those associated with oral allergy syndrome, that are unstable. Nevertheless, if stability in SGF is associated with the intrinsic allergenicity of many proteins irrespective of the route of exposure, then this may reflect some more fundamental property of proteins, and possibly their stability in other biologic matrices and/or to intracellular proteases. Post-translational modification appears generally to enhance allergenicity, perhaps by increasing uptake and detection of the protein by the immune system. Some enzymatic activities also enhance allergenicity through what appear to be several different mechanisms, including nonspecific activation of cells participating in the immunologic response. Overall, it appears likely that many factors can contribute to the overall allergenicity of any given protein. Some, such as the presence of epitopes with allergenic potential, may be essential. Others, such as the glycosylation status, resistance to proteolysis, and enzymatic activity, may play a subsidiary but nevertheless critically important role. By better defining the limits within which these factors operate, we can hope to gain a better understanding of the fundamental origins of protein allergenicity, and therefore be in a position to identify and characterize the hazards and risks of allergic disease associated with novel proteins.	AstraZeneca, Safety Assessment, Macclesfield SK10 4TG, Cheshire, England; AstraZeneca Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England	Huby, RDJ (reprint author), AstraZeneca, Safety Assessment, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.						Abraham R, 1997, J IMMUNOL, V158, P4029; ABRAHAM R, 1995, J IMMUNOL, V154, P1; Aebischer I, 1996, ADV IMMUNOL, V61, P341, DOI 10.1016/S0065-2776(08)60871-8; Agnes M C, 1998, Int Immunol, V10, P1299, DOI 10.1093/intimm/10.9.1299; ARAKAWA H, 1995, INT ARCH ALLERGY IMM, V108, P274; Arps V, 1998, EUR J IMMUNOL, V28, P681, DOI 10.1002/(SICI)1521-4141(199802)28:02<681::AID-IMMU681>3.3.CO;2-1; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Atkinson HAC, 1996, FOOD CHEM TOXICOL, V34, P27, DOI 10.1016/0278-6915(95)00084-4; BARBER LD, 1994, J EXP MED, V180, P1191, DOI 10.1084/jem.180.4.1191; Bartnes K, 1997, INT IMMUNOL, V9, P1185, DOI 10.1093/intimm/9.8.1185; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BAUR X, 1982, CLIN ALLERGY, V12, P9, DOI 10.1111/j.1365-2222.1982.tb03121.x; Bleecker ER, 1998, CLIN EXP ALLERGY, V28, P6; BLEECKER ER, 1998, CLIN EXP ALLERGY, V28, P26; Bottger G, 1996, J BIOL CHEM, V271, P29191; Buchanan BB, 1997, P NATL ACAD SCI USA, V94, P5372, DOI 10.1073/pnas.94.10.5372; Chatila Talal A., 1998, Current Opinion in Pediatrics, V10, P584; Chen YZ, 1996, J IMMUNOL, V157, P3783; COLLINS DS, 1991, J IMMUNOL, V147, P4054; Comoy E, 1999, INT ARCH ALLERGY IMM, V118, P399, DOI 10.1159/000024147; Condaminet B, 1998, EUR J IMMUNOL, V28, P3541, DOI 10.1002/(SICI)1521-4141(199811)28:11<3541::AID-IMMU3541>3.0.CO;2-4; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Corthay A, 1998, EUR J IMMUNOL, V28, P2580, DOI 10.1002/(SICI)1521-4141(199808)28:08<2580::AID-IMMU2580>3.0.CO;2-X; Costello PS, 1996, ONCOGENE, V13, P2595; Das MP, 1997, J EXP MED, V186, P867, DOI 10.1084/jem.186.6.867; DEL PG, 1988, J IMMUNOL, V140, P4193; del Val G, 1999, J ALLERGY CLIN IMMUN, V103, P690, DOI 10.1016/S0091-6749(99)70244-7; DELPRETE G, 1986, EUR J IMMUNOL, V16, P1509, DOI 10.1002/eji.1830161207; DELPRETE G, 1992, ALLERGY, V47, P450; DIJKMAN JH, 1973, AM REV RESPIR DIS, V107, P387; DIMENT S, 1990, J IMMUNOL, V145, P417; DUDLER T, 1995, J IMMUNOL, V155, P2605; EmadiKhiav B, 1996, EUR J PHARMACOL, V295, P243, DOI 10.1016/0014-2999(95)00663-X; Engering AJ, 1997, EUR J IMMUNOL, V27, P2417, DOI 10.1002/eji.1830270941; Faith A, 1999, J IMMUNOL, V162, P1836; FERNANDEZBOTRAN R, 1988, J EXP MED, V168, P543, DOI 10.1084/jem.168.2.543; Ferreira F, 1998, FASEB J, V12, P231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FLINDT MLH, 1969, LANCET, V1, P1177; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P45, DOI 10.1016/S1043-4526(08)60092-3; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P63, DOI 10.1016/S1043-4526(08)60093-5; Gudmundsdottir H, 1999, J IMMUNOL, V162, P5212; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; HELM BA, 1994, ADV EXP MED BIOL, V347, P1; Helm RM, 1998, INT ARCH ALLERGY IMM, V117, P29, DOI 10.1159/000023987; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HEWLETT LJ, 1994, J CELL BIOL, V124, P689, DOI 10.1083/jcb.124.5.689; Hilton J, 1997, FOOD CHEM TOXICOL, V35, P1209, DOI 10.1016/S0278-6915(97)00119-1; HILTON J, 1994, TOXICOL LETT, V73, P43, DOI 10.1016/0378-4274(94)90187-2; HOPKIN JM, 1990, J ROY COLL PHYS LOND, V24, P159; INGANAS M, 1980, SCAND J IMMUNOL, V12, P23, DOI 10.1111/j.1365-3083.1980.tb00037.x; JANSEN RW, 1991, J BIOL CHEM, V266, P3343; Jenkins N, 1996, NAT BIOTECHNOL, V14, P975, DOI 10.1038/nbt0896-975; JIANG WP, 1995, NATURE, V375, P151, DOI 10.1038/375151a0; Kimber I, 1997, HUM EXP TOXICOL, V16, P516; KINDBERG GM, 1990, BIOCHEM J, V270, P197; Knippels LMJ, 1999, TOXICOL APPL PHARM, V156, P161, DOI 10.1006/taap.1999.8641; Knippels LMJ, 1998, CLIN EXP ALLERGY, V28, P368, DOI 10.1046/j.1365-2222.1998.00242.x; KUMAR V, 1995, P NATL ACAD SCI USA, V92, P9510, DOI 10.1073/pnas.92.21.9510; Longoni D, 1998, INT J CLIN LAB RES, V28, P162, DOI 10.1007/s005990050037; Lutz MB, 1997, J IMMUNOL, V159, P3707; Machado DC, 1996, EUR J IMMUNOL, V26, P2972, DOI 10.1002/eji.1830261224; MAGGI E, 1987, RES CLIN LAB, V17, P363; MAGGI E, 1988, CLIN EXP IMMUNOL, V73, P57; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; Manoury B, 1998, NATURE, V396, P695; Marsh DG, 1999, ALLERGY, V54, P198, DOI 10.1034/j.1398-9995.1999.00090.x; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; MERGET R, 1993, J ALLERGY CLIN IMMUN, V92, P264, DOI 10.1016/0091-6749(93)90170-K; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165; Metzger H, 1999, CELL, V97, P287, DOI 10.1016/S0092-8674(00)80738-2; MOURITSEN S, 1994, EUR J IMMUNOL, V24, P1066, DOI 10.1002/eji.1830240509; MURRAY JS, 1994, EUR J IMMUNOL, V24, P2337, DOI 10.1002/eji.1830241012; Nicholson LB, 1998, P NATL ACAD SCI USA, V95, P264, DOI 10.1073/pnas.95.1.264; Olsson S, 1998, MOL IMMUNOL, V35, P1017, DOI 10.1016/S0161-5890(98)00101-1; ORourke L, 1997, CURR OPIN IMMUNOL, V9, P324, DOI 10.1016/S0952-7915(97)80077-5; ORTOLANI C, 1988, ANN ALLERGY, V61, P47; PARRONCHI P, 1992, EUR J IMMUNOL, V22, P1615, DOI 10.1002/eji.1830220640; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENG ZK, 1994, INT ARCH ALLERGY IMM, V104, P204; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P87; PEPYS J, 1969, LANCET, V1, P1181; Petersen A, 1998, CLIN EXP ALLERGY, V28, P315; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; PHAM QT, 1978, J OCCUP ENVIRON MED, V20, P33; Pingel S, 1999, J EXP MED, V189, P1111, DOI 10.1084/jem.189.7.1111; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Press B, 1998, J CELL BIOL, V140, P1075, DOI 10.1083/jcb.140.5.1075; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; Rabinowitz JD, 1996, P NATL ACAD SCI USA, V93, P1401, DOI 10.1073/pnas.93.4.1401; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Ramachandra L, 1999, J IMMUNOL, V162, P3263; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457; Reizis B, 1998, IMMUNOL TODAY, V19, P212, DOI 10.1016/S0167-5699(97)01238-3; RHODES JM, 1993, IMMUNOL LETT, V37, P103, DOI 10.1016/0165-2478(93)90018-W; RITZ HL, 1993, FUND APPL TOXICOL, V21, P31, DOI 10.1006/faat.1993.1068; Robinson MK, 1998, TOXICOL SCI, V43, P39; Robinson MK, 1996, FUND APPL TOXICOL, V34, P15, DOI 10.1006/faat.1996.0171; RODRIGUEZ GM, 1992, J IMMUNOL, V149, P2894; RODRIGUEZ GM, 1995, EUR J IMMUNOL, V25, P1823, DOI 10.1002/eji.1830250705; Rogers PR, 1999, J IMMUNOL, V163, P1205; ROMAGNANI S, 1991, RES IMMUNOL, V142, P63, DOI 10.1016/0923-2494(91)90015-B; ROMAGNANI S, 1989, ALLERGY, V44, P9, DOI 10.1111/j.1398-9995.1989.tb04309.x; ROMAGNANI S, 1989, INT ARCH ALLER A IMM, V88, P111; Romagnani S, 1998, ALLERGY, V53, P12; Rosenwasser LJ, 1998, ALLERGY, V53, P8; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; Sarlo K, 1997, FUND APPL TOXICOL, V39, P44, DOI 10.1006/faat.1997.2356; Schountz T, 1996, J IMMUNOL, V157, P3893; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Selo I, 1998, INT ARCH ALLERGY IMM, V117, P20, DOI 10.1159/000023986; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Singh MB, 1999, INT ARCH ALLERGY IMM, V119, P75, DOI 10.1159/000024181; Singh N, 1998, J IMMUNOL, V160, P4869; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smyth LA, 1998, P NATL ACAD SCI USA, V95, P8193, DOI 10.1073/pnas.95.14.8193; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846; Takatsu K, 1997, P SOC EXP BIOL MED, V215, P121; Tan MCAA, 1997, ADV EXP MED BIOL, V417, P171; Tao X, 1997, J IMMUNOL, V159, P5956; Tao X, 1997, J IMMUNOL, V158, P4237; Taylor S.L., 1996, CRIT REV FOOD SCI NU, V36, P91; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; van Bergen J, 1998, EUR J IMMUNOL, V28, P2801, DOI 10.1002/(SICI)1521-4141(199809)28:09<2801::AID-IMMU2801>3.0.CO;2-N; vanHalteren AG, 1997, J IMMUNOL, V159, P3009; vanHalteren AGS, 1997, J ALLERGY CLIN IMMUN, V99, P94; Vidal K, 1996, J EXP MED, V183, P1311, DOI 10.1084/jem.183.4.1311; Vijh S, 1998, J IMMUNOL, V160, P3971; Viola A, 1996, SCIENCE, V273, P104, DOI 10.1126/science.273.5271.104; WEBER A, 1987, ALLERGY, V42, P464, DOI 10.1111/j.1398-9995.1987.tb00364.x; WEILL H, 1971, J AMER MED ASSOC, V217, P425, DOI 10.1001/jama.217.4.425; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WINDHAGEN A, 1995, IMMUNITY, V2, P373, DOI 10.1016/1074-7613(95)90145-0; Wymann D, 1998, CLIN EXP ALLERGY, V28, P839	141	115	120	0	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080			TOXICOL SCI	Toxicol. Sci.	JUN	2000	55	2					235	246		10.1093/toxsci/55.2.235		12	Toxicology	Toxicology	319JT	WOS:000087338300002	10828254	
J	Dodson, RE; Nishioka, M; Standley, LJ; Perovich, LJ; Brody, JG; Rudel, RA				Dodson, Robin E.; Nishioka, Marcia; Standley, Laurel J.; Perovich, Laura J.; Brody, Julia Green; Rudel, Ruthann A.			Endocrine Disruptors and Asthma-Associated Chemicals in Consumer Products	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						alkylphenols; asthma; bisphenol A; consumer products; cyclosiloxane; endocrine disruptors; fragrance compounds; parabens; phthalates; UV filters	POLYBROMINATED DIPHENYL ETHERS; PRENATAL PHTHALATE EXPOSURE; PERSONAL CARE PRODUCTS; SPRAGUE-DAWLEY RAT; OCCUPATIONAL ASTHMA; COSMETIC PRODUCTS; POLYCYCLIC MUSKS; BISPHENOL-A; UV FILTERS; INDOOR AIR	BACKGROUND: Laboratory and human studies raise concerns about endocrine disruption and asthma resulting from exposure to chemicals in consumer products. Limited labeling or testing information is available to evaluate products as exposure sources. OBJECTIVES: We analytically quantified endocrine disruptors and asthma-related chemicals in a range of cosmetics, personal care products, cleaners, sunscreens, and vinyl products. We also evaluated whether product labels provide information that can be used to select products without these chemicals. METHODS: We selected 213 commercial products representing 50 product types. We tested 42 composited samples of high-market-share products, and we tested 43 alternative products identified using criteria expected to minimize target compounds. Analytes included parabens, phthalates, bisphenol A (BPA), triclosan, ethanolamines, alkylphenols, fragrances, glycol ethers, cyclosiloxanes, and ultraviolet (UV) filters. RESULTS: We detected 55 compounds, indicating a wide range of exposures from common products. Vinyl products contained > 10% bis(2-ethylhexyl) phthalate (DEHP) and could be an important source of DEHP in homes. In other products, the highest concentrations and numbers of detects were in the fragranced products (e.g., perfume, air fresheners, and dryer sheets) and in sunscreens. Some products that did not contain the well-known endocrine-disrupting phthalates contained other less-studied phthalates (dicyclohexyl phthalate, diisononyl phthalate, and di-n-propyl phthalate; also endocrine-disrupting compounds), suggesting a substitution. Many detected chemicals were not listed on product labels. CONCLUSIONS: Common products contain complex mixtures of EDCs and asthma-related compounds. Toxicological studies of these mixtures are needed to understand their biological activity. Regarding epidemiology, our findings raise concern about potential confounding from co-occurring chemicals and misclassification due to variability in product composition. Consumers should be able to avoid some target chemicals-synthetic fragrances, BPA, and regulated active ingredients-using purchasing criteria. More complete product labeling would enable consumers to avoid the rest of the target chemicals.	[Dodson, Robin E.; Standley, Laurel J.; Perovich, Laura J.; Brody, Julia Green; Rudel, Ruthann A.] Silent Spring Inst, Newton, MA 02458 USA; [Nishioka, Marcia] Battelle Mem Inst, Columbus, OH 43201 USA; [Standley, Laurel J.] Clear Current LLC, Belmont, CA USA	Dodson, RE (reprint author), Silent Spring Inst, 29 Crafts St, Newton, MA 02458 USA.	dodson@silentspring.org			Goldman Fund; Hurricane Voices Breast Cancer Foundation; Centers for Disease Control and Prevention [1 R01 EH000632-01]	This work was funded by the Goldman Fund, the Hurricane Voices Breast Cancer Foundation, and a grant from the Centers for Disease Control and Prevention (1 R01 EH000632-01).	Adolfsson-Erici M, 2002, CHEMOSPHERE, V46, P1485, DOI 10.1016/S0045-6535(01)00255-7; Association of Occupational and Environmental Clinics, 2010, DESCR AOEC EXP COD S; Bickers DR, 2003, REGUL TOXICOL PHARM, V37, P218, DOI 10.1016/S0273-2300(03)00003-5; Bitsch N, 2002, ARCH ENVIRON CON TOX, V43, P257, DOI 10.1007/s00244-002-1192-5; Boberg J, 2011, REPROD TOXICOL, V31, P200, DOI 10.1016/j.reprotox.2010.11.001; Bonefeld-Jorgensen EC, 2007, ENVIRON HEALTH PERSP, V115, P69, DOI 10.1289/ehp.9368; Bornehag CG, 2010, INT J ANDROL, V33, P333, DOI 10.1111/j.1365-2605.2009.01023.x; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bridges B, 2002, FLAVOUR FRAG J, V17, P361, DOI 10.1002/ffj.1106; Brody Julia Green, 2009, Am J Public Health, V99 Suppl 3, pS600, DOI 10.2105/AJPH.2008.149088; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P893, DOI 10.1289/ehp.11269; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P39, DOI 10.1289/ehp.10753; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; Centers for Disease Control and Prevention, 2009, 4 CDCP; Chen JG, 2008, ENDOCRINOLOGY, V149, P1173, DOI 10.1210/en.2007-1057; Cherry N, 2008, OCCUP ENVIRON MED, V65, P708, DOI 10.1136/oem.2007.035824; Choi H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013423; COLBORN T, 1993, ENVIRON HEALTH PERSP, V101, P378, DOI 10.2307/3431890; Dodson RE, 2008, ATMOS ENVIRON, V42, P1569, DOI 10.1016/j.atmosenv.2007.10.088; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Dunagan SC, 2011, J CLEAN PROD, V19, P438, DOI 10.1016/j.jclepro.2010.06.012; Duty SM, 2003, ENVIRON HEALTH PERSP, V111, P1164, DOI 10.1289/ehp.5756; Engel SM, 2010, ENVIRON HEALTH PERSP, V118, P565, DOI 10.1289/ehp.0901470; Environmental Working Group, 2011, EWGS SKIN DEEP COSM; European Commission, 2002, 20387 EUR EN EUR COM; European Commission, 2011, COSING; FDA (Food and Drug Administration), 2009, COSM LAB MAN; Hannas BR, 2011, TOXICOL SCI, V120, P184, DOI 10.1093/toxsci/kfq386; Hauser R, 2007, HUM REPROD, V22, P688, DOI 10.1093/humrep/del428; Hauser R, 2005, Occup Environ Med, V62, P806, DOI 10.1136/oem.2004.017590; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; HEINDEL JJ, 1989, FUND APPL TOXICOL, V12, P508, DOI 10.1016/0272-0590(89)90024-9; Henley DV, 2007, NEW ENGL J MED, V356, P479, DOI 10.1056/NEJMoa064725; Heudorf U, 2007, INT J HYG ENVIR HEAL, V210, P623, DOI 10.1016/j.ijheh.2007.07.011; Heydorn S, 2003, CONTACT DERMATITIS, V48, P317, DOI 10.1034/j.1600-0536.2003.00133.x; Horii Y, 2008, ARCH ENVIRON CON TOX, V55, P701, DOI 10.1007/s00244-008-9172-z; Howdeshell KL, 2008, TOXICOL SCI, V105, P153, DOI 10.1093/toxsci/kfn077; Hubinger JC, 2006, J COSMET SCI, V57, P127; IARC, 1999, IARC MON, V73, P1; IARC, 2000, IARC MONOGR EVAL CAR, V77, P1; International Fragrance Association, 2010, INGR; Jie X, 2010, BIRTH DEFECTS RES B, V89, P418, DOI 10.1002/bdrb.20268; Kamijo Y, 2009, J APPL TOXICOL, V29, P15, DOI 10.1002/jat.1373; Kang KS, 2002, J VET MED SCI, V64, P227, DOI 10.1292/jvms.64.227; Kimber I, 2010, TOXICOLOGY, V271, P73, DOI 10.1016/j.tox.2010.03.020; Koniecki D, 2011, ENVIRON RES, V111, P329, DOI 10.1016/j.envres.2011.01.013; KUMAR P, 1995, ANN ALLERG ASTHMA IM, V75, P429; Kunz PY, 2006, TOXICOL APPL PHARM, V217, P86, DOI 10.1016/j.taap.2006.07.014; Kwon KD, 2008, ENVIRON SCI POLLUT R, V15, P521, DOI 10.1007/s11356-008-0028-x; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; Lorber M, 2008, J EXPO SCI ENV EPID, V18, P2, DOI 10.1038/sj.jes.7500572; Lu CS, 2006, ENVIRON HEALTH PERSP, V114, P260, DOI 10.1289/ehp.8418; Makela R, 2011, OCCUP MED-OXFORD, V61, P121, DOI 10.1093/occmed/kqq192; Meeker JD, 2009, PHILOS T R SOC B, V364, P2097, DOI 10.1098/rstb.2008.0268; Meeker JD, 2009, J ANDROL, V30, P287, DOI 10.2164/jandrol.108.006403; Mendiola J, 2012, J ANDROL, V33, P488, DOI 10.2164/jandrol.111.013557; National Library of Medicine, 2010, HOUS PROD DAT; National Research Council (US) Committee on the Health Risk of Phthalates, 2008, PHTHAL CUM RISK ASS; Nazaroff WW, 2004, ATMOS ENVIRON, V38, P2841, DOI 10.1016/j.atmosenv.2004.02.040; Newton E, 2007, ENVIRON SCI TECHNOL, V41, P221, DOI 10.1021/es0608444; Paul KB, 2010, TOXICOL SCI, V113, P367, DOI 10.1093/toxsci/kfp271; Perencevich EN, 2001, AM J INFECT CONTROL, V29, P281, DOI 10.1067/mic.2001.115469; Piipari R, 1998, CLIN EXP ALLERGY, V28, P358; Plaisance H, 2008, J ENVIRON MONITOR, V10, P517, DOI 10.1039/b802189a; Quinn AL, 2007, TOXICOL SCI, V96, P145, DOI 10.1093/toxsci/kfl185; Rakkestad KE, 2007, J ENVIRON MONITOR, V9, P1419, DOI 10.1039/b709947a; RASTOGI SC, 1995, CONTACT DERMATITIS, V32, P28, DOI 10.1111/j.1600-0536.1995.tb00836.x; Rastogi SC, 2002, CONTACT DERMATITIS, V46, P348, DOI 10.1034/j.1600-0536.2002.460605.x; Rastogi SC, 1996, CONTACT DERMATITIS, V34, P423, DOI 10.1111/j.1600-0536.1996.tb02246.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; Ravid U, 2010, FLAVOUR FRAG J, V25, P20, DOI 10.1002/ffj.1953; Reiner JL, 2006, CHEMOSPHERE, V62, P867, DOI 10.1016/j.chemosphere.2005.10.006; Rodriguez PEA, 2010, J TOXICOL ENV HEAL A, V73, P1678, DOI 10.1080/15287394.2010.516241; Rotroff DM, 2010, TOXICOL SCI, V117, P348, DOI 10.1093/toxsci/kfq220; Routledge EJ, 1998, TOXICOL APPL PHARM, V153, P12, DOI 10.1006/taap.1998.8544; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P914, DOI 10.1289/ehp.1003170; Rudel RA, 2010, ENVIRON SCI TECHNOL, V44, P6583, DOI 10.1021/es100159c; Rudel RA, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-2; Rudel RA, 2009, ATMOS ENVIRON, V43, P170, DOI 10.1016/j.atmosenv.2008.09.025; Saillenfait AM, 2009, J APPL TOXICOL, V29, P510, DOI 10.1002/jat.1436; SAVONIUS B, 1994, ALLERGY, V49, P877, DOI 10.1111/j.1398-9995.1994.tb00791.x; Schlumpf M, 2004, TOXICOLOGY, V205, P113, DOI 10.1016/j.tox.2004.06.043; Schreurs RHMM, 2005, TOXICOL SCI, V83, P264, DOI 10.1093/toxsci/kfi035; Seinen W, 1999, TOXICOL LETT, V111, P161, DOI 10.1016/S0378-4274(99)00177-0; Shen HY, 2007, J SEP SCI, V30, P48, DOI 10.1002/jssc.200600215; Silicones Environmental Health and Safety Council of North America, 2011, SCI HLTH SAF DEC; Silent Spring Institute, 2012, TABL CONS PROD TEST; Singer BC, 2006, ATMOS ENVIRON, V40, P6696, DOI 10.1016/j.atmosenv.2006.06.005; Smith SW, 2009, TOXICOL SCI, V110, P4, DOI 10.1093/toxsci/kfp097; Soni MG, 2001, FOOD CHEM TOXICOL, V39, P513, DOI 10.1016/S0278-6915(00)00162-9; Starek A, 2008, ARCH TOXICOL, V82, P125, DOI 10.1007/s00204-007-0236-z; Steinemann AC, 2011, ENVIRON IMPACT ASSES, V31, P328, DOI 10.1016/j.eiar.2010.08.002; Steinemann AC, 2009, ENVIRON IMPACT ASSES, V29, P32, DOI 10.1016/j.eiar.2008.05.002; Stoker TE, 2010, TOXICOL SCI, V117, P45, DOI 10.1093/toxsci/kfq180; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Swan SH, 2008, ENVIRON RES, V108, P177, DOI 10.1016/j.envres.2008.08.007; Food and Agriculture Organization of the United Nations/World Health Organization), 2010, JOINT FAO WHO EXP M; van der Burg B, 2008, INT J ANDROL, V31, P188, DOI 10.1111/j.1365-2605.2007.00831.x; Wang R, 2009, ENVIRON INT, V35, P900, DOI 10.1016/j.envint.2009.03.009; Weschler CJ, 2009, ATMOS ENVIRON, V43, P153, DOI 10.1016/j.atmosenv.2008.09.044; Ye XY, 2006, ENVIRON HEALTH PERSP, V114, P1843, DOI 10.1289/ehp.9413; Zhang XL, 2008, CHEMOSPHERE, V72, P1553, DOI 10.1016/j.chemosphere.2008.04.039; Zota AR, 2008, ENVIRON SCI TECHNOL, V42, P8158, DOI 10.1021/es801792z	104	114	119	23	190	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2012	120	7					935	943		10.1289/ehp.1104052		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	969DG	WOS:000306035300016	22398195	
J	Kim, HY; Chang, YJ; Subramanian, S; Lee, HH; Albacker, LA; Matangkasombut, P; Savage, PB; McKenzie, ANJ; Smith, DE; Rottman, JB; DeKruyff, RH; Umetsu, DT				Kim, Hye Young; Chang, Ya-Jen; Subramanian, Srividya; Lee, Hyun-Hee; Albacker, Lee A.; Matangkasombut, Ponpan; Savage, Paul B.; McKenzie, Andrew N. J.; Smith, Dirk E.; Rottman, James B.; DeKruyff, Rosemarie H.; Umetsu, Dale T.			Innate lymphoid cells responding to IL-33 mediate airway hyperreactivity independently of adaptive immunity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Innate; natural killer T; natural helper cells; T(H)2; IL-33; IL-13; glycolipid; asthma	KILLER T-CELLS; INVARIANT NKT CELLS; IN-VIVO; RHEUMATOID-ARTHRITIS; EXPERIMENTAL ASTHMA; TYPE-2 IMMUNITY; INFLAMMATION; RECEPTOR; EXPRESSION; RESPONSES	Background: Asthma has been considered an immunologic disease mediated by T(H)2 cells and adaptive immunity. However, clinical and experimental observations suggest that additional pathways might regulate asthma, particularly in its nonallergic forms, such as asthma associated with air pollution, stress, obesity, and infection. Objectives: Our goal was to understand T(H)2 cell-independent conditions that might lead to airway hyperreactivity (AHR), a cardinal feature of asthma. Methods: We examined a murine model of experimental asthma in which AHR was induced with glycolipid antigens, which activate natural killer T (NKT) cells. Results: In this model AHR developed rapidly when mice were treated with NKT cell-activating glycolipid antigens, even in the absence of conventional CD4(+) T cells. The activated NKT cells directly induced alveolar macrophages to produce IL-33, which in turn activated NKT cells, as well as natural helper cells, a newly described non-T, non-B, innate lymphoid cell type, to increase production of IL-13. Surprisingly, this glycolipid-induced AHR pathway required not only IL-13 but also IL-33 and its receptor, ST2, because it was blocked by an anti-ST2 mAb and was greatly reduced in ST2(-/-) mice. When adoptively transferred into IL-13(-/-) mice, both wild-type natural helper cells and NKT cells were sufficient for the development of glycolipid-induced AHR. Conclusion: Because plant pollens, house dust, and some bacteria contain glycolipids that can directly activate NKT cells, these studies suggest that AHR and asthma can fully develop or be greatly enhanced through innate immune mechanisms involving IL-33, natural helper cells, and NKT cells. (J Allergy Clin Immunol 2012;129:216-27.)	[Kim, Hye Young; Chang, Ya-Jen; Subramanian, Srividya; Lee, Hyun-Hee; Albacker, Lee A.; Matangkasombut, Ponpan; DeKruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Univ, Sch Med, Childrens Hosp, Div Immunol & Allergy, Boston, MA 02115 USA; [Savage, Paul B.] Brigham Young Univ, Dept Chem & Biochem, Provo, UT 84602 USA; [McKenzie, Andrew N. J.] MRC Lab Mol Biol, Cambridge, England; [Smith, Dirk E.] Amgen Inc, Dept Inflammat Res, Seattle, WA USA; [Rottman, James B.] Amgen Inc, Dept Pathol, Cambridge, MA USA	Umetsu, DT (reprint author), Harvard Univ, Sch Med, Childrens Hosp, Karp Labs,Div Immunol, Rm 10127,1 Blackfan Circle, Boston, MA 02115 USA.	dale.umetsu@childrens.harvard.edu			National Institutes of Health; Amgen, Inc.	P. B. Savage has received research support from the National Institutes of Health. J. B. Rottman is employed by and has received research support from Amgen, Inc. The rest of the authors declare that they have no relevant conflicts of interest.	Agea E, 2005, J EXP MED, V202, P295, DOI 10.1084/jem.20050773; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Bedoret D, 2009, J CLIN INVEST, V119, P3723, DOI 10.1172/JCI39717; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Geremia A, 2011, J EXP MED, V208, P1127, DOI 10.1084/jem.20101712; Global Initiative for Asthma (GINA) [homepage on the Internet, GLOB STRAT ASTHM MAN; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kim S, 2008, J CLIN INVEST, V118, P2301, DOI [10.1172/JCI33071, 10.1172/JC133071]; Kinjo Y, 2005, NATURE, V434, P520, DOI 10.1038/nature03407; Kinjo Y, 2006, NAT IMMUNOL, V7, P978, DOI 10.1038/ni1380; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lisbonne M, 2003, J IMMUNOL, V171, P1637; Lohning M, 2003, J EXP MED, V197, P181, DOI 10.1084/jem.20020632; Mangan NE, 2007, EUR J IMMUNOL, V37, P1302, DOI 10.1002/eji.200636520; Matangkasombut P, 2009, MUCOSAL IMMUNOL, V2, P383, DOI [10.1038/mi.2009.96, 10.1038/mi2009.96]; Mattner J, 2005, NATURE, V434, P525, DOI 10.1038/nature03408; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mu R, 2010, J RHEUMATOL, V37, P2006, DOI 10.3899/jrheum.100184; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Pastorelli L, 2010, P NATL ACAD SCI USA, V107, P8017, DOI 10.1073/pnas.0912678107; Pichavant M, 2008, J EXP MED, V205, P385, DOI 10.1084/jem.20071507; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Saenz SA, 2010, NATURE, V464, P1371; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Verri WA, 2010, ANN RHEUM DIS, V69, P1697, DOI 10.1136/ard.2009.122655; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229; Yagami A, 2010, J IMMUNOL, V185, P5743, DOI 10.4049/jimmunol.0903818; Zhou DP, 2004, SCIENCE, V306, P1786, DOI 10.1126/science/1103440	56	114	120	0	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2012	129	1					216	U319		10.1016/j.jaci.2011.10.036		18	Allergy; Immunology	Allergy; Immunology	869XT	WOS:000298634000028	22119406	
J	Strickland, MJ; Darrow, LA; Klein, M; Flanders, WD; Sarnat, JA; Waller, LA; Sarnat, SE; Mulholland, JA; Tolbert, PE				Strickland, Matthew J.; Darrow, Lyndsey A.; Klein, Mitchel; Flanders, W. Dana; Sarnat, Jeremy A.; Waller, Lance A.; Sarnat, Stefanie E.; Mulholland, James A.; Tolbert, Paige E.			Short-term Associations between Ambient Air Pollutants and Pediatric Asthma Emergency Department Visits	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						ambient particulate matter, asthma; minors; ozone	SOUTHEASTERN UNITED-STATES; CASE-CROSSOVER ANALYSES; FINE PARTICULATE MATTER; TIME-SERIES METHODS; SOURCE APPORTIONMENT; SPATIAL VARIABILITY; REFERENT SELECTION; AEROSOL RESEARCH; ORGANIC-CARBON; DAILY DEATHS	Rationale: Certain outdoor air pollutants cause asthma exacerbations in children. To advance understanding of these relationships, further characterization of the dose-response and pollutant lag effects are needed, as are investigations of pollutant species beyond the commonly measured criteria pollutants. Objectives: Investigate short-term associations between ambient air pollutant concentrations and emergency department visits for pediatric asthma. Methods: Daily counts of emergency department visits for asthma or wheeze among children aged 5 to 17 years were collected from 41 Metropolitan Atlanta hospitals during 1993-2004 (n = 91,386 visits). Ambient concentrations of gaseous pollutants and speciated particulate matter were available from stationary monitors during this time period Rate ratios for the warm season (May to October) and cold season (November to April) were estimated using Poisson generalized linear models in the framework of a case-crossover analysis Measurements and Main Results: Both ozone and primary pollutants from traffic sources were associated with emergency department visits for asthma or wheeze; evidence for independent effects of ozone and primary pollutants from traffic sources were observed in multipollutant models. These associations tended to be of the highest magnitude for concentrations on the day of the emergency department visit and were present at relatively low ambient concentrations. Conclusions. Even at relatively low ambient concentrations, ozone and primary pollutants from traffic sources independently contributed to the burden of emergency department visits for pediatric asthma	[Strickland, Matthew J.; Darrow, Lyndsey A.; Klein, Mitchel; Sarnat, Jeremy A.; Sarnat, Stefanie E.; Tolbert, Paige E.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA; [Flanders, W. Dana] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; [Waller, Lance A.] Emory Univ, Rollins Sch Publ Hlth, Dept Biostat & Bioinformat, Atlanta, GA 30322 USA; [Mulholland, James A.] Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA	Strickland, MJ (reprint author), Dept Environm & Occupat Hlth, 1518 Clifton Rd NE, Atlanta, GA 30322 USA.		Tolbert, Paige/A-5676-2015		National Institute of Environmental Health Sciences [R01ES012967]; Environmental Protection Agency [STAR R82921301]; Electric Power Research Institute [EP-P27723/C13172]; nonprofit Care, Inc	Supported by grants from National Institute of Environmental Health Sciences (R01ES012967), Environmental Protection Agency (STAR R82921301), and the Electric Power Research Institute (EP-P27723/C13172); M J S, L A D, M K, W D F, J A S, L A W, S E S, J A M, and P E T received more than 8100,001 from the non-profit Electric Power Research Institute in sponsored grants (grant EP-P27723/C13172) LAW received $10,001 to $50,000 from the nonprofit Care, Inc in sponsored grants	Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Bateson TF, 2008, J TOXICOL ENV HEAL A, V71, P238, DOI 10.1080/15287390701598234; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; DARROW LA, J EXPO SCI ENV EPIDE; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P550, DOI 10.1289/ehp.10911; Ding X, 2008, ENVIRON SCI TECHNOL, V42, P5171, DOI 10.1021/es7032636; Ding X, 2008, ENVIRON SCI TECHNOL, V42, P9122, DOI 10.1021/es802115t; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Dominici F, 2004, J AM STAT ASSOC, V99, P938, DOI 10.1198/016214504000000656; Edgerton ES, 2005, J AIR WASTE MANAGE, V55, P1527, DOI 10.1080/10473289.2005.10464744; Eggleston PA, 2009, PEDIATRICS, V123, pS160, DOI 10.1542/peds.2008-2233F; Flanders WD, 2005, J AGR BIOL ENVIR ST, V10, P246, DOI 10.1198/108571105X47010; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Hollingsworth John W, 2007, Proc Am Thorac Soc, V4, P240, DOI 10.1513/pats.200701-023AW; Ivy D, 2008, J AIR WASTE MANAGE, V58, P711, DOI 10.3155/1047-3289.58.5.711; Jalaludin B, 2008, INT ARCH OCC ENV HEA, V81, P967, DOI 10.1007/s00420-007-0290-0; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.edu.0000181315.18836.9d; Jansen KL, 2005, ENVIRON HEALTH PERSP, V113, P1741, DOI 10.1289/ehp.8153; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Lu Y, 2008, EPIDEMIOLOGY, V19, P169, DOI [10.1097/EDE.0b013e3181632c24, 10.1097/EDE.0b0l3e3181632c24]; Lu Y, 2007, BIOSTATISTICS, V8, P337, DOI 10.1093/biostatistics/kxl013; Marmur A, 2006, ATMOS ENVIRON, V40, P2533, DOI 10.1016/j.atmosenv.2005.12.019; Mauderly JL, 2009, ENVIRON HEALTH PERSP, V117, P1, DOI 10.1289/ehp.11654; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; Metzger KB, 2007, EPIDEMIOLOGY, V18, P585, DOI 10.1097/EDE.0b013e318124ff0e; Mohr LB, 2008, J ASTHMA, V45, P936, DOI 10.1080/02770900802404082; Moore K, 2008, ENVIRON HEALTH PERSP, V116, P1063, DOI 10.1289/ehp.10497; National Heart Lung and Blood Institute, 2007, NIH PUBL, V08-5846; National Research Council, 2004, RES PRIOR AIRB PART, VIV; Ostro B, 2009, ENVIRON HEALTH PERSP, V117, P475, DOI 10.1289/ehp.11848; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Pendergraft TB, 2005, J ASTHMA, V42, P265, DOI 10.1081/JAS-200057893; Reiss R, 2007, INHAL TOXICOL, V19, P419, DOI 10.1080/08958370601174941; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Sarnat SE, 2010, J EXPO SCI ENV EPID, V20, P135, DOI 10.1038/jes.2009.10; Schlesinger RB, 2007, INHAL TOXICOL, V19, P811, DOI 10.1080/08958370701402382; Schwartz J, 2004, OCCUP ENVIRON MED, V61, P956, DOI 10.1136/oem.2003.008250; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Selgrade MK, 2008, J TOXICOL ENV HEAL A, V71, P196, DOI 10.1080/15287390701597897; Strickland M, 2009, EPIDEMIOLOGY, V20, pS163; Szyszkowicz M, 2008, INT J OCCUP MED ENV, V21, P25, DOI 10.2478/v10001-008-0002-3; Tolbert PE, 2007, J EXPO SCI ENV EPID, V17, pS29, DOI 10.1038/sj.jes.7500625; Tolbert PE, 2000, J EXPO ANAL ENV EPID, V10, P446, DOI 10.1038/sj.jea.7500106; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; *US EPA, 2006, EPA600R05004AFCF US; US Environmental Protection Agency (US EPA), 2004, 600P99002AFBF US EPA; Van Loy M, 2000, J AIR WASTE MANAGE, V50, P1446; Villeneuve PJ, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-40; Wade KS, 2006, J AIR WASTE MANAGE, V56, P876; World Health Organization, 2004, HLTH ASP AIR POLL RE; Zheng M, 2007, J AIR WASTE MANAGE, V57, P228	54	114	118	0	23	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2010	182	3					307	316		10.1164/rccm.200908-1201OC		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	635ZP	WOS:000280697400005	20378732	
J	Martin, SF; Dudda, JC; Bachtanian, E; Lembo, A; Liller, S; Durr, C; Heimesaat, MM; Bereswill, S; Fejer, G; Vassileva, R; Jakob, T; Freudenberg, N; Termeer, CC; Johner, C; Galanos, C; Freudenberg, MA				Martin, Stefan F.; Dudda, Jan C.; Bachtanian, Eva; Lembo, Annalisa; Liller, Stefanie; Duerr, Christoph; Heimesaat, Markus M.; Bereswill, Stefan; Fejer, Gyoergy; Vassileva, Ralitsa; Jakob, Thilo; Freudenberg, Nikolaus; Termeer, Christian C.; Johner, Caroline; Galanos, Chris; Freudenberg, Marina A.			Toll-like receptor and IL-12 signaling control susceptibility to contact hypersensitivity	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							ACTIVATED PROTEIN-KINASE; CD8(+) T-CELLS; DENDRITIC CELLS; IFN-ALPHA; IMMUNE-RESPONSES; CUTTING EDGE; FLUORESCEIN ISOTHIOCYANATE; SENSITIZER TRINITROPHENYL; MEDIATED INHIBITION; C57BL/10SCCR MICE	Allergic contact hypersensitivity (CHS) is a T cell-mediated inflammatory skin disease. Interleukin (IL)-12 is considered to be important in the generation of the allergen-specific T cell response. Loss of IL-12 function in IL-12R beta 2-deficient mice, however, did not ameliorate the allergic immune response, suggesting alternate IL-12-independent pathways in the induction of CHS. Because exposure to contact allergens always takes place in the presence of microbial skin flora, we investigated the potential role of Toll-like receptors (TLRs) in the induction of CHS. Using mice deficient in TLR4, the receptor for bacterial lipopolysaccharide (LPS), IL-12 receptor (R) beta 2, or both, we show that the concomitant absence of TLR4 and IL-12R beta 2, but not the absence of TLR4 or IL-12R beta 2 alone, prevented DC-mediated sensitization, generation of effector T cells, and the subsequent CHS response to 2,4,6-trinitro-1-chlorobenzene (TNCB), oxazolone, and fluorescein isothiocyanate. Introduction of the TLR4 transgene into the TLR4/IL-12R beta 2 mutant restored the CHS inducibility, showing a requirement for TLR4 in IL-12-independent CHS induction. Furthermore, the concomitant absence of TLR2 and TLR4 prevented the induction of CHS to TNCB in IL-12-competent mice. Finally, CHS was inducible in germ-free wild-type and IL-12R beta 2-deficient mice, but not in germ-free TLR4/IL-12R beta 2 double deficient mice, suggesting that the necessary TLR activation may proceed via endogenous ligands.	[Martin, Stefan F.; Dudda, Jan C.; Bachtanian, Eva; Liller, Stefanie; Duerr, Christoph; Jakob, Thilo; Termeer, Christian C.] Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, D-79104 Freiburg, Germany; [Lembo, Annalisa; Fejer, Gyoergy; Vassileva, Ralitsa; Johner, Caroline; Galanos, Chris; Freudenberg, Marina A.] Max Planck Inst Immunobiol, D-79108 Freiburg, Germany; [Heimesaat, Markus M.; Bereswill, Stefan] Charite Univ Med Berlin, Inst Microbiol & Hyg, D-13353 Berlin, Germany; [Freudenberg, Nikolaus] Univ Med Ctr Freiburg, Inst Pathol, D-79106 Freiburg, Germany	Martin, SF (reprint author), Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, D-79104 Freiburg, Germany.	stefan.martin@uniklinik-freiburg.de; freudenberg@immunbio.mpg.de	Fejer, Gyorgy/D-5080-2011; Jakob, Thilo/J-1621-2012		Deutsche Forschungsgemeinschaft [DFG SP1110-FR 448/4-3, SFB633/A7]; Forschungskommission der Medizinischen Fakultat; Fritz-Thyssen-Stiftung [Az.: 10.05.2.194]	The study was supported in part by a grant of the Deutsche Forschungsgemeinschaft (DFG SP1110-FR 448/4-3) to M. A. Freudenberg and by a grant of the Forschungskommission der Medizinischen Fakultat, University Medical Center Freiburg, to S. F. Martin. M. M. Heimesaat and S. Bereswill were financed by the Fritz-Thyssen-Stiftung (Az.: 10.05.2.194) and by the Deutsche Forschungsgemeinschaft (SFB633/A7), respectively.	Agrawal S, 2003, J IMMUNOL, V171, P4984; Ahonen CL, 2004, J EXP MED, V199, P775, DOI 10.1084/jem.20031591; Aiba S, 2003, J INVEST DERMATOL, V120, P390, DOI 10.1046/j.1523-1747.2003.12065.x; Arrighi JF, 2001, J IMMUNOL, V166, P3837; Berdeli A, 2005, J MOL MED-JMM, V83, P535, DOI 10.1007/s00109-005-0677-x; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Blanco P, 2001, SCIENCE, V294, P1540, DOI 10.1126/science.1064890; Brand P, 2002, J INVEST DERMATOL, V119, P99, DOI 10.1046/j.1523-1747.2002.01791.x; Buelens C, 2002, BLOOD, V99, P993, DOI 10.1182/blood.V99.3.993; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Cooke GS, 2002, NEW ENGL J MED, V347, P1978; Curtsinger JM, 2005, J IMMUNOL, V174, P4465; Dearman RJ, 2005, CLIN EXP ALLERGY, V35, P498, DOI 10.1111/j.1365-2222.2005.02209.x; Dearman RJ, 2000, IMMUNOLOGY, V101, P442, DOI 10.1046/j.1365-2567.2000.00126.x; Doffinger R, 1999, ALLERGY, V54, P409, DOI 10.1034/j.1398-9995.1999.00088.x; Dudda JC, 2005, EUR J IMMUNOL, V35, P1056, DOI 10.1002/eji.200425817; Ehl S, 2004, EUR J IMMUNOL, V34, P1146, DOI 10.1002/eji.200324449; Freudenberg MA, 2002, J IMMUNOL, V169, P1665; Gabriele L, 2004, BLOOD, V103, P980, DOI 10.1182/blood-2003-03-0981; Gorbachev AV, 2004, J IMMUNOL, V173, P2443; Gorbachev AV, 2001, J IMMUNOL, V167, P156; Hamann L, 2005, J MOL MED-JMM, V83, P478, DOI 10.1007/s00109-005-0643-7; Hargreaves DC, 2005, J CLIN IMMUNOL, V25, P503, DOI 10.1007/s10875-005-8065-4; He DG, 2006, J IMMUNOL, V177, P6852; Hosogi M, 2004, J DERMATOL SCI, V36, P51, DOI 10.1016/j.jdermsci.2004.07.007; Hunter CA, 2005, NAT REV IMMUNOL, V5, P521, DOI 10.1038/nri1648; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Jiang DH, 2006, CELL RES, V16, P693, DOI 10.1038/sj.cr.7310085; Jiang ZF, 2005, NAT IMMUNOL, V6, P565, DOI 10.1038/ni1207; Kaisho T, 2001, J IMMUNOL, V166, P5688; Kalis C, 2005, J IMMUNOL, V174, P4295; Kalis C, 2003, EUR J IMMUNOL, V33, P798, DOI 10.1002/eji.200323431; Kalsch T, 2006, INT J CARDIOL, V107, P350, DOI 10.1016/j.ijcard.2005.03.047; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kolumam GA, 2005, J EXP MED, V202, P637, DOI 10.1084/jem.20050821; Krieg AM, 2003, SCAND J INFECT DIS, V35, P653, DOI 10.1080/00365540310015999; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Lapenta C, 2006, EUR J IMMUNOL, V36, P2046, DOI 10.1002/eji.200535579; Martin S, 2003, EXP DERMATOL, V12, P78, DOI 10.1034/j.1600-0625.2003.120110.x; Martin SF, 2006, MINI-REV MED CHEM, V6, P247, DOI 10.2174/138955706776073493; Martin SF, 2004, J IMMUNOL, V173, P3178; Martin SF, 2004, INT ARCH ALLERGY IMM, V134, P186, DOI 10.1159/000078765; Matsui E, 1999, BIOCHEM BIOPH RES CO, V266, P551, DOI 10.1006/bbrc.1999.1859; Merlin T, 2001, J IMMUNOL, V166, P566; Mummert ME, 2005, IMMUNOL RES, V31, P189, DOI 10.1385/IR:31:3:189; Mummert ME, 2002, J IMMUNOL, V169, P4322; Mummert ME, 2000, J EXP MED, V192, P769, DOI 10.1084/jem.192.6.769; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Peng JC, 2006, IMMUNOL CELL BIOL, V84, P227, DOI 10.1111/j.1440-1711.2006.01419.x; Poltorak A, 2001, J IMMUNOL, V167, P2106; Poltorak A, 2000, J ENDOTOXIN RES, V6, P51, DOI 10.1177/09680519000060010701; Sabroe I, 2002, CLIN EXP ALLERGY, V32, P984, DOI 10.1046/j.1365-2745.2002.01451.x; Santodonato L, 2003, J IMMUNOL, V170, P5195; Scheibner KA, 2006, J IMMUNOL, V177, P1272; Schuetze N, 2005, INT IMMUNOL, V17, P649, DOI 10.1093/intimm/dxh247; Sing A, 2000, INFECT IMMUN, V68, P1600, DOI 10.1128/IAI.68.3.1600-1607.2000; Sousa CR, 2003, PATHOL BIOL, V51, P67; Takakuwa T, 1996, EUR J IMMUNOL, V26, P2686, DOI 10.1002/eji.1830261121; Takanami-Ohnishi Y, 2002, J BIOL CHEM, V277, P37896, DOI 10.1074/jbc.M207326200; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; Takeshita K, 2004, INT IMMUNOL, V16, P685, DOI 10.1093/intimm/dxh073; Taylor KR, 2007, J BIOL CHEM, V282, P18265, DOI 10.1074/jbc.M606352200; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; Tsan MF, 2004, J LEUKOCYTE BIOL, V76, P514, DOI 10.1189/jlb.0304127; Watanabe H, 2002, J INTERF CYTOK RES, V22, P407, DOI 10.1089/10799900252952181	66	114	115	0	2	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	SEP 1	2008	205	9					2151	2162		10.1084/jem.20070509		12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	354RI	WOS:000259656300019	18725520	
J	Pilette, C; Nouri-Aria, KT; Jacobson, MR; Wilcock, LK; Detry, B; Walker, SM; Francis, JN; Durham, SR				Pilette, Charles; Nouri-Aria, Kayhan T.; Jacobson, Mikila R.; Wilcock, Louisa K.; Detry, Bruno; Walker, Samantha M.; Francis, James N.; Durham, Stephen R.			Grass pollen immunotherapy induces an allergen-specific IgA2 antibody response associated with mucosal TGF-beta expression	JOURNAL OF IMMUNOLOGY			English	Article							GROWTH-FACTOR-BETA; MESSENGER-RNA EXPRESSION; T-CELL DIFFERENTIATION; VENOM IMMUNOTHERAPY; DENDRITIC CELLS; B-CELLS; IGG ANTIBODIES; SECRETORY IGA; HOUSE-DUST; INTERLEUKIN-10	Allergen immunotherapy (IT) has long-term efficacy in IgE-mediated allergic rhinitis and asthma. IT has been shown to modify lymphocyte responses to allergen, inducing IL-10 production and IgG Abs. In contrast, a putative role for IgA and local TGF-beta-producing cells remains to be determined. In 44 patients with seasonal rhinitis/asthma, serum IgA1, IgA2, and polymeric (J chain-containing) Abs to the major allergen Phi p 5 were determined by ELISA before and after a 2-year double-blind trial of grass pollen (Phleum pratense) injection IT. Nasal TGF-beta expression was assessed by in situ hybridization. Sera from five IT patients were fractionated for functional analysis of the effects of IgA and IgG Abs on IL-10 production by blood monocytes and allergen-IgE binding to B cells. Serum Phi p 5-specific IgA2 Abs increased after a 2-year treatment (similar to 8-fold increase, p = 0.002) in contrast to IgA1. Increases in polymeric Abs to Phi p 5 (similar to 2-fold increase,p = 0.02) and in nasal TGF-beta mRNA (p = 0.05) were also observed, and TGF-beta mRNA correlated with serum Phi p 5 IgA2 (r = 0.61,p = 0.009). Post-IT IgA fractions triggered IL-10 secretion by monocytes while not inhibiting allergen-IgE binding to B cells as observed with IgG fractions. This study shows for the first time that the IgA response to IT is selective for IgA2, correlates with increased local TGF-beta expression, and induces monocyte IL-10 expression, suggesting that IgA Abs could thereby contribute to the tolerance developed in IT-treated allergic patients.	Imperial Coll Sch Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England; Univ Louvain, Unit Pneumol, Brussels, Belgium	Durham, SR (reprint author), Imperial Coll Sch Med, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, Dovehouse St, London, England.	s.durham@imperial.ac.uk	James, Louisa/C-9831-2010; Walker, Samantha/B-9740-2013	James, Louisa/0000-0002-2252-4636; Walker, Samantha/0000-0001-5503-8258	Medical Research Council [G0601303]		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; Allavena P, 1998, EUR J IMMUNOL, V28, P359, DOI 10.1002/(SICI)1521-4141(199801)28:01<359::AID-IMMU359>3.0.CO;2-4; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Benson M, 2003, ALLERGY, V58, P386, DOI 10.1034/j.1398-9995.2003.00113.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; Chen CH, 2003, J EXP MED, V197, P1689, DOI 10.1084/jem.20021170; COFFMAN RL, 1989, J EXP MED, V170, P1039, DOI 10.1084/jem.170.3.1039; DELACROIX DL, 1986, MOL IMMUNOL, V23, P367, DOI 10.1016/0161-5890(86)90134-3; Fayette J, 1997, J EXP MED, V185, P1909, DOI 10.1084/jem.185.11.1909; FLANAGAN JG, 1984, CELL, V36, P681, DOI 10.1016/0092-8674(84)90348-9; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Geissmann F, 2001, J IMMUNOL, V166, P346; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V75, P496, DOI 10.1016/S0091-6749(85)80023-3; Goerdt S, 1999, IMMUNITY, V10, P137, DOI 10.1016/S1074-7613(00)80014-X; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Heystek HC, 2002, J IMMUNOL, V168, P102; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; KITANI A, 1994, J IMMUNOL, V153, P1466; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; MALEFYT RD, 1991, J EXP MED, V174, P915; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Pilette C, 2003, AM J RESP CELL MOL, V28, P485, DOI 10.1165/rcmb.4913; Pilette Charles, 2004, Proc Am Thorac Soc, V1, P125, DOI 10.1513/pats.2306032; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Robertson AKL, 2003, J CLIN INVEST, V112, P1342, DOI 10.1172/JCI200318607; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; Schmidt-Weber CB, 2004, CURR OPIN IMMUNOL, V16, P709, DOI 10.1016/j.coi.2004.09.008; Schwarze J, 1998, AM J RESP CRIT CARE, V158, P519; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; STOKES CR, 1974, LANCET, V2, P485; Sutterwala FS, 1998, J EXP MED, V188, P217, DOI 10.1084/jem.188.1.217; TAUDORF E, 1994, ALLERGY, V49, P760, DOI 10.1111/j.1398-9995.1994.tb02099.x; TAYLOR B, 1973, LANCET, V2, P111; van der Boog PJM, 2002, J IMMUNOL, V168, P1252; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; WOLF HM, 1994, PEDIATR RES, V36, P235, DOI 10.1203/00006450-199408000-00016; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x	52	114	124	0	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	APR 1	2007	178	7					4658	4666				9	Immunology	Immunology	150EB	WOS:000245197300075	17372025	
J	Steinbuch, M; Youket, TE; Cohen, S				Steinbuch, M; Youket, TE; Cohen, S			Oral glucocorticoid use is associated with an increased risk of fracture	OSTEOPOROSIS INTERNATIONAL			English	Article; Proceedings Paper	World Congress on Osteoporosis	JUN 15-18, 2000	CHICAGO, IL			epidemiology; fracture; oral glucocorticoids; osteoporosis	LOW-DOSE CORTICOSTEROIDS; RHEUMATOID-ARTHRITIS PATIENTS; BONE-MINERAL DENSITY; INDUCED OSTEOPOROSIS; VERTEBRAL FRACTURES; INDUCED OSTEOPENIA; THERAPY; ASTHMA; MASS; SPINE	Oral glucocorticoids (GCs) are widely used and despite their adverse effects on bone mineral density, the risk of sustaining osteoporotic fractures is not well addressed. The objective of this retrospective, cohort study was to assess fracture risk in patients exposed to oral GCs. Patients from an administrative claims database who were prescribed oral GCs and were enrolled 1 year before and 1 year after the initial oral GC claim were matched with a comparison population on age, sex, and date of first claim. Measurements of exposure included amount, duration, and pattern of oral GC use. The osteoporosis-related risk of fracture was based on the ratio of hazard functions estimated using a Cox proportional hazards model. The adjusted relative risk (RR) estimates (and 95% CI) for fractures were hip 1.87 (95% CI, 1.2 to 2.9), vertebral 2.92 (95% CI, 2.0 to 4.3), wrist/forearm 1.03 (95% CI, 0.8 to 1.4), nonvertebral 1.68 (95% CI, 1.5 to 1.9), any fracture 1.75 (95% CI, 1.6 to 1.9). A dose dependence of fracture risk was observed for hip, vertebral, nonvertebral, and any fractures. Long duration and continuous pattern of GC use demonstrated a significant 5-fold increased risk of hip and 5.9-fold increased risk of vertebral fracture. The combined effect of higher dose, longer duration, and continuous pattern further increased RR estimates to 7-fold for hip and 17-fold for vertebral fractures. This study confirms previous observations that suggest oral GCs have a rapid deleterious effect on trabecular-rich bone. The emerging relationship between amount, duration, and pattern of oral GC exposure and fracture risk should be considered in clinical practice and managed care settings to avoid the debilitating effects of fractures in patients.	Procter & Gamble Co, Hlth Care Res Ctr, Mason, OH 45040 USA; St Paul Ramsey Med Ctr, Dept Rheumatol, Dallas, TX 75235 USA	Steinbuch, M (reprint author), Procter & Gamble Co, Hlth Care Res Ctr, 8700 Mason Montgomery Rd, Mason, OH 45040 USA.	Steinbuch.m@pg.com					ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; ALS OS, 1985, ARTHRITIS RHEUM, V28, P369, DOI 10.1002/art.1780280403; Buckley L, 2001, ARTHRITIS RHEUM, V44, P1496; BUCKLEY LM, 1995, J RHEUMATOL, V22, P1055; BUTLER RC, 1991, BRIT J RHEUMATOL, V30, P86; COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49; DEDEUXCHAISNES CN, 1984, ADV EXP MED BIOL, V171, P209; DYKMAN TR, 1985, ARTHRITIS RHEUM, V28, P361, DOI 10.1002/art.1780280402; GARTON MJ, 1993, ARTHRITIS RHEUM, V36, P222; GREENBERGER PA, 1982, CLIN ALLERGY, V12, P363, DOI 10.1111/j.1365-2222.1982.tb02540.x; HAHN TJ, 1979, J CLIN INVEST, V64, P655, DOI 10.1172/JCI109506; HOOYMAN JR, 1984, ARTHRITIS RHEUM, V27, P1353, DOI 10.1002/art.1780271205; LAAN RFJM, 1993, ANN INTERN MED, V119, P963; LAAN RFJM, 1992, BRIT J RHEUMATOL, V31, P91; LEMS WF, 1995, CLIN EXP RHEUMATOL, V13, P293; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; MICHEL BA, 1993, J RHEUMATOL, V20, P1666; Naganathan V, 2000, ARCH INTERN MED, V160, P2917, DOI 10.1001/archinte.160.19.2917; Ramsey-Goldman R, 1999, ARTHRITIS RHEUM, V42, P882, DOI 10.1002/1529-0131(199905)42:5<882::AID-ANR6>3.0.CO;2-C; REID DM, 1986, BRIT MED J, V293, P1463; REID IR, 1992, J BONE MINER RES, V7, P1221; RUEGSEGGER P, 1983, EUR J CLIN PHARMACOL, V25, P615, DOI 10.1007/BF00542348; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; SAMBROOK PN, 1987, ARTHRITIS RHEUM, V30, P721, DOI 10.1002/art.1780300701; van Staa TP, 2002, OSTEOPOROSIS INT, V13, P777; van Staa TP, 2002, ARTHRITIS RHEUM, V46, pS585; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852	28	114	130	0	1	SPRINGER-VERLAG LONDON LTD	GODALMING	SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND	0937-941X			OSTEOPOROSIS INT	Osteoporosis Int.	APR	2004	15	4					323	328		10.1007/s00198-003-1548-3		6	Endocrinology & Metabolism	Endocrinology & Metabolism	808HP	WOS:000220560500010	14762652	
J	Akdis, M; Trautmann, A; Klunker, S; Daigle, I; Kucuksezer, UC; Deglmann, W; Disch, R; Blaser, K; Akdis, CA				Akdis, M; Trautmann, A; Klunker, S; Daigle, I; Kucuksezer, UC; Deglmann, W; Disch, R; Blaser, K; Akdis, CA			T helper (Th) 2 predominance in atopic diseases is due to preferential apoptosis of circulating memory/effector Th1 cells	FASEB JOURNAL			English	Article						activation-induced cell death; atopic dermatitis; cytokines; T cells; Th1/Th2	LYMPHOCYTE-ASSOCIATED ANTIGEN; ACTIVATION-INDUCED APOPTOSIS; FAS-MEDIATED APOPTOSIS; SIGNALING COMPLEX; HECA-452 EPITOPE; IN-VIVO; DERMATITIS; DEATH; EXPRESSION; SKIN	T cells constitute a large population of cellular infiltrate in atopic/allergic inflammation and a dysregulated, Th2-biased peripheral immune response appears to be an important pathogenetic factor. In atopic dermatitis, circulating cutaneous lymphocyte-associated antigen-bearing (CLA(+)) CD45RO(+) T cells with skin-specific homing property represent an activated memory/effector T cell subset. They express high levels of Fas and Fas ligand and undergo activation-induced apoptosis. The freshly purified (CLA(+)) CD45RO(+) T cells of atopic individuals display distinct features of in vivo-triggered apoptosis such as procaspase degradation and active caspase-8 formation. In particular, the Th1 compartment of activated memory/effector T cells selectively undergoes activation-induced cell death, skewing the immune response toward surviving Th2 cells in atopic dermatitis patients. The apoptosis of circulating memory/effector T cells was confined to atopic individuals whereas non-atopic patients such as psoriasis, intrinsic-type asthma, contact dermatitis, intrinsic type of atopic dermatitis, bee venom allergic patients, and healthy controls showed no evidence for enhanced T cell apoptosis in vivo. These results define a novel mechanism for peripheral Th2 response in atopic diseases.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Istanbul Univ, Expt Med Res Inst, TR-34280 Istanbul, Turkey; Clin Dermatol & Allergy, CH-7270 Davos, Switzerland	Akdis, CA (reprint author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.unizh.ch					ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis CA, 1999, J INVEST DERMATOL, V113, P628, DOI 10.1046/j.1523-1747.1999.00720.x; Akdis CA, 2000, FASEB J, V14, P1666; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; BABI LFS, 1995, J EXP MED, V181, P1935; Belaud-Rotureau MA, 1999, CELL DEATH DIFFER, V6, P788, DOI 10.1038/sj.cdd.4400552; BRUNNER T, 1995, NATURE, V373, P441, DOI 10.1038/373441a0; CLOARK EA, 1995, SCIENCE, V268, P233; Dalton DK, 2000, J EXP MED, V192, P117, DOI 10.1084/jem.192.1.117; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; Enari M, 1996, NATURE, V380, P723, DOI 10.1038/380723a0; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hunger RE, 1999, BRIT J DERMATOL, V141, P565; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KOOPMAN G, 1994, BLOOD, V84, P1415; Ledru E, 1998, J IMMUNOL, V160, P3194; LI WC, 2000, J IMMUNOL, V164, P1193; LIU Y, 1990, Journal of Experimental Medicine, V172, P1735, DOI 10.1084/jem.172.6.1735; LYNCH DH, 1995, IMMUNOL TODAY, V16, P569, DOI 10.1016/0167-5699(95)80079-4; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953; MULLER G, 1994, J CLIN INVEST, V94, P1799, DOI 10.1172/JCI117528; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Ng TTC, 1997, J IMMUNOL, V158, P2984; Norris DA, 1997, APOPTOSIS, V2, P136, DOI 10.1023/A:1026456229688; PICKER LJ, 1990, AM J PATHOL, V136, P1053; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; RUOSLAHTI E, 1987, SCIENCE, V238, P491, DOI 10.1126/science.2821619; Salmon M, 1997, J CLIN INVEST, V99, P439, DOI 10.1172/JCI119178; Scaffidi C, 1999, CURR OPIN IMMUNOL, V11, P277, DOI 10.1016/S0952-7915(99)80045-4; SHYRTE J, 1995, NATURE, V373, P444; Stoll S, 1998, EUR J IMMUNOL, V28, P3231, DOI 10.1002/(SICI)1521-4141(199810)28:10<3231::AID-IMMU3231>3.0.CO;2-Q; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Trautmann A, 2001, TRENDS IMMUNOL, V22, P530, DOI 10.1016/S1471-4906(01)02004-X; Varadhachary AS, 1999, J IMMUNOL, V163, P4772; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VERCELLI D, 1989, J EXP MED, V169, P1295, DOI 10.1084/jem.169.4.1295; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; Wu CY, 2002, NAT IMMUNOL, V3, P852, DOI 10.1038/ni832; Yawalkar N, 2000, EUR J IMMUNOL, V30, P491, DOI 10.1002/1521-4141(200002)30:2<491::AID-IMMU491>3.3.CO;2-8; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	55	114	121	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JUN	2003	17	9					1026	1035		10.1096/fj.02-1070com		10	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	695EK	WOS:000183818000006	12773485	
J	Shaheen, SO; Newson, RB; Sherriff, A; Henderson, AJ; Heron, JE; Burney, PGJ; Golding, J				Shaheen, SO; Newson, RB; Sherriff, A; Henderson, AJ; Heron, JE; Burney, PGJ; Golding, J		ALSPAC Study Team	Paracetamol use in pregnancy and wheezing in early childhood	THORAX			English	Article							GLUTATHIONE S-TRANSFERASE; ATOPIC DISEASE; RISK-FACTORS; HUMAN-FETAL; ASTHMA; ACETAMINOPHEN; LUNG; CHILDREN; MOUSE; LIFE	Background: We recently reported links between frequent paracetamol (acetaminophen) use and wheezing and asthma in adults and children, but data are lacking on possible effects of prenatal exposure on wheezing in early childhood. Methods: In the population based Avon Longitudinal Study of Parents and Children (ALSPAC) women were asked twice during pregnancy (at 18-20 weeks and 32 weeks) about their usage of paracetamol and aspirin. Six months after birth, and at yearly intervals thereafter, mothers were asked about wheezing and eczema symptoms in their child. The effects of paracetamol and aspirin use in pregnancy on the risk in the offspring of wheezing at 30-42 months (n=9400) and eczema at 18-30 months (n=10 2 16) and on their risk of different wheezing patterns (defined by presence or absence of wheezing at <6 months and at 30-42 months) were examined. Results: Paracetamol was taken frequently (most days/daily) by only 1% of women. After controlling for potential confounders, frequent paracetamol use in late pregnancy (20-32 weeks), but not in early pregnancy (<18-20 weeks), was associated with an increased risk of wheezing in the offspring at 30-42 months (adjusted odds ratio (OR) compared with no use 2.10 (95% Cl 1.30 to 3.41); p=0.003), particularly if wheezing started before 6 months (OR 2.34 (95% Cl 1.24 to 4.40); P=0.008). Assuming a causal relation, only about 1% of wheezing at 30-42 months was attributable to this exposure. Frequent paracetomol use in pregnancy was not associated with an increased risk of eczema. Frequent aspirin use in pregnancy was associated with an increased risk of wheezing only at <6 months. Conclusions: Frequent use of paracetamol in late pregnancy may increase the risk of wheezing in the offspring, although such an effect could explain only about 1% of the population prevalence of wheezing in early childhood.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol BS8 1TQ, Avon, England	Shaheen, SO (reprint author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, Capital House,42 Weston St, London SE1 3QD, England.	seif.shaheen@kcl.ac.uk	Heron, Jon/D-5884-2011	Heron, Jon/0000-0001-6199-5644; Henderson, Alexander John/0000-0001-9650-231X			Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Bousquet J, 2000, ALLERGY, V55, P1194, DOI 10.1034/j.1398-9995.2000.00923.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; CHEN TC, 1990, ARCH NEUROL-CHICAGO, V47, P1227; CHEN TS, 1990, DRUG METAB DISPOS, V18, P882; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; COSSAR D, 1990, BIOCHIM BIOPHYS ACTA, V1037, P221, DOI 10.1016/0167-4838(90)90171-B; Dimova S, 2000, BIOCHEM PHARMACOL, V59, P1467, DOI 10.1016/S0006-2952(00)00257-4; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Goldwasser S, 2000, POPTRONICS, V1, P15; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HART SGE, 1995, FUND APPL TOXICOL, V24, P260, DOI 10.1006/faat.1995.1029; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519; JEFFERY EH, 1988, TOXICOL APPL PHARM, V93, P452, DOI 10.1016/0041-008X(88)90048-8; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; LEVY G, 1975, PEDIATRICS, V55, P895; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MICHELI L, 1994, ENVIRON HEALTH PERSP, V102, P63; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; PLACKE ME, 1987, TOXICOL PATHOL, V15, P381; ROLLINS DE, 1979, SCIENCE, V205, P1414, DOI 10.1126/science.38505; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461; Stata, 2001, STAT STAT SOFTW REL; Strachan DP, 1996, BRIT MED J, V312, P1195; Terwindt GM, 2000, NEUROLOGY, V55, P624; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, pS493, DOI 10.1016/S0091-6749(00)90049-6; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x	35	114	116	2	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	NOV	2002	57	11					958	963		10.1136/thorax.57.11.958		6	Respiratory System	Respiratory System	612WJ	WOS:000179098200010	12403878	
J	Bergner, A; Sanderson, MJ				Bergner, A; Sanderson, MJ			Acetylcholine-induced calcium signaling and contraction of airway smooth muscle cells in lung slices	JOURNAL OF GENERAL PHYSIOLOGY			English	Article						asthma; hyper-reactivity; confocal microscopy; Ca2+ oscillations; frequency modulation	INDIVIDUAL AIRWAYS; RESPONSIVENESS; HETEROGENEITY; METHACHOLINE; TRANSDUCTION; RAT; OSCILLATIONS; RESPONSES; EXPLANTS; CHANNELS	The Ca2+ signaling and contractility of airway smooth Muscle cells (SMCs) were investigated with confocal microscopy in murine lung slices (similar to75-mum thick) that maintained the in situ organization of the airways and the contractility of the SMCs for at least 5 d. 10-500 nM acetylcholine (ACH) induced a contraction of the air- way lumen and a transient increase in [Ca2+], in individual SMCs that subsequently declined to initiate multiple intracellular Ca2+ oscillations. These Ca2+ oscillations spread as Ca2+ waves through the SMCs at similar to48 mum/s. The magnitude of the airway contraction, the initial Ca2+ transient, and the frequency of the subsequent Ca2+ oscillations were all concentration-dependent. In a Ca2+-free solution, ACH induced a similar Ca2+ response, except that the Ca2+ oscillations ceased after 1-1.5 min. Incubation with thapsigargin, xestospongin, or ryanodine inhibited the ACH-induced Ca2+ signaling. A comparison of airway contraction with the ACH-induced Ca2+ response of the SMCs revealed that the onset of airway contraction correlated with the initial Ca2+ transient, and that sustained airway contraction correlated with the occurrence of the Ca2+ oscillations. Buffering intracellular Ca2+ with BATIA prohibited Ca2+ signaling and airway contraction, indicating a Ca2+-dependent pathway. Cessation of the Ca2+ oscillations, induced by ACH-esterase, halothane, or the absence of extracellular Ca2+ resulted in a relaxation of the airways The concentration dependence of the airway contraction matched the concentration dependeuce of the increased frequency of the Ca2+ oscillations. These results indicate that Ca2+ oscillations, induced by ACH in murine bronchial SMCs, are generated by Ca2+ release from the SR involving IPs and ryanodine receptors, and are required to maintain airway contraction.	Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA	Sanderson, MJ (reprint author), Univ Massachusetts, Sch Med, Dept Physiol, 55 Lake Ave, Worcester, MA 01655 USA.				NHLBI NIH HHS [HL49288]		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; DANDURAND RJ, 1994, AM J RESP CRIT CARE, V149, P1499; DANDURAND RJ, 1993, J APPL PHYSIOL, V75, P364; DIVIRGILIO F, 1990, CELL CALCIUM, V11, P57, DOI 10.1016/0143-4160(90)90059-4; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; Hall IP, 2000, EUR RESPIR J, V15, P1120, DOI 10.1034/j.1399-3003.2000.01523.x; HALL IP, 1995, AM J PHYSIOL-LUNG C, V268, pL1; Held HD, 1999, BRIT J PHARMACOL, V126, P1191, DOI 10.1038/sj.bjp.0702394; KUROSAWA H, 1995, J APPL PHYSIOL, V79, P41; Liu XB, 1996, J PHARMACOL EXP THER, V276, P178; Martin C, 1996, EUR RESPIR J, V9, P2479, DOI 10.1183/09031936.96.09122479; Martin C, 2000, EUR RESPIR J, V16, P316, DOI 10.1034/j.1399-3003.2000.16b21.x; Martin C, 2001, AM J RESP CELL MOL, V24, P139; Martin JG, 2000, EUR RESPIR J, V16, P349, DOI 10.1034/j.1399-3003.2000.16b25.x; Minshall E, 1997, CAN J PHYSIOL PHARM, V75, P911, DOI 10.1139/cjpp-75-7-911; Pabelick CM, 2001, ANESTHESIOLOGY, V95, P207, DOI 10.1097/00000542-200107000-00032; Pabelick CM, 2001, J APPL PHYSIOL, V91, P488; Pfitzer G, 2001, J APPL PHYSIOL, V91, P497; PLACKE ME, 1987, TOXICOL APPL PHARM, V90, P284, DOI 10.1016/0041-008X(87)90336-X; Prakash YS, 2000, CELL CALCIUM, V27, P153, DOI 10.1054/ceca.1999.0106; Prakash YS, 1997, AM J PHYSIOL-CELL PH, V272, pC966; Salerno FG, 1996, BRIT J PHARMACOL, V118, P734; SANDERSON MJ, 2002, IN PRESS METHODS ENZ; Savineau JP, 2000, NEWS PHYSIOL SCI, V15, P50; SHIEH CC, 1991, J PHARMACOL EXP THER, V256, P141; Sieck GC, 1997, CAN J PHYSIOL PHARM, V75, P878, DOI 10.1139/cjpp-75-7-878; Sims SM, 1996, AM J PHYSIOL-LUNG C, V271, pL300; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Tulic MK, 1999, THORAX, V54, P531; WIDDOP S, 1993, AM J RESP CELL MOL, V9, P541; Wohlsen A, 2001, AM J RESP CRIT CARE, V163, P1462	32	114	115	0	7	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1295			J GEN PHYSIOL	J. Gen. Physiol.	FEB	2002	119	2					187	198		10.1085/jgp.119.2.187		12	Physiology	Physiology	561LL	WOS:000176142100006	11815668	
J	Kimber, I; Basketter, DA; Gerberick, GF; Dearman, RJ				Kimber, I; Basketter, DA; Gerberick, GF; Dearman, RJ			Allergic contact dermatitis	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Review						allergic contact dermatitis; skin sensitization; hazard identification; risk assessment; Langerhans cells; T lymphocytes	LYMPH-NODE ASSAY; CD8(+) T-CELLS; CYTOKINE SECRETION PROFILES; SKIN SENSITIZATION RISK; CHEMICAL ALLERGENS; EFFECTOR CD8(+); LANGERHANS CELLS; CD4(+); MICE; HYPERSENSITIVITY	Allergic contact dermatitis (ACD) is a common occupational and environmental health issue. In common with other forms of allergy the disease progresses in two stages; an initial phase during which sensitization is acquired, followed later (after subsequent exposure to the same chemical allergen) by elicitation of a cutaneous inflammatory reaction. The development of skin sensitization is associated with, and requires, the activation and clonal expansion of allergen responsive T lymphocytes and it is these cells that orchestrate the cutaneous allergic reaction. In recent years, much has been: learned of the characteristics of immune responses to skin sensitizing chemicals and of the roles played by dendritic cells, cytokines and chemokines. Some of the more interesting cellular and molecular mechanisms are reviewed briefly in this article. A more detailed appreciation of responses induced by chemical allergens has in turn facilitated the design of novel approaches to the toxicological evaluation of skin sensitization. Real progress has been made, not only in the development of improved methods for hazard identification and characterization, but also in the application of new paradigms for risk assessment. The newer methods now available and the opportunities that exist for further advances are considered. Finally, progress has been made in the characterization of skin sensitization in humans and in the clinical management of ACD. This article seeks to consider skin sensitization and ACD in holistic fashion, bridging experimental observations with clinical disease and basic mechanisms with practical toxicology. (C) 2002 Elsevier Science B.V. All rights reserved.	Syngenta Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England; Unilever Res Labs Colworth, SEAC Toxicol Unit, Sharnbrook MK44 1LQ, Beds, England; Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH 45253 USA	Kimber, I (reprint author), Syngenta Cent Toxicol Lab, Alderley Pk, Macclesfield SK10 4TJ, Cheshire, England.						Andersen K.E., 1985, CONTACT ALLERGY PRED; BARRATT MD, 1996, TOXICOLOGY CONTACT H, P75; Basketter D. A., 1998, International Journal of Cosmetic Science, V20, P141, DOI 10.1046/j.1467-2494.1998.171746.x; Basketter DA, 2000, CONTACT DERMATITIS, V42, P344, DOI 10.1034/j.1600-0536.2000.042006344.x; Basketter DA, 1999, CONTACT DERMATITIS, V40, P150, DOI 10.1111/j.1600-0536.1999.tb06013.x; Basketter DA, 2001, FOOD CHEM TOXICOL, V39, P621, DOI 10.1016/S0278-6915(00)00169-1; Basketter DA, 1999, J APPL TOXICOL, V19, P261, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<261::AID-JAT572>3.0.CO;2-5; Basketter DA, 1999, TOXICOLOGY CONTACT D; BASKETTER DA, 1999, COMMENTS TOXICOL, V7, P79; BASKETTER DA, 2000, HAND ECZEMA, P105; BOUR H, 1995, EUR J IMMUNOL, V25, P3006, DOI 10.1002/eji.1830251103; Cavani A, 1998, J INVEST DERMATOL, V111, P621, DOI 10.1046/j.1523-1747.1998.00334.x; Cavani A, 2001, TRENDS IMMUNOL, V22, P118, DOI 10.1016/S1471-4906(00)01815-9; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; Cumberbatch M, 2000, CLIN EXP DERMATOL, V25, P413, DOI 10.1046/j.1365-2230.2000.00678.x; CUMBERBATCH M, 1993, TOXICOLOGY, V77, P181, DOI 10.1016/0300-483X(93)90148-L; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Dearman RJ, 1997, J APPL TOXICOL, V17, P53, DOI 10.1002/(SICI)1099-1263(199701)17:1<53::AID-JAT393>3.0.CO;2-W; Dearman RJ, 1996, IMMUNOLOGY, V89, P502, DOI 10.1046/j.1365-2567.1996.d01-778.x; Dearman RJ, 1996, TOXICOL APPL PHARM, V138, P308, DOI 10.1006/taap.1996.0129; Dearman RJ, 2001, J APPL TOXICOL, V21, P153, DOI 10.1002/jat.743; Dearman RJ, 2000, IMMUNOLOGY, V101, P442, DOI 10.1046/j.1365-2567.2000.00126.x; Dearman RJ, 1999, J APPL TOXICOL, V19, P299, DOI 10.1002/(SICI)1099-1263(199909/10)19:5<299::AID-JAT591>3.0.CO;2-C; Dearman RJ, 1995, IMMUNOLOGY, V86, P545; Dearman RJ, 1999, CLIN EXP ALLERGY, V29, P124; DILLARSTONE A, 1999, CONTACT DERMATITIS, V37, P190; Fehr B S, 1994, Exp Dermatol, V3, P189, DOI 10.1111/j.1600-0625.1994.tb00276.x; FRIEDMANN PS, 1983, CLIN EXP IMMUNOL, V53, P709; FRIEDMANN PS, 1983, BRIT J DERMATOL, V109, P86; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; Gerberick G F, 2001, Am J Contact Dermat, V12, P156, DOI 10.1053/ajcd.2001.23926; Gerberick G F, 2000, Am J Contact Dermat, V11, P65, DOI 10.1053/AC.2000.3191; Gerberick G F, 2000, Am J Contact Dermat, V11, P3; GERBERICK GF, IN PRESS CONTAC DERM; GOCINSKI B, 1990, J IMMUNOL, V144, P4142; Hilton J, 1998, Am J Contact Dermat, V9, P29, DOI 10.1016/S1046-199X(98)90142-7; *INT FRAGR RES ASS, 2000, GUID IS; Kehren J, 1999, J EXP MED, V189, P779, DOI 10.1084/jem.189.5.779; Kemeny DM, 1998, T LYMPHOCYTE SUBPOPULATIONS IN IMMUNOTOXICOLOGY, P33; Kimber I, 2000, BRIT J DERMATOL, V142, P401, DOI 10.1046/j.1365-2133.2000.03349.x; Kimber I, 1997, CLIN REV ALLERG IMMU, V15, P145, DOI 10.1007/BF02826584; Kimber I, 1998, T LYMPHOCYTE SUBPOPULATIONS IN IMMUNOTOXICOLOGY, P199; Kimber I, 1998, CURR OPIN IMMUNOL, V10, P614, DOI 10.1016/S0952-7915(98)80078-2; KIMBER I, 1994, TOXICOLOGY, V93, P13, DOI 10.1016/0300-483X(94)90193-7; KIMBER I, 1992, FOOD CHEM TOXICOL, V30, P165, DOI 10.1016/0278-6915(92)90153-C; KIMBER I, 1991, FOOD CHEM TOXICOL, V29, P125, DOI 10.1016/0278-6915(91)90167-6; Kimber I, 1997, HUM ECOL RISK ASSESS, V3, P385; Kimber I, 1996, TOXICOLOGY CONTACT H, P4; KIMBER I, 1999, COMMENTS TOXICOL, V7, P9; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P375, DOI 10.1038/jid.1966.159; Krishnan L, 1998, T LYMPHOCYTE SUBPOPULATIONS IN IMMUNOTOXICOLOGY, P7; Martin S, 2000, J INVEST DERMATOL, V115, P260, DOI 10.1046/j.1523-1747.2000.00038.x; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; MCKNIGHT AJ, 1991, EUR J IMMUNOL, V21, P1187, DOI 10.1002/eji.1830210514; MOSMANN TR, 1989, ADV IMMUNOL, V46, P111; REES JL, 1990, BRIT J DERMATOL, V122, P29, DOI 10.1111/j.1365-2133.1990.tb08236.x; RIETSCHEL R, 2000, FISHERS CONTACT DERM; RIETSCHEL R, 2000, FISHERS CONTACT DERM, P101; Robinson MK, 2000, CONTACT DERMATITIS, V42, P251, DOI 10.1034/j.1600-0536.2000.042005251.x; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rycroft RJG, 2001, TXB CONTACT DERMATIT; SMITH HS, 2000, CONTACT DERMATITIS, V41, P95; Traidl C, 2000, J IMMUNOL, V165, P3058; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Wang B, 1999, J IMMUNOL, V162, P277; Wang BH, 2000, J IMMUNOL, V165, P6783; Weltzien HU, 1996, TOXICOLOGY, V107, P141, DOI 10.1016/0300-483X(95)03253-C; WHITE SI, 1986, BRIT J DERMATOL, V115, P663, DOI 10.1111/j.1365-2133.1986.tb06646.x; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Xu H, 1997, J IMMUNOL, V158, P4721	71	114	116	1	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769			INT IMMUNOPHARMACOL	Int. Immunopharmacol.	FEB	2002	2	2-3					201	211		10.1016/S1567-5769(01)00173-4		11	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	513DA	WOS:000173361600006	11811925	
J	Diaz-Sanchez, D; Penichet-Garcia, M; Saxon, A				Diaz-Sanchez, D; Penichet-Garcia, M; Saxon, A			Diesel exhaust particles directly induce activated mast cells to degranulate and increase histamine levels and symptom severity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; pollution; mediators; clinical outcomes; hypersensitivity	IN-VIVO; IGE PRODUCTION; CYTOKINE PRODUCTION; MERCURIC-CHLORIDE; RAGWEED ALLERGEN; MESSENGER-RNA; DRY AIR; RELEASE; CHALLENGE; IL-4	Background: The ability of combustion products, such as diesel exhaust particles (DEPs), to modulate the immune system has now been firmly established. DEPs can synergize with allergen at the human upper respiratory mucosa to enhance allergen-specific IgE production, initiate a T(H)2 cytokine environment, and even promote primary allergic sensitization. Experiments suggest that these effects result from the initial activation of mast cells to produce IL-4. Objective: We sought to demonstrate that in vivo mast cell activation by DEPs plus allergen will also affect the release of classic mast cell mediators and consequently enhance the immediate-phase response. Methods: Dust mite-sensitive subjects were challenged intranasally with allergen, and symptom scores and histamine levels in nasal wash samples were compared after prechallenge with 0.3 mg of DEPs, Results: If the subjects were first sprayed with DEPs, mean symptom scores rose from 3.7 to 9.9; additionally, only one fifth of the amount of intranasal dust mite allergen was required to induce clinical symptoms. DEPs alone had no effect. The changes in symptoms correlated with histamine levels measured in nasal lavage specimens from these subjects, Although challenge with DEPs alone did not induce histamine release, challenge with both DEPs and allergen resulted in 3-fold higher histamine concentrations than those seen with allergen alone. In contrast, carbon black particles (elemental carbon devoid of chemicals) had no effect. The role of chemicals was confirmed because degranulation of a murine mast cell fine by Fc epsilon RI cross-linking was increased significantly (by 72%) by the soluble organic chemicals extracted from DEPs. Conclusions: Overall, these results suggest that exposure to DEPs can enhance the severity of clinical symptoms to allergen by enhancing mast cell degranulation.	Univ Calif Los Angeles, Sch Med, Hart & Louise Lyon Lab, Div Clin Immunol Allergy,Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	Diaz-Sanchez, D (reprint author), Univ Calif Los Angeles, Sch Med, Ctr Hlth Sci 52 175, Div Clin Immunol Allergy,Dept Med, Los Angeles, CA 90095 USA.				NIAID NIH HHS [AI-15251, AI-34567]		Beasley R., 2000, J ALLERGY CLIN IMMUN, V105, P466; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; *CENS TRANSP, 1995, US BUR CENS PUBL; CHURCH MK, 1983, BRIT J PHARMACOL, V80, P719; Dastych J, 1999, J ALLERGY CLIN IMMUN, V103, P1108, DOI 10.1016/S0091-6749(99)70186-7; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DIAZSANCHEZ D, 2000, IMMUNOLOGY, V101, P1; *FED HIGHW ADM, 1995, US DEP TRANSP PUBL; Fujieda S, 1998, CLIN CANCER RES, V4, P1583; Hiura TS, 1999, J IMMUNOL, V163, P5582; HUGHES PJ, 1984, BIOCHEM PHARMACOL, V33, P384; Kittelson DB, 1998, J AEROSOL SCI, V29, P575, DOI 10.1016/S0021-8502(97)10037-4; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MIYABARA Y, 1998, AM J RESP CRIT CARE, V157, P1; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V79, P639; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ng D, 1998, J IMMUNOL, V161, P942; OCHEL M, 1991, J IMMUNOL, V146, P3006; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; Polosa R, 1999, THORAX, V54, P230; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; PROUVOSTDANON A, 1981, J IMMUNOL, V126, P699; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Saneyoshi K, 1997, INT ARCH ALLERGY IMM, V114, P237; SCHWARTZ LB, 1979, J IMMUNOL, V123, P1445; Suzuki Takahito, 1993, Japanese Journal of Allergology, V42, P963; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; TOGIAS A, 1990, AM REV RESPIR DIS, V141, P1428; TOGIAS A, 1987, J ALLERGY CLIN IMMUN, V79, P699; Toru H, 1998, J ALLERGY CLIN IMMUN, V102, P491, DOI 10.1016/S0091-6749(98)70140-X; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628	38	114	117	2	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1140	1146		10.1067/mai.2000.111144		7	Allergy; Immunology	Allergy; Immunology	384ER	WOS:000165930300017	11112898	
J	Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA				Phipatanakul, W; Eggleston, PA; Wright, EC; Wood, RA		Natl Cooperative Inner City Asthma	Mouse allergen. I. The prevalence of mouse allergen in inner-city homes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; indoor allergens; inner-city asthma; sensitization	COCKROACH ALLERGEN; HOUSE DUST; ASTHMA; CHILDREN; EXPOSURE; MITE; SENSITIZATION; CAT	Background: Although mouse allergen is a well-defined cause of IgE-mediated hypersensitivity in occupational settings, it has not been web studied in the general population. Objective: We sought to determine the prevalence of mouse allergen in inner-city homes. Methods: A subset of 608 homes from the National Cooperative Inner-City Asthma Study population had dust samples adequate for analysis of mouse allergen. In addition, data regarding the demographics and housing of the subjects were related to the mouse allergen levels. Results: Ninety-five percent of all homes had detectable mouse allergen (Mus m 1) in at least one room, with the highest levels found in kitchens (kitchen: range, 0-618 mug/g; median, 1.60 mug/g; bedroom: range, 0-294 mug/g; median, 0.52 mug/g; television-living room: range, 0-203 mug/g; median, 0.57 mug/g). By city, 100% of the kitchens in Baltimore had detectable mouse allergen, with the lowest percentage (74%) in Cleveland Mouse allergen levels correlated among rooms (R = 0.65-0.75). Forty-nine percent of the homes had reported problems with mice within the last year, and 29% of the homes had evidence of mice in one or more rooms on home inspection and had higher levels of mouse allergen (P = .0001). Higher allergen levels were also associated with evidence of cockroach infestation in any room (P = .006), None of the other subject or housing demographics evaluated were associated with a higher prevalence or level of mouse allergen. Conclusions: We conclude that mouse allergen is widely distributed in inner-city homes and that cockroach infestation is associated with high mouse allergen levels.	Harvard Univ, Sch Med, Childrens Hosp, Dept Pediat,Div Allergy & Immunol, Boston, MA USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Div Allergy & Immunol, Baltimore, MD 21205 USA; New England Res Inst, Watertown, MA 02172 USA	Wood, RA (reprint author), Johns Hopkins Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.				NIAID NIH HHS [AI07007]; NIEHS NIH HHS [ES09606]		BIRKHEAD G, 1989, J ALLERGY CLIN IMMUN, V84, P484, DOI 10.1016/0091-6749(89)90361-8; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; CALL RS, 1992, J PEDIATR, V121, P362; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Evans R, 1987, CHEST S, V91, P65; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Mitchell H, 1997, PEDIATR PULM, V24, P237; MURRAY AB, 1983, PEDIATRICS, V71, P418; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; WALSHAW MJ, 1986, Q J MED, V58, P199; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358	18	114	114	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2000	106	6					1070	1074				5	Allergy; Immunology	Allergy; Immunology	384ER	WOS:000165930300007	11112888	
J	Trifilieff, A; El-Hashim, A; Bertrand, C				Trifilieff, A; El-Hashim, A; Bertrand, C			Time course of inflammatory and remodeling events in a murine model of asthma: effect of steroid treatment	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						airway hyperreactivity; dexamethasone; eosinophils	SUBEPITHELIAL FIBROSIS; AIRWAY INFLAMMATION; BRONCHIAL-ASTHMA; SMOOTH-MUSCLE; ALLERGEN; RESPONSIVENESS; HYPERRESPONSIVENESS; HYPERREACTIVITY; RESPONSES; EXPOSURE	The kinetics of airway inflammation and remodeling processes following ovalbumin aerosol challenge in sensitized BALB/c mice was studied. Mice were exposed to either single or five ovalbumin challenges over 5 days. In both protocols, time-dependent increases in bronchoalveolar lavage (BAL) cellular fibronectin, neutrophils and eosinophils were observed. The kinetics of these events were similar in both protocols; however, the magnitude of the response was much greater following repeated challenges. BAL protein levels and lymphocyte numbers were increased only following repeated challenges, whereas interleukin (IL)-5 and IL-4 were increased in both protocols. Histological analysis revealed a time-dependent increase in epithelial cell proliferation and in mucus-producing epithelial cells. Proliferation of alveolar cells was observed only following repeated challenges. Airway hyperreactivity was observed in both protocols but was much greater following repeated challenges. Pretreatment with dexamethasone fully inhibited the inflammatory response and airway hyperreactivity but only partially inhibited the remodeling process. These data suggest that glucocorticoids, although potent anti-inflammatory agents, may not be potent in reducing the lung remodeling process associated with asthma.	Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England	Trifilieff, A (reprint author), Novartis Horsham Res Ctr, Wimblehurst Rd, Horsham RH12 5AB, W Sussex, England.						AYERS MM, 1988, EUR RESPIR J, V1, P58; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; Gillis HL, 1999, J APPL PHYSIOL, V86, P2001; Haile S, 1999, EUR RESPIR J, V13, P961, DOI 10.1034/j.1399-3003.1999.13e06.x; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hogan SP, 1998, J IMMUNOL, V161, P1501; HOSSAIN S, 1973, AM REV RESPIR DIS, V107, P99; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; LEDERMANN F, 1991, J IMMUNOL METHODS, V141, P263, DOI 10.1016/0022-1759(91)90153-7; MACKLEM PT, 1987, CHEST, V91, pS189, DOI 10.1378/chest.91.6.189S; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864; PADRID P, 1995, AM J RESP CRIT CARE, V151, P184; Panettieri Reynold Jr., 1998, American Journal of Physiology, V274, pL417; RENNARD SI, 1980, ANAL BIOCHEM, V104, P205, DOI 10.1016/0003-2697(80)90300-0; ROCHE WR, 1989, LANCET, V1, P520; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; STEWART AG, 1993, TRENDS PHARMACOL SCI, V14, P275, DOI 10.1016/0165-6147(93)90130-C; TANIZAKI Y, 1993, J ASTHMA, V30, P257, DOI 10.3109/02770909309054525; Temelkovski J, 1998, THORAX, V53, P849; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251	27	114	119	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	DEC	2000	279	6					L1120	L1128				9	Physiology; Respiratory System	Physiology; Respiratory System	375GY	WOS:000165392200013	11076802	
J	Kennedy, SM; Le Moual, N; Choudat, D; Kauffmann, F				Kennedy, SM; Le Moual, N; Choudat, D; Kauffmann, F			Development of an asthma specific job exposure matrix and its application in the epidemiological study of genetics and environment in asthma (EGEA)	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article						job exposure matrix; asthma; occupational exposure; epidemiological methods; case-control	OCCUPATIONAL CASE-CONTROL; WORK HISTORIES; INFORMATION; RELIABILITY; ZUTPHEN; COHORT; ATOPY	Objectives-To develop a method suitable for estimating exposure risks in population studies of asthma from job titles and international codes, by combining a new job exposure matrix (JEM) with the expert judgement approach. The method was applied in the French epidemiological study of the genetics and environment in asthma (EGEA). Methods-The JEM contains 22 exposure groups including 18 high risk groups based on known risk factors for occupational asthma, divided into high molecular weight agents, low molecular weight agents, and mixed environments. After applying the JEM to job codes, exposure estimates for each subject were reevaluated by examining job title texts. Three high risk exposure estimates for asthma were compared: firstly, applying the JEM to original codes (from different coders in each study centre); secondly, applying the JEM to revised codes (from one experienced coder); and thirdly, after reviewing JEM exposure estimates in the light of job title texts. Results-The study comprised 173 cases with asthma and 285 controls (age 18-65). Odds ratios (ORs) for asthma for high risk jobs were 1.0 (95% confidence interval (95% CI) 0.6 to 1.7), applying the JEM to original codes; 1.4 (95% CI 0.8 to 2.3), applying the JEM to revised codes; and 1.7 (95% CI 1.1 to 2.7), applying the JEM and subsequently re-evaluating exposure estimates from job title texts. Asthma ORs were 1.4 (95% CI 0.6 to 2.9) for high molecular weight agents, 2.3 (95% CI 1.2 to 4.4) for low molecular weight agents, and 2.1 (95% CI 0.9 to 5.2) for mixed environments. Conclusions-This asthma JEM, when enhanced by expert re-evaluation of exposure estimates from job title texts, may be a useful tool in general population studies of asthma. In this study, a 1.7-fold increase in prevalence odds of high risk exposures was found among asthmatic workers compared with controls, with risk magnitude varying for different classes of exposure.	Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V6T 1Z3, Canada; INSERM U472, Villejuif, France; Hop Cochin, Serv Pathol Profess, Paris, France	Kennedy, SM (reprint author), Univ British Columbia, Sch Occupat & Environm Hyg, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada.		LeMoual, Nicole/R-8976-2016	LeMoual, Nicole/0000-0002-2723-5569			Benke G, 1997, INT J EPIDEMIOL, V26, P635, DOI 10.1093/ije/26.3.635; BOUYER J, 1993, AM J EPIDEMIOL, V137, P472; BOUYER J, 1993, INT J EPIDEMIOL, V22, pS65; Brower PS, 1998, AM J EPIDEMIOL, V148, P920; Chan-Yeung M., 1993, ASTHMA WORKPLACE, P595; DUBROW R, 1987, AM J IND MED, V11, P329, DOI 10.1002/ajim.4700110309; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; Hedman J, 1998, RESP MED, V92, P32, DOI 10.1016/S0954-6111(98)90029-4; HEEDERIK D, 1989, INT J EPIDEMIOL, V18, P382, DOI 10.1093/ije/18.2.382; Hoar S, 1983, J Toxicol Clin Toxicol, V21, P9; HSAIRI M, 1992, INT J EPIDEMIOL, V21, P972, DOI 10.1093/ije/21.5.972; *INT LAB ORG, 1991, INT LAB ORG INT STAN; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123; KAUPPINEN TP, 1992, SCAND J WORK ENV HEA, V18, P105; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; KROMHOUT H, 1992, AM J EPIDEMIOL, V136, P698; Le Moual N, 2000, OCCUP ENVIRON MED, V57, P126, DOI 10.1136/oem.57.2.126; NG TP, 1994, AM J IND MED, V25, P709, DOI 10.1002/ajim.4700250510; PANNETT B, 1985, BRIT J IND MED, V42, P777; ROSENBERG CR, 1993, BRIT J IND MED, V50, P822; SIEMIATYCKI J, 1989, AM J EPIDEMIOL, V130, P1236; STEWART WF, 1994, AM J IND MED, V26, P297, DOI 10.1002/ajim.4700260304; Toren K, 1999, INT J TUBERC LUNG D, V3, P192	25	114	115	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	SEP	2000	57	9					635	641		10.1136/oem.57.9.635		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	345KK	WOS:000088815000009	10935945	
J	Guarnieri, M; Balmes, JR				Guarnieri, Michael; Balmes, John R.			Outdoor air pollution and asthma	LANCET			English	Article							DIESEL EXHAUST PARTICLES; TOBACCO-SMOKE EXPOSURE; EMERGENCY-DEPARTMENT VISITS; AMBIENT PARTICULATE MATTER; NITROGEN-DIOXIDE EXPOSURE; EXHALED NITRIC-OXIDE; NEW-YORK-CITY; CHILDHOOD ASTHMA; LUNG-FUNCTION; OXIDATIVE STRESS	Traffic and power generation are the main sources of urban air pollution. The idea that outdoor air pollution can cause exacerbations of pre-existing asthma is supported by an evidence base that has been accumulating for several decades, with several studies suggesting a contribution to new-onset asthma as well. In this Series paper, we discuss the effects of particulate matter (PM), gaseous pollutants (ozone, nitrogen dioxide, and sulphur dioxide), and mixed traffic-related air pollution. We focus on clinical studies, both epidemiological and experimental, published in the previous 5 years. From a mechanistic perspective, air pollutants probably cause oxidative injury to the airways, leading to inflammation, remodelling, and increased risk of sensitisation. Although several pollutants have been linked to new-onset asthma, the strength of the evidence is variable. We also discuss clinical implications, policy issues, and research gaps relevant to air pollution and asthma.	[Guarnieri, Michael; Balmes, John R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Guarnieri, Michael; Balmes, John R.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA	Balmes, JR (reprint author), Univ Calif San Francisco, Box 0843, San Francisco, CA 94143 USA.	jbalmes@medsfgh.ucsf.edu			NHLBI NIH HHS [T32 HL007185]		Acciani TH, 2013, CLIN EXP ALLERGY, V43, P1406, DOI 10.1111/cea.12200; Adams C, 2009, J ENVIRON MONITOR, V11, P1331, DOI 10.1039/b903841h; Akinbami LJ, 2010, ENVIRON RES, V110, P294, DOI 10.1016/j.envres.2010.01.001; Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P47, DOI 10.1007/s11869-011-0144-5; Anderson HR, 2013, AIR QUAL ATMOS HLTH, V6, P57, DOI 10.1007/s11869-011-0145-4; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363; Balmes JR, 2014, RESPIR MED SER, V7, P383, DOI 10.1007/978-1-4614-8417-2_22; Balmes JR, 2009, J ALLERGY CLIN IMMUN, V123, P626, DOI 10.1016/j.jaci.2008.10.062; Barck C, 2002, RESP MED, V96, P907, DOI 10.1053/rmed.2002.1374; [Anonymous], 2014, LANCET, V383, P845; Barraza-Villarreal A, 2008, ENVIRON HEALTH PERSP, V116, P832, DOI 10.1289/ehp.10926; Bartoli ML, 2013, INHAL TOXICOL, V25, P127, DOI 10.3109/08958378.2013.763313; Bateson TF, 2008, J TOXICOL ENV HEAL A, V71, P238, DOI 10.1080/15287390701598234; Behndig AF, 2011, THORAX, V66, P12, DOI 10.1136/thx.2010.140053; Bloomer B.J., 2009, GEOPHYS RES LETT, V36; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brauer M, 2012, ENVIRON SCI TECHNOL, V46, P652, DOI 10.1021/es2025752; Brunekreef B, 2009, ENVIRON HEALTH PERSP, V117, P1791, DOI 10.1289/ehp.0800467; Brunst KJ, 2013, J ALLERGY CLIN IMMUN, V131, P592, DOI 10.1016/j.jaci.2012.10.042; Carlsten C, 2011, OCCUP ENVIRON MED, V68, P291, DOI 10.1136/oem.2010.055152; Chan JKW, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-34; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Cook AG, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-52; Dales R, 2008, ENVIRON HEALTH PERSP, V116, P1423, DOI 10.1289/ehp.10943; Delamater PL, 2012, SCI TOTAL ENVIRON, V425, P110, DOI 10.1016/j.scitotenv.2012.02.015; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P550, DOI 10.1289/ehp.10911; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Delfino RJ, 2014, EPIDEMIOLOGY, V25, P48, DOI 10.1097/EDE.0000000000000016; Delfino RJ, 2009, ANN ALLERG ASTHMA IM, V102, P138, DOI 10.1016/S1081-1206(10)60244-X; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Delucchi MA, 2014, PHILOS T R SOC A, V372, DOI 10.1098/rsta.2012.0325; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Division UEONRTP, INT SCI ASS OX NITR; Dong GH, 2013, INT J OBESITY, V37, P94, DOI 10.1038/ijo.2012.125; Dong GH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022470; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; Frampton MW, 2002, AM J PHYSIOL-LUNG C, V282, pL155; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gale SL, 2012, J EXPO SCI ENV EPID, V22, P386, DOI 10.1038/jes.2012.29; Gehring U, 2006, EUR RESPIR J, V27, P95, DOI 10.1183/09031936.06.00017205; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Goodman JE, 2009, CRIT REV TOXICOL, V39, P719, DOI 10.3109/10408440903283641; Gowers AM, 2012, RESPIROLOGY, V17, P887, DOI 10.1111/j.1440-1843.2012.02195.x; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Hernandez-Cadena L, 2009, CHEST, V136, P1529, DOI 10.1378/chest.08-1463; Hesterberg TW, 2009, CRIT REV TOXICOL, V39, P743, DOI 10.3109/10408440903294945; HEI Panel on the Health Effects of Traffic-Related Air Pollution, 2010, TRAFF REL AIR POLL C; International Institute for Applied Systems Analysis (IIASA), 2012, DATABASE; Iskandar A, 2012, THORAX, V67, P252, DOI 10.1136/thoraxjnl-2011-200324; Islam T, 2009, THORAX, V64, P197, DOI 10.1136/thx.2008.099366; Jacquemin B, 2012, J EPIDEMIOL COMMUN H, V66, P796, DOI 10.1136/jech.2010.130229; Jacquemin B, 2009, EPIDEMIOLOGY, V20, P119, DOI 10.1097/EDE.0b013e3181886e76; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Johns DO, 2011, INHAL TOXICOL, V23, P33, DOI 10.3109/08958378.2010.539290; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Kaundinya DP, 2009, RENEW SUST ENERG REV, V13, P2041, DOI 10.1016/j.rser.2009.02.002; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; Kelly F, 2011, RES REP HLTH EFF I, V163, P3; Kelly FJ, 2012, ATMOS ENVIRON, V60, P504, DOI 10.1016/j.atmosenv.2012.06.039; Kim BJ, 2011, ANN ALLERG ASTHMA IM, V107, P214, DOI 10.1016/j.anai.2011.05.025; Kohli A, 2012, CLIN EPIGENETICS, V4, DOI 10.1186/1868-7083-4-17; Kunzli N, 2009, THORAX, V64, P664, DOI 10.1136/thx.2008.110031; Lee GB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060632; Lewis TC, 2013, SCI TOTAL ENVIRON, V448, P48, DOI 10.1016/j.scitotenv.2012.11.070; Li N, 2008, FREE RADICAL BIO MED, V44, P1689, DOI 10.1016/j.freeradbiomed.2008.01.028; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Liu L, 2009, ENVIRON HEALTH PERSP, V117, P668, DOI 10.1289/ehp11813; Malig BJ, 2013, AM J EPIDEMIOL, V178, P58, DOI 10.1093/aje/kws451; Mann JK, 2010, ENVIRON HEALTH PERSP, V118, P1497, DOI 10.1289/ehp.0901292; Manners S, 2014, J ALLERGY CLIN IMMUN, V134, P63, DOI 10.1016/j.jaci.2013.10.047; Martin RA, 2013, AM J RESP CELL MOL, V48, P655, DOI 10.1165/rcmb.2012-0423OC; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Melia S, 2011, TRANSPORT POLICY, V18, P46, DOI 10.1016/j.tranpol.2010.05.007; Meng YY, 2010, J EPIDEMIOL COMMUN H, V64, P142, DOI 10.1136/jech.2009.083576; Miller MD, 2010, ENVIRON HEALTH PERSP, V118, P1155, DOI 10.1289/ehp.0901856; Modig L, 2009, EUR RESPIR J, V33, P1261, DOI 10.1183/09031936.00101108; Moon KY, 2014, INT J TOXICOL, V33, P21, DOI 10.1177/1091581813518355; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nagel G, 2010, THORAX, V65, P516, DOI 10.1136/thx.2009.128256; Neidell M, 2010, J EPIDEMIOL COMMUN H, V64, P921, DOI 10.1136/jech.2008.081489; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Neophytou AM, 2013, ENVIRON HEALTH-GLOB, V12, DOI 10.1186/1476-069X-12-105; Nishimura KK, 2013, AM J RESP CRIT CARE, V188, P309, DOI 10.1164/rccm.201302-0264OC; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; O'Connor GT, 2008, J ALLERGY CLIN IMMUN, V121, P1133, DOI 10.1016/j.jaci.2008.02.020; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Patel MM, 2013, ENVIRON RES, V121, P71, DOI 10.1016/j.envres.2012.10.012; Pathmanathan S, 2003, OCCUP ENVIRON MED, V60, P892, DOI 10.1136/oem.60.11.892; Penard-Morand C, 2010, EUR RESPIR J, V36, P33, DOI 10.1183/09031936.00116109; Perez L, 2013, EUR RESPIR J, V42, P594, DOI 10.1183/09031936.00031112; Perez L, 2012, ENVIRON HEALTH PERSP, V120, P1619, DOI 10.1289/ehp.1104785; Perez Laura, 2009, Am J Public Health, V99 Suppl 3, pS622, DOI 10.2105/AJPH.2008.154955; Poynter ME, 2006, AM J PHYSIOL-LUNG C, V290, pL144, DOI 10.1152/ajplung.00131.2005; Rabinovitch N, 2011, AM J RESP CRIT CARE, V184, P1350, DOI 10.1164/rccm.201010-1706OC; Rice MB, 2014, AM J RESP CRIT CARE, V189, P512, DOI 10.1164/rccm.201310-1924PP; Robinson CL, 2011, THORAX, V66, P1051, DOI 10.1136/thx.2011.158956; Rogers AJ, 2009, CLIN EXP ALLERGY, V39, P1721, DOI 10.1111/j.1365-2222.2009.03372.x; Rosa MJ, 2011, RESP MED, V105, P869, DOI 10.1016/j.rmed.2010.11.022; Rosenlund M, 2009, THORAX, V64, P573, DOI 10.1136/thx.2007.094953; Salon D, 2010, ENERG POLICY, V38, P2032, DOI 10.1016/j.enpol.2009.12.005; Samoli E, 2011, ENVIRON RES, V111, P418, DOI 10.1016/j.envres.2011.01.014; Schikowski T, 2013, ENVIRON HEALTH PERSP, V121, P1034, DOI 10.1289/ehp.1206145; Schultz EN, 2010, J ASTHMA, V47, P1049, DOI [10.1080/02770903.2010.508856, 10.3109/02770903.2010.508856]; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Silverman RA, 2010, J ALLERGY CLIN IMMUN, V125, P367, DOI 10.1016/j.jaci.2009.10.061; Solomon C, 2000, EUR RESPIR J, V15, P922, DOI 10.1034/j.1399-3003.2000.15e19.x; Son JY, 2013, EPIDEMIOLOGY, V24, P545, DOI 10.1097/EDE.0b013e3182953244; Stanek LW, 2011, TOXICOL SCI, V120, pS8, DOI 10.1093/toxsci/kfq367; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Sternthal MJ, 2011, J ALLERGY CLIN IMMUN, V128, P337, DOI 10.1016/j.jaci.2011.05.008; Strickland MJ, 2011, ENVIRON HEALTH-GLOB, V10, DOI 10.1186/1476-069X-10-36; Strickland MJ, 2010, AM J RESP CRIT CARE, V182, P307, DOI 10.1164/rccm.200908-1201OC; Takahashi G, 2010, J PHARMACOL SCI, V112, P192, DOI 10.1254/jphs.09276FP; Thurston GD, 2013, NAT CLIM CHANGE, V3, P863; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; US EPA ORD National Center for Environmental Assessment NCEA-RTP, INT SCI ASS OZ REL P; van Voorhis M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082545; Vrijheid M, 2012, ENVIRON HEALTH PERSP, V120, P29, DOI 10.1289/ehp.1103823; Wang PL, 2013, PART FIBRE TOXICOL, V10, DOI 10.1186/1743-8977-10-29; Wang PL, 2011, AM J RESP CELL MOL, V45, P977, DOI [10.1165/rcmb.2011-0001OC, 10.1165/rcmb.2011-00010C]; Weinmayr G, 2010, ENVIRON HEALTH PERSP, V118, P449, DOI 10.1289/ehp.0900844; West JJ, 2013, NAT CLIM CHANGE, V3, P885, DOI [10.1038/nclimate2009, 10.1038/NCLIMATE2009]; Wilhelm M, 2009, HEALTH PLACE, V15, P25, DOI 10.1016/j.healthplace.2008.02.002; Witten A, 2005, J OCCUP ENVIRON MED, V47, P1250, DOI 10.1097/01.jom.0000177081.62204.8d; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Zhou CL, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-506; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zhu YF, 2007, ENVIRON SCI TECHNOL, V41, P2138, DOI 10.1021/es0618797	139	113	118	1142	2510	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2014	383	9928					1581	1592				12	Medicine, General & Internal	General & Internal Medicine	AG5YO	WOS:000335495400030	24792855	
J	Lin, SY; Erekosima, N; Kim, JM; Ramanathan, M; Suarez-Cuervo, C; Chelladurai, Y; Ward, D; Segal, JB				Lin, Sandra Y.; Erekosima, Nkiruka; Kim, Julia M.; Ramanathan, Murugappan; Suarez-Cuervo, Catalina; Chelladurai, Yohalakshmi; Ward, Darcy; Segal, Jodi B.			Sublingual Immunotherapy for the Treatment of Allergic Rhinoconjunctivitis and Asthma A Systematic Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; RANDOMIZED CONTROLLED-TRIAL; GRASS-POLLEN EXTRACT; HOUSE-DUST-MITE; PARIETARIA-JUDAICA EXTRACT; JAPANESE CEDAR POLLINOSIS; QUALITY-OF-LIFE; SWALLOW IMMUNOTHERAPY; RESPIRATORY ALLERGY	Importance Allergic rhinitis affects up to 40% of the US population. To desensitize allergic individuals, subcutaneous injection immunotherapy or sublingual immunotherapy may be administered. In the United States, sublingual immunotherapy is not approved by the Food and Drug Administration. However, some US physicians use aqueous allergens, off-label, for sublingual desensitization. Objective To systematically review the effectiveness and safety of aqueous sublingual immunotherapy for allergic rhinoconjunctivitis and asthma. Evidence Acquisition The databases of MEDLINE, EMBASE, LILACS, and the Cochrane Central Register of Controlled Trials were searched through December 22, 2012. English-language randomized controlled trials were included if they compared sublingual immunotherapy with placebo, pharmacotherapy, or other sublingual immunotherapy regimens and reported clinical outcomes. Studies of sublingual immunotherapy that are unavailable in the United States and for which a related immunotherapy is unavailable in the United States were excluded. Paired reviewers selected articles and extracted the data. The strength of the evidence for each comparison and outcome was graded based on the risk of bias (scored on allocation, concealment of intervention, incomplete data, sponsor company involvement, and other bias), consistency, magnitude of effect, and the directness of the evidence. Results Sixty-three studies with 5131 participants met the inclusion criteria. Participants' ages ranged from 4 to 74 years. Twenty studies (n=1814 patients) enrolled only children. The risk of bias was medium in 43 studies (68%). Strong evidence supports that sublingual immunotherapy improves asthma symptoms, with 8 of 13 studies reporting greater than40% improvement vs the comparator. Moderate evidence supports that sublingual immunotherapy use decreases rhinitis or rhinoconjunctivitis symptoms, with 9 of 36 studies demonstrating greater than 40% improvement vs the comparator. Medication use for asthma and allergies decreased by more than 40% in 16 of 41 studies of sublingual immunotherapy with moderate grade evidence. Moderate evidence supports that sublingual immunotherapy improves conjunctivitis symptoms (13 studies), combined symptom and medication scores (20 studies), and disease-specific quality of life (8 studies). Local reactions were frequent, but anaphylaxis was not reported. Conclusions and Relevance The overall evidence provides a moderate grade level of evidence to support the effectiveness of sublingual immunotherapy for the treatment of allergic rhinitis and asthma, but high-quality studies are still needed to answer questions regarding optimal dosing strategies. There were limitations in the standardization of adverse events reporting, but no life-threatening adverse events were noted in this review. JAMA. 2013; 309(12): 1278-1288 www.jama.com	[Kim, Julia M.] Johns Hopkins Univ, Sch Med, Div Gen Pediat & Adolescent Med, Baltimore, MD 21287 USA; [Lin, Sandra Y.; Ramanathan, Murugappan] Johns Hopkins Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA; [Erekosima, Nkiruka; Suarez-Cuervo, Catalina; Chelladurai, Yohalakshmi; Ward, Darcy; Segal, Jodi B.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21287 USA; [Kim, Julia M.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA	Lin, SY (reprint author), Johns Hopkins Univ, Sch Med, 601 N Caroline St,Ste 6254, Baltimore, MD 21287 USA.	slin30@jhmi.edu	Segal, Jodi/A-2863-2009	Segal, Jodi/0000-0003-3978-9662	Agency for Healthcare Research and Quality (AHRQ) [HHSA 290 2007 10061]; Johns Hopkins University Evidence-based Practice Center [HHSA 290 2007 10061 I]	This study was funded by grant HHSA 290 2007 10061 I from the Agency for Healthcare Research and Quality (AHRQ) and is based on research conducted at the Johns Hopkins University Evidence-based Practice Center under contract HHSA 290 2007 10061 I.	Ahmadiafshar A, 2012, IRAN J ALLERGY ASTHM, V11, P175, DOI 011.02/ijaai.175181; Alvarez-Cuesta E, 2007, ALLERGY, V62, P1100, DOI 10.1111/j.1398-9995.2007.01520.x; Alvarez-Cuesta E, 2007, ALLERGY, V62, P810, DOI 10.1111/j.1398-9995.2007.01365.x; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, P1561; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Bush RK, 2011, J ALLERGY CLIN IMMUN, V127, P974, DOI 10.1016/j.jaci.2010.11.045; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Calderon MA, 2011, CLIN EXP ALLERGY, V41, P1263, DOI 10.1111/j.1365-2222.2011.03835.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Cortellini G, 2010, ANN ALLERG ASTHMA IM, V105, P382, DOI 10.1016/j.anai.2010.08.007; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; D'Ambrosio F P, 1996, Allergol Immunopathol (Madr), V24, P146; De Blay F, 2007, ANN ALLERG ASTHMA IM, V99, P453; de Bot Cindy M A, 2012, Pediatr Allergy Immunol, V23, P150, DOI 10.1111/j.1399-3038.2011.01219.x; Di Bona D, 2010, J ALLERGY CLIN IMMUN, V126, P558, DOI 10.1016/j.jaci.2010.06.013; Di Rienzo V., 2006, Clinical and Experimental Allergy Reviews, V6, P67, DOI 10.1111/j.1472-9725.2006.00102.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Fujimura T, 2011, CLIN IMMUNOL, V139, P65, DOI 10.1016/j.clim.2010.12.022; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Higgins JPT, 2005, COCHRANE HDB SYSTEMA; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Horiguchi S, 2008, INT ARCH ALLERGY IMM, V146, P76, DOI 10.1159/000112506; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Larenas-Linnemann DE, 2008, ALLERGY ASTHMA PROC, V29, P130, DOI 10.2500/aap.2008.29.3093; Leonardi S, 2009, ANN ALLERG ASTHMA IM, V102, P259, DOI 10.1016/S1081-1206(10)60093-2; Liberati A, 2009, J CLIN EPIDEMIOL, V62, pe1, DOI DOI 10.1016/J.JCLINEPI.2009.06.006; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Makino Y, 2010, J ALLERGY CLIN IMMUN, V126, P1163, DOI 10.1016/j.jaci.2010.06.031; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2010, J INVEST ALLERG CLIN, V20, P146; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274; Marogna M, 2010, J ALLERGY CLIN IMMUN, V126, P969, DOI 10.1016/j.jaci.2010.08.030; Marogna M, 2009, ANN ALLERG ASTHMA IM, V102, P69, DOI 10.1016/S1081-1206(10)60111-1; Moreno-Ancillo A, 2007, J INVEST ALLERG CLIN, V17, P399; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; Okubo Kimihiro, 2008, Allergol Int, V57, P265, DOI 10.2332/allergolint.O-07-514; Ott H, 2009, ALLERGY, V64, P1394, DOI [10.1111/j.1398-9995.2009.02194.x, 10.1111/j.1398-9995.2008.01875.x]; Owens DK, 2010, J CLIN EPIDEMIOL, V63, P513, DOI 10.1016/j.jclinepi.2009.03.009; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno GB, 2011, PEDIAT ALLERG IMM-UK, V22, P803, DOI 10.1111/j.1399-3038.2011.01196.x; Panzner P, 2008, RESP MED, V102, P1296, DOI 10.1016/j.rmed.2008.03.024; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Pozzan M, 2010, CURR MED RES OPIN, V26, P2801, DOI 10.1185/03007995.2010.532201; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Radulovic S, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002893.pub2; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rodriguez F, 2006, INT ARCH ALLERGY IMM, V140, P321, DOI 10.1159/000093710; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Salo PM, 2011, J ALLERGY CLIN IMMUN, V127, P1226, DOI 10.1016/j.jaci.2010.12.1106; Sambugaro R, 2003, Allergol Immunopathol (Madr), V31, P329, DOI 10.1157/13055212; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Sieber J, 2012, EXPERT OPIN DRUG SAF, V11, P7, DOI 10.1517/14740338.2012.626765; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P666; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, pe4; Skoner D, 2010, J ALLERGY CLIN IMMUN, V125, P660, DOI 10.1016/j.jaci.2009.12.931; Stelmach I, 2012, ALLERGY, V67, P312, DOI 10.1111/j.1398-9995.2011.02758.x; Stelmach I, 2009, CLIN EXP ALLERGY, V39, P401, DOI 10.1111/j.1365-2222.2008.03159.x; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, P215, DOI 10.1016/j.jaci.2012.04.021; Swamy RS, 2012, J ALLERGY CLIN IMMUN, V130, pe7; Tahamiler R, 2007, LARYNGOSCOPE, V117, P965, DOI 10.1097/MLG.0b013e31804f8141; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tseng SH, 2008, ASIAN PAC J ALLERGY, V26, P105; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; Vervloet D, 2007, INT ARCH ALLERGY IMM, V142, P239, DOI 10.1159/000097026; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Voltolini S, 2010, CURR MED RES OPIN, V26, P37, DOI 10.1185/03007990903431886; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wahn U, 2012, J ALLERGY CLIN IMMUN, V130, pe5; Wahn U, 2012, J ALLERGY CLIN IMMUN, V130, P886, DOI 10.1016/j.jaci.2012.06.047; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	91	113	116	1	38	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 27	2013	309	12					1278	1288		10.1001/jama.2013.2049		11	Medicine, General & Internal	General & Internal Medicine	112WO	WOS:000316625200028	23532243	
J	Rosenblum, MD; Gratz, IK; Paw, JS; Lee, K; Marshak-Rothstein, A; Abbas, AK				Rosenblum, Michael D.; Gratz, Iris K.; Paw, Jonathan S.; Lee, Karen; Marshak-Rothstein, Ann; Abbas, Abul K.			Response to self antigen imprints regulatory memory in tissues	NATURE			English	Article							T-CELLS; IN-VIVO; EXPRESSION; AUTOANTIGEN; HOMEOSTASIS; AUTOIMMUNE; DEPLETION; DISEASES; MICE	Immune homeostasis in tissues is achieved through a delicate balance between pathogenic T-cell responses directed at tissue-specific antigens and the ability of the tissue to inhibit these responses. The mechanisms by which tissues and the immune system communicate to establish and maintain immune homeostasis are currently unknown. Clinical evidence suggests that chronic or repeated exposure to self antigen within tissues leads to an attenuation of pathological autoimmune responses, possibly as a means to mitigate inflammatory damage and preserve function. Many human organ-specific autoimmune diseases are characterized by the initial presentation of the disease being the most severe, with subsequent flares being of lesser severity and duration(1). In fact, these diseases often spontaneously resolve, despite persistent tissue autoantigen expression(2). In the practice of antigen-specific immunotherapy, allergens or self antigens are repeatedly injected in the skin, with a diminution of the inflammatory response occurring after each successive exposure(3). Although these findings indicate that tissues acquire the ability to attenuate autoimmune reactions upon repeated responses to antigens, the mechanism by which this occurs is unknown. Here we show that upon expression of self antigen in a peripheral tissue, thymus-derived regulatory T cells (T-reg cells) become activated, proliferate and differentiate into more potent suppressors, which mediate resolution of organ-specific autoimmunity in mice. After resolution of the inflammatory response, activated T-reg cells are maintained in the target tissue and are primed to attenuate subsequent autoimmune reactions when antigen is re-expressed. Thus, T-reg cells function to confer 'regulatory memory' to the target tissue. These findings provide a framework for understanding how T-reg cells respond when exposed to self antigen in peripheral tissues and offer mechanistic insight into how tissues regulate autoimmunity.	[Gratz, Iris K.; Paw, Jonathan S.; Abbas, Abul K.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Rosenblum, Michael D.; Paw, Jonathan S.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94115 USA; [Lee, Karen] Columbia Univ, Dept Pediat, Med Ctr, New York, NY 10032 USA; [Marshak-Rothstein, Ann] Univ Massachusetts, Div Rheumatol, Dept Med, Worcester, MA 01655 USA	Abbas, AK (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.	Abul.Abbas@ucsf.edu	Gratz, Iris /L-6267-2015	Gratz, Iris /0000-0001-7470-7277	Dermatology Foundation; UCSF Department of Dermatology; NIH [P01 AI35297, R01 AI73656, U19 AI56388, AR055634]; Scleroderma Research Foundation; Austrian Science Fund (FWF) [J2997-B13]	We thank C. Benetiz for assistance with animal husbandry, S. Isakson for genotyping, S.-w. Jiang and M. Lee for cell sorting, and K. Ravid and G. Martin for derivation of TRE-TGO transgenic mice. We thank S. Ziegler, Benaroya Research Institute, for transgenic mice. M. D. R. is supported by a Dermatology Foundation Career Development Award and the UCSF Department of Dermatology. This work was partially funded through NIH grants P01 AI35297, R01 AI73656 and U19 AI56388 (to A. K. A.); NIH grant AR055634 to (A.M.-R.); and the Scleroderma Research Foundation (A.M.-R.). I. K. G. is supported by an Erwin Schroedinger Fellowship from the Austrian Science Fund (FWF), J2997-B13.	Akbar AN, 2007, NAT REV IMMUNOL, V7, P231, DOI 10.1038/nri2037; Diamond I, 2000, J INVEST DERMATOL, V115, P788, DOI 10.1046/j.1523-1747.2000.00144.x; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Gavin MA, 2002, NAT IMMUNOL, V3, P33, DOI 10.1038/ni743; James W, 2006, ANDREWS DIS SKIN CLI; Kurtulus S, 2010, IMMUNOL REV, V236, P54, DOI 10.1111/j.1600-065X.2010.00920.x; Lara-Corrales I, 2010, SEMIN CUTAN MED SURG, V29, P85, DOI 10.1016/j.sder.2010.03.005; Miyara M, 2009, IMMUNITY, V30, P899, DOI 10.1016/j.immuni.2009.03.019; Mouquet H, 2008, TISSUE ANTIGENS, V71, P464, DOI [10.1111/j.1399-0039.2008.01020.x, 10.1111/d.1399-0039.2008.01020.x]; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Tenorio EP, 2011, FEMS IMMUNOL MED MIC, V62, P362, DOI 10.1111/j.1574-695X.2011.00805.x; Sabatos-Peyton CA, 2010, CURR OPIN IMMUNOL, V22, P609, DOI 10.1016/j.coi.2010.08.006; Saff RR, 2004, J IMMUNOL, V172, P6598; Setiady YY, 2010, EUR J IMMUNOL, V40, P780, DOI 10.1002/eji.200939613; Wada N, 2011, J INVEST DERMATOL, V131, P410, DOI 10.1038/jid.2010.330; Wing K, 2008, SCIENCE, V322, P271, DOI 10.1126/science.1160062	17	113	115	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2011	480	7378					538	U164		10.1038/nature10664		6	Multidisciplinary Sciences	Science & Technology - Other Topics	865NQ	WOS:000298318000064	22121024	
J	Thyssen, JP; Menne, T				Thyssen, Jacob P.; Menne, Torkil			Metal Allergy-A Review on Exposures, Penetration, Genetics, Prevalence, and Clinical Implications	CHEMICAL RESEARCH IN TOXICOLOGY			English	Review							OCCUPATIONAL CONTACT-DERMATITIS; UNSELECTED DANISH POPULATION; PATCH TEST CONCENTRATIONS; GOLD SODIUM THIOSULFATE; TOTAL HIP-ARTHROPLASTY; IN-STENT RESTENOSIS; NICKEL ALLERGY; ON-METAL; ORTHOPEDIC IMPLANTS; FERROUS SULFATE	The prevalence of metal allergy is high in the general population, and it is estimated that up to 17% of women and 3% of men are allergic to nickel and that 1-3% are allergic to cobalt and chromium. Among dermatitis patients, the prevalence of metal allergy is even higher. Metal allergy is mainly an environmental disorder although null Mutations in the filaggrin gene complex were recently found to be associated with nickel allergy and dermatitis. Environmental metal exposures include jewelry, buttons, clothing fasteners, dental restorations, mobile phones, and leather. Although consumer exposure is responsible for most cases of metal allergy, the importance Of Occupational metal exposure remains present and should always be taken into consideration when one interprets allergic patch test reactions to metals. Traditionally, nickel, cobalt, and chromium have been the most important contact allergens. However, recently, gold and palladium have drawn much attention as the prevalence of contact allergy to these metals is high. Palladium allergy is mainly a result of cross-sensitization to nickel, whereas gold allergy is rarely clinically relevant when one takes its high prevalence into account. The epidemiology of metal allergy has recently changed in Europe as nickel allergy among ear-pierced Danish women has decreased following regulatory intervention oil nickel release from consumer products. In the United States, the prevalence of nickel allergy is still increasing, which may be explained by the absence of regulation. The prevalence of chromium allergy is increasing in the United States, Singapore, and Denmark among dermatitis patients. This increase is significantly associated with leather exposure in Denmark. Metal allergy may result in allergic contact dermatitis and systemic allergic (contact) dematitis. Furthermore, metal allergy has been associated with device failure following insertion of intracoronary stents, hip and knee prostheses, as well as other implants. This area is in need of more research.	[Thyssen, Jacob P.] Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, DK-2900 Hellerup, Denmark; [Menne, Torkil] Univ Copenhagen, Gentofte Hosp, Dept Dermatoallergol, DK-2900 Hellerup, Denmark	Thyssen, JP (reprint author), Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, Niels Andersens Vej 65, DK-2900 Hellerup, Denmark.	jacpth01@geh.regionh.dk					ABERER W, 1993, CONTACT DERMATITIS, V28, P163, DOI 10.1111/j.1600-0536.1993.tb03379.x; Agner T, 2002, CONTACT DERMATITIS, V47, P21, DOI 10.1034/j.1600-0536.2002.470105.x; Ahlgren C, 2002, ACTA DERM-VENEREOL, V82, P41, DOI 10.1080/000155502753600876; ALLENBY CF, 1989, CONTACT DERMATITIS, V20, P185, DOI 10.1111/j.1600-0536.1989.tb04655.x; ALLENBY CF, 1994, CONTACT DERMATITIS, V30, P135, DOI 10.1111/j.1600-0536.1994.tb00693.x; ALLENBY CF, 1983, CONTACT DERMATITIS, V9, P491, DOI 10.1111/j.1600-0536.1983.tb04470.x; Andersen KE, 2001, TOXICOL APPL PHARM, V170, P166, DOI 10.1006/taap.2000.9095; Aslan A, 2009, B ENVIRON CONTAM TOX, V82, P633, DOI 10.1007/s00128-009-9656-1; Athavale P, 2007, BRIT J DERMATOL, V157, P518, DOI 10.1111/j.1365-2133.2007.08030.x; AVNSTORP C, 1989, CONTACT DERMATITIS, V20, P365, DOI 10.1111/j.1600-0536.1989.tb03174.x; Back DL, 2005, CLIN ORTHOP RELAT R, P177, DOI 10.1097/01.blo.0000166901.85323.5d; BASKETTER DA, 1993, CONTACT DERMATITIS, V28, P15, DOI 10.1111/j.1600-0536.1993.tb03318.x; Basketter DA, 2003, CONTACT DERMATITIS, V49, P1, DOI 10.1111/j.0105-1873.2003.00149.x; BJORKNER B, 1994, CONTACT DERMATITIS, V30, P144, DOI 10.1111/j.1600-0536.1994.tb00695.x; BLASCHKO A, 1989, DEUT MED WOCHENSCHR, V15, P925; Bordel-Gomez MT, 2008, J EUR ACAD DERMATOL, V22, P1452, DOI 10.1111/j.1468-3083.2008.02892.x; Bordel-Gomez MT, 2008, ALLERGOL IMMUNOPATH, V36, P306, DOI 10.1016/S0301-0546(08)75227-3; BOSS A, 1982, CONTACT DERMATITIS, V8, P211, DOI 10.1111/j.1600-0536.1982.tb04191.x; BRANDRUP F, 1979, CONTACT DERMATITIS, V5, P148, DOI 10.1111/j.1600-0536.1979.tb04827.x; BRANDRUP F, 1991, CONTACT DERMATITIS, V25, P77, DOI 10.1111/j.1600-0536.1991.tb01788.x; BRUZE M, 1994, J AM ACAD DERMATOL, V31, P579; Bryld LE, 2004, J INVEST DERMATOL, V123, P1025, DOI 10.1111/j.0022-202X.2004.23452.x; BUCHET S, 1992, CONTACT DERMATITIS, V26, P46, DOI 10.1111/j.1600-0536.1992.tb00867.x; Caicedo MS, 2009, J ORTHOP RES, V27, P847, DOI 10.1002/jor.20826; CALNAN CD, 1956, BRIT J DERMATOL, V68, P229, DOI 10.1111/j.1365-2133.1956.tb12808.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cavani A, 2007, CURR OPIN ALLERGY CL, V7, P404; Cheng TY, 2008, CONTACT DERMATITIS, V59, P353, DOI 10.1111/j.1600-0536.2008.01468.x; Chou TC, 2008, CONTACT DERMATITIS, V59, P151, DOI 10.1111/j.1600-0536.2008.01403.x; COMAISH S, 1969, ARCH DERMATOL, V99, P720, DOI 10.1001/archderm.99.6.720; Dickel H, 2002, INT ARCH OCC ENV HEA, V75, P423, DOI 10.1007/s00420-002-0328-2; Dietrich KA, 2009, J DTSCH DERMATOL GES, V7, P410, DOI 10.1111/j.1610-0387.2008.06987.x; Dotterud LK, 2007, CONTACT DERMATITIS, V56, P10, DOI 10.1111/j.1600-0536.2007.00980.x; Ehrlich A, 2001, Am J Contact Dermat, V12, P151, DOI 10.1053/ajcd.2001.22774; Ekqvist S, 2007, BRIT J DERMATOL, V157, P730, DOI 10.1111/j.1365-2133.2007.08119.x; Filon FL, 2009, TOXICOL IN VITRO, V23, P574, DOI 10.1016/j.tiv.2009.01.015; Fischer LA, 2005, CONTACT DERMATITIS, V52, P57, DOI 10.1111/j.0105-1873.2005.00523.x; Fischer LA, 2007, CONTACT DERMATITIS, V56, P255, DOI 10.1111/j.1600-0536.2007.01096.x; FISCHER T, 1984, CONTACT DERMATITIS, V10, P39, DOI 10.1111/j.1600-0536.1984.tb00059.x; FISCHER T, 1984, CONTACT DERMATITIS, V10, P23, DOI 10.1111/j.1600-0536.1984.tb00056.x; FISCHER T, 1985, CONTACT DERMATITIS, V12, P93, DOI 10.1111/j.1600-0536.1985.tb01060.x; FISCHER T, 1983, CONTACT DERMATITIS, V9, P115, DOI 10.1111/j.1600-0536.1983.tb04316.x; Fleming C, 1997, CONTACT DERMATITIS, V37, P298, DOI 10.1111/j.1600-0536.1997.tb02471.x; FOWLER JF, 1988, ARCH DERMATOL, V124, P181, DOI 10.1001/archderm.124.2.181; Freeman S, 1997, CONTACT DERMATITIS, V36, P247, DOI 10.1111/j.1600-0536.1997.tb00211.x; FULLERTON A, 1995, CONTACT DERMATITIS, V32, P100, DOI 10.1111/j.1600-0536.1995.tb00755.x; FULLERTON A, 1988, BRIT J DERMATOL, V118, P509, DOI 10.1111/j.1365-2133.1988.tb02460.x; FULLERTON A, 1988, BRIT J DERMATOL, V119, P675, DOI 10.1111/j.1365-2133.1988.tb03482.x; Gamerdinger K, 2003, J EXP MED, V197, P1345, DOI 10.1084/jem.20030121; GAMMELGAARD B, 1992, CONTACT DERMATITIS, V27, P302, DOI 10.1111/j.1600-0536.1992.tb03284.x; GAWKRODGER DJ, 1995, CONTACT DERMATITIS, V32, P257, DOI 10.1111/j.1600-0536.1995.tb00778.x; Geier J, 2000, DERMATOL BERUF UMWEL, V48, P4; Geier J, 2009, CONTACT DERMATITIS, V60, P199, DOI 10.1111/j.1600-0536.2008.01476.x; Gleizes V, 1999, REV CHIR ORTHOP, V85, P217; GOH CL, 1989, CONTACT DERMATITIS, V20, P380, DOI 10.1111/j.1600-0536.1989.tb03179.x; Goon ATJ, 2005, CONTACT DERMATITIS, V52, P130, DOI 10.1111/j.0105-1873.2005.00518.x; HALBERT AR, 1992, CONTACT DERMATITIS, V27, P214, DOI 10.1111/j.1600-0536.1992.tb03248.x; Hallab N, 2001, J BONE JOINT SURG AM, V83A, P428; Hallab Nadim James, 2008, J Orthop Surg Res, V3, P6, DOI 10.1186/1749-799X-3-6; Hansen MB, 2006, CONTACT DERMATITIS, V54, P278, DOI 10.1111/j.0105-1873.2006.00824.x; Hansen MB, 2002, CONTACT DERMATITIS, V47, P127, DOI 10.1034/j.1600-0536.2002.470301.x; HARRISON PV, 1979, CONTACT DERMATITIS, V5, P229, DOI 10.1111/j.1600-0536.1979.tb04856.x; Heim KE, 2009, CONTACT DERMATITIS, V60, P100, DOI 10.1111/j.1600-0536.2008.01487.x; Hemmer W, 1996, CONTACT DERMATITIS, V34, P217, DOI 10.1111/j.1600-0536.1996.tb02179.x; Hextall JM, 2002, CONTACT DERMATITIS, V47, P96, DOI 10.1034/j.1600-0536.2002.470207.x; Hillen U, 2002, CONTACT DERMATITIS, V47, P353, DOI 10.1034/j.1600-0536.2002.470607.x; Hindsen M, 2005, CONTACT DERMATITIS, V53, P350, DOI 10.1111/j.0105-1873.2005.0592a.x; Hindsen M, 2005, CONTACT DERMATITIS, V53, P2, DOI 10.1111/j.0105-1873.2005.00577.x; Hosoki M, 2009, BIO-MED MATER ENG, V19, P53, DOI 10.3233/BME-2009-0563; Hostynek JJ, 2003, FOOD CHEM TOXICOL, V41, P327, DOI 10.1016/S0278-6915(02)00257-0; Hostynek JJ, 2001, ACTA DERM-VENEREOL, P5; Hostynek JJ, 2001, ACTA DERM-VENEREOL, P11; HOTCHKISS SAM, 1992, FOOD CHEM TOXICOL, V30, P145, DOI 10.1016/0278-6915(92)90150-J; Iijima R, 2005, INT J CARDIOL, V104, P319, DOI 10.1016/j.ijcard.2004.12.034; Jacob SE, 2009, J AM ACAD DERMATOL, V60, P1067, DOI 10.1016/j.jaad.2008.11.893; Jacobs JJ, 2009, J AM ACAD ORTHOP SUR, V17, P69; Jensen CS, 2003, CONTACT DERMATITIS, V49, P124, DOI 10.1111/j.0105-1873.2003.00157.x; Julander A, 2009, CONTACT DERMATITIS, V60, P165, DOI 10.1111/j.1600-0536.2008.01497.x; KAABER K, 1979, CONTACT DERMATITIS, V5, P221, DOI 10.1111/j.1600-0536.1979.tb04855.x; KAABER K, 1977, ACTA DERM-VENEREOL, V57, P321; KAABER K, 1983, CONTACT DERMATITIS, V9, P297, DOI 10.1111/j.1600-0536.1983.tb04394.x; Kalimo K, 1997, CONTACT DERMATITIS, V37, P121, DOI 10.1111/j.1600-0536.1997.tb00316.x; KAUFFMAN RE, 1990, PEDIATRICS, V86, P797; KiecSwierczynska M, 1996, OCCUP MED-OXFORD, V46, P205; Kim RH, 2008, J ARTHROPLASTY, V23, P44, DOI 10.1016/j.arth.2008.06.007; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P393, DOI 10.1038/jid.1966.160; Koch P, 1999, J AM ACAD DERMATOL, V41, P422, DOI 10.1016/S0190-9622(99)70116-7; Kosann M K, 1998, Am J Contact Dermat, V9, P92, DOI 10.1016/S1046-199X(98)90003-3; Koster R, 2000, LANCET, V356, P1895, DOI 10.1016/S0140-6736(00)03262-1; Kranke B, 1996, CONTACT DERMATITIS, V34, P225, DOI 10.1111/j.1600-0536.1996.tb02185.x; Larese Filon Francesca, 2004, Int Arch Occup Environ Health, V77, P85, DOI 10.1007/s00420-003-0455-4; Larese Filon Francesca, 2003, Am J Contact Dermat, V14, P78; Larese F, 2007, TOXICOL LETT, V170, P49, DOI 10.1016/j.toxlet.2007.02.009; Lepoittevin J.-P., 2006, CONTACT DERMATITIS, P45, DOI 10.1007/3-540-31301-X_3; Liden C, 2005, CONTACT DERMATITIS, V52, P29, DOI 10.1111/j.0105-1873.2005.00494.x; LIDEN C, 1994, ACTA DERM-VENEREOL, V74, P341; Liden C, 1998, CONTACT DERMATITIS, V39, P127, DOI 10.1111/j.1600-0536.1998.tb05861.x; Liden C, 2001, CONTACT DERMATITIS, V44, P7, DOI 10.1034/j.1600-0536.2001.440102.x; Liden C, 2006, CONTACT DERMATITIS, P537, DOI 10.1007/3-540-31301-X_32; Liden C, 2008, CONTACT DERMATITIS, V58, P347, DOI 10.1111/j.1600-0536.2008.01326.x; MacDonald SJ, 2003, CLIN ORTHOP RELAT R, P282, DOI 10.1097/01.blo.0000043066.62337.9d; Martial R, 1908, PRESSE MED, V64, P507; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; MEIJER C, 1995, CONTACT DERMATITIS, V32, P147, DOI 10.1111/j.1600-0536.1995.tb00804.x; MEMON AA, 1994, J AM ACAD DERMATOL, V30, P560; MENNE T, 1983, INT J DERMATOL, V22, P22, DOI 10.1111/j.1365-4362.1983.tb02108.x; Menne T, 1979, Derm Beruf Umwelt, V27, P37; MENNE T, 1990, CONTACT DERMATITIS, V23, P57, DOI 10.1111/j.1600-0536.1990.tb00093.x; Merritt K, 1996, CLIN ORTHOP RELAT R, P71; Mikhael MM, 2009, J BONE JOINT SURG AM, V91A, P443, DOI 10.2106/JBJS.H.00603; Moller H, 1996, BRIT J DERMATOL, V135, P423, DOI 10.1046/j.1365-2133.1996.d01-1015.x; MOSELEY JC, 1971, ARCH DERMATOL, V103, P58, DOI 10.1001/archderm.103.1.58; Nedorost S, 2005, DERMATITIS, V16, P67, DOI 10.2310/6620.2005.04047; Netterlid E, 2009, CONTACT DERMATITIS, V60, P41, DOI 10.1111/j.1600-0536.2008.01474.x; Nguyen SH, 2008, CONTACT DERMATITIS, V58, P101, DOI 10.1111/j.1600-0536.2007.01281.x; Nielsen NH, 1999, BRIT J DERMATOL, V141, P676; Nielsen NH, 2000, CONTACT DERMATITIS, V43, P212, DOI 10.1034/j.1600-0536.2000.043004212.x; NIELSEN NH, 1993, CONTACT DERMATITIS, V29, P16; Nielsen NH, 2001, CONTACT DERMATITIS, V45, P350, DOI 10.1034/j.1600-0536.2001.450606.x; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Norgaz T, 2005, TOHOKU J EXP MED, V206, P243, DOI 10.1620/tjem.206.243; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Pandit H, 2008, J BONE JOINT SURG BR, V90B, P847, DOI 10.1302/0301-620X.90B7.20213; PELTONEN L, 1983, CONTACT DERMATITIS, V9, P190, DOI 10.1111/j.1600-0536.1983.tb04356.x; Piela Zofia, 1998, Medycyna Pracy, V49, P457; Pratt Melanie D, 2004, Dermatitis, V15, P176, DOI 10.2310/6620.2004.04038; Raison-Peyron N, 2005, CONTACT DERMATITIS, V53, P222, DOI 10.1111/j.0105-1873.2005.00689.x; Rietschel RL, 2008, DERMATITIS, V19, P16, DOI 10.2310/6620.2008.06062; ROSEN RH, 1993, CONTACT DERMATITIS, V29, P88, DOI 10.1111/j.1600-0536.1993.tb03489.x; ROSTOKER G, 1987, J BONE JOINT SURG AM, V69A, P1408; Rudzki E, 1997, CONTACT DERMATITIS, V37, P46, DOI 10.1111/j.1600-0536.1997.tb00384.x; Ruff CA, 2006, J AM ACAD DERMATOL, V55, P32, DOI 10.1016/j.jaad.2006.04.015; Rustemeyer T., 2006, CONTACT DERMATITIS, P11, DOI 10.1007/3-540-31301-X_2; Rydin S, 2002, INVESTIGATION CONTEN; RYSTEDT I, 1979, CONTACT DERMATITIS, V5, P233, DOI 10.1111/j.1600-0536.1979.tb04857.x; RYSTEDT I, 1983, CONTACT DERMATITIS, V9, P195, DOI 10.1111/j.1600-0536.1983.tb04357.x; RYTTER M, 1971, DERMATOLOGICA, V142, P209; Saito Taro, 2009, Cardiovasc Revasc Med, V10, P17, DOI 10.1016/j.carrev.2008.01.004; SAMITZ M H, 1964, J Invest Dermatol, V42, P35; SANTUCCI B, 1988, CONTACT DERMATITIS, V19, P202, DOI 10.1111/j.1600-0536.1988.tb02895.x; SCANSETTI G, 1994, SCI TOTAL ENVIRON, V150, P141, DOI 10.1016/0048-9697(94)90141-4; Schafer T, 2001, ALLERGY, V56, P1192, DOI 10.1034/j.1398-9995.2001.00086.x; Schaffer AW, 1999, J TOXICOL-CLIN TOXIC, V37, P839; SCHITTENHELM A, 1925, Z GES EXP MED, V45, P58, DOI 10.1007/BF02626025; Schnuch A, 2003, CONTACT DERMATITIS, V49, P107, DOI 10.1111/j.0105-1873.2003.0128f.x; Schram SE, 2007, DERMATITIS, V18, P125, DOI 10.2310/6620.2007.06007; Shackelford KE, 2002, J AM ACAD DERMATOL, V47, P715, DOI 10.1067/mjd.2002.124697; Shah M, 1998, ARCH DERMATOL, V134, P1231, DOI 10.1001/archderm.134.10.1231; Shum KW, 2003, OCCUP ENVIRON MED, V60, P954, DOI 10.1136/oem.60.12.954; Skoet R, 2004, CONTACT DERMATITIS, V51, P159, DOI 10.1111/j.0105-1873.2004.00423.x; Smith E, 2009, CONTACT DERMATITIS, V60, P298, DOI [10.1111/j.1600-0536.2009.01535.x, 10.1111/j.1600-0536.2009.01539.x]; Sprigle AM, 2008, DERMATITIS, V19, P28, DOI 10.2310/6620.2008.07050; Svedman C, 2009, CONTACT DERMATITIS, V60, P158, DOI 10.1111/j.1600-0536.2008.01502.x; Thijs Leen, 2008, Dermatitis, V19, pE26; Thomas P, 2009, ALLERGY, V64, P1157, DOI 10.1111/j.1398-9995.2009.01966.x; Thomas P, 2006, CONTACT DERMATITIS, V55, P199, DOI 10.1111/j.1600-0536.2006.00931.x; Thyssen JP, 2008, J AM ACAD DERMATOL, V58, P1000, DOI 10.1016/j.jaad.2008.03.017; Thyssen JP, 2008, CONTACT DERMATITIS, V59, P38, DOI 10.1111/j.1600-0536.2008.01350.x; Thyssen JP, 2007, CONTACT DERMATITIS, V57, P287, DOI 10.1111/j.1600-0536.2007.01220.x; Thyssen JP, 2007, CONTACT DERMATITIS, V56, P185, DOI 10.1111/j.1600-0536.2006.01058.x; Thyssen JP, 2009, CONTACT DERMATITIS, V61, P56, DOI 10.1111/j.1600-0536.2009.01551.x; Thyssen JP, 2008, DERMATITIS, V19, P303, DOI 10.2310/6620.2008.08022; Thyssen JP, 2009, SCI TOTAL ENVIRON, V407, P5315, DOI 10.1016/j.scitotenv.2009.06.034; Thyssen JP, 2009, NEW ENGL J MED, V360, P2259, DOI 10.1056/NEJMc0809293; Thyssen JP, 2009, ACTA DERM-VENEREOL, V89, P384, DOI 10.2340/00015555-0649; THYSSEN JP, BR J DERMAT IN PRESS; THYSSEN JP, CONTACT DER IN PRESS; THYSSEN JP, 2009, J AM ACAD D IN PRESS; UPADHYE MR, 1992, CONTACT DERMATITIS, V27, P281, DOI 10.1111/j.1600-0536.1992.tb03280.x; UTER W, 1995, CONTACT DERMATITIS, V32, P135, DOI 10.1111/j.1600-0536.1995.tb00802.x; Uter W, 2009, CONTACT DERMATITIS, V61, P31, DOI 10.1111/j.1600-0536.2009.01572.x; Vamnes JS, 2000, CONTACT DERMATITIS, V42, P128, DOI 10.1034/j.1600-0536.2000.042003128.x; VANKETEL WG, 1981, CONTACT DERMATITIS, V7, P217; VANKETEL WG, 1984, CONTACT DERMATITIS, V11, P311; VEIEN NK, 1987, ACTA DERM-VENEREOL, V67, P321; VEIEN NK, 1993, J AM ACAD DERMATOL, V29, P1002; VILAPLANA J, 1987, CONTACT DERMATITIS, V16, P139, DOI 10.1111/j.1600-0536.1987.tb01407.x; Wahlberg J E, 2000, Am J Contact Dermat, V11, P42, DOI 10.1016/S1046-199X(00)90031-9; WALL L M, 1991, Contact Dermatitis, V24, P101, DOI 10.1111/j.1600-0536.1991.tb01660.x; WATZIG V, 1974, DERMATOL MONATSSCHR, V160, P233; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; White JML, 2007, CLIN EXP ALLERGY, V37, P1848, DOI 10.1111/j.1365-2222.2007.02846.x; Wohrl S, 2001, CONTACT DERMATITIS, V44, P224, DOI 10.1034/j.1600-0536.2001.044004224.x; Zachariae COC, 1996, CONTACT DERMATITIS, V35, P83, DOI 10.1111/j.1600-0536.1996.tb02295.x; ZEMBA C, 1992, CONTACT DERMATITIS, V27, P116, DOI 10.1111/j.1600-0536.1992.tb05224.x	185	113	115	9	48	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0893-228X			CHEM RES TOXICOL	Chem. Res. Toxicol.	FEB	2010	23	2					309	318		10.1021/tx9002726		10	Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology	Pharmacology & Pharmacy; Chemistry; Toxicology	555QU	WOS:000274529400003	19831422	
J	Cookson, H; Granell, R; Joinson, C; Ben-Shlomo, Y; Henderson, AJ				Cookson, Hannah; Granell, Raquel; Joinson, Carol; Ben-Shlomo, Yoav; Henderson, A. John			Mothers' anxiety during pregnancy is associated with asthma in their children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anxiety; pregnancy; prenatal programming; asthma; child	DAY-CARE ATTENDANCE; MATERNAL ANTENATAL ANXIETY; POSTNATAL DEPRESSION; COMORBID ANXIETY; INCREASED RISK; BIRTH-COHORT; EARLY-LIFE; STRESS; DISORDERS; CHILDHOOD	Background: Maternal stress in early life has been associated with the development of asthma in children, although it is unclear whether there are any critical periods of exposure. The association of asthma with prenatal exposure to maternal stress has not been reported. Objective: We tested whether prenatal and postnatal anxiety and/or depression in pregnant women predicted the risk of their offspring developing asthma in childhood. Methods: The Avon Longitudinal Study of Parents and Children is a population-based birth cohort recruited during pregnancy. Data were available on maternal anxiety scores and asthma at age 71/2 years in 5810 children. Anxiety was assessed at 18 and 32 weeks of gestation by using the validated Crown-Crisp Experiential Index. Asthma was defined at age 71/2 years as doctor-diagnosed asthma with current symptoms or treatment in the previous 12 months. Multivariable logistic regression was used to determine the association of prenatal anxiety with asthma (odds ratio; 95% CI). Results: Independent of postnatal anxiety and adjusted for a number of likely confounders, there was a higher likelihood of asthma at age 71/2 years (odds ratio, 1.64; 95% CI, 1.25-2.17) in children of mothers in the highest compared with lowest quartile of anxiety scores at 32 weeks of gestation, with evidence for a dose-response (P value for trend <0.001). Conclusions: Maternal anxiety symptoms as an indicator of stress during fetal life may program the development of asthma during childhood. (J Allergy Clin Immunol 2009;123:847-853.)	[Henderson, A. John] Univ Bristol, ALSPAC, Dept Community Based Med, Bristol BS8 2BN, Avon, England; [Cookson, Hannah] Sir Charles Gairdner Hosp, Dept Internal Med, Perth, WA, Australia; [Granell, Raquel; Ben-Shlomo, Yoav] Univ Bristol, Dept Social Med, Bristol BS8 2BN, Avon, England	Henderson, AJ (reprint author), Univ Bristol, ALSPAC, Dept Community Based Med, Oakfield House,Oakfield Grove, Bristol BS8 2BN, Avon, England.	a.j.henderson@bris.ac.uk		Henderson, Alexander John/0000-0001-9650-231X	UK Medical Research Council; Wellcome Trust; University of Bristol; Asthma UK	The UK Medical Research Council, the Wellcome Trust, and the University of Bristol provide core support for the Avon Longitudinal Study of Parents and Children. R.G. wits supported by a project grant from Asthma UK.	Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bardi M, 2004, BIOL PSYCHIAT, V55, P724, DOI 10.1016/j.biopsych.2004.01.002; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; BIRTCHNELL J, 1988, BRIT J MED PSYCHOL, V61, P255; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Deshmukh VM, 2008, RESPIROLOGY, V13, P695, DOI 10.1111/j.1440-1843.2008.01310.x; Glover V, 2004, EARLY HUM DEV, V79, P107, DOI 10.1016/j.earlhumdev.2004.04.012; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Goodman R, 2001, J AM ACAD CHILD PSY, V40, P1337, DOI 10.1097/00004583-200111000-00015; Goodwin Renee D, 2003, Adv Psychosom Med, V24, P51, DOI 10.1159/000073780; Gunnar MR, 1998, PREV MED, V27, P208, DOI 10.1006/pmed.1998.0276; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Hagerhed-Engman L, 2006, ALLERGY, V61, P447, DOI 10.1111/j.1398-9995.2006.01031.x; HENRY C, 1994, J NEUROENDOCRINOL, V6, P341, DOI 10.1111/j.1365-2826.1994.tb00591.x; Hobel CJ, 2008, CLIN OBSTET GYNECOL, V51, P333, DOI 10.1097/GRF.0b013e31816f2709; Kaplan LA, 2008, EARLY HUM DEV, V84, P249, DOI 10.1016/j.earlhumdev.2007.06.004; Katon WJ, 2004, PSYCHOSOM MED, V66, P349, DOI 10.1097/01.psy.0000126202.89941.ea; Kay G, 1998, PHYSIOL BEHAV, V63, P397, DOI 10.1016/S0031-9384(97)00456-3; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; LEVENSON RW, 1979, PSYCHOSOM MED, V41, P28; O'Connor TG, 2005, BIOL PSYCHIAT, V58, P211, DOI 10.1016/j.biopsych.2005.03.032; O'Connor TG, 2003, J CHILD PSYCHOL PSYC, V44, P1025, DOI 10.1111/1469-7610.00187; O'Connor TG, 2002, J AM ACAD CHILD PSY, V41, P1470, DOI 10.1097/01.CHI.0000024880.60748.38; Oberlander TF, 2008, EPIGENETICS, V3, P97; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484; Richardson LP, 2008, GEN HOSP PSYCHIAT, V30, P398, DOI 10.1016/j.genhosppsych.2008.06.004; Rietveld S, 2000, CLIN EXP ALLERGY, V30, P1058; Risbrough VB, 2006, HORM BEHAV, V50, P550, DOI 10.1016/j.yhbeh.2006.06.019; Ritz T, 2000, PSYCHOSOM MED, V62, P401; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Sarkar P, 2008, J NEUROENDOCRINOL, V20, P489, DOI 10.1111/j.1365-2826.2008.01659.x; Scott KM, 2008, PSYCHOSOM MED, V70, P1035, DOI 10.1097/PSY.0b013e318187a2fb; Smith GD, 2008, BASIC CLIN PHARMACOL, V102, P245, DOI 10.1111/j.1742-7843.2007.00191.x; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Young AF, 2006, AUST NZ J PUBL HEAL, V30, P353, DOI 10.1111/j.1467-842X.2006.tb00849.x	40	113	116	6	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					847	853		10.1016/j.jaci.2009.01.042		7	Allergy; Immunology	Allergy; Immunology	431JW	WOS:000265058600010	19348924	
J	Makita, H; Nasuhara, Y; Nagai, K; Ito, Y; Hasegawa, M; Betsuyaku, T; Onodera, Y; Hizawa, N; Nishimura, M				Makita, Hironi; Nasuhara, Yasuyuki; Nagai, Katsura; Ito, Yoko; Hasegawa, Masaru; Betsuyaku, Tomoko; Onodera, Yuya; Hizawa, Nobuyuki; Nishimura, Masaharu		Hokkaido COPD Cohort Study Grp	Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease	THORAX			English	Article							AIR-FLOW LIMITATION; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHODILATOR RESPONSE; SUBCLINICAL EMPHYSEMA; SMALL AIRWAYS; BODY-WEIGHT; COPD; HEALTH; MORTALITY; CAPACITY	Background: Airflow limitation in chronic obstructive pulmonary disease ( COPD) is caused by a mixture of small airway disease and emphysema, the relative contributions of which may vary among patients. Phenotypes of COPD classified purely based on severity of emphysema are not well defined and may be different from the classic phenotypes of "pink puffers'' and "blue bloaters''. Methods: To characterise clinical phenotypes based on severity of emphysema, 274 subjects with COPD were recruited, excluding those with physician-diagnosed bronchial asthma. For all subjects a detailed interview of disease history and symptoms, quality of life (QOL) measurement, blood sampling, pulmonary function tests before and after inhalation of salbutamol (0.4 mg) and high- resolution CT scanning were performed. Results: Severity of emphysema visually evaluated varied widely even among subjects with the same stage of disease. No significant differences were noted among three groups of subjects classified by severity of emphysema in age, smoking history, chronic bronchitis symptoms, blood eosinophil count, serum IgE level or bronchodilator response. However, subjects with severe emphysema had significantly lower body mass index (BMI) and poorer QOL scores, evaluated using St George's Respiratory Questionnaire (SGRQ), than those with no/mild emphysema (mean ( SD) BMI 21.2 (0.5) vs 23.5 (0.3) kg/m(2), respectively; SGRQ total score 40 (3) vs 28 (2), respectively; p < 0.001 for both). These characteristics held true even if subjects with the same degree of airflow limitation were chosen. Conclusions: The severity of emphysema varies widely even in patients with the same stage of COPD, and chronic bronchitis symptoms are equally distributed irrespective of emphysema severity. Patients with the phenotype in which emphysema predominates have lower BMI and poorer health-related QOL.	Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, Sapporo, Hokkaido 0608638, Japan	Nishimura, M (reprint author), Hokkaido Univ, Sch Med, Dept Med 1, Kita Ku, N-15 W-7, Sapporo, Hokkaido 0608638, Japan.	ma-nishi@med.hokudai.ac.jp	Nasuhara, Yasuyuki/G-1647-2012; Nishimura, Masaharu/A-4062-2012	Nishimura, Masaharu/0000-0002-6456-4361			*AM THOR SOC, 2004, STAND DIAGN MAN SUBJ; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Anthonisen NR, 2005, EUR RESPIR J, V26, P45, DOI 10.1183/09031936.05.00102604; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; Anthonisen NR, 1989, AM REV RESPIR DIS, V140, pS95; Betsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985; [Anonymous], 2006, CHEST; BURROWS B, 1966, LANCET, V1, P830; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Ciba Guest Symposium, 1959, THORAX, V14, P286; *COMM PULM PHYSL J, 2004, GUID PULM FUNCT TEST; Domingo-Salvany A, 2002, AM J RESP CRIT CARE, V166, P680, DOI 10.1164/rccm.2112043; FILLEY GF, 1968, AM J MED, V44, P26, DOI 10.1016/0002-9343(68)90234-9; Fukuchi Y, 2004, RESPIROLOGY, V9, P458, DOI 10.1111/j.1440-1843.2004.00637.x; GELB AF, 1993, AM REV RESPIR DIS, V147, P1157; Gelb AF, 1996, CHEST, V109, P353, DOI 10.1378/chest.109.2.353; GODDARD PR, 1982, CLIN RADIOL, V33, P379, DOI 10.1016/S0009-9260(82)80301-2; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2003, GLOB STRAT DIAGN MAN; GOULD GA, 1991, EUR RESPIR J, V4, P141; Hasegawa M, 2006, AM J RESP CRIT CARE, V173, P1309, DOI 10.1164/rccm.200601-037OC; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOGG JC, 1994, THORAX, V49, P473, DOI 10.1136/thx.49.5.473; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; *JAP RESP SOC, 2004, COPD GUID DIAGN TREA; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Marti S, 2006, EUR RESPIR J, V27, P689, DOI 10.1183/09031936.06.00076405; NETTER F, 1979, CIBA COLLECTION MED; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; Takabatake N, 2005, AM J RESP CRIT CARE, V172, P1097, DOI 10.1164/rccm.200503-319OC; Thurlbeck W M, 1982, Eur J Respir Dis Suppl, V121, P9; WRIGHT JL, 1984, AM REV RESPIR DIS, V129, P989; YANAI M, 1992, J APPL PHYSIOL, V72, P1016; YOSHIOKA A, 1995, AM J RESP CRIT CARE, V152, P2127	37	113	118	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	NOV	2007	62	11					932	937		10.1136/thx.2006.072777		6	Respiratory System	Respiratory System	224SU	WOS:000250467500005	17573447	
J	Park, KS; Korfhagen, TR; Bruno, MD; Kitzmiller, JA; Wan, HJ; Wert, SE; Hershey, GKK; Chen, G; Whitsett, JA				Park, Kwon-Sik; Korfhagen, Thomas R.; Bruno, Michael D.; Kitzmiller, Joseph A.; Wan, Huajing; Wert, Susan E.; Hershey, Gurjit K. Khurana; Chen, Gang; Whitsett, Jeffrey A.			SPDEF regulates goblet cell hyperplasia in the airway epithelium	JOURNAL OF CLINICAL INVESTIGATION			English	Article							TRANSCRIPTION FACTOR-I; SURFACTANT PROTEIN-C; SP-A GENE; RESPIRATORY EPITHELIUM; MOUSE LUNG; TRANSGENIC MICE; ETS-DOMAIN; EXPRESSION; DIFFERENTIATION; FACTOR-1	Goblet cell hyperplasia and mucous hypersecretion contribute to the pathogenesis of chronic pulmonary diseases including cystic fibrosis, asthma, and chronic obstructive pulmonary disease. In the present work, mouse SAM pointed domain-containing ETS transcription factor (SPDEF) mRNA and protein were detected in subsets of epithelial cells lining the trachea, bronchi, and tracheal glands. SPDEF interacted with the C-terminal domain of thyroid transcription factor 1, activating transcription of genes expressed selectively in airway epithelial cells, including Sftpa, Scgb1a1, Foxj1, and Sox17. Expression of Spdef in the respiratory epithelium of adult transgenic mice caused goblet cell hyperplasia, inducing both acidic and neutral mucins in vivo, and stainined for both acidic and neutral mucins in vivo. SPDEF expression was increased at sites of goblet cell hyperplasia caused by IL-13 and dust mite allergen in a process that was dependent upon STAT-6. SPDEF was induced following intratracheal allergen exposure and after Th2 cytokine stimulation and was sufficient to cause goblet cell differentiation of Clara cells in vivo.	Childrens Hosp, Med Ctr, Sect Neonatol Pulm & Perinatal Biol, Div Pulm Biol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH USA	Whitsett, JA (reprint author), Childrens Hosp, Med Ctr, Sect Neonatol Pulm & Perinatal Biol, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org		Khurana Hershey, Gurjit/0000-0001-6663-977X	NHLBI NIH HHS [R01 HL038859, HL38859, HL56387, P50 HL056387, R37 HL038859]		Bachurski CJ, 2003, MOL CELL BIOL, V23, P9014, DOI 10.1128/MCB.23.24.9014-9024.2003; Besnard V, 2005, AM J PHYSIOL-LUNG C, V289, pL750, DOI 10.1152/ajplung.00151.2005; BOHINSKI RJ, 1994, MOL CELL BIOL, V14, P5671; Brody SL, 2000, AM J RESP CELL MOL, V23, P45; BRUNO MD, 1995, J BIOL CHEM, V270, P16482; BRUNO MD, 1995, J BIOL CHEM, V270, P6531; Chen H, 2002, CANCER RES, V62, P338; Chen JC, 1998, J CLIN INVEST, V102, P1077, DOI 10.1172/JCI4786; deFelice M, 2003, J BIOL CHEM, V278, P35574, DOI 10.1074/jbc.M304885200; GUAZZI S, 1990, EMBO J, V9, P3631; Jackson AD, 2001, TRENDS PHARMACOL SCI, V22, P39, DOI 10.1016/S0165-6147(00)01600-X; JainVora S, 1997, AM J RESP CELL MOL, V17, P541; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; Kelly SE, 1996, J BIOL CHEM, V271, P6881; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Lin S, 2006, J BIOL CHEM, V281, P16716, DOI 10.1074/jbc.M602221200; Liu C, 2002, AM J PHYSIOL-LUNG C, V283, pL468, DOI 10.1152/ajplung.00044.2002; Liu C, 2002, J BIOL CHEM, V277, P4519, DOI 10.1074/jbc.M107585200; Liu YR, 2003, DEV BIOL, V261, P10, DOI 10.1016/S0012-1606(03)00359-2; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Mucenski ML, 2005, AM J PHYSIOL-LUNG C, V289, pL971, DOI 10.1152/ajplung.00172.2005; Nadel Jay A., 2001, Current Opinion in Pharmacology, V1, P254, DOI 10.1016/S1471-4892(01)00045-5; Naltner A, 2000, J BIOL CHEM, V275, P56, DOI 10.1074/jbc.275.1.56; Oettgen P, 2000, J BIOL CHEM, V275, P1216, DOI 10.1074/jbc.275.2.1216; Park KS, 2004, J BIOL CHEM, V279, P17384, DOI 10.1074/jbc.M312569200; Park KS, 2006, DEV BIOL, V294, P192, DOI 10.1016/j.ydbio.2006.02.038; Perl AKT, 2002, TRANSGENIC RES, V11, P21; Perl AKT, 2005, AM J RESP CELL MOL, V33, P455, DOI 10.1165/rcmb.2005-0180OC; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Ray MK, 1996, MOL CELL BIOL, V16, P2056; Rogers DF, 2004, CURR OPIN PHARMACOL, V4, P241, DOI 10.1016/j.coph.2004.01.011; Shroyer NF, 2005, GENE DEV, V19, P2412, DOI 10.1101/gad.1353905; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721; Wan HJ, 2004, P NATL ACAD SCI USA, V101, P14449, DOI 10.1073/pnas.0404424101; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamada N, 2000, GENE, V241, P267, DOI 10.1016/S0378-1119(99)00484-9; Yan C, 2001, J BIOL CHEM, V276, P21686; Yang HH, 2002, DEVELOPMENT, V129, P2233; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183	47	113	115	0	5	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	APR	2007	117	4					978	988		10.1172/JCI29176		11	Medicine, Research & Experimental	Research & Experimental Medicine	153RC	WOS:000245451700020	17347682	
J	Wright, RJ				Wright, RJ			Stress and atopic disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; atopy; psychological stress; oxidative stress; psychoneuroimmunology; genetics	PSYCHOSOCIAL STRESS; GENETIC-VARIATION; MATERNAL STRESS; BIRTH-COHORT; EXPOSURE; DISEASE; INFANCY; ASTHMA; MODEL; PSYCHONEUROIMMUNOLOGY	Evidence linking psychological stress to the expression of asthma and atopy continues to grow. Examining the underlying molecular mechanisms linking stress to asthma and other allergic phenomena is an active area of research. Evidence is reviewed for the influence of stress on neuroimmunoregulation and oxidative stress pathways, which, in turn, may affect biological hypersensitivity to environmental stimuli characteristic of atopic disorders. Critical periods of development, including in utero environment, are underscored. The role of genetics and gene-by-environment interactions is also discussed.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Cambridge, MA 02138 USA	Wright, RJ (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	rosalind.wright@channing.harvard.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NHLBI NIH HHS [R01 HL64108, U01 HL072494]; NIEHS NIH HHS [R01 ES10932]		Barker D J, 2001, Med Health Care Philos, V4, P31, DOI 10.1023/A:1009934412988; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; Bienenstock J, 2003, AUTONOMIC NEUROIMMUN; Bonham AC, 2004, PULM PHARMACOL THER, V17, P69; Buske-Kirschbaum A, 2004, PSYCHONEUROENDOCRINO, V29, P705, DOI 10.1016/S0306-4530(03)00100-8; Chen CY, 2003, J APPL PHYSIOL, V94, P819, DOI 10.1152/japplphysiol.00552.2002; Chen CY, 2001, J ALLERGY CLIN IMMUN, V108, P557; Child F, 2003, RESP MED, V97, P1247, DOI 10.1016/S0954-6111(03)00250-6; Chrousos GP, 1996, AM J RESP CRIT CARE, V154, pS39; Chrousos GP, 1998, ANN NY ACAD SCI, V851, P311, DOI 10.1111/j.1749-6632.1998.tb09006.x; CHROUSOS GP, 1996, AM J RESP CRIT CARE, V154, pS44; Cohen S, 1996, ANNU REV PSYCHOL, V47, P113, DOI 10.1146/annurev.psych.47.1.113; Cohen S, 2003, BRAIN BEHAV IMMUN, V17, P407, DOI 10.1016/S0889-1591(03)00110-7; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037//0278-6133.17.3.214; Cohen S, 1995, MEASURING STRESS GUI, P3; Dantzer R, 2004, BRAIN BEHAV IMMUN, V18, P1, DOI 10.1016/bbi.2003.09.008; Donaldson K, 2000, Respir Res, V1, P12, DOI 10.1186/rr5; Essex MJ, 2002, BIOL PSYCHIAT, V52, P776, DOI 10.1016/S0006-3223(02)01553-6; Fukata J, 1993, J ENDOCRINOL INVEST, V16, P141; Glosli H, 2002, FASEB J, V16, P1450, DOI 10.1096/fj.01-0948fje.; Gluckman PD, 2005, EARLY HUM DEV, V81, P51, DOI 10.1016/j.earlhumdev.2004.10.003; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Kelley KW, 2004, BRAIN BEHAV IMMUN, V18, P95, DOI 10.1016/j.bbi.2003.10.003; Lazarus R. S., 1984, STRESS APPRAISAL COP; McEwen BS, 1998, NEW ENGL J MED, V338, P171; Meaney MJ, 2005, TRENDS NEUROSCI, V28, P456, DOI 10.1016/j.tins.2005.07.006; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Osler W, 1892, PRINCIPLES PRACTICE; Pike JL, 1997, PSYCHOSOM MED, V59, P447; Rich EL, 2005, AM J PHYSIOL-REG I, V288, pR1628, DOI 10.1152/ajpregu.00484.2004; Seckl JR, 1997, STEROIDS, V62, P89, DOI 10.1016/S0039-128X(96)00165-1; SHANKS N, 2001, J CLIN INVEST, V108, P1667; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; STEWART PM, 1995, J CLIN ENDOCR METAB, V80, P885, DOI 10.1210/jc.80.3.885; Theoharides TC, 2004, TRENDS PHARMACOL SCI, V25, P563, DOI 10.1016/j.tips.2004.09.007; Tracey KJ, 2002, NATURE, V420, P853, DOI 10.1038/nature01321; UNDEM BJ, 2000, J ALLERGY CLIN IMMUN, V106, P213; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wamboldt MZ, 2003, J ALLERGY CLIN IMMUN, V111, P509, DOI 10.1067/mai.2003.140; WELBERG L, 2001, J NEUROENDOCRINOL, V17, P113; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; WRIGHT RJ, 2004, CURR OPIN ALLERGY CL, V5, P23; Wu Z, 2004, CLIN EXP IMMUNOL, V135, P194, DOI 10.1111/j.1365-2249.2004.02372.x; Wust S, 2004, ANN NY ACAD SCI, V1032, P52, DOI 10.1196/annals.1314.005; Wust S, 2004, J CLIN ENDOCR METAB, V89, P565, DOI 10.1210/jc.2003-031148; Zhou JF, 2000, BIOMED ENVIRON SCI, V13, P44	48	113	119	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2005	116	6					1301	1306		10.1016/j.jaci.2005.09.050		6	Allergy; Immunology	Allergy; Immunology	017IJ	WOS:000235687000022	16337463	
J	Lau, S; Illi, S; Platts-Mills, TAE; Riposo, D; Nickel, R; Gruber, C; Niggemann, B; Wahn, U				Lau, S; Illi, S; Platts-Mills, TAE; Riposo, D; Nickel, R; Gruber, C; Niggemann, B; Wahn, U		Multicentre Allergy Study Grp	Longitudinal study on the relationship between cat allergen and endotoxin exposure, sensitization, cat-specific IgG and development of asthma in childhood - report of the German Multicentre Allergy Study (MAS 90)	ALLERGY			English	Article						cat allergen exposure; childhood asthma; sensitization and immunoglobulin G antibodies to cat	MODIFIED TH2 RESPONSE; HOUSE-DUST; ATOPIC SENSITIZATION; PET OWNERSHIP; BIRTH COHORT; EARLY-LIFE; HAY-FEVER; CHILDREN; RISK; DISORDERS	Background: Controversial data have emerged regarding the question whether cat exposure in childhood favours or decreases the risk of sensitization and allergic airway disease. In a prospective birth-cohort study, we assessed the association between longitudinal cat allergen exposure, sensitization (immunoglobulin E, IgE), IgG antibody (ab) levels to cat and the development of asthma in children up to the age of 10 years. Methods: Of 1314 newborn infants enrolled in five German cities in 1990, follow-up data at age 10 years were available for 750 children. Assessments included yearly measurements of specific serum IgE to cat and at age 6 and 18 months, 3, 4 and 10 years measurement of cat allergen Fel d 1 in house dust samples. Additionally, Fel d 1-specific IgG ab were determined in 378 serum samples of 207 children. Endotoxin exposure in mattress dust was measured in a subgroup of 153 children at age 10 years. From age 4 years on, International Study of Asthma and Allergy in Childhood (ISAAC) questionnaires were completed yearly in order to assess the prevalence of wheeze and asthma. Results: Serum IgG-levels to cat showed a large variation, however, intraindividually values showed rather constant concentration over a longer time period. The IgG levels at school-age correlated with cat allergen exposure during the first 2 years of life. Specific IgE to cat was clearly associated with wheeze ever, current wheeze and bronchial hyperresponsiveness (BHR), this was also observed for children with specific IgE ab to cat (&GT; 0.35 kU/l) plus IgG levels above 125 U/ml. A large percentage of very highly exposed children showed high IgG but no IgE responses to cat, however, not all highly exposed children were found to be protected from sensitization. Children with IgG but without IgE ab to cat showed the lowest prevalence of wheeze ever and current wheeze despite high cat allergen exposure, however, this trend did not achieve significance. While homes of cat owners showed higher Fel d 1 concentrations than homes without cats, homes of cat owners were not found to have higher endotoxin levels in carpet dust samples than homes without cats. Conclusions: We could confirm that high cat allergen exposure in a cohort with lower community prevalence of cats is associated with higher serum IgG and IgE levels to cat in schoolchildren. Sensitization to cat allergen (IgE) is a risk factor for childhood asthma. While exposure to cat allergen during infancy is associated with sensitization (IgE), only in the very highly exposed children the likelihood of sensitization (IgE) is decreased and high IgG levels to cat without IgE were associated with low risk of wheeze. However, cat-specific IgG ab levels did not protect children with IgE-mediated sensitization from wheeze.	Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Univ Childrens Hosp von Hauner, Munich, Germany; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Lau, S (reprint author), Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Univ Childrens Hosp Charite Campus, D-13353 Berlin, Germany.						AALBERSE RC, 1983, J IMMUNOL, V130, P722; AKDIS CA, 2003, ARB P EHRLICH I BUND, V94, P219; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BOTTCHER MF, 2002, CLIN EXP ALLERGY, V32, P1679; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; CUSTOVIC A, 2001, LANCET, V31, P803; GARCIAROBAINA JC, 1997, CLIN EXP ALLERGY, V4, P412; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Hesselmar B, 2003, CLIN EXP ALLERGY, V33, P1681, DOI 10.1111/j.1365-2222.2003.01821.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HILL DJ, 1981, LANCET, V19, P1359; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; OWNBY PR, 2002, JAMA-J AM MED ASSOC, V288, P963; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Reefer AJ, 2004, J IMMUNOL, V172, P2763; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SIGSGAARD T, 1992, AM J IND MED, V22, P163, DOI 10.1002/ajim.4700220204; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Svanes C, 2003, J ALLERGY CLIN IMMUN, V112, P289, DOI 10.1067/mai.2003.1596; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x	38	113	115	0	8	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0105-4538			ALLERGY	Allergy	JUN	2005	60	6					766	773		10.1111/j.1398-9995.2005.00781.x		8	Allergy; Immunology	Allergy; Immunology	922VC	WOS:000228867000007	15876306	
J	Strid, J; Hourihane, J; Kimber, I; Callard, R; Strobel, S				Strid, J; Hourihane, J; Kimber, I; Callard, R; Strobel, S			Epicutaneous exposure to peanut protein prevents oral tolerance and enhances allergic sensitization	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						epicutaneous sensitization; food allergy; IgE; oral tolerance; peanut; skin	FOOD ALLERGY; ATOPIC-DERMATITIS; TH2 RESPONSES; MURINE MODEL; PREVALENCE; ANTIGEN; IMMUNIZATION; MECHANISMS; CHILDREN; DISEASES	Food allergies are an important cause of life-threatening hypersensitivity reactions. Oral tolerance can be considered the default immune response to dietary antigens, with immune deviation resulting in allergic sensitization. However, primary sensitization to food allergens may not solely be through the gastrointestinal mucosa, as strong T-helper type 2 (Th2)-biased immunity can result from exposure to protein allergens on barrier-disrupted skin. The purpose of this study was to examine whether exposure to allergens through the skin may interfere with the normal development of oral tolerance and promote allergic sensitization to food proteins. Female BALB/c mice were exposed epicutaneously to peanut protein and induction of systemic oral tolerance through high dose feeds of peanut protein was subsequently assessed. Other mice were rendered tolerant prior to epicutaneous peanut exposure. Sensitivity to peanut was determined by assessing delayed-type hypersensitivity, proliferative, cytokine and antibody responses. Epicutaneous exposure to peanut protein induced potent Th2-type immunity with high levels of IL-4 and serum IgE. Primary skin exposure prevented the subsequent induction of oral tolerance to peanut in an antigen-specific manner. Upon oral challenge, mice became further sensitized and developed strong peanut-specific IL-4 and IgE responses. Furthermore, animals with existing tolerance to peanut were partly sensitized following epicutaneous exposure. Epicutaneous exposure to peanut protein can prevent induction of oral tolerance, and may even modify existing tolerance to peanut. Epidermal exposure to protein allergens selectively drives Th2-type responses, and as such may promote sensitization to food proteins upon gastrointestinal exposure.	UCL, Inst Child Hlth, Immunobiol Unit, London WC1N 1EH, England; Univ Southampton, Div Infect Inflammat & Repair, Southampton, Hants, England; Syngenta, Cent Toxicol Lab, Macclesfield, Cheshire, England; Peninsula Postgrad Hlth Inst, Plymouth, Devon, England	Strid, J (reprint author), UCL, Inst Child Hlth, Immunobiol Unit, 30 Guilford St, London WC1N 1EH, England.	j.strid@ich.ucl.ac.uk	Callard, Robin/C-5682-2008; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Strid, Jessica/0000-0003-3690-2201			Armitage P., 1971, STAT METHODS MED RES; Bilsborough J, 2002, IMMUNOLOGY, V106, P139, DOI 10.1046/j.1365-2567.2002.01445.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Cochet O, 1998, IMMUNOLOGICAL TECHNI; Crespo JF, 2003, ALLERGY, V58, P98, DOI 10.1034/j.1398-9995.2003.02170.x; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; Garside P, 2001, SEMIN IMMUNOL, V13, P177, DOI 10.1006/smim.2001.0310; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hachem JP, 2003, J INVEST DERMATOL, V121, P345, DOI 10.1046/j.1523-1747.2003.12365.x; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Herrick CA, 2003, J IMMUNOL, V170, P2488; Hourihane JO, 1996, BRIT MED J, V313, P518; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Novak Natalija, 2003, Journal of Allergy and Clinical Immunology, V112, pS128, DOI 10.1016/j.jaci.2003.09.032; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Roy K, 1999, NAT MED, V5, P387; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schleimer RP, 2000, J ALLERGY CLIN IMMUN, V106, pS191; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200324843; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; STRID J, 2005, IN PRESS CURR DRUG T; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; Wang L F, 1996, J Immunol, V156, P4077; Warner RR, 2003, J INVEST DERMATOL, V120, P275, DOI 10.1046/j.1523-1747.2003.12046.x; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Werfel T, 2001, ALLERGY, V56, P98, DOI 10.1034/j.1398-9995.2001.00929.x; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x	36	113	116	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2005	35	6					757	766		10.1111/j.1365-2222.2005.02260.x		10	Allergy; Immunology	Allergy; Immunology	937WG	WOS:000229956100014	15969667	
J	Borkow, G; Gabbay, J				Borkow, G; Gabbay, J			Putting copper into action: copper-impregnated products with potent biocidal activities	FASEB JOURNAL			English	Article						HIV-1; filters; fabrics; dust mites; athlete's foot	METAL-IONS; INTRAUTERINE-DEVICES; BLOOD-TRANSFUSION; MARATHON RUNNERS; PLASMA-MEMBRANE; TINEA-PEDIS; VIRUS; INACTIVATION; MECHANISMS; HIV-1	Copper ions, either alone or in copper complexes, have been used for centuries to disinfect liquids, solids, and human tissue. Today copper is used as a water purifier, algaecide, fungicide, nematocide, molluscicide, and antibacterial and antifouling agent. Copper also displays potent antiviral activity. We hypothesized that introducing copper into clothing, bedding, and other articles would provide them with biocidal properties. A durable platform technology has been developed that introduces copper into cotton fibers, latex, and other polymeric materials. This study demonstrates the broad-spectrum antimicrobial ( antibacterial, antiviral, antifungal) and antimite activities of copper-impregnated fibers and polyester products. This technology enabled the production of antiviral gloves and filters (which deactivate HIV-1 and other viruses), antibacterial self-sterilizing fabrics (which kill antibiotic-resistant bacteria, including methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococci), antifungal socks (which alleviate symptoms of athlete's foot), and anti-dust mite mattress covers (which reduce mite-related allergies). These products did not have skin-sensitizing properties, as determined by guine pig maximization and rabbit skin irritation tests. Our study demonstrates the potential use of copper in new applications. These applications address medical issues of the greatest importance, such as viral transmissions; nosocomial, or healthcare-associated, infections; and the spread of antibiotic-resistant bacteria.	Cupron Inc, New York, NY 10165 USA	Borkow, G (reprint author), Hameyasdim 44, IL-76910 Kfar Gibton, Israel.	gadi@cupron.com					AUGER P, 1993, MYCOSES, V36, P35; Avery SV, 1995, BIOCHEM J, V312, P811; Biggerstaff BJ, 2002, TRANSFUSION, V42, P1019, DOI 10.1046/j.1537-2995.2002.00167.x; Bilian X, 2002, BEST PRACT RES CL OB, V16, P155, DOI 10.1053/beog.2002.0267; Borkow G, 1997, BIOCHEMISTRY-US, V36, P3179, DOI 10.1021/bi9624696; Brunton SA, 1999, HOSP PRACT, V34, P67; CERVANTES C, 1994, FEMS MICROBIOL REV, V14, P121; Cooney JJ, 1999, METHOD ENZYMOL, V310, P637; COONEY TE, 1995, INFECT CONT HOSP EP, V16, P444; CORONEL D, 2000, REANIMATION, V9, P86; CORONEL D, 2001, REANIMATION S, V10, P43; Dollwet HH, 2001, TRACE ELEM MED, V2, P80; *FDA, 2003, MIN SAF EFF METH RED; Fowler MG, 2002, J ACQ IMMUN DEF SYND, V30, P230, DOI 10.1097/01.QAI.0000018364.28828.14; FRASER WD, 2001, 211 INCRA HUNT RES C, P43; Goodnough LT, 2003, LANCET, V361, P161, DOI 10.1016/S0140-6736(03)12195-2; HAZEL JR, 1990, PROG LIPID RES, V29, P167, DOI 10.1016/0163-7827(90)90002-3; Hellstern P, 2002, THROMB RES, V107, pS3, DOI 10.1016/S0049-3848(02)00145-7; Hess C, 2002, LANCET, V359, P2230, DOI 10.1016/S0140-6736(02)09291-7; Hostynek Jurij J, 2003, Rev Environ Health, V18, P153; Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438; International Diabetes Federation, 2000, DIAB ATL; JORDAN FTW, 1971, VET REC, V89, P609; KARLSTROM AR, 1991, P NATL ACAD SCI USA, V88, P5552, DOI 10.1073/pnas.88.13.5552; Kim JH, 2000, ARCH BIOCHEM BIOPHYS, V382, P72, DOI 10.1006/abbi.2000.1996; KIMPTON J, 1992, J VIROL, V66, P2232; Lacroix C, 2002, J EUR ACAD DERMATOL, V16, P139, DOI 10.1046/j.1468-3083.2002.00400.x; LOUDER M, 1999, HIV PROTOCOLS, P23; MAGNUSSON B, 1980, CONTACT DERMATITIS, V6, P46, DOI 10.1111/j.1600-0536.1980.tb03894.x; MASCOLA JR, 1999, HIV PROTOCOLS, P317; OHSUMI Y, 1988, J BACTERIOL, V170, P2676; Pena MMO, 1999, J NUTR, V129, P1251; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557; ROBINSON MK, 1989, FOOD CHEM TOXICOL, V27, P479, DOI 10.1016/0278-6915(89)90036-7; RODRIGUEZMONTELONGO L, 1993, BIOCHIM BIOPHYS ACTA, V1144, P77, DOI 10.1016/0005-2728(93)90033-C; Sagripanti JL, 1996, AIDS RES HUM RETROV, V12, P333, DOI 10.1089/aid.1996.12.333; Sagripanti JL, 1997, ANTIMICROB AGENTS CH, V41, P812; SAGRIPANTI JL, 1993, APPL ENVIRON MICROB, V59, P4374; Silver S, 1996, GENE, V179, P9, DOI 10.1016/S0378-1119(96)00323-X; SKONER DP, 2000, J ALLERGY CLIN IMMUN, V100, pS2; Snyder E L, 2001, Hematology Am Soc Hematol Educ Program, P433; Spencer RC, 1994, INTENSIVE CARE ME S4, V20, P2; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; Stout JE, 1998, INFECT CONT HOSP EP, V19, P911; Strong DM, 2002, TRENDS MOL MED, V8, P355, DOI 10.1016/S1471-4914(02)02361-4; UEDA K, 1980, CHEM-BIOL INTERACT, V29, P145, DOI 10.1016/0009-2797(80)90029-0; Weber DJ, 2001, DISINFECTION STERILI, P415; Yahaya M.T., 2001, 48 INT COPP RES ASS; Youssefian T, 2002, BLOOD, V99, P4021, DOI 10.1182/blood-2001-12-0191; TAL M, 1999, Patent No. 5871816; 2002, DRUG THER B, V40, P67	51	113	121	6	51	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2004	18	12					1728	+		10.1096/fj.04-2029fje		19	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	859DQ	WOS:000224243200042	15345689	
J	Strid, J; Hourihane, J; Kimber, I; Callard, R; Strobel, S				Strid, J; Hourihane, J; Kimber, I; Callard, R; Strobel, S			Disruption of the stratum corneum allows potent epicutaneous immunization with protein antigens resulting in a dominant systemic Th2 response	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						skin; Th1/Th2 cells; allergy; Langerhans cells; vaccination	TUMOR-NECROSIS-FACTOR; DENDRITIC CELLS; LANGERHANS CELLS; PEANUT ALLERGY; AEROSOLIZED ANTIGEN; ATOPIC-DERMATITIS; IGE PRODUCTION; FOOD ALLERGY; FACTOR-ALPHA; BARE SKIN	The skin is an important immunological organ with an outer protective layer, the stratum corneum forming a barrier between the skin-associated lymphoid tissue and the environment. We show that gently removing the stratum corneum with adhesive tape permits potent epicutaneous immunization to protein antigens. IL-4 secretion by T cells from draining lymph nodes and high levels of specific IgE and IgG1 with no IgG2a showed that the immune responses induced following epicutaneous antigen exposure are strongly Th2 biased. Similar responses were obtained With different antigens and mouse strains. In contrast, subcutaneous immunization with antigen delivery into the dermis was less potent and gave predominantly Th1 responses. Removal of the stratum corneum increased expression of MHC class II, CD86, CD40, CD54 and CD11c on Langerhans cells, but did not cause them to migrate. Rapid migration from epidermis to draining lymph node was obtained, however, by exposure to antigen after removal of the stratum corneum, suggesting that maturation and migration of Langerhans cells are independently regulated events. These results suggest that antigen presentation by Langerhans cells gives predominantly Th2 responses. This may provide an explanation for allergic sensitization to some antigens. It may also be a useful non-invasive, non-adjuvant-dependent method of vaccination.	UCL, Inst Child Hlth, Immunobiol Unit, London WC1N 1EH, England; Southampton Univ Hosp NHS Trust, Wellcome Trust Clin Res Facil, Southampton, Hants, England; Syngenta, Cent Toxicol Lab, Macclesfield, Cheshire, England	Strid, J (reprint author), UCL, Inst Child Hlth, Immunobiol Unit, 30 Guilford St, London WC1N 1EH, England.	j.strid@ich.ucl.ac.uk	Callard, Robin/C-5682-2008	Strid, Jessica/0000-0003-3690-2201			Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Beignon AS, 2002, IMMUNOLOGY, V105, P204, DOI 10.1046/j.0019-2805.2001.01357.x; Beignon AS, 2001, IMMUNOLOGY, V102, P344, DOI 10.1046/j.1365-2567.2001.01183.x; Cochet O, 1998, IMMUNOLOGICAL TECHNI; Cumberbatch M, 2001, IMMUNOLOGY, V102, P323, DOI 10.1046/j.1365-2567.2001.01187.x; Cumberbatch M, 1997, IMMUNOLOGY, V92, P388, DOI 10.1046/j.1365-2567.1997.00360.x; Darsow U, 1996, BRIT J DERMATOL, V135, P182, DOI 10.1111/j.1365-2133.1996.tb01144.x; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; Elbe-Burger A, 2002, J INVEST DERMATOL, V118, P767, DOI 10.1046/j.1523-1747.2002.01753.x; ELIAS PM, 1991, ADV LIPID RES, V24, P1; Finkelman FD, 1996, J IMMUNOL, V157, P1406; Geissmann F, 2002, J EXP MED, V196, P417, DOI 10.1084/jem.20020018; Glenn GM, 1998, NATURE, V391, P851, DOI 10.1038/36014; HAUSER C, 1989, EUR J IMMUNOL, V19, P245, DOI 10.1002/eji.1830190205; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Herrick CA, 2003, J IMMUNOL, V170, P2488; Hourihane JO, 1996, BRIT MED J, V313, P518; Kimber I, 2000, BRIT J DERMATOL, V142, P401, DOI 10.1046/j.1365-2133.2000.03349.x; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Luft T, 2002, BLOOD, V100, P1362, DOI 10.1182/blood-2001-12-0360; Lutz MB, 1996, EUR J IMMUNOL, V26, P586, DOI 10.1002/eji.1830260313; Matsui K, 2002, CLIN EXP ALLERGY, V32, P783, DOI 10.1046/j.1365-2222.2002.01357.x; Maurer D, 2001, DENDRITIC CELLS, P35, DOI 10.1016/B978-012455851-9/50044-4; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; Nelde A, 2001, INT ARCH ALLERGY IMM, V124, P461, DOI 10.1159/000053781; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535; NICKOLOFF BJ, 1994, CLIN IMMUNOL IMMUNOP, V73, P63, DOI 10.1006/clin.1994.1170; Nishijima T, 1997, J INVEST DERMATOL, V109, P175, DOI 10.1111/1523-1747.ep12319282; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; ROAKE JA, 1995, J EXP MED, V181, P2237, DOI 10.1084/jem.181.6.2237; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Scandella E, 2002, BLOOD, V100, P1354, DOI 10.1182/blood-2002-11-0017; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Viney JL, 1998, J IMMUNOL, V160, P5815; Wang L F, 1996, J Immunol, V156, P4077; Werfel T, 2001, ALLERGY, V56, P98, DOI 10.1034/j.1398-9995.2001.00929.x; Williamson E, 1999, J IMMUNOL, V163, P3668; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884	42	113	117	0	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	AUG	2004	34	8					2100	2109		10.1002/eji.200324843		10	Immunology	Immunology	844RR	WOS:000223177800005	15259007	
J	Myou, S; Leff, AR; Myo, S; Boetticher, E; Tong, JK; Meliton, AY; Liu, J; Munoz, NM; Zhu, XD				Myou, S; Leff, AR; Myo, S; Boetticher, E; Tong, JK; Meliton, AY; Liu, J; Munoz, NM; Zhu, XD			Blockade of inflammation and airway hyperresponsiveness in immune-sensitized mice by dominant-negative phosphoinositide 3-kinase-TAT	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						allergy; cytokines; eosinophils; lung; inflammation	FC-EPSILON-RI; IN-VIVO; HUMAN EOSINOPHILS; PHOSPHATIDYLINOSITOL 3-KINASE; BRONCHIAL RESPONSIVENESS; GENE-EXPRESSION; GUINEA-PIGS; MAST-CELLS; B-CELLS; ASTHMA	Phosphoinositide 3-kinase (PI3K) is thought to contribute to the pathogenesis of asthma by effecting the recruitment, activation, and apoptosis of inflammatory cells. We examined the role of class IA PI3K in antigen-induced air-way inflammation and hyperresponsiveness by i.p. administration into mice of Deltap85 protein, a dominant negative form of the class IA PI3K regulatory subunit, p85alpha, which was fused to HIV-TAT (TAT-Deltap85). Intraperitoneal administration of TXT-Deltap85 caused time-dependent transduction into blood leukocytes, and inhibited activated phosphorylation of protein kinase B (PKB), a downstream target of PI3K, in lung tissues in mice receiving intranasal FMLP. Antigen challenge elicited pulmonary infiltration of lymphocytes, eosinophils and neutrophils, increase in mucus-containing epithelial cells, and airway hyperresponsiveness to methacholine. Except for modest airway neutrophilia, these effects all were blocked by treatment with 3-10 mg/kg of TAT-Deltap85. There was also significant reduction in IL-5 and IL-4 secretion into the BAL. Intranasal administration of IL-5 caused eosinophil migration into the air-way lumen, which was attenuated by systemic pretreatment with TAT-Deltap85. We conclude that PI3K has a regulatory role in Th2-cell cytokine secretion, airway inflammation, and air-way hyperresponsiveness in mice.	Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Mol Med, Chicago, IL 60637 USA; Univ Chicago, Comm Clin Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Comm Cell Physiol, Chicago, IL 60637 USA	Leff, AR (reprint author), Univ Chicago, Dept Med, Pulm & Crit Care Med Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA.	aleff@medicine.bsd.uchicago.edu			NHLBI NIH HHS [HL-46368, HL-56399, P50 HL056399, R01 HL046368]; NIAID NIH HHS [AI-52109, K08 AI052109]		ARCARO A, 1993, BIOCHEM J, V296, P297; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BONSER RW, 1991, BRIT J PHARMACOL, V103, P1237; Bracke M, 2000, J LEUKOCYTE BIOL, V68, P655; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; COFFMAN RL, 1986, J IMMUNOL, V136, P4538; CROSS MJ, 1995, J BIOL CHEM, V270, P25352; CUSS FM, 1986, LANCET, V2, P189; Dabbagh K, 1999, J IMMUNOL, V162, P6233; DHAND R, 1994, EMBO J, V13, P511; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; Dunzendorfer S, 1998, J LEUKOCYTE BIOL, V64, P828; Evans DJ, 1999, AM J PHYSIOL-LUNG C, V277, pL233; Ezeamuzie CI, 2001, AM J RESP CRIT CARE, V164, P1633; Ford JG, 2001, J IMMUNOL, V167, P1769; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fruman DA, 2000, NAT GENET, V26, P379; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fujitani Y, 2003, AM J RESP CRIT CARE, V167, P193, DOI 10.1164/rccm.200205-455OC; Fukao T, 2002, NAT IMMUNOL, V3, P295, DOI 10.1038/ni768; Fukao T, 2002, NAT IMMUNOL, V3, P875, DOI 10.1038/ni825; Hall DJ, 2001, BLOOD, V98, P2014, DOI 10.1182/blood.V98.7.2014; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Humbles AA, 2000, NATURE, V406, P998; KOTANI K, 1994, EMBO J, V13, P2313; Krymskaya VP, 1999, AM J PHYSIOL-LUNG C, V277, pL65; Kwak YG, 2003, J CLIN INVEST, V111, P1083, DOI 10.1172/JCI200316440; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lefort J, 1996, J CLIN INVEST, V97, P1117, DOI 10.1172/JCI118505; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467; MOSER R, 1992, J IMMUNOL, V149, P1432; Myou S, 2002, J IMMUNOL, V169, P2670; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Powell N, 2001, J ALLERGY CLIN IMMUN, V108, P915, DOI 10.1067/mai.2001.119742; RABE KF, 1994, AM J PHYSIOL, V267, pL326; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Smith AJ, 2001, J BIOL CHEM, V276, P17213, DOI 10.1074/jbc.M100417200; Strek ME, 1996, AM J PHYSIOL-LUNG C, V270, pL133; Vachier I, 1997, AM J RESP CRIT CARE, V155, P1211; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; WHITE SR, 1993, J CLIN INVEST, V91, P2118, DOI 10.1172/JCI116436; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; Zhu XD, 2002, J LEUKOCYTE BIOL, V72, P1046	51	113	126	0	3	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	NOV 17	2003	198	10					1573	1582		10.1084/jem.20030298		10	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	748CX	WOS:000186845600012	14623911	
J	Lehrer, P; Feldman, J; Giardino, N; Song, HS; Schmaling, K				Lehrer, P; Feldman, J; Giardino, N; Song, HS; Schmaling, K			Psychological aspects of asthma	JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY			English	Review							PEAK EXPIRATORY FLOW; NEAR-FATAL ASTHMA; SELF-MANAGEMENT PROGRAM; RESPIRATORY SINUS ARRHYTHMIA; INSPIRATORY RESISTIVE LOADS; LIFE-THREATENING ASTHMA; VOCAL CORD DYSFUNCTION; INNER-CITY CHILDREN; RANDOMIZED CONTROLLED-TRIAL; HEALTH BELIEF MODEL	Asthma can be affected by stress, anxiety, sadness, and suggestion, as well as by environmental irritants or allergens, exercise, and infection. It also is associated with an elevated prevalence of anxiety and depressive disorders. Asthma and these psychological states and traits may mutually potentiate each other through direct psychophysiological mediation, nonadherence to medical regimen, exposure to asthma triggers, and inaccuracy of asthma symptom perception. Defensiveness is associated with inaccurate perception of airway resistance and stress-related bronchoconstriction. Asthma education programs that teach about the nature of the disease, medications, and trigger avoidance tend to reduce asthma morbidity. Other promising psychological interventions as adjuncts to medical treatment include training in symptom perception, stress management, hypnosis, yoga, and several biofeedback procedures.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Psychol, Piscataway, NJ 08855 USA; Univ Texas, Dept Hlth Sci, El Paso, TX 79968 USA	Lehrer, P (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, 671 Hoes Lane, Piscataway, NJ 08854 USA.	lehrer@umdnj.edu	Schmaling, Karen/F-5217-2011	Schmaling, Karen/0000-0003-2085-134X	NHLBI NIH HHS [R01 HL058805-03, R01 HL58805]; NIMH NIH HHS [R21 MH058196-03, R21MH58196A]		ABDULWADUD O, 1997, PATIENT EDUC COUNS, V39, P253; Adams S, 1997, SOC SCI MED, V45, P189, DOI 10.1016/S0277-9536(96)00333-4; Afari N, 2001, J CLIN PSYCHOL MED S, V8, P245, DOI 10.1023/A:1011912712262; Affleck G, 2000, PSYCHOSOM MED, V62, P61; Ajzen I., 1985, ACTION CONTROL COGNI, P1; Apter AJ, 1997, J ALLERGY CLIN IMMUN, V99, P605, DOI 10.1016/S0091-6749(97)70020-4; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810; Apter AJ, 2001, ANN ALLERG ASTHMA IM, V86, P421; ARNTZ A, 1994, PAIN, V56, P307, DOI 10.1016/0304-3959(94)90169-4; Ballard RD, 1999, CHRONOBIOL INT, V16, P565, DOI 10.3109/07420529908998729; Bandura A, 1986, SOCIAL FDN THOUGHT A; Barboni E, 1997, Monaldi Arch Chest Dis, V52, P339; BARON C, 1992, CAN J PSYCHIAT, V37, P12; BARON C, 1994, PEDIATRICS, V94, P108; Bartholomew LK, 2000, PATIENT EDUC COUNS, V39, P253, DOI 10.1016/S0738-3991(99)00045-2; BASS C, 1985, BRIT MED J, V290, P1387; Bass C, 1997, J PSYCHOSOM RES, V42, P421, DOI 10.1016/S0022-3999(96)00365-0; BECKER MH, 1978, PUBLIC HEALTH REP, V93, P268; BELL IR, 1991, PSYCHOTHER PSYCHOSOM, V55, P24; Bender B, 1998, J ASTHMA, V35, P347, DOI 10.3109/02770909809075667; Berg J, 1998, ANN BEHAV MED, V20, P36, DOI 10.1007/BF02893807; BERNARDBONNIN AC, 1995, J ALLERGY CLIN IMMUN, V95, P34, DOI 10.1016/S0091-6749(95)70150-8; BERNSTEIN JA, 1991, ANN ALLERGY, V66, P311; Bock BC, 1997, INT J BEHAV MED, V4, P60, DOI 10.1207/s15327558ijbm0401_4; BOSLEY CM, 1995, EUR RESPIR J, V8, P899; BOULET LP, 1991, J ALLERGY CLIN IMMUN, V88, P838, DOI 10.1016/0091-6749(91)90239-K; BOULET LP, 1994, THORAX, V49, P965, DOI 10.1136/thx.49.10.965; Braunstein GL, 1996, EUR RESPIR J, V9, P893, DOI 10.1183/09031936.96.09050893; Brown RH, 2000, AM J RESP CRIT CARE, V161, P1256; Bruzzese JM, 2001, J ASTHMA, V38, P337; Burge PS, 1999, OCCUP ENVIRON MED, V56, P758; BUSSE W, 1988, ALLERGY PRINCIPLES P, P969; Bussing R, 1996, PSYCHOSOMATICS, V37, P108; CAMPBELL DA, 1995, THORAX, V50, P254, DOI 10.1136/thx.50.3.254; CARR RE, 1992, BEHAV RES THER, V30, P251, DOI 10.1016/0005-7967(92)90071-N; Carr RE, 1996, J ABNORM PSYCHOL, V105, P137; CARR RE, 1994, BEHAV RES THER, V32, P411, DOI 10.1016/0005-7967(94)90004-3; Castes M, 1999, BRAIN BEHAV IMMUN, V13, P1, DOI 10.1006/brbi.1999.0551; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHAMBERS CV, 1999, RESP MED, V91, P524; CHAMBLESS DL, 1984, J CONSULT CLIN PSYCH, V52, P1090, DOI 10.1037/0022-006X.52.6.1090; CHANDRA FA, 1994, BEHAV PSYCHOL APPROA, P221; CHAPMAN RW, 1980, J APPL PHYSIOL, V49, P497; CHARLTON I, 1990, BRIT MED J, V301, P1355; CHERNIGOVSKAYA NV, 1990, HUMAN PHYSL, V17, P105; CHERNIGOVSKAYA NV, 1990, SS KORSAKOVS J NEURO, V90, P24; CHONAN T, 1990, J APPL PHYSIOL, V68, P2100; Cluley S, 2001, RESP MED, V95, P37, DOI 10.1053/rmed.2000.0968; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Davenport PW, 2000, AM J RESP CRIT CARE, V161, P1830; DAVENPORT PW, 1986, J APPL PHYSIOL, V60, P1843; DECI EL, 1985, J RES PERS, V19, P109, DOI 10.1016/0092-6566(85)90023-6; Devine EC, 1996, RES NURS HEALTH, V19, P367, DOI 10.1002/(SICI)1098-240X(199610)19:5<367::AID-NUR1>3.0.CO;2-O; Devriese S, 2000, PSYCHOSOM MED, V62, P751; DIRKS JF, 1978, BRIT J MED PSYCHOL, V51, P119; Eid N, 2000, PEDIATRICS, V105, P354, DOI 10.1542/peds.105.2.354; ESTERLING BA, 1994, J CONSULT CLIN PSYCH, V62, P130, DOI 10.1037/0022-006X.62.1.130; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Feldman JM, 2000, MANAGEMENT OF STRESS AND ANXIETY IN MEDICAL DISORDERS, P220; Feldman JM, 2002, PSYCHOSOM MED, V64, P294; Fish L, 1996, AM J PUBLIC HEALTH, V86, P246, DOI 10.2105/AJPH.86.2.246; Fritz GK, 1996, J PEDIATR PSYCHOL, V21, P153, DOI 10.1093/jpepsy/21.2.153; Fritz GK, 1996, J AM ACAD CHILD PSY, V35, P1033, DOI 10.1097/00004583-199608000-00014; Garssen B, 1996, AM J PSYCHIAT, V153, P513; Gavin LA, 1999, J PEDIATR PSYCHOL, V24, P355, DOI 10.1093/jpepsy/24.4.355; Gavin LA, 1998, J ASTHMA, V35, P409, DOI 10.3109/02770909809048949; Giannini D, 1997, J ASTHMA, V34, P105, DOI 10.3109/02770909709075654; GIBSON NA, 1995, THORAX, V50, P1274, DOI 10.1136/thx.50.12.1274; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167; GLAUS KD, 1983, BIOL PSYCHOL, V17, P105, DOI 10.1016/0301-0511(83)90011-X; Godding V, 1997, FAM PROCESS, V36, P265, DOI 10.1111/j.1545-5300.1997.00265.x; *GRAMP ASTHM STUD, 1994, BRIT MED J, V308, P564; Greineder DK, 1999, J ALLERGY CLIN IMMUN, V103, P436, DOI 10.1016/S0091-6749(99)70468-9; GUSTAFSSON PA, 1986, J PSYCHOSOM RES, V30, P369, DOI 10.1016/0022-3999(86)90015-2; Hackman RM, 2000, J ASTHMA, V37, P1, DOI 10.3109/02770900009055424; Hammo AH, 1999, ANN ALLERG ASTHMA IM, V82, P574, DOI 10.1016/S1081-1206(10)63169-9; Hand CH, 1996, J ASTHMA, V33, P331, DOI 10.3109/02770909609055374; HARVER A, 1994, HEALTH PSYCHOL, V13, P52, DOI 10.1037/0278-6133.13.1.52; Harver A, 1998, SELF MANAGEMENT ASTH, P147; Hegel MT, 1997, PSYCHOSOM MED, V59, P224; HENDRICSON WD, 1994, ARCH PEDIAT ADOL MED, V148, P595; HENRY M, 1993, J PSYCHOSOM RES, V37, P265, DOI 10.1016/0022-3999(93)90035-E; HOLLAENDER J, 1983, J PSYCHOSOM RES, V27, P307, DOI 10.1016/0022-3999(83)90053-3; Homer C, 2000, PEDIATRICS, V106, P210; HORN CR, 1990, RESP MED, V84, P67, DOI 10.1016/S0954-6111(08)80097-2; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; HYLAND ME, 1993, BRIT J CLIN PSYCHOL, V32, P505; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353; INAMORI Y, 1995, JAPANESE J BIOFEEDBA, V22, P19; Irvine L, 1999, BRIT MED J, V318, P1456; Isenberg S, 1997, J BEHAV MED, V20, P461, DOI 10.1023/A:1025551532756; ISENBERG SA, 1992, J PSYCHOSOM RES, V36, P769, DOI 10.1016/0022-3999(92)90135-O; ISENBERG SA, 1992, PSYCHOSOM MED, V54, P192; Izbicki G, 1999, EUR RESPIR J, V14, P209, DOI 10.1034/j.1399-3003.1999.14a35.x; Jacobson NS, 1999, J CONSULT CLIN PSYCH, V67, P300, DOI 10.1037/0022-006X.67.3.300; JAIN SC, 1991, J ASTHMA, V28, P437, DOI 10.3109/02770909109110627; Jamner LD, 1999, PSYCHIAT RES, V85, P17, DOI 10.1016/S0165-1781(98)00134-6; JANSON C, 1994, AM J RESP CRIT CARE, V149, P930; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; JONES PK, 1987, J ASTHMA, V24, P199, DOI 10.3109/02770908709070940; KALLENBACH JM, 1985, CHEST, V87, P644, DOI 10.1378/chest.87.5.644; Kang DH, 1997, J INTERF CYTOK RES, V17, P481, DOI 10.1089/jir.1997.17.481; KAPLAN DM, 1995, MEAS EVAL COUNS DEV, V27, P195; Kapsali T, 2000, J APPL PHYSIOL, V89, P711; KARAJGI B, 1990, AM J PSYCHIAT, V147, P200; KAVANAGH DJ, 1993, J BEHAV MED, V16, P509, DOI 10.1007/BF00844820; Kazdin AE, 1999, J CONSULT CLIN PSYCH, V67, P332, DOI 10.1037/0022-006X.67.3.332; Kelloway JS, 2000, ANN ALLERG ASTHMA IM, V84, P324, DOI 10.1016/S1081-1206(10)62781-0; Kelloway Judy S., 1994, Archives of Internal Medicine, V154, P1349, DOI 10.1001/archinte.154.12.1349; KELSEN SG, 1979, AM REV RESPIR DIS, V120, P517; Kendall PC, 1999, J CONSULT CLIN PSYCH, V67, P285, DOI 10.1037//0022-006X.67.3.285; KENDRICK AH, 1993, BRIT MED J, V307, P422; Kern-Buell CL, 2000, APPL PSYCHOPHYS BIOF, V25, P79, DOI 10.1023/A:1009562708112; Kifle Y, 1997, AM J RESP CRIT CARE, V156, P1530; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; KILHAM H, 1979, THORAX, V34, P582, DOI 10.1136/thx.34.5.582; KINSMAN RA, 1980, PSYCHOL REP, V46, P196; KINSMAN RA, 1983, J BEHAV MED, V6, P339, DOI 10.1007/BF00846323; KINSMAN RA, 1973, PSYCHOSOM MED, V35, P250; Kinsman R.A., 1982, HDB CLIN HLTH PSYCHO, P435; KLEIN DF, 1993, ARCH GEN PSYCHIAT, V50, P306; Kohen DP, 1997, AM J CLIN HYPN, V39, P169; Kohen DP, 1995, HYPNOS, V22, P132; Kolbe J, 1996, CHEST, V109, P86, DOI 10.1378/chest.109.1.86; Kolbe J, 1996, CHEST, V110, P1463, DOI 10.1378/chest.110.6.1463; KOTSES H, 1991, BIOFEEDBACK SELF-REG, V16, P1, DOI 10.1007/BF01000442; KOTSES H, 1995, J ALLERGY CLIN IMMUN, V95, P529, DOI 10.1016/S0091-6749(95)70315-2; Kotses H, 1996, J ASTHMA, V33, P113, DOI 10.3109/02770909609054539; Kotses H, 1999, J PEDIATR PSYCHOL, V24, P331, DOI 10.1093/jpepsy/24.4.331; Kotses H, 1981, Biofeedback Self Regul, V6, P573, DOI 10.1007/BF00998741; KOTSES H, 1998, SELF MANAGEMENT ASTH, P309; LACEY JI, 1958, AM J PSYCHOL, V71, P50, DOI 10.2307/1419197; LASK B, 1979, ARCH DIS CHILD, V54, P116; Lehrer P, 1997, APPL PSYCHOPHYS BIOF, V22, P43, DOI 10.1023/A:1026237725681; Lehrer P, 1997, APPL PSYCHOPHYS BIOF, V22, P95, DOI 10.1023/A:1026224211993; Lehrer P, 2000, APPL PSYCHOPHYS BIOF, V25, P193, DOI 10.1023/A:1009506909815; LEHRER PM, 1994, J BEHAV MED, V17, P1, DOI 10.1007/BF01856879; LEHRER PM, 1992, J CONSULT CLIN PSYCH, V60, P639, DOI 10.1037//0022-006X.60.4.639; LEHRER PM, 1993, J PSYCHOSOM RES, V37, P515, DOI 10.1016/0022-3999(93)90007-3; Lehrer PM, 1997, APPL PSYCHOPHYS BIOF, V22, P183, DOI 10.1023/A:1026263826106; Lehrer PM, 1998, APPL PSYCHOPHYS BIOF, V23, P13, DOI 10.1023/A:1022170028979; Lehrer PM, 1996, PSYCHOSOM MED, V58, P413; Lehrer PM, 2000, APPL PSYCHOPHYS BIOF, V25, P177, DOI 10.1023/A:1009554825745; Ley R, 1999, BEHAV MODIF, V23, P441, DOI 10.1177/0145445599233006; LEY R, 1994, BIOFEEDBACK SELF-REG, V19, P95, DOI 10.1007/BF01776482; Loew TH, 1996, PSYCHOTHER PSYCHOSOM, V65, P124; LUM LC, 1976, MODERN TRENDS PSYCHO, V3, P196; LUPARELLO T, 1968, PSYCHOSOM MED, V30, P819; MANN MC, 1992, CHEST, V102, P1342, DOI 10.1378/chest.102.5.1342; MANTO PG, 1969, THESIS RUTGERS U; MARTIN AJ, 1995, PEDIATR PULM, V20, P1, DOI 10.1002/ppul.1950200102; Mass R, 1996, BEHAV RES THER, V34, P815, DOI 10.1016/0005-7967(96)00063-0; MASS R, 1991, BIOMED TECH, V36, P78, DOI 10.1515/bmte.1991.36.4.78; MASS R, 1992, J PSYCHOPHYSIOL, V6, P167; MASS R, 1993, BIOFEEDBACK SELF-REG, V18, P211, DOI 10.1007/BF00999080; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCINTOSH NA, 1994, J ASTHMA, V31, P453, DOI 10.3109/02770909409089487; MEIJER AM, 1995, J ASTHMA, V32, P265, DOI 10.3109/02770909509044834; Miles JF, 1996, THORAX, V51, P403, DOI 10.1136/thx.51.4.403; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; MILLER BD, 1989, AM J DIS CHILD, V143, P1294; Miller BD, 1997, J AM ACAD CHILD PSY, V36, P669, DOI 10.1097/00004583-199705000-00018; MILLER BD, 1994, J AM ACAD CHILD PSY, V33, P1236, DOI 10.1097/00004583-199411000-00004; MILLER DJ, 1995, PSYCHOSOM MED, V57, P148; MILLER SB, 1993, PSYCHOSOM MED, V55, P78; Miller W, 1991, MOTIVATIONAL INTERVI; MRAZEK DA, 1992, ANN ALLERGY, V69, P285; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; NAGARATHNA R, 1985, BRIT MED J, V291, P1077; NAGENDRA HR, 1986, J ASTHMA, V23, P123, DOI 10.3109/02770908609077486; Nassau JH, 2000, J PSYCHOSOM RES, V48, P133, DOI 10.1016/S0022-3999(99)00089-6; NEWMAN KB, 1994, SEM RESP CRIT CARE M, V15, P161, DOI 10.1055/s-2007-1006358; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382; Nguyen BP, 1996, ANN ALLERG ASTHMA IM, V77, P209; *NHLBI, 1997, 2 NHLBI US DEP HHS N; Nouwen A, 1999, BEHAV MODIF, V23, P217, DOI 10.1177/0145445599232002; PAPP LA, 1993, AM J PSYCHIAT, V150, P1149; Park SJ, 1996, J PAEDIATR CHILD H, V32, P183, DOI 10.1111/j.1440-1754.1996.tb00919.x; Pearce N, 1999, THORAX, V54, P268; PENNEBAKER JW, 1988, J CONSULT CLIN PSYCH, V56, P239, DOI 10.1037//0022-006X.56.2.239; PEPER E, 1992, BIOFEEDBACK SELF-REG, V17, P143, DOI 10.1007/BF01000104; Perna G, 1997, BIOL PSYCHIAT, V42, P625, DOI 10.1016/S0006-3223(96)00436-2; Persky V, 1999, CHEST, V116, p216S, DOI 10.1378/chest.116.suppl_2.216S; PETERSON C, 1984, PSYCHOL REV, V91, P347, DOI 10.1037/0033-295X.91.3.347; PICHUGIN VI, 1993, BIOFEEDBACK VISCERAL; PORGES SW, 1995, PSYCHOPHYSIOLOGY, V32, P301, DOI 10.1111/j.1469-8986.1995.tb01213.x; PORGES SW, 1992, PEDIATRICS, V90, P498; PRIEL B, 1994, J ASTHMA, V31, P479, DOI 10.3109/02770909409089490; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; RAND CS, 1994, AM J RESP CRIT CARE, V149, pS69; RAND CS, 1995, AM J RESP CRIT CARE, V152, P580; Redline S, 1996, PEDIATR PULM, V21, P203; REEDER KP, 1990, J ASTHMA, V27, P219, DOI 10.3109/02770909009073330; Rietveld S, 1996, J ASTHMA, V33, P221, DOI 10.3109/02770909609055363; Rietveld S, 1998, PSYCHOL MED, V28, P407, DOI 10.1017/S0033291797006387; Rietveld S, 2000, CLIN EXP ALLERGY, V30, P1058; Rietveld S, 1997, HEALTH PSYCHOL, V16, P547, DOI 10.1037/0278-6133.16.6.547; Ritz T, 1998, PSYCHOPHYSIOLOGY, V35, P549, DOI 10.1017/S0048577298961492; Ritz T, 2000, PSYCHOSOM MED, V62, P401; Roozendaal B, 1997, Acta Physiol Scand Suppl, V640, P51; Rushford N, 1998, J ASTHMA, V35, P251, DOI 10.3109/02770909809068215; Sathyaprabha T. N., 2001, Indian Journal of Physiology and Pharmacology, V45, P80; Scherer YK, 2001, HEART LUNG, V30, P250, DOI 10.1067/mhl.2001.116013; Schmaling KB, 2000, J ASTHMA, V37, P335, DOI 10.3109/02770900009055457; Schmaling KB, 2001, J CLIN PSYCHOL MED S, V8, P167, DOI 10.1023/A:1011365519345; Schmaling KB, 1998, J ASTHMA, V35, P631, DOI 10.3109/02770909809048965; Schmaling KB, 1997, ARCH FAM MED, V6, P20, DOI 10.1001/archfami.6.1.20; SCHMALING KB, 2002, UNPUB EFFECTS COUPLE; SCHMALING KB, IN PRESS J ASTHMA; SELIGMAN ME, 1984, S PSYCHOL, V2, P18; SHAPIRO D, 1993, PSYCHOSOM MED, V55, P309; SHAPIRO D, 1995, PSYCHOPHYSIOLOGY, V32, P425, DOI 10.1111/j.1469-8986.1995.tb02093.x; Shavitt R. G., 1993, European Psychiatry, V8, P41; SHAVITT RG, 1992, GEN HOSP PSYCHIAT, V14, P420, DOI 10.1016/0163-8343(92)90010-8; SIDDIQUE MI, 2000, AM J RESP CRIT CARE, V163, pA55; Silagy C, 1999, J Pediatr, V135, P650; SILVERGLADE L, 1994, J GEN PSYCHOL, V121, P199; SLY PD, 1994, BRIT MED J, V308, P572; SMETANKINE AA, 1995, ANN C ASS APPL PSYCH; Smith N A, 1994, Monaldi Arch Chest Dis, V49, P470; Smoller JW, 1996, AM J RESP CRIT CARE, V154, P6; Smyth JM, 1998, J CONSULT CLIN PSYCH, V66, P174, DOI 10.1037//0022-006X.66.1.174; Smyth JM, 1999, JAMA-J AM MED ASSOC, V281, P1304, DOI 10.1001/jama.281.14.1304; Smyth JM, 1999, PSYCHOL HEALTH, V14, P487, DOI 10.1080/08870449908407342; Sommaruga M, 1995, Monaldi Arch Chest Dis, V50, P398; SPINHOVEN P, 1994, BEHAV RES THER, V32, P647, DOI 10.1016/0005-7967(94)90021-3; Spinhoven P, 1997, THORAX, V52, P149; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stegen K, 1999, J ABNORM PSYCHOL, V108, P143; STEINER H, 1987, PSYCHOSOM MED, V49, P35; Stone AA, 2000, HEALTH PSYCHOL, V19, P619, DOI 10.1037/0278-6133.19.6.619; Stout C, 1997, PSYCHOSOM MED, V59, P201; STRUNK R C, 1985, Journal of the American Medical Association, V254, P1193, DOI 10.1001/jama.254.9.1193; Strunk RC, 1999, J ALLERGY CLIN IMMUN, V104, P763; Sudre P, 1999, THORAX, V54, P681; SVENSSON TH, 1987, PSYCHOPHARMACOLOGY, V92, P1, DOI 10.1007/BF00215471; TAITEL MS, 1995, J ALLERGY CLIN IMMUN, V95, P672, DOI 10.1016/S0091-6749(95)70171-0; ten Brinke A, 2001, AM J RESP CRIT CARE, V163, P1093; ten Brinke A, 2001, J PSYCHOSOM RES, V50, P7, DOI 10.1016/S0022-3999(00)00203-8; Thomas M, 2001, BRIT MED ASS, V308, P572; Tieffenberg JA, 2000, J URBAN HEALTH, V77, P280, DOI 10.1007/BF02390539; TILLER J, 1987, CHEST, V91, P547, DOI 10.1378/chest.91.4.547; TILLER JWG, 1990, OTAGO CON S, P151; Turner MO, 1998, AM J RESP CRIT CARE, V157, P540; VANDENBERGH O, 1995, BEHAV RES THER, V33, P517, DOI 10.1016/0005-7967(94)00080-4; VandenBergh O, 1997, PSYCHOSOM MED, V59, P13; vanderPalen J, 1997, EUR RESPIR J, V10, P652; VASCHILLO EG, 1983, HUMAN PHYSL, V10, P257; VAZQUEZ I, 1993, PSYCHOTHER PSYCHOSOM, V60, P106; VAZQUEZ MI, 1993, J ASTHMA, V30, P171, DOI 10.3109/02770909309054515; VAZQUEZ MI, 1993, J PSYCHOSOM RES, V37, P71, DOI 10.1016/0022-3999(93)90125-Y; Vedanthan PK, 1998, ALLERGY ASTHMA PROC, V19, P3, DOI 10.2500/108854198778557971; VERBURG K, 1995, J AFFECT DISORDERS, V33, P129, DOI 10.1016/0165-0327(94)00083-L; Verschelden P, 1996, EUR RESPIR J, V9, P880, DOI 10.1183/09031936.96.09050880; Vijayalakshmi S, 1988, J INDIAN PSYCHOL, V7, P32; Vila G, 1999, PSYCHOSOMATICS, V40, P404; Wamboldt FS, 1995, J PSYCHOSOM RES, V39, P995, DOI 10.1016/0022-3999(95)00507-2; WAMBOLDT FS, 1998, JOINT INT C AM LUNG; Wamboldt MZ, 1998, J CHILD PSYCHOL PSYC, V39, P1007, DOI 10.1017/S0021963098002972; Wamboldt MZ, 1996, J AM ACAD CHILD PSY, V35, P1042, DOI 10.1097/00004583-199608000-00015; Wamboldt MZ, 2000, AM J MED GENET, V96, P146, DOI 10.1002/(SICI)1096-8628(20000403)96:2<146::AID-AJMG4>3.0.CO;2-J; Watts R W, 1997, Aust Fam Physician, V26 Suppl 1, pS4; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; WEINBERGER DA, 1979, J ABNORM PSYCHOL, V88, P369, DOI 10.1037/0021-843X.88.4.369; Weinstein AG, 1997, ANN ALLERG ASTHMA IM, V79, P311; WEISSMAN MM, 1990, AM J PSYCHIAT, V147, P1504; WIGAL JK, 1993, CHEST, V104, P1144, DOI 10.1378/chest.104.4.1144; Wilson SR, 1996, J ASTHMA, V33, P239, DOI 10.3109/02770909609055365; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5; WOLLER W, 1993, PSYCHOTHER PSYCHOSOM, V59, P190; YELLOWLEES PM, 1987, MED J AUSTRALIA, V146, P305; YELLOWLEES PM, 1988, MED J AUSTRALIA, V149, P246; YELLOWLEES PM, 1989, CHEST, V95, P1298, DOI 10.1378/chest.95.6.1298; YOON R, 1991, THORAX, V46, P886, DOI 10.1136/thx.46.12.886; ZANDBERGEN J, 1991, AM J PSYCHIAT, V148, P1583; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	279	113	116	8	25	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0022-006X	1939-2117		J CONSULT CLIN PSYCH	J. Consult. Clin. Psychol.	JUN	2002	70	3					691	711		10.1037//0022-006X.70.3.691		21	Psychology, Clinical	Psychology	562LJ	WOS:000176198000016	12090377	
J	Downs, SH; Mitakakis, TZ; Marks, GB; Car, NG; Belousova, EG; Leuppi, JD; Xuan, W; Downie, SR; Tobias, A; Peat, JK				Downs, SH; Mitakakis, TZ; Marks, GB; Car, NG; Belousova, EG; Leuppi, JD; Xuan, W; Downie, SR; Tobias, A; Peat, JK			Clinical importance of Alternaria exposure in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						Alternaria; airway responsiveness; asthma; fungi; children	BRONCHIAL RESPONSIVENESS; ALLERGIC SENSITIZATION; LONGITUDINAL DATA; CHILDHOOD ASTHMA; CLIMATIC REGIONS; ALT-I; POPULATION; SEVERITY; OUTDOOR; SPORE	The fungus Alternaria is known to be allergenic and is one of the most common fungi worldwide. We investigated the extent to which exposure to Alternaria increases the severity of asthma. We undertook a prospective cohort study in Australia of 399 school children who had positive skin tests to one or more aeroallergens. Airway responsiveness to histamine, wheeze, and bronchodilator use in 1 mo was measured five times between 1997 and 1999. Airway hyperresponsiveness was defined as PD20FEV1 = 3.9 mu mol histamine. Airborne concentrations of Alternaria spores were measured throughout the study, and mean daily concentrations over 1 mo ranged from 2.2 to 307.7 spores/m(3) of ambient air. Using generalized estimating equations, we found that airway responsiveness, wheeze, and bronchodilator use increased significantly in association with increased spore concentrations and that the increase in airway responsiveness was greater in children sensitized to Alternarxia than in other children (p = 0.01). The odds ratio for airway hyperresponsiveness in children sensitized to Alternaria was 1.26 (95% CI, 1.14 to 1.39) after an increase in mean exposure of 100 spore/m(3)/d over 1 mo. These results suggest that Alternaria allergens contribute to severe asthma in regions where exposure to the fungus is high.	Univ Sydney, Inst Resp Med, Sydney, NSW, Australia; Univ Sydney, Sch Biol Sci, Sydney, NSW, Australia; Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW, Australia; New Childrens Hosp, Clin Epidemiol Unit, Westmead, NSW, Australia; Hosp Santa Cruz & San Pablo, Dept Clin Epidemiol & Publ Hlth, Barcelona, Spain	Downs, SH (reprint author), Inst Resp Med, POB M77,Missenden Rd Post Off, Camperdown, NSW 2050, Australia.		Downs, Sara/D-8478-2011	Downs, Sara/0000-0003-1044-3182			AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; Armstrong B.K., 1995, PRINCIPLES EXPOSURE; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Bass D, 1997, GRANA, V36, P293; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; CALVO MA, 1980, MYCOPATHOLOGIA, V71, P89, DOI 10.1007/BF00440614; Chelkowski J, 1992, ALTERNARIA BIOL PLAN; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; FADEL R, 1992, ANN ALLERGY, V69, P329; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HATCH M, 1993, ENVIRON HEALTH PERSP, V101, P49, DOI 10.2307/3431659; HJELMROOS M, 1993, GRANA, V32, P40; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; Mitakakis T, 1997, AEROBIOLOGIA, V13, P83, DOI 10.1007/BF02694423; Mitakakis TZ, 2000, GRANA, V39, P141; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1991, AM REV RESPIR DIS, V144, P663; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Pepys J., 1975, BRIT J HOSP MED, V14, P412; PLATTSMILLS TAE, 1982, LANCET, V2, P675; QUANJER PH, 1995, PEDIATR PULM, V19, P135, DOI 10.1002/ppul.1950190209; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; SNELLER MR, 1981, ANN ALLERGY, V46, P30; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; SRIVASTAVA AK, 1992, GRANA, V31, P61; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; USHERWOOD TP, 1990, ARCH DIS CHILD, V65, P779; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	42	113	117	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2001	164	3					455	459				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	466NG	WOS:000170651200022	11500349	
J	Johnson, PRA; Black, JL; Carlin, S; Ge, Q; Underwood, PA				Johnson, PRA; Black, JL; Carlin, S; Ge, Q; Underwood, PA			The production of extracellular matrix proteins by human passively sensitized airway smooth-muscle cells in culture - The effect of beclomethasone	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SUBEPITHELIAL FIBROSIS; ALTERED RESPONSIVENESS; FIBRONECTIN EXPRESSION; BRONCHIAL-ASTHMA; ADHESION; PROLIFERATION; DEXAMETHASONE; ANTIBODIES; INHIBITION; COLLAGEN	Airway remodeling is a key feature of persistent asthma. Part of the remodeling process involves the laying down of extracellular matrix (ECM) proteins within the airways. In this study we compared the production of ECM proteins by human airway smooth-muscle (ASM) cells in culture after exposure to 10% serum from an asthmatic individual or 10% serum from a nonasthmatic individual with or without beclomethasone (0.01 to 100 nM). Enzyme-linked immunosorbent assays were done with antibodies to human fibronectin; perlecan; elastin; the laminin beta (1), gamma (1), beta (2), alpha (1), chains; thrombospondin; chondroitin sulfate; collagen types I, III, IV, and V; versican; and decorin. Serum from the asthmatic individual, when compared with that from the nonasthmatic individual, caused a significant increase in the production of fibronectin, perlecan, laminin gamma (1), and chondroitin sulfate. Beclomethasone caused a significant reduction in the number of cells exposed to serum from either the asthmatic or nonasthmatic individual, but did not reverse the increase in ECM protein induced by the former. These results suggest an interaction between the ASM and the allergic process that may alter components of the airway wall in asthma, and that corticosteroids may not prevent the fibrosis induced by resident cells within the airways.	Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia; CSIRO Mol Sci, N Ryde, NSW, Australia	Johnson, PRA (reprint author), Univ Sydney, Dept Pharmacol, Sydney, NSW 2006, Australia.		Black, Judith/C-6559-2008; Ge, Qi/D-3988-2013				AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; BARNES PJ, 1990, AM REV RESPIR DIS S, V141, P70; Black JL, 2000, AM J RESP CRIT CARE, V161, pS207; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506; Dunsmore SE, 1996, AM J PHYSIOL-LUNG C, V270, pL215; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; ERLE DJ, 1992, AM J RESP CELL MOL, V6, P459; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77; GOSPODAROWICZ D, 1981, J CELL PHYSIOL, V109, P69, DOI 10.1002/jcp.1041090109; Hakonarson H, 1998, P NATL ACAD SCI USA, V95, P5257, DOI 10.1073/pnas.95.9.5257; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hakonarson H, 1997, J CLIN INVEST, V99, P117, DOI 10.1172/JCI119122; HIRST SJ, 1997, AM J RESP CRIT CARE, V155, pA371; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; John M, 1997, J IMMUNOL, V158, P1841; Kylmaniemi M, 1996, J DENT RES, V75, P919; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; LAITINEN LA, 1995, INT ARCH ALLERGY IMM, V107, P215; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V98, pS3, DOI 10.1016/S0091-6749(96)80122-9; NAKAMURA Y, 1995, AM J PHYSIOL-LUNG C, V269, pL377; Naureckas ET, 1999, AM J RESP CRIT CARE, V160, P2062; Rabe KF, 1998, AM J RESP CRIT CARE, V157, P1429; Roberts C R, 1998, Can Respir J, V5, P48; ROCHE WR, 1989, LANCET, V1, P520; SCHLEIMER RP, 1990, AM REV RESPIR DIS, V141, pS59; SCHLEIMER RP, 1987, AM REV RESPIR DIS, V135, P562; Schramm CM, 1996, BRIT J PHARMACOL, V119, P807; Shiels IA, 1996, INFLAMMATION, V20, P373, DOI 10.1007/BF01486740; Shiels IA, 1999, INFLAMMATION, V23, P321; STEWART AG, 1995, AM J RESP CELL MOL, V12, P110; Underwood PA, 1998, ATHEROSCLEROSIS, V141, P141, DOI 10.1016/S0021-9150(98)00164-6; UNDERWOOD PA, 1992, J CELL SCI, V102, P833; UOTILA P, 1986, ACTA DERM-VENEREOL, V66, P381; Vigano T, 1997, AM J RESP CRIT CARE, V155, P864; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591	37	113	123	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC	2000	162	6					2145	2151				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	381ZV	WOS:000165794700031	11112129	
J	Letuve, S; Kozhich, A; Arouche, N; Grandsaigne, M; Reed, J; Dombret, MC; Kiener, PA; Aubier, M; Coyle, AJ; Pretolani, M				Letuve, Severine; Kozhich, Alexander; Arouche, Nassim; Grandsaigne, Martine; Reed, Jennifer; Dombret, Marie-Christine; Kiener, Peter A.; Aubier, Michel; Coyle, Anthony J.; Pretolani, Marina			YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages	JOURNAL OF IMMUNOLOGY			English	Article							SERUM YKL-40; STIMULATES PROLIFERATION; CHITINASE FAMILY; SEVERE ASTHMA; PROTEIN; LUNG; INFLAMMATION; COLLAGEN; HC-GP39; DIFFERENTIATION	YKL-40 is a chitin-binding protein that is elevated in patients with various inflammatory conditions associated with ongoing remodeling. We investigated whether the levels of YKL-40 were up-regulated in the circulation and the airways of patients with chronic obstructive pulmonary disease (COPD), and whether it promoted the production of inflammatory mediators from macrophages. Serum, bronchoalveolar lavage (BAL), bronchial biopsies, lung tissue specimens, and alveolar macrophages from never-smokers (n = 15), smokers without COPD (n = 20), and smokers with COPD (n = 30) were assessed for YKL-40 levels and immunolocalization. In addition, YKL-40-induced mediator release from alveolar macrophages was examined. We found that smokers with COPD had elevated levels of YKL-40 in serum (p <= 0.027) and BAL (p <= 0.007), more YKL-40-positive cells in bronchial biopsies (p <= 0.03), and a greater proportion of alveolar macrophages expressing YKL-40 than smokers without COPD or never-smokers. YKL-40 levels in serum and BAL were associated with airflow obstruction (pre-beta(2) agonist forced expiratory volume in 1 s, r(s) = -0.3892,p = 0.0072 and r(s) = -0.5491, p < 0.0001, respectively) and impaired diffusion lung capacity (transfer factor of the lung for carbon monoxide, r(s) = -0.4667, p = 0.002 and r(s) = -0.3854, p = 0.0045, respectively). TNF-alpha stimulated YKL-40 synthesis in alveolar macrophages from smokers with COPD, and exposure of these cells to YKL-40 promoted the release of IL-8, MCP-1, MIP-1 alpha, and metalloproteinase-9. We conclude that YKL-40 is up-regulated in COPD, in which it may contribute to tissue inflammation and remodeling by sustaining the synthesis of proinflammatory and fibrogenic chemokines and of metalloproteinases by alveolar macrophages.	[Pretolani, Marina] INSERM, Unite 700, Fac Med Denis Diderot, F-75018 Paris, France; [Letuve, Severine; Arouche, Nassim; Grandsaigne, Martine; Aubier, Michel; Pretolani, Marina] Univ Paris 07, Fac Med Denis Diderot, Paris, France; [Kozhich, Alexander; Reed, Jennifer; Kiener, Peter A.; Coyle, Anthony J.] MedImmune, Dept Autoimmun Inflammat & Resp Dis, Gaithersburg, MD 20878 USA; [Dombret, Marie-Christine; Aubier, Michel] CHU Bichat Claude Bernard, Dept Pneumol A, Paris, France; [Dombret, Marie-Christine; Aubier, Michel; Pretolani, Marina] AP HP, Paris, France	Pretolani, M (reprint author), INSERM, Unite 700, Fac Med Denis Diderot, Site Bichat 16,Rue Henri Huchard, F-75018 Paris, France.	marina.pretolani@inserm.fr	Pretolani, Marina/G-6643-2017		Agence Nationale de la Recherche (Sante et Environnement-Sante Travail); MedImmune	This work was supported by the Fondation pour la Recherche Medicale (fellowship to S.L.) and by grants from the Agence Nationale de la Recherche (Sante et Environnement-Sante Travail) and from MedImmune.	Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR; Badariotti F, 2006, J BIOL CHEM, V281, P29583, DOI 10.1074/jbc.M605687200; Barnes PJ, 2004, PHARMACOL REV, V56, P515, DOI 10.1124/pr.56.4.2; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Barnes PJ, 2004, J COPD, V1, P59; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Bigg HF, 2006, J BIOL CHEM, V281, P21082, DOI 10.1074/jbc.M601153200; Bleau G, 1999, EXS, V87, P211; Boot RG, 1999, ARTERIOSCL THROM VAS, V19, P687; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chupp GL, 2007, NEW ENGL J MED, V357, P2016, DOI 10.1056/NEJMoa073600; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; GOLDSTEIN RA, 1985, AM REV RESPIR DIS, V132, P180; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Jacques C, 2007, OSTEOARTHR CARTILAGE, V15, P138, DOI 10.1016/j.joca.2006.07.003; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; Johansen JS, 2006, CANCER EPIDEM BIOMAR, V15, P194, DOI 10.1158/1055-EPI-05-0011; Kim SH, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-26; Kucur M, 2007, CORONARY ARTERY DIS, V18, P391, DOI 10.1097/MCA.0b013e328241d991; Lim S, 2000, AM J RESP CRIT CARE, V162, P1355; Martin-Mosquero C, 2006, HISTOL HISTOPATHOL, V21, P823, DOI 10.14670/HH-21.823; *NAT ASTH ED PREV, 1997, NAT HEART LUNG BLOOD; Pegorier S, 2007, J ALLERGY CLIN IMMUN, V120, P1301, DOI 10.1016/j.jaci.2007.09.023; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rathcke CN, 2006, INFLAMM RES, V55, P53, DOI 10.1007/s00011-005-0010-8; Recklies AD, 2005, J BIOL CHEM, V280, P41213, DOI 10.1074/jbc.M10146200; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469; Volck B, 1998, P ASSOC AM PHYSICIAN, V110, P351	33	112	115	1	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	OCT 1	2008	181	7					5167	5173		10.4049/jimmunol.181.7.5167		7	Immunology	Immunology	356CG	WOS:000259755700081	18802121	
J	Halonen, JI; Lanki, T; Yli-Tuomi, T; Kulmala, M; Tiittanen, P; Pekkanen, J				Halonen, J. I.; Lanki, T.; Yli-Tuomi, T.; Kulmala, M.; Tiittanen, P.; Pekkanen, J.			Urban air pollution, and asthma and COPD hospital emergency room visits	THORAX			English	Article							ULTRAFINE PARTICLES; PARTICULATE MATTER; SHORT-TERM; NUMBER; HEALTH; ADMISSIONS; INFLAMMATION; POLLUTANTS; EXPOSURE; DISEASE	Background: There is little previous information of the effects of size fractioned particulate air pollution and source specific fine particles (PM(2.5); <2.5 mu m) on asthma and chronic obstructive pulmonary disease (COPD) among children, adults and the elderly. Objectives: To determine the effects of daily variation in levels of different particle size fractions and gaseous pollutants on asthma and COPD by age group. Methods: Levels of particulate air pollution, NO(2) and CO were measured from 1998 to 2004 at central outdoor monitoring sites in Helsinki, Finland. Associations between daily pollution levels and hospital emergency room visits were evaluated for asthma (ICD10: J45+J46) in children,15 years old, and for asthma and COPD (ICD10: J41+J44) in adults (15-64 years) and the elderly (>= 65 years). Results: Three to 5 day lagged increases in asthma visits were found among children in association with nucleation (<0.03 mu m), Aitken (0.03-0.1 mu m) and accumulation (0.1-0.29 mu m) mode particles, gaseous pollutants and traffic related PM(2.5) (7.8% (95% CI 3.5 to 12.3) for 1.1 mu g/m(3) increase in traffic related PM(2.5) at lag 4). Pooled asthma-COPD visits among the elderly were associated with lag 0 of PM(2.5), coarse particles, gaseous pollutants and long range transported and traffic related PM(2.5) (3.9% (95% CI 0.28 to 7.7) at lag 0). Only accumulation mode and coarse particles were associated with asthma and COPD among adults. Conclusions: Among children, traffic related PM(2.5) had delayed effects, whereas among the elderly, several types of particles had effects that were more immediate. These findings suggest that the mechanisms of the respiratory effects of air pollution, and responsible pollutants, differ by age group.	[Halonen, J. I.; Lanki, T.; Yli-Tuomi, T.; Tiittanen, P.; Pekkanen, J.] Natl Publ Hlth Inst KTL, Environm Epidemiol Unit, FIN-70701 Kuopio, Finland; [Lanki, T.] GSF, Helmholtz Zentrum Munchen, Inst Epidemiol, Munich, Germany; [Kulmala, M.] Univ Helsinki, Dept Phys Sci, FIN-00014 Helsinki, Finland; [Pekkanen, J.] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	Halonen, JI (reprint author), Natl Publ Hlth Inst KTL, Environm Epidemiol Unit, POB 95, FIN-70701 Kuopio, Finland.	jaana.halonen@ktl.fi	Kulmala, Markku/I-7671-2016	Kulmala, Markku/0000-0003-3464-7825; Yli-Tuomi, Tarja/0000-0001-9332-2241			ANDERSEN ZJ, 2007, J EXPO SCI ENV EPID, V7, P625; Anderson HR, 1998, THORAX, V53, P842; ANDERSON PJ, 1990, CHEST, V97, P1115, DOI 10.1378/chest.97.5.1115; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Buzorius G, 1999, ATMOS ENVIRON, V33, P553, DOI 10.1016/S1352-2310(98)00287-8; Casillas AM, 1999, ANN ALLERG ASTHMA IM, V83, P624, DOI 10.1016/S1081-1206(10)62884-0; de Kok TMCM, 2006, MUTAT RES-REV MUTAT, V613, P103, DOI 10.1016/j.mrrev.2006.07.001; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Donaldson K, 2001, OCCUP ENVIRON MED, V58, P211, DOI 10.1136/oem.58.3.211; Eberly S.I., 2005, EPA PMF 1 1 USERS GU; Galan I, 2003, EUR RESPIR J, V22, P802, DOI 10.1183/09031936.03.00013003; Hoek G, 2008, ATMOS ENVIRON, V42, P156, DOI 10.1016/j.atmosenv.2007.09.026; Hussein T, 2004, ATMOS CHEM PHYS, V4, P391; JANSSEN NA, 2005, OCCUP ENVIRON MED, V12, P868; Kettunen J, 2007, STROKE, V38, P918, DOI 10.1161/01.STR.0000257999.49706.3b; Kraft M, 2005, INT J HYG ENVIR HEAL, V208, P305, DOI 10.1016/j.ijheh.2005.04.002; Kulmala M, 2004, J AEROSOL SCI, V35, P143, DOI 10.1016/j.jaerosci.2003.10.003; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Pekkanen J, 2004, SCAND J WORK ENV HEA, V30, P9; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pietropaoli AP, 2004, INHAL TOXICOL, V16, P59, DOI 10.1080/08958370490443079; R_Development_Core_Team, 2005, R LANG ENV STAT COMP; Schulz H, 2000, PARTICLE LUNG INTERA, P229; Schwarze PE, 2006, HUM EXP TOXICOL, V25, P559, DOI 10.1177/096032706072520; Thurston GD, 2005, ENVIRON HEALTH PERSP, V113, P1768, DOI 10.1289/ehp.7989; WHO, 2005, AIR QUAL GUID GLOB U, P275; Wong GWK, 2004, CURR OPIN PULM MED, V10, P62, DOI 10.1097/00063198-200401000-00011; Wood SN, 2000, J ROY STAT SOC B, V62, P413, DOI 10.1111/1467-9868.00240; Yang QY, 2005, ENVIRON RES, V99, P99, DOI 10.1016/j.envres.2004.09.014; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991	32	112	116	6	30	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUL	2008	63	7					635	641		10.1136/thx.2007.091371		7	Respiratory System	Respiratory System	319LY	WOS:000257166300014	18267984	
J	Elliott, DE; Summers, RW; Weinstock, JV				Elliott, David E.; Summers, Robert W.; Weinstock, Joel V.			Helminths as governors of immune-mediated inflammation	INTERNATIONAL JOURNAL FOR PARASITOLOGY			English	Review						immune regulation; inflammation; inflammatory bowel disease; asthma; multiple sclerosis; autoimmune type 1 diabetes; immune-mediated inflammatory disease; Trichuris suis; whipworm; hookworm	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRICHURIS-SUIS THERAPY; REGULATORY T-CELLS; BOWEL-DISEASE; NECATOR-AMERICANUS; INDUCED COLITIS; CROHNS-DISEASE; INTESTINAL PARASITES; MULTIPLE-SCLEROSIS; ULCERATIVE-COLITIS	Immune-mediated diseases (e.g. inflammatory bowel disease, asthma, multiple sclerosis and autoimmune diabetes) are increasing in prevalence and emerge as populations adopt meticulously hygienic lifestyles. This change in lifestyles precludes exposure to helminths (parasitic worms). Loss of natural helminth exposure removes a previously universal Th2 and regulatory immune biasing imparted by these organisms. Helminths protect animals from developing immune-mediated diseases (colitis, reactive airway disease, encephalitis and diabetes). Clinical trials show that exposure to helminths can reduce disease activity in patients with ulcerative colitis or Crohn's disease. This paper summarises work by multiple groups demonstrating that colonization with helminths alters immune reactivity and protects against disease from dysregulated inflammation. (c) 2007 Australian Society for Parasitology Inc. Published by Elsevier Ltd. All rights reserved.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Iowa City, IA 52242 USA; Tufts Univ New England Med Ctr, Dept Internal Med, Div Gastroenterol & Hepatol, Boston, MA USA	Elliott, DE (reprint author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, 200 Hawkins Dr, Iowa City, IA 52242 USA.	david-elliott@uiowa.edu			NIAID NIH HHS [AI49382]; NIDDK NIH HHS [DK58755, DK02428, DK25295, DK38327]		Araujo ML, 2004, MEM I OSWALDO CRUZ, V99, P27, DOI 10.1590/S0074-02762004000900005; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BEER RJS, 1976, RES VET SCI, V20, P47; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Cabre P, 2005, BRAIN, V128, P2899, DOI 10.1093/brain/awh624; Carr I, 1999, AM J GASTROENTEROL, V94, P2918; Cernea S, 2006, NAT CLIN PRACT ENDOC, V2, P89, DOI 10.1038/ncpendmet0082; Cooke A, 1999, PARASITE IMMUNOL, V21, P169, DOI 10.1046/j.1365-3024.1999.00213.x; Croese J, 2006, GUT, V55, P136, DOI 10.1136/gut.2005.079129; Crompton DWT, 1999, J PARASITOL, V85, P397, DOI 10.2307/3285768; Delco F, 1998, AM J GASTROENTEROL, V93, P1457, DOI 10.1111/j.1572-0241.1998.463_i.x; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Doria A, 2005, RHEUM DIS CLIN N AM, V31, P355, DOI 10.1016/j.rdc.2005.01.006; EKBOM A, 1991, GASTROENTEROLOGY, V100, P350; Eldeirawi KM, 2006, J ASTHMA, V43, P279, DOI 10.1080/0277090060022869; Elliott DE, 2005, CURR OPIN GASTROEN, V21, P51; Elliott DE, 2004, EUR J IMMUNOL, V34, P2690, DOI 10.1002/eji.200324833; Elliott DE, 2003, AM J PHYSIOL-GASTR L, V284, pG385, DOI 10.1152/ajpgi.00049.2002; Elliott DE, 2000, FASEB J, V14, P1848, DOI 10.1096/fj.99-0885hyp; Falcone FH, 2005, TRENDS PARASITOL, V21, P157, DOI 10.1016/j.pt.2005.02.002; FLEMING JO, 2006, MULTIPLE SCLEROSIS H; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Goncalves MLC, 2003, MEM I OSWALDO CRUZ, V98, P103, DOI 10.1590/S0074-02762003000900016; Hotez PJ, 2004, NEW ENGL J MED, V351, P799, DOI 10.1056/NEJMra032492; HUBBARD DW, 1974, PEDIATR RES, V8, P652, DOI 10.1203/00006450-197406000-00006; Hunter MM, 2005, J IMMUNOL, V174, P7368; Ince MN, 2006, J IMMUNOL, V176, P726; JAYANTHI V, 1992, Q J MED, V82, P125; Khan WI, 2002, INFECT IMMUN, V70, P5931, DOI 10.1128/IAI.70.11.5931-5937.2002; Kitagaki K, 2006, J IMMUNOL, V177, P1628; La Flamme AC, 2003, INFECT IMMUN, V71, P4996, DOI 10.1128/IAI.71.9.4996-5004.2003; Lakatos L, 2004, WORLD J GASTROENTERO, V10, P404; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Mangan NE, 2006, J IMMUNOL, V176, P138; Marrie RA, 2004, LANCET NEUROL, V3, P709, DOI 10.1016/S1474-4422(04)00933-0; MAXWELL C, 1987, AM J TROP MED HYG, V37, P126; Metwali A, 2006, AM J PHYSIOL-GASTR L, V291, pG253, DOI 10.1152/ajpgi.00409.2005; Moreels TG, 2004, GUT, V53, P99, DOI 10.1136/gut.53.1.99; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Pritchard DI, 2001, TRENDS PARASITOL, V17, P169, DOI 10.1016/S1471-4922(01)01941-9; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sellon RK, 1998, INFECT IMMUN, V66, P5224; Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; SONNENBERG A, 1990, GUT, V31, P1037, DOI 10.1136/gut.31.9.1037; SONNENBERG A, 1991, GASTROENTEROLOGY, V100, P143; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI 10.1016/S0002-9270(03)00623-3; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VERMUND SH, 1988, AM J DIS CHILD, V142, P566; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Zaccone P, 2006, PARASITE IMMUNOL, V28, P515, DOI 10.1111/j.1365-3024.2006.00879.x; Zaccone P, 2003, EUR J IMMUNOL, V33, P1439, DOI 10.1002/eji.200323910	57	112	119	1	31	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0020-7519			INT J PARASITOL	Int. J. Parasit.	APR	2007	37	5					457	464		10.1016/j.ijpara.2006.12.009		8	Parasitology	Parasitology	158ET	WOS:000245774800001	17313951	
J	Price, DB; Tinkelman, DG; Halbert, RJ; Nordyke, RJ; Isonaka, S; Nonikov, D; Juniper, EF; Freeman, D; Hausen, T; Levy, ML; Ostrem, A; van der Molen, T; van Schayck, CP				Price, David B.; Tinkelman, David G.; Halbert, R. J.; Nordyke, Robert J.; Isonaka, Sharon; Nonikov, Dmitry; Juniper, Elizabeth F.; Freeman, Daryl; Hausen, Thomas; Levy, Mark L.; Ostrem, Anders; van der Molen, Thys; van Schayck, Constant P.			Symptom-based questionnaire for identifying COPD in smokers	RESPIRATION			English	Article						chronic obstructive pulmonary disease; diagnosis; primary care; questionnaires; spirometry; validation studies	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; GENERAL-PRACTICE; RISK; POPULATION; GUIDELINES; DIAGNOSIS; SMOKING; PROGRAM; ASTHMA	Background: Symptom-based questionnaires may enhance chronic obstructive pulmonary disease (COPD) screening in primary care. Objectives: We prospectively tested questions to help identify COPD among smokers without prior history of lung disease. Methods: Subjects were recruited via random mailing to primary care practices in Aberdeen, UK, and Denver, Colo., USA. Current and former smokers aged 40 or older with no prior respiratory diagnosis and no respiratory medications in the past year were enrolled. Participants answered questions covering demographics and symptoms and then underwent spirometry with reversibility testing. A study diagnosis of COPD was defined as fixed airway obstruction as measured by postbronchodilator FEV1/FVC <0.70. We examined the ability of individual questions in a multivariate framework to correctly discriminate between persons with and without COPD. Results: 818 subjects completed all investigations and proceeded to analysis. The list of 54 questions yielded 52 items for analysis, which was reduced to 17 items for entry into multivariate regression. Eight items had significant relationships with the study diagnosis of COPD, including age, pack-years, body mass index, weather-affected cough, phlegm without a cold, morning phlegm, wheeze frequency, and history of any allergies. Individual items yielded odds ratios ranging from 0.23 to 12. This questionnaire demonstrated a sensitivity of 80.4 and specificity of 72.0. Conclusions: A simple patient self-administered questionnaire can be used to identify patients with a high likelihood of having COPD, for whom spirometric testing is particularly important. Implementation of this questionnaire could enhance the efficiency and diagnostic accuracy of current screening efforts. Copyright (C) 2006 S. Karger AG, Basel.	Cerner Hlth Insights, Beverly Hills, CA 90212 USA; Univ Aberdeen, Aberdeen, Scotland; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Calif Los Angeles, Sch Publ Hlth, Los Angeles, CA USA; McMaster Univ, Hamilton, ON, Canada; Univ Groningen, Groningen, Netherlands; Univ Maastricht, Maastricht, Netherlands; Univ Edinburgh, Edinburgh, Midlothian, Scotland	Halbert, RJ (reprint author), Cerner Hlth Insights, 9100 Wilshire Blvd,Suite 655E, Beverly Hills, CA 90212 USA.	rhalbert@cerner.com		Price, David/0000-0002-9728-9992			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Anthonisen N R, 2001, Can Respir J, V8, P421; Calverley PMA, 2003, LANCET, V362, P1053, DOI 10.1016/S0140-6736(03)14416-9; CALVERLEY PMA, 2005, J COPD, V2, P225; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; COX DR, 1975, BIOMETRIKA, V62, P441, DOI 10.1093/biomet/62.2.441; den Otter JJ, 1998, J ASTHMA, V35, P381, DOI 10.3109/02770909809075672; Fagerstrom KO, 2005, RESPIRATION, V72, P216, DOI 10.1159/000084057; Ferguson GT, 2000, CHEST, V117, P1146, DOI 10.1378/chest.117.4.1146; FLETCHER C, 1977, BRIT MED J, V1, P1645; Freeman D, 2005, RESP MED, V99, P1311, DOI 10.1016/j.rmed.2005.02.037; Godtfredsen NS, 2002, THORAX, V57, P967, DOI 10.1136/thorax.57.11.967; Hardie JA, 2002, EUR RESPIR J, V20, P1117, DOI 10.1183/09031936.02.00023202; Hurd Suzanne, 2000, Chest, V117, p1S, DOI 10.1378/chest.117.2_suppl.1S; Iqbal A, 2002, RESPIROLOGY, V7, P233, DOI 10.1046/j.1440-1843.2002.00399.x; Juniper EF, 1995, QUALITY LIFE PHARMAC, V2nd, P49; KIDA K, 2002, 12 ANN C EUR RESP SO; KIM JO, 1978, SAGE U PAPER SERIES, V714; Kornmann O, 2003, RESPIRATION, V70, P67, DOI 10.1159/000068417; Korsten AMMH, 2003, REV FR ALLERGOL, V43, P246, DOI 10.1016/S0335-7457(03)00111-4; LEBOWITZ MD, 1976, AM REV RESPIR DIS, V113, P627; LEVY M, 2003, 13 ANN C EUR RESP SO; Menard S., 2002, SAGE U PAPER SERIES, V07-106; Mullerova H, 2004, RESP MED, V98, P78, DOI 10.1016/j/rmed.2003.08.009; *NAT I CLIN EXC, 2004, THORAX S1, V59, P175; The National Lung Health Education Program Executive Committee, 1998, CHEST S, V113, p123S; *NIH NAT HEART LUN, 2001, GLOB IN CHRON OBSTR; Petty T L, 1998, Respir Care Clin N Am, V4, P345; StataCorp, 2001, STATA STAT SOFTW REL; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; van den Boom G, 1998, EUR RESPIR J, V11, P67, DOI 10.1183/09031936.98.11010067; Van Schayck CP, 2005, RESPIROLOGY, V10, P323, DOI 10.1111/j.1440-1843.2005.00720.x; van Schayck CP, 2002, BRIT MED J, V324, P1370, DOI 10.1136/bmj.324.7350.1370; van Weel C, 2002, Monaldi Arch Chest Dis, V57, P65; *WHO NAT HEART LUN, 2002, NIH PUBL	36	112	115	2	14	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0025-7931			RESPIRATION	Respiration		2006	73	3					285	295		10.1159/000090142		11	Respiratory System	Respiratory System	101XT	WOS:000241775300006	16330875	
J	Mehl, A; Wahn, U; Niggemann, B				Mehl, A; Wahn, U; Niggemann, B			Anaphylactic reactions in children - a questionnaire-based survey in Germany	ALLERGY			English	Article						anaphylaxis; children; food allergy; immunotherapy; infants; insect sting allergy	ALLERGIC DISEASES; FOOD ALLERGY; IMMUNOTHERAPY; EPIDEMIOLOGY; FATALITIES; FEATURES	Background: Severe anaphylactic reactions are medical emergencies requiring immediate recognition and treatment. Despite this, little is known on their clinical features, especially in infants and children. Objective: To evaluate trigger factors, patterns of clinical reaction, site of occurrence and treatment modalities of reported reaction in infants and children below 12 years of age in Germany. Methods: Paediatricians throughout Germany were asked by questionnaire to report accidental anaphylactic reactions over the previous 12 months. Severity of reported reactions was classified in grades I-IV according to reported symptoms. Results: Hundred and three cases of anaphylaxis were evaluated. Median age was 5 years, 58% were boys. Site of occurrence was the child's home in the majority of cases (58%). Foods were the most common causative allergen (57%), followed by insect stings (13%) and immunotherapy (SIT) (12%); in 8% anaphylactic agent was unknown. Among foods, peanuts and tree nuts were the most frequent allergens (20% of food allergens in each case). Severe reactions with cardiovascular involvement occurred in 24% of cases. No fatal reaction was observed. Recurrent episodes of anaphylaxis were reported in 27% of cases, half of these caused by the same allergen again. For treatment, 20% of children received adrenaline, in 8% of cases intravenously. Thirty-six per cent of patients with grade-IV reactions received adrenaline, 24% intravenously. In 17% of all children an adrenaline self-injector was prescribed after the episode. Conclusion: Our data: (i) shows an uncertainty of physicians in diagnosing anaphylaxis, (ii) reveals remarkable under-treatment of the majority of children with anaphylaxis, (iii) reflects the need for guidelines and training for physicians in managing children with anaphylaxis and (iv) should encourage the development of self-management programmes for patients and families.	Charite Univ Med Ctr Berlin, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany	Niggemann, B (reprint author), Charite Univ Med Ctr Berlin, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						AAAAI Board of Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brazil E, 1998, J ACCID EMERG MED, V15, P252; BUSINCO L, 1995, PEDIATR ALLERGY IMMU, V6, P44, DOI 10.1111/j.1399-3038.1995.tb00257.x; Cianferoni A, 2004, ANN ALLERG ASTHMA IM, V92, P464; Cianferoni A, 2001, ANN ALLERG ASTHMA IM, V87, P27; Dibs S D, 1997, Pediatrics, V99, pE7, DOI 10.1542/peds.99.1.e7; JOHANSSON SGO, 2003, ALLERGY, V113, P832; Lee JM, 2000, PEDIATRICS, V106, P762, DOI 10.1542/peds.106.4.762; Macdougall CF, 2002, ARCH DIS CHILD, V86, P236, DOI 10.1136/adc.86.4.236; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Niggemann B, 2005, ALLERGY, V60, P104, DOI 10.1111/j.1398-9995.2004.00591.x; Niggemann B, 2004, ALLERGY, V59, P806, DOI 10.1111/j.1398-9995.2004.00495.x; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Pumphrey Richard, 2004, Curr Opin Allergy Clin Immunol, V4, P285, DOI 10.1097/01.all.0000136762.89313.0b; Pumphrey RSH, 2000, J CLIN PATHOL, V53, P273, DOI 10.1136/jcp.53.4.273; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Sampson HA, 2003, PEDIATRICS, V111, P1601; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sheetz AH, 2004, J SCHOOL HEALTH, V74, P155; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; SIMONS FER, 2004, ALL CLIN IMMUNOL  S1, V242; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	26	112	117	1	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	NOV	2005	60	11					1440	1445		10.1111/j.1398-9995.2005.00909.x		6	Allergy; Immunology	Allergy; Immunology	969NS	WOS:000232241600017	16197479	
J	Schnuch, A; Lessmann, H; Geier, J; Frosch, PJ; Uter, W				Schnuch, A; Lessmann, H; Geier, J; Frosch, PJ; Uter, W			Contact allergy to fragrances: frequencies of sensitization from 1996 to 2002. Results of the IVDK	CONTACT DERMATITIS			English	Article						contact allergy; fragrance mix; frequency of sensitization; multicentre study; Myroxylon pereirae resin; oil of turpentine	PATCH-TEST; INFORMATION NETWORK; STANDARD SERIES; DERMATOLOGY IVDK; SKIN-SENSITIZATION; CHEMICAL-ANALYSIS; ESSENTIAL OILS; DERMATITIS; MULTICENTER; PERFUMES	Increasing frequencies of sensitization to the fragrance mix (FM) have been acknowledged as a serious problem for many years. It is well known that the single compounds (SCs) of the FM contribute differently to the FM patch rest reactions. In this study, we were interested in the time trends of the FM, the SCs, Myroxylon pereirae resin (MP; balsam of Peru) and oil of turpentine (OT) as possible further indicators of perfume allergy and analysed the data collected by the Information Network of Departments of Dermatology multicentre project from 1996 to 2002. During the study period (1996-2002), the FM [8% petrolatum (pet.)], MP (25% pet.) and OT (1% pet.) were tested in 59 298, 59 334 and 59 478 patients, respectively. SCs were tested in a selected group of patients, ranging from n = 1083 to n = 1924 per year. A significant increase in the proportions of patients with positive reactions to FM, MP and OT between 1996 and 1998 is noted, and a significant decline from 1999 to 2002 (Cochrane Armitage trend test, P < 0.0001). The highest frequency of sensitization to the FM was 13.1% in 1999, and the lowest 7.8% in 2002. The number of concomitant reactions to OT, a surrogate marker for terpenes, in FM-positive patients was significantly increased between 1997 and 1999. Reactions to SCs in FM-positive patients were observed in 29.9% (oak moss absolute) to 5.9% (geraniol). There was no time trend in reactions to SCs, although the relative share was increased for isoeugenol, cinnamic aldehyde and geraniol in 1999. In summary, we report for the first time, a significant decline in sensitization to the FM, very probably due to a reduced exposure (less potent allergens used in fine fragrances, possibly less use of natural ingredient-based cosmetics and lowered use concentration of important fragrance allergens). The differences in ranking of SCs could stimulate (a) a redefinition of the FM and (b) a differentiated preventive and regulatory approach, with oak moss and isoeugenol being regulated strictly by prohibition, concentration limits further reconsidered and/or health warnings and clearly less noxious substances like geraniol treated less restrictively.	Univ Gottingen, IVDK Zent Inst, Informat Network Dept Dermatol IVDK, D-37075 Gottingen, Germany; Klinikum Dortmund, Dept Dermatol, Dortmund, Germany; Univ Witten Herdecke, Dortmund, Germany; Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany	Schnuch, A (reprint author), Univ Gottingen, IVDK Zent Inst, Informat Network Dept Dermatol IVDK, Von Siebold Str 3, D-37075 Gottingen, Germany.	aschnuch@med.uni-goettingen.de		Uter, Wolfgang/0000-0002-4498-3710			Albert M R, 1999, Am J Contact Dermat, V10, P219, DOI 10.1016/S1046-199X(99)90072-6; Basketter DA, 2003, CLIN EXP DERMATOL, V28, P218, DOI 10.1046/j.1365-2230.2003.01247.x; Bertrand F, 1997, CHEM RES TOXICOL, V10, P335, DOI 10.1021/tx960087v; Bonnevie P, 1939, AETIOLOGIE PATHOGENE; BRASCH J, 1992, CONTACT DERMATITIS, V27, P203, DOI 10.1111/j.1600-0536.1992.tb05267.x; Brasch J, 2001, Am J Contact Dermat, V12, P197, DOI 10.1053/ajcd.2001.26669; Brites MM, 2000, CONTACT DERMATITIS, V43, P181; BRUN R, 1982, DERMATOLOGICA, V165, P24; Buckley DA, 2000, BRIT J DERMATOL, V142, P279, DOI 10.1046/j.1365-2133.2000.03298.x; CADBY PA, 2003, REGUL TOXICOL PHARM, V36, P246; Cheung C, 2003, J DERMATOL SCI, V31, P9, DOI 10.1016/S0923-1811(02)00139-1; CRONIN E, 1979, CONTACT DERMATITIS, V5, P308, DOI 10.1111/j.1600-0536.1979.tb04884.x; DAHLQUIST I, 1980, CONTACT DERMATITIS, V6, P111, DOI 10.1111/j.1600-0536.1980.tb03917.x; DAHLQUIST I, 1981, CONTACT DERMATITIS, V7, P168, DOI 10.1111/j.1600-0536.1981.tb04610.x; Dharmagunawardena B, 2002, CONTACT DERMATITIS, V47, P288, DOI 10.1034/j.1600-0536.2002.470506.x; FISHER AA, 1990, CUTIS, V45, P21; Fregert S, 1969, Trans St Johns Hosp Dermatol Soc, V55, P17; Frosch PJ, 2002, CONTACT DERMATITIS, V47, P279, DOI 10.1034/j.1600-0536.2002.470204.x; Frosch PJ, 2002, CONTACT DERMATITIS, V47, P78; FROSCH PJ, 1995, CONTACT DERMATITIS, V33, P333, DOI 10.1111/j.1600-0536.1995.tb02048.x; Frosch PJ, 1999, BRIT J DERMATOL, V141, P1076, DOI 10.1046/j.1365-2133.1999.03208.x; Frosch P. J., 1998, FRAGRANCES BENEFICIA; Frosh PJ, 1990, HAUTARZT S10, V41, P129; GARRIGUE JL, 1995, CLIN REV ALLERG IMMU, V13, P189; Geier J, 2002, CONTACT DERMATITIS, V46, P295, DOI 10.1034/j.1600-0536.2002.460509.x; Geier J, 2000, Am J Contact Dermat, V11, P207, DOI 10.1053/ajcd.2000.8011; Geier J, 1996, ALLERGOLOGIE, V19, P399; GEIER J, 2000, AM J CONTACT DERMAT, V11, P226; GEIER J, 2003, CONTACT DERMATITIS, V43, P280; Gerberick GF, 2001, CONTACT DERMATITIS, V45, P333, DOI 10.1034/j.1600-0536.2001.450603.x; GOLLHAUSEN R, 1988, CONTACT DERMATITIS, V18, P147, DOI 10.1111/j.1600-0536.1988.tb04501.x; Hausen B M, 2001, Am J Contact Dermat, V12, P93, DOI 10.1053/ajcd.2001.19314; Hausen B. M., 1995, AM J CONTACT DERMAT, V6, P199, DOI 10.1016/1046-199X(95)90043-8; Hendriks SA, 1999, CONTACT DERMATITIS, V41, P161; HJORTH N, 1961, ACTA DERM-VENER  S46, V41, P11; IPPEN H, 1998, DERMATOSEN, V46, P4; ISOLA D, 2001, AM COLL TOX M WASH D; JOHANSEN JD, 1995, CONTACT DERMATITIS, V32, P18, DOI 10.1111/j.1600-0536.1995.tb00834.x; Johansen JD, 2003, CONTACT DERMATITIS, V49, P180, DOI 10.1111/j.0105-1873.2003.0214.x; Johansen JD, 1997, ACTA DERM-VENEREOL, V77, P149; Johansen JD, 1996, BRIT J DERMATOL, V135, P419, DOI 10.1111/j.1365-2133.1996.tb01506.x; MOSS C, 1985, CLIN EXP IMMUNOL, V61, P232; Murphy LA, 2003, CONTACT DERMATITIS, V49, P52; Patlewicz G, 2001, CONTACT DERMATITIS, V44, P331, DOI 10.1034/j.1600-0536.2001.044006331.x; Pirker C, 2003, J Dtsch Dermatol Ges, V1, P629, DOI 10.1046/j.1610-0387.2003.03727.x; Rastogi SC, 2003, CONTACT DERMATITIS, V48, P130, DOI 10.1034/j.1600-0536.2003.00035.x; Rastogi SC, 1996, CONTACT DERMATITIS, V34, P423, DOI 10.1111/j.1600-0536.1996.tb02246.x; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; Reich K, 2003, J ALLERGY CLIN IMMUN, V112, P1191, DOI 10.1016/j.jaci.2003.09.012; Rudzki E, 1976, Contact Dermatitis, V2, P196; Scheinman PL, 2002, DERMATOLOGY, V205, P98, DOI 10.1159/000063156; Schnuch A, 1997, CONTACT DERMATITIS, V37, P200, DOI 10.1111/j.1600-0536.1997.tb02435.x; Schnuch A, 2002, CONTACT DERMATITIS, V47, P32, DOI 10.1034/j.1600-0536.2002.470107.x; Schnuch A, 2001, HAUTARZT, V52, P864, DOI 10.1007/s001050170048; SCHNUCH A, 1993, DERMATOS BER UMWELT, V41, P60; Schnuch A, 2003, CONTACT DERMATITIS, V49, P107, DOI 10.1111/j.0105-1873.2003.0128f.x; Schnuch A, 2002, CONTACT DERMATITIS, V46, P153, DOI 10.1034/j.1600-0536.2002.460305.x; Schnuch A, 2002, HUM EXP TOXICOL, V21, P439, DOI 10.1191/0960327102ht278oa; Schnuch A, 1998, BRIT J DERMATOL, V138, P467; Schnuch A., 2002, EXOG DERMATOL, V1, P231, DOI 10.1159/000068797; Schnuch A, 2002, ALLERGO J, V11, P39; TERAJIMA Y, 1988, FLAVORS FRAGRANCES W, P685; Thomson KF, 2000, BRIT J DERMATOL, V142, P84, DOI 10.1046/j.1365-2133.2000.03245.x; Treudler R, 2000, CONTACT DERMATITIS, V42, P68, DOI 10.1034/j.1600-0536.2000.042002068.x; Uter W, 1998, EUR J DERMATOL, V8, P36; Uter W, 2000, DERMATOLOGY, V200, P132, DOI 10.1159/000018346; Uter W, 1999, CONTACT DERMATITIS, V41, P343, DOI 10.1111/j.1600-0536.1999.tb06186.x; Uter W, 2001, CONTACT DERMATITIS, V44, P173, DOI 10.1034/j.1600-0536.2001.044003173.x; UTER W, 2002, SCHRIFTENREIHE BUNDE, V949; VEY M, 2003, COMMUNICATION; Wahlberg JE, 2001, TXB CONTACT DERMATIT, P435; Wesley NO, 2003, FOOD CHEM TOXICOL, V41, P857, DOI 10.1016/S0278-6915(03)00036-X; Westphal GA, 2003, CONTACT DERMATITIS, V48, P93, DOI 10.1034/j.1600-0536.2003.480208.x	74	112	116	0	7	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	FEB	2004	50	2					65	76		10.1111/j.0105-1873.2004.00302.x		12	Allergy; Dermatology	Allergy; Dermatology	818FC	WOS:000221230000003	15128316	
J	Mari, A; Schneider, P; Wally, V; Breitenbach, M; Simon-Nobbe, B				Mari, A; Schneider, P; Wally, V; Breitenbach, M; Simon-Nobbe, B			Sensitization to fungi: epidemiology, comparative skin tests, and IgE reactivity of fungal extracts	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergens; comparative study; epidemiology; fungal allergy diagnosis; fungal extract; IgE detection; immunoblotting; prevalence; skin tests	CANDIDA-ALBICANS; ALTERNARIA-ALTERNATA; IMMUNOLOGICAL CHARACTERIZATION; ASPERGILLUS-FUMIGATUS; CROSS-REACTIVITY; CLADOSPORIUM-HERBARUM; PENICILLIUM-CITRINUM; VAGINAL CANDIDIASIS; RESPIRATORY ALLERGY; DESERT ENVIRONMENT	Background Several fungal species are known to cause severe respiratory and cutaneous allergic diseases. Extracts from several allergenic fungi are used for in vivo and in vitro tests, as standard preparations are still not available. Objective The aims are to de. ne the pattern of in vivo and in vitro IgE reactivity to fungal species in an allergic population with respiratory symptoms; to determine the influence of different extract preparations on diagnostic results; and to evaluate whether there exists a relationship between the diagnostic pattern of reactivity and the pattern of specific IgE reactivity in immunoblots. Methods Skin prick tests were applied to a cohort of 4962 respiratory subjects, aged 3 - 80 years. Fungal extracts from Alternaria, Aspergillus, Candida, Cladosporium, Penicillium, Saccharomyces, and Trichophyton were used, along with extracts from pollens, mites, and animal dander. Demographical and diagnostic data were recorded. IgE detection was carried out with the same allergenic extracts plus Malassezia. Comparative skin tests and IgE detection were carried out using extracts from three commercial suppliers. IgE immunoblots were carried out with the same panel of commercial fungal extracts and were compared with in-house extracts. Data analysis was carried out by grouping the population on the basis of their reactivity to a single, to two or to more than two, mould species. Results Nineteen percent of the allergic population reacted to at least one fungal extract by means of the skin test. Alternaria and Candida accounted for the largest number of positive tests, and along with Trichophyton they were the main sensitizers in the subset of patients with an isolated sensitization. The prevalence of skin test reactivity increased for these three fungi in the subsets with two associated reactivities and, furthermore, in the subset showing reactivity to more than two mould species. In the latter group, a steady increase of the skin test reactivity was recorded for all the other fungal sources, suggesting a clustered reactivity. Comparative skin and IgE testing with different groups of subjects with a simple pattern of skin reactivity resulted in sensitivity differences between in vivo and in vitro tests, whereas discrepant results were recorded in the subsets of patients with multiple fungi sensitization. Although hampered by the limited reliability of fungal extracts, IgE immunoblots revealed differing patterns of reactivity when sera from the three subsets were used. This suggests a link between the diagnostic reactivity pattern and the IgE sensitization to extracts' components. Age and gender distribution differed among the Alternaria-, Candida-, and Trichophyton-sensitized subjects, but not in the subset with more than two fungi sensitizations. Conclusions The preliminary assessment of a new classification of the mould-sensitized population has been reached. The limiting quality of fungal extracts requires future studies using an allergenic molecule-based approach. The diagnostic process and the definition of the reactivity pattern would thus be easy, and it could lead to a novel specific immunotherapy approach.	Natl Hlth Serv, Allergy Unit, Rome, Italy; Salzburg Univ, Dept Genet & Gen Biol, A-5020 Salzburg, Austria	Mari, A (reprint author), Via Malipiero 28, I-04100 Latina, Italy.						ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Akiyama K, 1996, ALLERGY, V51, P887; AKIYAMA K, 1994, ALLERGY, V49, P778, DOI 10.1111/j.1398-9995.1994.tb02102.x; Ballantyne DS, 2000, BIOTECHNOL APPL BIOC, V31, P213, DOI 10.1042/BA19990106; Breitenbach M, 2002, CHEM IMMUNOL, V81, P48; BUSH RK, 1987, CLIN REV ALLERG, V5, P3; Bush R., 2001, J ALLERGY CLIN IMMUN, V107, P430, DOI 10.1067/mai.2001.113669; Chou H, 2002, INT ARCH ALLERGY IMM, V127, P15, DOI 10.1159/000048165; Clancy R, 1999, INT ARCH ALLERGY IMM, V118, P349, DOI 10.1159/000024131; Corsico R, 1998, ANN ALLERG ASTHMA IM, V80, P71; Crameri R, 2002, EUR RESPIR J, V19, P151, DOI 10.1183/09031936.02.00229102; Crameri R, 2002, CHEM IMMUNOL, V81, P73; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Escalante MT, 2000, J ALLERGY CLIN IMMUN, V105, P547, DOI 10.1067/mai.2000.104381; Ezeamuzie CI, 2000, INT ARCH ALLERGY IMM, V121, P300, DOI 10.1159/000024343; Gupta R, 2002, INT ARCH ALLERGY IMM, V127, P38, DOI 10.1159/000048167; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hawranek T, 2002, CHEM IMMUNOL, V81, P129; Helbling A, 2002, CHEM IMMUNOL, V81, P28; ITO K, 1995, CLIN EXP ALLERGY, V25, P522, DOI 10.1111/j.1365-2222.1995.tb01089.x; Kanbe T, 1997, CLIN EXP ALLERGY, V27, P1449, DOI 10.1046/j.1365-2222.1997.1620970.x; KARLSSONBORGA A, 1989, ANN ALLERGY, V63, P521; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; Kauffman HF, 2002, CHEM IMMUNOL, V81, P94; KIVITY S, 1992, CLIN EXP ALLERGY, V22, P498, DOI 10.1111/j.1365-2222.1992.tb00153.x; Lai HY, 2002, INT ARCH ALLERGY IMM, V127, P181, DOI 10.1159/000053862; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LEHRER SB, 1986, J ALLERGY CLIN IMMUN, V78, P478, DOI 10.1016/0091-6749(86)90036-9; Mari A, 2002, INT ARCH ALLERGY IMM, V129, P286, DOI 10.1159/000067591; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Moraes PSA, 1998, ANN ALLERG ASTHMA IM, V81, P165; NERMES M, 1995, INT ARCH ALLERGY IMM, V106, P118; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; Nissen D, 1998, ANN ALLERG ASTHMA IM, V81, P247; Nolles G, 2001, CLIN EXP ALLERGY, V31, P1564, DOI 10.1046/j.1365-2222.2001.01186.x; POTTER PC, 1991, ANN ALLERGY, V66, P149; Savolainen J, 1998, ALLERGY, V53, P359, DOI 10.1111/j.1398-9995.1998.tb03906.x; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Shen HD, 2000, J ALLERGY CLIN IMMUN, V105, P827, DOI 10.1067/mai.2000.105220; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Torricelli R, 1997, ALLERGY, V52, P747, DOI 10.1111/j.1398-9995.1997.tb01232.x; Unger A, 1999, INT ARCH ALLERGY IMM, V118, P220, DOI 10.1159/000024076; Ward GW, 1999, J ALLERGY CLIN IMMUN, V104, P541, DOI 10.1016/S0091-6749(99)70321-0; Woodfolk JA, 1998, J BIOL CHEM, V273, P29489, DOI 10.1074/jbc.273.45.29489	48	112	118	0	8	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2003	33	10					1429	1438		10.1046/j.1365-2222.2003.01783.x		10	Allergy; Immunology	Allergy; Immunology	727KN	WOS:000185657300017	14519151	
J	Vandenplas, O; Toren, K; Blanc, PD				Vandenplas, O; Toren, K; Blanc, PD			Health and socioeconomic impact of work-related asthma	EUROPEAN RESPIRATORY JOURNAL			English	Review						asthma; disability; occupational disease	AIRWAYS DYSFUNCTION SYNDROME; DIISOCYANATE-INDUCED ASTHMA; INDUCED OCCUPATIONAL ASTHMA; TOLUENE DIISOCYANATE; FOLLOW-UP; BRONCHIAL HYPERRESPONSIVENESS; PERSISTENT ASTHMA; REPEATED EXPOSURE; INHALATION CHALLENGE; CHLORINE INHALATION	There is accumulating evidence that the workplace environment contributes significantly to the general burden of asthma. The purpose of this review is to explore the respiratory health and socioeconomic consequences of work-related asthma by addressing a series of controversial issues: 1) what is the natural history of occupational asthma and in what ways does ongoing exposure to the causal agent impact clinical outcomes?; 2) how does the natural history of irritant-induced asthma differ in its health outcomes from immunologically-mediated occupational asthma?; 3) do working conditions have a significant impact on asthma regardless of the aetiology of the disease?; 4) what is the scope of work disability from work-related-asthma in social and economic terms?; 5) what is the clinician's role in reducing the respiratory health consequences of work-related asthma? 6) to what extent do existing compensation and other social insurance schemes successfully address occupational asthma and work-aggravated asthma?	Univ Catholique Louvain, Serv Pneumol, Clin Mont Godinne, B-5530 Yvoir, Belgium; Sahlgrens Univ Hosp, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Occupat & Environm Med, S-41345 Gothenburg, Sweden; Univ Calif San Francisco, Dept Med, Div Occupat & Environm Med, San Francisco, CA 94143 USA	Vandenplas, O (reprint author), Univ Catholique Louvain, Serv Pneumol, Clin Mont Godinne, B-5530 Yvoir, Belgium.						ABRAMSON MJ, 1995, MED J AUSTRALIA, V162, P78; Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; Ameille J, 1997, EUR RESPIR J, V10, P55, DOI 10.1183/09031936.97.10010055; ANDERSSON EB, 2001, EUR RESP S33, V18, pS508; AXON EJ, 1995, OCCUP MED-OXFORD, V45, P109, DOI 10.1093/occmed/45.2.109; Balder B, 1998, RESP MED, V92, P729, DOI 10.1016/S0954-6111(98)90003-8; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Beach JR, 1997, EUR RESPIR J, V10, P563; Bernstein IL, 1999, ASTHMA WORKPLACE, P1; BHERER L, 1994, OCCUP ENVIRON MED, V51, P225; Birnbaum HG, 2002, J ALLERGY CLIN IMMUN, V109, P264, DOI 10.1067/mai.2002.121310; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BLANC PD, 1991, JAMA-J AM MED ASSOC, V266, P664, DOI 10.1001/jama.266.5.664; BLANC PD, 1993, CHEST, V103, P1699, DOI 10.1378/chest.103.6.1699; Blanc PD, 1996, CHEST, V109, P688, DOI 10.1378/chest.109.3.688; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; BOULET LP, 1988, CHEST, V94, P476, DOI 10.1378/chest.94.3.476; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; CANNON J, 1995, BRIT MED J, V311, P602; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CHARAN NB, 1985, WESTERN J MED, V143, P333; CHESTER EH, 1977, CHEST, V72, P247, DOI 10.1378/chest.72.2.247; CONE JE, 1994, CHEST, V106, P500, DOI 10.1378/chest.106.2.500; Conrad E, 1998, SOUTHERN MED J, V91, P338, DOI 10.1097/00007611-199804000-00004; DAlessandro A, 1996, CHEST, V109, P331, DOI 10.1378/chest.109.2.331; de Bono J, 1999, OCCUP MED-OXFORD, V49, P217, DOI 10.1093/occmed/49.4.217; DELUCA S, 1988, EUR RESPIR J, V1, P540; Demeter SL, 2001, SCI TOTAL ENVIRON, V270, P49, DOI 10.1016/S0048-9697(00)00786-5; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; Frans A., 1993, Revue de Pneumologie Clinique, V49, P247; GANNON PFG, 1993, BRIT J IND MED, V50, P491; Gassert TH, 1998, J OCCUP ENVIRON MED, V40, P481, DOI 10.1097/00043764-199805000-00011; Gautrin D, 1995, EUR RESPIR J, V8, P2046, DOI 10.1183/09031936.95.08122046; Gautrin D, 1999, AM J RESP CRIT CARE, V160, P1232; Gautrin D, 1999, ASTHMA WORKPLACE, P565; GOE JK, 2002, AM J RESP CRIT CARE, V165, pA526; Gordon SB, 1997, AM J RESP CRIT CARE, V156, P206; GRAMMER LC, 1993, AM REV RESPIR DIS, V148, P54; GREEN DJ, 1987, AM REV RESPIR DIS, V135, P1261; HARVING H, 1991, AM REV RESPIR DIS, V143, P751; HARVING H, 1986, BRIT MED J, V293, P310; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058; KAUFMAN J, 1971, ARCH ENVIRON HEALTH, V23, P29; KERN DG, 1991, AM REV RESPIR DIS, V144, P1058; KONGERUD J, 1991, AM IND HYG ASSOC J, V52, P243, DOI 10.1202/0002-8894(1991)052<0243:TIOTHR>2.0.CO;2; Kopferschmitt-Kubler MC, 2002, EUR RESPIR J, V19, P84, DOI 10.1183/09031936.02.00102202; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lemiere C, 1996, ALLERGY, V51, P262; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; Leroyer C, 1998, THORAX, V53, P152; Leroyer C, 1998, OCCUP ENVIRON MED, V55, P356; Leroyer C, 1999, OCCUP ENVIRON MED, V56, P334; Liss GM, 1999, AM J IND MED, V35, P465, DOI 10.1002/(SICI)1097-0274(199905)35:5<465::AID-AJIM3>3.0.CO;2-V; Liss GM, 2000, AM J RESP CRIT CARE, V162, P112; Liss GM, 1996, CAN J PUBLIC HEALTH, V87, P401; LOZEWICZ S, 1987, BRIT J DIS CHEST, V81, P14, DOI 10.1016/0007-0971(87)90103-3; LUO JCJ, 1990, BRIT J IND MED, V47, P239; MAESTRELLI P, 1993, AM REV RESPIR DIS, V148, P407; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953; MALO JL, 1988, AM REV RESPIR DIS, V138, P807; MALO JL, 1994, AM J RESP CRIT CARE, V150, P1142; Malo JL, 1999, AM J IND MED, V35, P207; MANCUSO C, 2002, AM J RESP CRIT CARE, V165, pA526; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; MCCLELLAN VE, 1990, NEW ZEAL MED J, V103, P399; MEGGS WJ, 1994, J TOXICOL-CLIN TOXIC, V32, P487; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; MERGET R, 1994, AM J RESP CRIT CARE, V150, P1146; Milton DK, 1998, AM J IND MED, V33, P1, DOI 10.1002/(SICI)1097-0274(199801)33:1<1::AID-AJIM1>3.0.CO;2-2; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; Obase Y, 2000, OCCUP ENVIRON MED, V57, P62, DOI 10.1136/oem.57.1.62; Olin AC, 2002, SCAND J WORK ENV HEA, V28, P117; Ortega HG, 2002, CHEST, V121, P1323, DOI 10.1378/chest.121.4.1323; Ortega HG, 2002, AM J IND MED, V42, P50, DOI 10.1002/ajim.10088; PAGGIARO PL, 1993, CHEST, V103, P1123, DOI 10.1378/chest.103.4.1123; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; Perkner JJ, 1998, J OCCUP ENVIRON MED, V40, P136, DOI 10.1097/00043764-199802000-00009; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; Piirila PL, 1996, SCAND J WORK ENV HEA, V22, P191; PISATI G, 1993, BRIT J IND MED, V50, P60; ROSENBERG N, 1987, CLIN ALLERGY, V17, P55, DOI 10.1111/j.1365-2222.1987.tb02319.x; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; Ross DJ, 1998, OCCUP MED-OXFORD, V48, P219, DOI 10.1093/occmed/48.4.219; Sallie B, 1996, ANN OCCUP HYG, V40, P211, DOI 10.1016/0003-4878(95)00067-4; SCHWARTZ DA, 1990, CHEST, V97, P820, DOI 10.1378/chest.97.4.820; Shusterman D, 2002, EUR RESPIR J, V19, P381, DOI 10.1183/09031936.02.00274702; SHUSTERMAN D, 1988, J OCCUP ENVIRON MED, V30, P565; SIBBALD B, 1992, THORAX, V47, P19, DOI 10.1136/thx.47.1.19; SLOVAK AJM, 1985, AM IND HYG ASSOC J, V46, P411, DOI 10.1202/0002-8894(1985)046<0411:EOTHRI>2.3.CO;2; Taivainen AI, 1998, SCAND J WORK ENV HEA, V24, P503; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; TIMMER S, 1993, CHEST, V104, P816, DOI 10.1378/chest.104.3.816; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; Vandenplas O, 1999, EUR RESPIR J, V13, P1144, DOI 10.1034/j.1399-3003.1999.13e34.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Yelin E, 1999, AM J IND MED, V35, P472, DOI 10.1002/(SICI)1097-0274(199905)35:5<472::AID-AJIM4>3.0.CO;2-S	111	112	113	0	2	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2003	22	4					689	697		10.1183/09031936.03.00053203		9	Respiratory System	Respiratory System	732WR	WOS:000185969000022	14582924	
J	Pitchford, SC; Yano, H; Lever, R; Riffo-Vasquez, Y; Ciferri, S; Rose, MJ; Giannini, S; Momi, S; Spina, D; O'Connor, B; Gresele, P; Page, CP				Pitchford, SC; Yano, H; Lever, R; Riffo-Vasquez, Y; Ciferri, S; Rose, MJ; Giannini, S; Momi, S; Spina, D; O'Connor, B; Gresele, P; Page, CP			Platelets are essential for leukocyte recruitment in allergic inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						platelet; leukocyte; platelet-leukocyte interaction; asthma; allergy; eosinophil; lymphocyte; vascular endothelium; CD11b	P-SELECTIN; FLOW-CYTOMETRY; WHOLE-BLOOD; ASTHMA; ADHESION; ACTIVATION; NEUTROPHILS; CELLS; PAF; AGGREGATION	Background: The role of platelets in inflammation is recognized but poorly characterized, and little is known of their interaction with leukocytes. However, platelet-leukocyte interactions have been demonstrated in cardiovascular disease, culminating in enhanced leukocyte recruitment. Objectives: This study was undertaken to assess the possibility and potential role of similar phenomena occurring in asthmatic patients, a murine model of allergic inflammation, and in vitro adhesion studies. Methods: Asthmatic patients had blood taken at various time points to document the degree of leukocyte activation and the presence of platelet-leukocyte aggregates through FACS analysis before and after allergen exposure. Similar studies were carried out in mice exposed to allergen after previous sensitization, with some groups being selectively depleted of platelets through both an immunologic (antiplatelet antiserum) and nonimmunologic (busulfan) method. Additionally, lavage fluid and airway tissue were analyzed to assess the degree of pulmonary leukocyte recruitment. The importance of platelets on leukocyte adhesion to the endothelium was then assessed with in vitro incubation of radiolabeled leukocytes in the presence of activated platelets on cultured human vascular endothelial cells. Results: We have observed circulating platelet-leukocyte aggregates in the blood of allergic asthmatic patients during the allergen-induced late asthmatic response and in sensitized mice after allergen exposure. In platelet-depleted mice infiltration of leukocytes into airways after allergen challenge was significantly reduced and could be restored by means of infusion of platelets from allergic animals, indicating an essential role for platelets in leukocyte recruitment. CD11b expression on leukocytes involved in aggregates with platelets, although not on free leukocytes, was upregulated. Furthermore, the presence of autologous platelets augmented the adhesion of human polymorphonuclear leukocytes to cultured vascular endothelial cells, an effect that was found to be endothelial cell dependent and to involve platelet activation. Conclusion: These results suggest that platelet participation in cell recruitment occurs at the level of the circulation and might involve the priming of leukocytes for subsequent adhesion and transmigration into tissues.	Kings Coll London, GKT Sch Biomed Sci, Sackler Inst Pulm Pharmacol, London SE1 1UL, England; Univ Perugia, Dept Internal Med, Sect Internal & Cardiovasc Med, I-06100 Perugia, Italy; Kings Coll Hosp London, Dept Resp Med & Allergy, London, England	Page, CP (reprint author), Kings Coll London, GKT Sch Biomed Sci, Sackler Inst Pulm Pharmacol, 5th Floor,Hodgkin Bldg,Guys Campus, London SE1 1UL, England.		Gresele, Paolo/F-6775-2013	Gresele, Paolo/0000-0001-5365-8445; Spina, Domenico/0000-0002-6815-1564			Asman B, 1997, INT J CLIN LAB RES, V27, P185, DOI 10.1007/BF02912455; BARNES PJ, 1992, J INTERN MED, V231, P453; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; BEER JH, 1995, INT ARCH ALLERGY IMM, V106, P291; BRECHER G, 1950, J APPL PHYSIOL, V3, P365; Brown KK, 1998, AM J RESP CELL MOL, V18, P100; Cerletti C, 1999, THROMB HAEMOSTASIS, V82, P787; Chihara J, 1997, J ALLERGY CLIN IMMUN, V100, pS52, DOI 10.1016/S0091-6749(97)70005-8; Ciferri S, 2000, THROMB HAEMOSTASIS, V83, P157; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587; DEBRUIJNEADMIRAAL LG, 1992, BLOOD, V80, P134; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790; ELGENDI H, 1999, EUR HEART J, V20, P530; Freedman JE, 2002, CIRCULATION, V105, P2130, DOI 10.1161/01.CIR.0000017140.26466.F5; GRESELE P, 1982, NEW ENGL J MED, V306, P549; GRESELE P, 1993, J ALLERGY CLIN IMMUN, V91, P894, DOI 10.1016/0091-6749(93)90347-I; Harbinson PL, 1997, EUR RESPIR J, V10, P1008, DOI 10.1183/09031936.97.10051008; Herd CM, 1995, IMMUNOPHARMACOLOGY P, P1, DOI 10.1016/B978-012390120-0/50003-4; Jawien J, 2002, POL J PHARMACOL, V54, P157; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; KARPATKIN S, 1981, ANN INTERN MED, V95, P636; KUTER DJ, 1995, BLOOD, V85, P2720; Lauener RW, 1999, BBA-MOL CELL RES, V1452, P197, DOI 10.1016/S0167-4889(99)00125-1; LELLOUCHTUBIANA A, 1988, AM REV RESPIR DIS, V137, P948; Lever R, 2000, BRIT J PHARMACOL, V129, P533, DOI 10.1038/sj.bjp.0703099; Lynam E, 1998, J LEUKOCYTE BIOL, V64, P622; Merhi Y, 1997, ARTERIOSCL THROM VAS, V17, P1185; Mickelson JK, 1996, J AM COLL CARDIOL, V28, P345, DOI 10.1016/0735-1097(96)00164-7; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; Neumann FJ, 1999, J AM COLL CARDIOL, V34, P1420, DOI 10.1016/S0735-1097(99)00350-2; Ott I, 1996, CIRCULATION, V94, P1239; PAGE CP, 2000, PLATELETS, P531; PAGE CP, 1993, ALLERGY; Panes J, 1999, BRIT J PHARMACOL, V126, P537, DOI 10.1038/sj.bjp.0702328; Peters MJ, 1997, J IMMUNOL METHODS, V209, P125, DOI 10.1016/S0022-1759(97)00139-7; Powell CC, 1999, J VASC SURG, V30, P844, DOI 10.1016/S0741-5214(99)70009-1; RINDER HM, 1991, BLOOD, V78, P1730; RINDER HM, 1991, BLOOD, V78, P1760; Salter JW, 2001, AM J PHYSIOL-GASTR L, V281, pG1432; SCHNEIDER MD, 1974, SCAND J HAEMATOL, V12, P185; SIMON HU, 1994, PEDIATR PULM, V17, P304, DOI 10.1002/ppul.1950170507; Sullivan PJ, 2000, RESPIRATION, V67, P514, DOI 10.1159/000067466; TSICOPOULOS A, 1988, INT J IMMUNOPHARMACO, V10, P227, DOI 10.1016/0192-0561(88)90053-7; WALKER C, 1991, INT ARCH ALLER A IMM, V94, P241; YAMAMOTO H, 1993, J ALLERGY CLIN IMMUN, V91, P79, DOI 10.1016/0091-6749(93)90299-U; YARON M, 1978, ARTHRITIS RHEUM, V21, P607, DOI 10.1002/art.1780210509	46	112	114	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					109	118		10.1067/mai.2003.1514		10	Allergy; Immunology	Allergy; Immunology	698QQ	WOS:000184010600018	12847487	
J	Whitehead, GS; Walker, JKL; Berman, KG; Foster, WM; Schwartz, DA				Whitehead, GS; Walker, JKL; Berman, KG; Foster, WM; Schwartz, DA			Allergen-induced airway disease is mouse strain dependent	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Editorial Material						asthma; airway hyperreactivity; eosinophils; cytokines	LATE ASTHMATIC REACTIONS; LUNG DAMAGE; MICE; HYPERRESPONSIVENESS; HYPERREACTIVITY; INTERLEUKIN-5; INFLAMMATION; RESPONSIVENESS; EOSINOPHILIA; NEUTROPHILS	We investigated the development of airway hyperreactivity ( AHR) and inflammation in the lungs of nine genetically diverse inbred strains of mice [129/SvIm, A/J, BALB/cJ, BTBR+(T)/tf/tf, CAST/Ei, C3H/HeJ, C57BL/6J, DBA/2J, and FVB/NJ] after sensitization and challenge with ovalbumin (OVA). At 24, 48, and 72 h post-OVA exposure, the severity of AHR and eosinophilic inflammation of the mouse strains ranged from relatively unresponsive to responsive. The severity of the airway eosinophilia of some strains did not clearly correlate with the development of AHR. The temporal presence of T helper type 2 cytokines in lung lavage fluid also varied markedly among the strains. The levels of IL-4 and IL-13 were generally increased in the strains with the highest airway eosinophilia at 24 and 72 h postexposure, respectively; the levels of IL-5 were significantly increased in most of the strains with airway inflammation over the 72-h time period. The differences of physiological and biological responses among the inbred mouse strains after OVA sensitization and challenge support the hypothesis that genetic factors contribute, in part, to the development of allergen-induced airway disease.	Duke Univ, Med Ctr, Dept Pulm & Crit Care Med, Durham, NC 27710 USA	Whitehead, GS (reprint author), Duke Univ, Med Ctr, Dept Pulm & Crit Care Med, Rm 275 MSRB,DUMC Box 2629, Durham, NC 27710 USA.				NHLBI NIH HHS [HL-62641, HL-66604, HL-62628, HL-66611]; NIEHS NIH HHS [ES-07498, ES-09607]		Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150; BUCHANAN DR, 1987, AM REV RESPIR DIS, V136, P1397; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; CARROLL MP, 1985, J ALLERGY CLIN IMMUN, V75, P290, DOI 10.1016/0091-6749(85)90060-0; CHIBA Y, 1995, RES COMMUN MOL PATH, V90, P169; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DUFF AL, 1992, PEDIATR CLIN N AM, V39, P1277; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84; GLEICH GJ, 1990, CLIN EXP ALLERGY, V20, P245, DOI 10.1111/j.1365-2222.1990.tb02678.x; Gray L, 2000, CLIN EXP ALLERGY, V30, P393; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, J IMMUNOL, V161, P1501; Holberg CJ, 1998, AM J RESP CRIT CARE, V158, P162; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Kanehiro A, 2002, J IMMUNOL, V169, P4190; Kay A B, 1991, Clin Exp Allergy, V21 Suppl 1, P17, DOI 10.1111/j.1365-2222.1991.tb01700.x; Kellar KL, 2001, CYTOMETRY, V45, P27, DOI 10.1002/1097-0320(20010901)45:1<27::AID-CYTO1141>3.0.CO;2-I; Kips JC, 1999, ALLERGY, V54, P903, DOI 10.1034/j.1398-9995.1999.00098.x; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; LEVITT RC, 1990, AM J PHYSIOL, V258, pL157; Little SA, 2002, AM J MED, V112, P446, DOI 10.1016/S0002-9343(02)01047-1; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106; Los H, 1999, EUR RESPIR J, V14, P1210, DOI 10.1183/09031936.99.14512109; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; Miyabara Y, 1998, EUR RESPIR J, V11, P291, DOI 10.1183/09031936.98.11020291; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749; SPRY CJF, 1971, CELL TISSUE KINET, V4, P365, DOI 10.1111/j.1365-2184.1971.tb01546.x; SYBILLE Y, 1990, AM REV RESPIR DIS, V141, P471; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; WILLIAMS SC, 2000, RRD MOLEC CELL BIOL, V1, P19; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WillsKarp M, 1997, AM J RESP CRIT CARE, V156, pS89; Woodruff PG, 2002, AM J MED, V112, P498, DOI 10.1016/S0002-9343(02)01105-1; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661	48	112	114	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	JUL	2003	285	1					L32	L42		10.1152/ajplung.00390.2002		11	Physiology; Respiratory System	Physiology; Respiratory System	686HB	WOS:000183314400005	12626335	
J	Coulson, FR; Fryer, AD				Coulson, FR; Fryer, AD			Muscarinic acetylcholine receptors and airway diseases	PHARMACOLOGY & THERAPEUTICS			English	Review						prejunctional receptors; postjunctional receptors; parasympathetic nerves; airway hyperreactivity; eosinophils; viruses	OBSTRUCTIVE PULMONARY-DISEASE; UPPER RESPIRATORY-TRACT; MAJOR BASIC-PROTEIN; GUINEA-PIG TRACHEA; INDUCED BRONCHIAL HYPERREACTIVITY; INHALED IPRATROPIUM BROMIDE; EXERCISE-INDUCED ASTHMA; VITAMIN-A-DEFICIENCY; SMOOTH-MUSCLE; INDUCED BRONCHOCONSTRICTION	Parasympathetic nerves provide the dominant autonomic innervation of the airways. Release of acetylcholine from parasympathetic nerves activates postjunctional muscarinic receptors present on airway smooth muscle, submucosal glands, and blood vessels to cause bronchoconstriction, mucus secretion, and vasodilatation, respectively. Acetylcholine also feeds back onto prejunctional muscarinic receptors to enhance or inhibit further acetylcholine release. In asthma and chronic obstructive pulmonary disease, bronchoconstriction and mucus secretion is increased and the airways are hyperresponsive to contractile agents. These changes are due to increased parasympathetic nerve activity. The number and function of postjunctional muscarinic receptors in the airways are unchanged in animal models of asthma. Rather, it is the supply of acetylcholine to the postjunctional cells (smooth muscle and submucosal gland) that is increased. The increase in acetylcholine release occurs because prejunctional, inhibitory M-2 muscarinic receptors on the parasympathetic nerves are dysfunctional. M-2 muscarinic receptor dysfunction and subsequent airway hyperreactivity have been demonstrated to occur in animals in response to a variety of triggers, including antigen challenge, virus infection, ozone exposure, and vitamin A deficiency. In humans, there is evidence that loss of M-2 muscarinic receptor function is related to asthma. The mechanisms by which neuronal M-2 muscarinic receptor function is lost and its relevance to human airway disease are discussed in this review. (C) 2003 Elsevier Science Inc. All rights reserved.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Physiol, Baltimore, MD 21205 USA	Fryer, AD (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Div Physiol, 615 N Wolfe St, Baltimore, MD 21205 USA.		Fryer, Allison/F-2420-2014	Fryer, Allison/0000-0003-1712-9831	NHLBI NIH HHS [P01-HL-10342, R01-HL-54659, R01-HL-55543]		Aaron SD, 2001, J ASTHMA, V38, P521, DOI 10.1081/JAS-100107116; AAS P, 1990, BRIT J PHARMACOL, V101, P73; Abrahamson EM, 1941, J CLIN ENDOCRINOL, V1, P402; Adamko DJ, 1999, J EXP MED, V190, P1465, DOI 10.1084/jem.190.10.1465; ADAMKO DJ, 2000, AM J RESP CRIT CARE, V161, pA842; AHMED T, 1993, NEW ENGL J MED, V329, P90, DOI 10.1056/NEJM199307083290204; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; AQUILINA AT, 1980, AM REV RESPIR DIS, V122, P3; ASHE JH, 1984, NEUROPHARMACOLOGY, V23, P1321, DOI 10.1016/0028-3908(84)90053-4; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; AYALA LE, 1989, CHEST, V96, P1285, DOI 10.1378/chest.96.6.1285; AZEVEDO M, 1990, J INT MED RES, V18, P37; BAKER DG, 1992, AM J PHYSIOL, V263, pL142; BARNES PJ, 1982, EUR J PHARMACOL, V86, P103, DOI 10.1016/0014-2999(82)90405-8; BARNES PJ, 1992, PHYSIOL REV, V72, P699; BARNES PJ, 1995, LIFE SCI, V56, P853, DOI 10.1016/0024-3205(95)00020-7; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661; BAUM EA, 1993, J AEROSOL MED S, V6, P72; Belmonte KE, 1997, BRIT J PHARMACOL, V121, P1287, DOI 10.1038/sj.bjp.0701274; Belmonte KE, 1998, J APPL PHYSIOL, V85, P1708; BERNHEIM L, 1992, P NATL ACAD SCI USA, V89, P9544, DOI 10.1073/pnas.89.20.9544; BLABER LC, 1985, BRIT J PHARMACOL, V86, P723; BLAIR HT, 1976, AM REV RESPIR DIS, V114, P95; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; Bowerfind WML, 2002, J APPL PHYSIOL, V92, P1417, DOI 10.1152/japplphysiol.00934.2001; BRODY JS, 1972, J APPL PHYSIOL, V32, P160; BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6; BUCKNER CK, 1981, J CLIN INVEST, V67, P376, DOI 10.1172/JCI110045; BUCKNER CK, 1985, AM REV RESPIR DIS, V132, P305; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Caulfield MP, 1998, PHARMACOL REV, V50, P279; Cazzola M, 1998, RESP MED, V92, P354, DOI 10.1016/S0954-6111(98)90121-4; CHEUNG D, 1995, AM J RESP CRIT CARE, V152, P1490; CHIBA Y, 1995, COMP BIOCHEM PHYS C, V111, P351, DOI 10.1016/0742-8413(95)00061-5; CHILVERS ER, 1990, J PHARMACOL EXP THER, V252, P786; CHUNG KF, 1987, J APPL PHYSIOL, V62, P253; COLEBATCH HJH, 1963, J APPL PHYSIOL, V18, P881; Costello RW, 1999, AM J PHYSIOL-LUNG C, V276, pL709; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93; COSTELLO RW, 1997, ASTHMA, P965; COTTON DJ, 1977, J APPL PHYSIOL, V42, P101; Coulson FR, 2002, BRIT J PHARMACOL, V135, P1355, DOI 10.1038/sj.bjp.0704602; CRIMI N, 1992, EUR RESPIR J, V5, P560; Dahlquist G, 2000, J PEDIATR-US, V137, P470, DOI 10.1067/mpd.2000.109109; DISSE B, 1993, LIFE SCI, V52, P537, DOI 10.1016/0024-3205(93)90312-Q; DOUGLAS NJ, 1981, CLIN SCI, V61, P581; DUSSER DJ, 1989, J APPL PHYSIOL, V67, P1504; EISER NM, 1982, B EUR PHYSIOPATH RES, V18, P449; ELBON CL, 1995, AM J RESP CELL MOL, V12, P320; ELTZE M, 1994, PULM PHARMACOL, V7, P109, DOI 10.1006/pulp.1994.1013; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Evans CM, 2001, AM J RESP CRIT CARE, V163, P1484; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; Evans CM, 2000, AM J PHYSIOL-LUNG C, V279, pL477; FERNANDES LB, 1992, J PHARMACOL EXP THER, V262, P119; FRYER AD, 1992, J CLIN INVEST, V90, P2292, DOI 10.1172/JCI116116; FRYER AD, 1984, BRIT J PHARMACOL, V83, P973; FRYER AD, 1991, BRIT J PHARMACOL, V102, P267; FRYER AD, 1990, EUR J PHARMACOL, V181, P51, DOI 10.1016/0014-2999(90)90244-Z; Fryer AD, 1997, J CLIN INVEST, V99, P2036, DOI 10.1172/JCI119372; FRYER AD, 1991, J APPL PHYSIOL, V71, P2255; FRYER AD, 1994, BRIT J PHARMACOL, V112, P588; GALLAGHER JT, 1975, PROC R SOC SER B-BIO, V192, P49, DOI 10.1098/rspb.1975.0151; Garrigo J, 1996, AM J RESP CRIT CARE, V153, P1702; GOLD WM, 1972, J APPL PHYSIOL, V33, P719; GOLDEN JA, 1978, AM REV RESPIR DIS, V118, P287; GORDON T, 1984, J APPL PHYSIOL, V57, P1034; GRANDORDY BM, 1986, J PHARMACOL EXP THER, V238, P273; HADDAD EB, 1994, AM J PHYSIOL, V266, pL642; HALL WJ, 1976, AM REV RESPIR DIS, V113, P141; Handler A, 2000, J NEUROSCI RES, V60, P311, DOI 10.1002/(SICI)1097-4547(20000501)60:3<311::AID-JNR5>3.0.CO;2-X; HEATON RW, 1984, BRIT MED J, V289, P149; HELANDER E, 1958, ACTA MED SCAND, V162, P165; HEY C, 1994, N-S ARCH PHARMACOL, V350, P464; HOLTZMAN MJ, 1979, AM REV RESPIR DIS, V120, P1059; HOLTZMAN MJ, 1983, AM REV RESPIR DIS, V127, P686; HORVATH I, 1995, CHEST, V108, P701, DOI 10.1378/chest.108.3.701; HUDGEL DW, 1979, AM REV RESPIR DIS, V120, P393; ITKIN IH, 1970, J ALLERGY, V45, P178, DOI 10.1016/0021-8707(70)90126-7; ITO Y, 1988, BRIT J PHARMACOL, V93, P636; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; Jacoby DB, 1998, J CLIN INVEST, V102, P242, DOI 10.1172/JCI1114; JACOBY DB, 1988, J APPL PHYSIOL, V64, P2653; Jacoby DB, 2002, JAMA-J AM MED ASSOC, V287, P755, DOI 10.1001/jama.287.6.755; JOHANSON WG, 1969, AM REV RESPIR DIS, V100, P141; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; KARCZEWS.W, 1969, J PHYSIOL-LONDON, V201, P259; KERSTEN W, 1974, RESPIRATION, V31, P412; Kesler BS, 1999, J PHYSIOL-LONDON, V518, P843, DOI 10.1111/j.1469-7793.1999.0843p.x; KOLLER EA, 1969, EXPERIENTIA, V25, P368, DOI 10.1007/BF01899923; KUME H, 1991, AM J PHYSIOL, V261, pC1204; Laitinen L A, 1980, Eur J Respir Dis Suppl, V106, P51; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P358; LEE AM, 2001, AM J RESP CRIT CARE, V163, pA142; LEE LY, 1977, J APPL PHYSIOL, V43, P626; LITTLE JW, 1978, AM REV RESPIR DIS, V118, P295; MACLAGAN J, 1989, BRIT J PHARMACOL, V97, P499; MAESEN FPV, 1995, EUR RESPIR J, V8, P1506; MAGNUSSEN H, 1992, RESPIRATION, V59, P42; MAK JCW, 1993, LIFE SCI, V53, P1501, DOI 10.1016/0024-3205(93)90624-C; MAK JCW, 1992, AM J RESP CELL MOL, V7, P344; MAK JCW, 1990, AM REV RESPIR DIS, V141, P1559; MAKKER HK, 1993, J ALLERGY CLIN IMMUN, V92, P82, DOI 10.1016/0091-6749(93)90041-D; MARRION NV, 1989, BRIT J PHARMACOL, V98, P557; MARSH WR, 1985, AM REV RESPIR DIS, V131, P875; Matera MG, 1995, PULM PHARMACOL, V8, P267, DOI 10.1006/pulp.1995.1036; MATRAN R, 1991, ACTA PHYSIOL SCAND, V143, P387, DOI 10.1111/j.1748-1716.1991.tb09250.x; MCCAIG DJ, 1987, BRIT J PHARMACOL, V92, P809; McGowan SE, 2002, AM J PHYSIOL-LUNG C, V282, pL1031, DOI 10.1152/ajplung.00319.2001; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; MILLS JE, 1970, BRIT J PHARMACOL, V39, P724; MINETTE PA, 1988, J APPL PHYSIOL, V64, P2532; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461; MOLFINO NA, 1993, AM REV RESPIR DIS, V148, P1238; MORRISON JFJ, 1988, BRIT MED J, V296, P1427; MORRISON JFJ, 1989, BRIT J CLIN PHARMACO, V28, P545; MULLOL J, 1992, J APPL PHYSIOL, V73, P2069; MURLAS CG, 1985, AM REV RESPIR DIS, V131, P314; Myers AC, 1996, AM J PHYSIOL-LUNG C, V270, pL630; NICHOLSON KG, 1993, BRIT MED J, V307, P982; OConnor BJ, 1996, AM J RESP CRIT CARE, V154, P876; OKAYAMA M, 1993, AM J RESP CELL MOL, V8, P176; OLSEN CR, 1965, J APPL PHYSIOL, V20, P202; On LS, 2001, AM J RESP CRIT CARE, V163, P1320; OREHEK J, 1975, B PHYSIO-PATHOL RESP, V11, P193; OUELLETTE JJ, 1965, J ALLERGY, V36, P558, DOI 10.1016/0021-8707(65)90193-0; Paquette NC, 1996, AM J PHYSIOL-LUNG C, V270, pL475; PATEL HJ, 1995, AM J RESP CRIT CARE, V152, P872; PATTERSON R, 1971, INT ARCH ALLER A IMM, V41, P592; PAULET G, 1969, J PHYSIOL-PARIS, VS 61, P160; PHIPPS RJ, 1976, J PHYSIOL-LONDON, V258, pP116; PICKEN JJ, 1972, AM J MED, V52, P738, DOI 10.1016/0002-9343(72)90079-4; Polosa R, 1997, J ALLERGY CLIN IMMUN, V99, P338, DOI 10.1016/S0091-6749(97)70051-4; Ramnarine SI, 1996, J PHYSIOL-LONDON, V494, P577; RICHARDSON JB, 1979, AM REV RESPIR DIS, V119, P785; ROFFEL A F, 1990, Pulmonary Pharmacology, V3, P47, DOI 10.1016/0952-0600(90)90009-8; ROFFEL AF, 1988, EUR J PHARMACOL, V153, P73, DOI 10.1016/0014-2999(88)90589-4; Rogers DF, 2001, RESP PHYSIOL, V125, P129, DOI 10.1016/S0034-5687(00)00209-7; Salonen R O, 1990, Eur Respir J Suppl, V12, p630s; Sawatzky DA, 2002, AM J PHYSIOL-LUNG C, V282, pL1279, DOI 10.1152/ajplung.00279.2001; Scalvini S, 1999, EUR RESPIR J, V13, P119, DOI 10.1183/09031936.99.13111999; Schramm CM, 1995, AM J PHYSIOL-LUNG C, V269, pL783; SCHULTHEIS AH, 1994, J APPL PHYSIOL, V76, P1088; Schuster CE, 2001, MICROELECTRON RELIAB, V41, P239, DOI 10.1016/S0026-2714(00)00227-4; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321; SKOOGH BE, 1986, B EUR PHYSIOPATH RES, V22, P143; SOMMER A, 1984, AM J CLIN NUTR, V40, P1090; Song PF, 1997, AM J RESP CRIT CARE, V155, P1230; SORKNESS R, 1994, AM J RESP CRIT CARE, V150, P28; SZCZEKLIK A, 1980, J ALLERGY CLIN IMMUN, V66, P424, DOI 10.1016/0091-6749(80)90123-2; TAMAOKI J, 1994, THORAX, V49, P545, DOI 10.1136/thx.49.6.545; TenBerge REJ, 1996, EUR J PHARMACOL, V318, P131, DOI 10.1016/S0014-2999(96)00820-5; tenBerge REJ, 1996, AM J RESP CRIT CARE, V154, P43; van Noord JA, 2000, THORAX, V55, P289, DOI 10.1136/thorax.55.4.289; VANKOPPEN CJ, 1987, NEUROSCI LETT, V83, P237, DOI 10.1016/0304-3940(87)90092-9; VILLA MP, 1988, AM J DIS CHILD, V142, P726; Walch L, 2001, THERAPIE, V56, P223; Walch L, 1999, THERAPIE, V54, P99; WALTERS EH, 1986, CLIN SCI, V71, P605; WANG ZW, 1995, LIFE SCI, V56, P2255, DOI 10.1016/0024-3205(95)00215-R; WHICKER S D, 1990, Pulmonary Pharmacology, V3, P129, DOI 10.1016/0952-0600(90)90043-I; YANG ZJ, 1991, EUR J PHARMACOL, V193, P301, DOI 10.1016/0014-2999(91)90143-E; YEADON M, 1992, PULM PHARMACOL, V5, P39, DOI 10.1016/0952-0600(92)90016-A; Yost BL, 1999, J APPL PHYSIOL, V87, P1272; YU DYC, 1972, J APPL PHYSIOL, V32, P823; ZIMMERMANN I, 1976, RESPIRATION, V33, P95	166	112	122	0	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0163-7258			PHARMACOL THERAPEUT	Pharmacol. Ther.	APR	2003	98	1					59	69		10.1016/S0163-7258(03)00004-4		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	666XY	WOS:000182202800003	12667888	
J	Oddy, WH; Sly, PD; de Klerk, NH; Landau, LI; Kendall, GE; Holt, PG; Stanley, FJ				Oddy, WH; Sly, PD; de Klerk, NH; Landau, LI; Kendall, GE; Holt, PG; Stanley, FJ			Breast feeding and a birth cohort study respiratory morbidity in infancy: a birth cohort study	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							FORMULA-FED INFANTS; 1ST YEAR; TRACT ILLNESS; OTITIS-MEDIA; HUMAN-MILK; FOLLOW-UP; LIFE; INFECTIONS; CHILDHOOD; ASTHMA	Aim: To examine the relation between the duration of breast feeding and morbidity as a result of respiratory illness and infection in the first year of life. Methods: Prospective birth cohort study of 2602 live born children ascertained through antenatal clinics at the major tertiary obstetric hospital in Perth, Western Australia. Main outcome measures were hospital, doctor, or clinic visits, and hospital admissions for respiratory illness and infection in the first year of life. Main exposure measures were the duration of predominant breast feeding (defined as the age other milk was introduced) and partial (any) breast feeding (defined as the age breast feeding was stopped). Main confounders were gender, gestational age less than 37 weeks, smoking in pregnancy, older siblings, maternal education, and maternal age. Results: Hospital, doctor, or clinic visits for four or more upper respiratory tract infections were significantly greater if predominant breast feeding was stopped before 2 months or partial breast feeding was stopped before 6 months. Predominant breast feeding for less than six months was associated with an increased risk for two or more hospital, doctor, or clinic visits and hospital admission for wheezing, lower respiratory illness. Breast feeding for less than eight months was associated with a significantly increased risk for two or more hospital, doctor, or clinic visits or hospital admissions because of wheezing lower respiratory illnesses. Conclusions: Predominant breast feeding for at least six months and partial breast feeding for up to one year may reduce the prevalence and subsequent morbidity of respiratory illness and infection in infancy.	Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6872, Australia; Curtin Univ Technol, Dept Nutr Dietet & Food Sci, Bentley, WA 6845, Australia; Univ Western Australia, Fac Med & Dent, Nedlands, WA 6872, Australia	Oddy, WH (reprint author), Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, POB 855, Perth, WA 6872, Australia.		Sly, Peter/F-1486-2010; Holt, Patrick/H-1548-2011; Osborne, Nicholas/N-4915-2015; de Klerk, Nicholas/D-8388-2016	Sly, Peter/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935; Osborne, Nicholas/0000-0002-6700-2284; de Klerk, Nicholas/0000-0001-9223-0767			Armitage P, 1996, STAT METHODS MED RES; Ball TM, 1999, PEDIATRICS, V103, P870; BAUCHNER H, 1986, JAMA-J AM MED ASSOC, V256, P887, DOI 10.1001/jama.256.7.887; BEAUDRY M, 1995, J PEDIATR-US, V126, P191, DOI 10.1016/S0022-3476(95)70544-9; Betran AP, 2001, BRIT MED J, V323, P303, DOI 10.1136/bmj.323.7308.303; Cesar JA, 1999, BRIT MED J, V318, P1316; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691; Cushing AH, 1998, AM J EPIDEMIOL, V147, P863; DEWEY KG, 1995, J PEDIATR-US, V126, P696, DOI 10.1016/S0022-3476(95)70395-0; EIGER MS, 1984, CLIN PEDIATR, V23, P492, DOI 10.1177/000992288402300908; Elder DE, 1999, J PAEDIATR CHILD H, V35, P145, DOI 10.1046/j.1440-1754.1999.00308.x; FERGUSSON DM, 1981, AUST PAEDIATR J, V17, P191; Hamosh M, 2001, PEDIATR CLIN N AM, V48, P69, DOI 10.1016/S0031-3955(05)70286-8; Hanson LA, 1999, ACTA PAEDIATR, V88, P42, DOI 10.1080/080352599750029727; Hasselbalch H, 1999, EUR J PEDIATR, V158, P964, DOI 10.1007/s004310051258; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135; HOWIE PW, 1990, BRIT MED J, V300, P11; Jones CA, 2000, CLIN EXP ALLERGY, V30, P599, DOI 10.1046/j.1365-2222.2000.00884.x; KOVAR MG, 1984, PEDIATRICS 2 S, V74, P659; MAGENIS C, 1995, BR J GEN PRACT, V45, P65; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MYERS MG, 1984, AM J DIS CHILD, V138, P629; NEWNHAM JP, 1993, LANCET, V342, P887; Oddy WH, 1999, BRIT MED J, V319, P815; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; PARADISE JL, 1994, PEDIATRICS, V94, P853; RUBIN DH, 1990, PEDIATRICS, V85, P464; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P567, DOI 10.1111/j.1651-2227.1982.tb09476.x; SCARIATI PD, 1997, PEDIATRICS, V99, pE51; TAYLOR B, 1982, LANCET, V1, P1227; Victora CG, 2000, LANCET, V355, P451, DOI 10.1016/S0140-6736(00)82011-5; *WHO, 2001, NOTE PRESS, V7; *WHO, 1995, PONTIF ACAD SCI DOC, V20, P1; Wilson AC, 1998, BRIT MED J, V316, P21; WRIGHT AL, 1989, BRIT MED J, V299, P946; Wright AL, 1998, PEDIATRICS, V101, P837, DOI 10.1542/peds.101.5.837; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	39	112	121	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	MAR	2003	88	3					224	228		10.1136/adc.88.3.224		5	Pediatrics	Pediatrics	652ET	WOS:000181367400013	12598384	
J	von Mutius, E				von Mutius, E			Environmental factors influencing the development and progression of pediatric asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; environmental factors; risk factors; sensitization	ALLERGIC SENSITIZATION; HAY-FEVER; EARLY-CHILDHOOD; CHILDREN; EXPOSURE; COHORT; RISK; AGE; PREVALENCE; COMMUNITY	Recent data underscore the importance of environmental factors in the sensitization of children to certain allergens and the development of asthma. Maternal smoking and family (especially maternal) history of atopy appear to be risk factors for persistent sensitization and development of asthma. Indeed, exposure to tobacco smoke in utero significantly increases asthma risk and influences the timing of sensitization. It must be stated that any smoking at home has consequences for the development of asthma and other respiratory conditions. In addition, reports of possible protective effects of specific environmental conditions suggest that exposure to certain stimuli may reduce or block the development and progression of asthma. Attendance at a day care center early in life appears to offer protective effects against wheezing, as do early episodes of rhinitis, herpes, and measles. Children raised on a farm also have a decreased prevalence of atopic diseases. The protective effect of contact with livestock and poultry is consistent among several studies. Although the pathophysiologic mechanisms involved remain undefined, studies suggest that exposure to endotoxin and other components of bacteria may play an important role in protecting against childhood atopic diseases. Whether in utero exposure is beneficial remains to be determined.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany	von Mutius, E (reprint author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.			von Mutius, Erika/0000-0002-8893-4515			Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Cook DG, 1999, THORAX, V54, P357; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; Strachan DP, 1996, BRIT MED J, V312, P1195; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	19	112	116	0	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6		S			S525	S532		10.1067/mai.2002.124565		8	Allergy; Immunology	Allergy; Immunology	568JU	WOS:000176539300003	12063508	
J	Wolfe, AH; Patz, JA				Wolfe, AH; Patz, JA			Reactive nitrogen and human health: Acute and long-term implications	AMBIO			English	Article; Proceedings Paper	2nd International Nitrogen Conference	OCT, 2001	POTOMAC, MARYLAND				OUTDOOR AIR-POLLUTION; PUBLIC-HEALTH; DRINKING-WATER; DIOXIDE; ASTHMA; OZONE; CONTAMINATION; ENVIRONMENT; ADMISSIONS; MANAGEMENT	Reactive-nitrogen (Nr) has a wide variety of beneficial and detrimental effects on human health. The most important of the beneficial effects are increasing global and regional food supplies and increased nutritional quality of available foods. However, lack of adequate dietary intake of amino acids and proteins is a serious cause of malnutrition when food supplies are inadequate because of poverty, drought, floods, wars, and displacements of people as refugees. There is sufficient, though limited, quantitative data indicating that increased circulation of Nr in the environment is responsible for significant human health effects via other exposure pathways. Nr can lead to harmful health effects from airborne occupational exposures and population-wide indoor and outdoor air pollution exposures to nitrogen dioxide and ozone. Nr can also affect health via water pollution problems, including methemoglobinemia from contaminated ground water, eutrophication causing fish kills and algal blooms that can be toxic to humans, and via global warming. The environmental pollutants stemming from reactive nitrogen are ubiquitous, making it difficult to identify the extent to which Nr exerts a specific health effect. As all populations are susceptible, continued interdisciplinary investigations are needed to determine the extent and nature of the beneficial and harmful effects on human health of nitrogen-related pollutants and their derivatives.	Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Program Hlth Effects Global Environm Change, Baltimore, MD 21205 USA	Wolfe, AH (reprint author), Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Program Hlth Effects Global Environm Change, 615 N Wolfe St, Baltimore, MD 21205 USA.						Amann M, 2000, J HAZARD MATER, V78, P41, DOI 10.1016/S0304-3894(00)00216-8; Anderson HR, 1998, THORAX, V53, P842; ARMSTRONG FB, 1989, BIOCHEMISTRY; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BROWN LR, 1998, ENV TRENDS ARE SHAPI; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Cassman KG, 2002, AMBIO, V31, P132, DOI 10.1639/0044-7447(2002)031[0132:ANUEAN]2.0.CO;2; *CDC, 1999, MMWR-MORBID MORTAL W, V48, P381; *CDC, 2000, MMWR-MORBID MORTAL W, V49, P371; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P202; *COMM LIF CI NAT R, 1989, REC DIET ALL; Council for Agricultural Science and Technology, 1999, 135 COUNC AGR SCI TE; DENNEKAMP M, 2001, J OCCUP ENVIRON MED, V58, P511; DRISCOLL CT, 2001, SCI LINKS PUBLICATIO, V1, P1; Fan AM, 1996, REGUL TOXICOL PHARM, V23, P35, DOI 10.1006/rtph.1996.0006; Galloway JN, 2002, AMBIO, V31, P64, DOI 10.1639/0044-7447(2002)031[0064:RNATWY]2.0.CO;2; GOODLAND R, 1999, LIVESTOCK SECTOR ENV; Goyer N, 2001, AIHAJ, V62, P330, DOI 10.1202/0002-8894(2001)062<0330:EOCCAB>2.0.CO;2; Graczyk TK, 2000, ENVIRON RES, V82, P263, DOI 10.1006/enrs.1999.4022; GUINNUP D, 1997, TELLING OTAG OZONE S, V1; Hajat S, 1999, THORAX, V54, P597; Harrison P., 2001, AAAS ATLAS POPULATIO; HORRIGAN L, IN PRESS ENV HLTH PE; JOHNSON CJ, 1990, AM J IND MED, V18, P449, DOI 10.1002/ajim.4700180416; Knobeloch L, 2000, Environ Health Perspect, V108, P675; Koren HS, 1997, ENVIRON HEALTH PERSP, V105, P534, DOI 10.1289/ehp.97105534; LAST JM, 1993, ANNU REV PUBL HEALTH, V14, P115; LEITZMANN C, 1999, ENCY HUMAN NUTR; Linn W S, 1999, Curr Opin Pulm Med, V5, P21, DOI 10.1097/00063198-199901000-00004; Linn WS, 2000, ENVIRON HEALTH PERSP, V108, P427, DOI 10.2307/3454383; Loomis D, 2000, EPIDEMIOLOGY, V11, P2, DOI 10.1097/00001648-200001000-00002; Martini FH., 1995, FUNDAMENTALS ANATOMY; MCMICHAEL A, 2000, HUMAN HLTH, pCH9; Mueller BA, 2001, ENVIRON HEALTH PERSP, V109, P551, DOI 10.2307/3455026; *NAT ENV RES COUNC, 2001, GLOB NITR ENR; Oenema O, 2002, AMBIO, V31, P159, DOI 10.1639/0044-7447(2002)031[0159:NMIFPA]2.0.CO;2; Patz JA, 2000, ENVIRON HEALTH PERSP, V108, P367, DOI 10.2307/3454357; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; PATZ JA, 2001, ECOSYSTEM CHANGE PUB, P379; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Pimentel D, 1997, BIOSCIENCE, V47, P97, DOI 10.2307/1313020; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258; Schierhorn K, 1999, AM J RESP CELL MOL, V20, P1013; Smith BJ, 2000, EUR RESPIR J, V16, P879, DOI 10.1183/09031936.00.16587900; Socolow RH, 1999, P NATL ACAD SCI USA, V96, P6001, DOI 10.1073/pnas.96.11.6001; SPEIZER FE, 1980, AM REV RESPIR DIS, V121, P3; STIPANUK MH, 2000, BIOCH PHYSL ASPECTS, P212; Suarez-Varela Maria Morales, 1993, Journal of Environmental Pathology Toxicology and Oncology, V12, P229; TOME D, 2000, AM SOC NUTR SCI S, P1868; Tsezou A, 1996, ARCH ENVIRON HEALTH, V51, P458; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Turner RE, 1998, P NATL ACAD SCI USA, V95, P13048, DOI 10.1073/pnas.95.22.13048; *US EPA, 1996, AIR QUAL CRIT OZ REL, V3; *VA DEP HLTH, 1997, PROGR REP LAYS FDN P; Weinberger B, 2001, TOXICOL SCI, V59, P5, DOI 10.1093/toxsci/59.1.5; Weyer PJ, 2001, EPIDEMIOLOGY, V12, P327, DOI 10.1097/00001648-200105000-00013; WEYER PJ, 2001, EPIDEMIOLOGY, V11, P327; *WHO, 1997, ENV HLTH CRIT WHO, V188; Williams CM, 1999, REV ENVIRON CONTAM T, V162, P105; 1981, LANCET, V1, P81	62	112	126	3	43	ROYAL SWEDISH ACAD SCIENCES	STOCKHOLM	PUBL DEPT BOX 50005, S-104 05 STOCKHOLM, SWEDEN	0044-7447			AMBIO	Ambio	MAR	2002	31	2					120	125		10.1639/0044-7447(2002)031[0120:RNAHHA]2.0.CO;2		6	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	557YW	WOS:000175937500010	12078000	
J	Ziska, LH; Caulfield, FA				Ziska, LH; Caulfield, FA			Rising CO2 and pollen production of common ragweed (Ambrosia artemisiifolia), a known allergy-inducing species: implications for public health	AUSTRALIAN JOURNAL OF PLANT PHYSIOLOGY			English	Article						allergens; elevated carbon dioxide; photosynthesis; pollen; relative growth rate	CARBON-DIOXIDE; ELEVATED CO2; GROWTH-RESPONSE; ATMOSPHERIC CO2; UNITED-STATES; ENRICHMENT; PLANTS; PHOTOSYNTHESIS; WEEDS	Although environmental factors such as precipitation and temperature are recognized as influencing pollen production, the impact of rising atmospheric carbon dioxide concentration ([ CO2]) on the potential growth and pollen production of hay- fever- inducing plants is unknown. Here we present measurements of growth and pollen production of common ragweed (Ambrosia artemisiifolia L.) from pre- industrial [CO2] (280 mu mol mol(-1)) to current concentrations (370 mu mol mol(-1)) to a projected 21st century concentration (600 mu mol mol(-1)). We found that exposure to current and elevated [CO2] increased ragweed pollen production by 131 and 320%, respectively, compared to plants grown at pre- industrial [CO2]. The observed stimulations of pollen production from the pre- industrial [CO2] were due to an increase in the number (at 370 mu mol mol(-1)) and number and size (at 600 mu mol mol(-1)) of floral spikes. Overall, floral weight as a percentage of total plant weight decreased (from 21% to 13%), while investment in pollen increased (from 3.6 to 6%) between 280 and 600 mu mol mol(-1) CO2. Our results suggest that the continuing increase in atmospheric [CO2] could directly influence public health by stimulating the growth and pollen production of allergy- inducing species such as ragweed.	ARS, Climate Stress Lab, USDA, Beltsville Agr Res Ctr, Beltsville, MD 20705 USA	Ziska, LH (reprint author), ARS, Climate Stress Lab, USDA, Beltsville Agr Res Ctr, Bldg 046A,10300 Baltimore Ave, Beltsville, MD 20705 USA.						ACKERLY DD, 1995, GLOB CHANGE BIOL, V1, P199, DOI 10.1111/j.1365-2486.1995.tb00021.x; BIANCHI D. E., 1959, BOT GAZ, V120, P235, DOI 10.1086/336030; BUCK P, 1982, ANN ALLERGY, V49, P272; BUNCE JA, 1992, PLANT CELL ENVIRON, V15, P541, DOI 10.1111/j.1365-3040.1992.tb01487.x; CARLSON RW, 1982, OECOLOGIA, V54, P50, DOI 10.1007/BF00541106; Curtis PS, 1998, OECOLOGIA, V113, P299, DOI 10.1007/s004420050381; Deng X, 1998, ANN BOT-LONDON, V81, P67, DOI 10.1006/anbo.1997.0535; Durham OC, 1929, J ALLERGY, V1, P12, DOI 10.1016/S0021-8707(29)90080-0; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Frenz DA, 1999, ANN ALLERG ASTHMA IM, V82, P41, DOI 10.1016/S1081-1206(10)62658-0; Frenz DA, 1999, ANN ALLERG ASTHMA IM, V83, P341, DOI 10.1016/S1081-1206(10)62828-1; FRENZ DA, 1995, ANN ALLERG ASTHMA IM, V75, P417; GARBUTT K, 1984, NEW PHYTOL, V98, P443; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gregory P. H., 1973, MICROBIOLOGY ATMOSPH; Houghton J. T., 1996, IPCC CLIMATE CHANGE; IDSO KE, 1994, AGR FOREST METEOROL, V69, P153, DOI 10.1016/0168-1923(94)90025-6; Jablonski LM, 1997, CAN J BOT, V75, P533; KEELING CD, 1994, TRENDS 93 COMPENDIUM, P20; KIMBALL BA, 1993, VEGETATIO, V104, P65, DOI 10.1007/BF00048145; LAWLOR DW, 1991, PLANT CELL ENVIRON, V14, P807, DOI 10.1111/j.1365-3040.1991.tb01444.x; Meggs WJ, 1996, ARCH ENVIRON HEALTH, V51, P275; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; POORTER H, 1993, VEGETATIO, V104, P77, DOI 10.1007/BF00048146; Reekie JYC, 1997, ANN BOT-LONDON, V80, P57, DOI 10.1006/anbo.1997.0407; ROBINSON JM, 1984, PLANT PHYSIOL, V75, P397, DOI 10.1104/pp.75.2.397; TREMMEL DC, 1993, CAN J PLANT SCI, V73, P1249; WOOLCOCK AJ, 1997, CIBA F SYMP, V206, P123; Ziska LH, 1999, WEED SCI, V47, P608; Ziska LH, 1997, PHOTOSYNTH RES, V54, P199, DOI 10.1023/A:1005947802161	30	112	121	2	21	C S I R O PUBLISHING	COLLINGWOOD	150 OXFORD ST, PO BOX 1139, COLLINGWOOD, VICTORIA 3066, AUSTRALIA	0310-7841			AUST J PLANT PHYSIOL	Aust. J. Plant Physiol.		2000	27	10					893	898				6	Plant Sciences	Plant Sciences	362QU	WOS:000089790400002		
J	Cayrol, C; Girard, JP				Cayrol, Corinne; Girard, Jean-Philippe			IL-33: an alarmin cytokine with crucial roles in innate immunity, inflammation and allergy	CURRENT OPINION IN IMMUNOLOGY			English	Review							T-CELL RESPONSES; LYMPHOID-CELLS; TYPE-2 IMMUNITY; LUNG INFLAMMATION; AIRWAY INFLAMMATION; ENDOGENOUS IL-33; IN-VIVO; ASTHMA; EXPRESSION; ASSOCIATION	IL-33 is a nuclear cytokine from the IL-1 family constitutively expressed in epithelial barrier tissues and lymphoid organs, which plays important roles in type-2 innate immunity and human asthma. Recent studies indicate that IL-33 induces production of large amounts of IL-5 and IL-13 by group 2 innate lymphoid cells (ILC2s), for initiation of allergic inflammation shortly after exposure to allergens or infection with parasites or viruses. IL-33 appears to function as an alarmin (alarm signal) rapidly released from producing cells upon cellular damage or cellular stress. In this review, we discuss the cellular sources, mode of action and regulation of IL-33, and we highlight its crucial roles in vivo with particular emphasis on results obtained using IL33-deficient mice.	[Cayrol, Corinne; Girard, Jean-Philippe] CNRS, IPBS, F-31077 Toulouse, France; [Cayrol, Corinne; Girard, Jean-Philippe] Univ Toulouse, UPS, IPBS, F-31077 Toulouse, France	Girard, JP (reprint author), CNRS, IPBS, 205 Route Narbonne, F-31077 Toulouse, France.	Jean-Philippe.Girard@ipbs.fr	CAYROL, Corinne/C-2106-2011; GIRARD, Jean-Philippe/F-5229-2010		Agence Nationale pour la Recherche [ANR-12-BSV3-0005-01]; Fondation ARC [SL220110603471]	We thank members of the Girard lab for fruitful discussions. Research in Girard lab is supported by grants from Agence Nationale pour la Recherche (ANR-12-BSV3-0005-01) and Fondation ARC (SL220110603471).	Arshad MI, 2012, HEPATOLOGY, V56, P2353, DOI 10.1002/hep.25893; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Barlow JL, 2013, J ALLERGY CLIN IMMUN, V132, P933, DOI 10.1016/j.jaci.2013.05.012; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bessa J, 2014, J AUTOIMMUN; Bonilla WV, 2012, SCIENCE, V335, P984, DOI 10.1126/science.1215418; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Byers DE, 2013, J CLIN INVEST, V123, P3967, DOI 10.1172/JCI65570; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Haenuki Y, 2012, J ALLERGY CLIN IMMUN, V130, p[184, e111]; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Hara K, 2014, J IMMUNOL, V192, P4032, DOI 10.4049/jimmunol.1400110; Hardman CS, 2013, EUR J IMMUNOL, V43, P488, DOI 10.1002/eji.201242863; Hung LY, 2013, P NATL ACAD SCI USA, V110, P282, DOI 10.1073/pnas.1206587110; Kamijo S, 2013, J IMMUNOL, V190, P4489, DOI 10.4049/jimmunol.1201212; Kim BS, 2013, CURR OPIN IMMUNOL, V25, P738, DOI 10.1016/j.coi.2013.07.013; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Lefrancais E, 2012, P NATL ACAD SCI USA, V109, P1673, DOI 10.1073/pnas.1115884109; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Liu X, 2013, P NATL ACAD SCI USA, V110, P14918, DOI 10.1073/pnas.1308651110; Louten J, 2011, INT IMMUNOL, V23, P307, DOI 10.1093/intimm/dxr006; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nakanishi W, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078099; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nussbaum JC, 2013, NATURE, V502, P245, DOI 10.1038/nature12526; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Pichery M, 2012, J IMMUNOL, V188, P3488, DOI 10.4049/jimmunol.1101977; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Ramasamy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044008; Roussel L, 2008, EMBO REP, V9, P1006, DOI 10.1038/embor.2008.145; Salimi M, 2013, J EXP MED, V210, P2939, DOI 10.1084/jem.20130351; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Snelgrove RJ, 2014, J ALLERGY CLIN IMMUN, V134, P583, DOI 10.1016/j.jaci.2014.02.002; Spooner CJ, 2013, NAT IMMUNOL, V14, P1229, DOI 10.1038/ni.2743; Tjota MY, 2013, J CLIN INVEST, V123, P2287, DOI 10.1172/JCI63802; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; Walker JA, 2013, CURR OPIN IMMUNOL, V25, P148, DOI 10.1016/j.coi.2013.02.010; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109	49	111	120	6	29	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915	1879-0372		CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2014	31						31	37		10.1016/j.coi.2014.09.004		7	Immunology	Immunology	AX8BS	WOS:000347136200007	25278425	
J	Sastre, J				Sastre, J.			Molecular diagnosis in allergy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							LIPID-TRANSFER PROTEIN; CONTROLLED FOOD CHALLENGE; NATURAL-RUBBER LATEX; COMPONENT-RESOLVED DIAGNOSIS; EXERCISE-INDUCED ANAPHYLAXIS; PARIETARIA-JUDAICA POLLEN; COWS MILK ALLERGY; HOUSE-DUST MITE; ASPERGILLUS-FUMIGATUS ALLERGENS; PLANTAGO-LANCEOLATA POLLEN	Development and progress made in the field of recombinant allergens have allowed for the development of a new concept in allergy diagnosis, molecular diagnosis (MD), which makes it possible to identify potential disease-eliciting molecules. Microarray-based testing performed with a small amount of serum sample enables clinicians to determine specific-IgE antibodies against multiple recombinants or purified natural allergen components. Performance characteristics of allergens so far tested are comparable with current diagnostic tests, but have to be confirmed in larger studies. The use of allergen components and the successful interpretation of test results in the clinic require some degree of knowledge about the basis of allergen components and their clinical implications. Allergen components can be classified by protein families based on their function and structure. This review provides a brief overview of basic information on allergen components, recombinants or purified, currently available or soon to become commercially available in ImmunoCAP or ISAC (R) systems, including names, protein family and function. Special consideration is given to primary or species-specific sensitization and possible cross-reactivity, because one of the most important clinical utility of MD is its ability to reveal whether the sensitization is genuine in nature (primary, species-specific) or if it is due to cross-reactivity to proteins with similar protein structures, which may help to evaluate the risk of reaction on exposure to different allergen sources. MD can be a support tool for choosing the right treatment for the right patient with the right timing. Such information will eventually give clinicians the possibility to individualize the actions taken, including an advice on targeted allergen exposure reduction, selection of suitable allergens for specific immunotherapy, or the need to perform food challenges. Nevertheless, all in vitro tests should be evaluated together with the clinical history, because allergen sensitization does not necessarily imply clinical responsiveness.	[Sastre, J.] Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain; [Sastre, J.] Univ Autonoma Madrid, Inst Salud Carlos III, CIBER Enfermedades Resp CIBERES, Dept Med,Minist Sci & Innovat, Madrid, Spain	Sastre, J (reprint author), Fdn Jimenez Diaz, Dept Allergy, Av Reyes Catolicos 2, E-28040 Madrid, Spain.	jsastre@fjd.es			Novartis; GSK; Stallergenes; UCB; Phadia; ALK-Abello	Joaquin Sastre reports having served as a consultant to Phadia, Schering-Plough and GSK, having been paid lecture fees by Novartis, GSK, Stallergenes, UCB and having received grant support from Phadia, GSK and ALK-Abello.	Ahrazem O, 2006, INT ARCH ALLERGY IMM, V139, P96, DOI 10.1159/000090384; Akkerdaas JH, 2005, INT ARCH ALLERGY IMM, V138, P203, DOI 10.1159/000088720; Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; Andersen MBS, 2011, CLIN REV ALLERG IMMU, V41, P4, DOI 10.1007/s12016-009-8177-3; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Ando H, 2008, J ALLERGY CLIN IMMUN, V122, P583, DOI 10.1016/j.jaci.2008.06.016; Arilla MC, 2004, INT ARCH ALLERGY IMM, V134, P10, DOI 10.1159/000077528; Arruda LK, 2005, CURR ALLERGY ASTHM R, V5, P411, DOI 10.1007/s11882-005-0015-y; Arruda LK, 2001, J ALLERGY CLIN IMMUN, V107, P419, DOI 10.1067/mai.2001.112854; ASARNOJ A, 2009, ALLERGY, V65, P213; Asero R, 2005, INT ARCH ALLERGY IMM, V138, P1, DOI 10.1159/000087352; Asero R, 2004, ANN ALLERG ASTHMA IM, V92, P268; Asero R, 1999, ANN ALLERG ASTHMA IM, V83, P377, DOI 10.1016/S1081-1206(10)62834-7; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Asturias JA, 2006, CLIN EXP ALLERGY, V36, P1505, DOI 10.1111/j.1365-2222.2006.02591.x; Asturias JA, 2000, ALLERGY, V55, P898, DOI 10.1034/j.1398-9995.2000.00734.x; Asturias JA, 2003, CLIN EXP ALLERGY, V33, P518, DOI 10.1046/j.1365-2222.2003.01631.x; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023; Ayuso R, 2009, J ALLERGY CLIN IMMUN, V124, P114, DOI 10.1016/j.jaci.2009.04.016; Ballmer-Weber BK, 2008, CURR OPIN ALLERGY CL, V8, P270, DOI 10.1097/ACI.0b013e3282ffb157; Ballmer-Weber BK, 2007, J ALLERGY CLIN IMMUN, V119, P1489, DOI 10.1016/j.jaci.2007.01.049; Ballmer-Weber BK, 2005, CLIN EXP ALLERGY, V35, P970, DOI 10.1111/j.1365-2222.2005.02294.x; Ballmer-Weber BK, 2001, J ALLERGY CLIN IMMUN, V108, P301, DOI 10.1067/mai.2001.116430; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Barber D, 2009, CLIN EXP ALLERGY, V39, P1764, DOI 10.1111/j.1365-2222.2009.03351.x; Barderas R, 2007, CLIN EXP ALLERGY, V37, P1111, DOI 10.1111/j.1365-2222.2007.02744.x; Barre A, 2005, BIOCHIMIE, V87, P499, DOI 10.1016/j.biochi.2005.02.011; Barre A, 2007, MOL IMMUNOL, V44, P3243, DOI 10.1016/j.molimm.2007.01.023; Battais F, 2003, CLIN EXP ALLERGY, V33, P962, DOI 10.1046/j.1365-2222.2003.01592.x; Bauermeister K, 2009, J ALLERGY CLIN IMMUN, V124, P1273, DOI 10.1016/j.jaci.2009.07.033; Beardslee TA, 2000, INT ARCH ALLERGY IMM, V123, P299, DOI 10.1159/000053642; Benhamou AH, 2009, ALLERGY, V65, P283; BERNHISELBROADB.J, 1994, J ALLERGY CLIN IMMUN, V93, P1047; Beyer K, 2002, J ALLERGY CLIN IMMUN, V110, P154, DOI 10.1067/mai.2002.125487; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Binder M, 2001, J IMMUNOL, V167, P5470; Boyano Martnez T, 2001, CLIN EXP ALLERGY, V31, P1464; BUBLIN M, J ALLERGY CLIN IMMUN, V125, P687; BUGAJSKASCHRETTER, 1998, J ALLERGY CLIN IMM 1, V101, P67; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Caballero ML, 2002, ANN ALLERG ASTHMA IM, V89, P74; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; Calabozo B, 2003, BIOCHEM J, V372, P889, DOI 10.1042/BJ20021491; Calabozo B, 2001, CLIN EXP ALLERGY, V31, P322, DOI 10.1046/j.1365-2222.2001.00985.x; Caraballo L, 1998, INT ARCH ALLERGY IMM, V117, P38, DOI 10.1159/000023988; Cardaba B, 1998, CLIN EXP ALLERGY, V28, P413; Carnes J, 2003, ALLERGY, V58, P1152, DOI 10.1034/j.1398-9995.2003.00269.x; Casaulta C, 2005, PEDIATR ALLERGY IMMU, V16, P217, DOI 10.1111/j.1399-3038.2005.00262.x; Chardin H, 2002, INT ARCH ALLERGY IMM, V128, P195, DOI 10.1159/000064252; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; Chen ZP, 1997, J ALLERGY CLIN IMMUN, V100, P684, DOI 10.1016/S0091-6749(97)70174-X; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; Commins SP, 2009, J ALLERGY CLIN IMMUN, V124, P652, DOI 10.1016/j.jaci.2009.08.026; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; DE GRAAF DC, 2009, J PROTEOMICS, V72, P145; DE LEON MP, 2007, MOL IMMUNOL, V44, P463; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385; Diaz-Perales A, 2003, J ALLERGY CLIN IMMUN, V112, P1002, DOI [10.1067/mai.2003.1782, 10.1016/j.jaci.2003.07.006]; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; Drew AC, 2004, J IMMUNOL, V173, P5872; Durauer A, 2000, J CHROMATOGR A, V890, P145, DOI 10.1016/S0021-9673(00)00241-7; Duro G, 1996, FEBS LETT, V399, P295, DOI 10.1016/S0014-5793(96)01328-2; EBO DG, CLIN EXP ALLERGY, V40, P348; Egger M, 2006, ALLERGY, V61, P461, DOI 10.1111/j.1398-9995.2006.00994.x; Enrique E, 2004, J INVEST ALLERG CLIN, V14, P335; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; ESCH RE, 2008, ALLERGY, V21, P107; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Fernandez-Caldas Enrique, 2008, Clin Allergy Immunol, V21, P161; Fernandez-Rivas M, 2006, J ALLERGY CLIN IMMUN, V118, P481, DOI 10.1016/j.jaci.2006.05.012; Ferrer M, 2009, J INVEST ALLERG CLIN, V19, P19; Flinterman AE, 2007, CLIN EXP ALLERGY, V37, P1221, DOI 10.1111/j.1365-2222.2007.02764.x; Flinterman AE, 2008, CURR OPIN ALLERGY CL, V8, P261, DOI 10.1097/ACI.0b013e3282ffb145; Fujimura T, 2004, INT ARCH ALLERGY IMM, V133, P125, DOI 10.1159/000076438; Gadermaier G, 2009, MOL IMMUNOL, V46, P1919, DOI 10.1016/j.molimm.2009.03.021; Gall H, 2000, ALLERGY, V55, P1096, DOI 10.1034/j.1398-9995.2000.00812.x; Garcia-Robaina JC, 1998, J INVEST ALLERG CLIN, V8, P285; Garcia-Selles FJ, 2002, INT ARCH ALLERGY IMM, V128, P115, DOI 10.1159/000059401; Gonzalez-Mancebo E, 2008, J ALLERGY CLIN IMMUN, V121, P1507, DOI 10.1016/j.jaci.2008.01.029; Gronlund H, 2009, INT ARCH ALLERGY IMM, V151, P265; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hansen KS, 2009, J ALLERGY CLIN IMMUN, V123, P1134, DOI 10.1016/j.jaci.2009.02.005; Hejl C, 2009, CLIN EXP ALLERGY, V39, P752, DOI 10.1111/j.1365-2222.2008.03195.x; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.3.CO;2-Y; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P1251, DOI 10.1111/j.1365-2222.2004.02046.x; Henriksen A, 2001, PROTEINS, V45, P438, DOI 10.1002/prot.1160; Hilger C, 1997, ALLERGY, V52, P179, DOI 10.1111/j.1398-9995.1997.tb00972.x; Himly Martin, 2003, FASEB Journal, V17, P106; Hoffmann-Sommergruber K, 2009, ANAL BIOANAL CHEM, V395, P25, DOI 10.1007/s00216-009-2953-z; Holzhauser T, 2009, J ALLERGY CLIN IMMUN, V123, P452, DOI 10.1016/j.jaci.2008.09.034; Jacquenet S, 2009, INT ARCH ALLERGY IMM, V149, P74, DOI 10.1159/000176309; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; Jarvinen K. M., 2007, Allergy, V62, P758; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jimeno L, 2004, ALLERGY, V59, P995, DOI 10.1111/j.1398-9995.2004.00464.x; Jin C, 2008, J ALLERGY CLIN IMMUN, V121, P185, DOI 10.1016/j.jaci.2007.07.047; Johansen N, 2009, INT ARCH ALLERGY IMM, V150, P325, DOI 10.1159/000226233; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Karisola P, 2005, J ALLERGY CLIN IMMUN, V115, P598, DOI 10.1016/j.jaci.2004.09.015; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Krause S, 2009, J ALLERGY CLIN IMMUN, V124, P771, DOI 10.1016/j.jaci.2009.06.008; Kurup VP, 2000, MICROBES INFECT, V2, P1101, DOI 10.1016/S1286-4579(00)01264-8; Kurup VP, 2003, CURR ALLERGY ASTHM R, V3, P416, DOI 10.1007/s11882-003-0078-6; Lauer I, 2007, CLIN EXP ALLERGY, V37, P261, DOI 10.1111/j.1365-2222.2007.02653.x; Lauer I, 2009, CLIN EXP ALLERGY, V39, P1427, DOI 10.1111/j.1365-2222.2009.03312.x; Leb VM, 2008, J ALLERGY CLIN IMMUN, V121, P64, DOI 10.1016/j.jaci.2007.10.006; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Leonard R, 2005, J BIOL CHEM, V280, P7932, DOI 10.1074/jbc.M410407200; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Lluch-Bernal M, 2002, J INVEST ALLERG CLIN, V12, P21; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Lopata AL, 2009, CURR OPIN ALLERGY CL, V9, P270, DOI 10.1097/ACI.0b013e32832b3e6f; Caballero ML, 2008, PARASITOL RES, V103, P1231, DOI 10.1007/s00436-008-1105-2; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Ma Y, 2008, MOL NUTR FOOD RES, V52, pS196, DOI 10.1002/mnfr.200700284; Malandain H, 2007, Eur Ann Allergy Clin Immunol, V39, P216; Mari A, 2008, CLIN EXP ALLERGY, V38, P1089, DOI 10.1111/j.1365-2222.2008.03011.x; Marknell D. A., 2002, CLIN EXP ALLERGY, V32, P1329, DOI 10.1046/j.1365-2222.2002.01467.x; Martinez A, 2002, ALLERGY, V57, P17, DOI 10.1034/j.1398-9995.2002.057s71017.x; Matsuo H, 2005, J IMMUNOL, V175, P8116; Mattsson L, 2009, J ALLERGY CLIN IMMUN, V123, P362, DOI 10.1016/j.jaci.2008.11.021; McDermott RA, 2007, CLIN EXP ALLERGY, V37, P752, DOI 10.1111/j.1365-2222.2007.02701.x; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mohapatra Shyam S, 2008, Clin Allergy Immunol, V21, P127; Mohapatra SS, 2005, CURR ALLERGY ASTHM R, V5, P381, DOI 10.1007/s11882-005-0011-2; Mothes N, 2004, CURR ALLERGY ASTHM R, V4, P384, DOI 10.1007/s11882-004-0089-y; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Muller UR, 2009, ALLERGY, V64, P543, DOI 10.1111/j.1398-9995.2008.01794.x; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; NICOLAOU N, J ALLERGY CLIN IMMUN, V125, P191; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Oberhuber C, 2008, MOL NUTR FOOD RES, V52, pS230, DOI 10.1002/mnfr.200800146; Ott H, 2008, ALLERGY, V63, P1521, DOI 10.1111/j.1398-9995.2008.01748.x; Palacin A, 2008, CLIN EXP ALLERGY, V38, P1220, DOI 10.1111/j.1365-2222.2007.02927.x; Palacin A, 2009, CLIN EXP ALLERGY, V39, P1267, DOI 10.1111/j.1365-2222.2009.03280.x; Palacin A, 2008, ANN ALLERG ASTHMA IM, V101, P200, DOI 10.1016/S1081-1206(10)60210-4; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; Palomares O, 2005, CLIN EXP ALLERGY, V35, P345, DOI [10.1111/j.1365-2222.2004.02186.x, 10.1111/j.1365-2222.2005.02186.x]; Palomares O, 2006, INT ARCH ALLERGY IMM, V141, P110, DOI 10.1159/000094713; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Palosuo K, 2001, J ALLERGY CLIN IMMUN, V108, P634, DOI 10.1067/mai.2001.118602; Pamies R, 2006, PEDIATR ALLERGY IMMU, V17, P55, DOI 10.1111/j.1399-3038.2005.00341.x; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V102, P1021, DOI 10.1016/S0091-6749(98)70341-0; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V110, P310, DOI 10.1067/mai.2002.125830; Pastorello EA, 2004, J ALLERGY CLIN IMMUN, V114, P908, DOI 10.1016/j.jaci.2004.06.020; Pastorello EA, 2001, ALLERGY, V56, P45, DOI 10.1034/j.1398-9995.2001.00914.x; Pastorello EA, 2007, INT ARCH ALLERGY IMM, V144, P10, DOI 10.1159/000102609; PAULL BR, 1977, J ALLERGY CLIN IMMUN, V59, P334, DOI 10.1016/0091-6749(77)90056-2; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Perez-Perez J, 2000, INT ARCH ALLERGY IMM, V123, P120, DOI 10.1159/000024442; Phipatanakul W, 2007, J ALLERGY CLIN IMMUN, V120, P954, DOI 10.1016/j.jaci.2007.05.010; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Platts-Mills TAE, 2007, J ALLERGY CLIN IMMUN, V120, P1058, DOI 10.1016/j.jaci.2007.06.032; Posch A, 1998, CLIN EXP ALLERGY, V28, P134; Quirce S, 2001, ALLERGY, V56, P754, DOI 10.1034/j.1398-9995.2001.056008754.x; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Raulf-Heimsoth M, 2007, CLIN EXP ALLERGY, V37, P1657, DOI 10.1111/j.1365-2222.2007.02833.x; Reese G, 2006, CLIN EXP ALLERGY, V36, P517, DOI 10.1111/j.1365-2222.2006.02454.x; Restani P, 2009, ANAL BIOANAL CHEM, V395, P47, DOI 10.1007/s00216-009-2909-3; Rodriguez R, 2007, J INVEST ALLERG CLIN, V17, P4; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; Roux KH, 2003, INT ARCH ALLERGY IMM, V131, P234, DOI 10.1159/000072135; Saarelainen S, 2008, CLIN EXP ALLERGY, V38, P374, DOI 10.1111/j.1365-2222.2007.02895.x; Saarelainen S, 2004, CLIN EXP ALLERGY, V34, P1576, DOI 10.1111/j.1365-2222.2004.02071.x; Salo PW, 2009, ENVIRON HEALTH PERSP, V117, P387, DOI 10.1289/ehp.11847; Sastre J, 2006, ALLERGY, V61, P206, DOI 10.1111/j.1398-9995.2006.00976.x; Sastre J, 2004, ALLERGY, V59, P1181, DOI 10.1111/j.1398-9995.2004.00530.x; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Sastre J, 2000, ALLERGY, V55, P560, DOI 10.1034/j.1398-9995.2000.00422.x; Satoh R, 2008, BIOL PHARM BULL, V31, P1079, DOI 10.1248/bpb.31.1079; Schocker F, 2004, J ALLERGY CLIN IMMUN, V113, P141, DOI 10.1016/j.jaci.2003.09.013; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Simon-Nobbe Birgit, 2008, Int Arch Allergy Immunol, V145, P58, DOI 10.1159/000107578; Simon-Nobbe B, 2006, J BIOL CHEM, V281, P16354, DOI 10.1074/jbc.M513638200; Slater JE, 1996, J BIOL CHEM, V271, P25394; Smith W, 2004, CLIN EXP ALLERGY, V34, P1732, DOI 10.1111/j.1365-2222.2004.02090.x; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; Stumvoll S, 2003, J ALLERGY CLIN IMMUN, V111, P974, DOI 10.1067/mai.2003.1376; Sutherland MF, 2002, CLIN EXP ALLERGY, V32, P583, DOI 10.1046/j.0954-7894.2002.01355.x; Swoboda I, 2002, J IMMUNOL, V168, P4576; Swoboda Ines, 2008, Clin Allergy Immunol, V21, P87; Tamburrini M, 2005, PROTEIN J, V24, P423, DOI 10.1007/s10930-005-7638-7; Tanaka K, 2002, INT ARCH ALLERGY IMM, V129, P49, DOI 10.1159/000065173; Teuber SS, 2002, J AGR FOOD CHEM, V50, P6543, DOI 10.1021/jf025757j; Teuber SS, 1998, J ALLERGY CLIN IMMUN, V101, P807, DOI 10.1016/S0091-6749(98)70308-2; Teuber SS, 1999, J ALLERGY CLIN IMMUN, V104, P1311, DOI 10.1016/S0091-6749(99)70029-1; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Tsai JJ, 2003, ANN ALLERG ASTHMA IM, V91, P485; Unger A, 1999, INT ARCH ALLERGY IMM, V118, P220, DOI 10.1159/000024076; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; VAN DO T, 2005, MOL IMMUNOL, V42, P345; VAN REE R, 1999, J ALLERGY CLIN IMMUN, V104, P1223; vanRee R, 1996, ALLERGY, V51, P108; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Wal JM, 2004, ANN ALLERG ASTHMA IM, V93, pS2; Wallowitz M, 2006, J AGR FOOD CHEM, V54, P8369, DOI 10.1021/jf061329s; Wang F, 2003, INT ARCH ALLERGY IMM, V132, P27, DOI 10.1159/000073262; Wensing M, 2003, J ALLERGY CLIN IMMUN, V111, P420, DOI 10.1067/mai.2003.61; Wohrl S, 2006, ALLERGY, V61, P633, DOI 10.1111/j.1398-9995.2006.01078.x; Yagami A, 2009, J DERMATOL, V36, P50, DOI 10.1111/j.1346-8138.2008.00585.x; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Yu CJ, 2003, J IMMUNOL, V170, P445; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5	215	111	120	5	24	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2010	40	10					1442	1460		10.1111/j.1365-2222.2010.03585.x		19	Allergy; Immunology	Allergy; Immunology	647RJ	WOS:000281636000003	20682003	
J	Fitzpatrick, AM; Gaston, BM; Erzurum, SC; Teague, WG				Fitzpatrick, Anne M.; Gaston, Benjamin M.; Erzurum, Serpil C.; Teague, W. Gerald		Natl Inst Hlth; Natl Heart Lung Blood Inst Severe	Features of severe asthma in school-age children: Atopy and increased exhaled nitric oxide	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; asthma; atopy; nitric oxide; pulmonary function testing	TO-TREAT ASTHMA; CHILDHOOD ASTHMA; DIFFICULT ASTHMA; EOSINOPHILIC INFLAMMATION; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; ALLERGEN EXPOSURE; RISK-FACTORS; DISPARITIES; POPULATION	Background: Children with severe asthma have persistent symptoms despite treatment with inhaled corticosteroids (ICSs). The differentiating features of severe asthma in children are poorly defined. Objective: To identify features of severe versus mild-to-moderate asthma in school-age children using noninvasive assessments of lung function, atopy, and airway inflammation. Methods: A total of 75 children (median age, 10 years) with asthma underwent baseline characterization including spirometry and lung volume testing, methacholine bronchoprovocation, allergy evaluation, and offline measurement of exhaled nitric oxide (F-ENO). Twenty-eight were followed longitudinally over 6 months. Participants were assigned to the severe asthma subgroup if they required high-dose ICS plus 2 or more minor criteria. Results: Children with severe versus mild-to-moderate asthma had more symptoms, greater airway obstruction, more gas trapping, and increased bronchial responsiveness to methacholine. Subjects with severe asthma also had higher concentrations of F-ENO and significantly greater sensitization to aeroallergens. With long-term study, both the reduction in FEVI and increase in F-ENO persisted in the severe versus mild-to-moderate group. Furthermore, despite adjustments in ICS doses, the frequency of exacerbations was significantly higher in subjects with severe (83%) versus mild-to-moderate asthma (43%). Conclusion: Severe asthma in childhood is characterized by poor symptom control despite high-dose ICS treatment and can be differentiated from mild-to-moderate asthma by measurement of lung function and F-ENO. Clinical implications: Clinicians should suspect severe asthma in children with poor response to ICS, airway obstruction, and high F-ENO.	Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Univ Virginia, Dept Pediat, Charlottesville, VA 22903 USA	Fitzpatrick, AM (reprint author), Emory Univ, Sch Med, Dept Pediat, 2015 Uppergate Dr, Atlanta, GA 30322 USA.	anne.fitzpatrick@emory.edu			NHLBI NIH HHS [R01 HL069170-06, R01 HL069170, R01 HL69170]		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; *AM THOR SOC EUR R, 2005, AM H RESP CRIT CARE, V181, P912; Berkman N, 2005, THORAX, V60, P383, DOI 10.1136/thx.2004.031104; Borish L, 2005, ANN ALLERG ASTHMA IM, V95, P247; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; de Kluijver J, 2002, AM J RESP CRIT CARE, V166, P294, DOI 10.1164/rccm.2112097; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Higgins PS, 2005, CHEST, V128, P3846, DOI 10.1378/chest.128.6.3846; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; JONES SL, 2002, EUR RESPIR J, V60, P601; McDaniel M, 2006, PEDIATRICS, V117, pE868, DOI 10.1542/peds.2005-1721; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; *NAT ASTHM ED PREV, 2003, 025075 NAT HEART LUN; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376; Payne DNR, 2001, THORAX, V56, P345, DOI 10.1136/thorax.56.5.345; Pearlman DN, 2006, J NATL MED ASSOC, V98, P239; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Stirling RG, 1998, THORAX, V53, P1030; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383; Woodhead M, 2002, EUR RESPIR J, V20, P1, DOI 10.1183/09031936.02.01042002; Wraight JM, 2002, RESPIROLOGY, V7, P133, DOI 10.1046/j.1440-1843.2002.00374.x	37	111	112	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1218	1225		10.1016/j.jaci.2006.08.019		8	Allergy; Immunology	Allergy; Immunology	117NP	WOS:000242880300003	17157650	
J	Sakaguchi, H; Ashikaga, T; Miyazawa, M; Yoshida, Y; Ito, Y; Yoneyama, K; Hirota, M; Itagaki, H; Toyoda, H; Suzuki, H				Sakaguchi, H; Ashikaga, T; Miyazawa, M; Yoshida, Y; Ito, Y; Yoneyama, K; Hirota, M; Itagaki, H; Toyoda, H; Suzuki, H			Development of an in vitro skin sensitization test using human cell lines; human Cell Line Activation Test (h-CLAT) II. An inter-laboratory study of the h-CLAT	TOXICOLOGY IN VITRO			English	Article						THP-1; U-937; CD86; CD54; inter laboratory; validation; cell line; in vitro skin sensitization	EPIDERMAL LANGERHANS CELLS; DENDRITIC CELLS; CONTACT ALLERGENS; T-CELLS; COSTIMULATORY MOLECULES; EXPRESSION; IRRITANTS; CHEMICALS; EXPOSURE; HAPTENS	Recent regulatory changes have placed a major emphasis on in vitro, safety testing and alternative models. In regard to skin sensitization tests, dendritic cells (DCs) derived from human peripheral blood have been considered in the development of new in vitro alternatives. Human cell lines have been also reported recently. In our previous study, we suggested that measuring CD86 and/or CD54 expression on THP-1 cells (human monocytic leukemia cell line) could be used as an in vitro skin sensitization method. An inter-laboratory study among two laboratories was undertaken in Japan in order to further develop an in vitro skin sensitization model. In the present study, we used two human cell lines: THP-1 and U-937 (human histiocytic lymphoma cell line). First we optimized our test protocol (refer to the related paper entitled "optimization of the h-CLAT protocol" within this journal) and then we did an inter-laboratory validation with nine chemicals using the optimized protocol. We measured the expression of CD86 and CD54 on the above cells using flow cytometry after a 24 h and 48 h exposure to six known allergens (e.g., DNCB, pPD, NiSO4) and three non-allergens (e.g., SLS, tween 80). For the sample test concentration, four doses (0.1x, 0.5x, 1x, and 2x of the 50% inhibitory concentration (IC50)) were evaluated. IC50 was calculated using MTT assay. We found that allergens/non-allergens were better predicted using THP-1 cells compared to U-937 cells following a 24 h and a 48 h exposure. We also found that the 24 h treatment time tended to have a better accuracy than the 48 h treatment time for THP-1 cells. Expression of CD86 and CD54 were good predictive markers for THP-1 cells, but for U-937 cells, expression of CD86 was a better predictor than CD54, at the 24 h and the 48 h treatment time. The accuracy also improved when both markers (CD86 and CD54) were used as compared with a single marker for THP-1 cells. Both laboratories gave a good prediction of allergen/non-allergen, especially using THP-1 cells. These results suggest that our method, human Cell Line Activation Test (h-CLAT), using human cell lines THP-1 and U-937, but especially THP-1 cells at 24 h treatment, may be a useful in vitro skin sensitization model to predict various contact allergens. (c) 2005 Elsevier Ltd. All rights reserved.	Kao Corp, Safety & Microbial Control Res Ctr, Haga, Tochigi 3213497, Japan; Shiseido Co Ltd, Safety & Analyt Res Ctr, Kanazawa Ku, Yokohama, Kanagawa 2368643, Japan	Sakaguchi, H (reprint author), Kao Corp, Safety & Microbial Control Res Ctr, 2606 Akabane, Haga, Tochigi 3213497, Japan.	sakaguchi.hitoshi@kao.co.jp		Itagaki, Hiroshi/0000-0001-9756-0730			Aeby P, 2004, J INVEST DERMATOL, V122, P1154, DOI 10.1111/j.0022-202X.2004.22402.x; Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Ashikaga T, 2002, TOXICOL IN VITRO, V16, P711, DOI 10.1016/S0887-2333(02)00060-7; ASHIKAGA T, 2003, P 28 ANN M JAP COSM; BECKER D, 1994, J IMMUNOL METHODS, V169, P195, DOI 10.1016/0022-1759(94)90263-1; Boisleve F, 2004, J INVEST DERMATOL, V123, P494, DOI 10.1111/j.0022-202X.2004.23229.x; Champagne B, 1998, J IMMUNOL, V161, P6398; Coutant KD, 1999, TOXICOL SCI, V52, P189, DOI 10.1093/toxsci/52.2.189; De Smedt ACA, 2002, ARCH DERMATOL RES, V294, P109, DOI 10.1007/s00403-002-0296-0; Hulette BC, 2002, TOXICOL APPL PHARM, V182, P226, DOI 10.1006/taap.2002.9447; Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201; IWAMOTO S, 1999, DENDRITIC CELLS, V9, P41; Krasteva M, 1996, CLIN EXP ALLERGY, V26, P563, DOI 10.1046/j.1365-2222.1996.d01-342.x; Mossmann T, 1983, J IMMUNOL METHODS, V6, P55; MOULON C, 1993, IMMUNOLOGY, V80, P373; PYTHON F, 2004, P 10 INT C TOX; Rizova H, 1999, BRIT J DERMATOL, V140, P200, DOI 10.1111/j.1365-2133.1999.02650.x; Rougier N, 2000, TOXICOLOGY, V145, P73, DOI 10.1016/S0300-483X(99)00222-X; ROUSSET F, 2002, CONTACT DERMATITIS, V46, P6; Rustemeyer T, 2003, EXP DERMATOL, V12, P682, DOI 10.1034/j.1600-0625.2003.00077.x; Ryan CA, 2004, TOXICOL LETT, V150, P301, DOI 10.1016/j.toxlet.2004.02.002; Ryan CA, 2001, TOXICOL IN VITRO, V15, P43, DOI 10.1016/S0887-2333(00)00059-X; SAKAGUCHI H, 2003, P 17 ANN M JAP SOC A; Staquet MJ, 2004, TOXICOL IN VITRO, V18, P493, DOI 10.1016/j.tiv.2003.12.005; Verrier AC, 1999, INT ARCH ALLERGY IMM, V120, P56, DOI 10.1159/000024220; Yoshida Y, 2003, TOXICOL IN VITRO, V17, P221, DOI 10.1016/S0887-2333(03)00006-7	26	111	115	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-2333			TOXICOL IN VITRO	Toxicol. Vitro	AUG	2006	20	5					774	784		10.1016/j.tiv.2005.10.014		11	Toxicology	Toxicology	058YP	WOS:000238700800029	16337770	
J	Lannero, E; Wickman, M; Pershagen, G; Nordvall, L				Lannero, E; Wickman, M; Pershagen, G; Nordvall, L			Maternal smoking during pregnancy increases the risk of recurrent wheezing during the first years of life (BAMSE)	RESPIRATORY RESEARCH			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CHILDHOOD LUNG-FUNCTION; RESPIRATORY-FUNCTION; IN-UTERO; PARENTAL SMOKING; PASSIVE SMOKING; ASTHMA; EXPOSURE; CHILDREN; BRONCHITIS	Background: Exposure to cigarette smoking during foetal and early postnatal life may have implications for lung health. The aim of this study was to assess the possible effects of such exposure in utero on lower respiratory disease in children up to two years of age. Methods: A birth cohort of 4089 newborn infants was followed for two years using parental questionnaires. When the infant was two months old the parents completed a questionnaire on various lifestyle factors, including maternal smoking during pregnancy and after birth. At one and two years of age information was obtained by questionnaire on symptoms of allergic and respiratory diseases as well as on environmental exposures, particularly exposure to environmental tobacco smoke (ETS). Adjustments were made for potential confounders. Results: When the mother had smoked during pregnancy but not after that, there was an increased risk of recurrent wheezing up to two years' age, ORadj = 2.2, (95% CI 1.3-3.6). The corresponding OR was 1.6, ( 95% CI 1.2-2.3) for reported exposure to ETS with or without maternal smoking in utero. Maternal smoking during pregnancy but no exposure to ETS also increased the risk of doctor's diagnosed asthma up to two years of age, ORadj = 2.1, ( 95% CI 1.2-3.7). Conclusion: Exposure to maternal cigarette smoking in utero is a risk factor for recurrent wheezing, as well as doctor's diagnosed asthma in children up to two years of age.	Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Karolinska Univ Hosp, Dept Paediat, Huddinge, Sweden; Stockholm Cty Council, Dept Environm & Occupat Hlth, Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Uppsala Univ, Dept Womens & Childrens Hlth, Uppsala, Sweden	Lannero, E (reprint author), Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden.	eva.lannero@kbh.ki.se; magnus.wickman@sll.se; goran.pershagen@ki.se; lennart.nordvall@kbh.uu.se					Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Elliot J, 1998, AM J RESP CRIT CARE, V158, P802; Elliot JG, 2003, AM J RESP CRIT CARE, V167, P45, DOI 10.1164/rccm.2110005; Foundas M, 1997, AUST NZ J OBSTET GYN, V37, P383, DOI 10.1111/j.1479-828X.1997.tb02443.x; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Hoo AF, 1998, AM J RESP CRIT CARE, V158, P700; Horta BL, 1997, PAEDIATR PERINAT EP, V11, P140, DOI 10.1046/j.1365-3016.1997.d01-17.x; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; LANNERO E, 2002, PAEDIAT ALLERGY IMMU, V13, P1; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; Lodrup Carlsen K C, 1997, Eur Respir J, V10, P1774, DOI 10.1183/09031936.97.10081774; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517; Statistics Sweden, 1989, OCC POP HOUS CENS 19; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1997, THORAX, V52, P905; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Wennergren G, 1997, ACTA PAEDIATR, V86, P351, DOI 10.1111/j.1651-2227.1997.tb09021.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; WICKMAN M, 1992, PEDIATRIC ALLERGY IM, V3, P128, DOI 10.1111/j.1399-3038.1992.tb00036.x; Young S, 2000, PEDIATR PULM, V29, P331, DOI 10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A	26	111	119	0	5	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1465-9921			RESP RES	Respir. Res.	JAN 5	2006	7								3	10.1186/1465-9921-7-3		6	Respiratory System	Respiratory System	008ZD	WOS:000235080000001	16396689	
J	Brannan, JD; Anderson, SD; Perry, CP; Freed-Martens, R; Lassig, AR; Charlton, B				Brannan, JD; Anderson, SD; Perry, CP; Freed-Martens, R; Lassig, AR; Charlton, B		Aridol Study Grp	The safety and efficacy of inhaled dry powder mannitol as a bronchial provocation test for airway hyperresponsiveness: a phase 3 comparison study with hypertonic (4.5%) saline	RESPIRATORY RESEARCH			English	Article							ASTHMATIC SUBJECTS; INDUCED BRONCHOCONSTRICTION; EPIDEMIOLOGIC SURVEY; CHALLENGE; RESPONSIVENESS; EXERCISE; CHILDREN; METHACHOLINE; SENSITIVITY; HYPERVENTILATION	Background: Inhaled mannitol is a new bronchial provocation test (BPT) developed to improve portability and standardisation of osmotic challenge testing. Osmotic challenge tests have an advantage over the traditional methods of measuring airway hyperresponsiveness using methacholine as they demonstrate higher specificity to identify asthma and thus the need for treatment with inhaled corticosteroids (ICS). The safety and the efficacy of mannitol (M) as a BPT to measure airway hyperresponsiveness were compared to hypertonic (4.5%) saline (HS) in people both with and without signs and symptoms of asthma. Methods: A phase III, multi-centre, open label, operator-blinded, crossover design, randomised trial, with follow-up. Asthmatics and non-asthmatics (6-83 yr) were recruited and 592 subjects completed the study. Mannitol was delivered using a low resistance dry powder inhaler and HS was delivered using an ultrasonic nebuliser. The FEV1 was measured 60 seconds after each dose of mannitol (5,10,20,40,80,160,160,160 mg) and after each exposure to HS (0.5,1.0,2.0,4.0,8.0 minutes). A 15% fall in FEV1 defined a positive test. Adverse events were monitored and diaries kept for 7 days following the tests. Results: Mean pre-test FEV1 (mean +/- SD) was 95.5 +/- 14% predicted. 296 were positive to mannitol (M+) and 322 positive to HS (HS+). A post study physician conducted clinical assessment identified 82.3% asthmatic (44% classified mild) and 17.7% non-asthmatic. Of those M+, 70.1% were taking ICS and of those mannitol negative (M-), 81.1% were taking ICS. The % fall in FEV1 for mannitol in asthmatics was 21.0% +/- 5.7 and for the non-asthmatics, 5.5% +/- 4.8. The median PD15 M was 148 mg and PD15 HS 6.2 ml. The sensitivity of M to identify HS+ was 80.7% and the specificity 86.7%. The sensitivity of M compared with the clinical assessment was 59.8% and specificity 95.2% and increased to 88.7% and 95.0% respectively when the M- subjects taking ICS were excluded. Cough was common during testing. There were no serious adverse events. The diarised events were similar for mannitol and HS, the most common being headache (17.2% M, 19% HS), pharyngolaryngeal pain (5.1% M, 3% HS), nausea (4.3% M, 3% HS), and cough (2.2% M, 2.4% HS). Conclusion: The efficacy and safety of mannitol was demonstrated in non-asthmatic and clinically diagnosed asthmatic adults and children.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Pharmaxis Ltd, Frenchs Forest, NSW 2086, Australia	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, 11 W,Missenden Rd, Camperdown, NSW 2050, Australia.	johnb@med.usyd.edu.au; sandya@med.usyd.edu.au; clarep@med.usyd.edu.au; ruthm@med.usyd.edu.au; Anna.Lassig@pharmaxis.com.au; brett.charlton@pharmaxis.com.au					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P63; ANDERSON SD, 2005, MONITORING ASTHMA, P275; Anderson SD, 1995, PROVOCATION CHALLENG, P249; Barben J, 2005, PROG R RES, V33, P125; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Brannan JD, 2000, AM J RESP CRIT CARE, V161, P2096; Brannan JD, 2002, RESPIROLOGY, V7, P37, DOI 10.1046/j.1440-1843.2002.00357.x; Brannan JD, 2001, AM J RESP CRIT CARE, V163, P1420; Cockcroft DW, 2005, CHEST, V127, P839, DOI 10.1378/chest.127.3.839; Currie GP, 2003, BRIT J CLIN PHARMACO, V56, P11, DOI 10.1046/j.1365-2125.2003.01831.x; Currie GP, 2003, ALLERGY, V58, P762, DOI 10.1034/j.1398-9995.2003.00226.x; de Meer G, 2005, EUR RESPIR J, V25, P153, DOI 10.1183/09031936.04.00008004; Global Initiative for Asthma, 2002, GLOB STRAT ASTHM MAN; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Koskela HO, 2004, CHEST, V125, P1985, DOI 10.1378/chest.125.6.1985; Koskela HO, 2003, CHEST, V124, P1341, DOI 10.1378/chest.124.4.1341; Leuppi JD, 2002, SWISS MED WKLY, V132, P151; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; National Asthma Council, 2002, ASTHM MAN HDB 2002; Rabone SJ, 1996, OCCUP MED-OXFORD, V46, P177; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Riedler J, 1998, EUR RESPIR J, V11, P355, DOI 10.1183/09031936.98.11020355; SMITH CM, 1990, EUR RESPIR J, V3, P144; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; YAGER D, 1991, AM REV RESPIR DIS, V143, pS52	32	111	112	0	4	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1465-993X	1465-9921		RESP RES	Respir. Res.	DEC 9	2005	6								144	10.1186/1465-9921-6-144		12	Respiratory System	Respiratory System	006IM	WOS:000234891200001	16336673	
J	Duan, W; Chan, JHP; Mckay, K; Crosby, JR; Choo, HH; Leung, BP; Karras, JG; Wong, WSF				Duan, W; Chan, JHP; Mckay, K; Crosby, JR; Choo, HH; Leung, BP; Karras, JG; Wong, WSF			Inhaled p38 alpha mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; bronchoalveolar lavage fluid; eosinophilia; mucus hypersecretion; ovalbumin	AIRWAY SMOOTH-MUSCLE; CYTOKINE PRODUCTION; SIGNALING PATHWAYS; T-CELLS; ANTIGEN-RECEPTOR; EPITHELIAL-CELLS; MAP KINASE; MAST-CELL; EXPRESSION; INHIBITOR	The p38 mitogen-activated protein kinase (MAPK) plays a critical role in the activation of inflammatory cells. Therefore, we investigated the antiinflammatory effects of a respirable p38 alpha MAPK antisense oligonucleotide (p38 alpha-ASO) in a mouse asthma model. A potent and selective p38 alpha-ASO was characterized in vitro. Inhalation of aerosolized p38 alpha-ASO using an aerosol chamber dosing system produced measurable lung deposition of ASO and significant reduction of ovalbumin (OVA-)-induced increases in total cells, eosinophils, and interleukin 4 (IL-4), IL-5, and IL-13 levels in bronchoalveolar lavage fluid, and dose-dependent inhibition of airway hyperresponsiveness in allergen-challenged mice. Furthermore, inhaled p38 alpha-ASO markedly inhibited OVA-induced lung tissue eosinophilia and airway mucus hypersecretion. Quantitative polymerase chain reaction analysis of bronchoalveolar lavage fluid cells and peribronchial lymph node cells showed that p38 alpha-ASO significantly reduced p38 alpha MAPK mRNA expression. Nose-only aerosol exposure of mice verified the p38 alpha-ASO-induced inhibition of OVA-induced pulmonary eosinophilia, mucus hypersecretion, and airway hyperresponsiveness. None of the effects of the p38 alpha-ASO were produced by a six-base mismatched control oligonucleotide. These findings demonstrate antisense pharmacodynamic activity in the airways after aerosol delivery and suggest that a p38 alpha MAPK ASO approach may have therapeutic potential for asthma and other inflammatory lung diseases.	Natl Univ Singapore, Fac Med, Dept Pharmacol, Singapore 117597, Singapore; Tan Tock Seng Hosp, Dept Rheumatol Allergy & Immunol, Singapore, Singapore; ISIS Pharmaceut, Dept Antisense Drug Discovery, Carlsbad, CA 92008 USA	Wong, WSF (reprint author), Natl Univ Singapore, Fac Med, Dept Pharmacol, MD2,18 Med Dr, Singapore 117597, Singapore.	phcwongf@nus.edu.sg	Leung, Bernard/O-2409-2013; Wong, W.S. Fred/D-8205-2013				Adachi T, 2000, J IMMUNOL, V165, P2198; Adachi T, 2003, J ALLERGY CLIN IMMUN, V111, P113, DOI 10.1067/mai.2003.27; Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Busse WW, 2001, NEW ENGL J MED, V344, P350; CANDRA E, 2003, KOREAN J PHYSL PH S1, V7, P161; Cui CH, 2002, AM J RESP CELL MOL, V27, P329, DOI 10.1165/rcmb.4762; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; Duan W, 2004, J IMMUNOL, V172, P7053; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; Fitzgerald SM, 2004, AM J RESP CELL MOL, V30, P585, DOI 10.1165/rcmb.2003-0282OC; Geary RS, 1997, DRUG METAB DISPOS, V25, P1272; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Herrick CA, 2003, NAT REV IMMUNOL, V3, P1; Hirst SJ, 2003, RESP PHYSIOL NEUROBI, V137, P309, DOI 10.1016/S1569-9048(03)00155-1; Hirst SJ, 2002, AM J RESP CRIT CARE, V165, P1161, DOI 10.1164/rccm.2107158; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL1066, DOI 10.1152/ajplung.00195.2001; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kampen GT, 2000, BLOOD, V95, P1911; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Koo GC, 2003, AM J RESP CRIT CARE, V167, P1400, DOI 10.1164/rccm.200207-696OC; Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448; LARCHE M, 2002, J ALLERGY CLIN IMMUN, V111, P450; Leeds JM, 1996, ANAL BIOCHEM, V235, P36, DOI 10.1006/abio.1996.0088; Li L, 1999, J IMMUNOL, V162, P2477; Lu BF, 2004, NAT IMMUNOL, V5, P38, DOI 10.1038/ni1020; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; McKay RA, 1999, J BIOL CHEM, V274, P1715, DOI 10.1074/jbc.274.3.1715; Mori A, 1999, J IMMUNOL, V163, P4763; Nel AE, 2002, J ALLERGY CLIN IMMUN, V109, P758, DOI 10.1067/mai.2002.124259; Niiro H, 2002, NAT REV IMMUNOL, V2, P945, DOI 10.1038/nri955; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; Panettieri Reynold A. Jr., 2002, Journal of Allergy and Clinical Immunology, V110, pS269, DOI 10.1067/mai.2002.129429; Peng Q, 2004, AM J RESP CRIT CARE, V169, P596, DOI 10.1164/rccm.200307-888OC; Schafer PH, 1999, J IMMUNOL, V162, P7110; SILBAUGH SA, 1987, J PHARMACOL METHOD, V18, P295, DOI 10.1016/0160-5402(87)90061-1; Skapenko A, 2001, J IMMUNOL, V166, P4283; Tanaka M, 2001, RESPIR RES, V2, P5, DOI 10.1186/rr32; Taube C, 2004, AM J RESP CELL MOL, V30, P837, DOI 10.1165/rcmb.2003-0395OC; Taube C, 2002, J IMMUNOL, V169, P6482; Templin MV, 2000, ANTISENSE NUCLEIC A, V10, P359, DOI 10.1089/oli.1.2000.10.359; TUNG D, 2004, INFLAMM RES, V53, P220; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Vargaftig BB, 2003, AM J RESP CELL MOL, V28, P410, DOI 10.1165/rcmb.2002-0032OC; Wong CK, 2003, AM J RESP CELL MOL, V29, P133, DOI 10.1165/rcmb.2002-0289OC; Wu HJ, 2004, J BIOL CHEM, V279, P17181, DOI 10.1074/jbc.M311683200; Yu RZ, 2002, ANAL BIOCHEM, V304, P19, DOI 10.1006/abio.2002.5576; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	49	111	118	0	8	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 15	2005	171	6					571	578		10.1164/rccm.200408		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	905HV	WOS:000227560100006	15557129	
J	Bugiani, M; Carosso, A; Migliore, E; Piccioni, P; Corsico, A; Olivieri, M; Ferrari, M; Pirina, P; de Marco, R				Bugiani, M; Carosso, A; Migliore, E; Piccioni, P; Corsico, A; Olivieri, M; Ferrari, M; Pirina, P; de Marco, R		ISAYA ECRHS Italy Study Grp	Allergic rhinitis and asthma comorbidity in a survey of young adults in Italy	ALLERGY			English	Article						allergic rhinitis; asthma; comorbidity; epidemiology	RESPIRATORY HEALTH SURVEY; NATURAL-HISTORY; AIR-POLLUTION; RISK-FACTORS; PREVALENCE; COMMUNITY; SYMPTOMS; EPIDEMIOLOGY; LUNG; QUESTIONNAIRE	Background: Several studies have provided evidence of a strong association between asthma and allergic or nonallergic rhinitis, leading to the hypothesis that allergic rhinitis (AR) and asthma represent a continuum of the same disease. Aim: The aims of our study were: (i) to measure the comorbidity of AR and asthma and asthma-like symptoms and (ii) to assess whether asthma, AR, and their coexistence share a common pattern of individual risk factors. Methods: The subjects are participants from the Italian multicentre, cross-sectional survey on respiratory symptoms in the young adult general population (Italian Study of Asthma in Young Adults, ISAYA). The relationship between individual risk factors and asthma, AR and their coexistence, was studied by means of a multinomial logistic regression. Results: About 60% of asthmatics reported AR. On the other hand, subjects with AR presented an eightfold risk of having asthma compared to subjects without AR. Age was negatively associated with asthma [OR = 0.89, 95% confidence interval (CI): 0.82-0.96], AR (OR = 0.92, 95% CI: 0.86-0.98), and asthma associated with AR (OR = 0.83, 95% CI: 0.79-0.88). The risk of AR without asthma was significantly higher in the upper social classes (OR = 1.23, 95% CI: 1.08-1.39). Active current smoking exposure was positively associated with asthma alone (OR = 1.24, 95% CI: 1.09-1.41) and negatively associated with AR with (OR = 0.69, 95% CI: 0.54-0.88) or without (OR = 0.76, 95% CI: 0.69-0.84) asthma. Conclusions: Asthma and AR coexist in a substantial percentage of patients; bronchial asthma and AR, when associated, seem to share the same risk factors as AR alone while asthma without AR seems to be a different condition, at least with respect to some relevant risk factors.	NHS CPA ASL 4, Unit Pneumol, I-10100 Turin, Italy; Univ Pavia, IRCCS, Policlin San Matteo, Div Resp Dis, I-27100 Pavia, Italy; Univ Verona, Dept Med & Publ Hlth, Unit Occupat Med, I-37100 Verona, Italy; Univ Verona, Dept Biomed & Surg Sci, Unit Internal Med, I-37100 Verona, Italy; Univ Sassari, Dept Resp Dis, I-07100 Sassari, Italy; Univ Verona, Dept Med & Publ Hlth, Unit Epidemiol & Med Stat, I-37100 Verona, Italy	Bugiani, M (reprint author), NHS CPA ASL 4, Unit Pneumol, Lungo Dora Savona 26, I-10100 Turin, Italy.		; de Marco, Roberto/A-5470-2008; SESM, SESM/C-1440-2008; bucca, caterina/C-9886-2009; Dalmasso, Paola/F-8555-2013; Ciccone, Giovannino/K-3136-2016	/0000-0003-2517-6515; Montomoli, Cristina/0000-0002-8526-5846; bucca, caterina/0000-0002-9941-9236; Dalmasso, Paola/0000-0001-6081-6966; Ciccone, Giovannino/0000-0001-7644-9574; ROMANO, Canzio/0000-0001-5294-9793; Bono, Roberto/0000-0002-2471-6594; Fanfulla, Francesco/0000-0002-8601-423X; Corsico, Angelo Guido/0000-0002-8716-4694; Rolla, Giovanni/0000-0001-5997-7172			Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Asher MI, 1998, CLIN EXP ALLERGY, V28, P90; Biggeri A, 2001, Epidemiol Prev, V25, P83; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BUCCA C, 1995, LANCET, V346, P791, DOI 10.1016/S0140-6736(95)91617-2; Burney P, 1996, EUR RESPIR J, V9, P687; CORREN J, 1998, J ALLERGY CLIN IMMUN, V101, P352; D'Amato G, 2002, CLIN EXP ALLERGY, V32, P1391, DOI 10.1046/j.1365-2745.2002.01519.x; de Marco R, 1999, EUR RESPIR J, V14, P1044, DOI 10.1183/09031936.99.14510449; de Marco R, 2003, ALLERGY, V58, P221, DOI 10.1034/j.1398-9995.2003.00059.x; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; International Consensus Report on the diagnosis and management of rhinitis, 1994, ALLERGY S19, V49, P1; Janson C, 2001, LANCET, V358, P2103, DOI 10.1016/S0140-6736(01)07214-2; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jones NS, 1998, CLIN OTOLARYNGOL, V23, P547, DOI 10.1046/j.1365-2273.1998.2360547.x; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P138; Lack G, 2001, J ALLERGY CLIN IMMUN, V108, pS9, DOI 10.1067/mai.2001.115562; Leynaert B., 2000, J ALLERGY CLIN IMMUN, V106, P201; Oglesby L, 2000, AM J EPIDEMIOL, V152, P75, DOI 10.1093/aje/152.1.75; Olivieri M, 2002, ALLERGY, V57, P600, DOI 10.1034/j.1398-9995.2002.23537.x; Passalacqua G, 2000, THORAX, V55, P26; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHIM C, 1986, AM J MED, V80, P18, DOI 10.1016/0002-9343(86)90043-4; Shusterman D, 2002, ENVIRON HEALTH PERSP, V110, P649; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Smith JM, 1983, ALLERGY PRINCIPLES P, V771-803; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; StataCorp, 2003, STAT STAT SOFTW REL; Tobin MJ, 2002, AM J RESP CRIT CARE, V165, P598, DOI 10.1164/rccm.2201062; Togias A, 2001, AM J RESP CRIT CARE, V164, P726; Townley RG, 1998, ANN ALLERG ASTHMA IM, V80, P137; Vignola AM, 2001, CLIN EXP ALLERGY, V31, P674, DOI 10.1046/j.1365-2222.2001.01115.x; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WRIGHT AL, 1994, PEDIATRICS, V94, P895; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149	45	111	114	0	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	FEB	2005	60	2					165	170		10.1111/j.1398-9995.2005.00659.x		6	Allergy; Immunology	Allergy; Immunology	887VF	WOS:000226332900006	15647036	
J	Pittner, G; Vrtala, S; Thomas, WR; Weghofer, M; Kundi, M; Horak, F; Kraft, D; Valenta, R				Pittner, G; Vrtala, S; Thomas, WR; Weghofer, M; Kundi, M; Horak, F; Kraft, D; Valenta, R			Component-resolved diagnosis of house-dust mite allergy with purified natural and recombinant mite allergens	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						cross-reactivity; diagnosis; house-dust mites; IgE reactivity profile; immunotherapy; natural and recombinant allergens	DERMATOPHAGOIDES-PTERONYSSINUS ALLERGEN; DER-P-I; STANDARDIZED EXTRACTS; CROSS-REACTIVITY; HUMAN IGE; IMMUNOTHERAPY; BINDING; ASTHMA; CHILDREN; POLLEN	Background Mites belong to the most frequent and potent allergen sources. Immunotherapy with mite allergen extracts is frequently performed if allergen avoidance is not possible or successful. However, highly controversial results have been reported for mite-specific immunotherapy. Objective The aim of this study was to develop diagnostic concepts that may contribute to an improved selection of patients for immunotherapy with Der p allergen extracts and that may be used for immunological monitoring of patients undergoing this treatment. Methods The IgE reactivity profiles to Der p extract were determined in a Middle European mite-allergic population by IgE immunoblotting and by using a panel of seven purified natural or recombinant Der p allergens (nDer p 1, nDer p 4, rDer p 2, rDer p 5, rDer p 7, rDer p 8, rDer p 10). Furthermore, we investigated the sensitization and cross-reactivity to house-dust- and storage-mite allergen extracts by CAP FEIA measurements and by IgE competition studies. Results More than 95% of the patients could be diagnosed with a combination of nDer p 1 and rDer p 2. With the methods used, we could discriminate mite-allergic patients who were mainly sensitized to the major Der p allergens (Der p 1, Der p 2) from patients with a broad sensitization profile, including highly cross-reactive allergens (e.g. Der p 10: tropomyosin) as well as reactivity to storage mites. Conclusions Diagnostic tests containing the major mite allergens (i.e. Der p 1, Der p 2) and highly cross-reactive mite allergens (e.g. Der p 10) may improve the diagnostic selection of patients for immunotherapy with Der p extracts. These tests may also be used for the immunological monitoring of patients undergoing immunotherapy.	Med Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Div Immunopathol, A-1090 Vienna, Austria; Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Nedlands, WA 6009, Australia; Med Univ Vienna, Inst Environm Hlth, Dept Occupat & Social Hyg, A-1090 Vienna, Austria; Univ Vienna, Med Vienna Gen Hosp, Dept ENT, A-1010 Vienna, Austria	Vrtala, S (reprint author), Med Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Div Immunopathol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Susanne.vrtala@akh-wien.ac.at					BOUSQUET J, 1994, ALLERGY PROC, V15, P329, DOI 10.2500/108854194778816562; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P124; DEBLAY F, 1994, J ALLERGY CLIN IMMUN, V93, P136, DOI 10.1016/0091-6749(94)90242-9; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; FernandezCaldas E, 1997, ALLERGY, V52, P383, DOI 10.1111/j.1398-9995.1997.tb01016.x; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; FLING SP, 1986, ANAL BIOCHEM, V155, P83, DOI 10.1016/0003-2697(86)90228-9; FORD SA, 1989, INT ARCH ALLER A IMM, V89, P318; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P934, DOI 10.1046/j.1365-2222.2000.00901.x; Hales BJ, 2002, CLIN EXP ALLERGY, V32, P1461, DOI 10.1046/j.1365-2745.2002.01500.x; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Lundberg M, 2001, ALLERGY, V56, P794, DOI 10.1034/j.1398-9995.2001.056008794.x; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; Mills KL, 1999, INT ARCH ALLERGY IMM, V120, P100, DOI 10.1159/000024227; Niederberger V, 2002, CLIN EXP ALLERGY, V32, P933, DOI 10.1046/j.1365-2222.2002.01369.x; Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; PENE J, 1994, IMMUNOLOGY, V81, P58; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Shen HD, 1997, CLIN EXP ALLERGY, V27, P824, DOI 10.1046/j.1365-2222.1997.650890.x; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; vanRee R, 1996, ALLERGY, V51, P108; VRTALA S, 1993, INT ARCH ALLERGY IMM, V102, P160	36	111	119	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2004	34	4					597	603		10.1111/j.1365-2222.2004.1930.x		7	Allergy; Immunology	Allergy; Immunology	812RQ	WOS:000220857000016	15080813	
J	Arif, AA; Delclos, GL; Lee, ES; Tortolero, SR; Whitehead, LW				Arif, AA; Delclos, GL; Lee, ES; Tortolero, SR; Whitehead, LW			Prevalence and risk factors of asthma and wheezing among US adults: an analysis of the NHANES III data	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; epidemiology; National Health and Nutrition Examination; Survey III	NUTRITION EXAMINATION SURVEY; RESPIRATORY HEALTH SURVEY; 2ND NATIONAL-HEALTH; BODY-MASS INDEX; YOUNG-ADULTS; SYMPTOMS QUESTIONNAIRE; SOCIOECONOMIC-STATUS; CHILDHOOD ASTHMA; REPORTED ASTHMA; PUERTO-RICAN	The prevalence of asthma has been on the increase in the USA and worldwide. To understand the worsening epidemiological trends of asthma, this study analysed the data from the third National Health and Nutrition Examination Survey (NHANES III) to determine the prevalence and risk factors for asthma and wheezing among US adults. This analysis used data from, 18,825 US adults aged greater than or equal to 20 yrs who had participated in the NHANES III project. After excluding subjects with physician-diagnosed emphysema, a total of 18,393 subjects were included in the final analysis. The prevalence of current asthma (asthma) was 4.5% and the prevalence of wheezing in the previous 12 months (wheezing) was 16.4%. Mexican-Americans exhibited the lowest prevalence of asthma when compared with other race/ethnic groups. Multiple logistic regression analysis showed that Mexican-Americans were less likely to report asthma when compared to non-Hispanic whites. Low education level, female sex, current and past smoking status, pet ownership, lifetime diagnosis of physician-diagnosed hay fever and obesity were all significantly associated with asthma and/or wheezing. No significant effect of indoor air pollutants, as derived from the use of household heating/cooking appliances, on asthma and wheezing was observed in this study. In conclusion, this study observed racial/ethnic differences in the prevalence of asthma and wheezing and identified several important risk factors that may contribute to development and/or exacerbation of asthma and wheezing. Contrary to earlier reports, the proxy measures of indoor air pollution used in this study were not found to be associated with increased risk of asthma and wheezing.	Texas Tech Univ, Hlth Sci Ctr, Dept Hlth Serv Res & Management, Lubbock, TX 79430 USA; Univ Texas, Sch Publ Hlth, Houston, TX USA	Arif, AA (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Hlth Serv Res & Management, 3601 4th St,MS 8161, Lubbock, TX 79430 USA.			Arif, Ahmed A./0000-0002-0237-9937			ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172; Basagana X, 2001, AM J RESP CRIT CARE, V164, P1133; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; Burr ML, 1999, THORAX, V54, P27; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68; Duran-Tauleria E, 1999, THORAX, V54, P476; Field S K, 2000, Can Respir J, V7, P167; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; HIGGINS MW, 1977, AM REV RESPIR DIS, V116, P403; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Kaplan BA, 1997, J ASTHMA, V34, P219, DOI 10.3109/02770909709068192; Leynaert B, 1996, LANCET, V347, P1052, DOI 10.1016/S0140-6736(96)90197-X; LIAO Y, 1998, AM J PUBLIC HEALTH, V80, P227; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; National Center for Health Statistics, 1992, DHHS PUBL; *NHANES, 1988, DAT CD DAT OCT 1996; RAY CS, 1983, AM REV RESPIR DIS, V128, P501; SAMET JM, 1988, AM REV RESPIR DIS, V137, P815; SAMET JM, 1982, AM REV RESPIR DIS, V125, P152; SAMET JM, 1993, ENVIRON HEALTH PERSP, V101, P149, DOI 10.2307/3431671; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; Shaheen SO, 1999, THORAX, V54, P396; Sunyer J., 1997, European Respiratory Journal, V10, P2490, DOI 10.1183/09031936.97.10112490; Sunyer J, 1997, THORAX, V52, P235; TAYLOR WR, 1992, PEDIATRICS, V90, P657; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; VENABLES KM, 1993, THORAX, V48, P214, DOI 10.1136/thx.48.3.214	35	111	116	0	2	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAY	2003	21	5					827	833		10.1183/09031936.03.00054103		7	Respiratory System	Respiratory System	678WW	WOS:000182890500018	12765429	
J	Becker, S; Soukup, JM; Gallagher, JE				Becker, S; Soukup, JM; Gallagher, JE			Differential particulate air pollution induced oxidant stress in human granulocytes, monocytes and alveolar macrophages	TOXICOLOGY IN VITRO			English	Article						oxidant stress; human alveolar macrophages; monocytes; granulocytes; environmental pollution; particles; induced apoptosis; necrosis	OIL FLY-ASH; REACTIVE OXYGEN METABOLITES; HYDROGEN-PEROXIDE; RADICAL GENERATION; INDUCED ACTIVATION; INDUCED APOPTOSIS; MINERAL DUSTS; AMBIENT AIR; METAL-IONS; PARTICLES	It has been proposed that oxidant stress of cells in the lung is one of the underlying mechanisms of particulate pollution-induced exacerbation of lung disease. Individuals who are considered most sensitive to particulate pollution are those with pre-existing airways inflammation, such as chronic obstructive pulmonary disease (COPD), lung infection or asthma. These diseases are characterized by a presence of inflammatory cells in the airways including neutrophils (PMN), eosinophils and monocytes (Mo), and increased numbers of alveolar macrophages (AM). These cells have a high capacity for production of oxygen radicals, as compared to other cell types of the lung. To assess the oxidative response of these various cell types to pollution particles of various sources, luminol-dependent chemiluminescence was employed. Particles including transition metal-rich residual oil fly ashes (ROFAs), coal fly ashes, diesel, SiO2, TiO2 and fugitive dusts were co-cultured with AM, Mo and PMN in a dose range of 10-100 mug/2x 10(5) cells and chemiluminescence determined following a 20-min interaction. A strong oxidant response of AM was restricted to oil fly ashes, while the PMN were most reactive to the dusts containing aluminium silicate. In general, the Mo response was less vigorous, but overlapped both AM- and PMN-stimulating dusts. However, in response to SiO2, and volcanic ash the Mo chemiluminescence exceeded that of the other cell types. Oxygen radicals generated in response to ROFA by the AM were likely to be dependent on mitochondrial processes, while the response in PMN involved the membrane NADPH oxidase complex, as determined by targeting inhibitors. The response of AM to SiO2 of various sizes and TiO2 in the fine size range obtained from different commercial sources, was highly variable, implying that composition rather than size was responsible for the oxidant response. A strong chemiluminescence response was not consistently associated with cytotoxicity in the responsive cell. Taken together, these results suggest that oxidant activation by various sources of particulate matter is cell specific. Therefore, the inflamed lung is likely to be more susceptible to harm of ambient air particulates because of the oxidant stress posed by a broader range of particles. (C), 2002 Published by Elsevier Science Ltd.	US EPA, Off Res & Dev, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	Becker, S (reprint author), US EPA, Human Studies Bldg,104 Mason Farm Rd, Chapel Hill, NC 27599 USA.						Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Becker S, 1999, IMMUNOBIOLOGY, V201, P88; Becker S, 1998, J TOXICOL ENV HEAL A, V55, P455, DOI 10.1080/009841098158278; BERG I, 1993, J TOXICOL ENV HEALTH, V39, P341; DEMASTER EG, 1973, BIOCHEMISTRY-US, V12, P3616, DOI 10.1021/bi00743a007; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dye JA, 1997, AM J RESP CELL MOL, V17, P625; Gercken G, 1996, TOXICOL LETT, V88, P121, DOI 10.1016/0378-4274(96)03727-7; Ghio AJ, 1998, BIOMETALS, V11, P41, DOI 10.1023/A:1009257323963; Ghio AJ, 1997, INHAL TOXICOL, V9, P255; GUSEV VA, 1993, BRIT J IND MED, V50, P732; HATCH GE, 1985, ENVIRON RES, V36, P67, DOI 10.1016/0013-9351(85)90008-8; HATCH GE, 1978, J EXP MED, V147, P182, DOI 10.1084/jem.147.1.182; HATCH GE, 1980, ENVIRON RES, V23, P121, DOI 10.1016/0013-9351(80)90099-7; Holian A, 1998, ENVIRON HEALTH PERSP, V106, P127; Iyer R, 1996, TOXICOL APPL PHARM, V141, P84, DOI 10.1006/taap.1996.0263; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; JOHANSSON A, 1992, CELL BIOCHEM FUNCT, V10, P87, DOI 10.1002/cbf.290100204; KEHRER JP, 1993, CRIT REV TOXICOL, V23, P21, DOI 10.3109/10408449309104073; Keles N, 1999, AM J RHINOL, V13, P185, DOI 10.2500/105065899781389731; Kodavanti UP, 1998, TOXICOL SCI, V43, P204, DOI 10.1093/toxsci/43.2.204; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; LABEDZKA M, 1991, ARCH ENVIRON CON TOX, V21, P51; Li YB, 1999, BBA-GEN SUBJECTS, V1428, P1, DOI 10.1016/S0304-4165(99)00040-9; Li YB, 1998, BIOCHEM BIOPH RES CO, V253, P295, DOI 10.1006/bbrc.1998.9729; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; MUROI M, 1994, J BIOL CHEM, V269, P30561; NAGASE M, 1995, SCAND J RHEUMATOL, V24, P102; Nathan C., 1991, BEHRING I MITT, V88, P200; NYBERG P, 1990, INT J EXP PATHOL, V71, P537; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Prahalad AK, 1999, TOXICOL APPL PHARM, V158, P81, DOI 10.1006/taap.1999.8701; Pritchard RJ, 1996, INHAL TOXICOL, V8, P457, DOI 10.3109/08958379609005440; Samet JM, 1997, AM J PHYSIOL-LUNG C, V272, pL426; SARIH M, 1993, J LEUKOCYTE BIOL, V54, P407; Sawyer D W, 1989, Rev Infect Dis, V11 Suppl 7, pS1532; SCHLUTER T, 1995, TOXICOLOGY, V98, P47, DOI 10.1016/0300-483X(94)02959-X; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; VALLYATHAN V, 1994, ENVIRON HEALTH PERSP, V102, P111; VALLYATHAN V, 1992, AM J RESP CELL MOL, V6, P404; WEITZMAN SA, 1984, ARCH BIOCHEM BIOPHYS, V228, P373, DOI 10.1016/0003-9861(84)90078-X; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991	44	111	116	2	13	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-2333			TOXICOL IN VITRO	Toxicol. Vitro	JUN	2002	16	3					209	218	PII S0887-2333(02)00015-2	10.1016/S0887-2333(02)00015-2		10	Toxicology	Toxicology	568JM	WOS:000176538700001	12020593	
J	Wahn, U; von Mutius, E				Wahn, U; von Mutius, E			Childhood risk factors for atopy and the importance of early intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopy; prediction; prevention; epidemiology; atopic march; asthma	INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; HOUSE-DUST MITE; ALLERGIC SENSITIZATION; INHALANT ALLERGENS; DOMESTIC EXPOSURE; MATERNAL SMOKING; PARENTAL SMOKING; FOOD ALLERGY; HAY-FEVER	The increasing prevalence of atopic diseases, particularly atopy-associated asthma, has become a major challenge for allergists and public health authorities in many countries. The understanding of the natural history of the atopic march, including the determinants that are modifiable and might become candidates for preventive intervention, is still very limited, Information provided by cross-sectional studies can only generate hypotheses, which need to be supported by prospective, longitudinal, cohort studies. Ultimately, it will depend on the results of well-controlled intervention studies to identify which nutritional, environmental, or lifestyle-related factors should be considered for early intervention and might be useful to reverse the epidemiologic trend.	Charite Humboldt Univ Berlin, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Dr Von Haunersches Kinderspital, Munich, Germany	Wahn, U (reprint author), Charite Humboldt Univ Berlin, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; ARSHAD SH, 1992, LANCET, V339, P1439; Asher MI, 1998, EUR RESPIR J, V12, P315; Baker SS, 2000, PEDIATRICS, V106, P346; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Becker AB, 2000, PEDIATR PULM, V30, P63, DOI 10.1002/1099-0496(200007)30:1<63::AID-PPUL10>3.0.CO;2-7; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BERGMANN RL, IN PRESS CLIN EXP AL; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Buhrer C, 1999, LANCET, V353, P1674, DOI 10.1016/S0140-6736(98)03975-0; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; COOKSON WOCM, 1989, LANCET, V1, P1292; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Edenharter G, 1998, CLIN EXP ALLERGY, V28, P671; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Farooqi IS, 1998, THORAX, V53, P927; Gutgesell C, 1999, CLIN EXP ALLERGY, V29, P920, DOI 10.1046/j.1365-2222.1999.00553.x; Halken S, 2000, ALLERGY, V55, P793, DOI 10.1034/j.1398-9995.2000.00117.x; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Host A, 1999, ARCH DIS CHILD, V81, P80; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jung T, 1999, CLIN EXP ALLERGY, V29, P912; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; KJELLMANN NIM, 1984, ANN ALLERGY, V53, P571; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Kulig M, 1999, ALLERGY, V54, P220, DOI 10.1034/j.1398-9995.1999.00753.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lodrup Carlsen K C, 1995, Eur Respir J, V8, P1148; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 1997, BRIT MED J, V314, P999; MOLLER C, UNPUB POLLEN IMMUNOT; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Pohunek P, 1996, THORAX, V51, P615, DOI 10.1136/thx.51.6.615; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Schultz Larsen F, 1993, J Am Acad Dermatol, V28, P719; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shaheen SO, 1999, CLIN EXP ALLERGY, V29, P291; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1998, THORAX, V53, P204; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; Upton MN, 2000, BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806	79	111	116	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					567	574		10.1067/mai.2001.112943		8	Allergy; Immunology	Allergy; Immunology	423RG	WOS:000168190100001	11295640	
J	Park, JH; Spiegelman, DL; Burge, HA; Gold, DR; Chew, GL; Milton, DK				Park, JH; Spiegelman, DL; Burge, HA; Gold, DR; Chew, GL; Milton, DK			Longitudinal study of dust and airborne endotoxin in the home	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						endotoxin; house dust; humidity; indoor air pollution; seasonal variability; temperature	RESPIRATORY-INFECTIONS; LIMULUS ASSAY; EXPOSURE; ASTHMA; CHILDREN; SYMPTOMS; DAMPNESS; SEVERITY; HEALTH; WORKER	To characterize the seasonal variability of endotoxin levels, we measured endotoxin in dust from the bed, bedroom floor, and kitchen floor in 20 homes, and in air from the bedroom in 15 of the homes. All homes were located in the greater Boston, Massachusetts, area and were sampled each month from April 1995 to June 1996. Outdoor air was collected at two locations. We found greater within-home than between-home variance for bedroom floor, kitchen floor, and airborne endotoxin. However, the reverse was true for bed dust endotoxin. Thus, studies using single measurements of dust endotoxin are most likely to reliably distinguish between homes if bed dust is sampled. Dust endotoxin levels were not significantly associated with airborne endotoxin. Airborne endotoxin was significantly (p = 0.04) and positively associated with absolute humidity in a mixed-effect model adjusting for a random home effect and fixed effect of sampling month and home characteristics. This finding implies that indoor humidity may be an important factor controlling endotoxin exposure. We found a significant (p < 0.05) seasonal effect in kitchen door dust (spring > fall) and bedroom airborne endotoxin (spring > winter), but not in the other indoor samples. We found significant seasonal pattern in outdoor airborne endotoxin (summer > winter).	Harvard Univ, Sch Publ Hlth, Occupat Hlth Program, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Med Sch, Boston, MA USA; Columbia Univ, JL Mailman Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10027 USA	Milton, DK (reprint author), Harvard Univ, Sch Publ Hlth, Occupat Hlth Program, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Milton, Donald/G-3286-2010	Milton, Donald/0000-0002-0550-7834	NIEHS NIH HHS [2P30ES00002, R01 ES-07036]		ANDREWS JH, 1992, MICROBIAL ECOLOGY LE; Andriessen JW, 1998, CLIN EXP ALLERGY, V28, P1191; AYRES JG, 1993, BRIT J GEN PRACT, V43, P361; Carroll R. J., 1995, MEASUREMENT ERROR NO, V63; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; DELUCCA AJ, 1987, AM IND HYG ASSOC J, V48, P106, DOI 10.1080/15298668791384472; DOUWES J, 1998, RESP HLTH EFFECTS IN; DOUWES J, 1998, RESP HLTH EFFECTS IN, P109; Edmonds RL, 1979, AEROBIOLOGY ECOLOGIC; Hastie T, 1990, GEN ADDITIVE MODELS; HEEDERIK D, 1991, APPL OCCUP ENV HYG, V6, P458; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Kendrick B, 1992, 5 KINGDOM; Kleinbaum D.G., 1987, APPL REGRESSION ANAL; Lyles RH, 1997, ANN OCCUP HYG, V41, P63; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Milton DK, 1996, AM IND HYG ASSOC J, V57, P889, DOI 10.1202/0002-8894(1996)057<0889:WETEPC>2.0.CO;2; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; RAPPAPORT SM, 1995, ANN OCCUP HYG, V39, P469, DOI 10.1016/0003-4878(95)00021-6; RAPPAPORT SM, 1991, ANN OCCUP HYG, V35, P61, DOI 10.1093/annhyg/35.1.61; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Rosner B., 1995, FUNDAMENTALS BIOSTAT; SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709; SIMARD C, 1983, J HYG-CAMBRIDGE, V91, P277; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; Symanski E, 1996, AM IND HYG ASSOC J, V57, P724; Williamson IJ, 1997, THORAX, V52, P229; Yang CY, 1997, ENVIRON RES, V75, P49, DOI 10.1006/enrs.1997.3774	32	111	114	2	7	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	NOV	2000	108	11					1023	1028		10.1289/ehp.001081023		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	373XP	WOS:000165315600021	11102291	
J	Finkelstein, J; Cabrera, MR; Hripcsak, G				Finkelstein, J; Cabrera, MR; Hripcsak, G			Internet-based home asthma telemonitoring - Can patients handle the technology?	CHEST			English	Article						asthma; peak expiratory flow; self-management; spirometry; telemonitoring	EXPIRATORY FLOW-VOLUME; QUALITY-CONTROL; ALPHA(1)-ANTITRYPSIN DEFICIENCY; PULMONARY-FUNCTION; CYSTIC-FIBROSIS; SPIROMETRY; VARIABILITY; OBSTRUCTION; CHILDREN	Study objectice: To evaluate the validity of spirometry self-testing during home telemonitoring and to assess the acceptance of an Internet-based home asthma telemonitoring system by asthma patients. Design: We studied an Internet-based telemonitoring system that collected spirometry. data and symptom reports from asthma patients' homes for review by physicians in the medical center's clinical information system. After a 40-min training session, patients completed an electronic diary and performed spirometry testing twice daily on their own from their homes for 3 weeks. A medical professional visited each patient by the end of the third neck of monitoring, 10 to 40 min after the patient had performed self-testing, and asked the patient to perform the spirometry test again under his supervision, We evaluated the validity of self-testing and surveyed the patients attitude toward the technology using a standardized questionnaire, Setting: Telemonitoring was conducted in patients' homes in a low-income inner city area, Patients: Thirty-one consecutive asthma patients without regard to computer experience. Measurement and results: Thirty-one asthma patients completed 3 weeks of monitoring, A paired t test showed no difference between unsupervised and supervised home spirometry self-testing, The variability of FVC (4.1%), FEV(1), (3.7%), peak expiratory flow (7.9%), and other spirometric indexes in our study was similar to the within-subject variability reported by other researchers. Despite the fact that the majority of the patients (71%) had no computer experience, they indicated that the self-testing was "not complicated at all" or only "slightly complicated." The majority of patients (87.1%) were strongly interested in using home asthma telemonitoring in the future. Conclusions: Spirometry self-testing by asthma patients during telemonitoring is valid and comparable to those tests collected under the supervision of a trained medical professional, Internet-based home asthma telemonitoring can be successfully implemented in a group of patients with no computer background.	Columbia Univ, Dept Med Informat, New York, NY USA; Columbia Presbyterian Med Ctr, Div Pulm Med, New York, NY 10032 USA	Finkelstein, J (reprint author), Doctors Off Bldg,Suite 102,720 Harrison Ave, Boston, MA 02118 USA.	finkelj@bu.edu					AFSCHRIFT M, 1969, AM REV RESPIR DIS, V100, P147; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BEASLEY R, 1989, THORAX, V44, P200, DOI 10.1136/thx.44.3.200; BLAND JM, 1986, LANCET, V1, P307; BYE MR, 1992, AM J DIS CHILD, V146, P977; Chiang CH, 1997, J ASTHMA, V34, P15, DOI 10.3109/02770909709071199; COCHRANE GM, 1977, THORAX, V32, P171, DOI 10.1136/thx.32.2.171; CONNETT JE, 1990, CONTROL CLIN TRIALS, V11, P24, DOI 10.1016/0197-2456(90)90029-2; COOPER PJ, 1990, PEDIATR PULM, V8, P16, DOI 10.1002/ppul.1950080107; Cork RD, 1998, J AM MED INFORM ASSN, V5, P164; DAWSON A, 1966, AM REV RESPIR DIS, V93, P264; ENRIGHT P, 1992, AM REV RESPIR DIS, V146, P1367; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; FIELD MJ, 1996, TELEMEDICINE GUIDE A; Finkelstein J, 1998, ST HEAL T, V52, P272; FINKELSTEIN J, 1997, SPRING C AM MED INF; Friedman CP, 1997, EVALUATION METHODS M; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353; INTVEEN JCC, 1998, AM J RESP CRIT CARE, V158, P1134; LEEDER SR, 1977, B EUR PHYSIOPATH RES, V13, P249; LESSLER JT, 1995, MED CARE, V33, pAS203; LI JTC, 1995, MAYO CLIN PROC, V70, P649; Madsen F, 1996, RESP MED, V90, P131, DOI 10.1016/S0954-6111(96)90154-7; MCCARTHY DS, 1975, AM REV RESPIR DIS, V112, P407; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; National Asthma Education and Prevention Program, 1997, NIH PUBL, V97-4051; NICKERSON BG, 1980, AM REV RESPIR DIS, V122, P859; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; Rietveld S, 1997, J ASTHMA, V34, P133, DOI 10.3109/02770909709075658; RUBINFELD AR, 1976, LANCET, V1, P882; Stoller JK, 1997, CHEST, V111, P899, DOI 10.1378/chest.111.4.899; Valetta EA, 1997, J ASTHMA, V34, P127	33	111	112	3	10	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JAN	2000	117	1					148	155		10.1378/chest.117.1.148		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	274PN	WOS:000084774400028	10631213	
J	Nadeau, K; McDonald-Hyman, C; Noth, EM; Pratt, B; Hammond, SK; Balmes, J; Tager, I				Nadeau, Kari; McDonald-Hyman, Cameron; Noth, Elizabeth M.; Pratt, Boriana; Hammond, S. Katharine; Balmes, John; Tager, Ira			Ambient air pollution impairs regulatory T-cell function in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ambient air pollution; asthma; immune system; regulatory T cell; Treg; epigenetics	DIESEL EXHAUST PARTICLES; DNA METHYLATION; IN-VIVO; CYTOKINE PRODUCTION; FOXP3 EXPRESSION; ALLERGIC-ASTHMA; LUNG-FUNCTION; EXPOSURE; CHALLENGE; CHILDREN	Background: Asthma is the most frequent chronic disease in children, and children are at high risk for adverse health consequences associated with ambient air pollution (AAP) exposure. Regulatory T (Treg) cells are suppressors of immune responses involved in asthma pathogenesis. Treg-cell impairment is associated with increased DNA methylation of Forkhead box transcription factor 3 (Foxp3), a key transcription factor in Treg-cell activity. Because AAP exposure can induce epigenetic changes, we hypothesized that Treg-cell function would be impaired by AAP, allowing amplification of an inflammatory response. Objectives: To assess whether exposure to AAP led to hypermethylation of the Foxp3 gene, causing impaired Treg-cell suppression and worsened asthma symptom scores. Methods: Children with and without asthma from Fresno, Calif (high pollution, Fresno Asthma Group [FA], n = 71, and Fresno Non Asthmatic Group, n = 30, respectively), and from Stanford, Calif (low pollution, Stanford Asthma Group, n = 40, and Stanford Non Asthmatic Group, n 5 40), were enrolled in a cross-sectional study. Peripheral blood Treg cells were used in functional and epigenetic studies. Asthma outcomes were assessed by Global Initiative in Asthma score. Results: Fresno Asthma Group Treg-cell suppression was impaired and FA Treg-cell chemotaxis were reduced compared with other groups (P <= .05). Treg-cell dysfunction was associated with more pronounced decreases in asthma Global Initiative in Asthma score in FA versus the Stanford Asthma Group. Foxp3 was decreased in FA compared with the Fresno Non Asthmatic Group (P <= .05). FA also contained significantly higher levels of methylation at the Foxp3 locus (P <= .05). Conclusion: Increased exposure to AAP is associated with hypermethylation of the Foxp3 locus, impairing Treg-cell function and increasing asthma morbidity. AAP could play a role in mediating epigenetic changes in Treg cells, which may worsen asthma by an immune mechanism. (J Allergy Clin Immunol 2010;126:845-52.)	[Nadeau, Kari] Stanford Univ, Div Immunol & Allergy, Sch Med, Stanford, CA 94305 USA; [Noth, Elizabeth M.; Pratt, Boriana; Hammond, S. Katharine; Balmes, John; Tager, Ira] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Nadeau, K (reprint author), Stanford Univ, Div Immunol & Allergy, Sch Med, 269 Campus Dr,CCSR Bldg,Room 2115, Stanford, CA 94305 USA.	knadeau@stanford.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	McCormick Fund at Stanford; American Academy of Allergy, Asthma, and Immunology Junior Faculty Fund; Westly Foundation; Global Health Research Foundation; NIEHS [R01 HL081521]; CDC [5U19EH000097-04]; California Air Resources Board [99-322, 99-323, 01-346]; US EPA [2A-0540-NASX]; Austin Memorial Fund; Mickey Leland National Urban Air Toxics Research Center [RFA 2005-01]	Supported by the McCormick Fund at Stanford, the American Academy of Allergy, Asthma, and Immunology Junior Faculty Fund, the Westly Foundation, the Global Health Research Foundation, NIEHS (R01 HL081521), CDC cooperative agreement 5U19EH000097-04, the California Air Resources Board (contract nos. 99-322, 99-323, and 01-346), the US EPA (PO no. 2A-0540-NASX), the Austin Memorial Fund, and the Mickey Leland National Urban Air Toxics Research Center (RFA 2005-01).; Disclosure of potential conflict of interest: S. K. Hammond has received research support from the National Institutes of Health-National Heart, Lung, and Blood Institute and National Institute of Environmental Health Sciences, the National Institute for Occupational Safety and Health, the Flight Attendant Medical Research Institute, and the Environmental Protection Agency and has provided legal consultation or expert witness testimony on the topic of exposure to chemicals in semiconductor manufacturing. J. Balmes is a member of the California Air Resources Board and has received research support from the National Institutes of Health, Centers for Disease Control and Prevention, and the California Air Resource Board. The rest of the authors have declared that they have no conflict of interest.	Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Balmes JR, 2009, J ALLERGY CLIN IMMUN, V123, P626, DOI 10.1016/j.jaci.2008.10.062; Bergstrom SE, 2008, RESP MED, V102, P1335, DOI 10.1016/j.rmed.2008.03.020; Bluestone JA, 2008, AM J TRANSPLANT, V8, P2086, DOI 10.1111/j.1600-6143.2008.02377.x; Bour-Jordan H, 2009, J IMMUNOL, V183, P4147, DOI 10.4049/jimmunol.0990078; Cohen AC, 2006, J IMMUNOL, V177, P2770; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 2005, AM J PHYSIOL-LUNG C, V289, pL722, DOI 10.1152/ajplung.00217.2005; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Islam T, 2007, THORAX, V62, P957, DOI 10.1136/thx.2007.078964; Janson PCJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001612; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kohlmeier JE, 2006, CURR OPIN IMMUNOL, V18, P357, DOI 10.1016/j.coi.2006.03.012; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Lal G, 2009, J IMMUNOL, V182, P259; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Margolis HG, 2009, INT J ENVIRON HEAL R, V19, P139, DOI 10.1080/09603120802415792; Marson A, 2007, NATURE, V445, P931, DOI 10.1038/nature05478; Mastrangelo G, 2003, INT J IMMUNOPATH PH, V16, P145; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; NGUYEN KD, 2008, J IMMUNOL, V25, P5386; Nguyen KD, 2009, J ALLERGY CLIN IMMUN, V123, pe910; Nguyen KD, 2008, J IMMUNOL, V181, P5386; Nguyen KD, 2008, EUR J IMMUNOL, V38, P2034, DOI 10.1002/eji.200738082; Nguyen KD, 2009, J ALLERGY CLIN IMMUN, V123, P933, DOI 10.1016/j.jaci.2008.11.037; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Peters JH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002233; Sakaguchi S, 2009, EUR J IMMUNOL, V39, P2331, DOI 10.1002/eji.200939688; Sekiya T, 2002, ALLERGY, V57, P173, DOI 10.1034/j.1398-9995.2002.5720256.x; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Shea K. M., 2008, J ALLERGY CLIN IMMUN, V122, P454; TAGER I, 2006, FINAL REPORT FACES, P1; Taylor A, 2005, MICROBES INFECT, V7, P1049, DOI 10.1016/j.micinf.2005.03.029; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Umetsu D. T., 2006, ARB P EHRLICH I BUND, V95, P211; Umetsu D. T., 2006, ARB P EHRLICH I BUND, V95, P215; Yu GP, 2009, CLIN IMMUNOL, V131, P240, DOI 10.1016/j.clim.2008.12.006	43	110	118	3	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					845	U280		10.1016/j.jaci.2010.08.008		18	Allergy; Immunology	Allergy; Immunology	658SP	WOS:000282510000024	20920773	
J	Compalati, E; Passalacqua, G; Bonini, M; Canonica, GW				Compalati, E.; Passalacqua, G.; Bonini, M.; Canonica, G. W.			The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA(2);LEN meta-analysis	ALLERGY			English	Review						efficacy; house dust mites; meta-analysis; specific immunotherapy	RANDOMIZED-CLINICAL-TRIALS; DOUBLE-BLIND; PEDIATRIC-PATIENTS; RHINITIS; ASTHMA; CHILDREN; COLLABORATION; ORGANIZATION; REVIEWS; QUALITY	Recent meta-analyses documented the efficacy and safety of sublingual immunotherapy (SLIT) in patients with allergic rhinitis (AR) and asthma (AA). Although SLIT appeared globally effective, the sub-analyses for single allergens provided uncertain results. This study is aimed to investigate the efficacy of SLIT with house dust mite (HDM) extracts in AR and AA through an updated reassessment of randomized controlled trials. Electronic databases were searched up to March 31, 2008, for randomized DBPC trials, assessing the efficacy of SLIT in AR and AA due to HDM sensitization. Outcomes were symptom scores and rescue medications use. For AR, eight studies fulfilled the selection criteria. A significant reduction in symptoms of AR (SMD -0.95; CI 95%-1.77 to -0.14 P = 0.02) was found in 194 patients (adults and children) receiving SLIT compared to 188 receiving placebo. For AA, with nine studies, similar results were found for symptoms (SMD -0.95; CI 95%-1.74 to -0.15 P = 0.02) in 243 patients (adults and children) receiving SLIT compared to 209 receiving placebo. A reduction in rescue medication use was found for AR (SMD -1.88; CI 95%-3.65 to -0.12 P = 0.04) in 89 patients, and AA (SMD -1.48; CI 95%-2.70 to -0.26 P = 0.02) in 202 patients. A relevant inter-study heterogeneity was detected. Promising evidence of efficacy for SLIT, using mite extract in allergic patients suffering from AR and AA, are herein shown. These findings suggest that more data are needed, derived from large-population-based high quality studies, and corroborated by objective outcomes, mainly for AA.	[Compalati, E.; Passalacqua, G.; Bonini, M.; Canonica, G. W.] Univ Genoa, Dept Internal Med, Allergy & Resp Dis Clin, I-16132 Genoa, Italy	Canonica, GW (reprint author), Univ Genoa, Dept Internal Med, Allergy & Resp Dis Clin, Lgo R Benzi 10, I-16132 Genoa, Italy.			BONINI, Matteo/0000-0002-3042-0765	GA<SUP>2</SUP>LEN; ARMIA	This study has been partially supported by GA<SUP>2</SUP>LEN (Global Allergy and Asthma European Network) and ARMIA (Associazione Ricerca Malattie Immunologiche e Allergiche).	Alderson P, 2004, COCHRANE LIB; ALDERSON P, 2002, GREEN S COCHRANE COL; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Dawson BD, 2004, BASIC CLIN BIOSTATIS, P118; Deeks J, 2001, SYSTEMATIC REV HLTH, P285, DOI 10.1002/9780470693926.ch15; DICKERSIN K, 1994, BRIT MED J, V309, P1286; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jorgensen AW, 2006, BRIT MED J, V333, P782, DOI 10.1136/bmj.38973.444699.0B; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOHER D, 2007, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.MR000025; Moher D, 1999, HEALTH TECHNOL ASSES, V3, P12; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1395-9995.2006.01098.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Pham-Thi N, 2007, PEDIATR ALLERGY IMMU, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Shekelle PG, 1999, BRIT MED J, V318, P593; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; 2004, REVMAN 4 2 7 PROGRAM	33	110	117	0	1	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	NOV	2009	64	11					1570	1579		10.1111/j.1398-9995.2009.02129.x		10	Allergy; Immunology	Allergy; Immunology	504SR	WOS:000270638400002	19796205	
J	Jaakkola, JJK; Knight, TL				Jaakkola, Jouni J. K.; Knight, Trudy L.			The role of exposure to phthalates from polyvinyl chloride products in the development of asthma and allergies: A systematic review and meta-analysis	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						allergy; asthma; phthalates; polyvinyl chloride	MEAT-WRAPPERS ASTHMA; SUBCUTANEOUS INJECTION MODEL; INTERIOR SURFACE MATERIALS; BALB/C MICE; DI-(2-ETHYLHEXYL) PHTHALATE; MONO-2-ETHYLHEXYL PHTHALATE; OCCUPATIONAL ASTHMA; PULMONARY-FUNCTION; RESPIRATORY-TRACT; YOUNG-CHILDREN	BACKGROUND: Phthalates from polyvinyl chloride (PVC) plastics may have adverse effects on airways and immunologic systems, but the evidence has not been reviewed systematically. OBJECTIVE: We reviewed the evidence for the role of exposure to phthalates from PVC products in the development of asthma and allergies. Methods: We conducted a Medline database search (1950 through May 2007) for relevant studies on the respiratory and allergic effects of exposure to phthalates from PVC products. RESULTS: We based this review on 27 human and 14 laboratory toxicology studies. Two mouse inhalation experiments indicated that mono-2-ethylhexyl phthalate (MEHP) has the ability to modulate the immune response to exposure to a coallergen. The data suggested a no observed effect level of 30 mu g MEHp/m(3), calculated to be below the estimated level of human exposure in common environments. Case reports and series (n = 9) identified and verified cases of asthma that were very likely caused by fumes emitted from PVC film. Epidemiologic studies in adults (n = 10), mostly small studies in occupational settings, showed associations between heated PVC fumes and asthma and respiratory symptoms; studies in children (n = 5) showed an association between PVC surface materials in the home and the risk of asthma [fixed-effects model: summary odds ratio (OR), 1.55; 95% confidence interval (CI), 1.18-2-05; four studies] and allergies (OR, 1.32; 95% CI, 1.09-1.60; three studies). CONCLUSIONS: High levels of phthalates from PVC products can modulate the murine immune response to a coallergen. Heated PVC fumes possibly contribute to development of asthma in adults. Epidemiologic studies in children show associations between indicators of phthalate exposure in the home and risk of asthma and allergies. The lack of objective exposure information limits the epidemiologic data.	[Jaakkola, Jouni J. K.; Knight, Trudy L.] Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England	Jaakkola, JJK (reprint author), Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England.	j.jaakkola@bham.ac.uk	Jaakkola, Jouni/G-4314-2012				Adibi JJ, 2003, ENVIRON HEALTH PERSP, V111, P1719, DOI 10.1289/ehp.6235; ANDRASCH R H, 1976, Journal of the American Medical Association, V235, P937, DOI 10.1001/jama.235.9.937; ANDRASCH RH, 1976, J ALLERGY CLIN IMMUN, V58, P291, DOI 10.1016/0091-6749(76)90134-2; BALLY MB, 1980, TOXICOLOGY, V18, P49, DOI 10.1016/0300-483X(80)90037-2; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bornehag CG, 2004, INDOOR AIR, V14, P59, DOI 10.1111/j.1600-0668.2004.00274.x; BROOKS SM, 1977, J OCCUP ENVIRON MED, V19, P192; Brunetti G, 1984, Med Lav, V75, P120; Butala JH, 2004, TOXICOLOGY, V201, P77, DOI 10.1016/j.tox.2004.04.004; Butler J, 1981, Chest, V80, P71; Cipolla C, 1999, Med Lav, V90, P513; Clark K, 2003, HANDB ENVIRON CHEM, V3, P125; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOELMAN CJA, 1990, LANCET, V335, P725, DOI 10.1016/0140-6736(90)90839-W; EISEN EA, 1985, SCAND J WORK ENV HEA, V11, P21; *EUR CHEM BUR, 2006, R0420402ENVHH46 EUR; FALK H, 1976, JAMA-J AM MED ASSOC, V235, P915, DOI 10.1001/jama.235.9.915; Frederiksen H, 2007, MOL NUTR FOOD RES, V51, P899, DOI 10.1002/mnfr.20060243; Glue C, 2005, BASIC CLIN PHARMACOL, V96, P140, DOI 10.1111/j.1742-7843.2005.pto960208.x; Glue C, 2002, TOXICOL IN VITRO, V16, P657, DOI 10.1016/S0887-2333(02)00082-6; Hansen JS, 2007, TOXICOLOGY, V232, P79, DOI 10.1016/j.tox.2006.12.011; Hauser R, 2005, Occup Environ Med, V62, P806, DOI 10.1136/oem.2004.017590; Hoppin JA, 2004, ENVIRON HEALTH PERSP, V112, P571; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P560, DOI 10.2105/AJPH.94.4.560; Jaakkola JJK, 2006, AM J EPIDEMIOL, V164, P742, DOI 10.1093/aje/kwj249; Jepsen KF, 2004, TOXICOL IN VITRO, V18, P265, DOI 10.1016/j.tiv.2003.09.008; KLIMISCH HJ, 1992, FOOD CHEM TOXICOL, V30, P915, DOI 10.1016/0278-6915(92)90175-K; Kolarik B, 2008, ENVIRON HEALTH PERSP, V116, P98, DOI 10.1289/ehp.10498; Larsen ST, 2007, TOXICOLOGY, V235, P119, DOI 10.1016/j.tox.2007.03.010; Larsen ST, 2004, HUM EXP TOXICOL, V23, P537, DOI 10.1191/0960327104ht486oa; Larsen ST, 2003, FOOD CHEM TOXICOL, V41, P439, DOI 10.1016/S0278-6915(02)00248-X; Larsen ST, 2002, PHARMACOL TOXICOL, V91, P264, DOI 10.1034/j.1600-0773.2002.910508.x; Larsen ST, 2001, TOXICOL LETT, V125, P11; Larsen ST, 2001, TOXICOLOGY, V169, P37, DOI 10.1016/S0300-483X(01)00484-X; LEE HS, 1989, BRIT J IND MED, V46, P820; MANTEL N, 1959, J NATL CANCER I, V22, P719; MARKOWITZ JS, 1989, ARCH ENVIRON HEALTH, V44, P30; MEEK ME, 1994, ENVIRON CARCIN ECO R, V12, P179; MOISAN TC, 1991, J OCCUP ENVIRON MED, V33, P458; Munoz X, 2003, ARCH BRONCONEUMOL, V39, P324; Nakamura R, 2002, IMMUNOL LETT, V80, P119, DOI 10.1016/S0165-2478(01)00318-2; NIELSEN J, 1989, INT ARCH OCC ENV HEA, V61, P427, DOI 10.1007/BF00386474; Norback D, 2000, INT J TUBERC LUNG D, V4, P1016; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; OIO L, 1999, EPIDEMIOLOGY, V110, P294; PAULI G, 1980, CLIN ALLERGY, V10, P263, DOI 10.1111/j.1365-2222.1980.tb02106.x; Petersen JH, 2000, FOOD ADDIT CONTAM, V17, P133, DOI 10.1080/026520300283487; *PLAST INF CTR, 2007, WHAT AR PLAST; POLAKOFF PL, 1975, ARCH ENVIRON HEALTH, V30, P269; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; SOKOL WN, 1973, JAMA-J AM MED ASSOC, V226, P639, DOI 10.1001/jama.226.6.639; Sterne J, 2001, SYSTEMATIC REV HLTH, P347, DOI DOI 10.1002/9780470693926; Tuomainen A, 2006, ENVIRON HEALTH PERSP, V114, P1409, DOI 10.1289/ehp.8965; Tuomainen Anneli, 2004, Int Arch Occup Environ Health, V77, P222, DOI 10.1007/s00420-003-0481-2; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x	58	110	117	7	48	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2008	116	7					845	853		10.1289/ehp.10846		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	319ST	WOS:000257185000025	18629304	
J	Rogers, DF				Rogers, Duncan F.			Physiology of airway mucus secretion and pathophysiology of hypersecretion	RESPIRATORY CARE			English	Article; Proceedings Paper	39th Conference of the Respiratory-Care-Journal	2007	Orlando, FL	Respiratory Care Journal		mucin; mucus; asthma; chronic obstructive pulmonary disease; cystic fibrosis	GOBLET CELL HYPERPLASIA; OBSTRUCTIVE PULMONARY-DISEASE; HUMAN MUCIN GENES; RESPIRATORY-TRACT; MUCOCILIARY CLEARANCE; CYSTIC-FIBROSIS; PERIPHERAL AIRWAYS; SURFACE EPITHELIUM; CHRONIC-BRONCHITIS; STATUS-ASTHMATICUS	Mucus secretion is the first-line defense against the barrage of irritants that inhalation of approximately 500 L of air an hour brings into the lungs. The inhaled soot, dust, microbes, and gases can all damage the airway epithelium. Consequently, mucus secretion is extremely rapid, occurring in tens of milliseconds. In addition, mucus is held in cytoplasmic granules in a highly condensed state in which high concentrations of Ca2+ nullify the repulsive forces of the highly polyanionic mucin molecules. Upon initiation of secretion and dilution of the Ca2+, the repulsion forces of the mucin molecules cause many-hundred-fold swelling of the secreted mucus, to cover and protect the epithelium. Secretion is a highly regulated process, with coordination by several molecules, including soluble N-ethyl-maleimide-sensitive factor attachment protein receptor (SNARE) proteins, myristoylated alanine-rich C kinase substrate (MARCKS), and Munc proteins, to dock the mucin granules to the secretory cell membrane prior to exocytosis. Because mucus secretion appears to be such a fundamental airway homeostatic process, virtually all regulatory and inflammatory mediators and interventions that have been investigated increase secretion acutely. When given longer-term, many of these same mediators also increase mucin gene expression and mucin synthesis, and induce goblet cell hyperplasia. These responses induce (in contrast to the protective effects of acute secretion) long-term, chronic hypersecretion of airway mucus, which contributes to respiratory disease. In this case the homeostatic, protective function of airway mucus secretion is lost, and, instead, mucus hypersecretion contributes to pathophysiology of a number of severe respiratory conditions, including asthma, chronic obstructive pulmonary disease, and cystic fibrosis.	Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London, England	Rogers, DF (reprint author), Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London, England.	duncan.rogers@imperial.ac.uk					AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; AIKAWA T, 1989, AM REV RESPIR DIS, V140, P477; Aitken M L, 1989, Symp Soc Exp Biol, V43, P73; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479; AYERS MM, 1988, EUR RESPIR J, V1, P58; BASBAUM CB, 1990, ANNU REV PHYSIOL, V52, P97; BHASKAR KR, 1988, PEDIATR PULM, V5, P176, DOI 10.1002/ppul.1950050308; British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; BUIST AS, 2003, EXECUTIVE SUMMARY GL; Burgel PR, 2004, THORAX, V59, P992, DOI 10.1136/thx.2003.018879; Davies JR, 2002, NOVART FDN SYMP, V248, P76; Del Donno M, 2000, CHEST, V118, P1142, DOI 10.1378/chest.118.4.1142; Dell A, 2001, SCIENCE, V291, P2351, DOI 10.1126/science.1058890; Donnelly LE, 2003, EXPERT OPIN THER PAT, V13, P1345, DOI 10.1517/13543776.13.9.1345; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUNNILL MS, 1975, P INT C ASTH 1974 AS, P213; Eapen SS, 2002, CL ALLER IM, V16, P325; FICK RB, 1987, J APPL PHYSIOL, V63, P1147; Finkbeiner WE, 1999, RESP PHYSIOL, V118, P77, DOI 10.1016/S0034-5687(99)00080-8; Foster KA, 2005, DRUG DISCOV TODAY, V10, P563, DOI 10.1016/S1359-6446(05)03389-1; Guyonnet Duperat Veronique, 1995, Biochemical Journal, V305, P211; Hanisch FA, 2001, BIOL CHEM, V382, P143, DOI 10.1515/BC.2001.022; Henke MO, 2007, AM J RESP CRIT CARE, V175, P816, DOI 10.1164/rccm.200607-1011OC; Henke MO, 2004, AM J RESP CELL MOL, V31, P86, DOI 10.1165/rcmb.2003-0345OC; Hewson CA, 2004, J MOL BIOL, V344, P683, DOI 10.1016/j.jmb.2004.09.059; Hollander W, 1986, Arch Toxicol Suppl, V9, P74; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; Houtmeyers E, 1999, EUR RESPIR J, V13, P1177, DOI 10.1034/j.1399-3003.1999.13e39.x; Hovenberg HW, 1996, BIOCHEM J, V318, P319; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Koch H, 2000, BIOCHEM J, V349, P247, DOI 10.1042/0264-6021:3490247; Li YH, 2001, J BIOL CHEM, V276, P40982, DOI 10.1074/jbc.M105614200; LIPPMANN M, 1980, BRIT J IND MED, V37, P337; LIST SJ, 1978, BIOCHEM J, V175, P565; Maestrelli P, 2001, AM J RESP CRIT CARE, V164, pS76; MARRIOTT C, 1982, ADV EXP MED BIOL, V144, P89; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Moniaux N, 2001, FRONT BIOSCI, V6, pD1192, DOI 10.2741/Moniaux; MORGENROTH K, 1985, RESPIRATION, V47, P225; MULLEN JBM, 1987, THORAX, V42, P843, DOI 10.1136/thx.42.11.843; Nadel Jay A., 2001, Current Opinion in Pharmacology, V1, P254, DOI 10.1016/S1471-4892(01)00045-5; Newman TM, 1996, AM J RESP CELL MOL, V15, P529; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Reid CJ, 1997, AM J RESP CELL MOL, V17, P592; REID L, 1956, Proc R Soc Med, V49, P771; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; RESTREPO G, 1963, J PATHOL BACTERIOL, V85, P305, DOI 10.1002/path.1700850207; RESTREPO G. L., 1963, THORAX, V18, P334, DOI 10.1136/thx.18.4.334; Robinson M, 2002, PEDIATR PULM, V33, P293, DOI 10.1002/ppul.10079; ROGERS AV, 1993, EUR RESPIR J, V6, P498; Rogers DF, 2006, ANN MED, V38, P116, DOI 10.1080/07853890600585795; ROGERS DF, 1992, BRIT MED BULL, V48, P120; Rogers DF, 2004, CURR OPIN PHARMACOL, V4, P241, DOI 10.1016/j.coph.2004.01.011; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Rogers DF, 2002, CLIN EXP ALLERGY, V32, P1124, DOI 10.1046/j.1365-2745.2002.01474.x; ROGERS DF, 1994, EUR RESPIR J, V7, P1690; Rogers DF, 2007, RESP CARE, V52, P1176; Rogers DF, 2007, RESP CARE, V52, P1134; Rogers Duncan F, 2005, COPD, V2, P341, DOI 10.1080/15412550500218098; Rogerson P. A., 1997, INT J POPULATION GEO, V3, P121; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138; Saetta M, 2000, AM J RESP CRIT CARE, V161, P1016; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Sheehan JK, 1999, BIOCHEM J, V338, P507, DOI 10.1042/0264-6021:3380507; SHEEHAN JK, 1995, AM J RESP CELL MOL, V13, P748; SHEHAN JK, 1991, AM REV RESPIR DIS, V144, pS4; Singh G, 2000, ANN NY ACAD SCI, V923, P43; SLEIGH MA, 1988, AM REV RESPIR DIS, V137, P726; STEIGER D, 1994, AM J RESP CELL MOL, V10, P538; THORNTON DJ, 1994, AM J RESP CRIT CARE, V150, P823; THORNTON DJ, 1991, BIOCHEM J, V276, P677; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; Thornton DJ, 1996, BIOCHEM J, V316, P967; THORNTON DJ, 1990, BIOCHEM J, V265, P179; Toda M, 2002, J ALLERGY CLIN IMMUN, V109, P246, DOI 10.1067/mai.2002.121555; Vestbo J, 2002, NOVART FDN SYMP, V248, P3; Wickstrom C, 1998, BIOCHEM J, V334, P685; WILLIAMS IP, 1983, THORAX, V38, P682, DOI 10.1136/thx.38.9.682; Zhou YH, 2002, NOVART FDN SYMP, V248, P150	83	110	129	2	14	DAEDALUS ENTERPRISES INC	IRVING	9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA	0020-1324			RESP CARE	Respir. Care	SEP	2007	52	9					1134	1149				16	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	209OM	WOS:000249397900002	17716382	
J	Akei, HS; Mishra, A; Blanchard, C; Rothenberg, ME				Akei, HS; Mishra, A; Blanchard, C; Rothenberg, ME			Epicutaneous antigen exposure primes for experimental eosinophilic esophagitis in mice	GASTROENTEROLOGY			English	Article							STAT6-DEFICIENT MICE; ATOPIC-DERMATITIS; AIRWAY HYPERRESPONSIVENESS; GASTROINTESTINAL DISORDERS; ALLERGIC DERMATITIS; MURINE MODEL; T-CELLS; ASTHMA; CHILDREN; IL-5	Background & Aims: Eosinophilic esophagitis (EE) is frequently associated with atopic disease, including dermatitis and asthma. Data are emerging that atopic skin may provide an early entry point for antigen sensitization. We aimed to test the hypothesis that epicutaneous exposure to antigen primes for subsequent respiratory antigen-induced EE. Methods: Wild-type and genetically engineered mice were subjected to epicutaneous antigen sensitization and the development of experimental EE, and immune responses were examined. Results: We show that exposure to antigen via the epicutaneous route primes for marked eosinophilic inflammation in the esophagus triggered by a single airway antigen challenge. The development of experimental EE is associated with significant skin eosinophilia, accelerated bone marrow eosinophilopoiesis, blood eosinophilia, and large increases in serum antigen-specific immunoglobulin G1/immunoglobulin E using ovalbumin or Aspergillus fumigatus as the epicutaneous antigen. Mechanistic analysis with gene-targeted mice showed that interleukin-5 was required for esophageal eosinophilia and that interleukin-4, interleukin-13, and STAT6 contributed to a lesser extent. Conclusions: These findings provide the first evidence that epicutaneous exposure to allergens potently primes for EE via a Th2-dependent mechanism.	Univ Cincinnati, Childrens Hosp, Ctr Med, Div Allergy & Immunol,Dept Pediat, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45221 USA	Rothenberg, ME (reprint author), Univ Cincinnati, Childrens Hosp, Ctr Med, Div Allergy & Immunol,Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	rothenberg@cchmc.org			NIAID NIH HHS [AI42242, AI45898]		Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Blease K, 2002, AM J PATHOL, V160, P481, DOI 10.1016/S0002-9440(10)64867-5; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Brandt EB, 2001, J ALLERGY CLIN IMMUN, V108, P142, DOI 10.1067/mai.2001.116121; BUSSE WW, 2000, ANIMAL MODELS ASTHMA, V2, P1205; CELLO JP, 1979, AM J MED, V67, P1097, DOI 10.1016/0002-9343(79)90652-1; Corry David B, 2002, Am J Respir Med, V1, P185; Eichenfield LF, 2003, PEDIATRICS, V111, P608, DOI 10.1542/peds.111.3.608; Fox VL, 2002, GASTROINTEST ENDOSC, V56, P260, DOI 10.1067/mge.2002.126390; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Guajardo JR, 2002, J PEDIATR-US, V141, P576, DOI 10.1067/mpd.2002.127663; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Justinich CJ, 1997, J PEDIATR GASTR NUTR, V25, P194, DOI 10.1097/00005176-199708000-00011; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Lai SY, 1996, EMBO J, V15, P4506; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Lee NA, 1997, J IMMUNOL, V158, P1332; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; Liacouras CA, 2003, J PEDIATR GASTR NUTR, V37, pS23, DOI 10.1097/00005176-200311001-00006; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1053/S0016-5085(03)01352-0; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Murata T, 1996, J IMMUNOL, V156, P2972; Nicholson AG, 1997, J PATHOL, V183, P233, DOI 10.1002/(SICI)1096-9896(199710)183:2<233::AID-PATH936>3.0.CO;2-Z; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1053/S1542-3565(04)00240-X; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594; Rothenberg ME, 2004, J ALLERGY CLIN IMMUN, V113, P11, DOI 10.1016/j.jaci.2003.10.047; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Saito H, 2002, J IMMUNOL, V168, P3017; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/S0016-5085(03)01515-4; Takeda K, 1996, J IMMUNOL, V157, P3220; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; Trifilieff A, 2000, BRIT J PHARMACOL, V130, P1581, DOI 10.1038/sj.bjp.0703501; van Neste D, 1985, Acta Derm Venereol Suppl (Stockh), V114, P67; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; Wang L F, 1996, J Immunol, V156, P4077; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zimmermann N, 2004, J IMMUNOL, V172, P1815; ZURAWSKI G, 1994, STEM CELLS, V12, P169	55	110	113	0	1	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0016-5085			GASTROENTEROLOGY	Gastroenterology	SEP	2005	129	3					985	994		10.1053/j.gastro.2005.06.027		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	963PO	WOS:000231816500024	16143136	
J	Jaakkola, JJK; Hwang, BF; Jaakkola, N				Jaakkola, JJK; Hwang, BF; Jaakkola, N			Home dampness and molds, parental atopy, and asthma in childhood: A six-year population-based cohort study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; damp housing; effect modification; interaction; molds	ENVIRONMENTAL-FACTORS; RESPIRATORY SYMPTOMS; CHILDREN; HEALTH; INFLAMMATION; SIGNS	Previous studies of how parental atopy and exposure to dampness and molds contribute to the risk of asthma have been mainly cross-sectional or prevalent case-control studies, where selection and information bias and temporality constitute problems. We assessed longitudinally the independent and joint effects of parental atopy and exposure to molds in dwellings on the development of asthma in childhood. We conducted a population-based, 6-year prospective cohort study of 1,984 children 1-7 years of age at the baseline in 1991 (follow-up rate, 77%). The study population included 1,916 children without asthma at baseline and complete outcome information. The data collection included a baseline and follow-up survey. The outcome of interest was development of asthma during the study period. The studied determinants were parental allergic diseases and four indicators of exposure at baseline: histories of water damage, presence of moisture and visible molds, and perceived mold odor in the home. A total of 138 (7.2%) children developed asthma during the study period, resulting in an incidence rate of 125 cases per 10,000 person-years [95% confidence interval (CI), 104-146]. In Poisson regression adjusting for confounding, parental atopy [adjusted incidence rate ratio (IRR) 1.52; 95% Cl, 1.08-2.13] and the presence of mold odor in the home reported at baseline (adjusted IRR 2.44; 95% Cl, 1.07-5.60) were independent determinants of asthma incidence, but no apparent interaction was observed. The results of this cohort study with assessment of exposure before the onset of asthma strengthen the evidence on the independent effects of parental atopy and exposure to molds on the development of asthma.	Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, FIN-00014 Helsinki, Finland; Diwan Coll Management, Dept Hlth Care Adm, Tainan, Taiwan	Jaakkola, JJK (reprint author), Univ Birmingham, Inst Occupat & Environm Med, Birmingham B15 2TT, W Midlands, England.	j.jaakkola@bham.ac.uk	Jaakkola, Jouni/G-4314-2012; Hwang, Bing-Fang /O-2709-2015	Hwang, Bing-Fang /0000-0002-5951-9662			ANDRAE S, 1988, ARCH DIS CHILD, V63, P473; BELANGER K, AM J EPIDEMIOL, V158, P195; BOMEHAG CG, INDOOR AIR, V11, P72; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; BRUNEKREEF B, 1992, SCI TOTAL ENVIRON, V15, P79; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Johanning E, 1999, ENVIRON HEALTH PERSP, V107, P489; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073; Mutitts E, 1994, AM J RESP CRIT CARE, V149, P358; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Rothman KJ, 1985, MODERN EPIDEMIOLOGY, P311; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Yang CY, 1997, ENVIRON RES, V75, P49, DOI 10.1006/enrs.1997.3774	21	110	114	2	15	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2005	113	3					357	361		10.1289/ehp.7242		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	903MM	WOS:000227430100048	15743728	
J	Goodwin, RD; Fergusson, DM; Horwood, LJ				Goodwin, RD; Fergusson, DM; Horwood, LJ			Asthma and depressive and anxiety disorders among young persons in the community	PSYCHOLOGICAL MEDICINE			English	Article							POSTTRAUMATIC-STRESS-DISORDER; PSYCHIATRIC-DISORDERS; FUNCTIONAL STATUS; PANIC DISORDER; CHILDREN; PREVALENCE; CHILDHOOD; MORBIDITY; OUTCOMES; OUTPATIENTS	Background. The objectives of the study were to examine linkages between asthma and depressive and anxiety disorders in a birth cohort of over 1000 young persons studied to the age of 21 years. Specifically, the study aimed to ascertain the extent to which associations between asthma and depressive and anxiety disorders could be explained by non-observed fixed confounding factors. Method. Asthma and depressive and anxiety disorders were measured prospectively over the course of a 21-year longitudinal study. Fixed effects logistic regression models were used to determine the relationship between asthma and depressive and anxiety disorders, adjusting for potentially confounding factors. Results. Asthma in adolescence and young adulthood was associated with increased likelihood of major depression (OR 1(.)7, 95 % CI 1(.)3-2(.)3), panic attacks (OR 1(.)9, 95 % CI 1(.)3-2(.)8), and any anxiety disorder (OR 1(.)6, 95% CI 1(.)2-2(.)2). Associations between asthma and depressive and anxiety disorders were adjusted for confounding factors using a fixed effects regression model which showed that, after control for fixed confounding factors, asthma was no longer significantly related to major depression (OR 1(.)1), panic attacks (OR 1(.)1),or any anxiety disorder (OR 1(.)2). Additional post hoe analyses suggested that exposure to childhood adversity or unexamined familial factors may account for some of the co-morbidity of asthma and depressive and anxiety disorders. Conclusions. These results confirm and extend previous findings by documenting elevated rates of depressive and anxiety disorders among young adults with asthma, compared with their counterparts without asthma, in the community. The weight of the evidence from this study suggests that associations between asthma and depressive and anxiety symptoms may reflect effects of common factors associated with both asthma and depressive and anxiety disorders, rather than a direct causal link. Future research is needed to identify the specific factors underlying these associations.	Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, Unit 43, New York, NY 10032 USA; Christchurch Sch Med & Hlth Sci, Dept Psychol Med, Christchurch Hlth & Dev Study, Christchurch, New Zealand	Goodwin, RD (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, Unit 43, 1051 Riverside Dr, New York, NY 10032 USA.	rdg66@columbia.edu		Fergusson, David/0000-0002-8117-017X; Horwood, L./0000-0003-4881-1956	NIMH NIH HHS [MH64736]		Afari N, 2001, J CLIN PSYCHOL MED S, V8, P245, DOI 10.1023/A:1011912712262; American Psychiatric Association ( APA), 1994, DIAGN STAT MAN MENT; ASHER MI, 2000, NZ MED J, V23, P114; Brown ES, 2000, INT J PSYCHIAT MED, V30, P319; Bussing R, 1996, PSYCHOSOMATICS, V37, P108; Carlin JB, 1999, STAT MED, V18, P2655, DOI 10.1002/(SICI)1097-0258(19991015)18:19<2655::AID-SIM202>3.3.CO;2-R; Carr RE, 1998, J PSYCHOSOM RES, V44, P43, DOI 10.1016/S0022-3999(97)00137-2; Cunningham J, 1996, AM J PUBLIC HEALTH, V86, P1406, DOI 10.2105/AJPH.86.10.1406; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; Fergusson DM, 1996, J AM ACAD CHILD PSY, V35, P1355, DOI 10.1097/00004583-199610000-00023; Fergusson DM, 1997, CHILD ABUSE NEGLECT, V21, P617, DOI 10.1016/S0145-2134(97)00021-5; Fergusson D. M., 2003, RESILIENCE VULNERABI, P130, DOI DOI 10.1017/CBO9780511615788.008; Goethe JW, 2001, ANN ALLERG ASTHMA IM, V87, P205; Goodwin RD, 2003, PSYCHOL MED, V33, P879, DOI 10.1017/S0033291703007633; Greaves CJ, 2002, THORAX, V57, P217, DOI 10.1136/thorax.57.3.217; Hamerle A, 1995, HDB STAT MODELING SO, P401; HOLT S, 2000, NZ MED J, V11, P39; Koltek M, 1998, CAN J PSYCHIAT, V43, P64; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; McQuaid EL, 2001, J DEV BEHAV PEDIATR, V22, P430; Nascimento I, 2002, PSYCHIAT RES, V110, P73, DOI 10.1016/S0165-1781(02)00029-X; Ortega AN, 2002, J NERV MENT DIS, V190, P275, DOI 10.1097/01.NMD.0000016250.84828.0D; Ortega AN, 2003, SOC PSYCH PSYCH EPID, V38, P220, DOI 10.1007/s00127-003-0623-6; Perna G, 1997, BIOL PSYCHIAT, V42, P625, DOI 10.1016/S0006-3223(96)00436-2; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Slattery MJ, 2002, J AM ACAD CHILD PSY, V41, P947, DOI 10.1097/00004583-200208000-00013; *STAT, 1999, STAT STAT SOFTW; Sterk PJ, 1999, EUR RESPIR J, V14, P1435, DOI 10.1183/09031936.99.14614359; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Swadi H, 2001, J TROP PEDIATRICS, V47, P106, DOI 10.1093/tropej/47.2.106; Vila G, 2000, J AFFECT DISORDERS, V58, P223, DOI 10.1016/S0165-0327(99)00110-X; Weil CM, 1999, PEDIATRICS, V104, P1274, DOI 10.1542/peds.104.6.1274; Weisberg RB, 2002, PSYCHIATR SERV, V53, P848, DOI 10.1176/appi.ps.53.7.848; WEISS KB, 2000, ASTHMAS IMPACT SOC; World Health Organization, 1993, COMP INT DIAGN INT C; YELLOWLEES PM, 1987, MED J AUSTRALIA, V146, P305; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	37	110	115	1	11	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917			PSYCHOL MED	Psychol. Med.	NOV	2004	34	8					1465	1474		10.1017/S0033291704002739		10	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	878XM	WOS:000225680700009	15724877	
J	Marogna, M; Spadolini, I; Massolo, A; Canonica, GW; Passalacqua, G				Marogna, M; Spadolini, I; Massolo, A; Canonica, GW; Passalacqua, G			Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more	ALLERGY			English	Article						adherence; bronchial hyperreactivity; preventive effect; respiratory allergy; sublingual immunotherapy	HOUSE-DUST MITE; CONTROLLED-TRIAL; SEASONAL RHINOCONJUNCTIVITIS; DOUBLE-BLIND; ASTHMA; CHILDREN; SENSITIZATIONS; STANDARDIZATION; RESPONSIVENESS; PREVENTION	Background: Some aspects of sublingual immunotherapy (SLIT) still need to be addressed: magnitude of the clinical efficacy, effect on the bronchial hyperreactivity adherence to treatment, preventive effect. We attempted to clarify these points in a randomized open, controlled, two parallel group study in a real-life setting. Methods: Five hundred and eleven patients with allergic rhinitis with or without intermittent asthma were randomized to drugs only or drugs + SLIT (rate 2 : 3) for 3 years. The clinical score (symptoms + drug intake) was measured each year during the allergen exposure. Pulmonary function test, methacholine challenge and skin tests were performed at the beginning and at the end of the study. Adherence to treatment was assessed by measuring the consumed extract. Results: Three hundred and nineteen patients received SLIT and 192 drugs only. Dropouts were 15% in the SLIT group and 12% in the controls. There was a significant improvement of clinical scores in the SLIT group: baseline 147 +/- 3.3, first year 72.9 +/- 1.3, second year 68.3 +/- 1.8, third year 54.7 +/- 2.8 (P < 0.0001 vs baseline). Control group: baseline 138 +/- 2.3, first year 124.1 +/- 3.7, second year 111 +/- 3.3, third year 121 +/- 3.8 (P = NS). Only four patients reported systemic itching. Adherence was >80% in 72% and >60% in 18% of patients. The number of patients with a positive MCh challenge decreased significantly after 3 years only in the SLIT group. New skin sensitizations appeared in 38% of the controls and in 5.9% of the SLIT patients (P = 0.01). Conclusion: Sublingual immunotherapy approximately halved the clinical scores and significantly reduced the bronchial hyperreactivity. Similarly to subcutaneous immunotherapy, SLIT displayed a preventive effect on the onset of new skin sensitizations. The adherence rate was quantitatively satisfactory.	Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Macchi Hosp Fdn, Pneumol Unit, Varese, Italy; Anallergo SpA, Dept Med, Florence, Italy; Univ Siena, Sect Behav Ecol Ethol & Wildlife Management, Dept Environm Sci, I-53100 Siena, Italy	Passalacqua, G (reprint author), Univ Genoa, Dept Internal Med, Padiglione Maragliano Lgo R Benzi 10, I-16132 Genoa, Italy.		Massolo, Alessandro/I-3437-2012				Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ALESSANDRO F, 1994, ANN ALLERGY, V73, P135; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; BOUSQUET J, 1998, ALLERGY S, V53, P20; BOUSQUET J, 2001, J ALLERGY CLIN IMM S, V107, P240; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; GOOD P, 2002, PERMUTATION TESTS PR; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Kagi MK, 2002, ALLERGY, V57, P379, DOI 10.1034/j.1398-9995.2002.01153.x; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; Lee SY, 2002, J ASTHMA, V39, P537, DOI 10.1081/JAS-120004924; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; Lombardi C, 2001, ALLERGY, V56, P889; Malling H J, 2001, Curr Opin Allergy Clin Immunol, V1, P43, DOI 10.1097/00130832-200102000-00008; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; National Institutes of Health, 1997, NIH PUBL; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Siegel S., 1998, NONPARAMETRIC STAT B; Sokal RR, 1995, BIOMETRY PRINCIPLES; *SPSS INC, 1999, SPSS ADV MOD 9 0, P497; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Wilson DR, 2003, COCHRANE DB SYST REV, V2	34	110	121	0	2	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	NOV	2004	59	11					1205	1210		10.1111/j.1398-9995.2004.00508.x		6	Allergy; Immunology	Allergy; Immunology	859WI	WOS:000224298200011	15461603	
J	Mattos, W; Lim, S; Russell, R; Jatakanon, A; Chung, F; Barnes, PJ				Mattos, W; Lim, S; Russell, R; Jatakanon, A; Chung, F; Barnes, PJ			Matrix metalloproteinase-9 expression in asthma - Effect of asthma severity, allergen challenge, and inhaled corticosteroids	CHEST			English	Article						allergen challenge; asthma; corticosteroid; matrix metalloproteinase; matrix metalloproteinase-9; tisstue inhibitors of matrix metalloproteinase	BRONCHOALVEOLAR LAVAGE FLUID; MATRIX METALLOPROTEINASES; BASEMENT-MEMBRANE; TISSUE INHIBITOR; 92-KDA GELATINASE; IV COLLAGENASE; TNF-ALPHA; ALVEOLAR MACROPHAGES; AIRWAY INFLAMMATION; TIMP-1 PRODUCTION	Background: Asthma is associated with remodeling of the extracellular matrix (ECM) and increased airway obstruction, and the mechanisms of this process are unknown. Matrix metalloproteinases (MMPs) are a group of enzymes capable of degrading the ECM. They are released along with their inhibitors, tissue inhibitor of MMP (TIMP). Study objectives: To determine whether severe, persistent asthma is associated with increased levels of MMP-9 in the airway compared with mild asthma, and to assess the effect of both allergen exposure and steroid treatment on MMP-9 and TIMP-1 levels. Design: Prospective analysis of levels and activity of MMP-9 and TIMP-1 in BAL fluid (BALF) and induced sputum obtained from asthmatics of differing disease severity. In patients with mild asthma, MMP-9 and TIMP-1 levels were studied in induced sputum following allergen challenge and in BALF after inhaled steroid therapy. Patients: Eighteen patients with mild asthma, 10 patients with severe asthma, and 10 nonsmoking, atopic subjects had their sputum studied. Fourteen of the patients with mild asthma underwent allergen challenge. BAL was collected from 16 patients with mild asthma before and after 4 weeks treatment with inhaled budesonide, 800 mug bid, or placebo. Results: Patients with severe asthma had increased levels and activity of sputum MMP-9 in their sputum compared with patients with mild asthma and normal subjects. Allergen challenge increased the MMP-9/TIMP-1 ratio and MMP-9 activity. Inhaled budesonide had no effect on MMP-9 or TIMP-1 in patients with mild asthma. Conclusions: MMP-9 may play a role in chronic airway inflammation and remodeling in asthma, as concentrations are increased in severe, persistent asthma and following allergen challenge. Inhaled steroids may not affect MMP-9 and TIMP in patients with mild asthma, and additional studies in patients with more severe asthma are needed.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Thorac Med, London WS3 6LY, England	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London WS3 6LY, England.	p.j.barnes@ic.ac.uk		Chung, Kian Fan/0000-0001-7101-1426			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Bosse M, 1999, AM J RESP CRIT CARE, V159, P596; CORCORAN ML, 1992, J BIOL CHEM, V267, P515; Dahlen B, 1999, THORAX, V54, P590; Delclaux C, 1996, AM J RESP CELL MOL, V14, P288; Di Girolamo N, 1998, EUR J IMMUNOL, V28, P1773, DOI 10.1002/(SICI)1521-4141(199806)28:06<1773::AID-IMMU1773>3.0.CO;2-B; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; John M, 1998, AM J RESP CRIT CARE, V157, P256; Johnatty RN, 1997, J IMMUNOL, V158, P2327; KAYAGAKI N, 1995, J EXP MED, V182, P1777, DOI 10.1084/jem.182.6.1777; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298; LEPPERT D, 1995, J IMMUNOL, V154, P4379; Massova I, 1998, FASEB J, V12, P1075; Mautino G, 1999, AM J RESP CRIT CARE, V160, P324; Mautino G, 1997, AM J RESP CELL MOL, V17, P583; MERTZ PM, 1994, J BIOL CHEM, V269, P21322; MURPHY G, 1994, J BIOL CHEM, V269, P6632; MURPHY G, 1992, AM J RESP CELL MOL, V7, P120; OCONNOR CM, 1994, THORAX, V49, P602, DOI 10.1136/thx.49.6.602; Ohno I, 1997, AM J RESP CELL MOL, V16, P212; Okada S, 1997, AM J RESP CELL MOL, V17, P519; OKADA Y, 1992, J BIOL CHEM, V267, P21712; Redigton AE, 1998, ASTHMA ALLERGIC DIS, P443; Roberts CR, 1997, ASTHMA, P925; ROCHE WR, 1989, LANCET, V1, P520; Saren P, 1996, J IMMUNOL, V157, P4159; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; Warner JA, 1997, INT ARCH ALLERGY IMM, V113, P318; Xia MH, 1996, J IMMUNOL, V156, P160; Yao PM, 1997, AM J PHYSIOL-LUNG C, V273, pL866; Zhang YH, 1998, J IMMUNOL, V161, P3071	38	110	118	0	5	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2002	122	5					1543	1552		10.1378/chest.122.5.1543		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	617TH	WOS:000179376600013	12426251	
J	Lin, M; Chen, Y; Burnett, RT; Villeneuve, PJ; Krewski, D				Lin, M; Chen, Y; Burnett, RT; Villeneuve, PJ; Krewski, D			The influence of ambient coarse particulate matter on asthma hospitalization in children: Case-crossover and time-series analyses	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma hospitalization; case-crossover analysis; coarse particulate matter; risk assessment; time-series analysis	CARBON-MONOXIDE LEVELS; EMERGENCY ROOM VISITS; AIR-POLLUTION; DAILY MORTALITY; FINE PARTICLES; PHILADELPHIA; ASSOCIATION; ADMISSIONS; SEATTLE; CALIFORNIA	In this study, we used both case-crossover and time-series analyses to assess the associations between size-fractionated particulate matter and asthma hospitalization among children 6-12 years old living in Toronto between 1981 and 1993. Specifically, we used exposures averaged over periods varying from 1 to 7 days to assess the effects of particulate matter on asthma hospitalization. We calculated estimates of the relative risk of asthma hospitalization adjusted for daily weather conditions (maximum and minimum temperatures, and average relative humidity) for an incremental exposure corresponding to the interquartile range in particulate matter. Both bidirectional case-crossover and time-series analyses revealed that coarse particulate matter (PM10-2.5) averaged over 5-6 days was significantly associated with asthma hospitalization in both males and females. The magnitude of this effect appeared to increase with increasing number of days of exposure averaging for most models, with the relative risk estimates stabilizing at about 6 days. Using a bidirectional case-crossover analysis, the estimated relative risks were 1.14 [95% confidence interval (CI), 1.02, 1.28] for males and 1.18 (95% CI, 1.02, 1.36) for females, for an increment of 8.4 mug/m(3) in 6-day averages of PM10-2.5. The corresponding relative risk estimates were 1.10 and 1.18, respectively, when we used time-series analysis. The effect Of PM10-2.5 remained positive after adjustment for the effects of the gaseous pollutants carbon monoxide (CO), nitrogen dioxide (NO2), sulfur dioxide (SO2), and ozone (O-3). We did not find significant effects of fine particulate matter (PM2.5) or of thoracic particulate matter (PM10) on asthma hospitalizations using either of these two analytic approaches. For the most part, relative risk estimates from the unidirectional case-crossover analysis were more pronounced compared with both bidirectional case-crossover and time-series analyses.	Univ Ottawa, Dept Epidemiol & Community Med, Fac Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON, Canada; Hlth Canada, Environm Hlth Directorate, Ottawa, ON, Canada	Chen, Y (reprint author), Univ Ottawa, Dept Epidemiol & Community Med, Fac Med, 451 Smyth Rd, Ottawa, ON K1H 8M5, Canada.						Bateson TF, 1999, EPIDEMIOLOGY, V10, P539, DOI 10.1097/00001648-199909000-00013; BURNETT R, 1994, CAN J STAT, V22, P441, DOI 10.2307/3315403; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, EPIDEMIOLOGY, V8, P162, DOI 10.1097/00001648-199703000-00007; Burnett RT, 1998, J AIR WASTE MANAGE, V48, P689; Cakmak S, 1999, RISK ANAL, V19, P487, DOI 10.1023/A:1007008914354; CAKMAK S, 1997, J EXPO ANAL ENV EPID, V8, P129; Dreher K.L., 1996, AM J RESP CRIT CARE, V153, pA15; FIREMAN P, 1990, ATLAS ALLERGIES; KLEINMAN MT, 1995, INHAL TOXICOL, V7, P589, DOI 10.3109/08958379509014467; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; KOREN HS, 1995, ENVIRON HEALTH PERSP, V103, P235, DOI 10.2307/3432379; Lee JT, 1999, ENVIRON HEALTH PERSP, V107, P633, DOI 10.2307/3434454; LI YZ, 1995, INHAL TOXICOL, V7, P45, DOI 10.3109/08958379509014270; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Loomis D, 2000, EPIDEMIOLOGY, V11, P2, DOI 10.1097/00001648-200001000-00002; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91; MOOLGAVKAR SH, 1995, EPIDEMIOLOGY, V6, P476, DOI 10.1097/00001648-199509000-00003; Morgan G, 1998, AM J PUBLIC HEALTH, V88, P1761, DOI 10.2105/AJPH.88.12.1761; Navidi W, 1998, BIOMETRICS, V54, P596, DOI 10.2307/3109766; Neas LM, 1999, ENVIRON HEALTH PERSP, V107, P629, DOI 10.2307/3434453; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Ostro BD, 1999, ENVIRON RES, V81, P231, DOI 10.1006/enrs.1999.3978; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P9; Priestly M. B., 1981, SPECTRAL ANAL TIME S; Scarlett JF, 1996, THORAX, V51, P1109, DOI 10.1136/thx.51.11.1109; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; SCHWARTZ T, 1961, ANTHROPOL LINGUIST, V3, P1; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; THOMSON NC, 1990, HDB CLIN ALLERGY; *US EPA, 1995, AIR QUAL CRIT PART M; *US EPA OFF AIR QU, 2000, NAT AMB AIR QUAL STA; World Health Organization, 1975, MAN INT STAT CLASS D; Wordley J, 1997, OCCUP ENVIRON MED, V54, P108	38	110	113	1	11	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2002	110	6					575	581				7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	561HV	WOS:000176134900021	12055048	
J	Hunt, JF; Erwin, E; Palmer, L; Vaughan, J; Malhotra, N; Platts-Mills, TAE; Gaston, B				Hunt, JF; Erwin, E; Palmer, L; Vaughan, J; Malhotra, N; Platts-Mills, TAE; Gaston, B			Expression and activity of pH-regulatory glutaminase in the human airway epithelium	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; glutaminase; ammonia; lung; breath condensate	MYCOBACTERIUM-TUBERCULOSIS; RESPIRATORY MUCUS; BUFFER CAPACITY; SURFACE LIQUID; TRACHEAL; MACROPHAGES; AMMONIA; ASTHMA; EOSINOPHILS; METABOLISM	Fluid condensed from the breath of patients with acute asthma is acidic. Several features of asthma pathophysiology can be initiated by exposure of the airway to acid. In renal tubular epithelium, glutaminase produces ammonia to buffer urinary acid excretion. We hypothesized that human airway epithelium could also express glutaminase. Here, we demonstrate that human airway epithelial cells in vitro have biochemical evidence for glutaminase activity and express mRNA for two glutaminase isoforms (KGA and GAC). Glutaminase activity increased in response to acidic stress (media PH 5.8) and was associated with both increased culture medium pH and improved cell survival. In contrast, activity was inhibited by interferon-gamma and tumor necrosis factor-a. Glutaminase protein was expressed in the human airway in vivo. Further, ammonia levels in the breath condensate of subjects with acute asthma were low (30 muM [range: 0-233], n = 18, age 23 +/- 2.5 yr) compared with control subjects (327 muM [14-1,220], n 24, age 24 +/- 2.4 yr, p < 0.001), and correlated with condensate pH (r = 0.58, p < 0.001). These data demonstrate that glutaminase is expressed and active in the human airway epithelium and may be relevant both to the regulation of airway pH and to the pathophysiology of acute asthmatic airway inflammation.	Univ Virginia, Hlth Syst, Dept Pediat, Div Pediat Resp Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Div Allergy Asthma & Immunol, Charlottesville, VA 22908 USA	Gaston, B (reprint author), Univ Virginia, Hlth Syst, Dept Pediat, Div Pediat Resp Med, Box 386, Charlottesville, VA 22908 USA.				NHLBI NIH HHS [R01 HL59337]; PHS HHS [1U19-A134067]		ACEVEDO M, 1993, EXP PHYSIOL, V78, P383; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; CANGRO CB, 1985, BRAIN RES, V336, P158, DOI 10.1016/0006-8993(85)90428-7; CHAVALITTAMRONG B, 1979, RESPIRATION, V38, P112; CROW JP, 1994, FREE RADICAL BIO MED, V16, P331, DOI 10.1016/0891-5849(94)90034-5; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823; CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025; Elgadi KM, 1999, PHYSIOL GENOMICS, V1, P51; Gaston B, 1997, LUNG SCI FDN, P239; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; Govindaraju K, 1997, ANAL CHEM, V69, P2793, DOI 10.1021/ac961249v; Hack V, 1997, AM J PHYSIOL-ENDOC M, V272, pE788; HARTH G, 1994, P NATL ACAD SCI USA, V91, P9342, DOI 10.1073/pnas.91.20.9342; HOGG JC, 1984, CLIN CHEST MED, V5, P567; HOLMA B, 1985, SCI TOTAL ENVIRON, V41, P101, DOI 10.1016/0048-9697(85)90181-0; HOLMA B, 1977, ARCH ENVIRON HEALTH, V32, P216; HOLMA P, 1989, SCI TOTAL ENVIRON, V84, P71; Hunt J, 1999, AM J RESP CRIT CARE, V159, pA860; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; JACK CIA, 1995, THORAX, V50, P201, DOI 10.1136/thx.50.2.201; Kew S, 1999, J NUTR, V129, P1524; Kurashima K, 1996, LAB INVEST, V75, P689; KYLE H, 1990, J APPL PHYSIOL, V68, P135; LARSON TV, 1977, SCIENCE, V197, P161, DOI 10.1126/science.877545; Laterza OF, 1997, J BIOL CHEM, V272, P22481, DOI 10.1074/jbc.272.36.22481; LINDSEY JK, 1990, MODELS REPEATED MEAS; LUK CK, 1983, CLIN SCI, V64, P449; Murphy C, 1998, CLIN SCI, V95, P397, DOI 10.1042/CS19980194; NEELEY WE, 1968, CLIN CHEM, V34, P1868; Newcomb R, 1998, BRAIN RES, V813, P103, DOI 10.1016/S0006-8993(98)01006-3; Pacheco G, 1996, BBA-BIOMEMBRANES, V1282, P182, DOI 10.1016/0005-2736(96)00038-7; Piddington DL, 2000, INFECT IMMUN, V68, P4518, DOI 10.1128/IAI.68.8.4518-4522.2000; PIN I, 1994, REV MAL RESPIR, V11, P111; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557; RIECHELMANN H, 1995, LARYNGOSCOPE, V105, P295, DOI 10.1288/00005537-199503000-00013; ROBINSON NP, 1989, J APPL PHYSIOL, V66, P2129; SARANTOS P, 1994, SURGERY, V116, P276; Sethi SK, 1997, CLIN EXP IMMUNOL, V110, P362, DOI 10.1046/j.1365-2249.1997.4221440.x; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; Spanel P, 1998, RAPID COMMUN MASS SP, V12, P763, DOI 10.1002/(SICI)1097-0231(19980630)12:12<763::AID-RCM229>3.0.CO;2-S; SWENSON ER, 1993, J CLIN INVEST, V92, P702, DOI 10.1172/JCI116640; Wadsworth SJ, 1997, AM J PHYSIOL-LUNG C, V273, pL427; Walsh GM, 1997, BRIT J HAEMATOL, V97, P701, DOI 10.1046/j.1365-2141.1997.00125.x; WELBOURNE TC, 1984, GLUTAMINE METABOLISM, P161; Wimalasundera SS, 1997, J INFECT DIS, V176, P755	45	110	114	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 1	2002	165	1					101	107				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	509VY	WOS:000173171500019	11779738	
J	Rundell, KW; Jenkinson, DM				Rundell, KW; Jenkinson, DM			Exercise-induced bronchospasm in the elite athlete	SPORTS MEDICINE			English	Review							CROSS-COUNTRY SKIERS; ICE SKATING RINKS; HYPERTONIC SALINE CHALLENGE; NITROGEN-DIOXIDE EXPOSURES; VOCAL CORD DYSFUNCTION; INDUCED ASTHMA; INDUCED BRONCHOCONSTRICTION; FLUTICASONE PROPIONATE; RECEPTOR ANTAGONIST; WATER-LOSS	The term exercise-induced bronchospasm (EIB) describes the acute transient airway narrowing that occurs during and most often after exercise in 10 to 50% of elite athletes, depending upon the sport examined. Although multiple factors are unquestionably involved in the EIB response, airway drying caused by a high exercise-ventilation rate is primary in most cases. The severity of this reaction reflects the allergic predisposition of the athlete, the water content of the inspired air, the type and concentration of air pollutants inspired, and the intensity (or ventilation rate) of the exercise. The highest prevalence of EIB is seen in winter-sport populations, where athletes are chronically exposed to cold dry air and/or environmental pollutants found in indoor ice arenas. When airway surface liquid lost during the natural warming and humidification process of respiration is not replenished at a rate equal to the loss, the ensuing osmolarity change stimulates the release of inflammatory mediators and results in bronchospasm; this cascade of events is exacerbated by airway inflammation and airway remodelling. The acute EIB response is characterised by airway smooth muscle contraction, membrane swelling, and/or mucus plug formation. Evidence suggests that histamine, leukotrienes and prostanoids are likely mediators for this response. Although the presence of symptoms and a basic physical examination are marginally effective, objective measures of lung function should be used for accurate and reliable diagnosis of EIB. Diagnosis should include baseline spirometry, followed by an appropriate bronchial provocation test. To date, the best test to confirm EIB may simply be standard pulmonary function testing before and after high-intensity dry air exercise. A 10% post-challenge fall in forced expiratory volume in 1 second is used as diagnostic criteria. The goal of medical intervention is to limit EIB exacerbation and allow the athlete to train and compete symptom free. This is attempted through daily controller medications such as inhaled corticosteroids or by the prophylactic use of medications before exercise. In many cases, EIB is difficult to control. These and other data suggest that EIB in the elite athlete is in contrast with classic asthma.	Marywood Univ, Human Performance Lab, Scranton, PA 18509 USA; Univ Pittsburgh, Med Ctr, Ctr Sports Med, Pittsburgh, PA USA	Rundell, KW (reprint author), Marywood Univ, Human Performance Lab, Scranton, PA 18509 USA.						ALDEROTH E, 1986, NEW ENGL J MED, V315, P480; ALTON EW, 1996, J ALLERGY CLIN IMMUN, V98, P102; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P472; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Anderson SD, 1995, PROVOCATION CHALLENG, P249; Anderson SD, 1999, EXERCISE INDUCED AST, P77; BACKER V, 1992, CLIN EXP ALLERGY, V22, P741, DOI 10.1111/j.1365-2222.1992.tb02813.x; BARNES NC, 1993, EUR RESPIR J, V6, P877; BARYISHAY E, 1984, LUNG, V162, P195, DOI 10.1007/BF02715648; BEASLEY CRW, 1987, J CLIN INVEST, V79, P978, DOI 10.1172/JCI112909; BECK KC, 1994, AM J RESP CRIT CARE, V149, P352; BECKER AB, 1990, LUNG, V168, P99, DOI 10.1007/BF02718120; BELCHER NG, 1989, EUR RESPIR J, V2, P44; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Brauer M, 1997, J AIR WASTE MANAGE, V47, P1095, DOI 10.1080/10473289.1997.10464399; BRAUER M, 1994, AM J PUBLIC HEALTH, V84, P429, DOI 10.2105/AJPH.84.3.429; Brugman SM, 1998, PHYSICIAN SPORTSMED, V26, P63, DOI 10.3810/psm.1998.05.1013; BYE MR, 1992, AM J DIS CHILD, V146, P977; CHARPIN D, 1988, ALLERGY, V43, P481, DOI 10.1111/j.1398-9995.1988.tb01624.x; CHEN WY, 1977, RESPIRATION, V34, P305; CLOUGH JB, 1991, ARCH DIS CHILD, V66, P579; Coreno A, 2000, J ALLERGY CLIN IMMUN, V106, P500; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; CRAPO RO, 1994, NEW ENGL J MED, V331, P25, DOI 10.1056/NEJM199407073310107; DAHL R, 1993, CHEST, V104, P1352, DOI 10.1378/chest.104.5.1352; DALONZO GE, 1994, JAMA-J AM MED ASSOC, V271, P1412, DOI 10.1001/jama.271.18.1412; Davis MS, 2001, AM J RESP CRIT CARE, V164, P785; DEAL EC, 1979, J APPL PHYSIOL, V46, P467; DEAL EC, 1979, J APPL PHYSIOL, V46, P476; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985; Drazen JM, 1999, NEW ENGL J MED, V340, P197; Eady R P, 1986, Eur J Respir Dis Suppl, V147, P112; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; EISER NM, 1982, PHARMACOL THERAPEUT, V17, P239, DOI 10.1016/0163-7258(82)90015-8; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; Feinstein RA, 1996, CLIN J SPORT MED, V6, P119; FINNERTY JP, 1991, THORAX, V46, P190, DOI 10.1136/thx.46.3.190; FINNERTY JP, 1989, AM REV RESPIR DIS, V140, P593; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746; FITCH KD, 1976, JAMA-J AM MED ASSOC, V236, P152, DOI 10.1001/jama.236.2.152; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; Fujitaka M, 2001, ANN ALLERG ASTHMA IM, V86, P323; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358; GHOSH SK, 1991, THORAX, V46, P242, DOI 10.1136/thx.46.4.242; GODFREY S, 1999, EXERCISE INDUCED AST, P11; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HABY MM, 1995, EUR RESPIR J, V8, P729; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; HARTLEY JPR, 1980, THORAX, V35, P675, DOI 10.1136/thx.35.9.675; HEDBERG K, 1989, JAMA-J AM MED ASSOC, V262, P3014; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P128; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P134; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Helenius IJ, 1996, THORAX, V51, P628, DOI 10.1136/thx.51.6.628; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; Helenius IJ, 1997, THORAX, V52, P157; HOSHINO M, 1991, J ASTHMA, V28, P19, DOI 10.3109/02770909109073367; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LAL S, 1993, CHEST, V104, P438, DOI 10.1378/chest.104.2.438; LARSSON K, 1993, BRIT MED J, V307, P1326; Larsson L., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P124; LEE KY, 1994, J SPORT SCI, V12, P279, DOI 10.1080/02640419408732173; Levy JI, 1998, AM J PUBLIC HEALTH, V88, P1781, DOI 10.2105/AJPH.88.12.1781; Li JTC, 1996, ANN ALLERG ASTHMA IM, V76, P1; LIN CC, 1991, J ASTHMA, V28, P31, DOI 10.3109/02770909109073368; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; McFadden ER, 1996, AM J RESP CRIT CARE, V153, P942; MCFARLANE PI, 1991, THORAX, V46, P190; MCKENZIE DC, 1994, MED SCI SPORT EXER, V26, P951; MELTZER EO, 1996, J ALLERGY CLIN IMMUN, V65, P46; MORRIS JF, 1976, WESTERN J MED, V125, P110; Nagakura T, 1998, CLIN EXP ALLERGY, V28, P181; National Heart Lung and Blood Institute, 1997, 2 NAT HEART LUNG BLO; NOVISKI N, 1987, AM REV RESPIR DIS, V136, P592; Nystad W, 2000, MED SCI SPORT EXER, V32, P266, DOI 10.1097/00005768-200002000-00003; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; O'Sullivan S, 1999, Acta Physiol Scand Suppl, V644, P1; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; ODONNELL AE, 1993, CHEST, V103, P742, DOI 10.1378/chest.103.3.742; ORTEGACARR D, 1995, CONNS CURRENT THERAP, P678; PATEL KR, 1984, BRIT MED J, V288, P1496; Peters SP, 1995, ASTHMA RHINITIS, P221; Pohunek P, 2001, ALLERGY ASTHMA PROC, V22, P75, DOI 10.2500/108854101778250599; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; Rabone SJ, 1996, OCCUP MED-OXFORD, V46, P177; REIFF DB, 1989, AM REV RESPIR DIS, V139, P479; RICE SG, 1985, ANN ALLERGY, V55, P790; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Roquet A, 1997, AM J RESP CRIT CARE, V155, P1856; Rundell K. W., 2001, Medicine and Science in Sports and Exercise, V33, pS12, DOI 10.1097/00005768-200105001-00059; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; RUNDELL KW, 2002, EXERCISE INDUCED AST, P181; RUPP NT, 1992, AM J DIS CHILD, V146, P941; Ryu JH, 2001, MAYO CLIN PROC, V76, P1144; SCHNALL RP, 1980, THORAX, V35, P828, DOI 10.1136/thx.35.11.828; Schwartz HJ, 1996, CHEST, V109, P945, DOI 10.1378/chest.109.4.945; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; SMITH LJ, 1985, AM REV RESPIR DIS, V131, P368; STERLING GM, 1968, CLIN SCI, V34, P277; Storms WW, 1999, MED SCI SPORT EXER, V31, pS33, DOI 10.1097/00005768-199901001-00006; Sue-Chu M, 2000, RESPIRATION, V67, P417, DOI 10.1159/000029541; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Suman OE, 1999, J APPL PHYSIOL, V87, P1107; Tan RA, 1998, SPORTS MED, V25, P1, DOI 10.2165/00007256-199825010-00001; TOGIAS AG, 1985, J CLIN INVEST, V76, P1375, DOI 10.1172/JCI112113; TOGIAS AG, 1988, AM REV RESPIR DIS, V137, P625; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Wagner EM, 1999, J APPL PHYSIOL, V86, P294; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; WEISS JW, 1982, SCIENCE, V216, P196, DOI 10.1126/science.7063880; Westcott JY, 1999, CLIN REV ALLERG IMMU, V17, P153, DOI 10.1007/BF02737602; Wilber R. L., 2001, Medicine and Science in Sports and Exercise, V33, pS12, DOI 10.1097/00005768-200105001-00061; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; WILLIAMS PV, 1995, CONNS CURRENT THERAP, P682; Williams S. D., 2001, Medicine and Science in Sports and Exercise, V33, pS12, DOI 10.1097/00005768-200105001-00062; 2000, MED LETT DRUGS THER, V42, P19	140	110	110	2	11	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.		2002	32	9					583	600		10.2165/00007256-200232090-00004		18	Sport Sciences	Sport Sciences	580YZ	WOS:000177265500004	12096931	
J	Yu, OC; Sheppard, L; Lumley, T; Koenig, JQ; Shapiro, GG				Yu, OC; Sheppard, L; Lumley, T; Koenig, JQ; Shapiro, GG			Effects of ambient air pollution on symptoms of asthma in Seattle-area children enrolled in the CAMP study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						ambient air pollution; asthma; carbon monoxide; children; panel study; particulate matter; sulfur dioxide; symptoms; within-subject effects	RESPIRATORY HEALTH; PARTICULATE MATTER; LONGITUDINAL DATA; LOS-ANGELES; PARTICLES; EMERGENCY; EXPOSURE; VISITS; TIME	We observed a panel of 133 children (5-13 years of age) with asthma residing in the greater Seattle, Washington, area for an average of 58 days (range 28-112 days) during screening for enrollment in the Childhood Asthma Management Program (CAMP) study. Daily self-reports of asthma symp toms were obtained from study diaries and compared with ambient air pollution levels in marginal repeated measures logistic regression models. We defined days with asthma symptoms as any day a child reported at least one mild asthma episode. All analyses were controlled for subject-specific variables [age, race, sex, baseline height, and FEV1 PC20 concentration (methacholine provocative concentration required to produce a 20% decrease in forced expiratory volume in 1 sec)] and potential rime-dependent confounders (day of week, season, and temperature). Because of variable observation periods for participants, we estimated both between- and within-subject air pollutant effects. Our primary interest was in the within-subject effects: the effect of air pollutant excursions from typical levels in each child's observation period on the odds of asthma symptoms. In single-pollutant models, the population average estimates indicated a 30% [95% confidence interval (CI), 11-52%] increase for a 1-ppm increment in carbon monoxide lagged I day, an 18% (95% CI, 5-33%) increase for a 10-mug/m(3) increment in same-day particulate matter < 1.0 <mu>m (PM1.0), and an 11% (95% CI, 3-20%) increase for a 10-mug/m(3) increment in particulate matter < 10 <mu>m (PM10) lagged 1 day. Conditional on the previous day's asthma symptoms, we estimated 25% (95% CI, 10-42%), 14% (95% CI, 4-26%), and 10% (95% CI, 3-16%) increases in the odds of asthma symptoms associated with increases in CO, PM1.0, and PM10, respectively. We did not find any association between sulfur dioxide (SO2) and the odds of asthma symptoms. In multipollutant models, the separate pollutant effects were smaller. The overall effect of an increase in both CO and PM1.0 was a 31% (95% CI, 11-55%) increase in the odds of symptoms of asthma. We conclude that there is an association between change in shea-term air pollution levels, as indexed by PM and CO, and the occurrence of asthma symptoms among children in Seattle. Although PM effects on asthma have been found in other studies, it is likely that CO is a marker for vehicle exhaust and other combustion by-products that aggravate asthma.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Environm Hlth, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	Sheppard, L (reprint author), Univ Washington, Dept Biostat, Box 357232, Seattle, WA 98195 USA.				NHLBI NIH HHS [N01 HR 16050]		Anuszewski J, 1998, J EXPO ANAL ENV EPID, V8, P483; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Diggle P. J., 1994, ANAL LONGITUDINAL DA; Forsberg B, 1998, EUR RESPIR J, V12, P900, DOI 10.1183/09031936.98.12040900; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; LARSON T, 1996, TRANSPORT RES A-POL, V30, P497; LUMLEY T, IN PRESS ENVIRONMETR; Mage D, 1999, J AIR WASTE MANAGE, V49, P1280; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; Peters A, 1996, AM J EPIDEMIOL, V144, P570; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Segala C, 1998, EUR RESPIR J, V11, P677; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; *STAT CORP, 1999, STAT STAT SOFTW; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; VONMUTIUS E, 1995, EUR RESPIR J, V8, P723; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	28	110	112	4	15	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	DEC	2000	108	12					1209	1214		10.2307/3434835		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	385LJ	WOS:000166005700034	11133403	
J	Anderson, SD; Holzer, K				Anderson, SD; Holzer, K			Exercise-induced asthma: Is it the right diagnosis in elite athletes?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						exercise-induced asthma; athletes; dehydration; airway injury; osmolarity	LEUKOTRIENE-RECEPTOR ANTAGONIST; NEUTROPHIL CHEMOTACTIC FACTOR; 4.5-PERCENT SODIUM-CHLORIDE; CROSS-COUNTRY SKIERS; INDUCED BRONCHOCONSTRICTION; BRONCHIAL HYPERRESPONSIVENESS; INDUCED BRONCHOSPASM; HYPERTONIC SALINE; MAST-CELLS; COLD-AIR	Exercise-induced asthma, as recognized in asthmatic subjects, is an exaggerated airway response to airway dehydration in the presence of inflammatory cells and their mediators. The airway narrowing is primarily caused by contraction of bronchial smooth muscle. The milder airway narrowing documented in response to exercise in elite athletes and otherwise healthy subjects may simply be the result of the physiologic responses and pathologic changes in airway cells arising from dehydration injury. These changes, which include excessive mucus production and airway edema, would serve both to cause cough and to amplify the narrowing effects of normal bronchial smooth muscle contraction, resulting in symptoms. These changes are more likely to occur in healthy subjects who exercise intensely for long periods of time breathing cold air, dry air, or both. Under these conditions, the ability to humidify inspired air may be overwhelmed, causing significant dehydration of the airway mucosa and an increase in osmolarity, even in small airways. In addition to dehydration injury, airway narrowing to pharmacologic and physical agents may occur as a result of injury caused by large volumes of air containing irritant gases, particulate matter, or allergens being inspired during exercise. As a result, the airways may become inflamed, and the airway smooth muscle may become more sensitive. These events could result in the same exaggerated airway response to dehydration, as documented in asthmatic subjects.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia; Alfred Hosp, Dept Allergy Asthma & Clin Immunol, Prahan, Australia	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, Level 9 Page Chest Pavil,Missenden Rd, Camperdown, NSW 2050, Australia.			Anderson, Sandra/0000-0002-6308-8770			Alton EWFW, 1996, AM J RESP CELL MOL, V14, P380; ANDERSON SD, 1981, THORAX, V36, P259, DOI 10.1136/thx.36.4.259; ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; ANDERSON SD, 1994, CHEST, V105, P673, DOI 10.1378/chest.105.3.673; Anderson SD, 1998, ASTHMA: BASIC MECHANISMS AND CLINICAL MANAGEMENT, 3RD EDITION, P569, DOI 10.1016/B978-012079027-2/50113-1; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; ANDERSON SD, 1985, CHEST, V87, P191; Anderson SD, 1997, ALLERGY ALLERGIC DIS, P692; Anderson SD, 1999, EXERCISE INDUCED AST, P77; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; ASSOULINE G, 1977, EUR J PHARMACOL, V44, P271, DOI 10.1016/0014-2999(77)90073-5; BACKER V, 1992, CLIN EXP ALLERGY, V22, P741, DOI 10.1111/j.1365-2222.1992.tb02813.x; BANNER AS, 1984, NEW ENGL J MED, V311, P883, DOI 10.1056/NEJM198410043111404; BARDAGI S, 1993, AM REV RESPIR DIS, V147, P1112; BIANCO S, 1988, LANCET, V2, P252; BOULET LP, 1989, J ALLERGY CLIN IMMUN, V83, P882, DOI 10.1016/0091-6749(89)90101-2; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; BRANNAN JD, 2000, EUR RESP J S; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; BURR ML, 1974, ARCH DIS CHILD, V49, P923; BURY TB, 1994, ALLERGY, V49, P605, DOI 10.1111/j.1398-9995.1994.tb00126.x; Carlsen KH, 1998, RESP MED, V92, P308, DOI 10.1016/S0954-6111(98)90114-7; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRIMI E, 1992, AM REV RESPIR DIS, V146, P507; CUSTOVIC A, 1994, CHEST, V105, P1127, DOI 10.1378/chest.105.4.1127; Davis MS, 1999, EUR RESPIR J, V14, P57, DOI 10.1034/j.1399-3003.1999.14a11.x; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669; Drobnic F, 1996, MED SCI SPORT EXER, V28, P271, DOI 10.1097/00005768-199602000-00018; duToit JI, 1997, ALLERGY ASTHMA PROC, V18, P7, DOI 10.2500/108854197778612817; Dwyer TM, 1997, AM J PHYSIOL-LUNG C, V272, pL1121; EGGLESTON PA, 1987, AM REV RESPIR DIS, V135, P1043; EGGLESTON PA, 1984, AM REV RESPIR DIS, V130, P86; EVELOFF JL, 1987, AM J PHYSIOL, V252, P1; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; FINNEY MJB, 1990, AM REV RESPIR DIS, V141, P1151; FREED AN, 1989, J APPL PHYSIOL, V67, P1727; FREED AN, 1994, AM J RESP CELL MOL, V11, P724; FREED AN, 1995, EUR RESPIR J, V8, P1770, DOI 10.1183/09031936.95.08101770; GARLAND A, 1995, J CLIN INVEST, V95, P2359, DOI 10.1172/JCI117928; GIESBRECHT GG, 1995, AVIAT SPACE ENVIR MD, V66, P890; Gschwentner M, 1996, J ALLERGY CLIN IMMUN, V98, pS98, DOI 10.1016/S0091-6749(96)80135-7; HABY MM, 1995, EUR RESPIR J, V8, P729; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; ISHII Y, 1990, PROSTAGLANDINS, V39, P685, DOI 10.1016/0090-6980(90)90028-T; Jackson D M, 1989, Pulm Pharmacol, V2, P179, DOI 10.1016/0952-0600(89)90018-5; JACKSON DM, 1992, EUR J PHARMACOL, V221, P175, DOI 10.1016/0014-2999(92)90790-B; JONGEJAN RC, 1990, J APPL PHYSIOL, V68, P1568; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086; KARJALAINEN J, 1991, THORAX, V46, P100, DOI 10.1136/thx.46.2.100; KIKAWA Y, 1992, J ALLERGY CLIN IMMUN, V89, P1111, DOI 10.1016/0091-6749(92)90294-C; KOSKELA H, 2000, IN PRESS CLIN EXP AL; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; LARSSON K, 1993, BRIT MED J, V307, P1326; LEE TH, 1984, J ALLERGY CLIN IMMUN, V73, P634, DOI 10.1016/0091-6749(84)90296-3; LEE TH, 1982, J ALLERGY CLIN IMMUN, V70, P73, DOI 10.1016/0091-6749(82)90232-9; LEE TH, 1982, J CLIN INVEST, V69, P889, DOI 10.1172/JCI110528; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Leuppi JD, 1998, EUR RESPIR J, V12, P13, DOI 10.1183/09031936.98.12010013; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; MAKHDUM A, 1993, AGENTS ACTIONS, V38, pC191, DOI 10.1007/BF01996456; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1985, J CLIN INVEST, V76, P1007, DOI 10.1172/JCI112052; MELILLO E, 1994, AM J RESP CRIT CARE, V149, P1138; MOQBEL R, 1986, AM REV RESPIR DIS, V133, P609; MUNAKATA M, 1988, J APPL PHYSIOL, V64, P466; Nagakura T, 1998, CLIN EXP ALLERGY, V28, P181; NISH WA, 1992, ANN ALLERGY, V69, P239; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; OBYRNE PM, 1986, AM REV RESPIR DIS, V134, P69; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875; OMORI C, 1995, J APPL PHYSIOL, V78, P1043; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549; PAUL DW, 1993, INT J SPORTS MED, V14, P433, DOI 10.1055/s-2007-1021205; Pedersen KE, 1998, J APPL PHYSIOL, V84, P499; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; PISARRI TE, 1991, AM J PHYSIOL, V260, pH1522; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73; PRAZMA J, 1994, J APPL PHYSIOL, V76, P2275; Pribyl CR, 1996, CLIN J SPORT MED, V6, P232, DOI 10.1097/00042752-199610000-00005; Reiss TF, 1997, THORAX, V52, P1030; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; RODWELL LT, 1993, THORAX, V48, P208, DOI 10.1136/thx.48.3.208; RODWELL LT, 1992, AM REV RESPIR DIS, V146, P1149; Ronsen O., 1995, European Respiratory Journal, V8, p473S; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; RUNDELL KW, 2000, IN PRESS MED SCI SPO; RUPP NT, 1993, ANN ALLERGY, V70, P339; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; SATAKE T, 1981, ADV PHYSL SCI, V10, P369; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; Shimizu T, 1997, AM J RESP CRIT CARE, V155, P170; SINCLAIR DG, 1995, EUR RESPIR J, V8, P1314, DOI 10.1183/09031936.95.08081314; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SPOONER CH, 1998, NEDOCROMIL SODIUM SI, V3; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597; UMENO E, 1990, J CLIN INVEST, V85, P1905, DOI 10.1172/JCI114652; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; WILLUMSEN NJ, 1994, J CLIN INVEST, V94, P779, DOI 10.1172/JCI117397; Wilson BA, 1994, EUR RESPIR J, V12, P2174; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361; YAGER D, 1991, AM REV RESPIR DIS, V143, pS52; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879; Zimmerman MP, 2000, J APPL PHYSIOL, V88, P425; ZWICK H, 1990, LUNG, V168, P111	119	110	111	0	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					419	428		10.1067/mai.2000.108914		10	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900002	10984359	
J	Barnes, PJ				Barnes, PJ			Inhaled corticosteroids are not beneficial in chronic obstructive pulmonary disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Editorial Material							AIR-FLOW OBSTRUCTION; ASTHMA; COPD; GLUCOCORTICOIDS		Imperial Coll, Natl Heart & Lung Inst, London, England	Barnes, PJ (reprint author), Imperial Coll, Natl Heart & Lung Inst, London, England.						Barnes PJ, 1998, THORAX, V53, P137; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, pS1; Burge PS, 1999, THORAX, V54, P287; Confalonieri M, 1998, THORAX, V53, P583; COX G, 1995, J IMMUNOL, V154, P4719; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635; DOMPELING E, 1992, EUR RESPIR J, V5, P945; Hattotuwa K, 1999, AM J RESP CRIT CARE, V159, pA523; Jeffery PK, 1998, THORAX, V53, P129; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kertjens HA, 1992, NEW ENGL J MED, V327, P1413; Meagher LC, 1996, J IMMUNOL, V156, P4422; NIGHTINGALE JA, 1999, IN PRESS AM J RESP C; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; WATSON A, 1992, CHEST, V101, P350, DOI 10.1378/chest.101.2.350; WEIR DC, 1993, THORAX, V48, P309, DOI 10.1136/thx.48.4.309	19	110	116	0	2	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB	2000	161	2					342	344				3	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	285ED	WOS:000085376000002	10673166	
J	Masuoka, M; Shiraishi, H; Ohta, S; Suzuki, S; Arima, K; Aoki, S; Toda, S; Inagaki, N; Kurihara, Y; Hayashida, S; Takeuchi, S; Koike, K; Ono, J; Noshiro, H; Furue, M; Conway, SJ; Narisawa, Y; Izuhara, K				Masuoka, Miho; Shiraishi, Hiroshi; Ohta, Shoichiro; Suzuki, Shoichi; Arima, Kazuhiko; Aoki, Shigehisa; Toda, Shuji; Inagaki, Naoki; Kurihara, Yuichi; Hayashida, Sayaka; Takeuchi, Satoshi; Koike, Kenta; Ono, Junya; Noshiro, Hirokazu; Furue, Masutaka; Conway, Simon J.; Narisawa, Yutaka; Izuhara, Kenji			Periostin promotes chronic allergic inflammation in response to Th2 cytokines	JOURNAL OF CLINICAL INVESTIGATION			English	Article							THYMIC STROMAL LYMPHOPOIETIN; NF-KAPPA-B; ATOPIC-DERMATITIS; BRONCHIAL-ASTHMA; DENDRITIC CELLS; EXTRACELLULAR-MATRIX; CANCER DEVELOPMENT; EPITHELIAL-CELLS; MITE ALLERGEN; TENASCIN-C	Allergic inflammation triggered by exposure of an allergen frequently leads to the onset of chronic inflammatory diseases such as atopic dermatitis (AD) and bronchial asthma. The mechanisms underlying chronicity in allergic inflammation remain unresolved. Periostin, a recently characterized matricellular protein, interacts with several cell surface integrin molecules, providing signals for tissue development and remodeling. Here we show that periostin is a critical mediator for the amplification and persistence of allergic inflammation using a mouse model of skin inflammation. Th2 cytokines IL-4 and IL-13 stimulated fibroblasts to produce periostin, which interacted with alpha(v) integrin, a functional periostin receptor on keratinocytes, inducing production of proinflammatory cytokines, which consequently accelerated Th2-type immune responses. Accordingly, inhibition of periostin or alpha(v) integrin prevented the development or progression of allergen-induced skin inflammation. Thus, periostin sets up a vicious circle that links Th2-type immune responses to keratinocyte activation and plays a critical role in the amplification and chronicity of allergic skin inflammation.	[Masuoka, Miho; Shiraishi, Hiroshi; Suzuki, Shoichi; Arima, Kazuhiko; Izuhara, Kenji] Saga Med Sch, Dept Biomol Sci, Div Med Biochem, Saga 8498501, Japan; [Ohta, Shoichiro; Izuhara, Kenji] Saga Med Sch, Dept Lab Med, Saga 8498501, Japan; [Aoki, Shigehisa; Toda, Shuji] Saga Med Sch, Dept Pathol & Biodef, Saga 8498501, Japan; [Inagaki, Naoki] Gifu Pharmaceut Univ, Dept Pharmacol, Gifu, Japan; [Kurihara, Yuichi; Hayashida, Sayaka; Takeuchi, Satoshi; Furue, Masutaka] Kyushu Univ, Dept Dermatol, Fukuoka 812, Japan; [Koike, Kenta; Noshiro, Hirokazu] Saga Med Sch, Dept Surg, Saga 8498501, Japan; [Ono, Junya] Shino Test Corp, Sagamihara, Kanagawa, Japan; [Conway, Simon J.] Indiana Univ Sch Med, Dev Biol & Neonatal Med Program, HB Wells Ctr Pediat Res, Indianapolis, IN USA; [Narisawa, Yutaka] Saga Med Sch, Dept Internal Med, Div Dermatol, Saga 8498501, Japan	Izuhara, K (reprint author), Saga Med Sch, Dept Biomol Sci, Div Med Biochem, 5-1-1 Nabeshima, Saga 8498501, Japan.	kizuhara@cc.saga-u.ac.jp	Arima, Kazuhiko/I-8962-2014	Arima, Kazuhiko/0000-0002-0607-8787	Japan Society for the Promotion of Science	We thank Koichi Akashi, Doyle R. Wylie, Hiroyuki Ideguchi, and Yumiko Ohishi for critical review of this manuscript and technical assistance. This work was supported in part by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science.	Aoki S, 2004, MOL BIOL CELL, V15, P4647, DOI 10.1091/mbc.E04-01-0038; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; Blanchard C, 2008, MUCOSAL IMMUNOL, V1, P289, DOI 10.1038/mi.2008.15; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373; Cacciari B, 2005, CURR MED CHEM, V12, P51; Carmi-Levy I, 2011, CLIN REV ALLERG IMMU, V41, P245, DOI 10.1007/s12016-010-8239-6; Caruso R, 2009, NAT MED, V15, P1013, DOI 10.1038/nm.1995; Clemmons DR, 2007, GROWTH HORM IGF RES, V17, P265, DOI 10.1016/j.ghir.2007.01.004; Elliott CG, 2012, J CELL SCI, V125, P121, DOI 10.1242/jcs.087841; Furue M, 2008, JPN J DERMATOL, V118, P325; Gao XK, 2004, BIOL PHARM BULL, V27, P1376, DOI 10.1248/bpb.27.1376; Gordon ED, 2012, CLIN EXP ALLERGY, V42, P144, DOI 10.1111/j.1365-2222.2011.03840.x; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Griffiths CEM, 2005, CYTOKINE, V32, P67, DOI 10.1016/j.cyto.2005.07.011; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; Hamilton DW, 2008, J CELL COMMUN SIGNAL, V2, P9, DOI 10.1007/s12079-008-0023-5; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hayashi N, 2007, P NATL ACAD SCI USA, V104, P14765, DOI 10.1073/pnas.0706378104; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huang CH, 2003, J INVEST DERMATOL, V121, P289, DOI 10.1046/j.1523-1747.2003.12356.x; Izuhara K, 2006, CURR MED CHEM, V13, P2291, DOI 10.2174/092986706777935140; Jensen JM, 2004, J INVEST DERMATOL, V122, P1423, DOI 10.1111/j.0022-202X.2004.22621.x; Jin H, 2004, BRIT J CANCER, V90, P561, DOI 10.1038/sj.bjc.6601576; Kaiko GE, 2011, CURR OPIN ALLERGY CL, V11, P39, DOI 10.1097/ACI.0b013e328342322f; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Kii I, 2010, J BIOL CHEM, V285, P2028, DOI 10.1074/jbc.M109.051961; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Korn T, 2009, ANNU REV IMMUNOL, V27, P485, DOI 10.1146/annurev.immunol.021908.132710; Kuhn B, 2007, NAT MED, V13, P962, DOI 10.1038/nm1619; Lainer-Carr D, 2007, NAT CLIN PRACT RHEUM, V3, P434, DOI 10.1038/ncprheum0559; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Maruhashi T, 2010, J BIOL CHEM, V285, P13294, DOI 10.1074/jbc.M109.088864; Medzhitov R, 2010, CELL, V140, P771, DOI 10.1016/j.cell.2010.03.006; Meneghin A, 2007, J CLIN INVEST, V117, P530, DOI 10.1172/JCI30595; Midwood K, 2009, NAT MED, V15, P774, DOI 10.1038/nm.1987; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Nishiyama T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018410; Norris RA, 2009, J CELL COMMUN SIGNAL, V3, P275, DOI 10.1007/s12079-009-0063-5; Okamoto M, 2011, EUR RESPIR J, V37, P1119, DOI 10.1183/09031936.00059810; Ontsuka K, 2012, EXP DERMATOL, V21, P331, DOI 10.1111/j.1600-0625.2012.01454.x; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Rebholz B, 2007, IMMUNITY, V27, P296, DOI 10.1016/j.immuni.2007.05.024; Rios H, 2005, MOL CELL BIOL, V25, P11131, DOI 10.1128/MCB.25.24.11131-11144.2005; Romei I, 2005, CLIN REV ALLERG IMMU, V28, P59, DOI 10.1385/CRIAI:28:1:059; Ruan K, 2009, CELL MOL LIFE SCI, V66, P2219, DOI 10.1007/s00018-009-0013-7; Scatena M, 1998, J CELL BIOL, V141, P1083, DOI 10.1083/jcb.141.4.1083; Sehra S, 2011, J IMMUNOL, V186, P4959, DOI 10.4049/jimmunol.1002359; Shimazaki M, 2008, J EXP MED, V205, P295, DOI 10.1084/jem.20071297; Shinohara ML, 2008, IMMUNITY, V29, P68, DOI 10.1016/j.immuni.2008.05.008; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Simpson EL, 2006, DERMATOL THER, V19, P108, DOI 10.1111/j.1529-8019.2006.00059.x; Snider P, 2008, CIRC RES, V102, P752, DOI 10.1161/CIRCRESAHA.107.159517; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Souwer Y, 2010, CURR OPIN IMMUNOL, V22, P821, DOI 10.1016/j.coi.2010.10.013; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Takayama G, 2006, J ALLERGY CLIN IMMUN, V118, P98, DOI 10.1016/j.jaci.2006.02.046; Uchida M, 2012, AM J RESP CELL MOL, V46, P677, DOI [10.1165/rcmb.2011-0115OC, 10.1165/rcmb.2011-115OC]; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Yuyama N, 2002, CYTOKINE, V19, P287, DOI 10.1006/cyto.2002.1972; Zou GM, 2002, EUR CYTOKINE NETW, V13, P186	66	109	114	2	12	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	JUL	2012	122	7					2590	2600		10.1172/JCI58978		11	Medicine, Research & Experimental	Research & Experimental Medicine	969GV	WOS:000306044600030	22684102	
J	D'Amato, G; Cecchi, L				D'Amato, G.; Cecchi, L.			Effects of climate change on environmental factors in respiratory allergic diseases	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							RAGWEED AMBROSIA-ARTEMISIIFOLIA; PARTICULATE AIR-POLLUTION; PLACEBO-CONTROLLED TRIAL; GRASS-POLLEN; DIESEL EXHAUST; HAY-FEVER; CHILDHOOD ASTHMA; OZONE EXPOSURE; COMMON RAGWEED; PUBLIC-HEALTH	A body of evidence suggests that major changes involving the atmosphere and the climate, including global warming induced by human activity, have an impact on the biosphere and the human environment. Studies on the effects of climate change on respiratory allergy are still lacking and current knowledge is provided by epidemiological and experimental studies on the relationship between asthma and environmental factors, such as meteorological variables, airborne allergens and air pollution. However, there is also considerable evidence that subjects affected by asthma are at an increased risk of developing obstructive airway exacerbations with exposure to gaseous and particulate components of air pollution. It is not easy to evaluate the impact of climate change and air pollution on the prevalence of asthma in general and on the timing of asthma exacerbations. However, the global rise in asthma prevalence and severity suggests that air pollution and climate changes could be contributing. Pollen allergy is frequently used to study the interrelationship between air pollution, rhinitis and bronchial asthma. Epidemiological studies have demonstrated that urbanization, high levels of vehicle emissions and westernized lifestyle are correlated to an increase in the frequency of pollen-induced respiratory allergy, prevalent in people who live in urban areas compared with those who live in rural areas. Meteorological factors (temperature, wind speed, humidity, etc.) along with their climatological regimes (warm or cold anomalies and dry or wet periods, etc.), can affect both biological and chemical components of this interaction. In addition, by inducing airway inflammation, air pollution overcomes the mucosal barrier priming allergen-induced responses. In conclusion, climate change might induce negative effects on respiratory allergic diseases. In particular, the increased length and severity of the pollen season, the higher occurrence of heavy precipitation events and the increasing frequency of urban air pollution episodes suggest that environmental risk factors will have a stronger effect in the following decades.	[D'Amato, G.] High Special Hosp A Cardarelli, Dept Chest Dis, Div Resp & Allerg Dis, Naples, Italy; [Cecchi, L.] Univ Florence, Interdepartmental Ctr Bioclimatol, Florence, Italy; [Cecchi, L.] Allergy Clin, Florence, Italy	D'Amato, G (reprint author), High Special Hosp A Cardarelli, Dept Chest Dis, Div Resp & Allerg Dis, Naples, Italy.	gdamato@qubisoft.it	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Ahas R, 2002, INT J CLIMATOL, V22, P1727, DOI 10.1002/joc.818; Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Allam MF, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003538.pub2; Annesi-Maesano I, 2007, EUR RESPIR J, V29, P428, DOI 10.1183/09031936.00129506; Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Atkinson RW, 2004, THORAX, V59, P277, DOI 10.1136/thx.2003.019133; BALMES JR, 1993, ENVIRON HEALTH PERSP, V101, P219, DOI 10.2307/3431683; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Beggs PJ, 2005, ENVIRON HEALTH PERSP, V113, P915, DOI 10.1289/ehp.7724; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Bernard SM, 2001, ENVIRON HEALTH PERSP, V109, P199, DOI 10.2307/3435010; Bloomfield SF, 2006, CLIN EXP ALLERGY, V36, P402, DOI 10.1111/j.1365-2222.2006.02463.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BUCHANAN CM, 2002, ATMOS ENVIRON, V36, P1363; Burge HA, 2002, J ALLERGY CLIN IMMUN, V110, P544, DOI 10.1067/mai.2002.128674; Burr ML, 1999, CLIN EXP ALLERGY, V29, P735; CAREY MJ, 1986, BRIT MED J, V293, P843; Cecchi L, 2007, AEROBIOLOGIA, V23, P145, DOI 10.1007/s10453-007-9060-4; Cecchi Lorenzo, 2006, Ann Allergy Asthma Immunol, V96, P86; Chavarria JF, 2001, ARCH DIS CHILD, V84, P514, DOI 10.1136/adc.84.6.514; Chen KS, 2004, J AIR WASTE MANAGE, V54, P36; Confalonieri U, 2007, CLIMATE CHANGE 2007, P391; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; D'Amato G., 2002, EUROPEAN RESP MONOGR, V21; D'Amato G, 2004, DIET HUMAN IMMUNE FU, P397; DAMATO G, 2005, BMJ 2005         JAN; Davidson AC, 1996, BRIT MED J, V312, P601; Delfino RJ, 2006, AM J RESP CRIT CARE, V173, P1054, DOI 10.1164/rccm.2603001; *DEP HLTH, 2001, DEP HLTH EXP GROUP C, P199; Dockery DW, 2007, NEW ENGL J MED, V356, P511, DOI 10.1056/NEJMe068274; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Eccles R, 2002, ACTA OTO-LARYNGOL, V122, P183, DOI 10.1080/00016480252814207; *EEA, 2007, EN09 EM CO2 SO2 NOX; Ehara A, 2000, PEDIATR INT, V42, P272, DOI 10.1046/j.1442-200x.2000.01228.x; *EIA, 2007, ANN ENERGY OUTLOOK 2; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347; Englert N, 2004, TOXICOL LETT, V149, P235, DOI 10.1016/j.toxlet.2003.12.035; Epstein PR, 2005, NEW ENGL J MED, V353, P1433, DOI 10.1056/NEJMp058079; Epton MJ, 1997, THORAX, V52, P528; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Frenguelli G, 2002, Monaldi Arch Chest Dis, V57, P141; Gangoiti G, 2001, ATMOS ENVIRON, V35, P6267, DOI 10.1016/S1352-2310(01)00440-X; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; *GLOB STRAT ASTHM, 2006, GINA REP; Hashimoto M, 2004, PEDIATR INT, V46, P48, DOI 10.1111/j.1442-200X.2004.01835.x; HJELMROOS M, 1995, INT ARCH ALLERGY IMM, V108, P368; Hoyt K Sue, 2004, Disaster Manag Response, V2, P46, DOI 10.1016/j.dmr.2004.04.001; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jamason PF, 1997, AM J RESP CRIT CARE, V156, P1781; Jarvis D, 2004, ALLERGY, V59, P1063, DOI 10.1111/j.1398-9995.2004.00539.x; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; Jones AM, 2004, SCI TOTAL ENVIRON, V326, P151, DOI 10.1016/j.scitotenv.2003.11.021; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kelly FJ, 2004, P NUTR SOC, V63, P579, DOI 10.1079/PNS2004388; KHOT A, 1988, CLIN ALLERGY, V18, P351, DOI 10.1111/j.1365-2222.1988.tb02882.x; KISS L, 2007, J BIOGEOGR, V33, P2156; Kljakovic M, 1998, CLIMATE RES, V10, P109, DOI 10.3354/cr010109; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KREIT JW, 1989, J APPL PHYSIOL, V66, P217; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; Liu AH, 2006, J ALLERGY CLIN IMMUN, V117, P1063, DOI 10.1016/j.jaci.2006.03.027; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McCunney RJ, 2005, J OCCUP ENVIRON MED, V47, P1285, DOI 10.1097/01.jom.0000188561.75578.bf; Menzel A, 1999, NATURE, V397, P659, DOI 10.1038/17709; Mickley LJ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021216; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Moore D, 2006, CAN J PUBLIC HEALTH, V97, P105; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Namork E, 2006, TOXICOL LETT, V165, P71, DOI 10.1016/j.toxlet.2006.01.016; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Olesen JE, 2002, EUR J AGRON, V16, P239, DOI 10.1016/S1161-0301(02)00004-7; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; Pourazar J, 2005, AM J PHYSIOL-LUNG C, V289, pL724, DOI 10.1152/ajplung.00055.2005; Prather M, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016285; RIDOLO E, 2006, INT ARCH ALLERGY IMM, V142, P151; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SANDSTROM T, 2002, EUROPEAN RESP MONOGR, V21, P52; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schwartz J, 2004, PEDIATRICS, V113, P1037; Singer BD, 2005, FUNCT PLANT BIOL, V32, P667, DOI 10.1071/FP05039; Solomon S., 2007, CLIMATE CHANGE 2007, P1; Stach A, 2007, J INVEST ALLERG CLIN, V17, P39; Sun HL, 2006, AM J EMERG MED, V24, P709, DOI 10.1016/j.ajem.2006.03.006; SUZUKI S, 1988, INT J BIOMETEOROL, V32, P129, DOI 10.1007/BF01044906; Tager IB, 2005, EPIDEMIOLOGY, V16, P751, DOI 10.1097/01.ede.0000183166.68809.b0; Teranishi H, 2006, AEROBIOLOGIA, V22, P90, DOI 10.1007/s10453-006-9023-1; *UEPA, 1994, 400F92013 EPA; USEPA, 1996, EPA600P93004ACF; Van Vliet AJH, 2002, INT J CLIMATOL, V22, P1757, DOI 10.1002/joc.820; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Hertzen L, 2005, ALLERGY, V60, P283, DOI 10.1111/j.1398-9995.2005.00769.x; Wan SQ, 2002, AM J BOT, V89, P1843, DOI 10.3732/ajb.89.11.1843; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Xia T, 2004, ENVIRON HEALTH PERSP, V112, P1347, DOI 10.1289/ehp.7167; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	120	109	113	6	55	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	AUG	2008	38	8					1264	1274		10.1111/j.1365-2222.2008.03033.x		11	Allergy; Immunology	Allergy; Immunology	328DQ	WOS:000257778300005	18537982	
J	Riedl, MA; Nel, AE				Riedl, Marc A.; Nel, Andre E.			Importance of oxidative stress in the pathogenesis and treatment of asthma	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						air pollution; antioxidants; asthma; genetic polymorphisms; oxidative stress	DIESEL EXHAUST PARTICLES; PLACEBO-CONTROLLED TRIAL; AIRWAY EPITHELIAL-CELLS; GENE POLYMORPHISMS; ALLERGIC RESPONSES; RESPIRATORY HEALTH; N-ACETYLCYSTEINE; NASAL CHALLENGE; RISK-FACTORS; VITAMIN-C	Purpose of review The purpose of the current review is to summarize recent evidence demonstrating the important role of oxidative stress in asthma pathogenesis. The therapeutic implications of these findings will be presented. Recent findings Mechanistically, the effect of oxidative stress on dendritic cells has been demonstrated to have a potent effect on Th1/Th2 skewing of the immune response. Investigations of gene-environment interactions have identified genetic polymorphisms associated with individual susceptibility to poll utant-ind uced respiratory oxidative stress. The effects of current asthma therapy on oxidative stress are currently unclear, but previous trials using conventional antioxidant therapy in asthma have been largely ineffective. Recent investigations have identified two promising broad-based therapeutic approaches: Nrf2 pathway activation and the use of thiol precursors. Preliminary data suggest that fullerene nanomaterials and dietary interventions may also have potential benefits in asthma. Summary Our current understanding of the role of oxidative stress in asthma suggests that antioxidant therapy may be important in optimizing asthma treatment and prevention. The future success of antioxidant asthma therapy will require strategies with broad effects on airway redox equilibrium and the selection of appropriate target populations.	[Riedl, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Allergy & Clin Immunol Sect, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA; [Nel, Andre E.] Univ Calif Los Angeles, David Geffen Sch Med, Div Nanomed, Asthma & Allergy Dis Clin Res Ctr, Los Angeles, CA 90095 USA	Riedl, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Allergy & Clin Immunol Sect, Div Pulm & Crit Care Med, 10833 Le Conte Ave 37-131 CHS, Los Angeles, CA 90095 USA.	mriedl@mednet.ucla.edu	Nel, Andre/J-2808-2012		NIAID NIH HHS [U19 AI070453-01]; PHS HHS [K12 R011 7611]		Allam MF, 2004, COCHRANE DB SYST REV, V2004; Alzoghaibi MA, 2007, RESPIROLOGY, V12, P439, DOI 10.1111/j.1440-1843.2007.01034.x; Blesa S, 2003, EUR RESPIR J, V21, P394, DOI 10.1183/09031936.03.00039602; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Burns JS, 2007, CHEST, V132, P238, DOI 10.1378/chest.07-0038; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Fogarty A, 2006, RESP MED, V100, P174, DOI 10.1016/j.rmed.2005.03.038; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Garcia V, 2005, EUR RESPIR J, V26, P449, DOI 10.1183/09031936.05.00142104; Garte S, 2001, CANCER EPIDEM BIOMAR, V10, P1239; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Haque R, 2007, TOXICOL APPL PHARM, V220, P72, DOI 10.1016/j.taap.2006.12.017; He FJ, 2006, LANCET, V367, P320, DOI 10.1016/S0140-6736(06)68069-0; Hiura TS, 1999, J IMMUNOL, V163, P5582; Horwitz LD, 2003, CARDIOVASC DRUG REV, V21, P77; Ivaschenko TE, 2002, J MOL MED-JMM, V80, P39, DOI 10.1007/s001090100274; Johnson IT, 2007, P NUTR SOC, V66, P207, DOI 10.1017/S0029665107005459; Kamada F, 2007, INT ARCH ALLERGY IMM, V144, P275, DOI 10.1159/000106316; Kim HJ, 2007, J ALLERGY CLIN IMMUN, V119, P1225, DOI 10.1016/j.jaci.2007.01.016; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Martinez-Losa M, 2007, CLIN EXP ALLERGY, V37, P714, DOI 10.1111/j.1365-2222.2007.02694.x; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; Muijsers RBR, 2001, BRIT J PHARMACOL, V134, P434, DOI 10.1038/sj.bjp.0704235; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Ochs-Balcom HM, 2006, EUR J CLIN NUTR, V60, P991, DOI 10.1038/sj.ejcn.1602410; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; Pereira B, 1995, BIOCHEM PHARMACOL, V50, P2093, DOI 10.1016/0006-2952(95)02116-7; Persinger RL, 2002, MOL CELL BIOCHEM, V234, P71, DOI 10.1023/A:1015973530559; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Ram FS, 2004, COCHRANE DB SYST REV; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reynaert NL, 2007, J IMMUNOL, V178, P3814; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Ritz SA, 2007, AM J PHYSIOL-LUNG C, V292, pL33, DOI 10.1152/ajplung.00170.2006; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Ryan JJ, 2007, J IMMUNOL, V179, P665; Sadowska AM, 2007, STEROIDS, V72, P1, DOI 10.1016/j.steroids.2006.10.007; Sekiguchi Naoya, 2006, Mod Rheumatol, V16, P85; Shaheen SO, 2007, THORAX, V62, P483, DOI 10.1136/thx.2006.071563; Steerenberg PA, 1999, INHAL TOXICOL, V11, P1109; Tamer L, 2004, RESPIROLOGY, V9, P493, DOI 10.1111/j.1440-1843.2004.00657.x; Voutilainen S, 2006, AM J CLIN NUTR, V83, P1265; Wan JX, 2006, J IMMUNOL, V177, P3477; Wang JR, 2006, FREE RADICAL BIO MED, V40, P1914, DOI 10.1016/j.freeradbiomed.2006.01.017; Wells SM, 2007, AM J RESP CELL MOL, V36, P520, DOI 10.1165/rcmb.2006-0302SM; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; WIELANDT AM, 2006, BIOCHEM PHARMACOL, V14, P455; Willett WC, 2006, PUBLIC HEALTH NUTR, V9, P105, DOI 10.1079/PHN2005931	59	109	114	1	12	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1528-4050			CURR OPIN ALLERGY CL	Curr. Opin. Allergy Clin. Immunol.	FEB	2008	8	1					49	56				8	Allergy; Immunology	Allergy; Immunology	254JN	WOS:000252583000009	18188018	
J	Huurre, A; Kalliomaki, M; Rautava, S; Rinne, M; Salminen, S; Isolauri, E				Huurre, Anu; Kalliomaki, Marko; Rautava, Samuli; Rinne, Minna; Salminen, Seppo; Isolauri, Erika			Mode of delivery - Effects on gut microbiota and humoral immunity	NEONATOLOGY			English	Article						caesarean section; vaginal delivery; gut microbiota; humoral immunity	IN-SITU HYBRIDIZATION; ATOPIC-DERMATITIS; BLOOD-LYMPHOCYTES; CHILDREN; INFANTS; BACTERIA; ALLERGY; PROBES; IDENTIFICATION; MICROFLORA	Background: The rate of caesarean deliveries has increased 10-fold worldwide during the past decades. Objective: To evaluate differences in the establishment of gut microbiota in infants born by vaginal or caesarean delivery and its impact on mucosal immunity. Methods: Altogether, 165 consecutive children, prospectively followed from birth at our clinic in Turku, Finland, were gathered; 141 (85%) were born by vaginal delivery and 24 (15%) by caesarean section. Blood was drawn at physician visits for indirect evaluation of mucosal immunity by ELISPOT assay. Faecal samples were obtained for determination of the gut microbiota by fluorescence in situ hybridization of bacterial cells. Results: Infants delivered by caesarean section harboured fewer bifidobacteria at an early age and were shown to mount a stronger humoral immune response. At 1 month of age, the total gut bacterial cell counts per 1 g faeces were higher in vaginally delivered infants (9.9 x 10(9), 95% CI 7.9 x 10(9)-1.2 x 10(10)) as compared to caesarean section delivered (3.1 x 10(9), 95% CI 1.1 x 10(9)-8.6 x 10(9)) (p = 0.001). This distinction was mainly due to the greater number of bifidobacteria in vaginally delivered infants (1.9 x 10(9), 95% CI 6.3 x 10(8)-5.6 x 10(9) vs. 1.5 x 10(6), 95% CI 4.1 x 10(2)-5.7 x 10(9), respectively) (p = 0.001). During the first year of life, the total number of IgA-, IgG- and IgM-secreting cells was lower (p = 0.03, p = 0.02, p = 0.11, respectively) in infants born by vaginal delivery than in those born by caesarean section, possibly reflecting excessive antigen exposure across the vulnerable gut barrier. Conclusions: Our findings demonstrate that the mode of delivery may have, possibly via gut microbiota development, significant effects on immunological functions in the infant (http://www.clinicaltrials.gov/ct/gui/show/NCT00167700). Copyright (C) 2007 S. Karger AG, Basel.	[Huurre, Anu; Kalliomaki, Marko; Rautava, Samuli; Rinne, Minna; Isolauri, Erika] Univ Turku, Dept Pediat, Turku Univ Cent Hosp, FI-20520 Turku, Finland; [Salminen, Seppo] Univ Turku, Funct Foods Forum, FI-20520 Turku, Finland	Huurre, A (reprint author), Univ Turku, Dept Pediat, Turku Univ Cent Hosp, Kiinanmyllynkatu 4-8, FI-20520 Turku, Finland.	anu.huurre@utu.fi					Edwards CA, 2002, BRIT J NUTR, V88, pS11, DOI [10.1079/BJNBJN2002580, 10.1079/BJN2002625]; Favier CF, 2002, APPL ENVIRON MICROB, V68, P219, DOI 10.1128/AEM.68.1.219-226.2002; FORREST BD, 1988, LANCET, V1, P81; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; Harmsen Hermie J.M., 1999, Microbial Ecology in Health and Disease, V11, P3, DOI 10.1080/089106099435862; Harmsen HJM, 2000, FEMS MICROBIOL LETT, V183, P125, DOI 10.1016/S0378-1097(99)00649-7; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Isolauri E, 2005, GASTROENTEROL CLIN N, V34, P437, DOI 10.1016/j.gtc.2005.05.010; ISOLAURI E, 1990, PEDIATR RES, V28, P582, DOI 10.1203/00006450-199012000-00006; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Isolauri E, 2002, CURR OPIN ALLERGY CL, V2, P263, DOI 10.1097/00130832-200206000-00018; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Kraehenbuhl JP, 2004, SCIENCE, V303, P1624, DOI 10.1126/science.1096222; LANGENDIJK PS, 1995, APPL ENVIRON MICROB, V61, P3069; Li Y, 2005, J DENT RES, V84, P806; Manz W, 1996, MICROBIOL-UK, V142, P1097; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rigby RJ, 2005, CLIN EXP IMMUNOL, V139, P245, DOI 10.1111/j.1365-2249.2004.02674.x; Salminen S, 2004, GUT, V53, P1388, DOI 10.1136/gut.2004.041640; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3	22	109	119	5	35	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1661-7800			NEONATOLOGY	Neonatology		2008	93	4					236	240		10.1159/000111102		5	Pediatrics	Pediatrics	311AS	WOS:000256572900005	18025796	
J	Kim, YK; Oh, SY; Jeon, SG; Park, HW; Lee, SY; Chun, EY; Bang, B; Lee, HS; Oh, MH; Kim, YS; Kim, JH; Gho, YS; Cho, SH; Min, KU; Kim, YY; Zhu, Z				Kim, Yoon-Keun; Oh, Sun-Young; Jeon, Seong Gyu; Park, Heung-Woo; Lee, Soo-Yeon; Chun, Eun-Young; Bang, Boram; Lee, Hyun-Seung; Oh, Min-Hee; Kim, You-Sun; Kim, Jong-Hoon; Gho, Yong Song; Cho, Sang-Heon; Min, Kyung-Up; Kim, You-Young; Zhu, Zhou			Airway exposure levels of lipopolysaccharide determine type 1 versus type 2 experimental asthma	JOURNAL OF IMMUNOLOGY			English	Article							HOUSE-DUST ENDOTOXIN; T-CELL DEVELOPMENT; INTERFERON-GAMMA; DENDRITIC CELLS; ALLERGIC-ASTHMA; RESPONSES; MICE; HYPERRESPONSIVENESS; INFLAMMATION; ANTIGEN	Allergic asthma is characterized by airway inflammation initiated by adaptive immune responses to aeroallergens. Recent data suggest that severe asthma may be a different form of asthma rather than an increase in asthma symptoms and that innate immune responses to LPS can modulate adaptive immune responses to allergens. In this study, we evaluated the hypothesis that airway exposure to different doses of LPS induces different form of asthma. Our study showed that neutrophilic inflammation and IFN-gamma expression were higher in induced sputum from severe asthma patients than from mild to moderate asthmatics. Animal experiments indicated that allergen sensitization with low-dose LPS (0.1 mu g) induced type 2 asthma phenotypes, i.e., airway hyper-responsiveness, eosinophilic inflammation, and allergen-specific IgE up-regulation. In contrast, allergen sensitization with high-dose LPS (10 mu g) induced asthma phenotypes, i.e., airway hyperresponsiveness and noneosinophilic inflammation that were not developed in IFN-gamma-deficient mice, but unaffected in the absence of IL-4. During the allergen sensitization period, TNF-alpha expression was found to be enhanced by both low- and high-dose LPS, whereas IL-12 expression was only enhanced by high-dose LPS. Interestingly, the asthma phenotypes induced by low-dose LPS, but not by high-dose LPS, were completely inhibited in TNF-a receptor-deficient mice, whereas the asthma phenotypes induced by high-dose LPS were abolished in the homozygous null mutation of the STAT4 gene. These findings suggest that airway exposure levels of LPS induces different forms of asthma that are type 1 and type 2 asthma phenotypes by high and low LPS levels, respectively.	Johns Hopkins Univ, Div Clin Immunol & Allergy, Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Pohang Univ Sci & Technol, Postech Biotech Ctr, Dept Life Sci, Pohang, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Inst Allergy & Clin Immunol, Seoul 151, South Korea; Korea Univ, Coll Life Sci & Biotechnol, Div Biotechnol, Seoul 136701, South Korea	Zhu, Z (reprint author), Johns Hopkins Univ, Div Clin Immunol & Allergy, Asthma & Allergy Ctr, 5501 Hopkins Bayview Circle-1A-2, Baltimore, MD 21224 USA.	juinea@postech.ac.kr; zzhu@jhmi.edu	Min, Kyung-Up/J-5468-2012; Cho, Sang Heon/J-2793-2012; Kim, Jong-Hoon/F-2504-2013; Kim, Jong-Hoon/H-1476-2015		NHLBI NIH HHS [R01 HL079349]		Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Ashwell JD, 2000, ANNU REV IMMUNOL, V18, P309, DOI 10.1146/annurev.immunol.18.1.309; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; CORRIGAN CJ, 1991, INT ARCH ALLER A IMM, V94, P270; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2004, PEDIATR INFECT DIS J, V23, pS78, DOI 10.1097/01.inf.0000108196.46134.a6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325; HOGG JC, 1999, AM J RESP CRIT CARE, V160, P26; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P311, DOI 10.1016/S0091-6749(99)70372-6; Kuipers H, 2003, J IMMUNOL, V171, P3645; Lack G, 1996, J IMMUNOL, V157, P1432; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790; Magram J, 1996, IMMUNITY, V4, P471, DOI 10.1016/S1074-7613(00)80413-6; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Olenchock S A, 1987, Prog Clin Biol Res, V231, P475; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; SAVELKOUL HFJ, 1991, J IMMUNOL, V146, P1801; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; Szabo SJ, 2003, ANNU REV IMMUNOL, V21, P713, DOI 10.1146/annurev.immunol.21.120601.140942; Vrugt B, 1999, EUR RESPIR J, V13, P1245, DOI 10.1183/09031936.99.13612539; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	45	109	121	0	10	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	APR 15	2007	178	8					5375	5382				8	Immunology	Immunology	155VA	WOS:000245605300083	17404323	
J	Pattenden, S; Antova, T; Neuberger, M; Nikiforov, B; De Sario, M; Grize, L; Heinrich, J; Hruba, F; Janssen, N; Luttmann-Gibson, H; Privalova, L; Rudnai, P; Splichalova, A; Zlotkowska, R; Fletcher, T				Pattenden, Sam; Antova, Temenuga; Neuberger, Manfred; Nikiforov, Bojidar; De Sario, Manuela; Grize, Leticia; Heinrich, Joachim; Hruba, Frantiska; Janssen, Nicole; Luttmann-Gibson, Heike; Privalova, Larissa; Rudnai, Peter; Splichalova, Anna; Zlotkowska, Renata; Fletcher, Tony			Parental smoking and children's respiratory health: independent effects of prenatal and postnatal exposure	TOBACCO CONTROL			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; MATERNAL SMOKING; LUNG-FUNCTION; CHILDHOOD ASTHMA; PASSIVE SMOKING; AIR-POLLUTION; BIRTH-WEIGHT; IN-UTERO; SYMPTOMS; PREGNANCY	Objectives: Adverse effects have been reported of prenatal and/or postnatal passive exposure to smoking on children's health. Uncertainties remain about the relative importance of smoking at different periods in the child's life. We investigate this in a pooled analysis, on 53 879 children from 12 cross-sectional studies-components of the PATY study (Pollution And The Young). Methods: Effects were estimated, within each study, of three exposures: mother smoked during pregnancy, parental smoking in the first two years, current parental smoking. Outcomes were: wheeze, asthma, "woken by wheeze'', bronchitis, nocturnal cough, morning cough, "sensitivity to inhaled allergens'' and hay fever. Logistic regressions were used, controlling for individual risk factors and study area. Heterogeneity between study-specific results, and mean effects (allowing for heterogeneity) were estimated using meta-analytical tools. Results: There was strong evidence linking parental smoking to wheeze, asthma, bronchitis and nocturnal cough, with mean odds ratios all around 1.15, with independent effects of prenatal and postnatal exposures for most associations. Conclusions: Adverse effects of both pre- and postnatal parental smoking on children's respiratory health were confirmed. Asthma was most strongly associated with maternal smoking during pregnancy, but postnatal exposure showed independent associations with a range of other respiratory symptoms. All tobacco smoke exposure has serious consequences for children's respiratory health and needs to be reduced urgently.	Univ Vienna, Inst Environm Hlth, Ctr Publ Hlth, A-1095 Vienna, Austria; London Sch Hyg & Trop Med, London WC1, England; Hlth Author Rome, Dept Epidemiol, Rome, Italy; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Inst Publ Hlth, Dept Hlth Informat & Stat, Banska Bystrica, Slovakia; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Natl Publ Hlth Ctr, Natl Inst Environm Hlth, Budapest, Hungary; Inst Publ Hlth Ostrava, Ctr Occupat Med, Ostrava, Czech Republic; Inst Occupat Med & Environm Hlth, Dept Epidemiol, Sosnowiec, Poland	Neuberger, M (reprint author), Univ Vienna, Inst Environm Hlth, Ctr Publ Hlth, Kinderspitalgasse 15, A-1095 Vienna, Austria.	manfred.neuberger@meduniwien.ac.at	De sario, Manuela/K-1932-2016	De sario, Manuela/0000-0002-1117-2735; Neuberger, Manfred/0000-0002-8994-378X			Agabiti N, 1999, EPIDEMIOLOGY, V10, P692, DOI 10.1097/00001648-199911000-00008; Alati R, 2006, EPIDEMIOLOGY, V17, P138, DOI 10.1097/01.ede.0000198148.02347.33; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Butland BK, 1997, BRIT MED J, V315, P717; *CAL ENV PROG AG, 2004, PROP ID ENV TOB SMOK; Cook DG, 1999, THORAX, V54, P357; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Dales RE, 1997, EUR J EPIDEMIOL, V13, P541, DOI 10.1023/A:1007311912777; DELLORCO V, 1995, AM J EPIDEMIOL, V142, P419; Dempsey DA, 2001, DRUG SAFETY, V24, P277, DOI 10.2165/00002018-200124040-00005; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Gehring U, 2006, EUR RESPIR J, V27, P95, DOI 10.1183/09031936.06.00017205; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hajnal BL, 1999, SCHWEIZ MED WSCHR, V129, P723; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; *INT AG RES CANC, 2002, TOB SMOK INV SMOK SU, V83; Jaakkola JJK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-48; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jedrychowski W, 1997, ENVIRON HEALTH PERSP, V105, P302, DOI 10.1289/ehp.97105302; Kharrazi M, 2004, EPIDEMIOLOGY, V15, P660, DOI 10.1097/01.ede.0000142137.39619.60; Lam TH, 1998, INT J EPIDEMIOL, V27, P41, DOI 10.1093/ije/27.1.41; Leonardi GS, 2002, EUR RESPIR J, V20, P890, DOI 10.1183/09031936.02.00260802; Misra DP, 1999, ENVIRON HEALTH PERSP, V107, P897, DOI 10.2307/3434572; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Neuberger M, 2002, ATMOS ENVIRON, V36, P1733, DOI 10.1016/S1352-2310(02)00179-6; NORMAN E, 1994, ALLERGY, V49, P808; Olesen AB, 1997, BRIT MED J, V314, P1003; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Rudnai P., 2004, Egeszsegtudomany, V48, P173; Selcuk ZT, 1997, CLIN EXP ALLERGY, V27, P262, DOI 10.1111/j.1365-2222.1997.tb00704.x; SIERSTED HC, 2000, EUR RES REV, V10, P411; Skorge TD, 2005, AM J RESP CRIT CARE, V172, P61, DOI 10.1164/rccm.200409-1158OC; Spengler JD, 2004, AM J PUBLIC HEALTH, V94, P657, DOI 10.2105/AJPH.94.4.657; Stocks J, 2003, RESPIROLOGY, V8, P266, DOI 10.1046/j.1440-1843.2003.00478.x; Strachan DP, 1998, THORAX, V53, P204; U. S. Environmental Protection Agency, 1992, RESP HLTH EFF PASS S	40	109	116	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0964-4563			TOB CONTROL	Tob. Control	AUG	2006	15	4							294	10.1136/tc.2005.015065		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	069PA	WOS:000239459500012	16885578	
J	Blumer, N; Herz, U; Wegmann, M; Renz, H				Blumer, N; Herz, U; Wegmann, M; Renz, H			Prenatal lipopolysaccharide-exposure prevents allergic sensitization and airway inflammation, but not airway responsiveness in a murine model of experimental asthma	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						airway inflammation; allergy; immune response; lipopolysaccharide; materno-fetal interaction; mice; Th1/Th-2	HAY-FEVER; ATOPIC DISEASE; HOUSE-DUST; T-CELLS; ENDOTOXIN; CHILDREN; HYPERRESPONSIVENESS; HYPERREACTIVITY; PREVALENCE; ANTIBODIES	Background Epidemiological evidence underlines the impact of prenatal environmental factors on the development of postnatal allergies. In this regard an inverse correlation between lipopolysaccharide (LPS) exposure and development of childhood allergy has been found. Objective To assess the impact of prenatal LPS exposure on the development of postnatal respiratory allergies in a mouse model of experimental asthma. Methods Female BALB/c mice were exposed to LPS before conception and during pregnancy. Several weeks after birth offspring were sensitized to ovalbumin (OVA) followed by aerosol allergen challenges. Results Prenatal, maternal LPS-exposure enhanced neonatal IFN-gamma, but not IL-4 and IL-2 production. OVA sensitization of prenatally LPS-exposed mice was accompanied by a marked suppression in anti-OVA IgG1 and IgE as well as unchanged IgG2a antibody responses, paralleled by a significant reduction in IL-5 and IL-13 levels following mitogenic stimulation of splenic leucocytes. Assessment of bronchoalveolar lavage fluids following allergen challenges revealed a marked reduction in eosinophils and macrophages in these mice. Surprisingly, development of airway hyper-responsiveness, a hallmark of bronchial asthma, was not affected. Conclusion This study provides first experimental evidence that LPS may already operate in prenatal life in order to modulate the development of allergies in the offspring.	Hosp Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany	Renz, H (reprint author), Univ Marburg, Dept Clin Chem & Mol Diagnost, Baldinger Str, D-35033 Marburg, Germany.	renzh@med.uni-marburg.de					Alves-Rosa F, 2002, CLIN EXP IMMUNOL, V128, P221, DOI 10.1046/j.1365-2249.2002.01828.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURD RS, 1993, ANN SURG, V218, P250, DOI 10.1097/00000658-199309000-00004; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Glaab T, 2001, AM J PHYSIOL-LUNG C, V280, pL565; Hamada K, 2003, J IMMUNOL, V170, P1683; Herz U, 2000, EUR J IMMUNOL, V30, P714, DOI 10.1002/1521-4141(200002)30:2<714::AID-IMMU714>3.0.CO;2-P; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Herz U, 2001, INT ARCH ALLERGY IMM, V124, P193, DOI 10.1159/000053708; Holmlund U, 2002, IMMUNOLOGY, V107, P145, DOI 10.1046/j.1365-2567.2002.01491.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kopp MV, 2001, CLIN EXP ALLERGY, V31, P1536, DOI 10.1046/j.1365-2222.2001.01198.x; Lehmann I, 2002, ENVIRON TOXICOL, V17, P203, DOI 10.1002/tox.10055; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Piccinni MP, 1996, EUR J IMMUNOL, V26, P2293, DOI 10.1002/eji.1830261004; RENZ H, 1992, CLIN IMMUNOL IMMUNOP, V64, P233, DOI 10.1016/0090-1229(92)90205-3; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; SCOTT BB, 1987, VOX SANG, V52, P272; Sugimoto T, 2004, J EXP MED, V199, P535, DOI 10.1084/jem.20031368; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Uthoff H, 2003, J IMMUNOL, V171, P3485; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187	31	109	113	0	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2005	35	3					397	402		10.1111/j.1365-2222.2005.02184.x		6	Allergy; Immunology	Allergy; Immunology	909CS	WOS:000227837300024	15784121	
J	Noguchi, E; Nishimura, F; Fukai, H; Kim, J; Ichikawa, K; Shibasaki, M; Arinami, T				Noguchi, E; Nishimura, F; Fukai, H; Kim, J; Ichikawa, K; Shibasaki, M; Arinami, T			An association study of asthma and total serum immunoglobin E levels for Toll-like receptor polymorphisms in a Japanese population	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; IgE; polymorphism; TDT; Toll-like receptor	PATTERN-RECOGNITION; TRANSCRIPTIONAL REGULATION; LINKAGE DISEQUILIBRIUM; ACTIVATION; GENE; PREVALENCE; HAPLOTYPES; MUTATIONS; ENDOTOXIN; SYMPTOMS	Background The prevalence of atopic diseases has been increasing in developed countries. This could be explained by the hygiene hypothesis, which states that exposure to specific infections or endotoxins during infancy drives the maturing immune system towards a Th1 phenotype and away from the Th2 phenotype, which is associated with allergic diseases. Toll-like receptors (TLRs) play important roles in the signalling of many pathogen-related molecules and endogenous proteins associated with immune activation. Objective The aim of the present study was to investigate whether polymorphisms in genes encoding TLRs are associated with asthma or total serum IgE levels. Methods We screened the 5' flanking and coding regions of the TLR2,TLR3, TLR4, and TLR9 genes for polymorphisms by direct sequencing of DNA from 32 asthmatics, and analysed the effect of the polymorphisms on the development of atopic asthma and on total serum IgE levels. Results We identified 16 variants in TLRs. The transmission disequilibrium test of the families revealed that none of the alleles or haplotypes were associated with asthma or total IgE levels (P>0.05). However, we found an insertion/deletion polymorphism in the 5' untranslated region of TLR2, and an expression construct containing the deletion allele showed lower luciferase activity than the wild-type alleles, suggesting that the deletion allele has reduced transcriptional activity. Conclusion Our results indicate that polymorphisms in TLRs are not likely to be associated with the development of atopy-related phenotypes in a Japanese population.	Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Clin Med, Dept Paediat, Tsukuba, Ibaraki 3058575, Japan; Tsukuba Coll Technol, Dept Paediat, Tsukuba, Ibaraki, Japan	Noguchi, E (reprint author), Univ Tsukuba, Inst Basic Med Sci, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan.	mo00f210@md.tsukuba.ac.jp					Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbour NC, 2000, NAT GENET, V25, P187; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Clayton D, 1999, AM J HUM GENET, V65, P1161, DOI 10.1086/302566; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823; Haehnel V, 2002, J IMMUNOL, V168, P5629; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Lorenz E, 2002, PEDIATR RES, V52, P373, DOI 10.1203/01.PDR.0000025342.83436.53; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; NIH National Asthma Education and Prevention Program, 1997, GUID DIAGN MAN ASTHM; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch N, 1999, AM J HUM GENET, V65, P493, DOI 10.1086/302497; Risma KA, 2002, J IMMUNOL, V169, P1604; Sabroe I, 2002, CLIN EXP ALLERGY, V32, P984, DOI 10.1046/j.1365-2745.2002.01451.x; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Takeda K, 2001, GENES CELLS, V6, P733, DOI 10.1046/j.1365-2443.2001.00458.x; Takeuchi O, 2000, J IMMUNOL, V165, P5392; Takeuchi O, 2000, J IMMUNOL, V164, P554; van der Stoep N, 2002, J IMMUNOL, V169, P5061; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4; Warner JO, 1999, THORAX, V54, pS46; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201	35	109	120	0	9	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2004	34	2					177	183		10.1111/j.1365-2222.2004.01839.x		7	Allergy; Immunology	Allergy; Immunology	779KL	WOS:000189293900004	14987294	
J	Zmirou, D; Gauvin, S; Pin, I; Momas, I; Sahraoui, F; Just, J; Le Moullec, Y; Bremont, F; Cassadou, S; Reungoat, P; Albertini, M; Lauvergne, N; Chiron, M; Labbe, A				Zmirou, D; Gauvin, S; Pin, I; Momas, I; Sahraoui, F; Just, J; Le Moullec, Y; Bremont, F; Cassadou, S; Reungoat, P; Albertini, M; Lauvergne, N; Chiron, M; Labbe, A		Vesta Investigators	Traffic related air pollution and incidence of childhood asthma: results of the Vesta case-control study	JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH			English	Article							DIESEL EXHAUST; RESPIRATORY HEALTH; EAST-GERMANY; IN-VIVO; CHILDREN; EXPOSURE; ASSOCIATION; PREVALENCE; IMMUNOLOGY; RESIDENCE	Study objective: The Vesta project aims to assess the role of traffic related air pollution in the occurrence of childhood asthma. Design and setting: Case- control study conducted in five French metropolitan areas between 1998 and 2000. A set of 217 pairs of matched 4 to 14 years old cases and controls were investigated. An index of lifelong exposure to traffic exhausts was constructed, using retrospective information on traffic density close to all home and school addresses since birth; this index was also calculated for the 0 - 3 years age period to investigate the effect of early exposures. Main results: Adjusted on environmental tobacco smoke, personal and parental allergy, and several confounders, lifelong exposure was not associated with asthma. In contrast, associations before age of 3 were significant: odds ratios for tertiles 2 and 3 of the exposure index, relative to tertile 1, exhibited a positive trend ( 1.48 ( 95% CI = 0.7 to 3.0) and 2.28 ( 1.1 to 4.6)), with greater odds ratios among subjects with positive skin prick tests. Conclusions: These results suggest that traffic related pollutants might have contributed to the asthma epidemic that has taken place during the past decades among children.	Nancy Univ, Sch Med, Publ Hlth Lab, Nancy, France; Ctr Sci & Tech Batiment, Paris, France; Grenoble Univ Hosp, Dept Paediat, Grenoble, France; Univ Paris 05, Sch Pharm, Publ Hlth & Hyg Lab, Paris, France; Paris Univ Hosp Trousseau, Dept Paediat, Paris, France; City Paris, Hyg Lab, Paris, France; Toulouse Univ Hosp, Dept Paediat, Toulouse, France; Reg Hlth Observ Midi Pyrenees, Toulouse, France; Nice Univ Hosp, Dept Paediat, Nice, France; French Natl Inst Transport & Safety Res, INRETS, Lyon, France; Clermont Ferrand Univ Hosp, Dept Paediat, Clermont Ferrand, France	Zmirou, D (reprint author), Fac Med, INSERM, 9 Av Foret Haye,BP 164, F-54505 Vandoeuvre Les Nancy, France.		PIN, Isabelle/N-3020-2013; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Anderson HR, 1997, CIBA F SYMP, V206, P190; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Busse WW, 2001, NEW ENGL J MED, V344, P350; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Clark NM, 1999, ENVIRON HEALTH PERSP, V107, P421; *COMM MED EFF AIR, 1995, ASTHM OUTD POLL; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Ebelt S, 2001, ENVIRON HEALTH PERSP, V109, P325, DOI 10.2307/3454890; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; *HLTH EFF I, 1995, DIES EXH CRIT AN EM; Holgate ST, 1997, CIBA F SYMP, V206, P1; Jantunen MJ, 1998, J EXPO ANAL ENV EPID, V8, P495; Jarvis D, 1998, BRIT MED J, V316, P607; Kay AB, 2001, NEW ENGL J MED, V344, P30; Koistinen KJ, 1999, J AIR WASTE MANAGE, V49, P1212, DOI 10.1080/10473289.1999.10463916; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LEIKAUF GD, 1995, ENVIRON HEALTH PERSP, V103, P253, DOI 10.2307/3432382; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Mattes J, 1999, CLIN EXP ALLERGY, V29, P729; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Nyberg F, 2000, EPIDEMIOLOGY, V11, P487, DOI 10.1097/00001648-200009000-00002; Oglesby L, 2000, J EXPO ANAL ENV EPID, V10, P251, DOI 10.1038/sj.jea.7500088; PALTTSMILLS T, 1999, ASTHMA CAUSES MECH I, P2; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; PEDEN DB, 1999, ASTHMA CAUSES MECH I, P173; Pitz M, 2001, ATMOS ENVIRON, V35, P4357, DOI 10.1016/S1352-2310(01)00229-1; Platts-Mills TAE, 2000, ENVIRON HEALTH PERSP, V108, P725, DOI 10.2307/3454409; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; VANMUTIUS E, 1998, LANCET, V351, P862; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Wilkinson P, 1999, THORAX, V54, P1070; WJST M, 1993, BRIT MED J, V307, P596; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Zmirou D, 2002, J EXPO ANAL ENV EPID, V12, P186, DOI 10.1038/sj/jea/7500217	43	109	116	1	12	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0143-005X			J EPIDEMIOL COMMUN H	J. Epidemiol. Community Health	JAN	2004	58	1					18	23		10.1136/jech.58.1.18		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	755KK	WOS:000187401900005	14684722	
J	Kabesch, M; Peters, W; Carr, D; Leupold, W; Weiland, SK; von Mutius, E				Kabesch, M; Peters, W; Carr, D; Leupold, W; Weiland, SK; von Mutius, E			Association between polymorphisms in caspase recruitment domain containing protein 15 and allergy in two German populations	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopic dermatitis; allergic rhinitis; atopy; childhood; IgE; CARD15; NOD2; polymorphism; SNP	CROHNS-DISEASE; KAPPA-B; NOD2; SUSCEPTIBILITY; MONOCYTES; MUTATION; GENE	Background: Early exposure to microbial matter such as LPS may influence the development of asthma and allergies by activation of innate immunity pathways as indicated by studies in farming environments. Recently, polymorphisms in caspase recruitment domain containing protein 15 (CARD15), an intracellular LPS receptor protein, have been associated with Crohn's disease. Because these polymorphisms lead to changes in LPS recognition, they may affect the development of asthma and allergies. Objective: We genotyped a large population of German schoolchildren (N = 1872) from East and West Germany for 3 functional relevant CARD15 polymorphisms for their role in the development of asthma and allergy. Methods: By use of parental questionnaires, skin prick testing, pulmonary function tests, bronchial challenge tests, and measurements of serum IgE levels, children were phenotyped for the presence of atopic diseases. Genotyping was performed with PCR-based restriction enzyme assays. To assess associations between atopic phenotypes and genotypes standard statistical procedures were applied. Results: Children with the polymorphic allele C2722 had a more than 3-fold risk to develop allergic rhinitis (P < .001) and an almost 2-fold risk for atopic dermatitis (P < .05). Furthermore, the T2104 allele was associated with an almost 2-fold risk for allergic rhinitis (P < .05). When a C insertion at position 3020 was present, the risk of atopy increased by 50% (P < .05) and serum IgE levels were elevated (P < .01). Conclusion: The shared genetic background between Crohn's disease and atopy may indicate that an impaired recognition of microbial exposures results in an insufficient downregulation of excessive immune responses, giving rise to either T(H)2 dominated allergies or T(H)1 related Crohn's disease.	Univ Munich, Childrens Univ Hosp, D-80337 Munich, Germany; Univ Childrens Hosp, Dresden, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany	Kabesch, M (reprint author), Univ Munich, Childrens Univ Hosp, Lindwurmstr 4, D-80337 Munich, Germany.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; von Mutius, Erika/0000-0002-8893-4515			Arbour NC, 2000, NAT GENET, V25, P187; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; BERBIG B, 1991, ALLERGOLOGIE, V14, P51; DEVLIN B, 1995, GENOMICS, V29, P311; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Ten RM, 1999, J ALLERGY CLIN IMMUN, V104, P376, DOI 10.1016/S0091-6749(99)70382-9; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x	16	109	110	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					813	817		10.1067/mai.2003.1336		5	Allergy; Immunology	Allergy; Immunology	667WW	WOS:000182258500023	12704363	
J	Hoffmann-Sommergruber, K				Hoffmann-Sommergruber, K			Pathogenesis-related (PR)-proteins identified as allergens	BIOCHEMICAL SOCIETY TRANSACTIONS			English	Article; Proceedings Paper	Colloquium on Plant Food Allergens	JUL 16-18, 2002	CARDIFF UNIV, CARDIFF, WALES		CARDIFF UNIV	chitinase; IgE; latex; lipid transfer protein; pathogenesis-related protein; plant allergens	LIPID TRANSFER PROTEIN; PEACH PRUNUS-PERSICA; AMINO-ACID-SEQUENCE; CLASS-I CHITINASES; MAJOR ALLERGEN; MOLECULAR CHARACTERIZATION; POLLEN ALLERGENS; ROSACEAE FRUITS; PR PROTEINS; EXPRESSION	Type I allergies are recognized as an important disease affecting around 25 % of the population of industrialized countries of the Northern hemisphere. Allergic patients produce specific IgE antibodies after frequent exposure to either inhaled or nutritive allergens. Of the plant allergens listed in the Official Allergen Database of the International Union of Immunological Societies, approx. 25 % belong to the group of pathogenesis-related proteins (PR-proteins). PR-proteins are defined as proteins that are induced upon stress, pathogen attack and abiotic stimuli. This inhomogeneous group of proteins has been classified into 14 PR-protein families. So far, plant-derived allergens have been identified with sequence similarities to PR-protein families 2, 3, 4, 5, 8, 10 and 14. In general, both protein groups, i.e. PR-proteins and allergens, comprise rather small proteins, which are stable at low pH and resistant to proteolysis. These features, and their level of expression, make PR-proteins good candidates for evoking an immune response in predisposed humans, when coming into contact with mucosal surfaces. The identification of PR-proteins with allergenic potential and their homologues is of importance for the allergic patient and the management of this disease. Firstly, plant foods derived from genetically modified plants could represent new allergen sources, and therefore should be evaluated carefully for their potential allergenicity. Secondly, complex plant-derived foods should be analysed for hidden allergens and labelled accordingly.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria	Hoffmann-Sommergruber, K (reprint author), Univ Vienna, Dept Pathophysiol, AKH-EBO 3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.						ALENIUS H, 1995, CLIN EXP ALLERGY, V25, P659, DOI 10.1111/j.1365-2222.1995.tb01114.x; BERNASCONI P, 1987, BIOCHIM BIOPHYS ACTA, V915, P254, DOI 10.1016/0167-4838(87)90307-4; BLANCO C, 1994, ALLERGY, V49, P454, DOI 10.1111/j.1398-9995.1994.tb00839.x; BOWLES DJ, 1990, ANNU REV BIOCHEM, V59, P873, DOI 10.1146/annurev.bi.59.070190.004301; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Chen ZP, 1998, J ALLERGY CLIN IMMUN, V102, P476, DOI 10.1016/S0091-6749(98)70138-1; CONSTABEL CP, 1995, MOL PLANT MICROBE IN, V8, P104, DOI 10.1094/MPMI-8-0104; Curioni A, 1999, CLIN EXP ALLERGY, V29, P407, DOI 10.1046/j.1365-2222.1999.00491.x; Danieli W.F., 1852, PHARM J, V11, P445; Diaz-Perales A, 1998, J ALLERGY CLIN IMMUN, V102, P127, DOI 10.1016/S0091-6749(98)70063-6; Fernandez-Rivas M, 1999, CLIN EXP ALLERGY, V29, P1239, DOI 10.1046/j.1365-2222.1999.00628.x; Fernandez-Rivas M, 1997, J ALLERGY CLIN IMMUN, V100, P728, DOI 10.1016/S0091-6749(97)70265-3; GONZALEZ R, 1991, INT ARCH ALLER A IMM, V95, P53; Grison R, 1996, NAT BIOTECHNOL, V14, P643, DOI 10.1038/nbt0596-643; Hanninen AR, 1999, J ALLERGY CLIN IMMUN, V104, P194, DOI 10.1016/S0091-6749(99)70135-1; Hoffman Bruce, 1997, TERRORISM POLITICAL, V9, P1, DOI 10.1080=09546559708427381; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; HoffmannSommergruber K, 1996, ADV EXP MED BIOL, V409, P219; Hsieh LS, 1995, J ALLERGY CLIN IMMUN, V96, P960, DOI 10.1016/S0091-6749(95)70234-2; Inschlag C, 1998, INT ARCH ALLERGY IMM, V116, P22, DOI 10.1159/000023920; JAEGER L, 1998, NAHRUNGSMITTELALLERG; Kader JC, 1996, ANNU REV PLANT PHYS, V47, P627, DOI 10.1146/annurev.arplant.47.1.627; Leitner A, 1998, ALLERGY, V53, P36, DOI 10.1111/j.1398-9995.1998.tb03771.x; LLEONART R, 1992, ANN ALLERGY, V69, P128; MATTON DP, 1989, MOL PLANT MICROBE IN, V2, P325, DOI 10.1094/MPMI-2-325; Moiseyev GP, 1997, FEBS LETT, V407, P207, DOI 10.1016/S0014-5793(97)00337-2; Molina A, 1996, MOL GEN GENET, V252, P162, DOI 10.1007/BF02173216; NEUHAUS JM, 1991, P NATL ACAD SCI USA, V88, P10362, DOI 10.1073/pnas.88.22.10362; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V104, P1099, DOI 10.1016/S0091-6749(99)70095-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Pastorello EA, 1999, BIOL CHEM, V380, P1315, DOI 10.1515/BC.1999.167; Peumans WJ, 2000, EUR J BIOCHEM, V267, P1188, DOI 10.1046/j.1432-1327.2000.01117.x; Puhringer H, 2000, PLANT SCI, V152, P35, DOI 10.1016/S0168-9452(99)00222-8; ROBERTS WK, 1990, J GEN MICROBIOL, V136, P1771; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; Sanchez-Monge R, 1999, CLIN EXP ALLERGY, V29, P673, DOI 10.1046/j.1365-2222.1999.00526.x; Sanchez-Monge R, 1999, J ALLERGY CLIN IMMUN, V103, P514, DOI 10.1016/S0091-6749(99)70479-3; Scheurer S, 1997, MOL IMMUNOL, V34, P619, DOI 10.1016/S0161-5890(97)00072-2; SOMSSICH IE, 1986, P NATL ACAD SCI USA, V83, P2427, DOI 10.1073/pnas.83.8.2427; Sowka S, 1998, J BIOL CHEM, V273, P28091, DOI 10.1074/jbc.273.43.28091; STINTZI A, 1993, BIOCHIMIE, V75, P687, DOI 10.1016/0300-9084(93)90100-7; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; van Ree R, 2002, BIOCHEM SOC T, V30, P910; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Wagner S, 2002, BIOCHEM SOC T, V30, P935, DOI 10.1042/BST0300935; Walter MH, 1996, EUR J BIOCHEM, V239, P281, DOI 10.1111/j.1432-1033.1996.0281u.x; WALTER MH, 1990, MOL GEN GENET, V222, P353, DOI 10.1007/BF00633840; WARNER SAJ, 1992, PLANT MOL BIOL, V19, P555, DOI 10.1007/BF00026782; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379; Zhu BL, 1996, PLANTA, V198, P70; [Anonymous], 1992, FED REG, V57, p[22, 984, 988, 991]	52	109	117	3	9	PORTLAND PRESS	LONDON	59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND	0300-5127			BIOCHEM SOC T	Biochem. Soc. Trans.	NOV	2002	30		6				930	935		10.1042/BST0300930		6	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	625KX	WOS:000179816600023	12440949	
J	Omland, O				Omland, O			Exposure and respiratory health in farming in temperate zones - A review of the literature	ANNALS OF AGRICULTURAL AND ENVIRONMENTAL MEDICINE			English	Review						farming; agriculture; temperate zones; confinement buildings; measurements; exposure; sensitisation; asthma; chronic bronchitis; bronchial responsiveness; lung function	SWINE-CONFINEMENT BUILDINGS; DOSE-RESPONSE RELATIONSHIPS; CROSS-SECTIONAL SURVEY; LUNG-FUNCTION DECLINE; NEW-ZEALAND FARMERS; CHRONIC-BRONCHITIS; DAIRY FARMERS; PIG FARMERS; STORAGE MITES; RISK-FACTORS	To review studies in farming populations from temperate zones focusing on: (1) exposure to dust, bacteria, moulds, endotoxin, and ammonia, (2) sensitisation to common airborne allergens, (3) prevalence, incidence and risk factors of chronic bronchitis, asthma and bronchial hyperresponsiveness, and (4) measurements of lung function. Working in animal housings can be associated with exposure to organic dust, bacteria, moulds, endotoxin, and ammonia in concentrations that can induce cellular and immunological responses and result in respiratory diseases. Working in poultry housing might be associated with higher exposures to dust, bacteria, and ammonia than in swine and cow housings, and endotoxin exposure seems to be higher in North America than in Europe. Working exposure might influence the domestic area on farms, and there might be a protective effect of being raised on a farm regarding sensitisation and allergic diseases. Sensitisation to mites seems to be the most prevalent of the common inhalant allergens. Chronic bronchitis is frequent and data suggests that it is work related in farmers. Findings concerning asthma are less uniform, and data regarding bronchial hyperresponsiveness are too sparse and inconsistent to evaluate the effect on farming. Several risk factors have been described, and age is shared for all three clinical manifestations, while male gender, atopy, smoking, pig farming, and animal production are common risk factors for chronic bronchitis and asthma. FEV1, and FEV1/FVC seems to be reduced in farmers, and longitudinal studies indicate an increased annual loss in FEV1 in farmers, especially in pig farmers. The increased annual decline has been associated with lung function, bronchial hyperresponsiveness, smoking, automatic dry feeding systems, and endotoxin. Despite studies with methodological weaknesses, heterogenity in sampling times, measurement techniques, equipment, and diagnostic criteria, the review has revealed that the exposure to organic dust in farming can be substantial and might lead to respiratory diseases and increased annual loss in lung function. Working exposure seems to influence the domestic area in farms, and being raised on a farm might have a protective effect regarding sensitisation and allergic diseases.	Aarhus Univ, Inst Environm & Occupat Med, DK-8000 Aarhus C, Denmark	Omland, O (reprint author), Aarhus Univ, Inst Environm & Occupat Med, Univ Pk,Bldg 260,Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark.						AMISHIMA M, 1995, AM J RESP CRIT CARE, V151, P1794; Baur X, 1998, AM J IND MED, V33, P454; BESSETTE L, 1993, ARCH ENVIRON HEALTH, V48, P73; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; Bohadana AB, 1999, LUNG, V177, P191, DOI 10.1007/PL00007640; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BUNDY DS, 1973, MC73501 AM SOC AGR E; CARVALHEIRO MF, 1995, AM J IND MED, V27, P65, DOI 10.1002/ajim.4700270107; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CHEN Y, 1991, INT J EPIDEMIOL, V20, P416, DOI 10.1093/ije/20.2.416; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; CHOUDAT D, 1994, SCAND J WORK ENV HEA, V20, P48; CORMIER Y, 1990, AM IND HYG ASSOC J, V51, P304, DOI 10.1202/0002-8894(1990)051<0304:AMCITT>2.0.CO;2; CORMIER Y, 1991, SCAND J WORK ENV HEA, V17, P269; Cormier Y, 2000, EUR RESPIR J, V15, P560, DOI 10.1034/j.1399-3003.2000.15.22.x; CUTHBERT OD, 1984, CLIN ALLERGY, V14, P197, DOI 10.1111/j.1365-2222.1984.tb02653.x; Dalphin JC, 1998, AM J RESP CRIT CARE, V158, P1493; Dalphin JC, 1998, EUR RESPIR J, V11, P1287, DOI 10.1183/09031936.98.11061287; DALPHIN JC, 1989, CHEST, V95, P1244, DOI 10.1378/chest.95.6.1244; DALPHIN JC, 1993, BRIT J IND MED, V50, P941; *DAN LAB INSP SERV, 2000, AT ANV NO C 0 1 LIM; Danuser B, 2001, AM J IND MED, V39, P410, DOI 10.1002/ajim.1032.abs; DONHAM K, 1989, BRIT J IND MED, V46, P31; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; DONHAM KJ, 1985, AM IND HYG ASSOC J, V46, P658, DOI 10.1202/0002-8894(1985)046<0658:ALOSGI>2.3.CO;2; DONHAM KJ, 1990, AM J IND MED, V17, P73; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; DONHAM KJ, 1991, AM J VET RES, V52, P1723; DOSMAN JA, 1988, J OCCUP ENVIRON MED, V30, P715; Douwes J, 1997, INT J OCCUP ENV HL S, V3, pS26; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114; HELLER RF, 1986, THORAX, V41, P117, DOI 10.1136/thx.41.2.117; Hinze S, 1997, INT ARCH ALLERGY IMM, V112, P231; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; HURTS TS, 1990, AM J IND MED, V17, P27; HUSMAN K, 1987, EUR J RESPIR DIS, V71, P57; IVERSEN M, 1989, THORAX, V44, P645, DOI 10.1136/thx.44.8.645; Iversen M, 2000, EUR RESPIR J, V16, P404, DOI 10.1034/j.1399-3003.2000.016003404.x; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; IVERSEN M, 1990, THORAX, V45, P919, DOI 10.1136/thx.45.12.919; IVERSEN M, 1990, ALLERGY, V45, P347, DOI 10.1111/j.1398-9995.1990.tb00510.x; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; Iversen M, 1994, ANN AGR ENV MED, V1, P39; Jacobs R. R., 1989, APPL IND HYG, V4, P50; JORNA THJM, 1994, INT ARCH OCC ENV HEA, V66, P217; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; Kern J, 2001, J OCCUP ENVIRON MED, V43, P905, DOI 10.1097/00043764-200110000-00010; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kimbell-Dunn M, 1999, AM J IND MED, V35, P51, DOI 10.1002/(SICI)1097-0274(199901)35:1<51::AID-AJIM7>3.0.CO;2-F; Kimbell-Dunn MR, 2001, AM J IND MED, V39, P292, DOI 10.1002/1097-0274(200103)39:3<292::AID-AJIM1017>3.3.CO;2-6; Kirychuk S, 1998, Can Respir J, V5, P472; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Koerkamp PWGG, 1998, J AGR ENG RES, V70, P79; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kronqvist M, 1999, CLIN EXP ALLERGY, V29, P35; Kronqvist M, 1999, ALLERGY, V54, P1142, DOI 10.1034/j.1398-9995.1999.00115.x; Kullman GJ, 1998, AM IND HYG ASSOC J, V59, P403, DOI 10.1202/0002-8894(1998)059<0403:ODEFWI>2.0.CO;2; Langhammer A, 2000, J EPIDEMIOL COMMUN H, V54, P917, DOI 10.1136/jech.54.12.917; LARSSON K, 1992, CHEST, V101, P767, DOI 10.1378/chest.101.3.767; LOUHELAINEN K, 1987, EUR J RESPIR DIS, V71, P73; MALMBERG P, 1988, INT ARCH ALLER A IMM, V87, P47; MANFREDA J, 1989, AM J IND MED, V15, P7, DOI 10.1002/ajim.4700150103; Mauny F, 1997, EUR RESPIR J, V10, P2522, DOI 10.1183/09031936.97.10112522; Melbostad E, 1997, SCAND J WORK ENV HEA, V23, P271; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262; Monso E, 2000, AM J RESP CRIT CARE, V162, P1246; Montnemery P, 1998, RESP MED, V92, P1337, DOI 10.1016/S0954-6111(98)90139-1; Mustajbegovic J, 2001, J OCCUP ENVIRON MED, V43, P576, DOI 10.1097/00043764-200106000-00014; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; Pahl O, 1997, J AEROSOL SCI, V28, P427, DOI 10.1016/S0021-8502(96)00445-4; Pallasaho P, 1999, RESP MED, V93, P798, DOI 10.1016/S0954-6111(99)90265-2; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; PRELLER L, 1995, ANN OCCUP HYG, V39, P545, DOI 10.1016/0003-4878(95)00024-9; PRELLER L, 1995, OCCUP ENVIRON MED, V52, P654; Radon K, 2000, J OCCUP ENVIRON MED, V42, P814, DOI 10.1097/00043764-200008000-00010; Radon K, 2001, EUR RESPIR J, V17, P747, DOI 10.1183/09031936.01.17407470; Radon K, 2000, ALLERGY, V55, P219, DOI 10.1034/j.1398-9995.2000.00461.x; Rautalahti M, 1987, Eur J Respir Dis Suppl, V152, P188; Reynolds SJ, 1996, AM J IND MED, V29, P33, DOI 10.1002/(SICI)1097-0274(199601)29:1<33::AID-AJIM5>3.0.CO;2-#; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; RIJCKEN B, 1988, AM REV RESPIR DIS, V137, P826; ROSENMAN KD, 1997, JOEM, V41, P5; RYLANDER R, 1990, AM J IND MED, V17, P66; RYLANDER R, 1987, AM J IND MED, V12, P687, DOI 10.1002/ajim.4700120607; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47; Schwartz DA, 1994, AM J PHYSIOL, V267, P609; Seedorf J, 1998, J AGR ENG RES, V70, P97, DOI 10.1006/jaer.1997.0281; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884; Senthilselvan A, 1997, CHEST, V111, P1733, DOI 10.1378/chest.111.6.1733; SENTHILSELVAN A, 1993, AM REV RESPIR DIS, V148, P667; Sigsgaard T, 2000, EUR RESPIR J, V16, P50, DOI 10.1034/j.1399-3003.2000.16a09.x; Sigsgaard T., 1997, J AGROMED, V4, P63, DOI 10.1300/J096v04n01_09; Takai H, 1998, J AGR ENG RES, V70, P59, DOI 10.1006/jaer.1997.0280; TERHO EO, 1987, EUR J RESPIR DIS, V71, P165; TERHO EO, 1995, J EPIDEMIOL COMMUN H, V49, P296, DOI 10.1136/jech.49.3.296; TERHO EO, 1987, J EPIDEMIOL COMMUN H, V41, P300, DOI 10.1136/jech.41.4.300; Toren K, 1996, OCCUP ENVIRON MED, V53, P757; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; VANHAGEHAMSTEN M, 1991, ALLERGY, V46, P142; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; Varslot Magne, 1996, Tidsskrift for den Norske Laegeforening, V116, P1077; VIRTANEN T, 1992, INT ARCH ALLERGY IMM, V98, P252; Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Vogelzang PFJ, 2000, CHEST, V117, P1488, DOI 10.1378/chest.117.5.1488; VOGELZANG PFJ, 1998, JOEM, V40, P1045; VOHLONEN I, 1987, EUR J RESPIR DIS, V71, P37; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; WAHTES CM, 1998, J AGR ENG RES, V70, P3; WATHES CM, 1994, LIVESTOCK HOUSING, P1236; Yeung VP, 1998, J IMMUNOL, V161, P4146; ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49; ZEJDA JE, 1993, CHEST, V103, P702, DOI 10.1378/chest.103.3.702; ZHOU C, 1991, CHEST, V99, P941, DOI 10.1378/chest.99.4.941; Zuskin E, 1995, ENVIRON RES, V70, P11, DOI 10.1006/enrs.1995.1040; ZUSKIN E, 1993, INT ARCH OCC ENV HEA, V64, P521, DOI 10.1007/BF00381102	125	109	111	0	9	INST AGRICULTURAL MEDICINE	LUBLIN	JACZEWSKIEGO 2, PO BOX 185, 20-950 LUBLIN, POLAND	1232-1966			ANN AGR ENV MED	Ann. Agr. Env. Med.		2002	9	2					119	136				18	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	627WU	WOS:000179959900001	12498578	
J	Carter, MC; Perzanowski, MS; Raymond, A; Platts-Mills, TAE				Carter, MC; Perzanowski, MS; Raymond, A; Platts-Mills, TAE			Home intervention in the treatment of asthma among inner-city children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen avoidance; dust mite; children; inner city	HOUSE-DUST MITE; COCKROACH ALLERGEN; BRONCHIAL HYPERREACTIVITY; RISK-FACTORS; P-I; EXPOSURE; AVOIDANCE; SENSITIZATION; ENVIRONMENT; ANTIBODIES	Background: In Atlanta, as in other major urban areas of the United States, asthma is a leading cause of school absenteeism, emergency department use, and hospitalization. Recent guidelines for asthma management recommend reducing exposure to relevant allergens, but neither the feasibility nor the efficacy of this form of treatment has been established for children living in poverty. Objective: We sought to investigate allergen avoidance as a treatment for asthma among inner-city children. Methods: One hundred four children with asthma living in the city of Atlanta were enrolled into a controlled trial of avoidance without being skin tested. The children were randomized to an active avoidance group, a placebo avoidance group, and a second control group for which no house visits occurred until the end of the first year. Avoidance included bed and pillow covers, hot washing of bedding, and cockroach bait. Eighty-five children completed the study, and the outcome was measured as unscheduled clinic visits, emergency department visits, and hospitalization for asthma, as well as changes in mite and cockroach allergen levels. Results: There was a significant decrease in acute visits for asthma among children whose homes were visited (P <.001). However, there was no significant difference between the active and placebo homes either in the effect on asthma visits or in allergen concentrations. When the children with mite allergy were considered separately, there was a significant correlation between decreased mite allergen and change in acute visits (P <.01). The avoidance measures for cockroach allergen appeared to be ineffective, and the changes observed did not correlate with changes in visits. Conclusions: Applying allergen avoidance as a treatment for asthma among children living in poverty is difficult because of multiple sensitivities and problems applying the protocols in this environment. The current results demonstrate that home visiting positively influences the management of asthma among families living in poverty. Furthermore, the results for children with mite allergy strongly suggest that decreasing relevant allergen exposure should be an objective of treatment in this population.	Emory Univ, Dept Family Med, Atlanta, GA 30322 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Platts-Mills, TAE (reprint author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.				NIAID NIH HHS [1P01 AI50989, AI-20565]		Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Celano M, 1998, J PEDIATR PSYCHOL, V23, P345, DOI 10.1093/jpepsy/23.6.345; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GOETZSCHE PC, 1998, BRIT MED J, V317, P1105; Hayden ML, 1997, ANN ALLERG ASTHMA IM, V79, P437; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Mollet JA, 1997, J MED ENTOMOL, V34, P307; National Institutes of Health, 1997, NIH PUBL; PARSONS HM, 1974, SCIENCE, V183, P922, DOI 10.1126/science.183.4128.922; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; Piacentini GL, 1996, J ALLERGY CLIN IMMUN, V97, P1079, DOI 10.1016/S0091-6749(96)70261-0; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1982, LANCET, V2, P675; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Redline S, 1996, PEDIATR PULM, V21, P203; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; WEISS KB, 1990, AM J EPIDEMIOL, V132, pS107; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Yoos H L, 1997, J Pediatr Health Care, V11, P66	37	109	110	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					732	737		10.1067/mai.2001.119155		6	Allergy; Immunology	Allergy; Immunology	498RG	WOS:000172523800012	11692097	
J	Park, JH; Spiegelman, DL; Gold, DR; Burge, HA; Milton, DK				Park, JH; Spiegelman, DL; Gold, DR; Burge, HA; Milton, DK			Predictors of airborne endotoxin in the home	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						airborne endotoxin; dust endotoxin; predictive model; seasonal variability	LUNG-FUNCTION; HOUSE-DUST; RESPIRATORY SYMPTOMS; LIMULUS ASSAY; COTTON DUST; EXPOSURE; CHILDREN; ASTHMA; FARMERS; SEVERITY	We identified home characteristics associated with the level of airborne endotoxin in 111 Boston-area homes enrolled in a cohort study of home exposures and childhood asthma, and we developed a predictive model to estimate airborne endotoxin. We measured endotoxin in family-room air and in dust from the baby's bed, family room, bedroom, and kitchen floor. Level of airborne endotoxin was weakly correlated (r < 0.3) with level of endotoxin in each of the four types of dust samples and was significantly correlated with endotoxin in family-room dust (p < 0.05). Endotoxin in family-room dust accounted for < 6% of the variability of airborne endotoxin. In a multivariate model, certain home characteristics were positively (p < 0.05) associated with airborne endotoxin. These included current presence of dog (difference in level, dog vs. no dog = 72%, partial R-2 = 12.8%), past presence of dog (partial R-2 = 5.5%), and endotoxin level in family-room dust (partial R-2 = 5.3%). Use of a dehumidifier (partial R-2 = 6.4%) was negatively associated (p = 0.02; difference = -31%) with airborne endotoxin. Other home characteristics were identified as important determinants of increased airborne endotoxin in this model, but individual coefficients were not statistically significant (alpha = 0.05): total amount of fine dust collected in the home (partial R-2 = 3.8%), concrete floor in family room (3.7%), water damage (3.6%), and use of cool-mist humidifier in past year (2.7%). This multivariate model explained 42% of the variability of airborne endotoxin levels, a substantial improvement over that with dust endotoxin alone. Airborne endotoxin in Boston-area homes appears to be determined by the presence of dogs, moisture sources, and increased a-mounts of settled dust.	Harvard Univ, Sch Publ Hlth, Occupat Hlth Program, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Milton, DK (reprint author), Harvard Univ, Sch Publ Hlth, Occupat Hlth Program, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Milton, Donald/G-3286-2010	Milton, Donald/0000-0002-0550-7834	NIAID NIH HHS [R01 AI/EHS-35786]; NIEHS NIH HHS [2P30ES00002, R01 ES-07036]		ALLEN DM, 1971, TECHNOMETRICS, V13, P469, DOI 10.2307/1267161; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; Carroll R. J., 1995, MEASUREMENT ERROR NO; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Christiani DC, 1999, AM J IND MED, V35, P321, DOI 10.1002/(SICI)1097-0274(199904)35:4<321::AID-AJIM1>3.0.CO;2-L; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; DOUWES J, 1998, RESP HLTH EFFECTS IN, P109; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114; Kleinbaum D.G., 1987, APPL REGRESSION ANAL; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; Mohan A. K., 1998, APPL OCCUP ENV HYG, V13, P782; Nishioka MG, 1999, ENVIRON SCI TECHNOL, V33, P1359, DOI 10.1021/es980580o; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; PLATT SD, 1989, BRIT MED J, V298, P1673; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; RYLANDER R, 1978, CLIN ALLERGY, V8, P511, DOI 10.1111/j.1365-2222.1978.tb01504.x; Saraf A, 1999, J ENVIRON MONITOR, V1, P163, DOI 10.1039/a809019j; Saraf A, 1997, APPL ENVIRON MICROB, V63, P2554; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; SCHWARTZ DA, 1994, AM J PHYSIOL-LUNG C, V267, pL609; SMID T, 1992, AM REV RESPIR DIS, V146, P1474; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; Svendsgaard DJ, 1997, ENVIRON HEALTH PERSP, V105, P1106, DOI 10.1289/ehp.971051106; TYNDALL RL, 1995, INDOOR AIR, V5, P171, DOI 10.1111/j.1600-0668.1995.t01-1-00003.x; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Williamson IJ, 1997, THORAX, V52, P229; Yazicioglu M, 1998, Allergol Immunopathol (Madr), V26, P5; 1995, MORB MORTAL WKLY REP, V43, P952; 1992, MORB MORTAL WKLY REP, V41, P733	38	109	109	1	4	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2001	109	8					859	864		10.2307/3454831		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	470BZ	WOS:000170851700032	11564624	
J	Phipps, S; Lam, CE; Kaiko, GE; Foo, SY; Collison, A; Mattes, J; Barry, J; Davidson, S; Oreo, K; Smith, L; Mansell, A; Matthaei, KI; Foster, PS				Phipps, Simon; Lam, Chuan En; Kaiko, Gerard E.; Foo, Shen Yun; Collison, Adam; Mattes, Joerg; Barry, Jessica; Davidson, Sophia; Oreo, Kevin; Smith, Lauren; Mansell, Ashley; Matthaei, Klaus I.; Foster, Paul S.			Toll/IL-1 Signaling Is Critical for House Dust Mite-specific Th1 and Th2 Responses	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; innate immunity; eosinophil; neutrophil	ALLERGIC AIRWAY INFLAMMATION; ACTIVATED PROTEIN-KINASE; ANTIGEN-PRESENTING CELLS; TOLL-LIKE RECEPTORS; DENDRITIC CELLS; IMMUNE-RESPONSES; ASTHMATIC-PATIENTS; INHALED ANTIGEN; CUTTING EDGE; OX40 LIGAND	Rationale: One of the immunopathological features of allergic inflammation is the infiltrationof helper T type 2 (Th2) cells to the site of disease. Activation of innate pattern recognition receptors such as Toll-like receptors (TLRs) plays a critical role in helper T type I cell differentiation, yet their contribution to the generation of Th2 responses to clinically relevant aeroallergens remains poorly defined. Objectives: To determine the requirement for TLR2, TLR4, and the Toll/IL-1 receptor domain adaptor protein MyD88 in a murine model of allergic asthma. Methods: Wild-type and factor-deficient ((-/-)) mice were sensitized intranasally to the common allergen house dust mite (HDM) and challenged 2 weeks later on four consecutive days. Measurements of allergic airway inflammation, T-cell cytokine production, and airway hyperreactivity, were performed 24 hours later. Measurements and Main Results: Mice deficient in MyD88 were protected from the cardinal features of allergic asthma, including granulocytic inflammation, Th2 cytokine production and airway hyperreactivity. Although HDM activated NF-kappa B in TLR2- or TLR4-expressing HEK cells, only in TLR4(-/-) mice was the magnitude of allergic airway inflammation and hyperreactivity attenuated. The diminished Th2 response present in MyD88(-/-) and TLR4(-/-) mice was associated with fewer OX40 ligand-expressing myeloid dendritic cells in the draining lymph nodes during allergic sensitization. Finally, HDM-specific IL-17 production and airway neutrophilia were attenuated in MyD88(-/-) but not TLR4(-/-) mice. Conclusions: Together, these data suggest that Th2- and Th17-mediated inflammation generated on inhalational HDM exposure is differentially regulated by the presence of microbial products and the activation of distinct MyD88-dependent pattern recognition receptors.	[Phipps, Simon; Lam, Chuan En; Kaiko, Gerard E.; Foo, Shen Yun; Collison, Adam; Mattes, Joerg; Barry, Jessica; Davidson, Sophia; Oreo, Kevin; Smith, Lauren; Foster, Paul S.] Univ Newcastle, Ctr Asthma & Resp Dis, Sch Biomed Sci, Newcastle, NSW 2300, Australia; [Mansell, Ashley] Monash Univ, Monash Inst Med Res, Clayton, Vic, Australia; [Matthaei, Klaus I.] Australian Natl Univ, John Curtin Sch Med Res, Gene Targeting Grp, Canberra, ACT 2601, Australia; [Matthaei, Klaus I.] King Saud Univ, Coll Med, Dept Anat, Stem Cell Unit, Riyadh 11461, Saudi Arabia; [Matthaei, Klaus I.] King Saud Univ, King Khalid Univ Hosp, Riyadh 11461, Saudi Arabia	Foster, PS (reprint author), Univ Newcastle, Ctr Asthma & Resp Dis, Sch Biomed Sci, David Maddison Clin Sci Bldg,Watt St, Newcastle, NSW 2300, Australia.	simon.phipps@newcastle.edu.au; paul.foster@newcastle.edu.au	Mansell, Ashley/B-9553-2008; Klaus, Matthaei/D-8691-2011; Phipps, Simon/F-9170-2010; Foster, Paul/G-5057-2013	Mansell, Ashley/0000-0002-6540-1281; Phipps, Simon/0000-0002-7388-3612; 	National Health and Medical Research (NHMRC) [224207]; Australian Lung Foundation/Boehringer Ingelheim Chronic Airflow Limitation Research	Supported by a National Health and Medical Research (NHMRC) program grant (224207). S.P. is a recipient of an Australian Lung Foundation/Boehringer Ingelheim Chronic Airflow Limitation Research Fellowship.	Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Agrawal S, 2003, J IMMUNOL, V171, P4984; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Bates ME, 2004, AM J RESP CELL MOL, V30, P736, DOI 10.1165/rcmb.2003-0234OC; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Cates EC, 2004, J IMMUNOL, V173, P6384; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JC1200216109; Dabbagh K, 2002, J IMMUNOL, V168, P4524; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Didierlaurent A, 2008, J EXP MED, V205, P323, DOI 10.1084/jem.20070891; Dillon S, 2004, J IMMUNOL, V172, P4733; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Hartl D, 2007, NAT MED, V13, P1423, DOI 10.1038/nm1690; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; HAY DB, 1993, MED VET ENTOMOL, V7, P271, DOI 10.1111/j.1365-2915.1993.tb00687.x; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kiss A, 2007, J ALLERGY CLIN IMMUN, V120, P334, DOI 10.1016/j.jaci.2007.04.025; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mansell A, 2006, NAT IMMUNOL, V7, P148, DOI 10.1038/ni1299; Mathaba LT, 2002, FEMS IMMUNOL MED MIC, V33, P77, DOI 10.1016/S0928-8244(02)00280-8; McKinley L, 2008, J IMMUNOL, V181, P4089; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Ng N, 2006, J ALLERGY CLIN IMMUN, V117, P1074, DOI 10.1016/j.jaci.2006.03.025; Phipps S, 2002, J IMMUNOL, V169, P4604; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Redecke V, 2004, J IMMUNOL, V172, P2739; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Ribas A, 2006, ALLERGY ASTHMA PROC, V27, P347, DOI 10.2500/aap.2006.27.2878; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Simpson JL, 2007, THORAX, V62, P211, DOI 10.1136/thx.2006.061358; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sun YC, 2005, CHINESE MED J-PEKING, V118, P953; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Temple R, 2001, AM J RESP CELL MOL, V25, P425; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Trompette A, 2008, NATURE, V7, P7; Valerio CR, 2005, J ALLERGY CLIN IMMUN, V116, P1296, DOI 10.1016/j.jaci.2005.09.046; van Beelen AJ, 2007, IMMUNITY, V27, P660, DOI 10.1016/j.immuni.2007.08.013; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	61	108	110	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY 15	2009	179	10					883	893		10.1164/rccm.200806-974OC		11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	444AG	WOS:000265951500006	19246719	
J	McGrath, JA; Uitto, J				McGrath, John A.; Uitto, Jouni			The filaggrin story: novel insights into skin-barrier function and disease	TRENDS IN MOLECULAR MEDICINE			English	Review							OF-FUNCTION MUTATIONS; EPIDERMAL DIFFERENTIATION COMPLEX; CAUSE ICHTHYOSIS VULGARIS; ATOPIC-DERMATITIS; FUNCTION VARIANTS; GRANULAR LAYER; GENE; PREDISPOSE; EXPRESSION; PSORIASIS	Recent reports have uncovered the key role of the protein filaggrin in maintaining an effective skin barrier against the external environment. Loss-of-function mutations in the profilaggrin gene (FLG) are common and are present in up to 10% of the population. These mutations are the cause of the semi-dominant skin-scaling disorder ichthyosis vulgaris and are a major risk factor for the development of atopic dermatitis. The discovery of these mutations also provides new data concerning the genetics of atopic asthma as well as intriguing insight into disease mechanisms of systemic allergies involving antigen exposure in skin with defective barrier function. Collectively, these novel findings have significant implications for the classification and future clinical management of patients with atopic and allergic diseases.	[Uitto, Jouni] Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA; [Uitto, Jouni] Thomas Jefferson Univ, Jefferson Inst Mol Med, Philadelphia, PA 19107 USA; [McGrath, John A.] Guys Kings Coll, St Johns Inst Dermatol, Genet Skin Dis Grp, Div Genet & Mol Med, London, England; [McGrath, John A.] St Thomas Sch Med, London, England	Uitto, J (reprint author), Thomas Jefferson Univ, Jefferson Med Coll, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA.	Jouni.Uitto@jefferson.edu	McGrath, John/D-6824-2012	McGrath, John/0000-0002-3708-9964			Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Betz RC, 2007, J INVEST DERMATOL, V127, P2539, DOI 10.1038/sj.jid.5700915; Bouwstra JA, 2006, BBA-BIOMEMBRANES, V1758, P2080, DOI 10.1016/j.bbamem.2006.06.021; Callard RE, 2007, TRENDS IMMUNOL, V28, P294, DOI 10.1016/j.it.2007.05.003; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Compton JG, 2002, EXP DERMATOL, V11, P518, DOI 10.1034/j.1600-0625.2002.110604.x; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; ELELUND E, 2006, AM J HUM GENET, V78, P1060; Enomoto Hisako, 2007, BMC Dermatol, V7, P5, DOI 10.1186/1471-5945-7-5; Fleckman P, 2002, EXP DERMATOL, V11, P327, DOI 10.1034/j.1600-0625.2002.110406.x; GAN SQ, 1990, BIOCHEMISTRY-US, V29, P9432, DOI 10.1021/bi00492a018; Ginger RS, 2005, ARCH DERMATOL RES, V297, P235, DOI 10.1007/s00403-005-0590-8; Gruber R, 2007, EUR J HUM GENET, V15, P179, DOI 10.1038/sj.ejhg.5201742; HAMADA T, 2007, J INVEST DERMATOL; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Huffmeier U, 2007, J INVEST DERMATOL, V127, P1367, DOI 10.1038/sj.jid.5700720; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Judge MR, 2004, ROOKS TXB DERMATOLOG; KANG K, DERMATOLOGY, P199; Liao HH, 2007, J INVEST DERMATOL, V127, P2795, DOI 10.1038/sj.jid.5700971; Macaluso F, 2007, EXP DERMATOL, V16, P692, DOI 10.1111/j.1600-0625.2007.00589.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; McGrath JA, 2006, CLIN EXP DERMATOL, V31, P826, DOI 10.1111/j.1365-2230.2006.02287.x; McLean WHI, 2007, J INVEST DERMATOL, V127, P8, DOI 10.1038/sj.jid.5700609; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Nicotera P, 2007, NAT CELL BIOL, V9, P621, DOI 10.1036/ncb0607-619; NOMURA T, IN PRESS J INVEST DE; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Pulkkinen L, 2002, J AM ACAD DERMATOL, V47, P91, DOI 10.1067/mjd.2002.120601; Rawlings A V, 2004, Dermatol Ther, V17 Suppl 1, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; SANDILANDS A, 2007, NAT GENET, V39, P250; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/BF02505232; Shwayder Tor, 2005, Dermatol Ther, V18, P87, DOI 10.1111/j.1529-8019.2005.05011.x; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Sohn MH, 2007, J PEDIATR-US, V150, P106, DOI 10.1016/j.jpeds.2006.08.065; South AP, 1999, J INVEST DERMATOL, V112, P910, DOI 10.1046/j.1523-1747.1999.00613.x; Tsai KY, 2007, J AM ACAD DERMATOL, V56, P719, DOI 10.1016/j.jaad.2006.10.985; Uitto J, 2007, EXP CELL RES, V313, P1995, DOI 10.1016/j.yexcr.2007.03.029; Weichenthal M, 2007, J INVEST DERMATOL, V127, P1535, DOI 10.1038/sj.jid.5700771; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030; Zhao Y, 2007, J INVEST DERMATOL, V127, P1878, DOI 10.1038/sj.jid.5700817; Zhong W, 2003, J HUM GENET, V48, P390, DOI 10.1007/s10038-003-0043-1	49	108	117	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4914			TRENDS MOL MED	Trends Mol. Med	JAN	2008	14	1					20	27		10.1016/j.molmed.2007.10.006		8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	260HY	WOS:000253002600004	18068483	
J	Kercsmar, CM; Dearborn, DG; Schluchter, M; Xue, L; Kirchner, HL; Sobolewski, J; Greenberg, SJ; Vesper, SJ; Allan, T				Kercsmar, Carolyn M.; Dearborn, Dorr G.; Schluchter, Mark; Xue, Lintong; Kirchner, H. Lester; Sobolewski, John; Greenberg, Stuart J.; Vesper, Stephen J.; Allan, Terry			Reduction in asthma morbidity in children as a result of home remediation aimed at moisture sources	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; children; damp housing; home remediation; indoor mold	INNER-CITY ASTHMA; RESPIRATORY HEALTH SURVEY; ENVIRONMENTAL INTERVENTION; COCKROACH ALLERGEN; SYMPTOMS; EXPOSURE; DAMPNESS; SENSITIZATION; MOLDS; DUST	OBJECTIVES: Home dampness and the presence of mold and allergens have been associated with asthma morbidity. We examined changes in asthma morbidity in children as a result of home remediation aimed at moisture sources. DESIGN: In this prospective, randomized controlled trial, symptomatic, asthmatic children (n = 62), 2-17 years of age, living in a home with indoor mold, received an asthma intervention including an action plan, education, and individualized problem solving. The remediation group also received household repairs, including reduction of water infiltration, removal of water-damaged building materials, and heating/ventilation/air-conditioning alterations. The control group received only home cleaning information. We measured children's total and allergen-specific serum immunoglobulin E, peripheral blood eosinophil counts, and urinary cotinine. Environmental dust samples were analyzed for dust mite, cockroach, rodent urinary protein, endotoxin, and fungi. The follow-up period was 1 year. RESULTS: Children in both groups showed improvement in asthma symptomatic days during the preremediation portion of the study. The remediation group had a significant decrease in symptom days (p = 0.003, as randomized; p = 0.004, intent to treat) after remodeling, whereas these parameters in the control group did not significantly change. In the postremediation period, the remediation group had a lower rate of exacerbations compared with control asthmatics (as treated: 1 of 29 vs. 11 of 33, respectively, p = 0.003; intent to treat: 28.1% and 10.0%, respectively, p = 0.11). CONCLUSION: Construction remediation aimed at the root cause of moisture sources and combined with a medical/behavioral intervention significantly reduces symptom days and health care use for asthmatic children who live in homes with a documented mold problem.	Case Western Reserve Univ, Dept Pediat, Rainbow Babies & Childrens Hosp, Cleveland, OH 44106 USA; Cuyahoga Cty Board Hlth, Parma, OH USA; Environm Hlth Watch, Cleveland, OH USA; US EPA, Natl Environm Res Lab, Cincinnati, OH 45268 USA	Kercsmar, CM (reprint author), Case Sch Med, Dept Pediat, 11100 Euclid Ave, Cleveland, OH 44106 USA.	carolyn.kercsmar@uhhs.com			NCRR NIH HHS [M01 RR000080, M01 RR00080]		Asmussen L, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.6.e71; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; Dales RE, 1999, ENVIRON HEALTH PERSP, V107, P481; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842; Engvall K, 2001, INT J TUBERC LUNG D, V5, P468; *ENV HLTH WATCH, 2005, CONTR ASTHM TRIGG HO; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Institute of Medicine of the National Academies, 2004, DAMP IND SPAC HLTH; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; National institutes of Health National Heart Lung and Blood Institute, 1997, NIH PUBL, V97-4051; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rylander R, 2005, TOXICOLOGY OF 1- 3-BETA-GLUCANS: GLUCANS AS A MARKER FOR FUNGAL EXPOSURE, P53, DOI 10.1201/9780203020814.ch3; SAS Institute Inc, 2004, SAS STAT 9 1 US GUID; *SAS I INC, 2004, SAS STAT 8 2 US GUID; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; *US EPA, 2002, 402K02003 US EPA; Vesper SJ, 2004, J OCCUP ENVIRON MED, V46, P596, DOI 10.1097/01.jom.0000128160.17144.6e; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	28	108	109	1	20	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2006	114	10					1574	1580		10.1289/ehp.8742		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	090RW	WOS:000240969700036	17035145	
J	Salo, PM; Arbes, SJ; Sever, M; Jaramillo, R; Cohn, RD; London, SJ; Zeldin, DC				Salo, Paivi M.; Arbes, Samuel J., Jr.; Sever, Michelle; Jaramillo, Renee; Cohn, Richard D.; London, Stephanie J.; Zeldin, Darryl C.			Exposure to Alternaria alternata in US homes is associated with asthma symptoms	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alternaria alternata; fungal allergen; antigen; indoor; exposure; asthma; allergy	NUTRITION EXAMINATION SURVEY; FUNGAL ALLERGENS; INDOOR ALLERGENS; NATIONAL-HEALTH; AIRBORNE FUNGI; RISK-FACTOR; CHILDREN; OUTDOOR; SPORES; RHINITIS	Background: Exposure to the fungus Alternaria alternata is a risk factor for asthma. Few studies have examined Alternaria exposures in indoor environments. Objective: We examined whether exposure to A alternata in US homes was associated with asthma-related outcomes. Methods: The data for this study were collected as part of the National Survey of Lead and Allergens in Housing. This cross-sectional study surveyed a nationally representative sample of 831 housing units inhabited by 2456 individuals in 75 different locations throughout the United States. An interviewer-administered questionnaire obtained information on demographics, household characteristics, and occupants' health status. Exposure to A alternata was assessed by measuring concentrations of A alternata antigens in vacuumed dust samples using a polyclonal anti-A alternata antibody assay. Dust samples were collected from a bed, a sofa, or a chair, and from bedroom, living room, and kitchen floors. Results: Lifetime prevalence of doctor-diagnosed asthma was 11.2%, and 6.9% of the study subjects reported active asthma symptoms in the past 12 months. The prevalence of current symptomatic asthma increased with increasing Alternaria concentrations in US homes; higher levels of A alternata antigens increased the odds of having asthma symptoms in the past year (relative to the lowest tertile, adjusted odds ratio was 1.52, 95% CI, 0.90-2.55 for the 2nd tertile; and 1.84, 95% Cl, 1.18-2.85 for the 3rd tertile). Conclusion: Exposure to A alternata in US homes is associated with active asthma symptoms. Clinical implications: Measures that reduce indoor exposure to A alternata may help control asthma exacerbations.	NIH, NIEHS, Res Triangle Pk, NC 27709 USA; Constella Grp LLC, Durham, NC USA	Zeldin, DC (reprint author), NIH, NIEHS, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov		Sever, Michelle/0000-0002-2435-1214; London, Stephanie/0000-0003-4911-5290	Intramural NIH HHS [Z01 ES025041-10]		Andersson M, 2003, PEDIATR ALLERGY IMMU, V14, P100, DOI 10.1034/j.1399-3038.2003.00031.x; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P133, DOI 10.1016/j.jaci.2005.04.022; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P517; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Berger WE, 2003, ANN ALLERG ASTHMA IM, V90, P7; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Britton J, 1998, CLIN EXP ALLERGY, V28, P2; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Bush R., 2001, J ALLERGY CLIN IMMUN, V107, P430, DOI 10.1067/mai.2001.113669; *CDCP, 2005, ASTHM NAT HLTH INT S; Chapman MD, 2000, CLIN REV ALLERG IMMU, V18, P285, DOI 10.1385/CRIAI:18:3:285; *COMM ASS ASTHM IN, 2000, CLEAR AIR ASTHM IND, P105; Corden JM, 2001, AEROBIOLOGIA, V17, P127, DOI 10.1023/A:1010876917512; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Green BJ, 2005, J ALLERGY CLIN IMMUN, V115, P1043, DOI 10.1016/j.jaci.2005.02.009; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; Instanes C, 2004, CLIN EXP ALLERGY, V34, P1634, DOI 10.1111/j.1365-2222.2004.02076.x; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; Platts-Mills TAE, 2004, J ALLERGY CLIN IMMUN, V113, P388, DOI 10.1016/j.jaci.2003.12.027; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Portnoy JM, 2005, ANN ALLERG ASTHMA IM, V94, P313; Portnoy JM, 2004, J ALLERGY CLIN IMMUN, V113, P189, DOI 10.1016/j.jaci.2003.11.021; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; Schmechel D, 2005, INDOOR AIR, V15, P11, DOI 10.1111/j.1600-0668.2005.00340.x; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527	47	108	111	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					892	898		10.1016/j.jaci.2006.07.037		7	Allergy; Immunology	Allergy; Immunology	097GD	WOS:000241434200017	17030243	
J	Mondoulet, L; Paty, E; Drumare, MF; Ah-Leung, S; Scheinmann, P; Willemot, RM; Wal, JM; Bernard, H				Mondoulet, L; Paty, E; Drumare, MF; Ah-Leung, S; Scheinmann, P; Willemot, RM; Wal, JM; Bernard, H			Influence of thermal processing on the allergenicity of peanut proteins	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY			English	Article						thermal processing; peanut allergens; allergenicity	CONTROLLED FOOD CHALLENGE; ATOPIC-DERMATITIS; DOUBLE-BLIND; IGE-BINDING; ALLERGY; IDENTIFICATION; COOKING; UPDATE	Peanuts are one of the most common and severe food allergens. Nevertheless, the occurrence of peanut allergy varies between countries and depends on both the exposure and the way peanuts are consumed. Processing is known to influence the allergenicity of peanut proteins. The aim of this study was to assess the effect of thermal processing on the IgE-binding capacity of whole peanut protein extracts and of the major peanut allergens Ara h 1 and Ara h 2. Whole proteins, Ara h 1, and Ara h 2 were extracted and purified from raw, roasted and boiled peanuts using selective precipitation and multiple chromatographic steps, and were then characterized by electrophoresis and mass spectrometry. The immunoreactivity of whole peanut extracts and purified proteins was analyzed by the enzyme allergosorbent test (EAST) and EAST inhibition using the sera of 37 peanut-allergic patients. The composition of the whole protein extracts was modified after heat processing, especially after boiling. The electrophoretic pattern showed protein bands of low molecular weight that were less marked in boiled than in raw and roasted peanuts. The same low-molecular-weight proteins were found in the cooking water of peanuts. Whole peanut protein extracts obtained after the different processes were all recognized by the IgE of the 37 patients. The IgE-binding capacity of the whole peanut protein extracts prepared from boiled peanuts was 2-fold lower than that of the extracts prepared from raw and roasted peanuts. No significant difference was observed between protein extracts from raw and roasted peanuts. It is noteworthy that the proteins present in the cooking water were also recognized by the IgE of peanut-allergic patients. IgE immunoreactivity of purified Ara h 1 and Ara h 2 prepared from roasted peanuts was higher than that of their counterparts prepared from raw and boiled peanuts. The IgE-binding capacity of purified Ara h 1 and Ara h 2 was altered by heat treatment and in particular was increased by roasting. However, no significant difference in IgE immunoreactivity was observed between whole protein extracts from raw and roasted peanuts. The decrease in allergenicity of boiled peanuts results mainly from a transfer of low-molecular-weight allergens into the water during cooking.	CEA Saclay, SPI, INRA, Lab Immunoallergie Alimentaire, F-91191 Gif Sur Yvette, France; Grp Hop Necker, Serv Pneumol & Allergol Pediat, F-75743 Paris, France; INRA, CNRS, UMR 5504, Dept Genie Biochim & Alimentaire,Ctr Bioingn Gilb, F-31077 Toulouse, France	Mondoulet, L (reprint author), CEA Saclay, SPI, INRA, Lab Immunoallergie Alimentaire, F-91191 Gif Sur Yvette, France.	mondoulet@cea.fr	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Bannon G. A., 2000, INTERNET S FOOD ALLE, V2, P87; Bernard H, 2003, ALLERGY, V58, P1285, DOI 10.1046/j.1398-9995.2003.00300.x; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CARUELLE D, 1988, ANAL BIOCHEM, V173, P328, DOI 10.1016/0003-2697(88)90197-2; Chung SY, 2003, J AGR FOOD CHEM, V51, P4273, DOI 10.1021/jf02121d; Davis PJ, 1998, ALLERGY, V53, P102; Dean TP, 1996, PEDIATR ALLERGY IMMU, V7, P171, DOI 10.1111/j.1399-3038.1996.tb00128.x; GRASSI J, 1986, J ALLERGY CLIN IMMUN, V77, P808, DOI 10.1016/0091-6749(86)90378-7; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maleki S. J., 2004, Journal of Allergy and Clinical Immunology, V113, pS154, DOI 10.1016/j.jaci.2003.12.561; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Pastorello E., 2004, EFSA J, V34, P76; Pastorello EA, 2003, J ALLERGY CLIN IMMUN, V112, P775, DOI 10.1067/mai.2003.1748; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schocker F, 2000, EUR J NUTR, V39, P172, DOI 10.1007/s003940070021; SELLERS CL, 2000, J ALLERGY CLIN IMMUN, V105, P140; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Tariq SM, 1996, BRIT MED J, V313, P514; Wal JM, 2003, ALLERGY, V58, P727, DOI 10.1034/j.1398-9995.2003.00225.x; Wal JM, 1995, FOOD AGRIC IMMUNOL, V7, P175, DOI 10.1080/09540109509354876; Wigotzki M, 2001, J CHROMATOGR B, V756, P239, DOI 10.1016/S0378-4347(01)00084-6	27	108	119	4	28	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0021-8561			J AGR FOOD CHEM	J. Agric. Food Chem.	JUN 1	2005	53	11					4547	4553		10.1021/jf050091p		7	Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology	Agriculture; Chemistry; Food Science & Technology	930GX	WOS:000229405000036	15913323	
J	Zutavern, A; von Mutius, E; Harris, J; Mills, P; Moffatt, S; White, C; Cullinan, P				Zutavern, A; von Mutius, E; Harris, J; Mills, P; Moffatt, S; White, C; Cullinan, P			The introduction of solids in relation to asthma and eczema	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							FOLLOW-UP; INFANT DIET; CHILDREN; ATOPY; LIFE; SENSITIZATION; COHORT; RISK; FOOD; AGE	Background: Despite scarce scientific evidence, current feeding guidelines recommend delayed introduction of solids for the prevention of asthma and allergy. Aims: To explore whether late introduction of solids is protective against the development of asthma, eczema, and atopy. Methods: A total of 642 children were recruited before birth and followed to the age of 5 1/2 years. Main outcome measures were: doctor's diagnosis of eczema ever, atopy according to skin prick test results against inhalant allergens, preschool wheezing, transient wheezing, all defined at age 5 - 5 1/2 years. Introduction of solids as main exposure measure was assessed retrospectively at age 1 year. Results: There was no evidence for a protective effect of late introduction of solids for the development of preschool wheezing, transient wheezing, atopy, or eczema. On the contrary, there was a statistically significant increased risk of eczema in relation to late introduction of egg (aOR 1.6, 95% CI 1.1 to 2.4) and milk (aOR 1.7, 95% CI 1.1 to 2.5). Late introduction of egg was furthermore associated with a nonsignificant increased risk of preschool wheezing (aOR 1.5, 95% CI 0.92 to 2.4). There was no statistical evidence of feeding practices playing a different role in the development of asthma and eczema after stratification for parental asthma and atopy status. Conclusions: Results do not support the recommendations given by present feeding guidelines stating that a delayed introduction of solids is protective against the development of asthma and allergy.	Univ Childrens Hosp, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; Natl Heart & Lung Inst, Imperial Coll Sci & Technol, Dept Occupat & Environm Med, London SW3 6LR, England	Zutavern, A (reprint author), Univ Munich, Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany.	anne.zutavern@kk-i.med.uni-muenchen.de					*DGKJ, 2002, LEITL KIND JUG MED, pD11; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48; FORSYTH JS, 1993, BRIT MED J, V306, P1572; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2002, PEDIATRICS, V109, P362; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Office for National Statistics, 1990, STAND OCC CLASS; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; *SCHWEIZ GES PAED, 1998, EMPF SAEUGL, V79, P1143; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; *STAT JOINT WORK G, 1998, DIET CAN HLTH CAN NU; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; Wilson AC, 1998, BRIT MED J, V316, P21; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; 2001, BMJ, V322, P1266	19	108	119	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	APR 1	2004	89	4					303	308		10.1136/adc.2002.025353		6	Pediatrics	Pediatrics	805AX	WOS:000220340300006	15033835	
J	Taylor, PE; Flagan, RC; Valenta, R; Glovsky, MM				Taylor, PE; Flagan, RC; Valenta, R; Glovsky, MM			Release of allergens as respirable aerosols: A link between grass pollen and asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						grass; pollen; allergen; aerosol; asthma; air pollution	RYE-GRASS; ENVIRONMENTAL-FACTORS; DIESEL EXHAUST; AIR-POLLUTION; CITY; PARTICLES; MELBOURNE; WEATHER; RISK	Background: Asthma incidence has long been linked to pollen, even though pollen grains are too large to penetrate into the airways where asthmatic responses originate. Pollen allergens found in small, respirable particles have been implicated in a number of asthma epidemics, particularly ones following rainfall or thunderstorms. Objective: The aim of this study was to determine how pollen allergens form the respirable aerosols necessary for triggering asthma. Methods: Flowering grasses were humidified and then dried in a controlled-environment chamber connected to a cascade impactor and an aerosol particle counter. Particles shed from the flowers were analyzed with high-resolution microscopy and immunolabeled with rabbit anti-Phl p 1 antibody, which is specific for group 1 pollen allergens. Results: Contrary to what has been reported in other published accounts, most of the pollen in this investigation remained on the open anthers of wind pollinated plants unless disturbed-eg, by wind. Increasing humidity caused anthers to close. After a cycle of wetting and drying followed by wind disturbance, grasses flowering within a chamber produced an aerosol of particles that were collected in a cascade impactor. These particles consisted of fragmented pollen cytoplasm in the size range 0.12 to 4.67 mum; they were loaded with group I allergens. Conclusion: Here we provide the first direct observations of the release of grass pollen allergens as respirable aerosols. They can emanate directly from the flower after a moisture-drying cycle. This could explain asthmatic responses associated with grass pollination, particularly after moist weather conditions.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Huntington Mem Hosp, Huntington Med Res Inst, Ctr Asthma & Allergy, Pasadena, CA USA; Univ Vienna, Dept Pathophysiol, A-1010 Vienna, Austria	Flagan, RC (reprint author), CALTECH, Div Chem & Chem Engn, 210-41, Pasadena, CA 91125 USA.						ARBER A., 1934, GRAMINEAE; Bates D V, 1966, Health Phys, V12, P173; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Blackley CH, 1873, EXPT RES CAUSES NATU; Crane P. R., 1986, POLLEN SPORES FORM F, P179; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Davies RJ, 1998, CLIN EXP ALLERGY, V28, P8; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; EDWARDS J, 1992, AM J BOT, V79, P144, DOI 10.2307/2445101; Foster AS, 1974, COMP MORPHOLOGY VASC; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; Haberlandt G, 1914, PHYSL PLANT ANATOMY; HILL DJ, 1979, MED J AUSTRALIA, V1, P426; KNOX RB, 1981, P 6 AUSTR WEEDS C 19, V2, P125; Knox R. B., 1979, STUDIES BIOL, V107; Lindon JC, 1996, PROG NUCL MAG RES SP, V29, P1, DOI 10.1016/0079-6565(95)01027-0; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Newson R, 1997, THORAX, V52, P680; ONG EK, 1994, THESIS U MELBOURNE; PACINI E, 1992, ANN BOT-LONDON, V70, P179; PACINI E, 1982, CARYOLOGIA, V35, P205; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633; Schauer JJ, 1996, ATMOS ENVIRON, V30, P3837, DOI 10.1016/1352-2310(96)00085-4; SMART IJ, 1979, AUST J BOT, V27, P333, DOI 10.1071/BT9790333; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STEWART GA, 1985, MED J AUSTRALIA, V143, P426; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TAYLOR PE, 1994, HISTOCHEM J, V26, P392, DOI 10.1007/BF00160051; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; WUTHRICH B, 1991, ALLERGY CLIN IMMUNOL, V3, P41	38	108	108	10	30	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					51	56		10.1067/mai.2002.120759		6	Allergy; Immunology	Allergy; Immunology	519RM	WOS:000173739300008	11799365	
J	Yunginger, JW; Ahlstedt, S; Eggleston, PA; Homburger, HA; Nelson, HS; Ownby, DR; Platts-Mills, TAE; Sampson, HA; Sicherer, SH; Weinstein, AM; Williams, PB; Wood, RA; Zeiger, RS				Yunginger, JW; Ahlstedt, S; Eggleston, PA; Homburger, HA; Nelson, HS; Ownby, DR; Platts-Mills, TAE; Sampson, HA; Sicherer, SH; Weinstein, AM; Williams, PB; Wood, RA; Zeiger, RS			Quantitative IgE antibody assays in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE antibody; quantitative immunoassay; allergic disease	SKIN-TEST REACTIVITY; HIGH-RISK CHILDREN; ATOPIC-DERMATITIS; PERFORMANCE-CHARACTERISTICS; FOOD ALLERGENS; EGG ALLERGY; FOLLOW-UP; SENSITIZATION; DIAGNOSIS; ASTHMA	During the past several years, immunoassays for specific IgE antibodies have been refined to permit reporting results in mass units. Thus quantitative immunoassays for IgE antibodies may be an adjunct to skin tests. In cases of food allergy among children with atopic dermatitis, cutoff values for IgE antibody concentrations to egg, milk, peanut, and fish have been derived to provide 95% positive and 90% negative predictive values. Food-specific IgE antibody determinations can also be used to predict which food allergies are resolving spontaneously. Elevated egg-specific IgE antibody levels in infancy are associated with significantly increased risk for development of inhalant allergies later in childhood. In cases of inhalant allergy, specific IgE antibody levels correlate closely with results of inhalation challenge studies in cat-sensitive persons. Also, mite-specific IgE antibody levels correlate significantly with the mite allergen contents of reservoir dust in the homes of mite-sensitive persons. Immunoassays for quantitation of specific IgE antibodies may be used to document allergen sensitization over time and to evaluate the risk of reaction on allergen exposure. However, immunoassays and skin tests are not entirely interchangeable, and neither will replace the other in appropriate circumstances.	Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Rochester, MN 55905 USA; Univ Gothenburg, Dept Clin Immunol, Gothenburg, Sweden; Pharmacia & Upjohn Diagnost, Kalamazoo, MI USA; Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; Med Coll Georgia, Sect Allergy Immunol, Augusta, GA 30912 USA; Univ Virginia, Hlth Sci Ctr, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA USA; Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA; Georgetown Univ, Sch Med, Washington, DC USA; Univ Missouri Kansas City, Sch Med, IBT Reference Lab, Lenexa, KS USA; So Calif Permanente Med Grp, Dept Allergy, San Diego, CA 92120 USA	Yunginger, JW (reprint author), Mayo Clin & Mayo Fdn, Allerg Dis Res Lab, 406 Guggenheim Bldg,200 1st St SW, Rochester, MN 55905 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; AGATA H, 1993, J ALLERGY CLIN IMMUN, V91, P668, DOI 10.1016/0091-6749(93)90273-I; Bernardini R, 1999, CLIN EXP ALLERGY, V29, P681; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BONER AL, 1993, CLIN EXP ALLERGY, V23, P1021, DOI 10.1111/j.1365-2222.1993.tb00294.x; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; Brunnee T, 1996, CLIN EXP ALLERGY, V26, P1420; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; COSTONGS GMPJ, 1995, EUR J CLIN CHEM CLIN, V33, P295; CRESPO JF, 1994, ALLERGY PROC, V15, P73, DOI 10.2500/108854194778703099; Croner S, 1990, PEDIATR ALLERGY IMMU, V1, P14, DOI 10.1111/j.1399-3038.1990.tb00003.x; DANTZLER BS, 1980, ANN ALLERGY, V45, P213; DELOVINFOSSE S, 1994, ALLERGY, V49, P64; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, pS52; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; KELSO JM, 1991, ANN ALLERGY, V67, P511; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; LEIMGRUBER A, 1993, ALLERGY, V48, P415, DOI 10.1111/j.1398-9995.1993.tb00739.x; LIAPPIS N, 1996, CLIN LAB, V42, P707; LILJA G, 1991, PEDIATR ALLERGY IMMU, V2, P6, DOI 10.1111/j.1399-3038.1991.tb00173.x; LINDQVIST A, 1995, P 16 EUR C ALL CLIN, P195; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Paganelli R, 1998, ALLERGY, V53, P763; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; Peterman J. H., 1991, IMMUNOCHEMISTRY SOLI, P47; *PHS, REV CRIT ASS ALL SPE, P1; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sanz ML, 1996, J INVEST ALLERG CLIN, V6, P89; SENSI LG, 1994, CLIN EXP ALLERGY, V24, P377, DOI 10.1111/j.1365-2222.1994.tb00250.x; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507; SICHERER SH, 1998, PEDIATRICS, V102, P131; STRUCKEY MS, 1985, J ALLERGY CLIN IMMUN, V75, P373; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; 1992, FED REG 405, V57, P7002	49	108	114	0	7	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1077	1084		10.1067/mai.2000.107041		8	Allergy; Immunology	Allergy; Immunology	327EX	WOS:000087781800006	10856139	
J	Andre, C; Vatrinet, C; Galvain, S; Carat, F; Sicard, H				Andre, C; Vatrinet, C; Galvain, S; Carat, F; Sicard, H			Safety of sublingual-swallow immunotherapy in children and adults	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						immunotherapy, sublingual-swallow; asthma; rhinoconjunctivitis; mites; pollen	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; HOUSE-DUST MITE; POLLEN EXTRACT; RHINITIS; RHINOCONJUNCTIVITIS; EFFICACY; ASTHMA	Background: Immunotherapy is an established treatment of allergic diseases. The safety of this treatment, particularly when administered without direct medical surveillance, as in the case of the sublingual-swallow route needs to be established. The aim of this paper is to review the safety of the sublingual-swallow immunotherapy as reported in eight double-blind, placebo-controlled trials carried out in France, Italy and Greece. Methods: Six hundred and ninety subjects, 472 adults and 218 children, took part in trials of specific immunotherapy (SIT) for the treatment of rhinoconjunctivitis and/or asthma. Three hundred and forty-seven patients received SIT and 343 patients received placebo. Treatment with specific immunotherapy with allergen extracts or placebo was administered using the sublingual-swallow technique. The allergens administered were grass, ambrosia, parietaria and olive pollens, and mites. The daily dose taken during maintenance therapy ranged from 100 to 300 IR (index of reactivity) and cumulative doses ranged from 4,500 to 104,000 IR. Treatment duration ranged from 4 months to 2 years. Adverse events reported either spontaneously by the patient or on direct questioning by the investigator were analysed. Results: One hundred and forty-five unusual events were reported in the subjects receiving active SIT and 79 in those receiving placebo (p < 0.001). Of these 85 were children aged 15 years or less (50 received active SIT, 35 placebo) and 139 were adults (95 received SIT, 44 placebo). Unusual events involving the buccal cavity (61 SIT, 13 placebo) and the gastro-intestinal tract (47 SIT, 15 placebo) were significantly more frequent in the SIT-treated patients (p < 0.001). Wheezing (9 SIT, 21 placebo) was more frequent in the placebo-treated patients (p < 0.05). There were no differences in the frequency of unusual events between adults and children and in the frequency of events involving other body systems. No event was reported as serious. Two events reported as laryngeal oedema were not considered to be accurate descriptions. Conclusions: No serious adverse event was reported in the studies monitored, confirming the good safety profile of the sublingual-swallow method both in children and adults with rhinitis or moderate asthma. (C) 2000 S. Karger AG, Basel.	Stallergenes SA, Sci & Med Dept, F-92183 Antony, France	Andre, C (reprint author), Stallergenes SA, Sci & Med Dept, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.						Andre C., 1998, Allergy (Copenhagen), V53, P116; ANDRE C, UNPUB RAGWEED SUBLIN; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Committee on the safety of medicines, 1986, BRIT MED J, V293, P948, DOI 10.1136/bmj.293.6552.948; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Edwards A. M., 1998, Allergy (Copenhagen), V53, P169; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; GUEZ S, IN PRESS ALLERGY; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Malling HJ, 1998, ALLERGY, V53, P461; Malling HJ, 1993, ALLERGY, V14, P9; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; White P, 1998, CLIN EXP ALLERGY, V28, P266	23	108	112	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	MAR	2000	121	3					229	234		10.1159/000024322		6	Allergy; Immunology	Allergy; Immunology	298BW	WOS:000086120300008	10729782	
J	Schneider, L; Tilles, S; Lio, P; Boguniewicz, M; Beck, L; LeBovidge, J; Novak, N				Schneider, Lynda; Tilles, Stephen; Lio, Peter; Boguniewicz, Mark; Beck, Lisa; LeBovidge, Jennifer; Novak, Natalija			Atopic dermatitis: A practice parameter update 2012	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Atopic dermatitis/atopic eczema; pathogenesis; genetics; diagnosis; management; therapy; triggers; Staphylococcus; quality of life; sleep; cyclosporine; immunomodulating agents; phototherapy; allergen immunotherapy	PIMECROLIMUS CREAM 1-PERCENT; RANDOMIZED CONTROLLED-TRIAL; LONG-TERM TREATMENT; QUALITY-OF-LIFE; STAPHYLOCOCCUS-AUREUS COLONIZATION; PLACEBO-CONTROLLED TRIAL; ORAL FOOD CHALLENGES; WET-WRAP DRESSINGS; HOUSE-DUST MITE; THIOPURINE METHYLTRANSFERASE ACTIVITY	This parameter was developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Atopic dermatitis: a practice parameter update 2012.'' This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma & Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion. Published practice parameters of the Joint Task Force on Practice Parameters for Allergy & Immunology are available online at http://www.jcaai.org. (J Allergy Clin Immunol 2013;131:295-9.)	[Schneider, Lynda] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Pediat, Boston, MA USA; [Lio, Peter] Northwestern Univ, Feinberg Sch Med, Dept Clin Dermatol, Chicago, IL 60611 USA; [Lio, Peter] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA; [Boguniewicz, Mark] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Boguniewicz, Mark] Univ Colorado Denver, Sch Med, Denver, CO USA; [Beck, Lisa] Univ Rochester, Med Ctr, Dept Dermatol, Rochester, NY 14642 USA; [LeBovidge, Jennifer] Harvard Univ, Sch Med, Boston Childrens Hosp, Dept Psychol, Boston, MA USA; [Novak, Natalija] Univ Bonn, Dept Dermatol, Bonn, Germany; [Novak, Natalija] Univ Bonn, Dept Allergy, Bonn, Germany; [Tilles, Stephen] Univ Washington, Sch Med, Dept Med, Redmond, WA USA	Schneider, L (reprint author), Joint Task Force Practice Parameters, 59 N Brockway St,304, Palatine, IL 60067 USA.	info@jcaai.org			National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) Atopic Dermatitis Research Network; Astellas; Amphastar; Medimmune; Genentech; Merck; TEVA; Sunovion; Boehringer Ingelheim; Nutricia; Array; Rigel; AstraZeneca; Atopic Dermatitis Foundation; NIH; NIAID; National Institute of Arthritis and Musculoskeletal and Skin Diseases; German Research Council; Regeneron	L. Schneider has received research support from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Disease (NIAID) Atopic Dermatitis Research Network and Astellas, is on the Research Advisory Board for the Food Allergy Initiative, and is on the Scientific Advisory Board for the National Eczema Association. S. Tilles has consultant arrangements with SRXA, Sunovion, and Hyrox; has received grants from Astellas, Amphastar, Medimmune, Genentech, Merck, TEVA, Sunovion, Boehringer Ingelheim, Nutricia, Array, Rigel, and AstraZeneca; is Associate Editor for AllergyWatch and the Annals of Allergy; is Assistant Editor for the Joint Task Force for Practice Parameters; and is on the Executive Committee for the Seattle Food Allergy Consortium. P. Lio is a speaker and consultant for Johnson & Johnson's Neosporin line, has received grants from the Atopic Dermatitis Foundation, and is an Advisory Board Member for the National Eczema Association. M. Boguniewicz has received grants from the NIH. L. Beck has received remuneration from Regeneron and Genentech and has received grants from the NIH, the NIAID, and the National Institute of Arthritis and Musculoskeletal and Skin Diseases; is a board member for the Society for Investigative Dermatology; and is a Scientific Advisory Board member for the National Eczema Association. J. LeBovidge is a consultant/writer for Anaphylaxis Canada. N. Novak has received grants from the German Research Council and has consultant arrangements with ALK-Abello, Bencard Allergy Therapeutics, Astellas, GlaxoSmithKline, LETI Pharma, and HAL Allergy.	Abeck D, 2000, J AM ACAD DERMATOL, V42, P254, DOI 10.1016/S0190-9622(00)90134-8; Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Alanne S, 2011, ACTA PAEDIATR, V100, pE65, DOI 10.1111/j.1651-2227.2011.02229.x; Amrol D, 2010, SOUTH MED J, V103, P554, DOI 10.1097/SMJ.0b013e3181de0cf6; Arellano FM, 2007, J INVEST DERMATOL, V127, P808, DOI 10.1038/sj.jid.5700622; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Bae BG, 2012, ACTA DERM-VENEREOL, V92, P57, DOI 10.2340/00015555-1189; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125; Bath-Hextall F, 2009, ALLERGY, V64, P258, DOI 10.1111/j.1398-9995.2008.01917.x; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Benez A, 2001, BRIT J DERMATOL, V144, P638, DOI 10.1046/j.1365-2133.2001.04108.x; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; Meduri NB, 2007, PHOTODERMATOL PHOTO, V23, P106, DOI 10.1111/j.1600-0781.2007.00291.x; Bieber T, 2007, ALLERGY, V62, P184, DOI 10.1111/j.1398-9995.2006.01269.x; Bieber T, 2002, ATOPIC DERMATITIS; Birnie AJ, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003871.pub2; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; BOGUNIEWICZ M, 1990, AM J MED, V88, P365, DOI 10.1016/0002-9343(90)90490-5; Boguniewicz M, 2001, J ALLERGY CLIN IMMUN, V108, P651, DOI 10.1067/mai.2001.118598; Boguniewicz M, 2008, SEMIN CUTAN MED SURG, V27, P115, DOI 10.1016/j.sder.2008.05.001; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; BORK K, 1988, J AM ACAD DERMATOL, V19, P1024, DOI 10.1016/S0190-9622(88)70267-4; Bos JD, 1998, EXP DERMATOL, V7, P132, DOI 10.1111/j.1600-0625.1998.tb00313.x; Boyce JA, 2010, J ALLERGY CLIN IMMUN, V126, P1105, DOI 10.1016/j.jaci.2010.10.008; Brenninkmeijer EEA, 2008, BRIT J DERMATOL, V158, P754, DOI 10.1111/j.1365-2133.2007.08412.x; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brockow K, 1999, DERMATOLOGY, V199, P231, DOI 10.1159/000018253; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Buske-Kirschbaum A, 2002, J NEUROIMMUNOL, V129, P161, DOI 10.1016/S0165-5728(02)00168-6; Bussmann C, 2007, CLIN EXP ALLERGY, V37, P1277, DOI 10.1111/j.1365-2222.2007.02783.x; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Bussmann C, 2009, J DTSCH DERMATOL GES, V7, P205, DOI 10.1111/j.1610-0387.2008.06834.x; Caruso C, 2010, ALLERGY, V65, P278, DOI 10.1111/j.1398-9995.2009.02153.x; Chamlin SL, 2005, ARCH PEDIAT ADOL MED, V159, P745, DOI 10.1001/archpedi.159.8.745; Chamlin SL, 2004, PEDIATRICS, V114, P607, DOI 10.1542/peds.2004-0374; Chamlin SL, 2001, ARCH DERMATOL, V137, P1110; Chiang C, 2009, PEDIATR DERMATOL, V26, P273, DOI 10.1111/j.1525-1470.2009.00911.x; Chida Y, 2007, INT ARCH ALLERGY IMM, V144, P1, DOI 10.1159/000101940; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Chou JS, 2011, ALLERGY ASTHMA PROC, V32, P377, DOI 10.2500/aap.2011.32.3462; Chua K, 2011, CLIN INFECT DIS, V52, P99, DOI 10.1093/cid/ciq067; Clayton TH, 2007, CLIN EXP DERMATOL, V32, P28, DOI 10.1111/j.1365-2230.2006.02292.x; Cork MJ, 2003, BRIT J DERMATOL, V149, P582, DOI 10.1046/j.1365-2133.2003.05595.x; CORNELL RC, 1981, BRIT J DERMATOL, V105, P91, DOI 10.1111/j.1365-2133.1981.tb00888.x; Cox L, 2011, J ALLERGY CLIN IMMUN, V127, DOI 10.1016/j.jaci.2010.09.034; DAHL RE, 1995, ARCH PEDIAT ADOL MED, V149, P856; Darabi K, 2009, J AM ACAD DERMATOL, V60, P125, DOI 10.1016/j.jaad.2008.07.058; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Darsow U, 2010, J EUR ACAD DERMATOL, V24, P317, DOI 10.1111/j.1468-3083.2009.03415.x; DAUD LR, 1993, ARCH DIS CHILD, V69, P670; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773; Devillers ACA, 2006, BRIT J DERMATOL, V154, P579, DOI 10.1111/j.1365-2133.2006.07157.x; Diepgen TL, 2002, PEDIATR ALLERGY IMMU, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Drake L, 2001, J AM ACAD DERMATOL, V44, pS65, DOI 10.1067/mjd.2001.109814; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P613; Eichenfield LF, 2007, J DERMATOL, V34, P231, DOI 10.1111/j.1346-8138.2007.00259.x; Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Engler RJM, 2002, J ALLERGY CLIN IMMUN, V110, P357, DOI 10.1067/mai.2002.128052; Estelle F, 2001, J ALLERGY CLIN IMMUN, V107, P703, DOI 10.1067/mai.2001.113866; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI [10.1016/j.jaci.2008.10.031, 10.1016/j.jaci.2009.10.031]; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Feily A, 2010, DERMATITIS, V21, P174, DOI 10.2310/6620.2010.09087; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Fonacier L, 2006, ANN ALLERG ASTHMA IM, V97, P117; Forman SB, 2007, CUTIS, V80, P38; FRITZ KA, 1983, ANN ALLERGY, V50, P68; Frosch PJ, 1999, CONTACT DERMATITIS, V40, P66, DOI 10.1111/j.1600-0536.1999.tb05993.x; Fujita H, 2009, P NATL ACAD SCI USA, V106, P21795, DOI 10.1073/pnas.0911472106; GALLI E, 1994, ACTA PAEDIATR, V83, P315, DOI 10.1111/j.1651-2227.1994.tb18102.x; Gambichler T, 2009, BRIT J DERMATOL, V160, P652, DOI 10.1111/j.1365-2133.2008.08984.x; Gauger A, 2003, DERMATOLOGY, V207, P15, DOI 10.1159/000070935; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Goujon C, 2006, EUR J DERMATOL, V16, P155; Grillo M, 2006, PEDIATR DERMATOL, V23, P428, DOI 10.1111/j.1525-1470.2006.00277.x; Grimalt R, 2007, DERMATOLOGY, V214, P61, DOI 10.1159/000096915; Grundmann-Kollman M, 2001, ARCH DERMATOL, V137, P870; Gutgesell C, 2001, ALLERGY, V56, P1226, DOI 10.1034/j.1398-9995.2001.00403.x; Gutman AB, 2005, ARCH DERMATOL, V141, P1556, DOI 10.1001/archderm.141.12.1556; Guttman-Yassky E, 2008, J IMMUNOL, V181, P7420; Haeck IM, 2011, J AM ACAD DERMATOL, V64, P1074, DOI 10.1016/j.jaad.2010.04.027; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hanifin JM, 2001, J AM ACAD DERMATOL, V44, pS28, DOI 10.1067/mjd.2001.109810; Hanifin JM, 2007, DERMATITIS, V18, P82, DOI DOI 10.2310/6620.2007.06034; HANNUKSELA M, 1993, ANN ALLERGY, V70, P127; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Harper JI, 2001, DERMATOLOGY, V203, P3, DOI 10.1159/000051694; Hauk PJ, 2001, J ALLERGY CLIN IMMUN, V107, P391, DOI 10.1067/mai.2001.112848; HEDDLE RJ, 1984, BRIT MED J, V289, P651; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; Heller M, 2007, BRIT J DERMATOL, V157, P127, DOI 10.1111/j.1365-2133.2007.07947.x; Hoare C, 2000, Health Technol Assess, V4, P1; Holm L, 2001, ALLERGY, V56, P152, DOI 10.1034/j.1398-9995.2001.056002152.x; Hrachovec J, 2002, J ALLERGY CLIN IMMUN, V110, P818, DOI 10.1067/mai.2002.128054; Huang JT, 2009, PEDIATRICS, V123, pE808, DOI 10.1542/peds.2008-2217; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Imokawa G, 2001, J AM ACAD DERMATOL, V45, pS29, DOI 10.1067/mjd.2001.117020; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Javanbakht MH, 2011, J DERMATOL TREAT, V22, P144, DOI 10.3109/09546630903578566; Jee SJ, 2011, ALLERGY ASTHMA IMMUN, V3, P89, DOI 10.4168/aair.2011.3.2.89; Jolles S, 2002, CLIN EXP DERMATOL, V27, P3, DOI 10.1046/j.0307-6938.2001.00955.x; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; Kaufmann R, 2004, J ALLERGY CLIN IMMUN, V114, P1183, DOI 10.1016/j.jaci.2004.08.015; Kelsay K, 2006, J ALLERGY CLIN IMMUN, V118, P198, DOI 10.1016/j.jaci.2006.04.038; Kim M, 2010, EXP DERMATOL, V19, P501, DOI 10.1111/j.1600-0625.2009.00941.x; KING RM, 1991, J PSYCHOSOM RES, V35, P697, DOI 10.1016/0022-3999(91)90120-D; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Kodama A, 1999, J ALLERGY CLIN IMMUN, V104, P173, DOI 10.1016/S0091-6749(99)70130-2; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Krakowski AC, 2008, PEDIATRICS, V122, P812, DOI 10.1542/peds.2007-2232; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; KRUTMANN J, 1992, J AM ACAD DERMATOL, V26, P225, DOI 10.1016/0190-9622(92)70031-A; Kuanprasert Natita, 2002, Australas J Dermatol, V43, P125, DOI 10.1046/j.1440-0960.2002.00573.x; Kupfer J, 2010, J PSYCHOSOM RES, V68, P353, DOI 10.1016/j.jpsychores.2009.04.014; La Rosa Mario, 1995, Current Therapeutic Research, V56, P720, DOI 10.1016/0011-393X(95)85143-7; Lagos BR, 1998, BRIT J DERMATOL, V139, P763; LANGELAND T, 1994, ALLERGY, V49, P22, DOI 10.1111/j.1398-9995.1994.tb00768.x; LAROSA M, 1994, ANN ALLERGY, V73, P117; Lee CH, 2006, BRIT J DERMATOL, V154, P1100, DOI 10.1111/j.1365-2133.2006.07191.x; Lee JH, 2007, J EUR ACAD DERMATOL, V21, P1360, DOI 10.1111/j.1468-3083.2007.02277.x; Leo HL, 2004, J ALLERGY CLIN IMMUN, V114, P691, DOI 10.1016/j.jaci.2004.05.037; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Lintu P, 2001, ALLERGY, V56, P512, DOI 10.1034/j.1398-9995.2001.056006512.x; Lubbe J, 2000, DERMATOLOGY, V201, P249, DOI 10.1159/000018497; Lyakhovitsky A, 2010, J EUR ACAD DERMATOL, V24, P43, DOI 10.1111/j.1468-3083.2009.03351.x; Majoie IML, 2009, J AM ACAD DERMATOL, V60, P77, DOI 10.1016/j.jaad.2008.08.048; Mayser P, 2006, SKIN PHARMACOL PHYS, V19, P153, DOI 10.1159/000092596; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; Miller DW, 2011, J DRUGS DERMATOL, V10, P531; Moore EJ, 2009, AUSTRALAS J DERMATOL, V50, P100, DOI 10.1111/j.1440-0960.2009.00515.x; Moore K, 2006, BRIT J DERMATOL, V154, P514, DOI 10.1111/j.1365-2133.2005.07082.x; Msika P, 2008, PEDIATR DERMATOL, V25, P606, DOI 10.1111/j.1525-1470.2008.00783.x; Munday J, 2002, DERMATOLOGY, V205, P40, DOI 10.1159/000063138; NASSIF A, 1994, ARCH DERMATOL, V130, P1402, DOI 10.1001/archderm.130.11.1402; Niebuhr M, 2009, ALLERGY, V64, P1580, DOI 10.1111/j.1398-9995.2009.02050.x; Niggemann B, 2001, J ALLERGY CLIN IMMUN, V108, P1053, DOI 10.1067/mai.2001.120192; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; NIORDSON AM, 1985, BRIT J CLIN PRACT, V39, P67; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Novak N, 2011, CURR OPIN IMMUNOL, V23, P778, DOI 10.1016/j.coi.2011.09.007; NOVELLI VM, 1988, CLIN PEDIATR, V27, P231, DOI 10.1177/000992288802700502; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Onoue A, 2009, EXP DERMATOL, V18, P1036, DOI 10.1111/j.1600-0625.2009.00899.x; Oosting AJ, 2002, J ALLERGY CLIN IMMUN, V110, P500, DOI 10.1067/mai.2002.126791; Oyoshi MK, 2009, ADV IMMUNOL, V102, P135, DOI 10.1016/S0065-2776(09)01203-6; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Paller A, 2001, J AM ACAD DERMATOL, V44, pS47, DOI 10.1067/mjd.2001.109813; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Papp KA, 2005, J AM ACAD DERMATOL, V52, P240, DOI 10.1016/j.jaaf.2004.09.016; Papp KA, 2005, J AM ACAD DERMATOL, V52, P247, DOI 10.1016/j.jaad.2004.08.046; Park SY, 2010, ANN DERMATOL, V22, P349, DOI 10.5021/ad.2010.22.3.349; Paul C, 2006, PEDIATRICS, V117, pE118, DOI 10.1542/peds.2005-1188; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pei AYS, 2001, PEDIATR DERMATOL, V18, P343, DOI 10.1046/j.1525-1470.2001.01952.x; Peroni DG, 2011, BRIT J DERMATOL, V164, P1078, DOI 10.1111/j.1365-2133.2010.10147.x; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Ponte P, 2010, J AM ACAD DERMATOL, V63, P355, DOI 10.1016/j.jaad.2009.05.015; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; REINHOLD U, 1993, J AM ACAD DERMATOL, V29, P58; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P547, DOI 10.1067/mai.2002.121832; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P539, DOI 10.1067/mai.2002.121831; Reitamo S, 2010, J DERMATOL TREAT, V21, P34, DOI 10.3109/09546630903401488; Remitz A, 2001, J ALLERGY CLIN IMMUN, V107, P196, DOI 10.1067/mai.2001.112131; Reuveni H, 1999, ARCH PEDIAT ADOL MED, V153, P249; Ricci G, 2004, BRIT J DERMATOL, V150, P127, DOI 10.1111/j.1365-2133.2004.05705.x; Ring J, 2008, J EUR ACAD DERMATOL, V22, P195, DOI 10.1111/j.1468-3083.2007.02368.x; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1176, DOI 10.1111/j.1468-3083.2012.04636.x; Ring J, 2012, J EUR ACAD DERMATOL, V26, P1045, DOI 10.1111/j.1468-3083.2012.04635.x; Roelofzen JHJ, 2010, J INVEST DERMATOL, V130, P953, DOI 10.1038/jid.2009.389; Romanos M, 2010, J EPIDEMIOL COMMUN H, V64, P269, DOI 10.1136/jech.2009.093534; Rork JF, 2012, ARCH DERMATOL, V148, P391, DOI 10.1001/archdermatol.2011.2267; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; SALEK MS, 1993, BRIT J DERMATOL, V129, P422, DOI 10.1111/j.1365-2133.1993.tb03170.x; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V108, P455, DOI 10.1067/mai.2001.117800; Schmitt J, 2007, J EUR ACAD DERMATOL, V21, P606, DOI 10.1111/j.1468-3083.2006.02023.x; Schmitt J, 2011, BRIT J DERMATOL, V164, P415, DOI 10.1111/j.1365-2133.2010.10030.x; Schmitt J, 2010, BRIT J DERMATOL, V162, P661, DOI 10.1111/j.1365-2133.2009.09561.x; Schmitt J, 2009, BRIT J DERMATOL, V161, P878, DOI 10.1111/j.1365-2133.2009.09309.x; Schmitt J, 2010, J ALLERGY CLIN IMMUN, V125, P404, DOI 10.1016/j.jaci.2009.10.055; Schneider LC, 1998, ANN ALLERG ASTHMA IM, V80, P263; Schnopp C, 2002, DERMATOLOGY, V204, P56, DOI 10.1159/000051811; Schram ME, 2011, ARCH DERMATOL, V147, P474, DOI 10.1001/archdermatol.2011.79; Schram ME, 2011, J ALLERGY CLIN IMMUN, V128, P353, DOI 10.1016/j.jaci.2011.03.024; Schultz-Larsen F, 2002, IMMUNOL ALLERGY CLIN, V22, P1; Sediva A, 2008, J ALLERGY CLIN IMMUN, V121, P1515, DOI 10.1016/j.jaci.2008.03.007; Seidenari S, 2003, ALLERGY, V58, P426, DOI 10.1034/j.1398-9995.2003.00142.x; Sheinkopf LE, 2008, ALLERGY ASTHMA PROC, V29, P530, DOI 10.2500/aap.2008.29.3160; Shelley WB, 1996, J AM ACAD DERMATOL, V34, P143, DOI 10.1016/S0190-9622(96)90864-6; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Simpson AB, 2010, ALLERGY ASTHMA PROC, V31, P232, DOI 10.2500/aap.2010.31.3335; Sinagra JL, 2007, PEDIATR DERMATOL, V24, P1; Slutsky JB, 2010, J DRUGS DERMATOL, V9, P1258; SNOW JL, 1995, J AM ACAD DERMATOL, V32, P114, DOI 10.1016/0190-9622(95)90195-7; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Staab D, 2006, BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; Staab D, 2002, PEDIATR ALLERGY IMMU, V13, P84, DOI 10.1034/j.1399-3038.2002.01005.x; Strid J, 2006, IMMUNOLOGY, V119, P27, DOI 10.1111/j.1365-2567.2006.02401.x; Strid J, 2011, SCIENCE, V334, P1293, DOI 10.1126/science.1211250; Stuetz A, 2001, SEMIN CUTAN MED SURG, V20, P233, DOI 10.1053/sder.2001.29066; Su JC, 1997, ARCH DIS CHILD, V76, P159; Sugiura H, 2000, ARCH DERMATOL, V136, P1062, DOI 10.1001/archderm.136.8.1062; Suh KS, 2010, ANN DERMATOL, V22, P1, DOI 10.5021/ad.2010.22.1.1; TAKEI S, 1993, J CLIN INVEST, V91, P602, DOI 10.1172/JCI116240; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Tzaneva S, 2010, BRIT J DERMATOL, V162, P655, DOI 10.1111/j.1365-2133.2009.09514.x; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; van der Zee T, 2011, J ALLERGY CLIN IMMUN, V128, P1031, DOI 10.1016/j.jaci.2011.07.050; Van Leent EJM, 2002, DERMATOLOGY, V204, P63, DOI 10.1159/000051813; VANJOOST T, 1994, BRIT J DERMATOL, V130, P634; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.02324.x; Vigo PG, 2006, J AM ACAD DERMATOL, V55, P168, DOI 10.1016/j.jaad.2005.12.045; Vora S, 2008, CLIN INFECT DIS, V46, P1555, DOI 10.1086/587668; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; Warino Lindsey, 2006, J Drugs Dermatol, V5, P527; Weatherhead SC, 2007, BRIT J DERMATOL, V156, P346, DOI 10.1111/j.1365-2133.2006.07686.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Werfel T, 2006, GMS HLTH TECHNOL ASS, V2; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Wittkowski A, 2004, J PSYCHOSOM RES, V57, P195, DOI 10.1016/S0022-3999(03)00572-5; Wohlrab J, 2007, SKIN PHARMACOL PHYS, V20, P71, DOI 10.1159/000097653; Wolkerstorfer A, 1998, J AM ACAD DERMATOL, V39, P226, DOI 10.1016/S0190-9622(98)70080-5; Wollenberg A, 2008, ALLERGY, V63, P742, DOI 10.1111/j.1398-9995.2008.01683.x; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1067/mai.2003.1775; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P1; Zargari A, 2001, ACTA DERM-VENEREOL, V81, P418, DOI 10.1080/000155501317208363; Zuberbier T, 2001, J ALLERGY CLIN IMMUN, V108, P275, DOI 10.1067/mai.2001.116865; Zuberbier T, 2006, J ALLERGY CLIN IMMUN, V118, P226, DOI 10.1016/j.jaci.2006.02.031	249	107	107	0	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2013	131	2					295	+		10.1016/j.jaci.2012.12.672		32	Allergy; Immunology	Allergy; Immunology	086CT	WOS:000314661500004	23374261	
J	Volk, HE; Hertz-Picciotto, I; Delwiche, L; Lurmann, F; McConnell, R				Volk, Heather E.; Hertz-Picciotto, Irva; Delwiche, Lora; Lurmann, Fred; McConnell, Rob			Residential Proximity to Freeways and Autism in the CHARGE Study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						autism; epidemiology; gene-environment interaction; roadway proximity; traffic emissions	POLYCYCLIC AROMATIC-HYDROCARBONS; HAZARDOUS AIR-POLLUTANTS; SPECTRUM DISORDERS; PRENATAL EXPOSURE; CHILDHOOD ASTHMA; OXIDATIVE STRESS; MULTIETHNIC POPULATION; ULTRAFINE PARTICLES; NITROGEN-DIOXIDE; GENE-EXPRESSION	BACKGROUND: Little is known about environmental causes and contributing factors for autism. Basic science and epidemiologic research suggest that oxidative stress and inflammation may play a role in disease development. Traffic-related air pollution, a common exposure with established effects on these pathways, contains substances found to have adverse prenatal effects. OBJECTIVES: We examined the association between autism and proximity of residence to freeways and major roadways during pregnancy and near the time of delivery, as a surrogate for air pollution exposure. METHODS: Data were from 304 autism cases and 259 typically developing controls enrolled in the Childhood Autism Risks from Genetics and the Environment (CHARGE) study. The mother's address recorded on the birth certificate and trimester-specific addresses derived from a residential history obtained by questionnaire were geocoded, and measures of distance to freeways and major roads were calculated using ArcGIS software. Logistic regression models compared residential proximity to freeways and major roads for autism cases and typically developing controls. RESULTS: Adjusting for sociodemographic factors and maternal smoking, maternal residence at the time of delivery was more likely be near a freeway (<= 309 m) for cases than for controls [odds ratio (OR) = 1.86; 95% confidence interval (CI), 1.04-3.45]. Autism was also associated with residential proximity to a freeway during the third trimester (OR = 2.22; CI, 1.16-4.42). After adjustment for socioeconomic and sociodemographic characteristics, these associations were unchanged. Living near other major roads at birth was not associated with autism. CONCLUSIONS: Living near a freeway was associated with autism. Examination of associations with measured air pollutants is needed.	[Volk, Heather E.; McConnell, Rob] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Volk, Heather E.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Prevent Med,Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; [Volk, Heather E.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Pediat,Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA; [Hertz-Picciotto, Irva; Delwiche, Lora] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA	Volk, HE (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 209G, Los Angeles, CA 90033 USA.	hvolk@usc.edu			National Institute of Environmental Health Sciences [ES019002, ES009581, ES013578, ES007048, ES11269, ES015359, RD831861]; U.S. Environmental Protection Agency [R-823392, R-833292]; MIND Institute; Autism Speaks	This work was supported by National Institute of Environmental Health Sciences grants ES019002, ES009581, ES013578, ES007048, ES11269, ES015359, and RD831861; U.S. Environmental Protection Agency Science to Achieve Results (STAR) grants R-823392 and R-833292; the MIND Institute matching funds and pilot grant program; and Autism Speaks.	Abrahams BS, 2008, NAT REV GENET, V9, P341, DOI 10.1038/nrg2346; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ashwood P, 2008, J NEUROIMMUNOL, V204, P149, DOI 10.1016/j.jneuroim.2008.07.006; Block ML, 2009, TRENDS NEUROSCI, V32, P506, DOI 10.1016/j.tins.2009.05.009; Bocskay KA, 2005, CANCER EPIDEM BIOMAR, V14, P506, DOI 10.1158/1055-9965.EPI-04-0566; Boso M, 2006, NEUROSCI LETT, V410, P169, DOI 10.1016/j.neulet.2006.08.092; Bouayed J, 2009, TOXICOLOGY, V259, P97, DOI 10.1016/j.tox.2009.02.010; Braunschweig D, 2008, NEUROTOXICOLOGY, V29, P226, DOI 10.1016/j.neuro.2007.10.010; Brown LA, 2007, NEUROTOXICOLOGY, V28, P965, DOI 10.1016/j.neuro.2007.05.005; Brugge D, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-23; Buyske S, 2006, BMC GENET, V7, DOI 10.1186/1471-2156-7-8; Calderon-Garciduenas L, 2009, TOXICOL PATHOL, V37, P161, DOI 10.1177/0192623308329340; Caltrans, 2008, TRAFF VEH DAT SYST U; Castro-Giner F, 2009, ENVIRON HEALTH PERSP, V117, P1919, DOI 10.1289/ehp.0900589; Centers for Disease Control and Prevention, 2007, MMWR-MORBID MORTAL W, V56, P1; Centers for disease Control and Prevention (CDC), 2009, MMWR-MORBID MORTAL W, V58, P1; Center for Disease Control and Prevention, 2007, MMWR SURVEILL SUMM, V56, P12; Chauhan Abha, 2006, Pathophysiology, V13, P171, DOI 10.1016/j.pathophys.2006.05.007; Currie J, 2009, J HEALTH ECON, V28, P688, DOI 10.1016/j.jhealeco.2009.02.001; Enstrom A, 2009, BRAIN BEHAV IMMUN, V23, P389, DOI 10.1016/j.bbi.2008.12.005; Enstrom AM, 2009, BRAIN BEHAV IMMUN, V23, P124, DOI 10.1016/j.bbi.2008.08.001; Filipek PA, 2004, J AUTISM DEV DISORD, V34, P615, DOI 10.1007/s10803-004-5283-1; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gonzalez-Pina R, 2008, NEUROCHEM RES, V33, P912, DOI 10.1007/s11064-007-9534-3; Hansen CA, 2008, ENVIRON HEALTH PERSP, V116, P362, DOI 10.1289/ehp.10720; Herr CEW, 2011, PEDIAT ALLERG IMM-UK, V22, P75, DOI 10.1111/j.1399-3038.2010.01074.x; Herr CEW, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-46; Hertz-Picciotto I, 2006, ENVIRON HEALTH PERSP, V114, P1119, DOI 10.1289/ehp.8483; Hertz-Picciotto I, 2009, EPIDEMIOLOGY, V20, P84, DOI 10.1097/EDE.0b013e3181902d15; Hougaard KS, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-3; Islam T, 2009, THORAX, V64, P197, DOI 10.1136/thx.2008.099366; James SJ, 2006, AM J MED GENET B, V141B, P947, DOI 10.1002/ajmg.b.30366; James SJ, 2009, FASEB J, V23, P2374, DOI 10.1096/fj.08-128926; James SJ, 2004, AM J CLIN NUTR, V80, P1611; Kalkbrenner AE, 2010, EPIDEMIOLOGY, V21, P631, DOI 10.1097/EDE.0b013e3181e65d76; King M, 2009, INT J EPIDEMIOL, V38, P1224, DOI 10.1093/ije/dyp261; Kunzli N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009096; Le Couteur A., 2003, AUTISM DIAGNOSTIC IN; Li XH, 2009, J NEUROIMMUNOL, V207, P111, DOI 10.1016/j.jneuroim.2008.12.002; Lord C., 2003, AUTISM DIAGNOSTIC OB; Ma DQ, 2009, ANN HUM GENET, V73, P263, DOI 10.1111/j.1469-1809.2009.00523.x; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; Ming X, 2005, PROSTAG LEUKOTR ESS, V73, P379, DOI 10.1016/j.plefa.2005.06.002; Ming X, 2009, BRAIN DEV, V32, P105; Morales E, 2009, AM J EPIDEMIOL, V169, P1327, DOI 10.1093/aje/kwp067; Muhle R, 2004, PEDIATRICS, V113, pE472, DOI 10.1542/peds.113.5.e472; Mullen E., 1995, MULLEN SCALES EARLY; Pan IJ, 2009, ENVIRON HEALTH PERSP, V117, P488, DOI 10.1289/ehp.0800063; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P626, DOI 10.1289/ehp.6617; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perera FP, 2007, ENVIRON HEALTH PERSP, V115, P1497, DOI 10.1289/ehp.10144; Perera FP, 2006, ENVIRON HEALTH PERSP, V114, P1287, DOI 10.1289/ehp.9084; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Rutter M., 2003, SOCIAL COMMUNICATION; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; SEXTON K, 1993, TOXICOL IND HEALTH, V9, P843; Sogut S, 2003, CLIN CHIM ACTA, V331, P111, DOI 10.1016/S0009-8981(03)00119-0; Sparrow S.S., 1984, VINELAND ADAPTIVE BE; Suglia SF, 2008, AM J EPIDEMIOL, V167, P280, DOI 10.1093/aje/kwm308; Van Meter KC, 2010, AUTISM RES, V3, P19, DOI 10.1002/aur.110; Vassilev ZP, 2001, AM J IND MED, V40, P255, DOI 10.1002/ajim.1096; Wang K, 2009, NATURE, V459, P528, DOI 10.1038/nature07999; Watanabe Nobue, 2001, Environmental Health Perspectives, V109, P111, DOI 10.2307/3434762; Williams TA, 2007, ARCH PEDIAT ADOL MED, V161, P356, DOI 10.1001/archpedi.161.4.356; Windham GC, 2006, ENVIRON HEALTH PERSP, V114, P1438, DOI 10.1289/ehp.9120; Yao YM, 2006, ARCH NEUROL-CHICAGO, V63, P1161, DOI 10.1001/archneur.63.8.1161; Zhu YF, 2006, ENVIRON SCI TECHNOL, V40, P2531, DOI 10.1021/es0516514; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032	71	107	111	3	51	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2011	119	6					873	877		10.1289/ehp.1002835		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	771JC	WOS:000291152000034	21156395	
J	Richardson, SD; DeMarini, DM; Kogevinas, M; Fernandez, P; Marco, E; Lourencetti, C; Balleste, C; Heederik, D; Meliefste, K; McKague, AB; Marcos, R; Font-Ribera, L; Grimalt, JO; Villanueva, CM				Richardson, Susan D.; DeMarini, David M.; Kogevinas, Manolis; Fernandez, Pilar; Marco, Esther; Lourencetti, Carolina; Balleste, Clara; Heederik, Dick; Meliefste, Kees; McKague, A. Bruce; Marcos, Ricard; Font-Ribera, Laia; Grimalt, Joan O.; Villanueva, Cristina M.			What's in the Pool? A Comprehensive Identification of Disinfection By-products and Assessment of Mutagenicity of Chlorinated and Brominated Swimming Pool Water	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						bromination; bromine; chlorination; chlorine; DBPs; disinfection by-products; mutagenicity; swimming pools; Salmonella; water	GLUTATHIONE-S-TRANSFERASE; DRINKING-WATER; TRIHALOMETHANE CONCENTRATIONS; SALMONELLA MUTAGENICITY; EXPOSURE; GENOTOXICITY; BROMODICHLOROMETHANE; CHLORAMINES; CHLOROFORM; EXPRESSION	BACKGROUND: Swimming pool disinfectants and disinfection by-products (DBPs) have been linked to human health effects, including asthma and bladder cancer, but no studies have provided a comprehensive identification of DBPs in the water and related that to mutagenicity. OBJECTIVES: We performed a comprehensive identification of DBPs and disinfectant species in waters from public swimming pools in Barcelona, Catalonia, Spain, that disinfect with either chlorine or bromine and we determined the mutagenicity of the waters to compare with the analytical results. METHODS: We used gas chromatography/mass spectrometry (GC/MS) to measure trihalomethanes in water, GC with electron capture detection for air, low- and high-resolution GC/MS to comprehensively identify DBPs, photometry to measure disinfectant species (free chlorine, monochloroamine, dichloramine, and trichloramine) in the waters, and an ion chromatography method to measure trichloramine in air. We assessed mutagenicity with the Salmonella mutagenicity assay. RESULTS: We identified > 100 DBPs, including many nitrogen-containing DBPs that were likely formed from nitrogen-containing precursors from human inputs, such as urine, sweat, and skin cells. Many DBPs were new and have not been reported previously in either swimming pool or drinking waters. Bromoform levels were greater in brominated than in chlorinated pool waters, but we also identified many brominated DBPs in the chlorinated waters. The pool waters were mutagenic at levels similar to that of drinking water (similar to 1,200 revertants/L-equivalents in strain TA100-S9 mix). CONCLUSIONS: This study identified many new DBPs not identified previously in swimming pool or drinking water and found that swimming pool waters are as mutagenic as typical drinking waters.	[Richardson, Susan D.] US EPA, Natl Exposure Res Lab, Athens, GA 30605 USA; [DeMarini, David M.] US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; [Kogevinas, Manolis; Font-Ribera, Laia; Villanueva, Cristina M.] Ctr Res Environm Epidemiol, Barcelona, Spain; [Kogevinas, Manolis; Font-Ribera, Laia; Villanueva, Cristina M.] Hosp del Mar, Municipal Inst Med Res, Barcelona, Spain; [Kogevinas, Manolis; Villanueva, Cristina M.] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Kogevinas, Manolis] Univ Athens, Sch Med, GR-10679 Athens, Greece; [Fernandez, Pilar; Marco, Esther; Lourencetti, Carolina; Balleste, Clara; Grimalt, Joan O.] Inst Environm Assessment & Water Res, Dept Environm Chem, Barcelona, Spain; [Heederik, Dick; Meliefste, Kees] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands; [McKague, A. Bruce] CanSyn Chem Corp, Toronto, ON, Canada; [Marcos, Ricard] Univ Autonoma Barcelona, Dept Genet & Microbiol, Grp Mutagenesi, Bellaterra, Cerdanyola Vall, Spain	Richardson, SD (reprint author), US EPA, Natl Exposure Res Lab, 960 Coll Stn Rd, Athens, GA 30605 USA.	richardson.susan@epa.gov	Grimalt, Joan/E-2073-2011; Fernandez, Pilar/E-6182-2010; Villanueva, Cristina/N-1942-2014; Kogevinas, Manolis/C-3918-2017	Grimalt, Joan/0000-0002-7391-5768; Fernandez, Pilar/0000-0002-4535-5214; Villanueva, Cristina/0000-0002-0783-1259; Font-Ribera, Laia/0000-0001-8447-4905; Marcos, Ricard/0000-0001-7891-357X	U.S. Environmental Protection Agency (EPA); Plan Nacional [SAF2005-07643-C03-01]; Fondo de Investigacion Sanitaria [CP06/00341]; Instituto de Salud Carlos III [CP06/00341, FI06/00651]; Santander-Central Hispano; Consejo Superior de Investigaciones Cientificas	This research was supported by the U.S. Environmental Protection Agency (EPA) intramural research program and Spanish grants SAF2005-07643-C03-01 (Plan Nacional) and CP06/00341 (Fondo de Investigacion Sanitaria). C.M.V. and L.F.-R. have, respectively, a contract and a predoctoral fellowship by the Instituto de Salud Carlos III (CP06/00341, FI06/00651). C. L. acknowledges a grant from the Agreement between Santander-Central Hispano and Consejo Superior de Investigaciones Cientificas.	AGGAZZOTTI G, 1986, WATER RES, V20, P959, DOI 10.1016/0043-1354(86)90036-9; Ashley DL, 2005, ARCH ENVIRON HEALTH, V60, P7, DOI 10.3200/AEOH.60.1.7-15; BEECH JA, 1980, AM J PUBLIC HEALTH, V70, P79, DOI 10.2105/AJPH.70.1.79; Cantor KP, 2010, ENVIRON HEALTH PERSP, V118, P1545, DOI 10.1289/ehp.1002206; Chu H, 2002, OCCUP ENVIRON MED, V59, P243, DOI 10.1136/oem.59.4.243; Claxton LD, 2008, J TOXICOL ENV HEAL A, V71, P1187, DOI 10.1080/15287390802182508; DeMarini DM, 1995, ENVIRON MOL MUTAGEN, V26, P270, DOI 10.1002/em.2850260403; DeMarini DM, 1997, ENVIRON MOL MUTAGEN, V30, P440, DOI 10.1002/(SICI)1098-2280(1997)30:4<440::AID-EM9>3.0.CO;2-M; Egorov AI, 2003, INT J HYG ENVIR HEAL, V206, P539, DOI 10.1078/1438-4639-00244; Erdinger L, 2004, INT J HYG ENVIR HEAL, V207, P571, DOI 10.1078/1438-4639-00329; Font-Ribera L, 2010, ENVIRON HEALTH PERSP, V118, P1538, DOI 10.1289/ehp.1001961; Ford R, 2007, CERTIFIED POOL SPA O; Glauner T, 2005, WATER RES, V39, P4494, DOI 10.1016/j.watres.2005.09.005; Goodman M, 2008, J ASTHMA, V45, P639, DOI 10.1080/02770900802165980; Granville CA, 2005, MUTAT RES-FUND MOL M, V572, P98, DOI 10.1016/j.mrfmmm.2004.12.009; Haddad S, 2006, J TOXICOL ENV HEAL A, V69, P2095, DOI 10.1080/15287390600631789; HERY M, 1995, ANN OCCUP HYG, V39, P427, DOI 10.1016/0003-4878(95)00013-5; HONER WG, 1980, MUTAT RES, V78, P137, DOI 10.1016/0165-1218(80)90092-0; International Agency for Research on Cancer, 2004, IARC MONOGR EVAL CAR, V84, P1; Jacobs JH, 2007, EUR RESPIR J, V29, P690, DOI 10.1183/09031936.00024706; JAFVERT CT, 1992, ENVIRON SCI TECHNOL, V26, P577, DOI 10.1021/es00027a022; JUDD SJ, 1995, WATER RES, V29, P1203, DOI 10.1016/0043-1354(94)00230-5; Kim H, 2002, CHEMOSPHERE, V46, P123, DOI 10.1016/S0045-6535(00)00581-6; Kogevinas M, 2010, ENVIRON HEALTH PERSP, V118, P1531, DOI 10.1289/ehp.1001959; Lakind JS, 2010, ENVIRON SCI TECHNOL, V44, P3205, DOI 10.1021/es903241k; Leavens TL, 2007, TOXICOL SCI, V99, P432, DOI 10.1093/toxsci/kfm190; Lekkas TD, 2004, ENVIRON ENG SCI, V21, P493, DOI 10.1089/1092875041358566; Li J, 2007, ENVIRON SCI TECHNOL, V41, P6732, DOI 10.1021/es070871; Liviac D, 2010, ENVIRON SCI TECHNOL, V44, P3527, DOI 10.1021/es903593w; Lourencetti C, 2010, ANAL CHIM ACTA, V662, P23, DOI 10.1016/j.aca.2009.12.040; Marina LS, 2009, GAC SANIT, V23, P115, DOI 10.1016/j.gaceta.2008.02.002; MARON DM, 1983, MUTAT RES, V113, P173, DOI 10.1016/0165-1161(83)90010-9; Nakajima M, 2009, J HEALTH SCI, V55, P363; Pegram RA, 1997, TOXICOL APPL PHARM, V144, P183, DOI 10.1006/taap.1997.8123; Plewa MJ, 2008, ENVIRON SCI TECHNOL, V42, P955, DOI 10.1021/es071754h; Plewa MJ, 2008, ACS SYM SER, V995, P36; Richardson S. D., 1998, ENCY ENV ANAL REMEDI, V3, P1398; Richardson SD, 2008, J TOXICOL ENV HEAL A, V71, P1165, DOI 10.1080/15287390802182417; Richardson SD, 2007, MUTAT RES-REV MUTAT, V636, P178, DOI 10.1016/j.mrrev.2007.09.001; Shang C, 1999, ENVIRON SCI TECHNOL, V33, P2218, DOI 10.1021/es9812103; Stav D, 2005, NEW ENGL J MED, V353, P1635, DOI 10.1056/NEJMc050955; Takanashi H, 2009, CHEMOSPHERE, V77, P434, DOI 10.1016/j.chemosphere.2009.06.038; THIER R, 1995, CHEM RES TOXICOL, V8, P465, DOI 10.1021/tx00045a019; THIER R, 1993, P NATL ACAD SCI USA, V90, P8576, DOI 10.1073/pnas.90.18.8576; VENTURA F, 1985, B ENVIRON CONTAM TOX, V35, P73, DOI 10.1007/BF01636483; Villanueva CM, 2004, EPIDEMIOLOGY, V15, P357, DOI 10.1097/01.ede.0000121380.02594.fc; Villanueva CM, 2007, AM J EPIDEMIOL, V165, P148, DOI 10.1093/aje/kwj364; Walse SS, 2008, ENVIRON SCI TECHNOL, V42, P1032, DOI 10.1021/es702301p; Weaver WA, 2009, WATER RES, V43, P3308, DOI 10.1016/j.watres.2009.04.035; Weisel CP, 2009, ENVIRON HEALTH PERSP, V117, P500, DOI 10.1289/ehp.11513; WHO, 2000, GUID SAF RECR WAT EN, V2; XU W, 2004, J EXP ANAL ENV EPIDE, V15, P6; Xu X, 2005, J EXPO ANAL ENV EPID, V15, P289, DOI 10.1038/sj.jea.7500404; Zwiener C, 2007, ENVIRON SCI TECHNOL, V41, P363, DOI 10.1021/es062367v	54	107	109	17	141	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	NOV	2010	118	11					1523	1530		10.1289/ehp.1001965		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	674CR	WOS:000283711800021	20833605	
J	Weinmayr, G; Romeo, E; De Sario, M; Weiland, SK; Forastiere, F				Weinmayr, Gudrun; Romeo, Elisa; De Sario, Manuela; Weiland, Stephan K.; Forastiere, Francesco			Short-Term Effects of PM10 and NO2 on Respiratory Health among Children with Asthma or Asthma-like Symptoms: A Systematic Review and Meta-Analysis	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						air pollution; asthma; children; NO2; PM; short-term effects	PARTICULATE AIR-POLLUTION; ANTIINFLAMMATORY MEDICATION USE; PEAK EXPIRATORY FLOW; NITROGEN-DIOXIDE; AUSTRALIAN CHILDREN; PUBLICATION BIAS; MEXICO-CITY; PARTICLES; EXPOSURE; PROJECT	OBJECTIVE: Our goal was to quantify the short-term effects of particulate matter with aerodynamic diameter <= 10 mu m (PM10) and nitrogen dioxide (NO2) on respiratory health of asthmatic children from published panel studies, and to investigate the influence of study and population characteristics as effect modifiers. DATA EXTRACTION: After a systematic literature review, we extracted quantitative estimates of the association of PM10 and/or NO2 with respiratory symptoms and peak expiratory flow (PEF). Combined effect estimates for an increase of 10 mu g/m(3) were calculated by random effects meta-analysis for all studies and for different strata defined by study characteristics. The effect of publication bias was investigated with Egger's and Begg's tests and "trim-and-fill" analyses. DATA SYNTHESIS: We identified 36 studies; 14 were part of the European Pollution Effects on Asthmatic Children in Europe (PEACE) study. Adverse associations of PM10 with asthma symptoms were statistically significant [odds ratio (OR) = 1.028; 95% confidence interval (CI), 1.006-1.051]. There were also associations, although not statistically significant, of PM10 with cough (OR = 1.012; 95% CI, 0.997-1.026) and on PEF (decrease of-0.082 L/min; 95% CI, -0.214 to 0.050). NO2 had statistically significant associations with asthma symptoms in the overall analysis considering all possible lags (OR = 1.031; 95% CI, 1.001-1.062), but not when we evaluated only the 0-1 lag. We found no publication bias, although it appeared when excluding the PEACE studies. When we applied the trim-and-fill method to the data set without the PEACE studies, the results were similar to the overall estimates from all studies. There was an indication for stronger PM10 associations for studies conducted in summer, outside of Europe, with longer lags, and in locations with higher NO2 concentrations. CONCLUSIONS: We found clear evidence of effects of PM10 on the occurrence of asthma symptom episodes, and to a lesser extent on cough and PEF. The results for NO2 are more difficult to interpret because they depend on the lag times examined. There was an indication of effect modification by several study conditions.	[Weinmayr, Gudrun; Weiland, Stephan K.] Univ Ulm, Inst Epidemiol, D-89081 Ulm, Germany; [Romeo, Elisa; De Sario, Manuela; Forastiere, Francesco] Local Hlth Author Rome E, Dept Epidemiol, Rome, Italy	Weinmayr, G (reprint author), Univ Ulm, Inst Epidemiol, Helmholtzstr 22, D-89081 Ulm, Germany.	gudrun.weinmayr@uni-ulm.de	De sario, Manuela/K-1932-2016; Forastiere, Francesco/J-9067-2016	De sario, Manuela/0000-0002-1117-2735; Forastiere, Francesco/0000-0002-9162-5684			Ackermann-Liebrich U., 1999, AIR POLLUTION HLTH, P559; Aekplakorn W, 2003, INT J EPIDEMIOL, V32, P854, DOI 10.1093/ije/dyg237; Anderson HR, 2004, METAANALYSIS TIME SE; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; BALDINI G, 1998, EUR RESPIR REV, V8, P108; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; BEYER U, 1998, EUR RESPIR REV, V8, P61; CLENCHAAS J, 1998, EUR RESPIR REV, V8, P36; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Duval S, 2000, J AM STAT ASSOC, V95, P89, DOI 10.2307/2669529; Egger M, 1997, BRIT MED J, V315, P629; ENGLERT N, 1998, EUR RESPIR REV, V8, P53; FORSBERG B, 1998, EUR RESPIR REV, V8, P12; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; HALUSZKA J, 1998, EUR RESPIR REV, V8, P94; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Jalaludin BB, 2000, INT J EPIDEMIOL, V29, P549, DOI 10.1093/ije/29.3.549; Jalaludin BB, 2004, ENVIRON RES, V95, P32, DOI 10.1016/S0013-9351(03)00038-0; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; KALANDIDI A, 1998, EUR RESPIR REV, V8, P117; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Kimber Ian, 1998, Toxicology Letters (Shannon), V102-103, P301, DOI 10.1016/S0378-4274(98)00320-8; KOTESOVEC F, 1998, EUR RESPIR REV, V8, P70; Levy JI, 2000, ENVIRON HEALTH PERSP, V108, P109, DOI 10.2307/3454508; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; *NAT LIB MED, 2008, PUBMED; NIELSEN J, 1998, EUR RESPIR REV, V8, P20; Niepsuj G., 1998, EUR RESPIR REV, V8, P86; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Peacock JL, 2003, OCCUP ENVIRON MED, V60, P82, DOI 10.1136/oem.60.2.82; Peters A, 1997, EUR RESPIR J, V10, P872; Petitti DB, 2001, STAT MED, V20, P3625, DOI 10.1002/sim.1091; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; Roemer W, 2000, CLIN EXP ALLERGY, V30, P1067; ROEMER W, 1998, EUR RESPIR REV, V8, P4; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; RUDNAI P, 1998, EUR RESPIR REV, V8, P101; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Seaton A, 2003, THORAX, V58, P1012, DOI 10.1136/thorax.58.12.1012; Segala C, 1998, EUR RESPIR J, V11, P677; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; TIMONEN KL, 1998, EUR RESPIR REV, V8, P27; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; *US EPA, 2008, 2008 INT SCI ASS ISA; U.S. Environmental Protection Agency (E.P.A.), 2005, REV NAT AMB AIR QUAL; The U.S. Environmental Protection Agency (U.S. EPA), 2008, RISK EXP ASS SUPP RE; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; VANDERZEE S, 1998, EUR RESPIR REV, V8, P44; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; VONDRA V, 1998, EUR RESPIR REV, V8, P78; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; WHO Regional Office for Europe, 2006, AIR QUAL GUID GLOB U; *WHO REG OFF EUR, 2000, EUR SER WHO, V91; Williams M. L, 1999, AIR POLLUTION HLTH, P83, DOI 10.1016/B978-012352335-8/50081-8; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835	66	107	114	1	44	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2010	118	4					449	457		10.1289/ehp.0900844		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	580NA	WOS:000276454800015	20064785	
J	Brandtzaeg, P				Brandtzaeg, Per			The Mucosal Immune System and Its Integration with the Mammary Glands	JOURNAL OF PEDIATRICS			English	Article; Proceedings Paper	Conference on Emerging Roles Functioning Proteins in Pediatric Nutrition	OCT 29-31, 2008	San Francisco, CA				CESAREAN-SECTION; EPITHELIAL-CELLS; DENDRITIC CELLS; FOOD ALLERGY; B-CELLS; J-CHAIN; TOLERANCE; TRANSPORT; RESPONSES; COMPONENT	Mucosal immunity reduces the need for elimination of penetrating exogenous antigens by proinflammatory systemic immunity. The adult gut mucosa contains some 80% of the body's activated B cells-differentiated to plasmablasts and plasma cells (PCs). Most mucosal PCs produce dimeric immunoglobulin A (IgA), which, along with pentameric immunoglobulin M (IgM), can be exported by secretory epithelia expressing the polymeric immunoglobulin receptor. Immune exclusion of antigens is performed mainly by secretory IgA in cooperation with innate defenses, but, in newborns and in IgA deficiency, secretory IgM is important. In the gut, induction and regulation of mucosal immunity occurs primarily in gut-associated lymphoid tissue-particularly the Peyer's patches-and also in mesenteric lymph nodes. Terminal differentiation to PCs is accomplished in the lamina propria to which the activated memory/effector T and B cells home. Lactating mammary glands are part of the secretory immune system, and IgA antibodies in breast milk reflect antigenic stimulation of gut-associated lymphoid tissue and nasopharynx-associated lymphoid tissue such as the tonsils. Breast-milk antibodies are thus highly targeted against infectious agents and other exogenous antigens in the mother's environment, which are those likely to be encountered by the infant. Therefore breast-feeding represents an ingenious immunologic integration of mother and child. (J Pediatr 2010;156:S8-15).	[Brandtzaeg, Per] Univ Oslo, Rikshosp, Div Pathol, LIIPAT, N-0027 Oslo, Norway; [Brandtzaeg, Per] Univ Oslo, Rikshosp, Ctr Immune Regulat, Inst Pathol, N-0027 Oslo, Norway	Brandtzaeg, P (reprint author), Univ Oslo, Rikshosp, Div Pathol, LIIPAT, N-0027 Oslo, Norway.	per.brandtzaeg@medisin.uio.no					Agency for Healthcare Research and Quality (AHRQ), 2007, AHRQ PUBL; BRANDTZAEG P, 1991, GASTROENTEROL CLIN N, V20, P397; Brandtzaeg P, 2005, IMMUNOL REV, V206, P32, DOI 10.1111/j.0105-2896.2005.00283.x; BRANDTZAEG P, 1983, ANN NY ACAD SCI, V409, P353, DOI 10.1111/j.1749-6632.1983.tb26883.x; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; Brandtzaeg P, 2003, VACCINE, V21, P3382, DOI 10.1016/S0264-410X(03)00338-4; Brandtzaeg P, 2002, ANN NY ACAD SCI, V964, P13; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; Brandtzaeg P, 1998, NUTR REV, V56, pS5; Brandtzaeg P, 2002, FRONTIERS NUTR SCI, VI, P273; Brandtzaeg Per, 2007, P221, DOI 10.1007/978-0-387-72232-0_10; Dickinson EC, 1998, SURGERY, V124, P284, DOI 10.1016/S0039-6060(98)70132-1; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; GOLDMAN AS, 1993, PEDIATR INFECT DIS J, V12, P664, DOI 10.1097/00006454-199308000-00008; Hanson LA, 2007, P NUTR SOC, V66, P384, DOI 10.1017/S0029665107005654; Helgeland Lars, 2000, Microbial Ecology in Health and Disease, V12, P110, DOI 10.1080/089106000750060378; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Johansen FE, 2000, SCAND J IMMUNOL, V52, P240; Johansen FE, 2005, BLOOD, V106, P593, DOI 10.1182/blood-2004-12-4630; Johansen FE, 1999, J EXP MED, V190, P915, DOI 10.1084/jem.190.7.915; Kraus TA, 2004, GASTROENTEROLOGY, V126, P1771, DOI 10.1053/j.gastro.2004.03.076; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; Massacand JC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002588; MELLANDER L, 1985, J PEDIATR-US, V107, P430, DOI 10.1016/S0022-3476(85)80528-X; Mora JR, 2008, MUCOSAL IMMUNOL, V1, P96, DOI 10.1038/mi.2007.14; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Rimoldi M, 2005, NAT IMMUNOL, V6, P507, DOI 10.1038/ni1192; Sait LC, 2007, INT IMMUNOL, V19, P257, DOI 10.1093/intimm/dxl142; Tollanes MC, 2008, J PEDIATR-US, V153, P112, DOI 10.1016/j.jpeds.2008.01.029; Wilson E, 2004, J EXP MED, V200, P805, DOI 10.1084/jem.20041069; [Anonymous], 1994, LANCET, V344, P1239	32	107	110	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476			J PEDIATR-US	J. Pediatr.	FEB	2010	156	2		1			S8	S15		10.1016/j.jpeds.2009.11.014		8	Pediatrics	Pediatrics	549LV	WOS:000274051400003	20105666	
J	von Mutius, E				von Mutius, Erika			Gene-environment interactions in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; genes; environment; interactions	GLUTATHIONE-S-TRANSFERASE; CHILDHOOD ASTHMA; TOBACCO-SMOKE; AIR-POLLUTION; LUNG-FUNCTION; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY HEALTH; ORMDL3 EXPRESSION; MATERNAL SMOKING; IMMUNOGLOBULIN-E	Asthma is a complex disease, and its incidence is determined by an intricate interplay of genetic and environmental factors. The Identification of novel genes for asthma suggests that many genes with small effect,; rather than few genes with strong effects contribute to the development of asthma. These genetic effects may in part differ with respect to a subject's environmental exposures, although some genes may also exert their effect independently of the environment. Whereas the geneticist uses highly advanced, rapid, comprehensive technologies to assess even subtle changes in the human genome, the researcher interested in environmental exposures is often confronted with crude information obtained from questionnaires or interviews. There is thus substantial need to develop better tools for individual exposure assessment in all relevant environmental fields. Despite these limitations, a number of important gene-environment interactions have been identified. These interactions point to the biology of environmental exposures as the involved genetic variation is suggestive of certain underlying mechanisms. Furthermore, the identification of subjects who are particularly susceptible to environmental hazards through genetic analyses helps to estimate better the strength of effect of environmental exposures. Finally, the analysis of gene-environment interactions may result in a reconciliation of seemingly contradictory findings from studies not taking environmental exposures into account. (J Allergy Clin Immunol 2009;123:3-11.)	Univ Childrens Hosp, D-80337 Munich, Germany	von Mutius, E (reprint author), Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Erika.von.Mutius@med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515			Alexandrov K, 2002, CARCINOGENESIS, V23, P1969, DOI 10.1093/carcin/23.12.1969; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Atkinson RW, 2004, AM J RESP CRIT CARE, V169, P1257; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CALIGARI PDS, 1975, PROC R SOC SER B-BIO, V191, P387, DOI 10.1098/rspb.1975.0135; Cameron L, 2006, J IMMUNOL, V177, P8633; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Christiani DC, 2008, OCCUP ENVIRON MED, V65, P430, DOI 10.1136/oem.2007.033977; [Anonymous], 2008, OCCUP ENVIRON MED; [Anonymous], 2008, OCCUP ENVIRON MED; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Dizier MH, 2007, EUR J HUM GENET, V15, P810, DOI 10.1038/sj.ejhg.5201830; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Evans GS, 2008, J APPL TOXICOL, V28, P1, DOI 10.1002/jat.1294; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Guo SW, 2000, HUM HERED, V50, P286, DOI 10.1159/000022931; Hawkins Gregory A., 2008, V448, P359, DOI 10.1007/978-1-59745-205-2_11; Hawkins GA, 2008, PHARMACOGENOMICS, V9, P349, DOI 10.2217/14622416.9.3.349; Hawkins GA, 2006, AM J RESP CRIT CARE, V174, P1101, DOI 10.1164/rccm.200509-1405OC; Hersh CP, 2007, AM J RESP CRIT CARE, V176, P849, DOI 10.1164/rccm.200704-592OC; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jones MG, 2008, CURR OPIN ALLERGY CL, V8, P110, DOI 10.1097/ACI.0b013e3282f4b5f1; Jusufagic AS, 2006, CURR ALLERGY ASTHM R, V6, P521, DOI 10.1007/s11882-006-0031-6; Kabesch M, 2006, TOXICOL LETT, V162, P43, DOI 10.1016/j.toxlet.2005.10.009; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Karjalainen J, 2003, CLIN EXP ALLERGY, V33, P78, DOI 10.1046/j.1365-2222.2003.01577.x; Kurz Thorsten, 2004, Curr Opin Allergy Clin Immunol, V4, P335, DOI 10.1097/00130832-200410000-00002; Lee YL, 2007, ALLERGY, V62, P641, DOI 10.1111/j.1398-9995.2007.01380.x; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Li YF, 2008, ENVIRON HEALTH PERSP, V116, P409, DOI 10.1289/ehp.10655; Litonjua AA, 2006, CURR OPIN PULM MED, V12, P12, DOI 10.1097/01.mcp.0000198068.50457.95; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Madore AM, 2008, HUM GENET, V123, P93, DOI 10.1007/s00439-007-0444-x; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ortega VE, 2007, IMMUNOL ALLERGY CLIN, V27, P665, DOI 10.1016/j.iac.2007.09.007; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Payne Donald, 2004, Paediatr Respir Rev, V5, P116, DOI 10.1016/j.prrv.2004.01.006; Ramadas RA, 2007, EUR RESPIR J, V29, P502, DOI 10.1183/09031936.00029506; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Sadeghnejad A, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-2; Saglani S, 2007, CURR OPIN ALLERGY CL, V7, P83; Sheehan D, 2001, BIOCHEM J, V360, P1, DOI 10.1042/0264-6021:3600001; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1094; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2007, CLIN EXP ALLERGY, V37, P1602, DOI 10.1111/j.1365-2222.2007.02831.x; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Taylor DR, 2007, EXPERT OPIN PHARMACO, V8, P3195, DOI 10.1517/14656566.8.18.3195; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39	80	107	108	1	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2009	123	1					3	11		10.1016/j.jaci.2008.10.046		9	Allergy; Immunology	Allergy; Immunology	399IP	WOS:000262793900002	19130922	
J	Christensen, LH; Holm, J; Lund, G; Riise, E; Lund, K				Christensen, Lars Harder; Holm, Jens; Lund, Gitte; Riise, Erik; Lund, Kaare			Several distinct properties of the IgE repertoire determine effector cell degranulation in response to allergen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; recombinant IgE; human IgE; chimeric IgE; antibody; affinity; epitope; allergen; Der p 2; effector cell degranulation; basophil activation test; basophils; diagnosis	HUMAN BASOPHIL ACTIVATION; HISTAMINE-RELEASE; CROSS-REACTIVITY; LEUKEMIA-CELLS; MITE ALLERGEN; ANTI-IGE; AFFINITY; IMMUNOASSAY; EXPRESSION; EPITOPES	Background: On cross-linking of receptor-bound IgE antibodies by allergens, effector cells (basophils and mast cells) involved in type I allergic reactions degranulate and release the potent chemical mediators stored inside their granules. Total and allergen-specific IgE concentrations, IgE affinity for allergen, and IgE clonality are all distinct properties of allergic patients' IgE repertoires. However, the inability to isolate individual IgE antibodies from allergic patients' sera presents a major barrier to understanding the importance of patient-specific IgE repertoires for the manifestation and severity of allergic symptoms. Objective: We sought to investigate how individual properties of an IgE repertoire affect effector cell degranulation. Methods: A panel of recombinant IgE (rIgE) antibodies specific for the major house dust mite allergen Der p 2 was developed and characterized in regard to Der p 2 affinity, as well as Der p 2 epitope specificity, by using surface plasmon resonance technology. Human basophils were sensitized with different combinations of rIgEs, and degranulation responses were measured by means of flow cytometry after challenge with Der p 2. Results: A total of 31 Der p 2-specific rIgEs were produced. They bound a total of 9 different Der p 2 epitopes in the affinity range (KD value) of 0.0358 to 291 nM. Factors increasing human basophil degranulation were increased total IgE concentrations, increased concentrations of allergen-specific IgE relative to non-allergen-specific IgE, more even concentration of individual allergen-specific IgE clones, increased IgE affinity for allergen, and increased number of allergen epitopes recognized by the IgE repertoire (increased IgE clonality). Conclusion: This study demonstrates how distinct properties of the IgE repertoire, such as total and allergen-specific IgE antibody concentration, IgE affinity, and IgE clonality, affect effector cell degranulation.	[Christensen, Lars Harder; Holm, Jens; Lund, Gitte; Lund, Kaare] ALK Abello AS, Dept Expt Immunol, DK-2970 Horsholm, Denmark; [Christensen, Lars Harder; Riise, Erik] Univ Copenhagen, Fac Pharmaceut Sci, Antibody Technol Grp, Copenhagen, Denmark	Christensen, LH (reprint author), ALK Abello AS, Dept Expt Immunol, Boge Alle 6-8, DK-2970 Horsholm, Denmark.	lars-harder@hotmail.com					Aalberse RC, 2001, ALLERGY, V56, P27, DOI 10.1034/j.1398-9995.2001.00909.x; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118; COLLINS AM, 1995, INT ARCH ALLERGY IMM, V107, P547; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.0000/S0022-2836(02)00027-X; FEWTRELL C, 1980, J IMMUNOL, V125, P701; Gieras A, 2007, J ALLERGY CLIN IMMUN, V119, P384, DOI 10.1016/j.jaci.2006.09.034; Hahn EL, 2005, IMMUNOL ALLERGY CLIN, V25, P231, DOI 10.1016/j.iac.2005.02.004; HEALICON RM, 1986, IMMUNOLOGY, V57, P611; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Johansson SGO, 2006, ALLERGY, V61, P1216, DOI 10.1111/j.1398-9995.2006.01172.x; KAGEYSOBOTKA A, 1981, J IMMUNOL, V127, P2285; Kleine-Tebbe J, 2006, INT ARCH ALLERGY IMM, V141, P79, DOI 10.1159/000094495; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Marchand F, 2003, ALLERGY, V58, P1037, DOI 10.1034/j.1398-9995.2003.00251.x; Mita H, 2000, Clin Exp Allergy, V30, P1583, DOI 10.1046/j.1365-2222.2000.00921.x; Norderhaug L, 1997, J IMMUNOL METHODS, V204, P77, DOI 10.1016/S0022-1759(97)00034-3; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; Persson H, 2007, MOL IMMUNOL, V44, P2729, DOI 10.1016/j.molimm.2006.11.024; Pierson-Mullany LK, 2002, CLIN EXP ALLERGY, V32, P107, DOI 10.1046/j.0022-0477.2001.01244.x; PRUZANSKY JJ, 1988, IMMUNOLOGY, V64, P307; Romano A, 2007, CURR OPIN ALLERGY CL, V7, P299; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Turner H, 1999, NATURE, V402, pB24	28	107	108	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					298	304		10.1016/j.jaci.2008.05.026		7	Allergy; Immunology	Allergy; Immunology	337HO	WOS:000258426300013	18572230	
J	Marogna, M; Tomassetti, D; Bernasconi, A; Colombo, F; Massolo, A; Businco, ADR; Canonica, GW; Passalacqua, G; Tripodi, S				Marogna, Maurizio; Tomassetti, Dante; Bernasconi, Antonella; Colombo, Fausto; Massolo, Alessandro; Businco, Andrea Di Rienzo; Canonica, Giorgio W.; Passalacqua, Giovanni; Tripodi, Salvatore			Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							HOUSE-DUST MITE; ALLERGIC RHINITIS; LONG-TERM; PEDIATRIC-PATIENTS; RESPIRATORY ALLERGY; REAL-LIFE; FOLLOW-UP; CHILDREN; ASTHMA; EFFICACY	Background: Sublingual immunotherapy (SLIT) has been proved to be effective in allergic rhinitis and asthma, but there are few data on its preventive effects, especially in children. Objective: To evaluate the clinical and preventive effects of SLIT in children by assessing onset of persistent asthma and new sensitizations, clinical symptoms, and bronchial hyperreactivity. Methods: A total of 216 children with allergic rhinitis, with or without intermittent asthma, were evaluated and then randomized to receive drugs alone or drugs plus SLIT openly for 3 years. The clinical score was assessed yearly during allergen exposure. Pulmonary function testing, methacholine challenge, and skin prick testing were performed at the beginning and end of the study. Results: One hundred forty-four children received SLIT and 72 received drugs only. Dropouts were 9.7% in the SLIT group and 8.3% in the controls. New sensitizations appeared in 34.8% of controls and in 3.1% of SLIT patients (odds ratio, 16.85; 95% confidence interval, 5.73-49.13). Mild persistent asthma was less frequent in SLIT patients (odds ratio, 0.04; 95% confidence interval, 0.01-0.17). There was a significant decrease in clinical scores in the SLIT group vs the control group since the first year. The number of children with a positive methacholine challenge result decreased significantly after 3 years only in the SLIT group. Adherence was 80% or higher in 73.8% of patients. Only 1 patient reported systemic itching. Conclusions: In everyday clinical practice, SLIT reduced the onset of new sensitizations and mild persistent asthma and decreased bronchial hyperreactivity in children with respiratory allergy.	[Canonica, Giorgio W.; Passalacqua, Giovanni] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; [Marogna, Maurizio; Tomassetti, Dante; Bernasconi, Antonella; Colombo, Fausto] Macchi Hosp Fdn, Pneumol Unit, Varese, Italy; [Massolo, Alessandro] Univ Pavia, Dept Anim Biol, I-27100 Pavia, Italy; [Businco, Andrea Di Rienzo; Tripodi, Salvatore] S Pertini Hosp, Pediat Allergy Unit, Rome, Italy	Passalacqua, G (reprint author), Univ Genoa, Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	possalacqua@unige.it	Massolo, Alessandro/I-3437-2012				Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Gillings D, 1991, DRUG INF J, V25, P411; Global Initiative for Asthma, 2006, GLOB STRAT ASTHM MAN; GOOD P, 2002, PERMUTATION TESTS PR; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; KLEIJNEN J, 1994, LANCET, V344, P1347, DOI 10.1016/S0140-6736(94)90699-8; Lombardi C, 2001, ALLERGY, V56, P889; Madonini E, 2003, INT J IMMUNOPATH PH, V16, P73; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2007, INT ARCH ALLERGY IMM, V142, P70, DOI 10.1159/000096001; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Passalacqua G, 2007, PEDIATR ALLERGY IMMU, V18, P58, DOI 10.1111/j.1399-3038.2006.00471.x; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; SCADDING GK, 2003, COCHRANE DB SYST REV, V2, DOI UNSP CD002893; Siegel S., 1998, NONPARAMETRIC STAT B; Sokal RR, 1995, BIOMETRY PRINCIPLES; Sopo SM, 2004, ARCH DIS CHILD, V89, P620, DOI 10.1136/adc.2003.030411; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; Tripodi S, 2006, INT ARCH ALLERGY IMM, V139, P149, DOI 10.1159/000090391; Wilson DR, 2003, COCHRANE DB SYST REV, V2	34	107	117	0	2	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	AUG	2008	101	2					206	211				6	Allergy; Immunology	Allergy; Immunology	336LU	WOS:000258366100015	18727478	
J	Zock, JP; Plana, E; Jarvis, D; Anto, JM; Kromhout, H; Kennedys, SM; Kuenzli, N; Villani, S; Olivieri, M; Toren, K; Radon, K; Sunyer, J; Dahlman-Hoglund, A; Norbaeck, D; Kogevinas, M				Zock, Jan-Paul; Plana, Estel; Jarvis, Deborah; Anto, Josep M.; Kromhout, Hans; Kennedys, Susan M.; Kuenzli, Nino; Villani, Simona; Olivieri, Mario; Toren, Kjell; Radon, Katja; Sunyer, Jordi; Dahlman-Hoglund, Anna; Norbaeck, Dan; Kogevinas, Manolis			The use of household cleaning sprays and adult asthma - An international longitudinal study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway irritants; epidemiology; incidence; ECRHS	RESPIRATORY HEALTH SURVEY; HYDROCHLORIC-ACID; EXPOSURE; CLEANERS; PRODUCTS; RISK; SYMPTOMS; MIXTURE	Rationale Cleaning work and professional use of certain cleaning products have been associated with asthma, but respiratory effects of nonprofessional home cleaning have rarely been studied. Objectives: To investigate the risk of new-onset asthma in relation to the use of common household cleaners. Methods: Within the follow-up of the European Community Respiratory Health Survey in 10 countries, we identified 3,503 persons doing the cleaning in their homes and who were free of asthma at baseline. Frequency of use of 15 types of cleaning products was obtained in a face-to-face interview at follow-up. We studied the incidence of asthma defined as physician diagnosis and as symptoms or medication usage at follow-up. Associations between asthma and the use of cleaning products were evaluated using multivariable Cox proportional hazards or log-binomial regression analysis. Measurements and Main Results: The use of cleaning sprays at least weekly (42 70 of participants) was associated with the incidence of asthma symptoms or medication (relative risk [RR], 1.49; 95070 confidence interval [Cl], 1.12-1.99) and wheeze (RR, 1.39; 95 % Cl, 1.06-1.80). The incidence of physician-diagnosed asthma was higher among those using sprays at least 4 days per week (RR, 2.11; 95% Cl, 1.15-3.89). These associations were consistent for subgroups and not modified by atopy. Dose-response relationships (P < 0.05) were apparent for the frequency of use and the number of different sprays. Risks were predominantly found for the commonly used glass-cleaning, furniture, and air-refreshing sprays. Cleaning products not applied in spray form were not associated with asthma. Conclusions: Frequent use of common household cleaning sprays may be an important risk factor for adult asthma.	CREAL, IMIM, E-08003 Barcelona, Spain; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Resp Epidemiol & Publ Hlth Grp, London, England; Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, Spain; Univ Utrecht, Inst Risk Assessment Sci, Environm Epidemiol Div, Utrecht, Netherlands; Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V5Z 1M9, Canada; ICREA, Barcelona, Spain; Univ Pavia, Dept Hlth Sci, Sect Epidemiol & Med Stat, I-27100 Pavia, Italy; Univ Verona, Dept Med & Publ Hlt, Unit Occupat Med, I-37100 Verona, Italy; Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden; Univ Munich, Inst Occupat & Environm Med, Munich, Germany; Uppsala Univ, Dept med Sci Occupat & Environm Med, Uppsala, Sweden; Univ Crete, Sch Med, Dept Social Med, Iraklion, Crete, Greece	Zock, JP (reprint author), CREAL, IMIM, Dr Aiguader 88, E-08003 Barcelona, Spain.	jpzock@imim.es	Ciccone, Giovannino/K-3136-2016; Burgos, Felip/E-5734-2015; Kromhout, Hans/A-9159-2008; Kogevinas, Manolis/C-3918-2017; Sunyer, J/G-6909-2014; Jarvis, Deborah/E-6494-2011; bucca, caterina/C-9886-2009; Kunzli, Nino/F-7195-2014; Sanchez-Ramos, Jose Luis/G-1259-2011	Ciccone, Giovannino/0000-0001-7644-9574; Burgos, Felip/0000-0002-4938-4581; Sunyer, J/0000-0002-2602-4110; ROMANO, Canzio/0000-0001-5294-9793; bucca, caterina/0000-0002-9941-9236; Kunzli, Nino/0000-0001-8360-080X; Sanchez-Ramos, Jose Luis/0000-0001-7187-9989; Bono, Roberto/0000-0002-2471-6594; Basagana, Xavier/0000-0002-8457-1489; Corsico, Angelo Guido/0000-0002-8716-4694; Rolla, Giovanni/0000-0001-5997-7172; /0000-0003-2517-6515	NHLBI NIH HHS [1R01HL062633]		Baldwin CM, 1999, TOXICOL IND HEALTH, V15, P403, DOI 10.1177/074823379901500314; Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Basagana X, 2004, AM J EPIDEMIOL, V160, P178, DOI 10.1093/aje/kwh186; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DESCHAMPS D, 1994, CHEST, V105, P1895, DOI 10.1378/chest.105.6.1895; *EUR AER FED, 2006, EUR AER PROD 2005; Fedoruk MJ, 2005, J EXPO ANAL ENV EPID, V15, P534, DOI 10.1038/sj.jea.7500431; Gorguner M, 2004, INHAL TOXICOL, V16, P87, DOI 10.1080/08958370490265004; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Mapp CE, 2000, EUR RESPIR J, V16, P570, DOI 10.1034/j.1399-3003.2000.016003570.x; Medina M, 2000, EUR RESPIR J, V16, pS520; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; Nazaroff WW, 2004, ATMOS ENVIRON, V38, P2841, DOI 10.1016/j.atmosenv.2004.02.040; Nielsen J, 1999, OCCUP MED-OXFORD, V49, P291, DOI 10.1093/occmed/49.5.291; Pekkanen J, 2006, J CLIN EPIDEMIOL, V59, P281, DOI 10.1016/j.jclinepi.2005.07.013; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Sherriff A, 2005, THORAX, V60, P45, DOI 10.1136/thx.2004.021154; Tanen DA, 1999, NEW ENGL J MED, V341, P848, DOI 10.1056/NEJM199909093411115; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; ZOCK J, 2005, EUR RESP J S49, V26, pS207; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	24	107	108	0	28	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2007	176	8					735	741		10.1164/rccm.200612-17930C		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	220DF	WOS:000250136400004	17585104	
J	Olin, AC; Bake, B; Toren, K				Olin, Anna-Carin; Bake, Bjorn; Toren, Kjell			Fraction of exhaled nitric oxide at 50 mL/s - Reference values for adult lifelong never-smokers	CHEST			English	Article						allergy; asthma; practice	AGE; AIR; SENSITIZATION; SYMPTOMS; CHILDREN; HEIGHT; ASTHMA; ATOPY	Background: The measurement of fractional exhaled nitric oxide (FENO) is used as a marker of airway inflammation. The aim of this study was to establish reference values of FENO for adults. Methods: FENO at a flow rate of 50 mL/s was analyzed in 3,376 adults using a chemiluminescence analyzer according to American Thoracic Society/European Respiratory Society guidelines. Blood samples were analyzed, and atopy was defined as the presence of specific IgE. All subjects responded to a respiratory questionnaire. Those who had never smoked (n = 1,803) were selected for this study. After the exclusion of subjects with physician-diagnosed asthma, asthma symptoms, ever wheezing, dry cough, or use of inhaled steroids, 1,131 healthy never-smokers remained, including 845 nonatopic and 286 atopic subjects. Results: Based on multiple regression modeling, we propose the following reference equation for healthy never-smoking adults: Ln(FENO) = 0.057 + 0.013 x height (in centimeters) + 0.0088 x age (in years). The residual SD was 0.51, and the explanatory value was 9%. In a model, based on nonatopic subjects alone, the reference equation obtained was slightly different, as follows: Ln(FENO) = -0.0026 + 0.013 x height (in centimeters) + 0.010 x age (in years). The residual SD for this equation was 0.48, and the explanatory value was 11%. Conclusions: Normal values of FENO for adults may be predicted on the basis of age and height. However, as the reference equations only account for about 9 to 11% of the variation, the most important information that could be extracted from the study is that the upper limits of FENO range from 24.0 to 54.0 parts per billion, depending on age and height.	Sahlgrens Univ Hosp, Dept Occupat & Environm Med, SE-40530 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Resp Med & Allergol, SE-40530 Gothenburg, Sweden	Olin, AC (reprint author), Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Box 414, SE-40530 Gothenburg, Sweden.	anna-carin.olin@amm.gu.se					ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; Baranowska B, 2006, FRONT NEUROENDOCRIN, V27, P54, DOI 10.1016/j.yfrne.2006.03.110; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69; Grasemann H, 2003, AM J RESP CRIT CARE, V167, P1113, DOI 10.1164/rccm.200211-1342OC; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Haight RR, 2006, LUNG, V184, P113, DOI 10.1007/s00408-005-2570-3; Langhammer A, 2001, EUR RESPIR J, V18, P770, DOI 10.1183/09031936.01.00255301; Malmberg LP, 2006, PEDIATR PULM, V41, P635, DOI 10.1002/ppul.20417; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; Olin AC, 2004, CLIN EXP ALLERGY, V34, P221, DOI 10.1111/j.1365-2222.2004.01888.x; Olin AC, 2001, RESP MED, V95, P153, DOI 10.1053/rmed.2000.1010; Olin AC, 2006, CHEST, V130, P1319, DOI 10.1378/chest.130.5.1319; Olivieri M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-94; Pearce N, 1999, THORAX, V54, P268; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600	19	107	119	0	3	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2007	131	6					1852	1856		10.1378/chest.06-2928		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	180CD	WOS:000247336600038	17565022	
J	Jahnsen, FL; Strickland, DH; Thomas, JA; Tobagus, IT; Napoli, S; Zosky, GR; Turner, DJ; Sly, PD; Stumbles, PA; Holt, PG				Jahnsen, Frode L.; Strickland, Deborah H.; Thomas, Jennifer A.; Tobagus, Iriani T.; Napoli, Sylvia; Zosky, Graeme R.; Turner, Debra J.; Sly, Peter D.; Stumbles, Philip A.; Holt, Patrick G.			Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus	JOURNAL OF IMMUNOLOGY			English	Article							INHALED ANTIGEN; LYMPH-NODES; RESPONSES; EXPOSURE; INHIBITION; INDUCTION; TOLERANCE; ASTHMA; PHASE; MICE	An increase in the tempo of local dendritic cell (DC)-mediated immune surveillance is a recognized feature of the response to acute inflammation at airway mucosal surfaces, and transient up-regulation of the APC functions of these DC preceding their emigration to regional lymph nodes has recently been identified as an important trigger for T cell-mediated airway tissue damage in diseases such as asthma. In this study, using a rat model, we demonstrate that the kinetics of the airway mucosal DC (AMDC) response to challenge with heat-killed bacteria is considerably more rapid and as a consequence more effectively compartmentalized than that in recall responses to soluble Ag. Notably, Ag-bearing AMDC expressing full APC activity reach regional lymph nodes within 30 min of cessation of microbial exposure, and in contrast to recall responses to nonpathogenic Ags, there is no evidence of local expression of APC activity within the airway mucosa preceding DC emigration. We additionally demonstrate that, analogous to that reported in the gut, a subset of airway intraepithelial DC extend their processes into the airway lumen. This function is constitutively expressed within the AMDC population, providing a mechanism for continuous immune surveillance of the airway luminal surface in the absence of "danger", signals.	Univ Western Australia, Telethon Inst Child Hlth Res, Div Cell Biol, Perth, WA 6872, Australia; Univ Oslo, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0316 Oslo, Norway; Rikshosp Radiumhosp Med Ctr, Pathol Clin, Oslo, Norway	Holt, PG (reprint author), Univ Western Australia, Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Sly, Peter/F-1486-2010; Holt, Patrick/H-1548-2011; Zosky, Graeme/B-2048-2014	Sly, Peter/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935; Zosky, Graeme/0000-0001-9039-0302			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOLT PG, 1994, J IMMUNOL, V153, P256; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Legge KL, 2003, IMMUNITY, V18, P265, DOI 10.1016/S1074-7613(03)00023-2; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Vermaelen KY, 2001, J EXP MED, V193, P51	19	107	112	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	NOV 1	2006	177	9					5861	5867				7	Immunology	Immunology	097VN	WOS:000241477400014	17056510	
J	Kulkarni, N; Pierse, N; Rushton, L; Grigg, J				Kulkarni, Neeta; Pierse, Nevil; Rushton, Lesley; Grigg, Jonathan			Carbon in airway macrophages and lung function in children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FINE-PARTICLE DEPOSITION; INDUCED SPUTUM; ALVEOLAR MACROPHAGES; PHYSICAL-ACTIVITY; POLLUTION; ASTHMA; INHALATION; RETENTION; EXPOSURE; COTININE	Background Epidemiologic studies indirectly suggest that the inhalation of carbonaceous particulate matter impairs lung function in children. Using the carbon content of airway macrophages as a marker of individual exposure to particulate matter derived from fossil fuel, we sought direct evidence of this association. Methods Airway macrophages were obtained from healthy children through sputum induction, and the area of airway macrophages occupied by carbon was measured. Lung function was measured with the use of spirometry. We modeled the exposure to primary particulate matter ( PM) that is less than 10 mu m in aerodynamic diameter (PM10) at or near each child's home address. Linear regression was used to evaluate associations between carbon content of alveolar macrophages and variables that may affect individual exposure. To determine whether lung function that is reduced for other reasons is associated with an increase in the carbon content of airway macrophages, we also studied children with severe asthma. Results We were able to assess the carbon content of airway macrophages in 64 of 114 healthy children (56 percent). Each increase in primary PM10 of 1.0 mu g per cubic meter was associated with an increase of 0.10 mu m(2) (95 percent confidence interval, 0.01 to 0.18) in the carbon content of airway macrophages, and each increase of 1.0 mu m(2) in carbon content was associated with a reduction of 17 percent (95 percent confidence interval, 5.6 to 28.4 percent) in forced expiratory volume in one second, of 12.9 percent (95 percent confidence interval, 0.9 to 24.8 percent) in forced vital capacity, and of 34.7 percent ( 95 percent confidence interval, 11.3 to 58.1 percent) in the forced expiratory flow between 25 and 75 percent of the forced vital capacity. The carbon content of airway macrophages was lower in children with asthma than in healthy children. Conclusions There is a dose-dependent inverse association between the carbon content of airway macrophages and lung function in children. We found no evidence that reduced lung function itself causes an increase in carbon content.	Univ Leicester, Dept Infect Immun & Inflammat, Div Child Hlth, Leicester, Leics, England; Univ Leicester, Inst Environm & Hlth, Leicester, Leics, England	Grigg, J (reprint author), Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, London E1 2AT, England.	j.grigg@qmul.ac.uk					AARON DJ, 1993, MED SCI SPORT EXER, V25, P847, DOI 10.1249/00005768-199307000-00014; Alexis NE, 2001, AM J RESP CRIT CARE, V164, P1964; Alexis NE, 2001, AM J PHYSIOL-LUNG C, V280, pL369; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Artinano B, 2004, SCI TOTAL ENVIRON, V334, P111, DOI 10.1016/j.scitotenv.2004.04.032; Bennett WD, 2004, J APPL PHYSIOL, V97, P821, DOI 10.1152/japplphysiol.01403.2003; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1641; Brainard JS, 2002, ENVIRON PLANN A, V34, P695, DOI 10.1068/a34184; Brauer M, 2001, ENVIRON HEALTH PERSP, V109, P1039, DOI 10.2307/3454959; Brightling Christopher E., 2000, American Journal of Respiratory and Critical Care Medicine, V162, P878; Bunn HJ, 2001, THORAX, V56, P932, DOI 10.1136/thorax.56.12.932; Cataldo D, 2001, CHEST, V120, P1815, DOI 10.1378/chest.120.6.1815; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370390205065; FEYERABEND C, 1990, J PHARM PHARMACOL, V42, P450; Finch GL, 2002, INHAL TOXICOL, V14, P1017, DOI 10.1080/08958370290084764; Fireman E, 1999, CHEST, V115, P1720, DOI 10.1378/chest.115.6.1720; FIREMAN E, 1999, CHEST, V116, P588; Fireman EM, 2004, ENVIRON HEALTH PERSP, V112, P1564, DOI 10.1289/ehp.7233; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Edward Avol M. S., 2005, NEW ENGL J MED, V352, P1276; Gibson PG, 2003, THORAX, V58, P116, DOI 10.1136/thorax.58.2.116; HE QC, 1993, ARCH ENVIRON HEALTH, V48, P382; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; JARVIS MJ, 1992, AM J PUBLIC HEALTH, V82, P1225, DOI 10.2105/AJPH.82.9.1225; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KRISKA AM, 1990, DIABETES CARE, V13, P401, DOI 10.2337/diacare.13.4.401; Kulkarni NS, 2005, SCI TOTAL ENVIRON, V345, P23, DOI 10.1016/j.scitotenv.2004.10.016; Lay JC, 1998, AM J RESP CELL MOL, V18, P687; *LEIC CIT COUNC PO, 2000, REV ASS AIR QUAL LEI; MCNEILL AD, 1987, BRIT J ADDICT, V82, P1355; Pavord ID, 1997, THORAX, V52, P498; Pierse N, 2006, THORAX, V61, P216, DOI 10.1136/thx.2004.036418; PILLING M, 2005, PARTICULATE MATTER U, P29; PILLING M, 2005, PARTICULATE MATTER U, P6; POLGAR G, 1979, AM REV RESPIR DIS, V120, P625; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; ROSENTHAL M, 1993, THORAX, V48, P794, DOI 10.1136/thx.48.8.794; STROM KA, 1990, J TOXICOL ENV HEALTH, V29, P377	38	107	113	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 6	2006	355	1					21	30		10.1056/NEJMoa052972		10	Medicine, General & Internal	General & Internal Medicine	060DT	WOS:000238783200004	16822993	
J	Novak, N; Allam, JP; Hagemann, T; Jenneck, C; Laffer, S; Valenta, R; Kochan, J; Bieber, T				Novak, N; Allam, JP; Hagemann, T; Jenneck, C; Laffer, S; Valenta, R; Kochan, J; Bieber, T			Characterization of Fc epsilon RI-bearing CD123(+) blood dendritic cell antigen-2(+) plasmacytoid dendritic cells in atopic dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						plasmacytoid dendritic cells; IgE; Fc epsilon RI; atopic dermatitis; IFN-alpha/beta	EPIDERMAL LANGERHANS CELLS; HIGH-AFFINITY RECEPTOR; PERIPHERAL-BLOOD; ALLERGEN PRESENTATION; ADAPTIVE IMMUNITY; PRESENTING CELLS; IGE RECEPTORS; SERUM IGE; INTERFERON; EXPRESSION	Background: The high-affinity receptor for IgE (FcepsilonRI) on myeloid dendritic cells has been shown to play a major role in atopic dermatitis (AD). Plasmacytoid dendritic cells (pDCs), which are instrumental in the defense of viral infections, are present in reduced amounts in the skin of patients with AD, which is characterized by a high susceptibility to viral infections. Objective: We explored phenotypical and functional characteristics of pDC in the peripheral blood of patients with AD and healthy individuals. Methods: Blood dendritic cell antigen-2(+)CD123(+) pDCs were enriched from the peripheral blood of patients with AD and studied in functional assays. Results: Skin-homing molecules such as cutaneous lymphocyte antigen and L-selectin CD62L were expressed in lower levels on pDCs of patients with AD. pDCs expressed high amounts of IgE-occupied FcepsilonRI. Further, FcepsilonRI aggregation on pDCs impaired the surface expression of MHC I and II, induced the production of IL-10, and enhanced the apoptosis of pDCs. Importantly, FcepsilonRI preactivated pDC produced less IFN-alpha and IFN-beta after stimulation with CpG motifs and enhanced the outcome of immune responses of the T(H)2 type. Conclusion: From these data, we conclude that FcepsilonRI-bearing pDCs from patients with AD (1) are different from pDCs of healthy individuals, (2) might be important in the pathophysiology of AD, and (3) contribute to the enhanced susceptibility of patients with AD to viral infections.	Univ Bonn, Dept Dermatol, Immunol Lab, D-53105 Bonn, Germany; Med Univ Vienna, Dept Pathophysiol, Allgemeines Krankenhaus Wien, Vienna, Austria; Hoffmann La Roche Inc, Dept Metabol Dis, Nutley, NJ USA	Novak, N (reprint author), Univ Bonn, Dept Dermatol, Immunol Lab, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de					Banchereau J, 2003, ANN NY ACAD SCI, V987, P180; Bangert C, 2003, J INVEST DERMATOL, V121, P1409, DOI 10.1111/j.1523-1747.2003.12623.x; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Borkowski TA, 2001, J IMMUNOL, V167, P1290; Cella M, 2000, NAT IMMUNOL, V1, P305, DOI 10.1038/79747; Cella M, 1999, NAT MED, V5, P919; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Duramad O, 2003, BLOOD, V102, P4487, DOI 10.1182/blood-2003-07-2465; Dzionek A, 2002, HUM IMMUNOL, V63, P1133, DOI 10.1016/S0198-8859(02)00752-8; Dzionek A, 2001, J EXP MED, V194, P1823, DOI 10.1084/jem.194.12.1823; Farkas L, 2001, AM J PATHOL, V159, P237, DOI 10.1016/S0002-9440(10)61689-6; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Jahnsen FL, 2000, J IMMUNOL, V165, P4062; JURGENS M, 1995, J IMMUNOL, V155, P5184; Kadowaki N, 2000, J EXP MED, V192, P219, DOI 10.1084/jem.192.2.219; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2003, J EXP MED, V197, P899, DOI 10.1084/jem.20021091; Lambrecht B N, 2001, Curr Opin Allergy Clin Immunol, V1, P51, DOI 10.1097/00130832-200102000-00010; Matsuda H, 2002, AM J RESP CRIT CARE, V166, P1050, DOI 10.1164/rccm.2110066; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1998, J IMMUNOL, V161, P2731; Maurer D, 1997, ADV EXP MED BIOL, V417, P175; Nolan KF, 2004, J IMMUNOL, V172, P2201; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2004, ALLERGY, V59, P5, DOI 10.1046/j.1398-9995.2003.00337.x; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; Novak N, 2001, J IMMUNOL, V167, P797; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Uchida Y, 2001, J ALLERGY CLIN IMMUN, V108, P1005, DOI 10.1067/mai.2001.119741; von Bubnoff D, 2002, J IMMUNOL, V169, P1810; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1067/mai.2003.1775; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x	38	107	112	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					364	370		10.1016/j.jaci.2004.05.038		7	Allergy; Immunology	Allergy; Immunology	847OU	WOS:000223405600024	15316517	
J	Rubin, RN; Navon, L; Cassano, PA				Rubin, RN; Navon, L; Cassano, PA			Relationship of serum antioxidants to asthma prevalence in youth	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						antioxidants; asthma; child; second-hand smoke	NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; KAPPA-B ACTIVATION; CHILDHOOD ASTHMA; REDUCED SELENIUM; DIETARY FACTORS; UNITED-STATES; LUNG-FUNCTION; VITAMIN-C; CHILDREN	The relationship of serum vitamin E, beta-carotene, vitamin C, and selenium to asthma was investigated among 7,505 youth (4-16 years old) in the Third National Health and Nutrition Examination Survey. Logistic regression models adjusted for potentially confounding variables, which generally had no effect on the coefficients for the antioxidants. Serum vitamin E had little or no association with asthma. In separate models, a SD increase in beta-carotene (odds ratio [OR], 0.9; 95% confidence interval [CI], 0.7, 1.0), vitamin C (OR, 0.8; 95% Cl, 0.7,0.9), and selenium (OR, 0.9; 95% Cl, 0.7, 1.1) was associated with a 10-20% reduction in asthma prevalence. Serum cotinine was used to identify youth with no cigarette smoke exposure and passive exposure (7%): Active smokers were too few to be studied further. The selenium-asthma association was stronger in youth who were smoke exposed (p = 0.075). A SD increase in selenium was associated with a 50% reduction in asthma prevalence (OR, 0.5; 95% Cl, 0.2, 1.4) in youth with passive smoke exposure compared with a 10% reduction in youth with no smoke exposure. The findings support an association of antioxidants with prevalent asthma, which for some antioxidants is stronger among children exposed to cigarette smoke.	Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA	Cassano, PA (reprint author), Cornell Univ, Div Nutr Sci, 209 Savage Hall, Ithaca, NY 14853 USA.	pac6@cornell.edu			NHLBI NIH HHS [R03-HL6659, R03 HL066539]		Baker JC, 2000, RESP MED, V94, P925, DOI 10.1053/rmed.2000.0873; BLACKWELL DL, 1999, VITAL HLTH STAT, V10; Bowie AG, 2000, J IMMUNOL, V165, P7180; Burney P, 1997, CIBA F SYMP, V206, P111; Cook DG, 1997, THORAX, V52, P628; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; FLATT A, 1990, THORAX, V45, P95, DOI 10.1136/thx.45.2.95; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; Forastiere F, 2000, THORAX, V55, P283, DOI 10.1136/thorax.55.4.283; Fuhlbrigge AL, 2002, AM J RESP CRIT CARE, V166, P1044, DOI 10.1164/rccm.2107057; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Greene LS, 1999, NUTRITION, V15, P899, DOI 10.1016/S0899-9007(99)00209-9; Gunter EW, 1996, LAB PROCEDURES USED; Hatch GE, 1995, AM J CLIN NUTR S, V61, p625S; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Huang SL, 2001, CLIN EXP ALLERGY, V31, P259, DOI 10.1046/j.1365-2222.2001.00938.x; Jeffery P, 2001, Pediatr Pulmonol Suppl, V21, P3; Jeong DW, 2002, J BIOL CHEM, V277, P17871, DOI 10.1074/jbc.M200808200; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; Misso NLA, 1996, CLIN EXP ALLERGY, V26, P838, DOI 10.1046/j.1365-2222.1996.d01-376.x; Picado C, 2001, ALLERGY, V56, P43, DOI 10.1034/j.1398-9995.2001.00793.x; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu I, 2001, EPIDEMIOL REV, V23, P268; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; Seear M, 1997, EUR RESPIR J, V10, P342, DOI 10.1183/09031936.97.10020342; Shaheen SO, 2001, AM J RESP CRIT CARE, V164, P1823; STONE J, 1989, CLIN SCI, V77, P495; SUNDE R, 2000, BIOCH PHYSL ASPECTS; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401; *US DEP HHS, 2002, NCHS CD ROM SER 11 A, V1; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Willett W., 1998, NUTR EPIDEMIOLOGY; Woods RK, 2003, AM J CLIN NUTR, V78, P414; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; YOUNGMAN L, 1998, BIOMARKERS MED WORKP, P257; 2002, TRENDS ASTHMA MORBID	43	107	116	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 1	2004	169	3					393	398		10.1164/rccm.200301-055OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	767BA	WOS:000188417800016	14630617	
J	Gur, C; Diav-Citrin, O; Shechtman, S; Arnon, J; Ornoy, A				Gur, C; Diav-Citrin, O; Shechtman, S; Arnon, J; Ornoy, A			Pregnancy outcome after first trimester exposure to corticosteroids: a prospective controlled study	REPRODUCTIVE TOXICOLOGY			English	Article						glucocorticosteroids; prednisone; pregnancy; congenital anomalies	SYSTEMIC-LUPUS-ERYTHEMATOSUS; CHILDREN BORN; WOMEN; PREDNISONE; THERAPY; HUMANS; COHORT; ASTHMA; GROWTH	Objective: To evaluate the safety of glucocorticosteroids (GCS) in pregnancy. Study design: The Israeli Teratogen Information Service (TIS) prospectively collected and followed 311 pregnancies counseled regarding systemic use of different GCS in the first trimester. The rate of major congenital anomalies was compared to that of 790 controls who were counseled for non-teratogenic exposure. Results: The rate of major anomalies did not significantly differ between the groups [12/262 = 4.6% (GCS), 19/728 = 2.6% (control), P = 0.116]. There was no case of oral cleft and no pattern of anomalies among the GCS exposed group. Higher rates of miscarriages (11.5% versus 7.0%, P = 0.013) and preterm births (22.7% versus 10.8%, P < 0.001) were observed among the GCS exposed group compared to the controls. GCS exposed infants had a lower median birth weight [3080g versus 3290g, P < 0.001] and were born at an earlier median gestational age [39 weeks versus 40, P < 0.001] compared to the control. Conclusions: The present study supports that GCS do not represent a major teratogenic risk in humans. The study was powered to find a 2.5-fold increase in the overall rate of major anomalies. (C) 2003 Elsevier Inc. All rights reserved.	Israeli Minist Hlth, Israeli Teratogen Informat Serv, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Israeli Minist Hlth, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Anat & Cell Biol, Lab Teratol, IL-91120 Jerusalem, Israel	Diav-Citrin, O (reprint author), Israeli Minist Hlth, Israeli Teratogen Informat Serv, Hadassah Med Sch, POB 12272, IL-91120 Jerusalem, Israel.	diavcit@netvision.net.il					BEHRMAN RE, 1987, NELSON TXB PEDIAT, P268; BRIGGS GG, 2002, DRUGS PREGNANCY LACT, P326; Carmichael SL, 1999, AM J MED GENET, V86, P242, DOI 10.1002/(SICI)1096-8628(19990917)86:3<242::AID-AJMG9>3.0.CO;2-U; CUNNINGHAM FG, 1997, WILLIAMS OBSTETRICS, P2579; Czeizel AE, 1997, TERATOLOGY, V56, P335, DOI 10.1002/(SICI)1096-9926(199711)56:5<335::AID-TERA7>3.0.CO;2-W; Diav-Citrin O, 2001, TERATOLOGY, V63, P186, DOI 10.1002/tera.1033; DOIG RK, 1956, LANCET, V2, P730; FINE LG, 1981, ANN INTERN MED, V94, P667; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; FRASER FC, 1995, TERATOLOGY, V51, P45, DOI 10.1002/tera.1420510107; HARPER PS, 1998, PRACTICAL GENETIC CO, P210; HARRIS JWS, 1956, LANCET, V1, P1045; Heinonen OP, 1977, BIRTH DEFECTS DRUGS, P389; Holmes LB, 1999, TERATOLOGY, V59, P1; Laskin CA, 1997, NEW ENGL J MED, V337, P148, DOI 10.1056/NEJM199707173370302; MINTZ G, 1986, J RHEUMATOL, V13, P732; MOGADAM M, 1981, GASTROENTEROLOGY, V80, P72; Mok CC, 2001, POSTGRAD MED J, V77, P157, DOI 10.1136/pmj.77.905.157; ORNOY A, 1972, TERATOLOGY, V6, P153, DOI 10.1002/tera.1420060206; PARFITT K, 1999, MARTINDALE COMPLETE, P1010; Park-Wyllie L, 2000, TERATOLOGY, V62, P385, DOI 10.1002/1096-9926(200012)62:6<385::AID-TERA5>3.0.CO;2-Z; PIRSON Y, 1985, NEW ENGL J MED, V313, P328; POLLARD JK, 1992, OBSTET GYNECOL, V80, P365; POPERT AJ, 1962, BMJ-BRIT MED J, P967; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; Robert E, 1994, Int J Risk Saf Med, V6, P75, DOI 10.3233/JRS-1994-6201; Rodriguez-Pinilla E, 1998, TERATOLOGY, V58, P2, DOI 10.1002/(SICI)1096-9926(199807)58:1<2::AID-TERA2>3.0.CO;2-4; RUDOLPH AM, 1987, PEDIATRICS, P1291; SCHARDEIN JL, 1993, CHEM INDUCED BIRTH D, P1; SCHATZ M, 1975, JAMA-J AM MED ASSOC, V233, P804, DOI 10.1001/jama.233.7.804; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; WARRELL DW, 1968, LANCET, V1, P117	32	107	112	0	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0890-6238			REPROD TOXICOL	Reprod. Toxicol.	JAN-FEB	2004	18	1					93	101		10.1016/j.reprotox.2003.10.007		9	Reproductive Biology; Toxicology	Reproductive Biology; Toxicology	775YP	WOS:000189088500009	15013068	
J	Arshad, SH; Bateman, B; Matthews, SM				Arshad, SH; Bateman, B; Matthews, SM			Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study	THORAX			English	Article							HOUSE-DUST MITE; EXPOSURE; RISK; INTERVENTION; PREDICTION; PREVALENCE; RHINITIS; AGE	Background: Recent increases in the prevalence of asthma and atopy emphasise the need for devising effective methods for primary prevention in children at high risk of atopy. Method: A birth cohort of genetically at risk infants was recruited in 1990 to a randomised controlled study. Allergen avoidance measures were instituted from birth in the prophylactic group (n=58). Infants were either breast fed with mother on a low allergen diet or given an extensively hydrolysed formula. Exposure to house dust mite was reduced by the use of an acaricide and mattress covers. The control group (n=62) followed standard advice as normally given by the health visitors. At age 8, all 120 children completed a questionnaire and 110 (92%) had all assessments (skin prick test, spirometry, and bronchial challenges). Results: In the prophylactic group eight children (13.8%) had current wheeze compared with 17 (27.4%) in the control group (p=0.08). Respective figures were eight (13.8%) and 20 (32.3%) for nocturnal cough (p=0.02) and 11 of 55 (20.0%) and 29 of 62 (46.8%) for atopy (p=0.003). After adjusting for confounding variables, the prophylactic group was found to be at a significantly reduced risk for current wheeze (odds ratio (OR) 0.26 (95% confidence interval (CI) 0.07 to 0.96)), nocturnal cough (OR 0.22 (95% CI 0.06 to 0.83)), asthma as defined by wheeze and bronchial hyperresponsiveness (OR 0.11 (95% CI 0.01 to 1.02)), and atopy (OR 0.21 (95% CI 0.07 to 0.62)). Conclusion: Strict allergen avoidance in infancy in high risk children reduces the development of allergic sensitisation to house dust mite. Our results suggest that this may prevent some cases of childhood asthma.	St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, England	Arshad, SH (reprint author), St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, England.						ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ASHER MI, 1995, EUR RESPIR J, V8, P383; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; COOKSON W, 1999, NATURE S, V402, pB12; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; Global Initiative for Asthma, 1995, PUBL NIH; HIDE DW, 1991, CLIN EXP ALLERGY, V21, P739, DOI 10.1111/j.1365-2222.1991.tb03204.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; Kjellman NLM, 1998, ALLERGY, V53, P67; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; Pearce N, 1999, THORAX, V54, P268; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; RIDOUT S, 1993, BRIT J CLIN PRACT, V47, P141; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUONIEMI I, 1981, ALLERGY, V36, P236; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	27	107	117	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2003	58	6					489	493		10.1136/thorax.58.6.489		5	Respiratory System	Respiratory System	684HR	WOS:000183199800006	12775858	
J	Celedon, JC; Wright, RJ; Litonjua, AA; Sredl, D; Ryan, L; Weiss, ST; Gold, DR				Celedon, JC; Wright, RJ; Litonjua, AA; Sredl, D; Ryan, L; Weiss, ST; Gold, DR			Day care attendance in early life, maternal history of asthma, and asthma at the age of 6 years	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						day care; maternal history; asthma	LOWER RESPIRATORY ILLNESS; HOUSE-DUST ENDOTOXIN; EARLY-CHILDHOOD; SCHOOL-AGE; RISK; EXPOSURE; CHILDREN; WHEEZE; SENSITIZATION; COCKROACH	Among children not selected on the basis of a parental history of atopy, day care attendance in early life is inversely associated with asthma at school age. We examined the relation between day care in the first year of life and asthma, recurrent wheezing, and eczema at the age of 6 years and wheezing in the first 6 years of life among 453 children with parental history of atopy followed from birth. Among all study participants, day care in the first year of life was inversely associated with eczema (odds ratio [OR] = 0.3, 95% confidence interval [CI] = 0.1-0.8). Day care attendance in early life was associated with a decreased risk of asthma (OR = 0.3, 95% CI = 0.1-0.7) and recurrent wheezing (OR = 0.3, 95% CI = 0.1-0.9) at the age of 6 years and with a decreased risk of any wheezing after the age of 4 years only among children without maternal history of asthma. Among children with maternal history of asthma, day care in early life had no protective effect on asthma or recurrent wheezing at the age of 6 years but was instead associated with an increased risk of wheezing in the first 6 years of life. Our findings suggest that maternal history of asthma influences the relation between day care-related exposures and childhood asthma.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; Dana Farber Canc Inst, Boston, MA 02115 USA	Celedon, JC (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Ryan, Louise/A-4562-2009	Ryan, Louise/0000-0001-5957-2490	NHLBI NIH HHS [KO1 HL04370-01A1]; NIAID NIH HHS [AIEHS35786]		Andersen P.K., 1982, ANN STAT, V10, P1110; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; *CDC, 1995, MMWR-MORBID MORTAL W, V43, P952; Centers for Disease Control and Prevention [CDC], 1998, MMWR-MORBID MORTAL W, V47, P1; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kramer U, 1998, LANCET, V352, P450; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259; THERNEAU TM, 2000, MODELING SURVIVAL DA, P185; WEST J, 1995, DHEW PUBLICATION; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	24	107	109	0	3	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY 1	2003	167	9					1239	1243		10.1164/rccm.200209-1063OC		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	675NC	WOS:000182700600015	12446273	
J	Hauswirth, AW; Natter, S; Ghannadan, M; Majlesi, Y; Schernthaner, GH; Sperr, WR; Buhring, HJ; Valenta, R; Valent, P				Hauswirth, AW; Natter, S; Ghannadan, M; Majlesi, Y; Schernthaner, GH; Sperr, WR; Buhring, HJ; Valenta, R; Valent, P			Recombinant allergens promote expression of CD203c on basophils in sensitized individuals	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						basophils; allergy; recombinant allergens; diagnostic test; E-NPP3; CD203c	FC-EPSILON-RI; HISTAMINE-RELEASE; POLLEN ALLERGENS; BLOOD BASOPHILS; ANTIBODY 97A6; ACTIVATION; GRASS; IGE; DIAGNOSIS; CYCLOSPORINE	Background: Traditionally, the diagnosis of type I allergies is based on clinical data, skin test results, and laboratory test results with allergen extracts. During the past few years, several attempts have been made to refine diagnostic assays in clinical allergy by introducing recombinant allergens and novel markers of IgE-dependent cell activation. Objectives: We have identified the ectoenzyme CD203c as a novel basophil antigen that is upregulated on IgE receptor cross-linkage. In this study A e applied CD203c and a panel of recombinant allergens to establish a novel basophil test that,allows for a reliable quantification of IgE-dependent responses at the effector cell level. Methods: Patients allergic to birch (Bet v, 1, n = 15; Bet v 2, n := 8) and grass (Phl p 1, n = 15; Phl p 2, n = 10; Phl p 5, n = 14) pollen allergens, as well as 10 nonallergic donors, were examined. Basophils were exposed to various concentrations of recombinant allergens for 15 minutes and then examined for expression of CD203c by means of flow cytometry. CD203c upregulation was correlated with the increase in CD63. Results: Exposure to recombinant allergens resulted in a dose-dependent increase in expression of CD203c on peripheral blood basophils in sensitized individuals, whereas no increase,was seen in healthy control subjects. The effects of the recombinant allergens on CD203c expression were also time dependent. There was a good correlation between allergen-induced upregulation of CD203c and upregulation of CD63 (R = 0.76). Conclusion: Flow cytometric quantitation of CD203c on blood basophils exposed to recombinant allergens is a useful approach to determine the allergic state in sensitized individuals and represents a basis for a sensitive novel allergy test.	Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, A-1090 Vienna, Austria; Univ Vienna, Inst Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 2, Div Angiol, A-1090 Vienna, Austria; Univ Tubingen, Dept Internal Med 2, Div Hematol & Immunol, Tubingen, Germany	Valent, P (reprint author), Univ Vienna, Dept Internal Med 1, Div Hematol & Hemostaseol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.						BALL T, 1994, J BIOL CHEM, V269, P28323; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P292; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BREITENEDER H, 1989, EMBO J, V8, P1935; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Buhring HJ, 1999, BLOOD, V94, P2343; CIRILLO R, 1990, J IMMUNOL, V144, P3891; DATTWYLER R, 1985, ALLERGY, P599; GANE P, 1995, CYTOMETRY, V19, P361, DOI 10.1002/cyto.990190411; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; KATHO N, 2000, J CLIN INVEST, V105, P183; Kay A. B., 1997, ALLERGY ALLERGIC DIS; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MODDERMAN PW, 1989, LEUKOCYTE TYPING, V4, P1042; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; PELIKAN Z, 1983, ANN ALLERGY, V51, P395; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; SOBOTKA AK, 1979, J IMMUNOL, V122, P511; Sperr WR, 1997, INT ARCH ALLERGY IMM, V114, P68; SUSANI M, 1995, BIOCHEM BIOPH RES CO, V215, P250, DOI 10.1006/bbrc.1995.2460; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; VALENTI JAM, 1995, ENCYC ENVIR, V7, P1; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4	33	107	112	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					102	109		10.1067/mai.2002.125257		8	Allergy; Immunology	Allergy; Immunology	574CF	WOS:000176870300020	12110828	
J	Deykin, A; Massaro, AF; Drazen, JM; Israel, E				Deykin, A; Massaro, AF; Drazen, JM; Israel, E			Exhaled nitric oxide as a diagnostic test for asthma - Online versus offline techniques and effect of flow rate	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						nitric oxide; asthma; diagnosis	REPEATED SPIROMETRY; INHALATION; COLLECTION; AIR; NO	Measurement of the fraction of exhaled nitric oxide (FENO) has been proposed as a noninvasive assessment of asthmatic airway inflammation. The influence of the expiratory flow rate during the collection maneuver on the ability of FENO to discriminate healthy subjects from those with asthma is unknown. We compared online and offline measurement of FENO at different flow rates. FENO was collected with expiratory flows of 50-500 ml/second in 34 patients with asthma (PC20 of less than 8 mg/ml) and 28 healthy subjects (PC20 of more than 10 mg/ml) using offline collection techniques. In a subgroup of 18 individuals with asthma and 17 healthy subjects, we additionally measured FENO at multiple expiratory flow rates (47-250 ml/second) using online methods. FENO fell with an increasing expiratory flow rate; FENO was higher in subjects with asthma as compared with healthy subjects at each flow rate studied with both techniques (p < 0.001). Receiver operating characteristic (ROC) curves for the diagnosis of asthma indicated that FENO is a robust discriminator between individuals with asthma and healthy subjects (area under the ROC curves 0.79 +/- 0.06 to 0.86 +/- 0.06, p for significant discrimination < 0.0001). Neither expiratory flow rate nor collection technique (online versus offline) significantly altered this discriminatory capacity (area under the ROC curves = 0.84 +/- 0.07 with the slowest online method versus 0.80 +/- 0.07 with the fastest offline method, p = 0.46). These data indicate that the choice of expiratory flow rate and collection method can be based on practicality and patient comfort without compromising the utility of this test for asthma.	Brigham & Womens Hosp, Dept Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Deykin, A (reprint author), Brigham & Womens Hosp, Div Pulm, 75 Francis St, Boston, MA 02115 USA.		Drazen, Jeffrey/E-5841-2012		NHLBI NIH HHS [P50-HL-56383]		BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; Canady RG, 1999, AM J RESP CRIT CARE, V159, P311; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806; Delclaux C, 2002, AM J RESP CRIT CARE, V165, P332; Deykin A, 2000, AM J RESP CRIT CARE, V161, P1237; Deykin A, 1998, AM J RESP CRIT CARE, V157, P769; Deykin A, 2000, AM J RESP CRIT CARE, V162, P1685; Georges G, 1999, J ASTHMA, V36, P467, DOI 10.3109/02770909909087289; HANLEY JA, 1983, RADIOLOGY, V148, P839; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kissoon N, 2000, AM J RESP CRIT CARE, V162, P539; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; MASSARO AF, 1998, AM J RESP CRIT CARE, V157, pA614; PULEO PR, 1994, NEW ENGL J MED, V331, P561, DOI 10.1056/NEJM199409013310901; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911; Silkoff PE, 1999, CHEST, V116, P754, DOI 10.1378/chest.116.3.754; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Tobin MJ, 2001, AM J RESP CRIT CARE, V164, P1559; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; [Anonymous], 1987, AM REV RESP DIS, V136, P225	28	107	110	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 15	2002	165	12					1597	1601		10.1164/rccm.2201081		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	566AB	WOS:000176402200007	12070059	
J	Heinrich, J; Gehring, U; Douwes, J; Koch, A; Fahlbusch, B; Bischof, W; Wichmann, HE				Heinrich, J; Gehring, U; Douwes, J; Koch, A; Fahlbusch, B; Bischof, W; Wichmann, HE		INGA-Study Grp	Pets and vermin are associated with high endotoxin levels in house dust	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						pets; vermin; endotoxin; indoor factors; house dust	HAY-FEVER; ALLERGIC SENSITIZATION; EXPOSURE; ASTHMA; CHILDREN; FARMERS; ENVIRONMENT; COMMUNITY; SEVERITY; PROTECT	Background Previous studies have shown that the risk for allergic sensitization is lower in children who grew up on farms and in young adults who were exposed to dogs in early childhood. A higher microbial exposure in general and in particular to endotoxin in early childhood might contribute to this lower risk of atopy. Objective We examined whether the presence of pets or vermin in the home is associated with higher endotoxin concentrations in settled house dust. Methods House dust was sampled in a standardized manner on the living room floors of 454 homes of German children aged 5-10 years (participation rate 61%). Endotoxin was assessed with a quantitative kinetic chromogenic Limulus Amebocyte Lysate (LAL) method. Associations between endotoxin levels, pets and vermin are presented as ratios of the crude and confounder adjusted geometric means (means ratios) in the category of study vs. a reference category using multiple linear regression models. Results Endotoxin concentrations in living room floor dust sampled in homes without pets and vermin were lower (1246 ng per square meter, 1519 no, endotoxin/g dust, n = 157) than those sampled in homes with pets or vermin (2267 ng per square meter, 2200 ng endotoxin/g dust, n = 296). After adjustment for city of residence, season of dust sampling, age of the building and story of the dwelling, means ratios for endotoxin expressed per gram of dust were statistically significantly increased for dog (1.64, 95% Cl 1.09-2.46), for cat (1.50, 95% CI 1.03-2.18) and for cockroach (3.01, 95% CI 1.37-6.60), whereas no major statistically significant associations were found for other pets, ants and mice. Conclusion Keeping a dog or, a cat in the home is consistent with higher exposure to endotoxin and might therefore contribute to the lower risk of atopy in later life.	GSF, Inst Epidemiol, D-85758 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; Univ Utrecht, Inst Risk Assessment Sci, Div Environm & Occupat Hlth, Utrecht, Netherlands; Univ Jena, Dept Indoor Climatol, D-6900 Jena, Germany; Inst Clin Immunol, Erfurt, Germany	Heinrich, J (reprint author), GSF, Inst Epidemiol, POB 1129, D-85758 Neuherberg, Germany.			Douwes, Jeroen/0000-0003-3599-4036; Gehring, Ulrike/0000-0003-3612-5780			Bischof W, 2000, P HLTH BUILDINGS, V1, P251; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; Douwes J, 1997, INT J OCCUP ENV HEAL, V3, pS26; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; HEILEMANN KJ, 1999, GESUNDHEITS INGENIEU, V120, P239; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HINES CJ, 1998, BIOAEROSOLS PAPERS A, P146; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Martinez FD, 1999, LANCET S2, V354, pSII12; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O., 1997, INT J OCCUP ENV HL S, V3, P18; Nowak D, 1998, ARBEITSMED SOZIALMED, V33, P233; PARK JH, 2000, AM J RESP CRIT CARE, V161, pA908; Pearce N, 2000, J Epidemiol Biostat, V5, P5; Richter K, 1999, ALLERGOLOGIE, V22, P14; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Shaheen SO, 1996, BRIT MED J, V313, P969; SMID T, 1992, AM REV RESPIR DIS, V146, P1474; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; THORNE PS, 2000, AM J RESP CRIT CARE, V161, P1; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	30	107	107	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	DEC	2001	31	12					1839	1845		10.1046/j.1365-2222.2001.01220.x		7	Allergy; Immunology	Allergy; Immunology	503NP	WOS:000172804800008	11737034	
J	Marple, BF				Marple, BF			Allergic fungal rhinosinusitis: Current theories and management strategies	LARYNGOSCOPE			English	Review						fungus; allergy; rhinosinusitis	NEWLY RECOGNIZED FORM; ASPERGILLUS-SINUSITIS; SURGICAL-MANAGEMENT; IMMUNOTHERAPY; DIAGNOSIS; EXPERIENCE; ORGANISMS; THERAPY; DISEASE; CT	The combination of nasal polyposis, crust formation, and sinus cultures yielding Aspergillus was first noted in 1976 by Safirstein,(1) who observed the clinical similarity that this constellation of findings shared with allergic bronchopulmonary Aspergillosis (ABPA). Eventually this disease came to be known as allergic fungal rhinosinusitis (AFS), As clinical evidence of AFS accumulated, controversy regarding its etiology, pathogenesis, natural history, and appropriate treatment naturally emerged. Despite past and current efforts, many of these controversies remain incompletely resolved, but continuing clinical study has illuminated some aspects of the disease and has Zed to an improved understanding of AFS and its treatment. Fungi associated with the development of AFS are ubiquitous and predominantly of the dematiaceous family, The eosinophilic host response to the presence of these fungi within the nose and paranasal sinuses gives rise to those clinical manifestations of the disease (nasal polyps, expansile mucocele formation, allergic fungal mucin, etc.). Exposure alone to these fungi, however, appears to be insufficient to initiate the disease. At the present time it is likely that initiation of the inflammatory cascade leading to AFS is a multifactorial event, requiring the simultaneous occurrence of such things as IgE-mediated sensitivity (atopy), specific T-cell HLA receptor expression, exposure to specific fungi, and aberration of local mucosal defense mechanisms. A variety of treatment plans for AFS have emerged, but the potential for recidivism remains well recognized, ranging from 10% to nearly 100% suggesting the need for continued study of this disease and fueling present controversy. This article is intended to review current data and theories regarding the pathophysiology of AFS, as well as the role of various surgical and nonsurgical forms of therapy.	Parkland Mem Hosp, Dept Otolaryngol, Dallas, TX USA; Dallas Vet Adm Hosp, Dept Otolaryngol, Dallas, TX USA	Marple, BF (reprint author), Univ Texas, SW Med Ctr, Dept Otolaryngol Head & Neck Surg, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.						ALLPHIN L, 1991, LARYNGOSCOPE, V10, P815; Bent JP, 1996, LARYNGOSCOPE, V106, P1331, DOI 10.1097/00005537-199611000-00005; Bent JP, 1996, ALLERGY ASTHMA PROC, V17, P259, DOI 10.2500/108854196778662273; BENT JP, 1994, OTOLARYNG HEAD NECK, V111, P580, DOI 10.1016/S0194-5998(94)70525-9; Berrettini S, 1996, Acta Otorhinolaryngol Ital, V16, P447; Carter KD, 1999, AM J OPHTHALMOL, V127, P189, DOI 10.1016/S0002-9394(98)00371-7; Chrzanowski RR, 1997, ANN ALLERG ASTHMA IM, V79, P431; CODY DT, 1994, LARYNGOSCOPE, V104, P1074; COREY J, 1995, OTOLARYNGOL HEAD NEC, P110; COREY JP, 1992, OTOLARYNG CLIN N AM, V25, P225; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DESHAZO RD, 1997, J ALLERGY CLIN IMMUN, V99, P4755; Deshpande R B, 1995, J Assoc Physicians India, V43, P98; Feger TA, 1997, ANN ALLERG ASTHMA IM, V79, P221; Ferguson BJ, 2000, OTOLARYNG CLIN N AM, V33, P441; Ferguson BJ, 1998, ARCH OTOLARYNGOL, V124, P1174; FERGUSON BJ, 1993, 1993 ANN M AM AC OT, P29; Folker RJ, 1998, LARYNGOSCOPE, V108, P1623, DOI 10.1097/00005537-199811000-00007; GREENBERGER PA, 1993, ALLERGY PRINCIPLES P, P1395; Gungor A, 1998, Ear Nose Throat J, V77, P207; Jackson CG, 1997, AM J OTOL, V18, P198; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KING HC, 1998, ALLERGY ENT PRACTICE, P227; Klapper SR, 1997, OPHTHALMOLOGY, V104, P2094; Kupferberg SB, 1997, OTOLARYNG HEAD NECK, V117, P35, DOI 10.1016/S0194-5998(97)70203-1; LAMB D, 1982, J PATHOL, V137, P56; LOURY MC, 1993, ARCH OTOLARYNGOL, V119, P1042; Lydiatt W M, 1994, Ear Nose Throat J, V73, P402; Mabry RL, 1999, OTOLARYNG HEAD NECK, V121, P252, DOI 10.1016/S0194-5998(99)70180-4; Mabry RL, 1997, OTOLARYNG HEAD NECK, V117, P367, DOI 10.1016/S0194-5998(97)70128-1; Mabry RL, 1995, OTOLARYNG HEAD NECK, V113, P721, DOI 10.1016/S0194-5998(95)70011-0; Mabry RL, 2000, OTOLARYNG HEAD NECK, V122, P104, DOI 10.1016/S0194-5998(00)70153-7; Mabry RL, 1998, OTOLARYNG HEAD NECK, V119, P648, DOI 10.1016/S0194-5998(98)70027-0; Mabry RL, 1997, OTOLARYNG HEAD NECK, V116, P31, DOI 10.1016/S0194-5998(97)70348-6; Manning SC, 1997, LARYNGOSCOPE, V107, P170, DOI 10.1097/00005537-199702000-00007; MANNING SC, 1989, LARYNGOSCOPE, V99, P681; Manning SC, 1998, LARYNGOSCOPE, V108, P1485, DOI 10.1097/00005537-199810000-00012; MANNING SC, 1993, LARYNGOSCOPE, V103, P717; MANNING SC, 1991, ARCH OTOLARYNGOL, V117, P174; Marple BF, 1998, AM J RHINOL, V12, P263, DOI 10.2500/105065898781390037; Marple BF, 2000, OTOLARYNG CLIN N AM, V33, P409; Marple BF, 1999, AM J RHINOL, V13, P191, DOI 10.2500/105065899781389740; Marple BF, 2000, AM J RHINOL, V14, P223, DOI 10.2500/105065800779954482; MARPLE BF, 1999, CURR OPIN OTOLARYNGO, V7, P383, DOI 10.1097/00020840-199912000-00018; MCGUIRT WF, 1979, LARYNGOSCOPE, V89, P1563; *MED EC CO, 1999, PHYS DESK REF; MILLAR JW, 1981, THORAX, V36, P710; Mirante J P, 1998, Ear Nose Throat J, V77, P678; Mukherji SK, 1998, RADIOLOGY, V207, P417; Nussenbaum B, 2001, OTOLARYNG HEAD NECK, V124, P150, DOI 10.1067/mhn.2001.112573; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877; ROBSON JMB, 1989, AUST NZ J MED, V19, P351, DOI 10.1111/j.1445-5994.1989.tb00278.x; SAFIRSTEIN BH, 1976, CHEST, V70, P788, DOI 10.1378/chest.70.6.788; SARTI EJ, 1988, LARYNGOSCOPE, V98, P632; SCHANADIG VJ, 1999, ACTA CYTOL, V43, P268; Schubert MS, 1998, J ALLERGY CLIN IMMUN, V102, P395, DOI 10.1016/S0091-6749(98)70126-5; SCHWIETZ LA, 1992, ALLERGY PROC, V13, P3, DOI 10.2500/108854192778878980; SOM PM, 1993, RADIOL CLIN N AM, V31, P33; Torres C, 1996, HUM PATHOL, V27, P793, DOI 10.1016/S0046-8177(96)90451-7; TRAVIS WD, 1991, HUM PATHOL, V22, P1240, DOI 10.1016/0046-8177(91)90106-Y; TSIMIKAS S, 1994, J ALLERGY CLIN IMMUN, V94, P264, DOI 10.1016/0091-6749(94)90051-5; ZINREICH SJ, 1988, RADIOLOGY, V169, P439	62	107	116	1	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0023-852X			LARYNGOSCOPE	Laryngoscope	JUN	2001	111	6					1006	1019		10.1097/00005537-200106000-00015		14	Medicine, Research & Experimental; Otorhinolaryngology	Research & Experimental Medicine; Otorhinolaryngology	439GR	WOS:000169102900014	11404613	
J	Vadas, P; Wai, Y; Burks, W; Perelman, B				Vadas, P; Wai, Y; Burks, W; Perelman, B			Detection of peanut allergens in breast milk of lactating women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BOVINE BETA-LACTOGLOBULIN; COWS MILK; MATERNAL DIET; NUT ALLERGY; FED INFANTS; FOOD; CHILDREN; MOTHERS; EGG; HYPERSENSITIVITY	Context Most individuals who react to peanuts do so on their first known exposure. A potential but unproven route of occult exposure resulting in sensitization to peanut is via breast milk during lactation. Objective To investigate the ability of maternal dietary peanut protein to pass into breast milk during lactation, Design and Setting Clinical investigation conducted at 2 North American hospitals from March 1999 to October 2000, Patients Twenty-three healthy, lactating women aged 21 to 35 years. Intervention Each woman consumed 50 g of dry roasted peanuts, after which breast milk samples were collected at hourly intervals. Main Outcome Measures Presence in breast milk of total peanut protein, analyzed by a sandwich enzyme-linked immunosorbent assay, and 2 major peanut allergens, Ara h 1 and Ara h 2, detected by immunoblot analysis. Results Peanut protein was detected in 11 of 23 subjects, It was detected in 10 subjects within 2 hours of ingestion and in 1 subject within 6 hours. The median peak peanut protein concentration in breast milk was 200 ng/mL (mean, 222 ng/mL; range, 120-430 ng/mL). Both major peanut allergens Ara h 1 and Ara h 2 were detected. Conclusions Peanut protein is secreted into breast milk of lactating women following maternal dietary ingestion, Exposure to peanut protein during breastfeeding is a route of occult exposure that may result in sensitization of at-risk infants.	Univ Toronto, St Michaels Hosp, Div Clin Immunol & Allergy, Toronto, ON M5B 1W8, Canada; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Little Rock, AR 72205 USA	Vadas, P (reprint author), Univ Toronto, St Michaels Hosp, Div Clin Immunol & Allergy, Room 8-161,Victoria Wing,30 Bond St, Toronto, ON M5B 1W8, Canada.						ASSEM ESK, 1990, BRIT MED J, V300, P1377; AXELSSON I, 1986, ACTA PAEDIATR SCAND, V75, P702, DOI 10.1111/j.1651-2227.1986.tb10277.x; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; CANT A, 1985, BRIT MED J, V291, P932; Chirdo FG, 1998, SCAND J GASTROENTERO, V33, P1186; Duchen K, 1991, Adv Exp Med Biol, V310, P427; Ewan PW, 1996, BRIT MED J, V312, P1074; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; Fukushima Y, 1997, AM J CLIN NUTR, V65, P30; GERRARD JW, 1986, ANN ALLERGY, V56, P351; HOST A, 1990, CLIN EXP ALLERGY, V20, P383, DOI 10.1111/j.1365-2222.1990.tb02798.x; Hourihane JO, 1996, BRIT MED J, V313, P518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P1240, DOI 10.1046/j.1365-2222.1997.1520954.x; Hourihane JO, 1998, BRIT MED J, V316, P1271; KILSHAW PJ, 1984, INT ARCH ALLER A IMM, V75, P8; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SORVA R, 1994, J ALLERGY CLIN IMMUN, V93, P787, DOI 10.1016/0091-6749(94)90259-3; Tariq SM, 1996, BRIT MED J, V313, P514; TRONCONE R, 1987, ACTA PAEDIATR SCAND, V76, P453, DOI 10.1111/j.1651-2227.1987.tb10498.x; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x	23	107	113	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	APR 4	2001	285	13					1746	1748		10.1001/jama.285.13.1746		3	Medicine, General & Internal	General & Internal Medicine	415FR	WOS:000167710600028	11277829	
J	Han, JY; Takeshita, K; Utsumi, H				Han, JY; Takeshita, K; Utsumi, H			Noninvasive detection of hydroxyl radical generation in lung by diesel exhaust particles	FREE RADICAL BIOLOGY AND MEDICINE			English	Article						l-band ESR; diesel exhaust particles; nitroxide radical; lung; free radicals; reactive oxygen species; superoxide dismutase	RESPIRATORY-DISTRESS-SYNDROME; REACTIVE OXYGEN METABOLITES; IN-VIVO ESR; OXIDATIVE STRESS; WHOLE MICE; INTRATRACHEAL INSTILLATION; RESONANCE SPECTROSCOPY; NITROXIDE RADICALS; PULSE-RADIOLYSIS; INSPIRED OXYGEN	Diesel exhaust particles (DEP) induce pulmonary tumors, asthma-like symptoms, and the like in experimental animals. The involvement of reactive oxygen species (ROS) is suggested in the injuries induced by DEP, though the generation of ROS has not been proven. The present study provided the first direct evidence of (OH)-O-. generation in the lungs of living mice after intratracheal instillation of DEP, using noninvasive L-band ESR spectroscopy and a membrane-impermeable nitroxyl probe. (OH)-O-. generation is confirmed with the enhancement of in vivo ESR signal decay rate of the probe. The decay rate at mid-thorax was significantly enhanced in DEP-treated mice compared to that in vehicle-treated mice. The enhancement was completely suppressed by the administration of either (OH)-O-. scavengers, catalase, or desferrioxamine, while the administration of SOD further increased the rate. The administration of Fenton's reagents into the lung also enhanced the decay rate of the probe at mid-thorax of mice. These results clearly provided evidence that the intratracheal exposure to DEP in mice produced (OH)-O-. in the lung through an iron-catalyzed reaction of superoxide/H2O2. This first direct evidence of (OH)-O-. generation in DEP-treated mice lung may be utilized to determine treatments for DEP-induced lung injury. (C) 2001 Elsevier Science Inc.	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Biophys, Fukuoka 8128582, Japan	Kyushu Univ, Grad Sch Pharmaceut Sci, Dept Biophys, Fukuoka 8128582, Japan.	utsumi@pch.phar.kyushu-u.ac.jp	U-ID, Kyushu/C-5291-2016				ASMUS KD, 1976, INT J RADIAT BIOL, V29, P211, DOI 10.1080/09553007614550241; BACIC G, 1989, MAGNET RESON MED, V10, P266, DOI 10.1002/mrm.1910100211; BERLINER LJ, 1989, MAGNET RESON MED, V9, P430, DOI 10.1002/mrm.1910090317; BUFFINTON GD, 1992, FREE RADICAL RES COM, V16, P99, DOI 10.3109/10715769209049163; CHENG YS, 1984, AM IND HYG ASSOC J, V45, P547, DOI 10.1202/0002-8894(1984)045<0547:CODEIA>2.3.CO;2; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DRAPER WM, 1986, CHEMOSPHERE, V15, P437, DOI 10.1016/0045-6535(86)90537-0; Eaton GR, 1991, EPR IMAGING IN VIVO; FERRARI M, 1990, BIOCHEM BIOPH RES CO, V166, P168, DOI 10.1016/0006-291X(90)91926-J; FIELDEN EM, 1971, INT J RADIAT BIOL RE, V20, P355, DOI 10.1080/09553007114551241; FINKELSTEIN E, 1984, BIOCHIM BIOPHYS ACTA, V802, P90; Gonzalez PK, 1996, SHOCK, V6, pS23, DOI 10.1097/00024382-199610001-00006; GOODGLICK LA, 1986, CANCER RES, V46, P5558; HALLIWELL B, 1987, ANAL BIOCHEM, V165, P215, DOI 10.1016/0003-2697(87)90222-3; Halliwell B., 1985, FREE RADICALS BIOL M; HEINRICH U, 1986, J APPL TOXICOL, V6, P383, DOI 10.1002/jat.2550060602; HENDERSON RF, 1988, FUND APPL TOXICOL, V11, P546, DOI 10.1016/0272-0590(88)90119-4; HYDE DM, 1985, LAB INVEST, V52, P195; ICHINOSE T, 1995, TOXICOLOGY, V99, P153, DOI 10.1016/0300-483X(94)03013-R; Ichinose T, 1997, INT J ONCOL, V11, P571; ISHIDA S, 1989, PHYS MED BIOL, V34, P1317, DOI 10.1088/0031-9155/34/9/017; IWAI K, 1986, J JPN SOC AIR POLLUT, V21, P38; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; KAMP DW, 1992, FREE RADICAL BIO MED, V12, P293, DOI 10.1016/0891-5849(92)90117-Y; KRISHNA MC, 1992, P NATL ACAD SCI USA, V89, P5537, DOI 10.1073/pnas.89.12.5537; KVEDER M, 1988, MAGNET RESON MED, V8, P241, DOI 10.1002/mrm.1910080302; Liu KJ, 1999, FREE RADICAL BIO MED, V26, P714, DOI 10.1016/S0891-5849(98)00251-2; MASUDA S, 1992, INT CONGR SER, V998, P175; MATUSHITA H, 1986, CARCINOGENIC MUTAGEN, P103; MAUDERLY JL, 1987, FUND APPL TOXICOL, V9, P208, DOI 10.1016/0272-0590(87)90044-3; MCCLELLAN RO, 1987, ANNU REV PHARMACOL, V27, P279; MCCORD JM, 1994, ENVIRON HEALTH PERSP, V102, P57, DOI 10.2307/3432215; MIURA Y, 1995, FREE RADICAL RES, V22, P209, DOI 10.3109/10715769509147540; MIURA Y, 1992, BIOCHEM BIOPH RES CO, V182, P1108, DOI 10.1016/0006-291X(92)91846-I; NAGASHIMA M, 1995, CARCINOGENESIS, V16, P1441, DOI 10.1093/carcin/16.6.1441; NIGAM S, 1976, PHYS ORG CHEM, V85, P2324; Omar B A, 1992, Adv Pharmacol, V23, P109, DOI 10.1016/S1054-3589(08)60964-3; OZAWA T, 1991, J CHEM SOC CHEM COMM, P330, DOI 10.1039/c39910000330; Phumala N, 1999, FREE RADICAL BIO MED, V26, P1209, DOI 10.1016/S0891-5849(98)00314-1; Reymao MSF, 1997, ENVIRON RES, V74, P150, DOI 10.1006/enrs.1997.3740; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Sano T, 1998, DIABETOLOGIA, V41, P1355, DOI 10.1007/s001250051076; SCHUETZLE D, 1986, ANAL CHEM, V58, P1060, DOI 10.1021/ac00124a001; SCHUETZLE D, 1983, ENVIRON HEALTH PERSP, V47, P65, DOI 10.2307/3429500; Schuetzle D, 1986, CARCINOGENIC MUTAGEN, P41; SUBCZYNSKI WK, 1986, MAGNET RESON MED, V3, P747, DOI 10.1002/mrm.1910030510; SUN JD, 1985, FUND APPL TOXICOL, V5, P913, DOI 10.1016/0272-0590(85)90173-3; SUZUKI T, 1990, J JPN SOC AIR POLLUT, V25, P192; SWARTZ HM, 1986, BIOCHIM BIOPHYS ACTA, V888, P82, DOI 10.1016/0167-4889(86)90073-X; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takeshita K, 1999, FREE RADICAL BIO MED, V26, P951, DOI 10.1016/S0891-5849(98)00278-0; TUOMALA MH, 1992, FEBS LETT, V296, P57, DOI 10.1016/0014-5793(92)80402-3; UTSUMI H, 1993, FREE RADICAL RES COM, V19, pS219; UTSUMI H, 1990, BIOCHEM BIOPH RES CO, V172, P1342, DOI 10.1016/0006-291X(90)91597-L; VALLYATHAN V, 1995, AM J RESP CRIT CARE, V152, P1003; VOGL G, 1989, TOXICOL LETT, V47, P17, DOI 10.1016/0378-4274(89)90082-9; White H, 1983, J Appl Toxicol, V3, P332, DOI 10.1002/jat.2550030612; WILLSON RL, 1972, INT J RADIAT BIOL RE, V21, P401, DOI 10.1080/09553007214550471	60	107	111	2	14	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849	1873-4596		FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAR 1	2001	30	5					516	525		10.1016/S0891-5849(00)00501-3		10	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	406HJ	WOS:000167208600007	11182522	
J	Pritchard, JN				Pritchard, JN			The influence of lung deposition on clinical response	JOURNAL OF AEROSOL MEDICINE-DEPOSITION CLEARANCE AND EFFECTS IN THE LUNG			English	Article						asthma; chronic obstructive disease; lung deposition; efficacy; metered dose inhalers	BECLOMETHASONE DIPROPIONATE; BUDESONIDE; PHARMACOKINETICS; TURBUHALER(R); TERBUTALINE	Delivery of more drug to the lung may appear to be a desirable goal in the treatment of asthma and chronic obstructive pulmonary disease, since only 10 to 15% of a drug dose administered via a metered dose inhaler (MDI) reaches the lung. However, increasing the dose of most inhaled drugs may only lead to an increase in side effects, since maximal clinical benefit is usually obtained with the currently recommended dosages. Improving the regional deposition of inhaled drugs may be a more effective way of modifying clinical response. Particle size is the most significant determinant of the deposition pattern of inhaled drugs. Optimum drug delivery to the conducting airways occurs with particles ranging from 2.5 to 6 mum; particles <2.5 <mu>m are deposited mainly in the alveoli where they may exert no pharmacodynamic effect and are rapidly absorbed, increasing the risk of systemic adverse events. Delivery devices can be compared by estimating the lung and systemic exposures, taking into account the efficacy and safety dose-response relationships for the drug-device combination. Current devices have profoundly different lung deposition profiles that could affect clinical efficacy when switching devices. Devices that achieve a high lung to systemic ratio for the inhaled drug are preferable.	Glaxo Wellcome Plc, Uxbridge UB11 1BT, Middx, England	Pritchard, JN (reprint author), Glaxo Wellcome Plc, Stockley Pk W, Uxbridge UB11 1BT, Middx, England.						Arvidsson Peter, 1998, European Respiratory Journal, V12, p67S; Barnes NC, 1998, RESP MED, V92, P95, DOI 10.1016/S0954-6111(98)90039-7; Borgstrom L, 1998, J AEROSOL MED, V11, P55, DOI 10.1089/jam.1998.11.55; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; BUSSE W, 1998, AM J RESP CRIT CARE, V157, pA405; Derendorf H, 1998, J ALLERGY CLIN IMMUN, V101, pS440, DOI 10.1016/S0091-6749(98)70156-3; ENGEL T, 1992, BRIT J CLIN PHARMACO, V33, P439; Harrison L., 1997, European Respiratory Journal Supplement, V10, p349S; Harrison L., 1997, AM J RESP CRIT CAR S, V155, pA666; Jeffery PK, 1998, EUR RESPIR J, V11, P524; Kobrich R, 1994, ANN OCCUP HYG     S1, V38, P15; Lipworth BJ, 1997, EUR J CLIN PHARMACOL, V53, P47, DOI 10.1007/s002280050335; Mackie A. E., 1997, British Journal of Clinical Pharmacology, V43, p540P; MARTONEN TB, 1993, J AEROSOL MED, V6, P251, DOI 10.1089/jam.1993.6.251; PRITCHARD J, 1998, RESP DRUG DELIVERY, V6, P401; PRITCHARD JN, 1996, P 6 C DRUG DEL LUNGS, P101; Rott Z., 1998, European Respiratory Journal, V12, p324S; Seale JP, 1998, RESP MED, V92, P9, DOI 10.1016/S0954-6111(98)90212-8; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839	19	107	108	0	5	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0894-2684			J AEROSOL MED	J. Aerosol Med.-Depos. Clear. Eff. Lung		2001	14			1			S19	S26				8	Public, Environmental & Occupational Health; Respiratory System	Public, Environmental & Occupational Health; Respiratory System	408NQ	WOS:000167332600004	11424889	
J	Wyler, C; Braun-Fahrlander, C; Kunzli, N; Schindler, C; Ackermann-Liebrich, U; Perruchoud, AP; Leuenberger, P; Wuthrich, B				Wyler, C; Braun-Fahrlander, C; Kunzli, N; Schindler, C; Ackermann-Liebrich, U; Perruchoud, AP; Leuenberger, P; Wuthrich, B		Swiss Study Air Pollution Lung Di	Exposure to motor vehicle traffic and allergic sensitization	EPIDEMIOLOGY			English	Article						air pollution; allergies; pollen; traffic density	CHRONIC RESPIRATORY SYMPTOMS; DIESEL EXHAUST PARTICLES; AIR-POLLUTANTS; ADJUVANT ACTIVITY; ASTHMA; POLLUTION; CHILDREN; MICE; POLLEN; ADULTS	We examined the association between the presence of an allergic sensitization and seasonal allergic diseases or symptoms and the exposure to road traffic in Basel, Switzerland. Traffic counts at the domiciles of subjects ranged from 24 to 32,504 cars per 24 hours, with a median of 1,624. To investigate the relation of road traffic and allergies, we matched the data of the traffic inventory of Basel with those of the 820 participants of the SAPALDIA study (Swiss Study on Air Pollution and Lung Diseases in Adults), ages 18-60 years, who had completed a detailed respiratory health questionnaire and had undergone allergy testing (skin prick tests and serologic examinations). We observed a positive association with a sensitization to pollen that was most pronounced among persons with a duration of residence of at least 10 years. The odds ratios (adjusted for educational level, smoking behavior, number of siblings, age, sex, and family history of atopy) for cars, contrasting four exposure categories with the lowest quartile as referent category, were 1.99 [95% confidence interval (CI) = 0.91-4.38], 2.47 (95% CI = 1.06-5.73), and 2.83 (95% CI = 1.26-6.31). These results suggest that living on busy roads is associated with a higher risk for a sensitization to pollen and could possibly he interpreted as an indication for interactions between pollen and air pollutants. We did not, however, find a similar relation between motor vehicle traffic and hay fever or seasonal allergic symptoms, and we saw no trend that increasing traffic exposure was associated with a rise in sensitization rates to indoor allergens.	Univ Basel, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland; Univ Lausanne Hosp, Dept Pneumol, Lausanne, Switzerland; Univ Zurich Hosp, Dept Dermatol, Allergy Unit, CH-8091 Zurich, Switzerland	Braun-Fahrlander, C (reprint author), Univ Basel, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.		Schindler, Christian/D-3472-2015; Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X			AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; *BAUD KANT BAS STA, 1994, GES REG BAS KURZB, P1; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; BRAUNFAHRLANDER C, 1996, NEW TRENDS ALLERGY 4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Chinn S, 1996, EUR J EPIDEMIOL, V12, P155, DOI 10.1007/BF00145501; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Devalia JL, 1997, ALLERGY, V52, P45; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Emberlin J, 1995, CLIN EXP ALLERGY, V25, P33, DOI 10.1111/j.1365-2222.1995.tb00040.x; HELSTAB J, 1998, NO2 IMMISIONEN KANTO; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; JUNKER M, IN PRESS ATMOSPH ENV; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Dolgner R, 1991, EPIDEMIOLOGIE ALLERG, P165; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; Martin BW, 1997, SOZ PRAVENTIV MED, V42, P67, DOI 10.1007/BF01318136; MATSUMUR.Y, 1970, AM REV RESPIR DIS, V102, P430; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RUFFIN J, 1986, CYTOBIOS, V46, P119; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; USSETTI P, 1984, LANCET, V1, P156; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149	35	107	110	3	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	JUL	2000	11	4					450	456		10.1097/00001648-200007000-00015		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	326CD	WOS:000087713600015	10874554	
J	Papadopoulos, NG; Arakawa, H; Carlsen, KH; Custovic, A; Gern, J; Lemanske, R; Le Souef, P; Makela, M; Roberts, G; Wong, G; Zar, H; Akdis, CA; Bacharier, LB; Baraldi, E; van Bever, HP; de Blic, J; Boner, A; Burks, W; Casale, TB; Castro-Rodriguez, JA; Chen, YZ; El-Gamal, YM; Everard, ML; Frischer, T; Geller, M; Gereda, J; Goh, DY; Guilbert, TW; Hedlin, G; Heymann, PW; Hong, SJ; Hossny, EM; Huang, JL; Jackson, DJ; de Jongste, JC; Kalayci, O; Ait-Khaled, N; Kling, S; Kuna, P; Lau, S; Ledford, DK; Lee, SI; Liu, AH; Lockey, RF; Lodrup-Carlsen, K; Lotvall, J; Morikawa, A; Nieto, A; Paramesh, H; Pawankar, R; Pohunek, P; Pongracic, J; Price, D; Robertson, C; Rosario, N; Rossenwasser, LJ; Sly, PD; Stein, R; Stick, S; Szefler, S; Taussig, LM; Valovirta, E; Vichyanond, P; Wallace, D; Weinberg, E; Wennergren, G; Wildhaber, J; Zeiger, RS				Papadopoulos, N. G.; Arakawa, H.; Carlsen, K. -H.; Custovic, A.; Gern, J.; Lemanske, R.; Le Souef, P.; Makela, M.; Roberts, G.; Wong, G.; Zar, H.; Akdis, C. A.; Bacharier, L. B.; Baraldi, E.; van Bever, H. P.; de Blic, J.; Boner, A.; Burks, W.; Casale, T. B.; Castro-Rodriguez, J. A.; Chen, Y. Z.; El-Gamal, Y. M.; Everard, M. L.; Frischer, T.; Geller, M.; Gereda, J.; Goh, D. Y.; Guilbert, T. W.; Hedlin, G.; Heymann, P. W.; Hong, S. J.; Hossny, E. M.; Huang, J. L.; Jackson, D. J.; de Jongste, J. C.; Kalayci, O.; Ait-Khaled, N.; Kling, S.; Kuna, P.; Lau, S.; Ledford, D. K.; Lee, S. I.; Liu, A. H.; Lockey, R. F.; Lodrup-Carlsen, K.; Lotvall, J.; Morikawa, A.; Nieto, A.; Paramesh, H.; Pawankar, R.; Pohunek, P.; Pongracic, J.; Price, D.; Robertson, C.; Rosario, N.; Rossenwasser, L. J.; Sly, P. D.; Stein, R.; Stick, S.; Szefler, S.; Taussig, L. M.; Valovirta, E.; Vichyanond, P.; Wallace, D.; Weinberg, E.; Wennergren, G.; Wildhaber, J.; Zeiger, R. S.			International consensus on (ICON) pediatric asthma	ALLERGY			English	Review						asthma; children; consensus; guidelines; wheeze	INHALED FLUTICASONE PROPIONATE; RANDOMIZED CONTROLLED-TRIAL; GRASS-POLLEN IMMUNOTHERAPY; NITRIC-OXIDE MEASUREMENTS; ACTING BETA-AGONISTS; HOUSE-DUST MITE; LONG-TERM; CHILDHOOD ASTHMA; AIRWAY HYPERRESPONSIVENESS; PRESCHOOL-CHILDREN	Asthma is the most common chronic lower respiratory disease in childhood throughout the world. Several guidelines and/or consensus documents are available to support medical decisions on pediatric asthma. Although there is no doubt that the use of common systematic approaches for management can considerably improve outcomes, dissemination and implementation of these are still major challenges. Consequently, the International Collaboration in Asthma, Allergy and Immunology (iCAALL), recently formed by the EAACI, AAAAI, ACAAI, and WAO, has decided to propose an International Consensus on (ICON) Pediatric Asthma. The purpose of this document is to highlight the key messages that are common to many of the existing guidelines, while critically reviewing and commenting on any differences, thus providing a concise reference. The principles of pediatric asthma management are generally accepted. Overall, the treatment goal is disease control. To achieve this, patients and their parents should be educated to optimally manage the disease, in collaboration with healthcare professionals. Identification and avoidance of triggers is also of significant importance. Assessment and monitoring should be performed regularly to re-evaluate and fine-tune treatment. Pharmacotherapy is the cornerstone of treatment. The optimal use of medication can, in most cases, help patients control symptoms and reduce the risk for future morbidity. The management of exacerbations is a major consideration, independent of chronic treatment. There is a trend toward considering phenotype-specific treatment choices; however, this goal has not yet been achieved.	[Papadopoulos, N. G.] Univ Athens, Dept Allergy, Pediat Clin 2, Athens 11527, Greece; [Arakawa, H.] Gunma Univ, Grad Sch Med, Dept Pediat, Gunma, Japan; [Carlsen, K. -H.] Oslo Univ Hosp, Dept Pediat, Oslo, Norway; [Custovic, A.] Univ Hosp S Manchester NHS Fdn Trust, Resp Res Grp, Manchester, Lancs, England; [Gern, J.] Univ Wisconsin, Sch Med, Dept Pediat, Madison, WI USA; [Lemanske, R.] Univ Wisconsin, Sch Med & Publ Hlth, Div Pediat Allergy Immunol & Rheumatol, Madison, WI USA; [Le Souef, P.] Univ Western Australia, Princess Margaret Hosp, Sch Pediat & Child Hlth, Perth, WA 6009, Australia; [Makela, M.] Univ Helsinki, Cent Hosp, Pediat Unit, Helsinki, Finland; [Roberts, G.] Southampton Univ Hosp NHS Trust, Acad Unit Human Dev & Hlth, Southampton, Hants, England; [Wong, G.] Chinese Univ Hong Kong, Dept Pediat, Sha Tin, Hong Kong, Peoples R China; [Zar, H.] Univ Cape Town, Red Cross War Mem Childrens Hosp, Dept Pediat & Child Hlth, ZA-7925 Cape Town, South Africa; [Akdis, C. A.] Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Bacharier, L. B.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Baraldi, E.] Univ Padua, Dept Pediat, Unit Allergy & Resp Med, Padua, Italy; [Bacharier, L. B.] St Louis Childrens Hosp, St Louis, MO 63178 USA; [van Bever, H. P.] Natl Univ Hlth Syst, Natl Univ Hosp, Childrens Med Inst, Dept Paediat, Singapore, Singapore; [de Blic, J.] Univ Paris 05, AP HP, Serv Pneumol & Allergol Pediat, Paris, France; [Boner, A.] Univ Verona, Dept Paediat, I-37100 Verona, Italy; [Burks, W.] Duke Univ, Med Ctr, Dept Pediat, Div Allergy & Immunol, Durham, NC 27710 USA; [Casale, T. B.] Creighton Univ, Div Allergy & Immunol, Dept Med, Omaha, NE 68178 USA; [Castro-Rodriguez, J. A.] Pontificia Univ Catolica Chile, Sch Med, Santiago, Chile; [El-Gamal, Y. M.] Ain Shams Univ, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Chen, Y. Z.] Capital Inst Pediat, Beijing, Peoples R China; [Everard, M. L.] Sheffield Childrens Hosp, Dept Resp Med, Sheffield, S Yorkshire, England; [Geller, M.] Geller Allergy & Immunol Clin, Rio De Janeiro, Brazil; [Frischer, T.] Univ Childrens Hosp Vienna, Vienna, Austria; [Gereda, J.] Clin Ricardo Palma, Dept Allergy & Immunol, Lima, Peru; [Goh, D. Y.] Natl Univ Singapore Hosp, Dept Paediat, Singapore 117548, Singapore; [Hedlin, G.] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Heymann, P. W.] Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA; [Hong, S. J.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pediat,Childhood Asthma Atopy Ctr, Seoul, South Korea; [Hossny, E. M.] Ain Shams Univ, Childrens Hosp, Pediat Allergy & Immunol Unit, Cairo, Egypt; [Huang, J. L.] Chang Gung Childrens Hosp, Dept Pediat, Div Allergy Asthma & Rheumatol, Tao Yuan, Taiwan; [Jackson, D. J.] Univ Wisconsin, Dept Pediat, Sch Med & Publ Hlth, Madison, WI USA; [de Jongste, J. C.] Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat, Rotterdam, Netherlands; [Kalayci, O.] Hacettepe Univ, Sch Med, Ihsan Dogramaci Childrens Hosp, Pediat Allergy & Asthma Unit, Ankara, Turkey; [Ait-Khaled, N.] Int Union TB & Lung Dis, Algiers, Algeria; [Kling, S.] Univ Stellenbosch, Tygerberg Childrens Hosp, Dept Paediat & Child Hlth, Cape Town, South Africa; [Kuna, P.] Med Univ Lodz, Barlicki Univ Hosp, Dept Med 2, Lodz, Poland; [Lau, S.] Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Ledford, D. K.; Lockey, R. F.] Univ S Florida, Div Allergy Immunol, Tampa, FL USA; [Lee, S. I.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pediat,Environm Hlth Ctr, Seoul, South Korea; [Liu, A. H.] Univ Colorado Denver, Sch Med, Denver, CO USA; [Szefler, S.] Natl Jewish Hlth, Dept Pediat, Denver, CO USA; [Lodrup-Carlsen, K.] Ullevaal Univ Hosp, Dept Paediat, Woman & Child Div, Oslo, Norway; [Morikawa, A.] Gunma Univ, Kita Kanto Allergy Inst, Gunma, Japan; [Lotvall, J.] Univ Gothenburg, Krefting Res Ctr, Gothenburg, Sweden; [Nieto, A.] Childrens Hosp La Fe, Pediat Allergy Unit, Valencia, Spain; [Paramesh, H.] Lakeside Med Ctr & Hosp, Bangalore, Karnataka, India; [Pawankar, R.] Nippon Med Sch, Dept Pediat, Div Allergy & Immunol, Tokyo 113, Japan; [Pohunek, P.] Charles Univ Prague, Dept Pediat, Univ Hosp Motol, Prague, Czech Republic; [Pongracic, J.] Childrens Mem Hosp, Div Allergy & Immunol, Chicago, IL 60614 USA; [Price, D.] Univ Aberdeen, Primary Care Resp Soc UK, Aberdeen, Scotland; [Robertson, C.] Royal Childrens Hosp, Melbourne, Vic, Australia; [Rosario, N.] Hosp Clin UFPR, Div Pediat Allergy, Curitiba, Parana, Brazil; [Rossenwasser, L. J.] Childrens Mercy Hosp, Kansas City, MO 64108 USA; [Sly, P. D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia; [Stein, R.] Pontificia Univ Catolica RGS, Hosp Sao Lucas, Pediat Pulm Serv, Porto Alegre, RS, Brazil; [Stick, S.] Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia; [Taussig, L. M.] Univ Denver, Off Provost, Denver, CO USA; [Valovirta, E.] Univ Turku, Allergy Clin, Terveystalo Turku, Turku, Finland; [Vichyanond, P.] Siriraj Hosp, Fac Med, Int Affairs & Ctr Excellence, Bangkok, Thailand; [Weinberg, E.] Univ Cape Town, Red Cross Childrens Hosp, Allergy Unit, ZA-7925 Cape Town, South Africa; [Wallace, D.] Nova SE Univ, Ft Lauderdale, FL 33314 USA; [Wennergren, G.] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden; [Wildhaber, J.] Univ Childrens Hosp, Dept Resp Med, Zurich, Switzerland; [Zeiger, R. S.] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA	Papadopoulos, NG (reprint author), Univ Athens, Dept Allergy, Pediat Clin 2, 41 Fidippidou St, Athens 11527, Greece.	ngp@allergy.gr	Sly, Peter/F-1486-2010; Casale, Thomas/K-4334-2013; Stein, Renato/K-2568-2014; Stick, Stephen/O-5683-2014; Van Bever, Hugo PS/D-8473-2015; Goh, Daniel/D-8573-2015; Custovic, Adnan/A-2435-2012	Sly, Peter/0000-0001-6305-2201; Papadopoulos, Nikolaos/0000-0002-2508-3872; BARALDI, EUGENIO/0000-0002-1829-3652; Kling, Sharon/0000-0002-4498-1811; Casale, Thomas/0000-0002-3149-7377; Custovic, Adnan/0000-0001-5218-7071; Guilbert, Theresa/0000-0002-6932-712X; Lotvall, Jan/0000-0001-9195-9249; Price, David/0000-0002-9728-9992; Makela, Mika/0000-0002-2933-3111	Nestle; MSD; Deviblis (EBT); MRC Moulton Charitable Foundation; Merck Inc; Astra Zeneca; GlaxoSmithKline; AstraZeneca; Novartis Research; PREDICTA: European Commission [260895]; Swiss National Science Foundation Research; MeDALL: European Commission [261357]; Christine Kuhne-Center for Allergy Research and Education Research; Food Allergy and Anaphylaxis Network; Food Allergy Initiative; NIH; National Peanut Board; SHS; Wallace Research Foundation; Altus Pharmaceuticals; Inspire Pharmaceuticals; National Institutes of Health; NIH [U01]; AAAAI/GlaxoSmithKline; Pharmaxis; Grupo Uriach Pharma; Turkish National Science Foundation; Hacettepe University; GSK; Adamed; SymbioPharm; Airsonett; Forest Pharmaceuticals; Viro Pharma; Novartis; ALA, Pharmaceuticals; National and regional grants for research in our group; Novartis Pharma; MEDA Pharma; CBF LETI; Allergopharma; Inmunotek; UK National Health Service; Aerocrine; Boehringer Ingelheim; Merck; Mundipharma; Nycomed; Pfizer; Teva; Ross; Abbott; Merck Sharp Dohme; Genentech; MedImmune; Thermofisher	N. G. Papadopoulos has received payment for consultancy from Abbott and for lectures from MSD, and grants from Nestle, MSD, Deviblis (EBT). K.-H. Carlsen has served on an international consultatory paediatric board for GSK, and given presentations for GSK, MSD, PolarMed and Schering Plough. A. Custovic has received payment for consultancy and lectures from Novartis and for lectures from Glaxo-SmithKline, Thermo Fisher Scientific, Airsonet, MSD, and grants from MRC Moulton Charitable Foundation. J. Gern has received payment for board membership from 3V Bio-Sciences, for consultancy form GlaxoSmithKline, Biota, Centocor, Boehringer Ingelheim, MedImmune, Gilead, Theraclone, Synairgen, Pulmatrix, and grants from Merck Inc, Astra Zeneca, GlaxoSmithKline. R. Lemanske has received payment for consultancy from Merck, Sepracor, SA Boney and Associates Ltd, GlaxoSmithKline, American Institute of Research, Genentech, Inc., Double Helix Development, Inc., for lectures from Michigan Public Health Institute, Allegheny General Hospital, American Academy of Pediatrics, West Allegheny Health Systems, Inc., California Chapter 4, AAP, Colorado Allergy Society, Pennsylvania Allergy and Asthma Association, Harvard Pilgrim Health, California Society of Allergy, NYC Allergy Society, World Allergy Organization, American College of Chest Physicians, AAAAI, for Employment from University of Wisconsin School of Medicine and Public Health, for Royalties from Elsevier, and grants from National Heart Lung and Blood Institute, Pharmaxis. P. Le Souef has received a grant from AstraZeneca. G. Roberts is a member of the steering committee for the GAP trial, paid by ALK. C. A. Akdis has received payment for consultancy from Actellion, Aventis, Stallergenes, Allergopharma, Circacia, Swiss Institute of Allergy and Asthma Research, University of Zurich, Switzerland, and grants from Novartis Research on immunoregulation in asthma, PREDICTA: European Commission's Seventh Framework programme No. 260895 Research on virus induced exacerbations, Swiss National Science Foundation Research on T cell interaction with the epithelium, MeDALL: European Commission's Seventh Framework Programme No. 261357 Research on early initiation of asthma, Christine Kuhne-Center for Allergy Research and Education Research on severe allergies. L. B. Bacharier has received payment for consultancy from Aerocrine, GlaxoSmithKline, Genentech/Novartis, Merck, Schering, Cephalon and for lectures from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, Merck, Schering. J. de Blic is member of the steering committee for the GAP trial, paid by ALK. He is also a member of the advisory board on asthma in children for GSK, MSD, CHIESI, and Stallergenes. W. Burks has consulted for Dannon Co. Probiotics, Exploramed Development LLC, Intelliject, McNeil Nutritionals, Merck & Co., Novartis, Nutricia, Pfizer, Portola Pharmaceuticals and Schering-Plough; has received grants from the Food Allergy and Anaphylaxis Network, the Food Allergy Initiative, the NIH, the National Peanut Board, SHS, and the Wallace Research Foundation; and owns stock or stock options in Allertein and Mast Cell, Inc. T. B. Casale has received payment from consultancy from MedImmune. J. A. Castro-Rodriguez has received payment for development of educational presentation from AZ, GSK, MSD, Novartis. T. Frischer has worked on a national advisory board for MSD. T. W.; Guilbert has received honoraria from GlaxoSmithKline, AstraZeneca, PeerPoint Medical Education Institute, Merck, and Antidote; has received research support from Altus Pharmaceuticals, Inspire Pharmaceuticals, and the National Institutes of Health; and is a member of the American Lung Association, the American Thoracic Society, and the American Academy of Pediatrics. P. W. Heymann has received payment for Employment from University of Virginia and grant from NIH/U01 grant. D. J. Jackson has received payment for consultancy from Gilead and grants from NIH, AAAAI/GlaxoSmithKline, Pharmaxis. O. Kalayci has received payment for consultancy from MERCK and received lecture fee from Grupo Uriach Pharma, and grants from Turkish National Science Foundation, Hacettepe University. S. Kling has received payment for Ethics lectures from MSD (Merck) and travel expenses from Cipla Medpro with Sponsorship to Allergy Society of South Africa (ALLSA) Congress 2010; money paid to ALLSA. P. Kuna has received payment for board membership and for lectures from AstraZeneca, Boehringer, MSD, and lecture fee from GSK, Adamed. S. Lau has received payment for consultancy from Merck, for lectures from Symbiopharm, Novartis, ALK, AstraZeneca, and grants from SymbioPharm, Airsonett. D. K. Ledford has received payment for consultancy from Genentech, for expert testimony from Shook Hardy & Bacon, and grants from Forest Pharmaceuticals, Viro Pharma. A. H. Liu has served on the speakers' bureau for Merck, Aerocrine, and Phadia; has served on the speakers' bureau and advisory board for GlaxoSmithKline and AstraZeneca; and has received a research grant from Novartis. R. F. Lockey has received payment for Board membership from the World Allergy Organization, for consultancy from Merck, ALK, for employment from the University of Florida, VA Hospital, for expert testimony from two law firms, and received grants from ALA, Pharmaceuticals. He has also received payment for lectures from Merck, AstraZeneca, royalties from Informa Publishing, for travel expenses to World Allergy Organization meetings, international congresses for presenting lectures; and owns stock or stock options in Roth IRA acct. K. Lodrup Carlsen has received payment for lectures from GlaxoSmithKline in the last year (once) and grants from National and regional grants for research in our group. J. Lotvall has consulted for Glaxo-SmithKline, Novartis, and Merck; has received grants from GlaxoSmithKline; and has received payment for lectures from AstraZeneca, Glaxo-SmithKline, Novartis, and Merck. A. Nieto has received payment for board membership, consultancy and lecture fee from Novartis Pharma, MEDA Pharma, CBF LETI, MSD, Allergopharma, and also for development of educational presentations from Schering-Plough and grants from Inmunotek. P. Pohunek has received lecture honoraria from AstraZeneca, GSK, MSD, UCB Pharma and travel support for scientific meetings by AstraZeneca, GSK, MSD and Chiesi. D. Price has consultant arrangements with Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis and Teva; he or his research team have received grants and support for research in respiratory disease from the following organizations in the last 5 years: UK National Health Service, Aerocrine, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck, Mundipharma, Novartis, Nycomed, Pfizer and Teva. He has spoken for Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Merck, Mundipharma, Pfizer and Teva, he has shares in AKL Ltd.; , which produces phytopharmaceuticals, and he is the sole owner of Research n Real Life Ltd. N. Rosario has received payment for board membership from Sanofi Aventis, Takeda, MSD, for consultancy from MSD, Sanofi Aventis, GSK, for lectures from MSD, Sanofi Aventis, GSK, Takeda, Ache, Danone and for development of educational presentations from MSD, Sanofi Aventis, Danone. L. J. Rosenwasser has received payment for board membership from WAO and for consultancy from Genentech, Novartis, AZ, Regeneron, Sanofi. R. Stein has received payment for lectures from Abbott. S. Szefler has received payment for consultancy from Merck, Genentech, Schering, Boehringer-Ingehlheim, Novartis, GlaxoSmithKline, for lectures from Merck, manuscript preparation from Genentech, for patents from NHLBI CARE Network, and grants from GlaxoSmithKline, Ross, Abbott. G. Wennergren has received has received fees for lectures from Novartis, Merck Sharp & Dohme, AstraZeneca and GlaxoSmithKline. J. Wildhaber has served on national and international advisory boards of Nycomed and MSD and has received research grants from AstraZeneca, GSK and MSD. R. S. Zeiger has received payment for consultancy from Aerocrine, AstraZeneca, Genentech, GlaxoSmithKline, MedImmune, ScheringPlough, Sunovion, Novartis, NHLBI/Penn State and grants from Genentech, GlaxoSmithKline, Aerocrine, Merck, MedImmune, Thermofisher. H. Arakawa, M. Makela, G. Wong, H. Zar, E. Baraldi, H. P. van Bever, A. Boner, Y. Z. Chen, Y. M. El-Gamal, M. L. Everard, M. Geller, J. Gereda, D. Y. Goh, G. Hedlin, S. J. Hong, E. M. Hossny, J. L. Huang, J. C. de Jongste, N. Ait-Khaled, S. I. Lee, A. Morikawa, H. Paramesh, R. Pawankar, J. Pongracic, C. Robertson, D. Sly, S. Stick, L. M. Taussig, E. Valovirta, P. Vichyanond, D. Wallace, E. Weinberg, have no conflicts of interest to declare.	Ait-Khaled N, 2008, MANAGEMENT ASTHMA GU; Andrade WCC, 2010, ALLERGY, V65, P1472, DOI 10.1111/j.1398-9995.2010.02405.x; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Ballardini N, 2012, ALLERGY, V67, P537, DOI 10.1111/j.1398-9995.2012.02786.x; BARNES PJ, 1995, NEW ENGL J MED, V332, P868; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bisgaard H, 2005, CHEST, V128, P355, DOI 10.1378/chest.128.1.355; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P198; Bisgaard H, 2006, CHEST, V130, P1733, DOI 10.1378/chest.130.6.1733; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bisgaard H, 2009, PEDIATR PULM, V44, P568, DOI 10.1002/ppul.21018; Bleecker ER, 2000, J ALLERGY CLIN IMMUN, V105, P1123, DOI 10.1067/mai.2000.106043; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bozzetto S, 2012, ALLERGY, V67, P10, DOI 10.1111/j.1398-9995.2011.02711.x; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Brand PLP, 2011, J ALLERGY CLIN IMMUN, V127, P293, DOI 10.1016/j.jaci.2010.10.012; British Thoracic Society and Scottish Intercollegiate Guidelines Network, 2011, BRIT GUID MAN ASTHM; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Busse WW, 2001, NEW ENGL J MED, V344, P350; Calderon MA, 2012, J ALLERGY CLIN IMMUN, V129, P929, DOI 10.1016/j.jaci.2011.11.019; Carlsen KCL, 2010, ALLERGY, V65, P1134, DOI 10.1111/j.1398-9995.2010.02344.x; Castro-Rodriguez JA, 2004, J PEDIATR-US, V145, P172, DOI 10.1016/j.jpeds.2004.04.007; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Castro-Rodriguez JA, 2010, PEDIATR PULM, V45, P395, DOI 10.1002/ppul.21205; Cates CJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000052.pub2; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chung KF, 2000, EUR RESPIR J, V15, P961, DOI 10.1034/j.1399-3003.2000.15e26.x; Cockcroft D, 2009, ANN ALLERG ASTHMA IM, V103, P400; Cockcroft D, 2009, ANN ALLERG ASTHMA IM, V103, P369; Cockcroft D, 2009, ANN ALLERG ASTHMA IM, V103, P363, DOI 10.1016/S1081-1206(10)60353-5; Covar RA, 2010, J ALLERGY CLIN IMMUN, V125, P359, DOI 10.1016/j.jaci.2009.10.037; De Benedictis Fernando Maria, 2003, Paediatr Drugs, V5, P629, DOI 10.2165/00148581-200305090-00005; Dolovich MB, 2005, CHEST, V127, P335, DOI 10.1378/chest.127.1.335; Drazen JM, 1999, NEW ENGL J MED, V340, P197; Ducharme FM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005535.pub2; Ducharme FM, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005533.pub2; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI [10.1164/rccm.9120-11ST, 10.1164/rccm.912011ST]; EDWARDS AM, 1993, EUR RESPIR J, V6, P35; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; European Academy of Allergy and Clinical Immunology, 2011, EUR DECL ALL IMM; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; FitzGerald J M, 2000, Can Respir J, V7, P61; Fixman ED, 2007, EUR RESPIR J, V29, P379, DOI 10.1183/09031936.00053506; Frey Urs, 2005, Paediatr Respir Rev, V6, P246, DOI 10.1016/j.prrv.2005.09.010; Garcia MLG, 2005, PEDIATRICS, V116, P360, DOI 10.1542/peds.2004-1172; GIBSON NA, 1995, THORAX, V50, P1274, DOI 10.1136/thx.50.12.1274; GINA, 2011, GLOB STRAT ASTHM MAN; Global Initiative for Asthma (GINA), 2009, GLOB STRAT DIAGN MAN; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Guilbert TW, 2011, J ALLERGY CLIN IMMUN, V128, P956, DOI 10.1016/j.jaci.2011.06.027; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hamid Q, 2009, ANNU REV PHYSIOL, V71, P489, DOI 10.1146/annurev.physiol.010908.163200; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2011, J ALLERGY CLIN IMMUN, V128, P1165, DOI 10.1016/j.jaci.2011.10.024; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jadad AR, 2000, BRIT MED J, V320, P537, DOI 10.1136/bmj.320.7234.537; Joos G F, 2001, Curr Allergy Asthma Rep, V1, P134, DOI 10.1007/s11882-001-0081-8; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; Kopp MV, 2011, ALLERGY, V66, P792, DOI 10.1111/j.1398-9995.2011.02553.x; Kupczyk M, 2010, ALLERGY, V65, P415, DOI 10.1111/j.1398-9995.2009.02265.x; Laube BL, 2011, EUR RESPIR J, V37, P1308, DOI 10.1183/09031936.00166410; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V126, P449, DOI 10.1016/j.jaci.2010.05.039; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Leonardi NA, 2011, J ALLERGY CLIN IMMUN, V127, P1466, DOI 10.1016/j.jaci.2011.03.001; Leone FT, 2003, CHEST, V124, P2329, DOI 10.1378/chest.124.6.2329; Lipworth BJ, 1999, LANCET, V353, P57, DOI 10.1016/S0140-6736(98)09019-9; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Lotvall J, 2012, ALLERGY, V67, P449, DOI 10.1111/j.1398-9995.2012.02813.x; Main C, 2008, HEALTH TECHNOL ASSES, V12, P1; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2011, J ALLERGY CLIN IMMUN, V128, P939, DOI 10.1016/j.jaci.2011.09.020; Masoli M, 2004, ARCH DIS CHILD, V89, P902, DOI 10.1136/adc.2003.035709; McKean M, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001107, DOI 10.1002/14651858.CD001107]; McMahon AW, 2011, PEDIATRICS, V128, pE1147, DOI 10.1542/peds.2010-1720; Minai Beena A, 2004, Respir Care, V49, P600; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Muraro A, 2010, ALLERGY, V65, P681, DOI 10.1111/j.1398-9995.2010.02343.x; Murphy KR, 2009, J ALLERGY CLIN IMMUN, V123, P833, DOI 10.1016/j.jaci.2009.01.058; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; National Asthma Council Australia, 2006, ASTHM MAN HDB; National Heart Lung, 2007, 3 NAT HEART LUNG BLO; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Nishimuta Toshiyuki, 2011, Allergology International, V60, P147, DOI [10.2332/allergolint. 11-RAI-0328, 10.2332/allergolint.11-RAI-0328]; Nuijsink M, 2007, EUR RESPIR J, V30, P457, DOI 10.1183/09031936.0011806; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Paramesh H, 2008, INT J ENV HLTH, V4, P410; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pedersen Soren, 2007, Prim Care Respir J, V16, P4, DOI 10.3132/pcrj.2007.00011; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Petsky HL, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006340.pub3; Pierart F, 1999, EUR RESPIR J, V13, P673, DOI 10.1183/09031936.99.13367399; Price D, 2011, NEW ENGL J MED, V364, P1695, DOI 10.1056/NEJMoa1010846; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Ram FS, 2005, COCHRANE DB SYST REV; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Rodrigo GJ, 2012, THORAX, V67, P342, DOI 10.1136/thx.2010.155648; Rodrigo GJ, 2011, CHEST, V139, P28, DOI 10.1378/chest.10-1194; Rodriguez-Martinez CE, 2011, PEDIATR PULM, V46, P1175, DOI 10.1002/ppul.21493; Ruotsalainen M, 2010, ALLERGY, V65, P503, DOI 10.1111/j.1398-9995.2009.02212.x; Sackesen C, 2011, ALLERGY, V66, P48, DOI 10.1111/j.1398-9995.2010.02428.x; Schwartz LB, 2008, ALLERGY, V63, P953, DOI 10.1111/j.1398-9995.2008.01802.x; Sears MR, 2009, CHEST, V136, P604, DOI 10.1378/chest.09-1214; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Snijders D, 2010, ALLERGY, V65, P978, DOI 10.1111/j.1398-9995.2009.02282.x; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stelmach I, 2008, J ALLERGY CLIN IMMUN, V121, P383, DOI 10.1016/j.jaci.2007.09.007; Strunk RC, 2009, J PEDIATR-US, V154, P682, DOI 10.1016/j.jpeds.2008.11.036; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Szefler SJ, 1998, J ALLERGY CLIN IMM 2, V2, pS23; Szefler SJ, 2011, J ALLERGY CLIN IMMUN, V128, P485, DOI 10.1016/j.jaci.2011.07.010; Taylor DR, 2008, EUR RESPIR J, V32, P545, DOI 10.1183/09031936.00155307; Tesse R, 2011, ALLERGY, V66, P307, DOI 10.1111/j.1398-9995.2010.02489.x; Tischer CG, 2011, ALLERGY, V66, P1570, DOI 10.1111/j.1398-9995.2011.02712.x; Vahlkvist S, 2010, ALLERGY, V65, P1464, DOI 10.1111/j.1398-9995.2010.02406.x; van der Valk RJP, 2012, ALLERGY, V67, P265, DOI 10.1111/j.1398-9995.2011.02734.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Watelet JB, 2006, ALLERGY, V61, P1249, DOI 10.1111/j.1398-9995.2006.01226.x; Weinberger M, 1996, NEW ENGL J MED, V334, P1380; Wennergren G, 2010, PEDIAT ALLERG IMM-UK, V21, P806, DOI 10.1111/j.1399-3038.2010.01057.x; Wildfire JJ, 2012, J ALLERGY CLIN IMMUN, V129, P694, DOI 10.1016/j.jaci.2011.12.962; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481; Xepapadaki P, 2005, J ALLERGY CLIN IMMUN, V116, P299, DOI 10.1016/j.jaci.2005.04.007; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; Zar HJ, 1999, LANCET, V354, P979, DOI 10.1016/S0140-6736(98)12445-5; Zhang LJ, 2011, PEDIATRICS, V127, P129, DOI 10.1542/peds.2010-1223; [Anonymous], 2000, N ENGL J MED, V343, P1054	142	106	140	5	62	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538			ALLERGY	Allergy	AUG	2012	67	8					976	997		10.1111/j.1398-9995.2012.02865.x		22	Allergy; Immunology	Allergy; Immunology	972WR	WOS:000306312500002	22702533	
J	Holz, O; Khalilieh, S; Ludwig-Sengpiel, A; Watz, H; Stryszak, P; Soni, P; Tsai, M; Sadeh, J; Magnussen, H				Holz, O.; Khalilieh, S.; Ludwig-Sengpiel, A.; Watz, H.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.; Magnussen, H.			SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects	EUROPEAN RESPIRATORY JOURNAL			English	Article						Anti-inflammatory; chronic obstructive pulmonary disease; interleukin-8; myeloperoxidase; pharmacodynamics	OBSTRUCTIVE PULMONARY-DISEASE; AIRWAY INFLAMMATION; HISTONE DEACETYLASE; ACTIVATION MARKERS; INDUCED SPUTUM; BONE-MARROW; ASTHMA; COPD; RECRUITMENT; EXPOSURES	SCH527123 is a novel, selective CXC chemokine receptor 2 antagonist that inhibits neutrophil activation and modulates neutrophil trafficking in animal models, characteristics that may be beneficial in the treatment of conditions with unbalanced pulmonary neutrophilia, such as chronic obstructive pulmonary disease. The purpose of this proof-of-principle study was to determine whether SCH527123 inhibits ozone-induced neutrophil recruitment in healthy humans. In a randomised, double-blind, placebo-controlled, three-way crossover study, oral SCH527123 (50 mg once daily, 4 days), prednisolone (50 mg once), or placebo was alternated with 2-week washouts. 18 healthy ozone responders (>20% increase in sputum neutrophils) underwent ozone challenge tests (250 ppb, 3 h intermittent exercise) 1 h after the last treatment dose. Sputum was induced at 3 h post-challenge. After SCH527123 treatment, the ozone challenge resulted in significantly lower sputum neutrophil counts (0.13 x 10(6).mL(-1)) compared with prednisolone (0.84 x 10(6).mL(-1); p<0.001) or placebo (2.98 x 10(6).mL(-1); p<0.001). Comparable results were obtained for total cell count, percentage of sputum neutrophils, and for interleukin-8 and myeloperoxidase in sputum supernatant. Post-challenge, SCH527123 inhibited neutrophilia in peripheral blood but significantly less than in sputum. All treatments were safe and well tolerated. SCH527123 causes significant attenuation of ozone-induced airway neutrophilia in healthy subjects. Further evaluation in a large trial of patients with pulmonary disorders is warranted.	[Holz, O.; Ludwig-Sengpiel, A.; Watz, H.; Magnussen, H.] Hosp Grosshansdorf, Pulm Res Inst, D-22927 Grosshansdorf, Germany; [Khalilieh, S.; Stryszak, P.; Soni, P.; Tsai, M.; Sadeh, J.] Schering Plough Res Inst, Kenilworth, NJ USA	Magnussen, H (reprint author), Hosp Grosshansdorf, Pulm Res Inst, Woehrendamm 80, D-22927 Grosshansdorf, Germany.	magnussen@pulmoresearch.de			Schering-Plough Research Institute	This research was funded by Schering-Plough Research Institute.	Adams DH, 1997, LANCET, V349, P490, DOI 10.1016/S0140-6736(96)07524-1; Alexis NE, 2008, ENVIRON HEALTH PERSP, V116, P799, DOI 10.1289/ehp.10981; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904; Barnes PJ, 2006, CHEST, V129, P151, DOI 10.1378/chest.129.1.151; Chapman RW, 2007, J PHARMACOL EXP THER, V322, P486, DOI 10.1124/jpet.106.119040; EVANS E, 2007, EUR RESP J S51, V30, pS775; Holz O, 1998, CLIN EXP ALLERGY, V28, P284; Holz O, 1999, AM J RESP CRIT CARE, V159, P776; Holz O, 2005, J CLIN PHARMACOL, V45, P498, DOI 10.1177/0091270004273527; Holz O, 2002, CLIN EXP ALLERGY, V32, P681, DOI 10.1046/j.1365-2222.2002.01358.x; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Jorres RA, 1997, CHEST, V111, P866, DOI 10.1378/chest.111.4.866; Jorres RA, 2000, AM J RESP CRIT CARE, V161, P1855; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Khalilieh S, 2007, EUR RESP J S51, V30, p613s; KHALILIEH S, 2007, EUR RESP J S51, V30, pS612; Mann BS, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-59; Martin C, 2003, IMMUNITY, V19, P583, DOI 10.1016/S1074-7613(03)00263-2; Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785; O'Donnell RA, 2004, THORAX, V59, P837, DOI 10.1136/thx.2003.019349; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Semerad CL, 2002, IMMUNITY, V17, P413, DOI 10.1016/S1074-7613(02)00424-7; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49; Stockley RA, 2002, CHEST, V121, P151, DOI DOI 10.1378/CHEST.121.5_; Suratt BT, 2004, BLOOD, V104, P565, DOI 10.1182/blood-2003-10-3638; Thatcher TH, 2005, AM J PHYSIOL-LUNG C, V289, pL322, DOI 10.1152/ajplung.00039.2005; van Beurden WJC, 2003, RESP MED, V97, P401, DOI 10.1053/rmed.2002.1461	30	106	107	1	4	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2010	35	3					564	570		10.1183/09031936.00048509		7	Respiratory System	Respiratory System	564TA	WOS:000275239000016	19643947	
J	Adenuga, D; Yao, H; March, TH; Seagrave, J; Rahman, I				Adenuga, David; Yao, Hongwei; March, Thomas H.; Seagrave, Jeanclare; Rahman, Irfan			Histone Deacetylase 2 Is Phosphorylated, Ubiquitinated, and Degraded by Cigarette Smoke	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						COPD; HDAC2; cigarette smoke; lung; inflammation	PROINFLAMMATORY CYTOKINE RELEASE; PROTEIN-KINASE CK2; NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; ALVEOLAR EPITHELIAL-CELLS; INDUCED LUNG INFLAMMATION; OXIDATIVE STRESS; CHROMATIN MODIFICATION; REDOX REGULATION; DEGRADATION	Cigarette smoke (CS)-induced lung inflammation involves the reduction of histone deacetylase 2 (HDAC2) abundance, which is associated with steroid resistance in patients with chronic obstructive pulmonary disease and in individuals with severe asthma who smoke cigarettes. However, the molecular mechanism of CS-mediated reduction of HDAC2 is not clearly known. We hypothesized that HDAC2 is phosphorylated and subsequently degraded by the proteasome in vitro in macrophages (MonoMac6), human bronchial and primary small airway epithelial cells, and in vivo in mouse lungs in response to chronic CS exposure. Cigarette smoke extract (CSE) exposure in MonoMac6 and in bronchial and airway epithelial cells led to phosphorylation of HDAC2 on serine/threonine residues by a protein kinase CK2-mediated mechanism, decreased HDAC2 activity, and increased ubiquitin-proteasome-dependent HDAC2 degradation. CK2 and proteasome inhibitors reversed CSE-mediated HDAC2 degradation, whereas serine/threonine phosphatase inhibitor, okadaic acid, caused phosphorylation and subsequent ubiquitination of HDAC2. CS-induced HDAC2 phosphorylation was detected in mouse lungs from 2 weeks to 4 months of CS exposure, and mice showed significantly lower lung HDAC2 levels. Thus, CS-mediated down-regulation of HDAC2 in human macrophages and lung epithelial cells in vitro and in mouse lung in vivo involves the induction of serine/threonine phosphorylation and proteasomal degradation, which may have implications for steroid resistance and abnormal inflammation caused by cigarette smoke.	[Adenuga, David; Yao, Hongwei; Rahman, Irfan] Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, Rochester, NY 14642 USA; [Adenuga, David; Yao, Hongwei; Rahman, Irfan] Univ Rochester, Med Ctr, Dept Environm Med, Toxicol Training Program, Rochester, NY 14642 USA; [March, Thomas H.; Seagrave, Jeanclare] Lovelace Resp Res Inst, Albuquerque, NM USA	Rahman, I (reprint author), Univ Rochester, Med Ctr, Dept Environm Med, Lung Biol & Dis Program, 601 Elmwood Ave,Box 850, Rochester, NY 14642 USA.	Irfan_Rahman@urmc.rochester.edu	Yao, Hongwei/G-6444-2010		National Institutes of Health-NHLBI [R01-HL-085613]; NIEHS Toxicology [ES-07026]; NIEHS Environmental Health Sciences Center [ES-01247]	This work was supported by the National Institutes of Health-NHLBI Grant R01-HL-085613 (to I.R.), NIEHS Toxicology training grant ES-07026, and NIEHS Environmental Health Sciences Center Grant ES-01247.	Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342; BARNES PJ, 2008, ANN REV PHY IN PRESS; Breusing N, 2008, BIOL CHEM, V389, P203, DOI 10.1515/BC.2008.029; Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; FAILLA M, 2007, AM J RESP CRIT CARE, V176, pA45; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Ito K., 2001, FASEB Journal, V15, P1110; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kode A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-132; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Liu C, 2004, J NUTR, V134, P2705; March TH, 2006, TOXICOL SCI, V92, P545, DOI 10.1093/toxsci/kfl016; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; MARWICK JA, AM J RESP CRIT CARE; Meja KK, 2008, AM J RESP CELL MOL, V39, P312, DOI 10.1165/rcmb.2008-0012OC; Moodie FM, 2004, FASEB J, V18, P1897, DOI 10.1096/fj.04-1506fje; Nott A, 2008, NATURE, V455, P411, DOI 10.1038/nature07238; Pluemsampant S, 2008, INT J CANCER, V122, P333, DOI 10.1002/ijc.23094; Pryor WA, 1993, ANN NY ACAD SCI, V686, P27; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Rajendrasozhan S, 2008, ANTIOXID REDOX SIGN, V10, P799, DOI 10.1089/ars.2007.1938; Sarno S, 2001, FEBS LETT, V496, P44, DOI 10.1016/S0014-5793(01)02404-8; Sun JM, 2007, J BIOL CHEM, V282, P33227, DOI 10.1074/jbc.M703549200; Tsai SC, 2002, J BIOL CHEM, V277, P31826, DOI 10.1074/jbc.M204149200; VASHISHT GYN, 2006, EMBO REP, V7, P291; Yang SR, 2008, AM J RESP CELL MOL, V38, P689, DOI 10.1165/rcmb.2007-0379OC; Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005; Yao HW, 2008, AM J PHYSIOL-LUNG C, V294, pL1174, DOI 10.1152/ajplung.00439.2007; Yao HW, 2008, AM J PATHOL, V172, P1222, DOI 10.2353/ajpath.2008.070765; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324	39	106	117	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	APR	2009	40	4					464	473		10.1165/rcmb.2008-0255OC		10	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	425UQ	WOS:000264663300009	18927347	
J	Byrne, M; Walsh, J; Murphy, AW				Byrne, M; Walsh, J; Murphy, AW			Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour	JOURNAL OF PSYCHOSOMATIC RESEARCH			English	Article						coronary heart disease; health-related behaviour; illness perceptions; primary care; secondary prevention; self-regulatory model	RANDOMIZED CONTROLLED-TRIAL; CHRONIC-FATIGUE-SYNDROME; ILLNESS PERCEPTION QUESTIONNAIRE; MYOCARDIAL-INFARCTION; PRIMARY-CARE; GENERAL-PRACTICE; PERSONAL MODELS; SELF-MANAGEMENT; CLINICAL-PRACTICE; INTERVENTION	Objective: Coronary heart disease (CHD) is a leading cause of illness and death in Western society. The present study was designed to evaluate the utility of illness perceptions and medication beliefs in predicting secondary preventive behaviour among patients with CHD. An extended version of Leventhal's self-regulatory model (SRM) was used as a theoretical framework for this study [Leventhal H, Nerenz DR, Steele DJ. Illness perceptions and coping with health threat. In: Baum A, Taylor SE, Singer JE, editors. Handbook of psychology and health, Volume IV: social psychological aspects of health. Hillsdale (NJ): Erlbaum,1984. pp. 21952; Home R, Weinman J. Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 2002;17(l):17-32]. Method: Medical and demographic data were gathered from the medical charts of 1611 patients with established C14D from 35 randomly selected general practices. Self-report data about patients' lifestyles (diet, exercise, smoking, alcohol consumption and medication adherence) and information on illness and medication beliefs were provided from postal questionnaire (1084 patients responded; 69% response rate). The relationship between patients' beliefs and their secondary preventive behaviour was examined using regression analyses. Results: Illness perceptions appeared to be only weak predictors of smoking, exercise, diet, alcohol consumption and medication adherence, accounting for about 2% of the variance in these behaviours. Medication beliefs were moderately related to medication adherence, accounting for about 7% of the variance in scores. A strong belief in the necessity of one's medication and a lower level of concern about one's medication were associated with higher levels of adherence. Conclusions: An illness perception approach did not prove helpful in predicting secondary preventive behaviour among this group of patients. However, beliefs about medications appear to be reasonable predictive of medication adherence. (c) 2005 Elsevier Inc. All rights reserved.	Natl Univ Ireland Univ Coll Galway, Dept Psychol, Galway, Ireland; Natl Univ Ireland Univ Coll Galway, Dept Gen Practice, Galway, Ireland	Byrne, M (reprint author), Natl Univ Ireland Univ Coll Galway, Dept Psychol, Galway, Ireland.	molly.byrne@nuigalway.ie		Walsh, Jane/0000-0001-5476-1348			Campbell NC, 1998, BRIT MED J, V316, P1430; Campbell NC, 1998, HEART, V80, P447; Cooper A, 1999, HEART, V82, P234; CUPPLES ME, 1994, BRIT MED J, V309, P993; Department of Health, 2000, NAT SERV FRAM COR HE; Edwards R, 2001, J PSYCHOSOM RES, V50, P65, DOI 10.1016/S0022-3999(00)00204-X; Feder G, 1999, BRIT MED J, V318, P1522; Fortune DG, 2000, BRIT J HEALTH PSYCH, V5, P71, DOI 10.1348/135910700168775; FRIEL S, 1999, NATL HLTH LIFESTYLES; Glasgow RE, 1997, DIABETES CARE, V20, P556, DOI 10.2337/diacare.20.4.556; GODIN G, 1985, Canadian Journal of Applied Sport Sciences, V10, P141; Griva K, 2000, PSYCHOL HEALTH, V15, P733, DOI 10.1080/08870440008405578; Hagger MS, 2003, PSYCHOL HEALTH, V18, P141, DOI 10.1080/088704403100081321; Hampson S E, 1993, Arthritis Care Res, V6, P17, DOI 10.1002/art.1790060105; HAMPSON SE, 1990, HEALTH PSYCHOL, V9, P632, DOI 10.1037//0278-6133.9.5.632; Hampson SE, 2000, BRIT J HEALTH PSYCH, V5, P27, DOI 10.1348/135910700168748; HAMPSON SE, 1994, J BEHAV MED, V17, P143, DOI 10.1007/BF01858102; Haynes RB, 1996, LANCET, V348, P383; Horne R, 1999, J PSYCHOSOM RES, V47, P555, DOI 10.1016/S0022-3999(99)00057-4; Horne R, 2002, PSYCHOL HEALTH, V17, P17, DOI 10.1080/08870440290001502; Horne R, 2000, HEART, V83, P388, DOI 10.1136/heart.83.4.388; Horne R., 1997, PERCEPTIONS HLTH ILL, P155; HORNE R, IN PRESS MEDICATION; HORNE R, 1999, PSYCHOL HEALTH, V44, P1; JOHNSTON M, 1992, BRIT J CLIN PSYCHOL, V31, P89; Jolly K, 1999, BRIT MED J, V318, P706; Kahan T, 2001, J CARDIOVASC RISK, V8, P73, DOI 10.1097/00043798-200104000-00003; Ketterer MW, 2000, J PSYCHOSOM RES, V48, P357, DOI 10.1016/S0022-3999(00)00099-4; Leventhal H., 1984, HDB PSYCHOL HLTH, P219; Leventhal H, 1980, MED PSYCHOL, V2, P7; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; Moss-Morris R, 2002, PSYCHOL HEALTH, V17, P1, DOI 10.1080/08870440290001494; MossMorris R, 1996, BRIT J HEALTH PSYCH, V1, P15; Murphy H, 1999, J PSYCHOSOM RES, V46, P155, DOI 10.1016/S0022-3999(98)00073-7; Ogden J, 1996, HLTH PSYCHOL TXB; PETRIE K, 1995, J PSYCHOSOM RES, V39, P31, DOI 10.1016/0022-3999(94)00071-C; Petrie KJ, 2002, PSYCHOSOM MED, V64, P580; Petrie KJ, 1996, BRIT MED J, V312, P1191; ROE L, 1994, FAM PRACT, V11, P375, DOI 10.1093/fampra/11.4.375; ROSENSTOCK IM, 1974, HEALTH EDUC QUART, V2, P354; Rudd P., 1993, DEV ASPECTS HLTH COM, P185; Scharloo M, 2000, J ASTHMA, V37, P17, DOI 10.3109/02770900009055425; Schauble R, 1998, DIAGNOSTICA, V44, P5; SCHIFFMAN S, 1998, HEALTH PSYCHOL, V17, P3; Skinner B. F., 1953, SCI HUMAN BEHAV; *SPSS INC, 1999, SPSS WIND VERS 10; Svilaas A, 2000, SCAND J PRIM HEALTH, V18, P232; Tabachnick B. G., 2001, USING MULTIVARIATE S; Weinman J, 2000, BRIT J HEALTH PSYCH, V5, P263, DOI 10.1348/135910700168900; Weinman J, 1996, PSYCHOL HEALTH, V11, P431, DOI 10.1080/08870449608400270; Wiles R, 1998, SOC SCI MED, V46, P1477, DOI 10.1016/S0277-9536(97)10140-X; Wood D, 1998, J HYPERTENS, V16, P1407, DOI 10.1097/00004872-199816100-00003; Wood D, 1998, EUR HEART J, V19, P1434; [Anonymous], 1988, J CLIN EPIDEMIOL, V41, P105	54	106	109	5	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0022-3999			J PSYCHOSOM RES	J. Psychosomat. Res.	MAY	2005	58	5					403	415		10.1016/j.jpsychores.2004.11.010		13	Psychiatry	Psychiatry	955BV	WOS:000231200600003	16026655	
J	Colilla, S; Nicolae, D; Pluzhnikov, A; Blumenthal, MN; Beaty, TH; Bleecker, ER; Lange, EM; Rich, SS; Meyers, DA; Ober, C; Cox, NJ				Colilla, S; Nicolae, D; Pluzhnikov, A; Blumenthal, MN; Beaty, TH; Bleecker, ER; Lange, EM; Rich, SS; Meyers, DA; Ober, C; Cox, NJ		Collaborative Study Genetics Asthm	Evidence for gene-environment interactions in a linkage study of asthma and smoking exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; genetics; linkage; smoking; gene-environment interaction; environmental tobacco smoke; genetic epidemiology	GENOME-WIDE SEARCH; TOBACCO-SMOKE; CHILDHOOD ASTHMA; HOUSEHOLD SMOKING; PAIR LINKAGE; RISK-FACTORS; CHILDREN; CHROMOSOME-5; POPULATION; MARKERS	Background: Asthma, a common and chronic disease of the airways, has a multifactorial cause involving both genetic and environmental factors. As a result, mapping genes that influence asthma susceptibility has been challenging. Objective: This study tests the hypothesis that inclusion of exposure to environmental tobacco smoke (ETS), a potential risk factor for asthma, would improve the ability to map genes for asthma. Methods: By using 144 white families from the Collaborative Study for the Genetics of Asthma, environmental information about exposure to ETS during infancy was incorporated into a genome-wide multipoint linkage analysis. Statistical significance of observed gene-environment interactions was assessed by means of simulation. Results: Three regions with nominal evidence for linkage when stratified on the basis of ETS exposure were identified (P < .01) and showed a significant increase from the baseline lod score (1p at 97 cM, D1S1669-D1S1665; 5q at 135 cM, D5S1505-D5S816; and 9q at 106 cM, D9S910; all P < .05). In addition, 2 other regions, although not meeting nominal significance after stratification on the basis of ETS exposure, showed a significant increase from baseline lod score when ETS was taken into account (1q at 240 cM, D1S549; 17p at 3 cM, D17S1308; all P < .01). Conclusion: These results illustrate how evidence for linkage of asthma can depend on exposure to an environmental factor, such as ETS. Future linkage analyses should include information on suspected environmental factors for asthma to help target new candidate susceptibility genes for asthma.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Publ Hlth Sci, Winston Salem, NC 27103 USA	Cox, NJ (reprint author), Univ Chicago, Dept Human Genet, 920 E 58th St,Room 507, Chicago, IL 60637 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NCRR NIH HHS [RR 00055, RR 00400]; NHLBI NIH HHS [HL 49596, HL 49602, HL 49609, HL 49612, HL 58977]; NIDDK NIH HHS [DK 55889]		American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Barnes KC, 1999, CLIN EXP ALLERGY, V29, P47; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812; Ehrlich R, 2001, J ASTHMA, V38, P239, DOI 10.1081/JAS-100000111; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Gauderman WJ, 2001, HUM HERED, V52, P34, DOI 10.1159/000053352; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Goddard KAB, 2001, AM J HUM GENET, V68, P1197, DOI 10.1086/320103; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Greenwood CMT, 1997, GENET EPIDEMIOL, V14, P635; Greenwood CMT, 1999, AM J HUM GENET, V64, P871, DOI 10.1086/302288; Gudbjartsson DF, 2000, NAT GENET, V25, P12, DOI 10.1038/75514; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Jordaan ER, 1999, ARCH ENVIRON HEALTH, V54, P319; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Larsson ML, 2001, CHEST, V120, P711, DOI 10.1378/chest.120.3.711; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martin LJ, 2002, GENET EPIDEMIOL, V22, P105, DOI 10.1002/gepi.0135; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2000, CLIN CHEST MED, V21, P245, DOI 10.1016/S0272-5231(05)70264-1; Olson JM, 1999, AM J HUM GENET, V65, P1760, DOI 10.1086/302662; Palmer LJ, 2001, CLIN EXP ALLERGY, V31, P152; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	42	106	108	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					840	846		10.1067/mai.2003.170		7	Allergy; Immunology	Allergy; Immunology	667WW	WOS:000182258500027	12704367	
J	Gilliland, FD; Berhane, K; Li, YF; Rappaport, EB; Peters, JM				Gilliland, FD; Berhane, K; Li, YF; Rappaport, EB; Peters, JM			Effects of early onset asthma and in utero exposure to maternal smoking on childhood lung function	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; children; ETS; maternal smoking	ENVIRONMENTAL TOBACCO-SMOKE; SOUTHERN CALIFORNIA COMMUNITIES; PULMONARY-FUNCTION; CIGARETTE-SMOKING; PARENTAL SMOKING; RESPIRATORY ILLNESS; DIFFERING LEVELS; AIR-POLLUTION; IN-UTERO; CHILDREN	Both in utero exposures to maternal smoking and asthma are associated with chronic deficits in lung function. We hypothesized that in utero exposure affects lung function in children without asthma and synergistically affects children with early onset asthma. To investigate ate effects of in utero exposure and age at asthma diagnosis on lung function, we examined longitudinal medical history, tobacco smoke exposure, and lung function data from 5,933 participants in the Children's Health Study. We found that children exposed in utero, but without asthma, showed decreased FEV1/FVC, FEF25-75, and FEF25-75/FVC ratio. Among children without in utero exposure, early asthma diagnosis was associated. with larger decreases in FEV1, FEF25-75, and FEV1/FVC ratio compared with later diagnosed asthma. Children with in utero exposure alone and early onset asthma showed deficits in FEV1 (-13.6%; 95% confidence interval [CI], -18.9 to -8.2) and FEF25-75 (-29.7%; 95% Cl, -37.8 to -20.5) among boys; and FEF25-75 (-26.6%; 95% Cl, -36.4 to -15.1) and FEV1/FVC (-9.3%; 95% Cl, -12.9 to -5.4) among girls. The absolute differences in FEF25-75 associated with in utero exposure increased with age in children with early onset asthma. We found little evidence for effects from environmental tobacco smoke exposure alone. In summary, deficits in lung function were largest among children with in. utero exposure and early onset asthma.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St, Los Angeles, CA 90033 USA.		LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [1 R01 HL61768-03]; NIEHS NIH HHS [1 P01 ES09581-04, 5 P30 ES07048-08]		Berhane K, 2000, AM J RESP CRIT CARE, V162, P1723; BURR ML, 1975, THORAX, V30, P663, DOI 10.1136/thx.30.6.663; BURROWS B, 1980, AM REV RESPIR DIS, V122, P813; *CA EPA, 1997, HLTH EFF EXP ENV TOB; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; Cook DG, 1998, THORAX, V53, P884; COULTAS DB, 1989, AM J EPIDEMIOL, V130, P338; COULTAS DB, 1990, AM REV RESPIR DIS, V142, P602; CUNNINGHAM J, 1995, AM J RESP CRIT CARE, V152, P565; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Dezateux C, 1997, BRIT MED BULL, V53, P40; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Hanrahan J P, 1998, Eur Respir J Suppl, V27, p46s; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; HASTIE T, 1993, J ROY STAT SOC B MET, V55, P757; Hastie T, 1990, GEN ADDITIVE MODELS; Joad JP, 1999, TOXICOL APPL PHARM, V155, P253, DOI 10.1006/taap.1998.8612; LI Y, 2001, AM J RESP CRIT CARE, V163, pA263; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Neas LM, 1998, AM J EPIDEMIOL, V147, P1011; ORYSZCZYN MP, 1991, J ALLERGY CLIN IMMUN, V87, P1169, DOI 10.1016/0091-6749(91)92163-U; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; RONCHETTI R, 1994, EUR RESPIR J, V7, P472, DOI 10.1183/09031936.94.07030472; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TAGER IB, 1987, AM REV RESPIR DIS, V136, P1366; WANG XB, 1993, PEDIATR PULM, V15, P75, DOI 10.1002/ppul.1950150204; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Wypij D, 1996, AM J RESP CRIT CARE, V154, pS223; WYPIJ D, 1994, STAT SINICA, V3, P329	40	106	115	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 15	2003	167	6					917	924		10.1164/rccm.200206-616OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	653MA	WOS:000181439100019	12480608	
J	Wiemels, JL; Wiencke, JK; Sison, JD; Miike, R; McMillan, A; Wrensch, M				Wiemels, JL; Wiencke, JK; Sison, JD; Miike, R; McMillan, A; Wrensch, M			History of allergies among adults with glioma and controls	INTERNATIONAL JOURNAL OF CANCER			English	Article						allergy; glioma; brain cancer; case-control study	BRAIN-TUMORS; MEDICAL HISTORY; RISK-FACTORS; ASSOCIATION; ASTHMA; INTERLEUKIN-4; INFECTION; CHILDREN; CANCERS; SAMPLE	The causes of most adult gliomas are essentially unknown. Previous studies have indicated associations between immune system factors and the incidence of adult glioma, specifically that those individuals with certain allergic conditions may have decreased risk of glioma. We obtained detailed allergy histories for 405 adults newly diagnosed with glioma in the San Francisco Bay Area from 1997-1999 and 402 age-gender-ethnicity frequency-matched population-based controls. Seventy-nine percent of eligible cases or their proxies and 74% of eligible controls completed in-person interviews about allergies, age at onset, frequency, duration and severity. Overall, cases were less likely than controls to report any allergy (72% vs. 85%; odds ratio [OR] = 0.5 [0.3-0.7]); for self-reported cases (n = 269), OR = 0.7 (0.4-0.97) and for proxy-reported cases, OR = 0.3 (0.2-0.5). Pollen, dairy and nut allergies were significantly less common in cases than controls and most other allergens had odds ratios of less than one. There were no apparent trends with numbers of symptoms, route of exposure of allergen or reported severity of allergy, but there was a significant dose-response with increasing numbers of allergens (p < 0.0001 for linear trend among all cases vs. controls and p = 0.02 among self-reported cases only vs. controls). Although our work displays strong and consistent associations, future efforts must attempt to establish whether an immune system typified by proclivity to allergies, or an immunologic consequence of the allergies themselves, might be capable of preventing nascent brain tumors. The dominance of humoral immunity in the central nervous system is consistent with either of these models. Alternatively, common genetic or environmental causes for allergies and gliomagenesis may mediate or confound these observed inverse risks for allergies and gliomas, or other explanations may exist. Future work might reveal an important role for immunologic factors in gliomagenesis and potential preventative and/or therapeutic modalities. (C) 2002 Wiley-Liss, Inc.	Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA 94102 USA; Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94102 USA	Wrensch, M (reprint author), Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, 44 Page St,Suite 503, San Francisco, CA 94102 USA.				NCI NIH HHS [CA89032, R01CA52689]; NIEHS NIH HHS [ES04705, ES06717]		Antel J, 1998, CLIN NEUROIMMUNOLOGY; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BARKER CF, 1977, ADV IMMUNOL, V25, P1; Benedetti S, 2000, NAT MED, V6, P447; Bischoff SC, 1997, GUT, V40, P745; BONDY M, 1994, J NEURO-ONCOL, V18, P69, DOI 10.1007/BF01324606; BRENNER A, 2001, TOR C EP, pS120; BURR ML, 1993, MONOGR ALLERGY, V31, P1; Caggana M, 2001, CANCER EPIDEM BIOMAR, V10, P355; Chen PC, 2000, CANCER EPIDEM BIOMAR, V9, P843; Chen PC, 2001, CANCER RES, V61, P3949; Debinski W, 1999, CLIN CANCER RES, V5, P985; Del Valle L, 2001, CANCER RES, V61, P4287; Dix AR, 1999, J NEUROIMMUNOL, V100, P216, DOI 10.1016/S0165-5728(99)00203-9; Harling-Berg CJ, 1999, J NEUROIMMUNOL, V101, P111, DOI 10.1016/S0165-5728(99)00130-7; Howarth PH, 1998, CLIN EXP ALLERGY, V28, P2; Kawano N, 2000, ACTA NEUROPATHOL, V99, P214; Knopf PM, 1998, J IMMUNOL, V161, P692; Legler JM, 1999, J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; MANJULA S, 1992, ACTA NEUROCHIR, V115, P103, DOI 10.1007/BF01406366; NASCA PC, 1988, AM J EPIDEMIOL, V128, P1256; Peat JK, 1996, ALLERGY, V51, P804, DOI 10.1111/j.1398-9995.1996.tb04470.x; Percy C, 1990, INT CLASSIFICATION D; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; *SAS I INC, 1990, AS STAT US GUID; Sawamura Yutaka, 1995, P113; SCHLEHOFER B, 1992, CANCER, V69, P2541, DOI 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>3.0.CO;2-H; Schlehofer B, 1999, INT J CANCER, V82, P155, DOI 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Shah KV, 2000, REV MED VIROL, V10, P31, DOI 10.1002/(SICI)1099-1654(200001/02)10:1<31::AID-RMV260>3.0.CO;2-I; TEPPER RI, 1992, SCIENCE, V257, P548, DOI 10.1126/science.1636093; VENA JE, 1985, AM J EPIDEMIOL, V122, P66; Wrensch M, 1997, AM J EPIDEMIOL, V145, P581; Wrensch M, 2001, AM J EPIDEMIOL, V154, P161, DOI 10.1093/aje/154.2.161; Wrensch M, 1997, AM J EPIDEMIOL, V145, P594; Zou JP, 1999, J IMMUNOL, V162, P4882	37	106	109	1	3	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0020-7136			INT J CANCER	Int. J. Cancer	APR 1	2002	98	4					609	615		10.1002/ijc.10239		7	Oncology	Oncology	527DT	WOS:000174171800018	11920623	
J	Custovic, A; Hallam, CL; Simpson, BM; Craven, M; Simpson, A; Woodcock, A				Custovic, A; Hallam, CL; Simpson, BM; Craven, M; Simpson, A; Woodcock, A		Natl Asthma Campaign Manchester As	Decreased prevalence of sensitization to cats with high exposure to cat allergen	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						sensitization; asthma; allergic disease; cat; dog; dust mite; allergens; exposure	ASTHMA; ENVIRONMENT; CHILDREN; RISK	We investigated the relationship between current exposure to cat allergen and sensitization to cats. A questionnaire was administered and skin prick testing and home visits for collection of dust samples (Fel d 1; ELISA) were performed in 2502 adults (mean age, 31.8 years; age range, 18-58 years; 1251 women). The results for Fel d 1 in relation to sensitization to cats were analyzed for 10 deciles of cat allergen exposure (cut points [mug/g]: 0.05, 0.34, 0.48, 0.72, 1.13, 1.92, 7.2, 44, 151). The prevalence of sensitization to cat was significantly decreased in the lowest and the highest exposure groups. In the multivariate regression analysis (age, sex, socioeconomic status, and current smoking being adjusted for), the risk of sensitization to cats was significantly increased with medium exposure to Fel d 1 (3rd centile, OR 2.3, 95% CI 1.2-4.4, P = .01; 4th centile, OR 2.1, 95% CI 1.1-4.0, P = .03; 5th centile, OR 2.2, 95% CI 1.2-4.3, P = .04, 6th centile, OR 2.5, 95% CI 1.3-4.9, P = .005). These results indicate that the prevalence of sensitization to cat is decreased in the lowest and highest cat allergen exposure groups.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Custovic, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666			Custovic A, 1998, THORAX, V53, P33; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; MILLS TAE, 2001, LANCET, V357, P752; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; Wickens K, 1999, PEDIATR ALLERGY IMMU, V10, P199, DOI 10.1034/j.1399-3038.1999.00033.x	10	106	107	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					537	539				3	Allergy; Immunology	Allergy; Immunology	485NK	WOS:000171760300011	11590378	
J	Bousquet, J				Bousquet, J			Global Initiative for Asthma (GINA) and its objectives	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; guidelines; GINA; corticosteroids; leukotriene receptor antagonists; prevalence	CLINICAL GUIDELINES	Guidelines for the diagnosis and management of asthma have been available for the past 13 years and are updated regularly. However, asthma guidelines are rarely completely up-to-date because our knowledge about the pathophysiology and treatment of asthma is continually evolving. Guidelines are an increasingly familiar part of clinical practice and may have potential benefits and harms. The potential harms of guidelines can be minimized if they are rigorously developed using evidence-based medicine. Guidelines should identify key decisions and their consequences and should review the consequences of alternative decisions. In addition, guidelines should be simple, user-friendly and widely disseminated. Guidelines evolve over time and their recommendations should be supported by evidence from clinical trials. Evidence-based medicine is the new paradigm but the results and reaction to the recent meta-analysis on house-dust mite control measures highlights the need for care when incorporating such information into guidelines. Newer therapeutic agents such as the leukotriene receptor antagonists are included in the most recent revision of the GINA guidelines, but their position in asthma therapy is not yet fully established. In countries where asthma guidelines have been implemented, there appears to have been a reduction in the prevalence of moderate persistent asthma but no decrease in severe asthma. This indicates that there is still room for improvement.	Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France	Bousquet, J (reprint author), Hop Arnaud de Villeneuve, Serv Malad Resp, F-34295 Montpellier 5, France.						Gotzsche PC, 1998, BRIT MED J, V317, P1105; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; Jackson R, 1998, BRIT MED J, V317, P427; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; REDDEL H, 1999, LANCET, V553, P14; Strachan DP, 1998, BRIT MED J, V317, P1096; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403; WARNER JO, 1998, INT PEDIAT ASTHMA CO, V25, P1; *WHO NHLBI, 1995, NATL HEART LUNG BLOO; Woolf SH, 1999, BRIT MED J, V318, P527; [Anonymous], 1997, NIH PUBLICATION	13	106	114	1	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2000	30			1			2	5				4	Allergy; Immunology	Allergy; Immunology	328RM	WOS:000087863900002	10849466	
J	Subbarao, P; Mandhane, PJ; Sears, MR				Subbarao, Padmaja; Mandhane, Piush J.; Sears, Malcolm R.			Asthma: epidemiology, etiology and risk factors	CANADIAN MEDICAL ASSOCIATION JOURNAL			English	Review							RESPIRATORY-SYNCYTIAL-VIRUS; HOUSE-DUST MITE; PROSPECTIVE BIRTH-COHORT; SKIN-TEST REACTIVITY; ADULT-ONSET ASTHMA; BODY-MASS INDEX; 1ST 2 YEARS; CHILDHOOD ASTHMA; LUNG-FUNCTION; PULMONARY-FUNCTION		[Subbarao, Padmaja] Univ Toronto, Hosp Sick Children, Dept Pediat Respirol, Toronto, ON M5G 1X8, Canada; [Mandhane, Piush J.] Univ Alberta, Dept Pediat Respirol, Edmonton, AB, Canada; [Sears, Malcolm R.] McMaster Univ, Dept Med, Hamilton, ON, Canada	Sears, MR (reprint author), Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	searsm@mcmaster.ca			AstraZeneca Canada; GlaxoSmithKline Inc.; Merck Frosst Canada; Novartis Pharmaceuticals	The Canadian Thoracic Society has received funding to facilitate the knowledge translation activities of the CTS Asthma Committee from AstraZeneca Canada, GlaxoSmithKline Inc., Merck Frosst Canada and Novartis Pharmaceuticals. None of the sponsors played a role in the collection, review, analysis or interpretation of the scientific literature or in any decisions regarding the key messages presented in the case studies.	Alm B, 2008, PEDIATRICS, V121, P697, DOI 10.1542/peds.2007-1232; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Annesi-Maesano I, 2001, ALLERGY, V56, P491, DOI 10.1034/j.1398-9995.2001.056006491.x; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P153, DOI 10.1097/01.all.0000162308.89857.6c; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Bakerly ND, 2008, OCCUP MED-OXFORD, V58, P169, DOI 10.1093/occmed/kqn007; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Bauer BA, 1997, CHEST, V111, P303, DOI 10.1378/chest.111.2.303; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Becklake MR, 1999, THORAX, V54, P1119; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P72, DOI 10.1067/mai.2002.125833; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bernsen RMD, 2003, PEDIATR ALLERGY IMMU, V14, P464, DOI 10.1046/j.0905-6157.2003.00108.x; Bjornson C L, 2000, J Gend Specif Med, V3, P57; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; BUSINCO L, 1983, CLIN ALLERGY, V13, P503, DOI 10.1111/j.1365-2222.1983.tb02631.x; Butland BK, 2007, ANN ALLERG ASTHMA IM, V98, P337; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Carlsen KCL, 2002, PEDIATR ALLERGY IMMU, V13, P29; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chen CH, 2006, J ASTHMA, V43, P287, DOI 10.1080/02770900600622935; Chen Y, 2003, J CLIN EPIDEMIOL, V56, P180, DOI 10.1016/S0895-4356(02)00593-0; Chen Y, 2003, PEDIATR PULM, V36, P22, DOI 10.1002/ppul.10307; CLARKE JR, 1992, ARCH DIS CHILD, V67, P1454; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; CLINE MG, 1989, THORAX, V44, P425, DOI 10.1136/thx.44.5.425; Cohen RT, 2007, CHEST, V131, P1331, DOI 10.1378/chest.06-1917; CRAWFORD WA, 1976, MED J AUSTRALIA, V1, P430; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; Dell S, 2001, ARCH PEDIAT ADOL MED, V155, P1261; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Devereux G, 2007, AM J CLIN NUTR, V85, P853; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Eagan TML, 2002, AM J RESP CRIT CARE, V166, P933, DOI 10.1164/rccm.200203-238OC; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570; Erzen D, 1997, AM J RESP CRIT CARE, V155, P1060; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; FALTHMAGNUSSON K, 1987, J ALLERGY CLIN IMMUN, V80, P868, DOI 10.1016/S0091-6749(87)80279-8; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Frey U, 2004, AM J RESP CRIT CARE, V170, P260, DOI 10.1164/rccm.200307-1002OC; Friedlander Samuel L, 2005, Pediatr Infect Dis J, V24, pS170, DOI 10.1097/01.inf.0000187273.47390.01; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1094, DOI DOI 10.1164/RCCM.200605-722OC; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106; Goldberg S, 2007, CHEST, V131, P1747, DOI 10.1378/chest.06-2818; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; Gustafsson PM, 2000, RESP MED, V94, P466, DOI 10.1053/rmed.1999.0763; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; HALFON N, 1993, PEDIATRICS, V91, P56; HAMMAN RF, 1975, BRIT J PREV SOC MED, V29, P228; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hattevig G, 1999, ACTA PAEDIATR, V88, P7; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Holberg CJ, 1996, AM J RESP CRIT CARE, V154, P144; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jaakkola MS, 2006, J ALLERGY CLIN IMMUN, V117, P642, DOI 10.1016/j.jaci.2005.11.003; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jedrychowski Wieslaw, 2006, International Journal of Occupational Medicine and Environmental Health, V19, P70, DOI 10.2478/v10001-006-0010-0; Johnston FH, 2006, INT J ENVIRON HEAL R, V16, P391, DOI 10.1080/09603120601093642; Johnston NW, 2006, THORAX, V61, P722, DOI 10.1136/thx.2005.045161; Joseph CLM, 1998, J ALLERGY CLIN IMMUN, V101, P484, DOI 10.1016/S0091-6749(98)70355-0; Joshi P, 2003, CLIN EXP IMMUNOL, V131, P143, DOI 10.1046/j.1365-2249.2003.02039.x; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956; Kao CC, 2001, ASIAN PAC J ALLERGY, V19, P63; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Kinra S, 2006, THORAX, V61, P48, DOI 10.1136/thx.2004.034595; KJELLMAN B, 1994, ACTA PAEDIATR, V83, P854; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; KLINNERT MD, 1994, PSYCHIATRY, V57, P51; Kogevinas M, 2007, LANCET, V370, P336, DOI 10.1016/S0140-6736(07)61164-7; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Kramer MS, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000133.pub2; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kummeling I, 2007, PEDIATRICS, V119, pE225, DOI 10.1542/peds.2006-0896; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; Le Moual N, 2004, AM J EPIDEMIOL, V160, P1108, DOI 10.1093/aje/kwh316; Lemanske RF, 2006, J ALLERGY CLIN IMMUN, V117, pS456, DOI 10.1016/j.jaci.2005.07.006; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LESOUEF PN, 1995, AM J RESP CRIT CARE, V152, P576; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413; LILJA G, 1988, CLIN ALLERGY, V18, P131, DOI 10.1111/j.1365-2222.1988.tb02852.x; Lin RY, 1995, J MED, V26, P261; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903; LOVEGROVE JA, 1994, BRIT J NUTR, V71, P223, DOI 10.1079/BJN19940129; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MARTINEZ FD, 1999, LANCET S2, V354; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Meurer JR, 2000, ARCH PEDIAT ADOL MED, V154, P143; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Nafstad P, 2003, EUR J EPIDEMIOL, V18, P755; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Nicolai T, 2001, PEDIATR ALLERGY IMMU, V12, P142, DOI 10.1034/j.1399-3038.2001.0007.x; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Oddy W H, 2000, Breastfeed Rev, V8, P5; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Oryszczyn MP, 2007, J ALLERGY CLIN IMMUN, V119, P57, DOI 10.1016/j.jaci.2006.09.026; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; PECKHAM C, 1978, J EPIDEMIOL COMMUN H, V32, P79, DOI 10.1136/jech.32.2.79; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Prescott SL, 2003, ALLERGY, V58, P1187, DOI 10.1034/j.1398-9995.2003.00263.x; Qiu J, 2006, NATURE, V441, P143, DOI 10.1038/441143a; Roche WR, 1998, AM J RESP CRIT CARE, V157, pS191; Romieu I, 2007, CLIN EXP ALLERGY, V37, P518, DOI 10.1111/j.1365-2222.2007.02685.x; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schaubel D, 1996, J ASTHMA, V33, P97, DOI 10.3109/02770909609054537; SCHWARTZ J, 1995, AM J RESP CRIT CARE, V152, P2176; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 1996, ARCH DIS CHILD, V75, P392; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SEARS MR, 1994, BRIT MED J, V309, P72; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; SHERRILL D, 1992, PEDIATR PULM, V13, P78, DOI 10.1002/ppul.1950130204; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136; SIGURS N, 1992, PEDIATRICS, V89, P735; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simpson A, 2005, CURR ALLERGY ASTHM R, V5, P212, DOI 10.1007/s11882-005-0040-x; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; STRACHAN DP, 1989, BRIT MED J, V299, P1259; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174; Subbarao P, 2009, EXPERT REV CLIN IMMU, V5, P77, DOI 10.1586/1744666X.5.1.77; Takkouche B, 2008, ALLERGY, V63, P857, DOI 10.1111/j.1398-9995.2008.01732.x; Tariq SM, 1999, CLIN EXP ALLERGY, V29, P1042; Tariq SM, 2000, POSTGRAD MED J, V76, P694, DOI 10.1136/pmj.76.901.694; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Taylor DR, 2002, ADDICTION, V97, P1055, DOI 10.1046/j.1360-0443.2002.00169.x; Tetrault JM, 2007, ARCH INTERN MED, V167, P221, DOI 10.1001/archinte.167.3.221; To T, 1996, PEDIATRICS, V98, P191; Trawick DR, 2001, CHEST, V119, P115, DOI 10.1378/chest.119.1.115; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183; Tulic MK, 2004, LANCET, V363, P1689, DOI 10.1016/S0140-6736(04)16253-3; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Von Behren J, 1999, J ASTHMA, V36, P575, DOI 10.3109/02770909909087294; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wang HY, 2008, CAN MED ASSOC J, V179, P1133, DOI 10.1503/cmaj.071797; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; WEISS ST, 1993, J ASTHMA, V30, P329, DOI 10.3109/02770909309056738; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; WILKINS K, 1993, CAN MED ASSOC J, V148, P185; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; WILLIAMS H, 1969, BRIT MED J, V4, P321; Wright AL, 2000, ADV EXP MED BIOL, V478, P131; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; Zannolli R, 1997, MED HYPOTHESES, V48, P27, DOI 10.1016/S0306-9877(97)90020-7; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	196	105	112	3	27	CMA-CANADIAN MEDICAL ASSOC	OTTAWA	1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 3Y6, CANADA	0820-3946			CAN MED ASSOC J	Can. Med. Assoc. J.	OCT 27	2009	181	9					E181	E190		10.1503/cmaj.080612		10	Medicine, General & Internal	General & Internal Medicine	507PI	WOS:000270866300023	19752106	
J	Marsh, SE; Travers, J; Weatherall, M; Williams, MV; Aldington, S; Shirtcliffe, PM; Hansell, AL; Nowitz, MR; McNaughton, AA; Soriano, JB; Beasley, RW				Marsh, S. E.; Travers, J.; Weatherall, M.; Williams, M. V.; Aldington, S.; Shirtcliffe, P. M.; Hansell, A. L.; Nowitz, M. R.; McNaughton, A. A.; Soriano, J. B.; Beasley, R. W.			Proportional classifications of COPD phenotypes	THORAX			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; LUNG-FUNCTION; REFERENCE VALUES; VENN-DIAGRAM; RISK-FACTORS; MILD ASTHMA; FOLLOW-UP; POPULATION; PREVALENCE	Background: Chronic obstructive pulmonary disease (COPD) encompasses a group of disorders characterised by the presence of incompletely reversible airflow obstruction with overlapping subsets of different phenotypes including chronic bronchitis, emphysema or asthma. The aim of this study was to determine the proportion of adult subjects aged > 50 years within each phenotypic subgroup of COPD, defined as a post-bronchodilator ratio of forced expiratory volume in 1 s/forced vital capacity (FEV(1)/FVC) < 0.7, in accordance with current international guidelines. Methods: Adults aged > 50 years derived from a random population-based survey undertook detailed questionnaires, pulmonary function tests and chest CT scans. The proportion of subjects in each of 16 distinct phenotypes was determined based on combinations of chronic bronchitis, emphysema and asthma, with and without incompletely reversible airflow obstruction defined by a post-bronchodilator FEV(1)/FVC ratio of 0.7. Results: A total of 469 subjects completed the investigative modules, 96 of whom (20.5%) had COPD. Diagrams were constructed to demonstrate the relative proportions of the phenotypic subgroups in subjects with and without COPD. 18/96 subjects with COPD (19%) had the classical phenotypes of chronic bronchitis and/or emphysema but no asthma; asthma was the predominant COPD phenotype, being present in 53/96 (55%). When COPD was defined as a post-bronchodilator FEV(1)/FVC less than the lower limit of normal, there were one-third fewer subjects with COPD and a smaller proportion without a defined emphysema, chronic bronchitis or asthma phenotype. Conclusion: This study provides proportional classifications of the phenotypic subgroups of COPD which can be used as the basis for further research into the pathogenesis and treatment of this heterogeneous disorder.	[Marsh, S. E.; Travers, J.; Williams, M. V.; Aldington, S.; Shirtcliffe, P. M.; McNaughton, A. A.; Beasley, R. W.] Med Res Inst New Zealand, Wellington 6143, New Zealand; [Weatherall, M.; Nowitz, M. R.] Wellington Sch Med & Hlth Sci, Wellington, New Zealand; [Hansell, A. L.] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London, England; [Nowitz, M. R.] Pacific Radiol Ltd, Wellington, New Zealand; [Soriano, J. B.] Fundacao Caubet CIMERA Illes, Balears, Bunyola, Spain; [Beasley, R. W.] Univ Southampton, Southampton, Hants, England	Beasley, RW (reprint author), Med Res Inst New Zealand, POB 10055, Wellington 6143, New Zealand.	richard.beasley@mrinz.ac.nz		Travers, Justin/0000-0002-5992-7682; Beasley, Richard/0000-0003-0337-406X; Soriano, Joan B/0000-0001-9740-2994	GlaxoSmithKline; ALH [075883]	The study was funded by a research grant from GlaxoSmithKline. ALH is a Wellcome Trust Intermediate Clinical Fellow supported by Grant Number 075883.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P2185; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Celli Bartolome R, 2006, Proc Am Thorac Soc, V3, P461, DOI 10.1513/pats.200603-029MS; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Cerveri I, 2004, CHEST, V125, P1714, DOI 10.1378/chest.125.5.1714; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chow S, 2004, LECT NOTES COMPUT SC, V2912, P466; Coxson HO, 2005, ACAD RADIOL, V12, P1457, DOI 10.1016/j.acra.2005.08.013; Di Battista G., 1999, GRAPH DRAWING ALGORI; ENRIGHT PL, 1993, AM REV RESPIR DIS, V147, P125; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; GINA, 2004, GLOB STRAT ASTHM MAN; Global Initiative for Chronic Obstructive Lung Disease (GOLD), GLOB STRAT DIAGN MAN; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Johannessen A, 2005, THORAX, V60, P842, DOI 10.1136/thx.2005.043943; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Mannino DM, 2007, EUR RESPIR J, V30, P189, DOI 10.1183/09031936.00058707; Mannino DM, 2006, EUR RESPIR J, V27, P627, DOI 10.1183/09031936.06.00024605; Mannino DM, 2002, CHEST, V121, p121S, DOI 10.1378/chest.121.5_suppl.121S; Marsh S, 2007, RESP MED, V101, P1512, DOI 10.1016/j.rmed.2007.01.002; Marsh Suzanne, 2006, N Z Med J, V119, pU2281; Marshall RJ, 2005, J CLIN EPIDEMIOL, V58, P974, DOI 10.1016/j.jclinepi.2005.01.018; Mishima M, 1999, J COMPUT ASSIST TOMO, V23, P380, DOI 10.1097/00004728-199905000-00011; Muller NL, 2002, THORAX, V57, P982, DOI 10.1136/thorax.57.11.982; National Institute for Health and Clinical Excellence, 2004, THORAX S1, V59, pS1; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Shirtcliffe P, 2007, EUR RESPIR J, V30, P232, DOI 10.1183/09031936.00157906; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; SNIDER GL, 1989, AM REV RESPIR DIS, V140, pS3; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Sterk PJ, 2004, EUR RESPIR J, V23, P497, DOI 10.1183/09031936.04.00017104; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Travers J, 2007, RESP MED, V101, P1313, DOI 10.1016/j.rmed.2006.10.011; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; Viegi G, 2004, CHEST, V126, P1093, DOI 10.1378/chest.126.4.1093; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; [Anonymous], 1959, THORAX, V14, P286	44	105	111	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	SEP	2008	63	9					761	767		10.1136/thx.2007.089193		7	Respiratory System	Respiratory System	341PF	WOS:000258725700004	18728201	
J	Jacobsen, EA; Taranova, AG; Lee, NA; Lee, JJ				Jacobsen, Elizabeth A.; Taranova, Anna G.; Lee, Nancy A.; Lee, James J.			Eosinophils: Singularly destructive effector cells or purveyors of immunoregulation?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eosinophil; immunoregulation; inflammation; innate; antigen presentation; granulocyte	SMOOTH-MUSCLE-CELLS; MAST-CELLS; CHEMOTACTIC ACTIVITIES; AIRWAY INFLAMMATION; LYMPH-NODES; T-CELLS; EXPRESSION; IL-4; ANTIGEN; ASTHMA	Eosinophils are granulocytes typically associated with immune responses to a limited number of specific insults, including helminth infection and exposure to various allergens. Moreover, the overwhelming consensus from the literature is that eosinophils evolved as uniquely destructive leukocytes with cytotoxic activities as an adaptation for host defense. However, recent studies now suggest that the parochial caricature of eosinophils as effector cells with nonspecific killing abilities that evolved as a host defense mechanism against large nonphagotizable parasites is incomplete. A new paradigm has emerged describing eosinophils as initial responders to cell death/tissue damage that are a part of remodeling/repair processes and, more importantly, significant contributors to localized innate and acquired immune responses as well as systemic adaptive immunity. Significantly, this new paradigm does not preclude roles for cosinophils in host defense leading to tissue damage but instead suggests the equal importance of eosinophil-associated regulatory mechanisms modulating local tissue immune responses. The goal of this review is to summarize the data in support of this new paradigm. In turn, we believe that this expanded role provides a probable explanation for the presence of eosinophils in diverse disease settings such as asthma, allergy, cancer, transplant rejection, gastrointestinal inflammation, and viral or helminth infection.	Mayo Clin, Coll Med, Div Pulm Med, Scottsdale, AZ 85259 USA; Mayo Clin, Coll Med, Div Hematol & Oncol, Dept Biochem & Mol Biol, Scottsdale, AZ 85259 USA	Lee, JJ (reprint author), Mayo Clin, Coll Med, Div Pulm Med, SC Johnson Med Res Bldg,13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	jjlee@mayo.edu			NCI NIH HHS [CA112442]; NHLBI NIH HHS [F32HL085014, F32 HL083718, HL07897, HL58723, HL65228]		Chen LQ, 2004, J IMMUNOL, V172, P2059; Cormier SA, 2006, J LEUKOCYTE BIOL, V79, P1131, DOI 10.1189/jlb.0106027; DEBINSKI W, 1995, J BIOL CHEM, V270, P16775; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; Fryer AD, 2006, J CLIN INVEST, V116, P228, DOI 10.1172/JCI25423; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Fulkerson PC, 2005, CLIN EXP ALLERGY, V35, P1251, DOI 10.1111/j.1365-2222.2005.02354.x; Gessner A, 2005, J IMMUNOL, V174, P1063; Gharaee-Kermani M, 1998, INT J MOL MED, V1, P43; GLEICH GJ, 1984, ANNU REV IMMUNOL, V2, P429, DOI 10.1146/annurev.immunol.2.1.429; Gordon S, 1998, RES IMMUNOL, V149, P685, DOI 10.1016/S0923-2494(99)80039-X; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; Joubert P, 2005, J IMMUNOL, V175, P2702; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL302; Lamkhioued B, 1996, ANN NY ACAD SCI, V796, P203, DOI 10.1111/j.1749-6632.1996.tb32582.x; Lampinen M, 2004, ALLERGY, V59, P793, DOI 10.1111/j.1398-9995.2004.00469.x; LEE I, 1995, PATHOL INT, V45, P655, DOI 10.1111/j.1440-1827.1995.tb03518.x; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; MacKenzie JR, 2001, J IMMUNOL, V167, P3146; Miyahara N, 2005, J IMMUNOL, V174, P4979; MULLER E, 1977, HISTOCHEMISTRY, V52, P273, DOI 10.1007/BF00495862; Nagase H, 2003, J IMMUNOL, V171, P3977; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909; Ohno I, 1996, AM J RESP CELL MOL, V15, P404; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Pang LH, 2006, J IMMUNOL, V176, P3788; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Puxeddu I, 2005, J ALLERGY CLIN IMMUN, V116, P531, DOI 10.1016/j.jaci.2005.06.007; Raines EW, 2005, J LIPID RES, V46, P1081, DOI 10.1194/jlr.R500004-JLR200; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871; Schmid-Grendelmeier P, 2002, J IMMUNOL, V169, P1021; Shakoory B, 2004, J INTERF CYTOK RES, V24, P271, DOI 10.1089/107999004323065057; Shi HZ, 2004, ALLERGY, V59, P428, DOI 10.1046/j.1398-9995.2003.00405.x; Spina D, 2002, TRENDS PHARMACOL SCI, V23, P311, DOI 10.1016/S0165-6147(02)02022-9; Spoelstra FM, 2001, CLIN EXP ALLERGY, V31, P808, DOI 10.1046/j.1365-2222.2001.01111.x; Stellato C, 2000, CHEM IMMUNOL, V76, P156; Sur S, 1998, J LEUKOCYTE BIOL, V63, P715; Surquin M, 2002, J IMMUNOL, V169, P500; Swartz JM, 2006, BLOOD, V108, P2420, DOI 10.1182/blood-2006-04-015933; Tachimoto H, 2000, CHEM IMMUNOL, V76, P45; Throsby M, 2000, J IMMUNOL, V165, P1965; van Rijt LS, 2003, J IMMUNOL, V171, P3372; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Walsh GM, 2001, CLIN EXP ALLERGY, V31, P351, DOI 10.1046/j.1365-2222.2001.01032.x; Watt A. P., 2005, Current Drug Targets - Inflammation and Allergy, V4, P415, DOI 10.2174/1568010054526313; Yang D, 2003, BLOOD, V102, P3396, DOI 10.1182/blood-2003-01-0151	48	105	113	3	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1313	1320		10.1016/j.jaci.2007.03.043		8	Allergy; Immunology	Allergy; Immunology	178PO	WOS:000247232800003	17481717	
J	Landrigan, PJ; Trasande, L; Thorpe, LE; Gwynn, C; Lioy, PJ; D'Alton, ME; Lipkind, HS; Swanson, J; Wadhwa, PD; Clark, EB; Rauh, VA; Perera, FP; Susser, E				Landrigan, Philip J.; Trasande, Leonardo; Thorpe, Lorna E.; Gwynn, Charon; Lioy, Paul J.; D'Alton, Mary E.; Lipkind, Heather S.; Swanson, James; Wadhwa, Pathik D.; Clark, Edward B.; Rauh, Virginia A.; Perera, Frederica P.; Susser, Ezra			The National Children's Study: A 21-year prospective study of 100 000 American children	PEDIATRICS			English	Review						National Children's Study; epidemiology; asthma; attention-deficit/hyperactivity disorder; autism; schizophrenia; obesity	CORONARY HEART-DISEASE; TESTICULAR DYSGENESIS SYNDROME; IMPAIRED GLUCOSE-TOLERANCE; ABDOMINAL-WALL DEFECTS; ADULT-BLOOD PRESSURE; INNER-CITY HOMES; BONE LEAD LEVELS; PHYSICAL-ACTIVITY; ENVIRONMENTAL-HEALTH; RISK-FACTORS	Prospective, multiyear epidemiologic studies have proven to be highly effective in discovering preventable risk factors for chronic disease. Investigations such as the Framingham Heart Study have produced blueprints for disease prevention and saved millions of lives and billions of dollars. To discover preventable environmental risk factors for disease in children, the US Congress directed the National Institute of Child Health and Human Development, through the Children's Health Act of 2000, to conduct the National Children's Study. The National Children's Study is hypothesis-driven and will seek information on environmental risks and individual susceptibility factors for asthma, birth defects, dyslexia, attention-deficit/hyperactivity disorder, autism, schizophrenia, and obesity, as well as for adverse birth outcomes. It will be conducted in a nationally representative, prospective cohort of 100 000 US-born children. Children will be followed from conception to 21 years of age. Environmental exposures (chemical, physical, biological, and psychosocial) will be assessed repeatedly during pregnancy and throughout childhood in children's homes, schools, and communities. Chemical assays will be performed by the Centers for Disease Control and Prevention, and banks of biological and environmental samples will be established for future analyses. Genetic material will be collected on each mother and child and banked to permit study of gene-environment interactions. Recruitment is scheduled to begin in 2007 at 7 Vanguard Sites and will extend to 105 sites across the United States. The National Children's Study will generate multiple satellite studies that explore methodologic issues, etiologic questions, and potential interventions. It will provide training for the next generation of researchers and practitioners in environmental pediatrics and will link to planned and ongoing prospective birth cohort studies in other nations. Data from the National Children's Study will guide development of a comprehensive blueprint for disease prevention in children.	Ctr Childrens Hlth & Environm, Dept Community & Prevent Med, Mt Sinai Sch Med, New York, NY 10029 USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; New York City Dept Hlth & Mental Hyg, Div Epidemiol, New York, NY USA; Univ Med & Dent New Jersey, Environm & Occupat Hlth & Safety Inst, Piscataway, NJ 08854 USA; Columbia Univ, Med Ctr, Div Maternal Fetal Med, New York, NY USA; Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Psychiat & Human Behav, Irvine, CA 92717 USA; Univ Utah, Dept Pediat, Salt Lake City, UT USA; Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, Dept Environm Hlth Sci, New York, NY USA; Mailman Sch Publ Hlth, Heilbrunn Dept Populat & Family Hlth, Dept Epidemiol, New York, NY USA	Landrigan, PJ (reprint author), Ctr Childrens Hlth & Environm, Dept Community & Prevent Med, Mt Sinai Sch Med, 1 Gustave L Levy Pl,POB 1057, New York, NY 10029 USA.	phil.landrigan@mssm.edu	Lioy, Paul/F-6148-2011	Trasande, Leonardo/0000-0002-1928-597X	NICHD NIH HHS [N01-HD-5-3411]		Ahlgren M, 2004, NEW ENGL J MED, V351, P1619, DOI 10.1056/NEJMoa040576; Ananth CV, 2005, AM J OBSTET GYNECOL, V193, P1076, DOI 10.1016/j.ajog.2005.06.042; *AUSTR I FAM STUD, GROW AUSTR; BAGHURST PA, 1987, NEUROTOXICOLOGY, V8, P395; Barker D., 1992, FETAL INFANT ORIGINS; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1995, BRIT MED J, V311, P171; BARKER DJP, 1986, LANCET, V1, P1077; BECERRA JE, 1990, PEDIATRICS, V85, P1; Bellinger DC, 2004, PEDIATRICS, V113, P1016; Berkowitz GS, 2004, ENVIRON HEALTH PERSP, V112, P388, DOI 10.1289/ehp.6414; Berkowitz GS, 2001, ENVIRON RES, V85, P59, DOI 10.1006/enrs.2000.4109; Berrigan D, 2002, AM J PREV MED, V23, P74, DOI 10.1016/S0749-3797(02)00476-2; Bertrand J, 2001, PEDIATRICS, V108, P1155, DOI 10.1542/peds.108.5.1155; Broman SH, 1984, HDB LONGITUDINAL RES, P166; Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774; BUKA SL, 1993, ARCH GEN PSYCHIAT, V50, P151; Buka SL, 2003, AM J PSYCHIAT, V160, P1978, DOI 10.1176/appi.ajp.160.11.1978; Caspi A, 2000, PSYCHOL SCI, V11, P338, DOI 10.1111/1467-9280.00267; Caspi A, 2002, SCIENCE, V297, P851, DOI 10.1126/science.1072290; *CDCP, 2004, NAT CTR VIT STAT HLT; Centers for Disease Control and Prevention (CDC), 2004, DEV DIS; Centers for Disease Control and Prevention (CDC), 2005, 3 NAT REP HUM EXP EN; Centers for Disease Control and Prevention (CDC), 2004, MMWR-MORBID MORTAL W, V53, P57, DOI 10.1016/s1479-3547(03)03011-2; *CDCP NAT CTR HLTH, 2006, PREV OV CHILDR AD; *CHANN LAB, NURS HLTH STUD; Chen J, 2003, ENVIRON HEALTH PERSP, V111, P1403, DOI 10.1289/ehp.6105; Curry JI, 2000, BRIT J OBSTET GYNAEC, V107, P1339, DOI 10.1111/j.1471-0528.2000.tb11645.x; Daniels JL, 2001, EPIDEMIOLOGY, V12, P20, DOI 10.1097/00001648-200101000-00005; DAWBER TR, 1960, CIRCULATION, V22, P164; DEVESA SS, 1995, J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; Dietrich KN, 2005, ENVIRON HEALTH PERSP, V113, P1437, DOI 10.1289/ehp.7672; DIETRICH KN, 1987, PEDIATRICS, V80, P721; Dietrich KN, 2001, NEUROTOXICOL TERATOL, V23, P511, DOI 10.1016/S0892-0362(01)00184-2; Eskenazi B, 2005, ENVIRON HEALTH PERSP, V113, P1419, DOI 10.1289/ehp.7670; Ewing R, 2003, AM J HEALTH PROMOT, V18, P47; Farrell T, 2002, DIABETIC MED, V19, P322, DOI 10.1046/j.1464-5491.2002.00700.x; Farrow A, 1996, INT J EPIDEMIOL, V25, P797, DOI 10.1093/ije/25.4.797; Fisher JS, 2004, REPRODUCTION, V127, P305, DOI 10.1530/rep.1.00025; Frank LD, 2004, AM J PREV MED, V27, P87, DOI 10.1016/j.amepre.2004.04.011; Freedman DS, 2005, PEDIATRICS, V115, P22, DOI 10.1542/peds.2004-0220; Freedman DS, 1999, PEDIATRICS, V103, P1175, DOI 10.1542/peds.103.6.1175; Freedman DS, 2001, PEDIATRICS, V108, P712, DOI 10.1542/peds.108.3.712; Freeman NCG, 2001, J EXPO ANAL ENV EPID, V11, P501, DOI 10.1038/sj.jea.7500193; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Frumkin H, 2002, PUBLIC HEALTH REP, V117, P201, DOI 10.1016/S0033-3549(04)50155-3; Galvez MP, 2003, ENVIRON HEALTH PERSP, V111, pA684, DOI 10.1289/ehp.111-a684; GAUDERMAN WJ, N ENGL J MED, V351, P1057; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; HADDOW JE, 1988, AM J OBSTET GYNECOL, V159, P481; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; HALES CN, 1991, BRIT MED J, V303, P1019; Hardy JB, 1997, PEDIATRICS, V99, P80, DOI 10.1542/peds.99.1.80; HERBST AL, 1970, CANCER, V25, P745, DOI 10.1002/1097-0142(197004)25:4<745::AID-CNCR2820250402>3.0.CO;2-2; Horowitz CR, 2004, AM J PUBLIC HEALTH, V94, P1549, DOI 10.2105/AJPH.94.9.1549; Jackson RJ, 2003, AM J PUBLIC HEALTH, V93, P1382, DOI 10.2105/AJPH.93.9.1382; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; JORGENSEN EB, 2004, ADVERSE MERCURY EFFE; KANNEL WB, 1961, ANN INTERN MED, V55, P33; KANNEL WB, 1978, GERIATRICS, V33, P71; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Kelada SN, 2003, ENVIRON HEALTH PERSP, V111, P1055, DOI 10.1289/ehp.6065; Kilby MD, 1998, PRENATAL DIAG, V18, P1283, DOI 10.1002/(SICI)1097-0223(199812)18:12<1283::AID-PD480>3.0.CO;2-4; Kilpatrick N, 2002, ENVIRON HEALTH PERSP, V110, P823; Kjellstrom T., 1989, 3642 NAT SWED ENV PR; Kjellstrom T., 1986, 3080 NAT SWED ENV PR; Lammer EJ, 2004, EPIDEMIOLOGY, V15, P150, DOI 10.1097/01.ede.0000112214.33432.cc; Laraque D, 2005, PEDIATR REV, V26, P435; Lauer R M, 1997, Zhonghua Min Guo Xiao Er Ke Yi Xue Hui Za Zhi, V38, P432; LAUER RM, 1993, PEDIATR CLIN N AM, V40, P23; Lee WJ, 2004, INT J CANCER, V111, P298, DOI 10.1002/ijc.20273; LeFever GB, 1999, AM J PUBLIC HEALTH, V89, P1359, DOI 10.2105/AJPH.89.9.1359; LENZ W, 1962, DEUT MED WOCHENSCHR, V87, P1232; Lidegaard O, 2005, HUM REPROD, V20, P950, DOI 10.1093/humrep/deh714; Lioy PJ, 1999, J EXPO ANAL ENV EPID, V9, P273, DOI 10.1038/sj.jea.7500060; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P969; Lopez R, 2004, AM J PUBLIC HEALTH, V94, P1574, DOI 10.2105/AJPH.94.9.1574; Lupton C, 2004, AM J MED GENET C, V127C, P42, DOI 10.1002/ajmg.c.30015; Lyman WD, 2005, J PEDIATR-US, V147, P563, DOI 10.1016/j.jpeds.2005.08.071; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MATTE T, 2006, IN PRESS ENV HLTH PE; Matte TD, 2001, BRIT MED J, V323, P310, DOI 10.1136/bmj.323.7308.310; McDonnell R, 2002, Ir Med J, V95, P238; Meyer H, 2000, BRAIN RES, V880, P147, DOI 10.1016/S0006-8993(00)02787-6; MOLL PP, 1991, AM J HUM GENET, V49, P1243; Morland K, 2002, AM J PUBLIC HEALTH, V92, P1761, DOI 10.2105/AJPH.92.11.1761; Morland K, 2002, AM J PREV MED, V22, P23, DOI 10.1016/S0749-3797(01)00403-2; Murata K, 2004, J PEDIATR-US, V144, P177, DOI 10.1016/j.jpeds.2003.10.059; *NAT AC SCI COMM D, 2000, SCI FRONT DEV TOX RI; *NAT HEART LUNG BL, WOM HLTH IN; *NAT HEART LUNG BL, BOG HEART STUD; *NAT I CHILD HLTH, NAT CHILDR STUD HYP; *NAT I HLTH OFF BE, 2001, NIH PUBL; *NAT RES COUNC, 1984, TOX TEST NEEDS PRIOR; National Research Council, 2000, TOX EFF METH; National Research Council, 1993, PEST DIETS INF CHILD; National Research Council, 1991, HUM EXP ASS AIRB POL, P1; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; Needleman HL, 2002, NEUROTOXICOL TERATOL, V24, P711, DOI 10.1016/S0892-0362(02)00269-6; NEWCOMBE HB, 1971, LANCET, V2, P1151; Nichols C R, 1997, J Matern Fetal Med, V6, P225; Nicholson JM, 2004, J PAEDIATR CHILD H, V40, P87, DOI 10.1111/j.1440-1754.2004.00327.x; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.2012.40; Olden K, 2004, TOXICOLOGY, V198, P19, DOI 10.1016/j.tox.2004.01.015; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Penman DG, 1998, BRIT J OBSTET GYNAEC, V105, P328, DOI 10.1111/j.1471-0528.1998.tb10095.x; Pew Charitable Trusts, 1999, PUBL OP RES PUBL HLT; Poulter NR, 1999, BRIT MED J, V319, P1330; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Ramchandani PG, 2005, PEDIATRICS, V116, P46, DOI 10.1542/peds.2004.1854; ROBISON LL, 1995, ENVIRON HEALTH PERSP, V103, P111, DOI 10.2307/3432358; Saelens BE, 2003, AM J PUBLIC HEALTH, V93, P1552, DOI 10.2105/AJPH.93.9.1552; Safer DJ, 1996, PEDIATRICS, V98, P1084; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Sallis JF, 2002, AM J PREV MED, V22, P208, DOI 10.1016/S0749-3797(01)00435-4; Sallis JF, 1998, AM J PREV MED, V15, P379, DOI 10.1016/S0749-3797(98)00076-2; SALLIS JF, 1990, PUBLIC HEALTH REP, V105, P179; Schaefer UM, 1997, AM J OBSTET GYNECOL, V177, P1165, DOI 10.1016/S0002-9378(97)70035-8; Schaefer-Graf UM, 2000, AM J OBSTET GYNECOL, V182, P313, DOI 10.1016/S0002-9378(00)70217-1; Schardein JL, 1993, CHEM INDUCED BIRTH D; Schechter CB, 1999, J NATL CANCER I, V91, P2050, DOI 10.1093/jnci/91.23.2050; SERDULA MK, 1993, PREV MED, V22, P167, DOI 10.1006/pmed.1993.1014; Sharpe PB, 2005, BIRTH DEFECTS RES A, V73, P605, DOI 10.1002/bdra.20172; Sheffield JS, 2002, OBSTET GYNECOL, V100, P925, DOI 10.1016/S0029-7844(02)02242-1; Sinha R, 2002, NEW ENGL J MED, V346, P802, DOI 10.1056/NEJMoa012578; Skakkebaek NE, 2001, HUM REPROD, V16, P972, DOI 10.1093/humrep/16.5.972; Solantaus T, 2005, LANCET, V365, P2158, DOI 10.1016/S0140-6736(05)66754-2; Srinivasan S, 2003, AM J PUBLIC HEALTH, V93, P1446, DOI 10.2105/AJPH.93.9.1446; STEWART A, 1970, LANCET, V1, P1185; Stoll C, 2001, ANN GENET-PARIS, V44, P201, DOI 10.1016/S0003-3995(01)01094-2; Suh HH, 2000, ENVIRON HEALTH PERSP, V108, P625, DOI 10.2307/3454398; Suita S, 2000, J PEDIATR SURG, V35, P66, DOI 10.1016/S0022-3468(00)80079-2; Susser E, 2000, PAEDIATR PERINAT EP, V14, P98, DOI 10.1046/j.1365-3016.2000.00249.x; Susser E, 2003, LANCET, V361, P797, DOI 10.1016/S0140-6736(03)12721-3; SUSSER E, 2004, LIFE COURSE APPROACH, P306; Susser ES, 2000, SCHIZOPHRENIA BULL, V26, P257; Szneke P, 1994, Conn Med, V58, P131; Thorpe LE, 2004, AM J PUBLIC HEALTH, V94, P1496, DOI 10.2105/AJPH.94.9.1496; Trasande L, 2006, AM J IND MED, V49, P153, DOI 10.1002/ajim.20268; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Trasande L, 2004, ENVIRON HEALTH PERSP, V112, pA789; Trasande L, 2005, ENVIRON HEALTH PERSP, V113, P590, DOI 10.1289/ehp.7743; Trasande Leonardo, 2006, WMJ, V105, P45; Trasande Leonardo, 2006, WMJ, V105, P50; Trasande L, 2006, J URBAN HEALTH, V83, P760, DOI 10.1007/s11524-006-9071-0; *US DEP HHS, 2004, PRES TASK FORC ENV H; *US EPA, 1998, CHEM IN COMM INF SYS; U.S. Environmental Protection Agency, 1998, CHEM HAZ DAT AV STUD; *US EPA OFF PEST P, 2003, FRAM CUM RISK ASS, P1; *USDA NAT RES CONS, NAT RES INV 2001 ANN; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; Wadhwa PD, 2001, PAEDIATR PERINAT EP, V15, P17, DOI 10.1046/j.1365-3016.2001.00005.x; Wallace LA, 2003, ENVIRON HEALTH PERSP, V111, P1265, DOI 10.1289/ehp.6135; *WHO, 2004, 1999 INT COUNS ENV T; Williams LJ, 2005, BIRTH DEFECTS RES A, V73, P177, DOI 10.1002/bdra.20114; Zito JM, 2000, JAMA-J AM MED ASSOC, V283, P1025, DOI 10.1001/jama.283.8.1025	156	105	110	5	28	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	NOV	2006	118	5					2173	2186		10.1542/peds.2006-0360		14	Pediatrics	Pediatrics	101HK	WOS:000241731700044	17079592	
J	Perkin, MR; Strachan, DP				Perkin, MR; Strachan, DP			Which aspects of the farming lifestyle explain the inverse association with childhood allergy?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; farm; unpasteurized milk; skin prick tests; children	FARMERS CHILDREN; HAY-FEVER; ASTHMA; PREVALENCE; ENDOTOXIN; LIMULUS; MILK; SENSITIZATION; EXPOSURE; DISEASES	Background: Farmers' children have a reduced prevalence of allergic disorders. The specific protective environmental factors responsible are not yet identified. Objective: We sought to determine whether farmers' children in the rural county of Shropshire, England, have a reduced risk of atopy and, if so, to identify the factors responsible. Methods: The Study of Asthma and Allergy in Shropshire was a 2-stage cross-sectional study. In stage 1 a questionnaire to elicit allergic status, diet, and farming exposure was completed by the parents of 4767 children. In stage 2 a stratified subsample of 879 children underwent skin prick testing and measurement of domestic endotoxin. Results: Compared with rural nonfarming children, farmers' children had significantly less current asthma symptoms. (adjusted odds ratio (OR), 0.67; 95% CI, 0.49-0.91; P =.01) and current seasonal allergic rhinitis (adjusted OR, 0.50; 95% CI, 0.33-0.77; P =.002) but not current eczema symptoms (adjusted OR, 0.91; 95% CI, 0.68-1.21; P =.53) or atopy (adjusted OR, 0.68; 95% CI, 0.40-1.16; P =.15). In contrast, current unpasteurized milk consumption was associated with significantly less current eczema symptoms (adjusted OR, 0.59; 95% CI, 0.40-0.87; P =.008) and a greater reduction in atopy (adjusted OR, 0.24; 95% CI, 0.10-0.53; P =.001). The effect was seen in all children, independent of farming status. Unpasteurized milk consumption was associated with a 59% reduction in total IgE levels (P <.001) and higher production of whole blood stimulated IFN-gamma (P = .02). Conclusion: Unpasteurized milk consumption was the exposure mediating the protective effect on skin prick test positivity. The effect was independent of farming status and present with consumption of infrequent amounts of unpasteurized milk. Clinical implications: Unpasteurized milk might be a modifiable influence on allergic sensitization in children.	Univ London, St Georges, Div Clin Dev Sci, London SW17 0RE, England; Univ London, St Georges, Div Community Hlth Sci, London SW17 0RE, England	Perkin, MR (reprint author), Univ London, St Georges, Div Clin Dev Sci, Cranmer Terrace, London SW17 0RE, England.	m.perkin@sgul.ac.uk			Wellcome Trust [056906/Z/99/Z]		Allerberger F, 2001, Euro Surveill, V6, P147; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BRAUNFAHRLANDER C, 1996, EPIDEMIOLOGY, V7, pS47; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Cooper JF, 1997, PDA J PHARM SCI TECH, V51, P2; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Harper Catherine M, 2002, Commun Dis Intell Q Rep, V26, P449; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; KLEINETEBBE J, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb02174.x; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; LEVIN J, 1968, THROMB DIATH HAEMOST, V19, P186; MORGAN D, 1994, EUR J EPIDEMIOL, V10, P581, DOI 10.1007/BF01719576; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Remes ST, 2002, ACTA PAEDIATR, V91, P1163; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; StataCorp, 2003, STAT STAT SOFTW REL; SUHREN G, 1986, MILCHWISSENSCHAFT, V41, P156; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x	24	105	108	5	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1374	1381		10.1016/j.jaci.2006.03.008		8	Allergy; Immunology	Allergy; Immunology	053UX	WOS:000238332300026	16751000	
J	Ross, Z; English, PB; Scalf, R; Gunier, R; Smorodinsky, S; Wall, S; Jerrett, M				Ross, Z; English, PB; Scalf, R; Gunier, R; Smorodinsky, S; Wall, S; Jerrett, M			Nitrogen dioxide prediction in Southern California using land use regression modeling: potential for environmental health analyses	JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY			English	Article						nitrogen dioxide; traffic; land use regression; GIS	PARTICULATE AIR-POLLUTION; MORTALITY; INDICATORS; EXPOSURE; COHORT; ASTHMA	We modeled the intraurban distribution of nitrogen dioxide (NO2), a marker for traffic pollution, with land use regression, a promising new exposure classification technique. We deployed diffusion tubes to measure NO2 levels at 39 locations in the fall of 2003 in San Diego County, CA, USA. At each sample location, we constructed circular buffers in a geographic information system and captured information on roads, traffic flow, land use, population and housing. Using multiple linear regression, we were able to predict 79% of the variation in NO2 levels with four variables: traffic density within 40-300m of the sampling location, traffic density within 300-1000m, length of road within 40m and distance to the Paci. c coast. Applying this model to validation samples showed that the model predicted NO2 levels within, on average, 2.1 p.p.b for 12 training sites initially excluded from t he model. Our evaluation of this land use regression model showed that this method had excellent prediction and robustness in a North American context. These models may be useful tools in evaluating health effects of long-term exposure to traffic-related pollution.	Calif Dept Hlth Serv, Div Environm & Occupat Dis Control, Environm Hlth Invest Branch, Oakland, CA 94612 USA; ZevRoss Spatial Anal, Ithaca, NY 14850 USA; Impact Assessment Inc, Oakland, CA 94612 USA; Univ So Calif, Div Biostat, Dept Prevent Med, Los Angeles, CA 90089 USA; Univ So Calif, Div Biostat, Dept Geog, Los Angeles, CA 90089 USA	English, PB (reprint author), Calif Dept Hlth Serv, Div Environm & Occupat Dis Control, Environm Hlth Invest Branch, 1515 Clay St 1700, Oakland, CA 94612 USA.	PEnglish@dhs.ca.gov		Gunier, Robert/0000-0001-5485-9919	NCI NIH HHS [5-R21-CA094723-03]; NIEHS NIH HHS [5P01 ES09581, 1P01 ES11627, 5P30 ES05605-14, 5P30 ES07048]		Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Finkelstein MM, 2003, CAN MED ASSOC J, V169, P397; Finkelstein MM, 2004, AM J EPIDEMIOL, V160, P173, DOI 10.1093/aje/kwh181; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; JERRETT M, IN PRESS MODELLING I; Krewski D, 2000, REANALYSIS HARVARD 6; National Research Council, 2002, EST PUBL HLTH BEN PR; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; *SANDAG, 2004, SANDAG GIS MET CURR; *USEPA, 2001, NAT SCAL AIR TOX ASS; Wilkinson P, 1999, THORAX, V54, P1070	18	105	106	5	31	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1559-0631			J EXPO SCI ENV EPID	J. Expo. Sci. Environ. Epidemiol.	MAR	2006	16	2					106	114		10.1038/sj.jea.7500442		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	020EG	WOS:000235890600001	16047040	
J	Penard-Morand, C; Charpin, D; Raherison, C; Kopferschmitt, C; Caillaud, D; Lavaud, F; Annesi-Maesano, I				Penard-Morand, C; Charpin, D; Raherison, C; Kopferschmitt, C; Caillaud, D; Lavaud, F; Annesi-Maesano, I			Long-term exposure to background air pollution related to respiratory and allergic health in schoolchildren	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						air pollution; allergic rhinitis; asthma; atopy; background monitoring stations; children; eczema; exercise-induced bronchial reactivity; skin prick test positivity	DIESEL EXHAUST PARTICLES; SPATIAL VARIABILITY; NITROGEN-DIOXIDE; CHILDHOOD ISAAC; SULFUR-DIOXIDE; CHILDREN; ASTHMA; SYMPTOMS; SENSITIZATION; OZONE	Background The impact of air pollution on asthma and allergies still remains a debate. Objective Our cross-sectional study was intended to analyse the associations between long-term exposure to background air pollution and atopic and respiratory outcomes in a large population-based sample of schoolchildren. Methods Six thousand six hundred and seventy-two children aged 9-11 years recruited from 108 randomly schools in six French cities underwent a clinical examination including a skin prick test (SPT) to common allergens, exercise-induced bronchial reactivity (EIB) and skin examination for flexural dermatitis. The prevalence of asthma, allergic rhinitis (AR) and atopic dermatitis was assessed by a standardized health questionnaire completed by the parents. Three-year-averaged concentrations of air pollutants (NO2, SO2, PM10 and O-3) were calculated at children' schools using measurements of background monitoring stations. Results After adjusting for confounders, EIB, lifetime asthma and lifetime AR were found to be positively related to an increase in the exposure to SO2, PM10 and O-3. The adjusted odds ratios (aOR) per increase of 5 mu g/m(3) of SO2 was 1.39 (95% confidence interval (CI)=1.15-1.66) for EIB and 1.19 (1.00-1.41) for lifetime asthma. The aOR for lifetime AR per increase of 10 mu g/m(3) of PM10 was 1.32 (CI=1.04-1.68). Moreover, SPT positivity was associated with O-3 (aOR=1.34; CI=1.24-1.46). Associations with past year symptoms were consistent, even if not always statistically significant. Results persisted in long-term resident (current address for at least 8 years) children. However, no consistent positive association was found with NO2. Conclusions A moderate increase in long-term exposure to background ambient air pollution was associated with an increased prevalence of respiratory and atopic indicators in children.	INSERM, EPAR, Epidemiol Allerg & Resp Dis Dept, U472, F-94807 Villejuif, France; Hop Nord Marseille, Marseille, France; ISPED Univ, Bordeaux, France; Hop Civils, Strasbourg, France; Hop Montpied, Clermont Ferrand, France; Hop Maison Blanche, Reims, France	Penard-Morand, C (reprint author), INSERM, EPAR, Epidemiol Allerg & Resp Dis Dept, U472, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	celine.morand@polytechnique.org	Annesi-Maesano, Isabella/D-9173-2016				ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baldi I, 1999, EUR RESPIR J, V14, P132, DOI 10.1034/j.1399-3003.1999.14a22.x; BALMES JR, 1987, AM REV RESPIR DIS, V136, P1117; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blomberg A, 1997, AM J RESP CRIT CARE, V156, P418; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Charpin D, 1999, CLIN EXP ALLERGY, V29, P1474; Chavance M, 1999, REV EPIDEMIOL SANTE, V47, P535; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Debrock C, 2002, REV EPIDEMIOL SANTE, V50, P519; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Monn C, 1997, ATMOS ENVIRON, V31, P2243, DOI 10.1016/S1352-2310(97)00030-7; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nerriere E, 2005, ENVIRON RES, V97, P32, DOI 10.1016/j.envres.2004.07.009; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; OSEBOLD JW, 1988, P SOC EXP BIOL MED, V188, P259; Penard-Morand C, 2004, BREATHE, V1, P28; Priftanji A, 2001, LANCET, V358, P1426, DOI 10.1016/S0140-6736(01)06521-7; RIEDEL F, 1988, J ALLERGY CLIN IMMUN, V82, P527, DOI 10.1016/0091-6749(88)90961-X; SCHMITZBERGER R, 1993, PEDIATR PULM, V15, P68, DOI 10.1002/ppul.1950150203; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; WJST M, 1993, BRIT MED J, V307, P596; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	48	105	111	5	19	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2005	35	10					1279	1287		10.1111/j.1365-2222.2005.02336.x		9	Allergy; Immunology	Allergy; Immunology	976ZK	WOS:000232772000005	16238786	
J	Akira, S; Uematsu, S; Takeuchi, O				Akira, S; Uematsu, S; Takeuchi, O			Pathogen recognition and innate immunity	CELL			English	Review							TOLL-LIKE RECEPTORS; NF-KAPPA-B; DOUBLE-STRANDED-RNA; PLASMACYTOID DENDRITIC CELLS; INTERFERON-ALPHA INDUCTION; IFN-BETA PROMOTER; HEPATITIS-C VIRUS; SIGNALING PATHWAY; RIG-I; ANTIVIRAL RESPONSE	Microorganisms that invade a vertebrate host are initially recognized by the innate immune system through germline-encoded pattern-recognition receptors (PRRs). Several classes of PRRs, including Toll-like receptors and cytoplasmic receptors, recognize distinct microbial components and directly activate immune cells. Exposure of immune cells to the ligands of these receptors activates intracellular signaling cascades that rapidly induce the expression of a variety of overlapping and unique genes involved in the inflammatory and immune responses. New insights into innate immunity are changing the way we think about pathogenesis and the treatment of infectious diseases, allergy, and autoimmunity.	Osaka Univ, Res Inst Microbial Dis, Dept Host Defense, Suita, Osaka 5650871, Japan; ERATO, Japan Sci & Technol Agcy, Suita, Osaka 5650871, Japan	Akira, S (reprint author), Osaka Univ, Res Inst Microbial Dis, Dept Host Defense, 3-1 Yamadaoka, Suita, Osaka 5650871, Japan.	sakira@biken.osaka-u.ac.jp	Yang, Chen/G-1379-2010; Takeuchi, Osamu/D-6007-2011; Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878			Adachi K, 2001, J IMMUNOL, V167, P5928; Agrawal S, 2003, J IMMUNOL, V171, P4984; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Andersen-Nissen E, 2005, P NATL ACAD SCI USA, V102, P9247, DOI 10.1073/pnas.0502040102; Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Balachandran S, 2004, NATURE, V432, P401, DOI 10.1038/nature03124; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Belkhadir Y, 2004, CURR OPIN PLANT BIOL, V7, P391, DOI 10.1016/j.pbi.2004.05.009; Beutler B, 2004, NATURE, V430, P257, DOI 10.1038/nature02761; Bieback K, 2002, J VIROL, V76, P8729, DOI 10.1128/JVI.76.17.8729-8736.2002; Blander JM, 2004, SCIENCE, V304, P1014, DOI 10.1126/science.1096158; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508; Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Burzyn D, 2004, J VIROL, V78, P576, DOI 10.1128/JVI.78.2.576-584.2004; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Choe J, 2005, SCIENCE, V309, P581, DOI 10.1126/science.1115253; Coban C, 2005, J EXP MED, V201, P19, DOI 10.1084/jem.20041836; Compton T, 2003, J VIROL, V77, P4588, DOI 10.1128/JVI.77.8.4588-4596.2003; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Couillault C, 2004, NAT IMMUNOL, V5, P488, DOI 10.1038/ni1060; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Diebold SS, 2004, SCIENCE, V303, P1529, DOI 10.1126/science.1093616; Diez E, 2003, NAT GENET, V33, P55, DOI 10.1038/ng1065; DiPerna G, 2004, J BIOL CHEM, V279, P36570, DOI 10.1074/jbc.M400567200; Dostert C, 2005, NAT IMMUNOL, V6, P946, DOI 10.1038/ni1237; Echchannaoui H, 2002, J INFECT DIS, V186, P798, DOI 10.1086/342845; Edelmann KH, 2004, VIROLOGY, V322, P231, DOI 10.1016/j.virol.2004.01.033; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fitzgerald KA, 2003, J EXP MED, V198, P1043, DOI 10.1084/jem.20031023; Fortune SM, 2004, J IMMUNOL, V172, P6272; Gantner BN, 2003, J EXP MED, V197, P1107, DOI 10.1084/jem.20021787; Gazzinelli RT, 2004, IMMUNOL REV, V201, P9, DOI 10.1111/j.0105-2896.2004.00174.x; Gilleron M, 2003, J BIOL CHEM, V278, P29880, DOI 10.1074/jbc.M303446200; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Gottar M, 2002, NATURE, V416, P640, DOI 10.1038/nature734; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hawn TR, 2003, J EXP MED, V198, P1563, DOI 10.1084/jem.20031220; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2004, J EXP MED, V199, P1641, DOI 10.1084/jem.20040520; Hemmi H, 2000, NATURE, V408, P740; Hochrein H, 2004, P NATL ACAD SCI USA, V101, P11416, DOI 10.1073/pnas.0403555101; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Honda K, 2005, NATURE, V434, P1035, DOI 10.1038/nature03547; Honda K, 2005, NATURE, V434, P772, DOI 10.1038/nature03464; Honda K, 2004, P NATL ACAD SCI USA, V101, P15416, DOI 10.1079/pnas.1016933101; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Inohara N, 2005, ANNU REV BIOCHEM, V74, P355, DOI 10.1146/annurev.biochem.74.082803.133347; ISHII KJ, 2005, NAT IMMUNOL, V7, P40, DOI DOI 10.1038/NI1282; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kaisho T, 2001, J IMMUNOL, V166, P5688; Kang DC, 2002, P NATL ACAD SCI USA, V99, P637, DOI 10.1073/pnas.022637199; KANNEGANTI TD, 2003, NATURE; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; Kawai T, 2005, NAT IMMUNOL, V6, P981, DOI 10.1038/ni1243; Kawai T, 2004, NAT IMMUNOL, V5, P1061, DOI 10.1038/ni1118; Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Krug A, 2001, EUR J IMMUNOL, V31, P2154, DOI 10.1002/1521-4141(200107)31:7<2154::AID-IMMU2154>3.0.CO;2-U; Krug A, 2004, IMMUNITY, V21, P107, DOI 10.1016/j.immuni.2004.06.007; Krug A, 2004, BLOOD, V103, P1433, DOI 10.1182/blood-2003-08-2674; Krutzik SR, 2003, NAT MED, V9, P525, DOI 10.1038/nm864; Kurt-Jones EA, 2004, P NATL ACAD SCI USA, V101, P1315, DOI 10.1073/pnas.0308057100; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Latz E, 2004, NAT IMMUNOL, V5, P190, DOI 10.1038/ni1028; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lin RT, 2004, J VIROL, V78, P1675, DOI 10.1128/JVI.78.4.1675-1684.2004; Lopez CB, 2004, J IMMUNOL, V173, P6882; Lund J, 2003, J EXP MED, V198, P513, DOI 10.1084/jem.20030162; Malhotra D, 2005, HUM GENET, V116, P413, DOI 10.1007/s00439-004-1249-9; Mariathasan S, 2004, NATURE, V430, P213, DOI 10.1038/nature02664; MARIATHASAN S, 2006, NATURE; Martinon F, 2005, TRENDS IMMUNOL, V26, P447, DOI 10.1016/j.it.2005.06.004; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; MARTINON F, 2006, NATURE; McWhirter SM, 2004, P NATL ACAD SCI USA, V101, P233; Meylan E, 2005, NATURE, V437, P1167, DOI 10.1038/nature04193; Meylan E, 2004, NAT IMMUNOL, V5, P503, DOI 10.1038/ni1061; Michel T, 2001, NATURE, V414, P756, DOI 10.1038/414756a; Netea MG, 2004, EUR J CLIN MICROBIOL, V23, P672, DOI 10.1007/s10096-004-1192-7; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Pai RK, 2003, J IMMUNOL, V171, P175; Perry AK, 2004, J EXP MED, V199, P1651, DOI 10.1084/jem.20040528; Picard C, 2003, SCIENCE, V299, P2076, DOI 10.1126/science.1081902; Pichyangkul S, 2004, J IMMUNOL, V172, P4926; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Quesniaux V, 2004, MICROBES INFECT, V6, P946, DOI 10.1016/j.micinf.2004.04.016; Roach JC, 2005, P NATL ACAD SCI USA, V102, P9577, DOI 10.1073/pnas.0502272102; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Rothenfusser S, 2005, J IMMUNOL, V175, P5260; Rutz M, 2004, EUR J IMMUNOL, V34, P2541, DOI 10.1002/eji.200425218; Sakaguchi S, 2003, BIOCHEM BIOPH RES CO, V306, P860, DOI 10.1016/S0006-291X(03)01049-0; Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326; Seth RB, 2005, CELL, V122, P669, DOI 10.1016/j.cell.2005.08.012; Sharma S, 2003, SCIENCE, V300, P1148, DOI 10.1126/science.1081315; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Suzuki N, 2003, J IMMUNOL, V170, P4031; Tabeta K, 2004, P NATL ACAD SCI USA, V101, P3516, DOI 10.1073/pnas.0400525101; Takahara K, 2004, INT IMMUNOL, V16, P819, DOI 10.1093/intimm/dxh084; Takaoka A, 2005, NATURE, V434, P243, DOI 10.1038/nature03308; Takeuchi O, 2000, J IMMUNOL, V165, P5392; Takeuchi O, 2002, J IMMUNOL, V169, P10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; THOMAUSZYNSKI S, 2001, SCIENCE, V291, P154; Travassos LH, 2004, EMBO REP, V5, P1000, DOI 10.1038/sj.embor.7400248; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; UNDERHILL DM, 2004, BLOOD, V106, P2543; Verthelyi D, 2001, J IMMUNOL, V166, P2372; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang T, 2004, NAT MED, V10, P1366, DOI 10.1038/nm1140; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354; Xu LG, 2005, MOL CELL, V19, P727, DOI 10.1016/j.molcel.2005.08.014; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2003, SCIENCE, V301, P640, DOI 10.1126/science.1087262; Yamamoto M, 2002, J IMMUNOL, V169, P6668; Yamamoto M, 2004, NATURE, V430, P218, DOI 10.1038/nature02738; Yamamoto M, 2003, NAT IMMUNOL, V4, P1144, DOI 10.1038/ni986; Yarovinsky F, 2005, SCIENCE, V308, P1626, DOI 10.1126/science.1109893; Yates RM, 2005, IMMUNITY, V23, P409, DOI 10.1016/j.immuni.2005.09.007; Yonekura K, 2003, NATURE, V424, P643, DOI 10.1038/nature01830; Yoneyama M, 2005, J IMMUNOL, V175, P2851; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087; Yu YX, 2005, IMMUNITY, V22, P59, DOI 10.1016/j.immuni.2004.11.011; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351	141	5045	5354	157	1251	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	FEB 24	2006	124	4					783	801		10.1016/j.cell.2006.02.015		19	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	038RO	WOS:000237240900021	16497588	
J	Chen, WJ; Jin, WW; Hardegen, N; Lei, KJ; Li, L; Marinos, N; McGrady, G; Wahl, SM				Chen, WJ; Jin, WW; Hardegen, N; Lei, KJ; Li, L; Marinos, N; McGrady, G; Wahl, SM			Conversion of peripheral CD4(+)CD25(-) naive T cells to CD4(+)CD25(+) regulatory T cells by TGF-beta induction of transcription factor Foxp3	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						anergy; IL-10; OVA TCR transgenic; house dust mite; asthma	GROWTH-FACTOR-BETA; IMMUNOLOGICAL SELF-TOLERANCE; ANTIGEN 4; ALLERGIC-ASTHMA; IN-VITRO; DISRUPTION; CTLA-4; MOUSE; IMMUNOSUPPRESSION; PROLIFERATION	CD4(+)CD25(+) regulatory T cells (T-reg) are instrumental in the maintenance of immunological tolerance. One critical question is whether T-reg can only be generated in the thymus or can differentiate from peripheral CD4(+)CD25(-) naive T cells. In this paper, we present novel evidence that conversion of naive peripheral CD4(+)CD25(-) T cells into anergic/suppressor cells that are CD25(+), CD45RB(-/low) and intracellular CTLA-4(+) can be achieved through costimulation with T cell receptors (TCRs) and transforming growth factor beta (TGF-beta). Although transcription factor Foxp3 has been shown recently to be associated with the development of T-reg, the physiological inducers for Foxp3 gene expression remain a mystery. TGF-beta induced Foxp3 gene expression in TCR-challenged CD4(+)CD25(-) naive T cells, which mediated their transition toward a regulatory T cell phenotype with potent immunosuppressive potential. These converted anergic/suppressor cells are not only unresponsive to TCR stimulation and produce neither T helper cell 1 nor T helper cell 2 cytokines but they also express TGF-beta and inhibit normal T cell proliferation in vitro. More importantly, in an ovalbumin peptide TCR transgenic adoptive transfer model, TGF-beta-converted transgenic CD4(+)CD25(+) suppressor cells proliferated in response to immunization and inhibited antigen-specific naive CD4(+) T cell expansion in vivo. Finally, in a murine asthma model, coadministration of these TGF-beta-induced suppressor T cells prevented house dust mite-induced allergic pathogenesis in lungs.	Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, Cellular Immunol Sect, NIH, Bethesda, MD 20892 USA	Chen, WJ (reprint author), Natl Inst Dent & Craniofacial Res, Oral Infect & Immun Branch, Cellular Immunol Sect, NIH, Bethesda, MD 20892 USA.		Ain, Kenneth/A-5179-2012	Ain, Kenneth/0000-0002-2668-934X			Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Chen Wanjun, 2002, Curr Dir Autoimmun, V5, P62; Chen WJ, 2001, J EXP MED, V194, P439, DOI 10.1084/jem.194.4.439; Chen WJ, 2001, IMMUNITY, V14, P715, DOI 10.1016/S1074-7613(01)00147-9; Chen WJ, 2003, CYTOKINE GROWTH F R, V14, P85, DOI 10.1016/S1359-6101(03)00003-0; Chen WJ, 1998, J EXP MED, V188, P1849, DOI 10.1084/jem.188.10.1849; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gorelik L, 2000, IMMUNITY, V12, P171, DOI 10.1016/S1074-7613(00)80170-3; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Groux H, 1997, NATURE, V389, P737; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; ITOH H, 1999, JPN J HOSP PHARM, V25, P162; Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Schwartz RH, 1996, J EXP MED, V184, P1, DOI 10.1084/jem.184.1.1; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Walker LSK, 2003, J EXP MED, V198, P249, DOI 10.1084/jem.20030315; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woo EY, 2002, J IMMUNOL, V168, P4272; Yamagiwa S, 2001, J IMMUNOL, V166, P7282; Zhang XM, 2001, J IMMUNOL, V167, P4245	40	2630	2792	35	187	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	DEC 15	2003	198	12					1875	1886		10.1084/jem.20030152		12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	756CZ	WOS:000187449400012	14676299	
J	Bousquet, J; Khaltaev, N; Cruz, AA; Denburg, J; Fokkens, WJ; Togias, A; Zuberbier, T; Baena-Cagnani, CE; Canonica, GW; van Weel, C; Agache, I; Ait-Khaled, N; Bachert, C; Blaiss, MS; Bonini, S; Boulet, LP; Bousquet, PJ; Camargos, P; Carlsen, KH; Chen, Y; Custovic, A; Dahl, R; Demoly, P; Douagui, H; Durham, SR; van Wijk, RG; Kalayci, O; Kaliner, MA; Kim, YY; Kowalski, ML; Kuna, P; Le, LTT; Lemiere, C; Li, J; Lockey, RF; Mavale-Manuel, S; Meltzer, EO; Mohammad, Y; Mullol, J; Naclerio, R; Hehir, REO; Ohta, K; Ouedraogo, S; Palkonen, S; Papadopoulos, N; Passalacqua, G; Pawankar, R; Popov, TA; Rabe, KF; Rosado-Pinto, J; Scadding, GK; Simons, FER; Toskala, E; Valovirta, E; van Cauwenberge, P; Wang, DY; Wickman, M; Yawn, BP; Yorgancioglu, A; Yusuf, OM; Zar, H; Annesi-Maesano, I; Bateman, ED; Ben Kheder, A; Boakye, DA; Bouchard, J; Burney, P; Busse, WW; Chan-Yeung, M; Chavannes, NH; Chuchalin, A; Dolen, WK; Emuzyte, R; Grouse, L; Humbert, M; Jackson, C; Johnston, SL; Keith, PK; Kemp, JP; Klossek, JM; Larenas-Linnemann, D; Lipworth, B; Malo, JL; Marshall, GD; Naspitz, C; Nekam, K; Niggemann, B; Nizankowska-Mogilnicka, E; Okamoto, Y; Orru, MP; Potter, P; Price, D; Stoloff, SW; Vandenplas, O; Viegi, G; Williams, D				Bousquet, J.; Khaltaev, N.; Cruz, A. A.; Denburg, J.; Fokkens, W. J.; Togias, A.; Zuberbier, T.; Baena-Cagnani, C. E.; Canonica, G. W.; van Weel, C.; Agache, I.; Ait-Khaled, N.; Bachert, C.; Blaiss, M. S.; Bonini, S.; Boulet, L. -P.; Bousquet, P. -J.; Camargos, P.; Carlsen, K. -H.; Chen, Y.; Custovic, A.; Dahl, R.; Demoly, P.; Douagui, H.; Durham, S. R.; van Wijk, R. Gerth; Kalayci, O.; Kaliner, M. A.; Kim, Y. -Y.; Kowalski, M. L.; Kuna, P.; Le, L. T. T.; Lemiere, C.; Li, J.; Lockey, R. F.; Mavale-Manuel, S.; Meltzer, E. O.; Mohammad, Y.; Mullol, J.; Naclerio, R.; Hehir, R. E. O.; Ohta, K.; Ouedraogo, S.; Palkonen, S.; Papadopoulos, N.; Passalacqua, G.; Pawankar, R.; Popov, T. A.; Rabe, K. F.; Rosado-Pinto, J.; Scadding, G. K.; Simons, F. E. R.; Toskala, E.; Valovirta, E.; van Cauwenberge, P.; Wang, D. -Y.; Wickman, M.; Yawn, B. P.; Yorgancioglu, A.; Yusuf, O. M.; Zar, H.; Annesi-Maesano, I.; Bateman, E. D.; Ben Kheder, A.; Boakye, D. A.; Bouchard, J.; Burney, P.; Busse, W. W.; Chan-Yeung, M.; Chavannes, N. H.; Chuchalin, A.; Dolen, W. K.; Emuzyte, R.; Grouse, L.; Humbert, M.; Jackson, C.; Johnston, S. L.; Keith, P. K.; Kemp, J. P.; Klossek, J. -M.; Larenas-Linnemann, D.; Lipworth, B.; Malo, J. -L.; Marshall, G. D.; Naspitz, C.; Nekam, K.; Niggemann, B.; Nizankowska-Mogilnicka, E.; Okamoto, Y.; Orru, M. P.; Potter, P.; Price, D.; Stoloff, S. W.; Vandenplas, O.; Viegi, G.; Williams, D.			Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)	ALLERGY			English	Review						ARIA; asthma; guideline; management; rhinitis	QUALITY-OF-LIFE; HOUSE-DUST-MITE; AQUEOUS NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; SKIN-TEST REACTIVITY; COMMUNITY-RESPIRATORY-HEALTH; RANDOMIZED CONTROLLED-TRIAL; INTRANASAL FLUTICASONE PROPIONATE; NATURAL-RUBBER LATEX; LABORATORY-ANIMAL ALLERGY	Allergic rhinitis is a symptomatic disorder of the nose induced after allergen exposure by an IgE-mediated inflammation of the membranes lining the nose. It is a global health problem that causes major illness and disability worldwide. Over 600 million patients from all countries, all ethnic groups and of all ages suffer from allergic rhinitis. It affects social life, sleep, school and work and its economic impact is substantial. Risk factors for allergic rhinitis are well identified. Indoor and outdoor allergens as well as occupational agents cause rhinitis and other allergic diseases. The role of indoor and outdoor pollution is probably very important, but has yet to be fully understood both for the occurrence of the disease and its manifestations. In 1999, during the Allergic Rhinitis and its Impact on Asthma (ARIA) WHO workshop, the expert panel proposed a new classification for allergic rhinitis which was subdivided into 'intermittent' or 'persistent' disease. This classification is now validated. The diagnosis of allergic rhinitis is often quite easy, but in some cases it may cause problems and many patients are still under-diagnosed, often because they do not perceive the symptoms of rhinitis as a disease impairing their social life, school and work. The management of allergic rhinitis is well established and the ARIA expert panel based its recommendations on evidence using an extensive review of the literature available up to December 1999. The statements of evidence for the development of these guidelines followed WHO rules and were based on those of Shekelle et al. A large number of papers have been published since 2000 and are extensively reviewed in the 2008 Update using the same evidence-based system. Recommendations for the management of allergic rhinitis are similar in both the ARIA workshop report and the 2008 Update. In the future, the GRADE approach will be used, but is not yet available. Another important aspect of the ARIA guidelines was to consider co-morbidities. Both allergic rhinitis and asthma are systemic inflammatory conditions and often co-exist in the same patients. In the 2008 Update, these links have been confirmed. The ARIA document is not intended to be a standard-of-care document for individual countries. It is provided as a basis for physicians, health care professionals and organizations involved in the treatment of allergic rhinitis and asthma in various countries to facilitate the development of relevant local standard-of-care documents for patients.	[Bousquet, J.] Univ Hosp, Montpellier, France; [Demoly, P.] Hop Arnaud Villeneuve, INSERM, Univ Hosp Montpellier, U657, Montpellier, France; [Khaltaev, N.] GARD ARIA, Geneva, Switzerland; [Cruz, A. A.] Univ Fed Bahia, Sch Med, BR-41170290 Salvador, BA, Brazil; [Denburg, J.] McMaster Univ, AllerGen NCE, Hamilton, ON L8S 4L8, Canada; [Fokkens, W. J.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; [Togias, A.] NIAID, Bethesda, MD 20892 USA; [Zuberbier, T.] Charite, Allergy Ctr Charite, D-13353 Berlin, Germany; [Baena-Cagnani, C. E.] WAO, Cordoba, Argentina; [Baena-Cagnani, C. E.] Catholic Univ Cordoba, Cordoba, Argentina; [Canonica, G. W.] Univ Genoa, Allergy & Resp Dis Clin, Genoa, Italy; [van Weel, C.] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands; [Agache, I.] Transylvania Univ, Brasov, Romania; [Bachert, C.] Univ Hosp Ghent, UZG, Ghent, Belgium; [Blaiss, M. S.] Univ Tennessee, Ctr Hlth Sci, Memphis, TN 38163 USA; [Bonini, S.] Univ Naples 2, INMM CNR, Rome, Italy; [Boulet, L. -P.] Hop Laval, Inst Cardiol & Pneumol, Quebec City, PQ, Canada; [Boulet, L. -P.] Univ Laval, Quebec City, PQ, Canada; [Bousquet, P. -J.] Univ Nimes Hosp, F-30006 Nimes, France; [Camargos, P.] Univ Fed Minas Gerais, Univ Hosp, Sch Med, Belo Horizonte, MG, Brazil; [Carlsen, K. -H.] Univ Oslo, Rikshosp, Norwegian Sch Sport Sci, Fac Med, N-0027 Oslo, Norway; [Chen, Y.] Capital Inst Pediat, Asthma Clin & Educ Ctr, Natl Cooperat Grp Pediat Res Asthma, Beijing, Peoples R China; [Custovic, A.] Univ Manchester, Manchester, Lancs, England; [Dahl, R.] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark; [Douagui, H.] Ctr Hosp Univ Beni Messous, Algiers, Algeria; [Durham, S. R.] Univ London Imperial Coll Sci Technol & Med, London, England; [van Wijk, R. Gerth] Erasmus MC, Rotterdam, Netherlands; [Kalayci, O.] Pediat Allergy & Asthma Unit, Ankara, Turkey; [Kaliner, M. A.] Geo Washington Univ, Sch Med, Washington, DC USA; [Kaliner, M. A.] Inst Asthma & Allergy, Chevy Chase, MD USA; [Kim, Y. -Y.] Seoul Natl Univ Hosp, Seoul 110744, South Korea; [Kuna, P.] Med Univ Lodz, Barlicki Univ Hosp, Lodz, Poland; [Le, L. T. T.] Univ Med & Pharm, Ho Chi Minh City, Vietnam; [Lemiere, C.; Malo, J. -L.] Univ Montreal, Montreal, PQ, Canada; [Li, J.] First Affiliated Hosp, Guangzhou Med Sch, Guangzhou Inst Resp Dis, Guangzhou, Peoples R China; [Lockey, R. F.] Univ S Florida, Coll Med, Tampa, FL 33620 USA; [Mavale-Manuel, S.] Childrens Hosp, Maputo, Mozambique; [Meltzer, E. O.] Univ Calif San Diego, Allergy & Asthma Med Grp & Res Ctr, San Diego, CA 92103 USA; [Mohammad, Y.] Tishreen Univ Sch Med, Latakia, Syria; [Mullol, J.] Hosp Clin IDIBAPS, Barcelona, Catalonia, Spain; [Naclerio, R.] Univ Chicago, Chicago, IL 60637 USA; [Hehir, R. E. O.] Alfred Hosp, Melbourne, Vic, Australia; [Hehir, R. E. O.] Monash Univ, Melbourne, Vic 3004, Australia; [Ohta, K.] Teikyo Univ, Sch Med, Tokyo 173, Japan; [Ouedraogo, S.] Ctr Hosp Univ Pediat Charles de Gaulle, Ouagadougou, Burkina Faso; [Palkonen, S.] EFA European Federat Allergy & Airways Dis Patien, Brussels, Belgium; [Papadopoulos, N.] Univ Athens, Allergy Res Ctr, Athens, Greece; [Passalacqua, G.] Univ Genoa, Genoa, Italy; [Pawankar, R.] Nippon Med Sch, Bunkyo Ku, Tokyo 113, Japan; [Popov, T. A.] Med Univ Sofia, Clin Allergy & Asthma, Sofia, Bulgaria; [Rabe, K. F.; Chavannes, N. H.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Rosado-Pinto, J.] Hosp Dona Estefania, Lisbon, Portugal; [Scadding, G. K.] UCL, Royal Natl TNE Hosp London, London, England; [Simons, F. E. R.] Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; [Toskala, E.] Helsinki Univ Hosp, Helsinki, Finland; [Toskala, E.] Finnish Inst Occupat Hlth, Helsinki, Finland; [Valovirta, E.] Turku Allergy Ctr, Turku, Finland; [van Cauwenberge, P.] Univ Ghent, B-9000 Ghent, Belgium; [Wang, D. -Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Singapore 117548, Singapore; [Wickman, M.] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Wickman, M.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Yawn, B. P.] Univ Minnesota, Olmsted Med Ctr, Rochester, MN USA; [Yorgancioglu, A.] Celal Bayar Univ, Sch Med, Manisa, Turkey; [Yusuf, O. M.] Allergy & Asthma Inst, Islamabad, Pakistan; [Zar, H.] Univ Cape Town, Sch Child & Adolescent Hlth, Red Cross Childrens Hosp, ZA-7925 Cape Town, South Africa; [Annesi-Maesano, I.] INSERM, EPAR U707, F-75654 Paris 13, France; [Annesi-Maesano, I.] UPMC, EPAR, UMR S, Paris, France; [Bateman, E. D.] Univ Cape Town, Fac Hlth Sci, ZA-7925 Cape Town, South Africa; [Ben Kheder, A.] Univ Tunis, Tunisian Soc Resp Dis, Pan African Thorac Soc, Tunis, Tunisia; [Boakye, D. A.] Univ Ghana, Coll Hlth Sci, Noguchi Mem Inst Med Res, Legon, Accra, Ghana; [Bouchard, J.] Hop Malbaie, Quebec City, PQ, Canada; [Burney, P.; Johnston, S. L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Busse, W. W.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; [Chan-Yeung, M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [Chuchalin, A.] Pulmonol Res Inst, Moscow, Russia; [Chuchalin, A.] Russian Resp Soc, Moscow, Russia; [Dolen, W. K.] Med Coll Georgia, Augusta, GA 30912 USA; [Emuzyte, R.] Vilnius State Univ, Fac Med, Vilnius, Lithuania; [Grouse, L.] Univ Washington, Sch Med, Seattle, WA 98195 USA; [Humbert, M.] Univ Paris Sud, Hop Antoine Beclere, Clamart, France; [Jackson, C.] Univ Dundee, Tayside Ctr Gen Practice, Dundee, Scotland; [Keith, P. K.] McMaster Univ, Hamilton, ON, Canada; [Kemp, J. P.] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; [Klossek, J. -M.] Univ Poitiers, Poitiers, France; [Larenas-Linnemann, D.] Hosp Med Sur, Mexico City, DF, Mexico; [Malo, J. -L.] Hop Sacre Coeur Montreal, Montreal, PQ, Canada; [Marshall, G. D.] Univ Mississippi, Jackson, MS 39216 USA; [Naspitz, C.] Univ Fed Sao Paulo, Sao Paulo, Brazil; [Nekam, K.] Hosp Hospitaller Bros Buda, Budapest, Hungary; [Niggemann, B.] German Red Cross Hosp Berlin, Berlin, Germany; [Nizankowska-Mogilnicka, E.] Jagiellonian Univ, Sch Med, Krakow, Poland; [Okamoto, Y.] Chiba Univ, Chiba, Japan; [Potter, P.] Groote Schuur Hosp, ZA-7925 Cape Town, South Africa; [Potter, P.] Univ Cape Town, Lung Inst, ZA-7700 Rondebosch, South Africa; [Price, D.] Univ Aberdeen, Aberdeen, Scotland; [Stoloff, S. W.] Univ Nevada, Sch Med, Reno, NV 89557 USA; [Vandenplas, O.] Catholic Univ Louvain, Univ Hosp Mt Godinne, Yvoir, Belgium; [Viegi, G.] CNR, Inst Clin Physiol, I-56100 Pisa, Italy; [Williams, D.] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27515 USA	Bousquet, J (reprint author), Univ Hosp, Montpellier, France.		; Chavannes, Niels/F-1148-2011; Johnston, Sebastian/I-2423-2012; Dahl, Ronahl/F-8170-2013; jackson, cathy/H-4869-2013; Custovic, Adnan/A-2435-2012; Annesi-Maesano, Isabella/D-9173-2016; van Weel, Chris/D-4375-2009; Cruz, Alvaro/I-1676-2012	Price, David/0000-0002-9728-9992; Popov, Todor/0000-0001-5052-5866; O'Hehir, Robyn/0000-0002-3489-7595; Bonini, Sergio/0000-0003-0079-3031; Chavannes, Niels/0000-0002-8607-9199; Custovic, Adnan/0000-0001-5218-7071; van Weel, Chris/0000-0003-3653-4701; Cruz, Alvaro/0000-0002-7403-3871; Papadopoulos, Nikolaos/0000-0002-2508-3872; Bousquet, Philippe Jean/0000-0002-0217-5483			Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; Abelson MB, 2004, CLIN THER, V26, P1237, DOI 10.1016/S0149-2918(04)80065-1; ABERG N, 1989, CLIN EXP ALLERGY, V19, P643, DOI 10.1111/j.1365-2222.1989.tb02761.x; ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; Abkowitz JL, 2003, BLOOD, V102, P1249, DOI 10.1182/blood-2003-01-0318; Abrams Don-Carlos, 1997, Rhinology (Utrecht), V35, P22; Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Addo Yobo Emmanuel O. D., 1997, Thorax, V52, P161; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; ADKINSON NF, 2001, AM J RESP CRIT CARE, V12, P2140; Agertoft L, 1999, J ALLERGY CLIN IMMUN, V104, P948; Agius AM, 2004, CLIN OTOLARYNGOL, V29, P247, DOI 10.1111/j.1365-2273.2004.00803.x; Agius RM, 2000, OCCUP MED, V15, P369; Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; AGREE Collaboration, 2003, Qual Saf Health Care, V12, P18; Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Ahlstedt Staffan, 2006, Prim Care Respir J, V15, P228, DOI 10.1016/j.pcrj.2006.05.004; AHRQ, AHRQ PUBL; Airaksinen L, 2007, RHINOLOGY, V45, P40; Ait-Khaled N, 2007, ALLERGY, V62, P247, DOI 10.1111/j.1398-9995.2007.01325.x; Ait-Khaled N, 2006, INT J TUBERC LUNG D, V10, P133; Ait-Khaled N, 2000, INT J TUBERC LUNG D, V4, P268; Ajaiyeoba A I, 2003, West Afr J Med, V22, P15; Akcakaya N, 2000, EUR J EPIDEMIOL, V16, P693, DOI 10.1023/A:1026593509093; Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Akpinar-Elci M, 2004, CHEST, V125, P2336, DOI 10.1378/chest.125.6.2336; Al Frayh AR, 2001, ANN ALLERG ASTHMA IM, V86, P292; Al-Dowaisan A, 2004, ANN ALLERG ASTHMA IM, V92, P262; Al-Shadli AM, 2001, J ASTHMA, V38, P121, DOI 10.1081/JAS-100000029; Alanko K, 1970, Scand J Respir Dis Suppl, V76, P1; Alaranta A, 2006, INT J SPORTS MED, V27, P919, DOI 10.1055/s-2006-923811; Alaranta A, 2005, MED SCI SPORT EXER, V37, P707, DOI 10.1249/01.MSS.0000162689.69517.60; Allansmith M R, 1990, J Am Optom Assoc, V61, pS42; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; Allegra L, 1993, Pediatr Allergy Immunol, V4, P157, DOI 10.1111/j.1399-3038.1993.tb00085.x; Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407; Allen DB, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00704.x; Alles R, 2001, PEDIATR ALLERGY IMMU, V12, P102, DOI 10.1046/j.0905-6157.2000.00008.x; Alm JS, 1998, ALLERGY, V53, P537, DOI 10.1111/j.1398-9995.1998.tb04093.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694; Alobid I, 2006, OTOLARYNG HEAD NECK, V134, P609, DOI 10.1016/j.otohns.2005.10.061; Al Sayyad JJ, 2007, COCHRANE DB SYST REV; ALVAREZ C, 2006, ALLERGY S82, V61, P1; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Alvarez-Puebla MJ, 2003, RESP MED, V97, P30, DOI 10.1053/rmed.2002.1420; Board of Directors of the American Academy of Allergy, 1993, J ALLERGY CLIN IMMUN, V92, P636; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; ANDERSSON M, 1995, ACTA OTO-LARYNGOL, V115, P705, DOI 10.3109/00016489509139391; Andersson M, 2003, PEDIATR ALLERGY IMMU, V14, P100, DOI 10.1034/j.1399-3038.2003.00031.x; ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Anhoj C, 2001, ALLERGY, V56, P548, DOI 10.1034/j.1398-9995.2001.056006548.x; Annesi-Maesano I, 2004, CLIN EXP ALLERGY, V34, P1017, DOI 10.1111/j.1365-2222.2004.02002.x; AnnesiMaesano I, 1997, INT ARCH ALLERGY IMM, V114, P193; ANNESIMAESANO I, 2003, SERIES LUNG BIOL HLT, V81, P105; ANNESIMAESANO I, 1998, EUR RESPIR J, V10, pS143; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Annus T, 2005, PEDIATR ALLERGY IMMU, V16, P315, DOI 10.1111/j.1399-3038.2005.00276.x; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Anto JM, 1997, THORAX, V52, P669; Antonicelli L, 2007, CLIN EXP ALLERGY, V37, P954, DOI 10.1111/j.1365-2222.2007.02729.x; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; APTER AJ, 1995, ANN ALLERG ASTHMA IM, V75, P311; APTER AJ, 1992, J ALLERGY CLIN IMMUN, V90, P670, DOI 10.1016/0091-6749(92)90141-N; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P133, DOI 10.1016/j.jaci.2005.04.022; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; ARIANO R, 1994, J INVEST ALLERG CLIN, V4, P81; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; Armstrong M, 2005, OTOLARYNG CLIN N AM, V38, P1327, DOI 10.1016/j.otc.2005.08.009; Aronsson D, 2005, CLIN EXP ALLERGY, V35, P1457, DOI 10.1111/j.1365-2222.2005.02363.x; ARRUDA LK, 1992, EXP APPL ACAROL, V16, P129, DOI 10.1007/BF01201496; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Arshad SH, 2002, ACTA PAEDIATR, V91, P1334; Arshad SH, 2002, CLIN EXP ALLERGY, V32, P843, DOI 10.1046/j.1365-2222.2002.01378.x; Arvidsson MB, 2002, J ALLERGY CLIN IMMUN, V109, P777, DOI 10.1067/mai.2002.123868; ASAKURA K, 1984, ARCH OTO-RHINO-LARYN, V239, P273, DOI 10.1007/BF00464255; Asher I, 2004, INT ARCH ALLERGY IMM, V135, P83, DOI 10.1159/000080524; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Asher MI, 2001, NEW ZEAL MED J, V114, P114; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Asher MI, 1998, CLIN EXP ALLERGY, V28, P90; Ashraf N, 2001, OTOLARYNG HEAD NECK, V125, P483, DOI 10.1016/S0194-5998(01)43777-6; Assanasen P, 2001, AM J RESP CRIT CARE, V164, P1640; Assanasen P, 1999, J ALLERGY CLIN IMMUN, V104, P285, DOI 10.1016/S0091-6749(99)70368-4; Assefa G, 2000, ETHIOPIAN MED J, V38, P1; Assing K, 2007, ALLERGY, V62, P373, DOI 10.1111/j.1398-9995.2006.01280.x; ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Atkins D, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-25; Atkinson JJ, 2003, AM J RESP CELL MOL, V28, P12, DOI 10.1165/rcmb.2002-0166TR; Atkinson RW, 2006, OCCUP ENVIRON MED, V63, P580, DOI 10.1136/oem.2005.024448; Atlas SJ, 2005, QUAL LIFE RES, V14, P1375, DOI 10.1007/s11136-004-6674-7; AXELSSON IGK, 1987, ALLERGY, V42, P604, DOI 10.1111/j.1398-9995.1987.tb00391.x; Azpiri A, 1999, ALLERGY, V54, P1100, DOI 10.1034/j.1398-9995.1999.00146.x; Bach JF, 2005, CELL IMMUNOL, V233, P158, DOI 10.1016/j.cellimm.2005.04.006; Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.1054.x; Bachert C, 2004, IMMUNOL ALLERGY CLIN, V24, P19, DOI 10.1016/S0889-8561(03)00104-8; Bachert C, 2004, ALLERGY, V59, P11, DOI 10.1111/j.0108-1675.2004.00389.x; Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Bachert C, 2002, ANN ALLERG ASTHMA IM, V89, P292; BACHERT C, 2004, ALLERGY S76, V59, P5; BACKER V, 1992, ANN ALLERGY, V69, P116; Baena-Cagnani CE, 2005, CURR OPIN ALLERGY CL, V5, P173, DOI 10.1097/01.all.0000162311.87178.9e; Baena-Cagnani CE, 2004, DRUG SAFETY, V27, P883, DOI 10.2165/00002018-200427120-00005; Baena-Cagnani CE, 2001, ALLERGY, V56, P21; Bager P, 2003, CLIN EXP ALLERGY, V33, P1512, DOI 10.1046/j.1365-2222.2003.01796.x; Bager P, 2003, J ALLERGY CLIN IMMUN, V111, P51, DOI 10.1067/mai.2003.34; Bahna S L, 1978, Adv Pediatr, V25, P1; Baiardini I, 2003, ALLERGY, V58, P289, DOI 10.1034/j.1398-9995.2003.00079.x; BAIARDINI I, 2006, ANN ALLERG ASTHMA IM, V97, P29; BAIARDINI I, 2006, ANN ALLERG ASTHMA IM, V97, P76; Baiardini I, 2006, ANN ALLERG ASTHMA IM, V97, P419; BAKKE P, 1990, ALLERGY, V45, P515, DOI 10.1111/j.1398-9995.1990.tb00527.x; Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb04579.x; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; Baldwin CM, 1999, TOXICOL IND HEALTH, V15, P403, DOI 10.1177/074823379901500314; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; BALMES J, 2003, AM J RESP CRIT CARE, V1, P167; Banac S, 2004, CROAT MED J, V45, P721; Banov CH, 1996, CLIN THER, V18, P265, DOI 10.1016/S0149-2918(96)80007-5; BANOV CH, 1994, ANN ALLERGY, V73, P240; Baraniuk JN, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-149; BARBEE RA, 1976, ANN INTERN MED, V84, P129; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BARDANA EJ, 1983, EUR J RESPIR DIS, V64, P241; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Barnes Kathleen C., 1996, International Archives of Allergy and Immunology, V109, P68; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Barnes ML, 2007, ALLERGY, V62, P73, DOI 10.1111/j.1398-9995.2006.01263.x; Barnes ML, 2006, CLIN EXP ALLERGY, V36, P676, DOI 10.1111/j.1365-2222.2006.02478.x; Barnes ML, 2005, RHINOLOGY, V43, P291; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, P1227; BAROODY F, 2004, UPPER LOWER RESP DIS, V181, P1; Baroody FM, 1997, J ALLERGY CLIN IMMUN, V100, P563; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661; Bascom R, 1996, FUND APPL TOXICOL, V29, P86, DOI 10.1006/faat.1996.0009; BASCOM R, 1995, ENVIRON HEALTH PERSP, V103, P1026, DOI 10.2307/3432630; BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; Basu S, 2005, EUR ARCH OTO-RHINO-L, V262, P751, DOI 10.1007/s00405-004-0891-0; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P519, DOI 10.1016/j.jaci.2006.01.028; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Baudoin T, 1999, AM J RHINOL, V13, P229, DOI 10.2500/105065899781389786; BAUER GE, 1973, MED J AUSTRALIA, V1, P930; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Bauman A, 1996, BRIT MED J, V312, P590; Baur X, 1998, J ALLERGY CLIN IMMUN, V102, P984, DOI 10.1016/S0091-6749(98)70337-9; Baur X, 2005, INT ARCH OCC ENV HEA, V78, P279, DOI 10.1007/s00420-004-0590-6; Baur X, 1992, Arerugi, V41, P81; BAUR X, 1992, INT ARCH OCC ENV HEA, V64, P185, DOI 10.1007/BF00380907; Baur X, 1999, INT ARCH OCC ENV HEA, V72, P292, DOI 10.1007/s004200050377; Bavbek S, 2002, J INVEST ALLERG CLIN, V12, P204; Bavbek S, 1996, J INVEST ALLERG CLIN, V6, P172; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BEAUMONT F, 1984, ANN ALLERGY, V53, P486; BEAUMONT G, 1990, BRIT J CLIN PRACT, V44, P183; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; BECKER A, 2005, CMAJ S6, V173, pS20; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Beeh KM, 2003, CLIN EXP ALLERGY, V33, P475, DOI 10.1046/j.1365-2222.2003.01632.x; Beggs PJ, 2005, ENVIRON HEALTH PERSP, V113, P915, DOI 10.1289/ehp.7724; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Bellussi L, 2004, INT J IMMUNOPATH PH, V17, P201; BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; Benson M, 2002, CYTOKINE, V18, P20, DOI 10.1006/cyto.2002.1012; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BENVENISTE J, 1981, CLIN ALLERGY, V11, P1, DOI 10.1111/j.1365-2222.1981.tb01559.x; Berdeaux G, 1998, QUAL LIFE RES, V7, P501, DOI 10.1023/A:1008874324258; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Berger WE, 2005, ANN PHARMACOTHER, V39, P1984, DOI 10.1345/aph.1G202; Berger WE, 2003, ANN ALLERG ASTHMA IM, V91, P205; Berger WE, 2002, ANN ALLERG ASTHMA IM, V89, P485; Berger William E, 2004, Paediatr Drugs, V6, P233, DOI 10.2165/00148581-200406040-00003; Berkowitz RB, 2004, ALLERGY ASTHMA PROC, V25, P335; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; BERMAN BA, 1990, J ALLERGY CLIN IMMUN, V86, P1004, DOI 10.1016/S0091-6749(05)80244-1; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bernd LAG, 1996, J INVEST ALLERG CLIN, V6, P94; Bernsen R., 2006, CLIN EXP ALLERGY, V36, P859; Bernstein DI, 2004, CLIN EXP ALLERGY, V34, P952, DOI 10.1111/j.1365-2222.2004.01952.x; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; Berrens L, 1978, Clin Allergy, V8, P311, DOI 10.1111/j.1365-2222.1978.tb03229.x; Bertrand B., 1996, Rhinology (Utrecht), V34, P91; Bez C, 2004, CLIN EXP ALLERGY, V34, P1079, DOI 10.1111/j.1365-2222.2004.01998.x; Bhatia S, 2005, ARCH OTOLARYNGOL, V131, P223, DOI 10.1001/archotol.131.3.223; Bhattacharyya N, 2003, LARYNGOSCOPE, V113, P125, DOI 10.1097/00005537-200301000-00023; Biagini JM, 2006, PEDIATR ALLERGY IMMU, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; Bibakis I, 2005, CLIN EXP ALLERGY, V35, P624, DOI 10.1111/j.1365-2222.2005.02230.x; Bielory L, 2006, ANN ALLERG ASTHMA IM, V96, P514; Bielory L, 2004, ANN ALLERG ASTHMA IM, V93, pS45; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Birch DS, 2001, RHINOLOGY, V39, P191; BIRCHER AJ, 1995, CLIN EXP ALLERGY, V25, P228, DOI 10.1111/j.1365-2222.1995.tb01033.x; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; Bjornsdottir US, 2003, ANN ALLERG ASTHMA IM, V91, P189; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63; Black PN, 2005, ALLERGY, V60, P30, DOI 10.1111/j.1398-9995.2005.00697.x; BLACKLEY C, 1873, LANCET, V2, P231; Blackwell DL, 2003, VITAL HLTH STAT, V10, P1; Blaiss MS, 2006, ALLERGY ASTHMA PROC, V27, P254, DOI 10.2500/aap.2006.27.2852; Blaiss MS, 2006, ANN ALLERG ASTHMA IM, V97, P121; Blaiss MS, 2004, CURR MED RES OPIN, V20, P1937, DOI 10.1185/030079904X13266; Blanc PD, 2006, EUR RESPIR J, V27, P85, DOI 10.1183/09031936.06.00061205; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Blom HM, 1997, J ALLERGY CLIN IMMUN, V100, P739, DOI 10.1016/S0091-6749(97)70267-7; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Blom HM, 1998, CLIN EXP ALLERGY, V28, P1351; BLOM HM, 1995, EUR ARCH OTO-RHINO-L, V1, pS33; Blomgren K, 2005, SCAND J INFECT DIS, V37, P245, DOI 10.1080/00365540410020857; Blomgren K, 2002, SCAND J PRIM HEALTH, V20, P40, DOI 10.1080/028134302317282734; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bochner BS, 2004, J ALLERGY CLIN IMMUN, V113, P868, DOI 10.1016/j.jaci.2004.02.016; BOCK SA, 1986, J ALLERGY CLIN IMMUN, V78, P165, DOI 10.1016/0091-6749(86)90009-6; Bodtger U, 2006, ALLERGY, V61, P712, DOI 10.1111/j.1398-9995.2006.01140.x; Bodtger U, 2004, J ALLERGY CLIN IMMUN, V114, P1384, DOI 10.1016/j.jaci.2004.08.039; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30; Bohle B, 2007, ALLERGY, V62, P3, DOI 10.1111/j.1398-9995.2006.01258.x; BOJKOWSKI CJ, 1989, J INT MED RES, V17, pB54; Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Bonay M, 2006, ALLERGY, V61, P111, DOI 10.1111/j.1398-9995.2006.00967.x; BONER A, 1995, ALLERGY, V50, P498, DOI 10.1111/j.1398-9995.1995.tb01185.x; Boner A L, 1994, Rev Med Suisse Romande, V114, P217; Bonini S, 2006, CHEM IMMUNOL ALLERGY, V91, P110; Bonini S, 2006, ALLERGY, V61, P681, DOI 10.1111/j.1398-9995.2006.01080.x; Bonini S, 2004, ALLERGY, V59, P71, DOI 10.1111/j.1398-9995.2004.00570.x; Bonini S, 2004, EYE, V18, P345, DOI 10.1038/sj.eye.6700675; Bonini S, 1998, ALLERGY AND ALLERGIC DISEASES, P509; BONINI S, 1987, CHIBRET INT J OPHTHA, V5, P12; Boot JD, 2007, ALLERGY, V62, P378, DOI 10.1111/j.1398-9995.2007.01328.x; Borkow G, 2000, J CLIN INVEST, V106, P1053, DOI 10.1172/JCI10182; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; BORUM P, 1979, CLIN OTOLARYNGOL, V4, P407, DOI 10.1111/j.1365-2273.1979.tb01773.x; BORUM P, 1987, ALLERGY, V42, P26, DOI 10.1111/j.1398-9995.1987.tb02183.x; BOSTOCK J, 1819, MED SURG T LONDON, V14, P437; Botey J, 1999, Pediatr Pulmonol Suppl, V18, P157; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1046/j.1365-2222.1997.d01-418.x; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Bousquet J, 2001, ANN ALLERG ASTHMA IM, V87, P38; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; Bousquet J, 2000, ALLERGY, V55, P1194, DOI 10.1034/j.1398-9995.2000.00923.x; BOUSQUET J, 1991, CLIN REV ALLERG, V9, P357; BOUSQUET J, 1986, CLIN ALLERGY, V16, P57, DOI 10.1111/j.1365-2222.1986.tb01954.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1994, DRUG SAFETY, V10, P5; Bousquet J, 2007, ALLERGY, V62, P216, DOI 10.1111/j.1398-9995.2007.01307.x; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; Bousquet J, 2006, ALLERGY, V61, P1086, DOI 10.1111/j.1398-9995.2006.01144.x; Bousquet J, 1999, ALLERGY, V54, P562, DOI 10.1034/j.1398-9995.1999.00984.x; Bousquet J, 2006, ALLERGY, V61, P1155, DOI 10.1111/j.1398-9995.2006.01237.x; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V75, P70, DOI 10.1016/0091-6749(85)90015-6; Bousquet J, 1998, ALLERGY, V53, P3; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P728, DOI 10.1111/j.1365-2222.2005.02274.x; Bousquet J, 2005, CLIN EXP ALLERGY, V35, P723, DOI 10.1111/j.1365-2222.2005.02251.x; Bousquet J, 2005, ALLERGY, V60, P788, DOI 10.1111/j.1398-9995.2005.00820.x; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 2004, ALLERGY, V59, P12, DOI 10.1111/j.1398-9995.2004.00654.x; Bousquet J, 2004, CLIN EXP ALLERGY, V34, P897, DOI 10.1111/j.1365-2222.2004.01969.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; Bousquet J, 2004, ALLERGY, V59, P373; Bousquet J, 2004, J ALLERGY CLIN IMMUN, V113, P43, DOI 10.1016/j.jaci.2003.09.047; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; BOUSQUET J, 1992, EUR RESPIR J, V5, P1137; Bousquet J, 2003, ALLERGY, V58, P192, DOI 10.1034/j.1398-9995.2003.00054.x; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; Bousquet J, 2001, AM J RESP CRIT CARE, V164, P2139, DOI 10.1164/rccm2110107; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BOUSQUET J, 1990, ANN ALLERGY, V65, P504; Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207; Bousquet J, 1997, ACI INT, V9, P10; BOUSQUET J, 2001, J ALLERGY CLIN IM S5, V147, pS334; BOUSQUET J, 1998, ALLERGY S, V53, P54; Bousquet Jean, 2005, Prim Care Respir J, V14, P122, DOI 10.1016/j.pcrj.2005.03.006; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V118, P447, DOI 10.1016/j.jaci.2006.03.048; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Bousquet PJ, 2004, ALLERGY, V59, P1015, DOI 10.1111/j.1398-9995.2004.00579.x; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Braat JPM, 2002, CLIN EXP ALLERGY, V32, P690, DOI 10.1046/j.1365-2222.2002.01359.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Braback L, 2005, EUR RESPIR J, V26, P1064, DOI 10.1183/09031936.05.00022105; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Braback L, 2005, RESP MED, V99, P1010, DOI 10.1016/j.rmed.2005.02.004; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; BRABACK L, 1988, ACTA PAEDIATR SCAND, V77, P821, DOI 10.1111/j.1651-2227.1988.tb10762.x; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; BRASCH A, 2006, J MED GENET, V43, pE10; Brattmo M, 2002, AM J RHINOL, V16, P323; Braun H, 2003, LARYNGOSCOPE, V113, P264, DOI 10.1097/00005537-200302000-00013; Braun JJ, 1997, ALLERGY, V52, P650, DOI 10.1111/j.1398-9995.1997.tb01044.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Braun-Fahrlander Charlotte, 2003, Curr Opin Allergy Clin Immunol, V3, P325, DOI 10.1097/00130832-200310000-00001; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Braunstahl Gert-Jan, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P176, DOI 10.1097/01.moo.0000193186.15440.39; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2003, CURR OPIN PULM MED, V9, P46, DOI 10.1097/00063198-200301000-00008; Braunstahl GJ, 2003, CLIN EXP ALLERGY, V33, P579, DOI 10.1046/j.1365-2222.2003.01652.x; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858; Breborowicz A, 1995, Pneumonol Alergol Pol, V63, P157; Brehler R, 1998, ALLERGY, V53, P402, DOI 10.1111/j.1398-9995.1998.tb03912.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Bremner SA, 2005, ARCH DIS CHILD, V90, P567, DOI 10.1136/adc.2004.051714; BRILLE D, 1962, HIGH AUTHORITY QUEST; Brisman J, 1999, EUR RESPIR J, V13, P502, DOI 10.1183/09031936.99.13350299; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BROMS P, 1982, ALLERGY, V37, P67, DOI 10.1111/j.1398-9995.1982.tb01879.x; BRONSKY E, 1995, J ALLERGY CLIN IMMUN, V96, P139, DOI 10.1016/S0091-6749(95)70001-3; Brown JL, 2007, CLIN EXP ALLERGY, V37, P688, DOI 10.1111/j.1365-2222.2007.02695.x; Brown R, 2007, ALLERGY, V62, P149, DOI 10.1111/j.1398-9995.2006.01310.x; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; BRUNO G, 1989, J INT MED RES, V17, pB40; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; BRUTTMANN G, 1989, J ALLERGY CLIN IMMUN, V83, P411, DOI 10.1016/0091-6749(89)90127-9; BUCHOLTZ GA, 1985, ANN ALLERGY, V55, P805; BUCHOLTZ GA, 1991, ANN ALLERGY, V67, P534; Budde IK, 2002, ANN ALLERG ASTHMA IM, V89, P606; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Bugiani M, 2005, ALLERGY, V60, P165, DOI 10.1111/j.1398-9995.2005.00659.x; Bunnag C, 2005, RHINOLOGY, V43, P99; Bunnag C, 2000, ASIAN PAC J ALLERGY, V18, P1; Burches E, 1996, CLIN EXP ALLERGY, V26, P1262, DOI 10.1046/j.1365-2222.1996.d01-286.x; BURGE PS, 1979, THORAX, V34, P13, DOI 10.1136/thx.34.1.13; Burgess JK, 2003, AM J RESP CRIT CARE, V167, P71, DOI 10.1164/rccm.200205-416OC; Burgess SW, 2006, PEDIATRICS, V117, pE787, DOI 10.1542/peds.2005-1753; Burks W, 1999, INT ARCH ALLERGY IMM, V119, P165, DOI 10.1159/000024191; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Burr M L, 1999, Pediatr Pulmonol Suppl, V18, P3; Burr ML, 2003, CLIN EXP ALLERGY, V33, P1675, DOI 10.1111/j.1365-2222.2003.01816.x; Burr ML, 1999, THORAX, V54, P27; Burr ML, 2004, OCCUP ENVIRON MED, V61, P212, DOI 10.1136/oem.2002.003244; Burr ML, 1999, CLIN EXP ALLERGY, V29, P1442; Burtin B, 2000, J INVEST ALLERG CLIN, V10, P66; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; Bush RK, 2006, J ALLERGY CLIN IMMUN, V117, P326, DOI 10.1016/j.jaci.2005.12.001; BUSSE PJ, 2007, AM J MED, V120, P4978; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Busse WW, 2006, ANN ALLERG ASTHMA IM, V96, P60; Busse WW, 1996, AM J RESP CRIT CARE, V153, P122; Butland BK, 2006, THORAX, V61, P383, DOI 10.1136/thx.2005.043646; Butland BK, 1997, BRIT MED J, V315, P717; Caballero T, 1996, CLIN EXP ALLERGY, V26, P197, DOI 10.1111/j.1365-2222.1996.tb00080.x; Caffarelli C, 1998, CLIN EXP ALLERGY, V28, P591; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, V24, P1; CALDERONGARCIDUENAS L, 1992, AM J PATHOL, V140, P225; CALDERONGARCIDUENAS L, 1994, ENVIRON HEALTH PERSP, V102, P1074, DOI 10.2307/3431995; CALDERONGARCIDUENAS L, 1993, ENVIRON HEALTH PERSP, V101, P138, DOI 10.2307/3431423; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661; Camargos P, 2007, ALLERGY, V62, P310, DOI 10.1111/j.1398-9995.2006.01241.x; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Canning Brendan J, 2002, Curr Allergy Asthma Rep, V2, P210, DOI 10.1007/s11882-002-0021-2; Canonica GW, 2007, ALLERGY, V62, P359, DOI 10.1111/j.1398-9995.2006.01277.x; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2006, ALLERGY, V61, P20, DOI 10.1111/j.1398-9995.2006.01161.x; Canonica GW, 2006, RESP MED, V100, P1706, DOI 10.1016/j.rmed.2006.03.039; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CANONICA GW, 2003, J ALLERGY CLIN IMMUN, V111, P49; Cap P, 2005, ALLERGY, V60, P171, DOI 10.1111/j.1398-9995.2005.00675.x; CARABALLO L, 1994, CLIN EXP ALLERGY, V24, P1056, DOI 10.1111/j.1365-2222.1994.tb02743.x; Cardesin A, 2006, RHINOLOGY, V44, P83; Carlsen Kai-Hakon, 2004, Paediatr Respir Rev, V5, P45, DOI 10.1016/j.prrv.2003.09.010; Carlsen KCL, 2002, ALLERGY, V57, P529, DOI 10.1034/j.1398-9995.2002.13305.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 2003, J ALLERGY CLIN IMMUN, V111, pS835, DOI 10.1067/mai.2003.1550; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Cassano P, 2003, INT J PEDIATR OTORHI, V67, P1303, DOI 10.1016/j.ijporl.2003.07.018; Castellano F, 2002, DRUG EXP CLIN RES, V28, P27; Cathcart M, 1997, OCCUP MED-OXFORD, V47, P473, DOI 10.1093/occmed/47.8.473; Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108; Celik G, 2004, ALLERGY ASTHMA PROC, V25, P107; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Cengel S, 2006, INT J PEDIATR OTORHI, V70, P639, DOI 10.1016/j.ijporl.2005.08.013; Chae SC, 2005, IMMUNOGENETICS, V56, P760, DOI 10.1007/s00251-004-0746-2; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Chakir J, 1996, LAB INVEST, V75, P735; Chan-Yeung M, 2006, CURR OPIN ALLERGY CL, V6, P146, DOI 10.1097/01.all.0000225150.91661.34; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; CHAND N, 1988, BRIT J PHARMACOL, V94, P1057; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588; CHANG AB, 2006, COCHRANE DB SYST REV, V3, P5604; Chang Y, 2006, J ALLERGY CLIN IMMUN, V118, P354, DOI 10.1016/j.jaci.2006.04.050; Chantzi FM, 2006, ALLERGY, V61, P332, DOI 10.1111/j.1398-9995.2006.00971.x; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; Chapman MD, 1997, INT ARCH ALLERGY IMM, V113, P102; Charlet L.D., 1978, International Journal of Acarology, V4, P23; Charpin D, 1996, ALLERGY, V51, P293, DOI 10.1111/j.1398-9995.1996.tb04612.x; Charpin D, 2005, ALLERGY, V60, P293, DOI 10.1111/j.1398-9995.2005.00731.x; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHARPIN D, 1993, CLIN EXP ALLERGY, V23, P435, DOI 10.1111/j.1365-2222.1993.tb00350.x; Chatkin MN, 2003, PEDIATR PULM, V35, P296, DOI 10.1002/ppul.10229; Chen H, 2004, J ALLERGY CLIN IMMUN, V114, P845, DOI 10.1016/j.jaci.2004.07.008; Chen Hubert, 2005, Health Qual Life Outcomes, V3, P68, DOI 10.1186/1477-7525-3-68; Chen PC, 1998, ENVIRON HEALTH PERSP, V106, P331, DOI 10.1289/ehp.98106331; Chen W, 2007, ALLERGY, V62, P571, DOI 10.1111/j.1398-9995.2007.01334.x; Chen WY, 2003, ENVIRON RES, V93, P1, DOI 10.1016/S0013-9351(03)00070-7; Chen Y, 2003, LARYNGOSCOPE, V113, P1199, DOI 10.1097/00005537-200307000-00016; Chervinsky P, 2004, ANN ALLERG ASTHMA IM, V92, P367; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160; Chinoy B, 2005, CLIN MOL ALLERGY, V3, P4, DOI 10.1186/1476-7961-3-4; Choudat D, 2005, SCAND J WORK ENV HEA, V31, P59; Ciprandi G, 2005, OTOLARYNG HEAD NECK, V133, P429, DOI 10.1016/j.otohns.2005.05.049; Ciprandi G, 2005, ALLERGY, V60, P882, DOI 10.1111/j.1398-9995.2005.00602.x; Ciprandi G, 1997, J INVEST ALLERG CLIN, V7, P557; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Ciprandi G, 1997, ALLERGY, V52, P752, DOI 10.1111/j.1398-9995.1997.tb01233.x; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Ciprandi G, 2002, ALLERGY, V57, P586, DOI 10.1034/j.1398-9995.2002.03228.x; Ciprandi G, 2006, AM J RHINOL, V20, P641, DOI 10.2500/ajr.2006.20.2914; Cirillo I, 2006, ANN ALLERG ASTHMA IM, V96, P692; Civelek E, 2006, ALLERGY, V61, P1454, DOI 10.1111/j.1398-9995.2006.01214.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Clement P A, 1984, Rhinology, V22, P151; Clement PAR, 2005, RHINOLOGY, V43, P169; Cobbaert CM, 2005, CLIN CHEM LAB MED, V43, P772, DOI 10.1515/CCLM.2005.132; Cockburn IM, 1999, J OCCUP ENVIRON MED, V41, P948, DOI 10.1097/00043764-199911000-00005; Cockcroft DW, 2005, ALLERGY, V60, P56, DOI 10.1111/j.1398-9995.2004.00612.x; CODY DT, 1994, LARYNGOSCOPE, V104, P1074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Colas C, 2006, J ALLERGY CLIN IMMUN, V117, P810, DOI 10.1016/j.jaci.2005.11.039; Collins JG, 1997, VITAL HLTH STAT, V10, P1; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; COLLOFF MJ, 1991, EXP APPL ACAROL, V11, P177, DOI 10.1007/BF01246090; Colombo P, 2003, INT ARCH ALLERGY IMM, V130, P173, DOI 10.1159/000069520; Condemi J, 2000, ANN ALLERG ASTHMA IM, V84, P533; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; CORBI AL, 1985, INT ARCH ALLER A IMM, V77, P377; EAACI, 1993, ALLERGY, V48, P48; International Consensus Report on Diagnosis and Management of Rhinitis, 1994, ALLERGY S19, V49, P1; *MRC COMM AET CHRO, 1960, BRIT MED J, V2, P1665; *NHLBI WHO, 2006, NHLBI WHO WORKSH REP; Nordic Council on Medicines, 1989, NLN PUBL, V23, P1; S. American Thoracic and S. European Respiratory, 2005, AM J RESP CRIT CARE, V171, P912; STALDER JF, 1993, DERMATOLOGY, V186, P23; THOMPSON RA, 1989, ALLERGY, V44, P369; *WAQA, 2006 PROH LIST; World Health Organization, ESS MED WHO MOD LIST; World Health Organization, 2003, EIPGPEEQC20031 WHO; World Health Organization, 1996, WHO TECHN REP SER, V863, P178; *WHO NHLBI, 1995, NHLBI PUBL; 2007, ALLERGY, V62, P102; 2004, FED REG, V11, P69; 1997, EUR PHARMACOPEIA, P1063; 1993, RES GUIDELINES EVALU, P35; 2007, INFORM HLTH CARE PRO; 2007, PUBLIC HLTH ADVISORY; 1992, ALLERGY S13, V47, P1; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; Corren J, 2004, J ALLERGY CLIN IMMUN, V113, P415, DOI 10.1016/j.jaci.2003.11.034; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Corsico R, 1998, ANN ALLERG ASTHMA IM, V80, P71; Corver K, 2006, PEDIATR ALLERGY IMMU, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; Costongs GMPJ, 1997, EUR J CLIN CHEM CLIN, V35, P885; Cox L, 2007, ANN ALLERG ASTHMA IM, V98, P416; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Craig TJ, 2004, J ALLERGY CLIN IMMUN, V114, pS139, DOI 10.1016/j.jaci.2004.08.044; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633; Craig TJ, 2003, ALLERGY ASTHMA PROC, V24, P53; Crameri R, 1996, CLIN EXP ALLERGY, V26, P1411, DOI 10.1046/j.1365-2222.1996.d01-296.x; CRANSTON PS, 1983, ANN TROP MED PARASIT, V77, P527; Cranswick N, 2005, INT J CLIN PHARM TH, V43, P172; Creticos P, 1998, ALLERGY ASTHMA PROC, V19, P285, DOI 10.2500/108854198778557692; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Crighton EJ, 2001, BMC HEALTH SERV RES, V1, DOI 10.1186/1472-6963-1-7; CRIMI E, 1990, J ALLERGY CLIN IMMUN, V85, P1014, DOI 10.1016/0091-6749(90)90045-6; Crimi E, 2001, J APPL PHYSIOL, V91, P1029; Criscuoli G, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e236; CROBACH MJJS, 1994, ALLERGY, V49, P170, DOI 10.1111/j.1398-9995.1994.tb00821.x; CROCKETT AJ, 1995, J PAEDIATR CHILD H, V31, P213, DOI 10.1111/j.1440-1754.1995.tb00788.x; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Cruz AA, 2005, ALLERGY, V60, P871, DOI 10.1111/j.1398-9995.2005.00858.x; Crystal-Peters J, 2000, AM J MANAG CARE, V6, P373; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Cudowska B, 2004, Rocz Akad Med Bialymst, V49, P111; Cuel B, 1999, PSYCHOSOMATICS, V40, P491; Cuervo LG, 2003, BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; Cuesta-Herranz J, 1998, ALLERGY, V53, P78, DOI 10.1111/j.1398-9995.1998.tb03777.x; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Cullinan P, 2003, EUR RESPIR J, V22, P853, DOI 10.1183/09031936.03.00119502; Curran MP, 2004, DRUGS, V64, P523, DOI 10.2165/00003495-200464050-00008; Custovic A, 1998, ALLERGY, V53, P115; Custovic A., 2006, Clinical and Experimental Allergy Reviews, V6, P1, DOI 10.1111/j.1365-2222.2005.00093.x; Custovic A, 1998, THORAX, V53, P33; Custovic A, 2005, ALLERGY, V60, P1112, DOI 10.1111/j.1398-9995.2005.00934.x; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1046/j.1365-2222.1996.d01-278.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94; Cutler David L., 2006, Pediatric Asthma Allergy & Immunology, V19, P146, DOI 10.1089/pai.2006.19.146; Cuttitta G, 2003, PEDIATR ALLERGY IMMU, V14, P458, DOI 10.1046/j.0905-6157.2003.00067.x; Cuzzolin L, 2003, FUND CLIN PHARMACOL, V17, P125, DOI 10.1046/j.1472-8206.2003.00123.x; CVITANOVIC S, 1986, ALLERGY, V41, P543, DOI 10.1111/j.1398-9995.1986.tb00341.x; CVITANOVIC S, 1993, ALLERGY, V48, P592, DOI 10.1111/j.1398-9995.1993.tb00754.x; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; D'Urzo A, 2002, CAN FAM PHYSICIAN, V48, P1311; Dahl R, 2005, ALLERGY, V60, P875, DOI 10.1111/j.1398-9995.2005.00819.x; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R., 1995, Rhinology (Utrecht), V33, P121; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Daley-Yates PT, 2004, CLIN THER, V26, P1905, DOI 10.1016/j.clinthera.2004.11.017; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; Danielsson J, 1997, ALLERGY, V52, P331, DOI 10.1111/j.1398-9995.1997.tb00999.x; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; DAVIES BH, 1993, ALLERGY, V48, P519, DOI 10.1111/j.1398-9995.1993.tb01108.x; Davies JCA, 2001, S AFR MED J, V91, P562; Davies JM, 2005, ALLERGY, V60, P251, DOI 10.1111/j.1398-9995.2005.00663.x; Davies R. J., 1993, Rhinology (Utrecht), V31, P159; DAVIES RJ, 1998, CLIN EXP ALLERGY, V6, P8; DAX EM, 1990, ANN ALLERGY, V64, P261; Day JH, 1998, J ALLERGY CLIN IMMUN, V101, P638; Day JH, 2001, ANN ALLERG ASTHMA IM, V87, P474; De Amici M, 2003, ANN ALLERG ASTHMA IM, V91, P490; de Blic J, 2005, PEDIATR ALLERGY IMMU, V16, P267, DOI 10.1111/j.1399-3038.2005.00216.x; De Lucca GV, 2006, CURR OPIN DRUG DISC, V9, P516; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; DEBLAY F, 1993, J ALLERGY CLIN IMMUN, V92, P255, DOI 10.1016/0091-6749(93)90169-G; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; Deinhofer K, 2004, METHODS, V32, P249, DOI 10.1016/j.ymeth.2003.08.018; DELGADO J, 1994, CLIN EXP ALLERGY, V24, P477, DOI 10.1111/j.1365-2222.1994.tb00937.x; DelGaudio JM, 2002, ARCH OTOLARYNGOL, V128, P677; Demir E, 2005, ALLERGY ASTHMA PROC, V26, P410; Demoly P, 2006, REV FR ALLERGOL, V46, P626, DOI 10.1016/j.allerg.2006.07.001; Demoly P, 1997, CLIN EXP ALLERGY, V27, P672; Demoly P, 2006, ALLERGY, V61, P699, DOI 10.1111/j.1398-9995.01112.x; Demoly P, 2005, ALLERGY, V60, P1089, DOI 10.1111/j.1398-9995.2005.00843.x; Demoly P, 2003, DRUGS, V63, P1813, DOI 10.2165/00003495-200363170-00004; Demoly P, 2003, ALLERGY, V58, P672, DOI 10.1034/j.1398-9995.2003.t01-1-00202.x; Demoly P, 2002, ALLERGY, V57, P546, DOI 10.1034/j.1398-9995.2002.t01-1-13370.x; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Demoly P, 1998, CLIN EXP ALLERGY, V28, P278; Demoly P, 1998, ALLERGY PRINCIPLES P, P530; DENBURG JA, 1994, J ALLERGY CLIN IMMUN, V94, P1135, DOI 10.1016/0091-6749(94)90321-2; Dennis R, 2004, ANN ALLERG ASTHMA IM, V93, P568; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Dessing RP, 2000, PHARM WORLD SCI, V22, P10, DOI 10.1023/A:1008723226368; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; DeWester J, 2003, ALLERGY ASTHMA PROC, V24, P331; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dibildox J, 2001, J ALLERGY CLIN IMMUN, V108, pS54, DOI 10.1067/mai.2001.115567; Didier A, 2006, ALLERGY, V61, P29, DOI 10.1111/j.1398-9995.2006.01160.x; Dinmezel S, 2005, ALLERGY ASTHMA PROC, V26, P403; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Dockhorn R, 1999, ANN ALLERG ASTHMA IM, V82, P349; Dockhorn RJ, 1996, ANN ALLERG ASTHMA IM, V76, P204; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734; DOTTERUD LK, 1994, ACTA DERM-VENEREOL, V74, P124; Dotterud LK, 2000, J EUR ACAD DERMATOL, V14, P107, DOI 10.1046/j.1468-3083.2000.00027.x; Dotterud LK, 2001, ACTA DERM-VENEREOL, V81, P198; Doty RL, 2001, LARYNGOSCOPE, V111, P409, DOI 10.1097/00005537-200103000-00008; Downie SR, 2004, ALLERGY, V59, P320, DOI 10.1111/j.1398-9995.2003.00419.x; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Downs SH, 2001, MED J AUSTRALIA, V175, P10; DOYLE WJ, 1995, ANN ALLERG ASTHMA IM, V74, P171; DREBORG S, 1988, ANN ALLERGY, V61, P41; DREBORG S, 1993, ALLERGY S, V48, P14; Dreborg S, 1989, ALLERGY S10, V44, P1; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; DRUCE HM, 1992, ANN ALLERGY, V69, P53; DRUCE HM, 1990, ANN ALLERGY, V65, P212; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Duran-Tauleria E, 2004, ALLERGY, V59, P35, DOI 10.1111/j.1398-9995.2004.00566.x; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Dykewicz Mark S., 2003, Journal of Allergy and Clinical Immunology, V111, pS520; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P469, DOI 10.1016/S1081-1206(10)63153-5; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Dykewicz MS, 2003, ANN ALLERG ASTHMA IM, V91, P44; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; DYKEWICZ MS, 1991, J ALLERGY CLIN IMMUN, V87, P48, DOI 10.1016/0091-6749(91)90212-7; EATON KK, 1982, CLIN ALLERGY, V12, P107, DOI 10.1111/j.1365-2222.1982.tb03132.x; Ebbens FA, 2006, J ALLERGY CLIN IMMUN, V118, P1149, DOI 10.1016/j.jaci.2006.07.058; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ebner C, 1996, MONOGR ALLERGY, V32, P73; ECCLES R, 1981, Rhinology (Utrecht), V19, P121; ECCLES R, 2004, UPPER LOWER RESP DIS, V181, P87; Edelstein DR, 1996, LARYNGOSCOPE, V106, P1, DOI 10.1097/00005537-199609001-00001; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; Egger M, 2006, ALLERGY, V61, P461, DOI 10.1111/j.1398-9995.2006.00994.x; Eggleston PA, 2005, ANN ALLERG ASTHMA IM, V95, P518; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; Ehrlich R, 2005, AM J IND MED, V48, P153, DOI 10.1002/ajim.20188; Eigenmann PA, 2005, ALLERGY, V60, P6, DOI 10.1111/j.1398-9995.2005.00850.x; Eisner MD, 2006, AM J MED, V119, P884, DOI 10.1016/j.amjmed.2006.01.016; Eliashar Ron, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P171, DOI 10.1097/01.moo.0000162258.03997.58; Ellegard E, 1999, CLIN OTOLARYNGOL, V24, P307, DOI 10.1046/j.1365-2273.1999.00264.x; ELLEGARD E, 1994, CLIN OTOLARYNGOL, V19, P400, DOI 10.1111/j.1365-2273.1994.tb01256.x; Ellegard EK, 2001, CLIN OTOLARYNGOL, V26, P394, DOI 10.1046/j.1365-2273.2001.00491.x; ELLGARD EK, 2004, CLIN REV ALLERG IMMU, V26, P149; Ellis AK, 2006, CURR ALLERGY ASTHM R, V6, P215, DOI 10.1007/s11882-006-0037-0; Elms J, 2003, OCCUP ENVIRON MED, V60, P802, DOI 10.1136/oem.60.10.802; Emanuel IA, 2000, OTOLARYNG HEAD NECK, V123, P687, DOI 10.1067/mhn.2000.110961; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347; Emberlin JC, 2006, CURR MED RES OPIN, V22, P275, DOI 10.1185/030079906X80440; Enarson DA, 1999, PEDIATR PULM, V28, P297, DOI 10.1002/(SICI)1099-0496(199910)28:4<297::AID-PPUL9>3.0.CO;2-S; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; ENGLER DB, 1992, J ALLERGY CLIN IMMUN, V90, P985, DOI 10.1016/0091-6749(92)90472-E; ENGSTROM I, 1971, ANN ALLERGY, V29, P505; Enright PL, 1994, AM J RESP CRIT CARE, V149, pS19; Enrique E, 2002, ALLERGY, V57, P351, DOI 10.1034/j.1398-9995.2002.1s3509.x; Erdmann SM, 2005, INT ARCH ALLERGY IMM, V136, P230, DOI 10.1159/000083949; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; ERIKSSON NE, 1984, ALLERGY, V39, P610, DOI 10.1111/j.1398-9995.1984.tb01981.x; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; Esamai F, 2002, East Afr Med J, V79, P514; ESAMAI F, 1996, KENYA E AFR MED J, V73, P474; Eskandari HG, 2006, OTOLARYNG HEAD NECK, V134, P997, DOI 10.1016/j.otohns.2006.02.007; Esterhuizen TM, 2001, S AFR MED J, V91, P502; Esterhuizen TM, 2001, S AFR MED J, V91, P509; Etzel R., 1999, ENV HLTH PERSPECT, V3, P463; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4; FADEL R, 1992, ANN ALLERGY, V69, P329; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Falade AG, 2004, MED PRIN PRACT, V13, P20, DOI 10.1159/000074046; Falade AG, 1998, E AFR MED J, V75, P695; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; Fatti L M, 2001, Pituitary, V4, P259, DOI 10.1023/A:1020702631793; Fatusi A, 1996, J ROY SOC HEALTH, V116, P232, DOI 10.1177/146642409611600408; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Ferdousi HA, 2005, PEDIATR ALLERGY IMMU, V16, P478, DOI 10.1111/j.1399-3038.2005.00296.x; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FernandezRivas M, 1997, ALLERGY, V52, P196, DOI 10.1111/j.1398-9995.1997.tb00974.x; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Ferrer M, 1998, J INVEST ALLERG CLIN, V8, P17; Field S K, 2001, Minerva Gastroenterol Dietol, V47, P137; Filon FL, 2006, OCCUP ENVIRON MED, V63, P121, DOI 10.1136/oem.2003.011460; Fink RS, 2002, J CLIN ENDOCR METAB, V87, P4541, DOI 10.1210/jc.2002-020287; Finn AF, 1998, AM J RHINOL, V12, P441, DOI 10.2500/105065898780707919; Fiocchi A, 2004, ANN ALLERG ASTHMA IM, V93, P328; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P77; FIOCCHI A, 2006, ASTHMA IMMUNOLOGY AN, V97, P1; Fiocchi A, 2006, ANN ALLERG ASTHMA IM, V97, P10; Fiorina A, 2002, ALLERGY, V57, P861, DOI 10.1034/j.1398-9995.2002.23575_4.x; Fireman P, 1997, ALLERGY ASTHMA PROC, V18, P63, DOI 10.2500/108854197778605482; FIRST G, 2006, FDA CONSUM, V40, P5; Fitch KD, 2006, CLIN REV ALLERG IMMU, V31, P259, DOI 10.1385/CRIAI:31:2:259; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; FLAY BR, 1986, PREV MED, V15, P451, DOI 10.1016/0091-7435(86)90024-1; FLEMING DM, 1987, BRIT MED J, V294, P279; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; Fokkens W, 2006, ALLERGY, V61, P653, DOI 10.1111/j.1398-9995.2006.01169.x; Fokkens W, 2005, ALLERGY, V60, P583, DOI 10.1111/j.1398-9995.2005.00830.x; Fokkens W, 2005, RHINOLOGY, V43, P1; Fokkens WJ, 2007, ALLERGY, V62, P1078, DOI 10.1111/j.1398-9995.2007.01522.x; Fokkens WJ, 2004, PEDIATR ALLERGY IMMU, V15, P261, DOI 10.1111/j.1399-3038.2004.00135.x; FOKKENS WJ, 1991, IMMUNOBIOLOGY, V182, P135; Fokkens Wytske J, 2002, Curr Allergy Asthma Rep, V2, P203, DOI 10.1007/s11882-002-0020-3; Fonseca Fonseca Lisandra, 2003, P R Health Sci J, V22, P353; Forastiere F, 2005, ALLERGY, V60, P510, DOI 10.1111/j.1398-9995.2005.00736.x; FRADIS M, 1987, J LARYNGOL OTOL, V101, P666, DOI 10.1017/S002221510010249X; Franchi M, 2006, ALLERGY, V61, P864, DOI 10.1111/j.1398-9995.2006.01106.x; Francis JN, 2007, ALLERGY, V62, P59, DOI 10.1111/j.1398-9995.2006.01253.x; Frank RA, 2006, ARCH OTOLARYNGOL, V132, P532, DOI 10.1001/archotol.132.5.532; Freche C, 2002, ANN ALLERG ASTHMA IM, V89, P304; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; FREW AJ, 1993, BRIT MED J, V307, P919; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; FRISCHER TM, 1993, AM REV RESPIR DIS, V148, P961; Frosh AC, 1999, CLIN EXP ALLERGY, V29, P457; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Galant SP, 2003, PEDIATRICS, V112, P96, DOI 10.1542/peds.112.1.96; Galassi C, 2006, PEDIATRICS, V117, P34, DOI 10.1542/peds.2004-2709; Ganbo Tetsuya, 1995, Auris Nasus Larynx, V22, P158; GANE P, 1995, CYTOMETRY, V19, P361, DOI 10.1002/cyto.990190411; Gannon PFG, 2005, OCCUP MED-OXFORD, V55, P600, DOI 10.1093/occmed/kqi184; Garavello W, 2005, INT ARCH ALLERGY IMM, V137, P310, DOI 10.1159/000086462; GARCIA DP, 1994, ANN ALLERGY, V72, P203; GARCIA M, 2006, ANN AGR ENV MED, V13, P209; Garcia Ortiz J. C., 1995, Allergy (Copenhagen), V50, P269, DOI 10.1111/j.1398-9995.1995.tb01145.x; Garcia-Marcosa L, 2005, INT ARCH ALLERGY IMM, V137, P303, DOI 10.1159/000086461; Gargano D, 2002, ALLERGY, V57, P1044, DOI 10.1034/j.1398-9995.2002.23745.x; Gaugris S, 2006, J ASTHMA, V43, P1, DOI 10.1080/027700500446823; Gautrin D, 2006, CURR OPIN ALLERGY CL, V6, P77; Gautrin D, 2002, ALLERGY, V57, P913, DOI 10.1034/j.1398-9995.2002.23636.x; Gawchik S, 2003, ANN ALLERG ASTHMA IM, V90, P416; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gelfand Erwin W, 2005, Ear Nose Throat J, V84, P163; Gendo K, 2004, ANN INTERN MED, V140, P278; Gentile D, 2003, PEDIAT ALLERGY PRINC, P287; Georgalas C, 2005, ANN OTO RHINOL LARYN, V114, P638; Georgy V, 2006, EUR RESPIR J, V28, P756, DOI 10.1183/09031936.06.00089005; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gerth van Wijk R, 1991, Clin Otolaryngol Allied Sci, V16, P133; Gerth van Wijk R, 1991, Clin Exp Allergy, V21, P661; Ghunaim N, 2006, CLIN EXP ALLERGY, V36, P722, DOI 10.1111/j.1365-2222.2006.02489.x; Giavina-Bianchi PF, 1997, ANN ALLERG ASTHMA IM, V79, P449; Gibson PG, 2004, THORAX, V59, P449; Giede-Tuch C, 1998, ALLERGY, V53, P857, DOI 10.1111/j.1398-9995.1998.tb03991.x; GILLAM SJ, 1989, BRIT MED J, V299, P953; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; GIOVANNINI M, 2007, PEDIAT RES; GIRGIS I H, 1974, Journal of Laryngology and Otology, V88, P1163, DOI 10.1017/S0022215100079895; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Gleeson M, 1996, CLIN EXP ALLERGY, V26, P697, DOI 10.1111/j.1365-2222.1996.tb00596.x; GLEICH GJ, 1980, NEW ENGL J MED, V302, P617, DOI 10.1056/NEJM198003133021107; Gluck U, 2000, ORL J OTO-RHINO-LARY, V62, P68, DOI 10.1159/000027720; Goh DYT, 1996, ARCH DIS CHILD, V74, P131; Gold MS, 2005, MED J AUSTRALIA, V182, P298; Goldberg A, 1998, J ALLERGY CLIN IMMUN, V102, P210, DOI 10.1016/S0091-6749(98)70088-0; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Goodman W S, 1973, Otolaryngol Clin North Am, V6, P773; Gordon S, 1997, CLIN EXP ALLERGY, V27, P479, DOI 10.1046/j.1365-2222.1997.d01-537.x; Gordts F, 1996, ORL J OTO-RHINO-LARY, V58, P315; Gosepath J, 2005, LARYNGOSCOPE, V115, P512, DOI 10.1097/01.MLG.0000149682.56426.6B; Gosepath J, 1999, AM J RHINOL, V13, P385, DOI 10.2500/105065899781367456; Gotoh M, 2005, RHINOLOGY, V43, P266; Gotzsche PC, 2004, COCHRANE DB SYST REV, V18; GOUBRAN B. H., 1996, IMMUNOLOGY, V88, P340; Graf P, 1997, ALLERGY, V52, P28; Graf P, 1996, LARYNGOSCOPE, V106, P605, DOI 10.1097/00005537-199605000-00016; GRAF P, 1995, ACTA OTO-LARYNGOL, V115, P71, DOI 10.3109/00016489509133350; Graf Peter, 2005, Treat Respir Med, V4, P21, DOI 10.2165/00151829-200504010-00003; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; Graham C, 1997, REGUL TOXICOL PHARM, V26, P296, DOI 10.1006/rtph.1997.1170; GRAHAM DE, 1990, AM REV RESPIR DIS, V142, P152; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; Graudenz GS, 2006, J ALLERGY CLIN IMMUN, V118, P1126, DOI 10.1016/j.jaci.2006.07.005; Gray RD, 2004, ANN ALLERG ASTHMA IM, V93, P56; Gregoire C, 1996, J BIOL CHEM, V271, P32951; Greiff L, 1998, EUR RESPIR J, V11, P1268, DOI 10.1183/09031936.98.11061268; Greiner AN, 2006, MED CLIN N AM, V90, P17, DOI 10.1016/j.mcna.2005.08.011; Greisner WA, 1996, ALLERGY ASTHMA PROC, V17, P283, DOI 10.2500/108854196778662192; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; Grimfeld A, 2004, CLIN EXP ALLERGY, V34, P1665, DOI 10.1111/j.1365-2222.2004.02098.x; Grize L, 2006, ALLERGY, V61, P556, DOI 10.1111/j.1398-9995.2006.01030.x; Groenewoud GCM, 2002, ALLERGY, V57, P614, DOI 10.1034/j.1398-9995.2002.203511.x; Groneberg David A, 2006, J Occup Med Toxicol, V1, P3, DOI 10.1186/1745-6673-1-3; Gross G, 2002, ANN ALLERG ASTHMA IM, V89, P56; GROSSMAN J, 1993, PEDIATRICS, V92, P594; GROSSMAN J, 1989, ANN ALLERGY, V63, P317; Gruber C, 2002, PEDIATR ALLERGY IMMU, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Gryczynska D, 1999, INT J PEDIATR OTORHI, V49, pS275; Guadano EM, 2004, ALLERGY, V59, P766, DOI 10.1111/j.1398-9995.2004.00576.x; Guerin B, 1996, INT ARCH ALLERGY IMM, V110, P91; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Guerra S, 2005, ALLERGY, V60, P343, DOI 10.1111/j.1398-9995.2005.00717.x; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Gulbahar O, 2003, ANN ALLERG ASTHMA IM, V90, P635; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; GUTKOWSKI A, 1988, J ALLERGY CLIN IMMUN, V81, P902, DOI 10.1016/0091-6749(88)90948-7; Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174; GUYATT G, EMERGING CONSENSUS G; Haagerup A, 2001, EUR J HUM GENET, V9, P945, DOI 10.1038/sj.ejhg.5200753; HAAHTELA T, 1980, ALLERGY, V35, P15, DOI 10.1111/j.1398-9995.1980.tb01712.x; HAAHTELA TMK, 1979, CLIN ALLERGY, V9, P53, DOI 10.1111/j.1365-2222.1979.tb01522.x; Habbick BF, 1999, CAN MED ASSOC J, V160, P1824; Hadley JA, 1997, OTOLARYNG HEAD NECK, V117, pS8, DOI 10.1016/S0194-5998(97)70002-0; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; Hahn EL, 2005, IMMUNOL ALLERGY CLIN, V25, P231, DOI 10.1016/j.iac.2005.02.004; Hahn E. L., 2005, IMMUNOL ALLERGY CLIN, V25, pv; Hailu S, 2003, PEDIATR PULM, V35, P427, DOI 10.1002/ppul.10215; Hajat S, 2001, AM J EPIDEMIOL, V153, P704, DOI 10.1093/aje/153.7.704; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; Hallen H, 2001, ORL J OTO-RHINO-LARY, V63, P92, DOI 10.1159/000055717; Hallstrand TS, 2003, PEDIATR PULM, V36, P536, DOI 10.1002/ppul.10395; Halpern MT, 2004, J ASTHMA, V41, P117, DOI 10.1081/JAS-120026069; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Hanes LS, 2006, CLIN EXP ALLERGY, V36, P26, DOI 10.1111/j.1365-2222.2006.02364.x; Hanf G, 2004, EUR RESPIR J, V23, P414, DOI 10.1183/09031936.04.00024504; Hannaford PC, 2005, FAM PRACT, V22, P227, DOI 10.1093/fampra/cmi004; Hansel F, 1929, J ALLERGY, V1, P43, DOI 10.1016/S0021-8707(29)90083-6; Hansen JG, 2004, J CLIN EPIDEMIOL, V57, P864, DOI 10.1016/j.jclinepi.2004.01.009; Hara J, 2006, INT ARCH ALLERGY IMM, V140, P327, DOI 10.1159/000093711; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; HARF R, 1992, Allergie et Immunologie (Paris), V24, P95; Harvey RP, 1996, J ALLERGY CLIN IMMUN, V97, P1233, DOI 10.1016/S0091-6749(96)70190-2; Harwanegg C, 2005, CLIN CHEM LAB MED, V43, P1321, DOI 10.1515/CCLM.2005.226; HASEGAWA M, 1982, ANN OTO RHINOL LARYN, V91, P112; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hayden M L, 2001, J Am Acad Nurse Pract, V13, P545; Hayden ML, 2001, J AM ACAD NURSE PRAC, V13, P52; Hebert JR, 1996, ALLERGY, V51, P569; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Heine RG, 2006, PEDIATR ALLERGY IMMU, V17, P213, DOI 10.1111/j.1399-3038.2005.00368.x; Heinemann C, 2002, ALLERGY, V57, P641, DOI 10.1034/j.1398-9995.2002.23438.x; Heinrich J, 1998, EUR J EPIDEMIOL, V14, P239, DOI 10.1023/A:1007465205976; Heinrich J, 1999, Eur J Med Res, V4, P107; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; Helenius I, 2005, SPORTS MED, V35, P565, DOI 10.2165/00007256-200535070-00002; Helenius I, 2004, ALLERGY, V59, P39, DOI 10.1046/j.1398-9995.2003.00353.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Hellgren J, 2002, AM J IND MED, V42, P23, DOI 10.1002/ajim.10083; Hellgren J, 2002, CLIN EXP ALLERGY, V32, P64, DOI 10.1046/j.0022-0477.2001.01253.x; Hellings P, 2000, Acta Otorhinolaryngol Belg, V54, P237; Hellings PW, 2006, ALLERGY, V61, P656, DOI 10.1111/j.1398-9995.2006.01109.x; Henneberger PK, 2006, OCCUP ENVIRON MED, V63, P551, DOI 10.1136/oem.2005.024786; HENRIKSEN S. D., 1959, ACTA PATHOL ET MICROBIOL SCAND, V47, P380; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; Herman D, 1997, INT J PEDIATR OTORHI, V39, P1, DOI 10.1016/S0165-5876(96)01457-7; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hill SL, 2003, OTOLARYNG HEAD NECK, V129, P199, DOI 10.1016/S0194-5998(03)00607-7; Hiller KM, 1997, J ALLERGY CLIN IMMUN, V100, P335, DOI 10.1016/S0091-6749(97)70246-X; Hindmarch I, 2001, CURR MED RES OPIN, V17, P273; HIRSCH SR, 1982, J ALLERGY CLIN IMMUN, V70, P183, DOI 10.1016/0091-6749(82)90040-9; HIRSCH SR, 1981, J ALLERGY CLIN IMMUN, V68, P133, DOI 10.1016/0091-6749(81)90172-X; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Hnizdo E, 2000, OCCUP ENVIRON MED, V57, P698, DOI 10.1136/oem.57.10.698; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; Hoekstra MO, 2005, J ALLERGY CLIN IMMUN, V115, P1324, DOI 10.1016/j.jaci.2005.03.012; Hoffmann A, 1999, ALLERGY, V54, P446, DOI 10.1034/j.1398-9995.1999.00917.x; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; HOGMAN M, 1993, EUR RESPIR J, V6, P177; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 1999, NATURE, V402, pB2; Holgate ST, 2003, CLIN EXP ALLERGY, V33, P1305, DOI 10.1046/j.1365-2222.2003.01769.x; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; HOLGATE ST, 1988, CLIN ALLERGY, V18, P549, DOI 10.1111/j.1365-2222.1988.tb02906.x; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Hollins PD, 2004, INT J BIOMETEOROL, V48, P137, DOI 10.1007/s00484-003-0188-9; Holm AF, 1998, CLIN OTOLARYNGOL, V23, P69; HORAK F, 1985, ARCH OTO-RHINO-LARYN, V242, P239, DOI 10.1007/BF00453546; Horak F, 1998, ALLERGY, V53, P68, DOI 10.1111/j.1398-9995.1998.tb03775.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; HORNBLOW AR, 1976, AUST NZ J PSYCHIAT, V10, P339, DOI 10.3109/00048677609159523; Horner WE, 1998, ALLERGY, V53, P1114, DOI 10.1111/j.1398-9995.1998.tb03830.x; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Host Arne, 2003, Paediatr Respir Rev, V4, P312, DOI 10.1016/S1526-0542(03)00094-0; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Houser SM, 2002, OTOLARYNG HEAD NECK, V126, P475, DOI 10.1067/mhn.2002.124848; HOUSTON D, 1982, AM REV RESPIR DIS, V125, P484; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; Huang SL, 2001, CLIN EXP ALLERGY, V31, P259, DOI 10.1046/j.1365-2222.2001.00938.x; Huang SW, 2001, ANN ALLERG ASTHMA IM, V87, P350; HUGGINS KG, 1975, LANCET, V2, P148; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Humbert M, 2007, ALLERGY, V62, P95, DOI 10.1111/j.1398-9995.2006.01308.x; HUMMEL T, 2006, EUR ARCH OTORHINOLAR; Hurst DS, 2000, ALLERGY, V55, P435, DOI 10.1034/j.1398-9995.2000.00289.x; Hurst M, 2000, DRUGS, V59, P981, DOI 10.2165/00003495-200059040-00018; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Huurre TM, 2004, J ASTHMA, V41, P311, DOI 10.1081/JAS-120026088; Hwang BF, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-23; Hytonen M, 1997, ACTA OTO-LARYNGOL, P133; Hytonen M, 1997, INT ARCH OCC ENV HEA, V69, P487, DOI 10.1007/s004200050178; Hytonen Maija, 1996, Rhinology (Utrecht), V34, P86; Iacovacci P, 1998, J ALLERGY CLIN IMMUN, V101, P755, DOI 10.1016/S0091-6749(98)70304-5; Ichimura Keiichi, 1996, Auris Nasus Larynx, V23, P48; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; Ige O M, 2000, Afr J Med Med Sci, V29, P101; IIKURA Y, 1992, ANN ALLERGY, V68, P233; Ijadunola KT, 2004, AM J IND MED, V45, P251, DOI 10.1002/ajim.10344; ILIOPOULOS O, 1988, AM REV RESPIR DIS, V138, P400; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; IMBUS HR, 1985, J ALLERGY CLIN IMMUN, V76, P831, DOI 10.1016/0091-6749(85)90757-2; Inal A, 2007, J INVEST ALLERG CLIN, V17, P85; INCAUDO G, 1991, NASAL MANIFESTATIONS; Inouye T, 1999, Ann Otol Rhinol Laryngol Suppl, V180, P3; Ipsen H, 1997, CLIN REV ALLERG IMMU, V15, P389, DOI 10.1007/BF02737734; IRANDER K, 1993, INT J PEDIATR OTORHI, V26, P1, DOI 10.1016/0165-5876(93)90191-5; Irwin RS, 2000, NEW ENGL J MED, V343, P1715, DOI 10.1056/NEJM200012073432308; Irwin RS, 1999, HOSP PRACT, V34, P53; IRWIN RS, 1999, HOSP PRACT, V34, P129; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Isolauri E, 1998, J PEDIATR-US, V132, P1004, DOI 10.1016/S0022-3476(98)70399-3; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; JAAKKOLA JJ, 1993, J EXPO ANAL ENV EPID, V1, P129; Jackson-Menaldi CA, 1999, J VOICE, V13, P113, DOI 10.1016/S0892-1997(99)80065-4; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; Jahn-Schmid B, 2003, CLIN EXP ALLERGY, V33, P1443, DOI 10.1046/j.1365-2222.2003.01784.x; James IGV, 2003, CURR MED RES OPIN, V19, P313, DOI 10.1185/030079903125001785; Janahi IA, 2006, PEDIATR PULM, V41, P80, DOI 10.1002/ppul.20331; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; JANSSENS MM, 1991, CLIN EXP ALLERGY, V2, P29; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jarvis D, 1999, THORAX, V54, P1054; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Jeal W, 1997, DRUGS, V53, P257, DOI 10.2165/00003495-199753020-00006; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; Jeong KY, 2004, CLIN DIAGN LAB IMMUN, V11, P320, DOI 10.1128/CDLI.11.2.320-324.2004; Jessen M, 1997, ALLERGY, V52, P3; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297; Jinot Jennifer, 1996, Reviews on Environmental Health, V11, P89; Johannssen V., 1997, Rhinology (Utrecht), V35, P161; JOHANSSO.SG, 1967, LANCET, V2, P951; Johansson A, 2000, RESP MED, V94, P1119, DOI 10.1053/rmed.2000.0924; JOHANSSON SG, 1973, INT ARCH ALLER A IMM, V45, P55; Johnsen CR, 1997, OCCUP ENVIRON MED, V54, P671; Johnson DA, 1993, PHARMACOTHERAPY, V13, P110; JOHNSON DA, 1993, PHARMACOTHERAPY, V13, pS43; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; JOHNSTONE DE, 1981, ANN ALLERGY, V46, P1; Joki-Erkkila VP, 2003, ANN ALLERG ASTHMA IM, V91, P275; Jones MG, 2006, J ALLERGY CLIN IMMUN, V117, P663, DOI 10.1016/j.jaci.2005.09.053; Jones NS, 1999, J LARYNGOL OTOL, V113, P1; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019; Jones NS, 1998, CLIN OTOLARYNGOL, V23, P547, DOI 10.1046/j.1365-2273.1998.2360547.x; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Juhn YJ, 2005, J ALLERGY CLIN IMMUN, V116, P510, DOI 10.1016/j.jaci.2005.05.043; JULIUSSON S, 1988, CLIN ALLERGY, V18, P615, DOI 10.1111/j.1365-2222.1988.tb02913.x; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; Juniper EF, 1999, J ALLERGY CLIN IMMUN, V104, P364, DOI 10.1016/S0091-6749(99)70380-5; JUNIPER EF, 1992, CAN MED ASSOC J, V147, P887; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kabesch M, 2007, ALLERGY, V62, P423, DOI 10.1111/j.1398-9995.2006.01300.x; Kabir M L, 2005, Mymensingh Med J, V14, P41; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P423; KAISER HB, 2007, J ALLERGY CLIN IMMUN; Kaiser R, 1998, AM J EPIDEMIOL, V148, P600; Kaliner M, 2003, ALLERGY ASTHMA PROC, V24, P163; Kaliner MA, 2004, CURR ALLERGY ASTHM R, V4, P237, DOI 10.1007/s11882-004-0032-2; Kaliner MA, 2001, ALLERGY ASTHMA PROC, V22, pS11; Kaliner MA, 2001, ALLERGY ASTHMA PROC, V22, pS17; Kaliner Michael A, 2002, Clin Allergy Immunol, V17, P465; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; Kalyoncu A F, 2001, Allergol Immunopathol (Madr), V29, P264; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261; KAM KL, 1994, ANN ALLERGY, V73, P329; Kanani AS, 2005, ANN ALLERG ASTHMA IM, V94, P341; KANERVA L, 1993, INT ARCH OCC ENV HEA, V64, P565, DOI 10.1007/BF00517702; KANERVA L, 1995, ALLERGY, V50, P174; KANFER I, 1993, PHARMACOTHERAPY, V13, pS116; KANFER I, 1993, PHARMACOTHERAPY, V13, pS43; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; KARLSSON G, 1994, ACTA OTO-LARYNGOL, P26; KARLSSON G, 1989, ORL J OTO-RHINO-LARY, V51, P171; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2003, PEDIATR ALLERGY IMMU, V14, P470, DOI 10.1046/j.0905-6157.2003.00089.x; Kaszuba SM, 2001, ARCH INTERN MED, V161, P2581, DOI 10.1001/archinte.161.21.2581; Katelaris CH, 2000, J ALLERGY CLIN IMMUN, V106, P260; Katelaris CH, 2002, CLIN THER, V24, P1561, DOI 10.1016/S0149-2918(02)80060-1; Katelaris CH, 2002, CLIN J SPORT MED, V12, P296, DOI 10.1097/01.JSM.0000022765.86942.85; KATOTOMICHELAKI. M, 2007, LARYNGOSCOPE, V117, P114; Kattan M, 2005, J ALLERGY CLIN IMMUN, V116, P1058, DOI 10.1016/j.jaci.2005.07.032; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; KATZ RM, 1984, J ALLERGY CLIN IMMUN, V73, P708, DOI 10.1016/0091-6749(84)90311-7; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; KAUFMAN HS, 1990, ANN ALLERGY, V64, P293; KAUFMAN HS, 1986, ARCH OPHTHALMOL-CHIC, V104, P967; Kay AB, 1999, ALLERGY, V54, P29, DOI 10.1111/j.1398-9995.1999.tb04434.x; KAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P345, DOI 10.1016/0091-6749(83)90090-8; Kay AB, 2001, NEW ENGL J MED, V344, P109; Kay DJ, 2003, OTOLARYNG HEAD NECK, V128, P17, DOI 10.1067/mhn.2003.41; Kearns GL, 2003, NEW ENGL J MED, V349, P1157; Keil T, 2006, ALLERGY, V61, P1104, DOI 10.1111/j.1398-9995.2006.01167.x; Keil T, 2006, ALLERGY, V61, P221, DOI 10.1111/j.1398-9995.2006.00989.x; Keil U, 1996, TOXICOL LETT, V86, P99, DOI 10.1016/0378-4274(96)03680-6; Keles N, 1999, AM J RHINOL, V13, P185, DOI 10.2500/105065899781389731; KELSO JM, 1991, ANN ALLERGY, V67, P511; KEMP AS, 1979, MED J AUSTRALIA, V1, P263; KEMP J, 1987, AM J RHINOL, V3, P151; Kerkhof M, 1999, EUR RESPIR J, V14, P839, DOI 10.1034/j.1399-3003.1999.14d20.x; Kerkhof M, 2000, CLIN EXP ALLERGY, V30, P1387, DOI 10.1046/j.1365-2222.2000.00907.x; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; KERREBIJN JDF, 1992, EUR RESPIR J, V5, P1239; Kessler RC, 2001, ANN ALLERG ASTHMA IM, V87, P289; Khan DA, 2000, J ALLERGY CLIN IMMUN, V106, P1096, DOI 10.1067/mai.2000.110929; Kharitonov SA, 2005, RESP MED, V99, P1105, DOI 10.1016/j.rmed.2005.02.019; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Kilpelainen M, 2001, RESP MED, V95, P911, DOI 10.1053/rmed.2001.1175; Kilpelainen M, 2006, RESP MED, V100, P1518, DOI 10.1016/j.rmed.2006.01.011; Kim JJ, 2004, ANN OTO RHINOL LARYN, V113, P297; Kim K, 2006, ANN ALLERG ASTHMA IM, V96, P460; Kim KT, 2004, ANN ALLERG ASTHMA IM, V93, P61; Kim LS, 2005, ANN PHARMACOTHER, V39, P617, DOI 10.1345/aph.1E387; Kim SH, 2002, CLIN EXP ALLERGY, V32, P1054, DOI 10.1046/j.1365-2222.2002.01431.x; Kim YK, 1999, CLIN EXP ALLERGY, V29, P1102, DOI 10.1046/j.1365-2222.1999.00607.x; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P1285; King C, 1998, J IMMUNOL, V161, P3645; King MJ, 2003, DRUG AGING, V20, P1011, DOI 10.2165/00002512-200320140-00001; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; Kirchhoff CH, 2003, RHINOLOGY, V41, P159; KIRKPATRICK MB, 1982, AM REV RESPIR DIS, V125, P627; Kirmaz C, 2005, ANN ALLERG ASTHMA IM, V95, P525; Kirmaz C, 2005, J INVEST ALLERG CLIN, V15, P140; Kivity S, 2001, PEDIATR PULM, V32, P217, DOI 10.1002/ppul.1111; Kjellman N I, 1994, Pediatr Allergy Immunol, V5, P13, DOI 10.1111/j.1399-3038.1994.tb00342.x; Kleine-Tebbe J, 2002, J ALLERGY CLIN IMMUN, V110, P797, DOI 10.1067/mai.2002.12946; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; KLUNKER S, 2007, J ALLERGY CLIN IMMUN; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KNUTSON JW, 1995, DRUG AGING, V7, P310; Kocabas CN, 2005, PEDIATR PULM, V40, P235, DOI 10.1002/ppul.20247; KOENIG JQ, 1985, J ALLERGY CLIN IMMUN, V76, P813, DOI 10.1016/0091-6749(85)90754-7; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P1055, DOI 10.1016/0091-6749(88)90180-7; KOH YY, 1994, CLIN EXP ALLERGY, V24, P337, DOI 10.1111/j.1365-2222.1994.tb00244.x; KOIVIKKO A, 1988, ALLERGY, V43, P192; Kompauer I, 2006, PUBLIC HEALTH NUTR, V9, P472, DOI 10.1079/PHN2005868; Kondo Y, 2002, CLIN EXP ALLERGY, V32, P590, DOI 10.1046/j.0954-7894.2002.01337.x; Kongerud J, 2006, INHAL TOXICOL, V18, P589, DOI 10.1080/08958370600743027; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; KopferschmitKubler MC, 1996, REV MAL RESPIR, V13, P305; Kopp MV, 1999, EUR RESPIR J, V14, P854, DOI 10.1034/j.1399-3003.1999.14d22.x; Koreck AI, 2005, J ALLERGY CLIN IMMUN, V115, P541, DOI 10.1016/j.jaci.2004.11.005; KORSGAARD J, 1991, ALLERGY, V46, P14, DOI 10.1111/j.1398-9995.1991.tb00643.x; Kosrirukvongs P, 2003, ASIAN PAC J ALLERGY, V21, P25; Kosrirukvongs P, 2001, ASIAN PAC J ALLERGY, V19, P237; Kowalski Marek L, 2006, Treat Respir Med, V5, P399, DOI 10.2165/00151829-200605060-00005; Kowalski ML, 2005, ALLERGY, V60, P1139, DOI 10.1111/j.1398-9995.2005.00836.x; Kowalski ML, 2005, ALLERGY, V60, P80, DOI 10.1111/j.1398-9995.2005.00642.x; Kowalski ML, 2000, THORAX, V55, pS84, DOI 10.1136/thorax.55.suppl_2.S84; Krakowiak A, 1999, EUR RESPIR J, V14, P352, DOI 10.1034/j.1399-3003.1999.14b19.x; Kramer MF, 2001, ACTA OTO-LARYNGOL, V121, P494, DOI 10.1080/000164801300366651; Kramer MS, 2004, ADV EXP MED BIOL, V554, P63; Kramer MS, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000133.PUB2; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Kremer B, 2002, CLIN EXP ALLERGY, V32, P1310, DOI 10.1046/j.1365-2745.2002.01483.x; Kremer Bernd, 2004, Curr Opin Allergy Clin Immunol, V4, P171, DOI 10.1097/00130832-200406000-00006; Kronqvist M, 2000, CLIN EXP ALLERGY, V30, P670, DOI 10.1046/j.1365-2222.2000.00822.x; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Kuehni CE, 2006, INT J EPIDEMIOL, V35, P779, DOI 10.1093/ije/dyl022; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2005, J ALLERGY CLIN IMMUN, V116, P657, DOI 10.1016/j.jaci.2005.04.028; Kung YY, 2006, ALLERGY, V61, P1316, DOI 10.1111/j.1398-9995.2006.01152.x; KURNIAWAN A, 1993, J IMMUNOL, V150, P3941; Kurowski M, 2004, ALLERGY, V59, P280, DOI 10.1046/j.1398-9995.2003.00416.x; Kurtz KM, 2001, ALLERGY, V56, P857, DOI 10.1034/j.1398-9995.2001.00075.x; Kurtz KM, 2001, J ALLERGY CLIN IMMUN, V107, P178, DOI 10.1067/mai.2001.112125; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Kurz T, 2005, ALLERGY, V60, P192, DOI 10.1111/j.1398-9995.2005.00646.x; Kushida CA, 1997, ALLERGY ASTHMA PROC, V18, P69, DOI 10.2500/108854197778605509; Kusunoki T, 2000, ANN ALLERG ASTHMA IM, V84, P366, DOI 10.1016/S1081-1206(10)62788-3; Kuyucu S, 2006, PEDIATR ALLERGY IMMU, V17, P269, DOI 10.1111/j.1399-3038.2006.00407.x; Laaidi M, 2003, ANN ALLERG ASTHMA IM, V91, P195; Lack G, 2001, J ALLERGY CLIN IMMUN, V108, pS9, DOI 10.1067/mai.2001.115562; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P88, DOI 10.1016/0091-6749(94)90075-2; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Laffer S, 1996, MOL IMMUNOL, V33, P417, DOI 10.1016/0161-5890(95)00152-2; LaForce C, 1996, ANN ALLERG ASTHMA IM, V76, P181; LaForce CF, 2004, ANN ALLERG ASTHMA IM, V93, P154; Laforest L, 2005, INT ARCH ALLERGY IMM, V136, P281, DOI 10.1159/000083955; Lai DS, 2002, ANN ALLERG ASTHMA IM, V89, P589; Laliberte F, 2000, ALLERGY, V55, P718, DOI 10.1034/j.1398-9995.2000.00649.x; Lamb CE, 2006, CURR MED RES OPIN, V22, P1203, DOI 10.1185/030079906X112552; Lambiase A, 2003, ARCH OPHTHALMOL-CHIC, V121, P615, DOI 10.1001/archopht.121.5.615; LaMontagne AD, 2006, OCCUP ENVIRON MED, V63, P359, DOI 10.1136/oem.2005.025221; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; Lane AP, 2001, OTOLARYNG HEAD NECK, V124, P9, DOI 10.1067/mhn.2001.111602; Lange B, 2005, ANN ALLERG ASTHMA IM, V95, P272; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Larese F, 1998, AM J IND MED, V34, P623, DOI 10.1002/(SICI)1097-0274(199812)34:6<623::AID-AJIM11>3.0.CO;2-R; LAST J, 1995, DICT EPIDEMIOLOGY, P135; Latvala J, 2005, BRIT MED J, V330, P1186, DOI 10.1136/bmj.38448.603921.AF; Latza U, 2005, AM J IND MED, V48, P144, DOI 10.1002/ajim.20186; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Lau YL, 1998, J PAEDIATR CHILD H, V34, P47, DOI 10.1046/j.1440-1754.1998.00217.x; LAURENT J, 1993, CLIN EXP ALLERGY, V23, P39, DOI 10.1111/j.1365-2222.1993.tb02482.x; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; Lazaar AL, 2006, CLIN CHEST MED, V27, P53, DOI 10.1016/j.ccm.2005.10.003; Lazo-Saenz JG, 2005, OTOLARYNG HEAD NECK, V132, P626, DOI 10.1016/j.otohns.2005.01.029; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; Lebowitz MD, 1996, EUR RESPIR J, V9, P1029, DOI 10.1183/09031936.96.09051029; Lee HM, 2006, INT J PEDIATR OTORHI, V70, P1085, DOI 10.1016/j.ijporl.2005.11.006; Lee MH, 2001, ANN ALLERG ASTHMA IM, V86, P691; Lee SL, 2004, PEDIATR ALLERGY IMMU, V15, P72, DOI 10.1046/j.0905-6157.2003.00109.x; Lee YL, 2003, EUR RESPIR J, V21, P964, DOI 10.1183/09031936.03.00094602; Leger D, 2006, ARCH INTERN MED, V166, P1744, DOI 10.1001/archinte.166.16.1744; LEHRER SB, 1980, AM REV RESPIR DIS, V121, P168; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; Leino T, 1998, SCAND J WORK ENV HEA, V24, P398; Leipzig JR, 1996, J ALLERGY CLIN IMMUN, V98, P1130, DOI 10.1016/S0091-6749(96)80206-5; Lenfant C, 2004, UPPER LOW RESP DIS L, V181, piii; Leone C, 1997, J ALLERGY CLIN IMMUN, V100, P775, DOI 10.1016/S0091-6749(97)70273-2; Leong KP, 2005, CLIN EXP ALLERGY, V35, P288, DOI 10.1111/j.1365-2222.2005.02201.x; Leong KP, 1999, ASIAN PAC J ALLERGY, V17, P163; Leroyer C, 1999, OCCUP ENVIRON MED, V56, P334; Leuenberger P., 1994, American Journal of Respiratory and Critical Care Medicine, V150, P1221; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; LEUSCHNER RM, 1993, EXPERIENTIA, V49, P931, DOI 10.1007/BF02125639; Levesque Benoit, 2004, Can Respir J, V11, P343; Levetin E, 2001, Curr Allergy Asthma Rep, V1, P506, DOI 10.1007/s11882-001-0059-6; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/rccm.2103044; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615; LEWIS WH, 1975, ANN ALLERGY, V35, P113; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Leynaert B., 2000, J ALLERGY CLIN IMMUN, V106, P201; Leynaert Benedicte, 2004, Journal of Allergy and Clinical Immunology, V113, P86, DOI 10.1016/j.jaci.2003.10.010; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; Li JT, 2005, J ALLERGY CLIN IMMUN, V116, pS3, DOI 10.1016/j.jaci.2005.08.017; Liccardi G, 1996, INT ARCH ALLERGY IMM, V111, P210; Lildholdt T, 1997, ARCH OTOLARYNGOL, V123, P595; Lilja G, 1996, CLIN EXP ALLERGY, V26, P1073; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Linblad J, 1961, J ALLERGY, V32, P392; LINDBERG S, 1993, ALLERGY, V48, P602, DOI 10.1111/j.1398-9995.1993.tb00756.x; Linde K, 2001, INT J EPIDEMIOL, V30, P526, DOI 10.1093/ije/30.3.526; LINDE K, 2001, HOMEOPATHY BMC COMPL, V3, P1; LINDE K, 2001, ACUPUNCTURE BMC COMP, V1, P1; LINDER A, 1988, CLIN ALLERGY, V18, P29, DOI 10.1111/j.1365-2222.1988.tb02840.x; Linders JBHJ, 2001, NATO SCI S SS IV EAR, V2, P1; LINDGREN L, 1995, ACTA DERM-VENEREOL, V75, P300; Linn WS, 1996, J EXPO ANAL ENV EPID, V6, P449; LINNA O, 1992, ACTA PAEDIATR, V81, P100, DOI 10.1111/j.1651-2227.1992.tb12182.x; Linneberg A, 1999, ALLERGY, V54, P1194, DOI 10.1034/j.1398-9995.1999.00180.x; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Linneberg A, 2001, RESP MED, V95, P258, DOI 10.1053/rmed.2001.1031; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Litvyakova LI, 2001, ANN ALLERG ASTHMA IM, V86, P355; Litvyakova L. I., 2001, ANN ALLERG ASTHMA IM, V86, P64; Litvyakova L. I., 2001, ANN ALLERG ASTHMA IM, V86, P86; LLOYD GAS, 1991, J LARYNGOL OTOL, V105, P181, DOI 10.1017/S0022215100115300; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2006, J ALLERGY CLIN IMMUN, V118, P1017, DOI 10.1016/j.jaci.2006.06.018; Lodrup Carlsen K C, 1997, Eur Respir J, V10, P1774, DOI 10.1183/09031936.97.10081774; Loewenson R, 1999, EPIDEMIOLOGY, V10, P632, DOI 10.1097/00001648-199909000-00033; Lombardero M, 2004, CLIN EXP ALLERGY, V34, P1415, DOI 10.1111/j.1365-2222.2004.02053.x; Lopata AL, 2005, ALLERGY, V60, P200, DOI 10.1111/j.1398-9995.2005.00661.x; Lopuhaa CE, 2002, CLIN EXP ALLERGY, V32, P1720, DOI 10.1046/j.1365-2222.2002.01542.x; Lovborg U, 1998, INT ARCH ALLERGY IMM, V117, P220, DOI 10.1159/000024014; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361; LUGO G, 1994, INT ARCH OCC ENV HEA, V65, P291, DOI 10.1007/BF00405691; Lund VJ, 1997, ENT J S, V76, P1; Lund Valerie J., 1993, Rhinology (Utrecht), V31, P183; Lund VJ, 2006, RHINOLOGY, V44, P26; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Lundberg JON, 1995, ACTA PHYSIOL SCAND, V155, P467, DOI 10.1111/j.1748-1716.1995.tb09998.x; Lundberg JON, 1996, EUR RESPIR J, V9, P2671, DOI 10.1183/09031936.96.09122671; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; Luong A, 2004, CURR ALLERGY ASTHM R, V4, P465, DOI 10.1007/s11882-004-0013-5; LUTSKY I, 1984, J ALLERGY CLIN IMMUN, V73, P56, DOI 10.1016/0091-6749(84)90484-6; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; LYNCH NR, 1994, INT ARCH ALLERGY IMM, V105, P70; MABRY RL, 1986, SOUTHERN MED J, V79, P965, DOI 10.1097/00007611-198608000-00012; MacIntyre UE, 2001, S AFR MED J, V91, P667; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Mafee MF, 2006, CLIN REV ALLERG IMMU, V30, P165, DOI 10.1385/CRIAI:30:3:165; MAFEE MF, 1993, AM J ROENTGENOL, V160, P735; MAGNUSSEN H, 1993, THORAX, V48, P879, DOI 10.1136/thx.48.9.879; MAGYAR P, 1993, ALLERGY, V48, P631, DOI 10.1111/j.1398-9995.1993.tb00761.x; Mahillon V, 2006, ALLERGY, V61, P1138, DOI 10.1111/j.1398-9995.2006.01026.x; Maitra A, 2004, CLIN EXP ALLERGY, V34, P1349, DOI 10.1111/j.1365-2222.2004.02048.x; Majani G, 2001, ALLERGY, V56, P313, DOI 10.1034/j.1398-9995.2001.00852.x; Makinen-Kiljunen S, 2001, ALLERGY, V56, P696, DOI 10.1034/j.1398-9995.2001.00142.x; MALLING H, 1988, ALLERGY S, V43, P6; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MALLING HJ, 1982, ALLERGY, V37, P563, DOI 10.1111/j.1398-9995.1982.tb02341.x; MALLING HJ, 1984, ALLERGY, V39, P596, DOI 10.1111/j.1398-9995.1984.tb01979.x; MALLING HJ, 1986, ALLERGY, V41, P57, DOI 10.1111/j.1398-9995.1986.tb00276.x; Malling HJ, 1993, ALLERGY, V14, P9; Malm L, 2000, RHINOLOGY, V38, P1; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; MALMBERG H, 1986, ALLERGIC VASOMOTOR R, P91; Malmberg LP, 2006, PEDIATR PULM, V41, P635, DOI 10.1002/ppul.20417; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; Malo JL, 1999, AM J RESP CRIT CARE, V159, P1879; Malo JL, 2005, OCCUP MED-OXFORD, V55, P606, DOI 10.1093/occmed/kqi185; Malo JL, 2005, ALLERGY, V60, P138, DOI 10.1111/j.1398-9995.2005.00522.x; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; Mamessier E, 2006, ALLERGY, V61, P581, DOI 10.1111/j.1398-9995.2006.01056.x; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198; MANGLA PK, 1981, CLIN ALLERGY, V11, P433, DOI 10.1111/j.1365-2222.1981.tb01616.x; Manning PJ, 1997, IRISH MED J, V90, P110; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; Marcucci F, 2007, RESP MED, V101, P1600, DOI 10.1016/j.rmed.2006.06.006; Mari A, 2003, CLIN EXP ALLERGY, V33, P1419, DOI 10.1046/j.1365-2222.2003.01773.x; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; MARIANA A, 2000, MALAYSIA SE ASIAN J, V31, P712; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Marinho S, 2007, ALLERGY, V62, P385, DOI 10.1111/j.1398-9995.2006.01294.x; Marinho Susana, 2006, Prim Care Respir J, V15, P152, DOI 10.1016/j.pcrj.2006.02.005; MARINKER M, 1998, COMPLIANCE ACCORDANC; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; Marogna M, 2006, ALLERGY, V61, P1209, DOI 10.1111/j.1398-9995.2006.01164.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marple B, 2004, OTOLARYNG HEAD NECK, V130, P131, DOI 10.1016/j.otohns.2003.07.005; Marquez F, 2000, AM J RHINOL, V14, P251, DOI 10.2500/105065800779954419; Marshall PS, 2002, PSYCHOSOM MED, V64, P684, DOI 10.1097/01.PSY.0000021944.35402.44; Marshall PS, 2000, ANN ALLERG ASTHMA IM, V84, P403; MARTIN B, 2007, ALLERGY ASTHMA PROC, V28, P210; Martin BG, 2006, ANN ALLERG ASTHMA IM, V96, P851; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Martinez-Cocera C, 2005, J INVEST ALLERG CLIN, V15, P22; Masi M, 1993, Pediatr Allergy Immunol, V4, P47; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matheson MC, 2005, CLIN EXP ALLERGY, V35, P907, DOI 10.1111/j.1365-2222.2005.02272.x; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999; Matsuya T, 2006, ANAL BIOANAL CHEM, V385, P797, DOI 10.1007/s00216-006-0455-9; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; MAURER M, 2007, ALLERGY; MAURICE F, 1986, J ALLERGY CLIN IMMUN, V77, P594, DOI 10.1016/0091-6749(86)90351-9; MAVALE M, 2007, MAPUTO ALLERGY, V62, P265; MCBRIDE DE, 1994, AM J RESP CRIT CARE, V149, P1192; McCormack PL, 2006, DRUGS, V66, P931, DOI 10.2165/00003495-200666070-00004; McGarvey LPA, 2004, PULM PHARMACOL THER, V17, P351, DOI 10.1016/j.pupt.2004.09.017; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P800, DOI 10.1067/mai.2002.124046; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; McLane ML, 2000, J APPL PHYSIOL, V88, P1043; MCMANUS MS, 1989, EXP LUNG RES, V15, P849, DOI 10.3109/01902148909069631; McNeely W, 1999, DRUGS, V57, P8; McNeely W, 1998, DRUGS, V56, P91, DOI 10.2165/00003495-199856010-00011; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; Medrala W, 1997, J INVEST ALLERG CLIN, V7, P32; Mehl A, 2005, ALLERGY, V60, P1034, DOI 10.1111/j.1398-9995.2005.00806.x; Melamed J, 2000, ALLERGY ASTHMA PROC, V21, P235, DOI 10.2500/108854100778248863; Meldrum M, 2005, OCCUP ENVIRON MED, V62, P212, DOI 10.1136/oem.2004.015511; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; Meltzer EO, 2006, J ALLERGY CLIN IMMUN, V118, pS17, DOI 10.1016/j.jaci.2006.09.005; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; MELTZER EO, 1990, J OCCUP ENVIRON MED, V32, P327, DOI 10.1097/00043764-199004000-00013; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; Meltzer EO, 1997, J ALLERGY CLIN IMMUN, V99, pS815, DOI 10.1016/S0091-6749(97)80041-3; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2005, ANN ALLERG ASTHMA IM, V95, P600; Meltzer EO, 1999, ANN ALLERG ASTHMA IM, V83, P311, DOI 10.1016/S1081-1206(10)62671-3; Meltzer EO, 2004, ANN ALLERG ASTHMA IM, V93, P452; Meltzer EO, 1998, ANN ALLERG ASTHMA IM, V81, P128; Meltzer EO, 2002, CLIN THER, V24, P942, DOI 10.1016/S0149-2918(02)80009-1; Meltzer EO, 2001, ANN ALLERG ASTHMA IM, V86, P286; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Mengesha YA, 1998, AM J IND MED, V34, P373, DOI 10.1002/(SICI)1097-0274(199810)34:4<373::AID-AJIM11>3.0.CO;2-#; Menz G, 1998, ALLERGY, V53, P15; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Metson RB, 2000, LARYNGOSCOPE, V110, P24, DOI 10.1097/00005537-200003002-00007; MIADONNA A, 1983, CLIN ALLERGY, V13, P155, DOI 10.1111/j.1365-2222.1983.tb02583.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Millqvist E, 2006, CURR OPIN ALLERGY CL, V6, P7, DOI 10.1097/01.all.0000199796.64304.ca; Millqvist E, 2000, CLIN PHYSIOL, V20, P212; Min YG, 2001, J KOREAN MED SCI, V16, P697; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1177/019459989811800514; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Mittag D, 2005, CLIN EXP ALLERGY, V35, P1049, DOI 10.1111/j.1365-2222.2005.02309.x; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Miyamoto T, 1997, ALLERGY, V52, P30; MIYAMOTO T, 1997, ALLERGY S38, V52, P5; Moinuddin R, 2004, ANN ALLERG ASTHMA IM, V92, P73; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; Moll B, 1998, ALLERGY, V53, P297, DOI 10.1111/j.1398-9995.1998.tb03890.x; MOLLER C, 1994, CLIN EXP ALLERGY, V24, P884, DOI 10.1111/j.1365-2222.1994.tb01811.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883; MONERETVAUTRIN DA, 1990, ANN ALLERGY, V64, P513; Monn C, 1998, SCI TOTAL ENVIRON, V215, P243, DOI 10.1016/S0048-9697(98)00124-7; Montefort S, 1998, CLIN EXP ALLERGY, V28, P1089; Monteil MA, 2004, REV PANAM SALUD PUBL, V16, P193, DOI 10.1590/S1020-49892004000900006; Montnemery P, 2001, EUR RESPIR J, V17, P596, DOI 10.1183/09031936.01.17405960; MORAIS A, 2008, IN PRESS ASTHMA P; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mori J, 1998, ACTA OTO-LARYNGOL, P197; Mori S, 1999, CLIN EXP ALLERGY, V29, P1542; Mori S, 2000, ORL J OTO-RHINO-LARY, V62, P303, DOI 10.1159/000027773; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; Morice AH, 2004, PULM PHARMACOL THER, V17, P343, DOI 10.1016/j.pupt.2004.09.005; Morita Eishin, 1999, Journal of Dermatology (Tokyo), V26, P282; Morris JB, 1999, J APPL PHYSIOL, V87, P1877; Morsy Tosson A., 1995, Journal of the Egyptian Society of Parasitology, V25, P195; Mortz CG, 2005, PEDIATR ALLERGY IMMU, V16, P501, DOI 10.1111/j.1399-3038.2005.00302.x; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Moscato G, 2005, CHEST, V128, P3590, DOI 10.1378/chest.128.5.3590; Moscato G, 1997, OCCUP MED-OXFORD, V47, P249, DOI 10.1093/occmed/47.4.249; MOSCATO G, 1995, EUR RESPIR J, V8, P467, DOI 10.1183/09031936.95.08030467; MOSER M, 1992, J IMMUNOL, V149, P454; Mothes N, 2006, CLIN CHEM LAB MED, V44, P125, DOI 10.1515/CCLM.2006.024; Mothes N, 2004, CURR ALLERGY ASTHM R, V4, P384, DOI 10.1007/s11882-004-0089-y; Mothes Nadine, 2004, Clin Allergy Immunol, V18, P165; MOURAD W, 1988, J IMMUNOL, V141, P3486; MOUSTAFA AF, 1976, MYCOPATHOLOGIA, V59, P29, DOI 10.1007/BF00491201; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Mowad C M, 2001, Am J Contact Dermat, V12, P115, DOI 10.1053/ajcd.2001.23004; MOYES CD, 1995, NEW ZEAL MED J, V108, P358; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; Muller U, 1997, CLIN EXP ALLERGY, V27, P915; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P196, DOI 10.1111/j.1399-3038.2004.00128.x; Murdoch D, 2003, DRUGS, V63, P2051, DOI 10.2165/00003495-200363190-00010; MUSK AW, 1989, BRIT J IND MED, V46, P636; Musken H, 2000, J INVEST ALLERG CLIN, V10, P346; Mygind N, 1989, Rhinol Suppl, V9, P37; Naclerio RM, 1997, ARCH OTOLARYNGOL, V123, P193; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NACLERIO RM, 1988, PEDIATR INFECT DIS J, V7, P218, DOI 10.1097/00006454-198803000-00031; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; NACLERIO RM, 1995, J APPL PHYSIOL, V79, P467; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; Naito Kensei, 1999, Rhinology (Utrecht), V37, P66; Naito Kensei, 1993, Auris Nasus Larynx, V20, P31; Nakamura H, 2004, INT ARCH ALLERGY IMM, V135, P40, DOI 10.1159/000080222; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Narang I, 2002, THORAX, V57, P586, DOI 10.1136/thorax.57.7.586; Nash DB, 2000, AM J MANAG CARE, V6, pS3; NASH DB, 2000, AM J MANAGE CARE S1, V6, pS9; Nassenstein C, 2005, CURR ALLERGY ASTHM R, V5, P204, DOI 10.1007/s11882-005-0039-3; NATHAN A, 2002, PHARM J, V268, P575; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; NAYAK AS, 2000, COCHRANE DB SYST REV, V2, P417; Nelson Harold S., 2003, Journal of Allergy and Clinical Immunology, V111, pS793, DOI 10.1067/mai.2003.150; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P635, DOI 10.1016/j.jaci.2004.01.741; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628; NEUKIRCH F, 1995, RESP MED, V89, P685, DOI 10.1016/0954-6111(95)90136-1; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1417, DOI 10.1046/j.1365-2222.2000.00913.x; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1314; NG TP, 1994, INT J EPIDEMIOL, V23, P553, DOI 10.1093/ije/23.3.553; Nga NN, 2003, PEDIATR ALLERGY IMMU, V14, P272, DOI 10.1034/j.1399-3038.2003.00043.x; Ngamphaiboon J, 1997, ANN ALLERG ASTHMA IM, V78, P479; Nguyen LHP, 2004, J ALLERGY CLIN IMMUN, V114, P1110, DOI 10.1016/j.jaci.2004.07.061; Nickel R, 2005, CLIN EXP ALLERGY, V35, P619, DOI 10.1111/j.1365-2222.2005.02237.x; Nickel R, 2002, PEDIATR ALLERGY IMMU, V13, P7, DOI 10.1034/j.1399-3038.13.s.15.4.x; NICKELSEN JA, 1986, J ALLERGY CLIN IMMUN, V77, P43, DOI 10.1016/0091-6749(86)90320-9; NICKLAS R, 1996, J ALLERGY CLIN IMMUN, V6, P1001; Nicolaou N, 2005, ALLERGY, V60, P1357, DOI 10.1111/j.1398-9995.2005.00961.x; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nielsen J, 2006, ALLERGY, V61, P743, DOI 10.1111/j.1398-9995.2006.01028.x; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; NIEMEIJER NR, 1993, ALLERGY, V48, P498, DOI 10.1111/j.1398-9995.1993.tb01105.x; Nieters A, 2004, CLIN EXP ALLERGY, V34, P346, DOI 10.1111/j.1365-2222.2004.01889.x; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Niggemann B, 2005, ALLERGY, V60, P865, DOI 10.1111/j.1398-9995.2005.00828.x; Niggemann B, 2005, ALLERGY, V60, P104, DOI 10.1111/j.1398-9995.2004.00591.x; Niggemann B, 2004, J INVEST ALLERG CLIN, V14, P98; Niggemann B, 2003, ALLERGY, V58, P707, DOI 10.1034/j.1398-9995.2003.00219.x; Niggemann B, 2001, PEDIATR ALLERGY IMMU, V12, P37, DOI 10.1034/j.1399-3038.2001.121408.x; Nihlen U, 2006, ALLERGY, V61, P1299, DOI 10.1111/j.1398-9995.2006.01166.x; Nikasinovic L, 2006, J ALLERGY CLIN IMMUN, V117, P1382, DOI 10.1016/j.jaci.2006.03.023; NINAN TK, 1992, BRIT MED J, V304, P873; Nishiike S, 2004, AURIS NASUS LARYNX, V31, P135, DOI 10.1016/j.anl.2004.01.002; NIZANKOWSKAMOGI.E, 2007, ALLERGY, V62, P111; Nomeir AA, 1996, J CLIN PHARMACOL, V36, P923; Noon L, 1911, LANCET, V1, P1572; Noonan MJ, 2003, CLIN EXP ALLERGY, V33, P351, DOI 10.1046/j.1365-2222.2003.01596.x; Noone PG, 2004, AM J RESP CRIT CARE, V169, P459, DOI 10.1164/rccm.200303-365OC; Nopp A, 2006, ALLERGY, V61, P298, DOI 10.1111/j.1398-9995.2006.00987.x; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; NORDVALL SL, 1990, ACTA PAEDIATR SCAND, V79, P343, DOI 10.1111/j.1651-2227.1990.tb11467.x; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1225; NORMAN PS, 1992, ANN ALLERGY, V69, P309; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; NORRMAN E, 1994, ALLERGY, V49, P808, DOI 10.1111/j.1398-9995.1994.tb00779.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Numminen J, 2003, RHINOLOGY, V41, P65; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Oba Y, 2004, J ALLERGY CLIN IMMUN, V114, P265, DOI 10.1016/j.jaci.2004.05.049; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P70, DOI 10.1111/j.1365-2222.2005.02408.x; Obihara CC, 2005, ALLERGY, V60, P1121, DOI 10.1111/j.1398-9995.2005.00834.x; Obihara CC, 2005, EUR RESPIR J, V25, P970, DOI 10.1183/09031936.05.00116504; Oddy WH, 1999, BRIT MED J, V319, P815; ODELRAM H, 1989, ALLERGY, V44, P432, DOI 10.1111/j.1398-9995.1989.tb04175.x; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; OGINO S, 1990, Rhinology (Utrecht), V28, P163; Ohtani T, 2005, J IMMUNOL, V174, P2412; Ojima M, 2002, TOHOKU J EXP MED, V198, P163, DOI 10.1620/tjem.198.163; Okano M, 1999, ACTA OTO-LARYNGOL, P58; Okoromah Christy N, 2002, Niger Postgrad Med J, V9, P221; Okubo K, 2005, INT ARCH ALLERGY IMM, V136, P148, DOI 10.1159/000083322; Okuda M, 2005, ACTA OTO-LARYNGOL, V125, P736, DOI 10.1080/00016480510026944; Okuda M., 1998, ALLERGY IMMUNOL, V5, P86; Okuma M, 1994, Arerugi, V43, P492; Olin AC, 2004, CLIN EXP ALLERGY, V34, P221, DOI 10.1111/j.1365-2222.2004.01888.x; OLONITOLA OS, 1994, ANN ALLERGY, V73, P273; OLSEN E, 1994, ANN ALLERGY, V72, P499; OLSEN KD, 1981, OTOLARYNG HEAD NECK, V89, P804; Olsson P, 2003, ACTA OTO-LARYNGOL, V123, P75, DOI 10.1080/0036554021000028071; Estelle F, 2007, PEDIATR ALLERGY IMMU, V18, P535, DOI 10.1111/j.1399-3038.2007.00558.x; ESTELLE F, 1991, CLIN PHARMACOKINET, V21, P372, DOI 10.2165/00003088-199121050-00005; O'Meara TJ, 2005, ALLERGY, V60, P529, DOI 10.1111/j.1398-9995.2005.00741.x; Olthoff A, 2002, ORL J OTO-RHINO-LARY, V64, P180, DOI 10.1159/000058022; Omenaas E, 2000, THORAX, V55, P454, DOI 10.1136/thorax.55.6.454; OMNES LF, 2007, FRANCE ALLERG IMMUNO, V39, P148; Omokhodion F O, 2005, West Afr J Med, V24, P256; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; Oppenheimer J, 2006, ANN ALLERG ASTHMA IM, V96, pS6; OPPENHEIMER JJ, 1993, ANN ALLERGY, V71, P227; Orozco-Levi M, 2006, EUR RESPIR J, V27, P542, DOI 10.1183/09031936.06.00052705; Orriols R, 2006, OCCUP ENVIRON MED, V63, P255, DOI 10.1136/oem.2005.022525; Ortega N, 1999, ANN ALLERG ASTHMA IM, V82, P194, DOI 10.1016/S1081-1206(10)62596-3; ORTOLANI C, 1981, CLIN ALLERGY, V11, P249, DOI 10.1111/j.1365-2222.1981.tb01591.x; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241; Osborn DA, 2006, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003664.PUB3; Osborn DA, 2004, COCHRANE DB SYST REV, V3; Osborne M, 2006, PEDIATR ALLERGY IMMU, V17, P450, DOI 10.1111/j.1399-3038.2006.00414.x; Osguthorpe JD, 1999, MED CLIN N AM, V83, P27, DOI 10.1016/S0025-7125(05)70085-7; OSGUTHORPE JD, 1999, MED CLIN N AM, V83, pR7; Osim EE, 1999, TROP MED INT HEALTH, V4, P621, DOI 10.1046/j.1365-3156.1999.00460.x; Osim EE, 1998, S AFR MED J, V88, P1127; Osterballe M, 2005, ALLERGY, V60, P218, DOI 10.1111/j.1398-9995.2005.00674.x; OSTERBALLE O, 1979, ALLERGY, V34, P209, DOI 10.1111/j.1398-9995.1979.tb01700.x; OSTRO BD, 1994, AM J RESP CRIT CARE, V149, P1400; Ota MOC, 2003, CLIN EXP ALLERGY, V33, P731, DOI 10.1046/j.1365-2222.2003.01599.x; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; Ott H, 2006, ALLERGY, V61, P1146, DOI 10.1111/j.1398-9995.2006.01074.x; Ottaviano G, 2006, RHINOLOGY, V44, P32; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; Overlack A, 1996, DRUG SAFETY, V15, P72, DOI 10.2165/00002018-199615010-00006; Owen CG, 2004, BRIT J GEN PRACT, V54, P451; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V94, P662, DOI 10.1016/0091-6749(94)90171-6; Ozdemir N, 2000, RESP MED, V94, P536, DOI 10.1053/rmed.1999.0728; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Palczynski C, 2000, ALLERGY, V55, P34, DOI 10.1034/j.1398-9995.2000.00037.x; Palczynski Cezary, 2003, Int J Occup Med Environ Health, V16, P231; PALLASAHO P, 2006, FINLAND CLIN EXP ALL, V36, P503; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Papageorgiou N, 1997, RESP MED, V91, P83, DOI 10.1016/S0954-6111(97)90072-X; Papatziamos G, 1999, ALLERGY, V54, P916, DOI 10.1034/j.1398-9995.1999.00033.x; Pariente PD, 1997, PHARMACOECONOMICS, V12, P585; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; Park HS, 1997, ANN ALLERG ASTHMA IM, V78, P225; Park JW, 2002, CLIN EXP ALLERGY, V32, P1042, DOI 10.1046/j.1365-2222.2002.01421.x; Partti-Pellinen K, 2000, ALLERGY, V55, P65, DOI 10.1034/j.1398-9995.2000.00226.x; Pasquali M, 2006, CLIN EXP ALLERGY, V36, P1161, DOI 10.1111/j.1365-2222.2006.02548.x; Passalacqua G, 1996, ALLERGY, V51, P666; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1395-9995.2006.01098.x; Passalacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P1054, DOI 10.1016/j.jaci.2005.12.1308; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P31, DOI 10.1097/00130832-200402000-00007; Passalacqua Giovanni, 2002, Clin Allergy Immunol, V17, P65; Passali D, 2005, ARCH OTOLARYNGOL, V131, P788, DOI 10.1001/archotol.131.9.788; PASSALI D, 1999, ALLERGY, V55, P4; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; PASTORELLO EA, 1992, ALLERGY, V47, P463, DOI 10.1111/j.1398-9995.1992.tb00665.x; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Patel P, 2005, ANN ALLERG ASTHMA IM, V95, P551; Patel P, 2006, EXPERT REV VACCINES, V5, P617, DOI 10.1586/14760584.5.5.617; PATTEMORE PK, 1989, THORAX, V44, P168, DOI 10.1136/thx.44.3.168; Patussi V, 1994, Med Lav, V85, P402; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; PAULI G, 1993, CLIN EXP ALLERGY, V23, P606, DOI 10.1111/j.1365-2222.1993.tb00901.x; Pauli G, 1997, J ALLERGY CLIN IMMUN, V99, P261, DOI 10.1016/S0091-6749(97)70107-6; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; Pauli Gabrielle, 2003, Curr Opin Allergy Clin Immunol, V3, P95, DOI 10.1097/00130832-200304000-00002; Pawankar R, 2005, CHEM IMMUNOL ALLERGY, V87, P111; PAWANKAR R, 2008, IN PRESS ALLERGY; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Pedersen P A, 1983, Scand J Prim Health Care, V1, P97, DOI 10.3109/02813438309038476; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; Pekkarinen PT, 2007, ALLERGY, V62, P281, DOI 10.1111/j.1398-9995.2006.01249.x; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PEPYS J, 1985, CLIN ALLERGY, V15, P101, DOI 10.1111/j.1365-2222.1985.tb02262.x; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; Pepys J., 1975, BRIT J HOSP MED, V14, P412; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Peroni DG, 2003, CLIN EXP ALLERGY, V33, P1349, DOI 10.1046/j.1365-2222.2003.01766.x; PERRIN LF, 1984, CLIN ALLERGY, V14, P581, DOI 10.1111/j.1365-2222.1984.tb02246.x; PETERS G, 2006, CLIN EXP ALLERGY, V36, P689; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; Pham-Thi N, 2006, ALLERGY, V61, P7, DOI 10.1111/j.1398-9995.2006.01162.x; Pham-Thi N, 2007, PEDIATR ALLERGY IMMU, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; PHEOBUS P, 1859, LANCET, V2, P655; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V94, P1035, DOI 10.1016/0091-6749(94)90122-8; Philip G, 2007, ALLERGY ASTHMA PROC, V28, P296, DOI 10.2500/aap.2007.28.3000; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; Philpott CM, 2004, CLIN OTOLARYNGOL, V29, P343, DOI 10.1111/j.1365-2273.2004.00815.x; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Piette V, 2004, ALLERGY, V59, P863, DOI 10.1111/j.1398-9995.2004.00509.x; Piette V, 2002, ALLERGY, V57, P940, DOI 10.1034/j.1398-9995.2002.23536.x; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Piipari R, 2005, CLIN EXP ALLERGY, V35, P1632, DOI 10.1111/j.1365-2222.2005.02386.x; Piirila P, 1997, EUR RESPIR J, V10, P1918, DOI 10.1183/09031936.97.10081918; Piirila P, 2002, INT ARCH OCC ENV HEA, V75, P209, DOI 10.1007/s00420-001-0302-4; PINCUS T, 2002, ANN INTERN MED, V136, P79; PIPKORN U, 1988, ALLERGY, V8, P41; Pirila T, 1997, ACTA OTO-LARYNGOL, V117, P596, DOI 10.3109/00016489709113444; Placido JL, 1996, ALLERGY, V51, P633, DOI 10.1111/j.1398-9995.1996.tb04683.x; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; PLATTS M, 1997, J ALLERGY CLIN IMMUN, V100, pS2; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; Platts-Mills TAE, 2006, CHEM IMMUNOL ALLERGY, V91, P3; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, pS1; Platts-Mills TAE, 1998, CURR OPIN IMMUNOL, V10, P634, DOI 10.1016/S0952-7915(98)80081-2; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; Polosa R, 2003, CLIN EXP ALLERGY, V33, P873, DOI 10.1046/j.1365-2222.2003.01676.x; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877; Poole JA, 2005, CURR ALLERGY ASTHM R, V5, P252, DOI 10.1007/s11882-005-0045-5; Poon AW, 1998, AM J MANAG CARE, V4, P969; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Porsbjerg C, 2006, CHEST, V129, P309, DOI 10.1378/chest.129.2.309; Potter PC, 2003, ALLERGY, V58, P893, DOI 10.1034/j.1398-9995.2003.00171.x; Potter PC, 2001, SAMJ S AFR MED J, V91, P760; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; PRADALIER A, 2007, ALLERGY; PRAHL P, 1981, ALLERGY, V36, P561, DOI 10.1111/j.1398-9995.1981.tb01874.x; Pratter MR, 2006, CHEST, V129, p63S, DOI 10.1378/chest.129.1_suppl.63S; Premaratna R, 2002, ARCH ENVIRON HEALTH, V57, P579; Prenner BM, 1996, J ALLERGY CLIN IMMUN, V98, P302, DOI 10.1016/S0091-6749(96)70154-9; Prescott SL, 2005, MED J AUSTRALIA, V182, P464; Price D, 2005, CLIN EXP ALLERGY, V35, P282, DOI 10.1111/j.1365-2222.2005.02182.x; Price David, 2006, Prim Care Respir J, V15, P58, DOI 10.1016/j.pcrj.2005.11.002; Price DB, 2006, ALLERGY, V61, P737, DOI 10.1111/j.1398-9995.2006.01007.x; PRICE DD, 1983, PAIN, V17, P45, DOI 10.1016/0304-3959(83)90126-4; Price KS, 2007, ALLERGY ASTHMA PROC, V28, P313, DOI 10.2500/aap.2007.28.3003; PRIETO L, 1994, EUR RESPIR J, V7, P1845, DOI 10.1183/09031936.94.07101845; Prioult G, 2005, IMMUNOL REV, V206, P204, DOI 10.1111/j.0105-2896.2005.00277.x; PROCTOR DF, 1977, AM REV RESPIR DIS, V115, P97; PROUD D, 1990, INT ARCH ALLER A IMM, V93, P165; PROUD D, 1992, J ALLERGY CLIN IMMUN, V89, P1098, DOI 10.1016/0091-6749(92)90293-B; Prussin C, 2006, J ALLERGY CLIN IMMUN, V117, pS450, DOI 10.1016/j.jaci.2005.11.016; Psarras S, 2006, J ALLERGY CLIN IMMUN, V117, P291, DOI 10.1016/j.jaci.2005.11.005; PUERTA L, 1993, J INVEST ALLERG CLIN, V3, P198; PUKANDER J S, 1990, Rhinology (Utrecht), V28, P249; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Pumhirun P, 1997, ASIAN PAC J ALLERGY, V15, P183; PUNNONEN J, 1992, J IMMUNOL, V148, P3398; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Pynnonen MA, 2006, ARCH OTOLARYNGOL, V132, P748, DOI 10.1001/archotol.132.7.748; Quah BS, 1997, ACTA PAEDIATR JAPON, V39, P329; Quah BS, 2005, RESPIROLOGY, V10, P244, DOI 10.1111/j.1440-1843.2005.00645.x; Quiralte J, 2000, INT ARCH ALLERGY IMM, V122, P101, DOI 10.1159/000024365; Quiralte J, 2005, ALLERGY, V60, P360, DOI 10.1111/j.1398-9995.2005.00698.x; Quirce S, 2006, ALLERGY, V61, P1202, DOI 10.1111/j.1398-995.2006.01189.x; QUIRCE S, 1994, J ALLERGY CLIN IMMUN, V93, P44, DOI 10.1016/0091-6749(94)90231-3; Radauer C, 2006, CLIN EXP ALLERGY, V36, P920, DOI 10.1111/j.1365-2222.2006.02521.x; Radon K, 2006, J ALLERGY CLIN IMMUN, V118, P1279, DOI 10.1016/j.jaci.2006.08.033; Raebel MA, 2004, ARCH INTERN MED, V164, P2135, DOI 10.1001/archinte.164.19.2135; Ragab SM, 2006, ALLERGY, V61, P717, DOI 10.1111/j.1398-9995.2005.01044.x; Ragab SM, 2004, LARYNGOSCOPE, V114, P923, DOI 10.1097/00005537-200405000-00027; Raherison C, 2007, RESP MED, V101, P107, DOI 10.1016/j.rmed.2006.04.010; RAJAKUKASINGAM K, 2004, UPPER LOWER RESP DIS, V181, P139; Rak S, 2005, ALLERGY, V60, P643, DOI 10.1111/j.1398-9995.2005.00763.x; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Rak S, 2007, QUAL LIFE RES, V16, P191, DOI 10.1007/s11136-006-9110-3; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; Rasanen M, 2001, Twin Res, V4, P392; Rasmussen F, 2000, CHEST, V117, P1330, DOI 10.1378/chest.117.5.1330; RASP G, 1994, CLIN EXP ALLERGY, V24, P1151; Ratner P, 1996, ALLERGY ASTHMA PROC, V17, P149, DOI 10.2500/108854196779165049; Ratner PH, 2006, J ALLERGY CLIN IMMUN, V118, P1142, DOI 10.1016/j.jaci.2006.07.050; Ratner PH, 2006, ANN ALLERG ASTHMA IM, V97, P657; Ratner PH, 2000, J ALLERGY CLIN IMMUN, V105, P1101, DOI 10.1067/mai.2000.105525; Ratner PH, 1998, J FAM PRACTICE, V47, P118; Raulf-Heimsoth M, 2000, CLIN EXP ALLERGY, V30, P110; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P401, DOI 10.1016/S0091-6749(99)70463-X; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; REED CE, 2004, J ALLERGY CLIN IMMUN, V114, P9; Reed SD, 2004, PHARMACOECONOMICS, V22, P345, DOI 10.2165/00019053-200422060-00002; REES D, 1994, S AFR MED J, V84, P851; Rees D, 1998, S AFR MED J, V88, P1110; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Reijula K, 2003, ANN ALLERG ASTHMA IM, V91, P280; Reinartz SM, 2005, ALLERGY, V60, P1301, DOI 10.1111/j.1398-9995.2005.00911.x; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; RENSTROM A, 1994, ALLERGY, V49, P548, DOI 10.1111/j.1398-9995.1994.tb01127.x; Renz H, 2006, CHEM IMMUNOL ALLERGY, V91, P30; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Renzoni E, 1999, EUR RESPIR J, V14, P597, DOI 10.1034/j.1399-3003.1999.14c19.x; REUTER A, 2006, EUROPE CLIN EXP ALLE, V36, P815; Revicki DA, 1999, PHARMACOECONOMICS, V15, P423, DOI 10.2165/00019053-199915050-00001; Revicki DA, 1998, QUAL LIFE RES, V7, P693, DOI 10.1023/A:1008860113818; Reynaert NL, 2005, ANTIOXID REDOX SIGN, V7, P129, DOI 10.1089/ars.2005.7.129; RiarioSforza GG, 1997, ALLERGY ASTHMA PROC, V18, P23, DOI 10.2500/108854197778612790; Ricca V, 2000, J ALLERGY CLIN IMMUN, V105, P54, DOI 10.1016/S0091-6749(00)90177-5; Ricci G, 2005, MOL IMMUNOL, V42, P1251, DOI 10.1016/j.molimm.2004.11.011; Riccioni G, 2002, INT J IMMUNOPATH PH, V15, P69; Rice D P, 1985, Health Care Financ Rev, V7, P61; RICHARDS S, 1992, BRIT J GEN PRACT, V42, P284; Riedi CA, 2005, J INVEST ALLERG CLIN, V15, P183; Riediker M, 2001, ANN ALLERG ASTHMA IM, V87, P311; Riikjarv MA, 2000, EUR RESPIR J, V16, P86, DOI 10.1034/j.1399-3003.2000.16a15.x; RIMPELA AH, 1995, SCAND J SOC MED, V23, P60; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P379; Rizzo MC, 1997, J INVEST ALLERG CLIN, V7, P242; ROANE J, 1968, ANN ALLERGY, V26, P443; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Roberts G, 2005, CLIN EXP ALLERGY, V35, P1295, DOI 10.1111/j.1365-2222.2005.02333.x; Roberts G, 2003, J ALLERGY CLIN IMMUN, V111, P491, DOI 10.1067/mai.2003.138; Robertson CF, 2004, MED J AUSTRALIA, V180, P273; Robertson CF, 1998, MED J AUSTRALIA, V168, P434; Roche N, 1997, EUR RESPIR J, V10, P719; Roche N, 2005, RESP MED, V99, P793, DOI 10.1016/j.rmed.2005.03.011; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rodrigo GJ, 2006, ANN ALLERG ASTHMA IM, V96, P779; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Romagnani S, 2006, ALLERGY, V61, P3, DOI 10.1111/j.1398-9995.2006.01005; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.02J	Kalliomaki, M; Salminen, S; Arvilommi, H; Kero, P; Koskinen, P; Isolauri, E				Kalliomaki, M; Salminen, S; Arvilommi, H; Kero, P; Koskinen, P; Isolauri, E			Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial	LANCET			English	Article							GROWTH-FACTOR-BETA; ORAL TOLERANCE; 4 REGIONS; COW MILK; CHILDREN; DERMATITIS; ANTIGEN; CELLS; PREVALENCE; ALLERGY	Background Reversal of the progressive increase in frequency of atopic disease would be an important breakthrough for health care and wellbeing in western societies. In the hygiene hypothesis this increase is attributed to reduced microbial exposure in early life. Probiotics are cultures of potentially beneficial bacteria of the healthy gut microflora. We assessed the effect on atopic disease of Lactobacillus GG (which is safe at an early age and effective in treatment of allergic inflammation and food allergy). Methods In a double-blind, randomised placebo-controlled trial we gave Lactobacillus GG prenatally to mothers who had at least one first-degree relative (or partner) with atopic eczema. allergic rhinitis, or asthma, and postnatally for 6 months to their infants. Chronic recurring atopic eczema, which is the main sign of atopic disease in the first years of life, was the primary endpoint. Findings Atopic eczema was diagnosed in 46 of 132 (35%) children aged 2 years. Asthma was diagnosed in six of these children and allergic rhinitis in one. The frequency of atopic eczema in the probiotic group was half that of the placebo group (15/64 [23%] vs 31/68 [46%]; relative risk 0.51 [95% CI 0.32-0.84]). The number needed to treat was 4.5 (95% CI 2.6-15.6). Interpretations Lactobacillus GG was effective in prevention of early atopic disease in children at high risk. Thus, gut microflora might be a hitherto unexplored source of natural immunomodulators and probiotics, for prevention of atopic disease.	Turku Univ Hosp, Dept Paediat, FI-20521 Turku, Finland; Univ Turku, Dept Paediat, Turku, Finland; Univ Turku, Dept Biochem & Food Chem, Turku, Finland; Univ Turku, Dept Clin Chem, Turku, Finland; Natl Publ Hlth Inst, Turku, Finland	Kalliomaki, M (reprint author), Turku Univ Hosp, Dept Paediat, POB 52, FI-20521 Turku, Finland.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Barone KS, 2000, CELL IMMUNOL, V199, P65, DOI 10.1006/cimm.1999.1603; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; COOK RJ, 1995, BRIT MED J, V310, P452; GARDNER MJ, 1986, BRIT MED J, V292, P746; Gaskins H. R., 1997, GASTROINTESTINAL MIC, V2, P537; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Harrigan E, 1999, IMMUNOL ALLERGY CLIN, V19, P383, DOI 10.1016/S0889-8561(05)70094-1; Holgate ST, 1999, NATURE, V402, pB2; ISOLAURI E, 1992, J PEDIATR-US, V120, P9, DOI 10.1016/S0022-3476(05)80589-X; ISOLAURI E, 1993, GASTROENTEROLOGY, V105, P1643; Isolauri E., 2000, CLIN EXP ALLERGY, V30, P1605, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Majamaa H, 1996, J ALLERGY CLIN IMMUN, V97, P985, DOI 10.1016/S0091-6749(96)80074-1; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Miettinen M, 1998, INFECT IMMUN, V66, P6058; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; Pekkanen J, 1997, EUR RESPIR J, V10, P1787, DOI 10.1183/09031936.97.10081787; Pessi T, 1998, J NUTR, V128, P2313; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Salminen S, 1998, BR J NUTR S1, V1, P147, DOI 10.1079/BJN19980108; Sanfilippo L, 2000, CLIN EXP IMMUNOL, V119, P456, DOI 10.1046/j.1365-2249.2000.01155.x; Sato M, 1999, IMMUNOL LETT, V70, P29, DOI 10.1016/S0165-2478(99)00122-4; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STALDER JF, 1993, DERMATOLOGY, V186, P23; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sudo N, 1997, J IMMUNOL, V159, P1739; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; WARNER JO, 1992, ARCH DIS CHILD, V67, P240; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	39	1380	1481	31	272	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 7	2001	357	9262					1076	1079		10.1016/S0140-6736(00)04259-8		4	Medicine, General & Internal	General & Internal Medicine	420GA	WOS:000167996200009	11297958	
J	Bousquet, J; van Cauwenberge, P; Khaltaev, N; Ait-Khaled, N; Annesi-Maesano, I; Bachert, C; Baena-Cagnani, C; Bateman, E; Bonini, S; Canonica, GW; Carlsen, KH; Demoly, P; Durham, SR; Enarson, D; Fokkens, WJ; van Wijk, RG; Howarth, P; Ivanova, NA; Kemp, JP; Klossek, JM; Lockey, RF; Lund, V; Mackay, I; Malling, HJ; Meltzer, EO; Mygind, N; Okunda, M; Pawankar, R; Price, D; Scadding, GK; Simons, FER; Szczeklik, A; Valovirta, E; Vignola, AM; Wang, DY; Warner, JO; Weiss, KB				Bousquet, J; van Cauwenberge, P; Khaltaev, N; Ait-Khaled, N; Annesi-Maesano, I; Bachert, C; Baena-Cagnani, C; Bateman, E; Bonini, S; Canonica, GW; Carlsen, KH; Demoly, P; Durham, SR; Enarson, D; Fokkens, WJ; van Wijk, RG; Howarth, P; Ivanova, NA; Kemp, JP; Klossek, JM; Lockey, RF; Lund, V; Mackay, I; Malling, HJ; Meltzer, EO; Mygind, N; Okunda, M; Pawankar, R; Price, D; Scadding, GK; Simons, FER; Szczeklik, A; Valovirta, E; Vignola, AM; Wang, DY; Warner, JO; Weiss, KB		ARIA Workshop Grp	Allergic rhinitis and its impact on asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							AQUEOUS NASAL SPRAY; HOUSE-DUST MITE; QUALITY-OF-LIFE; FC-EPSILON-RI; TORSADES-DE-POINTES; PLACEBO-CONTROLLED TRIAL; INTRANASAL FLUTICASONE PROPIONATE; BRONCHIAL EPITHELIAL-CELLS; DOUBLE-BLIND PLACEBO; MESSENGER-RNA EXPRESSION			Bousquet, J (reprint author), Hop Amaud Villeneuve, Serv Malad Resp, ARIA, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.		Bachert, Claus/J-8825-2012; Annesi-Maesano, Isabella/D-9173-2016				AARONSON DW, 1991, ANN ALLERGY, V67, P541; Aaronson DW, 1996, ANN ALLERG ASTHMA IM, V76, P440; AAS K, 1978, ALLERGY, V33, P130, DOI 10.1111/j.1398-9995.1978.tb01522.x; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410; ABE Y, 1993, CLIN EXP ALLERGY, V23, P132, DOI 10.1111/j.1365-2222.1993.tb00308.x; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P520; ABELSON MB, 1980, AM J OPHTHALMOL, V90, P254; ABERG N, 1989, CLIN EXP ALLERGY, V19, P643, DOI 10.1111/j.1365-2222.1989.tb02761.x; ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ACHTERRATHTUCKERMANN U, 1988, AGENTS ACTIONS, V24, P217, DOI 10.1007/BF02028274; ACKERMAN MN, 1984, J ALLERGY CLIN IMMUN, V73, P604, DOI 10.1016/0091-6749(84)90519-0; ADAMUS WS, 1987, EUR J CLIN PHARMACOL, V33, P381, DOI 10.1007/BF00637634; Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771; Adelsberg BR, 1997, ARCH INTERN MED, V157, P494, DOI 10.1001/archinte.157.5.494; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; Adkins TN, 1998, ANN ALLERG ASTHMA IM, V81, P181; AFZELIUS BA, 1976, SCIENCE, V193, P317, DOI 10.1126/science.1084576; AFZELIUS BA, 1994, VIRCHOWS ARCH, V424, P295; Agertoft L, 1993, Pediatr Allergy Immunol, V4, P152, DOI 10.1111/j.1399-3038.1993.tb00084.x; Agertoft L, 1999, J ALLERGY CLIN IMMUN, V104, P948; AHN HS, 1986, EUR J PHARMACOL, V127, P153, DOI 10.1016/0014-2999(86)90219-0; Ait-Khaled N, 2000, INT J TUBERC LUNG D, V4, P268; AITKHALED N, 1996, MANAGEMENT ASTHMA AD; Akdis CA, 1999, FASEB J, V13, P603; AKDIS CA, 1999, ALLERGY, V56, P31; AKERLUND A, 1989, J LARYNGOL OTOL, V103, P743, DOI 10.1017/S0022215100109958; ALAM R, 1992, J IMMUNOL METHODS, V155, P25, DOI 10.1016/0022-1759(92)90267-W; ALAM R, 1993, J IMMUNOL, V150, P3442; Alanko K, 1970, Scand J Respir Dis Suppl, V76, P1; Albiin N, 1986, Ann Otol Rhinol Laryngol Suppl, V126, P2; AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Alicea E, 1999, P R Health Sci J, V18, P19; Allansmith M R, 1990, J Am Optom Assoc, V61, pS42; ALLANSMITH MR, 1988, CLIN ALLERGY, V18, P1, DOI 10.1111/j.1365-2222.1988.tb02837.x; Allegra L, 1993, Pediatr Allergy Immunol, V4, P157, DOI 10.1111/j.1399-3038.1993.tb00085.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; ALONSO R, 1995, J INVEST ALLERG CLIN, V5, P156; Altamura Maria, 1999, Regulatory Peptides, V80, P13, DOI 10.1016/S0167-0115(99)00003-8; ALTHAUS MA, 1994, ALLERGY, V49, P184, DOI 10.1111/j.1398-9995.1994.tb00823.x; Altman GB, 1997, CELL BIOL TOXICOL, V13, P205, DOI 10.1023/A:1007318514715; ALTMAN LC, 1993, J ALLERGY CLIN IMMUN, V92, P527, DOI 10.1016/0091-6749(93)90077-S; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Board of Directors of the American Academy of Allergy, 1993, J ALLERGY CLIN IMMUN, V92, P636; Amelung PJ, 1998, CLIN EXP ALLERGY, V28, P397; American Thoracic Society Workshop, 1999, AM J RESP CRIT CARE, V160, P1778; AMOORE J E, 1983, Rhinology (Utrecht), V21, P49; ANDERSEN I, 1974, ARCH ENVIRON HEALTH, V29, P290; Anderson DF, 1997, CLIN EXP ALLERGY, V27, P1060, DOI 10.1111/j.1365-2222.1997.tb01258.x; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; ANDERSON WV, 1972, PRACTITIONER, V208, P676; ANDERSSON KE, 1984, ANN OTO RHINOL LARYN, V93, P179; ANDERSSON M, 1995, ACTA OTO-LARYNGOL, V115, P705, DOI 10.3109/00016489509139391; ANDERSSON M, 1993, CLIN OTOLARYNGOL, V18, P30, DOI 10.1111/j.1365-2273.1993.tb00805.x; ANDERSSON M, 1994, ALLERGY, V49, P242, DOI 10.1111/j.1398-9995.1994.tb02656.x; ANDERSSON M, 1988, J ALLERGY CLIN IMMUN, V82, P1019, DOI 10.1016/0091-6749(88)90139-X; ANDERSSON M, 1991, ALLERGY, V46, P540, DOI 10.1111/j.1398-9995.1991.tb00618.x; ANDERSSON M, 1989, AM REV RESPIR DIS, V139, P911; Andersson Morgan, 1995, Rhinology (Utrecht), V33, P18; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; Andri L, 1996, J ALLERGY CLIN IMMUN, V97, P34, DOI 10.1016/S0091-6749(96)70280-4; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGGARD A, 1977, ACTA OTO-LARYNGOL, V83, P22, DOI 10.3109/00016487709128806; ANGGARD A, 1979, Rhinology (Utrecht), V17, P31; ANGGARD A, 1993, ACTA OTO-LARYNGOL, V113, P394, DOI 10.3109/00016489309135832; ANKIER SI, 1989, J INTERN MED, V226, P453; AnnesiMaesano I, 1997, INT ARCH ALLERGY IMM, V114, P193; ANNESIMAESANO I, 2001, ALLERGY CLIN IMMUNOL, V13, P1; ANNESIMAESANO I, 1998, EUR RESPIR J, V10, pS143; Anto JM, 1997, THORAX, V52, P669; Aparicio S, 1992, Allergol Immunopathol (Madr), V20, P207; APTER AJ, 1995, ANN ALLERG ASTHMA IM, V75, P311; APTER AJ, 1992, J ALLERGY CLIN IMMUN, V90, P670, DOI 10.1016/0091-6749(92)90141-N; Arai K, 1997, MOL CELLS, V7, P1; ARBESMAN CE, 1964, J ALLERGY, V35, P12, DOI 10.1016/0021-8707(64)90044-9; ARIANO R, 1994, J INVEST ALLERG CLIN, V4, P81; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARMITAGE RJ, 1992, NATURE, V357, P80, DOI 10.1038/357080a0; Arnal JF, 1999, EUR RESPIR J, V13, P307, DOI 10.1034/j.1399-3003.1999.13b15.x; AROLA M, 1988, J PEDIATR-US, V113, P693, DOI 10.1016/S0022-3476(88)80380-9; ARRANG JM, 1987, NATURE, V327, P117, DOI 10.1038/327117a0; ARRIAGA F, 1990, ALLERGY, V45, P552, DOI 10.1111/j.1398-9995.1990.tb00531.x; ARRUDA LK, 1992, EXP APPL ACAROL, V16, P129, DOI 10.1007/BF01201496; ASAKO H, 1994, J CLIN INVEST, V93, P1508, DOI 10.1172/JCI117129; ASAKURA K, 1984, ARCH OTO-RHINO-LARYN, V239, P273, DOI 10.1007/BF00464255; ASCALONE V, 1993, J CHROMATOGR-BIOMED, V619, P275, DOI 10.1016/0378-4347(93)80117-M; ASH ASF, 1966, BRIT J PHARM CHEMOTH, V27, P427; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Assanasen P, 1999, J ALLERGY CLIN IMMUN, V104, P285, DOI 10.1016/S0091-6749(99)70368-4; ASSAND G, 1982, RHINOLOGY, V20, P205; ASTARITA C, 1988, CLIN ALLERGY, V18, P341, DOI 10.1111/j.1365-2222.1988.tb02881.x; AUBIER M, 1991, AM REV RESPIR DIS, V143, P346; AUBIER M, 1992, AM REV RESPIR DIS, V146, P122; AUSTIN CE, 1994, BRIT J PHARMACOL, V111, P969; *AUSTR BUR STAT, 1991, 43730 AUSTR BUR STAT; *AUSTR BUR STAT, 1991, NAT HLTH SURV ASTHM, V4373, P1; AWOUTERS F, 1992, AGENTS ACTIONS, V35, P12, DOI 10.1007/BF01990945; AWOUTERS FHL, 1983, ARZNEIMITTEL-FORSCH, V33-1, P381; AXELSSON IGK, 1987, ALLERGY, V42, P604, DOI 10.1111/j.1398-9995.1987.tb00391.x; AZEVEDO M, 1991, CLIN EXP ALLERGY, V21, P689, DOI 10.1111/j.1365-2222.1991.tb03197.x; Azpiri A, 1999, ALLERGY, V54, P1100, DOI 10.1034/j.1398-9995.1999.00146.x; Bachert C, 1998, CLIN EXP ALLERGY, V28, P15; Bachert C, 1998, AM J RHINOL, V12, P3, DOI 10.2500/105065898782103007; BACHERT C, 1995, INT ARCH ALLERGY IMM, V107, P106; Bachert C, 1998, ALLERGY, V53, P969, DOI 10.1111/j.1398-9995.1998.tb03798.x; Bachert C, 1999, INT ARCH ALLERGY IMM, V118, P375, DOI 10.1159/000024141; BACHERT C, 1990, ALLERGOLOGIE, P13; BACHERT C, 1995, EUR ARCH OTO-RHINO-L, V1, pS44; Bachert Claus, 1996, Rhinology (Utrecht), V34, P140; BACKHOUSE CI, 1986, J INT MED RES, V14, P35; BAELDE Y, 1992, DRUG INVEST, V4, P466; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; BAGGIOLINI M, 1995, INT J IMMUNOPHARMACO, V17, P103, DOI 10.1016/0192-0561(94)00088-6; BAHNA SL, 1992, ALLERGY PROC, V13, P21, DOI 10.2500/108854192778879006; BAKKE P, 1990, ALLERGY, V45, P515, DOI 10.1111/j.1398-9995.1990.tb00527.x; Balda BR, 1998, ALLERGY, V53, P740; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; BALDWIN AL, 1995, AM J PHYSIOL-HEART C, V269, pH1528; Baldwin CM, 1999, TOXICOL IND HEALTH, V15, P403, DOI 10.1177/074823379901500314; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; BALLE V, 1977, ACTA OTO-LARYNGOL, V84, P287, DOI 10.3109/00016487709123969; BALLE VH, 1982, ACTA OTO-LARYNGOL, V94, P169, DOI 10.3109/00016488209128901; BALZANO G, 1992, CLIN EXP ALLERGY, V22, P371, DOI 10.1111/j.1365-2222.1992.tb03098.x; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banov CH, 1996, CLIN THER, V18, P265, DOI 10.1016/S0149-2918(96)80007-5; BANOV CH, 1994, ANN ALLERGY, V73, P240; BANTZ EW, 1987, J ALLERGY CLIN IMMUN, V80, P99, DOI 10.1016/S0091-6749(87)80198-7; BARANIUK JN, 1990, J ALLERGY CLIN IMMUN, V86, P620, DOI 10.1016/S0091-6749(05)80226-X; BARANIUK JN, 1990, AM J RESP CELL MOL, V3, P165; BARANIUK JN, 1990, J CLIN INVEST, V85, P998, DOI 10.1172/JCI114577; BARANIUK JN, 1991, AM J RESP CELL MOL, V4, P228; BARANIUK JN, 1990, J CLIN INVEST, V86, P825, DOI 10.1172/JCI114780; BARANIUK JN, 1992, J APPL PHYSIOL, V73, P1867; BARANIUK JN, 1993, J APPL PHYSIOL, V74, P272; BARANIUK JN, 1995, ALLERGY PROC, V16, P227, DOI 10.2500/108854195778702585; BARANIUK JN, 1990, AM REV RESPIR DIS, V141, P706; BARANIUK JN, 1992, AM J PHYSIOL, V262, pL48; Baraniuk J. N., 1997, J ALLERGY CLIN IMMUN, V99, P763; BARANIUK JN, 1990, J APPL PHYSIOL, V258, P81; Barbey JT, 1999, AM J RHINOL, V13, P235, DOI 10.2500/105065899781389759; Bardare M, 1996, J INVEST ALLERG CLIN, V6, P359; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Barnes Kathleen C., 1996, International Archives of Allergy and Immunology, V109, P68; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P485, DOI 10.1016/S0091-6749(99)70398-2; Barnes NC, 1999, CLIN REV ALLERG IMMU, V17, P27, DOI 10.1007/BF02737595; BARNES PJ, 1995, CHEST, V107, pS119, DOI 10.1378/chest.107.3_Supplement.119S; Barnes PJ, 1999, NATURE, V402, pB31; Barnes PJ, 1997, PULM PHARMACOL THER, V10, P3, DOI 10.1006/pupt.1997.0074; Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, P1227; Baroody FM, 1999, J APPL PHYSIOL, V86, P659; BAROODY FM, 1994, AM J RESP CRIT CARE, V149, P1457; BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V89, P1065, DOI 10.1016/0091-6749(92)90290-I; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661; BAROODY FM, 1995, EUR ARCH OTO-RHINO-L, V1, pS50; Barrett B, 1999, ALTERN THER HEALTH M, V5, P40; Bartels Joachim, 1997, Rhinology (Utrecht), V35, P171; Bartley J, 1999, AM J RHINOL, V13, P401, DOI 10.2500/105065899781367528; BASCOM R, 1989, J ALLERGY CLIN IMMUN, V84, P338, DOI 10.1016/0091-6749(89)90418-1; Bascom R, 1996, FUND APPL TOXICOL, V29, P86, DOI 10.1006/faat.1996.0009; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406; BASCOM R, 1995, ENVIRON HEALTH PERSP, V103, P1026, DOI 10.2307/3432630; BASCOM R, 1988, Journal of Allergy and Clinical Immunology, V81, P580, DOI 10.1016/0091-6749(88)90198-4; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304; BASOMBA A, 1985, ALLERGY, V40, P395, DOI 10.1111/j.1398-9995.1985.tb02677.x; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BATEMAN DN, 1983, EUR J CLIN PHARMACOL, V25, P567, DOI 10.1007/BF00542130; Baudoin T, 1999, AM J RHINOL, V13, P229, DOI 10.2500/105065899781389786; BAUER GE, 1973, MED J AUSTRALIA, V1, P930; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; Bauman A, 1996, BRIT MED J, V312, P590; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P1323; BAUMGARTEN CR, 1986, J IMMUNOL, V137, P977; Baumgarten CR, 1997, CLIN EXP ALLERGY, V27, P1322; BAUMGARTEN CR, 1985, J CLIN INVEST, V76, P191, DOI 10.1172/JCI111945; BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; Baur X, 1998, J ALLERGY CLIN IMMUN, V102, P984, DOI 10.1016/S0091-6749(98)70337-9; Baur X, 1996, CLIN EXP ALLERGY, V26, P232, DOI 10.1111/j.1365-2222.1996.tb00084.x; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; BAUR X, 1992, INT ARCH OCC ENV HEA, V64, P185, DOI 10.1007/BF00380907; Baur X, 1999, INT ARCH OCC ENV HEA, V72, P292, DOI 10.1007/s004200050377; Baur X, 1997, ALLERGY, V52, P306, DOI 10.1111/j.1398-9995.1997.tb00995.x; Bavbek S, 1999, J ASTHMA, V36, P657, DOI 10.3109/02770909909055417; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BEAUMONT F, 1984, ANN ALLERGY, V53, P486; Beaven M A, 1978, Monogr Allergy, V13, P1; BECHTOLD WE, 1993, J EXPO ANAL ENV EPID, V3, P371; BECK RA, 1992, ARCH INTERN MED, V152, P1242, DOI 10.1001/archinte.152.6.1242; BECKER S, 1993, AM J RESP CELL MOL, V8, P20; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BELAICH S, 1990, ANN ALLERGY, V64, P191; Bellioni P., 1996, Rhinology (Utrecht), V34, P101; BELLIONI P, 1988, Rhinology (Utrecht), V26, P281; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; BENAVIDES J, 1995, ARZNEIMITTEL-FORSCH, V45-1, P551; BENDE M, 1986, J LARYNGOL OTOL, V100, P285, DOI 10.1017/S0022215100099151; BENDE M, 1985, ORL J OTO-RHINO-LARY, V47, P303; Benninger MS, 1997, ARCH OTOLARYNGOL, V123, P1175; Benninger MS, 1997, AM J RHINOL, V11, P177, DOI 10.2500/105065897782537205; Bentley AM, 1996, CLIN EXP ALLERGY, V26, P909, DOI 10.1046/j.1365-2222.1996.d01-389.x; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENVENISTE J, 1981, CLIN ALLERGY, V11, P1, DOI 10.1111/j.1365-2222.1981.tb01559.x; Berdeaux G, 1998, QUAL LIFE RES, V7, P501, DOI 10.1023/A:1008874324258; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Berger G, 1997, AM J RHINOL, V11, P63, DOI 10.2500/105065897781446775; Berger G, 1997, AM J RHINOL, V11, P233, DOI 10.2500/105065897781751875; Berger G, 1999, AM J RHINOL, V13, P473, DOI 10.2500/105065899781329728; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; BERKOWITZ RB, 1989, ANN ALLERGY, V63, P336; Bernardini R, 1998, J UROLOGY, V160, P1775, DOI 10.1016/S0022-5347(01)62403-0; Bernd LAG, 1996, J INVEST ALLERG CLIN, V6, P94; Bernstein DI, 1996, J ALLERGY CLIN IMMUN, V97, P749, DOI 10.1016/S0091-6749(96)80151-5; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bernstein IL, 1999, ENVIRON HEALTH PERSP, V107, P575, DOI 10.2307/3434400; BERNSTEIN IL, 1988, J ALLERGY CLIN IMMUN, V82, P487, DOI 10.1016/0091-6749(88)90958-X; BERNSTEIN JM, 1993, OTOLARYNG HEAD NECK, V109, P611; Berrens L, 1978, Clin Allergy, V8, P311, DOI 10.1111/j.1365-2222.1978.tb03229.x; Berrettini S, 1999, ALLERGY, V54, P242, DOI 10.1034/j.1398-9995.1999.00813.x; Bertoni M, 1999, ANN ALLERG ASTHMA IM, V82, P47, DOI 10.1016/S1081-1206(10)62659-2; Bertrand B., 1996, Rhinology (Utrecht), V34, P91; Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/0165-6147(96)10027-4; BERUL CI, 1995, CIRCULATION, V91, P2220; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; BHATIA M, 1991, CURR MED RES OPIN, V12, P287, DOI 10.1185/03007999109112663; BHATTI JZ, 1989, CLIN EXP ALLERGY, V19, P609, DOI 10.1111/j.1365-2222.1989.tb02754.x; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; BIEWENGA J, 1991, ANN CLIN BIOCHEM, V28, P260; BIGLIN KE, 1994, ANN PHARMACOTHER, V28, P282; Bijl-Hofland ID, 1999, THORAX, V54, P15; BIKHAZI P, 1995, LARYNGOSCOPE, V105, P629, DOI 10.1288/00005537-199506000-00013; BINDER E, 1982, ALLERGY, V37, P389, DOI 10.1111/j.1398-9995.1982.tb02317.x; BIRCHALL MA, 1995, CLIN OTOLARYNGOL, V20, P204, DOI 10.1111/j.1365-2273.1995.tb01848.x; Bircher AJ, 1996, BRIT J DERMATOL, V135, P310, DOI 10.1111/j.1365-2133.1996.tb01169.x; BIRCHER AJ, 1995, CLIN EXP ALLERGY, V25, P228, DOI 10.1111/j.1365-2222.1995.tb01033.x; Bischoff ERC, 1996, CLIN EXP ALLERGY, V26, P945, DOI 10.1111/j.1365-2222.1996.tb00631.x; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; BJORKSTEN F, 1980, ALLERGY, V35, P671, DOI 10.1111/j.1398-9995.1980.tb02020.x; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BLACK JW, 1972, NATURE, V236, P385, DOI 10.1038/236385a0; BLAIR H, 1975, Clinical Allergy, V5, P139, DOI 10.1111/j.1365-2222.1975.tb01846.x; BLAIR H, 1973, Clinical Allergy, V3, P283, DOI 10.1111/j.1365-2222.1973.tb01335.x; BLANC P, 1999, LUNG BIOL HLTH DIS, V138, P55; *BLAX INC, 1992, NAT ASTHM CAMP; BLEECKER ER, 1998, CLIN EXP ALLERGY   S, V5, P6; Blom HM, 1997, J ALLERGY CLIN IMMUN, V100, P739, DOI 10.1016/S0091-6749(97)70267-7; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Blom HM, 1998, CLIN EXP ALLERGY, V28, P1351; Bluestone C, 1996, PEDIAT OTOLARYNGOLOG, P533; BLUMENTHAL M, 1992, AM J OPHTHALMOL, V113, P56; BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; BOCCAGNI P, 1994, INT J CLIN LAB RES, V24, P102, DOI 10.1007/BF02593909; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1986, J ALLERGY CLIN IMMUN, V78, P165, DOI 10.1016/0091-6749(86)90009-6; BOERNER D, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1356; Boesiger J, 1998, J EXP MED, V188, P1135, DOI 10.1084/jem.188.6.1135; BOGGS PB, 1989, ANN ALLERGY, V63, P616; BOJKOWSKI CJ, 1989, J INT MED RES, V17, pB54; BOLAND N, 1977, IRISH MED J, V70, P333; Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604; BOLGER WE, 1992, OTOLARYNG CLIN N AM, V25, P791; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Bonavia M, 1996, EUR RESPIR J, V9, P905, DOI 10.1183/09031936.96.09050905; BONER A, 1995, ALLERGY, V50, P498, DOI 10.1111/j.1398-9995.1995.tb01185.x; BONINI S, 1990, J ALLERGY CLIN IMMUN, V86, P869, DOI 10.1016/S0091-6749(05)80148-4; Bonini S, 1999, CURR PROBL DERMATOL, V28, P88; BONINI S, 1992, J ALLERGY CLIN IMMUN, V89, P103, DOI 10.1016/S0091-6749(05)80046-6; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BONINI S, 1989, INT ARCH ALLER A IMM, V88, P144; Bonini S, 1998, ALLERGY AND ALLERGIC DISEASES, P509; Bonini S, 1997, ALLERGY, V52, P44; BONINI S, 1987, CHIBRET INT J OPHTHA, V5, P12; Borchers AT, 1997, AM J CLIN NUTR, V66, P1303; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; BORISH L, 1991, J IMMUNOL, V146, P63; Born W, 1999, Adv Immunol, V71, P77; BORUM P, 1979, CLIN OTOLARYNGOL, V4, P407, DOI 10.1111/j.1365-2273.1979.tb01773.x; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; BORUM P, 1987, ALLERGY, V42, P26, DOI 10.1111/j.1398-9995.1987.tb02183.x; Botey J, 1999, Pediatr Pulmonol Suppl, V18, P157; Botros HG, 1996, IMMUNOLOGY, V88, P340; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1046/j.1365-2222.1997.d01-418.x; BOULET LP, 1993, J ALLERGY CLIN IMMUN, V91, P883, DOI 10.1016/0091-6749(93)90346-H; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; Bousquet J, 1998, CLIN EXP ALLERGY, V28, P49; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1991, CLIN REV ALLERG, V9, P357; BOUSQUET J, 1986, CLIN ALLERGY, V16, P57, DOI 10.1111/j.1365-2222.1986.tb01954.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1985, CLIN ALLERGY, V15, P29, DOI 10.1111/j.1365-2222.1985.tb02251.x; BOUSQUET J, 1994, DRUG SAFETY, V10, P5; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; Bousquet J, 1999, ALLERGY, V54, P562, DOI 10.1034/j.1398-9995.1999.00984.x; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V75, P70, DOI 10.1016/0091-6749(85)90015-6; Bousquet J, 1998, ALLERGY, V53, P3; BOUSQUET J, 1993, ALLERGY, V48, P327, DOI 10.1111/j.1398-9995.1993.tb02401.x; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P881, DOI 10.1016/0091-6749(88)90094-2; BOUSQUET J, 1992, EUR RESPIR J, V5, P1137; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 1996, ALLERGY, V51, P251, DOI 10.1111/j.1398-9995.1996.tb04601.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; BOUSQUET J, 1990, ANN ALLERGY, V65, P504; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P248, DOI 10.1016/S0091-6749(05)80072-7; Bousquet J, 1998, ALLERGY, V53, P579, DOI 10.1111/j.1398-9995.1998.tb03933.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; Bousquet J, 1996, INT ARCH ALLERGY IMM, V110, P207; BOUSQUET J, 1996, FOOD ALLERGY ADVERSE, P235; BOUSQUET J, 1996, IMMUNOPHARMACOLOGY A, P263; BOUSQUET J, 1998, ALLERGY S54, V53; BOUSQUET J, 1992, THERAPEUTIC INDEX AN, P57; Bousquet J, 1997, ACI INT, V9, P10; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; Bovet D, 1944, CR SOC BIOL, V138, P99; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BRABACK L, 1988, ACTA PAEDIATR SCAND, V77, P821, DOI 10.1111/j.1651-2227.1988.tb10762.x; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1900; BRADDING P, 1995, CLIN EXP ALLERGY, V25, P406, DOI 10.1111/j.1365-2222.1995.tb01071.x; BRADDING P, 1995, J IMMUNOL, V155, P297; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRADLEY JG, 1991, POSTGRAD MED, V89, P195; BRANDES LJ, 1994, J NATL CANCER I, V86, P770, DOI 10.1093/jnci/86.10.770; BRANDTZAEG P, 1995, EUR ARCH OTO-RHINO-L, V1, pS8; BRANNAN MD, 1995, CLIN PHARMACOL THER, V58, P269, DOI 10.1016/0009-9236(95)90243-0; Brannan MD, 1997, CLIN THER, V19, P1330, DOI 10.1016/S0149-2918(97)80008-2; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; Braun JJ, 1997, ALLERGY, V52, P650, DOI 10.1111/j.1398-9995.1997.tb01044.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; BRAUNSTEIN G, 1992, BRIT J CLIN PHARMACO, V33, P445; BRAUNSTEIN G, 1991, AM REV RESPIR DIS, V144, P630; Breborowicz A, 1995, Pneumonol Alergol Pol, V63, P157; Brehler R, 1998, ALLERGY, V53, P402, DOI 10.1111/j.1398-9995.1998.tb03912.x; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BRENEMAN D, 1995, J AM ACAD DERMATOL, V33, P192, DOI 10.1016/0190-9622(95)90233-3; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; Brille D, 1962, EUROPEAN COAL STEEL; Brisman J, 1998, INT ARCH OCC ENV HEA, V71, P525, DOI 10.1007/s004200050318; Brisman J, 1999, EUR RESPIR J, V13, P502, DOI 10.1183/09031936.99.13350299; BROADHURST P, 1993, BRIT HEART J, V70, P469; BRODER I, 1974, J ALLERGY CLIN IMMUN, V53, P127, DOI 10.1016/0091-6749(74)90001-3; BROFELDT S, 1986, AM REV RESPIR DIS, V133, P1138; BROGDEN RN, 1991, DRUGS, V41, P927; BROGDEN RN, 1992, DRUGS, V44, P375, DOI 10.2165/00003495-199244030-00007; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BROMS P, 1982, ALLERGY, V37, P67, DOI 10.1111/j.1398-9995.1982.tb01879.x; BRONSKY E, 1995, J ALLERGY CLIN IMMUN, V96, P139, DOI 10.1016/S0091-6749(95)70001-3; BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6; Bronsky EA, 1997, ANN ALLERG ASTHMA IM, V79, P51; Bronsky EA, 1996, J ALLERGY CLIN IMMUN, V97, P915, DOI 10.1016/S0091-6749(96)80065-0; Bronsky EA, 1998, ALLERGY ASTHMA PROC, V19, P135, DOI 10.2500/108854198778604112; BROOKHUIS KA, 1993, BRIT J CLIN PHARMACO, V36, P67; BROOKS CD, 1988, ANN ALLERGY, V61, P151; BROOKS CD, 1984, J ALLERGY CLIN IMMUN, V73, P584, DOI 10.1016/0091-6749(84)90515-3; BROOKS CD, 1988, J ALLERGY CLIN IMMUN, V81, P1110, DOI 10.1016/0091-6749(88)90877-9; BROOKS CD, 1990, CLIN EXP ALLERGY, V20, P21, DOI 10.1111/j.1365-2222.1990.tb02770.x; BROOKS CD, 1993, J CLIN PHARMACOL, V33, P816; BROWN BL, 1979, ARCH OTOLARYNGOL, V105, P413; BROWN HM, 1991, ANN ALLERGY, V67, P25; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BRUIJNZEEL PLB, 1990, BRIT J PHARMACOL, V99, P798; Brunekreef B, 1999, CLIN EXP ALLERGY, V29, P433; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; BRUTTMANN G, 1989, ACTA THERAP, V15, P99; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; BRUTTMANN G, 1987, J INT MED RES, V15, P63; BRUTTMANN G, 1989, J ALLERGY CLIN IMMUN, V83, P411, DOI 10.1016/0091-6749(89)90127-9; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; Buchheit KH, 1999, PULM PHARMACOL THER, V12, P103, DOI 10.1006/pupt.1999.0183; BUCHOLTZ GA, 1985, ANN ALLERGY, V55, P805; BUCHOLTZ GA, 1991, ANN ALLERGY, V67, P534; Bufe A, 1996, PLANTA, V199, P413; Bukstein DA, 1996, ALLERGY, V51, P20; BUNNAG C, 1992, ALLERGY, V47, P313, DOI 10.1111/j.1398-9995.1992.tb02060.x; BUNNAG C, 1976, P INT S INF ALL NOS, P273; Burches E, 1996, CLIN EXP ALLERGY, V26, P1262, DOI 10.1046/j.1365-2222.1996.d01-286.x; Burdach S, 1998, Curr Opin Hematol, V5, P177, DOI 10.1097/00062752-199805000-00005; Burks W, 1999, INT ARCH ALLERGY IMM, V119, P165, DOI 10.1159/000024191; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURNS M, 1980, EUR J CLIN PHARMACOL, V17, P259, DOI 10.1007/BF00625799; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Burr M L, 1999, Pediatr Pulmonol Suppl, V18, P3; Burr ML, 1999, THORAX, V54, P27; Burrows PD, 1997, CURR OPIN IMMUNOL, V9, P239, DOI 10.1016/S0952-7915(97)80142-2; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; BUSSE W, 1989, J ALLERGY CLIN IMMUN, V83, P400, DOI 10.1016/0091-6749(89)90125-5; BUSSE WW, 1994, AM J RESP CRIT CARE, V150, pS77; Busse WW, 1996, AM J RESP CRIT CARE, V153, P122; Busse WW, 1996, CLIN EXP ALLERGY, V26, P868, DOI 10.1046/j.1365-2222.1996.d01-390.x; BUSTOS GJ, 1995, CLIN EXP ALLERGY, V25, P568, DOI 10.1111/j.1365-2222.1995.tb01096.x; Butland BK, 1997, BRIT MED J, V315, P717; Caballero T, 1996, CLIN EXP ALLERGY, V26, P197, DOI 10.1111/j.1365-2222.1996.tb00080.x; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)81046-9; CalderonGarciduenas L, 1997, ENVIRON MOL MUTAGEN, V30, P11, DOI 10.1002/(SICI)1098-2280(1997)30:1<11::AID-EM3>3.0.CO;2-F; CALDERONGARCIDUENAS L, 1992, AM J PATHOL, V140, P225; CALDERONGARCIDUENAS L, 1994, ENVIRON HEALTH PERSP, V102, P1074, DOI 10.2307/3431995; CALDERONGARCIDUENAS L, 1993, ENVIRON HEALTH PERSP, V101, P138, DOI 10.2307/3431423; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661; CAMERON AW, 1984, BRIT MED J, V288, P1881; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330; Campbell A, 1997, ALLERGY, V52, P1022, DOI 10.1111/j.1398-9995.1997.tb02425.x; CAMPBELL A, 1996, DRUGS, V1, P15; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529; CAMPBELL AM, 1993, ALLERGY, V48, P125, DOI 10.1111/j.1398-9995.1993.tb00697.x; Campbell AM, 1998, AM J RESP CELL MOL, V19, P92; CAMPBELL AM, 1994, IMMUNOLOGY, V82, P506; CAMPBELL M, 1992, CLIN PHARMACOKINET, V23, P147; CAMPOLIRICHARDS DM, 1990, DRUGS, V40, P762, DOI 10.2165/00003495-199040050-00009; CANONICA GW, 1994, ALLERGY, V49, P135, DOI 10.1111/j.1398-9995.1994.tb00815.x; CANONICA GW, 1995, INT ARCH ALLERGY IMM, V107, P99; CAPLIN I, 1971, ANN ALLERGY, V29, P631; CAPRON M, 1991, EUR J IMMUNOL, V21, P2423, DOI 10.1002/eji.1830211019; CAPRON M, 1995, ALLERGY, V50, P20, DOI 10.1111/j.1398-9995.1995.tb04270.x; Capron M, 1997, RES IMMUNOL, V148, P29, DOI 10.1016/S0923-2494(97)86271-2; CARABALLO L, 1994, CLIN EXP ALLERGY, V24, P1056, DOI 10.1111/j.1365-2222.1994.tb02743.x; CARLSEN K, 1977, TIDSSKR NOR LAEGEFOR, V97, P1261; CARLSEN KH, 1993, ALLERGY, V48, P431, DOI 10.1111/j.1398-9995.1993.tb00741.x; Carmeliet E, 1998, BRIT J PHARMACOL, V124, P663, DOI 10.1038/sj.bjp.0701879; CARNIMEO N, 1981, ALLERGOL IMMUNOPATH, V9, P1; CARR AA, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1157; Carroll MA, 1996, AM J PHYSIOL-REG I, V271, pR863; Casale TB, 1999, ALLERGY ASTHMA PROC, V20, P193, DOI 10.2500/108854199778553046; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; CASALE TB, 1989, J ALLERGY CLIN IMMUN, V83, P771, DOI 10.1016/0091-6749(89)90013-4; CASTELLS M, 1988, J ALLERGY CLIN IMMUN, V82, P348, DOI 10.1016/0091-6749(88)90005-X; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Cave A, 1999, PHARMACOL THERAPEUT, V83, P153, DOI 10.1016/S0163-7258(99)00019-4; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cervin A, 1999, AM J RESP CRIT CARE, V160, P1724; Cervin Anders, 1998, Rhinology (Utrecht), V36, P128; Chachin M, 1999, EUR J PHARMACOL, V374, P457, DOI 10.1016/S0014-2999(99)00375-1; CHAEN T, 1993, ANN OTO RHINOL LARYN, V102, P16; CHAI H, 1968, J ALLERGY, V41, P23, DOI 10.1016/0021-8707(68)90005-1; Chakir J, 1996, LAB INVEST, V75, P735; Challita-Eid PM, 1998, J IMMUNOL, V160, P3419; [Anonymous], 1993, ALLERGY, V48, P48; HENNEE WR, 1987, JAMA-J AM MED ASSOC, V258, P1363; International Consensus Report on Diagnosis and Management of Rhinitis, 1994, ALLERGY S, V49, P1; Kemp JP, 1996, J ALLERGY CLIN IMMUN, V97, P1218; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Medical Research Council, 1960, BRIT MED J, V2, P1665; *NAT I HLTH, 1995, PUBL NIH; 1972, LANCET, V2, P1239; 1994, FDA TALK PAPER  0517; 1996, MED LETT DRUGS THER, V38, P95; [Anonymous], 1991, AM REV RESP DIS, V144, P1202; [Anonymous], 1997, OTOLARYNGOL HEAD NEC, V117, pS1; 1997, EUROPEAN PHARMACOPEI, P1063; 1990, J ALLERGY CLIN IMMUN, V85, P526; [Anonymous], 1997, AM J HLTH SYST PHARM, V54, P342; 1994, J PEDIAT, V125, P628; 1998, PED ALLERGY IMMUNOL, V9, P116; [Anonymous], 1993, DERMATOLOGY, V186, P23; [Anonymous], 1997, NIH PUBLICATION; 1992, ALLERGY S, V47, P1; 1989, ALLERTY, V44, P369; 1992, LANCET, V340, P85; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; CHANAL I, 1988, J ALLERGY CLIN IMMUN, V82, P878, DOI 10.1016/0091-6749(88)90093-0; CHAND N, 1985, INT ARCH ALLER A IMM, V77, P451; CHAND N, 1985, AGENTS ACTIONS, V16, P318, DOI 10.1007/BF01982866; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588; CHANEZ P, 1994, J ALLERGY CLIN IMMUN, V94, P997, DOI 10.1016/0091-6749(94)90118-X; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; CHANONA NR, 1986, ALERGIA, V33, P9; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHARLESWORTH EN, 1989, J ALLERGY CLIN IMMUN, V83, P905, DOI 10.1016/0091-6749(89)90104-8; Charpin D, 1996, ALLERGY, V51, P293, DOI 10.1111/j.1398-9995.1996.tb04612.x; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Chaufour S, 1998, INT J CLIN PHARM TH, V36, P286; Chaufour S, 1999, BRIT J CLIN PHARMACO, V47, P515; Chen PC, 1998, ENVIRON HEALTH PERSP, V106, P331, DOI 10.1289/ehp.98106331; Cherkin DC, 1998, NEW ENGL J MED, V339, P1021, DOI 10.1056/NEJM199810083391502; Chervinsky P, 1996, CLIN THER, V18, P790, DOI 10.1016/S0149-2918(96)80039-7; Chew FT, 1999, ALLERGY, V54, P1150, DOI 10.1034/j.1398-9995.1999.00050.x; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CHURCH MK, 1980, AGENTS ACTIONS, V10, P4, DOI 10.1007/BF02024171; CHURCHILL L, 1991, INT ARCH ALLER A IMM, V95, P322; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653; Ciprandi G, 1998, CLIN EXP ALLERGY, V28, P293; CIPRANDI G, 1994, INT ARCH ALLERGY IMM, V104, P92; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; Ciprandi G, 1997, J INVEST ALLERG CLIN, V7, P557; CIPRANDI G, 1995, CLIN EXP ALLERGY, V25, P871, DOI 10.1111/j.1365-2222.1995.tb00030.x; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; Ciprandi G, 1996, J ALLERGY CLIN IMMUN, V98, P1088, DOI 10.1016/S0091-6749(96)80196-5; Ciprandi G, 1996, Int Arch Allergy Immunol, V111, P278; CIPRANDI G, 1993, INT ARCH ALLERGY IMM, V100, P185; CIPRANDI G, 1993, EUR J CLIN PHARMACOL, V45, pS35, DOI 10.1007/BF01844202; CIPRANDI G, 1991, INT ARCH ALLER A IMM, V96, P344; CIPRANDI G, 1992, ALLERGY, V47, P309, DOI 10.1111/j.1398-9995.1992.tb02059.x; Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P182; CIPRANDI G, 1995, ANN ALLERG ASTHMA IM, V75, P446; CIPRANDI G, 1993, INT ACAD B, V6, P115; Ciprandi G, 1998, ALLERGY, V53, P545, DOI 10.1111/j.1398-9995.1998.tb04099.x; Ciprandi G, 1997, ANN ALLERG ASTHMA IM, V79, P507; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; Ciprandi G, 1999, ALLERGY, V54, P358, DOI 10.1034/j.1398-9995.1999.00920.x; Ciprandi G, 1997, CLIN EXP ALLERGY, V27, P1160; Ciprandi G, 1999, CLIN EXP ALLERGY, V29, P49, DOI 10.1046/j.1365-2222.1999.00012.x; CIPRANDI G, 1997, J ALLERGY CLIN IMMUN; Cirla AM, 1996, ALLERGY, V51, P299, DOI 10.1111/j.1398-9995.1996.tb04613.x; CLARK EA, 1994, NATURE, V367, P425, DOI 10.1038/367425a0; CLARKE RW, 1994, CLIN OTOLARYNGOL, V19, P502, DOI 10.1111/j.1365-2273.1994.tb01277.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Clement P A, 1984, Rhinology, V22, P151; CLEMENT PAR, 1981, CLIN ALLERGY, V11, P293, DOI 10.1111/j.1365-2222.1981.tb01597.x; Clement PAR, 1997, ALLERGY, V52, P26; CLEMENT PAR, 1984, ORL J OTO-RHINO-LARY, V46, P173; CLISSOLD SP, 1989, DRUGS, V37, P42; Cockburn IM, 1999, J OCCUP ENVIRON MED, V41, P948, DOI 10.1097/00043764-199911000-00005; COCKCROFT DW, 1977, J ALLERGY CLIN IMMUN, V60, P56, DOI 10.1016/0091-6749(77)90083-5; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; COHAN RH, 1976, J ALLERGY CLIN IMMUN, V58, P121, DOI 10.1016/0091-6749(76)90147-0; COHEN AF, 1987, EUR J CLIN PHARMACOL, V32, P279, DOI 10.1007/BF00607576; COHEN B, 1996, DRUGS, V1, P26; Cohen S, 1993, Ocul Immunol Inflamm, V1, P19, DOI 10.3109/09273949309086531; COLLOFF MJ, 1991, CLIN EXP ALLERGY, V21, P225, DOI 10.1111/j.1365-2222.1991.tb00834.x; COLLOFF MJ, 1995, CLIN EXP ALLERGY, V25, P1061, DOI 10.1111/j.1365-2222.1995.tb03252.x; COLLOFF MJ, 1991, EXP APPL ACAROL, V11, P177, DOI 10.1007/BF01246090; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V2, P1; Come J., 1997, J CLIN INVEST, V99, P879; CONLEY SF, 1994, ANN ALLERGY, V72, P529; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; COOKE R, 1919, J IMMUNOL, V1, P201; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1989, LANCET, V1, P1292; CORBI AL, 1985, INT ARCH ALLER A IMM, V77, P377; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; COREY JP, 1994, AM J OTOLARYNG, V15, P138, DOI 10.1016/0196-0709(94)90063-9; COREY JP, 1993, OTOLARYNG HEAD NECK, V109, P584; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; CORRADO OJ, 1986, THORAX, V41, P863, DOI 10.1136/thx.41.11.863; Correia I, 1996, BIOCHEM PHARMACOL, V52, P413, DOI 10.1016/0006-2952(96)00243-2; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Corren J, 1997, J ALLERGY CLIN IMMUN, V99, pS781, DOI 10.1016/S0091-6749(97)70127-1; Corren J, 1998, J ALLERGY CLIN IMMUN, V101, pS352, DOI 10.1016/S0091-6749(98)70218-0; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Corsico R, 1998, ANN ALLERG ASTHMA IM, V80, P71; Costa JJ, 1997, JAMA-J AM MED ASSOC, V278, P1815, DOI 10.1001/jama.278.22.1815; Costa JJ, 1996, J EXP MED, V183, P2681, DOI 10.1084/jem.183.6.2681; Costongs GMPJ, 1997, EUR J CLIN CHEM CLIN, V35, P885; Couto J S, 1998, J Eval Clin Pract, V4, P267; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; COX JSG, 1967, NATURE, V216, P1328, DOI 10.1038/2161328a0; CRAFT TM, 1986, BRIT MED J, V292, P660; CRAIG S, 1977, CLIN ALLERGY, V7, P569, DOI 10.1111/j.1365-2222.1977.tb01487.x; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633; Crampette L, 1996, ALLERGY, V51, P346, DOI 10.1111/j.1398-9995.1996.tb00098.x; CRANE JK, 1993, AM J MED, V95, P445, DOI 10.1016/0002-9343(93)90317-I; CRANSTON PS, 1983, ANN TROP MED PARASIT, V77, P527; Crater SE, 1999, AM J ROENTGENOL, V173, P127; Creticos P, 1998, ALLERGY ASTHMA PROC, V19, P285, DOI 10.2500/108854198778557692; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Crobach M, 1996, SCAND J PRIM HEALTH, V14, P116, DOI 10.3109/02813439608997081; Crobach MJJS, 1998, SCAND J PRIM HEALTH, V16, P30; CROBACH MJJS, 1994, ALLERGY, V49, P170, DOI 10.1111/j.1398-9995.1994.tb00821.x; CROCKETT AJ, 1995, J PAEDIATR CHILD H, V31, P213, DOI 10.1111/j.1440-1754.1995.tb00788.x; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; CROMWELL O, 1997, ALLERGY ALLERGIC DIS, P797; Cupp MJ, 1999, AM FAM PHYSICIAN, V59, P1239; Cuss FM, 1998, ALLERGY, V53, P89; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1243, DOI 10.1046/j.1365-2222.1996.d01-276.x; CUSTOVIC A, 1994, CLIN EXP ALLERGY, V24, P1164; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1046/j.1365-2222.1996.d01-278.x; CVITANOVIC S, 1986, ALLERGY, V41, P543, DOI 10.1111/j.1398-9995.1986.tb00341.x; CVITANOVIC S, 1993, ALLERGY, V48, P592, DOI 10.1111/j.1398-9995.1993.tb00754.x; CZERNIAWSKAMYSIK G, 1981, ALLERGY, V36, P381, DOI 10.1111/j.1398-9995.1981.tb01842.x; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; DACHMAN WD, 1994, J ALLERGY CLIN IMMUN, V93, P606, DOI 10.1016/S0091-6749(94)70072-9; Dahinden CA, 1997, INT ARCH ALLERGY IMM, V113, P134; Dahl R., 1995, Rhinology (Utrecht), V33, P121; Dahl R, 1998, CLIN EXP ALLERGY, V28, P17; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187; Dahlen B, 1998, RESP MED, V92, P378, DOI 10.1016/S0954-6111(98)90279-7; Dale HH, 1910, J PHYSIOL-LONDON, V41, P318; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P149, DOI 10.1111/j.1365-2222.1995.tb01020.x; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P141, DOI 10.1111/j.1365-2222.1995.tb01019.x; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; DAMON M, 1989, EUR RESPIR J, V2, P202; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Danielsson J, 1997, ALLERGY, V52, P331, DOI 10.1111/j.1398-9995.1997.tb00999.x; DANJOU P, 1992, BRIT J CLIN PHARMACO, V34, P328; DANNAEUS A, 1981, CLIN ALLERGY, V11, P533, DOI 10.1111/j.1365-2222.1981.tb02171.x; DARNELL R, 1994, CLIN EXP ALLERGY, V24, P1144; Davidsson Ake, 1994, Rhinology (Utrecht), V32, P184; Davies A, 1998, ALTERN THER HEALTH M, V4, P70; DAVIES BH, 1993, ALLERGY, V48, P519, DOI 10.1111/j.1398-9995.1993.tb01108.x; Davies R. J., 1993, Rhinology (Utrecht), V31, P159; Davies RJ, 1997, CLIN THER, V19, P27; DAVIES RJ, 1998, CLIN EXP ALLERGY, V6, P8; DAVIS FM, 1993, SPRINGER SEMIN IMMUN, V15, P51; Davis PA, 1998, J INVEST ALLERG CLIN, V8, P73; DAX EM, 1990, ANN ALLERGY, V64, P261; Day J, 1998, J ALLERGY CLIN IMMUN, V102, P902, DOI 10.1016/S0091-6749(98)70326-4; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163; Day JH, 1996, J ALLERGY CLIN IMMUN, V97, P1050, DOI 10.1016/S0091-6749(96)70257-9; Day JH, 1998, J ALLERGY CLIN IMMUN, V101, P638; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P533; DAY JH, 1990, ANN ALLERGY, V64, P445; DAYER JM, 1994, EUR CYTOKINE NETW, V5, P563; de Benedictis FM, 1999, CHEST, V115, P550, DOI 10.1378/chest.115.2.550; De Graaf-In't Veld C., 1996, Clinical and Experimental Allergy, V26, P903, DOI 10.1046/j.1365-2222.1996.d01-395.x; de Graaf-in 't Veld T, 1995, Ann Allergy Asthma Immunol, V75, P261; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; De Waal Malefy Rene, 1995, International Immunology, V7, P1405; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334; DEBLAY F, 1993, J ALLERGY CLIN IMMUN, V92, P255, DOI 10.1016/0091-6749(93)90169-G; deBruinWeller MS, 1996, EUR RESPIR J, V9, P1701, DOI 10.1183/09031936.96.09081701; DECHANT KL, 1991, DRUGS, V41, P202; deGraafintVeld C, 1997, THORAX, V52, P143; deGraafintVeld T, 1996, J ALLERGY CLIN IMMUN, V98, P508, DOI 10.1016/S0091-6749(96)70083-0; Deichmann KA, 1999, J MED GENET, V36, P379; Del Prete G, 1998, Int Rev Immunol, V16, P427, DOI 10.3109/08830189809043004; DELACUADRA J, 1994, DERMATOLOGY, V188, P131; DELAUCHECAVALLI.MC, 1999, CLIN EXP ALLERGY, V3, P206; DELCARPIO J, 1989, J ALLERGY CLIN IMMUN, V84, P741; DELGADO J, 1994, CLIN EXP ALLERGY, V24, P477, DOI 10.1111/j.1365-2222.1994.tb00937.x; DELNESTE Y, 1995, CLIN EXP IMMUNOL, V101, P164; DELNESTE Y, 1994, CLIN EXP IMMUNOL, V98, P344; de Molina M, 1989, DRUG INVEST, V1, P40; Demoly P, 1997, CLIN EXP ALLERGY, V27, P672; Demoly P, 1998, CLIN EXP ALLERGY, V28, P731, DOI 10.1046/j.1365-2222.1998.00308.x; DEMOLY P, 1991, J ALLERGY CLIN IMMUN, V88, P758, DOI 10.1016/0091-6749(91)90183-O; Demoly P, 1999, CURR PROBL DERMATOL, V28, P119; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Demoly P, 1998, CLIN EXP ALLERGY, V28, P278; Demoly P, 1998, ALLERGY PRINCIPLES P, P530; DEMOLY P, 1999, CLIN EXP ALLERGY, V3, P72; Denburg JA, 1999, IMMUNOL TODAY, V20, P111, DOI 10.1016/S0167-5699(98)01423-6; DENBURG JA, 1994, J ALLERGY CLIN IMMUN, V94, P1135, DOI 10.1016/0091-6749(94)90321-2; DEPOORTERE H, 1995, NEUROPSYCHOBIOLOGY, V32, P214, DOI 10.1159/000119238; DEREBERY MJ, 1993, OTOLARYNG CLIN N AM, V26, P593; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Desrosiers M, 1997, J ALLERGY CLIN IMMUN, V99, P77; Desrosiers M, 1996, ANN OTO RHINOL LARYN, V105, P146; DEUSCHL H, 1977, CLIN ALLERGY, V7, P195, DOI 10.1111/j.1365-2222.1977.tb01442.x; Dev S, 1999, ENVIRON HEALTH PERSP, V107, P783, DOI 10.2307/3454574; Devalia JL, 1999, INT ARCH ALLERGY IMM, V118, P437, DOI 10.1159/000024157; Devillier P, 1999, PHARMACOL RES, V40, P3, DOI 10.1006/phrs.1998.0458; DEVILLIER P, 1988, EUR RESPIR J, V1, P356; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811; DEVRIES JE, 1991, RES IMMUNOL, V142, P59, DOI 10.1016/0923-2494(91)90014-A; DEVRIES JE, 1992, CURR OPIN IMMUNOL, V3, P851; Di Lorenzo G, 1999, CLIN EXP ALLERGY, V29, P1367; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DICKSON DJ, 1984, BRIT J CLIN PRACT, V38, P416; Dieu-Nosjean MC, 1999, J LEUKOCYTE BIOL, V66, P252; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Dinarello CA, 1998, ANN NY ACAD SCI, V856, P1, DOI 10.1111/j.1749-6632.1998.tb08307.x; Dinis PB, 1997, AM J RHINOL, V11, P421, DOI 10.2500/105065897780914992; DISCEPOLA M, 1999, ACTA OPHTHALMOL SC S, V228, P43; DIXON CMS, 1989, BRIT J CLIN PHARMACO, V27, P831; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Dockhorn R, 1999, ANN ALLERG ASTHMA IM, V82, P349; Dockhorn RJ, 1996, ANN ALLERG ASTHMA IM, V76, P204; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735; DOHERTY TM, 1995, CURR OPIN IMMUNOL, V7, P400; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; DOLOVICH J, 1994, ANN ALLERGY, V72, P435; DOLOVICH J, 1994, ANN ALLERGY, V73, P235; DOLOVICH J, 1994, ANN ALLERGY, V73, P147; DOLOVICH J, 1987, J ALLERGY CLIN IMMUN, V80, P274, DOI 10.1016/0091-6749(87)90031-5; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; DOMS M, 1988, EUR J CLIN PHARMACOL, V34, P619, DOI 10.1007/BF00615227; DONNELLY A, 1993, J ALLERGY CLIN IMMUN, V91, P997, DOI 10.1016/0091-6749(93)90212-X; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734; Donnelly F, 1999, AVIAT SPACE ENVIR MD, V70, P89; DONNELLY JE, 1987, SOC SCI MED, V24, P431, DOI 10.1016/0277-9536(87)90216-4; DOROW P, 1993, ARZNEIMITTEL-FORSCH, V43-2, P909; DORWARD AJ, 1986, CLIN ALLERGY, V16, P309, DOI 10.1111/j.1365-2222.1986.tb01962.x; DOTTERUD LK, 1994, ACTA DERM-VENEREOL, V74, P124; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; DOULL IJM, 1995, AM J RESP CRIT CARE, V151, P1715; DOYLE WJ, 1985, ARCH OTOLARYNGOL, V111, P502; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; DOYLE WJ, 1985, J ALLERGY CLIN IMMUN, V76, P551, DOI 10.1016/0091-6749(85)90774-2; Drake-Lee A. B., 1994, Rhinology (Utrecht), V32, P1; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P795, DOI 10.1017/S0022215100147474; DRAKELEE AB, 1984, J ROY SOC MED, V77, P120; Drake-Lee AS, 1989, RHINITIS MECH MANAGE, P141; DREBORG S, 1988, ANN ALLERGY, V61, P41; DREBORG S, 1993, ALLERGY S1J, V48; Dreborg S, 1989, ALLERGY S10, V44, P1; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Drouin J, 1998, J STEROID BIOCHEM, V65, P59, DOI 10.1016/S0960-0760(97)00180-5; Drouin M, 1996, ANN ALLERG ASTHMA IM, V77, P153; Drouin MA, 1995, ADV THER, V12, P340; DRUCE HM, 1990, ANN ALLERGY, V65, P212; DSOUZA MF, 1983, CLIN ALLERGY, V13, P329, DOI 10.1111/j.1365-2222.1983.tb02608.x; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Dworski RT, 1997, AM J RESP CRIT CARE, V155, P351; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P469, DOI 10.1016/S1081-1206(10)63153-5; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P463, DOI 10.1016/S1081-1206(10)63152-3; DYKEWICZ MS, 1991, J ALLERGY CLIN IMMUN, V87, P48, DOI 10.1016/0091-6749(91)90212-7; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P474, DOI 10.1016/S1081-1206(10)63154-7; Earle CC, 1999, AM J MED, V106, P263; EATON KK, 1982, CLIN ALLERGY, V12, P107, DOI 10.1111/j.1365-2222.1982.tb03132.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ebner C, 1996, MONOGR ALLERGY, V32, P73; ECCLES R, 1992, CLIN EXP ALLERGY, V22, P319, DOI 10.1111/j.1365-2222.1992.tb03092.x; ECCLES R, 1981, Rhinology (Utrecht), V19, P121; ECCLES R, 1973, J PHYSIOL-LONDON, V230, P213; Eccles R, 1995, EUR ARCH OTO-RHINO-L, V1, pS2; Edelstein DR, 1996, LARYNGOSCOPE, V106, P1, DOI 10.1097/00005537-199609001-00001; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; Edwards TB, 1995, CLIN THER, V17, P1032, DOI 10.1016/0149-2918(95)80082-4; EGESTEN A, 1994, INT ARCH ALLERGY IMM, V104, P207; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; EGGLESTON PA, 1990, J ALLERGY CLIN IMMUN, V86, P63, DOI 10.1016/S0091-6749(05)80124-1; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Einarson A, 1997, ANN ALLERG ASTHMA IM, V78, P183; El-Bayoumy K, 1999, CANCER RES, V59, P1400; ELHENNAWI M, 1994, BRIT J OPHTHALMOL, V78, P365, DOI 10.1136/bjo.78.5.365; Ellegard E, 1999, ARCH OTOLARYNGOL, V125, P1121; Ellegard E, 1999, CLIN OTOLARYNGOL, V24, P307, DOI 10.1046/j.1365-2273.1999.00264.x; ELLEGARD E, 1994, CLIN OTOLARYNGOL, V19, P400, DOI 10.1111/j.1365-2273.1994.tb01256.x; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404; EMORINE LJ, 1987, P NATL ACAD SCI USA, V84, P6995, DOI 10.1073/pnas.84.20.6995; ENBERG RN, 1993, ANN ALLERGY, V70, P471; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; ENERBACK L, 1986, INT ARCH ALLER A IMM, V81, P289; Enerback L, 1997, ALLERGY, V52, P4, DOI 10.1111/j.1398-9995.1997.tb02539.x; ENERBACK L, 1966, ACTA PATHOL MIC SC, V66, P289; ENGLER DB, 1992, J ALLERGY CLIN IMMUN, V90, P985, DOI 10.1016/0091-6749(92)90472-E; ENGLISH GM, 1986, LARYNGOSCOPE, V96, P374; ENGSTROM I, 1971, ANN ALLERGY, V29, P505; Enright PL, 1994, AM J RESP CRIT CAR S, V149, P9; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Erhan Ertugrul, 1996, Tokai Journal of Experimental and Clinical Medicine, V21, P103; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; ERIKSSON NE, 1984, ALLERGY, V39, P610, DOI 10.1111/j.1398-9995.1984.tb01981.x; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; ERIKSSON NE, 1990, ALLERGY, V45, P285, DOI 10.1111/j.1398-9995.1990.tb00497.x; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; Esamai F, 1996, E AFR MED J, V73, P474; Eskola J, 1999, NEW ENGL J MED, V340, P312, DOI 10.1056/NEJM199901283400412; Etzel R., 1999, ENV HLTH PERSPECT, V3, P463; Euler AR, 1998, DIGEST DIS, V16, P111, DOI 10.1159/000016854; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; FADEL R, 1992, ANN ALLERGY, V69, P329; FADEL R, 1987, CLIN ALLERGY, V17, P373, DOI 10.1111/j.1365-2222.1987.tb02027.x; FADEN H, 1989, J INFECT DIS, V160, P999; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; FAIRLEY JW, 1993, CLIN OTOLARYNGOL, V18, P19, DOI 10.1111/j.1365-2273.1993.tb00803.x; Fajac I, 1995, ALLERGY, V50, P970, DOI 10.1111/j.1398-9995.1995.tb02509.x; Falade AG, 1998, E AFR MED J, V75, P695; FALLIERS CJ, 1991, ANN ALLERGY, V66, P257; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; FARAJ BA, 1992, ALLERGY, V47, P630, DOI 10.1111/j.1398-9995.1992.tb02386.x; Fasce L, 1996, INT ARCH ALLERGY IMM, V109, P272; FEDOROV A, 1997, STRUCTURE, V15, P33; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; FERGUSON BJ, 1995, POSTGRAD MED, V97, P45; FERGUSON BJ, 1995, POSTGRAD MED, V97, P5; FERGUSON BJ, 1995, POSTGRAD MED, V97, P51; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FernandezRivas M, 1997, ALLERGY, V52, P196, DOI 10.1111/j.1398-9995.1997.tb00974.x; Feroze H, 1996, PACE, V19, P1519, DOI 10.1111/j.1540-8159.1996.tb03169.x; Ferreira F, 1998, FASEB J, V12, P231; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; Ferrer M, 1998, J INVEST ALLERG CLIN, V8, P17; FIELDS DAS, 1984, J ALLERGY CLIN IMMUN, V73, P400, DOI 10.1016/0091-6749(84)90415-9; Filiaci F, 1999, Allergol Immunopathol (Madr), V27, P24; Findlay CA, 1998, BRIT MED J, V317, P739; FINDLAY S, 1992, ANN ALLERGY, V68, P228; Finn AF, 1998, AM J RHINOL, V12, P441, DOI 10.2500/105065898780707919; FINNERTY JP, 1990, BRIT J CLIN PHARMACO, V29, P79; Fireman P, 1997, ALLERGY ASTHMA PROC, V18, P63, DOI 10.2500/108854197778605482; FISHER WG, 1994, ANN ALLERGY, V73, P515; FLAY BR, 1986, PREV MED, V15, P451, DOI 10.1016/0091-7435(86)90024-1; FLEMING DM, 1987, BRIT MED J, V294, P279; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; Flockhart DA, 1996, J CLIN PSYCHOPHARM, V16, P101, DOI 10.1097/00004714-199604000-00001; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66; Fokkens WJ, 1998, AM J RHINOL, V12, P21, DOI 10.2500/105065898782102990; Fokkens WJ, 1999, ALLERGY, V54, P158, DOI 10.1034/j.1398-9995.1999.00747.x; FOKKENS WJ, 1991, IMMUNOBIOLOGY, V182, P135; FOKKENS WJ, 1989, J ALLERGY CLIN IMMUN, V84, P39, DOI 10.1016/0091-6749(89)90176-0; FOKKENS WJ, 1989, ALLERGY, V44, P167, DOI 10.1111/j.1398-9995.1989.tb02257.x; Fokkens WJ, 1997, ALLERGY, V52, P29; FORDHUTCHINSON AW, 1991, TRENDS PHARMACOL SCI, V12, P68, DOI 10.1016/0165-6147(91)90500-R; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; FOREMAN J, 1992, THERAPEUTIC INDEX AN, P32; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58; FOSTER CS, 1988, OPHTHALMOLOGY, V95, P194; Foster PS, 1999, AM J RESP CELL MOL, V21, P451; FOURNIER P, 1993, ANN CARDIOL ANGEIOL, V42, P249; Fozard JR, 1999, PULM PHARMACOL THER, V12, P111, DOI 10.1006/pupt.1999.0191; FRAENKEL DJ, 1994, AM J RESP CRIT CARE, V150, P1130; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; FRANKE W, 1989, ARZNEIMITTEL-FORSCH, V39-2, P1360; FRANKLAND AW, 1954, LANCET, V1, P1055; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; FREELAND HS, 1989, J ALLERGY CLIN IMMUN, V83, P634, DOI 10.1016/0091-6749(89)90076-6; FREIDHOFF LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI 10.1016/0091-6749(86)90271-X; Frew AJ, 1997, CLIN EXP ALLERGY, V27, P237; FREW AJ, 1993, BRIT MED J, V307, P919; Frew AJ, 1998, THORAX, V53, pS52; FRIEDMAN MM, 1985, J ALLERGY CLIN IMMUN, V76, P70, DOI 10.1016/0091-6749(85)90807-3; Friese KH, 1997, HNO, V45, P593, DOI 10.1007/s001060050134; FRISCHER TM, 1993, AM REV RESPIR DIS, V148, P961; FROLUND L, 1990, ALLERGY, V45, P254; Frosh AC, 1999, CLIN EXP ALLERGY, V29, P457; Frossard N, 1997, ALLERGY, V52, P205, DOI 10.1111/j.1398-9995.1997.tb00976.x; FROSTAD AB, 1993, CLIN EXP ALLERGY, V23, P406, DOI 10.1111/j.1365-2222.1993.tb00346.x; FROSTAD AB, 1977, CLIN ALLERGY, V7, P347, DOI 10.1111/j.1365-2222.1977.tb01462.x; FUGNER A, 1988, ARZNEIMITTEL-FORSCH, V38-2, P1446; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Fujikura T, 1998, ARCH OTOLARYNGOL, V124, P1331; FUJISAWA T, 1990, AM REV RESPIR DIS, V141, P689; Furukawa K, 1996, AM J RESP CRIT CARE, V153, P847; GABRIEL M, 1977, Clinical Allergy, V7, P325; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GALLI SJ, 1994, ADV IMMUNOL, V55, P1; Galli SJ, 1999, CURR OPIN IMMUNOL, V11, P53, DOI 10.1016/S0952-7915(99)80010-7; Ganbo Tetsuya, 1995, Auris Nasus Larynx, V22, P158; GANE P, 1995, CYTOMETRY, V19, P361, DOI 10.1002/cyto.990190411; GARCIA DP, 1994, ANN ALLERGY, V72, P203; Garcia Ortiz J. C., 1995, Allergy (Copenhagen), V50, P269, DOI 10.1111/j.1398-9995.1995.tb01145.x; GarciaRobaina JC, 1997, ALLERGY, V52, P727, DOI 10.1111/j.1398-9995.1997.tb01229.x; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GARIJO MAG, 1995, ALLERGY, V50, P833; Garman SC, 1999, ANNU REV IMMUNOL, V17, P973, DOI 10.1146/annurev.immunol.17.1.973; GARRELDS IM, 1995, EUR J PHARMACOL, V275, P295, DOI 10.1016/0014-2999(95)00049-Q; Garrelds IM, 1997, ANN ALLERG ASTHMA IM, V78, P319; GARRELDS IM, 1995, THORAX, V50, P275, DOI 10.1136/thx.50.3.275; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Gates GA, 1992, ANN OTOL RHINOL LA S, V155, P24; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUTRIN D, 1994, CHEST, V106, P1419, DOI 10.1378/chest.106.5.1419; GAWCHIK SM, 1982, PENN MED, V85, P42; Gehanno P, 1997, ALLERGY, V52, P445, DOI 10.1111/j.1398-9995.1997.tb01027.x; GENGO FM, 1990, J ALLERGY CLIN IMMUN, V86, P1034, DOI 10.1016/S0091-6749(05)80250-7; GENGO FM, 1990, ANN ALLERGY, V64, P520; GENGO FM, 1987, ANN ALLERGY, V59, P53; Genovese A, 1997, CLIN EXP ALLERGY, V27, P559, DOI 10.1046/j.1365-2222.1997.270860.x; Genovese A, 1997, ALLERGY, V52, P67; GEORGITIS JW, 1995, INT ARCH ALLERGY IMM, V106, P416; GEORGITIS JW, 1986, INT ARCH ALLER A IMM, V81, P170; GEORGITIS JW, 1994, CLIN EXP ALLERGY, V24, P1049, DOI 10.1111/j.1365-2222.1994.tb02742.x; GEORGITIS JW, 1992, J ALLERGY CLIN IMMUN, V90, P1071, DOI 10.1016/0091-6749(92)90125-L; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; GEORGITIS JW, 1985, J ALLERGY CLIN IMMUN, V75, P496, DOI 10.1016/S0091-6749(85)80023-3; GEPPETTI P, 1988, BRIT J PHARMACOL, V93, P509; GERBLICH AA, 1986, J ALLERGY CLIN IMMUN, V77, P676, DOI 10.1016/0091-6749(86)90408-2; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; GERRARD JW, 1978, AM J HUM GENET, V30, P46; Gerth van Wijk R, 1991, Clin Otolaryngol Allied Sci, V16, P133; Gerth van Wijk R, 1991, Clin Exp Allergy, V21, P661; GERVAIS P, 1975, ACTA ALLERGOL, V30, P286, DOI 10.1111/j.1398-9995.1975.tb00205.x; Ghaffar O, 2000, CLIN EXP ALLERGY, V30, P86; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17; Ghia P, 1998, IMMUNOL TODAY, V19, P480, DOI 10.1016/S0167-5699(98)01330-9; GHOSH SK, 1991, THORAX, V46, P242, DOI 10.1136/thx.46.4.242; Giavina-Bianchi PF, 1997, ANN ALLERG ASTHMA IM, V79, P449; GIBBS TG, 1989, BRIT J CLIN PRACT, V43, P11; GIBBS TG, 1988, J INT MED RES, V16, P413; GIBSON GJ, 1974, BRIT MED J, V4, P503; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331; Giede-Tuch C, 1998, ALLERGY, V53, P857, DOI 10.1111/j.1398-9995.1998.tb03991.x; GILBERT IA, 1992, J CLIN INVEST, V90, P699, DOI 10.1172/JCI115940; GILL TM, 1994, JAMA-J AM MED ASSOC, V272, P619, DOI 10.1001/jama.272.8.619; GILLAM SJ, 1989, BRIT MED J, V299, P953; GILLESPIE DN, 1985, ANN ALLERGY, V55, P122; Gilmore TM, 1996, AM J IND MED, V30, P234; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; GIRARD J P, 1975, Clinical Allergy, V5, P301, DOI 10.1111/j.1365-2222.1975.tb01867.x; Giraud T, 1999, LANCET, V353, P2072, DOI 10.1016/S0140-6736(05)77890-9; GIRGIS I H, 1974, Journal of Laryngology and Otology, V88, P1163, DOI 10.1017/S0022215100079895; Gleeson M, 1996, CLIN EXP ALLERGY, V26, P697, DOI 10.1111/j.1365-2222.1996.tb00596.x; GLEICH GJ, 1980, NEW ENGL J MED, V302, P617, DOI 10.1056/NEJM198003133021107; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLEICH GJ, 1975, J ALLERGY CLIN IMMUN, V55, P334, DOI 10.1016/0091-6749(75)90005-6; Gliklich RE, 1997, OTOLARYNG HEAD NECK, V117, P12, DOI 10.1016/S0194-5998(97)70199-2; GLOVSKY MM, 1991, ANN ALLERGY, V67, P21; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1111/j.1365-2222.1996.tb00594.x; GODTHELP T, 1995, ALLERGY, V50, P21, DOI 10.1111/j.1398-9995.1995.tb02737.x; Goh DYT, 1996, ARCH DIS CHILD, V74, P131; Goldberg A, 1998, J ALLERGY CLIN IMMUN, V102, P210, DOI 10.1016/S0091-6749(98)70088-0; GOLDBERG MJ, 1987, J PHARMACOL EXP THER, V240, P717; Goldstein MF, 1999, ARCH OTOLARYNGOL, V125, P314; GOMEZ E, 1986, J ALLERGY CLIN IMMUN, V78, P637, DOI 10.1016/0091-6749(86)90082-5; GOMEZ E, 1988, BRIT MED J, V296, P1572; GOOD AP, 1994, AM J CARDIOL, V74, P207, DOI 10.1016/0002-9149(94)90108-2; Goodman W S, 1973, Otolaryngol Clin North Am, V6, P773; GORDON JR, 1990, IMMUNOL TODAY, V11, P458, DOI 10.1016/0167-5699(90)90176-A; Gordon S, 1997, CLIN EXP ALLERGY, V27, P479, DOI 10.1046/j.1365-2222.1997.d01-537.x; GOSS JE, 1993, ARCH INTERN MED, V153, P2705; GOSSET P, 1993, J ALLERGY CLIN IMMUN, V92, P878, DOI 10.1016/0091-6749(93)90066-O; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; Gosset P, 1997, CLIN EXP ALLERGY, V27, P379; Gotzsche PC, 1998, BRIT MED J, V317, P1105; GOULD CAL, 1988, BRIT J CLIN PHARMACO, V26, P515; GOUNNI AS, 1994, NATURE, V367, P183; Graf P, 1999, CLIN THER, V21, P1749, DOI 10.1016/S0149-2918(99)80053-8; Graf P, 1997, ALLERGY, V52, P28; Graf P, 1996, LARYNGOSCOPE, V106, P605, DOI 10.1097/00005537-199605000-00016; Graf P, 1996, CLIN OTOLARYNGOL, V21, P72, DOI 10.1111/j.1365-2273.1996.tb01028.x; Graf P, 1999, ARCH OTOLARYNGOL, V125, P1128; GRAF P, 1995, ACTA OTO-LARYNGOL, V115, P71, DOI 10.3109/00016489509133350; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; GRAHAM DE, 1990, AM REV RESPIR DIS, V142, P152; GRAMMER LC, 1984, J ALLERGY CLIN IMMUN, V73, P484, DOI 10.1016/0091-6749(84)90359-2; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1986, J ALLERGY CLIN IMMUN, V78, P1180, DOI 10.1016/0091-6749(86)90269-1; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; Grant JA, 1999, ALLERGY, V54, P700, DOI 10.1034/j.1398-9995.1999.00032.x; GRANT JA, 1991, J ALLERGY CLIN IMMUN, V88, P683, DOI 10.1016/0091-6749(91)90170-S; GRANT SM, 1990, DRUGS, V40, P412, DOI 10.2165/00003495-199040030-00006; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; GREENBAUM J, 1977, J ALLERGY CLIN IMMUN, V59, P437, DOI 10.1016/0091-6749(77)90006-9; GREENBAUM J, 1988, ANN ALLERGY, V61, P305; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478; Greenhalgh T, 1997, BRIT MED J, V315, P180; Gregoire C, 1996, J BIOL CHEM, V271, P32951; Gregory C, 1999, AM J MANAG CARE, V5, P485; Greiff L, 1997, CLIN EXP ALLERGY, V27, P438; Greiff L, 1998, EUR RESPIR J, V11, P1268, DOI 10.1183/09031936.98.11061268; GREIFF L, 1993, THORAX, V48, P648, DOI 10.1136/thx.48.6.648; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; GriffithsJohnson DA, 1997, METHOD ENZYMOL, V288, P241; GROSSMAN J, 1993, PEDIATRICS, V92, P594; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; GROSSMAN J, 1994, ANN ALLERGY, V73, P141; GROSSMAN J, 1989, ANN ALLERGY, V63, P317; Groth S, 1983, Eur J Respir Dis Suppl, V128 (Pt 2), P490; Grudemo H, 1997, ORL J OTO-RHINO-LARY, V59, P50; GUARNACCIA S, 1994, ANN ALLERGY, V72, P515; Guengerich F P, 1997, Adv Pharmacol, V43, P7, DOI 10.1016/S1054-3589(08)60200-8; Guerin B, 1996, INT ARCH ALLERGY IMM, V110, P91; GUILL MF, 1986, J ALLERGY CLIN IMMUN, V78, P4, DOI 10.1016/0091-6749(86)90107-7; GUO DF, 1995, J STEROID BIOCHEM, V53, P69, DOI 10.1016/0960-0760(95)00023-S; Gupta I, 1998, Eur J Med Res, V3, P511; Gutgesell C, 1999, ALLERGY, V54, P897, DOI 10.1034/j.1398-9995.1999.00268.x; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; GUTKOWSKI A, 1988, J ALLERGY CLIN IMMUN, V81, P902, DOI 10.1016/0091-6749(88)90948-7; Guyatt GH, 1999, JAMA-J AM MED ASSOC, V281, P1836, DOI 10.1001/jama.281.19.1836; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; Guyatt GH, 1999, J CLIN EPIDEMIOL, V52, P187, DOI 10.1016/S0895-4356(98)00157-7; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209; HAAHTELA T, 1980, ALLERGY, V35, P15, DOI 10.1111/j.1398-9995.1980.tb01712.x; HAAHTELA TMK, 1979, CLIN ALLERGY, V9, P53, DOI 10.1111/j.1365-2222.1979.tb01522.x; Haas N, 1997, ALLERGY, V52, P436, DOI 10.1111/j.1398-9995.1997.tb01025.x; Habbick BF, 1999, CAN MED ASSOC J, V160, P1824; Hadley JA, 1997, OTOLARYNG HEAD NECK, V117, pS8, DOI 10.1016/S0194-5998(97)70002-0; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HAGY GW, 1969, J ALLERGY, V44, P323, DOI 10.1016/0021-8707(69)90024-0; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; Haimovici R, 1997, OPHTHALMOLOGY, V104, P1653; HAKANSSON L, 1989, J ALLERGY CLIN IMMUN, V83, P933, DOI 10.1016/0091-6749(89)90108-5; Hallen H, 1995, ORL J OTO-RHINO-LARY, V57, P328; Hallen H, 1997, CLIN EXP ALLERGY, V27, P552, DOI 10.1046/j.1365-2222.1997.d01-529.x; HALLEN H, 1994, ORL J OTO-RHINO-LARY, V56, P276; HALLEN H, 1995, CLIN EXP ALLERGY, V25, P401, DOI 10.1111/j.1365-2222.1995.tb01070.x; Halpern BN, 1942, ARCH INT PHARMACOD T, V68, P339; Halstead LA, 1999, OTOLARYNG HEAD NECK, V120, P208, DOI 10.1016/S0194-5998(99)70408-0; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HAMILTON LH, 1982, ANN ALLERGY, V48, P87; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Hammann C, 1996, J ALLERGY CLIN IMMUN, V98, P1045, DOI 10.1016/S0091-6749(96)80189-8; Hampel FC, 1999, AM J RHINOL, V13, P55, DOI 10.2500/105065899781389867; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; Hansen GR, 1999, AVIAT SPACE ENVIR MD, V70, P919; HARADA S, 1993, BIOL PHARM BULL, V16, P884; HARF R, 1992, Allergie et Immunologie (Paris), V24, P95; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HARRIES MG, 1984, PHARMATHERAPEUTICA, V3, P623; Harvey RP, 1996, J ALLERGY CLIN IMMUN, V97, P1233, DOI 10.1016/S0091-6749(96)70190-2; HASAN RA, 1993, PEDIATR EMERG CARE, V9, P23, DOI 10.1097/00006565-199302000-00008; HASEGAWA M, 1982, ANN OTO RHINOL LARYN, V91, P112; Hasegawa S, 1999, BLOOD, V93, P2543; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUSERKRONBERGER C, 1993, ACTA OTO-LARYNGOL, V113, P387, DOI 10.3109/00016489309135831; Hayakawa K, 1997, ANN NY ACAD SCI, V815, P15, DOI 10.1111/j.1749-6632.1997.tb52041.x; Haye R., 1993, Rhinology (Utrecht), V31, P169; Hebert JR, 1996, ALLERGY, V51, P569; HEDLIN G, 1990, CLIN EXP ALLERGY, V20, P491, DOI 10.1111/j.1365-2222.1990.tb03141.x; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; HEGARTY JM, 1995, RESP MED, V89, P279, DOI 10.1016/0954-6111(95)90088-8; Heikkinen T, 1999, NEW ENGL J MED, V340, P260, DOI 10.1056/NEJM199901283400402; Heinrich J, 1998, EUR J EPIDEMIOL, V14, P239, DOI 10.1023/A:1007465205976; HEINRICH J, EUR J MED RES, V19, P107; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; Hellgren J, 1997, CLIN OTOLARYNGOL, V22, P536, DOI 10.1046/j.1365-2273.1997.00073.x; HENDELES L, 1993, PHARMACOTHERAPY, V13, pS129; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HENRIKSEN S. D., 1959, ACTA PATHOL ET MICROBIOL SCAND, V47, P380; HENRIQUEZ AS, 1981, ARCH OPHTHALMOL-CHIC, V99, P1266; HERINGS RMC, 1993, PHARM WORLD SCI, V15, P212, DOI 10.1007/BF01880629; Herman D, 1997, INT J PEDIATR OTORHI, V39, P1, DOI 10.1016/S0165-5876(96)01457-7; Hermesch C B, 1999, J Dent Educ, V63, P814; Herschman HR, 1997, ADV EXP MED BIOL, V407, P61; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Heusser CH, 1997, INT ARCH ALLERGY IMM, V113, P231; Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P159; Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P834; Hey JA, 1996, ARZNEIMITTEL-FORSCH, V46, P153; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HILL MR, 1995, BRIT MED J, V311, P776; Hill SJ, 1997, PHARMACOL REV, V49, P253; HILLAS J, 1980, CLIN ALLERGY, V10, P253, DOI 10.1111/j.1365-2222.1980.tb02104.x; Hiller KM, 1997, J ALLERGY CLIN IMMUN, V100, P335, DOI 10.1016/S0091-6749(97)70246-X; Himmel MH, 1997, LANCET, V350, P69, DOI 10.1016/S0140-6736(05)66276-9; Hindmarch I, 1999, BRIT J CLIN PHARMACO, V48, P200, DOI 10.1046/j.1365-2125.1999.00993.x; HINDMARCH I, 1986, INT J CLIN PHARM RES, V6, P457; HINDMARCH I, 1999, CLIN EXP ALLERGY, V3, P133; HINRIKSDOTTIR I, 1994, ACTA OTO-LARYNGOL, P30; Hirano T, 1999, BIOCHEM BIOPH RES CO, V260, P303, DOI 10.1006/bbrc.1999.0609; HIRSCH SR, 1982, J ALLERGY CLIN IMMUN, V70, P183, DOI 10.1016/0091-6749(82)90040-9; HIRSCH SR, 1981, J ALLERGY CLIN IMMUN, V68, P133, DOI 10.1016/0091-6749(81)90172-X; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Hirvonen MR, 1999, AM J RESP CRIT CARE, V160, P1943; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Hohki G, 1997, BIOCHEM BIOPH RES CO, V241, P136, DOI 10.1006/bbrc.1997.7785; Holgate ST, 1999, NATURE, V402, pB2; Holgate ST, 1999, CLIN EXP ALLERGY, V29, pIV, DOI 10.1046/j.1365-2222.1999.00003.x; HOLGATE ST, 1988, CLIN ALLERGY, V18, P549, DOI 10.1111/j.1365-2222.1988.tb02906.x; Holm AF, 1998, CLIN OTOLARYNGOL, V23, P69; HOLM AF, 1995, ALLERGY, V50, P204, DOI 10.1111/j.1398-9995.1995.tb01134.x; Holm AF, 1999, CLIN EXP ALLERGY, V29, P1356; Holmberg K, 1996, CLIN EXP ALLERGY, V26, P23, DOI 10.1111/j.1365-2222.1996.tb00655.x; Holmberg K, 1997, ANN ALLERG ASTHMA IM, V78, P270; HOLMBERG K, 1988, Journal of Allergy and Clinical Immunology, V81, P541, DOI 10.1016/0091-6749(88)90192-3; HOLMBERG K, 1989, ALLERGY, V44, P281, DOI 10.1111/j.1398-9995.1989.tb01070.x; HOLMSTROM M, 1990, Rhinology (Utrecht), V28, P191; HOLOPAIN.E, 1971, LANCET, V1, P55; Holopainen E, 1982, Eur J Respir Dis Suppl, V122, P221; Holt PG, 1999, NAT MED, V5, P1127, DOI 10.1038/13447; HOLT PG, 1993, EUR RESPIR J, V6, P120; HOLT PG, 1994, J IMMUNOL, V153, P256; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Holt PG, 1997, IMMUNOLOGY, V91, P145, DOI 10.1046/j.1365-2567.1997.00321.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Holt PG, 1999, J LEUKOCYTE BIOL, V66, P272; Homer JJ, 1999, BRIT MED J, V318, P1355; HONIG PK, 1992, CLIN PHARMACOL THER, V52, P231; HONIG PK, 1993, CLIN PHARMACOL THER, V53, P630; Honig PK, 1996, J CLIN PHARMACOL, V36, P345; HONIG PK, 1993, J CLIN PHARMACOL, V33, P1201; HOPES H, 1992, EUR J CLIN PHARMACOL, V42, P55, DOI 10.1007/BF00314920; Hopper I, 1972, J Laryngol Otol, V86, P725; HOPPU K, 1991, LANCET, V338, P538, DOI 10.1016/0140-6736(91)91101-Y; HORAK F, 1985, ARCH OTO-RHINO-LARYN, V242, P239, DOI 10.1007/BF00453546; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Horak F, 1998, ALLERGY, V53, P849, DOI 10.1111/j.1398-9995.1998.tb03990.x; HORAK F, 1992, J INT MED RES, V20, P422; Horak F, 1998, ARZNEIMITTEL-FORSCH, V48, P379; HORAK F, 1988, ARZNEIMITTEL-FORSCH, V38-1, P124; HORAK FF, 1994, INT ARCH ALLERGY IMM, V103, P298; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Horner WE, 1998, ALLERGY, V53, P1114, DOI 10.1111/j.1398-9995.1998.tb03830.x; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; HOWARTH P, 1991, ADV PROSTAG THROMB L, V21, P449; HOWARTH PH, 1995, AM J RESP CELL MOL, V13, P288; Howarth PH, 1999, J ALLERGY CLIN IMMUN, V104, P927; HOWARTH PH, 1993, INT ARCH ALLERGY IMM, V101, P318; Howarth PH, 1997, ALLERGY, V52, P12; HOWARTH PH, 1989, RESP MED, V83, P179, DOI 10.1016/S0954-6111(89)80029-0; HOWARTH PH, 1984, BRIT J CLIN PHARMACO, V18, P1; HOWARTH PH, 1998, CLIN EXP ALLERGY, V6, P2; HOWIE VM, 1971, SOUTH MED J, V64, P233; HOWLAND W, 1996, CLIN EXP ALLERGY, V3, P18; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; Howland WC, 1996, CLIN THER, V18, P1106, DOI 10.1016/S0149-2918(96)80065-8; Hsieh MH, 1996, INT J CARDIOL, V54, P85, DOI 10.1016/0167-5273(96)02582-X; Hu Y, 1997, J Tradit Chin Med, V17, P53; Huang JC, 1997, PLANT MOL BIOL, V34, P681, DOI 10.1023/A:1005824306560; Huang M Y, 1998, Am J Ther, V5, P153, DOI 10.1097/00045391-199805000-00005; HUANG SK, 1995, J IMMUNOL, V154, P6157; HUGGINS KG, 1975, LANCET, V2, P148; HUNGINGER J, 1991, FOOD ALLERGY ADVERSE, P36; Hunt DL, 2000, JAMA-J AM MED ASSOC, V283, P1875, DOI 10.1001/jama.283.14.1875; Hunt LW, 1996, J OCCUP ENVIRON MED, V38, P765, DOI 10.1097/00043764-199608000-00011; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; HURST DS, 1993, OTOLARYNG HEAD NECK, V108, P711; Hurst DS, 1999, LARYNGOSCOPE, V109, P471, DOI 10.1097/00005537-199903000-00024; Hytonen M, 1997, ACTA OTO-LARYNGOL, P133; Hytonen M, 1997, INT ARCH OCC ENV HEA, V69, P487, DOI 10.1007/s004200050178; Hytonen Maija, 1996, Rhinology (Utrecht), V34, P86; Iacovacci P, 1998, J ALLERGY CLIN IMMUN, V101, P755, DOI 10.1016/S0091-6749(98)70304-5; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; ICHIKAWA K, 1991, Rhinology (Utrecht), V29, P143; ICHIMIYA I, 1990, ARCH OTOLARYNGOL, V116, P324; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; IGARASHI Y, 1995, J ALLERGY CLIN IMMUN, V95, P716, DOI 10.1016/S0091-6749(95)70177-X; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V91, P1082, DOI 10.1016/0091-6749(93)90223-3; IIKURA Y, 1992, ANN ALLERGY, V68, P233; Ikeda K, 1999, ANN OTO RHINOL LARYN, V108, P355; ILIOPOULOS O, 1988, AM REV RESPIR DIS, V138, P400; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; IMBUS HR, 1985, J ALLERGY CLIN IMMUN, V76, P831, DOI 10.1016/0091-6749(85)90757-2; INCAUDO G, 1991, NASAL MANIFESTATIONS; Ingels K, 1997, ALLERGY, V52, P338, DOI 10.1111/j.1398-9995.1997.tb01001.x; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; Inouye T, 1999, Ann Otol Rhinol Laryngol Suppl, V180, P3; Ipsen H, 1997, CLIN REV ALLERG IMMU, V15, P389, DOI 10.1007/BF02737734; IRANDER K, 1993, INT J PEDIATR OTORHI, V26, P1, DOI 10.1016/0165-5876(93)90191-5; IRANI AA, 1986, P NATL ACAD SCI USA, V83, P4464, DOI 10.1073/pnas.83.12.4464; Irwin RS, 1999, HOSP PRACT, V34, P53; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1970, J IMMUNOL, V105, P1459; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Isolauri E, 1998, J PEDIATR-US, V132, P1004, DOI 10.1016/S0022-3476(98)70399-3; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; IWAMOTO I, 1990, CLIN EXP ALLERGY, V20, P175, DOI 10.1111/j.1365-2222.1990.tb02664.x; Iwens P., 1994, Rhinology (Utrecht), V32, P65; JAAKKOLA JJ, 1993, J EXPO ANAL ENV EPID, V1, P129; Jackson EM, 2000, J EMERG MED, V18, P241, DOI 10.1016/S0736-4679(99)00202-4; Jackson R, 1998, BRIT MED J, V317, P427; JACKSON RT, 1981, PROSTAGLANDINS, V21, P1015, DOI 10.1016/0090-6980(81)90169-6; JACKSON RT, 1981, ARCH OTOLARYNGOL, V107, P288; Jacobi HH, 1999, J ALLERGY CLIN IMMUN, V103, P768, DOI 10.1016/S0091-6749(99)70418-5; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; Jacobsen L., 1996, Journal of Allergy and Clinical Immunology, V97, P232, DOI 10.1016/S0091-6749(96)80416-7; JACOBSEN L, 1995, P 16 EUR C ALL CLIN, P745; Jacobson MR, 1999, CLIN EXP ALLERGY, V29, P1347; JAEGER D, 1992, J ALLERGY CLIN IMMUN, V89, P759, DOI 10.1016/0091-6749(92)90385-F; JAHNSEN FL, 1995, AM J RESP CELL MOL, V12, P624; Jahnsen FL, 1999, J IMMUNOL, V163, P1545; Jankowski R., 1992, Rhinology (Utrecht), V30, P249; Jankowski R, 1996, ACTA OTO-LARYNGOL, V116, P160, DOI 10.3109/00016489609137813; JANSSENS M, 1993, DOC OPHTHALMOL, V84, P111, DOI 10.1007/BF01206245; JANSSENS MM, 1991, CLIN EXP ALLERGY, V2, P29; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P111; JANSSENS MML, 1993, CLIN REV ALLERG, V11, P35; JANTZEN HM, 1987, CELL, V49, P29, DOI 10.1016/0092-8674(87)90752-5; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jarvis D, 1999, THORAX, V54, P1054; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Jawad Suhair S. M., 1998, Rhinology (Utrecht), V36, P73; Jayawickreme SP, 1999, AM J PHYSIOL-LUNG C, V276, pL596; Jeal W, 1997, DRUGS, V53, P257, DOI 10.2165/00003495-199753020-00006; Jeffery PK, 1996, EUR RESPIR J, V9, P1583, DOI 10.1183/09031936.96.09081583; Jessen M, 1997, ALLERGY, V52, P3; JIMENEZ A, 1994, INT ARCH ALLERGY IMM, V105, P297; Jinot Jennifer, 1996, Reviews on Environmental Health, V11, P89; JOBST S, 1994, ALLERGY, V49, P598, DOI 10.1111/j.1398-9995.1994.tb00125.x; Johannssen V., 1997, Rhinology (Utrecht), V35, P161; JOHANSSO.SG, 1967, LANCET, V2, P951; JOHANSSON SG, 1973, INT ARCH ALLER A IMM, V45, P55; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V60, P447; JOHANSSON SGO, 1976, CLIN ALLERGY, V6, P91, DOI 10.1111/j.1365-2222.1976.tb01417.x; Johnsen CR, 1997, OCCUP ENVIRON MED, V54, P671; JOHNSON DA, 1993, PHARMACOTHERAPY, V13, pS110; JOHNSTON D, 1995, EDUC LEADERSHIP, V52, P46; Johnston S L, 1997, Pediatr Pulmonol Suppl, V16, P88; JOHNSTONE DE, 1981, ANN ALLERGY, V46, P1; Jones NS, 1999, J LARYNGOL OTOL, V113, P1; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019; Jones NS, 1998, CLIN OTOLARYNGOL, V23, P547, DOI 10.1046/j.1365-2273.1998.2360547.x; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; JOOS GF, 1994, EUR RESPIR J, V7, P1161; Jordana G, 1996, J ALLERGY CLIN IMMUN, V97, P588, DOI 10.1016/S0091-6749(96)70303-2; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; JOUBERT JR, 1983, S AFR MED J, V64, P623; JUHLIN L, 1987, INT J DERMATOL, V26, P653, DOI 10.1111/j.1365-4362.1987.tb02275.x; JULIUSSON S, 1988, CLIN ALLERGY, V18, P615, DOI 10.1111/j.1365-2222.1988.tb02913.x; JULIUSSON S, 1991, ACTA OTO-LARYNGOL, V111, P946, DOI 10.3109/00016489109138435; JULIUSSON S, 1991, ALLERGY, V46, P459; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; JULIUSSON S, 1993, CLIN EXP ALLERGY, V23, P591, DOI 10.1111/j.1365-2222.1993.tb00899.x; Jung T, 1996, EUR J IMMUNOL, V26, P571, DOI 10.1002/eji.1830260311; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, pS386, DOI 10.1016/S0091-6749(98)70227-1; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; JUNIPER EF, 1989, J ALLERGY CLIN IMMUN, V83, P627, DOI 10.1016/0091-6749(89)90075-4; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V94, P36, DOI 10.1016/0091-6749(94)90069-8; JUNIPER EF, 1993, J ALLERGY CLIN IMMUN, V92, P66, DOI 10.1016/0091-6749(93)90039-I; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, CAN MED ASSOC J, V147, P887; JUNIPER EF, 1990, J ALLERGY CLIN IMMUN, V86, P380, DOI 10.1016/S0091-6749(05)80101-0; Juniper EF, 1999, CHEST, V115, P1265, DOI 10.1378/chest.115.5.1265; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; JUTO JE, 1982, ACTA OTO-LARYNGOL, V94, P149, DOI 10.3109/00016488209128899; Kaiser H B, 1998, Am J Ther, V5, P245, DOI 10.1097/00045391-199807000-00007; KAISER HB, 1995, J ALLERGY CLIN IMMUN, V95, P1128, DOI 10.1016/S0091-6749(95)70217-2; Kaiser R, 1998, AM J EPIDEMIOL, V148, P600; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; KALRA S, 1990, LANCET, V336, P449, DOI 10.1016/0140-6736(90)92004-2; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261; KAMEI C, 1992, IMMUNOPHARM IMMUNOT, V14, P207, DOI 10.3109/08923979209009220; KAMEI C, 1992, IMMUNOPHARM IMMUNOT, V14, P191, DOI 10.3109/08923979209009219; KAMEI C, 1991, ARZNEIMITTEL-FORSCH, V41-2, P1150; KANAI N, 1994, AM J RESP CRIT CARE, V150, P1094; KANERVA L, 1993, INT ARCH OCC ENV HEA, V64, P565, DOI 10.1007/BF00517702; KANERVA L, 1995, ALLERGY, V50, P174; Kanfer I, 1993, PHARMACOTHERAPY, V13, p116S; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; Kanoh T, 1996, J Clin Lab Immunol, V48, P133; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; KARJALAINEN J, 1989, CLIN EXP ALLERGY, V19, P273, DOI 10.1111/j.1365-2222.1989.tb02383.x; KARLSSON G, 1994, ACTA OTO-LARYNGOL, P26; KARLSSON G, 1989, ORL J OTO-RHINO-LARY, V51, P171; KARLSSON MG, 1995, DIAGN MOL PATHOL, V4, P85, DOI 10.1097/00019606-199506000-00003; Karlsson MG, 1996, VIRCHOWS ARCH, V429, P49; KARMAKAR PR, 1994, INT ARCH ALLERGY IMM, V103, P194; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; Kato M, 1999, J ALLERGY CLIN IMMUN, V103, P1213, DOI 10.1016/S0091-6749(99)70202-2; Kato M, 1999, ALLERGY, V54, P278, DOI 10.1034/j.1398-9995.1999.00942.x; KATO M, 1995, CLIN EXP ALLERGY, V25, P744, DOI 10.1111/j.1365-2222.1995.tb00012.x; Kato M, 1998, ANN OTO RHINOL LARYN, V107, P232; Katyal V K, 1994, Indian Heart J, V46, P181; KATYAL VK, 1994, INDIAN HEART J, V46, P358; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; KAUFMAN HS, 1990, ANN ALLERGY, V64, P293; KAUFMAN HS, 1986, ARCH OPHTHALMOL-CHIC, V104, P967; Kawabori S, 1997, INT ARCH ALLERGY IMM, V112, P36; Kawamoto H, 1999, LARYNGOSCOPE, V109, P2015, DOI 10.1097/00005537-199912000-00023; KAY AB, 1995, INT ARCH ALLERGY IMM, V107, P208; KAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P345, DOI 10.1016/0091-6749(83)90090-8; KAY AB, 1992, CLIN EXP ALLERGY, V3, P1; Kay GG, 1999, CLIN EXP ALLERGY, V29, P147, DOI 10.1046/j.1365-2222.1999.0290s3147.x; Kay GG, 1997, ARCH INTERN MED, V157, P2350, DOI 10.1001/archinte.157.20.2350; Keil U, 1996, TOXICOL LETT, V86, P99, DOI 10.1016/0378-4274(96)03680-6; KEITH PK, 1994, J ALLERGY CLIN IMMUN, V93, P567, DOI 10.1016/S0091-6749(94)70068-0; Keles N, 1999, AM J RHINOL, V13, P185, DOI 10.2500/105065899781389731; KELLOWAY JS, 1995, MAYO CLIN PROC, V70, P197; KELLY CA, 1988, THORAX, V43, P335, DOI 10.1136/thx.43.4.335; KELSO JM, 1991, ANN ALLERGY, V67, P511; KEMP AS, 1979, MED J AUSTRALIA, V1, P263; KEMP J, 1987, AM J RHINOL, V3, P151; KEMP JP, 1985, ANN ALLERGY, V54, P502; KENNEY JS, 1994, J ALLERGY CLIN IMMUN, V93, P1060, DOI 10.1016/S0091-6749(94)70055-9; Kerkhof M, 1999, EUR RESPIR J, V14, P839, DOI 10.1034/j.1399-3003.1999.14d20.x; KERR JS, 1994, EUR J CLIN PHARMACOL, V47, P331; KESHAV S, 1990, DIAGN MICR INFEC DIS, V13, P439, DOI 10.1016/0732-8893(90)90016-O; Keslin M H, 1999, Am J Manag Care, V5, pS248; Kim YK, 1999, AM J RESP CELL MOL, V20, P388; Kim YK, 1999, CLIN EXP ALLERGY, V29, P1102, DOI 10.1046/j.1365-2222.1999.00607.x; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P1285; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; King C, 1998, J IMMUNOL, V161, P3645; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1995, ALLERGY, V50, P765, DOI 10.1111/j.1398-9995.1995.tb01222.x; KIRKEGAARD J, 1987, J ALLERGY CLIN IMMUN, V79, P585, DOI 10.1016/S0091-6749(87)80153-7; KIRSHENBAUM AS, 1991, J IMMUNOL, V146, P1410; Kishimoto W, 1997, RES COMMUN MOL PATH, V98, P273; Kivity S, 1996, IMMUNOL LETT, V53, P147, DOI 10.1016/S0165-2478(96)02627-2; Kjellman N I, 1994, Pediatr Allergy Immunol, V5, P13, DOI 10.1111/j.1399-3038.1994.tb00342.x; KJELLMAN NIM, 1995, ALLERGY, V50, P14, DOI 10.1111/j.1398-9995.1995.tb04252.x; KJELLMAN NIM, 1976, ACTA PAEDIATR SCAND, V65, P593, DOI 10.1111/j.1651-2227.1976.tb04938.x; Klein GL, 1996, ANN ALLERG ASTHMA IM, V77, P365; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; KLEMENTSSON H, 1992, CLIN EXP ALLERGY, V22, P1058, DOI 10.1111/j.1365-2222.1992.tb00130.x; KLEMENTSSON H, 1992, EUR J CLIN PHARMACOL, V42, P295; KLEMENTSSON H, 1990, CLIN EXP ALLERGY, V20, P539, DOI 10.1111/j.1365-2222.1990.tb03147.x; KLEMENTSSON H, 1990, J ALLERGY CLIN IMMUN, V86, P466, DOI 10.1016/S0091-6749(05)80201-5; Klepser TB, 1999, AM J HEALTH-SYST PH, V56, P125; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; KNIEST FM, 1991, CLIN EXP ALLERGY, V21, P39, DOI 10.1111/j.1365-2222.1991.tb00802.x; KNIEST FM, 1992, CLIN EXP ALLERGY, V22, P681, DOI 10.1111/j.1365-2222.1992.tb00191.x; KNIGHT A, 1985, J OTOLARYNGOL, V14, P85; KNIGHT A, 1983, ANN ALLERGY, V50, P81; KNIGHT A, 1976, J ALLERGY CLIN IMMUN, V58, P278, DOI 10.1016/0091-6749(76)90132-9; KNIGHT A, 1986, ANN ALLERGY, V57, P348; KNOL EF, 1991, EUR J IMMUNOL, V21, P881, DOI 10.1002/eji.1830210404; KNOL EF, 1991, J ALLERGY CLIN IMMUN, V88, P328, DOI 10.1016/0091-6749(91)90094-5; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kobayashi H, 1998, CLIN EXP ALLERGY, V28, P1219, DOI 10.1046/j.1365-2222.1998.00377.x; KOBAYASHI RH, 1995, CLIN THER, V17, P503, DOI 10.1016/0149-2918(95)80115-4; KOBAYASHI RH, 1989, ANN ALLERGY, V62, P205; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P1055, DOI 10.1016/0091-6749(88)90180-7; Koepke JW, 1997, ALLERGY ASTHMA PROC, V18, P33, DOI 10.2500/108854197778612844; KOH KK, 1994, J ELECTROCARDIOL, V27, P343; KOIVIKKO A, 1988, ALLERGY, V43, P192; Kolbeck KG, 1999, ANN ALLERG ASTHMA IM, V82, P55, DOI 10.1016/S1081-1206(10)62661-0; KOLLY M, 1986, BRIT J CLIN PHARMACO, V22, P389; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; KONTOUFILI K, 1989, EUR J CLIN PHARMACOL, V36, P617, DOI 10.1007/BF00637746; Kopp MV, 1999, EUR RESPIR J, V14, P854, DOI 10.1034/j.1399-3003.1999.14d22.x; KOREN HS, 1990, TOXICOLOGY, V60, P15, DOI 10.1016/0300-483X(90)90159-E; KORSGAARD J, 1991, ALLERGY, V46, P14, DOI 10.1111/j.1398-9995.1991.tb00643.x; KOWALSKI M, 1999, AM J RESP CRIT CARE, V160, P391; KOWALSKI ML, 1993, ALLERGY, V48, P409, DOI 10.1111/j.1398-9995.1993.tb00738.x; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Krakowiak A, 1999, EUR RESPIR J, V14, P352, DOI 10.1034/j.1399-3003.1999.14b19.x; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; KRAY KT, 1985, J ALLERGY CLIN IMMUN, V76, P623, DOI 10.1016/0091-6749(85)90785-7; Krouse JH, 1999, LARYNGOSCOPE, V109, P1223, DOI 10.1097/00005537-199908000-00007; KRSTENANSKY P M, 1987, Drug Intelligence and Clinical Pharmacy, V21, P947; KUBES P, 1994, J IMMUNOL, V152, P3570; KUBO N, 1987, JPN J PHARMACOL, V43, P277, DOI 10.1254/jjp.43.277; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Kujala V, 1999, OCCUP MED-OXFORD, V49, P3, DOI 10.1093/occmed/49.1.3; Kulkarni AB, 1997, RES IMMUNOL, V148, P453, DOI 10.1016/S0923-2494(97)82669-7; Kulkarni S M, 1994, Indian Heart J, V46, P179; Kuna P, 1996, J ALLERGY CLIN IMMUN, V97, P104, DOI 10.1016/S0091-6749(96)70288-9; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873; Kunkel SL, 1999, J CLIN INVEST, V104, P1333, DOI 10.1172/JCI8511; Kushida CA, 1997, ALLERGY ASTHMA PROC, V18, P69, DOI 10.2500/108854197778605509; KWASELOW A, 1985, ALLERGY, V40, P363, DOI 10.1111/j.1398-9995.1985.tb00248.x; Kyrein HJ, 1996, ARZNEIMITTEL-FORSCH, V46, P794; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569; Lacerda AE, 1997, MOL PHARMACOL, V52, P314; LACROIX JS, 1990, CELL TISSUE RES, V259, P119, DOI 10.1007/BF00571436; LACROIX JS, 1991, CLIN EXP ALLERGY, V21, P595, DOI 10.1111/j.1365-2222.1991.tb00852.x; LADURON PM, 1982, MOL PHARMACOL, V21, P294; LaForce C, 1996, ANN ALLERG ASTHMA IM, V76, P181; LaForce C, 1999, J ALLERGY CLIN IMMUN, V103, pS388, DOI 10.1016/S0091-6749(99)70218-6; Lagente V, 1998, PULM PHARMACOL THER, V11, P331, DOI 10.1006/pupt.1999.0162; Lagier B, 1997, CLIN EXP IMMUNOL, V108, P545, DOI 10.1046/j.1365-2249.1997.3791276.x; Lai X, 1993, J Tradit Chin Med, V13, P243; LAITINEN LA, 1987, AM REV RESPIR DIS, V136, pS38; Lamblin C, 1997, AM J RESP CRIT CARE, V155, P99; Lamblin C, 2000, AM J RESP CRIT CARE, V161, P406; Lamblin C, 1999, J ALLERGY CLIN IMMUN, V104, P85, DOI 10.1016/S0091-6749(99)70118-1; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; LAN JL, 1988, J ALLERGY CLIN IMMUN, V82, P736, DOI 10.1016/0091-6749(88)90072-3; Lane AP, 1996, ANN OTO RHINOL LARYN, V105, P811; Lane AP, 1997, OTOLARYNG HEAD NECK, V116, P294; Lane PJL, 1999, CURR OPIN IMMUNOL, V11, P308, DOI 10.1016/S0952-7915(99)80049-1; Lane SJ, 1998, RESP MED, V92, P795, DOI 10.1016/S0954-6111(98)90380-8; LANG DG, 1993, J CARDIOVASC PHARM, V22, P438, DOI 10.1097/00005344-199309000-00014; LANGLEY GB, 1985, RHEUMATOL INT, V5, P145, DOI 10.1007/BF00541514; LANGRICK AF, 1984, CURR MED RES OPIN, V9, P290, DOI 10.1185/03007998409109594; Larche M, 1998, J IMMUNOL, V161, P6375; Larese F, 1998, AM J IND MED, V34, P623, DOI 10.1002/(SICI)1097-0274(199812)34:6<623::AID-AJIM11>3.0.CO;2-R; LARSEN PL, 1986, AM J OTOLARYNG, V7, P28, DOI 10.1016/S0196-0709(86)80031-X; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Lau YL, 1998, J PAEDIATR CHILD H, V34, P47, DOI 10.1046/j.1440-1754.1998.00217.x; LAURENT J, 1993, CLIN EXP ALLERGY, V23, P39, DOI 10.1111/j.1365-2222.1993.tb02482.x; LAURSEN LC, 1987, ALLERGY, V42, P168, DOI 10.1111/j.1398-9995.1987.tb02194.x; LAVIE P, 1981, ACTA OTO-LARYNGOL, V92, P529, DOI 10.3109/00016488109133292; LAWSON W, 1993, OTOLARYNG CLIN N AM, V26, P1037; LEBEL B, 1988, J ALLERGY CLIN IMMUN, V82, P869, DOI 10.1016/0091-6749(88)90092-9; LEBOWITZ KD, 1997, EUR RESPIR J, V24, pS49; Lebowitz MD, 1996, EUR RESPIR J, V9, P1029, DOI 10.1183/09031936.96.09051029; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Lee CH, 1997, ANN OTO RHINOL LARYN, V106, P215; LEE HS, 1993, LARYNGOSCOPE, V103, P533; Lee JG, 1996, TOXICOL APPL PHARM, V141, P195; LEE TH, 1992, AM REV RESPIR DIS, V145, P34; Lee W. C., 1996, Rhinology (Utrecht), V34, P130; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEIMGRUBER A, 1991, CLIN EXP ALLERGY, V21, P127, DOI 10.1111/j.1365-2222.1991.tb00814.x; LEINO M, 1992, CLIN EXP ALLERGY, V22, P929, DOI 10.1111/j.1365-2222.1992.tb02066.x; LEINO M, 1990, ANN ALLERGY, V64, P398; Leipzig JR, 1996, J ALLERGY CLIN IMMUN, V98, P1130, DOI 10.1016/S0091-6749(96)80206-5; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Lenhard G, 1997, CURR MED RES OPIN, V14, P21, DOI 10.1185/03007999709113339; Leone C, 1997, J ALLERGY CLIN IMMUN, V100, P775, DOI 10.1016/S0091-6749(97)70273-2; Leroyer C, 1999, OCCUP ENVIRON MED, V56, P334; Leuenberger P., 1994, American Journal of Respiratory and Critical Care Medicine, V150, P1221; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; LEURS R, 1995, BIOCHEM BIOPH RES CO, V214, P110, DOI 10.1006/bbrc.1995.2263; LEUSCHNER RM, 1993, EXPERIENTIA, V49, P931, DOI 10.1007/BF02125639; LEVANDER S, 1991, EUR J CLIN PHARMACOL, V41, P435, DOI 10.1007/BF00626365; LEVINE HL, 1990, OTOLARYNG HEAD NECK, V102, P370; LeviSchaffer F, 1997, CLIN EXP ALLERGY, V27, P64, DOI 10.1111/j.1365-2222.1997.tb01829.x; LEVRIER J, 1995, ARZNEIMITTEL-FORSCH, V45-1, P559; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; Lewis SA, 1998, CLIN EXP ALLERGY, V28, P1493; LEWIS WH, 1975, TREES ANN ALLERGY, V35, P113; Lewith GT, 1996, ALLERGY, V51, P761, DOI 10.1111/j.1398-9995.1996.tb04464.x; Leynadier F, 1996, ANN ALLERG ASTHMA IM, V76, P163; LEYNADIER F, 1981, ALLERGY, V36, P239, DOI 10.1111/j.1398-9995.1981.tb01569.x; LEYNADIER F, 1991, ALLERGY, V46, P619, DOI 10.1111/j.1398-9995.1991.tb00633.x; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; Li L, 1999, ALLERGY, V54, P306, DOI 10.1034/j.1398-9995.1999.00086.x; Li L, 1999, J IMMUNOL, V162, P2477; Liccardi G, 1996, INT ARCH ALLERGY IMM, V111, P210; LICHTENS.LM, 1968, AM J MED, V44, P514, DOI 10.1016/0002-9343(68)90052-1; LICHTENSTEIN L, 1971, AM J MED, V44, P514; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Lichtman AH, 1997, CURR BIOL, V7, P242; Lildholdt T, 1997, ARCH OTOLARYNGOL, V123, P595; LILDHOLDT T, 1995, CLIN OTOLARYNGOL, V20, P26, DOI 10.1111/j.1365-2273.1995.tb00007.x; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; LINDEN M, 1995, CLIN EXP ALLERGY, V25, P166, DOI 10.1111/j.1365-2222.1995.tb01022.x; Linden M, 1999, ALLERGY, V54, P212, DOI 10.1034/j.1398-9995.1999.00756.x; LINDER A, 1988, CLIN ALLERGY, V18, P29, DOI 10.1111/j.1365-2222.1988.tb02840.x; LINDER A, 1987, ALLERGY, V42, P583, DOI 10.1111/j.1398-9995.1987.tb00388.x; LINDER A, 1987, ALLERGY, V42, P126, DOI 10.1111/j.1398-9995.1987.tb02370.x; LINDNER JF, 1995, PHYS REV LETT, V75, P3, DOI 10.1103/PhysRevLett.75.3; Lindquist M, 1997, LANCET, V349, P1322, DOI 10.1016/S0140-6736(97)26018-6; LINDQVIST N, 1989, CLIN OTOLARYNGOL, V14, P519, DOI 10.1111/j.1365-2273.1989.tb00416.x; LINDQVIST N, 1986, ALLERGY, V41, P179, DOI 10.1111/j.1398-9995.1986.tb00298.x; LINDSAYMILLER ACM, 1979, CLIN ALLERGY, V9, P271, DOI 10.1111/j.1365-2222.1979.tb01553.x; Linn WS, 1996, J EXPO ANAL ENV EPID, V6, P449; LINNA O, 1992, ACTA PAEDIATR, V81, P100, DOI 10.1111/j.1651-2227.1992.tb12182.x; Linneberg A, 1999, ALLERGY, V54, P1194, DOI 10.1034/j.1398-9995.1999.00180.x; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335; LITTLE MM, 1989, AGENTS ACTIONS, V28, P16, DOI 10.1007/BF02022975; Liu CM, 1998, ANN ALLERG ASTHMA IM, V81, P176; Liu TZ, 1998, J BIOMED SCI, V5, P415, DOI 10.1159/000025355; LLENAS J, 1992, DRUGS TODAY SB, V28, P29; LLOYD GAS, 1991, J LARYNGOL OTOL, V105, P181, DOI 10.1017/S0022215100115300; LOBATON P, 1975, Rhinology (Utrecht), V13, P91; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 1996, ANN ALLERG ASTHMA IM, V76, P448; LOFKVIST T, 1976, ACTA ALLERGOL, V31, P227, DOI 10.1111/j.1398-9995.1976.tb01683.x; LOFKVIST T, 1994, ALLERGY, V49, P100, DOI 10.1111/j.1398-9995.1994.tb00808.x; LOH RKS, 1994, J EXP MED, V180, P663, DOI 10.1084/jem.180.2.663; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LOTH S, 1985, CLIN OTOLARYNGOL, V10, P15, DOI 10.1111/j.1365-2273.1985.tb01159.x; Lotvall J, 1999, CURR PHARM DESIGN, V5, P757; LOUNDBACK B, 1998, CLIN EXP ALLERGY, V2, P3; Lovborg U, 1998, INT ARCH ALLERGY IMM, V117, P220, DOI 10.1159/000024014; LOWE E, 1946, J PHARMACOL EXP THER, V86, P229; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWENSTEIN H, 1995, INT ARCH ALLERGY IMM, V107, P285; LOWHAGEN O, 1985, J ALLERGY CLIN IMMUN, V75, P460, DOI 10.1016/S0091-6749(85)80018-X; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361; LUGO G, 1994, INT ARCH OCC ENV HEA, V65, P291, DOI 10.1007/BF00405691; Lund VJ, 1997, ENT J S, V76, P1; Lund VJ, 1998, ARCH OTOLARYNGOL, V124, P513; LUND VJ, 1991, J OTOLARYNGOL, V20, P379; LUND VJ, 1989, OTOLARYNG CLIN N AM, V22, P279; Lundberg JON, 1996, EUR RESPIR J, V9, P2671, DOI 10.1183/09031936.96.09122671; LUNDBLAD L, 1984, ACTA PHYSIOL SCAND, V121, P277, DOI 10.1111/j.1748-1716.1984.tb07457.x; LURIE A, 1992, EUR J CLIN PHARMACOL, V42, P213, DOI 10.1007/BF00278487; Luster AD, 1998, NEW ENGL J MED, V338, P436; LUTS A, 1993, INT ARCH ALLERGY IMM, V101, P52; LUTSKY I, 1984, J ALLERGY CLIN IMMUN, V73, P56, DOI 10.1016/0091-6749(84)90484-6; Lynch KR, 1999, NATURE, V399, P789; MABRY RL, 1986, SOUTHERN MED J, V79, P965, DOI 10.1097/00007611-198608000-00012; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MACCONNELL TJ, 1991, BRIT MED J, V302, P1469; MacGlashan D, 1999, J ALLERGY CLIN IMMUN, V104, P492, DOI 10.1016/S0091-6749(99)70399-4; MacGlashan D, 1998, BLOOD, V91, P1633; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MACGLASHAN DW, 1983, FED PROC, V42, P2504; MADONINI E, 1987, J ALLERGY CLIN IMMUN, V79, P358, DOI 10.1016/0091-6749(87)90156-4; MAFEE MF, 1993, AM J ROENTGENOL, V160, P735; Magnan A, 1998, EUR RESPIR J, V12, P1073, DOI 10.1183/09031936.98.12051073; MAGNUSSEN H, 1993, THORAX, V48, P879, DOI 10.1136/thx.48.9.879; MAGYAR P, 1993, ALLERGY, V48, P631, DOI 10.1111/j.1398-9995.1993.tb00761.x; Mahler V, 2000, CLIN EXP ALLERGY, V30, P509; Mahoney NM, 1997, NAT STRUCT BIOL, V4, P953, DOI 10.1038/nsb1197-953; MAJCHEL AM, 1990, CLIN EXP ALLERGY, V20, P701, DOI 10.1111/j.1365-2222.1990.tb02711.x; Majori M, 1998, EUR RESPIR J, V11, P1263, DOI 10.1183/09031936.98.11061263; Malanin K, 1995, ALLERGY, V50, P988, DOI 10.1111/j.1398-9995.1995.tb02513.x; MALLING H, 1988, ALLERGY S6, V43; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MALLING HJ, 1993, ALLERGY, V48, P9; Malling HJ, 1998, ALLERGY, V53, P461; MALLING HJ, 1982, ALLERGY, V37, P563, DOI 10.1111/j.1398-9995.1982.tb02341.x; MALLING HJ, 1985, ALLERGY, V40, P400, DOI 10.1111/j.1398-9995.1985.tb02678.x; MALLING HJ, 1984, ALLERGY, V39, P596, DOI 10.1111/j.1398-9995.1984.tb01979.x; MALLING HJ, 1986, ALLERGY, V41, P57, DOI 10.1111/j.1398-9995.1986.tb00276.x; Malling HJ, 2000, ALLERGY, V55, P214, DOI 10.1034/j.1398-9995.2000.00110.x; MALM L, 1994, ACTA OTO-LARYNGOL, P53; MALM L, 1976, ACTA ALLERGOL, V31, P245, DOI 10.1111/j.1398-9995.1976.tb01685.x; MALM L, 1999, RHINOLOGY, V37, P133; MALMBERG H, 1991, Rhinology (Utrecht), V29, P137; MALMBERG H, 1983, CLIN OTOLARYNGOL, V8, P273, DOI 10.1111/j.1365-2273.1983.tb01441.x; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; MALMBERG H, 1986, ALLERGIC VASOMOTOR R, P91; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; Malone DC, 1997, J ALLERGY CLIN IMMUN, V99, P22, DOI 10.1016/S0091-6749(97)81040-8; Malozowski S, 1999, BRIT MED J, V318, P1355; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Mandl M, 1997, ANN ALLERG ASTHMA IM, V79, P370; Manning PJ, 1997, IRISH MED J, V90, P110; Manning SC, 1998, LARYNGOSCOPE, V108, P1485, DOI 10.1097/00005537-199810000-00012; MANNING SC, 1994, ARCH OTOLARYNGOL, V120, P1142; MANSMANN HC, 1992, ANN ALLERGY, V68, P348; Mansur AH, 1999, AM J RESP CRIT CARE, V159, P1796; Mant D, 1999, LANCET, V353, P743, DOI 10.1016/S0140-6736(98)09102-8; MARCHIANDO RJ, 1995, ANN PHARMACOTHER, V29, P937; Markham A, 1998, DRUGS, V55, P269, DOI 10.2165/00003495-199855020-00012; MARKS G, 1993, J CLIN EPIDEMIOL, V10, P1103; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARSH DG, 1982, J EXP MED, V155, P1452, DOI 10.1084/jem.155.5.1452; Martin BW, 1997, SOZ PRAVENTIV MED, V42, P67, DOI 10.1007/BF01318136; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, AM J HUM GENET, V55, P555; Martinez FD, 1999, LANCET S2, V354, pSII12; Masi M, 1993, Pediatr Allergy Immunol, V4, P47; Mason J, 1999, CLIN EXP ALLERGY, V29, P163, DOI 10.1046/j.1365-2222.1999.0290s3163.x; Mastalerz L, 1997, ALLERGY, V52, P895, DOI 10.1111/j.1398-9995.1997.tb01248.x; Masuda K, 1999, BIOCHEM J, V342, P79, DOI 10.1042/0264-6021:3420079; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MASUYAMA K, 1998, INT ALLERGOL, V47, P103; MATHEWS DR, 1991, JAMA-J AM MED ASSOC, V266, P2375, DOI 10.1001/jama.266.17.2375; Mathieu M, 1999, GENE THER, V6, P245, DOI 10.1038/sj.gt.3300814; Matricardi PM, 1997, BRIT MED J, V314, P999; MATSIS PP, 1994, NEW ZEAL MED J, V107, P402; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; Mattila MJ, 1999, EUR J CLIN PHARMACOL, V55, P85, DOI 10.1007/s002280050600; MATTILA MJ, 1992, EUR J CLIN PHARMACOL, V43, P179, DOI 10.1007/BF01740667; Maune S., 1996, Rhinology (Utrecht), V34, P210; MAURER D, 1995, J INVEST DERMATOL, V104, P707, DOI 10.1111/1523-1747.ep12606958; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MAURICE F, 1986, J ALLERGY CLIN IMMUN, V77, P594, DOI 10.1016/0091-6749(86)90351-9; MAXWELL KS, 1994, LARYNGOSCOPE, V104, P989; Mazzotta P, 1999, DRUG SAFETY, V20, P361, DOI 10.2165/00002018-199920040-00005; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; MCBRIDE DE, 1994, AM J RESP CRIT CARE, V149, P1192; McCue JD, 1996, ARCH FAM MED, V5, P464, DOI 10.1001/archfami.5.8.464; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; McFadden EA, 1997, AM J RHINOL, V11, P263, DOI 10.2500/105065897781446702; McGill JI, 1998, BRIT J OPHTHALMOL, V82, P1203, DOI 10.1136/bjo.82.10.1203; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; MCLEOD AA, 1991, BRIT MED J, V302, P1469; McMahon C, 1997, CLIN OTOLARYNGOL, V22, P318, DOI 10.1046/j.1365-2273.1997.00042.x; MCMANUS MS, 1989, EXP LUNG RES, V15, P849, DOI 10.3109/01902148909069631; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; McNeely W, 1998, DRUGS, V56, P91, DOI 10.2165/00003495-199856010-00011; McNulty CA, 1999, AM J RESP CELL MOL, V20, P1251; MCTAVISH D, 1989, DRUGS, V38, P778, DOI 10.2165/00003495-198938050-00005; MCWILLIAM AS, 1995, IMMUNOL CELL BIOL, V73, P405, DOI 10.1038/icb.1995.63; Meager A, 1999, CYTOKINE GROWTH F R, V10, P27, DOI 10.1016/S1359-6101(98)00024-0; Mecheri S, 1997, IMMUNOL TODAY, V18, P212; MEDINA CM, 1985, ALERGIA, V32, P109; Medrala W, 1997, J INVEST ALLERG CLIN, V7, P32; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; MELAMED J, 1994, ANN ALLERGY, V73, P57; MELEN I, 1994, ACTA OTO-LARYNGOL, P45; MELILLO G, 1982, ARZNEIMITTEL-FORSCH, V32-2, P1202; MELLIS CM, 1991, MED J AUSTRALIA, V155, P522; Meltzer EO, 1999, RHINITIS MECH MANAGE, P175; MELTZER EO, 1994, J ALLERGY CLIN IMMUN, V94, P708, DOI 10.1016/0091-6749(94)90178-3; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 1999, ANN ALLERG ASTHMA IM, V83, P311, DOI 10.1016/S1081-1206(10)62671-3; Meltzer EO, 1998, ANN ALLERG ASTHMA IM, V81, P128; MELTZER EO, 1990, J ALLERGY CLIN IMMUN, V86, P613, DOI 10.1016/S0091-6749(05)80225-8; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; MELTZER EO, 1988, J ALLERGY CLIN IMMUN, V82, P447, DOI 10.1016/0091-6749(88)90018-8; MELTZER EO, 1990, ANN ALLERGY, V64, P536; MENARDO JL, 1982, ANN ALLERGY, V48, P235; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; MERINEY DK, 1986, ANN ALLERGY, V56, P34; MESLIER N, 1988, AM REV RESPIR DIS, V137, P617; Metcalfe D. D., 1996, CRITICAL REV FOOD SC, V36S, P165; Metson R, 1998, ARCH OTOLARYNGOL, V124, P1090; Metz DP, 1996, J ALLERGY CLIN IMMUN, V98, P686, DOI 10.1016/S0091-6749(96)70103-3; Metzger H, 1999, IMMUNOL LETT, V68, P53, DOI 10.1016/S0165-2478(99)00030-9; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; METZGER WJ, 1995, SPRINGER SEMIN IMMUN, V16, P467; Meyer JE, 1998, INT ARCH ALLERGY IMM, V117, P60, DOI 10.1159/000023991; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MIADONNA A, 1983, CLIN ALLERGY, V13, P155, DOI 10.1111/j.1365-2222.1983.tb02583.x; MIADONNA A, 1995, CLIN EXP ALLERGY, V25, P364, DOI 10.1111/j.1365-2222.1995.tb01055.x; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357; Miadonna A, 1998, EUR J CLIN PHARMACOL, V54, P515, DOI 10.1007/s002280050506; MIADONNA A, 1989, AM REV RESPIR DIS, V140, P142; MIADONNA A, 1988, ANN ALLERGY, V61, P220; MICHEL L, 1988, J ALLERGY CLIN IMMUN, V82, P101, DOI 10.1016/0091-6749(88)90058-9; Michelson PH, 1999, OTOLARYNG HEAD NECK, V120, P225, DOI 10.1016/S0194-5998(99)70411-0; MIGLETS A, 1973, LARYNGOSCOPE, V83, P1355, DOI 10.1288/00005537-197309000-00001; MIGLIOR M, 1993, ACTA OPHTHALMOL, V71, P73; Miki I, 1996, CELL IMMUNOL, V171, P285; Milewski M, 1998, J ALLERGY CLIN IMMUN, V101, P581; MILFORD CA, 1990, J LARYNGOL OTOL, V104, P123, DOI 10.1017/S0022215100112022; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 1999, ANN ALLERG ASTHMA IM, V83, P105, DOI 10.1016/S1081-1206(10)62620-8; Min YG, 1997, CLIN OTOLARYNGOL, V22, P139, DOI 10.1046/j.1365-2273.1997.00879.x; Ming M, 1996, KIDNEY INT, V50, P94, DOI 10.1038/ki.1996.291; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1177/019459989811800514; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683; MISAWA M, 1991, ARZNEIMITTEL-FORSCH, V41-2, P1277; MISAWA M, 1991, ARZNEIMITTEL-FORSCH, V41-2, P1145; MITCHELL JA, 1995, BIOCHEM PHARMACOL, V50, P1535, DOI 10.1016/0006-2952(95)00212-X; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; Miyamoto T, 1997, ALLERGY, V52, P30; Mlakar A, 1996, CHEM PHYS LIPIDS, V79, P47, DOI 10.1016/0009-3084(95)02506-5; Moffatt M. F., 1994, Lancet (North American Edition), V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; MOGI G, 1992, ACTA OTO-LARYNGOL, P155; MOGUILEVSKY N, 1995, J RECEPT SIGNAL TR R, V15, P91, DOI 10.3109/10799899509045210; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; MOLLER C, 1994, CLIN EXP ALLERGY, V24, P884, DOI 10.1111/j.1365-2222.1994.tb01811.x; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; Moller M, 1998, ALLERGY, V53, P289, DOI 10.1111/j.1398-9995.1998.tb03889.x; MOLONEY JR, 1977, BRIT J DIS CHEST, V71, P1; MOLONEY JR, 1977, J LARYNGOL OTOL, V91, P837, DOI 10.1017/S0022215100084450; MONAHAN BP, 1990, JAMA-J AM MED ASSOC, V264, P2788, DOI 10.1001/jama.264.21.2788; Moneret-Vautrin Denise Anne, 1992, Rhinology (Utrecht), V30, P161; MONERETVAUTRIN DA, 1990, ANN ALLERGY, V64, P513; Monn C, 1998, SCI TOTAL ENVIRON, V215, P243, DOI 10.1016/S0048-9697(98)00124-7; MONROE EW, 1992, CLIN THER, V14, P17; Montan PG, 1996, BRIT J OPHTHALMOL, V80, P556, DOI 10.1136/bjo.80.6.556; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393; MONTEFORT S, 1993, EUR RESPIR J, V6, P1044; Montefort S, 1998, CLIN EXP ALLERGY, V28, P1089; Moon JS, 1999, YONSEI MED J, V40, P238; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; Morelli Maria C., 1996, Allergology International, V45, P151, DOI 10.2332/allergolint.45.151; MORGANROTH J, 1993, AM J CARDIOL, V72, pB26, DOI 10.1016/0002-9149(93)90037-D; Mori J, 1998, Acta Otolaryngol Suppl, V538, P197; Mori S, 1999, CLIN EXP ALLERGY, V29, P1542; Morita Eishin, 1999, Journal of Dermatology (Tokyo), V26, P282; Morris JB, 1999, J APPL PHYSIOL, V87, P1877; Morris S, 1997, AM J RHINOL, V11, P109, DOI 10.2500/105065897782537197; Morrissette Naomi, 1999, Trends in Cell Biology, V9, P199, DOI 10.1016/S0962-8924(99)01540-8; MORROWBROWN H, 1984, ALLERGOL IMMUNOPATH, V12, P355; Morsy Tosson A., 1995, Journal of the Egyptian Society of Parasitology, V25, P195; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Moscato G, 1997, OCCUP MED-OXFORD, V47, P249, DOI 10.1093/occmed/47.4.249; MOSCATO G, 1995, EUR RESPIR J, V8, P467, DOI 10.1183/09031936.95.08030467; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Moss AJ, 1999, CLIN EXP ALLERGY, V29, P200, DOI 10.1046/j.1365-2222.1999.0290s3200.x; MOURAD W, 1988, J IMMUNOL, V141, P3486; MOUSTAFA AF, 1976, MYCOPATHOLOGIA, V59, P29, DOI 10.1007/BF00491201; MOYES CD, 1995, NEW ZEAL MED J, V108, P358; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; MUELLER R, 1994, EUR J IMMUNOL, V24, P2935, DOI 10.1002/eji.1830241203; Mukaida N, 1998, CYTOKINE GROWTH F R, V9, P9, DOI 10.1016/S1359-6101(97)00022-1; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; MULLINS RJ, 1989, J ALLERGY CLIN IMMUN, V83, P955, DOI 10.1016/0091-6749(89)90111-5; MULLOL J, 1992, NEUROPEPTIDES, V21, P231, DOI 10.1016/0143-4179(92)90027-T; MULLOL J, 1995, CLIN EXP ALLERGY, V25, P607, DOI 10.1111/j.1365-2222.1995.tb01108.x; MULLOL J, 1995, THORAX, V50, P270, DOI 10.1136/thx.50.3.270; Mullol J, 1997, CLIN EXP ALLERGY, V27, P1432, DOI 10.1046/j.1365-2222.1997.1750975.x; MULLOL J, 1992, J ALLERGY CLIN IMMUN, V89, P584, DOI 10.1016/0091-6749(92)90326-W; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; MUNIR AKM, 1995, CLIN EXP ALLERGY, V25, P119, DOI 10.1111/j.1365-2222.1995.tb01016.x; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; Munk ZM, 1996, ANN ALLERG ASTHMA IM, V77, P277; MUNK ZM, 1994, PEDIATR ASTHMA ALLER, V8, P39, DOI 10.1089/pai.1994.8.39; Munk ZM, 1997, ANN ALLERG ASTHMA IM, V78, P325; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; MURRAY AB, 1990, J ALLERGY CLIN IMMUN, V86, P732, DOI 10.1016/S0091-6749(05)80177-0; MURRAY AB, 1989, PEDIATRICS, V84, P451; MUSK AW, 1989, BRIT J IND MED, V46, P636; Mygind N, 1996, ACTA OTO-LARYNGOL, V116, P164, DOI 10.3109/00016489609137814; Mygind N, 1989, Rhinol Suppl, V9, P37; Mygind N, 1987, Eur J Respir Dis Suppl, V153, P26; MYGIND N, 1973, BRIT MED J, V4, P464; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505; Naclerio RM, 1997, ARCH OTOLARYNGOL, V123, P193; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1993, J ALLERGY CLIN IMMUN, V92, P717, DOI 10.1016/0091-6749(93)90015-8; NACLERIO RM, 1991, AM REV RESPIR DIS, V143, pS91; Naclerio RM, 1997, ALLERGY, V52, P7; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NACLERIO RM, 1986, J ALLERGY CLIN IMMUN, V78, P874, DOI 10.1016/0091-6749(86)90233-2; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; NACLERIO RM, 1990, AM REV RESPIR DIS, V142, P167; Naito Kensei, 1999, Rhinology (Utrecht), V37, P66; Naito Kensei, 1993, Auris Nasus Larynx, V20, P31; Nakamura H, 1999, ACTA OTO-LARYNGOL, V119, P592; Nassif PS, 1998, OTOLARYNG HEAD NECK, V119, P564, DOI 10.1016/S0194-5998(98)70012-9; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157; NEELEY SP, 1994, AM J RESP CELL MOL, V11, P206; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; NELSON BL, 1982, J ALLERGY CLIN IMMUN, V70, P125, DOI 10.1016/0091-6749(82)90240-8; NELSON DJ, 1995, AM J RESP CRIT CARE, V151, P475; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P750, DOI 10.1016/0091-6749(93)90019-C; NEUKIRCH F, 1995, RESP MED, V89, P685, DOI 10.1016/0954-6111(95)90136-1; NEUKIRCH F, 1992, AM REV RESPIR DIS, V146, P71; Neville RG, 1999, EUR RESPIR J, V14, P605, DOI 10.1034/j.1399-3003.1999.14c20.x; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; NewsonSmith G, 1997, EUR ARCH OTO-RHINO-L, V254, P236, DOI 10.1007/BF00874095; Ng PW, 1996, AUST NZ J MED, V26, P120, DOI 10.1111/j.1445-5994.1996.tb02923.x; NG TP, 1994, INT J EPIDEMIOL, V23, P553, DOI 10.1093/ije/23.3.553; Ngamphaiboon J, 1997, ANN ALLERG ASTHMA IM, V78, P479; NICHOLSON AN, 1983, EUR J CLIN PHARMACOL, V25, P563, DOI 10.1007/BF00542129; Nicholson AN, 1998, AVIAT SPACE ENVIR MD, V69, P166; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; NICKELSEN JA, 1986, J ALLERGY CLIN IMMUN, V77, P43, DOI 10.1016/0091-6749(86)90320-9; NICKLAS R, 1996, J ALLERGY CLIN IMMUN, V6, P1001; NIEMEIJER NR, 1993, ALLERGY, V48, P498, DOI 10.1111/j.1398-9995.1993.tb01105.x; NIIMI N, 1992, EUR J PHARMACOL, V221, P325; Nilsson G, 1998, ALLERGY, V53, P874, DOI 10.1111/j.1398-9995.1998.tb03994.x; NINAN TK, 1992, BRIT MED J, V304, P873; NISHIOKA GJ, 1994, OTOLARYNG HEAD NECK, V110, P494; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; NIZAMI RM, 1977, ANN ALLERGY, V38, P42; NIZAMI RM, 1981, ANN ALLERGY, V47, P5; Noguchi E, 1998, GENOMICS, V47, P121, DOI 10.1006/geno.1997.5054; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390; Nolte H, 1997, ANN ALLERG ASTHMA IM, V79, P27; Nomeir AA, 1996, J CLIN PHARMACOL, V36, P923; Nonaka M, 1996, AM J RESP CRIT CARE, V153, P1675; Nonaka M, 1999, INT ARCH ALLERGY IMM, V119, P314, DOI 10.1159/000024209; Noon L, 1911, LANCET, V1, P1572; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; NORDVALL SL, 1990, ACTA PAEDIATR SCAND, V79, P343, DOI 10.1111/j.1651-2227.1990.tb11467.x; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1225; NORMAN PS, 1992, ANN ALLERGY, V69, P309; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P384, DOI 10.1016/0091-6749(78)90118-5; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; NORRIS AA, 1996, CLIN EXP ALLERGY, V4, P5; NORRMAN E, 1994, ALLERGY, V49, P808, DOI 10.1111/j.1398-9995.1994.tb00779.x; Nouri-Aria KT, 1998, INT ARCH ALLERGY IMM, V117, P248, DOI 10.1159/000024019; Novak I, 1997, ACTA BIOL HUNG, V48, P385; NSOULI TM, 1994, ANN ALLERGY, V73, P215; NUTTER AF, 1979, BRIT J DERMATOL, V101, P597, DOI 10.1111/j.1365-2133.1979.tb11893.x; NUTTING CM, 1995, POSTGRAD MED J, V71, P231; O'Banion MK, 1999, CRIT REV NEUROBIOL, V13, P45; OCHENSBERGER B, 1995, BLOOD, V86, P4039; O'Connor GT, 1994, AM J RESP CRIT CARE, V149, pS29; ODELRAM H, 1989, ALLERGY, V44, P432, DOI 10.1111/j.1398-9995.1989.tb04175.x; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; OEI HD, 1988, ANN ALLERGY, V61, P436; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Ogata Yoichi, 1999, Rhinology (Utrecht), V37, P16; OGINO S, 1990, Rhinology (Utrecht), V28, P163; OHANLON JF, 1988, CUTIS, V42, P10; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; Ohashi Y, 1998, SCAND J IMMUNOL, V47, P596; Ohashi Y, 1997, LARYNGOSCOPE, V107, P932, DOI 10.1097/00005537-199707000-00019; Ohashi Y, 1998, ACTA OTO-LARYNGOL, V118, P243, DOI 10.1080/00016489850154973; Ohm M, 1997, AM J RHINOL, V11, P167, DOI 10.2500/105065897782537151; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Ohmura T, 1999, EUR J PHARMACOL, V378, P169, DOI 10.1016/S0014-2999(99)00457-4; Ohtani H, 1999, J PHARM PHARMACOL, V51, P1059, DOI 10.1211/0022357991773393; OHTOSHI T, 1991, INT ARCH ALLER A IMM, V95, P376; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Okano M, 1999, ACTA OTO-LARYNGOL, P58; OKAYAMA M, 1995, J ALLERGY CLIN IMMUN, V95, P96, DOI 10.1016/S0091-6749(95)70157-5; OKAYAMA M, 1993, AM J RESP CELL MOL, V8, P176; OKAZAKI T, 1977, PROSTAGLANDINS, V13, P681, DOI 10.1016/0090-6980(77)90239-8; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1985, ANN ALLERGY, V55, P721; OKUDA M, 1985, ANN ALLERGY, V54, P152; OKUDA M, 1982, Rhinology (Utrecht), V20, P13; Okuda M, 1983, Eur J Respir Dis Suppl, V128 (Pt 1), P7; OKUDA M, 1988, ANN ALLERGY, V60, P537; Okuda M., 1998, ALLERGY IMMUNOL, V5, P86; Okuma Minoru, 1994, Japanese Journal of Allergology, V43, P492; OLONITOLA OS, 1994, ANN ALLERGY, V73, P273; OLSEN E, 1994, ANN ALLERGY, V72, P499; Onishi M, 1998, Int Rev Immunol, V16, P617, DOI 10.3109/08830189809043011; Onrust SV, 1998, DRUGS, V56, P725, DOI 10.2165/00003495-199856040-00018; Onuigbo M, 1998, SOUTHERN MED J, V91, P1153; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; OPPENHEIMER JJ, 1993, ANN ALLERGY, V71, P227; ORGEL HA, 1991, ANN ALLERGY, V66, P237; Orr T S, 1977, Acta Allergol, VSuppl 13, P9; ORR TSC, 1969, NATURE, V223, P197, DOI 10.1038/223197b0; Ortega N, 1999, ANN ALLERG ASTHMA IM, V82, P194, DOI 10.1016/S1081-1206(10)62596-3; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; ORTOLANI C, 1981, CLIN ALLERGY, V11, P249, DOI 10.1111/j.1365-2222.1981.tb01591.x; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; Ortolani C, 1999, ALLERGY, V54, P1173, DOI 10.1034/j.1398-9995.1999.00200.x; Osguthorpe JD, 1999, MED CLIN N AM, V83, P27, DOI 10.1016/S0025-7125(05)70085-7; OSTERBALLE O, 1979, ALLERGY, V34, P209, DOI 10.1111/j.1398-9995.1979.tb01700.x; OSTINELLI J, 1998, J ALLERGY CLIN IMMUN, V101, pS246; OSTRO BD, 1994, AM J RESP CRIT CARE, V149, P1400; OSUR SL, 1989, ALLERGY PROC, V10, P133, DOI 10.2500/108854189778961071; OTSUKA H, 1985, J ALLERGY CLIN IMMUN, V76, P695, DOI 10.1016/0091-6749(85)90673-6; Otsuka H, 1998, J ALLERGY CLIN IMMUN, V102, P757, DOI 10.1016/S0091-6749(98)70015-6; OWEN WF, 1987, J IMMUNOL, V138, P532; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V94, P662, DOI 10.1016/0091-6749(94)90171-6; Pablos JL, 1999, CLIN EXP IMMUNOL, V115, P86; Paganelli R, 1998, ALLERGY, V53, P763; Palframan RT, 1998, BLOOD, V91, P2240; PALMACARLOS AG, 1988, INT J CLIN PHARM RES, V8, P25; Panagou P, 1998, ACTA OTO-LARYNGOL, V118, P847, DOI 10.1080/00016489850182567; PANAYOTOPOULOS SM, 1990, ANN ALLERGY, V65, P146; Paolieri F, 1998, ANN ALLERG ASTHMA IM, V81, P601, DOI 10.1016/S1081-1206(10)62712-3; Papageorgiou N, 1997, RESP MED, V91, P83, DOI 10.1016/S0954-6111(97)90072-X; Pariente PD, 1997, PHARMACOECONOMICS, V12, P585; PARIS DG, 1994, AM J EMERG MED, V12, P636, DOI 10.1016/0735-6757(94)90029-9; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; Park AH, 1998, J OTOLARYNGOL, V27, P275; Park HS, 1997, ANN ALLERG ASTHMA IM, V78, P225; Park HS, 1998, ANN ALLERG ASTHMA IM, V81, P219; Parronchi P, 1999, CURR TOP MICROBIOL, V238, P27; Pass RF, 1998, PEDIATRICS, V102, P400, DOI 10.1542/peds.102.2.400; Passalacqua G, 1996, ALLERGY, V51, P666; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461; Passalacqua G, 2000, ALLERGY, V55, P16, DOI 10.1034/j.1398-9995.2000.00370.x; Passalacqua G, 1993, Allergol Immunopathol (Madr), V21, P79; Passali D, 1999, ALLERGY S55, V54, P4; PASTORELLO E, 1985, ANN ALLERGY, V55, P854; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V94, P699, DOI 10.1016/0091-6749(94)90177-5; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V93, P85, DOI 10.1016/0091-6749(94)90236-4; Pastorello EA, 1996, J ALLERGY CLIN IMMUN, V98, P601, DOI 10.1016/S0091-6749(96)70094-5; PASTORELLO EA, 1992, ALLERGY, V47, P463, DOI 10.1111/j.1398-9995.1992.tb00665.x; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; PASTORELLO EA, 1990, ALLERGY, V45, P505, DOI 10.1111/j.1398-9995.1990.tb00526.x; PATAT A, 1995, EUR J CLIN PHARMACOL, V48, P143; PATRIARCA G, 1991, ANN ALLERGY, V67, P60; PATRIARCA G, 1986, ARCH OTO-RHINO-LARYN, V243, P16, DOI 10.1007/BF00457900; PATTEMORE PK, 1989, THORAX, V44, P168, DOI 10.1136/thx.44.3.168; Patussi V, 1994, Med Lav, V85, P402; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; PAULI G, 1993, CLIN EXP ALLERGY, V23, P606, DOI 10.1111/j.1365-2222.1993.tb00901.x; Pauli G, 1997, J ALLERGY CLIN IMMUN, V99, P261, DOI 10.1016/S0091-6749(97)70107-6; PAULI G, 1985, CLIN ALLERGY, V15, P273, DOI 10.1111/j.1365-2222.1985.tb02285.x; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; PAUWELS R, 1998, CLIN EXP ALLERGY, V2, P37; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Pawankar R, 2000, AM J RHINOL, V14, P309, DOI 10.2500/105065800781329582; PAWANKAR R, 1998, CLIN EXP ALLERGY, V3, P6; PAWANKAR R, 1996, J ALLERGY CLIN IMMUN, V98, P248; Pawankar RU, 1996, AM J RESP CRIT CARE, V153, P1655; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2049; Pawankar W., 1999, ALLERG INTER, V48, P171; PAZDRAK K, 1993, ALLERGY, V48, P598, DOI 10.1111/j.1398-9995.1993.tb00755.x; Pearlman DS, 1999, J ALLERGY CLIN IMMUN, V104, pS132; Pearlman DS, 1997, CLIN PEDIATR, V36, P209, DOI 10.1177/000992289703600405; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PECHADRE JC, 1988, EUR J CLIN PHARMACOL, V35, P255, DOI 10.1007/BF00558262; PECOUD A, 1987, INT ARCH ALLER A IMM, V82, P541; PECOUD A, 1986, CLIN ALLERGY, V16, P231, DOI 10.1111/j.1365-2222.1986.tb00770.x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; PEDERSEN B, 1991, ALLERGY, V46, P582, DOI 10.1111/j.1398-9995.1991.tb00627.x; PEDERSEN B, 1994, ALLERGY, V49, P855, DOI 10.1111/j.1398-9995.1994.tb00787.x; PEDERSEN B, 1990, ALLERGY, V45, P451, DOI 10.1111/j.1398-9995.1990.tb01096.x; PEDERSEN B, 1995, ALLERGY, V50, P794; PEDERSEN H, 1976, NATURE, V262, P494, DOI 10.1038/262494a0; PEDERSEN M, 1982, CLIN OTOLARYNGOL, V7, P373, DOI 10.1111/j.1365-2273.1982.tb01400.x; Pedersen P A, 1983, Scand J Prim Health Care, V1, P97, DOI 10.3109/02813438309038476; PEDERSEN PA, 1981, ALLERGY, V36, P375, DOI 10.1111/j.1398-9995.1981.tb01841.x; PELAEZ A, 1996, DRUGS, V1, P35; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; PELIKAN Z, 1988, J ALLERGY CLIN IMMUN, V82, P1103, DOI 10.1016/0091-6749(88)90150-9; PELIKAN Z, 1989, J ALLERGY CLIN IMMUN, V83, P1068, DOI 10.1016/0091-6749(89)90448-X; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PENE J, 1988, J IMMUNOL, V141, P1218; Penttila M, 2000, CLIN EXP ALLERGY, V30, P94; PEPYS J, 1985, CLIN ALLERGY, V15, P101, DOI 10.1111/j.1365-2222.1985.tb02262.x; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; Pepys J., 1975, BRIT J HOSP MED, V14, P412; PERERA BJC, 1995, ARCH DIS CHILD, V72, P312; Perez Sanchez Jose, 1993, Archivos del Instituto de Cardiologia de Mexico, V63, P185; PERKINS JA, 1989, OTOLARYNG HEAD NECK, V101, P641; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442; PERRIN LF, 1984, CLIN ALLERGY, V14, P581, DOI 10.1111/j.1365-2222.1984.tb02246.x; Persi L, 1999, J ALLERGY CLIN IMMUN, V103, P591, DOI 10.1016/S0091-6749(99)70229-0; Persi L, 1997, ALLERGY, V52, P451, DOI 10.1111/j.1398-9995.1997.tb01028.x; PERSI L, 1997, J ALLERGY CLIN IMMUN; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Petruzzelli L, 1999, AM J MED, V106, P467, DOI 10.1016/S0002-9343(99)00058-3; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; PHILIP G, 1994, J ALLERGY CLIN IMMUN, V94, P1035, DOI 10.1016/0091-6749(94)90122-8; Philip G, 1996, AM J RESP CRIT CARE, V153, P1222; Phillips A, 1997, MOL CELL BIOL, V17, P5952; PHILLIPS DE, 1992, CLIN OTOLARYNGOL, V17, P478, DOI 10.1111/j.1365-2273.1992.tb01700.x; PHILLIPS GD, 1989, J ALLERGY CLIN IMMUN, V84, P232, DOI 10.1016/0091-6749(89)90330-8; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; Picado C, 1999, AM J RESP CRIT CARE, V160, P291; Picado Valles C, 1991, Ann Allergy, V67, P615; PICCINILLO J, 1995, AM J RHINOL, V9, P927; Pichat P, 1998, ARZNEIMITTEL-FORSCH, V48, P173; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Piirila P, 1997, EUR RESPIR J, V10, P1918, DOI 10.1183/09031936.97.10081918; Pin I, 1999, ARCH PEDIATRIE, V6, p6S, DOI 10.1016/S0929-693X(99)80240-1; Pinto YM, 1999, LANCET, V353, P980, DOI 10.1016/S0140-6736(99)01009-0; PIPKORN U, 1989, AM REV RESPIR DIS, V140, P729; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1980, Rhinology (Utrecht), V18, P171; PIPKORN U, 1985, ALLERGY, V40, P491, DOI 10.1111/j.1398-9995.1985.tb00255.x; PIPKORN U, 1984, ANN ALLERGY, V52, P183; PIPKORN U, 1987, INT ARCH ALLER A IMM, V84, P123; PIPKORN U, 1987, ALLERGY, V42, P496, DOI 10.1111/j.1398-9995.1987.tb00371.x; PIPKORN U, 1988, CLIN ALLERGY, V18, P253, DOI 10.1111/j.1365-2222.1988.tb02867.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; PIPKORN U, 1988, ALLERGY, V8, P41; Pirila T, 1997, ACTA OTO-LARYNGOL, V117, P596, DOI 10.3109/00016489709113444; Pitkaranta A, 1998, J PEDIATR-US, V133, P390, DOI 10.1016/S0022-3476(98)70276-8; Placido JL, 1996, ALLERGY, V51, P633, DOI 10.1111/j.1398-9995.1996.tb04683.x; Plager DA, 1998, ALLERGY, V53, P33; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Platts-Mills TAE, 1998, CURR OPIN IMMUNOL, V10, P634, DOI 10.1016/S0952-7915(98)80081-2; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Plebani M, 1998, CLIN CHEM, V44, P1974; POHJOLASINTONEN S, 1993, EUR J CLIN PHARMACOL, V45, P191, DOI 10.1007/BF00315505; Ponsonby AL, 1999, THORAX, V54, P664; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; POSEY WC, 1977, CLIN ALLERGY, V7, P485, DOI 10.1111/j.1365-2222.1977.tb01479.x; ESTELLE F, 1994, DRUG SAFETY, V10, P350, DOI 10.2165/00002018-199410050-00002; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918; PRAHL P, 1981, ALLERGY, V36, P561, DOI 10.1111/j.1398-9995.1981.tb01874.x; PRAHL P, 1975, ARCH DIS CHILD, V50, P875; PRATT CM, 1994, AM J CARDIOL, V73, P346, DOI 10.1016/0002-9149(94)90006-X; Pratt CM, 1999, AM J CARDIOL, V83, P1451, DOI 10.1016/S0002-9149(99)00124-1; Prenner BM, 1996, J ALLERGY CLIN IMMUN, V98, P302, DOI 10.1016/S0091-6749(96)70154-9; PRESCOTT CAJ, 1995, INT J PEDIATR OTORHI, V32, P137, DOI 10.1016/0165-5876(94)01125-H; Prescott SL, 1998J	Bousquet, J; Jeffery, PK; Busse, WW; Johnson, M; Vignola, AM				Bousquet, J; Jeffery, PK; Busse, WW; Johnson, M; Vignola, AM			Asthma - From bronchoconstriction to airways inflammation and remodeling	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review							BRONCHOALVEOLAR LAVAGE FLUID; BRONCHIAL EPITHELIAL-CELLS; NECROSIS-FACTOR-ALPHA; COLONY-STIMULATING FACTOR; GROWTH-FACTOR-BETA; AIR-FLOW OBSTRUCTION; SMOOTH-MUSCLE CELLS; SEGMENTAL ANTIGEN CHALLENGE; INHALED BECLOMETHASONE DIPROPIONATE; IDIOPATHIC PULMONARY FIBROSIS		CHU Montpellier, Hop Arnaud Villeneuve, Clin Malad Resp, F-34295 Montpellier 5, France; Hop Arnaud Villeneuve, INSERM U454, Montpellier, France; Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London, England; Univ Wisconsin, Dept Med, Madison, WI USA; CNR, Ist Fisiopatol Resp, Palermo, Italy	Bousquet, J (reprint author), CHU Montpellier, Hop Arnaud Villeneuve, Clin Malad Resp, F-34295 Montpellier 5, France.						Adachi T, 1996, J ALLERGY CLIN IMMUN, V98, pS207, DOI 10.1016/S0091-6749(96)70068-4; ADELROTH E, 1986, NEW ENGL J MED, V315, P480, DOI 10.1056/NEJM198608213150803; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; AHMED T, 1993, NEW ENGL J MED, V329, P90, DOI 10.1056/NEJM199307083290204; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; ALAM R, 1993, J IMMUNOL, V150, P3442; ALMIND M, 1992, DAN MED BULL, V39, P561; Altraja A, 1996, AM J RESP CELL MOL, V15, P482; ALTRAJA A, 1996, J ALLERGY CLIN IMMUN, V98, pS64; Anderson GP, 1996, TRENDS PHARMACOL SCI, V17, P438, DOI 10.1016/S0165-6147(96)01004-8; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; ARM JP, 1993, CLIN SCI, V84, P501; ARNOUX B, 1982, AGENTS ACTIONS, V12, P713, DOI 10.1007/BF01965089; ARVIDSSON P, 1991, EUR RESPIR J, V4, P1168; AUBAS P, 1984, AM REV RESPIR DIS, V130, P875; AUBERT JD, 1994, AM J PHYSIOL, V266, pL655; AUBERT JD, 1994, THORAX, V49, P225, DOI 10.1136/thx.49.3.225; Awadh N, 1998, THORAX, V53, P248; AZZAWI M, 1992, AM REV RESPIR DIS, V145, P1477; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BARNES P, 1980, NEW ENGL J MED, V303, P263, DOI 10.1056/NEJM198007313030506; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1995, NEW ENGL J MED, V332, P868; Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218; BARNES PJ, 1992, J ASTHMA, V29, P165, DOI 10.3109/02770909209099025; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066; BARNES PJ, 1996, J ALLERGY CLIN IMMUN, V98, pS81; BATTEGAY EJ, 1995, J MOL MED-JMM, V73, P333; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Beck L, 1997, FASEB J, V11, P365; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/S0007-0971(75)80039-8; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; BENTLEY AM, 1996, AM J RESP CRIT CARE, V153, P51; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804; Bertrand C, 1996, TRENDS PHARMACOL SCI, V17, P255, DOI 10.1016/0165-6147(96)10027-4; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; BLACK PN, 1989, FEBS LETT, V255, P129, DOI 10.1016/0014-5793(89)81075-0; BLACKHAL.MI, 1970, ARCH DIS CHILD, V45, P363; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BORISH L, 1992, J IMMUNOL, V149, P3078; BOULET LP, 1994, AM J RESP CRIT CARE, V149, P482; BOULET LP, 1994, EUR RESPIR J, V7, P1567, DOI 10.1183/09031936.94.07091567; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865; BOUSHEY HA, 1982, J ALLERGY CLIN IMMUN, V69, P335, DOI 10.1016/0091-6749(82)90142-7; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P649, DOI 10.1016/0091-6749(91)90159-L; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648; BOWLER SD, 1993, AM REV RESPIR DIS, V147, P160; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BRADDING P, 1995, AM J RESP CRIT CARE, V151, P1201; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; BRITTON MG, 1992, EUR RESPIR J, V5, P1062; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BROWN LF, 1997, EXS, V79, P233; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BURKE C, 1992, EUR RESPIR J, V5, P73; BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; Busse W W, 1994, Adv Prostaglandin Thromboxane Leukot Res, V22, P241; Busse WW, 1997, J ALLERGY CLIN IMMUN, V100, P147, DOI 10.1016/S0091-6749(97)70216-1; BUSSE WW, 1994, AM J RESP CRIT CARE, V150, pS77; BUSSE WW, 1995, AM J RESP CRIT CARE, V152, P388; Busse WW, 1996, ARCH INTERN MED, V156, P1514, DOI 10.1001/archinte.156.14.1514; CADE JF, 1973, AUST NZ J MED, V3, P545, DOI 10.1111/j.1445-5994.1973.tb04293.x; CADE JF, 1971, CLIN SCI, V40, P381; Cairns JA, 1996, J IMMUNOL, V156, P275; CALHOUN WJ, 1993, AM REV RESPIR DIS, V147, P1465; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317; Calhoun WJ, 1996, J ALLERGY CLIN IMMUN, V98, pS46, DOI 10.1016/S0091-6749(96)80128-X; CAMBREY AD, 1995, CLIN SCI, V89, P611; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529; CAMPBELL AM, 1994, IMMUNOLOGY, V82, P506; CANONICA GW, 1994, ALLERGY, V49, P135, DOI 10.1111/j.1398-9995.1994.tb00815.x; Cardell BS, 1959, THORAX, V14, P341, DOI 10.1136/thx.14.4.341; CARMICHAEL J, 1981, BRIT MED J, V282, P1419; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; CASALE TB, 1983, ANN ALLERGY, V51, P2; Chakir J, 1996, LAB INVEST, V75, P735; CHANEZ P, 1994, J ALLERGY CLIN IMMUN, V94, P997, DOI 10.1016/0091-6749(94)90118-X; CHANEZ P, 1995, ALLERGY, V50, P878, DOI 10.1111/j.1398-9995.1995.tb02493.x; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; Chanez P, 1996, J ALLERGY CLIN IMMUN, V98, P412, DOI 10.1016/S0091-6749(96)70166-5; CHANEZ P, 1993, AM REV RESPIR DIS, V147, P1497; CHAPMAN HA, 1986, AM REV RESPIR DIS, V133, P437; CHERVINSKY P, 1994, J ALLERGY CLIN IMMUN, V94, P676, DOI 10.1016/0091-6749(94)90174-0; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chihara J, 1996, INT ARCH ALLERGY IMM, V111, P43; Ciba Guest Symposium, 1959, THORAX, V14, P286; CLUROE A, 1989, J CLIN PATHOL, V42, P1026, DOI 10.1136/jcp.42.10.1026; CLUROE AD, 1994, J ASTHMA, V31, P65, DOI 10.3109/02770909409056771; CLUZEL M, 1987, J ALLERGY CLIN IMMUN, V80, P195, DOI 10.1016/0091-6749(87)90129-1; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COHEN P, 1995, AM J PHYSIOL-LUNG C, V269, pL151; COLEBATCH HJ, 1973, J APPL PHYSIOL, V34, P143; COLLINS DS, 1993, AM REV RESPIR DIS, V147, P677; Connolly M J, 1988, Pulm Pharmacol, V1, P53, DOI 10.1016/0952-0600(88)90011-7; CONNOLLY MJ, 1995, CHEST, V108, P401, DOI 10.1378/chest.108.2.401; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4; CROMWELL O, 1992, IMMUNOLOGY, V77, P330; CRUIKSHANK WW, 1995, AM J RESP CELL MOL, V13, P738; CUTZ E, 1978, HISTOPATHOLOGY, V2, P407, DOI 10.1111/j.1365-2559.1978.tb01735.x; DAHLEN B, 1995, CLIN EXP ALLERGY, V2, P50; DAHLEN SE, 1980, NATURE, V288, P484, DOI 10.1038/288484a0; DAMON M, 1989, EUR RESPIR J, V2, P202; DATTA YH, 1995, CIRCULATION, V92, P3304; DE S, 1995, J APPL PHYSIOL, V78, P1555; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; DEMOLY P, 1992, AM J RESP CELL MOL, V7, P128; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Denburg JA, 1996, ALLERGY, V51, P141, DOI 10.1111/j.1398-9995.1996.tb04578.x; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; Diamant Z, 1997, AM J RESP CRIT CARE, V155, P1247; Diamant Z, 1996, AM J RESP CRIT CARE, V153, P1790; DiStefano A, 1996, AM J RESP CRIT CARE, V153, P629; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669; DJUKANOVIC R, 1995, EUR RESPIR J, V8, P831; DOMPELING E, 1992, EUR RESPIR J, V5, P945; DOMPELING E, 1993, ANN INTERN MED, V118, P770; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Doull IJM, 1997, BRIT MED J, V315, P858; Drazen JM, 1996, NEW ENGL J MED, V335, P841, DOI 10.1056/NEJM199609193351202; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; DRAZEN JM, 1994, NEW ENGL J MED, V331, P737, DOI 10.1056/NEJM199409153311110; DUDDRIDGE M, 1993, EUR RESPIR J, V6, P489; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; EBINA M, 1990, AM REV RESPIR DIS, V141, P1322; Ellis AG, 1908, AM J MED SCI, V136, P407, DOI 10.1097/00000441-190809000-00009; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; Evans DW, 1997, THORAX, V52, P136; *EXP PAN REP 2, 1997, NIH PUBL; FABBRI L, 1993, THORAX, V48, P817, DOI 10.1136/thx.48.8.817; FABBRI LM, 1994, AM J RESP CRIT CARE, V150, pS80; FABBRI LM, 1991, RESPIRATION, V1, P18; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; Finnerty JP, 1996, EUR RESPIR J, V9, P1672, DOI 10.1183/09031936.96.09081672; FITZPATRICK MF, 1992, CLIN SCI, V83, P227; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84; Fuller R W, 1988, Pulm Pharmacol, V1, P101, DOI 10.1016/S0952-0600(88)80006-1; Gabbrielli S., 1994, Pathologica (Genoa), V86, P157; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GARDINER PV, 1994, AM J RESP CRIT CARE, V150, P1006; GEORAS SN, 1992, AM J RESP CELL MOL, V7, P261; GERBER F, 1985, REV MAL RESPIR, V2, P313; GIBSON PG, 1993, AM REV RESPIR DIS, V148, P80; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.med.44.1.85; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GODARD P, 1982, J ALLERGY CLIN IMMUN, V70, P88, DOI 10.1016/0091-6749(82)90234-2; GODFREY RWA, 1995, EUR RESPIR J, V8, P922; GOLDIE RG, 1995, CLIN EXP PHARMACOL P, V22, P387, DOI 10.1111/j.1440-1681.1995.tb02028.x; Goldring K, 1997, CLIN EXP ALLERGY, V27, P22; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; GOSSET P, 1995, INT ARCH ALLERGY IMM, V106, P69; GOUNNI AS, 1994, NATURE, V367, P183; GRANGER DN, 1994, J LEUKOCYTE BIOL, V55, P662; GRANT MB, 1992, INVEST OPHTH VIS SCI, V33, P3292; Gratziou C, 1996, AM J RESP CRIT CARE, V153, P515; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25; GREEN WF, 1993, AM J RESP CELL MOL, V8, P518; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; GREENOUGH A, 1987, THORAX, V42, P500, DOI 10.1136/thx.42.7.500; GREIFF L, 1993, CLIN PHYSIOL, V13, P219, DOI 10.1111/j.1475-097X.1993.tb00322.x; Grenier P, 1996, EUR RADIOL, V6, P199; GRIFFIN M, 1983, NEW ENGL J MED, V308, P436, DOI 10.1056/NEJM198302243080807; Gruber BL, 1997, J IMMUNOL, V158, P2310; GUO CB, 1994, AM J RESP CELL MOL, V10, P384; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; HAAHTELA T, 1995, RESP MED, V89, P461, DOI 10.1016/0954-6111(95)90120-5; HALAYKO AJ, 1994, CAN J PHYSIOL PHARM, V72, P1448; Haley KJ, 1998, AM J RESP CRIT CARE, V157, P1; HALL FC, 1993, CLIN EXP ALLERGY, V23, P542, DOI 10.1111/j.1365-2222.1993.tb00892.x; HALLER H, 1991, AM J PHYSIOL, V261, pL478; HAMANN KJ, 1995, J IMMUNOL, V154, P4073; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HAMID Q, 1991, INT ARCH ALLER A IMM, V94, P169; HANCE AJ, 1993, EUR RESPIR J, V6, P1213; HARDINGHAM TE, 1992, FASEB J, V6, P861; HARKONEN E, 1995, AM J RESP CELL MOL, V13, P109; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; HELDIN CH, 1992, EMBO J, V11, P4251; HENDERSON WR, 1994, ANN INTERN MED, V121, P684; HENDERSONSELLER.A, 1996, MITIGATION ADAPTATIO, V1, P1, DOI 10.1007/BF00625613; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; Hirst SJ, 1996, EUR RESPIR J, V9, P808, DOI 10.1183/09031936.96.09040808; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; HOLGATE S, 1993, THORAX, V48, P103, DOI 10.1136/thx.48.2.103; Holgate ST, 1996, RESP MED, V90, P387, DOI 10.1016/S0954-6111(96)90110-9; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; HOLGATE ST, 1993, EUR RESPIR J, V6, P1507; HOLLOWAY L, 1995, ASTHMA RHINITIS, P109; Hoshino M, 1997, EUR RESPIR J, V10, P858; Hoshino M, 1998, THORAX, V53, P21; Hoshino M, 1996, EUR RESPIR J, V9, P696, DOI 10.1183/09031936.96.09040696; HOSSAIN S, 1970, J PATHOL, V101, P171, DOI 10.1002/path.1711010212; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Humbert M, 1996, CLIN EXP ALLERGY, V26, P735; Imamura T, 1996, LAB INVEST, V74, P861; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; INOUE K, 1992, BRIT J PHARMACOL, V105, P393; *INT ASTHM MAN PRO, 1992, ALLERGY          S13, V47, P1; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447; JAAKKOLA MS, 1993, AM REV RESPIR DIS, V147, P359; Jakowlew SB, 1997, BBA-GENE STRUCT EXPR, V1353, P157, DOI 10.1016/S0167-4781(97)00068-7; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JARJOUR NN, 1995, AM J RESP CRIT CARE, V152, P1474; Jarjour NN, 1997, AM J RESP CRIT CARE, V155, P1515; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905; JARJOUR NN, 1991, AM REV RESPIR DIS, V144, P83; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Jeffery PK, 1996, EUR RESPIR J, V9, P1583, DOI 10.1183/09031936.96.09081583; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; JEFFERY PK, 1992, BRIT MED BULL, V48, P23; John M, 1997, J IMMUNOL, V158, P1841; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; JOOS GF, 1994, EUR RESPIR J, V7, P1161; JORDANA M, 1993, AM J RESP CELL MOL, V8, P7; JOSEPH M, 1983, J CLIN INVEST, V71, P221, DOI 10.1172/JCI110762; Joseph M, 1987, Agents Actions Suppl, V21, P169; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128; KAMM RD, 1992, AM REV RESPIR DIS, V145, P1249; Kane GC, 1996, J ALLERGY CLIN IMMUN, V97, P646, DOI 10.1016/S0091-6749(96)70310-X; KAWANAMI O, 1979, LAB INVEST, V40, P717; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22; KELLY C, 1988, THORAX, V43, P684, DOI 10.1136/thx.43.9.684; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kinney PL, 1996, AM J RESP CRIT CARE, V154, P1430; KIPS JC, 1993, CLIN EXP ALLERGY, V23, P247, DOI 10.1111/j.1365-2222.1993.tb00317.x; KNIGHT DA, 1995, EUR J PHARMACOL, V272, P1, DOI 10.1016/0014-2999(94)00601-3; Kofford MW, 1997, J BIOL CHEM, V272, P7127; KOH YY, 1993, AM J RESP CELL MOL, V8, P493; KOSHINO T, 1995, INT ARCH ALLERGY IMM, V107, P378; KOVACS EJ, 1994, FASEB J, V8, P854; Kraft M, 1996, J ALLERGY CLIN IMMUN, V97, P1242, DOI 10.1016/S0091-6749(96)70191-4; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; Kraft M, 1994, Am J Respir Crit Care Med, V149, P946; KRAFT M, 1995, CHEST, V107, pL162; Krishna MT, 1996, J ROY COLL PHYS LOND, V30, P61; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; Krug N, 1996, AM J RESP CELL MOL, V14, P319; KUHN C, 1991, AM J PATHOL, V138, P1257; KUMAR RK, 1994, GROWTH FACTORS, V10, P163, DOI 10.3109/08977199409000234; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; LAITINEN LA, 1991, AM REV RESPIR DIS, V143, P423; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Laitinen LA, 1996, J ALLERGY CLIN IMMUN, V97, P153, DOI 10.1016/S0091-6749(96)80215-6; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; LAITINEN LA, 1987, AM REV RESPIR DIS, V135, P67; LAMA M, 1990, CONNECTIVE TISSUE HL, P123; Lambrecht BN, 1996, CELL BIOL INT, V20, P111, DOI 10.1006/cbir.1996.0015; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LASSALLE P, 1993, CLIN EXP IMMUNOL, V94, P105; Laurent Torvard C., 1996, Immunology and Cell Biology, V74, pA1, DOI 10.1038/icb.1996.32; Lebel B, 1996, ALLERGY, V51, P394, DOI 10.1111/j.1398-9995.1996.tb04636.x; LEFF AR, 1994, CHEST, V106, P1202, DOI 10.1378/chest.106.4.1202; LEIKAUF GD, 1990, AM J PHYSIOL, V259, pL255; LESLIE KO, 1992, CELL MOTIL CYTOSKEL, V22, P92, DOI 10.1002/cm.970220203; LEVINE SJ, 1995, J INVEST MED, V43, P241; Li X, 1997, AM J RESP CRIT CARE, V156, P229; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; LILLY CM, 1993, P SOC EXP BIOL MED, V203, P388; LIU MC, 1991, AM REV RESPIR DIS, V144, P51; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; LUNGARELLA G, 1992, ARCH BIOCHEM BIOPHYS, V292, P128, DOI 10.1016/0003-9861(92)90060-A; LUSCHER TF, 1992, AM REV RESPIR DIS, V146, pS56; LYBERG T, 1990, EUR RESPIR J, V3, P61; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; MACKAY TW, 1994, THORAX, V49, P257, DOI 10.1136/thx.49.3.257; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V151, P607; MAGNAN A, 1994, THORAX, V49, P789, DOI 10.1136/thx.49.8.789; Magnan A, 1997, CLIN EXP ALLERGY, V27, P389; *MAN PED ASTHM, 1997, PED PULM S, V15, P1; MANOLITSAS ND, 1995, AM J RESP CRIT CARE, V151, P1925; MARINELLI WA, 1991, AM J RESP CELL MOL, V5, P503; MAROM ZVI, 1982, AM REV RESPIR DIS, V126, P449; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mautino G, 1997, AM J RESP CELL MOL, V17, P583; MCCARTHY DS, 1980, THORAX, V35, P298, DOI 10.1136/thx.35.4.298; MCFADDEN ER, 1992, NEW ENGL J MED, V327, P1928, DOI 10.1056/NEJM199212313272708; McGill KA, 1996, LANCET, V348, P519, DOI 10.1016/S0140-6736(95)12297-4; MCGOWAN SE, 1992, FASEB J, V6, P2895; Mclean AN, 1998, THORAX, V53, P308; Meagher LC, 1996, J IMMUNOL, V156, P4422; MEDINA L, 1994, BBA-MOL CELL RES, V1224, P168, DOI 10.1016/0167-4889(94)90187-2; Meininger C J, 1992, Semin Cancer Biol, V3, P73; MESSER JW, 1960, DIS CHEST, V38, P616; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1046/j.1365-2222.1996.d01-337.x; MONTEFORT S, 1993, EUR RESPIR J, V6, P1257; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORRISON JFJ, 1991, THORAX, V46, P197, DOI 10.1136/thx.46.3.197; MOSER M, 1995, EUR J IMMUNOL, V25, P2818, DOI 10.1002/eji.1830251016; Mosher Deane F., 1992, Current Opinion in Cell Biology, V4, P810, DOI 10.1016/0955-0674(92)90104-K; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; MullerSuur C, 1997, EUR RESPIR J, V10, P376, DOI 10.1183/09031936.97.10020376; MUNOZ NM, 1994, J PHARMACOL EXP THER, V268, P139; Murray J J, 1985, Trans Assoc Am Physicians, V98, P275; NAGASE T, 1990, BIOCHEM BIOPH RES CO, V168, P485, DOI 10.1016/0006-291X(90)92347-3; NAGATA M, 1995, J IMMUNOL, V155, P4948; NAGATA Y, 1992, J LAB CLIN MED, V120, P707; NAKAMURA Y, 1995, AM J PHYSIOL-LUNG C, V269, pL377; Naseer T, 1997, AM J RESP CRIT CARE, V155, P845; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90; Nauck M, 1997, AM J RESP CELL MOL, V16, P398; NEELD DA, 1990, AM REV RESPIR DIS, V142, P1200; NEELEY SP, 1993, AM J RESP CELL MOL, V8, P633; NELSON HS, 1995, NEW ENGL J MED, V333, P499; NOGUCHI H, 1992, AM J PATHOL, V140, P521; NOMURA A, 1989, LANCET, V2, P747; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467; NOVERAL JP, 1992, AM J PHYSIOL, V263, pL555; NOVERAL JP, 1992, AM J PHYSIOL, V263, pL317; OByrne PM, 1996, NEW ENGL J MED, V335, P886, DOI 10.1056/NEJM199609193351211; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; Ochensberger B, 1996, BLOOD, V88, P3028; OCONNOR CM, 1994, THORAX, V49, P602, DOI 10.1136/thx.49.6.602; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469; OHICKEY SP, 1991, AM REV RESPIR DIS, V144, P1053; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4; OHNISHI T, 1993, J ALLERGY CLIN IMMUN, V92, P607, DOI 10.1016/0091-6749(93)90085-T; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; Ohno I, 1997, AM J RESP CELL MOL, V16, P212; OHNO KJ, 1995, TOXICOL APPL PHARM, V132, P227, DOI 10.1006/taap.1995.1103; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922; OOSTERHOFF Y, 1995, AM J RESP CRIT CARE, V151, P75; OOSTERHOFF Y, 1995, J ALLERGY CLIN IMMUN, V96, P219, DOI 10.1016/S0091-6749(95)70011-0; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; OTTESEN EA, 1992, ANNU REV MED, V43, P417, DOI 10.1146/annurev.med.43.1.417; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Padrid PA, 1996, AM J RESP CRIT CARE, V154, P1812; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084; Paganin F, 1997, EUR RESPIR J, V10, P2446, DOI 10.1183/09031936.97.10112446; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267; Park CS, 1997, RADIOLOGY, V203, P361; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; PAVIA D, 1985, THORAX, V40, P171, DOI 10.1136/thx.40.3.171; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PENE J, 1993, CELL BIOL INT, V17, P353, DOI 10.1006/cbir.1993.1072; Persson CGA, 1996, AM J RESP CRIT CARE, V153, pS9; PERSSON CGA, 1995, CLIN EXP ALLERGY, V25, P807, DOI 10.1111/j.1365-2222.1995.tb00022.x; PERTOVAARA L, 1994, J BIOL CHEM, V269, P6271; PESCI A, 1993, AM REV RESPIR DIS, V147, P684; PIGUET PF, 1993, AM J PATHOL, V143, P651; PINCUS SH, 1987, BLOOD, V70, P572; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; Platts-Mills T A, 1996, Curr Opin Pulm Med, V2, P29; Polosa R, 1997, J ALLERGY CLIN IMMUN, V99, P338, DOI 10.1016/S0091-6749(97)70051-4; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; POULTER LW, 1990, EUR RESPIR J, V3, P792; RABE KF, 1995, AM J PHYSIOL-LUNG C, V269, pL332; RABE KF, 1994, AM J PHYSIOL, V267, pL326; Racke K, 1996, IMMUNOL TODAY, V17, P147, DOI 10.1016/0167-5699(96)80608-6; RAGHOW R, 1994, FASEB J, V8, P823; REDINGTON AE, 1995, AM J RESP CRIT CARE, V151, P1034; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642; REID LM, 1987, J ALLERGY CLIN IMMUN, V80, P415, DOI 10.1016/0091-6749(87)90064-9; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334; Reiss TF, 1997, THORAX, V52, P45; Rennard SI, 1996, J ALLERGY CLIN IMMUN, V98, pS278, DOI 10.1016/S0091-6749(96)70076-3; RICKARD KA, 1992, AM J RESP CELL MOL, V6, P414; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1993, THORAX, V48, P26, DOI 10.1136/thx.48.1.26; ROBINSON DS, 1995, CLIN EXP ALLERGY, V25, P1118, DOI 10.1111/j.1365-2222.1995.tb03259.x; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROBINSON ME, 1992, J OCCUP REHABIL, V2, P1; ROCHE WR, 1989, LANCET, V1, P520; ROISMAN GL, 1995, J CLIN INVEST, V96, P12, DOI 10.1172/JCI118011; ROSS R, 1989, LANCET, V1, P1179; ROYLE X, 1952, BRIT MED J, V1, P577; RUOSS SJ, 1991, J CLIN INVEST, V88, P493, DOI 10.1172/JCI115330; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; Schlick W, 1993, Monaldi Arch Chest Dis, V48, P237; SCHOONBROOD DFM, 1994, AM J RESP CRIT CARE, V150, P1519; SCHWARTZ LB, 1992, AM REV RESPIR DIS, V145, pS18; Schwiebert LA, 1996, J ALLERGY CLIN IMMUN, V97, P143, DOI 10.1016/S0091-6749(96)80214-4; SEDGWICK JB, 1995, J ALLERGY CLIN IMMUN, V96, P375, DOI 10.1016/S0091-6749(95)70057-9; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Semper AE, 1995, ADV EXP MED BIOL, V378, P135; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; SHAW RJ, 1991, RESP MED, V85, P267, DOI 10.1016/S0954-6111(06)80095-8; SHAW RJ, 1991, AM REV RESPIR DIS, V143, P167; SHEEHAN JK, 1995, AM J RESP CELL MOL, V13, P748; SHEPPARD MN, 1992, THORAX, V47, P1064, DOI 10.1136/thx.47.12.1064; SHIELS IA, 1995, MED HYPOTHESES, V45, P37, DOI 10.1016/0306-9877(95)90198-1; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; SHOJI S, 1990, AM REV RESPIR DIS, V141, P218; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; SLADEK K, 1994, AM J RESP CRIT CARE, V149, P940; SMITH HR, 1992, J ALLERGY CLIN IMMUN, V89, P1076, DOI 10.1016/0091-6749(92)90291-9; SOLWAY J, 1991, J APPL PHYSIOL, V71, P2077; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557; Sousa AR, 1997, THORAX, V52, P407; SPARROW MP, 1995, CAN J PHYSIOL PHARM, V73, P180; SPARROW MP, 1991, BRIT J PHARMACOL, V103, P1160; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618; SPERBER K, 1995, J ALLERGY CLIN IMMUN, V95, P868, DOI 10.1016/S0091-6749(95)70131-1; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; STANDIFORD TJ, 1993, J IMMUNOL, V151, P2852; STERK PJ, 1995, CLIN EXP ALLERGY, V2, P8; STEWART AG, 1994, CLIN EXP PHARMACOL P, V21, P277, DOI 10.1111/j.1440-1681.1994.tb02513.x; SULLIVAN P, 1994, LANCET, V343, P1006, DOI 10.1016/S0140-6736(94)90127-9; SUNDERKOTTER C, 1994, J LEUKOCYTE BIOL, V55, P410; SUR S, 1995, J ALLERGY CLIN IMMUN, V96, P661, DOI 10.1016/S0091-6749(95)70265-2; SUR S, 1993, AM REV RESPIR DIS, V148, P713; Synek M, 1996, EUR RESPIR J, V9, P54, DOI 10.1183/09031936.96.09010054; SZEFLER SJ, 1991, CLIN PHARMACOL THER, V49, P59; Taipale J, 1997, FASEB J, V11, P51; Takafuji S, 1996, J IMMUNOL, V156, P3980; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235; TANIZAKI Y, 1993, J ASTHMA, V30, P485, DOI 10.3109/02770909309056758; TAYLOR IK, 1994, EUR RESPIR J, V7, P1966; TAYTARD A, 1986, AM REV RESPIR DIS, V134, P983; Teran LM, 1996, J IMMUNOL, V157, P1806; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76; THOMPSON HL, 1991, J CLIN INVEST, V87, P619, DOI 10.1172/JCI115038; TOMIOKA M, 1984, AM REV RESPIR DIS, V129, P1000; TONNEL AB, 1983, LANCET, V1, P1406; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1111/j.1365-2222.1996.tb00591.x; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Tyrell D J, 1995, Trends Pharmacol Sci, V16, P198; ULRIK CS, 1992, J ASTHMA, V29, P29, DOI 10.3109/02770909209110638; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; *WHO NHLBI, 1995, PUBL; vanderMolen T, 1997, THORAX, V52, P535; VANDERREST M, 1991, FASEB J, V5, P2814; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297; VANSCHAYCK CP, 1992, FAM PRACT, V9, P397, DOI 10.1093/fampra/9.4.397; VANVYVE T, 1995, J ALLERGY CLIN IMMUN, V95, P60, DOI 10.1016/S0091-6749(95)70153-2; Vergnenegre A, 1992, Allergol Immunopathol (Madr), V20, P190; VIGNAUD JM, 1991, AM J RESP CELL MOL, V5, P531; VIGNOLA AM, 1993, AM J RESP CELL MOL, V9, P411; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P505; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403; VIRCHOW JC, 1992, AM REV RESPIR DIS, V146, P604; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002; VNGNOLA A, 1997, IN PRESS AM J RESP C; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584; WALKER C, 1991, J IMMUNOL, V146, P1829; WALKER C, 1991, J ALLERGY CLIN IMMUN, V88, P935, DOI 10.1016/0091-6749(91)90251-I; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; WALLEN N, 1991, J IMMUNOL, V147, P3490; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1046/j.1365-2222.1997.d01-532.x; WALZ TM, 1993, LEUKEMIA, V7, P1531; WANG JH, 1994, J ALLERGY CLIN IMMUN, V94, P1025, DOI 10.1016/0091-6749(94)90121-X; Wang JH, 1996, AM J RESP CELL MOL, V14, P27; Wanner A, 1996, AM J RESP CRIT CARE, V154, P1868; WARD C, 1990, EUR RESPIR J, V3, P1008; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; WARDLAW AJ, 1992, J ALLERGY CLIN IMMUN, V89, P164; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; WENZEL SE, 1989, AM REV RESPIR DIS, V139, P450; White E, 1996, GENE DEV, V10, P1, DOI 10.1101/gad.10.1.1; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481; WOOLCOCK AJ, 1993, EUR RESPIR J, V6, P743; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788; WOOLLEY KL, 1994, EUR RESPIR J, V7, P1576, DOI 10.1183/09031936.94.07091576; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237; Yao PM, 1997, AM J PHYSIOL-LUNG C, V273, pL866; Yao PM, 1996, J BIOL CHEM, V271, P15580; YING S, 1995, AM J RESP CELL MOL, V12, P477; Ying S, 1997, J IMMUNOL, V158, P3539; Young LS, 1998, IMMUNOL TODAY, V19, P502, DOI 10.1016/S0167-5699(98)01340-1; ZANGRILLI JG, 1995, AM J RESP CRIT CARE, V151, P1346; ZAPLETAL A, 1993, PEDIATR PULM, V15, P13, DOI 10.1002/ppul.1950150103; Zhang S, 1996, EUR RESPIR J, V9, P1839, DOI 10.1183/09031936.96.09091839; Zhang S, 1996, J PATHOL, V180, P95	554	1105	1165	14	83	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY	2000	161	5					1720	1745				26	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	312LU	WOS:000086945400054	10806180	
J	Braun-Fahrlander, C; Riedler, J; Herz, U; Eder, W; Waser, M; Grize, L; Maisch, S; Carr, D; Gerlach, F; Bufe, A; Lauener, RP; Schierl, R; Renz, H; Nowak, D; von Mutius, E				Braun-Fahrlander, C; Riedler, J; Herz, U; Eder, W; Waser, M; Grize, L; Maisch, S; Carr, D; Gerlach, F; Bufe, A; Lauener, RP; Schierl, R; Renz, H; Nowak, D; von Mutius, E		Allergy Endotoxin Study Team	Environmental exposure to endotoxin and its relation to asthma in school-age children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOUSE-DUST ENDOTOXIN; AIRBORNE ENDOTOXIN; IMMUNE-RESPONSE; CHILDHOOD; LIFE; RISK; SENSITIZATION; ALLERGY	Background: In early life, the innate immune system can recognize both viable and nonviable parts of microorganisms. Immune activation may direct the immune response, thus conferring tolerance to allergens such as animal dander or tree and grass pollen. Methods: Parents of children who were 6 to 13 years of age and were living in rural areas of Germany, Austria, or Switzerland where there were both farming and nonfarming households completed a standardized questionnaire on asthma and hay fever. Blood samples were obtained from the children and tested for atopic sensitization; peripheral-blood leukocytes were also harvested from the samples for testing. The levels of endotoxin in the bedding used by these children were examined in relation to clinical findings and to the cytokine-production profiles of peripheral-blood leukocytes that had been stimulated with lipopolysaccharide and staphylococcal enterotoxin B. Complete data were available for 812 children. Results: Endotoxin levels in samples of dust from the child's mattress were inversely related to the occurrence of hay fever, atopic asthma, and atopic sensitization. Nonatopic wheeze was not significantly associated with the endotoxin level. Cytokine production by leukocytes (production of tumor necrosis factor (alpha), interferon-(gamma), interleukin-10, and interleukin-12) was inversely related to the endotoxin level in the bedding, indicating a marked down-regulation of immune responses in exposed children. Conclusions: A subject's environmental exposure to endotoxin may have a crucial role in the development of tolerance to ubiquitous allergens found in natural environments.	Univ Basel, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; Childrens Hosp Salzburg, Salzburg, Austria; Hosp Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; Dr von Hauner Childrens Hosp, Munich, Germany; Ruhr Univ Bochum, Dept Expt Pneumol, D-4630 Bochum, Germany; Univ Zurich, Childrens Hosp, Zurich, Switzerland; Univ Munich, Inst Occupat & Environm Med, Munich, Germany	Braun-Fahrlander, C (reprint author), Univ Basel, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.		Lauener, Roger/O-8612-2016	Lauener, Roger/0000-0002-8412-606X			AbouZeid C, 1997, INFECT IMMUN, V65, P1856; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Cleveland MG, 1996, INFECT IMMUN, V64, P1906; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Delves PJ, 2000, NEW ENGL J MED, V343, P37; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; ISAAC, 1998, PHAS 2 MOD INT STUD; Kabesch M, 1999, EUR RESPIR J, V13, P577, DOI 10.1183/09031936.99.13357799; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; *MATHS, 2000, S PLUS; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981; SAS Institute, 2001, SAS REL 8 02; Schade FU, 1996, J ENDOTOXIN RES, V3, P455; Silverman M, 1997, THORAX, V52, P936; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Strachan DP, 1996, BRIT MED J, V312, P1195; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009	27	1064	1090	16	94	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 19	2002	347	12					869	877		10.1056/NEJMoa020057		9	Medicine, General & Internal	General & Internal Medicine	594GJ	WOS:000178040700002	12239255	
J	Akbari, O; DeKruyff, RH; Umetsu, DT				Akbari, O; DeKruyff, RH; Umetsu, DT			Pulmonary dendritic cells producing IL-10 mediate tolerance induced by respiratory exposure to antigen	NATURE IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; MOUSE BONE-MARROW; CD4(+) T-CELLS; IN-VIVO; INTERFERON-GAMMA; IMMUNE DEVIATION; TH2 RESPONSES; INDUCTION; DIFFERENTIATION; INTERLEUKIN-10	Respiratory exposure to allergen induces T cell tolerance and protection against the development of airway hyperreactivity and asthma. However, the specific mechanisms by which tolerance is induced by respiratory allergen are not clear. We report here that pulmonary dendritic cells (DCs) from mice exposed to respiratory antigen transiently produced interleukin 10 (IL-10). These phenotypically mature pulmonary DCs, which were B-7(hi) as well as producing IL-10, stimulated the development of CD4(+)T regulatory I-like cells that also produced high amounts of IL-10. In addition, adoptive transfer of pulmonary DCs from IL-10(+/+), but not IL-10(-/-), mice exposed to respiratory antigen induced antigen-specific unresponsiveness in recipient mice. These studies show that IL-10 production by DCs is critical for the induction of tolerance, and that phenotypically mature pulmonary DCs mediate tolerance induced by respiratory exposure to antigen.	Stanford Univ, Sch Med, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA	Umetsu, DT (reprint author), Stanford Univ, Sch Med, Dept Pediat, Div Immunol & Allergy, Stanford, CA 94305 USA.				NHLBI NIH HHS [R01HL62348]; NIAID NIH HHS [AI24571, AI26322]		ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Borish L, 1998, J ALLERGY CLIN IMMUN, V101, P293; Chang CCJ, 2000, J IMMUNOL, V165, P3584; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; de Saint-Vis B, 1998, J IMMUNOL, V160, P1666; Dong HD, 1999, NAT MED, V5, P1365; Groux H, 1997, NATURE, V389, P737; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P597, DOI 10.1111/j.1365-2222.1989.tb02752.x; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; Hutloff A, 1999, NATURE, V397, P263; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; John M, 1998, AM J RESP CRIT CARE, V157, P256; Jonuleit H, 2000, GENE THER, V7, P249, DOI 10.1038/sj.gt.3301077; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Khanna A, 2000, J IMMUNOL, V164, P1346; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; LEVIN D, 1993, J IMMUNOL, V151, P6742; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Macaulay AE, 1998, J IMMUNOL, V160, P1694; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARRACK P, 1983, J EXP MED, V158, P1635, DOI 10.1084/jem.158.5.1635; McAdam AJ, 2000, J IMMUNOL, V165, P5035; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MCMENAMIN C, 1991, INT ARCH ALLER A IMM, V94, P78; MELAMED D, 1993, EUR J IMMUNOL, V23, P935, DOI 10.1002/eji.1830230426; POLLARD AM, 1990, J EXP MED, V172, P159, DOI 10.1084/jem.172.1.159; Pulendran B, 1997, J IMMUNOL, V159, P2222; REINER SL, 1993, J IMMUNOL METHODS, V165, P37, DOI 10.1016/0022-1759(93)90104-F; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; SCHEICHER C, 1992, J IMMUNOL METHODS, V154, P253, DOI 10.1016/0022-1759(92)90199-4; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; STOCKINGER B, 1994, INT IMMUNOL, V6, P247, DOI 10.1093/intimm/6.2.247; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Vremec D, 1997, J IMMUNOL, V159, P565; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wu L, 1996, J EXP MED, V184, P903, DOI 10.1084/jem.184.3.903; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582	44	874	909	0	22	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	AUG	2001	2	8					725	731		10.1038/90667		7	Immunology	Immunology	459BN	WOS:000170230100015	11477409	
J	Eisenbarth, SC; Piggott, DA; Huleatt, JW; Visintin, I; Herrick, CA; Bottomly, K				Eisenbarth, SC; Piggott, DA; Huleatt, JW; Visintin, I; Herrick, CA; Bottomly, K			Lipopolysaccharide-enhanced, toll-like receptor 4-dependent T helper cell type 2 responses to inhaled antigen	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						asthma; Toll-like receptor; T cell; dendritic cell; lung	EXPOSURE; ASTHMA; MOUSE; TLR4	Allergic asthma is an inflammatory lung disease initiated and directed by T helper cells type 2 (Th2). The mechanism involved in generation of Th2 responses to inert inhaled antigens, however, is unknown. Epidemiological evidence suggests that exposure to lipopolysaccharide (LPS) or other microbial products can influence the development and severity of asthma. However, the mechanism by which LPS influences asthma pathogenesis remains undefined. Although it is known that signaling through Toll-like receptors (TLR) is required for adaptive T helper cell type 1 (Th1) responses, it is unclear if TLRs are needed for Th2 priming. Here, we report that low level inhaled LPS signaling through TLR4 is necessary to induce Th2 responses to inhaled antigens in a mouse model of allergic sensitization. The mechanism by which LPS signaling results in Th2 sensitization involves the activation of antigen-containing dendritic cells. In contrast to low levels, inhalation of high levels of LPS with antigen results in Th1 responses. These studies suggest that the level of LPS exposure can determine the type of inflammatory response generated and provide a potential mechanistic explanation of epidemiological data on endotoxin exposure and asthma prevalence.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Bottomly, K (reprint author), Yale Univ, Sch Med, Immunobiol Sect, 310 Cedar St, New Haven, CT 06520 USA.			Eisenbarth, Stephanie/0000-0002-1244-208X	NHLBI NIH HHS [HL54450, R01 HL054450]; NIAID NIH HHS [R37 AI026791, AI26791, R01 AI026791]; NIGMS NIH HHS [5T32GM07205, T32 GM007205]		Arbour NC, 2000, NAT GENET, V25, P187; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Dabbagh K, 2002, J IMMUNOL, V168, P4524; Gern JE, 2000, J ALLERGY CLIN IMMUN, V105, pS497; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; VOGEL SN, 1994, INFECT IMMUN, V62, P4454; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426	19	770	803	2	22	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	DEC 16	2002	196	12					1645	1651		10.1084/jem.20021340		7	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	629PP	WOS:000180058300013	12486107	
J	Kunzli, N; Kaiser, R; Medina, S; Studnicka, M; Chanel, O; Filliger, P; Herry, M; Horak, F; Puybonnieux-Texier, V; Quenel, P; Schneider, J; Seethaler, R; Vergnaud, JC; Sommer, H				Kunzli, N; Kaiser, R; Medina, S; Studnicka, M; Chanel, O; Filliger, P; Herry, M; Horak, F; Puybonnieux-Texier, V; Quenel, P; Schneider, J; Seethaler, R; Vergnaud, JC; Sommer, H			Public-health impact of outdoor and traffic-related air pollution: a European assessment	LANCET			English	Article							TERM AMBIENT CONCENTRATIONS; RESPIRATORY HEALTH; TIME-SERIES; PARTICULATE MATTER; NONSMOKING POPULATION; INHALABLE PARTICLES; HOSPITAL ADMISSIONS; ASTHMATIC-CHILDREN; SULFUR-DIOXIDE; UNITED-STATES	Background Air pollution contributes to mortality and morbidity. We estimated the impact of outdoor (total) and traffic-related air pollution on public health in Austria, France, and Switzerland. Attributable cases of morbidity and mortality were estimated. Methods Epidemiology-based exposure-response functions for a 10 mu g/m(3) increase in particulate matter (PM10) were used to quantify the effects of air pollution. Cases attributable to air pollution were estimated for mortality (adults greater than or equal to 30 years), respiratory and cardiovascular hospital admissions tall ages), incidence of chronic bronchitis (adults greater than or equal to 25 years), bronchitis episodes in children (<15 years), restricted activity days (adults greater than or equal to 20 years), and asthma attacks in adults and children. Population exposure (PM10) was modelled for each km(2). The traffic-related fraction was estimated based on PM10 emission inventories. Findings Air pollution caused 6% of total mortality or more than 40 000 attributable cases per year. About half of all mortality caused by air pollution was attributed to motorised traffic, accounting also for: more than 25 000 new cases of chronic bronchitis (adults); more than 290 000 episodes of bronchitis (children); more than 0.5 million asthma attacks; and more than 16 million person-days of restricted activities. Interpretation This assessment estimates the public-health impacts of current patterns of air pollution. Although individual health risks of air pollution are relatively small, the public-health consequences are considerable. Traffic-related air pollution remains a key target for public-health action in Europe. Our results, which have also been used for economic valuation, should guide decisions on the assessment of environmental health-policy options.	Univ Basel, Inst Sozial & Pravent Med, CH-4051 Basel, Switzerland; Natl Inst Publ Hlth Surveillance, Dept Environm Hlth, St Maurice, France; Ctr Pulm Dis, Vienna, Austria; GREQAM, Dept Econ, French Natl Ctr Sci Res, Marseille, France; BUWAL, Swiss Agcy Environm Forest & Landscape, Bern, Switzerland; Consultancy Dr Max Henry, Vienna, Austria; Univ Childrens Hosp, Vienna, Austria; Univ Paris 07, LED, Paris, France; Fed Environm Agcy, Dept Air Qual Control, Vienna, Austria; Univ Sydney, Inst Transport Studies, Sydney, NSW 2006, Australia; EUREQUA, Dept Econ, Franch Natl Ctr Sci Res, Paris, France; ECOPLAN, Econ & Environm Studies, Bern, Switzerland; ECOPLAN, Econ & Environm Studies, Altdorf, Switzerland	Kunzli, N (reprint author), Univ Basel, Inst Sozial & Pravent Med, Steinengraben 49, CH-4051 Basel, Switzerland.		Chanel, Olivier/H-6500-2013; QUENEL, PHILIPPE/J-4351-2015; Kunzli, Nino/F-7195-2014	Chanel, Olivier/0000-0002-8221-7558; QUENEL, PHILIPPE/0000-0003-3361-3623; Kunzli, Nino/0000-0001-8360-080X			ABBEY DE, 1993, ARCH ENVIRON HEALTH, V48, P33; ABBEY DE, 1995, ARCH ENVIRON HEALTH, V50, P139; Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; *AM LUNG ASS, 1998, DOLL CENTS EC HLTH B; Baldi I, 1999, EUR RESPIR J, V24, pS392; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; Bates DV, 2000, ENVIRON HEALTH PERSP, V108, P91, DOI 10.2307/3454504; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Brunekreef B, 1999, EPIDEMIOLOGY, V10, P661, DOI 10.1097/00001648-199911000-00001; *DEP HLTH AD HOC G, 1999, EC APPR HLTH EFF AIR; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dora C, 1999, BRIT MED J, V318, P1686; Dusseldorp A, 1995, AM J RESP CRIT CARE, V152, P1032; Eder W, 1998, WIEN KLIN WOCHENSCHR, V110, P669; FILLIGER P, 1999, POPULATION EXPOSURE; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; HAIDINGER W, 1998, SCHLUSSBERICHT ISAAC; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; Holgate ST, 1999, AIR POLLUTION HLTH; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; Kunzli N, 1997, ENVIRON HEALTH PERSP, V105, P1078, DOI 10.2307/3433849; KUNZLI N., 1999, HLTH COSTS DUE ROAD; LA D, 1999, INT J EPIDEMIOL, V28, P894; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; Medina S, 1997, EVALUATION RISQUES P; National Research Council, 1999, RES PRIOR AIRB PART; *NAT RES DEF COUNC, 1996, BREATH TAK PREM MORT; Neukirch F, 1998, ARCH ENVIRON HEALTH, V53, P320; OBERFELD G, 1996, 1 SALZBURGER KINDERG; Ostro B, 1996, J EXPO ANAL ENV EPID, V6, P97; Ostro B, 1998, ENVIRON RES, V76, P94, DOI 10.1006/enrs.1997.3799; OSTRO BD, 1990, RISK ANAL, V10, P421, DOI 10.1111/j.1539-6924.1990.tb00525.x; Poloniecki JD, 1997, OCCUP ENVIRON MED, V54, P535; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Prescott GJ, 1998, OCCUP ENVIRON MED, V55, P697; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Samet JM, 1998, AM J EPIDEMIOL, V148, P929; Segala C, 1998, EUR RESPIR J, V11, P677; Smith KR, 1999, EPIDEMIOLOGY, V10, P573, DOI 10.1097/00001648-199909000-00027; SOMMER H, HLTH COSTS DUE ROAD; Sommer H, 1999, 3 WHO MIN C ENV HLTH; STUDNICKA M, 1997, EUR RESPIR J, V10, P2257; Wilson R., 1996, PARTICLES OUR AIR CO; Wordley J, 1997, OCCUP ENVIRON MED, V54, P108; Zemp E, 1999, AM J RESP CRIT CARE, V159, P1257; Zmirou D, 1998, EPIDEMIOLOGY, V9, P495, DOI 10.1097/00001648-199809000-00005; 1998, ANN STAT REP SWITZ S	49	767	812	20	187	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 2	2000	356	9232					795	801		10.1016/S0140-6736(00)02653-2		7	Medicine, General & Internal	General & Internal Medicine	350LF	WOS:000089101800009	11022926	
J	Riedler, J; Braun-Fahrlander, C; Eder, W; Schreuer, M; Waser, M; Maisch, S; Carr, D; Schierl, R; Nowak, D; von Mutius, E				Riedler, J; Braun-Fahrlander, C; Eder, W; Schreuer, M; Waser, M; Maisch, S; Carr, D; Schierl, R; Nowak, D; von Mutius, E		ALEX Study Team	Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey	LANCET			English	Article							HAY-FEVER; AUSTRIAN CHILDREN; IGE PRODUCTION; CHILDHOOD; SENSITIZATION; PREVALENCE; ATOPY; RISK; STIMULATION; CHALLENGE	Background A farming environment protects against development of asthma, hay fever, and atopic sensitisation in children. We aimed to establish whether increased exposure to microbial compounds has to occur early in life to affect maturation of the immune system and thereby reduces risk for development of allergic diseases. Methods We did a cross-sectional survey in rural areas of Austria, Germany, and Switzerland. 2618 (75%) of 3504 parents of 6-13-year-old children completed a standardised questionnaire on asthma, hay fever, and atopic eczema. Children from farming families, and a random sample of non-farmers' children, who gave consent for blood samples to be obtained for measurements of specific serum IgE antibodies to common allergens were invited to participate (n = 901). Findings Exposure of children younger than 1 year, compared with those aged 1-5 years, to stables and consumption of farm milk was associated with lower frequencies of asthma (1% [3/218] vs 11% [15/138]), hay fever (3% [7] vs 13% [18]), and atopic sensitisation (12% [27] vs 29% [40]). Protection against development of asthma was independent from effect on atopic sensitisation. Continual long-term exposure to stables until age 5 years was associated with the lowest frequencies of asthma (0.8% [1/122]), hay fever (0.8% [1]), and atopic sensitisation (8.2% [10]). Interpretation Long-term and early-life exposure to stables and farm milk induces a strong protective effect against development of asthma, hay fever, and atopic sensitisation.	Childrens Hosp, A-5020 Salzburg, Austria; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; Salzburg Univ, Dept Sociol, A-5020 Salzburg, Austria; Univ Munich, Dr von Hauner Childrens Hosp, Munich, Germany; Univ Munich, Inst Occupat & Environm Med, Munich, Germany	Riedler, J (reprint author), Childrens Hosp, Muellner Hauptstr 48, A-5020 Salzburg, Austria.						Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; KILEWEIN G, 1994, LEITFADEN MILCHKUNDE, P83; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Klinman DM, 1999, VACCINE, V17, P19, DOI 10.1016/S0264-410X(98)00151-0; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Riedler J, 1998, EUR RESPIR J, V11, P355, DOI 10.1183/09031936.98.11020355; Sudo N, 1997, J IMMUNOL, V159, P1739; SUHREN G, 1986, MILCHWISSENSCHAFT, V41, P156; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	24	764	785	21	104	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 6	2001	358	9288					1129	1133		10.1016/S0140-6736(01)06252-3		5	Medicine, General & Internal	General & Internal Medicine	479HM	WOS:000171399000009	11597666	
J	Nierman, WC; Pain, A; Anderson, MJ; Wortman, JR; Kim, HS; Arroyo, J; Berriman, M; Abe, K; Archer, DB; Bermejo, C; Bennett, J; Bowyer, P; Chen, D; Collins, M; Coulsen, R; Davies, R; Dyer, PS; Farman, M; Fedorova, N; Fedorova, N; Feldblyum, TV; Fischer, R; Fosker, N; Fraser, A; Garcia, JL; Garcia, MJ; Goble, A; Goldman, GH; Gomi, K; Griffith-Jones, S; Gwilliam, R; Haas, B; Haas, H; Harris, D; Horiuchi, H; Huang, J; Humphray, S; Jimenez, J; Keller, N; Khouri, H; Kitamoto, K; Kobayashi, T; Konzack, S; Kulkarni, R; Kumagai, T; Lafton, A; Latge, JP; Li, WX; Lord, A; Majoros, WH; May, GS; Miller, BL; Mohamoud, Y; Molina, M; Monod, M; Mouyna, I; Mulligan, S; Murphy, L; O'Neil, S; Paulsen, I; Penalva, MA; Pertea, M; Price, C; Pritchard, BL; Quail, MA; Rabbinowitsch, E; Rawlins, N; Rajandream, MA; Reichard, U; Renauld, H; Robson, GD; de Cordoba, SR; Rodriguez-Pena, JM; Ronning, CM; Rutter, S; Salzberg, SL; Sanchez, M; Sanchez-Ferrero, JC; Saunders, D; Seeger, K; Squares, R; Squares, S; Takeuchi, M; Tekaia, F; Turner, G; de Aldana, CRV; Weidman, J; White, O; Woodward, J; Yu, JH; Fraser, C; Galagan, JE; Asai, K; Machida, M; Hall, N; Barrell, B; Denning, DW				Nierman, WC; Pain, A; Anderson, MJ; Wortman, JR; Kim, HS; Arroyo, J; Berriman, M; Abe, K; Archer, DB; Bermejo, C; Bennett, J; Bowyer, P; Chen, D; Collins, M; Coulsen, R; Davies, R; Dyer, PS; Farman, M; Fedorova, N; Fedorova, N; Feldblyum, TV; Fischer, R; Fosker, N; Fraser, A; Garcia, JL; Garcia, MJ; Goble, A; Goldman, GH; Gomi, K; Griffith-Jones, S; Gwilliam, R; Haas, B; Haas, H; Harris, D; Horiuchi, H; Huang, J; Humphray, S; Jimenez, J; Keller, N; Khouri, H; Kitamoto, K; Kobayashi, T; Konzack, S; Kulkarni, R; Kumagai, T; Lafton, A; Latge, JP; Li, WX; Lord, A; Majoros, WH; May, GS; Miller, BL; Mohamoud, Y; Molina, M; Monod, M; Mouyna, I; Mulligan, S; Murphy, L; O'Neil, S; Paulsen, I; Penalva, MA; Pertea, M; Price, C; Pritchard, BL; Quail, MA; Rabbinowitsch, E; Rawlins, N; Rajandream, MA; Reichard, U; Renauld, H; Robson, GD; de Cordoba, SR; Rodriguez-Pena, JM; Ronning, CM; Rutter, S; Salzberg, SL; Sanchez, M; Sanchez-Ferrero, JC; Saunders, D; Seeger, K; Squares, R; Squares, S; Takeuchi, M; Tekaia, F; Turner, G; de Aldana, CRV; Weidman, J; White, O; Woodward, J; Yu, JH; Fraser, C; Galagan, JE; Asai, K; Machida, M; Hall, N; Barrell, B; Denning, DW			Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus	NATURE			English	Article							CELL-WALL; SACCHAROMYCES-CEREVISIAE; GENE-CLUSTER; SENSITIZATION; ARSENITE; COMPOST	Aspergillus fumigatus is exceptional among microorganisms in being both a primary and opportunistic pathogen as well as a major allergen(1-3). Its conidia production is prolific, and so human respiratory tract exposure is almost constant(4). A. fumigatus is isolated from human habitats(5) and vegetable compost heaps(6,7). In immunocompromised individuals, the incidence of invasive infection can be as high as 50% and the mortality rate is often about 50% (ref. 2). The interaction of A. fumigatus and other airborne fungi with the immune system is increasingly linked to severe asthma and sinusitis(8). Although the burden of invasive disease caused by A. fumigatus is substantial, the basic biology of the organism is mostly obscure. Here we show the complete 29.4-megabase genome sequence of the clinical isolate Af293, which consists of eight chromosomes containing 9,926 predicted genes. Microarray analysis revealed temperature-dependent expression of distinct sets of genes, as well as 700 A. fumigatus genes not present or significantly diverged in the closely related sexual species Neosartorya fischeri, many of which may have roles in the pathogenicity phenotype. The Af293 genome sequence provides an unparalleled resource for the future understanding of this remarkable fungus.	Inst Genom Res, Rockville, MD 20850 USA; George Washington Univ, Sch Med, Dept Biochem & Mol Biol, Washington, DC 20037 USA; Wellcome Trust Sanger Inst, Hinxton CB10 1SA, England; Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Med, Manchester M13 9PT, Lancs, England; Univ Complutense Madrid, Dept Microbiol 2, E-28040 Madrid, Spain; Tohoku Univ, Aoba Ku, Sendai, Miyagi 9808555, Japan; Univ Nottingham, Sch Biol, Nottingham NG7 2RD, England; Tulane Univ, Dept Cell & Mol Biol, New Orleans, LA 70118 USA; European Bioinformat Inst, Hinxton CB10 1SD, England; Univ Kentucky, Dept Plant Pathol, Lexington, KY 40546 USA; Max Planck Inst Terr Microbiol, D-35043 Marburg, Germany; CSIC, Ctr Invest Biol, Madrid 28040, Spain; Univ Salamanca, Dept Genet & Microbiol, Salamanca 37007, Spain; Univ Sao Paulo, Fac Ciencias Farmaceut Ribeirao Preto, BR-05508 Sao Paulo, Brazil; Innsbruck Med Univ, Dept Mol Biol, A-6020 Innsbruck, Austria; Univ Wisconsin, Dept Plant Pathol, Madison, WI 53706 USA; Univ Tokyo, Dept Biotechnol, Tokyo 1138657, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Biol Mech & Funct, Nagoya, Aichi 4648601, Japan; Natl Inst Adv Ind Sci 7 Technol AIST, Computat Biol Res Ctr, Koto Ku, Tokyo 1350064, Japan; Inst Pasteur, INRA USC 2019, Unite Postulante Biol & Pathogen Fong, F-75015 Paris, France; Inst Pasteur, Unite Aspergillus, F-75015 Paris, France; Univ Texas, MD Anderson Canc Ctr, Div Pathol & Lab Med, Houston, TX 77030 USA; Univ Idaho, Ctr Reprod Biol, Dept Microbiol, Moscow, ID 83844 USA; Univ Idaho, Ctr Reprod Biol, Dept Mol Biol & Biochem, Moscow, ID 83844 USA; CHU Vaudois, Dept Dermatol, CH-1011 Lausanne, Switzerland; Univ Gottingen, Dept Bacteriol, D-37077 Gottingen, Germany; Tokyo Univ Agr & Technol, Tokyo 1830054, Japan; Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; Univ Wisconsin, Dept Food Microbiol & Toxicol, Madison, WI 53706 USA; MIT, Broad Inst, Cambridge, MA 02139 USA; Harvard Univ, Cambridge, MA 02139 USA; Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Tsukuba, Ibaraki 3058566, Japan	Nierman, WC (reprint author), Inst Genom Res, Rockville, MD 20850 USA.	wnierman@tigr.org	Berriman, Matthew/A-7618-2011; mouyna, isabelle/F-3578-2011; Tekaia, Fredj/H-4553-2012; Paulsen, Ian/K-3832-2012; Hall, Neil/A-8717-2013; Goldman, Gustavo/F-1848-2013; Latge, Jean Paul/C-9846-2014; Griffiths-Jones, Sam/H-2998-2014; Vazquez de Aldana, Carlos/B-7772-2008; Rodriguez de Cordoba, Santiago/K-6727-2014; TAKEUCHI, Michio/H-6592-2013; Penalva, Miguel A/G-2295-2015; Pain, Arnab/L-5766-2015; Molina, Maria/F-7939-2015; Kobayashi, Tetsuo/I-6901-2014; Rodriguez-Pena, Jose/E-9624-2016; Abrams, Natalie/F-4845-2011; Salzberg, Steven/F-6162-2011; Arroyo, Javier/E-9308-2016; Rawlings, Neil/M-5566-2013	Paulsen, Ian/0000-0001-9015-9418; Hall, Neil/0000-0002-7995-3810; Griffiths-Jones, Sam/0000-0001-6043-807X; Vazquez de Aldana, Carlos/0000-0002-4513-3654; Rodriguez de Cordoba, Santiago/0000-0001-6401-1874; Penalva, Miguel A/0000-0002-3102-2806; Pain, Arnab/0000-0002-1755-2819; Molina, Maria/0000-0003-0074-3309; Kobayashi, Tetsuo/0000-0002-4008-454X; Rodriguez-Pena, Jose/0000-0002-8792-362X; Abrams, Natalie/0000-0001-9698-2819; Salzberg, Steven/0000-0002-8859-7432; Arroyo, Javier/0000-0002-1971-1721; Jimenez, Javier/0000-0002-0402-4427; Yates, Bethan/0000-0003-1658-1762; Wortman, Jennifer/0000-0002-8713-1227; Galagan, James/0000-0003-0542-3291; Rawlings, Neil/0000-0001-5557-7665; Denning, David/0000-0001-5626-2251; Murphy, Lee/0000-0001-6467-7449; Fraser, Claire/0000-0003-1462-2428; Hall, Neil/0000-0003-2808-0009	Biotechnology and Biological Sciences Research Council [CFB17726]; Wellcome Trust		Beffa T, 1998, MED MYCOL, V36, P137; Bentley R, 2002, MICROBIOL MOL BIOL R, V66, P250, DOI 10.1128/MMBR.66.2.250-271.2002; BLYTH W, 1977, CLIN ALLERGY, V7, P549, DOI 10.1111/j.1365-2222.1977.tb01485.x; Bok JW, 2004, EUKARYOT CELL, V3, P527, DOI 10.1128/EC.3.2.527-535.2004; Bozza S, 2002, MICROBES INFECT, V4, P1281, DOI 10.1016/S1286-4579(02)00007-2; Casadevall A, 1999, INFECT IMMUN, V67, P3703; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; Denning DW, 1998, CLIN INFECT DIS, V26, P804; Fontaine T, 2000, J BIOL CHEM, V275, P27594; Gardiner DM, 2005, FUNGAL GENET BIOL, V42, P257, DOI 10.1016/j.fgb.2004.12.001; Gasch AP, 2000, MOL BIOL CELL, V11, P4241; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Hayakawa T, 2005, ARCH TOXICOL, V79, P183, DOI 10.1007/s00204-004-0620-x; Hirsch T, 2000, ALLERGY, V55, P79, DOI 10.1034/j.1398-9995.2000.00250.x; Kim H, 2002, BIOTECHNIQUES, V33, P924; Klis FM, 2002, FEMS MICROBIOL REV, V26, P239, DOI 10.1111/j.1574-6976.2002.tb00613.x; Kodzius R, 2003, COMB CHEM HIGH T SCR, V6, P147; Koonin EV, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-2-r7; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310; Mousavi S Amin A, 2004, Microbiology, V150, P1937, DOI 10.1099/mic.0.26830-0; Nierman WC, 2004, P NATL ACAD SCI USA, V101, P14246, DOI 10.1073/pnas.0403306101; Pain A, 2004, FUNGAL GENET BIOL, V41, P443, DOI 10.1016/j.fgb.2003.12.003; Ryckeboer J, 2003, J APPL MICROBIOL, V94, P127, DOI 10.1046/j.1365-2672.2003.01800.x; Thrane C, 2004, FUNGAL GENET BIOL, V41, P361, DOI 10.1016/j.fgb.2003.11.003; Weichel M, 2003, CLIN EXP ALLERGY, V33, P72, DOI 10.1046/j.1365-2222.2003.01574.x; Wysocki R, 1997, J BIOL CHEM, V272, P30061, DOI 10.1074/jbc.272.48.30061; Zegers I, 2001, NAT STRUCT BIOL, V8, P843, DOI 10.1038/nsb1001-843; Zhou SG, 2003, GENOME RES, V13, P2142, DOI 10.1101/gr.1128803; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	29	744	1516	15	160	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 22	2005	438	7071					1151	1156		10.1038/nature04332		6	Multidisciplinary Sciences	Science & Technology - Other Topics	995OF	WOS:000234111500050	16372009	
J	Furuta, GT; Liacouras, CA; Collins, MH; Gupta, SK; Justinich, C; Putnam, PE; Bonis, P; Hassall, E; Straumann, A; Rothenberg, ME				Furuta, Glenn T.; Liacouras, Chris A.; Collins, Margaret H.; Gupta, Sandeep K.; Justinich, Chris; Putnam, Phil E.; Bonis, Peter; Hassall, Eric; Straumann, Alex; Rothenberg, Marc E.		FIGERS Subcommittees	Eosinophilic esophagitis in children and adults: A systematic review and consensus recommendations for diagnosis and treatment	GASTROENTEROLOGY			English	Review							GASTROESOPHAGEAL-REFLUX DISEASE; ATOPY PATCH TEST; ALLERGIC ESOPHAGITIS; RINGED ESOPHAGUS; SKIN PRICK; FLUTICASONE PROPIONATE; FOOD ALLERGY; FOLLOW-UP; ENDOSCOPIC MANIFESTATION; GASTROINTESTINAL-TRACT	During the last decade, clinical practice saw a rapid increase of patients with esophageal eosinophilia who were thought to have gastroesophageal reflux disease (GERD) but who did not respond to medical and/or surgical GERD management. Subsequent studies demonstrated that these patients had a "new" disease termed eosinophilic esophagitis (EE). As recognition of EE grew, so did confusion surrounding diagnostic criteria and treatment. To address these issues, a multidisciplinary task force of 31 physicians assembled with the goal of determining diagnostic criteria and making recommendations for evaluation and treatment of children and adults with suspected EE. Consensus recommendations were based upon a systematic review of the literature and expert opinion. EE is a clinicopathological disease characterized by (1) Symptoms including but not restricted to food impaction and dysphagia. in adults, and feeding intolerance and GERD symptoms in children; (2) 2 >= 15 eosinophils/HPF; (3) Exclusion of other disorders associated with similar clinical, histological, or endoscopic features, especially GERD. (Use of high dose proton pump inhibitor treatment or normal pH monitoring). Appropriate treatments include dietary approaches based upon eliminating exposure to food allergens, or topical corticosteroids. Since EE is a relatively new disease, the intent of this report is to provide current recommendations for care of affected patients and defining gaps in knowledge for future research studies.	Childrens Hosp, Sect Pediat Gastroenterol Hepatol & Nutr, Denver, CO 80218 USA; Univ Colorado, Sch Med, Denver, CO 80202 USA; Univ Penn, Childrens Hosp Philadelphia, Sch Med, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA; Univ Cincinnati, Childrens Hosp, Ctr Med, Div Pathol, Cincinnati, OH 45267 USA; Indiana Univ, Sch Med, Div Pediat Gastroenterol Hepatol & Nutr, Riley Hosp Children, Indianapolis, IN 46204 USA; Queens Univ, Kingston Gen Hosp, Div Pediat Gastroenterol, Kingston, ON, Canada; Univ Cincinnati, Childrens Hosp, Coll Med, Div Pediat Gastroenterol Hepatol & Nutr,Med Ctr, Cincinnati, OH 45267 USA; Tufts Univ, Sch Med, Div Gastroenterol, Boston, MA 02111 USA; Univ British Columbia, BC Childrens Hosp, Div Gastroenterol, Vancouver, BC V5Z 1M9, Canada; Univ Basel, Univ Basel Hosp, Dept Gastroenterol, Basel, Switzerland; Univ Cincinnati, Med Ctr, Coll Med, Childrens Hosp,Div Allergy & Immunol, Cincinnati, OH 45267 USA	Furuta, GT (reprint author), Amer Gasteroenterol Assoc Inst, Clin Practice & Qual Management Committee, 4930 Del Ray Ave, Bethesda, MD 20814 USA.				NIDDK NIH HHS [R13 DK076672]		Aceves SS, 2007, J ALLERGY CLIN IMMUN, V119, P206, DOI 10.1016/j.jaci.2006.10.016; Aceves SS, 2007, AM J GASTROENTEROL, V102; Ahmed A, 2000, ENDOSCOPY, V32, pS33; Akei HS, 2005, GASTROENTEROLOGY, V129, P985, DOI 10.1053/j.gastro.2005.06.027; Arora AS, 2003, MAYO CLIN PROC, V78, P830; Assa'ad AH, 2007, J ALLERGY CLIN IMMUN, V119, P731, DOI 10.1016/j.jaci.2006.10.044; ATTWOOD SEA, 1993, DIGEST DIS SCI, V38, P109, DOI 10.1007/BF01296781; Attwood SEA, 2003, GUT, V52, P181, DOI 10.1136/gut.52.2.181; BALATSINOU C, 2007, IN PRESS DIG LIVER D; Bax Kevin C., 2006, Indian Journal of Pediatrics, V73, P919, DOI 10.1007/BF02859286; Baxi S, 2006, GASTROINTEST ENDOSC, V64, P473, DOI 10.1016/j.gie.2006.03.931; Blanchard C, 2006, J CLIN INVEST, V116, P536, DOI 10.1172/JCI26679; BROWN LF, 1984, AM J SURG PATHOL, V8, P899, DOI 10.1097/00000478-198412000-00002; Bullock JZ, 2007, J PEDIATR GASTR NUTR, V45, P22, DOI 10.1097/MPG.0b013e318043c097; Byrne KR, 2007, DIGEST DIS SCI, V52, P717, DOI 10.1007/s10620-006-9499-0; Cantu P, 2005, DIGEST LIVER DIS, V37, P129, DOI 10.1016/j.dld.2004.04.008; Cheung KM, 2003, J PEDIATR GASTR NUTR, V37, P498, DOI 10.1097/00005176-200310000-00018; Croese J, 2003, GASTROINTEST ENDOSC, V58, P516, DOI 10.1067/S0016-5107(03)01870-4; Dahms BB, 2004, PEDIATR DEVEL PATHOL, V7, P5, DOI 10.1007/s10024-003-0203-5; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; De Angelis P, 2006, DIGEST LIVER DIS, V38, P245, DOI 10.1016/j.dld.2005.08.004; DeBrosse CW, 2006, PEDIATR DEVEL PATHOL, V9, P210, DOI 10.2350/11-05-0130.1; DELLON ES, 2007, IN PRESS AM J GASTRO; Desai TK, 2005, GASTROINTEST ENDOSC, V61, P795, DOI 10.1016/S0016-5107(05)00313-5; DOBBINS JW, 1977, GASTROENTEROLOGY, V72, P1312; Esposito S, 2004, J PEDIATR GASTR NUTR, V38, P452, DOI 10.1097/00005176-200404000-00016; Faubion WA, 1998, J PEDIATR GASTR NUTR, V27, P90, DOI 10.1097/00005176-199807000-00016; FECZKO PJ, 1985, GASTROINTEST RADIOL, V10, P321, DOI 10.1007/BF01893121; Fogg MI, 2003, J ALLERGY CLIN IMMUN, V112, P796, DOI 10.1016/S0091-6749(03)01715-9; Fox VL, 2003, GASTROINTEST ENDOSC, V57, P30, DOI 10.1067/mge.2003.33; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Gonsalves N, 2006, GASTROINTEST ENDOSC, V64, P313, DOI 10.1016/j.gie.2006.04.037; Gupta SK, 2006, AM J GASTROENTEROL, V101, P1125, DOI 10.1111/j.1572-0241.2006.00557.x; Gupta SK, 1997, GASTROINTEST ENDOSC, V45, P485, DOI 10.1016/S0016-5107(97)70178-0; Gupta SK, 2006, J PEDIATR GASTR NUTR, V42, P22, DOI 10.1097/01.mpg.0000188740.38757.d2; HYAMS JS, 1988, J PEDIATR GASTR NUTR, V7, P52, DOI 10.1097/00005176-198801000-00011; Inns Stephen, 2006, N Z Med J, V119, pU1889; Isolauri E, 1997, J ALLERGY CLIN IMMUN, V99, P707, DOI 10.1016/S0091-6749(97)70034-4; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Kagalwalla AF, 2006, CLIN GASTROENTEROL H, V4, P1097, DOI 10.1016/j.cgh.2006.05.026; Kalach N, 2005, J ALLERGY CLIN IMMUN, V116, P1321, DOI 10.1016/j.jaci.2005.08.033; Kaplan M, 2003, CLIN GASTROENTEROL H, V1, P433, DOI 10.1053/S1542-3565(03)00222-2; Kato M, 2001, INT ARCH ALLERGY IMM, V125, P55, DOI 10.1159/000053855; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Khan S, 2003, DIGEST DIS SCI, V48, P22, DOI 10.1023/A:1021769928180; Kirsch R, 2007, J PEDIATR GASTR NUTR, V44, P20, DOI 10.1097/MPG.0b013e31802c0d06; Konikoff MR, 2006, GASTROENTEROLOGY, V131, P1381, DOI 10.1053/j.gastro.2006.08.033; Konikoff MR, 2006, CLIN GASTROENTEROL H, V4, P1328, DOI 10.1016/j.cgh.2006.08.013; LANDRES RT, 1978, GASTROENTEROLOGY, V74, P1298; Langdon DE, 2000, AM J GASTROENTEROL, V95, P2123; Langdon DE, 2004, GASTROENTEROLOGY, V127, P364, DOI 10.1053/j.gastro.2004.05.049; LEAPE LL, 1981, J PEDIATR SURG, V16, P379, DOI 10.1016/S0022-3468(81)80699-9; Lee GSC, 2007, DYSPHAGIA, V22, P55, DOI 10.1007/s00455-006-9043-6; LEE RG, 1985, AM J SURG PATHOL, V9, P475, DOI 10.1097/00000478-198507000-00002; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Liacouras CA, 2005, CLIN GASTROENTEROL H, V3, P1198, DOI 10.1016/S1542-3565(05)00885-2; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Lim JR, 2004, GASTROINTEST ENDOSC, V59, P835, DOI 10.1016/S0016-5107(04)00364-5; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Lucendo AJ, 2007, AM J SURG PATHOL, V31, P598, DOI 10.1097/01.pas.0000213392.49698.8c; Markowitz JE, 2003, AM J GASTROENTEROL, V98, P777, DOI 10.1016/S0002-9270(03)00054-6; MATZINGER MA, 1983, PEDIATR RADIOL, V13, P35, DOI 10.1007/BF00975664; Meyer GW, 2005, GASTROINTEST ENDOSC, V61, P932, DOI 10.1016/S0016-5107(05)00508-0; Mishra A, 2003, GASTROENTEROLOGY, V125, P1419, DOI 10.1053/S0016-5085(03)01352-0; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2002, J IMMUNOL, V168, P2464; Mishra A, 2007, J LEUKOCYTE BIOL, V81, P916, DOI 10.1189/jlb.1106653; MITCHELL EB, 1982, LANCET, V1, P127; Morrow JB, 2001, AM J GASTROENTEROL, V96, P984; MUNCH R, 1982, SCHWEIZ MED WSCHR, V112, P731; Ngo P, 2006, AM J GASTROENTEROL, V101, P1666, DOI 10.1111/j.1572-0241.2006.00562.x; Noel RJ, 2004, CLIN GASTROENTEROL H, V2, P568, DOI 10.1053/S1542-3565(04)00240-X; Noel RJ, 2004, NEW ENGL J MED, V351, P940, DOI 10.1056/NEJM200408263510924; Nurko S, 2004, J PEDIATR GASTR NUTR, V38, P436, DOI 10.1097/00005176-200404000-00014; Ogden S, 2007, BRIT J DERMATOL, V156, P1388, DOI 10.1111/j.1365-2133.2007.07913.x; Onbasi K, 2005, CLIN EXP ALLERGY, V35, P1423, DOI 10.1111/j.1365-2222.2005.02351.x; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; Parfitt JR, 2006, MODERN PATHOL, V19, P90, DOI 10.1038/modpathol.3800498; Patel SM, 2005, GASTROINTEST ENDOSC, V61, P165, DOI 10.1016/S0016-5107(04)02459-9; PICUS D, 1981, AM J ROENTGENOL, V136, P1001; Potter JW, 2004, GASTROINTEST ENDOSC, V59, P355, DOI 10.1016/S0016-5107(03)02713-5; Quaglietta L, 2007, ALIMENT PHARM THERAP, V26, P487, DOI 10.1111/j.1365-2036.2007.03388.x; Rance F, 2004, PEDIATR ALLERGY IMMU, V15, P93, DOI 10.1046/j.0905-6157.2003.00086.x; Remedios M, 2006, GASTROINTEST ENDOSC, V63, P3, DOI 10.1016/j.gie.2005.07.049; Ronkainen J, 2007, GUT, V56, P615, DOI 10.1136/gut.2006.107714; Rostenberg A, 1937, ARCH DERMATOL SYPH, V35, P433; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Sant'Anna A. M. G. A., 2004, JPGN Journal of Pediatric Gastroenterology and Nutrition, V39, P373, DOI 10.1097/00005176-200410000-00013; SHUB MD, 1985, J PEDIATR-US, V107, P881, DOI 10.1016/S0022-3476(85)80180-3; Siafakas CG, 2000, AM J GASTROENTEROL, V95, P1572; Simon D, 2005, PATHOBIOLOGY, V72, P287, DOI 10.1159/000091326; Simon D, 2005, J ALLERGY CLIN IMMUN, V115, P1090, DOI 10.1016/j.jaci.2005.01.017; Spergel JM, 2005, ANN ALLERG ASTHMA IM, V95, P336; Spergel JM, 2002, J ALLERGY CLIN IMMUN, V109, P363, DOI 10.1067/mai.2002.121458; Spergel JM, 2005, CURR ALLERGY ASTHM R, V5, P86, DOI 10.1007/s11882-005-0061-5; Spergel JM, 2007, J ALLERGY CLIN IMMUN, V119, P509, DOI 10.1016/j.jaci.2006.11.016; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Steiner SJ, 2006, J PEDIATR GASTR NUTR, V42, P506, DOI 10.1097/01.mpg.0000221906.06899.1b; Steiner SJ, 2004, AM J GASTROENTEROL, V99, P801, DOI 10.1111/j.1572-0241.2004.04170.x; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Straumann A, 2005, INFLAMM BOWEL DIS, V11, P720, DOI 10.1097/01.MIB.0000172557.39767.53; Straumann A, 2004, DIGESTION, V70, P109, DOI 10.1159/000080934; Straumann A, 2003, GASTROENTEROLOGY, V125, P1660, DOI 10.1053/S0016-5085(03)01515-4; Straumann A, 2003, GASTROINTEST ENDOSC, V57, P407, DOI 10.1067/mge.2003.123; Straumann A, 2005, J ALLERGY CLIN IMMUN, V115, P418, DOI 10.1016/j.jaci.2004.11.006; Sundaram S, 2004, J PEDIATR GASTR NUTR, V38, P208, DOI 10.1097/00005176-200402000-00020; Teitelbaum JE, 2002, GASTROENTEROLOGY, V122, P1216, DOI 10.1053/gast.2002.32998; Thompson DM, 2006, OTOLARYNG CLIN N AM, V39, P205, DOI 10.1016/j.otc.2005.10.002; Untersmayr E, 2005, FASEB J, V19, P656, DOI 10.1096/fj.04-3170fje; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI 10.1016/mai.2003.1681; Vakil N, 2006, AM J GASTROENTEROL, V101, P1900, DOI 10.1111/j.1572-0241.2006.00630.x; Vanderheyden AD, 2007, ARCH PATHOL LAB MED, V131, P777; Vasilopoulos S, 2002, GASTROINTEST ENDOSC, V55, P99, DOI 10.1067/mge.2002.118645; Villarin AJL, 2005, REV ESP ENFERM DIG, V97, P229; VITELLAS KM, 1995, ABDOM IMAGING, V20, P406, DOI 10.1007/BF01213260; VITELLAS KM, 1993, RADIOLOGY, V186, P789; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; WINTER HS, 1982, GASTROENTEROLOGY, V83, P818; Yamazaki K, 2006, DIGEST DIS SCI, V51, P1934, DOI 10.1007/s10620-005-9048-2; Zimmerman SL, 2005, RADIOLOGY, V236, P159, DOI 10.1148/radiol.2361041100; Zink DA, 2007, GASTROINTEST ENDOSC, V65, P330, DOI 10.1016/j.gie.2006.07.021	121	737	756	4	41	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085			GASTROENTEROLOGY	Gastroenterology	OCT	2007	133	4					1342	1363		10.1053/j.gastro.2007.08.017		22	Gastroenterology & Hepatology	Gastroenterology & Hepatology	218SW	WOS:000250036200030	17919504	
J	Barnes, PJ; Shapiro, SD; Pauwels, RA				Barnes, PJ; Shapiro, SD; Pauwels, RA			Chronic obstructive pulmonary disease: molecular and cellular mechanisms	EUROPEAN RESPIRATORY JOURNAL			English	Review						chemokine; cytokine; emphysema; macrophage; oxidative stress; protease	BRONCHIAL EPITHELIAL-CELLS; AIR-FLOW OBSTRUCTION; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC MUCUS HYPERSECRETION; RANDOMIZED CONTROLLED-TRIAL; FACTOR-KAPPA-B; SECRETORY LEUCOPROTEASE INHIBITOR; LEUKOCYTE PROTEASE INHIBITOR; LATENT ADENOVIRAL INFECTION; EXHALED BREATH CONDENSATE	Chronic obstructive pulmonary disease is a leading cause of death and disability, but has only recently been extensively explored from a cellular and molecular perspective. There is a chronic inflammation that leads to fixed narrowing of small airways and alveolar wall destruction (emphysema). This is characterised by increased numbers of alveolar macrophages, neutrophils and cytotoxic T-lymphocytes, and the release of multiple inflammatory mediators (lipids, chemokines, cytokines, growth factors). A high level of oxidative stress may amplify this inflammation. There is also increased elastolysis and evidence for involvement of several elastolytic enzymes, including serine proteases, cathepsins and matrix metalloproteinases. The inflammation and proteolysis in chronic obstructive pulmonary disease is an amplification of the normal inflammatory response to cigarette smoke. This inflammation, in marked contrast to asthma, appears to be resistant to corticosteroids, prompting a search for novel anti-inflammatory therapies that may prevent the relentless progression of the disease.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, London SW3 6LY, England; Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA 02115 USA; State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sch Med, Dovehouse St, London SW3 6LY, England.						Aarbiou J, 2002, ANN MED, V34, P96, DOI 10.1080/07853890252953482; Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349; ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Adler KB, 2001, AM J RESP CELL MOL, V25, P397; Agusti AGN, 1999, EUR RESPIR J, V14, P523, DOI 10.1034/j.1399-3003.1999.14c08.x; Altose MD, 2000, NEW ENGL J MED, V343, P1902; Avissar N, 1996, AM J PHYSIOL-LUNG C, V270, pL173; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Barnes Peter J., 2001, Current Opinion in Pharmacology, V1, P217, DOI 10.1016/S1471-4892(01)00039-X; Barnes PJ, 1999, THORAX, V54, P245; Barnes PJ, 2002, NOVART FDN SYMP, V248, P237; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Barnes PJ, 2003, ANNU REV MED, V54, P113, DOI 10.1146/annurev.med.54.101601.152209; Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066; BARNES PJ, 2003, IN PRESS ANN INT MED; BAZZONI F, 1991, J EXP MED, V173, P771, DOI 10.1084/jem.173.3.771; BECKMAN JS, 1996, AM J PHYSIOL, V271, pC1432; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Betsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294; Bowler RP, 2002, AM J RESP CRIT CARE, V166, pS38, DOI 10.1164/rccm.2206014; Bresser P, 2000, AM J RESP CRIT CARE, V162, P947; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; BRITTON JR, 1995, AM J RESP CRIT CARE, V151, P1383; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Campbell EJ, 2000, J IMMUNOL, V165, P3366; CANTIN AM, 1990, J CLIN INVEST, V86, P962, DOI 10.1172/JCI114798; Capelli A, 1999, EUR RESPIR J, V14, P160, DOI 10.1034/j.1399-3003.1999.14a27.x; Caramori G, 2003, THORAX, V58, P348, DOI 10.1136/thorax.58.4.348; CARP H, 1978, AM REV RESPIR DIS, V118, P617; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; CASOLARO MA, 1988, AM REV RESPIR DIS, V137, P406; Cawston T, 2001, NOVART FDN SYMP, V234, P205; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chen G, 2003, AM J PHYSIOL-LUNG C, V284, pL548, DOI 10.1152/ajplung.00091.2002; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9; CHU FSF, 2003, AM J RESP CRIT CARE, V167, pA874; Comhair SAA, 2002, AM J PHYSIOL-LUNG C, V283, pL246, DOI 10.1152/ajplung.00491.2001; Condliffe AM, 1998, CLIN SCI, V94, P461; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Cosio MG, 2002, CHEST, V121, p160S, DOI 10.1378/chest.121.5_suppl.160S; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Dallas SL, 2002, J BIOL CHEM, V277, P21352, DOI 10.1074/jbc.M111663200; DAMIANO VV, 1986, J CLIN INVEST, V78, P482, DOI 10.1172/JCI112600; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951; de Boer WI, 2000, J PATHOL, V190, P619, DOI 10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6; DeJong JW, 1997, RESP MED, V91, P67, DOI 10.1016/S0954-6111(97)90070-6; Dekhuijzen PNR, 1996, AM J RESP CRIT CARE, V154, P813; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214; Devalia JL, 1997, ALLERGY, V52, P45; DHULST A, 2002, AM J RESP CRIT CARE, V164, pA604; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Donaldson GC, 1999, EUR RESPIR J, V13, P844, DOI 10.1034/j.1399-3003.1999.13d25.x; DONNELLY LE, 2003, AM J RESP CRIT CARE, V165, pA614; Duranton Jerome, 2003, American Journal of Respiratory Cell and Molecular Biology, V29, P57, DOI 10.1165/rcmb.2002-0258OC; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Fabbri L, 1998, THORAX, V53, P803; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666; Finlay GA, 1997, AM J RESP CRIT CARE, V156, P240; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447; FLETCHER C, 1977, BRIT MED J, V1, P1645; FLOREANI AA, 2003, IN PRESS AM J RESP C; Forman HJ, 2002, AM J RESP CRIT CARE, V166, pS4, DOI 10.1164/rccm.2206007; FRANCUS T, 1988, J IMMUNOL, V140, P1823; Franklin WA, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.31520; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1173/JCI200215021; Gelb AF, 1996, CHEST, V109, P353, DOI 10.1378/chest.109.2.353; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598; Gompertz S, 2001, EUR RESPIR J, V17, P1112, DOI 10.1183/09031936.01.99114901; Gompertz S, 2001, THORAX, V56, P36, DOI 10.1136/thorax.56.1.36; Gorrini M, 2001, AM J RESP CELL MOL, V25, P492; Gorter AD, 1998, J INFECT DIS, V178, P1067, DOI 10.1086/515667; GOSWAMI SK, 1990, AM REV RESPIR DIS, V141, P72; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V154, P1290; GREAVES IA, 1980, AM REV RESPIR DIS, V121, P127; Gross CP, 1999, NEW ENGL J MED, V340, P1881, DOI 10.1056/NEJM199906173402406; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hellermann GR, 2002, RESPIR RES, V3, DOI 10.1186/rr172; Henricks PAJ, 2001, PULM PHARMACOL THER, V14, P409, DOI 10.1006/pupt.2001.0319; Higashimoto Y, 2002, AM J RESP CRIT CARE, V166, P200, DOI 10.1164/rccm.2111032; Hill AT, 2000, AM J MED, V109, P288, DOI 10.1016/S0002-9343(00)00507-6; Hirano K, 2001, EUR RESPIR J, V18, P748, DOI 10.1183/09031936.01.00102101; HOGG JC, 1995, THORAX, V50, P819, DOI 10.1136/thx.50.8.819; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOGG JC, 1994, THORAX, V49, P473, DOI 10.1136/thx.49.5.473; Hogg JC, 2001, AM J RESP CRIT CARE, V164, pS71; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; HUTCHISON KA, 1991, J BIOL CHEM, V266, P10505; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Ihn H, 2002, CURR OPIN RHEUMATOL, V14, P681, DOI 10.1097/00002281-200211000-00009; Imai K, 2001, AM J RESP CRIT CARE, V163, P786; Ishii T, 2000, EUR J CLIN INVEST, V30, P543; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; ITO K, 2001, EUR RESPIR J, V18, pS316; Ito K, 2001, FASEB J, V15, P1100; Janssen LJ, 2001, AM J PHYSIOL-LUNG C, V280, pL1067; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Jin FY, 1997, CELL, V88, P417, DOI 10.1016/S0092-8674(00)81880-2; Kanner RE, 2001, AM J RESP CRIT CARE, V164, P358; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kawikova I, 1996, AM J RESP CRIT CARE, V153, P590; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KIM WD, 1991, AM REV RESPIR DIS, V144, P1385; Kim WD, 2002, CHEST, V122, P437, DOI 10.1378/chest.122.2.437; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LANGE P, 1990, THORAX, V45, P579, DOI 10.1136/thx.45.8.579; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Le-Barillec K, 1999, J CLIN INVEST, V103, P1039, DOI 10.1172/JCI5779; Leckie MJ, 2003, THORAX, V58, P23, DOI 10.1136/thorax.58.1.23; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912; Lim S, 2000, AM J RESP CRIT CARE, V162, P1355; Linnevers C, 1997, FEBS LETT, V405, P253, DOI 10.1016/S0014-5793(97)00118-X; Liu H, 1999, AM J PHYSIOL-LUNG C, V276, pL28; Lomas DA, 2002, J CLIN INVEST, V110, P1585, DOI 10.1172/JCI200216782; Lomas DA, 2001, RESPIR RES, V2, P20, DOI 10.1186/rr34; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Loppow D, 2001, RESP MED, V95, P115, DOI 10.1053/rmed.2000.0960; Luisetti M, 1996, EUR RESPIR J, V9, P1482, DOI 10.1183/09031936.96.09071482; Macklem PT, 1998, AM J RESP CRIT CARE, V157, pS181; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; Mahadeva R, 1998, THORAX, V53, P501; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; Majori M, 1999, J ALLERGY CLIN IMMUN, V103, P458, DOI 10.1016/S0091-6749(99)70471-9; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Meagher LC, 1996, J IMMUNOL, V156, P4422; Meshi B, 2002, AM J RESP CELL MOL, V26, P52; Mio T, 1997, AM J RESP CRIT CARE, V155, P1770; Miravitlles M, 2000, RESPIRATION, V67, P495, DOI 10.1159/000067462; Moller LVM, 1998, AM J RESP CRIT CARE, V157, P950; Montuschi P, 2002, TRENDS PHARMACOL SCI, V23, P232, DOI 10.1016/S0165-6147(02)02020-5; Montuschi P, 2001, CHEST, V120, P496, DOI 10.1378/chest.120.2.496; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175; Morris DG, 2003, NATURE, V422, P169, DOI 10.1038/nature01413; Morrow JD, 2000, DRUG METAB REV, V32, P377, DOI 10.1081/DMR-100102340; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; Nightingale JA, 2000, AM J RESP CRIT CARE, V161, P479; Noguera A, 2001, THORAX, V56, P432, DOI 10.1136/thorax.56.6.432; Nowak D, 1999, RESP MED, V93, P389, DOI 10.1053/rmed.1999.0574; Ogura M, 1998, J IMMUNOL, V161, P3569; Ohbayashi H, 2002, EXPERT OPIN INV DRUG, V11, P965, DOI 10.1517/13543784.11.7.965; Ohnishi K, 1998, LAB INVEST, V78, P1077; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; Okazawa A, 1997, AM J RESP CRIT CARE, V155, P436; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; Owen CA, 1997, AM J PHYSIOL, V272, P385; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; PARE PD, 1982, AM REV RESPIR DIS, V126, P54; Paredi P, 2002, AM J RESP CRIT CARE, V166, pS31, DOI 10.1164/rccm.2206012; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Peleman RA, 1999, EUR RESPIR J, V13, P839, DOI 10.1034/j.1399-3003.1999.13d24.x; Pesci A, 1998, EUR RESPIR J, V12, P380, DOI 10.1183/09031936.98.12020380; PETO R, 1983, AM REV RESPIR DIS, V128, P491; Pettersen CA, 2002, CHEST, V121, p142S, DOI 10.1378/chest.121.5_suppl.142S; Pilette C, 2001, EUR RESPIR J, V18, P571, DOI 10.1183/09031936.01.00228801; Pratico D, 1998, AM J RESP CRIT CARE, V158, P1709; PRESCOTT E, 1995, EUR RESPIR J, V8, P1333, DOI 10.1183/09031936.95.08081333; PRIDE NB, 2003, IN PRESS CHRONIC OBS; Prieto A, 2001, AM J RESP CRIT CARE, V163, P1578; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469; RICHARDS GA, 1989, AM REV RESPIR DIS, V139, P181; Rooney CP, 2001, AM J RESP CELL MOL, V24, P747; Russell REK, 2002, AM J RESP CELL MOL, V26, P602; Russell REK, 2002, AM J PHYSIOL-LUNG C, V283, pL867, DOI 10.1152/ajplung.00020.2002; Rusznak C, 1996, EUR RESPIR J, V9, P2298, DOI 10.1183/09031936.96.09112298; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1046/j.1365-2222.1996.d01-386.x; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633; Sallenave J M, 2000, Respir Res, V1, P87, DOI 10.1186/rr18; Schunemann HJ, 2001, EPIDEMIOL REV, V23, P248; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2001, CLIN MICROBIOL REV, V14, P336, DOI 10.1128/CMR.14.2.336-363.2001; Shapiro SD, 2002, AM J RESP CELL MOL, V26, P266; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100; Shapiro SD, 1999, AM J RESP CRIT CARE, V160, pS29; SOLER P, 1989, AM REV RESPIR DIS, V139, P1112; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; SPARROW D, 1984, CHEST, V86, P383, DOI 10.1378/chest.86.3.383; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Stockley RA, 2001, NOVART FDN SYMP, V234, P189; Taggart C, 2000, J BIOL CHEM, V275, P27258; Taggart CC, 2002, J BIOL CHEM, V277, P33648, DOI 10.1074/jbc.M203710200; Taggart CC, 2001, J BIOL CHEM, V276, P33345, DOI 10.1074/jbc.M103220200; Takeyabu K, 1998, EUR RESPIR J, V12, P1033, DOI 10.1183/09031936.98.12051033; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294; Takizawa H, 2001, AM J RESP CRIT CARE, V163, P1476; Takubo Y, 2002, AM J RESP CRIT CARE, V166, P1596, DOI 10.1164/rccm.2202001; Tanino M, 2002, THORAX, V57, P405, DOI 10.1136/thorax.57.5.405; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802; Tazi A, 1999, J IMMUNOL, V163, P3511; Tazi A, 2000, THORAX, V55, P405, DOI 10.1136/thorax.55.5.405; Terashima T, 1997, AM J RESP CRIT CARE, V155, P1441; Tomita K, 2003, BIOCHEM BIOPH RES CO, V301, P572, DOI 10.1016/S0006-291X(02)03029-2; Tomita K, 2002, AM J RESP CRIT CARE, V166, P724, DOI 10.1164/rccm.2104010; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; TRAVES SL, 2003, AM J RESP CRIT CARE, pA824; Turato G, 2001, RESPIRATION, V68, P117, DOI 10.1159/000050478; TURATO G, 1995, AM J RESP CRIT CARE, V152, P1262; Turk V, 2001, EMBO J, V20, P4629, DOI 10.1093/emboj/20.17.4629; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; van Schilfgaarde M, 1999, MICROB PATHOGENESIS, V26, P249, DOI 10.1006/mpat.1998.0269; VANALPHEN L, 1995, AM J RESP CRIT CARE, V151, P2094; VANBRABANDT H, 1983, J APPL PHYSIOL, V55, P1733; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; VERBEKEN EK, 1992, J APPL PHYSIOL, V72, P2343; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530; Vestbo J, 2002, NOVART FDN SYMP, V248, P3; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; VOGELMEIER C, 1991, J CLIN INVEST, V87, P482, DOI 10.1172/JCI115021; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Vukmanovic-Stejic M, 2000, BLOOD, V95, P231; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Wedzicha JA, 2002, CHEST, V121, p136S, DOI 10.1378/chest.121.5_suppl.136S; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729; Wright JL, 2002, AM J RESP CRIT CARE, V166, P954, DOI 10.1164/rccm.200202-098OC; Xanthoudakis S, 1996, ADV EXP MED BIOL, V387, P69; Yamada K, 2002, J ALLERGY CLIN IMMUN, V109, P35, DOI 10.1067/mai.2002.120525; Yamamoto C, 1997, CHEST, V112, P505, DOI 10.1378/chest.112.2.505; YANAI M, 1992, J APPL PHYSIOL, V72, P1016; Yu Q, 2000, GENE DEV, V14, P163; Zeid NA, 1995, PATHOLOGY, V27, P247; Zeidel A, 2002, ACTA ANAESTH SCAND, V46, P959, DOI 10.1034/j.1399-6576.2002.460806.x; Zhang YH, 1997, J CLIN INVEST, V99, P894, DOI 10.1172/JCI119254; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhu J, 2001, AM J RESP CRIT CARE, V164, P2220, DOI 10.1164/rccm2009060	265	726	762	6	65	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2003	22	4					672	688		10.1183/09031936.03.00040703		17	Respiratory System	Respiratory System	732WR	WOS:000185969000021	14582923	
J	Van Eerdewegh, P; Little, RD; Dupuis, J; Del Mastro, RG; Falls, K; Simon, J; Torrey, D; Pandit, S; McKenny, J; Braunschweiger, K; Walsh, A; Liu, ZY; Hayward, B; Folz, C; Manning, SP; Bawa, A; Saracino, L; Thackston, M; Benchekroun, Y; Capparell, N; Wang, M; Adair, R; Feng, Y; Dubois, J; FitzGerald, MG; Huang, H; Gibson, R; Allen, KM; Pedan, A; Danzig, MR; Umland, SP; Egan, RW; Cuss, FM; Rorke, S; Clough, JB; Holloway, JW; Holgate, ST; Keith, TP				Van Eerdewegh, P; Little, RD; Dupuis, J; Del Mastro, RG; Falls, K; Simon, J; Torrey, D; Pandit, S; McKenny, J; Braunschweiger, K; Walsh, A; Liu, ZY; Hayward, B; Folz, C; Manning, SP; Bawa, A; Saracino, L; Thackston, M; Benchekroun, Y; Capparell, N; Wang, M; Adair, R; Feng, Y; Dubois, J; FitzGerald, MG; Huang, H; Gibson, R; Allen, KM; Pedan, A; Danzig, MR; Umland, SP; Egan, RW; Cuss, FM; Rorke, S; Clough, JB; Holloway, JW; Holgate, ST; Keith, TP			Association of the ADAM33 gene with asthma and bronchial hyperresponsiveness	NATURE			English	Article							LINKAGE DISEQUILIBRIUM; PROTEASE; PROTEINS; MARKERS; MUTATION; DOMAIN; FAMILY	Asthma is a common respiratory disorder characterized by recurrent episodes of coughing, wheezing and breathlessness. Although environmental factors such as allergen exposure are risk factors in the development of asthma, both twin and family studies point to a strong genetic component(1,2). To date, linkage studies have identified more than a dozen genomic regions linked to asthma(3). In this study, we performed a genome-wide scan on 460 Caucasian families and identified a locus on chromosome 20p13 that was linked to asthma (log(10) of the likelihood ratio (LOD), 2.94) and bronchial hyperresponsiveness (LOD, 3.93). A survey of 135 polymorphisms in 23 genes identified the ADAM33 gene 4 as being significantly associated with asthma using case-control, transmission disequilibrium and haplotype analyses (P=0.04-0.000003). ADAM proteins are membrane-anchored metalloproteases with diverse functions, which include the shedding of cell-surface proteins such as cytokines and cytokine receptors(5). The identification and characterization of ADAM33, a putative asthma susceptibility gene identified by positional cloning in an outbred population, should provide insights into the pathogenesis and natural history of this common disease.	Genome Therapeut Corp, Waltham, MA 02453 USA; Schering Plough Corp, Res Inst, Kenilworth, NJ 07033 USA; Univ Southampton, Sch Med, Resp Cell & Mol Biol Infect Inflammat & Repair Re, Southampton Gen Hosp, Southampton, Hants, England	Keith, TP (reprint author), Genome Therapeut Corp, 100 Beaver St, Waltham, MA 02453 USA.		Holloway, John/B-5424-2009; Little, Randall/O-7172-2014	Holloway, John/0000-0001-9998-0464; Dupuis, Josee/0000-0003-2871-3603			Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; BOEHNKE M, 1991, AM J HUM GENET, V48, P22; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Das M, 2001, PHYSIOL GENOMICS, V6, P57; Del Mastro R G, 1997, Methods Mol Biol, V68, P183; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Dupuis J, 1999, GENETICS, V151, P373; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Ghosh S, 1997, GENOME RES, V7, P165, DOI 10.1101/gr.7.2.165; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Howard L, 2000, BIOCHEM J, V348, P21, DOI 10.1042/0264-6021:3480021; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; KRUGLYAK L, 1995, AM J HUM GENET, V57, P439; LANGE K, 1988, GENET EPIDEMIOL, V5, P471, DOI 10.1002/gepi.1370050611; Loechel F, 1999, J BIOL CHEM, V274, P13427, DOI 10.1074/jbc.274.19.13427; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/1369052012191; Maquat LE, 2001, NAT GENET, V27, P5, DOI 10.1038/83759; MATISE TC, 1994, NAT GENET, V6, P384, DOI 10.1038/ng0494-384; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Primakoff P, 2000, TRENDS GENET, V16, P83, DOI 10.1016/S0168-9525(99)01926-5; Richter A, 2001, AM J RESP CELL MOL, V25, P385; Soares M. B., 1994, AUTOMATED DNA SEQUEN, P110; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Stone AL, 1999, J PROTEIN CHEM, V18, P447, DOI 10.1023/A:1020692710029; Wilkinson J, 1998, GENOMICS, V53, P251, DOI 10.1006/geno.1998.5485; Wjst M, 1998, BIOINFORMATICS, V14, P827, DOI 10.1093/bioinformatics/14.9.827; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6	30	710	743	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 25	2002	418	6896					426	430		10.1038/nature00878		5	Multidisciplinary Sciences	Science & Technology - Other Topics	576MU	WOS:000177009700040	12110844	
J	Sears, MR; Greene, JM; Willan, AR; Wiecek, EM; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Silva, PA; Poulton, R				Sears, MR; Greene, JM; Willan, AR; Wiecek, EM; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Silva, PA; Poulton, R			A longitudinal, population-based, cohort study of childhood asthma followed to adulthood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RISK-FACTORS; LUNG-FUNCTION; AIRWAY HYPERRESPONSIVENESS; NEW-ZEALAND; WHEEZING ILLNESS; BIRTH COHORT; ATOPY; PREVALENCE; CHILDREN; LIFE	BACKGROUND: The outcome of childhood asthma in adults has been described in high-risk cohorts, but few population-based studies have reported the risk factors for persistence and relapse. METHODS: We assessed children born from April 1972 through March 1973 in Dunedin, New Zealand, repeatedly from 9 to 26 years of age with questionnaires, pulmonary-function tests, bronchial-challenge testing, and allergy testing. RESULTS: By the age of 26 years, 51.4 percent of 613 study members with complete respiratory data had reported wheezing at more than one assessment. Eighty-nine study members (14.5 percent) had wheezing that persisted from childhood to 26 years of age, whereas 168 (27.4 percent) had remission, but 76 (12.4 percent) subsequently relapsed by the age of 26. Sensitization to house dust mites predicted the persistence of wheezing (odds ratio, 2.41; P=0.001) and relapse (odds ratio, 2.18; P=0.01), as did airway hyperresponsiveness (odds ratio for persistence, 3.00; P<0.001; odds ratio for relapse, 3.03; P<0.001). Female sex predicted the persistence of wheezing (odds ratio, 1.71; P=0.03), as did smoking at the age of 21 years (odds ratio, 1.84; P=0.01). The earlier the age at onset, the greater the risk of relapse (odds ratio, 0.89 per year of increase in the age at onset; P<0.001). Pulmonary function was consistently lower in those with persistent wheezing than in those without persistent wheezing. CONCLUSIONS: In an unselected birth cohort, more than one in four children had wheezing that persisted from childhood to adulthood or that relapsed after remission. The factors predicting persistence or relapse were sensitization to house dust mites, airway hyperresponsiveness, female sex, smoking, and early age at onset. These findings, together with persistently low lung function, suggest that outcomes in adult asthma may be determined primarily in early childhood.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Otago, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dunedin Multidisciplinary Hlth & Dev Res Unit, Dunedin, New Zealand	Sears, MR (reprint author), McMaster Univ & St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.						Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRONNIMANN S, 1986, CHEST, V90, P480, DOI 10.1378/chest.90.4.480; BURNEY PGJ, 1987, CHEST, V91, P79; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Grol MH, 1996, ALLERGY, V51, P855; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; JENKINS MA, 1994, BRIT MED J, V309, P90; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Sears MR, 1996, ARCH DIS CHILD, V75, P392; Sears MR, 1997, EUR RESPIR J, V10, P51, DOI 10.1183/09031936.97.10010051; SEARS MR, 1994, BRIT MED J, V309, P72; Silva PA, 1996, CHILD ADULT DUNEDIN; SINCLAIR SW, 1980, NEW ZEAL MED J, V91, P1; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; Ulrik CS, 1996, RESP MED, V90, P623, DOI 10.1016/S0954-6111(96)90021-9; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104	28	672	685	6	31	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 9	2003	349	15					1414	1422		10.1056/NEJMoa022363		9	Medicine, General & Internal	General & Internal Medicine	729JF	WOS:000185769500004	14534334	
J	Moore, WC; Meyers, DA; Wenzel, SE; Teague, WG; Li, HS; Li, XN; D'Agostino, R; Castro, M; Curran-Everett, D; Fitzpatrick, AM; Gaston, B; Jarjour, NN; Sorkness, R; Calhoun, WJ; Chung, KF; Comhair, SAA; Dweik, RA; Israel, E; Peters, SP; Busse, WW; Erzurum, SC; Bleecker, ER				Moore, Wendy C.; Meyers, Deborah A.; Wenzel, Sally E.; Teague, W. Gerald; Li, Huashi; Li, Xingnan; D'Agostino, Ralph, Jr.; Castro, Mario; Curran-Everett, Douglas; Fitzpatrick, Anne M.; Gaston, Benjamin; Jarjour, Nizar N.; Sorkness, Ronald; Calhoun, William J.; Chung, Kian Fan; Comhair, Suzy A. A.; Dweik, Raed A.; Israel, Elliot; Peters, Stephen P.; Busse, William W.; Erzurum, Serpil C.; Bleecker, Eugene R.		Natl Heart Lung Blood Inst	Identification of Asthma Phenotypes Using Cluster Analysis in the Severe Asthma Research Program	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma phenotype; definition; cluster analysis; severe asthma	EXHALED NITRIC-OXIDE; RANDOMIZED CONTROLLED-TRIAL; AIR-FLOW OBSTRUCTION; CLINICAL CHARACTERISTICS; LUNG-FUNCTION; OBESITY; ADULTS; INFLAMMATION; CHILDREN; DISEASE	Rationale The Severe Asthma Research Program cohort includes subjects with persistent asthma who have undergone detailed phenotypic characterization. Previous univariate methods compared features of mild, moderate, and severe asthma. Objectives: To identify novel asthma phenotypes using an unsupervised hierarchical cluster analysis. Methods: Reduction of the initial 628 variables to 34 core variables was achieved by elimination of redundant data and transformation of categorical variables into ranked ordinal composite variables. Cluster analysis was performed on 726 subjects. Measurements and Main Results: Five groups were identified. Subjects in Cluster 1 (n = 110) have early onset atopic asthma with normal lung function treated with two or fewer controller medications (82%) and minimal health care utilization. Cluster 2 (n = 321) consists of subjects with early-onset atopic asthma and preserved lung function but increased medication requirements (29% on three or more medications) and health care utilization. Cluster 3 (n = 59) is a unique group of mostly older obese women with late-onset non-atopic asthma, moderate reductions in FEV1, and frequent oral corticosteroid use to manage exacerbations. Subjects in Clusters 4 (n = 120) and 5 (n = 116) have severe airflow obstruction with bronchodilator responsiveness but differ in to their ability to attain normal lung function, age of asthma onset, atopic status, and use of oral corticosteroids. Conclusions: Five distinct clinical phenotypes of asthma have been identified using unsupervised hierarchical cluster analysis. All clusters contain subjects who meet the American Thoracic Society definition of severe asthma, which supports clinical heterogeneity in asthma and the need for new approaches for the classification of disease severity in asthma.	[Moore, Wendy C.; Meyers, Deborah A.; Li, Huashi; Li, Xingnan; Peters, Stephen P.; Bleecker, Eugene R.] Wake Forest Univ, Ctr Human Genom, Sch Med, Winston Salem, NC 27157 USA; [Moore, Wendy C.; Meyers, Deborah A.; Wenzel, Sally E.; Teague, W. Gerald; Castro, Mario; Curran-Everett, Douglas; Fitzpatrick, Anne M.; Gaston, Benjamin; Jarjour, Nizar N.; Sorkness, Ronald; Calhoun, William J.; Chung, Kian Fan; Comhair, Suzy A. A.; Dweik, Raed A.; Israel, Elliot; Peters, Stephen P.; Busse, William W.; Erzurum, Serpil C.; Bleecker, Eugene R.; Natl Heart Lung Blood Inst] Severe Asthma Res Program, Bethesda, MD USA	Moore, WC (reprint author), Wake Forest Univ, Ctr Human Genom, Sch Med, Med Ctr Blvd, Winston Salem, NC 27157 USA.	wmoore@wfubmc.edu	Fain, Sean/K-4260-2016; Dagostino Jr, Ralph/C-4060-2017	Fain, Sean/0000-0001-5461-0646; Dagostino Jr, Ralph/0000-0002-3550-8395; Chung, Kian Fan/0000-0001-7101-1426	National Institute of Health [HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, M01 RR018390, M01 RR07122, M01 RR03186, HL087665]	Supported by National Institute of Health grants HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, M01 RR018390, M01 RR07122, M01 RR03186, and HL087665.	Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Breiman L., 1984, CLASSIFICATION REGRE; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Celedon JC, 2000, AM J RESP CRIT CARE, V162, P1679; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gelfand Erwin W, 2009, Proc Am Thorac Soc, V6, P278, DOI 10.1513/pats.200808-090RM; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Kiley J, 2007, CURR OPIN PULM MED, V13, P19; Lara A, 2008, AM J RESP CRIT CARE, V178, P673, DOI 10.1164/rccm.200710-1542OC; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moore WC, 2006, J ALLERGY CLIN IMMUN, V117, P487, DOI 10.1016/j.jaci.2006.01.033; Moore WC, 2009, AM J RESP CRIT CARE, V179, pA2522; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; *NAT ASTHM ED PREV, 2007, PUBL NIH NAT HEART L; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267; Pillai SG, 2008, CLIN EXP ALLERGY, V38, P421, DOI 10.1111/j.1365-2222.2007.02918.x; Rosi E, 1999, J ALLERGY CLIN IMMUN, V103, P232, DOI 10.1016/S0091-6749(99)70496-3; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-14270C; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Sutherland TJT, 2008, AM J RESP CRIT CARE, V177, P970, DOI [10.1164/rccm.200711-1738OC, 10.1164/rccm.200711-17380C]; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; WEATHERALL M, EUR RESP J IN PRESS; Wedes SH, 2009, CTS-CLIN TRANSL SCI, V2, P112, DOI 10.1111/j.1752-8062.2009.00095.x; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341	46	661	677	6	59	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 15	2010	181	4					315	323		10.1164/rccm.200906-0896OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	556ZR	WOS:000274637100006	19892860	
J	Galli, SJ; Tsai, M; Piliponsky, AM				Galli, Stephen J.; Tsai, Mindy; Piliponsky, Adrian M.			The development of allergic inflammation	NATURE			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; MAST-CELL ACTIVATION; REGULATORY T-CELLS; ATOPIC-DERMATITIS; HYGIENE HYPOTHESIS; IMMUNE-RESPONSES; EPITHELIAL-CELLS; BRONCHIAL-ASTHMA; DENDRITIC CELLS; NERVOUS-SYSTEM	Allergic disorders, such as anaphylaxis, hay fever, eczema and asthma, now afflict roughly 25% of people in the developed world. In allergic subjects, persistent or repetitive exposure to allergens, which typically are intrinsically innocuous substances common in the environment, results in chronic allergic inflammation. This in turn produces long-term changes in the structure of the affected organs and substantial abnormalities in their function. It is therefore important to understand the characteristics and consequences of acute and chronic allergic inflammation, and in particular to explore how mast cells can contribute to several features of this maladaptive pattern of immunological reactivity.	[Galli, Stephen J.; Tsai, Mindy; Piliponsky, Adrian M.] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; [Galli, Stephen J.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA	Galli, SJ (reprint author), Stanford Univ, Sch Med, Dept Pathol, 300 Pasteur Dr, Stanford, CA 94305 USA.	sgalli@stanford.edu			NCI NIH HHS [R01 CA072074, R01 CA072074-15]; NIAID NIH HHS [R01 AI023990, R01 AI023990-20, R01 AI070813, R01 AI070813-01]		Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Barnes PJ, 2006, TRENDS MOL MED, V12, P515, DOI 10.1016/j.molmed.2006.09.006; Bonness S, 2007, CURR OPIN ALLERGY CL, V7, P382; Boyce JA, 2007, IMMUNOL REV, V217, P168, DOI 10.1111/j.1600-065X.2007.00512.x; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bradding P, 1996, ANN NY ACAD SCI, V796, P272, DOI 10.1111/j.1749-6632.1996.tb32589.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JM, 2008, CLIN EXP ALLERGY, V38, P4, DOI 10.1111/j.1365-2222.2007.02886.x; Burgel PR, 2001, J IMMUNOL, V167, P5948; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Caughey GH, 2007, IMMUNOL REV, V217, P141, DOI 10.1111/j.1600-065X.2007.00509.x; Cevikbas F, 2007, CURR OPIN ALLERGY CL, V7, P365; Chanez P, 1998, AM J RESP CRIT CARE, V158, P985; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Dickey BF, 2007, NEW ENGL J MED, V357, P2082, DOI 10.1056/NEJMe0706634; Doherty T, 2007, CURR OPIN IMMUNOL, V19, P676, DOI 10.1016/j.coi.2007.07.017; Dvorak AM, 2005, J HISTOCHEM CYTOCHEM, V53, P1043, DOI 10.1369/jhc.5R6647.2005; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; GALLI SJ, 1986, RETICULOENDOTHELIAL, V9, P321; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gern JE, 2002, NAT REV IMMUNOL, V2, P132, DOI 10.1038/nri725; Gilfillan AM, 2006, NAT REV IMMUNOL, V6, P218, DOI 10.1038/nri1782; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grimbaldeston MA, 2007, NAT IMMUNOL, V8, P1095, DOI 10.1038/ni1503; Hall IP, 2007, EUR RESPIR J, V29, P1239, DOI 10.1183/09031936.00088206; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Holgate ST, 1999, NATURE, V402, pB2; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Jeon SK, 2008, J INVEST DERMATOL, V128, P1930, DOI 10.1038/jid.2008.13; Joos GF, 2003, ANN NY ACAD SCI, V992, P218; Kasperska-Zajac A, 2007, INFLAMMATION, V30, P161, DOI 10.1007/s10753-007-9033-3; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lalloo UG, 1996, J ALLERGY CLIN IMMUN, V98, pS91, DOI 10.1016/S0091-6749(96)80134-5; Lalloo UG, 1996, J ALLERGY CLIN IMM 2, V98, pS96; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lewis MJ, 2006, RESP MED, V100, P1688, DOI 10.1016/j.med.2006.01.019; Li MO, 2008, IMMUNITY, V28, P468, DOI 10.1016/j.immuni.2008.03.003; Lucas SR, 2005, J ALLERGY CLIN IMMUN, V115, P928, DOI 10.1016/j.jaci.2005.01.033; MacGlashan Donald Jr, 2002, Curr Allergy Asthma Rep, V2, P126, DOI 10.1007/s11882-002-0007-0; Marone G, 2005, TRENDS IMMUNOL, V26, P25, DOI 10.1016/j.it.2004.10.010; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; Mauad T, 2007, J ALLERGY CLIN IMMUN, V120, P997, DOI 10.1016/j.jaci.2007.06.031; McKerrow JH, 2006, ANNU REV PATHOL-MECH, V1, P497, DOI 10.1146/annurev.pathol.1.110304.100151; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Min B, 2008, NAT IMMUNOL, V9, P223, DOI 10.1038/ni0308-223; OLLERENSHAW SL, 1991, EUR RESPIR J, V4, P673; Opal SM, 2000, CHEST, V117, P1162, DOI 10.1378/chest.117.4.1162; Ownby Dennis R, 2003, Curr Opin Allergy Clin Immunol, V3, P517, DOI 10.1097/00130832-200312000-00015; Pawankar R, 2004, IMMUNOL ALLERGY CLIN, V24, P75, DOI 10.1016/S0889-8561(03)00109-7; Pejler G, 2007, ADV IMMUNOL, V95, P167, DOI 10.1016/S0065-2776(07)95006-3; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; Platts-Mills TAE, 2004, SPRINGER SEMIN IMMUN, V25, P271, DOI 10.1007/s00281-003-0149-8; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Rivera J, 2006, J ALLERGY CLIN IMMUN, V117, P1214, DOI 10.1016/j.jaci.2006.04.015; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; Ryan JJ, 2007, CRIT REV IMMUNOL, V27, P15; Saito H, 2001, INT ARCH ALLERGY IMM, V125, P1, DOI 10.1159/000053790; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI [10.1016/j.jaci.2005.01.008, 10.1016/j.jaci.2005.01.009]; Sandilands A, 2007, J INVEST DERMATOL, V127, P1282, DOI 10.1038/sj.jid.5700876; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; SAYED BA, 2008, ANNU REV IMMUNOL, V25, P705; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Serhan CN, 2008, ANNU REV PATHOL-MECH, V3, P279, DOI [10.1146/annurev.pathmechdis.3.121806.151409, 10.1146/annurev.patho1.3.121806.151409]; Silverstein AM, 2000, NAT IMMUNOL, V1, P453, DOI 10.1038/82691; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Stevens RL, 2007, IMMUNOL REV, V217, P155, DOI 10.1111/j.1600-065X.2007.00525.x; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/4A6539.2005; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Von Pirquet C., 1906, MUNCHEN MED WOCHEN, V30, P1457; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	100	618	651	17	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 24	2008	454	7203					445	454		10.1038/nature07204		10	Multidisciplinary Sciences	Science & Technology - Other Topics	329IC	WOS:000257860300039	18650915	
J	Barnes, PJ				Barnes, Peter J.			Immunology of asthma and chronic obstructive pulmonary disease	NATURE REVIEWS IMMUNOLOGY			English	Review							REGULATORY T-CELLS; THYMIC STROMAL LYMPHOPOIETIN; AIR-FLOW LIMITATION; PERIPHERAL AIRWAYS; GENE-EXPRESSION; DENDRITIC CELLS; INDUCED SPUTUM; ATOPIC ASTHMA; TH2 CELLS; ALLERGIC INFLAMMATION	Asthma and chronic obstructive pulmonary disease (COPD) are both obstructive airway diseases that involve chronic inflammation of the respiratory tract, but the type of inflammation is markedly different between these diseases, with different patterns of inflammatory cells and mediators being involved. As described in this Review, these inflammatory profiles are largely determined by the involvement of different immune cells, which orchestrate the recruitment and activation of inflammatory cells that drive the distinct patterns of structural changes in these diseases. However, it is now becoming clear that the distinction between these diseases becomes blurred in patients with severe asthma, in asthmatic subjects who smoke and during acute exacerbations. This has important implications for the development of new therapies.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk					Agusti A, 2003, THORAX, V58, P832, DOI 10.1136/thorax.58.10.832; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; ALEXANDER A, 1991, American Review of Respiratory Disease, V143, pA633; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Avila PC, 2007, ANNU REV MED, V58, P185, DOI 10.1146/annurev.med.58.061705.145252; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; BAMES PJ, 2006, CHEST, V129, P151; Barczyk A, 2006, J ALLERGY CLIN IMMUN, V117, P1484, DOI 10.1016/j.jaci.2006.02.013; Barnes PJ, 2007, PLOS MED, V4, P779, DOI 10.1371/journal.pmed.0040112; Barnes PJ, 2006, TRENDS MOL MED, V12, P515, DOI 10.1016/j.molmed.2006.09.006; Barnes PJ, 2006, LAB INVEST, V86, P867, DOI 10.1038/labinvest.3700456; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; Barnes PJ, 2000, CHEST, V117, P10; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; Barnes PJ, 2004, PHARMACOL REV, V56, P515, DOI 10.1124/pr.56.4.2; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 2003, AM J RESP CRIT CARE, V167, P813, DOI 10.1164/rccm.200210-1142PP; Barnes PJ, 2004, LANCET, V364, P985, DOI 10.1016/S0140-6736(04)17025-6; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 2004, J COPD, V1, P59; BARNES PJ, 2008, IN PRESS CURR MOL ME; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Caramori G, 2004, HISTOPATHOLOGY, V45, P477, DOI 10.1111/j.1365-2559.2004.01952.x; Caramori G, 2003, THORAX, V58, P348, DOI 10.1136/thorax.58.4.348; Caramori G, 2001, EUR RESPIR J, V18, P466, DOI 10.1183/09031936.01.00040701; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Celli BR, 2007, EUR RESPIR J, V29, P1224, DOI 10.1183/09031936.00109906; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Chrysofakis G, 2004, CHEST, V125, P71, DOI 10.1378/chest.125.1.71; Chung KF, 1999, THORAX, V54, P825; Chung K.F., 2001, EUR RESPIR J, V34, P50; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Costa C, 2008, CHEST, V133, P26, DOI 10.1378/chest.07-0393; Donnelly LE, 2006, TRENDS PHARMACOL SCI, V27, P546, DOI 10.1016/j.tips.2006.08.001; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408; Edwards JCW, 2006, NAT REV IMMUNOL, V6, P394, DOI 10.1038/nri1838; Evans DJ, 2001, COCHRANE DB SYST REV, V2, DOI 10.1002/14651858.CD002993; Finegold I, 2007, ALLERGY ASTHMA PROC, V28, P44, DOI 10.2500/aap.2007.28.2971; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; FRANCUS T, 1988, J IMMUNOL, V140, P1823; Galli SJ, 2005, ANNU REV IMMUNOL, V23, P749, DOI 10.1146/annurev.immunol.21.120601.141025; Gamble E, 2007, EUR RESPIR J, V30, P467, DOI 10.1183/09031936.00013006; Gould NJ, 2000, BRIT MED BULL, V56, P908; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Grumelli S, 2004, PLOS MED, V1, P75, DOI 10.1371/journal.pmed.0010008; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Hwang ES, 2005, SCIENCE, V307, P430, DOI 10.1126/science.1103336; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; JEFFERY PK, 2000, CHEST, V117, P251; Kay AB, 2006, CHEM IMMUNOL ALLERGY, V91, P59; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Komai-Koma M, 2007, EUR J IMMUNOL, V37, P2779, DOI 10.1002/eji.200737547; Kraft M, 2006, AM J RESP CRIT CARE, V174, P238, DOI 10.1164/rccm.2604007; Kurashima K, 2006, RESPIROLOGY, V11, P152, DOI 10.1111/j.1440-1843.2006.00822.x; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JH, 2007, CLIN EXP IMMUNOL, V148, P53, DOI 10.1111/j.1365-2249.2007.03329.x; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Lukacs Nicholas W., 2005, Current Drug Targets - Inflammation and Allergy, V4, P313, DOI 10.2174/1568010054022088; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Meyer EH, 2008, ANNU REV MED, V59, P281, DOI 10.1146/annurev.med.59.061506.154139; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Nurieva R, 2007, NATURE, V448, P480, DOI 10.1038/nature05969; Ohnishi K, 1998, LAB INVEST, V78, P1077; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; Papi Alberto, 2006, Proc Am Thorac Soc, V3, P245, DOI 10.1513/pats.200512-125SF; Paredi P, 2000, AM J RESP CRIT CARE, V162, P1450; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Reber L, 2006, EUR J PHARMACOL, V533, P327, DOI 10.1016/j.ejphar.2005.12.067; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469; Rogers AV, 2008, THORAX, V63, P108, DOI 10.1136/thx.2007.078253; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1046/j.1365-2222.1996.d01-386.x; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Siddiqui S, 2007, J ALLERGY CLIN IMMUN, V120, P813, DOI 10.1016/j.jaci.2007.05.028; Smit JJ, 2006, EUR J PHARMACOL, V533, P277, DOI 10.1016/j.ejphar.2005.12.064; Smyth LJC, 2007, CHEST, V132, P156, DOI 10.1378/chest.07-0083; SOLER P, 1989, AM REV RESPIR DIS, V139, P1112; SPOLSKI R, 2007, ANN REV IMMUNOL 1108; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Sullivan AK, 2005, AM J RESP CRIT CARE, V172, P590, DOI 10.1164/rccm.200410-1332OC; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; TAMOKI J, 2000, LANCET, V356, P273; Taraseviciene-Stewart Laima, 2006, Proc Am Thorac Soc, V3, P687, DOI 10.1513/pats.200605-105SF; Thomson NC, 2004, EUR RESPIR J, V24, P822, DOI 10.1183/09031936.04.00039004; Traves SL, 2004, J LEUKOCYTE BIOL, V76, P441, DOI 10.1189/jlb.1003495; Tuder Rubin M, 2006, Proc Am Thorac Soc, V3, P503, DOI 10.1513/pats.200603-054MS; Usui T, 2006, J EXP MED, V203, P755, DOI 10.1084/jem.20052165; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Wan Yisong Y, 2007, Proc Am Thorac Soc, V4, P271, DOI 10.1513/pats.200701-020AW; Wark PAB, 2006, THORAX, V61, P909, DOI 10.1136/thx.2005.045187; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wolk K, 2006, CYTOKINE GROWTH F R, V17, P367, DOI 10.1016/j.cytogfr.2006.09.001; Xanthou G, 2003, EUR J IMMUNOL, V33, P2241, DOI 10.1002/eji.200323787; Ying S, 2005, J IMMUNOL, V174, P8183; Yoshimoto T, 2007, J IMMUNOL, V179, P4415; Zhu J, 2001, AM J RESP CRIT CARE, V164, P109	122	574	611	8	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	MAR	2008	8	3					183	192		10.1038/nri2254		10	Immunology	Immunology	267ZV	WOS:000253548600013	18274560	
J	Adler, NE; Newman, K				Adler, NE; Newman, K			Socioeconomic disparities in health: Pathways and policies	HEALTH AFFAIRS			English	Article							UNITED-STATES; INCOME-DISTRIBUTION; RISK-FACTORS; US ADULTS; MORTALITY; INEQUALITIES; INSURANCE; DISEASE; ASTHMA; CARE	Socioeconomic status (SES) underlies three major determinants of health: health care, environmental exposure, and health behavior. In addition, chronic stress associated with lower SES may also increase morbidity and mortality. Reducing SES disparities in health will require policy initiatives addressing the components of socioeconomic status (income, education, and occupation) as well as the pathways by which these affect health, Lessons for U.S. policy approaches are taken from the Acheson Commission in England, which was charged with reducing health disparities in that country.	Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Hlth & Community, San Francisco, CA 94143 USA; Harvard Univ, John F Kennedy Sch Govt, Cambridge, MA 02138 USA; Harvard Univ, Radcliffe Inst Adv Study, Cambridge, MA 02138 USA	Adler, NE (reprint author), Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA.						Acheson D, 1998, BRIT MED J, V317, P1659; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; ADLER NE, 2000, AM PUBL HLTH ASS C B; ANGELL M, 1993, NEW ENGL J MED, V329, P126, DOI 10.1056/NEJM199307083290210; Baciu M, 1999, NEUROREPORT, V10, P1373, DOI 10.1097/00001756-199904260-00040; Baker DW, 2000, ARCH INTERN MED, V160, P1269, DOI 10.1001/archinte.160.9.1269; Barbeau EM, 2001, AM J PUBLIC HEALTH, V91, P1412, DOI 10.2105/AJPH.91.9.1412; Berkman LF, 2000, SOCIAL EPIDEMIOLOGY, P137; Bhatia R, 2001, AM J PUBLIC HEALTH, V91, P1398, DOI 10.2105/AJPH.91.9.1398; Brown MJ, 2001, AM J PUBLIC HEALTH, V91, P621, DOI 10.2105/AJPH.91.4.621; Brunner E, 1997, BRIT MED J, V314, P1472; Bullard R.D., 2001, ENV JUSTICE 21 CENTU; BURSTIN HR, 1992, JAMA-J AM MED ASSOC, V268, P2383, DOI 10.1001/jama.268.17.2383; CATALANO R, 1992, J HEALTH SOC BEHAV, V33, P363, DOI 10.2307/2137314; CHALOUPKA F, 1999, NBER WORKING PAPER, V7047; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Cruess S, 2000, PSYCHOSOM MED, V62, P828; DEATON A, 1999, C INCR IN AM TEX A M; Dunlop S, 2000, SOC SCI MED, V51, P123, DOI 10.1016/S0277-9536(99)00424-4; ELLWOOD D, 2000, J EC PERSPECTIVE WIN, P187; Ellwood David T., 2000, WORKING NATION WORKE; EVANS AW, 1997, HDB HLTH PSYCHOL; EVANS GW, 1992, J ENVIRON PSYCHOL, V12, P163, DOI 10.1016/S0272-4944(05)80068-4; Evans G. W., 2000, THEORETICAL PERSPECT, P247, DOI [10.1007/978-1-4615-4701-3, DOI 10.1007/978-1-4615-4701-3_20]; Fiscella K, 1997, BRIT MED J, V314, P1724; FULLILOVE M, 2001, REBUILDING UNITY HLT; Gregorio DI, 1997, AM J PUBLIC HEALTH, V87, P1472, DOI 10.2105/AJPH.87.9.1472; Gross DJ, 1999, HEALTH SERV RES, V34, P241; HAFNEREATON C, 1993, JAMA-J AM MED ASSOC, V269, P787, DOI 10.1001/jama.269.6.787; Hertzman C, 1999, DEVELOPMENTAL HEALTH AND THE WEALTH OF NATIONS, P21; Kaplan GA, 1996, BRIT MED J, V312, P999; KASL SV, 1980, PSYCHOTHER PSYCHOSOM, V34, P88; Kennedy BP, 1996, BRIT MED J, V312, P1004; Kennedy BP, 1998, BRIT MED J, V317, P917; Kotlowitz Alex, 1992, THERE ARE NO CHILDRE; KrebsSmith SM, 1995, AM J PUBLIC HEALTH, V85, P1623, DOI 10.2105/AJPH.85.12.1623; LaLonde M, 1981, NEW PERSPECTIVE HLTH; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; Lee P, 1997, ANNU REV PUBL HEALTH, V18, P1, DOI 10.1146/annurev.publhealth.18.1.1; LINK BG, 1995, J HEALTH SOC BEHAV, V35, P80, DOI 10.2307/2626958; LUNDBERG U, 2000, ENCY STRESS, V1, P408; Lynch JW, 1997, SOC SCI MED, V44, P809, DOI 10.1016/S0277-9536(96)00191-8; Mare RD, 1990, MEASUREMENT ANAL MOR, P362; Marmot M, 1999, HEALTH AFFAIR, V18, P42, DOI 10.1377/hlthaff.18.3.42; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; Martikainen PT, 1998, AM J PUBLIC HEALTH, V88, P1859, DOI 10.2105/AJPH.88.12.1859; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P57; Monheit AC, 2000, MED CARE RES REV, V57, P11; Morris P, 2000, SELF SUFFICIENCY PRO; NEWMAN K, 2000, J AFRICAN AM PUBLIC, V6, P17; Pamuk E., 1998, SOCIOECONOMIC STATUS; PAPPAS G, 1993, NEW ENGL J MED, V329, P103, DOI 10.1056/NEJM199307083290207; PIERCE JP, 1989, JAMA-J AM MED ASSOC, V261, P56, DOI 10.1001/jama.261.1.56; Putnam R., 2000, BOWLING ALONE COLLAP; Rodriguez E, 2001, AM J PUBLIC HEALTH, V91, P1403, DOI 10.2105/AJPH.91.9.1403; ROSS CE, 1995, AM SOCIOL REV, V60, P719, DOI 10.2307/2096319; ROSS CE, 1995, J HEALTH SOC BEHAV, V36, P230, DOI 10.2307/2137340; Sallis JF, 2001, AM J PUBLIC HEALTH, V91, P618, DOI 10.2105/AJPH.91.4.618; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; SCHNALL PL, 1992, AM J IND MED, V21, P417, DOI 10.1002/ajim.4700210314; Selden TM, 1999, HEALTH AFFAIR, V18, P126, DOI 10.1377/hlthaff.18.2.126; Shi LY, 1999, J FAM PRACTICE, V48, P275; Shkolnikov VM, 1998, SOC SCI MED, V47, P357, DOI 10.1016/S0277-9536(98)00096-3; SMALL M, 2001, THESIS HARVARD U; Smith GD, 1998, BRIT MED J, V317, P1465; SMITH GD, 1990, BRIT MED J, V301, P373; *STAT OFF, 1998, IND INQ IN HLTH REP; Stoddard JL, 1998, J HEALTH COMMUN, V3, P137; SURWIT RS, 1984, DIABETES CARE, V7, P203; Venkatesh SA, 2000, AM PROJECT RISE FALL; WATSON P, 1995, SOC SCI MED, V41, P923, DOI 10.1016/0277-9536(94)00405-I; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; Wilkinson R. G, 1996, UNHEALTHY SOC AFFLIC; WILSON SH, 1993, PUBLIC HEALTH, V107, P153, DOI 10.1016/S0033-3506(05)80436-6; WINKLEBY MA, 1992, AM J PUBLIC HEALTH, V82, P816, DOI 10.2105/AJPH.82.6.816; Winkleby MA, 1999, ANN NY ACAD SCI, V896, P191, DOI 10.1111/j.1749-6632.1999.tb08116.x; WOLKOWITZ OM, 2001, PHYSICAL CONSEQUENCE, P181; Wood E, 1999, SOC SCI MED, V48, P1751, DOI 10.1016/S0277-9536(99)00081-7	79	564	572	19	92	PROJECT HOPE	BETHESDA	7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA	0278-2715			HEALTH AFFAIR	Health Aff.	MAR-APR	2002	21	2					60	76		10.1377/hlthaff.21.2.60		19	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	530WN	WOS:000174382100007	11900187	
J	Christ-Crain, M; Jaccard-Stolz, D; Bingisser, R; Gencay, MM; Huber, PR; Tamm, M; Muller, B				Christ-Crain, M; Jaccard-Stolz, D; Bingisser, R; Gencay, MM; Huber, PR; Tamm, M; Muller, B			Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial	LANCET			English	Article							COMMUNITY-ACQUIRED PNEUMONIA; OBSTRUCTIVE PULMONARY-DISEASE; UNCOMPLICATED ACUTE BRONCHITIS; CRITICALLY ILL PATIENTS; MANAGEMENT; THERAPY; EXACERBATIONS; IMPACT; SEPSIS; RESISTANCE	Background Lower respiratory tract infections are often treated with antibiotics without evidence of clinically relevant bacterial disease. Serum calcitonin precursor concentrations, including procalcitonin, are raised in bacterial infections. We aimed to assess a procalcitonin-based therapeutic strategy to reduce antibiotic use in lower respiratory tract infections with a new rapid and sensitive assay. Methods 243 patients admitted with suspected lower respiratory tract infections were randomly assigned standard care (standard group; n=119) or procalcitonin-guided treatment (procalcitonin group; n=124). On the basis of serum procalcitonin concentrations, use of antibiotics was more or less discouraged (<0.1 &mu;g/L or <0.25 mug/L) or encouraged (greater than or equal to0.5 mug/L or greater than or equal to0.25 mug/L), respectively. Re-evaluation was possible after 6-24 h in both groups. Primary endpoint was use of antibiotics and analysis was by intention to treat. Findings Final diagnoses were pneumonia (n=87; 36%), acute exacerbation of chronic obstructive pulmonary disease (60; 25%), acute bronchitis (59; 24%), asthma (13; 5%), and other respiratory affections (24; 10%). Serological evidence of viral infection was recorded in 141 of 175 tested patients (81%). Bacterial cultures were positive from sputum in 51 (21%) and from blood in 16 (7%). In the procalcitonin group, the adjusted relative risk of antibiotic exposure was 0.49 (95% CI 0.44-0.55; p<0.0001) compared with the standard group. Antibiotic use was significantly reduced in all diagnostic subgroups. Clinical and laboratory outcome was similar in both groups and favourable in 235 (97%). Interpretation Procalcitonin guidance substantially reduced antibiotic use in lower respiratory tract infections. Withholding antimicrobial treatment did not compromise outcome. In view of the current overuse of antimicrobial therapy in often self-limiting acute respiratory tract infections, treatment based on procalcitonin measurement could have important clinical and financial implications.	Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Pneumol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Div Endocrinol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Res, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Clin Chem, CH-4031 Basel, Switzerland	Muller, B (reprint author), Univ Basel Hosp, Dept Internal Med, Petersgraben 4, CH-4031 Basel, Switzerland.	happymiller@bluewin.ch		Bingisser, Roland/0000-0001-8223-9792			ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196; ASSICOT M, 1993, LANCET, V341, P515, DOI 10.1016/0140-6736(93)90277-N; Ball P, 2002, J ANTIMICROB CHEMOTH, V49, P31, DOI 10.1093/jac/49.1.31; British Thoracic Society Standards of Care C, 2001, THORAX S4, V56, pIV1; Chen DK, 1999, NEW ENGL J MED, V341, P233, DOI 10.1056/NEJM199907223410403; Evans AT, 2002, LANCET, V359, P1648, DOI 10.1016/S0140-6736(02)08597-5; Fluckiger U, 2000, EUR J CLIN MICROBIOL, V19, P493, DOI 10.1007/s100960000306; Gonzales R, 2003, JAMA-J AM MED ASSOC, V289, P2701, DOI 10.1001/jama.289.20.2701; Gonzales R, 2000, ANN INTERN MED, V133, P981; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Guillemot D, 2001, CLIN INFECT DIS, V33, P542, DOI 10.1086/322583; HALLS GA, 1993, J ANTIMICROB CHEMOTH, V31, P985, DOI 10.1093/jac/31.6.985; Halm EA, 2002, NEW ENGL J MED, V347, P2039, DOI 10.1056/NEJMcp020499; Hament JM, 1999, FEMS IMMUNOL MED MIC, V26, P189, DOI 10.1016/S0928-8244(99)00159-5; Harbarth S, 2001, AM J RESP CRIT CARE, V164, P396; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977; Karzai W, 1997, INFECTION, V25, P329, DOI 10.1007/BF01740811; Korppi M, 2002, APMIS, V110, P515, DOI 10.1034/j.1600-0463.2002.11007801.x; MACFARLANE JT, 1993, LANCET, V341, P511, DOI 10.1016/0140-6736(93)90275-L; Marik PE, 2000, J CRIT CARE, V15, P85, DOI 10.1053/jcrc.2000.16460; Marrie TJ, 2003, EUR RESPIR J, V21, P779, DOI 10.1183/09031936.03.00095403; Meisner M, 2002, CLIN CHIM ACTA, V323, P17, DOI 10.1016/S0009-8981(02)00101-8; Muller B, 2000, CRIT CARE MED, V28, P977; Muller B, 2001, SWISS MED WKLY, V131, P595; NIEDERMAN MS, 1993, AM REV RESPIR DIS, V148, P1418; [Anonymous], 1997, NIH PUBL; Nylen E, 2003, CLIN INFECT DIS, V36, P823, DOI 10.1086/368088; Nylen ES, 1996, AM J MED SCI, V312, P12; ORTQVIST A, 1995, J ANTIMICROB CHEMOTH, V35, P205, DOI 10.1093/jac/35.1.205; Rohde G, 2003, THORAX, V58, P37, DOI 10.1136/thorax.58.1.37; Ruokonen E, 2002, ACTA ANAESTH SCAND, V46, P398, DOI 10.1034/j.1399-6576.2002.460412.x; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Sethi S, 2001, CLIN MICROBIOL REV, V14, P336, DOI 10.1128/CMR.14.2.336-363.2001; Snider RH, 1997, J INVEST MED, V45, P552; Stephenson J, 1996, JAMA-J AM MED ASSOC, V275, P175, DOI 10.1001/jama.275.3.175; Strausbaugh LJ, 2003, CLIN INFECT DIS, V36, P870, DOI 10.1086/368197; Uyeki TM, 2003, PEDIATR INFECT DIS J, V22, P164; Wenzel RP, 1999, CLIN INFECT DIS, V28, P1126, DOI 10.1086/514753	38	557	622	4	47	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 21	2004	363	9409					600	607		10.1016/S0140-6736(04)15591-8		8	Medicine, General & Internal	General & Internal Medicine	776EZ	WOS:000189104900008	14987884	
J	Akbari, O; Freeman, GJ; Meyer, EH; Greenfield, EA; Chang, TT; Sharpe, AH; Berry, G; DeKruyff, RH; Umetsu, DT				Akbari, O; Freeman, GJ; Meyer, EH; Greenfield, EA; Chang, TT; Sharpe, AH; Berry, G; DeKruyff, RH; Umetsu, DT			Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity	NATURE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; HEAT-KILLED LISTERIA; MOUSE BONE-MARROW; DENDRITIC CELLS; IN-VIVO; IMMUNE-RESPONSES; CO-STIMULATION; MOLECULE ICOS; INFLAMMATION; EXPRESSION	Asthma is caused by T-helper cell 2 (Th2)-driven immune responses, but the immunological mechanisms that protect against asthma development are poorly understood. T-cell tolerance, induced by respiratory exposure to allergen, can inhibit the development of airway hyperreactivity (AHR), a cardinal feature of asthma, and we show here that regulatory T (T-R) cells can mediate this protective effect. Mature pulmonary dendritic cells in the bronchial lymph nodes of mice exposed to respiratory allergen induced the development of TR cells, in a process that required T-cell costimulation via the inducible costimulator (ICOS)-ICOS-ligand pathway. The TR cells produced IL-10, and had potent inhibitory activity; when adoptively transferred into sensitized mice, TR cells blocked the development of AHR. Both the development and the inhibitory function of regulatory cells were dependent on the presence of IL-10 and on ICOS-ICOS-ligand interactions. These studies demonstrate that TR cells and the ICOS-ICOS-ligand signaling pathway are critically involved in respiratory tolerance and in downregulating pulmonary inflammation in asthma.	Stanford Univ, Dept Pediat, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol, Sch Med, Stanford, CA 94305 USA; Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Div Immunol Res, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA	Umetsu, DT (reprint author), Stanford Univ, Dept Pediat, Sch Med, Div Immunol & Allergy, Stanford, CA 94305 USA.				NCI NIH HHS [CA84500]; NHLBI NIH HHS [R01HL62348]; NIAID NIH HHS [AI24571, AI26322, AI38310, AI39671, T32 AI007290]		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; ASSENMACHER M, 1994, EUR J IMMUNOL, V24, P1097, DOI 10.1002/eji.1830240513; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COFFMAN RL, 1991, RES IMMUNOL, V142, P7, DOI 10.1016/0923-2494(91)90002-Z; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; DING L, 1993, J IMMUNOL, V151, P1224; Dong C, 2001, NATURE, V409, P97, DOI 10.1038/35051100; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Groux H, 1997, NATURE, V389, P737; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hansen G, 2000, J IMMUNOL, V164, P223; Holgate ST, 1999, NATURE, V402, P2, DOI 10.1038/35037000; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huang FP, 2000, J EXP MED, V191, P435, DOI 10.1084/jem.191.3.435; Hutloff A, 1999, NATURE, V397, P263; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; KEARNEY ER, 1994, IMMUNITY, V1, P327, DOI 10.1016/1074-7613(94)90084-1; Kim TS, 1997, J IMMUNOL, V158, P4137; LEVINGS MK, 2000, J ALLERGY CLIN IMMUN, V106, P109; Ling V, 2000, J IMMUNOL, V164, P1653; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; Mages HW, 2000, EUR J IMMUNOL, V30, P1040, DOI 10.1002/(SICI)1521-4141(200004)30:4<1040::AID-IMMU1040>3.0.CO;2-6; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; MALONEY DG, 1985, HYBRIDOMA, V4, P191, DOI 10.1089/hyb.1985.4.191; MARRACK P, 1983, J EXP MED, V158, P1635, DOI 10.1084/jem.158.5.1635; McAdam AJ, 2000, J IMMUNOL, V165, P5035; McAdam AJ, 2001, NATURE, V409, P102, DOI 10.1038/35051107; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nakajima A, 1997, INT IMMUNOL, V9, P637, DOI 10.1093/intimm/9.5.637; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Randolph DA, 1999, J IMMUNOL, V162, P2375; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Roncarolo MG, 2001, J EXP MED, V193, pF5, DOI 10.1084/jem.193.2.F5; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SANDER B, 1991, IMMUNOL REV, V119, P65, DOI 10.1111/j.1600-065X.1991.tb00578.x; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; SCHEICHER C, 1992, J IMMUNOL METHODS, V154, P253, DOI 10.1016/0022-1759(92)90199-4; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STOCKINGER B, 1994, INT IMMUNOL, V6, P247, DOI 10.1093/intimm/6.2.247; Swallow MM, 1999, IMMUNITY, V11, P423, DOI 10.1016/S1074-7613(00)80117-X; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Walter DM, 2001, J IMMUNOL, V167, P4668; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yeung VP, 1998, J IMMUNOL, V161, P4146; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1022	59	550	582	1	13	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	SEP	2002	8	9					1024	1032		10.1038/nm745		9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	589KQ	WOS:000177757900039	12145647	
J	Morgan, WJ; Crain, EF; Gruchalla, RS; O'Connor, GT; Kattan, M; Evans, RI; Stout, J; Malindzak, G; Smartt, E; Plaut, M; Walter, M; Vaughn, B; Mitchell, H				Morgan, WJ; Crain, EF; Gruchalla, RS; O'Connor, GT; Kattan, M; Evans, RI; Stout, J; Malindzak, G; Smartt, E; Plaut, M; Walter, M; Vaughn, B; Mitchell, H		Inner-City Asthma Study Grp	Results of a home-based environmental intervention among urban children with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HOUSE-DUST-MITE; INNER-CITY CHILDREN; COCKROACH ALLERGEN EXPOSURE; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND TRIAL; AVOIDANCE MEASURES; TOBACCO-SMOKE; RISK-FACTORS; LOW-INCOME; REDUCTION	Background: Children with asthma who live in the inner city are exposed to multiple indoor allergens and environmental tobacco smoke in their homes. Reductions in these triggers of asthma have been difficult to achieve and have seldom been associated with decreased morbidity from asthma. The objective of this study was to determine whether an environmental intervention tailored to each child's allergic sensitization and environmental risk factors could improve asthma-related outcomes. Methods: We enrolled 937 children with atopic asthma (age, 5 to 11 years) in seven major U.S. cities in a randomized, controlled trial of an environmental intervention that lasted one year (intervention year) and included education and remediation for exposure to both allergens and environmental tobacco smoke. Home environmental exposures were assessed every six months, and asthma-related complications were assessed every two months during the intervention and for one year after the intervention. Results: For every 2-week period, the intervention group had fewer days with symptoms than did the control group both during the intervention year (3.39 vs. 4.20 days, P<0.001) and the year afterward (2.62 vs. 3.21 days, P<0.001), as well as greater declines in the levels of allergens at home, such as Dermatophagoides farinae (Derf1) allergen in the bed (P<0.001) and on the bedroom floor (P=0.004), D. pteronyssinus in the bed (P=0.007), and cockroach allergen on the bedroom floor (P<0.001). Reductions in the levels of cockroach allergen and dust-mite allergen (Derf1) on the bedroom floor were significantly correlated with reduced complications of asthma (P<0.001). Conclusions: Among inner-city children with atopic asthma, an individualized, home-based, comprehensive environmental intervention decreases exposure to indoor allergens, including cockroach and dust-mite allergens, resulting in reduced asthma-associated morbidity.	Univ Arizona, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA; Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Boston Univ, Sch Med, Boston, MA 02118 USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Childrens Mem Hosp, Chicago, IL 60614 USA; Univ Washington, Sch Med & Publ Hlth, Seattle, WA USA; NIEHS, Res Triangle Pk, NC 27709 USA; NIAID, Bethesda, MD 20892 USA; Rho, Chapel Hill, NC USA	Morgan, WJ (reprint author), Univ Arizona, Arizona Resp Ctr, Coll Med, 1501 N Campbell Ave, Tucson, AZ 85724 USA.			O'Connor, George/0000-0002-6476-3926	NCRR NIH HHS [M01 RR00533]; NIAID NIH HHS [AI-39785, AI-39761, AI-39769, AI-39776, AI-39789, AI-39900, AI-39901, AI-39902]		BANDURA A, 1986, SOCIAL FDN THOUGHT A; Bandura A., 1986, SOCIAL LEARNING THEO; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cook DG, 1997, THORAX, V52, P1081; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hovell MF, 2002, PEDIATRICS, V110, P946, DOI 10.1542/peds.110.5.946; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; *I MED, 2000, CLEAR AIR ASTHM IND, P124; Irvine L, 1999, BRIT MED J, V318, P1456; Jalaludin B, 1998, J ALLERGY CLIN IMMUN, V102, P382, DOI 10.1016/S0091-6749(98)70124-1; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; McDonald E, 2002, CHEST, V122, P1535, DOI 10.1378/chest.122.5.1535; *NAT KIDN FDN INC, 1997, DIAL OUTC QUAL IN CL, P42; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Platts-Mills TAE, 2003, NEW ENGL J MED, V349, P207, DOI 10.1056/NEJMp030082; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; *THOM HEALTHC, 2004, DRUG TOP RED BOOK; vanderHeide S, 1997, ALLERGY, V52, P921; Vojta PJ, 2001, ENVIRON HEALTH PERSP, V109, P815, DOI 10.2307/3454824; Wakefield M, 2002, PREV MED, V34, P58, DOI 10.1006/pmed.2001.0953; WALSHAW MJ, 1986, Q J MED, V58, P199; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107	45	548	572	3	48	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 9	2004	351	11					1068	1080		10.1056/NEJMoa032097		13	Medicine, General & Internal	General & Internal Medicine	852CX	WOS:000223733900006	15356304	
J	Ball, TM; Castro-Rodriguez, JA; Griffith, KA; Holberg, CJ; Martinez, FD; Wright, AL				Ball, TM; Castro-Rodriguez, JA; Griffith, KA; Holberg, CJ; Martinez, FD; Wright, AL			Siblings, day-care attendance, and the risk of asthma and wheezing during childhood	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	39th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 01-04, 1999	SAN FRANCISCO, CALIFORNIA	Ambulat Pediatr Assoc			RESPIRATORY-TRACT ILLNESS; HAY-FEVER; 1ST YEAR; CHILDREN; ALLERGEN; ATOPY; LIFE; SENSITIZATION; RESPONSES; DISEASE	Background: Young children with older siblings and those who attend day care are at increased risk for infections, which in turn may protect against the development of allergic diseases, including asthma. However, the results of studies examining the relation between exposure to other children and the subsequent development of asthma have been conflicting. Methods: In a study involving 1035 children followed since birth as part of the Tucson Children's Respiratory Study, we determined the incidence of asthma (defined as at least one episode of asthma diagnosed by a physician when the child was 6 to 13 years old) and the prevalence of frequent wheezing (more than three wheezing episodes during the preceding year) in relation to the number of siblings at home and in relation to attendance at day care during infancy. Results: The presence of one or more older siblings at home protected against the development of asthma (adjusted relative risk for each additional older sibling, 0.8; 95 percent confidence interval, 0.7 to 1.0; P = 0.04), as did attendance at day care during the first six months of life (adjusted relative risk, 0.4; 95 percent confidence interval, 0.2 to 1.0; P = 0.04). Children with more exposure to other children at home or at day care were more likely to have frequent wheezing at the age of 2 years than children with little or no exposure (adjusted relative risk, 1.4; 95 percent confidence interval, 1.1 to 1.8; P = 0.01) but were less likely to have frequent wheezing from the age of 6 (adjusted relative risk, 0.8; 95 percent confidence interval, 0.6 to 1.0; P = 0.03) through the age of 13 (adjusted relative risk, 0.3; 95 percent confidence interval, 0.2 to 0.5; P<0.001). Conclusions: Exposure of young children to older children at home or to other children at day care protects against the development of asthma and frequent wheezing later in childhood. (N Engl J Med 2000;343:538-43.) (C)2000, Massachusetts Medical Society.	Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ 85724 USA; Univ Arizona, Coll Med, Dept Pediat, Tucson, AZ 85724 USA	Wright, AL (reprint author), Univ Arizona, Coll Med, Resp Sci Ctr, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL 03154, HL 14136, HL 56177]		ADAMS PF, 1995, VITAL HLTH STAT 10, V193; BACKMAN A, 1984, ALLERGY, V39, P309, DOI 10.1111/j.1398-9995.1984.tb00867.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Matricardi PM, 1997, BRIT MED J, V314, P999; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; OSTERHOLM MT, 1994, PEDIATRICS, V94, P987; Ponsonby AL, 1998, ARCH DIS CHILD, V79, P328; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein RT, 1997, THORAX, V52, P946; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219; TAUSSIG LM, 1995, AM J RESP CRIT CARE, V151, pS32; *US BUR CENS, 1998, CURR POP REP P20, V515; *US BUR CENS, 1976, CURR POP REP P20, V291, P4; VONMUTIUS E, 1994, BRIT MED J, V308, P692; WEST J, 1995, DHEW PUBL NCES; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WRIGHT AL, 1989, BRIT MED J, V299, P946; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	35	544	567	2	19	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 24	2000	343	8					538	543		10.1056/NEJM200008243430803		6	Medicine, General & Internal	General & Internal Medicine	346QM	WOS:000088882600003	10954761	
J	Jutel, M; Akdis, M; Budak, F; Aebischer-Casaulta, C; Wrzyszcz, M; Blaser, K; Akdis, CA				Jutel, M; Akdis, M; Budak, F; Aebischer-Casaulta, C; Wrzyszcz, M; Blaser, K; Akdis, CA			IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						specific immunotherapy; T cell; IL-10; TGF-beta; regulatory T cell	GROWTH-FACTOR-BETA; GRASS-POLLEN IMMUNOTHERAPY; BEE VENOM IMMUNOTHERAPY; HUMAN LYMPHOCYTES-T; IN-VITRO; HELPER CELLS; CUTANEOUS RESPONSES; PHOSPHOLIPASE A(2); INTERFERON-GAMMA; IGE SYNTHESIS	The regulation of normal and allergic immune responses to airborne allergens in the mucosa is still poorly understood, and the mechanism of specific immunotherapy (SIT) in normalizing the allergic response to such allergens is currently not clear. Accordingly, we have investigated the immunoregulatory mechanism of both normal and allergic responses to the major house-dust mite (HDM) and birch pollen allergens - Dermatophagoides pteroynyssinus (Der p)1 and Bet v 1, respectively - as well as the immunologic basis of SIT to HDM in rhinitis and asthma patients. In normal immunity to HDM and birch pollen, an allergen-specific peripheral T cell suppression to Der p 1 and Bet v 1 was observed. The deviated immune response was characterized by suppressed proliferative T cell and Th1 (IFN-gamma) and Th2 (IL-5, IL-13) cytokine responses, and increased IL-10 and TGF-beta secretion by allergen-specific T cells. Neutralization of cytokine activity showed that T cell suppression was induced by IL-10 and TGF-beta during SIT and in normal immunity to the mucosal allergens. In addition, SIT induced an antigen-specific suppressive activity in CD4(+) CD25(+) T cells of allergic individuals. Together, these results demonstrate a deviation towards a regulatory/suppressor T cell response during SIT and in normal immunity as a key event for the healthy immune response to mucosal antigens.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Med Acad Wroclaw, Wroclaw, Poland; Uludag Univ, Sch Med, Bursa, Turkey; Univ Hosp, Dept Pediat, Bern, Switzerland	Jutel, M (reprint author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.		Budak, Ferah/F-4657-2014				AALBERSE RC, 1983, J IMMUNOL, V130, P722; Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1999, FASEB J, V13, P603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 1997, J ALLERGY CLIN IMMUN, V99, P345, DOI 10.1016/S0091-6749(97)70052-6; Annunziato F, 2002, J EXP MED, V196, P379, DOI 10.1084/jem.20020110; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; CARBALLIDO JM, 1994, J ALLERGY CLIN IMMUN, V93, P758, DOI 10.1016/0091-6749(94)90256-9; Cazac BB, 2000, IMMUNITY, V13, P443, DOI 10.1016/S1074-7613(00)00044-3; CRETICOS PS, 2000, J ALLERGY CLIN IMMUN, V105, P559; DE WMR, 1991, J EXP MED, V174, P1209; Del PG, 1993, J IMMUNOL, V150, P353; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; FARGEAS C, 1992, EUR J IMMUNOL, V22, P2173, DOI 10.1002/eji.1830220833; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; GEISER AG, 1993, P NATL ACAD SCI USA, V90, P9944, DOI 10.1073/pnas.90.21.9944; Groux H, 1997, NATURE, V389, P737; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Holt P. G, 2000, AM J RESP CRIT CARE, V161, P172; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J; Jonuleit H, 2002, J EXP MED, V196, P255, DOI 10.1084/jem.20020394; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; JUTEL M, 1995, J IMMUNOL, V154, P4187; KAPSENBERG ML, 1992, CURR OPIN IMMUNOL, V4, P788, DOI 10.1016/0952-7915(92)90063-K; KEHRL JH, 1986, J EXP MED, V163, P1037, DOI 10.1084/jem.163.5.1037; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Liu Y, 1997, J IMMUNOL, V158, P604; Ludviksson BR, 2000, EUR J IMMUNOL, V30, P2101, DOI 10.1002/1521-4141(200007)30:7<2101::AID-IMMU2101>3.0.CO;2-P; Magnan A, 1997, CLIN EXP ALLERGY, V27, P389; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; NAGELKERKEN L, 1993, EUR J IMMUNOL, V23, P2306, DOI 10.1002/eji.1830230938; PARKER WA, 1989, J ALLERGY CLIN IMMUN, V84, P667, DOI 10.1016/0091-6749(89)90294-7; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shevach EM, 2000, ANNU REV IMMUNOL, V18, P423, DOI 10.1146/annurev.immunol.18.1.423; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; SPIEGELBERG HL, 1994, J CLIN INVEST, V93, P711, DOI 10.1172/JCI117024; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Takeuchi M, 1998, J IMMUNOL, V160, P1589; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; ZHANG XH, 1995, J EXP MED, V182, P699, DOI 10.1084/jem.182.3.699	57	543	584	2	18	WILEY-V C H VERLAG GMBH	WEINHEIM	PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	MAY	2003	33	5					1205	1214		10.1002/eji.200322919		10	Immunology	Immunology	680DM	WOS:000182961100008	12731045	
J	Olsen, J; Melbye, M; Olsen, SF; Sorensen, TIA; Aaby, P; Andersen, AMN; Taxbol, D; Hansen, KD; Juhl, M; Schow, TB; Sorensen, HT; Andresen, J; Mortensen, EL; Olesen, AW; Sondergaard, C				Olsen, J; Melbye, M; Olsen, SF; Sorensen, TIA; Aaby, P; Andersen, AMN; Taxbol, D; Hansen, KD; Juhl, M; Schow, TB; Sorensen, HT; Andresen, J; Mortensen, EL; Olesen, AW; Sondergaard, C			The Danish National Birth Cohort - its background, structure and aim	SCANDINAVIAN JOURNAL OF PUBLIC HEALTH			English	Article						cohort; pregnancy; life-course; epidemiology	IN-UTERO; REGISTER; EXPOSURE; CHILDHOOD; HEALTH; RISK; PREVENTION; WEIGHT	Background: It is well known that the time from conception to early childhood has importance for health conditions that reach into later stages of life. Recent research supports this view,, and diseases such as cardiovascular morbidity, cancer. mental illnesses. asthma. and allergy may all have component causes that act early in life. Exposures in this period, which influence fetal growth, cell divisions, and organ functioning, may have long-lasting impact on health and disease susceptibility. Methods: To investigate these issues the Danish National Birth Cohort (Better health for mother and child) was established. A large cohort of pregnant women with long-term follow-up of the offspring was the obvious choice because many of the exposures of interest cannot be reconstructed with sufficient validity back in time. The Study needs to be large, and it is aimed to recruit 100,000 women early in pregnancy, and to continue follow-up for decades. The Nordic countries are better Suited for this kind of research than most other countries because of their population-based registers on diseases, demography md social conditions, linkable at the individual level by means of the unique ID-number given to all citizens. Exposure information is mainly collected by computer-assisted telephone interviews with the women twice during pregnancy and when their children are six and 18 months old. participants are also asked to fill in a self-administered food frequency questionnaire in mid-pregnancy. Furthermore. a biological bank has been set up with blood taken from the mother twice during pregnancy and blood from the umbilical cord taken shortly after birth. Data collection started in 1996 and the project covered all regions in Denmark in 1999. By August 2000, a total of 60,000 pregnant women had been recruited to the study. It is expected that a large number of gene-environmental hypotheses need to be based on case-control analyses within a cohort like this.	Statens Serum Inst, Danish Epidemiol Sci Ctr, DK-2300 Copenhagen S, Denmark; Danish Epidemiol Sci Ctr, Aarhus, Denmark	Olsen, SF (reprint author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Artillerivej 5, DK-2300 Copenhagen S, Denmark.		Andersen, Anne-Marie Nybo/E-4993-2013	Andersen, Anne-Marie Nybo/0000-0002-4296-8488			Abel EL, 1998, ALCOHOL ALCOHOLISM, V33, P417; Andersen TF, 1999, DAN MED BULL, V46, P263; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BARKER D J P, 1992, Journal of Epidemiology and Community Health, V46, P8, DOI 10.1136/jech.46.1.8; Barker D. J. P., 1994, MOTHERS BABIES DIS L; BARR CE, 1990, ARCH GEN PSYCHIAT, V47, P869; Bingley PJ, 2000, BRIT MED J, V321, P420, DOI 10.1136/bmj.321.7258.420; CARLSEN E, 1992, BRIT MED J, V305, P609; Christensen K, 1998, DAN MED BULL, V45, P91; Ekbom A, 1998, SEMIN CANCER BIOL, V8, P237, DOI 10.1006/scbi.1998.0073; Gaist D, 1997, DAN MED BULL, V44, P445; GIUSTI RM, 1995, ANN INTERN MED, V122, P778; GODFREY KM, AM J CLIN NUTR, V71, pS1377; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Juel K, 1999, DAN MED BULL, V46, P354; Knudsen LB, 1998, DAN MED BULL, V45, P221; Kuh D, 1997, LIFE COURSE APPROACH; Kyvik KO, 1996, DAN MED BULL, V43, P467; MITTENDORF R, 1995, TERATOLOGY, V51, P435, DOI 10.1002/tera.1420510609; MunkJorgensen P, 1997, DAN MED BULL, V44, P82; Olsen J, 2000, EPIDEMIOL REV, V22, P76; REINISCH JM, 1995, JAMA-J AM MED ASSOC, V274, P1518, DOI 10.1001/jama.274.19.1518; Roed AS, 1999, DAN MED BULL, V46, P269; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Sorensen HT, 1997, BRIT MED J, V315, P401; Sorensen HT, 1997, BRIT MED J, V315, P1137; TRICHOPOULOS D, 1990, LANCET, V335, P939; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939	28	537	539	3	30	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	1403-4948			SCAND J PUBLIC HEALT	Scand. J. Public Health	DEC	2001	29	4					300	307		10.1177/14034948010290040201		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	499HY	WOS:000172566800011	11775787	
J	Bruce, N; Perez-Padilla, R; Albalak, R				Bruce, N; Perez-Padilla, R; Albalak, R			Indoor air pollution in developing countries: a major environmental and public health challenge	BULLETIN OF THE WORLD HEALTH ORGANIZATION			English	Review						air pollution, indoor-adverse effects; fossil fuels-toxicity; lung diseases; smoke inhalation injury; cataract; developing countries	PAPUA-NEW-GUINEA; BIOMASS FUEL COMBUSTION; LOWER RESPIRATORY-INFECTIONS; DOMESTIC SMOKE POLLUTION; DIFFERENT COOKING FUELS; YOUNG GAMBIAN CHILDREN; LUNG-CANCER MORTALITY; WOOD-BURNING STOVES; LOW-BIRTH-WEIGHT; RISK-FACTORS	Around 50% of people, almost all in developing countries, rely on coal and biomass in the form of wood, dung and crop residues for domestic energy. These materials are typically burnt in simple stoves with very incomplete combustion. Consequently, women and young children are exposed to high levels of indoor air pollution every clay. There is consistent evidence that indoor air pollution increases the risk of chronic obstructive pulmonary disease and of acute respiratory infections in childhood, the most important cause of death among children under 5 years of age in developing countries. Evidence also exists of associations with low birth weight, increased infant and perinatal mortality, pulmonary tuberculosis, nasopharyngeal and laryngeal cancer, cataract, and, specifically in respect of the use of coal, with lung cancer. Conflicting evidence exists with regard to asthma. All studies are observational and very few have measured exposure directly, while a substantial proportion have not dealt with confounding, As a result, risk estimates are poorly quantified and may be biased. Exposure to indoor air pollution may be responsible for nearly 2 million excess deaths in developing countries and for some 4% of the global burden of disease. Indoor air pollution is a major global public health threat requiring greatly increased efforts in the areas of research and policy-making. Research on its health effects should be strengthened, particularly in relation to tuberculosis and acute lower respiratory infections. A more systematic approach to the development and evaluation of interventions is desirable, with clearer recognition of the interrelationships between poverty and dependence on polluting fuels.	Univ Liverpool, Dept Publ Hlth, Liverpool L69 3GB, Merseyside, England; Natl Inst Resp Dis, Mexico City, DF, Mexico; Emory Univ, Rollins Sch Publ Hlth, Dept Int Hlth, Atlanta, GA 30322 USA	Bruce, N (reprint author), Univ Liverpool, Dept Publ Hlth, Whelan Bldg, Liverpool L69 3GB, Merseyside, England.						Albalak R, 1999, THORAX, V54, P1004; Albalak R, 1999, ENVIRON SCI TECHNOL, V33, P2505, DOI 10.1021/es981242q; Albalak R, 1997, THESIS U MICHIGAN; Altet MN, 1996, TUBERCLE LUNG DIS, V77, P537, DOI 10.1016/S0962-8479(96)90052-0; ANDERSON HR, 1978, INT J EPIDEMIOL, V7, P63, DOI 10.1093/ije/7.1.63; ANDERSON HR, 1979, THORAX, V34, P647, DOI 10.1136/thx.34.5.647; ANDERSON HR, 1976, AM REV RESPIR DIS, V114, P537; ANDERSON HR, 1979, INT J EPIDEMIOL, V8, P127, DOI 10.1093/ije/8.2.127; ANDERSON HR, 1988, INT J EPIDEMIOL, V17, P56, DOI 10.1093/ije/17.1.56; ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424; AZIZI BHO, 1995, J ASTHMA, V32, P413, DOI 10.3109/02770909409077752; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BECK BD, 1982, P RES WOOD COAL COMB; BEHERA D, 1994, RESPIRATION, V61, P89; BEHERA D, 1991, THORAX, V46, P344, DOI 10.1136/thx.46.5.344; BEHERA D, 1988, INDIAN J MED RES, V88, P522; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; BOY E, 2000, UNPUB BIRTH WEIGHT E; Bruce N, 1998, INT J EPIDEMIOL, V27, P454, DOI 10.1093/ije/27.3.454; BRUCE N, 1999, 3 ENV HLTH; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; CAMPBELL H, 1989, LANCET, V1, P1012; CARRILLO GR, 1999, AM J RESP CRIT CARE, V157, pA503; CERQUEIRO MC, 1990, REV INFECT DIS S8, V12; CHEN BH, 1990, WORLD HLTH STAT Q, V43, P27; CLIFFORD P, 1972, P ROY SOC MED, V65, P682; COLLINGS DA, 1990, TROP DOCT, V20, P151; DAIGLER GE, 1991, LARYNGOSCOPE, V101, P293; DARY O, 1981, B ENVIRON CONTAM TOX, V26, P24; DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174; DEKONING HW, 1985, B WORLD HEALTH ORGAN, V63, P11; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; DHAR SN, 1991, SEMIN RESPIR MED, V12, P69, DOI 10.1055/s-2007-1006227; DOSSING M, 1994, RESP MED, V88, P519, DOI 10.1016/S0954-6111(05)80334-8; Dutt D, 1996, NATL MED J INDIA, V9, P113; Ellegard A, 1996, ENVIRON HEALTH PERSP, V104, P980, DOI 10.2307/3433146; Ellegard A, 1997, ENVIRON RES, V75, P12, DOI 10.1006/enrs.1997.3771; Engel P, 1998, HUM ORGAN, V54, P408; Ezzati M, 2000, ENVIRON SCI TECHNOL, V34, P578, DOI 10.1021/es9905795; FICK B, 1984, AM REV RESPIR DIS, V129, P78; FRANCO EL, 1989, INT J CANCER, V43, P992, DOI 10.1002/ijc.2910430607; Gao YT, 1996, LUNG CANCER-J IASLC, V14, pS39, DOI 10.1016/S0169-5002(96)90209-3; Gharaibeh NS, 1996, ANN TROP PAEDIATR, V16, P97; GROBBELAAR JP, 1991, THORAX, V46, P334, DOI 10.1136/thx.46.5.334; GUNESER S, 1994, J TROP PEDIATRICS, V40, P114; Gupta BN, 1997, ENERGY ENV REV, V13, P61; Gupta R C, 1998, Indian J Chest Dis Allied Sci, V40, P109; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Houtmeyers E, 1999, EUR RESPIR J, V13, P1177, DOI 10.1034/j.1399-3003.1999.13e39.x; Hsu TH, 1998, LIFE SCI, V63, P1513, DOI 10.1016/S0024-3205(98)00418-4; JOHNSON AWBR, 1992, ANN TROP PAEDIATR, V12, P421; JOHNSON JD, 1990, CRIT REV TOXICOL, V20, P369, DOI 10.3109/10408449009089870; JUAREZCERON B, 1996, THESIS METROPOLITAN; KOSSOVE D, 1982, S AFR MED J, V61, P622; Lal Kewal, 1993, Indian Journal of Experimental Biology, V31, P761; Lin D, 1998, BIOMASS BIOENERG, V15, P181, DOI 10.1016/S0961-9534(98)00007-5; LIOY PJ, 1990, ENVIRON SCI TECHNOL, V24, P938, DOI 10.1021/es00077a001; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; Lopez Bravo I M, 1997, Rev Panam Salud Publica, V1, P9; LUVHIMBI JH, 1997, BOILING POINT, V38, P30; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; Malik S K, 1985, Indian J Chest Dis Allied Sci, V27, P171; MARTIN KS, 1991, LANCET, V337, P358, DOI 10.1016/0140-6736(91)90982-U; MASTER KM, 1974, JAMA-J AM MED ASSOC, V228, P1635; Mavlankar DV, 1991, B WORLD HEALTH ORGAN, V69, P435; McCracken JP, 1998, ENVIRON INT, V24, P739, DOI 10.1016/S0160-4120(98)00062-2; McKenna MT, 1996, AM J RESP CRIT CARE, V154, P587; Medina FM, 1996, LUNG CANCER-J IASLC, V14, P185, DOI 10.1016/0169-5002(96)00545-4; MENEZES AMB, 1994, THORAX, V49, P1217, DOI 10.1136/thx.49.12.1217; Mishra V K, 1999, Int J Infect Dis, V3, P119, DOI 10.1016/S1201-9712(99)90032-2; MISHRA VK, IN PRESS J ENV MED; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670; MORAN AO, 1992, THESIS NATL AUTONOMO; MORRIS K, 1990, AM J DIS CHILD, V144, P105; MTANGO FDE, 1992, TROP MED PARASITOL, V43, P229; Mumford JL, 1995, CARCINOGENESIS, V16, P3031, DOI 10.1093/carcin/16.12.3031; MUMFORD JL, 1990, CARCINOGENESIS, V11, P397, DOI 10.1093/carcin/11.3.397; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; NAEHER L, 1996, UNPUB ACUTE RESP INF; Noorhassim I, 1995, Med J Malaysia, V50, P263; NORBOO T, 1991, THORAX, V46, P341, DOI 10.1136/thx.46.5.341; NORBOO T, 1991, INT J EPIDEMIOL, V20, P749, DOI 10.1093/ije/20.3.749; ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885; PADMAVATI S, 1959, CIRCULATION, V20, P343; PADMAVATI S, 1964, DIS CHEST, V46, P457; Pandey M R, 1985, Tokai J Exp Clin Med, V10, P471; PANDEY MR, 1984, THORAX, V39, P331, DOI 10.1136/thx.39.5.331; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; PANDEY MR, 1989, ENVIRON INT, V15, P337, DOI 10.1016/0160-4120(89)90046-9; PANDEY MR, 1998, CHRONIC BRONCHITIS C; PEREZPADILLA JR, 1993, AM REV RESPIR DIS, V147, pA631; Pintos J, 1998, INT J EPIDEMIOL, V27, P936, DOI 10.1093/ije/27.6.936; Pistelly R, 1997, AM J RESP CRIT CARE, V155, pA941; Qureshi K A, 1994, Indian J Chest Dis Allied Sci, V36, P61; REGALADO J, 1996, AM J RESP CRIT CARE, V153, pA701; REID HF, 1986, MT RES DEV, V6, P293, DOI 10.2307/3673370; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341; RESTREPO J, 1983, J ACTA MED COLOMBIAN, V8, P191; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Robin LF, 1996, PEDIATR INFECT DIS J, V15, P859, DOI 10.1097/00006454-199610000-00006; SAIYED HN, 1991, BRIT J IND MED, V48, P825; SAKSENA S, 1992, ATMOS ENVIRON A-GEN, V26, P2125, DOI 10.1016/0960-1686(92)90096-4; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; SANDOVAL J, 1993, CHEST, V103, P12, DOI 10.1378/chest.103.1.12; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; SCOTT J, 1990, BRIT MED J, V301, P1015; SHAH N, 1994, J TROP PEDIATRICS, V40, P201; SHALINI VK, 1994, INDIAN J BIOCH BIOPH, V31, P262; SMITH K, 1989, ECON POLIT WEEKLY, V11, P517; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; SMITH KR, 1994, ENERGY, V19, P587, DOI 10.1016/0360-5442(94)90054-X; Smith K.R., 1999, INDOOR AIR 99, P13; Smith K. R., 1993, EPIDEMIOLOGY LUNG CA; Smith KR, 1987, BIOMASS FUELS AIR PO; Strachan DP, 1998, THORAX, V53, P50; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1998, THORAX, V53, P204; US Environmental Protection Agency. National Ambient Air Quality Standards for Particulate Matter, 1997, FED REGISTER, V62, P38651; VICTORA CG, 1994, PEDIATRICS, V93, P977; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; vonMutius E, 1996, BRIT MED J, V312, P1448; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; WESLEY AG, 1996, S AFR MED J, V64, P365; WEST S, 1992, JAMA-J AM MED ASSOC, V268, P1025, DOI 10.1001/jama.268.8.1025; World Health Organization [WHO], 1997, WHOEHG978; *WHO, 1992, WHOPEP923; *WHO, 2000, IN PRESS AIR QUAL GU; *WHO UNICEF, 1997, WHOCHD973AG UNICEF; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; [UNEP UNDP World Bank World Resources Institute], 1998, 1998 99 WORLD RES GU; WU AH, 1995, AM J EPIDEMIOL, V141, P1023; Xu X, 1996, INT J OCCUP ENV HEAL, V2, P172; Yu M C, 1985, Natl Cancer Inst Monogr, V69, P203; Zhang J, 1999, CHEMOSPHERE GLOBAL C, V1, P367, DOI 10.1016/S1465-9972(99)00003-3	137	534	561	12	132	WORLD HEALTH ORGANIZATION	GENEVA 27	MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND	0042-9686			B WORLD HEALTH ORGAN	Bull. World Health Organ.		2000	78	9					1078	1092				15	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	353FJ	WOS:000089263900003	11019457	
J	Platts-Mills, T; Vaughan, J; Squillace, S; Woodfolk, J; Sporik, R				Platts-Mills, T; Vaughan, J; Squillace, S; Woodfolk, J; Sporik, R			Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study	LANCET			English	Article							INNER-CITY CHILDREN; RISK FACTOR; IGG4 ANTIBODIES; SENSITIZATION; CHILDHOOD; MITE; IGE; LYMPHOCYTES; REACTIVITY; SUBCLASS	Background Although asthma is strongly associated with immediate hypersensitivity to indoor allergens, several studies have suggested that a cat in the house can decrease the risk of asthma. We investigated the immune response to cat and mite allergens, and asthma among children with a wide range of allergen exposure. Methods We did a population-based cross-sectional study of children (aged 12-14 years), some of whom had symptoms of asthma and bronchial hyper-reactivity, Antibodies to mite (Der f 1) and cat (Fel d 1) allergens measured by isotype (IgG and IgG4) specific radioimmunoprecipitation assays were compared with sensitisation and allergen concentrations in house dust. Findings 226 children were recruited, 47 of whom had symptoms of asthma and bronchial hyper-reactivity, Increasing exposure to mite was associated with increased prevalence of sensitisation and IgG antibody to Der f 1. By contrast, the highest exposure to cat was associated with decreased sensitisation, but a higher prevalence of IgG antibody to Fel d 1, Thus, among children with high exposure, the odds of sensitisation to mite rather than cat was 4.0 (99% CI 1.49-10.00). Furthermore. 31 of 76 children with 23 mug Fel d 1 at home, who were not sensitised to cat allergen had >125 units of IgG antibody to Fel d 1. Antibodies to Fel d 1 of the IgG4 isotype were strongly correlated with IgG antibody in both allergic and non-allergic children (r=0.84 and r=0.66, respectively). Sensitisation to mite or cat allergens was the strongest independent risk factor for asthma (p<0.001). Interpretation Exposure to cat allergen can produce an IgG and IgG4 antibody response without sensitisation or risk of asthma, This modified T-helper-2 cell response should be regarded as a form of tolerance and may be the correct objective of immunotherapy. The results may also explain the observation that animals in the house can decrease the risk of asthma.	Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	Platts-Mills, T (reprint author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.				NIAID NIH HHS [AI-20565, AI-34607]		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Agresti A, 1999, INT ARCH ALLERGY IMM, V118, P279, DOI 10.1159/000024099; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; ISHIZAKA K, 1967, J IMMUNOL, V98, P490; Jeannin P, 1998, J IMMUNOL, V160, P3555; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; Prescott SL, 1998, J IMMUNOL, V160, P4730; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Sawyer G, 1998, J ALLERGY CLIN IMMUN, V102, P765, DOI 10.1016/S0091-6749(98)70016-8; Schuurman J, 1999, IMMUNOLOGY, V97, P693, DOI 10.1046/j.1365-2567.1999.00845.x; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WHITE H, 1982, ECONOMETRICA, V50, P1, DOI 10.2307/1912526; ZHANG K, 1994, J IMMUNOL, V152, P3427	33	533	545	1	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 10	2001	357	9258					752	756		10.1016/S0140-6736(00)04168-4		5	Medicine, General & Internal	General & Internal Medicine	409TC	WOS:000167400900013	11253969	
J	Hammad, H; Chieppa, M; Perros, F; Willart, MA; Germain, RN; Lambrecht, BN				Hammad, Hamida; Chieppa, Marcello; Perros, Frederic; Willart, Monique A.; Germain, Ronald N.; Lambrecht, Bart N.			House dust mite allergen induces asthma via Toll-like receptor 4 triggering of airway structural cells	NATURE MEDICINE			English	Article							THYMIC STROMAL LYMPHOPOIETIN; DENDRITIC CELLS; EPITHELIAL-CELLS; ALVEOLAR MACROPHAGES; INHALED ENDOTOXIN; TYPE-2 RESPONSES; TH2 RESPONSES; LYMPH-NODES; T-CELLS; INFLAMMATION	Barrier epithelial cells and airway dendritic cells (DCs) make up the first line of defense against inhaled substances such as house dust mite (HDM) allergen and endotoxin (lipopolysaccharide, LPS). We hypothesized that these cells need to communicate with each other to cause allergic disease. We show in irradiated chimeric mice that Toll-like receptor 4 (TLR4) expression on radioresistant lung structural cells, but not on DCs, is necessary and sufficient for DC activation in the lung and for priming of effector T helper responses to HDM. TLR4 triggering on structural cells caused production of the innate proallergic cytokines thymic stromal lymphopoietin, granulocyte-macrophage colony-stimulating factor, interleukin-25 and interleukin-33. The absence of TLR4 on structural cells, but not on hematopoietic cells, abolished HDM-driven allergic airway inflammation. Finally, inhalation of a TLR4 antagonist to target exposed epithelial cells suppressed the salient features of asthma, including bronchial hyperreactivity. Our data identify an innate immune function of airway epithelial cells that drives allergic inflammation via activation of mucosal DCs.	[Hammad, Hamida; Perros, Frederic; Willart, Monique A.; Lambrecht, Bart N.] Univ Ghent, Dept Resp Med, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium; [Chieppa, Marcello; Germain, Ronald N.] NIAID, Immunol Lab, Sect Lymphocyte Biol, US Natl Inst Hlth, Bethesda, MD 20892 USA; [Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, Rotterdam, Netherlands	Lambrecht, BN (reprint author), Univ Ghent, Dept Resp Med, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be	Chieppa, Marcello/K-4846-2012; Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834	Intramural NIH HHS [ZIA AI000545-21]		Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Bajenoff M, 2006, IMMUNITY, V25, P989, DOI 10.1016/j.immuni.2006.10.011; Barnes PJ, 2008, NAT REV IMMUNOL, V8, P183, DOI 10.1038/nri2254; Berndt A, 2007, AM J PHYSIOL-LUNG C, V292, pL936, DOI 10.1152/ajplung.00394.2006; Beutler B, 2001, DRUG METAB DISPOS, V29, P474; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cates EC, 2004, J IMMUNOL, V173, P6384; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fattouh R, 2005, AM J RESP CRIT CARE, V172, P314, DOI 10.1164/rccm.200502-198OC; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; IROMPETTE A, 2009, NATURE, V457, P585; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106; Matute-Bello G, 2004, J IMMUNOL METHODS, V292, P25, DOI 10.1016/j.jim.2004.05.010; NATHAN AI, 2009, J ALLERGY CLIN  0127, DOI DOI 10.1016/J.JACI.2008.12; Nolte MA, 2007, J EXP MED, V204, P1487, DOI 10.1084/jem.20070325; Noulin N, 2005, J IMMUNOL, V175, P6861; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Poynter ME, 2003, J IMMUNOL, V170, P6257; Robays LJ, 2007, J IMMUNOL, V178, P5305; Saito T, 2005, CELL TISSUE RES, V321, P75, DOI 10.1007/s00441-005-1113-9; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-03880C; Skerrett SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL143, DOI 10.1152/ajplung.00030.2004; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Reis e Sousa, 2006, NAT REV IMMUNOL, V6, P476, DOI DOI 10.1038/NRI1845; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; Veres TZ, 2007, AM J RESP CELL MOL, V37, P553, DOI 10.1165/rcmb.2007-00870C; Vermaelen KY, 2001, J EXP MED, V193, P51; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2006, NAT IMMUNOL, V7, P709, DOI 10.1038/ni1360	45	522	539	3	42	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2009	15	4					410	416		10.1038/nm.1946		7	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	429RG	WOS:000264937200028	19330007	
J	Douwes, J; Thorne, P; Pearce, N; Heederik, D				Douwes, J; Thorne, P; Pearce, N; Heederik, D			Bioaerosol health effects and exposure assessment: Progress and prospects	ANNALS OF OCCUPATIONAL HYGIENE			English	Article; Proceedings Paper	5th International Conference of the International-Occupational-Hygiene-Association	JUN, 2002	BERGEN, NORWAY	Int Occupat Hygiene Assoc		asthma; beta(1,3)-glucans; bioaerosols; cancer; endotoxin; exposure assessment; infections; microorganisms	UPPER AIRWAY INFLAMMATION; WORK-RELATED SYMPTOMS; HOUSE-DUST ENDOTOXIN; LEGIONNAIRES-DISEASE; INHALED ENDOTOXIN; COTTON DUST; GRAIN DUST; HYPERSENSITIVITY PNEUMONITIS; ENVIRONMENTAL EXPOSURE; RESPONSE RELATIONSHIPS	Exposures to bioaerosols in the occupational environment are associated with a wide range of health effects with major public health impact, including infectious diseases, acute toxic effects, allergies and cancer. Respiratory symptoms and lung function impairment are the most widely studied and probably among the most important bioaerosol-associated health effects. In addition to these adverse health effects some protective effects of microbial exposure on atopy and atopic conditions has also been suggested. New industrial activities have emerged in recent years in which exposures to bioaerosols can be abundant, e.g. the waste recycling and composting industry, biotechnology industries producing highly purified enzymes and the detergent and food industries that make use of these enzymes. Dose-response relationships have not been established for most biological agents and knowledge about threshold values is sparse. Exposure limits are available for some contaminants, e.g. wood dust, subtilisins (bacterial enzymes) and flour dust. Exposure limits for bacterial endotoxin have been proposed. Risk assessment is seriously hampered by the lack of valid quantitative exposure assessment methods. Traditional culture methods to quantify microbial exposures have proven to be of limited use. Non-culture methods and assessment methods for microbial constituents [e.g. allergens, endotoxin, beta(1-->3)-glucans, fungal extracellular polysaccharides] appear more successful; however, experience with these methods is generally limited. Therefore, more research is needed to establish better exposure assessment tools and validate newly developed methods. Other important areas that require further research include: potential protective effects of microbial exposures on atopy and atopic diseases, inter-individual susceptibility for biological exposures, interactions of bioaerosols with non-biological agents and other potential health effects such as skin and neurological conditions and birth effects.	Univ Utrecht, Div Environm & Occupat Hlth, IRAS, NL-3508 TD Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA	Douwes, J (reprint author), Univ Utrecht, Div Environm & Occupat Hlth, IRAS, POB 80176, NL-3508 TD Utrecht, Netherlands.			Pearce, Neil/0000-0002-9938-7852; Douwes, Jeroen/0000-0003-3599-4036	NIEHS NIH HHS [P30 ES05605]		American Conference of Governmental Industrial Hygienists (ACGIH), 2002, THRESH LIM VAL TLVS; ACGIH, 1980, DOC THRESH LIM VAL; *ACGIH, 1990, DOC FLOUR DUST; AKETAGAWA J, 1993, J BIOCHEM-TOKYO, V113, P683; Allmers H, 2000, AM J IND MED, V37, P438, DOI 10.1002/(SICI)1097-0274(200004)37:4<438::AID-AJIM14>3.3.CO;2-1; ALVAREZ AJ, 1994, APPL ENVIRON MICROB, V60, P374; AUTRUP JL, 1993, ENVIRON HEALTH PERSP, V99, P195, DOI 10.2307/3431480; BANG FB, 1956, B JOHNS HOPKINS HOSP, V98, P325; Becklake M, 1996, CAN MED ASSOC J, V155, P1399; Bernstein IL, 1999, ASTHMA WORKPLACE; Bethwaite P, 2001, CANCER CAUSE CONTROL, V12, P635, DOI 10.1023/A:1011203809049; BLAIR A, 1992, SCAND J WORK ENV HEA, V18, P209; Bourke SJ, 2001, EUR RESPIR J, V18, p81S; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bray GA, 1991, MYCOTOXINS CANC HLTH; Brown CM, 1999, INT J EPIDEMIOL, V28, P353, DOI 10.1093/ije/28.2.353; BURELL R, 1981, EUR J RESPIR DIS, V62, P332; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; *CEN, 2001, CENTC137WG5 EUR STAN; CHARLES A, 1994, J CLIN PATHOL, V47, P94; Chun D T, 2000, Appl Occup Environ Hyg, V15, P152; CLAPP WD, 1994, AM J RESP CRIT CARE, V150, P611; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Cullinan P, 2001, ANN OCCUP HYG, V45, P97, DOI 10.1016/S0003-4878(00)00028-4; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; Demers PA, 1997, AM J IND MED, V31, P385, DOI 10.1002/(SICI)1097-0274(199704)31:4<385::AID-AJIM3>3.0.CO;2-V; DEMERS PA, 1998, 32 IARC; Den Boer JW, 2002, EMERG INFECT DIS, V8, P37; Dillon H.K., 1996, FIELD GUIDE DETERMIN; DONHAM KJ, 1986, AM J IND MED, V10, P339, DOI 10.1002/ajim.4700100336; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2000, AM J IND MED, V37, P459, DOI 10.1002/(SICI)1097-0274(200005)37:5<459::AID-AJIM2>3.0.CO;2-J; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Douwes J, 2001, ANN AGR ENV MED, V8, P39; Douwes J, 1997, INT J OCCUP ENV HL S, V3, pS26; DRIVER CR, 1994, JAMA-J AM MED ASSOC, V272, P1031, DOI 10.1001/jama.272.13.1031; Duchaine C, 2001, APPL ENVIRON MICROB, V67, P2775, DOI 10.1128/AEM.67.6.2775-2780.2001; *DUTCH EXP COMM OC, 1998, 199803WGD DUTCH EXP; EDUARD W, 1992, INT ARCH ALLERGY IMM, V97, P274; Eduard W, 1998, AM IND HYG ASSOC J, V59, P113, DOI 10.1202/0002-8894(1998)059<0113:MFQAOA>2.0.CO;2; Eduard W, 1988, ANN OCCUP HYG, V32, P447; FOGELMARK B, 1992, AGENTS ACTIONS, V35, P50, DOI 10.1007/BF01990951; FOGELMARK B, 1994, INT J EXP PATHOL, V75, P85; Fogelmark B, 2001, MEDIAT INFLAMM, V10, P13, DOI 10.1080/09629350151073748; GARIBALDI R, 1992, ENV OCCUPATIONAL MED, P607; GERBERDING JL, 1994, TXB CLIN OCCUPATIONA, P699; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HAYES RB, 1984, FOOD CHEM TOXICOL, V22, P39, DOI 10.1016/0278-6915(84)90050-4; Heederik D, 1999, OCCUP ENVIRON MED, V56, P735; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Houba R, 1997, J ALLERGY CLIN IMMUN, V99, P286, DOI 10.1016/S0091-6749(97)70044-7; IVERSEN M, 1990, ALLERGY, V45, P347, DOI 10.1111/j.1398-9995.1990.tb00510.x; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; KARLSSON K, 1989, SCAND J WORK ENV HEA, V15, P353; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; KHAN AA, 1994, APPL ENVIRON MICROB, V60, P3739; Khuder SA, 1998, AM J IND MED, V34, P252, DOI 10.1002/(SICI)1097-0274(199809)34:3<252::AID-AJIM7>3.0.CO;2-X; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kool JL, 1999, INFECT CONT HOSP EP, V20, P798, DOI 10.1086/501587; Kristensen P, 2000, SCAND J WORK ENV HEA, V26, P331; KROUGH P, 1984, MYCOTOXINS FOOD; LACEY J, 1994, AM J IND MED, V25, P141, DOI 10.1002/ajim.4700250139; Lange JL, 1997, APPL ENVIRON MICROB, V63, P1557; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MAHONEY FJ, 1992, J INFECT DIS, V165, P736; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1999, LANCET S2, V354, pSII12; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Michel O., 1997, INT J OCCUP ENV HL S, V3, P18; Miguel AG, 1996, ENVIRON HEALTH PERSP, V104, P1180, DOI 10.2307/3432911; Miller JD, 1997, AM IND HYG ASSOC J, V58, P39; Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.0.CO;2-V; *NAT TOX PROGR, 1991, 6 NAT TOX PROGR, V17, P309; Nelson P. E., 1983, FUSARIUM SPECIES ILL; NIOSH, 1997, DHHS NIOSH PUBL; OLSEN JH, 1988, BRIT J CANCER, V58, P392, DOI 10.1038/bjc.1988.226; OSTERHOLM MT, 1983, AM J EPIDEMIOL, V117, P60; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Pastoris MC, 1997, EUR J CLIN MICROBIOL, V16, P883; Pepys J, 1990, Allergy Proc, V11, P101, DOI 10.2500/108854190778993263; PEPYS J, 1990, ALLERGY PROC, V11, P97, DOI 10.2500/108854190778993281; PERNIS B, 1961, BRIT J IND MED, V18, P120; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; PICKERING CAC, 1994, OCCUPATIONAL LUNG DI; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; POULSEN OM, 1995, SCI TOTAL ENVIRON, V168, P33, DOI 10.1016/0048-9697(95)04521-2; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Reboux G, 2001, AM J RESP CRIT CARE, V163, P1534; REIF JS, 1989, SCAND J WORK ENV HEA, V15, P24; Reynolds SJ, 2002, AIHAJ, V63, P430, DOI 10.1080/15428110208984731; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rylander R, 1997, ARCH ENVIRON HEALTH, V52, P281; Rylander R, 1998, MEDIAT INFLAMM, V7, P105; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; Rylander R, 1999, EUR RESPIR J, V13, P1151, DOI 10.1034/j.1399-3003.1999.13e35.x; Rylander R., 1997, INT J OCCUP ENV HL S, V3, P32; RYLANDER R, 1996, INDOOR BUILT ENVIRON, V5, P106, DOI 10.1177/1420326X9600500206; RYLANDER R, 1997, MED INFLAMM, V6, P257; [Anonymous], 1994, INDOOR ENVIRON, DOI DOI 10.1177/1420326X9400300311; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; Salvaggio JE, 1997, CLIN EXP ALLERGY, V27, P18, DOI 10.1111/j.1365-2222.1997.tb01822.x; SALVAGGIO JE, 1986, ENVIRON HEALTH PERSP, V66, P17, DOI 10.2307/3430209; SANDIFORD CP, 1994, CLIN EXP ALLERGY, V24, P549, DOI 10.1111/j.1365-2222.1994.tb00952.x; SCHOU C, 1991, CLIN EXP ALLERGY, V21, P321, DOI 10.1111/j.1365-2222.1991.tb01663.x; Schweigert MK, 2000, CLIN EXP ALLERGY, V30, P1511, DOI 10.1046/j.1365-2222.2000.00893.x; SIGSGAARD T, 1994, AM J RESP CRIT CARE, V149, P1407; Sigsgaard T, 2000, EUR RESPIR J, V16, P140, DOI 10.1034/j.1399-3003.2000.16a25.x; SMID T, 1992, AM REV RESPIR DIS, V146, P1474; SONESSON A, 1990, APPL ENVIRON MICROB, V56, P1271; SONESSON A, 1988, J CHROMATOGR-BIOMED, V431, P1, DOI 10.1016/S0378-4347(00)83064-9; Sorenson W. G., 1990, Developments in Industrial Microbiology, V31, P205; SORENSON WG, 1984, J TOXICOL ENV HEALTH, V14, P525; STONE BA, 1992, CHEM BIOL BETA GLUCA; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; Thorn J, 1998, THORAX, V53, P1047; Thorn J, 1998, AM J IND MED, V33, P463; Thorne PS, 2003, ANN OCCUP HYG, V47, P31, DOI 10.1093/annhyg/meg009; THORNE PS, 1994, AM IND HYG ASSOC J, V55, P1072, DOI 10.1202/0002-8894(1994)055<1072:BSIFSC>2.0.CO;2; Thorne PS, 1997, AM IND HYG ASSOC J, V58, P792, DOI 10.1202/0002-8894(1997)058<0792:FEOEAS>2.0.CO;2; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; Van den Ende J, 1998, ACTA CLIN BELG, V53, P259; van der Zee JS, 1999, J ALLERGY CLIN IMMUN, V103, P950, DOI 10.1016/S0091-6749(99)70444-6; VANDENBOGART HGG, 1993, MYCOPATHOLOGIA, V122, P21; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; VANTONGEREN M, 1997, INT J IND MED, V33, P384; VIRTANEN T, 1986, INT ARCH ALLER A IMM, V81, P253; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONESSEN S, 1990, J TOXICOL-CLIN TOXIC, V28, P389; Walinder R, 2001, ARCH ENVIRON HEALTH, V56, P30; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Wan GH, 1999, EUR J IMMUNOL, V29, P2491, DOI 10.1002/(SICI)1521-4141(199908)29:08<2491::AID-IMMU2491>3.3.CO;2-I; WEBER S, 1993, AM J IND MED, V24, P365, DOI 10.1002/ajim.4700240403; Williams DL, 1997, MEDIAT INFLAMM, V6, P247, DOI 10.1080/09629359791550; Wouters IM, 2002, OCCUP ENVIRON MED, V59, P106, DOI 10.1136/oem.59.2.106; Zock JP, 1998, AM J IND MED, V33, P384, DOI 10.1002/(SICI)1097-0274(199804)33:4<384::AID-AJIM9>3.0.CO;2-U; 1993, MORBID MORTAL WEEKLY, V42, P21; 1999, MORBID MORTAL WEEKLY, V48, P98; [Anonymous], 1998, AM J RESP CRIT CARE, V158, pS1	154	509	537	21	123	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0003-4878			ANN OCCUP HYG	Ann. Occup. Hyg.	APR	2003	47	3					187	200		10.1093/annhyg/meg032		14	Public, Environmental & Occupational Health; Toxicology	Public, Environmental & Occupational Health; Toxicology	665KL	WOS:000182119200003	12639832	
J	Ricciardolo, FLM; Sterk, PJ; Gaston, B; Folkerts, G				Ricciardolo, FLM; Sterk, PJ; Gaston, B; Folkerts, G			Nitric oxide in health and disease of the respiratory system	PHYSIOLOGICAL REVIEWS			English	Review							AIRWAY SMOOTH-MUSCLE; OBSTRUCTIVE PULMONARY-DISEASE; GUINEA-PIG TRACHEA; VASOACTIVE-INTESTINAL-PEPTIDE; SYNTHASE GENE-EXPRESSION; BRONCHIAL EPITHELIAL-CELLS; HUMAN ALVEOLAR MACROPHAGES; PRIMARY CILIARY DYSKINESIA; NUCLEUS-TRACTUS-SOLITARII; EARLY ASTHMATIC REACTION	During the past decade a plethora of studies have unravelled the multiple roles of nitric oxide (NO) in airway physiology and pathophysiology. In the respiratory tract, NO is produced by a wide variety of cell types and is generated via oxidation Of L-arginine that is catalyzed by the enzyme NO synthase (NOS). NOS exists in three distinct isoforms: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS). NO derived from the constitutive isoforms of NOS (nNOS and eNOS) and other NO-adduct molecules (nitrosothiols) have been shown to be modulators of bronchomotor tone. On the other hand, NO derived from iNOS seems to be a proinflammatory mediator with immunomodulatory effects. The concentration of this molecule in exhaled air is abnormal in activated states of different inflammatory airway diseases, and its monitoring is potentially a major advance in the management of, e.g., asthma. Finally, the production of NO under oxidative stress conditions secondarily generates strong oxidizing agents (reactive nitrogen species) that may modulate the development of chronic inflammatory airway diseases and/or amplify the inflammatory response. The fundamental mechanisms driving the altered NO bioactivity under pathological conditions still need to be fully clarified, because their regulation provides a novel target in the prevention and treatment of chronic inflammatory diseases of the airways.	G Gaslini Inst Children, Dept Pulm, Genoa, Italy; Leiden Univ, Dept Pulmonol, Leiden, Netherlands; Univ Virginia Hlth Syst, Dept Pediat Resp Med, Charlottesville, VA USA; Univ Utrecht, Inst Pharmaceut Sci, Dept Pharmacol & Pathophysiol, Utrecht, Netherlands	Folkerts, G (reprint author), G Gaslini Inst Children, Dept Pulm, Genoa, Italy.	G.Folkerts@pharm.uu.nl					Abderrahmane A, 1998, AM J RESP CELL MOL, V19, P485; ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ADLER KB, 1995, AM J RESP CELL MOL, V13, P526; ADNOT S, 1991, J CLIN INVEST, V87, P155, DOI 10.1172/JCI114965; Agusti AGN, 1999, EUR RESPIR J, V14, P523, DOI 10.1034/j.1399-3003.1999.14c08.x; Ahren C, 1999, SCAND J INFECT DIS, V31, P405; AIMI Y, 1991, J COMP NEUROL, V306, P382, DOI 10.1002/cne.903060303; Aizawa H, 1999, EUR RESPIR J, V13, P775, DOI 10.1034/j.1399-3003.1999.13d13.x; Ali S, 1997, AM J PHYSIOL-LUNG C, V273, pL581; ALLIONE A, 1999, J IMMUNOL, V178, P102; ALVING K, 1993, BRIT J PHARMACOL, V110, P739; ALVING K, 1993, EUR RESPIR J, V6, P1368; Andersson C, 2002, BIOCHEM BIOPH RES CO, V297, P552, DOI 10.1016/S0006-291X(02)02245-3; ARIASDIAZ J, 1994, CANCER, V74, P1546, DOI 10.1002/1097-0142(19940901)74:5<1546::AID-CNCR2820740509>3.0.CO;2-F; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; Asikainen TM, 1998, AM J RESP CELL MOL, V19, P942; ASKEW SC, 1995, BIOORGAN MED CHEM, V3, P1, DOI 10.1016/0968-0896(94)00139-T; AVIADO DM, 1968, CARDIOLOGIA, V52, P287, DOI 10.1159/000166129; Babior BM, 1999, BLOOD, V93, P1464; BABIOR BM, 1978, NEW ENGL J MED, V298, P659, DOI 10.1056/NEJM197803232981205; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; Baile EM, 1998, J APPL PHYSIOL, V84, P809; BANNENBERG G, 1995, J PHARMACOL EXP THER, V272, P1238; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; Beall CM, 2001, NATURE, V414, P411, DOI 10.1038/35106641; BELVISI MG, 1991, EUR J PHARMACOL, V198, P219, DOI 10.1016/0014-2999(91)90626-2; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; Bernareggi M, 1997, AM J RESP CRIT CARE, V155, P869; Black PN, 1998, LANCET, V351, P449, DOI 10.1016/S0140-6736(05)78399-9; BLACKFORD JA, 1994, AM J RESP CELL MOL, V11, P426; Boucher JL, 1999, CELL MOL LIFE SCI, V55, P1015, DOI 10.1007/s000180050352; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Bozza M, 2001, J INTERF CYTOK RES, V21, P21, DOI 10.1089/107999001459123; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brockhaus F, 1998, EXP CELL RES, V238, P33, DOI 10.1006/excr.1997.3778; Budts W, 2000, CIRCULATION, V102, P2880; Buga GM, 1996, AM J PHYSIOL-HEART C, V271, pH1988; BULT H, 1990, NATURE, V345, P346, DOI 10.1038/345346a0; Bush A, 2000, Acta Otorhinolaryngol Belg, V54, P317; BUTTERY LDK, 1994, LAB INVEST, V71, P755; BYRICK RJ, 1983, ANESTH ANALG, V62, P421; Canning BJ, 2001, RESP PHYSIOL, V125, P113, DOI 10.1016/S0034-5687(00)00208-5; CANNING BJ, 1993, J PHYSIOL-LONDON, V471, P25; Canning BJ, 1998, J PHARMACOL EXP THER, V284, P370; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152; CANTIN AM, 1990, J CLIN INVEST, V86, P962, DOI 10.1172/JCI114798; Carvajal JA, 2000, J CELL PHYSIOL, V184, P409, DOI 10.1002/1097-4652(200009)184:3<409::AID-JCP16>3.0.CO;2-K; Champion HC, 2002, P NATL ACAD SCI USA, V99, P13248, DOI 10.1073/pnas.182225899; CHAN J, 1992, J EXP MED, V175, P1111, DOI 10.1084/jem.175.4.1111; Chang RH, 1997, IMMUNOLOGY, V90, P364, DOI 10.1111/j.1365-2567.1997.00364.x; Charan NB, 1997, J APPL PHYSIOL, V82, P686; Clark Reese H, 2003, J Perinatol, V23, P300, DOI 10.1038/sj.jp.7210908; Clini E, 1998, THORAX, V53, P881; Clini E, 2000, AM J RESP CRIT CARE, V162, P446; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Coers W, 1998, J HISTOCHEM CYTOCHEM, V46, P1385; Cooper CJ, 1996, CIRCULATION, V93, P266; Corradi M, 1999, THORAX, V54, P572; CREMONA G, 1991, LUNG, V169, P185, DOI 10.1007/BF02714154; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; de Boer J, 1999, BRIT J PHARMACOL, V128, P1114, DOI 10.1038/sj.bjp.0702882; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; deBoer J, 1996, BRIT J PHARMACOL, V119, P1109; DEDIAZ RO, 1993, NEUROSCI LETT, V162, P121; Delclaux C, 2002, AM J RESP CRIT CARE, V165, P332; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DeSanctis GT, 1997, AM J PHYSIOL-LUNG C, V273, pL883; Deves R, 1998, PHYSIOL REV, V78, P487; DEY RD, 1993, NEUROSCIENCE, V54, P839, DOI 10.1016/0306-4522(93)90578-4; DINHXUAN AT, 1991, NEW ENGL J MED, V324, P1539, DOI 10.1056/NEJM199105303242203; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Downey D, 2000, J PATHOL, V190, P115, DOI 10.1002/(SICI)1096-9896(200002)190:2<115::AID-PATH491>3.0.CO;2-V; Drab M, 2001, SCIENCE, V293, P2449, DOI 10.1126/science.1062688; Droma Y, 2002, CIRCULATION, V106, P826, DOI 10.1161/01.CIR.0000024409.30143.70; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894; DUPUY PM, 1992, J CLIN INVEST, V90, P421, DOI 10.1172/JCI115877; Duszyk M, 2001, AM J PHYSIOL-LUNG C, V281, pL450; Duszyk R, 2000, FREE RADICAL RES, V33, P449; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Eiserich Jason P., 1998, Molecular Aspects of Medicine, V19, P221, DOI 10.1016/S0098-2997(99)00002-3; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ELLIS JL, 1992, AM REV RESPIR DIS, V146, P1543; ELLIS JL, 1992, J PHARMACOL EXP THER, V262, P646; Emanueli C, 1998, BRIT J PHARMACOL, V125, P963, DOI 10.1038/sj.bjp.0702174; ERJEFALT JS, 1994, AM J RESP CRIT CARE, V150, P227; Ermert M, 2002, LAB INVEST, V82, P425; Exner R, 2000, WIEN KLIN WOCHENSCHR, V112, P610; Fang FC, 2002, AM J PHYSIOL-LUNG C, V282, pL941, DOI 10.1152/ajplung.00017.2002; Fang FC, 1997, J CLIN INVEST, V99, P2818, DOI 10.1172/JCI119473; Fang KH, 2000, AM J PHYSIOL-LUNG C, V279, pL716; Feletou M, 2001, AM J PHYSIOL-LUNG C, V281, pL258; Figini M, 1996, BRIT J PHARMACOL, V117, P1270; Figini M, 1996, AM J RESP CRIT CARE, V153, P918; FILEP JG, 1993, BRIT J PHARMACOL, V109, P637; FISCHER A, 1993, NEUROSCI LETT, V149, P157, DOI 10.1016/0304-3940(93)90760-I; Fischer A, 1996, J AUTONOM NERV SYST, V56, P157, DOI 10.1016/0165-1838(95)00085-2; Fischer A, 1998, J COMP NEUROL, V394, P326; Fischer A, 1996, AM J RESP CRIT CARE, V154, P209; Fischer A, 2002, PULM PHARMACOL THER, V15, P73, DOI 10.1006/pupt.2001.0332; FOLKERTS G, 1995, J CLIN INVEST, V95, P26, DOI 10.1172/JCI117649; Folkerts G, 2001, EUR J PHARMACOL, V429, P251, DOI 10.1016/S0014-2999(01)01324-3; Folkerts G, 1998, TRENDS PHARMACOL SCI, V19, P334, DOI 10.1016/S0165-6147(98)01232-2; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; Forstermann U, 1998, FASEB J, V12, P773; FORSTERMANN U, 1991, P NATL ACAD SCI USA, V88, P1788, DOI 10.1073/pnas.88.5.1788; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; FORTENBERRY JD, 1999, AM J PHYSIOL-CELL PH, V276, pC435; FRATACCI MD, 1991, ANESTHESIOLOGY, V75, P990, DOI 10.1097/00000542-199112000-00011; Fredberg JJ, 2000, J ALLERGY CLIN IMMUN, V106, P615, DOI 10.1067/mai.2000.109429; FRIDOVICH I, 1984, METHOD ENZYMOL, V105, P59; FROSTELL C, 1991, CIRCULATION, V83, P2038; Fujimoto H, 1998, JPN J CANCER RES, V89, P696; Fujimoto H, 1997, JPN J CANCER RES, V88, P1190; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; GASTON B, 1994, J PHARMACOL EXP THER, V268, P978; Gaston B, 2002, AM J RESP CRIT CARE, V165, P387; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; GASTON B, 1993, ENDOTHELIUM, V1, P87; Gaston B., 1994, BIOL NITRIC OXIDE, V3, P497; Gaston B, 1997, NITRIC OXIDE LUNG, P75; GENARO AM, 1995, J CLIN INVEST, V95, P1884, DOI 10.1172/JCI117869; Germann P, 1998, CHEST, V114, P29, DOI 10.1378/chest.114.1.29; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Gibson PG, 2000, EUR RESPIR J, V16, P1008; GIBSON QH, 1957, J PHYSIOL-LONDON, V136, P507; Gilchrist M, 2002, J LEUKOCYTE BIOL, V71, P618; Goldman D, 1996, AM J PATHOL, V148, P1275; Goldstein S, 2000, CHEM RES TOXICOL, V13, P736, DOI 10.1021/tx000099n; Gonzales RJ, 2001, AM J PHYSIOL-LUNG C, V280, pL555; GOODMAN LS, 1936, PHARMACOL BASIS THER, P631; Gow AJ, 1998, NATURE, V391, P169; Gow AJ, 2002, J BIOL CHEM, V277, P9637, DOI 10.1074/jbc.C100746200; Grasemann H, 1997, PEDIATR PULM, V24, P173, DOI 10.1002/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; GREEN SJ, 1990, J IMMUNOL, V144, P278; GRIFFITHS MJD, 1995, AM J PHYSIOL-LUNG C, V268, pL509; GRUETTER CA, 1989, AM REV RESPIR DIS, V139, P1192; Guembe L, 1999, AM J RESP CELL MOL, V20, P342; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 2000, J IMMUNOL, V164, P5970; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HADDAD EB, 1995, EUR J PHARM-ENVIRON, V293, P287, DOI 10.1016/S0922-4106(05)80057-4; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HALBOWER AC, 1994, AM J PHYSIOL-LUNG C, V267, pL585; Hamad AM, 2001, FEBS LETT, V506, P91, DOI 10.1016/S0014-5793(01)02883-6; Hamad AM, 1999, AM J PHYSIOL-LUNG C, V277, pL910; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Haque SJ, 1998, SEMIN ONCOL, V25, P14; HARAGUCHI Y, 1987, P NATL ACAD SCI USA, V84, P412, DOI 10.1073/pnas.84.2.412; HECKER M, 1995, FEBS LETT, V359, P251, DOI 10.1016/0014-5793(95)00039-C; HENRICKS PAJ, 1986, VET RES COMMUN, V10, P165, DOI 10.1007/BF02213979; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Hey C, 1997, BRIT J PHARMACOL, V121, P395, DOI 10.1038/sj.bjp.0701143; HIBBS JB, 1988, BIOCHEM BIOPH RES CO, V157, P87, DOI 10.1016/S0006-291X(88)80015-9; HIGENBOTTAM T, 1988, American Review of Respiratory Disease, V137, P107; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HISLOP AA, 1995, ARCH DIS CHILD, V73, pF17, DOI 10.1136/fn.73.1.F17; HOBBS AJ, 1997, NITRIC OXIDE LUNG, P1; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; HOGMAN M, 1993, EUR RESPIR J, V6, P177; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; Howard Marybeth, 2003, Journal of Biological Chemistry, V278, P35159, DOI 10.1074/jbc.M301924200; Huang FP, 1998, EUR J IMMUNOL, V28, P4062, DOI 10.1002/(SICI)1521-4141(199812)28:12<4062::AID-IMMU4062>3.0.CO;2-K; HUGOD C, 1979, INT ARCH OCC ENV HEA, V42, P159, DOI 10.1007/BF00377770; HUIE RE, 1993, FREE RADICAL RES COM, V18, P195, DOI 10.3109/10715769309145868; Hung K, 1998, J EXP MED, V188, P2357, DOI 10.1084/jem.188.12.2357; Hunt J, 2000, J PEDIATR-US, V137, P14, DOI 10.1067/mpd.2000.107526; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101; Hyde RW, 1997, J APPL PHYSIOL, V82, P1290; ICHINOSE F, 1995, J APPL PHYSIOL, V78, P1288; IGNARRO LJ, 1985, ANNU REV PHARMACOL, V25, P171, DOI 10.1146/annurev.pharmtox.25.1.171; IGNARRO LJ, 1989, CIRC RES, V65, P1; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Incalzi RA, 1999, CIRCULATION, V99, P1600; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; Ivan M, 2001, SCIENCE, V292, P449; Jadeski LC, 2000, INT J CANCER, V86, P30, DOI 10.1002/(SICI)1097-0215(20000401)86:1<30::AID-IJC5>3.0.CO;2-I; JAIN B, 1995, AM J PHYSIOL-LUNG C, V268, pL911; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; JANSEN A, 1992, J PHARMACOL EXP THER, V261, P154; Janssen LJ, 2000, AM J PHYSIOL-LUNG C, V278, pL899; Janssens SP, 1996, J CLIN INVEST, V98, P317, DOI 10.1172/JCI118795; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 1998, THORAX, V53, P91; JIA YL, 1995, AM J PHYSIOL-LUNG C, V269, pL85; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626; JORENS PG, 1993, EUR RESPIR J, V6, P258; JORENS PG, 1993, AGENTS ACTIONS, V38, P100, DOI 10.1007/BF02027220; JORENS PG, 1991, EUR J PHARMACOL, V200, P205, DOI 10.1016/0014-2999(91)90573-9; JORENS PG, 1992, EUR J PHARMACOL, V224, P7, DOI 10.1016/0014-2999(92)94811-9; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128; Kageyama N, 1997, EUR RESPIR J, V10, P13, DOI 10.1183/09031936.97.10010013; Kaisers U, 2003, CRIT CARE MED, V31, pS337, DOI 10.1097/01.CCM.0000057913.45273.1A; KANNAN MS, 1995, LIFE SCI, V56, P2229, DOI 10.1016/0024-3205(95)00212-O; Kannan MS, 1997, AM J PHYSIOL-LUNG C, V272, pL1; Karadag B, 1999, EUR RESPIR J, V13, P1402, DOI 10.1183/09031936.99.13614069; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Katayama Y, 1997, THORAX, V52, P120; KAWAI N, 1995, AM J PHYSIOL-LUNG C, V268, pL589; Kawamoto H, 1998, ACTA OTO-LARYNGOL, P65; KAWAMOTO S, 1987, J BIOL CHEM, V262, P6280; Keeble JE, 2002, BRIT J PHARMACOL, V137, P295, DOI 10.1038/sj.bjp.0704876; Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1; KELM M, 1990, CIRC RES, V66, P1561; KENNEDY T, 1981, JAMA-J AM MED ASSOC, V246, P145, DOI 10.1001/jama.246.2.145; Kesler BS, 2002, AM J RESP CRIT CARE, V165, P481, DOI 10.1164/rccm.2004005; Kettle AJ, 1997, REDOX REP, V3, P257; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, CLIN SCI, V88, P135; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, pA799; KINNULA VL, 1994, AM J RESP CELL MOL, V11, P568; KINSELLA JP, 1992, LANCET, V340, P819, DOI 10.1016/0140-6736(92)92687-B; Kirsch EA, 1999, AM J RESP CELL MOL, V20, P658; KLEBANOFF SJ, 1967, J CLIN INVEST, V46, P1078; KNOWLES RG, 1990, BIOCHEM J, V270, P833; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371; Kong LP, 1996, CLIN EXP METASTAS, V14, P335, DOI 10.1007/BF00123392; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Krishna M. T., 1998, Reviews on Environmental Health, V13, P59; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; Kubes P, 1997, EUR RESPIR J, V10, P4; KUMMER W, 1992, NEUROREPORT, V3, P653, DOI 10.1097/00001756-199207000-00028; KUMMER W, 1992, NEUROSCIENCE, V49, P715, DOI 10.1016/0306-4522(92)90239-X; KWON NS, 1991, J EXP MED, V174, P761, DOI 10.1084/jem.174.4.761; Lamas S., 1997, NITRIC OXIDE LUNG, P59; Lee YC, 2000, ALLERGY, V55, P959, DOI 10.1034/j.1398-9995.2000.00724.x; Lehtimaki L, 2001, AM J RESP CRIT CARE, V163, P1557; LEI YH, 1993, BRIT J PHARMACOL, V108, P228; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LEWIS SJ, 2002, AM J RESP CRIT CARE, V165, pA576; Li C G, 1991, Br J Pharmacol, V102, P91; LILLY CM, 1993, AM J PHYSIOL, V265, pL410; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; Lipton AJ, 2001, NATURE, V413, P171, DOI 10.1038/35093117; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; LIU SF, 1993, BIOCHEM BIOPH RES CO, V196, P1208, DOI 10.1006/bbrc.1993.2380; Liu XP, 1998, J BIOL CHEM, V273, P18709, DOI 10.1074/jbc.273.30.18709; Loesch A., 1995, Acta Neurobiologiae Experimentalis (Warsaw), V55, P45; Loesch A, 1996, CELL TISSUE RES, V283, P355, DOI 10.1007/s004410050546; Loukides S, 1998, LANCET, V352, P371, DOI 10.1016/S0140-6736(05)60471-0; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; Luhrs H, 2002, RESP PHYSIOL, V129, P367, DOI 10.1016/S0034-5687(01)00323-1; LYONS CR, 1992, J BIOL CHEM, V267, P6370; Lyons CR, 1996, HOSP PRACT, V31, P69; LYONS CR, 1996, HOSP PRACT, V31, P77; LYONS CR, 1996, HOSP PRACT, V31, P85; MACKAY TW, 1991, LANCET, V338, P1289, DOI 10.1016/0140-6736(91)92591-O; Malerba M, 2001, RESP MED, V95, P520, DOI 10.1053/rmed.2001.1082; Malmstrom RE, 2003, AM J RESP CRIT CARE, V168, P114, DOI 10.1164/rccm.200302-159OC; Mannick JB, 2001, J CELL BIOL, V154, P1111, DOI 10.1083/jcb.200104008; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Marshall C, 1996, AM J RESP CELL MOL, V15, P633; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; MATTES J, 1999, EUR RESPIR J, V159, P1434; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Megson IL, 2002, EXPERT OPIN INV DRUG, V11, P587; Mehta S, 1997, AM J PHYSIOL-LUNG C, V272, pL124; Messmer UK, 1996, J BIOL CHEM, V271, P20192; Meurs H, 2003, TRENDS PHARMACOL SCI, V24, P450, DOI 10.1016/S0165-6147(03)00227-X; Meurs H, 2002, BRIT J PHARMACOL, V136, P391, DOI 10.1038/sj.bjp.0704725; Meurs H, 1999, BRIT J PHARMACOL, V126, P559, DOI 10.1038/sj.bjp.0702372; Meurs H, 2000, BRIT J PHARMACOL, V130, P1793, DOI 10.1038/sj.bjp.0703488; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; MILLER WC, 1979, AM REV RESPIR DIS, V120, P471; Mills CD, 2000, J IMMUNOL, V164, P6166; Miura M, 1996, J ALLERGY CLIN IMMUN, V98, P144, DOI 10.1016/S0091-6749(96)70236-1; Miura M, 1997, AM J RESP CRIT CARE, V156, P217; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MONCADA S, 1991, PHARMACOL REV, V43, P109; MOODLEY VP, 1999, EUR RESPIR J, V14, P22; Mori M, 2000, BIOCHEM BIOPH RES CO, V275, P715, DOI 10.1006/bbrc.2000.3169; MORRIS SM, 1994, AM J PHYSIOL, V266, pE829; Morris SM, 1998, AM J PHYSIOL-ENDOC M, V275, pE740; Morris SM, 1997, GENE, V193, P157, DOI 10.1016/S0378-1119(97)00099-1; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Moya MP, 2001, P NATL ACAD SCI USA, V98, P5792, DOI 10.1073/pnas.091109498; MOYA MP, 2002, LANCET, V360, P2076; Muijsers RBM, 1997, LIFE SCI, V60, P1833, DOI 10.1016/S0024-3205(96)00651-0; Muijsers RBR, 2001, EUR RESPIR J, V18, P667, DOI 10.1183/09031936.01.00101301; Murphy MP, 1999, BBA-BIOENERGETICS, V1411, P401, DOI 10.1016/S0005-2728(99)00029-8; Nabeyrat E, 2003, AM J PHYSIOL-LUNG C, V284, pL1112, DOI 10.1152/ajplung.00178.2002; NAGAKI M, 1995, RESP PHYSIOL, V102, P89, DOI 10.1016/0034-5687(95)00042-C; Nelin LD, 2002, AM J RESP CELL MOL, V26, P348; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727; NIJKAMP FP, 1994, CLIN EXP ALLERGY, V24, P905, DOI 10.1111/j.1365-2222.1994.tb02721.x; Ninomiya H, 1996, BRIT J PHARMACOL, V119, P1341; NORMAN V, 1965, NATURE, V205, P915, DOI 10.1038/205915b0; O'Donnell VB, 1999, METHOD ENZYMOL, V301, P454; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; OCHOA JB, 1991, ANN SURG, V214, P621, DOI 10.1097/00000658-199111000-00013; ODA H, 1976, J JPN SOC AIR POLLUT, V11, P150; Ohshima H, 1999, NITRIC OXIDE-BIOL CH, V3, P132, DOI 10.1006/niox.1999.0216; Ohta H, 1997, BRAIN RES, V746, P98, DOI 10.1016/S0006-8993(96)01188-2; Okamoto T, 2002, AM J RESP CELL MOL, V27, P463, DOI 10.1165/rcmb-2002-0039OC; OKAYAMA M, 1984, EUR J CLIN PHARMACOL, V26, P151, DOI 10.1007/BF00630279; OLRY R, 1994, PORTL PR P, V8, P330; Ozaki M, 2001, HYPERTENSION, V37, P322; Pabelick CM, 2000, AM J PHYSIOL-LUNG C, V278, pL521; PACKER MA, 1995, EUR J BIOCHEM, V234, P231, DOI 10.1111/j.1432-1033.1995.231_c.x; Palmer LA, 2000, MOL PHARMACOL, V58, P1197; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Parker TA, 2000, AM J PHYSIOL-LUNG C, V278, pL202; Patel HJ, 1999, FASEB J, V13, P1810; Pawloski JR, 2001, NATURE, V409, P622, DOI 10.1038/35054560; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376; Pechkovsky DV, 2002, AM J PHYSIOL-LUNG C, V282, pL684, DOI 10.1152/ajplung.00320.2000; Pechkovsky DV, 2002, EUR RESPIR J, V19, P672, DOI 10.1183/09031936.02.00682001; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; Perez-Mato I, 1999, J BIOL CHEM, V274, P17075, DOI 10.1074/jbc.274.24.17075; Perkins WJ, 1998, AM J PHYSIOL-CELL PH, V275, pC468; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; PERSSON MG, 1990, ACTA PHYSIOL SCAND, V140, P449, DOI 10.1111/j.1748-1716.1990.tb09021.x; PERSSON MG, 1995, BRIT J PHARMACOL, V116, P2957; PERSSON MG, 1993, EUR J PHARMACOL, V249, P7; Phillips CR, 1996, J APPL PHYSIOL, V80, P1865; Phillips PG, 2001, AM J PHYSIOL-LUNG C, V281, pL278; Pietarinen-Runtti P, 2000, AM J PHYSIOL-CELL PH, V278, pC118; PISON U, 1993, J APPL PHYSIOL, V74, P7287; Pitt BR, 2002, AM J RESP CELL MOL, V26, P6; PRYOR WA, 1995, AM J PHYSIOL-LUNG C, V268, pL699; PUTENSEN C, 1994, CHEST, V106, P1563, DOI 10.1378/chest.106.5.1563; PUYBASSET L, 1994, ANESTHESIOLOGY, V80, P1254, DOI 10.1097/00000542-199406000-00013; Que LG, 1998, AM J PHYSIOL-LUNG C, V275, pL96; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; RAPOPORT RM, 1983, CIRC RES, V52, P352; Ratjen F, 1999, RESP MED, V93, P579, DOI 10.1016/S0954-6111(99)90158-0; Reiter CD, 2000, J BIOL CHEM, V275, P32460, DOI 10.1074/jbc.M910433199; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341; Ricciardolo FLM, 2000, BRIT J PHARMACOL, V129, P915, DOI 10.1038/sj.bjp.0703135; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Ricciardolo FLM, 2001, J ALLERGY CLIN IMMUN, V108, P198, DOI 10.1067/mai.2001.116572; Ricciardolo FLM, 2000, AM J RESP CELL MOL, V22, P97; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672; RICCIARDOLO FLM, 1994, BRIT J PHARMACOL, V113, P1147; Ricciardolo FLM, 1997, LANCET, V350, P1297, DOI 10.1016/S0140-6736(05)62474-9; RICCIARDOLO FLM, 2002, AM J RESP CRIT CARE, V165, pA310; Riley MS, 1997, CHEST, V111, P44, DOI 10.1378/chest.111.1.44; RIMAR S, 1993, CIRCULATION, V88, P2884; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P1027; ROBERTS JD, 1992, LANCET, V340, P818, DOI 10.1016/0140-6736(92)92686-A; Roger N, 1997, AM J RESP CRIT CARE, V156, P800; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Romanska HM, 2002, J PATHOL, V197, P372, DOI 10.1002/path.1116; Romanska HM, 2000, J PATHOL, V191, P71, DOI 10.1002/(SICI)1096-9896(200005)191:1<71::AID-PATH560>3.0.CO;2-I; ROSSAINT R, 1993, NEW ENGL J MED, V328, P399, DOI 10.1056/NEJM199302113280605; Ruggiero DA, 1996, J COMP NEUROL, V364, P51; Rutgers SR, 1999, THORAX, V54, P576; Sadeghi-Hashjin G, 1998, CLIN EXP ALLERGY, V28, P1464; SadeghiHashjin G, 1996, EUR J PHARMACOL, V302, P109, DOI 10.1016/0014-2999(96)00081-7; Saleh D, 1998, FASEB J, V12, P929; Samb A, 2001, AM J RESP CRIT CARE, V164, P149; Sapienza MA, 1998, THORAX, V53, P172; SASAKI F, 1995, J APPL PHYSIOL, V78, P539; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Sauzeau V, 2000, J BIOL CHEM, V275, P21722, DOI 10.1074/jbc.M000753200; Schmidt HHHW, 1996, P NATL ACAD SCI USA, V93, P14492, DOI 10.1073/pnas.93.25.14492; Schuiling M, 1998, BRIT J PHARMACOL, V123, P1450, DOI 10.1038/sj.bjp.0701738; Schuiling M, 1998, AM J RESP CRIT CARE, V158, P1442; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shaul PW, 2002, AM J PHYSIOL-LUNG C, V283, pL1192, DOI 10.1152/ajplung.00112.2002; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Sherman TS, 1999, AM J PHYSIOL-LUNG C, V276, pL383; SHIMOSEGAWA T, 1994, AM J RESP CRIT CARE, V150, P1402; Silkoff PE, 1998, AM J RESP CRIT CARE, V157, P1822; Silvestri M, 1999, EUR RESPIR J, V13, P321, DOI 10.1034/j.1399-3003.1999.13b17.x; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.1096618; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Snyder A, 2002, AM J RESP CRIT CARE, V165, P1; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; Sterk PJ, 1999, THORAX, V54, P565; STRETTON D, 1991, CLIN EXP PHARMACOL P, V18, P675, DOI 10.1111/j.1440-1681.1991.tb01380.x; Su YC, 1998, AM J RESP CELL MOL, V19, P819; SWISLOCKI A, 1995, AM J HYPERTENS, V8, P1009, DOI 10.1016/0895-7061(95)00161-1; Sylvester JT, 2001, J APPL PHYSIOL, V91, P474; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99; Taylor DA, 1998, THORAX, V53, P483; TAYLORROBINSON AW, 1993, SCIENCE, V260, P1931, DOI 10.1126/science.8100366; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; Ten Broeke R, 2001, FASEB J, V15, P1831, DOI 10.1096/fj.01-0018fje; TENBROEKE R, 2002, EUR RESPIR J, V20, pS28; THOMAE KR, 1993, SURGERY, V114, P272; Thomas DD, 2001, P NATL ACAD SCI USA, V98, P355, DOI 10.1073/pnas.011379598; Thomassen MJ, 1997, AM J RESP CELL MOL, V17, P279; Thompson DC, 1998, J PHARMACOL EXP THER, V284, P19; TORRES G, 1994, BRAIN RES, V647, P1, DOI 10.1016/0006-8993(94)91391-9; Toward TJ, 2000, BRIT J PHARMACOL, V131, P271, DOI 10.1038/sj.bjp.0703589; Trifilieff A, 2000, J IMMUNOL, V165, P1526; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; TUCKER JF, 1990, BRIT J PHARMACOL, V100, P663; Tulic MK, 2000, EUR RESPIR J, V15, P870, DOI 10.1183/09031936.00.15587000; Tzao C, 2000, HISTOCHEM CELL BIOL, V114, P421; Uetani K, 2001, AM J PHYSIOL-LUNG C, V280, pL1179; Uppu RM, 1996, ARCH BIOCHEM BIOPHYS, V327, P335, DOI 10.1006/abbi.1996.0131; Vallyathan Val, 1997, Environmental Health Perspectives, V105, P165, DOI 10.2307/3433405; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; van Rensen ELJ, 1999, THORAX, V54, P403; van's Gravesande Karin Storm, 2003, American Journal of Respiratory and Critical Care Medicine, V168, P228, DOI 10.1164/rccm.200212-1491BC; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Vockley JG, 1996, GENOMICS, V38, P118, DOI 10.1006/geno.1996.0606; Vonbank K, 2003, THORAX, V58, P289, DOI 10.1136/thorax.58.4.289; WARD JK, 1995, AM J RESP CELL MOL, V13, P175; WARD JK, 1995, J PHYSIOL-LONDON, V483, P525; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WARNER RL, 1995, AM J RESP CELL MOL, V12, P649; Watkins DN, 1997, AM J RESP CELL MOL, V16, P629; WATSON N, 1993, J APPL PHYSIOL, V74, P1964; Wechsler ME, 2000, AM J RESP CRIT CARE, V162, P2043; WEINBERG JB, 1998, MOL MED, V4, P57; White TA, 2002, AM J PHYSIOL-LUNG C, V283, pL1065, DOI 10.1152/ajplung.00064.2002; Widdicombe JG, 1998, AM J RESP CRIT CARE, V158, pS171; Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3; WIHELM E, 1977, CHEM REV, V77, P229; Wileman SM, 1995, BRIT J PHARMACOL, V116, P3243; Williams MS, 1998, J IMMUNOL, V161, P6526; Wink DA, 1998, CARCINOGENESIS, V19, P711, DOI 10.1093/carcin/19.5.711; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; Wu GY, 1998, BIOCHEM J, V336, P1; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; WU WT, 1994, NEUROSCI LETT, V179, P157, DOI 10.1016/0304-3940(94)90958-X; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; Xiong YL, 1999, J IMMUNOL, V162, P445; XUE C, 1994, AM J PHYSIOL-LUNG C, V267, pL667; Xue C, 1996, J HISTOCHEM CYTOCHEM, V44, P463; XUE C, 1996, AM J PHYSIOL, V270, P88; Yamakage M, 1996, AM J PHYSIOL-LUNG C, V270, pL338; YAN ZQ, 1995, ALLERGY, V50, P760, DOI 10.1111/j.1398-9995.1995.tb01221.x; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247; YEADON M, 1995, BRIT J PHARMACOL, V116, P2545; Yoshie Y, 1997, CARCINOGENESIS, V18, P1359, DOI 10.1093/carcin/18.7.1359; Zaman K, 2001, BIOCHEM BIOPH RES CO, V284, P65, DOI 10.1006/bbrc.2001.4935; ZAMAN K, 2002, AM J RESP CRIT CARE, V165, pA279; Zhu WF, 2003, TRENDS ENDOCRIN MET, V14, P114, DOI 10.1016/S1043-2760(03)00027-4; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zingarelli B, 1996, J IMMUNOL, V156, P350; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	471	487	521	9	51	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0031-9333			PHYSIOL REV	Physiol. Rev.	JUL	2004	84	3					731	765		10.1152/physrev.00034.2003		35	Physiology	Physiology	833RV	WOS:000222357500002	15269335	
J	Sokol, CL; Barton, GM; Farr, AG; Medzhitov, R				Sokol, Caroline L.; Barton, Gregory M.; Farr, Andrew G.; Medzhitov, Ruslan			A mechanism for the initiation of allergen-induced T helper type 2 responses	NATURE IMMUNOLOGY			English	Article							THYMIC STROMAL LYMPHOPOIETIN; DUST-MITE ALLERGEN; MAST-CELLS; TH2 DIFFERENTIATION; CYTOKINE PRODUCTION; NEMATODE PARASITES; DENDRITIC CELLS; IL-4 EXPRESSION; LYMPH-NODES; IN-VIVO	Both metazoan parasites and simple protein allergens induce T helper type 2 (T(H)2) immune responses, but the mechanisms by which the innate immune system senses these stimuli are unknown. In addition, the cellular source of cytokines that control T(H)2 differentiation in vivo has not been defined. Here we showed that basophils were activated and recruited to the draining lymph nodes specifically in response to T(H)2-inducing allergen challenge. Furthermore, we demonstrate that the basophil was the accessory cell type required for T(H)2 induction in response to protease allergens. Finally, we show that basophils were directly activated by protease allergens and produced T(H)2-inducing cytokines, including interleukin 4 and thymic stromal lymphopoietin, which are involved in T(H)2 differentiation in vivo.	[Sokol, Caroline L.; Medzhitov, Ruslan] Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06510 USA; [Barton, Gregory M.] Univ Calif Berkeley, Dept Mol Cell Biol, Berkeley, CA 94720 USA; [Farr, Andrew G.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Medzhitov, R (reprint author), Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, 333 Cedar St, New Haven, CT 06510 USA.	ruslan.medzhitov@yale.edu			NIAID NIH HHS [AI 055502, R01 AI055502]		Acosta-Rodriguez EV, 2007, NAT IMMUNOL, V8, P942, DOI 10.1038/ni1496; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Al-Shami A, 2004, J EXP MED, V200, P159, DOI 10.1084/jem.20031975; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Chambers L, 1998, BIOCHEM BIOPH RES CO, V253, P837, DOI 10.1006/bbrc.1998.9862; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Else KJ, 1998, INT J PARASITOL, V28, P1145, DOI 10.1016/S0020-7519(98)00087-3; FINKELMAN FD, 1992, PARASITOL TODAY, V8, P311, DOI 10.1016/0169-4758(92)90105-B; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Gessner A, 2005, J IMMUNOL, V174, P1063; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Grobe K, 1999, EUR J BIOCHEM, V263, P33, DOI 10.1046/j.1432-1327.1999.00462.x; Henri S, 2001, J IMMUNOL, V167, P741; Jones JDG, 2006, NATURE, V444, P323, DOI 10.1038/nature05286; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Khodoun MV, 2004, J EXP MED, V200, P857, DOI 10.1084/jem.20040598; Krammer PH, 2007, NAT REV IMMUNOL, V7, P532, DOI 10.1038/nri2115; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Liu ZG, 2005, J IMMUNOL, V174, P2242; Luccioli S, 2002, J ALLERGY CLIN IMMUN, V110, P117, DOI 10.1067/mai.2002.125828; Martin-Fontecha A, 2004, NAT IMMUNOL, V5, P1260, DOI 10.1038/ni1138; McKerrow JH, 2006, ANNU REV PATHOL-MECH, V1, P497, DOI 10.1146/annurev.pathol.1.110304.100151; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Mohrs K, 2005, IMMUNITY, V23, P419, DOI 10.1016/j.immuni.2005.09.006; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Mowen KA, 2004, IMMUNOL REV, V202, P203, DOI 10.1111/j.0105-2896.2004.00209.x; Mukai K, 2005, IMMUNITY, V23, P191, DOI 10.1016/j.immuni.2005.06.011; Noben-Trauth N, 2000, J IMMUNOL, V165, P3620; NOVEY HS, 1979, J ALLERGY CLIN IMMUN, V63, P98, DOI 10.1016/0091-6749(79)90198-2; Oh K, 2007, BLOOD, V109, P2921, DOI 10.1182/blood-2006-07-037739; Ohshima Y, 1998, BLOOD, V92, P3338; Omori M, 2007, J IMMUNOL, V178, P1396; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; Phillips C, 2003, J LEUKOCYTE BIOL, V73, P165, DOI 10.1189/jlb.0702356; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zingoni A, 1998, J IMMUNOL, V161, P547	49	486	505	7	30	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	MAR	2008	9	3					310	318		10.1038/ni1558		9	Immunology	Immunology	266BQ	WOS:000253406700017	18300366	
J	Isolauri, E; Arvola, T; Sutas, Y; Moilanen, E; Salminen, S				Isolauri, E; Arvola, T; Sutas, Y; Moilanen, E; Salminen, S			Probiotics in the management of atopic eczema	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic inflammation; atopy; breast-feeding; food allergy; infants; probiotics	GG-DERIVED ENZYMES; ASTHMA; INFANTS; PROLIFERATION; DERMATITIS; INFECTION; DISORDERS; RESPONSES; CHILDREN; DIARRHEA	Background Over the last two decades the incidence of allergic diseases has increased in industrialized countries, and consequently new approaches have to be explored. Objective The potential of probiotics to control allergic inflammation at an early age was assessed in a randomized double-blind placebo-controlled study. Methods A total of 27 infants, mean age 4.6 months, who manifested atopic eczema during exclusive breast-feeding and who have had no exposure to any infant or substitute formula were weaned to probiotic-supplemented. Bifidobacterium lactis Bb-12 or Lactobacillus strain GG (ATCC 53103), extensively hydrolysed whey formulas or to the same formula without probiotics. The extent and severity of atopic eczema, the growth and nutrition of infants, and concentrations of circulating cytokines/chemokines and soluble cell surface adhesion molecules in serum and methyl-histamine and eosinophilic protein X in urine were determined. Results The SCORAD score reflecting the extent and severity of atopic eczema was 16 (7-25) during breast-feeding, median (interquartile range). After 2 months, a significant improvement in skin condition occurred in patients given probiotic-supplemented formulas, as compared to the unsupplemented group; chi (2) = 12.27, P = 0.002. SCORAD decreased in the Bifidobacterium lactis Bb-12 group to 0 (0-3.8), and in the Lactobacillus GG group to 1 (0.1-8.7), vs unsupplemented 13.4 (4.5-18.2), median (interquartile range), in parallel with a reduction in the concentration of soluble CD4 in serum and eosinophilic protein X in urine. Conclusion The results provide the first clinical demonstration of specific probiotic strains modifying the changes related to allergic inflammation. The data further indicate that probiotics may counteract inflammatory responses beyond the intestinal milieu. The combined effects of these probiotic strains will guide infants through the weaning period, when sensitization to newly encountered antigens is initiated. The probiotic approach may thus offer a new direction in the search for future foods for allergy treatment and prevention strategies.	Univ Turku, Dept Paediat, FIN-20520 Turku, Finland; Tampere Univ Hosp, Dept Paediat, Tampere, Finland; Univ Tampere, Sch Med, Dept Pharmacol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, Tampere, Finland; Univ Turku, Dept Biochem & Food Chem, SF-20500 Turku, Finland	Isolauri, E (reprint author), Univ Turku, Dept Paediat, FIN-20520 Turku, Finland.						Baraniuk JN, 1997, J ALLERGY CLIN IMMUN, V99, pS763, DOI 10.1016/S0091-6749(97)70125-8; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Cebra JJ, 1999, AM J CLIN NUTR, V69, p1046S; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448; Erb KJ, 1999, IMMUNOL TODAY, V20, P317, DOI 10.1016/S0167-5699(99)01475-9; Goto H, 1996, SCAND J IMMUNOL, V43, P690, DOI 10.1046/j.1365-3083.1996.d01-264.x; HANIFIN JM, 1991, PEDIATR CLIN N AM, V38, P763; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; ISOLAURI E, 1994, DIGEST DIS SCI, V39, P2595, DOI 10.1007/BF02087695; ISOLAURI E, 1993, GASTROENTEROLOGY, V105, P1643; ISOLAURI E, 1991, PEDIATRICS, V88, P90; ISOLAURI E, 1995, J ALLERGY CLIN IMMUN, V97, P9; Kaila M., 1998, Bioscience and Microflora, V17, P149; KAILA M, 1992, PEDIATR RES, V32, P141, DOI 10.1203/00006450-199208000-00002; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; Koller DY, 1999, CLIN EXP ALLERGY, V29, P786; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; LEUNG DY, 1997, CLIN EXP IMMUNOL  S1, V27, P25; Mackie RI, 1999, AM J CLIN NUTR, V69, p1035S; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; MOREAU MC, 1978, INFECT IMMUN, V21, P532; Nikolaus S, 1998, GUT, V42, P470; O'Sullivan S, 1998, CLIN EXP ALLERGY, V28, P1332; PERDUE MH, 1994, AM J PHYSIOL, V267, pG151; Pessi T, 1999, APPL ENVIRON MICROB, V65, P4725; RASTAS M, 1993, PUBLICATION SOCIAL I; SAAVEDRA JM, 1994, LANCET, V344, P1046, DOI 10.1016/S0140-6736(94)91708-6; Salminen S, 1998, BRIT J NUTR, V80, pS147; SHROFF KE, 1995, INFECT IMMUN, V63, P3904; STALDER JF, 1993, DERMATOLOGY, V186, P23; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Sutas Y, 1996, SCAND J IMMUNOL, V43, P687, DOI 10.1046/j.1365-3083.1996.d01-258.x; Sutas Y, 1996, J ALLERGY CLIN IMMUN, V98, P216, DOI 10.1016/S0091-6749(96)70245-2; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; Wang CH, 1999, J ALLERGY CLIN IMMUN, V104, P803; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851	39	479	513	6	53	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2000	30	11					1604	1610				7	Allergy; Immunology	Allergy; Immunology	383WH	WOS:000165907100016	11069570	
J	Wright, JR				Wright, JR			Immunoregulatory functions of surfactant proteins	NATURE REVIEWS IMMUNOLOGY			English	Review							RESPIRATORY SYNCYTIAL VIRUS; INFLUENZA-A VIRUSES; PULMONARY HOST-DEFENSE; PROINFLAMMATORY CYTOKINE PRODUCTION; CARBOHYDRATE-RECOGNITION DOMAIN; HUMAN ALVEOLAR MACROPHAGES; BACILLUS-CALMETTE-GUERIN; AIRWAY DENDRITIC CELLS; GRAM-NEGATIVE BACTERIA; MANNOSE-BINDING LECTIN	Because the lungs function as the body's gas-exchange organ, they are inevitably exposed to air that is contaminated with pathogens, allergens and pollutants. Host-defence mechanisms within the lungs must facilitate clearance of inhaled pathogens and particles while minimizing an inflammatory response that could damage the thin, delicate gas-exchanging epithelium. Pulmonary surfactant is a complex of lipids and proteins that enhances pathogen clearance and regulates adaptive and innate immune-cell functions. In this article, I review the structure and functions of the surfactant proteins SP-A and SP-D in regulating host immune defence and in modulating inflammatory responses.	Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA	Wright, JR (reprint author), Duke Univ, Med Ctr, Dept Cell Biol, Box 3709,438 Nanaline Duke Bldg, Durham, NC 27710 USA.	j.wright@cellbio.duke.edu					Akgul C, 2001, FEBS LETT, V487, P318, DOI 10.1016/S0014-5793(00)02324-3; ANSFIELD MJ, 1979, J IMMUNOL, V122, P1062; ANSFIELD MJ, 1979, J IMMUNOL, V122, P542; Augusto LA, 2003, INFECT IMMUN, V71, P61, DOI 10.1128/IAI.71.1.61-67.2003; Augusto LA, 2002, J BIOL CHEM, V277, P23484, DOI 10.1074/jbc.M111925200; Beharka AA, 2002, J IMMUNOL, V169, P3565; BENNE CA, 1995, J INFECT DIS, V171, P335; BORDET J, 1909, ANN I PASTEUR, V49, P260; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840; Borron P, 1996, AM J RESP CELL MOL, V15, P115; Borron P, 1998, AM J PHYSIOL-LUNG C, V275, pL679; Borron PJ, 1998, J IMMUNOL, V161, P4599; Borron PJ, 2002, J IMMUNOL, V169, P5844; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brinker KG, 2001, AM J PHYSIOL-LUNG C, V281, pL1453; BRUNS G, 1987, HUM GENET, V76, P58; Burns AR, 2003, PHYSIOL REV, V83, P309, DOI 10.1152/physrev.00023.2002; Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375; Clark H, 2002, J IMMUNOL, V169, P2892; CLEMENTS JA, 1957, P SOC EXP BIOL MED, V95, P170; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; CROUCH E, 1993, J BIOL CHEM, V268, P2976; Crouch E, 2000, IMMUNOL REV, V173, P52, DOI 10.1034/j.1600-065X.2000.917311.x; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; Fadok VA, 2003, CURR BIOL, V13, pR655, DOI 10.1016/S0960-9822(03)00575-X; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Ferguson JS, 2002, J IMMUNOL, V168, P1309; Ferguson JS, 1999, J IMMUNOL, V163, P312; FISHER JH, 1987, AM J HUM GENET, V40, P503; Fisher JH, 2002, AM J RESP CELL MOL, V27, P24; Floros J, 2001, CLIN GENET, V60, P178, DOI 10.1034/j.1399-0004.2001.600303.x; Floros J, 2000, J INFECT DIS, V182, P1473, DOI 10.1086/315866; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Ghildyal R, 1999, J INFECT DIS, V180, P2009, DOI 10.1086/315134; GONG JL, 1992, J EXP MED, V175, P797, DOI 10.1084/jem.175.3.797; Guillot L, 2002, J IMMUNOL, V168, P5989; Guo XX, 2000, CHEST, V117, p249S, DOI 10.1378/chest.117.5_suppl_1.249S-a; HAAGSMAN HP, 1987, J BIOL CHEM, V262, P13877; Haller T, 2001, J CELL BIOL, V155, P279, DOI 10.1083/jcb.200102106; Hansen S, 2002, IMMUNOBIOLOGY, V205, P498, DOI 10.1078/0171-2985-00150; Hartshorn K, 1996, AM J PHYSIOL-LUNG C, V271, pL753; Hartshorn KL, 2000, BIOCHEM J, V351, P449, DOI 10.1042/0264-6021:3510449; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HARTSHORN KL, 1993, J CLIN INVEST, V91, P1414, DOI 10.1172/JCI116345; HAVENITH CEG, 1993, AM J RESP CELL MOL, V9, P484; HAVENITH CEG, 1993, J LEUKOCYTE BIOL, V53, P504; HAVENITH CEG, 1992, IMMUNOBIOLOGY, V184, P336; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hickling TP, 1998, FEBS LETT, V437, P65, DOI 10.1016/S0014-5793(98)01200-9; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.3.CO;2-N; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immumol.21.120601.140954; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; Jack DL, 2001, IMMUNOL REV, V180, P86, DOI 10.1034/j.1600-065X.2001.1800108.x; JOBE AH, 1993, NEW ENGL J MED, V328, P861; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Koziel H, 1998, AM J RESP CELL MOL, V18, P834; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712; Kremlev SG, 1997, AM J PHYSIOL-LUNG C, V272, pL996; Kuroki Y, 1998, BBA-MOL BASIS DIS, V1408, P334, DOI 10.1016/S0925-4439(98)00079-9; Kuronuma K, 2004, J BIOL CHEM, V279, P21421, DOI 10.1074/jbc.M312490200; Lahti M, 2002, PEDIATR RES, V51, P696, DOI 10.1023/01.PDR.0000015911.65104.93; Lambrecht BN, 1999, AM J RESP CELL MOL, V20, P1165; Leth-Larsen R, 2004, MOL HUM REPROD, V10, P149, DOI 10.1093/molehr/gah022; LeVine AM, 2004, AM J RESP CELL MOL, V31, P193, DOI 10.1165/rcmb.2003-0107OC; LeVine AM, 1997, J IMMUNOL, V158, P4336; LeVine AM, 2001, J IMMUNOL, V167, P5868; LeVine AM, 2000, J IMMUNOL, V165, P3934; LIM BL, 1994, BIOCHEM BIOPH RES CO, V202, P1674, DOI 10.1006/bbrc.1994.2127; Lin W, 2000, PHYS CHEM CHEM PHYS, V2, P43, DOI 10.1039/a907769c; Lipscomb MF, 2002, PHYSIOL REV, V82, P97; Lipscombe R. J., 1992, Human Molecular Genetics, V1, P709, DOI 10.1093/hmg/1.9.709; Lofgren J, 2002, J INFECT DIS, V185, P283, DOI 10.1086/338473; MacNeill C, 2004, IMMUNOLOGY, V111, P91, DOI 10.1046/j.1365-2567.2003.01782.x; Madsen J, 2000, J IMMUNOL, V164, P5866; MALHOTRA R, 1993, IMMUNOLOGY, V78, P341; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; Malhotra R, 1994, Clin Exp Immunol, V97 Suppl 2, P4; Malloy M H, 2000, J Perinatol, V20, P414, DOI 10.1038/sj.jp.7200420; McCormack FX, 2003, J BIOL CHEM, V278, P36250, DOI 10.1074/jbc.M303086200; McIntosh JC, 1996, AM J PHYSIOL-LUNG C, V271, pL310; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Nogee LM, 2004, BIOL NEONATE, V85, P314, DOI 10.1159/000078171; Nogee LM, 2004, ANNU REV PHYSIOL, V66, P601, DOI 10.1146/annurev.physiol.66.032102.134711; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Ohtani K, 2001, J BIOL CHEM, V276, P44222, DOI 10.1074/jbc.M103942200; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P471, DOI 10.1196/annals.1299.085; Palaniyar N, 2003, ANN NY ACAD SCI, V1010, P467, DOI 10.1196/annals.1299.084; Palaniyar N, 2004, J BIOL CHEM, V279, P32728, DOI 10.1074/jbc.M403763200; Pasula R, 1999, J CLIN INVEST, V103, P483, DOI 10.1172/JCI2991; PATTLE RE, 1955, NATURE, V175, P1125, DOI 10.1038/1751125b0; PERSSON A, 1990, J BIOL CHEM, V265, P5755; Prakobphol A, 2000, J BIOL CHEM, V275, P39860, DOI 10.1074/jbc.M006928200; Reading PC, 1997, J VIROL, V71, P8204; Reidy MF, 2003, AM J PHYSIOL-LUNG C, V285, pL854, DOI 10.1152/ajplung.00439.2002; ROMERO R, 1988, SEMIN PERINATOL, V12, P262; Rosseau S, 1999, J IMMUNOL, V163, P4495; RUBIO S, 1995, J BIOL CHEM, V270, P12162; Sano H, 1999, J IMMUNOL, V163, P387; Sato M, 2003, J IMMUNOL, V171, P417; Schaeffer LM, 2004, J IMMUNOL, V173, P1959; Schagat TL, 2001, J IMMUNOL, V166, P2727; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; Shepherd VL, 2002, AM J PHYSIOL-LUNG C, V282, pL516; Shepherd VL, 2002, AM J RESP CELL MOL, V26, P257; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; STAMME C, 2000, AM J RESP CRIT CARE, V161, pA515; Steinberger P, 2002, J LEUKOCYTE BIOL, V71, P133; SUPER M, 1989, LANCET, V2, P1236; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799; Vandivier RW, 2002, J IMMUNOL, V169, P3978; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91; WALKER SR, 1986, J HISTOCHEM CYTOCHEM, V34, P1137; Wang GR, 2004, BIOCHEMISTRY-US, V43, P4227, DOI 10.1021/bi036023i; Wang GR, 2000, AM J PHYSIOL-LUNG C, V278, pL946; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510; Weikert LF, 2000, AM J PHYSIOL-LUNG C, V279, pL216; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WIRTZ HRW, 1990, SCIENCE, V250, P1266, DOI 10.1126/science.2173861; Wong CJ, 1996, PEDIATR RES, V39, P930, DOI 10.1203/00006450-199606000-00002; Wright JR, 1997, PHYSIOL REV, V77, P931; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; XING Z, 1994, AM J RESP CELL MOL, V10, P148	136	478	502	4	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	JAN	2005	5	1					58	68		10.1038/nri1528		11	Immunology	Immunology	884VB	WOS:000226113700015	15630429	
J	Hunt, JF; Fang, KZ; Malik, R; Snyder, A; Malhotra, N; Platts-Mills, TAE; Gaston, B				Hunt, JF; Fang, KZ; Malik, R; Snyder, A; Malhotra, N; Platts-Mills, TAE; Gaston, B			Endogenous airway acidification - Implications for asthma pathophysiology	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							RESPIRATORY-DISTRESS-SYNDROME; EXHALED NITRIC-OXIDE; EXPIRED BREATH; SENSORY NERVES; PH; FLUID; ELECTROPHORESIS; ACETAZOLAMIDE; INFLAMMATION; EOSINOPHILS	Airway concentrations of many reactive nitrogen and oxygen species are high In asthma. The stability and bioactivities of these species are pH-dependent; however, the pH of the airway during acute asthma has not previously been studied. As with gastric and urinary acidification, asthmatic airway acidification could be expected dramatically to alter the concentrations and bioactivites/cytotoxicities of endogenous nitrogen oxides. Here, we demonstrate that the pH of deaerated exhaled airway vapor condensate is over two log orders lower in patients with acute asthma (5.23 +/- 0.21, n = 22) than in control subjects (7.65 +/- 0.20, n = 19, p < 0.001) and normalizes with corticosteroid therapy. Values are highly reproducible, unaffected by salivary or therapeutic artifact, and identical to samples taken directly from the lower airway. Further, at these low pH values the endogenous airway compound, nitrite, is converted to nitric oxide (NO) in quantities sufficient largely to account for the concentrations of NO in asthmatic expired air, and eosinophils undergo accelerated necrosis. We speculate that airway pH may be an important determinant of expired NO concentration and airway inflammation, and suggest that regulation of airway pH has a previously unsuspected role in asthma pathophysiology.	Univ Virginia Hlth Syst, Div Pediat Resp Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Div Pediat Hematol Oncol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Div Allergy Asthma & Immunol, Charlottesville, VA 22908 USA	Gaston, B (reprint author), Univ Virginia Hlth Syst, Dept Pediat, Box 386, Charlottesville, VA 22908 USA.				FDA HHS [1RO1BL59337]; PHS HHS [1U19-A134607]		ADLER K, 1972, AM REV RESPIR DIS, V106, P86; Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; ARIASDIAZ J, 1994, CANCER, V74, P1546, DOI 10.1002/1097-0142(19940901)74:5<1546::AID-CNCR2820740509>3.0.CO;2-F; BALDWIN SR, 1986, LANCET, V1, P11; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; Becher G, 1997, Pneumologie, V51 Suppl 2, P456; BEVAN S, 1994, TRENDS NEUROSCI, V17, P509, DOI 10.1016/0166-2236(94)90149-X; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; DeGroote MA, 1996, SCIENCE, V272, P414, DOI 10.1126/science.272.5260.414; Ehrt S, 1997, J EXP MED, V186, P1885, DOI 10.1084/jem.186.11.1885; Ehrt S, 1998, J EXP MED, V187, P141; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; GONG JP, 1994, ANAL BIOCHEM, V218, P314, DOI 10.1006/abio.1994.1184; Govindaraju K, 1997, ANAL CHEM, V69, P2793, DOI 10.1021/ac961249v; GUERRIN F, 1971, PROGRESS RESPIRATION, V6, P372; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; HOLMA B, 1977, ARCH ENVIRON HEALTH, V32, P216; HOLMA P, 1989, SCI TOTAL ENVIRON, V84, P71; HUNT J, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92947-9; Kanazawa H, 1997, J ALLERGY CLIN IMMUN, V99, P624, DOI 10.1016/S0091-6749(97)70024-1; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; KLEBANOFF SJ, 1993, FREE RADICAL BIO MED, V14, P351, DOI 10.1016/0891-5849(93)90084-8; KOPPENOL WH, 1992, CHEM RES TOXICOL, V5, P834, DOI 10.1021/tx00030a017; Long R, 1999, ANTIMICROB AGENTS CH, V43, P403; LOU YP, 1992, BIOCHEM BIOPH RES CO, V189, P537, DOI 10.1016/0006-291X(92)91591-D; LUK CK, 1983, CLIN SCI, V64, P449; Lundberg JON, 1996, ARCH DIS CHILD, V75, P323; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Metheny NA, 1999, NURS RES, V48, P189, DOI 10.1097/00006199-199907000-00001; NATHAN C, 1995, CELL, V82, P873, DOI 10.1016/0092-8674(95)90019-5; OCONNOR BJ, 1994, THORAX, V49, P1096, DOI 10.1136/thx.49.11.1096; ODONNELL WJ, 1992, AM REV RESPIR DIS, V146, P1518; PHENG LH, 1995, INFLAMMATION, V19, P599, DOI 10.1007/BF01539139; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532; Ricciardolo FLM, 1999, AM J RESP CRIT CARE, V159, P557; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Walsh GM, 1997, CLIN EXP ALLERGY, V27, P482, DOI 10.1046/j.1365-2222.1997.d01-532.x; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237	40	473	497	2	14	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR	2000	161	3					694	699				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	295YN	WOS:000085996400007	10712309	
J	Olszak, T; An, DD; Zeissig, S; Vera, MP; Richter, J; Franke, A; Glickman, JN; Siebert, R; Baron, RM; Kasper, DL; Blumberg, RS				Olszak, Torsten; An, Dingding; Zeissig, Sebastian; Vera, Miguel Pinilla; Richter, Julia; Franke, Andre; Glickman, Jonathan N.; Siebert, Reiner; Baron, Rebecca M.; Kasper, Dennis L.; Blumberg, Richard S.			Microbial Exposure During Early Life Has Persistent Effects on Natural Killer T Cell Function	SCIENCE			English	Article							INVARIANT NKT CELLS; ULCERATIVE-COLITIS; AIRWAY INFLAMMATION; HYGIENE HYPOTHESIS; CHEMOKINE CXCL16; B-CELLS; DISEASE; ASTHMA; COLONIZATION; ANTIBIOTICS	Exposure to microbes during early childhood is associated with protection from immune-mediated diseases such as inflammatory bowel disease (IBD) and asthma. Here, we show that in germ-free (GF) mice, invariant natural killer T (iNKT) cells accumulate in the colonic lamina propria and lung, resulting in increased morbidity in models of IBD and allergic asthma as compared with that of specific pathogen-free mice. This was associated with increased intestinal and pulmonary expression of the chemokine ligand CXCL16, which was associated with increased mucosal iNKT cells. Colonization of neonatal-but not adult-GF mice with a conventional microbiota protected the animals from mucosal iNKT accumulation and related pathology. These results indicate that age-sensitive contact with commensal microbes is critical for establishing mucosal iNKT cell tolerance to later environmental exposures.	[An, Dingding; Kasper, Dennis L.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02115 USA; [An, Dingding; Kasper, Dennis L.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA; [Olszak, Torsten; Blumberg, Richard S.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol Hepatol & Endoscopy, Boston, MA 02115 USA; [Zeissig, Sebastian] Univ Med Ctr Schleswig Holstein, Dept Internal Med 1, D-24105 Kiel, Germany; [Vera, Miguel Pinilla; Baron, Rebecca M.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Richter, Julia; Siebert, Reiner] Univ Kiel, Inst Human Genet, D-24105 Kiel, Germany; [Franke, Andre] Univ Kiel, Inst Clin Mol Biol, D-24105 Kiel, Germany; [Glickman, Jonathan N.] GI Pathol, Caris Diagnost, Caris Life Sci, Newton, MA 02464 USA	Kasper, DL (reprint author), Harvard Univ, Brigham & Womens Hosp, Channing Lab, Sch Med, Boston, MA 02115 USA.	dennis_kasper@hms.harvard.edu; rblumberg@partners.org	Siebert, Reiner/A-8049-2010; Zeissig, Sebastian/B-6297-2012; Franke, Andre/B-2151-2010	Franke, Andre/0000-0003-1530-5811	NIH [DK44319, DK51362, DK53056, DK88199, AI090102]; Crohn's Colitis Foundation of America; Harvard Digestive Diseases Center [DK034854]; Medizinausschuss Schleswig-Holstein, German Ministry of Education Research through the National Genome Research Network; Medical Faculty, Kiel; Deutsche Forschungsgemeinschaft (DFG) [OL 324/1-1, SZ 814/1-1, 814/4-1]; DFG Excellence Cluster "Inflammation at Interfaces"	We thank E. Troy and S. Edwards for handling of the GF mice, J. Cusick for technical assistance, E. Nieuwenhuis and K. Schneeberger for assistance with epigenetics studies, A. Bellacosa and K. Baker for helpful discussions and manuscript preparation, and the KinderKrebsInitiative Buchholz/Holm-Seppensen for providing pyrosequencing infrastructure. The work was supported by NIH grants DK44319, DK51362, DK53056, and DK88199 (R. S. B.) and AI090102 (D. L. K.); Crohn's Colitis Foundation of America Senior Research Award (D. L. K.) and Crohn's and Colitis Foundation of America Postdoctoral Fellowship Award (D. A. and S.Z.); the Harvard Digestive Diseases Center (DK034854); the Medizinausschuss Schleswig-Holstein, German Ministry of Education Research through the National Genome Research Network (A. F.); The Medical Faculty, Kiel (R. S.) and the Deutsche Forschungsgemeinschaft (DFG) (OL 324/1-1, SZ 814/1-1, 814/4-1); as well as DFG Excellence Cluster "Inflammation at Interfaces" (A.F. and S.Z.). The data reported in this manuscript are tabulated in the main paper and in the supplementary materials.	Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Cohen NR, 2009, ADV IMMUNOL, V102, P1, DOI 10.1016/S0065-2776(09)01201-2; Day C, 2009, EXP LUNG RES, V35, P272, DOI 10.1080/01902140802635517; Diegelmann J, 2010, INFLAMM BOWEL DIS, V16, P1871, DOI 10.1002/ibd.21306; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Fuss IJ, 2004, J CLIN INVEST, V113, P1490, DOI 10.1172/JCI200419836; Germanov E, 2008, J IMMUNOL, V181, P81; Goksor E, 2011, ACTA PAEDIATR, V100, P1561, DOI 10.1111/j.1651-2227.2011.02411.x; Heller F, 2002, IMMUNITY, V17, P629, DOI 10.1016/S1074-7613(02)00453-3; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Iwamura C, 2010, CURR OPIN IMMUNOL, V22, P807, DOI 10.1016/j.coi.2010.10.008; Kelly D, 2007, MUTAT RES-FUND MOL M, V622, P58, DOI 10.1016/j.mrfmmm.2007.03.011; Kronenberg M, 2005, ANNU REV IMMUNOL, V26, P877; Lopez-Serrano P, 2010, SCAND J GASTROENTERO, V45, P1464, DOI 10.3109/00365521.2010.510575; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Meyer EH, 2008, ANNU REV MED, V59, P281, DOI 10.1146/annurev.med.59.061506.154139; Mizoguchi A, 2006, J IMMUNOL, V176, P705; Neish AS, 2009, GASTROENTEROLOGY, V136, P65, DOI 10.1053/j.gastro.2008.10.080; Pufulete M, 2005, GUT, V54, P648, DOI 10.1136/gut.2004.054718; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Renz H, 2012, NAT REV IMMUNOL, V12, P9, DOI 10.1038/nri3112; Rishi V, 2010, P NATL ACAD SCI USA, V107, P20311, DOI 10.1073/pnas.1008688107; Roark JH, 1998, J IMMUNOL, V160, P3121; Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540; Shaw SY, 2010, AM J GASTROENTEROL, V105, P2687, DOI 10.1038/ajg.2010.398; Song CX, 2011, NAT BIOTECHNOL, V29, P68, DOI 10.1038/nbt.1732; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; Sullivan BA, 2007, CURR TOP MICROBIOL, V314, P165; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Wei B, 2010, J IMMUNOL, V184, P1218, DOI 10.4049/jimmunol.0902620; Wingender G, 2011, J EXP MED, V208, P1151, DOI 10.1084/jem.20102229; Yue SC, 2005, P NATL ACAD SCI USA, V102, P11811, DOI 10.1073/pnas.0503366102	33	471	488	18	153	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	APR 27	2012	336	6080					489	493		10.1126/science.1219328		5	Multidisciplinary Sciences	Science & Technology - Other Topics	931QC	WOS:000303233400051	22442383	
J	Oberg, M; Jaakkola, MS; Woodward, A; Peruga, A; Pruss-Ustun, A				Oberg, Mattias; Jaakkola, Maritta S.; Woodward, Alistair; Peruga, Armando; Pruess-Ustuen, Annette			Worldwide burden of disease from exposure to second-hand smoke: a retrospective analysis of data from 192 countries	LANCET			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; PASSIVE SMOKING; HEALTH; LEGISLATION; CHILDREN; IMPACT	Background Exposure to second-hand smoke is common in many countries but the magnitude of the problem worldwide is poorly described. We aimed to estimate the worldwide exposure to second-hand smoke and its burden of disease in children and adult non-smokers in 2004. Methods The burden of disease from second-hand smoke was estimated as deaths and disability-adjusted life-years (DALYs) for children and adult non-smokers. The calculations were based on disease-specific relative risk estimates and area-specific estimates of the proportion of people exposed to second-hand smoke, by comparative risk assessment methods, with data from 192 countries during 2004. Findings Worldwide, 40% of children, 33% of male non-smokers, and 35% of female non-smokers were exposed to second-hand smoke in 2004. This exposure was estimated to have caused 379 000 deaths from ischaemic heart disease, 165 000 from lower respiratory infections, 36 900 from asthma, and 21 400 from lung cancer. 603 000 deaths were attributable to second-hand smoke in 2004, which was about 1.0% of worldwide mortality. 47% of deaths from second-hand smoke occurred in women, 28% in children, and 26% in men. DALYs lost because of exposure to second-hand smoke amounted to 10.9 million, which was about 0.7% of total worldwide burden of diseases in DALYs in 2004. 61% of DALYs were in children. The largest disease burdens were from lower respiratory infections in children younger than 5 years (5 939 000), ischaemic heart disease in adults (2 836 000), and asthma in adults (1 246 000) and children (651 000). Interpretation These estimates of worldwide burden of disease attributable to second-hand smoke suggest that substantial health gains could be made by extending effective public health and clinical interventions to reduce passive smoking worldwide.	[Pruess-Ustuen, Annette] WHO, Dept Publ Hlth & Environm, CH-1211 Geneva 27, Switzerland; [Oberg, Mattias] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Jaakkola, Maritta S.] Univ Oulu, Resp Med Unit, Ctr Environm & Resp Hlth Res, Oulu, Finland; [Jaakkola, Maritta S.] Univ Oulu, Inst Clin Med, Oulu, Finland; [Woodward, Alistair] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand	Pruss-Ustun, A (reprint author), WHO, Dept Publ Hlth & Environm, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	pruessa@who.int		Oberg, Mattias/0000-0001-5377-530X; Woodward, Alistair/0000-0001-5425-6018	Swedish National Board of Health and Welfare; Bloomberg Philanthropies	We thank the Swedish National Board of Health and Welfare and the Bloomberg Philanthropies for their funding support. The authors alone are responsible for the views expressed in this publication, which do not necessarily reflect the decisions or the stated policy of WHO or of its Member States. (C) World Health Organization, 2010.	*CA EPA AIR RES BO, 2005, PROP ID ENV TOB SMOK; Centers for Disease Control and Prevention, GLOB YOUTH TOB SURV; Eriksen MP, 2008, ANNU REV PUBL HEALTH, V29, P171, DOI [10.1146/annurev.publhealth.29.020907.090920, 10.1146/annurev.publhealtb.29.020907.090920]; ETZEL RA, 1992, PEDIATRICS, V90, P228; Ezzati M, 2002, LANCET, V360, P1347, DOI 10.1016/S0140-6736(02)11403-6; Ezzati M, 2004, COMP QUANTIFICATION; Fontana L, 2007, G Ital Med Lav Ergon, V29, P484; *GALL ORG, 2009, SURV TOB AN REP; Gan Q, 2007, TOB CONTROL, V16, P417, DOI 10.1136/tc.2007.021477; *I MED, 2009, SECONDH SMOK EXP CAR; International Agency for Research on Cancer, 2009, EV EFF SMOK FREE POL; International Agency for Research on Cancer, 2004, TOB SMOK INV SMOK; International Labour Office, 2008, GLOB EMPL TRENDS WOM; Jaakkola MS, 2006, EUR RESPIR J, V28, P397, DOI 10.1183/09031936.06.00001306; Jaakkola MS, 2003, AM J PUBLIC HEALTH, V93, P2055, DOI 10.2105/AJPH.93.12.2055; Jaakkola MS, 1999, ENVIRON HEALTH PERSP, V107, P829, DOI 10.2307/3434561; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; Lightwood JM, 2009, CIRCULATION, V120, P1373, DOI 10.1161/CIRCULATIONAHA.109.870691; Lopez MJ, 2007, TOB CONTROL, V16, P373, DOI 10.1136/tc.2006.019679; McNabola A, 2009, INT J ENV RES PUB HE, V6, P741, DOI 10.3390/ijerph6020741; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; Musk AW, 2003, RESPIROLOGY, V8, P286, DOI 10.1046/j.1440-1843.2003.00483.x; Oberg M, 2010, 2 HAND SMOKE ASSESSI; OBERG M, GLOBAL ESTI IN PRESS; Pell JP, 2008, NEW ENGL J MED, V359, P482, DOI 10.1056/NEJMsa0706740; SCHONHERR E., 1928, ZEITSCHR KREBSFORSCH, V27, P436, DOI 10.1007/BF02125480; UN, 2009, MILL DEV GOALS REP 2; U.S. Department of Health Education and Welfare, 1972, DHEW PUBL; US Surgeon General, 2006, HLTH CONS INV EXP TO; World Health Organization, 2009, WHO FRAM CONV TOB CO; World Health Organization, 1999, INT CONS ENV TOB SMO; World Health Organisation, 2009, GLOB HLTH RISKS MORT; World Health Organization. (WHO), 2009, GLOB BURD DIS 2004 U; World Health Organization, 2009, WHO REP GLOB TOB EP; World Health Organization, 2009, GUID IMPL WHO FRAM C; World Health Organization, 2002, WORLD HLTH REP 2002; Wipfli H, 2008, AM J PUBLIC HEALTH, V98, P672, DOI 10.2105/AJPH.2007.126631; Woodward A, 2001, TOB CONTROL, V10, P383, DOI 10.1136/tc.10.4.383	38	468	479	12	109	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 8	2011	377	9760					139	146		10.1016/S0140-6736(10)61388-8		8	Medicine, General & Internal	General & Internal Medicine	707NH	WOS:000286292800026	21112082	
J	Sigurs, N; Gustafsson, PM; Bjarnason, R; Lundberg, F; Schmidt, S; Sigurbergsson, F; Kjellman, B				Sigurs, N; Gustafsson, PM; Bjarnason, R; Lundberg, F; Schmidt, S; Sigurbergsson, F; Kjellman, B			Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway obstruction; atopic hypersensitivity; children; respiratory syncytial virus	RSV BRONCHIOLITIS; AIRWAY FUNCTION; INFECTION; CHILDREN; SENSITIZATION; LIFE; DISEASE; RISK; MECHANISMS; WHEEZE	We have prospectively studied wheezing disorder and allergy in 47 children hospitalized with respiratory syncytial virus (RSV) bronchiolitis in infancy and 93 matched control subjects. Subjects with at least three episodes of wheezing were defined as recurrent wheezers and as having asthma if the episodes were doctor verified. Here we report the outcome at age 13 years in 46/47 children with RSV and 92/93 control subjects. Wheezing disorder and clinical allergy were estimated using a questionnaire. Skin prick tests were performed and serum IgE antibodies measured. Spirometry was undertaken at rest, after dry air challenge, and after beta(2)-agonist inhalation. The occurrence of symptoms over the previous 12 months was significantly higher in the RSV group than among the control subjects, 43% versus 8% for asthma/recurrent wheezing and 39% versus 15% for allergic rhinoconjunctivitis. Sensitization to common inhaled allergens was more frequent in the RSV group than in the control subjects, judged by skin prick tests (50% versus 28%; p = 0.022), or by serum IgE antibodies (45% versus 26%; p = 0.038). Compared with the control subjects, the RSV group showed mild airway obstruction both at rest and after bronchodilation, and had slightly more reactive airways. RSV bronchiolitis in infancy severe enough to cause hospitalization is a risk factor for allergic asthma in early adolescence.	Boras Cent Hosp, Dept Pediat, S-50182 Boras, Sweden; Queens Silvia Childrens Hosp, Gothenburg, Sweden; Skovde Cent Hosp, Dept Pediat, Skovde, Sweden; Landspitali Univ Hosp, Reykjavik, Iceland	Sigurs, N (reprint author), Boras Cent Hosp, Dept Pediat, S-50182 Boras, Sweden.	nele.sigurs@telia.com					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P1039, DOI 10.1016/0091-6749(90)90048-9; Choi EH, 2002, J INFECT DIS, V186, P1207, DOI 10.1086/344310; COURT SDM, 1973, POSTGRAD MED J, V49, P771; Forster J, 1996, PEDIATR ALLERGY IMMU, V7, P55; Gustafsson PM, 2003, EUR RESPIR J, V22, P972, DOI 10.1183/09031936.03.00049502; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hesselmar B, 2000, PEDIATR ALLERGY IMMU, V11, P74, DOI 10.1034/j.1399-3038.2000.00070.x; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; Holt PG, 2002, EUR RESPIR J, V19, P538, DOI 10.1183/09031936.02.00229302; Kneyber M, 2000, ACTA PAEDIATR, V89, P654, DOI 10.1080/080352500750043945; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; Ljungberg HK, 2003, PEDIATR PULM, V36, P339, DOI 10.1002/ppul.10356; Mallia P, 2002, ALLERGY, V57, P1118, DOI 10.1034/j.1398-9995.2002.02169.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCCONNOCHIE KM, 1989, PEDIATR PULM, V6, P138, DOI 10.1002/ppul.1950060303; MURRAY M, 1992, ARCH DIS CHILD, V67, P482; Noble V, 1997, ARCH DIS CHILD, V76, P315; Openshaw PJM, 2001, AM J RESP CRIT CARE, V163, pS10; PALA P, 2002, EUR RESPIR J, V20, P476; Peebles R. Stokes Jr., 2004, Journal of Allergy and Clinical Immunology, V113, pS15, DOI 10.1016/j.jaci.2003.10.033; Piedimonte G, 2003, PEDIATR INFECT DIS J, V22, pS66, DOI 10.1097/00006454-200302001-00010; PULLAN CR, 1982, BRIT MED J, V284, P1665; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; SIGURS N, 2004, AM J RESP CRIT CARE, V169, pA143; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; SOLYMAR L, 1980, EUR J RESPIR DIS, V61, P275; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strannegard O, 1997, PEDIATR ALLERGY IMMU, V8, P1, DOI 10.1111/j.1399-3038.1997.tb00134.x; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Turner SW, 2002, ARCH DIS CHILD, V87, P417, DOI 10.1136/adc.87.5.417; van Toorenenbergen A W, 1998, Ned Tijdschr Geneeskd, V142, P855; WELLIVER RC, 1995, LANCET, V346, P789, DOI 10.1016/S0140-6736(95)91615-6	37	467	508	1	12	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 15	2005	171	2					137	141		10.1164/rccm.200406-730OC		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	886UO	WOS:000226258400009	15516534	
J	Pope, CA				Pope, CA			Epidemiology of fine particulate air pollution and human health: Biologic mechanisms and who's at risk?	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						air pollution; cardiopulmonary disease; health effects; life expectancy; particulate pollution; review	EMERGENCY ROOM VISITS; PEAK EXPIRATORY FLOW; OBSTRUCTIVE PULMONARY-DISEASE; TIME-SERIES ANALYSIS; RESPIRATORY HOSPITAL ADMISSIONS; HEART-RATE-VARIABILITY; NORTH-AMERICAN CHILDREN; MINNEAPOLIS ST-PAUL; LONG-TERM EXPOSURE; SANTA-CLARA COUNTY	This article briefly summarizes the epidemiology of the health effects of fine particulate air pollution, provides an early, somewhat speculative, discussion of the contribution of epidemiology to evaluating biologic mechanisms, and evaluates who's at risk or is susceptible to adverse health effects. Based on preliminary epidemiologic evidence, it is speculated that a systemic response to fine particle-induced pulmonary inflammation, including cytokine release and altered cardiac autonomic function, may be part of the pathophysiologic mechanisms or pathways linking particulate pollution with cardiopulmonary disease. The elderly, infants, and persons with chronic cardiopulmonary disease, influenza, or asthma are most susceptible to mortality and serious morbidity effects from short-term acutely elevated exposures. Others are susceptible to less serious health effects such as transient increases in respiratory symptoms, decreased lung function, or other physiologic changes. Chronic exposure studies suggest relatively broad susceptibility to cumulative effects of long-term repeated exposure to fine particulate pollution, resulting in substantive estimates of population average loss of life expectancy in highly polluted environments. Additional knowledge is needed about the specific pollutants or mix of pollutants responsible for the adverse health effects and the biologic mechanisms involved.	Brigham Young Univ, Provo, UT 84602 USA	Pope, CA (reprint author), Brigham Young Univ, 142 FOB, Provo, UT 84602 USA.						ABBEY DE, 1995, ARCH ENVIRON HEALTH, V50, P139; Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; Anderson HR, 1996, BRIT MED J, V312, P665; ANDERSON HR, 1995, THORAX, V50, P1188, DOI 10.1136/thx.50.11.1188; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; ARCHER VE, 1990, ARCH ENVIRON HEALTH, V45, P325; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Ballester F, 1996, J EPIDEMIOL COMMUN H, V50, P527, DOI 10.1136/jech.50.5.527; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; BATES DV, 1989, ENVIRON HEALTH PERSP, V79, P69, DOI 10.2307/3430531; Bates DV, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_2.S3; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Boezen M, 1998, AM J RESP CRIT CARE, V158, P1848; Borja-Aburto VH, 1998, ENVIRON HEALTH PERSP, V106, P849, DOI 10.2307/3434129; BorjaAburto VH, 1997, AM J EPIDEMIOL, V145, P258; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Brimblecombe P., 1987, BIG SMOKE; BRUNEKREEF B, 1991, ENVIRON HEALTH PERSP, V90, P189, DOI 10.2307/3430867; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; Brunekreef B, 1997, OCCUP ENVIRON MED, V54, P781; Burnett RT, 1998, CAN J PUBLIC HEALTH, V89, P152; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, ENVIRON RES, V72, P24, DOI 10.1006/enrs.1996.3685; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; CASTELLSAGUE J, 1995, THORAX, V50, P1051, DOI 10.1136/thx.50.10.1051; *CEPA FPAC, 1998, NAT AMB AIR QUAL OBJ; CHESTNUT LG, 1991, ARCH ENVIRON HEALTH, V46, P135; Choudhury AH, 1997, ARCH ENVIRON HEALTH, V52, P113; CIOCCO A, 1961, AM J PUBLIC HEALTH N, V51, P155, DOI 10.2105/AJPH.51.2.155; DASSEN W, 1986, JAPCA J AIR WASTE MA, V36, P1223; deLeon AP, 1996, J EPIDEMIOL COMMUN H, V50, pS63; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; DELFINO RJ, 1994, ENVIRON RES, V67, P20, DOI 10.1006/enrs.1994.1062; DOCKERY DW, 1992, ENVIRON RES, V59, P362, DOI 10.1016/S0013-9351(05)80042-8; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOCKERY DW, 1982, JAPCA J AIR WASTE MA, V32, P937; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; DUSSELDORP A, 1995, AM J RESP CRIT CARE, V152, P1932; EVANS JS, 1984, ENVIRON INT, V10, P55, DOI 10.1016/0160-4120(84)90233-2; FAIRLEY D, 1990, ENVIRON HEALTH PERSP, V89, P159, DOI 10.2307/3430912; Firket J., 1931, B ACAD ROY MED BELG, V11, P683; GODLESKI JJ, 1996, AM J RESP CRIT CARE, V153, pA15; GODLESKI JJ, 1997, AM J RESP CRIT CARE, V155, pA246; Gold DR, 2000, CIRCULATION, V101, P1267; GOLD DR, 1999, EPIDEMIOLOGY, V10, P6; Gordian ME, 1996, ENVIRON HEALTH PERSP, V104, P290, DOI 10.2307/3432887; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; Hoek G, 1997, ARCH ENVIRON HEALTH, V52, P455; HOEK G, 1993, ARCH ENVIRON HEALTH, V48, P328; HOEK G, 1995, AM J RESP CRIT CARE, V151, P27; ITO K, 1993, ARCH ENVIRON HEALTH, V48, P213; JOHNSON KG, 1982, AM REV RESPIR DIS, V126, P1066; Johnson K, 1990, J OFF STAT, V5, P391; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; KINNEY PL, 1995, INHAL TOXICOL, V7, P59, DOI 10.3109/08958379509014271; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; LAVE LB, 1970, SCIENCE, V169, P723, DOI 10.1126/science.169.3947.723; Lee JT, 1999, ENVIRON HEALTH PERSP, V107, P149, DOI 10.2307/3434372; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; LIPFERT FW, 1992, ENVIRON RES, V59, P374, DOI 10.1016/S0013-9351(05)80043-X; LIPFERT FW, 1984, J ENVIRON ECON MANAG, V11, P208, DOI 10.1016/0095-0696(84)90019-6; LIPFERT FW, 1988, 52112 BNL; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; LOGAN W P D, 1953, Lancet, V1, P336; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; LUTZ LJ, 1983, J FAM PRACTICE, V16, P307; MENDELSOHN R, 1979, J ENVIRON ECON MANAG, V6, P85, DOI 10.1016/0095-0696(79)90022-6; Michelozzi P, 1998, OCCUP ENVIRON MED, V55, P605; *MIN HLTH, 1952, 95 MIN HLTH; MOOLGAVKAR SH, 1995, EPIDEMIOLOGY, V6, P476, DOI 10.1097/00001648-199509000-00003; MOOLGAVKAR SH, 1995, INHAL TOXICOL, V7, P35, DOI 10.3109/08958379509014269; Moolgavkar SH, 1996, EPIDEMIOLOGY, V7, P420, DOI 10.1097/00001648-199607000-00014; Moolgavkar SH, 1997, EPIDEMIOLOGY, V8, P364, DOI 10.1097/00001648-199707000-00003; Morgan G, 1998, AM J PUBLIC HEALTH, V88, P1761, DOI 10.2105/AJPH.88.12.1761; Morgan GE, 1998, AM J PUBLIC HEALTH, V88, P759, DOI 10.2105/AJPH.88.5.759; NADZIEJKO C, 1997, AM J RESP CRIT CARE, V155, pA24; Neas LM, 1996, AM J EPIDEMIOL, V143, P797; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111; Nevalainen J, 1998, SCI TOTAL ENVIRON, V217, P137, DOI 10.1016/S0048-9697(98)00172-7; Nolan J, 1998, CIRCULATION, V98, P1510; Odriozola JCA, 1998, INT ARCH OCC ENV HEA, V71, P543; Ostro B, 1996, J EXPO ANAL ENV EPID, V6, P97; Ostro B, 1995, ENVIRON RES, V70, P98, DOI 10.1006/enrs.1995.1053; OSTRO BD, 1993, AM J EPIDEMIOL, V137, P691; OSTRO BD, 1991, AM J PUBLIC HEALTH, V81, P694, DOI 10.2105/AJPH.81.6.694; OSTRO BD, 1990, RISK ANAL, V10, P421, DOI 10.1111/j.1539-6924.1990.tb00525.x; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; Ostro BD, 1999, ENVIRON HEALTH PERSP, V107, P69, DOI 10.2307/3434291; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; PANTAZOPOULOU A, 1995, ENVIRON RES, V69, P31, DOI 10.1006/enrs.1995.1022; Peters A, 1999, AM J EPIDEMIOL, V150, P1094; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Poloniecki JD, 1997, OCCUP ENVIRON MED, V54, P535; Ponka A, 1998, ARCH ENVIRON HEALTH, V53, P281; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; Pope CA, 2000, AEROSOL SCI TECH, V32, P4, DOI 10.1080/027868200303885; Pope CA, 1996, ENVIRON HEALTH PERSP, V104, P414, DOI 10.2307/3432686; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Pope CA, 1999, AM J RESP CRIT CARE, V159, P365; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; POPE CA, 1993, AM REV RESPIR DIS, V147, P1336; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; POPE CA, 1999, IN PRESS J AEROSOL M; Pope C. N., UNPUB; PORTNEY PR, 1990, REG SCI URBAN ECON, V20, P407, DOI 10.1016/0166-0462(90)90019-Y; Rahlenbeck SI, 1996, INT J EPIDEMIOL, V25, P1220, DOI 10.1093/ije/25.6.1220; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; SALDIVA PHN, 1995, ARCH ENVIRON HEALTH, V50, P159; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Samet J, 1998, ENVIRON RES, V77, P9, DOI 10.1006/enrs.1997.3821; SAMET JM, 1981, JAPCA J AIR WASTE MA, V31, P236; SAMET JM, 1995, PATICULATE AIR POLLU; Scarlett JF, 1996, THORAX, V51, P1109, DOI 10.1136/thx.51.11.1109; SCHWARTZ J, 1991, ENVIRON RES, V56, P1, DOI 10.1016/S0013-9351(05)80104-5; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; SCHWARTZ J, 1993, ENVIRON RES, V62, P7, DOI 10.1006/enrs.1993.1083; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1995, THORAX, V50, P531, DOI 10.1136/thx.50.5.531; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12; SCHWARTZ J, 1991, ENVIRON RES, V56, P204, DOI 10.1016/S0013-9351(05)80009-X; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; SCHWARTZ J, 1993, AM J EPIDEMIOL, V137, P1136; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; SCHWARTZ J, 1994, ENVIRON HEALTH PERSP, V102, P186, DOI 10.2307/3431609; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Simpson RW, 1997, ARCH ENVIRON HEALTH, V52, P442; Smith MA, 1996, INT J EPIDEMIOL, V25, P1227, DOI 10.1093/ije/25.6.1227; Souza MB, 1998, CHEST, V113, P1312, DOI 10.1378/chest.113.5.1312; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; SPIX C, 1993, ENVIRON HEALTH PERSP, V101, P518, DOI 10.2307/3431589; Spix C, 1996, J EPIDEMIOL COMMUN H, V50, pS52, DOI 10.1136/jech.50.Suppl_1.s52; SUNYER J, 1991, AM J EPIDEMIOL, V134, P277; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701; Sunyer J., 1996, J EPIDEMIOL COMMU S1, V50, P76; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213; TASHKIN DP, 1994, AM J RESP CRIT CARE, V149, P1209; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541; Terashima T, 1997, AM J RESP CRIT CARE, V155, P1441; THURSTON GD, 1989, ENVIRON HEALTH PERSP, V79, P73, DOI 10.2307/3430532; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; TOULOUMI G, 1994, INT J EPIDEMIOL, V23, P957, DOI 10.1093/ije/23.5.957; U.S. EPA, 1996, FED REG, V61, P65638; United States Environmental Protection Agency, 1996, EPA600P95001CF; VEDAL S, 1987, AM J PUBLIC HEALTH, V77, P694, DOI 10.2105/AJPH.77.6.694; Vedal S, 1997, J AIR WASTE MANAGE, V47, P551; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Verhoeff AP, 1996, EPIDEMIOLOGY, V7, P225, DOI 10.1097/00001648-199605000-00002; VONMUTIUS E, 1995, EUR RESPIR J, V8, P723; Wang B, 1999, Int J Occup Environ Health, V5, P14; Watkinson WP, 1998, TOXICOL SCI, V41, P209, DOI 10.1093/toxsci/41.2.209; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687; *WHO EURO, 1995, 9405PB01 EURICPEHAZ; WICHMANN HE, 1989, ENVIRON HEALTH PERSP, V79, P89, DOI 10.2307/3430534; Wietlisbach V, 1996, SOZ PRAVENTIV MED, V41, P107; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Wordley J, 1997, OCCUP ENVIRON MED, V54, P108; XU XP, 1995, ARCH ENVIRON HEALTH, V50, P214; XU XP, 1995, ENVIRON HEALTH PERSP, V103, P286; XU XP, 1994, ARCH ENVIRON HEALTH, V49, P216; Xu XP, 1998, ARCH ENVIRON HEALTH, V53, P44; Yang W, 1998, J TOXICOL ENV HEAL A, V55, P185; Yotsukura M, 1998, AM HEART J, V135, P1004, DOI 10.1016/S0002-8703(98)70065-1; Zeger SL, 1999, EPIDEMIOLOGY, V10, P171, DOI 10.1097/00001648-199903000-00015; Zmirou D, 1998, EPIDEMIOLOGY, V9, P495, DOI 10.1097/00001648-199809000-00005	197	467	483	12	122	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2000	108			4			713	723		10.2307/3454408		11	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	350VH	WOS:000089121500015	10931790	
J	Homey, B; Alenius, H; Muller, A; Soto, H; Bowman, EP; Yuan, W; McEvoy, L; Lauerma, AI; Assmann, T; Bunemann, E; Lehto, M; Wolff, H; Yen, D; Marxhausen, H; To, W; Sedgwick, J; Ruzicka, T; Lehmann, P; Zlotnik, A				Homey, B; Alenius, H; Muller, A; Soto, H; Bowman, EP; Yuan, W; McEvoy, L; Lauerma, AI; Assmann, T; Bunemann, E; Lehto, M; Wolff, H; Yen, D; Marxhausen, H; To, W; Sedgwick, J; Ruzicka, T; Lehmann, P; Zlotnik, A			CCL27-CCR10 interactions regulate T cell-mediated skin inflammation	NATURE MEDICINE			English	Article							PROTEIN-COUPLED RECEPTOR-2; ALLERGIC DERMATITIS; ENDOTHELIAL-CELLS; ATOPIC-DERMATITIS; CUTTING EDGE; CHEMOKINE; PSORIASIS; EXPRESSION; ANTIGEN; BINDING	The skin-associated chemokine CCL27 (also called CTACK, ALP and ESkine) and its receptor CCR10 (GPR-2) mediate chemotactic responses of skin-homing T cells in vitro. Here we report that most skin-infiltrating lymphocytes in patients suffering from psoriasis, atopic or allergic-contact dermatitis express CCR10. Epidermal basal keratinocytes produced CCL27 protein that bound to extracellular matrix, mediated adhesion and was displayed on the surface of dermal endothelial cells. Tumor necrosis factor-alpha and interleukin-1beta induced CCL27 production whereas the glucocorticosteroid clobetasol propionate suppressed it. Circulating skin-homing CLA(+) T cells, dermal microvascular endothelial cells and fibroblasts expressed CCR10 on their cell surface. In vivo, intracutaneous CCL27 injection attracted lymphocytes and, conversely, neutralization of CCL27-CCR10 interactions impaired lymphocyte recruitment to the skin leading to the suppression of allergen-induced skin inflammation. Together, these findings indicate that CCL27-CCR10 interactions have a pivotal role in T cell-mediated skin inflammation.	DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA USA; Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Helsinki, Finland; Univ Dusseldorf, Dept Dermatol, D-4000 Dusseldorf, Germany; Univ Dusseldorf, Dept Radiat Oncol, D-4000 Dusseldorf, Germany; Univ Helsinki, Cent Hosp, Dept Dermatol, FIN-00170 Helsinki, Finland; Finnish Inst Occupat Hlth, Dept Pathol, Helsinki, Finland; Kymenlaakso Cent Hosp, Kotka, Finland; R&D Syst, Minneapolis, MN USA	Homey, B (reprint author), DNAX Res Inst Molec & Cellular Biol Inc, Palo Alto, CA USA.		Zlotnik, Albert/C-3791-2011; Lauerma, Antti/J-8180-2016				ANCDREW DP, 2001, J IMMUNOL, V166, P103; Baekkevold ES, 2001, J EXP MED, V193, P1105, DOI 10.1084/jem.193.9.1105; Bondeson J, 2001, INT J CLIN PRACT, V55, P211; BOS JD, 1993, ARCH DERMATOL RES, V285, P179, DOI 10.1007/BF00372006; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cinamon G, 2001, NAT IMMUNOL, V2, P515, DOI 10.1038/88710; Goebeler M, 1998, J PATHOL, V184, P89, DOI 10.1002/(SICI)1096-9896(199801)184:1<89::AID-PATH975>3.0.CO;2-Z; GOTTLIEB AB, 1988, J EXP MED, V168, P941, DOI 10.1084/jem.168.3.941; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Homey B, 2000, J IMMUNOL, V164, P3465; Homey B, 2000, J IMMUNOL, V164, P6621; Hong K, 1999, J IMMUNOL, V162, P7480; Jarmin DI, 2000, J IMMUNOL, V164, P3460; Kirby B, 2001, CLIN EXP DERMATOL, V26, P27, DOI 10.1046/j.1365-2230.2001.00753.x; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Middleton J, 1997, CELL, V91, P385, DOI 10.1016/S0092-8674(00)80422-5; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nickoloff BJ, 2000, EXP DERMATOL, V9, P359, DOI 10.1034/j.1600-0625.2000.009005359.x; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PIGUET PF, 1993, RES IMMUNOL, V144, P320, DOI 10.1016/S0923-2494(93)80074-9; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; ROT A, 1992, IMMUNOL TODAY, V13, P291, DOI 10.1016/0167-5699(92)90039-A; Rot A, 1996, J LEUKOCYTE BIOL, V59, P39; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Ruzicka T, 1999, ARCH DERMATOL, V135, P574, DOI 10.1001/archderm.135.5.574; SANTAMARIA LF, 1995, INT ARCH ALLERGY IMM, V107, P359; Schon MP, 1999, J INVEST DERMATOL, V112, P405, DOI 10.1046/j.1523-1747.1999.00538.x; Schon MP, 1997, NAT MED, V3, P183, DOI 10.1038/nm0297-183; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SPRECHER E, 1992, ARCH VIROL, V126, P253, DOI 10.1007/BF01309699; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TANAKA Y, 1993, NATURE, V361, P79, DOI 10.1038/361079a0; TSAI JC, 1994, ARCH DERMATOL RES, V286, P242, DOI 10.1007/BF00387595; WEBB LMC, 1993, P NATL ACAD SCI USA, V90, P7158, DOI 10.1073/pnas.90.15.7158; WITT DP, 1994, CURR BIOL, V4, P394, DOI 10.1016/S0960-9822(00)00088-9; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	45	457	471	3	21	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1078-8956			NAT MED	Nat. Med.	FEB	2002	8	2					157	165		10.1038/nm0202-157		9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	517FN	WOS:000173600600025	11821900	
J	Ege, MJ; Mayer, M; Normand, AC; Genuneit, J; Cookson, WOCM; Braun-Fahrlander, C; Heederik, D; Piarroux, R; von Mutius, E				Ege, Markus J.; Mayer, Melanie; Normand, Anne-Cecile; Genuneit, Jon; Cookson, William O. C. M.; Braun-Fahrlaender, Charlotte; Heederik, Dick; Piarroux, Renaud; von Mutius, Erika		GABRIELA Transregio 22 Study Grp	Exposure to Environmental Microorganisms and Childhood Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SCHOOL-AGE-CHILDREN; IN-HOUSE DUST; ATOPIC SENSITIZATION; ALLERGIC DISEASES; FARM CHILDREN; MATTRESS DUST; ENDOTOXIN; BACTERIAL; INFLAMMATION; ASSOCIATION	BACKGROUND Children who grow up in environments that afford them a wide range of microbial exposures, such as traditional farms, are protected from childhood asthma and atopy. In previous studies, markers of microbial exposure have been inversely related to these conditions. METHODS In two cross-sectional studies, we compared children living on farms with those in a reference group with respect to the prevalence of asthma and atopy and to the diversity of microbial exposure. In one study - PARSIFAL (Prevention of Allergy - Risk Factors for Sensitization in Children Related to Farming and Anthroposophic Lifestyle) - samples of mattress dust were screened for bacterial DNA with the use of single-strand conformation polymorphism (SSCP) analyses to detect environmental bacteria that cannot be measured by means of culture techniques. In the other study - GABRIELA (Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community [GABRIEL] Advanced Study) - samples of settled dust from children's rooms were evaluated for bacterial and fungal taxa with the use of culture techniques. RESULTS In both studies, children who lived on farms had lower prevalences of asthma and atopy and were exposed to a greater variety of environmental microorganisms than the children in the reference group. In turn, diversity of microbial exposure was inversely related to the risk of asthma (odds ratio for PARSIFAL, 0.62; 95% confidence interval [CI], 0.44 to 0.89; odds ratio for GABRIELA, 0.86; 95% CI, 0.75 to 0.99). In addition, the presence of certain more circumscribed exposures was also inversely related to the risk of asthma; this included exposure to species in the fungal taxon eurotium (adjusted odds ratio, 0.37; 95% CI, 0.18 to 0.76) and to a variety of bacterial species, including Listeria monocytogenes, bacillus species, corynebacterium species, and others (adjusted odds ratio, 0.57; 95% CI, 0.38 to 0.86). CONCLUSIONS Children living on farms were exposed to a wider range of microbes than were children in the reference group, and this exposure explains a substantial fraction of the inverse relation between asthma and growing up on a farm. (Funded by the Deutsche Forschungsgemeinschaft and the European Commission.)	[Ege, Markus J.; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany; [Mayer, Melanie] Tech Univ Munich, Inst Anim Hyg, D-8050 Freising Weihenstephan, Germany; [Genuneit, Jon] Univ Ulm, Inst Epidemiol, Ulm, Germany; [Normand, Anne-Cecile] Univ Franche Comte, Chronoenvironm Lab, F-25030 Besancon, France; [Piarroux, Renaud] Assistance Publ Hop Marseille, Dept Parasitol & Mycol, Marseille, France; [Piarroux, Renaud] Univ Aix Marseille 2, Marseille, France; [Cookson, William O. C. M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW7 2AZ, England; [Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Braun-Fahrlaender, Charlotte] Univ Basel, Basel, Switzerland; [Heederik, Dick] Univ Utrecht, Inst Risk Assessment, Div Environm Epidemiol, Utrecht, Netherlands	Ege, MJ (reprint author), Univ Munich, Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.uni-muenchen.de	Loss, Georg/F-1557-2013; Genuneit, Jon/I-9323-2012	Genuneit, Jon/0000-0001-5764-1528; Ege, Markus/0000-0001-6643-3923	Deutsche Forschungsgemeinschaft [SFB Transregio 22, A1]; European Commission [LSH-2004-1.2.5-1, QLRT 1999-01391]	Supported by grants from Deutsche Forschungsgemeinschaft (SFB Transregio 22 Pulmonary Allergies, Project A1) and the European Commission (LSH-2004-1.2.5-1 and QLRT 1999-01391).	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Hansen G, 2000, J IMMUNOL, V164, P223; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; Kalliomaki M, 2008, ADV EXP MED BIOL, V635, P57, DOI 10.1007/978-0-387-09550-9_5; Korthals M, 2008, ENVIRON RES, V107, P299, DOI 10.1016/j.envres.2008.02.007; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Normand AC, 2009, APPL ENVIRON MICROB, V75, P7617, DOI 10.1128/AEM.01414-09; Noss I, 2008, APPL ENVIRON MICROB, V74, P5621, DOI 10.1128/AEM.00619-08; Pakarinen J, 2008, ENVIRON MICROBIOL, V10, P3317, DOI 10.1111/j.1462-2920.2008.01723.x; Sahakian NM, 2008, IMMUNOL ALLERGY CLIN, V28, P485, DOI 10.1016/j.iac.2008.03.009; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Smits HH, 2009, MUCOSAL IMMUNOL, V2, P331, DOI 10.1038/mi.2009.16; Sordillo JE, 2010, CLIN EXP ALLERGY, V40, P902, DOI 10.1111/j.1365-2222.2010.03509.x; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vartiainen E, 2002, J ALLERGY CLIN IMMUN, V109, P643, DOI 10.1067/mai.2002.123307; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Williams LK, 2005, ANN ALLERG ASTHMA IM, V94, P323	27	453	473	13	116	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	2011	364	8					701	709		10.1056/NEJMoa1007302		9	Medicine, General & Internal	General & Internal Medicine	725NP	WOS:000287652500004	21345099	
J	Wallace, DV; Dykewicz, MS; Bernstein, DI; Bernstein, IL; Blessing-Moore, J; Cox, L; Khan, DA; Lang, DM; Nicklas, RA; Oppenheimer, J; Portnoy, JM; Randolph, CC; Schuller, D; Spector, SL; Tilles, SA; May, KR; Miller, TA; Druce, HM; Baroody, FM; Bernstein, JA; Craig, TJ; Georgitis, JW; Pawankar, R; Rachelefsky, GS; Settipane, RA; Skoner, DP; Stoloff, SW				Wallace, Dana V.; Dykewicz, Mark S.; Bernstein, David I.; Bernstein, I. Leonard; Blessing-Moore, Joann; Cox, Linda; Khan, David A.; Lang, David M.; Nicklas, Richard A.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher C.; Schuller, Diane; Spector, Sheldon L.; Tilles, Stephen A.; May, Kathleen R.; Miller, Travis A.; Druce, Howard M.; Baroody, Faud M.; Bernstein, Jonathan A.; Craig, Timothy J.; Georgitis, John W.; Pawankar, Ruby; Rachelefsky, Gary S.; Settipane, Russell A.; Skoner, David P.; Stoloff, Stuart W.			The diagnosis and management of rhinitis: An updated practice parameter	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							SEASONAL ALLERGIC RHINITIS; QUALITY-OF-LIFE; AQUEOUS NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; HOUSE-DUST-MITE; LONG-TERM TREATMENT; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; INTRANASAL FLUTICASONE PROPIONATE; CONJUNCTIVAL PROVOCATION TEST; RANDOMIZED CONTROLLED-TRIAL	These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma & Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing "The diagnosis and Management of Rhinitis: An Updated Practice Parameter" This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for rise by pharmaceutical companies in drug promotion.	[Wallace, Dana V.; Cox, Linda] Nova SE Univ, Coll Osteopath Med, Davie, FL USA; [Dykewicz, Mark S.] St Louis Univ, Sch Med, Allergy & Immunol Fellowship Program, St Louis, MO USA; [Dykewicz, Mark S.] St Louis Univ, Allergy & Clin Immunol Sect, Div Immunol, St Louis, MO USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Div Allergy Immunol, Cincinnati, OH USA; [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Immunol, Palo Alto, CA 94304 USA; [Khan, David A.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Lang, David M.] Cleveland Clin Fdn, Allergy Immunol Sect, Div Med, Cleveland, OH 44195 USA; [Lang, David M.] Cleveland Clin Fdn, Allergy & Immunol Fellowship Training, Cleveland, OH 44195 USA; [Nicklas, Richard A.] George Washington Med Ctr, Washington, DC USA; [Oppenheimer, John] Pulm & Allergy Associates, New Jersey Med Sch, Dept Internal Med, Morristown, NJ USA; [Portnoy, Jay M.] Univ Missouri, Kansas City Sch Med, Kansas City, MO 64110 USA; [Portnoy, Jay M.] Childrens Mercy Hosp, Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Randolph, Christopher C.] Yale Affiliated Hosp, Ctr Allergy Asthma & Immunol, Waterbury, CT USA; [Schuller, Diane] Penn State Univ, Milton S Hershey Med Coll, Hershey, PA USA; [Spector, Sheldon L.] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Tilles, Stephen A.] Univ Washington, Sch Med, Redmond, WA USA; [May, Kathleen R.] Allegany Allergy & Asthma, Cumberland, MD USA; [Miller, Travis A.] Univ Michigan, Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Druce, Howard M.] Univ Hosp, Morris Plains, NJ USA; [Baroody, Faud M.] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Bernstein, Jonathan A.] Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol,Allergy Sect, Cincinnati, OH USA; [Georgitis, John W.] Lafayette Clin, Fayetteville, NC USA; [Pawankar, Ruby] Nippon Med Sch, Dept Otolaryngol, Div Rhinol & Allergy, Tokyo 113, Japan; [Rachelefsky, Gary S.] Univ Calif Los Angeles, Med Ctr, Ctr Asthma Allergy & Resp Dis, Los Angeles, CA 90024 USA; [Settipane, Russell A.] Brown Univ, Sch Med, Providence, RI 02912 USA; [Skoner, David P.] Allegheny Gen Hosp, Div Allergy Asthma & Immunol, Pittsburgh, PA 15212 USA; [Skoner, David P.] Drexel Univ, Coll Med, Pittsburgh, PA USA; [Stoloff, Stuart W.] Univ Nevada, Sch Med, Reno, NV 89557 USA	Wallace, DV (reprint author), Nova SE Univ, Coll Osteopath Med, Davie, FL USA.						AAAI Board of Directors, 1995, J ALLERGY CLIN IMMUN, V95, P652; AAP Practice Guidelines, 2001, PEDIATRICS, V108, P798; Aaronson DW, 1996, ANN ALLERG ASTHMA IM, V76, P440; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; Abelson M, 1998, J OCUL PHARMACOL TH, V14, P533, DOI 10.1089/jop.1998.14.533; Abelson M B, 2000, Acta Ophthalmol Scand Suppl, P60; ABELSON MB, 1984, OPHTHALMOLOGY, V91, P1364; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P520; ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Banuelos Arias Adel C, 2003, REV ALERG MED, V50, P147; ADINOFF AD, 1989, J ALLERGY CLIN IMMUN, V84, P168, DOI 10.1016/0091-6749(89)90321-7; Affrime M, 2002, CLIN PHARMACOKINET, V41, P13, DOI 10.2165/00003088-200241001-00003; AFZELIUS B, 2007, UPTODATE; Afzelius BA, 1998, THORAX, V53, P894; AFZELIUS BA, 1985, CRC CR REV BIOCH MOL, V19, P63, DOI 10.3109/10409238509086788; Afzelius B. A., 1995, METABOLIC MOL BASES; Alaranta A, 2005, MED SCI SPORT EXER, V37, P707, DOI 10.1249/01.MSS.0000162689.69517.60; Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; ALFORD C, 1992, HUM PSYCHOPHARM CLIN, V7, P25, DOI 10.1002/hup.470070104; Alho OP, 2004, AM J RHINOL, V18, P349; Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407; ALMIND M, 1988, ALLERGY, V43, P593, DOI 10.1111/j.1398-9995.1988.tb00932.x; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Alobid I, 2006, RHINOLOGY, V44, P8; Alobid Isam, 2007, Clin Allergy Immunol, V19, P221; ALTOUNYAN REC, 1980, CLIN ALLERGY, V10, P481, DOI 10.1111/j.1365-2222.1980.tb02162.x; Alvarez-Fernandez JA, 1998, ALLERGY, V53, P210, DOI 10.1111/j.1398-9995.1998.tb03873.x; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; Amin K, 2001, J ALLERGY CLIN IMMUN, V107, P249, DOI 10.1067/mai.2001.112266; ANCH AM, 1982, J APPL PHYSIOL, V53, P1158; ANDERSEN J, 1998, AM J HEALTH-SYST PH, V55, P1167; ANTEPARA I, 1995, CLIN EXP ALLERGY, V25, P133, DOI 10.1111/j.1365-2222.1995.tb01018.x; Arason VA, 1996, BRIT MED J, V313, P387; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Archambault S, 2001, J ALLERGY CLIN IMMUN, V107, P921; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Armengot M., 1996, Rhinology (Utrecht), V34, P35; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; ARRUDA LK, 1992, J ALLERGY CLIN IMMUN, V89, P1166, DOI 10.1016/0091-6749(92)90301-H; Arts JHE, 2006, REGUL TOXICOL PHARM, V44, P144, DOI 10.1016/j.yrtph.2005.11.006; ASELTON P, 1985, OBSTET GYNECOL, V65, P451; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; Atkinson RW, 2006, OCCUP ENVIRON MED, V63, P580, DOI 10.1136/oem.2005.024448; Aubart FC, 2006, MEDICINE, V85, P365, DOI 10.1097/01.md.0000236955.79966.07; AUSTIN CE, 1994, BRIT J CLIN PHARMACO, V37, P33; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; Bachmann G, 2000, EUR ARCH OTO-RHINO-L, V257, P537, DOI 10.1007/s004050000271; BADHWAR AK, 1992, MED CLIN N AM, V76, P789; Bagenstose SE, 1999, ANN ALLERG ASTHMA IM, V83, P524, DOI 10.1016/S1081-1206(10)62863-3; BAGIAN JP, 1994, J CLIN PHARMACOL, V34, P649; Baker AM, 2003, J FORENSIC SCI, V48, P425; Balemans WAF, 2006, CLIN EXP ALLERGY, V36, P198, DOI 10.1111/j.1365-2222.2006.02423.x; BALLAS Z, 1993, SURV OPHTHALMOL, V38, P141, DOI 10.1016/0039-6257(93)90038-9; Banauch Gisela I, 2005, Crit Care Med, V33, pS102, DOI 10.1097/01.CCM.0000151138.10586.3A; BANOV CH, 1994, ANN ALLERGY, V73, P240; BARDANA EJ, 1991, ANN ALLERGY, V66, P441; Barenholtz H, 1996, Ann Pharmacother, V30, P1324; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P517; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P166; Barnes ML, 2006, CLIN EXP ALLERGY, V36, P676, DOI 10.1111/j.1365-2222.2006.02478.x; Barnes ML, 2005, RHINOLOGY, V43, P291; BAROODY FM, 1994, AM J RESP CRIT CARE, V149, P1457; Baroody FM, 2001, ARCH OTOLARYNGOL, V127, P193; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661; Bartholomew LK, 2000, PATIENT EDUC COUNS, V39, P269, DOI 10.1016/S0738-3991(99)00046-4; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406; BASCOM R, 1991, AM REV RESPIR DIS, V143, P1304; Bateman ND, 2003, J LARYNGOL OTOL, V117, P186; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Baumgartner BJ, 2007, ENT-EAR NOSE THROAT, V86, P97; BAUR X, 1988, LUNG, V166, P113, DOI 10.1007/BF02714035; Bavbek S, 2007, INT ARCH ALLERGY IMM, V142, P64, DOI 10.1159/000096000; BAXI LV, 1985, AM J OBSTET GYNECOL, V153, P799; Bejar I, 1996, ARCH OTOLARYNGOL, V122, P816; Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; BELTRANI VS, 2003, DERMATOL ONLINE J, V9; BENDE M, 1983, ACTA OTO-LARYNGOL, V96, P175, DOI 10.3109/00016488309132889; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Bender BG, 2007, ANN ALLERG ASTHMA IM, V98, P322; Benninger MS, 2006, OTOLARYNG HEAD NECK, V134, P3, DOI 10.1016/j.otohns.2005.10.010; Benninger MS, 2002, OTOLARYNG HEAD NECK, V127, P7, DOI 10.1067/mhn.2002.124847; Berger WE, 2002, ANN ALLERG ASTHMA IM, V89, P485; Berger W, 2006, ANN ALLERG ASTHMA IM, V97, P375; Berger William E, 2004, Paediatr Drugs, V6, P233, DOI 10.2165/00148581-200406040-00003; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; BERGLUND B, 1992, CHEM SENSES, V17, P291, DOI 10.1093/chemse/17.3.291; Berkowitz RB, 1999, ALLERGY, V54, P64, DOI 10.1034/j.1398-9995.1999.00713.x; Berlucchi M, 2007, PEDIATRICS, V119, pE1392, DOI 10.1542/peds.2006-1769; Bernardo FP, 2004, COMP AID CH, V18, P151; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Bernstein DI, 2004, CLIN EXP ALLERGY, V34, P952, DOI 10.1111/j.1365-2222.2004.01952.x; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443; Bernstein IL, 2000, J ALLERGY CLIN IMMUN, V105, P39, DOI 10.1016/S0091-6749(00)90175-1; Bernstein JA, 1999, J ALLERGY CLIN IMMUN, V103, P1153, DOI 10.1016/S0091-6749(99)70192-2; LI Bernstein, 2008, ANN ALLERGY, V100, pS1; Biagini JM, 2006, PEDIATR ALLERGY IMMU, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; BICKERMAN HA, 2008, C SPONS SCI DEV COMM; Bielory L, 2006, MED CLIN N AM, V90, P129, DOI 10.1016/j.mcna.2005.08.013; BIELORY L, 2007, ANN ALLERG ASTHMA IM, V98, P52; BIELORY L, 2007, ANN ALLERG ASTHMA IM, V98, P14; Bielory L, 2008, ANN ALLERG ASTHMA IM, V100, P272, DOI 10.1016/S1081-1206(10)60453-X; Bielory L, 2007, ANN ALLERG ASTHMA IM, V98, P105; Bielory Leonard, 2002, Curr Opin Allergy Clin Immunol, V2, P447, DOI 10.1097/00130832-200210000-00013; BIKHAZI P, 1995, LARYNGOSCOPE, V105, P629, DOI 10.1288/00005537-199506000-00013; BINGHAM B, 1991, J OTOLARYNGOL, V20, P414; BIRCHALL MA, 1994, CLIN OTOLARYNGOL, V19, P521, DOI 10.1111/j.1365-2273.1994.tb01281.x; BIRCHALL MA, 1993, OTOLARYNG HEAD NECK, V109, P450; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Blaiss M, 2004, CLIN THER, V26, P1876, DOI 10.1016/j.clinthera.2004.11.003; Blaiss MS, 1997, ALLERGIC DIS, P15; Blaiss MS, 2003, ANN ALLERG ASTHMA IM, V90, P16; Bloom M, 2004, CURR MED RES OPIN, V20, P1959, DOI 10.1185/030079904X14148; BOCK SA, 1978, J ALLERGY CLIN IMMUN, V62, P327, DOI 10.1016/0091-6749(78)90132-X; BOGAERTS P A T, 1981, Rhinology (Utrecht), V19, P203; Bonadonna P, 2001, AM J RHINOL, V15, P297; Bonay M, 2006, ALLERGY, V61, P111, DOI 10.1111/j.1398-9995.2006.00967.x; Boner AL, 2001, J ALLERGY CLIN IMMUN, V108, pS32, DOI 10.1067/mai.2001.115564; Bonilla FA, 2005, ANN ALLERG ASTHMA IM, V94, pS1; Bonno M, 1996, J ALLERGY CLIN IMMUN, V97, P680, DOI 10.1016/S0091-6749(96)70314-7; BORUM P, 1981, AM REV RESPIR DIS, V123, P418; Botelho-Nevers E, 2007, INT J INFECT DIS, V11, P423, DOI 10.1016/j.ijid.2006.10.005; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BOUSQUET J, 1987, CLIN ALLERGY, V17, P529, DOI 10.1111/j.1365-2222.1987.tb02049.x; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1987, INT ARCH ALLER A IMM, V82, P550; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P309, DOI 10.1016/S0091-6749(96)70155-0; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1994, AM J RESP CRIT CARE, V149, P371; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; BRADLEY CM, 1987, EUR J CLIN PHARMACOL, V32, P419, DOI 10.1007/BF00543979; Brain D., 1987, SCOTT BROWNS OTOLARY, P154; BRANNAN MD, 1995, CLIN THER, V17, P637, DOI 10.1016/0149-2918(95)80040-9; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; BRAZIER JE, 1992, BRIT MED J, V305, P160; BRESOLIN D, 1984, PEDIATRICS, V73, P622; BRIK A, 1987, J ALLERGY CLIN IMMUN, V80, P51, DOI 10.1016/S0091-6749(87)80190-2; BRONSKY EA, 1995, J ALLERGY CLIN IMMUN, V95, P1117, DOI 10.1016/S0091-6749(95)70215-6; Bronsky EA, 1998, ALLERGY ASTHMA PROC, V19, P135, DOI 10.2500/108854198778604112; Brown Christopher L, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P9, DOI 10.1097/00020840-200402000-00004; BROWN HM, 1977, BRIT J CLIN PHARMACO, V4, pS259; BROWN HM, 1977, CLIN PHARM S3, V4, pS283; BRUTTMANN G, 1990, ANN ALLERGY, V64, P224; BRYANT D H, 1975, Clinical Allergy, V5, P145, DOI 10.1111/j.1365-2222.1975.tb01847.x; Bugiani M, 2005, ALLERGY, V60, P165, DOI 10.1111/j.1398-9995.2005.00659.x; Bunnag C., 1999, Rhinology (Utrecht), V37, P125; Burch M, 2002, INT J BIOMETEOROL, V46, P107, DOI 10.1007/s00484-002-0127-1; Burgess JA, 2007, J ALLERGY CLIN IMMUN, V120, P863, DOI 10.1016/j.jaci.2007.07.020; BURKE GW, 1977, JAMA-J AM MED ASSOC, V238, P2705, DOI 10.1001/jama.238.25.2705; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; Cabrera CE, 2007, OTOLARYNG HEAD NECK, V136, P176, DOI 10.1016/j.otohns.2006.09.003; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Canani RB, 2006, PEDIATRICS, V117, pE817, DOI 10.1542/peds.2005-1655; CANCIANI M, 1988, PEDIATR PULM, V5, P210, DOI 10.1002/ppul.1950050406; Cantani A, 2000, Eur Rev Med Pharmacol Sci, V4, P139; Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90; Cantu C, 2003, STROKE, V34, P1667, DOI 10.1161/01.STR.0000075393.45936.FA; Carayol N, 2000, ALLERGY, V55, P570, DOI 10.1034/j.1398-9995.2000.00588.x; CARLSEN KH, 1993, ALLERGY, V48, P431, DOI 10.1111/j.1398-9995.1993.tb00741.x; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; CARSON JL, 1985, NEW ENGL J MED, V312, P463, DOI 10.1056/NEJM198502213120802; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193; Casale TB, 2003, J ALLERGY CLIN IMMUN, V111, pS835, DOI 10.1067/mai.2003.1550; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; Causer S, 2006, J OCCUP ENVIRON HYG, V3, P161, DOI 10.1080/15459620600572068; Cavaliere M, 2005, OTOLARYNG HEAD NECK, V133, P972, DOI 10.1016/j.otohns.2005.08.006; Cengel S, 2006, INT J PEDIATR OTORHI, V70, P639, DOI 10.1016/j.ijporl.2005.08.013; Cervin Anders, 1998, Rhinology (Utrecht), V36, P128; Chan Danny T M, 2004, Asian J Surg, V27, P39, DOI 10.1016/S1015-9584(09)60242-6; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Chan KS, 2005, MED CARE, V43, P256, DOI 10.1097/00005650-200503000-00008; CHANDRA RK, 1982, ANN ALLERGY, V49, P131; Chang JC, 2004, BIOORGAN MED CHEM, V12, P53, DOI 10.1016/j.bmc.2003.10.049; Chapman M. D., 2006, MED MYCOL, V44, P29, DOI 10.1080/13693780600835740; Chen Shuei-Tu, 2006, Journal of Microbiology Immunology and Infection, V39, P212; Chen YL, 2007, INT J PEDIATR OTORHI, V71, P921, DOI 10.1016/j.ijporl.2007.03.002; Chervinsky P, 2004, ANN ALLERG ASTHMA IM, V92, P367; Chng SY, 2004, PEDIATR PULM, V38, P210, DOI 10.1002/ppul.20075; Choi SH, 2007, ALLERGY, V62, P1051, DOI 10.1111/j.1398-9995.2007.01403.x; CIMBURA G, 1982, J FORENSIC SCI, V27, P855; Cincik H, 2006, LARYNGOSCOPE, V116, P1562, DOI 10.1097/01.mlg.0000230402.66579.07; Ciprandi G, 2008, ALLERGY, V63, P255, DOI 10.1111/j.1398-9995.2007.01544.x; Ciprandi G, 2004, RESP MED, V98, P826, DOI 10.1016/j.rmed.2004.02.021; Ciprandi G, 2005, ALLERGY, V60, P882, DOI 10.1111/j.1398-9995.2005.00602.x; Ciprandi G, 2005, INT ARCH ALLERGY IMM, V136, P266, DOI 10.1159/000083953; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Ciprandi G, 2002, ALLERGY, V57, P586, DOI 10.1034/j.1398-9995.2002.03228.x; Ciprandi G, 2001, ALLERGY, V56, P1068, DOI 10.1034/j.1398-9995.2001.00191.x; CIPRANDI G, 1991, INT ARCH ALLER A IMM, V96, P344; Ciprandi G, 1997, ANN ALLERG ASTHMA IM, V79, P507; Ciprandi G, 2006, AM J RHINOL, V20, P641, DOI 10.2500/ajr.2006.20.2914; Cirillo I, 2007, ALLERGY, V62, P1087, DOI 10.1111/j.1398-9995.2007.01401.x; Claeys S, 2005, CLIN EXP ALLERGY, V35, P467, DOI 10.1111/j.1365-2222.2005.02215.x; CLAPP WD, 1993, CHEST, V104, P825, DOI 10.1378/chest.104.3.825; CLARK D, 1994, J NEUROL NEUROSUR PS, V57, P847, DOI 10.1136/jnnp.57.7.847; Clemens CJ, 1997, J PEDIATR-US, V130, P463, DOI 10.1016/S0022-3476(97)70211-7; CLISSOLD SP, 1984, DRUGS, V28, P485, DOI 10.2165/00003495-198428060-00001; Collins MM, 2002, CLIN OTOLARYNGOL, V27, P314, DOI 10.1046/j.1365-2273.2002.00573.x; COOK TJ, 1973, J ALLERGY CLIN IMMUN, V51, P71, DOI 10.1016/S0091-6749(73)80002-8; Corren J, 1999, J ALLERGY CLIN IMMUN, V104, pS144; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Corren J, 2005, CLIN THER, V27, P543, DOI 10.1016/j.clinthera.2005.04.012; Corren J, 2003, J ALLERGY CLIN IMMUN, V111, P87, DOI 10.1067/mai.2003.49; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Cox J S, 1970, Adv Drug Res, V5, P115; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Craig TJ, 2005, J ALLERGY CLIN IMMUN, V116, P1264, DOI 10.1016/j.jaci.2005.10.009; Crampton HJ, 2003, CLIN THER, V25, P1975, DOI 10.1016/S0149-2918(03)80199-6; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Criscuoli G, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e236; Cristaudo A, 2005, ALLERGY, V60, P159, DOI 10.1111/j.1398-9995.2004.00521.x; Crobach M, 1996, SCAND J PRIM HEALTH, V14, P116, DOI 10.3109/02813439608997081; Cruz AA, 2006, J ALLERGY CLIN IMMUN, V117, P1351, DOI 10.1016/j.jaci.2006.01.054; CURZEN N, 1987, THORAX, V42, P946, DOI 10.1136/thx.42.12.946; Dagan R, 1998, PEDIATR INFECT DIS J, V17, P880, DOI 10.1097/00006454-199810000-00006; DALY F, 2001, POISINDEX SYSTEM; Damialis A, 2005, INT J BIOMETEOROL, V49, P139, DOI 10.1007/s00484-004-0229-z; Dastidar P, 1999, EUR ARCH OTO-RHINO-L, V256, P192, DOI 10.1007/s004050050138; Dastidar P, 1999, Am J Rhinol, V13, P97; Day JH, 2000, J ALLERGY CLIN IMMUN, V105, P489, DOI 10.1067/mai.2000.104550; Day JH, 2004, ALLERGY ASTHMA PROC, V25, P59; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334; del Cuvillo A, 2006, J Investig Allergol Clin Immunol, V16 Suppl 1, P3; Dell SJ, 1998, J ALLERGY CLIN IMMUN, V102, P251, DOI 10.1016/S0091-6749(98)70094-6; Dell SJ, 1997, AM J OPHTHALMOL, V123, P791; DELUCA HS, 2003, EUR ANN ALLERGY CLIN, V35, P352; DEMAIN JG, 1995, PEDIATRICS, V95, P355; Demengeot J, 2006, SPRINGER SEMIN IMMUN, V28, P41, DOI 10.1007/s00281-006-0024-5; Demoly P, 2006, ALLERGY, V61, P699, DOI 10.1111/j.1398-9995.01112.x; Demoly P, 2002, ALLERGY, V57, P546, DOI 10.1034/j.1398-9995.2002.t01-1-13370.x; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DESHAZO RD, 1995, J ALLERGY CLIN IMMUN, V96, P24, DOI 10.1016/S0091-6749(95)70029-3; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; DeWester J, 2003, ALLERGY ASTHMA PROC, V24, P331; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; DIAMOND L, 1995, J ALLERGY CLIN IMMUN, V95, P1139, DOI 10.1016/S0091-6749(95)70219-9; Diav-Citrin O, 2003, J ALLERGY CLIN IMMUN, V111, P1239, DOI 10.1067/mai.2003.1499; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Diepgen TL, 2002, PEDIATR ALLERGY IMMU, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; DISCEPOLA M, 1999, ACTA OPHTHALMOL SC S, V228, P43; Dockhorn R, 1999, ANN ALLERG ASTHMA IM, V82, P349; DOCKHORN R, 1992, J ALLERGY CLIN IMMUN, V90, P1076, DOI 10.1016/0091-6749(92)90126-M; Dolen WK, 2001, IMMUNOL ALLERGY CLIN, V21, P273, DOI 10.1016/S0889-8561(05)70205-8; DOLEN WK, 1998, MIDDLETONS ALLERGY, P1017; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; Dombrowski M, 1999, J ALLERGY CLIN IMMUN, V103, pS356, DOI 10.1016/S0091-6749(99)70263-0; Dombrowski M P, 1996, J Matern Fetal Med, V5, P310; Donovan R, 1972, J Laryngol Otol, V86, P731; Doull I, 1996, ARCH DIS CHILD, V74, P497; DOWNEY R, 2004, SEATTLE WEEKLY; DOYLE WJ, 1994, J ALLERGY CLIN IMMUN, V93, P534, DOI 10.1016/0091-6749(94)90364-6; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; DRUCE HM, 1985, J ALLERGY CLIN IMMUN, V76, P445, DOI 10.1016/0091-6749(85)90725-0; DRUCE HM, 1992, ANN ALLERGY, V69, P53; Druce H. M., 1998, ALLERGY PRINCIPLES P, P1005; Dunn CJ, 2005, J LARYNGOL OTOL, V119, P12; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Dutt SN, 2005, J LARYNGOL OTOL, V119, P843; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Dykewicz MS, 2003, ANN ALLERG ASTHMA IM, V91, P44; DYKEWICZ MS, 1991, J ALLERGY CLIN IMMUN, V87, P48, DOI 10.1016/0091-6749(91)90212-7; DYMENT PG, 1970, PEDIATRICS, V46, P136; Eccles R, 2007, BRIT J CLIN PHARMACO, V63, P10, DOI 10.1111/j.1365-2125.2006.02833.x; Edelstein DR, 1996, LARYNGOSCOPE, V106, P1, DOI 10.1097/00005537-199609001-00001; Ediger D, 2005, CLIN EXP ALLERGY, V35, P319, DOI 10.1111/j.1365-2222.2005.02194.x; Einarson A, 1997, ANN ALLERG ASTHMA IM, V78, P183; Ekdahl K, 1997, CLIN INFECT DIS, V25, P1113, DOI 10.1086/516103; Ellegard E, 1998, ARCH OTOLARYNGOL, V124, P439; Ellegard E, 1999, CLIN OTOLARYNGOL, V24, P307, DOI 10.1046/j.1365-2273.1999.00264.x; Ellegard EK, 2001, CLIN OTOLARYNGOL, V26, P394, DOI 10.1046/j.1365-2273.2001.00491.x; Ellegard EK, 2006, IMMUNOL ALLERGY CLIN, V26, P119, DOI 10.1016/j.iac.2005.10.007; Ellis AK, 2006, CURR ALLERGY ASTHM R, V6, P215, DOI 10.1007/s11882-006-0037-0; *EMC, 2006, MULT ACT TABL; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Erez S, 1971, J Reprod Med, V7, P35; Ernst P, 2006, EUR RESPIR J, V27, P1168, DOI 10.1183/09031936.06.00043005; Escudier E, 2002, AM J RESP CRIT CARE, V166, P1257, DOI 10.1164/rccm.2111070; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; FALLIERS CJ, 1980, ANN ALLERGY, V45, P75; *FDA, 2007, NONP DRUG ADV COMM M; FEENY D, 1995, PHARMACOECONOMICS, V7, P490, DOI 10.2165/00019053-199507060-00004; Fellows J, 2006, J WOUND OSTOMY CONT, V33, P606; Fendrick AM, 2001, CLIN THER, V23, P1683, DOI 10.1016/S0149-2918(01)80137-5; Fireman P, 2000, J ALLERGY CLIN IMMUN, V105, pS616; FIREMAN P, 1991, ATLAS ALLERGIES; FISHER EW, 1994, J ROY SOC MED, V87, P411; Fisher LH, 2005, CLIN REV ALLERG IMMU, V29, P151, DOI 10.1385/CRIAI:29:2:151; FISONS C, 1987, EXCERPTA MED, P5; Fivgas GD, 1999, AM J OPHTHALMOL, V127, P104, DOI 10.1016/S0002-9394(98)00312-2; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Fougard T., 1991, ALLERGY, V46, P20, DOI 10.1111/j.1398-9995.1991.tb00537.x; FRAUNFELDER FT, 1990, AM J OPHTHALMOL, V109, P489; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Friedman M, 1999, LARYNGOSCOPE, V109, P1834, DOI 10.1097/00005537-199911000-00021; Frosh AC, 1999, CLIN EXP ALLERGY, V29, P457; Fukazawa K, 2001, LARYNGOSCOPE, V111, P147, DOI 10.1097/00005537-200101000-00025; GAFFEY MJ, 1988, ANTIMICROB AGENTS CH, V32, P1644; GALAN C, 2006, ALLERG IMMUNOL PARIS, V38, P203; Galant SP, 2003, PEDIATRICS, V112, P96, DOI 10.1542/peds.112.1.96; Gani F, 2001, ALLERGY, V56, P65, DOI 10.1034/j.1398-9995.2001.00794.x; GANIER M, 1980, CHEST, V77, P183, DOI 10.1378/chest.77.2.183; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; Gautrin D, 2002, EUR RESPIR J, V19, P96, DOI 10.1183/09031936.02.00230202; Gelfand EW, 2004, J ALLERGY CLIN IMMUN, V114, pS135, DOI 10.1016/j.jaci.2004.08.043; Gendo K, 2004, ANN INTERN MED, V140, P278; GENGO FM, 1990, ANN ALLERGY, V64, P520; GENTILE DA, 2002, ATLAS PEDIAT PHYS DI; GEORGITIS JW, 1994, CLIN EXP ALLERGY, V24, P1049, DOI 10.1111/j.1365-2222.1994.tb02742.x; GFR B, 1998, DRUGS PREGNANCY LACT, P5; Gigante J, 2005, PEDIATR REV, V26, P199, DOI 10.1542/pir.26-6-199; Gilain L, 1997, ARCH OTOLARYNGOL, V123, P401; Gilbert C, 2005, DRUG SAFETY, V28, P707, DOI 10.2165/00002018-200528080-00005; Gill B S, 1966, J Laryngol Otol, V80, P506, DOI 10.1017/S0022215100065567; Gluck PA, 2005, CURR MED RES OPIN, V21, P1075, DOI 10.1185/030079905X50570; Goetz DW, 2007, ALLERGY ASTHMA PROC, V28, P50, DOI 10.2500/aap.2007.28.2956; GOETZ DW, 1991, ANN ALLERGY, V67, P448; Gold SM, 1997, LARYNGOSCOPE, V107, P1586, DOI 10.1097/00005537-199712000-00002; Goldstein I, 2000, INT J IMPOT RES, V12, pS75, DOI 10.1038/sj.ijir.3900502; de Ana SG, 2006, J INVEST ALLERG CLIN, V16, P357; Gonzalo-Garijo MA, 2006, J INVEST ALLERG CLIN, V16, P37; Gorski P, 2000, INT ARCH OCC ENV HEA, V73, P488, DOI 10.1007/s004200000166; Gotoh M, 2005, RHINOLOGY, V43, P266; Gradman J, 2007, CLIN THER, V29, P1738, DOI 10.1016/j.clinthera.2007.08.017; Graf P, 1999, CLIN THER, V21, P1749, DOI 10.1016/S0149-2918(99)80053-8; Graf P, 1996, LARYNGOSCOPE, V106, P605, DOI 10.1097/00005537-199605000-00016; Graft D, 1996, J ALLERGY CLIN IMMUN, V98, P724, DOI 10.1016/S0091-6749(96)70119-7; GRAHAM D, 1988, ARCH ENVIRON HEALTH, V43, P228; Graudenz GS, 2006, J ALLERGY CLIN IMMUN, V118, P1126, DOI 10.1016/j.jaci.2006.07.005; Green Robin John, 2007, Prim Care Respir J, V16, P299; GREENBERGER PA, 1983, ANN INTERN MED, V98, P478; Greene RR, 2005, ARTHRITIS RHEUM, V52, P3314, DOI 10.1002/art.21292; Gregory C, 1999, AM J MANAG CARE, V5, P485; Greiner AN, 2006, J ALLERGY CLIN IMMUN, V118, P985, DOI 10.1016/j.jaci.2006.06.029; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; Grize L, 2006, ALLERGY, V61, P556, DOI 10.1111/j.1398-9995.2006.01030.x; GROSSMAN J, 1995, J ALLERGY CLIN IMMUN, V95, P1123, DOI 10.1016/S0091-6749(95)70216-4; Grossman J, 1997, CHEST, V111, P11; GRYMER L F, 1991, Rhinology (Utrecht), V29, P35; GRYMER LF, 1989, LARYNGOSCOPE, V99, P1180; Guendelman S, 2002, ARCH PEDIAT ADOL MED, V156, P114; Guerra S, 2002, ALLERGY ASTHMA PROC, V23, P303; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guyuron B, 1999, PLAST RECONSTR SURG, V104, P2202, DOI 10.1097/00006534-199912000-00039; GUYURON B, 1999, PLAST RECONSTR SURG, V104, P10; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; Gwaltney JM, 2002, OTOLARYNG HEAD NECK, V127, pS24, DOI 10.1067/mhn.2002.130028; Gwaltney JM, 1996, CLIN INFECT DIS, V23, P1209; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P62; GWALTNEY JM, 2008, UPTODATE; GWYNN CM, 1982, LANCET, V1, P254; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; Hagerhed-Engman L, 2006, ALLERGY, V61, P447, DOI 10.1111/j.1398-9995.2006.01031.x; HAGY GW, 1971, J ALLERGY CLIN IMMUN, V48, P200, DOI 10.1016/0091-6749(71)90066-2; HALLEN H, 1994, ORL J OTO-RHINO-LARY, V56, P51; HALLEN H, 1995, CLIN EXP ALLERGY, V25, P401, DOI 10.1111/j.1365-2222.1995.tb01070.x; HAMID M, 1990, CLIN EXP ALLERGY, V20, P261, DOI 10.1111/j.1365-2222.1990.tb02681.x; Hamilos DL, 1996, ALLERGY ASTHMA PROC, V17, P293, DOI 10.2500/108854196778662200; Hamilton JW, 1997, CLIN OTOLARYNGOL, V22, P408, DOI 10.1046/j.1365-2273.1997.00044.x; Hamilton Robert G., 2003, Journal of Allergy and Clinical Immunology, V111, pS687; HANDELMAN NI, 1977, J ALLERGY CLIN IMMUN, V59, P237, DOI 10.1016/0091-6749(77)90156-7; HARALDSSON PO, 1987, ORL J OTO-RHINO-LARY, V49, P218; HARDMAN JG, 1996, GOODMAN GILMANS PHAR, P148; Harvey R, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; Hayden FG, 1996, ANN INTERN MED, V125, P89; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; Heatley DG, 2001, OTOLARYNG HEAD NECK, V125, P44, DOI 10.1067/mhn.2001.115909; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Hee J, 1985, Eur J Respir Dis Suppl, V139, P86; HEINER DC, 1984, ANN ALLERGY, V53, P657; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HENGSTMANN JH, 1982, EUR J CLIN PHARMACOL, V21, P335, DOI 10.1007/BF00637623; Heppt W, 2004, CLIN EXP ALLERGY, V34, P1105, DOI 10.1111/j.1365-2222.2004.01990.x; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Higashi N, 2004, J ALLERGY CLIN IMMUN, V113, P277, DOI 10.1016/j.jaci.2003.10.068; HILBERG O, 1995, ALLERGY, V50, P166; HILBERG O, 1993, J APPL PHYSIOL, V75, P2811; Hilberg O, 2002, ALLERGY, V57, P5, DOI 10.1046/j.0908-665x.2001.all.doc.x; HILL LW, 1961, NEW ENGL J MED, V265, P1194, DOI 10.1056/NEJM196112142652406; Hill SL, 2003, OTOLARYNG HEAD NECK, V129, P199, DOI 10.1016/S0194-5998(03)00607-7; HILLBERG O, 1989, J APPL PHYSIOL, V66, P295; HINDMARCH I, 1995, ALLERGY, V50, P48, DOI 10.1111/j.1398-9995.1995.tb04264.x; HINDMARCH I, 1978, ARZNEIMITTEL-FORSCH, V28-1, P483; Hissaria P, 2006, J ALLERGY CLIN IMMUN, V118, P128, DOI 10.1016/j.jaci.2006.03.012; Hodson T, 1999, J ALLERGY CLIN IMMUN, V103, P581, DOI 10.1016/S0091-6749(99)70227-7; HOMBURGER HA, 1986, J ALLERGY CLIN IMMUN, V77, P427, DOI 10.1016/0091-6749(86)90176-4; Homer C, 2000, PEDIATRICS, V106, P210; Horak F, 2006, CURR MED RES OPIN, V22, P151, DOI 10.1185/030079906X80305; Horak F, 2003, CLIN DRUG INVEST, V23, P329, DOI 10.2165/00044011-200323050-00003; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HOWARD W, 2008, ALLERGIC DIS INFANCY, P282; Howes JF, 2000, PHARMAZIE, V55, P178; Howland WC, 1996, J ALLERGY CLIN IMMUN, V98, P32, DOI 10.1016/S0091-6749(96)70223-3; HUNT SM, 1985, J ROY COLL GEN PRACT, V35, P185; HURST DS, 1993, OTOLARYNG HEAD NECK, V108, P711; Huss Karen, 2003, J Pediatr Health Care, V17, P72, DOI 10.1016/S0891-5245(02)88328-6; HUTTON N, 1991, J PEDIATR-US, V118, P125, DOI 10.1016/S0022-3476(05)81865-7; Hwang Kyu-Yoon, 2001, Korean Journal of Parasitology, V39, P197; Hwang PH, 1999, OTOLARYNG HEAD NECK, V120, P678, DOI 10.1053/hn.1999.v120.a93047; Hytonen M, 1997, INT ARCH OCC ENV HEA, V69, P487, DOI 10.1007/s004200050178; Ibanez-Tallon I, 2003, HUM MOL GENET, V12, pR27, DOI 10.1093/hmg/ddg061; IGARASHI Y, 1993, J ALLERGY CLIN IMMUN, V92, P722, DOI 10.1016/0091-6749(93)90016-9; Iglesias P, 2005, J ENDOCRINOL INVEST, V28, P1019; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Illum P, 1997, EUR ARCH OTO-RHINO-L, V254, pS89, DOI 10.1007/BF02439733; Ingels K, 1997, ALLERGY, V52, P338, DOI 10.1111/j.1398-9995.1997.tb01001.x; Inouye T, 1999, Ann Otol Rhinol Laryngol Suppl, V180, P3; Iwens P., 1994, Acta Oto-Rhino-Laryngologica Belgica, V48, P383; JACINTO CM, 1992, J ALLERGY CLIN IMMUN, V90, P312, DOI 10.1016/S0091-6749(05)80008-9; JACOBS MB, 1986, POSTGRAD MED, V80, P159; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V67, P253, DOI 10.1016/0091-6749(81)90019-1; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Jacobsen L, 2001, ANN ALLERG ASTHMA IM, V87, P43; James JM, 2004, CURR ALLERGY ASTHM R, V4, P294, DOI 10.1007/s11882-004-0074-5; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59; Jang AS, 2002, J KOREAN MED SCI, V17, P761; Jean R, 1996, ALLERGY, V51, P932; JELKS M, 1986, ALLERGY PLANTS CAUSE; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; JENKINSON C, 1994, QUAL LIFE RES, V3, P7, DOI 10.1007/BF00647843; JENKINSON C, 1988, SOC SCI MED, V27, P1411, DOI 10.1016/0277-9536(88)90207-9; Jessen M, 1997, ALLERGY, V52, P3; JETTE AM, 1986, J GEN INTERN MED, V1, P143, DOI 10.1007/BF02602324; JICK H, 1981, JAMA-J AM MED ASSOC, V246, P343, DOI 10.1001/jama.246.4.343; Johansson L, 2006, ACTA OTO-LARYNGOL, V126, P288, DOI 10.1080/00016480500388877; Johansson L, 2003, ANN OTO RHINOL LARYN, V112, P625; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Jones AM, 2004, SCI TOTAL ENVIRON, V326, P151, DOI 10.1016/j.scitotenv.2003.11.021; Joniau S, 2006, LARYNGOSCOPE, V116, P1612, DOI 10.1097/01.mlg.0000227999.76713.d3; Joos GF, 2005, IMMUNOL ALLERGY CLIN, V25, P597, DOI 10.1016/j.iac.2005.06.001; Jorissen M, 2000, Acta Otorhinolaryngol Belg, V54, P343; Jose J, 2003, CLIN OTOLARYNGOL, V28, P352, DOI 10.1046/j.1365-2273.2003.00722.x; JOUSIMIESSOMER HR, 1988, J CLIN MICROBIOL, V26, P1926; JULIUSSON S, 1988, CLIN ALLERGY, V18, P615, DOI 10.1111/j.1365-2222.1988.tb02913.x; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 2002, ALLERGY, V57, P201, DOI 10.1034/j.1398-9995.2002.1o3306.x; JUNIPER EF, 1993, ANN ALLERGY, V70, P225; Juniper EF, 2003, J ALLERGY CLIN IMMUN, V111, P484, DOI 10.1067/mai.2003.137; Juniper EF, 1997, CAN MED ASSOC J, V156, P1123; Juniper EF, 1996, J ALLERGY CLIN IMMUN, V98, P843, DOI 10.1016/S0091-6749(96)70135-5; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163; Juniper EF, 2002, CHEST, V121, P1824, DOI 10.1378/chest.121.6.1824; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; JUNIPER EF, 1999, DEV VALIDATION MINI; JUNIPER EF, 1999, DEV VALIDATION STAND; Juniper Elizabeth F, 2005, J Allergy Clin Immunol, V115, pS390, DOI 10.1016/j.jaci.2004.12.014; Kaiser HB, 2007, J ALLERGY CLIN IMMUN, V119, P1430, DOI 10.1016/j.jaci.2007.02.022; Kallen B, 2002, J Matern Fetal Neonatal Med, V11, P146, DOI 10.1080/713605486; Kallen B, 1999, OBSTET GYNECOL, V93, P392, DOI 10.1016/S0029-7844(98)00454-2; Kalra M, 2006, CHEST, V129, P942, DOI 10.1378/chest.129.4.942; KANFER I, 1993, PHARMACOTHERAPY, V13, pS116; KANFER I, 1993, PHARMACOTHERAPY, V13, pS43; KANG BC, 1988, J ASTHMA, V25, P205; KANO S, 1994, PEDIATR PULM, V17, P312, DOI 10.1002/ppul.1950170508; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Kaszuba SM, 2001, ARCH INTERN MED, V161, P2581, DOI 10.1001/archinte.161.21.2581; KATZENSTEIN ALA, 1983, J ALLERGY CLIN IMMUN, V72, P89, DOI 10.1016/0091-6749(83)90057-X; KAUFMAN HS, 1982, ANN ALLERGY, V49, P270; KAY AB, 1987, J ALLERGY CLIN IMMUN, V80, P1, DOI 10.1016/S0091-6749(87)80183-5; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Keles N, 2004, AM J RHINOL, V18, P23; Keles N, 2002, RHINOLOGY, V40, P211; Kesavanathan J, 1996, J TOXICOL ENV HEALTH, V48, P295, DOI 10.1080/009841096161348; Keskin O, 2006, PEDIATR ALLERGY IMMU, V17, P259, DOI 10.1111/j.1399-3038.2006.00397.x; *NAT JEW MED RES C, 2007, ALL INTR SKIN TEST; National Heart L Blood I National Asthma E Prevention Program A Pregnancy WG, 2005, J ALLERGY CLIN IMMUN, V115, P34; Rosenfeld RM, 2004, PEDIATRICS, V113, P1412; *SIN ALL HLTH PART, 2000, OTOLARYNGOL HEAD NEC, V123, P5; *U TEX MB, 2006, UTMB POINT CAR TEST; 2000, ANN ALLERGY ASTHMA I, V84, P475; 2006, J ALLERGY CLIN IMMUN, V117, pS495; 2007, CYPROHEPTADINE LEXI; 1996, J ALLERGY CLIN IMMUN, V98, P1012; DIPHENHYDRAMINE; AFRIN 12 HOUR; 2006, BENADRYL DIPHENHYDRA; 2007, ASTELIN AZELASTINE H; 2000, DRUG INFORM HLTH CAR, P343; 1985, CLIN PHARM THER, V38, P24; 2008, PATANASE OLOPATADINE; 2006, ZYRTEC CETRIZINE HYD; Kessel A, 2008, PEDIATR ALLERGY IMMU, V19, P61, DOI 10.1111/j.1399-3038.2007.00588.x; Keyserling HF, 2006, EAR NOSE THROAT, V85, P8; Kezirian EJ, 2005, LARYNGOSCOPE, V115, P1298, DOI 10.1097/01.MLG.0000165373.78207.BF; Khan DA, 2000, J ALLERGY CLIN IMMUN, V106, P1096, DOI 10.1067/mai.2000.110929; Kiely JL, 2004, THORAX, V59, P50; Kim KT, 2005, ANN ALLERG ASTHMA IM, V94, P73; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P1285; KIMMELMAN CP, 1989, OTOLARYNG CLIN N AM, V22, P253; Kirmaz C, 2005, ANN ALLERG ASTHMA IM, V95, P525; KIRSHNA M, 2001, ESSENTIALS ALLERGY; Klein GL, 1996, ANN ALLERG ASTHMA IM, V77, P365; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; KleinJan A, 2006, J ALLERGY CLIN IMMUN, V118, P1117, DOI 10.1016/j.jaci.2006.05.030; Klossek JM, 2005, ALLERGY, V60, P233, DOI 10.1111/j.1398-9995.2005.00688.x; Klossek JM, 2001, RHINOLOGY, V39, P17; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; Knipping S, 2007, OTOLARYNG HEAD NECK, V136, P57, DOI 10.1016/j.otohns.2006.08.025; Kohno Y, 1998, J ALLERGY CLIN IMMUN, V102, P927, DOI 10.1016/S0091-6749(98)70330-6; KOMISAR A, 1989, OTOLARYNG CLIN N AM, V22, P351; Krakowiak Anna, 2003, Int J Occup Med Environ Health, V16, P125; Kramer MF, 2006, AM J OTOLARYNG, V27, P190, DOI 10.1016/j.amjoto.2005.09.013; Kramer MF, 2004, AM J OTOLARYNG, V25, P173, DOI 10.1016/j.amjoto.2003.12.004; Krishna S, 2003, PEDIATRICS, V111, P503, DOI 10.1542/peds.111.3.503; KROTOV AI, 1998, VESTN OTORINOLARINGO, V4, P51; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; KURILOFF DB, 1989, LARYNGOSCOPE, V99, P918; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; KUSAKA H, 1993, INTERNAL MED, V32, P106, DOI 10.2169/internalmedicine.32.106; Kvaerner KJ, 1996, INT J PEDIATR OTORHI, V35, P127; LaForce C, 1996, ANN ALLERG ASTHMA IM, V76, P181; LaForce C, 1999, J ALLERGY CLIN IMMUN, V103, pS388, DOI 10.1016/S0091-6749(99)70218-6; LaForce CF, 2004, ANN ALLERG ASTHMA IM, V93, P154; LANG DM, 2002, GERIATR TIMES, V3, P41; Larsen K, 1996, ALLERGY ASTHMA PROC, V17, P243, DOI 10.2500/108854196778662255; Larsen K, 2002, ACTA OTO-LARYNGOL, V122, P179, DOI 10.1080/00016480252814199; Law AW, 2003, J ALLERGY CLIN IMMUN, V111, P296, DOI 10.1067/mai.2003.68; LAZAR RH, 1992, OTOLARYNG HEAD NECK, V107, P29; Lee C, 2007, EXPERT OPIN PHARMACO, V8, P701, DOI 10.1517/14656566.8.5.701; LEE TH, 1982, LANCET, V2, P1048; Leger D, 2006, ARCH INTERN MED, V166, P1744, DOI 10.1001/archinte.166.16.1744; LEKAS MD, 1992, OTOLARYNG HEAD NECK, V107, P845; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Leonard DW, 1999, LARYNGOSCOPE, V109, P668, DOI 10.1097/00005537-199904000-00029; LEONARDI A, 1990, EYE, V4, P760; Leone FT, 2003, CHEST, V124, P2329, DOI 10.1378/chest.124.6.2329; Lerdlum Sukalaya, 2005, J Med Assoc Thai, V88 Suppl 4, pS110; LEUNG D, 2006, J ALLERGY CLIN IMMUN, V17, pS495; Lewis WH, 1983, AIRBORNE ALLERGIC PO; Leynaert Benedicte, 2004, Journal of Allergy and Clinical Immunology, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Liccardi G, 1998, J ALLERGY CLIN IMMUN, V102, P143, DOI 10.1016/S0091-6749(98)70065-X; Lieutier-Colas F, 2002, CLIN EXP ALLERGY, V32, P1424, DOI 10.1046/j.1365-2745.2002.01502.x; LINNA O, 1992, ACTA PAEDIATR, V81, P100, DOI 10.1111/j.1651-2227.1992.tb12182.x; Linneberg A, 2008, CLIN EXP ALLERGY, V38, P145, DOI 10.1111/j.1365-2222.2007.02837.x; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Loebstein R, 1999, J ALLERGY CLIN IMMUN, V104, P953; Loewen AHS, 2004, CAN MED ASSOC J, V171, P593, DOI 10.1503/cmaj.1040631; LONG WF, 1985, J ALLERGY CLIN IMMUN, V76, P113, DOI 10.1016/0091-6749(85)90813-9; Lopez Manuel A, 2005, J Long Term Eff Med Implants, V15, P283, DOI 10.1615/JLongTermEffMedImplants.v15.i3.50; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; Lowry KP, 2005, ANN PHARMACOTHER, V39, P1198, DOI 10.1345/aph.1E594; Loza MJ, 2005, CLIN EXP ALLERGY, V35, P8, DOI 10.1111/j.1365-2222.2005.02148.x; LUCENTE FE, 1989, OTOLARYNG CLIN N AM, V22, P307; LUTSKY BN, 1993, CLIN THER, V15, P855; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; MAGARGAL LE, 1985, ANN OPHTHALMOL, V17, P500; MAJCHEL AM, 1992, J ALLERGY CLIN IMMUN, V90, P85, DOI 10.1016/S0091-6749(06)80014-X; Makra L, 2004, INT J BIOMETEOROL, V49, P37, DOI 10.1007/s00484-004-0208-4; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; MALMBERG H, 1979, ALLERGY, V34, P331; MALMBERG H, 1979, ALLERGY, V34, P389, DOI 10.1111/j.1398-9995.1979.tb02008.x; MALTING HJ, 1986, ALLERGY, V41, P342; Mann RD, 2000, BRIT MED J, V320, P1184, DOI 10.1136/bmj.320.7243.1184; Marinetti L, 2005, J ANAL TOXICOL, V29, P738; Marinho S, 2007, ALLERGY, V62, P385, DOI 10.1111/j.1398-9995.2006.01294.x; MARKS MB, 1963, ANN ALLERGY, V21, P26; Marogna M, 2006, ALLERGY, V61, P1209, DOI 10.1111/j.1398-9995.2006.01164.x; Marogna M, 2004, INT ARCH ALLERGY IMM, V135, P336, DOI 10.1159/000082329; Martin BG, 2007, ALLERGY ASTHMA PROC, V28, P216, DOI 10.2500/aap.2007.28.2983; Martin PA, 2003, OTOLARYNG HEAD NECK, V128, P280, DOI 10.1067/mhn.2003.81; Martinez-Anton A, 2006, CLIN EXP ALLERGY, V36, P448, DOI 10.1111/j.1365-2222.2006.02451.x; Mason J, 1999, CLIN EXP ALLERGY, V29, P163, DOI 10.1046/j.1365-2222.1999.0290s3163.x; MATERSON BJ, 1992, AM J CARDIOL, V69, pC46, DOI 10.1016/0002-9149(92)90281-3; Mattila L, 2003, CLIN EXP ALLERGY, V33, P600, DOI 10.1046/j.1365-2222.2003.01661.x; Mazzotta P, 1999, DRUG SAFETY, V20, P361, DOI 10.2165/00002018-199920040-00005; McAlister W H, 2000, Radiology, V215 Suppl, P811; MCALISTER WH, 1989, AM J ROENTGENOL, V153, P1259; McCue JD, 1996, ARCH FAM MED, V5, P464, DOI 10.1001/archfami.5.8.464; McEvoy CE, 1998, AM J RESP CRIT CARE, V157, P704; McHorney CA, 1997, ANN INTERN MED, V127, P743; MCHORNEY CA, 1995, QUAL LIFE RES, V4, P293, DOI 10.1007/BF01593882; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; McLAURIN J. W., 1961, LARYNGOSCOPE, V71, P54, DOI 10.1288/00005537-196101000-00007; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; MCNICHOLAS WT, 1982, AM REV RESPIR DIS, V126, P625; Meggs WJ, 1996, J TOXICOL-CLIN TOXIC, V34, P383; MEGGS WJ, 1994, J TOXICOL-CLIN TOXIC, V32, P487; Meltzer EO, 2007, CLIN THER, V29, P1428, DOI 10.1016/j.clinthera.2007.07.013; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P242, DOI 10.1016/0091-6749(92)90078-G; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2005, AM J RHINOL, V19, P591; Meltzer EO, 2005, MAYO CLIN PROC, V80, P1170; Meltzer EO, 2002, CLIN THER, V24, P942, DOI 10.1016/S0149-2918(02)80009-1; Meltzer EO, 2001, ANN ALLERG ASTHMA IM, V86, P286; Meltzer EO, 2001, J ALLERGY CLIN IMMUN, V108, pS45, DOI 10.1067/mai.2001.115566; MELTZER EO, 1992, J ALLERGY CLIN IMMUN, V90, P1055, DOI 10.1016/0091-6749(92)90123-J; Metcalfe DD, 1983, PROVAOCATIVE CHALLEN, P119; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; MIADONNA A, 1983, CLIN ALLERGY, V13, P155, DOI 10.1111/j.1365-2222.1983.tb02583.x; Milgrom H, 1999, ANN ALLERG ASTHMA IM, V83, P105, DOI 10.1016/S1081-1206(10)62620-8; Milgrom H, 2007, ANN ALLERG ASTHMA IM, V99, P358; Miller JD, 2007, J ALLERGY CLIN IMMUN, V120, P977, DOI 10.1016/j.jaci.2007.06.048; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1177/019459989811800514; MITSCHKE H, 1980, FORTSCHR MED, V98, P437; Mlynarek A, 2004, J OTOLARYNGOL, V33, P360, DOI 10.2310/7070.2004.03074; Mlynski Gunter, 2006, Facial Plast Surg, V22, P223, DOI 10.1055/s-2006-954840; Moira Chan-Yeung, 2002, Ann Allergy Asthma Immunol, V88, P52; Molimard M, 2004, FUND CLIN PHARMACOL, V18, P399, DOI 10.1111/j.1472-8206.2004.00254.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moller C, 2003, CLIN EXP ALLERGY, V33, P816, DOI 10.1046/j.1365-2222.2003.01689.x; MONERETVAUTRIN DA, 1990, ANN ALLERGY, V64, P513; Moore EJ, 2001, AM J RHINOL, V15, P355; Moreno-Grau S, 2006, ANN ALLERG ASTHMA IM, V96, P858; Moretti ME, 2003, J ALLERGY CLIN IMMUN, V111, P479, DOI 10.1067/mai.2003.130; Mori S, 1999, CLIN EXP ALLERGY, V29, P1542; Mori S, 2002, LARYNGOSCOPE, V112, P865, DOI 10.1097/00005537-200205000-00016; Morris S, 1997, AM J RHINOL, V11, P109, DOI 10.2500/105065897782537197; Mortimer KJ, 2005, ANN ALLERG ASTHMA IM, V94, P15; MORTIMER KJ, 2005, ANN ALLERG ASTHMA IM, V94, P79; MORTIMER KJ, 2005, ANN ALLERG ASTHMA IM, V94, P2; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Mostafa BE, 2005, ORL J OTO-RHINO-LARY, V67, P148, DOI 10.1159/000086016; Mucha SM, 2006, ARCH OTOLARYNGOL, V132, P164, DOI 10.1001/archotol.132.2.164; MULLARKEY MF, 1988, J ALLERGY CLIN IMMUN, V82, P941, DOI 10.1016/0091-6749(88)90037-1; Munir A K, 1994, Pediatr Allergy Immunol, V5, P32, DOI 10.1111/j.1399-3038.1994.tb00216.x; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; MUNIR AKM, 1994, ALLERGY, V49, P508, DOI 10.1111/j.1398-9995.1994.tb01121.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Mygind N, 1989, Rhinol Suppl, V9, P37; Naclerio RM, 2003, OTOLARYNG HEAD NECK, V128, P220, DOI 10.1067/mhn.2003.70; Nakazawa T, 2007, J ALLERGY CLIN IMMUN, V119, P421, DOI 10.1016/j.jaci.2006.11.633; Namazy J, 2004, J ALLERGY CLIN IMMUN, V113, P427, DOI 10.1016/j.jaci.2003.11.046; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nandapalan V, 1996, CLIN OTOLARYNGOL, V21, P259, DOI 10.1111/j.1365-2273.1996.tb01737.x; Nathan RA, 2005, CHEST, V128, P1910, DOI 10.1378/chest.128.4.1910; Nayak AS, 1998, J ALLERGY CLIN IMMUN, V101, P157; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592; Neal JS, 2002, ANN ALLERG ASTHMA IM, V88, P410; Nease CJ, 2004, OTOLARYNG HEAD NECK, V130, P291, DOI 10.1016/j.otohns.2003.11.003; NELSON BL, 1982, J ALLERGY CLIN IMMUN, V70, P125, DOI 10.1016/0091-6749(82)90240-8; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P1218, DOI 10.1016/j.jaci.2004.01.566; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; NETO LM, 2007, REV BRAS OTORRINOLAR, V73, P75; NewsonSmith G, 1997, EUR ARCH OTO-RHINO-L, V254, P236, DOI 10.1007/BF00874095; Ngamphaiboon Jarungchit, 2005, J Med Assoc Thai, V88 Suppl 4, pS348; Nguyen LHP, 2004, J ALLERGY CLIN IMMUN, V114, P1110, DOI 10.1016/j.jaci.2004.07.061; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; NIELSEN J, 1994, CLIN EXP ALLERGY, V24, P440, DOI 10.1111/j.1365-2222.1994.tb00932.x; Nielsen Lars P, 2003, Am J Respir Med, V2, P55; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; NISSINEN A, 1995, CLIN INFECT DIS, V21, P1193, DOI 10.1093/clinids/21.5.1193; NIZAMI RM, 1981, ANN ALLERGY, V47, P5; NOBLE SL, 1995, AM FAM PHYSICIAN, V51, P837; NORMAN PS, 1973, J ALLERGY CLIN IMMUN, V52, P210, DOI 10.1016/0091-6749(73)90059-6; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; OHANLON JF, 1995, ALLERGY, V50, P234, DOI 10.1111/j.1398-9995.1995.tb01140.x; OHANLON JF, 1998, I DRUGS SAFETY BEHAV, P10; Ohashi Y, 1998, ARCH OTOLARYNGOL, V124, P1337; OHI M, 1984, Rhinology (Utrecht), V22, P241; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Okano M, 1999, ACTA OTO-LARYNGOL, P58; Okano M, 2006, AM J RHINOL, V20, P342, DOI 10.2500/ajr.2006.20.2865; Olnes S Q, 2000, Pediatr Rev, V21, P416; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Omnes LF, 2007, ALLERG IMMUNOL PARIS, V39, P148; OP SDH, 1977, BIRTH DEFECTS DRUGS; ORIE NGM, 1970, P S DIS CROM ALL AIR, P33; Osborne M, 2006, PEDIATR ALLERGY IMMU, V17, P450, DOI 10.1111/j.1399-3038.2006.00414.x; OTSUKA H, 1986, CLIN ALLERGY, V16, P589, DOI 10.1111/j.1365-2222.1986.tb01998.x; Ownby DR, 1993, ALLERGY PRINCIPLES P, P1059; Ozturk F, 1998, Ear Nose Throat J, V77, P846; [Anonymous], 1998, ENT-EAR NOSE THROAT; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Palczynski C, 2001, ALLERGY, V56, P1186, DOI 10.1034/j.1398-9995.2001.00236.x; Palczynski C, 2000, ALLERGY, V55, P34, DOI 10.1034/j.1398-9995.2000.00037.x; Panagou P, 1998, ACTA OTO-LARYNGOL, V118, P847, DOI 10.1080/00016489850182567; Papon JF, 2006, J APPL PHYSIOL, V100, P107, DOI 10.1152/japplphysiol.00575.2005; Parikh A, 2001, RHINOLOGY, V39, P75; Park GM, 2000, CLIN EXP ALLERGY, V30, P1293, DOI 10.1046/j.1365-2222.2000.00883.x; PARKERSON GR, 1990, MED CARE, V28, P1056, DOI 10.1097/00005650-199011000-00007; Parnes S M, 2000, Ear Nose Throat J, V79, P18; PASTORELLO E, 1985, ANN ALLERGY, V55, P854; Patel D, 2007, ALLERGY ASTHMA PROC, V28, P592, DOI 10.2500/aap2007.28.3033; Patel P, 2007, J ALLERGY CLIN IMMUN, V119, pS144, DOI 10.1016/j.jaci.2006.11.501; Patel P, 2005, ANN ALLERG ASTHMA IM, V95, P551; PAULI G, 1977, CLIN ALLERGY, V7, P337, DOI 10.1111/j.1365-2222.1977.tb01461.x; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PAUWELS R, 1986, CLIN ALLERGY, V16, P281, DOI 10.1111/j.1365-2222.1986.tb01959.x; Pearlman DS, 2003, ANN ALLERG ASTHMA IM, V91, P258; PEARLMAN DS, 1999, PATHOPHYSIOLOGY INFL, V104, pS132; PEDERSEN OF, 1994, LARYNGOSCOPE, V104, P1023; PEHKONEN E, 1994, ALLERGY, V49, P472, DOI 10.1111/j.1398-9995.1994.tb00842.x; PELIKAN Z, 1982, ANN ALLERGY, V49, P283; PELIKAN Z, 1987, ANN ALLERGY, V58, P164; PELIKAN Z, 1970, ANN ALLERGY, V28, P548; PENTEL P, 1984, JAMA-J AM MED ASSOC, V252, P1898, DOI 10.1001/jama.252.14.1898; PERELMUTTER L, 1983, CLIN REV ALLERG, V1, P267; PERERA MG, 1975, AM REV RESPIR DIS, V111, P605; Peternel R, 2004, ANN AGR ENV MED, V11, P303; Peters-Golden M, 2006, CLIN EXP ALLERGY, V36, P689, DOI 10.1111/j.1365-2222.2006.02498.x; PETERSSON G, 1986, ALLERGY, V41, P398, DOI 10.1111/j.1398-9995.1986.tb00319.x; PETRUSON B, 1981, Rhinology (Utrecht), V19, P167; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; PHILLIPS MJ, 1983, BRIT J CLIN PHARMACO, V15, P277; Philpott CM, 2004, CLIN OTOLARYNGOL, V29, P138, DOI 10.1111/j.1365-2273.2004.00801.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; PIPKORN U, 1983, ACTA OTO-LARYNGOL, V95, P167, DOI 10.3109/00016488309130931; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Plosker GL, 1997, PHARMACOECONOMICS, V11, P184; POLLART S, 1988, CLIN REV ALLERG, V6, P23; Polos Peter G, 2006, Prim Care Respir J, V15, P310, DOI 10.1016/j.pcrj.2006.07.003; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; Port A, 2006, ANN ALLERG ASTHMA IM, V96, P687; PORTNOY J, 1987, ANN ALLERGY, V59, P39; Portnoy J, 2004, J ALLERGY CLIN IMMUN, V114, P1235; Portnoy J, 2003, IMMUNOL ALLERGY CLIN, V23, P389, DOI 10.1016/S0889-8561(03)00028-6; PORTNOY J, 1990, ANN ALLERGY, V65, P109; Portnoy JM, 2001, CLIN REV ALLERG IMMU, V21, P241, DOI 10.1385/CRIAI:21:2-3:241; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Prenner BM, 2006, AM J MED, V119, P230, DOI 10.1016/j.amjmed.2005.06.015; Price DB, 2006, ALLERGY, V61, P737, DOI 10.1111/j.1398-9995.2006.01007.x; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; Raat H, 2005, J EPIDEMIOL COMMUN H, V59, P75, DOI 10.1136/jech.2003.012614; Raat H, 2002, J CLIN EPIDEMIOL, V55, P67, DOI 10.1016/S0895-4356(01)00411-5; Rabago D, 2002, J FAM PRACTICE, V51, P1049; Rabago D, 2006, ANN FAM MED, V4, P295, DOI 10.1370/afm.552; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369; Ragab S, 2001, CLIN EXP ALLERGY, V31, P1385, DOI 10.1046/j.1365-2222.2001.01160.x; Rahimi R, 2006, HUM EXP TOXICOL, V25, P447, DOI 10.1191/0960327106het647oa; RAMAEKERS JG, 1992, EUR J CLIN PHARMACOL, V42, P363; Ramey JT, 2006, J INVEST ALLERG CLIN, V16, P148; Rance F, 1999, PEDIATR ALLERGY IMMU, V10, P33, DOI 10.1034/j.1399-3038.1999.101008.x; RAPHAEL G, 1989, J ALLERGY CLIN IMMUN, V83, P110, DOI 10.1016/0091-6749(89)90484-3; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; Rathkopf MM, 2004, ANN ALLERG ASTHMA IM, V93, P147; Ratner P, 2005, INT ARCH ALLERGY IMM, V138, P312, DOI 10.1159/000088869; Ratner PH, 2008, ANN ALLERG ASTHMA IM, V100, P74, DOI 10.1016/S1081-1206(10)60408-5; RATNER PH, 1994, J ALLERGY CLIN IMMUN, V94, P818, DOI 10.1016/0091-6749(94)90148-1; Ratner PH, 2003, ANN ALLERG ASTHMA IM, V90, P536; Ratner PH, 1998, J FAM PRACTICE, V47, P118; Ratner PH, 2002, MAYO CLIN PROC, V77, P350; Ratner PH, 2001, J APPL RES, V1, P100; RAUTIAINEN M, 1992, ANN OTO RHINOL LARYN, V101, P982; Ray W A, 1993, Clin Geriatr Med, V9, P413; Redline S, 1999, AM J RESP CRIT CARE, V159, P1527; REED CE, 1988, J ALLERGY CLIN IMMUN, V81, P1042, DOI 10.1016/0091-6749(88)90177-7; Reh DD, 2007, AM J RHINOL, V21, P207, DOI 10.2500/ajr.2007.21.3005; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; REISS M, 2002, SCHWEIZ RUNDSCH MED, V91, P353; Revicki DA, 1998, QUAL LIFE RES, V7, P693, DOI 10.1023/A:1008860113818; RIVASI F, 1988, DIAGN CYTOPATHOL, V4, P99, DOI 10.1002/dc.2840040204; Roberge RJ, 1999, J EMERG MED, V17, P285, DOI 10.1016/S0736-4679(98)00193-0; Rodier F, 2003, J ALLERGY CLIN IMMUN, V112, P1105, DOI 10.1016/j.jaci.2003.08.011; Rodrigo GJ, 2006, ANN ALLERG ASTHMA IM, V96, P779; Rodriguez-Rajo FJ, 2005, MYCOL RES, V109, P497, DOI 10.1017/S0953756204001777; ROHR A, 1983, ANN ALLERGY, V50, P380; ROITHMANN R, 1994, J OTOLARYNGOL, V23, P454; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Romero Jose Narvas, 1992, Rhinology (Utrecht), V30, P169; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; ROSS RN, 1996, AM J MANAG CARE, V2, P285; RoweJones JM, 1997, ALLERGY, V52, P20; RUBIN DH, 1986, PEDIATRICS, V77, P1; RUPP GH, 1982, PEDIATRICS, V70, P437; RUSSO CA, 2007, AMBULATORY SURG US H; Sade K, 2003, ANN ALLERG ASTHMA IM, V91, P444; Saitoh Y, 2001, J INVEST ALLERG CLIN, V11, P183; Salerno SM, 2005, ARCH INTERN MED, V165, P1686, DOI 10.1001/archinte.165.15.1686; Salerno SM, 2005, J HUM HYPERTENS, V19, P643, DOI 10.1038/sj.jhh.1001869; Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64; SASAKI Y, 1973, ANN OTO RHINOL LARYN, V82, P203; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Sauder KL, 1997, AM J EMERG MED, V15, P521, DOI 10.1016/S0735-6757(97)90200-X; SAUNDERS WH, 1982, ANN OTO RHINOL LARYN, V91, P445; SAXEN I, 1974, LANCET, V1, P407; SAXEN I, 1975, INT J EPIDEMIOL, V4, P37, DOI 10.1093/ije/4.1.37; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633; Schatz M, 1997, J ALLERGY CLIN IMMUN, V100, P301, DOI 10.1016/S0091-6749(97)70241-0; Schatz M, 1988, Allergy Proc, V9, P545, DOI 10.2500/108854188778965627; Schenkel EJ, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e22; Schiavino D, 1997, ALLERGY ASTHMA PROC, V18, P363, DOI 10.2500/108854197778558061; SCHIDLOW DV, 1994, ANN ALLERGY, V73, P457; SCHOELZEL EP, 1985, JAMA-J AM MED ASSOC, V253, P2046; SCHOENEICH M, 1990, CLIN EXP ALLERGY, V20, P171, DOI 10.1111/j.1365-2222.1990.tb02663.x; Schoenwetter WF, 2004, CURR MED RES OPIN, V20, P305, DOI 10.1185/030079903125003053; Schran HF, 1996, J CLIN PHARMACOL, V36, P911; Schroeder K, 2002, ARCH DIS CHILD, V86, P170, DOI 10.1136/adc.86.3.170; SCHUMACHER MJ, 1979, J ALLERGY CLIN IMMUN, V64, P202, DOI 10.1016/0091-6749(79)90096-4; SEMPREX D, 2007, ELECT MED COMPENDIUM; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; Seppala H, 1995, CLIN INFECT DIS, V21, P1378; Serrano E, 2005, J LARYNGOL OTOL, V119, P543; SETO A, 1993, REPROD TOXICOL, V7, P393, DOI 10.1016/0890-6238(93)90028-6; Seto A, 1997, AM J PERINAT, V14, P119, DOI 10.1055/s-2007-994110; SETTIPANE GA, 1985, NEW ENGL REG ALLERGY, V6, P363; Settipane RA, 2003, ALLERGY ASTHMA PROC, V24, P147; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Settipane Russell A, 2007, Clin Allergy Immunol, V19, P23; Sever ML, 2007, J ALLERGY CLIN IMMUN, V120, P849, DOI 10.1016/j.jaci.2007.07.003; Shaaban R, 2007, AM J RESP CRIT CARE, V176, P659, DOI 10.1164/rccm.200703-427OC; Shamsi Z, 2000, HUM PSYCHOPHARM CLIN, V15, pS3, DOI 10.1002/1099-1077(200010)15:1+<::AID-HUP247>3.0.CO;2-S; Shamsi Z, 2001, EUR J CLIN PHARMACOL, V56, P865, DOI 10.1007/s002280000257; Sharma K, 2006, ANN ALLERG ASTHMA IM, V97, P528; Sheahan P, 2006, RHINOLOGY, V44, P68; Sheikh A, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001563.pub2; Sheikh A, 2001, COCHRANE DB SYST REV; Shoseyov D, 1998, J ALLERGY CLIN IMMUN, V101, P602; Shulman DG, 1999, OPHTHALMOLOGY, V106, P362, DOI 10.1016/S0161-6420(99)90077-5; Shusterman D, 2001, ENVIRON HEALTH PERSP, V109, P15, DOI 10.2307/3434915; Shusterman D, 2004, NEUROPEPTIDES, V38, P351, DOI 10.1016/j.npep.2004.08.002; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; SIBERT JR, 1980, J MED GENET, V17, P39, DOI 10.1136/jmg.17.1.39; Silvers WS, 2006, ANN ALLERG ASTHMA IM, V96, P334; SILVERS WS, 1991, ANN ALLERGY, V67, P32; Simons FE, 2007, PEDIAT ALLERGY IMMUN, V18, P535, DOI 10.1111/j.1399-3038.2007.00558.x; SIMONS FE, 2002, HISTAMINE H1 ANTIHIS; Simons FER, 1999, CLIN PHARMACOKINET, V36, P329, DOI 10.2165/00003088-199936050-00003; SIMONS FER, 1994, J PEDIATR-US, V124, P979; Simons FER, 1996, ANN ALLERG ASTHMA IM, V77, P337; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P1244, DOI 10.1067/mai.2003.1496; SIMONS FER, 1982, J ALLERGY CLIN IMMUN, V70, P458, DOI 10.1016/0091-6749(82)90009-4; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P44; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; Simpson A, 2005, CURR ALLERGY ASTHM R, V5, P212, DOI 10.1007/s11882-005-0040-x; SKEDROS DG, 1993, J OTOLARYNGOL, V22, P341; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; Skoner DR, 2001, J ALLERGY CLIN IMMUN, V108, pS2, DOI 10.1067/mai.2001.115569; Slater JW, 1999, DRUGS, V57, P31, DOI 10.2165/00003495-199957010-00004; Slavin Raymond G, 2005, J Allergy Clin Immunol, V116, pS13, DOI 10.1016/j.jaci.2005.09.048; Slavin RG, 2006, ALLERGY ASTHMA PROC, V27, P9; SLAVIN RG, 2006, ACP MED ONLINE; SMITH JM, 1971, J ALLERGY, V47, P23, DOI 10.1016/S0091-6749(71)80314-7; SMITH MBH, 1993, JAMA-J AM MED ASSOC, V269, P2258, DOI 10.1001/jama.269.17.2258; Smith TL, 2005, LARYNGOSCOPE, V115, P2199, DOI 10.1097/01.mlg.0000182825.82910.80; Smith TS, 2005, ALLERGY ASTHMA PROC, V26, P356; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; Solomon W, 1998, ALLERGY PRINCIPLES P, P367; SORRI M, 1980, Rhinology (Utrecht), V18, P83; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Spangler DL, 2003, CLIN THER, V25, P2245, DOI 10.1016/S0149-2918(03)80217-5; SPECTOR SL, 1982, CLIN ALLERGY, V12, P187, DOI 10.1111/j.1365-2222.1982.tb01638.x; Spector SL, 1997, J ALLERGY CLIN IMMUN, V99, pS773, DOI 10.1016/S0091-6749(97)70126-X; Spector SL, 2003, ANN ALLERG ASTHMA IM, V91, P105; SPECTOR SL, 1994, J ALLERGY CLIN IMMUN, V94, P134, DOI 10.1016/0091-6749(94)90081-7; STAFFORD CT, 1990, OTOLARYNG HEAD NECK, V103, P870; STANLEY PJ, 1986, THORAX, V41, P519, DOI 10.1136/thx.41.7.519; Stannard W, 2004, AM J RESP CRIT CARE, V169, P634, DOI 10.1164/rccm.200306-782OC; STANWORTH DR, 1983, CLIN REV ALLERG, V1, P183; STEM RC, 1982, AM J DIS CHILD, V136, P1067; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Stern MA, 1998, ANN ALLERG ASTHMA IM, V81, P354; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stimpel M, 1998, CARDIOLOGY, V89, P271, DOI 10.1159/000006799; STJARNE P, 1989, BRIT J PHARMACOL, V96, P693; STOKES TC, 1993, CLIN EXP ALLERGY, V23, P791, DOI 10.1111/j.1365-2222.1993.tb00368.x; Stoll D, 2006, Rev Laryngol Otol Rhinol (Bord), V127, P195; Strachan DP, 1998, THORAX, V53, P117; Strenkoski-Nix LC, 2000, AM J HEALTH-SYST PH, V57, P1499; Sundberg R, 2005, RESP MED, V99, P321, DOI 10.1016/j.rmed.2004.08.006; Sunderman FW, 2001, ANN CLIN LAB SCI, V31, P3; Suryadevara AC, 2007, AM J OTOLARYNG, V28, P242, DOI 10.1016/j.amjoto.2006.08.013; Suwandhi E, 2006, PEDIATR ANN, V35, P259; SYABBALO NC, 1985, B EUR PHYSIOPATH RES, V21, P507; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tai Chih-Feng, 1998, Kaohsiung Journal of Medical Sciences, V14, P548; Takayama M, 1985, Auris Nasus Larynx, V12 Suppl 1, pS166; Talbot AR, 1997, LARYNGOSCOPE, V107, P500, DOI 10.1097/00005537-199704000-00013; TAN R, 1995, DRUG AGING, V7, P168, DOI 10.2165/00002512-199507030-00002; TANG RB, 1990, CLIN EXP ALLERGY, V20, P33, DOI 10.1111/j.1365-2222.1990.tb02772.x; Tashiro M, 2005, HUM PSYCHOPHARM CLIN, V20, P501, DOI 10.1002/hup.713; TAUDORF E, 1988, INT ARCH ALLER A IMM, V86, P225; TAYLOR G, 1971, Clinical Allergy, V1, P189, DOI 10.1111/j.1365-2222.1971.tb03018.x; TAYLOR JA, 1993, J PEDIATR-US, V122, P799, DOI 10.1016/S0022-3476(06)80031-4; THEANDER C, 1989, CLIN EXP ALLERGY, V19, P57, DOI 10.1111/j.1365-2222.1989.tb02344.x; THOMPSON AK, 2000, ANN ALLERG ASTHMA IM, V85, P47; TOGIAS A, 1985, AM J MED, V79, P26, DOI 10.1016/0002-9343(85)90084-1; Tomooka LT, 2000, LARYNGOSCOPE, V110, P1189, DOI 10.1097/00005537-200007000-00023; TONKIN SL, 1979, PEDIATRICS, V63, P261; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; TOPPOZADA H, 1982, J LARYNGOL OTOL, V96, P613, DOI 10.1017/S0022215100092902; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Toth J, 1998, ALLERGY, V53, P1172, DOI 10.1111/j.1398-9995.1998.tb03837.x; TOURVILLE DR, 1972, J ALLERGY CLIN IMMUN, V49, P245, DOI 10.1016/0091-6749(72)90087-5; Tovey ER, 2001, J ALLERGY CLIN IMMUN, V108, P369, DOI 10.1067/mai.2001.117799; TRIPATHI A, 2002, PATTERSONS ALLERGIC, P145; Troutt C, 2001, INT J BIOMETEOROL, V45, P64, DOI 10.1007/s004840100087; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; Turner RB, 1997, CLIN INFECT DIS, V25, P824, DOI 10.1086/515546; TURNERBOWKER D, 2004, NEW TOOL MONITORING; Uller L, 2004, AM J RESP CRIT CARE, V170, P742, DOI 10.1164/rccm.200402-240OC; Uzzaman A, 2006, ANN ALLERG ASTHMA IM, V97, P745; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; VAINIOMATTILA J, 1974, ACTA OTO-LARYNGOL, P1; Valero A, 2005, ALLERGY, V60, P1126, DOI 10.1111/j.1398-9995.2005.00835.x; Valoti M, 2003, METHOD FIND EXP CLIN, V25, P377, DOI 10.1358/mf.2003.25.5.769660; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214; van Cauwenberge P, 2005, Immunol Allergy Clin North Am, V25, P489, DOI 10.1016/j.iac.2005.05.001; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; van der Molen T, 1998, EUR RESPIR J, V12, P30, DOI 10.1183/09031936.98.12010030; van Wijk R. Gerth, 2005, Clinical and Experimental Allergy Reviews, V5, P32; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; van's Gravesande KS, 2005, ANN MED, V37, P439, DOI 10.1080/07853890510011985; VANAS A, 1993, J ALLERGY CLIN IMMUN, V91, P1146, DOI 10.1016/0091-6749(93)90317-9; VANSCHAYCK CP, 1992, CHEST, V102, P1384, DOI 10.1378/chest.102.5.1384; Vargas R, 1998, J ALLERGY CLIN IMMUN, V102, P191, DOI 10.1016/S0091-6749(98)70085-5; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-1; Varni JW, 2007, HEALTH QUAL LIFE OUT, V5, DOI 10.1186/1477-7525-5-2; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Ventura MT, 2007, ANN ALLERG ASTHMA IM, V99, P232; VEREEREN A, 1998, J ALLERGY CLIN IMMUN, V101, P306; Vignola AM, 1998, ALLERGY, V53, P833, DOI 10.1111/j.1398-9995.1998.tb03988.x; VILENSKY W, 1982, J FORENSIC SCI, V27, P958; Vitezic D, 2002, INT J CLIN PHARM TH, V40, P393; Vogan JC, 2000, OTOLARYNG HEAD NECK, V122, P370, DOI 10.1016/S0194-5998(00)70051-9; Volpe B T, 1991, Conn Med, V55, P571; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WACHS M, 1989, J ALLERGY CLIN IMMUN, V84, P492, DOI 10.1016/0091-6749(89)90362-X; Wagenmann M, 2005, ALLERGY, V60, P1132, DOI 10.1111/j.1398-9995.2005.00867.x; WALD ER, 1991, PEDIATRICS, V87, P129; WALD ER, 2007, UPTODATE; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wang DY, 2000, AM J RHINOL, V14, P325, DOI 10.2500/105065800781329483; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WARNER EA, 1993, ANN INTERN MED, V119, P226; WARREN R, 1981, ALCOHOL DRUGS TRAFFI, P203; WASSERFALLEN JB, 1993, J ALLERGY CLIN IMMUN, V91, P1189, DOI 10.1016/0091-6749(93)90322-7; Watanabe H, 2003, RHINOLOGY, V41, P167; Weiler JM, 2000, ANN INTERN MED, V132, P354; Weiner JM, 1998, BRIT MED J, V317, P1624; Weinstein SF, 2005, ALLERGY ASTHMA PROC, V26, P41; WELSH PW, 1987, MAYO CLIN PROC, V62, P125; WERLER MM, 1992, TERATOLOGY, V45, P361, DOI 10.1002/tera.1420450407; Werler MM, 2002, AM J EPIDEMIOL, V155, P26, DOI 10.1093/aje/155.1.26; Weschta M, 2004, J ALLERGY CLIN IMMUN, V113, P1122, DOI 10.1016/j.jaci.2004.03.038; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425; WHITE MV, 1995, J ALLERGY CLIN IMMUN, V95, P1065, DOI 10.1016/S0091-6749(95)70209-1; White P, 2004, CLIN EXP ALLERGY, V34, P1438, DOI 10.1111/j.1365-2222.2004.02055.x; WIGHT RG, 1992, CLIN OTOLARYNGOL, V17, P354, DOI 10.1111/j.1365-2273.1992.tb01012.x; Wihl JA, 1997, ALLERGY, V52, P620, DOI 10.1111/j.1398-9995.1997.tb01040.x; WILLIAMS JW, 1992, J GEN INTERN MED, V7, P481, DOI 10.1007/BF02599447; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2000, AM J RESP CRIT CARE, V162, P1297; Wilson AM, 1998, J ALLERGY CLIN IMMUN, V102, P598, DOI 10.1016/S0091-6749(98)70275-1; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x; Winther B, 2007, PEDIATRICS, V119, P1069, DOI 10.1542/peds.2006-3294; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V108, P165; Wjst M, 2005, PLOS MED, V2, P977, DOI 10.1371/journal.pmed.0020294; Wolstenholme CR, 2006, AM J RHINOL, V20, P238; WOOD CC, 1995, J ALLERGY CLIN IMMUN, V95, P1111, DOI 10.1016/S0091-6749(95)70214-8; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358; WOOD RA, 1989, J ALLERGY CLIN IMMUN, V83, P730, DOI 10.1016/0091-6749(89)90006-7; WOODBAKER R, 1993, J ALLERGY CLIN IMMUN, V91, P1005, DOI 10.1016/0091-6749(93)90213-Y; WOODFOLK JA, 1995, J ALLERGY CLIN IMMUN, V96, P325, DOI 10.1016/S0091-6749(95)70051-X; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Wroe AL, 2002, J BEHAV MED, V25, P355, DOI 10.1023/A:1015866415552; Yanez A, 2002, ANN ALLERG ASTHMA IM, V89, P479; Yang YH, 2001, ASIAN PAC J ALLERGY, V19, P171; Yaylali V, 2003, ACTA OPHTHALMOL SCAN, V81, P378, DOI 10.1034/j.1600-0420.2003.00079.x; Yewell J, 2002, ANN OTO RHINOL LARYN, V111, P174; Yilmaz M, 2006, AM J RHINOL, V20, P32; Yoo JK, 1997, LARYNGOSCOPE, V107, P40, DOI 10.1097/00005537-199701000-00010; Yung MW, 2002, ANN OTO RHINOL LARYN, V111, P1081; Zayas JG, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-9; Zeghnoun A, 2005, ARCH ENVIRON OCCUP H, V60, P170, DOI 10.3200/AEOH.60.3.170-176; ZEIGER RS, 1989, AM J RHINOL, V3, P113, DOI 10.2500/105065889782009705; ZINREICH SJ, 1994, SINUSITIS PATHOPHYSI; ZOHAR Y, 1990, J OTOLARYNGOL, V19, P345	997	453	479	8	43	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2		S			S1	S84		10.1016/j.jaci.2008.06.003		84	Allergy; Immunology	Allergy; Immunology	337HP	WOS:000258426400001	18662584	
J	Arts, ICW; Hollman, PCH				Arts, ICW; Hollman, PCH			Polyphenols and disease risk in epidemiologic studies	AMERICAN JOURNAL OF CLINICAL NUTRITION			English	Article; Proceedings Paper	1st International Conference on Poplyphenols and Health	NOV 18-21, 2004	Vichy, FRANCE			review; epidemiology; polyphenols; flavonoids; flavonols; catechins; lignans; antioxidants; phytoestrogens; cancer; cardiovascular diseases; stroke	CORONARY HEART-DISEASE; BREAST-CANCER RISK; POTENTIALLY ANTICARCINOGENIC FLAVONOIDS; CARDIOVASCULAR-DISEASE; POSTMENOPAUSAL WOMEN; PHYTOESTROGEN INTAKE; DIETARY FLAVONOIDS; UNITED-STATES; MALE SMOKERS; ANTIOXIDANT FLAVONOLS	Plant polyphenols, a large group of natural antioxidants, are serious candidates in explanations of the protective effects of vegetables and fruits against cancer and cardiovascular diseases. Epidemiologic studies are useful for evaluation of the human health effects of long-term exposure to physiologic concentrations of polyphenols, but reliable data on polyphenol contents of foods are still scarce. The aim of this review is to summarize available epidemiologic data on the health effects of polyphenols, focusing on the flavonoid subclasses of flavonols, flavones, and catechins and on lignans. Data obtained to date suggest beneficial effects of both flavonoids and lignans on cardiovascular diseases but not on cancer, with the possible exception of lung cancer. There is a need for more research on stroke and lung diseases such as asthma and chronic obstructive pulmonary disease. Most studies to date have included only flavonols and flavones. With data becoming available for other polyphenols, these compounds should be included in future studies. Careful design of prospective studies is important to offset some of the major drawbacks of epidemiologic studies, including residual confounding (by smoking and other dietary factors) and exposure assessment.	Univ Wageningen & Res Ctr, RIKILT, Inst Food Safety, NL-6700 AE Wageningen, Netherlands	Arts, ICW (reprint author), Univ Wageningen & Res Ctr, RIKILT, Inst Food Safety, POB 230, NL-6700 AE Wageningen, Netherlands.	ilja.arts@wur.nl	Arts, Ilja/C-6946-2008; Hollman, Peter/I-7446-2013	Arts, Ilja/0000-0001-6462-6692; Hollman, Peter/0000-0002-7510-6809			Adlercreutz H, 1997, ANN MED, V29, P95; Arts ICW, 2002, CANCER CAUSE CONTROL, V13, P373, DOI 10.1023/A:1015290131096; Arts ICW, 2000, J AGR FOOD CHEM, V48, P1746, DOI 10.1021/jf000025h; Arts ICW, 2000, J AGR FOOD CHEM, V48, P1752, DOI 10.1021/jf000026+; Arts ICW, 2001, EPIDEMIOLOGY, V12, P668, DOI 10.1097/00001648-200111000-00015; Arts ICW, 2001, AM J CLIN NUTR, V74, P227; Arts ICW, 2001, INT J CANCER, V92, P298, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1187>3.0.CO;2-8; Burke V, 1997, PREV MED, V26, P724, DOI 10.1006/pmed.1997.0198; Dai Q, 2003, CANCER EPIDEM BIOMAR, V12, P497; Dai Q, 2002, CANCER EPIDEM BIOMAR, V11, P815; de Kleijn MJJ, 2001, J NUTR, V131, P1826; de Kleijn MJJ, 2002, J NUTR, V132, P276; den Tonkelaar I, 2001, CANCER EPIDEM BIOMAR, V10, P223; Geleijnse JM, 2002, AM J CLIN NUTR, V75, P880; GOLDBOHM RA, 1998, POLYPHENOLS FOOD, P159; Heinonen S, 2001, J AGR FOOD CHEM, V49, P3178, DOI 10.1021/jf010038a; HERTOG MGL, 1994, NUTR CANCER, V22, P175; Hertog MGL, 1997, AM J CLIN NUTR, V65, P1489; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Hertog MGL, 1997, LANCET, V349, P699, DOI 10.1016/S0140-6736(05)60135-3; HERTOG MGL, 1992, J AGR FOOD CHEM, V40, P2379, DOI 10.1021/jf00024a011; HERTOG MGL, 1993, J AGR FOOD CHEM, V41, P1242, DOI 10.1021/jf00032a015; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Hirvonen T, 2001, CANCER CAUSE CONTROL, V12, P789, DOI 10.1023/A:1012232008016; Hirvonen T, 2000, STROKE, V31, P2301; Hirvonen T, 2001, EPIDEMIOLOGY, V12, P62, DOI 10.1097/00001648-200101000-00011; Hollman PCH, 2001, FREE RADICAL RES, V34, P297, DOI 10.1080/10715760100300261; Hollman PCH, 2000, J SCI FOOD AGR, V80, P1081, DOI 10.1002/(SICI)1097-0010(20000515)80:7<1081::AID-JSFA566>3.0.CO;2-G; Horn-Ross PL, 2001, AM J EPIDEMIOL, V154, P434, DOI 10.1093/aje/154.5.434; Horn-Ross PL, 2002, CANCER CAUSE CONTROL, V13, P407, DOI 10.1023/A:1015786030864; Horn-Ross PL, 2003, J NATL CANCER I, V95, P1158, DOI 10.1093/jnci/djg015; Horn-Ross PL, 2002, CANCER EPIDEM BIOMAR, V11, P43; Horn-Ross PL, 2000, CANCER CAUSE CONTROL, V11, P289, DOI 10.1023/A:1008995606699; HULSHOF KFAM, 1992, J EPIDEMIOL COMMUN H, V46, P417, DOI 10.1136/jech.46.4.417; Hulten K, 2002, EUR J NUTR, V41, P168, DOI 10.1007/s00394-002-0373-3; Ingram D, 1997, LANCET, V350, P990, DOI 10.1016/S0140-6736(97)01339-1; Keli SO, 1996, ARCH INTERN MED, V156, P637, DOI 10.1001/archinte.156.6.637; Knekt P, 2002, AM J CLIN NUTR, V76, P560; Knekt P, 1997, AM J EPIDEMIOL, V146, P223; Knekt P, 1996, BRIT MED J, V312, P478; Law MR, 1998, EUR J CLIN NUTR, V52, P549, DOI 10.1038/sj.ejcn.1600603; Le Marchand L, 2000, JNCI-J NATL CANCER I, V92, P154, DOI 10.1093/jnci/92.2.154; Marshall JR, 1996, AM J EPIDEMIOL, V143, P1069; McCann SE, 2002, J NUTR, V132, P3036; McCann SE, 2003, J NUTR, V133, P1937; MCPHILLIPS JB, 1994, J AM DIET ASSOC, V94, P287, DOI 10.1016/0002-8223(94)90370-0; Milder IEJ, 2004, J AGR FOOD CHEM, V52, P4643, DOI 10.1021/jf0497556; Nesbitt PD, 1999, AM J CLIN NUTR, V69, P549; Nijveldt RJ, 2001, AM J CLIN NUTR, V74, P418; Olthof MR, 2003, J NUTR, V133, P1806; Peters U, 2001, AM J EPIDEMIOL, V154, P495, DOI 10.1093/aje/154.6.495; Pietinen P, 2001, CANCER EPIDEM BIOMAR, V10, P339; Pillow PC, 1999, NUTR CANCER, V33, P3; Riboli E., 1996, IARC SCI PUBL, P23; Rimm EB, 1996, ANN INTERN MED, V125, P384; Sesso HD, 2003, AM J CLIN NUTR, V77, P1400; Stattin P, 2002, INT J CANCER, V99, P124, DOI 10.1002/ijc.10313; Strom SS, 1999, NUTR CANCER, V33, P20; Stumpf K, 2000, ANAL BIOCHEM, V284, P153, DOI 10.1006/abio.2000.4655; Tabak C, 2001, AM J RESP CRIT CARE, V164, P61; Tjonneland A, 1999, AM J CLIN NUTR, V69, P49; Tsubono Y, 1997, PREV MED, V26, P704, DOI 10.1006/pmed.1997.0194; van der Schouw YT, 2002, ARTERIOSCL THROM VAS, V22, P1316, DOI 10.1161/01.ATV.0000027176.83618.1A; Vanharanta M, 1999, LANCET, V354, P2112, DOI 10.1016/S0140-6736(99)05031-X; Vanharanta M, 2003, ARCH INTERN MED, V163, P1099, DOI 10.1001/archinte.163.9.1099; Vanharanta M, 2002, ATHEROSCLEROSIS, V160, P465, DOI 10.1016/S0021-9150(01)00603-7; VEENSTRA J, 1993, EUR J CLIN NUTR, V47, P482; Walcott FL, 2002, NUTR CANCER, V44, P44, DOI 10.1207/S15327914NC441_6; *WORLD CANC RES FU, 1997, FOOD NUTR PREV CANC, P436; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; Yochum L, 1999, AM J EPIDEMIOL, V149, P943	71	452	469	3	59	AMER SOC CLINICAL NUTRITION	BETHESDA	9650 ROCKVILLE PIKE, SUBSCRIPTIONS, RM L-3300, BETHESDA, MD 20814-3998 USA	0002-9165			AM J CLIN NUTR	Am. J. Clin. Nutr.	JAN	2005	81	1		S			317S	325S				9	Nutrition & Dietetics	Nutrition & Dietetics	888VB	WOS:000226401200015		
J	Gereda, JE; Leung, DYM; Thatayatikom, A; Streib, JE; Price, MR; Klinnert, MD; Liu, AH				Gereda, JE; Leung, DYM; Thatayatikom, A; Streib, JE; Price, MR; Klinnert, MD; Liu, AH			Relation between house-dust endotoxin exposure, type 1 T cell development, and allergen sensitisation in infants at high risk of asthma	LANCET			English	Article							INTERFERON-GAMMA PRODUCTION; BLOOD MONONUCLEAR-CELLS; PERIPHERAL-BLOOD; CHILDREN; ATOPY; PREVALENCE; SENSITIZATION; ASSOCIATION; RESPONSES; INTERLEUKIN-4	Background Bacterial endotoxin is known to induce interferon gamma and interleukin 12 production, and therefore has the potential to decrease allergen sensitisation. To find out the role of early chronic endotoxin exposure in the development of allergen sensitisation and asthma, we compared concentrations of endotoxin in house dust with allergen sensitisation in infants at high risk for developing asthma. Methods 61 infants 9-24 months old with at. least three physician-documented episodes of wheezing were studied. Concentrations of house-dust endotoxin and allergens were measured in the infants' homes. Allergen sensitisation was measured by skin-prick testing with a panel of common inhalant and food allergens. In a subset of these infants, proportions of T lymphocytes producing interferon gamma, and interleukins 4, 5, and 13 were calculated by cell-surface and intracellular cytokine staining, with flow cytometry. Findings House-dust endotoxin concentrations ranged from 104 to 10 000 endotoxin units (EU) per mt (geometric mean 912 EU/mL). Concentrations did not vary significantly over a 6-month interval. Ten infants (16%) were sensitised to at least one allergen. The homes of allergen-sensitised infants contained significantly lower concentrations of house-dust endotoxin than those of non-sensitised infants (mean 468 vs 1035 EU/mL, respectively; p=0.01). Increased house-dust endotoxin concentrations correlated with increased proportions of interferon-gamma-producing CD4 T cells (p=0.01). Such concentrations did not correlate with proportions of cells that produced interleukins 4, 5, or 13. Interpretation This study may provide the first direct in-vivo evidence that indoor endotoxin exposure early in life may protect against allergen sensitisation by enhancing type 1 immunity.	Natl Jewish Med & REs Ctr, Dept Behav Sci, Denver, CO 80206 USA; Natl Jewish Med & REs Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Liu, AH (reprint author), Natl Jewish Med & REs Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Denver, CO 80206 USA.				NCRR NIH HHS [M01-RR00051]; NHLBI NIH HHS [HL-36577]; NIAID NIH HHS [R18AI41137]		Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DONHAM K, 1989, BRIT J IND MED, V46, P31; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; LE JM, 1986, J IMMUNOL, V136, P4525; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; PAUL WE, 1994, CELL, V76, P241, DOI 10.1016/0092-8674(94)90332-8; PLATTMILLS TAE, 1995, RELEVANCE INDOOR ALL, P111; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WEISS K, 1992, CHEST, V6, pS362; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273	35	449	463	2	9	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 13	2000	355	9216					1680	1683		10.1016/S0140-6736(00)02239-X		4	Medicine, General & Internal	General & Internal Medicine	313CY	WOS:000086983800010	10905243	
J	Lau, S; Illi, S; Sommerfeld, C; Niggemann, B; Bergmann, R; von Mutius, E; Wahn, U				Lau, S; Illi, S; Sommerfeld, C; Niggemann, B; Bergmann, R; von Mutius, E; Wahn, U		Multicentre Allergy Study Grp	Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study	LANCET			English	Article							SKIN-TEST REACTIVITY; RISK FACTOR; SENSITIZATION; CHILDREN; ASSOCIATION; ALTITUDE; FEL-D-1	Background In a prospective birth-cohort study, we assessed the relevance of mite and cat allergen exposure for the development of childhood asthma up to age 7 years. Methods Of 1314 newborn infants enrolled in five German cities in 1990, follow-up data at age 7 years were available far 939 children. Assessments included repeated measurement of specific IgE to food and inhalant allergens, measurement of indoor allergen exposure at 6 months, 18 months, and 3 years of age, and yearly interviews by a paediatrician. At age 7 years, pulmonary function was tested and bronchial hyper-responsiveness was measured in 645 children. Findings At age 7, the prevalence of wheezing in the past 12 months was 10.0% (94 of 938), and 6.1% (57 of 939) parents reported a doctor's diagnosis of asthma in their children. Sensitisation to indoor allergens was associated with asthma, wheeze, and increased bronchial responsiveness. However, no relation between early indoor allergen exposure and the prevalence of asthma, wheeze, and bronchial hyper-responsiveness was seen. Interpretation Our data do not support the hypothesis that exposure to environmental allergens causes asthma in childhood, but rather that the induction of specific IgE responses and the development of childhood asthma are determined by independent factors.	Humboldt Univ, Dept Paediat Pneumol & Immunol, Berlin, Germany; Univ Munich, Childrens Hosp, D-8000 Munich, Germany	Lau, S (reprint author), Charite Virchow Klinikum, Klin Padiat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Custovic A, 1998, J ALLERGY CLIN IMMUN, V101, pS81; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Demissie K, 1996, THORAX, V51, P59, DOI 10.1136/thx.51.1.59; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KUHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655; KUHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; MATTHYS H, 1993, RESPIRATION, V60, P343; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Peterson EL, 1999, J ALLERGY CLIN IMMUN, V104, P348, DOI 10.1016/S0091-6749(99)70378-7; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shaheen SO, 1999, CLIN EXP ALLERGY, V29, P291; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	35	445	462	6	26	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 21	2000	356	9239					1392	1397		10.1016/S0140-6736(00)02842-7		6	Medicine, General & Internal	General & Internal Medicine	365XQ	WOS:000089976100012	11052581	
J	Brunekreef, B; Forsberg, B				Brunekreef, B; Forsberg, B			Epidemiological evidence of effects of coarse airborne particles on health	EUROPEAN RESPIRATORY JOURNAL			English	Review						air pollution; coarse particles; epidemiology; morbidity; mortality	PARTICULATE AIR-POLLUTION; SOUTHERN CALIFORNIA CHILDREN; LUNG-FUNCTION GROWTH; DAILY MORTALITY; HOSPITAL ADMISSIONS; FINE PARTICLES; URBAN AIR; RESPIRATORY-DISEASES; TIME-SERIES; ASSOCIATION	Studies on health effects of airborne particulate matter (PM) have traditionally focused on particles <10 mu m in diameter (PM10) or particles <2.5 mu m in diameter (PM2.5). The coarse fraction of PM10, particles >2.5 mu m, has only been studied recently. These particles have different sources and composition compared with PM2.5. This paper is based on a systematic review of studies that have analysed fine and coarse PM jointly and examines the epidemiological evidence for effects of coarse particles on health. Time series studies relating ambient PM to mortality have in some places provided evidence of an independent effect of coarse PM on daily mortality, but in most urban areas, the evidence is stronger for fine particles. The few long-term studies of effects of coarse PM on survival do not provide any evidence of association. In studies of chronic obstructive pulmonary disease, asthma and respiratory admissions, coarse PM has a stronger or as strong short-term effect as fine PM, suggesting that coarse PM may lead to adverse responses in the lungs triggering processes leading to hospital admissions. There is also support for an association between coarse PM and cardiovascular admissions. It is concluded that special consideration should be given to studying and regulating coarse particles separately from fine particles.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden	Brunekreef, B (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.	b.brunekreef@iras.uu.nl		brunekreef, bert/0000-0001-9908-0060			Anderson HR, 2005, EPIDEMIOLOGY, V16, P155, DOI 10.1097/01.ede.0000152528.22746.0f; Anderson HR, 2001, OCCUP ENVIRON MED, V58, P504, DOI 10.1136/oem.58.8.504; Becker S, 2003, EXP LUNG RES, V29, P29, DOI 10.1080/01902140390116535; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Berner A, 2004, ATMOS ENVIRON, V38, P3959, DOI 10.1016/j.atmoenv.2004.02.056; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; Burnett RT, 2000, INHAL TOXICOL, V12, P15, DOI 10.1080/089583700750019495; Burnett R. T., 2003, REVISED ANAL TIME SE, P85; Castillejos M, 2000, INHAL TOXICOL, V12, P61, DOI 10.1080/089583700196392; Chen Y, 2004, INHAL TOXICOL, V16, P21, DOI 10.1080/0895837049258129; Cifuentes LA, 2000, J AIR WASTE MANAGE, V50, P1287; Claiborn CS, 2000, J AIR WASTE MANAGE, V50, P1440, DOI 10.1080/10473289.2000.10464179; Diociaiuti M, 2001, ENVIRON RES, V86, P254, DOI 10.1006/enrs.2001.4275; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; EPA United States Environmental Protection Agency, 2004, AIR QUAL CRIT PART M; Fairley D, 1999, ENVIRON HEALTH PERSP, V107, P637, DOI 10.2307/3434455; Fairley D, 2003, REVISED ANAL TIME SE, P97; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gordian ME, 1996, ENVIRON HEALTH PERSP, V104, P290, DOI 10.2307/3432887; HEFFLIN BJ, 1994, ARCH ENVIRON HEALTH, V49, P170; Heinrich J, 2003, ATMOS ENVIRON, V37, P3659, DOI 10.1016/S1352-2310(03)00467-9; *HLTH EFF I, 2003, REV AN TIM SER STUD; Hsiao WLW, 2000, MUTAT RES-GEN TOX EN, V471, P45; Ilabaca M, 1999, J AIR WASTE MANAGE, V49, P154; Ito K, 2003, REVISED ANAL TIME SE, P143; Klemm RJ, 2000, J AIR WASTE MANAGE, V50, P1433, DOI 10.1080/10473289.2000.10464188; Klemm RJ, 2000, J AIR WASTE MANAGE, V50, P1215; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; Lipfert FW, 2000, J AIR WASTE MANAGE, V50, P1501; Lippmann M., 2003, RES REP HLTH EFF I, P5; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; MAR TF, 2003, REVISED ANAL TIME SE, P177; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; Monn C, 2001, ATMOS ENVIRON, V35, P1, DOI 10.1016/S1352-2310(00)00330-7; Moolgavkar SH, 2000, J AIR WASTE MANAGE, V50, P1199; OSTRO B, 2003, REVISED ANAL TIME SE, P199; Ostro BD, 2000, J EXPO ANAL ENV EPID, V10, P412, DOI 10.1038/sj.jea.7500094; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Sheppard L., 2003, REVISED ANAL TIME SE, P227; Shi T, 2003, OCCUP ENVIRON MED, V60, P315, DOI 10.1136/oem.60.5.315; SLAUGHTER JC, 2004, J EXPO ANAL ENV EPID; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; Tolbert PE, 2000, J EXPO ANAL ENV EPID, V10, P446, DOI 10.1038/sj.jea.7500106; Venkataraman C, 1999, INHAL TOXICOL, V11, P151, DOI 10.1080/089583799197221; Villeneuve PJ, 2003, J EXPO ANAL ENV EPID, V13, P427, DOI 10.1038/sj.jea.7500292; Wilson WE, 1997, J AIR WASTE MANAGE, V47, P1238; Zhang JF, 2002, ENVIRON HEALTH PERSP, V110, P961	58	440	451	33	154	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	AUG	2005	26	2					309	318		10.1183/09031936.05.00001805		10	Respiratory System	Respiratory System	950RD	WOS:000230874000020	16055881	
J	Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S				Matricardi, PM; Rosmini, F; Riondino, S; Fortini, M; Ferrigno, L; Rapicetta, M; Bonini, S			Exposure to foodborne and orofecal microbes versus airborne viruses in relation to atopy and allergic asthma: epidemiological study	BRITISH MEDICAL JOURNAL			English	Article							FAMILY-SIZE; SERUM IGE; ASSOCIATION; INFECTIONS; PREVALENCE; CHILDHOOD; DISEASES; HYGIENE; CELLS; FLORA	Objective To investigate if markers of exposure to foodborne and orofecal microbes versus airborne viruses are associated with atopy and respiratory allergies. Design Retrospective case-control study. Participants 240 atopic cases and 240 non-atopic controls from a population sample of 1659 participants, all Italian male cadets aged 17-24. Setting Air force school in Caserta, Italy. Main outcome measures Serology for Toxoplasma gondii, Helicobacter pylori, hepatitis A virus, measles, mumps, rubella, chickenpox, cytomegalovirus, and herpes simplex virus type 1; skin sensitisation and IgE antibodies to relevant airborne allergens; total IgE concentration; and diagnosis of allergic asthma or rhinitis, Results Compared with controls there tvas a lower prevalence of T gondii (26% v 18%, P = 0.027), hepatitis A virus (30% v 16%, P = 0.004), and H pylori (18% v 15%, P = 0.325) in atopic participants. Adjusted odds ratios of atopy decreased with a gradient of exposure to H pylori, T gondii, and hepatitis A virus (none, odds ratio 1; one, 0.70; two or three, 0.37; P for trend = 0.000045) but not with cumulative exposure to the other viruses. Conversely, total IgE concentration was not independently associated with any infection. Allergic asthma was rare (1/245, 0.4%) and allergic rhinitis infrequent (16/245, 7%) among the participants (245/1659) exposed to at least two orofecal and foodborne infections (H pylori, T gondii, hepatitis A virus). Conclusion Respiratory allergy is less frequent in people heavily exposed to orofecal and foodborne microbes. Hygiene and a westernised, semisterile diet may facilitate atopy by influencing the overall pattern of commensals and pathogens that stimulate the gut associated lymphoid tissue thus contributing to the epidemic of allergic asthma and rhinitis in developed countries.	Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy; Ist Super Sanita, Virol Lab, I-00161 Rome, Italy; CNR, Ist Med Sperimentale, I-00137 Rome, Italy	Matricardi, PM (reprint author), Div Aerea Studi Ric & Sperimentaz, Lab Immunol & Allergol, I-00040 Pomezia, Italy.			Bonini, Sergio/0000-0003-0079-3031			AIM JS, 1997, LANCET, V350, P400; ALM J, 1999, LANCET, V353, P1483; Beaman MH, 1995, PRINCIPLES PRACTICE, P2455; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bodner C, 1998, THORAX, V53, P28; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; DIXON WJ, 1990, BMDP STAT SOFTWARE, V2; Dominici P, 1999, BRIT MED J, V319, P537; Dore MP, 1999, LANCET, V354, P132, DOI 10.1016/S0140-6736(99)01724-9; DURKIN HG, 1989, J IMMUNOL, V143, P1777; Goodwin CS, 1997, LANCET, V349, P265, DOI 10.1016/S0140-6736(96)07023-7; Grubel P, 1998, LANCET, V352, P788, DOI 10.1016/S0140-6736(05)60683-6; *GRUPP STUD INT SO, 1996, VACC IT; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1996, TOXICOL LETT, V86, P199; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; MATRICARDI PM, 1994, J ALLERGY CLIN IMMUN, V93, P68, DOI 10.1016/0091-6749(94)90234-8; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; Matricardi PM, 1997, BRIT MED J, V314, P999; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sousa CRE, 1997, J EXP MED, V186, P1819, DOI 10.1084/jem.186.11.1819; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1999, LANCET, V353, P1457, DOI 10.1016/S0140-6736(99)90038-7; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sudo N, 1997, J IMMUNOL, V159, P1739; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wold AE, 1998, ALLERGY, V53, P20; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	36	440	453	5	39	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	FEB 12	2000	320	7232					412	417		10.1136/bmj.320.7232.412		6	Medicine, General & Internal	General & Internal Medicine	285EU	WOS:000085377400022	10669445	
J	Leung, DYM				Leung, DYM			Atopic dermatitis: New insights and opportunities for therapeutic intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; keratinocytes; T cells; hypersensitivity; skin; allergy; superantigens; IgE	DOSE INTRAVENOUS IMMUNOGLOBULIN; LYMPHOCYTE-ASSOCIATED ANTIGEN; EPIDERMAL LANGERHANS CELLS; COLONY-STIMULATING FACTOR; INTERFERON-GAMMA-THERAPY; HIGH-AFFINITY RECEPTOR; IN-VIVO EXPRESSION; HOUSE-DUST MITE; MEMORY T-CELLS; FC-EPSILON-RI	Atopic dermatitis (AD) is a chronic inflammatory skin disease that frequently predates the development of allergic rhinitis or asthma. It is an important skin condition with significant costs and morbidity to patients and their families; the disease affects more than 10% of children. Recent studies have demonstrated the complex interrelationship of genetic, environmental, skin barrier, pharmacologic, psychologic, and immunologic factors that contribute to the development and severity of AD. The current review will examine the cellular and molecular mechanisms that contribute to AD as well as the immunologic triggers involved in its pathogenesis. These insights provide new opportunities for therapeutic intervention in this common skin condition.	Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	Leung, DYM (reprint author), Natl Jewish Med & Res Ctr, Div Pediat Allergy Immunol, 1400 Jackson St,Room K926, Denver, CO 80206 USA.				NHLBI NIH HHS [HL36577, HL37260]; NIAMS NIH HHS [AR41256]		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 1999, J IMMUNOL, V163, P466; BACK O, 1995, ARCH DERMATOL RES, V287, P448, DOI 10.1007/BF00373427; Beltrani VS, 1999, J ALLERGY CLIN IMMUN, V104, pS87, DOI 10.1016/S0091-6749(99)70050-3; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; BRATTOND L, 1999, J ALLERGY CLIN IMMUN, V103, P895; Bright JJ, 1999, J LEUKOCYTE BIOL, V65, P665; Bruijnzeel-Koomen CAFM, 1986, ARCH DERMATOL RES, V278, P199; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Carucci JA, 1998, ARCH DERMATOL, V134, P785, DOI 10.1001/archderm.134.7.785; Cheng JF, 1997, J ALLERGY CLIN IMMUN, V99, P683, DOI 10.1016/S0091-6749(97)70031-9; CLARK RAF, 1989, CLIN IMMUNOL IMMUNOP, V53, pS132, DOI 10.1016/0090-1229(89)90078-0; CLAYTON MH, 1995, J ALLERGY CLIN IMMUN, V96, P421, DOI 10.1016/S0091-6749(95)70062-5; de Vries IJM, 1998, J ALLERGY CLIN IMMUN, V102, P461, DOI 10.1016/S0091-6749(98)70136-8; Dinarello CA, 1999, J ALLERGY CLIN IMMUN, V103, P11, DOI 10.1016/S0091-6749(99)70518-X; Dworzak MN, 1999, J ALLERGY CLIN IMMUN, V103, P901, DOI 10.1016/S0091-6749(99)70436-7; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Ellis CN, 1999, CLIN IMMUNOL, V92, P49, DOI 10.1006/clim.1999.4731; Fischer B, 1999, J ALLERGY CLIN IMMUN, V104, P836; Fleischer AB, 1999, J ALLERGY CLIN IMMUN, V104, pS126, DOI 10.1016/S0091-6749(99)70055-2; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066; Fung AYP, 1999, INT J DERMATOL, V38, P387, DOI 10.1046/j.1365-4362.1999.00732.x; GARRONE P, 1991, EUR J IMMUNOL, V21, P1365, DOI 10.1002/eji.1830210606; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Grassberger M, 1999, BRIT J DERMATOL, V141, P264; Grewe M, 1998, J IMMUNOL, V161, P415; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HAGERMARK O, 1972, ACTA DERM-VENEREOL, V52, P125; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HAMPTON STANLEY F., 1941, JOUR ALLERGY, V13, P63, DOI 10.1016/S0021-8707(41)90008-4; Hanifin JM, 1999, J ALLERGY CLIN IMMUN, V104, pS123, DOI 10.1016/S0091-6749(99)70054-0; Hanifin JM, 1996, J INVEST DERMATOL, V107, P51, DOI 10.1111/1523-1747.ep12297888; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; HASHEM N, 1963, LANCET, V2, P269; HAUK PJ, 2000, J ALLERGY CLIN IMMUN, V105, P726; HAUSER C, 1989, EUR J IMMUNOL, V19, P2435; HERRSCHER RF, 1992, J CLIN INVEST, V90, P596, DOI 10.1172/JCI115898; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Hofer MF, 1998, J ALLERGY CLIN IMMUN, V101, P96, DOI 10.1016/S0091-6749(98)70199-X; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P523, DOI 10.1111/1523-1747.ep12470233; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P44, DOI 10.1016/S0091-6749(05)80039-9; Jirapongsananuruk O, 1998, J IMMUNOL, V160, P4622; Jolles S, 1999, J AM ACAD DERMATOL, V40, P121, DOI 10.1016/S0190-9622(99)70544-X; JURGENS M, 1995, J IMMUNOL, V155, P5184; KANE JA, 1995, GUT, V36, P146, DOI 10.1136/gut.36.1.146; Kawashima T, 1998, J MED GENET, V35, P502, DOI 10.1136/jmg.35.6.502; Keane FM, 1999, BRIT MED J, V318, P563; Keller P, 1924, ARCH DERMATOL SYPH-G, V148, P82, DOI 10.1007/BF01827500; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; Kimura M, 1998, J ALLERGY CLIN IMMUN, V102, P238, DOI 10.1016/S0091-6749(98)70092-2; KINO T, 1987, J ANTIBIOT, V40, P1249; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; Kodama A, 1999, J ALLERGY CLIN IMMUN, V104, P173, DOI 10.1016/S0091-6749(99)70130-2; Kolmer HL, 1996, J ALLERGY CLIN IMMUN, V98, P702, DOI 10.1016/S0091-6749(96)70106-9; Koro O, 1999, J ALLERGY CLIN IMMUN, V103, P663, DOI 10.1016/S0091-6749(99)70240-X; Kraft S, 1998, J IMMUNOL, V161, P1000; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Kusunoki T, 1999, J ALLERGY CLIN IMMUN, V103, P1148, DOI 10.1016/S0091-6749(99)70191-0; Laberge S, 1998, J ALLERGY CLIN IMMUN, V102, P645, DOI 10.1016/S0091-6749(98)70282-9; Lacy P, 1999, BLOOD, V94, P23; Leung DYM, 1999, J ALLERGY CLIN IMMUN, V104, pS99, DOI 10.1016/S0091-6749(99)70051-5; LEUNG DYM, 1995, J ALLERGY CLIN IMMUN, V96, P302, DOI 10.1016/S0091-6749(95)70049-8; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1987, CLIN IMMUNOL IMMUNOP, V42, P328, DOI 10.1016/0090-1229(87)90021-3; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEUNG DYM, 1998, DERMATOLOGY GEN MED, P1464; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; MAGNARIN M, 1995, J ALLERGY CLIN IMMUN, V96, P200, DOI 10.1016/S0091-6749(95)70009-9; Maurer D, 1996, J IMMUNOL, V157, P607; MAUSER PJ, 1993, AM REV RESPIR DIS, V148, P1623; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAZER BD, 1991, J ALLERGY CLIN IMMUN, V87, P976, DOI 10.1016/0091-6749(91)90420-S; Mekori YA, 1999, J ALLERGY CLIN IMMUN, V104, P517, DOI 10.1016/S0091-6749(99)70316-7; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; NASSIF A, 1994, ARCH DERMATOL, V130, P1402, DOI 10.1001/archderm.130.11.1402; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; Novak N, 1999, ALLERGY, V54, P792, DOI 10.1034/j.1398-9995.1999.00101.x; Ochiai K, 1999, CLIN EXP IMMUNOL, V118, P340; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Ohki O, 1997, BRIT J DERMATOL, V136, P838, DOI 10.1111/j.1365-2133.1997.tb03922.x; Pastore S, 1997, J CLIN INVEST, V99, P3009, DOI 10.1172/JCI119496; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; PAUKKONEN K, 1993, ACTA DERM-VENEREOL, V73, P141; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; PINCELLI C, 1990, BRIT J DERMATOL, V122, P745, DOI 10.1111/j.1365-2133.1990.tb06261.x; Pucci N, 2000, J ALLERGY CLIN IMMUN, V105, P353, DOI 10.1016/S0091-6749(00)90087-3; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; Reitamo S, 1998, J INVEST DERMATOL, V111, P396, DOI 10.1046/j.1523-1747.1998.00323.x; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rukwied R, 1999, EXP DERMATOL, V8, P39, DOI 10.1111/j.1600-0625.1999.tb00346.x; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Santamaria Babi L F, 1995, J Exp Med, V181, P1935, DOI 10.1084/jem.181.5.1935; Santamaria LF, 1999, J INVEST DERMATOL, V113, P82, DOI 10.1046/j.1523-1747.1999.00639.x; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Shimada Y, 1999, J ALLERGY CLIN IMMUN, V104, P163, DOI 10.1016/S0091-6749(99)70128-4; Shimizu T, 1999, J ALLERGY CLIN IMMUN, V104, P659, DOI 10.1016/S0091-6749(99)70339-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; SIGURS N, 1992, PEDIATRICS, V89, P735; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; Skov L, 2000, J ALLERGY CLIN IMMUN, V105, P820, DOI 10.1067/mai.2000.105524; SOTER NA, 1983, J INVEST DERMATOL, V80, P115, DOI 10.1111/1523-1747.ep12531738; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Spahn JD, 1999, J ALLERGY CLIN IMMUN, V103, P421, DOI 10.1016/S0091-6749(99)70466-5; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Taha RA, 1998, J ALLERGY CLIN IMMUN, V102, P245, DOI 10.1016/S0091-6749(98)70093-4; TAHA RA, 1998, J ALLERGY CLIN IMMUN, V101, pA946; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TOBIN D, 1992, J ALLERGY CLIN IMMUN, V90, P613, DOI 10.1016/0091-6749(92)90134-N; TUFT L, 1952, J ALLERGY, V23, P528, DOI 10.1016/0021-8707(52)90040-3; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Van Leent EJM, 1998, ARCH DERMATOL, V134, P805, DOI 10.1001/archderm.134.7.805; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WAHLGREN CF, 1995, ARCH DERMATOL RES, V287, P572, DOI 10.1007/BF00374079; Walker IC, 1918, J AMER MED ASSOC, V70, P897; Wheatley LM, 2000, ALLERGIC SKIN DIS MU, P423; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Yamada H, 1997, INT ARCH ALLERGY IMM, V114, P28; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	147	439	459	4	33	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2000	105	5					860	876		10.1067/mai.2000.106484		17	Allergy; Immunology	Allergy; Immunology	316TW	WOS:000087185000002	10808164	
J	Suissa, S				Suissa, Samy			Immortal time bias in pharmacoepidemiology	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						bias (epidemiology); cohort studies; databases; epidemiologic methods; pharmaceutical preparations; relative biological effectiveness; statistics; treatment outcome	OBSTRUCTIVE PULMONARY-DISEASE; ACUTE MYOCARDIAL-INFARCTION; INHALED CORTICOSTEROIDS; CARDIAC TRANSPLANTATION; ASTHMA; RISK; MORTALITY; SURVIVAL; COPD; STEROIDS	Immortal time is a span of cohort follow-up during which, because of exposure definition, the outcome under study could not occur. Bias from immortal time was first identified in the 1970s in epidemiology in the context of cohort studies of the survival benefit of heart transplantation. It recently resurfaced in pharmacoepidemiology, with several observational studies reporting that various medications can be extremely effective at reducing morbidity and mortality. These studies, while using different cohort designs, all involved some form of immortal time and the corresponding bias. In this paper, the author describes various cohort study designs leading to this bias, quantifies its magnitude under different survival distributions, and illustrates it by using data from a cohort of lung cancer patients. The author shows that for time-based, event-based, and exposure-based cohort definitions, the bias in the rate ratio resulting from misclassified or excluded immortal time increases proportionately to the duration of immortal time. The bias is more pronounced with a decreasing hazard function for the outcome event, as illustrated with the Weibull distribution compared with a constant hazard from the exponential distribution. In conclusion, observational studies of drug benefit in which computerized databases are used must be designed and analyzed properly to avoid immortal time bias.	[Suissa, Samy] McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; [Suissa, Samy] McGill Univ, Dept Med, Montreal, PQ, Canada	Suissa, S (reprint author), Royal Victoria Hosp, McGill Pharmacoepidemiol Res Unit, 687 pine Ave W,Ross 4-29, Montreal, PQ H3A 1A1, Canada.	samy.suissa@clinepi.mcgill.ca					Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Adams RJ, 2001, PEDIATRICS, V107, P706, DOI 10.1542/peds.107.4.706; CHERRY DK, 2002, NATL AMBULATORY MED, P1; CLARK DA, 1971, ANN INTERN MED, V75, P15; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; DUCK BW, 1975, LANCET, V2, P1197; ELLWOOD PM, 1988, NEW ENGL J MED, V318, P1549, DOI 10.1056/NEJM198806093182329; ENTERLINE PE, 1976, J OCCUP ENVIRON MED, V18, P150, DOI 10.1097/00043764-197603000-00006; EPTSTEIN AM, 1990, NEW ENGL J MED, V323, P266; GAIL MH, 1972, ANN INTERN MED, V76, P815; Gail M. H., 2000, ENCY EPIDEMIOLOGIC M; Gelfand JM, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P337; Glesby MJ, 1996, ANN INTERN MED, V124, P999; Kiri VA, 2005, AM J RESP CRIT CARE, V172, P460, DOI 10.1164/rccm.200502-210OC; Mamdani M, 2003, ARCH INTERN MED, V163, P481, DOI 10.1001/archinte.163.4.481; MANCUSO TF, 1967, JOM-J OCCUP MED, V9, P147; MANTEL N, 1974, J AM STAT ASSOC, V69, P81, DOI 10.2307/2285503; MESSMER BJ, 1969, LANCET, V1, P954; Redelmeier DA, 2001, ANN INTERN MED, V134, P955; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; Robins JM, 2000, BIOMETRICS, V56, P779, DOI 10.1111/j.0006-341X.2000.00779.x; Rochon PA, 2000, LANCET, V356, P639, DOI 10.1016/S0140-6736(00)02606-4; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Samet JM, 2003, AM J RESP CRIT CARE, V168, P1, DOI 10.1164/rccm.2304004; Sin DD, 2001, AM J RESP CRIT CARE, V164, P580; Soriano JB, 2002, EUR RESPIR J, V20, P819, DOI 10.1183/09031936.02.00301302; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Strom BL, 2005, PHARMACOEPIDEMIOLOGY, 4TH EDITION, P1; Suissa S, 2006, AM J RESP CRIT CARE, V173, P464; Suissa S, 2005, J ALLERGY CLIN IMMUN, V115, P714, DOI 10.1016/j.jaci.2004.12.1118; Suissa S, 2004, EUR RESPIR J, V23, P391, DOI 10.1183/09031936.04.00062504; Suissa S, 2003, AM J RESP CRIT CARE, V168, P49, DOI 10.1164/rccm.200210-1231OC; Suissa S, 2003, THORAX, V58, P43, DOI 10.1136/thorax.58.1.43; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Suissa S, 2007, PHARMACOEPIDEM DR S, V16, P241, DOI 10.1002/pds.1357; Sylvestre MP, 2006, ANN INTERN MED, V145, P361; Szklo M, 2000, EPIDEMIOLOGY BASICS; WAGONER JK, 1976, LANCET, V2, P194; Walker AM, 1991, OBSERVATION INFERENC; Zhou Z, 2005, AM J EPIDEMIOL, V162, P1016, DOI 10.1093/aje/kwi307	40	434	434	6	34	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	FEB 15	2008	167	4					492	499		10.1093/aje/kwm324		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	263WC	WOS:000253246200016	18056625	
J	Moore, WC; Bleecker, ER; Curran-Everett, D; Erzurum, SC; Ameredes, BT; Bacharier, L; Calhoun, WJ; Castro, M; Chung, KF; Clark, MP; Dweik, RA; Fitzpatrick, AM; Gaston, B; Hew, M; Hussain, I; Jarjour, NN; Israel, E; Levy, BD; Murphy, JR; Peters, SP; Teague, WG; Meyers, DA; Busse, WW; Wenzel, SE				Moore, Wendy C.; Bleecker, Eugene R.; Curran-Everett, Douglas; Erzurum, Serpil C.; Ameredes, Bill T.; Bacharier, Leonard; Calhoun, William J.; Castro, Mario; Chung, Kian Fan; Clark, Melissa P.; Dweik, Raed A.; Fitzpatrick, Anne M.; Gaston, Benjamin; Hew, Mark; Hussain, Iftikhar; Jarjour, Nizar N.; Israel, Elliot; Levy, Bruce D.; Murphy, James R.; Peters, Stephen P.; Teague, W. Gerald; Meyers, Deborah A.; Busse, William W.; Wenzel, Sally E.		Natl Heart Lung Blood Inst Severe	Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						severe asthma; definition; bronchodilator response; pathophysiology; phenotype; pneumonia	EXHALED NITRIC-OXIDE; AIR-FLOW OBSTRUCTION; NEAR-FATAL ASTHMA; TO-TREAT ASTHMA; INHALED-CORTICOSTEROIDS; RISK-FACTORS; EOSINOPHILIC INFLAMMATION; DISEASE; ADULTS; EXACERBATIONS	Background: Severe asthma causes the majority of asthma morbidity. Understanding mechanisms that contribute to the development of severe disease is important. Objective: The goal of the Severe Asthma Research Program is to identify and characterize subjects with severe asthma to understand pathophysiologic mechanisms in severe asthma. Methods: We performed a comprehensive phenotypic characterization (questionnaires, atopy and pulmonary function testing, phlebotomy, exhaled nitric oxide) in subjects with severe and not severe asthma. Results: A total of 438 subjects with asthma were studied (204 severe, 70 moderate, 164 mild). Severe subjects with asthma were older with longer disease duration (P < .0001), more daily symptoms, intense urgent health care utilization, sinusitis, and pneumonia (P < .0001). Lung function was lower in severe asthma with marked bronchodilator reversibility (P < .001). The severe group had less atopy by skin tests (P = .0007), but blood eosinophils, IgE, and exhaled nitric oxide levels did not differentiate disease severity. A reduced FEV1, history of pneumonia, and fewer positive skin tests were risk factors for severe disease. Early disease onset (age < 12 years) in severe asthma was associated with longer disease duration (P < .0001) and more urgent health care, especially intensive care (P = .002). Later disease onset (age >= 12 years) was associated with lower lung function and sinopulmonary infections (P <= .02). Conclusion: Severe asthma is characterized by abnormal lung function that is responsive to bronchodilators, a history of sinopulmonary infections, persistent symptoms, and increased health care utilization. Clinical implications: Lung function abnormalities in severe asthma are reversible in most patients, and pneumonia is a risk factor for the development of severe disease.	Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27157 USA; Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Denver, CO 80202 USA; Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA	Moore, WC (reprint author), Wake Forest Univ, Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.	wmoore@wfubmc.edu		Chung, Kian Fan/0000-0001-7101-1426	NCRR NIH HHS [M01 RR003186, M01 RR003186-22, M01 RR007122, M01 RR007122-14, M01 RR007122-17, M01 RR018390, M01 RR018390-03, M01 RR03186]; NHLBI NIH HHS [R01 HL069170, HL69116, HL69130, HL69149, HL69155, HL69167, HL69170, HL69174, HL69349, R01 HL069116, R01 HL069116-09, R01 HL069130, R01 HL069130-03, R01 HL069149, R01 HL069149-05, R01 HL069155, R01 HL069155-05, R01 HL069167, R01 HL069167-09, R01 HL069170-09, R01 HL069174, R01 HL069174-09, R01 HL069349, R01 HL069349-05]		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; Bergmann MM, 2004, EUR J EPIDEMIOL, V19, P411; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Colice Gene L, 2004, Clin Med Res, V2, P155; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; Curran-Everett D, 2000, AM J PHYSIOL-REG I, V279, pR1; De Smet BD, 2006, ANN PHARMACOTHER, V40, P414, DOI 10.1345/aph.1G475; Des Roches Anne, 1996, Journal of Allergy and Clinical Immunology, V98, P522, DOI 10.1016/S0091-6749(96)70085-4; Diette GB, 2004, ANN ALLERG ASTHMA IM, V93, P546; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Eisner MD, 2005, J ASTHMA, V42, P315, DOI 10.1081/JAS-200062959; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Griswold SK, 2005, CHEST, V127, P1579, DOI 10.1378/chest.127.5.1579; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Koga T, 2006, RESP MED, V100, P273, DOI 10.1016/j.rmed.2005.05.017; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Liou Aimee, 2003, Chest, V124, P1781, DOI 10.1378/chest.124.5.1781; Mahler DA, 1999, CHEST, V115, P957, DOI 10.1378/chest.115.4.957; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Mitchell I, 2002, CHEST, V121, P1407, DOI 10.1378/chest.121.5.1407; *NAT HEART LUNG BL, 2002, 023659 NHLBIWHO, P1; *NAT I HLTH NAT HE, 1997, 974051 NAT I HLTH NA; *NAT I HLTH NAT HE, 2002, 025075 NAT I HLTH NA; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Stirling RG, 1998, THORAX, V53, P1030; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341	43	434	440	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					405	413		10.1016/j.jaci.2006.11.639		9	Allergy; Immunology	Allergy; Immunology	137YB	WOS:000244327900019	17291857	
J	D'Amato, G; Cecchi, L; Bonini, S; Nunes, C; Annesi-Maesano, I; Behrendt, H; Liccardi, G; Popov, T; van Cauwenberge, P				D'Amato, G.; Cecchi, L.; Bonini, S.; Nunes, C.; Annesi-Maesano, I.; Behrendt, H.; Liccardi, G.; Popov, T.; van Cauwenberge, P.			Allergenic pollen and pollen allergy in Europe	ALLERGY			English	Review						airway hypersensitivity; allergenic pollens; allergic asthma; allergic rhinitis; bronchial asthma; outdoor air-pollution; pollinosis; respiratory allergy; seasonal allergy.	RAGWEED AMBROSIA-ARTEMISIIFOLIA; RESPIRATORY HEALTH SURVEY; LONG-DISTANCE TRANSPORT; BENJAMINA WEEPING FIG; NATURAL-RUBBER LATEX; ALPHA-LINOLENIC ACID; GRASS-POLLEN; FICUS-BENJAMINA; BIRCH-POLLEN; ENVIRONMENTAL-FACTORS	The allergenic content of the atmosphere varies according to climate, geography and vegetation. Data on the presence and prevalence of allergenic airborne pollens, obtained from both aerobiological studies and allergological investigations, make it possible to design pollen calendars with the approximate flowering period of the plants in the sampling area. In this way, even though pollen production and dispersal from year to year depend on the patterns of preseason weather and on the conditions prevailing at the time of anthesis, it is usually possible to forecast the chances of encountering high atmospheric allergenic pollen concentrations in different areas.Aerobiological and allergological studies show that the pollen map of Europe is changing also as a result of cultural factors (for example, importation of plants such as birch and cypress for urban parklands), greater international travel (e.g. colonization by ragweed in France, northern Italy, Austria, Hungary etc.) and climate change. In this regard, the higher frequency of weather extremes, like thunderstorms, and increasing episodes of long range transport of allergenic pollen represent new challenges for researchers.Furthermore, in the last few years, experimental data on pollen and subpollen-particles structure, the pathogenetic role of pollen and the interaction between pollen and air pollutants, gave new insights into the mechanisms of respiratory allergic diseases.	High Special Hosp A Cardarelli, Dept Chest Dis, Div Resp & Allerg Dis, Naples, Italy; Univ Florence, Interdept Ctr Bioclimatol, Florence, Italy; Azienda Sanitaria 10 Firenze, Allerg Clin, Florence, Italy; Univ Naples 2, Naples, Italy; CNR, Inst Mol Neurobiol Med, ARTOV, Rome, Italy; Ctr Imunoalerlogia Algarve, Portimao, Portugal; INSERM, UMR S 707, EPAR, Paris, France; Univ Paris 06, UMR S 707, EPAR, Paris, France; Tech Univ Munich, Div Environm Dermatol & Allerg GSF, D-8000 Munich, Germany; Med Univ, Clin Ctr Allergol, Sofia, Bulgaria; State Univ Ghent Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium	D'Amato, G (reprint author), High Special Hosp A Cardarelli, Dept Chest Dis, Div Resp & Allerg Dis, Naples, Italy.		Annesi-Maesano, Isabella/D-9173-2016; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Bonini, Sergio/0000-0003-0079-3031; Popov, Todor/0000-0001-5052-5866			AALBERSE RC, 1992, INT ARCH ALLERGY IMM, V99, P261; AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; Agea E, 2002, ALLERGY, V57, P959, DOI 10.1034/j.1398-9995.2002.23832_4.x; Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Allakhverdi Z, 2005, ALLERGY, V60, P1157, DOI 10.1111/j.1398-9995.2005.00861.x; ANTEPARA I, 1995, CLIN EXP ALLERGY, V25, P133, DOI 10.1111/j.1365-2222.1995.tb01018.x; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Asero R, 2006, CLIN EXP ALLERGY, V36, P658, DOI 10.1111/j.1365-2222.2006.02477.x; Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; AXELSSON IGK, 1987, ALLERGY, V42, P161, DOI 10.1111/j.1398-9995.1987.tb02193.x; AXELSSON IGK, 1995, ALLERGY, V50, P284, DOI 10.1111/j.1398-9995.1995.tb01149.x; Bacsi A, 2006, J ALLERGY CLIN IMMUN, V118, P844, DOI 10.1016/j.jaci.2006.07.006; BALMES JR, 1993, ENV HLTH PERSPECT S4, V101; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Bartkova-Scevkova J, 2003, INT J BIOMETEOROL, V48, P1, DOI 10.1007/s00484-003-0166-2; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Belmonte J., 2000, AEROBIOLOGIA, V16, P93, DOI DOI 10.1023/A:1007649427549; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; Caballero T, 1996, CLIN EXP ALLERGY, V26, P197, DOI 10.1111/j.1365-2222.1996.tb00080.x; Cabezudo B, 1997, ATMOS ENVIRON, V31, P3323, DOI 10.1016/S1352-2310(97)00161-1; Calleja M, 2003, ALLERGY IMMUNOL, V35, P92; Campbell ID, 1999, NATURE, V399, P29, DOI 10.1038/19891; CARAMIELLO R, 1991, GRANA, V30, P109; Carinanos P, 2002, ALLERGY, V57, P92, DOI 10.1034/j.1398-9995.2002.1o3261.x; Cecchi Lorenzo, 2006, Ann Allergy Asthma Immunol, V96, P86; Charpin D, 2005, ALLERGY, V60, P293, DOI 10.1111/j.1398-9995.2005.00731.x; Charpin D, 2000, Allerg Immunol (Paris), V32, P83; Charpin D, 2003, ALLERGY, V58, P383; Chen ZP, 2000, INT ARCH ALLERGY IMM, V123, P291, DOI 10.1159/000053641; Clot B, 2002, Allerg Immunol (Paris), V34, P126; Colombo P, 1998, ALLERGY, V53, P917, DOI 10.1111/j.1398-9995.1998.tb03791.x; Colombo P, 2003, INT ARCH ALLERGY IMM, V130, P173, DOI 10.1159/000069520; Corden JM, 2001, AEROBIOLOGIA, V17, P127, DOI 10.1023/A:1010876917512; Cortes L, 2006, J ALLERGY CLIN IMMUN, V118, P878, DOI 10.1016/j.jaci.2006.05.029; CVITANOVIC S, 1986, ALLERGY, V41, P543, DOI 10.1111/j.1398-9995.1986.tb00341.x; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; D'Amato G, 2001, ALLERGY, V56, P1109, DOI 10.1034/j.1398-9995.2001.00317.x; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; Dahl A., 1999, AEROBIOLOGIA, V15, P293, DOI DOI 10.1023/A:1007678107552; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; DAMATO G, 1983, CLIN ALLERGY, V13, P537, DOI 10.1111/j.1365-2222.1983.tb02635.x; DAMATO G, 1992, ADVANCES IN ALLERGOLOGY AND CLINICAL IMMUNOLOGY, P387; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DAMATO G, 1992, ALLERGY, V47, P443, DOI 10.1111/j.1398-9995.1992.tb00661.x; DAMATO G, 1992, ANN ALLERGY, V68, P433; DAMATO G, 1991, ANN ALLERGY, V67, P421; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P210, DOI 10.1111/j.1365-2222.1994.tb00222.x; D'Amato G., 1991, ALLERGENIC POLLEN PO, P66; D'Amato G., 2002, EUROPEAN RESP MONOGR, V21; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; D'Amato G, 1990, GRANA, V30, P67; DAMATO G, POLLENOSIS 2000 GLOB; DAMATO G, 2005, BMJ              JAN; D'Amato G, 2001, POLLENOSIS 2000 GLOB; D'Amato G, 1991, ALLERGENIC POLLEN PO, P109; Davidson AC, 1996, BRIT MED J, V312, P601; DAVIES R R, 1973, Clinical Allergy, V3, P263, DOI 10.1111/j.1365-2222.1973.tb01332.x; DECLAVIJO ER, 1988, ALLERGOL IMMUNOPATH, V16, P175; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Emberlin J, 1995, CLIN EXP ALLERGY, V25, P33, DOI 10.1111/j.1365-2222.1995.tb00040.x; EMBERLIN J, 1993, CLIN EXP ALLERGY, V23, P911, DOI 10.1111/j.1365-2222.1993.tb00275.x; Emberlin J. C., 1997, ALLERGY ALLERGIC DIS, P845; Eriksson NE, 1996, J INVEST ALLERG CLIN, V6, P36; Estrella N, 2006, INT J BIOMETEOROL, V51, P49, DOI 10.1007/s00484-006-0038-7; FERNANDEZCALDAS E, 1989, GRANA, V28, P205; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Florido JF, 1999, INT ARCH ALLERGY IMM, V119, P133, DOI 10.1159/000024188; Fraile R, 2006, AEROBIOLOGIA, V22, P35, DOI 10.1007/s10453-005-9014-7; Frenguelli G., 1998, AEROBIOLOGIA, V14, P39, DOI 10.1007/BF02694593; Friedhoff LR, 1986, J ALLERGY CLIN IMMUN, V78, P1190, DOI http://dx.doi.org/10.1016/0091-6749(87)90283-1; Geller-Bernstein C, 2000, Allerg Immunol (Paris), V32, P92; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Gioulekas D, 2004, ALLERGY, V59, P174, DOI 10.1046/j.1398-9995.2003.00312.x; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; GUERRA F, 1992, ALLERGY S, V47, P72; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; Hemmer W, 2004, CLIN EXP ALLERGY, V34, P1251, DOI 10.1111/j.1365-2222.2004.02046.x; Hemmer W, 2000, ALLERGY, V55, P923, DOI 10.1034/j.1398-9995.2000.00671.x; Conde Hernandez J., 2002, ALLERGY, V71, P60; Hidalgo PJ, 2003, TREES-STRUCT FUNCT, V17, P336, DOI 10.1007/s00468-002-0243-x; HJELMROOS M, 1995, INT ARCH ALLERGY IMM, V108, P368; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HOLGATE ST, 1988, CLIN ALLERGY, V18, P549, DOI 10.1111/j.1365-2222.1988.tb02906.x; Huynen M, 2003, WHO M ROM IT 16 17 J; HYDE HA, 1972, CLIN ALLERGY, V2, P152; Imbusch R, 2000, FREE RADICAL BIO MED, V28, P720, DOI 10.1016/S0891-5849(00)00154-4; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Italian Association of Aerobiology, 2002, J INVESTIG ALLERGOL, V12, P287; Jager S, 2000, AEROBIOLOGIA, V16, P149, DOI 10.1023/A:1007603321556; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; KAUFMAN HS, 1990, ANN ALLERGY, V64, P293; Kirmaz C, 2005, J INVEST ALLERG CLIN, V15, P140; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kortekangas-Savolainen O, 2006, ALLERGY, V61, P393, DOI 10.1111/j.1398-9995.2006.01015.x; KREIT JW, 1989, J APPL PHYSIOL, V66, P217; Laaidi M, 2003, ANN ALLERG ASTHMA IM, V91, P195; LAFFER S, 1992, ALLERGY S, V47, P25; Liccardi G, 1996, INT ARCH ALLERGY IMM, V111, P210; Liccardi G., 1992, Aerobiologia, V8, P34, DOI 10.1007/BF02291326; Liccardi G, 1999, ALLERGY, V54, P643, DOI 10.1034/j.1398-9995.1999.00041.x; Liccardi G, 1996, ALLERGY ASTHMA PROC, V17, P23, DOI 10.2500/108854196778662381; Mahillon V, 2006, ALLERGY, V61, P1138, DOI 10.1111/j.1398-9995.2006.01026.x; Makra L, 2004, INT J BIOMETEOROL, V49, P37, DOI 10.1007/s00484-004-0208-4; Mandrioli P., 1998, AEROBIOLOGIA, V14, P13, DOI DOI 10.1007/BF02694590; Mandrioli P, 2000, ALLERGY IMMUNOL, V31, P116; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; MARTIN BG, 1987, ANN ALLERGY, V59, P149; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Menzel A, 2000, INT J BIOMETEOROL, V44, P76, DOI 10.1007/s004840000054; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Mueller MJ, 2004, CURR OPIN PLANT BIOL, V7, P441, DOI 10.1016/j.pbi.2004.04.001; Mueller MJ, 1998, CHEM BIOL, V5, pR323, DOI 10.1016/S1074-5521(98)90660-3; NAMORK E, 2006, TOXICOL LETT, V16, P571; Newhouse CP, 2004, ANN ALLERG ASTHMA IM, V92, P356; ORTOLANI C, 1991, GIORN IT ALLERGOL IM, V1, P515; Pace E, 2006, ALLERGY, V61, P1459, DOI 10.1111/j.1398-9995.2006.01234.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Papa G, 2001, SCI TOTAL ENVIRON, V270, P83, DOI 10.1016/S0048-9697(00)00795-6; Parchmann S, 1998, J BIOL CHEM, V273, P32650, DOI 10.1074/jbc.273.49.32650; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peternel R, 2006, AEROBIOLOGIA, V22, P161, DOI 10.1007/s10453-006-9028-9; PHARM NH, 1994, CLIN EXP ALLERGY, V24, P558; Piotrowska K, 2006, AEROBIOLOGIA, V22, P151, DOI 10.1007/s10453-006-9020-4; Plotz SG, 2004, J ALLERGY CLIN IMMUN, V113, P1152, DOI 10.1016/j.jaci.2004.03.011; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; PRANDINI M, 1991, G IT ALLERGOL IMMUNO, V1, P519; Priftanji A, 2000, ALL IMMUNOL, V31, P122; RANTIOLEHTIMAKI A, 1991, ALLERGY, V46, P68, DOI 10.1111/j.1398-9995.1991.tb00545.x; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; Ridolo E., 2006, INT ARCH ALLERGY IMM, V20, P142; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Riotte-Flandrois F, 1995, Allerg Immunol (Paris), V27, P345; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Rousseau DD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017539; Rybncek O, 2001, ALLERGY CLIN IMMUNOL, V13, P60, DOI 10.1027/0838-1925.13.2.60; SANDSTROM T, 2002, EUROPEAN RESP MONOGR, V21, P52; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; SCHMID P, 1993, ALLERGY, V48, P466, DOI 10.1111/j.1398-9995.1993.tb00746.x; SCHUMACHER MJ, 1988, J ALLERGY CLIN IMMUN, V82, P608, DOI 10.1016/0091-6749(88)90972-4; Sofiev M, 2006, INT J BIOMETEOROL, V50, P392, DOI 10.1007/s00484-006-0027-x; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SOLOMON WR, 1986, GRANA, V25, P85; SPIEKSMA FTM, 1995, GRANA, V34, P51; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; Spieksma F. T. M., 1991, ALLERGENIC POLLEN PO, P49; STEWART GA, 1985, MED J AUSTRALIA, V28, P143; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TAKAHASHI Y, 1991, ALLERGY, V46, P588, DOI 10.1111/j.1398-9995.1991.tb00628.x; Taramarcaz P, 2005, SWISS MED WKLY, V135, P538; Thoma I, 2003, PLANT J, V34, P363, DOI 10.1046/j.1365-313X.2003.01730.x; TOURAINE R, 1966, B MENSUEL SOC LINNEE, V6, P279; Traidl-Hoffmann C, 2003, INT ARCH ALLERGY IMM, V131, P1, DOI 10.1159/000070428; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Troiste C., 1996, J INVESTIG ALLERGOL, V6, P36; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; WULFF RD, 1985, OECOLOGIA, V66, P458, DOI 10.1007/BF00378315; Yankova R., 2000, AEROBIOLOGIA, V16, P299, DOI 10.1023/A:1007690116728; Zanon P, 2002, Monaldi Arch Chest Dis, V57, P144; Zauli D, 2006, ANN ALLERG ASTHMA IM, V97, P122; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	190	433	447	24	140	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	SEP	2007	62	9					976	990		10.1111/j.1398-9995.2007.01393.x		15	Allergy; Immunology	Allergy; Immunology	197YM	WOS:000248593300002	17521313	
J	van den Biggelaar, AHJ; van Ree, R; Rodrigues, LC; Lell, B; Deelder, AM; Kremsner, PG; Yazdanbakhsh, M				van den Biggelaar, AHJ; van Ree, R; Rodrigues, LC; Lell, B; Deelder, AM; Kremsner, PG; Yazdanbakhsh, M			Decreased atopy in children infected with Schistosoma haematobium: a role for parasite-induced interleukin-10	LANCET			English	Article							HUMAN LYMPHATIC FILARIASIS; ALLERGIC REACTIVITY; CYTOKINE CONTROL; CELL RESPONSES; ASTHMA; MODULATION; ACTIVATION; INDUCTION; ANTIBODY; CD4(+)	Background Most of the effort directed at understanding the role infections have in preventing allergy has focused on bacteria and viruses and their ability to divert the immune system towards T-helper-1 responses and away from proallergic T-helper-2 responses. However, helminth infections, highly prevalent in large parts of the developing world, where allergy is uncommon, stimulate strong T-helper-2 responses. We investigated the influence of chronic helminth infections on the prevalence of atopy and aimed to understand the relation at a detailed immunological level. Methods 520 Gabonese schoolchildren were tested for shin reaction to house-dust mite and other allergens, for Schistosoma haematobium eggs In urine, and for microfilariae in blood samples. Total and mite-specific IgE antibodies were measured. A subsample selected on the basis of their skin test to house-dust mite received detailed immunological investigations. Findings Children with urinary schistosomiasis had a lower prevalence of a positive skin reaction to house-dust mite than those free of this infection (odds ratio 0.32 [95% CI 0.16-0.63]). The degree of sensitisation to house-dust mite could not explain this difference in skin-prick positivity. Schistosome-antigen-specific concentrations of interleukin-10 were significantly higher in infected children, and higher specific concentrations of this anti-inflammatory cytokine were negatively associated with the outcome of skin-test reactivity to mite (0.53 [0.30-0.96]). No association between polyclonal IgE antibodies and skin-test results was found. Interpretation The anti-inflammatory cytokine, interleukin-10, induced in chronic schistosomiasis, appears central to suppressing atopy in African children.	Leiden Univ, Med Ctr, Dept Parasitol, NL-2333 ZA Leiden, Netherlands; CLB, Dept Allergy, Amsterdam, Netherlands; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany; Albert Schweitzer Hosp, Res Unit, Lambarene, Gabon	Yazdanbakhsh, M (reprint author), Leiden Univ, Med Ctr, Dept Parasitol, L4-Q,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.						Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Cookson W, 1999, NATURE, V402, pB5; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Edwards-Smith CJ, 1999, HEPATOLOGY, V30, P526, DOI 10.1002/hep.510300207; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; Groux H, 1997, NATURE, V389, P737; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; Hirsch CS, 1996, P NATL ACAD SCI USA, V93, P3193, DOI 10.1073/pnas.93.8.3193; Holt PG, 1999, NATURE, V402, pB12; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; JARRETT E, 1980, NATURE, V283, P302, DOI 10.1038/283302a0; KING CL, 1993, J CLIN INVEST, V92, P1667, DOI 10.1172/JCI116752; King CL, 1996, J IMMUNOL, V156, P4715; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Oxenius A, 1998, IMMUNITY, V9, P449, DOI 10.1016/S1074-7613(00)80628-7; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STRACHAN DP, 1989, BRIT MED J, V351, P1225; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAZDANBAKHSH M, 1993, EUR J IMMUNOL, V23, P3312, DOI 10.1002/eji.1830231238; YEMANEBERHAN H, 1997, LANCET, V350, P400	30	425	438	2	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 18	2000	356	9243					1723	1727		10.1016/S0140-6736(00)03206-2		5	Medicine, General & Internal	General & Internal Medicine	376MX	WOS:000165462300011	11095260	
J	Wrensch, M; Minn, Y; Chew, T; Bondy, M; Berger, MS				Wrensch, M; Minn, Y; Chew, T; Bondy, M; Berger, MS			Epidemiology of primary brain tumors: Current concepts and review of the literature	NEURO-ONCOLOGY			English	Review							CENTRAL-NERVOUS-SYSTEM; FRANCISCO BAY AREA; PETROCHEMICAL RESEARCH FACILITY; OCCUPATIONAL RISK-FACTORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; INTERNATIONAL CASE-CONTROL; MAGNETIC-FIELD EXPOSURE; VINYL-CHLORIDE WORKERS; GROWTH-FACTOR RECEPTOR; CELLULAR-TELEPHONE USE	The purpose of this review is to provide a sufficiently detailed perspective on epidemiologic studies of primary brain tumors to encourage multidisciplinary etiologic and prognostic studies among surgeons, neuro-oncologists, epidemiologists, and molecular scientists. Molecular tumor markers that predict survival and treatment response are being identified with hope of even greater gains in this area from emerging array technologies. Regarding risk factors, studies of inherited susceptibility and constitutive polymorphisms in genes pertinent to carcinogenesis (for example, DNA repair and detoxification genes and mutagen sensitivity) have revealed provocative findings. Inverse associations of the history of allergies with glioma risk observed in 3 large studies and reports of inverse associations of glioma with common infections suggest a possible role of immune factors in glioma genesis or progression. Studies continue to suggest that brain tumors might result from workplace, dietary, and other personal and residential exposures, but studies of cell phone use and power frequency electromagnetic fields have found little to support a causal connection with brain tumors; caveats remain. The only proven causes of brain tumors (that is, rare hereditary syndromes, therapeutic radiation, and immune suppression giving rise to brain lymphomas) account for a small proportion of cases. Progress in understanding primary brain tumors might result from studies of well-defined histologic and molecular tumor types incorporating assessment of potentially relevant information on subject susceptibility and environmental and noninherited endogenous factors (viruses, radiation, and carcinogenic or protective chemical exposures through diet, workplace, oxidative metabolism, or other sources). Such studies will require the cooperation of researchers from many disciplines.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94102 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94102 USA; Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94102 USA; Stanford Univ, Dept Neurol, Stanford, CA 94305 USA; Univ Texas, MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA	Wrensch, M (reprint author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Box 1215,44 Page St,Suite 503, San Francisco, CA 94102 USA.		Rice, Terri/J-6071-2014		NCI NIH HHS [P01CA55261, R01CA52689, R01CA70917001]		*ACS, 1998, CANC FACTS FIG 1998; AHLBOM A, 1986, AM J EPIDEMIOL, V124, P334; Aldape K, 2000, CANCER, V88, P2342, DOI 10.1002/(SICI)1097-0142(20000515)88:10<2342::AID-CNCR19>3.0.CO;2-X; Alexander V, 2001, OCCUP MED-STATE ART, V16, P289; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; ARONSON KJ, 1994, AM J IND MED, V26, P89, DOI 10.1002/ajim.4700260108; BERLEUR MP, 1995, CANCER CAUSE CONTROL, V6, P240, DOI 10.1007/BF00051796; BITHELL JF, 1973, BRIT MED J, V1, P706; BLAIR A, 1990, SCAND J WORK ENV HEA, V16, P381; Blettner M, 1999, MED KLIN, V94, P150; Blot WJ, 1999, NUTR CANCER, V34, P111, DOI 10.1207/S15327914NC340115; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; BOHNEN NI, 1995, J NEUROL SCI, V132, P110, DOI 10.1016/0022-510X(95)00151-Q; Bondy M, 1996, J NEURO-ONCOL, V29, P197, DOI 10.1007/BF00165649; BONDY M, 1994, J NEURO-ONCOL, V18, P69, DOI 10.1007/BF01324606; Bondy ML, 1996, CANCER RES, V56, P1484; Bondy ML, 2001, J NATL CANCER I, V93, P1553; Brenner AV, 2002, INT J CANCER, V99, P252, DOI 10.1002/ijc.10320; Brinton LA, 2001, ANN EPIDEMIOL, V11, P248, DOI 10.1016/S1047-2797(00)00223-4; Bunin G, 2000, PEDIATR NEUROSURG, V32, P321, DOI 10.1159/000028961; BURCH JD, 1987, J NATL CANCER I, V78, P601; Burnett C, 1999, AM J IND MED, V36, P155, DOI 10.1002/(SICI)1097-0274(199907)36:1<155::AID-AJIM22>3.0.CO;2-Z; Caggana M, 2001, CANCER EPIDEM BIOMAR, V10, P355; Cairncross JG, 1998, J NATL CANCER I, V90, P1473, DOI 10.1093/jnci/90.19.1473; Cantor KP, 1999, AM J EPIDEMIOL, V150, P552; Carozza SE, 2000, AM J EPIDEMIOL, V152, P838, DOI 10.1093/aje/152.9.838; *CBTRUS, 1998, ANN REP; CBTRUS, 2000, STAT REP PRIM BRAIN; CDC, 1990, GUID INV CLUST HLTH; Chen PC, 2000, CANCER EPIDEM BIOMAR, V9, P843; Chen PC, 2001, CANCER RES, V61, P3949; CHOI NW, 1970, AM J EPIDEMIOL, V91, P467; CLEMMESEN J, 1978, ECOTOX ENVIRON SAFE, V1, P457, DOI 10.1016/0147-6513(78)90014-3; Cocco P, 1999, AM J IND MED, V36, P70, DOI 10.1002/(SICI)1097-0274(199907)36:1<70::AID-AJIM10>3.0.CO;2-5; CODD MB, 1990, NEUROEPIDEMIOLOGY, V9, P17, DOI 10.1159/000110748; Cooper Sharon P., 1997, Journal of Environmental Pathology Toxicology and Oncology, V16, P1; Cuomo L, 2001, J MED VIROL, V63, P45, DOI 10.1002/1096-9071(200101)63:1<45::AID-JMV1006>3.3.CO;2-B; CURRAN WJ, 1993, J NATL CANCER I, V85, P704, DOI 10.1093/jnci/85.9.704; Davis FG, 1998, J NEUROSURG, V88, P1, DOI 10.3171/jns.1998.88.1.0001; Davis FG, 2000, CURR OPIN NEUROL, V13, P635, DOI 10.1097/00019052-200012000-00004; Davis FG, 1997, NEUROEPIDEMIOLOGY, V16, P308, DOI 10.1159/000109703; Davis FG, 1999, NEUROIMAG CLIN N AM, V9, P581; Davis FG, 2001, NEURO-ONCOLOGY, V3, P152, DOI 10.1215/15228517-3-3-152; Davis FG, 1999, CANCER, V85, P485, DOI 10.1002/(SICI)1097-0142(19990115)85:2<485::AID-CNCR29>3.0.CO;2-L; DAVIS FG, 1998, RUSSELL RUBINSTEINS, P5; Davis S, 2001, AM J EPIDEMIOL, V154, P591, DOI 10.1093/aje/154.7.591; de Andrade M, 2001, GENET EPIDEMIOL, V20, P258, DOI 10.1002/1098-2272(200102)20:2<258::AID-GEPI8>3.0.CO;2-N; Del Valle L, 2001, CANCER RES, V61, P4287; Delzell E, 1999, AM J IND MED, V36, P450, DOI 10.1002/(SICI)1097-0274(199910)36:4<450::AID-AJIM6>3.0.CO;2-7; DEMERS PA, 1992, BRIT J IND MED, V49, P664; DEMERS PA, 1991, J OCCUP ENVIRON MED, V33, P1001; DEMERS PA, 1994, CANCER CAUSE CONTROL, V5, P129, DOI 10.1007/BF01830258; Deschamps S, 1995, EUR J EPIDEMIOL, V11, P643, DOI 10.1007/BF01720297; Devesa SS, 1999, ATLAS CANC MORTALITY; Divine BJ, 2000, OCCUP ENVIRON MED, V57, P411, DOI 10.1136/oem.57.6.411; Divine BJ, 1999, OCCUP ENVIRON MED, V56, P167; ELEXPURUCAMIRUAGA J, 1995, CANCER RES, V55, P4237; FARWELL JR, 1984, J NEUROSURG, V61, P657, DOI 10.3171/jns.1984.61.4.0657; Feychting M, 2000, CANCER CAUSE CONTROL, V11, P151, DOI 10.1023/A:1008922016813; Firth HM, 1996, INT J EPIDEMIOL, V25, P14, DOI 10.1093/ije/25.1.14; Fisher JL, 2000, AM J EPIDEMIOL, V151, pS29; Fisher SG, 1999, ANTICANCER RES, V19, P2173; Floderus B, 1999, CANCER CAUSE CONTROL, V10, P323, DOI 10.1023/A:1008953920877; Fremgen AM, 1999, CA-CANCER J CLIN, V49, P145, DOI 10.3322/canjclin.49.3.145; Gao LZ, 1997, CLIN CANCER RES, V3, P977; Gavin P, 1999, PEDIATR NEUROSURG, V31, P115, DOI 10.1159/000028845; GEISSLER E, 1988, Archiv fuer Geschwulstforschung, V58, P129; GLASER SL, 1996, CANC INCIDENCE RACE; Golden AL, 1995, OCCUP MED, V10, P803; Grossman SA, 1999, CANCER INVEST, V17, P299, DOI 10.3109/07357909909032870; Grotzer MA, 2000, KLIN PADIATR, V212, P196, DOI 10.1055/s-2000-10044; Grotzer MA, 2001, MED PEDIATR ONCOL, V36, P268, DOI 10.1002/1096-911X(20010201)36:2<268::AID-MPO1064>3.0.CO;2-F; Grovas A, 1997, CANCER, V80, P2321, DOI 10.1002/(SICI)1097-0142(19971215)80:12<2321::AID-CNCR14>3.0.CO;2-W; Guidotti TL, 1995, J OCCUP ENVIRON MED, V37, P1348, DOI 10.1097/00043764-199512000-00004; Gundestrup M, 1999, LANCET, V354, P2029, DOI 10.1016/S0140-6736(99)05093-X; Gurney JG, 1999, CANCER CAUSE CONTROL, V10, P101, DOI 10.1023/A:1008867024545; Gurney JG, 1996, EPIDEMIOLOGY, V7, P485, DOI 10.1097/00001648-199609000-00005; Hagel C, 1999, J EXP CLIN CANC RES, V18, P305; HAGMAR L, 1990, AM J IND MED, V17, P553, DOI 10.1002/ajim.4700170502; Hardell L, 1999, INT J ONCOL, V15, P113; Hardell L, 2001, EUR J CANCER PREV, V10, P523, DOI 10.1097/00008469-200112000-00007; HELSETH A, 1995, J NEUROSURG, V83, P999, DOI 10.3171/jns.1995.83.6.0999; Hemminki K, 2000, BRIT J CANCER, V83, P407, DOI 10.1054/bjoc.2000.1252; Hjalmars U, 1999, CANCER, V85, P2077, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2077::AID-CNCR27>3.3.CO;2-W; Hodges L C, 1992, J Neurosci Nurs, V24, P79; Holly EA, 1998, CANCER EPIDEM BIOMAR, V7, P797; Horn B, 1999, J PEDIAT HEMATOL ONC, V21, P203, DOI 10.1097/00043426-199905000-00008; Hu JF, 2000, ACTA ONCOL, V39, P979; Hu JF, 1999, INT J CANCER, V81, P20, DOI 10.1002/(SICI)1097-0215(19990331)81:1<20::AID-IJC4>3.0.CO;2-2; Huncharek M, 2000, ONCOL RES, V12, P107; Inskip PD, 2001, NEW ENGL J MED, V344, P79, DOI 10.1056/NEJM200101113440201; Inskip PD, 1998, CANCER CAUSE CONTROL, V9, P109, DOI 10.1023/A:1008861722901; Inskip PD, 1995, EPIDEMIOL REV, V17, P382; Irvine D, 1999, AVIAT SPACE ENVIR MD, V70, P548; JAMES CD, 2002, CANC NERVOUS SYSTEM, P239; Johansen C, 2001, J NATL CANCER I, V93, P203, DOI 10.1093/jnci/93.3.203; Johansen C, 1999, Ugeskr Laeger, V161, P2079; Jukich PJ, 2001, NEURO-ONCOLOGY, V3, P141, DOI 10.1215/15228517-3-3-141; Kaplan S, 1997, AM J EPIDEMIOL, V146, P832; Karak Asis Kumar, 2000, Pathology Oncology and Research, V6, P46; Karlsson P, 1998, RADIAT RES, V150, P357, DOI 10.2307/3579984; Kelsey KT, 1997, PHARMACOGENETICS, V7, P463, DOI 10.1097/00008571-199712000-00004; Kheifets L I, 1999, Rev Environ Contam Toxicol, V159, P111; Kheifets LI, 1995, J OCCUP ENVIRON MED, V37, P1327, DOI 10.1097/00043764-199512000-00002; Khuder SA, 1998, AM J IND MED, V34, P252, DOI 10.1002/(SICI)1097-0274(199809)34:3<252::AID-AJIM7>3.0.CO;2-X; Kleihues P, 2000, TOXICOL PATHOL, V28, P164, DOI 10.1177/019262330002800121; Krewski D, 2001, J TOXICOL ENV HEAL B, V4, P145, DOI 10.1080/109374001459467; Kristensen P, 1996, INT J CANCER, V65, P39, DOI 10.1002/(SICI)1097-0215(19960103)65:1<39::AID-IJC8>3.0.CO;2-2; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; KYRITSIS AP, 1994, J NATL CANCER I, V86, P344, DOI 10.1093/jnci/86.5.344; Lee M, 1997, CANCER CAUSE CONTROL, V8, P13, DOI 10.1023/A:1018470802969; Legler JM, 1999, J NATL CANCER I, V91, P1382, DOI 10.1093/jnci/91.16.1382; Levallois P, 2001, AM J EPIDEMIOL, V154, P601, DOI 10.1093/aje/154.7.601; Lewis R, 2001, Appl Occup Environ Hyg, V16, P188, DOI 10.1080/104732201460325; Li Y, 1998, CANCER EPIDEM BIOMAR, V7, P303; Linet MS, 1999, J NATL CANCER I, V91, P1051, DOI 10.1093/jnci/91.12.1051; Linos A, 1998, EUR J EPIDEMIOL, V14, P471, DOI 10.1023/A:1007437200858; Little MP, 1998, INT J CANCER, V78, P269, DOI 10.1002/(SICI)1097-0215(19981029)78:3<269::AID-IJC1>3.0.CO;2-T; Loning L, 2000, BLOOD, V95, P2770; Loomis DP, 1996, AM J IND MED, V29, P131, DOI 10.1002/(SICI)1097-0274(199602)29:2<131::AID-AJIM3>3.0.CO;2-V; Lopez-Gonzalez MA, 2000, SURG NEUROL, V53, P157, DOI 10.1016/S0090-3019(99)00177-9; Lote K, 1998, EUR J CANCER, V34, P98, DOI 10.1016/S0959-8049(97)00374-2; Lubin F, 2000, INT J CANCER, V86, P139, DOI 10.1002/(SICI)1097-0215(20000401)86:1<139::AID-IJC22>3.0.CO;2-C; Ma FC, 1998, J OCCUP ENVIRON MED, V40, P1134; Malmer B, 1999, INT J CANCER, V81, P366, DOI 10.1002/(SICI)1097-0215(19990505)81:3<366::AID-IJC9>3.0.CO;2-0; Malmer B, 2000, INT J CANCER, V85, P78, DOI 10.1002/(SICI)1097-0215(20000101)85:1<78::AID-IJC14>3.0.CO;2-S; Malmer B, 2001, BRIT J CANCER, V84, P429, DOI 10.1054/bjoc.2000.1612; McCarthy BJ, 1998, J NEUROSURG, V88, P831, DOI 10.3171/jns.1998.88.5.0831; McCredie M, 1999, PAEDIATR PERINAT EP, V13, P325; McKinley BP, 2000, J NEUROSURG, V93, P932, DOI 10.3171/jns.2000.93.6.0932; McLaughlin J K, 1999, J Epidemiol Biostat, V4, P253; Meinert R, 1996, RADIAT ENVIRON BIOPH, V35, P11, DOI 10.1007/BF01211237; Minder CE, 2001, AM J EPIDEMIOL, V153, P825, DOI 10.1093/aje/153.9.825; Mizumatsu S, 1999, CLIN CANCER RES, V5, P551; Mochizuki S, 1999, INT J ONCOL, V15, P983; Moen BE, 1997, J OCCUP ENVIRON MED, V39, P515, DOI 10.1097/00043764-199706000-00005; Morgan RW, 2000, EPIDEMIOLOGY, V11, P118, DOI 10.1097/00001648-200003000-00007; Mundt KA, 2000, OCCUP ENVIRON MED, V57, P774, DOI 10.1136/oem.57.11.774; Muscat JE, 2000, JAMA-J AM MED ASSOC, V284, P3001, DOI 10.1001/jama.284.23.3001; Nakamura M, 2000, ONCOLOGY-BASEL, V58, P108, DOI 10.1159/000012087; NAROD SA, 1991, BRIT J CANCER, V63, P993, DOI 10.1038/bjc.1991.216; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; Nichols KE, 2001, CANCER EPIDEM BIOMAR, V10, P83; NIEHS, 1999, NIH PUBL; Norman MA, 1996, CANCER EPIDEM BIOMAR, V5, P85; OLSEN JH, 1989, J NATL CANCER I, V81, P803, DOI 10.1093/jnci/81.10.803; Pace A, 1998, J EXP CLIN CANC RES, V17, P479; Petek E, 2001, CLIN DYSMORPHOL, V10, P151, DOI 10.1097/00019605-200104000-00015; Pobereskin LH, 2000, J NEUROL NEUROSUR PS, V69, P464, DOI 10.1136/jnnp.69.4.464; Pogoda JM, 1997, ENVIRON HEALTH PERSP, V105, P1214, DOI 10.1289/ehp.971051214; Prados MD, 1998, CA-CANCER J CLIN, V48, P331, DOI 10.3322/canjclin.48.6.331; PRADOS MD, 1998, CA CANC J CLIN, V48, P321; Preston-Martin S, 1998, INT J EPIDEMIOL, V27, P579, DOI 10.1093/ije/27.4.579; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; Preston-Martin S, 1996, CANC EPIDEMIOLOGY PR, P1231; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Rachet B, 2000, AM J IND MED, V38, P651, DOI 10.1002/1097-0274(200012)38:6<651::AID-AJIM6>3.0.CO;2-J; Rice JM, 2000, TOXICOL PATHOL, V28, P202, DOI 10.1177/019262330002800125; Robinson CF, 1999, AM J IND MED, V36, P630, DOI 10.1002/(SICI)1097-0274(199912)36:6<630::AID-AJIM5>3.0.CO;2-6; Robinson CF, 1999, AM J IND MED, V36, P186, DOI 10.1002/(SICI)1097-0274(199907)36:1<186::AID-AJIM26>3.0.CO;2-H; Rodu B, 2001, AM J IND MED, V39, P29; RYAN P, 1992, INT J CANCER, V51, P20, DOI 10.1002/ijc.2910510105; RYAN P, 1993, INT J EPIDEMIOL, V22, P412, DOI 10.1093/ije/22.3.412; Salminen E, 1999, EUR J CANCER, V35, P102, DOI 10.1016/S0959-8049(98)00341-4; SALVATI M, 1991, CANCER, V67, P392, DOI 10.1002/1097-0142(19910115)67:2<392::AID-CNCR2820670213>3.0.CO;2-V; Sant M, 1998, EUR J CANCER, V34, P2241, DOI 10.1016/S0959-8049(98)00336-0; Santana V S, 1999, Int J Occup Environ Health, V5, P88; Sathiakumar N, 2001, J OCCUP ENVIRON MED, V43, P166, DOI 10.1097/00043764-200102000-00017; Savitz DA, 2000, AM J IND MED, V38, P417; SCHLEHOFER B, 1992, CANCER, V69, P2541, DOI 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>3.0.CO;2-H; Schlehofer B, 1999, INT J CANCER, V82, P155, DOI 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P; Schreinemachers DM, 2000, ENVIRON HEALTH PERSP, V108, P873, DOI 10.2307/3434996; SCHUMAN LM, 1967, AM J PUBLIC HEALTH N, V57, P848, DOI 10.2105/AJPH.57.5.848; Scott JN, 1999, ANN NEUROL, V46, P183, DOI 10.1002/1531-8249(199908)46:2<183::AID-ANA7>3.0.CO;2-7; Shadan FF, 2000, MED HYPOTHESES, V55, P69, DOI 10.1054/mehy.1999.1027; SHAPIRO S, 1989, J NEUROSURG, V71, P77, DOI 10.3171/jns.1989.71.1.0077; Shintani T, 1999, J RADIAT RES, V40, P49, DOI 10.1269/jrr.40.49; SHIRTS SB, 1986, J NATL CANCER I, V77, P83; Simmons ML, 2001, CANCER RES, V61, P1122; SIMONATO L, 1991, SCAND J WORK ENV HEA, V17, P159; Singh GK, 2001, AM J PUBLIC HEALTH, V91, P392, DOI 10.2105/AJPH.91.3.392; Smith MA, 1999, J NATL CANCER I, V91, P973; Smith MA, 1998, J NATL CANCER I, V90, P1269, DOI 10.1093/jnci/90.17.1269; Socie G, 2000, J CLIN ONCOL, V18, P348; Sorahan T, 1999, AM J IND MED, V35, P348, DOI 10.1002/(SICI)1097-0274(199904)35:4<348::AID-AJIM5>3.0.CO;2-X; Straif K, 2000, OCCUP ENVIRON MED, V57, P180, DOI 10.1136/oem.57.3.180; Strauss D, 1999, DEV MED CHILD NEUROL, V41, P580, DOI 10.1017/S001216229900122X; Strickler HD, 1998, JAMA-J AM MED ASSOC, V279, P292, DOI 10.1001/jama.279.4.292; Strojnik T, 1999, CLIN CANCER RES, V5, P559; Kupelian V., 1999, NEURO-ONCOLOGY, V1, P14, DOI 10.1215/15228517-1-1-14; Taiwo B O, 2000, AIDS Read, V10, P486; Tedeschi-Blok N, 2001, NUTR CANCER, V39, P196, DOI 10.1207/S15327914nc392_6; Teppo L, 2001, EUR J CANCER, V37, P613, DOI 10.1016/S0959-8049(00)00428-7; THOMAS TL, 1986, SCAND J WORK ENV HEA, V12, P1; TORNLING G, 1994, AM J IND MED, V25, P219, DOI 10.1002/ajim.4700250208; Trizna Z, 1998, CANCER EPIDEM BIOMAR, V7, P553; Varner A, 1999, J NATL CANCER I, V91, P973; VENA JE, 1987, AM J IND MED, V11, P671, DOI 10.1002/ajim.4700110608; Weiland SK, 1996, OCCUP ENVIRON MED, V53, P289; Wennborg H, 1999, AM J IND MED, V35, P382, DOI 10.1002/(SICI)1097-0274(199904)35:4<382::AID-AJIM9>3.3.CO;2-6; WHITE SJ, 1979, LANCET, V2, P458; WIERNELS JL, 2002, INT J CANCER, V98, P609; Wong O, 2000, REGUL TOXICOL PHARM, V32, P78, DOI 10.1006/rtph.2000.1410; WONG O, 1991, AM J IND MED, V20, P317, DOI 10.1002/ajim.4700200305; Wrensch M, 2000, NEUROEPIDEMIOLOGY, V19, P234, DOI 10.1159/000026261; Wrensch M, 1997, AM J EPIDEMIOL, V145, P581; WRENSCH M, 1993, J NEURO-ONCOL, V17, P47, DOI 10.1007/BF01054274; Wrensch M, 2001, AM J EPIDEMIOL, V154, P161, DOI 10.1093/aje/154.2.161; Wrensch M, 1999, EPIDEMIOLOGY, V10, P523, DOI 10.1097/00001648-199909000-00010; Wrensch MR, 2000, NEUROONCOLOGY ESSENT, P2; WU WA, 1989, J OCCUP ENVIRON MED, V31, P518, DOI 10.1097/00043764-198906000-00007; Yeh HC, 2001, AM J EPIDEMIOL, V153, P749, DOI 10.1093/aje/153.8.749; Zahm SH, 1999, EPIDEMIOLOGY, V10, P473; Zheng TZ, 2001, J OCCUP ENVIRON MED, V43, P317, DOI 10.1097/00043764-200104000-00005	214	423	440	7	50	CARDEN JENNINGS PUBL CO LTD	CHARLOTTESVILLE	BLAKE CTR, STE 200, 1224 W MAIN ST, CHARLOTTESVILLE, VA 22903 USA	1522-8517			NEURO-ONCOLOGY	Neuro-Oncology	OCT	2002	4	4					278	299		10.1215/15228517-4-4-278		22	Oncology; Clinical Neurology	Oncology; Neurosciences & Neurology	596JP	WOS:000178161800006	12356358	
J	Chung, KF; Wenzel, SE; Brozek, JL; Bush, A; Castro, M; Sterk, PJ; Adcock, IM; Bateman, ED; Bel, EH; Bleecker, ER; Boulet, LP; Brightling, C; Chanez, P; Dahlen, SE; Djukanovic, R; Frey, U; Gaga, M; Gibson, P; Hamid, Q; Jajour, NN; Mauad, T; Sorkness, RL; Teague, WG				Chung, Kian Fan; Wenzel, Sally E.; Brozek, Jan L.; Bush, Andrew; Castro, Mario; Sterk, Peter J.; Adcock, Ian M.; Bateman, Eric D.; Bel, Elisabeth H.; Bleecker, Eugene R.; Boulet, Louis-Philippe; Brightling, Christopher; Chanez, Pascal; Dahlen, Sven-Erik; Djukanovic, Ratko; Frey, Urs; Gaga, Mina; Gibson, Peter; Hamid, Qutayba; Jajour, Nizar N.; Mauad, Thais; Sorkness, Ronald L.; Teague, W. Gerald			International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article							EXHALED NITRIC-OXIDE; AIR-FLOW OBSTRUCTION; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; SEVERE PERSISTENT ASTHMA; POORLY CONTROLLED ASTHMA; GENOME-WIDE ASSOCIATION; RELATIVE CORTICOSTEROID INSENSITIVITY; SPUTUM EOSINOPHIL COUNTS; ALLERGIC AIRWAYS DISEASE	Severe or therapy-resistant asthma is increasingly recognised as a major unmet need. A Task Force, supported by the European Respiratory Society and American Thoracic Society, reviewed the definition and provided recommendations and guidelines on the evaluation and treatment of severe asthma in children and adults. A literature review was performed, followed by discussion by an expert committee according to the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) approach for development of specific clinical recommendations. When the diagnosis of asthma is confirmed and comorbidities addressed, severe asthma is defined as asthma that requires treatment with high dose inhaled corticosteroids plus a second controller and/or systemic corticosteroids to prevent it from becoming "uncontrolled" or that remains "uncontrolled" despite this therapy. Severe asthma is a heterogeneous condition consisting of phenotypes such as eosinophilic asthma. Specific recommendations on the use of sputum eosinophil count and exhaled nitric oxide to guide therapy, as well as treatment with anti-IgE antibody, methotrexate, macrolide antibiotics, antifungal agents and bronchial thermoplasty are provided. Coordinated research efforts for improved phenotyping will provide safe and effective biomarker-driven approaches to severe asthma therapy.	[Chung, Kian Fan; Bush, Andrew; Adcock, Ian M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Chung, Kian Fan; Bush, Andrew] Royal Brompton Hosp, Biomed Res Unit, London SW3 6LY, England; [Brightling, Christopher] Univ Leicester, Inst Lung Hlth, Leicester, Leics, England; [Djukanovic, Ratko] Univ Southampton, Sch Med, Southampton NIHR Resp Biomed Res Unit, Southampton, Hants, England; [Djukanovic, Ratko] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; [Wenzel, Sally E.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA; [Castro, Mario] Washington Univ, Dept Med, St Louis, MO USA; [Bleecker, Eugene R.] Wake Forest Univ, Dept Med, Winston Salem, NC 27109 USA; [Jajour, Nizar N.; Sorkness, Ronald L.] Univ Wisconsin, Dept Med, Madison, WI USA; [Teague, W. Gerald] Univ Virginia, Sch Med, Dept Paediat, Div Resp Med Allergy & Immunol, Charlottesville, VA 22903 USA; [Brozek, Jan L.] McMaster Univ, Dept Clin Epidemiol & Biostat & Med, Hamilton, ON, Canada; [Boulet, Louis-Philippe] Inst Univ Cardiol & Pneumol Quebec, Ctr Rech, Quebec City, PQ, Canada; [Hamid, Qutayba] McGill Univ, Meakins Christie Labs, Montreal, PQ, Canada; [Sterk, Peter J.; Bel, Elisabeth H.] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, NL-1105 AZ Amsterdam, Netherlands; [Bateman, Eric D.] Univ Cape Town, Lung Inst, ZA-7925 Cape Town, South Africa; [Chanez, Pascal] Marseille Univ, Dept Malad Resp, Marseille, France; [Dahlen, Sven-Erik] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Frey, Urs] Univ Basel, Univ Childrens Hosp UKBB, Basel, Switzerland; [Gaga, Mina] Athens Chest Hosp, Resp Dept 7, Athens, Greece; [Gaga, Mina] Athens Chest Hosp, Asthma Ctr, Athens, Greece; [Gibson, Peter] John Hunter Hosp, Hunter Med Res Inst, Newcastle, NSW, Australia; [Mauad, Thais] Univ Med Sch, Dept Pathol, Sao Paulo, Brazil	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk	Mauad, Thais/G-1254-2012	Adcock, Ian/0000-0003-2101-8843; Chung, Kian Fan/0000-0001-7101-1426; Djukanovic, Ratko/0000-0001-6039-5612	Medical Research Council [G1000758]		Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adams NP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003534.pub3; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Al-Samri MT, 2010, J ALLERGY CLIN IMMUN, V125, P1161, DOI 10.1016/j.jaci.2010.02.005; Aldridge RE, 2000, AM J RESP CRIT CARE, V161, P1459; Allen David B, 2003, J Allergy Clin Immunol, V112, pS1, DOI 10.1016/S0091-6749(03)01859-1; Allen David B, 2007, Expert Rev Respir Med, V1, P65, DOI 10.1586/17476348.1.1.65; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; Auffray C, 2010, CHEST, V137, P1410, DOI 10.1378/chest.09-1850; AYRES J, 1984, BRIT MED J, V288, P1715; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; Baines KJ, 2011, J ALLERGY CLIN IMMUN, V127, P153, DOI 10.1016/j.jaci.2010.10.024; Balzar S, 2011, AM J RESP CRIT CARE, V183, P299, DOI 10.1164/rccm.201002-0295OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beisswenger C, 2006, J IMMUNOL, V177, P1833; Bel EH, 2011, THORAX, V66, P910, DOI 10.1136/thx.2010.153643; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Berry M, 2007, THORAX, V62, P1043, DOI 10.1136/thx.2006.073429; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bhavsar PK, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-71; Bossley CJ, 2009, EUR RESPIR J, V34, P1052, DOI 10.1183/09031936.00186508; Bossley CJ, 2012, J ALLERGY CLIN IMMUN, V129, P974, DOI 10.1016/j.jaci.2012.01.059; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Bousquet J, 2010, J ALLERGY CLIN IMMUN, V126, P926, DOI 10.1016/j.jaci.2010.07.019; Bracken M, 2009, ARCH DIS CHILD, V94, P780, DOI 10.1136/adc.2008.152140; Brasier AR, 2010, CTS-CLIN TRANSL SCI, V3, P147, DOI 10.1111/j.1752-8062.2010.00204.x; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brutsche MH, 2000, LANCET, V356, P556, DOI 10.1016/S0140-6736(00)02581-2; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busacker A, 2009, CHEST, V135, P48, DOI 10.1378/chest.08-0049; Bush A, 2010, LANCET, V376, P814, DOI 10.1016/S0140-6736(10)61054-9; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Castro M, 2011, AM J RESP CRIT CARE, V184, P1125, DOI 10.1164/rccm.201103-0396OC; Cates CJ, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000052.pub2; Chakir J, 2002, CLIN EXP ALLERGY, V32, P578, DOI 10.1046/j.0954-7894.2002.01323.x; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chang PJ, 2012, J ALLERGY CLIN IMMUN, V130, P877, DOI 10.1016/j.jaci.2012.07.017; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Chu HW, 2007, J IMMUNOL, V179, P3995; Chung KF, 1999, EUR RESPIR J, V13, P1198; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Collison A, 2011, J ALLERGY CLIN IMMUN, V128, P160, DOI 10.1016/j.jaci.2011.04.005; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; Comhair SAA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018574; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corren J, 2010, AM J RESP CRIT CARE, V181, P788, DOI 10.1164/rccm.200909-1448OC; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9; Davies H, 2000, COCHRANE DB SYST REV; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; Dixon AE, 2011, J ALLERGY CLIN IMMUN, V128, P508, DOI 10.1016/j.jaci.2011.06.009; Doe C, 2010, CHEST, V138, P1140, DOI 10.1378/chest.09-3058; Dolhnikoff M, 2009, J ALLERGY CLIN IMMUN, V123, P1090, DOI 10.1016/j.jaci.2009.02.032; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Ducharme FM, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003137.pub3; Dweik RA, 2011, AM J RESP CRIT CARE, V184, P602, DOI [10.1164/rccm.9120-11ST, 10.1164/rccm.912011ST]; Dweik RA, 2010, AM J RESP CRIT CARE, V181, P1033, DOI 10.1164/rccm.200905-0695OC; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Fens N, 2011, EUR RESPIR J, V38, P1301, DOI 10.1183/09031936.00032911; Fens N, 2011, CLIN EXP ALLERGY, V41, P1371, DOI 10.1111/j.1365-2222.2011.03800.x; Fitzpatrick AM, 2006, J ALLERGY CLIN IMMUN, V118, P1218, DOI 10.1016/j.jaci.2006.08.019; Fitzpatrick AM, 2008, J ALLERGY CLIN IMMUN, V121, P1372, DOI 10.1016/j.jaci.2008.03.008; Fitzpatrick AM, 2011, J ALLERGY CLIN IMMUN, V127, P382, DOI 10.1016/j.jaci.2010.11.015; Fitzpatrick AM, 2010, J ALLERGY CLIN IMMUN, V125, P851, DOI 10.1016/j.jaci.2010.01.048; Fleming L, 2012, THORAX, V67, P675, DOI 10.1136/thoraxjnl-2011-201064; Fleming L, 2012, THORAX, V67, P193, DOI 10.1136/thx.2010.156836; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Forno E, 2012, J ALLERGY CLIN IMMUN, V130, P83, DOI 10.1016/j.jaci.2012.03.020; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Frey U, 2008, LANCET, V372, P1088, DOI 10.1016/S0140-6736(08)61450-6; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gamble J, 2011, RESP MED, V105, P1308, DOI 10.1016/j.rmed.2011.03.019; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Good JT, 2012, CHEST, V141, P599, DOI 10.1378/chest.11-0741; Gras D, 2012, J ALLERGY CLIN IMMUN, V129, P1259, DOI 10.1016/j.jaci.2012.01.073; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenwald R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011919; Grossman JM, 2010, ARTHRIT CARE RES, V62, P1515, DOI 10.1002/acr.20295; Gupta A, 2011, AM J RESP CRIT CARE, V184, P1342, DOI 10.1164/rccm.201107-1239OC; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hanania NA, 2009, NEW ENGL J MED, V360, P1487; Haselkorn T, 2009, J ALLERGY CLIN IMMUN, V124, P921, DOI 10.1016/j.jaci.2009.09.006; Hassan M, 2010, J ALLERGY CLIN IMMUN, V125, P1037, DOI 10.1016/j.jaci.2010.02.031; Hastie AT, 2010, J ALLERGY CLIN IMMUN, V125, P1028, DOI 10.1016/j.jaci.2010.02.008; Hawkins GA, 2012, J ALLERGY CLIN IMMUN, V130, P510, DOI 10.1016/j.jaci.2012.03.018; Heaney LG, 2005, RESP MED, V99, P1152, DOI 10.1016/j.rmed.2005.02.013; Heaney LG, 2003, THORAX, V58, P561, DOI 10.1136/thorax.58.7.561; Henneberger PK, 2010, EUR RESPIR J, V36, P743, DOI 10.1183/09031936.00135109; Hew M, 2010, INTERN MED J, V40, P323, DOI 10.1111/j.1445-5994.2010.02192.x; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holbrook JT, 2012, JAMA-J AM MED ASSOC, V307, P373, DOI 10.1001/jama.2011.2035; Holguin F, 2011, J ALLERGY CLIN IMMUN, V127, P1486, DOI 10.1016/j.jaci.2011.03.036; HORN BR, 1975, NEW ENGL J MED, V292, P1152, DOI 10.1056/NEJM197505292922204; Humbert M, 2009, ALLERGY, V64, P1194, DOI 10.1111/j.1398-9995.2009.02122.x; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-0350C; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; James AL, 2009, EUR RESPIR J, V34, P1040, DOI 10.1183/09031936.00181608; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jatakanon A, 1999, THORAX, V54, P234; Jia GQ, 2012, J ALLERGY CLIN IMMUN, V130, P647, DOI 10.1016/j.jaci.2012.06.025; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kelly HW, 2012, NEW ENGL J MED, V367, P904, DOI 10.1056/NEJMoa1203229; Kerstjens HAM, 2012, NEW ENGL J MED, V367, P1198, DOI 10.1056/NEJMoa1208606; Kerstjens HAM, 2011, J ALLERGY CLIN IMMUN, V128, P308, DOI 10.1016/j.jaci.2011.04.039; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kishiyama JL, 1999, CLIN IMMUNOL, V91, P126, DOI 10.1006/clim.1999.4714; Knutsen AP, 2012, J ALLERGY CLIN IMMUN, V129, P280, DOI 10.1016/j.jaci.2011.12.970; Komakula S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-32; Kowalski ML, 2011, ALLERGY, V66, P32, DOI 10.1111/j.1398-9995.2010.02379.x; LAI CKW, 1989, AM REV RESPIR DIS, V140, P917; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lazarus SC, 2001, JAMA-J AM MED ASSOC, V285, P2583, DOI 10.1001/jama.285.20.2583; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-17460C; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Lemanske RF, 2010, NEW ENGL J MED, V362, P975, DOI 10.1056/NEJMoa1001278; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Levy BD, 2005, AM J RESP CRIT CARE, V172, P824, DOI 10.1164/rccm.200410-1413OC; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Li XN, 2011, J ALLERGY CLIN IMMUN, V127, P1457, DOI 10.1016/j.jaci.2011.01.056; Li XN, 2010, J ALLERGY CLIN IMMUN, V125, P328, DOI 10.1016/j.jaci.2009.11.018; Lock SH, 1996, AM J RESP CRIT CARE, V153, P509; Lotvall J, 2011, J ALLERGY CLIN IMMUN, V127, P355, DOI 10.1016/j.jaci.2010.11.037; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McGrath KW, 2012, AM J RESP CRIT CARE, V185, P612, DOI 10.1164/rccm.201109-1640OC; McKinley L, 2008, J IMMUNOL, V181, P4089; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nair P, 2012, CLIN EXP ALLERGY, V42, P1097, DOI 10.1111/j.1365-2222.2012.04014.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Naqvi M, 2008, ANN ALLERG ASTHMA IM, V100, P551, DOI 10.1016/S1081-1206(10)60055-5; National Heart Lung, 2007, 3 NAT HEART LUNG BLO; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; Lasserson TJ, 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD007949, DOI 10.1002/14651858.CD007949]; NIEROP G, 1992, THORAX, V47, P349, DOI 10.1136/thx.47.5.349; Oborne J, 2009, AM J RESP CRIT CARE, V180, P598, DOI 10.1164/rccm.200904-0616OC; OGIRALA RG, 1991, NEW ENGL J MED, V324, P585, DOI 10.1056/NEJM199102283240903; Pakhale S, CHEST, V137, P1316; Pasternack R, 2005, J ALLERGY CLIN IMMUN, V116, P1123, DOI 10.1016/j.jaci.2005.08.030; Pavord ID, 2012, LANCET, V380, P651, DOI 10.1016/S0140-6736(12)60988-X; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pedersen S, 2001, AM J RESP CRIT CARE, V164, P521; Pedersen SE, 2007, J ALLERGY CLIN IMMUN, V120, P1036, DOI 10.1016/j.jaci.2007.07.016; Peters SP, 2010, NEW ENGL J MED, V363, P1715, DOI 10.1056/NEJMoa1008770; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Piper E, 2013, EUR RESPIR J, V41, P330, DOI 10.1183/09031936.00223411; Reddel HK, 2006, EUR RESPIR J, V28, P182, DOI 10.1183/09031936.06.00105305; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Saglani S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-46; Sales J, 2008, J PEDIATR PSYCHOL, V33, P208, DOI 10.1093/jpepsy/jsm068; Salmun LM, 1999, J ALLERGY CLIN IMMUN, V103, P810, DOI 10.1016/S0091-6749(99)70424-0; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; SEARS MR, 1987, BRIT MED J, V294, P477; Seddon P, 2006, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002885.PUB2; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Simon MR, 2010, J ALLERGY CLIN IMMUN, V126, P527, DOI 10.1016/j.jaci.2010.05.016; Simpson JL, 2006, RESPIROLOGY, V11, P54, DOI 10.1111/j.1440-1843.2006.00784.x; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503.369OC; Sin DD, 2008, THORAX, V63, P1018, DOI 10.1136/thx.2007.086819; Slager RE, 2012, J ALLERGY CLIN IMMUN, V130, P516, DOI 10.1016/j.jaci.2012.03.030; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Spears M, 2009, EUR RESPIR J, V33, P1010, DOI 10.1183/09031936.00158208; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stern G, 2011, J ALLERGY CLIN IMMUN, V128, P293, DOI 10.1016/j.jaci.2011.03.010; Stirling RG, 1998, THORAX, V53, P1030; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; 't Veen JCCMI, 2000, AM J RESP CRIT CARE, V161, P1902; Tantisira KG, 2011, NEW ENGL J MED, V365, P1173, DOI 10.1056/NEJMoa0911353; Taylor DR, 2008, J ALLERGY CLIN IMMUN, V122, P836, DOI 10.1016/j.jaci.2008.07.025; TAYLOR DR, 1993, THORAX, V48, P134, DOI 10.1136/thx.48.2.134; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Teoh L, 2012, COCHRANE DB SYST REV, V4; Thamrin C, 2011, THORAX, V66, P1036, DOI 10.1136/thx.2010.156489; Thamrin C, 2011, J ALLERGY CLIN IMMUN, V127, P1494, DOI 10.1016/j.jaci.2011.01.018; Tillie-Leblond I, 2008, ALLERGY, V63, P533, DOI 10.1111/j.1398-9995.2008.01656.x; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Tsitsiou E, 2012, J ALLERGY CLIN IMMUN, V129, P95, DOI 10.1016/j.jaci.2011.08.011; Turchiarelli V, 2011, ALLERGY, V66, P1099, DOI 10.1111/j.1398-9995.2011.02600.x; Vachier I, 2005, J ALLERGY CLIN IMMUN, V115, P55, DOI 10.1016/j.jaci.2004.09.038; Vamos M, 1999, AUST NZ J PSYCHIAT, V33, P538, DOI 10.1080/j.1440-1614.1999.00591.x; Van Staa TP, 2003, J BONE MINER RES, V18, P913, DOI 10.1359/jbmr.2003.18.5.913; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; van Veen IH, 2009, J ALLERGY CLIN IMMUN, V124, P615, DOI 10.1016/j.jaci.2009.06.029; Vicencio AG, 2010, PEDIATRICS, V125, pE1255, DOI 10.1542/peds.2009-2443; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Wang CH, 2008, AM J RESP CRIT CARE, V178, P583, DOI 10.1164/rccm.200710-1557OC; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wechsler ME, 2011, AM J RESP CRIT CARE, V184, P1247, DOI 10.1164/rccm.201103-0514OC; Wenzel SE, 2007, AM J RESP CRIT CARE, V175, P570, DOI 10.1164/rccm.200607-909OC; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wos M, 2008, AM J RESP CRIT CARE, V177, P1082, DOI 10.1164/rccm.200607-973OC; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Yamamoto M, 2011, CLIN EXP ALLERGY, V42, P760; Yorke J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002982.pub3; Zhang QL, 2012, RESP RES, V13, DOI 10.1186/1465-9921-13-35; [Anonymous], 2000, AM J RESP CRIT CARE, V162, P2341; [Anonymous], 1987, AM REV RESP DIS, V136, P225	222	420	445	9	55	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936	1399-3003		EUR RESPIR J	Eur. Resp. J.	FEB	2014	43	2					343	373		10.1183/09031936.00202013		31	Respiratory System	Respiratory System	AA0YY	WOS:000330824500010	24337046	
J	Wilson, DR; Lima, MT; Durham, SR				Wilson, DR; Lima, MT; Durham, SR			Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis	ALLERGY			English	Reprint						allergic rhinitis; immunotherapy; sublingual; systematic review	PLACEBO-CONTROLLED EVALUATION; HOUSE-DUST-MITE; RANDOMIZED CONTROLLED-TRIAL; PARIETARIA-JUDAICA EXTRACT; GRASS-POLLEN IMMUNOTHERAPY; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; HAY-FEVER; SEASONAL RHINITIS; RHINOCONJUNCTIVITIS	Allergic rhinitis is a common condition which, at its most severe, can significantly impair quality of life despite optimal treatment with antihistamines and topical nasal corticosteroids. Allergen injection immunotherapy significantly reduces symptoms and medication requirements in allergic rhinitis but its use is limited by the possibility of severe systemic reactions. There has therefore been considerable interest in alternative routes for delivery of allergen immunotherapy, particularly the sublingual route. The objective was to evaluate the efficacy of sublingual immunotherapy (SLIT), compared with placebo, for reductions in symptoms and medication requirements. The Cochrane Controlled Clinical Trials Register, MEDLINE (1966-2002), EMBASE (1974-2002) and Scisearch were searched, up to September 2002, using the terms (Rhin* OR hay fever) AND (immunotherap* OR desensiti*ation) AND (sublingual). All studies identified by the searches were assessed by the reviewers to identify Randomized Controlled Trials involving participants with symptoms of allergic rhinitis and proven allergen sensitivity, treated with SLIT or corresponding placebo. Data from identified studies was abstracted onto a standard extraction sheet and subsequently entered into RevMan 4.1. Analysis was performed by the method of standardized mean differences (SMD) using a random effects model. P-values < 0.05 were considered statistically significant. Subgroup analyses were performed according to the type of allergen administered, the age of participants and the duration of treatment. Twenty-two trials involving 979 patients, were included. There were six trials of SLIT for house dust mite allergy, five for grass pollen, five for parietaria, two for olive and one each for, ragweed, cat, tree and cupressus. Five studies enrolled exclusively children. Seventeen studies administered the allergen by sublingual drops subsequently swallowed, three by drops subsequently spat out and two by sublingual tablets. Eight studies involved treatment for less than 6 months, 10 studies for 6-12 months and four studies for greater than 12 months. All included studies were double-blind placebo-controlled trials of parallell group design. Concealment of treatment allocation was considered adequate in all studies and the use of identical placebo preparations was almost universal. There was significant heterogeneity, most likely due to widely differing scoring systems between studies, for most comparisons. Overall there was a significant reduction in both symptoms (SMD -0.42, 95% confidence interval -0.69 to -0.15; P = 0.002) and medication requirements [SMD -0.43 (-0.63, -0.23); P = 0.00003] following immunotherapy. Subgroup analyses failed to identify a disproportionate benefit of treatment according to the allergen administered. There was no significant reduction in symptoms and medication scores in those studies involving only children but total numbers of participants was too small to make this a reliable conclusion. Increasing duration of treatment does not clearly increase efficacy. The total dose of allergen administered may be important but insufficient data was available to analyse this factor.	Natl Heart & Lung Inst, Imperial Coll London Sch Med, London SW3 6LY, England; Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England	Durham, SR (reprint author), Natl Heart & Lung Inst, Imperial Coll London Sch Med, Guy Scadding Bldg,Royal Brompton Campus,Dovehouse, London SW3 6LY, England.						Andre C, 2002, ALLERGY, V57, P31; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Committee on the safety of medicines, 1986, BRIT MED J, V293, P948, DOI 10.1136/bmj.293.6552.948; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; D'Ambrosio F P, 1996, Allergol Immunopathol (Madr), V24, P146; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; VARNEY VA, 1991, BRIT MED J, V302, P265; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	30	419	453	1	25	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JAN	2005	60	1					4	12		10.1111/j.1398-9995.2005.00699.x		9	Allergy; Immunology	Allergy; Immunology	876YW	WOS:000225535900002	15575924	
J	Finotto, S; Neurath, MF; Glickman, JN; Qin, SX; Lehr, HA; Green, FHY; Ackerman, K; Haley, K; Gatte, PR; Szabo, SJ; Drazen, JM; De Sanctis, GT; Glimcher, LH				Finotto, S; Neurath, MF; Glickman, JN; Qin, SX; Lehr, HA; Green, FHY; Ackerman, K; Haley, K; Gatte, PR; Szabo, SJ; Drazen, JM; De Sanctis, GT; Glimcher, LH			Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet	SCIENCE			English	Article							HYPERRESPONSIVENESS; INFLAMMATION; CELLS; TH2	Human asthma is associated with airway infiltration by T helper 2 (T(H)2) lymphocytes. We observed reduced expression of the T(H)1 transcription factor, T-bet, in T cells from airways of patients with asthma compared with that in T cells from airways of nonasthmatic patients, suggesting that loss of T-bet might be associated with asthma. Mice with a targeted deletion of the T-bet gene and severe combined immunodeficient mice receiving CD4(+) cells from T-bet knockout mice spontaneously demonstrated multiple physiological and inflammatory features characteristic of asthma, Thus, T-bet deficiency, in the absence of allergen exposure, induces a murine phenotype reminiscent of both acute and chronic human asthma.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Pulm & Crit Care, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Millenium Pharmaceut, Cambridge, MA 02138 USA; Univ Mainz, Dept Pathol, D-55131 Mainz, Germany; Univ Calgary, Dept Pathol & Lab Med, Calgary, AB T2N 4N1, Canada; Univ Mainz, Med Clin 1, D-55131 Mainz, Germany	Glimcher, LH (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Ain, Kenneth/A-5179-2012	Ain, Kenneth/0000-0002-2668-934X	NHLBI NIH HHS [HL-36110]		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Cohn L, 1998, J IMMUNOL, V161, P3813; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Finotto S, 1999, DEVELOPMENT, V126, P2935; FINOTTO S, UNPUB; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; LI XM, 1996, J IMMUNOL, V157, P2316; Mullen AC, 2001, SCIENCE, V292, P1907, DOI 10.1126/science.1059835; Papaioannou VE, 1997, TRENDS GENET, V13, P212, DOI 10.1016/S0168-9525(97)01144-X; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543	16	418	481	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 11	2002	295	5553					336	338		10.1126/science.1065544		3	Multidisciplinary Sciences	Science & Technology - Other Topics	511RD	WOS:000173278600052	11786643	
J	Larche, M; Akdis, CA; Valenta, R				Larche, Mark; Akdis, Cezmi A.; Valenta, Rudolf			Immunological mechanisms of allergen-specific immunotherapy	NATURE REVIEWS IMMUNOLOGY			English	Review							GRASS-POLLEN IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; T-CELL EPITOPES; IGG MONOCLONAL-ANTIBODIES; MONOPHOSPHORYL-LIPID-A; MAJOR PEANUT ALLERGEN; HOUSE-DUST MITE; BET V 1; SUBLINGUAL IMMUNOTHERAPY; BIRCH-POLLEN	Allergen-specific immunotherapy has been carried out for almost a century and remains one of the few antigen-specific treatments for inflammatory diseases. The mechanisms by which allergen-specific immunotherapy exerts its effects include the modulation of both T-cell and B-cell responses to allergen. There is a strong rationale for improving the efficacy of allergen-specific immunotherapy by reducing the incidence and severity of adverse reactions mediated by IgE. Approaches to address this problem include the use of modified allergens, novel adjuvants and alternative routes of administration. This article reviews the development of allergen-specific immunotherapy, our current understanding of its mechanisms of action and its future prospects.	McMaster Univ, Dept Med, Div Clin Immunol & Allergy, Hamilton, ON L8N 3Z5, Canada; Univ London Imperial Coll Sci Technol & Med, MRC & Asthma UK Ctr Allerg Mechanisms Asthma, Dept Allergy & Clin Immunol, Natl Heart & Lung Inst,Fac Med, London SW7 2AZ, England; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria	Larche, M (reprint author), McMaster Univ, Dept Med, Div Clin Immunol & Allergy, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	m.larche@imperial.ac.uk	Larche, Mark/B-4326-2010				Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; AALBERSE RC, 1983, J IMMUNOL, V130, P722; Achatz G, 1997, SCIENCE, V276, P409, DOI 10.1126/science.276.5311.409; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Akdis CA, 1999, FASEB J, V13, P603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Arquint O, 1999, J ALLERGY CLIN IMMUN, V104, P1239; ATTALLAH NA, 1969, IMMUNOCHEMISTRY, V6, P609, DOI 10.1016/0019-2791(69)90199-2; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Ball T, 1999, FASEB J, V13, P1277; Bannon GA, 1999, INT ARCH ALLERGY IMM, V118, P315, DOI 10.1159/000024115; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BLACK J. H., 1939, JOUR ALLERGY, V10, P156, DOI 10.1016/S0021-8707(39)90048-1; Bohle B, 2004, J IMMUNOL, V172, P6642; Bolhaar STHP, 2005, CLIN EXP ALLERGY, V35, P1638, DOI 10.1111/j.1365-2222.2005.02390.x; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; Buhot C, 2004, PROTEIN SCI, V13, P2970, DOI 10.1110/ps.04885404; CARBALLIDO JM, 1992, EUR J IMMUNOL, V22, P1357, DOI 10.1002/eji.1830220605; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Weck A L, 1972, Int Arch Allergy Appl Immunol, V42, P782; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Drew AC, 2004, J IMMUNOL, V173, P5872; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1995, J IMMUNOL, V154, P1932; Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Feinberg SM, 1940, J AMER MED ASSOC, V115, P23; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Flicker S, 2002, EUR J IMMUNOL, V32, P2156, DOI 10.1002/1521-4141(200208)32:8<2156::AID-IMMU2156>3.0.CO;2-A; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Freeman J, 1911, LANCET, V2, P814; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Ganglberger E, 2001, FASEB J, V15, P2524, DOI 10.1096/fj.00-0888fje; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; Gronlund H, 2002, IMMUNOLOGY, V107, P523, DOI 10.1046/j.1365-2567.2002.01535.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hirahara K, 2001, J ALLERGY CLIN IMMUN, V108, P94, DOI 10.1067/mai.2001.115481; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; Jeannin P, 1998, J IMMUNOL, V160, P3555; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Karamloo F, 2005, EUR J IMMUNOL, V35, P3268, DOI 10.1002/eji.200425522; KAWANO Y, 1994, J IMMUNOL, V153, P4948; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kay AB, 2001, NEW ENGL J MED, V344, P109; King TP, 2001, J IMMUNOL, V166, P6057; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.011.041; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; Loveless MH, 1940, J IMMUNOL, V38, P25; MALLEY A, 1969, J ALLERGY, V43, P59, DOI 10.1016/0021-8707(69)90126-9; Mark PG, 1996, CLIN EXP ALLERGY, V26, P1316, DOI 10.1046/j.1365-2222.1996.d01-283.x; MARSH DG, 1970, IMMUNOLOGY, V18, P705; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; MUDDE GC, 1990, IMMUNOL TODAY, V11, P440, DOI 10.1016/0167-5699(90)90172-6; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muller UR, 2005, CURR OPIN ALLERGY CL, V5, P343; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; Okada T, 1998, FEBS LETT, V434, P255, DOI 10.1016/S0014-5793(98)00992-2; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prausnitz C, 1921, ZBL BAKT           1, V86, P160; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Roth-Walter F, 2005, VACCINE, V23, P2703, DOI 10.1016/j.vaccine.2004.11.052; Roy K, 1999, NAT MED, V5, P387; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Shim JY, 2003, CLIN EXP ALLERGY, V33, P52, DOI 10.1046/j.1365-2222.2003.01567.x; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P469, DOI 10.1016/S0091-6749(98)70137-X; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Suphioglu C, 2001, FEBS LETT, V502, P46, DOI 10.1016/S0014-5793(01)02661-8; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; Takagi H, 2005, P NATL ACAD SCI USA, V102, P17525, DOI 10.1073/pnas.0503428102; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Vermaelen KY, 2001, J EXP MED, V193, P51; Visco V, 1996, J IMMUNOL, V157, P956; Von Pirquet C., 1906, MUNCHEN MED WOCHEN, V30, P1457; Vrtala S, 2000, J IMMUNOL, V165, P6653; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WARNER JO, 1978, LANCET, V2, P912; Weiss Richard, 2005, Current Drug Targets - Inflammation and Allergy, V4, P585, DOI 10.2174/156801005774322171; Westritschnig K, 2004, J IMMUNOL, V172, P5684; Wilcock LK, 2004, CLIN EXP ALLERGY, V34, P1373, DOI 10.1111/j.1365-2222.2004.02052.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219; Zoss A, 1937, J ALLERGY, V8, P329, DOI 10.1016/S0021-8707(37)90140-0	145	417	443	3	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	OCT	2006	6	10					761	771		10.1038/nri1934		11	Immunology	Immunology	094PN	WOS:000241251500015	16998509	
J	DiFranza, JR; Aligne, CA; Weitzman, M				DiFranza, JR; Aligne, CA; Weitzman, M			Prenatal and postnatal environmental tobacco smoke exposure and children's health	PEDIATRICS			English	Review						environmental tobacco smoke; children; prenatal; otitis media; asthma; SIDS	LOW-BIRTH-WEIGHT; MATERNAL CIGARETTE-SMOKING; INFANT-DEATH-SYNDROME; ADOLESCENT NICOTINE EXPOSURE; RAT-BRAIN REGIONS; RESPIRATORY-TRACT ILLNESS; MIDDLE-EAR DISEASE; AGE 7 YEARS; PARENTAL SMOKING; PASSIVE SMOKING	Children's exposure to tobacco constituents during fetal development and via environmental tobacco smoke (ETS) exposure is perhaps the most ubiquitous and hazardous of children's environmental exposures. A large literature links both prenatal maternal smoking and children's ETS exposure to decreased lung growth and increased rates of respiratory tract infections, otitis media, and childhood asthma, with the severity of these problems increasing with increased exposure. Sudden infant death syndrome, behavioral problems, neurocognitive decrements, and increased rates of adolescent smoking also are associated with such exposures. Studies of each of these problems suggest independent effects of both pre- and postnatal exposure for each, with the respiratory risk associated with parental smoking seeming to be greatest during fetal development and the first several years of life.	Univ Massachusetts, Sch Med, Dept Family Med & Community Hlth, Worcester, MA 01655 USA; Univ Rochester, Sch Med & Dent, Dept Pediat, Rochester, NY 14642 USA; Amer Acad Pediat, Ctr Child Hlth Res, Rochester, NY USA	DiFranza, JR (reprint author), Univ Massachusetts, Sch Med, Dept Family Med & Community Hlth, 55 Lake Ave, Worcester, MA 01655 USA.	difranzj@ummhc.org					Adair-Bischoff CE, 1998, ARCH PEDIAT ADOL MED, V152, P127; Agabiti N, 1999, EPIDEMIOLOGY, V10, P692, DOI 10.1097/00001648-199911000-00008; Al-Delaimy WK, 2002, TOB CONTROL, V11, P176, DOI 10.1136/tc.11.3.176; Aligne CA, 1997, ARCH PEDIAT ADOL MED, V151, P648; Alm B, 1998, ARCH DIS CHILD, V78, P329; Anderson HR, 1997, THORAX, V52, P1003; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; Baghurst P A, 1992, Paediatr Perinat Epidemiol, V6, P403, DOI 10.1111/j.1365-3016.1992.tb00784.x; BARROS FC, 1992, PEDIATRICS, V90, P238; BENOWITZ NL, 1998, NICOTINE SAFETY TOXI, P7; BLAND M, 1973, BR J PREV SOC MED, V27, P150; BREESEHALL C, 1984, J PEDIATR, V105, P358; Breslau N, 2000, BIOL PSYCHIAT, V47, P1005, DOI 10.1016/S0006-3223(99)00312-1; Breslau N, 2000, BIOL PSYCHIAT, V47, P71, DOI 10.1016/S0006-3223(99)00131-6; Brook JS, 2000, ARCH PEDIAT ADOL MED, V154, P381; Bush PG, 2000, PLACENTA, V21, P824, DOI 10.1053/plac.2000.0571; BUTLER NR, 1973, BRIT MED J, V4, P573; BYRD RS, 1994, PEDIATRICS, V93, P481; CAMERON P, 1967, J ALLERGY, V40, P12, DOI 10.1016/0021-8707(67)90054-8; CHARLTON A, 1984, BRIT MED J, V288, P1647; CHEN Y, 1986, BRIT MED J, V293, P303; CHEN Y, 1988, INT J EPIDEMIOL, V17, P348, DOI 10.1093/ije/17.2.348; COGHLIN J, 1989, AM J EPIDEMIOL, V130, P696; COLLEY JRT, 1974, LANCET, V2, P1031; Cook DG, 1997, THORAX, V52, P1081; Cook DG, 1998, THORAX, V53, P295; Cook DG, 1998, THORAX, V53, P884; Corbo GM, 1996, AM J RESP CRIT CARE, V154, P695; CORBO GM, 1989, BRIT MED J, V299, P1491; COURT C, 1995, BRIT MED J, V310, P7; DENSON R, 1975, CAN PSYCHIAT ASSOC J, V20, P183; DeSalvia MA, 1995, PSYCHOPHARMACOLOGY, V122, P66; DiFranza JR, 1996, PEDIATRICS, V97, P560; DIGIOVANNI V, 1993, BRAIN RES, V616, P126; DODGE R, 1982, ARCH ENVIRON HEALTH, V37, P151; Dube M. F., 1982, RECENT ADV TOBACCO S, V8, P42; DUFF AL, 1993, PEDIATRICS, V92, P535; DUNN HG, 1977, CAN J PUBLIC HEALTH, V68, P43; DUNN HG, 1976, CAN J PUBLIC HEALTH, V67, P499; Dwyer T, 1999, AM J EPIDEMIOL, V149, P593; DWYER T, 1995, PEDIATR ANN, V24, P350; Edwards K, 1999, HUM EXP TOXICOL, V18, P233, DOI 10.1191/096032799678839978; Ernst M, 2001, J AM ACAD CHILD PSY, V40, P630, DOI 10.1097/00004583-200106000-00007; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P991; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; FECHTER LD, 1987, NEUROTOXICOL TERATOL, V9, P277, DOI 10.1016/0892-0362(87)90013-4; Fergusson D M, 1985, Pediatr Pulmonol, V1, P99, DOI 10.1002/ppul.1950010208; Fergusson D M, 1991, Paediatr Perinat Epidemiol, V5, P189, DOI 10.1111/j.1365-3016.1991.tb00700.x; FERGUSSON DM, 1981, J EPIDEMIOL COMMUN H, V35, P180, DOI 10.1136/jech.35.3.180; FERGUSSON DM, 1993, PEDIATRICS, V92, P815; FOGELMAN KR, 1988, BRIT MED J, V297, P1233; FRIED PA, 1992, J DEV BEHAV PEDIATR, V13, P383; FRIED PA, 1988, NEUROTOXICOL TERATOL, V10, P305, DOI 10.1016/0892-0362(88)90032-3; FRIED PA, 1990, J DEV BEHAV PEDIATR, V11, P49; FRIED PA, 1987, J DEV BEHAV PEDIATR, V8, P318; FRISCHER T, 1992, J PEDIATR-US, V121, P17, DOI 10.1016/S0022-3476(05)82534-X; GERGEN PJ, 1998, PEDIATRICS, V101; HALKEN S, 1995, ALLERGY, V50, P97; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; HARDY JB, 1972, LANCET, V2, P1332; HARLAP S, 1974, LANCET, V1, P529; Haug K, 2000, ACTA OBSTET GYN SCAN, V79, P485, DOI 10.1034/j.1600-0412.2000.079006485.x; HINTON AE, 1993, CLIN OTOLARYNGOL, V18, P178; HOWARD RB, 1987, AM J OBSTET GYNECOL, V157, P1261; Huang SW, 2001, ANN ALLERG ASTHMA IM, V87, P350; Ilicali OC, 2001, LARYNGOSCOPE, V111, P163; Jauniaux E, 2001, OBSTET GYNECOL, V97, P57, DOI 10.1016/S0029-7844(00)01108-X; Jedrychowski W, 1997, ENVIRON HEALTH PERSP, V105, P302, DOI 10.1289/ehp.97105302; Jinot Jennifer, 1996, Reviews on Environmental Health, V11, P89; Joad JP, 2000, CLIN CHEST MED, V21, P37, DOI 10.1016/S0272-5231(05)70006-X; JOHNS JM, 1982, NEUROBEH TOXICOL TER, V4, P365; Johnson EO, 2000, BIOL PSYCHIAT, V47, P490, DOI 10.1016/S0006-3223(99)00223-1; Johnson JG, 2000, JAMA-J AM MED ASSOC, V284, P2348, DOI 10.1001/jama.284.18.2348; Kallen K, 2000, EARLY HUM DEV, V58, P197, DOI 10.1016/S0378-3782(00)00077-3; Kelley BM, 1999, J ADDICT DIS, V18, P27, DOI 10.1300/J069v18n03_04; KLEINMAN JC, 1985, AM J EPIDEMIOL, V121, P843; KLINE J, 1987, INT J EPIDEMIOL, V16, P44, DOI 10.1093/ije/16.1.44; Kohler E, 1999, HUM EXP TOXICOL, V18, P212, DOI 10.1191/096032799678839932; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; KRAMER MS, 1990, PEDIATRICS, V86, P18; KRAMER MS, 1987, PEDIATRICS, V80, P502; KRISTJANSSON EA, 1989, DRUG ALCOHOL DEPEN, V24, P11, DOI 10.1016/0376-8716(89)90003-3; L'Hoir MP, 1998, ARCH DIS CHILD, V79, P386; LEHTOVIRTA P, 1978, BRIT J OBSTET GYNAEC, V85, P729, DOI 10.1111/j.1471-0528.1978.tb15592.x; LESON S, 1995, J ASTHMA, V32, P285, DOI 10.3109/02770909509044836; Levin ED, 1996, DEV BRAIN RES, V97, P207, DOI 10.1016/S0165-3806(96)00144-7; LEVIN ED, 1993, NEUROTOXICOL TERATOL, V15, P251, DOI 10.1016/0892-0362(93)90006-A; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; LICHTENSTEIGER W, 1988, PROG BRAIN RES, V73, P137; LINDEMEYER RG, 1981, J AM DENT ASSOC, V103, P719; Lindley AA, 2000, AM J EPIDEMIOL, V152, P219, DOI 10.1093/aje/152.3.219; LONGO LD, 1977, AM J OBSTET GYNECOL, V129, P69; LUEPKER RV, 1981, AM J PUBLIC HEALTH, V71, P1320, DOI 10.2105/AJPH.71.12.1320; MACARTHUR C, 1988, BRIT J OBSTET GYNAEC, V95, P551, DOI 10.1111/j.1471-0528.1988.tb09481.x; MACMAHON B, 1965, AM J EPIDEMIOL, V82, P247; MACTUTUS CF, 1985, TERATOLOGY, V31, P1, DOI 10.1002/tera.1420310102; MALLOY MH, 1988, AM J EPIDEMIOL, V128, P46; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Matsubara F, 2000, J Epidemiol, V10, P335; Matte TD, 2001, BRIT MED J, V323, P310, DOI 10.1136/bmj.323.7308.310; MCCARTON C, 1998, PEDIATRICS, V102; MCGEE R, 1994, J PAEDIATR CHILD H, V30, P263, DOI 10.1111/j.1440-1754.1994.tb00631.x; McMartin KI, 2002, J PEDIATR-US, V140, P205, DOI 10.1067/mpd.2002.121937; MEINERT R, 1994, J EPIDEMIOL COMMUN H, V48, P325, DOI 10.1136/jech.48.3.325; Mereu G, 2000, J PHARMACOL EXP THER, V294, P728; MEYER MB, 1972, AM J EPIDEMIOL, V96, P1; Milberger S, 1996, AM J PSYCHIAT, V153, P1138; Mitchell E, 1999, BRIT MED J, V319, P1461; Mitchell EA, 1997, PEDIATRICS, V100, P835, DOI 10.1542/peds.100.5.835; MORROW RJ, 1988, AM J OBSTET GYNECOL, V159, P1069; MURRAY AB, 1993, J ALLERGY CLIN IMMUN, V91, P102, DOI 10.1016/0091-6749(93)90302-V; MURRIN LC, 1987, LIFE SCI, V40, P1699, DOI 10.1016/0024-3205(87)90020-8; NAEYE RL, 1984, OBSTET GYNECOL, V64, P601; NAEYE RL, 1992, J DEV BEHAV PEDIATR, V13, P425; National Cancer Institute, 1999, NIH PUB, V99-4649; National Research Council, 1986, ENV TOB SMOK MEAS EX; NEDDENRIEP D, 1990, American Review of Respiratory Disease, V141, pA282; Nelson E, 1999, HUM EXP TOXICOL, V18, P252, DOI 10.1191/096032799678840002; Newman MB, 1999, BEHAV PHARMACOL, V10, P699; OCONNELL EJ, 1974, ANN ALLERGY, V32, P142; Olds D, 1997, MENT RETARD DEV D R, V3, P257, DOI 10.1002/(SICI)1098-2779(1997)3:3<257::AID-MRDD6>3.0.CO;2-M; OLDS D, 1994, PEDIATRICS, V93, P973; OLDS DL, 1994, PEDIATRICS, V93, P221; OSTREA EM, 1994, J PEDIATR-US, V124, P471, DOI 10.1016/S0022-3476(94)70378-7; PATRICK DL, 1994, AM J PUBLIC HEALTH, V84, P1086, DOI 10.2105/AJPH.84.7.1086; PHAROAH POD, 1994, ARCH DIS CHILD, V70, P271; Pitsavos C, 2002, TOB CONTROL, V11, P220, DOI 10.1136/tc.11.3.220; PULLAN CR, 1982, BRIT MED J, V284, P1665; Ramsay MC, 2000, NEUROPSYCHOL REV, V10, P1, DOI 10.1023/A:1009065713389; RANTAKALLIO P, 1992, INT J EPIDEMIOL, V21, P1106, DOI 10.1093/ije/21.6.1106; RANTAKALLIO P, 1983, ACTA PAEDIATR SCAND, V72, P747, DOI 10.1111/j.1651-2227.1983.tb09805.x; RANTAKALLIO P, 1987, PREV MED, V16, P597; RYLANDER E, 1995, EPIDEMIOLOGY, V6, P289, DOI 10.1097/00001648-199505000-00017; SAID G, 1978, J EPIDEMIOL COMMUN H, V32, P97, DOI 10.1136/jech.32.2.97; SCHLUMPF M, 1988, PHARMACOL BIOCHEM BE, V30, P199, DOI 10.1016/0091-3057(88)90444-3; SEXTON M, 1984, JAMA-J AM MED ASSOC, V251, P911, DOI 10.1001/jama.251.7.911; SIMPSON WJ, 1957, AM J OBSTET GYNECOL, V73, P808; SLOTKIN TA, 1987, J PHARMACOL EXP THER, V242, P232; Slotkin TA, 1998, J PHARMACOL EXP THER, V285, P931; SLOTKIN TA, 1987, BRAIN RES BULL, V18, P601, DOI 10.1016/0361-9230(87)90130-4; Soothill PW, 1996, BRIT J OBSTET GYNAEC, V103, P78, DOI 10.1111/j.1471-0528.1996.tb09519.x; SORENSON CA, 1991, PHARMACOL BIOCHEM BE, V40, P991, DOI 10.1016/0091-3057(91)90117-K; STAHLBERG MR, 1986, PEDIATR INFECT DIS J, V5, P30; Stathis SL, 1999, PEDIATRICS, V104, P1; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P50; STRACHAN DP, 1995, BRIT MED J, V311, P1053; Strachan DP, 1998, THORAX, V53, P204; STREISSGUTH AP, 1986, NEUROTOXICOL TERATOL, V8, P717; STREISSGUTH AP, 1984, DEV PSYCHOL, V20, P533, DOI 10.1037//0012-1649.20.4.533; Tattoli M, 1999, PHARMACOL RES, V40, P271, DOI 10.1006/phrs.1999.0542; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786; Thomas JD, 2000, NEUROTOXICOL TERATOL, V22, P695, DOI 10.1016/S0892-0362(00)00096-9; Trauth JA, 2000, BRAIN RES, V873, P18, DOI 10.1016/S0006-8993(00)02465-3; Trauth JA, 2000, BRAIN RES, V867, P29, DOI 10.1016/S0006-8993(00)02208-3; Trauth JA, 1999, BRAIN RES, V851, P9, DOI 10.1016/S0006-8993(99)01994-0; TRAUTH JA, 2004, IN PRESS BRAIN RES; ULM MR, 1995, AM J OBSTET GYNECOL, V172, P1485, DOI 10.1016/0002-9378(95)90482-4; *US DEP HHS, 1986, DHHS PUBL CDC; U.S. EPA, 1992, EPA600690006F OFF RE; Vik T, 1996, EARLY HUM DEV, V45, P245, DOI 10.1016/0378-3782(96)01735-5; Wakschlag LS, 2002, AM J PUBLIC HEALTH, V92, P966, DOI 10.2105/AJPH.92.6.966; Wakschlag LS, 1997, ARCH GEN PSYCHIAT, V54, P670; Weitzman M, 2002, NEUROTOXICOL TERATOL, V24, P397, DOI 10.1016/S0892-0362(02)00201-5; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1992, PEDIATRICS, V90, P342; *WHO, 1999, TOB FREE IN INT CONS; Willatt D. J., 1996, CLIN OTOLARYNGOL, V11, P317; Williams GM, 1998, PEDIATRICS, V102; Wisborg K, 2000, ARCH DIS CHILD, V83, P203, DOI 10.1136/adc.83.3.203; WOODWARD A, 1990, J EPIDEMIOL COMMUN H, V44, P224, DOI 10.1136/jech.44.3.224; XU XP, 1995, AM J RESP CRIT CARE, V151, P41; YANAI J, 1992, BRAIN RES BULL, V29, P363, DOI 10.1016/0361-9230(92)90069-A	173	415	440	3	48	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR 1	2004	113	4		S			1007	1015				9	Pediatrics	Pediatrics	808RC	WOS:000220585200010	15060193	
J	Evans, GW; Kantrowitz, E				Evans, GW; Kantrowitz, E			Socioeconomic status and health: The potential role of environmental risk exposure	ANNUAL REVIEW OF PUBLIC HEALTH			English	Review						environmental justice; income; socioeconomic status; poverty; environmental risk	HOME ENVIRONMENTS; YOUNG-CHILDREN; COCKROACH ALLERGEN; CLASS-INEQUALITY; CARBON-MONOXIDE; MENTAL-HEALTH; UNITED-STATES; AIR-POLLUTION; SOCIAL-CLASS; QUALITY	Among several viable explanations for the ubiquitous SES-health gradient is differential exposure to environmental risk. We document evidence of inverse relations between income and other indices of SES with environmental risk factors including hazardous wastes and other toxins, ambient and indoor air pollutants, water quality, ambient noise, residential crowding, housing quality, educational facilities, work environments, and neighborhood conditions. We then briefly over-view evidence that such exposures are inimical to health and well-being. We conclude with a discussion of the research and policy implications of environmental justice, arguing that a particularly salient feature of poverty for health consequences is exposure to multiple environmental risk factors.	Cornell Univ, Coll Human Ecol, Dept Design & Environm Anal, Ithaca, NY 14853 USA; Cornell Univ, Coll Human Ecol, Dept Human Dev, Ithaca, NY 14853 USA	Evans, GW (reprint author), Cornell Univ, Coll Human Ecol, Dept Design & Environm Anal, Ithaca, NY 14853 USA.						*A CAS FOUND, 2000, KIDS COUNT DAT BOOK; ADLER NE, 1993, JAMA-J AM MED ASSOC, V269, P3140, DOI 10.1001/jama.269.24.3140; Aneshensel CS, 1996, J HEALTH SOC BEHAV, V37, P293, DOI 10.2307/2137258; Araki S, 1994, NEUROBEHAVIORAL METH; ATTAR BK, 1994, J CLIN CHILD PSYCHOL, V23, P391, DOI 10.1207/s15374424jccp2304_5; Bardana E. J., 1997, INDOOR AIR POLLUTION; Bartlett S, 1999, ENVIRON URBAN, V11, P63, DOI 10.1177/095624789901100207; Baum A., 1987, HDB ENV PSYCHOL, P533; Berglund B., 1995, ARCH CTR SENSORY RES, V2, P1; Berney L, 2000, SOCIOL HEALTH ILL, V22, P415, DOI 10.1111/1467-9566.00212; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; Blane D, 1997, EUR J PUBLIC HEALTH, V7, P385, DOI 10.1093/eurpub/7.4.385; BRADLEY RH, 1984, DEV PSYCHOL, V20, P315, DOI 10.1037//0012-1649.20.2.315; Bradley RH, 2001, CHILD DEV, V72, P1844, DOI 10.1111/1467-8624.t01-1-00382; Bradley R. H., 1999, MEASURING ENV LIFE S, P31, DOI 10.1037/10317-002; BRAJER V, 1992, CONTEMP POLICY ISSUE, V10, P63; Bronfrenbrenner U., 1998, HDB CHILD PSYCHOL, P992; BROWN L, 1986, J SPEC EDUC, V20, P339; Bullard R., 1990, DUMPING DIXIE; BURRIDGE R, 1993, UNHEALTHY HOUSING; Cabelli VJ., 1983, EPA600180031 OFF RES; CALDERON R, TOXICOL IND HLTH, V9, P879; CHI PSK, 1990, ENERGY, V15, P81, DOI 10.1016/0360-5442(90)90045-4; CIESIELSKI S, 1991, AM J PUBLIC HEALTH, V81, P762, DOI 10.2105/AJPH.81.6.762; Clinton W. J., 1994, FED REGISTER, V59, P7629; COHEN S, 1980, PSYCHOL BULL, V88, P82, DOI 10.1037//0033-2909.88.1.82; Cohen S., 1984, NOISE SOC, P221; COOK DG, 1994, BRIT MED J, V308, P384; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; DAVIES JE, 1972, AM J EPIDEMIOL, V96, P334; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; DUBOW EF, 1994, J CLIN CHILD PSYCHOL, V23, P401, DOI 10.1207/s15374424jccp2304_6; DUNCAN C, 1997, CONSEQUENCES GROWING; Evans GW, 2000, J CONSULT CLIN PSYCH, V68, P526, DOI 10.1037/0022-006X.68.3.526; Evans GW, 2000, J PERS SOC PSYCHOL, V79, P204, DOI 10.1037/0022-3514.79.2.204; Evans GW, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P365; EVANS GW, 1994, VULNERABLE BRAIN ENV, V3, P167; Evans G. W., 1993, CHILDRENS ENV, V10, P31; Evans G., 1987, HDB ENV PSYCHOL, P571; EVANS GW, 2002, IN PRESS J SOC ISSUE; Federman M., 1996, MON LABOR REV, P3; Fiese BH, 1993, J FAMILY PSYCHOL, V6, P290, DOI DOI 10.1037/0893-3200.6.3.290; Freeman A., 1972, ENV QUALITY ANAL THE, P243; *FRIENDS EARTH UK, 2001, ENV JUST IN; *FRIENDS EARTH UK, 2001, POLL POV BREAK LINK; Frumkin H., 1998, Maxcy Rosenau last public health and preventative medicine, P682; GALLUP G, 1993, AM YOUTH 1990S; Garbarino J., 1995, RAISING CHILDREN SOC; Garbarino J., 1992, CHILDREN DANGER COPI; GARRETT P, 1994, CHILD DEV, V65, P331; Garza G, 1996, ENVIRON URBAN, V8, P31, DOI 10.1177/095624789600800208; GIFFORD R, 2002, IN PRESS SOCIAL EFFE; Glass D. C., 1972, URBAN STRESS; GOLD DR, 1992, CLIN CHEST MED, V13, P215; GOLDSTEIN IF, 1988, ATMOS ENVIRON, V22, P2127, DOI 10.1016/0004-6981(88)90124-2; GOLDTOOTH TBK, 1995, ENV JUSTICE ISSUES P, P138; Graham H, 1998, SOCIOL HEALTH ILL, V20, P215, DOI 10.1111/1467-9566.00098; GRAHAM H, 1995, J SOC POLICY, V24, P509; GRONER J, 1998, WOMEN HLTH, V8, P19; HAAN M, 1987, AM J EPIDEMIOL, V125, P898; HAINES M, 2002, IN PRESS J EPIDEMIOL; HALPERN D, 1995, MORE BRICKS MORTAR; HAMERMESH D, 1999, MON LABOR REV    OCT, P22; HARBURG E, 1973, PSYCHOSOM MED, V35, P276; Hardoy Jorge E, 2001, ENV PROBLEMS URBANIZ; *HARV U JOINT CENT, 1999, STAT NAT HOUS; Holgate ST, 1999, AIR POLLUTION HLTH; HOMEL R, 1987, LANDSCAPE URBAN PLAN, V14, P101, DOI 10.1016/0169-2046(87)90016-8; Institute of Medicine, 1999, ENV JUST; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; INEICHEN B, 1993, HOUSING HLTH; Ingersoll R. M., 1999, ED RES, V28, P26, DOI DOI 10.3102/0013189X028002026; JARVIS MJ, 1992, AM J PUBLIC HEALTH, V82, P1225, DOI 10.2105/AJPH.82.9.1225; JOHNSON BL, 1999, IMPACT HAZARDOUS WAS; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kryter K. D., 1994, HDB HEARING EFFECTS; Larson RW, 1999, PSYCHOL BULL, V125, P701, DOI 10.1037/0033-2909.125.6.701; LeClere FB, 1998, J HEALTH SOC BEHAV, V39, P91, DOI 10.2307/2676393; Leventhal T, 2000, PSYCHOL BULL, V126, P309, DOI 10.1037//0033-2909.126.2.309; LIPPMAN N, 1992, ENV TOXICOLOGY; LUCAS REB, 1974, REV ECON STAT, V56, P530, DOI 10.2307/1924468; LUNDBERG O, 1991, SOC SCI MED, V32, P385, DOI 10.1016/0277-9536(91)90339-E; *MAC FOUND, 2001, NETW SOC STAT HLTH; MACINTYRE S, 1993, J SOC POLICY, V22, P213; Macpherson A, 1998, AM J PUBLIC HEALTH, V88, P1840, DOI 10.2105/AJPH.88.12.1840; Marmot M., 1999, SOCIAL DETERMINANTS, P105; MATHENY AP, 1995, J APPL DEV PSYCHOL, V16, P429, DOI 10.1016/0193-3973(95)90028-4; Matte TD, 2000, J URBAN HEALTH, V77, P7, DOI 10.1007/BF02350959; Maxwell LE, 1996, ENVIRON BEHAV, V28, P494, DOI 10.1177/0013916596284004; Mayer SE, 1997, CONSEQUENCES GROWING, P49; Miller JE, 1997, J MARRIAGE FAM, V59, P996, DOI 10.2307/353798; MOHAI P, 1992, RACE AND THE INCIDENCE OF ENVIRONMENTAL HAZARDS, P163; Moore G., 1993, CHILDRENS ENV, V10, P99; MOSES M, 1993, TOXICOL IND HEALTH, V9, P913; Myers D, 1996, J AM PLANN ASSOC, V62, P66, DOI 10.1080/01944369608975671; *NAT CENT ED STAT, 2000, 2000032 NCES US DEP; *NAT CENT HLTH STA, 1991, ADV DAT VIT HLTH STA, V202; *NAT CENT HLTH STA, 1998, SOC STAT HLTH CHART; *NAT I CHILD HLTH, 1997, CONS GROW UP POOR, P100; *NAT I ENV HLTH SC, 2001, HLTH DISP RES; *NAT RES COUNC, 1991, ENV EP, V1; Olds A. R., 2000, CHILD CARE DESIGN GU; OSOFSKY JD, 1995, AM PSYCHOL, V50, P782, DOI 10.1037//0003-066X.50.9.782; Perkins DD, 1996, AM J COMMUN PSYCHOL, V24, P63, DOI 10.1007/BF02511883; PHILLIPS DA, 1994, CHILD DEV, V65, P472; PIRKLE JL, 1994, JAMA-J AM MED ASSOC, V272, P284, DOI 10.1001/jama.272.4.284; PRYER J, 1993, ENVIRON URBAN, V5, P35, DOI 10.1177/095624789300500204; RICHTERS JE, 1993, PSYCHIATRY, V56, P7; RILEY E, 1991, HDB BEHAV TERATOLOGY; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROTTON J, 1983, BASIC APPL SOC PSYCH, V4, P171, DOI 10.1207/s15324834basp0402_5; RUTTER M, 1981, PREVENTION PSYCHOPAT, V1, P49; Samet J.M., 1991, INDOOR AIR POLLUTION; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Satterthwaite D., 1996, ENV CHILDREN; SCHWAB M, 1990, J AIR WASTE MANAGE, V40, P331; SCOTT R, 1990, CHEM HAZARDS WORKPLA; Sherman A., 1994, WASTING AM FUTURE; SINCLAIR JJ, 1994, INT J BEHAV DEV, V17, P675; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P399; SPENCER MB, 1997, NEIGHBORHOOD POVERTY, V2, P145; SPENCER NJ, 2001, ADDITIVE EFFECTS SOC; Stansfeld S. A., 1993, PSYCHOL MED        S, V22, P1; *STAT UN, 2000, INC FAM PRIM KIND SL; STEHRGREEN PA, 1989, J TOXICOL ENV HEALTH, V27, P405; Stephens C, 1997, ENVIRON URBAN, V9, P181, DOI 10.1177/095624789700900115; Stokols D., 1987, HDB ENV PSYCHOL; Stronks K, 1998, J EPIDEMIOL COMMUN H, V52, P548; Suecoff SA, 1999, ARCH PEDIAT ADOL MED, V153, P363; TAYLOR RB, 1999, PHYSICAL ENV CRIME; THOMPSON SJ, 1993, LARM KRANKHEIT, P107; Townsend P., 1979, POVERTY UK; Trancik AM, 1995, CHILDRENS ENV, V12, P311; *US DEP HHS, CLOS GAP; US Department of Health and Human Services, 2000, TRENDS WELL BEING AM; U. S. Environmental Protection Agency, 1992, 230R92008 EPA; *US EPA, 1977, 550977100 EPA; *US EPA, 1984, 570984004 EPA; WACHS TD, 1982, EARLY EXPERIENCE DEV; Wallace D., 1998, PLAGUE YOUR HOUSES; Wandersman A, 1998, AM PSYCHOL, V53, P647, DOI 10.1037/0003-066X.53.6.647; WEINSTEIN CS, 1987, SPACES CHILDREN; WEST PC, 1989, 1 U MICH SCH NAT RES; White HL, 1998, ENV INJUSTICES POLIT, P61; WOODARD BT, 1976, AM J DIS CHILD, V130, P400; World Bank, 1992, WORLD DEV REP; WRIGHT BH, 1992, RACE AND THE INCIDENCE OF ENVIRONMENTAL HAZARDS, P114	148	411	415	27	164	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0163-7525			ANNU REV PUBL HEALTH	Annu. Rev. Public Health		2002	23						303	331		10.1146/annurev.publhealth.23.112001.112349		29	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	553QK	WOS:000175686800015	11910065	
J	Gauderman, WJ				Gauderman, WJ			Sample size requirements for association studies of gene-gene interaction	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						association; case-control studies; genetics; interaction; research design; sample size	CASE-PARENT TRIADS; CASE-CONTROL DESIGNS; ENVIRONMENT INTERACTION; LINKAGE DISEQUILIBRIUM; POWER; TESTS; EXPOSURE; MODELS	In the study of complex diseases, it may be important to test hypotheses related to gene-gene (G x G) interaction. The success of such studies depends critically on obtaining adequate sample sizes. In this paper, the author investigates sample size requirements for studies of G x G interaction, focusing on four study designs: the matched-case-control design, the case-sibling design, the case-parent design, and the case-only design. All four designs provide an estimate of interaction on a multiplicative scale, which is used as a unifying theme in the comparison of sample size requirements. Across a variety of genetic models, the case-only and case-parent designs require fewer sampling units (cases and case-parent trios, respectively) than the case-control (pairs) or case-sibling (pairs) design. For example, the author describes an asthma study of two common recessive genes for which 270 matched case-control pairs would be required to detect a G x G interaction of moderate magnitude with 80% power. By comparison, the same study would require 319 case-sibling pairs but only 146 trios in the case-parent design or 116 cases in the case-only design. A software program that computes sample size for studies of G x G interaction and for studies of gene-environment (G x E) interaction is freely available (http://hydra.usc.edu/gxe).	Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	Gauderman, WJ (reprint author), Univ So Calif, Sch Med, Dept Prevent Med, 1540 Alcazar St,Suite 220, Los Angeles, CA 90089 USA.				NCI NIH HHS [CA 52862]; NIEHS NIH HHS [5P30 ES 07048-03, ES 10421]		Andrieu N., 2000, Genetic Epidemiology, V19, P235; Andrieu N, 2001, AM J EPIDEMIOL, V153, P265, DOI 10.1093/aje/153.3.265; Breslow N. E., 1980, IARC SCI PUBLICATION, V32; BROOKMEYER R, 1986, AM J EPIDEMIOL, V124, P693; Cotton SC, 2000, AM J EPIDEMIOL, V151, P7; Curtis D, 1997, ANN HUM GENET, V61, P319, DOI 10.1046/j.1469-1809.1998.6210089.x; Foppa I, 1997, AM J EPIDEMIOL, V146, P596; Gail MH, 1999, GENET EPIDEMIOL, V16, P15, DOI 10.1002/(SICI)1098-2272(1999)16:1<15::AID-GEPI3>3.0.CO;2-8; Garcia-Closas M, 1999, AM J EPIDEMIOL, V149, P689; Gauderman W, 2001, 157 U SO CAL DEP PRE; Gauderman W J, 1999, J Natl Cancer Inst Monogr, P31; Gauderman WJ, 2002, STAT MED, V21, P35, DOI 10.1002/sim.973; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; Goldstein AM, 1997, GENET EPIDEMIOL, V14, P1085, DOI 10.1002/(SICI)1098-2272(1997)14:6<1085::AID-GEPI87>3.0.CO;2-D; GREENLAND S, 1985, STAT MED, V4, P117, DOI 10.1002/sim.4780040203; HWANG SJ, 1994, AM J EPIDEMIOL, V140, P1029; Khoury MJ, 1996, AM J EPIDEMIOL, V144, P207; Khoury MJ, 1998, AM J EPIDEMIOL, V147, P1; Longmate JA, 2001, AM J HUM GENET, V68, P1229, DOI 10.1086/320106; Martin ER, 1997, AM J HUM GENET, V61, P439, DOI 10.1086/514860; Martin ER, 2000, GENET EPIDEMIOL, V18, P48, DOI 10.1002/(SICI)1098-2272(200001)18:1<48::AID-GEPI4>3.0.CO;2-S; Martin ER, 2000, AM J HUM GENET, V67, P146, DOI 10.1086/302957; OTTMAN R, 1990, GENET EPIDEMIOL, V7, P177, DOI 10.1002/gepi.1370070302; Ottman R, 1996, PREV MED, V25, P764, DOI 10.1006/pmed.1996.0117; PIEGORSCH WW, 1994, STAT MED, V13, P153, DOI 10.1002/sim.4780130206; ROTHMAN KJ, 1980, AM J EPIDEMIOL, V112, P467; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Schaid DJ, 1999, GENET EPIDEMIOL, V16, P261, DOI 10.1002/(SICI)1098-2272(1999)16:3<261::AID-GEPI3>3.0.CO;2-M; Schaid DJ, 1996, GENET EPIDEMIOL, V13, P423, DOI 10.1002/(SICI)1098-2272(1996)13:5<423::AID-GEPI1>3.0.CO;2-3; SELF SG, 1991, BIOMETRICS, V47, P53, DOI 10.2307/2532495; Siegmund KD, 2000, AM J HUM GENET, V67, P244, DOI 10.1086/302973; SIEMIATYCKI J, 1981, INT J EPIDEMIOL, V10, P383, DOI 10.1093/ije/10.4.383; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Spielman RS, 1998, AM J HUM GENET, V62, P450, DOI 10.1086/301714; Umbach DH, 2000, AM J HUM GENET, V66, P251, DOI 10.1086/302707; Weinberg C, 2000, AM J EPIDEMIOL, V152, P689, DOI 10.1093/aje/152.7.689; Weinberg CR, 1998, AM J HUM GENET, V62, P969, DOI 10.1086/301802; Weinberg CR, 1999, AM J HUM GENET, V65, P229, DOI 10.1086/302466; Weinberg CR, 1999, AM J HUM GENET, V64, P1186, DOI 10.1086/302337; Wilcox AJ, 1998, AM J EPIDEMIOL, V148, P893; Witte JS, 1999, AM J EPIDEMIOL, V149, P693; Yang QH, 1999, EPIDEMIOLOGY, V10, P167, DOI 10.1097/00001648-199903000-00014	42	409	417	1	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	MAR 1	2002	155	5					478	484		10.1093/aje/155.5.478		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	526WX	WOS:000174153800014	11867360	
J	Hawrylowicz, CM; O'Garra, A				Hawrylowicz, CM; O'Garra, A			Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma	NATURE REVIEWS IMMUNOLOGY			English	Review							GRASS-POLLEN IMMUNOTHERAPY; INDUCED AIRWAY HYPERREACTIVITY; IMMUNOLOGICAL SELF-TOLERANCE; COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTOR FOXP3; GROWTH-FACTOR-BETA; HOUSE-DUST MITE; FC-EPSILON-RI; CYTOKINE PRODUCTION; IN-VIVO	Allergic diseases are caused by aberrant T-helper-2 immune responses in susceptible individuals. Both naturally occurring CD4(+)CD25(+) regulatory T cells and inducible populations of antigen-specific interleukin-10-secreting regulatory T cells inhibit these inappropriate immune responses in experimental models. This article discusses the evidence that regulatory T-cell function might be impaired in allergic and asthmatic disease and that certain therapeutic regimens might function, at least in part, to promote regulatory T-cell generation. Current research strategies seek to exploit these observations to improve the generation of allergen-specific regulatory T-cell populations with the potential to provide the safe and long-term alleviation of disease symptoms.	Kings Coll London, Guys Hosp, Dept Asthma Allergy & Resp Sci, London SE1 9RT, England; Natl Inst Med Res, London NW7 1AA, England	Hawrylowicz, CM (reprint author), Kings Coll London, Guys Hosp, Dept Asthma Allergy & Resp Sci, London SE1 9RT, England.	catherine.hawrylowicz@kcl.ac.uk		O'Garra, Anne/0000-0001-9845-6134; Hawrylowicz, Catherine/0000-0002-2337-7463	Medical Research Council [MC_U117565642]		Aandahl EM, 2004, J VIROL, V78, P2454, DOI 10.1128/JVI.78.5.2454.2459.2004; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1997, J ALLERGY CLIN IMMUN, V99, P345, DOI 10.1016/S0091-6749(97)70052-6; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; ALL FR, 2004, AM J RESP CRIT CARE, V169, P20; Annacker O, 2001, J IMMUNOL, V166, P3008; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Arkwright PD, 2003, BRIT J DERMATOL, V149, P1029, DOI 10.1111/j.1365-2133.2003.05557.x; Arock M, 1996, EUR J IMMUNOL, V26, P166, DOI 10.1002/eji.1830260126; Asadullah K, 2003, PHARMACOL REV, V55, P241, DOI 10.1124/pr.55.2.4; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Asseman C, 2003, J IMMUNOL, V171, P971; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Baecher-Allan C, 2002, J IMMUNOL, V169, P6210; Barnes PJ, 1997, CHEST, V111, pS17, DOI 10.1378/chest.111.2_Supplement.17S; Barrett J, 2002, CYTOTHERAPY, V4, P1, DOI 10.1080/146532402317251464; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bennett CL, 2001, NAT GENET, V27, P20; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; Bergmann M, 2002, WIEN KLIN WOCHENSCHR, V114, P752; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Boussiotis VA, 2000, J CLIN INVEST, V105, P1317, DOI 10.1172/JCI9918; Buelens C, 1997, EUR J IMMUNOL, V27, P756, DOI 10.1002/eji.1830270326; Buer J, 1998, J EXP MED, V187, P177, DOI 10.1084/jem.187.2.177; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Canning MO, 2000, EUR J ENDOCRINOL, V143, P687, DOI 10.1530/eje.0.1430687; Casale TB, 2004, J ALLERGY CLIN IMMUN, V113, P1036, DOI 10.1016/j.jaci.2004.04.017; Casnici C, 2004, J NEUROIMMUNOL, V149, P210, DOI 10.1016/j.jneuroim.2003.12.020; Chatila TA, 2000, J CLIN INVEST, V106, P75; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cook DN, 2004, NAT IMMUNOL, V5, P975, DOI 10.1038/ni1116; Cookson W, 2004, NEW ENGL J MED, V351, P1794, DOI 10.1056/NEJMe048232; Corral LG, 1999, J IMMUNOL, V163, P380; Cottrez F, 2000, J IMMUNOL, V165, P4848; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Dong XY, 2003, TRANSPL IMMUNOL, V11, P323, DOI 10.1016/S0966-3274(03)00049-2; Duramad O, 2003, BLOOD, V102, P4487, DOI 10.1182/blood-2003-07-2465; DUREZ P, 1993, J EXP MED, V177, P551, DOI 10.1084/jem.177.2.551; Durez P, 1999, INT J IMMUNOPHARMACO, V21, P581, DOI 10.1016/S0192-0561(99)00037-5; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Edwards AD, 2002, J IMMUNOL, V169, P3652; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Friedberg JW, 2005, BLOOD, V105, P489, DOI 10.1182/blood-2004-06-2156; Fuchs AC, 1996, J CLIN IMMUNOL, V16, P291, DOI 10.1007/BF01541395; GAZZINELLI RT, 1992, J IMMUNOL, V148, P1792; Gerber JS, 2001, J IMMUNOL, V166, P6861; Gerosa F, 1999, CLIN IMMUNOL, V92, P224, DOI 10.1006/clim.1999.4752; Golgher D, 2002, EUR J IMMUNOL, V32, P3267, DOI 10.1002/1521-4141(200211)32:11<3267::AID-IMMU3267>3.0.CO;2-1; Gorelik L, 2002, NAT REV IMMUNOL, V2, P46, DOI 10.1038/nri704; Green EA, 2003, P NATL ACAD SCI USA, V100, P10878, DOI 10.1073/pnas.1834400100; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Groux H, 1997, NATURE, V389, P737; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Hadeiba H, 2003, J IMMUNOL, V170, P5502; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hara M, 2001, J IMMUNOL, V166, P3789; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hasko G, 2002, CURR OPIN PHARMACOL, V2, P440, DOI 10.1016/S1471-4892(02)00172-8; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; HAWRYLOWICZ C, 2004, J ALLERGY CLIN IMM S, V113, pA735; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Holgate Stephen T, 2003, Nat Rev Drug Discov, V2, P902; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; Jaffar Z, 2004, J IMMUNOL, V172, P3842; Jeannin P, 1998, J IMMUNOL, V160, P3555; John M, 1998, AM J RESP CRIT CARE, V157, P256; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jordan MS, 2001, NAT IMMUNOL, V2, P301, DOI 10.1038/86302; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kingsley CI, 2002, J IMMUNOL, V168, P1080; Kinter AL, 2004, J EXP MED, V200, P331, DOI 10.1084/jem.20032069; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Kullberg MC, 2002, J EXP MED, V196, P505, DOI 10.1084/jem.20020556; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Larche M, 2004, AM J RESP CRIT CARE, V169, P1331; Levings MK, 2001, J IMMUNOL, V166, P5530; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LING EM, 2004, J ALLERGY CLIN IMMUN, V113, pA333; Liu HY, 2003, J IMMUNOL, V171, P5012; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Maloy KJ, 2003, J EXP MED, V197, P111, DOI 10.1084/jem.20021345; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; MAURER D, 1995, J IMMUNOL, V154, P6285; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Miller C, 1999, J EXP MED, V190, P53, DOI 10.1084/jem.190.1.53; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1998, J ALLERGY CLIN IMMUN, V102, P1, DOI 10.1016/S0091-6749(98)70046-6; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novak N, 2001, J IMMUNOL, V167, P797; O'Garra A, 2004, J CLIN INVEST, V114, P1372, DOI 10.1172/JCI200423215; O'Garra A, 2004, NAT MED, V10, P801, DOI 10.1038/nm0804-801; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Oswald-Richter K, 2004, PLOS BIOL, V2, P955, DOI 10.1371/journal.pbio.0020198; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; PEEK E, 2004, J ALLERGY CLIN IMM S, V113, pA753; Pontoux C, 2002, INT IMMUNOL, V14, P233, DOI 10.1093/intimm/14.2.233; POWRIE F, 1994, IMMUNITY, V1, P553, DOI 10.1016/1074-7613(94)90045-0; PUNNONEN J, 1992, J IMMUNOL, V148, P3398; Ramsdell F, 2003, IMMUNITY, V19, P165, DOI 10.1016/S1074-7613(03)00207-3; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Read S, 1998, EUR J IMMUNOL, V28, P3435, DOI 10.1002/(SICI)1521-4141(199811)28:11<3435::AID-IMMU3435>3.0.CO;2-P; Richards DF, 2000, EUR J IMMUNOL, V30, P2344, DOI 10.1002/1521-4141(2000)30:8<2344::AID-IMMU2344>3.0.CO;2-7; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; ROLINCKWERNINGHAUS, 2004, ALLERGY, V59, P973; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sawicka E, 2003, J IMMUNOL, V171, P6206; Schafer PH, 2003, J PHARMACOL EXP THER, V305, P1222, DOI 10.1124/jpet.102.048496; SHEVACH E, 2004, NAT REV IMMUNOL, V2, P389; Shimizu J, 1999, J IMMUNOL, V163, P5211; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Soderlund A, 1997, IMMUNOL LETT, V57, P177, DOI 10.1016/S0165-2478(97)00051-5; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Stassen M, 2004, J IMMUNOL, V173, P267; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Sundstedt A, 1997, J IMMUNOL, V158, P180; Suri-Payer E, 2001, J AUTOIMMUN, V16, P115, DOI 10.1006/jaut.2000.0473; Suto A, 2001, AM J RESP CRIT CARE, V164, P680; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Tiemessen MM, 2002, J ALLERGY CLIN IMMUN, V110, P934, DOI 10.1067/mai.2002.128856; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Trinchieri G., 2001, J EXP MED, V194, P53; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Ulisse S, 2001, AM J GASTROENTEROL, V96, P2691, DOI 10.1016/S0002-9270(01)02701-0; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Van Bever HP, 1998, CLIN EXP ALLERGY, V28, P943; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Vieira PL, 2004, J IMMUNOL, V172, P5986; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wan S, 1997, ANN THORAC SURG, V63, P269; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wilson DR, 2003, COCHRANE DB SYST REV, V2; Xu DM, 2003, J IMMUNOL, V170, P394; Yagi H, 2004, INT IMMUNOL, V16, P1643, DOI 10.1093/intimm/dxh165; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	188	408	455	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	APR	2005	5	4					271	283		10.1038/nri1589		13	Immunology	Immunology	912PX	WOS:000228092800011	15775993	
J	Von Ehrenstein, OS; Von Mutius, E; Illi, S; Baumann, L; Bohm, O; Von Kries, R				Von Ehrenstein, OS; Von Mutius, E; Illi, S; Baumann, L; Bohm, O; Von Kries, R			Reduced risk of hay fever and asthma among children of farmers	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article							ALLERGIC RHINOCONJUNCTIVITIS; CHILDHOOD ISAAC; SCHOOL-CHILDREN; PREVALENCE; SYMPTOMS; ATOPY; TH1; SENSITIZATION; DISEASES; RHINITIS	Background The prevalence of atopic diseases is on the rise. Traditional lifestyles may be associated with a reduced risk of atopy. Objective To test the hypothesis that children living on a farm have lower prevalences of atopic diseases. To identify differences in living conditions between farmers and other families which are associated with the development of atopic conditions. Design Cross-sectional survey among children entering school (aged 5-7 years). A written questionnaire including the ISAAC core questions and asking for exposures on a farm and elsewhere was administered to the parents. Setting: School health entry examination in two Bavarian districts with extensive farming activity. Subjects: 10 163 children. Main outcome measures The prevalence of doctor's diagnoses and symptoms of hay fever, asthma and eczema as assessed by parental report. Results Farmers' children had lower prevalences of hay fever (adjusted odds ratio = 0.52, 95% CI 0.28-0.99), asthma (0.65, 0.39-1.09), and wheeze (0.55, 0.36-0.86) than their peers not living in an agricultural environment. The reduction in risk was stronger for children whose families were running the farm on a full-time basis as compared with families with part-time farming activity. Among farmers' children increasing exposure to livestock was related to a decreasing prevalence of atopic diseases (aOR = 0.41, 95% CI 0.23-0.74). Conclusions Factors related to environmental influences on a farm such as increased exposure to bacterial compounds in stables where livestock is kept prevent the development of allergic disorders in children.	Univ Munich, Univ Childrens Hosp, Munich, Germany; Univ Munich, Inst Social Paediat & Adolescent Med, Munich, Germany	Von Ehrenstein, OS (reprint author), Univ Munich, Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.						ANDREA S, 1988, ARCH DIS CHILD, V63, P474; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BATSCHELET E, 1960, SCHWEIZ MED WOCHENSC, V40, P1109; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Braback L, 1991, PEDIATR ALLERGY IMMU, V2, P14, DOI 10.1111/j.1399-3038.1991.tb00174.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Hilkens CMU, 1997, BLOOD, V90, P1920; Kaur B, 1998, BRIT MED J, V316, P118; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Lewis S, 1997, NEW ZEAL MED J, V110, P286; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; NOVAK D, 1998, ARBEITSMEDIZIN SOZIA, V6, P233; Nystad W, 1997, PEDIATR ALLERGY IMMU, V8, P35, DOI 10.1111/j.1399-3038.1997.tb00140.x; POPP W, 1989, ALLERGY, V44, P572, DOI 10.1111/j.1398-9995.1989.tb04202.x; REHSTEINER R, 1926, SCHWEIZ Z GESUNDHEIT, V1, P1; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692; VONMUTIUS E, 1996, BRIT MED J, V312, P448; WAEGEMAEKERS M, 1989, ALLERGY, V44, P142; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P909; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	32	406	413	0	27	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2000	30	2					187	193				7	Allergy; Immunology	Allergy; Immunology	287NF	WOS:000085511600007	10651770	
J	McCreanor, J; Cullinan, P; Nieuwenhuijsen, MJ; Stewart-Evans, J; Malliarou, E; Jarup, L; Harrington, R; Svartengren, M; Han, I; Ohman-Strickland, P; Chung, KF; Zhang, JF				McCreanor, James; Cullinan, Paul; Nieuwenhuijsen, Mark J.; Stewart-Evans, James; Malliarou, Eleni; Jarup, Lars; Harrington, Robert; Svartengren, Magnus; Han, In-Kyu; Ohman-Strickland, Pamela; Chung, Kian Fan; Zhang, Junfeng			Respiratory effects of exposure to diesel traffic in persons with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ULTRAFINE PARTICLES; AIRWAY INFLAMMATION; EPITHELIAL-CELLS; LUNG-FUNCTION; EXHAUST; HUMANS; HEALTH; POLLUTION; SYMPTOMS	Background: Air pollution from road traffic is a serious health hazard, and people with preexisting respiratory disease may be at increased risk. We investigated the effects of short-term exposure to diesel traffic in people with asthma in an urban, roadside environment. Methods: We recruited 60 adults with either mild or moderate asthma to participate in a randomized, crossover study. Each participant walked for 2 hours along a London street (Oxford Street) and, on a separate occasion, through a nearby park (Hyde Park). We performed detailed real-time exposure, physiological, and immunologic measurements. Results: Participants had significantly higher exposures to fine particles (<2.5 mu m in aerodynamic diameter), ultrafine particles, elemental carbon, and nitrogen dioxide on Oxford Street than in Hyde Park. Walking for 2 hours on Oxford Street induced asymptomatic but consistent reductions in the forced expiratory volume in 1 second (FEV1) (up to 6.1%) and forced vital capacity (FVC) (up to 5.4%) that were significantly larger than the reductions in FEV1 and FVC after exposure in Hyde Park (P=0.04 and P=0.01, respectively, for the overall effect of exposure, and P<0.005 at some time points). The effects were greater in subjects with moderate asthma than in those with mild asthma. These changes were accompanied by increases in biomarkers of neutrophilic inflammation (sputum myeloperoxidase, 4.24 ng per milliliter after exposure in Hyde Park vs. 24.5 ng per milliliter after exposure on Oxford Street; P=0.05) and airway acidification (maximum decrease in pH, 0.04% after exposure in Hyde Park and 1.9% after exposure on Oxford Street; P=0.003). The changes were associated most consistently with exposures to ultrafine particles and elemental carbon. Conclusions: Our observations serve as a demonstration and explanation of the epidemiologic evidence that associates the degree of traffic exposure with lung function in asthma.	Univ London Imperial Coll Sci & Technol, Dept Occupat & Environm Med, Natl Heart & Lung Inst, London SW3 6LR, England; Royal Brompton Hosp, London, England; Univ London Imperial Coll Sci & Technol, Dept Epidemiol & Publ Hlth, London SW3 6LR, England; Univ Med & Dent New Jersey, Sch Publ Hlth, Piscataway, NJ USA; Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden	Cullinan, P (reprint author), Univ London Imperial Coll Sci & Technol, Dept Occupat & Environm Med, Natl Heart & Lung Inst, 1b Manresa Rd, London SW3 6LR, England.	p.cullinan@imperial.ac.uk	Nieuwenhuijsen, Mark/C-3914-2017	Nieuwenhuijsen, Mark/0000-0001-9461-7981			Abe S, 2000, AM J RESP CELL MOL, V22, P296; Air Quality Expert Group, 2005, PART MATT UK; Fischer H, 2002, AM J PHYSIOL-CELL PH, V282, pC736, DOI 10.1152/ajpcell.00369.2001; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; Gong Jr H, 2003, RES REP HLTH EFF I, V118; HISHAM MWM, 1990, ATMOS ENVIRON A-GEN, V24, P2523, DOI 10.1016/0960-1686(90)90344-M; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Ising H, 2003, Noise Health, V5, P41; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; KAUFMAN DS, 1993, ARCH BIOCHEM BIOPHYS, V302, P245, DOI 10.1006/abbi.1993.1206; Kulkarni N, 2006, NEW ENGL J MED, V355, P21, DOI 10.1056/NEJMoa052972; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Manchester-Neesvig JB, 2003, J AIR WASTE MANAGE, V53, P1065; Nel A, 2005, SCIENCE, V309, P1326; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Polosa R, 2002, ARCH ENVIRON HEALTH, V57, P188; RUDELL B, 1994, INT ARCH OCC ENV HEA, V66, P77, DOI 10.1007/BF00383361; Rudell B, 1999, OCCUP ENVIRON MED, V56, P527; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; *SAS I, 2006, SAS MIX MOD; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x	28	405	418	17	105	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 6	2007	357	23					2348	2358		10.1056/NEJMoa071535		11	Medicine, General & Internal	General & Internal Medicine	237QA	WOS:000251389200005	18057337	
J	Wormuth, M; Scheringer, M; Vollenweider, M; Hungerbuhler, K				Wormuth, M; Scheringer, M; Vollenweider, M; Hungerbuhler, K			What are the sources of exposure to eight frequently used phthalic acid esters in Europeans?	RISK ANALYSIS			English	Review						consumer exposure; consumer products; exposure modeling; exposure pathways; phthalates; plasticizers	EXPERT PANEL REPORT; N-BUTYL PHTHALATE; MALE REPRODUCTIVE DEVELOPMENT; NURSERY-SCHOOL CHILDREN; DEUTERIUM-LABELED DEHP; DI-ISONONYL PHTHALATE; IN-HOUSE DUST; DEVELOPMENTAL TOXICITY; NTP CENTER; DI(2-ETHYLHEXYL)PHTHALATE DEHP	Phthalic acid esters (phthalates) are used as plasticizers in numerous consumer products, commodities, and building materials. Consequently, phthalates are found in human residential and occupational environments in high concentrations, both in air and in dust. Phthalates are also ubiquitous food and environmental contaminants. An increasing number of studies sampling human urine reveal the ubiquitous phthalate exposure of consumers in industrialized countries. At the same time, recent toxicological studies have demonstrated the potential of the most important phthalates to disturb the human hormonal system and human sexual development and reproduction. Additionally, phthalates are suspected to trigger asthma and dermal diseases in children. To find the important sources of phthalates in Europeans, a scenario-based approach is applied here. Scenarios representing realistic exposure situations are generated to calculate the age-specific range in daily consumer exposure to eight phthalates. The scenarios demonstrate that exposure of infant and adult consumers is caused by different sources in many cases. Infant consumers experience significantly higher daily exposure to phthalates in relation to their body weight than older consumers. The use of consumer products and different indoor sources dominate the exposure to dimethyl, diethyl, benzylbutyl, diisononyl, and diisodecyl phthalates, whereas food has a major influence on the exposure to diisobutyl, dibutyl, and di-2-ethylhexyl phthalates. The scenario-based approach chosen in the present study provides a link between the knowledge on emission sources of phthalates and the concentrations of phthalate metabolites found in human urine.	ETH Honggerberg, Swiss Fed Inst Technol Zurich, Inst Chem & Bioengn, CH-8093 Zurich, Switzerland	Scheringer, M (reprint author), ETH Honggerberg, Swiss Fed Inst Technol Zurich, Inst Chem & Bioengn, HCI G127, CH-8093 Zurich, Switzerland.	martin.scheringer@chem.ethz.ch					ADAMS WC, 1993, FINAL REPORT; Afshari A, 2004, INDOOR AIR, V14, P120, DOI 10.1046/j.1600-0668.2003.00220.x; Akingbemi BT, 2004, P NATL ACAD SCI USA, V101, P775, DOI 10.1073/pnas.0305977101; Alexy U, 2003, EUR J CLIN NUTR, V57, P1331, DOI 10.1038/sj.ejcn.1601696; Alexy U, 2002, BRIT J NUTR, V87, P595, DOI [10.1079/BJNBJN/2002572, 10.1079/BJN2002572]; Andersen LF, 2003, EUR J CLIN NUTR, V57, P881, DOI 10.1038/sj.ejcn.1601621; Anderson WAC, 2001, FOOD ADDIT CONTAM, V18, P1068, DOI 10.1080/02652030110050113; Barr DB, 2003, ENVIRON HEALTH PERSP, V111, P1148, DOI 10.1289/ehp.6074; Becker K, 2004, INT J HYG ENVIR HEAL, V207, P409, DOI 10.1078/1438-4639-00309; Blount BC, 2000, ENVIRON HEALTH PERSP, V108, P979, DOI 10.1289/ehp.00108979; Boekelheide K, 2004, TOXICOL SCI, V81, P1, DOI 10.1093/toxsci/kfh196; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Calafat AM, 2004, J CHROMATOGR B, V805, P49, DOI [10.1016/j.jchromb.2004.02.006, 10.1016/j.chromb.2004.02.006]; Casajuana N, 2004, J AGR FOOD CHEM, V52, P3702, DOI 10.1021/jf040027s; CHAN PKL, 1994, ENVIRON CARCIN ECO R, V12, P257; *CIR, 2003, BAS CTFA 2001 A B C; CLARK K, 2004, HDB ENV CHEM Q, V3, P227; CLAUSING P, 1987, International Archives of Occupational and Environmental Health, V59, P73, DOI 10.1007/BF00377681; *COM, 1999, OFFICIAL J L, V315, P46; *COM, 2003, EX SUBST 2 PRIOR LIS, V36; *COM, 2003, EX SUBST 2 PRIOR LIS, V35; *COM, 2003, EX SUBST 1 PRIORT LI, V29; *COM, 2004, EUR SPEND THEIR TIM; Crawley H, 1997, EUR J CLIN NUTR, V51, P87, DOI 10.1038/sj.ejcn.1600366; CSTEE (Scientific Committee on Toxicity Ecotoxicity and the Environment), 1998, 6 CSTEE PLEN M BRUSS; Deisinger PJ, 1998, FOOD CHEM TOXICOL, V36, P521, DOI 10.1016/S0278-6915(98)00015-5; DiGangi J, 2002, PRETTY NASTY PHTHALA; *DTI, 2002, REP RES MOUNT BEH CH; Duty SM, 2003, ENVIRON HEALTH PERSP, V111, P1164, DOI 10.1289/ehp.5756; Duty SM, 2005, HUM REPROD, V20, P604, DOI 10.1093/humrep/deh656; EFFTING SE, 1998, 630040002 RIVM NAT I; ELSISI AE, 1989, FUND APPL TOXICOL, V12, P70, DOI 10.1016/0272-0590(89)90063-8; Emmett P, 2002, PUBLIC HEALTH NUTR, V5, P55, DOI 10.1079/PHN2001241; *EPIC, 2002, PUBL HLTH NUTR, V5; Fiala F, 2000, DEUT LEBENSM-RUNDSCH, V96, P51; Ford RA, 1998, DEUT LEBENSM-RUNDSCH, V94, P268; Foster PMD, 2000, FOOD CHEM TOXICOL, V38, pS97, DOI 10.1016/S0278-6915(99)00128-3; Fromme H, 2004, INDOOR AIR, V14, P188, DOI 10.1046/j.1600-0668.2003.00223.x; Fujii M, 2003, ATMOS ENVIRON, V37, P5495, DOI 10.1016/j.atmosenv.2003.09.026; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; GROOT M, 1998, 3 WAG AGR U; Gruber L, 1998, DEUT LEBENSM-RUNDSCH, V94, P177; Hauser R, 2004, ENVIRON HEALTH PERSP, V112, P751, DOI 10.1289/ehp.6804; HAWLEY JK, 1985, RISK ANAL, V5, P289, DOI 10.1111/j.1539-6924.1985.tb00185.x; Henderson L., 2002, NATL DIET NUTR SURVE, V1; Houlihan J, 2002, NOT TOO PRETTY; Juberg DR, 2001, PEDIATRICS, V107, P135, DOI 10.1542/peds.107.1.135; Kato K, 2004, ENVIRON HEALTH PERSP, V112, P327, DOI 10.1289/ehp.6663; Kavlock R, 2002, REPROD TOXICOL, V16, P529, DOI 10.1016/S0890-6238(02)00032-1; Kavlock R, 2002, REPROD TOXICOL, V16, P489, DOI 10.1016/S0890-6238(02)00033-3; Kavlock R, 2002, REPROD TOXICOL, V16, P453, DOI 10.1016/S0890-6238(02)00029-1; Kavlock R, 2002, REPROD TOXICOL, V16, P655, DOI 10.1016/S0890-6238(02)00068-0; Kavlock R, 2002, REPROD TOXICOL, V16, P679, DOI 10.1016/S0890-6238(02)00034-5; Koch HM, 2005, ARCH TOXICOL, V79, P367, DOI 10.1007/s00204-004-0642-4; Koch HM, 2005, INT ARCH OCC ENV HEA, V78, P223, DOI 10.1007/s00420-004-0570-x; Koch HM, 2004, REPROD TOXICOL, V18, P759, DOI 10.1016/j/reprotox.2004.05.003; Koch HM, 2004, ARCH TOXICOL, V78, P123, DOI 10.1007/00204-003-0522-3; Koch HM, 2004, INT J HYG ENVIR HEAL, V207, P15, DOI 10.1078/1438-4639-00270; Koch HM, 2003, INT J HYG ENVIR HEAL, V206, P77, DOI 10.1078/1438-4639-00205; KOCH HM, 2004, REPROD TOXICOL, V18, P761; Kohn M.C., 2000, ENV HLTH PERSPECT, V108, P440; Kuchen Arnold, 1999, Mitteilungen aus Lebensmitteluntersuchung und Hygiene, V90, P78; Latini G, 2003, ENVIRON HEALTH PERSP, V111, P1783, DOI 10.1289/ehp.6202; Leclercq C, 2004, INT J FOOD SCI NUTR, V55, P265, DOI 10.1080/09637480412331290486; Lee KY, 2004, TOXICOLOGY, V203, P221, DOI 10.1016/j.tox.2004.06.013; Long CM, 2000, J AIR WASTE MANAGE, V50, P1236; Ma LL, 2003, B ENVIRON CONTAM TOX, V71, P394, DOI 10.1007/s00128-003-0177-z; Mackintosh CE, 2004, ENVIRON SCI TECHNOL, V38, P2011, DOI 10.1021/es034745r; *MAFF, 1996, PHTHAL FOOD FOOD SUR; *MAFF, 1998, PHTHAL INF FORM FOOD; MATTULAT A, 2002, 1656 VDI; McKee RH, 2002, J APPL TOXICOL, V22, P293, DOI 10.1002/jat.861; MEEK ME, 1994, ENVIRON CARCIN ECO R, V12, P179; MENSINK G, 2002, WHAT DO WE EAT TODAY; MINT A, 1994, TOXICOL IN VITRO, V8, P251, DOI 10.1016/0887-2333(94)90190-2; Mortensen GK, 2005, ANAL BIOANAL CHEM, V382, P1084, DOI 10.1007/s00216-005-3218-0; Muller A.K., 2003, 200315 I FOOD SAF NU; Mylchreest E, 1999, TOXICOL APPL PHARM, V156, P81, DOI 10.1006/taap.1999.8643; Noble S, 2001, EUR J CLIN NUTR, V55, P698, DOI 10.1038/sj.ejcn.1601210; OISHI S, 1980, TOXICOLOGY APPL PHAR, V53, P34; *ONS, 2000, PEOPL US THEIR LEIS; Parks LG, 2000, TOXICOL SCI, V58, P339, DOI 10.1093/toxsci/58.2.339; Peters R.J.B., 2003, HAZARDOUS CHEM CONSU; Petersen JH, 2000, FOOD ADDIT CONTAM, V17, P133, DOI 10.1080/026520300283487; Pfannhauser W., 1995, PHTHALATE LEBENSMITT; Pfordt J, 2004, DEUT LEBENSM-RUNDSCH, V100, P431; PFORDT J, 1999, PHTHALSAUREESTER ALS; Pors J. R., 2001, PHTHALATES ORGANIC T; Prynne CJ, 1999, PUBLIC HEALTH NUTR, V2, P537, DOI 10.1017/S1368980099000725; RASTOGI SC, 64 NERI DAN MIN ENV; RIJK R, 2001, V3932 TNO NETH ORG A; RODEWIJK J, 2003, LOOKS WHO KIDDING; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Scheringer M, 2001, RISK ANAL, V21, P481, DOI 10.1111/0272-4332.213127; SCHMID P, 1985, XENOBIOTICA, V15, P251; Sharpe RM, 2005, ENVIRON HEALTH PERSP, V113, pA504; Sharpe RM, 2004, BRIT MED J, V328, P447, DOI 10.1136/bmj.328.7437.447; SHELDON L, 1993, P IND AIR 93, V3; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; STANEK EJ, 1995, ENVIRON HEALTH PERSP, V103, P276, DOI 10.2307/3432549; Stringer R, 2000, ENVIRON SCI POLLUT R, V7, P27, DOI 10.1065/espr199910.007; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; THUREN A, 1990, ENVIRON SCI TECHNOL, V24, P554, DOI 10.1021/es00074a015; Tsumura Y, 2002, J HEALTH SCI, V48, P493, DOI 10.1248/jhs.48.493; Turrini A, 2001, EUR J CLIN NUTR, V55, P571, DOI 10.1038/sj.ejcn.1601185; *UBA, 2002, BIOZ AND SCHADST HAU; USEPA, 1997, EXP FACT HDB; Vermeire TG, 1997, CHEMOSPHERE, V34, P1823, DOI 10.1016/S0045-6535(97)00017-9; Vikelsoe J, 2002, SCI TOTAL ENVIRON, V296, P105, DOI 10.1016/S0048-9697(02)00063-3; VIKELSOE J, 2004, COMMUNICATION   1112; *VOED, 2002, RES VOED INN OND 200; Von Grote J, 2003, J EXPO ANAL ENV EPID, V13, P325, DOI 10.1038/sj.jea.7500288; Wang RM, 2002, POLYM ADVAN TECHNOL, V13, P6, DOI 10.1002/pat.99; Weegels MF, 2001, RISK ANAL, V21, P499, DOI 10.1111/0272-4332.213128; Wensing M, 2005, SCI TOTAL ENVIRON, V339, P19, DOI 10.1016/j.scitotenv.2004.10.028; Wormuth M, 2005, J IND ECOL, V9, P237, DOI 10.1162/1088198054084626; Yano K, 2005, B ENVIRON CONTAM TOX, V74, P373, DOI 10.1007/s00128-004-0594-7; Yano K, 2002, B ENVIRON CONTAM TOX, V68, P463, DOI 10.1007/s00128-001-0277-6	118	396	420	20	153	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0272-4332			RISK ANAL	Risk Anal.	JUN	2006	26	3					803	824		10.1111/j.1539-6924.2006.00770.x		22	Public, Environmental & Occupational Health; Mathematics, Interdisciplinary Applications; Social Sciences, Mathematical Methods	Public, Environmental & Occupational Health; Mathematics; Mathematical Methods In Social Sciences	055IG	WOS:000238442900022	16834635	
J	Zheng, T; Zhu, Z; Wang, ZD; Homer, RJ; Ma, B; Riese, RJ; Chapman, HA; Shapiro, SD; Elias, JA				Zheng, T; Zhu, Z; Wang, ZD; Homer, RJ; Ma, B; Riese, RJ; Chapman, HA; Shapiro, SD; Elias, JA			Inducible targeting of IL-13 to the adult lung causes matrix metalloproteinase-and cathepsin-dependent emphysema	JOURNAL OF CLINICAL INVESTIGATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; BRONCHOALVEOLAR LAVAGE FLUID; CHRONIC-BRONCHITIS; CYSTEINE PROTEINASES; AIRWAY HYPERRESPONSIVENESS; ALVEOLAR MACROPHAGES; T-LYMPHOCYTES; RESPONSIVENESS; SMOKERS; CELLS	Cigarette smoke exposure is the major cause of chronic obstructive pulmonary disease (COPD). However, only a minority of smokers develop significant COPD, and patients with asthma or asthma-like airway hyperresponsiveness or eosinophilia experience accelerated loss of lung function after cigarette smoke exposure. Pulmonary inflammation is a characteristic feature of lungs from patients with COPD. Surprisingly, the mediators of this inflammation and their contributions to the pathogenesis and varied natural history of COPD are not well defined. Here we show that IL-13, a critical cytokine in asthma, causes emphysema with enhanced lung volumes and compliance, mucus metaplasia, and inflammation, when inducibly overexpressed in the adult murine lung. MMP-2, -9, -12, -13, and -14 and cathepsins B, S, L, H, and K were induced by IL-13 in this setting. Zn addition, treatment with MMP or cysteine proteinase antagonists significantly decreased the emphysema and inflammation, but not the mucus in these animals. These studies demonstrate that IL-13 is a potent stimulator of MMP and cathepsin-based proteolytic pathways in the lung. They also demonstrate that IL-13 causes emphysema via a MMP- and cathepsin-dependent mechanism(s) and highlight common mechanisms that may underlie COPD and asthma.	Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; Vet Adm Connecticut Hlth Care Syst, Pathol & Lab Med Serv, W Haven, CT USA; Harvard Univ, Boston, MA 02115 USA; Univ Calif San Francisco, Sch Med, Inst Cardiovasc Res, San Francisco, CA USA; Washington Univ, Sch Med, Dept Med, St Louis, MO USA; Washington Univ, Sch Med, Dept Cell Biol, St Louis, MO USA; Washington Univ, Sch Med, Dept Pediat, Div Allergy & Pulm Med, St Louis, MO USA	Elias, JA (reprint author), Yale Univ, Sch Med, Dept Internal Med, Pulm & Crit Care Med Sect, 333 Cedar St,105 LCI, New Haven, CT 06520 USA.				NHLBI NIH HHS [HL-56389, HL-61904, HL-64242, P01 HL056389, P50 HL056389, R01 HL064242]		Boushey HA, 1999, NEW ENGL J MED, V340, P1990, DOI 10.1056/NEJM199906243402509; Bradding P.RedingtonAE, 1997, AIRWAY WALL REMODELL, P29; BURRI PH, 1997, LUNG BIOL HEALTH DIS, V100, P1; BURROWS B, 1988, AM REV RESPIR DIS, V138, P829; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Cosio MG, 1999, AM J RESP CRIT CARE, V160, pS21; Curci JA, 2000, J VASC SURG, V31, P325, DOI 10.1016/S0741-5214(00)90163-0; DELAISSE JM, 1984, BIOCHEM BIOPH RES CO, V125, P441, DOI 10.1016/0006-291X(84)90560-6; Diaz PT, 2000, ANN INTERN MED, V132, P369; ELIAS JA, 1994, J IMMUNOL, V152, P2421; Finlay GA, 1997, AM J RESP CRIT CARE, V156, P240; GALARDY RE, 1994, ANN NY ACAD SCI, V732, P315, DOI 10.1111/j.1749-6632.1994.tb24746.x; Graesser D, 1998, LAB INVEST, V78, P1445; Hooper NM, 1997, BIOCHEM J, V321, P265; Husain SR, 1997, CLIN CANCER RES, V3, P151; Klein SA, 1997, AIDS, V11, P1111, DOI 10.1097/00002030-199709000-00005; Lams BEA, 1998, AM J RESP CRIT CARE, V158, P1518; LEBOWITZ MD, 1995, CHEST, V108, P55, DOI 10.1378/chest.108.1.55; Minty A, 1997, EUR CYTOKINE NETW, V8, P203; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; OCONNOR GT, 1995, AM J RESP CRIT CARE, V152, P87; Ohnishi K, 1998, LAB INVEST, V78, P1077; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; PARKER DR, 1990, AM REV RESPIR DIS, V141, P589; Ray P, 1997, J CLIN INVEST, V100, P2501, DOI 10.1172/JCI119792; REDDY VY, 1995, P NATL ACAD SCI USA, V92, P3849, DOI 10.1073/pnas.92.9.3849; RIJCKEN B, 1993, AM REV RESPIR DIS, V148, P944; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; SALMINEN A, 1984, AM J PATHOL, V117, P64; SEATTA M, 1999, AM J RESP CRIT CARE, V160, P517; SENIOR RM, 1991, J BIOL CHEM, V266, P7870; SENIOR RM, 1998, FISHMANS PULMONARY D, V1, P659; Shapiro SD, 2000, AM J RESP CELL MOL, V22, P4; SHI GP, 1992, J BIOL CHEM, V267, P7258; SLUITER HJ, 1991, EUR RESPIR J, V4, P479; Smith GN, 1999, ARTHRITIS RHEUM, V42, P1140, DOI 10.1002/1529-0131(199906)42:6<1140::AID-ANR10>3.0.CO;2-7; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; SNIDER GL, 1994, AM J RESP CRIT CARE, V150, P5131; TAKAHASHI H, 1993, AM REV RESPIR DIS, V147, P1562; Takeyabu K, 1998, EUR RESPIR J, V12, P1033, DOI 10.1183/09031936.98.12051033; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802; VESTBO J, 1997, LANCET, V350, P1431; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1; Yoon HJ, 1999, J IMMUNOL, V162, P7461; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	53	393	410	1	8	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	NOV	2000	106	9					1081	1093		10.1172/JCI10458		13	Medicine, Research & Experimental	Research & Experimental Medicine	371PE	WOS:000165186700004	11067861	
J	McConnell, R; Berhane, K; Gilliland, F; London, SJ; Islam, T; Gauderman, WJ; Avol, E; Margolis, HG; Peters, JM				McConnell, R; Berhane, K; Gilliland, F; London, SJ; Islam, T; Gauderman, WJ; Avol, E; Margolis, HG; Peters, JM			Asthma in exercising children exposed to ozone: a cohort study	LANCET			English	Article							SOUTHERN CALIFORNIA CHILDREN; AIR-POLLUTION; BRONCHIAL RESPONSIVENESS; CHILDHOOD ASTHMA; SCHOOL CHILDREN; PREVALENCE; POLLUTANTS; ASSOCIATION; SYMPTOMS; TAIWAN	Background Little is known about the effect of exposure to air pollution during exercise or time spent outdoors on the development of asthma. We investigated the relation between newly-diagnosed asthma and team sports in a cohort of children exposed to different concentrations and mixtures of air pollutants. Methods 3535 children with no history of asthma were recruited from schools in 12 communities in southern California and were followed up for up to 5 years. 265 children reported a new diagnosis of asthma during follow-up. We assessed risk of asthma in children playing team sports at study entry in six communities with high daytime ozone concentrations, six with lower concentrations, and in communities with high or low concentrations of nitrogen dioxide, particulate matter, and inorganic-acid vapour. Findings In communities with high ozone concentrations, the relative risk of developing asthma in children playing three or more sports was 3.3 (95% CI 1.9-5.8), compared with children playing no sports. Sports had no effect in areas of low ozone concentration (0.8, 0.4-1.6). Time spent outside was associated with a higher incidence of asthma in areas of high ozone (1.4, 1.0-2.1), but not in areas of low ozone. Exposure to pollutants other than ozone did not alter the effect of team sports. Interpretation Incidence of new diagnoses of asthma is associated with heavy exercise in communities with high concentrations of ozone, thus, air pollution and outdoor exercise could contribute to the development of asthma in children.	Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA; NIEHS, Res Triangle Pk, NC 27709 USA; Calif Air Resources Board, Sacramento, CA USA	McConnell, R (reprint author), Univ So Calif, Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90089 USA.			London, Stephanie/0000-0003-4911-5290	NHLBI NIH HHS [1R01HL61768]; NIEHS NIH HHS [1PO1ES0939581-02, 5P30ES07048-05]		AINSWORTH BARBARA E., 2000, MED SCI SPORTS EXERC, P498, DOI DOI 10.1097/00005768-200009001-00009; Asher MI, 1998, EUR RESPIR J, V12, P315; Avol EL, 1998, ENVIRON SCI TECHNOL, V32, P463, DOI 10.1021/es970351m; Baldi I, 1999, EUR RESPIR J, V14, P132, DOI 10.1034/j.1399-3003.1999.14a22.x; Becklake MR, 1997, LANCET S2, V350, pS10, DOI 10.1016/S0140-6736(97)90030-1; BRUNEKREEF B, 1994, AM J RESP CRIT CARE, V150, P962; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Clark NM, 1999, ENVIRON HEALTH PERSP, V107, P421; Corrao W, 1996, CHEST, V109, P298, DOI 10.1378/chest.109.2.298; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Heir T., 1995, Scandinavian Journal of Medicine and Science in Sports, V5, P94; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; KOREN HS, 1995, ENVIRON HEALTH PERSP, V103, P235, DOI 10.2307/3432379; MCARDLE WD, 1996, EXERCISE PHYSL ENERG, P228; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Miller FJ, 1995, TOXICOL LETT, V82-3, P277, DOI 10.1016/0378-4274(95)03562-1; OSEBOLD JW, 1988, P SOC EXP BIOL MED, V188, P259; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Rasmussen F, 2000, EUR RESPIR J, V16, P866, DOI 10.1183/09031936.00.16586600; RUPP NT, 1992, AM J DIS CHILD, V146, P941; Samet JM., 1987, CHEST, V91, P74; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; TAGER IB, 1998, RES REP HLTH EFF I, V81, P27; Wang TN, 1999, ENVIRON RES, V81, P239, DOI 10.1006/enrs.1999.3985; WICHMANN HE, 1995, ENVIRON HEALTH PERSP, V103, P29, DOI 10.2307/3432446	32	391	401	3	51	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	FEB 2	2002	359	9304					386	391		10.1016/S0140-6736(02)07597-9		6	Medicine, General & Internal	General & Internal Medicine	518UP	WOS:000173686500008	11844508	
J	Salvi, SS; Barnes, PJ				Salvi, Sundeep S.; Barnes, Peter J.			Chronic obstructive pulmonary disease in non-smokers	LANCET			English	Review							INDOOR AIR-POLLUTION; NUTRITION EXAMINATION SURVEY; CHRONIC RESPIRATORY-DISEASE; CHRONIC-BRONCHITIS; LUNG-FUNCTION; BIOMASS SMOKE; OCCUPATIONAL EXPOSURES; SOCIOECONOMIC-STATUS; DEVELOPING-COUNTRIES; VENTILATORY FUNCTION	Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide. Tobacco smoking is established as a major risk factor, but emerging evidence suggests that other risk factors are important, especially in developing countries. An estimated 25-45% of patients with COPD have never smoked; the burden of non-smoking COPD is therefore much higher than previously believed. About 3 billion people, half the worldwide population, are exposed to smoke from biomass fuel compared with 1.01 billion people who smoke tobacco, which suggests that exposure to biomass smoke might be the biggest risk factor for COPD globally. We review the evidence for the association of COPD with biomass fuel, occupational exposure to dusts and gases, history of pulmonary tuberculosis, chronic asthma, respiratory-tract infections during childhood, outdoor air pollution, and poor socioeconomic status.	[Salvi, Sundeep S.] Chest Res Fdn, Pune 411014, Maharashtra, India; [Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Salvi, SS (reprint author), Chest Res Fdn, Pune 411014, Maharashtra, India.	ssalvi@crfindia.com			AstraZeneca; Boehringer Ingelheim; Chiesi Farmaceutici; GlaxoSmithKline; Novartis; Pfizer; Teva; Union Chimique Belge	PJB has received research funding and been a member of scientific advisory boards for AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, GlaxoSmithKline, Novartis, Pfizer, Teva, and Union Chimique Belge, some of which are marketing and developing treatments for COPD. SSS declares that he has no conflicts of interest.	ABHYANKAR A, 2008, PREVALENCE COPD REVE; Akhtar T, 2007, CHEST, V132, P1472, DOI 10.1378/chest.06-2529; ANDERSON DO, 1962, NEW ENGL J MED, V267, P787, DOI 10.1056/NEJM196210182671601; ANDERSON HR, 1979, THORAX, V34, P647, DOI 10.1136/thx.34.5.647; Arbex MA, 2009, J EPIDEMIOL COMMUN H, V63, P777, DOI 10.1136/jech.2008.078360; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Barnes D. F., 1994, WHAT MAKES PEOPLE CO; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P240, DOI 10.1164/rccm.2604008; BECKLAKE MR, 1989, AM REV RESPIR DIS, V140, pS85; BEHERA D, 1994, RESPIRATION, V61, P89; Behrendt CE, 2005, CHEST, V128, P1239, DOI 10.1378/chest.128.3.1239; Bergdahl IA, 2004, EUR RESPIR J, V23, P402, DOI 10.1183/09031936.04.00034304; BIRATH G, 1966, SCAND J RESPIR DIS, V47, P27; Birring SS, 2002, AM J RESP CRIT CARE, V166, P1078, DOI 10.1164/rccm.200203-245OC; Blanc P D, 2007, Int J Tuberc Lung Dis, V11, P251; Boy E, 2002, ENVIRON HEALTH PERSP, V110, P109; Brashier B, 2007, EUR RESP SOC ANN C S; Buist AS, 2008, INT J TUBERC LUNG D, V12, P703; BURROWS B, 1968, ARCH ENVIRON HEALTH, V16, P406; Caballero A, 2008, CHEST, V133, P343, DOI 10.1378/chest.07-1361; Cerveri I, 2001, EUR RESPIR J, V18, P85, DOI 10.1183/09031936.01.00087101; CHESTER EH, 1969, AM REV RESPIR DIS, V99, P365; de Marco R, 2004, THORAX, V59, P120, DOI 10.1136/thorax.2003.011163; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; DOSSING M, 1994, RESP MED, V88, P519, DOI 10.1016/S0954-6111(05)80334-8; Dutt D, 1996, NATL MED J INDIA, V9, P113; Eduard W, 2009, CHEST, V136, P716, DOI 10.1378/chest.08-2192; Ehrlich RI, 2004, INT J TUBERC LUNG D, V8, P369; Ekici A, 2005, ENVIRON RES, V99, P93, DOI 10.1016/j.envres.2005.01.004; Ezzati M, 2002, ENVIRON HEALTH PERSP, V110, P1057; FAIRBAIRN A S, 1958, Br J Prev Soc Med, V12, P94; FLETCHER C, 1977, BRIT MED J, V1, P1645; Fukuchi Y, 2004, RESPIROLOGY, V9, P458, DOI 10.1111/j.1440-1843.2004.00637.x; Fullerton DG, 2008, T ROY SOC TROP MED H, V102, P843, DOI 10.1016/j.trstmh.2008.05.028; Gunen H, 2008, EUR J INTERN MED, V19, P499, DOI 10.1016/j.ejim.2007.06.028; HAHN DL, 2002, 20 COMMON PROBLEMS R, P141; Hancox RJ, 2009, THORAX, V64, P228, DOI 10.1136/thx.2008.103978; Hardie JA, 2005, RESP MED, V99, P186, DOI 10.1016/j.rmed.2004.06.006; Hegewald MJ, 2007, CHEST, V132, P1608, DOI 10.1378/chest.07-1405; Hnizdo E, 2002, AM J EPIDEMIOL, V156, P738, DOI 10.1093/aje/kwf105; HOLLAND WW, 1965, LANCET, V1, P445; HUCHON G, 1997, REV MAL RESP, V14; Huhti E, 1982, Eur J Respir Dis Suppl, V118, P35; Husman K, 1987, Eur J Respir Dis Suppl, V152, P57; Kan HD, 2007, THORAX, V62, P873, DOI 10.1136/thx.2006.073015; Kara M, 2003, EUR RADIOL, V13, P2372, DOI 10.1007/s00330-003-1925-5; Kim DS, 2005, AM J RESP CRIT CARE, V172, P842, DOI 10.1164/rccm.200502-259OC; Kiraz K, 2003, CLIN INVEST MED, V26, P243; Kohansal R, 2009, AM J RESP CRIT CARE, V180, P3, DOI 10.1164/rccm.200901-0047OC; LAMBERT PM, 1970, LANCET, V295, P853, DOI DOI 10.1016/S0140-6736(70)91687-9; Lamprecht B, 2007, AM J IND MED, V50, P421, DOI 10.1002/ajim.20470; Lamprecht B, 2008, RESP MED, V102, P1833, DOI 10.1016/j.rmed.2008.07.007; LANCASTER JF, 1963, AM REV RESPIR DIS, V87, P435; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lindberg A, 2005, RESPIRATION, V72, P471, DOI 10.1159/000087670; Lindstrom M, 2001, CHEST, V119, P852, DOI 10.1378/chest.119.3.852; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Lopez AD, 2006, GLOBAL BURDEN OF DISEASE AND RISK FACTORS, P1, DOI 10.1596/978-0-8213-6262-4; Lundback B, 2003, RESP MED, V97, P115, DOI 10.1053/rmed.2003.1446; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; Moran-Mendoza O, 2008, INT J TUBERC LUNG D, V12, P1092; Murray CJL, 1996, GLOBAL BURDEN DIS; NORBOO T, 1991, INT J EPIDEMIOL, V20, P749, DOI 10.1093/ije/20.3.749; O'Byrne PM, 2006, CHEST, V129, P1478, DOI 10.1378/chest.129.6.1478; Orie NGM, 1961, BRONCHITIS, P43; OSWALD N C, 1955, Lancet, V269, P843; Ozbay B, 2001, Respirology, V6, P255, DOI 10.1046/j.1440-1843.2001.00339.x; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; Pena VS, 2000, CHEST, V118, P981, DOI 10.1378/chest.118.4.981; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701; PHILLIPS A. M., 1963, JOUR OCCUP MED, V5, P468; Plit ML, 1998, EUR RESPIR J, V12, P351, DOI 10.1183/09031936.98.12020351; Po JYT, 2009, AM J RESP CRIT CARE, V179; Prescott E, 1999, THORAX, V54, P737; Ramirez-Venegas A, 2006, AM J RESP CRIT CARE, V173, P393, DOI 10.1164/rccm.200504-568OC; Ran Pi-xin, 2006, Zhonghua Nei Ke Za Zhi, V45, P974; Reddy A., 1996, ENERGY RIO PROSPECTS; Regalado J, 2006, AM J RESP CRIT CARE, V174, P901, DOI 10.1164/rccm.200503-479OC; Rushton Lesley, 2007, Reviews on Environmental Health, V22, P255; Sezer H, 2006, ANN EPIDEMIOL, V16, P59, DOI 10.1016/j.annepidem.2004.12.014; Shahab L, 2006, THORAX, V61, P1043, DOI 10.1136/thx.2006.064410; Shavelle Robert M, 2009, Int J Chron Obstruct Pulmon Dis, V4, P137; Shirtcliffe P, 2007, EUR RESPIR J, V30, P232, DOI 10.1183/09031936.00157906; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Smith KR, 2002, INDOOR AIR, V12, P198, DOI 10.1034/j.1600-0668.2002.01137.x; SNIDER GL, 1971, AM REV RESPIR DIS, V103, P625; Sood A, 2009, AM J RESP CRIT CARE, V179; Sungu YS, 2001, TURKISH RESP J, V2, P26; Sunyer J, 2006, OCCUP ENVIRON MED, V63, P836, DOI 10.1136/oem.2006.027995; Sunyer J, 2001, EUR RESPIR J, V17, P1024, DOI 10.1183/09031936.01.17510240; Tan WC, 2003, RESPIROLOGY, V8, P192; Torres-Duque Carlos, 2008, Proc Am Thorac Soc, V5, P577, DOI 10.1513/pats.200707-100RP; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; Tzanakis N, 2004, CHEST, V125, P892, DOI 10.1378/chest.125.3.892; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; Ulvestad B, 2001, OCCUP ENVIRON MED, V58, P663, DOI 10.1136/oem.58.10.663; Viegi G, 2000, CHEST, V117, p339S; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; von Hertzen L, 2000, RESP MED, V94, P356, DOI 10.1053/rmed.1999.0715; Weinmann S, 2008, J OCCUP ENVIRON MED, V50, P561, DOI 10.1097/JOM.0b013e3181651556; WHITTEMORE AS, 1995, AM J PUBLIC HEALTH, V85, P702, DOI 10.2105/AJPH.85.5.702; *WHO, PROGR REP 2000 01 WH; *WHO, CHILDR ENV HLTH 2; *WHO, WHO STOP TB PARTN TU; WILLCOX PA, 1989, RESP MED, V83, P195, DOI 10.1016/S0954-6111(89)80031-9; Zhou Y, 2009, EUR RESPIR J, V33, P509, DOI 10.1183/09031936.00084408	107	390	406	1	58	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2009	374	9691					733	743				11	Medicine, General & Internal	General & Internal Medicine	489LV	WOS:000269422500030	19716966	
J	Brand, PLP; Baraldi, E; Bisgaard, H; Boner, AL; Castro-Rodriguez, JA; Custovic, A; de Blic, J; de Jongste, JC; Eber, E; Everard, ML; Frey, U; Gappa, M; Garcia-Marcos, L; Grigg, J; Lenney, W; Le Souef, P; McKenzie, S; Merkus, PJFM; Midulla, F; Paton, JY; Piacentini, G; Pohunek, P; Rossi, GA; Seddon, P; Silverman, M; Sly, PD; Stick, S; Valiulis, A; van Aalderen, WMC; Wildhaber, JH; Wennergren, G; Wilson, N; Zivkovic, Z; Bush, A				Brand, P. L. P.; Baraldi, E.; Bisgaard, H.; Boner, A. L.; Castro-Rodriguez, J. A.; Custovic, A.; de Blic, J.; de Jongste, J. C.; Eber, E.; Everard, M. L.; Frey, U.; Gappa, M.; Garcia-Marcos, L.; Grigg, J.; Lenney, W.; Le Souef, P.; McKenzie, S.; Merkus, P. J. F. M.; Midulla, F.; Paton, J. Y.; Piacentini, G.; Pohunek, P.; Rossi, G. A.; Seddon, P.; Silverman, M.; Sly, P. D.; Stick, S.; Valiulis, A.; van Aalderen, W. M. C.; Wildhaber, J. H.; Wennergren, G.; Wilson, N.; Zivkovic, Z.; Bush, A.			Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach	EUROPEAN RESPIRATORY JOURNAL			English	Review						asthma; episodic viral wheeze; inhaled corticosteroids; montelukast; multiple-trigger wheeze	EXHALED NITRIC-OXIDE; RESPIRATORY SYNCYTIAL VIRUS; BUDESONIDE INHALATION SUSPENSION; PLACEBO-CONTROLLED TRIAL; LEUKOTRIENE RECEPTOR ANTAGONIST; INHALED FLUTICASONE PROPIONATE; RANDOMIZED CONTROLLED-TRIAL; YOUNG ASTHMATIC-CHILDREN; EPISODIC VIRAL WHEEZE; PROSPECTIVE FOLLOW-UP	There is poor agreement on definitions of different phenotypes of preschool wheezing disorders. The present Task Force proposes to use the terms episodic (viral) wheeze to describe children who wheeze intermittently and are well between episodes, and multi pie-trigger wheeze for children who wheeze both during and outside discrete episodes. Investigations are only needed when in doubt about the diagnosis. Based on the limited evidence available, inhaled short-acting beta(2)-agonists by metered-dose inhaler/spacer combination are recommended for symptomatic relief. Educating parents regarding causative factors and treatment is useful. Exposure to tobacco smoke should be avoided; allergen avoidance may be considered when sensitisation has been established. Maintenance treatment with inhaled corticosteroids is recommended for multiple-trigger wheeze; benefits are often small. Montelukast is recommended for the treatment of episodic (viral) wheeze and can be started when symptoms of a viral cold develop. Given the large overlap in phenotypes, and the fact that patients can move from one phenotype to another, inhaled corticosteroids and montelukast may be considered on a trial basis in almost any preschool child with recurrent wheeze, but should be discontinued if there is no clear clinical benefit. Large well-designed randomised controlled trials with clear descriptions of patients are needed to improve the present recommendations on the treatment of these common syndromes.	[Brand, P. L. P.] Isala Klin, Princess Amalia Childrens Clin, NL-8000 K Zwolle, Netherlands; [de Jongste, J. C.] Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat Resp Med, Rotterdam, Netherlands; [Merkus, P. J. F. M.] Childrens Hosp, Radboud Med Ctr Nijmegen, Div Resp Med, Dept Paediat, Nijmegen, Netherlands; [van Aalderen, W. M. C.] Univ Amsterdam, Acad Med Ctr, Emma Childrens Hosp, Dept Paediat Pulm, NL-1105 AZ Amsterdam, Netherlands; [Baraldi, E.] Univ Padua, Sch Med, Neonatal Intens Care Unit,Unit Resp Med & Allergy, Dept Paediat, Padua, Italy; [Boner, A. L.; Piacentini, G.] GB Rossi Polyclin, Dept Paediat, Verona, Italy; [Midulla, F.] Univ Roma La Sapienza, Dept Paediat Emergency, Rome, Italy; [Rossi, G. A.] G Gaslini Inst Children, Pulm Dis Unit, Genoa, Italy; [Bisgaard, H.] Copenhagen Univ Hosp, Danish Paediat Asthma Ctr, Copenhagen, Denmark; [Castro-Rodriguez, J. A.] Pontificia Univ Catolica Chile, Sch Med, Santiago, Chile; [Custovic, A.] Wythenshawe Hosp, NW Lung Res Ctr, Manchester M23 9LT, Lancs, England; [Everard, M. L.] Sheffield Childrens Hosp, Univ Div Child Hlth, Sheffield, S Yorkshire, England; [Grigg, J.] Barts & London Med Sch, Inst Cell & Mol Sci, Acad Unit Paediat, London, England; [McKenzie, S.] Royal London Hosp, Barts & London NHS Trust, London E1 1BB, England; [Bush, A.] Royal Brompton Hosp, Dept Paediat, Natl Heart & Lung Inst, London, England; [Bush, A.] Univ London Imperial Coll Sci Technol & Med, London, England; [Lenney, W.] Univ Hosp N Staffordshire, Acad Dept Child Hlth, Stoke On Trent, Staffs, England; [Paton, J. Y.] Yorkhill Hosp, Univ Div Dev Med, Glasgow, Lanark, Scotland; [Seddon, P.; Silverman, M.] Royal Alexandra Childrens Hosp, Brighton, E Sussex, England; [Silverman, M.] Univ Leicester, Dept Infect Inflammat & Immunol, Leicester, Leics, England; [de Blic, J.] Necker Hosp Sick Children, Paris Publ Assistance Hosp, Paediat Pneumol & Allergol Serv, Paris, France; [Eber, E.] Med Univ Graz, Dept Paediat & Adolescent Med, Resp & Allerg Dis Div, Graz, Austria; [Frey, U.] Univ Hosp Bern, Inselspital, CH-3010 Bern, Switzerland; [Frey, U.] Univ Bern, Bern, Switzerland; [Wildhaber, J. H.] Fribourg Bertigny Hosp, Dept Paediat, Fribourg, Switzerland; [Gappa, M.] Med Univ Hanover, Dept Paediat Pulmonol & Neonatol, Hannover, Germany; [Garcia-Marcos, L.] Univ Murcia, Inst Resp Hlth, Murcia, Spain; [Stick, S.] Univ Western Australia, Ctr Asthma Allergy & Resp Res, Perth, WA 6009, Australia; [Pohunek, P.] Motol Univ Hosp, Prague, Czech Republic; [Valiulis, A.] Vilnius City Univ Hosp, Vilnius, Lithuania; [Wennergren, G.] Gothenburg Univ, Dept Paediat, Queen Silvia Childrens Hosp, Gothenburg, Sweden; [Zivkovic, Z.] Dr Dragisa Misov Med Ctr, Ctr Paediat Pulmonol, Belgrade, Serbia	Brand, PLP (reprint author), Isala Klin, Princess Amalia Childrens Clin, POB 10400, NL-8000 K Zwolle, Netherlands.	p.l.p.brand@isala.nl	Sly, Peter/F-1486-2010; Eber, Ernst/B-6381-2012; Kronow, Joern/B-1054-2011; Stick, Stephen/O-5683-2014; Merkus, P.J.F.M./L-4523-2015; Custovic, Adnan/A-2435-2012; Bisgaard, Hans/N-4761-2016; Osborne, Nicholas/N-4915-2015	Sly, Peter/0000-0001-6305-2201; Custovic, Adnan/0000-0001-5218-7071; Bisgaard, Hans/0000-0003-4131-7592; Osborne, Nicholas/0000-0002-6700-2284; BARALDI, EUGENIO/0000-0002-1829-3652; Stick, Stephen/0000-0002-5386-8482			Agertoft L, 1998, ACTA PAEDIATR, V87, P842, DOI 10.1080/080352598750013608; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; AVITAL A, 1995, PEDIAT PULMONOL, V17, P281; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2007, PEDIATR PULM, V42, P723, DOI 10.1002/ppul.20644; Bisgaard Hans, 2004, Pediatrics, V113, pe87, DOI 10.1542/peds.113.2.e87; Bont L, 2000, Paediatr Respir Rev, V1, P221, DOI 10.1053/prrv.2000.0052; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; British Thoracic Society, 2003, THORAX S1, V58, pi1; Brown JV, 2002, J PEDIATR PSYCHOL, V27, P677, DOI 10.1093/jpepsy/27.8.677; Browne GJ, 1997, LANCET, V349, P301, DOI 10.1016/S0140-6736(96)06358-1; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Bush A, 2006, THORAX, V61, P367, DOI 10.1136/thx.2005.048389; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Castro-Rodriguez JA, 2004, J PEDIATR-US, V145, P172, DOI 10.1016/j.jpeds.2004.04.007; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Chan EY, 2005, PEDIATR PULM, V39, P558, DOI 10.1002/ppul.20227; CONNER WT, 1989, PEDIATR PULM, V6, P263, DOI 10.1002/ppul.1950060410; Custovic A, 2005, ALLERGY, V60, P1112, DOI 10.1111/j.1398-9995.2005.00934.x; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; DEGOOIJER A, 1993, EUR RESPIR J, V6, P848; Doull IJM, 1997, BRIT MED J, V315, P858; Ducharme FM, 2007, AM J RESP CRIT CAR S, V175, pA958; Dundas I, 2005, THORAX, V60, P13, DOI 10.1136/thx.2004.029934; Elphick HE, 2000, EUR RESPIR J, V16, P593, DOI 10.1034/j.1399-3003.2000.16d04.x; Elphick HE, 2004, ARCH DIS CHILD, V89, P1059, DOI 10.1136/adc.2003.046458; Elphick HE, 2001, ARCH DIS CHILD, V84, P35, DOI 10.1136/adc.84.1.35; Everard ML, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001279.PUB2; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; FERGUSON AE, 1995, BRIT MED J, V310, P1161; Fox GF, 1996, EUR J PEDIATR, V155, P512, DOI 10.1007/BF01955192; Frey U, 2004, AM J RESP CRIT CARE, V170, P260, DOI 10.1164/rccm.200307-1002OC; Gabriele C, 2006, PEDIATR RES, V60, P461, DOI 10.1203/01.pdr.0000238242.39881.64; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Goksor E, 2006, ACTA PAEDIATR, V95, P471, DOI 10.1080/08035250500499440; Gore RB, 2002, CLIN EXP ALLERGY, V32, P662, DOI 10.1046/j.1365-2222.2002.01366.x; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hakim F, 2007, CHEST, V131, P180, DOI 10.1378/chest.06-1402; Hederos CA, 2004, PEDIATR ALLERGY IMMU, V15, P163, DOI 10.1046/j.1399-3038.2003.00098.x; Hess J, 2004, CLIN EXP ALLERGY, V34, P680, DOI 10.1111/j.1365-2222.2004.01961.x; Hofhuis W, 2005, AM J RESP CRIT CARE, V171, P328, DOI 10.1164/rccm.200402-227OC; Hofhuis W, 2003, ARCH DIS CHILD, V88, P246, DOI 10.1136/adc.88.3.246; HOLMGREN D, 1992, PEDIATR PULM, V14, P75, DOI 10.1002/ppul.1950140203; Holzheimer L, 1998, CHILD CARE HLTH DEV, V24, P85; Horn SD, 2003, J PEDIATR-US, V143, pS133, DOI 10.1067/S0022-3476(03)00509-2; Hyvarinen MK, 2005, PEDIATR PULM, V40, P316, DOI 10.1002/ppul.20273; Iles R, 1999, ARCH DIS CHILD, V81, P163; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Janssens HM, 1999, EUR RESPIR J, V13, P787, DOI 10.1034/j.1399-3003.1999.13d15.x; Janssens HM, 2000, EUR RESPIR J, V16, P850, DOI 10.1183/09031936.00.16585000; Kaditis AG, 2007, PEDIATR PULM, V42, P407, DOI 10.1002/ppul.2059; Kim DK, 2007, CLIN EXP ALLERGY, V37, P15, DOI 10.1111/j.1365-2222.2006.02557.x; Knorr B, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.3.e48; Koller DY, 1997, J ALLERGY CLIN IMMUN, V99, P752, DOI 10.1016/S0091-6749(97)80007-3; KRAEMER R, 1991, AM REV RESPIR DIS, V144, P347; Kuehni CE, 2005, SWISS MED WKLY, V135, P95; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Levy ML, 2004, J ASTHMA, V41, P845, DOI 10.1081/JAS-200038451; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Martinez F, 2003, WHEEZING DISORDERS P; Martinez FD, 2007, EUR RESPIR J, V29, P179, DOI 10.1183/09031936.00087906; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McDonald NJ, 2003, COCHRANE DB SYST REV; McKean M, 2000, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001107, DOI 10.1002/14651858.CD001107]; Mckean MC, 2003, CLIN EXP ALLERGY, V33, P912, DOI 10.1046/j.1365-2222.2003.01715.x; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124; MESTERS I, 1994, J ASTHMA, V31, P347, DOI 10.3109/02770909409061314; MESTERS I, 1991, PATIENT EDUC COUNS, V17, P23, DOI 10.1016/0738-3991(91)90048-A; Michel G, 2006, EUR RESPIR J, V28, P1124, DOI 10.1183/09031936.06.00008406; Moeller A, 2004, PEDIATR PULM, V38, P250, DOI 10.1002/ppul.20055; Monge R M Busquets, 2006, Allergol Immunopathol (Madr), V34, P88; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; National Heart Lung, 2007, 3 NAT HEART LUNG BLO; Neve V, 2006, PEDIATR PULM, V41, P735, DOI 10.1002/ppul.20389; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P256; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554; O'Callaghan C, 2000, ARCH DIS CHILD, V82, P185, DOI 10.1136/adc.82.3.185; Papadopoulos NG, 2007, CURR OPIN ALLERGY CL, V7, P91, DOI 10.1097/ACI.0b013e328013d501; Peroni DG, 2002, CLIN EXP ALLERGY, V32, P850, DOI 10.1046/j.1365-2222.2002.01372.x; Piippo-Savolainen E, 2004, ARCH PEDIAT ADOL MED, V158, P1070, DOI 10.1001/archpedi.158.11.1070; POOL JB, 1988, ARCH DIS CHILD, V63, P288; PRENDIVILLE A, 1987, THORAX, V42, P100, DOI 10.1136/thx.42.2.100; Primhak RA, 1999, EUR RESPIR J, V13, P78; Robertson CF, 2007, AM J RESP CRIT CARE, V175, P323, DOI 10.1164/rccm.200510-1546OC; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Rusconi F, 2001, ARCH DIS CHILD, V85, P23, DOI 10.1136/adc.85.1.23; RYLANDER E, 1988, ACTA PAEDIATR SCAND, V77, P711, DOI 10.1111/j.1651-2227.1988.tb10735.x; Saglani S, 2005, ARCH DIS CHILD, V90, P961, DOI 10.1136/adc.2004.071134; Saglani S, 2006, EUR RESPIR J, V27, P29, DOI 10.1183/09031936.06.00030605; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-14040C; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Saito J, 2006, PEDIATR PULM, V41, P709, DOI 10.1002/ppul.20387; Schokker S, 2008, PULM PHARMACOL THER, V21, P88, DOI 10.1016/j.pupt.2006.12.007; Schwarzer G., 2004, COCHRANE DB SYST REV; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Seddon P, 2006, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002885.PUB2; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Sheikh S, 1999, PEDIATR PULM, V28, P181, DOI 10.1002/(SICI)1099-0496(199909)28:3<181::AID-PPUL4>3.3.CO;2-J; Shields MD, 2008, THORAX, V63, P1, DOI 10.1136/thx.2007.077370; Silverman M, 2003, THORAX, V58, P431, DOI 10.1136/thorax.58.5.431; SILVERMAN M, 2002, CHILDHOOD ASTHMA OTH, P307; SIMOES EAF, 1993, AM J DIS CHILD, V147, P303; Skoner DP, 2005, PEDIATR PULM, V40, P477, DOI 10.1002/ppul.20288; Smith M, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002886; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Stevens CA, 2003, EUR RESPIR J, V21, P1000, DOI 10.1183/09031936.03.00057002; Stevens CA, 2002, THORAX, V57, P39, DOI 10.1136/thorax.57.1.39; Strachan DP, 1997, THORAX, V52, P905; Straub DA, 2005, CHEST, V127, P509, DOI 10.1378/chest.127.2.509; Straub DA, 2005, EUR RESPIR J, V25, P289, DOI 10.1183/09031936.05.00031904; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Tasche MJA, 1997, LANCET, V350, P1060, DOI 10.1016/S0140-6736(97)05333-6; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Teper AM, 2005, AM J RESP CRIT CARE, V171, P587, DOI 10.1164/rccm.200408-10880C; Torrent M, 2007, AM J RESP CRIT CARE, V176, P446, DOI 10.1164/rccm.200607-916OC; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Van der Wouden JC, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002173; Vuillermin P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005311.pub2; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; WENNERGREN G, 1992, ACTA PAEDIATR, V81, P40, DOI 10.1111/j.1651-2227.1992.tb12076.x; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; WILDHABER JH, 2006, EUR RESP MON, V11, P191; WILSON N, 1995, ARCH DIS CHILD, V72, P317; Wilson SR, 1996, J ASTHMA, V33, P239, DOI 10.3109/02770909609055365; Wolf FM, 2003, COCHRANE DB SYST REV, V4; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x	142	387	408	3	38	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2008	32	4					1096	1110		10.1183/09031936.00002108		15	Respiratory System	Respiratory System	358VB	WOS:000259944500034	18827155	
J	Illi, S; von Mutius, E; Lau, S; Niggemann, B; Gruber, C; Wahn, U				Illi, Sabina; von Mutius, Erika; Lau, Susanne; Niggemann, Bodo; Grueber, Christoph; Wahn, Ulrich		Multictr Allergy Study Grp	Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study	LANCET			English	Article							HOUSE-DUST MITE; AGE 3 YEARS; CHILDHOOD ASTHMA; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; PRESCHOOL-CHILDREN; EXPOSURE; PREVALENCE; SYMPTOMS; GERMANY	Background Reduced lung function is a feature of chronic asthma, which becomes apparent at school age. Unknown factors between birth and school age determine the progressive loss of pulmonary function in children with persistent asthma. We investigated the role of allergic sensitisation and allergen exposure early in life. Methods The German Multicentre Allergy Study followed 1314 children from birth to 13 years of age. We regularly interviewed parents about their child's asthma and measured IgE levels. Allergen exposure was assessed at age 6 months, 18 months, and at 3, 4, and 5 years; lung function was assessed at 7, 10, and 13 years; post-bronchodilator response at 10 and 13 years; and a bronchial histamine challenge was done at 7 years. Results 90% of children with wheeze but no atopy lost their symptoms at school age and retained normal lung function at puberty. By contrast, sensitisation to perennial allergens (eg, house dust mite, cat and dog hair) developing in the first 3 years of life was associated with a loss of lung function at school age. Concomitant exposure to high levels of perennial allergens early in life aggravated this process: forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio was 87.4 (SD 7.4) for those sensitised and with high exposure compared with 92.6 (6.0) for those not sensitised, p<0.0001; and maximal expiratory flow at 50% (MEF50) 86.4 (25.1) for sensitised and with high exposure compared with 101.5 (23.2; p=0.0031) for those not sensitised. Such exposure also enhanced the development of airway hyper-responsiveness in sensitised children with wheeze. Sensitisation and exposure later in life had much weaker effects and sensitisation to seasonal allergens did not play a part. Interpretation The chronic course of asthma characterised by airway hyper-responsiveness and impairment of lung function at school age is determined by continuing allergic airway inflammation beginning in the first 3 years of life. However, children with a non-atopic wheezing phenotype lose their symptoms over school age and retain normal lung function at puberty.	Charite Univ Med Berlin, Dept Pediat Pneumol & Immunol, Berlin, Germany; Univ Childrens Hosp, Munich, Germany	Illi, S (reprint author), Univ Munich, Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany.	sabina.illi@med.uni-muenchen.de	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 1997, Pediatr Pulmonol Suppl, V15, P27; Chen YZ, 2006, PEDIAT ALLERG IMM-UK, V17, P7, DOI 10.1111/j.1600-5562.2006.00379.x; Cnaan A, 1997, STAT MED, V16, P2349, DOI 10.1002/(SICI)1097-0258(19971030)16:20<2349::AID-SIM667>3.0.CO;2-E; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; *GLOB IN ASTHM, 2005, GINA GUID WORKSH REP; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hirsch T, 2000, CLIN EXP ALLERGY, V30, P529, DOI 10.1046/j.1365-2222.2000.00785.x; Holt PG, 2004, NAT IMMUNOL, V5, P695, DOI 10.1038/ni0704-695; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Niggemann B, 2001, EUR RESPIR J, V17, P246, DOI 10.1183/09031936.01.17202460; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-14040C; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Szefler S, 2000, NEW ENGL J MED, V343, P1054; van den Akker-van Marle ME, 2005, ALLERGY, V60, P140, DOI 10.1111/j.1398-9995.2005.00692.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wahn U, 1997, PEDIATR ALLERGY IMMU, V8, P16; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; WILLIAMS H, 1969, BRIT MED J, V4, P321; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	28	384	397	6	22	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	AUG-SEP	2006	368	9537					763	770		10.1016/S0140-6736(06)69286-6		8	Medicine, General & Internal	General & Internal Medicine	080ID	WOS:000240240200028	16935687	
J	Schmidt, M; Sun, G; Stacey, MA; Mori, L; Mattoli, S				Schmidt, M; Sun, G; Stacey, MA; Mori, L; Mattoli, S			Identification of circulating fibrocytes as precursors of bronchial myofibroblasts in asthma	JOURNAL OF IMMUNOLOGY			English	Article							BRONCHOALVEOLAR LAVAGE FLUID; HUMAN-LUNG FIBROBLASTS; EPITHELIAL-CELLS; SUBEPITHELIAL FIBROSIS; IN-SITU; EXPRESSION; AIRWAY; INFLAMMATION; ENDOTHELIN-1; OBSTRUCTION	The mechanisms contributing to airway wall remodeling in asthma are under investigation to identify appropriate therapeutic targets. Bronchial myofibroblasts would represent an important target because they play a crucial role in the genesis of subepithelial fibrosis, a characteristic feature of the remodeling process, but their origin is poorly understood. We hypothesized that they originate from fibrocytes, circulating cells with the unique characteristic of expressing the hemopoietic stem cell Ag CD34 and collagen I. In this study we show that allergen exposure induces the accumulation of fibrocyte-like cells in the bronchial mucosa of patients with allergic asthma. These cells are CD34-positive; express collagen I and a-smooth muscle actin, a marker of myofibroblasts; and localize to areas of collagen deposition below the epithelium. By tracking labeled circulating fibrocytes in a mouse model of allergic asthma, we provide evidence that fibrocytes are indeed recruited into the bronchial tissue following allergen exposure and differentiate into myofibroblasts. We also show that human circulating fibrocytes acquire the myofibroblast phenotype under in vitro stimulation with fibrogenic cytokines that are produced in exaggerated quantities in asthmatic airways. These results indicate that circulating fibrocytes may function as myofibroblast precursors and may contribute to the genesis of subepithelial fibrosis in asthma.	Avail GmbH, CH-4051 Basel, Switzerland; Avail Biomed Res Inst, Basel, Switzerland	Mattoli, S (reprint author), Avail GmbH, Spalentorweg 18, CH-4051 Basel, Switzerland.		Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X			Abe R, 2001, J IMMUNOL, V166, P7556; ACKERMAN V, 1995, J ALLERGY CLIN IMMUN, V96, P618, DOI 10.1016/S0091-6749(95)70260-1; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Brown JR, 1998, CLIN EXP IMMUNOL, V114, P137; BUCALA R, 1994, MOL MED, V1, P71; Chesney J, 2000, Curr Rheumatol Rep, V2, P501, DOI 10.1007/s11926-000-0027-5; Chesney J, 1997, P NATL ACAD SCI USA, V94, P6307, DOI 10.1073/pnas.94.12.6307; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Gabbrielli S., 1994, Pathologica (Genoa), V86, P157; GIZYCKI MJ, 1997, AM J RESPIR CELL MOL, V3, P507; GROULS V, 1981, STAIN TECHNOL, V56, P323; HAMADA K, 1995, HISTOCHEM J, V27, P309, DOI 10.1007/BF00398973; Hashimoto S, 2001, J ALLERGY CLIN IMMUN, V107, P1001, DOI 10.1067/mai.2001.114702; Hendrikx PJ, 1996, EXP HEMATOL, V24, P129; Herrera C, 2001, BRIT J HAEMATOL, V114, P920, DOI 10.1046/j.1365-2141.2001.02974.x; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; James AL, 1997, AIRWAY WALL REMODELI, P1; Krause DS, 1996, BLOOD, V87, P1; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; Lanzkron SM, 1999, BLOOD, V93, P1916; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; Marini M, 1996, BIOCHEM BIOPH RES CO, V220, P896, DOI 10.1006/bbrc.1996.0502; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; Mori L, 1995, BIOCHEM BIOPH RES CO, V217, P817, DOI 10.1006/bbrc.1995.2845; Morishima Y, 2001, AM J RESP CELL MOL, V24, P1; OBYME PM, 1987, AM REV RESPIR DIS, V136, P740; Pare P D, 1997, Monaldi Arch Chest Dis, V52, P589; Parish CR, 1999, IMMUNOL CELL BIOL, V77, P499, DOI 10.1046/j.1440-1711.1999.00877.x; Powell DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642; Redington AE, 1997, THORAX, V52, P310; Richter A, 2001, AM J RESP CELL MOL, V25, P385; ROBERTS CJ, 1988, J BIOL CHEM, V263, P4586; ROCHE WR, 1989, LANCET, V1, P520; Serini G, 1999, EXP CELL RES, V250, P273, DOI 10.1006/excr.1999.4543; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Teder P, 2000, AM J RESP CELL MOL, V23, P7; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Zhang S, 1996, J PATHOL, V180, P95; Zhang SL, 1999, LAB INVEST, V79, P395	46	384	413	2	15	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUL 1	2003	171	1					380	389				10	Immunology	Immunology	692RQ	WOS:000183674400048	12817021	
J	Atkinson, RW; Anderson, HR; Sunyer, J; Ayres, J; Baccini, M; Vonk, JM; Boumghar, A; Forastiere, F; Forsberg, B; Touloumi, G; Schwartz, J; Katsouyanni, K				Atkinson, RW; Anderson, HR; Sunyer, J; Ayres, J; Baccini, M; Vonk, JM; Boumghar, A; Forastiere, F; Forsberg, B; Touloumi, G; Schwartz, J; Katsouyanni, K			Acute effects of particulate air pollution on respiratory admissions - Results from APHEA 2 project	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						particles; respiratory admissions; heterogeneity; APHEA 2	TIME-SERIES DATA; HOSPITAL ADMISSIONS; EUROPEAN CITIES; HEALTH; ASTHMA; DISEASE; OZONE; URBAN	The APHEA 2 project investigated short-term health effects of particles in eight European cities. In each city associations between particles with an aerodynamic diameter of less than 10 mum (PM10) and black smoke and daily counts of emergency hospital admissions for asthma (0-14 and 15-64 yr), chronic obstructive pulmonary disease (COPD), and all-respiratory disease (65+ yr) controlling for environmental factors and temporal patterns were investigated. Summary PM10 effect estimates (percentage change in mean number of daily admissions per 10 mug/m(3) increase) were asthma (0-14 yr) 1.2% (95% Cl: 0.2, 2.3), asthma (15-64 yr) 1.1% (0.3, 1.8), and COPD plus asthma and all-respiratory (65+ yr) 1.0% (0.4, 1.5) and 0.9% (0.6, 1.3). The combined estimates for Black Smoke tended to be smaller and less precisely estimated than for PM10. Variability in the sizes of the PM10 effect estimates between cities was also investigated. In the 65+ groups PM10 estimates were positively associated with annual mean concentrations of ozone In the cities. For asthma admissions (0-14 yr) a number of city-specific factors, including smoking prevalence, explained some of their variability. This study confirms that particle concentrations in European cities are positively associated with increased numbers of admissions for respiratory diseases and that some of the variation in PM10 effect estimates between cities can be explained by city characteristics.	St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 ORE, England; Inst Municipal Invest Med, Unita Recerca Resp & Ambiental, E-08003 Barcelona, Spain; Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; Univ Florence, Dept Stat, Florence, Italy; Univ Groningen, Fac Med Sci, Det Epidemiol & Stat, Groningen, Netherlands; Hlth Reg Observ, Paris, France; Agcy Publ Hlth, Lazio, Italy; Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden; Dept Hyg Epidemiol, Athens, Greece; Harvard Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, Boston, MA USA	Atkinson, RW (reprint author), St George Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 ORE, England.		Katsouyanni, Klea/D-4856-2014; Forastiere, Francesco/J-9067-2016; Sunyer, J/G-6909-2014	Katsouyanni, Klea/0000-0002-0132-9575; Forastiere, Francesco/0000-0002-9162-5684; Sunyer, J/0000-0002-2602-4110			Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; CHAPMAN R, 1996, EPA600R95001CF US EP; Gamble JF, 1996, ENVIRON HEALTH PERSP, V104, P838, DOI 10.2307/3432938; HATCH M, 1993, ENVIRON HEALTH PERSP, V101, P49, DOI 10.2307/3431659; HOPPEL WA, 1990, ATMOS ENVIRON A-GEN, V24, P645, DOI 10.1016/0960-1686(90)90020-N; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; KATSOUYANNI K, 1995, EUR RESPIR J, V8, P1030; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; MCMURRY PH, 1983, J GEOPHYS RES-OCEANS, V88, P5101, DOI 10.1029/JC088iC09p05101; MENG ZY, 1994, AEROSOL SCI TECH, V20, P253, DOI 10.1080/02786829408959681; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Monn C, 2001, ATMOS ENVIRON, V35, P1, DOI 10.1016/S1352-2310(00)00330-7; Phalen RF, 1998, TOXICOL LETT, V96-7, P263, DOI 10.1016/S0378-4274(98)00081-2; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; Samet JM, 2000, NATL MORBIDITY MOR 2; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Schwartz J., 1997, HLTH CROSSROADS TRAN, P61; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; Sunyer J, 1997, THORAX, V52, P760	22	382	401	3	41	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2001	164	10					1860	1866				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	502TK	WOS:000172758700023	11734437	
J	Bornehag, CG; Blomquist, G; Gyntelberg, F; Jarvholm, B; Malmberg, P; Nordvall, L; Nielsen, A; Pershagen, G; Sundell, J				Bornehag, CG; Blomquist, G; Gyntelberg, F; Jarvholm, B; Malmberg, P; Nordvall, L; Nielsen, A; Pershagen, G; Sundell, J			Dampness in buildings and health - Nordic interdisciplinary review of the scientific evidence on associations between exposure to "dampness" in buildings and health effects (NORDDAMP)	INDOOR AIR-INTERNATIONAL JOURNAL OF INDOOR AIR QUALITY AND CLIMATE			English	Review						review; dampness; exposure; health effects; allergy; asthma	HOUSE-DUST MITES; DAY-CARE-CENTERS; CHILDHOOD RESPIRATORY SYMPTOMS; ENVIRONMENTAL RISK-FACTORS; VOLATILE ORGANIC-COMPOUNDS; PRIMARY-SCHOOL CHILDREN; REPORTED HOME DAMPNESS; INDOOR AIR-QUALITY; RESIDENTIAL CHARACTERISTICS; SUBTROPICAL CLIMATE	Several epidemiological investigations concerning indoor environments have indicated that "dampness" in buildings is associated to health effects such as respiratory symptoms, asthma and allergy The aim of the present interdisciplinary review is to evaluate this association as shown in the epidemiological literature. A literature search identified 590 peer-reviewed articles of which 61 have been the foundation for this review. The review shows that "dampness" in buildings appears to increase the risk for health effects in the airways, such as cough, wheeze and asthma. Relative risks are in the range of OR 1.4-2.2. There also seems to be an association between "dampness" and other symptoms Such as tiredness, headache and airways infections. It is concluded that the evidence for a causal association between "dampness" and health effects is strong. However, the mechanisms are unknown. Several definitions of dampness have been used in the studies, but all seems to be associated with health problems. Sensitisation to mites may be one but obviously not the only mechanism. Even if the mechanisms are unknown, there is sufficient evidence to take preventive measures against dampness in buildings.	Natl Testing & Res Inst, Karlstad, Sweden; Natl Inst Working Life, Umea, Sweden; Bispebjerg Hosp, DK-2400 Copenhagen, Denmark; Umea Univ, Umea, Sweden; Natl Inst Working Life, Stockholm, Sweden; Univ Uppsala Hosp, Uppsala, Sweden; Natl Testing & Res Inst, Boras, Sweden; Karolinska Inst, Stockholm, Sweden; Tech Univ Denmark, DK-2800 Lyngby, Denmark	Bornehag, CG (reprint author), Natl Testing & Res Inst, Karlstad, Sweden.		Sundell, Jan/B-2857-2012				Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; AHLBOM A, 1990, SCAND J WORK ENV HEA, V16, P153; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Andersson MA, 1997, APPL ENVIRON MICROB, V63, P387; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473; Austin JB, 1997, ARCH DIS CHILD, V76, P22; BECK HI, 1989, ACTA DERM-VENEREOL, V69, P162; BENER A, 1996, HUM BIOL, V68, P791; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BRABACK L, 1995, ARCH DIS CHILD, V72, P487; Braback L, 1991, PEDIATR ALLERGY IMMU, V2, P14, DOI 10.1111/j.1399-3038.1991.tb00174.x; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; BRUNEKREEF B, 1992, SCI TOTAL ENVIRON, V127, P79, DOI 10.1016/0048-9697(92)90471-4; BRUNEKREEF B, 1992, EUR RESPIR J, V5, P930; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; Burr M. I., 1988, J ROY SOC HEALTH, V3, P99, DOI 10.1177/146642408810800311; Chirila M, 1981, Med Interne, V19, P73; COLLOFF MJ, 1987, MED VET ENTOMOL, V1, P163, DOI 10.1111/j.1365-2915.1987.tb00338.x; COLLOFF MJ, 1992, BRIT J DERMATOL, V127, P322, DOI 10.1111/j.1365-2133.1992.tb00449.x; *COMM ENV HLTH, 1996, SOU, P124; CUIJPERS CEJ, 1995, ENVIRON RES, V68, P11, DOI 10.1006/enrs.1995.1003; DALES RE, 1994, INDOOR AIR, V4, P2, DOI 10.1111/j.1600-0668.1994.t01-3-00002.x; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172; DOTTERUD LK, 1995, ALLERGY, V50, P788; Dotterud LK, 1995, PEDIATR ALLERGY IMMU, V6, P181, DOI 10.1111/j.1399-3038.1995.tb00282.x; Dotterud LK, 1996, INDOOR AIR, V6, P71, DOI 10.1111/j.1600-0668.1996.t01-2-00002.x; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15; Finsnes Kolbein A., 1995, Tidsskrift for den Norske Laegeforening, V115, P3274; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Gustafsson D, 1996, ALLERGY, V51, P789, DOI 10.1111/j.1398-9995.1996.tb04468.x; GYNTELBERG F, 1994, INDOOR AIR, V4, P223, DOI 10.1111/j.1600-0668.1994.00003.x; HARRISON J, 1992, RESP MED, V86, P225, DOI 10.1016/S0954-6111(06)80060-0; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; Harving H, 1994, Ugeskr Laeger, V156, P1141; HARVING H, 1990, ANN ALLERGY, V65, P25; Hirvonen MR, 1997, ARCH ENVIRON HEALTH, V52, P426; Horabin JI, 1996, RNA, V2, P1; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; Huang SW, 1997, CLIN PEDIATR, V36, P695, DOI 10.1177/000992289703601205; HYNDMAN SJ, 1990, SOC SCI MED, V30, P131, DOI 10.1016/0277-9536(90)90336-Q; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; IVERSEN M, 1995, J INVEST ALLERG CLIN, V5, P205; IVERSEN M, 1990, ALLERGY, V45, P81, DOI 10.1111/j.1398-9995.1990.tb00462.x; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Kelly YJ, 1996, ARCH DIS CHILD, V75, P489; KERR AA, 1981, NEW ZEAL MED J, V93, P333; KODAMA AM, 1986, ARCH ENVIRON HEALTH, V41, P306; KORSGAARD J, 1983, ALLERGY, V38, P85, DOI 10.1111/j.1398-9995.1983.tb01591.x; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; Koskinen OM, 1997, INDOOR AIR, V7, P262, DOI 10.1111/j.1600-0668.1997.00005.x; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P68; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P200; Li CS, 1996, ARCH ENVIRON HEALTH, V51, P42; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; LI CS, 1994, J ALLERGY CLIN IMMUN, V94, P131, DOI 10.1016/0091-6749(94)90080-9; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P208; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; Li CS, 1996, J ALLERGY CLIN IMMUN, V97, P857, DOI 10.1016/S0091-6749(96)80166-7; LI CS, 1995, ARCH ENV HLTH, V51; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; MARTIN CJ, 1987, BRIT MED J, V294, P1125; MELIA RJW, 1982, INT J EPIDEMIOL, V11, P155, DOI 10.1093/ije/11.2.155; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; MURRAY AB, 1985, J ALLERGY CLIN IMMUN, V76, P108, DOI 10.1016/0091-6749(85)90812-7; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; [Anonymous], 1998, INDOOR AIR S; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; NORBACK D, 1991, BRIT J IND MED, V48, P451; NORDVALL SL, 1990, ANN ALLERGY, V65, P418; NORDVALL SL, 1990, PEDIATR ALLERGY IMMU, V1, P68, DOI 10.1111/j.1399-3038.1990.tb00013.x; Norrman E, 1998, ALLERGY, V53, P28, DOI 10.1111/j.1398-9995.1998.tb03770.x; NORRMAN E, 1994, ALLERGY, V49, P808, DOI 10.1111/j.1398-9995.1994.tb00779.x; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; Placido JL, 1996, ALLERGY, V51, P633, DOI 10.1111/j.1398-9995.1996.tb04683.x; PLATT SD, 1989, BRIT MED J, V298, P1673; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; RUOTSALAINEN R, 1995, INT ARCH OCC ENV HEA, V66, P369, DOI 10.1007/BF00383142; RYLANDER R, 1997, ARCH ENV HLTH, V52; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; STRACHAN D, 1989, BRIT MED J, V299, P325; STRACHAN DP, 1990, J LARYNGOL OTOL, V104, P4, DOI 10.1017/S0022215100111648; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; STRACHAN DP, 1995, BRIT MED J, V311, P1053; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; STRACHAN DP, 1988, BRIT MED J, V297, P1223; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; SUNDELL J, 1994, LUFTEN ANDAS INOMHUS; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; TIMONEN KL, 1995, EUR RESPIR J, V8, P1155, DOI 10.1183/09031936.95.08071155; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; VERHOEFF AP, 1992, ALLERGY, V47, P83; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Wessen B, 1996, ANALYST, V121, P1203, DOI 10.1039/an9962101203; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WICKMAN M, 1994, ALLERGY, V49, P114, DOI 10.1111/j.1398-9995.1994.tb00810.x; Williamson IJ, 1997, THORAX, V52, P229; Yang CY, 1997, ENVIRON RES, V75, P49, DOI 10.1006/enrs.1997.3774; Yang CY, 1997, PEDIATR PULM, V24, P73, DOI 10.1002/(SICI)1099-0496(199708)24:2<73::AID-PPUL1>3.3.CO;2-L	119	382	391	7	65	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air-Int. J. Indoor Air Qual. Clim.	JUN	2001	11	2					72	86				15	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	435VC	WOS:000168902000002	11394014	
J	Trompette, A; Divanovic, S; Visintin, A; Blanchard, C; Hegde, RS; Madan, R; Thorne, PS; Wills-Karp, M; Gioannini, TL; Weiss, JP; Karp, CL				Trompette, Aurelien; Divanovic, Senad; Visintin, Alberto; Blanchard, Carine; Hegde, Rashmi S.; Madan, Rajat; Thorne, Peter S.; Wills-Karp, Marsha; Gioannini, Theresa L.; Weiss, Jerry P.; Karp, Christopher L.			Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein	NATURE			English	Article							TLR4-MD-2 COMPLEX; CRYSTAL-STRUCTURE; ALLERGIC DISEASE; CELL ACTIVATION; ENDOTOXIN; MD-2; ASTHMA; LIPOPOLYSACCHARIDE; RESPONSES; EXPOSURE	Aeroallergy results from maladaptive immune responses to ubiquitous, otherwise innocuous environmental proteins(1). Although the proteins targeted by aeroallergic responses represent a tiny fraction of the airborne proteins humans are exposed to, allergenicity is a quite public phenomenon - the same proteins typically behave as aeroallergens across the human population. Why particular proteins tend to act as allergens in susceptible hosts is a fundamental mechanistic question that remains largely unanswered. The main house- dust- mite allergen, Der p 2, has structural homology with MD- 2 ( also known as LY96), the lipopolysaccharide ( LPS)- binding component of the Toll- like receptor ( TLR) 4 signalling complex(2-4). Here we show that Der p 2 also has functional homology, facilitating signalling through direct interactions with the TLR4 complex, and reconstituting LPS- driven TLR4 signalling in the absence of MD- 2. Mirroring this, airway sensitization and challenge with Der p 2 led to experimental allergic asthma in wild type and MD- 2- deficient, but not TLR4- deficient, mice. Our results indicate that Der p 2 tends to be targeted by adaptive immune responses because of its auto-adjuvant properties. The fact that other members of the MD- 2- like lipid- binding family are allergens, and that most defined major allergens are thought to be lipid- binding proteins(5), suggests that intrinsic adjuvant activity by such proteins and their accompanying lipid cargo may have some generality as a mechanism underlying the phenomenon of allergenicity.	[Trompette, Aurelien; Divanovic, Senad; Madan, Rajat; Karp, Christopher L.] Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA; [Blanchard, Carine] Childrens Hosp, Med Ctr, Div Allergy & Immunol, Cincinnati, OH 45229 USA; [Hegde, Rashmi S.] Childrens Hosp, Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA; [Wills-Karp, Marsha] Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Cincinnati, OH 45229 USA; [Visintin, Alberto] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Dept Med, Worcester, MA 01606 USA; [Thorne, Peter S.] Univ Iowa, Dept Occupat & Environm Med, Iowa City, IA 52241 USA; [Gioannini, Theresa L.; Weiss, Jerry P.] Univ Iowa, Inflammat Program, Dept Internal Med, Iowa City, IA 52241 USA; [Gioannini, Theresa L.; Weiss, Jerry P.] Vet Affairs Med Ctr, Iowa City, IA 52247 USA	Karp, CL (reprint author), Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA.	chris.karp@chmcc.org	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Karp, Christopher/0000-0002-0832-2659	Sandler Foundation for Asthma Research; National Institute of Allergy and Infectious Diseases; Veteran's Administration	We thank S. Vogel for re-purified LPS; E. Kurt-Jones and R. Finberg for HEK293 cells expressing TLR4 complex proteins, N.J. Gay for discussions, and L. Flick and J. Bohnert for technical assistance. This work was funded by grants from the Sandler Foundation for Asthma Research (C.L.K.), the National Institute of Allergy and Infectious Diseases (C.L.K., J.P.W.), and the Veteran's Administration (T.L.G.).	Blander JM, 2006, NATURE, V440, P808, DOI 10.1038/nature04596; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.0000/S0022-2836(02)00027-X; Divanovic S, 2005, NAT IMMUNOL, V6, P571, DOI 10.1038/ni1198; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Kawasaki K, 2003, J IMMUNOL, V170, P413; Kennedy MN, 2004, J BIOL CHEM, V279, P34698, DOI 10.1074/jbc.M405444200; Kim HM, 2007, CELL, V130, P906, DOI 10.1016/j.cell.2007.08.002; MAUNSELL K, 1968, LANCET, V1, P1267; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Ohto U, 2007, SCIENCE, V316, P1632, DOI 10.1126/science.1139111; Park GM, 2000, CLIN EXP ALLERGY, V30, P1293, DOI 10.1046/j.1365-2222.2000.00883.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Teghanemt A, 2007, J BIOL CHEM, V282, P36250, DOI 10.1074/jbc.M705995200; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P388, DOI 10.1007/s11882-005-0012-1; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Williams LK, 2005, ANN ALLERG ASTHMA IM, V94, P323; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	30	381	387	5	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 29	2009	457	7229					585	U91		10.1038/nature07548		5	Multidisciplinary Sciences	Science & Technology - Other Topics	400FA	WOS:000262852200042	19060881	
J	Lemanske, RF; Jackson, DJ; Gangnon, RE; Evans, MD; Li, ZH; Shult, PA; Kirk, CJ; Reisdorf, E; Roberg, KA; Anderson, EL; Carlson-Dakes, KT; Adler, KJ; Gilbertson-White, S; Pappas, TE; DaSilva, DF; Tisler, CJ; Gern, JE				Lemanske, RF; Jackson, DJ; Gangnon, RE; Evans, MD; Li, ZH; Shult, PA; Kirk, CJ; Reisdorf, E; Roberg, KA; Anderson, EL; Carlson-Dakes, KT; Adler, KJ; Gilbertson-White, S; Pappas, TE; DaSilva, DF; Tisler, CJ; Gern, JE			Rhinovirus illnesses during infancy predict subsequent childhood wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						rhinovirus; respiratory syncytial virus; virus; asthma; wheezing illnesses; allergic sensitization; atopy; infants; children; allergic disease	RESPIRATORY SYNCYTIAL VIRUS; DISEASE SEVERITY; EARLY-LIFE; BRONCHIOLITIS; ASTHMA; INFECTION; CHILDREN; RISK; ASSOCIATION; AGE	Background: The contribution of viral respiratory infections during infancy to the development of subsequent wheezing and/ or allergic diseases in early childhood is not established. Objective: To evaluate these relationships prospectively from birth to 3 years of age in 285 children genetically at high risk for developing allergic respiratory diseases. Methods: By using nasal lavage, the relationship of timing, severity, and etiology of viral respiratory infections during infancy to wheezing in the 3rd year of life was evaluated. In addition, genetic and environmental factors that could modify risk of infections and wheezing prevalence were analyzed. Results: Risk factors for 3rd year wheezing were passive smoke exposure (odds ratio [OR] = 2.1), older siblings (OR = 2.5), allergic sensitization to foods at age 1 year (OR = 2.0), any moderate to severe respiratory illness without wheezing during infancy (OR = 3.6), and at least 1 wheezing illness with respiratory syncytial virus (RSV; OR = 3.0), rhinovirus (OR 10) and/or non-rhinovirus/RSV pathogens (OR = 3.9) during infancy. When viral etiology was considered, 1st-year wheezing illnesses caused by rhinovirus infection were the strongest predictor of subsequent 3rd year wheezing (OR = 6.6; P < .0001). Moreover, 63% of infants who wheezed during rhinovirus seasons continued to wheeze in the 3rd year of life, compared with only 20% of all other infants (OR = 6.6; P < .0001). Conclusion: In this population of children at increased risk of developing allergies and asthma, the most significant risk factor for the development of preschool childhood wheezing is the occurrence of symptomatic rhinovirus; illnesses during infancy that are clinically and prognostically informative based on their seasonal nature.	Univ Wisconsin, Dept Pediat, Madison, WI 53706 USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53706 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA	Lemanske, RF (reprint author), Univ Wisconsin Hosp, K4-916,600 Highland Ave, Madison, WI 53792 USA.	rfl@medicine.wisc.edu		Evans, Michael/0000-0001-7449-3993	NHLBI NIH HHS [1P01HLPO, 1R01HL61879]		Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bont L, 2000, AM J RESP CRIT CARE, V161, P1518; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Choi EH, 2002, J INFECT DIS, V186, P1207, DOI 10.1086/344310; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Gern JE, 2002, PEDIATR ALLERGY IMMU, V13, P386, DOI 10.1034/j.1399-3038.2002.01093.x; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Hoebee B, 2004, J INFECT DIS, V189, P239, DOI 10.1086/380908; Hoebee B, 2003, J INFECT DIS, V187, P2, DOI 10.1086/345859; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023; Hull J, 2003, J INFECT DIS, V188, P904, DOI 10.1086/377587; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; IRELAND DC, 1993, J MED VIROL, V40, P96, DOI 10.1002/jmv.1890400204; Jartti T, 2004, EMERG INFECT DIS, V10, P1095; Korppi M, 2004, PEDIATR INFECT DIS J, V23, P995, DOI 10.1097/01.inf.0000143642.72480.53; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Lahti M, 2002, PEDIATR RES, V51, P696, DOI 10.1023/01.PDR.0000015911.65104.93; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; Lowe L, 2004, ARCH DIS CHILD, V89, P540, DOI 10.1136/adc.2003.038539; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1067/mai.2003.1716; Openshaw PJM, 2003, PEDIATR INFECT DIS J, V22, pS58, DOI 10.1097/00006454-200302001-00009; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-1188C; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5	33	377	393	3	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					571	577		10.1016/j.jaci.2005.06.024		7	Allergy; Immunology	Allergy; Immunology	017IE	WOS:000235686500016	16159626	
J	von Mutius, E; Braun-Fahrlander, C; Schierl, R; Riedler, J; Ehlermann, S; Maisch, S; Waser, M; Nowak, D				von Mutius, E; Braun-Fahrlander, C; Schierl, R; Riedler, J; Ehlermann, S; Maisch, S; Waser, M; Nowak, D			Exposure to endotoxin or other bacterial components might protect against the development of atopy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; endotoxin; children	ALLERGIC SENSITIZATION; RESPIRATORY HEALTH; AIRBORNE ENDOTOXIN; IMMUNE-RESPONSES; DUST; CHILDHOOD; ASTHMA; INTERLEUKIN-12; COMMUNITY; CHILDREN	Background Several recent studies have shown that growing up on a farm confers significant protection against the development of atopy. These findings point particularly towards the importance of exposure to stable dust and farm animals. It has furthermore been reported that endotoxin, an intrinsic part of the outer membrane of gram negative bacteria, is abundant in environments where livestock and poultry is kept. The aim of this study was therefore to measure the level of environmental endotoxin exposure in homes of farmers' children, children with regular contact to livestock and control children with no contact to farm animals. Methods Eighty-four farming and nonfarming families were identified in rural areas in Southern Germany and Switzerland. Samples of settled and airborne dust were collected in stables, and of settled dust indoors from kitchen floors and the children's mattresses. Endotoxin concentrations were determined by a kinetic Limulus assay. Results Endotoxin concentrations were highest in stables of farming families, but were also significantly higher indoors in dust from kitchen floors (143 EU/mg vs 39 EU/mg, P < 0.001) and children's mattresses (49479 EU/m(2) vs 9383 EU/m(2), P < 0.001) as compared to control children from nonfarming families. In addition, endotoxin levels were also significantly higher in mattresses and dust from kitchen floors in households where children had regular contact to farm animals (38.6 EU/mg and 23340 EU/m(2), respectively) as compared to control subjects. Conclusion We propose that the level of environmental exposure to endotoxin and other bacterial wall components is an important protective determinant for the development of atopic diseases in childhood.	Univ Childrens Hosp, Munich, Germany; Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Munich, Inst Occupat & Environm Med, D-80539 Munich, Germany; Childrens Hosp, Salzburg, Austria	von Mutius, E (reprint author), Univ Munich, Klinikum Innenstadt, Lindwurmstr 4, D-80337 Munich, Germany.						ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; AbouZeid C, 1997, INFECT IMMUN, V65, P1856; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Cleveland MG, 1996, INFECT IMMUN, V64, P1906; DUTKIEWICZ J, 1978, ARCH ENVIRON HEALTH, V33, P250; HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee, 1998, PHAS 2 MOD INT STUD; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Jahn-Schmid B, 1999, J ALLERGY CLIN IMMUN, V104, P1015; Lee SM, 1996, BLOOD, V88, P945; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MAGGI E, 1992, J IMMUNOL, V148, P2142; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Nicolai T, 1998, THORAX, V53, P1035; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rietschel E T, 1982, Scand J Infect Dis Suppl, V31, P8; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Thedell T D, 1980, Am J Ind Med, V1, P3, DOI 10.1002/ajim.4700010103; VINZENTS P, 1992, AM IND HYG ASSOC J, V53, P237, DOI 10.1202/0002-8894(1992)053<0237:VIETDA>2.0.CO;2; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Yeung VP, 1998, J IMMUNOL, V161, P4146	32	377	380	2	21	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2000	30	9					1230	1234				5	Allergy; Immunology	Allergy; Immunology	348PP	WOS:000088994100008	10971468	
J	Rahman, I; Biswas, SK; Kode, A				Rahman, I; Biswas, SK; Kode, A			Oxidant and antioxidant balance in the airways and airway diseases	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Review						oxidants; antioxidants; lungs; glutathione; superoxide dismutase; thioredoxin	EXTRACELLULAR-SUPEROXIDE-DISMUTASE; IDIOPATHIC PULMONARY-FIBROSIS; TUMOR-NECROSIS-FACTOR; HEME OXYGENASE-1 EXPRESSION; INDUCED LUNG INJURY; KAPPA-B ACTIVATION; GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; RESPIRATORY-DISTRESS-SYNDROME; ALVEOLAR INFLAMMATORY CELLS; BRONCHIAL EPITHELIAL-CELLS	Although oxygen is a prerequisite to life, at concentrations beyond the physiological limits it may be hazardous to the cells. Since the lungs are directly exposed to very high amounts of oxygen, it is imperative for the organ to possess defences against possible oxidative challenge. The lungs are therefore endowed with an armamentarium of a battery of endogenous agents called antioxidants. The antioxidant species help the lungs ward off the deleterious consequences of a wide variety of oxidants/reactive oxygen species such as superoxide anion, hydroxyl radical, hypohalite radical, hydrogen peroxide and reactive nitrogen species such as nitric oxide, peroxynitrite, nitrite produced endogenously and sometimes accessed through exposure to the environment. The major non-enzymatic antioxidants of the lungs are glutathione, vitamins C and E, beta-carotene, uric acid and the enzymatic antioxidants are superoxide dismutases, catalase and peroxidases. These antioxidants are the first lines of defence against the oxidants and usually act at a gross level. Recent insights into cellular redox chemistry have revealed the presence of certain specialized proteins such as peroxiredoxins, thioredoxins, glutaredoxins, heme oxygenases and reductases, which are involved in cellular adaptation and protection against an oxidative assault. These molecules usually exert their action at a more subtle level of cellular signaling processes. Aberrations in oxidant: antioxidant balance can lead to a variety of airway diseases, such as asthma, chronic obstructive Pulmonary disease and idiopathic pulmonary fibrosis which is the topic of discussion in this review. (c) 2005 Elsevier B.V. All rights reserved.	Univ Rochester, Med Ctr, Dept Environm Med, Div Lung Biol & Dis, Rochester, NY 14642 USA; Dr Ambedkar Coll, Dept Biochem, Nagpur, Maharashtra, India	Rahman, I (reprint author), Univ Rochester, Med Ctr, Dept Environm Med, Div Lung Biol & Dis, 601 Elmwood Ave,Bldg 850, Rochester, NY 14642 USA.	irfan_rahman@urmc.rochester.edu			NIEHS NIH HHS [ES01247]		ADAMSON IYR, 1974, AM J PATHOL, V77, P185; Allen RG, 1999, J CELL PHYSIOL, V180, P114, DOI 10.1002/(SICI)1097-4652(199907)180:1<114::AID-JCP13>3.0.CO;2-0; Amer E.S., 2000, EUR J BIOCHEM, V267, P6102, DOI DOI 10.1046/J.1432-1327.2000.01701.X.PMID:11012661; Andoh T, 2002, J BIOL CHEM, V277, P9655, DOI 10.1074/jbc.M110701200; Antuni JD, 2000, THORAX, V55, P138, DOI 10.1136/thorax.55.2.138; Asikainen TM, 1998, AM J RESP CELL MOL, V19, P942; AVISSAR N, 1996, AM J PHYSIOL, V270, pL447; Avissar NE, 2000, AM J RESP CRIT CARE, V162, P1342; Beeh KM, 2004, CHEST, V126, P1116, DOI 10.1378/chest.126.4.1116; Behr J, 2000, AM J RESP CRIT CARE, V161, P1968; BORZI RM, 1993, CLIN SCI, V85, P353; BUCKLEY BJ, 1987, J APPL PHYSIOL, V63, P359; Buhl R, 1996, CHEST, V110, pS267, DOI 10.1378/chest.110.6_Supplement.267S; BUNNELL E, 1993, AM REV RESPIR DIS, V148, P1174; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; Carraway MS, 2000, AM J PHYSIOL-LUNG C, V278, pL806; Casagrande S, 2002, P NATL ACAD SCI USA, V99, P9745, DOI 10.1073/pnas.152168599; CASAGRANDE S, 2000, CELL MOL BIOL, V16, P162; Chabot F, 1998, EUR RESPIR J, V11, P745; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHANG LY, 1995, LAB INVEST, V73, P29; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9; CHU FF, 1993, J BIOL CHEM, V268, P2571; CHURCH DF, 1985, ENVIRON HEALTH PERSP, V64, P111; Clerch LB, 1996, AM J PHYSIOL-LUNG C, V271, pL949; CLYDE BL, 1993, AM J RESP CELL MOL, V8, P530; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; COMHAIR SA, 2005, AM J PATHOL, V166, P649; Comhair SAA, 2005, AM J RESP CRIT CARE, V172, P306, DOI 10.1164/rccm.200502-180OC; Comhair SAA, 2005, ANTIOXID REDOX SIGN, V7, P72, DOI 10.1089/ars.2005.7.72; Comhair SAA, 2000, AM J RESP CELL MOL, V23, P350; Comhair SAA, 2002, AM J PHYSIOL-LUNG C, V283, pL246, DOI 10.1152/ajplung.00491.2001; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Copin JC, 2000, FREE RADICAL BIO MED, V28, P1571, DOI 10.1016/S0891-5849(00)00280-X; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Coursin DB, 1996, HISTOL HISTOPATHOL, V11, P851; COURSIN DB, 1992, AM J PHYSIOL, V263, P679; CRAPO JD, 1992, P NATL ACAD SCI USA, V89, P10405, DOI 10.1073/pnas.89.21.10405; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; CRYSTAL RG, 1991, AM J MED S3C, V91, P39; Cumming RC, 2004, J BIOL CHEM, V279, P21749, DOI 10.1074/jbc.M312267200; Das KC, 2001, J BIOL CHEM, V276, P4662, DOI 10.1074/jbc.M006206200; Dauletbaev N, 2004, J Cyst Fibros, V3, P119, DOI 10.1016/j.jcf.2004.03.005; Dauletbaev N, 2005, AM J PHYSIOL-LUNG C, V288, pL903, DOI 10.1152/ajplung.00349.2004; Davis JM, 2003, PEDIATRICS, V111, P469, DOI 10.1542/peds.111.3.469; EISERICH JP, 1995, AM J CLIN NUTR, V62, P1490; ENGSTROM PC, 1990, J APPL PHYSIOL, V69, P2078; ERZURUM SC, 1993, J APPL PHYSIOL, V75, P1256; Esworthy RS, 1997, ARCH BIOCHEM BIOPHYS, V340, P59, DOI 10.1006/abbi.1997.9901; ETHAN PC, 2004, AM J PHYSL CELL MOL, V287, pL24; Facchetti F, 1999, AM J PATHOL, V154, P145, DOI 10.1016/S0002-9440(10)65261-3; Favatier F, 2001, BIOCHEM J, V353, P475, DOI 10.1042/0264-6021:3530475; Ferris CD, 1999, NAT CELL BIOL, V1, P152; FINGLAS PM, 1993, BRIT J NUTR, V69, P563, DOI 10.1079/BJN19930056; Folkerts G, 2001, EUR J PHARMACOL, V429, P251, DOI 10.1016/S0014-2999(01)01324-3; Folz RJ, 1997, AM J RESP CELL MOL, V17, P393; FOLZ RJ, 1994, GENOMICS, V22, P162, DOI 10.1006/geno.1994.1357; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; Folz RJ, 1997, CHEST, V111, pS74, DOI 10.1378/chest.111.6_Supplement.74S; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; FREEMAN BA, 1985, FED PROC, V44, P2591; FRIDOVICH I, 1986, ANNU REV PHYSIOL, V48, P693; FRIDOVICH I, 1975, ANNU REV BIOCHEM, V44, P147, DOI 10.1146/annurev.bi.44.070175.001051; Gansauge S, 1997, FEBS LETT, V410, P160, DOI 10.1016/S0014-5793(97)00544-9; Gharaee-Kermani M, 2001, CYTOKINE, V15, P138, DOI 10.1006/cyto.2001.0903; Gilks CB, 1998, AM J PATHOL, V152, P269; Goldman D, 1996, AM J PATHOL, V148, P1275; GONZALEZ PK, 1995, J PHARMACOL EXP THER, V275, P798; GONZALEZFLECHA B, 2000, ANN NY ACAD SCI, V899, P103; Goth L, 2001, BLOOD CELL MOL DIS, V27, P512, DOI 10.1006/bcmd.2001.0415; HALLIWELL B, 1994, LANCET, V344, P721, DOI 10.1016/S0140-6736(94)92211-X; HALLIWELL B, 1991, FEBS LETT, V281, P9, DOI 10.1016/0014-5793(91)80347-6; Halliwell B, 1991, AM J MED S3C, V91, P14, DOI DOI 10.1016/0002-9343(91)90279-7; Halliwell B, 1989, FREE RADICALS BIOL M; Harju T, 2004, EUR RESPIR J, V24, P765, DOI 10.1183/09031936.04.00121203; Harju T, 2002, AM J RESP CRIT CARE, V166, P754, DOI 10.1164/rccm.2112014; HARRIS CA, 1991, J IMMUNOL, V147, P149; Hartsfield C, 1999, AM J PHYSIOL-LUNG C, V277, pL1133; HEFFNER JE, 1989, AM REV RESPIR DIS, V140, P531; Ho YS, 1998, AM J RESP CELL MOL, V18, P538; HOLLAND JA, 1990, J CELL PHYSIOL, V143, P21, DOI 10.1002/jcp.1041430104; Horvath I., 2001, European Respiratory Journal, V18, P420, DOI 10.1183/09031936.01.00231201; Horvath I, 1998, THORAX, V53, P668; Hoshino T, 2003, AM J RESP CRIT CARE, V168, P1075, DOI 10.1164/rccm.200209-982OC; Ichiki H, 2005, BIOCHEM BIOPH RES CO, V334, P1141, DOI 10.1016/j.bbrc.2005.07.007; Ishii T, 2001, AM J PHYSIOL-LUNG C, V280, pL1189; Jackson RM, 1996, AM J PHYSIOL-LUNG C, V271, pL955; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; JORNOT L, 1992, AM J RESP CELL MOL, V6, P107; Kaminski N, 2000, P NATL ACAD SCI USA, V97, P1778, DOI 10.1073/pnas.97.4.1778; Keane MP, 2001, AM J PHYSIOL-LUNG C, V281, pL92; Kim HJ, 2003, CELL BIOL TOXICOL, V19, P285, DOI 10.1023/B:CBTO.0000004952.07979.3d; KIM KW, 1988, J BIOL CHEM, V263, P4704; KINNULA VL, 1995, LAB INVEST, V73, P3; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; KINNULA VL, 1992, EXP LUNG RES, V18, P655, DOI 10.3109/01902149209031700; KINNULA VL, 1992, AM J PHYSIOL, V262, pL69; KINNULA VL, 1994, AM J RESP CELL MOL, V11, P568; Kinnula VL, 2004, THORAX, V59, P116, DOI 10.1136/thorax.2003.005611; KRINSKY NI, 1982, J NATL CANCER I, V69, P205; LANNAN S, 1994, AM J PHYSIOL, V266, pL92; Larsen GL, 2000, AM J PHYSIOL-LUNG C, V279, pL350; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556; Lehtonen ST, 2004, INT J CANCER, V111, P514, DOI 10.1002/ijc.20294; LEHTONEN ST, 2005, AM J PHYSIOL-LUNG C, V288, pL97; Lenz AG, 1996, EUR RESPIR J, V9, P307, DOI 10.1183/09031936.96.09020307; Li XY, 1996, THORAX, V51, P465, DOI 10.1136/thx.51.5.465; LI XY, 1994, AM J RESP CRIT CARE, V149, P1518; LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376; Liao Mei-Fen, 2004, Acta Paediatrica Taiwanica, V45, P213; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912; Liochev SI, 2000, J BIOL CHEM, V275, P38482, DOI 10.1074/jbc.M007891200; Loenders B, 1998, FREE RADICAL BIO MED, V24, P1097, DOI 10.1016/S0891-5849(97)00434-6; MACNEE W, 1995, THORAX, V50, pS53, DOI 10.1136/thx.50.Suppl_1.S53; Maestrelli P, 2001, AM J RESP CRIT CARE, V164, P1508; MAESTRELLI P, 2003, EUR RESPIR J, V23, P652; MAIER K, 1991, AM REV RESPIR DIS, V143, P271; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MARKLUND SL, 1992, J BIOL CHEM, V267, P6696; Matthay M A, 1999, Chest, V116, p119S, DOI 10.1378/chest.116.suppl_1.119S; MBEMBA F, 1985, BIOCHIM BIOPHYS ACTA, V838, P211, DOI 10.1016/0304-4165(85)90081-9; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; McFadden SL, 2005, HEARING RES, V202, P200, DOI 10.1016/j.heares.2004.10.011; MEYER A, 1995, AM J RESP CRIT CARE, V152, P1055; Morrison D, 1999, AM J RESP CRIT CARE, V159, P473; MULLENBACH GT, 1988, PROTEIN ENG, V2, P239, DOI 10.1093/protein/2.3.239; Muller T, 1998, CARCINOGENESIS, V19, P797, DOI 10.1093/carcin/19.5.797; MULLER T, 1994, CARCINOGENESIS, V15, P67, DOI 10.1093/carcin/15.1.67; Mumby S, 2004, CRIT CARE MED, V32, P1130, DOI 10.1097/01.CCM.0000124869.86399.F2; Nakamura T, 2005, ANTIOXID REDOX SIGN, V7, P60, DOI 10.1089/ars.2005.7.60; NAKAYAMA T, 1989, FREE RADICAL BIO MED, V7, P9, DOI 10.1016/0891-5849(89)90094-4; NATH KA, 1992, J CLIN INVEST, V90, P267, DOI 10.1172/JCI115847; Nishikawa M, 1999, AM J RESP CELL MOL, V20, P189; Nishiyama A, 2001, IUBMB LIFE, V52, P29, DOI 10.1080/15216540252774739; OBERLEY TD, 1993, HISTOCHEM J, V25, P267, DOI 10.1007/BF00159118; OGATA M, 1991, HUM GENET, V86, P331; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595; Otterbein L E, 2000, Am J Physiol Lung Cell Mol Physiol, V279, pL1029; Otterbein LE, 2000, NAT MED, V6, P422; Otterbein LE, 1999, AM J PHYSIOL, V276, P688; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 2001, AM J RESP CELL MOL, V25, P164; Oury TD, 1996, FREE RADICAL BIO MED, V20, P957, DOI 10.1016/0891-5849(95)02222-8; Park EM, 1998, FREE RADICAL BIO MED, V25, P79, DOI 10.1016/S0891-5849(98)00041-0; Pellacani A, 1998, CIRC RES, V83, P396; Peltoniemi M, 2004, HUM PATHOL, V35, P1000, DOI 10.1016/j.humpath.2004.04.009; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286; Poli G, 1997, FREE RADICAL BIO MED, V22, P287, DOI 10.1016/S0891-5849(96)00327-9; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; QUINLAN TR, 1994, AM J RESP CRIT CARE, V150, P200; Rahman I, 1999, FREE RADICAL BIO MED, V27, P60, DOI 10.1016/S0891-5849(99)00035-0; Rahman I, 2000, FREE RADICAL BIO MED, V28, P920, DOI 10.1016/S0891-5849(00)00179-9; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067; Rahman I, 1998, THORAX, V53, P601; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285; Rahman Irfan, 2005, Treat Respir Med, V4, P175, DOI 10.2165/00151829-200504030-00003; RANCOURT RC, 2003, AM J PHYSIOL-LUNG C, V286, pL931, DOI 10.1152/ajplung.00352.2003; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Rhee SG, 1999, BIOFACTORS, V10, P207; ROCK CL, 1993, ANN NY ACAD SCI, V691, P274, DOI 10.1111/j.1749-6632.1993.tb26193.x; Roum JH, 2001, J APPL PHYSIOL, V91, P748; Sakurai A, 2004, J CELL PHYSIOL, V198, P22, DOI 10.1002/jcp.10377; SALCH D, 1997, AM J RESP CRIT CARE, V155, P1763; Sato E, 1999, AM J PHYSIOL-LUNG C, V277, pL1149; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; SHULL S, 1991, J BIOL CHEM, V266, P24398; SIMON RH, 1989, AM J RESP CELL MOL, V1, P221; SJOSTROM K, 1983, LAB INVEST, V48, P68; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STRAUSZ J, 1990, AM REV RESPIR DIS, V141, P124; SU WY, 1997, AM J RESP CRIT CARE; Suliman HB, 2001, AM J PHYSIOL-LUNG C, V280, pL69; SUN Y, 1990, FREE RADICAL BIO MED, V8, P583, DOI 10.1016/0891-5849(90)90156-D; Svensk AM, 2004, AM J CLIN PATHOL, V122, P395, DOI 10.1309/A45QHB0QRRX6CT9A; Tamagawa K, 2000, AM J RESP CRIT CARE, V161, P1279; Taylor JL, 1998, AM J PHYSIOL-LUNG C, V274, pL582; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Terry CM, 1998, AM J PHYSIOL, V274, P883; Tiitto L, 2003, J PATHOL, V201, P363, DOI 10.1002/path.1435; Tsan MF, 1998, AM J RESP CELL MOL, V19, P114; TSAN MF, 1993, P SOC EXP BIOL MED, V203, P286; TSAN MF, 1990, J APPL PHYSIOL, V68, P1211; Tsan MF, 2001, INT J MOL MED, V7, P13; Tsoumakidou M, 2005, CHEST, V127, P1911, DOI 10.1378/chest.127.6.1911; TSUJI M, 1995, AM J PATHOL, V147, P1001; URSINI F, 1985, BIOCHIM BIOPHYS ACTA, V839, P62, DOI 10.1016/0304-4165(85)90182-5; Varshavsky BY, 2003, TERAPEVT ARKH, V75, P21; Vayssier M, 1998, AM J PHYSIOL-LUNG C, V275, pL771; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WALLAERT B, 1990, AM REV RESPIR DIS, V141, P129; Wang XS, 2003, J BIOL CHEM, V278, P25179, DOI 10.1074/jbc.M302706200; WARNER GA, 1991, AM J PHYSIOL, V260, P296; Watson WH, 2004, TOXICOL SCI, V78, P3, DOI 10.1093/toxsci/kfh050; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; WHITE CW, 1993, FREE RADICAL BIO MED, V15, P629, DOI 10.1016/0891-5849(93)90166-R; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WHITE CW, 1989, J APPL PHYSIOL, V66, P584; WHITE CW, 1989, J APPL PHYSIOL, V66, P1003; Willis D, 1996, NAT MED, V2, P87, DOI 10.1038/nm0196-87; WISPE JR, 1992, J BIOL CHEM, V267, P23937; WONG GHW, 1988, SCIENCE, V242, P941, DOI 10.1126/science.3263703; WONG HR, 1997, AM J PHYSIOL, V273, P1; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yamada Y, 2003, IMMUNOL LETT, V86, P199, DOI 10.1016/S0165-2478(03)00006-3; Yamaya M, 1998, AM J RESP CRIT CARE, V158, P311; Zhou HL, 2004, AM J RESP CRIT CARE, V170, P633, DOI 10.1164/rccm.200311-1607OC	220	373	401	4	29	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 8	2006	533	1-3					222	239		10.1016/j.ejphar.2005.12.087		18	Pharmacology & Pharmacy	Pharmacology & Pharmacy	025KS	WOS:000236265400022	16500642	
J	Wilson, MS; Taylor, MD; Balic, A; Finney, CAM; Lamb, JR; Maizels, RM				Wilson, MS; Taylor, MD; Balic, A; Finney, CAM; Lamb, JR; Maizels, RM			Suppression of allergic airway inflammation by helminth-induced regulatory T cells	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							HOUSE-DUST MITE; GROWTH-FACTOR-BETA; TOTAL SERUM IGE; IMMUNE-RESPONSES; HELIGMOSOMOIDES-POLYGYRUS; HYGIENE HYPOTHESIS; CUTTING EDGE; CHILDHOOD ASTHMA; INFECTION; DISEASE	Allergic diseases mediated by T helper type ( Th) 2 cell immune responses are rising dramatically in most developed countries. Exaggerated Th2 cell reactivity could result, for example, from diminished exposure to Th1 cell - inducing microbial infections. Epidemiological studies, however, indicate that Th2 cell - stimulating helminth parasites may also counteract allergies, possibly by generating regulatory T cells which suppress both Th1 and Th2 arms of immunity. We therefore tested the ability of the Th2 cell - inducing gastrointestinal nematode Heligmosomoides polygyrus to influence experimentally induced airway allergy to ovalbumin and the house dust mite allergen Der p 1. Inflammatory cell infiltrates in the lung were suppressed in infected mice compared with uninfected controls. Suppression was reversed in mice treated with antibodies to CD25. Most notably, suppression was transferable with mesenteric lymph node cells ( MLNC) from infected animals to uninfected sensitized mice, demonstrating that the effector phase was targeted. MLNC from infected animals contained elevated numbers of CD4(+)CD25(+)Foxp3(+) T cells, higher TGF-beta expression, and produced strong interleukin ( IL)-10 responses to parasite antigen. However, MLNC from IL-10-deficient animals transferred suppression to sensitized hosts, indicating that IL-10 is not the primary modulator of the allergic response. Suppression was associated with CD4(+) T cells from MLNC, with the CD4(+)CD25(+) marker defining the most active population. These data support the contention that helminth infections elicit a regulatory T cell population able to down-regulate allergen induced lung pathology in vivo.	Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland; Univ Edinburgh, Ctr Inflammat Res, Edinburgh EH9 3JT, Midlothian, Scotland	Maizels, RM (reprint author), Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland.	rick.maizels@ed.ac.uk	Taylor, Matthew/C-7973-2011; Balic, Adam/C-7718-2013		Wellcome Trust		Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Araujo MIAS, 2004, J INFECT DIS, V190, P1797, DOI 10.1086/425017; Bashir MEH, 2002, J IMMUNOL, V169, P3284; Belkaid Y, 2005, NAT IMMUNOL, V6, P353, DOI 10.1038/ni1181; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Elliott DE, 2004, EUR J IMMUNOL, V34, P2690, DOI 10.1002/eji.200324833; Fantini MC, 2004, J IMMUNOL, V172, P5149; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; FINKELMAN FD, ANN REV IMMUNOL; Fox JG, 2000, NAT MED, V6, P536, DOI 10.1038/75015; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Geha RS, 2003, CURR OPIN IMMUNOL, V15, P603, DOI 10.1016/j.coi.2003.09.017; Gomez-Escobar N, 2000, INFECT IMMUN, V68, P6402, DOI 10.1128/IAI.68.11.6402-6410.2000; Hadeiba H, 2003, J IMMUNOL, V170, P5502; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hoerauf A, 2002, TRENDS PARASITOL, V18, P25, DOI 10.1016/S1471-4922(01)02173-0; Hoffmann KF, 2002, ADV PARASIT, V52, P265, DOI 10.1016/S0065-308X(02)52014-5; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JARRETT E, 1974, NATURE, V251, P613, DOI 10.1038/251613a0; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; KARIM M, IN PRESS BLOOD; Kohm AP, 2002, J IMMUNOL, V169, P4712; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1999, THORAX, V54, P659; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; MARTINEZ FD, 1999, LANCET S2, V354; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; McHugh RS, 2002, J IMMUNOL, V168, P5979; McKee AS, 2004, J IMMUNOL, V173, P1224; MONROY FG, 1992, PARASITOL TODAY, V8, P49, DOI 10.1016/0169-4758(92)90084-F; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Paul Ellen Frankel, 1990, YALE L POLY REV, V8, P333; Rook Graham A W, 2002, Biologist (London), V49, P145; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Taylor MD, 2005, J IMMUNOL, V174, P4924; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; URBAN JF, 1991, P NATL ACAD SCI USA, V88, P5513, DOI 10.1073/pnas.88.13.5513; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Vieira PL, 2004, J IMMUNOL, V172, P5986; WAHID FN, 1994, PARASITOLOGY, V108, P461; Wang CC, 2001, CLIN EXP ALLERGY, V31, P495, DOI 10.1046/j.1365-2222.2001.01044.x; Weiner HL, 2001, NAT IMMUNOL, V2, P671, DOI 10.1038/90604; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wilson MS, 2004, CLIN REV ALLERG IMMU, V26, P35, DOI 10.1385/CRIAI:26:1:35; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Yang X, 2002, IMMUNOLOGY, V105, P336, DOI 10.1046/j.0019-2805.2002.01377.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Zheng SG, 2004, J IMMUNOL, V172, P1531; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	73	372	394	6	43	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	NOV 7	2005	202	9					1199	1212		10.1084/jem.20042572		14	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	981UB	WOS:000233112400007	16275759	
J	Olson, TS; Ley, K				Olson, TS; Ley, K			Chemokines and chemokine receptors in leukocyte trafficking	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Review						homing; chemoattractants; T cell; B cell; monocyte; neutrophil	MONOCYTE CHEMOATTRACTANT PROTEIN-1; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MACROPHAGE-DERIVED CHEMOKINE; CENTRAL-NERVOUS-SYSTEM; SMOOTH-MUSCLE CELLS; C-C CHEMOKINE; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; SIGNAL-TRANSDUCTION PATHWAYS; HUMAN NEUTROPHIL LEUKOCYTES; MESSENGER-RNA ACCUMULATION	Chemokines regulate inflammation, leukocyte trafficking, and immune cell differentiation. The role of chemokines in homing of naive T lymphocytes to secondary lymphatic organs is probably the best understood of these processes, and information on chemokines in inflammation, asthma, and neurological diseases is rapidly increasing. Over the past 15 years, understanding of the size and functional complexity of the chemokine family of peptide chemoattractants has grown substantially. In this review, we first present information regarding the structure, expression, and signaling properties of chemokines and their receptors. The second part is a systems physiology-based overview of the roles that chemokines play in tissue-specific homing of lymphocyte subsets and in trafficking of inflammatory cells. This review draws on recent experimental findings as well as current models proposed by experts in the chemokine field.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA	Ley, K (reprint author), Hlth Sci Ctr, Box 800759, Charlottesville, VA 22908 USA.						Adema GJ, 1997, NATURE, V387, P713, DOI 10.1038/42716; Afford SC, 1998, J PATHOL, V186, P82, DOI 10.1002/(SICI)1096-9896(199809)186:1<82::AID-PATH151>3.0.CO;2-D; Agace WW, 2000, CURR OPIN CELL BIOL, V12, P563, DOI 10.1016/S0955-0674(00)00132-0; Ali H, 1999, J BIOL CHEM, V274, P6027, DOI 10.1074/jbc.274.10.6027; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691; Ansel KM, 2000, NATURE, V406, P309; Arimilli S, 2000, IMMUNOL REV, V177, P43, DOI 10.1034/j.1600-065X.2000.17716.x; Asano T, 2000, CLIN EXP IMMUNOL, V122, P514, DOI 10.1046/j.1365-2249.2000.01395.x; BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; BAGGIOLINI M, 1994, IMMUNOL TODAY, V15, P127, DOI 10.1016/0167-5699(94)90156-2; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BALASINGAM V, 1994, J NEUROSCI, V14, P846; Balding CEJ, 2001, CLIN EXP IMMUNOL, V125, P332, DOI 10.1046/j.1365-2249.2001.125002332.x; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Biddison WE, 1997, J IMMUNOL, V158, P3046; Bleul CC, 1998, J EXP MED, V187, P753, DOI 10.1084/jem.187.5.753; Bochner BS, 1999, J ALLERGY CLIN IMMUN, V103, P527, DOI 10.1016/S0091-6749(99)70481-1; BOKOCH GM, 1995, BLOOD, V86, P1649; Bone-Larson CL, 2000, IMMUNOL REV, V177, P8, DOI 10.1034/j.1600-065X.2000.17703.x; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Bonecchi R, 1998, BLOOD, V92, P2668; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Brandtzaeg P, 1999, IMMUNOL TODAY, V20, P267, DOI 10.1016/S0167-5699(99)01468-1; Breitfeld D, 2000, J EXP MED, V192, P1545, DOI 10.1084/jem.192.11.1545; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell EM, 1999, J IMMUNOL, V163, P2160; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; CHAUDHURI A, 1994, J BIOL CHEM, V269, P7835; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; Colletti LM, 1998, SHOCK, V10, P248, DOI 10.1097/00024382-199810000-00004; Conti P, 1997, BLOOD, V89, P4120; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; Coulomb-L'Hermine A, 2001, HUM PATHOL, V32, P320, DOI 10.1053/hupa.2001.22757; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; Deng XY, 1999, BLOOD, V94, P1165; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133; Downey GP, 1999, CHEST, V116, p46S, DOI 10.1378/chest.116.suppl_1.46S-a; Dwinell MB, 2001, GASTROENTEROLOGY, V120, P49, DOI 10.1053/gast.2001.20914; Ellingsen T, 2000, ANN RHEUM DIS, V59, P775, DOI 10.1136/ard.59.10.775; FENG LL, 1995, J CLIN INVEST, V95, P1009, DOI 10.1172/JCI117745; Feng LL, 1999, KIDNEY INT, V56, P612, DOI 10.1046/j.1523-1755.1999.00604.x; Fisher NC, 1999, GUT, V45, P416; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; FORSTER R, 1994, BLOOD, V84, P830; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Foxman EF, 1999, J CELL BIOL, V147, P577, DOI 10.1083/jcb.147.3.577; Gao W, 2001, TRANSPLANTATION, V72, P1199, DOI 10.1097/00007890-200110150-00003; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Gerszten RE, 1999, NATURE, V398, P718; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Glabinski AR, 1995, BRAIN BEHAV IMMUN, V9, P315, DOI 10.1006/brbi.1995.1030; Glabinski AR, 1999, J NEUROVIROL, V5, P623, DOI 10.3109/13550289909021291; Glabinski AR, 1997, AM J PATHOL, V150, P617; Goddard S, 2001, TRANSPLANTATION, V72, P1957, DOI 10.1097/00007890-200112270-00016; GODISKA R, 1995, J NEUROIMMUNOL, V58, P167, DOI 10.1016/0165-5728(95)00008-P; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gonzalo JA, 2000, J IMMUNOL, V165, P499; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, NATURE, V391, P799; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; HAMANN A, 1994, J IMMUNOL, V152, P3282; Hancock WW, 2000, J EXP MED, V192, P1515, DOI 10.1084/jem.192.10.1515; Harrison JK, 1998, P NATL ACAD SCI USA, V95, P10896, DOI 10.1073/pnas.95.18.10896; Hogaboam CM, 2000, AM J PATHOL, V156, P1245, DOI 10.1016/S0002-9440(10)64995-4; Hogaboam CM, 1999, FASEB J, V13, P1565; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; Homey B, 2000, J IMMUNOL, V164, P3465; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Hub E, 1998, AM J PATHOL, V152, P749; Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI12877; Imai T, 1998, J BIOL CHEM, V273, P1764, DOI 10.1074/jbc.273.3.1764; Imai T, 1997, CELL, V91, P521, DOI 10.1016/S0092-8674(00)80438-9; Jia GQ, 1996, J EXP MED, V184, P1939, DOI 10.1084/jem.184.5.1939; Jinquan T, 1999, J Immunol, V162, P4285; Johnston B, 1999, J CLIN INVEST, V103, P1269, DOI 10.1172/JCI5208; Jones SA, 1996, P NATL ACAD SCI USA, V93, P6682, DOI 10.1073/pnas.93.13.6682; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Karpus WJ, 1998, J IMMUNOL, V161, P2667; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; Kim CH, 1999, J LEUKOCYTE BIOL, V65, P6; Kim CH, 2001, J CLIN INVEST, V107, P595, DOI 10.1172/JCI11902; Kim CH, 1998, BLOOD, V91, P4434; Kim CH, 1999, CELL IMMUNOL, V193, P226, DOI 10.1006/cimm.1999.1483; Kim Y, 2001, J IMMUNOL, V166, P5183; Kunkel EJ, 2000, J IMMUNOL, V164, P3301; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394; Laudanna C, 1996, SCIENCE, V271, P981, DOI 10.1126/science.271.5251.981; Le YY, 2000, IMMUNOL REV, V177, P185, DOI 10.1034/j.1600-065X.2000.17704.x; Legler DF, 1998, J EXP MED, V187, P655, DOI 10.1084/jem.187.4.655; Ley K, 2001, IMMUNOL RES, V24, P87, DOI 10.1385/IR:24:1:87; LHEUREUX GP, 1995, BLOOD, V85, P522; Lloyd Clare M., 1997, Journal of Experimental Medicine, V185, P1371, DOI 10.1084/jem.185.7.1371; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; Loetscher P, 2000, Adv Immunol, V74, P127; Loetscher P, 1996, J EXP MED, V184, P569, DOI 10.1084/jem.184.2.569; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lomize AL, 1999, J COMPUT AID MOL DES, V13, P325, DOI 10.1023/A:1008050821744; Lukacs NW, 1998, J LEUKOCYTE BIOL, V63, P746; Lukacs NW, 2000, IMMUNOL REV, V177, P21, DOI 10.1034/j.1600-065X.2000.17707.x; Lukacs NW, 1997, J IMMUNOL, V158, P4398; Luster AD, 2001, GASTROENTEROLOGY, V120, P291, DOI 10.1053/gast.2001.21403; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; Mackay CR, 2000, J EXP MED, V192, pF31, DOI 10.1084/jem.192.11.F31; Marquez G, 2001, J CLIN INVEST, V107, P791, DOI 10.1172/JCI12608; Marra F, 1998, AM J PATHOL, V152, P423; Matloubian M, 2000, NAT IMMUNOL, V1, P298, DOI 10.1038/79738; McTigue DM, 1998, J NEUROSCI RES, V53, P368, DOI 10.1002/(SICI)1097-4547(19980801)53:3<368::AID-JNR11>3.0.CO;2-1; Melter M, 2001, CIRCULATION, V104, P2558, DOI 10.1161/hc4601.098010; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Morgan SJ, 1997, MICROVASC RES, V54, P188, DOI 10.1006/mvre.1997.2029; Murphy Philip M., 1996, Methods (Orlando), V10, P104, DOI 10.1006/meth.1996.0084; Murphy PM, 2000, PHARMACOL REV, V52, P145; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nanji AA, 2001, AM J PHYSIOL-GASTR L, V281, pG1348; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; Nelson PJ, 2001, TRANSPLANTATION, V72, P1195; Nilsson G, 1999, BLOOD, V93, P2791; Nishiyori A, 1998, FEBS LETT, V429, P167, DOI 10.1016/S0014-5793(98)00583-3; Noris M, 1999, CIRCULATION, V100, P55; Pachynski RK, 1998, J IMMUNOL, V161, P952; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Patterson BK, 1999, CLIN IMMUNOL, V91, P254, DOI 10.1006/clim.1999.4713; Pattison JM, 1996, J HEART LUNG TRANSPL, V15, P1194; Pennington HL, 1998, ALCOHOL CLIN EXP RES, V22, P1713; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PlaterZyberk C, 1997, IMMUNOL LETT, V57, P117, DOI 10.1016/S0165-2478(97)00075-8; Porreca E, 1997, J VASC RES, V34, P58; Proudfoot AEI, 2000, IMMUNOL REV, V177, P246, DOI 10.1034/j.1600-065X.2000.17721.x; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Ralston DR, 1997, J CLIN INVEST, V100, P1416, DOI 10.1172/JCI119662; RANSOHOFF RM, 1993, FASEB J, V7, P592; RICHARDSON RM, 1995, BIOCHEMISTRY-US, V34, P14193, DOI 10.1021/bi00043a025; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Rossi DL, 1999, J IMMUNOL, V162, P5490; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rubbert A, 1998, J IMMUNOL, V160, P3933; Sallusto F, 1999, EUR J IMMUNOL, V29, P2037, DOI 10.1002/(SICI)1521-4141(199906)29:06<2037::AID-IMMU2037>3.0.CO;2-V; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 2000, IMMUNOL REV, V177, P134, DOI 10.1034/j.1600-065X.2000.17717.x; Sallusto F, 1999, J EXP MED, V189, P611, DOI 10.1084/jem.189.4.611; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Santamaria Babi L F, 1995, J Exp Med, V181, P1935, DOI 10.1084/jem.181.5.1935; Schaerli P, 2000, J EXP MED, V192, P1553, DOI 10.1084/jem.192.11.1553; Schroder JM, 1996, J LEUKOCYTE BIOL, V59, P1; Schwaeble WJ, 1998, FEBS LETT, V439, P203, DOI 10.1016/S0014-5793(98)01384-2; SEKIDO N, 1993, NATURE, V365, P654, DOI 10.1038/365654a0; Shibahara T, 2001, GASTROENTEROLOGY, V120, P60, DOI 10.1053/gast.2001.20904; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; SOZZANI S, 1995, J IMMUNOL, V155, P3292; Syrbe U, 1999, SPRINGER SEMIN IMMUN, V21, P263, DOI 10.1007/BF00812257; Tamaru M, 2000, CYTOKINE, V12, P299, DOI 10.1006/cyto.1999.0560; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Tani M, 1996, AM J PATHOL, V148, P889; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Thelen M, 1995, BIOCHEM BIOPH RES CO, V217, P1255, DOI 10.1006/bbrc.1995.2903; Tilton B, 1997, J BIOL CHEM, V272, P28096, DOI 10.1074/jbc.272.44.28096; TURNER L, 1995, J IMMUNOL, V155, P2437; Uguccioni M, 1999, AM J PATHOL, V155, P331, DOI 10.1016/S0002-9440(10)65128-0; Unutmaz D, 2000, J IMMUNOL, V165, P3284; Vicari AP, 1997, IMMUNITY, V7, P291, DOI 10.1016/S1074-7613(00)80531-2; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020; von Hundelshausen P, 2001, CIRCULATION, V103, P1772; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; Wang JM, 1998, INT J CLIN LAB RES, V28, P83, DOI 10.1007/s005990050024; Wang XK, 1996, J BIOL CHEM, V271, P24286; Wells TNC, 1999, INFLAMM RES, V48, P353, DOI 10.1007/s000110050472; Wojcik WJ, 1996, J PHARMACOL EXP THER, V278, P404; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; XIU Q, 1995, CLIN EXP ALLERGY, V25, P51, DOI 10.1111/j.1365-2222.1995.tb01002.x; Yamaguchi Y, 1999, TRANSPLANTATION, V68, P1459, DOI 10.1097/00007890-199911270-00005; Yamaguchi Y, 1998, HEPATOLOGY, V27, P727, DOI 10.1002/hep.510270314; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x; YING S, 1995, J EXP MED, V181, P2153, DOI 10.1084/jem.181.6.2153; Yoshida R, 1998, J BIOL CHEM, V273, P7118, DOI 10.1074/jbc.273.12.7118; Yoshida R, 1997, J BIOL CHEM, V272, P13803, DOI 10.1074/jbc.272.21.13803; Yoshie O, 1997, J LEUKOCYTE BIOL, V62, P634; YOSHIMURA T, 1987, P NATL ACAD SCI USA, V84, P9233, DOI 10.1073/pnas.84.24.9233; YUE TL, 1994, CIRC RES, V75, P1; Zingoni A, 1998, J IMMUNOL, V161, P547; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	203	369	384	0	12	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119			AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	JUL	2002	283	1					R7	R28		10.1152/ajpregu.00738.2001		22	Physiology	Physiology	563LQ	WOS:000176257500002	12069927	
J	Higa, KD; Boone, KB; Ho, TC				Higa, KD; Boone, KB; Ho, TC			Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients - What have we learned?	OBESITY SURGERY			English	Article; Proceedings Paper	5th Congress of the International-Federation-for-the-Surgery-of-Obesity	SEP   22, 2000	GENOA, ITALY	Int Federat Surg Obes		morbid obesity; bariatric surgery; laparoscopy; gastric bypass	PROSPECTIVE TRIAL; FOLLOW-UP	Background: The Roux-en-Y gastric bypass (RYGBP) is one of the most common operations for morbid obesity. Laparoscopic techniques have been reported, but suffer from small numbers of patients, longer operative times and seemingly higher initial complication rates as compared to the traditional "open" procedure. The minimally invasive approach continues to be a challenge even to the most experienced laparoscopic surgeons. The purpose of this study is to describe our experience and complications of the laparoscopic Roux-en-Y gastric bypass with a totally hand-sewn gastrojejunostomy, Methods: 1,040 consecutive laparoscopic procedures were evaluated prospectively. Only patients who had a previous open gastric procedure were excluded initially, Eventually, even patients with failed "open" bariatric procedures and other gastric procedures were revised laparoscopically to the RYGBP. All patients met NIH criteria for consideration for weight reductive surgery. Results: There were no anastomotic leaks from the hand-sewn gastrojejunostomy. Early complications and open conversions were related to sub-optimal exposure and bowel fixation techniques. Several staple failures were attributed to a manufacturer redesign of an instrument, Average hospital stay was 1.9 days for all patients and 1.5 days for patients without complications, Operative times consistently approach 60 minutes. Average excess weight loss was 70% at 12 months. There were 5 deaths: perioperative pulmonary embolism (1), late pulmonary embolism (2), asthma (1), and suicide (1), Conclusions: The laparoscopic Roux-en-Y gastric bypass for morbid obesity with a totally hand-sewn gastrojejunostomy can be safely performed by the bariatric surgeon with advanced laparoscopic skills in the community setting, Fixation and closure of all potential hernia sites with non-absorbable sutures is essential. Stenosis of the hand-sewn gastrojejunal anastomosis is amenable to endoscopic balloon dilation. Meticulous attention must be paid to the operative and perioperative care of the patient.	Bariatr Surg Ctr, Fresno, CA USA	Higa, KD (reprint author), 7202 N Millbrook Ave,Suite 105, Fresno, CA 93720 USA.						Catona A, 2000, OBES SURG, V10, P15, DOI 10.1381/09608920060674049; de la Torre RA, 1999, OBES SURG, V9, P492, DOI 10.1381/096089299765552800; Doherty C, 1998, J Gastrointest Surg, V2, P102, DOI 10.1016/S1091-255X(98)80110-8; GRUNDY SM, 1991, ANN INTERN MED, V115, P956; Higa KD, 2000, ARCH SURG-CHICAGO, V135, P1029, DOI 10.1001/archsurg.135.9.1029; Miller K, 1999, OBES SURG, V9, P183, DOI 10.1381/096089299765553467; Schauer PR, 1999, J LAPAROENDOSC ADV A, V9, P101, DOI 10.1089/lap.1999.9.101; Serra C, 1999, OBES SURG, V9, P546, DOI 10.1381/096089299765552648; SUGERMAN HJ, 1987, ANN SURG, V205, P613, DOI 10.1097/00000658-198706000-00002; SUGERMAN HJ, 1995, AM J SURG, V169, P91, DOI 10.1016/S0002-9610(99)80115-9; Wittgrove AC, 2000, OBES SURG, V10, P233, DOI 10.1381/096089200321643511	11	366	379	0	9	F D-COMMUNICATIONS INC	TORONTO	3100 BAYVIEW AVE, UNIT 4, TORONTO, ONTARIO MZN 5L3, CANADA	0960-8923			OBES SURG	Obes. Surg.	DEC	2000	10	6					509	513		10.1381/096089200321593706		5	Surgery	Surgery	388DQ	WOS:000166162500005	11175957	
J	Ownby, DR; Johnson, CC; Peterson, EL				Ownby, DR; Johnson, CC; Peterson, EL			Exposure to dogs and cats in the first year of life and risk of allergic sensitization at 6 to 7 years of age	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORD-BLOOD-IGE; HOUSE-DUST ENDOTOXIN; ASTHMATIC-CHILDREN; SERUM IGE; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; AUSTRALIAN SCHOOLCHILDREN; ATOPIC SENSITIZATION; PARENTAL HISTORY; MATERNAL SMOKING	Context Childhood asthma is strongly associated with allergic sensitization. Studies have suggested that animal exposure during infancy reduces subsequent allergic sensitization. Objective To evaluate the relationship between dog and cat exposure in the first year of life and allergic sensitization at 6 to 7 years of age. Design, Setting, and Subjects Prospective birth cohort study of healthy, fullterm infants enrolled in a health maintenance organization in suburban Detroit, Mich, who were born between April 15,1987, and August 31,1989, and followed up yearly to a mean age of 6.7 years. Of 835 children initially in the study at birth, 474 (57%) completed follow-up evaluations at age 6 to 7 years. Main Outcome Measures Atopy, defined as any skin prick test positivity to 6 common aeroallergens (dust mites [Dermatophagoides farinae, D pteronyssinus], dog, cat, short ragweed [Ambrosia artemisiifolia], and blue grass [Poa pratensis]); seroatopy, defined as any positive allergen-specific IgE test result for the same 6 allergens or for Alternaria species. Results The prevalence of any skin prick test positivity (atopy) at age 6 to 7 years was 33.6% with no dog or cat exposure in the first year of life, 34.3% with exposure to 1 dog or cat, and 15.4% with exposure to 2 or more dogs or cats (P = .005). The prevalence of any positive allergen-specific IgE test result (seroatopy) was 38.5% with no dog or cat exposure, 41.2% with exposure to 1 dog or cat, and 17.9% with exposure to 2 or more dogs or cats (P = .003). After adjustment for cord serum IgE concentration, sex, older siblings, parental smoking, parental asthma, bedroom dust mite allergen levels at 2 years, and current dog and cat ownership, exposure to 2 or more dogs or cats in the first year of life was associated with a significantly lower risk of atopy (adjusted odds ratio, 0.23; 95% confidence interval, 0.09-0.60) and seroatopy (adjusted odds ratio, 0.33; 95% confidence interval, 0.13-0.83). Conclusion Exposure to 2 or more dogs or cats in the first year of life may reduce subsequent risk of allergic sensitization to multiple allergens during childhood.	Med Coll Georgia, Dept Pediat, Sect Allergy & Immunol, Augusta, GA 30912 USA; Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI USA; Wayne State Univ, Natl Inst Environm Hlth Sci Ctr Mol & Cellular To, Detroit, MI USA	Ownby, DR (reprint author), Med Coll Georgia, Dept Pediat, Sect Allergy & Immunol, BG-1019, Augusta, GA 30912 USA.			Johnson, Christine Cole/0000-0002-6864-6604	NIAID NIH HHS [AI 24156]; NIEHS NIH HHS [P03ES06639]		Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; AVITAL A, 1991, AM REV RESPIR DIS, V144, P36; BACKER V, 1992, ALLERGY, V47, P484, DOI 10.1111/j.1398-9995.1992.tb00669.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; BRABACK L, 1995, ARCH DIS CHILD, V72, P487; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Cohen J., 1977, STAT POWER ANAL BEHA; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Everitt B. S., 1977, ANAL CONTINGENCY TAB; GALDESSEBALDT M, 1985, J PEDIATR-US, V107, P526, DOI 10.1016/S0022-3476(85)80009-3; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; Hosmer DW, 1989, APPL LOGISTIC REGRES; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; Johnson CC, 1996, CLIN EXP ALLERGY, V26, P624, DOI 10.1111/j.1365-2222.1996.tb00588.x; Joseph CLM, 2000, CHEST, V117, P1336, DOI 10.1378/chest.117.5.1336; KJELLMAN NIM, 1984, ANN ALLERGY, V53, P167; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Neter J, 1990, APPL STAT MODELS REG; Osborne ML, 1998, AM J RESP CRIT CARE, V157, P123; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; Ownby DR, 2000, AM J RESP CRIT CARE, V161, P1578; Ownby DR, 1996, PEDIATR ALLERGY IMMU, V7, P125, DOI 10.1111/j.1399-3038.1996.tb00119.x; Ownby DR, 1996, ANN ALLERG ASTHMA IM, V77, P304; Ownby DR, 2000, ARCH PEDIAT ADOL MED, V154, P1237; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; PEAT JK, 1989, CLIN EXP ALLERGY, V19, P299, DOI 10.1111/j.1365-2222.1989.tb02387.x; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; Peterson EL, 1999, J ALLERGY CLIN IMMUN, V104, P348, DOI 10.1016/S0091-6749(99)70378-7; Peterson EL, 1997, J CLIN EPIDEMIOL, V50, P917, DOI 10.1016/S0895-4356(97)00095-4; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; POPP W, 1990, ALLERGY, V45, P75, DOI 10.1111/j.1398-9995.1990.tb01087.x; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SAS Institute Inc, 1999, SAS STAT US GUID; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Steerenberg PA, 1999, CLIN EXP ALLERGY, V29, P1304, DOI 10.1046/j.1365-2222.1999.00658.x; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; TAKEDA K, 1993, CLIN EXP ALLERGY, V23, P450, DOI 10.1111/j.1365-2222.1993.tb00353.x; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352; WRIGHT AL, 1994, PEDIATRICS, V94, P895; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	60	363	375	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 28	2002	288	8					963	972		10.1001/jama.288.8.963		10	Medicine, General & Internal	General & Internal Medicine	587RM	WOS:000177656400021	12190366	
J	Bornehag, CG; Sundell, J; Weschler, CJ; Sigsgaard, T; Lundgren, B; Hasselgren, M; Hagerhed-Engman, L				Bornehag, CG; Sundell, J; Weschler, CJ; Sigsgaard, T; Lundgren, B; Hasselgren, M; Hagerhed-Engman, L			The association between asthma and allergic symptoms in children and phthalates in house dust: A nested case-control study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; BBzP; children; DEHP; homes; phthalates	SUBCUTANEOUS INJECTION MODEL; EXPERT PANEL REPORT; NONINDUSTRIAL INDOOR ENVIRONMENTS; AIRBORNE PARTICULATE MATTER; HUMAN REFERENCE POPULATION; DI-N-BUTYL; DEVELOPMENTAL TOXICITY; HUMAN-REPRODUCTION; NTP CENTER; DI(2-ETHYLHEXYL) PHTHALATE	Global phthalate ester production has increased from very low levels at the end of World War II to approximately 3.5 million metric tons/year. The aim of the present study was to investigate potential associations between persistent allergic symptoms in children, which have increased markedly in developed countries over the past three decades, and the concentration of phthalates in dust collected from their homes. This investigation is a case-control study nested within a cohort of 10,852 children. From the cohort, we selected 198 cases with persistent allergic symptoms and 202 controls without allergic symptoms. A clinical and a technical team investigated each child and her or his environment. We found higher median concentrations of butyl benzyl phthalate (BBzP) in dust among cases than among controls (0.15 vs. 0.12 mg/g dust). Analyzing the case group by symptoms showed that BBzP was associated with rhinitis (p = 0.001) and eczema (p = 0.001), whereas di(2-ethylhexyl) phthalate (DEHP) was associated with asthma (p = 0.022). Furthermore, dose-response relationships for these associations are supported by trend analyses. This study, shows that phthalates, within the range of what is normally found in indoor environments, are associated with allergic symptoms in children. We believe that the different associations of symptoms for the three major phthalates-BBzP, DEHP, and di-n-butyl phthalate-can be explained by a combination of chemical physical properties and toxicologic potential. Given the phthalate exposures of children worldwide, the results from this study of Swedish children have global implications.	Karlstad Univ, S-65188 Karlstad, Sweden; Swedish Natl Testing & Res Inst, Boras, Sweden; Tech Univ Denmark, DK-2800 Lyngby, Denmark; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; Rutgers State Univ, Piscataway, NJ USA; Aarhus Univ, Aarhus, Denmark	Bornehag, CG (reprint author), Karlstad Univ, S-65188 Karlstad, Sweden.	carl-gustaf.bornehag@kau.se	Sundell, Jan/B-2857-2012; Weschler, Charles/A-9788-2009	Weschler, Charles/0000-0002-9097-5850; Sigsgaard, Torben/0000-0002-2043-7571			Adibi JJ, 2003, ENVIRON HEALTH PERSP, V111, P1719, DOI 10.1289/ehp.6235; Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; ATLAS E, 1981, SCIENCE, V211, P163, DOI 10.1126/science.211.4478.163; Barr DB, 2003, ENVIRON HEALTH PERSP, V111, P1148, DOI 10.1289/ehp.6074; Beasley R, 2003, PEDIATR CLIN N AM, V50, P539, DOI 10.1016/S0031-3955(03)00050-6; Blount BC, 2000, ENVIRON HEALTH PERSP, V108, P979, DOI 10.1289/ehp.00108979; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2003, ALLERGY, V58, P939, DOI 10.1034/j.1398-9995.2003.00050.x; Butte W, 2001, GEFAHRST REINHALT L, V61, P19; Cadogan DF, 1996, KIRKOTHMER ENCY CHEM, V19, P258; CAUTREELS W, 1976, ATMOS ENVIRON, V10, P447, DOI 10.1016/0004-6981(76)90025-1; CAUTREELS W, 1976, WATER AIR SOIL POLL, V6, P103; *CDC, 2003, 2 CDC NAT CTR ENV HL; Clausen PA, 2003, J CHROMATOGR A, V986, P179, DOI 10.1016/S0021-9673(02)02007-1; Etzel RA, 2003, PEDIATRICS, V112, P233; Fromme H, 2004, INDOOR AIR, V14, P188, DOI 10.1046/j.1600-0668.2003.00223.x; GIAM CS, 1978, SCIENCE, V199, P419, DOI 10.1126/science.199.4327.419-a; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Kavlock R, 2002, REPROD TOXICOL, V16, P529, DOI 10.1016/S0890-6238(02)00032-1; Kavlock R, 2002, REPROD TOXICOL, V16, P489, DOI 10.1016/S0890-6238(02)00033-3; Kavlock R, 2002, REPROD TOXICOL, V16, P453, DOI 10.1016/S0890-6238(02)00029-1; Koch HM, 2003, INT J HYG ENVIR HEAL, V206, P77, DOI 10.1078/1438-4639-00205; Kohn M.C., 2000, ENV HLTH PERSPECT, V108, P440; Koo JW, 2002, ENVIRON HEALTH PERSP, V110, P405; Larsen ST, 2003, FOOD CHEM TOXICOL, V41, P439, DOI 10.1016/S0278-6915(02)00248-X; Larsen ST, 2002, PHARMACOL TOXICOL, V91, P264, DOI 10.1034/j.1600-0773.2002.910508.x; Larsen ST, 2001, TOXICOL LETT, V125, P11; Larsen ST, 2001, TOXICOLOGY, V169, P37, DOI 10.1016/S0300-483X(01)00484-X; Nazaroff WW, 2003, ATMOS ENVIRON, V37, P5451, DOI 10.1016/j.atmosenv.2003.09.021; *NTP, 2003, 10 NTP; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Palmer A., 1997, UMWELT GESUNDHEIT, V8, P79; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Schneider T, 2003, INDOOR AIR, V13, P38, DOI 10.1034/j.1600-0668.2003.02025.x; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; *UN, 2000, LEAG TABL CHILD POV; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x; WESCHLER CJ, 1984, ENVIRON SCI TECHNOL, V18, P648, DOI 10.1021/es00127a004; WESCHLER CJ, 1980, ENVIRON SCI TECHNOL, V14, P428, DOI 10.1021/es60164a008	40	362	384	9	113	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2004	112	14					1393	1397		10.1289/ehp.7187		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	860JG	WOS:000224337900034	15471731	
J	Riedler, J; Eder, W; Oberfeld, G; Schreuer, M				Riedler, J; Eder, W; Oberfeld, G; Schreuer, M			Austrian children living on a farm have less hay fever, asthma and allergic sensitization	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic sensitization; asthma; farm; hay fever	ENVIRONMENTAL-FACTORS; EAST-GERMANY; PREVALENCE; SCHOOLCHILDREN; ATOPY; STIMULATION; EXPOSURE; SYMPTOMS; IL-12; TH1	Background and objectives In some studies, the prevalence of hay fever and asthma has been found to be lower in children from rural areas than in children from an urban environment. We hypothesized that living on a farm might be protective against development of allergic sensitization and allergic diseases. Methods In a cross-sectional survey, parents of 2283 children aged 8-10 years from a mostly rural area in Austria answered a standardized questionnaire on allergic diseases and environmental factors. 1137 children performed a skin prick test to seven local allergens. Results The prevalence of hay fever (3.1 vs 10.3%, P = 0.0002), asthma (1.1 vs 3.9%, P = 0.017) and a positive skin prick reactivity to at least one of the common local allergens (18.8 vs 32.7%, P = 0.001) was significantly lower in children living on a farm than in children from a non-farming environment. In a multivariate logistic regression model, adjusting for genetic background, parent education, living and housing conditions and dietary factors did not change the odds ratio for the association of farming and allergic sensitization. Only after including 'regular contact with livestock and poultry' into the model did the odds ratio change significantly (cOR 0.48 95% CI 0.30-0.75 to aOR 0.75 95% CI 0.37-1.52) indicating an association between regular contact with farm animals and reduced risk of atopic sensitization. Conclusion Possible explanations for the lower prevalence of hay fever, asthma and allergic sensitization in children living on a farm might be the development of immunotolerance or the stimulation of TH1 cells and suppression of TH2 cells by increased exposure of farm children to microbial antigens in the stables or farmhouses.	Childrens Hosp, A-5020 Salzburg, Austria; Salzburg Univ, Dept Publ Hlth, A-5020 Salzburg, Austria; Salzburg Univ, Dept Sociol, A-5020 Salzburg, Austria	Riedler, J (reprint author), Childrens Hosp, Muellner Hauptstr 48, A-5020 Salzburg, Austria.						BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1996, EPIDEMIOLOGY, V7, pS47; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; *ISAAC STEER COMM, 1998, LANCET, V351, P1255; Jenmalm MC, 1998, J ALLERGY CLIN IMMUN, V102, P671, DOI 10.1016/S0091-6749(98)70286-6; Kilpelainen M., 1997, European Respiratory Journal Supplement, V10, p143S; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; NINAN TK, 1992, BRIT MED J, V304, P873; Oberfeld G., 1998, European Respiratory Journal, V12, p211S; POPP W, 1989, ALLERGY, V44, P572, DOI 10.1111/j.1398-9995.1989.tb04202.x; Riedler J, 1998, EUR RESPIR J, V11, P355, DOI 10.1183/09031936.98.11020355; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; vonMutius E, 1996, BRIT MED J, V312, P1448; VONOHRENSTEIN V, 1998, EPIDEMIOLOGY, V9, pS118	23	360	364	4	33	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2000	30	2					194	200				7	Allergy; Immunology	Allergy; Immunology	287NF	WOS:000085511600008	10651771	
J	Dang, JM; Leong, KW				Dang, Jiyoung M.; Leong, Kam W.			Natural polymers for gene delivery and tissue engineering	ADVANCED DRUG DELIVERY REVIEWS			English	Review						gene delivery; gene therapy; tissue engineering; natural polymers; collagen; alginate; chitosan; regenerative medicine	CHITOSAN-DNA NANOPARTICLES; MESENCHYMAL STEM-CELLS; DUST MITE ALLERGEN; IN-VIVO; PLASMID DNA; TRANSFECTION EFFICIENCY; INTRACELLULAR TRAFFICKING; CATIONIZED GELATIN; DRUG-DELIVERY; WOUND REPAIR	Although the field of gene delivery is dominated by viral vectors and synthetic polymeric or lipid gene carriers, natural polymers offer distinct advantages and may help advance the field of non-viral gene therapy. Natural polymers, such as chitosan, have been successful in oral and nasal delivery due to their mucoadhesive properties. Collagen has broad utility as gene activated matrices, capable of delivering large quantities of DNA in a direct, localized manner. Most natural polymers contain reactive sites amenable for ligand conjugation, cross-linking, and other modifications that can render the polymer tailored for a range of clinical applications. Natural polymers also often possess good cytocompatibility, making them popular choices for tissue engineering scaffolding applications. The marriage of gene therapy and tissue engineering exploits the power of genetic cell engineering to provide the biochemical signals to influence proliferation or differentiation of cells. Natural polymers with their ability to serve as gene carriers and tissue engineering scaffolds are poised to play an important role in the field of regenerative medicine. This review highlights the past and present research on various applications of natural polymers as particulate and matrix delivery vehicles for gene delivery. (c) 2006 Elsevier B.V All rights reserved.	Duke Univ, Dept Biomed Engn, Durham, NC 27708 USA; Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA	Leong, KW (reprint author), Duke Univ, Dept Biomed Engn, 136 Hudson Hall,Box 90281, Durham, NC 27708 USA.	kam.leong@duke.edu	Leong, Kam/A-7270-2009	Leong, Kam/0000-0002-8133-4955	NIBIB NIH HHS [EB003447]		Agrawal S, 2004, NAT BIOTECHNOL, V22, P1533, DOI 10.1038/nbt1042; Ahsan T, 2005, Orthod Craniofac Res, V8, P134, DOI 10.1111/j.1601-6343.2005.00326.x; Anderson DG, 2005, MOL THER, V11, P426, DOI 10.1016/j.ymthe.2004.11.015; Anusaksathien O, 2003, TISSUE ENG, V9, P745, DOI 10.1089/107632703768247421; BARQUINERO J, 2004, GENE THER, V1, pS3; Berry M, 2001, MOL CELL NEUROSCI, V17, P706, DOI 10.1006/mcne.2001.0975; Bonadio J, 2000, ADV DRUG DELIVER REV, V44, P185, DOI 10.1016/S0169-409X(00)00094-6; Bonadio J, 1999, NAT MED, V5, P753, DOI 10.1038/10473; Caplan AI, 2005, TISSUE ENG, V11, P1198, DOI 10.1089/ten.2005.11.1198; Chandler LA, 2000, WOUND REPAIR REGEN, V8, P473, DOI 10.1046/j.1524-475x.2000.00473.x; Chen H, 2003, CLIN ORTHOP RELAT R, P291, DOI 10.1097/01.blo.0000079443.64912.18; Chew JL, 2003, VACCINE, V21, P2720, DOI 10.1016/S0264-410X(03)00228-7; Christman KL, 2005, BIOMATERIALS, V26, P1139, DOI 10.1016/j.biomaterials.2004.04.025; Cohen-Sacks H, 2004, J CONTROL RELEASE, V95, P309, DOI 10.1016/j.jconrel.2003.11.001; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Conwell C. C., 2005, ADV GENET PA, V53, P1; Corsi K, 2003, BIOMATERIALS, V24, P1255, DOI 10.1016/S0142-9612(02)00507-0; Cutroneo KR, 2003, J CELL BIOCHEM, V88, P418, DOI 10.1002/jcb.10357; Douglas KL, 2005, J BIOMAT SCI-POLYM E, V16, P43, DOI 10.1163/1568562052843339; Doukas J, 2002, MOL THER, V5, P517, DOI 10.1006/mthe.2002.0579; Dunn CA, 2005, MOL THER, V11, P294, DOI 10.1016/j.ymthe.2004.10.005; Elouahabi A, 2005, MOL THER, V11, P336, DOI 10.1016/j.ymthe.2004.12.006; Finsinger D, 2000, GENE THER, V7, P1183, DOI 10.1038/sj.gt.3301227; Gu DL, 2004, MOL THER, V9, P699, DOI 10.1016/j.ymthe.2004.02.018; GUO T, 2005, BIOMATERIALS, V27, P1095; Hannon GJ, 2004, NATURE, V431, P371, DOI 10.1038/nature02870; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; Horvath KA, 2002, ANN THORAC SURG, V74, P481, DOI 10.1016/S0003-4975(02)03736-0; Huard J, 2003, J GENE MED, V5, P93, DOI 10.1002/jgm.344; Ishii T, 2001, BBA-BIOMEMBRANES, V1514, P51, DOI 10.1016/S0005-2736(01)00362-5; Jin QM, 2004, MOL THER, V9, P519, DOI 10.1016/j.ymthe.2004.01.016; Kamiya H, 2001, ADV DRUG DELIVER REV, V52, P153, DOI 10.1016/S0169-409X(01)00216-2; Kean T, 2005, J CONTROL RELEASE, V103, P643, DOI 10.1016/j.jconrel.2004.01.001; Kiang T, 2004, J BIOMAT SCI-POLYM E, V15, P1405, DOI 10.1163/1568562042368112; Kim A, 2003, J CONTROL RELEASE, V90, P81, DOI 10.1016/S0168-3659(03)00175-5; Kim AP, 2005, BIOMATERIALS, V26, P1585, DOI 10.1016/j.biomaterials.2004.05.015; Klugherz BD, 2000, NAT BIOTECHNOL, V18, P1181; Koping-Hoggard M, 2005, J GENE MED, V7, P1215, DOI 10.1002/jgm.762; Koping-Hoggard M, 2004, GENE THER, V11, P1441, DOI 10.1038/sj.gt.3302312; Koping-Hoggard M, 2003, J GENE MED, V5, P130, DOI 10.1002/jgm.327; Koping-Hoggard M, 2001, GENE THER, V8, P1108, DOI 10.1038/sj.gt.3301492; Kumar M, 1999, VACCINE, V18, P558, DOI 10.1016/S0264-410X(99)00185-1; Kumar M., 2003, GENETIC VACCINES THE, V1, P3, DOI 10.1186/1479-0556-1-3; Kushibiki T, 2005, BIOL PHARM BULL, V28, P2007, DOI 10.1248/bpb.28.2007; Kushibiki T, 2005, J CONTROL RELEASE, V105, P318, DOI 10.1016/j.jconrel.2005.02.030; Leong KW, 1998, J CONTROL RELEASE, V53, P183, DOI 10.1016/S0168-3659(97)00252-6; Levenberg S, 2005, CURR OPIN BIOTECH, V16, P516, DOI 10.1016/j.copbio.2005.08.007; LIM SH, 2006, IN PRESS MOL TH 0221; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Luo D, 2000, NAT BIOTECHNOL, V18, P893; MANSOURI S, 2005, BIOMATERIALS, V27, P2060; Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8; Meilander-Lin NJ, 2005, TISSUE ENG, V11, P546, DOI 10.1089/ten.2005.11.546; Melo LG, 2004, FASEB J, V18, P648, DOI 10.1096/fj.03-1171rev; Nakayama Y, 2001, J BIOMED MATER RES, V57, P559, DOI 10.1002/1097-4636(20011215)57:4<559::AID-JBM1202>3.0.CO;2-H; Okino H, 2003, J BIOMED MATER RES A, V66A, P643, DOI 10.1002/jbm.a.10016; Ono I, 2004, BIOMATERIALS, V25, P4709, DOI 10.1016/j.biomaterials.2003.11.038; Pakkanen TM, 2000, J GENE MED, V2, P52, DOI 10.1002/(SICI)1521-2254(200001/02)2:1<52::AID-JGM82>3.0.CO;2-4; Partridge KA, 2004, TISSUE ENG, V10, P295, DOI 10.1089/107632704322791934; Pascher A, 2004, GENE THER, V11, P133, DOI 10.1038/sj.gt.3302155; Portner R, 2005, J BIOSCI BIOENG, V100, P235, DOI 10.1263/jbb.100.235; Qian ZM, 2002, PHARMACOL REV, V54, P561, DOI 10.1124/pr.54.4.561; Ralph GS, 2005, J MOL MED-JMM, V83, P413, DOI 10.1007/s00109-005-0649-1; Ratner BD, 2004, ANNU REV BIOMED ENG, V6, P41, DOI 10.1146/annurev.bioeng.6.040803.140027; Roy K, 1999, NAT MED, V5, P387; Samuel RE, 2002, HUM GENE THER, V13, P791, DOI 10.1089/10430340252898975; Sano A, 2003, ADV DRUG DELIVER REV, V55, P1651, DOI 10.1016/j.addr.2003.08.005; Sato T, 2001, BIOMATERIALS, V22, P2075, DOI 10.1016/S0142-9612(00)00385-9; Schaffer DV, 2000, CURR OPIN MOL THER, V2, P155; Scherer F, 2002, J GENE MED, V4, P634, DOI 10.1002/jgm.298; Silva EA, 2004, CURR TOP DEV BIOL, V64, P181, DOI 10.1016/S0070-2153(04)64008-7; Stayton P S, 2005, Orthod Craniofac Res, V8, P219, DOI 10.1111/j.1601-6343.2005.00336.x; Truong-Le VL, 1999, ARCH BIOCHEM BIOPHYS, V361, P47, DOI 10.1006/abbi.1998.0975; Tuan RS, 2004, CLIN ORTHOP RELAT R, pS105, DOI 10.1097/01.blo.0000143560.41767.ee; Vijayanathan V, 2002, BIOCHEMISTRY-US, V41, P14085, DOI 10.1021/bi0203987; Wang J, 2004, INT J PHARMACEUT, V279, P115, DOI 10.1016/j.ijpharm.2004.04.014; Wattiaux R, 2000, ADV DRUG DELIVER REV, V41, P201, DOI 10.1016/S0169-409X(99)00066-6; Wiethoff CM, 2003, J PHARM SCI, V92, P203, DOI 10.1002/jps.10286; Wolfowicz CB, 2003, VACCINE, V21, P1195, DOI 10.1016/S0264-410X(02)00485-1; Xie YB, 2001, TISSUE ENG, V7, P585, DOI 10.1089/107632701753213200; Yoo HS, 2005, J CONTROL RELEASE, V103, P235, DOI 10.1016/j.jconrel.2004.11.033; Yun YH, 2004, BIOMATERIALS, V25, P147, DOI 10.1016/S0142-9612(03)00467-8	82	359	370	13	189	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-409X			ADV DRUG DELIVER REV	Adv. Drug Deliv. Rev.	JUL 7	2006	58	4					487	499		10.1016/j.addr.2006.03.001		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	062YE	WOS:000238982100003	16762443	
J	Hirschfeld, RMA; Calabrese, JR; Weissman, MM; Reed, M; Davies, MA; Frye, MA; Keck, PE; Lewis, L; McElroy, SL; McNulty, JP; Wagner, KD				Hirschfeld, RMA; Calabrese, JR; Weissman, MM; Reed, M; Davies, MA; Frye, MA; Keck, PE; Lewis, L; McElroy, SL; McNulty, JP; Wagner, KD			Screening for bipolar disorder in the community	JOURNAL OF CLINICAL PSYCHIATRY			English	Article							PSYCHIATRIC-DISORDERS; UNITED-STATES; SPECTRUM DISORDER; AMERICAN MIGRAINE; YOUNG-ADULTS; PREVALENCE; MANIA; EPIDEMIOLOGY; DIAGNOSIS; SUICIDALITY	Background: Our goal was to estimate the rate of positive screens for bipolar I and bipolar II disorders in the general population of the United States. Method: The Mood Disorder Questionnaire (MDQ), a validated screening instrument for bipolar I and II disorders, was sent to a sample of 127,800 people selected to represent the U.S. adult population by demographic variables. 85,358 subjects (66.8% response rate) that were 18 years of age or above returned the survey and had usable data. Of the nonrespondents, 3404 subjects matched demographically to the 2000 U.S. Census data completed a telephone interview to estimate nonresponse bias. Results: The overall positive screen rate for bipolar I and II disorders, weighted to match the 2000 U.S. Census demographics, was 3.4%. When adjusted for the nonresponse bias, the rate rose to 3.7%. Only 19.8% of the individuals with positive screens for bipolar I or II disorders reported that they had previously received a diagnosis of bipolar disorder from a physician, whereas 31.2% reported receiving a diagnosis of unipolar depression. An additional 49.0% reported receiving no diagnosis of either bipolar disorder or unipolar depression. Positive screens were more frequent in young adults and low income house-holds. The rates of migraine, allergies, asthma, and alcohol and drug abuse were substantially higher among those with positive screens. Conclusion: The positive MDQ screen rate of 3.7% suggests that nearly 4% of American adults may suffer from bipolar I and II disorders. Young adults and individuals with lower income are at greater risk for this largely underdiagnosed disorder.	Univ Texas, Med Branch, Dept Psychiat & Behav Sci, Galveston, TX 77555 USA; Natl Alliance Mentally Ill, Alexandria, VA USA; Depress & Bipolar Support Alliance, Chicago, IL USA; Univ Cincinnati, Coll Med, Dept Psychiat, Cincinnati, OH USA; Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA; Vedanta Associates Inc, Chapel Hill, NC USA; New York State Psychiat Inst & Hosp, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Case Western Reserve Univ, Dept Psychiat, Cleveland, OH 44106 USA	Hirschfeld, RMA (reprint author), Univ Texas, Med Branch, Dept Psychiat & Behav Sci, 1-302 Rebecca Sealy,301 Univ Blvd, Galveston, TX 77555 USA.			Weissman, Myrna/0000-0003-3490-3075	NIMH NIH HHS [R01 MH079261]		Akiskal HS, 2000, J AFFECT DISORDERS, V59, pS5, DOI 10.1016/S0165-0327(00)00203-2; Akiskal H. S., 1983, PSYCHIATRY UPDATE AM, V2, P271; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Angst J, 1998, J AFFECT DISORDERS, V50, P143, DOI 10.1016/S0165-0327(98)00142-6; Boerlin HL, 1998, J CLIN PSYCHIAT, V59, P374, DOI 10.4088/JCP.v59n0706; BRESLAU N, 1991, PSYCHIAT RES, V37, P11, DOI 10.1016/0165-1781(91)90102-U; Calabrese JR, 1999, EUR NEUROPSYCHOPHARM, V9, pS109, DOI 10.1016/S0924-977X(99)00023-1; CUMMINGS JL, 1986, PSYCHIAT CLIN N AM, V9, P293; DILSAVER SC, 1994, AM J PSYCHIAT, V151, P1312; First M, 2001, STRUCTURED CLIN INTE; Hirschfeld RMA, 2000, AM J PSYCHIAT, V157, P1873, DOI 10.1176/appi.ajp.157.11.1873; Hirschfeld RMA, 2003, AM J PSYCHIAT, V160, P178, DOI 10.1176/appi.ajp.160.1.178; Hirschfeld RMA, 2001, J CLIN PSYCHIAT, V62, P5; HIRSCHFELD RMA, IN PRESS J CLIN PSYC; Howland RH, 1996, J CLIN PSYCHOPHARM, V16, P425, DOI 10.1097/00004714-199612000-00003; Judd LL, 2000, AM J PSYCHIAT, V157, P1501, DOI 10.1176/appi.ajp.157.9.1501; Judd LL, 2000, ARCH GEN PSYCHIAT, V57, P375, DOI 10.1001/archpsyc.57.4.375; Judd LL, 2000, PHARMACOPSYCHIATRY, V33, P3; Keck PE, 1998, AM J PSYCHIAT, V155, P646; Kessler RC, 1997, PSYCHOL MED, V27, P1079, DOI 10.1017/S0033291797005333; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; LEWINSOHN PM, 1995, J AM ACAD CHILD PSY, V34, P454, DOI 10.1097/00004583-199504000-00012; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; LIPTON RB, 1992, ARCH INTERN MED, V152, P1273, DOI 10.1001/archinte.152.6.1273; Lipton RB, 2001, HEADACHE, V41, P646, DOI 10.1046/j.1526-4610.2001.041007646.x; LISH JD, 1994, J AFFECT DISORDERS, V31, P281, DOI 10.1016/0165-0327(94)90104-X; MERIKANGAS KR, 1990, ARCH GEN PSYCHIAT, V47, P849; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Osby U, 2001, ARCH GEN PSYCHIAT, V58, P844, DOI 10.1001/archpsyc.58.9.844; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Strakowski SM, 1996, AM J PSYCHIAT, V153, P674; STRAKOWSKI SM, 1994, INT J PSYCHIAT MED, V24, P305; *US BUR CENS, 2001, MONTHL EST US POP AP; WEHR TA, 1988, AM J PSYCHIAT, V145, P179; Weissman MM, 1996, JAMA-J AM MED ASSOC, V276, P293, DOI 10.1001/jama.276.4.293; WEISSMAN MM, 1991, PSYCHIAT DISORDERS A, P53	36	357	368	4	21	PHYSICIANS POSTGRADUATE PRESS	MEMPHIS	P O BOX 240008, MEMPHIS, TN 38124 USA	0160-6689			J CLIN PSYCHIAT	J. Clin. Psychiatry	JAN	2003	64	1					53	59				7	Psychology, Clinical; Psychiatry	Psychology; Psychiatry	641PQ	WOS:000180754500010	12590624	
J	Li, N; Xia, T; Nel, AE				Li, Ning; Xia, Tian; Nel, Andre E.			The role of oxidative stress in ambient particulate matter-induced lung diseases and its implications in the toxicity of engineered nanoparticles	FREE RADICAL BIOLOGY AND MEDICINE			English	Review						particulate matter; oxidative stress; asthma; dendritic cells; adjuvant effect; nanotoxicology; free radicals	DIESEL EXHAUST PARTICLES; AIRWAY EPITHELIAL-CELLS; RAT ALVEOLAR MACROPHAGES; EXHALED CARBON-MONOXIDE; LONG-TERM EXPOSURE; HOUSE-DUST MITE; DENDRITIC CELLS; CYTOKINE PRODUCTION; REACTIVE OXYGEN; IN-VITRO	Ambient particulate matter (PM) is an environmental factor that has been associated with increased respiratory morbidity and mortality. The major effect of ambient PM on the pulmonary system is the exacerbation of inflammation, especially in susceptible people. One of the mechanisms by which ambient PM exerts its proinflammatory effects is the generation of oxidative stress by its chemical compounds and metals. Cellular responses to PM-induced oxidative stress include activation of antioxidant defense, inflammation, and toxicity. The proinflammatory effect of PM in the lung is characterized by increased cytokine/chemokine production and adhesion molecule expression. Moreover, there is evidence that ambient PM can act as an adjuvant for allergic sensitization, which raises the possibility that long-term PM exposure may lead to increased prevalence of asthma. In addition to ambient PM, rapid expansion of nanotechnology has introduced the potential that engineered nanoparticles (NP) may also become airborne and may contribute to pulmonary diseases by novel mechanisms that could include oxidant injury. Currently, little is known about the potential adverse health effects of these particles. In this communication, the mechanisms by which particulate pollutants, including ambient PM and engineered NP, exert their adverse effects through the generation of oxidative stress and the impacts of oxidant injury in the respiratory tract will be reviewed. The importance of cellular antioxidant and detoxification pathways in protecting against particle-induced lung damage will also be discussed. (c) 2008 Elsevier Inc. All rights reserved.	[Li, Ning; Xia, Tian; Nel, Andre E.] Univ Calif Los Angeles, Dept Med, Div NanoMed, Los Angeles, CA 90095 USA; [Li, Ning; Nel, Andre E.] Univ Calif Los Angeles, Asthma & Allerg Dis Cooperat Res Ctr, Los Angeles, CA 90095 USA; [Li, Ning; Nel, Andre E.] Univ Calif Los Angeles, So Calif Particle Ctr, Los Angeles, CA 90095 USA; [Nel, Andre E.] Univ Calif Los Angeles, Calif NanoSyst Inst, Los Angeles, CA 90095 USA	Nel, AE (reprint author), Univ Calif Los Angeles, Dept Med, Div NanoMed, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	xia, tian/C-3158-2013; Nel, Andre/J-2808-2012	xia, tian/0000-0003-0123-1305; 	NIAID NIH HHS [U19 AI070453, U19 AI070453-01]; NIEHS NIH HHS [R01 ES010553, R01 ES010553-05, R01 ES015498, R01 ES015498-02, R01 ES10553]		ADES EW, 1992, J INVEST DERMATOL, V99, P683, DOI 10.1111/1523-1747.ep12613748; Antonini JM, 2004, MOL CELL BIOCHEM, V255, P257, DOI 10.1023/B:MCBI.0000007281.32126.2c; Arimoto T, 1999, JPN J PHARMACOL, V80, P49, DOI 10.1254/jjp.80.49; Baeza-Squiban A, 1999, CELL BIOL TOXICOL, V15, P375, DOI 10.1023/A:1007653900063; Baulig A, 2003, TOXICOL IN VITRO, V17, P567, DOI 10.1016/S0887-2333(03)00115-2; Becker S, 2005, ENVIRON HEALTH PERSP, V113, P1032, DOI 10.1289/ehp.7996; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; Becker Susanne, 2005, Toxicol Appl Pharmacol, V207, P269, DOI 10.1016/j.taap.2005.01.023; Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; Cho HY, 2002, AM J RESP CELL MOL, V26, P175; Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875; de Haar C, 2006, CLIN EXP ALLERGY, V36, P1469, DOI 10.1111/j.1365-2222.2006.02586.x; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 2004, OCCUP ENVIRON MED, V61, P727, DOI 10.1136/oem.2004.013243; DOOMAERT B, 2003, AM J PHYSIOL-LUNG C, V284, pL119; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Edwan JH, 2004, J IMMUNOL, V172, P5016; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Finkelman FD, 2004, J IMMUNOL, V172, P3808; Gamvrellis A, 2004, IMMUNOL CELL BIOL, V82, P506, DOI 10.1111/j.1440-1711.2004.01271.x; Ghio AJ, 2004, J AEROSOL MED, V17, P157, DOI 10.1089/0894268041457200; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Goldsmith CA, 1997, ENVIRON HEALTH PERSP, V105, P1191, DOI 10.2307/3433531; Grassian VH, 2007, ENVIRON HEALTH PERSP, V115, P397, DOI 10.1298/ehp.9469; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1067/mai.2003.1780; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hiura TS, 2000, J IMMUNOL, V165, P2703; Horvath I, 1998, THORAX, V53, P668; ICHINOSE T, 1995, TOXICOLOGY, V99, P153, DOI 10.1016/0300-483X(94)03013-R; Ichinose T, 2004, J APPL TOXICOL, V24, P69, DOI 10.1002/jat.949; Ichinose T, 2003, TOXICOL APPL PHARM, V187, P29, DOI 10.1016/S0041-008X(02)00038-8; Ichinose T, 1998, TOXICOL SCI, V44, P70, DOI 10.1093/toxsci/44.1.70; Inoue KI, 2006, ENVIRON HEALTH PERSP, V114, P1325, DOI 10.1289/ehp.8903; Izzotti A, 1996, CANCER RES, V56, P1533; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Jung EJ, 2007, PROTEOMICS, V7, P3906, DOI 10.1002/pmic.200700377; Kaewamatawong T, 2006, TOXICOL PATHOL, V34, P958, DOI 10.1080/01926230601094552; Kasprzak K.S., 2000, ROLE METALS OXIDATIV, P477; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kidd Parris, 2003, Altern Med Rev, V8, P223; Kleinman MT, 2007, INHAL TOXICOL, V19, P117, DOI 10.1080/08958370701495345; Kreyling WG, 2006, J AEROSOL MED, V19, P74, DOI 10.1089/jam.2006.19.74; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Lambrecht B N, 2001, Curr Opin Allergy Clin Immunol, V1, P51, DOI 10.1097/00130832-200102000-00010; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2005, ALLERGY, V60, P271, DOI 10.1111/j.1398-9995.2005.00708.x; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; LARNBRECHT BN, 1998, J IMMUNOL, V160, P4090; Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2002, J IMMUNOL, V169, P4531; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; MacNee W, 2000, CHEST, V117, p390S, DOI 10.1378/chest.117.5_suppl_2.390S; MAINES MD, 1988, FASEB J, V2, P2557; Marano F, 2002, CELL BIOL TOXICOL, V18, P315, DOI 10.1023/A:1019548517877; Martin LD, 1997, ENVIRON HEALTH PERSP, V105, P1301, DOI 10.2307/3433551; Matsumoto A, 2006, CLIN IMMUNOL, V121, P227, DOI 10.1016/j.clim.2006.08.003; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Miller KA, 2007, NEW ENGL J MED, V356, P447, DOI 10.1056/NEJMoa054409; Mittleman MA, 2007, NEW ENGL J MED, V357, P1147, DOI 10.1056/NEJMe078139; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Mutlu GM, 2007, J CLIN INVEST, V117, P2952, DOI 10.1172/JCI30639; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Nemmar A, 2003, AM J RESP CRIT CARE, V168, P1366, DOI 10.1164/rccm.200306-801OC; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565; Penning TM, 1999, CHEM RES TOXICOL, V12, P1, DOI 10.1021/tx980143n; Peters Annette, 2006, Part Fibre Toxicol, V3, P13, DOI 10.1186/1743-8977-3-13; Porter M, 2007, AM J RESP CELL MOL, V37, P706, DOI 10.1165/rcmb.2007-01990C; Rhoden CR, 2004, TOXICOL SCI, V79, P296, DOI 10.1093/toxsci/kfh122; Ritz SA, 2007, AM J PHYSIOL-LUNG C, V292, pL33, DOI 10.1152/ajplung.00170.2006; Sadakane K, 2002, INT ARCH ALLERGY IMM, V128, P220, DOI 10.1159/000064255; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Saldiva PHN, 2002, AM J RESP CRIT CARE, V165, P1610, DOI 10.1164/rccm.2106102; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; Schijns VEJC, 2001, CRIT REV IMMUNOL, V21, P75; Steerenberg PA, 1998, EXP LUNG RES, V24, P85; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Sunyer J, 2001, INT J EPIDEMIOL, V30, P1138, DOI 10.1093/ije/30.5.1138; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Takano H, 1999, TOXICOLOGY, V139, P19, DOI 10.1016/S0300-483X(99)00104-3; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438; Wan JX, 2007, INHAL TOXICOL, V19, P177, DOI 10.1080/08958370701496145; Wan JX, 2006, J IMMUNOL, V177, P3477; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; Wichmann HE, 2007, INHAL TOXICOL, V19, P241, DOI 10.1080/08958370701498075; Xia T, 2004, ENVIRON HEALTH PERSP, V112, P1347, DOI 10.1289/ehp.7167; Xia Tian, 2006, Clin Occup Environ Med, V5, P817; Xia T, 2006, NANO LETT, V6, P1794, DOI 10.1021/nl061025k; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Yamaya M, 2001, CLIN EXP ALLERGY, V31, P417, DOI 10.1046/j.1365-2222.2001.01013.x; Yanagisawa R, 2006, CLIN EXP ALLERGY, V36, P386, DOI 10.1111/j.1365-2222.2006.02452.x; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372	124	356	384	13	123	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	MAY 1	2008	44	9					1689	1699		10.1016/j.freeradbiomed.2008.01.028		11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	293OB	WOS:000255343500001	18313407	
J	Katz, LF; Kling, JR; Liebman, JB				Katz, LF; Kling, JR; Liebman, JB			Moving to opportunity in Boston: Early results of a randomized mobility experiment	QUARTERLY JOURNAL OF ECONOMICS			English	Article							CHILDREN; NEIGHBORHOODS; IDENTIFICATION; EXTERNALITIES; EDUCATION; COMMUNITY; PROGRAM; MATTER; CITY	We examine short-run impacts of changes in residential neighborhoods on the well-being of families residing in high-poverty public housing projects who received Section 8 housing vouchers through a random lottery. Households offered vouchers experienced improvements in multiple measures of well-being relative to a control group, including increased safety, improved health among household heads, and fewer behavior problems among boys. There were no significant short-run impacts of vouchers on the employment, earnings, or welfare receipt of household heads. Children in households offered vouchers valid only in low poverty neighborhoods also had reduced likelihood of injuries, asthma attacks, and victimizations by crime.	Harvard Univ, Cambridge, MA 02138 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA; Princeton Univ, Princeton, NJ 08544 USA	Katz, LF (reprint author), Harvard Univ, Cambridge, MA 02138 USA.						Aaronson D, 1998, J HUM RESOUR, V33, P915, DOI 10.2307/146403; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Augustyn M., 1995, CONT PEDIAT, V12, P35; BENABOU R, 1993, Q J ECON, V108, P619, DOI 10.2307/2118403; Black SE, 1999, Q J ECON, V114, P577, DOI 10.1162/003355399556070; BLOOM HS, 1984, EVALUATION REV, V8, P225, DOI 10.1177/0193841X8400800205; BORJAS GJ, 1995, AM ECON REV, V85, P365; McLoyd V., 1999, NEW HOPE PEOPLE LOW; BROCK WA, 2000, IN PRESS HDB ECONOME, V5; BROOKSGUNN J, 1993, AM J SOCIOL, V99, P353, DOI 10.1086/230268; *BUR JUST STAT, 1994, NCJ151172 US DEP JUS; Case A. C., 1991, 3705 NAT BUR EC RES; COLEMAN JS, 1988, AM J SOCIOL, V94, pS95, DOI 10.1086/228943; CORCORAN M, 1992, J HUM RESOUR, V27, P575, DOI 10.2307/146076; Currie J, 2000, J PUBLIC ECON, V75, P99, DOI 10.1016/S0047-2727(99)00065-1; Cutler DM, 1997, Q J ECON, V112, P827, DOI 10.1162/003355397555361; Cutler DM, 1999, J POLIT ECON, V107, P455, DOI 10.1086/250069; DANZIGER S, 1999, UNPUB BARRIERS EMPLO; Duncan G. J., 1997, NEIGHBORHOOD POVERTY, P219; Epp G, 1996, HOUS POLICY DEBATE, V7, P563; EVANS WN, 1992, J POLIT ECON, V100, P966, DOI 10.1086/261848; FEINS JD, 1994, MOVING OPPORTUNITY F; Gaviria A., 1999, 9721 U CAL DEP EC; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GELFAND DM, 1990, CLIN PSYCHOL REV, V10, P329, DOI 10.1016/0272-7358(90)90065-I; Glaeser EL, 2000, Q J ECON, V115, P811, DOI 10.1162/003355300554926; GLAESER EL, 1999, UNPUB MEASURING SOCI; Goering J, 1999, MOVING OPPORTUNITY F; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; HANRATTY M, 1998, UNPUB IMPACT LOS ANG; HAREL Y, 1994, AM J PUBLIC HEALTH, V84, P599, DOI 10.2105/AJPH.84.4.599; Heckman J., 1999, HDB LABOR EC, VIII; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; JACOB B, 2000, UNPUB PUBLIC HOUSING; Jargowsky P, 1997, POVERTY PLACE; Jargowsky PA, 1996, AM SOCIOL REV, V61, P984, DOI 10.2307/2096304; JENCKS C., 1990, INNER CITY POVERTY U, P111; KAIN JF, 1968, Q J ECON, V87, P175; KATZ LF, 2000, UNPUB EARLY IMPACT M; Kessler R. C., 1998, INT J METH PSYCH RES, V7, P171, DOI DOI 10.1002/MPR.47; KLING JR, 2001, UNPUB BULLETS DONT G; Kornfeld R, 1999, J LABOR ECON, V17, P168, DOI 10.1086/209917; LAZEAR E, 1983, CAN J ECON, V16, P212, DOI 10.2307/134997; LEVENTHAL T, 2000, UNPUB MOVING OPPORTU; LUCAS RE, 1988, J MONETARY ECON, V22, P3, DOI 10.1016/0304-3932(88)90168-7; Ludwig J, 2001, Q J ECON, V116, P655, DOI 10.1162/00335530151144122; LUDWIG J, 2000, UNPUB NEIGHBORHOOD E; MANSKI CF, 1993, REV ECON STUD, V60, P531, DOI 10.2307/2298123; Manski CF, 2000, J ECON PERSPECT, V14, P115, DOI 10.1257/jep.14.3.115; MOFFITT RA, 2000, IN PRESS SOCIAL DYNA; NELSON CB, 1998, UNPUB SCORING WHO CO; PEROFF KA, 1979, GAUTREAUX HOUSING DE; Putnam Robert, 1995, J DEMOCR, V6, P65; QUIGLEY JM, 1980, HOUSING POLICIES 198; Quinlan KP, 1996, ARCH PEDIAT ADOL MED, V150, P954; ROSENBAUM JE, 1995, HOUS POLICY DEBATE, V6, P231; Popkin S. J., 1991, URBAN UNDERCLASS; Sacerdote B, 2001, Q J ECON, V116, P681, DOI 10.1162/00335530151144131; SHARFSTEIN J, 1998, NOT SAFE HOME; Suh E, 1996, J PERS SOC PSYCHOL, V70, P1091, DOI 10.1037//0022-3514.71.5.842; THURSTON GD, 1997, ALA ATS INT C SAN FR; VONHOFFMAN A, 1996, HOUSING POLICY DEBAT, V7; WARE JE, 1994, SF36 HLTH SURVEY MAN; Weiss KB, 1992, CHEST, V101, P362; WEISSMAN MM, 1984, J AM ACAD CHILD PSY, V23, P78, DOI 10.1097/00004583-198401000-00011; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; Wilson W. J, 1987, TRULY DISADVANTAGED; Wright RJ, 1998, THORAX, V53, P1066; ZELON HB, 1994, SURVEY PUBLIC HOUSIN	69	356	357	4	38	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA	0033-5533			Q J ECON	Q. J. Econ.	MAY	2001	116	2					607	654		10.1162/00335530151144113		48	Economics	Business & Economics	429LA	WOS:000168517400007		
J	Li, N; Hao, MQ; Phalen, RF; Hinds, WC; Nel, AE				Li, N; Hao, MQ; Phalen, RF; Hinds, WC; Nel, AE			Particulate air pollutants and asthma - A paradigm for the role of oxidative stress in PM-induced adverse health effects	CLINICAL IMMUNOLOGY			English	Review						antioxidant enzyme; asthma exacerbation; diesel exhaust particles; inflammation; particulate matter; polycyclic aromatic hydrocarbons; quinone; reactive oxygen species; redox cycling; stratified oxidative stress response	DIESEL EXHAUST PARTICLES; GLUTATHIONE-S-TRANSFERASE; INDUCED EOSINOPHILIC INFLAMMATION; ANTIOXIDANT RESPONSE ELEMENTS; BRONCHIAL EPITHELIAL-CELLS; EXPIRED BREATH CONDENSATE; MURINE STRAIN DIFFERENCES; EXHALED CARBON-MONOXIDE; NITRIC-OXIDE; SUPEROXIDE-DISMUTASE	Asthma is a chronic inflammatory disease, which involves a variety of different mediators, including reactive oxygen species. There is growing awareness that particulate pollutants act as adjuvants during allergic sensitization and can also induce acute asthma exacerbations. In this communication we review the role of oxidative stress in asthma, with an emphasis on the pro-oxidative effects of diesel exhaust particles and their chemicals in the respiratory tract. We review the biology of oxidative stress, including protective and injurious effects that explain the impact of particulate matter-induced oxidative stress in asthma. (C) 2003 Elsevier Inc. All rights reserved.	Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, Los Angeles, CA 90095 USA; Univ Calif Irvine, Dept Community & Environm Med, Irvine, CA 92717 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA 90024 USA; So Calif Particulate Ctr & Supersite, Los Angeles, CA USA	Nel, AE (reprint author), Univ Calif Los Angeles, Dept Med, Div Clin Immunol & Allergy, 52-175 CHS,10833 Le Conte Ave, Los Angeles, CA 90095 USA.		Nel, Andre/J-2808-2012		NIAID NIH HHS [P01 AI50495]; NIEHS NIH HHS [R01 ES10553, R01 ES12053]		Al-Humadi NH, 2002, ENVIRON HEALTH PERSP, V110, P349; ALSBERG T, 1985, ENVIRON SCI TECHNOL, V19, P43, DOI 10.1021/es00131a003; Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; Antczak Adam, 1999, Archivum Immunologiae et Therapiae Experimentalis, V47, P119; Arimoto T, 1999, JPN J PHARMACOL, V80, P49, DOI 10.1254/jjp.80.49; Balashazy I, 2000, HEALTH PHYS, V78, P147; BAST A, 1989, PHARM WEEKBLAD, V11, P199, DOI 10.1007/BF01959411; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1641; Blomberg A, 2000, CLIN EXP ALLERGY, V30, P310; Blomberg A, 1998, FREE RADICAL RES, V28, P59, DOI 10.3109/10715769809097876; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515; Bowler RP, 2002, AM J RESP CRIT CARE, V166, pS38, DOI 10.1164/rccm.2206014; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Burkitt MJ, 2001, ARCH BIOCHEM BIOPHYS, V394, P117, DOI 10.1006/abbi.2001.2509; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; CHAN TL, 1980, AM IND HYG ASSOC J, V41, P399, DOI 10.1080/15298668091424942; CHANEZ P, 1990, EUR RESPIR J, V3, P1002; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; *CIIT, 2002, MULT PATH PART DOS M; COHEN AJ, 1998, AIR POLLUTION HLTH, P707; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Dai J, 2003, AM J RESP CELL MOL, V29, P352, DOI 10.1165/rcmb.2002-0318OC; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Diaz-Sanchez D, 2000, IMMUNOLOGY, V101, P11, DOI 10.1046/j.1365-2567.2000.00108.x; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DICKINSON DA, 2002, ANN NY ACAD SCI, V937, P488; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Doornaert B, 2003, AM J PHYSIOL-LUNG C, V284, pL119, DOI 10.1152/ajplung.00039.2002; Dworski R, 2001, CLIN EXP ALLERGY, V31, P387, DOI 10.1046/j.1365-2222.2001.01055.x; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Evans DJ, 1996, EUR RESPIR J, V9, P703, DOI 10.1183/09031936.96.09040703; FLATT A, 1990, THORAX, V45, P95, DOI 10.1136/thx.45.2.95; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Ganas K, 2001, RESP MED, V95, P649, DOI 10.1053/rmed.2001.1117; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Griffiths HR, 2000, FREE RADICAL RES, V33, pS47; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749; HALLIWELL B., 1999, FREE RADICALS BIOL M; Hatanaka N, 2001, CARCINOGENESIS, V22, P2033, DOI 10.1093/carcin/22.12.2033; Held HD, 2000, AM J RESP CRIT CARE, V162, P1547; Hemmingsen A, 2001, Respir Res, V2, P255, DOI 10.1186/rr64; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hiura TS, 2000, J IMMUNOL, V165, P2703; Horvath I, 1998, THORAX, V53, P668; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519; ICHINOSE T, 1995, TOXICOLOGY, V99, P153, DOI 10.1016/0300-483X(94)03013-R; Ichinose T, 2002, TOXICOLOGY, V180, P293, DOI 10.1016/S0300-483X(02)00420-1; Ichinose T, 1998, TOXICOL SCI, V44, P70, DOI 10.1093/toxsci/44.1.70; International Commission on Radiological Protection, 1975, ICRP PUBL, V23; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Ivaschenko TE, 2002, J MOL MED-JMM, V80, P39, DOI 10.1007/s001090100274; Izzotti A, 1996, CANCER RES, V56, P1533; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747; KANAZAWA H, 1991, CHEST, V100, P1319, DOI 10.1378/chest.100.5.1319; Kasprzak KS, 2000, MOL BIOL TOXICOLOGY, P477; KAYE S, 2000, J AEROSOL SCI, V7, P849; Kehrer JP, 2000, TOXICOLOGY, V149, P43, DOI 10.1016/S0300-483X(00)00231-6; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; KIM S, 2001, J AEROSOL SCI, V11, P1299; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; Krishna M. T., 1998, Reviews on Environmental Health, V13, P59; KROEMER G, 2003, BIOCHEM BIOPH RES CO, V304, P43343; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Kumagai Y, 2002, CHEM RES TOXICOL, V15, P483, DOI 10.1021/tx0100993; LANSING MW, 1993, AM REV RESPIR DIS, V147, P321; Li H, 1996, ATMOS ENVIRON, V30, P3537, DOI 10.1016/1352-2310(96)00051-9; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2002, J IMMUNOL, V169, P4531; Li N, 2000, J IMMUNOL, V165, P3393; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; Lippmann M, 2003, ENVIRON HEALTH PERSP, V111, P1074, DOI 10.1289/ehp.5750; MacPherson JC, 2001, J IMMUNOL, V166, P5763; Madden MC, 2000, TOXICOL APPL PHARM, V168, P140, DOI 10.1006/taap.2000.9024; MAINES MD, 1988, FASEB J, V2, P2557; Majori M, 1998, EUR RESPIR J, V11, P133, DOI 10.1183/09031936.98.11010133; MALMGREN R, 1986, ALLERGY, V41, P43, DOI 10.1111/j.1398-9995.1986.tb00273.x; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Marano F, 2002, CELL BIOL TOXICOL, V18, P315, DOI 10.1023/A:1019548517877; MARTONEN TB, 1987, HEALTH PHYS, V52, P213; Mastrangelo G, 2003, INT ARCH OCC ENV HEA, V76, P63, DOI 10.1007/s00420-002-0373-x; Miyabara Y, 1998, EUR RESPIR J, V11, P291, DOI 10.1183/09031936.98.11020291; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Mudway IS, 1999, OCCUP ENVIRON MED, V56, P473; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; National Council on Radiation Protection and Measurements, 1997, 125 NCRP; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ng D, 1998, J IMMUNOL, V161, P942; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Oberdorster G, 2002, ENVIRON HEALTH PERSP, V110, pA440, DOI 10.1289/ehp.110-a440; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; PACHT ER, 1988, J APPL PHYSIOL, V64, P2092; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; PANKOW JF, 1987, ATMOS ENVIRON, V21, P2275, DOI 10.1016/0004-6981(87)90363-5; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; Penning TM, 1999, CHEM RES TOXICOL, V12, P1, DOI 10.1021/tx980143n; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; Rahman Q, 1999, CRIT REV TOXICOL, V29, P543, DOI 10.1080/10408449991349276; Rengasamy A, 2003, J TOXICOL ENV HEAL A, V66, P153, DOI 10.1080/15287390390155813; Ryter SW, 2000, FREE RADICAL BIO MED, V28, P289, DOI 10.1016/S0891-5849(99)00223-3; Sadakane K, 2002, INT ARCH ALLERGY IMM, V128, P220, DOI 10.1159/000064255; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Saldiva PHN, 2002, AM J RESP CRIT CARE, V165, P1610, DOI 10.1164/rccm.2106102; Saleh D, 1998, FASEB J, V12, P929; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725; SCHLESINGER RB, 1982, ANN OCCUP HYG, V26, P47, DOI 10.1093/annhyg/26.1.47; SCHUETZLE D, 1981, INT J ENVIRON AN CH, V9, P93, DOI 10.1080/03067318108071903; Segal RA, 2002, INHAL TOXICOL, V14, P705, DOI 10.1080/08958370290084593; Sies H, 1991, AM J MED, V91, P31; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167; Stenfors N, 2002, RESP MED, V96, P352, DOI 10.1053/rmed.2001.1265; STEVENS WHM, 1995, AM J RESP CRIT CARE, V151, P1526; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Takano H, 2002, ARCH TOXICOL, V76, P146, DOI 10.1007/s00204-002-0323-0; Takano H, 1999, TOXICOLOGY, V139, P19, DOI 10.1016/S0300-483X(99)00104-3; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 1999, J IMMUNOL, V162, P4705; Tekin D, 2000, J ASTHMA, V37, P59, DOI 10.3109/02770900009055428; VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585; van der Vliet A, 1999, AM J PHYSIOL-LUNG C, V276, pL289; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; Vargas L, 1998, INFLAMMATION, V22, P45, DOI 10.1023/A:1022343707133; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yamada Y, 2003, IMMUNOL LETT, V86, P199, DOI 10.1016/S0165-2478(03)00006-3; Yamaya M, 2001, CLIN EXP ALLERGY, V31, P417, DOI 10.1046/j.1365-2222.2001.01013.x; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X	151	354	361	7	68	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1521-6616			CLIN IMMUNOL	Clin. Immunol.	DEC	2003	109	3					250	265		10.1016/j.clim.2003.08.006		16	Immunology	Immunology	756XM	WOS:000187511100002	14697739	
J	Arbes, SJ; Gergen, PJ; Elliott, L; Zeldin, DC				Arbes, SJ; Gergen, PJ; Elliott, L; Zeldin, DC			Prevalences of positive skin test responses to 10 common allergens in the US population: Results from the Third National Health and Nutrition Examination Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; allergic sensitization; allergy skin test; epidemiology; NHANES II; NHANES III; survey	TEST REACTIVITY; AEROALLERGENS; SMOKING; ASTHMA; LEAD; IGE	Background: Allergy skin tests were administered in the second and third National Health and Nutrition Examination Surveys (NHANES II and III) conducted in the United States from 1976 through 1980 and 1988 through 1994, respectively. Objectives: This study estimated positive skin test response rates in NHANES III and identified predictors of one or more positive test responses. Comparisons with NHANES II were also made. Methods: In NHANES III, 10 allergens and 2 controls were tested in all subjects aged 6 to 19 years and a random half-sample of subjects aged 20 to 59 years. A wheal-based definition of a positive test response was used. Results: In NHANES III, 54.3% of the population had positive test responses to 1 or more allergens. Prevalences were 27.5% for dust mite, 26.9% for perennial rye, 26.2% for short ragweed, 26.1% for German cockroach, 18.1% for Bermuda grass, 17.0% for cat, 15.2% for Russian thistle, 13.2% for white oak, 12.9% for Alternaria alternata, and 8.6% for peanut. Among those with positive test responses, the median number of positive responses was 3.0. Adjusted odds of a positive test response were higher for the following variables: age of 20 to 29 years, male sex, minority race, western region, old homes, and lower serum cotinine levels. For the 6 allergens common to NHANES II and III, prevalences were 2.1 to 5.5 times higher in NHANES III. Conclusions: The majority of the US population represented in NHANES III was sensitized to 1 or more allergens. Whether the higher prevalences observed in NHANES III reflect true changes in prevalence or methodological differences between the surveys cannot be determined with certainty.	NIEHS, NIH, Lab Resp Biol, Div Intramural Res, Res Triangle Pk, NC 27709 USA; NIAID, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA	Zeldin, DC (reprint author), NIEHS, NIH, Lab Resp Biol, Div Intramural Res, POB 12233, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov					Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; BURROWS B, 1982, J ALLERGY CLIN IMMUN, V70, P199, DOI 10.1016/0091-6749(82)90042-2; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1986, NATL CTR HIGH STAT U; GLEICH GJ, 1976, J ALLERGY CLIN IMMUN, V58, P31, DOI 10.1016/0091-6749(76)90104-4; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; *NAT CTR HLTH STAT, 1986, PUBL US DAT TAP DOC; *NAT HLTH NUTR EX, TRAIN MAN ALL COMP; Robertson CF, 2004, MED J AUSTRALIA, V180, P273; Rose G, 2001, B WORLD HEALTH ORGAN, V79, P990; SIBBALD B, 1990, BRIT J GEN PRACT, V40, P338; Sopori ML, 1998, J NEUROIMMUNOL, V83, P148, DOI 10.1016/S0165-5728(97)00231-2; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Strachan DP, 1998, THORAX, V53, P117; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; 1909, VITAL HLTH STAT, P1; 2001, ASTHMA PREVALENCE HL	22	351	355	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2005	116	2					377	383		10.1016/j.jaci.2005.05.017		7	Allergy; Immunology	Allergy; Immunology	017ID	WOS:000235686400021	16083793	
J	Gauderman, WJ; Vora, H; McConnell, R; Berhane, K; Gilliland, F; Thomas, D; Lurmann, F; Avol, E; Kunzli, N; Jerrett, M; Peters, J				Gauderman, W. James; Vora, Hita; McConnell, Rob; Berhane, Kiros; Gilliland, Frank; Thomas, Duncan; Lurmann, Fred; Avol, Edward; Kunzli, Nino; Jerrett, Michael; Peters, John			Effect of exposure to traffic on lung development from 10 to 18 years of age: a cohort study	LANCET			English	Article							SOUTHERN CALIFORNIA COMMUNITIES; AMBIENT NITROGEN-DIOXIDE; OUTDOOR AIR-POLLUTION; PULMONARY-FUNCTION; RESPIRATORY HEALTH; FUNCTION GROWTH; CHILDHOOD ASTHMA; MAJOR HIGHWAY; PREADOLESCENT CHILDREN; ULTRAFINE PARTICLES	Background Whether local exposure to major roadways adversely affects lung-function growth during the period of rapid lung development that takes place between 10 and 18 years of age is unknown. This study investigated the association between residential exposure to traffic and 8-year lung-function growth. Methods In this prospective study, 3677 children (mean age 10 years [SD 0.44]) participated from 12 southern California communities that represent a wide range in regional air quality. Children were followed up for 8 years, with yearly lung-function measurements recorded. For each child, we identified several indicators of residential exposure to traffic from large roads. Regression analysis was used to establish whether 8-year growth in lung function was associated with local traffic exposure, and whether local traffic effects were independent of regional air quality Findings Children who lived within 500 m of a freeway (motorway) had substantial deficits in 8-year growth of forced expiratory volume in 1 s (FEV(1)-81 mL, p=0.01 [95% CI -143 to -18]) and maximum midexpiratory flow rate (MMEF, -127 mL/s, p=0.03 [-243 to -11), compared with children who lived at least 1500 m from a freeway. joint models showed that both local exposure to freeways and regional air pollution had detrimental, and independent, effects on lung-function growth. Pronounced deficits in attained lung function at age 18 years were recorded for those living within 500 m of a freeway, with mean percent-predicted 97.0% for FEV(1) (p=0.013, relative to >1500 m [95% CI 94.6-99.4]) and 93.4% for MMEF (p=0.006 [95% CI 89.1-97.7]). Interpretation Local exposure to traffic on a freeway has adverse effects on children's lung development, which are independent of regional air quality, and which could result in important deficits in attained lung function in later life.	Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA; Sonoma Technol Inc, Petaluma, CA 94954 USA; Inst Municipal Invest Med, Resp & Environm Res Unit, E-08003 Barcelona, Spain; Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA	Gauderman, WJ (reprint author), Univ So Calif, Dept Prevent Med, 1540 Alcazar St,Suite 220, Los Angeles, CA 90033 USA.	jimg@usc.edu	Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	NIEHS NIH HHS [P01ES11627, P30ES07048]		ASHLEY F, 1975, ANN INTERN MED, V82, P739; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BENSEN PE, 1989, CALINE4 DISPERSION M; Berhane K, 2004, STAT SCI, V19, P414, DOI 10.1214/088342304000000413; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; FRIEDMAN GD, 1976, NEW ENGL J MED, V294, P1071, DOI 10.1056/NEJM197605132942001; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059; Gonzales M, 2005, SCI TOTAL ENVIRON, V337, P163, DOI 10.1016/j.scitotenv.2004.07.010; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hole DJ, 1996, BRIT MED J, V313, P711; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; KANNEL WB, 1983, AM HEART J, V105, P311, DOI 10.1016/0002-8703(83)90532-X; Khan AJ, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006505; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Knuiman MW, 1999, ANN EPIDEMIOL, V9, P297, DOI 10.1016/S1047-2797(98)00066-0; Kulkarni N, 2006, NEW ENGL J MED, V355, P21, DOI 10.1056/NEJMoa052972; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Manchester-Neesvig JB, 2003, J AIR WASTE MANAGE, V53, P1065; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; RAIZENNE M, 1993, AM REV RESPIR DIS, V147, pA635; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Schroeder EB, 2003, AM J EPIDEMIOL, V158, P1171, DOI 10.1093/aje/kwg276; Schunemann HJ, 2000, CHEST, V118, P656, DOI 10.1378/chest.118.3.656; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; Sugiri D, 2006, ENVIRON HEALTH PERSP, V114, P282, DOI 10.1289/ehp.8180; Tager IB, 2005, EPIDEMIOLOGY, V16, P751, DOI 10.1097/01.ede.0000183166.68809.b0; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WJST M, 1993, BRIT MED J, V307, P596; Zhu YF, 2006, ENVIRON SCI TECHNOL, V40, P2531, DOI 10.1021/es0516514; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	54	350	360	9	70	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	FEB 17	2007	369	9561					571	577		10.1016/S0140-6736(07)60037-3		7	Medicine, General & Internal	General & Internal Medicine	138MZ	WOS:000244368000030	17307103	
J	Cox, L; Nelson, H; Lockey, R; Calabria, C; Chacko, T; Finegold, I; Nelson, M; Weber, R; Bernstein, DI; Blessing-Moore, J; Khan, DA; Lang, DM; Nicklas, RA; Oppenheimer, J; Portnoy, JM; Randolph, C; Schuller, DE; Spector, SL; Tilles, S; Wallace, D				Cox, Linda; Nelson, Harold; Lockey, Richard; Calabria, Christopher; Chacko, Thomas; Finegold, Ira; Nelson, Michael; Weber, Richard; Bernstein, David I.; Blessing-Moore, Joann; Khan, David A.; Lang, David M.; Nicklas, Richard A.; Oppenheimer, John; Portnoy, Jay M.; Randolph, Christopher; Schuller, Diane E.; Spector, Sheldon L.; Tilles, Stephen; Wallace, Dana			Allergen immunotherapy: A practice parameter third update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy; subcutaneous immunotherapy; sublingual immunotherapy; allergic rhinitis; asthma; Hymenoptera; atopic dermatitis; anaphylaxis; epinephrine; beta-blockers; angiotensin-converting enzyme inhibitor; epicutaneous immunotherapy; intralymphatic immunotherapy; nasal immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; IMPORTED FIRE ANT; PLACEBO-CONTROLLED TRIAL; LOCAL NASAL IMMUNOTHERAPY; RAGWEED HAY-FEVER; HYMENOPTERA VENOM IMMUNOTHERAPY; BETA-ADRENERGIC-BLOCKADE; INTRADERMAL SKIN-TESTS		[Cox, Linda] Nova SE Univ, Coll Osteopath Med, Dept Med, Davie, FL USA; [Lockey, Richard] James A Haley Vet Hosp, Tampa, FL 33612 USA; [Lockey, Richard] Univ S Florida, Coll Med, Dept Internal Med, Div Allergy & Immunol, Tampa, FL 33612 USA; [Nelson, Harold] Natl Jewish Hlth, Dept Med, Denver, CO USA; [Bernstein, David I.] Univ Cincinnati, Coll Med, Dept Med & Environm Hlth, Cincinnati, OH USA; [Khan, David A.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Dallas, TX 75390 USA; [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Immunol, Dept Med, Palo Alto, CA 94304 USA; [Blessing-Moore, Joann] Stanford Univ, Med Ctr, Dept Immunol, Dept Pediat, Palo Alto, CA 94304 USA; [Lang, David M.] Cleveland Clin Fdn, Allergy Immunol Sect, Div Med Allergy & Immunol, Fellowship Training Program, Cleveland, OH 44195 USA; [Nicklas, Richard A.] George Washington Med Ctr, Dept Med, Washington, DC USA; [Oppenheimer, John] Univ Med & Dent New Jersey, Pulm & Allergy Associates, Dept Internal Med, Morristown, NJ USA; [Portnoy, Jay M.] Univ Missouri, Childrens Mercy Hosp, Kansas City Sch Med, Dept Pediat,Sect Allergy Asthma & Immunol, Kansas City, MO 64108 USA; [Randolph, Christopher] Yale Univ, New Haven, CT USA; [Schuller, Diane E.] Penn State Univ, Milton S Hershey Med Ctr, Dept Pediat, Hershey, PA 17033 USA; [Spector, Sheldon L.] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA; [Tilles, Stephen] Univ Washington, Sch Med, Dept Med, Redmond, WA USA	Cox, L (reprint author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St 3-3, Palatine, IL 60067 USA.	lindaswolfcox@msn.com			Stallergenes; ALK-Abello; Department of Defense; Novartis; GlaxoSmithKline; Merck; Schering-Plough; Meda; Vanberg Family Foundation; Sellars Family Foundation; Genentech/Novartis; AstraZeneca; Genentech; US Department of Housing and Urban Development; Aventis; Pharmaxis; Boehringer Ingelheim; Johnson Johnson; Xyzal; Alcon; Centocor; Sepracor; UCB; Amgen; Capnia; IVAX; Amphastar; Astellas; Ception; Icagen; MAP Pharma; Roxane	L. Cox is a consultant for Genentech/Novartis, Hollister-Stier, and Stallergenes; is a speaker for Novartis; has received research support from Stallergenes; is on the Board of Directors for the American Board of Allergy and Immunology; and is on the US Food and Drug Administration (FDA)'s Allergenic Product Advisory Committee. H. Nelson is a consultant for Merck and Planet Biopharmaceuticals, is a Data and Safety Monitoring Board member of DBV Technologies, and has received research support from ALK-Abello. M. Nelson has received research support from the Department of Defense, is a speaker for the American College of Allergy, Asthma & Immunology (ACAAI), and is a member of the FDA's Advisory Committee on Allergic Products. R. Weber is on the speakers' bureau for AstraZeneca and Genentech, has received research support from Novartis and GlaxoSmithKline, and is Committee Chair of the ACAAI. D. I. Bernstein is a consultant and on the advisory board for ALK America, is on the advisory board for Merck, and has received research support from Merck and Schering-Plough. J. Blessing-Moore is a speaker for Merck-Schering/AstraZeneca, Novartis, TEVA, and Meda Alcon and has received research support from Meda. D. A. Khan is a speaker for AstraZeneca and Merck, has received research support from the Vanberg Family Foundation and the Sellars Family Foundation, is Conjoint Board Review Chair for the ACAAI, and is a past president of the Texas Allergy, Asthma and Immunology Society. D. M. Lang is a speaker and consultant for GlaxoSmithKline; is a speaker for AstraZeneca, Merck, TEVA, Sanofi-Aventis, and Genentech/Novartis; and has received research support from Genentech/Novartis. R. A. Nicklas is a fellow for the ACAAI. J. Oppenheimer is a consultant and has provided lectures for AstraZeneca, Merck, and GlaxoSmithKline; and has received research support from AstraZeneca, Merck, GlaxoSmithKline, and Genentech. J. M. Portnoy is a speaker for Phadia, Merck, and CSL Behring; has received research support from the US Department of Housing and Urban Development; and is a board member of the ACAAI board of regents. S. L. Spector has received research support from Genentech, GlaxoSmithKline, Schering-Plough, Aventis, Novartis, Pharmaxis, Boehringer Ingelheim, AstraZeneca, Johnson & Johnson, Xyzal, Alcon, Centocor, Sepracor, UCB, Amgen, Capnia, and IVAX. S. Tilles is a speaker for Alcon; is on the advisory board for ALK, Ista, Merck, and Stallergenes; has received research support from Alcon, Amgen, Amphastar, Astellas, Boehringer Ingelheim, Ception, Genentech, Icagen, MAP Pharma, MEDA, Merck, Novartis, Roxane, and Sepracor; is Associate Editor of Allergy Watch and Annals of Allergy; and is a task force member for the Joint Task Force for Practice Parameters. D. Wallace is a speaker and advisor for Alcon, is a speaker for Merck and Sanofi-Aventis, and is President-Elect of the ACAAI. The rest of the authors have declared that they have no conflict of interest.	Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Abramson MJ, 2010, COCHRANE DB SYST REV, V8, DOI DOI 10.1002/14651858.CD001186.PUB2; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; [Anonymous], AM COLL MED QUAL POL; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; Andri L, 1996, J ALLERGY CLIN IMMUN, V97, P34, DOI 10.1016/S0091-6749(96)70280-4; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Antman Elliott M, 2004, Circulation, V110, P588, DOI 10.1161/01.CIR.0000134791.68010.FA; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Ariano R, 2006, ALLERGY ASTHMA PROC, V27, P159; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1051, DOI 10.1016/0091-6749(93)90219-6; Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; Asero R, 2004, INT ARCH ALLERGY IMM, V135, P332, DOI 10.1159/000082328; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P375; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; Bagg A, 2009, ANN ALLERG ASTHMA IM, V102, P400, DOI 10.1016/S1081-1206(10)60511-X; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BENITAH E, 1986, THERAPIE, V41, P139; BERCHTOLD E, 1992, CLIN EXP ALLERGY, V22, P59, DOI 10.1111/j.1365-2222.1992.tb00115.x; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; Bernstein DI, 2010, ANN ALLERG ASTHMA IM, V104, P530, DOI 10.1016/j.anai.2010.04.008; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; Black JH, 1929, J ALLERGY, V1, P71, DOI 10.1016/S0021-8707(29)90084-8; Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bonadonna P, 2009, J ALLERGY CLIN IMMUN, V123, pS242, DOI 10.1016/j.jaci.2008.12.935; Bonno M, 1996, J ALLERGY CLIN IMMUN, V97, P680, DOI 10.1016/S0091-6749(96)70314-7; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Bussmann C, 2007, CLIN EXP ALLERGY, V37, P1277, DOI 10.1111/j.1365-2222.2007.02783.x; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; Calabria CW, 2008, J ALLERGY CLIN IMMUN, V121, P222, DOI 10.1016/j.jaci.2007.08.016; Calabria CW, 2009, J ALLERGY CLIN IMMUN, V124, P739, DOI 10.1016/j.jaci.2009.07.048; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Cantani A, 2000, Eur Rev Med Pharmacol Sci, V4, P139; Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Casale TB, 2008, J ALLERGY CLIN IMMUN, V121, P288, DOI 10.1016/j.jaci.2007.11.040; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Centers for Disease Control and Prevention, 2006, MMWR-MORBID MORTAL W, V55, P14; Cochard MM, 2009, J ALLERGY CLIN IMMUN, V124, P378, DOI 10.1016/j.jaci.2009.04.040; Moncayo Coello CV, 2003, REV ALERG MEX, V50, P170; Confino-Cohen R, 2010, ANN ALLERG ASTHMA IM, V104, P73, DOI 10.1016/j.anai.2009.11.001; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; Coop CA, 2008, ANN ALLERG ASTHMA IM, V101, P96, DOI 10.1016/S1081-1206(10)60841-1; CORNAILLE G, 1985, PRESSE MED, V14, P790; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2008, J ALLERGY CLIN IMMUN, V122, P432, DOI 10.1016/j.jaci.2008.06.007; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Cox L, 2007, ANN ALLERG ASTHMA IM, V98, P416; Cox Linda, 2005, Expert Rev Clin Immunol, V1, P579, DOI 10.1586/1744666X.1.4.579; Cox L, 2010, J ALLERGY CLIN IMMUN, V125, P569, DOI 10.1016/j.jaci.2009.10.060; Cox L, 2009, ANN ALLERG ASTHMA IM, V103, P451, DOI 10.1016/S1081-1206(10)60259-1; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; DaVeiga SP, 2008, J ALLERGY CLIN IMMUN, V121, pS124, DOI 10.1016/j.jaci.2007.12.495; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dietrich JJ, 2009, ANN ALLERG ASTHMA IM, V103, P535, DOI 10.1016/S1081-1206(10)60271-2; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V101, P855, DOI 10.1016/S0091-6749(98)70318-5; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Enrique E, 2008, ANN ALLERG ASTHMA IM, V100, P283, DOI 10.1016/S1081-1206(10)60456-5; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; ESCH RE, 1992, ARB PEI GSH, V85, P171; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Esch RE, 2003, ARB P EHRLICH I BUND, V94, P17; Esch RE, 2008, J ALLERGY CLIN IMMUN, V122, P659, DOI 10.1016/j.jaci.2008.07.018; Escudero A I, 1993, Allergol Immunopathol (Madr), V21, P153; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Eusebius NP, 2002, INT ARCH ALLERGY IMM, V127, P234, DOI 10.1159/000053868; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; Fass PT, 2008, J ALLERGY CLIN IMMUN, V121, P269, DOI 10.1016/j.jaci.2007.10.030; Fernandez-Melendez S, 2007, J INVEST ALLERG CLIN, V17, P48; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Finegold I, 2007, ALLERGY ASTHMA PROC, V28, P698, DOI [10.2500/aap.2007.28.3053, 10.2500/aap2007.28.3053]; Flicker S, 2009, J ALLERGY CLIN IMMUN, V124, P1358, DOI 10.1016/j.jaci.2009.09.024; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANKLIN W, 1967, J AMER MED ASSOC, V201, P915, DOI 10.1001/jama.201.12.915; Freeman J, 1911, LANCET, V2, P814; Freeman J, 1930, LANCET, V1, P744; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; FRISHMAN WH, 1988, MED CLIN N AM, V72, pR9; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259; Galera C, 2009, J INVEST ALLERG CLIN, V19, P225; Gastaminza G, 2003, CLIN EXP ALLERGY, V33, P470, DOI 10.1046/j.1365-2222.2003.01644.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; GLOVSKY MM, 1991, ANN ALLERGY, V67, P21; Goldberg A, 2003, ANN ALLERG ASTHMA IM, V91, P405; GOLDBERG A, 1988, ANN ALLERGY, V61, P177; Goldberg A, 2001, J ALLERGY CLIN IMMUN, V107, P902, DOI 10.1067/mai.2001.114986; Goldberg A, 1997, J ALLERGY CLIN IMMUN, V100, P182, DOI 10.1016/S0091-6749(97)70222-7; Goldberg A, 2007, ANN ALLERG ASTHMA IM, V99, P352; Golden DBK, 2009, J ALLERGY CLIN IMMUN, V123, P1371, DOI 10.1016/j.jaci.2009.03.017; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI 10.1067/mai.2003.1606; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOMEZ J, 1989, J ASTHMA, V26, P243, DOI 10.3109/02770908909073256; GONZALEZ RM, 1987, ANN ALLERGY, V59, P149; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENBERG MA, 1988, J ALLERGY CLIN IMMUN, V82, P287, DOI 10.1016/0091-6749(88)91013-5; GREENBERGER PA, 1987, J ALLERGY CLIN IMMUN, V80, P698, DOI 10.1016/0091-6749(87)90290-9; GREENERT S, 1971, LANCET, V2, P1121; Grier TJ, 2007, ANN ALLERG ASTHMA IM, V99, P151; Grier TJ, 2009, ANN ALLERG ASTHMA IM, V103, P411, DOI 10.1016/S1081-1206(10)60361-4; Guardia P, 2004, Allergol Immunopathol (Madr), V32, P271, DOI 10.1157/13066304; Guarneri F, 2007, J ALLERGY CLIN IMMUN, V119, P512, DOI 10.1016/j.jaci.2006.10.010; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Hankin CS, 2010, ANN ALLERG ASTHMA IM, V104, P79, DOI 10.1016/j.anai.2009.11.010; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Harvey SM, 2004, ANN ALLERG ASTHMA IM, V92, P414; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Hollister-Stier, 2005, INSTRUCTIONS DOSAGE; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; Inal A, 2007, J INVEST ALLERG CLIN, V17, P85; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Jacobsen L, 2001, ANN ALLERG ASTHMA IM, V87, P43; Javeed N, 1996, CATHETER CARDIO DIAG, V39, P383, DOI 10.1002/(SICI)1097-0304(199612)39:4<383::AID-CCD13>3.0.CO;2-E; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Joint Commission on Accreditation of Healthcare Organizations, 2010, NAT PAT SAF GOALS; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; JUNG CM, 1995, J ALLERGY CLIN IMMUN, V95, P77, DOI 10.1016/S0091-6749(95)70155-9; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 1995, CLIN EXP ALLERGY, V25, P1205, DOI 10.1111/j.1365-2222.1995.tb03044.x; KANG BC, 1988, J ASTHMA, V25, P205; Kanter L, 2006, ANN ALLERG ASTHMA IM, V97, P7; Kanter LJ, 2003, ANN ALLERG ASTHMA IM, V90, P389; Kao N, 2000, ANN ALLERG ASTHMA IM, V84, P273, DOI 10.1016/S1081-1206(10)62769-X; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Karl S, 1988, Z Hautkr, V63 Suppl 4, P55; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; Katial RK, 1997, ANN ALLERG ASTHMA IM, V79, P340; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Kelso JM, 2004, ANN ALLERG ASTHMA IM, V92, P225; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; KERNERMAN SM, 1992, ANN ALLERGY, V69, P493; Kerzl R, 2007, J ALLERGY CLIN IMMUN, V119, P507, DOI 10.1016/j.jaci.2006.09.041; KIVITY S, 1990, J ALLERGY CLIN IMMUN, V85, P669, DOI 10.1016/0091-6749(90)90111-G; KOCHUYT AM, 1994, CLIN EXP ALLERGY, V24, P35, DOI 10.1111/j.1365-2222.1994.tb00914.x; Kohno Y, 1998, J ALLERGY CLIN IMMUN, V102, P927, DOI 10.1016/S0091-6749(98)70330-6; Kontou-Fili K, 2008, ALLERGY, V63, P376, DOI 10.1111/j.1398-9995.2007.01604.x; Kontou-Fili K, 2009, ALLERGY, V64, P1384, DOI 10.1111/j.1398-9995.2009.02045.x; Kopp MV, 2002, J ALLERGY CLIN IMMUN, V110, P728, DOI 10.1067/mai.128804; KORDASH TR, 1993, ANN ALLERGY, V71, P240; Koskela H, 2003, CHEST, V124, P383, DOI 10.1378/chest.124.1.383; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; La Shell MS, 2010, J ALLERGY CLIN IMMUN, V125, P1294, DOI 10.1016/j.jaci.2010.02.041; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; Lang DM, 2008, CURR ALLERGY ASTHM R, V8, P37, DOI 10.1007/s11882-008-0008-8; LANG DM, 1991, ANN INTERN MED, V115, P270; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; Larenas-Linnemann D, 2008, CURR ALLERGY ASTHM R, V8, P465, DOI 10.1007/s11882-008-0087-6; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; Lay PC, 2007, OTOLARYNG HEAD NECK, V137, P243, DOI 10.1016/j.otohns.2007.02.012; Lay P Chase, 2008, Otolaryngol Head Neck Surg, V139, P364, DOI 10.1016/j.otohns.2008.06.016; LEAVENGOOD DC, 1985, J ALLERGY CLIN IMMUN, V76, P789, DOI 10.1016/0091-6749(85)90749-3; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606; Lewis W. H., 1983, AIRBORNE ALLERGENIC; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1972, INT ARCH ALLER A IMM, V42, P615; Lieberman P, 2010, J ALLERGY CLIN IMMUN, V126, P477, DOI 10.1016/j.jaci.2010.06.022; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; LIN MS, 1993, ANN ALLERGY, V71, P557; Lin SY, 2008, OTOLARYNG HEAD NECK, V139, P5, DOI 10.1016/j.otohns.2008.04.012; Lin SY, 2008, OTOLARYNG HEAD NECK, V139, P195, DOI 10.1016/j.otohns.2008.05.013; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; Lockey R, 2003, MIDDLETONS ALLERGY P, P573; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; Lombardi C, 2009, ALLERGY, V64, P849, DOI 10.1111/j.1398-9995.2009.02063.x; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; LOWENSTEIN H, 1980, ALLERGY, V35, P188, DOI 10.1111/j.1398-9995.1980.tb01739.x; LOWENSTEIN H, 1983, J IMMUNOL, V130, P727; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; Lowenstein H, 1983, 11 INT C ALL CLIN IM, P545; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206; Marshall GD, 1999, ALLERGY ASTHMA PROC, V20, P301, DOI 10.2500/108854199778251979; MARTIN BG, 1985, ANN ALLERGY, V54, P99; Martinez-Canavate A, 2005, Allergol Immunopathol (Madr), V33, P138, DOI 10.1157/13075696; Massanari M, 2010, J ALLERGY CLIN IMMUN, V125, P383, DOI 10.1016/j.jaci.2009.11.022; MATLOFF SM, 1993, ALLERGY PROC, V14, P347, DOI 10.2500/108854193778774001; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; Michils A, 1998, J ALLERGY CLIN IMMUN, V102, P118, DOI 10.1016/S0091-6749(98)70062-4; MILLER DL, 1971, ANN ALLERGY, V29, P178; Miller JD, 2007, J ALLERGY CLIN IMMUN, V119, P512, DOI 10.1016/j.jaci.2006.09.015; Modrzynski Marek, 2003, Przegl Lek, V60, P130; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Montgomery JR, 2008, ALLERGY ASTHMA PROC, V29, P425, DOI 10.2500/aap.2008.29.3142; Moore M, 2010, ANN ALLERG ASTHMA IM, V104, P147, DOI 10.1016/j.anai.2009.11.037; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Muller UR, 2009, CLIN EXP ALLERGY, V39, P620, DOI 10.1111/j.1365-2222.2009.03251.x; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Muller Ulrich, 2008, Clin Allergy Immunol, V21, P377; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jsci.2004.11.012, 10.1016/j.jaci.2004.11.012]; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Narisety SD, 2009, J ALLERGY CLIN IMMUN, V124, P610, DOI 10.1016/j.jaci.2009.06.025; NELSON BL, 1986, ANN ALLERGY, V56, P331; Nelson HS, 2009, J ALLERGY CLIN IMMUN, V123, P763, DOI 10.1016/j.jaci.2008.12.013; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Niemeijer NR, 1996, ANN ALLERG ASTHMA IM, V76, P535; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; NISAM MR, 1978, J APPL PHYSIOL, V44, P455; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Novak N, 2007, CURR OPIN ALLERGY CL, V7, P542; Ober AI, 2003, J ALLERGY CLIN IMMUN, V112, P1008, DOI 10.1067/mai.2003.1746; ODEH M, 1991, J FAM PRACTICE, V32, P97; Ohashi Y, 1998, ARCH OTOLARYNGOL, V124, P1337; Ohashi Yoshihiro, 2006, Ann Allergy Asthma Immunol, V96, P600; OHMAN JL, 1976, CLIN ALLERGY, V6, P419, DOI 10.1111/j.1365-2222.1976.tb01926.x; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1987, CLIN REV ALLERG, V5, P37; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; Ott H, 2009, ALLERGY, V64, P179, DOI 10.1111/j.1398-9995.2008.01875.x; Pajno GB, 2005, J ALLERGY CLIN IMMUN, V116, P1380, DOI 10.1016/j.jaci.2005.07.034; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Parmiani S, 2002, Allergol Immunopathol (Madr), V30, P283; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Rodriguez Perez N, 2006, REV ALERG MEX, V53, P47; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Pfaar O, 2009, CURR OPIN ALLERGY CL, V9, P208, DOI 10.1097/ACI.0b013e32832aef57; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Pilette C, 2007, J IMMUNOL, V178, P4658; Plewako H, 2004, CLIN EXP ALLERGY, V34, P1862, DOI 10.1111/j.1365-2222.2004.02120.x; Pollack Chalres V. Jr., 1993, Journal of Emergency Medicine, V11, P195, DOI 10.1016/0736-4679(93)90519-D; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; Pomes Anna, 2008, Clin Allergy Immunol, V21, P183; PORTNOY J, 1992, ANN ALLERGY, V68, P493; PORTNOY J, 1994, ANN ALLERGY, V73, P409; Portnoy JM, 2001, ANN ALLERG ASTHMA IM, V87, P28; PRIGAL SJ, 1972, ANN ALLERGY, V30, P529; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; Ragusa VF, 2004, ALLERG IMMUNOL PARIS, V36, P52; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; Rance F, 2000, Allerg Immunol (Paris), V32, P366; Randhawa I, 2007, ANN ALLERG ASTHMA IM, V98, pA74; Rank MA, 2008, ALLERGY ASTHMA PROC, V29, P400, DOI 10.2500/aap.2008.29.3141; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Reimers A, 2000, ALLERGY, V55, P484, DOI 10.1034/j.1398-9995.2000.00520.x; REISMAN RE, 1994, NEW ENGL J MED, V331, P523, DOI 10.1056/NEJM199408253310808; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; REISMAN RE, 1992, J ALLERGY CLIN IMMUN, V89, P1189, DOI 10.1016/0091-6749(92)90304-K; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Roll A, 2006, J INVEST ALLERG CLIN, V16, P79; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; Roy SR, 2007, ANN ALLERG ASTHMA IM, V99, P82; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; Rueff F, 2010, J ALLERGY CLIN IMMUN, V126, P105, DOI 10.1016/j.jaci.2010.04.025; Rueff F, 2009, J ALLERGY CLIN IMMUN, V124, P1047, DOI 10.1016/j.jaci.2009.08.027; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; Schiavino D, 2004, ANN ALLERG ASTHMA IM, V92, P409; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; Schulze J, 2007, ALLERGY, V62, P963, DOI 10.1111/j.1398-9995.2007.01388.x; SCHWARTZ HJ, 1990, J ALLERGY CLIN IMMUN, V85, P709, DOI 10.1016/0091-6749(90)90188-A; Scranton SE, 2009, J ALLERGY CLIN IMMUN, V123, P493, DOI 10.1016/j.jaci.2008.10.026; Senti G, 2009, J ALLERGY CLIN IMMUN, V124, P997, DOI 10.1016/j.jaci.2009.07.019; Senti G, 2008, P NATL ACAD SCI USA, V105, P17908, DOI 10.1073/pnas.0803725105; Serrano P, 2009, ANN ALLERG ASTHMA IM, V102, P247, DOI 10.1016/S1081-1206(10)60088-9; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; SHAIKH WA, 1993, CLIN EXP ALLERGY, V23, P857, DOI 10.1111/j.1365-2222.1993.tb00264.x; Sharkey P, 1996, ANN ALLERG ASTHMA IM, V76, P175; Sharma HP, 2008, J ALLERGY CLIN IMMUN, V121, P933, DOI 10.1016/j.jaci.2008.01.023; Shekelle PG, 1999, BRIT MED J, V318, P593; Simons F Estelle R, 2005, J Allergy Clin Immunol, V115, P640; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Slater JE, 2007, CLIN EXP ALLERGY, V37, P1033, DOI 10.1111/j.1365-2222.2007.02751.x; Slater Jay E, 2008, Clin Allergy Immunol, V21, P273; SMITH PL, 1980, J CLIN INVEST, V66, P1072, DOI 10.1172/JCI109936; Solley GO, 2002, MED J AUSTRALIA, V176, P521; SRIDHARA S, 1992, ASIAN PAC J ALLERGY, V10, P33; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; STANALAND BE, 1994, J ALLERGY CLIN IMMUN, V94, P452, DOI 10.1016/0091-6749(94)90200-3; Steiner Urs C, 2009, World Allergy Organ J, V2, P57, DOI 10.1097/WOX.0b013e31819bcae7; Swedberg K, 2005, EUR HEART J, V26, P1115, DOI 10.1093/eurheartj/ehi204; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tabar AI, 2004, J INVEST ALLERG CLIN, V14, P193; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; Teuber Suzanne S, 2003, Curr Opin Allergy Clin Immunol, V3, P217, DOI 10.1097/00130832-200306000-00011; The discontinuation of Hymenoptera venom immunotherapy, 1998, J ALLERGY CLIN IMMUN, V101, P573; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Till Stephen J, 2004, Clin Allergy Immunol, V18, P85; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477; Tucker MH, 2008, ANN ALLERG ASTHMA IM, V101, P419, DOI 10.1016/S1081-1206(10)60320-1; TUNONDELARA JM, 1992, LANCET, V340, P908, DOI 10.1016/0140-6736(92)93314-D; Turkeltaub PC, 1988, ALLERGY PRINCIPLES P, P388; Tversky JR, 2010, CLIN EXP ALLERGY, V40, P94, DOI 10.1111/j.1365-2222.2009.03388.x; [Anonymous], 2008, USP 797 GUID PHARM C; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; VALENTINE MD, 1993, ANN ALLERGY, V70, P427; VALENTINE MD, 1984, J ALLERGY CLIN IMMUN, V73, P299, DOI 10.1016/0091-6749(84)90397-X; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; VANBEVER HP, 1988, ALLERGY, V43, P378; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VanMetre TE, 1996, J ALLERGY CLIN IMMUN, V97, P1033, DOI 10.1016/S0091-6749(96)70254-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Varshney P, 2009, J ALLERGY CLIN IMMUN, V124, P1351, DOI 10.1016/j.jaci.2009.09.042; VIJAY HM, 1987, INT ARCH ALLER A IMM, V83, P325; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Waibel KH, 2006, J ALLERGY CLIN IMMUN, V118, P525, DOI 10.1016/j.jaci.2006.04.008; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; WANTKE F, 1993, CLIN EXP ALLERGY, V23, P992, DOI 10.1111/j.1365-2222.1993.tb00289.x; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WEBER RW, 1984, ANN ALLERGY, V52, P226; WEBER RW, 1987, ANN ALLERGY, V58, P287; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425; White KM, 2008, ANN ALLERG ASTHMA IM, V101, P426, DOI 10.1016/S1081-1206(10)60321-3; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Windom HH, 2008, CURR OPIN ALLERGY CL, V8, P571, DOI 10.1097/ACI.0b013e32831845fb; Winther L, 2006, CLIN EXP ALLERGY, V36, P254, DOI 10.1111/j.1365-2222.2006.02340.; Wohrl S, 2007, INT ARCH ALLERGY IMM, V144, P137, DOI 10.1159/000103225; Wolf BL, 2006, ANN ALLERG ASTHMA IM, V97, P52; Wong S S Y, 2005, Hong Kong Med J, V11, P131; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; YOO TJ, 1975, ANN ALLERGY, V34, P87; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; ZALOGA GP, 1986, ANN INTERN MED, V105, P65; ZETTERST.O, 1972, ACTA ALLERGOL, V27, P15, DOI 10.1111/j.1398-9995.1972.tb01638.x; Zhang L, 2009, INT ARCH ALLERGY IMM, V148, P161, DOI 10.1159/000155747; [Anonymous], 2006, AAAAI ACAD NEWS  MAY; [Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; [Anonymous], 1998, ANN ALLERGY ASTHMA I, V81, P101; [Anonymous], 1998, ALLERGY, V53, P1	475	349	367	5	46	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN 11	2011	127	1		1						10.1016/j.jaci.2010.09.034		55	Allergy; Immunology	Allergy; Immunology	700XW	WOS:000285779900001	21122901	
J	Kasprzak, KS; Sunderman, FW; Salnikow, K				Kasprzak, Kazimierz S.; Sunderman, F. William, Jr.; Salnikow, Konstantin			Nickel carcinogenesis	MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS			English	Review						Nickel carcinogenesis; Epigenetic toxicity; Genotoxicity; Histones; Hypoxia; Oxidative damage		Human exposure to highly nickel-polluted environments, such as those associated with nickel refining, electroplating, and welding, has the potential to produce a variety of pathologic effects. Among them are skin allergies, lung fibrosis, and cancer of the respiratory tract. The exact mechanisms of nickel-induced carcinogenesis are not known and have been the subject of numerous epidemiologic and experimental investigations. These mechanisms are likely to involve genetic and epigenetic routes. The present review provides evidence for the genotoxic and mutagenic activity of Ni(II) particularly at high doses. Such doses are best delivered into the cells by phagocytosis of sparingly soluble nickel-containing dust particles. Ni(II) genotoxicity may be aggravated through the generation of DNA-damaging reactive oxygen species (ROS) and the inhibition of DNA repair by this metal. Broad spectrum of epigenetic effects of nickel includes alteration in gene expression resulting from DNA hypermethylation and histone hypoacetylation, as well as activation or silencing of certain genes and transcription factors, especially those involved in cellular response to hypoxia. The investigations of the pathogenic effects of nickel greatly benefit from the understanding of the chemical basis of Ni(II) interactions with intracellular targets/ligands and oxidants. Many pathogenic effects of nickel are due to the interference with the metabolism of essential metals such as Fe(II), Mn(II), Ca(II), Zn(II), or Mg(II). Research in this field allows for identification of putative Ni(II) targets relevant to carcinogenesis and prediction of pathogenic effects caused by exposure to nickel. Ultimately, the investigations of nickel carcinogenesis should be aimed at the development of treatments that would inhibit or prevent Ni(II) interactions with critical target molecules and ions, Fe(II) in particular, and thus avert the respiratory tract cancer and other adverse health effects in nickel workers. (C) 2003 Elsevier B.V. All rights reserved.	[Kasprzak, Kazimierz S.; Salnikow, Konstantin] NCI, Comparat Carcinogenesis Lab, Ft Detrick, MD 21702 USA; [Sunderman, F. William, Jr.] Univ Vermont, Dept Pathol, Coll Med, Burlington, VT 05401 USA	Kasprzak, KS (reprint author), NCI, Comparat Carcinogenesis Lab, Ft Detrick, MD 21702 USA.	kasprkaz@mail.ncifcrf.gov					ABDULWAJID AW, 1983, P NATL ACAD SCI-BIOL, V80, P4509, DOI 10.1073/pnas.80.14.4509; ALBERT DM, 1982, INVEST OPHTH VIS SCI, V22, P768; An WG, 1998, NATURE, V392, P405; ANTONIJCZUK K, 1995, BBA-PROTEIN STRUCT M, V1247, P81, DOI 10.1016/0167-4838(94)00210-8; ARROUIJAL FZ, 1990, MUTAGENESIS, V5, P583, DOI 10.1093/mutage/5.6.583; ASATO N, 1975, CLIN CHEM, V21, P521; Ausio J, 2002, BIOCHEMISTRY-US, V41, P5945, DOI 10.1021/bi020059d; AVERY JK, 1986, BIOCOMPATIBILITY TOX, P262; AZULA FJ, 1993, AM J PHYSIOL, V265, pC1681; Berufkrebs E.W. Baader, 1937, NEU ERGEB GEB KREBSK, V1, P104; Bal W, 1999, ARCH BIOCHEM BIOPHYS, V364, P161, DOI 10.1006/abbi.1999.1137; Bal W, 2000, CHEM RES TOXICOL, V13, P823, DOI 10.1021/tx000060i; Bal W, 1997, CHEM RES TOXICOL, V10, P906, DOI 10.1021/tx970028x; Bal W, 1998, CHEM RES TOXICOL, V11, P1014, DOI 10.1021/tx980051y; Bal W, 1997, CHEM RES TOXICOL, V10, P915, DOI 10.1021/tx970029p; Bal W, 1998, J INORG BIOCHEM, V70, P33, DOI 10.1016/S0162-0134(98)00010-5; Bal W, 2000, J INORG BIOCHEM, V79, P213, DOI 10.1016/S0162-0134(99)00169-5; BAL W, 1995, CHEM RES TOXICOL, V8, P683, DOI 10.1021/tx00047a007; Bal W, 2000, CHEM RES TOXICOL, V13, P616, DOI 10.1021/tx0000441; Bal WC, 2003, CHEM RES TOXICOL, V16, P242, DOI 10.1021/tx025639q; Barceloux DG, 1999, J TOXICOL-CLIN TOXIC, V37, P239; BAUMAN JW, 1993, FUND APPL TOXICOL, V21, P15, DOI 10.1006/faat.1993.1066; BERG JM, 1986, SCIENCE, V232, P485, DOI 10.1126/science.2421409; BERGELSON S, 1994, CANCER RES, V54, P36; BIEDERMANN KA, 1987, CANCER RES, V47, P3815; BIGGART NW, 1987, J VIROL, V61, P2378; BIGGART NW, 1986, MUTAT RES, V175, P209, DOI 10.1016/0165-7992(86)90056-4; Broday L, 2000, CANCER RES, V60, P238; BRYAN SE, 1981, METAL IONS GENETIC I, P87; Burns LG, 1997, BBA-GENE STRUCT EXPR, V1350, P159; Burrows CJ, 1998, CHEM REV, V98, P1109, DOI 10.1021/cr960421s; BURTAYRE P, 1984, IARC SCI PUBL, V53, P227; Buzard Gregory S., 2000, Journal of Environmental Pathology Toxicology and Oncology, V19, P179; Cai Ying, 1999, Zhonghua Yufang Yixue Zazhi, V33, P75; CALLAN WM, 1973, RES COMMUN CHEM PATH, V5, P459; Campbell J A, 1943, Br Med J, V1, P179; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Cheng RYS, 2003, TOXICOL APPL PHARM, V191, P22, DOI 10.1016/S0041-008X(03)00228-X; Chesney J, 1999, P NATL ACAD SCI USA, V96, P3047, DOI 10.1073/pnas.96.6.3047; CHIOCCA SM, 1991, MOL CARCINOGEN, V4, P61, DOI 10.1002/mc.2940040110; CHRISTIE NT, 1992, NICKEL HUMAN HLTH CU, P305; CONWAY K, 1989, CANCER RES, V49, P6032; COOGAN TP, 1989, CRIT REV TOXICOL, V19, P341, DOI 10.3109/10408448909029327; COSTA D, 1989, TOXICOL IND HEALTH, V5, P1079; COSTA M, 1979, CANCER RES, V39, P3591; Costa M, 2001, MOL CELL BIOCHEM, V222, P205, DOI 10.1023/A:1017978500031; COSTA M, 1981, TOXICOL APPL PHARM, V60, P313, DOI 10.1016/0041-008X(91)90234-6; COSTA M, 1981, CANCER RES, V41, P2868; COSTA M, 1980, SCIENCE, V209, P515, DOI 10.1126/science.7394519; Costa M, 1996, TOXICOLOGY METALS, P245; Crowe J, 1994, Methods Mol Biol, V31, P371; Dally H, 1997, CARCINOGENESIS, V18, P1021, DOI 10.1093/carcin/18.5.1021; DAMJANOV I, 1978, CANCER RES, V38, P268; DANIEL MR, 1966, BRIT J CANCER, V20, P886, DOI 10.1038/bjc.1966.102; DECSY MI, 1974, BIOINORG CHEM, V3, P87; Denkhaus E, 2002, CRIT REV ONCOL HEMAT, V42, P35, DOI 10.1016/S1040-8428(01)00214-1; DIPAOLO JA, 1979, CANCER RES, V39, P1008; DIWAN BA, 1992, CARCINOGENESIS, V13, P1351, DOI 10.1093/carcin/13.8.1351; DIZDAROGLU M, 1994, METHOD ENZYMOL, V234, P3; Doll R, 1990, SCAND J WORK ENV HEA, V16, P9; Donaldson LW, 2001, J AM CHEM SOC, V123, P9843, DOI 10.1021/ja011241p; DUBINS JS, 1986, MUTAT RES, V162, P187, DOI 10.1016/0027-5107(86)90085-0; DUNNICK JK, 1995, CANCER RES, V55, P5251; Eitinger T, 2000, ARCH MICROBIOL, V173, P1, DOI 10.1007/s002030050001; EVANS RM, 1982, CANCER RES, V42, P2729; FELL GS, 1986, LANCET, V2, P467; FISHER GL, 1986, ENVIRON RES, V40, P313, DOI 10.1016/S0013-9351(86)80106-2; FLETCHER GG, 1994, ENVIRON HEALTH PERSP, V102, P69, DOI 10.2307/3431766; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOULKES EC, 1986, TOXICOLOGY, V38, P35, DOI 10.1016/0300-483X(86)90170-8; Funakoshi T, 1997, TOXICOLOGY, V124, P21, DOI 10.1016/S0300-483X(97)00131-5; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Ghio AJ, 1998, TOXICOL PATHOL, V26, P388; GILMAN JPW, 1962, CANCER RES, V22, P158; GLENNON JD, 1982, BIOCHEM J, V203, P15; GOEBELER M, 1993, J INVEST DERMATOL, V100, P759, DOI 10.1111/1523-1747.ep12476328; GOEBELER M, 1995, J IMMUNOL, V155, P2459; GORDON PM, 1994, CONTACT DERMATITIS, V30, P181, DOI 10.1111/j.1600-0536.1994.tb00709.x; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Grandjean P, 1983, IARC SCI PUBL, V53, P469; Graven K. K., 1998, AM J PHYSIOL, V274, P347; GRBACIVANKOVIC S, 1994, MOL REPROD DEV, V38, P256, DOI 10.1002/mrd.1080380305; Grimsrud TK, 2003, J ENVIRON MONITOR, V5, P190, DOI 10.1039/b211722n; GROLLMAN AP, 1993, TRENDS GENET, V9, P246, DOI 10.1016/0168-9525(93)90089-Z; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; HANSEN K, 1983, ENVIRON HEALTH PERSP, V51, P223, DOI 10.2307/3429753; HARFORD C, 1995, BIOCHEM BIOPH RES CO, V209, P877, DOI 10.1006/bbrc.1995.1580; HARTWIG A, 1994, CANCER RES, V54, P4045; Hartwig A, 2002, ENVIRON HEALTH PERSP, V110, P797; Hartwig A, 2002, FOOD CHEM TOXICOL, V40, P1179, DOI 10.1016/S0278-6915(02)00043-1; HARTWIG A, 1995, BIOMETALS, V8, P3; HARTWIG A, 1998, TOXICOL LETT, V235, P102; Harty LC, 1996, CANCER EPIDEM BIOMAR, V5, P997; HAUGEN A, 1989, BIOL TRACE ELEM RES, V21, P451, DOI 10.1007/BF02917288; Hausinger R.P., 1993, BIOCH NICKEL; HECK JD, 1982, CANCER LETT, V15, P19, DOI 10.1016/0304-3835(82)90071-4; HERLANTPEERS MC, 1983, CARCINOGENESIS, V4, P387; Hernandez-Boussard T, 1999, HUM MUTAT, V14, P1; HERRERO MC, 1993, RES COMMUN CHEM PATH, V79, P243; HIGINBOTHAM KG, 1992, CANCER RES, V52, P4747; HILDEBRAND HF, 1979, EUR J CELL BIOL, V19, P276; HOPFER SM, 1985, TRACE ELEM MED, V2, P68; HORAK E, 1978, ANN CLIN LAB SCI, V8, P476; HOSTYNEK JJ, 2002, NICKEL SKIN, P1; HUANG X, 1995, CARCINOGENESIS, V16, P1753, DOI 10.1093/carcin/16.8.1753; HUANG X, 1994, CARCINOGENESIS, V15, P545, DOI 10.1093/carcin/15.3.545; Hughes K, 1995, REGUL TOXICOL PHARM, V22, P213, DOI 10.1006/rtph.1995.0003; International Agency for Research on Cancer, 1990, IARC MON EV CARC RIS, V49, P257; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iwitzki F, 1998, ARCH TOXICOL, V72, P681, DOI 10.1007/s002040050561; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; JASMIN G, 1975, P SOC EXP BIOL MED, V148, P774; JASMIN G, 1976, LAB INVEST, V35, P71; Jasmin G, 1977, Adv Exp Med Biol, V91, P69; Jewell UR, 2001, FASEB J, V15, P1312; KARGACIN B, 1993, MUTAT RES, V300, P63, DOI 10.1016/0165-1218(93)90141-Y; KASPRZACK KS, 1992, NICKEL HUMAN HLTH CU, P545; Kasprzak K. S., 1986, Essential nutrients in carcinogenesis, P497; KASPRZAK KS, 1989, CANCER RES, V49, P5964; KASPRZAK KS, 1991, CHEM RES TOXICOL, V4, P604, DOI 10.1021/tx00024a002; KASPRZAK KS, 1988, TOXICOLOGY, V52, P253, DOI 10.1016/0300-483X(88)90130-8; KASPRZAK KS, 1990, CARCINOGENESIS, V11, P647, DOI 10.1093/carcin/11.4.647; KASPRZAK KS, 1973, RES COMMUN CHEM PATH, V6, P237; KASPRZAK KS, 1992, CHEM RES TOXICOL, V5, P809, DOI 10.1021/tx00030a013; Kasprzak KS, 2002, FREE RADICAL BIO MED, V32, P958, DOI 10.1016/S0891-5849(02)00809-2; KASPRZAK KS, 1994, TOXICOLOGY, V90, P129, DOI 10.1016/0300-483X(94)90211-9; KASPRZAK KS, 1987, CARCINOGENESIS, V8, P1005, DOI 10.1093/carcin/8.7.1005; KASPRZAK KS, 1995, CANCER INVEST, V13, P411, DOI 10.3109/07357909509031921; KASPRZAK KS, 1985, CARCINOGENESIS, V6, P1161, DOI 10.1093/carcin/6.8.1161; KASPRZAK KS, 1985, CARCINOGENESIS, V6, P1819, DOI 10.1093/carcin/6.12.1819; Kasprzak KS, 2000, J INORG BIOCHEM, V79, P231, DOI 10.1016/S0162-0134(99)00240-8; KASPRZAK KS, 1977, RES COMMUN CHEM PATH, V16, P95; KASPRZAK KS, 1986, TOXICOL APPL PHARM, V82, P336, DOI 10.1016/0041-008X(86)90210-3; KASPRZAK KS, 1983, CARCINOGENESIS, V4, P275, DOI 10.1093/carcin/4.3.275; KASPRZAK KS, 1989, CARCINOGENESIS, V10, P621, DOI 10.1093/carcin/10.3.621; KASPRZAK KS, 1969, TOXICOL APPL PHARM, V15, P295, DOI 10.1016/0041-008X(69)90030-1; Kasprzak KS, 1997, CARCINOGENESIS, V18, P271, DOI 10.1093/carcin/18.2.271; Kasprzak K. S., 1996, TOXICOLOGY METALS, P299; Kasprzak KS, 2000, MOL BIOL TOXICOLOGY, P477; KASPRZAK KS, 1991, TOXICOLOGIST, V11, P233; KASPRZAK KS, 1992, NICKEL HUMAN HLTH CU, P387; KAWANISHI S, 1989, CARCINOGENESIS, V10, P2231, DOI 10.1093/carcin/10.12.2231; Kawanishi S, 2001, FREE RADICAL BIO MED, V31, P108, DOI 10.1016/S0891-5849(01)00558-5; Kerckaert GA, 1996, FUND APPL TOXICOL, V34, P67, DOI 10.1006/faat.1996.0176; KLEIN CB, 1991, CHEM RES TOXICOL, V4, P592, DOI 10.1021/tx00024a001; Knopfel M, 2000, BIOPHYS J, V79, P874; KONDO K, 1995, BIOCHEM BIOPH RES CO, V216, P209, DOI 10.1006/bbrc.1995.2612; Kotyza J, 1998, BBA-PROTEIN STRUCT M, V1382, P266, DOI 10.1016/S0167-4838(97)00165-9; KOUZARIDES T, 1995, SEMIN CANCER BIOL, V6, P91, DOI 10.1006/scbi.1995.0012; Kowara R, 2002, CHEM RES TOXICOL, V15, P319, DOI 10.1021/tx010112j; KOWARA R, MOL CELL BI IN PRESS; Krezel A, 2003, CHEM RES TOXICOL, V16, P855, DOI 10.1021/tx034012k; KUEHN K, 1982, J INORG BIOCHEM, V17, P29, DOI 10.1016/S0162-0134(00)80227-5; KUEHN K, 1982, CARCINOGENESIS, V3, P321, DOI 10.1093/carcin/3.3.321; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Landolph JR, 1999, MET IONS BIOL SYST, V36, P445; LAUSSAC JP, 1984, BIOCHEMISTRY-US, V23, P2832, DOI 10.1021/bi00307a046; LEACH CA, 1987, ANN CLIN LAB SCI, V17, P137; LEACH CN, 1985, NEW ENGL J MED, V313, P1232; LEE JE, 1982, BIOCHEMISTRY-US, V21, P771, DOI 10.1021/bi00533a030; Lee SH, 1999, BIOCHEM BIOPH RES CO, V258, P592, DOI 10.1006/bbrc.1999.0692; LEE WH, 1988, J CELL BIOCHEM, V38, P213, DOI 10.1002/jcb.240380309; LEE YW, 1995, MOL CELL BIOL, V15, P2547; Leonard A, 1986, MET IONS BIOL SYST, V20, P229; LI WD, 1993, TOXICOLOGY, V77, P65; Liang R, 1999, CARCINOGENESIS, V20, P893, DOI 10.1093/carcin/20.5.893; LIN XH, 1994, CANCER RES, V54, P2751; LIN XH, 1994, ENVIRON HEALTH PERSP, V102, P289, DOI 10.2307/3431804; Lloyd DR, 1998, CHEM RES TOXICOL, V11, P420, DOI 10.1021/tx970156l; LONGSTAFF A, 1984, IARC SCI PUBL, V53, P235; Luger K, 1997, NATURE, V389, P251; LUMB G, 1988, ANN CLIN LAB SCI, V18, P353; MAEHLE L, 1992, CANCER RES, V52, P218; MAENZA RM, 1971, CANCER RES, V31, P2067; Margerum D.W, 1988, BIOINORGANIC CHEM NI, P29; Mayer C, 1998, MUTAT RES-GEN TOX EN, V420, P85, DOI 10.1016/S1383-5718(98)00140-5; McDowell SA, 2000, AM J RESP CELL MOL, V23, P466; McGregor DB, 2000, EUR J CANCER, V36, P307, DOI 10.1016/S0959-8049(99)00312-3; McNeill LA, 2002, BIOCHEM J, V367, P571, DOI 10.1042/BJ20021162; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MEYER M, 1993, EMBO J, V12, P2005; MIKI H, 1987, CARCINOGENESIS, V8, P1757, DOI 10.1093/carcin/8.11.1757; Miller AC, 1998, ENVIRON HEALTH PERSP, V106, P465, DOI 10.1289/ehp.98106465; MISRA M, 1993, CHEM RES TOXICOL, V6, P33, DOI 10.1021/tx00031a005; MORRISON MK, 2003, BIOCHEMISTRY-US, V42, P9761; Muller-Fassbender M, 2003, TOXICOLOGY, V185, P141, DOI 10.1016/S0300-483X(02)00600-5; NACKERDIEN Z, 1991, CANCER RES, V51, P5837; NAKAMURO K, 1989, EISEI KAGAKU, V35, P19; Namiki A, 1995, J BIOL CHEM, V270, P31189; *NAS NICK, 1975, MED BIOL EFF ENV POL, P1; Nicotera P, 1998, CELL CALCIUM, V23, P173, DOI 10.1016/S0143-4160(98)90116-6; Nieboer E., 1992, NICKEL HUMAN HLTH; NIEBOER E, 1984, NICKEL HUMAN ENV, P321; NOMOTO S, 1971, BIOCHEMISTRY-US, V10, P1647; NOMOTO S, 1988, ANN CLIN LAB SCI, V18, P78; Norseth T, 1979, HDB TOXICOLOGY METAL, P541; Ohh M, 2000, NAT CELL BIOL, V2, P423; OKAMOTO M, 1987, CANCER RES, V47, P5213; Oller AR, 1997, TOXICOL APPL PHARM, V143, P152, DOI 10.1006/taap.1996.8075; ONKELINX C, 1973, RES COMMUN CHEM PATH, V6, P663; Oshiro S, 2002, BIOCHEM BIOPH RES CO, V290, P213, DOI 10.1006/bbrc.2001.6182; OSKARSSON A, 1979, ACTA PHARMACOL TOX, V45, P306; OSKARSSON A, 1979, CANCER RES, V39, P4175; OTTOLENGHI AD, 1975, J NATL CANCER I, V54, P1165; OZAKI T, 1995, CANCER RES, V55, P895; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; PARKER K, 1974, RES COMMUN CHEM PATH, V7, P755; PATIERNO SR, 1985, CANCER RES, V45, P5787; PATIERNO SR, 1993, MUTAT RES, V300, P179, DOI 10.1016/0165-1218(93)90049-J; PESKIN AV, 1986, FEBS LETT, V194, P317, DOI 10.1016/0014-5793(86)80109-0; PIKALEK P, 1983, FOLIA MICROBIOL, V28, P17, DOI 10.1007/BF02877379; POIRIER LA, 1984, CANCER RES, V44, P1520; Pott F., 1992, NICKEL HUMAN HLTH CU, P491; POZZAN T, 1994, PHYSIOL REV, V74, P595; PREDKI PF, 1992, BIOCHEM J, V287, P211; Ragsdale SW, 1998, CURR OPIN CHEM BIOL, V2, P208, DOI 10.1016/S1367-5931(98)80062-8; RANI AS, 1993, CARCINOGENESIS, V14, P947, DOI 10.1093/carcin/14.5.947; Refvik T., 1995, CARCINOGENESIS, V16, P1107; Requena JR, 2001, P NATL ACAD SCI USA, V98, P69, DOI 10.1073/pnas.011526698; RIVEDAL E, 1981, CANCER RES, V41, P2950; Rodriguez RE, 1996, TOXICOLOGY, V107, P131, DOI 10.1016/0300-483X(95)03251-A; RODRIGUEZ RE, 1991, TOXICOL LETT, V57, P269, DOI 10.1016/0378-4274(91)90201-G; RODRIGUEZARNAIZ R, 1986, MUTAT RES, V170, P115, DOI 10.1016/0165-1218(86)90023-6; Rokita SE, 2001, MET IONS BIOL SYST, V38, P289; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; ROSEN LB, 1995, ADV SEC MESS PHOSPH, V30, P225; ROSETTO FE, 1994, SCI TOTAL ENVIRON, V148, P201; ROSSETTO FE, 1994, J INORG BIOCHEM, V54, P167, DOI 10.1016/0162-0134(94)80011-1; SAHU R K, 1989, Molecular Toxicology, V2, P129; Sainte-Marie J, 1997, EUR J BIOCHEM, V250, P689, DOI 10.1111/j.1432-1033.1997.00689.x; SAKNYN AV, 1978, VOP ONKOL+, V24, P44; Salnikow K, 2003, CANCER RES, V63, P3524; Salnikow K, 1999, TOXICOL APPL PHARM, V160, P127, DOI 10.1006/taap.1999.8759; SALNIKOW K, 1994, CANCER RES, V54, P6407; Salnikow K, 2000, CANCER RES, V60, P3375; Salnikow K, 2002, ENVIRON HEALTH PERSP, V110, P831; Salnikow K, 1997, CANCER RES, V57, P5060; SALNIKOW K, 1994, MOL CELL BIOL, V14, P851; Salnikow K, 1999, CARCINOGENESIS, V20, P1819, DOI 10.1093/carcin/20.9.1819; Salnikow K, 2000, CANCER RES, V60, P38; SALNIKOW K, 2003, J ENVIRON MONITOR, V5, P1; SANO N, 1988, JPN J CANCER RES, V79, P212; Saplakoglu U, 1997, MUTAT RES-GEN TOX EN, V394, P133, DOI 10.1016/S1383-5718(97)00134-4; Savolainen H., 1996, Reviews on Environmental Health, V11, P167; SAXHOLM HJK, 1981, CANCER RES, V41, P4136; SCHAAPER RM, 1987, MUTAT RES, V177, P179, DOI 10.1016/0027-5107(87)90001-7; SCHAFER SG, 1983, ECOTOX ENVIRON SAFE, V7, P87, DOI 10.1016/0147-6513(83)90052-0; Schwerdtle T, 2002, CARCINOGENESIS, V23, P47, DOI 10.1093/carcin/23.1.47; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; SEN P, 1987, CANCER RES, V47, P2142; SEN P, 1985, CANCER RES, V7, P1527; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shiao YH, 1998, CARCINOGENESIS, V19, P1203, DOI 10.1093/carcin/19.7.1203; SHIBATA M, 1989, J PATHOL, V157, P263, DOI 10.1002/path.1711570314; Sigel H, 1974, J COORD CHEM, V3, P235, DOI 10.1080/00958977408073818; SIROVER MA, 1976, SCIENCE, V194, P1434, DOI 10.1126/science.1006310; SMITH JB, 1989, J BIOL CHEM, V264, P7115; SOLYMOSS B, 1978, EXP HEMATOL, V6, P43; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; STADTMAN ER, 1991, J BIOL CHEM, V266, P17201; STANDEVEN AM, 1991, CHEM RES TOXICOL, V4, P616, DOI 10.1021/tx00024a003; STONER GD, 1976, CANCER RES, V36, P1744; SUNDERMAN F W, 1959, AMA Arch Ind Health, V20, P36; SUNDERMAN F W JR, 1986, Toxicology and Industrial Health, V2, P17; Sunderman F W Jr, 1977, Adv Exp Med Biol, V91, P57; Sunderman F W Jr, 1983, Basic Life Sci, V24, P107; SUNDERMAN FW, 1983, RES COMMUN CHEM PATH, V39, P477; SUNDERMAN FW, 1982, YALE J BIOL MED, V55, P123; SUNDERMAN FW, 1981, ANN CLIN LAB SCI, V11, P488; SUNDERMAN FW, 1981, ENVIRON HEALTH PERSP, V40, P131, DOI 10.2307/3429227; SUNDERMAN FW, 1979, J ENVIRON PATHOL TOX, V2, P1511; SUNDERMAN FW, 1989, ANN CLIN LAB SCI, V19, P44; SUNDERMAN FW, 1976, CANCER RES, V36, P1790; SUNDERMAN FW, 1983, CARCINOGENESIS, V4, P461, DOI 10.1093/carcin/4.4.461; SUNDERMAN FW, 1984, CARCINOGENESIS, V5, P1511, DOI 10.1093/carcin/5.11.1511; Sunderman FW, 1996, MOL REPROD DEV, V44, P507; SUNDERMAN FW, 1989, FUND APPL TOXICOL, V13, P205, DOI 10.1016/0272-0590(89)90257-1; Sunderman F.W., 1988, HDB TOXICITY INORGAN, P453; Sunderman F.W., 1984, IARC SCI PUBL, V53, P127; SUNDERMAN FW, 2001, CLIN ENV HLTH TOXIC, P905; SUNDERMAN FW, 1968, TOXICOL APPL PHARM, V1, P297; SUNDERMAN FW, 1973, ANN CLIN LAB SCI, V3, P157; SUNDERMAN FW, ELEMENTS TH IN PRESS; Sutter CH, 2000, P NATL ACAD SCI USA, V97, P4748, DOI 10.1073/pnas.080072497; SWIERENGA SHH, 1976, J NATL CANCER I, V57, P125; SWIERENGA SHH, 1978, J CELL PHYSIOL, V94, P171, DOI 10.1002/jcp.1040940206; TALLKVIST J, 1994, PHARMACOL TOXICOL, V75, P244; Tallkvist J, 1998, TOXICOL APPL PHARM, V151, P117, DOI 10.1006/taap.1998.8453; TEMPLETON DM, 1985, BIOCHEM J, V230, P35; TEMPLETON DM, 1986, BIOCHIM BIOPHYS ACTA, V884, P382; TKESHELASHVILI LK, 1993, CANCER RES, V53, P4172; Trapasso F, 2003, P NATL ACAD SCI USA, V100, P1592, DOI 10.1073/pnas.0437915100; TROTT DA, 1995, CARCINOGENESIS, V16, P193, DOI 10.1093/carcin/16.2.193; TVEITO G, 1989, CANCER RES, V49, P1829; *US DHHS, 1996, NTP STUD TOX CARC ST; VANSOESTBERGEN M, 1972, CLIN CHEM, V18, P1478; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; WEGHORST CM, 1994, CANCER RES, V154, P215; WEITZMAN SA, 1997, MUTAT RES, V386, P141; YAMASHIRO S, 1980, ACTA PATHOL JAPON, V30, P9; YARITA T, 1978, CANCER RES, V38, P3140; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zamponi GW, 1996, J MEMBRANE BIOL, V151, P77, DOI 10.1007/s002329900059; ZAROOGIAN G, 1993, MAR ENVIRON RES, V35, P41, DOI 10.1016/0141-1136(93)90011-N; Zhou DJ, 1998, CANCER RES, V58, P2182; Zienolddiny S, 2000, CARCINOGENESIS, V21, P1521, DOI 10.1093/carcin/21.8.1521; Zoroddu MA, 2000, BBA-GEN SUBJECTS, V1475, P163, DOI 10.1016/S0304-4165(00)00066-0; Zoroddu MA, 2002, ENVIRON HEALTH PERSP, V110, P719; Zoroddu MA, 2001, J INORG BIOCHEM, V84, P47, DOI 10.1016/S0162-0134(00)00204-X	313	348	379	2	62	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0027-5107			MUTAT RES-FUND MOL M	Mutat. Res.-Fundam. Mol. Mech. Mutagen.	DEC 10	2003	533	1-2			SI		67	97		10.1016/j.mrfmmm.2003.08.021		31	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	V18WB	WOS:000208033800004	14643413	
J	Sonkoly, E; Muller, A; Lauerma, AI; Pivarcsi, A; Soto, H; Kemeny, L; Alenius, H; Dieu-Nosjean, MC; Meller, S; Rieker, J; Steinhoff, M; Hoffmann, TK; Ruzicka, T; Zlotnik, A; Homey, B				Sonkoly, E; Muller, A; Lauerma, AI; Pivarcsi, A; Soto, H; Kemeny, L; Alenius, H; Dieu-Nosjean, MC; Meller, S; Rieker, J; Steinhoff, M; Hoffmann, TK; Ruzicka, T; Zlotnik, A; Homey, B			IL-31: A new link between T cells and pruritus in atopic skin inflammation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IL-31; pruritus; atopic dermatitis; T cells; cytokines; superantigen	ACTIVATION-REGULATED CHEMOKINE; DISEASE-ACTIVITY; SERUM THYMUS; ONCOSTATIN-M; DERMATITIS; EXPRESSION; RECEPTOR; EOTAXIN-3/CCL26; INTERLEUKIN-31; RECRUITMENT	Background: IL-31 is a novel T-cell-derived cytokine that induces severe pruritus and dermatitis in transgenic mice, and signals through a heterodimeric receptor composed of IL-31 receptor A and oncostatin M receptor. Objective: To investigate the role of human IL-31 in pruritic and nonpruritic inflammatory skin diseases. Methods: The expression of IL-31 was analyzed by quantitative real-time PCR in skin samples of healthy individuals and patients with chronic inflammatory skin diseases. Moreover, IL-31 expression was analyzed in nonlesional skin of atopic dermatitis patients after allergen or superantigen exposure, as well as in stimulated leukocytes. The tissue distribution of the IL-31 receptor heterodimer was investigated by DNA microarray analysis. Results: IL-31 was significantly overexpressed in pruritic atopic compared with nonpruritic psoriatic skin inflammation. Highest IL-31 levels were detected in prurigo nodularis, one of the most pruritic forms of chronic skin inflammation. In vivo, staphylococcal superantigen rapidly induced IL-31 expression in atopic individuals. In vitro, staphylococcal enterotoxin B but not viruses or T(H)1 and T(H)2 cytokines induced IL-31 in leukocytes. In patients with atopic dermatitis.. activated leukocytes expressed significantly higher IL-31 levels compared with control subjects. IL-31 receptor A showed most abundant expression in dorsal root ganglia representing the site where the cell bodies of cutaneous sensory neurons reside. Conclusion: Our findings provide a new link among staphylococcal colonization, subsequent T-cell recruitment/activation, and pruritus induction in patients with atopic dermatitis. Taken together, these findings show that IL-31 may represent a novel target for antipruritic drug development.	Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; Univ Dusseldorf, Dept Radiat Oncol, Dusseldorf, Germany; Univ Dusseldorf, Dept Otorhinolaryngol, Dusseldorf, Germany; Helsinki Univ Hosp, Finnish Inst Occupat Hlth, Dermatol Sect, Helsinki, Finland; Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland; Univ Szeged, Dept Dermatol & Allergol, Szeged, Hungary; Neurocrine Biosci Inc, San Diego, CA USA; Finnish Inst Occupat Hlth, Dept Ind Hyd & Toxicol, Helsinki, Finland; INSERM, U255, Lab Immunol Cellulaire & Clin, Ctr Rech Biomed Cordeliers, Paris, France; Univ Hosp Munster, Dept Dermatol, Munster, Germany	Homey, B (reprint author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	Bemhard.Homey@uni-duesseldorf.de	Steinhoff, Martin/F-6312-2013; Lauerma, Antti/J-8180-2016	Sonkoly, Eniko/0000-0002-4909-5413; Pivarcsi, Andor/0000-0003-2196-1102; Steinhoff, Martin/0000-0002-7090-2187			Banwell ME, 2002, CYTOKINE, V17, P317, DOI 10.1006/cyto.2002.1021; BURTON JL, 1998, ROOK WILKINSON EBLIN, P629; Camp RDR, 1998, ROOK WILKINSON EBLIN, P1589; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Diveu C, 2004, EUR CYTOKINE NETW, V15, P291; Finlay AY, 2001, J AM ACAD DERMATOL, V45, pS64, DOI 10.1067/mjd.2001.117010; Ghilardi N, 2002, J BIOL CHEM, V277, P16831, DOI 10.1074/jbc.M201140200; Gombert M, 2005, J IMMUNOL, V174, P5082; Greaves MW, 2004, INT ARCH ALLERGY IMM, V135, P166, DOI 10.1159/000080898; Gunther C, 2005, J IMMUNOL, V174, P1723; Guzik TJ, 2005, CLIN EXP ALLERGY, V35, P448, DOI 10.1111/j.1365-2222.2005.02210.x; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hermann GE, 2005, CURR PHARM DESIGN, V11, P1391, DOI 10.2174/1381612053507828; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Homey B, 2000, J IMMUNOL, V164, P3465; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Kagami S, 2003, CLIN EXP IMMUNOL, V134, P309, DOI 10.1046/j.1365-2249.2003.02273.x; Kakinuma T, 2002, CLIN EXP IMMUNOL, V127, P270, DOI 10.1046/j.1365-2249.2002.01727.x; Kakinuma T, 2001, J ALLERGY CLIN IMMUN, V107, P535, DOI 10.1067/mai.2001.113237; Laouini D, 2003, J ALLERGY CLIN IMMUN, V112, P981, DOI 10.1067/mai.2003.1789; Lee HL, 2004, NEUROREPORT, V15, P2807; LEE J, 2005, FASEB J, V10, P1356; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Meller S, 2005, ARTHRITIS RHEUM, V52, P1504, DOI 10.1002/art.21034; Morikawa Y, 2004, J NEUROSCI, V24, P1941, DOI 10.1523/JNEUROSCI.4975-03.2004; Nickoloff BJ, 2004, J CLIN INVEST, V113, P1664, DOI 10.1172/JCI200422147; Pivarcsi A, 2004, J IMMUNOL, V173, P5810; Roll Antonie, 2004, Curr Opin Allergy Clin Immunol, V4, P373, DOI 10.1097/00130832-200410000-00008; Rottman JB, 2001, LAB INVEST, V81, P335; Stander S, 2002, EXP DERMATOL, V11, P12, DOI 10.1034/j.1600-0625.2002.110102.x; Tamura S, 2003, EUR J NEUROSCI, V17, P2287, DOI 10.1046/j.1460-9568.2003.02681.x; WAHLGREN CF, 1990, ACTA DERM-VENEREOL, V70, P323; Wallengren J, 2004, AM J CLIN DERMATOL, V5, P85, DOI 10.2165/00128071-200405020-00003; Yamashita T, 2003, ALLERGY, V58, P261, DOI 10.1034/j.1398-9995.2003.00062_2.x; Yosipovitch G, 2003, LANCET, V361, P690, DOI 10.1016/S0140-6736(03)12570-6; Zhang N, 2005, P NATL ACAD SCI USA, V102, P4536, DOI 10.1073/pnas.0406030102	38	346	357	4	15	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					411	417		10.1016/j.jaci.2005.10.033		7	Allergy; Immunology	Allergy; Immunology	017IM	WOS:000235687300023	16461142	
J	Holgate, ST				Holgate, Stephen T.			Pathogenesis of asthma	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							NERVE GROWTH-FACTOR; AIRWAY SMOOTH-MUSCLE; KILLER T-CELLS; BRONCHIAL EPITHELIAL-CELLS; CHEMOKINE RECEPTOR-3 EXPRESSION; SUBEPITHELIAL BASEMENT-MEMBRANE; NONATOPIC INTRINSIC ASTHMATICS; THYMIC STROMAL LYMPHOPOIETIN; MESENCHYMAL TROPHIC UNIT; NECROSIS-FACTOR-ALPHA	While asthma is considered an inflammatory disorder of the conducting airways, it is becoming increasingly apparent that the disease is heterogeneous with respect to immunopathology, clinical phenotypes, response to therapies, and natural history. Once considered purely an allergic disorder dominated by Th2-type lymphocytes, IgE, mast cells, eosinophils, macrophages, and cytokines, the disease also involves local epithelial, mesenchymal, vascular and neurologic events that are involved in directing the Th2 phenotype to the lung and through aberrant injury-repair mechanisms to remodeling of the airway wall. Structural cells provide the necessary "soil" upon which the "seeds" of the inflammatory response are able to take root and maintain a chronic phenotype and upon which are superimposed acute and subacute episodes usually driven by environmental factors such as exposure to allergens, microorganisms, pollutants or caused by inadequate antiinflammatory treatment. Greater consideration of additional immunologic and inflammatory pathways are revealing new ways of intervening in the prevention and treatment of the disease. Thus increased focus on environmental factors beyond allergic exposure (such as virus infection, air pollution, and diet) are identifying targets in structural as well as immune and inflammatory cells at which to direct new interventions.						Medical Research Council [G19/34]		Abdel-Rahman AMO, 2006, CHEST, V129, P266, DOI 10.1378/chest.129.2.266; Adcock IM, 2005, COPD, V2, P445, DOI 10.1080/15412550500346683; Agis H, 2006, AM J CLIN PATHOL, V125, P273, DOI 10.1309/M9FQMQGF66167N2X; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Al-Muhsen SZ, 2004, CLIN EXP ALLERGY, V34, P911, DOI 10.1111/j.1365-2222.2004.01975.x; Anderson GP, 2002, MED J AUSTRALIA, V177, pS47; Appleton SL, 2006, J ALLERGY CLIN IMMUN, V118, P1284, DOI 10.1016/j.jaci.2006.08.011; Babu KS, 2003, EUR RESPIR J, V21, P1046, DOI 10.1183/09031936.03.00069202; Bai TR, 2005, CLIN SCI, V108, P463; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnes PJ, 2006, BRIT J PHARMACOL, V148, P245, DOI 10.1038/sj.bjp.0706736; Basuroy S, 2006, BIOCHEM J, V393, P69; Beasley R, 2001, Pediatr Pulmonol, VSuppl 23, P149; Beck SA, 2001, ALLERGY ASTHMA PROC, V22, P1, DOI 10.1525/awr.2001.22.2.1; Berger P, 2001, J APPL PHYSIOL, V91, P1372; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Berlanga J, 2002, BURNS, V28, P435, DOI 10.1016/S0305-4179(02)00023-2; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bhandari V, 2006, P NATL ACAD SCI USA, V103, P11021, DOI 10.1073/pnas.0601057103; Bharadwaj A, 2004, INT IMMUNOPHARMACOL, V4, P495, DOI 10.1016/j.intimp.2004.02.001; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Boxall C, 2006, EUR RESPIR J, V27, P208, DOI 10.1183/09031936.06.00130004; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; BRADDING P, 1995, J IMMUNOL, V155, P297; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burgess JK, 2005, J ALLERGY CLIN IMMUN, V115, P302, DOI 10.1016/j.jaci.2004.11.004; Cairns JA, 2005, PULM PHARMACOL THER, V18, P55, DOI 10.1016/j.pupt.2004.09.032; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Casalino-Matsuda SM, 2006, AM J RESP CELL MOL, V34, P581, DOI 10.1165/rcmb.2005-0386OC; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chaudhuri R, 2005, CLIN EXP ALLERGY, V35, P949, DOI 10.1111/j.1365-2222.2005.02286.x; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Chetta A, 2005, CLIN EXP ALLERGY, V35, P1437, DOI 10.1111/j.1365-2222.2005.02360.x; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; Cohn L, 2006, J CLIN INVEST, V116, P306, DOI 10.1172/JCI27690; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Corrigan Chris, 2004, Curr Opin Allergy Clin Immunol, V4, P53, DOI 10.1097/00130832-200402000-00011; Dahlen B, 1999, THORAX, V54, P590; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9; Das AM, 2006, J PHARMACOL EXP THER, V318, P411, DOI 10.1124/jpet.105.099812; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Vries A, 2006, CLIN EXP ALLERGY, V36, P1192, DOI 10.1111/j.1365-2222.2006.02549.x; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669; DRAGON S, 2006, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; Frossard N, 2005, EUR RESPIR J, V26, P15, DOI 10.1183/09031936.05.00047804; Frossard N, 2004, EUR J PHARMACOL, V500, P453, DOI 10.1016/j.ejphar.2004.07.044; Gajewska Beata U., 2003, Current Drug Targets - Inflammation and Allergy, V2, P279, DOI 10.2174/1568010033484052; Gangur Venu, 2003, Current Drug Targets - Inflammation and Allergy, V2, P53, DOI 10.2174/1568010033344453; Garcia G, 2005, CURR ALLERGY ASTHM R, V5, P155, DOI 10.1007/s11882-005-0090-0; Gibson PG, 2006, SEM RESP CRIT CARE M, V27, P185, DOI 10.1055/s-2006-939521; Godfrey RWA, 1997, MICROSC RES TECHNIQ, V38, P488, DOI 10.1002/(SICI)1097-0029(19970901)38:5<488::AID-JEMT5>3.0.CO;2-E; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; HALDAR P, 2005, THORAX, V60, P33; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565; Hallgren J, 2006, FEBS J, V273, P1871, DOI 10.1111/j.1742-4658.2006.05211.x; Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hamzaoui A, 2005, MEDIAT INFLAMM, P160, DOI 10.1155/MI.2005.160; Hijazi Z, 2004, ARCH DIS CHILD, V89, P227, DOI 10.1136/adc.2003.027680; Ho LP, 2007, NEW ENGL J MED, V356, P1466, DOI 10.1056/NEJMe078014; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, pS7, DOI 10.1016/S0091-6749(96)80123-0; Holgate ST, 2005, AM J RESP CRIT CARE, V172, P941, DOI 10.1164/rccm.2507007; Holgate ST, 2001, INT ARCH ALLERGY IMM, V124, P253, DOI 10.1159/000053726; Holgate Stephen T, 2006, Proc Am Thorac Soc, V3, P440, DOI 10.1513/pats.200603-026AW; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Holloway JW, 2004, CHEM IMMUNOL, V84, P1; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Howell JE, 2006, CURR DRUG TARGETS, V7, P547, DOI 10.2174/138945006776818692; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Hughes JL, 2006, ALLERGY, V61, P1268, DOI 10.1111/j.1398-9995.2006.01207.x; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Humbert M, 2000, REV MAL RESPIR, V17, P245; Humrich JY, 2006, IMMUNOLOGY, V117, P238, DOI 10.1111/j.1365-2567.2005.02292.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; ILOWITE JS, 1989, AM REV RESPIR DIS, V139, P1139; Ishida T, 2006, LEUKEMIA, V20, P2162, DOI 10.1038/sj.leu.2404415; Jaffar Z, 1999, AM J RESP CELL MOL, V20, P153; Jaffar ZH, 1999, J IMMUNOL, V163, P6283; Jain N, 2005, PEDIATR PULM, V40, P211, DOI 10.1002/ppul.20215; James A, 2000, EUR RESPIR J, V15, P782, DOI 10.1034/j.1399-3003.2000.15d25.x; James A, 2005, CLIN EXP ALLERGY, V35, P703, DOI 10.1111/j.1365-2222.2005.02270.x; James AL, 2005, EUR RESPIR J, V26, P429, DOI 10.1183/09031936.05.00146404; Jayaratnam A, 2005, CLIN EXP ALLERGY, V35, P835, DOI 10.1111/j.1365-2222.2005.02283.x; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.01938.x; Kallinich T, 2005, CLIN EXP ALLERGY, V35, P26, DOI 10.1111/j.1365-2222.2004.02132.x; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kariyawasam HH, 2006, SEM RESP CRIT CARE M, V27, P117, DOI 10.1055/s-2006-939514; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kaur D, 2006, AM J RESP CRIT CARE, V174, P1179, DOI 10.1164/rccm.200603-394OC; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Kay AB, 2006, CHEM IMMUNOL ALLERGY, V91, P59; Kay AB, 2005, TRENDS MOL MED, V11, P148, DOI 10.1016/j.molmed.2005.02.002; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Kay AB, 2001, NEW ENGL J MED, V344, P109; Keogh KA, 2006, SEM RESP CRIT CARE M, V27, P148, DOI 10.1055/s-2006-939518; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Kitamura K, 2007, J IMMUNOL, V178, P480; Knight DA, 2004, CURR OPIN PHARMACOL, V4, P251, DOI 10.1016/j.coph.2004.02.002; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Kon OM, 1999, INFLAMM RES, V48, P516, DOI 10.1007/s000110050496; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228; Kraft M, 2006, J ALLERGY CLIN IMMUN, V117, P1197, DOI 10.1016/j.jaci.2006.03.001; Kuipers H, 2004, J LEUKOCYTE BIOL, V76, P1028, DOI 10.1189/jlb.0604325; Kumar Rakesh K., 2006, Inflammation & Allergy Drug Targets, V5, P253, DOI 10.2174/187152806779010909; KUMLIN M, 1992, AM REV RESPIR DIS, V146, P96; Larche M, 1998, J IMMUNOL, V161, P6375; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.2005409-1175OC; Leigh R, 2002, AM J RESP CRIT CARE, V166, P1212, DOI 10.1164/rccm.200206-S09OC; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lemiere C, 2006, J ALLERGY CLIN IMMUN, V118, P1033, DOI 10.1016/j.jaci.2006.08.003; Leung SY, 2006, J PHARMACOL EXP THER, V319, P586, DOI 10.1124/jpet.106.109314; Lewis-Tuffin LJ, 2006, ANN NY ACAD SCI, V1069, P1, DOI 10.1196/annals.1351.001; Liu LY, 2002, J IMMUNOL, V169, P6452; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Liu Z, 2005, ACTA PAEDIATR, V94, P386, DOI 10.1080/08035250410023304; Livingston E, 2007, EUR RESPIR J, V29, P64, DOI 10.1183/09031936.06.00120505; Loke TK, 2006, J ALLERGY CLIN IMMUN, V118, P368, DOI 10.1016/j.jaci.2006.04.055; Long AJ, 2006, AM J RESP CELL MOL, V35, P357, DOI 10.1165/rcmb.2005-0451OC; Lordan JL, 2001, J ALLERGY CLIN IMMUN, V108, P976, DOI 10.1067/mai.2001.119740; Macfarlane AJ, 2000, J ALLERGY CLIN IMMUN, V105, P99, DOI 10.1016/S0091-6749(00)90184-2; Malo JL, 2005, OCCUP MED-OXFORD, V55, P606, DOI 10.1093/occmed/kqi185; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; MCLACHLAN CR, 2006, J ALLERGY CLIN IMMUN, V119, P634; Meagher LC, 1996, J IMMUNOL, V156, P4422; Meurer JR, 2006, PEDIATR CLIN N AM, V53, P715, DOI 10.1016/j.pcl.2006.05.002; Meyts I, 2006, J IMMUNOL, V177, P6460; Misso NLA, 2005, REDOX REP, V10, P247, DOI 10.1179/135100005X70233; Mochizuki A, 2003, J ALLERGY CLIN IMMUN, V112, P102, DOI 10.1067/mai.2003.1511; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; Morcillo EJ, 2006, CURR OPIN PULM MED, V12, P1, DOI 10.1097/01.mcp.0000198064.27586.37; Morrison D, 2006, RESP MED, V100, P2227, DOI 10.1016/j.rmed.2005.10.005; Mullin JM, 2005, DRUG DISCOV TODAY, V10, P395, DOI 10.1016/S1359-6446(05)03379-9; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Nahm DH, 2002, AM J RESP CRIT CARE, V165, P1536, DOI 10.1164/rccm.200201-009OC; Nahm DH, 2006, J ALLERGY CLIN IMMUN, V118, P376, DOI 10.1016/j.jaci.2006.04.002; Nassenstein C, 2003, J EXP MED, V198, P455, DOI 10.1084/jem.20010897; Nassenstein C, 2006, EUR J PHARMACOL, V533, P195, DOI 10.1016/j.ejphar.2005.12.061; Neuber K, 2006, CLIN EXP IMMUNOL, V146, P262, DOI 10.1111/j.1365-2249.2006.03218.x; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; O'Sullivan Siobhan M, 2005, Proc Am Thorac Soc, V2, P162, DOI 10.1513/pats.200502-016AW; Ogawa Y, 2006, J ALLERGY CLIN IMMUN, V118, P789, DOI 10.1016/j.jaci.2006.08.009; OKAYAMA Y, 1995, J IMMUNOL, V155, P1796; Okayama Y, 2003, EUR J IMMUNOL, V33, P1450, DOI 10.1002/eji.200323563; Olgart Hoglund C, 2002, Eur Respir J, V20, P1110, DOI 10.1183/09031936.02.00205402; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pease JE, 2006, J ALLERGY CLIN IMMUN, V118, P305, DOI 10.1016/j.jaci.2006.06.010; PEREZVILAR J, 2006, AM J RESP CELL MOL B, V36, P183; Pham-Thi Nhan, 2006, N Engl J Med, V354, P2613; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Pini L, 2007, EUR RESPIR J, V29, P71, DOI 10.1183/09031936.00047905; Plante S, 2006, J ALLERGY CLIN IMMUN, V117, P1321, DOI 10.1016/j.jaci.2005.12.1349; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Quarcoo D, 2004, CLIN EXP ALLERGY, V34, P1146, DOI 10.1111/j.1365-2222.2004.01993.x; Qujeq D, 2003, CLIN CHEM LAB MED, V41, P200, DOI 10.1515/CCLM.2003.032; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Riese RJ, 2000, CURR OPIN IMMUNOL, V12, P107, DOI 10.1016/S0952-7915(99)00058-8; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; ROCHE WR, 1993, AM REV RESPIR DIS, V148, pS79; Russo C, 2005, CLIN SCI, V109, P135; Ryu HJ, 2006, INT ARCH ALLERGY IMM, V139, P209, DOI 10.1159/000091166; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-14040C; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Schmitz N, 2003, EUR J IMMUNOL, V33, P991, DOI 10.1002/eji.200323801; Scott K, 2005, CLIN EXP ALLERGY, V35, P693, DOI 10.1111/j.1365-2222.2005.02277.x; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Sen Yang, 2005, J Immunol, V175, P4914; Sexton DW, 2004, CLIN EXP ALLERGY, V34, P1514, DOI 10.1111/j.1365-2222.2004.02054.x; Shahana S, 2005, RESP MED, V99, P429, DOI 10.1016/j.rmed.2004.08.013; Shahana S, 2006, RESP MED, V100, P2018, DOI 10.1016/j.rmed.2006.02.012; Shaw TJ, 2004, EUR RESPIR J, V23, P813, DOI 10.1183/09031936.04.00119904; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Silvestri M, 2006, CLIN EXP ALLERGY, V36, P1373, DOI 10.1111/j.1365-2222.2006.02502.x; Simpson JL, 2005, AM J RESP CRIT CARE, V172, P559, DOI 10.1164/rccm.200503.369OC; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; Slavin RG, 2005, ALLERGY ASTHMA PROC, V26, P255; Smit JJ, 2006, EUR J PHARMACOL, V533, P277, DOI 10.1016/j.ejphar.2005.12.064; Stanford KI, 2006, EUR J APPL PHYSIOL, V96, P703, DOI 10.1007/s00421-005-0067-7; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Strek Mary E, 2006, Proc Am Thorac Soc, V3, P116, DOI 10.1513/pats.200510-115JH; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Temann UA, 2007, INT IMMUNOL, V19, P1, DOI 10.1093/intimm/dxl117; Thai P, 2005, AM J RESP CELL MOL, V33, P523, DOI 10.1165/rcmb.2004-0220RC; Thomas SY, 2006, NEW ENGL J MED, V354, P2613; TIGANI B, 2006, AM J PHYSIOL-LUNG C, V292, P644; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Tonnel AB, 2001, INT ARCH ALLERGY IMM, V124, P267, DOI 10.1159/000053729; Truong-Tran AQ, 2003, BIOCHEM PHARMACOL, V66, P1459, DOI 10.1016/S0006-2952(03)00498-2; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Tsoumakidou M, 2006, CHEST, V129, P1194, DOI 10.1378/chest.129.5.1194; Uller L, 2006, CLIN EXP ALLERGY, V36, P111, DOI 10.1111/j.1365-2222.2006.02396.x; Uller L, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-90; Uller L, 2004, AM J RESP CRIT CARE, V170, P742, DOI 10.1164/rccm.200402-240OC; Umetsu DT, 2006, NAT REV IMMUNOL, V6, P953, DOI 10.1038/nri1968; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; Vendelin J, 2005, AM J RESP CELL MOL, V33, P262, DOI 10.1165/rcmb.2004-0405OC; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; von Garnier C, 2005, J IMMUNOL, V175, P1609; Voynow JA, 2006, AM J RESP CELL MOL, V34, P661, DOI 10.1165/rcmb.2006-0035SF; Vrugt B, 2000, EUR RESPIR J, V15, P1014, DOI 10.1034/j.1399-3003.2000.01507.x; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Watson JJ, 2006, J PHARMACOL EXP THER, V316, P1122, DOI 10.1124/jpet.105.095844; Webb DC, 2007, J IMMUNOL, V178, P219; Weinblatt M, 2006, ARTHRITIS RHEUM, V54, P2807, DOI 10.1002/art.22070; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wicks J, 2006, THORAX, V61, P313, DOI 10.1136/thx.2005.050005; Williams TJ, 2000, CHEM IMMUNOL, V78, P166; Wilson John W, 2002, Paediatr Respir Rev, V3, P219, DOI 10.1016/S1526-0542(02)00200-2; Wilson SJ, 2000, CLIN EXP ALLERGY, V30, P493; Woodman L, 2006, CHEST, V130, P371, DOI 10.1378/chest.130.2.371; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Yang M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-18; Ye YM, 2006, YONSEI MED J, V47, P773; Ye YM, 2006, J KOREAN MED SCI, V21, P412, DOI 10.3346/jkms.2006.21.3.412; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; Ying S, 2005, J IMMUNOL, V174, P8183; Ying S, 1999, J IMMUNOL, V163, P6321; Ying S, 1997, J IMMUNOL, V158, P3539; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030	262	344	358	4	73	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2008	38	6					872	897		10.1111/j.1365-2222.2008.02971.x		26	Allergy; Immunology	Allergy; Immunology	304IL	WOS:000256103100002	18498538	
J	Pajno, GB; Barberio, G; De Luca, F; Morabito, L; Parmiani, S				Pajno, GB; Barberio, G; De Luca, F; Morabito, L; Parmiani, S			Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study.	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; children; house dust mite; new sensitizations; rhinitis; specific immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; ALLERGEN IMMUNOTHERAPY; INTERFERON-GAMMA; DERMATOPHAGOIDES-PTERONYSSINUS; MESSENGER-RNA; T-LYMPHOCYTES; ONSET; CELLS; INTERLEUKIN-4; EXTRACT	Background Specific immunotherapy (SIT) is a recognized way of treating IgE-mediated respiratory diseases. The clinical outcome is usually better in allergic children than in adults. Objective To increase our knowledge of the ability of SIT to prevent the onset of new sensitizations in monosensitized subjects, so far poorly documented. Methods 134 children (age range 5-8 years), who had intermittent asthma with or without rhinitis, with single sensitization to mite allergen (skin prick test and serum-specific IgE), were enrolled. SIT was proposed to all the children's parents, but was accepted by only 75 of them (SIT Group). The remaining 63 children were treated with medication only, and were considered the Control Group. Injective SIT with mite mix was administered to the SIT Group during the first three years and all patients were followed for a total of 6 years. All patients were checked for allergic sensitization(s) by skin prick test and serum-specific IgE every year until the end of the follow-up period. Results Both groups were comparable in terms of age, sex and disease characteristics. 123 children completed the follow-up study. At the end of the study, 52 out of 69 children (75.4%) in the SIT Group showed no new sensitization, compared to 18 out of 54 children (33.3%) in the Control Group (P < 0.0002). Parietaria, Gramineae and Olea were the most common allergens responsible for the new sensitization(s). Conclusions According to our data, SIT may prevent the onset of new sensitizations in children with respiratory symptoms monosensitized to house dust mite (HDM).	Univ Messina, Policlin Univ, Ist Clin Pediat, I-98124 Messina, Italy; ALK Abello SpA, Milan, Italy	Pajno, GB (reprint author), Univ Messina, Policlin Univ, Ist Clin Pediat, Via Consolare Valeria Gazzi, I-98124 Messina, Italy.						ABRAMSON MJ, 2000, COCHRANE DATABASE SY; Akoum H, 1996, IMMUNOLOGY, V87, P593, DOI 10.1046/j.1365-2567.1996.506585.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P210, DOI 10.1111/j.1365-2222.1994.tb00222.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; DESROCHES A, 1995, J ALLERGY CLIN IMMUN, V95, P309; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Gruber W, 1999, CLIN EXP ALLERGY, V29, P176; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; *I NAZ STAT, 1996, ANN STAT IT, P308; Jacobsen L., 1996, Journal of Allergy and Clinical Immunology, V97, P232, DOI 10.1016/S0091-6749(96)80416-7; JACOBSEN L, 1995, P 16 EUR C ALL CLIN, P745; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kjellman N I, 1994, Pediatr Allergy Immunol, V5, P13, DOI 10.1111/j.1399-3038.1994.tb00342.x; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; NELSON HS, 1985, ANN ALLERGY, V55, P441; *NIH NAT HEART LUN, 1995, PUBL NIH; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V94, P662, DOI 10.1016/0091-6749(94)90171-6; Paul K, 1998, EUR J PEDIATR, V157, P109, DOI 10.1007/s004310050780; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Valovirta E, 1997, J INVEST ALLERG CLIN, V7, P369; VANASPEREN PP, 1989, ACTA PAEDIATR SCAND, V78, P239; VANBEVER HP, 1988, ALLERGY, V43, P378; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x	28	344	368	1	5	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2001	31	9					1392	1397		10.1046/j.1365-2222.2001.01161.x		6	Allergy; Immunology	Allergy; Immunology	473CF	WOS:000171021400010	11591189	
J	Hammad, H; Lambrecht, BN				Hammad, Hamida; Lambrecht, Bart N.			Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma	NATURE REVIEWS IMMUNOLOGY			English	Review							THYMIC STROMAL LYMPHOPOIETIN; ALLERGIC AIRWAY INFLAMMATION; HOUSE-DUST MITE; BRONCHIAL LYMPH-NODE; REGULATORY T-CELLS; INHALED ANTIGEN; TH2 RESPONSES; MEDIATE TOLERANCE; RESPIRATORY-TRACT; PROTEASE ALLERGEN	Dendritic cells (DCs) are generally held responsible for initiating and maintaining allergic T helper 2 (TH2)-cell responses to inhaled allergens in asthma. Although the epithelium was initially considered to function solely as a physical barrier, it is now seen as a central player in the T H 2-cell sensitization process by influencing the function of DCs. Clinically relevant allergens, as well as known environmental and genetic risk factors for allergy and asthma, often interfere directly or indirectly with the innate immune functions of airway epithelial cells and DCs. A better understanding of these interactions, ascertained from human and animal studies, might lead to better prevention and treatment of asthma.	[Lambrecht, Bart N.] Erasmus Univ, Dept Pulm Med, Med Ctr, Rotterdam, Netherlands; [Hammad, Hamida] State Univ Ghent Hosp, Dept Resp Dis, Lab Immunolregulat & Mucosal Immunol, Ghent, Belgium	Lambrecht, BN (reprint author), Erasmus Univ, Dept Pulm Med, Med Ctr, Rotterdam, Netherlands.	bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014; Osborne, Nicholas/N-4915-2015	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834; Osborne, Nicholas/0000-0002-6700-2284			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Arora M, 2006, P NATL ACAD SCI USA, V103, P7777, DOI 10.1073/pnas.0508492103; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Aydogan M, 2007, PEDIATR ALLERGY IMMU, V18, P320, DOI 10.1111/j.1399-3038.2006.00527.x; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Beaty SR, 2007, J IMMUNOL, V178, P1882; Belz GT, 2004, P NATL ACAD SCI USA, V101, P8670, DOI 10.1073/pnas.0402644101; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Bleck B, 2006, J IMMUNOL, V176, P7431; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; Cleret A, 2007, J IMMUNOL, V178, P7994; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; COYLE AJ, 1990, AM REV RESPIR DIS, V142, P587; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; De Nadai P, 2006, J IMMUNOL, V176, P6286; del Rio ML, 2007, J IMMUNOL, V178, P6861; Ebeling C, 2007, J IMMUNOL, V179, P2910; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Reis e Sousa C, 2006, NAT REV IMMUNOL, V6, P476; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Gett AV, 2003, NAT IMMUNOL, V4, P355, DOI 10.1038/ni908; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Hammad H, 2003, EUR CYTOKINE NETW, V14, P219; Hammad H, 2003, J IMMUNOL, V171, P3936; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Harris J, 2004, CHEM BIOL, V11, P1361, DOI 10.1016/j.chembiol.2004.08.008; HELJINK IH, 2007, J IMMUNOL, V178, P7678; Hintzen G, 2006, J IMMUNOL, V177, P7346; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Hurst SD, 2001, J IMMUNOL, V166, P4922; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Itano AA, 2003, IMMUNITY, V19, P47, DOI 10.1016/S1074-7613(03)00175-4; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jahnsen FL, 2006, J IMMUNOL, V177, P5861; Jakubzick C, 2006, J IMMUNOL, V176, P3578; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kato A, 2007, J IMMUNOL, V179, P1080; Kauffman Henk F, 2006, Clin Mol Allergy, V4, P5, DOI 10.1186/1476-7961-4-5; Kauffman HF, 2006, CLIN REV ALLERG IMMU, V30, P129, DOI 10.1385/CRIAI:30:2:129; Kheradmand F, 2002, J IMMUNOL, V169, P5904; King C, 1998, J IMMUNOL, V161, P3645; Kiss A, 2007, J ALLERGY CLIN IMMUN, V120, P334, DOI 10.1016/j.jaci.2007.04.025; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kondo S, 2004, INFLAMM RES, V53, P489, DOI 10.1007/s00011-004-1287-8; Kornerup KN, 2007, PLATELETS, V18, P319, DOI 10.1080/09537100701230436; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Leonard WJ, 2002, NAT IMMUNOL, V3, P605, DOI 10.1038/ni0702-605; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martin P, 2002, BLOOD, V100, P383, DOI 10.1182/blood.V100.2.383; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; Nolte MA, 2007, J EXP MED, V204, P1487, DOI 10.1084/jem.20070325; Noulin N, 2005, J IMMUNOL, V175, P6861; Ochando JC, 2006, NAT IMMUNOL, V7, P652, DOI 10.1038/ni1333; Okada SF, 2006, J BIOL CHEM, V281, P22992, DOI 10.1074/jbc.M603019200; Olivera DS, 2007, INHAL TOXICOL, V19, P13, DOI 10.1080/08958370600985768; Omori M, 2007, J IMMUNOL, V178, P1396; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pearce N, 1999, THORAX, V54, P268; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Robays LJ, 2007, J IMMUNOL, V178, P5305; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rodriguez D, 2003, J IMMUNOL, V171, P1001; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Rusznak C, 2001, CLIN EXP ALLERGY, V31, P226, DOI 10.1046/j.1365-2222.2001.01000.x; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Shamim Z, 2007, INT J IMMUNOGENET, V34, P149, DOI 10.1111/j.1744-313X.2007.00657.x; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Sporri R, 2005, NAT IMMUNOL, V6, P163, DOI 10.1038/ni1162; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stumbles PA, 2001, J IMMUNOL, V167, P228; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Tai HY, 2006, ALLERGY, V61, P382, DOI 10.1111/j.1398-9995.2005.00958.x; Tesciuba AG, 2001, J IMMUNOL, V167, P1996; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Van Hove CL, 2007, AM J RESP CELL MOL, V36, P573, DOI 10.1165/rcmb.2006-0385OC; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vermaelen KY, 2003, J IMMUNOL, V171, P1016; Vermaelen KY, 2001, J EXP MED, V193, P51; von Garnier C, 2005, J IMMUNOL, V175, P1609; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Webb DC, 2007, J IMMUNOL, V178, P219; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; WILKSTROM ME, 2007, IMMUNOL CELL BIOL, V85, P182; Wills-Karp M, 2005, CURR ALLERGY ASTHM R, V5, P362, DOI 10.1007/s11882-005-0007-y; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Ying S, 2005, J IMMUNOL, V174, P8183; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou WS, 2007, J IMMUNOL, V178, P702; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	131	343	357	3	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	MAR	2008	8	3					193	204		10.1038/nri2275		12	Immunology	Immunology	267ZV	WOS:000253548600014	18301423	
J	Denning, DW; O'Driscoll, BR; Hogaboam, CM; Bowyer, P; Niven, RM				Denning, DW; O'Driscoll, BR; Hogaboam, CM; Bowyer, P; Niven, RM			The link between fungi and severe asthma: a summary of the evidence	EUROPEAN RESPIRATORY JOURNAL			English	Review						aspergillosis; asthma clinical/basic investigations; asthma epidemiology; asthma immunology; fungi	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; HOUSE-DUST-MITE; THUNDERSTORM-ASSOCIATED ASTHMA; SKIN-TEST REACTIVITY; OCCUPATIONAL ASTHMA; ENVIRONMENTAL-FACTORS; RESPIRATORY HEALTH; AIRWAY DISEASE; CHILDHOOD ASTHMA; DIFFICULT ASTHMA	There is current evidence to demonstrate a close association between fungal sensitisation and asthma severity. Whether such an association is causal remains to be confirmed, but this is explored by means of a detailed literature review. There is evidence from two randomised controlled trials that, in the example of allergic bronchopulmonary aspergillosis (ABPA), treatment with systemic antifungal therapy can offer a therapeutic benefit to similar to 60% of patients. ABPA is only diagnosed if a combination of clinical and immunological criteria is achieved. It is not known whether such cases are a discrete clinical entity or part of a spectrum of the pulmonary allergic response to fungi or fungal products. This paper describes the epidemiological evidence that associates severity of asthma with fungi and discusses possible pathogenetic mechanisms. Many airborne fungi are involved including species of Alternaria, Aspergillus, Cladosporium and Penicillium, and exposure may be indoors, outdoors or both. The potential for a therapeutic role of antifungal agents for patients with severe asthma and fungal sensitisation is also explored. Not only are many patients with severe asthma desperately disabled by their disease, but, in the UK alone, asthma accounts for 1,500 deaths per yr. The healthcare costs of these patients are enormous and any treatment option merits close scrutiny. Within this report, the case for the consideration of a new term related to this association is put forward. The current authors propose the term "severe asthma with fungal sensitisation". However, it is recognised that enhanced and precise definition of fungal sensitisation will require improvements in diagnostic testing.	Wythenshawe Hosp, Dept Cardiothorac Med, Manchester M23 9LT, Lancs, England; Univ Manchester, Sch Med, Manchester, Lancs, England; Hope Hosp, Manchester, Lancs, England; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA	Denning, DW (reprint author), Wythenshawe Hosp, Educ & Res Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.	ddenning@manchester.ac.uk	hogaboam, cory /M-3578-2014	Niven, Robert/0000-0003-2249-960X; Denning, David/0000-0001-5626-2251			AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; AINSWORTH GC, 1986, INTRO MED VET MYCOLO; AKIYAMA K, 1984, CHEST, V85, P699, DOI 10.1378/chest.85.5.699; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; BEAUMONT F, 1985, ALLERGY, V40, P181, DOI 10.1111/j.1398-9995.1985.tb00214.x; BEIJER L, 2003, EUR RESPIR J, V2, P317; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Bernton HS, 1930, J AMER MED ASSOC, V95, P189; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; BLACKLEY CH, 1973, EXPT RES CAUSES NATU; Blease K, 2001, J IMMUNOL, V167, P6583; Blease K, 2001, J IMMUNOL, V166, P1832; Blease K, 2000, J IMMUNOL, V165, P1564; Bouchon A, 2001, NATURE, V410, P1103, DOI 10.1038/35074114; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1046/j.1365-2222.1997.d01-418.x; Brander KA, 1999, J ALLERGY CLIN IMMUN, V104, P630, DOI 10.1016/S0091-6749(99)70335-0; BROWN GT, 1936, J ALLERGY, V7, P454; BURR ML, 1988, J ROY SOC HEALTH, V108, P99, DOI 10.1177/146642408810800311; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cadham F, 1924, JAMA-J AM MED ASSOC, V83, P27; *CDCP, 2002, AD SELF REP CURR AST; Celenza A, 1996, BRIT MED J, V312, P604; Chung KF, 1999, EUR RESPIR J, V13, P1198; CLARK EV, 1982, COGNITION, V12, P1, DOI 10.1016/0010-0277(82)90027-0; COHEN MILTON B., 1939, JOUR ALLERGY, V10, P561, DOI 10.1016/S0021-8707(39)90250-9; Colonna M, 2003, J INFECT DIS, V187, pS397, DOI 10.1086/374754; COTE J, 1991, BRIT J IND MED, V48, P279; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; CULLINAN P, 1993, THORAX, V48, P774, DOI 10.1136/thx.48.7.774; CURRIE DC, 1990, THORAX, V45, P447, DOI 10.1136/thx.45.6.447; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; DENNING DW, 2003, PUBLISHED INTERACTIO; Dharmage S, 2002, CLIN EXP ALLERGY, V32, P714, DOI 10.1046/j.1365-2222.2002.01371.x; DURHAM O. C., 1938, JOUR ALLERGY, V10, P40, DOI 10.1016/S0021-8707(38)90465-4; Fischer G, 1999, CHEMOSPHERE, V39, P795; FLOYER J, 1698, TREATISE ASTHMA, P74; Fluckiger S, 2002, INT ARCH ALLERGY IMM, V128, P292, DOI 10.1159/000063862; Fogelmark B, 2001, MEDIAT INFLAMM, V10, P13, DOI 10.1080/09629350151073748; Gamboa PM, 1996, THORAX, V51, P867, DOI 10.1136/thx.51.8.867; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; GOTTLIEB SJ, 1993, J OCCUP ENVIRON MED, V35, P1231; Green BJ, 2005, J ALLERGY CLIN IMMUN, V115, P1043, DOI 10.1016/j.jaci.2005.02.009; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; Gunnbjornsdottir MI, 2003, RESP MED, V97, P302, DOI 10.1053/rmed.2002.1389; HAENEY LG, 2003, THORAX, V58, P561; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hansen K., 1928, VERHANDL DTSCH GESEL, V40, P204; Hardin Bryan D., 2003, Journal of Occupational and Environmental Medicine, V45, P470; Harrison BDW, 2003, THORAX, V58, P555, DOI 10.1136/thorax.58.7.555; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956; HENDRICK DJ, 1975, THORAX, V30, P2, DOI 10.1136/thx.30.1.2; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; Hirsch T, 2000, ALLERGY, V55, P79, DOI 10.1034/j.1398-9995.2000.00250.x; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hopkins JG, 1930, J AMER MED ASSOC, V94, P6; Jarvis D, 1998, BRIT MED J, V316, P607; JENKINS PF, 1981, CLIN ALLERGY, V11, P611, DOI 10.1111/j.1365-2222.1981.tb02182.x; Jimenez-Diaz C, 1932, J ALLERGY, V3, P396, DOI 10.1016/S0021-8707(32)90237-8; Karkkainen M, 2004, INT ARCH ALLERGY IMM, V133, P136, DOI 10.1159/000076439; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; Kawano Tetsuya, 2003, Nihon Kokyuki Gakkai Zasshi, V41, P233; KEMENY DM, 1989, CLIN EXP ALLERGY, V19, P613, DOI 10.1111/j.1365-2222.1989.tb02755.x; Kheradmand F, 2002, J IMMUNOL, V169, P5904; KHOT A, 1984, BRIT MED J, V289, P233; Kuhn Frederick A, 2003, Curr Opin Otolaryngol Head Neck Surg, V11, P1, DOI 10.1097/00020840-200302000-00001; KURUP VP, 2001, ASPERGILLUS ANTIGENS; LANGLEY SJ, 2004, AM J RESP CRIT CARE, V169, pA309; LARSEN LS, 1981, ALLERGY, V36, P15, DOI 10.1111/j.1398-9995.1981.tb01819.x; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; MACKAY TW, 1992, SCOT MED J, V37, P5; MAO Y, 1990, CAN J PUBLIC HEALTH, V81, P226; Marini S, 2003, XENOBIOTICA, V33, P1, DOI 10.1080/0049825021000017894; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; MARTINEZ FD, 1997, EUR RESPIR REV, V40, P8; Matheson MC, 2005, CLIN EXP ALLERGY, V35, P907, DOI 10.1111/j.1365-2222.2005.02272.x; Maurya V, 2005, CHEST, V127, P1252, DOI 10.1378/chest.127.4.1252; MICHILS A, 1991, EUR RESPIR J, V4, P1143; MILES J, 1995, CLIN EXP ALLERGY, V25, P1074; Morrow Marie Betzner, 1943, MYCOLOGIA, V35, P638, DOI 10.2307/3754907; Neas LM, 1996, AM J EPIDEMIOL, V143, P797; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Netea MG, 2004, EUR J CLIN MICROBIOL, V23, P672, DOI 10.1007/s10096-004-1192-7; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; Newson R, 2000, OCCUP ENVIRON MED, V57, P786, DOI 10.1136/oem.57.11.786; Nicolai T, 1998, THORAX, V53, P1035; Nigam S, 2003, INT ARCH ALLERGY IMM, V132, P124, DOI 10.1159/000073713; Nolles G, 2001, CLIN EXP ALLERGY, V31, P1564, DOI 10.1046/j.1365-2222.2001.01186.x; ODriscoll RB, 2005, BMC PULM MED, V5, P4; Ogawa H, 2004, J ASTHMA, V41, P223, DOI 10.1081/JAS-120026080; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PACKE GE, 1985, LANCET, V2, P199; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; Patterson R, 2000, CHEST, V118, P7, DOI 10.1378/chest.118.1.7; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Rains BM, 2003, AM J RHINOL, V17, P1; Ramirez MA, 1930, M J REC, V132, P382; Redecke V, 2004, J IMMUNOL, V172, P2739; RICKETTI AJ, 1983, ARCH INTERN MED, V143, P1553, DOI 10.1001/archinte.143.8.1553; RIDING DM, EFFECT ITRACONAZOLE; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Saxena S, 2003, J ALLERGY CLIN IMMUN, V111, P1001, DOI 10.1067/mai.2003.1395; Schuh JM, 2003, EUR J IMMUNOL, V33, P3080, DOI 10.1002/eji.200323917; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Schuh JM, 2002, J IMMUNOL, V168, P1447; SCHWARTZ HJ, 1991, J LAB CLIN MED, V117, P138; SEATON A, 1994, OCCUP ENVIRON MED, V51, P54; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; Valencia M, 1993, Allergol Immunopathol (Madr), V21, P84; van Leeuwen W S, 1924, Proc R Soc Med, V17, P19; Van Leeuwen WS, 1925, Z IMMUNITATSFORSCH, V44, P1; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; Ward GW, 1999, J ALLERGY CLIN IMMUN, V104, P541, DOI 10.1016/S0091-6749(99)70321-0; WARD GW, 1989, LANCET, V1, P859; Wardman A E Dennis, 2002, Can Respir J, V9, P267; Wark PA, 2004, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD001108.PUB2; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323; Williamson IJ, 1997, THORAX, V52, P229; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Woodcock AA, 2006, ALLERGY, V61, P140, DOI 10.1111/j.1398-9995.2005.00941.x; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	135	343	365	3	38	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2006	27	3					615	626		10.1183/09031936.06.00074705		12	Respiratory System	Respiratory System	021CY	WOS:000235962200025	16507864	
J	Brauer, M; Hoek, G; Van Vliet, P; Meliefste, K; Fischer, PH; Wijga, A; Koopman, LP; Neijens, HJ; Gerritsen, J; Kerkhof, M; Heinrich, J; Bellander, T; Brunekreef, B				Brauer, M; Hoek, G; Van Vliet, P; Meliefste, K; Fischer, PH; Wijga, A; Koopman, LP; Neijens, HJ; Gerritsen, J; Kerkhof, M; Heinrich, J; Bellander, T; Brunekreef, B			Air pollution from traffic and the development of respiratory infections and asthmatic and allergic symptoms in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; allergy; respiratory infections; air pollution; vehicle emissions	NITROGEN-DIOXIDE; CHILDHOOD ASTHMA; EAST-GERMANY; PRESCHOOL-CHILDREN; EXPOSURE; INDOOR; HEALTH; PREVALENCE; OUTDOOR; DISORDERS	Despite the important contribution of traffic sources to urban air quality, relatively few studies have evaluated the effects of traffic-related air pollution on health, such as its influence on the development of asthma and other childhood respiratory diseases. We examined the relationship between traffic-related air pollution and the development of asthmatic/allergic symptoms and respiratory infections in a birth cohort (n similar to 4,000) study in The Netherlands. A validated model was used to assign outdoor concentrations of traffic-related air pollutants (nitrogen dioxide, particulate matter less than 2.5 mum in aerodynamic diameter, and "soot") at the home of each subject of the cohort. Question n a! re-derived data on wheezing, dry nighttime cough, ear, nose, and throat infections, skin rash, and physician-diagnosed asthma, bronchitis, influenza, and eczema at 2 years of age were analyzed in relation to air pollutants. Adjusted odds ratios for wheezing, physician-diagnosed asthma, ear/nose/ throat infections, and flu/serious colds indicated positive associations with air pollutants, some of which reached borderline statistical significance. No associations were observed for the other health outcomes analyzed. Sensitivity analyses generally supported these results and suggested somewhat stronger associations with traffic, for asthma that was diagnosed before I year of age. These findings are subject to confirmation at older ages, when asthma can be more readily diagnosed.	Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V6T 1Z3, Canada; Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Grp, Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands; Erasmus Univ, Dept Pediat, Rotterdam, Netherlands; Sophia Childrens Univ Hosp, Rotterdam, Netherlands; Beatrix Childrens Hosp, Groningen, Netherlands; Univ Groningen, Dept Epidemiol, Groningen, Netherlands; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Stockholm Cty Council, Dept Environm Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Brauer, M (reprint author), Univ British Columbia, Sch Occupat & Environm Hyg, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.		Kerkhof, Marjan/A-8846-2008; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; brunekreef, bert/0000-0001-9908-0060; Brauer, Michael/0000-0002-9103-9343			Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Bellander T, 2001, EPIDEMIOLOGY, V12, pS77; Brauer M, 2001, EPIDEMIOLOGY, V12, pS71; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Janssen NAH, 2000, J AIR WASTE MANAGE, V50, P1133; Koopman LP, 2001, PEDIATRICS, V108, P943, DOI 10.1542/peds.108.4.943; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; NAKATSUKA H, 1991, ENVIRON INT, V17, P51, DOI 10.1016/0160-4120(91)90337-P; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; VONMUTIUS E, 1995, EUR RESPIR J, V8, P723; VONMUTIUS E, 2001, J ALLERGY CLIN IMMUN, V105, P9; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x; WJST M, 1993, BRIT MED J, V307, P596; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232	41	343	350	19	105	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2002	166	8					1092	1098		10.1164/rccm.200108-007OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	602YY	WOS:000178533100016	12379553	
J	Gould, HJ; Sutton, BJ; Beavil, AJ; Beavil, RL; McCloskey, N; Coker, HA; Fear, D; Smurthwaite, L				Gould, HJ; Sutton, BJ; Beavil, AJ; Beavil, RL; McCloskey, N; Coker, HA; Fear, D; Smurthwaite, L			The biology of IgE and the basis of allergic disease	ANNUAL REVIEW OF IMMUNOLOGY			English	Review						IgE; IgE receptors; immediate hypersensitivity; allergy; mucosal immunity	FC-EPSILON-RI; CLASS-SWITCH RECOMBINATION; HUMAN B-CELLS; HIGH-AFFINITY RECEPTOR; LYMPHOCYTE TERMINAL DIFFERENTIATION; IMMUNOGLOBULIN CLASS SWITCH; GERMLINE GENE TRANSCRIPTS; ANTIGEN-PRESENTING CELLS; HUMAN MAST-CELLS; HUMAN T-CELLS	Allergic individuals exposed to minute quantities of allergen experience an immediate response. Immediate hypersensitivity reflects the permanent sensitization of mucosal mast cells by allergen-specific IgE antibodies bound to their high-affinity receptors (FcepsilonRI). A combination of factors contributes to such long-lasting sensitization of the mast cells. They include the homing of mast cells to mucosal tissues, the local synthesis of IgE, the induction of FcepsilonRI expression on mast cells by IgE, the consequent downregulation of FcgammaR (through an insufficiency of the common gamma-chains), and the exceptionally slow dissociation of IgE from FcepsilonRI. To understand the mechanism of the immediate hypersensitivity phenomenon, we need explanations of why IgE antibodies are synthesized in preference to IgG in mucosal tissues and why the IgE is so tenaciously retained on mast cell-surface receptors. There is now compelling evidence that the microenvironment of mucosal tissues of allergic disease favors class switching to IgE; and the exceptionally high affinity of IgE for FcepsilonRI can now be interpreted in terms of the recently determined crystal structures of IgE-FcepsilonRI and IgG-FcgammaR complexes. The rate of local IgE synthesis can easily compensate for the rate of the antibody dissociation from its receptors on mucosal mast cells. Effective mechanisms ensure that allergic reactions are confined to mucosal tissues, thereby minimizing the risk of systemic anaphylaxis.	Kings Coll London, Randall Ctr, London SE1 1UL, England	Gould, HJ (reprint author), Kings Coll London, Randall Ctr, London SE1 1UL, England.	hannah.gould@kcl.ac.uk	Beavil, Andrew/B-5624-2009	Beavil, Andrew/0000-0002-0768-122X; Gould, Hannah/0000-0003-0411-688X			Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; AUBRY JP, 1992, NATURE, V358, P505, DOI 10.1038/358505a0; Avni O, 2002, NAT IMMUNOL, V3, P643, DOI 10.1038/ni808; Avni O, 2000, CURR OPIN IMMUNOL, V12, P654, DOI 10.1016/S0952-7915(00)00158-8; Bajorath J, 1996, PROTEIN SCI, V5, P240; BARTLETT WC, 1993, J IMMUNOL, V150, pA223; Baskin B, 1997, EUR J IMMUNOL, V27, P130, DOI 10.1002/eji.1830270120; BEAVIL AJ, 1995, BIOCHEMISTRY-US, V34, P14449, DOI 10.1021/bi00044a023; Berek C, 1997, Semin Immunol, V9, P261, DOI 10.1006/smim.1997.0076; BEREK C, 1987, IMMUNOL REV, V96, P23, DOI 10.1111/j.1600-065X.1987.tb00507.x; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Bjerke T, 1999, INT ARCH ALLERGY IMM, V118, P440, DOI 10.1159/000024158; BONNEFOY JY, 1993, EUR J IMMUNOL, V23, P969; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; Borkowski TA, 2001, J IMMUNOL, V167, P1290; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330; Capron A, 1999, MICROBES INFECT, V1, P485, DOI 10.1016/S1286-4579(99)80086-0; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; Cerutti A, 1998, J IMMUNOL, V160, P2145; Chua KF, 2002, J EXP MED, V195, pF37, DOI 10.1084/jem.20020380; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Coffman RL, 1999, SCIENCE, V284, P1283, DOI 10.1126/science.284.5418.1283; COKER H, 2003, UNPUB LOCAL SOMATIC; COMOY E, 1999, INT ARCH ALLERGY IMM, V119, P399; Constant SL, 1997, ANNU REV IMMUNOL, V15, P297, DOI 10.1146/annurev.immunol.15.1.297; COOK GP, 1995, IMMUNOL TODAY, V16, P237, DOI 10.1016/0167-5699(95)80166-9; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; de Jong EC, 2002, J IMMUNOL, V168, P1704; DECHANET J, 1995, J CLIN INVEST, V95, P456, DOI 10.1172/JCI117685; Deenick EK, 1999, J IMMUNOL, V163, P4707; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DeSmedt T, 1997, EUR J IMMUNOL, V27, P1229, DOI 10.1002/eji.1830270526; DIERKS SE, 1993, J IMMUNOL, V150, P2372; Dombrowicz D, 1996, J IMMUNOL, V157, P1645; Dombrowicz D, 2000, J IMMUNOL, V165, P1266; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; Dombrowicz D, 2001, J EXP MED, V193, P25; Donnadieu E, 2000, IMMUNITY, V12, P515, DOI 10.1016/S1074-7613(00)80203-4; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1997, ALLERGY, P21; Ehrenstein MR, 2001, P NATL ACAD SCI USA, V98, P14553, DOI 10.1073/pnas.241525998; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; FEINSTEIN A, 1986, IMMUNOL TODAY, V7, P169, DOI 10.1016/0167-5699(86)90168-4; Finkelman FD, 1997, ANNU REV IMMUNOL, V15, P505, DOI 10.1146/annurev.immunol.15.1.505; FITCH FW, 1993, ANNU REV IMMUNOL, V11, P29, DOI 10.1146/annurev.immunol.11.1.29; FRANDJI P, 1995, CELL IMMUNOL, V163, P37, DOI 10.1006/cimm.1995.1096; FUJIEDA S, 1995, J IMMUNOL, V155, P2318; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; FungLeung WP, 1996, J EXP MED, V183, P49, DOI 10.1084/jem.183.1.49; GAGRO A, 1994, EUR J IMMUNOL, V24, P1109, DOI 10.1002/eji.1830240515; GALLI SJ, 1999, ALLERGY, P1127; Garman SC, 2000, NATURE, V406, P259; Garman SC, 2001, J MOL BIOL, V311, P1049, DOI 10.1006/jmbi.2001.4929; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Garman SC, 1999, ANNU REV IMMUNOL, V17, P973, DOI 10.1146/annurev.immunol.17.1.973; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Gauld SB, 2002, SCIENCE, V296, P1641, DOI 10.1126/science.1071546; GEHA RS, 1985, NATURE, V315, P577, DOI 10.1038/315577a0; Geiger E, 2000, J ALLERGY CLIN IMMUN, V105, P150, DOI 10.1016/S0091-6749(00)90190-8; Gett AV, 1998, P NATL ACAD SCI USA, V95, P9488, DOI 10.1073/pnas.95.16.9488; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P728, DOI 10.1046/j.1365-2222.2002.01374.x; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4<1211::AID-IMMU1211>3.0.CO;2-R; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; GOULD HJ, 1997, ALLERGY, P37; Gould NJ, 2000, BRIT MED BULL, V56, P908; GOUNNI AS, 1994, NATURE, V367, P183; Grant JA, 1997, INT ARCH ALLERGY IMM, V113, P376; GROSJEAN I, 1994, EUR J IMMUNOL, V24, P2982, DOI 10.1002/eji.1830241209; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; Harris LJ, 1998, J MOL BIOL, V275, P861, DOI 10.1006/jmbi.1997.1508; Harris LJ, 1997, BIOCHEMISTRY-US, V36, P1581, DOI 10.1021/bi962514+; Hasbold J, 1998, EUR J IMMUNOL, V28, P1040, DOI 10.1002/(SICI)1521-4141(199803)28:03<1040::AID-IMMU1040>3.0.CO;2-9; HELM BA, 1991, EUR J IMMUNOL, V21, P1543, DOI 10.1002/eji.1830210631; HENRY AJ, 1997, BIOCHEMISTRY-US, V361, P5568; HIBI T, 1986, EUR J IMMUNOL, V16, P139, DOI 10.1002/eji.1830160206; Holgate S. T., 2001, ALLERGY; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Hopfner KP, 2002, NATURE, V418, P562, DOI 10.1038/nature00922; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Humbert M, 1996, AM J RESP CRIT CARE, V153, P1931; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; ISHIZAKA K, 1971, PROGR IMMUNOLOGY, V1, P859; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; JABARA HH, 1993, J IMMUNOL, V151, P4528; Jankovic D, 1997, J IMMUNOL, V159, P1868; Jego G, 2001, BLOOD, V97, P1817, DOI 10.1182/blood.V97.6.1817; Jiang H, 2000, J ALLERGY CLIN IMMUN, V105, P1063, DOI 10.1067/mai.2000.107604; Joseph M, 1997, EUR J IMMUNOL, V27, P2212, DOI 10.1002/eji.1830270914; Jung J, 2000, EUR J IMMUNOL, V30, P2437, DOI 10.1002/1521-4141(2000)30:8<2437::AID-IMMU2437>3.0.CO;2-M; KAISERLIAN D, 1993, IMMUNOLOGY, V80, P90; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1997, J IMMUNOL, V159, P28; KARAGIANNIS S, 2003, UNPUB ACTIVITY HUMAN; Karagiannis SN, 2001, IMMUNOLOGY, V103, P319, DOI 10.1046/j.1365-2567.2001.01238.x; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kay A. B., 1997, ALLERGY ALLERGIC DIS; Kayaba H, 2001, J IMMUNOL, V167, P995; Keown MB, 1997, EUR BIOPHYS J BIOPHY, V25, P471, DOI 10.1007/s002490050062; Kilmon MA, 2001, J IMMUNOL, V167, P3139; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KING CL, 1991, J IMMUNOL, V146, P1478; King CL, 1997, J IMMUNOL, V158, P294; Kinoshita K, 2000, CURR OPIN IMMUNOL, V12, P195, DOI 10.1016/S0952-7915(99)00072-2; Kinoshita K, 2001, P NATL ACAD SCI USA, V98, P12620, DOI 10.1073/pnas.221454398; Kinoshita K, 2001, NAT REV MOL CELL BIO, V2, P493, DOI 10.1038/35080033; Kita H, 1999, J IMMUNOL, V162, P6901; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; LACK G, 1994, J IMMUNOL, V152, P2546; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Lamers MC, 1995, IMMUNOL REV, V148, P71, DOI 10.1111/j.1600-065X.1995.tb00094.x; Lantz CS, 1997, J IMMUNOL, V158, P2517; LANZAVECCHIA A, 1984, CLIN EXP IMMUNOL, V55, P197; Liew FY, 2002, NAT REV IMMUNOL, V2, P55, DOI 10.1038/nri705; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; LIO A, 1978, J IMMUNOL, V20, P1696; LIU YJ, 1991, EUR J IMMUNOL, V21, P1107, DOI 10.1002/eji.1830210504; Ludewig B, 1998, J EXP MED, V188, P1493, DOI 10.1084/jem.188.8.1493; LUNDGREN M, 1995, EUR J IMMUNOL, V25, P2042, DOI 10.1002/eji.1830250736; LUTZKER S, 1988, CELL, V53, P177, DOI 10.1016/0092-8674(88)90379-0; MA C, 2003, THESIS U LONDON; MacGlashan D, 1999, J ALLERGY CLIN IMMUN, V104, P492, DOI 10.1016/S0091-6749(99)70399-4; MacGlashan D, 1998, BLOOD, V91, P1633; MacGlashan D, 2000, J LEUKOCYTE BIOL, V68, P479; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MacGlashan DW, 1997, INT ARCH ALLERGY IMM, V113, P45; Macpherson AJS, 2001, NAT IMMUNOL, V2, P625, DOI 10.1038/89775; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; Malisan F, 1996, J EXP MED, V183, P937, DOI 10.1084/jem.183.3.937; MANDLER R, 1993, J IMMUNOL, V150, P407; Marolewski AE, 1998, BIOCHEM J, V333, P573; Martin A, 2002, NATURE, V415, P802; Mason D, 1996, J EXP MED, V183, P717, DOI 10.1084/jem.183.3.717; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; MAX EE, 1999, ALLERGY, P11; Maxwell KF, 1999, NAT STRUCT BIOL, V6, P437; McCall MN, 1999, BBA-GENE STRUCT EXPR, V1447, P43, DOI 10.1016/S0167-4781(99)00131-1; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033; MILLAR AJ, 1992, PLANT CELL, V4, P1075; MILLS FC, 1995, J IMMUNOL, V155, P3021; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Monticelli S, 2002, MOL IMMUNOL, V38, P1129, DOI 10.1016/S0161-5890(02)00037-8; Monticelli S, 2001, ALLERGY, V56, P270, DOI 10.1034/j.1398-9995.2001.00129.x; Morse L, 1997, IMMUNITY, V6, P47, DOI 10.1016/S1074-7613(00)80241-1; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagumo H, 1998, J IMMUNOL, V161, P6496; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Neuberger MS, 1998, IMMUNOL REV, V162, P107, DOI 10.1111/j.1600-065X.1998.tb01434.x; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Niu HF, 1998, GENE DEV, V12, P1953, DOI 10.1101/gad.12.13.1953; NOLA J, 2002, NATURE, V418, P99; Novak N, 2002, NAT IMMUNOL, V3, P607, DOI 10.1038/ni0702-607; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; O'Shea JJ, 2002, NAT IMMUNOL, V3, P506, DOI 10.1038/ni0602-506; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; Okazaki IM, 2002, NATURE, V416, P340, DOI 10.1038/nature727; OKUDAIRA H, 1981, INT ARCH ALLER A IMM, V65, P162; Ono SJ, 2000, ANNU REV IMMUNOL, V18, P347, DOI 10.1146/annurev.immunol.18.1.347; PADLAN EA, 1986, MOL IMMUNOL, V23, P1063, DOI 10.1016/0161-5890(86)90005-2; PADLAN EA, 1993, RECEPTOR, V3, P325; Patino CM, 2001, ALLERGY, V56, P279, DOI 10.1034/j.1398-9995.2001.00135.x; PATTERSON R, 1975, CLIN EXP IMMUNOL, V20, P265; PAUL WE, 1993, ADV IMMUNOL, V53, P1, DOI 10.1016/S0065-2776(08)60496-4; PAUL WE, 1999, ALLERGY, P1; Paul W. E., 1999, FUNDAMENTAL IMMUNOLO; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; Payet M, 1999, ALLERGY, V54, P1125; PENE J, 1988, EUR J IMMUNOL, V18, P929, DOI 10.1002/eji.1830180615; PERKINS SJ, 1991, J MOL BIOL, V221, P1345; Petersen S, 2001, NATURE, V414, P660, DOI 10.1038/414660a; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; RADA C, 2002, CURR BIOL, V12, P1746; Radaev S, 2001, J BIOL CHEM, V276, P16469, DOI 10.1074/jbc.M100350200; Radaev S, 2001, J BIOL CHEM, V276, P16478, DOI 10.1074/jbc.M100351200; Randall TD, 1998, IMMUNITY, V8, P733, DOI 10.1016/S1074-7613(00)80578-6; RANDEN I, 1992, J IMMUNOL, V148, P3296; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457; Reischl IG, 2000, CLIN EXP ALLERGY, V30, P1033; Reljic R, 2000, J EXP MED, V192, P1841, DOI 10.1084/jem.192.12.1841; Reljic R, 1997, EUR J IMMUNOL, V27, P572, DOI 10.1002/eji.1830270232; RENZ H, 1995, INT ARCH ALLERGY IMM, V106, P46; Rogers PR, 1999, J IMMUNOL, V163, P1205; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9; Romagnani S, 2001, Curr Opin Allergy Clin Immunol, V1, P73, DOI 10.1097/00130832-200102000-00013; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROSE SM, 1984, J BIOL CHEM, V259, P8534; Rosenwasser LJ, 1997, INT ARCH ALLERGY IMM, V113, P61; Rush JS, 2002, J IMMUNOL, V168, P2676; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; SANTAMARIA LF, 1993, HUM IMMUNOL, V37, P23, DOI 10.1016/0198-8859(93)90139-R; Saphire EO, 2001, SCIENCE, V293, P1155, DOI 10.1126/science.1061692; Sayers I, 1998, BIOCHEMISTRY-US, V37, P16152, DOI 10.1021/bi981456k; SCHARENBERG AM, 1994, CURR BIOL, V4, P140, DOI 10.1016/S0960-9822(94)00032-1; Schebesta M, 2002, CURR OPIN IMMUNOL, V14, P216, DOI 10.1016/S0952-7915(02)00324-2; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; SEDER RA, 1991, P NATL ACAD SCI USA, V88, P2835, DOI 10.1073/pnas.88.7.2835; Seminario MC, 1999, J IMMUNOL, V162, P6893; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; SHLOMCHIK MJ, 1987, P NATL ACAD SCI USA, V84, P9150, DOI 10.1073/pnas.84.24.9150; SIEBENKOTTEN G, 1992, EUR J IMMUNOL, V22, P1827, DOI 10.1002/eji.1830220723; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Smurthwaite Lyn, 2002, Curr Allergy Asthma Rep, V2, P231, DOI 10.1007/s11882-002-0024-z; Snapper CM, 1997, IMMUNITY, V6, P217, DOI 10.1016/S1074-7613(00)80324-6; SNOW RE, 1995, J IMMUNOL, V154, P5576; Snow RE, 1997, EUR J IMMUNOL, V27, P162, DOI 10.1002/eji.1830270124; Snow RE, 1999, IMMUNOLOGY, V98, P646, DOI 10.1046/j.1365-2567.1999.00910.x; Sondermann P, 2000, NATURE, V406, P267, DOI 10.1038/35018508; Sondermann P, 2001, J MOL BIOL, V309, P737, DOI 10.1006/jmbi.2001.4670; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; Stingl G, 1997, INT ARCH ALLERGY IMM, V113, P24; Stockinger B, 1996, J EXP MED, V183, P891, DOI 10.1084/jem.183.3.891; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sutton B, 2000, IMMUNOL TODAY, V21, P177, DOI 10.1016/S0167-5699(00)01589-9; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Szakonyi G, 2001, SCIENCE, V292, P1725, DOI 10.1126/science.1059118; TADA T, 1975, INT ARCH ALLER A IMM, V48, P116; Takemoto N, 2000, J IMMUNOL, V165, P6687; Tashiro J, 2001, INT IMMUNOL, V13, P495, DOI 10.1093/intimm/13.4.495; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; Tew JG, 2001, TRENDS IMMUNOL, V22, P361, DOI 10.1016/S1471-4906(01)01942-1; Tian M, 2000, J BIOL CHEM, V275, P24163, DOI 10.1074/jbc.M003343200; Tomlinson IM, 1996, J MOL BIOL, V256, P813, DOI 10.1006/jmbi.1996.0127; Toru H, 1996, INT IMMUNOL, V8, P1367; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Van der Kleij D, 2002, J INFECT DIS, V185, P531, DOI 10.1086/338574; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; VanKooten C, 1996, ADV IMMUNOL, V61, P1; Vercelli D, 2001, INT ARCH ALLERGY IMM, V124, P20, DOI 10.1159/000053658; Vercelli D, 2001, J ENDOTOXIN RES, V7, P45, DOI 10.1179/096805101101532521; VERCELLI D, 1997, IGE REGULATION; VERWAERDE C, 1987, J IMMUNOL, V138, P4441; Wan T, 2002, NAT IMMUNOL, V3, P681, DOI 10.1038/ni811; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; Wedemeyer J, 2000, BRIT MED BULL, V56, P936, DOI 10.1258/0007142001903616; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22; Wuerffel RA, 1997, J IMMUNOL, V159, P4139; Wurzburg BA, 2000, IMMUNITY, V13, P375, DOI 10.1016/S1074-7613(00)00037-6; Wurzburg BA, 2002, MOL IMMUNOL, V38, P1063, DOI 10.1016/S0161-5890(02)00035-4; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; YANAGIHARA Y, 1981, INT ARCH ALLER A IMM, V66, P251; Yang PC, 2000, J CLIN INVEST, V106, P879, DOI 10.1172/JCI9258; Yano K, 1997, LAB INVEST, V77, P185; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; YOSHIDA K, 1990, P NATL ACAD SCI USA, V87, P7829, DOI 10.1073/pnas.87.20.7829; ZHANG K, 1994, J IMMUNOL, V152, P3427; ZHANG K, 1995, J IMMUNOL, V154, P2237; Zhang YH, 2000, IMMUNITY, V13, P387, DOI 10.1016/S1074-7613(00)00038-8; ZHENG Y, 1992, BIOCHEMISTRY-US, V31, P7446, DOI 10.1021/bi00148a004; ZHENG Y, 1991, BIOCHEMISTRY-US, V30, P9125, DOI 10.1021/bi00102a002; Zhou J, 2002, MOL CELL BIOL, V22, P4876, DOI 10.1128/MCB.22.13.4876-4889.2002	282	340	354	2	66	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0732-0582			ANNU REV IMMUNOL	Annu. Rev. Immunol.		2003	21						579	628		10.1146/annurev.immunol.21.120601.141103		54	Immunology	Immunology	672MB	WOS:000182523500018	12500981	
J	Dolovich, MB; Ahrens, RC; Hess, DR; Anderson, P; Dhand, R; Rau, JL; Smaldone, GC; Guyatt, G				Dolovich, MB; Ahrens, RC; Hess, DR; Anderson, P; Dhand, R; Rau, JL; Smaldone, GC; Guyatt, G			Device selection and outcomes of aerosol therapy: Evidence-based guidelines	CHEST			English	Review						aerosols; bronchodilators; corticosteroids; drug delivery systems; dry powder inhalers; metaanalysis; metered-dose inhalers; nebulizers	METERED-DOSE INHALER; MECHANICALLY VENTILATED PATIENTS; AIR-FLOW OBSTRUCTION; EXERCISE-INDUCED ASTHMA; DRY-POWDER INHALER; INTERMITTENT NEBULIZED ALBUTEROL; BRONCHODILATOR DELIVERY METHODS; CHLOROFLUOROCARBON CFC INHALER; PRESSURIZED AEROSOL; COPD PATIENTS	Background: The proliferation of inhaler devices has resulted in a confusing number of choices for clinicians who are selecting a delivery device for aerosol therapy. There are advantages and disadvantages associated with each device category. Evidence-based guidelines for the selection of the appropriate aerosol delivery device in specific clinical settings are needed. Aim: (1) To compare the efficacy and adverse effects of treatment using nebulizers vs pressurized metered-dose inhalers (MDIs) with or without a spacer/bolding chamber vs dry powder inhalers (DPIs) as delivery, systems for beta-agonists, anticholinergic agents, and corticosteroids for several commonly encountered clinical settings and patient populations, and (2) to provide recommendations to clinicians to aid them in selecting a particular aerosol delivery device for their patients. Methods: A systematic review of pertinent randomized, controlled clinical trials (RCTs) was undertaken using MEDLINE, EmBase, and the Cochrane Library databases. A broad search strategy was chosen, combining terms related to aerosol devices or drugs with the diseases of interest in various patient groups and clinical settings. Only RCTs in which the same drug was administered with different devices were included. RCTs (394 trials) assessing inhaled corticosteroid, beta(2)-agonist, and anticholinergic agents delivered by an MDI, an MDI with a spacer/holding chamber, a nebulizer, or a DPI were identified for the years 1982 to 2001. A total of 254 outcomes were tabulated. Of the 131 studies that met the eligibility criteria, only 59 (primarily those that tested beta(2)-agonists) proved to have useable data. Results: None of the pooled metaanalyses showed a significant difference between devices in any efficacy, outcome in any, patient group for each of the clinical settings that was investigated. The adverse effects that were reported were minimal and were related to the increased drug dose that was delivered. Each of the delivery devices provided similar outcomes in patients using the correct technique for inhalation. Conclusions: Devices used for the delivery of bronchodilators and steroids can be equally efficacious. When selecting an aerosol delivery device for patients with asthma and COPD, the following should be considered: device/drug availability; clinical setting; patient age and the ability to use the selected device correctly; device use with multiple medications; cost and reimbursement; drug administration time; convenience in both outpatient and inpatient settings; and physician and patient preference.	McMaster Univ, Fac Hlth Sci, Hamilton, ON LSN 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON LSN 3Z5, Canada; Univ Iowa, Roy & Lucille A Carver Coll Med, Div Pediat Allergy & Pulm Dis, Iowa City, IA 52242 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Univ Arkansas Med Sci, Div Pulm & Crit Care Med, Little Rock, AR 72701 USA; Univ Missouri, Div Pulm Crit Care & Environm Med, Columbia, MO 65211 USA; SUNY Stony Brook, Dept Med, Pulm Crit Care Div, Stony Brook, NY 11794 USA; Georgia State Univ, Atlanta, GA 30303 USA	Dolovich, MB (reprint author), McMaster Univ, Fac Hlth Sci, 1200 Main St W,HSC 1V18, Hamilton, ON LSN 3Z5, Canada.	mdolovic@mcmaster.ca					AGARWAL S, 2002, BMJ; AHRENS RC, 1991, ANN ALLERGY, V67, P296; Ahrens RC, 1999, AM J RESP CRIT CARE, V160, P1238; Amirav I, 1997, ARCH PEDIAT ADOL MED, V151, P876; Bach PB, 2001, ANN INTERN MED, V134, P600; Balzano G, 2000, J AEROSOL MED, V13, P25, DOI 10.1089/jam.2000.13.25; Batra V, 1997, Indian Pediatr, V34, P497; BAUER K, 1993, CLIN PHARMACOL THER, V53, P76; BEATY R, 1992, American Review of Respiratory Disease, V145, pA66; BELL JH, 1971, J PHARM SCI, V60, P1559, DOI 10.1002/jps.2600601028; BERRY RB, 1989, CHEST, V96, P1241, DOI 10.1378/chest.96.6.1241; BLAKE KV, 1992, CHEST, V101, P309, DOI 10.1378/chest.101.2.309; BLOOMFIELD P, 1979, BRIT MED J, V2, P1479; BOE J, 1992, ANN ALLERGY, V68, P255; Bondesson E, 1998, RESP MED, V92, P325, DOI 10.1016/S0954-6111(98)90116-0; BUNDGAARD A, 1982, ANN ALLERGY, V48, P36; Bundgaard A, 1983, Eur J Respir Dis Suppl, V130, P59; CAMPBELL IA, 1995, THORAX, V50, P79, DOI 10.1136/thx.50.1.79; Cates C, 2003, RESP MED, V97, P762, DOI 10.1016/S0954-6111(03)00021-0; CATES CJ, 2002, HOLDING CHAMBERS VER; CHAMBERS S, 1980, ARCH DIS CHILD, V80, P73; CHOU KJ, 1995, ARCH PEDIAT ADOL MED, V149, P545; COLACONE A, 1993, CHEST, V104, P835, DOI 10.1378/chest.104.3.835; CORR D, 1982, J AEROSOL SCI, V13, P1, DOI 10.1016/0021-8502(82)90002-7; CROMPTON GK, 1982, EUR J RESPIR DIS, V63, P101; DEBLAQUIERE P, 1989, AM REV RESPIR DIS, V140, P910; Delgado A, 2003, ARCH PEDIAT ADOL MED, V157, P76; Dewar AL, 1999, ARCH DIS CHILD, V80, P421; Dhand R, 1997, AM J RESP CRIT CARE, V156, P3; DIOT P, 1995, AM J RESP CRIT CARE, V152, P1391; Dirksen H, 1983, Eur J Respir Dis Suppl, V130, P48; DOLOVICH M, 1981, CHEST, V80, P911; Dolovich M, 1999, Can Respir J, V6, P290; Dolovich M A, 2000, Respir Care, V45, P589; Dolovich M A, 2000, Respir Care, V45, P597; DOROW P, 1982, EUR J CLIN PHARMACOL, V22, P511, DOI 10.1007/BF00609623; Duarte A G, 2000, Respir Care, V45, P817; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; FORMGREN H, 1994, LUNG, V172, P271, DOI 10.1007/BF00164309; FREEDMAN T, 1956, Postgrad Med, V20, P667; FUGLSANG G, 1986, EUR J RESPIR DIS, V69, P109; FULLER HD, 1994, CHEST, V105, P214, DOI 10.1378/chest.105.1.214; GAY PC, 1991, CHEST, V99, P66, DOI 10.1378/chest.99.1.66; Geoffroy P, 1999, ANN ALLERG ASTHMA IM, V82, P377; GIMENO F, 1988, ANN ALLERGY, V61, P341; Goode ML, 2001, AM J RESP CRIT CARE, V163, P109; GUIDRY GG, 1992, CHEST, V101, P31, DOI 10.1378/chest.101.1.31; Guyatt G., 2002, USERS GUIDES MED LIT; HAAHTELA T, 1994, ANN ALLERGY, V72, P178; HANANIA NA, 1994, CHEST, V105, P111, DOI 10.1378/chest.105.1.111; HANSEN NCG, 1989, EUR RESPIR J, V2, P716; Hedges L. V., 1985, STAT METHODS METAANA; Hirsch T, 1997, RESP MED, V91, P341, DOI 10.1016/S0954-6111(97)90060-3; HUGHES J M, 1987, Respiratory Care, V32, P1131; IDRIS AH, 1993, CHEST, V103, P665, DOI 10.1378/chest.103.3.665; JACKSON L, 1994, EUR RESPIR J, V7, P1598, DOI 10.1183/09031936.94.07091598; JASPER AC, 1987, CHEST, V91, P614, DOI 10.1378/chest.91.4.614; JOHNSEN CR, 1988, ALLERGY, V43, P392, DOI 10.1111/j.1398-9995.1988.tb00434.x; Kamps AWA, 2000, PEDIATR PULM, V29, P39, DOI 10.1002/(SICI)1099-0496(200001)29:1<39::AID-PPUL7>3.0.CO;2-G; KESTEN S, 1993, CHEST, V104, P1737, DOI 10.1378/chest.104.6.1737; Khine H, 1996, ACAD EMERG MED, V3, P1019, DOI 10.1111/j.1553-2712.1996.tb03346.x; KIVIRANTA K, 1985, ALLERGY, V40, P305, DOI 10.1111/j.1398-9995.1985.tb00237.x; Lahdensuo A, 1983, Eur J Respir Dis Suppl, V128 (Pt 2), P515; LAHDENSUO A, 1986, EUR J RESPIR DIS, V68, P332; Lantos A, 1993, Ther Hung, V41, P146; LEACH CL, 1995, AEROSOL SCI TECH, V22, P328, DOI 10.1080/02786829408959750; LEVITT MA, 1995, ANN EMERG MED, V26, P273, DOI 10.1016/S0196-0644(95)70071-4; LIN RY, 1993, ANN EMERG MED, V22, P1847, DOI 10.1016/S0196-0644(05)80412-3; LIN YZ, 1995, ARCH DIS CHILD, V72, P214; LINDGREN S, 1987, EUR J RESPIR DIS, V70, P93; LINDSAY DA, 1994, EUR RESPIR J, V7, P342, DOI 10.1183/09031936.94.07020342; LIPWORTH B, 2001, BMJ; Lofdahl CG, 1997, EUR RESPIR J, V10, P2474, DOI 10.1183/09031936.97.10112474; MADSEN EB, 1982, EUR J CLIN PHARMACOL, V23, P27; Mandelberg A, 1997, CHEST, V112, P1501, DOI 10.1378/chest.112.6.1501; MANTHOUS CA, 1993, AM REV RESPIR DIS, V148, P1567; MATHIEU M, 1992, EUR J CLIN PHARMACOL, V42, P435; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V96, P278, DOI 10.1016/S0091-6749(95)70206-7; Mc Peck M, 1993, RESPIR CARE, V38, P887; MERCER TT, 1981, CHEST, V80, pS813; MOREN F, 1978, INT J PHARM, V1, P205, DOI 10.1016/0378-5173(78)90009-1; Morice AH, 2000, RESPIRATION, V67, P298, DOI 10.1159/000029514; Mouloudi E, 2001, INTENS CARE MED, V27, P42, DOI 10.1007/s001340000714; Mouloudi E, 1998, EUR RESPIR J, V12, P165, DOI 10.1183/09031936.98.12010165; Mouloudi E, 1999, INTENS CARE MED, V25, P1215, DOI 10.1007/s001340051049; Mouloudi E, 2000, EUR RESPIR J, V16, P263, DOI 10.1034/j.1399-3003.2000.16b13.x; Muers MF, 1997, THORAX, V52, pS25; Nana A, 1998, RESP MED, V92, P167, DOI 10.1016/S0954-6111(98)90090-7; National Asthma Education and Prevention Program, 1997, NIH PUBL, V97-4051; National Heart Lung and Blood institute World Health Organization, 2001, AM J RESP CRIT CARE, V163, P1256; Nava S, 2001, INTENS CARE MED, V27, P1627; Nelson H, 1999, CHEST, V115, P329, DOI 10.1378/chest.115.2.329; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V103, P267, DOI 10.1016/S0091-6749(99)70501-4; NELSON HS, 1994, ANN ALLERGY, V72, P337; NEWHOUSE MT, 1986, NEW ENGL J MED, V315, P870, DOI 10.1056/NEJM198610023151406; NEWMAN SP, 1981, AM REV RESPIR DIS, V124, P317; NEWMAN SP, 1981, EUR J RESPIR DIS, V62, P3; NIEMINEN MM, 1994, RESPIRATION, V61, P37; NIEMINEN MM, 1995, ACTA THERAP, V21, P179; ODOHERTY MJ, 1992, AM REV RESPIR DIS, V146, P383; ORIORDAN TG, 1992, AM REV RESPIR DIS, V145, P1117; OSTERMAN K, 1989, ALLERGY, V44, P294, DOI 10.1111/j.1398-9995.1989.tb01073.x; PAPO MC, 1993, CRIT CARE MED, V21, P1479, DOI 10.1097/00003246-199310000-00015; PARKIN PC, 1995, ARCH DIS CHILD, V72, P239; PAUWELS R, 1984, RESPIRATION, V45, P61; PEDERSEN JZ, 1983, EUR J CLIN PHARMACOL, V25, P739, DOI 10.1007/BF00542512; PEDERSEN S, 1986, ARCH DIS CHILD, V61, P11; PERSSON G, 1988, EUR RESPIR J, V1, P681; Ploin D, 2000, PEDIATRICS, V106, P311; POLLACK CV, 1995, ANN EMERG MED, V26, P552, DOI 10.1016/S0196-0644(95)70003-X; Raimondi AC, 1997, CHEST, V112, P24, DOI 10.1378/chest.112.1.24; Ram FSF, 2001, BRIT MED J, V323, P901, DOI 10.1136/bmj.323.7318.901; Ram FSF, 2002, COCHRANE DATABASE SY; RAMMELOO RHU, 1992, RESPIRATION, V59, P322; REISER J, 1986, PEDIATR PULM, V2, P237, DOI 10.1002/ppul.1950020412; REISNER C, 1995, ANN ALLERG ASTHMA IM, V75, P41; Robertson CF, 1998, J PAEDIATR CHILD H, V34, P142, DOI 10.1046/j.1440-1754.1998.00184.x; RODRIGO G, 1993, CURR THER RES CLIN E, V54, P797, DOI 10.1016/S0011-393X(05)80709-X; Rodrigo GJ, 2002, CHEST, V122, P160, DOI 10.1378/chest.122.1.160; Rubilar L, 2000, PEDIATR PULM, V29, P264, DOI 10.1002/(SICI)1099-0496(200004)29:4<264::AID-PPUL5>3.0.CO;2-S; RUDNITSKY GS, 1993, ANN EMERG MED, V22, P1842, DOI 10.1016/S0196-0644(05)80411-1; RUGGINS NR, 1993, ARCH DIS CHILD, V68, P477; SALZMAN GA, 1989, CHEST, V95, P1017, DOI 10.1378/chest.95.5.1017; Schuh S, 1999, J PEDIATR-US, V135, P22, DOI 10.1016/S0022-3476(99)70322-7; Shrestha M, 1996, CHEST, V110, P42, DOI 10.1378/chest.110.1.42; SUMMER W, 1989, ARCH INTERN MED, V149, P618, DOI 10.1001/archinte.149.3.618; SVEDMYR N, 1982, EUR J RESPIR DIS, V63, P81; SVENONIUS E, 1994, ALLERGY, V49, P408, DOI 10.1111/j.1398-9995.1994.tb00832.x; Tammivaara R, 1997, CURR THER RES CLIN E, V58, P734, DOI 10.1016/S0011-393X(97)80107-5; TOBIN MJ, 1982, AM REV RESPIR DIS, V126, P670; TONNESEN F, 1994, CHEST, V105, P697, DOI 10.1378/chest.105.3.697; Torres A, 1997, CHEST, V112, P484, DOI 10.1378/chest.112.2.484; TURNER JR, 1988, CHEST, V93, P476, DOI 10.1378/chest.93.3.476; Turner MO, 1997, ARCH INTERN MED, V157, P1736, DOI 10.1001/archinte.157.15.1736; VIDGREN M, 1995, ARZNEIMITTEL-FORSCH, V45-1, P44; VIDGREN P, 1994, ACTA THERAP, V20, P117; VILSVIK J, 1991, ANN ALLERGY, V67, P315; Williams JR, 1996, PEDIATR EMERG CARE, V12, P263, DOI 10.1097/00006565-199608000-00007; Wong A G, 1998, Can Respir J, V5, P119; ZAINUDIN BMZ, 1990, THORAX, V45, P469, DOI 10.1136/thx.45.6.469	140	339	368	6	58	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JAN	2005	127	1					335	371		10.1378/chest.127.1.335		41	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	888HQ	WOS:000226365200052	15654001	
J	Eder, W; Klimecki, W; Yu, LZ; von Mutius, E; Riedler, J; Braun-Fahrlander, C; Nowak, D; Martinez, FD				Eder, W; Klimecki, W; Yu, LZ; von Mutius, E; Riedler, J; Braun-Fahrlander, C; Nowak, D; Martinez, FD		ALEX Study Team	Toll-like receptor 2 as a major gene for asthma in children of European farmers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						farming; endotoxin; asthma; atopy; children; TLR2; TLR4; gene-environment interaction	HAY-FEVER; ALLERGIC SENSITIZATION; CELL ACTIVATION; INNATE IMMUNITY; CUTTING EDGE; EXPOSURE; LIPOPOLYSACCHARIDE; ENDOTOXIN; RECOGNITION; ATOPY	Background: The finding that the prevalence of asthma and allergies is less frequent in children raised on animal farms has led to the conjecture that exposure to microbial products modifies immune responses. The toll-like receptors (TLRs) represent an evolutionarily conserved family of innate immunity receptors with microbial molecules as ligands. Objectives: We reasoned that polymorphisms in genes encoding TLRs might modulate the protective effects observed in farming populations. Methods: Farmers' and nonfarmers' children living in rural areas in Austria and Germany and who were enrolled in the cross-sectional ALEX study were genotyped for single nucleotide polymorphisms in the TLR2 and TLR4 genes. The frequencies of asthma, allergic rhinitis, and atopic sensitization were compared between the genotypes in relation to exposure to farming and endotoxin. Results: Among farmers' children, those carrying a T allele in TLR2/-16934 compared with children with genotype AA were significantly less likely to have a diagnosis of asthma (3% vs 13%, P = .012), current asthma symptoms (3% vs 16%, P = .004), atopic sensitization (14% vs 27%, P = .023), and current hay fever symptoms (3% vs 14%, P = .01). The association between TLR2/-16934 and asthma among children of farmers was independent of atopy. No such association was found among children from the same rural communities but not living on farms. Conclusion: Our results suggest that genetic variation in TLR2 is a major determinant of the susceptibility to asthma and allergies in children of farmers.	Univ Arizona, Arizona Resp Ctr, Tucson, AZ 85724 USA; Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; Childrens Hosp, Salzburg, Austria; Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Munich, Inst Occupat & Environm Med, D-80539 Munich, Germany; Univ Munich, Outpatient Clin Occupat & Environm Med, D-80539 Munich, Germany	Martinez, FD (reprint author), Univ Arizona, Arizona Resp Ctr, 1501 N Campbell Ave,POB 245030, Tucson, AZ 85724 USA.			von Mutius, Erika/0000-0002-8893-4515	NHLBI NIH HHS [HL66800, HL67672]		Arbour NC, 2000, NAT GENET, V25, P187; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Clayton D., 2001, HDB STAT GENETICS, P519; DUTKIEWICZ J, 1978, ARCH ENVIRON HEALTH, V33, P250; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; Hirschfeld M, 2000, J IMMUNOL, V165, P618; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Lazarus R, 2002, IMMUNOL REV, V190, P9, DOI 10.1034/j.1600-065X.2002.19002.x; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; Martinez FD, 1997, AM J RESP CRIT CARE, V156, pS117; Martinez FD, 1999, LANCET S2, V354, pSII12; Means TK, 1999, J IMMUNOL, V163, P6748; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325; Miyake K, 2003, INT IMMUNOPHARMACOL, V3, P119, DOI 10.1016/S1567-5769(02)00258-8; Muzio M, 2000, J IMMUNOL, V164, P5998; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Sieling PA, 2002, CURR OPIN MICROBIOL, V5, P70, DOI 10.1016/S1369-5274(02)00288-6; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; WERNER M, 2003, J ALLERGY CLIN IMMUN, V112, P1; Yoshimura A, 1999, J IMMUNOL, V163, P1	31	338	352	1	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					482	488		10.1016/j.jaci.2003.12.374		7	Allergy; Immunology	Allergy; Immunology	802DM	WOS:000220144200021	15007351	
J	Mishra, A; Hogan, SP; Brandt, EB; Rothenberg, ME				Mishra, A; Hogan, SP; Brandt, EB; Rothenberg, ME			An etiological role for aeroallergens and eosinophils in experimental esophagitis	JOURNAL OF CLINICAL INVESTIGATION			English	Article							GASTROESOPHAGEAL REFLUX; CHEMOKINE EOTAXIN; ANTIGEN; ASTHMA; AIRWAYS; MOUSE; INTERLEUKIN-5; INFLAMMATION; ALLERGEN; CHILDREN	Eosinophil infiltration into the esophagus is observed in diverse diseases including gastroesophageal reflux and allergic gastroenteritis, but the processes involved are largely unknown. We now report an original model of experimental esophagitis induced by exposure of mice to respiratory allergen. Allergen-challenged mice develop marked levels of esophageal eosinophils, free eosinophil granules, and epithelial cell hyperplasia, features that mimic the human disorders. Interestingly, exposure of mice to oral or intragastric allergen does not promote eosinophilic esophagitis, indicating that hypersensitivity in the esophagus occurs with simultaneous development of pulmonary inflammation. Furthermore, in the absence of eotaxin, eosinophil recruitment is attenuated, whereas in the absence of IL-5, eosinophil accumulation and epithelial hyperplasia are ablated. These results establish a pathophysiological connection between allergic hypersensitivity responses in the lung and esophagus and demonstrate an etiologic role for inhaled allergens and eosinophils in gastrointestinal inflammation.	Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA	Rothenberg, ME (reprint author), Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA.				NIAID NIH HHS [R01 AI045898, R01 AI42242-02, R01 AI45898-01]; NIAMS NIH HHS [R01 AR042242]		Burks AW, 1998, J PEDIATR-US, V133, P175, DOI 10.1016/S0022-3476(98)70215-X; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DISCOMBE G, 1946, Lancet, V1, P195; DONALDSON K, 1995, EXP TOXICOL PATHOL, V47, P207; DVORAK AM, 1994, HISTOL HISTOPATHOL, V9, P339; Erjefalt JS, 1999, AM J RESP CRIT CARE, V160, P304; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Furuta GT, 1998, J PEDIATR GASTR NUTR, V26, P468, DOI 10.1097/00005176-199804000-00021; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; GREENSPON LW, 1986, J ALLERGY CLIN IMMUN, V77, P443, DOI 10.1016/0091-6749(86)90178-8; HAMEL R, 1986, J APPL PHYSIOL, V61, P2081; Harding SM, 1999, J ALLERGY CLIN IMMUN, V104, P251, DOI 10.1016/S0091-6749(99)70360-X; Holgate ST, 1999, NATURE, V402, pB2; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Kelly KJ, 2000, J PEDIATR GASTR NUTR, V30, pS28, DOI 10.1097/00005176-200001001-00005; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; MARRETTA J, 1979, IMMUNOLOGY, V37, P609; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723; Orenstein SR, 2000, AM J GASTROENTEROL, V95, P1422; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SCHUMACHER JH, 1988, J IMMUNOL, V141, P1576; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; WILLSKARP MA, 1999, IN VIVO MODELS INFLA, P137; WINTER HS, 1982, GASTROENTEROLOGY, V83, P818; Xia Y, 2000, PARASITOLOGY, V120, P211, DOI 10.1017/S0031182099005363; Yang Y, 1998, BLOOD, V92, P3912	37	337	348	0	6	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	JAN	2001	107	1					83	90		10.1172/JCI10224		8	Medicine, Research & Experimental	Research & Experimental Medicine	389GY	WOS:000166231300014	11134183	
J	Nazaroff, WW; Weschler, CJ				Nazaroff, WW; Weschler, CJ			Cleaning products and air fresheners: exposure to primary and secondary air pollutants	ATMOSPHERIC ENVIRONMENT			English	Review						indoor air quality; hazardous air pollutants; terpenes; ozone; hydroxyl radical; nitrate radical	VOLATILE ORGANIC-COMPOUNDS; GAS-PHASE REACTIONS; MIXING HOUSEHOLD CLEANERS; OH RADICAL FORMATION; OXIDIZED D-LIMONENE; INDOOR AIR; NO3 RADICALS; RATE CONSTANTS; OCCUPATIONAL ASTHMA; BUILDING-MATERIALS	Building occupants, including cleaning personnel, are exposed to a wide variety of airborne chemicals when cleaning agents and air fresheners are used in buildings. Certain of these chemicals are listed by the state of California as toxic air contaminants (TACs) and a subset of these are regulated by the US federal government as hazardous air pollutants (HAPs). California's Proposition 65 list of species recognized as carcinogens or reproductive toxicants also includes constituents of certain cleaning products and air fresheners. In addition, many cleaning agents and air fresheners contain chemicals that can react with other air contaminants to yield potentially harmful secondary products. For example, terpenes can react rapidly with ozone in indoor air generating many secondary pollutants, including TACs such as formaldehyde. Furthermore, ozone-terpene reactions produce the hydroxyl radical, which reacts rapidly with organics, leading to the formation of other potentially toxic air pollutants. Indoor reactive chemistry involving the nitrate radical and cleaning-product constituents is also of concern, since it produces organic nitrates as well as some of the same oxidation products generated by ozone and hydroxyl radicals. Few studies have directly addressed the indoor concentrations of TACs that might result from primary emissions or secondary pollutant formation following the use of cleaning agents and air fresheners. In this paper, we combine direct empirical evidence with the basic principles of indoor pollutant behavior and with information from relevant studies, to analyze and critically assess air pollutant exposures resulting from the use of cleaning products and air fresheners. Attention is focused on compounds that are listed as HAPs, TACs or Proposition 65 carcinogens/reproductive toxicants and compounds that can readily react to generate secondary pollutants. The toxicity of many of these secondary pollutants has yet to be evaluated. The inhalation intake of airborne organic compounds from cleaning product use is estimated to be of the order of 10 mg d(-1) person(-1) in California. More than two dozen research articles present evidence of adverse health effects from inhalation exposure associated with cleaning or cleaning products. Exposure to primary and secondary pollutants depends on the complex interplay of many sets of factors and processes, including cleaning product composition, usage, building occupancy, emission dynamics, transport and mixing, building ventilation, sorptive interactions with building surfaces, and reactive chemistry. Current understanding is sufficient to describe the influence of these variables qualitatively in most cases and quantitatively in a few. (C) 2004 Elsevier Ltd. All rights reserved.	Univ Calif Berkeley, Dept Civil & Environm Engn, Berkeley, CA 94720 USA; Univ Med & Dent New Jersey, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Piscataway, NJ 08854 USA; Tech Univ Denmark, Int Ctr Indoor Environm & Energy, DK-2800 Lyngby, Denmark	Nazaroff, WW (reprint author), Univ Calif Berkeley, Dept Civil & Environm Engn, Berkeley, CA 94720 USA.	nazaroff@ce.berkeley.edu	Nazaroff, William/C-4106-2008; Weschler, Charles/A-9788-2009	Nazaroff, William/0000-0001-5645-3357; Weschler, Charles/0000-0002-9097-5850			Adams W., 1993, MEASUREMENT BREATHIN; AKLAND G, 2000, RTI68300203; An Y, 1999, HVAC&R RES, V5, P297, DOI 10.1080/10789669.1999.10391240; Aschmann SM, 2001, ENVIRON SCI TECHNOL, V35, P4080, DOI 10.1021/es010831k; ATKINSON R, 1986, INT J CHEM KINET, V18, P287, DOI 10.1002/kin.550180303; ATKINSON R, 1990, INT J CHEM KINET, V22, P871, DOI 10.1002/kin.550220807; ATKINSON R, 1995, INT J CHEM KINET, V27, P941, DOI 10.1002/kin.550271002; ATKINSON R, 1991, J PHYS CHEM REF DATA, V20, P459; ATKINSON R, 1990, ATMOS ENVIRON A-GEN, V24, P2647, DOI 10.1016/0960-1686(90)90144-C; ATKINSON R, 1988, INT J CHEM KINET, V20, P513, DOI 10.1002/kin.550200703; Atkinson R., 2003, ATMOS ENV S2, V37, P197, DOI DOI 10.1016/S1352-2310(03)00391-1; BAUGHMAN AV, 1994, INDOOR AIR, V4, P114, DOI 10.1111/j.1600-0668.1994.t01-2-00006.x; Bennett DH, 2002, ENVIRON SCI TECHNOL, V36, p206A, DOI 10.1021/es0222770; Bennion JR, 1997, AM J IND MED, V31, P474, DOI 10.1002/(SICI)1097-0274(199704)31:4<474::AID-AJIM15>3.3.CO;2-L; Betts K, 2003, ENVIRON SCI TECHNOL, V37, p407A, DOI 10.1021/es0326569; Bloomfield SF, 1997, J APPL MICROBIOL, V83, P1, DOI 10.1046/j.1365-2672.1997.00199.x; Bodalal A, 2000, BUILD ENVIRON, V35, P101, DOI 10.1016/S0360-1323(99)00005-0; Bodin A, 2003, CHEM RES TOXICOL, V16, P575, DOI 10.1021/tx025609n; Bodin A, 2002, J SURFACTANTS DETERG, V5, P107, DOI 10.1007/s11743-002-0208-y; Bodin A, 2001, CONTACT DERMATITIS, V44, P207, DOI 10.1034/j.1600-0536.2001.044004207.x; Bodin A, 2000, CONTACT DERMATITIS, V43, P82, DOI 10.1034/j.1600-0536.2000.043002082.x; BORRAZZO JE, 1993, AM SOC TEST MATER, V1205, P25, DOI 10.1520/STP13098S; Bouhamra W, 1999, ENVIRON SCI TECHNOL, V33, P2100, DOI 10.1021/es980267m; Bouhamra WS, 1999, ENVIRON TECHNOL, V20, P531, DOI 10.1080/09593332008616849; BURGE PS, 1994, THORAX, V49, P842, DOI 10.1136/thx.49.8.842; Calogirou A, 1999, ATMOS ENVIRON, V33, P1423, DOI 10.1016/S1352-2310(98)00277-5; Calogirou A, 1999, ENVIRON SCI TECHNOL, V33, P453, DOI 10.1021/es980530j; *CARB, 2001, CAL CONS PROD REG; *CARB, 2003, 1997 CONS COMM PROD; CARSLAW N, 2003, ATMOS ENVIRON, V37, P5451; Chang JCS, 1997, INDOOR AIR, V7, P241, DOI 10.1111/j.1600-0668.1997.00003.x; Chang JCS, 1998, J AIR WASTE MANAGE, V48, P953, DOI 10.1080/10473289.1998.10463743; Chew AA, 1998, J CHEM SOC FARADAY T, V94, P1083, DOI 10.1039/a708183i; Clausen PA, 1997, ATMOS ENVIRON, V31, P715, DOI 10.1016/S1352-2310(96)00230-0; Clausen PA, 2001, ENVIRON INT, V26, P511, DOI 10.1016/S0160-4120(01)00035-6; COHLE SD, 2001, FORENSIC SCI INT, V24, P137; Colombo A., 1991, INDOOR AIR, V1, P13, DOI DOI 10.1111/J.1600-0668.1991.02-11.X; Colombo A., 1993, INDOOR AIR, V3, P276, DOI 10.1111/j.1600-0668.1993.00009.x; COOPER SD, 1995, J EXPO ANAL ENV EPID, V5, P57; CORCHNOY SB, 1990, ENVIRON SCI TECHNOL, V24, P1497, DOI 10.1021/es00080a007; Cox SS, 2001, ATMOS ENVIRON, V35, P3823, DOI 10.1016/S1352-2310(01)00175-3; Devos M., 1990, STANDARDIZED HUMAN O; DRESCHER AC, 1995, INDOOR AIR, V5, P204, DOI 10.1111/j.1600-0668.1995.t01-1-00007.x; DUNN S, 1966, CAN MED ASSOC J, V94, P401; Elkilani A, 2001, PROCESS SAF ENVIRON, V79, P233, DOI 10.1205/095758201750362271; Elkilani AS, 2003, ENVIRON INT, V29, P575, DOI 10.1016/S0160-4120(03)00014-X; EWERS L, 1994, AM IND HYG ASSOC J, V55, P650; FAIGEL HC, 1964, NEW ENGL J MED, V271, P618, DOI 10.1056/NEJM196409172711209; Fan ZH, 2003, ENVIRON SCI TECHNOL, V37, P1811, DOI 10.1021/es026231i; Fick J, 2003, ATMOS ENVIRON, V37, P4087, DOI 10.1016/S1352-2310(03)00522-3; Fick J, 2002, ATMOS ENVIRON, V36, P3299, DOI 10.1016/S1352-2310(02)00291-1; FICK J, 2003, THESIS UMEA U UMEA; Finlayson-Pitts B. J., 2000, CHEM UPPER LOWER ATM; FORTMANN R, 1999, P 8 INT C IND AIR QU, V3, P31; Franke DL, 1997, INDOOR AIR, V7, P41, DOI 10.1111/j.1600-0668.1997.t01-3-00006.x; GAPANYGAPANAVICIUS M, 1982, BRIT MED J, V285, P1086; GAPANYGAPANAVICIUS M, 1982, JAMA-J AM MED ASSOC, V248, P349; Gibson W B, 1991, J Expo Anal Environ Epidemiol, V1, P369; GIRMAN JR, 1987, ATMOS ENVIRON, V21, P315, DOI 10.1016/0004-6981(87)90007-2; Glasius M, 2000, ENVIRON SCI TECHNOL, V34, P1001, DOI 10.1021/es990445r; Gosselin RE, 1984, CLIN TOXICOLOGY COMM; GREENE CR, 1992, INT J CHEM KINET, V24, P803, DOI 10.1002/kin.550240905; Griffin RJ, 1999, J GEOPHYS RES-ATMOS, V104, P3555, DOI 10.1029/1998JD100049; GROSJEAN D, 1993, ENVIRON SCI TECHNOL, V27, P2754, DOI 10.1021/es00049a014; GROSJEAN D, 1992, ATMOS ENVIRON A-GEN, V26, P1395, DOI 10.1016/0960-1686(92)90124-4; Haghighat F, 1996, INDOOR AIR, V6, P278, DOI 10.1111/j.1600-0668.1996.00007.x; Hallquist M, 1997, ENVIRON SCI TECHNOL, V31, P3166, DOI 10.1021/es970151a; HATTIS RP, 1991, MORBIDITY MORTALITY, V40, P619; HEGARTY JM, 1995, RESP MED, V89, P279, DOI 10.1016/0954-6111(95)90088-8; Henneberger PK, 2003, J OCCUP ENVIRON MED, V45, P360, DOI 10.1097/01.jom.0000063620.37065.6f; HODGSON AT, 2003, ENV ENERGY TECHNOLOG; Hodgson A. T., 2003, LBNL51715; Howard-Reed C, 2002, J AIR WASTE MANAGE, V52, P147; Jang M, 1999, ATMOS ENVIRON, V33, P459, DOI 10.1016/S1352-2310(98)00222-2; JENKINS PL, 1992, ATMOS ENVIRON A-GEN, V26, P2141, DOI 10.1016/0960-1686(92)90402-7; Jerrim KL, 2002, J ALLERGY CLIN IMMUN, V109, P63, DOI 10.1067/mai.2002.120272; Jerrim KL, 2001, J ELECTROSTAT, V53, P39, DOI 10.1016/S0304-3886(01)00128-0; JONES FL, 1972, J AMER MED ASSOC, V222, P1312; Jorgensen RB, 1999, ENVIRON INT, V25, P17, DOI 10.1016/S0160-4120(98)00090-7; Jorgensen RB, 1999, INDOOR AIR, V9, P2, DOI 10.1111/j.1600-0668.1999.t01-3-00002.x; Jorgensen RB, 2000, INDOOR AIR, V10, P27, DOI 10.1034/j.1600-0668.2000.010001027.x; Josephson KL, 1997, J APPL MICROBIOL, V83, P737, DOI 10.1046/j.1365-2672.1997.00308.x; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; KARLBERG AT, 1994, ARCH DERMATOL RES, V286, P97, DOI 10.1007/BF00370734; KARLBERG AT, 1992, CONTACT DERMATITIS, V26, P332, DOI 10.1111/j.1600-0536.1992.tb00129.x; KIRKOTHMER, 1989, ENCY CHEM TECHNOLOGY, V15, P413; KNOPPEL H, 1989, ENVIRON INT, V15, P413, DOI 10.1016/0160-4120(89)90056-1; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kovacs DC, 1997, J EXPO ANAL ENV EPID, V7, P505; Kreiss K., 1982, ENVIRON INT, V8, P337, DOI 10.1016/0160-4120(82)90047-2; Kroll JH, 2002, J AM CHEM SOC, V124, P8518, DOI 10.1021/ja0266060; Lai ACK, 2000, J AIR WASTE MANAGE, V50, P1688; Li TH, 2002, ENVIRON SCI TECHNOL, V36, P3295, DOI 10.1021/es015842s; LI TH, 2001, THESIS GRADUATE SCH; Lioy PJ, 1998, J EXPO ANAL ENV EPID, V8, P17; Long CM, 2000, J AIR WASTE MANAGE, V50, P1236; Lynch RM, 2000, ENVIRON HEALTH PERSP, V108, P911, DOI 10.1289/ehp.00108911; Maroni M., 1995, INDOOR AIR QUALITY C; Marty MA, 2002, HUM ECOL RISK ASSESS, V8, P1723, DOI 10.1080/20028091057574; MATTHEWS TG, 1987, ENVIRON SCI TECHNOL, V21, P629, DOI 10.1021/es00161a002; Meininghaus R, 1999, ATMOS ENVIRON, V33, P2395, DOI 10.1016/S1352-2310(98)00367-7; Meininghaus R, 2000, INDOOR BUILT ENVIRON, V9, P277, DOI 10.1159/000057520; MEININGHAUS R, 2002, INDOOR AIR, V1, P215; Mendonca EMC, 2003, AM J IND MED, V43, P611, DOI 10.1002/ajim.10210; MORRRISON GC, 1999, THESIS U CALIFORNIA; MRVOS R, 1993, SOUTHERN MED J, V86, P654, DOI 10.1097/00007611-199306000-00013; MURPHY DMF, 1976, CHEST, V69, P372, DOI 10.1378/chest.69.3.372; MURRAY DM, 1995, RISK ANAL, V15, P459, DOI 10.1111/j.1539-6924.1995.tb00338.x; NAZAROFF WW, 1986, ENVIRON SCI TECHNOL, V20, P924, DOI 10.1021/es00151a012; Nielsen J, 1999, OCCUP MED-OXFORD, V49, P291, DOI 10.1093/occmed/49.5.291; Nilsen SK, 2002, BUILD ENVIRON, V37, P1373, DOI 10.1016/S0360-1323(01)00125-1; Nilsson U, 1996, CHROMATOGRAPHIA, V42, P199, DOI 10.1007/BF02269653; OEHHA (Office of Environmental Health Hazard Assessment), 2003, PROP 65 STAT REP SAF; OLSON W, 1994, J ENVIRON HEALTH, V56, P27; Pascuzzi TA, 1998, MIL MED, V163, P102; Persily A., 1989, IAQ 89 HUMAN EQUATIO, P128; Pommer L., 2003, THESIS UMEA U UMEA; Popa J, 2003, BUILD ENVIRON, V38, P959, DOI 10.1016/S0360-1323(03)00063-5; Purohit A, 2000, INT ARCH OCC ENV HEA, V73, P423, DOI 10.1007/s004200000162; REISZ GR, 1986, CHEST, V89, P49, DOI 10.1378/chest.89.1.49; Roache N, 2000, P ENG SOL IND AIR QU; ROBINSON PA, 1983, INFECT CONT HOSP EP, V4, P158; ROGERS JD, 1989, ENVIRON SCI TECHNOL, V23, P177, DOI 10.1021/es00179a006; Rohr AC, 2003, AEROSOL SCI TECH, V37, P65, DOI 10.1080/02786820390112597; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Rusin P, 1998, J APPL MICROBIOL, V85, P819, DOI 10.1046/j.1365-2672.1998.00598.x; SACK TM, 1992, ATMOS ENVIRON A-GEN, V26, P1063, DOI 10.1016/0960-1686(92)90038-M; SALTHAMMER T, 1999, ORGANIC INDOOR AIR P, P219, DOI 10.1002/9783527613663.ch16; Sarwar G, 2002, ATMOS ENVIRON, V36, P3973, DOI 10.1016/S1352-2310(02)00278-9; SARWAR G, 2002, INDOOR AIR 2002, V5, P80; SAVONIUS B, 1994, ALLERGY, V49, P877, DOI 10.1111/j.1398-9995.1994.tb00791.x; SCHNEIDER T, 1994, BUILD ENVIRON, V29, P363, DOI 10.1016/0360-1323(94)90035-3; Shepherd JL, 1996, J AIR WASTE MANAGE, V46, P631, DOI 10.1080/10473289.1996.10467497; SHOREES B, 1991, INT J CHEM KINET, V23, P897, DOI 10.1002/kin.550231005; SHU YG, 1994, INT J CHEM KINET, V26, P1193, DOI 10.1002/kin.550261207; SHU YH, 1995, J GEOPHYS RES-ATMOS, V100, P7275, DOI 10.1029/95JD00368; Sorensen DN, 2002, ATMOS ENVIRON, V36, P9, DOI 10.1016/S1352-2310(01)00479-4; Sparks LE, 1999, INDOOR AIR, V9, P10, DOI 10.1111/j.1600-0668.1999.t01-3-00003.x; Sparks LE, 1991, INDOOR AIR, V1, P577, DOI 10.1111/j.1600-0668.1991.00020.x; STEIBER RS, 1995, P ENG SOL IND AIR QU, P29; Stemmler K, 1997, ENVIRON SCI TECHNOL, V31, P1496, DOI 10.1021/es9607547; Stemmler K, 1996, J PHYS CHEM-US, V100, P2114, DOI 10.1021/jp9520355; Tanen DA, 1999, NEW ENGL J MED, V341, P848, DOI 10.1056/NEJM199909093411115; TICHENOR BA, 1988, JAPCA J AIR WASTE MA, V38, P264; Tichenor BA, 1991, INDOOR AIR, V1, P23, DOI 10.1111/j.1600-0668.1991.03-11.x; Tobias HJ, 2000, ENVIRON SCI TECHNOL, V34, P2105, DOI 10.1021/es9907156; Tobin C, 2000, POPTRONICS, V1, P3; TUAZON EC, 1993, ENVIRON SCI TECHNOL, V27, P1832, DOI 10.1021/es00046a011; U.S. Dept. of Labor Bureau of Labor Statistics, 2001, NAT OCC EMPL WAG EST; van der Wal JF, 1998, INDOOR AIR, V8, P103; VanOsdell DW, 1996, J AIR WASTE MANAGE, V46, P883; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; Vejrup KV, 2002, SCI TOTAL ENVIRON, V300, P51, DOI 10.1016/S0048-9697(02)00280-2; VEJRUP KV, 1996, THESIS DANISH TU COP; Virkkula A, 1999, J GEOPHYS RES-ATMOS, V104, P3569, DOI 10.1029/1998JD100017; Wainman T, 2000, ENVIRON HEALTH PERSP, V108, P1139, DOI 10.2307/3434825; WALLACE LA, 1987, ATMOS ENVIRON, V21, P385, DOI 10.1016/0004-6981(87)90017-5; WEBB AM, 2002, INDOOR AIR 2002, V3, P512; Weegels MF, 2001, RISK ANAL, V21, P499, DOI 10.1111/0272-4332.213128; Weschler CJ, 2000, INDOOR AIR, V10, P92, DOI 10.1034/j.1600-0668.2000.010002092.x; Weschler CJ, 1999, ATMOS ENVIRON, V33, P2301, DOI 10.1016/S1352-2310(99)00083-7; Weschler CJ, 1996, ENVIRON SCI TECHNOL, V30, P3250, DOI 10.1021/es960032f; Weschler CJ, 1997, ENVIRON SCI TECHNOL, V31, P3719, DOI 10.1021/es970669e; Weschler CJ, 2003, ATMOS ENVIRON, V37, P5455, DOI 10.1016/j.atmosenv.2003.09.022; WESCHLER CJ, 1992, ENVIRON SCI TECHNOL, V26, P179, DOI 10.1021/es00025a022; Weschler CJ, 1997, ATMOS ENVIRON, V31, P3487, DOI 10.1016/S1352-2310(97)00219-7; WESCHLER CJ, 1994, ENVIRON SCI TECHNOL, V28, P2120, DOI 10.1021/es00061a021; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x; Weschler CJ, 2003, INDOOR ENV AIRBORNE, P171; Wiley J.A., 1991, ACTIVITY PATTERNS CA; Wilson AL, 1996, J EXPO ANAL ENV EPID, V6, P311; Wolkoff P, 2001, ATMOS ENVIRON, V35, P4407, DOI 10.1016/S1352-2310(01)00244-8; WOLKOFF P, 1995, INDOOR AIR, V5, P196, DOI 10.1111/j.1600-0668.1995.t01-1-00006.x; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Won D, 2001, INDOOR AIR, V11, P246, DOI 10.1034/j.1600-0668.2001.110406.x; Won DY, 2001, ATMOS ENVIRON, V35, P4479, DOI 10.1016/S1352-2310(01)00223-0; Won DY, 2000, ENVIRON SCI TECHNOL, V34, P4193, DOI 10.1021/es9910412; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; WOOLEY J, 1990, J AIR WASTE MANAGE, V40, P1114; Yu JZ, 1998, ENVIRON SCI TECHNOL, V32, P2357, DOI 10.1021/es980129x; Zhu JP, 2001, ENVIRON INT, V26, P589, DOI 10.1016/S0160-4120(01)00046-0; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	183	336	343	15	181	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	JUN	2004	38	18					2841	2865		10.1016/j.atmosenv.2004.02.040		25	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	820XF	WOS:000221422400008		
J	Garcia-Aymerich, J; Farrero, E; Felez, MA; Izquierdo, J; Marrades, RM; Anto, JM				Garcia-Aymerich, J; Farrero, E; Felez, MA; Izquierdo, J; Marrades, RM; Anto, JM		EFRAM investigators	Risk factors of readmission to hospital for a COPD exacerbation: a prospective study	THORAX			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; CHRONIC LUNG-DISEASE; QUALITY-OF-LIFE; PHYSICAL ACTIVITIES; ASTHMA; MORTALITY; QUESTIONNAIRE; EFRAM	Background: Exacerbations of chronic obstructive pulmonary disease (COPD) are a leading cause of admission to hospital among men in many countries, although the factors causing exacerbations are largely unknown. The association between readmission for a COPD exacerbation and a wide range of modifiable potential risk factors, after adjusting for sociodemographic and clinical factors, has been assessed. Methods: Three hundred and forty patients with COPD recruited during an admission for an exacerbation in four tertiary hospitals in the Barcelona area of Spain were followed for a mean period of 1.1 years. Information on potential risk factors, including clinical and functional status, medical care and prescriptions, medication adherence, lifestyle, health status, and social support, was collected at the recruitment admission. A Cox's proportional hazards model was used to obtain independent relative risks of readmission for COPD. Results: During the follow up period 63% of patients were readmitted at least once, and 29% died. The final multivariate model showed the following risk (or protective) factors: greater than or equal to3 admissions for COPD in the year before recruitment (hazard ratio (HR)= 1.66, 95% Cl 1.16 to 2.39), forced expiratory volume in 1 second (FEV1 percentage predicted (0.97, 95% Cl 0.96 to 0.99), oxygen tension (0.88, 95% Cl 0.79 to 0.98), higher levels of usual physical activity (0.54, 95% Cl 0.34 to 0.86), and taking anticholinergic drugs (1.81, 95% 1.11 to 2.94). Exposure to passive smoking was also related to an increased risk of readmission with COPD after adjustment for clinical factors (1.63, 95% Cl 1.04 to 2.57) but did not remain in the final model. Conclusions: This is the first study to show a strong association between usual physical activity and reduced risk of readmission to hospital with COPD, which is potentially relevant for rehabilitation and other therapeutic strategies.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Univ Bellvitge, Ciutat Sanitaria, Dept Pneumol, Lhospitalet De Llobregat, Spain; Hosp del Mar, Dept Pneumol, Barcelona, Spain; Hosp Germans Trias & Pujol, Dept Pneumol, Badalona, Spain; Hosp Clin Barcelona, Dept Pneumol, Barcelona, Spain; Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain	Anto, JM (reprint author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Doctor Aiguader 80, E-08003 Barcelona, Spain.		Garcia-Aymerich, J/G-6867-2014; Alonso, Jordi/A-5514-2010; Anto, J/H-2676-2014	Garcia-Aymerich, J/0000-0002-7097-4586; Alonso, Jordi/0000-0001-8627-9636; Anto, J/0000-0002-4736-8529			AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196; Ashton CM, 1999, NEW ENGL J MED, V340, P32, DOI 10.1056/NEJM199901073400106; AYALA S, 1995, PAPELES MED, V4, P6; Barbera JA, 1997, EUR RESPIR J, V10, P1285, DOI 10.1183/09031936.97.10061285; Burge PS, 1999, THORAX, V54, P287; Cabello H, 1997, EUR RESPIR J, V10, P1137, DOI 10.1183/09031936.97.10051137; Celli BR, 1997, AM J RESP CRIT CARE, V155, P781; Collet JP, 1997, AM J RESP CRIT CARE, V156, P1719; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959; Coultas DB, 1998, THORAX, V53, P381; DONNER CF, 2000, EUROPEAN RESP MONOGR, V13, P132; ELOSUA R, 1994, AM J EPIDEMIOL, V139, P1197; Fabbri L, 1998, THORAX, V53, P803; Garcia-Aymerich J, 2000, EUR RESPIR J, V16, P1037, DOI 10.1034/j.1399-3003.2000.16f03.x; Garcia-Aymerich J, 2001, AM J RESP CRIT CARE, V164, P1002; Hosmer DW, 1989, APPL LOGISTIC REGRES; Kessler R, 1999, AM J RESP CRIT CARE, V159, P158; Madison JM, 1998, LANCET, V352, P467, DOI 10.1016/S0140-6736(97)11081-9; Maltais F, 1996, AM J RESP CRIT CARE, V154, P442; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; MURRAY PR, 1975, MAYO CLIN PROC, V50, P339; Nichol KL, 1999, ANN INTERN MED, V130, P397; Osman LM, 1997, THORAX, V52, P67; PATESSIO A, 1997, CLIN EXERCISE TESTIN, P129; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Sturmer T, 2000, J CLIN EPIDEMIOL, V53, P57, DOI 10.1016/S0895-4356(99)00137-7; Sunyer J, 1998, AM J RESP CRIT CARE, V158, P851; TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9; WEGNER RE, 1994, EUR RESPIR J, V7, P725, DOI 10.1183/09031936.94.07040725	36	336	341	3	28	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	FEB	2003	58	2					100	105		10.1136/thorax.58.2.100		6	Respiratory System	Respiratory System	644TB	WOS:000180934500004	12554887	
J	Dodd, M; Janson, S; Facione, N; Faucett, J; Froelicher, ES; Humphreys, J; Lee, K; Miaskowski, C; Puntillo, K; Rankin, S; Taylor, D				Dodd, M; Janson, S; Facione, N; Faucett, J; Froelicher, ES; Humphreys, J; Lee, K; Miaskowski, C; Puntillo, K; Rankin, S; Taylor, D			Advancing the science of symptom management	JOURNAL OF ADVANCED NURSING			English	Article						concepts/constructs related to health; symptom management model; symptom management theory	TYPE-2 DIABETES MANAGEMENT; AMERICAN MIDLIFE WOMEN; PRACTITIONER PERSPECTIVES; CONTRASTING PATIENT; PAIN; EXPERIENCE; ASTHMA; STIMULATION; EDUCATION; PATTERNS	Since the publication of the original Symptom Management Model (Larson et al. 1994), faculty and students at the University of California, San Francisco (UCSF) School of Nursing Centre for System Management have tested this model in research studies and expanded the model through collegial discussions and seminars. Aim. In this paper, we describe the evidence-based revised conceptual model, the three dimensions of the model, and the areas where further research is needed. Background/Rationale. The experience of symptoms, minor to severe, prompts millions of patients to visit their healthcare providers each year. Symptoms not only create distress, but also disrupt social functioning. The management of symptoms and their resulting outcomes often become the responsibility of the patient and his or her family members. Healthcare providers have difficulty developing symptom management strategies that can be applied across acute and home-care settings because few models of symptom management have been tested empirically. To date, the majority of research on symptoms was directed toward studying a single symptom, such as pain or fatigue, or toward evaluating associated symptoms, such as depression and sleep disturbance. While this approach has advanced our understanding of some symptoms, we offer a generic symptom management model to provide direction for selecting clinical interventions, informing research, and bridging an array of symptoms associated with a variety of diseases and conditions. Finally, a broadly-based symptom management model allows the integration of science from other fields.	Univ Calif San Francisco, Sch Nursing, San Francisco, CA 94143 USA	Dodd, M (reprint author), Univ Calif San Francisco, Sch Nursing, Box 0610, San Francisco, CA 94143 USA.				NINR NIH HHS [P30 NR03927]		BECK SL, 1999, CANC SYMPTOM MANAGEM, P328; Berg JA, 1999, NURS RES, V48, P71, DOI 10.1097/00006199-199903000-00005; Berg JA, 1999, MENOPAUSE, V6, P105; Dodd M J, 1996, Oncol Nurs Forum, V23, P921; Dodd MJ, 1999, CANCER INVEST, V17, P278, DOI 10.3109/07357909909040598; DODD MJ, 1999, RES STUDY EXERCISE I; Duncan GH, 1998, J NEUROPHYSIOL, V80, P3326; Facione N C, 1995, Cancer Pract, V3, P219; Facione NC, 1998, CANCER NURS, V21, P430, DOI 10.1097/00002820-199812000-00007; FAGERHAUGH S, 1977, POLITICS PAIN MANAGE; FAUCETT J, 1997, WOMENS HLTH COMPLEXI, P154; FAUCETT J, 1998, NONBIOMECHANICAL FAC; Franck LS, 1997, J PAIN SYMPTOM MANAG, V14, P343, DOI 10.1016/S0885-3924(97)00222-4; Franck LS, 1999, PEDIATRICS, V104, DOI 10.1542/peds.104.5.e62; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; Given B A, 1994, Cancer Pract, V2, P187; Golding J. M., 1996, J WOMENS HEALTH, V5, P143, DOI 10.1089/jwh.1996.5.143; Harver A, 1990, DYSPNEA, P1; HUMPHREYS JC, 1999, IMAGE, V2, P139; Hunt LM, 1998, WESTERN J NURS RES, V20, P656, DOI 10.1177/019394599802000602; Janson S, 1998, J ASTHMA, V35, P427, DOI 10.3109/02770909809048951; Janson S, 1999, AM J RESP CRIT CARE, V159, pA241; JANSONBJERKLIE S, 1986, NURS RES, V35, P154; JAYNE RL, 1996, PATIENT ED ISSUES PR, P41; Johnston CC, 1996, PEDIATRICS, V98, P925; KARAM JH, 1996, CURRENT MED DIAGNOSI, P1030; KOENIG K, 1999, THESIS U CALIFORNIA; Larson PJ, 1994, IMAGE J NURSING SCHO, V26, P272; Lee KA, 2000, OBSTET GYNECOL, V95, P14, DOI 10.1016/S0029-7844(99)00486-X; Lee KA, 1996, MENOPAUSE, V3, P154; Lenz ER, 1997, ADV NURS SCI, V19, P14; MIASKOWSKI C, 1995, RES STUDY SELF CARE; Paulson PE, 1998, PAIN, V76, P223, DOI 10.1016/S0304-3959(98)00048-7; PUNTILLO K, 1999, ENA ANN M WASH DC; Rankin SH, 1998, WESTERN J NURS RES, V20, P677; RANKIN SH, 1990, HEART LUNG, V19, P481; RANKIN SH, 1997, CIRCULATION S, V96, P191; RITTENHOUSE C, 1993, J WOMENS HEALTH, V2, P145, DOI 10.1089/jwh.1993.2.145; Robison JI, 1998, AM J HEALTH PROMOT, V13, P1; SHIBA G, 1997, THESIS U CALIFORNIA; Sidani S, 1997, EVALUATING NURSING I; Stevens B, 1999, NURS RES, V48, P35, DOI 10.1097/00006199-199901000-00006; STOMMEL M, 1993, CANCER, V71, P1867, DOI 10.1002/1097-0142(19930301)71:5<1867::AID-CNCR2820710525>3.0.CO;2-7; TAYLOR D, 1986, CULTURE SOC MENSTRUA, P159; TAYLOR D, 1991, MENSTRUATION HLTH IL, P103; TAYLOR D, 1995, WOMENS PRIMARY CARE, P141; TURK DC, 1991, PAIN, V44, P5, DOI 10.1016/0304-3959(91)90142-K; Whittemore R, 2000, QUAL HEALTH RES, V10, P260, DOI 10.1177/104973200129118408; WILSON SR, 1993, AM J MED, V94, P564, DOI 10.1016/0002-9343(93)90206-5	49	336	352	4	37	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0309-2402			J ADV NURS	J. Adv. Nurs.	MAR	2001	33	5					668	676		10.1046/j.1365-2648.2001.01697.x		9	Nursing	Nursing	420GL	WOS:000167997200013	11298204	
J	Sears, MR; Greene, JM; Willan, AR; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Poulton, R				Sears, MR; Greene, JM; Willan, AR; Taylor, DR; Flannery, EM; Cowan, JO; Herbison, GP; Poulton, R			Long-term relation between breastfeeding and development of atopy and asthma in children and young adults: a longitudinal study	LANCET			English	Article							CHILDHOOD ASTHMA; NEW-ZEALAND; FED INFANTS; EPIDEMIOLOGY; MICROFLORA; ALLERGY; BIRTH	Background Breastfeeding is widely advocated to reduce risk of atopy and asthma, but the evidence for such an effect is conflicting. We aimed to assess long-term outcomes of asthma and atopy related to breastfeeding in a New Zealand birth cohort. Methods Our cohort consisted of 1037 of 1139 children born in Dunedin, New Zealand, between April, 1972, and March, 1973, and residing in Otago province at age 3 years. Children were assessed every 2-5 years from ages 9 to 26 years with respiratory questionnaires, pulmonary function, bronchial challenge, and allergy skin tests. History of breastfeeding had been independently recorded in early childhood. Findings 504 (49%) of 1037 eligible children were breastfed (4 weeks or longer) and 533 (51%) were not. More children who were breastfed were atopic at all ages from 13 to 21 years to cats (p=0.0001), house dust mites (p=0.0010), and grass pollen (p<0.0001) than those who were not. More children who were breastfed reported current asthma at each assessment between age 9 (p=0.0008) and 26 years (p=0.0008) than those who were not. Breastfeeding effects were not affected by parental history of hayfever or asthma. Multifactor analysis controlling for socioeconomic status, parental smoking, birth order, and use of sheepskin bedding in infancy, showed odds ratios of 1.94 (95% Cl 1.42-2-65, p<0.0001) for any allergen positive at age 13 years, 2.40 (1-36-4.26, p=0.0003) for current asthma at 9 years, and 1.83 (1.35-2.47, p<0.0001) for current asthma at 9-26 years by repeated-measures analysis. Interpretation Breastfeeding does not protect children against atopy and asthma and may even increase the risk.	McMaster Univ, Dept Med, Hamilton, ON, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand; Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand	Sears, MR (reprint author), St Josephs Healthcare & McMaster Univ, Firestone Inst Resp Hlth, 50 Charlton Ave, Hamilton, ON L8N 4A6, Canada.						Aarts C, 2000, INT J EPIDEMIOL, V29, P1041, DOI 10.1093/ije/29.6.1041; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; BALDWIN A, 1999, UNPUB PLUNKET SOC PE; BEREZIN S, 1989, AM J DIS CHILD, V143, P361; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; BUCKFIELD PM, 1978, NEW ZEAL MED J, V88, P244; BURNEY PGJ, 1987, CHEST, V91, P79; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; Diggle P. J., 1994, ANAL LONGITUDINAL DA; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Heinig MJ, 2001, PEDIATR CLIN N AM, V48, P105, DOI 10.1016/S0031-3955(05)70288-1; HOOD LJ, 1978, NEW ZEAL MED J, V88, P273; JONES DT, 1987, BRIT J DIS CHEST, V81, P332, DOI 10.1016/0007-0971(87)90181-1; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; KAPLAN BA, 1985, J EPIDEMIOL COMMUN H, V39, P152, DOI 10.1136/jech.39.2.152; KAUFMAN HS, 1976, ANN ALLERGY, V37, P410; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; LAKE AM, 1982, J PEDIATR-US, V101, P906, DOI 10.1016/S0022-3476(82)80008-5; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1999, LANCET S2, V354, P1215; Oddy WH, 1999, BRIT MED J, V319, P815; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Romieu I, 2000, J ASTHMA, V37, P575, DOI 10.3109/02770900009090812; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Rubaltelli FF, 1998, J PERINAT MED, V26, P186, DOI 10.1515/jpme.1998.26.3.186; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1982, NEW ZEAL MED J, V95, P533; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; Wafula EM, 1999, E AFR MED J, V76, P606; Wright A. L., 1989, BRIT MED J, V299, P945; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	37	335	352	2	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	SEP 21	2002	360	9337					901	907		10.1016/S0140-6736(02)11025-7		7	Medicine, General & Internal	General & Internal Medicine	596AU	WOS:000178142200008	12354471	
J	Skoner, DR				Skoner, DR			Allergic rhinitis: Definition, epidemiology, detection, and pathophysiology, diagnosis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; IgE; mast cells; perennial rhinitis	PRACTICE PARAMETERS; NASAL-MUCOSA; DUST MITE; ASTHMA; CHILDHOOD; DISEASE; PREVALENCE; CYTOKINES; IL-4	Allergic rhinitis (AR) is a heterogeneous disorder that despite its high prevalence is often undiagnosed. It is characterized by one or more symptoms including sneezing, itching, nasal congestion, and rhinorrhea. Many causative agents have been linked to AR including pollens, molds, dust mites, and animal dander. Seasonal allergic rhinitis (SAR) is fairly easy to identify because of the rapid and reproducible onset and offset of symptoms in association with pollen exposure. Perennial AR is often more difficult to detect than SAR because of the overlap with sinusitis, respiratory infections, and vasomotor rhinitis. SAR can result in hyperresponsiveness to allergens such as cigarette smoke, once pollen season is over. Perennial AR is defined as occurring during approximately 9 months of the year. AR affects an estimated 20 to 40 million people in the United States alone, and the incidence is increasing; an estimated 20% of cases are SAR; 40% of cases are perennial rhinitis; and 40% of cases are mixed. The pathophysiology of SAR is complex. There is a strong genetic component to the allergic response, which is driven through mucosal infiltration and action on plasma cells, roast cells, and eosinophils. The allergic response occurs in two phases, which are considered the "early" and "late" phase responses. Early phase response occurs within minutes of exposure to the allergen and tends to produce sneezing, itching, and clear rhinorrhea; late phase response occurs 4 to 8 hours after allergen exposure and is characterized by congestion, fatigue, malaise, irritability, and possibly neurocognitive deficits. The key to diagnosis of AR is awareness of signs and symptoms. IgE antibody tests to detect specific allergens are the standard method used today; however, in addition, diagnosis must be confirmed with a positive history and demonstration that the symptoms are the result of IgE-mediated inflammation.	Univ Pittsburgh, Sch Med, Dept Pediat & Otolaryngol, Pittsburgh, PA 15231 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15231 USA	Skoner, DR (reprint author), Univ Pittsburgh, Sch Med, Dept Pediat & Otolaryngol, Pittsburgh, PA 15231 USA.						ABERG N, 1993, CLIN EXP ALLERGY, V23, P829, DOI 10.1111/j.1365-2222.1993.tb00260.x; ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; AFZELIUS BA, 1976, SCIENCE, V193, P317, DOI 10.1126/science.1084576; BARANIUK J, 1995, MECH ASTHMA RHINITIS, P652; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; BRADDING P, 1993, J IMMUNOL, V151, P3853; BROSTROM G, 1990, GRANA, V28, P123; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Evans R., 1993, ALLERGY PRINCIPLES P, P1109; FIREMAN P, 1991, ATLAS ALLERGIES; GERRARD JW, 1976, ANN ALLERGY, V36, P10; JELKS, 1986, ALLERGY PLANTS THAT; LINNA O, 1992, ACTA PAEDIATR, V81, P100, DOI 10.1111/j.1651-2227.1992.tb12182.x; LUCENTE FE, 1989, OTOLARYNG CLIN N AM, V22, P307; LUND VJ, 1991, J OTOLARYNGOL, V20, P379; MACKAY I, 1987, SCOTTBROWNS OTOLARYN, P61; MCMENAMIN P, 1994, ANN ALLERGY, V73, P35; Meltzer E O, 1997, J Allergy Clin Immunol, V99, pS805; Mygind N, 1993, ALLERGIC NONALLERGIC; MYGIND N, 1985, ALLERGIC VASOMOTOR R, P15; NACLERIO RM, 1991, NEW ENGL J MED, V325, P860; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; NEWACHECK PW, 1994, J PEDIATR-US, V124, P40, DOI 10.1016/S0022-3476(94)70252-7; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; RAPHAEL GD, 1991, J ALLERGY CLIN IMMUN, V87, P457, DOI 10.1016/0091-6749(91)90001-5; RIMPELA AH, 1995, SCAND J SOC MED, V23, P60; SCHACHTER J, 1976, J ALLERGY CLIN IMMUN, V57, P342, DOI 10.1016/0091-6749(76)90091-9; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927; SKONER D, 1996, ALLERGY ASTHMA IMMUN, P411; SKONER D, 1997, ATLAS PEDIAT PHYSICA, P75; SKONER DP, 1988, AM J RHINOL, V2, P155, DOI 10.2500/105065888781692998; TANG RB, 1990, CLIN EXP ALLERGY, V20, P33, DOI 10.1111/j.1365-2222.1990.tb02772.x; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WRIGHT AL, 1994, PEDIATRICS, V94, P895; YOUNG D, 1970, J REPROD FERTIL, V23, P541	39	329	346	1	35	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S2	S8		10.1067/mai.2001.115569		7	Allergy; Immunology	Allergy; Immunology	459BU	WOS:000170230600002	11449200	
J	Lough, GC; Schauer, JJ; Park, JS; Shafer, MM; Deminter, JT; Weinstein, JP				Lough, GC; Schauer, JJ; Park, JS; Shafer, MM; Deminter, JT; Weinstein, JP			Emissions of metals associated with motor vehicle roadways	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Article							AIRBORNE PARTICULATE MATTER; FINE ORGANIC AEROSOL; CHEMICAL-COMPOSITION; SOURCE PROFILES; LOS-ANGELES; URBAN AREAS; EXHAUST; TUNNEL; ASTHMA; CARBON	Emissions of metals and other particle-phase species from on-road motor vehicles were measured in two tunnels in Milwaukee, WI during the summer of 2000 and winter of 2001. Emission factors were calculated from measurements of fine (PM2.5) and coarse (PM10) particulate matter at tunnel entrances and exits, and effects of fleet composition and season were investigated. Cascade impactors (MOUDI) were used to obtain size-resolved metal emission rates. Metals were quantified with inductively-coupled plasma mass spectrometry (ICP-MS) and X-ray fluorescence (XRF). PM10 emission rates ranged from 38.7 to 201 mg km(-1) and were composed mainly of organic carbon (OC, 30%), inorganic ions (sulfate, chloride, nitrate, ammonium, 20%), metals (19%), and elemental carbon (EC, 9.3%). PM10 metal emissions were dominated by crustal elements Si, Fe, Ca, Na, Mg, Al, and K, and elements associated with tailpipe emissions and brake and tire wear, including Cu, Zn, Sb, Ba, Pb, and S. Metals emitted in PM2.5 were lower (11.6% of mass). Resuspension of roadway dust was dependent on weather and road surface conditions, and increased emissions were related to higher traffic volumes and fractions of heavy trucks. Emission of noble metals from catalytic converters appeared to be impacted by the presence of older vehicles. Elements related to brake wear were impacted by enriched road dust resuspension, but correlations between these elements in PM2.5 indicate that direct brake wear emissions are also important. A submicrometer particle mode was observed in the emissions of Pb, Ca, Fe, and Cu.	Univ Wisconsin, Environm Chem & Technol Program, Madison, WI 53706 USA; Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA; US EPA, Res Triangle Pk, NC USA	Schauer, JJ (reprint author), Univ Wisconsin, Environm Chem & Technol Program, Madison, WI 53706 USA.	jschauer@engr.wisc.edu		Lough, Glynis/0000-0002-9152-6520			Allen JO, 2001, ENVIRON SCI TECHNOL, V35, P4189, DOI 10.1021/es0015545; Aust A., 2002, PARTICLE CHARACTERIS; Cadle SH, 1997, ENVIRON SCI TECHNOL, V31, P3405, DOI 10.1021/es9700257; Cadle SH, 1999, ENVIRON SCI TECHNOL, V33, P2328, DOI 10.1021/es9810843; Chow JC, 2001, AEROSOL SCI TECH, V34, P23, DOI 10.1080/027868201300081923; Chow JC, 2003, ATMOS ENVIRON, V37, P1317, DOI 10.1016/S1352-2310(02)01021-X; Claiborn CS, 2002, ENVIRON HEALTH PERSP, V110, P547; Davis AP, 2001, CHEMOSPHERE, V44, P997, DOI 10.1016/S0045-6535(00)00561-0; Dietl C, 1997, SCI TOTAL ENVIRON, V205, P235, DOI 10.1016/S0048-9697(97)00204-0; El-Fadel M, 2001, CRIT REV ENV SCI TEC, V31, P125, DOI 10.1080/20016491089190; Fraser MP, 1998, ENVIRON SCI TECHNOL, V32, P2051, DOI 10.1021/es970916e; Fraser MP, 1999, ATMOS ENVIRON, V33, P2715, DOI 10.1016/S1352-2310(98)00311-2; Garg BD, 2000, ENVIRON SCI TECHNOL, V34, P4463, DOI 10.1021/es001108h; Gavett SH, 2001, INT ARCH ALLERGY IMM, V124, P109, DOI 10.1159/000053685; Gertler A.W., 2002, EMISSIONS DIESEL GAS; GERTLER AW, 1995, AWMA PARTICULATE HLT; Gillies JA, 2001, ENVIRON SCI TECHNOL, V35, P1054, DOI 10.1021/es991320p; Harrison RM, 1996, ENVIRON SCI TECHNOL, V30, P825, DOI 10.1021/es950252d; HILDEMANN LM, 1991, ENVIRON SCI TECHNOL, V25, P744, DOI 10.1021/es00016a021; HUANG XD, 1994, ATMOS ENVIRON, V28, P1385, DOI 10.1016/1352-2310(94)90201-1; Jaecker-Voirol A, 2000, ENVIRON MODELL SOFTW, V15, P575, DOI 10.1016/S1364-8152(00)00044-X; Kanitsar K, 2003, J ANAL ATOM SPECTROM, V18, P239, DOI 10.1039/b212218a; Kellog R., 1999, 1033 EPA; Kleeman MJ, 2000, ENVIRON SCI TECHNOL, V34, P1132, DOI 10.1021/es981276y; Kweon C. B., 2002, 2002012670 SAE; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; LOWENTHAL DH, 1994, ATMOS ENVIRON, V28, P731, DOI 10.1016/1352-2310(94)90050-7; Tarbuck EJ, 2000, ESSENTIALS GEOLOGY; Luttinger D, 2003, ENVIRON POLLUT, V123, P399, DOI 10.1016/S0269-7491(03)00025-3; Moosmuller H, 1998, J AIR WASTE MANAGE, V48, P398; NICHOLSON KW, 1989, J AEROSOL SCI, V20, P1425, DOI 10.1016/0021-8502(89)90853-7; Okada S., 2003, 2003010076 SAE; Palacios M, 2000, SCI TOTAL ENVIRON, V257, P1, DOI 10.1016/S0048-9697(00)00464-2; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565; Petrucci F, 2000, J ANAL ATOM SPECTROM, V15, P525, DOI 10.1039/a909792i; Pierson WR, 1996, ATMOS ENVIRON, V30, P2233, DOI 10.1016/1352-2310(95)00276-6; PIERSON WR, 1983, AEROSOL SCI TECH, V2, P1; Rauch S, 2000, ENVIRON SCI TECHNOL, V34, P3119, DOI 10.1021/es000001r; Rogak SN, 1998, J AIR WASTE MANAGE, V48, P545, DOI 10.1080/10473289.1998.10463707; ROGGE WF, 1993, ENVIRON SCI TECHNOL, V27, P1892, DOI 10.1021/es00046a019; Root RA, 2000, ENVIRON HEALTH PERSP, V108, P937, DOI 10.1289/ehp.00108937; Sagebiel JC, 1997, ENVIRON SCI TECHNOL, V31, P75, DOI 10.1021/es960137i; Schauer JJ, 1999, ENVIRON SCI TECHNOL, V33, P1578, DOI 10.1021/es980081n; Schauer JJ, 2003, ENVIRON SCI TECHNOL, V37, P993, DOI 10.1021/es020622f; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; Sternbeck J, 2002, ATMOS ENVIRON, V36, P4735, DOI 10.1016/S1352-2310(02)00561-7; Tsai FC, 2000, INHAL TOXICOL, V12, P121, DOI 10.1080/08958378.2000.11463204; WATSON JG, 1994, ATMOS ENVIRON, V28, P2493, DOI 10.1016/1352-2310(94)90400-6; Wrobel A, 2000, SCI TOTAL ENVIRON, V257, P199, DOI 10.1016/S0048-9697(00)00519-2; Young TM, 2002, ENVIRON SCI TECHNOL, V36, P2484, DOI 10.1021/es015609u; Zereini F, 2001, ENVIRON SCI TECHNOL, V35, P1996, DOI 10.1021/es001126z; Zielinska B, 1996, ATMOS ENVIRON, V30, P2269, DOI 10.1016/1352-2310(95)00116-6	52	327	337	32	267	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X			ENVIRON SCI TECHNOL	Environ. Sci. Technol.	FEB 1	2005	39	3					826	836		10.1021/es048715f		11	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	893IN	WOS:000226712600031	15757346	
J	Tlaskalova-Hogenova, H; Stepankova, R; Hudcovic, T; Tuckova, L; Cukrowska, B; Lodinova-Zadnikova, R; Kozakova, H; Rossmann, P; Bartova, J; Sokol, D; Funda, DP; Borovska, D; Rehakova, Z; Sinkora, J; Hofman, J; Drastich, P; Kokesova, A				Tlaskalova-Hogenova, H; Stepankova, R; Hudcovic, T; Tuckova, L; Cukrowska, B; Lodinova-Zadnikova, R; Kozakova, H; Rossmann, P; Bartova, J; Sokol, D; Funda, DP; Borovska, D; Rehakova, Z; Sinkora, J; Hofman, J; Drastich, P; Kokesova, A			Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases	IMMUNOLOGY LETTERS			English	Review						mucosal microbiota; intestinal barrier; germ-free animal; gut inflammation; allergy; autoimmunity; probioties	GERM-FREE PIGLETS; INTESTINAL EPITHELIAL-CELLS; PROBIOTIC ESCHERICHIA-COLI; INNATE IMMUNITY; GASTROINTESTINAL MICROFLORA; CONVENTIONAL CONDITIONS; ANTIBODY-FORMATION; MOLECULAR MIMICRY; BALB/C MICE; CPG-DNA	Commensal microflora (normal microflora, indigenous microbiota) consists of those micro-organisms, which are present on body surfaces covered by epithelial cells and are exposed to the external environment (gastrointestinal and respiratory tract, vagina, skin, etc.). The number of bacteria colonising mucosal and skin surfaces exceeds the number of cells forming human body. Commensal bacteria co-evolved with their hosts, however, under specific conditions they are able to overcome protective host responses and exert pathologic effects. Resident bacteria form complex ecosystems, whose diversity is enormous. The most abundant microflora. is present in the distal parts of the gut; the majority of the intestinal bacteria are Gram-negative anaerobes. More than 50% of intestinal bacteria cannot be cultured by conventional microbiological techniques. Molecular biological methods help in analysing the structural and functional complexity of the microflora and in identifying its components. Resident microflora contains a number of components able to activate innate and adaptive immunity. Unlimited immune activation in response to signals from commensal bacteria could pose the risk of inflammation; immune responses to mucosal microbiota therefore require a precise regulatory control. The mucosal immune system has developed specialised regulatory, anti-inflammatory mechanisms for eliminating or tolerating non-dangerous, food and airborne antigens and commensal micro-organisms (oral, mucosal tolerance). However, at the same time the mucosal immune system must provide local defense mechanisms against environmental threats (e.g. invading pathogens). This important requirement is fulfilled by several mechanisms of mucosal immunity: strongly developed innate defense mechanisms ensuring appropriate function of the mucosal barrier, existence of unique types of lymphocytes and their products, transport of polymeric immunoglobulins through epithelial cells into secretions (slgA) and migration and homing of cells originating from the mucosal organised tissues in mucosae and exocrine glands. The important role of commensal bacteria in development of optimally functioning mucosal immune system was demonstrated in germ-free animals (using gnotobiological techniques). Involvement of commensal microflora and its components with strong immunoactivating properties (e.g. LPS, peptidoglycans, superantigens, bacterial DNA, Hsp) in etiopathogenetic mechanism of various complex, multifactorial and multigenic diseases, including inflammatory bowel diseases, periodontal disease, rheumatoid arthritis, atherosclerosis, allergy, multiorgan failure, colon cancer has been recently suggested. Animal models of human diseases reared in defined gnotobiotic conditions are helping to elucidate the aetiology of these frequent disorders. An improved understanding of commensal bacteria-host interactions employing germ-free animal models with selective colonisation strategies combined with modern molecular techniques could bring new insights into the mechanisms of mucosal immunity and also into pathogenetic mechanisms of several infectious, inflammatory, autoimmune and neoplastic diseases. Regulation of microflora composition (e.g. by probiotics and prebiotics) offers the possibility to influence the development of mucosal and systemic immunity but it can play a role also in prevention and treatment of some diseases. (C) 2004 Elsevier B.V. All rights reserved.	Acad Sci Czech Republ, Inst Microbiol, Dept Immunol & Gnotobiol, CR-14220 Prague 4, Czech Republic; Childrens Mem Hlth Inst, Dept Pathol, Warsaw, Poland; Inst Care Mother & Child, Prague, Czech Republic; Inst Dent Res, Prague, Czech Republic; Inst Clin & Expt Med, Prague, Czech Republic; Hosp Motol, Fac Med 2, Prague, Czech Republic	Tlaskalova-Hogenova, H (reprint author), Acad Sci Czech Republ, Inst Microbiol, Dept Immunol & Gnotobiol, Videnska 1083, CR-14220 Prague 4, Czech Republic.	tlaskalo@biomed.cas.cz	Tlaskalova-Hogenova, Helena/J-8008-2014; stepankova, renata/J-9735-2014; Hudcovic, Tomas/H-7917-2014; Kozakova, Hana/I-1153-2014; Funda, David/J-8669-2014	stepankova, renata/0000-0001-7504-6300; Hudcovic, Tomas/0000-0002-4761-5040; Kozakova, Hana/0000-0001-7352-5922; 			Abreu MT, 2001, J IMMUNOL, V167, P1609; Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Bach JF, 2002, REV NEUROL-FRANCE, V158, P881; Bachert Claus, 2002, Curr Allergy Asthma Rep, V2, P252, DOI 10.1007/s11882-002-0027-9; Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Bevins CL, 1999, GUT, V45, P911; Bland PW, 1998, CHEM IMMUNOL, V71, P40; Boman HG, 2000, IMMUNOL REV, V173, P5, DOI 10.1034/j.1600-065X.2000.917301.x; Bos NA, 2000, CURR TOP MICROBIOL, V252, P211; Bos NA, 2001, GUT, V48, P762, DOI 10.1136/gut.48.6.762; Bry L, 1996, SCIENCE, V273, P1380, DOI 10.1126/science.273.5280.1380; Butler JE, 2000, IMMUNOLOGY, V100, P119, DOI 10.1046/j.1365-2567.2000.00013.x; Carmalho I, 2003, J EXP MED, V197, P403; Cebra JJ, 1999, AM J CLIN NUTR, V69, p1046S; Cebra J.J., 1999, MUCOSAL IMMUNOLOGY, P267; Cukrowska B, 2002, SCAND J IMMUNOL, V55, P204, DOI 10.1046/j.1365-3083.2002.01005.x; Cukrowska B, 2001, IMMUNOBIOLOGY, V204, P425, DOI 10.1078/0171-2985-00052; Denzel Angela, 2003, Immunology Letters, V86, P1, DOI 10.1016/S0165-2478(02)00277-8; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; Dziarski R, 2003, CELL MOL LIFE SCI, V60, P1793, DOI 10.1007/s00018-003-3019-6; Elson CO, 2002, IMMUNOL RES, V26, P87, DOI 10.1385/IR:26:1-3:087; Fagarasan S, 2003, NAT REV IMMUNOL, V3, P63, DOI 10.1038/nri982; Fasano A, 2001, GUT, V49, P159, DOI 10.1136/gut.49.2.159; Freudenberg MA, 1998, PROG CLIN BIOL RES, V397, P261; Fujihashi K, 2001, ACTA ODONTOL SCAND, V59, P301; Funda DP, 2001, INFECT IMMUN, V69, P3772, DOI 10.1128/IAI.69.6.3772-3781.2001; Funda DP, 1999, DIABETES-METAB RES, V15, P323; Granucci F, 2003, CURR OPIN MICROBIOL, V6, P72, DOI 10.1016/S1369-5274(03)00007-9; GUARNER F, 2003, LANCET, V8, P1831; GUSTAFSSON JA, 1948, ACTA PATHOL MICRO S1, V22, P1; Hacker G, 2002, IMMUNOLOGY, V105, P245; HARMSEN HJ, 2002, APPL ENVIRON MICROB, V6, P2982; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; Henderson B, 1999, CELLULAR MICROBIOLOG; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kozakova H, 1998, PHYSIOL RES, V47, P253; Lodinova-Zadnikova R, 2003, INT ARCH ALLERGY IMM, V131, P209, DOI 10.1159/000071488; LODINOVAZADNIKOVA R, 1991, PEDIATR RES, V29, P396, DOI 10.1203/00006450-199104000-00013; Macpherson AJ, 2000, SCIENCE, V288, P2222, DOI 10.1126/science.288.5474.2222; Medzhitov R, 2000, IMMUNOL REV, V173, P89, DOI 10.1034/j.1600-065X.2000.917309.x; MERCENIER A, 2003, CURR PHARM DESIGN, V9, P179; Mestecky J, 1999, GUT, V44, P2; MESTECKY J, 1995, ADV MUCOSAL IMMUNOLG; Neish AS, 2002, MICROBES INFECT, V4, P309, DOI 10.1016/S1286-4579(02)01543-5; OGRA PL, 1999, MUCUSAL IMMUNOLOGY; OLDSTONE MB, 1998, FASEB J, V12, P255; OLDSTONE MBA, 1987, CELL, V50, P819, DOI 10.1016/0092-8674(87)90507-1; Phalipon A, 2002, IMMUNITY, V17, P107, DOI 10.1016/S1074-7613(02)00341-2; PLEASANTS JR, 1986, J NUTR, V116, P1949; POWRIE F, 1995, IMMUNITY, V3, P171, DOI 10.1016/1074-7613(95)90086-1; Rappuoli R, 2000, P NATL ACAD SCI USA, V97, P13467, DOI 10.1073/pnas.010505497; RIETSCHEL ET, 1994, FASEB J, V8, P217; Rose NR, 2000, CELL MOL LIFE SCI, V57, P542, DOI 10.1007/PL00000716; Rossi M, 2002, IMMUNOL LETT, V81, P217, DOI 10.1016/S0165-2478(02)00038-X; Saemann MD, 2002, WIEN KLIN WOCHENSCHR, V114, P289; Salzman NH, 2002, MICROBIOL-SGM, V148, P3651; Savage DC, 1999, MUCOSAL IMMUNOLOGY, P19; SCHAEDLER RW, 1965, J EXP MED, V122, P77, DOI 10.1084/jem.122.1.77; SEEGERS JF, 2002, TRENDS BIOTECHNOL, V12, P508; Sellon RK, 1998, INFECT IMMUN, V66, P5224; Shoenfeld Yehuda, 2002, Trends in Immunology, V23, P278, DOI 10.1016/S1471-4906(02)02234-2; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Smith PD, 2001, J IMMUNOL, V167, P2651; Steidler L, 2000, SCIENCE, V289, P1352, DOI 10.1126/science.289.5483.1352; STERZL J, 1987, NAHRUNG, V31, P599; STIPANKOVA R, 1998, FOLIA MICROBIOL, V43, P531; Strober W, 2002, ANNU REV IMMUNOL, V20, P495, DOI 10.1146/annurev.immunol.20.100301.064816; TLASKALOVA H, 1970, FOLIA BIOL-PRAGUE, V16, P177; Tlaskalova-Hogenova H, 1998, FOLIA MICROBIOL, V43, P545, DOI 10.1007/BF02820817; Tlaskalova-Hogenova H, 2002, INT ARCH ALLERGY IMM, V128, P77, DOI 10.1159/000059397; TLASKALOVAHOGEN.H, 1997, IMMUNOLOGY METHODS M, P1524; TLASKALOVAHOGENOVA H, 1980, FOLIA BIOL-PRAGUE, V26, P81; TLASKALOVAHOGENOVA H, 1981, SCAND J IMMUNOL, V13, P467, DOI 10.1111/j.1365-3083.1981.tb00158.x; TLASKALOVAHOGENOVA H, 1983, ANN NY ACAD SCI, V409, P96, DOI 10.1111/j.1749-6632.1983.tb26862.x; Toivanen A, 2000, CURR OPIN RHEUMATOL, V12, P300, DOI 10.1097/00002281-200007000-00012; Ulevitch RJ, 1999, NAT MED, V5, P144, DOI 10.1038/5504; Umesaki Y, 1999, INFECT IMMUN, V67, P3504; VANEDEN W, 1991, IMMUNOL REV, V121, P5; Verdu EF, 2000, CLIN EXP IMMUNOL, V120, P46, DOI 10.1046/j.1365-2249.2000.01170.x; VITVIEKA V, 1983, FOLIA BIOL-PRAGUE, V29, P412; Wagner H, 2001, IMMUNITY, V14, P499, DOI 10.1016/S1074-7613(01)00144-3; Waksman BH, 2002, SCAND J IMMUNOL, V56, P12, DOI 10.1046/j.1365-3083.2002.01106.x; Walker WA, 2002, J PEDIATR GASTR NUTR, V34, pS33, DOI 10.1097/01.MPG.0000017295.92960.78; Wilson M, 2002, BACTERIAL DIS MECH; Wucherpfennig KW, 2002, NAT MED, V8, P455, DOI 10.1038/nm0502-455; Xavier RJ, 2000, SCIENCE, V289, P1483, DOI 10.1126/science.289.5484.1483; Yacyshyn B, 1996, DIGEST DIS SCI, V41, P2493, DOI 10.1007/BF02100148	91	326	357	14	204	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-2478			IMMUNOL LETT	Immunol. Lett.	MAY 15	2004	93	2-3					97	108		10.1016/j.imlet.2004.02.005		12	Immunology	Immunology	828SP	WOS:000221993600001	15158604	
J	Daisey, JM; Angell, WJ; Apte, MG				Daisey, JM; Angell, WJ; Apte, MG			Indoor air quality, ventilation and health symptoms in schools: an analysis of existing information	INDOOR AIR			English	Article						allergy; asthma; microbiological contaminant; carbon dioxide concentration; formaldehyde; sick building syndrome; ventilation rate	VOLATILE ORGANIC-COMPOUNDS; BUILDING SYNDROME SYMPTOMS; DAY-CARE-CENTERS; DER-P-I; FEL-D-I; RESPIRATORY SYMPTOMS; CO2 CONCENTRATIONS; SMOOTH FLOORS; DUST; CHILDREN	We reviewed the literature on Indoor Air Quality (IAQ), ventilation, and building-related health problems in schools and identified commonly reported building-related health symptoms involving schools until 1999. We collected existing data on ventilation rates, carbon dioxide (CO(2) ) concentrations and symptom-relevant indoor air contaminants, and evaluated information on causal relationships between pollutant exposures and health symptoms. Reported ventilation and CO(2) data strongly indicate that ventilation is inadequate in many classrooms, possibly leading to health symptoms. Adequate ventilation should be a major focus of design or remediation efforts. Total volatile organic compounds, formaldehyde (HCHO) and microbiological contaminants are reported. Low HCHO concentrations were unlikely to cause acute irritant symptoms (<0.05 ppm), but possibly increased risks for allergen sensitivities, chronic irritation, and cancer. Reported microbiological contaminants included allergens in deposited dust, fungi, and bacteria. Levels of specific allergens were sufficient to cause symptoms in allergic occupants. Measurements of airborne bacteria and airborne and surface fungal spores were reported in schoolrooms. Asthma and 'sick building syndrome' symptoms are commonly reported. The few studies investigating causal relationships between health symptoms and exposures to specific pollutants suggest that such symptoms in schools are related to exposures to volatile organic compounds (VOCs), molds and microbial VOCs, and allergens.	Univ Calif Berkeley, Lawrence Berkeley Lab, Indoor Environm Dept, Berkeley, CA 94720 USA; Univ Minnesota, Minnesota Extens Serv, Indoor Air Qual Project, St Paul, MN 55108 USA	Apte, MG (reprint author), Univ Calif Berkeley, Lawrence Berkeley Lab, Indoor Environm Dept, MS 90-3058,1 Cyclotron Rd, Berkeley, CA 94720 USA.	mgapte@lbl.gov			NIAID NIH HHS [K24 AI106822, R01 AI073964]		*ACGIH, 1995, AM C GOV HYG; Apte MG, 2000, INDOOR AIR, V10, P246, DOI 10.1034/j.1600-0668.2000.010004246.x; ASHRAE, 1999, 621999 ASHRAE; Bates J.M., 1996, P IND AIR 96 7 INT C, V1, P551; BAYER CW, 1992, P IAQ 92 ENV PEOPL A, P197; BAYER CW, 1995, P ASHRAE IAQ 95 C, P101; BLACK MS, 1995, P ASHRAE IAQ 95 C, P25; BRENNAN T, 1991, P ASHRAE IAQ 91 HLTH, P228; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; *CARB, 1991, FORM HOM IND AIR QUA; *CARB, 1991, FORM HOM IND AIR Q S; CASEY ME, 1995, P ENG SOL IND AIR QU; CAVALLO D, 1993, P 6 INT C IND AIR QU, V2, P45; *CDNHW, 1987, EXP GUID R ES IND AI; COUSINS DM, 1989, P ASHRAE C IAQ 87 HU, P104; Daisey J.M., 1998, LBNL41517; Dotterud LK, 1996, INDOOR AIR, V6, P71, DOI 10.1111/j.1600-0668.1996.t01-2-00002.x; DYBENDAL T, 1989, ALLERGY, V44, P401, DOI 10.1111/j.1398-9995.1989.tb04171.x; DYBENDAL T, 1992, CLIN EXP ALLERGY, V22, P1100, DOI 10.1111/j.1365-2222.1992.tb00136.x; FISHER G, 1994, RADIAT PROT DOSIM, V56, P51; FISK WJ, 2001, INDOOR AIR QUALITY H, P1; Gallup J. M., 1993, P INDOOR AIR 93, V4, P167; *GAO, 1995, GAOHEHS9561 US GEN A; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; GRAVESEN S, 1986, ALLERGY, V41, P520, DOI 10.1111/j.1398-9995.1986.tb00337.x; HANSEN L, 1987, IND AIR 87 P 4 INT C, V2, P727; HENKEL CL, 1999, P IND AIR 99 8 INT C, V4, P987; Hodgson AT, 1995, INDOOR AIR, V5, P247, DOI 10.1111/j.1600-0668.1995.00004.x; KOSKINEN O, 1995, INDOOR AIR, V5, P3, DOI 10.1111/j.1600-0668.1995.t01-3-00002.x; Koskinen OM, 1997, INDOOR AIR, V7, P262, DOI 10.1111/j.1600-0668.1997.00005.x; LAURENT AM, 1993, P IND AIR 93 6 INT C, V3, P23; Maroni M, 1993, P IND AIR 93 HELS FI, V4, P137; MEKLIN T, 1996, P 7 INT C IND AIR QU, V2, P1083; MOREY PR, 1984, ANN AM C GOV IND HYG, V10, P121; MOUILLESEAUX A, 1993, P 6 INT C IND AIR QU, V4, P195; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Myhrvold A. N., 1996, P IND AIR 96 7 INT C, P369; NIELSEN O, 1984, INDOOR AIR BUILDINGS, V5, P221; Norback D, 1995, INDOOR AIR, V5, P237, DOI 10.1111/j.1600-0668.1995.00003.x; NORBACK D, 1990, BRIT J IND MED, V47, P733; Norback D., 1987, IND AIR 87 P 4 INT C, V3, P357; Office of Environmental Health Hazard Assessment (OEHHA), 2000, AIR TOX HOT SPOTS 3; *OEHHA, 1999, AIR TOX HOT SPOTS 1; OLSEN JH, 1982, AM IND HYG ASSOC J, V43, P366, DOI 10.1202/0002-8894(1982)043<0366:FISIDC>2.3.CO;2; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301; POTTING J, 1987, IND AIR 87 P 4 INT C, V3, P582; Rao CY, 1996, J AIR WASTE MANAGE, V46, P899; REED C E, 1986, Environment International, V12, P115, DOI 10.1016/0160-4120(86)90021-8; RYLANDER R, 1989, INT CONGR SER, V860, P219; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; SHELDON LS, 1989, INDOOR AIR QUALITY P, V1; SHELDON LS, 1989, INDOOR AIR QUALITY P, V2; Smedje G, 1997, INDOOR AIR, V7, P143, DOI 10.1111/j.1600-0668.1997.00009.x; Smedje G., 1996, P INDOOR AIR 96, V1, P611; THORNE PS, 1993, VET HUM TOXICOL, V35, P141; Turk B.H., 1989, ASHRAE T, V95, P422; Turk B.H., 1993, P IND AIR 93 6 INT C, V6, P705; Turk B.H., 1987, P IND AIR 87 4 INT C, V1, P610; Turk B. H., 1987, LBNL22315; *USDE, 2000, STAT PROF PUBL EL SE; VERHOEFF AP, 1994, CLIN EXP ALLERGY, V24, P1061, DOI 10.1111/j.1365-2222.1994.tb02744.x; World Health Organization, 1987, WHO REGIONAL PUBLICA, V23; WILLERS S, 1996, INDOOR BUILT ENVIRON, V5, P232, DOI 10.1177/1420326X9600500406	65	324	333	25	167	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0905-6947			INDOOR AIR	Indoor Air	MAR	2003	13	1					53	64		10.1034/j.1600-0668.2003.00153.x		12	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	650UX	WOS:000181282700007	12608926	
J	Lake, SL; Lyon, H; Tantisira, K; Silverman, EK; Weiss, ST; Laird, NM; Schaid, DJ				Lake, SL; Lyon, H; Tantisira, K; Silverman, EK; Weiss, ST; Laird, NM; Schaid, DJ			Estimation and tests of haplotype-environment interaction when linkage phase is ambiguous	HUMAN HEREDITY			English	Article						haplotype; association; gene-environment interaction; generalized linear model	EM ALGORITHM; MAXIMUM-LIKELIHOOD; GENOMIC CONTROL; INCOMPLETE DATA; GENE PROMOTER; INTERLEUKIN-10; ASSOCIATION; POPULATION; ASTHMA; POLYMORPHISMS	In the study of complex traits, the utility of linkage analysis and single marker association tests can be limited for researchers attempting to elucidate the complex interplay between a gene and environmental covariates. For these purposes, tests of gene-environment interactions are needed. In addition, recent studies have indicated that haplotypes, which are specific combinations of nucleotides on the same chromosome, may be more suitable as the unit of analysis for statistical tests than single genetic markers. The difficulty with this approach is that, in standard laboratory genotyping, haplotypes are often not directly observable. Instead, unphased marker phenotypes are collected. In this article, we present a method for estimating and testing haplotype-environment interactions when linkage phase is potentially ambiguous. The method builds on the work of Schaid et al. [2002] and is applicable to any trait that can be placed in the generalized linear model framework. Simulations were run to illustrate the salient features of the method. addition, the method was used to test for haplotype-smoking exposure interaction with data from the Childhood Asthma Management Program. Copyright (C) 2003 S. Karger AG, Basel.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA USA; EigenStat, Brookline, MA USA; Harvard Partners Ctr Genet & Genom, Partners Hlth Care, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci, Rochester, MI USA; Mayo Clin & Mayo Fdn, Res Dept, Rochester, MI USA; Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MI USA	Lake, SL (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [N01-HR-16049]; NIDCR NIH HHS [DE13276]; NIGMS NIH HHS [GM65450]		Akey J, 2001, EUR J HUM GENET, V9, P291, DOI 10.1038/sj.ejhg.5200619; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Chiano MN, 1998, ANN HUM GENET, V62, P55, DOI 10.1046/j.1469-1809.1998.6210055.x; *CHILDH ASTHM MAN, 1999, CONTROLLED CLIN TRIA, V0020; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Devlin B, 2001, THEOR POPUL BIOL, V60, P155, DOI 10.1006/tpbi.2001.1542; Devlin B, 2000, Biostatistics, V1, P369, DOI 10.1093/biostatistics/1.4.369; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Efron B., 1993, INTRO BOOTSTRAP; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fallin D, 2001, GENOME RES, V11, P143, DOI 10.1101/gr.148401; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gibson AW, 2001, J IMMUNOL, V166, P3915; Hajeer AH, 1998, SCAND J RHEUMATOL, V27, P142; IBRAHIM JG, 1990, J AM STAT ASSOC, V85, P765, DOI 10.2307/2290013; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Judson R, 2000, Pharmacogenomics, V1, P15, DOI 10.1517/14622416.1.1.15; Kaluza W, 2001, ARTHRITIS RHEUM, V44, P1209, DOI 10.1002/1529-0131(200105)44:5<1209::AID-ANR205>3.0.CO;2-S; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Lin S, 2002, AM J HUM GENET, V71, P1129, DOI 10.1086/344347; Little R., 1987, STAT ANAL MISSING DA; LONG JC, 1995, AM J HUM GENET, V56, P799; LOUIS TA, 1982, J ROY STAT SOC B MET, V44, P226; LUCASSEN AM, 1993, NAT GENET, V4, P305, DOI 10.1038/ng0793-305; McLachlan G., 1997, EM ALGORITHM EXTENSI; MEILIJSON I, 1989, J ROY STAT SOC B MET, V51, P127; Nelson HH, 2002, CANCER RES, V62, P152; NUI T, 2002, AM J HUM GENET, V68, P978; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Stephens JC, 2001, SCIENCE, V293, P489, DOI 10.1126/science.1059431; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Turner DM, 1997, EUR J IMMUNOGENET, V24, P1, DOI 10.1111/j.1365-2370.1997.tb00001.x; Umetsu DT, 1999, AM J RESP CELL MOL, V21, P562; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; Zhang SL, 2001, AM J HUM GENET, V69, P906, DOI 10.1086/323622; Zhou W, 2001, CANCER EPIDEM BIOMAR, V10, P461	41	323	330	0	5	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0001-5652			HUM HERED	Hum. Hered.		2003	55	1					56	65		10.1159/000071811		10	Genetics & Heredity	Genetics & Heredity	712NT	WOS:000184804300008	12890927	
J	Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB				Glezen, WP; Greenberg, SB; Atmar, RL; Piedra, PA; Couch, RB			Impact of respiratory virus infections on persons with chronic underlying conditions	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYNCYTIAL VIRUS; AIR-POLLUTION; DISEASE HOSPITALIZATIONS; INFLUENZA EPIDEMICS; VIRAL-INFECTIONS; ASTHMA; CHILDREN; ADULTS; ILLNESS; VACCINE	Context While hospitalization rates have declined overall, hospitalizations for acute lower respiratory tract infections have increased steadily since 1980. Development of new approaches for prevention of acute respiratory tract conditions requires studies of the etiologies of infections and quantification of the risk of hospitalization for vulnerable patients. Objective To determine the frequency of specific virus infections associated with acute respiratory tract conditions leading to hospitalization of chronically ill patients. Design Analysis of viral etiology of patients hospitalized with acute respiratory tract conditions between July 1991 and June 1995. Setting Four large clinics and related hospitals serving diverse populations representative of Harris County, Texas. Patients A total of 1029 patients who were hospitalized for pneumonia, tracheobronchitis, bronchiolitis, croup, exacerbations of asthma or chronic obstructive pulmonary disease, and/or congestive heart failure. Main Outcome Measure Virus infection, defined by culture, antigen detection, and significant rise in serum antibodies, by underlying condition; hospitalization rates by low- vs middle-income status. Results Ninety-three percent of patients older than 5 years had a chronic underlying condition; a chronic pulmonary condition was most common. Patients with chronic pulmonary disease from low-income populations were hospitalized at a rate of 398.6 per 10 000, almost 8 times higher than the rate for patients from middle-income groups (52.2 per 10 000; P<.001). Of the 403 patients (44.4% of adults and 32.3% of children) who submitted convalescent serum specimens for antibody testing, respiratory tract virus infections were detected in 181 (44.9%). influenza, parainfluenza, and respiratory syncytial virus (RSV) infections accounted for 75% of all virus infections. Conclusions Our study suggests that respiratory virus infections commonly trigger serious acute respiratory conditions that result in hospitalization of patients with chronic underlying conditions, highlighting the need for development of effective vaccines for these viruses, especially for parainfluenza and RSV.	Baylor Coll Med, Dept Microbiol & Immunol, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Glezen, WP (reprint author), Baylor Coll Med, Dept Microbiol & Immunol, 1 Baylor Plaza, Houston, TX 77030 USA.				NIAID NIH HHS [AI15103]		ABRAMSON M, 1994, J ASTHMA, V31, P367, DOI 10.3109/02770909409061316; *ADV COMM IMM PRAC, 1998, MMWR-MORBID MORTAL W, V47, P1; AGIUS G, 1990, J MED VIROL, V30, P117, DOI 10.1002/jmv.1890300208; Atmar RL, 1998, ARCH INTERN MED, V158, P2453, DOI 10.1001/archinte.158.22.2453; BAXTER BD, 1977, J CLIN MICROBIOL, V6, P19; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; BUSSE WW, 1993, ASTHMA, P345; Dowell SF, 1996, J INFECT DIS, V174, P456; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; ENGLUND JA, 1988, ANN INTERN MED, V109, P203; FALSEY AR, 1995, J INFECT DIS, V172, P389; Fleiss J. L., 1981, STAT METHODS RATES P; FRANK AL, 1979, J CLIN MICROBIOL, V10, P32; FRANK AL, 1980, J CLIN MICROBIOL, V12, P426; GARDNER G, 1984, J EPIDEMIOL COMMUN H, V38, P42, DOI 10.1136/jech.38.1.42; GILL EP, 1994, J CLIN MICROBIOL, V32, P2372; GLEZEN WP, 1987, J INFECT DIS, V155, P1119; GLEZEN WP, 1987, AM REV RESPIR DIS, V136, P550; GLEZEN WP, 1977, PEDIATR RES, V11, P239; GLEZEN WP, 1984, CLIN CHEST MED, V5, P635; HALFON N, 1993, PEDIATRICS, V91, P56; Han LL, 1999, J INFECT DIS, V179, P25, DOI 10.1086/314567; Kim PE, 1996, CLIN INFECT DIS, V22, P100; LAMY ME, 1973, CHEST, V63, P336, DOI 10.1378/chest.63.3.336; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; MERTSOLA J, 1991, ARCH DIS CHILD, V66, P124; Nichol KL, 1999, ANN INTERN MED, V130, P397; NICHOL KL, 1994, NEW ENGL J MED, V331, P778, DOI 10.1056/NEJM199409223311206; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Pamuk E., 1998, SOCIOECONOMIC STATUS; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; PERROTTA DM, 1985, AM J EPIDEMIOL, V122, P468; PHILIT F, 1992, REV MAL RESPIR, V9, P191; PIEDRA PA, 1993, VACCINE, V11, P1415, DOI 10.1016/0264-410X(93)90170-3; PIEDRA PA, 1995, VACCINE, V13, P1095, DOI 10.1016/0264-410X(95)00034-X; Piedra PA, 1996, PEDIATR INFECT DIS J, V15, P23, DOI 10.1097/00006454-199601000-00006; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Simonsen L, 1998, ARCH INTERN MED, V158, P1923, DOI 10.1001/archinte.158.17.1923; SMITH CB, 1980, J INFECT DIS, V141, P271; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; WOOD PR, 1993, PEDIATRICS, V91, P62	42	323	338	1	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	2000	283	4					499	505		10.1001/jama.283.4.499		7	Medicine, General & Internal	General & Internal Medicine	276LT	WOS:000084879800029	10659876	
J	Douwes, J; Gibson, P; Pekkanen, J; Pearce, N				Douwes, J; Gibson, P; Pekkanen, J; Pearce, N			Non-eosinophilic asthma: importance and possible mechanisms	THORAX			English	Review							ANTI-IGE ANTIBODY; PARTICULATE AIR-POLLUTION; HOUSE-DUST ENDOTOXIN; INDUCED SPUTUM; NEUTROPHILIC INFLAMMATION; AMBIENT OZONE; BRONCHIAL HYPERREACTIVITY; INHALED CORTICOSTEROIDS; MONOCLONAL-ANTIBODY; OCCUPATIONAL ASTHMA	There is increasing evidence that inflammatory mechanisms other than eosinophilic inflammation may be involved in producing the final common pathway of enhanced bronchial reactivity and reversible airflow obstruction that characterises asthma. A review of the literature has shown that, at most, only 50% of asthma cases are attributable to eosinophilic airway inflammation. It is hypothesised that a major proportion of asthma is based on neutrophilic airway inflammation, possibly triggered by environmental exposure to bacterial endotoxin, particulate air pollution, and ozone, as well as viral infections. If there are indeed two (or more) subtypes of asthma, and if non-eosinophilic (neutrophil mediated) asthma is relatively common, this would have major consequences for the treatment and prevention of asthma since most treatment and prevention strategies are now almost entirely focused on allergic/eosinophilic asthma and allergen avoidance measures, respectively. It is therefore important to study the aetiology of asthma further, including the underlying inflammatory profiles.	Univ Utrecht, IRAS, Div Environm & Occupat Hlth, NL-3508 TD Utrecht, Netherlands; John Hunter Hosp, Newcastle, NSW, Australia; Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand	Douwes, J (reprint author), Univ Utrecht, IRAS, Div Environm & Occupat Hlth, POB 80176, NL-3508 TD Utrecht, Netherlands.			Douwes, Jeroen/0000-0003-3599-4036			Amin K, 2000, AM J RESP CRIT CARE, V162, P2295; Anticevich SZ, 1996, CLIN EXP ALLERGY, V26, P549, DOI 10.1046/j.1365-2222.1996.d01-341.x; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; Becker S, 1999, AM J RESP CRIT CARE, V160, P1309; BERLYNE GS, 1999, J ALLERGY CLIN IMMUN, V104, P182; Bernstein IL, 1999, ASTHMA WORKPLACE; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; CAMBELL P, 1999, NATURE, V402, pB1; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; CLAPP WD, 1994, AM J RESP CRIT CARE, V150, P611; COX G, 1995, J IMMUNOL, V154, P4719; de la Fuente PT, 1999, RESP MED, V93, P183, DOI 10.1016/S0954-6111(99)90006-9; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1997, INT J OCCUP ENV HL S, V3, pS26; ENARSON DA, 1988, CLIN INVEST MED, V11, P193; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Giannini D, 2000, CLIN EXP ALLERGY, V30, P1777, DOI 10.1046/j.1365-2222.2000.00919.x; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gibson PG, 1998, AM J RESP CRIT CARE, V158, P36; Gibson PG, 1999, PEDIATR PULM, V28, P261, DOI 10.1002/(SICI)1099-0496(199910)28:4<261::AID-PPUL5>3.0.CO;2-I; Gibson PG, 2001, AM J RESP CRIT CARE, V164, P977; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V102, pS100, DOI 10.1016/S0091-6749(98)70039-9; Global Initiative for Asthma, 1995, GLOB STRAT ASTHM MAN; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; HOLTZ O, 1999, AM J RESP CRIT CARE, V159, P776; JACOBS RR, 1993, AM REV RESPIR DIS, V148, P19; Jalaludin BB, 2000, INT J EPIDEMIOL, V29, P549, DOI 10.1093/ije/29.3.549; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Johnston S L, 1999, Pediatr Pulmonol Suppl, V18, P141; Jung K S, 1999, Respirology, V4, P303, DOI 10.1046/j.1440-1843.1999.00196.x; Kennedy T, 1998, AM J RESP CELL MOL, V19, P366; Kleeberger SR, 2001, AM J PHYSIOL-LUNG C, V280, pL326; KREIT JW, 1989, J APPL PHYSIOL, V66, P217; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Larsson BM, 1997, THORAX, V52, P638; LEBOWITZ MD, 1987, ENVIRON RES, V43, P332, DOI 10.1016/S0013-9351(87)80033-6; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533; Martinez FD, 1999, LANCET S2, V354, pSII12; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Mukae H, 2001, AM J RESP CRIT CARE, V163, P201; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Nightingale JA, 1999, THORAX, V54, P1061; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Nightingale JA, 1998, THORAX, V53, P563; Norzila MZ, 2000, AM J RESP CRIT CARE, V161, P769; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Ottanelli R, 2001, CHEST, V120, P770, DOI 10.1378/chest.120.3.770; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pearce N, 2000, J Epidemiol Biostat, V5, P5; Pearce N, 1999, THORAX, V54, P268; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; Priftanji A, 2001, LANCET, V358, P1426, DOI 10.1016/S0140-6736(01)06521-7; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 2000, NEW ENGL J MED, V342, P1292; Salvi SS, 2000, CLIN EXP ALLERGY, V30, P1499, DOI 10.1046/j.1365-2222.2000.00990.x; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; SEPULVEDA MJ, 1984, BRIT J IND MED, V41, P487; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Torres A, 1997, AM J RESP CRIT CARE, V156, P728; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; Ulmer AJ, 1997, INT J OCCUP ENV HEAL, V3, pS8; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wark P A, 2000, Respirology, V5, P51, DOI 10.1046/j.1440-1843.2000.00226.x; WEISEL CP, 1995, ENVIRON HEALTH PERSP, V103, P97, DOI 10.2307/3432456; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Wilson NM, 2000, THORAX, V55, P768, DOI 10.1136/thorax.55.9.768; Woolley KL, 1996, AM J RESP CRIT CARE, V154, P237; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	97	315	344	2	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUL	2002	57	7					643	648		10.1136/thorax.57.7.643		6	Respiratory System	Respiratory System	575MM	WOS:000176950100016	12096210	
J	McConnell, R; Berhane, K; Yao, L; Jerrett, M; Lurmann, F; Gilliland, F; Kunzli, N; Gauderman, J; Avol, E; Thomas, D; Peters, J				McConnell, R; Berhane, K; Yao, L; Jerrett, M; Lurmann, F; Gilliland, F; Kunzli, N; Gauderman, J; Avol, E; Thomas, D; Peters, J			Traffic, susceptibility, and childhood asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; child; epidemiology; traffic	ENVIRONMENTAL TOBACCO-SMOKE; CHRONIC RESPIRATORY SYMPTOMS; AMBIENT NITROGEN-DIOXIDE; AIR-POLLUTION; WHEEZING ILLNESS; PARENTAL SMOKING; MATERNAL SMOKING; SCHOOL-CHILDREN; MAJOR HIGHWAY; EXPOSURE	Results from studies of traffic and childhood asthma have been inconsistent, but there has been little systematic evaluation of susceptible subgroups. In this study, we examined the relationship of local traffic-related exposure and asthma and wheeze in southern California school children (5-7 years of age). Lifetime history of doctor-diagnosed asthma and prevalent asthma and wheeze were evaluated by questionnaire. Parental history of asthma and child's history of allergic symptoms, sex, and early-life exposure (residence at the same home since 2 years of age) were examined as susceptibility factors. Residential exposure was assessed by proximity to a major road and by modeling exposure to local traffic-related pollutants. Residence within 75 in of a major road was associated with an increased risk of lifetime asthma [odds ratio (OR) = 1.29; 95% confidence interval (CI), 1.01-1.86], prevalent asthma (OR = 1.50; 95% Cl, 1.16-1-95), and wheeze (OR = 1.40; 95% Cl, 1.09-1-78). Susceptibility increased in long-term residents with no parental history of asthma for lifetime asthma (OR = 1.85; 95% Cl, 1. 11-3.09), prevalent asthma (OR = 2.46; 95% Cl, 0.48-4.09), and recent wheeze (OR = 2.74; 95% Cl, 1.71-4-39). The higher risk of asthma near a major road decreased to background rates at 150-200 in from the road. In children with a parental history of asthma and in children moving to the residence after 2 years of age, there was no increased risk associated with exposure. Effect of residential proximity to roadways was also larger in girls. A similar pattern of effects was observed with traffic-modeled exposure. These results indicate that residence near a major road is associated with asthma. The reason for larger effects in those with no parental history of asthma merits further investigation.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Sonoma Technol Inc, Petaluma, CA USA	McConnell, R (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	rmcconne@usc.edu	Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	NHLBI NIH HHS [5R01HL61768, R01 HL061768]; NIEHS NIH HHS [P01 ES011627, 5 P01 ES009581, 5 P01 ES011627, 5P30ES007048, P01 ES009581, P30 ES007048]		Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Beasley R, 2001, Pediatr Pulmonol, VSuppl 23, P149; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gautrin D, 2003, EUR RESPIR J, V22, P551, DOI 10.1183/09031936.03.00047803; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; GORDIAN ME, 2005, J EXPO ANAL ENV EPID; Hastie T, 1990, GEN ADDITIVE MODELS; *ISAAC STEER COMM, 1998, INT STUD ASTHM ALL C; Ising H., 2002, NOISE HEALTH, V4, P13; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; KERSHAW CR, 1987, J ROY SOC MED, V80, P683; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; KITANI H, 1993, ACTA MED OKAYAMA, V47, P317; Kunzli N, 2003, AM J PUBLIC HEALTH, V93, P1494, DOI 10.2105/AJPH.93.9.1494; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Martinez JC, 1999, PEDIATRICS, V103, P1, DOI 10.1542/peds.103.1.1; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Morris SE, 2000, J EPIDEMIOL COMMUN H, V54, P75, DOI 10.1136/jech.54.1.75; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; PALMIERI M, 1990, EUR J PEDIATR, V149, P738, DOI 10.1007/BF01959535; Pearce N, 1999, THORAX, V54, P268; Peden DB, 2000, ENVIRON HEALTH PERSP, V108, P475, DOI 10.2307/3454539; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Ross Z, 2006, J EXPO SCI ENV EPID, V16, P106, DOI 10.1038/sj.jea.7500442; Schelegle ES, 2003, TOXICOL APPL PHARM, V191, P74, DOI 10.1016/S0041-008X(03)00218-7; Shima M, 2003, J EPIDEMIOL, V13, P108; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1998, THORAX, V53, P204; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venables WN, 2002, MODERN APPL STAT S P; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WJST M, 1993, BRIT MED J, V307, P596; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	52	314	321	4	49	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2006	114	5					766	772		10.1289/ehp.8594		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	039LZ	WOS:000237308500048	16675435	
J	Agostoni, A; Aygoren-Pursun, E; Binkley, KE; Blanch, A; Bork, K; Bouillet, L; Bucher, C; Castaldo, AJ; Cicardi, M; Davis, AE; De Carolis, C; Drouet, C; Duponchel, C; Farkas, H; Fay, K; Fekete, B; Fischer, B; Fontana, L; Fust, G; Giacomelli, R; Groner, A; Hack, CE; Harmat, G; Jakenfelds, J; Juers, M; Kalmar, L; Kaposi, PN; Karadi, I; Kitzinger, A; Kollar, T; Kreuz, W; Lakatos, P; Longhurst, HJ; Lopez-Trascasa, M; Martinez-Saguer, I; Monnier, N; Nagy, I; Nemeth, E; Nielsen, EW; Nuijens, JH; O'Grady, C; Pappalardo, E; Penna, V; Perricone, C; Perricone, R; Rauch, U; Roche, O; Rusicke, E; Spath, PJ; Szendei, G; Takacs, E; Tordai, A; Truedsson, L; Varga, L; Visy, B; Williams, K; Zanichelli, A; Zingale, L				Agostoni, Angelo; Aygoeren-Puersuen, Emel; Binkley, Karen E.; Blanch, Alvaro; Bork, Konrad; Bouillet, Laurence; Bucher, Christoph; Castaldo, Anthony J.; Cicardi, Marco; Davis, Alvin E., III; De Carolis, Caterina; Drouet, Christian; Duponchel, Christiane; Farkas, Henriette; Fay, Kalman; Fekete, Bela; Fischer, Bettina; Fontana, Luigi; Fuest, George; Giacomelli, Roberto; Groener, Albrecht; Hack, C. Erik; Harmat, George; Jakenfelds, John; Juers, Mathias; Kalmar, Lajos; Kaposi, Pal N.; Karadi, Istvan; Kitzinger, Arianna; Kollar, Timea; Kreuz, Wolfhart; Lakatos, Peter; Longhurst, Hilary J.; Lopez-Trascasa, Margarita; Martinez-Saguer, Inmaculada; Monnier, Nicole; Nagy, Istvan; Nemeth, Eva; Nielsen, Erik Waage; Nuijens, Jan H.; O'Grady, Caroline; Pappalardo, Emanuela; Penna, Vincenzo; Perricone, Carlo; Perricone, Roberto; Rauch, Ursula; Roche, Olga; Rusicke, Eva; Spaeth, Peter J.; Szendei, George; Takacs, Edit; Tordai, Attila; Truedsson, Lennart; Varga, Lilian; Visy, Beata; Williams, Kayla; Zanichelli, Andrea; Zingale, Lorenza			Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						AAE; acquired angioedema; angioedema; C1 esterase inhibitor; C1-INH; HAE; HANE; HANO; hereditary angioedema; hereditary angioneurotic edema; angioneurotic edema; chemically induced angioedema; human SERPING1 protein	HORMONE REPLACEMENT THERAPY; MOLECULAR-WEIGHT KININOGEN; FACTOR-VIII CONCENTRATE; FACTOR FACTOR-XII; CONVERTING-ENZYME-ACTIVITY; OVARIAN FOLLICULAR-FLUID; PLASMA KALLIKREIN/KININ SYSTEM; HELICOBACTER-PYLORI INFECTION; NORMAL C1-INHIBITOR ACTIVITY; EPSILON AMINOCAPROIC ACID	Hereditary angioedema (HAE), a rare but life-threatening condition, manifests as acute attacks of facial, laryngeal, genital, or peripheral swelling or abdominal pain secondary to intra-abdominal edema. Resulting from mutations affecting C1 esterase inhibitor (C1-INH), inhibitor of the first complement system component, attacks are not histamine-mediated and do not respond to antihistamines or corticosteroids. Low awareness and resemblance to other disorders often delay diagnosis; despite availability of C1-INH replacement in some countries, no approved, safe acute attack therapy exists in the United States. The biennial C1 Esterase Inhibitor Deficiency Workshops resulted from a European initiative for better knowledge and treatment of HAE and related diseases. This supplement contains work presented at the third workshop and expanded content toward a definitive picture of angioedema in the absence of allergy. Most notably, it includes cumulative genetic investigations; multinational laboratory diagnosis recommendations; current pathogenesis hypotheses; suggested prophylaxis and acute attack treatment, including home treatment; future treatment options; and analysis of patient subpopulations, including pediatric patients and patients whose angioedema worsened during pregnancy or hormone administration. Causes and management of acquired angioedema and a new type of angioedema with normal C1-INH are also discussed. Collaborative patient and physician efforts, crucial in rare diseases, are emphasized. This supplement seeks to raise awareness and aid diagnosis of HAE, optimize treatment for all patients, and provide a platform for further research in this rare, partially understood disorder. (J Allergy Clin Immunol 2004;114:S51-131.)	[Cicardi, Marco] Univ Milan, Osped S Giuseppe, Dipartimento Med Interna, Milan, Italy	Agostoni, A (reprint author), Care of Williams T, Dyax Corp, 300 Technol Sq, Cambridge, MA 02139 USA.		Kalmar, Lajos/C-3040-2014; Roche, Olga/K-9342-2014; Lopez-Trascasa, Margarita/L-2699-2014; cicardi, marco/K-9219-2016	Kalmar, Lajos/0000-0003-3691-8350; Lopez-Trascasa, Margarita/0000-0001-8594-282X; cicardi, marco/0000-0003-1251-225X; Giacomelli, Roberto/0000-0003-0670-9638; Perricone, Carlo/0000-0003-4771-6981; Roche, Olga/0000-0003-1884-8256	Kallikrein, LLC; Genzyme Corporation, Cambridge, Mass	Supported by Kallikrein, LLC, a joint venture of Dyax Corp., and Genzyme Corporation, Cambridge, Mass.	Abdi R, 2002, PHARMACOTHERAPY, V22, P1173, DOI 10.1592/phco.22.13.1173.33517; Adam A, 2002, LANCET, V359, P2088, DOI 10.1016/S0140-6736(02)08914-6; Agnello V, 1978, ARTHRITIS RHEUM, V21, pS146; AGOSTONI A, 1992, MEDICINE, V71, P206; Agostoni A, 1999, IMMUNOPHARMACOLOGY, V44, P21, DOI 10.1016/S0162-3109(99)00107-1; AGOSTONI A, 1980, ANN ALLERGY, V44, P299; Agostoni A, 2001, DRUG SAFETY, V24, P599, DOI 10.2165/00002018-200124080-00004; Agostoni Angelo, 2002, Recenti Progressi in Medicina, V93, P519; Ajayi AAL, 2000, BRIT J CLIN PHARMACO, V50, P81, DOI 10.1046/j.1365-2125.2000.00207.x; Akbary AM, 1996, IMMUNOPHARMACOLOGY, V33, P238, DOI 10.1016/0162-3109(96)00065-3; ALPER CA, 1987, IMMUNOL LETT, V14, P175, DOI 10.1016/0165-2478(87)90098-8; ALSENZ J, 1989, J CLIN INVEST, V83, P1794, DOI 10.1172/JCI114084; Andre F, 2003, TOXICOLOGY, V185, P155, DOI 10.1016/S0300-483X(02)00584-X; ANDREW M, 1983, P SOC EXP BIOL MED, V173, P495; ANDREW M, 1987, BLOOD, V70, P165; ARIGA T, 1990, GENOMICS, V8, P607, DOI 10.1016/0888-7543(90)90246-Q; ARIGA T, 1989, J CLIN INVEST, V83, P1888, DOI 10.1172/JCI114095; ARIGA T, 1993, CLIN IMMUNOL IMMUNOP, V69, P103, DOI 10.1006/clin.1993.1156; ATKINSON JC, 1991, J ORAL PATHOL MED, V20, P139, DOI 10.1111/j.1600-0714.1991.tb00908.x; AULAK KS, 1993, J BIOL CHEM, V268, P18088; AULAK KS, 1990, FEBS LETT, V266, P13, DOI 10.1016/0014-5793(90)81494-9; BAIN BJ, 1993, CANCER, V72, P3318, DOI 10.1002/1097-0142(19931201)72:11<3318::AID-CNCR2820721130>3.0.CO;2-N; BARAKAT AJ, 1993, AM J DIS CHILD, V147, P931; BARBIERI RL, 1981, AM J OBSTET GYNECOL, V141, P453; Barilla-Labarca ML, 2002, ARTHRIT RHEUM-ARTHR, V47, P223, DOI 10.1002/art1.10342; BERGAMASCHINI L, 1983, ALLERGY, V38, P81; Berkun Y, 2001, ANN ALLERG ASTHMA IM, V87, P138; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Binkley KE, 2000, J ALLERGY CLIN IMMUN, V106, P546; Binkley KE, 2003, TRANSFUS APHER SCI, V29, P215, DOI 10.1016/j.transci.2003.08.002; Binkley KE, 2001, J ALLERGY CLIN IMMUN, V107, P747, DOI 10.1067/mai.2001.114243; Binkley KE, 1996, CAN J ALLERGY CLIN I, V1, P134; BISSLER JJ, 1994, P NATL ACAD SCI USA, V91, P9622, DOI 10.1073/pnas.91.20.9622; Bissler JJ, 1998, MOL MED, V4, P795; Bissler JJ, 1997, P ASSOC AM PHYSICIAN, V109, P164; BISSLER JJ, 1994, HUM GENET, V93, P265, DOI 10.1007/BF00212020; Blais C, 1999, PEPTIDES, V20, P421, DOI 10.1016/S0196-9781(99)00020-0; Blanch Alvaro, 2002, Hum Mutat, V20, P405, DOI 10.1002/humu.9073; BLOHME G, 1972, ACTA MED SCAND, V191, P209; Blumel J, 2002, TRANSFUSION, V42, P1011, DOI 10.1046/j.1537-2995.2002.00158.x; BOCK SC, 1986, BIOCHEMISTRY-US, V25, P4292, DOI 10.1021/bi00363a018; BOECKERS M, 1987, Deutsche Medizinische Wochenschrift, V112, P507; BONNER G, 1990, J CARDIOVASC PHARM, V15, pS46; BOOTH NA, 1987, BLOOD, V69, P1600; Bork K, 2003, AM J MED, V114, P294, DOI 10.1016/S0002-9343(02)01526-7; Bork K, 2000, LANCET, V356, P213, DOI 10.1016/S0140-6736(00)02483-1; Bork K, 2000, MAYO CLIN PROC, V75, P349; Bork K, 2003, ARCH INTERN MED, V163, P1229, DOI 10.1001/archinte.163.10.1229; Bork K, 1999, LANCET, V353, P1066, DOI 10.1016/S0140-6736(99)00110-5; Bork K, 2002, J HEPATOL, V36, P707, DOI 10.1016/S0168-8278(02)00035-1; BORK K, 1989, J ALLERGY CLIN IMMUN, V83, P677, DOI 10.1016/0091-6749(89)90082-1; BORK K, 1984, DEUT MED WOCHENSCHR, V109, P1331, DOI 10.1055/s-2008-1069374; Bork K, 2001, ARCH INTERN MED, V161, P714, DOI 10.1001/archinte.161.5.714; Bork K, 1998, MED KLIN, V93, P554; Bork K, 1992, BIOMED PROGR, V5, P59; BORRADORI L, 1990, DERMATOLOGICA, V181, P78; Bos IGA, 2003, J BIOL CHEM, V278, P29463, DOI 10.1074/jbc.M302977200; Bos IGA, 2003, BBA-PROTEINS PROTEOM, V1648, P75, DOI 10.1016/S1570-9639(03)00107-9; Bos IGA, 2002, IMMUNOBIOLOGY, V205, P518, DOI 10.1078/0171-2985-00151; Bos IGAC, 2001, INT IMMUNOPHARMACOL, V1, P1583, DOI 10.1016/S1567-5769(01)00073-X; Bossi F, 2004, MOL IMMUNOL, V41, P212; Bouillet L, 2000, PRESSE MED, V29, P640; Bouillet L, 2003, DERMATOLOGY, V206, P106, DOI 10.1159/000068456; Bouillet-Claveyrolas L, 2003, AM J MED, V115, P420, DOI 10.1016/S0002-9343(03)00396-6; Bowen B, 2001, CLIN IMMUNOL, V98, P157, DOI 10.1006/clim.2000.4947; BRACKERTZ D, 1973, LANCET, V2, P680; Brennan VM, 2003, CLIN EXP IMMUNOL, V133, P247, DOI 10.1046/j.1365-2249.2003.02199.x; BRICKMAN CM, 1986, J ALLERGY CLIN IMMUN, V77, P749, DOI 10.1016/0091-6749(86)90424-0; BRICKMAN CM, 1986, J ALLERGY CLIN IMMUN, V77, P758, DOI 10.1016/0091-6749(86)90425-2; BURGHARDT W, 1987, LANCET, V2, P165; CALBO L, 1992, ITAL J GASTROENTEROL, V24, P464; Caldwell JR, 1972, CLIN IMMUNOL IMMUNOP, V1, P39, DOI 10.1016/0090-1229(72)90006-2; Caliezi C, 2000, PHARMACOL REV, V52, P91; Campanile E, 2001, PANMINERVA MED, V43, P307; Campbell DJ, 2003, HYPERTENSION, V41, P383, DOI 10.1161/01.HYP.0000054215.71691.16; CAMPBELL SJ, 1993, BRIT J OBSTET GYNAEC, V100, P79, DOI 10.1111/j.1471-0528.1993.tb12956.x; CARTER PE, 1991, EUR J BIOCHEM, V197, P301, DOI 10.1111/j.1432-1033.1991.tb15911.x; Carugati A, 2001, MOL IMMUNOL, V38, P161, DOI 10.1016/S0161-5890(01)00040-2; Chandra S, 2002, THROMB RES, V105, P391, DOI 10.1016/S0049-3848(02)00044-0; CHEN LM, 1992, BIOCHIM BIOPHYS ACTA, V1131, P145, DOI 10.1016/0167-4781(92)90069-C; Chiu AG, 2001, LARYNGOSCOPE, V111, P1729, DOI 10.1097/00005537-200110000-00011; Christie DRH, 1997, CANCER GENET CYTOGEN, V95, P159, DOI 10.1016/S0165-4608(96)00218-X; Cicardi M, 2003, MEDICINE, V82, P274, DOI 10.1097/00005792-200307000-00006; Cicardi M, 1996, CLIN EXP IMMUNOL, V106, P475, DOI 10.1046/j.1365-2249.1996.d01-866.x; Cicardi M, 1997, J ALLERGY CLIN IMMUN, V99, P194, DOI 10.1016/S0091-6749(97)70095-2; Cicardi M, 1998, IMMUNOBIOLOGY, V199, P366; CICARDI M, 1991, J ALLERGY CLIN IMMUN, V87, P768, DOI 10.1016/0091-6749(91)90120-D; Cicardi M, 1996, NEW ENGL J MED, V334, P1666, DOI 10.1056/NEJM199606203342510; CICARDI M, 1985, Complement, V2, P133; CICARDI M, 1993, AM J MED, V95, P169, DOI 10.1016/0002-9343(93)90257-P; CICARDI M, 1987, J CLIN INVEST, V79, P698, DOI 10.1172/JCI112873; CICARDI M, 1983, J ALLERGY CLIN IMMUN, V72, P294, DOI 10.1016/0091-6749(83)90034-9; CICARDI M, 1995, TRANSFUSION, V35, P209, DOI 10.1046/j.1537-2995.1995.35395184276.x; Citarella F, 1996, STEROIDS, V61, P270, DOI 10.1016/0039-128X(96)00037-2; Coats AJS, 2002, INT J CARDIOL, V86, P1, DOI 10.1016/S0167-5273(02)00389-3; COHEN AJ, 1992, J ALLERGY CLIN IMMUN, V90, P412, DOI 10.1016/S0091-6749(05)80025-9; COHEN N, 1993, J CLIN GASTROENTEROL, V16, P237, DOI 10.1097/00004836-199304000-00016; COHEN SH, 1978, J ALLERGY CLIN IMMUN, V62, P217, DOI 10.1016/0091-6749(78)90210-5; COLMAN RW, 1984, J CLIN INVEST, V73, P1249, DOI 10.1172/JCI111326; COTTON RGH, 1988, P NATL ACAD SCI USA, V85, P4397, DOI 10.1073/pnas.85.12.4397; COTTON RGH, 1993, MUTAT RES, V285, P125, DOI 10.1016/0027-5107(93)90060-S; COX M, 1995, ANAESTHESIA, V50, P547, DOI 10.1111/j.1365-2044.1995.tb06050.x; Crampon D, 1998, J HEPATOL, V29, P1035, DOI 10.1016/S0168-8278(98)80140-2; CROSHER R, 1987, BRIT J ORAL MAX SURG, V25, P500, DOI 10.1016/0266-4356(87)90143-4; Cugno M, 1997, BLOOD, V89, P3213; Cugno M, 2003, INT IMMUNOPHARMACOL, V3, P311, DOI 10.1016/S1567-5769(02)00162-5; Cugno M, 1996, IMMUNOPHARMACOLOGY, V33, P361, DOI 10.1016/0162-3109(96)00086-0; CUGNO M, 1994, J ALLERGY CLIN IMMUN, V93, P870, DOI 10.1016/0091-6749(94)90380-8; Cugno M, 2001, BLOOD COAGUL FIBRIN, V12, P253, DOI 10.1097/00001721-200106000-00005; CUGNO M, 1993, J LAB CLIN MED, V121, P38; Cumming SA, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.10.e114; CURD JG, 1980, J EXP MED, V152, P742, DOI 10.1084/jem.152.3.742; Cyr M, 2001, AM J PHYSIOL-HEART C, V281, pH275; D'Incan M, 1999, DERMATOLOGY, V199, P227, DOI 10.1159/000018252; Davis AE, 1997, ADV EXP MED BIOL, V425, P185; Davis AE, 2003, TRANSFUS APHER SCI, V29, P195, DOI 10.1016/j.transci.2003.08.012; DAVIS AE, 1988, ANNU REV IMMUNOL, V6, P595; DAVIS AE, 1992, NAT GENET, V1, P354, DOI 10.1038/ng0892-354; Davis A. E., 1998, HUMAN COMPLEMENT SYS, P455; DAVIS CA, 1979, PEDIATR RES, V13, P1043, DOI 10.1203/00006450-197909000-00019; DAWOOD MY, 1989, FERTIL STERIL, V52, P21; Day NK, 1988, COMPLEMENT SYSTEM; De Backer AI, 2001, AM J ROENTGENOL, V176, P649; De Filippi F, 1998, TRANSFUSION, V38, P307; DEAGOSTINI A, 1984, J CLIN INVEST, V73, P1542, DOI 10.1172/JCI111360; Decarie A, 1996, AM J PHYSIOL-HEART C, V271, pH1340; DEGROOTE DF, 1985, J ORAL MAXIL SURG, V43, P52; DENNEHY JJ, 1970, ANN INTERN MED, V73, P55; DESMET BJGL, 1993, BLOOD, V81, P56; Dinkel H P, 2001, Pediatr Radiol, V31, P296, DOI 10.1007/s002470000409; DMOWSKI WP, 1988, CLIN OBSTET GYNECOL, V31, P829, DOI 10.1097/00003081-198812000-00009; DMOWSKI WP, 1983, FERTIL STERIL, V39, P49; Dmowski WP, 1996, FERTIL STERIL, V66, P929; DODIN S, 1991, OBSTET GYNECOL, V77, P410; Donaldson V H, 1977, Trans Assoc Am Physicians, V90, P174; DONALDSON VH, 1963, AM J MED, V35, P37, DOI 10.1016/0002-9343(63)90162-1; DONALDSON VH, 1966, PEDIATRICS, V37, P1017; DONALDSON VH, 1992, J LAB CLIN MED, V119, P330; DONALDSON VH, 1992, J LAB CLIN MED, V119, P397; DUMENCO LL, 1988, J LAB CLIN MED, V112, P394; DUNCAN IJS, 1988, J RHEUMATOL, V15, P700; Duponchel C, 2001, HUM MUTAT, V17, P61, DOI 10.1002/1098-1004(2001)17:1<61::AID-HUMU7>3.0.CO;2-9; ELDERING E, 1995, J BIOL CHEM, V270, P2579; ELDERING E, 1992, J BIOL CHEM, V267, P7013; ELDERING E, 1993, J CLIN INVEST, V91, P1035, DOI 10.1172/JCI116260; ELDERING E, 1988, J BIOL CHEM, V263, P11776; Ellis TP, 1998, HUM MUTAT, V11, P345, DOI 10.1002/(SICI)1098-1004(1998)11:5<345::AID-HUMU1>3.0.CO;2-0; Erdos EG, 1997, HDB IMMUNOPHARMACOLO, P111; Ernst SC, 1996, J IMMUNOL, V157, P405; Familian A, 2001, J IMMUNOL, V167, P647; Farkas H, 1999, J ALLERGY CLIN IMMUN, V103, P711, DOI 10.1016/S0091-6749(99)70248-4; Farkas H, 1999, J ORAL MAXIL SURG, V57, P404, DOI 10.1016/S0278-2391(99)90280-X; Farkas H, 2002, ACTA PAEDIATR, V91, P971, DOI 10.1080/080352502760148720; Farkas H, 1999, IMMUNOL INVEST, V28, P43, DOI 10.3109/08820139909022722; Farkas H, 2002, AM J GASTROENTEROL, V97, P2682; Farkas H, 2001, ACTA DERM-VENEREOL, V81, P376; Farkas H, 1999, Z GASTROENTEROL, V37, P513; Farkas H, 1999, LANCET, V354, P1031, DOI 10.1016/S0140-6736(05)76637-X; Farkas H, 2002, PEDIATR ALLERGY IMMU, V13, P153, DOI 10.1034/j.1399-3038.2002.01014.x; Farkas H, 2001, LANCET, V358, P1695, DOI 10.1016/S0140-6736(01)06720-4; Farkas H, 2001, ACTA DERM-VENEREOL, V81, P298, DOI 10.1080/00015550152572985; Farkas H, 2001, EUR J GASTROEN HEPAT, V13, P1225, DOI 10.1097/00042737-200110000-00016; FARMER SG, 1992, ANNU REV PHARMACOL, V32, P511; FARSETTI A, 1995, ENDOCRINOLOGY, V136, P5076, DOI 10.1210/en.136.11.5076; FERLAZZO B, 1991, Recenti Progressi in Medicina, V82, P29; FERNANDEZ PG, 1978, CAN MED ASSOC J, V119, P455; FIELDS T, 1983, J ALLERGY CLIN IMMUN, V72, P54, DOI 10.1016/0091-6749(83)90052-0; Fletcher A, 1998, POSTGRAD MED J, V74, P41; FODDE R, 1994, HUM MUTAT, V3, P83, DOI 10.1002/humu.1380030202; FOSSUM S, 1994, THROMB RES, V74, P477, DOI 10.1016/0049-3848(94)90268-2; FRANGI D, 1992, FEBS LETT, V301, P34, DOI 10.1016/0014-5793(92)80204-T; FRANGI D, 1991, J CLIN INVEST, V88, P755, DOI 10.1172/JCI115373; FRANK MM, 1976, ANN INTERN MED, V84, P580; FRANK MM, 1972, NEW ENGL J MED, V286, P808, DOI 10.1056/NEJM197204132861503; FRANK MM, 1979, ARTHRITIS RHEUM, V22, P1295, DOI 10.1002/art.1780221118; Freiberger T, 2002, HUM MUTAT, V19, DOI 10.1002/humu.9029; Fremeaux-Bacchi V, 2002, AM J MED, V113, P194, DOI 10.1016/S0002-9343(02)01124-5; FRIGAS E, 1989, MAYO CLIN PROC, V64, P1269; GADEK JE, 1980, NEW ENGL J MED, V302, P542, DOI 10.1056/NEJM198003063021002; Gainer JV, 1998, NEW ENGL J MED, V339, P1285, DOI 10.1056/NEJM199810293391804; Gainer JV, 1996, J ALLERGY CLIN IMMUN, V98, P283, DOI 10.1016/S0091-6749(96)70151-3; Gallagher PE, 1999, HYPERTENSION, V33, P323; GELFAND JA, 1979, MEDICINE, V58, P321; GELFAND JA, 1976, NEW ENGL J MED, V295, P1444, DOI 10.1056/NEJM197612232952602; Gershov D, 2000, J EXP MED, V192, P1353, DOI 10.1084/jem.192.9.1353; Gibbs CR, 1999, BRIT J CLIN PHARMACO, V48, P861; Gompels MM, 2003, BRIT J DERMATOL, V148, P719, DOI 10.1046/j.1365-2133.2003.05231.x; Gompels MM, 2002, J CLIN PATHOL, V55, P145; Gonzalez-Quevedo Teresa, 2002, International Immunopharmacology, V2, P1318; GORDON EM, 1985, BLOOD, V66, P602; GORDON EM, 1988, J LAB CLIN MED, V111, P52; GORDON EM, 1980, J LAB CLIN MED, V96, P762; GORDON EM, 1991, J LAB CLIN MED, V117, P353; Goring HD, 1998, HAUTARZT, V49, P114, DOI 10.1007/s001050050710; Grattan C, 2001, BRIT J DERMATOL, V144, P708, DOI 10.1046/j.1365-2133.2001.04175.x; GREAVES M, 1991, J AM ACAD DERMATOL, V25, P155, DOI 10.1016/0190-9622(91)70183-3; Greaves M, 1991, J AM ACAD DERMATOL, V25; GRIEP MA, 1985, BIOCHEMISTRY-US, V24, P4124, DOI 10.1021/bi00336a047; GROMPE M, 1993, NAT GENET, V5, P111, DOI 10.1038/ng1093-111; Groner A, 2002, SEMIN THROMB HEMOST, V28, P79, DOI 10.1055/s-2002-30200; GUDAT W, 1989, DERMATOLOGICA, V179, P211; Hack CE, 1998, BLOOD, V92, P703; Hack CE, 2003, INT C1 EST DEF WORKS, V3, P34; HADJIYANNAKI K, 1971, Clinical Allergy, V1, P221, DOI 10.1111/j.1365-2222.1971.tb03021.x; HALBMAYER WM, 1991, THROMB HAEMOSTASIS, V65, P134; Hall JM, 1997, GEN PHARMACOL, V28, P1, DOI 10.1016/S0306-3623(96)00174-7; Hamilton SR, 2003, SCIENCE, V301, P1244, DOI 10.1126/science.1088166; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; Hara T, 1999, ENDOSCOPY, V31, P322; Hardie J, 1990, J Can Dent Assoc, V56, P1096; HARPEL P C, 1970, Journal of Clinical Investigation, V49, P568, DOI 10.1172/JCI106267; HARPEL PC, 1985, J BIOL CHEM, V260, P4257; HAUPTMANN G, 1979, CLIN EXP IMMUNOL, V37, P523; Hawthorne Nathaniel, 2001, HOUSE 7 GABLES; HEIMBURGER N, 1981, HAEMOSTASIS, V10, P204; HENRY ML, 1988, J LAB CLIN MED, V111, P519; HILFENHAUS J, 1994, VOX SANG, V67, P62; HILFENHAUS J, 1990, TRANSFUS SCI, V11, pS35, DOI 10.1016/0955-3886(90)90080-3; HOEM NO, 1991, THROMB RES, V64, P427, DOI 10.1016/0049-3848(91)90343-U; HORY B, 1989, CLIN NEPHROL, V31, P259; HUISMAN LGM, 1995, THROMB HAEMOSTASIS, V73, P466; HUNT LT, 1980, BIOCHEM BIOPH RES CO, V95, P864, DOI 10.1016/0006-291X(80)90867-0; Iamandescu I B, 1990, Med Interne, V28, P53; INTRATOR L, 1985, PRESSE MED, V14, P1668; Irons BK, 2003, ANN PHARMACOTHER, V37, P1024, DOI 10.1345/aph.1C520; JACKSON J, 1986, NATURE, V323, P722, DOI 10.1038/323722a0; JACKSON J, 1989, J CLIN INVEST, V83, P698, DOI 10.1172/JCI113934; Jacobson DL, 1997, CLIN IMMUNOL IMMUNOP, V84, P223, DOI 10.1006/clin.1997.4412; JANSON M, 1991, P NATL ACAD SCI USA, V88, P10609, DOI 10.1073/pnas.88.23.10609; JESPERSEN J, 1985, THROMB HAEMOSTASIS, V54, P454; JOHNSON U, 1983, ACTA PATH MICRO IM C, V91, P147; Joop K, 2001, THROMB HAEMOSTASIS, V85, P810; Joseph K, 2002, INT IMMUNOPHARMACOL, V2, P1851, DOI 10.1016/S1567-5769(02)00186-8; Joseph K, 2002, P NATL ACAD SCI USA, V99, P896, DOI 10.1073/pnas.022626899; Kalmar L, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9202; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Karim Y, 2004, J CLIN PATHOL, V57, P213, DOI 10.1136/jcp.2003.12021; Kawachi Y, 1998, J INVEST DERMATOL, V110, P837, DOI 10.1046/j.1523-1747.1998.00170.x; Kim SJ, 2002, J EXP MED, V196, P655, DOI 10.1084/jem.20020542; Klarmann D, 1996, TRANSFUSION, V36, P84, DOI 10.1046/j.1537-2995.1996.36196190522.x; Klasco RK, 2001, DRUGDEX SYSTEM; KLENIEWSKI J, 1992, J LAB CLIN MED, V120, P129; KOHLER PF, 1967, J IMMUNOL, V99, P1211; Koide M, 2002, J DERMATOL, V29, P503; Koles K, 2004, GLYCOBIOLOGY, V14, P51, DOI 10.1093/glycob/cwh010; Korb LC, 1997, J IMMUNOL, V158, P4525; Kostis John B., 2004, American Journal of Hypertension, V17, P103, DOI 10.1016/j.amjhyper.2003.09.014; KRAMER J, 1991, J CLIN INVEST, V87, P1614, DOI 10.1172/JCI115175; KRAMER J, 1993, J CLIN INVEST, V91, P1258, DOI 10.1172/JCI116290; Kranke B, 2000, LANCET, V356, P1440, DOI 10.1016/S0140-6736(05)74078-2; KRAUSE K-H, 1979, Journal of the Neurological Sciences, V42, P429, DOI 10.1016/0022-510X(79)90175-8; KREUZ W, 1991, THROMB HAEMOSTASIS, V65, P824; Ksiazek TG, 2003, NEW ENGL J MED, V348, P1953, DOI 10.1056/NEJMoa030781; Kunschak M, 1998, TRANSFUSION, V38, P540, DOI 10.1046/j.1537-2995.1998.38698326333.x; La Rocca E, 1986, G Ital Dermatol Venereol, V121, P203; Lachmann P J, 1984, Acta Pathol Microbiol Immunol Scand Suppl, V284, P35; Lakshminrusimha S, 1996, PEDIATR ASTHMA ALLER, V10, P155, DOI 10.1089/pai.1996.10.155; Lamark T, 2001, PROTEIN EXPRES PURIF, V22, P349, DOI 10.1006/prep.2001.1445; LANDERMAN NS, 1962, J ALLERGY, V33, P316, DOI 10.1016/0021-8707(62)90031-X; LANGTON D, 1994, MED J AUSTRALIA, V160, P383; LAUERSEN NH, 1976, OBSTET GYNECOL, V48, P93; LAURENT J, 1987, PRESSE MED, V16, P2132; LAURENT J, 1988, LANCET, V1, P761; LEGENDRE M, 1985, Revue de Pneumologie Clinique, V41, P251; Lehmann A, 2002, J CARDIOTHOR VASC AN, V16, P473, DOI 10.1053/jcan.2002.125132; LEIMGRUBER A, 1993, INT ARCH ALLERGY IMM, V101, P107; LEVI M, 1991, J CLIN INVEST, V88, P1155, DOI 10.1172/JCI115416; LEVY NJ, 1990, P NATL ACAD SCI USA, V87, P265, DOI 10.1073/pnas.87.1.265; LEY SJ, 1987, AM J MED, V82, P1046, DOI 10.1016/0002-9343(87)90173-2; Lipner H., 1988, P447; LUNDH B, 1968, Clinical and Experimental Immunology, V3, P733; Lung CC, 1997, J ALLERGY CLIN IMMUN, V99, P134, DOI 10.1016/S0091-6749(97)81054-8; Luong K V, 1997, Allergy Asthma Proc, V18, P239, DOI 10.2500/108854197778594098; Luyer MDP, 2001, J CLIN ENDOCR METAB, V86, P3629, DOI 10.1210/jc.86.8.3629; MADALINSKI K, 1991, IMMUNOL INVEST, V20, P133, DOI 10.3109/08820139109050781; Madeddu P, 1997, BRIT J PHARMACOL, V121, P1763, DOI 10.1038/sj.bjp.0701255; Madsen JS, 2003, J THROMB HAEMOST, V1, P1984, DOI 10.1046/j.1538-7836.2003.00362.x; MARASINI B, 1978, KLIN WOCHENSCHR, V56, P819, DOI 10.1007/BF01489716; Martin L, 2001, J ALLERGY CLIN IMMUN, V107, P747, DOI 10.1067/mai.2001.114242; Martinez-Saguer I, 2002, HAEMOPHILIA, V8, P574; Martinez-Saguer I, 1999, BLOOD S, V94, P2339; MATHEWS KP, 1980, ANN INTERN MED, V93, P443; MATHEWS KP, 1986, J CLIN IMMUNOL, V6, P87, DOI 10.1007/BF00915368; Matsushita M, 2000, J IMMUNOL, V165, P2637; MATTER L, 1981, SCHWEIZ MED WSCHR, V111, P1238; MAVES KK, 1994, ANN ALLERGY, V73, P435; Mayer MM, 1962, EXPT IMMUNOCHEMISTRY, P213; McEvoy GK, 2000, AHFS DURG INFORM 200; McGlinchey PG, 2000, AM J MED SCI, V320, P212, DOI 10.1097/00000441-200009000-00014; MCPHADEN AR, 1991, CLIN GENET, V39, P161; MELAMED J, 1986, J ALLERGY CLIN IMMUN, V77, P322; MILGROM H, 1980, J IMMUNOL, V124, P2780; Milton IL, 1876, EDINBURGH MED J, V22, P513; MINTA JO, 1981, J IMMUNOL, V126, P245; Mittelstadt CA, 1992, GEN ULTRASOUND; Molinaro G, 2002, STROKE, V33, P1712, DOI 10.1161/01.STR.0000017284.77838.87; MUNKVAD S, 1990, CLIN CHEM, V36, P737; NAKAMURA S, 1991, ANN RHEUM DIS, V50, P713, DOI 10.1136/ard.50.10.713; Nataraj AJ, 1999, ELECTROPHORESIS, V20, P1177, DOI 10.1002/(SICI)1522-2683(19990101)20:6<1177::AID-ELPS1177>3.0.CO;2-2; Ni AG, 1998, J BIOL CHEM, V273, P2784, DOI 10.1074/jbc.273.5.2784; Nielsen EW, 1996, SCAND J IMMUNOL, V44, P185; Nielsen EW, 1996, J INTERN MED, V239, P119, DOI 10.1046/j.1365-2796.1996.418764000.x; NIELSEN EW, 1994, PEDIATR RES, V35, P184, DOI 10.1203/00006450-199402000-00012; NIELSEN EW, 1994, J IMMUNOL METHODS, V173, P245, DOI 10.1016/0022-1759(94)90303-4; Nielsen EW, 1998, SCAND J IMMUNOL, V47, P273; Nielsen EW, 1995, SCAND J IMMUNOL, V42, P679, DOI 10.1111/j.1365-3083.1995.tb03711.x; Nogawa N, 2001, MENOPAUSE, V8, P210, DOI 10.1097/00042192-200105000-00011; NORMAN ME, 1975, J PEDIATR-US, V87, P912, DOI 10.1016/S0022-3476(75)80904-8; Norris LA, 1996, BRIT J OBSTET GYNAEC, V103, P261, DOI 10.1111/j.1471-0528.1996.tb09716.x; Nuijens J., 2002, International Immunopharmacology, V2, P1315; NUIJENS JH, 1989, J CLIN INVEST, V84, P443, DOI 10.1172/JCI114185; NUIJENS JH, 1988, BLOOD, V72, P1841; Nussberger J, 1998, LANCET, V351, P1693, DOI 10.1016/S0140-6736(97)09137-X; Nussberger J, 2002, NEW ENGL J MED, V347, P621, DOI 10.1056/NEJM200208223470820; Nussberger J, 1999, J ALLERGY CLIN IMMUN, V104, P1321; Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417; OCEJOVINYALS JG, 1995, MOL MED, V1, P700; OGSTON D, 1981, THROMB RES, V23, P453, DOI 10.1016/0049-3848(81)90206-1; OHELA K, 1977, ACTA MED SCAND, V201, P415; Ono H, 1996, HUM GENET, V98, P452, DOI 10.1007/s004390050238; Osler W., 1888, AM J MED SCI, V95, P362, DOI DOI 10.1097/00000441-188804000-00004; PAN CG, 1992, AM J KIDNEY DIS, V19, P526; Pappalardo E, 2000, J ALLERGY CLIN IMMUN, V106, P1147, DOI 10.1067/mai.2000.110471; PARAD RB, 1990, P NATL ACAD SCI USA, V87, P6786, DOI 10.1073/pnas.87.17.6786; Parfitt K., 1999, COMPLETE DRUG REFERE; PASCUAL M, 1987, AM J MED, V83, P959, DOI 10.1016/0002-9343(87)90659-0; Pavletic A, 2002, AM FAM PHYSICIAN, V66, P956; Peled M, 1997, Quintessence Int, V28, P169; PENCE HL, 1974, J ALLERGY CLIN IMMUN, V53, P298, DOI 10.1016/0091-6749(74)90109-2; PERRICONE R, 1992, CLIN EXP IMMUNOL, V89, P154; PERRICONE R, 1990, CLIN EXP IMMUNOL, V82, P359; PERRICONE R, 1989, IMMUNOPHARMACOLOGY, V18, P89, DOI 10.1016/0162-3109(89)90061-1; PERRICONE R, 1992, CLIN EXP IMMUNOL, V90, P401; Perricone R, 2000, SCAND J IMMUNOL, V51, P104; Phanish MK, 2002, J CLIN PATHOL, V55, P789, DOI 10.1136/jcp.55.10.789; Phillips K M, 1989, Spec Care Dentist, V9, P23, DOI 10.1111/j.1754-4505.1989.tb01016.x; PICHLER WJ, 1989, ANN ALLERGY, V63, P301; PICKERING RJ, 1969, LANCET, V1, P326; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Prada AE, 1998, IMMUNOBIOLOGY, V199, P377; Prado GN, 2002, J CELL PHYSIOL, V193, P275, DOI 10.1002/jcp.10175; PROUD G, 1976, LANCET, V2, P48; PROUDLER AJ, 1995, LANCET, V346, P89, DOI 10.1016/S0140-6736(95)92114-1; PURTELL A, 1983, J ALLERGY CLIN IMMUN, V71, P127, DOI 10.1016/0091-6749(83)90280-4; QUASTEL M, 1983, J CLIN INVEST, V71, P1041, DOI 10.1172/JCI110831; Quincke H, 1882, MONATSSCHR PRAKT DER, V1, P129; Raffai I, 1972, Orv Hetil, V113, P2471; Regoli D, 1996, IMMUNOPHARMACOLOGY, V33, P24, DOI 10.1016/0162-3109(96)00077-X; ROACH B, 1981, AM J DIS CHILD, V135, P918; ROCK JA, 1993, OBSTET GYNECOL, V82, P198; Rojkjaer R, 1999, IMMUNOPHARMACOLOGY, V43, P109, DOI 10.1016/S0162-3109(99)00069-7; Rojkjaer R, 1998, THROMB HAEMOSTASIS, V80, P74; ROSEN FS, 1965, SCIENCE, V148, P957, DOI 10.1126/science.148.3672.957; Ruschitzka F, 2001, NEPHROL DIAL TRANSPL, V16, P1532, DOI 10.1093/ndt/16.8.1532; Rusicke E, 2003, ANN HEMATOL S1, V82, pS73; SALVESEN GS, 1985, J BIOL CHEM, V260, P2432; Santagostino Elena, 2002, Paediatr Drugs, V4, P149, DOI 10.2165/00148581-200204030-00002; SCHAPIRA M, 1983, NEW ENGL J MED, V308, P1050, DOI 10.1056/NEJM198305053081802; SCHIMPF K, 1987, NEW ENGL J MED, V316, P918, DOI 10.1056/NEJM198704093161505; SCHIMPF K, 1989, NEW ENGL J MED, V321, P1148, DOI 10.1056/NEJM198910263211702; Schmaier AH, 2004, THROMB HAEMOSTASIS, V91, P1; Schmaier AH, 2002, J CLIN INVEST, V109, P1007, DOI 10.1172/JCI200215490; SCHOUSBOE I, 1994, BLOOD COAGUL FIBRIN, V5, P503; SCHREIBER AD, 1976, BLOOD, V48, P567; Schunkert H, 1997, CIRCULATION, V95, P39; SHEFFER AL, 1987, J ALLERGY CLIN IMMUN, V80, P855, DOI 10.1016/S0091-6749(87)80277-4; SHEFFER AL, 1985, J ALLERGY CLIN IMMUN, V75, P640, DOI 10.1016/0091-6749(85)90087-9; SHEFFER AL, 1977, J ALLERGY CLIN IMMUN, V60, P38, DOI 10.1016/0091-6749(77)90080-X; SHEPHERD GM, 1990, AM J MED, V88, P446, DOI 10.1016/0002-9343(90)90514-E; SIDDIQUE Z, 1992, HUM HERED, V42, P231, DOI 10.1159/000154075; SIDDIQUE Z, 1993, HUM GENET, V92, P189; SIDDIQUE Z, 1992, HUM HERED, V42, P298, DOI 10.1159/000154086; SIDDIQUE Z, 1991, HUM GENET, V88, P231; SIDDIQUE Z, 1995, HUM HERED, V45, P98, DOI 10.1159/000154267; SIDDIQUE Z, 1993, HUM HERED, V43, P155, DOI 10.1159/000154171; Siddique Z, 1991, CLIN EXP IMMUNOL S, V85S, P11; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; SIM RB, 1979, FEBS LETT, V97, P111, DOI 10.1016/0014-5793(79)80063-0; SKRIVER K, 1989, J BIOL CHEM, V264, P3066; SKRIVER K, 1991, J BIOL CHEM, V266, P9216; Sofia S, 1999, J CLIN ULTRASOUND, V27, P537, DOI 10.1002/(SICI)1097-0096(199911/12)27:9<537::AID-JCU9>3.0.CO;2-L; Sonntag J, 1997, THROMB RES, V87, P339, DOI 10.1016/S0049-3848(97)00136-9; Spaeth PJ, 1998, COMPLEMENT SYSTEM, P366; SPATH P J, 1984, Complement, V1, P147; Spath P J, 1990, Recenti Prog Med, V81, P513; SPATH PJ, 1989, ARCH INTERN MED, V149, P1213, DOI 10.1001/archinte.149.5.1213; Spath PJ, 1998, COMPLEMENT SYSTEM, P353; SPAULDING WB, 1960, ANN INTERN MED, V53, P739; STEVENSON JC, 1989, HORM RES, V32, P161, DOI 10.1159/000181335; STOPPALYONNET D, 1991, AM J HUM GENET, V49, P1055; STOPPALYONNET D, 1990, P NATL ACAD SCI USA, V87, P1551, DOI 10.1073/pnas.87.4.1551; STOPPALYONNET D, 1987, NEW ENGL J MED, V317, P1, DOI 10.1056/NEJM198707023170101; STRANG CJ, 1988, J EXP MED, V168, P1685, DOI 10.1084/jem.168.5.1685; Sturfelt G, 1996, J RHEUMATOL, V23, P378; Sugiyama E, 2001, ARTHRITIS RHEUM, V44, P974, DOI 10.1002/1529-0131(200104)44:4<974::AID-ANR155>3.0.CO;2-1; Sumino H, 2003, HYPERTENS RES, V26, P53; SUNDER TR, 1982, JAMA-J AM MED ASSOC, V247, P2005, DOI 10.1001/jama.247.14.2005; SUZUKI Y, 1986, JPN J MED, V25, P281; Tabrizchi R, 2001, Curr Opin Investig Drugs, V2, P1414; TALAVERA A, 1995, AM J GASTROENTEROL, V90, P471; Tan Y, 2004, AM J PHYSIOL-HEART C, V286, pH926, DOI 10.1152/ajpheart.00757.2003; Taylor GR, 1999, GENET ANAL-BIOMOL E, V14, P181, DOI 10.1016/S1050-3862(98)00029-1; Teede HJ, 2000, ARTERIOSCL THROM VAS, V20, P1404; THERIAULT A, 1990, HUM GENET, V84, P477; THIERY M, 1987, MED SCI RES-BIOCHEM, V15, P1231; Tosi M, 1998, IMMUNOBIOLOGY, V199, P358; TOSI M, 1986, GENE, V42, P265, DOI 10.1016/0378-1119(86)90230-1; Turner P, 2001, J ALLERGY CLIN IMMUN, V107, P105, DOI 10.1067/mai.2001.111145; Ueno A, 2003, J PHARMACOL SCI, V93, P1, DOI 10.1254/jphs.93.1; VANDELLEN RG, 1980, MAYO CLIN PROC, V55, P277; Venema RC, 2002, INT IMMUNOPHARMACOL, V2, P1755, DOI 10.1016/S1567-5769(02)00185-6; Verpy E, 1996, AM J HUM GENET, V59, P308; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663; VERPY E, 1994, P NATL ACAD SCI USA, V91, P1873, DOI 10.1073/pnas.91.5.1873; Verpy E, 1993, BEHRING I MITT, P120; Visentin DE, 1998, ANN ALLERG ASTHMA IM, V80, P457; Visy B, 2004, CLIN ENDOCRINOL, V60, P508, DOI 10.1111/j.1365-2265.2004.02009.x; WARIN RP, 1986, BRIT J DERMATOL, V115, P731, DOI 10.1111/j.1365-2133.1986.tb06656.x; Warner KK, 2000, ANN PHARMACOTHER, V34, P526, DOI 10.1345/aph.19294; Watson RD, 2000, J INVEST ALLERG CLIN, V10, P129; WAUTIER JL, 1986, PRESSE MED, V15, P2023; Waytes AT, 1996, NEW ENGL J MED, V334, P1630, DOI 10.1056/NEJM199606203342503; Wedi B, 1999, J PHYSIOL PHARMACOL, V50, P753; Weimer T, 2001, TRANSFUSION, V41, P1500, DOI 10.1046/j.1537-2995.2001.41121500.x; WEINBLATT ME, 1988, AM J DIS CHILD, V142, P1317; WEINSTOCK LB, 1987, GASTROENTEROLOGY, V93, P1116; Wessler S, 1992, Ann Epidemiol, V2, P439; Whaley K, 1996, CLIN EXP IMMUNOL, V106, P423, DOI 10.1046/j.1365-2249.1996.d01-879.x; WHITEHOUSE RW, 1990, CLIN ENDOCRINOL, V33, P365, DOI 10.1111/j.1365-2265.1990.tb00501.x; Williams A, 2003, TRANSFUS APHER SCI, V29, P255, DOI 10.1016/S1473-0502(03)00170-8; Winnewisser J, 1997, J INTERN MED, V241, P39, DOI 10.1046/j.1365-2796.1997.76893000.x; WOLBINK GJ, 1993, J IMMUNOL METHODS, V163, P67, DOI 10.1016/0022-1759(93)90240-8; Wong R C, 1999, Gastroenterology, V116, P777, DOI 10.1016/S0016-5085(99)70170-8; WOO P, 1985, CLIN EXP IMMUNOL, V61, P1; Wortsman J, 1990, OBSTET GYNECOL, V63, P630; Wuillemin WA, 1996, J BIOL CHEM, V271, P12913; Wuillemin WA, 1997, J IMMUNOL, V159, P1953; WUILLEMIN WA, 1995, BLOOD, V85, P1517; Wuillemin WA, 1996, THROMB HAEMOSTASIS, V76, P549; Wuthrich B, 1999, SCHWEIZ MED WSCHR, V129, P285; Xiao WZ, 2001, HUM MUTAT, V17, P439, DOI 10.1002/humu.1130.abs; Yip J, 1992, Australas J Dermatol, V33, P35, DOI 10.1111/j.1440-0960.1992.tb00050.x; YLIKORKALA O, 1990, GYNECOL ENDOCRINOL, V4, P251, DOI 10.3109/09513599009024979; Zahedi K, 1999, J IMMUNOL, V162, P7249; ZAHEDI R, 1995, J CLIN INVEST, V95, P1299, DOI 10.1172/JCI117780; Zahedi R, 1997, J IMMUNOL, V159, P983; Zahedi R, 2001, J IMMUNOL, V167, P1500; Zahedi R, 1996, J BIOL CHEM, V271, P24307; Zanoletti E, 2003, ACTA OTO-LARYNGOL, V123, P960, DOI 10.1080/00016480310005129; Zeana C, 1989, Med Interne, V27, P143; Zhi Yu-xiang, 2003, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V25, P664; ZICCARDI RJ, 1982, J IMMUNOL, V128, P2505; Zuraw BL, 2000, J ALLERGY CLIN IMMUN, V105, P541, DOI 10.1067/mai.2000.104780; ZURAW BL, 1991, J ALLERGY CLIN IMMUN, V88, P908, DOI 10.1016/0091-6749(91)90248-M; ZURLO JJ, 1990, FERTIL STERIL, V54, P64; [Anonymous], 1998, PRESCRIRE INT, V7, P92	456	312	319	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		2004	114	3		S			S51	S131		10.1016/j.jaci.2004.06.047		81	Allergy; Immunology	Allergy; Immunology	V17HU	WOS:000207929100001	15356535	
J	Krieger, J; Higgins, DL				Krieger, J; Higgins, DL			Housing and health: Time again for public health action	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Review							INNER-CITY CHILDREN; RISK-FACTORS; SOCIOECONOMIC-STATUS; TUBERCULOSIS INFECTION; BRONCHIAL OBSTRUCTION; ENVIRONMENTAL-CONTROL; RESPIRATORY SYMPTOMS; HOMELESS CHILDREN; IMPACT ASSESSMENT; ALAMEDA-COUNTY	Poor housing conditions are associated with a wide range of health conditions, including respiratory infections, asthma. lead poisoning. injuries, and mental health. Addressing housing issues offers public health practitioners an opportunity to address an important social determinant of health. Public health has long been involved in housing issues, In the 19th century. health officials targeted poor sanitation, crowding, and inadequate ventilation to reduce infectious diseases as well as fire hazards to decrease injuries, Today, public health departments can employ multiple strategies to improve housing, such as developing and enforcing housing guidelines and codes, implementing ''Healthy Homes'' programs to improve indoor environmental quality, assessing housing conditions, and advocating for healthy, affordable housing, Now is the time for public health to create healthier homes by confronting substandard housing.	Publ Hlth Seattle & King Cty, EPE, Seattle, WA 98104 USA; Univ Washington, Sch Med, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Krieger, J (reprint author), Publ Hlth Seattle & King Cty, EPE, 999 3rd Ave,12th Floor, Seattle, WA 98104 USA.						*AM PUBL HLTH ASS, 1971, BAS HLTH PRINC HOUS; *AM PUBL HLTH ASS, 1938, BAS PRINC HEALTHF HO; *APHA PROGR AR COM, 1969, AM J PUBLIC HEALTH, V59, P841; *ASHRAE, 1981, 621981 ANSIASHRAE; ASHRAE, 1981, 551981 ANSIASHRAE; Barr RG, 2001, AM J PUBLIC HEALTH, V91, P1487, DOI 10.2105/AJPH.91.9.1487; Bierman CW, 1996, IMMUNOL ALLERGY CLIN, V16, P753, DOI 10.1016/S0889-8561(05)70269-1; Billings C G, 1998, Monaldi Arch Chest Dis, V53, P43; Boardman B., 1993, UNHEALTHY HOUSING RE, P282; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bosma H, 2001, AM J EPIDEMIOL, V153, P363, DOI 10.1093/aje/153.4.363; Brownson RC, 2001, AM J PUBLIC HEALTH, V91, P1995, DOI 10.2105/AJPH.91.12.1995; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; Bull MJ, 2001, PEDIATRICS, V107, P1188; Burridge R., 1993, UNHEALTHY HOUSING RE, P420; BYRNE D, 1993, UNHEALTHY HOUSING RE, P41; CARP FM, 1977, GERONTOLOGIST, V17, P242; *CDCP, 2002, ABOUT LEAD; Centers for Disease Control and Prevention, 1999, MMWR-MORBID MORTAL W, V48, P143; Chadwick E., 1965, REPORT SANITARY COND; Cohen D, 2000, AM J PUBLIC HEALTH, V90, P230, DOI 10.2105/AJPH.90.2.230; Coleman William, 1982, DEATH IS SOCIAL DIS; COLLINS KJ, 1986, AGE AGEING, V15, P212, DOI 10.1093/ageing/15.4.212; Collins K., 1993, UNHEALTHY HOUSING RE, P117; CONWAY J, 1993, UNHEALTHY HOUSING RE, P283; Cook DG, 1997, THORAX, V52, P1081; *COUNC HYG PUBL HL, 1865, SAN COND CIT REP COU; Cubbin C, 2000, J EPIDEMIOL COMMUN H, V54, P517, DOI 10.1136/jech.54.7.517; Dales R. E., 1991, AM J EPIDEMIOL, V134, P96; Dedman DJ, 2001, J EPIDEMIOL COMMUN H, V55, P10, DOI 10.1136/jech.55.1.10; DEFOREST RW, 2003, TENEMENT HOUSE PROBL, V1, P18; DENNY FW, 1995, AM J RESP CRIT CARE, V152, pS4; *DEP HOUS URB DEV, 2002, HUD 67 MILL PROT CHI; Douglas M R, 1998, Inj Prev, V4, P28; Douglas MJ, 2001, J PUBLIC HEALTH MED, V23, P148, DOI 10.1093/pubmed/23.2.148; Duffy J., 1974, HIST PUBLIC HLTH NEW; Dunn JR, 2000, SOC SCI MED, V51, P563, DOI 10.1016/S0277-9536(99)00496-7; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS422, DOI 10.1067/mai.2001.113671; ELLAWAY A, 2000, HLTH B, V54, P336; ENGELS F, 1969, CONDITION WORKING CL; Evans J, 2000, J EPIDEMIOL COMMUN H, V54, P677, DOI 10.1136/jech.54.9.677; Evans R. J., 1987, DEATH HAMBURG SOC PO; FEE E, 1990, J HIST MED ALL SCI, V45, P570, DOI 10.1093/jhmas/45.4.570; Fonseca W, 1996, B WORLD HEALTH ORGAN, V74, P199; FREUDENBERG N, 1990, B NEW YORK ACAD MED, V66, P451; Frumkin Howard, 2001, American Journal of Preventive Medicine, V20, P234, DOI 10.1016/S0749-3797(00)00317-2; Fullilove MT, 1998, AM J PUBLIC HEALTH, V88, P924, DOI 10.2105/AJPH.88.6.924; GABE J, 1993, UNHEALTHY HOUSING RE, P191; Galishoff S., 1988, NEWARK NATIONS UNHEA; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823; GILLORAN JL, 1968, MED OFFICER, V120, P117; GRAHAM NMH, 1990, EPIDEMIOL REV, V12, P149; Griscom J. H., 1845, SANITARY CONDITION L; HAAN M, 1987, AM J EPIDEMIOL, V125, P989; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HENKIN R I, 1963, Am J Physiol, V204, P701; Hopton JL, 1996, J EPIDEMIOL COMMUN H, V50, P56, DOI 10.1136/jech.50.1.56; Howard M., 1993, UNHEALTHY HOUSING RE, P256; Hunt S., 1993, UNHEALTHY HOUSING RE, P67; HUSS K, 1994, ANN ALLERGY, V72, P173; Hyndman S, 1998, PUTTING HLTH PLACE M, P191; HYNDMAN SJ, 1990, SOC SCI MED, V30, P131, DOI 10.1016/0277-9536(90)90336-Q; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jackson R. J., 2001, CREATING HLTH ENV IM; JACOBS M, 1981, INT J HLTH SERV, V1, P105; Kane MP, 1999, J ASTHMA, V36, P371, DOI 10.3109/02770909909068230; KARIM YG, 1985, CAN J MICROBIOL, V31, P1058; KARTER MJ, 2000, FIRE LOSS US 1999; KATZ LF, 2001, EARLY IMPACT MOVING; Kermode M, 1999, INT J TUBERC LUNG D, V3, P901; Krieger J, 2002, ENVIRON HEALTH PERSP, V110, P311; Krieger JW, 2000, J URBAN HEALTH, V77, P50, DOI 10.1007/BF02350962; Landrigan PJ, 1998, NEW ENGL J MED, V338, P1618, DOI 10.1056/NEJM199805283382209; Lewis RG, 1999, ENVIRON HEALTH PERSP, V107, P721, DOI 10.2307/3434657; LEWIS RG, 1994, ARCH ENVIRON CON TOX, V26, P37; Lock K, 2000, BRIT MED J, V320, P1395, DOI 10.1136/bmj.320.7246.1395; Lubin JH, 1997, J NATL CANCER I, V89, P49, DOI 10.1093/jnci/89.1.49; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Markowitz G, 2000, AM J PUBLIC HEALTH, V90, P36, DOI 10.2105/AJPH.90.1.36; MARKUS TA, 1993, UNHEALTHY HOUSING RE, P141; Marmot M, 1999, SOCIAL DETERMINANTS; Marsh A., 1999, HOME SWEET HOME IMPA; MARSH BT, 1982, J ENVIRON HEALTH, V45, P123; McEwen BS, 1999, ANN NY ACAD SCI, V896, P30, DOI 10.1111/j.1749-6632.1999.tb08103.x; MCKEOWN T., 1976, ROLE MED DREAM MIRAG; Melosi Martin V., 2000, SANITARY CITY URBAN; MEYERS A, 1995, ARCH PEDIAT ADOL MED, V149, P1079; *MILB MEM FUND, 1951, HOUS HLTH, P5; MOOD E, 1986, APHA CDC RECOMMENDED; MOOD EW, 1993, UNHEALTHY HOUSING RE, P303; MURTAGH P, 1993, PEDIATR PULM, V16, P1, DOI 10.1002/ppul.1950160102; *NAT CTR ENV HLTH, 2001, CTR DIS CONTR PREV W; *NAT CTR HLTH STAT, 2000, PUBL PHS; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; Nuffield Institute for Health, 1996, EFFECTIVE HLTH CARE, V2, P1; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; PAULS J, 2002, INJURY CONTROL E FAL; Pearl M, 2001, AM J PUBLIC HEALTH, V91, P1808, DOI 10.2105/AJPH.91.11.1808; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Perlin SA, 2001, J AIR WASTE MANAGE, V51, P406; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; PIERCE J, 2000, MMWR-MORBID MORTAL W, V49, P153; PLATT SD, 1989, BRIT MED J, V298, P1673; Ranson R., 1991, HLTH HOUSING PRACTIC; RANSON R, 1993, UNHEALTHY HOUSING RE, P223; RAW GJ, 1993, UNHEALTHY HOUSING RE, P361; Riis Jacob, 1890, OTHER HALF LIVES STU; Roberts JW, 1995, REV ENVIRON CONTA<D>, V143, P59; ROBINSON T, 1992, HLTH ECOLOGY EFFECTS; RODERICK P, 1991, BRIT MED J, V302, P157; Rosen G., 1958, HIST PUBLIC HLTH; ROSEN JF, 1995, TOXICOLOGY, V97, P11, DOI 10.1016/0300-483X(94)02963-U; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rosner D., 1995, HIVES SICKNESS PUBLI; Roux AVD, 2001, NEW ENGL J MED, V345, P99, DOI 10.1056/NEJM200107123450205; SAHRFSTEIN J, 1998, NOT SAFE HOME AM HOU; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Schulz A, 2000, J HEALTH SOC BEHAV, V41, P314, DOI 10.2307/2676323; SCHWARTZ J, 1988, ENVIRON HEALTH PERSP, V78, P15, DOI 10.2307/3430493; Somerville M, 2000, PUBLIC HEALTH, V114, P434, DOI 10.1016/S0033-3506(00)00383-8; Stansfeld S, 2000, Rev Environ Health, V15, P43; Strachan DP, 1993, UNHEALTHY HOUSING RE, P94; TEIN L, 1950, BR J SOC MED, V4, P143; Thomson H, 2001, BRIT MED J, V323, P187, DOI 10.1136/bmj.323.7306.187; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; *US CENS BUR, 2002, AM HOUS SURV 1999; *US DEP HOUS URB D, 1997, RENT HOUS ASS WORS C; *US EPA, 1992, PUBL EPA; Van Cauter E, 1999, ANN NY ACAD SCI, V896, P254, DOI 10.1111/j.1749-6632.1999.tb08120.x; Vaughan JW, 2000, CLIN REV ALLERG IMMU, V18, P325, DOI 10.1385/CRIAI:18:3:325; VEILLER L, 1921, HALF CENTURY PUBLIC, P323; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; Walker E, 1999, BRIT MED J, V319, P1082; Walker WF, 1923, AM J PUBLIC HEALTH, V13, P897, DOI 10.2105/AJPH.13.11.897-a; WALLACE R, 1988, ENVIRON RES, V47, P1, DOI 10.1016/S0013-9351(88)80018-5; WAMBEM DB, 1973, HEALTH SERV REP, V88, P47, DOI 10.2307/4594728; WARGOCKI P, 2002, IN PRESS INDOOR AIR; WARNER M, 2000, VITAL HLTH STAT 10, V202; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Williamson IJ, 1997, THORAX, V52, P229; WINSLOW CEA, 1941, HOUSING HLTH; Wohl A., 1983, ENDANGERED LIVES PUB; WOOD DL, 1990, PEDIATRICS, V86, P858; Yen IH, 1999, AM J EPIDEMIOL, V149, P898; ZIMA BT, 1994, AM J PUBLIC HEALTH, V84, P260, DOI 10.2105/AJPH.84.2.260; ZOLOPA AR, 1994, JAMA-J AM MED ASSOC, V272, P455, DOI 10.1001/jama.272.6.455; 2002, APHA POLICY STATEMEN; 2001, MMWR MORB MORTAL WKL, V50, P623; 1985, GLASGOW HOUSE CONDIT; 2001, AM J PUBLIC HLTH, V91, P503; 2002, GUIDELINES ASSESSMEN; 1996, MMWR MORB MORTAL WKL, V45, P814	153	311	318	16	67	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	MAY	2002	92	5					758	768		10.2105/AJPH.92.5.758		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	545MV	WOS:000175222200025	11988443	
J	Gale, CR; Robinson, SM; Harvey, NC; Javaid, MK; Jiang, B; Martyn, CN; Godfrey, KM; Cooper, C				Gale, C. R.; Robinson, S. M.; Harvey, N. C.; Javaid, M. K.; Jiang, B.; Martyn, C. N.; Godfrey, K. M.; Cooper, C.		Princess Anne Hosp Study Grp	Maternal vitamin D status during pregnancy and child outcomes	EUROPEAN JOURNAL OF CLINICAL NUTRITION			English	Article						pregnancy; diet; vitamin D; infant; child	D DEFICIENCY; D SUPPLEMENTATION; HYPOVITAMINOSIS-D; FETAL GROWTH; ASIAN WOMEN; BONE MASS; WEIGHT; PREVALENCE; NUTRITION; ASTHMA	Objective: To investigate whether exposure to high maternal concentrations of 25(OH)-vitamin D in pregnancy poses any risk to the child. Design: Prospective study. Setting: Princess Anne Maternity Hospital, Southampton, UK. Subjects: A group of 596 pregnant women were recruited. A total of 466 (78%) children were examined at birth, 440 (74%) at age 9 months and 178 (30%) at age 9 years. Methods: Maternal 25 (OH)-vitamin D concentrations were measured in late pregnancy. Anthropometry of the child was recorded at birth, 9 months and 9 years. At 9 months, atopic eczema was assessed. At 9 years, children had an echocardiogram and a dual energy x-ray absorptiometry scan, blood pressure, arterial compliance and carotid intima-media thickness were measured and intelligence and psychological function assessed. Results: There were no associations between maternal 25(OH)-vitamin D concentrations and the child's body size or measures of the child's intelligence, psychological health or cardiovascular system. Children whose mothers had a 25(OH)-vitamin D concentration in pregnancy 475 nmol/l had an increased risk of eczema on examination at 9 months (OR 3.26, 95% CI 1.15-9.29, P=0.025) and asthma at age 9 years (OR 5.40, 95% CI, 1.09-26.65, P=0.038) compared to children whose mothers had a concentration of <30 nmol/l. Conclusion: Exposure to maternal concentrations of 25(OH)-vitamin D in pregnancy in excess of 75 nmol/l does not appear to influence the child's intelligence, psychological health or cardiovascular system; there could be an increased risk of atopic disorders, but this needs confirmation in other studies. Sponsorship: The study was supported by the Medical Research Council and WellChild (previously known as Children Nationwide).	[Gale, C. R.; Robinson, S. M.; Harvey, N. C.; Javaid, M. K.; Jiang, B.; Martyn, C. N.; Godfrey, K. M.; Cooper, C.; Princess Anne Hosp Study Grp] Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England	Gale, CR (reprint author), Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton SO16 6YD, Hants, England.	crg@mrc.soton.ac.uk	Gale, Catharine/B-1653-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Godfrey, Keith/0000-0002-4643-0618; Robinson, Sian/0000-0003-1766-7269	Medical Research Council [MC_U147585827, MC_U147574237, MC_UP_A620_1014, MC_UP_A620_1015, U.1475.00.003.00010.02(74237)]		ALFAHIM M, 1995, BRIT J NUTR, V73, P881, DOI 10.1079/BJN19950093; BONNER SE, 1995, FORTSCHR BER, V107, P43; BROOKE OG, 1981, BRIT MED J, V283, P1024; BROOKE OG, 1980, BRIT MED J, V280, P751; Butland BK, 2006, THORAX, V61, P383, DOI 10.1136/thx.2005.043646; Cole TJ, 1998, STAT MED, V17, P407, DOI 10.1002/(SICI)1097-0258(19980228)17:4<407::AID-SIM742>3.0.CO;2-L; Datt S, 2002, BJOG-INT J OBSTET GY, V109, P905, DOI 10.1016/S1470-0328(02)01171-0; Dawodu A, 2003, J PEDIATR-US, V142, P169, DOI 10.1067/mpd.2003.63; *DEP HLTH, 1998, DIET REF VAL FOOD EN; *DEP HLTH, 1998, NUTR BON HLTH REP HL, V49; FRIEDMAN WF, 1966, CIRCULATION, V34, P77; Godfrey K, 1996, BRIT MED J, V312, P410; Godfrey KM, 1996, EARLY HUM DEV, V46, P129, DOI 10.1016/0378-3782(96)01752-5; GOODENDAY LS, 1971, ANN INTERN MED, V75, P807; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Holick MF, 2004, AM J CLIN NUTR, V80, p1678S; HOLLIS BW, 1984, J CLIN ENDOCR METAB, V59, P652; HOLLIS BW, 2004, AM J CLIN NUTR, V79, P726; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Javaid MK, 2006, LANCET, V367, P36, DOI 10.1016/S0140-6736(06)67922-1; Jiang BY, 2006, PEDIATRICS, V117, pE257, DOI 10.1542/peds.2005-1325; Mahomed K, 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD000228, DOI 10.1002/14651858.CD000228]; MALABANAN AO, 1998, LANCET, V351, P806; MALLET E, 1986, OBSTET GYNECOL, V68, P300; MARYA RK, 1981, GYNECOL OBSTET INVES, V12, P155; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI 10.1037/mai.2003.1703; Meddeb N, 2005, OSTEOPOROSIS INT, V16, P180, DOI 10.1007/s00198-004-1658-6; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187; Norman P, 2002, CARDIOVASC RES, V55, P369, DOI 10.1016/S0008-6363(02)00444-3; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Robinson S, 1996, EUR J CLIN NUTR, V50, P302; Sachan A, 2005, AM J CLIN NUTR, V81, P1060; Schroth Robert J, 2005, Int J Circumpolar Health, V64, P112; Sproston K, 2003, HLTH SURVEY ENGLAND; TODA T, 1985, TOHOKU J EXP MED, V145, P303, DOI 10.1620/tjem.145.303; Wechsler D., 1999, WECHSLER ABBREVIATED; Weiler H, 2005, CAN MED ASSOC J, V172, P757, DOI 10.1503/cmaj.1040508; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P416; Wjst M, 1999, ALLERGY, V54, P757, DOI 10.1034/j.1398-9995.1999.00193.x; Zeghoud F, 1997, AM J CLIN NUTR, V65, P771	41	310	320	6	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0954-3007			EUR J CLIN NUTR	Eur. J. Clin. Nutr.	JAN	2008	62	1					68	77		10.1038/sj.ejcn.1602680		10	Nutrition & Dietetics	Nutrition & Dietetics	249IK	WOS:000252221300008	17311057	
J	Ley, K				Ley, K			The role of selectins in inflammation and disease	TRENDS IN MOLECULAR MEDICINE			English	Review							ADHESION-DEFICIENCY-II; ACUTE-RENAL-FAILURE; DOUBLE MUTANT MICE; ROLLING IN-VIVO; P-SELECTIN; LEUKOCYTE RECRUITMENT; APOLIPOPROTEIN-E; ENDOTHELIAL ADHESION; ISCHEMIA-REPERFUSION; ACTIVATED PLATELETS	Selectins are carbohydrate-binding molecules that bind to fucosylated and sialylated glycoprotein ligands, and are found on endothelial cells, leukocytes and platelets. They are involved in trafficking of cells of the innate immune system, T lymphocytes and platelets. An absence of selectins or selectin ligands has serious consequences in mice or humans, leading to recurrent bacterial infections and persistent disease. Selectins are involved in constitutive lymphocyte homing, and in chronic and acute inflammation processes, including post-ischemic inflammation in muscle, kidney and heart, skin inflammation, atherosclerosis, glomerulonephritis and lupus erythematosus. Selectin-neutralizing monoclonal antibodies, recombinant soluble P-selectin glycoprotein ligand 1 and small-molecule inhibitors of selectins have been tested in clinical trials on patients with multiple trauma, cardiac indications and pediatric asthma, respectively. Anti-selectin antibodies have also been successfully used in preclinical models to deliver imaging contrast agents and therapeutics to sites of inflammation. Further improvements in the efficiency, availability, specificity and pharmacokinetics of selectin inhibitors, and specialized application routes and schedules, hold promise for therapeutic indications.	Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22908 USA; Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	Ley, K (reprint author), Univ Virginia, Cardiovasc Res Ctr, MR5 Bldg,Room 1013,POB 801394, Charlottesville, VA 22908 USA.						Andre P, 2000, P NATL ACAD SCI USA, V97, P13835, DOI 10.1073/pnas.250475997; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; Bullard DC, 1999, J IMMUNOL, V163, P2844; Bullard DC, 1996, J EXP MED, V183, P2329, DOI 10.1084/jem.183.5.2329; BULLARD DC, 1995, J CLIN INVEST, V95, P1782, DOI 10.1172/JCI117856; Collins RG, 2001, BLOOD, V98, P727, DOI 10.1182/blood.V98.3.727; Demerath E, 2001, ANN HUM BIOL, V28, P664, DOI 10.1080/03014460110048530; Dong ZM, 2000, CIRCULATION, V101, P2290; Etzioni A, 1999, BLOOD, V94, P3281; Everts M, 2002, J IMMUNOL, V168, P883; Forlow SB, 2002, J IMMUNOL, V169, P4797; Forlow SB, 2001, BLOOD, V98, P3309, DOI 10.1182/blood.V98.12.3309; FORLOW SB, 2002, INTERACTIONS BLOOD P, P255; Frenette PS, 1996, CELL, V84, P563, DOI 10.1016/S0092-8674(00)81032-6; Fuggle SV, 1998, TRANSPLANTATION, V65, P763, DOI 10.1097/00007890-199803270-00001; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hemmerich S, 2000, GLYCOBIOLOGY, V10, P849, DOI 10.1093/glycob/10.9.849; Hickey MJ, 2000, J IMMUNOL, V165, P7164; Huo YQ, 2003, NAT MED, V9, P61, DOI 10.1038/nm810; Jung U, 1999, J IMMUNOL, V162, P6755; Kansas GS, 1996, BLOOD, V88, P3259; Keelan E T, 1994, Am J Physiol, V266, pH278; KUBES P, 1995, J CLIN INVEST, V95, P2510, DOI 10.1172/JCI117952; Kunkel EJ, 1996, CIRC RES, V79, P1196; LARSEN E, 1989, CELL, V59, P305, DOI 10.1016/0092-8674(89)90292-4; Ley K, 2002, IMMUNOL REV, V186, P8, DOI 10.1034/j.1600-065X.2002.18602.x; Lim YC, 1999, J IMMUNOL, V162, P3193; Lindner JR, 2001, CIRCULATION, V104, P2107, DOI 10.1161/hc4201.097061; Lowe JB, 2002, IMMUNOL REV, V186, P19, DOI 10.1034/j.1600-065X.2002.18603.x; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/88289; Lukacs NW, 2002, J IMMUNOL, V169, P2120; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Manka D, 2001, CIRCULATION, V103, P1000; MAYADAS TN, 1993, CELL, V74, P541, DOI 10.1016/0092-8674(93)80055-J; Moore KL, 1998, LEUKEMIA LYMPHOMA, V29, P1, DOI 10.3109/10428199809058377; Norman KE, 1998, BLOOD, V91, P475; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; PHILLIPS JW, IN PRESS CIRCULATION; Ramos CL, 1999, CIRC RES, V84, P1237; Rauchhaus M, 2002, INT J CARDIOL, V83, P249, DOI 10.1016/S0167-5273(02)00073-6; Robinson SD, 1999, P NATL ACAD SCI USA, V96, P11452, DOI 10.1073/pnas.96.20.11452; ROSEN SD, 1993, RES IMMUNOL, V144, P699, DOI 10.1016/S0923-2494(93)80054-3; Rosenkranz AR, 1999, J CLIN INVEST, V103, P649, DOI 10.1172/JCI5183; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; Simon SI, 1999, J IMMUNOL, V163, P2891; Singbartl K, 2000, FASEB J, V14, P48; Singbartl K, 2000, CRIT CARE MED, V28, P2507; SPERANDIO M, IN PRESS J EXP MED; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Subramaniam M, 1996, BLOOD, V87, P1238; TEDDER TF, 1995, J EXP MED, V181, P2259, DOI 10.1084/jem.181.6.2259; Wang K, 2002, THROMB HAEMOSTASIS, V88, P149; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; White SJ, 2001, J IMMUNOL, V167, P628; Wild MK, 2002, CELLS TISSUES ORGANS, V172, P161, DOI 10.1159/000066968; Wong J, 1997, J CLIN INVEST, V99, P2782, DOI 10.1172/JCI119468; Xia LJ, 2002, J CLIN INVEST, V109, P939; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Yoshida M, 1998, J IMMUNOL, V161, P933	61	309	325	8	34	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4914			TRENDS MOL MED	Trends Mol. Med	JUN	2003	9	6					263	268		10.1016/S1471-4914(03)00071-6		6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	700TD	WOS:000184126500008	12829015	
J	Aimanianda, V; Bayry, J; Bozza, S; Kniemeyer, O; Perruccio, K; Elluru, SR; Clavaud, C; Paris, S; Brakhage, AA; Kaveri, SV; Romani, L; Latge, JP				Aimanianda, Vishukumar; Bayry, Jagadeesh; Bozza, Silvia; Kniemeyer, Olaf; Perruccio, Katia; Elluru, Sri Ramulu; Clavaud, Cecile; Paris, Sophie; Brakhage, Axel A.; Kaveri, Srini V.; Romani, Luigina; Latge, Jean-Paul			Surface hydrophobin prevents immune recognition of airborne fungal spores	NATURE			English	Article							ASPERGILLUS-FUMIGATUS; CELL-WALL; INVASIVE ASPERGILLOSIS; ALVEOLAR MACROPHAGES; CLADOSPORIUM; RESPONSES; PROTEINS; ANTIGENS; CONIDIA; HOMES	The air we breathe is filled with thousands of fungal spores (conidia) per cubic metre, which in certain composting environments can easily exceed 10 9 per cubic metre. They originate from more than a hundred fungal species belonging mainly to the genera Cladosporium, Penicillium, Alternaria and Aspergillus(1-4). Although these conidia contain many antigens and allergens(5-7), it is not known why airborne fungal microflora do not activate the host innate immune cells continuously and do not induce detrimental inflammatory responses following their inhalation. Here we show that the surface layer on the dormant conidia masks their recognition by the immune system and hence prevents immune response. To explore this, we used several fungal members of the airborne microflora, including the human opportunistic fungal pathogen Aspergillus fumigatus, in in vitro assays with dendritic cells and alveolar macrophages and in in vivo murine experiments. In A. fumigatus, this surface 'rodlet layer' is composed of hydrophobic RodA protein covalently bound to the conidial cell wall through glycosylphosphatidylinositol-remnants. RodA extracted from conidia of A. fumigatus was immunologically inert and did not induce dendritic cell or alveolar macrophage maturation and activation, and failed to activate helper T-cell immune responses in vivo. The removal of this surface 'rodlet/hydrophobin layer' either chemically (using hydrofluoric acid), genetically (Delta rodA mutant) or biologically (germination) resulted in conidial morphotypes inducing immune activation. All these observations show that the hydrophobic rodlet layer on the conidial cell surface immunologically silences airborne moulds.	[Aimanianda, Vishukumar; Clavaud, Cecile; Paris, Sophie; Latge, Jean-Paul] Inst Pasteur, Unite Aspergillus, F-75015 Paris, France; [Bayry, Jagadeesh; Elluru, Sri Ramulu; Kaveri, Srini V.] Univ Paris 06, INSERM, UMR S 872, U872, F-75006 Paris, France; [Bayry, Jagadeesh; Elluru, Sri Ramulu; Kaveri, Srini V.] Univ Paris 06, Ctr Rech Cordeliers, UMR S 872, F-75006 Paris, France; [Bayry, Jagadeesh; Elluru, Sri Ramulu; Kaveri, Srini V.] Univ Paris 05, UMR S 872, F-75006 Paris, France; [Bozza, Silvia; Romani, Luigina] Univ Perugia, Dept Expt Med & Biochem Sci, I-06122 Perugia, Italy; [Perruccio, Katia] Univ Perugia, Dept Clin & Expt Med, I-06122 Perugia, Italy; [Kniemeyer, Olaf; Brakhage, Axel A.] Leibniz Inst Nat Prod Res & Infect Biol HKI, Dept Mol & Appl Microbiol, D-07745 Jena, Germany; [Kniemeyer, Olaf; Brakhage, Axel A.] Univ Jena, D-07745 Jena, Germany	Latge, JP (reprint author), Inst Pasteur, Unite Aspergillus, F-75015 Paris, France.	jplatge@pasteur.fr	Elluru, Sri Ramulu/B-1097-2009; Aimanianda, Vishukumar/E-9204-2011; Kniemeyer, Olaf/K-1253-2013; Latge, Jean Paul/C-9846-2014; Bayry, Jagadeesh/A-6589-2011; Marion-Poll, Frederic/D-8882-2011	Aimanianda, Vishukumar/0000-0001-5813-7497; Kniemeyer, Olaf/0000-0002-9493-6402; Marion-Poll, Frederic/0000-0001-6824-0180; Elluru, Sri Ramulu/0000-0001-9188-710X; Romani, Luigina/0000-0002-1356-525X	Deutsche Forschungsgemeinschaft (DFG); EU-STREP [LSHB-CT-2004-511952, MANASP LSGBH37899]; INSERM; CNRS; Universities Paris 5 and 6	We thank J. Vani, Y. Repesse and C. Galeotti for help with dendritic cell experiments; and R. Winkler, S. Behnken and M. Potsch for help with the MALDI-TOF/TOF analysis. The research of O. K. and A. A. B. was supported by the Deutsche Forschungsgemeinschaft (DFG) Priority Programme 1160, and the EU-STREP Fungwall LSHB-CT-2004-511952 and MANASP LSGBH37899 were also awarded to J.-P. L., A. A. B. and L. R. J. B and S. V. K are supported by INSERM, CNRS and Universities Paris 5 and 6.	Bayry J, 2007, J IMMUNOL, V178, P4184; Bernard M, 2001, MED MYCOL, V39, P9, DOI 10.1080/714030981; Boualem K, 2008, RES MICROBIOL, V159, P110, DOI 10.1016/j.resmic.2007.10.004; Bozza S, 2003, BLOOD, V102, P3807, DOI 10.1182/blood-2003-03-0748; Bozza S, 2002, J IMMUNOL, V168, P1362; Braedel S, 2004, BRIT J HAEMATOL, V125, P392, DOI 10.1111/j.1365-2141.2004.04922.x; Codina R, 2008, J INVEST ALLERG CLIN, V18, P156; Dague E, 2008, LANGMUIR, V24, P2955, DOI 10.1021/la703741y; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; Dubourdeau M, 2006, J IMMUNOL, V177, P3994; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Glaser AG, 2009, ALLERGY, V64, P1144, DOI 10.1111/j.1398-9995.2009.02029.x; de Ana SG, 2006, J INVEST ALLERG CLIN, V16, P357; Graham LM, 2006, J IMMUNOL METHODS, V314, P164, DOI 10.1016/j.jim.2006.05.013; Hektor HJ, 2005, CURR OPIN BIOTECH, V16, P434, DOI 10.1016/j.copbio.2005.05.004; Hohl TM, 2005, PLOS PATHOG, V1, P232, DOI 10.1371/journal.ppat.0010030; Kasprzyk I, 2008, ANN AGR ENV MED, V15, P1; Kniemeyer O, 2006, CURR GENET, V49, P178, DOI 10.1007/s00294-005-0047-9; Lamarre C, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-417; Latge JP, 2007, MOL MICROBIOL, V66, P279, DOI 10.1111/j.1365-2958.2007.05872.x; LATGE JP, 1988, CAN J MICROBIOL, V34, P1325; Latge JP, 1999, CLIN MICROBIOL REV, V12, P310; Lee T, 2006, ATMOS ENVIRON, V40, P2902, DOI 10.1016/j.atmosenv.2006.01.011; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; Romani L, 2004, NAT REV IMMUNOL, V4, P11, DOI 10.1038/nri1255; Romani L, 2008, NATURE, V451, P211, DOI 10.1038/nature06471; Sarfati J, 2006, DIAGN MICR INFEC DIS, V55, P279, DOI 10.1016/j.diagmicrobio.2006.02.002; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Steele C, 2005, PLOS PATHOG, V1, P323, DOI 10.1371/journal.ppat.0010042; THAU N, 1994, INFECT IMMUN, V62, P4380	30	307	316	8	78	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	AUG 27	2009	460	7259					1117	U79		10.1038/nature08264		7	Multidisciplinary Sciences	Science & Technology - Other Topics	487YE	WOS:000269314000036	19713928	
J	van Staa, TP; Leufkens, HGM; Abenhaim, L; Zhang, B; Cooper, C				van Staa, TP; Leufkens, HGM; Abenhaim, L; Zhang, B; Cooper, C			Oral corticosteroids and fracture risk: relationship to daily and cumulative doses	RHEUMATOLOGY			English	Article						osteoporosis; epidemiology; glucocorticoids; fracture; risk factors	BONE-MINERAL CONTENT; RHEUMATOID-ARTHRITIS; VERTEBRAL FRACTURES; OSTEOPOROSIS; THERAPY; UK; DATABASE; ASTHMA	Objective. This study examined the effects of daily and cumulative oral corticosteroid doses on the risk of fractures. Methods. Information was obtained from the General Practice Research Database, which contains medical records of general practitioners in England and Wales. The study included 244 235 oral corticosteroid users and 244 235 controls. Results. Patients taking higher doses (at least 7.5 mg daily of prednisolone or equivalent) had significantly increased risks of non-vertebral fracture [relative rate (RR) = 1.44, 95% confidence interval (CI) 1.34-1.54], hip fracture (RR = 2.21, 95% CI 1.85-2.64) and vertebral fracture (RR = 2.83, 95% CI 2.35-2.40) relative to patients using oral corticosteroids at lower doses (less than 2.5 mg per day). Fracture risk was also elevated among people with higher cumulative exposure to oral corticosteroids over the study period, but this effect was almost wholly removed by adjustment for daily dose, age, gender and other confounding variables. Conclusions. These findings suggest that the adverse skeletal effects of oral corticosteroids manifest rapidly and are related to daily dose. The level of previous exposure to oral corticosteroids was not a strong determinant of the risk of fracture. Preventive measures against corticosteroid-induced osteoporosis should therefore be instituted as soon after the commencement of glucocorticoid therapy as possible.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Univ Utrecht, Dept Pharmacoepidemiol & Pharmacotherapy, Utrecht, Netherlands; Procter & Gamble Pharmaceut, Staines, England; Sir Mortimer B Davis Jewish Gen Hosp, Ctr Clin Epidemiol & Community Studies, Montreal, PQ, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada	Cooper, C (reprint author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.		Research Datalink, Clinical Practice/H-2477-2013	van Staa, Tjeerd/0000-0001-9363-742X			ADINOFF AD, 1983, NEW ENGL J MED, V309, P265, DOI 10.1056/NEJM198308043090502; Breslow N.E., 1987, STAT METHODS CANC RE; British Medical Association the Royal Pharmaceutical Society of Great Britain, 1996, BRIT NATL FORMULARY; BUTLER RC, 1991, BRIT J RHEUMATOL, V30, P86; COOPER C, 1995, ANN RHEUM DIS, V54, P1, DOI 10.1136/ard.54.1.1; COOPER C, 1995, ANN RHEUM DIS, V54, P49, DOI 10.1136/ard.54.1.49; Silman A, 1993, BONE, V14, P89, DOI 10.1016/8756-3282(93)90358-H; DEQUEKER J, 1995, J RHEUMATOL, V22, P1013; DURRLEMAN S, 1989, STAT MED, V8, P551, DOI 10.1002/sim.4780080504; DYKMAN TR, 1985, ARTHRITIS RHEUM, V28, P361, DOI 10.1002/art.1780280402; Eastell R, 1998, J INTERN MED, V244, P271, DOI 10.1046/j.1365-2796.1998.00408.x; GREENLAND S, 1995, EPIDEMIOLOGY, V6, P356, DOI 10.1097/00001648-199507000-00005; HALL G, 1992, PHARMACOEPIDEM DR S, V1, P33, DOI 10.1002/pds.2630010108; Henderson N. Kathryn, 1996, Current Opinion in Rheumatology, V8, P365, DOI 10.1097/00002281-199607000-00015; Hollowell J, 1994, GEN PRACTICE RES DAT; HOOYMAN JR, 1984, ARTHRITIS RHEUM, V27, P1353, DOI 10.1002/art.1780271205; JICK H, 1991, BRIT MED J, V302, P766; Jick H, 1992, PHARMACOEPIDEM DR S, V1, P347, DOI 10.1002/pds.2630010607; LAAN RFJM, 1992, BRIT J RHEUMATOL, V31, P91; LEMS WF, 1995, CLIN EXP RHEUMATOL, V13, P293; LIS Y, 1995, J CLIN EPIDEMIOL, V48, P431, DOI 10.1016/0895-4356(94)00137-F; LUENGO M, 1991, THORAX, V46, P803, DOI 10.1136/thx.46.11.803; Lukert Barbara, 1996, P801; MANN RD, 1992, POSTMARKETING SURVEI, V5, P259; MCCONKEY B, 1962, Q J MED, V124, P419; MCDOUGALL R, 1994, J RHEUMATOL, V21, P1207; MICHEL BA, 1993, J RHEUMATOL, V20, P1666; MICHEL BA, 1991, J RHEUMATOL, V18, P804; NAZARETH I, 1993, BRIT MED J, V307, P32; PIZER M, 1975, NUMERICAL COMPUTING, P251; REID IR, 1998, OSTEOPOROSIS DIAGNOS, P233; SAAG KG, 1994, AM J MED, V96, P115, DOI 10.1016/0002-9343(94)90131-7; SAMBROOK PN, 1986, ANN RHEUM DIS, V45, P950, DOI 10.1136/ard.45.11.950; *SAS I, 1996, SAS GRAPH SOFTW REF, V1; SAVILLE PD, 1967, ARTHRITIS RHEUM, V10, P423, DOI 10.1002/art.1780100504; SPECTOR TD, 1993, BRIT MED J, V307, P519; Van Staa TP, 2000, J BONE MINER RES, V15, P993, DOI 10.1359/jbmr.2000.15.6.993; Van Staa TP, 1994, PHARMACOEPIDEM DR S, V3, P15, DOI 10.1002/pds.2630030106; VANSTAA TP, 2001, IN PRESS PHARMACOEPI; VERSTRAETEN A, 1986, ANN RHEUM DIS, V45, P852, DOI 10.1136/ard.45.10.852; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; 1996, GEN PRACTICE RES DAT	42	299	307	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324			RHEUMATOLOGY	RHEUMATOLOGY	DEC	2000	39	12					1383	1389		10.1093/rheumatology/39.12.1383		7	Rheumatology	Rheumatology	391RW	WOS:000166369800013	11136882	
J	Brehm, JM; Celedon, JC; Soto-Quiros, ME; Avila, L; Hunninghake, GM; Forno, E; Laskey, D; Sylvia, JS; Hollis, BW; Weiss, ST; Litonjua, AA				Brehm, John M.; Celedon, Juan C.; Soto-Quiros, Manuel E.; Avila, Lydiana; Hunninghake, Gary M.; Forno, Erick; Laskey, Daniel; Sylvia, Jody S.; Hollis, Bruce W.; Weiss, Scott T.; Litonjua, Augusto A.			Serum Vitamin D Levels and Markers of Severity of Childhood Asthma in Costa Rica	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							1,25-DIHYDROXYVITAMIN D-3; D DEFICIENCY; 25-HYDROXYVITAMIN-D; EPIDEMIC; EXPOSURE; CHILDREN; INSIGHTS; REALITY; 25-HYDROXYCHOLECALCIFEROL; RADIOIMMUNOASSAY	Rationale: Maternal vitamin D intake during pregnancy has been inversely associated with asthma symptoms in early childhood. However, no study has examined the relationship between measured vitamin D levels and markers of asthma severity in childhood. Objectives: To determine the relationship between measured vitamin D levels and both markers of asthma severity and allergy in childhood. Methods: We examined the relation between 25-hydroxyvitamin D levels (the major circulating form of vitamin D) and markers of allergy and asthma severity in a cross-sectional study of 616 Costa Rican children between the ages of 6 and 14 years. Linear, logistic, and negative binomial regressions were used for the univariate and multivariate analyses. Measurements and Main Results- Of the 616 children with asthma, 175 (28%) had insufficient levels of vitamin D (<30 ng/ml). In multivariate linear regression models, vitamin D levels were significantly and inversely associated with total IgE and eosinophil count. In multivariate logistic regression models, a log(10) unit increase in vitamin D levels was associated with reduced odds of any hospitalization in the previous year (odds ratio [OR], 0.05; 95% confidence interval [CI], 0.004-0.71; P = 0.03), any use of antiinflammatory medications in the previous year (OR, 0.18; 95% Cl, 0.05-0.67; P = 0.01), and increased airway responsiveness (a <= 8.58-mu mol provocative dose of methacholine producing a 20% fall in baseline FEV1 [OR, 0.15; 95% Cl, 0.024-0.97; P = 0.05]). Conclusions: Our results suggest that vitamin D insufficiency is relatively frequent in an equatorial population of children with asthma. In these children, lower vitamin D levels are associated with increased markers of allergy and asthma severity.	[Brehm, John M.; Celedon, Juan C.; Hunninghake, Gary M.; Forno, Erick; Laskey, Daniel; Sylvia, Jody S.; Weiss, Scott T.; Litonjua, Augusto A.] Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; [Brehm, John M.; Celedon, Juan C.; Hunninghake, Gary M.; Litonjua, Augusto A.] Brigham & Womens Hosp, Div Pulm Crit Care Med, Dept Med, Boston, MA 02115 USA; [Brehm, John M.; Celedon, Juan C.; Hunninghake, Gary M.; Forno, Erick; Weiss, Scott T.; Litonjua, Augusto A.] Harvard Univ, Sch Med, Boston, MA USA; [Celedon, Juan C.; Litonjua, Augusto A.] Brigham & Womens Hosp, Ctr Genom Med, Dept Med, Boston, MA 02115 USA; [Soto-Quiros, Manuel E.; Avila, Lydiana] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Dept Med, Div Pediat Pulmonol, San Jose, Costa Rica; [Forno, Erick] Childrens Hosp, Div Pediat Pulmonol, Boston, MA 02115 USA; [Hollis, Bruce W.] Med Univ S Carolina, Darby Childrens Res Inst, Charleston, SC 29425 USA	Celedon, JC (reprint author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875; Forno, Erick/0000-0001-6497-9885	National Institutes of Health [HL66289, HL089842, HL04370, T32 HL07427]	Supported by grants HL66289, HL089842, HL04370, and T32 HL07427 from the National Institutes of Health.	Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Binkley N, 2007, J CLIN ENDOCR METAB, V92, P2130, DOI 10.1210/jc.2006-2250; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; Bosse Y, 2007, PHYSIOL GENOMICS, V29, P161, DOI 10.1152/physiolgenomics.00134.2006; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; Devereux G, 2007, AM J CLIN NUTR, V85, P853; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; El-Hajj Fuleihan G, 2001, PEDIATRICS, V107; HADDAD JG, 1971, J CLIN ENDOCR METAB, V33, P992; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Heaney RP, 2003, AM J CLIN NUTR, V77, P204; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; HOLLIS BW, 1985, CLIN CHEM, V31, P1815; Hollis BW, 2005, J NUTR, V135, P317; Hollis BW, 2005, NEW ENGL J MED, V352, P515; HOLLIS BW, 1993, CLIN CHEM, V39, P529; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Kabagambe EK, 2005, J AM COLL NUTR, V24, P122; Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30; Lamberg-Allardt C, 2006, PROG BIOPHYS MOL BIO, V92, P33, DOI 10.1016/j.pbiomolbio.2006.02.017; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Ly NP, 2008, CHEST, V133, P107, DOI 10.1378/chest.07-2130; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; May Ekkehard, 2004, Current Drug Targets - Inflammation and Allergy, V3, P377, DOI 10.2174/1568010042634596; Neffen H, 2005, REV PANAM SALUD PUBL, V17, P191; [Anonymous], 2007, NIH PUBL, V07-4051; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; van der Mei IAF, 2007, ENVIRON HEALTH PERSP, V115, P1132; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002; Vieth R, 2007, AM J CLIN NUTR, V85, P649; WEILAND S, 2008, PHASE 2 MODULES INT; Weiss ST, 2007, THORAX, V62, P746, DOI 10.1136/thx.2007.079707; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	42	297	317	0	12	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY 1	2009	179	9					765	771		10.1164/rccm.200808-1361OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	439YX	WOS:000265665000005	19179486	
J	Holgate, ST; Polosao, R				Holgate, Stephen T.; Polosao, Riccardo			Treatment strategies for allergy and asthma	NATURE REVIEWS IMMUNOLOGY			English	Review							REGULATORY T-CELLS; HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; PLACEBO-CONTROLLED TRIAL; KINASE INHIBITOR R112; SMOOTH-MUSCLE-CELLS; IL-5 RECEPTOR-ALPHA; MAST-CELL; AIRWAY HYPERRESPONSIVENESS; ATOPIC-DERMATITIS	Allergic diseases have reached epidemic proportions worldwide. An understanding of the cellular and soluble mediators that are involved in allergic inflammatory responses not only helps in understanding the mechanisms of current treatments, but is also important for the identification of new targets that are amenable to both small-molecule and biological interventions. There is now considerable optimism with regards to tackling the allergy epidemic in light of improvements in systemic and mucosal allergen-specific immunotherapy, the identification of key cytokines and their receptors that drive T-helper-2-cell polarization, a clearer understanding of the pathways of leukocyte recruitment and the signalling pathways that are involved in cell activation and mediator secretion, and new approaches to vaccine development.	[Holgate, Stephen T.] Southampton Gen Hosp, IIR Div, Southampton SO16 6YD, Hants, England; [Polosao, Riccardo] Univ Catania, Dipartimento Med Interna & Specialist, I-95125 Catania, Italy	Holgate, ST (reprint author), Southampton Gen Hosp, IIR Div, F Level, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk			Medical Research Council [G0800766]		Abramson M. J., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001186; Alam R, 2004, J ALLERGY CLIN IMMUN, V113, P38, DOI 10.1016/j.jaci.2003.10.054; Allen LC, 2007, J ALLERGY CLIN IMMUN, V120, P462, DOI 10.1016/j.jaci.2007.04.019; ALTON EW, 1996, J ALLERGY CLIN IMMUN, V98, P102; Andrews AL, 2006, J ALLERGY CLIN IMMUN, V118, P858, DOI 10.1016/j.jaci.2006.06.041; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; BALLANTYNE SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1234; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 2003, ANN INTERN MED, V139, P359; Berlin AA, 2006, LAB INVEST, V86, P557, DOI 10.1038/labinvest.3700419; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bez C, 2004, CLIN EXP ALLERGY, V34, P1079, DOI 10.1111/j.1365-2222.2004.01998.x; BIRRELL MA, 2006, MOL PHARM, V69, P191; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; Boswell-Smith V, 2006, J ALLERGY CLIN IMMUN, V117, P1237, DOI 10.1016/j.jaci.2006.02.045; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Bree A, 2007, J ALLERGY CLIN IMMUN, V119, P1251, DOI 10.1016/j.jaci.2007.02.009; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Castells MC, 2001, NAT IMMUNOL, V2, P436; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chen Z, 2007, ARTHRITIS RHEUM, V56, P2936, DOI 10.1002/art.22866; CHERNOFF AE, 1995, J IMMUNOL, V154, P5492; Cockcroft DW, 2007, CAN RESPIR J, V14, P414; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Corver K, 2006, PEDIATR ALLERGY IMMU, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; Cousins DJ, 2002, J IMMUNOL, V169, P2498; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 2004, IMMUNOL ALLERGY CLIN, V24, P569, DOI 10.1016/j.iac.2004.06.012; Cruse G, 2006, THORAX, V61, P880, DOI 10.1136/thx.2006.060319; Daheshia M, 2001, J EXP MED, V194, P227, DOI 10.1084/jem.194.2.227; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; DEL CA, 2006, J INVEST ALLERG CLIN, V16, P3; Des RA, 1997, J ALLERGY CLIN IMMUN, V99, P450; Dieckgraefe BK, 2006, ANN NY ACAD SCI, V1072, P300, DOI 10.1196/annals.1326.007; Dragon S, 2007, AM J PHYSIOL-LUNG C, V292, pL1023, DOI 10.1152/ajplung.00306.2006; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EDER W, 2006, NEW ENGL J MED, V118, P331; Edwards AM, 2000, CLIN EXP ALLERGY, V30, P756; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; FINA D, 2007, ALLERGY DRUG TARGETS, V6, P63; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Friedmann PS, 2007, CLIN EXP ALLERGY, V37, P1536, DOI 10.1111/j.1365-2222.2007.02811.x; Fu CL, 2006, J GENE MED, V8, P1393, DOI 10.1002/jgm.974; Garrett JK, 2004, J ALLERGY CLIN IMMUN, V113, P115, DOI 10.1016/j.jaci.2003.10.049; Georas SN, 2005, EUR RESPIR J, V26, P1119, DOI 10.1183/09031936.05.00006005; Glimcher LH, 2007, NAT IMMUNOL, V8, P448, DOI 10.1038/ni0507-448; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guyer BJ, 2006, ALLERGY ASTHMA PROC, V27, P208, DOI 10.2500/aap.2006.27.2861; Gyllfors P, 2006, J ALLERGY CLIN IMMUN, V118, P78, DOI 10.1016/j.jaci.2006.03.040; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Hart TK, 2002, CLIN EXP IMMUNOL, V130, P93, DOI 10.1046/j.1365-2249.2002.01973.x; Hayakawa H, 2007, J BIOL CHEM, V282, P26369, DOI 10.1074/jbc.M704916200; Hijnen DJ, 2007, DERMATITIS, V18, P163, DOI 10.2310/6620.2007.06025; Hoffjan S, 2007, BRIT J DERMATOL, V157, P441, DOI 10.1111/j.1365-2133.2007.07999.x; Holgate ST, 2005, AM J RESP CRIT CARE, V172, P941, DOI 10.1164/rccm.2507007; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Holt PG, 2007, CURR OPIN ALLERGY CL, V7, P547; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; ISHIZAKA K, 1966, J IMMUNOL, V97, P840; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kelly M, 2007, J ALLERGY CLIN IMMUN, V120, P3, DOI 10.1016/j.jaci.2007.05.017; Kemp James P, 2003, Am J Respir Med, V2, P139; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Klunker S, 2003, J IMMUNOL, V171, P1078; Kraft S, 2005, J EXP MED, V201, P385, DOI 10.1084/jem.20042085; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Kroegel C, 2006, RESPIRATION, V73, P566, DOI 10.1159/000088660; KULPERS H, 2004, J LEUKOCYTE BIOL, V76, P1028; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; LE BH, 2007, VACCINE, V25, P7206; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Linhart B, 2007, J IMMUNOL, V178, P3924; Liu LY, 2002, J IMMUNOL, V169, P6459; Liu LY, 2002, J IMMUNOL, V169, P6452; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Lund L, 2007, CLIN EXP ALLERGY, V37, P564, DOI 10.1111/j.1365-2222.2007.02687.x; Ma Y, 2007, ALLERGY, V62, P675, DOI 10.1111/j.1398-9995.2007.01384.x; Ma YB, 2007, AM J RESP CRIT CARE, V176, P439, DOI 10.1164/rccm.200610-1405OC; Malbec O, 2007, IMMUNOL REV, V217, P206, DOI 10.1111/j.1600-065X.2007.00510.x; Mark DS, 2004, J ALLERGY CLIN IMMUN, V114, P66; Matsubara S, 2006, AM J RESP CRIT CARE, V173, P56, DOI 10.1164/rccm.200503-361OC; Matsubara S, 2007, AM J RESP CELL MOL, V36, P324, DOI 10.1165/rcmb.2006-0231OC; McCusker CT, 2007, J IMMUNOL, V179, P2556; McIvor RA, 1998, AM J RESP CRIT CARE, V158, P924; Meltzer EO, 2005, J ALLERGY CLIN IMMUN, V115, P791, DOI 10.1016/j.jaci.2005.01.040; Menzies-Gow AN, 2007, CLIN EXP ALLERGY, V37, P1023, DOI 10.1111/j.1365-2222.2007.02735.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nayak A, 2007, DRUGS, V67, P887, DOI 10.2165/00003495-200767060-00005; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; O'Byrne P, 2007, CHEST, V132, P478; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ott VL, 2002, J IMMUNOL, V168, P4430; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; PAJNO GB, 2005, J ALLERGY CLIN IMMUN, V119, P796; Palmqvist C, 2007, BRIT J PHARMACOL, V151, P725, DOI 10.1038/sj.bjp.0707263; Palmqvist M, 1997, EUR RESPIR J, V10, P2484, DOI 10.1183/09031936.97.10112489; Pease JE, 2006, BRIT J PHARMACOL, V147, pS212, DOI 10.1038/sj.bjp.0706475; Peng Z, 2007, CLIN EXP ALLERGY, V37, P1040, DOI 10.1111/j.1365-2222.2007.02741.x; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; Polosa R, 2007, CURR OPIN PULM MED, V13, P24, DOI 10.1097/MCP.0b013e3280107bda; Poole JA, 2005, J ALLERGY CLIN IMMUN, V116, P780, DOI 10.1016/j.jaci.2005.07.007; Popescu FD, 2005, J CELL MOL MED, V9, P840, DOI 10.1111/j.1582-4934.2005.tb00383.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Radtke Michelle L, 2005, J Oncol Pharm Pract, V11, P121, DOI 10.1191/1078155205jp159oa; Rahman MS, 2006, J IMMUNOL, V177, P4064; Reber L, 2006, EUR J PHARMACOL, V533, P327, DOI 10.1016/j.ejphar.2005.12.067; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V115, P973, DOI 10.1016/j.jaci.2005.01.021; Romagnani S, 2006, CLIN EXP ALLERGY, V36, P1357, DOI 10.1111/j.1365-2222.2006.02606.x; Rossi AB, 2006, J ALLERGY CLIN IMMUN, V118, P749, DOI 10.1016/j.jaci.2006.05.023; Ruckert R, 2005, J IMMUNOL, V174, P5507; Satoh M, 2006, EXPERT OPIN BIOL TH, V6, P1161, DOI 10.1517/14712598.6.11.1161; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Scholl I, 2006, IMMUNOL ALLERGY CLIN, V26, P349, DOI 10.1016/j.iac.2006.02.007; Seddiki N, 2006, J EXP MED, V203, P1693, DOI 10.1084/jem.20060468; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Simon HU, 2003, ALLERGY, V58, P1250, DOI 10.1046/j.1398-9995.2003.00424.x; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Stein ML, 2006, J ALLERGY CLIN IMMUN, V118, P1312, DOI 10.1016/j.jaci.2006.09.007; Stockinger B, 2007, IMMUNOL CELL BIOL, V85, P83, DOI 10.1038/sj.icb.7100035; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tillie-Leblond I, 2007, EUR RESPIR J, V30, P31, DOI 10.1183/09031936.00011606; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; Vernersson M, 2002, FASEB J, V16, P875, DOI 10.1096/fj.01-0879fje; von Garnier C, 2007, J IMMUNOL, V179, P5748; Wan YY, 2007, IMMUNOL REV, V220, P199, DOI 10.1111/j.1600-065X.2007.00565.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Waserman S, 2000, Can Respir J, V7, P229; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; WHEELER A, 2006, VACCINE, V24, P40; Williams AP, 2004, CLIN EXP ALLERGY, V34, P513, DOI 10.1111/j.1365-2222.2004.1927.x; Wing K, 2006, INT IMMUNOL, V18, P991, DOI 10.1093/intimm/dxl044; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wu K, 2007, CELL MOL IMMUNOL, V4, P269; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Ying S, 2005, J IMMUNOL, V174, P8183; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	174	296	312	6	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	MAR	2008	8	3					218	230		10.1038/nri2262		13	Immunology	Immunology	267ZV	WOS:000253548600016	18274559	
J	Gilliland, FD; Li, YF; Peters, JM				Gilliland, FD; Li, YF; Peters, JM			Effects of maternal smoking during pregnancy and environmental tobacco smoke on asthma and wheezing in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							PARENTAL SMOKING; CHILDHOOD ASTHMA; LUNG-FUNCTION; FAMILY HISTORY; RISK-FACTORS; PREVALENCE; EXPOSURE; COMMUNITIES; TRENDS; BIRTH	The effects of maternal smoking during pregnancy and childhood environmental tobacco smoke (ETS) exposure on asthma and wheezing were investigated in 5,762 school-aged children residing in 12 Southern California communities. Responses to a self-administered questionnaire completed by parents of 4th, 7th, and 10th grade students were used to ascertain children with wheezing or physician-diagnosed asthma. Lifetime household exposures to tobacco smoke were assessed using responses about past and current smoking histories of household members and any history of maternal smoking during pregnancy. Logistic regression models were fitted to cross-sectional data to estimate the effects of in utero exposure to maternal smoking and previous and current ETS exposure on the prevalence of wheezing and physician-diagnosed asthma. In utero exposure to maternal smoking without subsequent postnatal ETS exposure was associated with increased prevalence of physician-diagnosed asthma (OR, 1.8; 95% CI, 1.1 to 2.9), asthma with current symptoms (OR, 2.3; 95% CI, 1.3 to 4.0), asthma requiring medication use in the previous 12 mo (OR, 2.1; 95% CI, 1.2 to 3.6), lifetime history of wheezing (OR, 1.8; 95% CI, 1.2 to 2.6), current wheezing with colds (OR, 2.1; 95% CI, 1.3 to 3.4) and without colds (OR, 2.5; 95% CI, 1.4 to 4.4), persistent wheezing (OR, 3.1; 95% CI, 1.6 to 6.1), wheezing with exercise (OR, 2.4 95% CI; 1.3 to 4.3), attacks of wheezing causing shortness of breath (OR, 2.4; 95% CI, 1.3 to 4.4) or awakening at night in the previous 12 mo (OR, 3.2; 95% CI, 1.7 to 5.8), and wheezing requiring medication (OR 2.1; 95% CI, 1.2 to 3.7) or emergency room visits during the previous year (OR, 3.4; 95% CI, 1.4 to 7.8). In contrast, current and previous ETS exposure was not associated with asthma prevalence, but was consistently associated with subcategories of wheezing. Current ETS exposure was associated with lifetime wheezing (OR, 1.3; 95% CI, 1.1 to 1.5), current wheezing with colds (OR, 1.6; 95% CI, 1.3 to 2.0) and without colds (OR, 1.5; 95% CI, 1.1 to 1.9), wheezing with exercise (OR, 1.7; 95% CI, 1.3 to 2.2), attacks of wheezing causing shortness of breath (OR, 1.6; 95% CI, 1.2 to 2.1) or awakening at night (OR, 1.5; 95% CI, 1.1 to 2.0), and wheezing requiring medication (OR, 1.4; 95% CI, 1.1 to 1.8) or emergency room visits within the previous year (OR, 1.9; 95% CI, 1.2 to 3.0). The effects of current ETS exposure on subcategories of wheezing were most pronounced among children exposed to two or more smokers and remained significant after adjusting for maternal smoking during pregnancy. We conclude that maternal smoking during pregnancy increases the occurrence of physician-diagnosed asthma and wheezing during childhood. In contrast, current ETS exposure is associated with wheezing, but not physician-diagnosed asthma. Taken together, our findings support the hypothesis that ETS operates as a cofactor with other insults such as intercurrent infections as a trigger of wheezing attacks, rather than as a factor that induces asthma, whereas in utero exposure acts to increase physician-diagnosed asthma.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.		LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [1R01 HL61768-01]; NIEHS NIH HHS [5P01 ES09581, 5P30 ES07048-02]; PHS HHS [R826708-01]		ANDERSON HR, 1994, BRIT MED J, V308, P1600; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; California Environmental Protection Agency (Cal EPA) Office of Environmental Health Hazard Assessment, 1997, HLTH EFF EXP ENV TOB; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1038; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Cook DG, 1999, THORAX, V54, P357; Cook DG, 1997, THORAX, V52, P1081; Cook DG, 1998, THORAX, V53, P295; Cook DG, 1998, THORAX, V53, P884; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Ebrahim SH, 2000, JAMA-J AM MED ASSOC, V283, P361, DOI 10.1001/jama.283.3.361; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; FINGERHUT LA, 1990, AM J PUBLIC HEALTH, V80, P541, DOI 10.2105/AJPH.80.5.541; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Holt PG, 1999, NATURE, V402, pB12; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; Joad JP, 1999, TOXICOL APPL PHARM, V155, P253, DOI 10.1006/taap.1998.8612; Lackmann GM, 1999, J NATL CANCER I, V91, P459, DOI 10.1093/jnci/91.5.459; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; RAPPAPORT S, 1998, MMWR-MORBID MORTAL W, V47, P1022; Rothman K., 1986, MODERN EPIDEMIOLOGY; Samet JM, 1995, TOXICOL LETT, V82-3, P33, DOI 10.1016/0378-4274(95)03544-3; SAS INSTITUTE, 1990, SAS STAT US GUID VER, V2; *SCOTH, 2000, REP SCI COMM TOB HLT; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P204; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; Tager IB, 1998, AM J RESP CRIT CARE, V158, P349; *USEPA, 1992, EPA600690006F; World Health Organization, 1999, WHONCDTFI9910; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	35	296	313	1	18	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB	2001	163	2					429	436				8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	403PD	WOS:000167050900026	11179118	
J	Bacharier, LB; Boner, A; Carlsen, KH; Eigenmann, PA; Frischer, T; Goetz, M; Helms, PJ; Hunt, J; Liu, A; Papadopoulos, N; Platts-Mills, T; Pohunek, P; Simons, FER; Valovirta, E; Wahn, U; Wildhaber, J				Bacharier, L. B.; Boner, A.; Carlsen, K. -H.; Eigenmann, P. A.; Frischer, T.; Goetz, M.; Helms, P. J.; Hunt, J.; Liu, A.; Papadopoulos, N.; Platts-Mills, T.; Pohunek, P.; Simons, F. E. R.; Valovirta, E.; Wahn, U.; Wildhaber, J.		European Pediat Asthma Grp	Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report	ALLERGY			English	Review						diagnosis; education; guidelines; monitoring; pediatric asthma; treatment	EXHALED-NITRIC-OXIDE; EXERCISE-INDUCED ASTHMA; SHORT-TERM GROWTH; RANDOMIZED CONTROLLED-TRIAL; HOUSE-DUST MITE; INHALED FLUTICASONE PROPIONATE; RESPIRATORY-SYNCYTIAL-VIRUS; GRASS-POLLEN IMMUNOTHERAPY; METERED-DOSE INHALER; SKIN-TEST REACTIVITY	Asthma is the leading chronic disease among children in most industrialized countries. However, the evidence base on specific aspects of pediatric asthma, including therapeutic strategies, is limited and no recent international guidelines have focused exclusively on pediatric asthma. As a result, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology nominated expert teams to find a consensus to serve as a guideline for clinical practice in Europe as well as in North America. This consensus report recommends strategies that include pharmacological treatment, allergen and trigger avoidance and asthma education. The report is part of the PRACTALL initiative**, which is endorsed by both academies.	Charite Univ Med Berlin, Dept Med, Berlin, Germany; Washington Univ, Dept Pediat, St Louis, MO 63130 USA; Univ Verona, Dept Pediat, I-37100 Verona, Italy; Univ Oslo, Dept Pediat, Oslo, Norway; Univ Childrens Hosp Geneva, Geneva, Switzerland; Univ Childrens Hosp Vienna, Vienna, Austria; Med Univ Vienna, Dept Paediat & Adolescent Med, Vienna, Austria; Univ Aberdeen, Dept Child Hlth, Aberdeen, Scotland; Univ Virginia, Dept Pediat, Charlottesville, VA USA; Univ Colorado, Sch Med, Dept Pediat, Natl Jewish Med & Res Ctr, Denver, CO USA; Allergy Res Ctr, Goudi, Greece; Charles Univ Prague, Univ Hosp Motol, Dept Pediat, Prague, Czech Republic; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Turku Allergy Ctr, Turku, Finland; Univ Childrens Hosp, Dept Resp Med, Zurich, Switzerland	Wahn, U (reprint author), Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.		Papadopoulos, Nikolaos/L-8670-2013; Eigenmann, Philippe/A-6569-2017	Papadopoulos, Nikolaos/0000-0002-4448-3468; Eigenmann, Philippe/0000-0003-1738-1826; Papadopoulos, Nikolaos/0000-0002-2508-3872; BARALDI, EUGENIO/0000-0002-1829-3652; Fiocchi, Alessandro/0000-0002-2549-0523			Abramson M. J., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001186; Ahrens Richard C, 2005, Respir Care, V50, P1323; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Allen DB, 2005, ENDOCRIN METAB CLIN, V34, P555, DOI 10.1016/j.ecl.2005.04.013; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Balfour-Lynn I, 1999, ARCH DIS CHILD, V80, P201; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Baum WF, 2002, EXP CLIN ENDOCR DIAB, V110, P53, DOI 10.1055/s-2002-23486; Becker A, 2005, CAN MED ASSOC J, V173, pS12, DOI 10.1503/cmaj.045064; Berdel D, 2006, ASTHMA BRONCHIALE KI; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Bisgaard H, 2006, LANCET, V367, P286, DOI 10.1016/S0140-6736(06)68051-3; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187; Bisgaard H, 2005, AM J RESP CRIT CARE, V171, P315, DOI 10.1164/rccm.200407-894OC; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2003, AM J RESP CRIT CARE, V167, P379, DOI 10.1164/rccm.200207-747OC; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BONER AL, 1994, AM J RESP CRIT CARE, V149, P935; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Boyd R, 2005, EMERG MED J, V22, P641, DOI 10.1136/emj.2003.011296; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Burkhart PV, 2005, NURS CLIN N AM, V40, P167, DOI 10.1016/j.cnur.2004.08.010; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452; CARLSEN KH, 1995, EUR RESPIR J, V8, P1852, DOI 10.1183/09031936.95.08111852; CARTES CJ, 2006, COCHRANE DB SYST REV, DOI UNSP CD001491; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; CHANG KC, 1982, CLIN ALLERGY, V12, P369, DOI 10.1111/j.1365-2222.1982.tb02541.x; Chavasse R, 2002, COCHRANE DB SYST REV; Chernick V, 2006, KENDIGS DISORDERS RE, P29; Cokugras H, 2001, THORAX, V56, P25, DOI 10.1136/thorax.56.1.25; CONNER WT, 1989, PEDIATR PULM, V6, P263, DOI 10.1002/ppul.1950060410; Covar RA, 2004, J ALLERGY CLIN IMMUN, V114, P575, DOI 10.1016/j.jaci.2004.06.036; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Dahl R, 2000, RESP MED, V94, P299, DOI 10.1053/rmed.1999.0702; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; de Benedictis FM, 2006, EUR RESPIR J, V28, P291, DOI 10.1183/09031936.06.00020606; De Benedictis Fernando Maria, 2003, Paediatr Drugs, V5, P629, DOI 10.2165/00148581-200305090-00005; de Blic J, 2004, J ALLERGY CLIN IMMUN, V113, P94, DOI 10.1016/j.jaci.2003.10.045; de Jongste JC, 2005, EUR RESPIR J, V26, P379, DOI 10.1183/09031936.05.00080705; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; DEKKER FW, 1993, EUR RESPIR J, V6, P886; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; DEVULAPALLI CS, 2007, THORAX; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Ducharme Francine M, 2004, Can Respir J, V11, P541; Duiverman E J, 2003, Ned Tijdschr Geneeskd, V147, P1909; Dunlop KA, 2004, ARCH DIS CHILD, V89, P713, DOI 10.1136/adc.2002.022533; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eggleston PA, 2005, J ALLERGY CLIN IMMUN, V116, P122, DOI 10.1016/j.jaci.2005.04.012; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; EL AW, 2005, CHRONIC ILLN, V1, P87; ELLIS EF, 1985, J ALLERGY CLIN IMMUN, V76, P297, DOI 10.1016/0091-6749(85)90645-1; Elphick HE, 2001, ARCH DIS CHILD, V84, P35, DOI 10.1136/adc.84.1.35; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Everard ML, 2005, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001279.PUB2; Fiocchi A, 2004, ANN ALLERG ASTHMA IM, V93, P328; Flaherman V, 2006, ARCH DIS CHILD, V91, P334, DOI 10.1136/adc.2005.080390; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gebert N, 1998, PATIENT EDUC COUNS, V35, P213, DOI 10.1016/S0738-3991(98)00061-5; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; GIBSON NA, 1995, THORAX, V50, P1274, DOI 10.1136/thx.50.12.1274; Gissler M, 1999, ACTA PAEDIATR, V88, P310, DOI 10.1080/08035259950170088; Global Initiative for Asthma, 2006, GLOB STRAT ASTHM MAN; Gold MS, 2005, MED J AUSTRALIA, V182, P298; Gore Claudia, 2003, Paediatr Respir Rev, V4, P213, DOI 10.1016/S1526-0542(03)00055-1; GREENSTONE IR, 2006, COCHRANE DB SYST REV, DOI UNSP CD005533; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; GRUBER C, 2003, PEDIATRICS, V111, P282; Guevara JP, 2006, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003558.PUB2; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Gulliver T, 2005, IMMUNOL ALLERGY CLIN, V25, P541, DOI 10.1016/j.iac.2005.04.001; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; Halken Susanne, 2004, Pediatr Allergy Immunol, V15 Suppl 16, P4; Hall CB, 2001, J PEDIATR-US, V139, P267, DOI 10.1067/mpd.2001.116697; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; Heuck C, 2000, ARCH DIS CHILD, V83, P334, DOI 10.1136/adc.83.4.334; Heuck C, 1997, STEROIDS, V62, P659, DOI 10.1016/S0039-128X(97)00053-6; Heuck C, 1998, J PEDIATR-US, V133, P608, DOI 10.1016/S0022-3476(98)70098-8; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Hofhuis W, 2003, ARCH DIS CHILD, V88, P246, DOI 10.1136/adc.88.3.246; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Holzheimer L, 1998, CHILD CARE HLTH DEV, V24, P85; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Host A, 2003, ALLERGY, V58, P559, DOI 10.1034/j.1398-9995.2003.00238.x; HYLAND ME, 1993, BRIT MED J, V306, P487; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Jonasson G, 2000, ARCH DIS CHILD, V83, P330, DOI 10.1136/adc.83.4.330; Jones C, 2003, J ASTHMA, V40, P93, DOI 10.1081/JAS-120017212; Joos G F, 2001, Curr Allergy Asthma Rep, V1, P134, DOI 10.1007/s11882-001-0081-8; Kamps AWA, 2001, THORAX, V56, P180, DOI 10.1136/thorax.56.3.180; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Knorr B, 2001, PEDIATRICS, V108, P48; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; KRAEMER R, 1991, AM REV RESPIR DIS, V144, P347; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LEE TH, 1985, THORAX, V40, P481, DOI 10.1136/thx.40.7.481; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; LLOYD BW, 1992, BRIT MED J, V305, P1128; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; McCann DC, 2006, EUR RESPIR J, V27, P921, DOI 10.1183/09031936.06.0035604; McGhan S L, 2006, Can Respir J, V13, P23; MEILER F, 2006, CURR ALLERGY ASTHM R, V6, P94; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Mihrshahi S, 2004, PEDIATR ALLERGY IMMU, V15, P517, DOI 10.1111/j.1399-3038.2004.00187.x; Milgrom H, 2001, PEDIATRICS, V108, P36; Milligan G, 2005, J MOL NEUROSCI, V26, P161, DOI 10.1385/JMN/26:02:161; Millstein J, 2004, ARCH ENVIRON HEALTH, V59, P505; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MONGE RMB, 2004, ALLERGOL IMMUNOPATH, V32, P104; MONTGOMERY GL, 1990, AM REV RESPIR DIS, V142, P1372; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; MORGAN WJ, 2004, NEW ENGL J MED, V351, P1065; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Nair SJ, 2005, J PEDIATR-US, V147, P797, DOI 10.1016/j.jpeds.2005.07.023; *NAT HEART LUND BL, 2007, EXP PAN REP 3 GUID D; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; *NIH NAT ASTHM ED, 2006, NAEPP EXP PAN REP GU; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Norjavaara E, 2000, J PEDIATR-US, V137, P25, DOI 10.1067/mpd.2000.107384; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; O'Connor GT, 2005, J ALLERGY CLIN IMMUN, V116, P26, DOI 10.1016/j.jaci.2005.02.013; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Osman M, 2007, PEDIATR PULM, V42, P60, DOI 10.1002/ppul.20545; Ota MOC, 2003, CLIN EXP ALLERGY, V33, P731, DOI 10.1046/j.1365-2222.2003.01599.x; Pajno GB, 2005, CLIN EXP ALLERGY, V35, P551, DOI 10.1111/j.1365-2222.2005.02256.x; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Parsons JP, 2005, CHEST, V128, P3966, DOI 10.1378/chest.128.6.3966; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2001, J ASTHMA, V38, P189; Payne Donald, 2004, Paediatr Respir Rev, V5, P116, DOI 10.1016/j.prrv.2004.01.006; Pearlman DS, 2006, ANN ALLERG ASTHMA IM, V97, P98; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Petersen K D, 2005, Allergol Immunopathol (Madr), V33, P296, DOI 10.1016/S0301-0546(05)73246-8; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Priftis KN, 2006, EUR RESPIR J, V27, P316, DOI 10.1183/09031936.06.00071905; Rabinovitch N, 2006, J ALLERGY CLIN IMMUN, V118, P635, DOI 10.1016/j.jaci.2006.05.011; Randell Tabitha L, 2003, Paediatr Drugs, V5, P481, DOI 10.2165/00148581-200305070-00005; Randolph C, 1997, ALLERGY ASTHMA PROC, V18, P93, DOI 10.2500/108854197778605527; Rasmussen F, 2000, EUR RESPIR J, V16, P866, DOI 10.1183/09031936.00.16586600; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; Richeldi L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002997.pub3; Rodrigo GJ, 2005, THORAX, V60, P740, DOI 10.1136/thx.2005.040444; Roux C, 2003, PEDIATRICS, V111, pE706, DOI 10.1542/peds.111.6.e706; ROWE BH, 1992, AM J EMERG MED, V10, P301, DOI 10.1016/0735-6757(92)90007-K; Rubilar L, 2000, PEDIATR PULM, V29, P264, DOI 10.1002/(SICI)1099-0496(200004)29:4<264::AID-PPUL5>3.0.CO;2-S; S. American Thoracic and S. European Respiratory, 2005, AM J RESP CRIT CARE, V171, P912; Saglani S, 2006, EUR RESPIR J, V27, P29, DOI 10.1183/09031936.06.00030605; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-14040C; Salpeter SR, 2006, ANN INTERN MED, V144, P904; Scadding Glenis, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P258, DOI 10.1097/MOO.0b013e32825b0763; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schou AJ, 2004, ACTA PAEDIATR, V93, P623, DOI 10.1080/08035250410023818; Schou AJ, 2003, PEDIATR PULM, V36, P399, DOI 10.1002/ppul.10379; Schuh S, 2006, PEDIATRICS, V118, P644, DOI 10.1542/peds.2005-2842; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sharek PJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.1.e8; Sharek P, 1999, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001282, DOI 10.1002/14651858.CD001282]; Sheffer AL, 2005, ANN ALLERG ASTHMA IM, V94, P48; SHIM CS, 1983, ARCH INTERN MED, V143, P890; SHOHAT M, 1987, ARCH DIS CHILD, V62, P63; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2002, RESPIR RES, V3, DOI 10.1186/rr186; Sim D, 2003, EUR RESPIR J, V21, P633, DOI 10.1183/09031936.03.00306302; Simons FER, 1997, PEDIATRICS, V99, P655, DOI 10.1542/peds.99.5.655; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Simons FER, 2001, J PEDIATR-US, V138, P694, DOI 10.1067/mpd.2001.112899; Sizonenko PC, 2002, J PEDIATR ENDOCR MET, V15, P5; Skoner DP, 2005, PEDIATR PULM, V40, P477, DOI 10.1002/ppul.20288; Sly PD, 2001, THORAX, V56, P164, DOI 10.1136/thorax.56.3.164; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Smith M, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002886; Sopo SM, 2004, ARCH DIS CHILD, V89, P620, DOI 10.1136/adc.2003.030411; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Spahn JD, 2006, J PEDIATR-US, V148, P11, DOI 10.1016/j.jpeds.2005.08.077; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; Straub DA, 2005, CHEST, V127, P509, DOI 10.1378/chest.127.2.509; Straub DA, 2005, EUR RESPIR J, V25, P289, DOI 10.1183/09031936.05.00031904; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1067/mai.2003.1795; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; TAL A, 1990, PEDIATRICS, V86, P350; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Todd GRG, 2002, ARCH DIS CHILD, V87, P457, DOI 10.1136/adc.87.6.457; van Adelsberg J, 2005, CURR MED RES OPIN, V21, P971, DOI 10.1185/03009905X48458; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; Verberne AAPH, 1998, AM J RESP CRIT CARE, V158, P213; Vignola A M, 2001, Curr Allergy Asthma Rep, V1, P108, DOI 10.1007/s11882-001-0077-4; Villeneuve PJ, 2005, INT J BIOMETEOROL, V50, P48, DOI 10.1007/s00484-005-0262-6; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Walters EH, 2003, COCHRANE DB SYST REV; Ward A, 2001, J ASTHMA, V38, P141, DOI 10.1081/JAS-100000032; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Warner JO, 1998, PEDIATR PULM, V25, P1; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Wensley D, 2004, AM J RESP CRIT CARE, V170, P606, DOI 10.1164/rccm.200307-1025OC; Wenzel S, 2006, CLIN CHEST MED, V27, P29, DOI 10.1016/j.ccm.2005.10.002; WILLIAMS D, 1993, ARCH DIS CHILD, V69, P667; Wolf FM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000326; Wolthers OD, 2006, PEDIATR ALLERGY IMMU, V17, P613, DOI 10.1111/j.1399-3038.2006.00460.x; WOLTHERS OD, 1993, ARCH DIS CHILD, V68, P673; Wolthers OD, 2004, ALLERGY, V59, P1193, DOI 10.1111/j.1398-9995.2004.00541.x; WOLTHERS OD, 1992, PEDIATRICS, V89, P839; WOLTHERS OD, 1991, BRIT MED J, V303, P163; Wolthers OD, 2002, NEW ENGL J MED, V347, P1210, DOI 10.1056/NEJM200210103471522; Wood RA, 2002, ANN ALLERG ASTHMA IM, V88, P347; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; Xepapadaki P, 2005, J ALLERGY CLIN IMMUN, V116, P299, DOI 10.1016/j.jaci.2005.04.007; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; Zanconato S, 2005, PEDIATRICS, V116, pE792, DOI 10.1542/peds.2005-0487; Zapletal A, 2003, PEDIATR PULM, V35, P200, DOI 10.1002/ppul.10265; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zielen S, 2006, CURR MED RES OPIN, V22, P367, DOI 10.1185/030079906X89739; [Anonymous], 2003, THORAX S1, V58, pi1	292	295	353	4	27	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JAN	2008	63	1					5	34		10.1111/j.1398-9995.2007.01586.x		30	Allergy; Immunology	Allergy; Immunology	236UA	WOS:000251327700002	18053013	
J	Brauer, M; Hoek, G; van Vliet, P; Meliefste, K; Fischer, P; Gehring, U; Heinrich, J; Cyrys, J; Bellander, T; Lewne, M; Brunekreef, B				Brauer, M; Hoek, G; van Vliet, P; Meliefste, K; Fischer, P; Gehring, U; Heinrich, J; Cyrys, J; Bellander, T; Lewne, M; Brunekreef, B			Estimating long-term average particulate air pollution concentrations: Application of traffic indicators and geographic information systems	EPIDEMIOLOGY			English	Article						air pollution; environmental epidemiology; particles; geographic information systems; GIS; vehicle emissions	CHRONIC RESPIRATORY SYMPTOMS; NITROGEN-DIOXIDE; HOSPITAL ADMISSIONS; SPATIAL VARIABILITY; CHILDREN; EXPOSURE; HEALTH; ASTHMA; DENSITY; OUTDOOR	Background. As part of a multicenter study relating traffic-related air pollution with incidence of asthma in three birth cohort studies (TRAPCA), we used a measurement and modelling procedure to estimate long-term average exposure to traffic-related particulate air pollution in communities throughout the Netherlands; in Munich, Germany; and in Stockholm County, Sweden. Methods. In each of the three locations, 40-42 measurement sites were selected to represent rural, urban background and urban traffic locations. At each site and fine particles and filter absorbance (a marker for diesel exhaust particles) were measured for four 2-week periods distributed over approximately 1-year periods between February 1999 and July 2000. We used these measurements to calculate annual average concentrations after adjustment for temporal variation. Traffic-related variables (eg, population density and traffic intensity) were collected using Geographic Information Systems and used in regression models predicting annual average concentrations. From these models we estimated ambient air concentrations at the home addresses of the cohort members. Results. Regression models using traffic-related variables explained 73%, 56% and 50% of the variability in annual average fine particle concentrations for the Netherlands, Munich arid Stockholm County, respectively. For filter absorbance, the regression models explained 81%, 67% and 66% of the variability in the annual average concentrations. Cross-validation to estimate the model prediction errors indicated root mean squared errors of 1.1-1.6 mug/m(3) for PM2.5 and 0.22-0.31 *10(-5)m(-1) for absorbance. Conclusions. A substantial fraction of the variability in annual average concentrations for all locations was explained by traffic-related variables. This approach can be used to estimate individual exposures for epidemiologic studies and offers advantages over alternative techniques relying on surrogate variables or traditional approaches that utilize ambient monitoring data alone.	Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V6T 1Z3, Canada; Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Grp, Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Stockholm Cty Council, Dept Environm Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Brauer, M (reprint author), Univ British Columbia, Sch Occupat & Environm Hyg, 2206 E Mall, Vancouver, BC V6T 1Z3, Canada.		Cyrys, Josef/B-5359-2014; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Brauer, Michael/0000-0002-9103-9343			Brauer M, 2000, J EXPO ANAL ENV EPID, V10, P478, DOI 10.1038/sj.jea.7500136; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; BROWN PJ, 1994, CAN J STAT, V22, P489, DOI 10.2307/3315406; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; CARR D, 1999, EPIDEMIOLOGY, V10, pS511; *CENTR BUR STAT CE, 1999, HAAG BEV GEM; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Cyrys J, 1998, J EXPO ANAL ENV EPID, V8, P447; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hruba F, 2001, J EXPO ANAL ENV EPID, V11, P33, DOI 10.1038/sj.jea.7500141; JANSSEN NAH, 2001, AIR WASTE, V50, P1133; Korc ME, 1996, J AIR WASTE MANAGE, V46, P547; Kunzli N, 2000, ENVIRON HEALTH PERSP, V108, P915, DOI 10.2307/3435048; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Larssen S., 1999, 12 EUR ENV AG; LIU LJS, 1995, J AIR WASTE MANAGE, V45, P223, DOI 10.1080/10473289.1995.10467362; Monn C, 1997, ATMOS ENVIRON, V31, P2243, DOI 10.1016/S1352-2310(97)00030-7; *NAT I PUBL HLTH E, 2000, CAT GEG BEH BEL 2000; *NAT RES COUNC, 2000, MOD MOB SOURC EM, P151; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; POL HDP, 1986, 40812900831 RIVM; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; *STROCKH, 2000, TRAF STOCKH 1999; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilkinson P, 1999, THORAX, V54, P1070; WJST M, 1993, BRIT MED J, V307, P596; 1998, DETERMINATION ABSORP; 2002, STAT CENTR STAT SWED	39	295	300	4	99	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	MAR	2003	14	2					228	239		10.1097/00001648-200303000-00019		12	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	648WQ	WOS:000181174300018	12606891	
J	Friedman, MS; Powell, KE; Hutwagner, L; Graham, LM; Teague, WG				Friedman, MS; Powell, KE; Hutwagner, L; Graham, LM; Teague, WG			Impact of changes in transportation and commuting behaviors during the 1996 Summer Olympic Games in Atlanta on air quality and childhood asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL-FACTORS; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; UNITED-KINGDOM; MEXICO-CITY; POLLUTION; CHILDREN; OZONE; PREVALENCE; MORTALITY	Context Vehicle exhaust is a major source of ozone and other air pollutants. Although high ground-level ozone pollution is associated with transient increases in asthma morbidity, the impact of citywide transportation changes on air quality and childhood asthma has not been studied. The alternative transportation strategy implemented during the 1996 Summer Olympic Games in Atlanta, Ga, provided such an opportunity. Objective To describe traffic changes in Atlanta, Ca, during the 1996 Summer Olympic Games and concomitant changes in air quality and childhood asthma events. Design Ecological study comparing the 17 days of the Olympic Games (July 19-August 4, 1996) to a baseline period consisting of the 4 weeks before and 4 weeks after the Olympic Games. Setting and Subjects Children aged 1 to 16 years who resided in the 5 central counties of metropolitan Atlanta and whose data were captured in 1 of 4 databases. Main Outcome Measures Citywide acute care visits and hospitalizations for asthma (asthma events) and nonasthma events, concentrations of major air pollutants, meteorological variables, and traffic counts. Results During the Olympic Games, the number of asthma acute care events decreased 41.6% (4.23 vs 2.47 daily events) in the Georgia Medicaid claims file, 44.1% (1.36 vs 0.76 daily events) in a health maintenance organization database, 11.1% (4.77 vs 4.24 daily events) in 2 pediatric emergency departments, and 19.1% (2.04 vs 1.65 daily hospitalizations) in the Georgia Hospital Discharge Database. The number of nonasthma acute care events in the 4 databases changed -3.1%, +1.3%, -2.1%, and +1.0%, respectively. In multivariate regression analysis, only the reduction in asthma events recorded in the Medicaid database was significant (relative risk, 0.48; 95% confidence interval, 0.44-0.86). Peak daily ozone concentrations decreased 27.9%, from 81.3 ppb during the baseline period to 58.6 ppb during the Olympic Games (P<.001). Peak weekday morning traffic counts dropped 22.5% (P<.001). Traffic counts were significantly correlated with that day's peak ozone concentration (average r=0.36 for all 4 roads examined). Meteorological conditions during the Olympic Games did not differ substantially from the baseline period. Conclusions Efforts to reduce downtown traffic congestion in Atlanta during the Olympic Games resulted in decreased traffic density, especially during the critical morning period. This was associated with a prolonged reduction in ozone pollution and significantly lower rates of childhood asthma events. These data provide support for efforts to reduce air pollution and improve health via reductions in motor vehicle traffic.	Georgia Div Publ Hlth, Epidem Intelligence Serv, Atlanta, GA USA; Georgia Div Publ Hlth, Chron Dis Injury & Environm Epidemiol Sect, Epidemiol & Prevent Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Epidemiol Program Off, Atlanta, GA USA; Morehouse Sch Med, Dept Pediat, Atlanta, GA 30310 USA; Egleston Childrens Hosp, Div Pediat Pulm & Crit Care, Atlanta, GA USA; Georgia Pediat Pulm Associates, Atlanta, GA USA; Emory Univ, Atlanta, GA 30322 USA	Friedman, MS (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Abramson M, 1996, J ASTHMA, V33, P189, DOI 10.3109/02770909609054551; ABRAMSON MJ, 1995, MED J AUSTRALIA, V163, P542; Anderson HR, 1996, BRIT MED J, V312, P665; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; AVOL EL, 1985, AM REV RESPIR DIS, V132, P619; BALAGAS R, 1996, IMPROVED AIR QUALITY; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Becklake MR, 1997, LANCET, V350, P10; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; Buchdahl R, 1996, BRIT MED J, V312, P661; BUSSE WW, 1995, ASTHMA RHINITIS; *CDCP, 2000, MMWR-MORBID MORTAL W, V49, P153; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, pSS1; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P952; Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P908; Centers for Disease C Prevention, 1996, MMWR-MORBID MORTAL W, V45, P350; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Goren AI, 1997, J EPIDEMIOL COMMUN H, V51, P227, DOI 10.1136/jech.51.3.227; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; HAYES SR, 1991, J AIR WASTE MANAGEME, V41, P171; Holgate ST, 1999, AIR POLLUTION HLTH; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Livingstone AE, 1996, BRIT MED J, V312, P676; *METR ATL RAP TRAN, 1996, WAY GAM REP MASS TRA; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MULLALLY DI, 1984, ANN ALLERGY, V53, P15; MURAKAMI M, 1990, Journal of Human Ergology, V19, P101; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; PORTER C, 1997, 833 NCHRP; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; SCHENKER M, 1993, NEW ENGL J MED, V329, P1807, DOI 10.1056/NEJM199312093292410; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Tattersfield AE, 1996, THORAX, V51, P13, DOI 10.1136/thx.51.1.13; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; *US EPA, 1992, EPA450K92002 US EPA; *US EPA, 1994, EPA451K94001 US EPA; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WJST M, 1993, BRIT MED J, V307, P596; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 2001, CLEAN AIR CAMPAIGN	45	290	297	7	58	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 21	2001	285	7					897	905		10.1001/jama.285.7.897		9	Medicine, General & Internal	General & Internal Medicine	402BE	WOS:000166965500027	11180733	
J	Josefowicz, SZ; Niec, RE; Kim, HY; Treuting, P; Chinen, T; Zheng, Y; Umetsu, DT; Rudensky, AY				Josefowicz, Steven Z.; Niec, Rachel E.; Kim, Hye Young; Treuting, Piper; Chinen, Takatoshi; Zheng, Ye; Umetsu, Dale T.; Rudensky, Alexander Y.			Extrathymically generated regulatory T cells control mucosal T(H)2 inflammation	NATURE			English	Article							TRANSCRIPTION FACTOR FOXP3; IN-VIVO; BOWEL-DISEASE; INDUCTION; RESPONSES; LINEAGE; FATE; GENE; MICE; HOMEOSTASIS	A balance between pro- and anti-inflammatory mechanisms at mucosal interfaces, which are sites of constitutive exposure to microbes and non-microbial foreign substances, allows for efficient protection against pathogens yet prevents adverse inflammatory responses associated with allergy, asthma and intestinal inflammation(1). Regulatory T (T-reg) cells prevent systemic and tissue-specific autoimmunity and inflammatory lesions at mucosal interfaces. These cells are generated in the thymus (tT(reg) cells) and in the periphery (induced (i)T-reg cells), and their dual origin implies a division of labour between tT(reg) and iT(reg) cells in immune homeostasis. Here we show that a highly selective blockage in differentiation of iT(reg) cells in mice did not lead to unprovoked multi-organ autoimmunity, exacerbation of induced tissue-specific autoimmune pathology, or increased pro-inflammatory responses of T helper 1 (T(H)1) and T(H)17 cells. However, mice deficient in iT(reg) cells spontaneously developed pronounced T(H)2-type pathologies at mucosal sites-in the gastrointestinal tract and lungs-with hallmarks of allergic inflammation and asthma. Furthermore, iT(reg)-cell deficiency altered gut microbial communities. These results suggest that whereas T-reg cells generated in the thymus appear sufficient for control of systemic and tissue-specific autoimmunity, extrathymic differentiation of T-reg cells affects commensal microbiota composition and serves a distinct, essential function in restraint of allergic-type inflammation at mucosal interfaces.	[Josefowicz, Steven Z.; Niec, Rachel E.; Chinen, Takatoshi; Rudensky, Alexander Y.] Howard Hughes Med Inst, New York, NY 10021 USA; [Josefowicz, Steven Z.; Niec, Rachel E.; Chinen, Takatoshi; Rudensky, Alexander Y.] Sloan Kettering Inst, Program Immunol, New York, NY 10021 USA; [Josefowicz, Steven Z.] Rockefeller Univ, Lab Chromatin Biol & Epigenet, New York, NY 10065 USA; [Kim, Hye Young; Umetsu, Dale T.] Harvard Univ, Childrens Hosp, Sch Med, Div Immunol, Boston, MA 02115 USA; [Treuting, Piper] Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA; [Chinen, Takatoshi] Keio Univ, Dept Microbiol & Immunol, Sch Med, Tokyo 1608582, Japan; [Zheng, Ye] Salk Inst Biol Studies, Nomis Fdn Labs Immunobiol & Microbial Pathogenesi, La Jolla, CA 92037 USA	Rudensky, AY (reprint author), Howard Hughes Med Inst, New York, NY 10021 USA.	rudenska@mskcc.org	Zheng, Ye/G-4866-2015	Zheng, Ye/0000-0001-5012-4309; josefowicz, steven/0000-0001-7453-779X	NIH MSTP [GM07739]; NINDS [1F31NS073203-01]; Department of Microbiology and Immunology, Keio University School of Medicine; NIH [R37 AI034206]	We thank T. Tedder for depleting CD20 antibody, R. Tudor for assistance interpreting lung pathology, P. DeRoos for assistance with Ig ELISA assays, B. Johnson for immunohistochemical expertise, Y. Chen for assistance with airway measurements, and E. Pamer, L. Lipuma, A. Gobourne and R. Khanin for help with analysis of intestinal microbiota. This work was supported by NIH MSTP grant GM07739 and NINDS grant 1F31NS073203-01 (R.E.N.), Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from Department of Microbiology and Immunology, Keio University School of Medicine (T. C.) and NIH grant R37 AI034206 (A. Y. R.). A. Y. R is an investigator with the Howard Hughes Medical Institute.	Anders S, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-10-r106; Bautista JL, 2009, NAT IMMUNOL, V10, P610, DOI 10.1038/ni.1739; Burich A, 2001, AM J PHYSIOL-GASTR L, V281, pG764; Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Gottschalk RA, 2010, J EXP MED, V207, P1701, DOI 10.1084/jem.20091999; Hill JA, 2008, IMMUNITY, V29, P758, DOI 10.1016/j.immuni.2008.09.018; Hori S, 2011, TRENDS IMMUNOL, V32, P295, DOI 10.1016/j.it.2011.04.004; Josefowicz SZ, 2009, IMMUNITY, V30, P616, DOI 10.1016/j.immuni.2009.04.009; Koch MA, 2009, NAT IMMUNOL, V10, P595, DOI 10.1038/ni.1731; Komatsu N, 2009, P NATL ACAD SCI USA, V106, P1903, DOI 10.1073/pnas.0811556106; Kretschmer K, 2005, NAT IMMUNOL, V6, P1219, DOI 10.1038/ni1265; Lathrop SK, 2011, NATURE, V478, P250, DOI 10.1038/nature10434; Leung MWL, 2009, J EXP MED, V206, P2121, DOI 10.1084/jem.20091033; Liu YZ, 2008, NAT IMMUNOL, V9, P632, DOI 10.1038/ni.1607; Magurran A. E, 2004, MEASURING BIOL DIVER; Maloy KJ, 2011, NATURE, V474, P298, DOI 10.1038/nature10208; Moran AE, 2011, J EXP MED, V208, P1279, DOI 10.1084/jem.20110308; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Nolting J, 2009, J EXP MED, V206, P2131, DOI 10.1084/jem.20090639; Nossa CW, 2010, WORLD J GASTROENTERO, V16, P4135, DOI 10.3748/wjg.v16.i33.4135; Ouyang WM, 2010, IMMUNITY, V32, P642, DOI 10.1016/j.immuni.2010.04.012; Rubtsov YP, 2010, SCIENCE, V329, P1667, DOI 10.1126/science.1191996; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Stromnes IM, 2006, NAT PROTOC, V1, P1810, DOI 10.1038/nprot.2006.285; Tian L, 2011, BLOOD, V118, P1845, DOI 10.1182/blood-2011-04-346056; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Ubeda C, 2010, J CLIN INVEST, V120, P4332, DOI 10.1172/JCI43918; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wang YQ, 2011, IMMUNITY, V35, P337, DOI 10.1016/j.immuni.2011.08.012; Wohlfert EA, 2011, J CLIN INVEST, V121, P4503, DOI 10.1172/JCI57456; Xu LL, 2010, IMMUNITY, V33, P313, DOI 10.1016/j.immuni.2010.09.001; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zhou XY, 2009, NAT IMMUNOL, V10, P1000, DOI 10.1038/ni.1774	39	288	302	0	46	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 16	2012	482	7385					395	U1510		10.1038/nature10772		6	Multidisciplinary Sciences	Science & Technology - Other Topics	892LG	WOS:000300287100045	22318520	
J	Breton, CV; Byun, HM; Wenten, M; Pan, F; Yang, A; Gilliland, FD				Breton, Carrie V.; Byun, Hyang-Min; Wenten, Made; Pan, Fei; Yang, Allen; Gilliland, Frank D.			Prenatal Tobacco Smoke Exposure Affects Global and Gene-specific DNA Methylation	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						DNA methylation; epigenetics; prenatal; smoke	CHILDHOOD ASTHMA; TYROSINE PHOSPHATASES; EPIGENETIC REGULATION; MATERNAL SMOKING; CIGARETTE-SMOKE; PASSIVE SMOKING; EXPRESSION; CHILDREN; SUSCEPTIBILITY	Rationale: Prenatal exposure to tobacco smoke increases the risk for diseases later in the child's life that may be mediated through alterations in DNA methylation. Objectives: To demonstrate that differences in DNA methylation patterns occur in children exposed to tobacco smoke and that variation in detoxification genes may alter these associations. Methods: Methylation of DNA repetitive elements, LINE1 and AluYb8, was measured using bisulfite conversion and pyrosequencing in buccal cells of 348 children participating in the Children's Health Study. Gene-specific CpG methylation differences associated with smoke exposure were screened in 272 participants in the Children's Health Study children using an Illumina GoldenGate panel. CpG loci that demonstrated a statistically significant difference in methylation were validated by pyrosequencing. Estimates were standardized across loci using a Z score to enable cross-comparison of results. Measurements and Main Results: DNA methylation patterns were associated with in utero exposure to maternal smoking. Exposed children had significantly lower methylation of AluYb8 (beta, -0.31; P = 0.03). Differences in smoking-related effects on LINE1 methylation were observed in children with the common GSTM1 null genotype. Differential methylation of CpG loci in eight genes was identified through the screen. Two genes, AXL and PTPRO, were validated by pyrosequencing and showed significant increases in methylation of 0.37 (P = 0.005) and 0.34 (P = 0.02) in exposed children. The associations with maternal smoking varied by a common GSTP1 haplotype. Conclusions: Life-long effects of in utero exposures may be mediated through alterations in DNA methylation. Variants in detoxification genes may modulate the effects of in utero exposure through epigenetic mechanisms.	[Breton, Carrie V.; Wenten, Made; Gilliland, Frank D.] Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90033 USA; [Byun, Hyang-Min; Yang, Allen] Univ So Calif, Keck Sch Med, Dept Hematol, Los Angeles, CA 90033 USA; [Pan, Fei; Yang, Allen] Univ So Calif, Keck Sch Med, Epigenome Canc Ctr, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Dept Prevent Med, Keck Sch Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu		Byun, Hyang-Min/0000-0002-6278-3165	NIEHS [5P01 E5009581, SP01 ES011627, 5P30 ES007048]; Hastings Foundation; American Society of Clinical Oncology Career Development Award in Geriatric Oncology	Supported by NIEHS grants 5P01 E5009581, SP01 ES011627, and 5P30 ES007048; by the Hastings Foundation; and by a American Society of Clinical Oncology Career Development Award in Geriatric Oncology (A.Y.).	BACCARELLI A, 2008, ISEE C 2008 PAS CA O; Bhutani M, 2008, CANCER PREV RES, V1, P39, DOI 10.1158/1940-6207.CAPR-08-0058; Bollati V, 2009, MECH AGEING DEV, V130, P234, DOI 10.1016/j.mad.2008.12.003; Carlsen Kai-Hakon, 2005, Treat Respir Med, V4, P337, DOI 10.2165/00151829-200504050-00005; Lodrup Carlsen K., 2001, CURR OPIN ALLERGY CL, V1, P139; Colella S, 2003, BIOTECHNIQUES, V35, P146; Dahl C, 2003, BIOGERONTOLOGY, V4, P233, DOI 10.1023/A:1025103319328; Feil R, 2006, MUTAT RES-FUND MOL M, V600, P46, DOI 10.1016/j.mrfmmm.2006.05.029; Franco R, 2008, CANCER LETT, V266, P6, DOI 10.1016/j.canlet.2008.02.026; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Islam T, 2009, THORAX, V64, P197, DOI 10.1136/thx.2008.099366; Jacob ST, 2005, CANCER GENE THER, V12, P665, DOI 10.1038/sj.cgt.7700828; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Kroll TC, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.11.e50; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Li YF, 2008, ENVIRON HEALTH PERSP, V116, P409, DOI 10.1289/ehp.10655; Liu H, 2007, ONCOGENE, V26, P5900, DOI 10.1038/sj.onc.1210400; Mathers JC, 2007, FORUM NUTR, V60, P42, DOI 10.1159/000107066; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Mudduluru G, 2008, BIOSCIENCE REP, V28, P161, DOI 10.1042/BSR20080046; Nafee TM, 2008, BJOG-INT J OBSTET GY, V115, P158, DOI 10.1111/j.1471-0528.2007.01528.x; Nephew Kenneth R., 2009, V507, P35, DOI 10.1007/978-1-59745-522-0_3; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Pulling LC, 2004, CANCER RES, V64, P3844, DOI 10.1158/0008-5472.CAN-03-2119; Reamon-Buettner SM, 2007, REPROD TOXICOL, V24, P20, DOI 10.1016/j.protox.2007.05.002; Reik W, 2001, SCIENCE, V293, P1089, DOI 10.1126/science.1063443; Robertson KD, 2000, CARCINOGENESIS, V21, P461, DOI 10.1093/carcin/21.3.461; Shankar SL, 2003, J NEUROSCI, V23, P4208; Stepanek L, 2005, J NEUROSCI, V25, P3813, DOI 10.1523/NEUROSCI-4531-04.2005; Terry MB, 2008, CANCER EPIDEM BIOMAR, V17, P2306, DOI 10.1158/1055-9965.EPI-08-0312; Yang AS, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh032	32	286	295	2	31	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2009	180	5					462	467		10.1164/rccm.200901-0135OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	489ZW	WOS:000269467100012	19498054	
J	Jaddoe, VWV; van Duijn, CM; Franco, OH; van der Heijden, AJ; van Ijzendoorn, MH; de Jongste, JC; van der Lugt, A; Mackenbach, JP; Moll, HA; Raat, H; Rivadeneira, F; Steegers, EAP; Tiemeier, H; Uitterlinden, AG; Verhulst, FC; Hofman, A				Jaddoe, Vincent W. V.; van Duijn, Cornelia M.; Franco, Oscar H.; van der Heijden, Albert J.; van Ijzendoorn, Marinus H.; de Jongste, Johan C.; van der Lugt, Aad; Mackenbach, Johan P.; Moll, Henriette A.; Raat, Hein; Rivadeneira, Fernando; Steegers, Eric A. P.; Tiemeier, Henning; Uitterlinden, Andre G.; Verhulst, Frank C.; Hofman, Albert			The Generation R Study: design and cohort update 2012	EUROPEAN JOURNAL OF EPIDEMIOLOGY			English	Article						Cohort; Pregnancy; Child; Fetal	POPULATION-BASED COHORT; QUALITY-OF-LIFE; CHILD HEALTH QUESTIONNAIRE; GENOME-WIDE ASSOCIATION; ISCHEMIC-HEART-DISEASE; ALL-CAUSE MORTALITY; FETAL-GROWTH; BEHAVIOR QUESTIONNAIRE; PHYSICAL-ACTIVITY; COMMON VARIANTS	The Generation R Study is a population-based prospective cohort study from fetal life until adulthood. The study is designed to identify early environmental and genetic causes and causal pathways leading to normal and abnormal growth, development and health during fetal life, childhood and adulthood. The study focuses on six areas of research: (1) maternal health; (2) growth and physical development; (3) behavioural and cognitive development; (4) respiratory health and allergies; (5) diseases in childhood; and (6) health and healthcare for children and their parents. Main exposures of interest include environmental, endocrine, genetic and epigenetic, lifestyle related, nutritional and socio-demographic determinants. In total, n = 9,778 mothers with a delivery date from April 2002 until January 2006 were enrolled in the study. Response at baseline was 61 %, and general follow-up rates until the age of 6 years exceed 80 %. Data collection in mothers, fathers and children include questionnaires, detailed physical and ultrasound examinations, behavioural observations, and biological samples. A genome and epigenome wide association screen is available in the participating children. From the age of 5 years, regular detailed hands-on assessments are performed in a dedicated research center including advanced imaging facilities such as Magnetic Resonance Imaging. Eventually, results forthcoming from the Generation R Study contribute to the development of strategies for optimizing health and healthcare for pregnant women and children.	[Jaddoe, Vincent W. V.] Erasmus MC, Generat Study Grp AE006 R, NL-3000 CA Rotterdam, Netherlands; [Jaddoe, Vincent W. V.; van Duijn, Cornelia M.; Franco, Oscar H.; Tiemeier, Henning; Uitterlinden, Andre G.; Hofman, Albert] Erasmus MC, Dept Epidemiol, NL-3000 CA Rotterdam, Netherlands; [Jaddoe, Vincent W. V.; van der Heijden, Albert J.; de Jongste, Johan C.; Moll, Henriette A.] Erasmus MC, Dept Pediat, Sophia Childrens Hosp, NL-3000 CA Rotterdam, Netherlands; [van Ijzendoorn, Marinus H.] Erasmus Univ, Sch Pedag & Educ Sci, Rotterdam, Netherlands; [van der Lugt, Aad] Erasmus MC, Dept Radiol, NL-3000 CA Rotterdam, Netherlands; [Tiemeier, Henning; Verhulst, Frank C.] Erasmus MC, Dept Child & Adolescent Psychiat, Sophia Childrens Hosp, NL-3000 CA Rotterdam, Netherlands; [Steegers, Eric A. P.] Erasmus MC, Dept Obstet & Gynaecol, NL-3000 CA Rotterdam, Netherlands; [Rivadeneira, Fernando; Uitterlinden, Andre G.] Erasmus MC, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; [Mackenbach, Johan P.; Raat, Hein] Erasmus MC, Dept Publ Hlth, NL-3000 CA Rotterdam, Netherlands	Jaddoe, VWV (reprint author), Erasmus MC, Generat Study Grp AE006 R, POB 2040, NL-3000 CA Rotterdam, Netherlands.	v.jaddoe@erasmusmc.nl	Rivadeneira, Fernando/O-5385-2015	Rivadeneira, Fernando/0000-0001-9435-9441; Tiemeier, Henning/0000-0002-4395-1397	Erasmus Medical Center, Rotterdam; Erasmus University Rotterdam; Netherlands Organization for Health Research and Development (ZonMw); Netherlands Organisation for Scientific Research (NWO); Ministry of Health, Welfare and Sport; Netherlands Organization for Health Research and Development [ZonMw 907.00303, ZonMw 916.10159]	The Generation R Study is conducted by the Erasmus Medical Center in close collaboration with the School of Law and Faculty of Social Sciences of the Erasmus University Rotterdam, the Municipal Health Service Rotterdam area, Rotterdam, the Rotterdam Homecare Foundation, Rotterdam and the Stichting Trombosedienst & Artsenlaboratorium Rijnmond (STAR-MDC), Rotterdam. We gratefully acknowledge the contribution of children and parents, general practitioners, hospitals, midwives and pharmacies in Rotterdam. We thank Marjolein Kooijman, Claudia Kruithof, Natalia Loekabino, Patricia Maeijer, Ronald van den Nieuwenhof, and Karien Toebes for their study coordination. The general design of Generation R Study is made possible by financial support from the Erasmus Medical Center, Rotterdam, the Erasmus University Rotterdam, the Netherlands Organization for Health Research and Development (ZonMw), the Netherlands Organisation for Scientific Research (NWO), the Ministry of Health, Welfare and Sport. Vincent Jaddoe received an additional grant from the Netherlands Organization for Health Research and Development (ZonMw 907.00303, ZonMw 916.10159).	Achenbach TM, 1991, MANUAL CHILD BEHAV C; Adamsson Eryd S, 2011, EUR J EPIDEMIOL, V26, P449, DOI 10.1007/s10654-011-9565-6; Alatupa S, 2010, EUR J EPIDEMIOL, V25, P267, DOI 10.1007/s10654-010-9428-6; Alberts VP, 2010, EUR J EPIDEMIOL, V25, P807, DOI 10.1007/s10654-010-9520-y; Altmaier E, 2011, EUR J EPIDEMIOL, V26, P145, DOI 10.1007/s10654-010-9524-7; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Autenrieth CS, 2011, EUR J EPIDEMIOL, V26, P91, DOI 10.1007/s10654-010-9517-6; Ay L, 2008, INT J OBESITY, V32, P1050, DOI 10.1038/ijo.2008.76; Ay L, 2009, J CLIN ENDOCR METAB, V94, P2023, DOI 10.1210/jc.2008-2045; Bakker H, 2011, EUR J EPIDEMIOL, V26, P763, DOI 10.1007/s10654-011-9621-2; Behrens G, 2011, EUR J EPIDEMIOL, V26, P81, DOI 10.1007/s10654-011-9545-x; Bellocco R, 2010, EUR J EPIDEMIOL, V25, P777, DOI 10.1007/s10654-010-9497-6; Berard E, 2011, EUR J EPIDEMIOL, V26, P359, DOI 10.1007/s10654-010-9541-6; Bergen NE, 2012, BJOG-INT J OBSTET GY, V119, P739, DOI 10.1111/j.1471-0528.2012.03321.x; Bernstein AM, 2011, EUR J EPIDEMIOL, V26, P877, DOI 10.1007/s10654-011-9626-x; Beyerlein A, 2011, EUR J EPIDEMIOL, V26, P413, DOI 10.1007/s10654-011-9560-y; Birch LL, 2001, APPETITE, V36, P201, DOI 10.1006/appe.2001.0398; Borne Y, 2011, EUR J EPIDEMIOL, V26, P275, DOI 10.1007/s10654-010-9536-3; Bot M, 2010, EUR J EPIDEMIOL, V25, P125, DOI 10.1007/s10654-009-9419-7; Both MI, 2010, EUR J EPIDEMIOL, V25, P421, DOI 10.1007/s10654-010-9458-0; Bradfield JP, 2012, NAT GENET, V44, P526, DOI 10.1038/ng.2247; Burgmeijer RJF, 1999, NED C OUD KINDZ; Carlsson AC, 2010, EUR J EPIDEMIOL, V25, P547, DOI 10.1007/s10654-010-9472-2; Carver DJ, 1999, AGE AGEING, V28, P169, DOI 10.1093/ageing/28.2.169; Castello A, 2011, EUR J EPIDEMIOL, V26, P563, DOI 10.1007/s10654-011-9591-4; Cerqueira C, 2011, EUR J EPIDEMIOL, V26, P629, DOI 10.1007/s10654-011-9590-5; Clark EM, 2008, J BONE MINER RES, V23, P173, DOI 10.1359/JBMR.071010; Cnattingius S, 2011, EUR J EPIDEMIOL, V26, P485, DOI 10.1007/s10654-011-9556-7; Constantino JN, 2003, J AUTISM DEV DISORD, V33, P427, DOI 10.1023/A:1025014929212; Coolman M, 2010, J CLIN EPIDEMIOL; Coolman M, 2012, OBSTET GYNECOL, V119, P1190, DOI 10.1097/AOG.0b013e318256187f; Costanzo S, 2011, EUR J EPIDEMIOL, V26, P833, DOI 10.1007/s10654-011-9631-0; COX JL, 1987, BRIT J PSYCHIAT, V150, P782, DOI 10.1192/bjp.150.6.782; Daniel M, 2010, EUR J EPIDEMIOL, V25, P711, DOI 10.1007/s10654-010-9499-4; Danziger PD, 2011, EUR J EPIDEMIOL, V26, P571, DOI 10.1007/s10654-011-9592-3; de Jonge LL, 2011, HYPERTENSION, V57, P934, DOI 10.1161/HYPERTENSIONAHA.110.163303; Vermulst AA, 1992, NIJMEESGE OUDERLIJKE; DEROGATIS LR, 1983, PSYCHOL MED, V13, P595; Dierckx B, 2009, PSYCHOSOM MED, V71, P313, DOI 10.1097/PSY.0b013e318198a82c; Diouf I, 2011, EUR J EPIDEMIOL, V26, P789, DOI 10.1007/s10654-011-9599-9; Duijts L, 2008, EUR J EPIDEMIOL, V23, P547, DOI 10.1007/s10654-008-9264-0; Duijts L, 2008, PEDIATR RES, V63, P292, DOI 10.1203/PDR.0b013e318163a29f; Duijts L, 2010, PEDIATRICS, V126, pE18, DOI 10.1542/peds.2008-3256; Durmus B, 2010, CLIN ENDOCRINOL, V72, P633, DOI 10.1111/j.1365-2265.2009.03708.x; Durmus B, 2011, EUR J EPIDEMIOL, V26, P295, DOI 10.1007/s10654-010-9544-3; El Marroun H, 2011, EUR ADDICT RES, V17, P37, DOI 10.1159/000320550; Empana JP, 2011, EUR J EPIDEMIOL, V26, P887, DOI 10.1007/s10654-011-9618-x; Engeland A, 2011, EUR J EPIDEMIOL, V26, P157, DOI 10.1007/s10654-010-9527-4; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; Ernst GD, 2011, AM J OBSTET GYNECOL, V205; Faeh D, 2011, EUR J EPIDEMIOL, V26, P647, DOI 10.1007/s10654-011-9593-2; Faramawi MF, 2011, EUR J EPIDEMIOL, V26, P101, DOI 10.1007/s10654-010-9534-5; Feart C, 2011, EUR J EPIDEMIOL, V26, P747, DOI 10.1007/s10654-011-9611-4; Fedorowski A, 2011, EUR J EPIDEMIOL, V26, P537, DOI 10.1007/s10654-011-9578-1; Fenson L, 1983, MACARTHUR COMMUNICAT; Flohr C, 2009, BRIT J DERMATOL, V161, P846, DOI 10.1111/j.1365-2133.2009.09261.x; Fraga AMA, 2010, EUR J EPIDEMIOL, V25, P211, DOI 10.1007/s10654-009-9420-1; Freathy RM, 2010, NAT GENET, V42, P430, DOI 10.1038/ng.567; Gabriele C, 2008, EUR RESPIR J, V32, P307, DOI 10.1183/09031936.00132607; Gaillard R, 2012, AM J EPIDEM IN PRESS; Gaillard R, 2011, EUR J EPIDEMIOL, V26, P919, DOI 10.1007/s10654-011-9629-7; Gartstein MA, 2003, INFANT BEHAV DEV, V26, P64, DOI 10.1016/S0163-6383(02)00169-8; Geelhoed JJM, 2010, EUR J EPIDEMIOL, V25, P677, DOI 10.1007/s10654-010-9510-0; Geelhoed JJM, 2009, AM J KIDNEY DIS, V53, P248, DOI 10.1053/j.ajkd.2008.07.030; Gerris J. R. M., 1993, PARENTING DUTCH FAMI; Ghasemi A, 2010, EUR J EPIDEMIOL, V25, P45, DOI 10.1007/s10654-009-9382-3; Ghassabian A, 2013, J CHILD PSYCHOL PSYC, V54, P96, DOI 10.1111/j.1469-7610.2012.02590.x; Gimeno D, 2011, EUR J EPIDEMIOL, V26, P135, DOI 10.1007/s10654-010-9526-5; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Goodman R, 1997, J CHILD PSYCHOL PSYC, V38, P581, DOI 10.1111/j.1469-7610.1997.tb01545.x; Greenwood DC, 2010, EUR J EPIDEMIOL, V25, P275, DOI 10.1007/s10654-010-9443-7; Gudmundsson P, 2011, EUR J EPIDEMIOL, V26, P55, DOI 10.1007/s10654-010-9508-7; Hansen JL, 2011, EUR J EPIDEMIOL, V26, P439, DOI 10.1007/s10654-011-9564-7; Henrichs J, 2010, J CLIN ENDOCR METAB, V95, P4227, DOI 10.1210/jc.2010-0415; Heys M, 2010, EUR J EPIDEMIOL, V25, P507, DOI 10.1007/s10654-010-9466-0; Hoekstra RA, 2011, J AUTISM DEV DISORD, V41, P589, DOI 10.1007/s10803-010-1073-0; Hofman A, 2004, PAEDIATR PERINAT EP, V18, P61, DOI 10.1111/j.1365-3016.2003.00521.x; Hofman A, 2011, EUR J EPIDEMIOL, V26, P657, DOI 10.1007/s10654-011-9610-5; Honjo K, 2011, EUR J EPIDEMIOL, V26, P13, DOI 10.1007/s10654-010-9515-8; Hui WS, 2010, EUR J EPIDEMIOL, V25, P375, DOI 10.1007/s10654-010-9459-z; Huisman M, 2010, EUR J EPIDEMIOL, V25, P569, DOI 10.1007/s10654-010-9473-1; Ikram MA, 2012, NAT GENET, V44, P539, DOI 10.1038/ng.2245; Ikram MA, 2011, EUR J EPIDEMIOL, V26, P811, DOI 10.1007/s10654-011-9624-z; IRETON H, 1995, CLIN PEDIATR, V34, P248, DOI 10.1177/000992289503400504; Isquith PK, 2004, DEV NEUROPSYCHOL, V26, P403, DOI 10.1207/s15326942dn2601_3; Israel AC, 2001, ASSESSMENT, V8, P417, DOI 10.1177/107319110100800406; Jacobsen BK, 2011, EUR J EPIDEMIOL, V26, P711, DOI 10.1007/s10654-011-9598-x; Jacobsen TN, 2010, EUR J EPIDEMIOL, V25, P349, DOI 10.1007/s10654-010-9448-2; Jaddoe VWV, 2007, EUR J EPIDEMIOL, V22, P917, DOI 10.1007/s10654-007-9209-z; Jaddoe VWV, 2010, EUR J EPIDEMIOL, V25, P823, DOI 10.1007/s10654-010-9516-7; Jaddoe VWV, 2008, EUR J EPIDEMIOL, V23, P767, DOI 10.1007/s10654-008-9304-9; Jaddoe VWV, 2008, EUR J EPIDEMIOL, V23, P801, DOI 10.1007/s10654-008-9309-4; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Joseph J, 2011, EUR J EPIDEMIOL, V26, P117, DOI 10.1007/s10654-010-9540-7; Kardys I, 2010, EUR J EPIDEMIOL, V25, P481, DOI 10.1007/s10654-010-9453-5; Kataja-Tuomola M, 2010, EUR J EPIDEMIOL, V25, P333, DOI 10.1007/s10654-010-9444-6; Kerneis S, 2010, EUR J EPIDEMIOL, V25, P55, DOI 10.1007/s10654-009-9403-2; Kjelsberg E, 2010, EUR J EPIDEMIOL, V25, P237, DOI 10.1007/s10654-010-9436-6; KOCHANSKA G, 1994, CHILD DEV, V65, P852, DOI 10.2307/1131423; Kok R, 2013, CHILD CARE HLTH DEV, V39, P277, DOI 10.1111/j.1365-2214.2012.01374.x; Kok R, 2013, DEV PSYCHOBIOL, V55, P451, DOI 10.1002/dev.21049; Kowall B, 2011, EUR J EPIDEMIOL, V26, P637, DOI 10.1007/s10654-011-9609-y; Kowall B, 2010, EUR J EPIDEMIOL, V25, P393, DOI 10.1007/s10654-010-9452-6; Kvamme JM, 2010, EUR J EPIDEMIOL, V25, P183, DOI 10.1007/s10654-009-9422-z; Laaksonen MA, 2010, EUR J EPIDEMIOL, V25, P115, DOI 10.1007/s10654-009-9405-0; Labout JAM, 2011, EUR J EPIDEMIOL, V26, P61, DOI 10.1007/s10654-010-9500-2; Labout JAM, 2008, J PEDIATR, V153, P771, DOI 10.1016/j.jpeds.2008.05.061; Lagiou P, 2011, EUR J EPIDEMIOL, V26, P39, DOI 10.1007/s10654-010-9528-3; Landgraf JM, 1998, QUAL LIFE RES, V7, P433, DOI 10.1023/A:1008810004694; Langeslag SJE, 2013, HUM BRAIN MAPP, V34, P3299, DOI 10.1002/hbm.22143; Lehto HR, 2011, EUR J EPIDEMIOL, V26, P851, DOI 10.1007/s10654-011-9601-6; Lehto SM, 2010, EUR J EPIDEMIOL, V25, P403, DOI 10.1007/s10654-010-9457-1; Lindman AS, 2010, EUR J EPIDEMIOL, V25, P789, DOI 10.1007/s10654-010-9501-1; Liu GF, 2011, EUR J EPIDEMIOL, V26, P463, DOI 10.1007/s10654-011-9583-4; Liu JH, 2011, EUR J EPIDEMIOL, V26, P237, DOI 10.1007/s10654-010-9538-1; Lloyd-Jones DM, 2010, CIRCULATION, V121, P586, DOI 10.1161/CIRCULATIONAHA.109.192703; Mackenbach JP, 2011, EUR J EPIDEMIOL, V26, P903, DOI 10.1007/s10654-011-9633-y; Marsh RW, 2011, EUR J EPIDEMIOL, V26, P915, DOI 10.1007/s10654-011-9634-x; Moebus S, 2011, EUR J EPIDEMIOL, V26, P719, DOI 10.1007/s10654-011-9608-z; Montonen J, 2011, EUR J EPIDEMIOL, V26, P29, DOI 10.1007/s10654-010-9539-0; Morkedal B, 2011, EUR J EPIDEMIOL, V26, P457, DOI 10.1007/s10654-011-9572-7; Morseth B, 2010, EUR J EPIDEMIOL, V25, P325, DOI 10.1007/s10654-010-9450-8; Nagaya T, 2010, EUR J EPIDEMIOL, V25, P195, DOI 10.1007/s10654-009-9423-y; Neovius K, 2010, EUR J EPIDEMIOL, V25, P703, DOI 10.1007/s10654-010-9485-x; Ngo AD, 2010, EUR J EPIDEMIOL, V25, P37, DOI 10.1007/s10654-009-9401-4; Niedhammer I, 2011, EUR J EPIDEMIOL, V26, P1, DOI 10.1007/s10654-010-9506-9; Oksuzyan A, 2010, EUR J EPIDEMIOL, V25, P471, DOI 10.1007/s10654-010-9460-6; Owens J, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.3.e27; Pan XQ, 2010, EUR J EPIDEMIOL, V25, P813, DOI 10.1007/s10654-010-9504-y; Parker JG, 2005, DEV PSYCHOL, V41, P235, DOI 10.1037/0012-1649.41.1.235; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pedersen GS, 2011, EUR J EPIDEMIOL, V26, P527, DOI 10.1007/s10654-011-9594-1; Perquin CW, 2000, PAIN, V87, P51, DOI 10.1016/S0304-3959(00)00269-4; Puddu PE, 2011, EUR J EPIDEMIOL, V26, P595, DOI 10.1007/s10654-011-9600-7; Putnam SP, 2006, J PERS ASSESS, V87, P102, DOI 10.1207/s15327752jpa8701_09; Qin L, 2010, EUR J EPIDEMIOL, V25, P5, DOI 10.1007/s10654-009-9395-y; Raat H, 2005, J EPIDEMIOL COMMUN H, V59, P75, DOI 10.1136/jech.2003.012614; Raat H, 2006, CURR OPIN ALLERGY CL, V6, P180, DOI 10.1097/01.all.0000225157.67897.c2; Raat H, 2007, QUAL LIFE RES, V16, P445, DOI 10.1007/s11136-006-9134-8; Raat H, 2011, EARLY HUM DEV, V87, P729, DOI 10.1016/j.earlhumdev.2011.08.022; Raat H, 2010, QUAL LIFE RES, V19, P1439, DOI 10.1007/s11136-010-9773-7; Rasquin A, 2006, GASTROENTEROLOGY, V130, P1527, DOI 10.1053/j.gastro.2005.08.063; Regidor E, 2011, EUR J EPIDEMIOL, V26, P265, DOI 10.1007/s10654-010-9511-z; Reuser M, 2011, EUR J EPIDEMIOL, V26, P395, DOI 10.1007/s10654-011-9553-x; Rijlaarsdam J, 2012, INT J METH PSYCH RES, V21, P195, DOI 10.1002/mpr.1361; Risselada R, 2010, EUR J EPIDEMIOL, V25, P261, DOI 10.1007/s10654-010-9432-x; Rours GIJG, 2011, EUR J EPIDEMIOL, V26, P493, DOI 10.1007/s10654-011-9586-1; Rours GIJG, 2011, EUR J EPIDEMIOL, V26, P421, DOI 10.1007/s10654-011-9569-2; Rours GIJG, 2005, J CLIN MICROBIOL, V43, P4684, DOI 10.1128/JCM.43.9.4684-4690.2005; Roza SJ, 2008, AM J EPIDEMIOL, V168, P1145, DOI 10.1093/aje/kwn233; Roza SJ, 2008, NEUROIMAGE, V39, P1491, DOI 10.1016/j.neuroimage.2007.11.004; Saridjan NS, 2010, HORM BEHAV, V57, P247, DOI 10.1016/j.yhbeh.2009.12.001; Saudino KJ, 1998, BRIT J DEV PSYCHOL, V16, P349; Savela S, 2010, EUR J EPIDEMIOL, V25, P619, DOI 10.1007/s10654-010-9483-z; Schneider C, 2010, EUR J EPIDEMIOL, V25, P253, DOI 10.1007/s10654-010-9435-7; Schottker B, 2011, EUR J EPIDEMIOL, V26, P779, DOI 10.1007/s10654-011-9619-9; Schuur M, 2010, EUR J EPIDEMIOL, V25, P561, DOI 10.1007/s10654-010-9476-y; Sellier E, 2010, EUR J EPIDEMIOL, V25, P635, DOI 10.1007/s10654-010-9474-0; Silva LM, 2010, INT J EPIDEMIOL, V39, P1250, DOI 10.1093/ije/dyq069; Slachtova H, 2011, EUR J EPIDEMIOL, V26, P45, DOI 10.1007/s10654-010-9513-x; Smith JG, 2010, EUR J EPIDEMIOL, V25, P95, DOI 10.1007/s10654-009-9404-1; Sonestedt E, 2011, EUR J EPIDEMIOL, V26, P609, DOI 10.1007/s10654-011-9589-y; Statistics Netherlands, 2004, STAND OND 2003; Statistics Netherlands, 2004, ALL NED 2004; Steenweg-de Graaff J, 2012, AM J CLIN NUTR, V95, P1413, DOI 10.3945/ajcn.111.030791; STJAMESROBERTS I, 1991, J CHILD PSYCHOL PSYC, V32, P951; STJAMESROBERTS I, 1988, J CHILD PSYCHOL PSYC, V29, P21; STJAMESROBERTS I, 1989, J CHILD PSYCHOL PSYC, V30, P189; St James-Roberts I, 1983, J REPROD INFANT PSYC, V1, P53, DOI DOI 10.1080/02646838308403151; Strand BH, 2011, EUR J EPIDEMIOL, V26, P475, DOI 10.1007/s10654-011-9562-9; Strandhagen E, 2010, EUR J EPIDEMIOL, V25, P163, DOI 10.1007/s10654-010-9427-7; Taal HR, 2012, NAT GENET, V44, P532, DOI 10.1038/ng.2238; Tamakoshi K, 2011, EUR J EPIDEMIOL, V26, P771, DOI 10.1007/s10654-011-9623-0; Tharner A, 2012, J DEV BEHAV PEDIATR, V33, P396, DOI 10.1097/DBP.0b013e318257fac3; Thomas S, 2010, EUR J EPIDEMIOL, V25, P135, DOI 10.1007/s10654-009-9408-x; Timmermans S, 2011, EUR J EPIDEMIOL, V26, P165, DOI 10.1007/s10654-010-9542-5; Tolonen H, 2010, EUR J EPIDEMIOL, V25, P69, DOI 10.1007/s10654-009-9389-9; Troe EJWM, 2007, BJOG-INT J OBSTET GY, V114, P1557, DOI 10.1111/j.1471-0528.2007.01508.x; van Batenburg-Eddes T, 2008, EARLY HUM DEV, V84, P659, DOI 10.1016/j.earlhumdev.2008.04.007; van Beelen MEJ, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-466; van den Berg MP, 2009, PEDIATRICS, V124, pE96, DOI 10.1542/peds.2008-3100; van der Horst K, 2008, BMC PUBLIC HEALTH, V8, DOI 10.1186/1471-2458-8-142; van Houten VAA, 2009, J HYPERTENS, V27, P1152, DOI 10.1097/HJH.0b013e3283299973; van Noord C, 2010, EUR J EPIDEMIOL, V25, P21, DOI 10.1007/s10654-009-9406-z; van Rossem L, 2009, PEDIATRICS, V123, pE1017, DOI 10.1542/peds.2008-2663; Veldhuis L, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-177; Verburg BO, 2008, ULTRASOUND OBST GYN, V31, P388, DOI 10.1002/uog.5225; Verburg BO, 2007, KIDNEY INT, V72, P754, DOI 10.1038/sj.ki.5002420; Verburg BO, 2008, CIRCULATION, V117, P649, DOI 10.1161/CIRCULATIONAHA.107.709717; Verhulst FC, 1996, MANUAL CBCL 4 18 ROT; Vogel I, 2010, AM J PUBLIC HEALTH, V100, P1095, DOI 10.2105/AJPH.2009.168690; Walker LS, 1997, PSYCHOL ASSESSMENT, V9, P392, DOI 10.1037/1040-3590.9.4.392; Waller K, 2010, EUR J EPIDEMIOL, V25, P731, DOI 10.1007/s10654-010-9493-x; Wang A, 2011, EUR J EPIDEMIOL, V26, P547, DOI 10.1007/s10654-011-9574-5; Wardle J, 2001, J CHILD PSYCHOL PSYC, V42, P963, DOI 10.1111/1469-7610.00792; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Wijtzes AI, 2012, PREV MED, V55, P325, DOI 10.1016/j.ypmed.2012.07.023; Wolff NJ, 2009, HEALTH PSYCHOL, V28, P605, DOI 10.1037/a0015202; Ye XB, 2008, ENVIRON RES, V108, P260, DOI 10.1016/j.envres.2008.07.014; Yetkin E, 2011, EUR J EPIDEMIOL, V26, P429, DOI 10.1007/s10654-011-9570-9; Zhang HL, 2010, EUR J EPIDEMIOL, V25, P897, DOI 10.1007/s10654-010-9509-6	202	285	285	7	67	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0393-2990	1573-7284		EUR J EPIDEMIOL	Eur. J. Epidemiol.	SEP	2012	27	9					739	756		10.1007/s10654-012-9735-1		18	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	030SF	WOS:000310589700008	23086283	
J	Hiller, R; Laffer, S; Harwanegg, C; Huber, M; Schmidt, WM; Twardosz, A; Barletta, B; Becker, WM; Blaser, K; Breiteneder, H; Chapman, M; Crameri, R; Duchene, M; Ferreira, F; Fiebig, H; Hoffmann-Sommergruber, K; King, TP; Kleber-Janke, T; Kurup, VP; Lehrer, SB; Lidholm, J; Muller, U; Pini, C; Reese, G; Scheiner, O; Scheynius, A; Shen, HD; Spitzauer, S; Suck, R; Swoboda, I; Thomas, W; Tinghino, R; Van Hage-Hamsten, M; Virtanen, T; Kraft, D; Muller, MW; Valenta, R				Hiller, R; Laffer, S; Harwanegg, C; Huber, M; Schmidt, WM; Twardosz, A; Barletta, B; Becker, WM; Blaser, K; Breiteneder, H; Chapman, M; Crameri, R; Duchene, M; Ferreira, F; Fiebig, H; Hoffmann-Sommergruber, K; King, TP; Kleber-Janke, T; Kurup, VP; Lehrer, SB; Lidholm, J; Muller, U; Pini, C; Reese, G; Scheiner, O; Scheynius, A; Shen, HD; Spitzauer, S; Suck, R; Swoboda, I; Thomas, W; Tinghino, R; Van Hage-Hamsten, M; Virtanen, T; Kraft, D; Muller, MW; Valenta, R			Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment	FASEB JOURNAL			English	Article						type I allergy; IgE; microarray technology; recombinant allergen; diagnosis	GRASS PHLEUM-PRATENSE; HOUSE-DUST MITE; BIRCH POLLEN ALLERGEN; IGE-BINDING EPITOPES; AMINO-ACID-SEQUENCE; ASPERGILLUS-FUMIGATUS ALLERGENS; PENICILLIUM-CITRINUM ALLERGEN; COCKROACH BLATTELLA-GERMANICA; SURFACE DISPLAY TECHNOLOGY; ANTIGENIC CROSS-REACTIVITY	Type I allergy is an immunoglobulin E (IgE)-mediated hypersensitivity disease affecting more than 25% of the population. Currently, diagnosis of allergy is performed by provocation testing and IgE serology using allergen extracts. This process defines allergen-containing sources but cannot identify the disease-eliciting allergenic molecules. We have applied microarray technology to develop a miniaturized allergy test containing 94 purified allergen molecules that represent the most common allergen sources. The allergen microarray allows the determination and monitoring of allergic patients' IgE reactivity profiles to large numbers of disease-causing allergens by using single measurements and minute amounts of serum. This method may change established practice in allergy diagnosis, prevention, and therapy. In addition, microarrayed antigens may be applied to the diagnosis of autoimmune and infectious diseases.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Internal Med 4, Div Pulm, A-1090 Vienna, Austria; VBC GENOMICS, A-1030 Vienna, Austria; Ist Super Sanita, Immunol Lab, I-00161 Rome, Italy; Res Ctr Borstel, D-23845 Borstel, Germany; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Virginia, Dept Internal Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Salzburg Univ, Dept Genet & Biol, A-5020 Salzburg, Austria; Allergopharma Joachim Ganzer KG, D-21465 Reinbek, Germany; Rockefeller Univ, New York, NY 10021 USA; Med Coll Wisconsin, Milwaukee, WI 53295 USA; Tulane Univ, Med Ctr, Dept Med, Sect Clin Immunol & Allergy, New Orleans, LA 70112 USA; Pharmacia Diagnost AB, Uppsala, Sweden; Zieglerspital Bern, Dept Internal Med, CH-3007 Bern, Switzerland; Karolinska Inst, S-17176 Stockholm, Sweden; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Univ Vienna, Inst Med & Lab Diagnost, A-1090 Vienna, Austria; Univ W Australia, TVW Telethon Inst Child Hlth Res, Perth 6872, Australia; Karolinska Hosp & Inst, Div Clin Immunol, Dept Lab Med, S-17176 Stockholm, Sweden; Univ Kuopio, Dept Clin Microbiol, FIN-70211 Kuopio, Finland	Valenta, R (reprint author), Univ Vienna, Vienna Gen Hosp AKH, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@akh-wien.ac.at	Ferreira, Fatima/E-4889-2011; BARLETTA, BIANCA/B-9980-2016; van Hage, Marianne/A-9678-2017	Ferreira, Fatima/0000-0003-0989-2335; van Hage, Marianne/0000-0003-3091-1596; Lidholm, Jonas/0000-0002-7779-3411			Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Bieber T, 1997, IMMUNOL TODAY, V18, P311, DOI 10.1016/S0167-5699(97)01046-3; Blackley Charles Harrison, 1880, HAY FEVER ITS CAUSES; BREITENBACH M, 1995, INT ARCH ALLERGY IMM, V107, P458; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Breiteneder H, 1998, INT ARCH ALLERGY IMM, V116, P83, DOI 10.1159/000023930; BREITENEDER H, 1989, EMBO J, V8, P1935; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; DOLECEK C, 1993, FEBS LETT, V335, P299, DOI 10.1016/0014-5793(93)80406-K; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Duro G, 1996, FEBS LETT, V399, P295, DOI 10.1016/S0014-5793(96)01328-2; Eriksson TLJ, 2001, EUR J BIOCHEM, V268, P287, DOI 10.1046/j.1432-1327.2001.01879.x; Eriksson TLJ, 1998, EUR J BIOCHEM, V251, P443, DOI 10.1046/j.1432-1327.1998.2510443.x; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; Ganglberger E, 2001, INT ARCH ALLERGY IMM, V125, P216, DOI 10.1159/000053819; Haab B.B., 2001, GENOME BIOL, V2, P2; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P115, DOI 10.1159/000024367; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Kay A. B., 1997, ALLERGY ALLERGIC DIS; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; KOS T, 1993, BIOCHEM BIOPH RES CO, V196, P1086, DOI 10.1006/bbrc.1993.2362; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; Lindborg M, 1999, J INVEST DERMATOL, V113, P156, DOI 10.1046/j.1523-1747.1999.00661.x; Lueking A, 1999, ANAL BIOCHEM, V270, P103, DOI 10.1006/abio.1999.4063; MacBeath G, 2000, SCIENCE, V289, P1760; Mendoza LG, 1999, BIOTECHNIQUES, V27, P778; Monsalve RI, 1999, PROTEIN EXPRES PURIF, V16, P410, DOI 10.1006/prep.1999.1082; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; MOSER M, 1992, J IMMUNOL, V149, P454; Natter S, 1998, FASEB J, V12, P1559; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 1999, FASEB J, V13, P843; Olsson S, 1998, CLIN EXP ALLERGY, V28, P984; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; Pandjaitan B, 2000, J ALLERGY CLIN IMMUN, V105, P279, DOI 10.1016/S0091-6749(00)90077-0; RASANEN L, 1994, ALLERGY, V49, P342, DOI 10.1111/j.1398-9995.1994.tb02279.x; Rasool O, 2000, EUR J BIOCHEM, V267, P4355, DOI 10.1046/j.1432-1327.2000.01475.x; Rautiainen J, 1998, BIOCHEM BIOPH RES CO, V247, P746, DOI 10.1006/bbrc.1998.8851; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240; SCHMIDT M, 1995, FEBS LETT, V370, P11, DOI 10.1016/0014-5793(95)98164-E; Schmidt M, 1997, EUR J BIOCHEM, V246, P181, DOI 10.1111/j.1432-1033.1997.00181.x; Schweitzer B, 2000, P NATL ACAD SCI USA, V97, P10113, DOI 10.1073/pnas.170237197; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; Shen HD, 1999, CLIN EXP ALLERGY, V29, P642; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; Shen HD, 2000, J ALLERGY CLIN IMMUN, V105, P827, DOI 10.1067/mai.2000.105220; Shen HD, 1997, CLIN EXP ALLERGY, V27, P682, DOI 10.1046/j.1365-2222.1997.d01-546.x; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; Singh MB, 1999, INT ARCH ALLERGY IMM, V119, P75, DOI 10.1159/000024181; Smith W, 1999, INT ARCH ALLERGY IMM, V118, P15, DOI 10.1159/000024026; Soldatova LN, 1998, J ALLERGY CLIN IMMUN, V101, P691; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Suck R, 2000, INT ARCH ALLERGY IMM, V121, P284, DOI 10.1159/000024341; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Twardosz A, 1997, BIOCHEM BIOPH RES CO, V239, P197, DOI 10.1006/bbrc.1997.6860; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; VALENTA R, 1994, BIOCHEM BIOPH RES CO, V199, P106, DOI 10.1006/bbrc.1994.1201; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Virtanen T, 1999, INT ARCH ALLERGY IMM, V120, P247, DOI 10.1159/000024277; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1999, J IMMUNOL, V163, P5489; Wagner B, 1999, J ALLERGY CLIN IMMUN, V104, P1084, DOI 10.1016/S0091-6749(99)70093-X; Wagner S, 2000, EUR J BIOCHEM, V267, P7006, DOI 10.1046/j.1432-1327.2000.01801.x; WIDE L, 1967, LANCET, V2, P1105; Yeang HY, 1996, J ALLERGY CLIN IMMUN, V98, P628, DOI 10.1016/S0091-6749(96)70097-0; Zargari A, 1999, J ALLERGY CLIN IMMUN, V103, P877, DOI 10.1016/S0091-6749(99)70433-1	90	285	305	0	17	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JAN	2002	16	1					414	+		10.1096/fj.01-0711fje		21	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	518FU	WOS:000173656600022	11790727	
J	Bernstein, JA; Alexis, N; Barnes, C; Bernstein, IL; Bernstein, JA; Nel, A; Peden, D; Diaz-Sanchez, D; Tarlo, SM; Williams, PB				Bernstein, JA; Alexis, N; Barnes, C; Bernstein, IL; Bernstein, JA; Nel, A; Peden, D; Diaz-Sanchez, D; Tarlo, SM; Williams, PB			Health effects of air pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						outdoor air pollution; particulate matter; ozone; nitrogen dioxide; sulfur dioxide; diesel exhaust; asthma; exposure; interactions between allergens and pollutants	DIESEL EXHAUST PARTICLES; NITROGEN-DIOXIDE EXPOSURE; DAILY ASTHMA SEVERITY; MILD ALLERGIC-ASTHMA; 20 US CITIES; OZONE EXPOSURE; INHALED ALLERGEN; SULFUR-DIOXIDE; FUNGAL SPORES; INFLAMMATORY RESPONSES	The general public, especially patients with upper or lower respiratory symptoms, is aware from media reports that adverse respiratory effects can occur from air pollution. It is important for the allergist to have a current knowledge of the potential health effects of air pollution and how they might affect their patients to advise them accordingly. Specifically, the allergist-clinical immunologist should be keenly aware that both gaseous and particulate outdoor pollutants might aggravate or enhance the underlying pathophysiology of both the upper and lower airways. Epidemiologic and laboratory exposure research studies investigating the health effects of outdoor air pollution each have advantages and disadvantages. Epidemiologic studies can show statistical associations between levels of individual or combined air pollutants and outcomes, such as rates of asthma, emergency visits for asthma, or hospital admissions, but cannot prove a causative role. Human exposure studies, animal models, and tissue or cellular studies provide further information on mechanisms of response but also have inherent limitations. The aim of this rostrum is to review the relevant publications that provide the appropriate context for assessing the risks of air pollution relative to other more modifiable environmental factors in patients with allergic airways disease.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol,Allergy Sect, Cincinnati, OH USA; Univ N Carolina, Dept Pediat, Chapel Hill, NC USA; Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA; Univ Calif Los Angeles, Sch Med, Dept Internal Med, Los Angeles, CA USA; Toronto Western Hosp, Dept Internal Med, Toronto, ON M5T 2S8, Canada	Bernstein, JA (reprint author), 231 Albert Sabin Way,ML 563, Cincinnati, OH 45267 USA.	Jonathan.Bernstein@uc.edu	Nel, Andre/J-2808-2012				Anderson W, 2001, QJM-MON J ASSOC PHYS, V94, P429, DOI 10.1093/qjmed/94.8.429; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Baulig A, 2003, TOXICOL IN VITRO, V17, P567, DOI 10.1016/S0887-2333(03)00115-2; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; CARTELLEJOS M, 1995, AM J RESP CRIT CARE, V152, P1501; CARTELLEJOS M, 1995, AM J RESP CRIT CARE, V152; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; D'Amato G, 2002, Monaldi Arch Chest Dis, V57, P161; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; DAMATO G, 2003, ENVIRON RES, V91, P21; de Hartog J J, 1997, Ned Tijdschr Geneeskd, V141, P1814; de Hartog JJ, 2003, AM J EPIDEMIOL, V157, P613, DOI 10.1093/aje/kwg021; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; DeLorme MP, 2002, J TOXICOL ENV HEAL A, V65, P1453, DOI 10.1080/00984100290071432; Diaz-Sanchez D, 2003, CURR ALLERGY ASTHM R, V3, P146, DOI 10.1007/s11882-003-0027-4; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Fahy O, 2002, J IMMUNOL, V168, P5912; FAHY O, 2002, J IMMUNOL, V168; FERNANDES ALG, 1994, CHEST, V106, P1077, DOI 10.1378/chest.106.4.1077; Finkelman FD, 2004, J IMMUNOL, V172, P3808; GHIO AJ, 1998, AIR POLLUTION HLTH, P653; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1067/mai.2003.1780; Harrod KS, 2003, AM J RESP CELL MOL, V28, P451, DOI 10.1165/rcmb.2002-0100OC; Higgins BG, 2000, EUR RESPIR J, V16, P61, DOI 10.1034/j.1399-3003.2000.16a11.x; Horstman D. H., 1989, SUSCEPTIBILITY INHAL; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Kafoury RM, 1999, AM J RESP CRIT CARE, V160, P1934; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; Koken PJM, 2003, ENVIRON HEALTH PERSP, V111, P1312, DOI 10.1289/ehp.5957; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; LI N, 2003, CLIN IMMUNOL, V3, P250; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; LINN WS, 1984, ARCH ENVIRON HEALTH, V39, P339; Longphre M, 1999, J APPL PHYSIOL, V86, P341; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonnell WF, 1997, AM J RESP CRIT CARE, V156, P715; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nightingale JA, 1999, THORAX, V54, P1061; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Parnia S, 2002, ALLERGY, V57, P1111, DOI 10.1034/j.1398-9995.2002.02167.x; Pearson AC, 1997, J TOXICOL ENV HEALTH, V50, P143, DOI 10.1080/009841097160546; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Pereira PM, 1995, ENVIRON RES, V69, P96, DOI 10.1006/enrs.1995.1030; Ritz SA, 2002, AM J RESP CELL MOL, V27, P428, DOI 10.1165/rcmb.4824; Romieu I, 2004, THORAX, V59, P8; Rutherford S, 2000, J OCCUP ENVIRON MED, V42, P882, DOI 10.1097/00043764-200009000-00006; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SANDSTROM T, 1992, BRIT J IND MED, V49, P850; SANDSTROM T, 1991, EUR RESPIR J, V4, P332; Sarnat JA, 2001, NEW ENGL J MED, V344, P1253; Shima M, 2003, J EPIDEMIOL, V13, P108; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Sunyer J, 1997, THORAX, V52, P760; Sunyer J, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.8.e2; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P52, DOI 10.1067/mai.2001.116574; TSAI SS, 2003, STROKE, V34, P1; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Utell MJ, 2000, J AEROSOL MED, V13, P355, DOI 10.1089/jam.2000.13.355; Vagaggini B, 1999, EUR RESPIR J, V13, P274, DOI 10.1034/j.1399-3003.1999.13b09.x; VAGAGGINI B, 2002, AM J RESP CRIT CARE, V16, P1073; VAGGAGGINI B, 2002, AM J RESP CRIT CARE, V16, P1073; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Wagner JG, 2003, TOXICOL SCI, V74, P437, DOI 10.1093/toxsci/kfg120; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Winterton DL, 2001, ANN ALLERG ASTHMA IM, V86, P232; WOLFINO NA, 1991, LANCET, V338, P199; Wong GWK, 2004, CURR OPIN PULM MED, V10, P62, DOI 10.1097/00063198-200401000-00011; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Yin XJJ, 2004, TOXICOL SCI, V77, P263, DOI 10.1093/toxsci/kfh035; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	82	283	295	10	91	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1116	1123		10.1016/j.jaci.2004.08.030		8	Allergy; Immunology	Allergy; Immunology	870HI	WOS:000225047800019	15536419	
J	Busse, WW; Morgan, WJ; Gergen, PJ; Mitchell, HE; Gern, JE; Liu, AH; Gruchalla, RS; Kattan, M; Teach, SJ; Pongracic, JA; Chmiel, JF; Steinbach, SF; Calatroni, A; Togias, A; Thompson, KM; Szefler, SJ; Sorkness, CA				Busse, William W.; Morgan, Wayne J.; Gergen, Peter J.; Mitchell, Herman E.; Gern, James E.; Liu, Andrew H.; Gruchalla, Rebecca S.; Kattan, Meyer; Teach, Stephen J.; Pongracic, Jacqueline A.; Chmiel, James F.; Steinbach, Suzanne F.; Calatroni, Agustin; Togias, Alkis; Thompson, Katherine M.; Szefler, Stanley J.; Sorkness, Christine A.			Randomized Trial of Omalizumab (Anti-IgE) for Asthma in Inner-City Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SEVERE ALLERGIC-ASTHMA; MONOCLONAL-ANTIBODY; COST-EFFECTIVENESS; CHILDHOOD ASTHMA; EXACERBATIONS; VIRUSES; ADULTS; CELLS; ADOLESCENTS; RHINOVIRUS	BACKGROUND Research has underscored the effects of exposure and sensitization to allergens on the severity of asthma in inner-city children. It has also revealed the limitations of environmental remediation and guidelines-based therapy in achieving greater disease control. METHODS We enrolled inner-city children, adolescents, and young adults with persistent asthma in a randomized, double-blind, placebo-controlled, parallel-group trial at multiple centers to assess the effectiveness of omalizumab, as compared with placebo, when added to guidelines-based therapy. The trial was conducted for 60 weeks, and the primary outcome was symptoms of asthma. RESULTS Among 419 participants who underwent randomization (at which point 73% had moderate or severe disease), omalizumab as compared with placebo significantly reduced the number of days with asthma symptoms, from 1.96 to 1.48 days per 2-week interval, a 24.5% decrease (P<0.001). Similarly, omalizumab significantly reduced the proportion of participants who had one or more exacerbations from 48.8 to 30.3% (P<0.001). Improvements occurred with omalizumab despite reductions in the use of inhaled glucocorticoids and long-acting beta-agonists. CONCLUSIONS When added to a regimen of guidelines-based therapy for inner-city children, adolescents, and young adults, omalizumab further improved asthma control, nearly eliminated seasonal peaks in exacerbations, and reduced the need for other medications to control asthma.	[Busse, William W.; Gern, James E.; Sorkness, Christine A.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI 53719 USA; [Morgan, Wayne J.] Univ Arizona, Coll Med, Tucson, AZ USA; [Gergen, Peter J.; Togias, Alkis; Thompson, Katherine M.] NIAID, Bethesda, MD 20892 USA; [Mitchell, Herman E.; Calatroni, Agustin] Rho Fed Syst Div, Chapel Hill, NC USA; [Liu, Andrew H.; Szefler, Stanley J.] Natl Jewish Hlth, Denver, CO USA; [Liu, Andrew H.; Szefler, Stanley J.] Univ Colorado Hlth Sci, Denver, CO USA; [Gruchalla, Rebecca S.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA; [Kattan, Meyer] Columbia Univ, Coll Phys & Surg, New York, NY USA; [Teach, Stephen J.] Childrens Natl Med Ctr, Washington, DC 20010 USA; [Pongracic, Jacqueline A.] Childrens Mem Hosp, Chicago, IL 60614 USA; [Chmiel, James F.] Rainbow Babies & Childrens Hosp, Cleveland, OH USA; [Steinbach, Suzanne F.] Boston Univ, Sch Med, Boston, MA 02118 USA	Busse, WW (reprint author), Univ Wisconsin, Sch Med & Publ Hlth K4 910 CSC, MC 9988,600 Highland Ave, Madison, WI 53719 USA.	wwb@medicine.wisc.edu			National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) [NO1-AI-25496, NO1-AI-25482]; National Center for Research Resources, NIH [M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5M01RR020359-040]; Novartis Pharmaceuticals; Dey Pharma; Boehringer Ingelheim; Teva; Amgen; Pfizer; Genentech; AstraZeneca; GlaxoSmithKline; MedImmune; Novartis; Ception; Phadia; Vertex; Biota; Centocor; Synairgen; Merck; 3V BioSciences; EraGen Biosciences; Ross Abbott; Sandoz; ScheringPlough	Supported by contracts with the National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH) (NO1-AI-25496 and NO1-AI-25482); grants from the National Center for Research Resources, NIH (M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5M01RR020359-040); Novartis Pharmaceuticals, under a clinical trial agreement with the University of Wisconsin-Madison; Dey Pharma (which provided EpiPens), and SC Johnson (which provided household pest control).; Dr. Busse reports receiving board membership fees from Centocor and Merck, consulting fees from Boehringer Ingelheim, Teva, Amgen, Pfizer, and Genentech; consulting fees and grant support from AstraZeneca, GlaxoSmithKline, MedImmune, and Novartis; and grant support from Ception. Dr. Morgan reports receiving consulting fees from Novartis, lecture fees from Phadia and Vertex, royalties from Elsevier, consulting fees from Genentech, and payment to his institution for development of educational presentations from Genentech. Dr Gern reports receiving consulting fees from GlaxoSmithKline, Biota, Centocor, Synairgen, and Boehringer Ingelheim; grant support from Merck and AstraZeneca; stock options and consulting fees from 3V BioSciences; and stock payments from EraGen Biosciences. Dr. Liu reports receiving consulting fees from AstraZeneca and Novartis and lecture fees from Glaxo-SmithKline, Merck and Phadia. Dr. Teach reports receiving consulting fees from AstraZeneca. Dr. Steinbach reports providing expert testimony for Harvard Medical Institutions. Dr. Szefler reports receiving consulting fees from Schering, Boehringer Ingelheim, and Novartis, consulting fees and grant support from Merck and Genentech, and grant support from GlaxoSmithKline and Ross Abbott. Dr. Sorkness reports receiving consulting fees from GlaxoSmithKline and AstraZeneca, grant support from Pharmaxis and Sandoz, and consulting fees and grant support from ScheringPlough. No other potential conflict of interest relevant to this article was reported. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.	Arbes SJ, 2005, ENVIRON HEALTH PERSP, V113, P665, DOI 10.1289/ehp.7648; Bisgaard H, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4978; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Campbell JD, 2010, ALLERGY, V65, P1141, DOI 10.1111/j.1398-9995.2010.02336.x; Corren J, 2009, CLIN EXP ALLERGY, V39, P788, DOI 10.1111/j.1365-2222.2009.03214.x; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Deniz YM, 2005, CLIN REV ALLERG IMMU, V29, P31, DOI 10.1385/CRIAI:29:1:031; ECKMAN JA, 2010, J ALLERGY CLIN IMMUN, V125; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Holgate ST, 2005, CLIN EXP ALLERGY, V35, P408, DOI 10.1111/j.1365-2222.2005.02191.x; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; Johnston NW, 2005, J ALLERGY CLIN IMMUN, V115, P132, DOI 10.1016/j.jaci.2004.09.025; Lanier B, 2009, J ALLERGY CLIN IMMUN, V124, P1210, DOI 10.1016/j.jaci.2009.09.021; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Liu AH, 2007, J ALLERGY CLIN IMMUN, V119, P817, DOI 10.1016/j.jaci.2006.12.662; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; National Heart Lung and Blood Institute, 2007, EPR3 NAT HEART LUNG; Oba Y, 2004, J ALLERGY CLIN IMMUN, V114, P265, DOI 10.1016/j.jaci.2004.05.049; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; R Development Core Team, 2010, R LANG ENV STAT COMP; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schatz M, 2006, J ALLERGY CLIN IMMUN, V117, P549, DOI 10.1016/j.jaci.2006.01.011; SCHATZ M, 2009, J ALLERGY CLIN IMMUN, V124; Sears MR, 2007, J ALLERGY CLIN IMMUN, V120, P526, DOI 10.1016/j.jaci.2007.05.047; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Soler M, 2001, EUR RESPIR J, V18, P739; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Wahn U, 2009, ALLERGY, V64, P1780, DOI 10.1111/j.1398-9995.2009.02119.x; Wang R, 2007, NEW ENGL J MED, V357, P2189, DOI 10.1056/NEJMsr077003; WJ M, 2004, NEW ENGL J MED, V351, P1068; Wood SN, 2004, J AM STAT ASSOC, V99, P673, DOI 10.1198/016214504000000980; Wu AC, 2007, J ALLERGY CLIN IMMUN, V120, P1146, DOI 10.1016/j.jaci.2007.07.055	42	281	291	1	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAR 17	2011	364	11					1005	1015				11	Medicine, General & Internal	General & Internal Medicine	735SX	WOS:000288439000006	21410369	
J	Vahter, M; Akesson, A; Liden, C; Ceccatelli, S; Berglund, M				Vahter, Marie; Akesson, Agneta; Liden, Carola; Ceccatelli, Sandra; Berglund, Marika			Gender differences in the disposition and toxicity of metals	ENVIRONMENTAL RESEARCH			English	Review						gender; females; males; exposure; toxicity; metabolism; susceptibility	BREAST-CANCER CELLS; ENVIRONMENTAL CADMIUM EXPOSURE; ESTROGEN-RECEPTOR-ALPHA; MERCURY-TREATED RATS; FOREARM BONE-DENSITY; WATER SUPPLY-SYSTEM; LOW-LEVEL EXPOSURE; BLOOD LEAD LEVELS; DRINKING-WATER; METHYL MERCURY	There is increasing evidence that health effects of toxic metals differ in prevalence or are manifested differently in men and women. However, the database is small. The present work aims at evaluating gender differences in the health effects of cadmium, nickel, lead, mercury and arsenic. There is a markedly higher prevalence of nickel-induced allergy and hand eczema in women compared to men, mainly due to differences in exposure. Cadmium retention is generally higher in women than in men, and the severe cadmium-induced Itai-itai disease was mainly a woman's disease. Gender differences in susceptibility at lower exposure are uncertain, but recent data indicate that cadmium has estrogenic effects and affect female offspring. Men generally have higher blood lead levels than women. Lead accumulates in bone and increased endogenous lead exposure has been demonstrated during periods of increased bone turnover, particularly in women in pregnancy and menopause. Lead and mercury, in the form of mercury vapor and methylmercury, are easily transferred from the pregnant women to the fetus. Recent data indicate that boys are more susceptible to neurotoxic effects of lead and methylmercury following exposure early in life, while experimental data suggest that females are more susceptible to immunotoxic effects of lead. Certain gender differences in the biotransformation of arsenic by methylation have been reported, and men seem to be more affected by arsenic-related skin effect than women. Experimental studies indicate major gender differences in arsenic-induced cancer. Obviously, research on gender-related differences in health effects caused by metals needs considerable more focus in the future. (c) 2006 Elsevier Inc. All rights reserved.	Karolinska Inst, Div Met & Hlth, Inst Environm Med, SE-17177 Stockholm, Sweden; Karolinska Inst, Div Toxicol & Neurotoxicol, Inst Environm Med, SE-17177 Stockholm, Sweden; Karolinska Inst, Dept Med, SE-17177 Stockholm, Sweden; Stockholm Cty Council, Stockholm, Sweden	Vahter, M (reprint author), Karolinska Inst, Div Met & Hlth, Inst Environm Med, Box 210, SE-17177 Stockholm, Sweden.	Marie.Vahter@imm.ki.se		Liden, Carola/0000-0001-9951-5896; Berglund, Marika/0000-0003-4241-4706; Ceccatelli, Sandra/0000-0002-9367-8480			Ahsan H, 2006, AM J EPIDEMIOL, V163, P1138, DOI 10.1093/aje/kwj154; Akesson A, 2002, AM J PUBLIC HEALTH, V92, P284, DOI 10.2105/AJPH.92.2.284; Akesson A, 2006, ENVIRON HEALTH PERSP, V114, P830, DOI 10.1289/ehp.8763; Akesson AA, 2005, ENVIRON HEALTH PERSP, V113, P1627, DOI 10.1289/ehp.8033; Alam M G M, 2002, Int J Environ Health Res, V12, P235, DOI 10.1080/0960312021000000998; Alfven T, 2004, J BONE MINER RES, V19, P900, DOI 10.1359/JBMR.040202; ATCHISON WD, 1994, FASEB J, V8, P622; Auger N, 2005, NEUROTOXICOLOGY, V26, P149, DOI 10.1016/j.neuro.2004.12.005; Baecklund M, 1999, ENVIRON RES, V80, P222; BAGHURST PA, 1992, ARCH ENVIRON HEALTH, V47, P203; BAKO G, 1982, CAN J PUBLIC HEALTH, V73, P92; Bannon DI, 2003, AM J PHYSIOL-CELL PH, V284, pC44, DOI 10.1152/ajpcell.00184.2002; Barany E, 2005, ENVIRON RES, V98, P215, DOI 10.1016/j.envres.2004.09.010; Barregard L, 1999, ENVIRON HEALTH PERSP, V107, P867, DOI 10.2307/3454473; BATES MN, 1995, AM J EPIDEMIOL, V141, P523; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Becker K, 2002, INT J HYG ENVIR HEAL, V205, P297, DOI 10.1078/1438-4639-00155; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Berglund M, 2000, TOXICOL LETT, V112, P219, DOI 10.1016/S0378-4274(99)00272-6; BERGLUND M, 1994, ENVIRON HEALTH PERSP, V102, P1058, DOI 10.2307/3431993; BHATTACHARYYA MH, 1988, P NATL ACAD SCI USA, V85, P8761, DOI 10.1073/pnas.85.22.8761; Bjorkman L, 2000, ENVIRON HEALTH PERSP, V108, P719, DOI 10.2307/3434724; Bjornberg KA, 2003, ENVIRON HEALTH PERSP, V111, P637, DOI 10.1289/ehp.5618; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; Brzoska MM, 2005, ARCH TOXICOL, V79, P636, DOI 10.1007/s00204-005-0680-6; Brzoska MM, 2005, TOXICOL APPL PHARM, V207, P195, DOI 10.1016/j.taap.2005.01.003; Bunn TL, 2000, J TOXICOL ENV HEAL A, V61, P677, DOI 10.1080/00984100050195152; Bunn TL, 2001, J TOXICOL ENV HEAL A, V64, P223, DOI 10.1080/15287390152543708; Burger J, 2000, ENVIRON RES, V83, P140, DOI 10.1006/enrs.2000.4060; Bustamante J, 1997, TOXICOLOGY, V118, P129, DOI 10.1016/S0300-483X(96)03607-4; CARRILLO MC, 1992, MECH AGEING DEV, V65, P187, DOI 10.1016/0047-6374(92)90035-C; *CDC, 2001, JAMA-J AM MED ASSOC, V285, P1436; Chattopadhyay Sandip, 1999, Journal of Toxicological Sciences, V24, P425; Chen GC, 2002, ANTICANCER RES, V22, P633; Chen YC, 2003, J OCCUP ENVIRON MED, V45, P241, DOI 10.1097/01.jom.0000058336.05741.e8; Chiu HF, 2006, J OCCUP ENVIRON MED, V48, P63, DOI 10.1097/01.jom.0000184854.75053.03; Chiu HF, 2004, LUNG CANCER-J IASLC, V46, P265, DOI 10.1016/j.lungcan.2004.05.012; Choe SY, 2003, SCI TOTAL ENVIRON, V312, P15, DOI 10.1016/S0048-9697(03)00190-6; Christian MS, 2001, INT J TOXICOL, V20, P145, DOI 10.1080/109158101317097719; CLARKSON TW, 1972, ANNU REV PHARMACOLOG, V12, P375, DOI 10.1146/annurev.pa.12.040172.002111; Concha G, 1998, INT ARCH OCC ENV HEA, V71, P42, DOI 10.1007/s004200050248; Dare E, 2000, J NEUROSCI RES, V62, P557, DOI 10.1002/1097-4547(20001115)62:4<557::AID-JNR10>3.0.CO;2-9; Davidson PW, 2004, PEDIATRICS, V113, P1023; Egeland GM, 1997, SCIENCE, V278, P1904, DOI 10.1126/science.278.5345.1904; FREDRIKSSON A, 1993, PHARMACOL TOXICOL, V72, P377; Gandhi M, 2004, ANNU REV PHARMACOL, V44, P499, DOI 10.1146/annurev.pharmtox.44.101802.121453; GARCIAMORALES P, 1994, J BIOL CHEM, V269, P16896; Gimenez-Llort L, 2001, ENVIRON TOXICOL PHAR, V9, P61, DOI 10.1016/S1382-6689(00)00060-0; Goyer RA, 1997, ANNU REV NUTR, V17, P37, DOI 10.1146/annurev.nutr.17.1.37; Grandjean P, 1998, ENVIRON RES, V77, P165, DOI 10.1006/enrs.1997.3804; Guha Mazumder Debendra N., 1998, International Journal of Epidemiology, V27, P871, DOI 10.1093/ije/27.5.871; Gulson BL, 1998, J LAB CLIN MED, V131, P324, DOI 10.1016/S0022-2143(98)90182-2; Gunshin H, 1997, NATURE, V388, P482, DOI 10.1038/41343; Guo HR, 2004, CANCER EPIDEM BIOMAR, V13, P638; Hellstrom L, 2001, AM J KIDNEY DIS, V38, P1001, DOI 10.1053/ajkd.2001.28589; Hopenhayn C, 2003, ENVIRON HEALTH PERSP, V111, P1888, DOI 10.1289/ehp.6254; HopenhaynRich C, 1996, ENVIRON HEALTH PERSP, V104, P1200, DOI 10.2307/3432913; Houston DK, 1999, NUTR REV, V57, P277; Hsueh YM, 2003, TOXICOL LETT, V137, P49, DOI 10.1016/S0378-4274(02)00380-6; Hsueh YM, 1998, J TOXICOL ENV HEAL A, V54, P431; Hultman P, 2001, J AUTOIMMUN, V17, P27, DOI 10.1006/jaut.2001.0521; Hunter FT, 1942, J PHARMACOL EXP THER, V76, P207; IARC, 2004, IARC MONOGRAPHS EVAL, V84; Jana K, 2006, REPROD BIOL ENDOCRIN, V4, DOI 10.1186/1477-7827-4-9; Jarup L, 2000, OCCUP ENVIRON MED, V57, P668, DOI 10.1136/oem.57.10.668; Jarup Lars, 1998, Scandinavian Journal of Work Environment and Health, V24, P1; Jin TY, 2004, BIOMETALS, V17, P525, DOI 10.1023/B:BIOM.0000045732.91261.e2; Johnson MD, 2003, NAT MED, V9, P1081, DOI 10.1038/nm902; Kadono T, 2002, INT J DERMATOL, V41, P841, DOI 10.1046/j.1365-4362.2002.01668.x; Keitt SK, 2004, ENVIRON HEALTH PERSP, V112, P604; KJELLSTROM T, 1986, CADMIUM HLTH TOXICOL, P257; Kligerman AD, 2003, ENVIRON MOL MUTAGEN, V42, P192, DOI 10.1002/em.10192; KOBAYASHI E, 2006, ENV RES; Korrick SA, 1999, AM J PUBLIC HEALTH, V89, P330, DOI 10.2105/AJPH.89.3.330; Leazer TM, 2002, TOXICOL APPL PHARM, V185, P18, DOI 10.1006/taap.2002.9505; Li AM, 2000, ARCH DIS CHILD, V83, P174, DOI 10.1136/adc.83.2.174; Liden C, 1996, BRIT J DERMATOL, V134, P193; Liden C, 2005, CONTACT DERMATITIS, V52, P29, DOI 10.1111/j.0105-1873.2005.00494.x; Liden C, 2001, CONTACT DERMATITIS, V44, P65, DOI 10.1034/j.1600-0536.2001.440201.x; Liden C, 2001, CONTACT DERMATITIS, V44, P160, DOI 10.1034/j.1600-0536.2001.044003160.x; Liden C, 2001, CONTACT DERMATITIS, V44, P7, DOI 10.1034/j.1600-0536.2001.440102.x; LIDEN C, 2000, HDB OCCUPATIONAL DER, P524; LIDEN S, 2006, CONTACT DERMATITIS, V54, P233; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; LINDGREN A, 1982, ACTA PHARMACOL TOX, V51, P253; Loffredo CA, 2003, ENVIRON RES, V92, P85, DOI 10.1016/S0013-9351(02)00081-6; LOPEZ S, 1990, J BIOL CHEM, V265, P16039; MAGOS L, 1981, ARCH TOXICOL, V48, P11, DOI 10.1007/BF00297071; Manton WI, 2003, ENVIRON RES, V92, P139, DOI 10.1016/S0013-9351(03)00020-3; Marks James G Jr, 2003, Am J Contact Dermat, V14, P59; Martin MB, 2002, ENDOCRINOLOGY, V143, P263, DOI 10.1210/en.143.1.263; Mazumder DNG, 2000, INT J EPIDEMIOL, V29, P1047, DOI 10.1093/ije/29.6.1047; MCKEOWNEYSSEN GE, 1983, AM J EPIDEMIOL, V118, P470; McRill C, 2000, J OCCUP ENVIRON MED, V42, P4, DOI 10.1097/00043764-200001000-00004; Meding B, 2001, CONTACT DERMATITIS, V45, P341, DOI 10.1034/j.1600-0536.2001.450604.x; Miettinen JK, 1973, MERCURY MERCURIALS M, P233; Miller MA, 2001, INT J TOXICOL, V20, P149, DOI 10.1080/109158101317097728; Miyazaki K, 2005, TOXICOLOGY, V208, P357, DOI 10.1016/j.tox.2004.11.030; Mocarelli P, 1996, LANCET, V348, P409, DOI 10.1016/S0140-6736(05)65030-1; Muldoon SB, 1996, NEUROEPIDEMIOLOGY, V15, P62, DOI 10.1159/000109891; Nagata C, 2005, CANCER EPIDEM BIOMAR, V14, P705, DOI 10.1158/1055-9965.EPI-04-0619; Nakamura K, 2002, INT J ONCOL, V20, P543; Nash D, 2003, JAMA-J AM MED ASSOC, V289, P1523, DOI 10.1001/jama.289.12.1523; Nesatyy VJ, 2005, ANALYST, V130, P1087, DOI 10.1039/b501192b; Niedhammer I, 2000, OCCUP ENVIRON MED, V57, P521, DOI 10.1136/oem.57.8.521; NIELSEN JB, 1991, PHARMACOL TOXICOL, V68, P208; Nielsen NH, 2002, BRIT J DERMATOL, V147, P487, DOI 10.1046/j.1365-2133.2002.04668.x; Nishijo M, 2004, MOL CELL BIOCHEM, V255, P87, DOI 10.1023/B:MCBI.0000007264.37170.39; National Research Council (NRC), 2001, ARS DRINK WAT; NRC, 2000, TOX EFF METH; Ogawa T, 2004, INT J ENVIRON HEAL R, V14, P243, DOI 10.1080/09603120410001725586; Olivieri G, 2002, NEUROSCIENCE, V113, P849, DOI 10.1016/S0306-4522(02)00211-7; Onalaja AO, 2000, ENVIRON HEALTH PERSP, V108, P23, DOI 10.2307/3454630; Pant N, 2001, BIOMETALS, V14, P113, DOI 10.1023/A:1016686113763; Payton M, 1998, NEUROTOXICOL TERATOL, V20, P19, DOI 10.1016/S0892-0362(97)00075-5; Petersson G. K., 2000, ARCH TOXICOL, V73, P519; Pillet S, 2005, TOXICOLOGY, V209, P289, DOI 10.1016/j.tox.2004.12.007; PILLET S, 2006, TOXICOL SCI; Pirkle JL, 1998, ENVIRON HEALTH PERSP, V106, P745, DOI 10.1289/ehp.98106745; Platz EA, 2002, PROSTATE, V52, P288, DOI 10.1002/pros.10115; Popovic M, 2005, ENVIRON HEALTH PERSP, V113, P478, DOI 10.1289/ehp.7386; POUNDS JG, 1991, ENVIRON HEALTH PERSP, V91, P17, DOI 10.2307/3430978; Pratt Melanie D, 2004, Dermatitis, V15, P176, DOI 10.2310/6620.2004.04038; Rahman M, 2006, J EPIDEMIOL COMMUN H, V60, P242, DOI 10.1136/jech.2005.040212; Regunathan A, 2003, TOXICOL APPL PHARM, V191, P272, DOI 10.1016/S0041-008X(03)00163-7; Rietschel Robert L, 2002, Am J Contact Dermat, V13, P170, DOI 10.1053/ajcd.2002.36635; Ris MD, 2004, J INT NEUROPSYCH SOC, V10, P261, DOI 10.1017/S1355617704102154; Rossi AD, 1997, EXP BRAIN RES, V117, P428, DOI 10.1007/s002210050237; RYBO G, 1966, ACTA OBSTET GYN SCAN, V45, P389; Sager P R, 1984, Brain Res, V314, P1; Sakamoto M, 2001, ENVIRON RES, V87, P92, DOI 10.1006/enrs.2001.4293; SARAFIAN T, 1991, INT J DEV NEUROSCI, V9, P147, DOI 10.1016/0736-5748(91)90005-7; Sarkar M, 2003, ASIAN J ANDROL, V5, P27; SCARPA M, 1987, P SOC EXP BIOL MED, V185, P129; Schwartz BS, 2000, NEUROLOGY, V55, P1144; Schwerdtle T, 2003, CARCINOGENESIS, V24, P967, DOI 10.1093/carcin/bgg018; Shen J, 2006, TOXICOL APPL PHARM, V210, P171, DOI 10.1016/j.taap.2005.04.018; Shoemaker PA, 2003, AM J PUBLIC HEALTH, V93, P1997, DOI 10.2105/AJPH.93.12.1997; SILBERGELD EK, 1988, ENVIRON RES, V47, P79, DOI 10.1016/S0013-9351(88)80023-9; Singer CA, 1998, NEUROREPORT, V9, P2565, DOI 10.1097/00001756-199808030-00025; Smith AH, 2000, ENVIRON HEALTH PERSP, V108, P617, DOI 10.2307/3434881; Smith AH, 1998, AM J EPIDEMIOL, V147, P660; Sogawa N, 2001, METHOD FIND EXP CLIN, V23, P395, DOI 10.1358/mf.2001.23.7.662127; Soo YOY, 2003, AM J KIDNEY DIS, V41, P250, DOI 10.1053/ajkd.2003.50017; Staessen JA, 1999, LANCET, V353, P1140, DOI 10.1016/S0140-6736(98)09356-8; Steinmaus C, 2005, CANCER EPIDEM BIOMAR, V14, P919, DOI 10.1158/1055-9965.EPI-04-0277; Stoica A, 2000, MOL ENDOCRINOL, V14, P545, DOI 10.1210/me.14.4.545; Stoica A, 2000, ENDOCRINOLOGY, V141, P3595, DOI 10.1210/endo.141.10.7704; Stromberg U, 2003, OCCUP ENVIRON MED, V60, P370, DOI 10.1136/oem.60.5.370; Sukocheva OA, 2005, ENVIRON TOXICOL, V20, P32, DOI 10.1002/tox.20075; Suwazono Y, 2000, ENVIRON RES, V84, P44, DOI 10.1006/enrs.2000.4086; SYMANSKI E, 1995, AM J EPIDEMIOL, V141, P1047; Tallkvist J, 2001, TOXICOL LETT, V122, P171, DOI 10.1016/S0378-4274(01)00363-0; Taskiran D, 1997, NEUROREPORT, V8, P881, DOI 10.1097/00001756-199703030-00013; THIRUMARAN RK, 2006, CARCINOGENESIS; THOMAS DJ, 1987, ENVIRON RES, V43, P203, DOI 10.1016/S0013-9351(87)80072-5; THOMAS DJ, 1986, ENVIRON RES, V41, P219, DOI 10.1016/S0013-9351(86)80184-0; Tsai SM, 1999, ARCH ENVIRON HEALTH, V54, P186; Tseng CH, 2005, TOXICOL APPL PHARM, V206, P299, DOI 10.1016/j.taap.2004.11.022; TSENG WP, 1977, ENVIRON HEALTH PERSP, V19, P109, DOI 10.2307/3428460; Uno T, 2005, SCAND J WORK ENV HEA, V31, P307; Uriu K, 2000, TOXICOL APPL PHARM, V164, P264, DOI 10.1006/taap.2000.8908; Usuki F, 2001, NEUROSCI LETT, V304, P199, DOI 10.1016/S0304-3940(01)01764-5; Vahter M, 2000, ENVIRON RES, V84, P186, DOI 10.1006/enrs.2000.4098; Vahter M, 2002, TOXICOLOGY, V181, P211, DOI 10.1016/S0300-483X(02)00285-8; Vahter M, 2002, ENVIRON RES, V88, P145, DOI 10.1006/enrs.2002.4338; Waalkes MP, 2003, TOXICOL APPL PHARM, V186, P7, DOI 10.1016/S0041-008X(02)00022-4; WALLKES MP, 2004, CARCINOGENESIS, V25, P133; Wang HF, 2003, J BONE MINER RES, V18, P553, DOI 10.1359/jbmr.2003.18.3.553; Wang SL, 2003, ENVIRON HEALTH PERSP, V111, P155, DOI 10.1289/ehp.5457; Watanabe C, 2001, ENVIRON HEALTH PERSP, V109, P1265, DOI 10.2307/3454749; *WHO, 1995, IN LEAD ENV HLTH CRI, V165; *WHO, 1991, IN MERC ENV HLTH CRI, V118; Wilson VS, 2004, TOXICOL SCI, V81, P69, DOI 10.1093/toxsci/kfh180; WU MM, 1989, AM J EPIDEMIOL, V130, P1123; Yang CY, 2005, ENVIRON RES, V98, P127, DOI 10.1016/j.envres.2004.07.013	176	281	290	11	68	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	MAY	2007	104	1					85	95		10.1016/j.envres.2006.08.003		11	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	166VQ	WOS:000246409200008	16996054	
J	Martin-Morales, A; Sanchez-Cruz, JJ; de Tejada, IS; Rodriguez-Vela, L; Jimenez-Cruz, JF; Burgos-Rodriguez, R				Martin-Morales, A; Sanchez-Cruz, JJ; de Tejada, IS; Rodriguez-Vela, L; Jimenez-Cruz, JF; Burgos-Rodriguez, R			Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina study	JOURNAL OF UROLOGY			English	Article						impotence; questionnaires; epidemiology; risk factors	MALE SEXUAL DYSFUNCTION; INTERNATIONAL INDEX; FUNCTION DOMAIN; SELF-ASSESSMENT; IMPOTENCE; ALCOHOLISM; SMOKING	Purpose: We determined the prevalence of and risks factors for erectile dysfunction in Spain in a cross-sectional study. Materials and Methods: A total of 2,476 noninstitutionalized Spanish men 25 to 70 years old were interviewed at home and answered a self-administered questionnaire of 71 items, including 2 instruments to define erectile dysfunction, a simple self-assessment question to estimate erectile function and the International Index of Erectile Function. Data on disease, medication and toxic habits were also obtained. Results: With an overall participation rate of 75% the prevalence of erectile dysfunction according to the simple question was 12.1%. According to the erectile function domain of the International Index of Erectile Function the overall prevalence was 18.9%. Several independent risk factors were significantly associated with the probability of erectile dysfunction. Some differences arose according to the tool used to define the condition. However, there was a strong relationship of patient age with frequency or severity no matter which instrument was used to define erectile dysfunction. Diabetes (age adjusted odds ratio 4), high blood pressure (odds ratio 1.58), high cholesterol (1.63), peripheral vascular disorder (2.63), lung disease (3.11), prostate disease (2.93), cardiac problems (1.79), rheumatism (2.37) and allergy (3.08) were significantly associated with erectile dysfunction. Drug intake, which respondents called medication for nerves and sleeping pills, correlated strongly (odds ratio 2.78 and 4.27, respectively), as did tobacco use (2.5) and alcohol consumption (1.53). Conclusions: This study provides data on the prevalence of and risks factors for erectile dysfunction in Spain. The relationship of erectile dysfunction with certain risk factors, such as cardiovascular risk factors and drugs intake, are well known and our study corroborates these associations. Other associations with erectile dysfunction, such as prostate disease, allergy and rheumatism, support findings in previous reports, although to our knowledge the pathophysiological mechanisms remain unclear. Estimating the strength of the association of erectile dysfunction with distinct risk factors in terms of odds ratios enabled us to identify the factors to pursue when seeking to prevent erectile dysfunction. Furthermore, the relationship of tobacco with erectile dysfunction, which has been controversial in previous series, was well characterized in our study.	Carlos Haya Hosp, Dept Urol, Malaga, Spain; Andalusian Sch Publ Hlth, Granada, Spain; Fdn Inves & Desarrollo Androl, Madrid, Spain; Spanish Urol Assoc, Madrid, Spain	Martin-Morales, A (reprint author), Carlos Haya Hosp, Dept Urol, Malaga, Spain.						AKKUS E, 2000, ESIR M BARC SPAIN; Aytac IA, 1999, BJU INT, V84, P50; BATISTA JE, 1993, 2 CONS BEN PROST HYP, P129; BENET AE, 1995, UROL CLIN N AM, V22, P699; BURNSCOX N, 1999, PRESCRIBER, V3, P77; Cappelleri JC, 2000, UROLOGY, V56, P477, DOI 10.1016/S0090-4295(00)00697-X; Cappelleri JC, 1999, UROLOGY, V54, P346, DOI 10.1016/S0090-4295(99)00099-0; CONDRA M, 1986, UROLOGY, V27, P495, DOI 10.1016/0090-4295(86)90326-2; Derby CA, 2000, INT J IMPOT RES, V12, P197, DOI 10.1038/sj.ijir.3900542; DOGUNRO S, 2000, ESIR M BARC SPAIN; DROLLER MJ, 1993, JAMA-J AM MED ASSOC, V270, P83; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; FELDMAN HA, 1994, J UROLOGY, V151, P54; GLASSER D, 1999, INT CONS ER DYSF PAR; HUSSAIN SS, 2000, EUR SOC IMP RES M BA; *I MUN INV MED, 1998, MAN PUNT VERS ESP CU; KADIRI N, 2000, ESIR M BARC SPAIN; Kayigil O., 1996, International Urology and Nephrology, V28, P717, DOI 10.1007/BF02552171; KOSKIMAKI K, 2000, ESIR M BARC SPAIN; LAPERA G, 2000, ESIR M BARC SPAIN; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; MAHMOUD KZ, 2000, ESIR M BARC SPAIN; MANNINO DM, 1994, AM J EPIDEMIOL, V140, P1003; Parazzini F, 2000, EUR UROL, V37, P43, DOI 10.1159/000020098; Rosen RC, 1997, UROLOGY, V49, P822, DOI 10.1016/S0090-4295(97)00238-0; SCHIAVI RC, 1990, J SEX MARITAL THER, V16, P23; VIBEPETESEN J, 2000, ESIR M BARC SPAIN; Ware J. E., 1993, SF 36 HLTH SURVEY MA; WEIN AJ, 1988, UROL CLIN N AM, V15, P23	29	278	291	1	13	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0022-5347			J UROLOGY	J. Urol.	AUG	2001	166	2					569	574		10.1016/S0022-5347(05)65986-1		6	Urology & Nephrology	Urology & Nephrology	451KE	WOS:000169800600046	11458070	
J	Dahl, R; Kapp, A; Colombo, G; deMonchy, JGR; Rak, S; Emminger, W; Rivas, MF; Ribel, M; Durham, SR				Dahl, Ronald; Kapp, Alexander; Colombo, Giselda; deMonchy, Jan G. R.; Rak, Sabina; Emminger, Waltraud; Rivas, Montserrat Fernandez; Ribel, Mette; Durham, Stephen R.			Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; grass pollen; immunotherapy; sublingual; rhinoconjunctivitis; tablet-based; double-blind; placebo-controlled; Phleum pratense	RANDOMIZED CONTROLLED-TRIAL; POLLEN IMMUNOTHERAPY; HAY-FEVER; RHINITIS; ASTHMA; METAANALYSIS; CHILDREN	Background: Allergen immunotherapy (desensitization) by injection is effective for seasonal allergic rhinitis and has been shown to induce long-term disease remission. The sublingual route also has potential, although definitive evidence from large randomized controlled trials has been lacking. Objective: The aim was to confirm the efficacy of a rapidly dissolving grass allergen tablet (GRAZAX, ALK-Abello, Horsholm, Denmark) compared with placebo in patients with seasonal rhinoconjunctivitis. Methods: A longitudinal, double-blind, placebo-controlled, parallel-group study that included 51 centers from 8 countries. Subjects were randomized (1:1) to receive a grass allergen tablet or placebo once daily. A total of 634 subjects with a history of grass pollen-induced rhinoconjunctivitis for at least 2 years and confirmation of IgE sensitivity (positive skin prick test and serum-specific IgE) were included in the study. Subjects commenced treatment at least 16 weeks before the grass pollen season, and treatment was continued throughout the entire season. Results: The primary efficacy analysis showed a reduction of 30% in rhinoconjunctivitis symptom score (P < .0001) and a reduction of 38% in rhinoconjunctivitis medication score (P < .0001) compared with placebo. Side effects mainly comprised mild itching and swelling in the mouth that was in general well tolerated and led to treatment withdrawal in less than 4% of participants. There were no serious local side effects and no severe systemic adverse events. Conclusion: Sublingual immunotherapy with grass allergen tablets was effective in grass pollen-induced rhinoconjunctivitis. The tablet was well tolerated with minor local side effects. Clinical implications: The grass allergen tablet represents a safe alternative to injection immunotherapy suitable for home use.	Royal Brompton Hosp,Imperial Coll, MRC & Asthma UK Ctr Allerg Mech Asthma, Allergy & Clin Immunol Sect, Natl Heart & Lung Inst, London SW3 6LY, England; Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark; Hannover Med Univ, Dept Dermatol & Allergol, Hannover, Germany; Osped San Raffaele, I-20127 Milan, Italy; Univ Groningen, Div Allergol, NL-9700 AB Groningen, Netherlands; Sahlgrenska Univ Hosp, Sect Allergy, Gothenburg, Sweden; Allergie Ambulatorium Rennweg, Vienna, Austria; Fdn Hosp Alcorcon, Madrid, Spain; ALK Abello AS, Grp Clin Dev, Horsholm, Denmark	Durham, SR (reprint author), Royal Brompton Hosp,Imperial Coll, MRC & Asthma UK Ctr Allerg Mech Asthma, Allergy & Clin Immunol Sect, Natl Heart & Lung Inst, Guy Scadding Bldg,Royal Brompton Campus,Dovehouse, London SW3 6LY, England.	s.durham@imperial.ac.uk	Dahl, Ronahl/F-8170-2013				Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2004, RESP MED, V98, P398, DOI 10.1016/j.rmed.2003.11.015; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Malling HJ, 2002, CURR OPIN ALLERGY CL, V2, P523, DOI 10.1097/01.all.0000044538.45448.80; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P31, DOI 10.1097/00130832-200402000-00007; Passalacqua Giovanni, 2003, Curr Opin Allergy Clin Immunol, V3, P139, DOI 10.1097/00130832-200304000-00008; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Roches Anne Des, 1997, Journal of Allergy and Clinical Immunology, V99, P450; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; VARNEY VA, 1991, BRIT MED J, V302, P265; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; White P, 1998, CLIN EXP ALLERGY, V28, P266; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	21	277	280	0	16	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					434	440		10.1016/j.jaci.2006.05.003		7	Allergy; Immunology	Allergy; Immunology	075IH	WOS:000239877700020	16890769	
J	Sicherer, SH; Sampson, HA				Sicherer, Scott H.; Sampson, Hugh A.			Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Food allergy; food hypersensitivity; oral tolerance; gastrointestinal food hypersensitivity; food allergens; anaphylaxis	SKIN PRICK TEST; COWS MILK ALLERGY; RED MEAT ALLERGY; QUALITY-OF-LIFE; ARA H 2; INDUCED ENTEROCOLITIS SYNDROME; PROSPECTIVE BIRTH COHORT; LONG-TERM OUTCOMES; PEANUT ALLERGY; EGG ALLERGY	This review focuses on advances and updates in the epidemiology, pathogenesis, diagnosis, and treatment of food allergy over the past 3 years since our last comprehensive review. On the basis of numerous studies, food allergy likely affects nearly 5% of adults and 8% of children, with growing evidence of an increase in prevalence. Potentially rectifiable risk factors include vitamin D insufficiency, unhealthful dietary fat, obesity, increased hygiene, and the timing of exposure to foods, but genetics and other lifestyle issues play a role as well. Interesting clinical insights into pathogenesis include discoveries regarding gene-environment interactions and an increasing understanding of the role of nonoral sensitizing exposures causing food allergy, such as delayed allergic reactions to carbohydrate moieties in mammalian meats caused by sensitization from homologous substances transferred during tick bites. Component-resolved diagnosis is being rapidly incorporated into clinical use, and sophisticated diagnostic tests that indicate severity and prognosis are on the horizon. Current management relies heavily on avoidance and emergency preparedness, and recent studies, guidelines, and resources provide insight into improving the safety and well-being of patients and their families. Incorporation of extensively heated (heat-denatured) forms of milk and egg into the diets of children who tolerate these foods, rather than strict avoidance, represents a significant shift in clinical approach. Recommendations about the prevention of food allergy and atopic disease through diet have changed radically, with rescinding of many recommendations about extensive and prolonged allergen avoidance. Numerous therapies have reached clinical trials, with some showing promise to dramatically alter treatment. Ongoing studies will elucidate improved prevention, diagnosis, and treatment.	[Sicherer, Scott H.; Sampson, Hugh A.] Kravis Childrens Hosp, Dept Pediat, Icahn Sch Med Mt Sinai, Elliot & Roslyn Jaffe Food Allergy Inst,Div Aller, New York, NY USA	Sicherer, SH (reprint author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu			Novartis; Food Allergy Research Education; National Institute of Allergy and Infectious Diseases (NIAID); NIAID/National Institutes of Health; Allertein Therapeutics; Regeneron; Thermo Fisher Scientific; UCB; Pfizer	S. H. Sicherer is on the American Board of Allergy and Immunology; has received consultancy fees from Novartis and Food Allergy Research & Education; has received research support from the National Institute of Allergy and Infectious Diseases (NIAID) and Food Allergy Research & Education; and receives royalties from UpToDate. H. A. Sampson has received research support from the NIAID/National Institutes of Health and Food Allergy Research & Education; has received travel support as Chair of the PhARF Award review committee; has received consultancy fees from Allertein Therapeutics and Regeneron; and has received lecture fees from Thermo Fisher Scientific, UCB, and Pfizer.	Alessandri C, 2012, CLIN EXP ALLERGY, V42, P441, DOI 10.1111/j.1365-2222.2011.03915.x; Allen KJ, 2013, J ALLERGY CLIN IMMUN, V131, P1109, DOI 10.1016/j.jaci.2013.01.017; Allen K.J., 2013, J ALLERGY CLIN IMMUN; Alonzi C, 2011, J ALLERGY CLIN IMMUN, V127, P1627, DOI 10.1016/j.jaci.2011.01.050; Amoah AS, 2013, J ALLERGY CLIN IMMUN, V132, P639, DOI 10.1016/j.jaci.2013.04.023; Asai Y, 2013, J ALLERGY CLIN IMMUN, V132, P239, DOI 10.1016/j.jaci.2013.03.043; Asarnoj A, 2012, INT ARCH ALLERGY IMM, V159, P209, DOI 10.1159/000336027; Asarnoj A, 2012, J ALLERGY CLIN IMMUN, V130, P468, DOI 10.1016/j.jaci.2012.05.019; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Ayuso R, 2012, CLIN EXP ALLERGY, V42, P293, DOI 10.1111/j.1365-2222.2011.03920.x; Ayuso R, 2010, J ALLERGY CLIN IMMUN, V125, P1286, DOI 10.1016/j.jaci.2010.03.010; Bartnikas LM, 2013, J ALLER CL IMM-PRACT, V1, P354, DOI 10.1016/j.jaip.2013.04.002; Begin P, 2011, J ALLERGY CLIN IMMUN, V127, P1624, DOI 10.1016/j.jaci.2011.01.028; Ben-Shoshan M, 2012, J ALLERGY CLIN IMMUN, V129, P1401, DOI 10.1016/j.jaci.2012.01.078; Berin M. C., 2008, Journal of Allergy and Clinical Immunology, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Berin MC, 2013, TRENDS IMMUNOL, V34, P390, DOI 10.1016/j.it.2013.04.003; Berin MC, 2013, CURR BIOL, V23, pR389, DOI 10.1016/j.cub.2013.02.043; Berin MC, 2013, J ALLERGY CLIN IMMUN, V131, P14, DOI 10.1016/j.jaci.2012.10.058; Berni CR, 2013, J PEDIAT, V163, P771, DOI DOI 10.1016/J.JPEDS.2013.03.008; Berns SH, 2007, J ASTHMA, V44, P377, DOI 10.1080/02770900701364031; Blom WM, 2013, J ALLERGY CLIN IMMUN, V131, P172, DOI 10.1016/j.jaci.2012.10.034; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boyce J. A., 2010, Journal of Allergy and Clinical Immunology, V126, pS1; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Burks AW, 2012, J ALLERGY CLIN IMMUN, V129, P906, DOI 10.1016/j.jaci.2012.02.001; Burks AW, 2014, J ALLERGY CLIN IMMUN, V133, P318; Camargo CA, 2013, J ALLER CL IMM-PRACT, V1, P266, DOI 10.1016/j.jaip.2013.02.004; Caubet JC, 2012, J ALLERGY CLIN IMMUN, V129, P739, DOI 10.1016/j.jaci.2011.11.053; Caubet JC, 2013, J ALLERGY CLIN IMMUN, V131, P222, DOI 10.1016/j.jaci.2012.06.049; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Chapman JA, 2006, ANN ALLERG ASTHMA IM, V96, pS1; Commins SP, 2013, CURR ALLERGY ASTHM R, V13, P72, DOI 10.1007/s11882-012-0315-y; Crotty MP, 2010, J ALLERGY CLIN IMMUN, V125, P935, DOI 10.1016/j.jaci.2009.12.003; D'Urbano LE, 2010, CLIN EXP ALLERGY, V40, P1561, DOI 10.1111/j.1365-2222.2010.03568.x; Dang TD, 2012, J ALLERGY CLIN IMMUN, V129, P1056, DOI 10.1016/j.jaci.2012.01.056; DeBrosse CW, 2011, J ALLERGY CLIN IMMUN, V128, P132, DOI 10.1016/j.jaci.2011.05.006; Des Roches A, 2012, J ALLERGY CLIN IMMUN, V130, P1213, DOI 10.1016/j.jaci.2012.07.046; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Ebisawa M, 2013, J ALLERGY CLIN IMMUN, V132, P976, DOI 10.1016/j.jaci.2013.04.028; Elizur A, 2012, J PEDIATR-US, V161, P482, DOI 10.1016/j.jpeds.2012.02.028; Federly TJ, 2013, ANN ALLERG ASTHMA IM, V111, P20, DOI 10.1016/j.anai.2013.05.012; Fiocchi Alessandro, 2012, World Allergy Organ J, V5, P148, DOI 10.1097/WOX.0b013e3182784ee0; Fiocchi A, 2010, J ALLERGY CLIN IMMUN, V126, P1119, DOI 10.1016/j.jaci.2010.10.011; Fleischer DM, 2013, J ALLER CL IMM-PRACT, V1, P29, DOI 10.1016/j.jaip.2012.09.003; Fleischer DM, 2011, J PEDIATR-US, V158, P578, DOI 10.1016/j.jpeds.2010.09.027; Flinterman AE, 2010, CLIN EXP ALLERGY, V40, P590, DOI 10.1111/j.1365-2222.2009.03431.x; Ford LS, 2013, J ALLERGY CLIN IMMUN, V131, P180, DOI 10.1016/j.jaci.2012.06.003; Ford LS, 2010, J ALLERGY CLIN IMMUN, V126, P384, DOI 10.1016/j.jaci.2010.05.034; Forsberg A, 2013, CLIN EXP ALLERGY, V43, P434, DOI 10.1111/cea.12082; Dunn Galvin A, 2011, J ALLERGY CLIN IMMUN, V127, P633; Galvin AD, 2013, J ALLERGY CLIN IMMUN, V131, P230; Gao ZS, 2013, J ALLERGY CLIN IMMUN, V131, P224, DOI 10.1016/j.jaci.2012.07.015; Glaumann S, 2012, ALLERGY, V67, P242, DOI 10.1111/j.1398-9995.2011.02754.x; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grimshaw KE, 2013, J ALLERGY CLIN IMMUN; Gupta R, 2013, JAMA PEDIATR, V167, P1026, DOI 10.1001/jamapediatrics.2013.2376; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V126, P33, DOI 10.1016/j.jaci.2010.03.014; Hamsten C, 2013, ALLERGY, V68, P549, DOI 10.1111/all.12128; Hamsten C, 2013, J ALLERGY CLIN IMMUN, V132, P1431, DOI 10.1016/j.jaci.2013.07.050; Haneda Y, 2012, J ALLERGY CLIN IMMUN, V129, P1681, DOI 10.1016/j.jaci.2012.03.041; Henderson CJ, 2012, J ALLERGY CLIN IMMUN, V129, P1570, DOI 10.1016/j.jaci.2012.03.023; Hormannsperger G, 2012, J ALLERGY CLIN IMMUN, V129, P1452, DOI 10.1016/j.jaci.2011.12.993; Hong XM, 2011, J ALLERGY CLIN IMMUN, V128, P374, DOI 10.1016/j.jaci.2011.05.007; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Hu Y, 2010, PEDIATR INT, V52, P820, DOI 10.1111/j.1442-200X.2010.03166.x; Hylander T, 2013, J ALLERGY CLIN IMMUN, V131, P412, DOI 10.1016/j.jaci.2012.10.056; Ilchmann A, 2010, J ALLERGY CLIN IMMUN, V125, P175, DOI 10.1016/j.jaci.2009.08.013; Jackson Kristen D, 2013, NCHS Data Brief, P1; Jarvinen KM, 2013, J ALLER CL IMM-PRACT, V1, P317, DOI 10.1016/j.jaip.2013.04.004; Jarvinen KM, 2012, ANN ALLERG ASTHMA IM, V109, P221, DOI 10.1016/j.anai.2012.06.020; Jensen MP, 2012, J ALLERGY CLIN IMMUN, V130, P1209, DOI 10.1016/j.jaci.2012.07.018; Jones SM, 2013, J ALLERGY CLIN IMMUN, V131, P3, DOI 10.1016/j.jaci.2012.11.012; Joseph CLM, 2011, J ALLERGY CLIN IMMUN, V127, P1203, DOI 10.1016/j.jaci.2011.02.018; Jouvin MH, 2012, J ALLERGY CLIN IMMUN, V130, P3, DOI 10.1016/j.jaci.2012.05.028; Jyonouchi S, 2011, J ALLERGY CLIN IMMUN, V128, P102, DOI 10.1016/j.jaci.2011.02.026; Kagalwalla AF, 2011, J PEDIATR GASTR NUTR, V53, P145, DOI 10.1097/MPG.0b013e31821cf503; Katz Y, 2011, J ALLERGY CLIN IMMUN, V127, P647, DOI 10.1016/j.jaci.2010.12.1105; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Keet CA, 2013, J ALLER CL IMM-PRACT, V1, P101, DOI 10.1016/j.jaip.2012.08.007; Keet CA, 2012, J ALLERGY CLIN IMMUN, V130, P1207, DOI 10.1016/j.jaci.2012.07.020; Keet CA, 2012, J ALLERGY CLIN IMMUN, V129, P169, DOI 10.1016/j.jaci.2011.10.002; Kelso JM, 2013, ANN ALLERG ASTHMA IM, V111, P301, DOI 10.1016/j.anai.2013.07.030; Kennedy JL, 2013, PEDIATRICS, V131, pE1545, DOI 10.1542/peds.2012-2585; Khodoun MV, 2013, J ALLERGY CLIN IMMUN, V131, P1555, DOI 10.1016/j.jaci.2013.02.043; Kim JS, 2011, J ALLERGY CLIN IMMUN, V128, P125, DOI 10.1016/j.jaci.2011.04.036; Klemans RJB, 2013, J ALLERGY CLIN IMMUN, V131, P157, DOI 10.1016/j.jaci.2012.08.010; Kollmann D, 2013, J ALLERGY CLIN IMMUN, V132, P1008, DOI 10.1016/j.jaci.2013.05.030; Koplin JJ, 2012, ALLERGY, V67, P1415, DOI 10.1111/all.12015; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kotz D, 2011, J ALLERGY CLIN IMMUN, V127, P623, DOI 10.1016/j.jaci.2010.11.021; Kuitunen M, 2013, CURR OPIN ALLERGY CL, V13, P280, DOI 10.1097/ACI.0b013e328360ed66; Kumar S, 2013, IMMUNOL LETT, V149, P101, DOI 10.1016/j.imlet.2012.12.003; Kuo HC, 2011, INT ARCH ALLERGY IMM, V154, P310, DOI 10.1159/000321823; Kusunoki T, 2012, PEDIAT ALLERG IMM-UK, V23, P250, DOI 10.1111/j.1399-3038.2011.01246.x; Lack G, 2012, J ALLERGY CLIN IMMUN, V129, P1187, DOI 10.1016/j.jaci.2012.02.036; Le TM, 2013, J ALLERGY CLIN IMMUN, V131, P164, DOI 10.1016/j.jaci.2012.09.009; Leischer DM, 2012, PEDIATRICS, V130, pe25; Leonard SA, 2012, J ALLERGY CLIN IMMUN, V130, P473, DOI 10.1016/j.jaci.2012.06.006; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Liacouras C, 2011, J ALLERGY CLIN IMMUN, V128, P3, DOI 10.1016/j.jaci.2011.02.040; Lieberman JA, 2013, J ALLER CL IMM-PRACT, V1, P75, DOI 10.1016/j.jaip.2012.11.002; Lieberman JA, 2012, J ALLERGY CLIN IMMUN, V129, P1682, DOI 10.1016/j.jaci.2012.04.007; Lieberman JA, 2011, J ALLERGY CLIN IMMUN, V128, P1120, DOI 10.1016/j.jaci.2011.07.012; Lieberman JA, 2011, CURR OPIN ALLERGY CL, V11, P236, DOI 10.1097/ACI.0b013e3283464cf0; Lieberman JA, 2010, ANN ALLERG ASTHMA IM, V105, P282, DOI 10.1016/j.anai.2010.07.011; Lin J, 2012, J ALLERGY CLIN IMMUN, V129, P1321, DOI 10.1016/j.jaci.2012.02.012; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Liu X, 2011, ALLERGY, V66, P1442, DOI 10.1111/j.1398-9995.2011.02681.x; Liu Y, 2013, J ALLERGY CLIN IMMUN, V131, P213, DOI 10.1016/j.jaci.2012.10.018; de Oliveira LCL, 2013, J ALLER CL IMM-PRACT, V1, P394, DOI 10.1016/j.jaip.2013.05.010; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; Lucendo AJ, 2013, J ALLERGY CLIN IMMUN, V131, P797, DOI 10.1016/j.jaci.2012.12.664; Ma SK, 2013, J ALLERGY CLIN IMMUN, V132, P764, DOI 10.1016/j.jaci.2013.04.017; Maloney JM, 2011, J ALLERGY CLIN IMMUN, V128, P214, DOI 10.1016/j.jaci.2011.04.024; Marrs T, 2013, PEDIAT ALLERG IMM-UK, V24, DOI 10.1111/pai.12064; Masilamani M, 2011, J ALLERGY CLIN IMMUN, V128, P1242, DOI 10.1016/j.jaci.2011.05.009; Maslova E, 2012, J ALLERGY CLIN IMMUN, V130, P724, DOI 10.1016/j.jaci.2012.05.014; Masthoff LJN, 2013, J ALLERGY CLIN IMMUN, V132, P393, DOI 10.1016/j.jaci.2013.02.024; McGowan EC, 2013, J ALLERGY CLIN IMMUN, V132, P1216, DOI 10.1016/j.jaci.2013.07.018; Mehl A, 2005, ALLERGY, V60, P1034, DOI 10.1111/j.1398-9995.2005.00806.x; Mullins RJ, 2012, J ALLERGY CLIN IMMUN, V129, P1334, DOI 10.1016/j.jaci.2012.02.038; Nadeau KC, 2011, J ALLERGY CLIN IMMUN, V127, P1622, DOI 10.1016/j.jaci.2011.04.009; Nakamura R, 2013, J ALLERGY CLIN IMMUN, V132, P1426; Neuman-Sunshine DL, 2012, ANN ALLERG ASTHMA IM, V108, P326, DOI 10.1016/j.anai.2011.11.010; Nicolaou N, 2011, J ALLERGY CLIN IMMUN, V127, P684, DOI 10.1016/j.jaci.2010.12.012; Nicolaou N, 2010, J ALLERGY CLIN IMMUN, V125, P191, DOI 10.1016/j.jaci.2009.10.008; Niggemann B, 2012, J ALLERGY CLIN IMMUN, V130, P261, DOI 10.1016/j.jaci.2012.03.021; Noval RM, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI DOI 10.1016/J.JACI.2012.10.026; Nowak-Wegrzyn A, 2011, J ALLERGY CLIN IMMUN, V127, P558, DOI 10.1016/j.jaci.2010.12.1098; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Nwaru BI, 2013, ALLERGY, V68, P507, DOI 10.1111/all.12118; Nwaru BI, 2013, J ALLERGY CLIN IMMUN, V131, P78, DOI 10.1016/j.jaci.2012.10.028; Nwaru BI, 2010, PEDIATR ALLERGY IMMU, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Osborn DA, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006474.pub3; Osborne NJ, 2012, J ALLERGY CLIN IMMUN, V129, P865, DOI 10.1016/j.jaci.2012.01.037; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Oyoshi MK, 2014, J ALLERGY CLIN IMMUN, V133, P309, DOI 10.1016/j.jaci.2013.12.1045; Pahr S, 2013, J ALLERGY CLIN IMMUN, V132, P1000, DOI 10.1016/j.jaci.2013.05.016; Park JH, 2011, J ALLERGY CLIN IMMUN, V128, P1127, DOI 10.1016/j.jaci.2011.08.026; Patel DA, 2011, J ALLERGY CLIN IMMUN, V128, P110, DOI 10.1016/j.jaci.2011.03.013; Patil SP, 2011, J ALLERGY CLIN IMMUN, V128, P1259, DOI 10.1016/j.jaci.2011.06.015; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Peeters KABM, 2011, INT ARCH ALLERGY IMM, V155, P23, DOI 10.1159/000318654; Peters RL, 2013, J ALLERGY CLIN IMMUN, V132, P874, DOI 10.1016/j.jaci.2013.05.038; Pfefferle PI, 2013, J ALLERGY CLIN IMMUN, V131, P1453, DOI 10.1016/j.jaci.2013.03.020; Pongracic JA, 2012, J ALLERGY CLIN IMMUN, V129, P564, DOI 10.1016/j.jaci.2011.09.024; Posthumus J, 2013, J ALLERGY CLIN IMMUN, V131, P923, DOI 10.1016/j.jaci.2012.12.665; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Resnick ES, 2010, ANN ALLERG ASTHMA IM, V105, P364, DOI 10.1016/j.anai.2010.09.006; Rinaldi M, 2012, J ALLERGY CLIN IMMUN, V130, P945, DOI 10.1016/j.jaci.2012.07.042; Ruffner MA, 2013, J ALLER CL IMM-PRACT, V1, P343, DOI 10.1016/j.jaip.2013.05.011; Ruiter B, 2012, J ALLERGY CLIN IMMUN, V129, P921, DOI 10.1016/j.jaci.2012.01.080; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, J ALLERGY CLIN IMMUN; Sampson HA, 2011, J ALLERGY CLIN IMMUN, V127, P1309, DOI 10.1016/j.jaci.2011.01.051; Sato S, 2011, INT ARCH ALLERGY IMM, V155, P96, DOI 10.1159/000327490; Savage JH, 2012, J ALLERGY CLIN IMMUN, V130, P453, DOI 10.1016/j.jaci.2012.05.006; Savage JH, 2010, J ALLERGY CLIN IMMUN, V125, P683, DOI 10.1016/j.jaci.2009.12.994; Savilahti EM, 2010, J ALLERGY CLIN IMMUN, V125, P1315, DOI 10.1016/j.jaci.2010.03.025; Schneider L, 2013, J ALLERGY CLIN IMMUN, V131, P295, DOI 10.1016/j.jaci.2012.12.672; Schneider LC, 2013, J ALLERGY CLIN IMMUN, V132, P1368, DOI 10.1016/j.jaci.2013.09.046; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Sheehan WJ, 2009, J ALLERGY CLIN IMMUN, V124, P850, DOI 10.1016/j.jaci.2009.06.044; Shemesh E, 2013, PEDIATRICS, V131, pE10, DOI 10.1542/peds.2012-1180; Sicherer SH, 2007, PEDIATRICS, V119, P638, DOI 10.1542/peds.2006-3689; Sicherer SH, 2013, J ALLER CL IMM-PRACT, V1, P1, DOI 10.1016/j.jaip.2012.10.004; Sicherer SH, 2012, J PEDIATR-US, V160, P651, DOI 10.1016/j.jpeds.2011.09.056; Sicherer SH, 2012, PEDIATRICS, V129, P193, DOI 10.1542/peds.2011-2382; Sicherer SH, 2011, J ALLERGY CLIN IMMUN, V127, P594, DOI 10.1016/j.jaci.2010.11.044; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, PEDIATRICS, V126, P1232, DOI 10.1542/peds.2010-2575; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1322, DOI 10.1016/j.jaci.2010.03.029; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Simons E, 2013, J ALLER CL IMM-PRACT, V1, P309, DOI 10.1016/j.jaip.2013.02.001; Simons E, 2012, ANN ALLERG ASTHMA IM, V108, P321, DOI 10.1016/j.anai.2012.03.004; Soller L, 2012, J ALLERGY CLIN IMMUN, V130, P986, DOI 10.1016/j.jaci.2012.06.029; Spergel JM, 2012, J ALLERGY CLIN IMMUN, V130, P461, DOI 10.1016/j.jaci.2012.05.021; Tan HTT, 2012, J ALLERGY CLIN IMMUN, V130, P1211, DOI 10.1016/j.jaci.2012.07.022; Tey D, 2012, CLIN EXP ALLERGY, V42, P1782, DOI 10.1111/j.1365-2222.2012.04061.x; Untersmayr E, 2008, J ALLERGY CLIN IMMUN, V121, P1301, DOI 10.1016/j.jaci.2008.04.025; van der Velde JL, 2012, J ALLERGY CLIN IMMUN, V130, P1136, DOI 10.1016/j.jaci.2012.05.037; van der Zee T, 2011, J ALLERGY CLIN IMMUN, V128, P1031, DOI 10.1016/j.jaci.2011.07.050; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011; Vassallo MF, 2010, ANN ALLERG ASTHMA IM, V104, P307, DOI 10.1016/j.anai.2010.01.019; Vereda A, 2011, J ALLERGY CLIN IMMUN, V127, P603, DOI 10.1016/j.jaci.2010.09.010; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; Wainstein BK, 2010, PEDIAT ALLERG IMM-UK, V21, P603, DOI 10.1111/j.1399-3038.2010.01063.x; Wang JL, 2011, J ALLERGY CLIN IMMUN, V128, P834, DOI 10.1016/j.jaci.2011.07.045; Wang J, 2010, J ALLERGY CLIN IMMUN, V125, P695, DOI 10.1016/j.jaci.2009.12.017; Weisse K, 2013, ALLERGY, V68, P220, DOI 10.1111/all.12081; Wood RA, 2013, ALLERGY, V68, P803, DOI 10.1111/all.12158; Wood RA, 2013, J ALLERGY CLIN IMMUN, V131, P805, DOI 10.1016/j.jaci.2012.10.060; Yang AC, 2010, J ALLERGY CLIN IMMUN, V125, P872, DOI 10.1016/j.jaci.2009.11.043; Yu LCH, 2001, GASTROENTEROLOGY, V121, P370, DOI 10.1053/gast.2001.26470	199	275	296	35	227	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2014	133	2					291	+		10.1016/j.jaci.2013.11.020		22	Allergy; Immunology	Allergy; Immunology	AC3EF	WOS:000332397100001	24388012	
J	Brightling, CE; Monteiro, W; Ward, R; Parker, D; Morgan, MDL; Wardlaw, AJ; Pavord, ID				Brightling, CE; Monteiro, W; Ward, R; Parker, D; Morgan, MDL; Wardlaw, AJ; Pavord, ID			Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial	LANCET			English	Article							AIR-FLOW OBSTRUCTION; INHALED CORTICOSTEROIDS; AIRWAYS OBSTRUCTION; CHRONIC-BRONCHITIS; ASTHMA; INFLAMMATION; SMOKERS; COPD; BUDESONIDE; MILD	Background Some patients wit chronic obstructive pulmonary disease (COPD) respond toe corticosteroid therapy. Whether these patients have different airway pathology from other COPD patients is unclear. We tested the hypothesis that response to prednisolone is related to the presence of eosinophilic airway inflammation. Methods We did a randomised, double-blind, crossover trial. Patients who had COPD treated with bronchodilators only were assigned placebo and 30 mg prednisolone daily for 2 weeks each, in a random order, separated by a 4-week washout period. Before and after each treatment period, we assessed patients with spirometry, symptom scores, the chronic respiratory disease questionnaire (CRQ), incremental shuttle walk test, and induced sputum. Analysis was done by intention to treat. Findings 83 patients were recruited, of whom 67 were randomised. The geometric mean sputum eosinophil count fell significantly after prednisolone (from 2.4% to 0.4%; mean difference six-fold [95% CI 3.1-11.4]) but not after placebo. Other sputum cell counts did not change. After stratification into tertiles by baseline eosinophil count, postbronchodilator forced expiratory volume in 1 s (FEV1) and total scores on the CRQ improved progressively after prednisolone from the lowest to the highest eosinophilic tertile, compared with placebo. The mean change in postbronchodilator FEV1, total CRQ score, and shuttle walk distance with prednisolone compared with placebo in the highest tertile was 0.19 L (0.06-0.32), 0.62 (0.31-0.93), and 20 m (5-35), respectively. Interpretation Our findings suggest that eosinophilic airway inflammation contributes to airflow obstruction and symptoms in some patients with COPD and that the short-term effects of prednisolone are due to modification of this feature of the inflammatory response. The possibility that sputum eosinophilia identifies a subgroup of patients who particularly respond to long-term treatment with inhaled corticosteroids should be investigated.	Glenfield Gen Hosp, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	Brightling, CE (reprint author), Glenfield Gen Hosp, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.						Barnes NC, 1998, LANCET, V351, P766, DOI 10.1016/S0140-6736(98)22011-3; Boushey HA, 1999, NEW ENGL J MED, V340, P1990, DOI 10.1056/NEJM199906243402509; Brightling CE, 1999, EUR RESPIR J, V14, P1228, DOI 10.1183/09031936.99.14512289; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406; *BRIT THOR SOC, 1997, THORAX S1, V52, P9; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley PMA, 1999, THORAX, V54, P3; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; CLIFTON M, 1962, LANCET, V1, P1311; Confalonieri M, 1998, THORAX, V53, P583; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277; GUYATT GH, 1987, THORAX, V136, P1285; Hunter CJ, 1999, RESP MED, V93, P345, DOI 10.1016/S0954-6111(99)90317-7; JANOFF A, 1983, AM REV RESPIR DIS, V127, P540; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Matsumoto K, 1998, EUR RESPIR J, V12, P387, DOI 10.1183/09031936.98.12020387; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pavord ID, 1997, THORAX, V52, P498; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511; PIZZICHINI E, 1996, AM J RESP CRIT CARE, V154, P808; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; SHIM C, 1978, J ALLERGY CLIN IMMUN, V62, P363, DOI 10.1016/0091-6749(78)90137-9; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; TWEEDDALE PM, 1987, THORAX, V42, P87; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112	29	275	288	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 28	2000	356	9240					1480	1485		10.1016/S0140-6736(00)02872-5		6	Medicine, General & Internal	General & Internal Medicine	367NA	WOS:000090067300012	11081531	
J	Lambrecht, BN; Hammad, H				Lambrecht, Bart N.; Hammad, Hamida			The airway epithelium in asthma	NATURE MEDICINE			English	Review							HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; RESPIRATORY SYNCYTIAL VIRUS; EPIDERMAL-GROWTH-FACTOR; PROTEASE-ACTIVATED RECEPTOR-2; INFLAMMATORY DENDRITIC CELLS; ALLERGIC LUNG INFLAMMATION; INNATE IMMUNE-RESPONSES; FACTOR-KAPPA-B; IN-VIVO	Asthma is a T lymphocyte-controlled disease of the airway wall caused by inflammation, overproduction of mucus and airway wall remodeling leading to bronchial hyperreactivity and airway obstruction. The airway epithelium is considered an essential controller of inflammatory, immune and regenerative responses to allergens, viruses and environmental pollutants that contribute to asthma pathogenesis. Epithelial cells express pattern recognition receptors that detect environmental stimuli and secrete endogenous danger signals, thereby activating dendritic cells and bridging innate and adaptive immunity. Improved understanding of the epithelium's function in maintaining the integrity of the airways and its dysfunction in asthma has provided important mechanistic insight into how asthma is initiated and perpetuated and could provide a framework by which to select new therapeutic strategies that prevent exacerbations and alter the natural course of the disease.	[Lambrecht, Bart N.; Hammad, Hamida] VIB, Dept Mol Biomed Res, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium; [Lambrecht, Bart N.] Univ Hosp, Dept Resp Med, Ghent, Belgium; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Lambrecht, BN (reprint author), VIB, Dept Mol Biomed Res, Lab Immunoregulat & Mucosal Immunol, Ghent, Belgium.	bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834	Flemish Organization for Scientific Research (FWO); ERC; UGent; National Institutes of Health [5R21AI083690-02]	B.N.L. is a recipient of an Odysseus Grant of the Flemish Organization for Scientific Research (FWO) and recipient of an ERC Consolidator grant and a UGent Multidisciplinary Research Partnership grant (Group-ID). H.H. and B.N.L. are supported by National Institutes of Health grant 5R21AI083690-02. H.H. is a recipient of an FWO program grant.	Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; Agresti A, 2003, BIOCHEM BIOPH RES CO, V302, P421, DOI 10.1016/S0006-291X(03)00184-0; Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Ather JL, 2011, J IMMUNOL, V187, P64, DOI 10.4049/jimmunol.1100500; Ather JL, 2011, AM J RESP CELL MOL, V44, P631, DOI 10.1165/rcmb.2010-0106OC; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Bleck B, 2006, J IMMUNOL, V176, P7431; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Busse WW, 2010, LANCET, V376, P826, DOI 10.1016/S0140-6736(10)61380-3; Cantero-Recasens G, 2010, HUM MOL GENET, V19, P111, DOI 10.1093/hmg/ddp471; Cates EC, 2004, J IMMUNOL, V173, P6384; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Chen G, 2010, J IMMUNOL, V184, P6133, DOI 10.4049/jimmunol.1000223; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Chen JC, 2011, J BIOL CHEM, V286, P26667, DOI 10.1074/jbc.M110.193987; Cho JY, 2011, INT IMMUNOPHARMACOL, V11, P1038, DOI 10.1016/j.intimp.2011.02.024; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Ckless K, 2011, BBA-GEN SUBJECTS, V1810, P1025, DOI 10.1016/j.bbagen.2011.03.005; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dabbagh K, 1999, J IMMUNOL, V162, P6233; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI 10.1139/y08-004; Doherty TA, 2011, NAT MED, V17, P596, DOI 10.1038/nm.2356; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; Enomoto Y, 2009, J ALLERGY CLIN IMMUN, V124, P913, DOI 10.1016/j.jaci.2009.08.044; Finkelman MA, 2006, J ENDOTOXIN RES, V12, P241, DOI 10.1179/096805106X102237; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Gregorieff A, 2009, GASTROENTEROLOGY, V137, P1333, DOI 10.1053/j.gastro.2009.06.044; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hackett TL, 2011, AM J RESP CELL MOL, V45, P1090, DOI 10.1165/rcmb.2011-0031OC; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Hasnain SZ, 2011, PARASITE IMMUNOL, V33, P45, DOI 10.1111/j.1365-3024.2010.01258.x; Heijink IH, 2010, EUR RESPIR J, V36, P1016, DOI 10.1183/09031936.00125809; Heijink IH, 2007, J IMMUNOL, V178, P7678; Hertz CJ, 2003, J IMMUNOL, V171, P6820; Hirota N., 1998, FASEB J, V26, P1704; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Jia HP, 2004, AM J PHYSIOL-LUNG C, V287, pL428, DOI 10.1152/ajplung.00377.2003; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; Kaiko GE, 2010, J IMMUNOL, V185, P4681, DOI 10.4049/jimmunol.1001758; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021; Kelly C, 2011, AM J RESP CELL MOL, V44, P743, DOI 10.1165/rcmb.2010-0339TR; Kim SR, 2010, EUR J IMMUNOL, V40, P2858, DOI 10.1002/eji.200939948; Koltsida O, 2011, EMBO MOL MED, V3, P348, DOI 10.1002/emmm.201100142; Kool M, 2008, J IMMUNOL, V181, P3755; Kool M, 2011, IMMUNITY, V35, P82, DOI 10.1016/j.immuni.2011.05.013; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Le Cras TD, 2011, AM J PHYSIOL-LUNG C, V300, pL414, DOI 10.1152/ajplung.00346.2010; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Lee S.H., 2012, AM J RESP CELL MOL B, DOI [10.1165/rcmb.2011-0369O, DOI 10.1165/RCMB.2011-03690]; Liang JR, 2011, J ALLERGY CLIN IMMUN, V128, P403, DOI 10.1016/j.jaci.2011.04.006; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lordan JL, 2002, J IMMUNOL, V169, P407; Maeda Y, 2011, AM J RESP CRIT CARE, V184, P421, DOI 10.1164/rccm.201101-0106OC; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; Marino R, 2011, J IMMUNOL, V186, P4433, DOI 10.4049/jimmunol.1001539; Martino MEB, 2009, J BIOL CHEM, V284, P14904, DOI 10.1074/jbc.M809180200; Martinon F, 2010, NAT IMMUNOL, V11, P411, DOI 10.1038/ni.1857; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Medoff BD, 2009, AM J RESP CELL MOL, V40, P286, DOI 10.1165/rcmb.2008-0129OC; Mitchell C, 2011, J IMMUNOL, V187, P3815, DOI 10.4049/jimmunol.1100436; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Monick MM, 2007, J IMMUNOL, V179, P1648; Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moriwaki A, 2011, BIOCHEM BIOPH RES CO, V404, P922, DOI 10.1016/j.bbrc.2010.12.082; Muller T, 2010, ALLERGY, V65, P1545, DOI 10.1111/j.1398-9995.2010.02426.x; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nawijn MC, 2011, TRENDS IMMUNOL, V32, P248, DOI 10.1016/j.it.2011.03.004; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nold MF, 2010, NAT IMMUNOL, V11, P1014, DOI 10.1038/ni.1944; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Olivera DS, 2007, INHAL TOXICOL, V19, P13, DOI 10.1080/08958370600985768; Pace E, 2008, IMMUNOLOGY, V124, P401, DOI 10.1111/j.1365-2567.2007.02788.x; Page K, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-62; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Poynter ME, 2002, AM J PATHOL, V160, P1325, DOI 10.1016/S0002-9440(10)62559-X; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Provoost S, 2011, J IMMUNOL, V187, P3331, DOI 10.4049/jimmunol.1004062; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Ramadas RA, 2011, AM J RESP CELL MOL, V44, P134, DOI 10.1165/rcmb.2009-0315OC; Rangasamy T, 2010, AM J RESP CELL MOL, V43, P276, DOI 10.1165/rcmb.2008-0438OC; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rate A, 2009, J IMMUNOL, V182, P72; Reardon C, 2011, IMMUNITY, V35, P223, DOI 10.1016/j.immuni.2011.05.015; Rezaee F., 2011, J ALLERGY CLIN IMMUN, V128, P1216; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Royce SG, 2011, J ASTHMA, V48, P653, DOI 10.3109/02770903.2011.599906; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Saito T, 2005, CELL TISSUE RES, V321, P75, DOI 10.1007/s00441-005-1113-9; Schmidt LM, 2011, J IMMUNOL, V186, P2095, DOI 10.4049/jimmunol.1002414; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-03880C; Sidhaye VK, 2011, AM J RESP CELL MOL, V45, P120, DOI 10.1165/rcmb.2010-0235OC; Sidhu SS, 2010, P NATL ACAD SCI USA, V107, P14170, DOI 10.1073/pnas.1009426107; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sivaprasad U, 2011, J ALLERGY CLIN IMMUN, V127, P254, DOI 10.1016/j.jaci.2010.10.009; Song DJ, 2010, INT ARCH ALLERGY IMM, V151, P285, DOI 10.1159/000250437; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Tan AM, 2010, J IMMUNOL, V184, P3535, DOI 10.4049/jimmunol.0900340; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Torres D, 2010, J IMMUNOL, V185, P451, DOI 10.4049/jimmunol.0902833; Tourdot S, 2008, CLIN EXP ALLERGY, V38, P1016, DOI 10.1111/j.1365-2222.2008.02974.x; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Uehara A, 2007, MOL IMMUNOL, V44, P3100, DOI 10.1016/j.molimm.2007.02.007; van Rijt LS, 2011, AM J RESP CRIT CARE, V184, P303, DOI 10.1164/rccm.201101-0019OC; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vigne S, 2011, BLOOD, V118, P5813, DOI 10.1182/blood-2011-05-356873; Volckaert T, 2011, J CLIN INVEST, V121, P4409, DOI 10.1172/JCI58097; Walter MJ, 2001, J EXP MED, V193, P339, DOI 10.1084/jem.193.3.339; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Whitsett JA, 2011, AM J RESP CRIT CARE, V184, P401, DOI 10.1164/rccm.201103-0495PP; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Xirakia C, 2010, AM J RESP CRIT CARE, V181, P1207, DOI 10.1164/rccm.200908-1255OC; Xu J, 2005, J IMMUNOL, V174, P5758; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; Ying S, 2005, J IMMUNOL, V174, P8183; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	156	273	281	10	76	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2012	18	5					684	692		10.1038/nm.2737		9	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	938WE	WOS:000303763500036	22561832	
J	Schwartz, J				Schwartz, J			Air pollution and children's health	PEDIATRICS			English	Article						asthma; particles; ozone; lung reaction	LOW-BIRTH-WEIGHT; PEAK EXPIRATORY FLOW; EXHALED NITRIC-OXIDE; LUNG-FUNCTION GROWTH; RESPIRATORY SYMPTOMS; PARTICULATE MATTER; SOUTHERN CALIFORNIA; PULMONARY-FUNCTION; INFANT-MORTALITY; CHILDHOOD ASTHMA	Children's exposure to air pollution is a special concern because their immune system and lungs are not fully developed when exposure begins, raising the possibility of different responses than seen in adults. In addition, children spend more time outside, where the concentrations of pollution from traffic, powerplants, and other combustion sources are generally higher. Although air pollution has long been thought to exacerbate minor acute illnesses, recent studies have suggested that air pollution, particularly traffic-related pollution, is associated with infant mortality and the development of asthma and atopy. Other studies have associated particulate air pollution with acute bronchitis in children and demonstrated that rates of bronchitis and chronic cough declined in areas where particle concentrations have fallen. More mixed results have been reported for lung function. Overall, evidence for effects of air pollution on children have been growing, and effects are seen at concentrations that are common today. Although many of these associations seem likely to be causal, others require and warrant additional investigation.	Harvard Univ, Sch Publ Hlth, Environm Epidemiol Program, Dept Environm Hlth, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA USA	Schwartz, J (reprint author), Harvard Univ, Sch Publ Hlth, Environm Epidemiol Program, Dept Environm Hlth, 401 Pk Dr, Boston, MA 02215 USA.	jschwrtz@hsph.harvard.edu					ANDERSON H.R., 1999, AIR POLLUTION HLTH, P461, DOI 10.1016/B978-012352335-8/50096-X; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; BATES DV, 1989, ENVIRON HEALTH PERSP, V79, P69, DOI 10.2307/3430531; BATESON TF, 2004, IN PRESS EPIDEMIOLOG; BERRY M, 1991, ENVIRON RES, V54, P135, DOI 10.1016/S0013-9351(05)80096-9; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; Bobak M, 2001, EPIDEMIOLOGY, V12, P358, DOI 10.1097/00001648-200105000-00018; BOBAK M, 2000, ENV HLTH PERSPECT, V108, P539; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; DASSEN W, 1986, JAPCA-INT J AIR POLL, V36, P1123; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; DOCKERY DW, 1982, JAPCA J AIR WASTE MA, V32, P937; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Fischer PH, 2002, INT ARCH OCC ENV HEA, V75, P348, DOI 10.1007/s00420-002-0320-x; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Galizia A, 1999, ENVIRON HEALTH PERSP, V107, P675, DOI 10.2307/3434461; GARVEY DJ, 1978, BIOL REPROD, V19, P8, DOI 10.1095/biolreprod19.1.8; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Giroux M, 2001, ENVIRON INT, V27, P335, DOI 10.1016/S0160-4120(01)00065-4; Gold DR, 2000, CIRCULATION, V101, P1267; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; Her Majesty's Public Health Service, 1954, 95 HER MAJ PUBL HLTH; Higgins BG, 2000, EUR RESPIR J, V16, P61, DOI 10.1034/j.1399-3003.2000.16a11.x; Holt PG, 1998, ENVIRON HEALTH PERSP, V106, P795, DOI 10.2307/3434191; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Jalaludin BB, 2000, INT J EPIDEMIOL, V29, P549, DOI 10.1093/ije/29.3.549; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; KAVLOCK R, 1979, TOXICOL APPL PHARM, V48, P19, DOI 10.1016/S0041-008X(79)80004-6; KHARITONOV SA, 1995, CHEST, V107, pS156, DOI 10.1378/chest.107.3_Supplement.156S; Kinney PL, 2000, ARCH ENVIRON HEALTH, V55, P210; KINNEY PL, 1989, AM REV RESPIR DIS, V139, P56; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; Lee K, 2002, ENVIRON HEALTH PERSP, V110, P145; Levy JI, 2002, J EXPO ANAL ENV EPID, V12, P104, DOI 10.1038/sj/jea/7500203; LIN MC, 2001, J TOXICOL ENV HEAL A, V64, P37; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Medina S, 1997, ENVIRON RES, V75, P73, DOI 10.1006/enrs.1997.3773; Mudway IS, 1999, OCCUP ENVIRON MED, V56, P473; Norris G, 2000, THORAX, V55, P466, DOI 10.1136/thorax.55.6.466; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; PRYOR WA, 1991, OXIDATIVE DAMAGE & REPAIR, P496; Rice TM, 2001, TOXICOL APPL PHARM, V177, P46, DOI 10.1006/taap.2001.9287; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Roemer W, 1999, OCCUP ENVIRON MED, V56, P86; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Saintot M, 1999, ARCH ENVIRON HEALTH, V54, P34; SALDIVA PHN, 1994, ENVIRON RES, V65, P218, DOI 10.1006/enrs.1994.1033; Saldiva PHN, 2002, AM J RESP CRIT CARE, V165, P1610, DOI 10.1164/rccm.2106102; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Sunyer J, 1997, THORAX, V52, P760; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541; US Environmental Protection Agency, 1997, EXP FACT HDB US EPA; VANDERZEE S, 1999, OCCUP ENVIRON MED, V12, P802; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407; Zanobetti A, 2001, AM J RESP CRIT CARE, V164, P831; ZELIKOFF JT, 1999, P 3 C PART AIR POLL	90	273	282	3	34	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR 1	2004	113	4		S			1037	1043				7	Pediatrics	Pediatrics	808RC	WOS:000220585200014	15060197	
J	Rennard, S; Decramer, M; Calverley, PMA; Pride, NB; Soriano, JB; Vermeire, PA; Vestbo, J				Rennard, S; Decramer, M; Calverley, PMA; Pride, NB; Soriano, JB; Vermeire, PA; Vestbo, J			Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey	EUROPEAN RESPIRATORY JOURNAL			English	Article						chronic obstructive pulmonary disease; epidemiology; guidelines; management; subject perspective	OBSTRUCTIVE PULMONARY-DISEASE; ECONOMIC BURDEN; UNITED-STATES; LUNG-FUNCTION; ASTHMA; HEALTH; EPIDEMIOLOGY; ADULTS; RISK; EXACERBATIONS	To date, no international surveys estimating the burden of chronic obstructive pulmonary disease (COPD) in the general population have been published. The Confronting COPD International Survey aimed to quantify morbidity and burden in COPD subjects in 2000. From a total of 201,921 households screened by random-digit dialling in the USA, Canada, France, Italy, Germany, the Netherlands, Spain and the UK, 3,265 subjects with a diagnosis of COPD, chronic bronchitis or emphysema, or with symptoms of chronic bronchitis, were identified. The mean age of the subjects was 63.3 yrs and 44.2%) were female. Subjects with COPD in North America and Europe appear to underestimate their morbidity, as shown by the high proportion of subjects with limitations to their basic daily life activities, frequent work loss (45.3% of COPD subjects of <65 yrs reported work loss in the past year) and frequent use of health services (13.8%. of subjects required emergency care in the last year), and may be undertreated. There was a significant disparity between subjects' perception of disease severity and the degree of severity indicated by an objective breathlessness scale. Of those with the most severe breathlessness (too breathless to leave the house), 35.8%, described their condition as mild or moderate, as did 60.3% of those with the next most severe degree of breathlessness (breathless after walking a few minutes on level ground). This international survey confirmed the great burden to society and high individual morbidity associated with chronic obstructive pulmonary disease in subjects in North America and Europe.	Univ Nebraska, Med Ctr, Pulm & Crit Care Med Sect, Nebraska Med Ctr 985125, Omaha, NE 68198 USA; Univ Catholique Louvain, Div Resp, B-1348 Louvain, Belgium; Univ Liverpool, Dept Med, Ctr Clin Sci, Aintree Hosp, Liverpool L69 3BX, Merseyside, England; Imperial Coll Sch Med, Natl Heart & Lung Inst, Sch Med, London, England; GlaxoSmithKline Res & Dev, Worldwide Epidemiol, Greenford, Middx, England; Univ Antwerp, Dept Resp Med, B-2020 Antwerp, Belgium; Hvidovre Univ Hosp, Dept Resp Med, Copenhagen, Denmark	Rennard, S (reprint author), Univ Nebraska, Med Ctr, Pulm & Crit Care Med Sect, Nebraska Med Ctr 985125, Omaha, NE 68198 USA.			Vestbo, Jorgen/0000-0001-6355-6362; Soriano, Joan B/0000-0001-9740-2994			Anto JM, 2001, EUR RESPIR J, V17, P982, DOI 10.1183/09031936.01.17509820; Asher MI, 1998, EUR RESPIR J, V12, P315; Bestall JC, 1999, THORAX, V54, P581; *BRIT LUNG FDN, 1999, CHRON OBSTR PULM DIS; Burney P, 1996, EUR RESPIR J, V9, P687; Chen X, 1999, OPT EXPRESS, V5, P93; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372; Fabbri L, 1998, Curr Opin Pulm Med, V4, P76, DOI 10.1097/00063198-199803000-00004; Ferris BG, 1979, AM REV RESP DIS S, V118, p1S; Friedman M, 2001, PHARMACOECONOMICS, V19, P245, DOI 10.2165/00019053-200119030-00003; Galobardes B, 1998, J CLIN EPIDEMIOL, V51, P875, DOI 10.1016/S0895-4356(98)00063-8; Gross NJ, 2001, AM J RESP CRIT CARE, V163, P1047; Grossman RF, 2000, SEM RESP CRIT CARE M, V21, P113, DOI 10.1055/s-2000-9932; Gulsvik A, 1999, Monaldi Arch Chest Dis, V54, P160; HURD S, 2001, CHEST, V117, pS336; Hurd Suzanne, 2000, Chest, V117, p1S, DOI 10.1378/chest.117.2_suppl.1S; *INT TEL UN, 2001, WORLD TEL IND 2000 2; Kim N, 2000, SEM RESP CRIT CARE M, V21, P73, DOI 10.1055/s-2000-9845; Lacasse Y, 2001, ARCH INTERN MED, V161, P69, DOI 10.1001/archinte.161.1.69; Lynn J, 2000, J AM GERIATR SOC, V48, pS91; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; POTTHOFF RF, 1994, AM J EPIDEMIOL, V139, P967; Prescott E, 1997, EUR RESPIR J, V10, P822; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Rossi A, 2000, LANCET, V356, pS56, DOI 10.1016/S0140-6736(00)92042-7; Silverman EK, 1996, MED CLIN N AM, V80, P501; Sullivan SD, 2000, CHEST, V117, P5; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Viegi G, 2001, RESPIRATION, V68, P4, DOI 10.1159/000050456; WAKSBERG J, 1978, J AM STAT ASSOC, V73, P40, DOI 10.2307/2286513; World Health Organization, 1998, WORLD HLTH REP 1998	33	273	281	2	10	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2002	20	4					799	805		10.1183/09031936.02.03242002		7	Respiratory System	Respiratory System	606BF	WOS:000178712200004	12412667	
J	Anderson, SD; Daviskas, E				Anderson, SD; Daviskas, E			The mechanism of exercise-induced asthma is ...	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise; airway cooling; airway drying; osmolarity; respiratory water loss	CANINE PERIPHERAL AIRWAYS; THERMALLY-INDUCED ASTHMA; BRONCHIAL BLOOD-FLOW; DRY AIR; ISOCAPNIC HYPERVENTILATION; MUCOCILIARY CLEARANCE; WATER-LOSS; HYPERTONIC SALINE; RESPIRATORY-TRACT; HEALTHY-SUBJECTS	Exercise-induced asthma (EIA) refers to the transient narrowing of the airways that follows vigorous exercise. The mechanism whereby EIA occurs is thought to relate to the consequences of heating and humidifying large volumes of air during exercise. In 1978 airway cooling was identified as an important stimulus for EIA; however, severe EIA also occurred when hot dry air was inspired, and there was no abnormal cooling of the airways. In 1986 the thermal hypothesis proposed that cooling of the airways needed to be followed by rapid rewarming and that these two events caused a vasoconstriction and a reactive hyperemia of the bronchial microcirculation, together with edema of the airway wall, causing the airways to narrow after exercise. The osmotic, or airway-drying, hypothesis developed from 1982-1992 because neither airway cooling nor rewarming appeared to be necessary for EIA to occur. As water is evaporated from the airway surface liquid, it becomes hyperosmolar and provides an osmotic stimulus for water to move from any cell nearby, resulting in cell volume loss. It is proposed that the regulatory volume increase, after cell shrinkage, is the key event resulting in release of inflammatory mediators that cause airway smooth muscle to contract and the airways of asthmatic subjects to narrow. This event may or may not be associated with airway edema. The osmotic and thermal theories come together by considering that inspiration of cold air not only cools the airways but also increases the numbers of airway generations becoming dehydrated in the humidifying process.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, Level 9,Page Chest Pavil,Missenden Rd, Camperdown, NSW 2050, Australia.			Anderson, Sandra/0000-0002-6308-8770			AGOSTONI P, 1990, CHEST, V97, P1377, DOI 10.1378/chest.97.6.1377; AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; ANDERSON SD, 1993, ASTHMA, P323; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; ANDERSON SD, 1989, ALLERGY PROC, V10, P215, DOI 10.2500/108854189778960054; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Anderson SD, 1999, EXERCISE INDUCED AST, P77; ANDERSON SD, 1994, ASTHMA RHINITIS, P1178; ARGYROS GJ, 1993, AM REV RESPIR DIS, V147, P1419; BAILE EM, 1987, J APPL PHYSIOL, V62, P526; BLOSSER S, 1994, J APPL PHYSIOL, V76, P1624; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Daviskas E, 1996, EUR RESPIR J, V9, P716, DOI 10.1183/09031936.96.09040716; DAVISKAS E, 1995, EUR RESPIR J, V8, P742; DAVISKAS E, 1990, J APPL PHYSIOL, V69, P362; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; Daviskas E, 1996, EUR RESPIR J, V9, P725, DOI 10.1183/09031936.96.09040725; DEAL EC, 1979, J APPL PHYSIOL, V46, P467; ESCHENBACHER WL, 1985, AM REV RESPIR DIS, V131, P894; EVELOFF JL, 1987, AM J PHYSIOL, V252, P1; Freed AN, 1999, AM J RESP CRIT CARE, V159, P1101; FREED AN, 1994, AM J RESP CELL MOL, V11, P724; GILBERT IA, 1987, J APPL PHYSIOL, V63, P1681; GILBERT IA, 1992, J CLIN INVEST, V90, P699, DOI 10.1172/JCI115940; HAHN A, 1984, AM REV RESPIR DIS, V130, P575; INGENITO E, 1988, AM REV RESPIR DIS, V138, P540; Matsui H, 2000, J CLIN INVEST, V105, P1419, DOI 10.1172/JCI4546; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCFADDEN ER, 1993, ASTHMA, P337; MCFADDEN ER, 1990, LANCET, V335, P880; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1999, EXERCISE INDUCED AST, P115; Nadel JA, 1985, HDB PHYSL 3, VI, P419; Peters SP, 1995, ASTHMA RHINITIS, P221; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285; SMITH CM, 1989, EUR RESPIR J, V2, P36; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SMITH CM, 1989, AM REV RESPIR DIS, V140, P598; SMITH TL, 1993, OTOLARYNG HEAD NECK, V109, P646; SOLWAY J, 1990, EUR RESPIR J, V3, pS608; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; TABKA Z, 1988, CHEST, V94, P81, DOI 10.1378/chest.94.1.81; VANOOSTDAM JC, 1986, J APPL PHYSIOL, V61, P312; ZAWADSKI DK, 1988, AM REV RESPIR DIS, V138, P1553; ZIMMERMAN MP, 2000, J APPL PHYSIOL, V88, P42	50	272	282	0	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					453	459				7	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900006	10984363	
J	Hammad, H; Plantinga, M; Deswarte, K; Pouliot, P; Willart, MAM; Kool, M; Muskens, F; Lambrecht, BN				Hammad, Hamida; Plantinga, Maud; Deswarte, Kim; Pouliot, Philippe; Willart, Monique A. M.; Kool, Mirjam; Muskens, Femke; Lambrecht, Bart N.			Inflammatory dendritic cells-not basophils-are necessary and sufficient for induction of Th2 immunity to inhaled house dust mite allergen	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							EOSINOPHILIC AIRWAY INFLAMMATION; IN-VIVO DEPLETION; CD4(+) T-CELLS; TYPE-2 IMMUNITY; CUTTING EDGE; LYMPH-NODES; ADAPTIVE IMMUNITY; IL-4 PRODUCTION; STEADY-STATE; RESPONSES	It is unclear how Th2 immunity is induced in response to allergens like house dust mite (HDM). Here, we show that HDM inhalation leads to the TLR4/MyD88-dependent recruitment of IL-4 competent basophils and eosinophils, and of inflammatory DCs to the draining mediastinal nodes. Depletion of basophils only partially reduced Th2 immunity, and depletion of eosinophils had no effect on the Th2 response. Basophils did not take up inhaled antigen, present it to T cells, or express antigen presentation machinery, whereas a population of FceRI(+) DCs readily did. Inflammatory DCs were necessary and sufficient for induction of Th2 immunity and features of asthma, whereas basophils were not required. We favor a model whereby DCs initiate and basophils amplify Th2 immunity to HDM allergen.	[Hammad, Hamida; Plantinga, Maud; Deswarte, Kim; Pouliot, Philippe; Willart, Monique A. M.; Kool, Mirjam; Lambrecht, Bart N.] Univ Ghent, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium; [Muskens, Femke; Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, NL-3000 CA Rotterdam, Netherlands	Lambrecht, BN (reprint author), Univ Ghent, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium.	hamida.hammad@ugent.be; Bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834	Flemish government; University of Ghent [GOA 01G01009]; National Institutes of Health; Ghent University; EU	Bart N. Lambrecht and Hamida Hammad were supported by an Odysseus Grant of the Flemish government and by a concerted research initiative grant (GOA 01G01009), a 4 year project grant, and a Multidisciplinary Research Initiative Grant of University of Ghent and a National Institutes of Health R21 grant. Maud Plantinga was supported by a grant of Ghent University. Mirjam Kool was supported by an EU Marie Curie Intra-european Fellowship and Philippe Pouliot was supported by a EU Marie Curie International Incoming Fellowship.	Allenspach EJ, 2008, IMMUNITY, V29, P795, DOI 10.1016/j.immuni.2008.08.013; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Barrett NA, 2009, J IMMUNOL, V182, P1119; Baumeister T, 2003, J INVEST DERMATOL, V121, P280, DOI 10.1046/j.1523-1747.2003.12380.x; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Denzel A, 2008, NAT IMMUNOL, V9, P733, DOI 10.1038/ni.1621; Ebner S, 2002, J IMMUNOL, V168, P6199; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; ELLIOTT EA, 1994, J EXP MED, V179, P681, DOI 10.1084/jem.179.2.681; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Imai Y, 2008, CELL, V133, P235, DOI 10.1016/j.cell.2008.02.043; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Jankovic D, 2004, J IMMUNOL, V173, P2419; Jung S, 2002, IMMUNITY, V17, P211, DOI 10.1016/S1074-7613(02)00365-5; Kim S, 2010, J IMMUNOL, V184, P1143, DOI 10.4049/jimmunol.0902447; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kuipers H, 2009, J LEUKOCYTE BIOL, V85, P64, DOI 10.1189/jlb.0807519; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lantz CS, 1998, NATURE, V392, P90, DOI 10.1038/32190; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; MacDonald AS, 2002, J IMMUNOL, V168, P537; Matsubara S, 2006, AM J RESP CELL MOL, V34, P426, DOI 10.1165/rcmb.2005-0298OC; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1998, J IMMUNOL, V161, P2731; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Mohrs K, 2005, IMMUNITY, V23, P419, DOI 10.1016/j.immuni.2005.09.006; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Naik SH, 2005, J IMMUNOL, V174, P6592; Naik SH, 2007, NAT IMMUNOL, V8, P1217, DOI 10.1038/ni1522; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Obata K, 2007, BLOOD, V110, P913, DOI 10.1182/blood-2007-01-068718; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; ROCHE PA, 1995, IMMUNITY, V3, P259, DOI 10.1016/1074-7613(95)90111-6; Schneider E, 2009, J IMMUNOL, V183, P3591, DOI 10.4049/jimmunol.0900328; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Shen T, 2008, INT IMMUNOL, V20, P1201, DOI 10.1093/intimm/dxn077; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shortman K, 2007, NAT REV IMMUNOL, V7, P19, DOI 10.1038/nri1996; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sung SSJ, 2001, J IMMUNOL, V166, P1261; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vermaelen KY, 2001, J EXP MED, V193, P51; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Xu YK, 2007, J IMMUNOL, V179, P7577; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	68	269	272	3	19	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	SEP 27	2010	207	10					2097	2111		10.1084/jem.20101563		15	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	660NH	WOS:000282649800008	20819925	
J	Staden, U; Rolinck-Werninghaus, C; Brewe, F; Wahn, U; Niggemann, B; Beyer, K				Staden, U.; Rolinck-Werninghaus, C.; Brewe, F.; Wahn, U.; Niggemann, B.; Beyer, K.			Specific oral tolerance induction in food allergy in children: efficacy and clinical patterns of reaction	ALLERGY			English	Article						children; food allergy; specific oral tolerance induction	EXERCISE-INDUCED ANAPHYLAXIS; PEANUT ALLERGY; COWS MILK; RUSH DESENSITIZATION; EGG ALLERGY; HYPERSENSITIVITY; IMMUNOTHERAPY; POPULATION; PREVALENCE; SENSITIZATION	Background: Specific oral tolerance induction (SOTI) seems to be a promising treatment of food allergy. Specific oral tolerance induction and elimination diet were compared with respect to efficacy rate and patterns of clinical reaction. Methods: Children with challenge proven immunoglobulin E (IgE)-mediated cow's milk (CM) allergy or hen's egg (HE) allergy were randomly assigned to SOTI or elimination diet as a control group. Specific oral tolerance induction treatment was performed at home on a daily basis according to a study protocol with fresh CM or lyophilized HE protein. Re-evaluation of clinically relevant food allergy was performed by food challenge after a median of 21 months. Children in the SOTI group received a secondary elimination diet for 2 months prior to follow-up challenge to evaluate persistence of induced oral tolerance. Results: At follow-up challenge, nine of 25 children (36%) showed permanent tolerance in the SOTI group, three of 25 (12%) were tolerant with regular intake and four of 25 (16%) were partial responders. In the control group, seven of 20 children (35%) were tolerant. Allergen-specific immunoglobulin E decreased significantly both in children who developed natural tolerance during the elimination diet (P < 0.05) and in those with SOTI (P < 0.001). Conclusions: Specific oral tolerance induction seems a valid treatment option for patients with persistent food allergy. Indications may be given if avoidance cannot be guaranteed or for those who are eager to eat the food in question. Advantages of SOTI are the increased threshold dose for allergic reactions and the substantially reduced risk of severe allergic reactions after inadvertent ingestion of the allergen. However, careful monitoring during SOTI is mandatory.	Univ Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Childrens Hosp Osnabruck, Osnabruck, Germany	Staden, U (reprint author), Univ Childrens Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						Bauer A, 1999, ALLERGY, V54, P894, DOI 10.1034/j.1398-9995.1999.00228.x; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Calvani M, 2007, ANN ALLERG ASTHMA IM, V98, P98; Caminiti L, 2007, ALLERGY, V62, P335, DOI 10.1111/j.1398-9995.2006.01289.x; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; Eigenmann PA, 2003, ALLERGY, V58, P1217, DOI 10.1046/j.1398-9995.2003.00303.x; ERIQUE E, 2005, J ALLERGY CLIN IMMUN, V116, P1073; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Mansfield L, 2006, ANN ALLERG ASTHMA IM, V97, P266; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Mehl A, 2005, ALLERGY, V60, P1440, DOI 10.1111/j.1398-9995.2005.00909.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; Nucera E, 2006, J INVEST ALLERG CLIN, V16, P214; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Osterballe M, 2005, PEDIATR ALLERGY IMMU, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Patriarca G, 2006, DIGEST DIS SCI, V51, P471, DOI 10.1007/s10620-006-3157-4; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; Patriarca G, 1998, HEPATO-GASTROENTEROL, V45, P52; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Roehr CC, 2004, CLIN EXP ALLERGY, V34, P1534, DOI 10.1111/j.1365-2222.2004.02080.x; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; STALDER JF, 1993, DERMATOLOGY, V186, P23; Venter C, 2006, PEDIATR ALLERGY IMMU, V17, P356, DOI 10.1111/j.1399-3038.2006.00428.x; Wuthrich B, 1996, MONOGR ALLERGY, V32, P236; WUTHRICH B, 1986, SCHWEIZ MED WSCHR, V116, P1401; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1	33	268	273	2	23	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	NOV	2007	62	11					1261	1269		10.1111/j.1398-9995.2007.01501.x		9	Allergy; Immunology	Allergy; Immunology	217MZ	WOS:000249953300006	17919140	
J	Hedayati, MT; Pasqualotto, AC; Warn, PA; Bowyer, P; Denning, DW				Hedayati, M. T.; Pasqualotto, A. C.; Warn, P. A.; Bowyer, P.; Denning, D. W.			Aspergillus flavus: human pathogen, allergen and mycotoxin producer	MICROBIOLOGY-SGM			English	Review							PRIMARY CUTANEOUS ASPERGILLOSIS; PARANASAL SINUS MYCOSES; HEMATOPOIETIC STEM-CELL; INTENSIVE-CARE-UNIT; IN-VITRO ACTIVITIES; AIR-BORNE FUNGI; INVASIVE ASPERGILLOSIS; AMPHOTERICIN-B; SECTION FLAVI; BRONCHOPULMONARY ASPERGILLOSIS	Aspergillus infections have grown in importance in the last years. However, most of the studies have focused on Aspergillus fumigatus, the most prevalent species in the genus. In certain locales and hospitals, Aspergillus flavus is more common in air than A. fumigatus, for unclear reasons. After A. fumigatus, A. flavus is the second leading cause of invasive aspergillosis and it is the most common cause of superficial infection. Experimental invasive infections in mice show A. flavus to be 100-fold more virulent than A. fumigatus in terms of inoculum required. Particularly common clinical syndromes associated with A. flavus include chronic granulonnatous sinusitis, keratitis, cutaneous aspergillosis, wound infections and osteomyelitis following trauma and inoculation. Outbreaks associated with A. flavus appear to be associated with single or closely related strains, in contrast to those associated with A. fumigatus. In addition, A. flavus produces aflatoxins, the most toxic and potent hepatocarcinogenic natural compounds ever characterized. Accurate species identification within Aspergillus flavus complex remains difficult due to overlapping morphological and biochemical characteristics, and much taxonomic and population genetics work is necessary to better understand the species and related species. The flavus complex currently includes 23 species or varieties, including two sexual species, Petromyces alliaceus and P. albertensis. The genome of the highly related Aspergillus oryzae is completed and available; that of A. flavus in the final stages of annotation. Our understanding of A. flavus lags far behind that of A. fumigatus. Studies of the genomics, taxonomy, population genetics, pathogenicity, allergenicity and antifungal susceptibility of A. flavus are all required.	Univ Manchester, Sch Med, Manchester M23 9PL, Lancs, England; Wythenshawe Hosp, Manchester M23 9PL, Lancs, England; Mazandaran Univ Med Sci, Sch Med, Dept Med Mycol & Parasitol, Sari, Iran	Denning, DW (reprint author), Univ Manchester, Sch Med, Southmoor Rd, Manchester M23 9PL, Lancs, England.	ddenning@manchester.ac.uk	Hedayati, Mohammad T./E-2304-2017	Hedayati, Mohammad T./0000-0001-6415-4648; Denning, David/0000-0001-5626-2251	NIAID NIH HHS [N01-AI-30041]		ABDALLA MH, 1988, MYCOPATHOLOGIA, V104, P137, DOI 10.1007/BF00437427; ACQUATI F, 1987, Giornale Italiano di Cardiologia, V17, P467; Adhikari A, 2004, SCI TOTAL ENVIRON, V326, P123, DOI 10.1016/j.scitotenv.2003.12.007; AKIYAMA K, 1987, CHEST, V91, P285, DOI 10.1378/chest.91.2.285; ALLO MD, 1987, NEW ENGL J MED, V317, P1105, DOI 10.1056/NEJM198710293171802; Alrajhi AA, 2001, AM J TROP MED HYG, V65, P83; Anaissie EJ, 2002, CLIN INFECT DIS, V34, P780, DOI 10.1086/338958; BARTOLI A, 1978, T BRIT MYCOL SOC, V71, P383; BATISTA AC, 1955, AN SOC BIOL PERNAMB, V8, P94; Bayman P, 2002, APPL ENVIRON MICROB, V68, P2326, DOI 10.1128/AEM.68.5.2326-2329.2002; Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003; Bhatnagar D., 2000, ENCY FOOD MICROBIOLO, P72; Bowyer P, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-251; BRUNS TD, 1991, ANNU REV ECOL SYST, V22, P525, DOI 10.1146/annurev.ecolsys.22.1.525; BUFFINGTON J, 1994, PEDIATR INFECT DIS J, V13, P386, DOI 10.1097/00006454-199405000-00011; CALVO A, 1980, MYCOPATHOLOGIA, V71, P41, DOI 10.1007/BF00625313; CAMERON JA, 1991, ARCH OPHTHALMOL-CHIC, V109, P54; CAMPBELL CK, 1994, FEMS SYMP, P313; Cesaro S, 2004, EUR J HAEMATOL, V73, P50, DOI 10.1111/j.1600-0609.2004.00254.x; Chakrabarti A, 2002, MYCOSES, V45, P295, DOI 10.1046/j.1439-0507.2002.00738.x; Chakrabarti A, 1997, J MED VET MYCOL, V35, P295; CHAKRABARTI A, 1992, OTOLARYNG HEAD NECK, V107, P745; Chakrabarti A, 1998, J INFECTION, V37, P24, DOI 10.1016/S0163-4453(98)90303-6; Cheikh-Rouhou F, 2001, B SOC PATHOL EXOT, V94, P11; CHRISTENSEN M, 1978, MYCOLOGIA, V70, P200, DOI 10.2307/3758705; COHN A, 1983, JAHRESBER SCHLES VAT, V61, P226; COOPER JAD, 1981, AM J MED, V71, P903, DOI 10.1016/0002-9343(81)90396-X; COTTY PJ, 1989, PHYTOPATHOLOGY, V79, P808, DOI 10.1094/Phyto-79-808; Currens J, 2002, AM J RHINOL, V16, P165; de Valk HA, 2005, J CLIN MICROBIOL, V43, P4112, DOI 10.1128/JCM.43.8.4112-4120.2005; Demaria RG, 2000, J HEART VALVE DIS, V9, P786; DEMICCO DD, 1984, CANCER, V53, P1995, DOI 10.1002/1097-0142(19840501)53:9<1995::AID-CNCR2820530932>3.0.CO;2-S; Denning DW, 2006, J INFECTION, V53, P337, DOI 10.1016/j.jinf.2006.03.003; Denning DW, 2003, CLIN INFECT DIS, V37, pS265, DOI 10.1086/376526; Denning DW, 1997, ANTIMICROB AGENTS CH, V41, P1364; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; Diaz-Guerra TM, 2000, J CLIN MICROBIOL, V38, P2419; Diekema DJ, 2003, J CLIN MICROBIOL, V41, P3623, DOI 10.1128/JCM.41.8.3623-3626.2003; Dogan Muzeyyen, 2004, Ear Nose Throat J, V83, P331; EGEL DS, 1994, PHYTOPATHOLOGY, V84, P906, DOI 10.1094/Phyto-84-906; Espinel-Ingroff A, 2003, J CLIN MICROBIOL, V41, P403, DOI 10.1128/JCM.41.1.403-409.2003; Espinel-Ingroff A, 2001, ANTIMICROB AGENTS CH, V45, P1828, DOI 10.1128/AAC.45.6.1828-1835.2001; Ferreiro JA, 1997, HEAD NECK-J SCI SPEC, V19, P481; FISHER MS, 1992, SKELETAL RADIOL, V21, P410; FORD S, 1967, J BACTERIOL, V94, P928; Frisvad JC, 2005, SYST APPL MICROBIOL, V28, P442, DOI 10.1016/j.syampm.2005.02.012; Galagan JE, 2005, NATURE, V438, P1105, DOI 10.1038/nature04341; Geiser DM, 1998, P NATL ACAD SCI USA, V95, P388, DOI 10.1073/pnas.95.1.388; Geiser DM, 2000, FUNGAL GENET BIOL, V31, P169, DOI 10.1006/fgbi.2000.1215; GIBSON AM, 1994, INT J FOOD MICROBIOL, V23, P419, DOI 10.1016/0168-1605(94)90167-8; GOLDBLATT LA, 1969, AFATOXIN SCIENTIFIC; Gomez-Lopez A, 2003, ANTIMICROB AGENTS CH, V47, P3085, DOI 10.1128/AAC.47.10.3085-3088.2003; Gottlich E, 2002, INT J HYG ENVIR HEAL, V205, P269, DOI 10.1078/1438-4639-00158; GROSSMAN ME, 1985, J AM ACAD DERMATOL, V12, P313, DOI 10.1016/S0190-9622(85)80042-6; Guarro J, 2005, MED MYCOL, V43, P365, DOI 10.1080/13693780400005809; GUGNANI HC, 1978, MYCOPATHOLOGIA, V65, P155, DOI 10.1007/BF00447186; Guinea J, 2005, DIAGN MICR INFEC DIS, V53, P333, DOI 10.1016/j.diagmicrobio.2005.07.002; GUMAA SA, 1992, T ROY SOC TROP MED H, V86, P93, DOI 10.1016/0035-9203(92)90460-T; GUPTA SK, 1993, ASIAN PAC J ALLERGY, V11, P19; Hedayati Mohammad Taghi, 2005, Iran J Allergy Asthma Immunol, V4, P189; Heinemann S, 2004, J HOSP INFECT, V57, P149, DOI 10.1016/j.jhin.2004.02.007; Hope WW, 2005, MED MYCOL, V43, pS207, DOI 10.1080/13693780400025179; HORN B, 1997, FLAVI MYCOTAXON, V56, P185; Hsueh PR, 2005, ANTIMICROB AGENTS CH, V49, P512, DOI 10.1128/AAC.49.2.512-817.2005; HUSSAIN S, 1995, EUR J RADIOL, V20, P151, DOI 10.1016/0720-048X(95)00644-6; Irles D, 2004, ARCH MAL COEUR VAISS, V97, P172; Ito Y, 2001, MYCOL RES, V105, P233, DOI 10.1017/S0953756200003385; Iwen PC, 1997, CLIN INFECT DIS, V24, P1178, DOI 10.1086/513662; James MJ, 2000, J CLIN MICROBIOL, V38, P3612; Kaliamurthy J, 2003, MYCOSES, V46, P174, DOI 10.1046/j.1439-0507.2003.00865.x; Kamai Y, 2002, ANTIMICROB AGENTS CH, V46, P367, DOI 10.1128/AAC.46.2.367-370.2002; KAMAL KS, 1969, T BR MYCOL, V52, P336; KAMESWARAN M, 1992, J LARYNGOL OTOL, V106, P981, DOI 10.1017/S0022215100121528; Kennedy CA, 1997, OTOLARYNG HEAD NECK, V116, P610, DOI 10.1016/S0194-5998(97)70236-5; KHAIRALLAH SH, 1992, DOC OPHTHALMOL, V79, P269, DOI 10.1007/BF00158257; KHAN ZU, 1976, SCAND J RESPIR DIS, V57, P73; KHAN ZU, 1995, CLIN INFECT DIS, V21, P210; KITA, 1913, CENTBL BAKT PARASIT, V37, P433; KLICH MA, 1988, T BRIT MYCOL SOC, V91, P99; KLICH MA, 1987, EXP MYCOL, V11, P170, DOI 10.1016/0147-5975(87)90002-8; Kozakiewicz Z, 1989, ASPERGILLUS SPECIES; Kueter Joseph C, 2002, Urology, V59, P601, DOI 10.1016/S0090-4295(01)01666-1; Kumeda Y, 1996, APPL ENVIRON MICROB, V62, P2947; KUROSAWA M, 1990, BRIT J CLIN PRACT, V44, P482; KURTZMAN CP, 1987, A VAN LEEUW J MICROB, V53, P147, DOI 10.1007/BF00393843; KURTZMAN CP, 1986, MYCOLOGIA, V78, P955, DOI 10.2307/3807436; LANCE SE, 1988, OPHTHALMOLOGY, V95, P947; Lass-Florl C, 1998, J ANTIMICROB CHEMOTH, V42, P497, DOI 10.1093/jac/42.4.497; Lass-Florl C, 2001, ANTIMICROB AGENTS CH, V45, P124, DOI 10.1128/AAC.45.1.124-128.2001; Li Dong Mei, 1998, Mycoscience, V39, P299, DOI 10.1007/BF02464012; LIAO WQ, 1988, CHINESE MED J-PEKING, V101, P601; Link HF, 1809, MAGAZIN GESELLSCHAFT, V3, P1; Lionakis MS, 2005, DIAGN MICR INFEC DIS, V52, P15, DOI 10.1016/j.diagmicrobio.2005.01.001; Machida M, 2005, NATURE, V438, P1157, DOI 10.1038/nature04300; Maertens J, 2004, CLIN INFECT DIS, V39, P1563, DOI 10.1086/423381; Maesaki S, 2000, J Infect Chemother, V6, P101, DOI 10.1007/PL00012145; MAHGOUB ES, 1972, THORAX, V27, P33, DOI 10.1136/thx.27.1.33; MALLEA M, 1972, ACTA ALLERGOL, V27, P273, DOI 10.1111/j.1398-9995.1972.tb01426.x; MARCHAL E, 1893, REV MYCOL, V15, P101; Mari A, 2004, J ALLERGY CLIN IMMUN, V113, pS301; Marr KA, 2002, CLIN INFECT DIS, V34, P909, DOI 10.1086/339202; MEHROTRA BS, 1962, MYCOLOGIA, V54, P403; Mendicute J, 2000, J CATARACT REFR SURG, V26, P1660, DOI 10.1016/S0886-3350(00)00443-0; MILOSEV B, 1969, BRIT J SURG, V56, P132, DOI 10.1002/bjs.1800560213; Montiel D, 2003, MYCOL RES, V107, P1427, DOI 10.1017/S0953756203008797; MOODY SF, 1990, APPL ENVIRON MICROB, V56, P2441; Morgan J, 2005, MED MYCOL, V43, pS49, DOI 10.1080/13693780400020113; Morrow P E, 1980, Ann N Y Acad Sci, V353, P71, DOI 10.1111/j.1749-6632.1980.tb18908.x; Mosquera J, 2001, ANTIMICROB AGENTS CH, V45, P1456, DOI 10.1128/AAC.45.5.1456-1462.2001; MOUBASHER AH, 1981, Z ALLG MIKROBIOL, V21, P247, DOI 10.1002/jobm.3630210310; MURAKAMI H, 1971, J GEN APPL MICROBIOL, V17, P281, DOI 10.2323/jgam.17.281; Myoken Y, 2003, J ORAL PATHOL MED, V32, P215; NIEMI RM, 1982, APPL ENVIRON MICROB, V43, P378; NOZAWA K, 1989, CHEM PHARM BULL, V37, P626; Oakley KL, 1998, ANTIMICROB AGENTS CH, V42, P2726; Odds FC, 1998, ANTIMICROB AGENTS CH, V42, P282; Panda NK, 2004, MYCOSES, V47, P277, DOI 10.1111/j.1439-0507.2004.00986.x; Panda NK, 1998, MYCOSES, V41, P281; Pasqualotto AC, 2006, CLIN MICROBIOL INFEC, V12, P1060, DOI 10.1111/j.1469-0691.2006.01512.x; Paterson PJ, 2003, J ANTIMICROB CHEMOTH, V52, P873, DOI 10.1093/jac/dkg434; Paterson RRM, 1997, LETT APPL MICROBIOL, V25, P435, DOI 10.1046/j.1472-765X.1997.00070.x; Perez-Arellano JL, 2001, J INFECTION, V42, P163, DOI 10.1053/jinf.2000.0786; Peterson SW, 2001, MYCOLOGIA, V93, P689, DOI 10.2307/3761823; Peterson SW, 2000, INTEGRATION MODERN T, P323; Pfaller MA, 2002, ANTIMICROB AGENTS CH, V46, P1032, DOI 10.1128/AAC.46.4.1032-1037.2002; Ramani R, 1994, Ear Nose Throat J, V73, P420; Rao K, 2000, PEDIATR HEMAT ONCOL, V17, P425, DOI 10.1080/08880010050034382; Raper K, 1965, GENUS ASPERGILLUS; Rath PM, 1997, J HOSP INFECT, V37, P47, DOI 10.1016/S0195-6701(97)90072-4; Rath PM, 2001, MYCOSES, V44, P65, DOI 10.1046/j.1439-0507.2001.00620.x; RICHARD JL, 1984, MYCOPATHOLOGIA, V87, P3, DOI 10.1007/BF00436615; Rigo K, 2002, J GEN APPL MICROBIOL, V48, P9, DOI 10.2323/jgam.48.9; ROSA RH, 1994, OPHTHALMOLOGY, V101, P1005; RUDWAN MA, 1976, CLIN RADIOL, V27, P497, DOI 10.1016/S0009-9260(76)80116-X; Saito M., 1993, P JPN ASS MYCOTOXICO, V37, P31; SAKAGUCHI K, 1944, NIPPON NOGEIKAGAKU K, V20, P65; Samson RA, 2000, INTRO FOOD AIRBORNE, P64; Saravanan K, 2006, ARCH OTOLARYNGOL, V132, P173, DOI 10.1001/archotol.132.2.173; SARUBBI FA, 1982, AM REV RESPIR DIS, V125, P33; Scheidegger KA, 2003, J TOXICOL-TOXIN REV, V22, P423, DOI 10.1081/TXR-120024100; Seo K, 1999, MICROBIOL IMMUNOL, V43, P1017; Singer S, 1998, MYCOSES, V41, P223; SMITH G, 1943, BR MYCOL SOC T, V25, P24; SMITH G, 1951, BR MYCOL SOC T, V34, P17; Speare A, 1912, HAWAIIAN SUGAR PLANT, V12, P1; Sridhar MS, 2000, AM J OPHTHALMOL, V129, P802, DOI 10.1016/S0002-9394(00)00406-2; STAIB F, 1983, ZBL BAKT-INT J MED M, V255, P361; STAMMBERGER H, 1984, ANN OTO RHINOL LARYN, V93, P251; STATES JS, 1966, MYCOLOGIA, V58, P738, DOI 10.2307/3756848; Sutton D. A., 2004, MED MYCOL S1, V43, pS1; Taj-Aldeen SJ, 2003, EUR ARCH OTO-RHINO-L, V260, P331, DOI 10.1007/s00405-002-0547-x; Taj-Aldeen SJ, 2004, AM J OTOLARYNG, V25, P213, DOI 10.1016/j.amjoto.2003.12.003; TEWARI JP, 1985, MYCOLOGIA, V77, P114, DOI 10.2307/3793255; Thakar A, 2004, OTOLARYNG HEAD NECK, V130, P209, DOI 10.1016/j.otohns.2003.09.004; Church M.B, 1926, ASPERGILLI; THOM C, 1921, AM J BOT, V8, P125; Tran-Dinh N, 1999, MYCOL RES, V103, P1485, DOI 10.1017/S0953756299008710; van Burik JAH, 1998, J CLIN MICROBIOL, V36, P3115; Vanbreuseghem R, 1985, Bull Mem Acad R Med Belg, V140, P147; Vandecasteele SJ, 2002, CLIN INFECT DIS, V35, P887, DOI 10.1086/342699; VandenBergh MFQ, 1999, DIAGN MICR INFEC DIS, V34, P221, DOI 10.1016/S0732-8893(99)00026-7; Varga J, 2003, FOOD TECHNOL BIOTECH, V41, P29; Vonberg RP, 2006, J HOSP INFECT, V63, P246, DOI 10.1016/j.jhin.2006.02.014; Vujanovic V, 2001, ENVIRON TOXICOL, V16, P1; Wang L, 2001, INT J FOOD MICROBIOL, V71, P75, DOI 10.1016/S0168-1605(01)00597-9; Warris A, 2001, J HOSP INFECT, V47, P143, DOI 10.1053/jhin.2000.0876; Wong TY, 1997, INT OPHTHALMOL, V21, P127, DOI 10.1023/A:1026462631716; Yagi HI, 1999, J OTOLARYNGOL, V28, P90; Yu J., 2004, FUNGAL BIOTECHNOLOGY, V21, P343; Yu Jiujiang, 2005, Revista Iberoamericana de Micologia, V22, P194; Yu JJ, 2004, FEMS MICROBIOL LETT, V237, P333, DOI 10.1016/j.femsle.2004.06.054; Zaini F, 1995, J MED COUNCIL ISLAM, V13, P17	172	268	289	5	35	SOC GENERAL MICROBIOLOGY	READING	MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND	1350-0872			MICROBIOL-SGM	Microbiology-(UK)	JUN	2007	153		6				1677	1692		10.1099/mic.0.2007/007641-0		16	Microbiology	Microbiology	179QM	WOS:000247304900001	17526826	
J	Cohen, D; Spear, S; Scribner, R; Kissinger, P; Mason, K; Wildgen, J				Cohen, D; Spear, S; Scribner, R; Kissinger, P; Mason, K; Wildgen, J			"Broken windows" and the risk of gonorrhea	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							SEXUALLY-TRANSMITTED DISEASES; UNITED-STATES POPULATION; COCKROACH ALLERGEN; DRUG-USE; HEALTH; SYPHILIS; BEHAVIOR; CHILDREN; ALCOHOL; NEIGHBORHOODS	Objectives. We examined the relationships between neighborhood conditions and gonorrhea. Methods. We assessed 55 block soups by rating housing and street conditions. We mapped all cases of gonorrhea between 1994 and 1996 and calculated aggregated case rates by block group. We obtained public school inspection reports and assigned findings to the block groups served by the neighborhood schools. A "broken windows" index measured housing quality, abandoned cars, graffiti: trash and public school deterioration. Using data from the 1990 census and 1995 updates, we determined the association between "broken windows," demographic characteristics, and gonorrhea rates. Results. The broken windows index explained more of the variance in gonorrhea rates than did a poverty index measuring: income, unemployment, and low education. in high-poverty neighborhoods, block groups with high broken windows scores had significantly higher gonorrhea rates than block groups with low broken windows scores(46.6 per 1000 vs 25.8 per 1000; P<.001). Conclusions. The robust association of deteriorated physical conditions of local neighborhoods with gonorrhea rates, independent of poverty, merits an intervention trial to test whether the environment has a, causal role in influencing high-risk sexual behaviors.	Louisiana State Univ, Med Ctr, New Orleans, LA 70112 USA; Univ New Orleans, Coll Publ & Urban Affairs, New Orleans, LA 70148 USA	Cohen, D (reprint author), Louisiana State Univ, Med Ctr, 1600 Canal St, New Orleans, LA 70112 USA.						ANDERSON E, 1991, URBAN UNDERCLASS, P375; ARAL SO, 1993, INFECT DIS CLIN N AM, V7, P861; ARAL SO, 1994, SEX TRANSM DIS, V21, pS59; Arfken C L, 1996, Ethn Health, V1, P317; BANDURA A, 1986, SOCIAL FDN THOUGHT A; CIALDINI RB, 1990, J PERS SOC PSYCHOL, V58, P1015, DOI 10.1037/0022-3514.58.6.1015; Cohen MS, 1996, J INFECT DIS, V174, pS223; Diez-Roux AV, 1999, AM J PUBLIC HEALTH, V89, P302, DOI 10.2105/AJPH.89.3.302; Eachus J, 1996, BRIT MED J, V312, P287; Ellen JM, 1998, SEX TRANSM DIS, V25, P125, DOI 10.1097/00007435-199803000-00002; FEATHERMAN DL, 1985, AM SOCIOL REV, V50, P659, DOI 10.2307/2095380; HAHN RA, 1989, AM J PUBLIC HEALTH, V79, P467, DOI 10.2105/AJPH.79.4.467; Hays RD, 1996, ADDICT BEHAV, V21, P291, DOI 10.1016/0306-4603(95)00059-3; *I MED, 1997, PREV STDS; Jacobs J., 1961, DEATH LIFE GREAT AM; Johnstone B., 1994, RES MONOGRAPH, V26, P169; KANDEL DB, 1992, J STUD ALCOHOL, V53, P447; Kelling G. L., 1996, FIXING BROKEN WINDOW; Kenyon TA, 1998, PEDIATRICS, V101, P612, DOI 10.1542/peds.101.4.612; Kilmarx PH, 1997, AM J PUBLIC HEALTH, V87, P1937, DOI 10.2105/AJPH.87.12.1937; Lacey CJN, 1997, BRIT MED J, V314, P1715; Landrine H, 1997, J BLACK PSYCHOL, V23, P135, DOI 10.1177/009579849702320041997-04329-003.; MACKENBACH JP, 1994, BRIT MED J, V309, P1487; MARMOT MG, 1991, LANCET, V337, P1387; MARX R, 1991, SEX TRANSM DIS, V18, P92; Moore David J., 1996, Ethnicity and Disease, V6, P83; MORAN JS, 1989, PUBLIC HEALTH REP, V104, P560; MYRDAL G, 1944, AM DILEMMA, V1, P1290; Nakashima AK, 1996, SEX TRANSM DIS, V23, P16, DOI 10.1097/00007435-199601000-00006; O'Loughlin J, 1998, ANN EPIDEMIOL, V8, P422, DOI 10.1016/S1047-2797(98)00009-X; PINCUS T, 1987, J CHRON DIS, V40, P865, DOI 10.1016/0021-9681(87)90186-X; RENO RR, 1993, J PERS SOC PSYCHOL, V64, P104, DOI 10.1037//0022-3514.64.1.104; ROSE G., 1992, STRATEGY PREVENTIVE; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHORR AL, 1970, NEIGHBORHOOD CITY ME, P709; Scribner RA, 1998, SEX TRANSM DIS, V25, P544, DOI 10.1097/00007435-199811000-00009; Shao C, 1996, Chin Med Sci J, V11, P252; SHEWRY MC, 1992, BRIT J GEN PRACT, V42, P406; Skogan W., 1990, DISORDER DECLINE CRI; SMITH GD, 1990, J EPIDEMIOL COMMUN H, V44, P265, DOI 10.1136/jech.44.4.265; Wallace R, 1996, SOC SCI MED, V43, P339, DOI 10.1016/0277-9536(95)00395-9; WALLACE R, 1990, SOC SCI MED, V31, P801, DOI 10.1016/0277-9536(90)90175-R; WILKINSON RG, 1996, UNHEALTHY SOC AFFLIC, P137; WILNER DM, 1960, AM J PUBLIC HEALTH N, V50, P55; Wilson JQ, 1989, CRITICAL ISSUES POLI; Wilson W. J, 1987, TRULY DISADVANTAGED; Wingood GM, 1998, AM J PREV MED, V15, P54, DOI 10.1016/S0749-3797(98)00027-0; ZENILMAN JM, 1994, SEX TRANSM DIS, V21, P220, DOI 10.1097/00007435-199407000-00008; 1998, MMWR MORB MORTAL WKL, V47, P956	51	267	268	11	33	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	FEB	2000	90	2					230	236		10.2105/AJPH.90.2.230		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	278QA	WOS:000084999400012	10667184	
J	Eisner, MD; Anthonisen, N; Coultas, D; Kuenzli, N; Perez-Padilla, R; Postma, D; Romieu, I; Silverman, EK; Balmes, JR				Eisner, Mark D.; Anthonisen, Nicholas; Coultas, David; Kuenzli, Nino; Perez-Padilla, Rogelio; Postma, Dirkje; Romieu, Isabelle; Silverman, Edwin K.; Balmes, John R.		Environm & Occupational Hlth	An Official American Thoracic Society Public Policy Statement: Novel Risk Factors and the Global Burden of Chronic Obstructive Pulmonary Disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						pulmonary disease, chronic obstructive; pulmonary emphysema; chronic bronchitis; respiratory function tests; genetics; diet; asthma; air pollution; air pollution, indoor; tobacco smoke pollution; biomass; occupational exposure; occupational diseases; diet; nutritional status; tuberculosis	AIR-FLOW OBSTRUCTION; LUNG-FUNCTION DECLINE; CHRONIC RESPIRATORY SYMPTOMS; 3RD NATIONAL-HEALTH; NUTRITION EXAMINATION SURVEY; ENVIRONMENTAL TOBACCO-SMOKE; HOGG-DUBE-SYNDROME; SEVERE ALPHA(1)-ANTITRYPSIN DEFICIENCY; RESOLUTION COMPUTED-TOMOGRAPHY; SOUTHERN CALIFORNIA CHILDREN	Rationale: Although cigarette smoking is the most important cause of chronic obstructive pulmonary disease (COPD), a substantial proportion of COPD cases cannot be explained by smoking alone. Objectives: To evaluate the risk factors for COPD besides personal cigarette smoking. Methods: We constituted an ad hoc subcommittee of the American Thoracic Society Environmental and Occupational Health Assembly. An international group of members was invited, based on their scientific expertise in a specific risk factor for COPD. For each risk factor area, the committee reviewed the literature, summarized the evidence, and developed conclusions about the likelihood of it causing COPD. All conclusions were based on unanimous consensus. Measurements and Main Results: The population-attributable fraction for smoking as a cause of COPD ranged from 9.7 to 97.9%, but was less than 80% in most studies, indicating a substantial burden of disease attributable to nonsmoking risk factors. On the basis of our review, we concluded that specific genetic syndromes and occupational exposures were causally related to the development of COPD. Traffic and other outdoor pollution, secondhand smoke, biomass smoke, and dietary factors are associated with COPD, but sufficient criteria for causation were not met. Chronic asthma and tuberculosis are associated with irreversible loss of lung function, but there remains uncertainty about whether there are important phenotypic differences compared with COPD as it is typically encountered in clinical settings. Conclusions: In public health terms, a substantive burden of COPD is attributable to risk factors other than smoking. To prevent COPD-related disability and mortality, efforts must focus on prevention and cessation of exposure to smoking and these other, less well-recognized risk factors.				Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	Roche; NIH; State of California Tobacco-Related Disease Research Program; Flight Attendant Medical Research Institute; GlaxoSmithKline; Boehringer Ingelheim; Nycomed	M.D.E. became an employee of Genentech subsequent to submission of manuscript; he was a consultant to Genentech ($5,001-$10,000) and Novartis ($5,001-$10,000), was an expert witness for DLA Piper LLP ($5,001-$10,000), received research grants from Roche ($50,001-$100,000) and NIH (more than $100,001), and an NIH study section reviewer (up to $1,000). N.A. served on an advisory board of GlaxoSmithKline ($5,001-$10,000) and as chair of the American Lung Association asthma clinical centers research project ($15,000/year). D.C. served on advisory boards of Boehringer Ingelheim (up tp $1,000) and Pfizer (up to $1,000) and as a grant reviewer for the State of California Tobacco-Related Disease Research Program (up to $1,000) and the Flight Attendant Medical Research Institute (up to $1,000). N.K. holds stock in Roche Holding Basel ($1,001-$5,000). R.P-P. received lecture fees from GlaxoSmithKline (up to $1,000) and Boehringer Ingelheim (up to $1,000). D.P. served on advisory boards of GlaxoSmithKline (up to $1,000), AstraZeneca (up to $1,000) and Nycomed (up to $1,000); he received lecture fees from GlaxoSmithKline ($1,001-$5,000), AstraZeneca ($1,001-5,000), and Nycomed ($1,001-$5,000), and received research grants from GlaxoSmithKline (more than $100,001), AstraZeneca ($50,001-100,000) and Nycomed ($50,001-100,000). I.R. reported she had nothing to disclose relevant to this manuscript. E.K.S. was a consultant to GlaxoSmithKline ($10,001-$50,000) and AstraZeneca ($5,001-$10,000), received lecture fees from GlaxoSmithKline ($1,001-$5,000), AstraZeneca ($1,001-$5,000) and Bayer ($1,001-$5,000), and research grants from GlaxoSmithKline (more than $100,001) and NIH (more than $100,001). J.R.B. served on an advisory board of the U.S. EPA ($1,001-$5,000), chaired the California Air Resources Board ($10,001-$50,000), and received book royalties from McGraw-Hill (up to $1,000).	Abbey DE, 1998, AM J RESP CRIT CARE, V158, P289; AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; Akhtar T, 2007, CHEST, V132, P1472, DOI 10.1378/chest.06-2529; Albalak R, 1999, THORAX, V54, P1004; Allwright S, 2005, BRIT MED J, V331, P1117, DOI 10.1136/bmj.38636.499225.55; ALMIND M, 1992, DAN MED BULL, V39, P561; ANDERSON HR, 1979, THORAX, V34, P647, DOI 10.1136/thx.34.5.647; ANDERSON HR, 1976, AM REV RESPIR DIS, V114, P537; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; ASTEMBORSKI JA, 1985, AM J MED GENET, V21, P741, DOI 10.1002/ajmg.1320210417; ATTFIELD MD, 1992, AM REV RESPIR DIS, V145, P605; ATTFIELD MD, 1985, THORAX, V40, P132, DOI 10.1136/thx.40.2.132; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; Ayo DS, 2007, CHEST, V132, P679, DOI 10.1378/chest.07-0042; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; BAKKE P, 1991, EUR RESPIR J, V4, P273; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BECKLAKE MR, 1987, AM REV RESPIR DIS, V135, P1234; Behera D, 1997, Indian J Chest Dis Allied Sci, V39, P235; BEHERA D, 1991, CHEST, V100, P385, DOI 10.1378/chest.100.2.385; BEHERA D, 1994, RESPIRATION, V61, P89; Bense L, 2002, CHEST, V121, P297, DOI 10.1378/chest.121.1.297; Bergdahl IA, 2004, EUR RESPIR J, V23, P402, DOI 10.1183/09031936.04.00034304; Berglund DJ, 1999, CHEST, V115, P49, DOI 10.1378/chest.115.1.49; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; BLACK LF, 1978, AM REV RESPIR DIS, V117, P421; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Blanc P D, 2007, Int J Tuberc Lung Dis, V11, P251; Blanc PD, 2009, THORAX, V64, P6, DOI 10.1136/thx.2008.099390; Boggia B, 2008, J OCCUP ENVIRON MED, V50, P366, DOI 10.1097/JOM.0b013e318162f601; Bonner JC, 2000, AM J PHYSIOL-LUNG C, V278, pL209; BORSBOOM GJJM, 1993, AM REV RESPIR DIS, V147, P372; Boulet L P, 1998, Can Respir J, V5, P270; BRAMAN SS, 1991, AM REV RESPIR DIS, V143, P336; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; BURROWS B, 1987, NEW ENGL J MED, V317, P1309, DOI 10.1056/NEJM198711193172103; Butland BK, 2000, THORAX, V55, P102, DOI 10.1136/thorax.55.2.102; Caballero A, 2008, CHEST, V133, P343, DOI 10.1378/chest.07-1361; Carey IM, 1998, AM J RESP CRIT CARE, V158, P728; Cassino C, 2000, AM J RESP CRIT CARE, V162, P1423; Cetinkaya F, 2000, Monaldi Arch Chest Dis, V55, P189; Chan-Yeung M, 2007, INT J TUBERC LUNG D, V11, P502; Chapman RS, 2005, BRIT MED J, V331, P1050, DOI 10.1136/bmj.38628.676088.55; Chen RL, 2001, AM J EPIDEMIOL, V153, P157, DOI 10.1093/aje/153.2.157; Chen Y, 2000, J CLIN EPIDEMIOL, V53, P755, DOI 10.1016/S0895-4356(99)00211-5; CHURG A, 1989, EXP LUNG RES, V15, P813, DOI 10.3109/01902148909069628; Chuwers P, 1997, AM J RESP CRIT CARE, V155, P1066; COCKCROFT A, 1982, LANCET, V2, P600; Collins R, 2002, LANCET, V360, P23; Committee on Gulf War and Health, 2005, GULF WAR HLTH, V3; CONNOLLY CK, 1988, POSTGRAD MED J, V64, P422; Cowie HA, 2006, OCCUP ENVIRON MED, V63, P320, DOI 10.1136/oem.2005.021253; DAYAL HH, 1994, ENVIRON RES, V65, P161, DOI 10.1006/enrs.1994.1029; de Marco R, 2004, THORAX, V59, P120, DOI 10.1136/thorax.2003.011163; de Marco R, 2007, AM J RESP CRIT CARE, V175, P32, DOI 10.1164/rccm.200603-381OC; de Meer Gea, 2004, Environ Health, V3, P6; DeMeo DL, 2007, THORAX, V62, P806, DOI 10.1136/thx.2006.075846; Demeo DL, 2008, AM J RESP CELL MOL, V38, P114, DOI 10.1165/rcmb.2007-0107OC; DeMeo DL, 2004, AM J RESP CRIT CARE, V170, P1294, DOI 10.1164/rccm.200404-5240C; DeMeo DL, 2004, THORAX, V59, P396, DOI 10.1136/thx.2003.012856; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; DEVOR EJ, 1984, ANN HUM BIOL, V11, P439, DOI 10.1080/03014468400007331; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; DIMICHWARD H, 1998, AM J RESP CRIT CARE, V157, pA505; DOMINGUEZ R, 1987, PEDIATR RADIOL, V17, P365, DOI 10.1007/BF02396609; Donaldson K, 2002, J AEROSOL MED, V15, P213, DOI 10.1089/089426802320282338; DOSSING M, 1994, RESP MED, V88, P519, DOI 10.1016/S0954-6111(05)80334-8; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Dowton SB, 1996, CLIN GENET, V50, P510; Dutt D, 1996, NATL MED J INDIA, V9, P113; Eagan TML, 2006, TOB CONTROL, V15, P242, DOI 10.1136/tc.2005.015479; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Eisner MD, 1998, JAMA-J AM MED ASSOC, V280, P1909, DOI 10.1001/jama.280.22.1909; Ekici A, 2005, ENVIRON RES, V99, P93, DOI 10.1016/j.envres.2005.01.004; Ellegard A, 1996, ENVIRON HEALTH PERSP, V104, P980, DOI 10.2307/3433146; Ellingsen DG, 2006, J ENVIRON MONITOR, V8, P362, DOI 10.1039/b600050a; EULER GL, 1987, ARCH ENVIRON HEALTH, V42, P213; Ezzati M, 2003, LANCET, V362, P847, DOI 10.1016/S0140-6736(03)14338-3; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Farrelly MC, 2005, TOB CONTROL, V14, P236, DOI 10.1136/tc.2004.008839; Fishwick D, 1997, AM J RESP CRIT CARE, V156, P1440; FLETCHER C, 1977, BRIT MED J, V1, P1645; Fletcher C, 1976, NATURAL HIST CHRONIC; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390; Frye C, 2003, ENVIRON HEALTH PERSP, V111, P383, DOI 10.1289/ehp.5355; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Geijer RMM, 2006, BRIT J GEN PRACT, V56, P656; GERRITSEN J, 1990, J ALLERGY CLIN IMMUN, V85, P116, DOI 10.1016/0091-6749(90)90232-S; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325; GHIO AJ, 1989, CHEST, V96, P743, DOI 10.1378/chest.96.4.743; Goodman P, 2007, AM J RESP CRIT CARE, V175, P840, DOI 10.1164/rccm.200608-1085OC; GOTSCHI T, 2007, THESIS U SO CALIFORN, P172; Grievink L, 1998, THORAX, V53, P166; Grol MH, 1999, AM J RESP CRIT CARE, V160, P150; Guenegou A, 2006, THORAX, V61, P320, DOI 10.1136/thx.2005.047373; Hahn EJ, 2006, J OCCUP ENVIRON MED, V48, P906, DOI 10.1097/01.jom.0000215709.09305.01; Halbert RJ, 2003, CHEST, V123, P1684, DOI 10.1378/chest.123.5.1684; HARKEMA JR, 1993, TOXICOL LETT, V68, P251, DOI 10.1016/0378-4274(93)90136-L; Hersh CP, 2005, AM J RESP CELL MOL, V33, P71, DOI 10.1165/rcmb.2005-0073OC; Hertzberg VS, 2002, CHEST, V122, P721, DOI 10.1378/chest.122.2.721; HIGGINS M, 1975, J CHRON DIS, V28, P239, DOI 10.1016/0021-9681(75)90053-3; HILL AB, 1965, P ROY SOC MED, V58, P295; HNIZDO E, 1990, SCAND J WORK ENV HEA, V16, P411; HNIZDO E, 1991, AM REV RESPIR DIS, V143, P1241; Hnizdo E, 2002, AM J EPIDEMIOL, V156, P738, DOI 10.1093/aje/kwf105; Hnizdo E, 2000, THORAX, V55, P32, DOI 10.1136/thorax.55.1.32; Hogervorst JGF, 2006, J TOXICOL ENV HEAL A, V69, P245, DOI 10.1080/15287390500227431; Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC; HOLMAN CDJ, 1987, BRIT J IND MED, V44, P810; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Hu GZ, 2000, AM J EPIDEMIOL, V151, P975; Hu Y, 2006, THORAX, V61, P290, DOI 10.1136/thx.2005.051524; HUBERT HB, 1982, AM REV RESPIR DIS, V125, P409; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; HUMERFELT S, 1993, EUR RESPIR J, V6, P1095; HUNTER DJ, 1993, NEW ENGL J MED, V329, P234, DOI 10.1056/NEJM199307223290403; Ihorst G, 2004, EUR RESPIR J, V23, P292, DOI 10.1183/09031936.04.00021704; Iribarren C, 2001, J EPIDEMIOL COMMUN H, V55, P721, DOI 10.1136/jech.55.10.721; JAAKKOLA MS, 1993, AM REV RESPIR DIS, V147, P359; Jaen Angeles, 2006, Environ Health, V5, P2, DOI 10.1186/1476-069X-5-2; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; JANUS ED, 1985, LANCET, V1, P152; Jayet PY, 2005, SCAND J WORK ENV HEA, V31, P465; Jiang R, 2008, AM J CLIN NUTR, V87, P1002; Jiang R, 2007, AM J RESP CRIT CARE, V175, P798, DOI 10.1164/rccm.200607-9690C; Jindal S K, 2006, Indian J Chest Dis Allied Sci, V48, P23; Johannessen A, 2005, THORAX, V60, P842, DOI 10.1136/thx.2005.043943; Kan HD, 2007, THORAX, V62, P873, DOI 10.1136/thx.2006.073015; Karakatsani A, 2003, EUR J EPIDEMIOL, V18, P45; KAUFFMANN F, 1982, BRIT J IND MED, V39, P221; KELLY WJW, 1987, BRIT MED J, V294, P1059; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26; Kelly Y, 2003, EUR RESPIR J, V21, P664, DOI 10.1183/09031936.03.00055702; Kim DS, 2005, AM J RESP CRIT CARE, V172, P842, DOI 10.1164/rccm.200502-259OC; Kim SJ, 2006, INT J TUBERC LUNG D, V10, P1393; Kiraz K, 2003, CLIN INVEST MED, V26, P243; KOKKONEN J, 1993, EUR RESPIR J, V6, P657; KONDOH Y, 1990, CHEST, V97, P845, DOI 10.1378/chest.97.4.845; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298; KRZYZANOWSKI M, 1988, INT J EPIDEMIOL, V17, P397, DOI 10.1093/ije/17.2.397; KRZYZANOWSKI M, 1990, INT ARCH OCC ENV HEA, V62, P311, DOI 10.1007/BF00640839; KRZYZANOWSKI M, 1986, AM REV RESPIR DIS, V134, P1011; Kulkarni N, 2006, NEW ENGL J MED, V355, P21, DOI 10.1056/NEJMoa052972; Lal Kewal, 1993, Indian Journal of Experimental Biology, V31, P761; Lamprecht B, 2007, AM J IND MED, V50, P421, DOI 10.1002/ajim.20470; Lange P, 2006, THORAX, V61, P100, DOI 10.1136/thx.2004.037978; Lange P, 2003, AGE AGEING, V32, P636, DOI 10.1093/ageing/afg108; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LARSSON C, 1978, ACTA MED SCAND, V204, P345; LEBOWITZ MD, 1977, ENVIRON RES, V14, P59, DOI 10.1016/0013-9351(77)90066-4; LEBOWITZ MD, 1984, AM REV RESPIR DIS, V129, P8; LEIGH J, 1994, OCCUP ENVIRON MED, V51, P400; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; LeVan TD, 2006, AM J EPIDEMIOL, V163, P1118, DOI 10.1093/aje/kwj144; LEWITTER FI, 1984, AM J EPIDEMIOL, V120, P518; Lindberg A, 2006, CHEST, V129, P879, DOI 10.1378/chest.129.4.879; Lindberg A, 2006, RESP MED, V100, P264, DOI 10.1016/j.rmed.2005.04.029; Lindberg A, 2005, RESPIRATION, V72, P471, DOI 10.1159/000087670; Lindberg A, 2005, CHEST, V127, P1544, DOI 10.1378/chest.127.5.1544; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802; LOVE RG, 1982, THORAX, V37, P193, DOI 10.1136/thx.37.3.193; LOWE CR, 1956, BRIT MED J, V2, P1081; Lundback B, 2003, RESP MED, V97, P115, DOI 10.1053/rmed.2003.1446; Mak GK, 2001, AM J MED SCI, V322, P121, DOI 10.1097/00000441-200109000-00002; Malarcher AM, 2000, AM J EPIDEMIOL, V152, P573, DOI 10.1093/aje/152.6.573; Malik S K, 1985, Indian J Chest Dis Allied Sci, V27, P171; MALIK S K, 1984, Indian Journal of Chest Diseases and Allied Sciences, V26, P200; MAN SFP, 1976, J APPL PHYSIOL, V41, P874; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Mannino DM, 2003, AM J MED, V114, P758, DOI 10.1016/S0002-9343(03)00185-2; MASTER KM, 1974, JAMA-J AM MED ASSOC, V228, P1653, DOI 10.1001/jama.228.13.1653; Matheson MC, 2005, THORAX, V60, P645, DOI 10.1136/thx.2004.035170; Mayer AS, 2000, AM J RESP CRIT CARE, V162, P553; Maziak W, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-13; McCloskey SC, 2001, AM J RESP CRIT CARE, V164, P1419; McKeever TM, 2008, THORAX, V63, P208, DOI 10.1136/thx.2007.090399; McKeever TM, 2002, AM J RESP CRIT CARE, V165, P1299, DOI 10.1164/rccm.2109030; Meijer E, 2001, AM J IND MED, V40, P133, DOI 10.1002/ajim.1080; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; MENEZES AMB, 1994, THORAX, V49, P1217, DOI 10.1136/thx.49.12.1217; Menezes A.M.B., 2007, EURRESPIRJ, V30, P1; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; MIEDEMA I, 1993, AM J EPIDEMIOL, V138, P37; Mishra V K, 1999, Int J Infect Dis, V3, P119, DOI 10.1016/S1201-9712(99)90032-2; Monso E, 2000, AM J RESP CRIT CARE, V162, P1246; Montnemery P, 2001, RESP MED, V95, P744, DOI 10.1053/rmed.2001.1129; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Nakai S, 1999, ARCH ENVIRON HEALTH, V54, P26; Neuberger M, 2002, ATMOS ENVIRON, V36, P1733, DOI 10.1016/S1352-2310(02)00179-6; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nihlen U, 2004, RESP MED, V98, P263, DOI 10.1016/j.rmed.2003.10.006; Nocturnal Oxygen Therapy Trial Group, 1980, ANN INTERN MED, V93, P391; *OFF ENV HLTH HAZ, 2005, HLTH EFF ASS ENV TOB; Orozco-Levi M, 2006, EUR RESPIR J, V27, P542, DOI 10.1183/09031936.06.00052705; OSTERGAARD PAA, 1988, ACTA PAEDIATR SCAND, V77, P112, DOI 10.1111/j.1651-2227.1988.tb10608.x; PADMAVATI S, 1976, BRIT J DIS CHEST, V70, P251, DOI 10.1016/0007-0971(76)90040-1; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; Painter JN, 2005, AM J HUM GENET, V76, P522, DOI 10.1086/428455; Palmer LJ, 2001, EUR RESPIR J, V17, P696, DOI 10.1183/09031936.01.17406960; Pandey M R, 1985, Tokai J Exp Clin Med, V10, P471; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; Pandey MR, 1988, CHRONIC BRONCHITIS C; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267; Panhuysen CI, 1997, AM J RESP CRIT CARE, V156, P674; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pelkonen M, 2006, CHEST, V130, P1129, DOI 10.1378/chest.130.4.1129; Perez-Padilla R, 2001, INT J TUBERC LUNG D, V5, P441; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Piitulainen E, 1997, THORAX, V52, P244; POST WK, 1994, EUR RESPIR J, V7, P1048; Postma DS, 2005, AM J RESP CRIT CARE, V172, P446, DOI 10.1164/rccm.200407-864OC; POSTMA DS, 1995, ARCH INTERN MED, V155, P1393, DOI 10.1001/archinte.155.13.1393; Ramirez-Venegas A, 2006, AM J RESP CRIT CARE, V173, P393, DOI 10.1164/rccm.200504-568OC; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Rautalahti M, 1997, AM J RESP CRIT CARE, V156, P1447; REDLINE S, 1987, AM REV RESPIR DIS, V135, P217; Regalado J, 2006, AM J RESP CRIT CARE, V174, P901, DOI 10.1164/rccm.200503-479OC; Ricciardolo FLM, 2006, EUR J PHARMACOL, V533, P240, DOI 10.1016/j.cjphar.2005.12.057; Rinne ST, 2006, RESP MED, V100, P1208, DOI 10.1016/j.rmed.2005.10.020; ROBBINS AS, 1993, INT J EPIDEMIOL, V22, P809, DOI 10.1093/ije/22.5.809; Rodriguez-Revenga L, 2004, ARCH DERMATOL, V140, P1135, DOI 10.1001/archderm.140.9.1135; Rojas-Martinez R, 2007, AM J RESP CRIT CARE, V176, P377, DOI 10.1164/rccm.200510-1678OC; Romieu I, 2001, EPIDEMIOL REV, V23, P268; ROORDA RJ, 1994, J ALLERGY CLIN IMMUN, V93, P575, DOI 10.1016/S0091-6749(94)70069-9; RUCKLEY VA, 1984, BRIT J IND MED, V41, P459; Saha A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-127; SANDOVAL J, 1993, CHEST, V103, P12, DOI 10.1378/chest.103.1.12; SCHACHTER EN, 1984, CHEST, V85, P623, DOI 10.1378/chest.85.5.623; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; Schunemann HJ, 2001, EPIDEMIOL REV, V23, P248; Schunemann HJ, 2002, AM J EPIDEMIOL, V155, P463, DOI 10.1093/aje/155.5.463; Schunemann HJ, 2001, AM J RESP CRIT CARE, V163, P1246; SEERSHOLM N, 1994, THORAX, V49, P1184; SEERSHOLM N, 1994, THORAX, V49, P695, DOI 10.1136/thx.49.7.695; Seersholm N, 1998, THORAX, V53, P78; SEIXAS NS, 1993, BRIT J IND MED, V50, P929; Sekine K, 2004, OCCUP ENVIRON MED, V61, P350, DOI 10.1136/oem.2002.005934; Sezer H, 2006, ANN EPIDEMIOL, V16, P59, DOI 10.1016/j.annepidem.2004.12.014; SHAHAR E, 1994, NEW ENGL J MED, V331, P228, DOI 10.1056/NEJM199407283310403; Shapiro S., 2000, CHEST, V117, P223; SHARP DS, 1994, AM J RESP CRIT CARE, V150, P983; SHORE S, 1995, AM J RESP CRIT CARE, V151, P1931; Shrestha IL, 2005, INT J OCCUP ENV HEAL, V11, P150; Silverman Edwin K, 2006, Proc Am Thorac Soc, V3, P405, DOI 10.1513/pats.200603-092AW; Silverman EK, 1998, AM J RESP CRIT CARE, V157, P1770; Simoni M, 2007, RESP MED, V101, P531, DOI 10.1016/j.rmed.2006.06.021; Sitas F, 2004, TOB CONTROL, V13, P396, DOI 10.1136/tc.2004.007682; Skogstad M, 2006, OCCUP ENVIRON MED, V63, P482, DOI 10.1136/oem.2005.024638; Smith K. R., 1987, BIOFUELS AIR POLLUTI; Suadicani P, 2001, OCCUP ENVIRON MED, V58, P160, DOI 10.1136/oem.58.3.160; Sugiri D, 2006, ENVIRON HEALTH PERSP, V114, P282, DOI 10.1289/ehp.8180; Sunyer J, 2005, AM J RESP CRIT CARE, V172, P1139, DOI 10.1164/rccm.200504-648OC; Sunyer J, 2001, EUR RESPIR J, V17, P1024, DOI 10.1183/09031936.01.17510240; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512; Tabak C, 2001, CLIN EXP ALLERGY, V31, P747, DOI 10.1046/j.1365-2222.2001.01064.x; Tabak C, 1998, EUR J CLIN NUTR, V52, P819, DOI 10.1038/sj.ejcn.1600653; Tager IB, 2005, EPIDEMIOLOGY, V16, P751, DOI 10.1097/01.ede.0000183166.68809.b0; TAGER IB, 1976, AM REV RESPIR DIS, V114, P485; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Tennant PWG, 2008, THORAX, V63, P823, DOI 10.1136/thx.2008.096388; Tesfaigzi Y, 2005, TOXICOL SCI, V88, P505, DOI 10.1093/toxsci/kfi317; TOBIN MJ, 1983, BRIT J DIS CHEST, V77, P14, DOI 10.1016/S0007-0971(83)80054-0; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; TURNERSTOKES L, 1983, THORAX, V38, P790, DOI 10.1136/thx.38.10.790; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; ULRIK CS, 1995, RESP MED, V89, P547, DOI 10.1016/0954-6111(95)90156-6; Ulvestad B, 2001, OCCUP ENVIRON MED, V58, P663, DOI 10.1136/oem.58.10.663; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; U. S. Department of Health and Human Services, 1984, HLTH CONS SMOK CHRON; United States Department of Health and Human Services, 2004, HLTH CONS SMOK REP S; [Anonymous], 1964, REP ADV COMM SURG GE; VANMALDERGEM L, 1988, AM J MED GENET, V31, P455, DOI 10.1002/ajmg.1320310226; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Wang M-L, 2005, Occup Environ Med, V62, P800, DOI 10.1136/oem.2005.020271; Weinmann S, 2008, J OCCUP ENVIRON MED, V50, P561, DOI 10.1097/JOM.0b013e3181651556; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Wilk JB, 2007, AM J RESP CRIT CARE, V175, P554, DOI 10.1164/rccm.200601-110OC; Wilson David, 2005, Chest, V128, P2035, DOI 10.1378/chest.128.4.2035; WOOD JR, 1984, THORAX, V39, P780, DOI 10.1136/thx.39.10.780; WOOLCOCK AJ, 1970, AM REV RESPIR DIS, V102, P575; WOOLCOCK AJ, 1967, AUSTRALAS ANN MED, V16, P11; XU XP, 1992, AM REV RESPIR DIS, V146, P413; Yilmaz S, 2006, EUR J RADIOL, V59, P238, DOI 10.1016/j.ejrad.2006.03.004; Yin P, 2007, LANCET, V370, P751, DOI 10.1016/S0140-6736(07)61378-6; Zbar B, 2002, CANCER EPIDEM BIOMAR, V11, P393; Zhong N, 2007, AM J RESP CRIT CARE, V176, P753, DOI 10.1164/rccm.200612-17490C; Zhou Xiaotie, 1995, Zhonghua Yufang Yixue Zazhi, V29, P38; Zock JP, 2001, AM J RESP CRIT CARE, V163, P1572	306	265	278	8	42	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2010	182	5					693	718		10.1164/rccm.200811-1757ST		26	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	645UP	WOS:000281492000015	20802169	
J	Corbett, JJ; Winebrake, JJ; Green, EH; Kasibhatla, P; Eyring, V; Lauer, A				Corbett, James J.; Winebrake, James J.; Green, Erin H.; Kasibhatla, Prasad; Eyring, Veronika; Lauer, Axel			Mortality from ship emissions: A global assessment	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Article							AIR-POLLUTION; OCEAN; MODEL; HEALTH	Epidemiological studies consistently link ambient concentrations of particulate matter (PM) to negative health impacts, including asthma, heart attacks, hospital admissions, and premature mortality. We model ambient PM concentrations from oceangoing ships using two geospatial emissions inventories and two global aerosol models. We estimate global and regional mortalities by applying ambient PM increases due to ships to cardiopulmonary and lung cancer concentration-risk functions and population models. Our results indicate that shipping-related PM emissions are responsible for approximately 60,000 cardiopulmonary and lung cancer deaths annually, with most deaths occurring near coastlines in Europe, East Asia, and South Asia. Under current regulation and with the expected growth in shipping activity, we estimate that annual mortalities could increase by 40% by 2012.	[Corbett, James J.] Univ Delaware, Coll Marine & Earth Studies, Newark, DE 19716 USA; [Winebrake, James J.; Green, Erin H.] Rochester Inst Technol, Dept STS Publ Policy, Rochester, NY 14623 USA; [Kasibhatla, Prasad] Duke Univ, Nicholas Sch Environm, Durham, NC USA; [Eyring, Veronika; Lauer, Axel] Deutches Zentrum Luft & Raumfahrt, Inst Phys Atmosphaere, Wessling, Germany	Corbett, JJ (reprint author), Univ Delaware, Coll Marine & Earth Studies, 305 Robinson Hall, Newark, DE 19716 USA.	jcorbett@udel.edu	Corbett, James/B-3321-2009; Kasibhatla, Prasad/A-2574-2010; Winebrake, James/D-2478-2010; Eyring, Veronika/O-9999-2016	Corbett, James/0000-0002-2588-3474; Eyring, Veronika/0000-0002-6887-4885; Kasibhatla, Prasad/0000-0003-3562-3737			*ABT ASS, 2005, BENMAP ENV BEN MAPP, P275; Anderson HR, 2004, METAANALYSIS TIME SE; Bailey D, 2004, ENVIRON IMPACT ASSES, V24, P749, DOI 10.1016/j.eiar.2004.06.005; Bey I, 2001, J GEOPHYS RES-ATMOS, V106, P23073, DOI 10.1029/2001JD000807; *CAL AIR RES BOARD, 2006, APP QUANT HLTH IMP E; *CAL AIR RES BOARD, 2006, PROP EM RED PLAN POR; Capaldo K, 1999, NATURE, V400, P743; Cofala J, 2007, FINAL REPORT ANAL PO, P74; Cohen AJ, 2005, J TOXICOL ENV HEAL A, V68, P1301, DOI 10.1080/15287390590936166; Cohen A. J., 2004, COMP QUANTIFICATION, V2, P1353; Corbett JJ, 1999, J GEOPHYS RES-ATMOS, V104, P3457, DOI 10.1029/1998JD100040; Corbett JJ, 2000, ENVIRON SCI TECHNOL, V34, P3254, DOI 10.1021/es9911768; Corbett JJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003751; Corbett J.J., 2007, ALLOCATION FORECASTI, P26; Davis DL, 1997, LANCET, V350, P1341, DOI 10.1016/S0140-6736(97)10209-4; Endresen O, 2003, J GEOPHYS RES D, V108; European Commission ENTECUK Limited, 2002, QUANT EM SHIPS ASS S; Eyring V, 2005, J GEOPHYS RES-ATMOS, V110, DOI DOI 10.1029/2004JD005619; Hodan W. B., 2004, EVALUATING CONTRIBUT; KAISER J, 2005, SCIENCE, V307, pA1858, DOI 10.1126/science.307.5717.1858a; Krewski D, 2000, REANALYSIS HARVARD 6; Lauer A, 2007, ATMOS CHEM PHYS, V7, P5061; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Ostro B, 2004, OUTDOOR AIR POLLUTIO; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132; *SEDAC, 2007, GRIDD POP WORLD; Streets DG, 2000, ATMOS ENVIRON, V34, P4425, DOI 10.1016/S1352-2310(00)00175-8; Streets D. G., 2003, J GEOPHYS RES, V108; *US CENS BUR, 2006, INT DAT BAS IDB DAT; Wang CF, 2007, ENVIRON SCI TECHNOL, V41, P3226, DOI 10.1021/es060752e; World Health Organization, 2004, REV GLOB BURD DIS GB	32	264	272	10	82	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X			ENVIRON SCI TECHNOL	Environ. Sci. Technol.	DEC 15	2007	41	24					8512	8518		10.1021/es071686z		7	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	240JB	WOS:000251582800050	18200887	
J	Rabe, KF; Bateman, ED; O'Donnell, D; Witte, S; Bredenbroker, D; Bethke, TD				Rabe, KF; Bateman, ED; O'Donnell, D; Witte, S; Bredenbroker, D; Bethke, TD			Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial	LANCET			English	Article							AIR-FLOW LIMITATION; PHOSPHODIESTERASE-4 INHIBITOR; PDE4 INHIBITOR; HEALTH-STATUS; IN-VITRO; ASTHMA; COPD; BURDEN; FLUTICASONE; SALMETEROL	Background Chronic-obstructive pulmonary disease (COPD) is characterised by progressive airflow limitation associated with chronic inflammation. There are few treatment options for the disease. This study assessed the efficacy and safety of roflumilast, a phosphodiesterase-4 inhibitor, in patients with moderate to severe COPD. Methods This phase III, multicentre, double-blind, randomised, placebo-controlled study was undertaken in an outpatient setting. 1411 patients with COPD were randomly assigned roflumilast 250 mu g (n=576), roflumilast 500 mu g (n=555), or placebo (n=280) given orally once daily for 24 weeks. Primary outcomes were postbronchodilator FEV1 and health-related quality of life. Secondary outcomes included other lung function parameters and COPD exacerbations. Analyses were by intention to treat. Findings 1157 (82%) patients completed the study; 32 (11%) withdrew from the placebo group, 100 (17%) from the roflumilast 250 mu g group, and 124 (22%) from the roflumilast 500 mu g group. Postbronchodilator FEV1 at the end of treatment significantly improved with roflumilast 250 mu g (by 74 mL [SD 18]) and roflumilast 500 mu g (by 97 mL [18]) compared with placebo (p<0.0001). Improvement in health-related quality of life was greater with roflumilast 250 mu g (-3.4 units [0.6]) and roflumilast 500 mu g (-3.5 units [0.6]) than with placebo (-1.8 units [0.8]), although the differences between treatment groups were not significant. The mean numbers of exacerbations per patient were 1.13 (2.37), 1.03 (2.33), and 0.75 (1.89) with placebo, roflumilast 250 mu g, and roflumilast 500 mu g, respectively. Most adverse events were mild to moderate in intensity and resolved during the study. Interpretation Roflumilast is a promising candidate for anti-inflammatory COPD treatment because it improved lung function and reduced exacerbations compared with placebo. Long-term studies are needed to fully assess the effect on health-related quality of life.	Leiden Univ, Med Ctr, Dept Pulmonol, NL-2333 ZA Leiden, Netherlands; Univ Cape Town, ZA-7925 Cape Town, South Africa; Kingston Gen Hosp, Kingston, ON K7L 2V7, Canada; ALTANA Pharma AG, Constance, Germany	Rabe, KF (reprint author), Leiden Univ, Med Ctr, Dept Pulmonol, C3P,Albinusdreef 2, NL-2333 ZA Leiden, Netherlands.	k.f.rabe@lumc.nl					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Barnette M S, 1999, Prog Drug Res, V53, P193; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Calverley PMA, 2003, LANCET, V362, P1053, DOI 10.1016/S0140-6736(03)14416-9; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; *CPMP, 1999, CPMPEWP56298 EUR AG; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Engelstaetter R., 2005, ANN ALLERG ASTHMA IM, V94, P169; Global Initiative for Chronic Obstructive Lung Disease, 2004, GLOB STRAT DIAGN MAN; Global Initiative for Chronic Obstructive Lung Disease, 2001, NHLBI WHO WORKSH REP; Grootendorst DC, 2003, PULM PHARMACOL THER, V16, P115, DOI 10.1016/S1094-5539(02)00172-4; Halbert RJ, 2003, CHEST, V123, P1684, DOI 10.1378/chest.123.5.1684; Hansen EF, 2001, AM J RESP CRIT CARE, V163, P690; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; Kumar RK, 2003, J PHARMACOL EXP THER, V307, P349, DOI 10.1124/jpet.103.053819; Lipworth BJ, 2005, LANCET, V365, P167, DOI 10.1016/S0140-6736(05)17708-3; Muise ES, 2002, BIOCHEM PHARMACOL, V63, P1527, DOI 10.1016/S0006-2952(02)00903-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542; ODONNELL DE, 1994, CHEST, V106, P904, DOI 10.1378/chest.106.3.904; Pauwels RA, 2004, LANCET, V364, P613; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Swanney MP, 2000, AM J RESP CRIT CARE, V162, P917; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Timmer W, 2002, J CLIN PHARMACOL, V42, P297, DOI 10.1177/00912700222011328; Viegi G, 2001, RESPIRATION, V68, P4, DOI 10.1159/000050456	33	264	271	1	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 13	2005	366	9485					563	571		10.1016/S0140-6736(05)67100-0		9	Medicine, General & Internal	General & Internal Medicine	955LL	WOS:000231227300028	16099292	
J	Barnes, PJ				Barnes, PJ			Scientific rationale for inhaled combination therapy with long-acting beta(2)-agonists and corticosteroids	EUROPEAN RESPIRATORY JOURNAL			English	Review						asthma; budesonide; fluticasone propionate; formoterol; salmeterol	AIRWAY SMOOTH-MUSCLE; LUNG MAST-CELLS; SALMETEROL/FLUTICASONE PROPIONATE COMBINATION; NK2 RECEPTOR EXPRESSION; DOWN-REGULATION; IN-VIVO; MU-G; GLUCOCORTICOID RECEPTOR; ADENOSINE-MONOPHOSPHATE; MICROVASCULAR LEAKAGE	The addition of an inhaled long-acting beta(2)-agonist (LABA) to an inhaled corticosteroid (ICS) gives optimal control of asthma in most patients and two fixed combination inhalers (salmeterol/fluticasone and formoterol/budesonide) are increasingly used as a convenient controller in patients with persistent asthma. There is a strong scientific rationale for the combination of these two drug classes. ICS suppress the chronic inflammation of asthma and reduce airway hyperresponsiveness and this is achieved at low doses in most patients. LABA act on different aspects of the pathophysiology of asthma. In addition to their bronchodilator action, LABA also inhibit mast cell mediator release, plasma exudation and may reduce sensory nerve activation. Thus these two classes of drug address complementary aspects of the pathophysiology of asthma that neither drug class is able to achieve alone. There are several positive interactions between LABA and ICS. Corticosteroids increase the expression of beta(2)-receptors by increasing gene transcription. Experimentally this protects against the loss of beta(2)-receptors in response to long-term exposure to beta(2)-agonists. While this is unlikely to be important in bronchodilator responses to beta(2)-agonists, in view of the large beta-receptor reserve, it is probably important in preventing loss of beta-agonist effects on the nonbronchodilator actions of LABA discussed earlier. beta(2)-Agonists may potentiate the molecular mechanism of corticosteroid actions, with increased nuclear localization of glucocorticoid receptors and additive or sometimes synergistic suppression of inflammatory mediator release. Thus LABA and ICS may optimize each others beneficial actions in the airways, but the low systemic effects of these drugs do not result in any increase in adverse effects. Long-acting beta(2)-agonists corticosteroid inhaler therapy is therefore a logical advance and results in effective control of asthma in the majority of patients without significant adverse effects. This simplified approach to long-term asthma therapy has a strong scientific rationale.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.						ADAMS N, 2001, COCHRANE DATABASE SY, V1; Adcock IM, 1996, EUR RESPIR J, V9, P160, DOI 10.1183/09031936.96.09010160; Aubier M, 1999, RESP MED, V93, P876, DOI 10.1016/S0954-6111(99)90053-7; Aziz I, 2000, CHEST, V118, P1049, DOI 10.1378/chest.118.4.1049; BALUK P, 1994, AM J PHYSIOL, V266, pL461; Baraniuk JN, 1997, AM J RESP CRIT CARE, V155, P704; Barnes PJ, 1999, NATURE, V402, pB31; Barnes PJ, 2001, RESP MED, V95, pS12, DOI 10.1053/rmed.2001.1140; Barnes PJ, 2000, INT ARCH ALLERGY IMM, V123, P196, DOI 10.1159/000024444; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, P1; Barnes PJ., 1999, J ALLERGY CLIN IMMUN, V104, pS10; BARNES PJ, 2000, EUR J INT MED, V11, P9, DOI 10.1016/S0953-6205(99)00071-0; BATEMAN ED, 2001, EUR RESPIR J, V17, P59; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; Bolton PB, 1997, AM J RESP CRIT CARE, V155, P1428; BOSCHETTO P, 1989, AM REV RESPIR DIS, V139, P416; BOWDEN JJ, 1994, J APPL PHYSIOL, V77, P397; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, P457, DOI 10.1016/S0091-6749(98)70353-7; Chong LK, 1998, BRIT J PHARMACOL, V123, P1009, DOI 10.1038/sj.bjp.0701703; Chong LK, 1999, EUR J PHARMACOL, V378, P115, DOI 10.1016/S0014-2999(99)00425-2; Chong LK, 1997, BRIT J PHARMACOL, V121, P717, DOI 10.1038/sj.bjp.0701185; COLLINS S, 1988, J BIOL CHEM, V263, P9067; CUSHLEY MJ, 1985, J ALLERGY CLIN IMMUN, V75, P272, DOI 10.1016/0091-6749(85)90057-0; Donohue JF, 2000, CHEST, V118, P283, DOI 10.1378/chest.118.2.283; Drury DEJ, 1998, BRIT J PHARMACOL, V124, P711, DOI 10.1038/sj.bjp.0701897; Eickelberg O, 1999, J BIOL CHEM, V274, P1005, DOI 10.1074/jbc.274.2.1005; ERJEFALT I, 1991, AM REV RESPIR DIS, V144, P788; Evans DJ, 1997, NEW ENGL J MED, V337, P1412, DOI 10.1056/NEJM199711133372002; Farmer P, 2000, AM J PHYSIOL-LUNG C, V279, pL675; Finney PA, 2000, J CLIN INVEST, V106, P125, DOI 10.1172/JCI8374; Fish JE, 2001, CHEST, V120, P423, DOI 10.1378/chest.120.2.423; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Greiff L, 1998, THORAX, V53, P1010; Grootendorst DC, 2001, EUR RESPIR J, V17, P374, DOI 10.1183/09031936.01.17303740; Hansen T.V., 2001, NEW DRUGS ASTHMA COP, P1; Heuck C, 2000, ARCH DIS CHILD, V83, P334, DOI 10.1136/adc.83.4.334; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Howarth PH, 2000, RESP MED, V94, pS22, DOI 10.1016/S0954-6111(00)90129-X; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Jatakanon A, 1999, THORAX, V54, P108; Jenkins C, 2000, RESP MED, V94, P715, DOI 10.1053/rmed.2000.0875; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kankaanranta H, 2000, J ALLERGY CLIN IMMUN, V106, P77; Katsunuma T, 1999, AM J RESP CELL MOL, V21, P409; Katsunuma T, 1998, EUR J PHARMACOL, V344, P99, DOI 10.1016/S0014-2999(97)01562-8; Kavuru M, 2000, J ALLERGY CLIN IMMUN, V105, P1108, DOI 10.1067/mai.2000.105711; Kips JC, 2000, AM J RESP CRIT CARE, V161, P996; KIPS JC, 2000, AM J RESP CRIT CARE, V161, pA505; Kirby S, 2001, EUR J CLIN PHARMACOL, V56, P781, DOI 10.1007/s002280000233; Korn SH, 2001, EUR RESPIR J, V17, P1070, DOI 10.1183/09031936.01.00073301; Koto H, 1996, J CLIN INVEST, V98, P1780, DOI 10.1172/JCI118977; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lim S, 2000, THORAX, V55, P837, DOI 10.1136/thorax.55.10.837; MAK JCW, 1995, J CLIN INVEST, V96, P99, DOI 10.1172/JCI118084; Mak JCW, 1995, AM J PHYSIOL, V12, pL41; MAK JCW, 2001, AM J RESP CRIT CARE, V163, pA228; Markham A, 2000, DRUGS, V60, P1207, DOI 10.2165/00003495-200060050-00012; Markham A, 2000, PHARMACOECONOMICS, V18, P591, DOI 10.2165/00019053-200018060-00006; McGavin JK, 2001, DRUGS, V61, P71, DOI 10.2165/00003495-200161010-00007; Meagher LC, 1996, J IMMUNOL, V156, P4422; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Nelson Harold S., 2001, Journal of Allergy and Clinical Immunology, V107, P398, DOI 10.1067/mai.2001.112939; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P1088; *NHLBI WHO, 1995, PUBL NHLBI WHO WORKS; NIALS AT, 1994, EUR J PHARMACOL, V251, P127, DOI 10.1016/0014-2999(94)90392-1; NICHOL G, 1990, THORAX, V45, P694, DOI 10.1136/thx.45.9.694; Nightingale JA, 1999, AM J RESP CRIT CARE, V159, P1786; NISHIKAWA M, 1993, EUR J PHARM-MOLEC PH, V247, P131, DOI 10.1016/0922-4106(93)90070-P; NISHIKAWA M, 1994, AM J RESP CELL MOL, V10, P91; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392; OCONNOR BJ, 1992, NEW ENGL J MED, V327, P1204, DOI 10.1056/NEJM199210223271704; OCONNOR BJ, 1994, AM J RESP CRIT CARE, V150, P381; Oddera S, 1998, RESPIRATION, V65, P199, DOI 10.1159/000029260; Orsida BE, 2001, AM J RESP CRIT CARE, V164, P117; Palmqvist M, 2001, PULM PHARMACOL THER, V14, P29, DOI 10.1006/pupt.2000.0260; Pang LH, 2001, FASEB J, V15, P261, DOI 10.1096/fj.00-0103com; Pang LH, 2000, AM J RESP CELL MOL, V23, P79; Pauwels RA, 1997, NEW ENGL J MED, V337, P1412; PETERS MJ, 1995, EUR J PHARM-MOLEC PH, V289, P275, DOI 10.1016/0922-4106(95)90104-3; Proud D, 1998, CLIN EXP ALLERGY, V28, P868; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Roberts JA, 1999, EUR RESPIR J, V14, P275, DOI 10.1034/j.1399-3003.1999.14b07.x; Robinson DS, 2001, LANCET, V357, P2007, DOI 10.1016/S0140-6736(00)05113-8; Rosenborg J, 2000, EUR J CLIN PHARMACOL, V56, P363, DOI 10.1007/s002280000160; Scott MGH, 1999, BRIT J PHARMACOL, V126, P841, DOI 10.1038/sj.bjp.0702385; Seldon PM, 1998, AM J RESP CRIT CARE, V157, P803; Shapiro G, 2000, AM J RESP CRIT CARE, V161, P527; Shrewsbury S, 2000, BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Silvestri M, 2001, EUR RESPIR J, V18, P139, DOI 10.1183/09031936.01.00067901; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; SULAKVELIDZE I, 1994, AM J RESP CRIT CARE, V149, P232; SVENSSON C, 1995, ALLERGY, V50, P884, DOI 10.1111/j.1398-9995.1995.tb02494.x; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594; Taylor DA, 1997, AM J RESP CRIT CARE, V156, P1731; TOKUYAMA K, 1991, EUR J PHARMACOL, V193, P35, DOI 10.1016/0014-2999(91)90197-X; Ukena D, 1997, EUR RESPIR J, V10, P2754, DOI 10.1183/09031936.97.10122754; Van den Berg NJ, 2000, PEDIATR PULM, V30, P97, DOI 10.1002/1099-0496(200008)30:2<97::AID-PPUL4>3.0.CO;2-P; VERLEDEN GM, 1993, J APPL PHYSIOL, V74, P1195; Weston MC, 1998, GEN PHARMACOL, V31, P715, DOI 10.1016/S0306-3623(98)00080-9; WILSON AJ, 2000, COCHRANE DATABASE SY; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481; Yates DH, 1996, AM J RESP CRIT CARE, V154, P1603; ZETTERSTROM O, 2001, EUR RESP DIS, V18, P254	106	263	280	0	7	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JAN	2002	19	1					182	191		10.1183/09031936.02.00283202		10	Respiratory System	Respiratory System	516JE	WOS:000173549500029	11843317	
J	Mendell, MJ; Heath, GA				Mendell, MJ; Heath, GA			Do indoor pollutants and thermal conditions in schools influence student performance? A critical review of the literature	INDOOR AIR			English	Review						indoor environment; indoor air quality; performance; schools; education; children	SICK BUILDING SYNDROME; PERCEIVED AIR-QUALITY; VOLATILE ORGANIC-COMPOUNDS; SYNDROME SBS SYMPTOMS; MODERATE HEAT-STRESS; DAY-CARE-CENTERS; OFFICE WORKERS; ALLERGIC SENSITIZATION; RESPIRATORY SYMPTOMS; YOUNG-CHILDREN	To assess whether school environments can adversely affect academic performance, we review scientific evidence relating indoor pollutants and thermal conditions, in schools or other indoor environments, to human performance or attendance. We critically review evidence for direct associations between these aspects of indoor environmental quality (IEQ) and performance or attendance. Secondarily, we summarize, without critique, evidence on indirect connections potentially linking IEQ to performance or attendance. Regarding direct associations, little strongly designed research was available. Persuasive evidence links higher indoor concentrations of NO2 to reduced school attendance, and suggestive evidence links low ventilation rates to reduced performance. Regarding indirect associations, many studies link indoor dampness and microbiologic pollutants (primarily in homes) to asthma exacerbations and respiratory infections, which in turn have been related to reduced performance and attendance. Also, much evidence links poor IEQ (e.g. low ventilation rate, excess moisture, or formaldehyde) with adverse health effects in children and adults and documents dampness problems and inadequate ventilation as common in schools. Overall, evidence suggests that poor IEQ in schools is common and adversely influences the performance and attendance of students, primarily through health effects from indoor pollutants. Evidence is available to justify (i) immediate actions to assess and improve IEQ in schools and (ii) focused research to guide IEQ improvements in schools.	Univ Calif Berkeley, Lawrence Berkeley Lab, Environm Energy Technol Div, Indoor Environm Dept, Berkeley, CA 94720 USA; Univ Calif Berkeley, Energy & Resources Grp, Berkeley, CA 94720 USA	Mendell, MJ (reprint author), Univ Calif Berkeley, Lawrence Berkeley Lab, Environm Energy Technol Div, Indoor Environm Dept, 1 Cyclotron Rd,MS 90-3058, Berkeley, CA 94720 USA.	mjmendell@lbl.gov					Apte M., 1999, P IND AIR 99 8 INT C, V1, P117; Austin JK, 1998, DEV MED CHILD NEUROL, V40, P248; Bako-Biro Z, 2004, INDOOR AIR, V14, P178, DOI 10.1111/j.1600-0668.2004.00218.x; BARTLETT KH, 1999, IND AIR 99 P 8 INT C, V1, P252; BAYER CW, 2000, CAUES INDOOR AIR QUA; BERNER MM, 1993, URBAN EDUC, V28, P6, DOI 10.1177/0042085993028001002; BLONDEAU P, 2004, IN PRESS INDOOR AIR; Bornehag CG, 2001, INDOOR AIR, V11, P72; BORNEHAG CG, 2002, IND AIR 02 P 9 INT C, V3, P431; BRAGANZA E, 2000, P HLTH BUILD 2000, V1, P193; Burton WN, 2001, J OCCUP ENVIRON MED, V43, P64, DOI 10.1097/00043764-200101000-00013; BUSSING R, 1995, ARCH PEDIAT ADOL MED, V149, P565; Chaloulakou A, 2003, CHEMOSPHERE, V52, P1007, DOI 10.1016/S0045-6535(03)00263-7; CHALOULAKOU A, 2002, ATMOS ENVIRON, V36, P1169; Chen L, 2000, INHAL TOXICOL, V12, P997; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Campbell D. T., 1979, QUASI EXPT DESIGN; Corsi RL, 2002, IND AIR 02 P 9 INT C, V2, P74; Crystal-Peters J, 2000, AM J MANAG CARE, V6, P373; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; DAISEY JM, 1998, SURVEY CRITICAL REV; Diette GB, 2000, ARCH PEDIAT ADOL MED, V154, P923; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; DIXON RE, 1985, AM J MED, V78, P45, DOI 10.1016/0002-9343(85)90363-8; DOUGLAS JWB, 1965, BRIT J EDUC PSYCHOL, V35, P28; DUKE PL, 1998, DOES IT MATTER WHERE; EHRENBERG RG, 1991, J HUM RESOUR, V26, P72, DOI 10.2307/145717; FANG L, 2002, IND AIR 2002 P 9 INT, V3, P466; Faustman EM, 2000, ENVIRON HEALTH PERSP, V108, P13, DOI 10.2307/3454629; FEDERSPIEL CC, 2002, IND AIR 02 P 9 INT C, V1, P796; Fisk WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; FISK WJ, 2002, IND AIR 02 P 9 INT C, V1, P790; Fisk WJ, 2000, INDOOR AIR QUALITY H, P41; FOWLER MG, 1992, PEDIATRICS, V90, P939; FRANKLIN PJ, 2000, P HLTH BUILD 2000 EX, V1, P65; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Garrett MH, 1998, INDOOR AIR, V8, P236, DOI 10.1111/j.1600-0668.1998.00004.x; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Green G. H., 1985, ASHRAE T, V91, P643; Green G. H., 1974, ASHRAE T, V80, P131; Green RS, 2004, ENVIRON HEALTH PERSP, V112, P61, DOI 10.1289/ehp.6566; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471; GYNTELBERG F, 1994, INDOOR AIR, V4, P223, DOI 10.1111/j.1600-0668.1994.00003.x; HALL HI, 1991, P IAQ 91 HLTH BUILD, V1, P33; HANSEN L, 1987, IND AIR 87 P 4 INT C, V2, P727; HODGSON MJ, 1987, AM J EPIDEMIOL, V125, P631; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89; HUSMAN T, 2002, IND AIR 02 P 9 INT C, V1, P484; Hwang JS, 2000, AM J EPIDEMIOL, V152, P67, DOI 10.1093/aje/152.1.67; HYVARINEN A, 2002, IND AIR 02 P 9 INT C, V3, P404; JAAKKOLA JJK, 1991, ENVIRON INT, V17, P371, DOI 10.1016/0160-4120(91)90025-L; JAAKKOLA JJK, 1989, ENVIRON INT, V15, P163, DOI 10.1016/0160-4120(89)90022-6; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jacob B, 2002, ENVIRON HEALTH PERSP, V110, P647; Jarvis J Q, 2001, Appl Occup Environ Hyg, V16, P380, DOI 10.1080/104732201750154242; Kemp PC, 1998, INDOOR AIR, V8, P153, DOI 10.1111/j.1600-0668.1998.t01-1-00003.x; KIM CS, 2002, IND AIR 02 P 9 INT C, V1, P492; KREISS K, 1989, OCCUP MED, V4, P575; Kroner WM, 1994, ASHRAE T, V100, P750; Lagercrantz L., 2000, P HLTH BUILDINGS 200, V1, P653; Landrigan P J, 1998, Int J Occup Med Environ Health, V11, P189; LANDRUS G, 1990, IND AIR 90 P 5 INT C, V1, P49; LEVIN H, 1995, OCCUP MED, V10, P59; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P68; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P200; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; Marburger DR, 2001, J ECON EDUC, V32, P99, DOI 10.2307/1183486; MCCOACH J, 1999, INDOOR AIR 99, V5, P459; McCowan C, 1996, Health Bull (Edinb), V54, P307; MCLOUGHLIN J, 1983, ANN ALLERGY, V51, P506; MCNALL PE, 1967, ASHRAE T, V73; MEKLIN T, 2000, P HLTH BUILDINGS, V1, P335; MENDALL MJ, 2000, AM J IND MED, V43, P630; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; Mendell MJ, 2002, AM J PUBLIC HEALTH, V92, P1430, DOI 10.2105/AJPH.92.9.1430; Mendell MJ, 2002, EPIDEMIOLOGY, V13, P296, DOI 10.1097/00001648-200205000-00010; Mendell MJ, 1993, INDOOR AIR, V3, P227, DOI 10.1111/j.1600-0668.1993.00003.x; Menzies D, 2000, ANN INTERN MED, V133, P779; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; MEYER HW, 2002, IND AIR 02 P 9 INT C, V5, P19; MEYER HWA, 1999, INDOOR AIR, V2, P298; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Milton DK, 2000, INDOOR AIR, V10, P212, DOI 10.1034/j.1600-0668.2000.010004212.x; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; Molhave L, 1993, INDOOR AIR, V3, P155, DOI 10.1111/j.1600-0668.1993.t01-1-00002.x; MOLHAVE L, 2000, P HLTH BUILDINGS 200, V1, P501; Muller A, 2002, INT J HYG ENVIR HEAL, V204, P363, DOI 10.1078/1438-4639-00110; Myatt TA, 2002, IND AIR 02 P 9 INT C, V1, P778; Myhrvold AN, 1996, INDOOR AIR, V4, P369; Nagda NL, 2001, INDOOR AIR, V11, P200, DOI 10.1034/j.1600-0668.2001.011003200.x; Niemela R, 2002, ENERG BUILDINGS, V34, P759, DOI 10.1016/S0378-7788(02)00094-4; NILSEN SK, 2002, IND AIR 02 P 9 INT C, V3, P472; NORBACK D, 1990, BRIT J IND MED, V47, P733; Norback D, 2000, ALLERGY, V55, P163, DOI 10.1034/j.1398-9995.2000.00353.x; NORBACK D, 2002, IND AIR 02 P 9 INT C, V3, P410; NUNES F, 1993, INDOOR AIR 93, V1, P53; O'Brien L. M., 1985, THEOR RES SOC EDUC, V8, P57; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; ONEIL SL, 1985, J SCHOOL HEALTH, V55, P237; OTTO DA, 1992, ARCH ENVIRON HEALTH, V47, P23; PARCEL GS, 1979, PEDIATRICS, V64, P878; Park H, 2002, ARCH PEDIAT ADOL MED, V156, P1235; PARK JH, 2002, IND AIR 02 P 9 INT C, V5, P27; PAZDRAK K, 1993, INT ARCH OCC ENV HEA, V64, P515, DOI 10.1007/BF00381101; Pepler R. D., 1968, ASHRAE T 2, V74, P211; Pilcher JJ, 2002, ERGONOMICS, V45, P682, DOI 10.1080/00140130210158419; Pilotto LS, 1997, INT J EPIDEMIOL, V26, P788, DOI 10.1093/ije/26.4.788; PLATTSMILLS TAE, 2000, INDOOR AIR QUALITY H; Port R. J., 1979, ED PERSPECT, V18, P18; Preller L., 1990, INDOOR AIR 90, V1, P227; Ramadour M, 2000, ALLERGY, V55, P1163, DOI 10.1034/j.1398-9995.2000.00637.x; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; RAW GJ, 1990, INDOOR AIR 90, V1, P231; RAW GJ, 1993, INDOOR AIR, V3; Reinikainen LM, 2001, ARCH ENVIRON HEALTH, V56, P365; Reynolds S J, 2001, Appl Occup Environ Hyg, V16, P1065; RICHARDS W, 1986, J SCHOOL HEALTH, V56, P151; Rietveld S, 1999, J ASTHMA, V36, P409, DOI 10.3109/02770909909087283; Rodgers JR, 2001, AUST J EDUC, V45, P284; ROMIEU I, 1992, AM J EPIDEMIOL, V136, P1524; Roponen M, 2002, INHAL TOXICOL, V14, P541, DOI 10.1080/089583701753678616; Rosen KG, 1999, SCI TOTAL ENVIRON, V234, P87, DOI 10.1016/S0048-9697(99)00266-1; Rothman K., 1986, MODERN EPIDEMIOLOGY; RUDBLAD S, 1999, IND AIR 99 8 INT C I, V5, P489; RUMCHEV K, 2002, IND AIR 02 P 9 INT C, V1, P472; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; SAFER DJ, 1986, J LEARN DISABIL, V19, P500; SALE CS, 1972, SOUTHERN MED J, V65, P882; Savilahti R, 2001, ALLERGY, V56, P175, DOI 10.1034/j.1398-9995.2001.056002175.x; Shaffran J., 1973, ASHRAE T, V79, P97; Sensharma N. P., 1998, ASHRAE T, V104, P686; Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; Seuri M, 2000, INDOOR AIR, V10, P138, DOI 10.1034/j.1600-0668.2000.010003138.x; SEURI M, 2000, P HLTH BUILD 2000 EX, V1, P579; Sieber W.K., 1996, APPL OCCUP ENV HYG, V11, P1387; SIGSGAARD T, 2002, IND AIR 02 P 9 INT C, V3, P421; Silverstein MD, 2001, J PEDIATR-US, V139, P278, DOI 10.1067/mpd.2001.115573; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18; SMEDJE G, 1996, IND AIR 96 P 7 INT C, V1, P413; SMITH AP, 1990, PHILOS T ROY SOC B, V327, P519, DOI 10.1098/rstb.1990.0095; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Spee-van der Wekke J, 1998, J EPIDEMIOL COMMUN H, V52, P359; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; Spengler JD, 2000, INDOOR AIR QUALITY H; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; Sundell J., 1993, INDOOR AIR, V3, P82, DOI 10.1111/j.1600-0668.1993.t01-2-00003.x; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; TASKINEN T, 2000, P HLTH BUILDINGS 200, V1, P233; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; Ten Brinke J, 1998, INDOOR AIR, V8, P140; THOM DH, 1990, AM J EPIDEMIOL, V132, P248; *US GEN ACC OFF, 1995, SCH FAC COND AM SCH; Walinder R, 1998, INT ARCH OCC ENV HEA, V71, P479, DOI 10.1007/s004200050309; Walinder R, 2001, INDOOR AIR, V11, P2; Walinder R, 1999, SCAND J WORK ENV HEA, V25, P137; Wantke F, 1996, CLIN EXP ALLERGY, V26, P276; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wargocki P, 1999, INDOOR AIR, V9, P165, DOI 10.1111/j.1600-0668.1999.t01-1-00003.x; Weiss K B, 1994, Pediatr Allergy Immunol, V5, P7, DOI 10.1111/j.1399-3038.1994.tb00341.x; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x; Wilken JA, 2002, ANN ALLERG ASTHMA IM, V89, P372; Witterseh T., 2002, INDOOR AIR 02, V4, P1084; WOODARD ED, 1988, JAMA-J AM MED ASSOC, V259, P1965, DOI 10.1001/jama.259.13.1965; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; WYON DP, 1975, ERGONOMICS, V18, P359, DOI 10.1080/00140137508931470; WYON DP, 1992, ENVIRON TECHNOL, V13, P313; WYON DP, 1974, ERGONOMICS, V17, P309, DOI 10.1080/00140137408931356; WYON DP, 1979, SCAND J WORK ENV HEA, V5, P352; WYON DP, 1996, IAQ 96 PATHS BETT BU, V1, P5; WYON DP, 1993, INDOOR AIR 93, V6, P3; WYON DP, 2000, INDOOR AIR QUALITY H; ZIOMEK RL, 1983, ELEM SCHOOL J, V84, P232, DOI 10.1086/461359; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	183	262	269	17	85	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air	JAN	2005	15	1					27	52		10.1111/j.1600-0668.2004.00320.x		26	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	890ME	WOS:000226514500004	15660567	
J	Mucida, D; Kutchukhidze, N; Erazo, A; Russo, M; Lafaille, JJ; de Lafaille, MAC				Mucida, D; Kutchukhidze, N; Erazo, A; Russo, M; Lafaille, JJ; de Lafaille, MAC			Oral tolerance in the absence of naturally occurring Tregs	JOURNAL OF CLINICAL INVESTIGATION			English	Article							REGULATORY T-CELLS; TRANSCRIPTION FACTOR FOXP3; RECEPTOR TRANSGENIC MICE; GROWTH-FACTOR-BETA; IN-VIVO EXPANSION; TGF-BETA; AUTOIMMUNE ENCEPHALOMYELITIS; CUTTING EDGE; PERIPHERAL TOLERANCE; AIRWAY INFLAMMATION	Mucosal tolerance prevents pathological reactions against environmental and food antigens, and its failure results in exacerbated inflammation typical of allergies and asthma. One of the proposed mechanisms of oral tolerance is the induction of Tregs. Using a mouse model of hyper-IgE and asthma, we found that oral tolerance could be effectively induced in the absence of naturally occurring thymus-derived Tregs. Oral antigen administration prior to i.p. immunization prevented effector/memory Th2 cell development, germinal center formation, class switching to IgE, and lung inflammation. Oral exposure to antigen induced development of antigen-specific CD4(+)CD25(+)Foxp3(+)CD45RB(low) cells that were anergic and displayed suppressive activity in vivo and in vitro. Oral tolerance to the Th2 allergic response was in large part dependent on TGF-beta and independent of IL-10. Interestingly, Tregs were also induced by single i.p. immunization with antigen and adjuvant. However, unlike oral administration of antigen, which induced Tregs but not effector T cells, i.p. immunization led to the simultaneous induction of Tregs and effector Th2 cells displaying the same antigen specificity.	NYU, Sch Med, Skirball Inst Biomol Med, Program Mol Pathogenesis, New York, NY USA; Univ Sao Paulo, Dept Imunol, Sao Paulo, Brazil; NYU, Sch Med, Dept Pathol, New York, NY USA	Lafaille, JJ (reprint author), NYU, Med Ctr, Dept Pathol, Skirball Inst Biomol Med, 540 First Ave, New York, NY 10016 USA.	lafaille@saturn.med.nyu.edu; curotto@saturn.med.nyu.edu		Mucida, Daniel/0000-0002-0000-0452			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Alpan O, 2004, NAT IMMUNOL, V5, P615, DOI 10.1038/ni1077; Annacker O, 2001, J IMMUNOL, V166, P3008; Antov A, 2003, J IMMUNOL, V171, P3435; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Barone KS, 1998, J IMMUNOL, V161, P154; BOTTOMLY K, 1989, EUR J IMMUNOL, V19, P617, DOI 10.1002/eji.1830190407; Bynoe MS, 2003, IMMUNITY, V19, P317, DOI 10.1016/S1074-7613(03)00239-5; Chen C, 2003, J IMMUNOL, V171, P733; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen YG, 2002, IMMUNOLOGY, V105, P171, DOI 10.1046/j.1365-2567.2002.01348.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Cobbold SP, 2004, J IMMUNOL, V172, P6003; Cohn L, 1998, J IMMUNOL, V161, P3813; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; de Lafaille MAC, 2004, J IMMUNOL, V173, P7259; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Fantini MC, 2004, J IMMUNOL, V172, P5149; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fowler S, 2002, EUR J IMMUNOL, V32, P2997, DOI 10.1002/1521-4141(2002010)32:10<2997::AID-IMMU2997>3.0.CO;2-D; Fukura H, 1996, J CLIN INVEST, V98, P70; Furtado GC, 2002, J EXP MED, V196, P851, DOI 10.1084/jem.20020190; Gutgemann I, 1998, IMMUNITY, V8, P667, DOI 10.1016/S1074-7613(00)80571-3; Hauet-Broere F, 2003, EUR J IMMUNOL, V33, P2801, DOI 10.1002/eji.200324115; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Huber S, 2004, J IMMUNOL, V173, P6526; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Kobets N, 2003, IMMUNOL LETT, V88, P147, DOI 10.1016/S0165-2478(03)00076-2; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; MATTINGLY JA, 1978, J IMMUNOL, V121, P1878; Mayer L, 2004, NAT REV IMMUNOL, V4, P407, DOI 10.1038/nri1370; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Park HB, 2004, INT IMMUNOL, V16, P1203, DOI 10.1093/intimm/dxh123; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; Piccirillo CA, 2004, SEMIN IMMUNOL, V16, P81, DOI 10.1016/j.smim.2003.12.003; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; RICHMAN LK, 1978, J IMMUNOL, V121, P2429; Rizzo LV, 1999, J IMMUNOL, V162, P2613; Russo M, 2001, AM J RESP CELL MOL, V24, P518; Russo M, 1998, IMMUNOL LETT, V61, P15, DOI 10.1016/S0165-2478(97)00155-7; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Samsom JN, 2004, CRIT REV IMMUNOL, V24, P157, DOI 10.1615/CritRevImmunol.v24.i3.10; Sawicka E, 2003, J IMMUNOL, V171, P6206; Schramm C, 2004, INT IMMUNOL, V16, P1241, DOI 10.1093/intimm/dxh126; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Takaoka A, 2001, J IMMUNOL, V167, P2349; Thorstenson KM, 2001, J IMMUNOL, V167, P188; Unger WWJ, 2003, J IMMUNOL, V171, P4592; VanHouten N, 1996, J IMMUNOL, V157, P1337; Vaz NM, 2003, BRAZ J MED BIOL RES, V36, P13, DOI 10.1590/S0100-879X2003000100003; Vieira PL, 2004, J IMMUNOL, V172, P5986; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Weiner HL, 2001, MICROBES INFECT, V3, P947, DOI 10.1016/S1286-4579(01)01456-3; Wu HY, 2003, IMMUNOL RES, V28, P265, DOI 10.1385/IR:28:3:265; Zhang XM, 2001, J IMMUNOL, V167, P4245; Zheng SG, 2002, J IMMUNOL, V169, P4183	69	258	267	0	9	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	JUL	2005	115	7					1923	1933		10.1172/JCI24487		11	Medicine, Research & Experimental	Research & Experimental Medicine	942OX	WOS:000230292800033	15937545	
J	Weingart, SN; Toth, M; Sands, DZ; Aronson, MD; Davis, RB; Phillips, RS				Weingart, SN; Toth, M; Sands, DZ; Aronson, MD; Davis, RB; Phillips, RS			Physicians' decisions to override computerized drug alerts in primary care	ARCHIVES OF INTERNAL MEDICINE			English	Article							MEDICATION ERRORS; CONTROLLED TRIAL; AMBULATORY-CARE; ORDER ENTRY; REMINDERS; SYSTEM; RECORD; EVENTS	Background: Although computerized physician order entry reduces medication errors among inpatients, little is known about the use of this system in primary care. Methods: We calculated the override rate among 3481 consecutive alerts generated at 5 adult primary care practices that use a common computerized physician order entry system for prescription writing. For detailed review, we selected a random sample of 67 alerts in which physicians did not prescribe an alerted medication and 122 alerts that resulted in a written prescription. We identified factors associated with the physicians' decisions to override a medication alert, and determined whether an adverse drug event (ADE) occurred. Results: Physicians overrode 91.2% of drug allergy and 89.4% of high-severity drug interaction alerts. In the multivariable analysis using the medical chart review sample (n=189), physicians were less likely to prescribe an alerted medication if the prescriber was a house officer (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.08-0.84) and if the patient had many drug allergies (OR, 0.70; 95% CI, 0.53-0.93). They were more likely to override alerts for renewals compared with new prescriptions (OR, 17.74; 95% CI, 5.60-56.18). We found no ADEs in cases where physicians observed the alert and 3 ADEs among patients with alert overrides, a nonsignificant difference (P=.55). Physician reviewers judged that 36.5% of the alerts were inappropriate. Conclusions: Few physicians changed their prescription in response to a drug allergy or interaction alert, and there were few ADEs, suggesting that the threshold for alerting was set too low. Computerized physician order entry systems should suppress alerts for renewals of medication combinations that patients currently tolerate.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Weingart, SN (reprint author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Rose 112,330 Brookline Ave, Boston, MA 02215 USA.				AHRQ HHS [1K08 HS 11644-01]		Abookire S A, 2000, Proc AMIA Symp, P2; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; GANDHI TK, 2001, J GEN INTERN MED S, V16, P133; Kuperman G J, 1996, Proc AMIA Annu Fall Symp, P704; Kuperman G J, 1994, Proc Annu Symp Comput Appl Med Care, P836; Kuperman GJ, 1999, J AM MED INFORM ASSN, V6, P512; The Leapfrog Group, FACT SHEET; *MASS COAL PREV ME, MHA BEST PRACT REC R; MCDONALD CJ, 1992, M D COMPUT, V9, P304; MCDONALD CJ, 1976, NEW ENGL J MED, V295, P1351, DOI 10.1056/NEJM197612092952405; MCDONALD CJ, 1977, AM J PUBLIC HEALTH, V67, P240, DOI 10.2105/AJPH.67.3.240; MCDONALD CJ, 1984, ANN INTERN MED, V100, P130; Overhage JM, 2001, J AM MED INFORM ASSN, V8, P361; Peterson JF, 2001, J GEN INTERN MED S, V16, P212; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; RIND DM, 1994, ARCH INTERN MED, V154, P1511, DOI 10.1001/archinte.154.13.1511; Safran C, 2001, JAMA-J AM MED ASSOC, V285, P1766, DOI 10.1001/jama.285.13.1766; Schiff GD, 2000, AM J MED, V109, P494, DOI 10.1016/S0002-9343(00)00546-5; TIERNEY WM, 1993, JAMA-J AM MED ASSOC, V269, P379, DOI 10.1001/jama.269.3.379; TIERNEY WM, 1986, MED CARE, V24, P659, DOI 10.1097/00005650-198608000-00001	21	258	262	2	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9926			ARCH INTERN MED	Arch. Intern. Med.	NOV 24	2003	163	21					2625	2631		10.1001/archinte.163.21.2625		7	Medicine, General & Internal	General & Internal Medicine	747TQ	WOS:000186821300010	14638563	
J	Schuster, E; Dunn-Coleman, N; Frisvad, JC; van Dijck, PWM				Schuster, E; Dunn-Coleman, N; Frisvad, JC; van Dijck, PWM			On the safety of Aspergillus niger - a review	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Review							FRAGMENT-LENGTH-POLYMORPHISMS; GREEN COFFEE BEANS; BLACK ASPERGILLI; OCHRATOXIN-A; CUTANEOUS ASPERGILLOSIS; AFLATOXIN PRODUCTION; MICROBIAL ESTERASES; BIOTECHNOLOGY PLANT; STORED COTTONSEED; MOLECULAR-CLONING	Aspergillus niger is one of the most important microorganisms used in biotechnology. It has been in use already for many decades to produce extracellular (food) enzymes and citric acid. In fact, citric acid and many A. niger enzymes are considered GRAS by the United States Food and Drug Administration. In addition, A. niger is used for biotransformations and waste treatment. In the last two decades, A. niger has been developed as an important transformation host to over-express food enzymes. Being pre-dated by older names, the name A. niger has been conserved for economical and information retrieval reasons and there is a taxonomical consensus based on molecular data that the only other common species closely related to A. niger in the Aspergillus series Nigri is A. tubingensis. A. niger, like other filamentous fungi, should be treated carefully to avoid the formation of spore dust. However, compared with other filamentous fungi, it does not stand out as a particular problem concerning allergy or mycopathology. A few medical cases, e.g. lung infections, have been reported, but always in severely immunocompromised patients. In tropical areas, ear infections (otomycosis) do occur due to A. niger invasion of the outer ear canal but this may be caused by mechanical damage of the skin barrier. A. niger strains produce a series of secondary metabolites, but it is only ochratoxin A that can be regarded as a mycotoxin in the strict sense of the word. Only 3-10% of the strains examined for ochratoxin A production have tested positive under favourable conditions. New and unknown isolates should be checked for ochratoxin A production before they are developed as production organisms. It is concluded, with these restrictions, that A. niger is a safe production organism.	DSM Food Specialt, Dept Regulatory Affairs, NL-2600 MA Delft, Netherlands; Rohm GmbH, Enzyme Technol, D-64293 Darmstadt, Germany; Genencor Int Inc, Palo Alto, CA 94304 USA; Tech Univ Denmark, BioCentrum, DK-2800 Kgs Lyngby, Denmark	van Dijck, PWM (reprint author), DSM Food Specialt, Dept Regulatory Affairs, 600-0245,POB 1, NL-2600 MA Delft, Netherlands.	piet.dijck-van@dsm.com					ABARCA ML, 1994, APPL ENVIRON MICROB, V60, P2650; Abarca ML, 2001, J FOOD PROTECT, V64, P903; ABRAMSON C, 1986, J AM PODIAT MED ASSN, V76, P168; Accensi F, 1999, FEMS MICROBIOL LETT, V180, P191, DOI 10.1111/j.1574-6968.1999.tb08795.x; ALMUSSALAM A, 1980, THESIS RIJKSUNIVERSI; ANDEREGG RJ, 1976, J AM CHEM SOC, V98, P3365, DOI 10.1021/ja00427a051; BALLANCE DJ, 1983, BIOCHEM BIOPH RES CO, V112, P284, DOI 10.1016/0006-291X(83)91828-4; BARBESGAARD P, 1992, APPL MICROBIOL BIOT, V36, P569; BENNETT JW, 1989, MYCOPATHOLOGIA, V100, P3; *BER CHEM IND, 1998, MERKBL B 007; BERCOVITZ A, 1990, APPL ENVIRON MICROB, V56, P1594; Berka RM, 1992, ASPERGILLUS BIOL IND, P155; BHATIA YN, 1969, MYKOSEN, V12, P651; BINDER RE, 1982, MEDICINE, V61, P109, DOI 10.1097/00005792-198203000-00005; BLOCH F, 1973, AM POTATO J, V50, P357, DOI 10.1007/BF02851891; BULLERMAN LB, 1968, APPL MICROBIOL, V16, P1945; BUSSINK HJD, 1991, CURR GENET, V19, P467, DOI 10.1007/BF00312738; BUSSINK HJD, 1990, FEBS LETT, V273, P127, DOI 10.1016/0014-5793(90)81066-W; BUXTON FP, 1985, GENE, V37, P207, DOI 10.1016/0378-1119(85)90274-4; CAESAR F, 1969, HELV PHYSL PHARM ACT, V44, P676; CAHILL KM, 1967, ARCH DERMATOL, V96, P545, DOI 10.1001/archderm.96.5.545; CAMPBELL EI, 1989, MOL GEN GENET, V206, P71; Cole R. J., 1981, HDB TOXIC FUNGAL MET; CULLEN D, 1987, BIO-TECHNOL, V5, P369, DOI 10.1038/nbt0487-369; DAS A, 1978, CAN J MICROBIOL, V24, P622; DEGRAAFF LH, 1994, MOL MICROBIOL, V12, P479; DELUCCA AJ, 1983, J FOOD SAFETY, V5, P95, DOI 10.1111/j.1745-4565.1983.tb00460.x; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; DUNNCOLEMAN NS, 1991, BIO-TECHNOL, V9, P976, DOI 10.1038/nbt1091-976; EHRLICH KC, 1984, APPL ENVIRON MICROB, V48, P1; ELMAYERGI H, 1973, J GEN APPL MICROBIOL, V19, P385, DOI 10.2323/jgam.19.385; FAO/WHO, 1987, 31 M JOINT FAO WHO E; *FAO WHO, 1972, 1K REP JOINT FAO WHO; *FAO WHO, 1978, 22 M JOINT FAO WHO E; FAO/WHO, 1981, 25 M JOINT FAO WHO E; FAO/WHO, 1990, 35 M JOINT FAO WHO E; FRISVAD JC, 1990, NATO ADV SCI I A-LIF, V185, P83; [Anonymous], 2000, STUD MYCOL; Frost G.M., 1987, BIOTECHNOLOGY A, V7a, P65; Gams W, 1985, ADV PENICILLIUM ASPE, P55; GHOSAL S, 1979, J AGR FOOD CHEM, V27, P1347, DOI 10.1021/jf60226a018; Gielkens MMC, 1997, CURR GENET, V31, P22, DOI 10.1007/s002940050172; Godfrey T., 1983, IND ENZYMOLOGY APPL; GRASSIN C, 1999, ENCY BIOPROCESS TECH; GROOT GSP, 2000, FOOD BIOTECHNOLOGY P, V17, P95; HANG YD, 1976, PROG WATER TECHNOL, V8, P325; HANG YD, 1979, J FOOD SCI, V44, P1548, DOI 10.1111/j.1365-2621.1979.tb06485.x; HANG YD, 1975, APPL MICROBIOL, V30, P879; HANG YD, 1977, J FOOD SCI, V42, P383, DOI 10.1111/j.1365-2621.1977.tb01504.x; HANSSEN E, 1969, NATURWISSENSCHAFTEN, V56, P90, DOI 10.1007/BF00590582; HARMSEN JAM, 1990, CURR GENET, V18, P161, DOI 10.1007/BF00312604; HASANY SM, 1973, CAN J OPHTHALMOL, V8, P119; Heenan CN, 1998, J FOOD MYCOL, V1, P67; Horie Yoshikazu, 1995, Nippon Kingakukai Kaiho, V36, P73; IBEKWE AO, 1983, TROP GEOGR MED, V35, P389; IWAI M, 1983, AGR BIOL CHEM TOKYO, V47, P1865; JACOB Z, 1984, Biological Memoirs, V9, P87; JAHN F, 1977, WIEN TIERARZTL MONAT, V64, P79; KELLY JM, 1985, EMBO J, V4, P475; Kluyver AJ, 1933, BIOCHEM Z, V266, P68; KOZAKIEWICZ Z, 1992, Taxon, V41, P109, DOI 10.2307/1222500; Kozakiewicz Z, 1989, MYCOL PAP, V161, P1; KULIK MM, 1966, MYCOPATH MYCOL APPL, V30, P137, DOI 10.1007/BF02130360; KUSTERSVANSOMEREN MA, 1991, CURR GENET, V19, P21, DOI 10.1007/BF00362083; LEMENSE EH, 1947, J BACTERIOL, V54, P149; Loh K. S., 1998, Annals Academy of Medicine Singapore, V27, P215; MEGNEGNEAU B, 1993, CURR GENET, V23, P323, DOI 10.1007/BF00310893; MISLIVEC PB, 1968, APPL MICROBIOL, V16, P1053; Moreau C., 1979, MOULDS TOXINS FOOD; MUGLISTON T, 1985, J LARYNGOL OTOL, V99, P327, DOI 10.1017/S002221510009678X; MULLANEY EJ, 1991, APPL MICROBIOL BIOT, V35, P611; MURAKAMI H, 1967, J GEN APPL MICROBIOL, V13, P323, DOI 10.2323/jgam.13.323; Nakajima M, 1997, FOOD AGR IMMUNOL, V9, P77, DOI 10.1080/09540109709354938; NGUYEN QK, 1991, GENE, V106, P71; NIME FA, 1973, JOHNS HOPKINS MED J, V133, P183; NUNBERG J, 1983, P ASM C GEN MAN EXPL; NUNBERG JH, 1984, MOL CELL BIOL, V4, P2306; NYIREDY I, 1975, ACTA VET ACAD SCI H, V25, P123; OKUMURA S, 1983, AGR BIOL CHEM TOKYO, V47, P1869; Ono H., 1995, MYCOTOXINS, V41, P47; PALDROK H, 1965, ACTA DERM-VENEREOL, V45, P275; Parenicova L, 2001, APPL ENVIRON MICROB, V67, P521, DOI 10.1128/AEM.67.2.521-527.2001; Parenicova L, 1997, MYCOL RES, V101, P810, DOI 10.1017/S0953756297003444; Parenicova L., 2000, INTEGRATION MODERN T, P413; PARIZA MW, 2001, REGUL TOXICOL PHARM, V33, P1; PARRISH FW, 1966, APPL MICROBIOL, V14, P139; PAULOSE KO, 1989, J LARYNGOL OTOL, V103, P30, DOI 10.1017/S0022215100107960; PIDDINGTON CS, 1993, GENE, V133, P55, DOI 10.1016/0378-1119(93)90224-Q; Pitt JI, 2000, INTEGRATION MODERN T, P51; Pitt JI, 2000, INTEGRATION MODERN T, P9; Raper K, 1965, GENUS ASPERGILLUS; REISS J, 1986, SCHIMMELPILZE LEBENS, P33; REISS J, 1981, MYCOTOXINE LEBENSMIT; Rippel-Baldes A., 1955, GRUNDZUGE MIKROBIOLO; RIPPON JW, 1982, MED MYCOLOGY PATHOGE, P565; Roukas T, 2000, J IND MICROBIOL BIOT, V25, P298, DOI 10.1038/sj.jim.7000101; SAMSON RA, 1992, ASPERGILLUS BIOL IND, P355; SARAVIAGOMEZ J, 1979, HDB CLIN NUEROLOGY 3, V35, P395; SEATON A, 1994, OCCUP ENVIRON MED, V51, P54; SELTEN G, 1994, GIST, V60, P5; SEMENIUK G, 1971, MYCOPATH MYCOL APPL, V43, P137, DOI 10.1007/BF02051714; Severo Luiz Carlos, 1997, Revista Iberoamericana de Micologia, V14, P104; SHU P, 1947, J BACTERIOL, V54, P161; SONEREN MAK, 1990, MODERN CONCEPTS PENI, P83; STEYN PS, 1977, PURE APPL CHEM, V49, P1771, DOI 10.1351/pac197749111771; Taniwaki MH, 1999, 18TH INTERNATIONAL SCIENTIFIC COLLOQUIUM ON COFFEE, P239; Teren J, 1996, MYCOPATHOLOGIA, V134, P171, DOI 10.1007/BF00436726; Teren J, 1997, CEREAL RES COMMUN, V25, P303; TILBURN J, 1983, GENE, V26, P205, DOI 10.1016/0378-1119(83)90191-9; TOMSIKOVA A, 1981, MYKOSEN, V24, P354; TOPPING MD, 1985, BRIT J IND MED, V42, P312; Ueno Y., 1991, IARC SCI PUBL, P71; van Dijck PWM, 1999, J BIOTECHNOL, V67, P77, DOI 10.1016/S0168-1656(98)00124-2; VANHARTINGSVELD.W, 1987, MOL GEN GENET, V206, P1; VANHARTINGSVELDT W, 1993, GENE, V127, P87, DOI 10.1016/0378-1119(93)90620-I; VARGA J, 1993, MYCOL RES, V97, P1207; VARGA J, 1994, CAN J MICROBIOL, V40, P612; Varga J, 2000, INTEGRATION MODERN T, P397; WARD M, 1988, CURR GENET, V14, P37, DOI 10.1007/BF00405851; WASHBURN RG, 1986, J INFECT DIS, V154, P944; Wicklow DT, 1996, CAN J MICROBIOL, V42, P1100; WILSON BJ, 1968, APPL MICROBIOL, V16, P819; WILSON BJ, 1971, MICROBIAL TOXINS, V6, P207; YOSHIZAWA T, 1975, AGR BIOL CHEM TOKYO, V39, P1325; 1993, FED REG, V58, P27197; Berka RM, 1994, US Patent, Patent No. 5360732; 1991, Patent No. [420358, 0420358]; SELTEN GCM, 1995, Patent No. 0635574; SELTEN GCM, 1998, Patent No. 9846772; BERKA RM, 1994, Patent No. 5360901	130	257	279	13	103	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598			APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	AUG	2002	59	4-5					426	435		10.1007/s00253-002-1032-6		10	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	589AF	WOS:000177734800005	12172605	
J	Humbles, AA; Lu, B; Friend, DS; Okinaga, S; Lora, J; Al-garawi, A; Martin, TR; Gerard, NP; Gerard, C				Humbles, AA; Lu, B; Friend, DS; Okinaga, S; Lora, J; Al-garawi, A; Martin, TR; Gerard, NP; Gerard, C			The murine CCR3 receptor regulates both the role of eosinophils and mast cells in allergen-induced airway inflammation and hyperresponsiveness	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							GUINEA-PIG MODEL; ASTHMA MODEL; CHEMOKINE EOTAXIN; IN-VIVO; EXPRESSION; MICE; LUNG; INTERLEUKIN-5; RECRUITMENT; ACTIVATION	CCR3 is a chemokine receptor initially thought specific to eosinophils but subsequently identified on TH2 cell subsets, basophils, mast cells, neural tissue, and some epithelia. Because of the prominent role of these cells in allergic disease, including asthma, we generated mice deficient in CCR3 to determine its contribution in a model of allergic airway disease. Here we show that CCR3 is important for the basal trafficking of eosinophils to the intestinal mucosa but not the lung. In contrast, CCR3 disruption significantly curtails eosinophil recruitment to the lung after allergen challenge, with the majority of the eosinophils being arrested in the subendothelial space. Further, a role for CCR3 in mast cell homing has been identified; after sensitization and allergen challenge, we find increased numbers of intraepithelial mast cells in the trachea of knockout mice. Physiologically, we find that the net result of these complex cell fates after sensitization and allergen challenge is a paradoxical increase in airway responsiveness to cholinergic stimulation. These data underscore a more complex role for CCR3 in allergic disease than was anticipated.	Harvard Univ, Ina Sue Perlmutter Lab, Sch Med, Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Dept Biol, Inflammat Div, Cambridge, MA 02139 USA; Tufts Univ, New England Med Ctr, Boston, MA 02111 USA	Gerard, C (reprint author), Harvard Univ, Ina Sue Perlmutter Lab, Sch Med, Childrens Hosp, Enders Bldg,Room 144,320 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL10463-01, F32 HL010463, HL39759]		BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; CORRIGAN CJ, 1993, AM REV RESPIR DIS, V147, P540; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FRIEND DS, 2000, J IMMUNOL, V157, P1806; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933; Gonzalo JA, 1996, IMMUNITY, V4, P1, DOI 10.1016/S1074-7613(00)80293-9; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Humbles AA, 2000, NATURE, V406, P998; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kobayashi T, 2000, J IMMUNOL, V164, P3855; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; MA W, 2002, IN PRESS J CLIN INVE; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Matthews D. A., 1997, MIND BODY MED, V2, P9; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Nagai H, 1996, CLIN EXP ALLERGY, V26, P642, DOI 10.1111/j.1365-2222.1996.tb00590.x; Nakamura H, 1999, AM J RESP CRIT CARE, V160, P1952; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Teran LM, 1996, J IMMUNOL, V157, P1806; Teran LM, 1999, AM J RESP CELL MOL, V20, P777; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; WILLSKARP M, 1999, SCIENCE, V292, P2258; Yang Y, 1998, BLOOD, V92, P3912	41	257	266	1	2	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	FEB 5	2002	99	3					1479	1484		10.1073/pnas.261462598		6	Multidisciplinary Sciences	Science & Technology - Other Topics	519YF	WOS:000173752500070	11830666	
J	Kellogg, CA; Griffin, DW				Kellogg, Christina A.; Griffin, Dale W.			Aerobiology and the global transport of desert dust	TRENDS IN ECOLOGY & EVOLUTION			English	Review							AMBIENT FUNGAL SPORES; AERIAL DISPERSAL; AIRBORNE SPREAD; MOUTH-DISEASE; AFRICAN DUST; CORAL-REEFS; ASIAN DUST; SOIL DUST; BACTERIA; DIVERSITY	Desert winds aerosolize several billion tons of soil-derived dust each year, including concentrated seasonal pulses from Africa and Asia. These transoceanic and transcontinental dust events inject a large pulse of microorganisms and pollen into the atmosphere and could therefore have a role in transporting pathogens or expanding the biogeographical range of some organisms by facilitating long-distance dispersal events. As we discuss here, whether such dispersal events are occurring is only now beginning to be investigated. Huge dust events create an atmospheric bridge over land and sea, and the microbiota contained within them could impact downwind ecosystems. Such dispersal is of interest because of the possible health effects of allergens and pathogens that might be carried with the dust.	US Geol Survey, St Petersburg, FL 33701 USA	Kellogg, CA (reprint author), US Geol Survey, 600 4th St S, St Petersburg, FL 33701 USA.	ckellogg@usgs.gov	Kellogg, Christina/B-3257-2009; MORENO-GRAU, STELLA/E-6540-2012	Kellogg, Christina/0000-0002-6492-9455			Blades E, 1998, W INDIAN MED J S2, V47, P34; Bovallius A, 1980, Ann N Y Acad Sci, V353, P186, DOI 10.1111/j.1749-6632.1980.tb18922.x; BREITMAN L, 2001, J LONGEVITY, V7, P9; Brown JKM, 2002, SCIENCE, V297, P537, DOI 10.1126/science.1072678; Buttner MP, 1997, MANUAL ENV MICROBIOL, P629; Capone DG, 2005, ASM NEWS, V71, P179; Carinanos P, 2004, ARCH ENVIRON CON TOX, V46, P141, DOI 10.1007/s00244-003-2273-9; Carlson T. N., 1972, Journal of Applied Meteorology, V11, P283, DOI 10.1175/1520-0450(1972)011<0283:TLSMOS>2.0.CO;2; Chiapello I, 1999, J GEOPHYS RES-ATMOS, V104, P9277, DOI 10.1029/1998JD200083; Choi DS, 1997, J MICROBIOL, V35, P1; CLOSE RC, 1978, INT J BIOMETEOROL, V22, P1, DOI 10.1007/BF01553136; CORBAZ R, 1979, DERMATOLOGICA, V159, P56; DONALDSON AI, 1982, VET REC, V110, P53; DUCE RA, 1980, SCIENCE, V209, P1522, DOI 10.1126/science.209.4464.1522; Fenchel T, 2004, BIOSCIENCE, V54, P777, DOI 10.1641/0006-3568(2004)054[0777:TUOSSP]2.0.CO;2; FRANZEN LG, 1994, ATMOS ENVIRON, V28, P3587, DOI 10.1016/1352-2310(94)00191-M; Gage SH, 1999, AGR FOREST METEOROL, V97, P249, DOI 10.1016/S0168-1923(99)00070-2; Garrison VH, 2003, BIOSCIENCE, V53, P469, DOI 10.1641/0006-3568(2003)053[0469:AAADFD]2.0.CO;2; GARRISON VH, 2005, HLTH DIS AQUATIC ORG, P152; GLOSTER J, 1982, VET REC, V111, P290; Goudie AS, 2001, EARTH-SCI REV, V56, P179, DOI 10.1016/S0012-8252(01)00067-8; Gregory P. H., 1973, MICROBIOLOGY ATMOSPH; Griffin D.W., 2001, GLOBAL CHANGE HUMAN, V2, P20, DOI DOI 10.1023/A:1011910224374; Griffin Dale W., 2003, Aerobiologia, V19, P143, DOI 10.1023/B:AERO.0000006530.32845.8d; Griffin D.W., 2004, ECOHEALTH, V1, P284, DOI DOI 10.1007/S10393-004-0120-8; Griffin D. W., 2001, AEROBIOLOGIA, V17, P203, DOI DOI 10.1023/A:1011868218901; Gyan K, 2005, INT J BIOMETEOROL, V49, P371, DOI 10.1007/s00484-005-0257-3; Hedlund B. P., 2003, MICROBIAL DIVERSITY, P225; Ho HM, 2005, ATMOS ENVIRON, V39, P5839, DOI 10.1016/j.atmonsenv.2005.06.034; Horner-Devine MC, 2004, P ROY SOC B-BIOL SCI, V271, P113, DOI 10.1098/rspb.2003.2549; Huxel GR, 1999, BIOL CONSERV, V89, P143, DOI 10.1016/S0006-3207(98)00153-0; Jaspers E, 2004, APPL ENVIRON MICROB, V70, P4831, DOI 10.1128/AEM.70.8.4831-4839.2004; Kar A, 2004, J ARID ENVIRON, V59, P167, DOI 10.1016/j.jaridenv.2004.01.010; Kellogg Christina A., 2004, Aerobiologia, V20, P99, DOI 10.1023/B:AERO.0000032947.88335.bb; KNIGHT AW, 1995, CATENA, V24, P195, DOI 10.1016/0341-8162(95)00026-O; Lighthart B, 1997, FEMS MICROBIOL ECOL, V23, P263, DOI 10.1016/S0168-6496(97)00036-6; Lobitz B, 2000, P NATL ACAD SCI USA, V97, P1438, DOI 10.1073/pnas.97.4.1438; Maron PA, 2005, ATMOS ENVIRON, V39, P3687, DOI 10.1016/j.atosenv.2005.03.002; Mims SA, 2004, ATMOS ENVIRON, V38, P651, DOI 10.1016/j.atmosenv.2003.10.043; Moulin C, 1997, NATURE, V387, P691; MUHS DR, 1990, QUATERNARY RES, V33, P157, DOI 10.1016/0033-5894(90)90016-E; Nathan R, 2005, DIVERS DISTRIB, V11, P131, DOI 10.1111/j.1366-9516.2005.00146.x; Nicholson WL, 2002, CELL MOL LIFE SCI, V59, P410, DOI 10.1007/s00018-002-8433-7; Papke RT, 2004, FEMS MICROBIOL ECOL, V48, P293, DOI 10.1016/j.femsec.2004.03.013; Prospero JM, 2005, AEROBIOLOGIA, V21, P1, DOI 10.1007/s10453-004-5872-7; PROSPERO JM, 2001, GEOTIMES, V11, P24; Radosevich JL, 2002, LETT APPL MICROBIOL, V34, P162, DOI 10.1046/j.1472-765x.2002.01048.x; REASONER DJ, 1985, APPL ENVIRON MICROB, V49, P1; Shinn EA, 2000, GEOPHYS RES LETT, V27, P3029, DOI 10.1029/2000GL011599; SIMMER C, 1993, INT J REMOTE SENS, V14, P1447; Staley JT, 1999, ANNU REV MICROBIOL, V53, P189, DOI 10.1146/annurev.micro.53.1.189; Subramaniam A, 2002, DEEP-SEA RES PT II, V49, P107; Tong YY, 1997, PHOTOCHEM PHOTOBIOL, V65, P103, DOI 10.1111/j.1751-1097.1997.tb01884.x; TORSVIK V, 1990, APPL ENVIRON MICROB, V56, P782; Torsvik V, 2002, SCIENCE, V296, P1064, DOI 10.1126/science.1071698; TU KW, 1977, J COLLOID INTERF SCI, V62, P40, DOI 10.1016/0021-9797(77)90063-7; Weir-Brush J. R., 2004, Aerobiologia, V20, P119, DOI 10.1023/B:AERO.0000032949.14023.3a; Whitaker RJ, 2003, SCIENCE, V301, P976, DOI 10.1126/science.1086909; Whitfield J, 2005, SCIENCE, V310, P960, DOI 10.1126/science.310.5750.960; Wu PC, 2004, ATMOS ENVIRON, V38, P4879, DOI 10.1016/j.atmosenv.2004.05.039; Yeo HG, 2002, ATMOS ENVIRON, V36, P5437, DOI 10.1016/S1352-2310(02)00672-6	61	256	271	12	80	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0169-5347			TRENDS ECOL EVOL	Trends Ecol. Evol.	NOV	2006	21	11					638	644		10.1016/j.tree.2006.07.004		7	Ecology; Evolutionary Biology; Genetics & Heredity	Environmental Sciences & Ecology; Evolutionary Biology; Genetics & Heredity	105DQ	WOS:000242010000009	16843565	
J	Janssen, NAH; Brunekreef, B; van Vliet, P; Aarts, F; Meliefste, K; Harssema, H; Fischer, P				Janssen, NAH; Brunekreef, B; van Vliet, P; Aarts, F; Meliefste, K; Harssema, H; Fischer, P			The relationship between air pollution from heavy traffic and allergic sensitization, bronchial hyperresponsiveness, and respiratory symptoms in Dutch schoolchildren	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; allergy; bronchial hyperresponsiveness; children; diesel; lung function; respiratory symptoms	DIESEL EXHAUST PARTICLES; LUNG-FUNCTION; ADJUVANT ACTIVITY; CHILDHOOD ASTHMA; EXPIRATORY FLOW; CHILDREN; EXPOSURE; HEALTH; ROAD; ATOPY	Studies have suggested that children living close to busy roads may have impaired respiratory health. This study was designed to test the hypothesis that exposure to exhaust from heavy traffic in particular is related to childhood respiratory health. Children attending 24 schools located within 400 in from busy motorways were investigated. The motorways carried between 5,190 and 22,326 trucks per weekday and between 30,399 and 155,656 cars per day. Locations were chosen so that the correlation between truck and car traffic counts was low. Air pollution measurements were performed at the schools for I year. Respiratory symptoms were collected by parent-completed questionnaire. Sensitization to common allergens was measured by serum immunoglobulin E and skin prick tests. Bronchial hyperresponsiveness (BHR) was measured with a hypertonic saline challenge. Respiratory symptoms were increased near motorways with high truck but not high car traffic counts. They were also related to air pollutants that increased near motorways with high truck traffic counts. Lung function and BHR were not related to pollution. Sensitization to pollen increased in relation to truck but not car traffic counts. The relation between symptoms and measures of exposure to (truck) traffic-related air pollution were almost entirely restricted to children with BHR and/or sensitization to common allergens, indicating that these are a sensitive subgroup among all children for these effects.	Univ Utrecht, Inst Risk Assessment Sci, Dept Environm Epidemiol, NL-3508 TD Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands	Brunekreef, B (reprint author), Univ Utrecht, Inst Risk Assessment Sci, Dept Environm Epidemiol, POB 80176, NL-3508 TD Utrecht, Netherlands.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Buckeridge DL, 2002, ENVIRON HEALTH PERSP, V110, P293; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, ALLERGY, V52, P52; DUC J, 1988, ALLERGY, V43, P332, DOI 10.1111/j.1398-9995.1988.tb00426.x; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EAACI, 1989, ALLERGY S10, V44, P1; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; *ERS, 1993, EUR RESPIR J, V16, P1; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; GIBSON GJ, 1993, EUR RESPIR J, V6, P155; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; *ISAAC, 1998, PHASE 2 MOD INT STUD; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Livingstone AE, 1996, BRIT MED J, V312, P676; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; RASBASH J, 2001, USERS FUID MLWIN VER; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; RIEDLER J, 1994, PEDIATR PULM, V18, P330, DOI 10.1002/ppul.1950180511; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Rudell B, 1999, OCCUP ENVIRON MED, V56, P527; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658; van Zlverden M, 2000, TOXICOLOGY, V152, P69, DOI 10.1016/S0300-483X(00)00293-6; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; ZAPLETAL A, 1969, J APPL PHYSIOL, V26, P308	42	256	259	3	45	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2003	111	12					1512	1518		10.1289/ehp.6243		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	733HZ	WOS:000185995500033	12948892	
J	Calverley, PMA; Burge, PS; Spencer, S; Anderson, JA; Jones, PW				Calverley, PMA; Burge, PS; Spencer, S; Anderson, JA; Jones, PW		ISOLDE Study Investigators	Bronchodilator reversibility testing in chronic obstructive pulmonary disease	THORAX			English	Article							AIR-FLOW OBSTRUCTION; CORTICOSTEROID TRIALS; COPD; MANAGEMENT; SMOKING; ASTHMA; FEV1	Background: A limited or absent bronchodilator response is used to classify chronic obstructive pulmonary disease (COPD) and can determine the treatment offered. The reliability of the recommended response criteria and their relationship to disease progression has not been established. Methods: 660 patients meeting European Respiratory Society (ERS) diagnostic criteria for irreversible COPD were studied. Spirometric parameters were measured on three occasions before and after salbutamol and ipratropium bromide sequentially or in combination over 2 months. Responses were classified using the American Thoracic Society/GOLD (ATS) and ERS criteria. Patients were followed for 3 years with post-bronchodilator FEV1 and exacerbation history recorded 3 monthly and health status 6 monthly. Results: FEV1 increased significantly with each bronchodilator, a response that was normally distributed. Mean post-bronchodilator FEV1 was reproducible between visits (intraclass correlation 0.93). The absolute change in FEV1 was independent of the pre-bronchodilator value but the percentage change correlated with pre-bronchodilator FEV1 (r=-0.44; p<0.0001). Using ATS criteria, 52.1% of patients changed responder status between visits compared with 38.2% using ERS criteria. Smoking status, atopy, and withdrawing inhaled corticosteroids were unrelated to bronchodilator response, as was the rate of decline in FEV1, decline in health status, and exacerbation rate. Conclusion: In moderate to severe COPD bronchodilator responsiveness is a continuous variable. Classifying patients as "responders" and "non-responders" can be misleading and does not predict disease progression.	Univ Liverpool, Dept Med, Liverpool L69 3BX, Merseyside, England; Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; GlaxoSmithKline R&D, Dept Med Stat, Stevenage, Herts, England; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England	Calverley, PMA (reprint author), Univ Hosp Aintree, Ctr Clin Sci, Liverpool L69 7AL, Merseyside, England.		Spencer, Sally/D-6963-2013				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14; Bland M., 1987, INTRO MED STAT; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; British Thoracic Society (BTS), 1997, THORAX S5, V52, pS1; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216; Davies L, 1999, QJM-MON J ASSOC PHYS, V92, P395, DOI 10.1093/qjmed/92.7.395; DOMPELING E, 1992, EUR RESPIR J, V5, P975; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215; GROSS NJ, 1989, CHEST, V96, P984, DOI 10.1378/chest.96.5.984; GROSS NJ, 1989, AM REV RESPIR DIS, V139, P1188; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267; HAY JG, 1992, EUR RESPIR J, V5, P659; Jarad NA, 1999, RESP MED, V93, P161, DOI 10.1016/S0954-6111(99)90001-X; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; Kerstjens HAM, 1996, AM J RESP CRIT CARE, V154, pS266; Lofdahl CG, 1998, RESP MED, V92, P467, DOI 10.1016/S0954-6111(98)90293-1; NISAR M, 1992, AM REV RESPIR DIS, V146, P555; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; TWEEDDALE PM, 1987, THORAX, V42, P487, DOI 10.1136/thx.42.7.487; VATHENEN AS, 1988, AM REV RESPIR DIS, V138, P850; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112	29	256	271	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	AUG	2003	58	8					659	664		10.1136/thorax.58.8.659		6	Respiratory System	Respiratory System	705YP	WOS:000184425100006	12885978	
J	Lieu, TA; Lozano, P; Finkelstein, JA; Chi, FW; Jensvold, NG; Capra, AM; Quesenberry, CP; Selby, JV; Farber, HJ				Lieu, TA; Lozano, P; Finkelstein, JA; Chi, FW; Jensvold, NG; Capra, AM; Quesenberry, CP; Selby, JV; Farber, HJ			Racial/ethnic variation in asthma status and management practices among children in managed medicaid	PEDIATRICS			English	Article						asthma; race; race/ethnicity; health status; quality of care; processes of care; managed care	HEALTH MAINTENANCE ORGANIZATION; PATIENT-PHYSICIAN RELATIONSHIP; AFRICAN-AMERICAN CHILDREN; INNER-CITY CHILDREN; RACIAL-DIFFERENCES; ETHNIC-DIFFERENCES; CHILDHOOD ASTHMA; UNITED-STATES; RENAL-TRANSPLANTATION; CULTURAL COMPETENCE	Objective. Racial/ethnic disparities in hospitalization rates among children with asthma have been documented but are not well-understood. Medicaid programs, which serve many minority children, have markedly increased their use of managed care in recent years. It is unknown whether racial/ethnic disparities in health care use or other processes of care exist in managed Medicaid populations. This study of Medicaid-insured children with asthma in 5 managed care organizations aimed to 1) compare parent-reported health status and asthma care processes among black, Latino, and white children and 2) test the hypothesis that racial/ ethnic variations in processes of asthma care exist after adjusting for socioeconomic status and asthma status. Methods. This cross-sectional study collected data via telephone interviews with parents and computerized records for Medicaid-insured children with asthma in 5 managed care organizations in California, Washington, and Massachusetts. The American Academy of Pediatrics (AAP) Children's Health Survey for Asthma was used to measure parent-reported asthma status. We used multivariate models to evaluate associations between race/ethnicity and asthma status while controlling for other sociodemographic variables. We evaluated racial/ ethnic variations in selected processes of asthma care while controlling for other demographic variables and asthma status. Results. The response rate was 63%. Of the 1658 children in the respondent group, 38% were black, 19% were Latino, and 31% were white. Black children had worse asthma status than white children on the basis of the AAP asthma physical and emotional health scores, symptom-days, and school days missed in the past 2 weeks. Latino children had equivalent AAP scores but missed more school days than white children. On the basis of the AAP asthma physical health score, the black-white disparity persisted after adjusting for other sociodemographic variables. After adjusting for sociodemographic variables and asthma status, black and Latino children were less likely to be using inhaled antiinflammatory medication than white children (relative risk for blacks: 0.69; relative risk for Latinos: 0.58). They were more likely to have home nebulizers. Other processes of asthma care, including ratings of providers and asthma care, use of written management plans, use of preventive visits and specialists, and having no pets or smokers at home, were equal or better for minority children compared with white children. Conclusions. Black and Latino children had worse asthma status and less use of preventive asthma medications than white children within the same managed Medicaid populations. Most other processes of asthma care seemed to be equal or better for minorities in the populations that we studied. Increasing the use of preventive medications is a natural focus for reducing racial disparities in asthma.	Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Grp Hlth Cooperat Puget Sound, Ctr Hlth Studies, Seattle, WA 98101 USA; Univ Washington, Seattle, WA 98195 USA; Kaiser Permanente, Dept Pediat Vallejo, Oakland, CA USA; Kaiser Permanente, Div Res Oakland, Oakland, CA USA	Lieu, TA (reprint author), Harvard Pilgrim Hlth Care, Dept Ambulatory Care & Prevent, 126 Brookline Ave,Ste 200, Boston, MA 02215 USA.				AHRQ HHS [HS09935]		Aday L A, 1974, Health Serv Res, V9, P208; Alessandrini EA, 2001, PEDIATRICS, V107, P1335, DOI 10.1542/peds.107.6.1335; Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; ANDERSEN R, 1973, MILBANK FUND Q, V51, P95, DOI 10.2307/3349613; ASMUSSEN L, 1999, PEDIATRICS, V104; Ayanian JZ, 1999, NEW ENGL J MED, V341, P1661, DOI 10.1056/NEJM199911253412206; Bender B, 1998, J ASTHMA, V35, P347, DOI 10.3109/02770909809075667; Blixen CE, 1999, J ASTHMA, V36, P195, DOI 10.3109/02770909909056317; Brach C, 2000, MED CARE RES REV, V57, P181, DOI 10.1177/107755800773743655; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Carrasquillo O, 1998, AM J PUBLIC HEALTH, V88, P464, DOI 10.2105/AJPH.88.3.464; Centers for Disease Control and Prevention, 1998, CDC SURVEILL SUMM, V47, P1; Cooper-Patrick L, 1999, JAMA-J AM MED ASSOC, V282, P583, DOI 10.1001/jama.282.6.583; Council of American Survey Research Organizations, 1982, DEF RESP RAT SPEC RE; Cunningham J, 1996, AM J PUBLIC HEALTH, V86, P1406, DOI 10.2105/AJPH.86.10.1406; Diaz T, 2000, PEDIATRICS, V105, P1188, DOI 10.1542/peds.105.6.1188; Eggleston PA, 1998, PEDIATRICS, V101, P349, DOI 10.1542/peds.101.3.349; Epstein AM, 1997, JAMA-J AM MED ASSOC, V278, P1617; Epstein AM, 2000, NEW ENGL J MED, V343, P1537, DOI 10.1056/NEJM200011233432106; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Farber HJ, 1998, J ASTHMA, V35, P547, DOI 10.3109/02770909809048957; Finkelstein JA, 2000, ARCH PEDIAT ADOL MED, V154, P563; Fiscella K, 2000, JAMA-J AM MED ASSOC, V283, P2579, DOI 10.1001/jama.283.19.2579; Flores G, 2000, J PEDIATR-US, V136, P14, DOI 10.1016/S0022-3476(00)90043-X; Flores G, 1998, ARCH PEDIAT ADOL MED, V152, P1119; Flores G, 1999, AM J PUBLIC HEALTH, V89, P1066, DOI 10.2105/AJPH.89.7.1066; Furth SL, 2000, PEDIATRICS, V106, P756, DOI 10.1542/peds.106.4.756; GAMBLE VN, 2000, I RACISM ITS EFFECTS; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; Guarnaccia P J, 1985, Med Anthropol, V9, P203; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; HAHN BA, 1995, PEDIATRICS, V95, P727; HALFON N, 1993, PEDIATRICS, V91, P56; Halterman JS, 2000, PEDIATRICS, V105, P272; Hargraves JL, 2001, HEALTH SERV RES, V36, P853; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504; Joseph CLM, 1996, J PEDIATR-US, V129, P735, DOI 10.1016/S0022-3476(96)70158-0; KAHN KL, 1994, JAMA-J AM MED ASSOC, V271, P1169, DOI 10.1001/jama.271.15.1169; *KAIS COMM MED UN, 2001, MED MAN CAR FACT SHE; Kelly CS, 2000, PEDIATRICS, V105, P1029, DOI 10.1542/peds.105.5.1029; Kogan MD, 2000, AM J PUBLIC HEALTH, V90, P245, DOI 10.2105/AJPH.90.2.245; Krieger N, 1997, ANNU REV PUBL HEALTH, V18, P341, DOI 10.1146/annurev.publhealth.18.1.341; Krishnan JA, 2001, ARCH INTERN MED, V161, P1660, DOI 10.1001/archinte.161.13.1660; Lannin DR, 1998, JAMA-J AM MED ASSOC, V279, P1801, DOI 10.1001/jama.279.22.1801; Lara M, 2000, MED CARE, V38, P342, DOI 10.1097/00005650-200003000-00011; LARA M, 1998, PEDIATRICS, V102; LaVeist TA, 2000, MED CARE RES REV, V57, P146, DOI 10.1177/107755800773743637; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; McCarthy PL, 2000, PEDIATRICS, V105, P1349; McCullagh P., 1989, GEN LINEAR MODELS; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; MOY E, 1995, JAMA-J AM MED ASSOC, V273, P1515, DOI 10.1001/jama.273.19.1515; Murray-Garcia JL, 2000, MED CARE, V38, P300, DOI 10.1097/00005650-200003000-00007; National Asthma Education and Prevention Program, 1997, 2 NAT ASTHM ED PREV; Office of Management and Budget. Revisions to the Standards for the Classification of Federal Data on Race and Ethnicity, 1997, FED REGISTER, V62, P58781; *OFF MAN BUDG, 2001, PROV GUID IMPL 1997; OLIVE RML, 1997, BLACK WEALTH WHITE W; PACHTER LM, 2000, WORKING PATIENTS HLT, P36; PEREZSTABLE EJ, 1994, ARCH INTERN MED, V154, P1073, DOI 10.1001/archinte.154.10.1073; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; Racine AD, 2001, PEDIATRICS, V108, P1135, DOI 10.1542/peds.108.5.1135; Rand CS, 2000, J ALLERGY CLIN IMMUN, V105, P83, DOI 10.1016/S0091-6749(00)90182-9; Ronsaville DS, 2000, AM J PUBLIC HEALTH, V90, P1436, DOI 10.2105/AJPH.90.9.1436; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; Schneider EC, 2001, JAMA-J AM MED ASSOC, V286, P1455, DOI 10.1001/jama.286.12.1455; Schwartz LM, 1999, NEW ENGL J MED, V341, P279, DOI 10.1056/NEJM199907223410411; Sisk JE, 1996, JAMA-J AM MED ASSOC, V276, P50, DOI 10.1001/jama.276.1.50; Stevens MW, 2001, PEDIATRICS, V107, P1357, DOI 10.1542/peds.107.6.1357; Weech-Maldonado R, 2001, HEALTH SERV RES, V36, P575; Weinick RM, 2000, MED CARE RES REV, V57, P36, DOI 10.1177/107755800773743592; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WOOD D, 1993, JAMA-J AM MED ASSOC, V270, P1334, DOI 10.1001/jama.270.11.1334; WOOD PR, 1993, PEDIATRICS, V91, P62; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371; 2000, MMWR MORB MORIAL WKL, V49, P908	81	256	260	3	20	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAY	2002	109	5					857	865		10.1542/peds.109.5.857		9	Pediatrics	Pediatrics	547EZ	WOS:000175321200036	11986447	
J	Lewkowich, IP; Herman, NS; Schleifer, KW; Dance, MP; Chen, BL; Dienger, KM; Sproles, AA; Shah, JS; Kohl, J; Belkaid, Y; Wills-Karp, M				Lewkowich, IP; Herman, NS; Schleifer, KW; Dance, MP; Chen, BL; Dienger, KM; Sproles, AA; Shah, JS; Kohl, J; Belkaid, Y; Wills-Karp, M			CD4(+) CD25(+) T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							INDUCED AIRWAY HYPERRESPONSIVENESS; TRYPTOPHAN CATABOLISM; HYGIENE HYPOTHESIS; IMMUNE-RESPONSES; ALLERGIC DISEASE; REGULATORY CELLS; CUTTING EDGE; ANTIGEN; SUPPRESSION; INDUCTION	The role of natural CD4(+)CD25(+) regulatory T ( T reg) cells in the control of allergic asthma remains poorly understood. We explore the impact of T reg cell depletion on the allergic response in mice susceptible (A/J) or comparatively resistant (C3H) to the development of allergen-induced airway hyperresponsiveness ( AHR). In C3H mice, anti-CD25-mediated T reg cell depletion before house dust mite treatment increased several features of the allergic diathesis ( AHR, eosinophilia, and IgE), which was concomitant with elevated T helper type 2 ( Th2) cytokine production. In similarly T reg cell-depleted A/J mice, we observed a moderate increase in airway eosinophilia but no effects on AHR, IgE levels, or Th2 cytokine synthesis. As our experiments suggested that T reg cell depletion in C3H mice before sensitization was sufficient to enhance the allergic phenotype, we characterized dendritic cells ( DCs) in T reg cell-depleted C3H mice. T reg cell-depleted mice had increased numbers of pulmonary myeloid DCs with elevated expression of major histocompatibility complex class II, CD80, and CD86. Moreover, DCs from T reg cell-depleted mice demonstrated an increased capacity to stimulate T cell proliferation and Th2 cytokine production, which was concomitant with reduced IL-12 expression. These data suggest that resistance to allergen-driven AHR is mediated in part by CD4(+)CD25(+) T reg cell suppression of DC activation and that the absence of this regulatory pathway contributes to susceptibility.	Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Childrens Hosp, Med Ctr, Div Mol Immunol, Cincinnati, OH 45229 USA	Wills-Karp, M (reprint author), Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA.	wildc7@cchmc.org	Koehl, Joerg/C-8531-2011	Koehl, Joerg/0000-0003-1121-3178	NHLBI NIH HHS [HL076383, HL67736, P01 HL076383, R01 HL067736, R01 HL067736-06]		Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Cederbom L, 2000, EUR J IMMUNOL, V30, P1538, DOI 10.1002/1521-4141(200006)30:6<1538::AID-IMMU1538>3.0.CO;2-X; Coombes JL, 2005, IMMUNOL REV, V204, P184, DOI 10.1111/j.0105-2896.2005.00250.x; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Finkelman FD, 2005, J IMMUNOL, V174, P4630; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frasca L, 2002, J IMMUNOL, V168, P1060; Greenwald RJ, 2005, ANNU REV IMMUNOL, V23, P515, DOI 10.1146/annurev.immunol.23.021704.115611; Hadeiba H, 2003, J IMMUNOL, V170, P5502; Haeryfar SMM, 2005, J IMMUNOL, V174, P3344; Jaffar Z, 2004, J IMMUNOL, V172, P3842; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Keane-Myers A, 1998, J IMMUNOL, V161, P919; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; McHugh RS, 2002, J IMMUNOL, V168, P5979; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Min WP, 2003, J IMMUNOL, V170, P1304; Nakamura K, 2004, J IMMUNOL, V172, P834; Ostroukhova M, 2005, CURR ALLERGY ASTHM R, V5, P35, DOI 10.1007/s11882-005-0052-6; Piccirillo CA, 2004, SEMIN IMMUNOL, V16, P81, DOI 10.1016/j.smim.2003.12.003; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Shimizu J, 1999, J IMMUNOL, V163, P5211; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Suto A, 2001, AM J RESP CRIT CARE, V164, P680; Thornton AM, 2004, J IMMUNOL, V172, P6519; Vermaelen K, 2004, CYTOM PART A, V61A, P170, DOI 10.1002/cyto.a.20064; Wan YSY, 2005, P NATL ACAD SCI USA, V102, P5126, DOI 10.1073/pnas.0501701102; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	40	255	286	0	9	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	DEC 5	2005	202	11					1549	1561		10.1084/jem.20051506		13	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	990OU	WOS:000233753900011	16314437	
J	Janes, H; Sheppard, L; Lumley, T				Janes, H; Sheppard, L; Lumley, T			Case-crossover analyses of air pollution exposure data - Referent selection strategies and their implications for bias	EPIDEMIOLOGY			English	Article							BIDIRECTIONAL CASE-CROSSOVER; PRIMARY CARDIAC-ARREST; DAILY MORTALITY; PARTICULATE MATTER; TIME-SERIES; ASTHMA HOSPITALIZATION; MYOCARDIAL-INFARCTION; RISK; DESIGNS; TAIWAN	The case-crossover design has been widely used to study the association between short-term air pollution exposure and the risk of an acute adverse health event. The design uses cases only; for each individual case, exposure just before the event is compared with exposure at other control (or "referent") times. Time-invariant confounders are controlled by making within-subject comparisons. Even more important in the air pollution setting is that time-varying confounders can also be controlled by design by matching referents to the index time. The referent selection strategy is important for reasons in addition to control of confounding. The case-crossover design makes the implicit assumption that there is no trend in exposure across the referent times. In addition, the statistical method that is used-conditional logistic regression-is unbiased only with certain referent strategies. We review here the case-crossover literature in the air pollution context, focusing on key issues regarding referent selection. We conclude with a set of recommendations for choosing a referent strategy with air pollution exposure data. Specifically, we advocate the time-stratified approach to referent selection because it ensures unbiased conditional logistic regression estimates, avoids bias resulting from time trend in the exposure series, and can be tailored to match on specific time-varying confounders.	Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Occupat & Environm Hlth Sci, Seattle, WA 98195 USA	Sheppard, L (reprint author), Univ Washington, Dept Biostat, Hlth Sci Bldg,Box 357232, Seattle, WA 98195 USA.	sheppard@u.washington.edu					AUSTIN H, 1989, INT J EPIDEMIOL, V18, P713, DOI 10.1093/ije/18.3.713; Bateson TF, 1999, EPIDEMIOLOGY, V10, P539, DOI 10.1097/00001648-199909000-00013; Bateson TF, 2001, EPIDEMIOLOGY, V12, P654, DOI 10.1097/00001648-200111000-00013; Breslow N. E., 1980, STAT METHODS CANC RE; Clyde M, 2000, ENVIRONMETRICS, V11, P745, DOI 10.1002/1099-095X(200011/12)11:6<745::AID-ENV431>3.3.CO;2-E; Clyde M.A., 1999, BAYESIAN STAT, V6, P157; D'Ippoliti D, 2003, EPIDEMIOLOGY, V14, P528, DOI 10.1097/01.ede.0000082046.22919.72; Dominici F, 2004, J AM STAT ASSOC, V99, P938, DOI 10.1198/016214504000000656; Dominici F, 2003, INT STAT REV, V71, P243; Fung KY, 2003, INT J EPIDEMIOL, V32, P1064, DOI 10.1093/ije/dyg246; Greenland S, 1996, EPIDEMIOLOGY, V7, P231, DOI 10.1097/00001648-199605000-00003; JAAKOLA JJK, 2003, EUR RESPIR J, V21, P40; Janes H, 2005, STAT MED, V24, P285, DOI 10.1002/sim.1889; Kan HD, 2003, J OCCUP HEALTH, V45, P119, DOI 10.1539/joh.45.119; Kwon HJ, 2001, EPIDEMIOLOGY, V12, P413, DOI 10.1097/00001648-200107000-00011; Lee JT, 1999, ENVIRON HEALTH PERSP, V107, P633, DOI 10.2307/3434454; Lee JT, 2000, ENVIRON HEALTH PERSP, V108, P1107, DOI 10.2307/3434821; Levy D, 2001, EPIDEMIOLOGY, V12, P193, DOI 10.1097/00001648-200103000-00011; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; Little R., 1987, STAT ANAL MISSING DA; Lumley T, 2000, ENVIRONMETRICS, V11, P689, DOI 10.1002/1099-095X(200011/12)11:6<689::AID-ENV439>3.0.CO;2-N; Lumley T, 2000, ENVIRONMETRICS, V11, P705, DOI 10.1002/1099-095X(200011/12)11:6<705::AID-ENV444>3.0.CO;2-H; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144; MARSHALL RJ, 1993, STAT MED, V12, P2333, DOI 10.1002/sim.4780122409; MITTLEMAN MA, 1995, AM J EPIDEMIOL, V142, P91; Navidi W, 1998, BIOMETRICS, V54, P596, DOI 10.2307/3109766; Navidi W, 2002, EPIDEMIOLOGY, V13, P100, DOI 10.1097/00001648-200201000-00016; Neas LM, 1999, ENVIRON HEALTH PERSP, V107, P629, DOI 10.2307/3434453; Peters A, 2001, CIRCULATION, V103, P2810; Robins J, 1990, Epidemiology, V1, P273; Schwartz J, 2004, ENVIRON HEALTH PERSP, V112, P557; Sullivan J, 2003, AM J EPIDEMIOL, V157, P501, DOI 10.1093/aje/kwg015; Sunyer J, 2002, THORAX, V57, P687, DOI 10.1136/thorax.57.8.687; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; Sunyer J, 2001, INT J EPIDEMIOL, V30, P1138, DOI 10.1093/ije/30.5.1138; Tsai SS, 2003, STROKE, V34, P2612, DOI 10.1161/01.STR.0000095564.33543.64; Tsai SS, 2003, J TOXICOL ENV HEAL A, V66, P1341, DOI 10.1080/15287390390199194; Varadhan R, 2004, AM J EPIDEMIOL, V159, P596, DOI 10.1093/aje/kwh078; Vines SK, 2001, STAT MED, V20, P3039, DOI 10.1002/sim.960.abs; Yang CY, 2004, ENVIRON INT, V30, P519, DOI 10.1016/j.envint.2003.10.006; Yang CY, 2004, J TOXICOL ENV HEAL A, V67, P483, DOI 10.1080/15287390490276502; Yang QY, 2003, INHAL TOXICOL, V15, P1297, DOI 10.1080/08958370390241768	44	255	263	7	34	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	NOV	2005	16	6					717	726		10.1097/01.edu.0000181315.18836.9d		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	976CD	WOS:000232709500002	16222160	
J	Romagnani, S				Romagnani, S			The increased prevalence of allergy and the hygiene hypothesis: missing immune deviation, reduced immune suppression, or both?	IMMUNOLOGY			English	Review						hygiene hypothesis; immune deviation; immune suppression; Th1/Th2 cells; Treg cells	REGULATORY T-CELLS; INDUCED AIRWAY HYPERRESPONSIVENESS; GRASS-POLLEN IMMUNOTHERAPY; TOLL-LIKE RECEPTOR-2; MULTIPLE-SCLEROSIS; IFN-GAMMA; INTERFERON-GAMMA; DENDRITIC CELLS; GENE-TRANSFER; HELPER-CELLS	Allergic atopic disorders, such as rhinitis, asthma, and atopic dermatitis, are the result of a systemic inflammatory reaction triggered by type 2 T helper (Th2) cell-mediated immune responses against 'innocuous' antigens (allergens) of complex genetic and environmental origin. A number of epidemiological studies have suggested that the increase in the prevalence of allergic disorders that has occurred over the past few decades is attributable to a reduced microbial burden during childhood, as a consequence of Westernized lifestyle (the 'hygiene hypothesis'). However, the mechanisms by which the reduced exposure of children to pathogenic and nonpathogenic microbes results in enhanced responses of Th2 cells are still controversial. The initial interpretation proposed a missing immune deviation of allergen-specific responses from a Th2 to a type 1 Th (Th1) profile, as a result of the reduced production of interleukin-12 and interferons by natural immunity cells which are stimulated by bacterial products via their Toll-like receptors. More recently, the role of reduced activity of T regulatory cells has been emphasized. The epidemiological findings and the experimental evidence available so far suggest that both mechanisms may be involved. A better understanding of this question is important not only from a theoretical point of view, but also because of its therapeutic implications.	Univ Florence, Ctr Res Transfer & High Educ MCIDNENT, Florence, Italy	Romagnani, S (reprint author), Viale Morgagni 85, I-50134 Florence, Italy.	s.romagnani@dmi.unifi.it					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Agrawal S, 2003, J IMMUNOL, V171, P4984; Alm J. S., 1999, LANCET, V353, P1484; Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102; Campbell J. Darren, 2004, FASEB Journal, V18, P329; Chatelain R, 1999, PARASITE IMMUNOL, V21, P211, DOI 10.1046/j.1365-3024.1999.00224.x; COOK SD, 1985, NEUROLOGY, V35, P545; Cosmi L, 2004, BLOOD, V103, P3117, DOI 10.1182/blood-2003-09-3302; Cottrez F, 2000, J IMMUNOL, V165, P4848; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Dow SW, 1999, HUM GENE THER, V10, P1905, DOI 10.1089/10430349950017266; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; Gangur V, 1998, FASEB J, V12, P705; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hilliquin P, 2000, RHEUMATOLOGY, V39, P1020, DOI 10.1093/rheumatology/39.9.1020; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; Irvine EJ, 2001, SCAND J GASTROENTERO, V36, P2; Jaffar Z, 2004, J IMMUNOL, V172, P3842; Johnson RJ, 2003, AM J KIDNEY DIS, V42, P575, DOI 10.1016/S0272-6386(03)00801-1; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kaplan MH, 1996, NATURE, V382, P174, DOI 10.1038/382174a0; KAPSENBERG ML, 1991, IMMUNOL TODAY, V12, P392, DOI 10.1016/0167-5699(91)90137-I; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535; Klinman D. M., 2004, NAT REV IMMUNOL, V4, P1; Koski GK, 2004, J IMMUNOL, V172, P3989; LACK G, 1994, J IMMUNOL, V152, P2546; Lack G, 1996, J IMMUNOL, V157, P1432; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Li XM, 1996, J IMMUNOL, V157, P3216; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; MAGGI E, 1992, J IMMUNOL, V148, P2142; Major T, 2002, VACCINE, V20, P1532, DOI 10.1016/S0264-410X(01)00496-0; MANETTI R, 1995, EUR J IMMUNOL, V25, P2656, DOI 10.1002/eji.1830250938; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; MARDSLAND BJ, 2004, P NATL ACAD SCI USA, V101, P6116; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; MARTIN RJ, 1993, AM REV RESPIR DIS, V148, P1677; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Netea MG, 2004, J IMMUNOL, V172, P3712; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; OH WJ, 2002, J ALLERGY CLIN IMMUN, V110, P460; Oro AS, 1996, J ALLERGY CLIN IMMUN, V97, P1402, DOI 10.1016/S0091-6749(96)70210-5; Parronchi P, 1999, J IMMUNOL, V163, P5946; PARRONCHI P, 1992, J IMMUNOL, V149, P2977; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Pochard P, 2002, J ALLERGY CLIN IMMUN, V110, P617, DOI 10.1067/mai.2002.128528; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Pugliatti M, 2001, ACTA NEUROL SCAND, V103, P20, DOI 10.1034/j.1600-0404.2001.00207.x; RANDOLPH DA, 1999, J IMMUNOL, V162, P1375; REDECKE V, 2004, J IMMUNOL, V172, P2729; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Renz H, 2002, J ALLERGY CLIN IMMUN, V109, P338, DOI 10.1067/mai.2002.121459; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Roncarolo MG, 2001, IMMUNOL REV, V182, P68, DOI 10.1034/j.1600-065X.2001.1820105.x; SABROE I, 2003, J IMMUNOL, V74, P1630; Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1; Shahid SK, 2002, AM J RESP CRIT CARE, V165, P1290, DOI 10.1164/rccm.2108082; SHAPENKO A, 2004, J EXP MED, V199, P423; SHAPENKO A, 2004, J IMMUNOL, V172, P6427; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Smart JM, 2002, J ALLERGY CLIN IMMUN, V110, P450, DOI 10.1067/mai.2002.127283; Smit JJ, 2003, CLIN EXP ALLERGY, V33, P1083, DOI 10.1046/j.1365-2222.2003.01727.x; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Stefano S, 2003, AUTOIMMUNITY, V36, P257, DOI 10.1080/0891693031000151607; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sugimoto T, 2004, J EXP MED, V199, P535, DOI 10.1084/jem.20031368; Suri-Payer E, 1998, J IMMUNOL, V160, P1212; Suto A, 2001, AM J RESP CRIT CARE, V164, P680; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tang LL, 1998, J ALLERGY CLIN IMMUN, V102, P428, DOI 10.1016/S0091-6749(98)70131-9; Tiemessen MM, 2002, J ALLERGY CLIN IMMUN, V110, P934, DOI 10.1067/mai.2002.128856; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; TOURNOY KG, 2002, CLIN EXPT ALLERGY, V31, P17; Townley RG, 2004, ANN ALLERG ASTHMA IM, V92, P350; Tremlett HL, 2002, QJM-INT J MED, V95, P753, DOI 10.1093/qjmed/95.11.753; Tsai Jaw-Ji, 2002, Journal of Microbiology Immunology and Infection, V35, P152; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; van Roon JAG, 2002, ANN RHEUM DIS, V61, P951, DOI 10.1136/ard.61.11.951; Walter DM, 2001, J IMMUNOL, V166, P6392; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; WOLLHEBEN G, 2003, J IMMUNOL, V170, P4601; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	110	255	278	4	49	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0019-2805			IMMUNOLOGY	Immunology	JUL	2004	112	3					352	363		10.1111/j.1365-2567.2004.01925.x		12	Immunology	Immunology	829LW	WOS:000222051000002	15196202	
J	Dhabhar, FS				Dhabhar, Firdaus S.			Enhancing versus Suppressive Effects of Stress on Immune Function: Implications for Immunoprotection and Immunopathology	NEUROIMMUNOMODULATION			English	Review						Acute stress-induced enhancement; Fight-or-flight stress; Immune cell distribution; Immune function, effects of stress; Immune function, enhancing vs. suppressive effects; Immunoprotection vs. immunopathology; Innate/primary immune responses; Leukocyte trafficking; Adaptive/secondary immune responses	CELL-MEDIATED-IMMUNITY; PERIPHERAL-BLOOD LYMPHOCYTES; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; CORTICOTROPIN-RELEASING HORMONE; ACUTE PSYCHOLOGICAL STRESS; PITUITARY-ADRENAL AXIS; ACUTE-PHASE RESPONSE; INDUCED ENHANCEMENT; GLUCOCORTICOID HORMONES; LEWIS RATS	Stress is known to suppress immune function and increase susceptibility to infections and cancer. Paradoxically, stress is also known to exacerbate asthma, and allergic, autoimmune and inflammatory diseases, although such diseases should be ameliorated by immunosuppression. Moreover, the short-term fight-or-flight stress response is one of nature's fundamental defense mechanisms that enables the cardiovascular and musculoskeletal systems to promote survival, and it is unlikely that this response would suppress immune function at a time when it is most required for survival (e. g. in response to wounding and infection by a predator or aggressor). These observations suggest that stress may suppress immune function under some conditions while enhancing it under others. The effects of stress are likely to be beneficial or harmful depending on the type (immunoprotective, immunoregulatory/inhibitory, or immunopathological) of immune response that is affected. Studies have shown that several critical factors influence the direction (enhancing vs. suppressive) of the effects of stress or stress hormones on immune function: (1) Duration (acute vs. chronic) of stress: Acute or short-term stress experienced at the time of immune activation can enhance innate and adaptive immune responses. Chronic or long-term stress can suppress immunity by decreasing immune cell numbers and function and/or increasing active immunosuppressive mechanisms (e. g. regulatory T cells). Chronic stress can also dysregulate immune function by promoting proinflammatory and type-2 cytokine-driven responses. (2) Effects of stress on leukocyte distribution: Compartments that are enriched with immune cells during acute stress show immunoenhancement, while those that are depleted of leukocytes, show immunosuppression. (3) The differential effects of physiologic versus pharmacologic concentrations of glucocorticoids, and the differential effects of endogenous versus synthetic glucocorticoids: Endogenous hormones in physiological concentrations can have immunoenhancing effects. Endogenous hormones at pharmacologic concentrations, and synthetic hormones, are immunosuppressive. (4) The timing of stressor or stress hormone exposure relative to the time of activation and time course of the immune response: Immunoenhancement is observed when acute stress is experienced at early stages of immune activation, while immunosuppression may be observed at late stages of the immune response. We propose that it is important to study and, if possible, to clinically harness the immunoenhancing effects of the acute stress response, that evolution has finely sculpted as a survival mechanism, just as we study its maladaptive ramifications (chronic stress) that evolution has yet to resolve. In view of the ubiquitous nature of stress and its significant effects on immunoprotection as well as immunopathology, it is important to further elucidate the mechanisms mediating stress-immune interactions and to meaningfully translate findings from bench to bedside. Copyright (C) 2009 S. Karger AG, Basel	[Dhabhar, Firdaus S.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; [Dhabhar, Firdaus S.] Stanford Univ, Stanford Inst Immun Transplantat & Infect, Stanford, CA 94305 USA	Dhabhar, FS (reprint author), Stanford Univ, Dept Psychiat & Behav Sci, 300 Pasteur Dr,MC 5135, Stanford, CA 94305 USA.	dhabhar@gmail.com			NIH [AI48995, CA107498]; Dana Foundation	I wish to thank current and previous members of my laboratory, particularly, Jean Tillie, Dr. Kavitha Viswanathan, Dr. Alison Saul, Kanika Ghai, and Christine Daugherty, whose work and publications are among those discussed in this chapter. The work described here was supported by grants from the NIH (AI48995 and CA107498) and The Dana Foundation.	Ader R, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, pXV, DOI 10.1016/B978-012088576-3/50001-0; AKAHOSHI T, 1988, J EXP MED, V167, P924, DOI 10.1084/jem.167.3.924; Altemus M, 2001, J INVEST DERMATOL, V117, P309, DOI 10.1046/j.1523-1747.2001.01373.x; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; Benschop RJ, 1996, BRAIN BEHAV IMMUN, V10, P77, DOI 10.1006/brbi.1996.0009; BESEDOVSKY H, 1986, SCIENCE, V233, P652, DOI 10.1126/science.3014662; Bilbo SD, 2002, P NATL ACAD SCI USA, V99, P4067, DOI 10.1073/pnas.062001899; BLECHA F, 1982, P SOC EXP BIOL MED, V169, P239; Bluestone JA, 2005, CURR OPIN IMMUNOL, V17, P638, DOI 10.1016/j.coi.2005.09.002; BONNEAU RH, 1991, BRAIN BEHAV IMMUN, V5, P274, DOI 10.1016/0889-1591(91)90023-4; BOUMPAS DT, 1991, CLIN EXP RHEUMATOL, V9, P413; Buske-Kirschbaum A, 2003, ANN NY ACAD SCI, V992, P231; Buske-Kirschbaum A, 2003, PSYCHOSOM MED, V65, P806, DOI 10.1097/01.PSY.0000095916.25975.4F; Buske-Kirschbaum A, 2001, PSYCHOTHER PSYCHOSOM, V70, P6, DOI 10.1159/000056219; CALANDRA T, 1995, NATURE, V377, P68, DOI 10.1038/377068a0; Chrousos GP, 2007, STRESS, V10, P213, DOI 10.1080/10253890701292119; Chrousos George P., 2000, Journal of Allergy and Clinical Immunology, V106, pS275; COCKE R, 1993, BRAIN BEHAV IMMUN, V7, P36, DOI 10.1006/brbi.1993.1004; COE CL, 1989, INFANT STRESS COPING, V45; CUNNICK JE, 1990, PHARMACOL BIOCHEM BE, V36, P645, DOI 10.1016/0091-3057(90)90270-R; DANES RA, 1989, EUR J IMMUNOL, V19, P2319; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Del Rey A, 1998, AM J PHYSIOL-REG I, V275, pR1146; Dhabhar FS, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P723; Dhabhar Firdaus S, 2008, Allergy Asthma Clin Immunol, V4, P2, DOI 10.1186/1710-1492-4-1-2; Dhabhar FS, 2005, AM J PHYSIOL-REG I, V289, pR738, DOI 10.1152/ajpregu.00145.2005; Dhabhar FS, 1999, P NATL ACAD SCI USA, V96, P1059, DOI 10.1073/pnas.96.3.1059; Dhabhar FS, 1997, NEUROENDOCRINOLOGY, V65, P360, DOI 10.1159/000127196; Dhabhar FS, 1998, ANN NY ACAD SCI, V840, P359, DOI 10.1111/j.1749-6632.1998.tb09575.x; DHABHAR FS, 1994, BRAIN BEHAV IMMUN, V8, P66, DOI 10.1006/brbi.1994.1006; Dhabhar FS, 2000, P NATL ACAD SCI USA, V97, P2846, DOI 10.1073/pnas.050569397; DHABHAR FS, 1993, BRAIN RES, V616, P89, DOI 10.1016/0006-8993(93)90196-T; Dhabhar FS, 1996, J IMMUNOL, V157, P1638; DHABHAR FS, 1995, J NEUROIMMUNOL, V56, P77, DOI 10.1016/0165-5728(94)00135-B; Dhabhar FS, 1997, BRAIN BEHAV IMMUN, V11, P286, DOI 10.1006/brbi.1997.0508; Dhabhar FS, 1996, J IMMUNOL, V156, P2608; DHABHAR FS, 1995, J IMMUNOL, V154, P5511; Dhabhar FS, 2001, PSYCHONEUROIMMUNOLOG, P301; Dougherty T. F, 1949, ANAT REC, V103, P24; Edwards KM, 2008, PSYCHOSOM MED, V70, P147, DOI 10.1097/PSY.0b013e318164232e; Edwards KM, 2006, BRAIN BEHAV IMMUN, V20, P159, DOI 10.1016/j.bbi.2005.07.001; Elenkov IJ, 2004, ANN NY ACAD SCI, V1024, P138, DOI 10.1196/annals.1321.010; Epel ES, 2004, P NATL ACAD SCI USA, V101, P17312, DOI 10.1073/pnas.0407162101; Esparza EM, 2005, J IMMUNOL, V174, P7869; FAUCI AS, 1974, J CLIN INVEST, V53, P240, DOI 10.1172/JCI107544; Finn OJ, 2008, NEW ENGL J MED, V358, P2704, DOI 10.1056/NEJMra072739; Fischer JM, 2001, CAN J PHILOS, V31, P427; Flint MS, 2000, BRAIN BEHAV IMMUN, V14, P256, DOI 10.1006/brbi.2000.0604; GIRARD MT, 1987, J IMMUNOL, V138, P3235; Glaser R, 2005, NAT REV IMMUNOL, V5, P243, DOI 10.1038/nri1571; Glaser R, 2001, J GERONTOL A-BIOL, V56, pM477; Goldstein David S, 2002, Stress, V5, P55, DOI 10.1080/102538902900012345; Gomez-Serrano M, 2001, BEHAV GENET, V31, P427, DOI 10.1023/A:1012742405141; Granstein RD, 2004, CUTIS, V74, P4; GRAYSON J, 1981, J CLIN INVEST, V68, P1539, DOI 10.1172/JCI110408; Gunnar M, 2007, ANNU REV PSYCHOL, V58, P145, DOI 10.1146/annurev.psych.58.110405.085605; HALLIDAY WJ, 1964, J IMMUNOL, V93, P757; HOAGLAND H, 1946, J CLIN ENDOCR METAB, V6, P301; IRWIN M, 1990, BIOL PSYCHIAT, V27, P22, DOI 10.1016/0006-3223(90)90016-U; Kavelaars A, 1998, ANN NY ACAD SCI, V840, P698, DOI 10.1111/j.1749-6632.1998.tb09608.x; Kizaki T, 1996, ENDOCRINOLOGY, V137, P4260, DOI 10.1210/en.137.10.4260; KRIPKE ML, 1994, CANCER RES, V54, P6102; KROEMER G, 1988, IMMUNOL TODAY, V9, P163, DOI 10.1016/0167-5699(88)91289-3; LAMAS M, 1993, CELL IMMUNOL, V151, P437, DOI 10.1006/cimm.1993.1252; MACKENZIE FJ, 1989, J NEUROIMMUNOL, V23, P93, DOI 10.1016/0165-5728(89)90027-1; Maes M, 1993, Rev Neurosci, V4, P407; MANUCK SB, 1991, PSYCHOL SCI, V2, P111, DOI 10.1111/j.1467-9280.1991.tb00110.x; MARX J, 1995, SCIENCE, V270, P232, DOI 10.1126/science.270.5234.232; MASON D, 1991, IMMUNOL TODAY, V12, P57, DOI 10.1016/0167-5699(91)90158-P; McEwen BS, 1998, NEW ENGL J MED, V338, P171; McEwen B. S., 2002, END STRESS WE KNOW I; Mekaouche Mourad, 1994, Neuroimmunomodulation, V1, P292, DOI 10.1159/000097179; MILLER AH, 1994, ENDOCRINOLOGY, V135, P1934, DOI 10.1210/en.135.5.1934; MILLS PJ, 1995, BRAIN BEHAV IMMUN, V9, P61, DOI 10.1006/brbi.1995.1006; MONJAN AA, 1977, SCIENCE, V196, P307, DOI 10.1126/science.557841; MORROWTESCH JL, 1993, PSYCHONEUROENDOCRINO, V18, P383, DOI 10.1016/0306-4530(93)90013-B; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; MUNCK A, 1984, ENDOCR REV, V5, P25; NALIBOFF BD, 1991, PSYCHOSOM MED, V53, P121; PLAUT M, 1987, ANNU REV IMMUNOL, V5, P621, DOI 10.1146/annurev.immunol.5.1.621; Priftis KN, 2008, TRENDS ENDOCRIN MET, V19, P32, DOI 10.1016/j.tem.2007.10.005; Redwine L, 2004, PSYCHOSOM MED, V66, P770, DOI 10.1097/01.psy.0000138118.62018.87; REED JC, 1986, J IMMUNOL, V137, P150; RINNER I, 1992, BRAIN BEHAV IMMUN, V6, P130, DOI 10.1016/0889-1591(92)90013-E; Saint-Mezard P, 2003, J IMMUNOL, V171, P4073; Sapolsky RM, 2005, SCIENCE, V308, P648, DOI 10.1126/science.1106477; Saul AN, 2005, J NATL CANCER I, V97, P1760, DOI 10.1093/jnci/dji401; SCHEDLOWSKI M, 1993, J CLIN IMMUNOL, V13, P119, DOI 10.1007/BF00919268; SCHLEIMER RP, 1989, ANTIINFLAMMATORY STE, P1; Schwab CL, 2005, TOXICOL SCI, V83, P101, DOI 10.1093/toxsci/kfi014; Sephton S, 2003, BRAIN BEHAV IMMUN, V17, P321, DOI 10.1016/S0889-1591(03)00078-3; Smith A, 2004, BRAIN BEHAV IMMUN, V18, P65, DOI 10.1016/S0889-1591(03)00107-7; SPRENT J, 1994, SCIENCE, V265, P1395, DOI 10.1126/science.8073282; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P2374, DOI 10.1073/pnas.86.7.2374; STERNBERG EM, 1992, BRAIN RES, V570, P54, DOI 10.1016/0006-8993(92)90563-O; STERNBERG EM, 1989, P NATL ACAD SCI USA, V86, P4771, DOI 10.1073/pnas.86.12.4771; Sternberg E. M., 1989, PROGR NEUROENDOCR IM, V2, P102; Takaki Atsushi, 1994, Neuroimmunomodulation, V1, P335, DOI 10.1159/000097185; Tone M, 2003, P NATL ACAD SCI USA, V100, P15059, DOI 10.1073/pnas.2334901100; Torpy DJ, 1996, BAILLIERE CLIN RHEUM, V10, P181; Van Gaal LF, 2006, NATURE, V444, P875, DOI 10.1038/nature05487; Viswanathan K, 2005, INT IMMUNOL, V17, P1059, DOI 10.1093/intimm/dxh286; Viswanathan K, 2005, P NATL ACAD SCI USA, V102, P5808, DOI 10.1073/pnas.0501650102; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Wick G, 1998, ANN NY ACAD SCI, V840, P591, DOI 10.1111/j.1749-6632.1998.tb09598.x; WIEGERS GJ, 1994, ENDOCRINOLOGY, V135, P2351, DOI 10.1210/en.135.6.2351; WIEGERS GJ, 1995, J IMMUNOL, V155, P1893; Wiegers GJ, 1998, TRENDS PHARMACOL SCI, V19, P317, DOI 10.1016/S0165-6147(98)01229-2; Wiegers GJ, 2001, NEUROENDOCRINOLOGY, V73, P139, DOI 10.1159/000054630; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; WOOD PG, 1993, BRAIN BEHAV IMMUN, V7, P121, DOI 10.1006/brbi.1993.1014; ZALCMAN S, 1993, PHARMACOL BIOCHEM BE, V46, P445, DOI 10.1016/0091-3057(93)90377-6	112	254	261	12	82	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1021-7401	1423-0216		NEUROIMMUNOMODULAT	Neuroimmunomodulation		2009	16	5					300	317		10.1159/000216188		18	Endocrinology & Metabolism; Immunology; Neurosciences	Endocrinology & Metabolism; Immunology; Neurosciences & Neurology	466GD	WOS:000267648300006	19571591	
J	Sydbom, A; Blomberg, A; Parnia, S; Stenfors, N; Sandstrom, T; Dahlen, SE				Sydbom, A; Blomberg, A; Parnia, S; Stenfors, N; Sandstrom, T; Dahlen, SE			Health effects of diesel exhaust emissions	EUROPEAN RESPIRATORY JOURNAL			English	Review						air pollution; allergy incidence; animal studies; asthma exacerbation; diesel; human exposure	PARTICULATE AIR-POLLUTION; BRONCHIAL EPITHELIAL-CELLS; SYSTEMIC IGE PRODUCTION; HEART-RATE-VARIABILITY; LUNG-TISSUE RESPONSES; SHORT-TERM EXPOSURE; IN-VITRO; CYTOKINE PRODUCTION; ALLERGEN CHALLENGE; PARTICLE RETENTION	Epidemiological studies have demonstrated an association between different levels of air pollution and various health outcomes including mortality, exacerbation of asthma, chronic bronchitis, respiratory tract infections, ischaemic heart disease and stroke. Of the motor vehicle generated air pollutants, diesel exhaust particles account for a highly significant percentage of the particles emitted in many towns and cities. This review is therefore focused on the health effects of diesel exhaust, and especially the particular matter components. Acute effects of diesel exhaust exposure include irritation of the nose and eyes, lung function changes, respiratory changes, headache, fatigue and nausea. Chronic exposures are associated with cough, sputum production and lung function decrements. In addition to symptoms, exposure studies in healthy humans have documented a number of profound inflammatory changes in the airways, notably, before changes in pulmonary function can be detected. It is likely that such effects may be even more detrimental in asthmatics and other subjects with compromised pulmonary function. There are also observations supporting the hypothesis that diesel exhaust is one important factor contributing to the allergy pandemic. For example, in many experimental systems, diesel exhaust particles can be shown to act as adjuvants to allergen and hence increase the sensitization response. Much of the research on adverse effects of diesel exhaust, both in vivo and in vitro, has however been conducted in animals. Questions remain concerning the relevance of exposure levels and whether findings in such models can be extrapolated into humans. It is therefore imperative to further assess acute and chronic effects of diesel exhaust in mechanistic studies with careful consideration of exposure levels. Whenever possible and ethically justified, studies should be carried out in humans.	Karolinska Inst, Natl Inst Environm Med, Unit Expt Asthma & Allergy Res, SE-17177 Stockholm, Sweden; Univ Hosp, Dept Resp Med & Allergy, Umea, Sweden; So Gen Hosp, Resp Cell & Mol Biol Res Div, Southampton, Hants, England	Dahlen, SE (reprint author), Karolinska Inst, Natl Inst Environm Med, Unit Expt Asthma & Allergy Res, SE-17177 Stockholm, Sweden.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Anderson M, 1994, J AEROSOL SCI, V25, P567; Arshad SH, 1998, AM J RESP CRIT CARE, V157, P1900; BARRY CC, 1994, ENVIRONMENT, V36, P5; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; BICE DE, 1985, FUND APPL TOXICOL, V5, P1075, DOI 10.1016/0272-0590(85)90143-5; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Boland S, 1999, AM J PHYSIOL-LUNG C, V276, pL604; BRAIN JD, 1979, AM REV RESPIR DIS, V120, P1325; CAMMER P, 1988, HLTH EFFECTS DIESEL; CHOW JC, 1995, J AIR WASTE MANAGE, V45, P320; D'Amato G, 1994, Monaldi Arch Chest Dis, V49, P406; *DEPT HLTH, 1995, PART DOS NONB PART H, P29; Devalia JL, 1997, ALLERGY, V52, P45; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Falk R, 1999, EXP LUNG RES, V25, P495; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Glovsky MM, 1997, ALLERGY ASTHMA PROC, V18, P163, DOI 10.2500/108854197778984392; Gold DR, 2000, CIRCULATION, V101, P1267; Gorski P, 1992, Pol J Occup Med Environ Health, V5, P227; Henricsson S, 1996, GRANA, V35, P179; HIRAFUJI M, 1995, RES COMMUN MOL PATH, V90, P221; Hiruma KR, 1999, ANN OTO RHINOL LARYN, V108, P582; HOBBS CH, 1991, J TOXICOL-CLIN TOXIC, V29, P375; HYDE DM, 1985, LAB INVEST, V52, P195; Ichinose T, 1997, TOXICOLOGY, V122, P183, DOI 10.1016/S0300-483X(97)00096-6; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; Kanemitsu H, 1998, BIOL PHARM BULL, V21, P129; KATO A, 1992, JPN J THORAC DIS, V30, P238; Kim CS, 1998, J APPL PHYSIOL, V84, P1834; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kobayashi T, 1997, FUND APPL TOXICOL, V38, P166, DOI 10.1006/faat.1997.2347; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Maejima K, 1997, J TOXICOL ENV HEALTH, V52, P231, DOI 10.1080/009841097159674; MAUDERLY JL, 1990, AM REV RESPIR DIS, V141, P1333; MAUDERLY JL, 1989, RES REP HLTH EFF I, V30, P1; Mauderly JL, 1987, RES REP HLTH EFF I, V8, P3; Miyabara Y, 1998, INT ARCH ALLERGY IMM, V116, P124, DOI 10.1159/000023935; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; MOHR U, 1986, CARCINOGENIC MUTAGEN, P459; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; MONTEFORT S, 1994, AM J RESP CRIT CARE, V149, P1149; MOORMAN WJ, 1985, J APPL TOXICOL, V5, P301, DOI 10.1002/jat.2550050508; Morgan WKC, 1997, ANN OCCUP HYG, V41, P643, DOI 10.1016/S0003-4878(97)00024-0; MOTLEY HL, 1971, AEROSPACE MED    OCT, P1108; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Muto E, 1996, LIFE SCI, V59, P1563, DOI 10.1016/0024-3205(96)00487-0; Nauss K. M., 1995, DIESEL EXHAUST CRITI, P13; Nikula KJ, 1997, FUND APPL TOXICOL, V37, P37, DOI 10.1006/faat.1997.2297; Nikula KJ, 1997, ENVIRON HEALTH PERSP, V105, P1231, DOI 10.2307/3433538; Nilsen A, 1997, TOXICOLOGY, V124, P225, DOI 10.1016/S0300-483X(97)00150-9; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; OLANDER L, 1996, LUFTFORORENINGAR FOR; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 1999, AM J RESP CRIT CARE, V159, P365; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; PRITCHARD JN, 1989, EXP PATHOL-JENA, V37, P39; RUDELL B, 1994, INT ARCH OCC ENV HEA, V66, P77, DOI 10.1007/BF00383361; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658; Rudell B, 1999, OCCUP ENVIRON MED, V56, P222; Rudell B, 1990, J AEROSOL SCI     S1, V21, P411; RUSZNAK C, 1994, ALLERGY, V49, P21, DOI 10.1111/j.1398-9995.1994.tb04234.x; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; SAGAI M, 1995, JPN J THORAC DIS, V33, P212; SAKAKIBARA M, 1994, RES COMMUN MOL PATH, V86, P99; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1187; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; SANDSTROM T, 1998, EUR RESPIR REV, V8, P168; SCHEEPERS PTJ, 1992, INT ARCH OCC ENV HEA, V64, P163, DOI 10.1007/BF00380905; SCHEEPERS PTJ, 1992, INT ARCH OCC ENV HEA, V64, P149, DOI 10.1007/BF00380904; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Seaton A, 1999, THORAX, V54, P1027; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Sjogren B, 1997, OCCUP ENVIRON MED, V54, P466; Sjogren B, 1998, OCCUP ENVIRON MED, V55, P503; Sjogren B, 1998, SCAND J WORK ENV HEA, V24, P236; Steerenberg PA, 1998, EXP LUNG RES, V24, P85; STROM KA, 1990, J TOXICOL ENV HEALTH, V29, P377; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 1999, J IMMUNOL, V162, P4705; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; *US EPA, 1996, QUALITY CRITERIA PAR, V2, P1; VOGL G, 1989, TOXICOL LETT, V47, P17, DOI 10.1016/0378-4274(89)90082-9; WADE JF, 1993, J OCCUP ENVIRON MED, V35, P149, DOI 10.1097/00043764-199302000-00015; WOLFF RK, 1987, FUND APPL TOXICOL, V9, P154, DOI 10.1016/0272-0590(87)90162-X; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372; Yoshino S, 1999, J PHARMACOL EXP THER, V290, P524; Yu C.P., 1991, RES REP HLTH EFF I, V40, P1	110	254	260	7	48	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	APR	2001	17	4					733	746		10.1183/09031936.01.17407330		14	Respiratory System	Respiratory System	438JT	WOS:000169050400026	11401072	
J	Ferguson, GT; Enright, PL; Buist, AS; Higgins, MW				Ferguson, GT; Enright, PL; Buist, AS; Higgins, MW			Office spirometry for lung health assessment in adults - A consensus statement from the National Lung Health Education Program	CHEST			English	Review						COPD; risk assessment; smoking; spirometry	OBSTRUCTIVE PULMONARY-DISEASE; SMOKING CESSATION INTERVENTIONS; AIR-FLOW LIMITATION; FORCED EXPIRATORY VOLUME; CONTROLLED TRIAL; RESPIRATORY SYMPTOMS; RANDOMIZED TRIAL; REFERENCE VALUES; GENERAL-PRACTICE; NICOTINE PATCH	COPD is easily detected in its preclinical phase using spirometry, and successful smoking cessation (a cost-effective intervention) prevents further disease progression, This consensus statement recommends the widespread use of office spirometry by primary-care providers for patients greater than or equal to 45 years old who smoke cigarettes. Discussion of the spirometry results with current smokers should be accompanied by strong advice to quit smoking and referral to local smoking cessation resources. Spirometry also is recommended for patients with respiratory symptoms such as chronic cough, episodic wheezing, and exertional dyspnea in order to detect airways obstruction due to asthma or COPD, Although diagnostic-quality spirometry may be used to detect COPD, we recommend the development, validation, and implementation of a new type of spirometry-office spirometry-for this purpose in the primary-care setting, In order to encourage the widespread use of office spirometers, their specifications differ somewhat from those for diagnostic spirometers, allowing lower instrument cost, smaller size, less effort to perform the test, improved ease of calibration checks, and an improved quality-assurance program.	Botsford Pulm Associates, Framington Hills, MI USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA; Univ Michigan, Ann Arbor, MI 48109 USA	Enright, PL (reprint author), Univ Arizona, Tucson, AZ 85721 USA.						American Association for Respiratory Care, 1996, RESP CARE, V41, P629; *AM THOR SOC, 1983, AM REV RESPIR DIS, V128, P768; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; ANTHONISEN NR, 1989, AM REV RESPIR DIS, V140, pS95; BADGETT RG, 1994, CHEST, V106, P1427, DOI 10.1378/chest.106.5.1427; Badgett RG, 1997, PREV MED, V26, P466, DOI 10.1006/pmed.1997.0177; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; BAKER TR, 1970, J AMER MED ASSOC, V214, P1448, DOI 10.1001/jama.214.8.1448; BANG KM, 1993, CHEST, V103, P536, DOI 10.1378/chest.103.2.536; Banks DE, 1996, J OCCUP ENVIRON MED, V38, P279, DOI 10.1097/00043764-199603000-00013; BATES DV, 1974, CHEST, V65, P437, DOI 10.1378/chest.65.4.437; BEATY TH, 1982, AM J EPIDEMIOL, V116, P102; BEATY TH, 1984, AM REV RESPIR DIS, V129, P660; BECKLAKE MR, 1985, CHEST, V88, P608, DOI 10.1378/chest.88.4.608; BENSON V, 1994, VITAL HLTH STAT SERI, V10; British Thoracic Society; Association of Respiratory Technicians and Physiologists, 1994, RESP MED, V88, P165; BUIST AS, 1973, AM REV RESPIR DIS, V107, P735; BUIST AS, 1993, CHEST, V103, P1863, DOI 10.1378/chest.103.6.1863; BURGE PS, 1994, AM J RESP CRIT CARE, V149, pA312; BURT VL, 1995, HYPERTENSION, V25, P305; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794; CHAPMAN KR, 1992, CAN MED ASSOC J, V147, P420; Chyou PH, 1996, AM J EPIDEMIOL, V143, P750; COCHRANE AL, 1971, BRIT MED BULL, V27, P3; COLLINS JG, 1997, VITAL HLTH STAT SERI, V10; COOK DJ, 1992, CHEST, V102, pS305; CRAPO RO, 1994, NEW ENGL J MED, V331, P25, DOI 10.1056/NEJM199407073310107; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Dale LC, 1998, POSTGRAD MED, V104, P75; DOMPELING E, 1993, ANN INTERN MED, V118, P770; Eaton T, 1999, CHEST, V116, P416, DOI 10.1378/chest.116.2.416; EDELMAN NH, 1992, CHEST, V102, P243; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215; Enright PLHR, 1987, OFFICE SPIROMETRY; FERGUSON GT, 1993, NEW ENGL J MED, V328, P1017; Fiore MC, 1996, JAMA-J AM MED ASSOC, V275, P1270; FIORE MC, 1994, JAMA-J AM MED ASSOC, V271, P1940, DOI 10.1001/jama.271.24.1940; FLAY BR, 1987, AM J PUBLIC HEALTH, V77, P153, DOI 10.2105/AJPH.77.2.153; Freund K M, 1993, Ann Epidemiol, V3, P417; GARDNER RM, 1992, CHEST, V101, P948, DOI 10.1378/chest.101.4.948; Gentry S E, 1983, J Community Health, V8, P263, DOI 10.1007/BF01666779; GLINDMEYER HW, 1987, AM REV RESPIR DIS, V136, P449; GOLDBLOOM R, 1988, CAN MED ASSOC J, V138, P618; GOULD GA, 1991, EUR RESPIR J, V4, P141; HAHN DL, 1994, J FAM PRACTICE, V38, P373; HANKINSON JL, 1993, OCCUP MED, V8, P353; HANKINSON JL, 1986, J OCCUP ENVIRON MED, V28, P1081, DOI 10.1097/00043764-198610000-00032; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; HANSEN J G, 1991, Scandinavian Journal of Primary Health Care, V9, P227, DOI 10.3109/02813439109018524; HEPPER NGG, 1980, AM REV RESPIR DIS, V121, P97; HIGGINS MW, 1990, CLIN EPIDEMIOLOGY CH, P23; Hole DJ, 1996, BRIT MED J, V313, P711; HOLLEMAN DR, 1995, JAMA-J AM MED ASSOC, V273, P131; HUGHES JA, 1982, Q J MED, V202, P115; Humerfelt S, 1998, EUR RESPIR J, V11, P284, DOI 10.1183/09031936.98.11020284; JOHNSON CL, 1993, JAMA-J AM MED ASSOC, V269, P3002, DOI 10.1001/jama.269.23.3002; Jorenby DE, 1999, NEW ENGL J MED, V340, P685, DOI 10.1056/NEJM199903043400903; KANNEL WB, 1974, CIRCULATION, V49, P1160; Kerstjens HAM, 1997, THORAX, V52, P820; Kerstjens HAM, 1996, AM J RESP CRIT CARE, V154, pS266; KESTEN S, 1993, CHEST, V104, P254, DOI 10.1378/chest.104.1.254; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882; KULLER LH, 1990, AM J EPIDEMIOL, V132, P266; LEBOWITZ MD, 1990, AM REV RESPIR DIS, V141, P1491; LOSS RW, 1979, AM J MED SCI, V278, P27, DOI 10.1097/00000441-197907000-00004; MADAN I, 1993, EUR RESPIR J, V6, P1556; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Marshall KG, 1996, CAN MED ASSOC J, V154, P1493; Marshall KG, 1996, CAN MED ASSOC J, V155, P169; Miller W, 1991, MOTIVATIONAL INTERVI; MOSTOW SR, 1990, AM REV RESPIR DIS, V142, P487; *NAT ASTHM ED PREV, 1997, NIH PUBLICATION, P12; *NAT CTR HLTH STAT, 1995, US PHS PUBLICATION; National Heart Lung and Blood Institute, 1998, MORB MORT CHARTB CAR; OCONNOR GT, 1989, AM REV RESPIR DIS, V140, P225; OHagan J, 1996, NEW ZEAL MED J, V109, P1; OLFSSON J, 1986, EUR J RESPIR DIS, V69, P46; OTTER JJ, 1998, J ASTHMA, V35, P381, DOI 26177136,12,1; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Petty TL, 1997, JAMA-J AM MED ASSOC, V277, P246, DOI 10.1001/jama.277.3.246; PETTY TL, 1976, AM REV RESPIR DIS, V114, P881; POSTMA DS, 1985, EUR J RESPIR DIS, V67, P56; *PREV SERV TASK FO, 1989, GUID CLIN PREV SERV; PROCHASICA JO, 1986, TREATING ADDICTIVE B; QUANJER PH, 1993, EUR RESPIR J, V6, P5; RICHMOND RL, 1993, ADDICT BEHAV, V18, P187, DOI 10.1016/0306-4603(93)90049-F; RISSER NL, 1990, J GEN INTERN MED, V5, P16, DOI 10.1007/BF02602303; SACKETT DL, 1975, B NEW YORK ACAD MED, V51, P39; SEGNAN N, 1991, CANCER CAUSE CONTROL, V2, P239, DOI 10.1007/BF00052140; SHERMAN CB, 1992, AM REV RESPIR DIS, V146, P855; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SILAGY C, 1994, LANCET, V343, P139, DOI 10.1016/S0140-6736(94)90933-4; SINGH GK, 1994, 43 NAT CTR HLTH STAT; SNIDER GL, 1989, ANN INTERN MED, V111, P957; SOX HC, 1994, NEW ENGL J MED, V330, P1589, DOI 10.1056/NEJM199406023302208; STERN EJ, 1994, AM J ROENTGENOL, V162, P791; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; TASHKIN DP, 1994, AM J RESP CRIT CARE, V149, P1209; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301; THURLBECK WM, 1990, CLIN CHEST MED, V11, P389; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512; TOCKMAN MS, 1995, AM J RESP CRIT CARE, V151, P390; TRAVER GA, 1979, AM REV RESPIR DIS, V119, P895; *US SURG GEN, 1994, DHHS PUBLICATION; VANSCHAYCK CP, 1991, BRIT MED J, V303, P1426; VEDAL S, 1983, B EUR PHYSIOPATH RES, V19, P263; Wanger J, 1997, J ASTHMA, V34, P93, DOI 10.3109/02770909709075653; WANNAMETHEE SG, 1995, JAMA-J AM MED ASSOC, V274, P155; WEISS ST, 1995, AM J EPIDEMIOL, V142, P493; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573; WIJKSTRA PJ, 1994, THORAX, V49, P468, DOI 10.1136/thx.49.5.468; Wise RA, 1997, PREV MED, V26, P418, DOI 10.1006/pmed.1997.0181; Wise RA, 1998, AM J RESP CRIT CARE, V157, P866; XU X, 1995, AM J RESP CRIT CARE, V15, P41	118	254	267	5	15	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	APR	2000	117	4					1146	1161		10.1378/chest.117.4.1146		18	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	307AK	WOS:000086631100038	10767253	
J	Litonjua, AA; Weiss, ST				Litonjua, Augusto A.; Weiss, Scott T.			Is vitamin D deficiency to blame for the asthma epidemic?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; allergy; vitamin D; prevention	REGULATORY T-CELLS; NUTRITION EXAMINATION SURVEY; 3RD NATIONAL-HEALTH; D-RECEPTOR GENE; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 1,25-DIHYDROXYVITAMIN D-3; HYGIENE HYPOTHESIS; HYPOVITAMINOSIS-D; IGE PRODUCTION; II CELLS	In the 1960s, the prevalence of asthma and allergic diseases began to increase worldwide. Currently, the burden of the disease is more than 300 million people affected. We hypothesize that as populations grow more prosperous, more time is spent indoors, and there is less exposure to sunlight, leading to decreased cutaneous vitamin D production. Coupled with inadequate intake from foods and supplements, this then leads to vitamin D deficiency, particularly in pregnant women, resulting in more asthma and allergy in their offspring. Vitamin D has been linked to immune system and lung development in utero, and our epiderniologic studies show that higher vitamin D intake by pregnant mothers reduces asthma risk by as much as 40% in children 3 to 5 years old. Vitamin D deficiency has been associated with obesity, African American race (particularly in urban, inner-city settings), and recent immigrants to westernized countries, thus reflecting the epiderniologic patterns observed in the asthma epidemic. Providing adequate vitamin D supplementation in pregnancy may lead to significant decreases in asthma incidence in young children.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Brigham & Womens Hosp, Ctr Genom Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Litonjua, AA (reprint author), 181 Longwood Ave, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875			Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Akeno N, 1997, ENDOCRINOLOGY, V138, P2233, DOI 10.1210/endo.138.6.5170; Annesi-Maesano I, 2002, PEDIATR RES, V52, P3, DOI 10.1023/01.PDR/0000017228.29635.EF; Binkley N, 2007, J CLIN ENDOCR METAB, V92, P2130, DOI 10.1210/jc.2006-2250; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Boonstra A, 2001, J IMMUNOL, V167, P4974; Bosse Y, 2007, PHYSIOL GENOMICS, V29, P161, DOI 10.1152/physiolgenomics.00134.2006; BURNS JS, 2006, P AM THORACIC SOC, V3, pA526; Calvo MS, 2004, AM J CLIN NUTR, V80, p1710S; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Cantorna MT, 2006, PROG BIOPHYS MOL BIO, V92, P60, DOI 10.1016/j.pbiomolbio.2006.02.020; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S; Cantorna MT, 1998, J IMMUNOL, V160, P5314; Devereux G, 2007, AM J CLIN NUTR, V85, P853; DICKSON I, 1987, NATURE, V325, P18, DOI 10.1038/325018a0; EDELSON JD, 1994, BBA-MOL CELL RES, V1221, P159, DOI 10.1016/0167-4889(94)90008-6; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; *FOOD NUTR B I MED, 1997, DIET REF INT CAL PHO; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; GALE C, 2007, EUR J CLIN NUTR 0221; Gannage-Yared MH, 2000, J BONE MINER RES, V15, P1856, DOI 10.1359/jbmr.2000.15.9.1856; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Gregori S, 2001, J IMMUNOL, V167, P1945; Guzel R, 2001, J WOMEN HEALTH GEN-B, V10, P765, DOI 10.1089/15246090152636523; Heine G, 2002, EUR J IMMUNOL, V32, P3395, DOI 10.1002/1521-4141(200212)32:12<3395::AID-IMMU3395>3.0.CO;2-#; Hewison M, 2007, J STEROID BIOCHEM, V103, P316, DOI 10.1016/j.jsbmb.2006.12.078; HOLICK MF, 1995, ARCH DERMATOL, V131, P1337, DOI 10.1001/archderm.131.11.1337; Holick MF, 2006, MAYO CLIN PROC, V81, P353; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollis BW, 2007, J STEROID BIOCHEM, V103, P631, DOI 10.1016/j.jsbmb.2006.12.066; Hollis BW, 2004, AM J CLIN NUTR, V79, P717; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; IHO S, 1985, IMMUNOL LETT, V11, P331, DOI 10.1016/0165-2478(85)90116-6; Lamberg-Allardt C, 2006, PROG BIOPHYS MOL BIO, V92, P33, DOI 10.1016/j.pbiomolbio.2006.02.017; Lee JM, 2007, CLIN PEDIATR, V46, P42, DOI 10.1177/0009922806289311; Liu PT, 2007, TRENDS MOL MED, V13, P117, DOI 10.1016/j.molmed.2007.01.006; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Lu Z, 2007, J STEROID BIOCHEM, V103, P642, DOI 10.1016/j.jsbmb.2006.12.010; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; Mallbris L, 2005, J INVEST DERMATOL, V125, P1072, DOI 10.1111/j.0022-202X.2005.23872.x; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; MAT E, 2004, CURR DRUG TARGETS IN, V3, P377; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI 10.1037/mai.2003.1703; MATSUOKA LY, 1992, J CLIN ENDOCR METAB, V75, P1099, DOI 10.1210/jc.75.4.1099; Meddeb N, 2005, OSTEOPOROSIS INT, V16, P180, DOI 10.1007/s00198-004-1658-6; MEEHAN MA, 1992, CELL IMMUNOL, V140, P400, DOI 10.1016/0008-8749(92)90206-5; MINGHETTI PP, 1988, FASEB J, V2, P3043; Munns C, 2006, MED J AUSTRALIA, V185, P268; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187; Nguyen M, 2004, J STEROID BIOCHEM, V89-90, P93, DOI 10.1016/j.jsbmb.2004.03.054; Nguyen TM, 1996, AM J PHYSIOL-LUNG C, V271, pL392; Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1023/01.PDR.0000017267.23950.48; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Ramsey CD, 2005, CURR OPIN PULM MED, V11, P14, DOI 10.1097/01.mcp.0000145791.13714.ae; REICHEL H, 1987, P NATL ACAD SCI USA, V84, P3385, DOI 10.1073/pnas.84.10.3385; Romagnani S, 2004, IMMUNOLOGY, V112, P352, DOI 10.1111/j.1365-2567.2004.01925.x; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Skull SA, 2003, INTERN MED J, V33, P47, DOI 10.1046/j.1445-5994.2003.00344.x; Strachan DP, 2000, THORAX S1, V55, pS2; Taback SP, 2007, J ALLERGY CLIN IMMUN, V120, P128, DOI 10.1016/j.jaci.2007.05.020; van Etten E, 2005, J STEROID BIOCHEM, V97, P93, DOI 10.1016/j.jsbmb.2005.06.002; Vieth R, 2007, AM J CLIN NUTR, V85, P649; Vollmert C, 2004, CLIN EXP ALLERGY, V34, P1841, DOI 10.1111/j.1365-2222.2004.02047.x; Wang TT, 2004, J IMMUNOL, V173, P2909; Wittke A, 2004, J IMMUNOL, V173, P3432; Wittke A, 2007, ARCH BIOCHEM BIOPHYS, V460, P306, DOI 10.1016/j.abb.2006.12.011; Wjst M, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-2; Wjst M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-60; Wjst M, 2006, PEDIATR ALLERGY IMMU, V17, P477, DOI 10.1111/j.1399-3038.2006.00456.x; Wortsman J, 2000, AM J CLIN NUTR, V72, P690; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zasloff M, 2006, NAT MED, V12, P388, DOI 10.1038/nm0406-388	75	253	272	1	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2007	120	5					1031	1035		10.1016/j.jaci.2007.08.028		5	Allergy; Immunology	Allergy; Immunology	231TZ	WOS:000250973400008	17919705	
J	Brauer, M; Hoek, G; Smit, HA; de Jongste, JC; Gerritsen, J; Postma, DS; Kerkhof, M; Brunekreef, B				Brauer, M.; Hoek, G.; Smit, H. A.; de Jongste, J. C.; Gerritsen, J.; Postma, D. S.; Kerkhof, M.; Brunekreef, B.			Air pollution and development of asthma, allergy and infections in a birth cohort	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; allergy; asthma; respiratory infections; vehicle emissions	CHRONIC RESPIRATORY SYMPTOMS; 3 EUROPEAN AREAS; TOTAL SERUM IGE; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE; PRESCHOOL-CHILDREN; SCHOOL-CHILDREN; EXPOSURE; HEALTH; ATOPY	Few studies have addressed associations between traffic-related air pollution and respiratory disease in young children. The present authors assessed the development of asthmatic/allergic symptoms and respiratory infections during the first 4 yrs of life in a birth cohort study (n=similar to 4,000). Outdoor concentrations of traffic-related air pollutants (nitrogen dioxide PM2.5, particles with a 50% cut-off aerodynamic diameter of 2.5 mu m and soot) were assigned to birthplace home addresses with a land-use regression model. They were linked by logistic regression to questionnaire data on doctor-diagnosed asthma, bronchitis, influenza and eczema and to self-reported wheeze, dry night-time cough, ear/nose/throat infections and skin rash. Total and specific immunoglobulin (Ig)E to common allergens were measured in a subgroup (n=713). Adjusted odds ratios (95% confidence intervals) per interquartile pollution range were elevated for wheeze (1.2 (1.0-1.4) for soot), doctor-diagnosed asthma (1.3 (1.0-1.7)), ear/nose/throat infections (1.2 (1.0-1.3)) and flu/serious colds (1.2 (1.0-1.4)). No consistent associations were observed for other end-points. Positive associations between air pollution and specific sensitisation to common food allergens (1.6 (1.2-2.2) for soot), but not total IgE, were found in the subgroup with IgE measurements. Traffic-related pollution was associated with respiratory infections and some measures of asthma and allergy during the first 4 yrs of life.	Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V6T 1Z3, Canada; Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Univ Utrecht, Med Ctr, Ctr Hlth Sci & Primary Care, NL-3508 TC Utrecht, Netherlands; RIVM, Ctr Prevent & Hlth Serv Res, Bilthoven, Netherlands; Erasmus Univ, Sophia Childrens Hosp, Erasmus Med Ctr, Dept Paediat,Div Resp Med, NL-3000 DR Rotterdam, Netherlands; Univ Groningen, Dept Paediat Resp Med, NL-9700 AB Groningen, Netherlands; Univ Groningen, Dept Pulmonol, NL-9700 AB Groningen, Netherlands; Univ Groningen, Dept Epidemiol, NL-9700 AB Groningen, Netherlands	Brauer, M (reprint author), Univ British Columbia, Sch Occupat & Environm Hyg, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.	brauer@interchange.ubc.ca	Kerkhof, Marjan/A-8846-2008; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; brunekreef, bert/0000-0001-9908-0060; Brauer, Michael/0000-0002-9103-9343			Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Hwang BF, 2005, THORAX, V60, P467, DOI 10.1136/thx.2004.033977; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Koopman LP, 2001, PEDIATRICS, V108, P943, DOI 10.1542/peds.108.4.943; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Lewne M, 2004, SCI TOTAL ENVIRON, V332, P217, DOI 10.1016/j.scitotenv.2004.04.014; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Shima M, 2003, J EPIDEMIOL, V13, P108; Sinclair D, 2004, J CLIN PATHOL, V57, P956, DOI 10.1136/jcp.2004.017681; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Van Roosbroeck S, 2006, SCI TOTAL ENVIRON, V368, P565, DOI 10.1016/j.scitotenv.2006.03.034; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; VONMUTIUS E, 1995, EUR RESPIR J, V8, P723; VONMUTIUS E, 2001, J ALLERGY CLIN IMMUN, V105, P9; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wichmann J, 2005, ATMOS ENVIRON, V39, P7384, DOI 10.1016/j.atmosenv.2005.09.015; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x; WJST M, 1993, BRIT MED J, V307, P596; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	42	253	262	9	60	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAY	2007	29	5					879	888		10.1183/09031936.00083406		10	Respiratory System	Respiratory System	166VR	WOS:000246409300007	17251230	
J	Till, SJ; Francis, JN; Nouri-Aria, K; Durham, SR				Till, SJ; Francis, JN; Nouri-Aria, K; Durham, SR			Molecular mechanisms in allergy and clinical immunology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; allergy; IgE; IL-10; regulatory T cells	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; MESSENGER-RNA EXPRESSION; BEE VENOM IMMUNOTHERAPY; ANTIGEN-PRESENTING CELL; MONOPHOSPHORYL-LIPID-A; HUMAN DENDRITIC CELLS; IGG ANTIBODIES; HAY-FEVER; IN-VITRO	Specific allergen injection immunotherapy is highly effective in IgE-mediated diseases, such as allergic rhinitis and venom anaphylaxis. Immunotherapy inhibits both early and late responses to allergen exposure. Immunotherapy is accompanied by increases in allergen-specific IgG, particularly the IgG4 isotype, which blocks not only IgE-dependent histamine release from basophils but also IgE-mediated antigen presentation to T cells. Immunotherapy acts on T cells to modify peripheral and mucosal T(H)2 responses to allergen in favor of T(H)1 responses. Recent studies have identified increased IL-10 production in peripheral blood and mucosal surfaces after immunotherapy. IL-10 has numerous potential antiallergic properties, including suppression of mast cell, eosinophil, and T-cell responses, as well as acting on B cells to favor heavy chain class switching to IgG4. These IL-10-producing cells might be so-called regulatory T cells and appear to be identified by the CD4(+)CD25(+) phenotype. Studies in mice suggest that dendritic cells play a vital role in induction of regulatory T cells. Novel approaches to immunotherapy currently being explored include the use of adjuvants, such as monophosphoryl lipid A or nucleotide immunostimulatory sequences derived from bacteria that potentiate T(H)1 responses. Alternative strategies include the use of allergen-derived peptides; or modified recombinant allergen vaccines that act on T cells while minimizing the IgE-dependent mast cell activation that is dependent on the native allergen conformation.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Doverhouse St, London SW3 6LY, England.	stephen.till@imperial.ac.uk					Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1999, FASEB J, V13, P603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bellinghausen I, 2001, INT ARCH ALLERGY IMM, V126, P97, DOI 10.1159/000049499; Bellinghausen I, 2001, J ALLERGY CLIN IMMUN, V108, P242, DOI 10.1067/mai.2001.117177; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Broide D, 1998, J IMMUNOL, V161, P7054; Cua DJ, 2001, J IMMUNOL, V166, P602; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eusebius NP, 2002, INT ARCH ALLERGY IMM, V127, P234, DOI 10.1159/000053868; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; FloresVillanueva PO, 1996, J IMMUNOL, V156, P3315; Francis JN, 2004, J IMMUNOL, V172, P268; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Golden DBK, 1996, J ALLERGY CLIN IMMUN, V97, P579, DOI 10.1016/S0091-6749(96)70302-0; Groux H, 1997, NATURE, V389, P737; HAGEHAMSTEN M, 2002, CLIN EXP ALLERGY, V32, P1448; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Ismaili J, 2002, J IMMUNOL, V168, P926; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kingsley CI, 2002, J IMMUNOL, V168, P1080; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; KOLBE L, 1995, IMMUNOLOGY, V84, P285; Larche M, 1998, J IMMUNOL, V161, P6375; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; Malbec O, 1998, J IMMUNOL, V160, P1647; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; Michils A, 1998, J ALLERGY CLIN IMMUN, V102, P118, DOI 10.1016/S0091-6749(98)70062-4; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Muller G, 2002, J INVEST DERMATOL, V119, P836, DOI 10.1046/j.1523-1747.2002.00496.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Nopp A, 2000, J ALLERGY CLIN IMMUN, V106, P101, DOI 10.1067/mai.2000.106924; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Quattrocchi E, 2001, J IMMUNOL, V166, P5970; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Stanberry LR, 2002, NEW ENGL J MED, V347, P1652, DOI 10.1056/NEJMoa011915; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till S, 1997, CLIN EXP IMMUNOL, V110, P114, DOI 10.1111/j.1365-2249.1997.494-ce1392.x; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Varga EM, 2000, J IMMUNOL, V165, P2877; VARNEY VA, 1991, BRIT MED J, V302, P265; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	82	253	267	1	31	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2004	113	6					1025	1034		10.1016/j.jaci.2004.03.024		10	Allergy; Immunology	Allergy; Immunology	829ZI	WOS:000222091000002	15208578	
J	Park, JH; Gold, DR; Spiegelman, DL; Burge, HA; Milton, DK				Park, JH; Gold, DR; Spiegelman, DL; Burge, HA; Milton, DK			House dust endotoxin and wheeze in the first year of life	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							LUNG-FUNCTION; LIPOPOLYSACCHARIDE LPS; RESPIRATORY ILLNESS; LIMULUS ASSAY; GRAIN DUST; ASTHMA; EXPOSURE; INHALATION; INTERLEUKIN-1; SENSITIZATION	We examined endotoxin exposure and wheezing episodes during the first year of life in a birth cohort of 499 infants with one or both parents having a history of asthma or allergy. We measured endotoxin in settled dust from the baby's bed, bedroom floor, family room, and kitchen floor within the first 3 mo after birth. The primary outcomes were any wheeze (versus no wheeze), and repeated wheeze (versus one or no report of wheeze). We found a significant univariate association of elevated endotoxin (greater than or equal to 100 EU/mg) in family room dust with increased risk of any wheeze (Relative Risk = 1.29, 95% CI = 1.03-1.62). The association was not confounded by cockroach allergen, lower respiratory illness (croup, bronchitis, bronchiolitis, and pneumonia), smoking during pregnancy, tower birth weight, maternal asthma, presence of dog, and race/ethnicity in a multivariate model; the multivariate relative risk (RR = 1.33) was marginally significant (95% CI: 1.00-1.76, p < 0.05). In a multivariate model, controlling for the above covariates, elevated endotoxin in family room dust was significantly associated with increased risk (RR = 1.56, 95% CI = 1.03-2.38) of repeated wheeze. These results suggest that home endotoxin exposure may independently increase risk of any wheeze and repeated wheeze during the first year of life for children with a familial predisposition to asthma or allergy.	Harvard Sch Publ Hlth, Occupat Hlth Program, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Sch Publ Hlth, Dept Epidemiol & Biostat, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA	Milton, DK (reprint author), Harvard Sch Publ Hlth, Occupat Hlth Program, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Milton, Donald/G-3286-2010	Milton, Donald/0000-0002-0550-7834	NIAID NIH HHS [R01 AI/EHS-35786]; NIEHS NIH HHS [2P30ES00002, R01 ES-07036]		Baldini M, 1999, AM J RESP CELL MOL, V20, P976; BAYNE EK, 1986, J EXP MED, V163, P1267, DOI 10.1084/jem.163.5.1267; Busse WW, 1997, CIBA F SYMP, V206, P208; CLAPP WD, 1994, AM J RESP CRIT CARE, V150, P611; DINARELLO CA, 1984, REV INFECT DIS, V6, P51; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; DOUWES J, 1998, RESP HLTH EFFECTS IN, P109; Fahrmeir L., 1994, MULTIVARIATE STAT MO; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Holt PG, 1997, CIBA F SYMP, V206, P35; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471; Iwasaki Y, 1998, HISTOCHEM CELL BIOL, V109, P339, DOI 10.1007/s004180050234; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Keman S, 1998, INT ARCH OCC ENV HEA, V71, P131, DOI 10.1007/s004200050260; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHIE HR, 1988, NEW ENGL J MED, V318, P1481, DOI 10.1056/NEJM198806093182301; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; MILTON DK, 1992, ENVIRON RES, V57, P212, DOI 10.1016/S0013-9351(05)80081-7; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; RYLANDER R, 1990, AM J IND MED, V17, P39; SANDSTROM T, 1992, EUR RESPIR J, V5, P992; SIRAGANIAN RP, 1979, J ALLERGY CLIN IMMUN, V64, P526, DOI 10.1016/0091-6749(79)90063-0; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; WILSON NM, 1994, CLIN EXP ALLERGY, V24, P522, DOI 10.1111/j.1365-2222.1994.tb00949.x; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Zimmer S., 1996, Journal of Burn Care and Rehabilitation, V17, P491, DOI 10.1097/00004630-199611000-00004	35	253	260	0	3	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB	2001	163	2					322	328				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	403PD	WOS:000167050900008	11179100	
J	von Mutius, E; Schwartz, J; Neas, LM; Dockery, D; Weiss, ST				von Mutius, E; Schwartz, J; Neas, LM; Dockery, D; Weiss, ST			Relation of body mass index to asthma and atopy in children: the National Health and Nutrition Examination Study III	THORAX			English	Article						body mass index; obesity; atopy; asthma	OVERWEIGHT; OBESITY; WEIGHT; ASSOCIATION; CHILDHOOD; PREVALENCE; ADULTS; AGE; OLD	Background-An increase in the prevalence of obesity and asthma over recent decades has been reported in affluent societies. Both overweight and obesity have been shown to be inversely related to having been breastfed, which is also a potential protective factor against childhood atopic diseases. The aim of this analysis was to explore the relation of body mass index (BMI) to asthma and atopy in a large representative sample of the United States population. Methods-Children aged 4-17 years were included in the NHANES III survey. Prevalences of atopic diseases and potential confounding factors such as exposure to environmental tobacco smoke, birth weight, breast feeding, and household size were assessed using structured interviews with parents. Height and weight were measured, and BMI was calculated as kg/m(2) and transformed into Z scores. Children underwent skin prick tests for atopy to a battery of food and inhalant allergens. Results-The prevalence of asthma (8.7% v 9.3% v 10.3% v 14.9%, p=0.0001) and atopy (48.6% v 50.5% v 53.0% v 53.2%, p=0.05) rose significantly with increasing quartiles of BMI. After adjustment for confounders, a significant positive association between BMI and asthma remained (adjusted OR 1.77, 95% confidence interval 1.44 to 2.19 between the highest and lowest quartiles of BMI), whereas no independent relation between BMI and atopy was evident. No effect modification by sex or ethnic group was seen. Conclusions-The effects of increased BMI on asthma may be mediated by mechanical properties of the respiratory system associated with obesity or by upregulation of inflammatory mechanisms rather than by allergic eosinophilic inflammation of the airway epithelium.	Univ Munich, Childrens Hosp, D-80337 Munich, Germany; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA USA	von Mutius, E (reprint author), Univ Munich, Childrens Hosp, D-80337 Munich, Germany.		Neas, Lucas/J-9378-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Camargo CA, 1999, AM J RESP CRIT CARE, V159, pA150; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; CHINN S, 1994, PAEDIATR PERINAT EP, V8, P90, DOI 10.1111/j.1365-3016.1994.tb00438.x; Ezzati TM, 1992, VITAL HLTH STAT, V2; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Jedrychowski W, 1998, PUBLIC HEALTH, V112, P189, DOI 10.1038/sj.ph.1900438; Litonjua A, 1999, AM J RESP CRIT CARE, V159, pA131; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; NEGRI E, 1988, J EPIDEMIOL COMMUN H, V42, P24, DOI 10.1136/jech.42.1.24; Oddy WH, 1999, BRIT MED J, V319, P815; POSKITT EME, 1978, BRIT MED J, V1, P603; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Shaheen SO, 1999, THORAX, V54, P396; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; von Kries R, 1999, BRIT MED J, V319, P147; Von Mutius E, 1999, LUNG BIOL HEALTH DIS, V126, P1; WILKINSON PW, 1977, LANCET, V1, P350; Woolcock AJ, 1997, CIBA F SYMP, V206, P122	22	252	263	1	10	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	NOV	2001	56	11					835	838		10.1136/thorax.56.11.835		4	Respiratory System	Respiratory System	486ZZ	WOS:000171850400005	11641506	
J	Dishy, V; Sofowora, GG; Xie, HG; Kim, RB; Byrne, DW; Stein, CM; Wood, AJJ				Dishy, V; Sofowora, GG; Xie, HG; Kim, RB; Byrne, DW; Stein, CM; Wood, AJJ			The effect of common polymorphisms of the beta(2)-adrenergic receptor on agonist-mediated vascular desensitization	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BETA-2-ADRENERGIC RECEPTOR; ADULT-POPULATION; BLOOD-PRESSURE; HYPERTENSION; VASODILATION; ASTHMA; INDIVIDUALS; CELLS	Background: With continuous exposure to beta (2)-adrenergic agonists, vascular tissue becomes desensitized to agonist-mediated vasodilatation. We studied the effects of two common polymorphisms of the beta (2)-adrenergic receptor, one at codon 16 and one at codon 27, on agonist-mediated vasodilatation and desensitization in the vascular bed. Methods: We studied 26 healthy subjects who were selected to represent three genotypes: 7 were homozygous for the alleles encoding Arg16 and GIn27, 8 were homozygous for the alleles encoding Gly16 and Gln27, and 11 were homozygous for the alleles encoding Gly16 and Glu27. Vascular responses were assessed by measuring changes in the diameter of a dorsal hand vein. A dose-response curve of the effect of the beta (2)-adrenergic-receptor agonist isoproterenol was constructed (dose range, 4 to 480 ng per minute). Desensitization was then induced by a 2-hour continuous infusion of isoproterenol, and venodilatation was measured 30, 60, 90, and 120 minutes after the start of the infusion. Results: Subjects who were homozygous for Arg16 had almost complete desensitization; venodilatation in response to isoproterenol in this group decreased from a mean (+/-SE) of 44+/-11 percent to 8+/-4 percent (P=0.006). In contrast, subjects who were homozygous for Gly16 did not have significant desensitization, irrespective of the amino acid encoded by codon 27. Subjects who were homozygous for Glu27 had higher maximal venodilatation in response to isoproterenol than those who were homozygous for Gln27 (86+/-13 percent vs. 54+/-8 percent, P=0.03). Conclusions: The Arg16 polymorphism of the beta (2)-adrenergic receptor is associated with enhanced agonist-mediated desensitization in the vasculature, and the Glu27 polymorphism is associated with increased agonist-mediated responsiveness. Therefore, polymorphisms of the beta (2)-adrenergic receptor are potentially important determinants of the vascular response to stress. (N Engl J Med 2001;345:1030-5.) Copyright (C) 2001 Massachusetts Medical Society.	Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Gen Clin Res Ctr, Nashville, TN 37232 USA	Wood, AJJ (reprint author), Vanderbilt Univ, Sch Med, Div Clin Pharmacol, Rm 550,Med Res Bldg 1, Nashville, TN 37232 USA.		Sofowora, Gbemiga/E-4118-2011		NHLBI NIH HHS [HL-04012, HL-56251]; NIGMS NIH HHS [GM-RR0095]		AELLIG WH, 1981, BRIT J CLIN PHARMACO, V11, P237; Black HR, 1997, ARCH INTERN MED, V157, P2413; BRISTOW MR, 1989, MOL PHARMACOL, V35, P295; BURT VL, 1995, HYPERTENSION, V25, P305; Chong LK, 2000, PHARMACOGENETICS, V10, P153, DOI 10.1097/00008571-200003000-00007; Cockcroft JR, 2000, HYPERTENSION, V36, P371; Dewar JC, 1998, CLIN EXP ALLERGY, V28, P442; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; FELDMAN RD, 1990, J CLIN INVEST, V85, P647, DOI 10.1172/JCI114487; Flier J, 1996, NEW ENGL J MED, V334, P580, DOI 10.1056/NEJM199602293340907; GOLDSTEIN DS, 1983, HYPERTENSION, V5, P86; Gratze G, 1999, HYPERTENSION, V33, P1425; GREEN SA, 1993, J BIOL CHEM, V268, P23116; GREEN SA, 1995, AM J RESP CELL MOL, V13, P25; Hoit BD, 2000, AM HEART J, V139, P537, DOI 10.1067/mhj.2000.101781; Israel E, 2000, AM J RESP CRIT CARE, V162, P75; LANDAU R, 2000, ANESTHESIOLOGY S, V93, pA1053; LANG CC, 1995, NEW ENGL J MED, V333, P155, DOI 10.1056/NEJM199507203330304; NASLUND T, 1990, CLIN PHARMACOL THER, V48, P87; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334; Schobel HP, 1996, NEW ENGL J MED, V335, P1480, DOI 10.1056/NEJM199611143352002; STEIN CM, 1995, J CLIN INVEST, V96, P579, DOI 10.1172/JCI118070; Stein CM, 2001, PHARMACOGENETICS, V11, P95, DOI 10.1097/00008571-200103000-00001; STEIN M, 1993, CLIN PHARMACOL THER, V54, P187; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; VINCENT J, 1992, J CARDIOVASC PHARM, V19, P447, DOI 10.1097/00005344-199203000-00023; Xie HG, 1999, PHARMACOGENETICS, V9, P511	28	252	266	1	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 4	2001	345	14					1030	1035		10.1056/NEJMoa010819		6	Medicine, General & Internal	General & Internal Medicine	478HF	WOS:000171340400004	11586955	
J	Ege, MJ; Bieli, C; Frei, R; van Strien, RT; Riedler, J; Ublagger, E; Schram-Bijkerk, D; Brunekreef, B; van Hage, M; Scheynius, A; Pershagen, G; Benz, MR; Lauener, R; von Mutius, E; Braun-Fahrlander, C				Ege, MJ; Bieli, C; Frei, R; van Strien, RT; Riedler, J; Ublagger, E; Schram-Bijkerk, D; Brunekreef, B; van Hage, M; Scheynius, A; Pershagen, G; Benz, MR; Lauener, R; von Mutius, E; Braun-Fahrlander, C		PARSIFAL Study Team	Prenatal farm exposure is related to the expression of receptors of the innate immunity and to atopic sensitization in school-age children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy; atopic sensitization; gene expression; Toll-like receptors; CD14; farming; maternal exposure; microbial exposure	TOLL-LIKE RECEPTORS; DAY-CARE ATTENDANCE; HOUSE-DUST; EARLY-LIFE; MATERNAL HISTORY; CHILDHOOD ASTHMA; RISK; PREGNANCY; SMOKING; SCHOOLCHILDREN	Background: There is increasing evidence that environmental exposures determining childhood illnesses operate early in life. Prenatal exposure to a farming environment through the mother might also play an important role. Objective: We sought to investigate the role of maternal exposures to environments rich in microbial compounds for the development of atopic sensitization, asthma, and corresponding alterations in the innate immune system in offspring. Methods: In the children of the cross-sectional Prevention of Allergy Risk Factors for Sensitization in Children Related to Farming and Anthroposophic Life Style study, asthma and atopy were assessed by means of standardized questionnaires (n = 8263) and serum IgE measurements (n = 2086). In a subsample (n = 322) gene expression of Toil-like receptors (TLR2 and TLR4) and CD14 was assessed. Maternal exposures were defined through questionnaire information. Results: Both atopic sensitization (adjusted odds ratio, 0.58; 95% CI, 0.39-0.86) and the gene expression of receptors of innate immunity were strongly determined by maternal exposure to stables during pregnancy, whereas current exposures had much weaker or no effects. A dose-response relation was found between the extent of upregulation of these genes and the number of different farm animal species the mother had encountered in her pregnancy. Each additional farm animal species increased the expression of TLR2, TLR4, and CD14 by a factor of 1.16 (95% CI, 1.07-1.26), 1.12 (95% Cl, 1.04-1.2), and 1.10 (95% Cl, 1.03-1.23), respectively. Conclusion: Maternal exposure to an environment rich in microbial compounds might protect against the development of atopic sensitization and lead to upregulation of receptors of the innate immune system. The underlying mechanisms potentially operating through the intrauterine milieu or epigenetic inheritance await further elucidation. Clinical implications: When assessing risk factors of allergies in an infant's medical history, attention must also be paid to environmental exposures affecting the mother.	Univ Childrens Hosp Munich, Munich, Germany; Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Zurich, Childrens Hosp, CH-8006 Zurich, Switzerland; Childrens Hosp, Schwarzach, Austria; Childrens Hosp, Salzburg, Austria; Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TC Utrecht, Netherlands; Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Ege, MJ (reprint author), Univ Munich, Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.uni-muenchen.de	Lauener, Roger/O-8612-2016; van Hage, Marianne/A-9678-2017	Lauener, Roger/0000-0002-8412-606X; van Hage, Marianne/0000-0003-3091-1596; Pershagen, Goran/0000-0002-9701-1130; brunekreef, bert/0000-0001-9908-0060; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515			ALFVEN T, 2006, IN PRESS ALLERGY; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Eisenbarth SC, 2004, CURR OPIN PEDIATR, V16, P659, DOI 10.1097/01.mop.0000145920.00101.e4; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Holt P, 2004, CHEM IMMUNOL, V84, P102; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kihlstrom A, 2003, ALLERGY, V58, P871, DOI 10.1034/j.1398-9995.2003.00232.x; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Musikacharoen T, 2003, J BIOL CHEM, V278, P9167, DOI 10.1074/jbc.M211829200; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Piani A, 2000, EUR J IMMUNOL, V30, P3140, DOI 10.1002/1521-4141(200011)30:11<3140::AID-IMMU3140>3.0.CO;2-O; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schonberger HJ, 2005, PEDIATR ALLERGY IMMU, V16, P27, DOI 10.1111/j.1399-3038.2005.00243.x; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Smits HH, 2005, CURR ALLERGY ASTHM R, V5, P42, DOI 10.1007/s11882-005-0053-5; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TAYLOR A, 2005, MICROBES INFECT, V25, P25; Toelle BG, 2004, BRIT MED J, V328, P386, DOI 10.1136/bmj.328.7436.386; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Warner JO, 2004, ARCH DIS CHILD, V89, P97, DOI 10.1136/adc.2003.013029; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x	36	251	259	5	25	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					817	823		10.1016/j.jaci.2005.12.1307		7	Allergy; Immunology	Allergy; Immunology	033QB	WOS:000236862800015	16630939	
J	Cox, LS; Linnemann, DL; Nolte, H; Weldon, D; Finegold, I; Nelson, HS				Cox, LS; Linnemann, DL; Nolte, H; Weldon, D; Finegold, I; Nelson, HS			Sublingual immunotherapy: A comprehensive review	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						sublingual-swallow immunotherapy; sublingual-spit immunotherapy; allergen immunotherapy; allergic asthma; allergic rhinitis	RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND PLACEBO; HOUSE-DUST MITES; SEASONAL ALLERGIC RHINOCONJUNCTIVITIS; STANDARDIZED 5-GRASS-POLLEN EXTRACT; GRASS-POLLEN EXTRACT; SWALLOW IMMUNOTHERAPY; SYSTEMIC REACTIONS; RESPIRATORY ALLERGY; RUSH IMMUNOTHERAPY	Sublingual immunotherapy (SLIT) has been used with increasing frequency in Europe and is viewed with increasing interest by allergists in the United States. To address this interest, a Joint Task Force of the American College of Allergy, Asthma and Immunology and the American Academy of Allergy, Asthma and Immunology's Immunotherapy and Allergy Diagnostic Committees reviewed the available literature on SLIT and prepared this report. The task force concluded that despite clear evidence that SLIT is an effective treatment, many questions remained unanswered, including effective dose, treatment schedules, and overall duration of treatment. Until these have been determined, an assessment of the cost/benefit ratio of the treatment cannot be made. SLIT does appear to be associated with few serious side effects, but it has not been administered in high-risk asthmatic patients, nor in the studies reviewed has it been administered as a mixture of non-cross-reacting allergens. Furthermore, there is currently no allergy extract approved for this use in the United States, nor is there a Current Procedural Terminology code for billing purposes. All of these factors should be given careful consideration by anyone contemplating initiating SLIT treatment for their allergic patients.	Nova Southeastern Univ, Sch Osteopath Med, Davie, FL USA; Hosp Med Sur, Juarez, Mexico; Univ Copenhagen Hosp, DK-2100 Copenhagen, Denmark; Texas A&M Univ, Hlth Sci Ctr, Allergy & Pulm Serv, Scott & White Clin, College Stn, TX USA; Columbia Univ, St Lukes Roosevelt Hosp, New York, NY USA; Natl Jewish Med & Res Ctr, Denver, CO USA	Cox, LS (reprint author), Amer Acad Allergy, 611 E Wells St, Milwaukee, WI 53203 USA.	lsweetman@aaaai.org					Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; American Academy of Allergy Asthma and Immunology (AAAAI), 1997, J ALLERGY CLIN IMMUN, V99, P583; American Medical Association, 2005, CURR PROC TERM CPT 2; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; Baena-Cagnani CE, 2005, CURR OPIN ALLERGY CL, V5, P173, DOI 10.1097/01.all.0000162311.87178.9e; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bahima AC, 2004, J INVEST ALLERG CLIN, V14, P17; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bordignon V, 2003, J INVEST ALLERG CLIN, V13, P170; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Canonica GW, 2004, IMMUNOL ALLERGY CLIN, V24, P685, DOI 10.1016/j.iac.2004.07.001; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Cirla A M, 2003, Allergol Immunopathol (Madr), V31, P31, DOI 10.1157/13042841; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; DAMBROSIO FP, 1996, ALLERGOL IMMUNOPATH, V21, P146; DAMBROSIO FP, 1999, ALLERGY, V54, P968; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Di Rienzo V, 1999, Allergol Immunopathol (Madr), V27, P145; DIRENZO V, 2005, CLIN EXP ALLERGY, V35, P560; Drachenberg K J, 2004, Allergol Immunopathol (Madr), V32, P76; Drachenberg KJ, 2001, ALLERGOLOGIE, V24, P525; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Feliziani V, 1993, Allergol Immunopathol (Madr), V21, P173; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Gammeri E, 2005, Allergol Immunopathol (Madr), V33, P142, DOI 10.1157/13075710; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Gozalo F, 1997, Allergol Immunopathol (Madr), V25, P219; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Joint Task Force on Practice Parameters, 2003, ANN ALLERGY ASTHM S1, V90, P1; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kinchi MS, 2004, ALLERGY, V59, P45; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; LOCKEY R, 2003, SIMMONS MIDDLETONS A, P573; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47; Lombardi C, 2000, ALLERGY, V55, P677, DOI 10.1034/j.1398-9995.2000.00687.x; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j/jaci.2004.03.013; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; Madonini E, 2000, INT J IMMUNOPATH PH, V13, P77; Madonini E, 2003, INT J IMMUNOPATH PH, V16, P73; Malling Hans-Jorgen, 2004, Curr Opin Allergy Clin Immunol, V4, P539, DOI 10.1097/00130832-200412000-00011; Malling HJ, 2002, CURR OPIN ALLERGY CL, V2, P523, DOI 10.1097/01.all.0000044538.45448.80; Marcucci F, 2005, ALLERGY, V60, P952, DOI 10.1111/j.1398-9995.2005.00786.x; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Marcucci F, 2001, ALLERGY, V56, P1091, DOI 10.1034/j.1398-9995.2001.00226.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; Mastrandrea F, 2000, J INVEST ALLERG CLIN, V10, P142; Miller C, 2000, LANDSCAPE ECOL, V15, P145, DOI 10.1023/A:1008181313360; MITSCH A, 1996, TW PADIATRIE, V9, P628; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 2003, CHEM IMMUNOL, V82, P109; Passalacqua G, 2001, ALLERGY, V56, P578, DOI 10.1034/j.1398-9995.2001.056006578.x; PORTNOY J, 1992, ANN ALLERGY, V68, P493; PORTNOY J, 1994, ANN ALLERGY, V73, P409; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Ragusa VF, 2004, ALLERG IMMUNOL PARIS, V36, P52; Rakoski J, 2001, INT ARCH ALLERGY IMM, V126, P185, DOI 10.1159/000049512; Reich M, 2003, CHEM IMMUNOL, V82, P99; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Rossi RE, 2005, INT J IMMUNOPATH PH, V18, P277; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Sambugaro R, 2003, Allergol Immunopathol (Madr), V31, P329, DOI 10.1157/13055212; Silvestri M, 2002, J INVEST ALLERG CLIN, V12, P52; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Tari M G, 1994, Allergol Immunopathol (Madr), V22, P209; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Valle C, 2000, Allergol Immunopathol (Madr), V28, P311; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WILSON DR, 2005, SUBLINGUAL IMMUNOTHE; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	121	250	267	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1021	1035		10.1016/j.jaci.2006.02.040		15	Allergy; Immunology	Allergy; Immunology	041EM	WOS:000237436300008	16675328	
J	Janson, C; Anto, J; Burney, P; Chinn, S; de Marco, R; Heinrich, J; Jarvis, D; Kuenzli, N; Leynaert, B; Luczynska, C; Neukirch, F; Svanes, C; Sunyer, J; Wjst, M				Janson, C; Anto, J; Burney, P; Chinn, S; de Marco, R; Heinrich, J; Jarvis, D; Kuenzli, N; Leynaert, B; Luczynska, C; Neukirch, F; Svanes, C; Sunyer, J; Wjst, M		European Community Resp Hlth Surve	The European Community Respiratory Health Survey: what are the main results so far?	EUROPEAN RESPIRATORY JOURNAL			English	Review						asthma; atopy; epidemiology; incidence; prevalence; risk factors	ASTHMA-LIKE SYMPTOMS; VOLATILE ORGANIC-COMPOUNDS; TOTAL SERUM IGE; YOUNG-ADULTS; BRONCHIAL HYPERRESPONSIVENESS; ATOPIC SENSITIZATION; LUNG-FUNCTION; INDIVIDUAL ALLERGENS; OCCUPATIONAL ASTHMA; REPORTED ASTHMA	The European Community Respiratory Heath Survey (ECRHS) was the first study to assess the geographical variation in asthma and allergy in adults using the same instruments and definitions. The database of the ECRHS includes information from similar to 140,000 individuals from 22 countries. The aim of this review is to summarize the results of the ECRHS to date. The ECRHS has shown that there are large geographical differences in the prevalence of asthma, atopy and bronchial responsiveness, with high prevalence rates in English speaking countries and low prevalence rates in the Mediterranean region and Eastern Europe. Analyses of risk factors have highlighted the importance of occupational exposure for asthma in adulthood. The association between sensitization to individual allergens and bronchial responsiveness was strongest for indoor allergens (mite and cat). Analysis of treatment practices has confirmed that the treatment of asthma varies widely between countries and that asthma is often undertreated. In conclusion, the European Community Respiratory Health Survey has shown that the prevalence of asthma varies widely. The fact that the geographical pattern is consistent with the distribution of atopy and bronchial responsiveness supports the conclusion that the geographical variations in the prevalence of asthma are true and most likely due to environmental factors.	Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway; INSERM U408, Paris, France; Univ Basel, Dept Environm & Hlth, Inst Social & Prevent Med, Basel, Switzerland; Gesell Strahlen & Umweltforsch MbH, GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-8042 Neuherberg, Germany; Univ Verona, Div Epidemiol & Med Stat, I-37100 Verona, Italy; Univ London Kings Coll, Dept Publ Hlth Sci, London WC2R 2LS, England; IMIM, Resp & Environm Hlth Res Unit, Barcelona, Spain; Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden	Janson, C (reprint author), Akad Sjukhuset, Dept Resp Med, SE-75185 Uppsala, Sweden.		de Marco, Roberto/A-5470-2008; SESM, SESM/C-1440-2008; Jarvis, Deborah/E-6494-2011; Kunzli, Nino/F-7195-2014; Sunyer, J/G-6909-2014	Kunzli, Nino/0000-0001-8360-080X; Sunyer, J/0000-0002-2602-4110			ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; Abramson M, 1996, J ASTHMA, V33, P189, DOI 10.3109/02770909609054551; Abramson M, 1996, Respirology, V1, P291, DOI 10.1111/j.1440-1843.1996.tb00045.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BJORNSSON E, 1994, EUR RESPIR J, V7, P2146, DOI 10.1183/09031936.94.07122146; Bjornsson E, 1996, SCAND J INFECT DIS, V28, P63, DOI 10.3109/00365549609027152; Bjornsson E, 1996, Ups J Med Sci, V101, P159; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30; Bousquet J, 1996, J ALLERGY CLIN IMMUN, V98, P514, DOI 10.1016/S0091-6749(96)70084-2; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURNEY PGJ, 1987, CHEST, V91, P79; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Campello C, 1998, Monaldi Arch Chest Dis, V53, P505; Celik G, 1999, J ASTHMA, V36, P281, DOI 10.3109/02770909909075412; Cerveri I, 1997, EUR RESPIR J, V10, P2761, DOI 10.1183/09031936.97.10122761; Cerveri I, 1999, EUR RESPIR J, V14, P288, DOI 10.1034/j.1399-3003.1999.14b09.x; Chinn S, 1997, EUR RESPIR J, V10, P452, DOI 10.1183/09031936.97.10020452; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; Chinn S, 1996, J APPL STAT, V23, P395, DOI 10.1080/02664769624134; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chinn S, 1998, THORAX, V53, P662; Chowgule RV, 1998, AM J RESP CRIT CARE, V158, P547; Ciprandi G, 1996, Int Arch Allergy Immunol, V111, P278; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68; de Marco R, 1998, ALLERGY, V53, P673; Dharmage SC, 1998, J ASTHMA, V35, P391, DOI 10.3109/02770909809048947; *EUR COMM RESP HLT, 1993, PROT EUR COMM RESP H; Ferrari M, 2000, INFECTION, V28, P38, DOI 10.1007/s150100050009; Ferrari M, 1999, ANN ALLERG ASTHMA IM, V83, P391, DOI 10.1016/S1081-1206(10)62836-0; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; Fluge O, 1998, EUR RESPIR J, V12, P336, DOI 10.1183/09031936.98.12020336; Heinrich J, 1998, EUR J EPIDEMIOL, V14, P239, DOI 10.1023/A:1007465205976; Heinrich J, 1998, ALLERGY, V53, P89, DOI 10.1111/j.1398-9995.1998.tb03779.x; HOLLAND W, 1988, COMMISSION EC HLTH S, V3; Janson C, 1998, EUR RESPIR J, V12, P557, DOI 10.1183/09031936.98.12030557; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Jarvis D, 1998, EUR RESPIR J, V11, P651; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; JARVIS D, 1994, BRIT J GEN PRACT, V44, P493; Jogi R, 1998, CLIN EXP ALLERGY, V28, P1072; Jogi R, 1996, ALLERGY, V51, P331, DOI 10.1111/j.1398-9995.1996.tb00094.x; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; Kogevinas M, 1998, EUR RESPIR J, V11, P1363, DOI 10.1183/09031936.98.11061363; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413; Leynaert B, 1996, LANCET, V347, P1052, DOI 10.1016/S0140-6736(96)90197-X; Ludviksdottir D, 1996, CHEST, V109, P1262, DOI 10.1378/chest.109.5.1262; *NAT HEART LUNG BL, 1992, NIH PUBL; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; NEUKIRCH F, 1995, RESP MED, V89, P685, DOI 10.1016/0954-6111(95)90136-1; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Norrman E, 1998, RESP MED, V92, P480, DOI 10.1016/S0954-6111(98)90295-5; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Omenaas E, 2000, THORAX, V55, P454, DOI 10.1136/thorax.55.6.454; Papageorgiou N, 1997, RESP MED, V91, P83, DOI 10.1016/S0954-6111(97)90072-X; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb04652.x; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; Priftanji AV, 1999, ALLERGY, V54, P1042, DOI 10.1034/j.1398-9995.1999.00108.x; Richter K, 2000, RESP MED, V94, P668, DOI 10.1053/rmed.2000.0795; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Ruggieri F, 1989, Eur Respir J Suppl, V6, p536s; Saraclar Y, 1997, RESP MED, V91, P461; Soriano JB, 1999, INT J EPIDEMIOL, V28, P728, DOI 10.1093/ije/28.4.728; Soriano JB, 1996, AM J RESP CRIT CARE, V154, P1636; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Sunyer J., 1997, European Respiratory Journal, V10, P2490, DOI 10.1183/09031936.97.10112490; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Sunyer J, 1997, THORAX, V52, P235; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; Sunyer J, 2000, AM J RESP CRIT CARE, V162, P930; Svanes C, 1998, RESP MED, V92, P1003, DOI 10.1016/S0954-6111(98)90345-6; Svanes C, 1998, EUR RESPIR J, V12, P1366, DOI 10.1183/09031936.98.12061366; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VERMEIRE P, 1994, EUR RESPIR REV, V4, P279; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; Wassmer G, 1997, Eur J Med Res, V2, P47; Wieringa M, 1996, LANCET, V347, P1490, DOI 10.1016/S0140-6736(96)91729-8; Wieringa MH, 1998, INT J EPIDEMIOL, V27, P630, DOI 10.1093/ije/27.4.630; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115	104	249	258	0	11	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2001	18	3					598	611		10.1183/09031936.01.00205801		14	Respiratory System	Respiratory System	473XF	WOS:000171073700022	11589359	
J	Canonica, GW; Bousquet, J; Casale, T; Lockey, RF; Baena-Cagnani, CE; Pawankar, R; Potter, PC; Bousquet, PJ; Cox, LS; Durham, SR; Nelson, HS; Passalacqua, G; Ryan, DP; Brozek, JL; Compalati, E; Dahl, R; Delgado, L; van Wijk, RG; Gower, RG; Ledford, DK; Filho, NR; Valovirta, EJ; Yusuf, OM; Zuberbier, T; Akhanda, W; Almarales, RC; Ansotegui, I; Bonifazi, F; Ceuppens, J; Chivato, T; Dimova, D; Dumitrascu, D; Fontana, L; Katelaris, CH; Kaulsay, R; Kuna, P; Larenas-Linnemann, D; Manoussakis, M; Nekam, K; Nunes, C; O'Hehir, R; Olaguibel, JM; Onder, NB; Park, JW; Priftanji, A; Puy, R; Sarmiento, L; Scadding, G; Schmid-Grendelmeier, P; Seberova, E; Sepiashvili, R; Sole, D; Togias, A; Tomino, C; Toskala, E; Van Beever, H; Vieths, S				Canonica, G. Walter; Bousquet, Jean; Casale, Thomas; Lockey, Richard F.; Baena-Cagnani, Carlos E.; Pawankar, Ruby; Potter, Paul C.; Bousquet, Philippe J.; Cox, Linda S.; Durham, Stephen R.; Nelson, Harold S.; Passalacqua, Giovanni; Ryan, Dermot P.; Brozek, Jan L.; Compalati, Enrico; Dahl, Ronald; Delgado, Luis; van Wijk, Roy Gerth; Gower, Richard G.; Ledford, Dennis K.; Filho, Nelson Rosario; Valovirta, Erkka J.; Yusuf, Osman M.; Zuberbier, Torsten; Akhanda, Wahiduzzaman; Almarales, Raul Castro; Ansotegui, Ignacio; Bonifazi, Floriano; Ceuppens, Jan; Chivato, Tomas; Dimova, Darina; Dumitrascu, Diana; Fontana, Luigi; Katelaris, Constance H.; Kaulsay, Ranbir; Kuna, Piotr; Larenas-Linnemann, Desiree; Manoussakis, Manolis; Nekam, Kristof; Nunes, Carlos; O'Hehir, Robyn; Olaguibel, Jose M.; Onder, Nerin Bahceciler; Park, Jung Won; Priftanji, Alfred; Puy, Robert; Sarmiento, Luis; Scadding, Glenis; Schmid-Grendelmeier, Peter; Seberova, Ester; Sepiashvili, Revaz; Sole, Dirceu; Togias, Alkis; Tomino, Carlo; Toskala, Elina; Van Beever, Hugo; Vieths, Stefan			Sub-lingual Immunotherapy: World Allergy Organization Position Paper 2009	ALLERGY			English	Review							HOUSE-DUST-MITE; GRASS-POLLEN IMMUNOTHERAPY; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND PLACEBO; FC-EPSILON-RI; STANDARDIZED 5-GRASS-POLLEN EXTRACT; SYSTEMIC IMMUNOLOGICAL CHANGES; PARIETARIA-JUDAICA EXTRACT		[Canonica, G. Walter] Univ Genoa, DIMI, Dept Internal Med, I-16132 Genoa, Italy	Canonica, GW (reprint author), Univ Genoa, DIMI, Dept Internal Med, I-16132 Genoa, Italy.		ceuppens, jan/F-2819-2010; O'Hehir, Robyn/H-3627-2011; Sole, Dirceu/D-7789-2013; FMUP, CINTESIS/C-6631-2014; Delgado, Luis/L-8035-2013	O'Hehir, Robyn/0000-0002-3489-7595; FMUP, CINTESIS/0000-0001-7248-2086; Delgado, Luis/0000-0003-2375-9071; Puy, Robert/0000-0001-7001-6313			Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; Agostinis F, 2008, ALLERGY, V63, P1637, DOI 10.1111/j.1398-9995.2008.01742.x; Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; ALEXANDER HL, 1948, J ALLERGY, V19, P1, DOI 10.1016/0021-8707(48)90071-9; *ALL PROD, 0120101063 ALL PROD; Allam JP, 2008, ALLERGY, V63, P720, DOI 10.1111/j.1398-9995.2007.01611.x; Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Als-Nielsen B, 2003, JAMA-J AM MED ASSOC, V290, P921, DOI 10.1001/jama.290.7.921; Altman Douglas G, 2002, BMJ, V325, P491; Alvarez-Cuesta E, 2008, ALLERGY, V63, P939, DOI 10.1111/j.1398-9995.2008.01648.x; Alvarez-Cuesta E, 2007, ALLERGY, V62, P810, DOI 10.1111/j.1398-9995.2007.01365.x; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Antunez C, 2008, PEDIATR ALLERGY IMMU, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Atkins D, 2004, BMJ-BRIT MED J, V328, P1490; Atkins D, 2005, BMC HEALTH SERV RES, V5, DOI 10.1186/1472-6963-5-25; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Baena-Cagnani CE, 2007, CURR OPIN ALLERGY CL, V7, P201, DOI 10.1097/ACI.0b013e3280895d36; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; Bagnasco M, 2005, INT ARCH ALLERGY IMM, V138, P197, DOI 10.1159/000088719; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; BAGNASCO M, 1997, J ALLERGY CLIN IMMUN, V100, P121; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bahima AC, 2004, J INVEST ALLERG CLIN, V14, P17; Baptist AP, 2004, ANN ALLERG ASTHMA IM, V93, P227; Barber D, 2008, ALLERGY, V63, P1550, DOI 10.1111/j.1398-9995.2008.01807.x; Barton S, 2000, BRIT MED J, V321, P255, DOI 10.1136/bmj.321.7256.255; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Bernardini R, 2006, CURR MED RES OPIN, V22, P1515, DOI 10.1185/030079906X115711; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Berto P, 2008, CURR MED RES OPIN, V24, P261, DOI 10.1185/030079908X253726; Berto P, 2008, CURR OPIN ALLERGY CL, V8, P585, DOI 10.1097/ACI.0b013e32831411e9; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Black JH, 1927, J LAB CLIN MED, V12, P1156; Black JH, 1928, J LAB CLIN MED, V13, P709; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Blumberga G, 2006, ALLERGY, V61, P843, DOI 10.1111/j.1398-9995.2006.01088.x; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2008, ALLERGY, V63, P1, DOI 10.1111/j.1398-9995.2007.01594.x; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2008, ALLERGY S, V86, P8; BOUSQUET P, 2009, ALLERGY IN PRESS; Bousquet PJ, 2008, ALLERGY, V63, P341, DOI 10.1111/j.1398-9995.2007.01581.x; Bousquet PJ, 2007, CURR OPIN ALLERGY CL, V7, P561; Boutron I, 2008, ANN INTERN MED, V148, P295; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; *BRIT MED J GROUP, 2008, DRUG THER B, V46, P9; Brown EG, 1999, DRUG SAFETY, V20, P109, DOI 10.2165/00002018-199920020-00002; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; Bruggenjurgen B, 2008, ANN ALLERG ASTHMA IM, V101, P316, DOI 10.1016/S1081-1206(10)60498-X; Bufe A, 2008, J ALLERGY CLIN IMMUN, V121, pS127, DOI 10.1016/j.jaci.2007.12.507; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Cadario G, 2007, CURR MED RES OPIN, V23, P2503, DOI 10.1185/030079907X226096; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Canonica GW, 2007, RESP MED, V101, P1885, DOI 10.1016/j.rmed.2007.05.003; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Casanovas M, 2007, CLIN EXP ALLERGY, V37, P434, DOI 10.1111/j.1365-2222.2007.02667.x; Caubet JC, 2008, ALLERGY, V63, P1561, DOI 10.1111/j.1398-9995.2008.01868.x; Charron M, 2006, J NURS CARE QUAL, V21, P187; Ciprandi G, 2008, ALLERGY, V63, P945, DOI 10.1111/j.1398-9995.2008.01727.x; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Ciprandi G, 2006, INT IMMUNOPHARMACOL, V6, P1370, DOI 10.1016/j.intimp.2006.03.007; Clark J, 2007, ALLERGY, V62, P1023, DOI 10.1111/j.1398-9995.2007.01469.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Cohen S., 2008, ALLERGENS ALLERGEN I, P1; Coifman RE, 2007, J ALLERGY CLIN IMMUN, V119, P1012, DOI 10.1016/j.jaci.2007.01.029; Committee for Medicinal Products for Human Use, 2008, CHMPEWP185042006 COM; Committee on the safety of medicines, 1986, BRIT MED J, V293, P948, DOI 10.1136/bmj.293.6552.948; Committee on the Safety of Medicines (CSM) in Great Britain, 1986, BR MED J CLIN RES ED, V293, P948; Compalati E, 2009, ALLERGY, V64, P1570, DOI 10.1111/j.1398-9995.2009.02129.x; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; COX L, 2009, ALLERGY IN PRESS; Cox L, 2008, J ALLERGY CLIN IMMUN, V122, P432, DOI 10.1016/j.jaci.2008.06.007; Cox L, 2007, CURR ALLERGY ASTHM R, V7, P410, DOI 10.1007/s11882-007-0063-6; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; *CPMP, 2008, EMEACHMPBWP304831200; *CPMP, EMEACPMPBWP304831200; CRAIG T, 1998, AM FAM PHYS     0415; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Cruz AA, 2007, ALLERGY, V62, P1, DOI 10.1111/j.1398-9995.2007.01551.x; Cuervo LG, 2003, BRIT MED J, V327, P65, DOI 10.1136/bmj.327.7406.65; Curtis HH, 1900, MED NEWS, V77, P16; D'Ambrosio F P, 1996, Allergol Immunopathol (Madr), V24, P146; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; De Blay F, 2007, ANN ALLERG ASTHMA IM, V99, P453; de Boissieu D, 2006, ALLERGY, V61, P1238, DOI 10.1111/j.1398-9995.2006.01196.x; de Bot CMA, 2008, BMC FAM PRACT, V9, DOI 10.1186/1471-2296-9-59; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Elstein AS, 2002, BRIT MED J, V324, P729, DOI 10.1136/bmj.324.7339.729; European Medicine Agency (EMEA), 2008, CHMPEWP185042006 EME; [Anonymous], 2008, CHMPBWP3048312007 EM; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Enrique E, 2006, CURR OPIN ALLERGY CL, V6, P466; Ernst E, 2001, BRIT MED J, V323, P546, DOI 10.1136/bmj.323.7312.546; Esch RE, 2008, J ALLERGY CLIN IMMUN, V121, pS127, DOI 10.1016/j.jaci.2007.12.505; Esch RE, 2008, CURR OPIN OTOLARYNGO, V16, P260, DOI 10.1097/MOO.0b013e3282fc706f; Esch RE, 2008, ANN ALLERG ASTHMA IM, V100, P475, DOI 10.1016/S1081-1206(10)60474-7; ETAC Study Group, 1998, PEDIAT ALLERGY IMMUN, V9, P116; Fairall LR, 2005, BRIT MED J, V331, P750, DOI 10.1136/bmj.331.7519.750; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; FELIZIANI V, 1995, ALLERGOL IMMUNOPATH, V23, P173; Fenoglio D, 2005, Eur Ann Allergy Clin Immunol, V37, P147; Fernandez-Rivas M, 2009, ALLERGY, V64, P876, DOI 10.1111/j.1398-9995.2008.01921.x; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Freeman J, 1911, LANCET, V2, P814; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GEORGITIS JW, 1986, INT ARCH ALLER A IMM, V81, P170; Global Initiative for Asthma (GINA), 2012, NHLBI WHO WORKSH REP; *GLOB PROGR EV HLT, 2003, EIPGPEEQC20031 FLOB; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Gozalo F, 1997, Allergol Immunopathol (Madr), V25, P219; Guerra Laura, 2006, Allergol Immunopathol (Madr), V34, P82, DOI 10.1016/S0301-0546(06)73518-2; Guerra S, 2005, ALLERGY, V60, P343, DOI 10.1111/j.1398-9995.2005.00717.x; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Gupta R, 2003, BRIT MED J, V327, P1142, DOI 10.1136/bmj.327.7424.1142; GUYATT G, 2005, EMERGING CONSENSUS G; Halken S, 2008, PEDIAT ALLERG IMM-UK, V19, P60, DOI 10.1111/j.1399-3038.2008.00768.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; HAUBRICH WS, 2004, MED MEANINGS GLOSSAR, P10; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Herland K, 2005, RESP MED, V99, P11, DOI 10.1016/j.rmed.2004.03.026; Herxeimer H, 1951, INT ARCH ALLER A IMM, V40, P40; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P159; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hollis S, 1999, BRIT MED J, V319, P670; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; HORIGUCHI S, 2007, INT ARCH ALLERGY IMM, V146, P76; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Houston D, 2008, MOL INTERV, V8, P160, DOI 10.1124/mi.8.4.3; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; JAMES TL, 2003, ANN ALLERG ASTHMA IM, V90, P2; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Joint Task Force on Practice Parameters; American Academy of Allergy Asthma and Immunology; American College of Allergy Asthma and Immunology; and Joint Council of Allergy Asthma and Immunology, 2007, J ALLERGY CLIN IMM S, V120, pS25; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; KRAMER J, J HEALTHC QUAL; KRAMER J, 2003, J HLTH QUAL, V25, P13; Kramer Joan, 2003, J Healthc Qual, V25, P8; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Larenas-Linnemann D, 2009, PEDIATR ALLERGY IMMU, V20, P399, DOI 10.1111/j.1399-3038.2008.00809.x; Larsen TH, 2006, ALLERGY, V61, P1173, DOI 10.1111/j.1398-9995.2006.01203.x; Leynaert Benedicte, 2004, Journal of Allergy and Clinical Immunology, V113, P86, DOI 10.1016/j.jaci.2003.10.010; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Limb SL, 2006, INT ARCH ALLERGY IMM, V140, P245, DOI 10.1159/000093250; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lombardi C, 2008, ALLERGY, V63, P375, DOI 10.1111/j.1398-9995.2007.01608.x; Lombardi C, 2001, RESP MED, V95, P9, DOI 10.1053/rmed.2000.0945; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; LOMBARDI C, 2004, J ALLERGY CLIN IMMUN, V113, P219; Lorenz AR, 2008, INT ARCH ALLERGY IMM, V147, P263, DOI 10.1159/000146074; LORENZ AR, 2008, INT ARCH ALLERGY IMM, V148, P1; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Malling HJ, 2006, ALLERGY, V61, P24, DOI 10.1111/j.1398-9995.2006.01158.x; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MALLING HJ, 1993, ALLERGY, V48, P9; Malling HJ, 1993, ALLERGY, V14, P9; Malling H-J, 1988, ALLERGY S6, V43, P9; Marcucci F, 2007, ALLERGY, V62, P1475, DOI 10.1111/j.1398-9995.2007.01519.x; Marcucci F, 2005, ALLERGY, V60, P952, DOI 10.1111/j.1398-9995.2005.00786.x; Marcucci F, 2001, ALLERGY, V56, P1091, DOI 10.1034/j.1398-9995.2001.00226.x; Markert UR, 2003, CHEM IMMUNOL, V82, P127; Marogna M, 2006, ALLERGY, V61, P1209, DOI 10.1111/j.1398-9995.2006.01164.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Marogna M., 2007, 26 EAACI M GOT, P276; Marogna M, 2008, ANN ALLERG ASTHMA IM, V101, P206; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274; Marogna M, 2007, INT ARCH ALLERGY IMM, V142, P70, DOI 10.1159/000096001; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; METHA SB, 1975, CLIN ALLERGY, V5, P279; Mosges R, 2007, ALLERGY, V62, P969, DOI 10.1111/j.1398-9995.2007.01440.x; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Moreno-Ancillo A, 2007, J INVEST ALLERG CLIN, V17, P399; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Mosges R, 2007, Acta Dermatovenerol Alp Pannonica Adriat, V16, P143; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nasser S, 2008, ALLERGY, V63, P1624, DOI 10.1111/j.1398-9995.2008.01743.x; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Nettis E, 2007, BRIT J DERMATOL, V156, P674, DOI 10.1111/j.1365-2133.2006.07738.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; Niggemann B, 2008, PEDIAT ALLERG IMM-UK, V19, P325, DOI 10.1111/j.1399-3038.2007.00651.x; NINAN TK, 1992, BRIT MED J, V304, P873; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Noon L, 1911, LANCET, V1, P1572; NORMAN PS, 1968, J ALLERGY, V42, P93, DOI 10.1016/0021-8707(68)90139-1; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novak N, 2001, J IMMUNOL, V167, P797; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Nuhoglu Y, 2007, J INVEST ALLERG CLIN, V17, P375; O'Hehir RE, 2009, AM J RESP CRIT CARE, V180, P936, DOI 10.1164/rccm.200905-0686OC; OKUBO S, 2008, ALLERGOL INT, V57, P265; Omnes LF, 2007, ALLERG IMMUNOL PARIS, V39, P148; Ott H, 2009, ALLERGY, V64, P179, DOI 10.1111/j.1398-9995.2008.01875.x; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2005, J ALLERGY CLIN IMMUN, V116, P1380, DOI 10.1016/j.jaci.2005.07.034; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V120, P164, DOI 10.1016/j.jaci.2007.04.008; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; Palma-Carlos A G, 2006, Allergol Immunopathol (Madr), V34, P194, DOI 10.1157/13094026; Panzner P, 2008, RESP MED, V102, P1296, DOI 10.1016/j.rmed.2008.03.024; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1395-9995.2006.01098.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461; Passalacqua Giovanni, 2006, Treat Respir Med, V5, P225, DOI 10.2165/00151829-200605040-00001; Passalacqua G, 2007, PEDIATR ALLERGY IMMU, V18, P58, DOI 10.1111/j.1399-3038.2006.00471.x; Passalacqua G, 2007, J ALLERGY CLIN IMMUN, V119, P881, DOI 10.1016/j.jaci.2007.01.045; Passalacqua Giovanni, 2007, Curr Drug Saf, V2, P117, DOI 10.2174/157488607780598340; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Petticrew M, 2002, BRIT MED J, V324, P545; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256; Pham-Thi N, 2007, PEDIATR ALLERGY IMMU, V18, P47, DOI 10.1111/j.1399-3038.2006.00475.x; Pharande RR, 2007, INDIAN J VIROL, V18, P57; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Pilette C, 2007, J IMMUNOL, V178, P4658; Platts-Mills T, 2007, AM FAM PHYSICIAN, V76, P675; Pokladnikova J, 2008, ANN ALLERG ASTHMA IM, V100, P482, DOI 10.1016/S1081-1206(10)60475-9; PORTNOY J, 1994, ANN ALLERGY, V73, P409; POTTER PC, 2009, WORLD ALLERGY ORG J, V2, P50; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Price David, 2006, Prim Care Respir J, V15, P58, DOI 10.1016/j.pcrj.2005.11.002; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rak S, 2007, QUAL LIFE RES, V16, P191, DOI 10.1007/s11136-006-9110-3; REBIEN W, 1980, Allergologie, V3, P101; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Rienzo VD, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Roder E, 2008, CLIN EXP ALLERGY, V38, P1659, DOI 10.1111/j.1365-2222.2008.03060.x; Roder E, 2008, PEDIATR ALLERGY IMMU, V19, P197, DOI 10.1111/j.1399-3038.2007.00648.x; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rodriguez-Perez N, 2008, ANN ALLERG ASTHMA IM, V101, P304; RODRIGUEZSANTOS O, 2008, REV ALERGIA MEXICO, V55, P71; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Rossi RE, 2005, INT J IMMUNOPATH PH, V18, P277; Ryan D, 2008, ALLERGY, V63, P981, DOI 10.1111/j.1398-9995.2008.01653.x; Ryan Dermot, 2005, Prim Care Respir J, V14, P195, DOI 10.1016/j.pcrj.2005.01.003; Ryan Dermot, 2005, Prim Care Respir J, V14, P204, DOI 10.1016/j.pcrj.2005.03.009; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Sackett DL, 1995, J ROY SOC MED, V88, P620; Sackett D. L., 2000, EVIDENCE BASED MED P; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sander I, 2009, ALLERGY, V64, P1486, DOI 10.1111/j.1398-9995.2009.02040.x; Saporta D, 2007, ENT-EAR NOSE THROAT, V86, P493; Savolainen J, 2007, ALLERGY, V62, P949, DOI 10.1111/j.1398-9995.2007.01426.x; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; Schunemann HJ, 2006, AM J RESP CRIT CARE, V174, P605, DOI 10.1164/rccm.200602-197ST; Schulz KF, 2002, JAMA-J AM MED ASSOC, V288, P831; Sculpher M, 2006, ALLERGY, V61, P527, DOI 10.1111/j.1398-9995.2006.01053.x; Severino MG, 2008, J ALLERGY CLIN IMMUN, V122, P44, DOI 10.1016/j.jaci.2008.03.031; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Shehata Yasser, 2007, Prim Care Respir J, V16, P16, DOI 10.3132/pcrj.2007.00004; Shekelle PG, 1999, BRIT MED J, V318, P593; SHERMAN WILLIAM B., 1940, JOUR ALLERGY, V11, P225, DOI 10.1016/S0021-8707(40)90568-8; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI 10.1016/j.jaci.2007.05.001; Simons FE, 2007, PEDIAT ALLERGY IMMUN, V18, P535, DOI 10.1111/j.1399-3038.2007.00558.x; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Sopo SM, 2004, ARCH DIS CHILD, V89, P620, DOI 10.1136/adc.2003.030411; Spergel JM, 2005, CURR OPIN ALLERGY CL, V5, P17, DOI 10.1097/00130832-200502000-00005; Stelmach I, 2009, CLIN EXP ALLERGY, V39, P401, DOI 10.1111/j.1365-2222.2008.03159.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; Stokes JR, 2006, AM J MED, V119, P820, DOI 10.1016/j.amjmed.2006.02.019; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tahamiler R, 2007, LARYNGOSCOPE, V117, P965, DOI 10.1097/MLG.0b013e31804f8141; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TAUDORF E, 1983, ALLERGY, V38, P561, DOI 10.1111/j.1398-9995.1983.tb04140.x; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; Till S, 1997, CLIN EXP IMMUNOL, V110, P114, DOI 10.1111/j.1365-2249.1997.494-ce1392.x; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Toren K, 2002, RESP MED, V96, P635, DOI 10.1053/rmed.2002.1319; TOWNLEY R G, 1975, Journal of Allergy and Clinical Immunology, V56, P429, DOI 10.1016/0091-6749(75)90061-5; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; URBANEK R, 1982, MONATSSCHR KINDERH, V130, P150; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; Van Ree R, 2008, ALLERGY, V63, P310, DOI 10.1111/j.1398-9995.2007.01612.x; van Weel C, 2008, ALLERGY, V63, P1005, DOI 10.1111/j.1398-9995.2008.01655.x; van Wijk RG, 2008, EXPERT OPIN BIOL TH, V8, P291, DOI 10.1517/14712598.8.3.291 ; VANWILSEM EJG, 1994, IMMUNOLOGY, V83, P128; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Vervloet D, 2007, INT ARCH ALLERGY IMM, V142, P239, DOI 10.1159/000097026; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; von Bubnoff D, 2002, J IMMUNOL, V169, P1810; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; Weber RW, 2008, PRIMARY CARE, V35, P1, DOI 10.1016/j.pop.2007.09.001; *WHO NHLBI, 2007, WHO NHLBI WORKSH REP; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; WILSON DR, 2005, ALLERGY, V60, P1; Wilson DR, 2005, ALLERGY, V60, P3; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI 10.1067/mai.2003.1411; 1996, INT C HARM TOP E 3 S; 1989, LANCET, V1, P259; 2000, INT C HARM TOP E10 I; 2008, DRUG THER B, V46, P9; 2007, J ALLERGY CLIN IM S3, V120, pS25	391	248	266	1	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy		2009	64			91			1	59				59	Allergy; Immunology	Allergy; Immunology	543XT	WOS:000273614800001	20041860	
J	Gauderman, WJ; Avol, E; Lurmann, F; Kuenzli, N; Gilliland, F; Peters, J; McConnell, R				Gauderman, WJ; Avol, E; Lurmann, F; Kuenzli, N; Gilliland, F; Peters, J; McConnell, R			Childhood asthma and exposure to traffic and nitrogen dioxide	EPIDEMIOLOGY			English	Article							SOUTHERN CALIFORNIA CHILDREN; AIR-POLLUTION; BRONCHITIC SYMPTOMS; PRESCHOOL-CHILDREN; RESPIRATORY HEALTH; SCHOOL-CHILDREN; ATOPY; ROAD; PREVALENCE; PARTICLES	Background: Evidence for a causal relationship between traffic-related air pollution and asthma has not been consistent across studies, and comparisons among studies have been difficult because of the use of different indicators of exposure. Methods: We examined the association between traffic-related pollution and childhood asthma in 208 children from 10 southern California communities using multiple indicators of exposure. Study subjects were randomly selected from participants in the Children's Health Study. Outdoor nitrogen dioxide (NO2) was measured in summer and winter outside the home of each child. We also determined residential distance to the nearest freeway, traffic volumes on roadways within 150 meters, and model-based estimates of pollution from nearby roadways. Results: Lifetime history of doctor-diagnosed asthma was associated with outdoor NO2; the odds ratio (OR) was 1.83 (95% confidence interval = 1.04-3.22) per increase of 1 interquartile range (IQR = 5.7 ppb) in exposure. We also observed increased asthma associated with closer residential distance to a freeway (1.89 per IQR; 1.19-3.02) and with model-based estimates of outdoor pollution from a freeway (2.22 per IQR; 1.36-3.63). These 2 indicators of freeway exposure and measured NO2 concentrations were also associated with wheezing and use of asthma medication. Asthma was not associated with traffic volumes on roadways within 150 meters of homes or with model-based estimates of pollution from nonfreeway roads. Conclusions: These results indicate that respiratory health in children is adversely affected by local exposures to outdoor NO2 or other freeway-related pollutants.	Univ So Calif, Dept Prevent Med, Keck Sch Med, Los Angeles, CA 90089 USA; Sonoma Technol Inc, Petaluma, CA USA	Gauderman, WJ (reprint author), Univ So Calif, Dept Prevent Med, Keck Sch Med, 1540 Alcazar St,Suite 220, Los Angeles, CA 90089 USA.	jimg@use.edu	Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	NIEHS NIH HHS [1P01ES11627, 5P30 ES07048]		Alm S, 1998, J EXPO ANAL ENV EPID, V8, P79; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P243, DOI 10.2307/3432380; BENSEN PE, 1989, CALINE4 DISPERSION M; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Clark NM, 1999, ENVIRON HEALTH PERSP, V107, P421; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Linaker CH, 2000, THORAX, V55, P930, DOI 10.1136/thorax.55.11.930; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Nicolai T, 1999, Pediatr Pulmonol Suppl, V18, P9; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258; Samet JM., 1987, CHEST, V91, P74; Seaton A, 2003, THORAX, V58, P1012, DOI 10.1136/thorax.58.12.1012; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Trainer M, 2000, ATMOS ENVIRON, V34, P2045, DOI 10.1016/S1352-2310(99)00459-8; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WJST M, 1993, BRIT MED J, V307, P596; Wu J, 2005, ATMOS ENVIRON, V39, P259, DOI 10.1016/j.atmosenv.2004.09.061; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	40	248	257	4	46	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	NOV	2005	16	6					737	743		10.1097/01.ede.00001813087.51440.75		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	976CD	WOS:000232709500004	16222162	
J	Hellings, PW; Kasran, A; Liu, ZJ; Vandekerckhove, P; Wuyts, A; Overbergh, L; Mathieu, C; Ceuppens, JL				Hellings, PW; Kasran, A; Liu, ZJ; Vandekerckhove, P; Wuyts, A; Overbergh, L; Mathieu, C; Ceuppens, JL			Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							TUMOR-NECROSIS-FACTOR; NEUTROPHIL RECRUITMENT; HUMAN KERATINOCYTES; EPITHELIAL-CELLS; TNF-ALPHA; IN-VIVO; T-CELL; CHEMOTACTIC PROTEIN-2; IL-17; EXPRESSION	Interleukin (IL)-17 is produced by activated memory CD4(+) cells and induces cytokines and chemokines that stimulate neutrophil generation and recruitment. Here, we investigated the involvement of IL-17 in the bronchial influx of neutrophils in experimental allergic asthma. Inhalation of nebulized ovalbumin (OVA) by sensitized mice with bronchial eosinophilic inflammation resulting from chronic OVA exposure induced early IL-17 mRNA expression in inflamed lung tissue, concomitant with a prominent bronchial neutrophilic influx. Anti-IL-17 monoclonal antibodies (mAb) injected before allergen inhalation strongly reduced bronchial neutrophilic influx, in a manner equally as potent as the anti-inflammatory dexamethasone. Remarkably, anti-IL-17 mAb significantly enhanced IL-5 levels in both BAL fluid and serum, and aggravated allergen-induced bronchial eosinophilia. In another series of experiments, anti-IL-17 mAb were given repeatedly during the inhalatory challenge phase with OVA of sensitized mice. This treatment regimen abated bronchial neutrophilia in parallel with reduction of bone marrow and blood neutrophilia. In addition, anti-IL-17 mAb treatment elevated eosinophil counts in the bone marrow and bronchial IL-5 production, without alteration of allergen-induced bronchial hyperresponsiveness. In summary, our results demonstrate that IL-17 expression in airways is upregulated upon allergen inhalation, and constitutes the link between allergen-induced T cell activation and neutrophilic influx. Because neutrophils may be important in airway remodeling in chronic severe asthma, targeting IL-17 may hold therapeutic potential in human asthma.	Katholieke Univ Leuven, Fac Med, Univ Hosp, Lab Expt Immunol,Dept Otorhinolaryngol Head & Nec, Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Univ Hosp, Hematol Lab, Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Univ Hosp, Lab Mol Immunol,Rega Inst, Louvain, Belgium; Katholieke Univ Leuven, Fac Med, Univ Hosp, Lab Expt Geneeskunde & Endocrinol,Dept Internal M, Louvain, Belgium	Ceuppens, JL (reprint author), Univ Hosp Gasthuisberg, Expt Immunol Lab, Onderwijs & Navorsing, Herestr 49, B-3000 Louvain, Belgium.						Aarvak T, 1999, J IMMUNOL, V162, P1246; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Albanesi C, 1999, J IMMUNOL, V162, P494; Antonysamy MA, 1999, J IMMUNOL, V162, P577; Awane M, 1999, J IMMUNOL, V162, P5337; BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cai XY, 1998, IMMUNOL LETT, V62, P51, DOI 10.1016/S0165-2478(98)00027-3; Carroll N, 1996, EUR RESPIR J, V9, P709, DOI 10.1183/09031936.96.09040709; Chabaud M, 1998, J IMMUNOL, V161, P409; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Chung DR, 2002, J EXP MED, V195, P1471, DOI 10.1084/jem.20020028; DENIS M, 1994, AM J RESP CELL MOL, V10, P658; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Hellings PW, 2002, EUR J IMMUNOL, V32, P585, DOI 10.1002/1521-4141(200202)32:2<585::AID-IMMU585>3.0.CO;2-U; Hellings PW, 2001, CLIN EXP ALLERGY, V31, P782, DOI 10.1046/j.1365-2222.2001.01081.x; Hoshino H, 2000, J ALLERGY CLIN IMMUN, V105, P143, DOI 10.1016/S0091-6749(00)90189-1; Infante-Duarte C, 2000, J IMMUNOL, V165, P6107; Jovanovic DV, 1998, J IMMUNOL, V160, P3513; Karin M, 1996, PHILOS T ROY SOC B, V351, P127, DOI 10.1098/rstb.1996.0008; Kennedy J, 1996, J INTERF CYTOK RES, V16, P611, DOI 10.1089/jir.1996.16.611; KIM KC, 1989, AM J RESP CELL MOL, V1, P137; Laan M, 1999, J IMMUNOL, V162, P2347; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394; Liu H, 1999, AM J PHYSIOL-LUNG C, V276, pL28; Matusevicius D, 1999, MULT SCLER, V5, P101, DOI 10.1191/135245899678847275; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; PAUWELS RA, 1990, AM REV RESPIR DIS, V141, P540; Pelidou SH, 2000, EXP NEUROL, V163, P165, DOI 10.1006/exnr.2000.7357; PERSSON CGA, 1986, LANCET, V2, P1126; Renzi PM, 1996, AM J RESP CRIT CARE, V153, P1214; ROUVIER E, 1993, J IMMUNOL, V150, P5445; Schwandner R, 2000, J EXP MED, V191, P1233, DOI 10.1084/jem.191.7.1233; Schwarzenberger P, 1998, J IMMUNOL, V161, P6383; SUR S, 1993, AM REV RESPIR DIS, V148, P713; Tartour E, 1999, CANCER RES, V59, P3698; Teunissen MBM, 1998, J INVEST DERMATOL, V111, P645, DOI 10.1046/j.1523-1747.1998.00347.x; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; Witowski J, 2000, J IMMUNOL, V165, P5814; Wuyts A, 1999, J IMMUNOL, V163, P6155; Wuyts A, 1996, J IMMUNOL, V157, P1736; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Yao Zhengbin, 1995, Journal of Immunology, V155, P5483; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519; Ziolkowska M, 2000, J Immunol, V164, P2832	51	248	273	1	12	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	JAN	2003	28	1					42	50		10.1165/rcmb.4832		9	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	630VU	WOS:000180131500007	12495931	
J	Bowler, RP; Crapo, JD				Bowler, RP; Crapo, JD			Oxidative stress in allergic respiratory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						antioxidants; asthma; superoxide dismutase; oxidative stress	EXTRACELLULAR-SUPEROXIDE DISMUTASE; EXHALED HYDROGEN-PEROXIDE; OXYGEN RADICAL PRODUCTION; NITRIC-OXIDE SYNTHASE; AIRWAY SMOOTH-MUSCLE; ASTHMATIC-PATIENTS; ATOPIC-DERMATITIS; NITROTYROSINE FORMATION; ANTIOXIDANT STATUS; BREATH CONDENSATE	There is ample evidence that allergic disorders, such as asthma, rhinitis, and atopic dermatitis, are mediated by oxidative stress. Excessive exposure to reactive oxygen and nitrogen species is the hallmark of oxidative stress and leads to damage of proteins, lipids, and DNA. Oxidative stress occurs not only as a result of inflammation but also from environmental exposure to air pollution and cigarette smoke. The specific localization of antioxidant enzymes in the lung and the rapid reaction of nitric oxide with reactive oxygen species, such as superoxide, suggest that antioxidant enzymes might also function as cell-signaling agents or regulators of cell signaling. Therapeutic interventions that decrease exposure to environmental reactive oxygen species or augment endogenous antioxidant defenses might be beneficial as adjunctive therapies for allergic respiratory disorders.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	Bowler, RP (reprint author), Natl Jewish Med & Res Ctr, K736A,1400 Jackson St, Denver, CO 80206 USA.				NHLBI NIH HHS [HL-04407, HL-31992, HL-42444]		ABE MK, 1994, AM J RESP CELL MOL, V11, P577; Andersson JA, 2002, CLIN EXP ALLERGY, V32, P224, DOI 10.1046/j.1365-2222.2002.00532.x; Arnal JF, 1997, CLIN EXP ALLERGY, V27, P358; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Ashutosh K, 2000, Curr Opin Pulm Med, V6, P21, DOI 10.1097/00063198-200001000-00005; Azumi H, 1999, CIRCULATION, V100, P1494; BARNES PJ, 1995, MOL MED TODAY, V1, P149, DOI 10.1016/S1357-4310(95)80093-X; Briganti S, 2001, CLIN EXP DERMATOL, V26, P284, DOI 10.1046/j.1365-2230.2001.00817.x; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V93, P108, DOI 10.1016/0091-6749(94)90239-9; DEMOLY P, 1995, ANN ALLERG ASTHMA IM, V75, P162; Dworski R, 2001, CLIN EXP ALLERGY, V31, P387, DOI 10.1046/j.1365-2222.2001.01055.x; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Epperlein MM, 1996, INT J EXP PATHOL, V77, P197, DOI 10.1046/j.1365-2613.1996.9930331.x; Evans DJ, 1996, EUR RESPIR J, V9, P703, DOI 10.1183/09031936.96.09040703; Fang KH, 2000, AM J PHYSIOL-LUNG C, V279, pL716; Frieri M, 1998, ALLERGY ASTHMA PROC, V19, P349, DOI 10.2500/108854198778612708; GAILLARD MC, 1992, AM REV RESPIR DIS, V145, P1311; Ganas K, 2001, RESP MED, V95, P649, DOI 10.1053/rmed.2001.1117; Gilmour MI, 1995, TOXICOLOGY, V105, P335, DOI 10.1016/0300-483X(95)03230-D; GOEPTAR AR, 1995, CRIT REV TOXICOL, V25, P25, DOI 10.3109/10408449509089886; HALLIWELL B., 1999, FREE RADICALS BIOL M; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; Heinecke JW, 2000, J CLIN INVEST, V105, P1331, DOI 10.1172/JCI10072; Horvath I, 1999, CLIN EXP ALLERGY, V29, P1276; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701; Iijima MK, 2001, TOXICOL LETT, V123, P77, DOI 10.1016/S0378-4274(01)00392-7; IKUTA N, 1992, AM REV RESPIR DIS, V145, P561; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747; Kang BH, 2000, EUR ARCH OTO-RHINO-L, V257, P242, DOI 10.1007/s004050050231; KATSUMATA U, 1990, AM REV RESPIR DIS, V141, P1158; Kaur BRB, 2001, COCHRANE DB SYST REV, V4; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; KHARITONOV SA, 1995, CHEST, V107, pS156, DOI 10.1378/chest.107.3_Supplement.156S; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; Kopp MV, 1999, EUR RESPIR J, V14, P854, DOI 10.1034/j.1399-3003.1999.14d22.x; Kuratsuji T, 1987, Acta Paediatr Jpn, V29, P680; MacPherson JC, 2001, J IMMUNOL, V166, P5763; Marshall HE, 2000, AM J RESP CRIT CARE, V161, P685; Marumo T, 1998, HYPERTENSION, V32, P1083; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Merenyi G, 1998, CHEM RES TOXICOL, V11, P712, DOI 10.1021/tx980043h; Monma M, 1999, CLIN EXP ALLERGY, V29, P1537; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; NAKAYAMA T, 1989, FREE RADICAL BIO MED, V7, P9, DOI 10.1016/0891-5849(89)90094-4; NIJKAMP FP, 1990, AM REV RESPIR DIS, V141, pS145; OGASAWARA H, 1991, Auris Nasus Larynx, V18, P133; OLUSI SO, 1979, CLIN CHIM ACTA, V92, P161, DOI 10.1016/0009-8981(79)90110-4; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 2001, AM J RESP CELL MOL, V25, P164; Oury TD, 1996, FREE RADICAL BIO MED, V20, P957, DOI 10.1016/0891-5849(95)02222-8; Paredi P, 2000, AM J RESP CRIT CARE, V162, P1450; POLLA BS, 1992, J ALLERGY CLIN IMMUN, V89, P545, DOI 10.1016/0091-6749(92)90321-R; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; Quinlan GJ, 1997, AM J RESP CRIT CARE, V155, P479; REYNOLDS HY, 1974, J LAB CLIN MED, V84, P559; RHODEN KJ, 1989, BRIT J PHARMACOL, V98, P325; Riediker M, 2001, ANN ALLERG ASTHMA IM, V87, P311; Rowe A, 1997, BRIT J DERMATOL, V136, P18, DOI 10.1111/j.1365-2133.1997.tb08740.x; RUBBO H, 1994, J BIOL CHEM, V269, P26066; SADEGHIHASHJIN G, 1996, AM J RESP CRIT CARE, V153, P697; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725; Sato M, 1998, CLIN EXP ALLERGY, V28, P597; SEDGWICK JB, 1990, AM REV RESPIR DIS, V142, P120; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; STEWART RM, 1981, RESP PHYSIOL, V45, P333, DOI 10.1016/0034-5687(81)90016-5; Su WY, 1997, AM J RESP CELL MOL, V16, P162; Taniuchi S, 2001, ALLERGY, V56, P693, DOI 10.1034/j.1398-9995.2001.00131.x; Teramoto S, 1996, J ASTHMA, V33, P149, DOI 10.3109/02770909609054546; THANNICKAL VJ, 2000, AM J PHYSL LUNG CELL, V279; TING S, 1983, J ASTHMA, V20, P39, DOI 10.3109/02770908309070911; Tokimoto T, 2001, BIOL CHEM, V382, P1613, DOI 10.1515/BC.2001.196; Tsuboi H, 1998, BRIT J DERMATOL, V138, P1033; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161; VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585; van der Vliet A, 1999, AM J PHYSIOL-LUNG C, V276, pL289; Vural H, 2000, Can Respir J, V7, P476; WINSTON GW, 1993, ARCH BIOCHEM BIOPHYS, V304, P371, DOI 10.1006/abbi.1993.1364; Woschnagg C, 1996, CLIN EXP ALLERGY, V26, P1064, DOI 10.1046/j.1365-2222.1996.d01-408.x; Wright DT, 1996, AM J PHYSIOL-LUNG C, V271, pL854; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Yamaya M, 2001, CLIN EXP ALLERGY, V31, P417, DOI 10.1046/j.1365-2222.2001.01013.x	85	248	257	4	22	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					349	356		10.1067/mai.2002.126780		8	Allergy; Immunology	Allergy; Immunology	592KM	WOS:000177936900002	12209079	
J	Plantinga, M; Guilliams, M; Vanheerswynghels, M; Deswarte, K; Branco-Madeira, F; Toussaint, W; Vanhoutte, L; Neyt, K; Killeen, N; Malissen, B; Hammad, H; Lambrecht, BN				Plantinga, Maud; Guilliams, Martin; Vanheerswynghels, Manon; Deswarte, Kim; Branco-Madeira, Filipe; Toussaint, Wendy; Vanhoutte, Leen; Neyt, Katrijn; Killeen, Nigel; Malissen, Bernard; Hammad, Hamida; Lambrecht, Bart N.			Conventional and Monocyte-Derived CD11b(+) Dendritic Cells Initiate and Maintain T Helper 2 Cell-Mediated Immunity to House Dust Mite Allergen	IMMUNITY			English	Article							CHEMOKINE RECEPTOR CCR2; AIRWAY INFLAMMATION; TH2 RESPONSES; INHALED ALLERGENS; VIRAL-INFECTION; LYMPH-NODES; BONE-MARROW; URIC-ACID; T-CELLS; MICE	Dendritic cells (DCs) are crucial for mounting allergic airway inflammation, but it is unclear which subset of DCs performs this task. By using CD64 and MAR-1 staining, we reliably separated CD11b(+) monocyte-derived DCs (moDCs) from conventional DCs (cDCs) and studied antigen uptake, migration, and presentation assays of lung and lymph node (LN) DCs in response to inhaled house dust mite (HDM). Mainly CD11b(+) cDCs but not CD103(+) cDCs induced T helper 2 (Th2) cell immunity in HDM-specific T cells in vitro and asthma in vivo. Studies in Flt3l(-/-) mice, lacking all cDCs, revealed that moDCs were also sufficient to induce Th2 cell-mediated immunity but only when high-dose HDM was given. The main function of moDCs was the production of proinflammatory chemokines and allergen presentation in the lung during challenge. Thus, we have identified migratory CD11b(+) cDCs as the principal subset inducing Th2 cell-mediated immunity in the LN, whereas moDCs orchestrate allergic inflammation in the lung.	[Plantinga, Maud; Guilliams, Martin; Vanheerswynghels, Manon; Deswarte, Kim; Branco-Madeira, Filipe; Toussaint, Wendy; Vanhoutte, Leen; Neyt, Katrijn; Hammad, Hamida; Lambrecht, Bart N.] VIB, Dept Mol Biomed Res, Lab Immunoregulat & Mucosal Immunol, B-9050 Ghent, Belgium; [Plantinga, Maud; Deswarte, Kim; Branco-Madeira, Filipe; Toussaint, Wendy; Vanhoutte, Leen; Neyt, Katrijn; Hammad, Hamida; Lambrecht, Bart N.] Univ Ghent, Dept Pulm Med, B-9000 Ghent, Belgium; [Guilliams, Martin; Malissen, Bernard] Univ Aix Marseille 2, Ctr Immunol Marseille Luminy, CNRS, INSERM, F-13288 Marseille, France; [Vanhoutte, Leen] Ghent Univ Hosp, Dept Clin Genet, B-9000 Ghent, Belgium; [Killeen, Nigel] Trianni Inc, Emeryville, CA 94143 USA; [Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, NL-3015 Rotterdam, Netherlands	Lambrecht, BN (reprint author), VIB, Dept Mol Biomed Res, Lab Immunoregulat & Mucosal Immunol, B-9050 Ghent, Belgium.	bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834; Guilliams, Martin/0000-0003-3525-7570; Malissen, Bernard/0000-0003-1340-9342	ERC consolidator grant; University of Gent MRP grant (GROUP-ID consortium); Marie Curie Career Integration Grant (CIG); BELSPO Return Grant; FWO Post-Doc Fellowship; FWO project grant	This work was supported by an ERC consolidator grant to B.N.L., by a University of Gent MRP grant (GROUP-ID consortium) to B.N.L., by a Marie Curie Career Integration Grant (CIG), a BELSPO Return Grant, and FWO Post-Doc Fellowship to M. G., and by a FWO project grant to H.H.	Beaty SR, 2007, J IMMUNOL, V178, P1882; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; del Rio ML, 2007, J IMMUNOL, V178, P6861; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; Gautier EL, 2012, NAT IMMUNOL, V13, P1118, DOI 10.1038/ni.2419; Geissmann F, 2010, SCIENCE, V327, P656, DOI 10.1126/science.1178331; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; Ginhoux F, 2009, J EXP MED, V206, P3115, DOI 10.1084/jem.20091756; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grinnan D, 2006, J ALLERGY CLIN IMMUN, V118, P1234, DOI 10.1016/j.jaci.2006.07.036; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hohl TM, 2009, CELL HOST MICROBE, V6, P470, DOI 10.1016/j.chom.2009.10.007; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Jakubzick C, 2008, J IMMUNOL, V180, P3019; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Langlet C, 2012, J IMMUNOL, V188, P1751, DOI 10.4049/jimmunol.1102744; Leon B, 2007, IMMUNITY, V26, P519, DOI 10.1016/j.immuni.2007.01.017; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Medoff BD, 2009, J IMMUNOL, V182, P623; Nakano H, 2012, MUCOSAL IMMUNOL, V5, P53, DOI 10.1038/mi.2011.47; Nakano H, 2009, NAT IMMUNOL, V10, P394, DOI 10.1038/ni.1707; Onai N, 2007, NAT IMMUNOL, V8, P1207, DOI 10.1038/ni1518; Ortiz-Stern A, 2011, MUCOSAL IMMUNOL, V4, P343, DOI 10.1038/mi.2010.73; Robays LJ, 2007, J IMMUNOL, V178, P5305; Serbina NV, 2006, NAT IMMUNOL, V7, P311, DOI 10.1038/ni1309; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Tamoutounour S, 2012, EUR J IMMUNOL, V42, P3150, DOI 10.1002/eji.201242847; Turcotte K, 2005, J EXP MED, V201, P881, DOI 10.1084/jem.20042170; van Rijt LS, 2011, AM J RESP CRIT CARE, V184, P303, DOI 10.1164/rccm.201101-0019OC; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Walzer T, 2005, J ALLERGY CLIN IMMUN, V115, P192, DOI 10.1016/j.jaci.2004.08.046; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Wuthrich M, 2012, IMMUNITY, V36, P680, DOI 10.1016/j.immuni.2012.02.015	42	246	248	8	34	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613	1097-4180		IMMUNITY	Immunity	FEB 21	2013	38	2					322	335		10.1016/j.immuni.2012.10.016		14	Immunology	Immunology	AA2RC	WOS:000330940800014	23352232	
J	Gibson, PG; Simpson, JL				Gibson, P. G.; Simpson, J. L.			The overlap syndrome of asthma and COPD: what are its features and how important is it?	THORAX			English	Review							AIR-FLOW OBSTRUCTION; PULMONARY-FUNCTION TESTS; LUNG-FUNCTION DECLINE; RISK-FACTORS; FOLLOW-UP; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; COMPUTED-TOMOGRAPHY; CIGARETTE-SMOKING; PARENTAL SMOKING	There is a need to re-evaluate the concept of asthma and chronic obstructive pulmonary disease (COPD) as separate conditions, and to consider situations when they may coexist, or when one condition may evolve into the other. Epidemiological studies show that in older people with obstructive airway disease, as many as half or more may have overlapping diagnoses of asthma and COPD (overlap syndrome). These people are typically excluded from current therapy trials, which limit the generalisability of these trials, and this presents a problem for evidence-based guidelines for obstructive airway diseases. Studying overlap syndrome may shed light on the mechanisms of COPD development. Overlap syndrome is recognised by the coexistence of increased variability of airflow in a patient with incompletely reversible airway obstruction. Patients typically have inflammatory features that resemble COPD, with increased airway neutrophilia, as well as features of airway wall remodelling. Overlap syndrome can develop when there is accelerated decline in lung function, or incomplete lung growth, or both. The risk factors for these events are shared, such that increasing age, bronchial hyper-responsiveness, tobacco smoke exposure, asthma and lower respiratory infections/exacerbations are significant risk factors for both incomplete lung growth and accelerated loss of lung function. Studying these events may offer new insights into the mechanisms and treatment of obstructive airway diseases.	[Gibson, P. G.] John Hunter Hosp, Dept Resp & Sleep Med, Hunter Mail Ctr, Newcastle, NSW 2310, Australia; [Gibson, P. G.; Simpson, J. L.] Univ Newcastle, Ctr Asthma & Resp Dis, Newcastle, NSW 2308, Australia	Gibson, PG (reprint author), John Hunter Hosp, Dept Resp & Sleep Med, Hunter Mail Ctr, Level 3 HMRI,Locked Bag 1, Newcastle, NSW 2310, Australia.	peter.gibson@hnehealth.nsw.gov.au			NHMRC Practitioner Fellowship; NHMRC Centre of Respiratory Research Excellence Fellowship	PGG holds an NHMRC Practitioner Fellowship and JLS holds am NHMRC Centre of Respiratory Research Excellence Fellowship.	American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; Backman KS, 1997, CHEST, V112, P1234, DOI 10.1378/chest.112.5.1234; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; BARKER DJP, 1991, BRIT MED J, V303, P671; Betz R, 2001, LUNG, V179, P119, DOI 10.1007/s004080000055; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; Boulet LP, 2003, RESP MED, V97, P739, DOI 10.1053/rmed.2003.1491; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burrows B, 1977, AM REV RESPIR DIS, V115, P51; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chinn S, 2005, AM J RESP CRIT CARE, V172, P156; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-11740C; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Horvat JC, 2007, AM J RESP CRIT CARE, V176, P556, DOI 10.1164/rccm.200607-1005OC; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jang AS, 2007, ANN ALLERG ASTHMA IM, V99, P408; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lindberg A, 2005, CHEST, V127, P1544, DOI 10.1378/chest.127.5.1544; Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802; Marsh SE, 2008, THORAX, V63, P761, DOI 10.1136/thx.2007.089193; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; NAGAI A, 1985, AM REV RESPIR DIS, V132, P946; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Panizza JA, 2006, INTERN MED J, V36, P773, DOI 10.1111/j.1445-5994.2006.01214.x; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; PRIDE NB, 1989, EUR RESPIR J, V2, P702; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; RIJCKEN B, 1993, AM REV RESPIR DIS, V147, P1447; Roberts HR, 2000, THORAX, V55, P198, DOI 10.1136/thorax.55.3.198; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shaw DE, 2007, CHEST, V132, P1871, DOI 10.1378/chest.07-1047; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stern DA, 2007, AM J RESP CRIT CARE, V158, P700; Stick S, 2000, THORAX, V55, P587, DOI 10.1136/thorax.55.7.587; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Van De Ven MOM, 2009, J PEDIATR PSYCHOL, V34, P118, DOI 10.1093/jpepsy/jsn063; van Veen IH, 2008, EUR RESPIR J, V32, P344, DOI 10.1183/09031936.00135907; Vestbo J, 1998, THORAX, V53, pS15; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; WRIGHT AL, 1991, J PEDIATR-US, V118, P207, DOI 10.1016/S0022-3476(05)80484-6; WRIGHT JL, 1983, AM REV RESPIR DIS, V127, P474; Xu XP, 1997, LANCET, V350, P1431, DOI 10.1016/S0140-6736(97)10041-1	53	246	260	0	18	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	AUG	2009	64	8					728	735		10.1136/thx.2008.108027		8	Respiratory System	Respiratory System	476AB	WOS:000268408000019	19638566	
J	Kishore, U; Greenhough, TJ; Waters, P; Shrive, AK; Ghai, R; Kamran, MF; Bernal, AL; Reid, KBM; Madan, T; Chakraborty, T				Kishore, U; Greenhough, TJ; Waters, P; Shrive, AK; Ghai, R; Kamran, MF; Bernal, AL; Reid, KBM; Madan, T; Chakraborty, T			Surfactant proteins SP-A and SP-D: Structure, function and receptors	MOLECULAR IMMUNOLOGY			English	Review						surfactant; immunity; lung; allergy; infection; crystal structure	RESPIRATORY SYNCYTIAL VIRUS; GENE-TARGETED MICE; CARBOHYDRATE-RECOGNITION DOMAINS; GRAM-NEGATIVE BACTERIA; HUMAN AMNIOTIC-FLUID; EOSINOPHILIC AIRWAY INFLAMMATION; HEPATOCYTE NUCLEAR FACTOR-3-BETA; MEDIATES ENHANCED PHAGOCYTOSIS; COLONY-STIMULATING FACTOR; MANNAN-BINDING PROTEIN	Surfactant proteins. SP-A and SP-D, are collagen-containing C-type (calcium dependent) lectins called collectins, which contribute significantly to surfactant homeostasis and pulmonary immunity. These highly versatile innate immune molecules are involved in a range of immune functions including viral neutralization. clearance of bacteria, fungi and apoptotic and necrotic cells, down regulation of allergic reaction and resolution of inflammation. Their basic structures include a triple-helical collagen region and a C-terminal homotrimeric lectin or carbohydrate recognition domain (CRD). The trimeric CRDs can recognize carbohydrate or charge patterns on microbes, allergens and dying cells, while the collagen region can interact with receptor molecules present on a variety of immune cells in order to initiate clearance mechanisms. Studies involving gene knock-out mice. murine models of lung hypersensitivity and infection, and functional characterization of cell surface receptors have revealed the diverse roles of SP-A and SP-D in the control of lung inflammation. A recently proposed model based on studies with the calreticulin-CD91 complex as a receptor for SP-A and SP-D has suggested an anti-inflammatory role for SP-A and SP-D in naive lungs which would help minimise the potential damage that continual low level exposure to pathogens, allergens and apoptosis can cause. However, when the lungs are overwhelmed with exogenous insults, SP-A and SP-D can assume pro-inflammatory roles in order to complement pulmonary innate and adaptive immunity. This review is an update on the structural and functional aspects of SP-A and SP-D, with emphasis on their roles in controlling pulmonary infection, allergy and inflammation. We also try to put in perspective the controversial subject of the candidate receptor molecules for SP-A and SP-D. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Univ Giessen, Inst Med Microbiol, D-35392 Giessen, Germany; Univ Keele, Sch Life Sci, Keele ST5 5BG, Staffs, England; Univ Keele, Inst Sci & Technol Med, Keele ST5 5BG, Staffs, England; Univ Nottingham, Sch Med, Sch Biomed Sci, Queens Med Ctr, Nottingham NG7 2UH, England; St Michaels Hosp, Div Obstet & Gynecol, Bristol BS2 8EG, Avon, England; Univ Oxford, MRC, Dept Biochem, Immunochem Unit, Oxford OX1 3QU, England; Inst Genom & Integrat Biol, Council Sci & Ind Res, Delhi 110007, India	Kishore, U (reprint author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	ukishore@hotmail.com	Ganju, Shahji/F-3409-2012; Ghai, Rohit/E-7086-2012	Kishore, Uday/0000-0002-6033-6759	Medical Research Council [G0400743]		Allen MJ, 2001, INFECT IMMUN, V69, P2037, DOI 10.1128/IAI.69.4.2037-2044.2001; Atochina EN, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-15; Bachurski CJ, 2001, AM J PHYSIOL-LUNG C, V280, pL279; BALLARD PL, 1990, AM J RESP CELL MOL, V2, P137; Barr FE, 2000, AM J RESP CELL MOL, V23, P586; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; BENNE CA, 1995, J INFECT DIS, V171, P335; Binder RJ, 2004, TISSUE ANTIGENS, V64, P442, DOI 10.1111/j.1399-0039.2004.00299.x; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Boggaram V, 2003, FRONT BIOSCI, V8, pD751, DOI 10.2741/1062; BOGGARAM V, 1991, MOL ENDOCRINOL, V5, P414; Borron PJ, 1998, J IMMUNOL, V161, P4599; Botas C, 1998, P NATL ACAD SCI USA, V95, P11869, DOI 10.1073/pnas.95.20.11869; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; Brinker KG, 2003, AM J PHYSIOL-LUNG C, V284, pL232, DOI 10.1152/ajplung.00187.2002; Brinker KG, 2001, AM J PHYSIOL-LUNG C, V281, P1453; Brown KP, 1996, NEW ZEAL J ECOL, V20, P271; Bry K, 1997, J CLIN INVEST, V99, P2992, DOI 10.1172/JCI119494; ChailleyHeu B, 1997, BIOCHEM J, V328, P251; Cheng G, 1998, INT ARCH ALLERGY IMM, V117, P59, DOI 10.1159/000053574; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; Cho K, 1999, BIOL NEONATE, V75, P104, DOI 10.1159/000014085; Chroneos ZC, 1996, J BIOL CHEM, V271, P16375; Clark H, 2002, J IMMUNOL, V169, P2892; Condon JC, 2004, P NATL ACAD SCI USA, V101, P4978, DOI 10.1073/pnas.0401124101; DiAngelo S, 1999, DIS MARKERS, V15, P269; Dobbie JW, 1996, PERITON DIALYSIS INT, V16, P574; DOYLE IR, 1995, AM J RESP CRIT CARE, V152, P307; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; Eliakim R, 1997, AM J PHYSIOL-GASTR L, V272, pG425; Erpenbeck VJ, 2005, AM J PHYSIOL-LUNG C, V288, pL692, DOI 10.1152/ajplung.00362.2004; Ferguson JS, 2002, J IMMUNOL, V168, P1309; Ferguson JS, 1999, J IMMUNOL, V163, P312; FISHER JH, 1995, AM J RESP CELL MOL, V12, P13; Fisher JH, 2000, AM J PHYSIOL-LUNG C, V278, pL365; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; GAYNOR CD, 1995, J IMMUNOL, V155, P5343; GEERTSMA MF, 1994, AM J PHYSIOL-LUNG C, V267, pL578; Ghildyal R, 1999, J INFECT DIS, V180, P2009, DOI 10.1086/315134; GROENEVELD TWL, 2005, IN PRESS J IMMUNOL; HAAGSMAN HP, 1991, ANNU REV PHYSIOL, V53, P441, DOI 10.1146/annurev.physiol.53.1.441; Hakansson K, 1999, STRUCT FOLD DES, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; Harrod KS, 1999, AM J PHYSIOL-LUNG C, V277, pL580; Hartshorn KL, 2003, AM J PHYSIOL-LUNG C, V285, pL1066, DOI 10.1152/ajplung.00057.2003; Hartshorn KL, 1998, AM J PHYSIOL-LUNG C, V274, pL958; Hartshorn KL, 1996, BLOOD, V87, P3450; Hartshorn KL, 1997, AM J PHYSIOL-LUNG C, V273, pL1156; HARTSHORN KL, 1994, J CLIN INVEST, V94, P311, DOI 10.1172/JCI117323; HAURUM JS, 1993, BIOCHEM J, V293, P873; Hawgood S, 2004, J VIROL, V78, P8565, DOI 10.1128/JVI.78.16.8565-8572.2004; Hawgood S, 2002, AM J PHYSIOL-LUNG C, V283, pL1002, DOI 10.1152/ajplung.00118.2002; Hawgood S, 2001, AM J PHYSIOL-LUNG C, V280, pL1148; He YC, 2000, J BIOL CHEM, V275, P31051, DOI 10.1074/jbc.M003499200; Head JF, 2003, J BIOL CHEM, V278, P43254, DOI 10.1074/jbc.M305628200; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI13992; Hickling TP, 1998, FEBS LETT, V437, P65, DOI 10.1016/S0014-5793(98)01200-9; Hickling TP, 1999, EUR J IMMUNOL, V29, P3478, DOI 10.1002/(SICI)1521-4141(199911)29:11<3478::AID-IMMU3478>3.3.CO;2-N; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Holmskov U, 2003, ANNU REV IMMUNOL, V21, P547, DOI 10.1146/annurev.immumol.21.120601.140954; Holmskov U, 1997, J BIOL CHEM, V272, P13743, DOI 10.1074/jbc.272.21.13743; Holmskov U, 1999, P NATL ACAD SCI USA, V96, P10794, DOI 10.1073/pnas.96.19.10794; Homer RJ, 2002, AM J PHYSIOL-LUNG C, V283, pL52, DOI 10.1152/ajplung.00438.2001; Hoover RR, 1998, AM J RESP CELL MOL, V18, P353; Hoover RR, 1999, BIOCHEM J, V340, P69, DOI 10.1042/0264-6021:3400069; Ikegami M, 1996, AM J PHYSIOL-LUNG C, V270, pL650; Ikegami M, 2001, AM J PHYSIOL-LUNG C, V281, pL697; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; Kabha K, 1997, AM J PHYSIOL-LUNG C, V272, pL344; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311; Kishore U, 2004, TRENDS IMMUNOL, V25, P551, DOI 10.1016/j.it.2004.08.006; Kishore U, 2005, ARCH IMMUNOL THER EX, V53, P399; Kishore U, 2001, Results Probl Cell Differ, V33, P225; Kishore U, 1996, BIOCHEM J, V318, P505; Kishore U, 1997, BIOCHEM J, V322, P543; Kishore U, 2002, IMMUNOBIOLOGY, V205, P610, DOI 10.1078/0171-2985-00158; Kishore U, 1997, CLIN EXP IMMUNOL, V108, P181, DOI 10.1046/j.1365-2249.1997.3761273.x; Korfhagen TR, 1998, BBA-MOL BASIS DIS, V1408, P296, DOI 10.1016/S0925-4439(98)00075-1; Korfhagen TR, 1998, J BIOL CHEM, V273, P28438, DOI 10.1074/jbc.273.43.28438; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; Kresch MJ, 1998, AM J RESP CELL MOL, V19, P216; KUROKI Y, 1991, J BIOL CHEM, V266, P3068; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; Lahra MM, 2004, AM J OBSTET GYNECOL, V190, P147, DOI 10.1016/j.ajog.2003.07.012; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Leth-Larsen R, 2004, MOL HUM REPROD, V10, P149, DOI 10.1093/molehr/gah022; LeVine AM, 1999, AM J RESP CELL MOL, V20, P279; LeVine AM, 1998, AM J RESP CELL MOL, V19, P700; LeVine AM, 2001, J IMMUNOL, V167, P5868; LeVine AM, 1999, J CLIN INVEST, V103, P1015, DOI 10.1172/JCI5849; Ligtenberg TJM, 2001, BIOCHEM J, V359, P243, DOI 10.1042/0264-6021:3590243; Liu CF, 2005, CLIN EXP ALLERGY, V35, P515, DOI 10.1111/j.1365-2222.2005.02205.x; Lu JH, 2002, BBA-GEN SUBJECTS, V1572, P387, DOI 10.1016/S0304-4165(02)00320-3; Madan T, 1997, CLIN EXP IMMUNOL, V110, P241; Madan T, 2005, J IMMUNOL, V174, P6943; Madan T, 1997, INFECT IMMUN, V65, P3171; Madan T, 2001, INFECT IMMUN, V69, P2728, DOI 10.1128/IAI.69.4.2728-2731.2001; Madan T, 2001, J CLIN INVEST, V107, P467, DOI 10.1172/JCI10124; Madsen J, 2003, EUR J IMMUNOL, V33, P2327, DOI 10.1002/eji.200323972; Madsen J, 2000, J IMMUNOL, V164, P5866; MALHOTRA R, 1994, IMMUNOLOGY, V82, P439; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1993, BIOSCIENCE REP, V13, P79, DOI 10.1007/BF01145960; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MASUDA T, 1991, LANCET, V337, P580, DOI 10.1016/0140-6736(91)91640-G; McCormack FX, 2003, J BIOL CHEM, V278, P36250, DOI 10.1074/jbc.M303086200; McCormack FX, 1999, J BIOL CHEM, V274, P3173, DOI 10.1074/jbc.274.5.3173; McGreal EP, 2002, J IMMUNOL, V168, P5222; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114; Miakotina OL, 1998, BBA-GENE STRUCT EXPR, V1442, P60, DOI 10.1016/S0167-4781(98)00121-3; Miakotina OL, 2002, AM J PHYSIOL-LUNG C, V283, pL418, DOI 10.1152/ajplung.00470.2001; Mikerov AN, 2005, AM J PHYSIOL-LUNG C, V288, pL150, DOI 10.1152/ajplung.00135.2004; MIYAMURA K, 1994, BBA-LIPID LIPID MET, V1210, P303, DOI 10.1016/0005-2760(94)90233-X; Mollenhauer J, 2000, CANCER RES, V60, P1704; MOTWANI M, 1995, J IMMUNOL, V155, P5671; Muller-Taubenberger A, 2001, EMBO J, V20, P6772, DOI 10.1093/emboj/20.23.6772; Murray E, 2002, INFECT IMMUN, V70, P1481, DOI 10.1128/IAI.70.3.1481-1487.2002; Nadesalingam J, 2003, J BIOL CHEM, V278, P25678, DOI 10.1074/jbc.M210186200; Nepomuceno RR, 1997, IMMUNITY, V6, P119, DOI 10.1016/S1074-7613(00)80419-7; Ni M, 2005, INFECT IMMUN, V73, P2147, DOI 10.1128/IAI.73.4.2147-2156.2005; Norsworthy PJ, 2004, J IMMUNOL, V172, P3406; NORWITZ ER, 1992, OBSTET GYNECOL, V80, P440; NORWITZ ER, 1992, AM J OBSTET GYNECOL, V167, P815; Oberley RE, 2004, MOL HUM REPROD, V10, P861, DOI 10.1093/molehr/gah117; Oberley RE, 2004, AM J PHYSIOL-LUNG C, V287, pL296, DOI 10.1152/ajplung.00440.2003; Oberley RE, 2003, AM J PHYSIOL-LUNG C, V284, pL871, DOI 10.1152/ajplung.00241.2002; Ochs M, 2004, AM J PHYSIOL-LUNG C, V287, pL1333, DOI 10.1152/ajplung.00137.2004; OGASAWARA Y, 1994, J BIOL CHEM, V269, P29785; OGASAWARA Y, 1992, J BIOL CHEM, V267, P21244; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; OHMERSCHROCK D, 1995, J CELL SCI, V108, P3695; PAANANEN R, 2001, LUNG CELL MOL PHYSL, V281, pL660; Pasula R, 1997, AM J RESP CELL MOL, V17, P209; Piboonpocanun S, 2005, J BIOL CHEM, V280, P9, DOI 10.1074/jbc.M411570200; PIKAAR JC, 1995, J INFECT DIS, V172, P481; PRYHUBER GS, 1991, PEDIATR RES, V30, P597, DOI 10.1203/00006450-199112000-00023; Quintero OA, 2002, AM J PHYSIOL-LUNG C, V283, pL76, DOI 10.1152/ajplung.00418.2001; Ramet M, 2001, J PEDIATR-US, V138, P266, DOI 10.1067/mpd.2001.110133; Reading PC, 1997, J VIROL, V71, P8204; Reed JA, 2000, AM J PHYSIOL-LUNG C, V278, pL1164; REID MF, 2002, J IMMUNOL, V169, P5844; ROBERT MF, 1976, NEW ENGL J MED, V294, P357, DOI 10.1056/NEJM197602122940702; ROMERO R, 1992, AM J REPROD IMMUNOL, V27, P117; Rosseau S, 1997, J INFECT DIS, V175, P421; Rosseau S, 1999, J IMMUNOL, V163, P4495; RUBIO S, 1995, J BIOL CHEM, V270, P12162; Rust K, 1996, AM J RESP CELL MOL, V14, P121; Sahly H, 2002, J IMMUNOL, V169, P3267; Sano H, 1999, J IMMUNOL, V163, P387; Sano H, 1998, J BIOL CHEM, V273, P4783, DOI 10.1074/jbc.273.8.4783; Sano H, 2000, J BIOL CHEM, V275, P22442, DOI 10.1074/jbc.M001107200; Schagat TL, 2001, J IMMUNOL, V166, P2727; Schaub B, 2004, CLIN EXP ALLERGY, V34, P1819, DOI 10.1111/j.1365-2222.2004.02068.x; SCHELENZ S, 1995, INFECT IMMUN, V63, P3360; Shrive AK, 2003, J MOL BIOL, V331, P509, DOI 10.1016/S0022-2836(03)00761-7; Singh M, 2003, IMMUNOL LETT, V86, P299, DOI 10.1016/S0165-2478(03)00033-6; SNYDER JM, 1988, PEDIATR RES, V24, P728, DOI 10.1203/00006450-198812000-00016; Song MC, 2000, INFECT IMMUN, V68, P6611, DOI 10.1128/IAI.68.12.6611-6617.2000; Stahlman MT, 1998, J HISTOCHEM CYTOCHEM, V46, P955; Stahlman MT, 2002, J HISTOCHEM CYTOCHEM, V50, P651; STEVENS PA, 1995, BIOCHEM J, V308, P77; Strong P, 2003, CLIN EXP IMMUNOL, V134, P181, DOI 10.1046/j.1365-2249.2003.02281.x; Strong P, 2002, CLIN EXP IMMUNOL, V130, P19, DOI 10.1046/j.1365-2249.2002.01968.x; Takeda K, 2003, AM J RESP CRIT CARE, V168, P783, DOI 10.1164/rccm.200304-548OC; Tino MJ, 1998, BBA-MOL BASIS DIS, V1408, P241, DOI 10.1016/S0925-4439(98)00071-4; Tino MJ, 1999, AM J RESP CELL MOL, V20, P759; van de Wetering JK, 2001, J INFECT DIS, V184, P1143; van Eijk M, 2000, J IMMUNOL, V164, P1442; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799; Vandivier RW, 2002, J IMMUNOL, V169, P3978; VANIWAARDEN JF, 1994, BIOCHEM J, V303, P407; VANIWAARDEN JF, 1992, J BIOL CHEM, V267, P25039; VOORHOUT WF, 1992, J HISTOCHEM CYTOCHEM, V40, P1589; Wang GR, 2004, BIOCHEMISTRY-US, V43, P4227, DOI 10.1021/bi036023i; Wang GR, 2000, AM J PHYSIOL-LUNG C, V278, pL946; Wang JY, 1996, CLIN EXP IMMUNOL, V106, P367, DOI 10.1046/j.1365-2249.1996.d01-838.x; Wang JY, 1998, AM J RESP CRIT CARE, V158, P510; Watford WT, 2001, J IMMUNOL, V167, P6593; WEAVER TE, 1991, BIOCHEM J, V273, P249; Weikert LF, 1997, AM J PHYSIOL-LUNG C, V272, pL989; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; WHITSETT JA, 1987, J BIOL CHEM, V262, P5256; Wright JR, 2005, NAT REV IMMUNOL, V5, P58, DOI 10.1038/nri1528; WRIGHT JR, 1991, ANNU REV PHYSIOL, V53, P395, DOI 10.1146/annurev.physiol.53.1.395; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; YAMANAKA N, 1991, ANN OTO RHINOL LARYN, V100, P835; Yi M, 2002, J BIOL CHEM, V277, P2997, DOI 10.1074/jbc.M109793200; Yuan HT, 1997, AM J PHYSIOL-LUNG C, V273, pL900; Zhang LQ, 2002, J BIOL CHEM, V277, P38709, DOI 10.1074/jbc.M206200200; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	194	245	264	3	41	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0161-5890			MOL IMMUNOL	Mol. Immunol.	MAR	2006	43	9					1293	1315		10.1016/j.molimm.2005.08.004		23	Biochemistry & Molecular Biology; Immunology	Biochemistry & Molecular Biology; Immunology	022JT	WOS:000236052500001	16213021	
J	Raghu, G; Freudenberger, TD; Yang, S; Curtis, JR; Spada, C; Hayes, J; Sillery, JK; Pope, CE; Pellegrini, CA				Raghu, G; Freudenberger, TD; Yang, S; Curtis, JR; Spada, C; Hayes, J; Sillery, JK; Pope, CE; Pellegrini, CA			High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis	EUROPEAN RESPIRATORY JOURNAL			English	Article						aspiration; cryptogenic fibrosing alveolitis; gastro-oesophageal reflux disease; idiopathic pulmonary fibrosis; usual interstitial pneumonia	SURGICAL THERAPY; HIATAL HERNIA; DISEASE; ASPIRATION; FREQUENCY; PRESSURE; ASTHMA	The aim of this prospective study was to determine the prevalence and characteristics of acid gastro-oesophageal reflux (GER) in patients with idiopathic pulmonary fibrosis (IPF). Sixty-five consecutive patients with well-defined IPF were subjected to 24-h pH monitoring and oesophageal manometry. A total of 133 consecutive patients with intractable asthma and symptoms of GER were used as comparisons. The prevalence of abnormal acid GER in IPF patients was 87%, with 76% and 63% demonstrating abnormal distal and proximal oesophageal acid exposures, respectively. Abnormal acid GER was significantly more common in IPF patients than asthma patients. Only 47% of IPF patients experienced classic GER symptoms. Despite treatment with standard doses of proton pump inhibitors (PPIs), 12 out of 19 patients receiving PPIs during the 24-h pH monitoring had abnormal oesophageal acid exposures by pH probe. There was no correlation between IPF severity and acid GER severity. In conclusion, abnormal acid gastro-oesophageal reflux is highly prevalent, but often clinically occult in patients with idiopathic pulmonary fibrosis. Standard doses of proton pump inhibitors may not suppress the acid gastro-oesophageal reflux in this population. Therefore, further studies are needed to determine if acid abnormal gastro-oesophageal reflux represents an important risk factor for idiopathic pulmonary fibrosis development or progression, and if optimal suppression of acid gastro-oesophageal reflux slows the progression of idiopathic pulmonary fibrosis and/or decreases episodic exacerbations of idiopathic pulmonary fibrosis.	Univ Washington, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Seattle, WA 98195 USA; Univ Washington, Dept Surg, Gastrointestinal Motil Clin, Seattle, WA 98195 USA; Singapore Gen Hosp, Dept Resp & Crit Care Med, Singapore 0316, Singapore	Raghu, G (reprint author), Univ Washington, Med Ctr, Dept Med, Div Pulm & Crit Care Med, Campus Box 356522, Seattle, WA 98195 USA.	graghu@u.washington.edu					American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P646; American Thoracic Society European Respiratory Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias, 2002, AM J RESP CRIT CARE, V165, P277; Baumgartner KB, 2000, AM J EPIDEMIOL, V152, P307, DOI 10.1093/aje/152.4.307; Baumgartner KB, 1997, AM J RESP CRIT CARE, V155, P242; Bremner RM, 1998, AM J GASTROENTEROL, V93, P183; BRENNAN NJ, 1983, THORAX, V38, P62, DOI 10.1136/thx.38.1.62; CARRINGTON CB, 1978, NEW ENGL J MED, V298, P801, DOI 10.1056/NEJM197804132981501; COULTAS DB, 1994, AM J RESP CRIT CARE, V150, P967; DANGELO E, 1974, J APPL PHYSIOL, V37, P311; DAVIS MV, 1972, NEW YORK STATE J MED, V72, P935; DOBHAN R, 1993, AM J GASTROENTEROL, V88, P25; DUCOLONE A, 1987, AM REV RESPIR DIS, V135, P327; ElSerag HB, 1997, GASTROENTEROLOGY, V113, P755, DOI 10.1016/S0016-5085(97)70168-9; Harding SM, 2000, AM J RESP CRIT CARE, V162, P34; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640; LAM HGT, 1994, DIGEST DIS SCI, V39, P402, DOI 10.1007/BF02090215; Matsuse T, 1996, CHEST, V110, P1289, DOI 10.1378/chest.110.5.1289; MAYS EE, 1976, CHEST, V69, P512, DOI 10.1378/chest.69.4.512; MITSUHASHI T, 1985, EXP MOL PATHOL, V42, P261, DOI 10.1016/0014-4800(85)90032-2; PEARSON JEG, 1971, THORAX, V26, P300, DOI 10.1136/thx.26.3.300; PELLEGRINI CA, 1979, SURGERY, V86, P110; PERRINFAYOLLE M, 1990, CLIN REV ALLERG, V8, P457; POPE CE, 1994, NEW ENGL J MED, V331, P656, DOI 10.1056/NEJM199409083311007; POPPER H, 1986, VIRCHOWS ARCH A, V409, P105, DOI 10.1007/BF00705410; RAIHA I, 1992, AGE AGEING, V21, P250, DOI 10.1093/ageing/21.4.250; ROUSSOS CS, 1977, AM REV RESPIR DIS, V116, P457; SONTAG SJ, 1990, GASTROENTEROLOGY, V99, P613; TEABEAUT JR, 1952, AM J PATHOL, V28, P51; Tobin RW, 1998, AM J RESP CRIT CARE, V158, P1804; WIENER GJ, 1989, AM J GASTROENTEROL, V84, P1503	30	245	258	2	8	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JAN	2006	27	1					136	142		10.1183/09031936.06.00037005		7	Respiratory System	Respiratory System	002TT	WOS:000234635100021	16387946	
J	Fisk, WJ; Lei-Gomez, Q; Mendell, MJ				Fisk, W. J.; Lei-Gomez, Q.; Mendell, M. J.			Meta-analyses of the associations of respiratory health effects with dampness and mold in homes	INDOOR AIR			English	Article							PRIMARY-SCHOOL CHILDREN; ADULT-ONSET ASTHMA; INDOOR ENVIRONMENT; BUILDING DAMPNESS; RISK-FACTORS; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; PARENTAL ATOPY; SYMPTOMS; EXPOSURES	The Institute of Medicine (TOM) of the National Academy of Sciences recently completed a critical review of the scientific literature pertaining to the association of indoor dampness and mold contamination with adverse health effects. In this paper, we report the results of quantitative meta-analyses of the studies reviewed in the TOM report plus other related studies. We developed point estimates and confidence intervals (CIs) of odds ratios (ORs) that summarize the association of several respiratory and asthma-related health outcomes with the presence of dampness and mold in homes. The ORs and CIs from the original studies were transformed to the log scale and random effect models were applied to the log ORs and their variance. Models accounted for the correlation between multiple results within the studies analyzed. Central estimates of ORs for the health outcomes ranged from 1.34 to 1.75. CIs (95%) excluded unity in nine of 10 instances, and in most cases the lower bound of the CI exceeded 1.2. Based on the results of the meta-analyses, building dampness and mold are associated with approximately 30-50% increases in a variety of respiratory and asthma-related health outcomes.	Lawrence Berkeley Natl Lab, Environm Energy Technol Div, Indoor Environm Dept, Berkeley, CA 94720 USA	Fisk, WJ (reprint author), Lawrence Berkeley Natl Lab, Environm Energy Technol Div, Indoor Environm Dept, 1 Cyclotron Rd 90R3058, Berkeley, CA 94720 USA.	wjfisk@lbl.gov	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ANDRAE S, 1988, ARCH DIS CHILD, V63, P473; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; BRUNEKREEF B, 1992, SCI TOTAL ENVIRON, V127, P79, DOI 10.1016/0048-9697(92)90471-4; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; CUIJPERS CEJ, 1995, ENVIRON RES, V68, P11, DOI 10.1006/enrs.1995.1003; Dales RE, 1999, ENVIRON HEALTH PERSP, V107, P481; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Egger M, 1998, BRIT MED J, V316, P140; Emenius G, 2004, ACTA PAEDIATR, V93, P899, DOI 10.1080/08035250410025582; Engvall K, 2001, INT ARCH OCC ENV HEA, V74, P270, DOI 10.1007/s004200000218; Gent J., 2002, ENV HLTH PERSPECT, V110, P781; Gunnbjornsdottir MI, 2006, THORAX, V61, P221, DOI 10.1136/thx.2005.057430; Gunnbjornsdottir MI, 2003, RESP MED, V97, P302, DOI 10.1053/rmed.2002.1389; Haverinen U, 2001, INDOOR AIR, V11, P192, DOI 10.1034/j.1600-0668.2001.011003192.x; Institute of Medicine [IOM], 2004, DAMP IND SPAC HLTH I; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543; Jedrychowski W, 1998, Int J Occup Med Environ Health, V11, P19; Koskinen OM, 1999, EUR RESPIR J, V14, P1363, DOI 10.1183/09031936.99.14613639; Lee YL, 2003, PEDIATRICS, V112, pE389, DOI 10.1542/peds.112.5.e389; LEVIN H, 2005, LBNL58694; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; Mommers M, 2005, INT J HYG ENVIR HEAL, V208, P373, DOI 10.1016/j.ijheh.2005.04.007; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; Ronmark E, 2002, RESP MED, V96, P1006, DOI 10.1053/rmed.2002.1391; Simoni M, 2005, OCCUP ENVIRON MED, V62, P616, DOI 10.1136/oem.2004.018291; Skorge TD, 2005, THORAX, V60, P937, DOI 10.1136/thx.2004.025973; Slezak JA, 1998, J ASTHMA, V35, P203, DOI 10.3109/02770909809068208; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Williamson IJ, 1997, THORAX, V52, P229; Yang CY, 1997, ENVIRON RES, V75, P49, DOI 10.1006/enrs.1997.3774; Yang CY, 1997, PEDIATR PULM, V24, P73, DOI 10.1002/(SICI)1099-0496(199708)24:2<73::AID-PPUL1>3.3.CO;2-L; Yang CY, 1998, CHEST, V114, P393, DOI 10.1378/chest.114.2.393	41	244	249	7	48	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	AUG	2007	17	4					284	296		10.1111/j.1600-0668.2007.00475.x		13	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	201QX	WOS:000248848800004	17661925	
J	Zureik, M; Neukirch, C; Leynaert, B; Liard, R; Bousquet, L; Neukirch, F				Zureik, M; Neukirch, C; Leynaert, B; Liard, R; Bousquet, L; Neukirch, F		European Community Respiratory Hlt	Sensitisation to airborne moulds and severity of asthma: cross sectional study from European Community respiratory health survey	BRITISH MEDICAL JOURNAL			English	Article							SKIN-TEST REACTIVITY; YOUNG-ADULTS; RISK FACTOR; INDIVIDUAL ALLERGENS; LUNG-FUNCTION; CHILDREN; ASSOCIATION; SYMPTOMS; EXPOSURE; SENSITIZATION	Objective To assess whether the.. severity of asthma is associated with sensitisation to airborne moulds rather than to other seasonal or perennial allergens. Design Multicentre epidemiological survey in 30 centres. Setting European Community respiratory health survey. Participants 1132 adults. aged 20-44 years with current asthma and with skin prick test results. Main outcome measure Severity of asthma according to score based on forced expiratory volume in one second, number of asthma attacks, hospital admissions for breathing problems, and use of corticosteroids in past 12 months. Results The frequency of sensitisation to moulds (Alternaria alternata or Cladosporium herbarum, or both) increased significantly with increasing asthma severity (odds ratio 2.34 (95% confidence interval 1.56 to 3.52) for either for severe v mild asthma). This association existed in all of the study areas (gathered into regions), although there were differences in the frequency of sensitisation. There was no association between asthma severity and sensitisation to pollens or cats. Sensitisation to Dermatophagoides pteronyssinus was also positively associated with severity. In multivariable logistic regressions including sensitisation to moulds, pollens, D pteronyssinus, and cats simultaneously, the odds ratios for sensitisation to moulds were 1.48 (0.97 to 2.26) for moderate v mild asthma and 2.16 (1.37 to 3.35) for severe v mild asthma (P < 0.001 for trend)., Conclusions Sensitisation to moulds is a powerful risk factor for severe asthma in adults. This should be taken into account in primary prevention, management and patients' education.	Univ Paris 07, Natl Inst Hlth & Med Res, INSERM,U408, Unite Epidemiol, F-75870 Paris 18, France; Hop Arnaud Villeneuve, INSERM, U454, Natl Inst Hlth & Med Res, F-34295 Montpellier, France	Zureik, M (reprint author), Univ Paris 07, Natl Inst Hlth & Med Res, INSERM,U408, Unite Epidemiol, BP 416, F-75870 Paris 18, France.		bucca, caterina/C-9886-2009	bucca, caterina/0000-0002-9941-9236	NCRR NIH HHS [2 S07 RR05521-28]		Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Chinn S, 1998, THORAX, V53, P662; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Codina R, 1998, J ALLERGY CLIN IMMUN, V102, P318, DOI 10.1016/S0091-6749(98)70102-2; Des Roches Anne, 1996, Journal of Allergy and Clinical Immunology, V98, P522, DOI 10.1016/S0091-6749(96)70085-4; *EUR COMM DIR GEN, 1993, PROT EUR COMM RESP H; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786; Hopkinson L., 1997, European Respiratory Journal Supplement, V10, p28S; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jarvis D, 1998, EUR RESPIR J, V11, P651; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Liard R, 2000, EUR RESPIR J, V16, P615, DOI 10.1034/j.1399-3003.2000.16d08.x; *NAT HEART LUNG BL, 1995, NATL HEART LUNG BLOO; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; Newson R, 1997, THORAX, V52, P680; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; POLLART SM, 1988, J ALLERGY CLIN IMMUN, V82, P224, DOI 10.1016/0091-6749(88)91003-2; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; Ronchetti R, 1997, EUR RESPIR J, V10, P1248, DOI 10.1183/09031936.97.10061248; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross MA, 2000, ALLERGY, V55, P705, DOI 10.1034/j.1398-9995.2000.00551.x; SCHWARTZ J, 1995, AM J RESP CRIT CARE, V152, P2176; SNELLER MR, 1981, ANN ALLERGY, V46, P30; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1	33	244	258	1	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 24	2002	325	7361					411	414		10.1136/bmj.325.7361.411		6	Medicine, General & Internal	General & Internal Medicine	588RY	WOS:000177715500016	12193354	
J	Niederberger, V; Horak, F; Vrtala, S; Spitzauer, S; Krauth, MT; Valent, P; Reisinger, J; Pelzmann, M; Hayek, B; Kronqvist, M; Gafvelin, G; Gronlund, H; Purohit, A; Suck, R; Fiebig, H; Cromwell, O; Pauli, G; van Hage-Hamsten, M; Valenta, R				Niederberger, V; Horak, F; Vrtala, S; Spitzauer, S; Krauth, MT; Valent, P; Reisinger, J; Pelzmann, M; Hayek, B; Kronqvist, M; Gafvelin, G; Gronlund, H; Purohit, A; Suck, R; Fiebig, H; Cromwell, O; Pauli, G; van Hage-Hamsten, M; Valenta, R			Vaccination with genetically engineered allergens prevents progression of allergic disease	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article; Proceedings Paper	Arthur M Sackler Colloquium of the National-Academy-of-Sciences on therapeutic Vaccines	APR 01-03, 2004	Natl Acad Sci, Washington, DC		Natl Acad Sci		BIRCH POLLEN ALLERGEN; B-CELL EPITOPES; HAY-FEVER; V 1; IMMUNOTHERAPY; IGE; GENE; DERIVATIVES; CANDIDATES; RESPONSES	IgE-mediated allergy affects >25% of the population in industrialized countries. Repeated contact with the disease-eliciting allergens induces rises of allergen-specific IgE Abs and progression of the disease to more severe manifestations. Our study uses a type of vaccine that is based on genetically modified allergen derivatives to treat allergic patients. We developed hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, by genetic engineering and vaccinated birch pollen-allergic patients (n = 124) in a double-blind, placebo-controlled study. Active treatment induced protective IgG Abs that inhibited allergen-induced release of inflammatory mediators. We also observed a reduction of cutaneous sensitivity as well as an improvement of symptoms in actively treated patients. Most important, rises of allergen-specific IgE induced by seasonal birch pollen exposure were significantly reduced in vaccinated patients. Vaccination with genetically engineered allergen derivatives is a therapy for allergy that not only ameliorates allergic reactions but also reduces the IgE production underlying the disease.	Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Med & Chem Lab Diagnost, A-1090 Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Hematol & Hemostaseol, A-1090 Vienna, Austria; Karolinska Univ Hosp, Dept Med, Allergy & Clin Immunol Unit, SE-17177 Stockholm, Sweden; Allergopharma Joachim Ganzer KG, D-21465 Reinbek, Germany; Hop Univ Strasbourg, Serv Pneumol, F-67000 Strasbourg, France	Valenta, R (reprint author), Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Waehringer Guertel 18, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Gafvelin, Guro/0000-0003-1618-4011			Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; Ball T, 1999, FASEB J, V13, P1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1989, EMBO J, V8, P1935; CLINTON PM, 1989, INT ARCH ALLER A IMM, V89, P43; Cromwell O, 2004, METHODS, V32, P300, DOI 10.1016/j.ymeth.2003.08.009; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Kay A. B., 1997, ALLERGY ALLERGIC DIS; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Mahler V, 2004, CLIN EXP ALLERGY, V34, P115, DOI 10.1111/j.1365-2222.2004.01857.x; MATHES N, 2003, CLIN EXP ALLERGY, V33, P1; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P384, DOI 10.1016/0091-6749(78)90118-5; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; VANHAGEHAMSTEN S, 1999, J ALLERGY CLIN IMMUN, V104, P969; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Woodfolk JA, 2002, INT ARCH ALLERGY IMM, V129, P277, DOI 10.1159/000067595	31	243	253	2	18	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	OCT 5	2004	101			2			14677	14682		10.1073/pnas.0404735101		6	Multidisciplinary Sciences	Science & Technology - Other Topics	861NT	WOS:000224424300020	15310844	
J	Wenzel, SE; Barnes, PJ; Bleecker, ER; Bousquet, J; Busse, W; Dahlen, SE; Holgate, ST; Meyers, DA; Rabe, KF; Antczak, A; Baker, J; Horvath, I; Mark, Z; Bernstein, D; Kerwin, E; Schlenker-Herceg, R; Lo, KH; Watt, R; Barnathan, ES; Chanez, P				Wenzel, Sally E.; Barnes, Peter J.; Bleecker, Eugene R.; Bousquet, Jean; Busse, William; Dahlen, Sven-Erik; Holgate, Stephen T.; Meyers, Deborah A.; Rabe, Klaus F.; Antczak, Adam; Baker, James; Horvath, Ildiko; Mark, Zsuzsanna; Bernstein, David; Kerwin, Edward; Schlenker-Herceg, Rozsa; Lo, Kim Hung; Watt, Rosemary; Barnathan, Elliot S.; Chanez, Pascal		T03 Asthma Investigators	A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-alpha Blockade in Severe Persistent Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						golimumab; asthma; tumor necrosis factor-alpha	AIR-FLOW LIMITATION; SMOOTH-MUSCLE; TNF-ALPHA; CLINICAL CHARACTERISTICS; RHEUMATOID-ARTHRITIS; MONOCLONAL-ANTIBODY; REFRACTORY ASTHMA; BRONCHIAL-ASTHMA; CANCER INCIDENCE; RISK-FACTORS	Rationale: The treatment effect of golimumab, a human monoclonal antibody against tumor necrosis factor (TNF)-alpha, in severe persistent asthma is unknown. Objectives: To assess the safety and efficacy of golimumab in a large population of patients with uncontrolled, severe persistent asthma. Methods: From 2004 to 2006, 309 patients with severe and uncontrolled asthma, despite high-dose inhaled corticosteroids and long-acting beta(2) agonists, were randomized 1:1:1:1 to monthly subcutaneous injections of placebo or golimumab (50, 100, or 200 mg) through Week 52. Coprimary endpoints were the change from baseline through Week 24 in prebronchodilator percent-predicted FEV(1) and the number of severe asthma exacerbations through Week 24. Measurements and Main Results: No significant differences were observed for the change in percent-predicted FEV(1) (least squares mean: placebo, 2.44 [95% confidence interval (CI) -0.574 to 5.461]; combined 100-mg and 200-mg, 2.91 [0.696-5.116]) or severe exacerbations (mean +/- SD: placebo, 0.5 +/- 1.07 vs. combined 100-mg and 200-mg 0.5 +/- 0.97) through week 24. Through Week 24, 2.6% of patients treated with placebo vs. 19.5% of those treated with golimumab discontinued the study agent, and 1.3% and 7.8% discontinued study participation, respectively. An unfavorable risk-benefit profile led to early discontinuation of study-agent administration after the Week-24 database lock. Through Week 76, 20.5% of patients treated with placebo and 30.3% of patients treated with golimumab experienced serious adverse events, with serious infections occurring more frequently in golimumab-treated patients. One death and all eight malignancies occurred in the active groups. Conclusions Overall, treatment with golimumab did not demonstrate a favorable risk-benefit profile in this study population of patients	[Wenzel, Sally E.] Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; [Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London, England; [Bleecker, Eugene R.; Meyers, Deborah A.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA; [Bousquet, Jean] Hop Arnaud Villeneuve, Clin Malad Resp, Montpellier, France; [Busse, William] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA; [Dahlen, Sven-Erik] Karolinska Inst, Unit Expt Asthma & Allergy Res, Stockholm, Sweden; [Holgate, Stephen T.] Southampton Gen Hosp, AIR Div, Southampton SO9 4XY, Hants, England; [Rabe, Klaus F.] Leiden Univ, Dept Pulmonol, Med Ctr, Leiden, Netherlands; [Antczak, Adam] Prywatny Gabinet Specjalisty, Lodz, Poland; [Baker, James] Allergy Asthma & Dermatol Res Ctr LLC, Oswego, OR USA; [Horvath, Ildiko] Semmelweis Univ, Natl Koranyi TBC & Pulmonol Inst, Budapest, Hungary; [Horvath, Ildiko] Semmelweis Univ, Inst Expt Clin Res, Budapest, Hungary; [Mark, Zsuzsanna] Pulm Med Inst Torokbalint, Torokbalint, Hungary; [Bernstein, David] Bernstein Allergy Grp, Cincinnati, OH USA; [Kerwin, Edward] Clin Res Inst So Oregon PC, Medford, OR USA; [Schlenker-Herceg, Rozsa; Lo, Kim Hung; Watt, Rosemary; Barnathan, Elliot S.] Centocor Res & Dev Inc, Malvern, PA USA; [Chanez, Pascal] Hop Arnaud Villeneuve, Montpellier, France	Wenzel, SE (reprint author), Univ Pittsburgh, Med Ctr, Div Pulm Allergy & Crit Care Med, NW 628 Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.	wenzelse@upmc.edu		Horvath, Ildiko/0000-0001-6891-1044	Centocor, Inc.; Centocor BV	Supported by Centocor, Inc. and Centocor BV.	Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; AMRANI Y, 1995, BRIT J PHARMACOL, V114, P4; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Baraniuk JN, 2005, AM J RESP CRIT CARE, V171, P5; BATEMAN ED, 2008, GLOBAL INTIATIVE AST; Bellia V, 1998, CHEST, V114, P1336, DOI 10.1378/chest.114.5.1336; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bongartz T, 2006, JAMA-J AM MED ASSOC, V295, P2275, DOI 10.1001/jama.295.19.2275; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594; Egberts JH, 2008, CANCER RES, V68, P1443, DOI 10.1158/0008-5472.CAN-07-5704; Eisner MD, 2006, AM J MED, V119, P884, DOI 10.1016/j.amjmed.2006.01.016; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Godard P, 2002, EUR RESPIR J, V19, P61, DOI 10.1183/09031936.02.00232001; Gonzalez-Perez A, 2006, PHARMACOEPIDEM DR S, V15, P131, DOI 10.1002/pds.1163; Harju TH, 2006, THORAX, V61, P579, DOI 10.1136/thx.2005.056291; Harrison ML, 2007, J CLIN ONCOL, V25, P4542, DOI 10.1200/JCO.2007.11.2136; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; KALLEN B, 1993, EUR RESPIR J, V6, P694; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; LASSALLE P, 1991, INT ARCH ALLER A IMM, V94, P233; Leggett JJ, 2005, CHEST, V127, P1227, DOI 10.1378/chest.127.4.1227; LI K, 2008, AM J RESP CRIT CARE, V177, pA336; Little RJA, 2002, STAT ANAL MISSING DA; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Meyers DA, 2008, J ALLERGY CLIN IMMUN, V121, P798, DOI 10.1016/j.jaci.2008.01.065; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; Misior AM, 2008, MOL PHARMACOL, V73, P566, DOI 10.1124/mol.107.040519; Moore WC, 2001, J ALLERGY CLIN IMMUN, V108, P908, DOI 10.1067/mai.2001.119413; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; [Anonymous], 2007, NIH PUBL, V07-4051; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Tennis P, 2005, ANN ALLERG ASTHMA IM, V95, P354; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76; TILLIELEBLOND I, 2002, AM J PHYSIOL-LUNG C, V283, P1303; Tliba O, 2003, J BIOL CHEM, V278, P50615, DOI 10.1074/jbc.M303680200; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214; VESTERINEN E, 1993, INT J EPIDEMIOL, V22, P976, DOI 10.1093/ije/22.6.976; WENZEL S, 2007, EUR RESP SOC ANN C S; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Zhou HH, 2007, J CLIN PHARMACOL, V47, P383, DOI 10.1177/0091270006298188	52	241	249	3	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2009	179	7					549	558		10.1164/rccm.200809-1512OC		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	425UU	WOS:000264663700007	19136369	
J	Buchanan, AD; Green, TD; Jones, SM; Scurlock, AM; Christie, L; Althage, KA; Steele, PH; Pons, L; Heim, RM; Lee, LA; Burks, AW				Buchanan, Ariana D.; Green, Todd D.; Jones, Stacie M.; Scurlock, Amy M.; Christie, Lynn; Althage, Karen A.; Steele, Pamela H.; Pons, Laurent; Heim, Rick M.; Lee, Laurie A.; Burks, A. Wesley			Egg oral immunotherapy in nonanaphylactic children with egg allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						egg allergy; food allergy; anaphylaxis; allergen immunotherapy; oral immunotherapy	QUALITY-OF-LIFE; FOOD ALLERGY; PEANUT ALLERGY; TOLERANCE; FAMILIES; PARENTS; FUTURE; IMPACT	Background: There is no current active treatment for food allergy. Traditional injection immunotherapy has been proved unsafe, and thus there is a need for other forms of immunotherapy. Objective: The purpose was to study the safety and immunologic effects of egg oral immunotherapy (OIT). The short-term goal was to desensitize subjects to protect against accidental ingestion reactions. The eventual goal was to induce lasting clinical and immunologic tolerance. Methods: Subjects with a history of egg allergy but without a history of anaphylaxis to egg underwent a 24-month egg OIT protocol involving modified rush, build-up, and maintenance phases. Double-blind, placebo-controlled food challenges were performed at study conclusion. Egg-specific IgE and IgG concentrations were followed. Results: Seven subjects completed the protocol. Egg-specific IgG concentrations increased significantly, whereas egg-specific IgE concentrations did not significantly change. Three subjects tolerated known or possible accidental egg ingestions while receiving OIT. During double-blind, placebo-controlled food challenges at study conclusion, all tolerated significantly more egg protein than at study onset and than that found in the typical accidental exposure. Two subjects demonstrated oral tolerance. Conclusion: This study provides proof of concept that OIT can be safely used for patients with egg allergy without a history of anaphylaxis to egg. Egg OIT does not heighten sensitivity to egg and might protect against reaction on accidental ingestion. Whether OIT will induce clinical oral tolerance cannot be concluded from this initial cohort. Clinical implications: Use of allergen-specific OIT to protect subjects with food allergy from reaction on accidental ingestion would represent a significant paradigm change in the treatment of food allergy.	Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Univ Arkansas Med Sci, Dept Pediat, Little Rock, AR 72205 USA; Arkansas Childrens Hosp, Little Rock, AR 72202 USA; Univ Arkansas Med Sci, Dept Microbiol, Little Rock, AR 72205 USA	Burks, AW (reprint author), Duke Univ, Med Ctr, Dept Pediat, Box 2644, Durham, NC 27710 USA.	wesley.burks@duke.edu			NCRR NIH HHS [5M01-RR-000030-45]		Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Altschul AS, 2001, J ALLERGY CLIN IMMUN, V108, P468, DOI 10.1067/mai.2001.117794; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; BURKS AW, 2003, ALLERGY, V67, P121; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Eigenmann PA, 2003, ALLERGY, V58, P1217, DOI 10.1046/j.1398-9995.2003.00303.x; FREW AJ, 2003, J ALLERGY CLIN IMMUN, V11, pS712; Gruchalla R. S., 1998, Clinical and Experimental Allergy, V28, P63; Hamelmann Eckard, 2003, Curr Opin Allergy Clin Immunol, V3, P501, DOI 10.1097/00130832-200312000-00013; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Lehrer SB, 1999, CLIN REV ALLERG IMMU, V17, P361, DOI 10.1007/BF02737616; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li Xiu-Min, 2004, Clin Allergy Immunol, V18, P663; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Sampson HA, 2003, PEDIATRICS, V111, P1601; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; SAMPSON HA, 2003, NEW PERSPECTIVES TRE, V94, P236; Scurlock AM, 2004, ANN ALLERG ASTHMA IM, V93, pS12; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461; VARNEY VA, 1991, BRIT MED J, V302, P265; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500; Wilson DR, 2003, COCHRANE DB SYST REV, V2	35	241	246	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2007	119	1					199	205		10.1016/j.jaci.2006.09.016		7	Allergy; Immunology	Allergy; Immunology	127YL	WOS:000243622200028	17208602	
J	Togias, A				Togias, A			Rhinitis and asthma: Evidence for respiratory system integration	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; nasal function; lung function; rhinitis epidemiology; asthma epidemiology	SKIN-TEST REACTIVITY; NITRIC-OXIDE SYNTHASE; PERENNIAL ALLERGIC RHINITIS; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; INDEPENDENT RISK FACTOR; SERUM IGE LEVELS; BRONCHIAL RESPONSIVENESS; NASAL-MUCOSA; MAST-CELL	The vast majority of patients with asthma have rhinitis, and rhinitis is a major independent risk factor for asthma in cross-sectional and longitudinal studies. The relationships between rhinitis and asthma can be viewed under the concept that the 2 conditions are manifestations of one syndrome, the chronic allergic respiratory syndrome, in 2 parts of the respiratory tract. At the low end of the syndrome's severity spectrum, rhinitis appears to be the sole manifestation, although pathologic abnormalities in the lower airways are already present. At the higher end, rhinitis is worse, and the lower airways disease becomes clinically evident. Once manifested, the 2 conditions track in parallel in terms of severity. This parallel relationship is influenced by many interactions between the nasal and the lower airways: some interactions stem from the fact that the nasal passages play a major homeostatic role by conditioning inhaled air, but perhaps even more important is the bidirectional interaction that results from the systemic inflammation that is produced after local allergic reactions. Successful management of the chronic allergic respiratory syndrome requires an integrated view of the airways and an understanding of their interactions.	Johns Hopkins Univ, Sch Med, Div Clin Immunol, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Div Resp & Crit Care Med, Dept Med, Baltimore, MD USA	Togias, A (reprint author), Johns Hopkins Asthma & Allergy Ctr, Unit Off 7,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.						ANDERSEN IB, 1979, AM REV RESPIR DIS, V119, P619; ANDERSON S, 2000, ASTHMA RHINITIS, P1449, DOI 10.1002/9780470694923.ch25; ARIA Workshop Group, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI DOI 10.1067/MAI.2001.118891; Assanasen P, 2001, AM J RESP CRIT CARE, V164, P1640; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; BAROODY FM, 1992, J ALLERGY CLIN IMMUN, V90, P373, DOI 10.1016/S0091-6749(05)80017-X; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BERMAN AR, 1995, J APPL PHYSIOL, V78, P1844; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1046/j.1365-2222.1997.d01-418.x; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRAMAN SS, 1987, CHEST, V91, P671, DOI 10.1378/chest.91.5.671; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Braunstahl GJ, 2001, AM J RESP CRIT CARE, V164, P858; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, pS64; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; CAUNA N, 1970, ANAT REC, V168, P9, DOI 10.1002/ar.1091680102; CAUNA N, 1975, ANAT REC, V181, P1, DOI 10.1002/ar.1091810102; Celedon JC, 2001, AM J RESP CRIT CARE, V163, P1108; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588; Colantonio D, 2002, CLIN EXP ALLERGY, V32, P698, DOI 10.1046/j.1365-2222.2002.01379.x; COLE P, 1953, J Laryngol Otol, V67, P669, DOI 10.1017/S0022215100049161; Cole P, 1982, NOSE UPPER AIRWAY PH, P351; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; Crimi E, 2001, J APPL PHYSIOL, V91, P1029; CROEN KD, 1993, J CLIN INVEST, V91, P2446, DOI 10.1172/JCI116479; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Csoma Z, 2002, AM J RESP CRIT CARE, V166, P1345, DOI 10.1164/rccm.200203-233OC; Dahl R, 2001, J ALLERGY CLIN IMMUN, V107, pS154; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739; Fontanari P, 1997, EUR RESPIR J, V10, P2250, DOI 10.1183/09031936.97.10102250; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; GERGEN PJ, 1991, ARCH INTERN MED, V151, P487, DOI 10.1001/archinte.151.3.487; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; Greisner WA, 2000, ALLERGY ASTHMA PROC, V21, P371, DOI 10.2500/108854100778249123; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; HALPERN M, 2003, IN PRESS J ASTHMA; Hellgren J, 2002, CLIN EXP ALLERGY, V32, P64, DOI 10.1046/j.0022-0477.2001.01253.x; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; HOEHNE JH, 1971, J ALLERGY CLIN IMMUN, V48, P36, DOI 10.1016/0091-6749(71)90053-4; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; Horowitz E, 2001, J ALLERGY CLIN IMMUN, V107, pS280; Huse D. M., 1996, European Respiratory Journal Supplement, V9, p351S; HUSE D, 1998, EUR RESPIR J, V12, pS50; HUSE DM, 1998, EUR RESPIR J, V12, pS49; Huse DM, 1996, AM J RESP CRIT CARE, V153, pA860; HUXLEY EJ, 1978, AM J MED, V64, P564, DOI 10.1016/0002-9343(78)90574-0; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; INGELSTEDT S, 1951, ACTA OTO-LARYNGOL, V39, P286, DOI 10.3109/00016485109119255; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P138; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KAUFMAN J, 1970, AM REV RESPIR DIS, V101, P768; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; KNOWLES M, 1983, ALLERGIC VASOMOTOR R, P77; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; Laprise C, 1997, AM J RESP CRIT CARE, V156, P403; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; LEVI CR, 1990, AUST NZ J MED, V20, P578, DOI 10.1111/j.1445-5994.1990.tb01317.x; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136; Lindberg S, 1997, ACTA OTO-LARYNGOL, V117, P113, DOI 10.3109/00016489709118001; Linneberg A, 2002, ALLERGY, V57, P1048, DOI 10.1034/j.1398-9995.2002.23664.x; LITTELL NT, 1990, AM REV RESPIR DIS, V141, P580; Liu MC, 2001, J ALLERGY CLIN IMMUN, V108, P29; Lundberg JON, 1995, ACTA PHYSIOL SCAND, V155, P467, DOI 10.1111/j.1748-1716.1995.tb09998.x; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; LUNDBERG JON, 1994, ACTA PHYSIOL SCAND, V152, P431, DOI 10.1111/j.1748-1716.1994.tb09826.x; Lusuardi M, 2000, RESP MED, V94, P436, DOI 10.1053/rmed.1999.0761; Magnan A, 1998, EUR RESPIR J, V12, P1073, DOI 10.1183/09031936.98.12051073; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198; MANGLA PK, 1981, CLIN ALLERGY, V11, P433, DOI 10.1111/j.1365-2222.1981.tb01616.x; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Masuda S., 2003, Journal of Allergy and Clinical Immunology, V111, pS138, DOI 10.1016/S0091-6749(03)80433-5; MATTHEWS LW, 1963, AM REV RESPIR DIS, V88, P199; MCALLISTER P, 1993, J ALLERGY CLIN IMMUN, V91, pS176; Meng QH, 1998, J PATHOL, V184, P323, DOI 10.1002/(SICI)1096-9896(199803)184:3<323::AID-PATH2>3.0.CO;2-2; Milanese M, 2001, J APPL PHYSIOL, V91, P1035; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nakano H, 2000, AM J RESP CRIT CARE, V162, P2218; NOLTE D, 1983, EUR J RESPIR DIS, V64, P110; NOUREDDINE G, 1994, J ALLERGY CLIN IMMUN, V93, P177; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; Peebles RS, 2001, J ALLERGY CLIN IMMUN, V107, P805; PELUCCHI A, 1995, J ALLERGY CLIN IMMUN, V95, P515, DOI 10.1016/S0091-6749(95)70313-6; PIN I, 1992, AM REV RESPIR DIS, V145, P1265; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; Polosa R, 2000, J ALLERGY CLIN IMMUN, V106, P1124; POTTER JL, 1967, AM REV RESPIR DIS, V96, P83; RAMSDALE EH, 1985, J ALLERGY CLIN IMMUN, V75, P573; REYNOLDS C, 2001, CLIN EXP ALLERGY, V32, P1174; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; Ricciardolo FLM, 2001, J ALLERGY CLIN IMMUN, V108, P198, DOI 10.1067/mai.2001.116572; ROBERTSON DG, 1974, J ALLERGY CLIN IMMUN, V54, P244, DOI 10.1016/0091-6749(74)90067-0; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROESSLER F, 1988, LARYNGOSCOPE, V98, P1261; Sanders SP, 1998, J VIROL, V72, P934; Sanders SP, 2001, AM J RESP CELL MOL, V24, P317; Sandrini A, 2003, J ALLERGY CLIN IMMUN, V111, P313, DOI 10.1067/mai.2003.64; Sanico AM, 1998, CLIN EXP ALLERGY, V28, P92; Sanico AM, 1999, J APPL PHYSIOL, V86, P1202; SANICO AM, 1999, INT ARCH ALLERGY IMM, V118, P153; Sarti W, 1995, Sao Paulo Med J, V113, P968; SCHUMACHER MJ, 1986, J ALLERGY CLIN IMMUN, V78, P30, DOI 10.1016/0091-6749(86)90111-9; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Shaida A, 2001, J ALLERGY CLIN IMMUN, V108, P791; SHAVER JR, 1995, AM J RESP CRIT CARE, V152, P1189; SHTURMANELLSTEIN R, 1978, AM REV RESPIR DIS, V118, P65; Steagall WK, 2000, AM J RESP CELL MOL, V22, P45; STEPHENS L, 1996, J ALLERGY CLIN IMMUN, V97, pA315; STEVENS WJ, 1989, ALLERGY, V44, P471, DOI 10.1111/j.1398-9995.1989.tb04185.x; Togias A, 2002, J ALLERGY CLIN IMMUN, V109, pS262, DOI 10.1016/S0091-6749(02)81934-0; TOGIAS A, 2001, AM J RESP CRIT CARE, V164, P727; Togias Alkis G., 2000, Journal of Allergy and Clinical Immunology, V106, pS247; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776; Tos M., 1982, NOSE UPPER AIRWAY PH, P99; Varga EM, 1999, ALLERGY, V54, P338, DOI 10.1034/j.1398-9995.1999.00957.x; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Weille FL, 1936, NEW ENGL J MED, V215, P235, DOI 10.1056/NEJM193608062150602; WELSH PW, 1987, MAYO CLIN PROC, V62, P125; WINDOM HH, 1992, J ALLERGY CLIN IMMUN, V89, P334; WOOD RA, 1995, AM J RESP CRIT CARE, V151, P315; YAN K, 1983, EUR J RESPIR DIS, V64, P105	142	241	272	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1171	1183		10.1067/mai.2003.1592		13	Allergy; Immunology	Allergy; Immunology	688FZ	WOS:000183424700001	12789212	
J	Jatakanon, A; Lim, S; Barnes, PJ				Jatakanon, A; Lim, S; Barnes, PJ			Changes in sputum eosinophils predict less of asthma control	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							EXHALED NITRIC-OXIDE; AIRWAY INFLAMMATION; RESPIRATORY-TRACT; MILD ASTHMA; EXACERBATIONS; GLUCOCORTICOIDS; PREDNISONE; BUDESONIDE; EXPOSURE; EXAMINE	Exacerbations of asthma are likely to be due to an increase in airway inflammation. We have studied noninvasive markers of airway inflammation in asthma exacerbations induced by reducing the dose of inhaled corticosteroids. Following a 2-wk run-in period, mild exacerbations were induced in subjects with stable asthma controlled with medium- to high-dose inhaled corticosteroids (beclomethasone dipropionate greater than or equal to 800 mu g or equivalent daily) by switching them to budesonide 200 mu g daily given from a dry-powder inhaler (Turbohaler). Fifteen subjects were enrolled and were seen twice weekly for 8 wk after steroid reduction. At each visit, exhaled nitric oxide (NO), and methacholine airway responsiveness were measured and spirometry and sputum induction were performed. Mild exacerbation was defined as: (1) a decrease in morning peak expiratory flow (PEF) of greater than or equal to 20% but < 30% on at least two consecutive days as compared with the mean for the last 7 d of the run-in period; (2) awakening on two consecutive nights because of asthma; or (3) increased use of a short-acting beta(2)-agonist to eight or more puffs daily. Eight subjects did not develop exacerbations during the 8-wk study, whereas seven subjects developed mild exacerbations at Week 4 (n = 1), Week 6 (n = 1), and Week 8 (n = 5). The only significant difference between these two groups at baseline was a higher baseline sputum eosinophil count in subjects with subsequent exacerbations (p < 0.05). The increases in sputum eosinophils and exhaled NO were correlated with decreases in airway function, including decreases in morning PEF and FEV1. However, multiple regression analysis suggested that the change in sputum eosinophils is a potentially useful marker in predicting loss of asthma control reflected by loss of airway function.	Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, Sch Med, London SW3 6LY, England	Barnes, PJ (reprint author), Natl Heart & Lung Inst, Dept Thorac Med, Imperial Coll, Sch Med, Dovehouse St, London SW3 6LY, England.						BAIGELMAN W, 1983, AM J MED, V75, P929, DOI 10.1016/0002-9343(83)90871-9; BOULET LP, 1993, J ALLERGY CLIN IMMUN, V91, P883, DOI 10.1016/0091-6749(93)90346-H; British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; Djukanovic R, 1996, THORAX, V51, P575, DOI 10.1136/thx.51.6.575; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Jatakanon A, 1998, EUR RESPIR J, V12, P1084, DOI 10.1183/09031936.98.12051084; Jatakanon A, 1999, THORAX, V54, P108; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Kips JC, 1998, EUR RESPIR J, V11, P529; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; National Heart Lung and Blood Institute National Asthma Education Program, 1997, NIH PUBL; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Pizzichini MMM, 1996, EUR RESPIR J, V9, P449, DOI 10.1183/09031936.96.09030449; Pizzichini MMM, 1997, AM J RESP CRIT CARE, V155, P1501; SMITH L, 1995, ANN ALLERG ASTHMA IM, V74, P454; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; SPENCE DPS, 1994, AM J RESP CRIT CARE, V149, P1142; Tamaoki J, 1997, AM J RESP CRIT CARE, V155, P1235; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317	32	240	254	0	2	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN	2000	161	1					64	72				9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	275KW	WOS:000084820200012	10619799	
J	Meiler, F; Zumkehr, J; Klunker, S; Ruckert, B; Akdis, CA; Akdis, M				Meiler, Flurina; Zumkehr, Judith; Klunker, Sven; Rueckert, Beate; Akdis, Cezmi A.; Akdis, Muebeccel			In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							PHASE CUTANEOUS REACTIONS; BEE VENOM; AUTOIMMUNE-DISEASES; IMMUNE-RESPONSES; GENE-EXPRESSION; DENDRITIC CELLS; ATOPIC SUBJECTS; SELF-TOLERANCE; ORAL TOLERANCE; IL-10 RECEPTOR	High dose bee venom exposure in beekeepers by natural bee stings represents a model to understand mechanisms of T cell tolerance to allergens in healthy individuals. Continuous exposure of nonallergic beekeepers to high doses of bee venom antigens induces diminished T cell-related cutaneous late-phase swelling to bee stings in parallel with suppressed allergen-specific T cell proliferation and T helper type 1 (Th1) and Th2 cytokine secretion. After multiple bee stings, venom antigen-specific Th1 and Th2 cells show a switch toward interleukin (IL) 10-secreting type 1 T regulatory (Tr1) cells. T cell regulation continues as long as antigen exposure persists and returns to initial levels within 2 to 3 mo after bee stings. Histamine receptor 2 up-regulated on specific Th2 cells displays a dual effect by directly suppressing allergen-stimulated T cells and increasing IL-10 production. In addition, cytotoxic T lymphocyte-associated antigen 4 and programmed death 1 play roles in allergen-specific T cell suppression. In contrast to its role in mucosal allergen tolerance, transforming growth factor beta does not seem to be an essential player in skin-related allergen tolerance. Thus, rapid switch and expansion of IL-10-producing Tr1 cells and the use of multiple suppressive factors represent essential mechanisms in immune tolerance to a high dose of allergens in nonallergic individuals.	[Meiler, Flurina; Zumkehr, Judith; Klunker, Sven; Rueckert, Beate; Akdis, Cezmi A.; Akdis, Muebeccel] Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Akdis, M (reprint author), Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland.	akdism@siaf.unizh.ch			Swiss National Science Foundation [32-112306/1, 32-118226]; Global Allergy and Asthma European Network	This work was funded by the Swiss National Science Foundation (grants 32-112306/1 and 32-118226) and the Global Allergy and Asthma European Network.	Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Akdis CA, 2006, CURR OPIN IMMUNOL, V18, P718, DOI 10.1016/j.coi.2006.09.016; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2006, CURR OPIN IMMUNOL, V18, P738, DOI 10.1016/j.coi.2006.06.003; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Bacchetta R, 2002, EUR J IMMUNOL, V32, P2237, DOI 10.1002/1521-4141(200208)32:8<2237::AID-IMMU2237>3.0.CO;2-2; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; Brosterhus H, 1999, EUR J IMMUNOL, V29, P4053, DOI 10.1002/(SICI)1521-4141(199912)29:12<4053::AID-IMMU4053>3.0.CO;2-C; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cong YZ, 2002, J IMMUNOL, V169, P6112; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P437, DOI 10.1016/0091-6749(94)90352-2; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Groux H, 1997, NATURE, V389, P737; Hill JA, 2007, NAT IMMUNOL, V8, P124, DOI 10.1038/ni0207-124; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Van der Pouw Kraan T. C., 1998, J CLIN INVEST, V102, P1866; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LIU Y, 1994, J IMMUNOL, V152, P1821; Maurer M, 2003, J CLIN INVEST, V112, P432, DOI 10.1172/JCI200318106; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1986, J IMMUNOL, V136, P2357; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nishimura H, 1999, IMMUNITY, V11, P141, DOI 10.1016/S1074-7613(00)80089-8; Peek EJ, 2005, AM J RESP CELL MOL, V33, P105, DOI 10.1165/rcmb.2005-0100OC; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; Sakaguchi S, 2007, SCIENCE, V317, P627, DOI 10.1126/science.1142331; Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x; Sundrud MS, 2003, J IMMUNOL, V171, P3542; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Texier C, 2000, J IMMUNOL, V164, P3177; Thurmond RL, 2008, NAT REV DRUG DISCOV, V7, P41, DOI 10.1038/nrd2465; Van Parijs L, 1998, SCIENCE, V280, P243; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Ying S, 1997, J IMMUNOL, V158, P5050	52	239	249	0	12	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	NOV 24	2008	205	12					2887	U120		10.1084/jem.20080193		18	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	378BE	WOS:000261295300021	19001136	
J	Abrahamsson, TR; Jakobsson, T; Bottcher, MF; Fredrikson, M; Jenmalm, MC; Bjorksten, B; Oldaeus, G				Abrahamsson, Thomas R.; Jakobsson, Ted; Bottcher, Malin Fageras; Fredrikson, Mats; Jenmalm, Maria C.; Bjorksten, Bengt; Oldaeus, Goran			Probiotics in prevention of IgE-associated eczema: A double-blind, randomized, placebo-controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						children; eczema; IgE; Lactobacillus; prevention; probiotics; sensitization; skin prick test	ATOPIC-DERMATITIS; LACTOBACILLUS-REUTERI; IN-VITRO; CHILDREN; INFANTS; DISEASE; COLONIZATION; SUPPLEMENTATION; SENSITIZATION; INFECTIONS	Background: An altered microbial exposure may underlie the increase of allergic diseases in affluent societies. Probiotics may alleviate and even prevent eczema in infants. Objective: To prevent eczema and sensitization in infants with a family history of allergic disease by oral supplementation with the probiotic Lactobacillus reuteri. Methods: Double-blind, randomized, placebo-controlled trial, which comprised 232 families with allergic disease, of whom 188 completed the study. The mothers received L reuteri ATCC 55730(1 x 10(8) colony forming units) daily from gestational week 36 until delivery. Their babies then continued with the same product from birth until 12 months of age and were followed up for another year. Primary outcome was allergic disease, with or without positive skin prick test or circulating IgE to food allergens. Results: The cumulative incidence of eczema was similar, 36% in the treated versus 34% in the placebo group. The L reuteri group had less IgE-associated eczema during the second year, 8% versus 20% (P = .02), however. Skin prick test reactivity was also less common in the treated than in the placebo group, significantly so for infants with mothers with allergies, 14% versus 31% (P = .02). Wheeze and other potentially allergic diseases were not affected. Conclusion: Although a preventive effect of probiotics on infant eczema was not confirmed, the treated infants had less IgE-associated eczema at 2 years of age and therefore possibly run a reduced risk to develop later respiratory allergic disease. Clinical implication: Probiotics may reduce the incidence of IgE-associated eczema in infancy.	Linkoping Univ, Div Pediat, Div Mol & Clin Med, S-58183 Linkoping, Sweden; Linkoping Univ, Dept Mol & Clin Med, Div Environm & Occupat Med, S-58183 Linkoping, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Cty Hosp Ryhov, Dept Pediat, Jonkoping, Sweden	Abrahamsson, TR (reprint author), Linkoping Univ Hosp, Div Paediat, S-58185 Linkoping, Sweden.	Thomas.Abrahamsson@lio.se	Jenmalm, Maria/C-9679-2009	Jenmalm, Maria/0000-0002-2117-5366			ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; BJORKSTEN B, 1999, CLIN EXP ALLERGY, V29, P1; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Brouwer ML, 2006, CLIN EXP ALLERGY, V36, P899, DOI 10.1111/j.1365-2222.2006.02513.x; Eom TH, 2005, KOREAN J PEDIAT, V48, P986; Guarner F, 1998, INT J FOOD MICROBIOL, V39, P237, DOI 10.1016/S0168-1605(97)00136-0; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jacobsen CN, 1999, APPL ENVIRON MICROB, V65, P4949; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1067/mai.2003.1812; Ma DL, 2004, INFECT IMMUN, V72, P5308, DOI 10.1128/IAI.72.9.5308-5314.2004; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Novembre E, 2001, ALLERGY, V56, P452, DOI 10.1034/j.1398-9995.2001.056005452.x; Pena JA, 2005, INFECT IMMUN, V73, P912, DOI 10.1128/IAI.73.2.912-920.2005; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; SEYMOUR JL, 1987, J AM ACAD DERMATOL, V17, P988, DOI 10.1016/S0190-9622(87)70288-6; Shornikova AV, 1997, PEDIATR INFECT DIS J, V16, P1103, DOI 10.1097/00006454-199712000-00002; Shornikova AV, 1997, J PEDIATR GASTR NUTR, V24, P399, DOI 10.1097/00005176-199704000-00008; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; STALDER JF, 1993, DERMATOLOGY, V186, P23; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; Vaarala O, 2003, CLIN EXP ALLERGY, V33, P1634, DOI 10.1111/j.1365-2222.2003.01835.x; Valeur N, 2004, APPL ENVIRON MICROB, V70, P1176, DOI 10.1128/AEM.70.2.1176-1181.2004; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Weizman Z, 2005, PEDIATRICS, V115, P5, DOI 10.1542/peds.2004-1815; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; WOLF BW, 1995, MICROB ECOL HEALTH D, V8, P41; Wolf BW, 1998, FOOD CHEM TOXICOL, V36, P1085, DOI 10.1016/S0278-6915(98)00090-8; Zeuthen L., 2005, CLIN VACCINE IMMUNOL, V13, P365	35	239	260	4	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1174	1180		10.1016/j.jaci.2007.01.007		7	Allergy; Immunology	Allergy; Immunology	167CB	WOS:000246427200018	17349686	
J	Hayashi, T; Beck, L; Rossetto, C; Gong, X; Takikawa, O; Takabayashi, K; Broide, DH; Carson, DA; Raz, E				Hayashi, T; Beck, L; Rossetto, C; Gong, X; Takikawa, O; Takabayashi, K; Broide, DH; Carson, DA; Raz, E			Inhibition of experimental asthma by indoleamine 2,3-dioxygenase	JOURNAL OF CLINICAL INVESTIGATION			English	Article							T-CELL PROLIFERATION; DENDRITIC CELLS; IMMUNOSTIMULATORY DNA; TRYPTOPHAN CATABOLISM; HYGIENE HYPOTHESIS; IN-VIVO; AIRWAY INFLAMMATION; ALLERGIC DISEASES; EPITHELIAL-CELLS; INTERFERON-GAMMA	Epidemiological evidence points to the inverse relationship between microbial exposure and the prevalence of allergic asthma and autoimmune diseases in Westernized countries. The molecular basis for this observation has not yet been completely delineated. Here we report that the administration of certain toll-like receptor (TLR) ligands, via the activation of innate immunity, induces high levels of indoleamine 2,3-dioxygenase (IDO), the rate-limiting enzyme of tryptophan catabolism in various organs. TLR9 ligand-induced pulmonary IDO activity inhibits Th2-driven experimental asthma. IDO activity expressed by resident lung cells rather than by pulmonary DCs suppressed lung inflammation and airway hyperreactivity. Our results provide a mechanistic insight into the various formulations of the hygiene hypothesis and underscore the notion that activation of innate immunity can inhibit adaptive Th cell responses.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Hokkaido Univ, Grad Sch Med, Cent Res Inst, Sapporo, Hokkaido, Japan	Raz, E (reprint author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	eraz@ucsd.edu			NIAID NIH HHS [AI40682, AI56453, P01 AI040682, U01 AI056453]; NIAMS NIH HHS [AR47360, P30 AR047360]; NIDDK NIH HHS [P01 DK035108, DK35108]		Babcock TA, 2000, CYTOKINE, V12, P588, DOI 10.1006/cyto.1999.0661; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barnes PJ, 2001, PULM PHARMACOL THER, V14, P329, DOI 10.1006/pupt.2000.0318; Bodaghi B, 1999, J IMMUNOL, V162, P957; Broide D, 1998, J IMMUNOL, V161, P7054; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Caucheteux SM, 2003, IMMUNITY, V18, P169, DOI 10.1016/S1074-7613(03)00028-1; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; Datta SK, 2003, J IMMUNOL, V170, P4102; Daubener W, 2001, INFECT IMMUN, V69, P6527, DOI 10.1128/IAI.69.10.6527-6531.2001; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fallarino F, 2003, NAT IMMUNOL, V4, P1206, DOI 10.1038/ni1003; Fallarino I, 2002, CELL DEATH DIFFER, V9, P1069, DOI 10.1038/sj.cdd.4401073; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; GODFREY DG, 1978, NATURE, V273, P600, DOI 10.1038/273600a0; Grogan JL, 2002, CURR OPIN IMMUNOL, V14, P366, DOI 10.1016/S0952-7915(02)00340-0; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hayashi T, 2001, INFECT IMMUN, V69, P6156, DOI 10.1128/IAI.69.10.6156-6164.2001; HISSONG BD, 1995, CELL IMMUNOL, V160, P264, DOI 10.1016/0008-8749(95)80037-J; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Howarth PH, 1998, CLIN EXP ALLERGY, V28, P2; Hwu P, 2000, J IMMUNOL, V164, P3596; Ikeda RK, 2003, AM J RESP CELL MOL, V28, P655, DOI 10.1165/rcmb.4853; Kemp A, 2003, PEDIATR ALLERGY IMMU, V14, P74, DOI 10.1034/j.1399-3038.2003.00017.x; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Mackler AM, 2003, J IMMUNOL, V170, P823; Martinez FD, 1999, LANCET S2, V354, pSII12; Mellor AL, 2003, J IMMUNOL, V171, P1652; Mellor AL, 2001, SEMIN IMMUNOL, V13, P213, DOI 10.1006/smim.2000.0317; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 1999, J EXP MED, V189, P1363, DOI 10.1084/jem.189.9.1363; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Sedlmayr P, 2002, MOL HUM REPROD, V8, P385, DOI 10.1093/molehr/8.4.385; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Suzuki S, 2001, BIOCHEM J, V355, P425, DOI 10.1042/0264-6021:3550425; SWANSON KA, 2003, AM J RESP CELL MOL B, V30, P311, DOI 10.1165/rcmb.2003-0268OC; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Takikawa O, 1999, ADV EXP MED BIOL, V467, P553; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; van Kooyk Y, 2003, NAT REV IMMUNOL, V3, P697, DOI 10.1038/nri1182; Vermaelen KY, 2001, J EXP MED, V193, P51; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	50	239	255	1	11	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	JUL	2004	114	2					270	279		10.1172/JCI200421275		10	Medicine, Research & Experimental	Research & Experimental Medicine	837UX	WOS:000222667600018	15254594	
J	Knight, DA; Holgate, ST				Knight, DA; Holgate, ST			The airway epithelium: Structural and functional properties in health and disease	RESPIROLOGY			English	Review						asthma; epithelium; human; inflammation; respiratory disease	EPIDERMAL-GROWTH-FACTOR; V BETA 3; EXTRACELLULAR-MATRIX COMPONENTS; ASTHMATIC BRONCHIAL EPITHELIUM; PROTEASE-ACTIVATED RECEPTORS; ARACHIDONIC-ACID METABOLISM; DIESEL EXHAUST PARTICLES; CELL-ADHESION RECEPTORS; NITRIC-OXIDE SYNTHASES; REPAIR IN-VIVO	The major function of the respiratory epithelium was once thought to be that of a physical barrier. However, it constitutes the interface between the internal milieu and the external environment as well as being a primary target for inhaled respiratory drugs. It also responds to changes in the external environment by secreting a large number of molecules and mediators that signal to cells of the immune system and underlying mesenchyme. Thus, the epithelium is in a unique position to translate gene-environment interactions. Normally, the epithelium has a tremendous capacity to repair itself following injury. However, evidence is rapidly accumulating to show that the air-way epithelium of asthmatics is abnormal and has increased susceptibility to injury compared to normal epithelium. Areas of detachment and fragility are a characteristic feature not observed in other inflammatory diseases such as COPD. In addition to being more susceptible to damage, normal repair processes are also compromised. Failure of appropriate growth and differentiation of airway epithelial cells will cause persistent mucosal injury. The response to traditional therapy such as glucocorticoids may also be compromised. However, whether the differences observed in asthmatic epithelium are a cause of or secondary to the development of the disease remains unanswered. Strategies to address this question include careful examination of the ontogeny of the disease in children and use of gene array technology should provide some important answers, as well as allow a better understanding of the critical role that the epithelium plays under normal conditions and in diseases such as asthma.	Sir Charles Gairdner Hosp, Asthma & Allergy Res Inst, Nedlands, WA 6009, Australia; Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Brooke Lab, Southampton SO9 4XY, Hants, England; Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia	Knight, DA (reprint author), Sir Charles Gairdner Hosp, Asthma & Allergy Res Inst, Ground Floor,E Block,Verdun St, Nedlands, WA 6009, Australia.						ADCOCK IM, 1993, J MOL ENDOCRINOL, V11, P1; ADRIAENSEN D, 1993, ANAT REC, V236, P70, DOI 10.1002/ar.1092360111; ALVING K, 1993, EUR RESPIR J, V6, P1368; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907; Asokananthan N, 2002, J IMMUNOL, V168, P3577; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; AYERS MM, 1988, EUR RESPIR J, V1, P58; BARNES PJ, 1988, PHARMACOL REV, V40, P49; Barnes PJ, 1997, PULM PHARMACOL THER, V10, P3, DOI 10.1006/pupt.1997.0074; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Bayram H, 2002, CLIN EXP ALLERGY, V32, P1285, DOI 10.1046/j.1365-2745.2002.01435.x; Boers JE, 1996, AM J RESP CRIT CARE, V154, P758; Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000; Boland S, 1996, J CELL SCI, V109, P2207; BORSON DB, 1991, AM J PHYSIOL, V260, pL212; Boudreau N, 1996, P NATL ACAD SCI USA, V93, P3509, DOI 10.1073/pnas.93.8.3509; Boudreau Nancy J., 1999, Biochemical Journal, V339, P481, DOI 10.1042/0264-6021:3390481; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; Cambier S, 2000, CANCER RES, V60, P7084; Carayol N, 2002, AM J RESP CRIT CARE, V166, P1290; CARVER W, 1995, J CELL PHYSIOL, V165, P425, DOI 10.1002/jcp.1041650224; Chen G, 2003, AM J PHYSIOL-LUNG C, V284, pL548, DOI 10.1152/ajplung.00091.2002; Chung KF, 1999, THORAX, V54, P825; Churg A, 1996, AM J RESP CRIT CARE, V154, P1124; Cichy J, 2002, J BIOL CHEM, V277, P44440, DOI 10.1074/jbc.M207437200; Clark RAF, 1996, AM J PATHOL, V148, P1407; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Cruet S, 1999, GYNECOL ONCOL, V75, P254, DOI 10.1006/gyno.1999.5572; Dahm LM, 1998, J CELL SCI, V111, P1175; DAMJANOVICH L, 1992, AM J RESP CELL MOL, V6, P197; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Davies DE, 2002, INT J BIOCHEM CELL B, V34, P1520, DOI 10.1016/S1357-2725(02)00048-1; DEMARZO N, 1992, AM J PHYSIOL, V262, pL198; DEWATER R, 1986, AM REV RESPIR DIS, V133, P882; Donnelly LE, 2002, AM J RESP CELL MOL, V26, P144; Dorscheid DR, 2001, AM J RESP CRIT CARE, V164, P1939; Dupuit F, 2000, AM J PHYSIOL-LUNG C, V278, pL165; Ediger TL, 2000, J PHARMACOL EXP THER, V294, P1076; ELING TE, 1986, J BIOL CHEM, V261, P2841; ERJEFALT JS, 1995, CELL TISSUE RES, V281, P305, DOI 10.1007/s004410050427; Erjefalt JS, 1997, CLIN EXP ALLERGY, V27, P1344; Erjefalt JS, 1997, THORAX, V52, P1010; ERJEFALT JS, 1994, MICROVASC RES, V48, P161, DOI 10.1006/mvre.1994.1047; EVANS MJ, 1990, AM J RESP CELL MOL, V3, P341; EVANS MJ, 1988, AM REV RESPIR DIS, V138, P481; EVANS MJ, 1989, AM J RESP CELL MOL, V1, P463; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Fan JM, 1999, KIDNEY INT, V56, P1455, DOI 10.1046/j.1523-1755.1999.00656.x; Folkerts G, 2001, EUR J PHARMACOL, V429, P251, DOI 10.1016/S0014-2999(01)01324-3; GAO YS, 1993, J APPL PHYSIOL, V74, P2421; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; GOLDMAN MJ, 1995, HUM GENE THER, V6, P839, DOI 10.1089/hum.1995.6.7-839; GOLDMAN MJ, 1995, J VIROL, V69, P5951; GOSNEY JR, 1988, THORAX, V43, P878, DOI 10.1136/thx.43.11.878; Grosset C, 1999, CYTOKINE, V11, P29, DOI 10.1006/cyto.1998.0394; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Hargreave FE, 1998, J ALLERGY CLIN IMMUN, V102, pS102, DOI 10.1016/S0091-6749(98)70040-5; Harkema JRMA, 1991, AIRWAY EPITHELIUM PH, P3; Hastie AT, 2002, AM J RESP CRIT CARE, V165, P266; HERBERT CA, 1990, LANCET, V336, P1132, DOI 10.1016/0140-6736(90)92611-K; HERTLE MD, 1992, J CLIN INVEST, V89, P1892, DOI 10.1172/JCI115794; Hicks W, 1997, EXP CELL RES, V237, P357, DOI 10.1006/excr.1997.3796; Hill EM, 1998, AM J RESP CELL MOL, V18, P662; Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; Holgate ST, 2001, AM J RESP CRIT CARE, V164, P1997; Holgate ST, 2001, INT ARCH ALLERGY IMM, V124, P253, DOI 10.1159/000053726; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; Holt P G, 1991, Eur Respir J Suppl, V13, p6s; HOLTZMAN MJ, 1992, ANNU REV PHYSIOL, V54, P303; Hong KU, 2001, AM J RESP CELL MOL, V24, P671; HORIBA K, 1994, VIRCHOWS ARCH, V425, P425; Hoshino M, 1998, THORAX, V53, P21; HOWARTH PH, 1995, AM J RESP CELL MOL, V13, P288; HOWARTH PH, 1994, AM J RESP CRIT CARE, V150, pS18; Howat WJ, 2002, J STRUCT BIOL, V139, P137, DOI 10.1016/S1047-8477(02)00589-0; Howat WJ, 2001, AM J PATHOL, V158, P673, DOI 10.1016/S0002-9440(10)64009-6; Howat WJ, 2002, AM J PHYSIOL-LUNG C, V282, pL115; HUHTALA P, 1995, J CELL BIOL, V129, P867, DOI 10.1083/jcb.129.3.867; HUNTER JA, 1985, P NATL ACAD SCI USA, V82, P4633, DOI 10.1073/pnas.82.14.4633; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518; Jeffery PK, 1998, AM J RESP CRIT CARE, V157, pS174; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152; JEFFERY PK, 1983, AM REV RESPIR DIS, V128, P14; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kalinski P, 1997, J IMMUNOL, V159, P28; Kawamoto M, 1997, CLIN SCI, V93, P355; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; KNIGHT DA, 1995, EUR J PHARMACOL, V272, P13, DOI 10.1016/0014-2999(94)00602-4; KNIGHT DA, 1995, EUR J PHARMACOL, V272, P1, DOI 10.1016/0014-2999(94)00601-3; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Knight DR, 2001, IMMUNOL CELL BIOL, V79, P160, DOI 10.1046/j.1440-1711.2001.00988.x; KOGA Y, 1992, EUR J PHARMACOL, V220, P141; Kowalski ML, 2000, AM J RESP CRIT CARE, V161, P391; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14; Lamb JP, 2002, AM J RESP CRIT CARE, V166, P1269, DOI 10.1164/rccm.2112018; LESLIE KO, 1992, CELL MOTIL CYTOSKEL, V22, P92, DOI 10.1002/cm.970220203; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lindner JR, 2000, J IMMUNOL, V165, P6504; LUMSDEN AB, 1984, THORAX, V39, P844, DOI 10.1136/thx.39.11.844; Matsumoto K, 1996, RESPIRATION, V63, P205; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; MINOO P, 1994, ANNU REV PHYSIOL, V56, P13; MONTEFORT S, 1992, THORAX, V47, P499, DOI 10.1136/thx.47.7.499; MONTEFORT S, 1994, AM J RESP CRIT CARE, V149, P1149; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; Moustakas A, 2001, J CELL SCI, V114, P4359; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; NADEL JA, 1991, AM REV RESPIR DIS, V143, pS33; OHRUI T, 1992, J PHARMACOL EXP THER, V261, P1268; Okada H, 1997, AM J PHYSIOL, V273, P563; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; Persson CGA, 1996, AM J RESP CRIT CARE, V153, pS9; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pilewski JM, 1997, AM J PHYSIOL-LUNG C, V273, pL256; POHUNEK P, 2000, RESP J, V11, pS160; Polosa R, 1999, AM J RESP CELL MOL, V20, P914; Powell DW, 1999, AM J PHYSIOL, V277, P1; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; RAEBURN D, 1994, EUR RESPIR J, V7, P2226, DOI 10.1183/09031936.94.07122226; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; RICKARD KA, 1993, AM J RESP CELL MOL, V8, P63; RICKARD KA, 1991, AM J RESP CELL MOL, V4, P440; ROGERS AV, 1993, EUR RESPIR J, V6, P498; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Sarkissian M, 1999, J IMMUNOL, V162, P1772; Scaffidi AK, 2001, J CELL SCI, V114, P3507; SCHELLENBERG RR, 1994, ANN NY ACAD SCI, V744, P243, DOI 10.1111/j.1749-6632.1994.tb52742.x; SCHMITTGRAFF A, 1994, VIRCHOWS ARCH, V425, P3, DOI 10.1007/BF00193944; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Schwiebert LM, 1996, AM J RESP CRIT CARE, V154, pS16; SCHWIEBERT LM, 1996, AM J RESP CRIT CARE, V154, pS19; Shang T, 1999, J LEUKOCYTE BIOL, V66, P809; Shang XZ, 1997, IMMUNOLOGY, V92, P527, DOI 10.1046/j.1365-2567.1997.00372.x; Sheppard D, 1998, AM J RESP CELL MOL, V19, P349; Sheppard D, 1996, BIOESSAYS, V18, P655, DOI 10.1002/bies.950180809; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134; SIGAL E, 1992, AM J PHYSIOL, V262, P392; SPARROW MP, 1995, CAN J PHYSIOL PHARM, V73, P180; Spina D, 1998, AM J RESP CRIT CARE, V158, pS141; Steinhoff M, 2000, NAT MED, V6, P151; Storgard CM, 1999, J CLIN INVEST, V103, P47, DOI 10.1172/JCI3756; STRUTZ F, 1995, NEPHROL DIAL TRANSPL, V10, P1504; STRUTZ F, 1995, J CELL BIOL, V130, P393, DOI 10.1083/jcb.130.2.393; Strutz F, 2001, KIDNEY INT, V59, P579, DOI 10.1046/j.1523-1755.2001.059002579.x; Sweeney C, 2001, J BIOL CHEM, V276, P22685, DOI 10.1074/jbc.M100602200; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; TERRANOVA VP, 1980, CELL, V22, P719, DOI 10.1016/0092-8674(80)90548-6; Trusolino L, 2000, FASEB J, V14, P1629, DOI 10.1096/fj.14.11.1629; Tseng SCG, 1999, J CELL PHYSIOL, V179, P325, DOI 10.1002/(SICI)1097-4652(199906)179:3<325::AID-JCP10>3.0.CO;2-X; Turner M O, 1998, Can Respir J, V5, P261; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; Wang A, 1996, AM J RESP CELL MOL, V15, P664; Watkins DN, 1997, AM J RESP CELL MOL, V16, P629; WEICHSELBAUM M, 2002, RESPIROLOGY S, V7, pA32; Xu JH, 1996, J CELL BIOL, V132, P239, DOI 10.1083/jcb.132.1.239; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Yu L, 2002, EMBO J, V21, P3749, DOI 10.1093/emboj/cdf366; Zhang SL, 1999, LAB INVEST, V79, P395; Zhang YL, 1995, J CLIN INVEST, V96, P2997, DOI 10.1172/JCI118372; Zieske JD, 2001, INVEST OPHTH VIS SCI, V42, P1465; Zwick E, 1999, TRENDS PHARMACOL SCI, V20, P408, DOI 10.1016/S0165-6147(99)01373-5	180	239	248	1	11	BLACKWELL PUBLISHING ASIA	CARLTON	54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA	1323-7799			RESPIROLOGY	Respirology	DEC	2003	8	4					432	446		10.1046/j.1440-1843.2003.00493.x		15	Respiratory System	Respiratory System	753JE	WOS:000187227600003	14708552	
J	Soubani, AO; Chandrasekar, PH				Soubani, AO; Chandrasekar, PH			The clinical spectrum of pulmonary aspergillosis	CHEST			English	Review						allergic pulmonary aspergillosis; aspergillus; fungal diseases; immunocompromised host; pulmonary infection	ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS; BONE-MARROW TRANSPLANTATION; INVASIVE FUNGAL-INFECTIONS; ACQUIRED-IMMUNODEFICIENCY-SYNDROME; CHRONIC EOSINOPHILIC PNEUMONIA; LINKED-IMMUNOSORBENT-ASSAY; LIPOSOMAL AMPHOTERICIN-B; LATEX AGGLUTINATION-TEST; AIR CRESCENT SIGN; ACUTE-LEUKEMIA	Aspergillus is a ubiquitous fungus that causes a variety of clinical syndromes in the lung, ranging from aspergilloma in patients with lung cavities, to chronic necrotizing aspergillosis in those who are mildly immunocompromised or have chronic lung disease. Invasive pulmonary aspergillosis (IPA) is a severe and commonly fatal disease that is seen in immunocompromised patients, while allergic bronchopulmonary aspergillosis is a hypersensitivity reaction to Aspergillus antigens that mainly affects patients with asthma. In light of the increasing risk factors leading to IPA, such as organ transplantation and immunosuppressive therapy, and recent advances in the diagnosis and treatment of Aspergillus-related lung diseases, it is essential for clinicians to be familiar with the clinical presentation, diagnostic methods, and approach to management of the spectrum of pulmonary aspergillosis.	Wayne State Univ, Sch Med, Div Pulm Crit Care & Sleep Med, Detroit, MI USA; Wayne State Univ, Sch Med, Div Infect Dis, Detroit, MI USA	Soubani, AO (reprint author), Harper Univ Hosp, Div Pulm Crit Care & Sleep Med, 3990 John,R-3 Hudson, Detroit, MI 48201 USA.						AddrizzoHarris DJ, 1997, CHEST, V111, P612, DOI 10.1378/chest.111.3.612; ALBELDA SM, 1985, AM REV RESPIR DIS, V131, P115; ALBELDA SM, 1984, AM J MED, V76, P1027, DOI 10.1016/0002-9343(84)90853-2; ALLO MD, 1987, NEW ENGL J MED, V317, P1105, DOI 10.1056/NEJM198710293171802; ASLAM PA, 1971, CHEST, V59, P28, DOI 10.1378/chest.59.1.28; Bandoh S, 1999, LUNG CANCER-J IASLC, V26, P195, DOI 10.1016/S0169-5002(99)00080-X; Bartlett JG, 2000, MEDICINE, V79, P281, DOI 10.1097/00005792-200007000-00009; BASICH JE, 1981, J ALLERGY CLIN IMMUN, V68, P98, DOI 10.1016/0091-6749(81)90165-2; Bernard A, 1997, ANN THORAC SURG, V64, P1441, DOI 10.1016/S0003-4975(97)00858-8; BERNHISELBROADBENT J, 1991, J INFECT DIS, V163, P908; BINDER RE, 1982, MEDICINE, V61, P109, DOI 10.1097/00005792-198203000-00005; Bohme A, 2000, ANTIBIOT CHEMOTHER, V50, P69; BOSKEN CH, 1988, AM J SURG PATHOL, V12, P216, DOI 10.1097/00000478-198803000-00007; Bowden RA, 1996, J INFECT DIS, V173, P1208; BRETAGNE S, 1995, J CLIN MICROBIOL, V33, P1164; British Thoracic Association, 1979, BR J DIS CHEST, V73, P349; British Tuberculosis Association, 1968, TUBERCLE, V49, P1; Bulpa PA, 2001, INTENS CARE MED, V27, P59, DOI 10.1007/s001340000768; Caillot D, 1997, J CLIN ONCOL, V15, P139; CAMPBELL JH, 1991, THORAX, V46, P839, DOI 10.1136/thx.46.11.839; CAPEWELL S, 1989, THORAX, V44, P925, DOI 10.1136/thx.44.11.925; Caras WE, 1996, MAYO CLIN PROC, V71, P25; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chen JC, 1997, THORAX, V52, P810; Cockrill BA, 1999, ANNU REV MED, V50, P303; Cote CG, 1998, CHEST, V114, P1465, DOI 10.1378/chest.114.5.1465; CURTIS AM, 1979, RADIOLOGY, V133, P17; DALY RC, 1986, J THORAC CARDIOV SUR, V92, P981; DENNING DW, 1989, AM J MED, V86, P791, DOI 10.1016/0002-9343(89)90475-0; DENNING DW, 1994, AM J MED, V97, P135, DOI 10.1016/0002-9343(94)90023-X; DENNING DW, 1991, NEW ENGL J MED, V324, P654, DOI 10.1056/NEJM199103073241003; Denning DW, 1996, CLIN INFECT DIS, V23, P608; DENNING DW, 1990, REV INFECT DIS, V12, P1147; Denning DW, 1998, CLIN INFECT DIS, V26, P781, DOI 10.1086/513943; Donnelly JP, 2000, INT J ANTIMICROB AG, V16, P127, DOI 10.1016/S0924-8579(00)00217-X; DUPONT B, 1990, J AM ACAD DERMATOL, V23, P607, DOI 10.1016/0190-9622(90)70263-H; DUTHIE R, 1995, CLIN INFECT DIS, V20, P598; FAULKNER SL, 1978, ANN THORAC SURG, V25, P389; GANASSINI A, 1995, RESP MED, V89, P143, DOI 10.1016/0954-6111(95)90198-1; GARVEY J, 1977, J THORAC CARDIOV SUR, V74, P542; GEFTER WB, 1985, RADIOLOGY, V157, P605; GEFTER WB, 1992, J THORAC IMAG, V7, P56, DOI 10.1097/00005382-199209000-00009; GEFTER WB, 1981, RADIOLOGY, V140, P313; GERSON SL, 1984, ANN INTERN MED, V100, P345; GLIMP RA, 1983, ARCH INTERN MED, V143, P303, DOI 10.1001/archinte.143.2.303; GRAHAMECLARKE CNE, 1994, RESP MED, V88, P465, DOI 10.1016/S0954-6111(05)80051-4; Greenberger PA, 1997, JAMA-J AM MED ASSOC, V278, P1924, DOI 10.1001/jama.278.22.1924; GREENBERGER PA, 1986, ANN ALLERGY, V56, P444; Groll AH, 1996, J INFECTION, V33, P23, DOI 10.1016/S0163-4453(96)92700-0; HAMMERMAN KJ, 1974, AM REV RESPIR DIS, V109, P57; HEWLETT RI, 1974, CHEST, V66, P738, DOI 10.1378/chest.66.6.738; Hibberd P.L., 1994, CLIN INFECT DIS   S1, V19, P33; Hinojosa M, 1996, J ALLERGY CLIN IMMUN, V98, P985, DOI 10.1016/S0091-6749(96)80016-9; Horvath JA, 1996, AM J MED, V100, P171, DOI 10.1016/S0002-9343(97)89455-7; Iwen PC, 1998, CLIN INFECT DIS, V26, P1092, DOI 10.1086/520297; JEDERLINIC PJ, 1988, MEDICINE, V67, P154; JENNINGS TS, 1993, ANN PHARMACOTHER, V27, P1206; JEWKES J, 1983, THORAX, V38, P572, DOI 10.1136/thx.38.8.572; JUDSON MA, 1994, CHEST, V105, P1314, DOI 10.1378/chest.105.5.1314; KAHN FW, 1986, AM J CLIN PATHOL, V86, P518; KARAM GH, 1986, REV INFECT DIS, V8, P357; KARAS A, 1976, ANN THORAC SURG, V22, P1; Kauffman CA, 1996, LANCET, V347, P1640, DOI 10.1016/S0140-6736(96)91481-6; Kawamura S, 2000, INTERNAL MED, V39, P209, DOI 10.2169/internalmedicine.39.209; KEMPER CA, 1993, CLIN INFECT DIS, V17, P344; KILMAN JW, 1969, J THORAC CARDIOV SUR, V57, P642; KNUTSEN AP, 1989, J LAB CLIN MED, V113, P428; KOKKARINEN JI, 1992, AM REV RESPIR DIS, V145, P3; KUHLMAN JE, 1987, CHEST, V92, P95, DOI 10.1378/chest.92.1.95; KUHLMAN JE, 1985, RADIOLOGY, V157, P611; KUHLMAN JE, 1988, AM J ROENTGENOL, V150, P1015; LETHI HD, 1995, SCAND J RHEUMATOL, V24, P260; LEVITZ SM, 1984, ADV INTERNAL MED, V30, P153; LIBSHITZ HI, 1981, RADIOLOGY, V140, P301; LORTHOLARY O, 1993, AM J MED, V95, P177, DOI 10.1016/0002-9343(93)90258-Q; MASSARD G, 1992, ANN THORAC SURG, V54, P1159; MCCABE RE, 1985, AM J MED, V78, P609, DOI 10.1016/0002-9343(85)90403-6; McCarthy D S, 1973, Clin Allergy, V3, P57, DOI 10.1111/j.1365-2222.1973.tb01310.x; MCWHINNEY PHM, 1993, CLIN INFECT DIS, V17, P397; MELCHERS WJG, 1994, J CLIN MICROBIOL, V32, P1710; MILLER WT, 1994, CHEST, V105, P37, DOI 10.1378/chest.105.1.37; MILLS W, 1994, BRIT J HAEMATOL, V86, P754, DOI 10.1111/j.1365-2141.1994.tb04825.x; MINAMOTO GY, 1992, CLIN INFECT DIS, V14, P66; MINTZER RA, 1978, RADIOLOGY, V127, P301; MROUEH S, 1994, CHEST, V105, P32, DOI 10.1378/chest.105.1.32; MUNK PL, 1993, RADIOLOGY, V188, P821; NALESNIK MA, 1980, J CLIN MICROBIOL, V11, P370; Nathan SD, 2000, CHEST, V118, P403, DOI 10.1378/chest.118.2.403; NG TTC, 1995, ARCH INTERN MED, V155, P1093, DOI 10.1001/archinte.155.10.1093; PAGANI JJ, 1981, AM J ROENTGENOL, V137, P1033; PAGANO L, 1995, BRIT J HAEMATOL, V89, P500, DOI 10.1111/j.1365-2141.1995.tb08355.x; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; PATTERSON R, 1982, ANN INTERN MED, V96, P286; Patterson TF, 2000, MEDICINE, V79, P250, DOI 10.1097/00005792-200007000-00006; PENNINGTON JE, 1980, MED CLIN N AM, V64, P475; Pittet D, 1996, AM J RESP CRIT CARE, V154, P541; PRYSTOWSKY SD, 1976, NEW ENGL J MED, V295, P655, DOI 10.1056/NEJM197609162951206; RAFFERTY P, 1983, THORAX, V38, P579, DOI 10.1136/thx.38.8.579; Regnard JF, 2000, ANN THORAC SURG, V69, P898, DOI 10.1016/S0003-4975(99)01334-X; Ribaud P, 1999, CLIN INFECT DIS, V28, P322, DOI 10.1086/515116; RICHERSON HB, 1989, J ALLERGY CLIN IMMUN, V84, P839, DOI 10.1016/0091-6749(89)90349-7; RINALDI MG, 1983, REV INFECT DIS, V5, P1061; ROBERTS CM, 1987, RADIOLOGY, V165, P123; ROBINSON LA, 1995, J THORAC CARDIOV SUR, V109, P1182, DOI 10.1016/S0022-5223(95)70202-4; ROGERS TR, 1990, LANCET, V336, P1210, DOI 10.1016/0140-6736(90)92831-2; Rohrlich P, 1996, PEDIATR INFECT DIS J, V15, P232, DOI 10.1097/00006454-199603000-00011; ROSENBERG M, 1977, ANN INTERN MED, V86, P405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; ROSENHEIM SH, 1975, AM REV RESPIR DIS, V111, P549; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P450; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P940; SALVAGGIO JE, 1987, J ALLERGY CLIN IMMUN, V79, P558, DOI 10.1016/S0091-6749(87)80149-5; Saraceno JL, 1997, CHEST, V112, P541, DOI 10.1378/chest.112.2.541; SAROSI GA, 1971, AM REV RESPIR DIS, V104, P581; SAUGIERVEBER P, 1993, BONE MARROW TRANSPL, V12, P121; SCHAFFNER A, 1993, MYCOSES, V36, P421; SCHAFFNER A, 1985, J CLIN INVEST, V76, P1755, DOI 10.1172/JCI112166; SCHWARTZ RS, 1984, CANCER, V53, P411, DOI 10.1002/1097-0142(19840201)53:3<411::AID-CNCR2820530308>3.0.CO;2-E; SHERERTZ RJ, 1987, AM J MED, V83, P709, DOI 10.1016/0002-9343(87)90902-8; SOLTANZADEH H, 1977, ANN SURG, V186, P13, DOI 10.1097/00000658-197707000-00002; Soubani AO, 1996, CHEST, V109, P1066, DOI 10.1378/chest.109.4.1066; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Stevens DA, 2000, CLIN INFECT DIS, V30, P696, DOI 10.1086/313756; Sulahian A, 1996, EUR J CLIN MICROBIOL, V15, P139, DOI 10.1007/BF01591487; SULAVIK SB, 1988, CLIN CHEST MED, V9, P609; TANG CM, 1992, J CLIN PATHOL, V45, P1, DOI 10.1136/jcp.45.1.1; Thompson C A, 2001, Am J Health Syst Pharm, V58, P560; TOMEE JFC, 1995, AM J RESP CRIT CARE, V151, P199; Tomee JFC, 1996, ANN INTERN MED, V125, P197; TUNCEL E, 1984, RESPIRATION, V46, P139; UFLACKER R, 1985, RADIOLOGY, V157, P637; Varkey B, 1998, IMMUNOL ALLERGY CLIN, V18, P479, DOI 10.1016/S0889-8561(05)70018-7; VERWEIJ PE, 1995, J CLIN MICROBIOL, V33, P1912; Verweij PE, 1997, INFECTION, V25, P86, DOI 10.1007/BF02113581; VONEIFF M, 1995, RESPIRATION, V62, P341; Wald A, 1997, J INFECT DIS, V175, P1459; Walsh TJ, 1998, CLIN INFECT DIS, V26, P1383, DOI 10.1086/516353; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87; WARNOCK ML, 1974, AM J CLIN PATHOL, V62, P73; YAMADA H, 1993, CHEST, V103, P1421, DOI 10.1378/chest.103.5.1421; YOUNG RC, 1970, MEDICINE, V49, P147; YU VL, 1986, AM J MED, V81, P249, DOI 10.1016/0002-9343(86)90259-7; Zizzo G, 1996, Radiol Med, V91, P817; [Anonymous], 1970, TUBERCLE, V51, P227	145	239	287	1	15	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2002	121	6					1988	1999		10.1378/chest.121.6.1988		12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	563TN	WOS:000176271800041	12065367	
J	Peel, JL; Tolbert, PE; Klein, M; Metzger, KB; Flanders, WD; Todd, K; Mulholland, JA; Ryan, PB; Frumkin, H				Peel, JL; Tolbert, PE; Klein, M; Metzger, KB; Flanders, WD; Todd, K; Mulholland, JA; Ryan, PB; Frumkin, H			Ambient air pollution and respiratory emergency department visits	EPIDEMIOLOGY			English	Article							HOSPITAL ADMISSIONS; SIZE DISTRIBUTIONS; ONTARIO HOSPITALS; CHILDHOOD ASTHMA; HUMAN HEALTH; TIME-SERIES; ROOM VISITS; NEW-YORK; ATLANTA; EPIDEMIOLOGY	Background: A number of emergency department studies have corroborated findings from mortality and hospital admission studies regarding an association of ambient air pollution and respiratory outcomes. More refined assessment has been limited by study size and available air quality data. Methods: Measurements of 5 pollutants (particulate matter [PM10] ozone, nitrogen dioxide [NO2] carbon monoxide [CO], and sulfur dioxide [SO2]) were available for the entire study period (I January 1993 to 31 August 2000); detailed measurements of particulate matter were available for 25 months. We obtained data on 4 million emergency department visits from 31 hospitals in Atlanta. Visits for asthma, chronic obstructive pulmonary disease, upper respiratory infection, and pneumonia were assessed in relation to air pollutants using Poisson generalized estimating equations. Results: In single-pollutant models examining 3-day moving averages of pollutants (lags 0, 1, and 2): standard deviation increases of ozone, NO2, CO, and PM10 were associated with 1-3% increases in UR1 visits; a 2 mug/m(3) increase of PM2.5 organic carbon was associated with a 3% increase in pneumonia visits; and standard deviation increases of NO2 and CO were associated with 2-3% increases in chronic obstructive pulmonary disease visits. Positive associations persisted beyond 3 days for several of the outcomes, and over a week for asthma. Conclusions: The results of this study contribute to the evidence of an association of several correlated gaseous and particulate pollutants, including ozone, NO2, CO, PM, and organic carbon, with specific respiratory conditions.	Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA; Emory Univ, Rollins Sch Publ Hlth, Dept Environm & Occupat Hlth, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Dept Emergency Med, Atlanta, GA 30322 USA; Georgia Inst Technol, Sch Civil & Environm Engn, Atlanta, GA 30332 USA	Peel, JL (reprint author), Colorado State Univ, Dept Environm & Radiol Hlth Sci, 1681 Campus Delivery, Ft Collins, CO 80523 USA.	jennifer.peel@colostate.edu	Ryan, P. Barry/A-7662-2009; Tolbert, Paige/A-5676-2015	Frumkin, Howard/0000-0001-7079-3534	NIEHS NIH HHS [R01ES11294]		Albritton D.L., 1998, ATMOSPHERIC OBSERVAT; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; Butler AJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002234; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Dominici F, 2002, AM J EPIDEMIOL, V156, P193, DOI 10.1093/aje/kwf062; *ENV PROT AG, 2001, EPA600P66002BB NAT C; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; Gwynn RC, 2000, ENVIRON HEALTH PERSP, V108, P125, DOI 10.2307/3454510; Hastie T, 1990, GEN ADDITIVE MODELS; Janssen NAH, 2002, ENVIRON HEALTH PERSP, V110, P43; LIPPMANN M, 2000, ASS PARTICULATE MATT; McCullagh P., 1989, GEN LINEAR MODELS; McMurry PH, 2002, J AEROSOL MED, V15, P169, DOI 10.1089/089426802320282293; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; Rusznak C, 1996, THORAX, V51, P1105, DOI 10.1136/thx.51.11.1105; Samet J., 2000, 94 HLTH EFF I; Schlesinger RB, 2000, INHAL TOXICOL, V12, P23, DOI 10.1080/089583700196338; Schwartz J, 2003, REVISED ANAL TIME SE, P25; Stieb DM, 2000, J EXPO ANAL ENV EPID, V10, P461, DOI 10.1038/sj.jea.7500112; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; *US CENS BUR, 1997, CURR HOUS REP; Van Loy M, 2000, J AIR WASTE MANAGE, V50, P1446; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Woo KS, 2001, AEROSOL SCI TECH, V34, P75, DOI 10.1080/027868201300082049; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	35	238	240	3	56	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	MAR	2005	16	2					164	174		10.1097/01.ede.0000152905.42113.db		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	898MF	WOS:000227080200004	15703530	
J	Noverr, MC; Huffnagel, GB				Noverr, MC; Huffnagel, GB			Does the microbiota regulate immune responses outside the gut?	TRENDS IN MICROBIOLOGY			English	Review							CHAIN FATTY-ACIDS; ANTHROPOSOPHIC LIFE-STYLE; PLACEBO-CONTROLLED TRIAL; INTESTINAL MICROFLORA; ORAL TOLERANCE; CANDIDA-ALBICANS; ATOPIC DISEASE; T-CELLS; PROBIOTIC BACTERIA; ALLERGIC DISEASE	Perturbations in the gastrointestinal (GI) microbiota composition that occur as a result of antibiotics and diet in 'westernized' countries are strongly associated with allergies and asthma ('hygiene hypothesis'). The microbiota ('microflora') plays a crucial role in the development of mucosal tolerance, including the airways. Significant attention has been focused on the role of the microbiota in GI development, immune adaptation and initiation of GI inflammatory diseases. This review covers the post-develop mental functions that the microbiota plays in regulating immunological tolerance to allergen exposure outside the GI tract and proposes the question: is the microbiota a major regulator of the immune system?.	Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Huffnagel, GB (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.	ghuff@umich.edu			NHLBI NIH HHS [2T32 HL 007749-11, R01 HL 65912]; NIAID NIH HHS [R01 AI 59201]		ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Alm JS, 2002, PEDIATR ALLERGY IMMU, V13, P402, DOI 10.1034/j.1399-3038.2002.01062.x; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bohmig GA, 1997, IMMUNOLOGY, V92, P234, DOI 10.1046/j.1365-2567.1997.00337.x; Calderone RA, 2001, CANDIDA CANDIDIASIS; Christensen HR, 2002, J IMMUNOL, V168, P171; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.3.CO;2-C; Drasar B S, 1974, Soc Appl Bacteriol Symp Ser, V3, P187; DRASAR BS, 1973, P NUTR SOC, V32, P49, DOI 10.1079/PNS19730014; DUBOS R, 1963, J EXP MED, V117, P231, DOI 10.1084/jem.117.2.231; DUBOS R, 1971, MAN ADAPTING; Eyles JE, 2001, J PHARM PHARMACOL, V53, P601, DOI 10.1211/0022357011775929; Fanaro S, 2003, ACTA PAEDIATR, V92, P48; Farooqi IS, 1998, THORAX, V53, P927; Fogelmark B, 2001, MEDIAT INFLAMM, V10, P13, DOI 10.1080/09629350151073748; Fooks LJ, 2002, BRIT J NUTR, V88, pS39, DOI [10.1079/BJNBJN2002591, 10.1079/BJN2002628]; GIBSON GR, 1999, PROBIOTICS OTHER NUT, V42, P139; HALLETT M, 2003, HAND CLIN N, V1, P549, DOI 10.1016/S1567-4231(09)70181-9; HOBERG KA, 1983, ANTIMICROB AGENTS CH, V24, P401; Hooper LV, 2004, TRENDS MICROBIOL, V12, P129, DOI 10.1016/j.tim.2004.01.001; HOVE H, 1994, AM J CLIN NUTR, V59, P74; HOVERSTAD T, 1986, SCAND J GASTROENTERO, V21, P621, DOI 10.3109/00365528609003109; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Kirjavainen PV, 2003, J PEDIATR GASTR NUTR, V36, P223, DOI 10.1097/00005176-200302000-00012; Kirjavainen PV, 2001, FEMS IMMUNOL MED MIC, V32, P1, DOI 10.1016/S0928-8244(01)00272-3; Laiho K, 2002, BRIT J NUTR, V88, pS19, DOI 10.1079/BJNBJN2002581; Leakey R., 1994, ORIGIN HUMANKIND; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Matsuzaki T, 1998, J DAIRY SCI, V81, P48; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; Molin G, 2001, AM J CLIN NUTR, V73, p380S; MOREAU MC, 1988, INFECT IMMUN, V56, P2766; Nair RG, 2001, APMIS, V109, P147, DOI 10.1034/j.1600-0463.2001.d01-116.x; Noverr MC, 2004, INFECT IMMUN, V72, P4996, DOI 10.1128/IAI.72.9.4996-5003.2004; Noverr MC, 2003, CLIN MICROBIOL REV, V16, P517, DOI 10.1128/CMR.16.3.517-533.2003; Noverr MC, 2001, INFECT IMMUN, V69, P2957, DOI 10.1128/IAI.69.5.2957-2963.2001; NOVERR MC, IN PRESS INFECT IMMU; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Pickett TE, 2000, INFECT IMMUN, V68, P205; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Russo M, 1998, IMMUNOL LETT, V61, P15, DOI 10.1016/S0165-2478(97)00155-7; Saavedra JM, 2002, BRIT J NUTR, V87, pS241, DOI [10.1079/BJN/2002543, 10.1079/BJNBJN/2002543]; Sellon RK, 1998, INFECT IMMUN, V66, P5224; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Sullivan A, 2001, Lancet Infect Dis, V1, P101, DOI 10.1016/S1473-3099(01)00066-4; Takabayashi K, 2003, J IMMUNOL, V170, P3898; Tannock GW, 2000, APPL ENVIRON MICROB, V66, P2578, DOI 10.1128/AEM.66.6.2578-2588.2000; Tannock GW, 2002, EUR J CLIN NUTR, V56, pS44, DOI 10.1038/sj.ejcn.1601661; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; Tissier H., 1905, ANN I PASTEUR PARIS, V19, P109; von der Weid T, 2001, CLIN DIAGN LAB IMMUN, V8, P695, DOI 10.1128/CDLI.8.4.695-701.2001; Wagner RD, 1997, INFECT IMMUN, V65, P4165; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wu XM, 1998, EUR J IMMUNOL, V28, P134, DOI 10.1002/(SICI)1521-4141(199801)28:01<134::AID-IMMU134>3.0.CO;2-3; Xu J, 2004, TRENDS MICROBIOL, V12, P21, DOI 10.1016/j.tim.2003.11.007; Yamanaka T, 2003, J IMMUNOL, V170, P816; Zhang XM, 2001, J IMMUNOL, V167, P4245	67	238	249	7	62	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0966-842X			TRENDS MICROBIOL	Trends Microbiol.	DEC	2004	12	12					562	568		10.1016/j.tim.2004.10.008		7	Biochemistry & Molecular Biology; Microbiology	Biochemistry & Molecular Biology; Microbiology	880GY	WOS:000225778200008	15539116	
J	Murray, CS; Poletti, G; Kebadze, T; Morris, J; Woodcock, A; Johnston, SL; Custovic, A				Murray, CS; Poletti, G; Kebadze, T; Morris, J; Woodcock, A; Johnston, SL; Custovic, A			Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children	THORAX			English	Article							ANTIGEN BRONCHOPROVOCATION; INHALED CORTICOSTEROIDS; VIRAL-INFECTIONS; RHINOVIRUS-16; PRECIPITANTS; EMERGENCY; CITY; AGE	Background: Asthma exacerbation is the most common cause of hospital admission in children. A study was undertaken to investigate the importance of allergen exposure in sensitised individuals in combination with viral infections and other potentially modifiable risk factors precipitating asthma hospital admission in children. Methods: Eighty four children aged 3 - 17 years admitted to hospital over a 1 year period with an acute asthma exacerbation (AA) were matched for age and sex with two control groups: stable asthmatics (SA) and children admitted to hospital with non-respiratory conditions (IC). Risk factors were assessed by questionnaires and determination of allergen sensitisation, home allergen exposure, pollen exposure, and respiratory virus infection. Results: Several non-modifiable factors (atopy, duration of asthma) were associated with increased risk. Among the modifiable factors, pet ownership, housing characteristics, and parental smoking did not differ between the groups. Regular inhaled corticosteroid treatment was significantly less common in the AA group than in the SA group (OR 0.2, 95% CI 0.1 to 0.6; p = 0.002). A significantly higher proportion of the AA group were virus infected ( 44%) and sensitised and highly exposed to sensitising allergen (76%) compared with the SA (18% and 48%) and IC groups (17% and 28%; both p < 0.001). In a multiple conditional logistic regression ( AA v SA), allergen sensitisation and exposure or virus detection alone were no longer independently associated with hospital admission. However, the combination of virus detection and sensitisation with high allergen exposure substantially increased the risk of admission to hospital ( OR 19.4, 95% CI 3.7 to 101.5, p < 0.001). Conclusions: Natural virus infection and real life allergen exposure in allergic asthmatic children increase the risk of hospital admission. Strategies for preventing exacerbations will need to address these factors.	Univ Manchester, S Manchester Univ Hosp NHS Trust, NW Lung Ctr, Acad Div Med & Surg S, Manchester M23 9LT, Lancs, England; S Manchester Univ Hosp NHS Trust, Dept Med Stat, Manchester M23 9LT, Lancs, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Med, London, England	Murray, CS (reprint author), Univ Manchester, S Manchester Univ Hosp NHS Trust, NW Lung Ctr, Acad Div Med & Surg S, Manchester M23 9LT, Lancs, England.	clare.murray@manchester.ac.uk	Johnston, Sebastian/I-2423-2012; Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578			Bacharier LB, 2003, PEDIATRICS, V112, pE85, DOI 10.1542/peds.112.2.e85; BEASLEY R, 1988, THORAX, V43, P679, DOI 10.1136/thx.43.9.679; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; CALHOUN WJ, 1991, AM REV RESPIR DIS, V144, P1267; Campbell MJ, 1997, BRIT MED J, V315, P1012; CHAUHAN AJ, 2000, ASTHMA RESP INFECT, P221; de Kluijver Josephine, 2003, American Journal of Respiratory and Critical Care Medicine, V168, P1174, DOI 10.1164/rccm.200212-1520OC; Doull IJM, 1997, BRIT MED J, V315, P858; Doull IJM, 2003, J PEDIATR-US, V142, pS21, DOI 10.1067/mpd.2003.22; DUFF AL, 1993, PEDIATRICS, V92, P535; Freymuth F, 1999, J CLIN VIROL, V13, P131, DOI 10.1016/S1386-6532(99)00030-X; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; HORN MEC, 1979, THORAX, V34, P23, DOI 10.1136/thx.34.1.23; INHAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; KEUHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; MINOR TE, 1974, JAMA-J AM MED ASSOC, V227, P292, DOI 10.1001/jama.227.3.292; MINOR TE, 1976, AM REV RESPIR DIS, V113, P149; NICHOLSON KG, 1993, BRIT MED J, V307, P982; pidemiology Standardization Project. II, 1978, AM REV RESP DIS S, V118, P7; Pollack CV, 2002, ARCH PEDIAT ADOL MED, V156, P934; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schatz M, 2003, AM J MANAG CARE, V9, P538; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191	34	237	245	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY	2006	61	5					376	382		10.1136/thx.2005.042523		7	Respiratory System	Respiratory System	037JQ	WOS:000237143400005	16384881	
J	Romagnani, S				Romagnani, S			Immunologic influences on allergy and theT(H)1/T(H)2 balance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)1T(H)2 cells; immune deviation; treg cells; immune suppression; hygiene hypothesis	REGULATORY T-CELLS; IMMUNE-RESPONSE; HYGIENE HYPOTHESIS; DENDRITIC CELLS; TH2 RESPONSES; DISEASE; LYMPHOCYTES; ASTHMA; CHILDREN; IL-10	T(H)2 cell-mediated immune responses against "innocuous" antigens play a triggering role in atopic allergy. Several epidemiologic studies have clearly shown that the reduced microbial exposure of children caused by the westernized lifestyle is responsible for the increased prevalence of allergy that has occurred in the last decades in developed countries ("hygiene hypothesis"). The immunologic changes caused by the reduced exposure to pathogenic and nonpathogenic microbes during childhood are still controversial. The initial interpretation has been a lack of shift of allergen-specific responses from the T(H)2 to the T(H)1 phenotype. This is because of reduced production of IL-12 and IFNs by cells of the natural immunity stimulated by bacterial products through their Toll-like receptors (missing immune deviation). Another interpretation emphasizes the importance of reduced activity of T-regulatory cells (reduced immune suppression). However, although there are impressive amounts of data in favor of the missing immune deviation, experimental evidence supporting the role of reduced immune suppression in explaining the increased prevalence of allergy is currently weak or even contradictory. The solution to this question is very important not only from a theoretic point of view but also because of its therapeutic implications.	Univ Florence, Dept Internal Med, Sect Clin Immunol Allergy & Resp Dis, I-50134 Florence, Italy	Romagnani, S (reprint author), Univ Florence, Dept Internal Med, Sect Clin Immunol Allergy & Resp Dis, Viale Morgagni 85, I-50134 Florence, Italy.						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akdis CA, 2001, MICROBES INFECT, V3, P891, DOI 10.1016/S1286-4579(01)01449-6; Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brugnolo F, 2003, J ALLERGY CLIN IMMUN, V111, P380, DOI 10.1067/mai.2003.102; Chatelain R, 1999, PARASITE IMMUNOL, V21, P211, DOI 10.1046/j.1365-3024.1999.00224.x; COSMI L, 2004, IN PRESS BLOOD; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Rengarajan J, 2000, IMMUNOL TODAY, V21, P479, DOI 10.1016/S0167-5699(00)01712-6; Renz H, 2002, J ALLERGY CLIN IMMUN, V109, P338, DOI 10.1067/mai.2002.121459; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROMAGNANI S, 2004, IN PRESS NESTLE NUTR, V53; Sabroe I, 2002, CLIN EXP ALLERGY, V32, P984, DOI 10.1046/j.1365-2745.2002.01451.x; Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1; Suto A, 2001, AM J RESP CRIT CARE, V164, P680; Tang LL, 1998, J ALLERGY CLIN IMMUN, V102, P428, DOI 10.1016/S0091-6749(98)70131-9; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; van Roon JAG, 2002, ANN RHEUM DIS, V61, P951, DOI 10.1136/ard.61.11.951; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	33	237	253	1	20	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2004	113	3					395	400		10.1016/j.jaci.2003.11.025		6	Allergy; Immunology	Allergy; Immunology	802DM	WOS:000220144200006	14758340	
J	Akdis, CA; Akdis, M; Bieber, T; Bindslev-Jensen, C; Boguniewicz, M; Eigenmann, P; Hamid, Q; Kapp, A; Leung, DYM; Lipozencic, JK; Luger, TA; Muraro, A; Novak, N; Platts-Mills, TAE; Rosenwasser, L; Scheynius, A; Simons, FER; Spergel, J; Turjanmaa, K; Wahn, U; Weidinger, S; Werfel, T; Zuberbier, T				Akdis, Cezmi A.; Akdis, Mubeccel; Bieber, Thomas; Bindslev-Jensen, Carsten; Boguniewicz, Mark; Eigenmann, Philippe; Hamid, Qutayba; Kapp, Alexander; Leung, Donald Y. M.; Lipozencic, Jasna K.; Luger, Thomas A.; Muraro, Antonella; Novak, Natalija; Platts-Mills, Thomas A. E.; Rosenwasser, Lanny; Scheynius, Annika; Simons, F. Estelle R.; Spergel, Jonathan; Turjanmaa, Kristiina; Wahn, Ulrich; Weidinger, Stefan; Werfel, Thomas; Zuberbier, Torsten		European Acad Allergol, CI; Amer Acad Allergy Asthma Immunol; PRACTALL Consensus Grp	Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL Consensus Report	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; children; adults; risk factors; immunopathology; diagnosis; systemic treatment; topical treatment	RANDOMIZED CONTROLLED-TRIAL; STAPHYLOCOCCUS-AUREUS COLONIZATION; TOPICAL CALCINEURIN INHIBITORS; PIMECROLIMUS CREAM 1-PERCENT; PLASMACYTOID DENDRITIC CELLS; PLACEBO-CONTROLLED TRIAL; DUST-MITE ALLERGENS; REGULATORY T-CELLS; LONG-TERM EFFICACY; DOUBLE-BLIND	There are remarkable differences in the diagnostic and therapeutic management of atopic dermatitis practiced by dermatologists and pediatricians in different countries. Therefore, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology nominated expert teams who were given the task of finding a consensus to serve as a guideline for clinical practice in Europe as well as in North America. The consensus report is part of the PRACTALL initiative, which is endorsed by both academies.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Bonn, D-5300 Bonn, Germany; Odense Univ Hosp, DK-5000 Odense, Denmark; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Sch Med, Denver, CO 80202 USA; Univ Geneva, Childrens Hosp, CH-1211 Geneva 4, Switzerland; McGill Univ, Montreal, PQ H3A 2T5, Canada; Hannover Med Univ, Hannover, Germany; Univ Zagreb, Zagreb Hosp Ctr, Zagreb 41000, Croatia; Univ Zagreb, Sch Med, Zagreb 41000, Croatia; Univ Munster, D-4400 Munster, Germany; Univ Padua, I-35100 Padua, Italy; Asthma & Allerg Dis Ctr, Charlottesville, VA USA; Karolinska Univ Hosp, Solna, Sweden; Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Tampere Univ Hosp, Tampere, Finland; Univ Berlin, Charite, Berlin, Germany; Tech Univ Munich, D-8000 Munich, Germany; Hannover Med Sch, D-3000 Hannover, Germany	Wahn, U (reprint author), Univ Med Berlin, Charite, Augustenburger Pl 1, D-13353 Berlin, Germany.	ulrich.wahn@charite.de	Weidinger, Stephan/C-8461-2011; Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826			Abeck D, 1998, BRIT J DERMATOL, V139, P13; Abeck D, 2000, J AM ACAD DERMATOL, V42, P254, DOI 10.1016/S0190-9622(00)90134-8; Ainley-Walker PF, 1998, ARCH DIS CHILD, V79, P149; Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akhavan A, 2003, CLIN DERMATOL, V21, P225, DOI 10.1016/S0738-081X(02)00362-0; Anstey AV, 2004, BRIT J DERMATOL, V151, P1123, DOI 10.1111/j.1365-2133.2004.06323.x; Arikawa J, 2002, J INVEST DERMATOL, V119, P433, DOI 10.1046/j.1523-1747.2002.01846.x; Ashcroft DM, 2005, BRIT MED J, V330, P516, DOI 10.1136/bmj.38376.439653.D3; *AST PHARM MAN INC, 2006, PROT PACK INS; Aylett S E, 1992, Acta Derm Venereol Suppl (Stockh), V176, P123; BAECK O, 2001, J EUR ACAD DERMATOL, V15, P34; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; BerthJones J, 1996, J AM ACAD DERMATOL, V34, P1016, DOI 10.1016/S0190-9622(96)90281-9; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1111/j.1365-2133.1997.tb08750.x; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bloch AM, 2002, ACTA PAEDIATR, V91, P275, DOI 10.1080/08035250252833914; Boguniewicz M, 2002, IMMUNOL ALLERGY CLIN, V22, P107, DOI 10.1016/S0889-8561(03)00072-9; Boguniewicz M, 2001, J ALLERGY CLIN IMMUN, V108, P651, DOI 10.1067/mai.2001.118598; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; Breuer K, 2005, AM J CLIN DERMATOL, V6, P65, DOI 10.2165/00128071-200506020-00001; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; Breuer K, 2004, CLIN EXP ALLERGY, V34, P817, DOI [10.1111/j.1365-2222.2004.1953.x, 10.1111/j.1365-2222.2004.01953.x]; BROBERG A, 1990, ACTA DERM-VENEREOL, V70, P495; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; Capristo C, 2004, ALLERGY, V59, P53, DOI 10.1111/j.1398-9995.2004.00652.x; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Chinn DJ, 2002, BRIT J DERMATOL, V146, P432, DOI 10.1046/j.1365-2133.2002.04603.x; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Darsow U, 2005, J EUR ACAD DERMATOL, V19, P286, DOI 10.1111/j.1468-3083.2005.01249.x; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Diepgen TL, 2002, PEDIATR ALLERGY IMMU, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; DIMITROFF CJ, 2004, J CLIN INVEST, V112, P1008; Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Eigenmann P.A., 1998, PEDIATRICS, V101, P8; Ellis C, 2003, BRIT J DERMATOL, V148, P3, DOI 10.1046/j.1365-2133.148.s63.1.x; Faergemann J, 1999, ALLERGY, V54, P413, DOI 10.1034/j.1398-9995.1999.00089.x; Foelster-Holst R, 2006, DERMATOLOGY, V212, P66, DOI 10.1159/000089025; Gauger A, 2003, DERMATOLOGY, V207, P15, DOI 10.1159/000070935; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Grewe M, 1998, J IMMUNOL, V161, P415; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Haagerup A, 2004, ACTA DERM-VENEREOL, V84, P346, DOI 10.1080/00015550410034426; Halken S, 2004, PEDIATR ALLERGY IMMU, V15, P9, DOI 10.1111/j.1399-3038.2004.0148b.x; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halken Susanne, 2004, Pediatr Allergy Immunol, V15 Suppl 16, P4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Harper J, 2001, BRIT J DERMATOL, V144, P781, DOI 10.1046/j.1365-2133.2001.04133.x; Hauk PJ, 2001, J ALLERGY CLIN IMMUN, V107, P391, DOI 10.1067/mai.2001.112848; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Hoeger PH, 2004, PEDIATR ALLERGY IMMU, V15, P474, DOI 10.1111/j.1399-3038.2004.00182.x; Hoetzenecker W, 2005, J ALLERGY CLIN IMMUN, V115, P1276, DOI 10.1016/j.jaci.2005.02.011; Hoffjan S, 2005, J MOL MED-JMM, V83, P682, DOI 10.1007/s00109-005-0672-2; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Hultsch T, 2005, DERMATOLOGY, V211, P174, DOI 10.1159/000086739; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jappe U, 2003, BRIT J DERMATOL, V149, P87, DOI 10.1046/j.1365-2133.2003.05290.x; Johnke H, 2005, BRIT J DERMATOL, V153, P352, DOI 10.1111/j.1365-2133.2005.06491.x; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; KAY J, 1994, J AM ACAD DERMATOL, V30, P35; Kempers S, 2004, J AM ACAD DERMATOL, V51, P515, DOI 10.1016/j.jaad.2004.01.051; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P195, DOI 10.1067/mai.2003.1; KERSCHER MJ, 1995, INT J CLIN PHARM TH, V33, P187; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Klunker S, 2003, J IMMUNOL, V171, P1078; KOBLENZER CS, 1988, ARCH DERMATOL, V124, P1673, DOI 10.1001/archderm.124.11.1673; KORTING HC, 1992, J AM ACAD DERMATOL, V27, P87, DOI 10.1016/0190-9622(92)70162-9; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lear JT, 1996, J AM ACAD DERMATOL, V35, P642, DOI 10.1016/S0190-9622(96)90701-X; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leo HL, 2004, J ALLERGY CLIN IMMUN, V114, P691, DOI 10.1016/j.jaci.2004.05.037; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1977, BRIT J DERMATOL, V96, P179, DOI 10.1111/j.1365-2133.1977.tb12541.x; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Lintu P, 2001, ALLERGY, V56, P512, DOI 10.1034/j.1398-9995.2001.056006512.x; Loden M, 2003, AM J CLIN DERMATOL, V4, P771; Lubbe J, 2003, AM J CLIN DERMATOL, V4, P641; Luger T, 2001, BRIT J DERMATOL, V144, P788, DOI 10.1046/j.1365-2133.2001.04134.x; Mallon E, 1994, J DERMATOL TREAT, V5, P97, DOI 10.3109/09546639409084540; Mastrandrea F, 2004, AM J CLIN DERMATOL, V5, P281, DOI 10.2165/00128071-200405050-00001; MCHENRY PM, 1995, BRIT MED J, V310, P843; McSkimming J, 1984, Australas J Dermatol, V25, P8; Meggitt SJ, 2001, CLIN EXP DERMATOL, V26, P369, DOI 10.1046/j.1365-2230.2001.00837.x; MITCHELL EB, 1982, LANCET, V1, P127; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467; MOTHES N, 2005, J ALLERGY CLIN IMMUN, V16, P706; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P196, DOI 10.1111/j.1399-3038.2004.00128.x; Natter S, 1998, FASEB J, V12, P1559; Nikkels AF, 2003, DERMATOLOGY, V206, P398, DOI 10.1159/000069968; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; Nomura I, 2003, J IMMUNOL, V171, P3262; *NOV PHARM CORP, 2006, EL PACK INS; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P828, DOI 10.1016/j.jaci.2005.01.030; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Novak Natalija, 2003, Journal of Allergy and Clinical Immunology, V112, pS128, DOI 10.1016/j.jaci.2003.09.032; Novembre E, 2001, ALLERGY, V56, P452, DOI 10.1034/j.1398-9995.2001.056005452.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oranje AP, 1999, J DERMATOL TREAT, V10, P73, DOI 10.3109/09546639909055916; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Ozkaya E, 2005, J AM ACAD DERMATOL, V52, P579, DOI 10.1016/j.jaad.2004.11.037; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; Paul C, 2006, PEDIATRICS, V117, P118; Peeters KABM, 2004, INT J DERMATOL, V43, P235, DOI 10.1111/j.1365-4632.2004.02172.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Plaut M, 2003, J ALLERGY CLIN IMMUN, V112, P683, DOI 10.1067/mai.2003.1776; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; Raap U, 2005, J ALLERGY CLIN IMMUN, V115, P1268, DOI 10.1016/j.jaci.2005.02.007; Ravenscroft JC, 2000, CLIN EXP DERMATOL, V25, P327, DOI 10.1046/j.1365-2230.2000.00654.x; Ravenscroft JC, 2003, BRIT J DERMATOL, V148, P1010, DOI 10.1046/j.1365-2133.2003.05292.x; Reynolds NJ, 2001, LANCET, V357, P2012, DOI 10.1016/S0140-6736(00)05114-X; Ricci G, 2004, BRIT J DERMATOL, V150, P127, DOI 10.1111/j.1365-2133.2004.05705.x; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Rudolph R, 2004, CONTACT DERMATITIS, V50, P354, DOI 10.1111/j.0105-1873.2004.00368.x; Sampson HA, 2005, ALLERGY, V60, P19, DOI 10.1111/j.1398-9995.2005.00853.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sator PG, 2003, J AM ACAD DERMATOL, V48, P352, DOI 10.1067/mjd.2003.105; Sayama K, 2005, EUR J IMMUNOL, V35, P1886, DOI 10.1002/eji.20425827; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schafer T, 2005, HAUTARZT, V56, P232, DOI 10.1007/s00105-004-0884-3; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Scheinfeld NS, 2003, CLIN DERMATOL, V21, P241, DOI 10.1016/S0738-081X(02)00364-4; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Schmid-Grendelmeier P, 2006, CHEM IMMUNOL ALLERGY, V91, P98; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Sporik R, 1997, J ALLERGY CLIN IMMUN, V99, P861, DOI 10.1016/S0091-6749(97)80029-2; Staab D, 2006, BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; Staab D, 2000, DERMATOL PSYCHOSOM, V1, P173, DOI 10.1159/000057973; STALDER JF, 1994, BRIT J DERMATOL, V131, P536; Subramanyan Kumar, 2004, Dermatol Ther, V17 Suppl 1, P26, DOI 10.1111/j.1396-0296.2004.04S1003.x; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Takaoka A, 2005, EUR J PHARMACOL, V516, P180, DOI 10.1016/j.ejphar.2005.04.040; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tan BB, 1997, BRIT J DERMATOL, V136, P351, DOI 10.1111/j.1365-2133.1997.tb14942.x; THOMAS KS, 2003, BRIT MED J, V30, P768; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; Turjanmaa K, 2005, CURR OPIN ALLERGY CL, V5, P425, DOI 10.1097/01.all.0000182538.63273.a3; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; VERBIST L, 1990, J ANTIMICROB CHEMOTH, V25, P1; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; WAHLGREN CF, 1990, BRIT J DERMATOL, V122, P545, DOI 10.1111/j.1365-2133.1990.tb14732.x; WAN U, 2002, PEDIATRICS, V110, pE2; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2005, ALLERGY, V60, P1256, DOI 10.1111/j.1398-9995.2005.00879.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Werfel Thomas, 2004, Curr Opin Allergy Clin Immunol, V4, P379, DOI 10.1097/00130832-200410000-00009; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Wojnarowska F, 2002, BRIT J DERMATOL, V147, P214, DOI 10.1046/j.1365-2133.2002.04835.x; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zaki I, 1996, BRIT J DERMATOL, V135, P21, DOI 10.1111/j.1365-2133.1996.tb00705.x	201	236	259	1	22	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					152	169		10.1016/j.jaci.2006.03.045		18	Allergy; Immunology	Allergy; Immunology	065UH	WOS:000239184800019	16815151	
J	Bohle, B; Kinaciyan, T; Gerstmayr, M; Radakovics, A; Jahn-Schmid, B; Ebner, C				Bohle, Barbara; Kinaciyan, Tamar; Gerstmayr, Marianne; Radakovics, Astrid; Jahn-Schmid, Beatrice; Ebner, Christof			Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						specific immunotherapy; sublingual immunotherapy; T-cell tolerance; immune deviation; regulatory T cells; Bet v 1; IL-10	BIRCH-POLLEN ALLERGEN; BET V 1; DUST MITE IMMUNOTHERAPY; GRASS-POLLEN; IMMUNOLOGICAL CHANGES; CROSS-REACTIVITY; ORAL TOLERANCE; MAJOR ALLERGEN; IFN-GAMMA; IN-VITRO	Background: The immunologic mechanisms underlying sublingual immunotherapy (SLIT) are still unclear, particularly the role of regulatory T cells. Objective: We sought to characterize allergen-specific T-cell responses during successful birch pollen SLIT. Methods: Proliferation of PBMCs and PBMCs depleted of CD25(+) cells obtained from 9 patients before, after 4 weeks. and after 52 weeks of SLIT was assessed in response to the major birch pollen allergen Bet v 1, the homologous apple allergen Mal d 1, or tetanus toxoid. Allergen-induced cytokine responses and FoxP3 expression of T cells were analyzed by using real-time PCR. The role of IL-10 for regulatory activity of T cells was investigated. Results: After 4 weeks, higher frequencies of circulating CD4(+)CD25(+) T cells were detected together with increased FoxP3 and IL-10 and reduced IL-4 and IFN-gamma mRNA expression levels compared with those before SLIT. Proliferation to all 3 antigens was markedly reduced but increased significantly after depletion of CD25(+) cells or addition of anti-IL-10 antibodies. After 52 weeks, proliferation in response to Mal d I or tetanus toxoid returned to pre-SLIT levels, whereas Bet v I-induced proliferation remained significantly suppressed and was enhanced by neither depletion of CD25(+) cells nor addition of anti-IL-10 antibodies. In parallel, increased IFN-gamma and reduced IL-4, IL-10, and FoxP3 mRNA expression was detected. Neither TGF-beta levels nor cell-cell contact-mediated suppression of CD4(+)CD25(+) cells changed during the course of SLIT. Conclusion: SLIT induces regulatory T-cell suppression through IL-10 during the early phase and specific nonreactivity and immune deviation of allergen-specific T cells during the later phase of therapy. Clinical implications: SLIT induces immune mechanisms comparable with subcutaneous specific immunotherapy.	Med Univ Vienna, Ctr Physiol Pathophysiol & Immunol, Dept Pathophysiol, A-1090 Vienna, Austria; Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria	Bohle, B (reprint author), Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Waehringer Guertel 18, A-1090 Vienna, Austria.	barbara.bohle@meduniwien.ac.at					Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1999, FASEB J, V13, P603; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bohle B, 2005, CLIN EXP ALLERGY, V35, P367, DOI 10.1111/j.1365-2222.2005.02180.x; Bohle B, 2006, J ALLERGY CLIN IMMUN, V118, P242, DOI 10.1016/j.jaci.2006.03.01; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; BOUSQUET J, 1998, ALLERGY S, V53, P20; Bousquet J, 2006, ALLERGY, V61, P5, DOI 10.1111/j.1398-9995.2006.01183.x; BREITENEDER H, 1989, EMBO J, V8, P1935; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Eusebius NP, 2002, INT ARCH ALLERGY IMM, V127, P234, DOI 10.1159/000053868; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gardner LM, 2004, INT ARCH ALLERGY IMM, V133, P1, DOI 10.1159/000075248; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Hori S, 2004, MICROBES INFECT, V6, P745, DOI 10.1016/j.micinf.2004.02.020; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jensen-Jarolim E, 1998, FASEB J, V12, P1635; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kinaciyan T, 2007, J ALLERGY CLIN IMMUN, V119, P937, DOI 10.1016/j.jaci.2006.11.010; Mirza O, 2000, J IMMUNOL, V165, P331; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Spangfort MD, 1999, ACTA CRYSTALLOGR D, V55, P2035, DOI 10.1107/S0907444999011804; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; Vukmanovic-Stejic M, 2006, J CLIN INVEST, V116, P2423, DOI 10.1172/JCI28941; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	46	234	251	2	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					707	713		10.1016/j.jaci.2007.06.013		7	Allergy; Immunology	Allergy; Immunology	211DV	WOS:000249505400033	17681368	
J	Beuther, DA; Weiss, ST; Sutherland, ER				Beuther, David A.; Weiss, Scott T.; Sutherland, E. Rand			Pulmonary perspective - Obesity and asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; epidemiology; inflammation; obesity; pathogenesis	BODY-MASS INDEX; ADULT-ONSET ASTHMA; ADIPOSE-TISSUE; MORBID-OBESITY; WEIGHT-LOSS; AIRWAY HYPERRESPONSIVENESS; GASTROESOPHAGEAL-REFLUX; RESPIRATORY-FUNCTION; PROSPECTIVE COHORT; CHILDHOOD ASTHMA	Asthma and obesity are prevalent disorders, each with a significant public health impact, and a large and growing body of literature suggests an association between the two. The systemic inflammatory milieu in obesity leads to metabolic and cardiovascular complications, but whether this environment alters asthma risk or phenotype is not yet known. Animal experiments have evaluated the effects of leptin and obesity on airway inflammation in response to both allergic and nonallergic exposures and suggest that airway inflammatory response is enhanced by both endogenous and exogenous leptin. Cross-sectional and prospective cohort studies of humans have shown a modest overall increase in asthma incidence and prevalence in the obese, although body mass index does not appear be a significant modifier of asthma severity. Studying the obesity-asthma relationship in large cohorts, in which self-reports are frequently used to ascertain the diagnosis of asthma, has been complicated by alterations in pulmonary physiology caused by obesity, which may lead to dyspnea or other respiratory symptoms but do not fulfill accepted physiologic criteria for asthma. Recent investigations toward elucidating a shared genetic basis for these two disorders have identified polymorphisms in specific regions of chromosomes 5q, 6p, 11q13, and 12q, each of which contains one or more genes encoding receptors relevant to asthma, inflammation, and metabolic disorders, including the beta(2)-adrenergic receptor gene ADRB2 and the glucocorticoid receptor gene NR3C1. Further research is warranted to synthesize these disparate observations into a cohesive understanding of the relationship between obesity and asthma.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Harvard Univ, Sch Med, Boston, MA USA; Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA	Sutherland, ER (reprint author), Natl Jewish Med & Res Ctr, 1400 Jackson St,J220, Denver, CO 80206 USA.	sutherlande@njc.org	Sutherland, Everett/B-7666-2008		NHLBI NIH HHS [K23HL04385]		Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; BARRERA F, 1973, AM REV RESPIR DIS, V108, P819; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045; BEDELL GN, 1958, J CLIN INVEST, V37, P1049, DOI 10.1172/JCI103686; Beuther DA, 2005, J ALLERGY CLIN IMMUN, V115, P1100, DOI 10.1016/j.jaci.2004.12.1141; Bibi H, 2004, J ASTHMA, V41, P403, DOI 10.1081/JAS-120026297; Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; CLEMENT K, 1995, NEW ENGL J MED, V333, P352, DOI 10.1056/NEJM199508103330605; COURNAND A, 1954, T ASSOC AM PHYSICIAN, V67, P162; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; FADELL E J, 1962, N Engl J Med, V266, P861, DOI 10.1056/NEJM196204262661704; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Flegal KM, 1998, INT J OBESITY, V22, P39, DOI 10.1038/sj.ijo.0800541; Ford ES, 2004, EUR RESPIR J, V24, P740, DOI 10.1183/09031936.04.00088003; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; Gurkan F, 2004, ANN ALLERG ASTHMA IM, V93, P277; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hamano N, 1998, ALLERGY ASTHMA PROC, V19, P263, DOI 10.2500/108854198778557773; Hamano N, 1998, Acta Otolaryngol Suppl, V537, P27; Hampel H, 2005, ANN INTERN MED, V143, P199; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; HASLER G, IN PRESS INT J OBES; HEDENSTIERNA G, 1976, ACTA ANAESTH SCAND, V20, P334; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hellings PW, 2003, CLIN EXP ALLERGY, V33, P1457, DOI 10.1046/j.1365-2222.2003.01743.x; Huovinen E, 2003, RESP MED, V97, P273, DOI 10.1053/rmed.2003.1419; Ishiyama-Shigemoto S, 1999, DIABETOLOGIA, V42, P98, DOI 10.1007/s001250051120; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; KAUFMAN BJ, 1959, J CLIN INVEST, V38, P500, DOI 10.1172/JCI103827; Larsson I, 2006, AM J CLIN NUTR, V83, P252; Lilly CM, 1999, J ALLERGY CLIN IMMUN, V104, P786; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Mai XM, 2004, PEDIATR ALLERGY IMMU, V15, P523, DOI 10.1111/j.1399-3038.2004.00195.x; Mancuso P, 2006, AM J RESP CRIT CARE, V173, P212, DOI 10.1164/rccm.200506-909OC; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Moffatt MF, 1999, THORAX, V54, P757; NAIMARK A, 1960, J APPL PHYSIOL, V15, P377; Nakamura H, 1999, AM J RESP CRIT CARE, V160, P1952; NORMAN RA, 1995, J CLIN INVEST, V96, P158, DOI 10.1172/JCI118016; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Romieu I, 2003, AM J EPIDEMIOL, V158, P165, DOI 10.1093/aje/kwg131; RUBINSTEIN I, 1990, ANN INTERN MED, V112, P828; Salem ML, 2000, INT ARCH ALLERGY IMM, V121, P161, DOI 10.1159/000024312; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Schiller JS, 2004, VITAL HLTH STAT, V10, P1; Shaheen SO, 1999, THORAX, V54, P396; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sin DD, 2002, ARCH INTERN MED, V162, P1477, DOI 10.1001/archinte.162.13.1477; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Sulit LG, 2005, AM J RESP CRIT CARE, V171, P659, DOI 10.1164/rccm.200403-398OC; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; THOMAS PS, 1989, THORAX, V44, P382, DOI 10.1136/thx.44.5.382; Torday JS, 2002, AM J PHYSIOL-LUNG C, V282, pL405; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weiner P, 1998, THORAX, V53, P39; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; Wellen KE, 2003, J CLIN INVEST, V112, P1785, DOI 10.1172/JCI200320514; Wilson MM, 1999, ARCH INTERN MED, V159, P2513, DOI 10.1001/archinte.159.21.2513; ZERAH F, 1993, CHEST, V103, P1470, DOI 10.1378/chest.103.5.1470	81	234	251	3	19	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2006	174	2					112	119		10.1164/rccm.200602-231PP		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	064QR	WOS:000239104700003	16627866	
J	Gruchalla, RS; Pongracic, J; Plaut, M; Evans, R; Visness, CM; Walter, M; Crain, EF; Kattan, M; Morgan, WJ; Steinbach, S; Stout, J; Malindzak, G; Smartt, E; Mitchell, H				Gruchalla, RS; Pongracic, J; Plaut, M; Evans, R; Visness, CM; Walter, M; Crain, EF; Kattan, M; Morgan, WJ; Steinbach, S; Stout, J; Malindzak, G; Smartt, E; Mitchell, H			Inner City Asthma Study: Relationships among sensitivity, allergen exposure, and asthma morbidity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergen exposure; allergen sensitivity; morbidity; allergens; cockroach; dust mite; cat; dog	RISK-FACTORS; CHILDHOOD ASTHMA; INDOOR ALLERGENS; COCKROACH ALLERGEN; MANAGEMENT PROGRAM; CAT ALLERGEN; CHILDREN; SENSITIZATION; SEVERITY; MITE	Background: Asthma-associated morbidity is rising, especially in inner city children. Objective: We evaluated the allergen sensitivities, allergen exposures, and associated morbidity for participants in the Inner City Asthma Study. We also determined geographic variations of indoor allergen levels. Methods: Nine hundred thirty-seven inner city children 5 to 11 years old with moderate to severe asthma underwent allergen skin testing. Bedroom dust samples were evaluated for Der p 1, Der f 1, Bla g 1, Fel d 1, and Can f 1. Results: Skin test sensitivities to cockroach (69%), dust mites (62%), and molds (50%) predominated, with marked study site-specific differences. Cockroach sensitivity was highest in the Bronx, New York, and Dallas (81.2%, 78.7%, and 78.5%, respectively), and dust mite sensitivity was highest in Dallas and Seattle (83.7% and 78.0%, respectively). A majority of homes in Chicago, New York, and the Bronx had cockroach allergen levels greater than 2 U/g, and a majority of those in Dallas and Seattle had dust mite allergen levels greater than 2 mu g/g. Levels of both of these allergens were influenced by housing type. Cockroach allergen levels were highest in high-rise apartments, whereas dust mite allergen levels were highest in detached homes. Children who were both sensitive and exposed to cockroach allergen had significantly more asthma symptom days, more caretaker interrupted sleep, and more school days missed than children who were not sensitive or exposed. Conclusion: Geographic differences in allergen exposure and sensitivity exist among inner city children. Cockroach exposure and sensitivity predominate in the Northeast, whereas dust mite exposure and sensitivity are highest in the South and Northwest. Cockroach allergen appears to have a greater effect on asthma morbidity than dust mite or pet allergen in these children.	Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Childrens Mem Hosp, Chicago, IL 60614 USA; NIAID, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA; Rho Inc, Chapel Hill, NC USA; Albert Einstein Coll Med, Jacobi Med Ctr, Bronx, NY 10467 USA; Mt Sinai Sch Med, New York, NY USA; Univ Arizona, Coll Med, Tucson, AZ 85721 USA; Boston Univ, Sch Med, Boston, MA 02215 USA; Univ Washington, Sch Med & Publ Hlth, Seattle, WA 98195 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Gruchalla, RS (reprint author), Univ Texas, SW Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Rebecca.Gruchalla@utsouthwestern.edu			NCRR NIH HHS [M01 RR00533]; NIAID NIH HHS [AI-39902, AI-39761, AI-39769, AI-39776, AI-39785, AI-39789, AI-39900, AI-39901]		Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Green RM, 2002, BRIT MED J, V324, P1; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Institute of Medicine, 2000, CLEAR AIR ASTHM IND, P105; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KITCH B, 2000, ENV HLTH PERSPECT, V108, P310; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/rccm.2103044; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sporik R, 1999, THORAX, V54, P675; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673	22	233	243	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					478	485		10.1016/j.jaci.2004.12.006		8	Allergy; Immunology	Allergy; Immunology	907AN	WOS:000227687000007	15753892	
J	Prezant, DJ; Weiden, M; Banauch, GI; McGuinness, G; Rom, WN; Aldrich, TK; Kelly, KJ				Prezant, DJ; Weiden, M; Banauch, GI; McGuinness, G; Rom, WN; Aldrich, TK; Kelly, KJ			Cough and bronchial responsiveness in firefighters at the World Trade Center site	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HIGH-RESOLUTION CT; AIRWAY RESPONSIVENESS; RESPIRATORY SYMPTOMS; OCCUPATIONAL ASTHMA; PERSISTENT ASTHMA; POPULATION-SAMPLE; METHACHOLINE; EXPOSURE; ISOCYANATES; INHALATION	Background: Workers from the Fire Department of New York City were exposed to a variety of inhaled materials during and after the collapse of the World Trade Center. We evaluated clinical features in a series of 332 firefighters in whom severe cough developed after exposure and the prevalence and severity of bronchial hyperreactivity in firefighters without severe cough classified according to the level of exposure. Methods: ``World Trade Center cough'' was defined as a persistent cough that developed after exposure to the site and was accompanied by respiratory symptoms severe enough to require medical leave for at least four weeks. Evaluation of exposed firefighters included completion of a standard questionnaire, spirometry, airway-responsiveness testing, and chest imaging. Results: In the first six months after September 11, 2001, World Trade Center cough occurred in 128 of 1636 firefighters with a high level of exposure (8 percent), 187 of 6958 with a moderate level of exposure (3 percent), and 17 of 1320 with a low level of exposure (1 percent). In addition, 95 percent had symptoms of dyspnea, 87 percent had gastroesophageal reflux disease, and 54 percent had nasal congestion. Of those tested before treatment of World Trade Center cough, 63 percent of firefighters (149 of 237) had a response to a bronchodilator and 24 percent (9 of 37) had bronchial hyperreactivity. Chest radiographs were unchanged from precollapse findings in 319 of the 332 with World Trade Center cough. Among the cohort without severe cough, bronchial hyperreactivity was present in 77 firefighters with a high level of exposure (23 percent) and 26 with a moderate level of exposure (8 percent). Conclusions: Intense, short-term exposure to materials generated during the collapse of the World Trade Center was associated with bronchial responsiveness and the development of cough. Clinical and physiological severity was related to the intensity of exposure.	Fire Dept New York City, Bur Hlth Serv, New York, NY USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Montefiore Med Ctr, Dept Med, Div Pulm Med, Bronx, NY 10467 USA; NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, New York, NY USA; NYU, Sch Med, Dept Environm Med, New York, NY USA; NYU, Sch Med, Dept Radiol, New York, NY USA	Prezant, DJ (reprint author), Montefiore Med Ctr, Div Pulm, Centennial 423, Bronx, NY 10467 USA.				NIOSH CDC HHS [R01-OH07350]; ODCDC CDC HHS [U1Q/CCU221158-01]; PHS HHS [M010096]		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Arakawa H, 1998, AM J ROENTGENOL, V170, P1349; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CHIA KS, 1990, BRIT J IND MED, V47, P524; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; EBER CD, 1993, J COMPUT ASSIST TOMO, V17, P853, DOI 10.1097/00004728-199311000-00003; ERNST P, 1989, THORAX, V44, P116, DOI 10.1136/thx.44.2.116; Field SK, 2002, CHEST, V121, P1024, DOI 10.1378/chest.121.4.1024; HARGREAVE FE, 1985, AIRWAY RESPONSIVENES, P94; HARLESS KW, 1978, ENVIRON RES, V16, P360, DOI 10.1016/0013-9351(78)90169-X; HERVE P, 1986, AM REV RESPIR DIS, V134, P986; HUDGEL DW, 1988, J LAB CLIN MED, V111, P684; Irwin RS, 1997, ARCH INTERN MED, V157, P1981, DOI 10.1001/archinte.157.17.1981; Irwin RS, 2000, NEW ENGL J MED, V343, P1715, DOI 10.1056/NEJM200012073432308; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640; JACK CIA, 1995, THORAX, V50, P201, DOI 10.1136/thx.50.2.201; KINSELLA J, 1991, LANCET, V337, P595, DOI 10.1016/0140-6736(91)91650-J; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298; KOUFMAN JA, 1998, OTOLARYNGOLOGY HEAD; Lemiere C, 1996, MED CLIN N AM, V80, P749, DOI 10.1016/S0025-7125(05)70466-1; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326; Petran M, 2000, OCCUP MED-OXFORD, V50, P103; PRATTER MR, 1993, ANN INTERN MED, V119, P977; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62; RIJCKEN B, 1993, AM REV RESPIR DIS, V147, P1447; RODRIGUEZROISIN R, 1986, B EUR PHYSIOPATH RES, V22, P225; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489; SHERMAN CB, 1989, AM REV RESPIR DIS, V140, P185; Tarlo SM, 2000, OCCUP MED, V15, P471; Townsend MC, 2000, J OCCUP ENVIRON MED, V42, P228, DOI 10.1097/00043764-200003000-00003; VANGANSE WF, 1972, AM REV RESPIR DIS, V105, P30; Verlato G, 1996, EUR RESPIR J, V9, P506, DOI 10.1183/09031936.96.09030506; Vijayan VK, 1996, EUR RESPIR J, V9, P1977, DOI 10.1183/09031936.96.09101977; WRIGHT RA, 1990, GASTROENTEROLOGY, V99, P71; Zuskin E, 1998, J OCCUP ENVIRON MED, V40, P814, DOI 10.1097/00043764-199809000-00011; 2002, MMWR MORB MORTAL WKL, V51, P453	37	233	233	0	5	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	SEP 12	2002	347	11					806	815		10.1056/NEJMoa021300		10	Medicine, General & Internal	General & Internal Medicine	592DK	WOS:000177921300005	12226151	
J	Cork, MJ; Robinson, DA; Vasilopoulos, Y; Ferguson, A; Moustafa, M; MacGowan, A; Duff, GW; Ward, SJ; Tazi-Ahnini, R				Cork, Michael J.; Robinson, Darren A.; Vasilopoulos, Yiannis; Ferguson, Adam; Moustafa, Manar; MacGowan, Alice; Duff, Gordon W.; Ward, Simon J.; Tazi-Ahnini, Rachid			New perspectives on epidermal barrier dysfunction in atopic dermatitis: Gene-environment interactions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						atopic dermatitis; eczema; environmental triggers; genome; proteases; protease inhibitors; skin barrier dysfunction; topical corticosteroids	CORNEUM CHYMOTRYPTIC ENZYME; MAST-CELL CHYMASE; SKIN IN-VIVO; CUTANEOUS PERMEABILITY BARRIER; CORTICOSTEROID-INDUCED ATROPHY; CLINICALLY UNINVOLVED SKIN; THIN-LAYER CHROMATOGRAPHY; HUMAN STRATUM-CORNEUM; DUST-MITE ALLERGEN; NETHERTON-SYNDROME	Atopic dermatitis (AD) is a multifactorial, chronic inflammatory skin disorder in which genetic mutations and cutaneous hyperreactivity to environmental stimuli play a causative role. Genetic mutations alone might not be enough to cause clinical manifestations of AD, and this review will propose a new perspective on the importance of epidermal barrier dysfunction in genetically predisposed individuals, predisposing them to the harmful effects of environmental agents. The skin barrier is known to be damaged in patients with AD, both in acute eczematous lesions and also in clinically unaffected skin. Skin barrier function can be impaired first by a genetic predisposition to produce increased levels of stratum corneum chymotryptic enzyme. This protease enzyme causes premature breakdown of corneodesmosomes, leading to impairment of the epidermal barrier. The addition of environmental interactions, such as washing with soap and detergents, or long-term application of topical corticosteroids can further increase production of stratum corneum chymotryptic enzyme and impair epidermal barrier function. The epidermal barrier can also be damaged by exogenous proteases from house dust mites and Staphylococcus aureus. One or more of these factors in combination might lead to a defective barrier, thereby increasing the risk of allergen penetration and succeeding inflammatory reaction, thus contributing to exacerbations of this disease.	Univ Sheffield, Sch Med, Div Genom Med, Sheffield S10 2RX, S Yorkshire, England; Sheffield Childrens Hosp, Pediat Dermatol Clin, Sheffield S10 2TH, S Yorkshire, England; Derbyshire Royal Infirm, Dept Dermatol, Derby DE1 2QY, England	Cork, MJ (reprint author), Univ Sheffield, Sch Med, Div Genom Med, Royal Hallamshire Hosp, D Floor,Beech Hill Rd, Sheffield S10 2RX, S Yorkshire, England.	m.j.cork@sheffield.ac.uk	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Cork, Michael/0000-0003-4428-2428			ABE T, 1978, Journal of Dermatology (Tokyo), V5, P223; ALJABERI H, 1984, BRIT J DERMATOL, V111, P437, DOI 10.1111/j.1365-2133.1984.tb06606.x; ALKEMADE JAC, 1994, J CELL SCI, V107, P2335; ALY R, 1975, J INFECT DIS, V131, P579; Ament W, 1997, INT J SPORTS MED, V18, P35, DOI 10.1055/s-2007-972592; Ananthapadmanabhan K P, 2004, Dermatol Ther, V17 Suppl 1, P16, DOI 10.1111/j.1396-0296.2004.04S1002.x; ANDERSON DS, 1951, BRIT J DERMATOL, V63, P283, DOI 10.1111/j.1365-2133.1951.tb13728.x; Badertscher K, 2005, ARCH DERMATOL RES, V296, P503, DOI 10.1007/s00403-005-0542-3; BARKER DE, 1951, PLAST RECONSTR SURG, V7, P115, DOI 10.1097/00006534-195102000-00004; Behne MJ, 2003, J INVEST DERMATOL, V120, P998, DOI 10.1046/j.1523-1747.2003.12262.x; Behne MJ, 2002, J BIOL CHEM, V277, P47399, DOI 10.1074/jbc.M204759200; BEHRENDT H, 1958, AMA J DIS CHILD, V95, P35; Bernard D, 2003, J INVEST DERMATOL, V120, P592, DOI 10.1046/j.1523-1747.2003.12086.x; BIBEL DJ, 1987, J MED MICROBIOL, V23, P75; Bilenoglu O, 2002, BRIT J HAEMATOL, V119, P1106, DOI 10.1046/j.1365-2141.2002.03989.x; BJORNBERG A, 1982, ACTA DERM-VENEREOL, V62, P147; BLICHMANN CW, 1987, ACTA DERM-VENEREOL, V67, P206; Bos JD, 2002, BRIT J DERMATOL, V147, P426, DOI 10.1046/j.1365-2133.2002.05010.x; BRAUNFALCO O, 1986, HAUTARZT, V37, P126; BUXTON RS, 1993, J CELL BIOL, V121, P481, DOI 10.1083/jcb.121.3.481; Caubet C, 2004, J INVEST DERMATOL, V122, P1235, DOI 10.1111/j.0022-202X.2004.22512.x; CAUBET C, 2004, J INVEST DERMATOL, V83, P761; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Chavanas S, 2000, NAT GENET, V25, P141; Chidgey M, 2001, J CELL BIOL, V155, P821, DOI 10.1083/jcb.200105009; COLLOFF MJ, 1992, BRIT J DERMATOL, V127, P322, DOI 10.1111/j.1365-2133.1992.tb00449.x; COMEL M, 1949, Dermatologica, V98, P133; Comoy EE, 1998, J IMMUNOL, V160, P2456; COOKSON WOCM, 1989, LANCET, V1, P1292; Cork M, 2006, J AM ACAD DERMATOL, V54, pAB3; Cork MJ, 2005, J INVEST DERMATOL, V125, P611; Cork MJ, 2003, BRIT J DERMATOL, V149, P582, DOI 10.1046/j.1365-2133.2003.05595.x; Cork MJ, 1997, J DERMATOL TREAT, V8, pS7; CORK MJ, 2005, J AM ACAD DERMATO S3, V52, P9; Cork M, 2002, DERMATOL PRACT, V10, P22; Cork BMJ, 2003, PHARM J, V271, P746; COWLEY NC, 1992, ACTA DERM-VENEREOL, V72, P432; CRONIN E, 1962, BRIT J DERMATOL, V74, P265, DOI 10.1111/j.1365-2133.1962.tb13504.x; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Deleuran M, 1998, ACTA DERM-VENEREOL, V78, P241; Denda M, 1998, J INVEST DERMATOL, V111, P873, DOI 10.1046/j.1523-1747.1998.00364.x; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Di Paola R, 2002, AM J HUM GENET, V70, P806, DOI 10.1086/339270; DOTTERUD LK, 1995, ACTA DERM-VENEREOL, V75, P50; Dubin G, 2005, CELL MOL LIFE SCI, V62, P653, DOI 10.1007/s00018-004-4445-9; Eberlein-Konig B, 2000, ACTA DERM-VENEREOL, V80, P188; Egberts F, 2004, J CELL SCI, V117, P2295, DOI 10.1242/jcs.01075; EGELRUD T, 1993, J INVEST DERMATOL, V101, P200, DOI 10.1111/1523-1747.ep12363804; EGELRUD T, 1991, ARCH DERMATOL RES, V283, P108, DOI 10.1007/BF00371618; EGELRUD T, 1990, J INVEST DERMATOL, V95, P456, DOI 10.1111/1523-1747.ep12555620; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Ekholm E, 1998, BRIT J DERMATOL, V139, P585; Ekholm IE, 2000, J INVEST DERMATOL, V114, P56, DOI 10.1046/j.1523-1747.2000.00820.x; Elias P M, 1999, Am J Contact Dermat, V10, P119, DOI 10.1016/S1046-199X(99)90054-4; Elias PM, 2004, J INVEST DERMATOL, V122, pXXXVI, DOI 10.1046/j.0022-202X.2004.22233.x; Elias PM, 2001, J CELL BIOL, V153, P243, DOI 10.1083/jcb.153.2.243; Elias P.M., 1983, J INVEST DERMATOL, V80, P44, DOI DOI 10.1038/JID.1983.12); Esche C, 2004, CURR ALLERGY ASTHM R, V4, P276, DOI 10.1007/s11882-004-0071-8; FARTASCH M, 1989, DERMATOLOGICA, V178, P202; Fartasch M, 1992, Acta Derm Venereol Suppl (Stockh), V176, P26; FELDMANN RJ, 1967, J INVEST DERMATOL, V48, P181; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; Flohr C, 2004, J ALLERGY CLIN IMMUN, V114, P150, DOI 10.1016/j.jaci.2004.04.027; Fluhr JW, 2004, J INVEST DERMATOL, V123, P140, DOI 10.1111/j.0022-202X.2004.22726.x; Fluhr JW, 2001, J INVEST DERMATOL, V117, P44, DOI 10.1046/j.0022-202x.2001.01399.x; Fluhr JW, 2002, EXOG DERMATOL, V1, P163, DOI 10.1159/000066140; Fox C, 1998, J Perinatol, V18, P272; Franzke CW, 1996, J BIOL CHEM, V271, P21886; Frittitta L, 2001, DIABETES, V50, P1952, DOI 10.2337/diabetes.50.8.1952; FROEBE CL, 1990, DERMATOLOGICA, V181, P277; FROSCH PJ, 1985, MODELS DERMATOLOGY, V2, P5; Furue M, 2003, BRIT J DERMATOL, V148, P128, DOI 10.1046/j.1365-2133.2003.04934.x; Gallicano GI, 1998, J CELL BIOL, V143, P2009, DOI 10.1083/jcb.143.7.2009; Garg A, 2001, ARCH DERMATOL, V137, P53; Ghadially R, 1996, J INVEST DERMATOL, V107, P558, DOI 10.1111/1523-1747.ep12582813; GHADIALLY R, 1995, J CLIN INVEST, V95, P2281, DOI 10.1172/JCI117919; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Goulding NJ, 2004, CURR OPIN PHARMACOL, V4, P629, DOI 10.1016/j.coph.2004.06.009; Guerrin M, 1998, J BIOL CHEM, V273, P22640, DOI 10.1074/jbc.273.35.22640; Haapasaari KM, 1997, SKIN PHARMACOL, V10, P261; HAAPASAARI KM, 1995, ACTA DERM-VENEREOL, V75, P269; Hachem JP, 2003, J INVEST DERMATOL, V121, P345, DOI 10.1046/j.1523-1747.2003.12365.x; HAFTEK M, 1991, J HISTOCHEM CYTOCHEM, V39, P1531; HALKIERSORENSEN L, 1993, CONTACT DERMATITIS, V29, P1; Hallock P, 1998, J FORAMIN RES, V28, P1; HAMAMI I, 1988, CLIN EXP DERMATOL, V13, P328, DOI 10.1111/j.1365-2230.1988.tb00715.x; Hanifin JM, 2002, BRIT J DERMATOL, V147, P430, DOI 10.1046/j.1365-2133.2002.05011.x; Marks RM, 1992, ECZEMA, P77; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Hara J, 2000, J INVEST DERMATOL, V115, P406, DOI 10.1046/j.1523-1747.2000.00072.x; Harper JI, 2000, BRIT J DERMATOL, V142, P52, DOI 10.1046/j.1365-2133.2000.03241.x; HILDEBRANDT F, 2003, ALLERGY, V58, P5; HOLLERAN WM, 1993, J CLIN INVEST, V91, P1656, DOI 10.1172/JCI116374; Holt Patrick G, 2004, Paediatr Respir Rev, V5 Suppl A, pS27, DOI 10.1016/S1526-0542(04)90006-1; Horikoshi T, 1998, J INVEST DERMATOL, V110, P547; Horikoshi T, 1999, BRIT J DERMATOL, V141, P453; Hornby SJ, 2002, ANN TROP PAEDIATR, V22, P67, DOI 10.1179/027249302125000193; IMOKAWA G, 1980, J SOC COSMET CHEM, V31, P45; Iwanaga T, 2004, CLIN EXP ALLERGY, V34, P1037, DOI 10.1111/j.1365-2222.2004.02000.x; Jensen JM, 1999, J CLIN INVEST, V104, P1761, DOI 10.1172/JCI5307; Johansson C, 2004, INT ARCH ALLERGY IMM, V135, P93, DOI 10.1159/000080651; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kao Jack S., 2003, Journal of Investigative Dermatology, V120, P456, DOI 10.1046/j.1523-1747.2003.12053.x; Kapp A, 2002, J ALLERGY CLIN IMMUN, V110, P277, DOI 10.1067/mai.2002.126500; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; KIRK JF, 1966, ACTA DERM-VENEREOL, V57, P24; KLIGMAN AM, 1967, J INVEST DERMATOL, V49, P78, DOI 10.1038/jid.1967.106; Koch PJ, 1997, J CELL BIOL, V137, P1091, DOI 10.1083/jcb.137.5.1091; Kolbe L, 2001, SKIN RES TECHNOL, V7, P73, DOI 10.1034/j.1600-0846.2001.70203.x; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Kunz B, 2002, TXB PEDIAT DERMATOLO, P199; LAVKER R M, 1970, Journal of Cell Biology, V44, P501, DOI 10.1083/jcb.44.3.501; LAVKER RM, 1976, J ULTRA MOL STRUCT R, V55, P79, DOI 10.1016/S0022-5320(76)80083-4; Lee Y, 2002, SURG RADIOL ANAT, V24, P183, DOI 10.1007/s00276-002-0034-5; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1978, ARCH DERMATOL, V114, P56, DOI 10.1001/archderm.114.1.56; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P523; LOCKER G, 1961, DERMATOLOGICA, V124, P159; LUNDSTROM A, 1994, ARCH DERMATOL RES, V286, P369, DOI 10.1007/BF00371795; LUNDSTROM A, 1988, J INVEST DERMATOL, V91, P340, DOI 10.1111/1523-1747.ep12475679; MAIBACH HI, 1976, DERMATOLOGICA, V152, P11; Mao XQ, 1998, HUM HERED, V48, P38, DOI 10.1159/000022782; Marchionini A, 1938, KLIN WOCHENSCHR, V17, P663, DOI 10.1007/BF01778645; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MARZULLI FN, 1962, J INVEST DERMATOL, V39, P387, DOI 10.1038/jid.1962.129; Mauro T, 1998, ARCH DERMATOL RES, V290, P215, DOI 10.1007/s004030050293; McNally NJ, 1998, LANCET, V352, P527, DOI 10.1016/S0140-6736(98)01402-0; McNally NJ, 2001, BRIT J DERMATOL, V145, P730, DOI 10.1046/j.1365-2133.2001.04474.x; Mecheleidt O, 2002, J INVEST DERMATOL, V119, P166; MEDING B, 1987, BRIT J DERMATOL, V116, P627, DOI 10.1111/j.1365-2133.1987.tb05895.x; MELNIK BC, 1989, J INVEST DERMATOL, V92, P231, DOI 10.1111/1523-1747.ep12276757; MENON GK, 1992, J INVEST DERMATOL, V98, P279, DOI 10.1111/1523-1747.ep12497866; Merritt AJ, 2002, MOL CELL BIOL, V22, P5846, DOI 10.1128/MCB.22.16.5846-5858.2002; Miedzobrodzki J, 2002, EUR J CLIN MICROBIOL, V21, P269, DOI 10.1007/s10096-002-0706-4; MOLHUIZEN HOF, 1993, J BIOL CHEM, V268, P12028; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; MUCKE H, 1993, PHARMAZIE, V48, P468; MURPHY R, 1999, BR J DERMATOL S55, V141, P25; NEAME RL, 1995, BRIT J DERMATOL, V132, P772; NICKOLOFF BJ, 1994, J AM ACAD DERMATOL, V30, P535; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Novembre E, 2001, ALLERGY, V56, P452, DOI 10.1034/j.1398-9995.2001.056005452.x; OESTMANN E, 1993, BRIT J DERMATOL, V128, P130, DOI 10.1111/j.1365-2133.1993.tb15141.x; OGAWA H, 1992, PEDIATR DERMATOL, V9, P383, DOI 10.1111/j.1525-1470.1992.tb00638.x; Oikarinen A, 1998, BRIT J DERMATOL, V139, P1106; Otto M, 2004, FRONT BIOSCI, V9, P841, DOI 10.2741/1295; Pepys J., 1975, , Clinical aspects of immunology., P877; PRZYBILLA B, 1991, HDB ATOPIC ECZEMA, P132; PUHVEL SM, 1975, J INVEST DERMATOL, V64, P406, DOI 10.1111/1523-1747.ep12512337; Rapaport MJ, 2003, CLIN DERMATOL, V21, P201, DOI 10.1016/S0738-081X(02)00365-6; Rawlings A. V., 2003, International Journal of Cosmetic Science, V25, P63, DOI 10.1046/j.1467-2494.2003.00174.x; REBELL G, 1950, J INVEST DERMATOL, V14, P247; Reitamo S, 2005, BRIT J DERMATOL, V152, P1282, DOI 10.1111/j.1365-2133.2005.06592.x; Rippke Frank, 2002, Am J Clin Dermatol, V3, P261, DOI 10.2165/00128071-200203040-00004; Roth W, 2000, FASEB J, V14, P2075, DOI 10.1096/fj.99-0970com; SCHADE H., 1928, KLIN WOCHENSCHR, V7, P12, DOI 10.1007/BF01711684; Schaefer H, 1978, Curr Probl Dermatol, V7, P80; Schaefer H., 1982, SKIN PERMEABILITY; SCHAEFER K. E., 1951, EXPTL MED AND SURG, V9, P449; SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Schmuth M, 2000, J INVEST DERMATOL, V115, P459, DOI 10.1046/j.1523-1747.2000.00081.x; SCHUDEL P, 1985, Z HAUTKRANKHEITEN, V60, P479; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; SERRE G, 1991, J INVEST DERMATOL, V97, P1061, DOI 10.1111/1523-1747.ep12492589; Sheu H M, 1991, J Formos Med Assoc, V90, P664; Sheu Hamm-Ming, 1998, Journal of Dermatology (Tokyo), V25, P281; Sheu HM, 1997, BRIT J DERMATOL, V136, P884, DOI 10.1111/j.1365-2133.1997.tb03929.x; SHULTZLARSEN F, 1986, J AM ACAD DERMATOL, V15, P487; SIMON M, 2001, J INVEST DERMATOL, V117, P710; SONDELL B, 1994, J HISTOCHEM CYTOCHEM, V42, P459; SOUTHWOOD W F, 1955, Plast Reconstr Surg (1946), V15, P423; Sprecher E, 2001, J INVEST DERMATOL, V117, P179, DOI 10.1046/j.1523-1747.2001.01389.x; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; STORCK H, 1948, DERMATOLOGICA HELVET, V96, P177; Suzuki Y., 1994, ARCH DERMATOL RES, V286, P369; TADA J, 1994, ACTA DERM-VENEREOL, V74, P129; TADDEI A, 1935, RIV ITAL GINECOL, V18, P496; Taggart CC, 2001, J BIOL CHEM, V276, P33345, DOI 10.1074/jbc.M103220200; Taieb A, 1999, CONTACT DERMATITIS, V41, P177, DOI 10.1111/j.1600-0536.1999.tb06125.x; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TAYLOR B, 1984, LANCET, V2, P1255; THESTRUPPEDERSE.K, 1996, J EUR ACAD DERMAT S1, V7, P53; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; Tomimori Y, 2002, LAB INVEST, V82, P789, DOI 10.1097/01.LAB.0000018827.78602.F4; Tomimori Y, 2002, BIOCHEM PHARMACOL, V64, P1187, DOI 10.1016/S0006-2952(02)01265-0; Uchida Y, 2000, J LIPID RES, V41, P2071; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Vasioukhin V, 2001, NAT CELL BIOL, V3, P1076, DOI 10.1038/ncb1201-1076; Visscher MO, 2000, PEDIATR DERMATOL, V17, P45, DOI 10.1046/j.1525-1470.2000.01711.x; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Watkinson A, 1999, ARCH DERMATOL RES, V291, P260, DOI 10.1007/s004030050406; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; WHITE FH, 1984, J SUBMICR CYTOL PATH, V16, P407; WHITE MI, 1987, BRIT J DERMATOL, V116, P525, DOI 10.1111/j.1365-2133.1987.tb05873.x; WIEDOW O, 1993, J INVEST DERMATOL, V101, P305, DOI 10.1111/1523-1747.ep12365430; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Wollenberg A, 2000, ALLERGY, V55, P205, DOI 10.1034/j.1398-9995.2000.00115.x; Wood LC, 1997, EXP DERMATOL, V6, P98, DOI 10.1111/j.1600-0625.1997.tb00154.x; Wood LC, 1996, J INVEST DERMATOL, V106, P397, DOI 10.1111/1523-1747.ep12343392; WUHN U, 2002, PEDIATRICS, V110, pE2; WUTHRICH B, 1989, DERMATOLOGICA, V178, P51; Yang T, 2004, GENE DEV, V18, P2354, DOI 10.1101/gad.1232104; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x; Yousef GM, 2000, GENE, V254, P119, DOI 10.1016/S0378-1119(00)00280-8; YURA A, 2001, BRIT J DERMATOL, V115, P966; Zeeuwen PLJM, 2004, HUM MOL GENET, V13, P1069, DOI 10.1093/hmg/ddh115; Zeeuwen PLJM, 2001, J INVEST DERMATOL, V116, P693, DOI 10.1046/j.1523-1747.2001.01309.x; ZHENG P, 1984, J INVEST DERMATOL, V82, P345, DOI 10.1111/1523-1747.ep12260665	215	232	256	5	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					3	21		10.1016/j.jaci.2006.04.042		19	Allergy; Immunology	Allergy; Immunology	065UH	WOS:000239184800001	16815133	
J	Weisglas-Kuperus, N; Patandin, S; Berbers, GAM; Sas, TCJ; Mulder, PGH; Sauer, PJJ; Hooijkaas, H				Weisglas-Kuperus, N; Patandin, S; Berbers, GAM; Sas, TCJ; Mulder, PGH; Sauer, PJJ; Hooijkaas, H			Immunologic effects of background exposure to polychlorinated biphenyls and dioxins in Dutch preschool children	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						allergic diseases; antibody levels; breast-feeding; infectious diseases; leucocyte (sub)populations; PCBs; PCDDs; PCDFs	LYMPHOCYTE SUBSETS; OTITIS-MEDIA; INFANTS; ANTIBODIES; DIBENZOFURANS; NETHERLANDS; PREVALENCE; CHILDHOOD; MEASLES; ASTHMA	Prenatal exposure to polychlorinated biphenyls (PCBs) and dioxins is associated with changes in the T-cell lymphocyte population in healthy Dutch infants. We investigated whether these changes persist into later childhood and whether background exposure to PCBs and dioxins is associated with the prevalence of infectious or allergic diseases and humoral immunity at preschool age. The total study group consisted of 207 healthy mother-infant pairs. We estimated prenatal exposure to PCBs and dioxins by the sum of PCBs 118, 138, 153, and 180 (Sigma PCB) in maternal and cord plasma and in breast-fed infants by the dioxin, planar, and mono-ortho PCB toxic equivalent (TEQ) levels in human milk At 42 months of age, current body burden was estimated by the Sigma PCB in plasma. We assessed the prevalence of infectious and allergic diseases by parent questionnaire, and measured humoral immunity by antibody levels for mumps, measles, and rubella after primary vaccination. We performed immunologic marker analyses of lymphocytes in a subgroup of 85 children. Prenatal PCB exposure was associated with an increased number of lymphocytes, T-cells, and CD3CD8(+) (cytotoxic), CD4(+)CD45RO(+) (memory), T-cell receptor (TcR) alpha beta (+), and CD3(+)HLA-DR+ (activated) T cells and lower antibody levels to mumps and measles at preschool age. Adjusted for confounders, prenatal PCB exposure was associated with less shortness of breath with wheeze, and current PCB body burden was associated with a higher prevalence of recurrent middle-ear infections and of chicken pox and a lower prevalence of allergic reactions. A higher dioxin TEQ was associated with a higher prevalence of coughing, chest congestion, and phlegm. We conclude that in Dutch preschool children the effects of perinatal background exposure to PCBs and dioxins persist into childhood and might be associated with a greater susceptibility to infectious diseases. Common infections acquired early in life may prevent the development of allergy, so PCB exposure might be associated with a lower prevalence of allergic diseases.	Univ Rotterdam Hosp, Sophia Childrens Hosp, Rotterdam, Netherlands; Erasmus Univ, Dept Paediat, Div Neonatol, Rotterdam, Netherlands; Natl Inst Publ Hlth & Environm, Dept Clin Vaccine Res, NL-3720 BA Bilthoven, Netherlands; Erasmus Univ, Inst Epidemiol & Biostat, Rotterdam, Netherlands; Erasmus Univ, Dept Immunol, NL-3000 DR Rotterdam, Netherlands	Weisglas-Kuperus, N (reprint author), Sophia Childrens Hosp, Dept Paediat, Div Neonatol, POB 2060, NL-3000 CB Rotterdam, Netherlands.						ANIANSSON G, 1994, PEDIATR INFECT DIS J, V13, P183, DOI 10.1097/00006454-199403000-00003; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; Chao WY, 1997, ARCH ENVIRON HEALTH, V52, P257; COMANSBITTERS WM, 1997, J PEDIATR, V1330, P388; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; DAHL P, 1995, CHEMOSPHERE, V30, P2297, DOI 10.1016/0045-6535(95)00102-E; De Haas R, 1999, EPIDEMIOL INFECT, V123, P263, DOI 10.1017/S0950268899002939; Dewailly E, 2000, ENVIRON HEALTH PERSP, V108, P205, DOI 10.2307/3454435; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; DUNCAN B, 1993, PEDIATRICS, V91, P867; Fokkens WJ, 1999, ALLERGY, V54, P158, DOI 10.1034/j.1398-9995.1999.00747.x; HARMSEN T, 1992, J CLIN MICROBIOL, V30, P2139; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V28, P1721, DOI 10.1016/0045-6535(94)90428-6; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lai ZW, 1998, TOXICOL APPL PHARM, V149, P167, DOI 10.1006/taap.1998.8368; Lanting CI, 1998, ACTA PAEDIATR, V87, P1224; Matricardi PM, 1997, BRIT MED J, V314, P999; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; Patandin S, 1997, AM J PUBLIC HEALTH, V87, P1711, DOI 10.2105/AJPH.87.10.1711; Patandin S, 1999, ENVIRON HEALTH PERSP, V107, P45, DOI 10.2307/3434288; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; Ross P, 1996, TOXICOLOGY, V112, P157, DOI 10.1016/0300-483X(96)03396-3; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Van den Berg M, 1998, ENVIRON HEALTH PERSP, V106, P775, DOI 10.1289/ehp.98106775; van den Hof S, 1999, VACCINE, V18, P931, DOI 10.1016/S0264-410X(99)00348-5; Van Loveren H., 1999, Biomarkers, V4, P135; VANDEMERWE JP, 1992, NETH J MED, V40, P158; Vos J. G., 1989, HALOGENATED BIPHENYL, P295; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022	30	232	239	2	18	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	DEC	2000	108	12					1203	1207		10.2307/3434834		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	385LJ	WOS:000166005700033	11133402	
J	Buchvald, F; Baraidi, E; Carraro, S; Gaston, B; De Jongste, J; Pijnenburg, MWH; Silkoff, PE; Bisgaard, H				Buchvald, F; Baraidi, E; Carraro, S; Gaston, B; De Jongste, J; Pijnenburg, MWH; Silkoff, PE; Bisgaard, H			Measurements of exhaled nitric oxide in healthy subjects age 4 to 17 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exhaled nitric oxide; children; normal values	EXERCISE-INDUCED BRONCHOCONSTRICTION; ASTHMATIC-CHILDREN; AIR; DECREASES; SENSITIZATION; RHINITIS; ONLINE; VALUES; ADULTS; ATOPY	Background: Fractional exhaled nitric oxide (FENO) is used in monitoring of asthma. Objectives: The aim of this multicenter study was to establish normal values of FENO and assess feasibility in children with a standardized method and equipment approved for clinical use. Methods: FENO was measured in healthy subjects of 4 to 17 years according to American Thoracic Society guidelines (single breath online, exhalation flow 50 mL/s) with a chemilumineseence analyzer (NIOX Exhaled Nitric Oxide Monitoring System, Aerocrine, Sweden) in 3 European and 2 US centers. Each child performed 3 acceptable nitric oxide measurements within 6 attempts and completed an extended International Study of Asthma and Allergy in Children questionnaire. Results: Measurement of FENO was attempted in 522 children. Four hundred five children completed the study according to the protocol. Geometric mean FENO in 405 children was 9.7 pph, and the upper 95% confidence limit was 25.2 pph. FENO increased significantly with age, and higher FENO was seen in children with self-reported rhinitis/conjunctivitis or hay fever. The success rate was age-dependent and improved from 40% in the children 4 years old to almost 100%, front the age of 10 years. The repeatability of 3 approved measurements was 1.6 ppb (95% CI, 1.49-1.64 ppb). Conclusion: FENO in healthy children is below 15 to 25 pph depending on age and self-reported atopy. Measurement of FENO by NIOX is simple and safe and has a good repeatability. Feasibility depends on age and may be difficult in the preschool child.	Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Studies Asthma Childhood Res Clin, DK-2900 Hellerup, Denmark; Univ Padua, Dept Pediat, Sch Med, Padua, Italy; Univ Virginia, Charlottesville, VA 22903 USA; Erasmus Med Univ Ctr, Sophia Childrens Hosp, Rotterdam, Netherlands; Natl Jewish Med & Res Ctr, Denver, CO USA	Bisgaard, H (reprint author), Copenhagen Univ Hosp, Danish Pediat Asthma Ctr, Studies Asthma Childhood Res Clin, Niels Andersensvej 79, DK-2900 Hellerup, Denmark.		Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592; BARALDI, EUGENIO/0000-0002-1829-3652; silkoff, philip/0000-0001-6018-5199			ALVING K, 1993, EUR RESPIR J, V6, P1368; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Avital A, 2003, PEDIATR PULM, V36, P433, DOI 10.1002/ppul.10377; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Baraldi E, 1999, PEDIATR PULM, V27, P54, DOI 10.1002/(SICI)1099-0496(199901)27:1<54::AID-PPUL10>3.0.CO;2-V; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Bruce C, 2002, THORAX, V57, P361, DOI 10.1136/thorax.57.4.361; Buchvald F, 2003, CLIN EXP ALLERGY, V33, P1735, DOI 10.1111/j.1365-2222.2003.01822.x; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Horvath I, 1999, CLIN EXP ALLERGY, V29, P1276; Jobsis Q, 2001, EUR RESPIR J, V17, P898, DOI 10.1183/09031936.01.17508980; Jungersten L, 1997, J APPL PHYSIOL, V82, P760; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903; Kissoon N, 2002, PEDIATR PULM, V33, P283, DOI 10.1002/ppul.10023; Latzin P, 2002, PEDIATR ALLERGY IMMU, V13, P37; Mattes J, 2002, PEDIATR RES, V51, P190, DOI 10.1203/00006450-200202000-00011; Olin AC, 2001, RESP MED, V95, P153, DOI 10.1053/rmed.2000.1010; Piacentini GL, 1998, AM J RESP CRIT CARE, V158, P1299; Pijnenburg MWH, 2002, EUR RESPIR J, V20, P919, DOI 10.1183/09031936.02.01282002; Scollo M, 2000, AM J RESP CRIT CARE, V161, P1047; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; ten Hacken NHT, 1998, AM J RESP CRIT CARE, V158, P902; Terada A, 2001, AM J RESP CRIT CARE, V164, P1879; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; Tsang KW, 2001, LUNG, V179, P83, DOI 10.1007/s004080000050; van Amsterdam JGC, 2003, CLIN EXP ALLERGY, V33, P187, DOI 10.1046/j.1365-2222.2003.01597.x; Van Amsterdam JGC, 1999, ARCH ENVIRON HEALTH, V54, P331; Yates DH, 2001, AM J RESP CRIT CARE, V164, P1043; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x	36	231	246	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1130	1136		10.1016/j.jaci.2005.03.020		7	Allergy; Immunology	Allergy; Immunology	935WZ	WOS:000229815400004	15940124	
J	Vozoris, NT; Tarasuk, VS				Vozoris, NT; Tarasuk, VS			Household food insufficiency is associated with poorer health	JOURNAL OF NUTRITION			English	Article						food insecurity; health status; welfare; body mass index; Canada	BODY-MASS INDEX; NUTRITION EXAMINATION SURVEY; CHILDRENS FEEDING PROGRAMS; 3RD NATIONAL-HEALTH; POPULATION HEALTH; UNITED-STATES; ATLANTIC CANADA; FAMILY INCOME; INSECURITY; HUNGER	The purposes of this study were to estimate the prevalence of household food insufficiency in Canada, to identify sociodemographic characteristics of households most likely to report food insufficiency and to examine the relationship between food insufficiency and physical, mental and social health. These objectives were achieved through an analysis of data from the 1996/1997 National Population Health Survey. An estimated 4% of Canadians, 1.1 million people, were found to be living in food-insufficient households. Single-parent families, households reporting their major source of income as welfare, unemployment insurance or workers' compensation, those who did not own their own homes and households in Western Canada were more likely to report food insufficiency. The likelihood of reporting food insufficiency increased dramatically as income adequacy deteriorated. Individuals from food-insufficient households had significantly higher odds of reporting poor/fair health, of having poor functional health, restricted activity and multiple chronic conditions, of suffering from major depression and distress, and of having poor social support. Individuals in food-insufficient households were also more likely to report heart disease, diabetes, high blood pressure and food allergies. Men in food-insufficient households were less likely to be overweight; after adjusting for potentially confounding variables, no other associations were found between food insufficiency and body mass index. These findings suggest that food insufficiency is one dimension of a more pervasive vulnerability to a range of physical, mental and social health problems among households struggling with economic constraints.	Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada	Tarasuk, VS (reprint author), Univ Toronto, Fac Med, Dept Nutr Sci, Toronto, ON M5S 3E2, Canada.						Alaimo K, 1998, AM J PUBLIC HEALTH, V88, P419, DOI 10.2105/AJPH.88.3.419; Alaimo K, 2002, J NUTR, V132, P719; Alaimo K, 2001, PEDIATRICS, V108, P44; Alaimo K, 2001, AM J PUBLIC HEALTH, V91, P781, DOI 10.2105/AJPH.91.5.781; Alaimo K, 2001, ARCH PEDIAT ADOL MED, V155, P1161; Andrews M., 2000, HOUSEHOLD FOOD SECUR; Beaudet M P, 1996, Health Rep, V7, P11; BRIEFEL RR, 1992, J NUTR EDUC, V24, pS24; Cairney J, 1998, INT J OBESITY, V22, P584, DOI 10.1038/sj.ijo.0800632; Cairney J, 1999, CAN J PUBLIC HEALTH, V90, P320; Casey PH, 2001, ARCH PEDIAT ADOL MED, V155, P508; Che J, 2001, Health Rep, V12, P11; Cook JT, 2002, ARCH PEDIAT ADOL MED, V156, P678; Corcoran M. E., 1999, OHIO STATE LAW J, V60, P1395; CRISTOFAR SP, 1992, J NUTR EDUC, V24, P53; Dayle JB, 2000, SOC SCI MED, V51, P1783, DOI 10.1016/S0277-9536(00)00110-6; Denton M, 1999, SOC SCI MED, V48, P1221, DOI 10.1016/S0277-9536(98)00421-3; EMES J, 2000, ADEQUACY WELFARE BEN; Hamelin AM, 2002, SOC SCI MED, V54, P119, DOI 10.1016/S0277-9536(01)00013-2; HAMELIN AM, 1998, REV CANADIENNE ETUDE, V19, P277; Hamilton WL, 1997, HOUSEHOLD FOOD SECUR; Hobbs K., 1993, CAN REV SOC POLICY, V31, P94; Humphries KH, 2000, SOC SCI MED, V50, P663, DOI 10.1016/S0277-9536(99)00319-6; Jacobs-Starkey L., 1998, CAN MED ASSOC J, V158, P1143; KENDALL A, 1995, J NUTR, V125, P2793; Kleinman R. E., 1998, PEDIATRICS, V101, P1; Klesges LM, 2001, AM J PUBLIC HEALTH, V91, P68; Kopec JA, 2000, CAN J PUBLIC HEALTH, V91, P465; Lee KK, 2000, URBAN POVERTY CANADA; Macdonald SM, 1997, CAN MED ASSOC J, V157, pS3; McIntyre L, 1999, CAN J PUBLIC HEALTH, V90, P196; McIntyre L, 2000, CAN MED ASSOC J, V163, P961; MCINTYRE L, 1998, GLIMPSE CHILD HUNGER; *NAT COUNC WELF, 1999, POV PROF 1997; Nelson K, 1998, JAMA-J AM MED ASSOC, V279, P1211, DOI 10.1001/jama.279.15.1211; NESTLE M, 1992, J NUTR EDUC, V24, pS18; NORD M, 1999, PREVALENCE FOOD INSE; ODERKIRK J, 1992, CAN SOC TRENDS, V24, P6; OSTBYE T, 1995, CAN MED ASSOC J, V152, P1811; Patten S B, 1997, Chronic Dis Can, V18, P109; Patten SB, 2001, J AFFECT DISORDERS, V63, P35, DOI 10.1016/S0165-0327(00)00186-5; Rabkin SW, 1997, CAN MED ASSOC J, V157, pS26; Radimer KL, 1997, AUST NZ J PUBL HEAL, V21, P303, DOI 10.1111/j.1467-842X.1997.tb01704.x; RICHES G, 1997, HUNGER CANADA ABANDO; Rose D, 1997, AM J PUBLIC HEALTH, V87, P1956, DOI 10.2105/AJPH.87.12.1956; ROSE D, 1997, VALIDATION SELF REPO; Rosenberg MW, 2000, SOC SCI MED, V51, P275, DOI 10.1016/S0277-9536(99)00453-0; Sarlio-Lahteenkorva S, 2001, J NUTR, V131, P2880; SIEFERT K, 2001, WOMEN HLTH, V59, P159; *STAT CAN, 1998, NAT POP HLTH SURV 19; SULLIVAN AF, 2000, HUNGER US SUMAMRY RE; Swain L, 1999, Health Rep, V10, P69; Tambay J L, 1995, Health Rep, V7, P29; Tarasuk V, 1996, J NUTR EDUC, V28, P71, DOI 10.1016/S0022-3182(96)70029-8; Tarasuk V, 2001, HEALTH EDUC BEHAV, V28, P487, DOI 10.1177/109019810102800408; Tarasuk VS, 1999, J NUTR, V129, P672; Tarasuk VS, 1999, CAN J PUBLIC HEALTH, V90, P109; TARASUK VS, 1990, CAN J PUBLIC HEALTH, V81, P331; Tarasuk VS, 2001, J NUTR, V131, P2670; Teron AC, 1999, CAN J PUBLIC HEALTH, V90, P382; Torrance GW, 1996, MED CARE, V34, P702, DOI 10.1097/00005650-199607000-00004; Townsend MS, 2001, J NUTR, V131, P1738; Trakas K, 2001, INT J OBESITY, V25, P662, DOI 10.1038/sj.ijo.0801591; Travers KD, 1997, J CAN DIET ASSOC, V58, P176; Vozoris N, 2002, CAN J PUBLIC HEALTH, V93, P36; Wade TJ, 1997, CAN J PUBLIC HEALTH, V88, P297; Wade TJ, 2000, CAN J PUBLIC HEALTH, V91, P307; WHO, 1995, REP WHO EXP COMM TEC, V854; WILSON B, 2000, HUNGERCOUNT 2000 SUR; Yeo D., 1999, 1999 P SURV RES METH, P778	70	231	235	7	28	AMER INST NUTRITION	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3166			J NUTR	J. Nutr.	JAN	2003	133	1					120	126				7	Nutrition & Dietetics	Nutrition & Dietetics	633VV	WOS:000180305900022	12514278	
J	Howard, TD; Koppelman, GH; Xu, JF; Zheng, SQL; Postma, DS; Meyers, DA; Bleecker, ER				Howard, TD; Koppelman, GH; Xu, JF; Zheng, SQL; Postma, DS; Meyers, DA; Bleecker, ER			Gene-gene interaction in asthma: IL4RA and IL13 in a Dutch population with asthma	AMERICAN JOURNAL OF HUMAN GENETICS			English	Article							SKIN-TEST REACTIVITY; SERUM IGE LEVELS; INTERLEUKIN-4 RECEPTOR; AIRWAY INFLAMMATION; BRONCHIAL RESPONSIVENESS; IL4-RECEPTOR GENE; ATOPIC ASTHMA; ALPHA-GENE; ASSOCIATION; IL-4	Asthma is a common respiratory disease that is characterized by variable airways obstruction caused by acute and chronic bronchial inflammation; associated phenotypes include bronchial hyperresponsiveness (BHR), elevated total serum immunoglobulin E (IgE) levels, and skin tests positive to common allergens. Binding of interleukin-13 (IL13) or interleukin-4 (IL4) to the IL4 receptor (IL4R) induces the initial response for Th2 lymphocyte polarization. Both IL13 and IL4 are produced by Th2 cells and are capable of inducing isotype class-switching of B-cells to produce IgE after allergen exposure. These cytokines also share a common receptor component, IL4R. We have investigated five IL4RA single-nucleotide polymorphisms in a population of Dutch families ascertained through a proband with asthma. By considering the probands and their spouses as an unrelated sample, we observed significant associations of atopy and asthma-related phenotypes with several IL4RA polymorphisms, including S478P and total serum IgE levels (P=.0007). A significant gene-gene interaction between S478P in IL4RA and the - 1111 promoter variation in IL13, previously shown to be associated with BHR (P = .003), was detected. Individuals with the risk genotype for both genes were at almost five times greater risk for the development of asthma compared to individuals with both nonrisk genotypes (P = .0004). These data suggest that variations in IL4RA contribute to elevated total serum IgE levels, and interaction between IL4RA and IL13 markedly increases an individual's susceptibility to asthma.	Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genome, Winston Salem, NC 27157 USA; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Beatrixoord, Dept Pulm Rehabil, Haren, Netherlands	Bleecker, ER (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genome, Med Ctr Blvd, Winston Salem, NC 27157 USA.				NHLBI NIH HHS [R01 HL048341, R01 HL066393, R01HL/48341, R01HL/66393]		Aman MJ, 1996, J BIOL CHEM, V271, P29265; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; Deichmann KA, 1998, CLIN EXP ALLERGY, V28, P151; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Gauchat JF, 1997, EUR J IMMUNOL, V27, P971, DOI 10.1002/eji.1830270425; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hackstein H, 2001, IMMUNOGENETICS, V53, P264, DOI 10.1007/s002510100324; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Henderson WR, 2000, J IMMUNOL, V164, P1086; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Howard TD, 2001, AM J RESP CELL MOL, V25, P377; Howard TD, 1999, BIOTECHNIQUES, V26, P380; Kraan TCTMV, 1999, GENES IMMUN, V1, P61; Kruse S, 1999, IMMUNOLOGY, V96, P365; Kruse S, 1999, INT IMMUNOL, V11, P1965, DOI 10.1093/intimm/11.12.1965; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; ZAYKIN D, 1995, GENETICA, V96, P169, DOI 10.1007/BF01441162	29	231	253	1	3	UNIV CHICAGO PRESS	CHICAGO	1427 E 60TH ST, CHICAGO, IL 60637-2954 USA	0002-9297			AM J HUM GENET	Am. J. Hum. Genet.	JAN	2002	70	1					230	236		10.1086/338242		7	Genetics & Heredity	Genetics & Heredity	499LD	WOS:000172571900020	11709756	
J	Morgenstern, V; Zutavern, A; Cyrys, J; Brockow, I; Koletzko, S; Kramer, U; Behrendt, H; Herbarth, O; von Berg, A; Bauer, CP; Wichmann, HE; Heinrich, J				Morgenstern, Verena; Zutavern, Anne; Cyrys, Josef; Brockow, Inken; Koletzko, Sibylle; Kraemer, Ursula; Behrendt, Heidrun; Herbarth, Olf; von Berg, Andrea; Bauer, Carl Peter; Wichmann, H. -Erich; Heinrich, Joachim		GINI Study Grp; LISA Study Grp	Atopic diseases, allergic sensitization, and exposure to traffic-related air pollution in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollution; GIS; allergic sensitization; allergy	INDIVIDUAL ESTIMATED EXPOSURE; PROSPECTIVE BIRTH COHORT; SOLID FOOD INTRODUCTION; RESPIRATORY HEALTH; SPATIAL VARIABILITY; PARTICULATE MATTER; NITROGEN-DIOXIDE; TERM EXPOSURE; SYMPTOMS; ASTHMA	Rationale: In vitro studies, animal experiments, and human exposure studies have shown how ambient air pollution increases the risk of atopic diseases. However, results derived from observational studies are inconsistent. Objectives: To assess the relationship between individual-based exposure to traffic-related air pollutants and allergic disease outcomes in a prospective birth cohort study during the first 6 years of life. Methods: We studied 2,860 children at the age of 4years and 3,061 at the age of 6 years to investigate atopic diseases and allergic sensitization. Long-term exposure to particulate matter (PM2.5), PM2.5 absorbance, and long-term exposure to nitrogen dioxide (NO2) was assessed at residential addresses using geographic information systems based regression models and air pollution measurements. The distance to the nearest main road was used as a surrogate for traffic-related air pollutants. Measurements and Main Results: Strong positive associations were found between the distance to the nearest main road and asthmatic bronchitis, hay fever, eczema, and sensitization. A distance-dependent relationship could be identified, with the highest odds ratios (ORs) for children living less than 50 m from busy streets. For PM2.5 absorbance, statistically significant effects were found for asthmatic bronchitis (OR, 1.56; 95% confidence interval [CI], 1.03-2.37), hay fever (OR, 1.59; 95% CI, 1.11-2.27), and allergic sensitization to pollen (OR, 1.40; 95% CI, 1.20-1.64). NO2 exposure was associated with eczema, whereas no association was found for allergic sensitization. Conclusions: This study provides strong evidence for increased risk of atopic diseases and allergic sensitization when children are exposed to ambient particulate matter.	[Morgenstern, Verena; Zutavern, Anne; Cyrys, Josef; Wichmann, H. -Erich; Heinrich, Joachim] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; [Zutavern, Anne; Koletzko, Sibylle] Univ Munich, Dr V Hauners Childrens Hosp, Munich, Germany; [Cyrys, Josef] Univ Augsburg, WZU Environm Sci Ctr, Augsburg, Germany; [Brockow, Inken; Bauer, Carl Peter] Tech Univ Munich, Childrens Hosp, Munich, Germany; [Kraemer, Ursula] Inst Umweltmed Forsch, Working Area Epidemiol, Dusseldorf, Germany; [Behrendt, Heidrun] Tech Univ Munich, Div Environm Dermatol & Allergy, ZAUM Ctr Allergy & Environm, Munich, Germany; [Herbarth, Olf] UFZ Helmholtz Ctr Environm Res, UFZ Human Exposure Res & Epidemiol, Leipzig, Germany; [Herbarth, Olf] Univ Leipzig, Fac Med Environm Med & Environm Hyg, Leipzig, Germany; [von Berg, Andrea] Marien Hosp Wesel, Wesel, Germany; [Wichmann, H. -Erich] Univ Munich, Inst Med Data Management, Munich, Germany	Heinrich, J (reprint author), Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	joachim.heinrich@helmholtz-muenchen.de	Weidinger, Stephan/C-8461-2011; Cyrys, Josef/B-5359-2014; Osborne, Nicholas/N-4915-2015; Sack, Ulrich/J-6301-2015; Buters, Jeroen/G-5070-2011	Osborne, Nicholas/0000-0002-6700-2284; Sack, Ulrich/0000-0002-7813-0492; Cyrys, Josef/0000-0002-2105-8696; Traidl-Hoffmann, Claudia/0000-0001-5085-5179			Amann M., 2005, BASELINE SCENARIOS C; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bayer-Oglesby L, 2005, ENVIRON HEALTH PERSP, V113, P1632, DOI 10.1289/ehp.8159; Bayer-Oglesby L, 2006, AM J EPIDEMIOL, V164, P1190, DOI 10.1093/aje/kwj338; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2006, ENVIRON HEALTH PERSP, V114, P1414, DOI 10.1289/ehp.9089; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; de Haar C, 2006, CLIN EXP ALLERGY, V36, P1469, DOI 10.1111/j.1365-2222.2006.02586.x; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.01; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059; Gordian ME, 2006, J EXPO SCI ENV EPID, V16, P49, DOI 10.1038/sj.jea.7500436; Heinrich J, 2005, OCCUP ENVIRON MED, V62, P517, DOI 10.1136/oem.2004.016766; Heinrich J, 2005, ENVIRON RES, V98, P240, DOI 10.1016/j.envres.2004.08.004; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hochadel M, 2006, ATMOS ENVIRON, V40, P542, DOI 10.1016/j.atmosenv.2005.09.067; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jerrett M, 2007, J TOXICOL ENV HEAL A, V70, P200, DOI 10.1080/15287390600883018; Krzyzanowski M., 2005, WHO HLTH EFFECTS TRA; *LAND MUNCH SA, 2001, MUN FACTS FIG; Livingstone AE, 1996, BRIT MED J, V312, P676; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Morgenstern V, 2007, EPIDEMIOLOGY, V18, pS10; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Oftedal B, 2007, CLIN EXP ALLERGY, V37, P1632, DOI 10.1111/j.1365-2222.2007.02823.x; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Traidl-Hoffmann C, 2003, INT ARCH ALLERGY IMM, V131, P1, DOI 10.1159/000070428; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; WATKISS P, 2005, CLEAN AIR EUROPE COS; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	42	230	237	12	54	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 15	2008	177	12					1331	1337		10.1164/rccm.200701-036OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	310SE	WOS:000256549700007	18337595	
J	Ford, RA; Domeyer, B; Easterday, O; Maier, K; Middleton, J				Ford, RA; Domeyer, B; Easterday, O; Maier, K; Middleton, J			Criteria for development of a database for safety evaluation of fragrance ingredients	REGULATORY TOXICOLOGY AND PHARMACOLOGY			English	Article							IDENTIFYING CONTACT ALLERGENS; EXPERT-SYSTEM RULEBASE; GENOTOXICITY TESTS; CHEMICAL-STRUCTURE; CARCINOGENICITY; MUTAGENICITY	Over 2000 different ingredients are used in the manufacture of fragrances. The majority of these ingredients have been used for many decades. Despite this long history of use, all of these ingredients need continued monitoring to ensure that each ingredient meets acceptable safety standards. As with other large databases of existing chemicals, fulfilling this need requires an organized approach to identify the most important potential hazards. One such approach, specifically considering the dermal route of exposure as the most relevant one for fragrance ingredients, has been developed. This approach provides a rational selection of materials for review and gives guidance for determining the test data that would normally be considered necessary for the elevation of safety under intended conditions of use. As a first step, the process takes into account the following criteria: quantity of use, consumer exposure, and chemical structure. These are then used for the orderly selection of materials for review with higher quantity, higher exposure, and the presence of defined structural alerts all contributing to a higher priority for review. These structural alerts along with certain exposure and volume limits are then used to develop guidelines for determining the quality and quantity of data considered necessary to support an adequate safety evaluation of the chosen materials, taking into account existing data on the substance itself as well as on closely related analogs. This approach can be considered an alternative to testing; therefore, it is designed to be conservative but not so much so as to require excessive effort when not justified. (C) 2000 Academic Press.	Res Inst Fragrance Mat Inc, Hackensack, NJ 07601 USA; Procter & Gamble Co, Ross, OH 45061 USA; Flavors & Fragrances Inc, Union Beach, NJ 07735 USA; Haarmann & Reimer GmbH, D-37603 Holzminden, Germany; Quest Int Ltd, Ashford TN24 0LT, Kent, England	Ford, RA (reprint author), Res Inst Fragrance Mat Inc, 2 Univ Plaza,Suite 406, Hackensack, NJ 07601 USA.						Adams TB, 1998, FOOD CHEM TOXICOL, V36, P249, DOI 10.1016/S0278-6915(97)00163-4; AHBY J, 1993, MUTAT RES, V286, P3; Api AM, 1995, FOOD CHEM TOXICOL, V33, P1039, DOI 10.1016/0278-6915(95)00076-3; Api AM, 1996, FOOD CHEM TOXICOL, V34, P633, DOI 10.1016/0278-6915(96)00028-2; ASHBY J, 1985, ENVIRON MUTAGEN, V7, P919, DOI 10.1002/em.2860070613; ASHBY J, 1994, MUTAT RES, V305, P3, DOI 10.1016/0027-5107(94)90122-8; ASHBY J, 1991, MUTAT RES, V257, P229, DOI 10.1016/0165-1110(91)90003-E; BARRATT MD, 1994, TOXICOL IN VITRO, V8, P837, DOI 10.1016/0887-2333(94)90081-7; BARRATT MD, 1994, TOXICOL IN VITRO, V8, P1053, DOI 10.1016/0887-2333(94)90244-5; BARRATT MD, 1994, ALTERN METH, V10, P293; BASKETTER DA, 1994, FOOD CHEM TOXICOL, V32, P239; BOECK A, 1991, PERFUMES ART SCI TEC, P422; Bronaugh RL, 1995, TOXICOL METHOD, V5, P265, DOI 10.3109/15376519509084030; BUEHLER EV, 1965, ARCH DERMATOL, V91, P171; CLAYSON DB, 1998, CARCINOGENICITY TEST, P837; CRAMER GM, 1978, FOOD COSMET TOXICOL, V16, P255, DOI 10.1016/S0015-6264(76)80522-6; CRONIN E, 1984, CONTACT DERMATITIS, V11, P88, DOI 10.1111/j.1600-0536.1984.tb00933.x; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; Draize JH, 1959, DERMAL TOXICITY APPR, P46; *EUR COMM, 1996, OFFICIAL J EUR COMMU, V39, P526; *FDA, 1993, REDBOOK, V2; *FDA, 1982, REDB; FORD R A, 1992, Food and Chemical Toxicology, V30, p1S; Ford RA, 1999, TOXICOL LETT, V111, P133, DOI 10.1016/S0378-4274(99)00174-5; *IFRA, 1999, COD PRACT; KORNHAUSER A, 1987, DERMATOTOXICOLOGY, P378; Munro IC, 1998, FOOD CHEM TOXICOL, V36, P529, DOI 10.1016/S0278-6915(98)00016-7; Munro IC, 1996, FOOD CHEM TOXICOL, V34, P829, DOI 10.1016/S0278-6915(96)00049-X; OPDYKE DLJ, 1973, FOOD COSMET TOXICOL, V11, P95, DOI 10.1016/0015-6264(73)90065-5; *RIFM, 1997, SURV VOL US SUBST US; Rulis AM, 1989, RISK ASSESSMENT SETT, P271; SCHAEFER H, 1996, SKIN BARRIER PRINCIP, P254; Silverstein R. M., 1981, SPECTROMETRIC IDENTI, P305; Somogyi L. P., 1995, FLAVORS FRAGRANCES; Spielmann H, 1998, TOXICOL IN VITRO, V12, P305, DOI 10.1016/S0887-2333(98)00006-X; TENNANT RW, 1991, MUTAT RES, V257, P209, DOI 10.1016/0165-1110(91)90002-D; Vuilleumier C., 1995, International Journal of Cosmetic Science, V17, P61, DOI 10.1111/j.1467-2494.1995.tb00110.x; WINGROVE AS, 1981, SPECTROSCOPY, V1, P502	38	230	230	0	6	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0273-2300			REGUL TOXICOL PHARM	Regul. Toxicol. Pharmacol.	APR	2000	31	2	1				166	181		10.1006/rtph.1999.1362		16	Medicine, Legal; Pharmacology & Pharmacy; Toxicology	Legal Medicine; Pharmacology & Pharmacy; Toxicology	319AK	WOS:000087316700002	10854123	
J	McDonnell, PJ; Jacobs, MR				McDonnell, PJ; Jacobs, MR			Hospital admissions resulting from preventable adverse drug reactions	ANNALS OF PHARMACOTHERAPY			English	Article						adverse drug reaction; hospital admission	INDUCED ILLNESS; EVENTS	BACKGROUND: Adverse drug reactions (ADRs) are a significant cause of hospital admissions. These events can lead to significant morbidity and mortality and financial costs. ADRs that may be preventable might be considered a form of medication error. OBJECTIVE: To assess the potential preventability of ADRs directly related to a patient's hospital admission. METHODS: A retrospective chart review of 437 ADRs occurring during an 11-month period was conducted at a university hospital. A subset of these events leading to hospital admissions was identified for further review. Those that resulted in admission were further examined to determine probability of causality, severity, and preventability. RESULTS: Over 11 months, 158 ADRs were directly related to hospital admission. The relationship of these admissions to drug exposure was determined to be probable or highly probable in 154 (97.4%) of these cases. From this group, 96 (62.3%) of these events were considered potentially preventable, with 23 (24%) considered severe to life-threatening. Characteristics associated with these ADRs included documentation of a toxic drug concentration or abnormal laboratory value (80%), inadequate monitoring of a patient's drug therapy (67%), inappropriate dose (51%), patient noncompliance (33%), drug-drug interaction (26%), contraindication to therapy (3%), and documented allergy (1%). These ADRs resulted in 595 hospital days, with an average length of stay of 6.1 days. CONCLUSIONS: ADRs leading to hospital admissions are often preventable. Approximately 25% of these events were serious to life-threatening. Most resulted from inadequate monitoring of therapy or inappropriate dosing. Patient noncompliance and drug interactions were also common causes. Multidisciplinary prevention strategies among physicians, pharmacists, other healthcare professionals, and patients focusing on communication and education should be targeted.	Temple Univ, Sch Pharm, Philadelphia, PA 19140 USA	McDonnell, PJ (reprint author), Temple Univ, Sch Pharm, 3307 N Broad ST, Philadelphia, PA 19140 USA.						BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; BOSH TK, 1992, 49 AM SOC HOSP PHARM; BURNUM JF, 1976, ANN INTERN MED, V85, P80; CARANASOS GJ, 1974, JAMA-J AM MED ASSOC, V228, P713, DOI 10.1001/jama.228.6.713; COLT HG, 1989, J AM GERIATR SOC, V37, P323; Dartnell JGA, 1996, MED J AUSTRALIA, V164, P659; EINARSON TR, 1993, ANN PHARMACOTHER, V27, P832; Institute of Medicine, 1999, ERR HUM BUILD SAF HL; JICK H, 1994, J ALLERGY CLIN IMMUN, V74, P55; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; LAKSHMANAN MC, 1986, ARCH INTERN MED, V146, P1931, DOI 10.1001/archinte.146.10.1931; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE L, 1999, MED ERROR; MELMON KL, 1971, NEW ENGL J MED, V284, P1361; MILLER RR, 1974, ARCH INTERN MED, V134, P219, DOI 10.1001/archinte.134.2.219; NARANJO CA, 1981, CLIN PHARMACOL THER, V30, P239; PORTER J, 1977, JAMA-J AM MED ASSOC, V237, P879, DOI 10.1001/jama.237.9.879; Pouyanne P, 2000, BRIT MED J, V320, P1036, DOI 10.1136/bmj.320.7241.1036; Roughead EE, 1998, MED J AUSTRALIA, V168, P405; Schumock G T, 1992, Hosp Pharm, V27, P538; TALLEY RB, 1974, JAMA-J AM MED ASSOC, V229, P1043; 1969, WHO TECH REP SER, V426, P5	22	229	239	1	12	HARVEY WHITNEY BOOKS CO	CINCINNATI	PO BOX 42696, CINCINNATI, OH 45242 USA	1060-0280			ANN PHARMACOTHER	Ann. Pharmacother.	SEP	2002	36	9					1331	1336		10.1345/aph.1A333		6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	587UA	WOS:000177660600001	12196047	
J	Kilpelainen, M; Terho, EO; Helenius, H; Koskenvuo, M				Kilpelainen, M; Terho, EO; Helenius, H; Koskenvuo, M			Farm environment in childhood prevents the development of allergies	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic conjunctivitis; allergic rhinitis; asthma; atopic dermatitis; epidemiology; family size; farm environment; rural; urban	SKIN-TEST REACTIVITY; HAY-FEVER; RESPIRATORY SYMPTOMS; SIBSHIP SIZE; EAST-GERMANY; FAMILY-SIZE; ASTHMA; ATOPY; PREVALENCE; CHILDREN	Background A protective effect of infections in early life might explain the firmly reported finding of an inverse association between atopic disorders and large sibships. Objective To study the effect of childhood farm, rural non-farm and urban environment, as well as family size and other factors on the occurrence of asthma, wheezing and atopic disorders up to young adulthood. Methods Data on lifetime prevalence of physician-diagnosed asthma, allergic rhinitis and/or allergic conjunctivitis, atopic dermatitis, as well as self-reported episodic wheezing from 10 667 Finnish first-year university students aged 18-24 years were collected by a postal questionnaire. Associations of lifetime prevalence of the diseases with living on a farm, in a rural non-farm and urban environment during childhood were estimated by logistic regression analysis. Adjustment was made for potential confounding by gender, parental atopy, parental education, number of older siblings, day care outside the home and passive smoking. Results The childhood farm environment independently reduced the risk for physician-diagnosed allergic rhinitis and/or allergic conjunctivitis (adjusted odds ratio 0.63, 95% CI 0.50-0.79, P < 0.001), and for diagnosed asthma and episodic wheezing analysed together (OR 0.71, 95% CI 0.54-0.93, P < 0.05), but not for atopic dermatitis during lifetime. Urban childhood environment did not show independent increased risk when compared with rural non-farm residence. The inverse association of sibship size with the occurrence of allergic rhinitis and/or allergic conjunctivitis was found among subjects with one (OR 0.86, 95% CI 0.77-0.96, P < 0.01) or at least four older siblings (OR 0.47, 95% CI 0.26-0.84, P < 0.05). Conclusion Childhood farm environment seems to have a protective effect against allergic rhinitis and/or conjunctivitis, and more weakly against asthma and wheezing irrespective of family size. Environmental exposure to immune modulating agents, such as environmental mycobacteria and actinomycetes, favouring manifestation of a nonatopic phenotype could explain the finding.	Univ Turku, Dept Pulm Dis & Clin Allergol, SF-20500 Turku, Finland; Univ Turku, Dept Biostat, SF-20500 Turku, Finland; Univ Turku, Dept Publ Hlth, SF-20500 Turku, Finland	Kilpelainen, M (reprint author), Univ Turku, Cent Hosp, Dept Pulm Dis & Clin Allergol, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.						AABY P, 1986, INT J EPIDEMIOL, V15, P101, DOI 10.1093/ije/15.1.101; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; BACKMAN A, 1984, ALLERGY, V39, P305; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Hijazi N, 1998, EUR RESPIR J, V12, P41, DOI 10.1183/09031936.98.12010041; HOLT PG, 1994, LANCET, V344, P45; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; NINAN TK, 1992, BRIT MED J, V304, P873; Olesen AB, 1997, BRIT MED J, V314, P1003; Rasanen M, 1997, CLIN EXP ALLERGY, V27, P515, DOI 10.1046/j.1365-2222.1997.440855.x; RAUTALAHTI M, 1990, ANN ALLERGY, V64, P455; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; SAS Institute Inc, 1996, SAS STAT SOFTW CHANG; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; Strachan DP, 1998, THORAX, V53, P117; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Sunyer Y, 1997, EUR RESPIR J, V10, P2490; SUSITAIVAL P, 1996, TUOHILAMPI QUESTIONN; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Wahlstrom J, 1997, EUR RESPIR J, V10, P772; Wang CC, 1998, IMMUNOLOGY, V93, P307; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; 1996, HELSINKI POPULATION	41	229	231	1	19	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2000	30	2					201	208				8	Allergy; Immunology	Allergy; Immunology	287NF	WOS:000085511600009	10651772	
J	Almqvist, C; Worm, M; Leynaert, B				Almqvist, C.; Worm, M.; Leynaert, B.		Working Grp GA2 LEN WP 25 'Gender'	Impact of gender on asthma in childhood and adolescence: a GA(2)LEN review	ALLERGY			English	Review						adolescence; asthma; child; GA(2)LEN; gender	BODY-MASS INDEX; RESPIRATORY SYMPTOMS; SEX-DIFFERENCES; LUNG-FUNCTION; BIRTH COHORT; BRONCHIAL RESPONSIVENESS; EMERGENCY-DEPARTMENT; DIAGNOSED ASTHMA; SWISS CHILDREN; RISK-FACTORS	A number of studies have shown gender differences in the prevalence of wheeze and asthma. The aim of this review was to examine published results on gender differences in childhood and adolescent asthma incidence and prevalence, define current concepts and to identify new research needs. A Medline search was performed with the search words (gender OR sex) AND (child OR childhood OR adolescence) AND (asthma). Articles that reported on abscence or prescence of gender differences in asthma were included and reviewed, and cross-references were checked. Boys are consistently reported to have more prevalent wheeze and asthma than girls. In adolescence, the pattern changes and onset of wheeze is more prevalent in females than males. Asthma, after childhood, is more severe in females than in males, and is underdiagnosed and undertreated in female adolescents. Possible explanations for this switch around puberty in the gender susceptibility to develop asthma include hormonal changes and gender-specific differences in environmental exposures. This aspect needs consideration of the doctors and allergists who diagnose and treat asthmatic individuals. In conclusion, sex hormones are likely to play an important role in the development and outcome of the allergic immune response and asthma in particular. By obtaining functional data from appropriate models, the exact underlying mechanisms can be unravelled. To examine the effect of gender-specific differences in environmental exposures and changes of asthma prevalence and severity in puberty, larger populations may need to be investigated.	Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Woman & Child Hlth, SE-17176 Stockholm, Sweden; Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Med Epidemiol & Biostat, SE-17176 Stockholm, Sweden; Univ Med Berlin, Dept Dermatol & Allergy, Allergy Ctr Charite, Berlin, Germany; INSERM, Natl Inst Hlth & Med Res, U700, Paris, France	Almqvist, C (reprint author), Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Woman & Child Hlth, Q2-05, SE-17176 Stockholm, Sweden.						ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Becklake MR, 1999, THORAX, V54, P1119; Berhane K, 2000, AM J RESP CRIT CARE, V162, P1723; Carlsen KCL, 2006, ALLERGY, V61, P454, DOI 10.1111/j.1398-9995.2005.00938.x; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; CHEN Y, 1991, AM REV RESPIR DIS, V143, P1224; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; Chen Y, 2003, J CLIN EPIDEMIOL, V56, P180, DOI 10.1016/S0895-4356(02)00593-0; Chen Y, 2003, PEDIATR PULM, V36, P22, DOI 10.1002/ppul.10307; Chen Y, 2002, EUR RESPIR J, V20, P1162, DOI 10.1183/09031936.02.00273102; Ciccone G, 1997, EUR RESPIR J, V10, P1780; Debley JS, 2004, PEDIATR PULM, V38, P443, DOI 10.1002/ppul.20108; Devenny A, 2004, BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Forastiere F, 1996, AM J RESP CRIT CARE, V153, P1098; Gold DR, 1996, NEW ENGL J MED, V335, P931, DOI 10.1056/NEJM199609263351304; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Harju T, 1996, ALLERGY, V51, P693; Henriksen AH, 2003, RESP MED, V97, P491, DOI 10.1053/rmed.2002.1470; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Jarvis D, 1998, EUR RESPIR J, V11, P651; Johnson CC, 1998, AM J EPIDEMIOL, V147, P1145; KUHN CE, 1995, PEDIATR PULM, V19, P156, DOI 10.1002/ppul.1950190303; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; LARSSON L, 1995, THORAX, V50, P260, DOI 10.1136/thx.50.3.260; Lichtenstein P, 1997, ALLERGY, V52, P1079, DOI 10.1111/j.1398-9995.1997.tb00179.x; LUYT DK, 1993, BRIT MED J, V306, P1386; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; MARTIN AJ, 1980, BRIT MED J, V280, P1397; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Melen E, 2004, CLIN EXP ALLERGY, V34, P839, DOI 10.1111/j.1365-2222.2004.01957.x; MESSINEO TD, 1990, J APPL PHYSIOL, V69, P96; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; Mommers M, 2005, THORAX, V60, P97, DOI 10.1136/thx.2004.024786; Nicolai T, 2003, PEDIATR ALLERGY IMMU, V14, P280, DOI 10.1034/j.1399-3038.2003.00047.x; Nicolai T, 2001, PEDIATR ALLERGY IMMU, V12, P142, DOI 10.1034/j.1399-3038.2001.0007.x; Osman M, 2007, PEDIATR PULM, V42, P60, DOI 10.1002/ppul.20545; PAGTAKHAN RD, 1984, J APPL PHYSIOL, V56, P1204; PISTELLI R, 1992, EUR RESPIR J, V5, P463; Schatz M, 2004, PEDIATR PULM, V37, P523, DOI 10.1002/ppul.20018; Schatz M, 2003, ANN ALLERG ASTHMA IM, V91, P553; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SENNHAUSER FH, 1995, PEDIATR PULM, V19, P161, DOI 10.1002/ppul.1950190304; Senthilselvan A, 1998, CHEST, V114, P388, DOI 10.1378/chest.114.2.388; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Venn A, 1998, BRIT MED J, V316, P1945; vonMutius E, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_1.S3; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Yeatts K, 2003, PEDIATRICS, V111, P1046, DOI 10.1542/peds.111.5.1046	54	228	236	5	18	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JAN	2008	63	1					47	57		10.1111/j.1398-9995.2007.01524.x		11	Allergy; Immunology	Allergy; Immunology	236UA	WOS:000251327700005	17822448	
J	Monneret, G; Gravel, S; Diamond, M; Rokach, J; Powell, WS				Monneret, G; Gravel, S; Diamond, M; Rokach, J; Powell, WS			Prostaglandin D-2 is a potent chemoattractant for human eosinophils that acts via a novel DIP receptor	BLOOD			English	Article							5-OXO-6,8,11,14-EICOSATETRAENOIC ACID; PROSTANOID RECEPTORS; HUMAN NEUTROPHILS; L-SELECTIN; HUMAN-PLATELETS; HUMAN AIRWAYS; D SYNTHETASE; MAST-CELLS; INHIBITION; EXPRESSION	Prostaglandin D-2 (PGD(2)) is released following exposure of asthmatics to allergen and acts via the adenylyl cyclase-coupled receptor for PGD(2) (DID receptor). In this study, it is reported that human eosinophils possess this receptor, which would be expected to inhibit their activation. In contrast, it was found that prostaglandin D-2 is a potent stimulator of eosinophil chemotaxis, actin polymerization, CD11b expression, and L-selectin shedding. These responses are specific for eosinophils, as neutrophils display little or no response to prostaglandin D-2 They were not due to interaction with receptors for other prostanoids, as prostaglandins E-2 and F-2 alpha, U46619 (a thromboxane A(2) analogue), and carbaprostacyclin (a prostacyclin analogue) displayed little or no activity. Furthermore, they were not shared by the selective DID receptor agonist BW245C and were not prevented by the selective DID receptor antagonist BWA868C, indicating that they were not mediated by DID receptors. In contrast, the prostaglandin D2 metabolite 13,14-dihydro-15-oxoprostaglandin D-2 induced eosinophil activation but did not stimulate DID receptor-mediated adenosine 3 ' ,5 ' -cyclic monophosphate (cAMP) formation. These results indicate that in addition to the classic inhibitory DID, receptor, eosinophils possess a second, novel DP2 receptor that is associated with PGD(2)-induced cell activation. These 2 receptors appear to interact to regulate eosinophil responses to PGD(2), as blockade of DPI receptor-mediated cAMP production by BWA868C resulted in enhanced DP2 receptor-mediated stimulation of CD11b expression. The balance between DPI and DP2 receptors could determine the degree to which prostaglandin D-2 can activate eosinophils and may play a role in eosinophil recruitment in asthma.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Florida Inst Technol, Dept Chem, Melbourne, FL 32901 USA; Florida Inst Technol, Claude Pepper Inst, Melbourne, FL 32901 USA	Powell, WS (reprint author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.				NIDDK NIH HHS [DK44730]		Barnes PJ, 1998, PHARMACOL REV, V50, P515; Berends C, 1997, EUR RESPIR J, V10, P1000, DOI 10.1183/09031936.97.10051000; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Butchers P R, 1990, Agents Actions Suppl, V31, P103; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688; DENT G, 1991, BRIT J PHARMACOL, V103, P1339; EBISAWA M, 1992, J IMMUNOL, V149, P4021; Eguchi N, 1999, P NATL ACAD SCI USA, V96, P726, DOI 10.1073/pnas.96.2.726; EMERY DL, 1989, J APPL PHYSIOL, V67, P959; Giembycz MA, 1999, PHARMACOL REV, V51, P213; GILES H, 1989, BRIT J PHARMACOL, V96, P291; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; HOWARD TH, 1985, J CELL BIOL, V101, P1078, DOI 10.1083/jcb.101.3.1078; KANEKO T, 1995, CELL SIGNAL, V7, P527, DOI 10.1016/0898-6568(95)00023-I; KAY A B, 1970, Clinical and Experimental Immunology, V7, P723; Khanapure SP, 1998, J ORG CHEM, V63, P337, DOI 10.1021/jo9716993; Kiriyama M, 1997, BRIT J PHARMACOL, V122, P217, DOI 10.1038/sj.bjp.0701367; KITA H, 1991, J IMMUNOL, V146, P2712; LEWIS RA, 1982, J IMMUNOL, V129, P1627; MARSDEN KA, 1984, PROSTA LEUKOTR MED, V15, P387, DOI 10.1016/0262-1746(84)90137-9; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MCKENNIFF M, 1988, EUR J PHARMACOL, V153, P149, DOI 10.1016/0014-2999(88)90601-2; MILLER OV, 1979, J PHARMACOL EXP THER, V210, P134; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nagata K, 1999, J IMMUNOL, V162, P1278; NARUMIYA S, 1985, BRIT J PHARMACOL, V85, P367; Narumiya S, 1999, PHYSIOL REV, V79, P1193; NEY P, 1991, EICOSANOIDS, V4, P21; Norel X, 1999, BRIT J PHARMACOL, V126, P867, DOI 10.1038/sj.bjp.0702392; Powell WS, 1999, BLOOD, V93, P1086; Powell WS, 1999, AM J RESP CELL MOL, V20, P163; POWELL WS, 1975, EUR J BIOCHEM, V56, P73, DOI 10.1111/j.1432-1033.1975.tb02208.x; Powell WS, 2001, J ALLERGY CLIN IMMUN, V107, P272, DOI 10.1067/mai.2001.112847; POWELL WS, 1993, J BIOL CHEM, V268, P9280; POWELL WS, 1995, J IMMUNOL, V154, P4123; Preece G, 1996, J BIOL CHEM, V271, P11634; RAIBLE DG, 1992, J IMMUNOL, V148, P3536; RANGACHARI PK, 1995, J PHARMACOL EXP THER, V275, P611; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; Santamaria LF, 1997, BRIT J PHARMACOL, V121, P1150, DOI 10.1038/sj.bjp.0701243; Tanaka K, 2000, J IMMUNOL, V164, P2277; Tenor H, 1996, BRIT J PHARMACOL, V118, P1727; TOWN MH, 1983, PROSTAGLANDINS, V25, P13; URADE Y, 1989, J IMMUNOL, V143, P2982; Urade Y, 1999, BBA-MOL CELL BIOL L, V1436, P606, DOI 10.1016/S0005-2760(98)00163-5; URADE Y, 1990, J BIOL CHEM, V265, P371; Walch L, 1999, BRIT J PHARMACOL, V126, P859, DOI 10.1038/sj.bjp.0702393; Willoughby DA, 2000, NAT MED, V6, P137, DOI 10.1038/72224; Wright DH, 1998, BRIT J PHARMACOL, V123, P1317	53	228	237	1	3	AMER SOC HEMATOLOGY	WASHINGTON	1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA	0006-4971			BLOOD	Blood	SEP 15	2001	98	6					1942	1948		10.1182/blood.V98.6.1942		7	Hematology	Hematology	471UV	WOS:000170947800047	11535533	
J	Gent, JF; Triche, EW; Holford, TR; Belanger, K; Bracken, MB; Beckett, WS; Leaderer, BP				Gent, JF; Triche, EW; Holford, TR; Belanger, K; Bracken, MB; Beckett, WS; Leaderer, BP			Association of low-level ozone and fine particles with respiratory symptoms in children with asthma	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AFRICAN-AMERICAN CHILDREN; AIR-POLLUTION; MEXICO-CITY; MEDICATION USE; AMBIENT OZONE; 1ST YEAR; PARTICULATE; EXPOSURE; SUMMER; HEALTH	Context Exposure to ozone and particulate matter of 2.5 mum or less (PM2.5) in air at levels above current US Environmental Protection Agency (EPA) standards is a risk factor for respiratory symptoms in children with asthma. Objective To examine simultaneous effects of ozone and PM2.5 at levels below EPA standards on daily respiratory symptoms and rescue medication use among children with asthma. Design, Setting, and Participants Daily respiratory symptoms and medication use were examined prospectively for 271 children younger than 12 years with physician-diagnosed, active asthma residing in southern New England. Exposure to ambient concentrations of ozone and PM2.5 from April 1 through September 30, 2001, was assessed using ozone (peak 1-hour and 8-hour) and 24-hour PM2.5. Logistic regression analyses using generalized estimating equations were performed separately for maintenance medication users (n=130) and nonusers (n=141). Associations between pollutants (adjusted for temperature, controlling for same- and previous-day levels) and respiratory symptoms and use of rescue medication were evaluated. Main Outcome Measures Respiratory symptoms and rescue medication use recorded on calendars by subjects' mothers. Results Mean (SD) levels were 59 (19) ppb (1-hour average) and 51 (16) ppb (8-hour average) for ozone and 13 (8) mug/m(3) for PM2.5. In copollutant models, ozone level but not PM2.5 was significantly associated with respiratory symptoms and rescue medication use among children using maintenance medication; a 50-ppb increase in 1-hour ozone was associated with increased likelihood of wheeze (by 35%) and chest tightness (by 47%). The highest levels of ozone (1-hour or 8-hour averages) were associated with increased shortness of breath and rescue medication use. No significant, exposure-dependent associations were observed for any outcome by any pollutant among children who did not use maintenance medication. Conclusion Asthmatic children using maintenance medication are particularly vulnerable to ozone, controlling for exposure to fine particles, at levels below EPA standards.	Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY USA	Gent, JF (reprint author), Yale Univ, Ctr Perinatal Pediat & Environm Epidemiol, Sch Med, Dept Epidemiol & Publ Hlth, 1 Church St,6th Floor, New Haven, CT 06510 USA.		Triche, Elizabeth/I-4986-2014		NIEHS NIH HHS [ES11013, ES01247, ES05410, ES07456]		Allison PD, 1999, LOGISTIC REGRESSION; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; *COMM MASS DEP ENV, 2000, AIR QUAL REP; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hanania NA, 1998, CHEST, V114, P752, DOI 10.1378/chest.114.3.752; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; *SAS I INC, 2001, SAS VERS 8; SILVERMAN F, 1979, ENVIRON HEALTH PERSP, V29, P131, DOI 10.2307/3429055; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313; *STAT CONN DEP ENV, 1999, ANN AIR QUAL SUMM; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Ulmer C, 1997, PEDIATR PULM, V23, P344, DOI 10.1002/(SICI)1099-0496(199705)23:5<344::AID-PPUL6>3.0.CO;2-K; *US EPA, 1996, EPA600AP93004AC US E	24	227	236	4	29	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 8	2003	290	14					1859	1867		10.1001/jama.290.14.1859		9	Medicine, General & Internal	General & Internal Medicine	729CB	WOS:000185752600026	14532314	
J	Briggs, DJ; de Hoogh, C; Guiliver, J; Wills, J; Elliott, P; Kingham, S; Smallbone, K				Briggs, DJ; de Hoogh, C; Guiliver, J; Wills, J; Elliott, P; Kingham, S; Smallbone, K			A regression-based method for mapping traffic-related air pollution: application and testing in four contrasting urban environments	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						air pollution; exposure assessment; road traffic; GIS; mapping	NITROGEN-DIOXIDE CONCENTRATIONS; RESPIRATORY HEALTH; UNITED-KINGDOM; CHILDREN; ASTHMA; GIS; SAMPLERS; MODELS; ROADS	Accurate, high-resolution maps of traffic-related air pollution are needed both as a basis for assessing exposures as part of epidemiological studies, and to inform urban air-quality policy and traffic management. This paper assesses the use of a GIS-based, regression mapping technique to model spatial patterns of traffic-related air pollution. The model - developed using data from 80 passive sampler sites in Huddersfield, as part of the SAVIAH (Small Area Variations in Air Quality and Health) project - uses data on traffic flows and land cover in the 300-m buffer zone around each site, and altitude of the site, as predictors of NO, concentrations. It was tested here by application in four urban areas in the UK: Huddersfield (for the year following that used for initial model development), Sheffield, Northampton, and part of London. In each case, a GIS was built in ArcInfo, integrating relevant data on road traffic, urban land use and topography. Monitoring of NO2 was undertaken using replicate passive samplers (in London, data were obtained from surveys carried out as part of the London network). In Huddersfield, Sheffield and Northampton, the model was first calibrated by comparing modelled results with monitored NO2 concentrations at 10 randomly selected sites; the calibrated model was then validated against data from a further 10-28 sites. In London, where data for only 11 sites were available, validation was not undertaken. Results showed that the model performed well in all cases. After local calibration, the model gave estimates of mean annual NO2 concentrations within a factor of 1.5 of the actual mean (approx. 70-90%) of the time and within a factor of 2 between 70 and 100% of the time. r(2) values between modelled and observed concentrations are in the range of 0.58-0.76. These results are comparable to those achieved by more sophisticated dispersion models. The model also has several advantages over dispersion modelling. It is able, for example, to provide high-resolution maps across a whole urban area without the need to interpolate between receptor points. It also offers substantially reduced costs and processing times compared to formal dispersion modelling. It is concluded that the model might thus be used as a means of mapping long-term air pollution concentrations either in support of local authority air-quality management strategies, or in epidemiological studies. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, London W2 1PG, England; Univ Coll Northampton, Nene Ctr Res, Northampton NN2 7AL, England; Univ Hertfordshire, Dept Environm Sci, Hatfield AL10 9AB, Herts, England; Univ Brighton, Sch Construct Geog & Surveying, Brighton BN2 4AT, E Sussex, England	Briggs, DJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Publ Hlth, Norfolk Pl, London W2 1PG, England.						Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BENSON PE, 1992, ATMOS ENVIRON B-URB, V26, P379, DOI 10.1016/0957-1272(92)90013-I; BERKOWITZ R, 1994, P IMA C FLOW DISP GR; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; BRIGGS DJ, 1980, J ENVIRON MANAGE, V10, P263; BRIGGS DJ, 1998, SURVEYOR        1001, P22; CAMPBELL GW, 1994, ATMOS ENVIRON, V28, P477, DOI 10.1016/1352-2310(94)90125-2; CARRUTHERS DJ, 1999, P 6 INT C HARM ATM D; *CERC LTD ADSM URB, 1999, URB AIR QUAL MAN SYS; COLLINS S, 1998, GIS DATA, V6, P81; *COMM MED EFF AIR, 1995, ASTHM OUTD AIR POLL; DEHOOGH C, 1999, THESIS U LEICESTER; *DEP ENV TRANSP RE, 1999, REV UK NAT AIR QUAL; *DEP ENV TRANSP RE, 1997, UK NAT AIR QUAL STRA; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; EERHENS HC, 1993, ATMOS ENVIRON, V27, P389; ELLIOTT P, 1998, PROGR PUBLIC HLTH, P101; Fischer PH, 1998, INDOOR AIR, V8, P244, DOI 10.1111/j.1600-0668.1998.00005.x; Fuller RM, 1998, J ENVIRON MANAGE, V54, P101, DOI 10.1006/jema.1998.0213; GIFFORD FA, 1973, ATMOS ENVIRON, V7, P131, DOI 10.1016/0004-6981(73)90202-3; HANNA SR, 1999, P 6 INT C HARM ATM D; Heal MR, 1997, ATMOS ENVIRON, V31, P1911, DOI 10.1016/S1352-2310(97)00025-3; HENRIQUES W, 1998, ENV HLTH ALL RISK AS, P113; HEWITT CN, 1991, ATMOS ENVIRON B-URB, V25, P429; KNOTTERS M, 1995, GEODERMA, V67, P227, DOI 10.1016/0016-7061(95)00011-C; LAXEN DPH, 1987, ATMOS ENVIRON, V21, P1899, DOI 10.1016/0004-6981(87)90150-8; Lebret E, 2000, ATMOS ENVIRON, V34, P177, DOI 10.1016/S1352-2310(99)00292-7; Li JL, 1998, NEW ZEAL J AGR RES, V41, P31; Livingstone AE, 1996, BRIT MED J, V312, P676; Magnus P, 1998, INT J EPIDEMIOL, V27, P995, DOI 10.1093/ije/27.6.995; MATTSON MD, 1994, ENVIRON MANAGE, V18, P767, DOI 10.1007/BF02394639; MCHUGH CA, 1999, P 6 INT C HARM ATM D; Namdeo AK, 1996, SCI TOTAL ENVIRON, V189, P311, DOI 10.1016/0048-9697(96)05224-2; *NILU, 1991, HLTH EFF TRAFF POLL; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; RAO KS, 1989, ATMOS ENVIRON, V23, P793, DOI 10.1016/0004-6981(89)90483-6; REYNOLDS AW, 1999, P 6 INT C HARM ATM D; SCHWARTZ J, 1993, ENVIRON RES, V62, P7, DOI 10.1006/enrs.1993.1083; SMALLBONE K, 1998, THESIS U HUDDERSFIEL; *USEPA, 1998, REV DRAFT US GUID AM; Van Reeuwijk H, 1998, ENVIRON MONIT ASSESS, V50, P37, DOI 10.1023/A:1005703722232; VANPUL WAJ, 1996, URBAN AIR QUALITY AS; WAGNER E, 1994, ENVIRON MANAGE, V18, P759, DOI 10.1007/BF02394638; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilkinson P, 1999, THORAX, V54, P1070; WILLS J, 1998, THESIS U COLL NORTHA; WJST M, 1993, BRIT MED J, V307, P596; YAMARTINO RJ, 1986, ATMOS ENVIRON, V20, P2137, DOI 10.1016/0004-6981(86)90307-0	51	227	232	9	82	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697			SCI TOTAL ENVIRON	Sci. Total Environ.	MAY 15	2000	253	1-3					151	167		10.1016/S0048-9697(00)00429-0		17	Environmental Sciences	Environmental Sciences & Ecology	318ZU	WOS:000087315200013	10843339	
J	von Mutius, E				von Mutius, E			The environmental predictors of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; environment; epidemiology; atopy; asthma	RESPIRATORY SYNCYTIAL VIRUS; SKIN-TEST REACTIVITY; DIESEL EXHAUST PARTICLES; SERUM IGE LEVELS; RISK-FACTORS; PULMONARY-FUNCTION; ATOPIC DISEASE; OZONE EXPOSURE; AIR-POLLUTION; HAY-FEVER	The prevalence of allergic diseases has been on the rise for the last 200 years, when hay fever, an easy and obvious-to-recognize illness, was virtually unknown in Europe and North America. Genetic factors are unlikely to explain these rapid increases, Among the potential environmental factors, exposure to ambient air pollution has been intensely debated, Besides passive smoking, which has convincingly been shown to increase the risk for asthma and bronchial hyperresponsiveness among exposed children, the evidence to suggest that outdoor pollution to sulfur dioxide, particulate matter, diesel exhaust, and ozone is causally related with the inception of allergic diseases is poor. Rather, factors associated with the lifestyle of populations or families, such as socioeconomic status, allergen exposure, sibship size, early childhood infections, dietary habits, and growing up in anthroposophic families or a farming environment, may prove to be of greater relevance. The future challenge is to tackle the complex interplay between environmental factors and genetic determinants that will eventually contribute to a better understanding and to better prevention strategies for such multifactorial conditions as asthma and allergies.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany	von Mutius, E (reprint author), Dr Von Haunerschen Kinderspital, Lindwurmstr 4, D-80337 Munich, Germany.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; ANDERSON HR, 1974, CLIN ALLERGY, V4, P171, DOI 10.1111/j.1365-2222.1974.tb01374.x; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Barnes KC, 1998, IMMUNOL TODAY, V19, P325, DOI 10.1016/S0167-5699(97)01241-3; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BRABACK L, 1995, ARCH DIS CHILD, V72, P487; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRUANFAHRLANDER CH, 1999, CLIN EXP ALLERGY, V29, P28; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CAREY OJ, 1993, THORAX, V48, P714, DOI 10.1136/thx.48.7.714; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Cook DG, 1999, THORAX, V54, P357; CRANE J, 1994, BRIT MED J, V309, P272; DETELS R, 1981, AM REV RESPIR DIS, V124, P873; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DIMEO MJ, 1981, AM REV RESPIR DIS, V124, P245; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; Farooqi IS, 1998, THORAX, V53, P927; FARRELL BP, 1979, AM REV RESPIR DIS, V119, P725; FERGUSSON DM, 1981, AUST PAEDIATR J, V17, P191; FLYNN MGL, 1994, THORAX, V49, P1201, DOI 10.1136/thx.49.12.1201; FLYNN MGL, 1994, AM J RESP CRIT CARE, V150, P415; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; HALKEN S, 1995, EUR J CLIN NUTR S1, V49, P77; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HANDERSON J, 1999, BRIT MED J, V318, P1173; HAZUCHA MJ, 1987, J APPL PHYSIOL, V62, P1671; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Holt PG, 1998, ALLERGY, V53, P16; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; Kramer U, 1998, LANCET, V352, P450; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; KULLE TJ, 1982, AM IND HYG ASSOC J, V43, P832, DOI 10.1202/0002-8894(1982)043<0832:DOPFAT>2.3.CO;2; LAN S, 1989, J ALLERGY CLIN IMMUN, V84, P718; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; LINN W S, 1986, Toxicology and Industrial Health, V2, P99; LINN WS, 1982, AM REV RESPIR DIS, V125, P491; LINN WS, 1976, AM REV RESPIR DIS, V114, P477; LONG CE, 1995, AM J RESP CRIT CARE, V151, P1678; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999; MCDONNELL WF, 1987, TOXICOL IND HEALTH, V3, P507; National Research Council, 1986, ENV TOB SMOK MEAS EX; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; Nilsson L, 1998, ARCH PEDIAT ADOL MED, V152, P734; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Olesen AB, 1997, BRIT MED J, V314, P1003; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEAT JK, 1995, AM J RESP CRIT CAR S, V151, pA469; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; PRICE JF, 1990, LUNG, V168, P414, DOI 10.1007/BF02718159; PULLAN CR, 1982, BRIT MED J, V284, P1665; Rasanen M, 1997, CLIN EXP ALLERGY, V27, P515, DOI 10.1046/j.1365-2222.1997.440855.x; RIEDLER J, 1999, IN PRESS CLIN EXP AL; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; ROSE G., 1992, STRATEGY PREVENTIVE; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1187; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; SCHWARTZ J, 1994, EUR RESPIR J, V7, P1821, DOI 10.1183/09031936.94.07101821; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIMS DG, 1978, BRIT MED J, V1, P11; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sunyer Y, 1997, EUR RESPIR J, V10, P2490; TAYLOR B, 1983, J EPIDEMIOL COMMUN H, V37, P95, DOI 10.1136/jech.37.2.95; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167; VONEHRENSTEIN O, 1999, IN PRESS CLIN EXP AL; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692; vonMutius E, 1996, AM J RESP CRIT CARE, V153, P1266; VONMUTIUS E, 1999, EUR RESPIR J, V354, P541; VONMUTIUS E, 1999, LUNG BIOL HLTH DIS P, P1; VONMUTIUS E, 1999, LUNG BIOL HLTH DIS I, P497; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; WEINMANN GG, 1995, AM J RESP CRIT CARE, V151, P33; Weiss ST, 1997, CIBA F SYMP, V206, P244; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; WJST M, 1993, BRIT MED J, V307, P596; Wold AE, 1998, ALLERGY, V53, P20; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1986, J ALLERGY CLIN IMMUN, V78, P224, DOI 10.1016/0091-6749(86)90016-3; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	124	227	233	3	29	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2000	105	1	1				9	19		10.1016/S0091-6749(00)90171-4		11	Allergy; Immunology	Allergy; Immunology	278LW	WOS:000084992100002	10629447	
J	Bessac, BF; Sivula, M; Von Hehn, CA; Escalera, J; Cohn, L; Jordt, SE				Bessac, Bret F.; Sivula, Michael; Von Hehn, Christian A.; Escalera, Jasmine; Cohn, Lauren; Jordt, Sven-Eric			TRPA1 is a major oxidant sensor in murine airway sensory neurons	JOURNAL OF CLINICAL INVESTIGATION			English	Article							SENSING ION CHANNELS; GENE-RELATED PEPTIDE; AIRBORNE CHEMICALS; CHLORINE INHALATION; IRRITATION RESPONSE; HYPOCHLOROUS ACID; LONGITUDINAL DISTRIBUTION; RESPIRATORY RESPONSES; COVALENT MODIFICATION; OXIDATIVE STRESS	Sensory neurons in the airways are finely tuned to respond to reactive chemicals threatening airway function and integrity. Nasal trigeminal nerve endings are particularly sensitive to oxidants formed in polluted air and during oxidative stress as well as to chlorine, which is frequently released in industrial and domestic accidents. Oxidant activation of airway neurons induces respiratory depression, nasal obstruction, sneezing, cough, and pain. While normally protective, chemosensory airway reflexes can provoke severe complications in patients affected by inflammatory airway conditions like rhinitis and asthma. Here, we showed that both hypochlorite, the oxidizing mediator of chlorine, and hydrogen peroxide, a reactive oxygen species, activated Ca2+ influx and membrane currents in an oxidant-sensitive subpopulation of chemosensory neurons. These responses were absent in neurons from mice lacking TRPA1, an ion channel of the transient receptor potential (TRP) gene family. TRPA1 channels were strongly activated by hypochlorite and hydrogen peroxide in primary sensory neurons and heterologous cells. In tests of respiratory function, Trpa1(-/-) mice displayed profound deficiencies in hypochlorite- and hydrogen peroxide-induced respiratory depression as well as decreased oxidant-induced pain behavior. Our results indicate that TRPA1 is an oxidant sensor in sensory neurons, initiating neuronal excitation and subsequent physiological responses in vitro and in vivo.	[Bessac, Bret F.; Sivula, Michael; Von Hehn, Christian A.; Escalera, Jasmine; Jordt, Sven-Eric] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA; [Cohn, Lauren] Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06510 USA	Bessac, BF (reprint author), Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06510 USA.				NIEHS NIH HHS [F31 ES015932, R01 ES015056, U01 ES015674]		ALARIE Y, 1973, TOXICOL APPL PHARM, V24, P279, DOI 10.1016/0041-008X(73)90148-8; Andersen JK, 2004, NAT MED, V10, pS18, DOI 10.1038/nm1434; BABIUK C, 1985, TOXICOL APPL PHARM, V79, P143, DOI 10.1016/0041-008X(85)90376-X; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Bang S, 2007, EUR J NEUROSCI, V26, P2516, DOI 10.1111/j.1460-9568.2007.05882.x; BARANIUK JN, 1990, AM J PHYSIOL, V258, pL81; BARROW CS, 1977, ARCH ENVIRON HEALTH, V32, P68; Bautista DM, 2005, P NATL ACAD SCI USA, V102, P12248, DOI 10.1073/pnas.0505356102; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; BLASCO A, 1992, J INVEST ALLERG CLIN, V2, P167; BOS PM, 1991, CRIT REV TOXICOL, V21, P423; Brand G, 2002, CHEM SENSES, V27, P593, DOI 10.1093/chemse/27.7.593; Caterina MJ, 1997, NATURE, V389, P816; CHANG JCF, 1984, TOXICOL APPL PHARM, V76, P319, DOI 10.1016/0041-008X(84)90013-9; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; COLERIDGE HM, 1994, ANNU REV PHYSIOL, V56, P69; Dai Y, 2007, J CLIN INVEST, V117, P1979, DOI 10.1172/JCI3095; DAlessandro A, 1996, CHEST, V109, P331, DOI 10.1378/chest.109.2.331; Dhaka A, 2006, ANNU REV NEUROSCI, V29, P135, DOI 10.1146/annurev.neuro.29.051605.112958; Eaton A. D, 2005, STANDARD METHODS EXA; Evans RB, 2005, LUNG, V183, P151, DOI 10.1007/s00408-004-2530-3; Feldman EL, 2003, J CLIN INVEST, V111, P431, DOI 10.1172/JC1200317863; GAGNAIRE F, 1994, J APPL TOXICOL, V14, P405, DOI 10.1002/jat.2550140604; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hammerschmidt S, 2004, BBA-MOL BASIS DIS, V1690, P258, DOI 10.1016/j.bbadis.2004.07.003; Hinman A, 2006, P NATL ACAD SCI USA, V103, P19564, DOI 10.1073/pnas.0609598103; Immke DC, 2003, NEURON, V37, P75, DOI 10.1016/S0896-6273(02)01130-3; Jordt SE, 2003, CURR OPIN NEUROBIOL, V13, P487, DOI 10.1016/S0959-4388(03)00101-6; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; KAO JPY, 1994, METHOD CELL BIOL, V40, P155; Kawai Y, 2006, BIOCHEMISTRY-US, V45, P14201, DOI 10.1021/bi0610909; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kilburn KH, 2003, ARCH ENVIRON HEALTH, V58, P746, DOI 10.3200/AEOH.58.12.746-755; Kim BM, 2004, NEUROSCI LETT, V361, P159, DOI 10.1016/j.neulet.2004.01.019; Kwan KY, 2006, NEURON, V50, P277, DOI 10.1016/j.neuron.2006.03.042; Lai J, 2003, CURR OPIN NEUROBIOL, V13, P291, DOI 10.1016/S0959-4388(03)00074-6; Lee LY, 2001, ENVIRON HEALTH PERSP, V109, P585, DOI 10.2307/3454674; LEIKAUF GD, 1989, J APPL PHYSIOL, V66, P171; Macpherson LJ, 2007, NATURE, V445, P541, DOI 10.1038/nature05544; Macpherson LJ, 2005, CURR BIOL, V15, P929, DOI 10.1016/j/cub.2005.04.018; Mapp CE, 2000, EUR RESPIR J, V16, P570, DOI 10.1034/j.1399-3003.2000.016003570.x; MAPP PI, 1995, BRIT MED BULL, V51, P419; MCLEOD RL, 2007, IN PRESS LUNG; McLeod Robbie L, 2006, Cough, V2, P10, DOI 10.1186/1745-9974-2-10; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Michel P.P., 2006, SCI STKE, V2006, ppe19; Morris JB, 2005, TOXICOL SCI, V83, P380, DOI 10.1093/toxsci/kfi038; Morris JB, 1999, J APPL PHYSIOL, V87, P1877; Morris JB, 2003, J APPL PHYSIOL, V94, P1563, DOI 10.1152/japplphysiol.00572.2002; Mutlu GM, 2006, AM J RESP CELL MOL, V34, P670, DOI 10.1165/rcmb.2005-0329OC; Nagata K, 2005, J NEUROSCI, V25, P4052, DOI 10.1523/JNEUROSCI.0013-05.2005; NIELSEN GD, 1991, CRIT REV TOXICOL, V21, P183, DOI 10.3109/10408449109089879; Nodelman V, 1999, J APPL PHYSIOL, V86, P1984; Nodelman V, 1999, J APPL PHYSIOL, V87, P2073; PEREIRA WE, 1973, BIOCHIM BIOPHYS ACTA, V313, P170, DOI 10.1016/0304-4165(73)90198-0; Petak F, 2001, J APPL PHYSIOL, V90, P2221; PETERSSON G, 1989, BRIT J PHARMACOL, V98, P930; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; Pryor WA, 1993, ANN NY ACAD SCI, V686, P27; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; ROTMAN HH, 1983, J APPL PHYSIOL, V54, P1120; Ruan T, 2005, J PHYSIOL-LONDON, V565, P563, DOI 10.1113/jphysiol.2005.086181; Ruan T, 2003, J APPL PHYSIOL, V94, P1987, DOI 10.1152/japplphysiol.01047.2002; Rupp H, 1967, Int Arch Arbeitsmed, V23, P79, DOI 10.1007/BF00376170; Shin J, 2002, P NATL ACAD SCI USA, V99, P10150, DOI 10.1073/pnas.152002699; Shusterman D, 2004, NEUROPEPTIDES, V38, P351, DOI 10.1016/j.npep.2004.08.002; Shusterman D, 2003, INHAL TOXICOL, V15, P1179, DOI 10.1080/08958370390229852; Shusterman D, 2003, EUR RESPIR J, V21, P652, DOI 10.1183/09031936.03.00049102; Shusterman D, 2002, RHINOLOGY, V40, P141; Shusterman DJ, 1998, J ALLERGY CLIN IMMUN, V101, P732, DOI 10.1016/S0091-6749(98)70302-1; Stokes A, 2006, CELL SIGNAL, V18, P1584, DOI 10.1016/j.cellsig.2005.12.009; Story GM, 2003, CELL, V112, P819, DOI 10.1016/S0092-8674(03)00158-2; Takebayashi T, 1998, J APPL PHYSIOL, V85, P442; Taylor-Clark T, 2006, J APPL PHYSIOL, V101, P950, DOI 10.1152/japplphysiol.00222.2006; Trevisani M, 2007, P NATL ACAD SCI USA, V104, P13519, DOI 10.1073/pnas.0705923104; Undem Bradley J, 2002, Curr Allergy Asthma Rep, V2, P159, DOI 10.1007/s11882-002-0011-4; Uysal N, 2003, CURR OPIN PULM MED, V9, P144, DOI 10.1097/00063198-200303000-00009; Vesely KR, 1999, J APPL PHYSIOL, V86, P951; VIJAYARAGHAVAN R, 1994, ARCH TOXICOL, V68, P490, DOI 10.1007/s002040050101; VIJAYARAGHAVAN R, 1993, ARCH TOXICOL, V67, P478, DOI 10.1007/BF01969919; Watanabe N, 2005, PULM PHARMACOL THER, V18, P187, DOI 10.1016/j.pupt.2004.12.002; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Winterbourn CC, 2002, TOXICOLOGY, V181, P223, DOI 10.1016/S0300-483X(02)00286-X; Wu ZX, 2001, J APPL PHYSIOL, V91, P371; Xu HX, 2006, NAT NEUROSCI, V9, P628, DOI 10.1038/nn1692; Xu HX, 2005, J NEUROSCI, V25, P8924, DOI 10.1523/JNEUROSCI.2574-05.2005; ZHOU ZA, 1993, J PHYSIOL-LONDON, V469, P245	87	226	230	1	9	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	MAY	2008	118	5					1899	1910		10.1172/JCI34192		12	Medicine, Research & Experimental	Research & Experimental Medicine	295QX	WOS:000255490100033	18398506	
J	Pijnenburg, MW; Bakker, EM; Hop, WC; De Jongste, JC				Pijnenburg, MW; Bakker, EM; Hop, WC; De Jongste, JC			Titrating steroids on exhaled nitric oxide in children with asthma - A randomized controlled trial	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway hyperresponsiveness; corticosteroids; lung function; symptoms; treatment	AIRWAY INFLAMMATION; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; LONGITUDINAL POPULATION; CLINICAL REMISSION; ALLERGIC-ASTHMA; ATOPIC ASTHMA; LUNG-FUNCTION; RISK-FACTORS; MARKERS	Rationale: Corticosteroids are the antiinflammatory treatment of choice in asthma. Treatment guidelines are mainly symptom-driven but symptoms are not closely related to airway inflammation. The fraction of nitric oxide in exhaled air (F-ENO) is a marker of airway inflammation in asthma. Objective: We evaluated whether titrating steroids on F-ENO improved asthma management in children. Methods: Eighty-five children with atopic asthma, using inhaled steroids, were allocated to a F-ENO group (n = 39) in which treatment decisions were made on both F-ENO and symptoms, or to a symptom group (n = 46) treated on symptoms only. Children were seen eve 3 months over a 1-year period. Measurements: Symptoms were scored during 2 weeks before visits and 4 weeks before the final visit. FeNO was measured at all visits, and airway hyperresponsiveness and FEV1 were measured at the start and end of the study. Primary endpoint was cumulative steroid dose. Results: Changes in steroid dose from baseline did not differ between groups. In the F-ENO group, hyperresponsiveness improved more than in the symptom group (2.5 vs. 1.1 doubling dose, p = 0.04). FEV1 in the F-ENO group improved, and the change in FEV1 was not significantly different between groups. The F-ENO group had 8 severe exacerbations versus 18 in the symptom group. The change in symptom scores did not differ between groups. F-ENO increased in the symptom group; the change in F-ENO from baseline differed between groups (p = 0.02). Conclusion: In children with asthma, 1 year of steroid titration on F-ENO did not result in higher steroid doses and did improve airway hyperresponsiveness and inflammation.	Erasmus Univ, Ctr Med, Sophia Childrens Hosp, Dept Pediat Pediat Resp Med, NL-3000 CB Rotterdam, Netherlands; Erasmus Univ, Ctr Med, Sophia Childrens Hosp, Dept Epidemiol & Biostat, NL-3000 CB Rotterdam, Netherlands	Pijnenburg, MW (reprint author), Erasmus Univ, Ctr Med, Sophia Childrens Hosp, Dept Pediat Pediat Resp Med, POB 2060, NL-3000 CB Rotterdam, Netherlands.	m.pijnenburg@erasmusmc.nl					ALVING K, 1993, EUR RESPIR J, V6, P1368; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Cochrane MG, 2000, CHEST, V117, P542, DOI 10.1378/chest.117.2.542; Delgado-Corcoran Claudia, 2004, Pediatr Crit Care Med, V5, P48, DOI 10.1097/01.CCM.0000105310.00799.51; Djukanovic R, 2002, J ALLERGY CLIN IMMUN, V109, pS539, DOI 10.1067/mai.2002.124568; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Hunt J, 2000, J PEDIATR-US, V137, P14, DOI 10.1067/mpd.2000.107526; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; Kharitonov SA, 2001, AM J RESP CRIT CARE, V164, P727; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; [Anonymous], 2002, NIH PUBL, V01-4913; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376; Piacentini GL, 1999, EUR RESPIR J, V13, P1386, DOI 10.1183/09031936.99.13613919; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; PIJNENBURG MW, 2005, P AM THORAC SOC, V2, pA690; Powell H, 2004, COCHRANE DB SYST REV; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SHERRILL D, 1992, PEDIATR PULM, V13, P78, DOI 10.1002/ppul.1950130204; Silvestri M, 2003, PEDIATR PULM, V35, P358, DOI 10.1002/ppul.10264; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Spallarossa D, 2003, J ASTHMA, V40, P301, DOI 10.1081/JAS-120018629; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1067/mai.2003.1795; Tsai YG, 2001, J PEDIATR-US, V139, P433, DOI 10.1067/mpd.2001.116295; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953; van Grunsven PM, 2001, J ASTHMA, V38, P113, DOI 10.1081/JAS-100000028; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Warke TJ, 2002, EUR RESPIR J, V19, P284, DOI 10.1183/09031936.02.00882002; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	41	225	236	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2005	172	7					831	836		10.1164/rccm.200503-458OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	967UD	WOS:000232115800009	15976380	
J	Weiland, SK; Bjorksten, B; Brunekreef, B; Cookson, WOC; von Mutius, E; Strachan, DP				Weiland, SK; Bjorksten, B; Brunekreef, B; Cookson, WOC; von Mutius, E; Strachan, DP		International Study Asthma Aller	Phase II of the international study of asthma and allergies in childhood (ISAAC II): rationale and methods	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; childhood; eczema; epidemiology; international study of asthma and allergies; in childhood phase II; rhinitis	RESPIRATORY-HEALTH-SURVEY; WORLDWIDE VARIATIONS; BLOOD-PRESSURE; ATOPIC ECZEMA; PREVALENCE; SYMPTOMS; CHILDREN; RHINOCONJUNCTIVITIS	International comparative studies, investigating whether disease incidence or prevalence rates differ between populations and, if so, which factors explain the observed differences, have made important contributions to the understanding of disease aetiology in many areas. In Phase I of the International Study of Asthma and Allergies in Childhood (ISAAC), the prevalence rates of symptoms of asthma, allergic rhinitis and atopic eczema in 13-14-yr-olds, assessed by standardised questionnaires, were found to differ >20-fold between the 155 study centres around the world. Phase II of ISAAC aims to identify determinants of these differences by studying informative populations. A detailed study protocol was developed for use in community-based random samples of children aged 9-11 yrs. The study modules include standardised questionnaires with detailed questions on the occurrence and severity of symptoms of asthma, allergic rhinitis and atopic eczema, their clinical management, and a broad range of previous and current exposure conditions. In addition, standardised protocols were applied for examination of flexural dermatitis, skin-prick testing, bronchial challenge with hypertonic saline, blood sampling for immunoglobulin E analyses and genotyping, and dust sampling for assessment of indoor exposures to allergens and endotoxin. To date, ISAAC II field work had been completed or started in 30 study centres in 22 countries. The majority of centres are in countries that participated in International Study of Asthma and Allergies in Childhood Phase I and reflect almost the full range of the observed variability in Phase I prevalence rates.	Univ Ulm, Dept Epidemiol, D-89081 Ulm, Germany; Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England	Weiland, SK (reprint author), Univ Ulm, Dept Epidemiol, Helmholzstr 22, D-89081 Ulm, Germany.	stephan.weiland@medizin.uni-ulm.de	MARTINEZ-GIMENO, ANTONIO/A-9416-2010; Ellwood, Philippa/G-7555-2015; Jones, Marcus/A-3580-2011; Forastiere, Francesco/J-9067-2016; De sario, Manuela/K-1932-2016; Osborne, Nicholas/N-4915-2015	MARTINEZ-GIMENO, ANTONIO/0000-0003-4051-1860; Ellwood, Philippa/0000-0002-1994-4023; Jones, Marcus/0000-0002-8263-1265; Forastiere, Francesco/0000-0002-9162-5684; De sario, Manuela/0000-0002-1117-2735; Osborne, Nicholas/0000-0002-6700-2284; brunekreef, bert/0000-0001-9908-0060			Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; *DEP EP U ULM, INT STUD ASTHM ALL C; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Marmot MG, 1998, LANCET, V351, P57, DOI 10.1016/S0140-6736(97)08084-7; Parkin DM, 2002, IARC SCI PUBL, VVIII, P1; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; PFEFFERMANN D, 1993, INT STAT REV, V61, P317, DOI 10.2307/1403631; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Rose G., 1992, STRATEGY PREVENTION; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; *U AUCKL, INT STUD ASTHM ALL C; van den Hoogen PCW, 2000, NEW ENGL J MED, V342, P1, DOI 10.1056/NEJM200001063420101; VANSTRIEN RT, 2002, ENV HLTH PERSPECT, V110, P693; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; WILLIAMS HC, SO HOW DO I DEFINE A; Wolf-Maier K, 2003, JAMA-J AM MED ASSOC, V289, P2363, DOI 10.1001/jama.289.18.2363; ZHANG L, 1992, P NATL ACAD SCI USA, V89, P5847, DOI 10.1073/pnas.89.13.5847	25	225	234	1	15	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2004	24	3					406	412		10.1183/09031936.04.00090303		7	Respiratory System	Respiratory System	852LS	WOS:000223757400017	15358699	
J	Holgate, ST				Holgate, Stephen T.			Epithelium dysfunction in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; environment; epithelium; epithelial mesenchymal trophic unit; airway remodeling; origins of asthma; progression of asthma; tight junctions; impaired barrier function	RETICULAR BASEMENT-MEMBRANE; RESOLUTION COMPUTED-TOMOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; ALLERGIC AIRWAY INFLAMMATION; LUNG-TRANSPLANT RECIPIENTS; GOBLET CELL HYPERPLASIA; GROWTH-FACTOR RECEPTOR; KILLER T-CELLS; BRONCHIAL EPITHELIUM; EOSINOPHILIC BRONCHITIS	Although asthma is an inflammatory disorder of the conducting airways involving T(H)2-type T cells, there is increasing evidence for an important role played by the epithelium in orchestrating the inflammatory response by interacting with multiple environmental factors to produce a chronic wound scenario involving tissue injury and aberrant repair. Part of this abnormal response is the consequence of impaired barrier function caused by a primary disruption of epithelial tight junctions that allows inhaled substances to pass more easily into the airway wall to interact with immune and inflammatory cells. Aberrant communication between the damaged and stressed epithelium leads to the generation of growth factors that interact with the underlying mesenchyme to promote airway remodeling responses and a more chronic and persistent inflammatory phenotype. Disordered epithelial function with reduced antioxidant defense and impaired capacity to produce primary IFNs may also account for asthmatic susceptibility to air pollution and respiratory virus infection, respectively. Considering asthma as a disease of impaired barrier function opens new opportunities for therapeutic intervention or prevention by agents that could increase the airways resistance to the inhaled environment rather than suppressing the immune or inflammatory response.	[Holgate, Stephen T.] Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair Div, Southampton SO16 6YD, Hants, England; [Holgate, Stephen T.] Univ Southampton, Southampton SO16 6YD, Hants, England	Holgate, ST (reprint author), Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair Div, MP810,Level F,South Block, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk			Medical Research Council [G0501506, G0800766]		Akbari O, 2007, NEW ENGL J MED, V357, P193; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Ayres Jon G, 2004, Paediatr Respir Rev, V5, P40, DOI 10.1016/j.prrv.2003.09.003; Bai TR, 2005, CLIN SCI, V108, P463; Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Bellini A, 2007, LAB INVEST, V87, P858, DOI 10.1038/labinvest.3700654; Berry MA, 2005, CLIN EXP ALLERGY, V35, P598, DOI 10.1111/j.1365-2222.2005.02222.x; Bertorelli G, 1998, CLIN EXP ALLERGY, V28, P551; Bochner BS, 2003, J ALLERGY CLIN IMMUN, V112, P930, DOI 10.1067/mai.2003.1793; Bousquet J, 2000, ALLERGY, V55, P1194, DOI 10.1034/j.1398-9995.2000.00923.x; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; Burgel PR, 2007, THORAX, V62, P153, DOI 10.1136/thx.2006.062190; Castillo SS, 2007, EXP CELL RES, V313, P816, DOI 10.1016/j.yexcr.2006.12.001; Choe MM, 2003, AM J PHYSIOL-LUNG C, V285, pL427, DOI 10.1152/ajplung.00005.2003; Chu EK, 2006, AM J RESP CELL MOL, V35, P628, DOI 10.1165/rcmb.2006-0040OC; Chung KF, 2006, AM J RESP CRIT CARE, V174, P1066, DOI 10.1164/rccm.200608-1158ED; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Cohn L, 2002, NOVART FDN SYMP, V248, P201; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Davies JA, 1997, BIOESSAYS, V19, P699, DOI 10.1002/bies.950190810; Deshmukh HS, 2005, AM J RESP CRIT CARE, V171, P305, DOI 10.1164/rccm.200408-1003OC; Dreschers S, 2007, CELL MOL LIFE SCI, V64, P181, DOI 10.1007/s00018-006-6266-5; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Elias Jack A, 2006, Proc Am Thorac Soc, V3, P494, DOI 10.1513/pats.200603-068MS; Ercan H, 2006, J ALLERGY CLIN IMMUN, V118, P1097, DOI 10.1016/j.jaci.2006.08.012; Farhadi A, 2003, J GASTROEN HEPATOL, V18, P479, DOI 10.1046/j.1440-1746.2003.03032.x; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Fehniger TE, 2004, J PROTEOME RES, V3, P307, DOI 10.1021/pr0499702; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hackett TL, 2007, CURR OPIN ALLERGY CL, V7, P63, DOI 10.1097/ACI.0b013e328013d61b; Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; HOGG JC, 1993, J ALLERGY CLIN IMMUN, V92, P1, DOI 10.1016/0091-6749(93)90029-F; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Izuhara Kenji, 2006, Allergol Int, V55, P361, DOI 10.2332/allergolint.55.361; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Joad JP, 2006, TOXICOL APPL PHARM, V214, P237, DOI 10.1016/j.taap.2005.12.012; Kaplan AP, 2002, J ALLERGY CLIN IMMUN, V109, P195, DOI 10.1067/mai.2002.121316; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Karjalainen EM, 2003, RESP MED, V97, P1045, DOI 10.1016/S0954-6111(03)00136-7; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Kim KK, 2006, P NATL ACAD SCI USA, V103, P13180, DOI 10.1073/pnas.0605669103; Kips JC, 2003, AM J RESP CRIT CARE, V167, P1655, DOI 10.1164/rccm.200206-525OC; Kiwamoto T, 2006, AM J RESP CRIT CARE, V174, P142, DOI 10.1164/rccm.200601-079OC; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Knight D, 2002, CLIN EXP ALLERGY, V32, P1263, DOI 10.1046/j.1365-2745.2002.01486.x; Knight DA, 2004, CURR OPIN PHARMACOL, V4, P251, DOI 10.1016/j.coph.2004.02.002; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Kuperman DA, 2005, J ALLERGY CLIN IMMUN, V116, P305, DOI 10.1016/j.jaci.2005.03.024; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lankford SM, 2005, IN VITRO CELL DEV-AN, V41, P217; Law L, 2005, J HEART LUNG TRANSPL, V24, P1571, DOI 10.1016/j.healun.2005.01.007; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee YM, 2004, CHEST, V126, P1840, DOI 10.1378/chest.126.6.1840; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Leung SY, 2006, J PHARMACOL EXP THER, V319, P586, DOI 10.1124/jpet.106.109314; Liu LY, 2002, J IMMUNOL, V169, P6459; Locke NR, 2007, AM J RESP CELL MOL, V36, P625, DOI 10.1165/rcmb.2006-0083OC; Long AJ, 2006, AM J RESP CELL MOL, V35, P357, DOI 10.1165/rcmb.2005-0451OC; Lordan JL, 2002, J IMMUNOL, V169, P407; Mak JCW, 2007, CLIN EXP ALLERGY, V37, P1150, DOI 10.1111/j.1365-2222.2007.02704.x; Mak JCW, 2006, CLIN EXP ALLERGY, V36, P440, DOI 10.1111/j.1365-2222.2006.02458.x; Merendino AM, 2006, AM J RESP CELL MOL, V35, P155, DOI 10.1165/rcmb.2005-0433OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Nakano T, 2006, AM J RESP CRIT CARE, V173, P1216, DOI 10.1164/rccm.200410-1420OC; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Park CS, 1998, EUR RESPIR J, V12, P872, DOI 10.1183/09031936.98.12040872; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Park SW, 2006, THORAX, V61, P41, DOI 10.1136/thx.2005.044420; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Pearce N, 1999, THORAX, V54, P268; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Phipps S, 2004, AM J RESP CELL MOL, V31, P626, DOI 10.1165/rcmb.2004-0193OC; Phipps S, 2002, J IMMUNOL, V169, P4604; Pini L, 2007, EUR RESPIR J, V29, P71, DOI 10.1183/09031936.00047905; Plopper CG, 2007, TOXICOL PATHOL, V35, P97, DOI 10.1080/01926230601132030; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Ramsey CD, 2005, CURR OPIN PULM MED, V11, P14, DOI 10.1097/01.mcp.0000145791.13714.ae; Ritter Mirko, 2005, J Inflamm (Lond), V2, P16, DOI 10.1186/1476-9255-2-16; ROCHE WR, 1993, AM REV RESPIR DIS, V148, pS79; ROCHE WR, 1989, LANCET, V1, P520; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rousseau K, 2007, ANN HUM GENET, V71, P561, DOI 10.1111/j.1469-1809.2007.00374.x; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-14040C; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Schmidt M, 2003, J IMMUNOL, V171, P380; Seiskari T, 2007, CLIN EXP IMMUNOL, V148, P47, DOI 10.1111/j.1365-2249.2007.03333.x; Shahana S, 2006, RESP MED, V100, P2018, DOI 10.1016/j.rmed.2006.02.012; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shaw TJ, 2004, EUR RESPIR J, V23, P813, DOI 10.1183/09031936.04.00119904; Shebani E, 2005, TISSUE CELL, V37, P145, DOI 10.1016/j.tice.2004.12.002; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tesfaigzi Y, 2003, ARCH IMMUNOL THER EX, V51, P283; Truong-Tran AQ, 2002, AM J RESP CELL MOL, V27, P286, DOI 10.1165/rcmb.2001-0014OC; Truong-Tran AQ, 2003, BIOCHEM PHARMACOL, V66, P1459, DOI 10.1016/S0006-2952(03)00498-2; Tschumperlin DJ, 2006, ANNU REV PHYSIOL, V68, P563, DOI 10.1146/annurev.physiol.68.072304.113102; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Vijayanand P, 2007, NEW ENGL J MED, V356, P1410, DOI 10.1056/NEJMoa064691; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Ward C, 2005, THORAX, V60, P865, DOI 10.1136/thx.2005.043026; Ward C, 2005, J HEART LUNG TRANSPL, V24, P533, DOI 10.1016/j.healun.2004.02.018; Wardlaw AJ, 2002, CLIN SCI, V103, P201; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Wu Z, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-1; Zhang SL, 1999, LAB INVEST, V79, P395	130	224	236	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2007	120	6					1233	1246		10.1016/j.jaci.2007.10.025		14	Allergy; Immunology	Allergy; Immunology	241JX	WOS:000251653800001	18073119	
J	Cockcroft, DW; Davis, BE				Cockcroft, Donald W.; Davis, Beth E.			Mechanisms of airway hyperresponsiveness	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; airway hyperresponsiveness; airway inflammation; airway smooth muscle	LATE ASTHMATIC RESPONSE; INDIRECT BRONCHIAL HYPERRESPONSIVENESS; ALLERGEN-INDUCED INCREASES; SMOOTH-MUSCLE; MONOCLONAL-ANTIBODY; INHALED BUDESONIDE; MAST-CELLS; ADENOSINE 5'-MONOPHOSPHATE; BRONCHOALVEOLAR LAVAGE; TOLUENE DIISOCYANATE	Airway hyperresponsiveness (AHR) to direct (histamine and methacholine) and indirect (exercise, cold air, hyperventilation, AMP) challenges is a universal and defining feature of asthma. One component of AHR is transient or inducible and occurs after allergen exposure, for example, and improves occasionally rapidly after inhaled corticosteroids or environmental control. This transient airway hyperresponsiveness is more marked to the indirect stimuli. There are convincing data linking this component of AHR to airway inflammation; however, the precise mechanisms linking airway inflammation and hyperresponsiveness of the airway smooth muscle are not clear. The other component of AHR is more persistent and is relatively refractory to environmental control and inhaled corticosteroids. This is likely secondary to structural airway changes, which are collectively referred to as airway remodeling, and which are a result of the chronic (rather than the acute) effects of airway inflammation. This persistent AHR is best reflected by airway hyperresponsiveness to direct stimuli such as methacholine. The mechanisms are also uncertain, but reduced airway caliber, increased airway wall thickness, increased airway smooth muscle mass, and perhaps contractility likely all play a role.	Univ Saskatchewan, Div Respirol Crit Care & Sleep Med, Dept Med, Royal Univ Hosp, Saskatoon, SK S7N 0W8, Canada	Cockcroft, DW (reprint author), Univ Saskatchewan, Div Respirol Crit Care & Sleep Med, Dept Med, Royal Univ Hosp, 103 Hosp Dr,Ellis Hall,5th Floor, Saskatoon, SK S7N 0W8, Canada.	cockcroft@sask.usask.ca					Akdis CA, 2006, EUR J PHARMACOL, V533, P69, DOI 10.1016/j.ejphar.2005.12.044; ALTOUNYAN R. E. C., 1964, THORAX, V19, P406, DOI 10.1136/thx.19.5.406; ARMOUR CL, 1984, AM REV RESPIR DIS, V129, P907; Baelder R, 2005, J IMMUNOL, V174, P783; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; BARNES PJ, 1984, THORAX, V39, P561, DOI 10.1136/thx.39.8.561; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; BENSON MK, 1975, BRIT J DIS CHEST, V69, P227, DOI 10.1016/S0007-0971(75)80039-8; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Black JL, 2001, AM J RESP CRIT CARE, V164, pS63; Blumchen K, 2004, CLIN EXP ALLERGY, V34, P1124, DOI 10.1111/j.1365-2222.2004.01974.x; BOOIJNOORD H, 1971, J ALLERGY CLIN IMMUN, V48, P344, DOI 10.1016/0091-6749(71)90080-7; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; BOUCHER RC, 1979, J ALLERGY CLIN IMMUN, V64, P197, DOI 10.1016/0091-6749(79)90095-2; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Bryce PJ, 2003, J ALLERGY CLIN IMMUN, V112, P149, DOI 10.1067/mai.2003.1616; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P1185, DOI 10.1016/0091-6749(86)90270-8; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Cho JY, 2005, J ALLERGY CLIN IMMUN, V116, P1116, DOI 10.1016/j.jaci.2005.08.015; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; COCKCROFT DW, 1993, BRONCHIAL ASTHMA MEC, P32; Cohn L, 1998, J IMMUNOL, V161, P3813; Cui JQ, 2005, J ALLERGY CLIN IMMUN, V115, P309, DOI 10.1016/j.jaci.2004.10.046; DEJONGSTE JC, 1988, AM REV RESPIR DIS, V138, P321; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; DOLOVICH J, 1981, THORAX, V36, P641; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P565, DOI 10.1164/rccm.200307-1024OC; Dorman SC, 2004, AM J RESP CRIT CARE, V169, P573, DOI 10.1164/rccm.200307-1004OC; DUBOIS AB, 1964, HDB PHYSIOLOGY     3, V1, P451; DUTOIT JI, 1986, AM REV RESPIR DIS, V134, P498; Ebeling C, 2005, J ALLERGY CLIN IMMUN, V115, P623, DOI 10.1016/j.jaci.2004.11.042; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Eum SY, 2005, AM J PHYSIOL-LUNG C, V288, pL576, DOI 10.1152/ajplung.00380.2003; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; FERGUSON AC, 1989, CHEST, V96, P988, DOI 10.1378/chest.96.5.988; FLINT KC, 1985, BRIT MED J, V291, P923; Gauvreau GM, 2003, J ALLERGY CLIN IMMUN, V112, P331, DOI 10.1067/mai.2003.1689; Gauvreau GM, 2005, J ALLERGY CLIN IMMUN, V116, P285, DOI 10.1016/j.jaci.2005.05.021; Gauvreau GM, 1996, AM J RESP CRIT CARE, V154, P1267; Gauvreau GM, 2000, AM J RESP CRIT CARE, V162, P2139; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253; Gelfand EW, 2006, J ALLERGY CLIN IMMUN, V117, P577, DOI 10.1016/j.jaci.2005.12.1340; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331; GODFREY S, 1991, THORAX, V46, P488, DOI 10.1136/thx.46.7.488; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Halayko AJ, 2006, CURR DRUG TARGETS, V7, P525, DOI 10.2174/138945006776818728; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; HARGREAVE FE, 1986, J ALLERGY CLIN IMMUN, V78, P825, DOI 10.1016/0091-6749(86)90226-5; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Hirota S, 2005, CAN J PHYSIOL PHARM, V83, P725, DOI 10.1139/Y05-070; Hogan SP, 1998, J IMMUNOL, V161, P1501; HOGG JC, 1981, J ALLERGY CLIN IMMUN, V67, P421, DOI 10.1016/0091-6749(81)90094-4; Homer RJ, 2005, PHYSIOLOGY, V20, P28, DOI 10.1152/physiol.00035.2004; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Janssen L J, 1998, Can Respir J, V5, P491; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; John AE, 2005, AM J PATHOL, V166, P345, DOI 10.1016/S0002-9440(10)62258-4; Johnson PRA, 2001, AM J RESP CRIT CARE, V164, P474; KIRBY JG, 1986, CLIN ALLERGY, V16, P191, DOI 10.1111/j.1365-2222.1986.tb00765.x; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Laporte JC, 2001, AM J RESP CRIT CARE, V164, P141; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Leigh R, 2004, AM J RESP CRIT CARE, V170, P851, DOI 10.1164/rccm.200311-1488OC; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403; Martin JG, 2000, EUR RESPIR J, V16, P349, DOI 10.1034/j.1399-3003.2000.16b25.x; Mattes J, 2001, J IMMUNOL, V167, P1683; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; Meijer RJ, 1999, THORAX, V54, P894; METZGER WJ, 1986, CHEST, V89, P477, DOI 10.1378/chest.89.4.477; Miller M, 2006, AM J PHYSIOL-LUNG C, V290, pL162, DOI 10.1152/ajplung.00252.2005; Miyahara N, 2005, AM J RESP CRIT CARE, V172, P161, DOI 10.1164/rccm.200502-205OC; Miyahara N, 2005, J IMMUNOL, V174, P4979; MOORE PE, 2002, AM J PHYSIOL-LUNG C, V282, P847; MURPHY KR, 1986, AM REV RESPIR DIS, V134, P62; Nielsen KG, 2000, AM J RESP CRIT CARE, V162, P1500; OBYRNE PM, 1984, AM REV RESPIR DIS, V130, P214; OBYRNE PM, 1984, J APPL PHYSIOL, V57, P77; Parameswaran K, 2002, CHEST, V121, P621, DOI 10.1378/chest.121.2.621; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; Peng T, 2005, J CLIN INVEST, V115, P1590, DOI 10.1172/JCI22906; PIN I, 1992, AM REV RESPIR DIS, V145, P1265; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, pS1; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1183/09031936.00.15103000; Polosa R, 1998, EUR RESPIR J, V12, P551, DOI 10.1183/09031936.98.12030551; PRIME FJ, 1972, CLIN SCI, V42, pP13; Proust B, 2003, CLIN EXP ALLERGY, V33, P119, DOI 10.1046/j.1365-2222.2003.01560.x; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RAMSDALE EH, 1985, THORAX, V40, P422, DOI 10.1136/thx.40.6.422; RAMSDELL JW, 1982, AM REV RESPIR DIS, V126, P829; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SCHELLENBERG RR, 1984, INT ARCH ALLER A IMM, V75, P237; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Sehmi R, 2003, IMMUNOLOGY, V109, P536, DOI 10.1046/j.1365-2567.2003.01686.x; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; SZENTIVANYI A, 1968, J ALLERGY, V42, P203, DOI 10.1016/S0021-8707(68)90117-2; Taube C, 2006, J IMMUNOL, V176, P3157; Taube C, 2004, J IMMUNOL, V172, P6398; TWENTYMAN OP, 1993, J ALLERGY CLIN IMMUN, V91, P1169, DOI 10.1016/0091-6749(93)90320-F; Upham JW, 2002, CLIN EXP ALLERGY, V32, P818, DOI 10.1046/j.1365-2222.2002.01375.x; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546; Van Schoor J, 2005, CLIN EXP ALLERGY, V35, P250, DOI 10.1111/j.1365-2222.2005.02177.x; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V285, pL808, DOI 10.1152/ajplung.00377.2002; VERMA VK, 1988, CHEST, V94, P456; VINCENC KS, 1983, AM REV RESPIR DIS, V128, P875; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Wood LJ, 2002, AM J RESP CRIT CARE, V166, P883, DOI 10.1164/rccm.2108015; Wood Lorna J., 1998, American Journal of Respiratory and Critical Care Medicine, V157, P99; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; WOOLCOCK AJ, 1986, AM REV RESPIR DIS, V133, pA177; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Yoshida M, 2005, J ALLERGY CLIN IMMUN, V115, P1004, DOI 10.1016/j.jaci.2005.02.003	130	224	228	1	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					551	559		10.1016/j.jaci.2006.07.012		9	Allergy; Immunology	Allergy; Immunology	086BV	WOS:000240649000002	16950269	
J	Aalberse, RC; Schuurman, J				Aalberse, RC; Schuurman, J			IgG4 breaking the rules	IMMUNOLOGY			English	Review							FACILITATED ALLERGEN PRESENTATION; HINGE REGION; COMPLEMENT ACTIVATION; BLOCKING ANTIBODY; SEROLOGIC ASPECTS; HUMAN FILARIASIS; IMMUNOGLOBULIN-G; PLASMA-MEMBRANE; DISULFIDE BONDS; ATOPIC DISEASE	Immunoglobulin G4 (IgG4) antibodies have been known for some time to be functionally monovalent. Recently, the structural basis for this monovalency has been elucidated: the in vivo exchange of IgG half-molecules (one H-plus one L-chain) among IgG4. This process results in bispecific antibodies that in most situations will behave as functionally monovalent antibodies. The structural basis for the abnormal behaviour of IgG4 seems to be largely the result of a single amino acid change relative to human IgG1: the change of a proline in core hinge of IgG1 to serine. This results in a marked shift in the equilibrium between interchain disulphide bridges and intrachain disulphide bridges, which for IgG4 results in 25-75% absence of a covalent interaction between the H-chains. Because of strong non-covalent interactions between the CH3 domains (and possibly also between the CH1 domain and the trans-CH2 domain) IgG4 is a stable four-chain molecule and does not easily exchange half-molecules under standard physiological conditions in vitro. We postulate that the exchange is catalysed in vivo by protein disulphide isomerase (PDI) and/or FcRn (the major histocompatibility complex (MHC)-related Fc receptor) during transit of IgG4 in the endosomal pathway in endothelial cells. Because IgG4 is predominantly expressed under conditions of chronic antigen exposure, the biological relevance of this exchange of half-molecules is that it generates antibodies that are unable to form large immune complexes and therefore have a low potential for inducing immune inflammation. In contrast to monovalent immunoglobulin fragments, these scrambled immunoglobulins have a normal half-life. The significance of the ensuing bispecificity needs further evaluation, because thus will be relevant only in situations where high IgG4 responses are found to two unrelated antigens that happen to be present in the body at the same time and place. In this context the significance of IgG4 autoreactivity might have to be re-evaluated. The main function of IgG4, however, is presumably to interfere with immune inflammation induced by complement-fixing antibodies, or, in the case of helminth infection or allergy, by IgE antibodies.	Univ Amsterdam, CLB, Dept Immunopathol, Acad Med Ctr, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Expt & Clin Immunol Lab, Acad Med Ctr, NL-1066 CX Amsterdam, Netherlands	Aalberse, RC (reprint author), Univ Amsterdam, CLB, Dept Immunopathol, Acad Med Ctr, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			AAAI Board of Directors, 1995, J ALLERGY CLIN IMMUN, V95, P652; Aalberse JA, 2001, J ALLERGY CLIN IMMUN, V107, pS182; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; AALBERSE RC, 1993, ALLERGY, V48, P559, DOI 10.1111/j.1398-9995.1993.tb00749.x; AALBERSE RC, 1983, J IMMUNOL, V130, P722; AALBERSE RC, 1983, CLIN REV ALLERG, V1, P289; AALBERSE RC, 1985, LAB MANAGE, V23, P19; Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; ANGAL S, 1993, MOL IMMUNOL, V30, P105, DOI 10.1016/0161-5890(93)90432-B; Bernstein IL, 1995, ANN ALLERG ASTHMA IM, V75, P543; Bloom JW, 1997, PROTEIN SCI, V6, P407; Burgess JK, 2000, J BIOL CHEM, V275, P9758, DOI 10.1074/jbc.275.13.9758; BURTON DR, 1986, MONOGR ALLERGY, V19, P7; CARINI C, 1992, INT ARCH ALLERGY IMM, V98, P227; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; COLCHER D, 1989, CANCER RES, V49, P1738; Corper AL, 1997, NAT STRUCT BIOL, V4, P374, DOI 10.1038/nsb0597-374; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P9266, DOI 10.1021/bi980270i; DANGL JL, 1988, EMBO J, V7, P1989; Donoghue N, 2000, PROTEIN SCI, V9, P2436; DORRINGTON KJ, 1985, NATURE, V314, P500, DOI 10.1038/314500d0; Fenouillet E, 2001, J INFECT DIS, V183, P744, DOI 10.1086/318823; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; GREGORY L, 1987, MOL IMMUNOL, V24, P821, DOI 10.1016/0161-5890(87)90184-2; Guddat LW, 1997, PROTEIN SCI, V6, P1893; Guddat LW, 1998, STRUCT FOLD DES, V6, P757, DOI 10.1016/S0969-2126(98)00077-X; HAGAN P, 1991, NATURE, V349, P243, DOI 10.1038/349243a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; HORGAN C, 1993, J IMMUNOL, V150, P5400; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; ISENMAN DE, 1975, J IMMUNOL, V114, P1726; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; KESSLER H, 1991, BIOPOLYMERS, V31, P1189, DOI 10.1002/bip.360311007; KING DJ, 1992, BIOCHEM J, V281, P317; KRONING H, 1994, SCAND J IMMUNOL, V39, P346, DOI 10.1111/j.1365-3083.1994.tb03384.x; KURNIAWAN A, 1993, J IMMUNOL, V150, P3941; Lessof M H, 1977, Monogr Allergy, V12, P253; LOSEVA OI, 1986, MOL IMMUNOL, V23, P743, DOI 10.1016/0161-5890(86)90085-4; Margni RA, 1998, IMMUNOL REV, V163, P77, DOI 10.1111/j.1600-065X.1998.tb01189.x; MICHAELSEN TE, 1988, MOL IMMUNOL, V25, P639, DOI 10.1016/0161-5890(88)90099-5; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MUDDE GC, 1995, ALLERGY, V50, P193, DOI 10.1111/j.1398-9995.1995.tb01132.x; NAGPAL S, 1991, INT ARCH ALLER A IMM, V95, P1; NORDERHAUG L, 1990, EUR J IMMUNOL, V21, P2379; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; PETERSEN JG, 1974, J BIOL CHEM, V249, P5633; PHILLIPS ML, 1994, MOL IMMUNOL, V31, P1201, DOI 10.1016/0161-5890(94)90034-5; Raina S, 1997, ANNU REV MICROBIOL, V51, P179, DOI 10.1146/annurev.micro.51.1.179; RIHET P, 1992, EUR J IMMUNOL, V22, P2063, DOI 10.1002/eji.1830220816; ROCK B, 1989, NEW ENGL J MED, V320, P1463, DOI 10.1056/NEJM198906013202206; Roux KH, 1997, J IMMUNOL, V159, P3372; Schuurman J, 2001, MOL IMMUNOL, V38, P1, DOI 10.1016/S0161-5890(01)00050-5; Schuurman J, 1999, IMMUNOLOGY, V97, P693, DOI 10.1046/j.1365-2567.1999.00845.x; SHAKIB F, 1988, NEW ENGL REG ALLERGY, V9, P35; TAN LK, 1990, P NATL ACAD SCI USA, V87, P162, DOI 10.1073/pnas.87.1.162; TURNER M W, 1970, Clinical and Experimental Immunology, V7, P627; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERZEE JS, 1986, J IMMUNOL, V137, P3566; VANDERZEE JS, 1986, CLIN EXP IMMUNOL, V64, P415; VANREE R, 1989, J ALLERGY CLIN IMMUN, V84, P562, DOI 10.1016/0091-6749(89)90371-0; WIDE L, 1970, RADIOIMMUNOASSAY MET, P405; WUNSCH E, 1991, INT J PEPT PROT RES, V37, P61; WUNSCH E, 1988, INT J PEPT PROT RES, V32, P368	65	224	235	1	21	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0019-2805			IMMUNOLOGY	Immunology	JAN	2002	105	1					9	19		10.1046/j.0019-2805.2001.01341.x		11	Immunology	Immunology	516FX	WOS:000173544200002	11849310	
J	Christman, JW; Sadikot, RT; Blackwell, TS				Christman, JW; Sadikot, RT; Blackwell, TS			The role of nuclear factor-kappa B in pulmonary diseases	CHEST			English	Article						air pollution; ARDS; asbestosis; asthma; ozone; respiratory syncytial virus; rhinovirus; sepsis; silicosis	RESPIRATORY SYNCYTIAL VIRUS; BRONCHIAL EPITHELIAL-CELLS; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTORS; ALVEOLAR MACROPHAGES; GENE-EXPRESSION; RAT LUNG; PSEUDOMONAS-AERUGINOSA; INTERLEUKIN-8 GENE; OXIDATIVE STRESS	Nuclear factor-kappa B (NF-kappa B) is a family of DNA-binding protein factors that are required for transcription of most proinflammatory molecules, including adhesion molecules, enzymes, cytokines, and chemokines. NF-kappa B activation seems to be a key early event in a variety of cell and animal model systems developed to elucidate the pathobiology of lung diseases. The purpose of this short review is to describe what is known about the molecular biology of NF-kappa B and to review information that implicates NF-kappa B in the pathogenesis of lung disease, including ARDS, systemic inflammatory response syndrome, asthma, respiratory viral infections, occupational and environmental lung disease, and cystic fibrosis.	Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Med, Nashville, TN USA; Dept Vet Affairs Med Ctr, Nashville, TN 37212 USA	Christman, JW (reprint author), Vanderbilt Univ, Sch Med, Div Allergy Pulm & Crit Care Med, Dept Med, T-1217 MCN, Nashville, TN USA.				NHLBI NIH HHS [HL 07123, HL 61419]		Biagioli MC, 1999, FREE RADICAL BIO MED, V26, P454, DOI 10.1016/S0891-5849(98)00233-0; Bitko V, 1997, VIROLOGY, V232, P369, DOI 10.1006/viro.1997.8582; Blackwell TS, 1999, CHEST, V116, p73S, DOI 10.1378/chest.116.suppl_1.73S; Blackwell TS, 1997, AM J RESP CELL MOL, V17, P3; Bohrer H, 1997, J CLIN INVEST, V100, P972, DOI 10.1172/JCI119648; Christman JW, 1998, INTENS CARE MED, V24, P1131, DOI 10.1007/s001340050735; Christman JW, 1999, AM J RESP CRIT CARE, V159, pA382; DEMARTIN R, 1993, EMBO J, V12, P2773; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Farver CF, 1998, CYTOKINE, V10, P868, DOI 10.1006/cyto.1998.0373; Fiedler MA, 1996, AM J PHYSIOL-LUNG C, V271, pL963; Garofalo R, 1996, J VIROL, V70, P8773; Ghio AJ, 1996, AM J RESP CRIT CARE, V154, P783; Gilmour PS, 1997, ENVIRON HEALTH PERSP, V105, P1313, DOI 10.2307/3433553; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Graziano FM, 1999, ALLERGY ASTHMA PROC, V20, P141, DOI 10.2500/108854199778553055; Haddad EB, 1996, FEBS LETT, V379, P265, DOI 10.1016/0014-5793(95)01524-8; Hancox RJ, 1999, THORAX, V54, P488; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585; JANSSEN YMW, 1995, P NATL ACAD SCI USA, V92, P8458, DOI 10.1073/pnas.92.18.8458; Janssen YMW, 1997, AM J PATHOL, V151, P389; Jaspers I, 1998, J CELL PHYSIOL, V177, P313, DOI 10.1002/(SICI)1097-4652(199811)177:2<313::AID-JCP13>3.0.CO;2-A; Jaspers I, 1997, AM J PHYSIOL-LUNG C, V272, pL504; Kennedy T, 1998, AM J RESP CELL MOL, V19, P366; LEBAIL O, 1993, EMBO J, V12, P5043; Lentsch AB, 1999, AM J RESP CELL MOL, V20, P692; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Liu SF, 1997, BRIT J PHARMACOL, V121, P1241; Luster Michael I., 1998, Toxicology Letters (Shannon), V102-103, P271, DOI 10.1016/S0378-4274(98)00321-X; Mastronarde JG, 1996, J INFECT DIS, V174, P262; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; SACHS M, 1998, BIOCHEM BIOPH RES CO, V253, P181; SCHMITZ ML, 1991, EMBO J, V10, P3805; Schwartz MD, 1996, CRIT CARE MED, V24, P1285, DOI 10.1097/00003246-199608000-00004; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Simeonova PP, 1997, J IMMUNOL, V159, P3921; Simeonova PP, 1996, AM J RESP CELL MOL, V15, P787; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; Suyang H, 1996, MOL CELL BIOL, V16, P5444; Takizawa H, 1999, J IMMUNOL, V162, P4705; Thomas LH, 1998, J IMMUNOL, V161, P1007; Venkatakrishnan A, 1999, AM J RESP CRIT CARE, V159, pA270; Zhao QY, 1998, AM J PHYSIOL-LUNG C, V274, pL39	45	224	265	2	11	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2000	117	5					1482	1487		10.1378/chest.117.5.1482		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	315DL	WOS:000087097300041	10807839	
J	Ito, K; Chung, KF; Adcock, IM				Ito, K; Chung, KF; Adcock, IM			Update on glucocorticoid action and resistance	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						severe asthma; steroid resistance; glucocorticoid receptor; molecular mechanisms; future therapies	NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; STEROID-INSENSITIVE ASTHMA; HISTONE DEACETYLASE ACTIVITY; COLONY-STIMULATING FACTOR; BLOOD MONONUCLEAR-CELLS; PITUITARY-ADRENAL AXIS; RECEPTOR-BETA-ISOFORM; LIGAND-BINDING DOMAIN; NECROSIS-FACTOR-ALPHA	Extensive development of inhaled and oral glucocorticoids has resulted in highly potent molecules that have been optimized to target activity to the lung and minimize systemic exposure. These have proved highly effective for most asthmatic subjects, but despite these developments, there are a number of subjects with asthma who fail to respond to even high doses of inhaled or even oral glucocorticoids. Advances in delineating the fundamental mechanisms of glucocorticoid pharmacology, especially the concepts of transactivation and transrepression and cofactor recruitment, have resulted in better understanding of the molecular mechanisms whereby glucocorticoids suppress inflammation. The existence of multiple mechanisms underlying glucocorticoid insensitivity raises the possibility that this might indeed reflect different diseases with a common phenotype, and studies examining the efficacy of potential new agents should be targeted toward subgroups of patients with severe corticosteroid-resistant asthma who clearly require effective new drugs and other approaches to improved asthma control.	Natl Heart & Lung Inst, Imperial Coll London, Airways Dis Sect, London SW3 6LY, England	Adcock, IM (reprint author), Natl Heart & Lung Inst, Imperial Coll London, Airways Dis Sect, Dovehouse St, London SW3 6LY, England.	ian.adcock@imperial.ac.uk		Adcock, Ian/0000-0003-2101-8843; Chung, Kian Fan/0000-0001-7101-1426	Wellcome Trust		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adcock Ian M., 2002, Journal of Allergy and Clinical Immunology, V110, pS261, DOI 10.1067/mai.2002.129705; Adcock IM, 2004, BIODRUGS, V18, P167, DOI 10.2165/00063030-200418030-00003; Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; ADCOCK IM, 1995, J EXP MED, V182, P1951, DOI 10.1084/jem.182.6.1951; ADCOCK IM, 1995, J IMMUNOL, V154, P3500; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Bamberger CM, 2004, EXP CLIN ENDOCR DIAB, V112, P595, DOI 10.1055/s-2004-830405; Bantel H, 2002, FASEB J, V16, P1832, DOI 10.1096/fj.02-0223fje; Baraldi E, 2003, CHEST, V124, P25, DOI 10.1378/chest.124.1.25; Barker M, 2005, J MED CHEM, V48, P4507, DOI 10.1021/jm050345y; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 1998, PHARMACOL REV, V50, P515; BARNES PJ, 1995, AM J RESP CRIT CARE, V152, pS125; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066; Barnes PJ, 2003, ANN INTERN MED, V139, P359; Beger C, 2003, BRIT J HAEMATOL, V122, P245, DOI 10.1046/j.1365-2141.2003.04426.x; BELLETTATO C, 2003, EUR RESPIR J, V22, pS565; Bender B, 2003, J ALLERGY CLIN IMMUN, V112, P489, DOI 10.1067/mai.2003.1680; Bergmann MW, 2004, AM J RESP CELL MOL, V30, P555, DOI 10.1165/rcmb.2003-0295OC; Biola A, 2000, FEBS LETT, V487, P229, DOI 10.1016/S0014-5793(00)02297-3; Bledsoe RK, 2002, CELL, V110, P93, DOI 10.1016/S0092-8674(02)00817-6; Bodwell JE, 1996, AM J RESP CRIT CARE, V154, pS2; BODWELL JE, 1995, J STEROID BIOCHEM, V52, P135, DOI 10.1016/0960-0760(94)00157-H; Brightling Christopher E, 2005, Treat Respir Med, V4, P309, DOI 10.2165/00151829-200504050-00002; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919; Busse PJ, 2005, J ALLERGY CLIN IMMUN, V116, P146, DOI 10.1016/j.jaci.2005.03.031; Busse WW, 2001, NEW ENGL J MED, V344, P350; Caelli T, 1997, INT J PATTERN RECOGN, V11, P1, DOI 10.1142/S0218001497000652; Camps M, 2005, NAT MED, V11, P936, DOI 10.1038/nm1284; Canfield S, 2005, J IMMUNOL, V174, P2494; Cetkovic-Cvrlje M, 2003, CLIN IMMUNOL, V106, P213, DOI 10.1016/S1521-6616(02)00049-9; Chakir J, 2002, CLIN EXP ALLERGY, V32, P578, DOI 10.1046/j.0954-7894.2002.01323.x; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594; Charman C, 2003, CLIN DERMATOL, V21, P193, DOI 10.1016/S0738-081X(02)00368-1; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen Y Z, 1999, Mol Cell Biol Res Commun, V2, P145, DOI 10.1006/mcbr.1999.0163; Cho YJ, 2003, ALLERGY ASTHMA PROC, V24, P353; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Chung K Fan, 2004, Treat Respir Med, V3, P279, DOI 10.2165/00151829-200403050-00002; Chung KF, 1999, EUR RESPIR J, V13, P1198; Clark AR, 2003, CURR OPIN PHARMACOL, V3, P404, DOI 10.1016/S1471-4892(03)00073-0; Cookson W, 2004, NEW ENGL J MED, V351, P1794, DOI 10.1056/NEJMe048232; Corrigan Chris J, 2002, Am J Respir Med, V1, P47; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1016; CORRIGAN CJ, 1991, AM REV RESPIR DIS, V144, P1026; Covar Ronina A., 2000, Journal of Allergy and Clinical Immunology, V106, P651, DOI 10.1067/mai.2000.109830; Covert MW, 2005, SCIENCE, V309, P1854, DOI 10.1126/science.1112304; Creed TJ, 2003, ALIMENT PHARM THERAP, V18, P65, DOI 10.1046/j.0269-2813.2003.01639.x; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Croxtall JD, 2002, BRIT J PHARMACOL, V135, P511, DOI 10.1038/sj.bjp.0704474; Da Silva CA, 2003, FASEB J, V17, P2334, DOI 10.1096/fj.03-0136fje; De AntonioSergioR, 2002, J Rheumatol, V29, P46; DE LP, 2001, CANCER RES, V61, P3937; deGroot RP, 1997, J BIOL CHEM, V272, P2319; DEKASKI MC, 1991, GUT, V32, P657, DOI 10.1136/gut.32.6.657; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; Eckstein JW, 2003, EXPERT OPIN INV DRUG, V12, P647, DOI 10.1517/13543784.12.4.647; Elliott J, 2004, TRENDS IMMUNOL, V25, P434, DOI 10.1016/j.it.2004.05.012; Evans SJ, 2000, J STEROID BIOCHEM, V72, P209, DOI 10.1016/S0960-0760(00)00031-5; Fan J, 2005, EUR RESPIR J, V26, P933, DOI 10.1183/09031936.05.00120204; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Feingold K, 2004, AM J PHYSIOL-ENDOC M, V286, pE201, DOI 10.1152/ajpendo.00205.2003; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Freedman ND, 2004, MOL BIOL CELL, V15, P2276, DOI 10.1091/mbc.E03-11-0839; Friend DR, 1998, ALIMENT PHARM THERAP, V12, P591; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7; Galigniana MD, 1999, MOL PHARMACOL, V55, P317; Galigniana MD, 1999, J BIOL CHEM, V274, P16222, DOI 10.1074/jbc.274.23.16222; Garside H, 2004, J BIOL CHEM, V279, P50050, DOI 10.1074/jbc.M407309200; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Global Initiative for Asthma, 2002, NIH PUBL; Goleva E, 2002, J IMMUNOL, V169, P5934; GOLEVA E, 2005, AM J RESP CRIT CARE; Haarman EG, 2004, LEUKEMIA, V18, P530, DOI 10.1038/sj.leu.2403225; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hakonarson H, 2005, P NATL ACAD SCI USA, V102, P14789, DOI 10.1073/pnas.0409904102; Hall SE, 1999, AM J PHYSIOL-LUNG C, V276, pL114; Hasegawa Y, 2005, BIOCHEM BIOPH RES CO, V336, P1049, DOI 10.1016/j.bbrc.2005.08.231; Hauk PJ, 1999, J ALLERGY CLIN IMMUN, V104, P37, DOI 10.1016/S0091-6749(99)70111-9; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Heaney LG, 2003, THORAX, V58, P561, DOI 10.1136/thorax.58.7.561; Heasman SJ, 2004, EUR J IMMUNOL, V34, P1752, DOI 10.1002/eji.200324698; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hermoso MA, 2004, MOL CELL BIOL, V24, P4743, DOI 10.1128/MCB.24.11.4743-4756.2004; Hinrichs CS, 2005, J IMMUNOTHER, V28, P517, DOI 10.1097/01.cji.0000177999.95831.7b; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; HSU SC, 1992, EMBO J, V11, P3457; HU JM, 1994, MOL ENDOCRINOL, V8, P1709, DOI 10.1210/me.8.12.1709; Hu XY, 2003, J IMMUNOL, V170, P4833; Huang ZQ, 2003, EMBO J, V22, P2146, DOI 10.1093/emboj/cdg219; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; Huynh MLN, 2005, AM J RESP CRIT CARE, V172, P972, DOI 10.1164/rccm.200501-0350C; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Isidoro-Garcia Maria, 2005, Clin Mol Allergy, V3, P15, DOI 10.1186/1476-7961-3-15; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Itoh M, 2002, MOL ENDOCRINOL, V16, P2382, DOI 10.1210/me.2002-0144; Jalonen U, 2005, BIOCHEM PHARMACOL, V69, P733, DOI 10.1016/j.bcp.2004.11.027; Jayaram L, 2005, EUR RESPIR J, V25, P41, DOI 10.1183/09031936.04.00008104; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW; Kanniess F, 2001, PULM PHARMACOL THER, V14, P141, DOI 10.1006/pupt.2001.0288; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Katsoulis K, 2003, J ASTHMA, V40, P847, DOI 10.1081/JAS-120023575; Kauppi B, 2003, J BIOL CHEM, V278, P22748, DOI 10.1074/jbc.M212711200; Kharitonov SA, 2003, CURR ALLERGY ASTHM R, V3, P121, DOI 10.1007/s11882-003-0024-7; Kharitonov Sergei A, 2004, Proc Am Thorac Soc, V1, P191, DOI 10.1513/pats.200402-011MS; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kino T, 2004, ESSAYS BIOCHEM, V40, P137; Kon OM, 2001, EUR RESPIR J, V18, P45, DOI 10.1183/09031936.01.00064101; KOTZIN BL, 1993, ADV IMMUNOL, V54, P99, DOI 10.1016/S0065-2776(08)60534-9; Kumar S, 2004, BBA-MOL CELL RES, V1691, P73, DOI 10.1016/j.bbamer.2004.03.003; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lane SJ, 1996, AM J RESP CRIT CARE, V154, pS62; LANE SJ, 1991, AM REV RESPIR DIS, V143, P1020; LANE SJ, 1994, AM J RESP CELL MOL, V11, P42; Lane SJ, 1996, AM J RESP CRIT CARE, V153, P557; Lasa M, 2002, MOL CELL BIOL, V22, P7802, DOI 10.1128/MCB.22.22.7802-7811.2002; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Le DY, 2002, ENDOCRINOLOGY, V143, P3482; Ledford D, 1998, J ALLERGY CLIN IMMUN, V102, P353, DOI 10.1016/S0091-6749(98)70120-4; Lee KY, 2006, J IMMUNOL, V176, P603; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Leung DYM, 1999, ALLERGY ASTHMA PROC, V20, P9, DOI 10.2500/108854199778681512; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Li LB, 2004, J ALLERGY CLIN IMMUN, V114, P1059, DOI 10.1016/j.jaci.2004.08.005; Li XT, 2003, MOL CELL BIOL, V23, P3763, DOI 10.1128/MCB.23.11.3763-3773.2003; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Lofberg R, 1996, GASTROENTEROLOGY, V110, P1713, DOI 10.1053/gast.1996.v110.pm8964395; Lu NZ, 2005, MOL CELL, V18, P331, DOI 10.1016/j.molcel.2005.03.025; Luecke HF, 2005, GENE DEV, V19, P1116, DOI 10.1101/gad.1297105; Magiakou MA, 2002, J ENDOCRINOL INVEST, V25, P181; MALCHOFF DM, 1993, J CLIN INVEST, V91, P1918, DOI 10.1172/JCI116410; Manning AM, 2003, NAT REV DRUG DISCOV, V2, P554, DOI 10.1037/nrd.1132; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Matthews JG, 2004, J ALLERGY CLIN IMMUN, V113, P1100, DOI 10.1016/j.jaci.2004.03.018; Mendes ES, 2003, EUR RESPIR J, V21, P989, DOI 10.1183/09031936.03.00072402; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; Mittelstadt PR, 2001, J BIOL CHEM, V276, P29603, DOI 10.1074/jbc.M101522200; Mullick J, 2001, J BIOL CHEM, V276, P18007, DOI 10.1074/jbc.M100671200; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Nelson HS, 2005, CURR ALLERGY ASTHM R, V5, P123, DOI 10.1007/s11882-005-0085-x; Nie M, 2005, J IMMUNOL, V175, P478; Nimmagadda SR, 1997, AM J RESP CRIT CARE, V155, P87; Nissen RM, 2000, GENE DEV, V14, P2314, DOI 10.1101/gad.827900; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; Norman M, 2002, CURR OPIN PHARMACOL, V2, P723, DOI 10.1016/S1471-4892(02)00232-1; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Okamoto K, 1999, J BIOL CHEM, V274, P10363, DOI 10.1074/jbc.274.15.10363; Pascual G, 2005, NATURE, V437, P759, DOI 10.1038/nature03988; Pawliczak R, 2005, PHYSIOL GENOMICS, V23, P28, DOI 10.1152/physiolgenomics.00011.2005; PICARD D, 1987, EMBO J, V6, P3333; Powell CE, 1999, ENDOCRINE, V10, P271, DOI 10.1007/BF02738626; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Ray DW, 1996, CANCER RES, V56, P3276; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Reichardt HM, 2001, EMBO J, V20, P7168, DOI 10.1093/emboj/20.24.7168; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rice JC, 2001, NATURE, V414, P258, DOI 10.1038/35104721; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Schaaf MJM, 2005, MOL ENDOCRINOL, V19, P1501, DOI 10.1210/me.2005-0050; Schacke H, 2004, P NATL ACAD SCI USA, V101, P227, DOI 10.1073/pnas.0300372101; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schacke Heike, 2005, Curr Opin Investig Drugs, V6, P503; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Shim J, 2002, MOL CELLS, V14, P323; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Sizemore N, 2004, P NATL ACAD SCI USA, V101, P7994, DOI 10.1073/pnas.0401593101; Smith CL, 2004, ENDOCR REV, V25, P45, DOI 10.1210/er.2003-0023; SOMERS JP, 1992, MOL ENDOCRINOL, V6, P26, DOI 10.1210/me.6.1.26; Sousa AR, 1999, J ALLERGY CLIN IMMUN, V104, P565, DOI 10.1016/S0091-6749(99)70325-8; Sousa AR, 2000, J ALLERGY CLIN IMMUN, V105, P943, DOI 10.1067/mai.2000.106486; Stevens A, 2003, MOL ENDOCRINOL, V17, P845, DOI 10.1210/me.2002.0320; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1999, J STEROID BIOCHEM, V69, P195, DOI 10.1016/S0960-0760(99)00052-7; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585; Szatmary Z, 2004, J BIOL CHEM, V279, P43708, DOI 10.1074/jbc.M406568200; Szefler S, 2005, CHEST, V128, P1104, DOI 10.1378/chest.128.3.1104; Szefler SJ, 1997, EUR RESPIR J, V10, P1640, DOI 10.1183/09031936.97.10071640; Takahashi E, 2002, INT IMMUNOPHARMACOL, V2, P1419, DOI 10.1016/S1567-5769(02)00083-8; Tanigawa K, 2002, INT IMMUNOPHARMACOL, V2, P941, DOI 10.1016/S1567-5769(02)00036-X; ten BA, 2005, EUR RESPIR J, V26, P812; TEN BA, 2004, AM J RESP CRIT CARE, V170, P601; Tliba O, 2006, MOL PHARMACOL, V69, P588, DOI 10.1124/mol.105.019679; Torrego A, 2004, AM J RESP CRIT CARE, V170, P420, DOI 10.1164/rccm.200308.1143OC; Tsitoura DC, 2004, J CLIN INVEST, V113, P619, DOI 10.1172/JCI200418975; Turlais F, 2001, ANAL BIOCHEM, V298, P62, DOI 10.1006/abio.2001.5340; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Varga Eva-Maria, 2003, Current Drug Targets - Inflammation and Allergy, V2, P31, DOI 10.2174/1568010033344507; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Wallace AD, 2001, J BIOL CHEM, V276, P42714, DOI 10.1074/jbc.M106033200; Walmsley SR, 2005, TRENDS IMMUNOL, V26, P434, DOI 10.1016/j.it.2005.06.007; Wamboldt FS, 1999, ANN ALLERG ASTHMA IM, V83, P55; WANG CY, 1994, MOL CELL BIOL, V14, P1153; Wang JC, 2004, P NATL ACAD SCI USA, V101, P15603, DOI 10.1073/pnas.0407008101; Weiss ST, 2004, HUM MOL GENET, V13, pR83, DOI 10.1093/hmg/ddh080; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Werner SL, 2005, SCIENCE, V309, P1857, DOI 10.1126/science.1113319; Wu RC, 2005, ENDOCR REV, V26, P393, DOI 10.1210/er.2004-0018; Xu Q, 2003, J BIOL CHEM, V278, P27112, DOI 10.1074/jbc.M300824200; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Yudt MR, 2002, MOL ENDOCRINOL, V16, P1719, DOI 10.1210/me.2002-0106; Zhang XZ, 2002, LIFE SCI, V71, P1523, DOI 10.1016/S0024-3205(02)01921-5; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zuo Z, 1999, BIOCHEMISTRY-US, V38, P8849, DOI 10.1021/bi990842e	234	223	242	10	33	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2006	117	3					522	543		10.1016/j.jaci.2006.01.032		22	Allergy; Immunology	Allergy; Immunology	025JY	WOS:000236263100006	16522450	
J	Chehade, M; Mayer, L				Chehade, M; Mayer, L			Oral tolerance and its relation to food hypersensitivities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						oral tolerance; food allergy; food hypersensitivity; mucosal immunity; antigen uptake; intestine	REGULATORY T-CELLS; TRANSFORMING GROWTH FACTOR-BETA-1; TRANSEPITHELIAL ANTIGEN TRANSPORT; INFLAMMATORY-BOWEL-DISEASE; MYELIN BASIC-PROTEIN; DENDRITIC CELLS; PEYERS-PATCHES; MURINE MODEL; ACTIVE SUPPRESSION; IMMUNE TOLERANCE	The gastrointestinal tract is the largest immunologic organ in the body. It is constantly bombarded by a myriad of dietary proteins. Despite the extent of protein exposure, very few patients have food allergies because of development of oral tolerance to these antigens. Once proteins contact the intestinal surface, they are sampled by different cells and, depending on their characteristics, result in different responses. Antigens might be taken up by Microfold cells overlying Peyer's patches, dendritic cells, or epithelial cells. Different cells of the immune system participate in oral tolerance induction, with regulatory T cells being the most important. Several factors can influence tolerance induction. Some are antigen related, and others are inherent to the host. Disturbances at different steps in the path to oral tolerance have been described in food hypersensitivity. In this review we provide an overview of oral tolerance and cite data related to food hypersensitivity wherever evidence available.	CUNY Mt Sinai Sch Med, Div Allergy Immunol, Dept Pediat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Div Gastroenterol, Dept Pediat, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Med, Div Clin Immunol, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Immunobiol, Div Clin Immunol, New York, NY 10029 USA	Chehade, M (reprint author), CUNY Mt Sinai Sch Med, Div Allergy Immunol, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.	mima.chehade@mssm.edu			NIAID NIH HHS [AI 44236]		Appleman LJ, 2003, IMMUNOL REV, V192, P161, DOI 10.1034/j.1600-065X.2003.00009.x; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Barone KS, 2000, CELL IMMUNOL, V199, P65, DOI 10.1006/cimm.1999.1603; BARONE KS, 1995, CELL IMMUNOL, V163, P19, DOI 10.1006/cimm.1995.1094; Bashir MEH, 2004, J IMMUNOL, V172, P6978; Bennett CL, 2001, NAT GENET, V27, P20; Berin MC, 1998, J IMMUNOL, V161, P2561; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; BLAND PW, 1986, IMMUNOLOGY, V58, P9; Borsutzky S, 2004, J IMMUNOL, V173, P3305; Brandt EB, 2003, J CLIN INVEST, V112, P1666, DOI 10.1172/JCI19785; BRUCE MG, 1986, IMMUNOLOGY, V57, P627; CALLERY MP, 1989, J SURG RES, V46, P391, DOI 10.1016/0022-4804(89)90208-4; Chambers SJ, 2004, IMMUNOLOGY, V112, P72, DOI 10.1111/j.1365-2567.2004.01846.x; CHASE MW, 1946, P SOC EXP BIOL MED, V61, P257; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, J IMMUNOL, V155, P910; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; DUPONT C, 1989, J PEDIATR GASTR NUTR, V8, P459, DOI 10.1097/00005176-198905000-00007; EASTHAM EJ, 1978, J PEDIATR-US, V93, P561, DOI 10.1016/S0022-3476(78)80888-9; ERICKSON RH, 1990, ANNU REV MED, V41, P133; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V114, P377, DOI 10.1016/j.jaci.2004.03.040; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V113, P958, DOI 10.1016/j.jaci.2003.12.017; GARSIDE P, 1995, INT IMMUNOL, V7, P501, DOI 10.1093/intimm/7.3.501; Gonnella PA, 1998, J IMMUNOL, V160, P4708; Groux H, 1997, NATURE, V389, P737; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Howell WM, 1998, CLIN EXP ALLERGY, V28, P156, DOI 10.1046/j.1365-2222.1998.00224.x; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Jain SL, 1996, CELL IMMUNOL, V167, P170, DOI 10.1006/cimm.1996.0024; KAHN R, 1993, CELL, V0075; Karlsson M, 2001, EUR J IMMUNOL, V31, P2892, DOI 10.1002/1521-4141(2001010)31:10<2892::AID-IMMU2892>3.0.CO;2-I; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; KIM PH, 1990, J IMMUNOL, V144, P3411; Kraehenbuhl J P, 1992, Trends Cell Biol, V2, P170, DOI 10.1016/0962-8924(92)90036-M; Kraus TA, 2004, GASTROENTEROLOGY, V126, P1771, DOI 10.1053/j.gastro.2004.03.076; Kunkel D, 2003, EUR J IMMUNOL, V33, P1292, DOI 10.1002/eji.200323383; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LAMONT AG, 1988, IMMUNOLOGY, V63, P737; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; LIU LM, 1991, IMMUNOLOGY, V73, P281; MACDONALD TT, 1982, IMMUNOLOGY, V45, P769; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Man AL, 2004, J ALLERGY CLIN IMMUN, V113, P965, DOI 10.1016/j.jaci.2004.02.038; Marth T, 1998, ANN NY ACAD SCI, V859, P290, DOI 10.1111/j.1749-6632.1998.tb11148.x; MASON DW, 1981, NATURE, V293, P150, DOI 10.1038/293150a0; MAYER L, 1987, J EXP MED, V166, P1471, DOI 10.1084/jem.166.5.1471; MAYER L, 1990, J CLIN INVEST, V86, P1255, DOI 10.1172/JCI114832; MCCLELLAND DBL, 1976, SCAND J IMMUNOL, V5, P909, DOI 10.1111/j.1365-3083.1976.tb03041.x; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; MEADE R, 1992, J IMMUNOL, V149, P521; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; MOREAU MC, 1988, INFECT IMMUN, V56, P2766; MOWAT AM, 1987, EUR J IMMUNOL, V17, P1673, DOI 10.1002/eji.1830171126; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; PANJA A, 1993, J EXP MED, V178, P1115, DOI 10.1084/jem.178.3.1115; PAVLI P, 1990, IMMUNOLOGY, V70, P40; PEREZMACHADO MA, EUR J IMMUNOL; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; ROUX ME, 1981, CELL IMMUNOL, V61, P141, DOI 10.1016/0008-8749(81)90361-0; Ruedl C, 1996, EUR J IMMUNOL, V26, P1801, DOI 10.1002/eji.1830260821; SANTOS LMB, 1994, CELL IMMUNOL, V157, P439, DOI 10.1006/cimm.1994.1240; Scheinecker C, 2002, J EXP MED, V196, P1079, DOI 10.1084/jem.20020991; SCOTT H, 1980, SCAND J IMMUNOL, V12, P77, DOI 10.1111/j.1365-3083.1980.tb00043.x; Shreedhar VK, 2003, INFECT IMMUN, V71, P504, DOI 10.1128/IAI.71.1.504-509.2003; SICINSKI P, 1990, GASTROENTEROLOGY, V98, P56; Spahn TW, 2001, EUR J IMMUNOL, V31, P1278, DOI 10.1002/1521-4141(200104)31:4<1278::AID-IMMU1278>3.0.CO;2-A; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; Sudo N, 1997, J IMMUNOL, V159, P1739; Trop S, 1999, HEPATOLOGY, V29, P746, DOI 10.1002/hep.510290334; Tsuji NM, 2001, IMMUNOLOGY, V103, P458, DOI 10.1046/j.1365-2567.2001.01265.x; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI 10.1016/mai.2003.1681; VERKASALO M, 1983, ACTA PAEDIATR SCAND, V72, P19, DOI 10.1111/j.1651-2227.1983.tb09657.x; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Viney JL, 1998, J IMMUNOL, V160, P5815; WALKER WA, 1974, GASTROENTEROLOGY, V67, P531; WANNEMUEHLER MJ, 1982, J IMMUNOL, V129, P959; WARSHAW AL, 1974, GASTROENTEROLOGY, V66, P987; WEAVER LT, 1984, ARCH DIS CHILD, V59, P236; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Williamson E, 1999, J IMMUNOL, V163, P3668; Yio XY, 1997, J BIOL CHEM, V272, P12786, DOI 10.1074/jbc.272.19.12786; YOUNG V R, 1987, American Journal of Clinical Nutrition, V45, P1323; Yu LCH, 2001, GASTROENTEROLOGY, V121, P370, DOI 10.1053/gast.2001.26470; Zhang XM, 2001, J IMMUNOL, V167, P4245; Zivny JH, 2001, CLIN IMMUNOL, V101, P158, DOI 10.1006/clim.2001.5103	93	223	237	2	22	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					3	12		10.1016/j.jaci.2004.11.008		10	Allergy; Immunology	Allergy; Immunology	886XS	WOS:000226267000001	15637539	
J	Bass, JL; Corwin, M; Gozal, D; Moore, C; Nishida, H; Parker, S; Schonwald, A; Wilker, RE; Stehle, S; Kinane, TB				Bass, JL; Corwin, M; Gozal, D; Moore, C; Nishida, H; Parker, S; Schonwald, A; Wilker, RE; Stehle, S; Kinane, TB			The effect of chronic or intermittent hypoxia on cognition in childhood: A review of the evidence	PEDIATRICS			English	Review						hypoxia; cognition; development; behavior; academic achievement	OBSTRUCTIVE SLEEP-APNEA; CONGENITAL HEART-DISEASE; DEFICIT-HYPERACTIVITY DISORDER; OXYGEN-SATURATION; TERM INFANTS; RESPIRATORY INSTABILITY; ACADEMIC-PERFORMANCE; SCHOOL PERFORMANCE; PROSPECTIVE COHORT; MOTOR DEVELOPMENT	Objective. A review of the evidence concerning the effect of chronic or intermittent hypoxia on cognition in childhood was performed by using both a systematic review of the literature and critical appraisal criteria of causality. Because of the significant impact of behavioral disorders such as attention-deficit/hyperactivity disorder on certain cognitive functions as well as academic achievement, the review also included articles that addressed behavioral outcomes. Methods. Both direct and indirect evidence were collected. A structured Medline search was conducted from the years 1966-2000 by using the OVID interface. Both English- and non - English- language citations were included. Significant articles identified by the reviewers up to 2003 were also included. To be included as direct evidence, an article needed to be an original report in a peer-reviewed journal with data on cognitive, behavioral, or academic outcomes in children up to 14 years old, with clinical conditions likely to be associated with exposure to chronic or intermittent hypoxia. Indirect evidence from other reviews and publications in closely related fields, including experimental studies in adults, was used to help formulate conclusions. Two reviewers screened abstracts and titles. Each article included as direct evidence received a structured evaluation by 2 reviewers. Adjudication of differences was performed by a group of 2 reviewers and a research consultant. After this review, tables of evidence were constructed that were used as the basis for group discussion and consensus development. Indirect evidence assigned by topic to specific reviewers was also presented as part of this process. A formal procedure was used to rank the studies by design strength. The critical appraisal criteria for causation described in Evidence Based Pediatrics and Child Health (Moyer V, Elliott E, Davis R, et al, eds. London, United Kingdom: BMJ Books; 2000: 46 - 55) were used to develop consensus on causality. Results. A total of 788 literature citations were screened. For the final analysis, 55 articles met the criteria for inclusion in the direct evidence. Of these, 43 (78.2%) reported an adverse effect. Of the 37 controlled studies, 31 (83.8%) reported an adverse effect. Adverse effects were noted at every level of arterial oxygen saturation and for exposure at every age level except for premature newborns. The studies were classified into 5 clinical categories: congenital heart disease (CHD), sleep-disordered breathing (SDB), asthma, chronic ventilatory impairment, and respiratory instability in infants. Two of these categories, CHD and SDB, which accounted for 42 (76.4%) of the included articles, fulfilled the Evidence Based Pediatrics and Child Health criteria for causation. The indirect evidence included 8 reviews, 1 meta-analysis, and 10 original reports covering the fields of adult anoxia, animal research, SDB in adults, natural and experimental high-altitude studies, perinatal hypoxic-ischemic encephalopathy, anemia, and carbon-monoxide poisoning. The studies of high-altitude and carbon-monoxide poisoning provided evidence for causality. Conclusions. Adverse impacts of chronic or intermittent hypoxia on development, behavior, and academic achievement have been reported in many well-designed and controlled studies in children with CHD and SDB as well as in a variety of experimental studies in adults. This should be taken into account in any situation that may expose children to hypoxia. Because adverse effects have been noted at even mild levels of oxygen desaturation, future research should include precisely defined data on exposure to all levels of desaturation.	Harvard Univ, Sch Med, MassGen Hosp Children, Newton Wellesley Hosp,Dept Pediat, Newton, MA 02462 USA; Boston Univ, Sch Med, CareStat Inc, Boston Med Ctr,Dept Pediat, Newton, MA USA; Univ Louisville, Kosair Childrens Hosp Res Inst, Dept Pediat, Louisville, KY 40292 USA; Tokyo Womens Med Univ, Maternal & Perinatal Ctr, Tokyo, Japan; Boston Univ, Sch Med, Boston Med Ctr, Dept Pediat, Boston, MA 02118 USA; Harvard Univ, Sch Med, Childrens Hosp, Med Ctr,Dev Med Ctr, Boston, MA USA; Greater Lawrence Family Hlth Ctr, Lawrence, MA USA; Harvard Univ, Sch Med, MassGen Hosp Children, Boston, MA USA	Bass, JL (reprint author), Harvard Univ, Sch Med, MassGen Hosp Children, Newton Wellesley Hosp,Dept Pediat, 2014 Washington St, Newton, MA 02462 USA.	jbass@partners.org		Corwin, Michael/0000-0002-6591-209X			AISENBERG RB, 1982, PEDIATR CARDIOL, V3, P133; AISENBERG RB, 1977, AM J DIS CHILD, V45, P595; AISENBERG RB, 1994, AM J DIS CHILD, V128, P335; ALI NJ, 1994, ARCH DIS CHILD, V71, P74; Ali NJ, 1996, EUR J PEDIATR, V155, P56, DOI 10.1007/BF02309859; ALI NJ, 1993, ARCH DIS CHILD, V68, P360; ARAM DM, 1985, J AM COLL CARDIOL, V6, P889; Askie LM, 2003, NEW ENGL J MED, V349, P959, DOI 10.1056/NEJMoa023080; BAHRKE MS, 1993, SPORTS MED, V16, P97, DOI 10.2165/00007256-199316020-00003; BARONI MA, 1994, J DEV BEHAV PEDIATR, V13, P158; Bass JL, 2002, PEDIATRICS, V110, P401, DOI 10.1542/peds.110.2.401; BASS JL, 1993, PEDIATRICS, V92, P544; BASS JL, 1995, PEDIATRICS, V96, P288; BENDER BG, 1987, PEDIATRICS, V79, P723; BERG BO, 1996, PRINCIPLES CHILD NEU, P310; BLACK L, 1979, CHILD DEV, V50, P561; Blunden S, 2000, J CLIN EXP NEUROPSYC, V22, P554, DOI 10.1076/1380-3395(200010)22:5;1-9;FT554; BROUILLETTE RT, 1982, J PEDIATR-US, V100, P31, DOI 10.1016/S0022-3476(82)80231-X; Caine D, 2000, J INT NEUROPSYCH SOC, V6, P86; Cannon TD, 2000, SCHIZOPHRENIA BULL, V26, P351; Cannon TD, 1999, DEV PSYCHOPATHOL, V11, P467, DOI 10.1017/S0954579499002163; CHANG YL, 1991, POSTGRAD MED J, V67, P471; Chervin RD, 1997, SLEEP, V20, P1185; Chervin RD, 2002, PEDIATRICS, V109, P449, DOI 10.1542/peds.109.3.449; CZERWENK.G, 1973, PADIATR PADOL, V8, P430; DEYKIN E, 1984, PEDIATRICS, V73, P638; DUNLEAVY RA, 1980, J CONSULT CLIN PSYCH, V48, P214, DOI 10.1037//0022-006X.48.2.214; FELDT RH, 1969, AM J DIS CHILD, V117, P281; Ferreira AM, 2000, PEDIATRICS, V106; FINDLEY LJ, 1986, CHEST, V90, P686, DOI 10.1378/chest.90.5.686; GARLAND H, 1967, Q J MED, V36, P445; Goldstein NA, 2000, ARCH OTOLARYNGOL, V126, P494; GOLDSTEIN RF, 1995, PEDIATRICS, V95, P238; Goodwin JL, 2003, SLEEP, V26, P587; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; Gozal D, 2001, PEDIATRICS, V107, P1394, DOI 10.1542/peds.107.6.1394; Greene M G, 1997, Curr Opin Pulm Med, V3, P456, DOI 10.1097/00063198-199711000-00013; GUILLEMINAULT C, 1981, LUNG, V159, P275, DOI 10.1007/BF02713925; GUILLEMINAULT C, 1976, PEDIATRICS, V58, P23; GUYTON A, 1991, TXB MED PHYSL, P465; Hansen DE, 1997, J CLIN CHILD PSYCHOL, V26, P304, DOI 10.1207/s15374424jccp2603_9; Harvey JMM, 1999, J PAEDIATR CHILD H, V35, P140; Harvey JMM, 1999, J PAEDIATR CHILD H, V35, P136; HECHT JT, 1991, AM J MED GENET, V41, P208, DOI 10.1002/ajmg.1320410215; Herman GE, 1999, J PEDIATR-US, V134, P206, DOI 10.1016/S0022-3476(99)70417-8; HILL AB, 1965, P ROY SOC MED, V58, P295; Hunt CE, 1999, J PEDIATR-US, V135, P580, DOI 10.1016/S0022-3476(99)70056-9; ISBISTER C, 1970, MED J AUSTRALIA, V2, P917; KAHN A, 1989, PEDIATRICS, V83, P668; KELLY D A, 1990, Neuropsychology Review, V1, P323, DOI 10.1007/BF01109028; KLEES M, 1985, J TOXICOL CLIN EXPER, V5, P301; KOONS AH, 1993, AM J PERINAT, V10, P208; KOROBKIN R, 1979, PEDIATRICS, V64, P369; KRAMER HH, 1989, J CHILD PSYCHOL PSYC, V30, P299, DOI 10.1111/j.1469-7610.1989.tb00242.x; KREMNEVA LF, 1972, ZH NEVROPATOL PSIKH, V8, P579; Lee AP, 2002, PEDIATR EMERG CARE, V18, P78, DOI 10.1097/00006565-200204000-00004; Lewin DS, 2002, SLEEP MED, V3, P5, DOI 10.1016/S1389-9457(01)00070-3; LINDE LM, 1970, ACTA PAEDIATR SCAND, V59, P169, DOI 10.1111/j.1651-2227.1970.tb08984.x; LINDE LM, 1967, J PEDIATR-US, V71, P198, DOI 10.1016/S0022-3476(67)80072-6; Lou HC, 1996, ACTA PAEDIATR, V85, P1266, DOI 10.1111/j.1651-2227.1996.tb13909.x; LOZOFF B, 1991, NEW ENGL J MED, V325, P687, DOI 10.1056/NEJM199109053251004; MARCUS CL, 1992, AM REV RESPIR DIS, V146, P1235; MARTIN PR, 1981, CAN MED ASSOC J, V124, P978; Menkes J.H., 1995, TXB CHILD NEUROLOGY, P873; Merchant JR, 2001, PEDIATRICS, V108, P647, DOI 10.1542/peds.108.3.647; MONTORI V, 2002, USERS GUIDES MED LIT, P533; Nagase H, 2002, PEDIATR INT, V44, P60, DOI 10.1046/j.1442-200X.2002.01507.x; NEWBURGER JW, 1984, NEW ENGL J MED, V310, P1495, DOI 10.1056/NEJM198406073102303; NIERMEYER S, 1995, NEW ENGL J MED, V333, P1248, DOI 10.1056/NEJM199511093331903; Nyakas C, 1996, PROG NEUROBIOL, V49, P1; O'Brien LM, 2003, PEDIATRICS, V111, P554, DOI 10.1542/peds.111.3.554; ODOUGHERTY M, 1985, NEUROLOGY, V35, P42; ODOUGHERTY M, 1984, J ABNORM PSYCHOL, V93, P178, DOI 10.1037//0021-843X.93.2.178; Owens J, 1998, PEDIATRICS, V102, P1178, DOI 10.1542/peds.102.5.1178; Owens J, 2000, SLEEP BREATH, V4, P67, DOI DOI 10.1055/S-2000-19814; Paditz E, 1996, Wien Med Wochenschr, V146, P327; POETS CF, 1993, PEDIATRICS, V92, P686; Poets CF, 1998, PEDIATR PULM, V26, P424, DOI 10.1002/(SICI)1099-0496(199812)26:6<424::AID-PPUL7>3.3.CO;2-7; POLLITT E, 1976, J PEDIATR-US, V88, P372, DOI 10.1016/S0022-3476(76)80250-8; RAINA P, 2000, EVIDENCE BASED PEDIA, P46; RAINS JC, 1995, CLIN PEDIATR, V34, P535, DOI 10.1177/000992289503401005; RHODES SK, 1995, J PEDIATR-US, V127, P741, DOI 10.1016/S0022-3476(95)70164-8; Richdale AL, 1999, J INTELL DISABIL RES, V43, P380, DOI 10.1046/j.1365-2788.1999.043005380.x; Rietveld S, 1999, J ASTHMA, V36, P409, DOI 10.3109/02770909909087283; ROSENTHAL A, 1967, AM J DIS CHILD, V114, P139; Rosso IM, 2000, AM J PSYCHIAT, V157, P801, DOI 10.1176/appi.ajp.157.5.801; Saugstad OD, 2001, PEDIATRICS, V108, P1203, DOI 10.1542/peds.108.5.1203; SCHECHTER MS, 2002, PEDIATRICS, V109; SHAYWITZ BA, 1993, SEMIN PERINATOL, V17, P357; SILBERT A, 1969, PEDIATRICS, V43, P192; SPILLMANN R, 1968, ACTA PAEDOPSYCHIATR, V35, P18; Stening W, 2002, PEDIATRICS, V110, P879, DOI 10.1542/peds.110.5.879; Stevens CP, 1999, NEUROPSYCHOLOGY, V13, P598, DOI 10.1037//0894-4105.13.4.598; Stieh J, 1999, NEUROPEDIATRICS, V30, P77, DOI 10.1055/s-2007-973464; STRADLING JR, 1990, LANCET, V335, P249, DOI 10.1016/0140-6736(90)90068-G; Toft PB, 1999, PEDIATR NEUROL, V21, P602, DOI 10.1016/S0887-8994(99)00046-6; Urschitz MS, 2003, AM J RESP CRIT CARE, V168, P464, DOI 10.1164/rccm.200212-1397OC; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P862; van Erp TGM, 2002, AM J PSYCHIAT, V159, P1514, DOI 10.1176/appi.ajp.159.9.1514; Verdoux H, 1997, AM J PSYCHIAT, V154, P1220; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; WEISSBLUTH M, 1983, J DEV BEHAV PEDIATR, V4, P119, DOI 10.1097/00004703-198306000-00008; WRIGHT M, 1994, ARCH DIS CHILD, V71, P64	103	223	231	7	43	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	SEP	2004	114	3					805	816		10.1542/peds.2004-0227		12	Pediatrics	Pediatrics	851AU	WOS:000223657600034	15342857	
J	Dick, CAJ; Brown, DM; Donaldson, K; Stone, V				Dick, CAJ; Brown, DM; Donaldson, K; Stone, V			The role of free radicals in the toxic and inflammatory effects of four different ultrafine particle types	INHALATION TOXICOLOGY			English	Article							PARTICULATE AIR-POLLUTION; NF-KAPPA-B; OXIDATIVE STRESS; CARBON-BLACK; TRANSITION-METALS; INTRATRACHEAL INSTILLATION; SURFACE-AREA; EXPOSURE; LUNG; GLUTATHIONE	PM10 contains an ultrafine component, which is generally derived from combustion processes. This ultrafine fraction may be a factor in the increases in exacerbations of respiratory disease and deaths from cardiorespiratory causes associated with transient increases in levels of PM10. By using four different ultrafine particles (carbon black, cobalt, nickel, and titanium dioxide), we set out to determine the attributes of the ultrafine particle (surface area, chemical composition, particle number, or surface reactivity) that contribute most to its toxicity and proinflammatory effects both in vivo and in vitro. Instillation of 125 mug ultrafine carbon black (UFCB) and ultrafine cobalt (UFCo) particles induced a significant influx of neutrophils at both 4 and 18 h postinstillation. Accompanying the influx of neutrophils was an increase in macrophage inflammatory protein-2 (MIP-2) (at 4 h) and an increase in gamma-glutamyl transpeptidase (at 18 h) in bronchoalveolar lavage fluid (BAL). Ultrafine nickel (UFNi) did not induce a significant increase in neutrophil influx until 18 h postinstillation. The increase in neutrophils induced by UFNi at this timepoint was comparable to that induced by UFCo and UFCB. UFTi did not induce a significant increase in neutrophils following instillation into the rat lung. The levels of MIP-2 observed at 4 h and neutrophil influx at 18 h induced by the particle samples were consistent with the pattern of surface free radical generation (as measured by the plasmid scission assay) whereby UFCo, UFCB, and UFNi all cause significant increases in inflammatory markers, as well as inducing a significant depletion of supercoiled plasmid DNA, indicative of hydroxyl radical generation. A role for free radicals and reactive oxygen species (ROS) in mediating ultrafine inflammation is further strengthened by the ability of the antioxidants N-acetylcysteine (NAC) and glutathione monoethyl ester (GSHme) to block the particle induced release of tumour necrosis factor-alpha (TNF-alpha) from alveolar macrophages in vitro. The ultrafine particles in PM10 may cause adverse effects via oxidative stress, and this could have implications for susceptible individuals. Susceptible individuals, such as those with COPD or asthma, already exhibit preexisting oxidative stress and hence are in a primed state for further oxidative stress induced by occupational or environmental particles.	Napier Univ, Sch Life & Hlth Sci, Edinburgh EH14 1DJ, Midlothian, Scotland	Scottish Biomed, Todd Campus,W Scotland Sci Pk,G200X, Glasgow, Lanark, Scotland.	colin.dick@scottish-biomedical.com					Beck-Speier I, 2001, ENVIRON HEALTH PERSP, V109, P613, DOI 10.2307/3454679; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Brown DM, 2000, OCCUP ENVIRON MED, V57, P685, DOI 10.1136/oem.57.10.685; Bucher JR, 1999, TOXICOL SCI, V49, P56, DOI 10.1093/toxsci/49.1.56; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; Dennekamp M, 2001, OCCUP ENVIRON MED, V58, P511, DOI 10.1136/oem.58.8.511; *DEP HLTH, 1993, ADV GROUP MED ASP AI; Donaldson K, 1998, J AEROSOL SCI, V29, P553, DOI 10.1016/S0021-8502(97)00464-3; Donaldson K, 1997, ENVIRON HEALTH PERSP, V105, P1285, DOI 10.2307/3433548; Donaldson K, 1996, TOXICOL LETT, V88, P293, DOI 10.1016/0378-4274(96)03752-6; Driscoll KE, 2000, TOXICOL LETT, V112, P177, DOI 10.1016/S0378-4274(99)00282-9; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; Gilmour PS, 1997, ENVIRON HEALTH PERSP, V105, P1313, DOI 10.2307/3433553; GRATTAGLIANO I, 1995, J PHARMACOL EXP THER, V272, P484; HALLIWELL B, 1989, FREE RADICAL BIO MED, V2, P1; Jimenez LA, 2000, TOXICOL APPL PHARM, V166, P101, DOI 10.1006/taap.2000.8957; Lay JC, 1999, AM J RESP CELL MOL, V20, P631; Li XY, 1999, INHAL TOXICOL, V11, P709; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Lundborg M, 1999, ENVIRON RES, V81, P309, DOI 10.1006/enrs.1999.3992; MACNEE W, 1991, AM J MED, V91, P60; NOLAN RP, 1987, BRIT J IND MED, V44, P687; Oberdorster G, 1996, PARTICUL SCI TECHNOL, V14, P135, DOI 10.1080/02726359608906690; Pahl HL, 1997, TRENDS BIOCHEM SCI, V22, P63, DOI 10.1016/S0968-0004(96)10073-6; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 2001, BIOCHEM PHARMACOL, V62, P787, DOI 10.1016/S0006-2952(01)00702-X; Rice TM, 2001, TOXICOL APPL PHARM, V177, P46, DOI 10.1006/taap.2001.9287; SCHRECK R, 1992, FREE RADICAL RES COM, V17, P221, DOI 10.3109/10715769209079515; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Serita F, 1999, IND HEALTH, V37, P353, DOI 10.2486/indhealth.37.353; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Stone V, 1998, TOXICOL IN VITRO, V12, P649, DOI 10.1016/S0887-2333(98)00050-2; Stone V, 2000, EUR RESPIR J, V15, P297, DOI 10.1034/j.1399-3003.2000.15b13.x; Tran CL, 2000, INHAL TOXICOL, V12, P1113, DOI 10.1080/08958370050166796; Zhang QW, 1998, J TOXICOL ENV HEAL A, V53, P423; Zhang QW, 1998, J OCCUP HEALTH, V40, P171, DOI 10.1539/joh.40.171	38	223	239	4	33	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0895-8378	1091-7691		INHAL TOXICOL	Inhal. Toxicol.	JAN	2003	15	1					39	52		10.1080/08958370304454		14	Toxicology	Toxicology	627CR	WOS:000179911900003	12476359	
J	Melani, AS; Bonavia, M; Cilenti, V; Cinti, C; Lodi, M; Martucci, P; Serra, M; Scichilone, N; Sestini, P; Aliani, M; Neri, M				Melani, Andrea S.; Bonavia, Marco; Cilenti, Vincenzo; Cinti, Cristina; Lodi, Marco; Martucci, Paola; Serra, Maria; Scichilone, Nicola; Sestini, Piersante; Aliani, Maria; Neri, Margherita		Grp Educ Assoc Italiana Pneumologi	Inhaler mishandling remains common in real life and is associated with reduced disease control	RESPIRATORY MEDICINE			English	Article						Asthma; COPD; MDI; DPI; Inhaler technique; Patient education	METERED-DOSE INHALER; DRY POWDER INHALERS; INHALATION TECHNIQUE; DRUG-DELIVERY; CLINICAL CONSEQUENCES; LUNG DEPOSITION; PATIENT; ASTHMA; MISUSE; VOLUMES	Proper inhaler technique is crucial for effective management of asthma and COPD. This multi-centre, cross-sectional, observational study investigates the prevalence of inhaler mishandling in a large population of experienced patients referring to chest clinics; to analyze the variables associated with misuse and the relationship between inhaler handling and health-care resources use and disease control. We enrolled 1664 adult subjects (mean age 62 years) affected mostly by COPD (52%) and asthma (42%). Respectively, 843 and 1113 patients were using MDIs and DP's at home; of the latter, the users of Aerolizer (R), Diskus (R), HandiHaler (R) and Turbuhaler (R) were 82, 467, 505 and 361. We have a total of 2288 records of inhaler technique. Critical mistakes were widely distributed among users of all the inhalers, ranging from 12% for MDIs, 35% for Diskus (R) and HandiHaler (R) and 44% for Turbuhaler (R). Independently of the inhaler, we found the strongest association between inhaler misuse and older age (p = 0.008), lower schooling (p = 0.001) and lack of instruction received for inhaler technique by health caregivers (p < 0.001). Inhaler misuse was associated with increased risk of hospitalization (p = 0.001), emergency room visits (p < 0.001), courses of oral steroids (p < 0.001) and antimicrobials (p < 0.001) and poor disease control evaluated as an ACT score for the asthmatics (p < 0.0001) and the whole population (p < 0.0001). We conclude that inhaler mishandling continues to be common in experienced outpatients referring to chest clinics and associated with increased unscheduled health-care resource use and poor clinical control. Instruction by health caregivers is the only modifiable factor useful for reducing inhaler mishandling (C) 2011 Elsevier Ltd. All rights reserved.	[Melani, Andrea S.] Azienda Osped Senese, Policlin Le Scotte, Siena, Italy; [Bonavia, Marco] Osped La Colletta, Arenzano, Ge, Italy; [Cilenti, Vincenzo] IRCCS Regina Elena, Rome, Italy; [Cinti, Cristina] Osped Bellaria, Bologna, Italy; [Lodi, Marco] Osped Copparo, Ferrara, Italy; [Martucci, Paola] Osped Antonio Cardarelli, Ctr Antifumo, Naples, Italy; [Serra, Maria] Osped Villa Scassi, Genoa, Italy; [Scichilone, Nicola] Univ Palermo, Dipartimento Med Pneumol Fisiol & Nutr Umana, I-90133 Palermo, Italy; [Sestini, Piersante] Univ Siena, Clin Malattie Apparato Resp, I-53100 Siena, Italy	Melani, AS (reprint author), Azienda Osped Senese, Policlin Le Scotte, Siena, Italy.	a.melani@ao-siena.toscana.it		Scichilone, Nicola/0000-0001-6400-6573	Chiesi; Artsana; AstraZeneca; GSK; Menarini; Novartis; Pfizer; Abbott	The study was supported from Chiesi, which does not interfere with the study design, analysis and interpretation of the results and writing of the manuscript.; Andrea S Melani has received consulting fees or for lectures from Artsana, AstraZeneca, Chiesi, GSK, Menarini, Novartis, Pfizer.; Margherita Neri has received consulting fees or for lectures from GSK, Menarini, Abbott, Chiesi, AstraZeneca, Pfizer.	Al-Showair RAM, 2007, CHEST, V131, P1776, DOI 10.1378/chest.06-2765; Basheti IA, 2008, PATIENT EDUC COUNS, V72, P26, DOI 10.1016/j.pec.2008.01.014; CHAPMAN KR, 1993, CHEST, V104, P1332, DOI 10.1378/chest.104.5.1332; ENGEL T, 1992, BRIT J CLIN PHARMACO, V33, P439; Epstein S, 2001, CHEST, V120, P1480, DOI 10.1378/chest.120.5.1480; FARR SJ, 1995, THORAX, V50, P639, DOI 10.1136/thx.50.6.639; Giraud V, 2002, EUR RESPIR J, V19, P246, DOI 10.1183/09031936.02.00218402; HINDLE M, 1993, THORAX, V48, P607, DOI 10.1136/thx.48.6.607; Kamin WES, 2003, J AEROSOL MED, V16, P21, DOI 10.1089/089426803764928329; Lavorini F, 2008, RESP MED, V102, P593, DOI 10.1016/j.rmed.2007.11.003; Leach CL, 2005, J AEROSOL MED, V18, P379, DOI 10.1089/jam.2005.18.379; Lenney J, 2000, RESP MED, V94, P496, DOI 10.1053/rmed.1999.0767; LINDGREN S, 1987, EUR J RESPIR DIS, V70, P93; MAHLER DA, 1988, CHEST, V93, P580, DOI 10.1378/chest.93.3.580; MCFADDEN ER, 1995, J ALLERGY CLIN IMMUN, V96, P278, DOI 10.1016/S0091-6749(95)70206-7; Melani AS, 2004, ANN ALLERG ASTHMA IM, V93, P439; MELANI AS, 2006, CLIN DRUG INVEST, V25, P543; Molimard M, 2003, J AEROSOL MED, V16, P249, DOI 10.1089/089426803769017613; Nathan RA, 2004, J ALLERGY CLIN IMMUN, V113, P59, DOI 10.1016/j.jaci.2003.09.008; NEWMAN SP, 1982, EUR J RESPIR DIS, V63, P57; NEWMAN SP, 1991, THORAX, V46, P712, DOI 10.1136/thx.46.10.712; NEWMAN SP, 1994, INT J PHARM, V102, P127, DOI 10.1016/0378-5173(94)90047-7; Newman SP, 2005, EUR RESPIR REV, V14, P102, DOI DOI 10.1183/09059180.05.00009605; Nsour WM, 2001, RESP MED, V95, P965, DOI 10.1053/rmed.2001.1190; QUANJER PH, 1993, EUR RESPIR J, V6, P5; SAUNDERS KB, 1965, BRIT MED J, V1, P1037; Serra-Batlles J, 2002, J AEROSOL MED, V15, P59, DOI 10.1089/08942680252908584; Sestinti P, 2006, J AEROSOL MED, V19, P127, DOI 10.1089/jam.2006.19.127; Thorsson L, 1998, EUR RESPIR J, V12, P1340, DOI 10.1183/09031936.98.12061340; van der Palen J, 1999, EUR RESPIR J, V14, P1034, DOI 10.1183/09031936.99.14510349; Verver S, 1996, FAM PRACT, V13, P35, DOI 10.1093/fampra/13.1.35	31	222	235	1	14	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111			RESP MED	Respir. Med.	JUN	2011	105	6					930	938		10.1016/j.rmed.2011.01.005		9	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	771DG	WOS:000291136800016	21367593	
J	McConnell, R; Islam, T; Shankardass, K; Jerrett, M; Lurmann, F; Gilliland, F; Gauderman, J; Avol, E; Kunzli, N; Yao, L; Peters, J; Berhane, K				McConnell, Rob; Islam, Talat; Shankardass, Ketan; Jerrett, Michael; Lurmann, Fred; Gilliland, Frank; Gauderman, Jim; Avol, Ed; Kuenzli, Nino; Yao, Ling; Peters, John; Berhane, Kiros			Childhood Incident Asthma and Traffic-Related Air Pollution at Home and School	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; child; epidemiology; vehicular traffic	CHILDRENS RESPIRATORY HEALTH; NITROGEN-DIOXIDE; ALLERGIC SENSITIZATION; ULTRAFINE PARTICLES; SIZE DISTRIBUTION; PUBLIC-SCHOOLS; MAJOR HIGHWAY; LOS-ANGELES; BUSY ROADS; EXPOSURE	BACKGROUND: Traffic-related air pollution has been associated with adverse cardiorespiratory effects, including increased asthma prevalence. However, there has been little study of effects of traffic exposure at school on new-onset asthma. OBJECTIVES: We evaluated the relationship of new-onset asthma with traffic-related pollution near homes and schools. Methods: Parent-reported physician diagnosis of new-onset asthma (n = 120) was identified during 3 years of follow-up of a cohort of 2,497 kindergarten and first-grade children who were asthma-and wheezing-free at study entry into the Southern California Children's Health Study. We assessed traffic-related pollution exposure based on a line source dispersion model of traffic volume, distance from home and school, and local meteorology. Regional ambient ozone, nitrogen dioxide (NO(2)), and particulate matter were measured continuously at one central site monitor in each of 13 study communities. Hazard ratios (HRs) for new-onset asthma were scaled to the range of ambient central site pollutants and to the residential interquartile range for each traffic exposure metric. RESULTS: Asthma risk increased with modeled traffic-related pollution exposure from roadways near homes [HR 1.51; 95% confidence interval (CI), 1.25-1.82] and near schools (HR 1.45; 95% CI, 1.06-1.98). Ambient NO(2) measured at a central site in each community was also associated with increased risk (HR 2.18; 95% CI, 1.18-4.01). In models with both NO(2) and modeled traffic exposures, there were independent associations of asthma with traffic-related pollution at school and home, whereas the estimate for NO(2) was attenuated (HR 1.37; 95% CI, 0.69-2.71). CONCLUSIONS: Traffic-related pollution exposure at school and homes may both contribute to the development of asthma.	[McConnell, Rob] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; [Shankardass, Ketan] St Michaels Hosp, Toronto, ON M5B 1W8, Canada; [Jerrett, Michael] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Lurmann, Fred] Sonoma Technol Inc, Petaluma, CA USA; [Kuenzli, Nino] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Kuenzli, Nino] Univ Basel, CH-4003 Basel, Switzerland; [Yao, Ling] City Hope Hosp Med Ctr, United Hlth Grp, Los Angeles, CA USA	McConnell, R (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	rmcconne@usc.edu	Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	National Institutes of Health [5P30ES007048, 5P01ES009581, 5 P01ES011627, 1R01ES016535, 5R01ES014447, 5R03ES014046, 5R01HL61768]; U.S. Environmental Protection Agency [R826708, RD831861, R831845, R82735201]; South Coast Air Quality Management District; Hastings Foundation	This study was supported by National Institutes of Health grants 5P30ES007048, 5P01ES009581, 5 P01ES011627, 1R01ES016535, 5R01ES014447, 5R03ES014046, and 5R01HL61768; U.S. Environmental Protection Agency grants R826708, RD831861, R831845, and R82735201; the South Coast Air Quality Management District, and the Hastings Foundation.	Appatova AS, 2008, J ENVIRON PLANN MAN, V51, P631, DOI 10.1080/09640560802208173; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Benson PE, 1989, CALINE4 DISPERSION M; Braman SS, 2006, CHEST S1, V130, p4S, DOI DOI 10.1378/CHEST.130.1_; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gehring U, 2009, AM J RESP CRIT CARE, V181, P596; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Green RS, 2004, ENVIRON HEALTH PERSP, V112, P61, DOI 10.1289/ehp.6566; Hastie T, 1990, GEN ADDITIVE MODELS; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Islam T, 2009, THORAX, V64, P197, DOI 10.1136/thx.2008.099366; Islam T, 2008, AM J RESP CRIT CARE, V177, P388, DOI 10.1164/rccm.200706-863OC; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Kim JJ, 2008, ENVIRON HEALTH PERSP, V116, P1274, DOI 10.1289/ehp.10735; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kim S, 2002, J AIR WASTE MANAGE, V52, P297; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Krewski D, 2009, RES REP HLTH EFF I, V140, P5; Kunzli N, 2003, AM J PUBLIC HEALTH, V93, P1494, DOI 10.2105/AJPH.93.9.1494; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Ning Z, 2007, ENVIRON SCI TECHNOL, V41, P6000, DOI 10.1021/es070653g; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; Oftedal B, 2009, ENVIRON HEALTH PERSP, V117, P839, DOI 10.1289/ehp.11491; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Ross Z, 2006, J EXPO SCI ENV EPID, V16, P106, DOI 10.1038/sj.jea.7500442; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a; Salam MT, 2007, AM J RESP CRIT CARE, V176, P1192, DOI 10.1164/rccm.200704-561OC; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; SAMET JM, 1987, CHEST, V91, pS74, DOI 10.1378/chest.91.6.74S; Sarnat JA, 2007, CURR OPIN PULM MED, V13, P63, DOI 10.1097/MCP.0b013e3280117d25; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Xue JP, 2004, J EXPO ANAL ENV EPID, V14, P222, DOI 10.1038/sj.jea.7500319; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032	50	221	231	13	81	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2010	118	7					1021	1026		10.1289/ehp.0901232		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	619MX	WOS:000279435400035	20371422	
J	Schroeder, HW; Cavacini, L				Schroeder, Harry W., Jr.; Cavacini, Lisa			Structure and function of immunoglobulins	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Antibody structure; antibody function; immunoglobulin structure; immunoglobulin function; immunoglobulin gene rearrangement; class switching; somatic hypermutation	MONOCLONAL-ANTIBODY; SOMATIC HYPERMUTATION; IGG1 ANTIBODIES; BINDING; LOCUS; GLYCOSYLATION; DIVERSITY; SEQUENCE; REGION; GENES	Immunoglobulins are heterodimeric proteins composed of 2 heavy and 2 light chains. They can be separated functionally into variable domains that bind antigens and constant domains that specify effector functions, such as activation of complement or binding to Fc receptors. The variable domains are created by means of a complex series of gene rearrangement events and can then be subjected to somatic hypermutation after exposure to antigen to allow affinity maturation. Each variable domain can be split into 3 regions of sequence variability termed the complementarity-determining regions (CDRs) and 4 regions of relatively constant sequence termed the framework regions. The 3 CDRs of the heavy chain are paired with the 3 CDRs of the light chain to form the antigen-binding site, as classically defined. The constant domains of the heavy chain can be switched to allow altered effector function while maintaining antigen specificity. There are 5 main classes of heavy chain constant domains. Each class defines the IgM, IgG, IgA, IgD, and IgE isotypes. IgG can be split into 4 subclasses, IgG1, IgG2, IgG3, and IgG4, each with its own biologic properties, and IgA can similarly be split into IgA1 and IgA2. (J Allergy Clin Immunol 2010;125:S41-52.)	[Schroeder, Harry W., Jr.] Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Schroeder, Harry W., Jr.] Univ Alabama, Dept Microbiol, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Schroeder, Harry W., Jr.] Univ Alabama, Dept Genet, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA; [Cavacini, Lisa] Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02215 USA	Schroeder, HW (reprint author), Univ Alabama, Dept Med, Div Clin Immunol & Rheumatol, SHEL 176,1530 3rd Ave S, Birmingham, AL 35294 USA.	hwsj@uab.edu			National Institutes of Health/National Institute of Allergy and Infectious Diseases; United States Immunodeficiency Network; NABI Pharmaceuticals	Disclosure of potential conflict of interest: H. W. Schroeder receives research support from the National Institutes of Health/National Institute of Allergy and Infectious Diseases, the United States Immunodeficiency Network, and NABI Pharmaceuticals and is a councilor for the Henry Kunkel Society. L. Cavacini is a consultant for GTC Biotherapeutics and receives research support from the National Institutes of Health.	ALBERT H, 2009, P NATL ACAD SCI USA, V105, P15005; Anthony RM, 2008, P NATL ACAD SCI USA, V105, P19571, DOI 10.1073/pnas.0810163105; Arnold JN, 2007, ANNU REV IMMUNOL, V25, P21, DOI 10.1146/annurev.immunol.25.022106.141702; Arnold JN, 2006, IMMUNOL LETT, V106, P103, DOI 10.1016/j.imlet.2006.05.007; Bankovich AJ, 2007, SCIENCE, V316, P291, DOI 10.1126/science.1139412; Boes M, 2000, MOL IMMUNOL, V37, P1141, DOI 10.1016/S0161-5890(01)00025-6; BRODEUR PH, 1984, EUR J IMMUNOL, V14, P922, DOI 10.1002/eji.1830141012; Cavacini LA, 2003, AIDS RES HUM RETROV, V19, P785, DOI 10.1089/088922203769232584; Chang TW, 2007, ADV IMMUNOL, V93, P63, DOI 10.1016/S0065-2776(06)93002-8; Collin M, 2008, P NATL ACAD SCI USA, V105, P4265, DOI 10.1073/pnas.0711271105; Corbett SJ, 1997, J MOL BIOL, V270, P587, DOI 10.1006/jmbi.1997.1141; Corthesy B, 2007, J IMMUNOL, V178, P27; Dorner T, 1998, EUR J IMMUNOL, V28, P3384; Dudley DD, 2005, ADV IMMUNOL, V86, P43, DOI 10.1016/S0065-2776(04)86002-4; Geisberger R, 2006, IMMUNOLOGY, V118, P429, DOI 10.1111/j.1365-2567.2006.02386.x; HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0; HARPAZ Y, 1994, J MOL BIOL, V238, P528, DOI 10.1006/jmbi.1994.1312; Hinton PR, 2004, J BIOL CHEM, V279, P6213, DOI 10.1074/jbc.C300470200; HONJO T, 1983, ANNU REV IMMUNOL, V1, P499, DOI 10.1146/annurev.iy.01.040183.002435; JAZWINSKA EC, 1988, AM J HUM GENET, V43, P175; Kanda Y, 2007, GLYCOBIOLOGY, V17, P104, DOI 10.1093/glycob/cwl057; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; Kirkham P M, 1994, Semin Immunol, V6, P347, DOI 10.1006/smim.1994.1045; LEDER P, 1982, SCI AM, V246, P102; LEE SK, 1992, ARTHRITIS RHEUM, V35, P905, DOI 10.1002/art.1780350809; Liu HC, 2006, IMMUNOL LETT, V106, P144, DOI 10.1016/j.imlet.2006.05.011; Matsuda F, 1998, J EXP MED, V188, P2151, DOI 10.1084/jem.188.11.2151; Matthias P, 2005, NAT REV IMMUNOL, V5, P497, DOI 10.1038/nri1633; Miranda LR, 2007, J IMMUNOL, V178, P7132; Muramatsu Masamichi, 2007, Adv Immunol, V94, P1, DOI 10.1016/S0065-2776(06)94001-2; Natsume A, 2005, J IMMUNOL METHODS, V306, P93, DOI 10.1016/j.jim.2005.07.025; Neuberger MS, 2008, IMMUNOL CELL BIOL, V86, P124, DOI 10.1038/sj.icb.7100160; Nimmerjahn F, 2007, ADV IMMUNOL, V96, P179, DOI 10.1016/S0065-2776(07)96005-8; NORMANSELL DE, 1987, DIAGN CLIN IMMUNOL, V5, P115; Parlowsky T, 2003, J AM ACAD DERMATOL, V48, P623, DOI 10.1067/mjd.2003.170; Petkova SB, 2006, INT IMMUNOL, V18, P1759, DOI 10.1093/intimm/dxl110; Rada C, 1998, IMMUNITY, V9, P135, DOI 10.1016/S1074-7613(00)80595-6; Riesbeck K, 2006, CRIT REV IMMUNOL, V26, P353; Roux KH, 1998, P NATL ACAD SCI USA, V95, P11804, DOI 10.1073/pnas.95.20.11804; Sazinsky SL, 2008, P NATL ACAD SCI USA, V105, P20167, DOI 10.1073/pnas.0809257105; Scharf O, 2001, J VIROL, V75, P6558, DOI 10.1128/JVI.75.14.6558-6565.2001; Siberil S, 2006, CLIN IMMUNOL, V118, P170, DOI 10.1016/j.clim.2005.10.008; Smith KA, 2004, J CLIN PATHOL, V57, P912, DOI 10.1136/jcp.2003.014407; Stubbe H, 2000, J IMMUNOL, V164, P1952; TONEGAWA S, 1983, NATURE, V302, P575, DOI 10.1038/302575a0; Torres MAJ, 2008, PHILIPP AGRIC SCI, V91, P7; TORRES RM, 2008, CLIN IMMUNOLOGY PRIN, P53, DOI 10.1016/B978-0-323-04404-2.10004-1; Vincke C, 2009, J BIOL CHEM, V284, P3273, DOI 10.1074/jbc.M806889200; WILLIAMS AF, 1988, ANNU REV IMMUNOL, V6, P381, DOI 10.1146/annurev.iy.06.040188.002121; Woof JM, 2005, IMMUNOL REV, V206, P64, DOI 10.1111/j.0105-2896.2005.00290.x; Yeh SW, 2006, CLIN IMMUNOL, V120, P68, DOI 10.1016/j.clim.2006.03.006; Zachau H. G., 1995, IMMUNOGLOBULIN GENES, P173, DOI 10.1016/B978-012053640-5/50011-2	52	221	224	11	103	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S41	S52		10.1016/j.jaci.2009.09.046		12	Allergy; Immunology	Allergy; Immunology	629CC	WOS:000280170600005	20176268	
J	Kim, JJ; Smorodinsky, S; Lipsett, M; Singer, BC; Hodgson, AT; Ostro, B				Kim, JJ; Smorodinsky, S; Lipsett, M; Singer, BC; Hodgson, AT; Ostro, B			Traffic-related air pollution near busy roads - The East Bay children's respiratory health study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollution; asthma; bronchitis; epidemiology; vehicle emissions	SOUTHERN CALIFORNIA COMMUNITIES; CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION; CARBON CONCENTRATION; DIFFERING LEVELS; LUNG-FUNCTION; SYMPTOMS; EXPOSURE; PARTICLES; AMBIENT	Recent studies, primarily in Europe, have reported associations between respiratory symptoms and residential proximity to traffic; however, few have measured traffic pollutants or provided information about local air quality. We conducted a school-based, cross-sectional study in the San Francisco Bay Area in 2001. Information on current bronchitis symptoms and asthma, home environment, and demographics was obtained by parental questionnaire (n = 1,109). Concentrations of traffic pollutants (particulate matter, black carbon, total nitrogen oxides [NOX], and nitrogen dioxide [NO2]) were measured at 10 school sites during several seasons. Although pollutant concentrations were relatively low, we observed differences in concentrations between schools nearby versus those more distant (or upwind) from major roads. Using a two-stage multiple-logistic regression model, we found associations between respiratory symptoms and traffic-related pollutants. Among,those living at their current residence for at least 1 year, the adjusted odds ratio for asthma in relationship to an interquartile difference in NOX was 1.07 (95% confidence interval, 1.00-1.14). Thus, we found spatial variability in traffic pollutants and associated differences in respiratory symptoms in a region with good air quality. Our findings support the hypothesis that traffic-related pollution is associated with respiratory symptoms in children.	Calif Environm Protect Agcy, Off Environm Hlth Hazard Assessment, Oakland, CA 94612 USA; Lawrence Berkeley Lab, Dept Atmospher Sci, Berkeley, CA USA; Lawrence Berkeley Lab, Indoor Environm Dept, Environm Energy Technol Div, Berkeley, CA USA	Ostro, B (reprint author), Calif Environm Protect Agcy, Off Environm Hlth Hazard Assessment, 1515 Clay St,16th Floor, Oakland, CA 94612 USA.	bostro@oehha.ca.gov	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Bornehag CG, 2001, INDOOR AIR, V11, P72; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; *CAL DEP HLTH SERV, 2004, TOB CONTR SECT CAL T; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Cook DG, 1997, THORAX, V52, P1081; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; EDWARDS JD, 1983, ATMOS ENVIRON, V17, P2337, DOI 10.1016/0004-6981(83)90233-0; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; GUNDEL LA, 1984, SCI TOTAL ENVIRON, V36, P197, DOI 10.1016/0048-9697(84)90266-3; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Kim JJ, 2002, EPIDEMIOLOGY, V13, pS100; Klinnert MD, 2002, AM J PUBLIC HEALTH, V92, P792, DOI 10.2105/AJPH.92.5.792; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644; Martinez FD, 1997, CIBA F SYMP, V206, P233; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Singer BC, 2004, ATMOS ENVIRON, V38, P393, DOI 10.1016/j.atmosenv.2003.10.005; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015	38	221	224	5	63	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2004	170	5					520	526		10.1164/rccm.200403-2810C		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	850IR	WOS:000223605000011	15184208	
J	Gilliland, FD; Li, YF; Saxon, A; Diaz-Sanchez, D				Gilliland, FD; Li, YF; Saxon, A; Diaz-Sanchez, D			Effect of glutathione-S-transferase M1 and P1 genotypes on xenobiotic enhancement of allergic responses: randomised, placebo-controlled crossover study	LANCET			English	Article							DIESEL EXHAUST PARTICLES; AIR-POLLUTION; IN-VIVO; NASAL CHALLENGE; CYTOKINE PRODUCTION; TOBACCO-SMOKE; LUNG-CANCER; ASTHMA; EXPOSURE; CHILDREN	Background Particulate pollution is associated with the occurrence of asthma and allergy. The model pollutant, diesel exhaust particles, can participate with allergens in starting and exacerbating allergic airway diseases in part by production of reactive oxygen species. Glutathione-S-transferases (GSTs) can metabolise reactive oxygen species and detoxify xenobiotics present in diesel exhaust particles. We tested the hypothesis that null genotypes for GSTM1 and GSTT1, and GSTP1 codon 105 variants (I105 and V105) are key regulators of the adjuvant effects of diesel exhaust particles on allergic responses. Methods Patients sensitive to the ragweed allergen were challenged intranasally with allergen alone and with allergen plus diesel exhaust particles in a randomised order at separate visits. Nasal allergen-specific IgE, histamine, interleukin 4, and interferon gamma concentrations were measured before and 24 h after challenge. Findings Individuals with GSTM1 null or the GSTP1 I105 wildtype genotypes showed enhanced nasal allergic responses in the presence of diesel exhaust particles. Compared with patients with a functional GSTM1 genotype, GSTM1 null patients had a significantly larger increase in IgE (median 102.5 U/mL [range 1.0-510.5] vs 45.5 U/mL [1.5-60.6], p=0.03) and histamine (14.0 nmol/L [-0.2-24.7] vs 7.4 nmol/L [1.2-12.3], p=0.02) after diesel exhaust particles plus allergen challenge. The I105 GSTP1 genotype was associated with an increase in IgE (120.3 U/mL [6.7-510.5] vs 27.7 U/mL [-1.5-60.6], p=0.03) and histamine (13.8 nmol/L [3.1-24.7] vs 5.2 nmol/L [-0.2-19.6], p=0.01) after challenge with diesel exhaust particles and allergens. The diesel exhaust particles enhancement was largest in patients with both the GSTM1 null and GSTP1 I/I genotypes. Interpretation GSTM1 and GSTP1 modify the adjuvant effect of diesel exhaust particles on allergic inflammation.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol,Hart & Louis Lab, Los Angeles, CA USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [HL-61768]; NIAID NIH HHS [AI-40945]; NIEHS NIH HHS [ES-07048, ES-09581]		Al-Humadi NH, 2002, ENVIRON HEALTH PERSP, V110, P349; Barfknecht T R, 1982, Dev Toxicol Environ Sci, V10, P277; BASCOM R, 1991, PHARMACOGENETICS, V1, P102, DOI 10.1097/00008571-199111000-00008; BASCOM R, 1990, AM REV RESPIR DIS, V142, P594; D'Amato G, 2002, Monaldi Arch Chest Dis, V57, P136; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DIAZSANCHEZ D, 2000, IMMUNOLOGY, V101, P1; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P346, DOI 10.1164/rccm.2111048; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hiura TS, 2000, J IMMUNOL, V165, P2703; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; MANCHESTER J, 2001, DETERMINATION ELEM B, P1; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Ng D, 1998, J IMMUNOL, V161, P942; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; SAGAI M, 1998, INVOLVEMENTS SUPEROX; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; ToFigueras J, 1997, CARCINOGENESIS, V18, P1529, DOI 10.1093/carcin/18.8.1529; Trenga CA, 1999, OCCUP ENVIRON MED, V56, P544; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; WILLIAMS PT, 1986, FUEL, V65, P1150, DOI 10.1016/0016-2361(86)90184-5; XU GB, 1987, AEROSOL SCI TECH, V7, P117, DOI 10.1080/02786828708959152	44	220	227	2	13	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JAN 10	2004	363	9403					119	125		10.1016/S0140-6736(03)15262-2		7	Medicine, General & Internal	General & Internal Medicine	761WV	WOS:000187939200009	14726165	
J	Landrigan, PJ; Schechter, CB; Lipton, JM; Fahs, MC; Schwartz, J				Landrigan, PJ; Schechter, CB; Lipton, JM; Fahs, MC; Schwartz, J			Environmental pollutants and disease in American children: Estimates of morbidity, mortality, and costs for lead poisoning, asthma, cancer, and developmental disabilities	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; cancer; developmental disabilities; environmental pediatrics; health economics; lead poisoning	UNITED-STATES; OCCUPATIONAL INJURY; CHILDHOOD CANCERS; AIR-POLLUTION; HEALTH; TRENDS; EXPOSURE; BENEFITS; ILLNESS; RISK	In this study, we aimed to estimate the contribution of environmental pollutants to the incidence, prevalence, mortality, and costs of pediatric disease in American children. We examined four categories of illness: lead poisoning, asthma, cancer, and neurobehavioral disorders. To estimate the proportion of each attributable to toxins in the environment, we used an environmentally attributable fraction (EAF) model. EAFs for lead poisoning, asthma, and cancer were developed by panels of experts through a Delphi process, whereas that for neurobehavioral disorders was based on data from the National Academy of Sciences. We define environmental pollutants as toxic chemicals of human origin in air, food, water, and communities. To develop estimates of costs, we relied on data from the U.S. Environmental Protection Agency, Centers for Disease Control and Prevention, National Center for Health Statistics, the Bureau of Labor Statistics, the Health Care Financing Agency, and the Practice Management Information Corporation. EAFs were judged to be 100% for lead poisoning, 30% for asthma (range, 10-35%), 5% for cancer (range, 2-10%), and 10% for neurobehavioral disorders (range, 5-20%). Total annual costs are estimated to be $54.9 billion (range $48.8-64.8 billion): $43.4 billion for lead poisoning, $2.0 billion for asthma, $0.3 billion for childhood cancer, and $9.2 billion for neurobehavioral disorders. This sum amounts to 2.8 percent of total U.S. health care costs. This estimate is likely low because it considers only four categories of illness, incorporates conservative assumptions, ignores costs of pain and Suffering, and does not include late complications for which etiologic associations are poorly quantified. The costs of pediatric environmental disease are high, in contrast with the limited resources directed to research, tracking, and prevention.	CUNY Mt Sinai Sch Med, Dept Community & Prevent Med, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Ctr Childrens Hlth & Environm, New York, NY 10029 USA; CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; New Sch Social Res, Ctr Hlth Policy Res, New York, NY 10011 USA; Harvard Univ, Sch Publ Hlth, Environm Epidemiol Program, Boston, MA 02115 USA	Landrigan, PJ (reprint author), CUNY Mt Sinai Sch Med, Dept Community & Prevent Med, Box 1057,1 Gustave L Levy Pl, New York, NY 10029 USA.						ADAMS PF, 1995, VITAL HLTH STAT, V10, P81; Arrow KJ, 1996, SCIENCE, V272, P221, DOI 10.1126/science.272.5259.221; ATSDR (Agency for Toxic Substances and Disease Registry), 1993, TOX PROF LEAD; BEHRMANN RE, 1999, NELSON TXB PEDIAT, P664; BERKOWITZ GS, 2000, ENVIRON RES, V85, P59; Brook R H, 1986, Int J Technol Assess Health Care, V2, P53; BUXBAUM L, 2000, ETIOLOGY MENTAL RETA; Byers RK, 1943, AM J DIS CHILD, V66, P471; Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P141; *CDCP, 1995, MMWR-MORBID MORTAL W, V43, P952; CHESTNUT LG, 2000, NATL COSTS ASTHMA 19; Cohen MA, 1998, J QUANT CRIMINOL, V14, P5, DOI 10.1023/A:1023092324459; Colt JS, 1998, ENVIRON HEALTH PERSP, V106, P909, DOI 10.2307/3434208; *CTR DEF INF, MIL COSTS REAL TOT; Daniels JL, 1997, ENVIRON HEALTH PERSP, V105, P1068, DOI 10.1289/ehp.971051068; DEKONING HJ, 1991, INT J CANCER, V49, P531, DOI 10.1002/ijc.2910490410; DEVATHAIRE F, 1989, BRIT J CANCER, V59, P448, DOI 10.1038/bjc.1989.92; DEVESA SS, 1995, J NATL CANCER I, V87, P175, DOI 10.1093/jnci/87.3.175; DiLiberti JH, 1999, AM J PUBLIC HEALTH, V89, P1883, DOI 10.2105/AJPH.89.12.1883; Douglass J, 1990, J FORENSIC EC, V4, P25, DOI 10.5085/0898-5510-4.1.25; *DUK U CTR HLTH PO, COST ILLN DIS RANK; *EX OFF PRES OFF S, 1997, INV OUR FUT NAT RES; FAHS MC, 1992, ANN INTERN MED, V117, P520; FAHS MC, 1989, AM J IND MED, V16, P437, DOI 10.1002/ajim.4700160409; Farquhar I, 1998, RES HUM CAP, V12, P35; FINK A, 1984, AM J PUBLIC HEALTH, V74, P979, DOI 10.2105/AJPH.74.9.979; Goldman LR, 2000, ENVIRON HEALTH PERSP, V108, P443, DOI 10.2307/3454535; Greenland S, 2000, EPIDEMIOLOGY, V11, P624, DOI 10.1097/00001648-200011000-00003; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Haggerty RJ, 1975, CHILD HLTH COMMUNITY; *HLTH CAR FIN ADM, NAT HLTH EXP SOURC F; HONEYCUTT A, 2000, 062109 RES TRIANGL I; Hussain N, 2002, PEDIATRICS, V109, P473, DOI 10.1542/peds.109.3.473; Institute of Medicine, 1981, COSTS ENV REL HLTH E; Keating Daniel P., 1999, DEV HLTH WEALTH NATI; KIELY M, 1987, EPIDEMIOL REV, V9, P194; KOPLAN JP, 1980, JAMA-J AM MED ASSOC, V244, P2736, DOI 10.1001/jama.244.24.2736; LAMPHEAR BP, 2000, PUBLIC HLTH REP, V115, P521; LANDRIGAN PJ, 1995, FUTURE CHILD, V5, P34, DOI 10.2307/1602356; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; Leigh JP, 2000, COSTS OCCUPATIONAL I; MAGE DT, 1992, WHOPEP924; MARQUIS MS, 1992, EC CONSEQUENCE WORK; MEADOWS AT, 1988, B CANCER, V75, P125; MIKE V, 1982, LANCET, V2, P1326; Miller TR, 1995, ACCIDENT ANAL PREV, V27, P741, DOI 10.1016/0001-4575(95)00022-4; *NAT AC SCI, 1984, TOX TEST NEEDS PRIOR; *NAT AC SCI COMM D, 2000, SCI FRONT DEV TOX RI; *NAT HEART BLOOD L, 1997, NIH PUBL NAT HEART B; National Research Council, 1993, PEST DIETS INF CHILD; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NEEDLEMAN HL, IN PRESS NEUROBEHAV; NEUMARK D, 1991, J OCCUP ENVIRON MED, V33, P971; Ostro B, 1998, ENVIRON RES, V76, P94, DOI 10.1006/enrs.1997.3799; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; Paulozzi LJ, 1997, PEDIATRICS, V100, P831, DOI 10.1542/peds.100.5.831; *PEW ENV HLTH COMM, ATT ASTHM WHY AM NEE; Pirkle JL, 1998, ENVIRON HEALTH PERSP, V106, P745, DOI 10.1289/ehp.98106745; *PMIC, 1995, PHYS FEES COMPR GUID; Rice D P, 1985, Health Care Financ Rev, V7, P61; RICE DP, 1985, CANC CARE COST DRGS, P39; Rice D. P., 1989, COST INJURY US REPOR; ROBISON LL, 1995, ENVIRON HEALTH PERSP, V103, P111, DOI 10.2307/3432358; Rogan WJ, 2001, NEW ENGL J MED, V344, P1421, DOI 10.1056/NEJM200105103441902; Salkever DS, 1995, ENVIRON RES, V70, P1, DOI 10.1006/enrs.1995.1038; SAYER G, UNPUB; SCHWARTZ J, 1994, ENVIRON RES, V66, P105, DOI 10.1006/enrs.1994.1048; SCHWARTZ J, 1991, ENVIRON HEALTH PERSP, V91, P71, DOI 10.2307/3430985; Schwartz J, 1985, EPA2300585006; SILBER JH, 1992, J CLIN ONCOL, V10, P1390; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Smith KR, 1999, EPIDEMIOLOGY, V10, P573, DOI 10.1097/00001648-199909000-00027; Stempel DA, 1996, ARCH FAM MED, V5, P36, DOI 10.1001/archfami.5.1.36; TAYLOR WR, 1992, PEDIATRICS, V90, P657; *US BUR CENS, 1993, CURR POP REP SER; *US BUR LAB STAT, 1999, CPI DET REP; US Census Bureau, ANN POP EST AG GROUP; *US EPA, 1999, COST ILLN; *US EPA, 1996, ENV THREATS CHILDR H; US Environmental Protection Agency, 1997, BEN COSTS CLEAN AIR; U.S. EPA, 1999, BEN COSTS CLEAN AIR; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; WOODWELL DA, 2000, ADV DATA VITAL HLTH, V315; ZAHM SH, 1995, ENVIRON HEALTH PERSP, V103, P177, DOI 10.2307/3432371; Zahm SH, 1998, ENVIRON HEALTH PERSP, V106, P893, DOI 10.2307/3434207	90	220	225	6	41	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2002	110	7					721	728				8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	585VZ	WOS:000177546400033	12117650	
J	Arshad, SH; Tariq, SM; Matthews, S; Hakim, E				Arshad, SH; Tariq, SM; Matthews, S; Hakim, E			Sensitization to common allergens and its association with allergic disorders at age 4 years: A whole population birth cohort study	PEDIATRICS			English	Article						atopy; allergic diseases; asthma; eczema; rhinitis; skin-prick test	SKIN-TEST REACTIVITY; HOUSE-DUST MITE; CHILDHOOD ASTHMA; SERUM IGE; AIRWAY RESPONSIVENESS; ENVIRONMENTAL-FACTORS; INHALANT ALLERGENS; RISK-FACTORS; HAY-FEVER; ATOPY	Background. Atopy is defined as the genetic propensity to develop immunoglobulin E antibodies in response to exposure to allergens and assessed by skin prick test responses to common allergens. Although it is generally agreed that atopy is an important risk factor for allergic diseases such as asthma, rhinitis, and eczema, the extent to which atopy accounts for these diseases is controversial. Objective. We aim to describe the prevalence of sensitization to common allergens and investigate the degree of association of atopy (as defined by positive skin prick test to 1 or more common allergens) to asthma, rhinitis, and eczema in a birth cohort at the age of 4 years. Methods. A birth cohort of 1456 children was recruited over a 14-month period (1989-1990). These children have been seen previously at 1 and 2 years of age. At 4 years, 1218 children were reviewed and an interview was administered or postal questionnaire was completed for the presence of allergic diseases (asthma, rhinitis, and eczema). Additionally, in 981 children, skin prick tests with a battery of 12 common allergens were performed. Allergens were house dust mite (Dermatophagoides pteronyssimus), grass pollen mix, cat, dog, Alternaria alternata, Cladosporium herbarum, cow's milk, hen's egg, soya, cod, wheat, and peanut. A mean wheal diameter of at least 3 mm greater than the negative control was taken as positive. This analysis is confined to the 981 (67% of the original population) who also had skin prick tests to the standard battery. chi (2) tests were used to test the univariate association between each allergic disease and positive skin test. Multiple logistic regression analysis was performed to obtain the adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for the independent effect of sensitization to each allergen on allergic disease, adjusting for the effect of sensitization to other allergens. To ascertain how much of allergic disease is attributable to atopy, we estimated the population-attributable risk. This was calculated with the formula: P(R - 1) where R is the OR for the allergic disease under consideration and P is the proportion of atopy in children with that disease. Results. Children who were skin prick-tested at 4 years were similar in most characteristics to the rest of the population, except that they had a higher prevalence of allergic disease. Allergic disorders (asthma, rhinitis, and eczema) were present in 276 (28.1%) of 981. One hundred ninety-two (19.6%) children were atopic (positive reaction to 1 or more allergens). Sensitization to inhalant allergens was relatively common (19.2%) as compared with food allergens (3.5%). House dust mite (11.9%), grass pollen (7.8%), and cat (5.8%) were the most common positive reactions. A test to the 4 most common allergens (house dust mite, grass pollen, cat, and A alternata) could detect 94% of the atopic children. Sensitization to the 4 most common allergens was strongly associated with the presence of allergic disorders. There was a graded effect with the potent allergens, such as house dust mite, having the greatest impact. For example, 50% of children sensitized to house dust mite had asthma as opposed to 44% sensitized to cat, 42% sensitized to grass pollen, and 32% sensitized to A alternata. Overall, 68.4% of children sensitized to house dust mite had asthma, eczema, and/or rhinitis. The respective figures for grass pollen, cat, and A alternata were 64.9%, 66.7%, and 57.4%. The proportion of children sensitized to cat was not higher in households with cat ownership (households with cats: 5.1% [19/374]; households without cats: 6.2% [36/580]; not significant [NS]). Similarly, no difference was seen in sensitization to dog in households with and without dogs (households with dogs: 1.8% [5/282]; households without dogs: 2.8% [19/673]; NS). Boys were atopic more often than girls at this age (male: 112 of 497 [22.5%] vs female: 80 of 484 [16.5%]; OR: 1.47, 95% CI: 1.07-2.02). Male preponderance was observed with most allergens, but this was statistically significant only for house dust mite (male: 75/497 [15.1%] vs female: 42/484 [8.7%]; OR: 1.87; CI: 1.25-2.79) and grass pollen (male: 51/497 [10.3%] vs female: 26/484 [5.4%]; OR: 2.01; CI: 1.23-3.29). An independent effect of allergen sensitization on asthma was observed only with house dust mite with an OR of 8.07 (CI: 4.60-14.14). The highest independent risk for rhinitis was sensitization to grass pollen (OR: 5.02; CI: 2.21-11.41), and for eczema, sensitization to peanut (OR: 4.65; CI: 1.02-21.34). The majority of children (98/192) were sensitized to >1 allergen. A graded effect was observed with the risk of allergic disease in the child increasing with the number of positive skin prick test reactions. This effect was consistent throughout the spectrum of allergic diseases (asthma, eczema, and rhinitis). Nearly 80% of the children with positive skin test reactions to 4 or more allergens had asthma, eczema, and/or rhinitis compared with 20%, if they were nonatopic. The prevalence of atopy in asthmatic children was 44%. With an OR of 4.56, the population-attributable risk was calculated to be 35%. Fifty-five percent of children with rhinitis were atopic, and the OR of rhinitis was 5.85. Therefore, 46% of the cases of rhinitis could be attributable to atopy. The population-attributable risk of atopy for eczema was 32% (the prevalence of atopy in children with eczema: 43%; and the OR for the development of eczema: 3.86). Conclusion. Atopy is closely associated with asthma, rhinitis, and eczema at 4 years of age, with a direct and linear relationship. However, the proportion of cases of allergic disease attributable to atopy is <50%. We propose a model for the development of allergic disorders, where 30% to 40% of cases of allergic disease (asthma, eczema, and rhinitis) in early childhood are attributable to atopy and 60% to 70% of cases could be accounted for by organ-based and other factors.	St Marys Hosp, DAvid Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, England	Arshad, SH (reprint author), St Marys Hosp, DAvid Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, England.						ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; DUFF AL, 1993, PEDIATRICS, V92, P535; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; KEUR J, 1992, J ALLERGY CLIN IMMUN, V90, P358; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; MACAUBAS C, 1999, PERINATAL EARLY CHIL; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; NORMAN E, 1994, ALLERGY, V49, P808; OLESEN AB, 1997, BRIT MED J, V314, P1004; Pastorello EA., 1993, ALLERGY          S14, V48, P57, DOI 10.1111/j.1398-9995.1993.tb04758.x; Pearce N, 1999, THORAX, V54, P268; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Scrivener S, 2000, CLIN EXP ALLERGY, V30, P304; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; Tariq SM, 1999, CLIN EXP ALLERGY, V29, P1042; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794; Tschopp JM, 1998, ALLERGY, V53, P608, DOI 10.1111/j.1398-9995.1998.tb03937.x; Wickens K, 1999, PEDIATR ALLERGY IMMU, V10, P199, DOI 10.1034/j.1399-3038.1999.00033.x; WILLIAMS PB, 1992, ANN ALLERGY, V68, P35; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7	34	220	229	0	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2001	108	2					art. no.	e33		10.1542/peds.108.2.e33		8	Pediatrics	Pediatrics	458TZ	WOS:000170211800014	11483843	
J	Monn, C				Monn, C			Exposure assessment of air pollutants: a review on spatial heterogeneity and indoor/outdoor/personal exposure to suspended particulate matter, nitrogen dioxide and ozone	ATMOSPHERIC ENVIRONMENT			English	Review						exposure assessment; particles; PM10; PM2.5; NO2; O-3; bioaerosols	VOLATILE ORGANIC-COMPOUNDS; RESIDENTIAL NO2 CHARACTERIZATION; SOUTHERN CALIFORNIA COMMUNITY; GRASS-POLLEN ALLERGEN; PERSONAL EXPOSURE; AIRBORNE PARTICLES; ENVIRONMENTAL EPIDEMIOLOGY; BIOLOGICAL MARKERS; PULMONARY-FUNCTION; MASS CONCENTRATION	This review describes databases of small-scale spatial variations and indoor, outdoor and personal measurements of air pollutants with the main focus on suspended particulate matter, and to a lesser extent, nitrogen dioxide and photochemical pollutants. The basic definitions and concepts of an exposure measurement are introduced as well as some study design considerations and implications of imprecise exposure measurements. Suspended particulate matter is complex with respect to particle size distributions, the chemical composition and its sources. With respect to small-scale spatial variations in urban areas, largest variations occur in the ultrafine (<0.1 <mu>m) and the coarse mode (PM10-2.5, resuspended dust). Secondary aerosols which contribute to the accumulation mode (0.1-2 mum) show quite homogenous spatial distribution. In general, small-scale spatial variations of PM2.5 were described to be smaller than the spatial variations of PM10. Recent studies in outdoor air show that ultrafine particle number counts have large spatial variations and that they are not well correlated to mass data. Sources of indoor particles are from outdoors and some specific indoor sources such as smoking and cooking for fine particles or moving of people (resuspension of dust) for coarse particles. The relationships between indoor, outdoor and personal levels are complex. The finer the particle size, the better becomes the correlation between indoor, outdoor and personal levels. Furthermore, correlations between these parameters are better in longitudinal analyses than in cross-sectional analyses. For NO2 and O-3 the air chemistry is important. Both have considerable small-scale spatial variations within urban areas. In the absence of indoor sources such as gas appliances, NO2 indoor/outdoor relationships are strong. For ozone, indoor levels are quite small. The study hypothesis largely determines the choice of a specific concept in exposure assessment, i.e. whether personal sampling is needed or if ambient monitoring is sufficient. Careful evaluation of the validity and improvements in precision of an exposure measure reduce error in the measurements and bias in the exposure-effect relationship. (C) 2000 Published by Elsevier Science Ltd.	ETH Zurich, Inst Hyg & Appl Physiol, CH-8092 Zurich, Switzerland	Monn, C (reprint author), ETH Zurich, Inst Hyg & Appl Physiol, Clausiusstr 25, CH-8092 Zurich, Switzerland.		Weschler, Charles/A-9788-2009	Weschler, Charles/0000-0002-9097-5850			Abt E, 2000, ENVIRON HEALTH PERSP, V108, P35, DOI 10.2307/3454293; AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; AHLBOM A, 1992, AM J IND MED, V21, P107, DOI 10.1002/ajim.4700210113; hlbom A., 1990, INTRO MODERN EPIDEMI; ALEANKIRKPATRIC.P, 1993, THESIS U ZURICH ZURI; Allen M., 1979, INTRO MEASUREMENT TH; ALTSHULLER AP, 1988, ATMOS ENVIRON, V22, P499, DOI 10.1016/0004-6981(88)90195-3; ARMSTRONG BG, 1990, AM J EPIDEMIOL, V132, P1176; ARMSTRONG BK, 1992, EXPOSURE MEASUREMENT, P49; ATKINSON R, 1990, ATMOS ENVIRON A-GEN, V24, P1, DOI 10.1016/0960-1686(90)90438-S; Baur X, 1995, ALLERGOLOGIE, V18, P568; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; BILLICK IH, 1990, TOXICOL IND HEALTH, V6, P325; Blanchard CL, 1999, ATMOS ENVIRON, V33, P4775, DOI 10.1016/S1352-2310(99)00284-8; BRAUER M, 1991, J AIR WASTE MANAGE, V41, P171; Brauer M, 1997, ATMOS ENVIRON, V31, P2113, DOI 10.1016/S1352-2310(96)00129-X; BRAUER M, 1995, ENVIRON HEALTH PERSP, V103, P482, DOI 10.2307/3432587; BREITENDER H, 1990, ALLERGOLOGIE, V13; BRENNER H, 1992, AM J EPIDEMIOL, V135, P85; Brimblecombe P., 1986, AIR COMPOSITION CHEM; Brook JR, 1997, ATMOS ENVIRON, V31, P4223, DOI 10.1016/S1352-2310(97)00248-3; BROOK JR, 1997, J AIR WASTE MANAGEME, V42, P2; BROWN RH, 1993, PURE APPL CHEM, V65, P1859, DOI 10.1351/pac199365081859; BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252; BRUNEKREEF B, 1987, AM J EPIDEMIOL, V125, P892; BULLIN JA, 1985, JAPCA J AIR WASTE MA, V35, P355; Burge Harriet A., 1995, P579; Burton JJ, 1996, FUTURIST, V30, P2; BURTSCHER H, 1994, COMBUST SCI TECHNOL, V101, P327, DOI 10.1080/00102209408951880; BURTSCHER H, 1993, WATER AIR SOIL POLL, V68, P125, DOI 10.1007/BF00479397; *BUWAL, 1996, 63 BUWAL FED OFF ENV; CARTER WPL, 1995, ATMOS ENVIRON, V29, P2499, DOI 10.1016/1352-2310(95)00149-S; Celenza A, 1996, BRIT MED J, V312, P604; Chen ML, 1998, SCI TOTAL ENVIRON, V209, P225, DOI 10.1016/S0048-9697(97)00318-5; CHOW JC, 1995, J AIR WASTE MANAGE, V45, P320; CLAYTON CA, 1993, J EXPO ANAL ENV EPID, V3, P227; CLAYTON CA, 1991, J EXPO ANAL ENV EPID, V1, P401; COCHRAN WG, 1968, TECHNOMETRICS, V10, P637, DOI 10.2307/1267450; Colls JJ, 1999, SCI TOTAL ENVIRON, V235, P221, DOI 10.1016/S0048-9697(99)00194-1; *COST, 1993, 14988 COST EUR; DOCKERY DW, 1981, ATMOS ENVIRON, V15, P335, DOI 10.1016/0004-6981(81)90036-6; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOCKERY DW, 1981, JAPCA J AIR WASTE MA, V31, P153; DRYE EE, 1989, JAPCA J AIR WASTE MA, V39, P1169; Duan N, 1982, ENVIRON INT, V8, P305, DOI 10.1016/0160-4120(82)90041-1; Duan NH, 1997, J EXPO ANAL ENV EPID, V7, P439; EMBERLIN J, 1995, CLIN EXP ALLERGY, V25, P202, DOI 10.1111/j.1365-2222.1995.tb01029.x; Emberlin J, 1995, CLIN EXP ALLERGY, V25, P33, DOI 10.1111/j.1365-2222.1995.tb00040.x; EMBERLIN J, 1997, GRASS TREE WEED POLL, V3, P835; *EMPA, 1994, SWISS FED LAB MAT TE; Finlayson-Pitts B. J., 1986, ATMOSPHERIC CHEM; Fluckiger B, 1998, INDOOR AIR, V8, P197, DOI 10.1111/j.1600-0668.1998.t01-1-00007.x; FLUCKIGER B, 1999, P IND AIR 99 ED, V1, P914; FOGEL DB, 1994, IEEE T NEURAL NETWOR, V1, P3; Georgopoulos PG, 1997, ENVIRON SCI TECHNOL, V31, P17, DOI 10.1021/es950764s; GRAHAM DE, 1990, AM REV RESPIR DIS, V142, P152; GRANDJEAN P, 1995, CLIN CHEM, V41, P1800; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747; Hangartner M, 1996, ANALYST, V121, P1269, DOI 10.1039/an9962101269; HANGARTNER M, 1990, EINSATZ PASSIVSAMMLE, V838, P515; HANNA SR, 1982, DEOTIC11223 US DEP E; Harrison RM, 1998, ENVIRON TECHNOL, V19, P121, DOI 10.1080/09593331908616664; Harrison RM, 1999, ATMOS ENVIRON, V33, P309, DOI 10.1016/S1352-2310(98)00164-2; HARRISON RM, 1986, AIR POLLUTION ANAL; HEGNER H, 1994, THESIS ETH ZURICH ZU; Hinds W. C., 1982, AEROSOL TECHNOLOGY; Hopke P. K., 1985, RECEPTOR MODELING EN; HULKA BS, 1988, ARCH ENVIRON HEALTH, V43, P83; Hulka BS, 1990, BIOL MARKERS EPIDEMI; Ihrig MM, 1998, EPIDEMIOLOGY, V9, P290, DOI 10.1097/00001648-199805000-00013; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; ITO K, 1995, INHAL TOXICOL, V7, P735, DOI 10.3109/08958379509014477; Janssen LHJM, 1999, ATMOS ENVIRON, V33, P3325, DOI 10.1016/S1352-2310(98)00435-X; JANSSEN NA, 1995, EPIDEMIOLOGY S, V6, P45; Janssen NAH, 1998, AM J EPIDEMIOL, V147, P537; Janssen NAH, 1997, OCCUP ENVIRON MED, V54, P888; Janssen NAH, 1999, OCCUP ENVIRON MED, V56, P482; Jantunen MJ, 1998, J EXPO ANAL ENV EPID, V8, P495; JU C, 1981, ENVIRON SCI TECHNOL, V15, P592, DOI 10.1021/es00087a600; Junker M, 2000, ATMOS ENVIRON, V34, P3171, DOI 10.1016/S1352-2310(99)00372-6; KAINKASTANICKE E, 1988, ALLERGY, V43, P57; Keywood MD, 1999, ATMOS ENVIRON, V33, P2907, DOI 10.1016/S1352-2310(99)00102-8; Kingham S, 2000, ATMOS ENVIRON, V34, P905, DOI 10.1016/S1352-2310(99)00321-0; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; Knox B, 1996, TRENDS PLANT SCI, V1, P156, DOI 10.1016/S1360-1385(96)80051-3; Knox RB, 1996, SEX PLANT REPROD, V9, P318; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KOUTRAKIS P, 1988, ENVIRON SCI TECHNOL, V22, P1463, DOI 10.1021/es00177a013; KOUTRAKIS P, 1993, ANAL CHEM, V65, P209, DOI 10.1021/ac00051a004; KOUTRAKIS P, 1989, ATMOS ENVIRON, V23, P2767, DOI 10.1016/0004-6981(89)90557-X; Krzyzanowski M, 1997, OCCUP ENVIRON MED, V54, P145; Kunzli N, 1997, ENVIRON HEALTH PERSP, V105, P1078, DOI 10.2307/3433849; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; LACEY J, 1994, J AEROSOL SCI, V25, P1371, DOI 10.1016/0021-8502(94)90215-1; Last JM, 1988, DICT EPIDEMIOLOGY; Leaderer BP, 1999, ENVIRON HEALTH PERSP, V107, P223; LEADERER BP, 1994, INDOOR AIR, V4, P23, DOI 10.1111/j.1600-0668.1994.t01-3-00004.x; LEADERER BP, 1990, RISK ANAL, V10, P19, DOI 10.1111/j.1539-6924.1990.tb01016.x; LEADERER BP, 1993, ENVIRON HEALTH PERSP, V101, P167, DOI 10.2307/3431673; LEADERER BP, 1986, AM J EPIDEMIOL, V124, P275; LEBOWITZ MD, 1989, JAPCA J AIR WASTE MA, V39, P1411; LEBRET E, 1990, TOXICOL IND HEALTH, V6, P147; LEE K, 1992, ENVIRON SCI TECHNOL, V26, P697, DOI 10.1021/es00028a005; Lewis W. H., 1983, AIRBORNE ALLERGENIC; LEWTAS J, 1993, ENVIRON HEALTH PERSP, V99, P89, DOI 10.2307/3431463; LIOY PJ, 1995, ENVIRON HEALTH PERSP, V103, P35, DOI 10.2307/3432558; LIOY PJ, 1990, ENVIRON SCI TECHNOL, V24, P938, DOI 10.1021/es00077a001; LIOY PJ, 1991, HUMAN EXPOSURE ASSES; LIPPMANN M, 1989, JAPCA J AIR WASTE MA, V39, P672; Liu LJS, 1997, ENVIRON HEALTH PERSP, V105, P58, DOI 10.1289/ehp.9710558; LIU LJS, 1993, ENVIRON HEALTH PERSP, V101, P318, DOI 10.2307/3431442; LOWRY LK, 1995, TOXICOL LETT, V77, P31, DOI 10.1016/0378-4274(95)03268-1; LUSTENBERGER J, 1990, P IND AIR 90 TOR CAN, V2, P555; MAGE DT, 1985, ENVIRON INT, V11, P407, DOI 10.1016/0160-4120(85)90036-4; MAGE DT, 1995, 88 M AIR WAST MAN AS; Magliano KL, 1999, ATMOS ENVIRON, V33, P4757, DOI 10.1016/S1352-2310(99)00265-4; MARPLE VA, 1987, JAPCA J AIR WASTE MA, V37, P1303; Martin BW, 1997, SOZ PRAVENTIV MED, V42, P67, DOI 10.1007/BF01318136; MASUCH G, 1997, 4 EUR POLL SEM BAD L; MATHYS P, 1999, EPIDEMIOLOGY, V9, P50; Matthias-Maser S., 1998, ATMOSPHERIC PARTICLE, P349; MCCONNAUGHEY PW, 1985, AM IND HYG ASSOC J, V46, P357, DOI 10.1202/0002-8894(1985)046<0357:PCDTFA>2.3.CO;2; McGrath JM, 1999, QUAL HEALTH RES, V9, P731, DOI 10.1177/104973299129122243; Meyer MJ, 1996, ENVIRON HEALTH PERSP, V104, P879, DOI 10.2307/3433005; Micallef A, 1998, ATMOS ENVIRON, V32, P3795, DOI 10.1016/S1352-2310(98)00076-4; Miguel AG, 1996, ENVIRON HEALTH PERSP, V104, P1180, DOI 10.2307/3432911; Monn C, 1999, TOXICOL APPL PHARM, V155, P245, DOI 10.1006/taap.1998.8591; Monn C, 1997, ATMOS ENVIRON, V31, P2243, DOI 10.1016/S1352-2310(97)00030-7; MONN C, 1990, J AIR WASTE MANAGE, V40, P357; Monn C, 1998, SCI TOTAL ENVIRON, V215, P243, DOI 10.1016/S0048-9697(98)00124-7; MONN C, 1995, ATMOS ENVIRON, V29, P2565, DOI 10.1016/1352-2310(95)94999-U; Monn C, 1997, SCI TOTAL ENVIRON, V208, P15, DOI 10.1016/S0048-9697(97)00271-4; Monn C, 1999, ATMOS ENVIRON, V33, P2411, DOI 10.1016/S1352-2310(99)00068-0; MONN C, 2000, IN PRESS AEROBIOLOGI; MONN C, 1993, P IND AIR 93 HELS, V3, P319; MOSCHANDREAS DJ, 1981, B NEW YORK ACAD MED, V57, P845; Muguerza J, 1996, CLIN EXP ALLERGY, V26, P1177, DOI 10.1046/j.1365-2222.1996.d01-269.x; Mumford JL, 1996, MUTAT RES-ENVIR MUTA, V359, P171, DOI 10.1016/S0165-1161(96)90264-2; NEAS LM, 1994, AM J EPIDEMIOL, V139, P1088; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; NOY D, 1990, ATMOSPHERIC ENV A, V24, P1903; OBERDORSTER G, 1995, REGUL TOXICOL PHARM, V21, P123, DOI 10.1006/rtph.1995.1017; OGLESBY L, 2000, IN PRESS J AIR WASTE; Ong E, 1995, AEROBIOLOGIA, V11, P219, DOI 10.1007/BF02447202; OTT W R, 1982, Environment International, V7, P179, DOI 10.1016/0160-4120(82)90104-0; OTT WR, 1990, J AIR WASTE MANAGE, V40, P966; OTT WR, 1986, JAPCA J AIR WASTE MA, V36, P883; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P35; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; PALMES ED, 1976, J AM IND HYG ASSOC, V10, P570; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; POSSANZINI M, 1983, ATMOS ENVIRON, V17, P2605, DOI 10.1016/0004-6981(83)90089-6; Pritchard RJ, 1996, INHAL TOXICOL, V8, P457, DOI 10.3109/08958379609005440; Profos P., 1994, HDB IND MESSTECHNIK; Quackenboss J J, 1991, J Expo Anal Environ Epidemiol, V1, P83; QUACKENBOSS JJ, 1986, ENVIRON SCI TECHNOL, V20, P775, DOI 10.1021/es00150a003; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; RAPPAPORT SM, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432560; Riediker M, 2000, CLIN EXP ALLERGY, V30, P867; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Rubino FM, 1998, ATMOS ENVIRON, V32, P3569, DOI 10.1016/S1352-2310(98)00074-0; RYAN PB, 1988, JAPCA J AIR WASTE MA, V38, P22; RYAN PB, 1988, ATMOS ENVIRON, V22, P2115, DOI 10.1016/0004-6981(88)90123-0; RYLANDER R, 1998, INDOOR AIR S, V4, P59; SANTANAM S, 1990, P IND AIR 90 TOR CAN, V2, P583; Schappi GF, 1996, INT ARCH ALLERGY IMM, V110, P364; Schappi GF, 1997, SEX PLANT REPROD, V10, P315, DOI 10.1007/s004970050105; Schindler C, 1998, EPIDEMIOLOGY, V9, P405, DOI 10.1097/00001648-199807000-00010; SCHINKO HAE, 1994, ALLERGOLOGIE, V17, P514; SCHULTE PA, 1995, TOXICOLOGY, V101, P73, DOI 10.1016/0300-483X(95)03020-G; SCHWAB M, 1994, INDOOR AIR, V4, P8, DOI 10.1111/j.1600-0668.1994.t01-3-00003.x; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SEIFERT B, 1995, SCI TOTAL ENVIRON, V168, P101, DOI 10.1016/0048-9697(95)04613-6; Seinfeld J. H., 1986, ATMOSPHERIC CHEM PHY; SEXTON K, 1984, ATMOS ENVIRON, V18, P1385, DOI 10.1016/0004-6981(84)90046-5; Sexton K, 1988, AIR POLLUTION AUTOMO, P207; SHELDON LS, 1989, INVESTIGATION INFILT; SHIELDS HC, 1987, JAPCA J AIR WASTE MA, V37, P1039; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SPENGLER J, 1994, J AIR WASTE MANAGE, V44, P39; SPENGLER JD, 1981, ATMOS ENVIRON, V15, P23, DOI 10.1016/0004-6981(81)90121-9; Spengler JD, 1996, ENVIRON HEALTH PERSP, V104, P492, DOI 10.2307/3432989; SPENGLER JD, 1990, ENVIRON SCI TECHNOL, V24, P946, DOI 10.1021/es00077a002; Spieksma F T, 1995, Allergol Immunopathol (Madr), V23, P20; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STOCK TH, 1985, JAPCA J AIR WASTE MA, V35, P1266; Suh HH, 1997, ENVIRON HEALTH PERSP, V105, P826, DOI 10.2307/3433700; SUH HH, 1993, J AIR WASTE MANAGE, V43, P845; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; SWOBODA I, 1994, BBA-GENE STRUCT EXPR, V1219, P457, DOI 10.1016/0167-4781(94)90072-8; TAGER IB, 1993, ENVIRON HEALTH PERSP, V101, P205; TAMURA KAM, 1996, EPA600P95001AF, V1; THATCHER TL, 1995, ATMOS ENVIRON, V29, P1487, DOI 10.1016/1352-2310(95)00016-R; U. S. EPA (U. S. Environmental Protection Agency), 1996, EPA600P93004AF; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; WALDMAN JM, 1990, ATMOS ENVIRON B-URB, V24, P115, DOI 10.1016/0957-1272(90)90017-O; Wallace L, 1996, J AIR WASTE MANAGE, V46, P98; WALLACE LA, 1989, ENVIRON RES, V50, P37, DOI 10.1016/S0013-9351(89)80047-7; WALLACE LA, 1988, ATMOS ENVIRON, V22, P2141, DOI 10.1016/0004-6981(88)90125-4; WESCHLER CJ, 1989, JAPCA J AIR WASTE MA, V39, P1562; WESCHLER CJ, 1990, AM IND HYG ASSOC J, V51, P261, DOI 10.1202/0002-8894(1990)051<0261:COVOCA>2.0.CO;2; WESCHLER CJ, 1992, ENVIRON SCI TECHNOL, V26, P179, DOI 10.1021/es00025a022; Whitby KT, 1980, ADV ENV SCI TECHNOL, V10, P477; WIJNAND E, 1996, ANALYST, V121, P1197; Willeke K., 1993, AEROSOL MEASUREMENTS; WILLIAMS ML, 1995, SCI TOTAL ENVIRON, V168, P169, DOI 10.1016/0048-9697(95)04620-G; WILSON AF, 1973, NEW ENGL J MED, V288, P1056, DOI 10.1056/NEJM197305172882006; Wilson R, 1996, PARTICLES OUR AIR; Wilson WE, 1997, J AIR WASTE MANAGE, V47, P1238; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149; YANAGISAWA Y, 1988, ATMOS ENVIRON, V22, P2195, DOI 10.1016/0004-6981(88)90129-1; Yanagisawa Y., 1982, ENVIRON INT, V8, P235, DOI 10.1016/0160-4120(82)90033-2; YEH HC, 1976, ENVIRON HEALTH PERSP, V15, P147, DOI 10.2307/3428398; YOCOM JE, 1982, JAPCA J AIR WASTE MA, V32, P500	219	220	224	21	169	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.		2001	35	1					1	32		10.1016/S1352-2310(00)00330-7		32	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	390YL	WOS:000166327300001		
J	von Mutius, E; Vercelli, D				von Mutius, Erika; Vercelli, Donata			Farm living: effects on childhood asthma and allergy	NATURE REVIEWS IMMUNOLOGY			English	Article							NORMAL HUMAN MONOCYTES; IFN-GAMMA PRODUCTION; SCHOOL-AGE-CHILDREN; HAY-FEVER; EARLY-LIFE; BIRTH-COHORT; ATOPIC SENSITIZATION; INVERSE ASSOCIATION; MICROBIAL EXPOSURE; DENDRITIC CELLS	Numerous epidemiological studies have shown that children who grow up on traditional farms are protected from asthma, hay fever and allergic sensitization. Early-life contact with livestock and their fodder, and consumption of unprocessed cow's milk have been identified as the most effective protective exposures. Studies of the immunobiology of farm living point to activation and modulation of innate and adaptive immune responses by intense microbial exposures and possibly xenogeneic signals delivered before or soon after birth.	[von Mutius, Erika] Univ Munich, Dr von Haunersche Kinderklin, D-80337 Munich, Germany; [Vercelli, Donata] Univ Arizona, Arizona Ctr Biol Complex Dis, Arizona Resp Ctr, Tucson, AZ 85719 USA; [Vercelli, Donata] Univ Arizona, Dept Cell Biol, Tucson, AZ 85719 USA	von Mutius, E (reprint author), Univ Munich, Dr von Haunersche Kinderklin, D-80337 Munich, Germany.	erika.von.mutius@med.lmu.de; donata@arc.arizona.edu		von Mutius, Erika/0000-0002-8893-4515			Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; BACH FH, 1995, NAT MED, V1, P869, DOI 10.1038/nm0995-869; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chen X, 2007, J IMMUNOL, V179, P154; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; COSENTINO G, 1995, J IMMUNOL, V155, P3145; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Dimich-Ward H, 2006, CLIN EXP ALLERGY, V36, P1122, DOI 10.1111/j.1365-2222.2006.02556.x; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Douwes J, 2007, ALLERGY, V62, P1158, DOI 10.1111/j.1398-9995.2007.01490.x; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2008, ALLERGY, V63, P1505, DOI 10.1111/j.1398-9995.2008.01793.x; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Eriksson J, 2010, ALLERGY, V65, P1397, DOI 10.1111/j.1398-9995.2010.02397.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Forte P, 2005, J IMMUNOL, V175, P5463; Friedlander Samuel L, 2005, Pediatr Infect Dis J, V24, pS170, DOI 10.1097/01.inf.0000187273.47390.01; Gorelik L, 2008, INNATE IMMUN, V14, P345, DOI 10.1177/1753425908098006; Halonen M, 2009, J IMMUNOL, V182, P3285, DOI 10.4049/jimmunol.0711996; Holt PG, 2009, J EXP MED, V206, P2861, DOI 10.1084/jem.20092469; Hoppin JA, 2008, AM J RESP CRIT CARE, V177, P11, DOI 10.1164/rccm.200706-821OC; Horak F, 2002, CLIN EXP ALLERGY, V32, P1155, DOI 10.1046/j.1365-2745.2002.01448.x; Kiechl-Kohlendorfer U, 2007, ACTA PAEDIATR, V96, P1606, DOI 10.1111/j.1651-2227.2007.00449.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Koskela HO, 2005, OCCUP ENVIRON MED, V62, P607, DOI 10.1136/oem.2004.014852; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; LAUENER RP, 1990, EUR J IMMUNOL, V20, P2375, DOI 10.1002/eji.1830201103; Levy O, 2007, NAT REV IMMUNOL, V7, P379, DOI 10.1038/nri2075; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Ma Y, 2009, PEDIATR PULM, V44, P793, DOI 10.1002/ppul.21061; Martinez Fernando D, 2009, Proc Am Thorac Soc, V6, P272, DOI 10.1513/pats.200808-092RM; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; Midodzi WK, 2007, RESPIROLOGY, V12, P692, DOI 10.1111/j.1440-1843.2007.01134.x; Muzio M, 2000, J IMMUNOL, V164, P5998; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Perkin MR, 2007, CLIN EXP ALLERGY, V37, P627, DOI 10.1111/j.1365-2222.2007.02715.x; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; Peters M, 2010, J ALLERGY CLIN IMMUN, V126, P648, DOI 10.1016/j.jaci.2010.05.011; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2005, DIABETES, V54, P3212, DOI 10.2337/diabetes.54.11.3212; Radon K, 2004, AM J IND MED, V46, P349, DOI 10.1002/ajim.20000; Radon K, 2007, PEDIATRICS, V120, P354, DOI 10.1542/peds.2006-3624; Radon K, 2010, BMC MUSCULOSKEL DIS, V11, DOI 10.1186/1471-2474-11-73; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schulze A, 2007, EUR RESPIR J, V29, P1169, DOI 10.1183/09031936.00127906; Seedorf J, 1998, J AGR ENG RES, V70, P97, DOI 10.1006/jaer.1997.0281; Smit LAM, 2007, OCCUP ENVIRON MED, V64, P101, DOI 10.1136/oem.2006.028167; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; Stern DA, 2007, J ALLERGY CLIN IMMUN, V120, P835, DOI 10.1016/j.jaci.2007.05.050; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174; Sudre B, 2009, ALLERGY, V64, P1068, DOI 10.1111/j.1398-9995.2009.01958.x; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Viinanen A, 2007, ALLERGY, V62, P272, DOI 10.1111/j.1398-9995.2006.01279.x; Viinanen A, 2005, ALLERGY, V60, P1370, DOI 10.1111/j.1398-9995.2005.00877.x; Vogel K, 2008, J ALLERGY CLIN IMMUN, V122, P307, DOI 10.1016/j.jaci.2008.05.016; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wennergren G, 2010, PEDIAT ALLERG IMM-UK, V21, P806, DOI 10.1111/j.1399-3038.2010.01057.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wong GWK, 2006, PAEDIATR RESPIR REV, V7, pS119, DOI 10.1016/j.prrv.2006.04.154; Wright Anne L., 2004, Journal of Allergy and Clinical Immunology, V113, pS2, DOI 10.1016/j.jaci.2003.09.050	80	219	223	0	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	DEC	2010	10	12					861	868		10.1038/nri2871		8	Immunology	Immunology	685CD	WOS:000284601100012	21060319	
J	van Odijk, J; Kull, I; Borres, MP; Brandtzaeg, P; Edberg, U; Hanson, LA; Host, A; Kuitunen, M; Olsen, SF; Skerfving, S; Sundell, J; Wille, S				van Odijk, J; Kull, I; Borres, MP; Brandtzaeg, P; Edberg, U; Hanson, LA; Host, A; Kuitunen, M; Olsen, SF; Skerfving, S; Sundell, J; Wille, S			Breastfeeding and allergic disease: a multidisciplinary review of the literature (1966-2001) on the mode of early feeding in infancy and its impact on later atopic manifestations	ALLERGY			English	Review						allergy; asthma; atopic disease; breast feeding; cow's milk formula; wheezing	COWS MILK ALLERGY; HIGH-RISK INFANTS; RESPIRATORY-TRACT INFECTIONS; PARTIAL WHEY HYDROLYSATE; PROSPECTIVE FOLLOW-UP; FAMILY HISTORY; PATHOGENETIC ROLE; PARENTAL SMOKING; CHILDHOOD ASTHMA; MATERNAL SMOKING	Background: Strategies to prevent children from developing allergy have been elaborated on the basis of state-of-the-art reviews of the scientific literature regarding pets and allergies, building dampness and health, and building ventilation and health. A similar multidisciplinary review of infant feeding mode in relation to allergy has not been published previously. Here, the objective is to review the scientific literature regarding the impact of early feeding (breast milk and/or cow's milk and/or formula) on development of atopic disease. The work was performed by a multidisciplinary group of Scandinavian researchers. Methods: The search in the literature identified 4323 articles that contained at least one of the exposure and health effect terms. A total of 4191 articles were excluded mainly because they did not contain information on both exposure and health effects. Consequently, 132 studies have been scrutinized by this review group. Results: Of the 132 studies selected, 56 were regarded as conclusive. Several factors contributed to the exclusions. The studies considered conclusive by the review group were categorized according to population and study design. Conclusions: The review group concluded that breastfeeding seems to protect from the development of atopic disease. The effect appears even stronger in children with atopic heredity. If breast milk is unavailable or insufficient, extensively hydrolysed formulas are preferable to unhydrolysed or partially hydrolysed formulas in terms of the risk of some atopic manifestations.	Odense Univ Hosp, Dept Pediat, DK-5000 Odense C, Denmark; Univ Gothenburg, Dept Clin Nutr, Sahlgrenska Acad, Gothenburg, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Univ Gothenburg, Dept Woman & Child Hlth, Sahlgrenska Acad, Gothenburg, Sweden; Univ Oslo, Rikshosp, Inst Pathol, LIIPAT, Oslo, Norway; Swedish Natl Food Adm, Uppsala, Sweden; Univ Gothenburg, Dept Clin Immunol, Sahlgrenska Acad, Gothenburg, Sweden; Univ Helsinki Hosp, Skin & Allergy Hosp, Helsinki, Finland; Danish Epidemiol Sci Ctr, Copenhagen, Denmark; Lund Univ, Dept Environm & Occupat Med, Lund, Sweden; Tech Univ Denmark, Int Ctr Indoor Air & Energy, DK-2800 Lyngby, Denmark; Helsingborg Hosp, Dept Paediat, Helsingborg, Sweden	Host, A (reprint author), Odense Univ Hosp, Dept Pediat, Sdr Blvd 29, DK-5000 Odense C, Denmark.		Sundell, Jan/B-2857-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Baker D, 1998, J EPIDEMIOL COMMUN H, V52, P451; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; BerthJones J, 1997, BRIT J DERMATOL, V136, P498, DOI 10.1111/j.1365-2133.1997.tb02130.x; Bjorksten B, 2001, Curr Opin Allergy Clin Immunol, V1, P225, DOI 10.1097/01.all.0000011018.32315.1d; Bornehag CG, 2001, INDOOR AIR, V11, P72; Brandtzaeg P, 2002, NUTR IMMUNE FUNCTION, V1, P273; BRUNO G, 1993, ALLERGY PROC, V14, P181, DOI 10.2500/108854193778878682; BRUNO G, 1993, ALLERGY PROC, V14, P186; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1993, ARCH DIS CHILD, V68, P724; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; Donath S, 2000, J PAEDIATR CHILD H, V36, P164, DOI 10.1046/j.1440-1754.2000.00486.x; Elder DE, 1996, ARCH DIS CHILD, V74, pF165, DOI 10.1136/fn.74.3.F165; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48; Fidler N, 2000, EUR J NUTR, V39, P31, DOI 10.1007/s003940050073; GELLERBERNSTEIN G, 1987, ALLERGY, V42, P85, DOI 10.1111/j.1398-9995.1987.tb02364.x; GRUSKAY FL, 1982, CLIN PEDIATR, V21, P486, DOI 10.1177/000992288202100807; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; Halken S, 1994, Ugeskr Laeger, V156, P308; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; HOST A, 1991, ALLERGY PROC, V12, P227, DOI 10.2500/108854191778879287; HUTTLY SRA, 1990, AM J EPIDEMIOL, V132, P572; Jarvis D, 1998, BRIT MED J, V316, P607; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; LINDFORS A, 1988, ALLERGY, V43, P11, DOI 10.1111/j.1398-9995.1988.tb02038.x; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; LUCAS A, 1990, BRIT MED J, V300, P837; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; MCCONNOCHIE KM, 1986, PEDIATR PULM, V2, P260, DOI 10.1002/ppul.1950020503; MERRETT TG, 1988, ANN ALLERGY, V61, P13; MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388; MOORE WJ, 1985, ARCH DIS CHILD, V60, P722; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Oberle D, 2001, THORAX, V56, P896; Oddy WH, 1999, BRIT MED J, V319, P815; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; Pershagen G, 1997, ALLERGY, V52, P1045, DOI 10.1111/j.1398-9995.1997.tb00174.x; PRATT HF, 1984, EARLY HUM DEV, V9, P283, DOI 10.1016/0378-3782(84)90039-2; Raisler J, 1999, AM J PUBLIC HEALTH, V89, P25; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; RYLANDER E, 1995, EPIDEMIOLOGY, V6, P289, DOI 10.1097/00001648-199505000-00017; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAARINEN UM, 1979, LANCET, V2, P163; SAULS HS, 1979, PEDIATRICS, V64, P523; SAVILAHTI E, 1987, ARCH DIS CHILD, V62, P269; STINTZING G, 1979, ACTA PAEDIATR SCAND, V68, P383, DOI 10.1111/j.1651-2227.1979.tb05024.x; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; VANDENPLAS Y, 1986, EUR J PEDIATR, V145, P493, DOI 10.1007/BF02429049; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wetzig H, 2000, INT J HYG ENVIR HEAL, V203, P17, DOI 10.1078/S1438-4639(04)70003-6; Wilson AC, 1998, BRIT MED J, V316, P21; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758; WRIGHT AL, 1989, BRIT MED J, V299, P946; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	73	219	235	7	22	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	SEP	2003	58	9					833	843				11	Allergy; Immunology	Allergy; Immunology	707QK	WOS:000184521200001	12911410	
J	Beck, LA; Marcotte, GV; MacGlashan, D; Togias, A; Saini, S				Beck, LA; Marcotte, GV; MacGlashan, D; Togias, A; Saini, S			Omalizumab-induced reductions in mast cell Fc epsilon RI expression and function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mast cells; Fc epsilon RI; omalizumab; basophils	ANTI-IGE ANTIBODY; DOWN-REGULATION; IN-VIVO	Background: By design, omalizumab binds free IgE in the circulation and prevents its attachment to the surface of mast cells and basophils, thereby preventing them from responding to allergens. Previously, omalizumab rapidly reduced free IgE levels, as well as basophil high-affinity IgE receptors, leading to significant reductions in basophil mediator response to allergen. It is assumed that tissue mast cells are similarly altered in their FcepsilonRI density and function. Objective: We examined the phenotypic shift of skin mast cells in parallel to that of blood basophils in 3 subjects infused with omalizumab. Methods: Three subjects with allergic rhinitis underwent intradermal skin test titration with house dust mite antigen at days 0, 7, 70, and 196 of omalizumab treatment. As control subjects, 5 untreated subjects with allergic rhinitis were evaluated at similar time points. All subjects underwent skin biopsy 18 to 24 hours later at the site of allergen injection. Biopsy specimens were characterized by means of immunohistochemisty for tryptase and FcepsilonRIalpha immunoreactivity, as well other markers (CD3, CD45RO, CD68, cutaneous lymphocyte antigen, and major basic protein). Results: Omalizumab recipients, but not control subjects, demonstrated reductions in FcepsilonRIalpha immunoreactivity at days 70 and 196 in parallel with reductions in the acute wheal response to allergen. However, no reductions in tryptase-positive cells were noted at these time points. Conclusion: Reductions in free IgE levels by omalizumab leads to a rapid reduction in basophil FcepsilonRI receptor expression. In contrast, the time course for the decrease of FcepsilonRI expression in skin mast cells is slower and associated with decreased acute allergen wheal size.	Johns Hopkins Asthma & Allergy Ctr, Unit Off 1, Dept Med, Div Clin Immunol, Baltimore, MD 21224 USA	Saini, S (reprint author), Johns Hopkins Asthma & Allergy Ctr, Unit Off 1, Dept Med, Div Clin Immunol, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	ssaini@jhmi.edu			NIAID NIH HHS [AI045839, K08 AI001564, AI01564, K08 AI001564-05, R01 AI045839]		Beck LA, 1997, J IMMUNOL, V159, P2962; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Ong Y., 2004, Journal of Allergy and Clinical Immunology, V113, pS84, DOI 10.1016/j.jaci.2003.12.280; PETERS MS, 1983, J INVEST DERMATOL, V81, P39, DOI 10.1111/1523-1747.ep12538380; Saini SS, 1999, J IMMUNOL, V162, P5624; Togias A, 1998, J ALLERGY CLIN IMMUN, V101, pS171	9	217	222	1	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					527	530		10.1016/j.jaci.2004.06.032		4	Allergy; Immunology	Allergy; Immunology	853AX	WOS:000223799600009	15356552	
J	Herrick, CA; Bottomly, K				Herrick, CA; Bottomly, K			To respond or not to respond: T cells in allergic asthma	NATURE REVIEWS IMMUNOLOGY			English	Review							INDUCED AIRWAY HYPERREACTIVITY; IFN-GAMMA PRODUCTION; DENDRITIC CELLS; TH2 RESPONSES; MURINE MODEL; CYTOKINE PRODUCTION; TRANSGENIC MICE; BRONCHIAL HYPERRESPONSIVENESS; EOSINOPHILIC INFLAMMATION; INTERLEUKIN-10 PRODUCTION	The incidence of allergic asthma has almost doubled in the past two decades. Numerous epidemiological studies have linked the recent surge in atopic disease with decreased exposure to infections in early childhood as a result of a more westernized lifestyle. However, a clear mechanistic explanation for how this might occur is still lacking. An answer might lie in the presently unfolding story of various regulatory T-cell populations that can limit adaptive immune responses, including T helper 2 (T(H)2)-cell-mediated allergic airway disease.	Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA	Bottomly, K (reprint author), Yale Univ, Sch Med, Immunobiol Sect, 300 Cedar St, New Haven, CT 06520 USA.						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Armitage E, 2001, EUR J GASTROEN HEPAT, V13, P1439, DOI 10.1097/00042737-200112000-00007; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barner M, 1998, CURR BIOL, V8, P669, DOI 10.1016/S0960-9822(98)70256-8; BARNES PF, 1992, J IMMUNOL, V149, P541; Blease K, 2001, J IMMUNOL, V166, P5219; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; Bonnefoy JY, 1996, ANN NY ACAD SCI, V796, P59, DOI 10.1111/j.1749-6632.1996.tb32567.x; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Busse WW, 2001, NEW ENGL J MED, V344, P350; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 2001, J IMMUNOL, V166, P2760; Cohn L, 1999, J IMMUNOL, V162, P6178; Cookson W, 1999, NATURE, V402, pB5; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Cottrez F, 2000, J IMMUNOL, V165, P4848; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; D'Orazio TJ, 1998, J IMMUNOL, V160, P2089; Dabbagh K, 2002, J IMMUNOL, V168, P4524; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Fallon PG, 2002, IMMUNITY, V17, P7, DOI 10.1016/S1074-7613(02)00332-1; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Fonager K, 1997, INT J EPIDEMIOL, V26, P1003, DOI 10.1093/ije/26.5.1003; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Groux H, 1997, NATURE, V389, P737; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Holgate ST, 1999, NATURE, V402, P2, DOI 10.1038/35037000; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HUANG SK, 1995, J IMMUNOL, V155, P2688; Huang TJ, 2001, J IMMUNOL, V166, P207; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jilek S, 2001, J IMMUNOL, V166, P3612; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Katagiri K, 2002, J IMMUNOL, V169, P84; KIM J, 1985, J EXP MED, V162, P188, DOI 10.1084/jem.162.1.188; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kosiewicz MM, 1998, J IMMUNOL, V161, P5382; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lee JS, 1997, J FOOD DRUG ANAL, V5, P185; Li L, 1998, J IMMUNOL, V161, P3128; Liu XD, 2002, AM J PHYSIOL-LUNG C, V282, pL1049, DOI 10.1152/ajplung.00321.2001; Mahanty S, 1996, J INFECT DIS, V173, P769; MARTIN RJ, 1993, AM REV RESPIR DIS, V148, P1677; McGuirk P, 2002, TRENDS IMMUNOL, V23, P450, DOI 10.1016/S1471-4906(02)02288-3; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; POSTLETHWAITE AE, 1991, J CLIN INVEST, V87, P2147, DOI 10.1172/JCI115247; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; Schwarze J, 1999, J IMMUNOL, V163, P5729; Schwarze J, 1999, J IMMUNOL, V162, P4207; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; TOUMOY KG, 2002, CLIN EXP ALLERGY, V32, P17; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Van der Kleij D, 2002, J INFECT DIS, V185, P531, DOI 10.1086/338574; VANOOSTERHOUT AJM, 1995, J ALLERGY CLIN IMMUN, V96, P104, DOI 10.1016/S0091-6749(95)70039-0; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, BRIT MED J, V308, P692; WAKKACH A, IN PRESS IMMUNITY; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; Walter DM, 2001, J IMMUNOL, V167, P4668; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yssel H, 2001, MICROBES INFECT, V3, P899, DOI 10.1016/S1286-4579(01)01450-2; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	116	217	233	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	MAY	2003	3	5					405	412		10.1038/nri1084		8	Immunology	Immunology	679MC	WOS:000182925400021	12766762	
J	Valenta, R				Valenta, R			The future of antigen-specific immunotherapy of allergy	NATURE REVIEWS IMMUNOLOGY			English	Editorial Material							FC-EPSILON-RI; BIRCH POLLEN ALLERGEN; HIGH-AFFINITY RECEPTOR; T-CELL EPITOPE; BEE VENOM IMMUNOTHERAPY; DUST MITE ALLERGEN; ENGINEERED HYPOALLERGENIC DERIVATIVES; QUANTITATIVE IGE INHIBITION; EPIDERMAL LANGERHANS CELLS; SITE-DIRECTED MUTAGENESIS		Univ Vienna, Sch Med, Vienna Gen Hosp AKH, Mol Immunopathol Grp,Dept Pathophysiol, A-1090 Vienna, Austria	Valenta, R (reprint author), Univ Vienna, Sch Med, Vienna Gen Hosp AKH, Mol Immunopathol Grp,Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.valenta@akh-wien.ac.at					Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 2001, INT ARCH ALLERGY IMM, V124, P180, DOI 10.1159/000053704; Arquint O, 1999, J ALLERGY CLIN IMMUN, V104, P1239; ASAL K, 2001, IMMUNITY, V14, P791; Ball T, 1999, FASEB J, V13, P1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; BALL T, 1994, J BIOL CHEM, V269, P28323; Bohle B, 1998, J IMMUNOL, V160, P2022; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Campbell AM, 1998, AM J RESP CELL MOL, V19, P92; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.3.CO;2-C; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; DARIETS SE, 1996, NATURE, V383, P247; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; DOLECEK C, 1995, CLIN EXP ALLERGY, V25, P879, DOI 10.1111/j.1365-2222.1995.tb00031.x; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ferreira F, 1998, FASEB J, V12, P231; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; FLICKER S, IN PRESS EUR J IMMUN; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; GOUNNI AS, 1994, NATURE, V367, P183; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; Groux H, 1997, NATURE, V389, P737; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; Hasegawa S, 1999, BLOOD, V93, P2543; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Jahnsen FL, 2000, J IMMUNOL, V165, P4062; JUTEL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kita H, 1999, J IMMUNOL, V162, P6901; Korematsu S, 2000, J IMMUNOL, V165, P2895; Kraft S, 1998, J IMMUNOL, V161, P1000; Kubo S, 2001, J IMMUNOL, V167, P3427; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; LECLDE MJ, 2000, LANCET, V356, P2144; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; Lonjou C, 2000, P NATL ACAD SCI USA, V97, P10942, DOI 10.1073/pnas.97.20.10942; Loveless MH, 1940, J IMMUNOL, V38, P25; LSE YA, 2000, NAT GENET, V26, P470; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MARSH DG, 1970, IMMUNOLOGY, V18, P449; Masten BJ, 1999, J IMMUNOL, V162, P1310; Maurer D, 1996, J IMMUNOL, V157, P607; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Noon L, 1911, LANCET, V1, P1572; Nopp A, 2000, J ALLERGY CLIN IMMUN, V106, P101, DOI 10.1067/mai.2000.106924; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Prausnitz C, 1921, ZBL BAKT           1, V86, P160; ROCKLIN RE, 1980, NEW ENGL J MED, V302, P1213, DOI 10.1056/NEJM198005293022201; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Schramm G, 1999, J IMMUNOL, V162, P2406; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; SLUMBLES PA, 1998, J EXP MED, V188, P2019; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith SJ, 2000, J ALLERGY CLIN IMMUN, V105, P309, DOI 10.1016/S0091-6749(00)90081-2; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; STEINBERGER P, 1995, J ALLERGY CLIN IMMUN, V96, P209, DOI 10.1016/S0091-6749(95)70010-2; Steinberger P, 1996, J BIOL CHEM, V271, P10967; STULL ARTHUR, 1940, JOUR ALLERGY, V11, P439, DOI 10.1016/S0021-8707(40)90456-7; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Treter S, 2000, CELL IMMUNOL, V206, P116, DOI 10.1006/cimm.2000.1739; Turner H, 1999, NATURE, V402, pB24; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANFLEIJSEN FC, 1997, J INVEST DERMATOL, V108, P530; vanHalteren AG, 1997, J IMMUNOL, V159, P3009; VANREE R, 1996, J ALLERGY CLIN IMMUN, V98, P1028; Vrtala S, 2000, J IMMUNOL, V165, P6653; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339	120	217	227	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733			NAT REV IMMUNOL	Nat. Rev. Immunol.	JUN	2002	2	6					446	453		10.1038/nri824		8	Immunology	Immunology	636DE	WOS:000180438600024	12093011	
J	Sicherer, SH; Furlong, TJ; Munoz-Furlong, A; Burks, AW; Sampson, HA				Sicherer, SH; Furlong, TJ; Munoz-Furlong, A; Burks, AW; Sampson, HA			A voluntary registry for peanut and tree nut allergy: Characteristics of the first 5149 registrants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; anaphylaxis; peanut; tree nuts	FOOD; PREVALENCE; SENSITIZATION; CHILDREN; BIRTH; SKIN	Background: A voluntary registry of individuals with peanut and/or tree nut allergy was established in 1997 to learn more about these food allergies. Objective: The purpose of this study was to elucidate a variety of features of peanut and tree nut allergy among the first 5149 registry participants. Methods: The registry was established through use of a structured questionnaire distributed to all members of the Food Allergy and Anaphylaxis Network and to patients by allergists. Parental surrogates completed the forms for children under the age of 18 years. Results: Registrants were primarily children (89% of registrants were younger than 18 years of age: the median age was 5 years), reflecting the membership of the Network. Isolated peanut allergy was reported by 3482 registrants (68%), isolated tree nut allergy by 464 (9%), and allergy to both foods by 1203 (23%). Registrants were more likely to have been born in October, November, or December (odds ratio, 1.2; 95% CI, 1.18-1.23; P < .0001). The median age of reaction to peanut was 14 months, and the median age of reaction to tree nuts was 36 months; these represented the first known exposure for 74% and 68% of registrants, respectively. One half of the reactions involved more than 1 organ system, and more than 75% required treatment, frequently from medical personnel. Registrants with asthma were more likely than those without asthma to have severe reactions (33% vs 21%; P < .0001). In comparison with initial reactions, subsequent reactions due to accidental ingestion were more severe. more common outside the home, and more likely to be treated with epinephrine. Conclusions: Allergic reactions to peanut and tree nut are frequently severe, often occur on the first known exposure, and can become more severe over time.	CUNY Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY 10029 USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA; Univ Arkansas Med Sci, Arkansas Childrens Hosp, Little Rock, AR 72205 USA	Sicherer, SH (reprint author), CUNY Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [K23 AI 01709-01]; NICHD NIH HHS [HD28822-08]		AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; *CDCP, 2000, NATL VIT STAT REP, V48, P1; Emmett SE, 1999, ALLERGY, V54, P380, DOI 10.1034/j.1398-9995.1999.00768.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Furlong TJ, 1998, J ALLERGY CLIN IMMUN, V101, pS104; Hourihane JO, 1996, BRIT MED J, V313, P518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Hourihane JO, 1998, BRIT MED J, V316, P1271; KEATING MU, 1990, J ALLERGY CLIN IMMUN, V86, P41, DOI 10.1016/S0091-6749(05)80121-6; Kusunoki T, 1999, J ALLERGY CLIN IMMUN, V103, P1148, DOI 10.1016/S0091-6749(99)70191-0; Moneret-Vautrin DA, 1998, CLIN EXP ALLERGY, V28, P1113, DOI 10.1046/j.1365-2222.1998.00370.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sarpong SB, 1998, J ALLERGY CLIN IMMUN, V101, P566, DOI 10.1016/S0091-6749(98)70369-0; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI 10.1067/mai.2000.108105; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V107, pS231; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SICHERER SH, 1999, J ALLERGY CLIN IMMUN, V103, P186; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473; Tariq SM, 1996, BRIT MED J, V313, P514; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	27	217	226	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1					128	132				5	Allergy; Immunology	Allergy; Immunology	458AN	WOS:000170171200019	11447394	
J	Peng, RD; Dominici, F; Pastor-Barriuso, R; Zeger, SL; Samet, JM				Peng, RD; Dominici, F; Pastor-Barriuso, R; Zeger, SL; Samet, JM			Seasonal analyses of air pollution and mortality in 100 US cities	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						air pollution; epidemiologic methods; models; statistical; mortality; seasons	PARTICULATE MATTER; TIME-SERIES; RESPONSE RELATIONSHIPS; PHILADELPHIA; HEALTH; EXPOSURE; CHILDREN; PROJECT; MODELS; ASTHMA	Time series models relating short-term changes in air pollution levels to daily mortality counts typically assume that the effects of air pollution on the log relative rate of mortality do not vary with time. However, these short-term effects might plausibly vary by season. Changes in the sources of air pollution and meteorology can result in changes in characteristics of the air pollution mixture across seasons. The authors developed Bayesian semiparametric hierarchical models for estimating time-varying effects of pollution on mortality in multisite time series studies. The methods were applied to the database of the National Morbidity and Mortality Air Pollution Study, which includes data for 100 US cities, for the period 1987-2000. At the national level, a 10-mug/m(3) increase in particulate matter less than 10 mum in aerodynamic diameter at a 1-day lag was associated with 0.15% (95% posterior interval (PI): -0.08, 0.39), 0.14% (95% PI: -0.14, 0.42), 0.36% (95% PI: 0.11, 0.61), and 0.14% (95% PI: -0.06, 0.34) increases in mortality for winter, spring, summer, and fall, respectively. An analysis by geographic region found a strong seasonal pattern in the Northeast (with a peak in summer) and little seasonal variation in the southern regions of the country. These results provide useful information for understanding particle toxicity and guiding future analyses of particle constituent data.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD 21205 USA; Inst Salud Carlos III, Natl Ctr Epidemiol, Epidemiol & Biostat Sect, Madrid, Spain; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Peng, RD (reprint author), Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, 615 N Wolfe St, Baltimore, MD 21205 USA.	rpeng@jhsph.edu			NHLBI NIH HHS [T32 HL 07024]; NIEHS NIH HHS [P30 ES 03819, R01 ES 012054]		Bell ML, 2004, ANNU REV PUBL HEALTH, V25, P247, DOI 10.1146/annurev.publhealth.25.102802.124329; Daniels MJ, 2000, AM J EPIDEMIOL, V152, P397, DOI 10.1093/aje/152.5.397; Dockery D., 1996, PARTICLES OUR AIR CO, P123; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2002, AM J EPIDEMIOL, V156, P193, DOI 10.1093/aje/kwf062; Dominici F, 2002, J AM STAT ASSOC, V97, P100, DOI 10.1198/016214502753479266; Dominici F, 2003, MORTALITY RESIDENTS, P9; Everson PJ, 2000, J ROY STAT SOC B, V62, P399, DOI 10.1111/1467-9868.00239; Hastie T., 1990, GENERALIZED ADDITIVE; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Keeler GJ, 2002, ENVIRON HEALTH PERSP, V110, P173; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Klepeis NE, 2001, J EXPO ANAL ENV EPID, V11, P231, DOI 10.1038/sj.jea.7500165; Moolgavkar SH, 2003, INHAL TOXICOL, V15, P877, DOI 10.1080/08958370390215767; MOOLGAVKAR SH, 1995, EPIDEMIOLOGY, V6, P476, DOI 10.1097/00001648-199509000-00003; Moolgavkar SH, 1996, EPIDEMIOLOGY, V7, P420, DOI 10.1097/00001648-199607000-00014; *NATL CTR ENV ASS, 1996, OFF RES DEV NAT CTR; *NATL RES COUNC, 2004, NAT AC SCI RES PRIOR; *OFF RES DEV, 1996, EPA600P95001AF; *OFF RES DEV, 2003, EPA600P99002AD; Peng RD, 2004, R NEWS, V4, P10; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; R Development Core Team. R, 2004, LANG ENV STAT COMP; Samet J, 1998, ENVIRON RES, V77, P9, DOI 10.1006/enrs.1997.3821; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samet J.M., 2000, NATL MORBIDITY MORTA; Samoli E, 2001, ENVIRON HEALTH PERSP, V109, P349, DOI 10.2307/3454893; SCHWARTZ J, 1994, CAN J STAT, V22, P471, DOI 10.2307/3315405; SCHWARTZ J, 1994, ENVIRON HEALTH PERSP, V102, P186, DOI 10.2307/3431609; Spengler J.D., 1996, PARTICLES OUR AIR CO, P41; Stolwijk AM, 1999, J EPIDEMIOL COMMUN H, V53, P235; STYER P, 1995, ENVIRON HEALTH PERSP, V103, P490, DOI 10.2307/3432588; Touloumi G, 2004, ENVIRONMETRICS, V15, P101, DOI 10.1002/env.623; Wallace LA, 2003, ENVIRON HEALTH PERSP, V111, P1265, DOI 10.1289/ehp.6135	34	216	227	5	26	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	MAR 15	2005	161	6					585	594		10.1093/aje/kwi075		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	903DQ	WOS:000227406100010	15746475	
J	Scrivener, S; Yemaneberhan, H; Zebenigus, M; Tilahun, D; Girma, S; Ali, S; McElroy, P; Custovic, A; Woodcock, A; Pritchard, D; Venn, A; Britton, J				Scrivener, S; Yemaneberhan, H; Zebenigus, M; Tilahun, D; Girma, S; Ali, S; McElroy, P; Custovic, A; Woodcock, A; Pritchard, D; Venn, A; Britton, J			Independent effects of intestinal parasites infection and domestic allergen exposure on risk of wheeze in Ethiopia: a nested case-control study	LANCET			English	Article							EXERCISE-INDUCED BRONCHOSPASM; KENYAN SCHOOL-CHILDREN; PAPUA-NEW-GUINEA; HOUSE-DUST MITE; ASTHMA; PREVALENCE; URBAN; ATOPY; HOOKWORM; ASSOCIATION	Background Why asthma is rare in rural subsistence societies is not clear. We tested the hypotheses that the risk of asthma is reduced by intestinal parasites or hepatitis A infection, and increased by exposure to dust-mite allergen or organophosphorus insecticides in urban and rural areas of Jimma, Ethiopia. Methods From 12876 individuals who took part in a study of asthma and atopy in urban and rural Jimma in 1996, we identified all who reported wheeze in the previous 12 months, and a random subsample of controls. In 1999, we assessed parasites in faecal samples, Der p 1 levels in bedding, hepatitis A antibodies, serum cholinesterase (a marker of organophosphorus exposure), total and specific serum IgE, and skin sensitisation to Dermatophagoides pteronyssinus in 205 cases and 399 controls aged over 16 years. The effects of parasitosis, Der p 1 level, hepatitis A seropositivity, and cholinesterase concentration on risk of wheeze, and the role of IgE and skin sensitisation in these associations, were analysed by multiple logistic regression. Findings The risk of wheeze was independently reduced by hookworm infection by an odds ratio of 0.48 (95% CI 0.24-0.93, p=0.03), increased in relation to Der p 1 level (odds ratio per quartile 1.26 [1.00-1.59], p=0.05), and was unrelated to hepatitis A seropositivity or cholinesterase concentration. In the urban population, D pteronyssinus skin sensitisation was more strongly related to wheeze (9.45 [5.03-17.75]) than in the rural areas (1.95 [0.58-6.61], p for interaction=0.017), where D pteronyssinus sensitisation was common, but unrelated to wheeze in the presence of high-intensity parasite infection. Interpretation High degrees of parasite infection might prevent asthma symptoms in atopic individuals.	Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England; Jimma Univ, Dept Internal Med, Jima, Ethiopia; Univ Nottingham, Sch Pharmaceut Sci, Boots Sci Inst, Nottingham NG7 2RD, England; Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Britton, J (reprint author), Univ Nottingham, City Hosp, Div Resp Med, Nottingham NG5 1PB, England.		Britton, John/G-9705-2011; Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578			Armstrong PB, 2001, TRENDS IMMUNOL, V22, P47, DOI 10.1016/S1471-4906(00)01803-2; BUCHANAN DJ, 1974, POSTGRAD MED J, V50, P680; Chow SC, 2000, PARASITE IMMUNOL, V22, P21, DOI 10.1046/j.1365-3024.2000.00270.x; CLYMER JM, SABIN I DEV HOOKWORM; Culley FJ, 2000, J IMMUNOL, V165, P6447; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Faniran AO, 1999, THORAX, V54, P606; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Ng'ang'a LW, 1998, THORAX, V53, P919; NUTMAN TB, 1991, MEASUREMENT IGE RESP; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; PRITCHARD DI, 1990, PARASITOLOGY, V100, P317; Pritchard DI, 1999, PARASITE IMMUNOL, V21, P439, DOI 10.1046/j.1365-3024.1999.00238.x; QUINNELL RJ, 1993, PARASITOLOGY, V106, P379; ROACH TIA, 1988, PARASITE IMMUNOL, V10, P279, DOI 10.1111/j.1365-3024.1988.tb00221.x; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VENN AJ, IN PRESS AM J RESP C; WARRELL DA, 1975, Q J MED, V44, P325; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; Weiss ST, 2000, J ALLERGY CLIN IMMUN, V105, P205, DOI 10.1016/S0091-6749(00)90067-8; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Yobo EODA, 1997, THORAX, V52, P161	30	216	228	2	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 3	2001	358	9292					1493	1499		10.1016/S0140-6736(01)06579-5		7	Medicine, General & Internal	General & Internal Medicine	490MN	WOS:000172055800011	11705561	
J	Ernst, P; Cormier, Y				Ernst, P; Cormier, Y			Relative scarcity of asthma and atopy among rural adolescents raised on a farm	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							RESPIRATORY-HEALTH-SURVEY; HAY-FEVER; ALLERGIC RHINITIS; EAST-GERMANY; PREVALENCE; CHILDHOOD; COMMUNITY; INCREASE; SCHOOLCHILDREN; ENVIRONMENT	We determined the prevalence of markers of atopy and asthma among 1,199 rural secondary school students ages 12 to 19 yr. Subjects identified as having been raised on a farm and half as many subjects without regular exposure to a farming environment from the same school class completed a respiratory symptom questionnaire and underwent allergy skin tests and a methacholine bronchoprovocation test. Current wheeze, airways hyperresponsiveness (AHR), and skin test positivity to inhaled allergens were all significantly less common among adolescents raised on the farm and these differences were especially pronounced in girls. After adjusting for gender and current smoking, the odds ratios for being raised on a farm were: 0.70 (95% CI 0.52 to 0.95) for current wheeze; 0.59 (95% CI 0.37 to 0.95) for asthma, defined as the concomitant occurrence of wheeze and AHR; and 0.58 (95% CI 0.46 to 0.75) for atopy defined as a positive reaction to any one of 24 common inhaled allergens. These associations were also not significantly altered by adjusting for the difference in the number of siblings.	Hop Laval, Ctr Pneumol, Unite Rech, Quebec City, PQ, Canada; McGill Univ, Ctr Hlth, Div Resp, Montreal, PQ, Canada	Ernst, P (reprint author), Royal Victoria Hosp, 687 Pine Ave W,R4-29, Montreal, PQ H3A 1A1, Canada.						ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; American Thoracic Society, 1998, AM J RESP CRIT CARE, V158, pS1; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BJORKSTEN B, 1997, EUR RESPIR REV, V7, P11; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Butland BK, 1999, EUR RESPIR J, V13, P744, DOI 10.1034/j.1399-3003.1999.13d08.x; Helms PJ, 1999, ARCH DIS CHILD, V80, P401; Holt PG, 1997, THORAX, V52, P1; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; Omran M, 1996, BRIT MED J, V312, P34; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; vonMutius E, 1996, BRIT MED J, V312, P1448; VONMUTIUS E, 1994, BRIT MED J, V308, P692; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	26	216	218	0	6	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY	2000	161	5					1563	1566				4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	312LU	WOS:000086945400029	10806155	
J	James, AL; Palmer, LJ; Kicic, E; Maxwell, PS; Lagan, SE; Ryan, GF; Musk, AW				James, AL; Palmer, LJ; Kicic, E; Maxwell, PS; Lagan, SE; Ryan, GF; Musk, AW			Decline in lung function in the Busselton Health Study - The effects of asthma and cigarette smoking	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; epidemiology; lung function tests; smoking	OBSTRUCTIVE PULMONARY-DISEASE; PERIPHERAL LEUKOCYTE COUNT; AIR-FLOW OBSTRUCTION; LONGITUDINAL DECLINE; WESTERN-AUSTRALIA; CHILDHOOD ASTHMA; MILD ASTHMA; INFLAMMATION; ADULTS; HYPERRESPONSIVENESS	Asthma in adults may be associated with chronic airflow obstruction, possibly resulting from airway disease in early life and/or a greater rate of decline in lung function in adult life compared with those with asthma. Treatment and cigarette smoking may also influence the rate of decline of lung function. The aim of this analysis was to examine the level and rate of decline in lung function in relationship to asthma and cigarette smoking in adults. Subjects (n = 9,317) had participated as adults (> 18 years) in one or more of the cross-sectional Busselton Health Surveys between 1966 and 1981 or in the follow-up study of 1994/1995. The effects of sex, doctor-diagnosed asthma, smoking status, and anthropometric data on the level and rate of decline in FEV1 were examined in a linear mixed effects model. At the age of 19 years, FEV1 was reduced in subjects with asthma but was similar in smokers and nonsmokers. Males, taller subjects, smokers, and subjects with asthma had greater declines in FEV1 with age. Smoking and asthma had additive but not multiplicative effects on decline. Thus, asthma is associated with reduced lung function at the beginning of adult life as well as an increased rate of decline during adult life.	Queen Elizabeth II Med Ctr, W Australian Sleep Disorders Res Inst, Nedlands, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Sch Med & Pharmacol, Nedlands, WA 6009, Australia; Western Australia Inst Med Res, Lab Genet Epidemiol, Nedlands, WA, Australia; Sir Charles Gairdner Hosp, Dept Resp Med, Nedlands, WA 6009, Australia	James, AL (reprint author), Queen Elizabeth II Med Ctr, W Australian Sleep Disorders Res Inst, Level 5,G Block,Hosp Ave, Nedlands, WA 6009, Australia.	ajames@it.net.au	Palmer, Lyle/K-3196-2014	Palmer, Lyle/0000-0002-1628-3055			Altose MD, 2000, NEW ENGL J MED, V343, P1902; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1979, AM REV RESPIR DIS, V119, P831; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Brieman L., 1984, CLASSIFICATION REGRE; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BURCHFIEL CM, 1995, AM J RESP CRIT CARE, V151, P1778; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; CHANYEUNG M, 1988, THORAX, V43, P462, DOI 10.1136/thx.43.6.462; DOMPELING E, 1993, ANN INTERN MED, V118, P770; Fletcher C, 1976, NATURAL HIST CHRONIC; James AL, 1999, EUR RESPIR J, V13, P1115, DOI 10.1034/j.1399-3003.1999.13e29.x; JAMES AL, 1998, BUSSELTON STUDY MAPP, P92; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LAITINEN LA, 1988, EUR RESPIR J, V1, P488; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Medical Research Council on the aetiology of chronic bronchitis, 1960, BRIT MED J, V2, P1965; MUSK AW, 1998, BUSSELTON HLTH STUDY, P99; OSWALD H, 1994, BRIT MED J, V309, P95; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Panizza J, 1999, AM J RESP CRIT CARE, V159, pA134; PEAT JK, 1992, BRIT MED J, V305, P1326; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; PEAT JK, 1990, THORAX, V45, P32, DOI 10.1136/thx.45.1.32; SAETTA M, 1994, EUR RESPIR J, V7, P1505, DOI 10.1183/09031936.94.07081505; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sherrill D, 2003, EUR RESPIR J, V21, P95, DOI 10.1183/09031936.03.00017103; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; SPARROW D, 1984, CHEST, V86, P383, DOI 10.1378/chest.86.3.383; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; Wang ML, 1999, OCCUP ENVIRON MED, V56, P837; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309	38	215	220	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 15	2005	171	2					109	114		10.1164/rccm.200402-230OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	886UO	WOS:000226258400005	15486340	
S	Gold, DR; Wright, R				Gold, DR; Wright, R			Population disparities in asthma	ANNUAL REVIEW OF PUBLIC HEALTH	Annual Review of Public Health		English	Review; Book Chapter						children; hygiene hypothesis; smoking; allergens; traffic pollution; obesity	POSTTRAUMATIC-STRESS-DISORDER; DAY-CARE ATTENDANCE; SMALL-AREA ANALYSIS; INNER-CITY ASTHMA; LOWER RESPIRATORY ILLNESS; CORONARY HEART-DISEASE; BODY-MASS INDEX; TOTAL SERUM IGE; CHILDHOOD ASTHMA; UNITED-STATES	The prevalence of asthma in the United States is higher than in many other countries in the world. Asthma, the most common chronic disease of childhood in the United States, disproportionately burdens many socioeconomically disadvantaged urban communities. In this review we discuss hypotheses for between-country disparities in asthma prevalence, including differences in "hygiene" (e.g., family size, use of day care, early-life respiratory infection exposures, endotoxin and other farm-related exposures, microbial colonization of the infant bowel, exposure to parasites, and exposure to large domestic animal sources of allergen), diet, traffic pollution, and cigarette smoking. We present data on socioeconomic and ethnic disparities in asthma prevalence and morbidity in the United States and discuss environmental factors contributing to asthma disparities (e.g., housing conditions, indoor environmental exposures including allergens, traffic air pollution, disparities in treatment and access to care, and cigarette smoking). We discuss environmental influences on somatic growth (low birth weight, prematurity, and obesity) and their relevance to asthma disparities. The relevance of the hygiene hypothesis to the U.S. urban situation is reviewed. Finally, we discuss community-level factors contributing to asthma disparities.	Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02467 USA	Gold, DR (reprint author), Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02467 USA.	diane.gold@channing.harvard.edu; rosalind.wright@channing.harvard.edu			NHLBI NIH HHS [K08 HL04187, U10 HL72494]; NIAID NIH HHS [R01 AI 35786]; NIEHS NIH HHS [ES10932]		Acierno R, 1996, BEHAV MODIF, V20, P363, DOI 10.1177/01454455960204001; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; ATTAR BK, 1994, J CLIN CHILD PSYCHOL, V23, P391, DOI 10.1207/s15374424jccp2304_5; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; BECKHAM JC, 1995, J TRAUMA STRESS, V8, P461, DOI 10.1007/BF02102970; BENSON CB, 1998, DIAGNOSTIC ULTRASOUN, P1013; BENSON V, 1998, VITAL HLTH STAT, P10; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; BOYCE WT, 1995, PSYCHOSOM MED, V57, P411; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Britton J, 2003, AM J RESP CRIT CARE, V168, P266, DOI 10.1164/rccm.2305011; BUSSE WE, 1994, AM J RESP CRIT CARE, V151, P249; BVALDINI M, 1999, AM J RESP CELL MOL B, V20, P976; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; CDC, 1998, TOB US US RAC ETHN M; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; *COMM UND EL RAC E, 2002, UN TREAT CONFR RAC E; CURRY SJ, 1993, AM J PREV MED, V9, P78; DEKKER C, 1991, CHEST, V100, P92; DERANT R, 1995, DEV BEHAV PEDIAT, V16, P233; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiezRoux AV, 1997, AM J EPIDEMIOL, V146, P48; DOHRENWEND BP, 2000, SOCIAL STATUS PSYCHO; Doubilet PM, 2000, ULTRASONOGRAPHY OBST, P206; Evans GW, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P365; FEIGELMAN W, 1989, J PSYCHOACTIVE DRUGS, V21, P299; Ganz ML, 2000, AM J PUBLIC HEALTH, V90, P367, DOI 10.2105/AJPH.90.3.367; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GRAVES E, 1996, NATL CENT HLTH STAT, V13, pR1; Green RS, 2003, ENV HLTH PERSPECT, V112, P61, DOI DOI 10.1289/EHP.6566; Grischkan J, 2004, J PEDIATR-US, V144, P321, DOI 10.1016/j.jpeds.2003.11.029; HAAN M, 1987, AM J EPIDEMIOL, V125, P989; Haan M. N., 1989, PATHWAYS HLTH ROLE S, P76; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; HOLDEN G, 1991, SOC WORK HEALTH CARE, V16, P53; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504; HORROBIN DF, 1987, MED HYPOTHESES, V22, P421, DOI 10.1016/0306-9877(87)90037-5; Howard DE, 1999, J ADOLESCENT HEALTH, V25, P396, DOI 10.1016/S1054-139X(99)00102-0; *INT MED COMM ASS, 2000, CLEAR AIR ASTHM IND; ISAACS MR, 1992, VIOLENCE IMPACT COMM; Isaacs SL, 2004, NEW ENGL J MED, V351, P1137, DOI 10.1056/NEJMsb040329; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Karvonen S, 1996, SOC SCI MED, V43, P1467, DOI 10.1016/0277-9536(96)00044-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kaufman JS, 2001, EPIDEMIOLOGY, V12, P157, DOI 10.1097/00001648-200103000-00006; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Kawachi I, 2003, NEIGHBORHOODS HLTH; Kennedy BP, 1996, BRIT MED J, V312, P1004; Kennedy BP, 1998, SOC SCI MED, V47, P7, DOI 10.1016/S0277-9536(98)00097-5; Kilpatrick KL, 1998, CHILD ABUSE NEGLECT, V22, P319, DOI 10.1016/S0145-2134(97)00178-6; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; KLEINSCHMIDT I, 1997, J EPIDEMIOL COMMUNIT, V87, P1113; Krebs NF, 2003, PEDIATRICS, V112, P424; LAVEIST TA, 1993, MILBANK Q, V71, P41, DOI 10.2307/3350274; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/rccm.2103044; Lochner K, 1999, HEALTH PLACE, V5, P259, DOI 10.1016/S1353-8292(99)00016-7; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; MCKINLAY JB, 1975, POVERTY HLTH SOCIOLO, P224; MCLEAN DE, 1993, AM J PREV MED, V9, P39; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; MURPHY S, 1997, 974051 NATL I HLTH N; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; PEAT JK, 1992, EUR RESPIR J, V5, P921; Perez-Stable EJ, 2001, AM J PUBLIC HEALTH, V91, P1424, DOI 10.2105/AJPH.91.9.1424; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; PIERSON WE, 1992, J ALLERGY CLIN IMMUN, V90, P557, DOI 10.1016/0091-6749(92)90128-O; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339; RABKIN JG, 1976, SCIENCE, V194, P1013, DOI 10.1126/science.790570; RAPER NR, 1992, J AM COLL NUTR, V11, P304; RAPPAPORT S, 1998, MMWR-MORBID MORTAL W, V47, P1022; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Reijneveld SA, 1998, INT J EPIDEMIOL, V27, P33, DOI 10.1093/ije/27.1.33; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Robert SA, 1998, J HEALTH SOC BEHAV, V39, P18, DOI 10.2307/2676387; Roberts EM, 2002, J NATL MED ASSOC, V94, P215; Roberts EM, 1997, AM J PUBLIC HEALTH, V87, P597, DOI 10.2105/AJPH.87.4.597; ROMANO PS, 1991, AM J PUBLIC HEALTH, V81, P1415, DOI 10.2105/AJPH.81.11.1415; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rowley D L, 2001, Matern Child Health J, V5, P71, DOI 10.1023/A:1011392830732; Salmond C, 1999, J EPIDEMIOL COMMUN H, V53, P476; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; Schwartz J, 2004, PEDIATRICS, V113, P1037; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SHAGENA MM, 1988, J DEV BEHAV PEDIATR, V9, P252; STEIN MJ, 1988, ARTHRITIS RHEUM, V31, P876, DOI 10.1002/art.1780310708; Strachan DP, 1997, THORAX, V52, P905; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1998, THORAX, V53, P204; Strachan DP, 2000, THORAX S1, V55, pS2; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Tager IB, 1998, AM J RESP CRIT CARE, V158, P349; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401; U.S. Department of Health and Human Services, 1991, HLTH PEOPL 2000 NAT; Vintzileos AM, 2002, AM J OBSTET GYNECOL, V187, P1254, DOI 10.1067/mob.2002.127140; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; WAGENER DK, 1993, TOXICOL IND HEALTH, V9, P775; Watson JP, 1996, EUR RESPIR J, V9, P2087, DOI 10.1183/09031936.96.09102087; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; Wilkinson R. G, 1996, UNHEALTHY SOC AFFLIC; Wilson W. J, 1987, TRULY DISADVANTAGED; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Wright RJ, 2003, NEIGHBORHOODS HLTH, P233; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3; Yamada E, 2002, J INVEST ALLERG CLIN, V12, P34	155	215	219	17	50	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0163-7525		978-0-8243-2726-2	ANNU REV PUBL HEALTH	Annu. Rev. Public Health		2005	26						89	113		10.1146/annurev.publhealth.26.021304.144528		25	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	924LY	WOS:000228981500005	15760282	
J	Akdis, CA; Blaser, K				Akdis, CA; Blaser, K			Mechanisms of interleukin-10-mediated immune suppression	IMMUNOLOGY			English	Review							BEE VENOM PHOSPHOLIPASE-A2; T-CELL EPITOPE; PERIPHERAL-BLOOD EOSINOPHILS; INHIBITS CYTOKINE PRODUCTION; HUMAN LYMPHOCYTES-T; PHOSPHATIDYLINOSITOL 3-KINASE; IN-VITRO; B-CELL; TYROSINE PHOSPHORYLATION; DIFFERENTIAL REGULATION	Specific immune suppression and induction of anergy are essential processes in the regulation and circumvention of immune defence. Interleukin-10 (IL-10), a suppressor cytokine of T-cell proliferative and cytokine responses, plays a key regulatory role in tolerizing exogenous antigens during specific immunotherapy (SIT) of allergy and natural exposure to antigens. Specific T-cell tolerance is directed against the T-cell epitopes of an antigen and characterized by suppressed proliferative and T helper type 1 (Th1) and type 2 (Th2) cytokine responses. IL-10 elicits tolerance in T cells by selective inhibition of the CD28 co-stimulatory pathway and thereby controls suppression and development of antigen-specific immunity. IL-10 only inhibits T cells stimulated by low numbers of triggered T-cell receptors and which therefore depend on CD28 co-stimulation. T cells receiving a strong signal from the T-cell receptor alone, and thus not requiring CD28 co-stimulation, are not affected by IL-10. IL-10 inhibits CD28 tyrosine phosphorylation, the initial step of the CD28 signalling pathway, and consequently the phosphatidylinositol 3-kinase p85 binding to CD28. Together these results demonstrate that IL-10-induced selective inhibition of the CD28 co-stimulatory pathway acts as a decisive mechanism in determining whether a T cell will contribute to an immune response or become anergic.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Akdis, CA (reprint author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.						Akdis CA, 2000, INT ARCH ALLERGY IMM, V121, P261, DOI 10.1159/000024352; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1998, EUR J IMMUNOL, V28, P914, DOI 10.1002/(SICI)1521-4141(199803)28:03<914::AID-IMMU914>3.0.CO;2-C; Akdis CA, 1999, FASEB J, V13, P603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Akdis CA, 1997, EUR J IMMUNOL, V27, P2351, DOI 10.1002/eji.1830270933; Akdis CA, 1997, J ALLERGY CLIN IMMUN, V99, P345, DOI 10.1016/S0091-6749(97)70052-6; BACETTA R, 1994, J EXP MED, V179, P493; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Blaser K, 1998, INT ARCH ALLERGY IMM, V117, P1, DOI 10.1159/000023984; BOUSSIOTIS VA, 1994, SCIENCE, V266, P1039, DOI 10.1126/science.7973657; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1992, IMMUNOTHERAPY IGE ME, P13; DE WMR, 1991, J EXP MED, V174, P1209; DELPRETE G, 1993, J IMMUNOL, V150, P353; DHAND R, 1994, EMBO J, V13, P511; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; ESSERY G, 1988, IMMUNOLOGY, V64, P413; Faith A, 1999, J IMMUNOL, V162, P1836; Faith A, 1997, J IMMUNOL, V159, P53; FINBLOOM DS, 1995, J IMMUNOL, V155, P1979; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FREEMAN GJ, 1993, SCIENCE, V262, P909, DOI 10.1126/science.7694363; Gaglani B, 1997, ANN ALLERG ASTHMA IM, V79, P259; GREEN DR, 1983, ANNU REV IMMUNOL, V1, P493; GREENSTEIN JL, 1992, J ALLERGY CLIN IMMUN, V89, P322; Groux H, 1997, NATURE, V389, P737; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; IPPOLITI F, 1997, ALLERG IMMUNOL PARIS, V29, P123; Ito S, 1999, BLOOD, V93, P1456; Joss A, 2000, EUR J IMMUNOL, V30, P1683, DOI 10.1002/1521-4141(200006)30:6<1683::AID-IMMU1683>3.0.CO;2-A; Jutel M, 1995, J IMMUNOL, V154, P4178; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; LEE KP, 1990, J IMMUNOL, V145, P344; LINSLEY PS, 1991, J EXP MED, V173, P721, DOI 10.1084/jem.173.3.721; Marcotte GV, 1998, J ALLERGY CLIN IMMUN, V101, P506, DOI 10.1016/S0091-6749(98)70358-6; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; MOSMANN TR, 1996, IMMUNOL TODAY, V17, P142; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; Parijs L., 1998, SCIENCE, V280, P243, DOI 10.1126/science.280.5361.243; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; WALKER C, 1991, J IMMUNOL, V146, P1829; Ward SG, 1996, IMMUNOL TODAY, V17, P187, DOI 10.1016/0167-5699(96)80618-9; WETTERWALD A, 1985, INT ARCH ALLER A IMM, V77, P195	66	215	235	1	7	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0019-2805			IMMUNOLOGY	Immunology	JUN	2001	103	2					131	136		10.1046/j.1365-2567.2001.01235.x		6	Immunology	Immunology	443ZL	WOS:000169373400001	11412299	
J	Lack, G				Lack, Gideon			Epidemiologic risks for food allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						risk factors; food allergy; allergen	ATOPIC-DERMATITIS; PEANUT ALLERGY; VITAMIN-D; QUESTIONNAIRE SURVEY; ORAL TOLERANCE; NUT ALLERGY; SKIN PRICK; FOLLOW-UP; CHILDREN; INFANT	This article reviews possible risk factors and theories for the development of food allergy. It is noted that previous strategies to prevent food allergy through allergen avoidance during pregnancy, breast-feeding, and infancy have more recently been called into question. Alternative hypotheses are examined with respect to food allergy, namely the hygiene hypothesis, the dietary fat hypothesis, the antioxidant hypothesis, and the vitamin D hypotheses. An alternative hypothesis is proposed, suggesting that sensitization to allergen occurs through environmental exposure to allergen through the skin and that consumption of food allergen induces oral tolerance. This hypothesis provides a possible explanation for the close link between eczema and the development of food allergies. It also suggests novel interventional strategies to prevent the development of food allergies.	Kings Coll London, St Thomas Hosp, Childrens Allergies Dept, London SE1 7EH, England	Lack, G (reprint author), Kings Coll London, St Thomas Hosp, Childrens Allergies Dept, 2nd Floor,S Wing, London SE1 7EH, England.	gideon.lack@kcl.ac.uk					*54 WORLD HLTH ASS, 2001, PROV AG IT 1311 GLOB; ALBERTO EJC, 2008, PEDIAT ALLERGY  0116; Amoli MM, 2002, GENES IMMUN, V3, P220, DOI 10.1038/sj.gene.6363872; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Baker SS, 2000, PEDIATRICS, V106, P346; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S; Cohen A, 2007, PEDIATR ALLERGY IMMU, V18, P217, DOI 10.1111/j.1399-3038.2006.00506.x; *COMM TOX CHEM FOO, 1998, CONS PROD ENV PEAN A; Derby CJ, 2005, PEDIATR ALLERGY IMMU, V16, P171, DOI 10.1111/j.1399-3038.2005.00232.x; Dioun AF, 2003, PEDIATR ALLERGY IMMU, V14, P307, DOI 10.1034/j.1399-3038.2003.00063.x; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Eigenmann PA, 2000, PEDIATR ALLERGY IMMU, V11, P95, DOI 10.1034/j.1399-3038.2000.00071.x; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; Host A, 2008, PEDIATR ALLERGY IMMU, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Hourihane JO, 1996, BRIT MED J, V313, P518; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LACK G, 2007, CONCEPT ORAL TOLERAN, V59, P63; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Levy Y, 2003, ALLERGY, V58, P1206, DOI 10.1046/j.1398-9995.2003.00307.x; Liu X, 2004, J ALLERGY CLIN IMMUN, V113, P489, DOI 10.1016/j.jaci.2003.12.037; Lucas JSA, 2003, PEDIATR ALLERGY IMMU, V14, P420, DOI 10.1046/j.0905-6157.2003.00095.x; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; SAARINEN UM, 1980, LANCET, V1, P166; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; SAMPSON HA, 1998, PEDIATRICS, V101, pE8; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI 10.1067/mai.2000.108105; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200324843; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Sudo N, 1997, J IMMUNOL, V159, P1739; van Reijsen FC, 1998, J ALLERGY CLIN IMMUN, V101, P207; WIST M, 2005, CLIN MOL ALLERGY, V3, P7; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019; LEAP LEARNING EARLY	52	214	226	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1331	1336		10.1016/j.jaci.2008.04.032		6	Allergy; Immunology	Allergy; Immunology	313WW	WOS:000256771700005	18539191	
J	Audicana, MT; Kennedy, MW				Audicana, M. Teresa; Kennedy, Malcolm W.			Anisakis simplex: from obscure infectious worm to inducer of immune hyersensitivity	CLINICAL MICROBIOLOGY REVIEWS			English	Review							EXCRETORY-SECRETORY PRODUCTS; PSEUDOTERRANOVA-DECIPIENS NEMATODA; GASTRO-ALLERGIC ANISAKIASIS; SERINE-PROTEASE INHIBITOR; ANI S 1; MAJOR ALLERGEN; ASCARIS-SUUM; ANTIBODY REPERTOIRE; MOLECULAR-CLONING; CROSS-REACTIVITY	Infection of humans with the nematode worm parasite Anisakis simplex was first described in the 1960s in association with the consumption of raw or undercooked fish. During the 1990s it was realized that even the ingestion of dead worms in food fish can cause severe hypersensitivity reactions, that these may be more prevalent than infection itself, and that this outcome could be associated with food preparations previously considered safe. Not only may allergic symptoms arise from infection by the parasites ("gastroallergic anisakiasis"), but true anaphylactic reactions can also occur following exposure to allergens from dead worms by food-borne, airborne, or skin contact routes. This review discusses A. simplex pathogenesis in humans, coveting immune hypersensitivity reactions both in the context of a living infection and in terms of exposure to its allergens by other routes. Over the last 20 years, several studies have concentrated on A. simplex antigen characterization and innate as well as adaptive immune response to this parasite. Molecular characterization of Anisakis allergens and isolation of their encoding cDNAs is now an active field of research that should provide improved diagnostic tools in addition to tools with which to enhance our understanding of pathogenesis and controversial aspects of A. simplex allergy. We also discuss the potential relevance of parasite products such as allergens, proteinases, and proteinase inhibitors and the activation of basophils, eosinophils, and mast cells in the induction of A. simplex-related immune hypersensitivity states induced by exposure to the parasite, dead or alive.	[Audicana, M. Teresa] Santiago Apostol Hosp, Dept Allergy & Clin Immunol, Vitoria 01004, Basque Country, Spain; [Kennedy, Malcolm W.] Univ Glasgow, Div Environm & Evolut Biol, Inst Biomed & Life Sci, Glasgow, Lanark, Scotland	Audicana, MT (reprint author), Santiago Apostol Hosp, Dept Allergy & Clin Immunol, C-Olaguibel 29, Vitoria 01004, Basque Country, Spain.	mariateresa.audicanaberasategi@hsan.osakidetza.net					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ADAMS AM, 1994, J FOOD PROTECT, V57, P311; Adams AM, 1999, J FOOD PROTECT, V62, P403; AKAO N, 1990, J HELMINTHOL, V64, P310; AKAO N, 1989, GASTRIC ANISAKIASIS, P97; Aljurf MA, 2003, ANN ONCOL, V14, P1595, DOI 10.1093/annonc/mdg442; Allen JE, 1996, INT ARCH ALLERGY IMM, V109, P3; Alonso A, 1999, ALLERGY, V54, P517, DOI 10.1034/j.1398-9995.1999.00046.x; Alonso-Gomez A, 2004, PARASITOL RES, V93, P378, DOI 10.1007/s00436-004-1085-9; Angot V, 1995, REV MED VET-TOULOUSE, V146, P791; Anibarro B, 2007, J INVEST ALLERG CLIN, V17, P168; Anibarro B, 1998, J ALLERGY CLIN IMMUN, V102, P331, DOI 10.1016/S0091-6749(98)70108-3; Arenal Vera J J, 1991, Rev Esp Enferm Dig, V79, P355; Arlian LG, 2003, ALLERGY, V58, P1299, DOI 10.1046/j.1398-9995.2003.00344.x; Armentia A, 2006, J INVEST ALLERG CLIN, V16, P258; Armentia A, 1998, J ALLERGY CLIN IMMUN, V102, P831, DOI 10.1016/S0091-6749(98)70024-7; Arrieta I, 2000, MOL BIOCHEM PARASIT, V107, P263, DOI 10.1016/S0166-6851(00)00192-4; Asaishi K., 1989, P31; ASAISHI K, 1980, Gastroenterologia Japonica, V15, P120; ASATO R, 1991, Japanese Journal of Parasitology, V40, P181; Asturias JA, 2000, ALLERGY, V55, P898, DOI 10.1034/j.1398-9995.2000.00734.x; Asturias JA, 2000, MOL BIOCHEM PARASIT, V108, P263, DOI 10.1016/S0166-6851(00)00218-8; Audicana L, 1997, VET REC, V140, P235; Audicana M, 2000, ALLERGY, V55, P28, DOI 10.1034/j.1398-9995.2000.03405.x; Audicana M. T., 2003, International handbook of foodborne pathogens, P613; Audicana MT, 2002, TRENDS PARASITOL, V18, P20, DOI 10.1016/S1471-4922(01)02152-3; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; AUDICANA MT, 2002, THESIS CASQUE COUNTR; Babu S, 2005, J IMMUNOL, V175, P1170; Baeza ML, 2005, CLIN EXP IMMUNOL, V142, P433, DOI 10.1111/j.1365-2249.2005.02952.x; Bahna SL, 2004, J ALLERGY CLIN IMMUN, V114, P125, DOI 10.1016/j.jaci.2004.04.026; Bahna SL, 2001, ANN ALLERG ASTHMA IM, V86, P414; Balic A, 2004, EUR J IMMUNOL, V34, P3047, DOI 10.1002/eji.200425167; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Belkaid Y, 2006, IMMUNOL REV, V212, P287, DOI 10.1111/j.0105-2896.2006.00409.x; BIER JW, 1988, P HELM SOC WASH, V55, P91; BIER JW, 1976, J MILK FOOD TECHNOL, V39, P132; BLAXTER ML, 1992, PARASITOL TODAY, V8, P243, DOI 10.1016/0169-4758(92)90126-M; BOUREE P, 1995, COMP IMMUNOL MICROB, V18, P75, DOI 10.1016/0147-9571(95)98848-C; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Brattig NW, 2004, J IMMUNOL, V173, P437; BRITTON C, 1992, PARASITOLOGY, V105, P325; Buzoni-Gatel D, 2006, CELL MICROBIOL, V8, P535, DOI 10.1111/j.1462-5822.2006.00692.x; Buzoni-Gatel D, 2006, TRENDS PARASITOL, V22, P448, DOI 10.1016/j.pt.2006.08.002; BUZZELL GR, 1985, T AM MICROSC SOC, V104, P86, DOI 10.2307/3226360; Caballero ML, 2004, PARASITOL RES, V93, P248, DOI 10.1007/s00436-004-1099-3; Caballero ML, 2002, ANN ALLERG ASTHMA IM, V89, P74; Cabrera Rufino, 2004, Rev. gastroenterol. Perú, V24, P335; Carretero Anibarro P., 1997, Contact Dermatitis, V37, P247; CARRETERO P, 1998, REV ESP ALERGOLOGIA, V13, P226; Carvalho EM, 2006, PARASITE IMMUNOL, V28, P525, DOI 10.1111/j.1365-3024.2006.00894.x; Cho TH, 2006, CLIN EXP IMMUNOL, V143, P203, DOI 10.1111/j.1365-2249.2005.02981.x; CHRISTIE JF, 1993, CLIN EXP IMMUNOL, V92, P125; Chung JG, 1996, CANCER LETT, V106, P1, DOI 10.1016/0304-3835(96)04288-7; Claerebout E., 2000, PARASITOLOGY S, V120, P25, DOI 10.1017/S0031182099005776; Clavel Antonio, 1993, Japanese Journal of Parasitology, V42, P445; Cliffe LJ, 2005, SCIENCE, V308, P1463, DOI 10.1126/science.1108661; Codex Alimentarius Commission, 2004, PROP DRAFT STAND REA; Comas D, 1998, TISSUE ANTIGENS, V51, P30, DOI 10.1111/j.1399-0039.1998.tb02944.x; Conde-Salazar L, 2002, CONTACT DERMATITIS, V46, P361, DOI 10.1034/j.1600-0536.2002.460612.x; Cooper PJ, 2001, INFECT IMMUN, V69, P1574, DOI 10.1128/IAI.69.3.1574-1580.2001; Couture C, 2003, AM J SURG PATHOL, V27, P1167, DOI 10.1097/00000478-200308000-00017; Creagh EM, 2006, TRENDS IMMUNOL, V27, P352, DOI 10.1016/j.it.2006.06.003; Crespo JF, 2003, ALLERGY, V58, P98, DOI 10.1034/j.1398-9995.2003.02170.x; Cuellar C, 1998, SCAND J INFECT DIS, V30, P603; Cuellar C, 2001, SCAND J IMMUNOL, V53, P483, DOI 10.1046/j.1365-3083.2001.00905.x; Cuende E, 1998, CLIN EXP RHEUMATOL, V16, P303; Daschner A, 2005, Allergol Immunopathol (Madr), V33, P31; Daschner A, 2000, Allergol Immunopathol (Madr), V28, P67; Daschner A, 2002, PARASITE IMMUNOL, V24, P243, DOI 10.1046/j.1365-3024.2002.00458.x; Daschner A, 1998, BRIT J DERMATOL, V139, P822; Daschner A, 1999, CLIN EXP ALLERGY, V29, P1260, DOI 10.1046/j.1365-2222.1999.00569.x; Daschner A, 2000, J ALLERGY CLIN IMMUN, V105, P176, DOI 10.1016/S0091-6749(00)90194-5; Daschner A, 2001, ALLERGY, V56, P1003, DOI 10.1034/j.1398-9995.2001.00207.x; Deardorff T L, 1991, Hawaii Med J, V50, P9; DEARDORFF TL, 1991, J HELMINTHOL SOC W, V58, P131; DEARDORFF TL, 1984, J FOOD PROTECT, V47, P49; DEARDORFF TL, 1989, J WILDLIFE DIS, V25, P416; DEARDORFF TL, 1990, MICROBIOLOGY MARINE, P211; deCorres LF, 1996, J INVEST ALLERG CLIN, V6, P315; del Pozo V, 1999, J ALLERGY CLIN IMMUN, V104, P637, DOI 10.1016/S0091-6749(99)70336-2; DelPozo MD, 1997, ALLERGY, V52, P576; delPozo MD, 1996, J ALLERGY CLIN IMMUN, V97, P977, DOI 10.1016/S0091-6749(96)80073-X; DESOWITZ RS, 1985, T ROY SOC TROP MED H, V79, P256, DOI 10.1016/0035-9203(85)90351-7; *E C SCIENT COMM V, 1998, ALL REACT ING AN SIM; Ellyard JI, 2007, TISSUE ANTIGENS, V70, P1, DOI 10.1111/j.1399-0039.2007.00869; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; Elston DM, 2006, J AM ACAD DERMATOL, V54, P172, DOI 10.1016/j.jaad.2005.09.020; FABRESSE FX, 1984, PRESSE MED, V13, P1004; Falcao H, 2002, ALLERGY, V57, P44, DOI 10.1034/j.1398-9995.2002.13429.x; Falcone FH, 2006, EXP DERMATOL, V15, P855, DOI 10.1111/j.1600-0625.2006.00477.x; Feldmeier H., 1993, European Microbiology, V2, P30; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Foti C, 2002, ACTA DERM-VENEREOL, V82, P121, DOI 10.1080/00015550252948167; Garcia F, 2001, J INVEST ALLERG CLIN, V11, P49; Garcia M, 1997, J ALLERGY CLIN IMMUN, V99, P497, DOI 10.1016/S0091-6749(97)70076-9; Garcia-Hernandez P, 2007, EXP PARASITOL, V115, P1, DOI 10.1016/j.exppara.2006.04.013; Gazzinelli RT, 2006, NAT REV IMMUNOL, V6, P895, DOI 10.1038/nri1978; Gomez-Aguado F, 2003, PARASITOL RES, V89, P379, DOI 10.1007/s00436-002-0726-0; Gonzalez-Munoz M, 2005, CYTOM PART B-CLIN CY, V68B, P31, DOI 10.1002/cyto.b.20070; GOTO C, 1990, PARASITOL RES, V76, P653, DOI 10.1007/BF00931082; Gracia-Bara MT, 2001, ANN ALLERG ASTHMA IM, V86, P679; Guarneri F, 2007, INT J DERMATOL, V46, P146; Harnett W, 2006, PARASITE IMMUNOL, V28, P535, DOI 10.1111/j.1365-3024.2006.00893.x; Hartmann S, 2003, PARASITE IMMUNOL, V25, P9, DOI 10.1046/j.1365-3024.2003.00496.x; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; Holland MJ, 2005, IMMUNOL LETT, V96, P93, DOI 10.1016/j.imlet.2004.08.005; HOTEZ P, 1994, J INFECT DIS, V170, P918; Hunter MM, 2004, ALIMENT PHARM THERAP, V19, P167, DOI 10.1111/j.0269-2813.2004.01803.x; Hwang YK, 2003, PARASITE IMMUNOL, V25, P1, DOI 10.1046/j.1365-3024.2003.00493.x; Iglesias R, 1997, PARASITOL RES, V83, P755, DOI 10.1007/s004360050335; IGLESIAS R, 1993, PARASITE IMMUNOL, V15, P243, DOI 10.1111/j.1365-3024.1993.tb00607.x; Iglesias R, 1995, J HELMINTHOL, V69, P319; IKEDA K, 1989, GASTROINTEST ENDOSC, V35, P305; Im Kyung-Il, 1995, Korean Journal of Parasitology, V33, P179; Ishikura H., 1990, P159; Ishikura H., 1990, P3; Ishikura H, 1993, Prog Clin Parasitol, V3, P43; ISHIKURA H, 1990, INTESTINAL ANISAKIAS, P89; IWASAKI K, 1982, CLIN IMMUNOL IMMUNOP, V23, P593, DOI 10.1016/0090-1229(82)90322-1; JACKSON GJ, 1990, J ANIM SCI, V68, P884; JAMES SL, 1995, MICROBIOL REV, V59, P533; JARRETT EEE, 1976, CLIN EXP IMMUNOL, V24, P346; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; Jensen T, 1997, PARASITOL RES, V83, P380, DOI 10.1007/s004360050266; JENSEN T, 1997, J ANIM SCI, V83, P380; Johansson E, 2001, ALLERGY, V56, P660, DOI 10.1034/j.1398-9995.2001.00798.x; JONES RE, 1990, EXP PARASITOL, V70, P305, DOI 10.1016/0014-4894(90)90112-P; KAGEI N, 1992, INT J PARASITOL, V22, P251; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Karl H., 1995, International Journal of Food Science & Technology, V29, P661; KASSAI T, 1988, VET PARASITOL, V29, P299, DOI 10.1016/0304-4017(88)90148-3; Kasuya S, 1992, Arerugi, V41, P106; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; Kasuya S, 1989, ACI NEWS, V1, P13; KAY AB, 2000, BR MED B, V56, P853; Kennedy MW, 2006, TOXOCARA: THE ENIGMATIC PARASITE, P32; KENNEDY MW, 1991, IMMUNOLOGY, V73, P36; Kennedy MW, 2000, ALLERGY, V55, P7, DOI 10.1034/j.1398-9995.2000.03402.x; KENNEDY MW, 1988, MOL BIOCHEM PARASIT, V31, P35, DOI 10.1016/0166-6851(88)90143-0; KENNEDY MW, 1990, IMMUNOLOGY, V71, P317; KENNEDY MW, 1987, PARASITE IMMUNOL, V9, P269, DOI 10.1111/j.1365-3024.1987.tb00506.x; KENNEDY MW, 1991, IMMUNOLOGY, V72, P577; KENNEDY MW, 1989, CLIN EXP IMMUNOL, V75, P493; KENNEDY MW, 1995, BIOCHEMISTRY-US, V34, P6700, DOI 10.1021/bi00020a015; KIKUCHI Y, 1990, INTESTINAL ANISAKIAS, P191; Kimura S, 1999, ALLERGY, V54, P1225, DOI 10.1034/j.1398-9995.1999.00329.x; KING CL, 1992, J CLIN INVEST, V89, P1403, DOI 10.1172/JCI115729; KLIKS MM, 1986, JAMA-J AM MED ASSOC, V255, P2605; KLIKS MM, 1983, AM J TROP MED HYG, V32, P526; Knox DP, 2007, PARASITE IMMUNOL, V29, P57, DOI 10.1111/j.1365-3024.2006.00913.x; KNOX DP, 1988, MOL BIOCHEM PARASIT, V28, P207, DOI 10.1016/0166-6851(88)90005-9; Kobayashi Y, 2007, MOL BIOCHEM PARASIT, V155, P138, DOI 10.1016/j.molbiopara.2007.06.012; Kobayashi Y, 2007, PARASITOL RES, V100, P1233, DOI 10.1007/s00436-006-0396-4; KUIPERS FC, 1964, PATHOL MICROBIOL, V27, P925, DOI 10.1159/000161548; LAWRENCE CE, 1998, EUR J IMMUNOL, V28, P2627; Liew FY, 1997, PHILOS T R SOC B, V352, P1311; Lobos E, 1997, CHEM IMMUNOL, V66, P1; Lorenzo S, 2000, ALLERGY, V55, P627, DOI 10.1034/j.1398-9995.2000.00471.x; Lorenzo S, 2000, CLIN EXP ALLERGY, V30, P551, DOI 10.1046/j.1365-2222.2000.00758.x; Lorenzo S, 1999, PARASITOL RES, V85, P441, DOI 10.1007/s004360050575; Lorenzo S, 1999, CLIN EXP ALLERGY, V29, P1095, DOI 10.1046/j.1365-2222.1999.00574.x; Lu CC, 1998, EXP PARASITOL, V89, P257, DOI 10.1006/expr.1998.4284; LUCAS SB, 1985, LANCET          1012, P843; Magen E, 2005, MED HYPOTHESES, V64, P904, DOI 10.1016/j.mehy.2004.09.028; MAIZELS RM, 1984, PARASITE IMMUNOL, V6, P23, DOI 10.1111/j.1365-3024.1984.tb00779.x; Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001; Maldonado-Bernal C, 2005, PARASITE IMMUNOL, V27, P127, DOI 10.1111/j.1365-3024.2005.00754.x; MARGOLIS L, 1977, J FISH RES BOARD CAN, V34, P887; Marques JF, 2006, J HELMINTHOL, V80, P47, DOI 10.1079/JOH2005325; MATSUI T, 1990, INTESTINAL ANISAKIAS, P101; MATSUZAKA M, 2007, J EXP MED, V212, P207; MATTHEWS BE, 1984, J HELMINTHOL, V58, P175; MATTHEWS BE, 1982, J HELMINTHOL, V56, P177; Mattiucci S, 2005, SYST PARASITOL, V61, P157, DOI 10.1007/s11230-005-3158-2; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; MCKERROW JH, 1989, EXP PARASITOL, V68, P111, DOI 10.1016/0014-4894(89)90016-7; Mercado R, 1997, REV SAUDE PUBL, V31, P178, DOI 10.1590/S0034-89101997000200012; Mineta Sho, 2006, J Nippon Med Sch, V73, P169, DOI 10.1272/jnms.73.169; MITCHELL G F, 1991, Immunology Today, V12, pA2, DOI 10.1016/S0167-5699(05)80002-7; Moneo I, 2005, PARASITOL RES, V96, P285, DOI 10.1007/s00436-005-1362-2; Moneo I, 1997, ALLERGY, V52, P565, DOI 10.1111/j.1398-9995.1997.tb02601.x; Moneo I, 2000, J ALLERGY CLIN IMMUN, V106, P177, DOI 10.1067/mai.2000.106732; Moneret-Vautrin DA, 2005, ALLERGY, V60, P443, DOI 10.1111/j.1398-9995.2005.00785.x; Montoro A, 1997, ALLERGY, V52, P985, DOI 10.1111/j.1398-9995.1997.tb02418.x; Moreels TG, 2005, INFLAMM BOWEL DIS, V11, P178, DOI 10.1097/00054725-200502000-00012; MorenoAncillo A, 1997, ANN ALLERG ASTHMA IM, V79, P246; MORRIS SR, 1994, J BIOL CHEM, V269, P27650; Moschella CM, 2004, J HELMINTHOL, V78, P271, DOI 10.1079/JOH2004237; MUDRY J, 1986, GASTROEN CLIN BIOL, V10, P83; Muraoka A, 1996, DIGEST DIS SCI, V41, P2362, DOI 10.1007/BF02100128; Nagasawa K., 1990, P23; Namiki N, 1989, GASTRIC ANISAKIASIS, P47; Newton SE, 2003, PARASITE IMMUNOL, V25, P283, DOI 10.1046/j.1365-3024.2003.00631.x; Nguyen TT, 1999, MOL BIOCHEM PARASIT, V102, P79, DOI 10.1016/S0166-6851(99)00088-2; Nieuwenhuizen N, 2006, J ALLERGY CLIN IMMUN, V117, P1098, DOI 10.1016/j.jaci.2005.12.1357; OGILVIE BM, 1990, J PARASITOL, V76, P607, DOI 10.2307/3282969; Ohtaki R., 1989, GASTRIC ANISAKIASIS, P37; Ortega-Deballon P, 2005, ANN CHIR, V130, P407, DOI 10.1016/j.anchir.2005.03.009; OSHIMA T, 1987, PARASITOL TODAY, V3, P44, DOI 10.1016/0169-4758(87)90212-2; Oshima T., 1972, Progress med Parasit Japan, V4, P301; PAGGI L, 1991, INT J PARASITOL, V21, P195, DOI 10.1016/0020-7519(91)90010-5; Pampiglione S, 2002, PATHOL RES PRACT, V198, P429, DOI 10.1078/0344-0338-00277; Paterson JCM, 2002, INFECT IMMUN, V70, P6058, DOI 10.1128/IAI.70.11.6058-6067.2002; Pavon-Martinez N, 2007, ANN NY ACAD SCI, V1107, P271, DOI 10.1196/annals.1381.029; Peisong G, 2004, GENES IMMUN, V5, P58, DOI 10.1038/sj.gene.6364030; Perez-Perez J, 2000, INT ARCH ALLERGY IMM, V123, P120, DOI 10.1159/000024442; Perteguer MJ, 1996, INT J PARASITOL, V26, P105, DOI 10.1016/0020-7519(95)00111-5; PETITHORY JC, 1991, B ACAD NAT MED PARIS, V175, P273; PETITHORY JC, 1990, LANCET, V336, P1002, DOI 10.1016/0140-6736(90)92459-U; Petithory JC, 2007, B ACAD NAT MED PARIS, V191, P53; PETITIHORY JC, 1986, MED MALADIES INFECT, V53, P157; Phillips C, 2003, J LEUKOCYTE BIOL, V73, P165, DOI 10.1189/jlb.0702356; Plath F, 2001, Z GASTROENTEROL, V39, P177, DOI 10.1055/s-2001-11150; Pulido-Marrero Z, 2000, ALLERGY, V55, P586, DOI 10.1034/j.1398-9995.2000.00643.x; Purello-D'Ambrosio F, 2000, ANN ALLERG ASTHMA IM, V84, P439; Ramos JDA, 2004, ALLERGY, V59, P539, DOI 10.1046/j.1398-9995.2003.00409.x; RAYBOURNE R, 1986, EXP PARASITOL, V62, P92, DOI 10.1016/0014-4894(86)90012-3; RAYBOURNE R, 1983, EXP PARASITOL, V55, P289, DOI 10.1016/0014-4894(83)90025-5; Rhoads ML, 2000, EXP PARASITOL, V95, P36, DOI 10.1006/expr.2000.4502; Rhoads ML, 2000, EXP PARASITOL, V94, P1, DOI 10.1006/expr.1999.4466; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; Rodriguez E, 2008, ALLERGY, V63, P219, DOI 10.1111/j.1398-9995.2007.01564.x; Rodriguez-Mahillo AI, 2007, INT J PARASITOL, V37, P907, DOI 10.1016/j.ijpara.2007.01.007; Rodriguez-Perez R, 2007, MOL BIOCHEM PARASIT, V154, P115, DOI 10.1016/j.molbiopara.2007.04.005; RUITENBERG EJ, 1971, J PARASITOL, V57, P149; Sajid M, 2002, MOL BIOCHEM PARASIT, V120, P1, DOI 10.1016/S0166-6851(01)00438-8; SAKANARI JA, 1989, P NATL ACAD SCI USA, V86, P4863, DOI 10.1073/pnas.86.13.4863; SAKANARI JA, 1989, CLIN MICROBIOL REV, V2, P278; SAKANARI JA, 1990, J PARASITOL, V76, P625, DOI 10.2307/3282971; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Sanchez-Monsalvez I, 2003, DIGEST DIS SCI, V48, P2342, DOI 10.1023/B:DDAS.0000007873.48287.f6; Sanchez-Velasco P, 2003, TISSUE ANTIGENS, V61, P384, DOI 10.1034/j.1399-0039.2003.00041.x; Sanchez-Velasco P, 2000, HUM IMMUNOL, V61, P314, DOI 10.1016/S0198-8859(99)00167-6; Sastre J, 2000, ALLERGY, V55, P560, DOI 10.1034/j.1398-9995.2000.00422.x; Scala E, 2001, EUR J DERMATOL, V11, P249; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Scott Phillip A., 1993, P1179; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Shaw RJ, 2003, INT J PARASITOL, V33, P1233, DOI 10.1016/S0020-7519(03)00157-7; Shea-Donohue T, 2004, CURR OPIN GASTROEN, V20, P3, DOI 10.1097/00001574-200401000-00003; Shimakura K, 2004, MOL BIOCHEM PARASIT, V135, P69, DOI 10.1016/j.molbiopara.2004.01.007; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Skirnisson Karl, 2006, Laeknabladid, V92, P21; SMITH HV, 1981, MOL BIOCHEM PARASIT, V4, P183, DOI 10.1016/0166-6851(81)90017-7; Smith J.W., 1978, Advances in Parasitology, V16, P93, DOI 10.1016/S0065-308X(08)60573-4; Sohn Woon-Mok, 1994, Korean Journal of Parasitology, V32, P53; Stewart GR, 1999, CLIN EXP IMMUNOL, V117, P517; Strait RT, 2003, J IMMUNOL, V170, P3835; SUGANE K, 1992, J HELMINTHOL, V66, P25; SUGIMACHI K, 1985, JAMA-J AM MED ASSOC, V253, P1012, DOI 10.1001/jama.253.7.1012; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P194, DOI 10.1159/000086331; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583; TANAKA J, 1978, J IMMUNOL, V120, P745; Taylor MD, 2005, J IMMUNOL, V174, P4924; Thompson R.C.A., 1994, P146; TODOROVA VK, 1995, PARASITOLOGY, V111, P201; TOMLINSON LA, 1989, J IMMUNOL, V143, P2349; Toro C, 2006, CLIN MICROBIOL INFEC, V12, P453, DOI 10.1111/j.1469-0691.2006.01376.x; Turner JD, 2005, MICROBES INFECT, V7, P990, DOI 10.1016/j.micinf.2005.03.036; *U CAL SEAF NETW I, 2007, GEN HACCP; Umebayashi Y, 2001, Arerugi, V50, P1090; URBAN FJ, 1993, J IMMUNOL, V143, P7086; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; *US FDA, 2007, ANIS SIMP REL WORMS; van der Kleij D, 2003, EUR J IMMUNOL, V33, P2953, DOI 10.1002/eji.200324340; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANNEERVEN RJ, 2000, E CLIN EXP ALLERGY, V30, P242; VANTHIEL PH, 1976, TROP GEOGR MED, V28, P75; VERHAMME MAM, 1988, GUT, V29, P843, DOI 10.1136/gut.29.6.843; VERMA RJ, 2005, AM J GASTROENTEROL, V100, P191; Watanapa P, 2002, BRIT J SURG, V89, P962, DOI 10.1046/j.1365-2168.2002.02143.x; WATT IA, 1979, LANCET, P893; Weiler CR, 2007, INT J DERMATOL, V46, P224; WEIR E, 2005, CMAJ, V173, P329; *WHO, 2008, SOIL TRANSM HELM WHO; WILLIAMS H, 1994, PARASITIC WORMS FISH, P371; Xia Y, 2000, PARASITOLOGY, V120, P211, DOI 10.1017/S0031182099005363; YAGIHASHI A, 1990, J INFECT DIS, V161, P995; Yu Jae-Ran, 2001, Korean Journal of Parasitology, V39, P193; Zaccone P, 2006, PARASITE IMMUNOL, V28, P515, DOI 10.1111/j.1365-3024.2006.00879.x	281	214	221	15	75	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0893-8512			CLIN MICROBIOL REV	Clin. Microbiol. Rev.	APR	2008	21	2					360	+		10.1128/CMR.00012-07		21	Microbiology	Microbiology	290BX	WOS:000255098800007	18400801	
J	Schwarze, PE; Ovrevik, J; Lag, M; Refsnes, M; Nafstad, P; Hetland, RB; Dybing, E				Schwarze, P. E.; Ovrevik, J.; Lag, M.; Refsnes, M.; Nafstad, P.; Hetland, R. B.; Dybing, E.			Particulate matter properties and health effects: consistency of epidemiological and toxicological studies	HUMAN & EXPERIMENTAL TOXICOLOGY			English	Review						ambient particulate matter; epidemiology; health effects; particle composition; toxicology	DIESEL EXHAUST PARTICLES; AIRWAY EPITHELIAL-CELLS; POLYCYCLIC AROMATIC-HYDROCARBONS; CORONARY-HEART-DISEASE; INSOLUBLE IRIDIUM PARTICLES; LONG-TERM EXPOSURE; NF-KAPPA-B; AMBIENT AIR; IN-VITRO; DAILY MORTALITY	Identifying the ambient particulate matter (PM) fractions or constituents, critically involved in eliciting adverse health effects, is crucial to the implementation of more cost-efficient abatement strategies to improve air quality. This review focuses on the importance of different particle properties for PM-induced effects, and whether there is consistency in the results from epidemiological and experimental studies. An evident problem for such comparisons is that epidemiological and experimental data on the effects of specific components of ambient PM are limited. Despite this, some conclusions can be drawn. With respect to the importance of the PM size-fractions experimental and epidemiological studies are somewhat conflicting, but there seems to be a certain consistency in that the coarse fraction (PM10-2.5) has an effect that should not be neglected. Better exposure characterization may improve the consistency between the results from experimental and epidemiological studies, in particular for ultrafine particles. Experimental data indicate that surface area is an important metric, but composition may play an even greater role in eliciting effects. The consistency between epidemiological and experimental findings for specific PM-components appears most convincing for metals, which seem to be important for the development of both pulmonary and cardiovascular disease. Metals may also be involved in PM-induced allergic sensitization, but the epidemiological evidence for this is scarce. Soluble organic compounds appear to be implicated in PM-induced allergy and cancer, but the data from epidemiological studies are insufficient for any conclusions. The present review suggests that there may be a need for improvements in research designs. In particular, there is a need for better exposure assessments in epidemiological investigations, whereas experimental data would benefit from an improved comparability of studies. Combined experimental and epidemiological investigations may also help answer some of the unresolved issues.	Norwegian Inst Publ Hlth, N-0403 Oslo, Norway	Schwarze, PE (reprint author), Norwegian Inst Publ Hlth, POB4404 Nydalen, N-0403 Oslo, Norway.	per.schwarze@fhi.no	Schwarze, Per/I-2080-2016				Abrahamowicz M, 2003, J TOXICOL ENV HEAL A, V66, P1625, DOI 10.1080/15287390390211676; AGATE K, 2005, IN PRESS TOXICOL IN; Anderson HR, 2004, METAANALYSIS TIME SE; Armstrong B, 2004, ENVIRON HEALTH PERSP, V112, P970, DOI 10.1289/ehp.6895; Aukrust P, 2005, ANN MED, V37, P74, DOI 10.1080/07853890510007232; Avogbe PH, 2005, CARCINOGENESIS, V26, P613, DOI 10.1093/carcin/bgh353; Barchowsky A, 2003, FREE RADICAL BIO MED, V34, P1130, DOI 10.1016/S0891-5849(03)00059-5; Bauer H, 2002, ATMOS RES, V64, P109, DOI 10.1016/S0169-8095(02)00084-4; Becher R, 2001, INHAL TOXICOL, V13, P789, DOI 10.1080/089583701316941311; Becker S, 2005, TOXICOL APPL PHARM, V203, P45, DOI 10.1016/j.taap.2004.07.007; BECKER S, 2005, IN PRESS TOXICOL APP; Binkovda B, 2003, MUTAT RES-FUND MOL M, V525, P43, DOI 10.1016/S0027-5107(02)00312-3; Boland S, 2000, AM J PHYSIOL-LUNG C, V278, pL25; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515; Borja-Aburto VH, 1998, ENVIRON HEALTH PERSP, V106, P849, DOI 10.2307/3434129; Brits E, 2004, ENVIRON RES, V96, P109, DOI 10.1016/j.envres.2004.03.006; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Brunekreef Bert, 2005, Res Rep Health Eff Inst, P1; Burnett RT, 2000, INHAL TOXICOL, V12, P15, DOI 10.1080/089583700750019495; Campen MJ, 2002, J TOXICOL ENV HEAL A, V65, P1615, DOI 10.1080/00984100290071694; Campen MJ, 2001, TOXICOL SCI, V64, P243, DOI 10.1093/toxsci/64.2.243; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Carty CL, 2003, J ENVIRON MONITOR, V5, P953, DOI 10.1039/b308488d; CASSEE F, 2003, 863001001 RIVM; Cassee FR, 2002, ARCH TOXICOL, V76, P277, DOI 10.1007/s00204-002-0344-8; Castillejos M, 2000, INHAL TOXICOL, V12, P61, DOI 10.1080/089583700196392; Choudhury AH, 1997, ARCH ENVIRON HEALTH, V52, P113; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; Clouter A, 2001, TOXICOL SCI, V63, P90, DOI 10.1093/toxsci/63.1.90; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Davies DE, 2002, INT J BIOCHEM CELL B, V34, P1520, DOI 10.1016/S1357-2725(02)00048-1; de Hartog JJ, 2003, AM J EPIDEMIOL, V157, P613, DOI 10.1093/aje/kwg021; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; DeMarini DM, 2004, ENVIRON HEALTH PERSP, V112, P814; Devlin RB, 2003, EUR RESPIR J, V21, p76S, DOI 10.1183/09031936.03.00402403; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454663; Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3; Donaldson Ken, 2003, Ann Ist Super Sanita, V39, P405; Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; Du Four VA, 2004, MUTAT RES-GEN TOX EN, V558, P155, DOI 10.1016/j.mrgentox.2003.12.002; Dybing E, 2004, TOXICOLOGY, V198, P307, DOI 10.1016/j.tox.2004.02.007; Dye JA, 2001, ENVIRON HEALTH PERSP, V109, P395, DOI 10.2307/3434787; Emmendoerffer A, 2000, TOXICOL LETT, V112, P185, DOI 10.1016/S0378-4274(99)00285-4; Fadeel B, 2005, J INTERN MED, V258, P479, DOI 10.1111/j.1365-2796.2005.01570.x; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Fahy O, 2002, J IMMUNOL, V168, P5912; Forsberg B, 2005, AMBIO, V34, P11, DOI 10.1639/0044-7447(2005)034[0011:CHIAOL]2.0.CO;2; Frampton MW, 1999, AM J PHYSIOL-LUNG C, V277, pL960; Fubini B, 2003, FREE RADICAL BIO MED, V34, P1507, DOI 10.1016/S0891-5849(03)00149-7; Gangur V, 2002, VET IMMUNOL IMMUNOP, V86, P127, DOI 10.1016/S0165-2427(02)00018-1; Garshick E, 2004, ENVIRON HEALTH PERSP, V112, P1539; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P1471, DOI 10.1289/ehp.6300; Gavett SH, 1999, AM J RESP CRIT CARE, V160, P1897; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Ghio AJ, 2004, J AEROSOL MED, V17, P157, DOI 10.1089/0894268041457200; Ghio AJ, 2004, INHAL TOXICOL, V16, P53, DOI 10.1080/08958370490258390; Gil L, 2000, INHAL TOXICOL, V12, P1185, DOI 10.1080/08958370050198539; Gong Henry Jr, 2003, Res Rep Health Eff Inst, P1; Gordian ME, 2003, ARCH ENVIRON HEALTH, V58, P42, DOI 10.3200/AEOH.58.1.42-47; Gordian ME, 1996, ENVIRON HEALTH PERSP, V104, P290, DOI 10.2307/3432887; Graff DW, 2004, ENVIRON HEALTH PERSP, V112, P792, DOI 10.1289/txg.6865; Grahame TJ, 2005, INHAL TOXICOL, V17, P15, DOI 10.1080/08958370590885672; Haase H, 2005, BIOMETALS, V18, P333, DOI 10.1007/s10534-005-3707-9; Hagen JA, 2000, EPIDEMIOLOGY, V11, P136, DOI 10.1097/00001648-200003000-00009; Hamoir J, 2003, TOXICOL APPL PHARM, V190, P278, DOI 10.1016/S0041-008X(03)00192-3; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; HEFFLIN BJ, 1994, ARCH ENVIRON HEALTH, V49, P170; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Heinrich J, 2003, ATMOS ENVIRON, V37, P3659, DOI 10.1016/S1352-2310(03)00467-9; Heinrich J, 2005, HLTH EFFECTS TRANSPO, P125; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Henneberger A, 2005, ENVIRON HEALTH PERSP, V113, P440, DOI 10.1289/ehp.7579; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Hernandez-Garduno E, 2004, INT J TUBERC LUNG D, V8, P377; Hetland Ragna B, 2005, Part Fibre Toxicol, V2, P4, DOI 10.1186/1743-8977-2-4; Hetland RB, 2000, J TOXICOL ENV HEAL A, V60, P47, DOI 10.1080/009841000156583; Hetland RB, 2004, TOXICOL IN VITRO, V18, P203, DOI 10.1016/S0887-2333(03)00142-5; Hetland RB, 2001, TOXICOLOGY, V165, P133, DOI 10.1016/S0300-483X(01)00418-8; Hext PM, 2005, ANN OCCUP HYG, V49, P461, DOI 10.1093/annhyg/mei012; Hiura TS, 1999, J IMMUNOL, V163, P5582; HOEK G, 1994, ENVIRON RES, V64, P136, DOI 10.1006/enrs.1994.1012; Hohr D, 2002, INT J HYG ENVIR HEAL, V205, P239, DOI 10.1078/1438-4639-00123; Holgate ST, 2003, EUR RESPIR J, V22, p24S, DOI 10.1183/09031936.03.00000803; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; Holopainen M, 2004, SCAND J WORK ENV HEA, V30, P91; Holtzman MJ, 2002, PHYSIOL REV, V82, P19; Hong YC, 2002, STROKE, V33, P2165, DOI 10.1161/01.STR.0000026865.52610.5B; Hosiokangas J, 2004, SCAND J WORK ENV HEA, V30, P28; Huang SL, 2002, J TOXICOL ENV HEAL A, V65, P1261, DOI 10.1080/00984100290071441; Ibald-Mulli A, 2002, J AEROSOL MED, V15, P189, DOI 10.1089/089426802320282310; Jacob B, 2002, ENVIRON HEALTH PERSP, V110, P647; Jarvholm B, 2003, OCCUP ENVIRON MED, V60, P516, DOI 10.1136/oem.60.7.516; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Jimenez LA, 2000, TOXICOL APPL PHARM, V166, P101, DOI 10.1006/taap.2000.8957; Kang YJ, 2001, ENVIRON HEALTH PERSP, V109, P27, DOI 10.2307/3434844; Kanoh T, 1996, J Clin Lab Immunol, V48, P133; Kappos AD, 2004, INT J HYG ENVIR HEAL, V207, P399, DOI 10.1078/1438-4639-00306; Kim E, 2005, ENVIRON SCI TECHNOL, V39, P4172, DOI 10.1021/es049824x; Kinney PL, 2002, ENVIRON HEALTH PERSP, V110, P539; Klot SV, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Kocbach A, 2005, SCI TOTAL ENVIRON, V346, P231, DOI 10.1016/j.scitotenv.2004.10.025; Kodavanti UP, 2003, TOXICOL SCI, V71, P237, DOI 10.1093/toxsci/71.2.237; Koike E, 2005, TOXICOL APPL PHARM, V209, P277, DOI 10.1016/j.taap.2005.04.017; Kreyling WG, 2002, J TOXICOL ENV HEAL A, V65, P1513, DOI 10.1080/00984100290071649; Kristovich R, 2004, CHEM RES TOXICOL, V17, P1303, DOI 10.1021/tx049893p; Kuljukka-Rabb T, 2001, MUTAGENESIS, V16, P353, DOI 10.1093/mutage/16.4.353; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Lambert AL, 2000, TOXICOL APPL PHARM, V165, P84, DOI 10.1006/taap.2000.8932; Li ZW, 2005, ENVIRON HEALTH PERSP, V113, P1009, DOI 10.1289/ehp.7736; Liu YQ, 2005, J ENVIRON MONITOR, V7, P60, DOI 10.1039/b407375d; Magari SR, 2001, CIRCULATION, V104, P986, DOI 10.1161/hc3401.095038; Mar TF, 2004, INHAL TOXICOL, V16, P809, DOI 10.1080/08958370490506646; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P214, DOI 10.1513/pats.200504-031AC; Matsuo M, 2001, BIOL PHARM BULL, V24, P357, DOI 10.1248/bpb.24.357; MCCLELLAN RO, 1987, ANNU REV PHARMACOL, V27, P279; Molinelli AR, 2002, INHAL TOXICOL, V14, P1069, DOI 10.1080/08958370290084737; Monn C, 1999, TOXICOL APPL PHARM, V155, P245, DOI 10.1006/taap.1998.8591; Montealegre F, 2004, J ASTHMA, V41, P485, DOI 10.1081/JAS-120033993; Nafstad P, 2004, ENVIRON HEALTH PERSP, V112, P610, DOI 10.1289/ehp.6684; Nemmar A, 2004, TOXICOL LETT, V149, P243, DOI 10.1016/j.toxlet.2003.12.061; Nemmar A, 2003, TOXICOL APPL PHARM, V186, P38, DOI 10.1016/S0041-008X(02)00024-8; NERI M, 2005, IN PRESS MUTAT RES R; Nicolai T, 1997, Arch Toxicol Suppl, V19, P201; Nilsen A, 1997, TOXICOLOGY, V124, P225, DOI 10.1016/S0300-483X(97)00150-9; Nygaard UC, 2005, TOXICOLOGY, V207, P241, DOI 10.1016/j.tox.2004.09.016; Nygaard UC, 2004, TOXICOL SCI, V82, P515, DOI 10.1093/toxsci/kfh287; O'Neill MS, 2005, CIRCULATION, V111, P2913, DOI 10.1161/CIRCULATIONAHA.104.517110; Oberdorster G, 2002, J TOXICOL ENV HEAL A, V65, P1531, DOI 10.1080/00984100290071658; Obot CJ, 2002, TOXICOL APPL PHARM, V184, P98, DOI 10.1006/taap.2002.9493; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Omland O, 2002, ANN AGR ENV MED, V9, P119; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Osornio-Vargas AR, 2003, ENVIRON HEALTH PERSP, V111, P1289, DOI 10.1289/ehp.5913; Ostro BD, 1999, ENVIRON RES, V81, P231, DOI 10.1006/enrs.1999.3978; Ostro BD, 2000, J EXPO ANAL ENV EPID, V10, P412, DOI 10.1038/sj.jea.7500094; Ovrevik J, 2005, ANN OCCUP HYG, V49, P219, DOI 10.1093/annhyg/meh087; OVREVIK J, 2006, IN PRESS TOXICOL LET; Pacheco KA, 2001, CLIN EXP IMMUNOL, V126, P374, DOI 10.1046/j.1365-2249.2001.01698.x; Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Pekkanen J, 2002, CIRCULATION, V106, P933, DOI 10.1161/01.CIR.0000027561.41736.3C; Peng RD, 2005, AM J EPIDEMIOL, V161, P585, DOI 10.1093/aje/kwi075; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pohjola SK, 2003, MUTAGENESIS, V18, P429, DOI 10.1093/mutage/geg021; Pope CA, 1999, ENVIRON HEALTH PERSP, V107, P567; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pozzi R, 2003, TOXICOLOGY, V183, P243, DOI 10.1016/S0300-483X(02)00545-0; Prahalad AK, 1999, TOXICOL APPL PHARM, V158, P81, DOI 10.1006/taap.1999.8701; Proskuryakov SY, 2002, BIOCHEMISTRY-MOSCOW+, V67, P387, DOI 10.1023/A:1015289521275; Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227; Rivedal E, 2003, ARCH TOXICOL, V77, P533, DOI 10.1007/s00204-003-0483-6; Roemer W, 2000, EUR RESPIR J, V15, P553, DOI 10.1034/j.1399-3003.2000.15.21.x; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1187; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Samet JM, 1998, AM J PHYSIOL-LUNG C, V275, pL551; Samoli E, 2005, ENVIRON HEALTH PERSP, V113, P88; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; Schins RPF, 2004, TOXICOL APPL PHARM, V195, P1, DOI 10.1016/j.taap.2003.10.002; Schins RPF, 2002, INHAL TOXICOL, V14, P57, DOI 10.1080/089583701753338631; Schlesinger RB, 2003, INHAL TOXICOL, V15, P197, DOI 10.1080/08958370390168247; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Scott J, 2004, CURR OPIN GENET DEV, V14, P271, DOI 10.1016/j.gde.2004.04.012; Seaton A, 1999, THORAX, V54, P1027; Semmler M, 2004, INHAL TOXICOL, V16, P453, DOI 10.1080/08958370490439650; Simpson RW, 1997, ARCH ENVIRON HEALTH, V52, P442; Smith KR, 2003, INT J HYG ENVIR HEAL, V206, P279, DOI 10.1078/1438-4639-00224; Solhaug A, 2004, CARCINOGENESIS, V25, P809, DOI 10.1093/carcin/bgh069; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Soukup JM, 2000, INHAL TOXICOL, V12, P401; St-Pierre AC, 2005, ATHEROSCLEROSIS, V182, P315, DOI 10.1016/j.atherosclerosis.2005.02.009; Steerenberg PA, 2004, TOXICOL APPL PHARM, V200, P186, DOI 10.1016/j.tapp.2004.04.011; Steffen C, 2004, OCCUP ENVIRON MED, V61, P773, DOI 10.1136/oem.2003.010868; Sutherland ER, 2003, J ALLERGY CLIN IMMUN, V112, P819, DOI 10.1067/mai.2003.1760; Suzuki Takahito, 1993, Japanese Journal of Allergology, V42, P963; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; TAL TL, 2006, TOXICOL APPL PHARM; Tavernier GOG, 2005, INDOOR AIR, V15, P25, DOI 10.1111/j.1600-0668.2005.00354.x; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; Timonen KL, 2004, OCCUP ENVIRON MED, V61, P908, DOI 10.1136/oem.2004.012849; VALLEJO M, 2005, J EXPO ANAL ENV EPID; Veranth JM, 2006, ENVIRON HEALTH PERSP, V114, P341, DOI 10.1289/ehp.8360; Veranth JM, 2004, TOXICOL SCI, V82, P88, DOI 10.1093/toxsci/kfh248; Vermylen J, 2005, J THROMB HAEMOST, V3, P1955, DOI 10.1111/j.1538-7836.2005.01471.x; Vione D, 2004, ANN CHIM-ROME, V94, P257, DOI 10.1002/adic.200490031; Walczak-Drzewiecka A, 2003, ENVIRON HEALTH PERSP, V111, P708, DOI 10.1289/ehp.5960; Warheit David B., 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P133; *WHO, 2004, HLTH EFF AIR POLL RE; World Health Organization (WHO), 2005, HLTH EFF TRANSP REL; World Health Organization (WHO), 1987, AIR QUAL GUID EUR; World Health Organization, 2005, HLTH RISK PART MATT; Wichmann H E, 2000, Res Rep Health Eff Inst, P5; Willis A, 2003, J TOXICOL ENV HEAL A, V66, P1605, DOI 10.1080/15287390390211559; Wilson MR, 2002, TOXICOL APPL PHARM, V184, P172, DOI 10.1006/taap.2002.9501; Xia T, 2004, ENVIRON HEALTH PERSP, V112, P1347, DOI 10.1289/ehp.7167; Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8; Yang HM, 1999, J TOXICOL ENV HEAL A, V58, P261, DOI 10.1080/009841099157232; Zhao XS, 2003, MUTAT RES-GEN TOX EN, V540, P107, DOI 10.1016/S1383-5718(03)00178-5; Zhou YM, 2003, TOXICOL APPL PHARM, V190, P157, DOI 10.1016/S0041-008X(03)00157-1	210	214	220	10	66	SAGE PUBLICATIONS LTD	LONDON	1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND	0960-3271			HUM EXP TOXICOL	Hum. Exp. Toxicol.	OCT	2006	25	10					559	579		10.1177/096032706072520		21	Toxicology	Toxicology	109XA	WOS:000242341700001	17165623	
J	Reed, CE; Kita, H				Reed, CE; Kita, H			The role of protease activation of inflammation in allergic respiratory diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen; proteases; allergic inflammation; asthma; sinusitis	MAST-CELL TRYPTASE; AIRWAY SMOOTH-MUSCLE; DUST-MITE ALLERGEN; LUNG EPITHELIAL-CELLS; SEVERE ALPHA(1)-ANTITRYPSIN DEFICIENCY; INDUCE CYTOKINE RELEASE; FACTOR XA; ENDOTHELIAL-CELLS; DERMATOPHAGOIDES-FARINAE; ASPERGILLUS-FUMIGATUS	Extracellular endogenous proteases, as well as exogenous proteases from mites and molds, react with cell-surface receptors in the airways to generate leukocyte infiltration and to amplify the response to allergens. Stimulation leads to increased intracellular Ca++ and gene transcription. The most thoroughly investigated receptors, protease-activated receptors (PARs), are 7-transmembrane proteins coupled to G proteins. PARs are widely distributed on the cells of the airways, where they contribute to the inflammation characteristic of allergic diseases. PAR stimulation of epithelial cells opens tight junctions, causes desquamation, And produces cytokines, chemokines, and growth factors. They degranulate eosinophils and mast cells. Proteases contract bronchial smooth muscle and cause it to proliferate. PARs also promote maturation, proliferation, and collagen production of fibroblast precursors and mature fibroblasts. PAR-2, apparently the most important of the 4 PARs that have been characterized, is increased on the epithelium of patients with asthma. Trypsin, a product of injured epithelial cells, and mast cell tryptase are potent activators of PAR-2. Mast cell chymase activates PAR-I. Proteases from mites and molds appear to act through similar receptors. They amplify IgE production to allergens, degranulate eosinophils, and can generate inflammation, even in the absence of IgE. Proteases produced by Aspergillus species to support its growth are presumably responsible for the exuberant IgE, IgG, and granulomatous response of allergic bronchopulmonary aspergillosis. Similar proteases from molds germinating on the respiratory mucosa have been recently been implicated in the pathogenesis of chronic hyperplastic rhinitis and polyps and, by extension, of intrinsic asthma. Finally, proteases from mites and fungi growing in damp, water-damaged buildings might be the basis for the increased prevalence in these buildings of rhinitis, asthma, and other respiratory diseases. Future research promises to promote our understanding of the pathogenesis of allergic respiratory diseases and point the way to new therapies.	Mayo Clin, Allerg Dis Res Lab, Rochester, MN 55905 USA	Kita, H (reprint author), Mayo Clin, Allerg Dis Res Lab, Guggenheim Bldg,Room 401, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu	Tang, Amy/L-3226-2016	Tang, Amy/0000-0002-5772-2878			Adam E., 2004, Journal of Allergy and Clinical Immunology, V113, pS339, DOI 10.1016/j.jaci.2004.01.730; Akers IA, 2000, AM J PHYSIOL-LUNG C, V278, pL193; ALTIERI DC, 1994, CELL IMMUNOL, V155, P372, DOI 10.1006/cimm.1994.1130; ANDO T, 1991, INT ARCH ALLER A IMM, V96, P199; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; Andrade-Gordon P, 1999, P NATL ACAD SCI USA, V96, P12257, DOI 10.1073/pnas.96.22.12257; Asokananthan N, 2002, J IMMUNOL, V168, P3577; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Barrios VE, 2003, BIOCHEM PHARMACOL, V66, P519, DOI 10.1016/S0006-2952(03)00292-2; Berger P, 2001, J APPL PHYSIOL, V91, P1372; Berger P, 2001, J APPL PHYSIOL, V91, P995; Blanc-Brude OP, 2001, AM J PHYSIOL-CELL PH, V281, pC681; Borger P, 1999, J INFECT DIS, V180, P1267, DOI 10.1086/315027; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JK, 2002, AM J PHYSIOL-LUNG C, V282, pL197; Cairns JA, 1997, J CLIN INVEST, V99, P1313, DOI 10.1172/JCI119290; Cairns JA, 1996, J IMMUNOL, V156, P275; Camerer E, 2002, J BIOL CHEM, V277, P16081, DOI 10.1074/jbc.M108555200; Chambers LS, 2001, AM J PHYSIOL-LUNG C, V281, pL1369; Chambers RC, 2002, BIOCHEM SOC T, V30, P194, DOI 10.1042/BST0300194; Cheong N, 2003, ALLERGY, V58, P352, DOI 10.1034/j.1398-9995.2003.00033.x; Chi LQ, 2001, J INTERF CYTOK RES, V21, P231, DOI 10.1089/107999001750169871; Chow JM, 2000, BRIT J PHARMACOL, V131, P1584, DOI 10.1038/sj.bjp.0703738; Cirino G, 1997, J CLIN INVEST, V99, P2446, DOI 10.1172/JCI119428; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076; Cocks TM, 2001, PULM PHARMACOL THER, V14, P183, DOI 10.1006/pupt.2001.0285; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Colognato R, 2003, BLOOD, V102, P2645, DOI 10.1182/blood-2002-08-2497; Compton SJ, 2002, BIOCHEM J, V368, P495, DOI 10.1042/BJ20020706; Compton SJ, 2002, CAN J PHYSIOL PHARM, V80, P987, DOI 10.1139/Y02-125; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Corvera CU, 1999, J PHYSIOL-LONDON, V517, P741, DOI 10.1111/j.1469-7793.1999.0741s.x; Cottrell Graeme S, 2002, Essays Biochem, V38, P169; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Coughlin SR, 2003, J CLIN INVEST, V111, P25, DOI 10.1172/JCI200317564; Covic L, 2002, P NATL ACAD SCI USA, V99, P643, DOI 10.1073/pnas.022460899; D'Andrea MR, 2000, BIOTECH HISTOCHEM, V75, P85, DOI 10.3109/10520290009064152; Derian CK, 2003, EXPERT OPIN INV DRUG, V12, P209; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429; DEWATER R, 1986, AM REV RESPIR DIS, V133, P882; Eden E, 2003, CHEST, V123, P765, DOI 10.1378/chest.123.3.765; Flores I, 2003, INT ARCH ALLERGY IMM, V130, P12, DOI 10.1159/000068375; Forteza RM, 2001, PULM PHARMACOL THER, V14, P107, DOI 10.1006/pupt.2000.0276; Gaca MDA, 2002, J HEPATOL, V36, P362, DOI 10.1016/S0168-8278(01)00285-9; Gordon JR, 2000, CELL IMMUNOL, V205, P128, DOI 10.1006/cimm.2000.1714; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Greenberger PA, 2003, ALLERGY PRINCIPLES P, P1353; Gruber BL, 1997, J IMMUNOL, V158, P2310; GUPTA RP, 1987, BIOCHEM J, V248, P337; Hauck RW, 1999, AM J PHYSIOL-LUNG C, V277, pL22; Herbert JM, 1998, J CLIN INVEST, V101, P993, DOI 10.1172/JCI1833; Hou L, 1998, BRIT J HAEMATOL, V101, P1; Howells GL, 1997, J CELL SCI, V110, P881; Huang CF, 1999, J BIOL CHEM, V274, P19670, DOI 10.1074/jbc.274.28.19670; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; HYDE JS, 1979, ANN ALLERGY, V43, P8; INO Y, 1989, INT ARCH ALLER A IMM, V89, P321; Inoue Y, 2002, J ALLERGY CLIN IMMUN, V109, pS165, DOI 10.1016/S0091-6749(02)81624-4; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; Kannan S, 2002, MED HYPOTHESES, V59, P266, DOI 10.1016/S0306-9877(02)00214-1; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P101, DOI 10.1007/s11882-003-0021-x; Kauffman HF, 2003, FRONT BIOSCI, V8, pE190, DOI 10.2741/990; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; Kawabata A, 2001, J CLIN INVEST, V107, P1443, DOI 10.1172/JCI10806; Kawabata A, 1998, BRIT J PHARMACOL, V125, P419, DOI 10.1038/sj.bjp.0702063; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; King C, 1998, J IMMUNOL, V161, P3645; Knight DA, 2000, BRIT J PHARMACOL, V131, P465, DOI 10.1038/sj.bjp.0703612; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Kurup VP, 2002, INT ARCH ALLERGY IMM, V129, P129, DOI 10.1159/000065882; Lindner JR, 2000, J IMMUNOL, V165, P6504; Malamud V, 2003, J NEUROIMMUNOL, V138, P115, DOI 10.1016/S0165-5728(03)00090-0; Mari B, 1996, FASEB J, V10, P309; Mascia F, 2002, J ALLERGY CLIN IMMUN, V109, P532, DOI 10.1067/mai.2002.121830; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Miike S, 2001, J IMMUNOL, V167, P6615; Miki Mari, 2003, Journal of Medical Investigation, V50, P95; Mora C, 2003, CLIN EXP ALLERGY, V33, P28, DOI 10.1046/j.1365-2222.2003.01480.x; Nigam S, 2003, INT ARCH ALLERGY IMM, V132, P124, DOI 10.1159/000073713; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ollivier V, 2000, ARTERIOSCL THROM VAS, V20, P1374; Pantera B, 2003, BBA-GEN SUBJECTS, V1623, P72, DOI 10.1016/j.bbagen.2003.07.001; Papapetropoulos A, 1998, P NATL ACAD SCI USA, V95, P4738, DOI 10.1073/pnas.95.8.4738; Piitulainen E, 2002, THORAX, V57, P705, DOI 10.1136/thorax.57.8.705; Pina JS, 1997, POSTGRAD MED, V101, P153; Ponikau JU, 2002, J ALLERGY CLIN IMMUN, V110, P862, DOI 10.1067/mai.2002.130051; Ponikau JU, 1999, MAYO CLIN PROC, V74, P877; Prados M, 1995, Allergol Immunopathol (Madr), V23, P24; ROBINSON BWS, 1990, J ALLERGY CLIN IMMUN, V86, P726, DOI 10.1016/S0091-6749(05)80176-9; Roche N, 2003, J ALLERGY CLIN IMMUN, V111, P367, DOI 10.1067/mai.2003.6; RUBINSTEIN I, 1990, J CLIN INVEST, V86, P555, DOI 10.1172/JCI114744; RUDOLPH R, 1978, ALLERGY, V33, P310, DOI 10.1111/j.1398-9995.1978.tb01556.x; Saifeddine M, 2001, BRIT J PHARMACOL, V132, P556, DOI 10.1038/sj.bjp.0703839; SAVOLAINEN H, 1991, RES COMMUN CHEM PATH, V71, P385; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; Schmidlin F, 2002, J IMMUNOL, V169, P5315; SEGHAL N, 2004, J ALLERGY CLIN IMMUN, V113, pS336; Senden NHM, 1998, J IMMUNOL, V161, P4318; Sherris D. A., 2004, Journal of Allergy and Clinical Immunology, V113, pS331, DOI 10.1016/j.jaci.2004.01.700; Shimizu S, 2000, AM J PHYSIOL-LUNG C, V279, pL503; Shinohara T, 2002, CYTOKINE, V19, P66, DOI 10.1006/cyto.2002.1946; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Sigsgaard T, 2000, EUR RESPIR J, V16, P50, DOI 10.1034/j.1399-3003.2000.16a09.x; Stark PC, 2003, AM J RESP CRIT CARE, V168, P232, DOI 10.1164/rccm.200207-730OC; Stenton GR, 2002, J PHARMACOL EXP THER, V302, P466, DOI 10.1124/jpet.302.2.466; STEWART GA, 1992, EXP APPL ACAROL, V16, P165, DOI 10.1007/BF01201499; STEWART GA, 1994, ALLERGY, V49, P553, DOI 10.1111/j.1398-9995.1994.tb01128.x; STEWART GA, 1994, AM J IND MED, V25, P105, DOI 10.1002/ajim.4700250128; Sun G, 2001, J IMMUNOL, V167, P1014; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; Taylor MJ, 2002, OTOLARYNG HEAD NECK, V127, P377, DOI 10.1067/mhn.2002.128896; Temkin V, 2002, J IMMUNOL, V169, P2662; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; Tomee JFC, 1997, J INFECT DIS, V176, P740; Tomimori Y, 2002, LAB INVEST, V82, P789, DOI 10.1097/01.LAB.0000018827.78602.F4; Trejo J, 1996, J BIOL CHEM, V271, P21536; Ubl JJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1339, DOI 10.1152/ajplung.00392.2001; Uehara A, 2003, J IMMUNOL, V170, P5690; Umarova BA, 2000, B EXP BIOL MED+, V129, P314, DOI 10.1007/BF02439253; Vergnolle N, 2001, TRENDS PHARMACOL SCI, V22, P146, DOI 10.1016/S0165-6147(00)01634-5; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; Vliagoftis H, 2002, J IMMUNOL, V169, P4551; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, pC1351, DOI 10.1152/ajpcell.00001.2002; Wei JL, 2003, LARYNGOSCOPE, V113, P303, DOI 10.1097/00005537-200302000-00019; Wright CD, 1999, J PHARMACOL EXP THER, V289, P1007; XIA HZ, 1995, J IMMUNOL, V154, P5472; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x; Yu CJ, 1999, BIOCHEM BIOPH RES CO, V261, P669, DOI 10.1006/bbrc.1999.1093	134	214	230	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					997	1008		10.1016/j.jaci.2004.07.060		12	Allergy; Immunology	Allergy; Immunology	870HI	WOS:000225047800001	15536399	
J	Thomas, WR; Smith, WA; Hales, BJ; Mills, KL; O'Brien, RM				Thomas, WR; Smith, WA; Hales, BJ; Mills, KL; O'Brien, RM			Characterization and immunobiology of house dust mite allergens	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Review						house dust mite; allergen; IgE; T cell; recombinant mite allergens	DER-P-I; T-CELL RESPONSES; SITE-DIRECTED MUTAGENESIS; HUMAN IGE ANTIBODIES; CYSTEINE PROTEASE ACTIVITY; GLUTATHIONE-S-TRANSFERASE; MOLECULAR-WEIGHT ALLERGEN; MAJOR SECRETORY PROTEIN; ACID-BINDING PROTEINS; GROUP-III ALLERGEN	The examination of house dust mite extracts has indicated that over 30 different proteins can induce IgE antibody in patients allergic to the house dust mite. There are however dominant specificities especially the group 1 and 2 allergens which can account for much of the allergenicity of extracts. Of the 19 denominated allergens, the major IgE binding has been reported for the group 1, 2, 3, 9, 11, 14 and 15 allergens. The high-molecular-weight group 11, 14 and 15 allergens have only recently been described and although high IgE binding has been anticipated from immunoblotting, there is a need for considerable corroboration. Similarly, the study of the group 3 and 9 serine protease allergens has been incomplete. The group 4, 5, 7 and 8 allergens have shown intermediate IgE binding and the group 10 tropomyosins are of interest because of their potential cross-reactivity with allergen from disparate species. Although the progress with the production of recombinant group 1 allergens has been recent, many of the allergens can be produced as high IgE-binding polypeptides. The tertiary structure of the group 2 allergens has been determined from recombinant proteins and they are an excellent model for the investigation of modified allergens. An unexpected property of the group 1, 2 and 3 allergens has been the high degree of polymorphism found by cDNA analysis. It has however been possible to identify sequences to represent the variation in the natural allergens. The group 7 and 14 allergens show secondary modifications which vary in different extracts creating batch variation. While some estimate of the importance of allergens can be obtained from IgE binding, few analyses of T-cell responses have been made and these regulate both the development of, and the protection from sensitization. Copyright (C) 2002 S. Karger AG, Basel.	Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6872, Australia; Univ Melbourne, Western Gen Hosp, Dept Med, Footscray, Vic, Australia	Thomas, WR (reprint author), Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, POB 855, Perth, WA 6872, Australia.		Hales, Belinda/C-3858-2013	Hales, Belinda/0000-0003-2193-3996			ABE T, 1987, ALLERGY, V42, P352, DOI 10.1111/j.1398-9995.1987.tb02221.x; AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; AKI T, 1994, INT ARCH ALLERGY IMM, V103, P349; ANDO T, 1991, INT ARCH ALLER A IMM, V96, P199; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343; ARRUDA LK, 1994, J ALLERGY CLIN IMMUN, V93, P205; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Baker E. N., 1987, BIOL MACROMOL, V3, P313; Baldo B.A., 1989, Advances in the Biosciences, V74, P13; Bennett BJ, 1996, CLIN EXP ALLERGY, V26, P1150, DOI 10.1046/j.1365-2222.1996.d01-268.x; Best EA, 2000, PROTEIN EXPRES PURIF, V20, P462, DOI 10.1006/prep.2000.1327; BREITENEDER H, 1989, EMBO J, V8, P1935; BYRON KA, 1994, CLIN EXP ALLERGY, V24, P878, DOI 10.1111/j.1365-2222.1994.tb01810.x; Caraballo L, 1997, INT ARCH ALLERGY IMM, V112, P341; CAVAILLON JM, 1988, ALLERGY, V43, P146, DOI 10.1111/j.1398-9995.1988.tb00409.x; Chang JH, 1996, J ALLERGY CLIN IMMUN, V98, P922, DOI 10.1016/S0091-6749(96)80008-X; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1991, CLIN EXP ALLERGY, V21, P161, DOI 10.1111/j.1365-2222.1991.tb00825.x; CHUA KY, 1992, J ALLERGY CLIN IMMUN, V89, P95, DOI 10.1016/S0091-6749(05)80045-4; CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364; Chua KY, 1996, CLIN EXP ALLERGY, V26, P829, DOI 10.1046/j.1365-2222.1996.d01-378.x; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; De Lucca S, 1999, J ALLERGY CLIN IMMUN, V103, P174, DOI 10.1016/S0091-6749(99)70543-9; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; Epton MJ, 2001, INT ARCH ALLERGY IMM, V124, P57, DOI 10.1159/000053668; Epton MJ, 1999, INT ARCH ALLERGY IMM, V120, P185, DOI 10.1159/000024266; EPTON MJ, 2002, IN PRESS CLIN EXP AL; EPTON MJ, 2001, J ALLERGY CLIN IMMUN, V107, pS107; Eriksson TLJ, 1999, INT ARCH ALLERGY IMM, V119, P275, DOI 10.1159/000024204; Eriksson TLJ, 2001, EUR J BIOCHEM, V268, P287, DOI 10.1046/j.1432-1327.2001.01879.x; FERRANDIZ R, 1995, CLIN EXP ALLERGY, V25, P922, DOI 10.1111/j.1365-2222.1995.tb00393.x; Ferrandiz R, 1997, CLIN EXP ALLERGY, V27, P700; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58; FORD SA, 1989, CLIN EXP ALLERGY, V20, P27; Frohlich O, 1996, BIOL REPROD, V54, P857, DOI 10.1095/biolreprod54.4.857; Fujii S, 1997, CLIN EXP IMMUNOL, V108, P284, DOI 10.1046/j.1365-2249.1997.3431244.x; Fujikawa A, 1998, CLIN EXP ALLERGY, V28, P1549; Fujikawa A, 1996, MOL IMMUNOL, V33, P311, DOI 10.1016/0161-5890(95)00127-1; Gafvelin G, 2001, J ALLERGY CLIN IMMUN, V107, P511, DOI 10.1067/mai.2001.112264; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4<1211::AID-IMMU1211>3.0.CO;2-R; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; GREENE WK, 1990, INT ARCH ALLER A IMM, V92, P30; GREENE WK, 1991, J IMMUNOL, V147, P3768; GREENE WK, 1992, MOL IMMUNOL, V29, P257, DOI 10.1016/0161-5890(92)90107-9; GREER J, 1981, J MOL BIOL, V153, P1027, DOI 10.1016/0022-2836(81)90465-4; Hakkaart GAJ, 1997, INT ARCH ALLERGY IMM, V114, P202; Hakkaart GAJ, 1998, ALLERGY, V53, P165, DOI 10.1111/j.1398-9995.1998.tb03865.x; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P45; Hales BJ, 1997, CLIN EXP ALLERGY, V27, P868; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P934, DOI 10.1046/j.1365-2222.2000.00901.x; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; HALES BJ, 2002, IN PRESS CLIN EXP AL; Hewitt CRA, 1997, CLIN EXP ALLERGY, V27, P201, DOI 10.1111/j.1365-2222.1997.tb00694.x; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; Iwamoto N, 1996, INT ARCH ALLERGY IMM, V109, P356; Jacquet A, 2000, CLIN EXP ALLERGY, V30, P677, DOI 10.1046/j.1365-2222.2000.00823.x; Jarnicki AG, 2002, CLIN EXP ALLERGY, V32, P942, DOI 10.1046/j.1365-2745.2002.01407.x; Johansson E, 1997, CLIN EXP ALLERGY, V27, P691; JURASEK L, 1976, PROTEOLYSIS PHYSL RE, P93; Kawamoto S, 1999, BBA-MOL BASIS DIS, V1454, P201, DOI 10.1016/S0925-4439(99)00041-1; KENT NA, 1992, INT ARCH ALLERGY IMM, V99, P150; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; King C, 1998, J IMMUNOL, V161, P3645; Kircher MF, 2002, J ALLERGY CLIN IMMUN, V109, P517, DOI 10.1067/mai.2002.121945; Kirchhoff C, 1996, BIOL REPROD, V54, P847, DOI 10.1095/biolreprod54.4.847; KRILIS S, 1984, J ALLERGY CLIN IMMUN, V74, P142, DOI 10.1016/0091-6749(84)90277-X; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; Larsen LB, 1997, EUR J BIOCHEM, V243, P437, DOI 10.1111/j.1432-1033.1997.0437a.x; Li CS, 1996, J ALLERGY CLIN IMMUN, V97, P857, DOI 10.1016/S0091-6749(96)80166-7; Liaw SH, 1998, J STRUCT BIOL, V123, P265, DOI 10.1006/jsbi.1998.4031; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LIN KL, 1991, ANN ALLERGY, V67, P63; LIND P, 1988, J IMMUNOL, V140, P4256; LIND P, 1983, SCAND J IMMUNOL, V17, P263, DOI 10.1111/j.1365-3083.1983.tb00789.x; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; LIND P, 1987, SCAND J IMMUNOL, V25, P1, DOI 10.1111/j.1365-3083.1987.tb01040.x; LYNCH NR, 1997, INT ARCH ALLERGY IMM, V114, P68; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MALAINUAL N, 2002, THESIS U W AUSTR PER; Maruo K, 1997, J ALLERGY CLIN IMMUN, V100, P253, DOI 10.1016/S0091-6749(97)70233-1; Masuda K, 1999, VET IMMUNOL IMMUNOP, V72, P303, DOI 10.1016/S0165-2427(99)00142-7; McCall C, 2001, VET IMMUNOL IMMUNOP, V78, P231, DOI 10.1016/S0165-2427(00)00258-0; Meszaros M, 1996, INSECT BIOCHEM MOLEC, V26, P7, DOI 10.1016/0965-1748(95)00077-1; Meszaros M, 1996, J EXP BIOL, V199, P1555; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; Mills KL, 2002, J ALLERGY CLIN IMMUN, V109, pS180, DOI 10.1016/S0091-6749(02)81668-2; Mills KL, 1999, INT ARCH ALLERGY IMM, V120, P100, DOI 10.1159/000024227; Mita H, 2000, Clin Exp Allergy, V30, P1583, DOI 10.1046/j.1365-2222.2000.00921.x; MONTEIRO PB, 1994, J BIOL CHEM, V269, P10461; Mueller GA, 2001, J BIOL CHEM, V276, P9359, DOI 10.1074/jbc.M010812200; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; MUSIL D, 1991, EMBO J, V10, P2321; NAKANISHI K, 1990, ANN ALLERGY, V64, P219; Naureckiene S, 2000, SCIENCE, V290, P2298, DOI 10.1126/science.290.5500.2298; NISHIYAMA C, 1994, INT ARCH ALLERGY IMM, V105, P62; Nishiyama C, 1995, FEBS LETT, V377, P62, DOI 10.1016/0014-5793(95)01291-5; NISHIYAMA C, 1993, INT ARCH ALLERGY IMM, V101, P159; Nuttall TJ, 2002, VET IMMUNOL IMMUNOP, V84, P143, DOI 10.1016/S0165-2427(01)00405-6; O'Brien RM, 2000, CLIN EXP ALLERGY, V30, P333; OBRIEN RM, 1995, IMMUNOLOGY, V86, P176; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OBRIEN RM, 1994, CLIN EXP ALLERGY, V24, P737, DOI 10.1111/j.1365-2222.1994.tb00984.x; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; OHEHIR RE, 1993, J ALLERGY CLIN IMMUN, V92, P105, DOI 10.1016/0091-6749(93)90044-G; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; ONEILL GM, 1994, MOL IMMUNOL, V31, P1447, DOI 10.1016/0161-5890(94)90161-9; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; ONEILL GM, 1993, ELECTROPHORESIS, V14, P923, DOI 10.1002/elps.11501401147; Park GM, 2000, CLIN EXP ALLERGY, V30, P1293, DOI 10.1046/j.1365-2222.2000.00883.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Puerta L, 1996, J ALLERGY CLIN IMMUN, V98, P932, DOI 10.1016/S0091-6749(96)80009-1; Ramos JDA, 2001, INT ARCH ALLERGY IMM, V126, P286, DOI 10.1159/000049525; RAWLE FC, 1984, J IMMUNOL, V133, P195; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; SCHMIDT M, 1995, FEBS LETT, V370, P11, DOI 10.1016/0014-5793(95)98164-E; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; SHEN HD, 1995, CLIN EXP ALLERGY, V25, P1000, DOI 10.1111/j.1365-2222.1995.tb00403.x; Shen HD, 1996, CLIN EXP ALLERGY, V26, P308; Shen HD, 1997, CLIN EXP ALLERGY, V27, P824, DOI 10.1046/j.1365-2222.1997.650890.x; SHEN HD, 1995, CLIN EXP ALLERGY, V25, P416, DOI 10.1111/j.1365-2222.1995.tb01072.x; SHIBASAKI M, 1994, INT ARCH ALLERGY IMM, V103, P53; Shoji H, 1999, BIOSCI BIOTECH BIOCH, V63, P703, DOI 10.1271/bbb.63.703; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smith AM, 1997, CLIN EXP ALLERGY, V27, P593, DOI 10.1111/j.1365-2222.1997.tb00750.x; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith AM, 1998, J ALLERGY CLIN IMMUN, V101, P423; Smith AM, 2001, J ALLERGY CLIN IMMUN, V107, P977, DOI 10.1067/mai.2001.115629; Smith W, 1999, INT ARCH ALLERGY IMM, V118, P15, DOI 10.1159/000024026; SMITH W, 1995, THESIS U W AUSTR PER; Smith WA, 1996, INT ARCH ALLERGY IMM, V109, P133; Smith WA, 1996, CLIN EXP ALLERGY, V26, P571, DOI 10.1046/j.1365-2222.1996.d01-339.x; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; SMITH WA, 1994, CLIN EXP ALLERGY, V24, P220, DOI 10.1111/j.1365-2222.1994.tb00223.x; STEWART GA, 1989, LANCET, V2, P154; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STEWART GA, 1991, INT ARCH ALLER A IMM, V95, P248; STEWART GA, 1994, ALLERGY, V49, P553, DOI 10.1111/j.1398-9995.1994.tb01128.x; Sun G, 2001, J IMMUNOL, V167, P1014; Takahashi K, 2001, INT ARCH ALLERGY IMM, V124, P454, DOI 10.1159/000053780; Takahashi K, 2000, INT ARCH ALLERGY IMM, V122, P108, DOI 10.1159/000024366; Takai T, 1997, MOL IMMUNOL, V34, P255, DOI 10.1016/S0161-5890(97)00020-5; Takai T, 2000, EUR J BIOCHEM, V267, P6650, DOI 10.1046/j.1432-1327.2000.01760.x; Takai T, 1999, MOL IMMUNOL, V36, P1055, DOI 10.1016/S0161-5890(99)00098-X; Takai T, 2000, FEBS LETT, V484, P102, DOI 10.1016/S0014-5793(00)02096-2; TAKAI Y, 1997, NAT BIOTECHNOL, V1997, P754; Tame A, 1996, CLIN EXP ALLERGY, V26, P43, DOI 10.1111/j.1365-2222.1996.tb00055.x; Tategaki A, 2000, ACI INT S, V1, P74; Thomas W.R., 1989, Advances in the Biosciences, V74, P139; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127; THOMAS WR, 1992, EXP APPL ACAROL, V16, P153, DOI 10.1007/BF01201498; THOMAS WR, 1995, CLIN EXP ALLERGY, V25, P667, DOI 10.1111/j.1365-2222.1995.tb01117.x; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; TOVEY ER, 1989, ELECTROPHORESIS, V10, P243, DOI 10.1002/elps.1150100405; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; TRUDINGER M, 1991, CLIN EXP ALLERGY, V21, P33, DOI 10.1111/j.1365-2222.1991.tb00801.x; TSAI L, 1999, CLIN EXP ALLERGY, V29, P1583; Tsai LC, 1998, J ALLERGY CLIN IMMUN, V102, P295, DOI 10.1016/S0091-6749(98)70099-5; Tsitoura DC, 1996, J IMMUNOL, V157, P2160; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Van Der Veen MJ, 2001, CLIN EXP ALLERGY, V31, P705, DOI 10.1046/j.1365-2222.2001.01120.x; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VANHAGEHAMSTEN M, 1995, CLIN EXP ALLERGY, V25, P539; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1994, IMMUNOLOGY, V82, P351; vanRee R, 1996, ALLERGY, V51, P108; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225; VARELA J, 1994, EUR J BIOCHEM, V225, P93, DOI 10.1111/j.1432-1033.1994.00093.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; WESTRITSCHNIG K, 2002, IN PRESS CLIN EXP AL; Witteman AM, 1996, CLIN EXP ALLERGY, V26, P1171, DOI 10.1046/j.1365-2222.1996.d01-265.x; YASEUDA H, 1989, INT ARCH ALLER A IMM, V88, P402; YASEUDA H, 1996, CLIN EXP ALLERGY, V26, P171; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x; YUUKI T, 1990, Japanese Journal of Allergology, V39, P557; Yuuki T, 1997, INT ARCH ALLERGY IMM, V112, P44	196	214	243	2	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	SEP	2002	129	1					1	18		10.1159/000065179		18	Allergy; Immunology	Allergy; Immunology	605YA	WOS:000178703600001	12372994	
J	Liu, AH				Liu, AH			Endotoxin exposure in allergy and asthma: Reconciling a paradox	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; asthma; therapy; prevention; endotoxin; LPS; infection; hygiene; IFN-gamma; IL-12; T(H)1	CD4(+) T-CELLS; GROWTH-FACTOR-BETA; INDUCED AIRWAY HYPERRESPONSIVENESS; STIMULATORY FACTOR INTERLEUKIN-12; INTERFERON-GAMMA PRODUCTION; GRASS-POLLEN IMMUNOTHERAPY; HAY-FEVER; MESSENGER-RNA; COLLAGEN-SYNTHESIS; INHALED ENDOTOXIN	Well-established evidence links endotoxin exposure, especially in the workplace, to airways disease. Endotoxin can increase disease severity by acting as a natural adjuvant to augment asthma and atopic inflammation. Recent studies suggest that it can even act on its own, causing a distinct endotoxic form of asthma. Other studies, however, contradict the paradigm that endotoxin's influence is solely a negative one. Epidemiologic associations of environmental endotoxin exposure with allergy and asthma prevention are consistent with hygiene hypothesis associations of other microbial exposures or infections with a lower incidence of atopic disease. Currently, microbe-derived products are being developed as potential therapies for allergy and asthma. Thus it is an ideal time to consider endotoxin as a prototype of a natural intervention with microbial components. Nature's ongoing experiment with endotoxin can provide clues for the development of effective and safe microbe-based products for disease treatment and prevention. This article will discuss (1) conventional paradigms in which endotoxin-induced immune modulation by T(H)1-type induction leads to mitigation of T(H)2-type immune development, allergen sensitization, and atopic inflammation; (2) newer concepts of T(H)1-type immune responses that may provide additional asthma-protective effects by preventing airways remodeling; (3) home and environmental features that significantly contribute to endotoxin exposure; (4) different aspects of asthma mediated by endotoxin exposure; and (5) how to understand endotoxin's paradoxical nature of serving as both friend and foe.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA	Liu, AH (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Pediat Allergy & Immunol, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NHLBI NIH HHS [K23-HL-04272]		Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Arbour NC, 2000, NAT GENET, V25, P187; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.20001.113081; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Becker MN, 2000, J BIOL CHEM, V275, P29731, DOI 10.1074/jbc.M000184200; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BRIGHAM KL, 1994, ENDOTOXIN LUNGS, V77; Broide D, 1998, J IMMUNOL, V161, P7054; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CHILLER JM, 1973, J EXP MED, V137, P740, DOI 10.1084/jem.137.3.740; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1999, J IMMUNOL, V162, P6178; Cole AM, 2001, J IMMUNOL, V167, P623; CRIMI E, 1991, AM REV RESPIR DIS, V144, P1282; Crouch EC, 1998, AM J RESP CELL MOL, V19, P177; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2000, AM J IND MED, V38, P426, DOI 10.1002/1097-0274(200010)38:4<426::AID-AJIM8>3.3.CO;2-I; Dow SW, 1999, HUM GENE THER, V10, P2961, DOI 10.1089/10430349950016375; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DRESSER DW, 1961, NATURE, V191, P1169, DOI 10.1038/1911169a0; DUNCAN MR, 1985, J EXP MED, V162, P516, DOI 10.1084/jem.162.2.516; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Dutton S, 2002, J ALLERGY CLIN IMMUN, V109, pS48, DOI 10.1016/S0091-6749(02)81233-7; Eickelberg O, 2001, FASEB J, V15, P797, DOI 10.1096/fj.00-0233com; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fanucchi MV, 1998, TOXICOL APPL PHARM, V152, P1, DOI 10.1006/taap.1998.8484; Farooqi IS, 1998, THORAX, V53, P927; FOREHAND JR, 1989, J CLIN INVEST, V83, P74, DOI 10.1172/JCI113887; Gao JJ, 1999, J IMMUNOL, V163, P4095; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; George CLS, 2001, AM J PHYSIOL-LUNG C, V280, pL203; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Ghosh AK, 2001, J BIOL CHEM, V276, P11041, DOI 10.1074/jbc.M004709200; GILLERY P, 1992, FEBS LETT, V302, P231, DOI 10.1016/0014-5793(92)80448-P; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; GOLDRING MB, 1986, J BIOL CHEM, V261, P9049; HAGMAR L, 1990, INT ARCH OCC ENV HEA, V62, P159, DOI 10.1007/BF00383592; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hansen G, 2000, J IMMUNOL, V164, P223; Hartmann G, 1999, GENE THER, V6, P893, DOI 10.1038/sj.gt.3300880; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HAYES MP, 1995, BLOOD, V86, P646; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hilkens CMU, 1997, BLOOD, V90, P1920; Hofstra CL, 1998, AM J RESP CELL MOL, V19, P826; Hogan SP, 1998, EUR J IMMUNOL, V28, P413; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jeffery P, 2001, Pediatr Pulmonol Suppl, V21, P3; JIMENEZ SA, 1984, J CLIN INVEST, V74, P1112, DOI 10.1172/JCI111480; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kassel O, 2001, CLIN EXP ALLERGY, V31, P1432, DOI 10.1046/j.1365-2222.2001.01177.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kim TS, 1997, J IMMUNOL, V158, P4137; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535; Kirshenbaum AS, 1998, EXP HEMATOL, V26, P245; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Lack G, 1997, J ALLERGY CLIN IMMUN, V99, P530, DOI 10.1016/S0091-6749(97)70081-2; LACK G, 1994, J IMMUNOL, V152, P2546; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LE JM, 1986, J IMMUNOL, V136, P4525; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; LOUAHED J, 2000, AM J RESP CELL MOL B, V22, P637; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 2000, ANN ALLERG ASTHMA IM, V85, P305; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; MICHEL O, 1991, ANN ALLERGY, V66, P39; Michel O, 2000, TOXICOLOGY, V152, P25, DOI 10.1016/S0300-483X(00)00288-2; Monn C, 1999, TOXICOL APPL PHARM, V155, P245, DOI 10.1006/taap.1998.8591; Mungan D, 2001, ALLERGY ASTHMA PROC, V22, P87, DOI 10.2500/108854101778250643; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ng'ang'a LW, 1998, THORAX, V53, P919; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; PABST MJ, 1982, J IMMUNOL, V128, P123; PABST MJ, 1980, J EXP MED, V151, P101, DOI 10.1084/jem.151.1.101; Pape KA, 1997, J IMMUNOL, V159, P591; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Parry DE, 2000, J ALLERGY CLIN IMMUN, V105, P692, DOI 10.1067/mai.2000.104785; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; POSTLETHWAITE AE, 1992, J CLIN INVEST, V90, P1479, DOI 10.1172/JCI116015; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Reijonen TM, 2000, PEDIATRICS, V106, P1406, DOI 10.1542/peds.106.6.1406; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; Roy SR, 2002, J ALLERGY CLIN IMMUN, V109, pS41, DOI 10.1016/S0091-6749(02)81209-X; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Salkowski CA, 1997, INFECT IMMUN, V65, P3239; Saraf A, 1997, APPL ENVIRON MICROB, V63, P2554; Schelegle ES, 2001, AM J PATHOL, V158, P333, DOI 10.1016/S0002-9440(10)63973-9; SCHILLING RSF, 1956, LANCET, V2, P319; Schilling RSF, 1956, LANCET, V2, P261; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; SEMPOWSKI GD, 1994, J IMMUNOL, V152, P3606; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shnyra A, 1998, J IMMUNOL, V160, P3729; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; Sorkness RL, 1999, AM J RESP CRIT CARE, V160, P705; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; SOUSA CR, 1997, J EXP MED, V186, P1799; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Su HJ, 2001, ENVIRON RES, V85, P135, DOI 10.1006/enrs.2000.4113; Sur S, 1996, J IMMUNOL, V157, P4173; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tredget EE, 2000, J INTERF CYTOK RES, V20, P143, DOI 10.1089/107999000312540; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Ulloa L, 1999, NATURE, V397, P710; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VELLA AT, 1995, IMMUNITY, V2, P261, DOI 10.1016/1074-7613(95)90050-0; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; Wagner JG, 2001, TOXICOL SCI, V60, P338, DOI 10.1093/toxsci/60.2.338; Wickens K, 1999, J ALLERGY CLIN IMMUN, V104, P554, DOI 10.1016/S0091-6749(99)70323-4; Zhiping Wang, 1996, American Journal of Respiratory and Critical Care Medicine, V154, P1261; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	161	214	222	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2002	109	3					379	392		10.1067/mai.2002.122157		14	Allergy; Immunology	Allergy; Immunology	534KW	WOS:000174586400001	11897980	
J	Sigurs, N; Aljassim, F; Kjellman, B; Robinson, PD; Sigurbergsson, F; Bjarnason, R; Gustafsson, PM				Sigurs, Nele; Aljassim, Fatma; Kjellman, Bengt; Robinson, Paul D.; Sigurbergsson, Fridrik; Bjarnason, Ragnar; Gustafsson, Per M.			Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life	THORAX			English	Article							RESPIRATORY-SYNCYTIAL-VIRUS; VENTILATION MALDISTRIBUTION; VIRAL-INFECTIONS; REFERENCE RANGES; AGE 13; INFANCY; SENSITIZATION; CHILDREN; RISK; SPIROMETRY	Background An increased prevalence of asthma/recurrent wheeze (RW), clinical allergy and allergic sensitisation up to age 13 years has previously been reported in subjects hospitalised with respiratory syncytial virus (RSV) bronchiolitis in their first year of life compared with matched controls. A study was undertaken to examine whether these features persist into early adulthood, to report longitudinal wheeze and allergy patterns, and to see how large and small airway function relates to RSV infection and asthma. Methods Follow-up at age 18 years was performed in 46 of 47 subjects with RSV and 92 of 93 controls. Assessments included questionnaire, clinical examination, skin prick tests, serum IgE antibodies to inhaled allergens, blood eosinophils, fraction of exhaled nitric oxide (FeNO), spirometry, multiple breath washout (lung clearance index, LCI) and dry air hyperventilation challenge. Results Increased prevalence of asthma/RW (39% vs 9%), clinical allergy (43% vs 17%) and sensitisation to perennial allergens (41% vs 14%) were present at age 18 in the RSV cohort compared with controls. Persistent/relapsing wheeze associated with early allergic sensitisation predominated in the RSV cohort compared with controls (30% vs 1%). Spirometric function was reduced in subjects with RSV with or without current asthma, but not in asthmatic controls. LCI was linked only to current asthma, airway hyperresponsiveness and FeNO. Conclusions Severe early RSV bronchiolitis is associated with an increased prevalence of allergic asthma persisting into early adulthood. Small airway dysfunction (LCI) is related to current asthma and airway inflammation but not to RSV bronchiolitis. Reduced spirometry after RSV may reflect airway remodelling.	[Sigurs, Nele] Boras Cent Hosp, Dept Paediat, S-50182 Boras, Sweden; [Aljassim, Fatma] Govt Dubai, Dubai Hlth Author, Alwasl Hosp, Dept Paediat, Dubai, U Arab Emirates; [Kjellman, Bengt; Gustafsson, Per M.] Cent Hosp Skovde, Dept Paediat, S-54185 Skovde, Sweden; [Aljassim, Fatma; Gustafsson, Per M.] Queen Silvia Childrens Hosp, Gothenburg, Sweden; [Robinson, Paul D.] Childrens Hosp Westmead, Dept Resp Med, Westmead, NSW, Australia; [Robinson, Paul D.] Univ Sydney, Fac Med, Discipline Paediat & Child Hlth, Childrens Hosp Westmead,Clin Sch, Sydney, NSW 2006, Australia; [Sigurbergsson, Fridrik] Landspitali Univ Hosp, Emergency Dept, Reykjavik, Iceland; [Bjarnason, Ragnar] Univ Iceland, Dept Paediat, Landspitali Univ Hosp Iceland, Reykjavik, Iceland; [Gustafsson, Per M.] Univ Gothenburg, Sahlgrenska Acad, Gothenburg, Sweden	Sigurs, N (reprint author), Boras Cent Hosp, Dept Paediat, S-50182 Boras, Sweden.	nele.sigurs@vgregion.se			Regional Health Care Authority of West Sweden; Boras Hospital; Fokus Foundation; SeBe's Fund	The study was supported by grants from the Regional Health Care Authority of West Sweden, from Boras Hospital, the Fokus Foundation and SeBe's Fund.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Castro M, 2008, J ALLERGY CLIN IMMUN, V122, P726, DOI 10.1016/j.jaci.2008.07.010; Cole TJ, 2009, STAT MED, V28, P880, DOI 10.1002/sim.3504; COURT SDM, 1973, POSTGRAD MED J, V49, P771; CRAWFORD ABH, 1985, J APPL PHYSIOL, V59, P838; Downie SR, 2007, THORAX, V62, P684, DOI 10.1136/thx.2006.069682; Forton JT, 2009, THORAX, V64, P345, DOI 10.1136/thx.2008.102111; Gelfand Erwin W, 2009, Proc Am Thorac Soc, V6, P278, DOI 10.1513/pats.200808-090RM; Gustafsson PM, 2003, EUR RESPIR J, V22, P972, DOI 10.1183/09031936.03.00049502; Hesselmar B, 2000, PEDIATR ALLERGY IMMU, V11, P74, DOI 10.1034/j.1399-3038.2000.00070.x; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Johnson JE, 2007, MODERN PATHOL, V20, P108, DOI 10.1038/modpathol.3800725; JUNIPER EF, 1981, THORAX, V36, P575, DOI 10.1136/thx.36.8.575; King GG, 1998, AM J RESP CRIT CARE, V158, P1900; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; Kuehni CE, 2009, AM J RESP CRIT CARE, V179, P1079, DOI 10.1164/rccm.200904-0567ED; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Macleod KA, 2009, THORAX, V64, P33, DOI 10.1136/thx.2007.095018; Mallia P, 2002, ALLERGY, V57, P1118, DOI 10.1034/j.1398-9995.2002.02169.x; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; PAIVA M, 1988, RESP PHYSIOL, V72, P257, DOI 10.1016/0034-5687(88)90085-0; PULLAN CR, 1982, BRIT MED J, V284, P1665; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; Stanojevic S, 2008, AM J RESP CRIT CARE, V177, P253, DOI 10.1164/rccm.200708-1248OC; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; SWIERKOSZ EM, 1989, J CLIN MICROBIOL, V27, P1151; Thomsen SF, 2008, PEDIATRICS, V121, P493, DOI 10.1542/peds.2007-1889; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; Walton RP, 2008, CURR OPIN ALLERGY CL, V8, P150, DOI 10.1097/ACI.0b013e3282f889df; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC	38	213	226	1	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	DEC	2010	65	12					1045	1052		10.1136/thx.2009.121582		8	Respiratory System	Respiratory System	681WQ	WOS:000284354800006	20581410	
J	Henderson, J; Granell, R; Heron, J; Sherriff, A; Simpson, A; Woodcock, A; Strachan, DP; Shaheen, SO; Sterne, JAC				Henderson, J.; Granell, R.; Heron, J.; Sherriff, A.; Simpson, A.; Woodcock, A.; Strachan, D. P.; Shaheen, S. O.; Sterne, J. A. C.			Associations of wheezing phenotypes in the first 6 years of life with atopy, lung function and airway responsiveness in mid-childhood	THORAX			English	Article							PRESCHOOL-CHILDREN; HIGH-RISK; ASTHMA; INFANTS; BIRTH; SENSITIZATION; PATTERNS; EXPOSURE; SOUNDS; COHORT	Background: Patterns of wheezing during early childhood may indicate differences in aetiology and prognosis of respiratory illnesses. Improved characterisation of wheezing phenotypes could lead to the identification of environmental influences on the development of asthma and airway diseases in predisposed individuals. Methods: Data collected on wheezing at seven time points from birth to 7 years from 6265 children in a longitudinal birth cohort (the ALSPAC study) were analysed. Latent class analysis was used to assign phenotypes based on patterns of wheezing. Measures of atopy, airway function ( forced expiratory volume in 1 s (FEV(1)), mid forced expiratory flow (FEF(25-75))) and bronchial responsiveness were made at 7-9 years of age. Results: Six phenotypes were identified. The strongest associations with atopy and airway responsiveness were found for intermediate onset (18 months) wheezing (OR for atopy 8.36, 95% CI 5.2 to 13.4; mean difference in dose response to methacholine 1.76, 95% CI 1.41 to 2.12 %FEV(1) per mu mol, compared with infrequent/never wheeze phenotype). Late onset wheezing (after 42 months) was also associated with atopy (OR 6.6, 95% CI 4.7 to 9.4) and airway responsiveness (mean difference 1.61, 95% CI 1.37 to 1.85 % FEV(1) per mmol). Transient and prolonged early wheeze were not associated with atopy but were weakly associated with increased airway responsiveness and persistent wheeze had intermediate associations with these outcomes. Conclusions: The wheezing phenotypes most strongly associated with atopy and airway responsiveness were characterised by onset after age 18 months. This has potential implications for the timing of environmental influences on the initiation of atopic wheezing in early childhood.	[Henderson, J.] Univ Bristol, Dept Community Based Med, Bristol, Avon, England; [Granell, R.; Heron, J.; Sherriff, A.; Sterne, J. A. C.] Univ Bristol, Dept Social Med, Bristol, Avon, England; [Simpson, A.; Woodcock, A.] Univ Manchester, North West Lung Ctr, Manchester, Lancs, England; [Strachan, D. P.] St Georges Hosp Med Sch, Dept Community Hlth Sci, London, England; [Shaheen, S. O.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London & Resp Epidemiol & Publ Hlth Grp, London, England	Henderson, J (reprint author), ALSPAC, 24 Tyndall Ave, Bristol BS8 1TQ, Avon, England.	a.j.henderson@bris.ac.uk	Heron, Jon/D-5884-2011	Heron, Jon/0000-0001-6199-5644; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666	Asthma UK [Senior Research Fellow]; British Lung Foundation; UK Medical Research Council; University of Bristol; Wellcome Trust	This research was specifically funded by a grant from Asthma UK to establish a research network of UK asthma birth cohorts (the STELAR network). The skin prick tests were funded by a grant from the British Lung Foundation and the measurements of lung function and airway responsiveness were supported by a grant from the UK Medical Research Council. SOS is an Asthma UK Senior Research Fellow. The UK Medical Research Council, the Wellcome Trust and the University of Bristol provide core support for ALSPAC.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baker D, 1999, J EPIDEMIOL COMMUN H, V53, P636; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Brussee JE, 2005, J ALLERGY CLIN IMMUN, V115, P946, DOI 10.1016/j.jaci.2005.02.035; CHINN S, 1992, THORAX, V47, P707, DOI 10.1136/thx.47.9.707; Elphick HE, 2000, EUR RESPIR J, V16, P593, DOI 10.1034/j.1399-3003.2000.16d04.x; Elphick HE, 2001, ARCH DIS CHILD, V84, P35, DOI 10.1136/adc.84.1.35; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; JENKINS MA, 1994, BRIT MED J, V309, P90; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Oddy WH, 1999, BRIT MED J, V319, P815; PEMBREY M, 2004, EUR J ENDOCRINOL S3, V151, pU127; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Rabe-Hesketh S, 2008, STAT METHODS MED RES, V17, P5, DOI 10.1177/0962280207081236; Roberts G, 2005, CLIN EXP ALLERGY, V35, P933, DOI 10.1111/j.1365-2222.2005.02280.x; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Singh AM, 2007, AM J RESP CRIT CARE, V175, P108, DOI 10.1164/rccm.200603-435PP; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Stein RT, 1997, THORAX, V52, P946; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Turner SW, 2002, AM J RESP CRIT CARE, V165, P1294, DOI 10.1164/rccm.200110-018OC; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Young AF, 2006, AUST NZ J PUBL HEAL, V30, P353, DOI 10.1111/j.1467-842X.2006.tb00849.x; [Anonymous], 2006, LANCET, V368, P705	36	213	224	3	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	NOV	2008	63	11					974	980		10.1136/thx.2007.093187		7	Respiratory System	Respiratory System	368GY	WOS:000260610800010	18678704	
J	Holgate, ST; Polosa, R				Holgate, Stephen T.; Polosa, Riccardo			The mechanisms, diagnosis, and management of severe asthma in adults	LANCET			English	Review							LUNG-FUNCTION DECLINE; SEVERE PERSISTENT ASTHMA; NECROSIS-FACTOR-ALPHA; TO-TREAT ASTHMA; DOSE INTRAVENOUS IMMUNOGLOBULIN; PLACEBO-CONTROLLED TRIAL; GROWTH-FACTOR RECEPTOR; CHURG-STRAUSS-SYNDROME; AIRWAY SMOOTH-MUSCLE; QUALITY-OF-LIFE	There has been a recent increase in the prevalence of asthma worldwide; however, the 5-10% of patients with severe disease account for a substantial proportion of the health costs. Although most asthma cases can be satisfactorily managed with a combination of anti-inflammatory drugs and bronchodilators, patients who remain symptomatic despite maximum combination treatment represent a heterogeneous group consisting of those who are under-treated or non-adherent with their prescribed medication. After excluding under-treatment and poor compliance, corticosteroid refractory asthma can be identified as a subphenotype characterised by a heightened neutrophilic airway inflammatory response in the presence or absence of eosinophils, with evidence of increased tissue injury and remodelling. Although a wide range of environmental factors such as allergens, smoking, air pollution, infection, hormones, and specific drugs can contribute to this phenotype, other features associated with changes in the airway inflammatory response should be taken into account. Aberrant communication between an injured airway epithelium and underlying mesenchyme contributes to disease chronicity and refractoriness to corticosteroids. The importance of identifying underlying causative factors and the recent introduction of novel therapeutic approaches, including the targeting of immunoglobulin E and tumour necrosis factor a with biological agents, emphasise the need for careful phenotyping of patients with severe disease to target improved management of the individual patient's needs.	Southampton Gen Hosp, AIR Div, Southampton SO16 6YD, Hants, England; Univ Catania, Dipartimento Med Interna & Specialist, Catania, Italy	Holgate, ST (reprint author), Southampton Gen Hosp, AIR Div, MP810,F Level,S Block, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk			Medical Research Council [G0800766]		Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Adcock IM, 2003, J ENDOCRINOL, V178, P347, DOI 10.1677/joe.0.1780347; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; An SS, 2006, AM J RESP CELL MOL, V35, P55, DOI 10.1165/rcmb.2005-0453OC; Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Ayres Jon G, 2004, Paediatr Respir Rev, V5, P40, DOI 10.1016/j.prrv.2003.09.003; Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Bachert C, 2006, CURR OPIN ALLERGY CL, V6, P29, DOI 10.1097/01.all.0000200504.54425.0e; Bachert C, 2002, Allergy, V57, P841; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Barnes N, 2006, PAEDIATR RESPIR REV, V7, P141, DOI 10.1016/j.prrv.2006.03.008; Barton CA, 2005, J ASTHMA, V42, P249, DOI 10.1081/JAS-200057881; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bisgaard H, 2006, LANCET, V367, P286, DOI 10.1016/S0140-6736(06)68051-3; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; BRECIANI M, 2001, J ALLERGY CLIN IMMUN, V107, P73; Brenner BE, 2005, THORAX, V60, P806, DOI 10.1136/thx.2004.033928; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Busse PJ, 2005, J ALLERGY CLIN IMMUN, V116, P1256, DOI 10.1016/j.jaci.2005.08.059; Busse W. W., 2004, Journal of Allergy and Clinical Immunology, V113, pS286, DOI 10.1016/j.jaci.2004.01.508; Campbell MJ, 1997, BRIT MED J, V314, P1439; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Casalino-Matsuda SM, 2006, AM J RESP CELL MOL, V34, P581, DOI 10.1165/rcmb.2005-0386OC; Cazzola M, 2006, CURR OPIN ALLERGY CL, V6, P43, DOI 10.1097/01.all.0000199798.10047.74; Cohn L, 2006, J CLIN INVEST, V116, P306, DOI 10.1172/JCI27690; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Coughlan JL, 2001, THORAX, V56, P198, DOI 10.1136/thorax.56.3.198; Currie GP, 2005, CHEST, V128, P2954, DOI 10.1378/chest.128.4.2954; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9; Davies H, 2000, COCHRANE DB SYST REV, V2; de Marco R, 2005, INT ARCH ALLERGY IMM, V138, P225, DOI 10.1159/000088723; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; Erzurum SC, 2006, NEW ENGL J MED, V354, P754, DOI 10.1056/NEJMe058266; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Frey U, 2005, NATURE, V438, P667, DOI 10.1038/nature04176; Gerdtham UG, 1996, MED CARE, V34, P1188, DOI 10.1097/00005650-199612000-00004; Gibson PG, 2006, SEM RESP CRIT CARE M, V27, P185, DOI 10.1055/s-2006-939521; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Coughlan J. L., 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001496; Gibson PG, 2005, COCHRANE DB SYST REV, V4; Global Initiative for Asthma, NIH PUBL, V02-3659; GODDARD P, 2002, EUR RESPIR J, V19, P61; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Greene R, 2005, MED MYCOL, V43, pS147, DOI 10.1080/13693780500064771; GRUNBERG K, 2001, AM J RESP CRIT CARE, V109, P35; HAMILTON L, 2003, CLIN EXP ALLERGY, V33, P1; Haque S, 2003, INTERN MED J, V33, P341, DOI 10.1046/j.1445-5994.2003.t01-1-00419.x; Harju TH, 2006, THORAX, V61, P579, DOI 10.1136/thx.2005.056291; Harrison BDW, 2005, INTERN MED J, V35, P543, DOI 10.1111/j.1445-5994.2005.00901.x; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Heaney LG, 2005, LANCET, V365, P974, DOI 10.1016/S0140-6736(05)71087-4; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Howarth Peter H, 2004, J Allergy Clin Immunol, V114, pS32, DOI 10.1016/j.jaci.2004.04.041; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; INTVEEN JCC, 1998, AM J RESP CRIT CARE, V158, P1134; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Jain S, 2006, J ASTHMA, V43, P207, DOI 10.1080/02770900600566892; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Jang An-Soo, 2005, Chest, V128, P1140, DOI 10.1378/chest.128.3.1140; Janson C, 2005, EUR RESPIR J, V26, P1047, DOI 10.1183/09031936.05.00031905; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Johnston SL, 2006, NEW ENGL J MED, V354, P1589, DOI 10.1056/NEJMoa044080; JONGEPIER H, 2004, CLIN EXP ALLERGY, V34, P357; Kawakami T, 2005, ARCH DERMATOL, V141, P873, DOI 10.1001/archderm.141.7.873; Kiljander TO, 2006, AM J RESP CRIT CARE, V173, P1091, DOI 10.1164/rccm.200507-1167OC; KING S, 2005, CLIN EXP ALLERGY, V35, P672; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Koga T, 2006, RESP MED, V100, P273, DOI 10.1016/j.rmed.2005.05.017; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; Kroegel C, 2006, RESPIRATION, V73, P566, DOI 10.1159/000088660; Lee YM, 2004, CHEST, V126, P1840, DOI 10.1378/chest.126.6.1840; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128; Luong KVQ, 2000, J ASTHMA, V37, P125, DOI 10.3109/02770900009055435; Malo JL, 2005, AM J RESP CRIT CARE, V172, P406, DOI 10.1164/rccm.2506006; Marchac V, 2002, AM J ROENTGENOL, V179, P1245; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Miller MK, 2005, J ALLERGY CLIN IMMUN, V116, P990, DOI 10.1016/j.jaci.2005.08.018; MITSUNOBU F, 2005, CURR OPIN ALLERGY CL, V5, P57; Mjaanes CM, 2006, CLIN CHEST MED, V27, P119, DOI 10.1016/j.ccm.2005.10.005; MORE WC, 2006, J ALERGY CLIN IMMUNO, V117, P487; Mortimer KJ, 2005, IMMUNOL ALLERGY CLIN, V25, P523, DOI 10.1016/j.iac.2005.05.002; Neffen H, 2006, RESP MED, V100, P1431, DOI 10.1016/j.rmed.2005.11.004; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Niebauer K, 2006, ANN ALLERG ASTHMA IM, V96, P316; Nieves A, 2005, RESP MED, V99, P347, DOI 10.1016/j.rmed.2004.08.004; Nouwen A, 1999, BEHAV MODIF, V23, P217, DOI 10.1177/0145445599232002; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Pavord ID, 1997, THORAX, V52, P498; Pedersen B, 1996, AM J RESP CRIT CARE, V153, P1519; PEPE C, 2005, J ALLERGY CLIN IMMUN, V116, P554; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; RHEN T, 2005, NEW ENGL J MED, V353, P17111; Richeldi L, 2005, COCHRANE DB SYST REV, V4; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Russo C, 2005, CLIN SCI, V109, P135; SAGLANI S, 2006, EUR RESP J      0426, DOI UNSP 09031936.06.00056405V1; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Salmun LM, 1999, J ALLERGY CLIN IMMUN, V103, P810, DOI 10.1016/S0091-6749(99)70424-0; Sanak M, 2000, THORAX, V55, pS45, DOI 10.1136/thorax.55.suppl_2.S45; Schatz M, 1999, J ALLERGY CLIN IMMUN, V103, pS330, DOI 10.1016/S0091-6749(99)70258-7; SHAH L, 2003, COCHRANE DB SYST REV, V3, P1281; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Silverman RA, 2003, CHEST, V123, P1472, DOI 10.1378/chest.123.5.1472; Simon HU, 2006, CURR ALLERGY ASTHM R, V6, P117, DOI 10.1007/s11882-006-0049-9; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Sturdy PM, 2005, THORAX, V60, P909, DOI 10.1136/thx.2004.025593; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Szczeklik A, 2006, EUR J PHARMACOL, V533, P145, DOI 10.1016/j.ejphar.2005.12.053; Szefler S, 2005, CHEST, V128, P1104, DOI 10.1378/chest.128.3.1104; Szczeklik A, 2000, EUR RESPIR J, V16, P432; Takigawa N, 2005, J ASTHMA, V42, P639, DOI 10.1080/02770900500263822; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Thomson NC, 2005, CURR OPIN ALLERGY CL, V5, P57, DOI 10.1097/00130832-200502000-00011; Tinkelman DG, 2006, J ASTHMA, V43, P75, DOI 10.1080/02770900500448738; Tough SC, 1998, J ASTHMA, V35, P657, DOI 10.3109/02770909809048968; Truyen E, 2006, THORAX, V61, P202, DOI 10.1136/thx.2005.052399; Tulic MK, 2003, CHEST, V123, p348S, DOI 10.1378/chest.123.3_suppl.348S; van Diemen CC, 2005, AM J RESP CRIT CARE, V172, P329, DOI 10.1164/rccm.200411-1486OC; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; van Rensen ELJ, 2005, AM J RESP CRIT CARE, V172, P837, DOI 10.1164/rccm.200504-619OC; Vrugt B, 1997, THORAX, V52, P662; Ward C, 2005, CURR OPIN ALLERGY CL, V5, P43, DOI 10.1097/00130832-200502000-00009; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Waserman S, 2000, Can Respir J, V7, P229; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-15190C; Weiss Scott T, 2004, Proc Am Thorac Soc, V1, P364, DOI 10.1513/pats.200409-043MS; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Westby M, 2004, COCHRANE DB SYST REV, V3; Wirtz HR, 2005, J HEART LUNG TRANSPL, V24, P1700, DOI 10.1016/j.healun.2005.01.015; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Yigla M, 2003, J ASTHMA, V40, P865, DOI 10.1081/JAS-120023577	162	213	226	1	18	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG-SEP	2006	368	9537					780	793		10.1016/S0140-6736(06)69288-X		18	Medicine, General & Internal	General & Internal Medicine	080ID	WOS:000240240200030	16935689	
J	Sun, G; Stacey, MA; Schmidt, M; Mori, L; Mattoli, S				Sun, G; Stacey, MA; Schmidt, M; Mori, L; Mattoli, S			Interaction of mite allergens Der P3 and Der P9 with protease-activated receptor-2 expressed by lung epithelial cells	JOURNAL OF IMMUNOLOGY			English	Article							GROUP-III ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; AIRWAY HYPERRESPONSIVENESS; THROMBIN RECEPTORS; GENE-EXPRESSION; ATOPIC ASTHMA; RELEASE; CLONING; KERATINOCYTES; INFLAMMATION	The respiratory epithelium represents the first barrier encountered by airborne Ags. Two major dust mite Ags, Der p3 and Der p9, are serine proteases that may activate lung epithelial cells by interaction with the protease-activated receptor 2 (PAR-2). In this study both Der p3 and Der p9 cleaved the peptide corresponding to the N terminus of PAR-2 at the activation site. Both Ags sequentially stimulated phosphoinositide hydrolysis, transient cytosolic Ca2+ mobilization, and release of GM-CSF and eotaxin in human pulmonary epithelial cells. These responses were similar to those observed with trypsin and a specific PAR-2 agonist and were related to the serine protease activity of Der p3 and Der p9. Cell exposure to the Ags resulted in a refractory period, indicating that a PAR had been cleaved. Partial desensitization to Der p3 and Der p9 by the PAR-2 agonist suggested that PAR-2 was one target of the Ags. However, PAR-2 was not the only target, because the PAR-2 agonist caused less desensitization to Der p3 and Der p9 than did trypsin. A phospholipase C inhibitor prevented the cytokine-releasing effect of the PAR-2 agonist and abolished or reduced (> 70%) the cytokine-releasing effects of Der p3 and Der p9. Our results suggest that Der p 3 and Der p9 may induce a nonallergic inflammatory response in the airways through the release of proinflammatory cytokines from the bronchial epithelium and that this effect is at least in part mediated by PAR-2.	Avail GmbH, AVAIL Biomed Res Inst, CH-4051 Basel, Switzerland	Mattoli, S (reprint author), Avail GmbH, AVAIL Biomed Res Inst, Spalentorweg 18, CH-4051 Basel, Switzerland.		Mattoli, Sabrina/H-8211-2014	Mattoli, Sabrina/0000-0002-6866-604X			ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; Blackhart BD, 1996, J BIOL CHEM, V271, P16466; Bohm SK, 1996, J BIOL CHEM, V271, P22003; BROWN JR, 1998, CLIN EXP IMMUNOL, V114, P134; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; EVANS MD, 1994, AM J PHYSIOL, V266, P593; FERGUSON P, 1995, AM J RESP CRIT CARE, V151, P71; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hou L, 1998, IMMUNOLOGY, V94, P356, DOI 10.1046/j.1365-2567.1998.00528.x; Howells GL, 1997, J CELL SCI, V110, P881; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; King C, 1998, J IMMUNOL, V161, P3645; Loew D, 2000, BIOCHEMISTRY-US, V39, P10812, DOI 10.1021/bi0003341; Madison JM, 2000, AM J RESP CELL MOL, V22, P513; Mattoli S, 1997, BIOCHEM BIOPH RES CO, V236, P299, DOI 10.1006/bbrc.1997.6958; MATTOLI S, 2001, HLTH PERSPECT S, V109; Molino M, 1997, J BIOL CHEM, V272, P11133; Molino M, 1997, J BIOL CHEM, V272, P4043; Mori L, 1995, BIOCHEM BIOPH RES CO, V217, P817, DOI 10.1006/bbrc.1995.2845; Pavord ID, 1994, LANCET, V344, P436; Pina JS, 1997, POSTGRAD MED, V101, P153; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672; Ritz Stacey A., 2000, Journal of Allergy and Clinical Immunology, V106, pS206; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; Shibata Y, 1996, J IMMUNOL, V156, P772; SMITH WA, 1994, CLIN EXP ALLERGY, V24, P220, DOI 10.1111/j.1365-2222.1994.tb00223.x; SOLOPERTO M, 1991, AM J PHYSIOL, V260, pL530; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; Steinhoff M, 2000, NAT MED, V6, P151; STEWART GA, 1992, IMMUNOLOGY, V75, P29; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; Sun G, 1997, PEPTIDES, V18, P1449, DOI 10.1016/S0196-9781(97)00194-0; Thompson PJ, 1998, CLIN EXP ALLERGY, V28, P110; Tomee JFC, 1997, J INFECT DIS, V176, P300, DOI 10.1086/517272; Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wakita H, 1997, P ASSOC AM PHYSICIAN, V109, P190; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252	47	213	223	1	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUL 15	2001	167	2					1014	1021				8	Immunology	Immunology	471VL	WOS:000170949300050	11441110	
J	Christakis, DA; Mell, L; Koepsell, TD; Zimmerman, FJ; Connell, FA				Christakis, DA; Mell, L; Koepsell, TD; Zimmerman, FJ; Connell, FA			Association of lower continuity of care with greater risk of emergency department use and hospitalization in children	PEDIATRICS			English	Article						continuity of patient care; pediatrics; ambulatory care; emergency department; hospitalization	HEALTH-CARE; SERVICES; EXPERIENCE; SEVERITY; CHOICE; ASTHMA	Context. The benefits of continuity of pediatric care remain controversial. Objective. To determine whether there is an association between having a continuous relationship with a primary care pediatric provider and decreased risk of emergency department (ED) visitation and hospitalization. Design. Retrospective cohort study. Setting and Population. We used claims data from 46 097 pediatric patients enrolled at Group Health Cooperative, a large staff-model health maintenance organization, between January 1, 1993, and December 31, 1998, for our analysis. To be eligible, patients had to have been continuously enrolled for at least a 2-year period or since birth and to have made at least 4 visits to one of the Group Health Cooperative clinics. Main Exposure Variable. A continuity of care (COC) index that quantifies the degree to which a patient has experienced continuous care with a provider. Main Outcome Measures. ED utilization and hospitalization. Results. Compared with children with the highest COC, children with medium continuity were more likely to have visited the ED (hazard ratio [HR]: 1.28 [1.20-1.36]) and more likely to be hospitalized (HR: 1.22 [1.09-1.38]). Children with the lowest COC were even more likely to have visited the ED (HR: 1.58 [1.49-1.66]) and to be hospitalized (HR: 1.54 [1.33-1.75]). These risks were even greater for children on Medicaid and those with asthma. Conclusions. Lower continuity of primary care is associated with higher risk of ED utilization and hospitalization. Efforts to improve and maintain continuity may be warranted.	Univ Washington, Inst Child Hlth, Dept Pediat, Seattle, WA 98103 USA; Inst Child Hlth, Seattle, WA USA; Grp Hlth Cooperat Puget Sound, Seattle, WA 98121 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Robert Wood Johnson Clin Scholars Program, Seattle, WA USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA	Christakis, DA (reprint author), Univ Washington, Inst Child Hlth, Dept Pediat, 146 N Canal St,Suite 300, Seattle, WA 98103 USA.		Zimmerman, Frederick/C-7259-2008	Zimmerman, Frederick/0000-0002-4163-9893; Mell, Loren/0000-0003-2277-6080			ALPERT JJ, 1976, PEDIATRICS, V57, P917; BECKER MH, 1974, AM J PUBLIC HEALTH, V64, P1062, DOI 10.2105/AJPH.64.11.1062; BECKER MH, 1974, J PEDIATR-US, V84, P599, DOI 10.1016/S0022-3476(74)80689-X; BICE TW, 1977, MED CARE, V15, P347, DOI 10.1097/00005650-197704000-00010; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Bodenheimer T, 1999, JAMA-J AM MED ASSOC, V281, P2045, DOI 10.1001/jama.281.21.2045; BRESLAU N, 1975, J MED EDUC, V50, P965; Chamberlain JM, 1998, ANN EMERG MED, V32, P161, DOI 10.1016/S0196-0644(98)70132-5; CHARNEY E, 1967, PEDIATRICS, V40, P188; Christakis DA, 1999, PEDIATRICS, V103, P738, DOI 10.1542/peds.103.4.738; Clayton D, 1993, STAT MODELS EPIDEMIO; EJLERTSSON G, 1984, MED CARE, V22, P231, DOI 10.1097/00005650-198403000-00006; ERIKSSON EA, 1983, MED CARE, V21, P858, DOI 10.1097/00005650-198309000-00003; Ettner SL, 1996, AM J PUBLIC HEALTH, V86, P1748, DOI 10.2105/AJPH.86.12.1748; Fishman PA, 1999, MED CARE, V37, P874, DOI 10.1097/00005650-199909000-00004; FRANKS P, 1992, NEW ENGL J MED, V327, P424, DOI 10.1056/NEJM199208063270613; FREEMAN GK, 1993, BRIT J GEN PRACT, V43, P493; GORDIS L, 1971, PEDIATRICS, V48, P766; GRAZIER KL, 1986, HEALTH SERV RES, V20, P659; Halfon N, 1996, PEDIATRICS, V98, P28; HENNEKENNS CH, 1987, EPIDEMIOLOGY MED; Kelleher KJ, 1997, ARCH PEDIAT ADOL MED, V151, P1109; Kleinbaum DG, 1998, APPL REGRESSION ANAL, P798; Krug SE, 1997, PEDIATR EMERG CARE, V13, P87, DOI 10.1097/00006565-199704000-00001; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; McCaig LF, 1998, PUBLIC HEALTH REP, V113, P75; Rae D. W., 1970, ANAL POLITICAL CLEAV; Robinson JC, 1998, JAMA-J AM MED ASSOC, V279, P144, DOI 10.1001/jama.279.2.144; ROOS LL, 1980, MED CARE, V18, P174, DOI 10.1097/00005650-198002000-00004; SACKETT DL, 1991, CLIN EPIDEMIOLOGY BA, P307; Schaeffer HA, 1999, PEDIATRICS, V103, P1050; SHENKIN BN, 1995, JAMA-J AM MED ASSOC, V273, P1937, DOI 10.1001/jama.273.24.1937; Starfield B, 1998, PRIMARY CARE BALANCI; STARFIELD BH, 1976, MED CARE, V14, P625, DOI 10.1097/00005650-197607000-00008; STONE EL, 1995, PEDIATRICS, V96, P844; THOMPSON RS, 1995, JAMA-J AM MED ASSOC, V273, P1130; WASSON JH, 1984, JAMA-J AM MED ASSOC, V252, P2413; Weiss LJ, 1996, AM J PUBLIC HEALTH, V86, P1742, DOI 10.2105/AJPH.86.12.1742; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WILLNER JH, 1980, NEW ENGL J MED, V303, P138, DOI 10.1056/NEJM198007173030306	40	213	216	2	11	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2001	107	3					524	529		10.1542/peds.107.3.524		6	Pediatrics	Pediatrics	406KW	WOS:000167216200027	11230593	
J	Marenholz, I; Nickel, R; Ruschendorf, F; Schulz, F; Esparza-Gordillo, J; Kerscher, T; Gruber, C; Lau, S; Worm, M; Keil, T; Kurek, M; Zaluga, E; Wahn, U; Lee, YA				Marenholz, Ingo; Nickel, Renate; Rueschendorf, Franz; Schulz, Florian; Esparza-Gordillo, Jorge; Kerscher, Tamara; Grueber, Christoph; Lau, Susanne; Worm, Margitta; Keil, Thomas; Kurek, Michael; Zaluga, Elisabetha; Wahn, Ulrich; Lee, Young-Ae			Filaggrin loss-of-function mutations predispose to phenotypes involved in the atopic march	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopic march; asthma; allergic rhinitis; atopy; filaggrin; genetic association; skin barrier	CORNIFIED ENVELOPE; DERMATITIS; ASTHMA; SKIN; ASSOCIATION; PROTEIN; SENSITIZATION; EXPOSURE; LINKAGE; MICE	Background: Childhood eczema often precedes the development of asthma and allergic rhinitis in the so-called atopic march. Recently, 2 loss-of-function mutations in the gene encoding the epidermal barrier protein filaggrin were reported to be predisposing factors for eczema and concomitant asthma, suggesting a possible role in disease transition. Objective: We aimed to assess the importance of filaggrin loss-of-function mutations in the susceptibility to eczema and associated clinical phenotypes. Methods: The filaggrin mutations were genotyped and tested for association with allergic disorders in 2 large European populations including 1092 children with eczema. Results: Highly significant association of the filaggrin null mutations with eczema and concomitant asthma was replicated. Moreover, we found that these mutations predispose to asthma, allergic rhinitis, and allergic sensitization only in the presence of eczema. We show that the presence of 2 filaggrin null alleles is an independent risk factor for asthma in children with eczema, and that the 2 investigated mutations account for about 11% of eczema cases in the German population. Conclusion: These results lend strong support to the role of filaggrin in the pathogenesis of eczema and in the subsequent progression along the atopic march. The fact that previous expression of eczema is a prerequisite for the manifestation of allergic airways disease and specific sensitization highlights the importance of the epidermal barrier in the pathogenesis of these disorders. Clinical implications: Our results suggest that the maintenance and repair of the epidermal barrier in infants with eczema may prevent the subsequent development of allergic airways disease.	Charite Univ Med, D-13353 Berlin, Germany; Charite Univ Med, Dept Dermatol & Allergy, D-13353 Berlin, Germany; Charite Univ Med, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; Max Delbruck Ctr Mol Med, Berlin, Germany; Pomeranian Acad Med, Dept Clin Allergol, Szczecin, Poland	Lee, YA (reprint author), Charite Univ Med, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	yo.lee@charite.de	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Ginger RS, 2005, ARCH DERMATOL RES, V297, P235, DOI 10.1007/s00403-005-0590-8; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; HENNEKENS CH, 2006, EPIDEMIOLOGY MED, P54; Hinds DA, 1996, ASPEX PACKAGE AFFECT; Hoffjan S, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-14; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Kunz B, 1997, DERMATOLOGY, V195, P10; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 1997, ANN ALLERG ASTHMA IM, V79, P197; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Nickel R, 2002, CLIN EXP ALLERGY, V32, P1274, DOI 10.1046/j.1365-2745.2002.01482.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Spielman RS, 1996, AM J HUM GENET, V59, P983; Sugiura H, 2005, BRIT J DERMATOL, V152, P146, DOI 10.1111/J.1365-2133.2005.06352.X; Tay YK, 1999, INT J DERMATOL, V38, P689, DOI 10.1046/j.1365-4362.1999.00667.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Zutavern A, 2005, CLIN EXP ALLERGY, V35, P1301, DOI 10.1111/j.1365-2222.2005.02350.x	27	211	222	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2006	118	4					866	871		10.1016/j.jaci.2006.07.026		6	Allergy; Immunology	Allergy; Immunology	097GD	WOS:000241434200013	17030239	
J	Penagos, M; Compalati, E; Tarantini, F; Baena-Cagnani, R; Huerta, J; Passalacqua, G; Canonica, GW				Penagos, Martin; Compalati, Enrico; Tarantini, Francesco; Baena-Cagnani, Rodrigo; Huerta, Jose; Passalacqua, Giovanni; Canonica, Giorgio Walter			Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Review							HOUSE-DUST MITE; SWALLOW IMMUNOTHERAPY; GRASS-POLLEN; CLINICAL-EFFICACY; CHILDREN; SAFETY; ASTHMA; RHINOCONJUNCTIVITIS; QUALITY; EXTRACT	Objective: To evaluate the efficacy of sublingual immunotherapy (SLIT) in the treatment of allergic rhinitis in children. Data Sources: A comprehensive search of the EMBASE, MEDLINE, LILACS, and CINAHL databases from January 1966 to February 10, 2006, was performed. Study Selection: Randomized, double-blind, placebo-controlled trials of SLIT in the treatment of allergic rhinitis in patients 18 years or younger were selected. Outcomes measured were symptom scores and rescue medication use. Analysis was performed with standardized mean differences (SMDs) and a random-effects model. Results: Seventy articles were identified and reviewed. Ten studies, published between 1990 and 2004, fulfilled the selection criteria. Five hundred seventy-seven patients were initially included in the studies. Of these patients, 484 (245 SLIT and 239 placebo) had a final clinical evaluation and could be evaluated. A relevant heterogeneity due to widely differing scoring systems was found. Overall, there was a significant reduction in both symptoms (SMD, 0.56, 95% confidence interval, 1.01-0.10; P = .02) and medication use (SMD, 0.76; 95% confidence interval, 1.46-0.06; P = .03) after immunotherapy. The subanalyses performed for treatment duration and type of allergen showed that SLIT for more than 18 months and with pollen extracts was effective compared with SLIT courses shorter than 18 months and with mites. Conclusion: The results of this meta-analysis showed that, compared with placebo, SLIT with standardized extracts is effective in pediatric patients with allergic rhinitis.	Univ Genoa, DIMI, Allergy & Resp Dis Clin, Dept Internal Med, I-16132 Genoa, Italy; Pediat Hosp, IMSS, CMN Siglo XXI, Infants Serv, Mexico City, DF, Mexico; Natl Pediat Inst, Allergy Serv, Mexico City, DF, Mexico	Canonica, GW (reprint author), Univ Genoa, DIMI, Allergy & Resp Dis Clin, Dept Internal Med, Pad Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	canonica@unige.it					Alderson P., 2002, COCHRANE COLLABORATI; *AM AC PED COUNC C, 1972, PEDIATRICS, V49, P463; Bachert C, 2003, CHEM IMMUNOL, V82, P119; Baena-Cagnani CE, 2005, CURR OPIN ALLERGY CL, V5, P173, DOI 10.1097/01.all.0000162311.87178.9e; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; *BORM, 2003, DIG 1 5 7 PROGR COMP; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; *COCHR COLL, 2004, REVM 4 2 7 PROGR COM; Cohen J., 1988, STAT POWER ANAL BEHA; Dawson BD, 2004, BASIC CLIN BIOSTATIS, P118; Deeks J, 2001, SYSTEMATIC REV HLTH, P285, DOI 10.1002/9780470693926.ch15; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Ioannidis JPA, 1998, NEW ENGL J MED, V338, P59; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jenkins CNH, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.6.e78; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Litt IF, 1998, PEDIATRICS, V102, P249; Lombardi C, 2001, ALLERGY, V56, P889; MALLING H, 1993, ALLERGY, V48, pS9; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; Moher D, 1999, HEALTH TECHNOL ASSES, V3, P12; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Nelson Harold S., 2003, Journal of Allergy and Clinical Immunology, V111, pS793, DOI 10.1067/mai.2003.150; NIU CK, 2006, RESP MED        0103; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P31, DOI 10.1097/00130832-200402000-00007; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Rodriguez Santos Olimpio, 2004, Rev Alerg Mex, V51, P177; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145	48	211	226	0	8	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	AUG	2006	97	2					141	148				8	Allergy; Immunology	Allergy; Immunology	075AF	WOS:000239853400003	16937742	
J	Frew, AJ; Powell, RJ; Corrigan, CJ; Durham, SR				Frew, AJ; Powell, RJ; Corrigan, CJ; Durham, SR		UK Immunotherapy Study Grp	Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						immunotherapy; allergic rhinitis; efficacy; safety; quality of life; grass pollen	GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; CLINICAL-EFFICACY; GENERAL-PRACTICE; POSITION PAPER; HAY-FEVER; SENSITIZATIONS; RHINITIS; CHILDREN; ASTHMA	Background: Specific immunotherapy is widely used to treat allergic rhinitis, but few large-scale clinical trials have been performed. Objective: We sought to assess the efficacy and safety of specific immunotherapy with 2 doses of Alutard grass pollen in patients with moderately severe seasonal allergic rhinitis inadequately controlled with standard drug therapy. Methods: We performed a double-blind, randomized, placebo-controlled study of 410 subjects (203 randomized to 100,000 standardized quality units [SQ-U] maintenance, 104 to 10,000 SQ-U, and 103 to placebo). Three hundred forty-seven (85%) completed treatment. Groups were well matched for demographics and symptoms. Results: Across the whole pollen season, mean symptom and medication scores were 29% and 32% lower, respectively, in the 100,000-SQ-U group compared with those in the placebo group (both P < .001). Over the peak pollen season, mean symptom and medication scores were 32% and 41% lower, respectively, than those in the placebo group. The 10,000-SQ-U group had 22% less symptoms than the placebo group over the whole season (P < .01), but medication scores reduced by only 16% (P = .16). Quality-of-life measures confirmed the superiority of both doses to placebo. Local and delayed side effects were common but generally mild. Clinically significant early and delayed systemic side effects were confined to the 100,000-SQ-U group, but no life-threatening reactions occurred. Conclusions: One season of immunotherapy with Alutard grass pollen reduced symptoms and medication use and improved the quality of life of subjects with moderately severe hay fever. The 100,000-SQ-U regimen was more effective, but the 10,000-SQ-U regimen caused fewer side effects.	Univ Southampton, Sch Med, Allergy & Inflammat Res Subdiv, Southampton, Hants, England; Queens Med Ctr, Clin Immunol Unit, Nottingham, England; Guys Kings & St Thomas Sch Med, Dept Resp Med & Allergy, London, England; Royal Brompton Hosp, Dept Upper Resp Med, London, England	Frew, AJ (reprint author), Brighton Gen Hosp, Dept Resp Med, Brighton BN2 3EW, E Sussex, England.	ajf@eaaci.org					Arvidsson MB, 2002, J ALLERGY CLIN IMMUN, V109, P777, DOI 10.1067/mai.2002.123868; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; MALLING HJ, 1993, ALLERGY, V48, P9; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; ROSS AM, 1994, BRIT MED J, V308, P897; VARNEY VA, 1991, BRIT MED J, V302, P265; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; White P, 1998, CLIN EXP ALLERGY, V28, P266	17	210	220	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					319	325		10.1016/j.jaci.2005.11.014		7	Allergy; Immunology	Allergy; Immunology	017IM	WOS:000235687300014	16461133	
J	Asokananthan, N; Graham, PT; Stewart, DJ; Bakker, AJ; Eidne, KA; Thompson, PJ; Stewart, GA				Asokananthan, N; Graham, PT; Stewart, DJ; Bakker, AJ; Eidne, KA; Thompson, PJ; Stewart, GA			House dust mite allergens induce proinflammatory cytokines from respiratory epithelial cells: The cysteine protease allergen, Der p 1, activates protease-activated receptor (PAR)-2 and inactivates PAR-1	JOURNAL OF IMMUNOLOGY			English	Article							THROMBIN RECEPTOR; DERMATOPHAGOIDES-PTERONYSSINUS; BRONCHIAL EPITHELIUM; AIRWAY INFLAMMATION; TIGHT JUNCTIONS; CATHEPSIN-G; ASTHMA; CLEAVAGE; INTERLEUKIN-8; PERMEABILITY	In previous studies, we demonstrated that allergenic house dust mite proteases are potent inducers of proinflammatory cytokines from the respiratory epithelium, although the precise mechanisms involved were unclear. In this study, we investigated whether this was achieved through activation of protease-activated receptor (PAR)-1 or -2. Pretreatment of A549 respiratory epithelial cells with the clinically important cysteine protease allergen, Der p 1, ablated subsequent PAR-1, but not PAR-2 agonist peptide-induced IL-6 and IL-8 release. HeLa cells transfected with the plasmid coding for PAR-2, in contrast to PAR-1, released significant concentration of IL-6 after exposure to Der p 1. Exposure of HeLa cells transfected with either PAR-1/enhanced yellow fusion protein or PAR-2/enhanced yellow fusion protein to Der p 1 caused receptor internalization in the latter cells only, as judged by confocal microscopy with re-expression of the receptor within 120-min postenzyme exposure. Der p 1-induced cytokine release from both A549 and transfected HeLa cells was accompanied by changes in intracellular C2+ concentrations. Desensitization studies showed that Der p 1 pretreatment of the A549 cells resulted in the abolition of both trypsin- and PAR-2 agonist peptide-induced Ca2+ release, but not that induced by subsequent exposure to either thrombin or PAR-1 agonist peptide. These data indicate for the first time that the house dust mite allergen Der p 1-induced cytokine release from respiratory epithelial cells is, in part, mediated by activation of PAR-2, but not PAR-1.	Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia; Univ Western Australia, Asthma & Allergy Res Inst, Perth, WA 6009, Australia; Univ Western Australia, Western Australian Inst Med Res, Perth, WA 6009, Australia	Stewart, GA (reprint author), Univ Western Australia, Dept Microbiol, 35 Stirling Highway, Crawley, WA 6009, Australia.		Bakker, Anthony/B-1185-2011; Bakker, Anthony/B-8163-2014	Bakker, Anthony/0000-0002-6889-8932			Alm AK, 1999, THROMB HAEMOSTASIS, V81, P984; Asokananthan N, 2002, J IMMUNOL, V168, P3577; BAHOU WF, 1994, BLOOD, V84, P4195; Blackhart BD, 2000, MOL PHARMACOL, V58, P1178; Blackhart BD, 1996, J BIOL CHEM, V271, P16466; BRASS LF, 1994, J BIOL CHEM, V269, P2943; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Dery O, 1999, J BIOL CHEM, V274, P18524, DOI 10.1074/jbc.274.26.18524; DEVLIN RB, 1994, AM J PHYSL, V266; ECKMANN L, 1993, INFECT IMMUN, V61, P4569; Hamilton L M, 2001, Monaldi Arch Chest Dis, V56, P48; HARTMANN T, 1994, AM J PHYSIOL, V267, pL113; HERBERT CA, 1990, LANCET, V336, P1132, DOI 10.1016/0140-6736(90)92611-K; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Holgate ST, 1999, CLIN EXP ALLERGY, V29, P90, DOI 10.1046/j.1365-2222.1999.00016.x; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; King C, 1998, J IMMUNOL, V161, P3645; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Loew D, 2000, BIOCHEMISTRY-US, V39, P10812, DOI 10.1021/bi0003341; Lordan JL, 2002, J IMMUNOL, V169, P407; MARINI M, 1992, J ALLERGY CLIN IMMUN, V89, P1001, DOI 10.1016/0091-6749(92)90223-O; MOLINO M, 1995, J BIOL CHEM, V270, P11168, DOI 10.1074/jbc.270.19.11168; Nanevicz T, 1996, J BIOL CHEM, V271, P702; NOAH TL, 1993, AM J PHYSIOL, V265, P472; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; O'Brien PJ, 2001, ONCOGENE, V20, P1570, DOI 10.1038/sj.onc.1204194; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; Renesto P, 1997, BLOOD, V89, P1944; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Schulz O, 1997, EUR J IMMUNOL, V27, P584, DOI 10.1002/eji.1830270303; Schulz O, 1998, J CLIN PATHOL-MOL PA, V51, P222; STEWART GA, 1992, IMMUNOLOGY, V75, P29; Sun G, 2001, J IMMUNOL, V167, P1014; Thompson P. J., 2001, Clinical and Experimental Allergy Reviews, V1, P107, DOI 10.1046/j.1472-9725.2001.00018.x; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Trejo J, 2000, J BIOL CHEM, V275, P31255, DOI 10.1074/jbc.M003770200; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; Wan H, 2000, EUR RESPIR J, V15, P1058, DOI 10.1034/j.1399-3003.2000.01514.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x	48	210	217	1	7	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	OCT 15	2002	169	8					4572	4578				7	Immunology	Immunology	602NU	WOS:000178512000065	12370395	
J	Smith, KR				Smith, KR			National burden of disease in India from indoor air pollution	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Review							ENVIRONMENTAL TOBACCO-SMOKE; LOWER RESPIRATORY-INFECTIONS; BIOMASS FUEL COMBUSTION; YOUNG GAMBIAN CHILDREN; WOOD-BURNING STOVES; LOW-BIRTH-WEIGHT; RISK-FACTORS; DEVELOPING-COUNTRIES; UNITED-STATES; CHRONIC-BRONCHITIS	In the last decade, a number of quantitative epidemiological studies of specific diseases have been done in developing countries that for the first time allow estimation of the total burden of disease (mortality and morbidity) attributable to use of solid fuels in adult women and young children, who jointly receive the highest exposures because of their household roles. Few such studies are available as yet for adult men or children over 5 years. This paper evaluates the existing epidemiological studies and applies the resulting risks to the more than three-quarters of all Indian households dependent on such fuels. Allowance is made for the existence of improved stoves with chimneys and other factors that may lower exposures. Attributable risks are calculated in reference to the demographic conditions and patterns of each disease in India. Sufficient evidence is available to estimate risks most confidently for acute respiratory infections (ARI), chronic obstructive pulmonary disease (COPD), and lung cancer, Estimates for tuberculosis (TB), asthma, and blindness are of intermediate confidence. Estimates for heart disease have the lowest confidence. Insufficient quantitative evidence is currently available to estimate the impact of adverse pregnancy outcomes (e.g., low birthweight and stillbirth). The resulting conservative estimates indicate that some 400-550 thousand premature deaths can be attributed annually to use of biomass fuels in these population groups. Using a disability-adjusted lost life-year approach, the total is 4-6% of the Indian national burden of disease, placing indoor air pollution as a major risk factor in the country.	East West Ctr, Honolulu, HI 96848 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Smith, KR (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.						Albalak R, 1999, THORAX, V54, P1004; Albalak R, 1999, ENVIRON SCI TECHNOL, V33, P2505, DOI 10.1021/es981242q; ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424; AZIZI BHO, 1995, J ASTHMA, V32, P413, DOI 10.3109/02770909409077752; Barker DJP, 1997, NUTRITION, V13, P807, DOI 10.1016/S0899-9007(97)00193-7; Beaglehole R, 1993, BASIC EPIDEMIOLOGY; Becker S, 1999, J TOXICOL ENV HEAL A, V57, P445, DOI 10.1080/009841099157539; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Boffetta P, 1997, CANCER CAUSE CONTROL, V8, P444, DOI 10.1023/A:1018465507029; Borja-Aburto VH, 1998, ENVIRON HEALTH PERSP, V106, P849, DOI 10.2307/3434129; BOY E, 1998, BIRTH WEIGHT EXPOSUR; Brandon C., 1995, COST INACTION VALUIN; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; CAMPBELL H, 1989, LANCET, V1, P1012; CERQUEIRO MC, 1990, REV INFECT DIS, V12, pS1021; CHEN B H, 1990, World Health Statistics Quarterly, V43, P127; COLLINGS DA, 1990, TROP DOCT, V20, P151; Dai XD, 1996, LUNG CANCER-J IASLC, V14, pS85, DOI 10.1016/S0169-5002(96)90213-5; Davis DL, 1997, LANCET, V350, P1341, DOI 10.1016/S0140-6736(97)10209-4; DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; DHAR SN, 1991, SEMIN RESPIR MED, V12, P69, DOI 10.1055/s-2007-1006227; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DOSSING M, 1994, RESP MED, V88, P519, DOI 10.1016/S0954-6111(05)80334-8; Finkelman RB, 1999, P NATL ACAD SCI USA, V96, P3427, DOI 10.1073/pnas.96.7.3427; FLORIG HK, 1997, ENVIRON SCI TECHNOL, V31, pA276; FRANCO EL, 1989, INT J CANCER, V43, P992, DOI 10.1002/ijc.2910430607; Garcia-Marcos L, 1999, PEDIATR ALLERGY IMMU, V10, P96, DOI 10.1034/j.1399-3038.1999.00024.x; GLANTZ SA, 1995, JAMA-J AM MED ASSOC, V273, P1047, DOI 10.1001/jama.273.13.1047; Goldemberg Jose, 2000, WORLD ENERGY ASSESSM; Gupta BN, 1997, ENERGY ENV REV, V13, P61; HILTS PJ, 1993, NY TIMES        1016, P1; HOLGATE S, 1998, QUANTIFICATION EFFEC; Holgate ST, 1999, AIR POLLUTION HLTH; Hong CJ, 1995, GLOBAL BURDEN DIS AI; JOHNSON AWBR, 1992, ANN TROP PAEDIATR, V12, P421; Johnson DL, 1999, PSYCHOL REP, V84, P149, DOI 10.2466/PR0.84.1.149-154; Kohli S., 1996, SOLAR ENERGY SOC IND, V6, P101; KOSSOVE D, 1982, S AFR MED J, V61, P622; KUMAR P, 1997, DOWN EARTH, V6, P29; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; LIPPMANN M, 2000, ENV TOXICANTS; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; Luo RX, 1996, LUNG CANCER-J IASLC, V14, pS113, DOI 10.1016/S0169-5002(96)90217-2; Malik S K, 1985, Indian J Chest Dis Allied Sci, V27, P171; MAYALANKAR DV, 1991, B WORLD HEALTH ORGAN, V69, P435; MCCRACKEA JD, 1997, ARI INDOOR AIR POLLU; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; *MIN NONC EN SOURC, 1999, ANN REP 1998 99; Mishra V K, 1999, Int J Infect Dis, V3, P119, DOI 10.1016/S1201-9712(99)90032-2; MISHRA VK, 2000, IN PRESS J ENV MED, V1; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; MOHAN M, 1989, ARCH OPHTHALMOL-CHIC, V107, P670; MORRIS K, 1990, AM J DIS CHILD, V144, P105; MTANGO FDE, 1992, TROP MED PARASITOL, V43, P229; Murray CJL, 1996, GLOBAL BURDEN DIS; *NAT COUNC APPL EC, 1993, EV NAT PROGR IMPR CA, V2; *NAT COUNC APPL EC, 1993, EV NAT PROGR IMPR CA, V1; *NAT FAM HLTH SURV, 1995, NAT FAM HLTH SURV MC; NATARAJAN I, 1999, OBJECTIVES NATL PROG; NORBOO T, 1991, THORAX, V46, P341, DOI 10.1136/thx.46.5.341; ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885; Ostro B., 1996, WHOEHG965; PADMAVATI S, 1959, CIRCULATION, V20, P343; PANDEY MR, 1989, LANCET, V1, P427; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; Pandey MR, 1988, CHRONIC BRONCHITIS C; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701; Petitti DB, 2000, METAANALYSIS DECISIO; Pintos J, 1998, INT J EPIDEMIOL, V27, P936, DOI 10.1093/ije/27.6.936; PREUSS A, 2000, B WORLD HEALTH ORGAN, V78, P258; Purvis CR, 2000, ENVIRON SCI TECHNOL, V34, P1653, DOI 10.1021/es981006f; RAMAGE JE, 1988, AM REV RESPIR DIS, V137, P1229; RAMAKRISHNA J, 1989, ENVIRON INT, V15, P341, DOI 10.1016/0160-4120(89)90047-0; RAMAKRISHNA J, 1991, INDIAN COUNTRY REPOR; RAO CM, 1995, CURR EYE RES, V14, P295, DOI 10.3109/02713689509033529; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Robin LF, 1996, PEDIATR INFECT DIS J, V15, P859, DOI 10.1097/00006454-199610000-00006; SAIYED HN, 1991, BRIT J IND MED, V48, P825; SAKSENA S, 1997, ENERGY ENV MONITOR, V13, P93; SAMET J, 1999, AIR POLLUTION HLTH; Samet J. M., 1994, EPIDEMIOLOGY LUNG CA; SANKARANARAYANAN R, 1990, ORAL SURG ORAL MED O, V69, P325, DOI 10.1016/0030-4220(90)90294-3; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185; Schwela D, 1996, TOXICOL LETT, V86, P131, DOI 10.1016/0378-4274(96)03684-3; SCRAM R, 1999, ENV HLTH PERSPECT, V107, pA542; Seaton A, 1999, THORAX, V54, P1027; SHAH N, 1994, J TROP PEDIATRICS, V40, P201; SHALINI VK, 1994, INDIAN J BIOCHEM BIO, V31, P261; Shen XB, 1996, LUNG CANCER-J IASLC, V14, pS107, DOI 10.1016/S0169-5002(96)90216-0; SHPRENTZ DS, 1996, BREATH TAKING PREMAT; SHUKLA N, 1997, ENERGY ENV MONITOR, V13, P69; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; SMITH KR, 1994, ENERGY, V19, P587, DOI 10.1016/0360-5442(94)90054-X; SMITH KR, 1993, ANNU REV ENERG ENV, V18, P529, DOI 10.1146/annurev.energy.18.1.529; Smith KR, 1994, EPIDEMIOLOGY LUNG CA, P151; Smith KR, 2000, EPA600R00052; Smith K. R., 1987, BIOFUELS AIR POLLUTI; SMITH KR, 2001, IN PRESS ATMOS ENV, V35; SMITH KR, 1994, WORKSH EN ENV NEX IN; SOBUE T, 1990, INT J EPIDEMIOL, V19, pS62; Steenland K, 1998, AM J EPIDEMIOL, V147, P932; Strachan DP, 1998, THORAX, V53, P204; *TAT EN RES I, 1989, EV IMPR CHULH PROGR; Thomas P, 1999, AIR POLLUTION HLTH; Thylefors B, 1995, Ophthalmic Epidemiol, V2, P5, DOI 10.3109/09286589509071448; Tominaga S, 1999, CANCER LETT, V143, pS19, DOI 10.1016/S0304-3835(99)90005-8; *US NAT RES COUNC, 1998, RES PRIOR AIRB PART; *US NAT RES COUNC, 1990, EXP ASS; Verma B K, 1995, Cent Eur J Public Health, V3, P25; VICTORA CG, 1994, PEDIATRICS, V93, P977; WALSH JA, 1993, DIS CONTROL PRIORITI; Wang SY, 1996, LUNG CANCER-J IASLC, V14, pS99, DOI 10.1016/S0169-5002(96)90215-9; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; WEST S, 1992, JAMA-J AM MED ASSOC, V268, P1025, DOI 10.1001/jama.268.8.1025; WHO (World Health Organization), 1999, AIR MAN INF SYST AMI; [Anonymous], 1997, TOB HLTH GLOB STAT R; WHO, 2000, AIR QUAL GUID EUR; WHO, 1999, GLOB AIR QUAL GUID; WHO, 1997, HLTH ENV SUST DEV; Windham GC, 1999, AM J EPIDEMIOL, V149, P243; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; World Bank, 1997, CLEAR WAT BLUE SKIES; Xu X, 1996, INT J OCCUP ENV HEAL, V2, P172; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407; XU Z, 1995, AIR POLLUTION ITS HL, P47; Xu ZY, 1996, LUNG CANCER-J IASLC, V14, pS149, DOI 10.1016/S0169-5002(96)90220-2; ZELIKOFF J, 1994, CTR INDOOR AIR RES C, V1, P3; Zhang J, 2000, ATMOS ENVIRON, V34, P4537, DOI 10.1016/S1352-2310(99)00450-1; Zhong LJ, 1999, CANCER CAUSE CONTROL, V10, P607, DOI 10.1023/A:1008962025001; Zhong LJ, 1999, EPIDEMIOLOGY, V10, P488, DOI 10.1097/00001648-199909000-00005	133	210	217	3	43	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 21	2000	97	24					13286	13293		10.1073/pnas.97.24.13286		8	Multidisciplinary Sciences	Science & Technology - Other Topics	376UZ	WOS:000165476300071	11087870	
J	Kappos, AD; Bruckmann, P; Eikmann, T; Englert, N; Heinrich, U; Hoppe, P; Koch, E; Krause, GHM; Kreyling, WG; Rauchfuss, K; Rombout, P; Schulz-Klemp, V; Thiel, WR; Wichmann, HE				Kappos, AD; Bruckmann, P; Eikmann, T; Englert, N; Heinrich, U; Hoppe, P; Koch, E; Krause, GHM; Kreyling, WG; Rauchfuss, K; Rombout, P; Schulz-Klemp, V; Thiel, WR; Wichmann, HE			Health effects of particles in ambient air	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Article						particulate matter; air pollution; PM10; PM2.5; ultra fine particles; health effects; review; limit values	LONG-TERM EXPOSURE; OIL FLY-ASH; NORTH-AMERICAN CHILDREN; RESPIRATORY SYMPTOMS; INFANT-MORTALITY; INFLAMMATORY RESPONSES; PARTICULATE MATTER; HUMAN VOLUNTEERS; UNITED-STATES; ACID AEROSOLS	A summary of a critical review by a working group of the German commission on Air Pollution Prevention of VDI and DIN of the actual data on exposure and health effects (excluding cancer) of fine particulate air pollution is presented. Exposure: Typical ambient particle concentrations for PM10 (PM2.5) in Germany are in the range of 10-45 (10-30) mug/m(3) as annual mean and 50-200 (40-150) mug/m(3) as maximum daily mean. The ratio Of PM2.5/PM10 generally amounts between 0.7 and 0.9. Health effects: During the past 10 years many new epidemiological and toxicological studies on health effects of particulate matter (PM) have been published. In summary, long-term exposure against PM for years or decades is associated with elevated total, cardiovascular, and infant mortality. With respect to morbidity, respiratory symptoms, lung growth, and function of the immune system are affected. Short-term studies show consistant associations of exposure to daily concentrations of PM with mortality and morbidity on the same day or the subsequent days. Patients with asthma, COPD, pneumonia, and other respiratory diseases as well as patients with cardio-vascular diseases and diabetes are especially affected. The strongest associations are found for PM2.5 followed by PM10, with no indication of a threshold value for the health effects. The data base for ultra fine particles is too small for final conclusions.	Behorde Umwelt & Gesundheit, Hamburg, Germany; Landesumweltamt NRW, Essen, Germany; Univ Giessen, Inst Hyg & Umweltmed, Giessen, Germany; Umweltbundesamt, Berlin, Germany; Fraunhofer Inst Toxicol & Expt Med, Hannover, Germany; Univ Munich, Inst Arbeitsmed, Munich, Germany; Minist Umwelt & Naturschutz, NRW, Dusseldorf, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Inhalat Biol, Neuherberg, Germany; Verein Deutsch Eisenhuttenleute, Dusseldorf, Germany; GSF Forschungszentrum Umwelt & Gesundheit, Inst Epidemiol, Neuherberg, Germany	Kappos, AD (reprint author), Dr Phil Nat Andreas Kappos,Im Geeren 36, D-60433 Frankfurt, Germany.	adkappos@t-online.de		Kreyling, Wolfgang/0000-0002-0702-6567			Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; BRAND P, 1992, ATMOS ENVIRON A-GEN, V26, P2451, DOI 10.1016/0960-1686(92)90375-U; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; *CEN, 1998, LUFTBESCHAFFENHEIT E; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; Clarke RW, 2000, INHAL TOXICOL, V12, P73, DOI 10.1080/089583700196400; COSTA DL, 1997, ENV HLTH PERSPECT, V105, P1060; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; Dye JA, 2001, ENVIRON HEALTH PERSP, V109, P395, DOI 10.2307/3434787; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; Ghio AJ, 2000, AM J RESP CRIT CARE, V162, P981; GODLESKI JJ, 2000, MECH MORBIDITY MORTA; GODLESKI JJ, 1996, AM J RESPIR CRIT C A, V5; *HEI, 2003, REV AN TIM SER STUD; Heinrich J., 2002, Umweltmedizin in Forschung und Praxis, V7, P91; Heinrich J, 2002, EPIDEMIOLOGY, V13, P394, DOI 10.1097/01.EDE.00000016977.59359.B6; Heinrich J, 1999, Eur J Med Res, V4, P107; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; Kodavanti UP, 1997, INHAL TOXICOL, V9, P679; Kramer U, 1999, INT J EPIDEMIOL, V28, P865, DOI 10.1093/ije/28.5.865; Krewski D, 2000, REANALYSIS HARVARD 6; KREYLING WG, 2003, IN PRESS ATM ENV, V37; KUHLBUSCH TAJ, 2002, PMX MASSENKONZENTRAT; Kuschner WG, 1997, ENVIRON HEALTH PERSP, V105, P1234, DOI 10.1289/ehp.971051234; LEONARDI GS, 2000, INHAL TOXICOL, P1; Li XY, 1999, INHAL TOXICOL, V11, P709; Li XY, 1997, ENVIRON HEALTH PERSP, V105, P1279, DOI 10.2307/3433547; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Lipfert FW, 2000, J AIR WASTE MANAGE, V50, P1350; Lipfert FW, 2000, INHAL TOXICOL, V12, P41, DOI 10.1080/089583700750019503; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McDonnell WF, 2000, J EXPO ANAL ENV EPID, V10, P427, DOI 10.1038/sj.jea.7500095; Muggenburg BA, 2000, INHAL TOXICOL, V12, P189, DOI 10.1080/089583700750019567; OBERDORSTER G, 1994, ENVIRON HEALTH PERSP, V102, P173, DOI 10.2307/3432080; Peters A, 1996, AM J EPIDEMIOL, V144, P570; Peters A., 2002, Umweltmedizin in Forschung und Praxis, V7, P101; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; PITZ M, 2001, ATMOS ENVIRON, V35, P4366; Pope CA, 1999, ENVIRON HEALTH PERSP, V107, P567; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Samet J.M., 2000, NATL MORBIDITY MORTA; Schwartz J, 2000, ENVIRON HEALTH PERSP, V108, P563, DOI 10.2307/3454620; Tuch T, 2000, ATMOS ENVIRON, V34, P139, DOI 10.1016/S1352-2310(99)00248-4; *US EPA, 2003, 4 EXT REV DRAFT AIR, V2; *WHO, 2003, WHO WORK GROUP M BON; Wichmann HE, 2000, PHILOS T ROY SOC A, V358, P2751; WICHMANN HE, 2002, SOURCES ELEMENTAL CO; WICHMANN HE, 2000, DAILY MORTALITY FI 1, V98, P1; WICHMANN HE, 2002, WIRKUNGEN FEINSTAUB; Wiedensohler A, 2002, J AEROSOL MED, V15, P237, DOI 10.1089/089426802320282365; Bruckmann P., 2002, GUIDANCE MEMBER STAT; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Zemp E, 1999, AM J RESP CRIT CARE, V159, P1257	65	209	215	13	73	URBAN & FISCHER VERLAG	JENA	BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY	1438-4639			INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.	SEP	2004	207	4					399	407		10.1078/1438-4639-00306		9	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	857DU	WOS:000224097200012	15471105	
J	Mendell, MJ; Mirer, AG; Cheung, K; Tong, M; Douwes, J				Mendell, Mark J.; Mirer, Anna G.; Cheung, Kerry; Tong, My; Douwes, Jeroen			Respiratory and Allergic Health Effects of Dampness, Mold, and Dampness-Related Agents: A Review of the Epidemiologic Evidence	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						allergy; asthma; dampness; fungi; indoor air; moisture; mold	HOUSE-DUST ENDOTOXIN; ENVIRONMENTAL RISK-FACTORS; INCIDENT CASE-CONTROL; ADULT-ONSET ASTHMA; BIRTH-COHORT; CHILDHOOD ASTHMA; INDOOR MOLD; HYPERSENSITIVITY PNEUMONITIS; BRONCHIAL OBSTRUCTION; SCIENTIFIC EVIDENCE	OBJECTIVES: Many studies have shown consistent associations between evident indoor dampness or mold and respiratory or allergic health effects, but causal links remain unclear. Findings on measured microbiologic factors have received little review. We conducted an updated, comprehensive review on these topics. DATA SOURCES: We reviewed eligible peer-reviewed epidemiologic studies or quantitative meta-analyses, up to late 2009, on dampness, mold, or other microbiologic agents and respiratory or allergic effects. DATA EXTRACTION: We evaluated evidence for causation or association between qualitative/subjective assessments of dampness or mold (considered together) and specific health outcomes. We separately considered evidence for associations between specific quantitative measurements of microbiologic factors and each health outcome. DATA SYNTHESIS: Evidence from epidemiologic studies and meta-analyses showed indoor dampness or mold to be associated consistently with increased asthma development and exacerbation, current and ever diagnosis of asthma, dyspnea, wheeze, cough, respiratory infections, bronchitis, allergic rhinitis, eczema, and upper respiratory tract symptoms. Associations were found in allergic and nonallergic individuals. Evidence strongly suggested causation of asthma exacerbation in children. Suggestive evidence was available for only a few specific measured microbiologic factors and was in part equivocal, suggesting both adverse and protective associations with health. CONCLUSIONS: Evident dampness or mold had consistent positive associations with multiple allergic and respiratory effects. Measured microbiologic agents in dust had limited suggestive associations, including both positive and negative associations for some agents. Thus, prevention and remediation of indoor dampness and mold are likely to reduce health risks, but current evidence does not support measuring specific indoor microbiologic factors to guide health-protective actions.	[Mendell, Mark J.; Tong, My] Calif Dept Publ Hlth, Indoor Air Qual Sect, Environm Hlth Lab Branch, Richmond, CA 94804 USA; [Mendell, Mark J.] Univ Calif Berkeley, Lawrence Berkeley Lab, Indoor Environm Dept, Environm Energy Technol Div, Berkeley, CA 94720 USA; [Mirer, Anna G.] Univ Wisconsin Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI USA; [Cheung, Kerry; Douwes, Jeroen] Massey Univ, Ctr Publ Hlth, Wellington, New Zealand	Mendell, MJ (reprint author), Calif Dept Publ Hlth, Indoor Air Qual Sect, Environm Hlth Lab Branch, 850 Marina Bay Pkwy,G365, Richmond, CA 94804 USA.	mark.mendell@cdph.ca.gov		Douwes, Jeroen/0000-0003-3599-4036	WHO Regional Office for Europe	An earlier version of this review, Chapter 4.1 in World Health Organization (WHO) Guidelines for Indoor Air Quality: Dampness and Mould (available: http://www.euro.who.int/__data/assets/pdf_file/0017/43325/E92645.pdf), was supported in part by the WHO Regional Office for Europe.	ANDO M, 1995, INTERNAL MED, V34, P707, DOI 10.2169/internalmedicine.34.707; Antova T, 2008, J EPIDEMIOL COMMUN H, V62, P708, DOI 10.1136/jech.2007.065896; Bennett JW, 2003, CLIN MICROBIOL REV, V16, P497, DOI 10.1128/CMR.16.3.497-516.2003; Biagini JM, 2006, PEDIATR ALLERGY IMMU, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, INDOOR AIR, V14, P243, DOI 10.1111/j.1600-0668.2004.00240.x; Burr ML, 2007, THORAX, V62, P767, DOI 10.1136/thx.2006.070847; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Cox-Ganser JM, 2009, INDOOR AIR, V19, P280, DOI 10.1111/j.1600-0668.2009.00586.x; Cox-Ganser JM, 2005, ENVIRON HEALTH PERSP, V113, P485, DOI 10.1289/ehp.7559; Cummings KJ, 2008, AM J PUBLIC HEALTH, V98, P869, DOI 10.2105/AJPH.2007.118398; Dales R, 2006, ENVIRON HEALTH PERSP, V114, P610, DOI 10.1289/ehp.8142; Dales R, 2010, ENVIRON RES, V110, P692, DOI 10.1016/j.envres.2010.07.007; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Douwes J, 2007, ALLERGY, V62, P1158, DOI 10.1111/j.1398-9995.2007.01490.x; Douwes J, 2005, INDOOR AIR, V15, P160, DOI 10.1111/j.1600-0668.2005.00333.x; Douwes J, 2004, J ALLERGY CLIN IMMUN, V114, P1051, DOI 10.1016/j.jaci.2004.08.004; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Fink JN, 2005, AM J RESP CRIT CARE, V171, P792, DOI 10.1164/rccm.200409-1205WS; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Fisk WJ, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-72; Gehring U, 2008, CLIN EXP ALLERGY, V38, P1911, DOI 10.1111/j.1365-2222.2008.03087.x; Gillespie J, 2006, J ALLERGY CLIN IMMUN, V118, P1265, DOI 10.1016/j.jaci.2006.07.051; Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002; Gunnbjornsdottir MI, 2006, THORAX, V61, P221, DOI 10.1136/thx.2005.057430; Hyvarinen A, 2006, ARCH ENVIRON OCCUP H, V61, P149, DOI 10.3200/AEOH.61.4.149-157; IOM (Institute of Medicine), 2004, DAMP IND SPAC HLTH; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543; Jarvis BB, 2005, APPL MICROBIOL BIOT, V66, P367, DOI 10.1007/s00253-004-1753-9; Karvonen AM, 2009, PEDIATRICS, V124, pE329, DOI 10.1542/peds.2008-1590; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; KREISS K, 1989, OCCUP MED, V4, P575; Krieger J, 2010, J PUBLIC HEALTH MAN, V16, pS11, DOI 10.1097/PHH.0b013e3181ddcbd9; Kuyucu S, 2006, PEDIATR ALLERGY IMMU, V17, P269, DOI 10.1111/j.1399-3038.2006.00407.x; Laney AS, 2009, INDOOR AIR, V19, P83, DOI 10.1111/j.1600-0668.2008.00564.x; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2006, J ALLERGY CLIN IMMUN, V117, P1063, DOI 10.1016/j.jaci.2006.03.027; Matheson MC, 2005, CLIN EXP ALLERGY, V35, P907, DOI 10.1111/j.1365-2222.2005.02272.x; MATTHEWS TG, 1986, JAPCA J AIR WASTE MA, V36, P1244; McGwin G, 2010, ENVIRON HEALTH PERSP, V118, P313, DOI 10.1289/ehp.0901143; Mendell MJ, 2007, INDOOR AIR, V17, P259, DOI 10.1111/j.1600-0668.2007.00478.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Miller JD, 2010, CHEM-BIOL INTERACT, V183, P113, DOI 10.1016/j.cbi.2009.09.023; Mudarri D, 2007, INDOOR AIR, V17, P226, DOI 10.1111/j.1600-0668.2007.00474.x; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; National Library of Medicine, 2010, PUBMED; Norback D, 2000, INT J TUBERC LUNG D, V4, P1016; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2006, INDOOR AIR, V16, P192, DOI 10.1111/j.1600-0668.2005.00415.x; Park JH, 2004, INDOOR AIR, V14, P425, DOI 10.1111/j.1600-0668.2004.00291.x; Park JH, 2008, ENVIRON HEALTH PERSP, V116, P45, DOI 10.1289/ehp.10355; Pekkanen J, 2007, EUR RESPIR J, V29, P509, DOI 10.1183/09031936.00040806; Penttinen P, 2006, TOXICOL APPL PHARM, V217, P342, DOI 10.1016/j.taap.2006.09.010; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Rand TG, 2010, ARCH TOXICOL, V84, P205, DOI 10.1007/s00204-009-0481-4; Rao CY, 2005, INDOOR AIR, V15, P89, DOI 10.1111/j.1600-0668.2005.00348.x; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Thomson Reuters, 2010, ISI WEB KNOWL; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; Venkatesh Purnima, 2005, Paediatr Drugs, V7, P235, DOI 10.2165/00148581-200507040-00003; Vesper S, 2007, J ENVIRON MONITOR, V9, P826, DOI 10.1039/b704359g; World Health Organiszation Europe, 2009, WHO GUID IND AIR QUA; Williamson IJ, 1997, THORAX, V52, P229; Wu AC, 2010, AM J RESP CRIT CARE, V182, P884, DOI 10.1164/rccm.201003-0322OC; Yang CY, 1998, PEDIATR PULM, V26, P120, DOI 10.1002/(SICI)1099-0496(199808)26:2<120::AID-PPUL8>3.0.CO;2-Q; Yli-Pirila T, 2007, ENVIRON TOXICOL, V22, P357, DOI 10.1002/tox.20274; Zhao ZH, 2008, PEDIAT ALLERG IMM-UK, V19, P455, DOI 10.1111/j.1399-3038.2007.00664.x	74	208	210	9	79	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2011	119	6					748	756		10.1289/ehp.1002410		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	771JC	WOS:000291152000016	21269928	
J	Grainge, CL; Lau, LCK; Ward, JA; Dulay, V; Lahiff, G; Wilson, S; Holgate, S; Davies, DE; Howarth, PH				Grainge, Christopher L.; Lau, Laurie C. K.; Ward, Jonathon A.; Dulay, Valdeep; Lahiff, Gemma; Wilson, Susan; Holgate, Stephen; Davies, Donna E.; Howarth, Peter H.			Effect of Bronchoconstriction on Airway Remodeling in Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GROWTH-FACTOR RECEPTOR; ALLERGEN CHALLENGE; MECHANICAL-STRESS; EPITHELIAL-CELLS; MODEL; RAT; INFLAMMATION; EXPRESSION; GUIDELINES; CHILDREN	BACKGROUND Asthma is characterized pathologically by structural changes in the airway, termed airway remodeling. These changes are associated with worse long-term clinical outcomes and have been attributed to eosinophilic inflammation. In vitro studies indicate, however, that the compressive mechanical forces that arise during broncho-constriction may induce remodeling independently of inflammation. We evaluated the influence of repeated experimentally induced bronchoconstriction on airway structural changes in patients with asthma. METHODS We randomly assigned 48 subjects with asthma to one of four inhalation challenge protocols involving a series of three challenges with one type of inhaled agent presented at 48-hour intervals. The two active challenges were with either a dust-mite allergen (which causes bronchoconstriction and eosinophilic inflammation) or methacholine (which causes bronchoconstriction without eosinophilic inflammation); the two control challenges (neither of which causes bronchoconstriction) were either saline alone or albuterol followed by methacholine (to control for non-bronchoconstrictor effects of methacholine). Bronchial-biopsy specimens were obtained before and 4 days after completion of the challenges. RESULTS Allergen and methacholine immediately induced similar levels of bronchoconstriction. Eosinophilic inflammation of the airways increased only in the allergen group, whereas both the allergen and the methacholine groups had significant airway remodeling not seen in the two control groups. Subepithelial collagen-band thickness increased by a median of 2.17 mu m in the allergen group (interquartile range [IQR], 0.70 to 3.67) and 1.94 mu m in the methacholine group (IQR, 0.37 to 3.24) (P<0.001 for the comparison of the two challenge groups with the two control groups); periodic acid-Schiff staining of epithelium (mucus glands) also increased, by a median of 2.17 percentage points in the allergen group (IQR, 1.03 to 4.77) and 2.13 percentage points in the methacholine group (IQR, 1.14 to 7.96) (P=0.003 for the comparison with controls). There were no significant differences between the allergen and methacholine groups. CONCLUSIONS Bronchoconstriction without additional inflammation induces airway remodeling in patients with asthma. These findings have potential implications for management.	[Grainge, Christopher L.; Lau, Laurie C. K.; Ward, Jonathon A.; Dulay, Valdeep; Lahiff, Gemma; Wilson, Susan; Holgate, Stephen; Davies, Donna E.; Howarth, Peter H.] Univ Southampton, Sch Med, Div Infect Inflammat & Immun, Southampton, Hants, England; [Grainge, Christopher L.; Howarth, Peter H.] Wellcome Trust Clin Res Facil, Southampton, Hants, England; [Holgate, Stephen; Howarth, Peter H.] Natl Inst Hlth Res Resp Biomed Res Unit, Southampton, Hants, England	Howarth, PH (reprint author), Southampton Gen Hosp, Sir Henry Wellcome Labs, Mailpoint 810,S Block, Southampton SO16 6YD, Hants, England.	p.h.howarth@soton.ac.uk	Davies, Donna/H-2993-2012		Defence Postgraduate Medical Deanery; Medical Research Council [G0900453]	Supported by the Defence Postgraduate Medical Deanery and by a grant from the Medical Research Council (G0900453).	Beckett PA, 2003, THORAX, V58, P163, DOI 10.1136/thorax.58.2.163; British Thoracic Society Standards of Care C, 2001, THORAX S4, V56, pIV1; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Grainge C, 2010, CLIN RESP J     0607; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hashimoto M, 2005, CHEST, V127, P965, DOI 10.1378/chest.127.3.965; Hatzivlassiou M, 2010, ALLERGY, V65, P355, DOI 10.1111/j.1398-9995.2009.02184.x; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Huang CYC, 2005, STEM CELLS, V23, P1113, DOI 10.1634/stemcells.2005-0202; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kelly MM, 2010, J ALLERGY CLIN IMMUN, V125, p[349, e13, e13]; Labonte I, 2009, AM J PHYSIOL-LUNG C, V297, pL698, DOI 10.1152/ajplung.00142.2009; MCMANUS JFA, 1946, NATURE, V158, P202, DOI 10.1038/158202a0; Miyagawa A, 2009, J DENT RES, V88, P752, DOI 10.1177/0022034509341637; Niimi A, 2005, J ALLERGY CLIN IMMUN, V116, P565, DOI 10.1016/j.jaci.2005.07.010; Nishimura Y, 2008, CIRC J, V72, P647; Park JA, 2010, J BIOL CHEM, V285, P29817, DOI 10.1074/jbc.M110.103416; Park JA, 2009, AM J RESP CELL MOL, V41, P459, DOI 10.1165/rcmb.2008-0195OC; Pascual RM, 2009, J ALLERGY CLIN IMMUN, V124, P883, DOI 10.1016/j.jaci.2009.09.047; Proschan MA, 2000, CONTROL CLIN TRIALS, V21, P527, DOI 10.1016/S0197-2456(00)00106-9; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tamaoka M, 2008, EUR RESPIR J, V32, P1213, DOI 10.1183/09031936.00166907; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Tschumperlin DJ, 2001, AM J RESP CRIT CARE, V164, pS90; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814; Zhang SL, 1999, LAB INVEST, V79, P395	33	208	216	1	29	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	MAY 26	2011	364	21					2006	2015				10	Medicine, General & Internal	General & Internal Medicine	768QR	WOS:000290952000005	21612469	
J	Heymann, PW; Carper, HT; Murphy, DD; Platts-Mills, TAE; Patrie, J; McLaughlin, AP; Erwin, EA; Shaker, MS; Hellems, M; Peerzada, J; Hayden, FG; Hatley, TK; Chamberlain, R				Heymann, PW; Carper, HT; Murphy, DD; Platts-Mills, TAE; Patrie, J; McLaughlin, AP; Erwin, EA; Shaker, MS; Hellems, M; Peerzada, J; Hayden, FG; Hatley, TK; Chamberlain, R			Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						wheezing; asthma; children; hospitalization; viral respiratory tract infections; rhinovirus; respiratory syncytial virus; influenza; total serum IgE; inhaled allergens	RESPIRATORY SYNCYTIAL VIRUS; POLYMERASE-CHAIN-REACTION; SERUM IGE; AIRWAY RESPONSIVENESS; INHALANT ALLERGENS; CHILDHOOD ASTHMA; GRASS-POLLEN; RISK-FACTORS; DUST MITE; EXACERBATIONS	Background: Viral respiratory tract infections and atopy are associated with attacks of wheezing during childhood. However, information about the relationship between viral infections and atopy among children whose attacks of wheezing lead to hospitalization is unclear. Objective: To evaluate the prevalence of viral respiratory tract pathogens among infants and children hospitalized for wheezing and to analyze the results in relation to the patient's age, atopic characteristics, and season of admission. Methods: This was a case-control study of children (age 2 months to 18 years) admitted for wheezing to the University of Virginia Medical Center over a period of 12 months. Children without wheezing were enrolled as controls. Nasal secretions were evaluated for viral pathogens by using cultures, PCR tests, and antigen detection. Total IgE and specific IgE antibody to common aeroallergens; was measured in serum. Results: Seventy percent of children hospitalized for wheezing before age 3 years (n = 79) were admitted between December and March, whereas 46% of children age 3 to 18 years (n = 54) were hospitalized between September and November. Among children younger than 3 years, viral pathogens were detected in 84% (66/79) of wheezing children and 55% (42/77) of controls (P < .001). Respiratory syncytial virus was the dominant pathogen during the winter months, but rhinovirus was more common during other months. Total serum IgE levels were generally low, and values from wheezing and control subjects overlapped considerably. Among children 3 years and older, 61% (33/54) of subjects admitted for wheezing tested positive for virus (predominantly rhinovirus), compared with 21% (12/ 56) of controls (P < .001). The total serum IgE values among wheezing children (geometric mean, 386 IU/mL; 95% CI, 259573) were substantially elevated compared with those of controls (geometric mean, 38 IU/mL; 95% CI, 26-56; P < .001). A significantly higher percentage of wheezing children compared with controls was sensitized to at least 1 of the inhaled allergens tested: 84% (36/43) compared with 33% (15/45; P < .001). The atopic characteristics of wheezing children who tested positive or negative for virus were similar. Conclusions: Viral infections were the dominant risk factor for wheezing among children hospitalized before 3 years of age. By comparison, a large majority of the wheezing children age 3 to 18 years had striking atopic characteristics that may be critical as a risk factor for hospitalization and an adverse response to viral infections, especially infections caused by rhinovirus.	Univ Virginia, Hlth Syst, Dept Pediat, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Internal Med, Charlottesville, VA 22908 USA; Univ Virginia, Hlth Syst, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA	Heymann, PW (reprint author), Univ Virginia, Hlth Syst, Dept Pediat, POB 800386, Charlottesville, VA 22908 USA.	pwh5a@virginia.edu			NIAID NIH HHS [1P01 AI50989, AI 20565]		Agresti A, 2001, BIOMETRICS, V57, P963, DOI 10.1111/j.0006-341X.2001.00963.x; Agresti A., 1990, CATEGORICAL DATA ANA; ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ARRUDA E, 1993, MOL CELL PROBE, V7, P373, DOI 10.1006/mcpr.1993.1055; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P908; Chang MY, 2000, PEDIATR PULM, V29, P257, DOI 10.1002/(SICI)1099-0496(200004)29:4<257::AID-PPUL4>3.0.CO;2-V; Chiu SS, 2002, NEW ENGL J MED, V347, P2097, DOI 10.1056/NEJMoa020546; *CYT SOFTW CORP, 2001, STATSXACT 5 STAT SOF; DUFF AL, 1993, PEDIATRICS, V92, P535; GERGEN PJ, 2001, J ALLERGY CLIN IMMUN, V107, P445; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; HENDERSON FW, 1979, J PEDIATR-US, V95, P183; Heymann PW, 1998, IMMUNOL ALLERGY CLIN, V18, P35, DOI 10.1016/S0889-8561(05)70345-3; HIERHOLZER JC, 1993, J CLIN MICROBIOL, V31, P1886; ISAACS D, 2002, MED J AUST S, V117, pS50; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; LAVIA WV, 1992, J PEDIATR-US, V121, P503; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; LOYANO P, 1999, J ALLERGY CLIN IMMUN, V104, P957; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; McCullagh P., 1989, GEN LINEAR MODELS; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Pitkaranta A, 1998, PEDIATRICS, V102, P291, DOI 10.1542/peds.102.2.291; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; SUMYER J, 1996, EUR RESPIR J, V9, P1880; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104; WU TC, 1992, AM J PATHOL, V140, P991; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; ZUMBRANO JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008	43	208	213	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2004	114	2					239	247		10.1016/j.jaci.2004.04.006		9	Allergy; Immunology	Allergy; Immunology	847OU	WOS:000223405600004	15316497	
J	Que, LG; Liu, LM; Yan, Y; Whitehead, GS; Gavett, SH; Schwartz, DA; Stamler, JS				Que, LG; Liu, LM; Yan, Y; Whitehead, GS; Gavett, SH; Schwartz, DA; Stamler, JS			Protection from experimental asthma by an endogenous bronchodilator	SCIENCE			English	Article							NITRIC-OXIDE SYNTHASE; PROTEIN S-NITROSYLATION; AIRWAY HYPERRESPONSIVENESS; CYSTIC-FIBROSIS; NITROGEN-OXIDES; EXHALED AIR; NITROSOTHIOLS; DISEASE; INFLAMMATION; INHIBITION	Mechanisms that protect against asthma remain poorly understood. S-nitrosoglutathione (GSNO), an endogenous bronchodilator, is depleted from asthmatic airways, suggesting a protective role. We report that, following allergen challenge, witd-type mice exhibiting airway hyperresponsivity have increased airway levels of the enzyme GSNO reductase (GSNOR) and are depleted of lung S-nitrosothiols (SNOs). In contrast, mice with genetic deletion of GSNOR exhibit increases in lung SNOs and are protected from airway hyperresponsivity. Our results indicate that endogenous SNOs, governed by GSNOR, are critical regulators of airway responsivity and may provide new therapeutic approaches to asthma.	Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; US EPA, Expt Toxicol Div, Res Triangle Pk, NC 27711 USA	Stamler, JS (reprint author), Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.	STAML001@mc.duke.edu			NHLBI NIH HHS [HL004171, K08 HL004171, K08 HL004171-05]; NIEHS NIH HHS [ES012496, P01 ES012496, P01 ES012496-010004]		ALVING K, 1993, EUR RESPIR J, V6, P1368; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Foster MW, 2003, TRENDS MOL MED, V9, P160, DOI 10.1016/S1471-4914(03)00028-5; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Jaffrey SR, 2001, NAT CELL BIOL, V3, P193, DOI 10.1038/35055104; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; Liu L, 2004, CELL, V116, P617, DOI 10.1016/S0092-8674(04)00131-X; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; QUE L, UNPUB; Saleh D, 1998, FASEB J, V12, P929; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/rccm.2105032; Whalen EJ, 2000, HYPERTENSION, V36, P376; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xiong YL, 1999, J IMMUNOL, V162, P445	25	207	212	2	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 10	2005	308	5728					1618	1621		10.1126/science.1108228		4	Multidisciplinary Sciences	Science & Technology - Other Topics	936BH	WOS:000229827000054	15919956	
J	Jarvis, D				Jarvis, D		European Community Resp Health Su	The European Community Respiratory Health Survey II	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; atopy; cohort; epidemiology; European Community Respiratory Health Survey; forced expiratory volume in one second	PARTY DIAGNOSTIC-CRITERIA; SKIN-TEST REACTIVITY; LUNG-FUNCTION; ATOPIC-DERMATITIS; PULMONARY-FUNCTION; POPULATION-SAMPLE; AEROSOL OUTPUT; AIR-POLLUTION; ASTHMA; DECLINE	The European Community Respiratory Health Survey (ECRHS) II will determine the incidence of and risk factors for the development of allergic disease, atopy and rapid loss of lung function in middle-aged adults living in Europe. From 1991-1993, >18,000 individuals took part in ECRHS I and provided information on symptoms and exposure to known or suspected risk factors for asthma. Blood samples for assessment of specific immunoglobulin E to environmental allergen were taken and lung function and bronchial responsiveness to methacholine were assessed. From 1999-2001, study participants were re-contacted to determine symptom status and exposure to a variety of factors, including tobacco smoke, animals, occupational agents and air pollutants (including particulate matter). In a subsample of responders, exposure to house dust-mite allergen was assessed by analysis of dust samples taken from participants' mattresses. In addition, blood samples suitable for deoxyribonucleic acid extraction were collected and stored. Currently, European Community Respiratory Health Survey II is being conducted in 29 centres in 14 countries. At the time of writing this paper, 27 centres had begun the study and similar to12,000 participants had completed a short postal questionnaire, similar to9,000 had completed a more detailed health assessment and 3,500 participants had provided dust samples. Historical air-pollution data have been collated and the programme of monitoring particles with a 50% cut-off aerodynamic diameter of 2.5 mum has been completed in 21 centres in 10 countries.	Kings Coll London, Dept Publ Hlth Sci, London SE1 3QD, England	Jarvis, D (reprint author), Kings Coll London, Dept Publ Hlth Sci, 5th Floor,Capital House,42 Weston St, London SE1 3QD, England.	deborah.jarvis@kcl.ac.uk	de Marco, Roberto/A-5470-2008; SESM, SESM/C-1440-2008; Jarvis, Deborah/E-6494-2011				Abbey DE, 1998, AM J RESP CRIT CARE, V158, P289; ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; ADAMS N, 2001, INHALED BECLOMETHASO; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURNEY PGJ, 1987, CHEST, V91, P79; Chinn S, 1997, EUR RESPIR J, V10, P452, DOI 10.1183/09031936.97.10020452; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; DENNIS JH, 1990, THORAX, V45, P728, DOI 10.1136/thx.45.10.728; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561; Hendrick DJ, 2001, CLIN EXP ALLERGY, V31, P1; *INT LAB OFF, 1999, INT STAND CLASS OCC; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jantunen MJ, 1998, J EXPO ANAL ENV EPID, V8, P495; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MATHYS P, 2001, ICP INFORMATION NEWS, V27; *NAT HEART LABI GL, 1995, GLOB STRAT ASTHM MAN; Oglesby L, 2000, AM J EPIDEMIOL, V152, P75, DOI 10.1093/aje/152.1.75; OHMAN JL, 1993, J ALLERGY CLIN IMMUN, V91, P752, DOI 10.1016/0091-6749(93)90195-L; Panhuysen CIM, 1997, AM J RESP CRIT CARE, V155, P1267; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; RODRIGUEZ BL, 1994, AM J EPIDEMIOL, V140, P398; Ryan G, 1999, J EPIDEMIOL COMMUN H, V53, P230; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SPARROW D, 1993, AM REV RESPIR DIS, V147, P367; Strachan DP, 1996, BRIT MED J, V312, P1195; TOCKMAN MS, 1995, AM J RESP CRIT CARE, V151, P390; Tracey M, 1995, Am J Respir Crit Care Med, V151, P656; TROISI RJ, 1995, AM J RESP CRIT CARE, V152, P1183; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; VANSCHAYCK CP, 1991, AM REV RESPIR DIS, V144, P1297; Ware JE, 1994, SF 36 PHYSICAL MENTA; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	45	207	210	0	4	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	NOV	2002	20	5					1071	1079		10.1183/09031936.02.00046802		9	Respiratory System	Respiratory System	614EZ	WOS:000179176500002		
J	Penttinen, P; Timonen, KL; Tiittanen, P; Mirme, A; Ruuskanen, J; Pekkanen, J				Penttinen, P; Timonen, KL; Tiittanen, P; Mirme, A; Ruuskanen, J; Pekkanen, J			Ultrafine particles in urban air and respiratory health among adult asthmatics	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; asthma; particles; particle size; peak expiratory flow rate; respiratory symptoms	CYTOKINE PRODUCTION; POLLUTION; CHILDREN; PM10; ASSOCIATION; INVOLVEMENT; GENERATION; MORTALITY; EXPOSURE; SYMPTOMS	Airborne particles are associated with adverse health effects and contribute to excess mortality in epidemiological studies. A recent hypothesis proposes that the high numbers of ultrafine (<0.1 pm diameter) particles in ambient air might provoke alveolar inflammation and subsequently cause exacerbations in pre-existing cardiopulmonary diseases. To test the hypothesis adult asthmatics were followed with daily peak expiratory flow (PEF) measurements and symptom and medication diaries for sis months, while simultaneously monitoring particulate pollution in ambient air. The associations between daily health endpoints of 57 asthmatics and indicators of air pollution mere examined by multivariate regression models. Daily mean number concentration of particles, but not particle mass (PM10 (particle mass < 10 pm), PM2.5-10, PM2.5, PM1), was negatively associated with daily PEF deviations. The strongest effects were seen for particles in the ultrafine range. However, the effect of ultrafine particles could not definitely be separated from other traffic generated pollutants, namely nitric oxide, nitrogen dioxide and carbon monoxide. No associations were observed with respiratory symptoms or medication use. Particle mass measurements can be strongly influenced by mechanically produced, soil-derived particles, which may not be associated with adverse health effects. Therefore, air quality monitoring should include particle number concentrations, which mainly reflect ultrafine particles.	Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio 70701, Finland; Univ Tartu, Inst Environm Phys, EE-2400 Tartu, Estonia; Univ Kuopio, Dept Environm Sci, Kuopio 70211, Finland	Pekkanen, J (reprint author), Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio 70701, Finland.						Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; Buzorius G, 1999, ATMOS ENVIRON, V33, P553, DOI 10.1016/S1352-2310(98)00287-8; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DUSSELDORP A, 1995, AM J RESP CRIT CARE, V152, P1932; Gilmour PS, 1996, OCCUP ENVIRON MED, V53, P817; HOSIOKANGAS J, 1995, J AEROSOL SCI, V26, pS423, DOI 10.1016/0021-8502(95)97119-Y; Johnston CJ, 1996, TOXICOL APPL PHARM, V140, P154, DOI 10.1006/taap.1996.0208; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Osier M, 1997, FUND APPL TOXICOL, V40, P220, DOI 10.1006/faat.1997.2390; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; Tuch T, 2000, ATMOS ENVIRON, V34, P139, DOI 10.1016/S1352-2310(99)00248-4; Vallius MJ, 2000, ENVIRON SCI TECHNOL, V34, P1919, DOI 10.1021/es990603e; Vedal S, 1997, J AIR WASTE MANAGE, V47, P551; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Venkataraman C, 1998, INHAL TOXICOL, V10, P183; Vincent R, 1997, AM J PATHOL, V151, P1563; 1997, FINNISH POLLEN B, V22	24	207	216	4	35	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2001	17	3					428	435		10.1183/09031936.01.17304280		8	Respiratory System	Respiratory System	437TK	WOS:000169009500017	11405521	
J	Mattes, J; Collison, A; Plank, M; Phipps, S; Foster, PS				Mattes, Joerg; Collison, Adam; Plank, Maximilian; Phipps, Simon; Foster, Paul S.			Antagonism of microRNA-126 suppresses the effector function of T(H)2 cells and the development of allergic airways disease	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						animal model; asthma; inflammation; microRNA; T(H)2 cytokines	TOLL-LIKE RECEPTORS; DENDRITIC CELLS; EXPERIMENTAL ASTHMA; IMMUNE-RESPONSES; INHALED ANTIGEN; LINKING INNATE; PLASMA-CELLS; IN-VIVO; EXPRESSION; HYPERREACTIVITY	Allergic asthma is an inflammatory disease of the lung characterized by abnormal T helper-2 (T(H)2) lymphocyte responses to inhaled antigens. The molecular mechanisms leading to the generation of T(H)2 responses remain unclear, although toll-like receptors (TLRs) present on innate immune cells play a pivotal role in sensing molecular patterns and in programming adaptive T cell responses. Here we show that in vivo activation of TLR4 by house dust mite antigens leads to the induction of allergic disease, a process that is associated with expression of a unique subset of small, noncoding microRNAs. Selective blockade of microRNA (miR)-126 suppressed the asthmatic phenotype, resulting in diminished T(H)2 responses, inflammation, airways hyperresponsiveness, eosinophil recruitment, and mucus hypersecretion. miR-126 blockade resulted in augmented expression of POU domain class 2 associating factor 1, which activates the transcription factor PU. 1 that alters T(H)2 cell function via negative regulation of GATA3 expression. In summary, this study presents a functional connection between miRNA expression and asthma pathogenesis, and our data suggest that targeting miRNA in the airways may lead to anti-inflammatory treatments for allergic asthma.	[Mattes, Joerg; Collison, Adam; Plank, Maximilian] Univ Newcastle, Immunol & Resp Res Grp, Callaghan, NSW 2300, Australia; [Mattes, Joerg] Univ Newcastle, John Hunter Childrens Hosp, Callaghan, NSW 2300, Australia; [Collison, Adam; Plank, Maximilian; Phipps, Simon; Foster, Paul S.] Univ Newcastle, Fac Hlth, Sch Biomed Sci & Pharm, CARD, Callaghan, NSW 2300, Australia; Hunter Med Res Inst, Callaghan, NSW 2300, Australia	Mattes, J (reprint author), Univ Newcastle, Immunol & Resp Res Grp, Callaghan, NSW 2300, Australia.	joerg.mattes@newcastle.edu.au; paul.foster@newcastle.edu.au	Phipps, Simon/F-9170-2010; Foster, Paul/G-5057-2013	Phipps, Simon/0000-0002-7388-3612; 	National Health and Medical Research Council; Cooperative Research Centre Asthma and Airways	Wethank Prof. Akira (Osaka University, Japan) for the generous provision of MyD88-and TLR4-deficient mice, and Ana Pereira de Siqueira, Stuart Reeves, and Fiona Eyers for technical assistance. This work was supported by a National Health and Medical Research Council project grant (to J. M. and P. S. F.), a National Health and Medical Research Council Health Professional Research Fellowship (to J. M.), and the Cooperative Research Centre Asthma and Airways (J. M. and P. S. F.).	Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Asirvatham AJ, 2008, MOL IMMUNOL, V45, P1995, DOI 10.1016/j.molimm.2007.10.035; Baltimore D, 2008, NAT IMMUNOL, V9, P839, DOI 10.1038/ni.f.209; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bazzoni F, 2009, P NATL ACAD SCI USA, V106, P5282, DOI 10.1073/pnas.0810909106; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Brunner C, 2007, EMBO J, V26, P3191, DOI 10.1038/sj.emboj.7601742; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Care A, 2007, NAT MED, V13, P613, DOI 10.1038/nm1582; Cates EC, 2004, J IMMUNOL, V173, P6384; Ceppi M, 2009, P NATL ACAD SCI USA, V106, P2735, DOI 10.1073/pnas.0811073106; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eisenbarth SC, 2004, CURR OPIN PEDIATR, V16, P659, DOI 10.1097/01.mop.0000145920.00101.e4; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Herbert C, 2008, CLIN EXP ALLERGY, V38, P847, DOI 10.1111/j.1365-2222.2008.02950.x; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; Kumar RK, 2002, LAB INVEST, V82, P495; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lichtinger M, 2007, J BIOL CHEM, V282, P26874, DOI 10.1074/jbc.M703856200; Lindsay MA, 2008, TRENDS IMMUNOL, V29, P343, DOI 10.1016/j.it.2008.04.004; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2008, CURR OPIN MOL THER, V10, P150; Mattes J, 2007, AM J RESP CELL MOL, V36, P8, DOI 10.1165/rcmb.2006-0227TR; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; O'Connell RM, 2009, P NATL ACAD SCI USA, V106, P7113, DOI 10.1073/pnas.0902636106; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103; Taylor MJ, 2000, J EXP MED, V191, P1429, DOI 10.1084/jem.191.8.1429; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027	44	206	231	1	14	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	NOV 3	2009	106	44					18704	18709		10.1073/pnas.0905063106		6	Multidisciplinary Sciences	Science & Technology - Other Topics	514XM	WOS:000271429800053	19843690	
J	Schaub, B; Lauener, R; von Mutius, E				Schaub, B; Lauener, R; von Mutius, E			The many faces of the hygiene hypothesis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; asthma; infection; innate; microbial; virus; toll	TOLL-LIKE RECEPTORS; RESPIRATORY SYNCYTIAL VIRUS; REGULATORY T-CELLS; KILLED MYCOBACTERIUM-VACCAE; DAY-CARE ATTENDANCE; BRONCHIAL EPITHELIAL-CELLS; EARLY BCG VACCINATION; SCHOOL-AGE-CHILDREN; HEPATITIS-A VIRUS; EARLY-LIFE	About 15 years have gone by since Strachan first proposed the idea that infections and unhygienic contact might confer protection against the development of allergic illnesses. The so-called hygiene hypothesis has ever since undergone numerous more or less subtle modifications by various researchers in the fields of epidemiology, clinical science, and immunology. Three major tracts have developed exploring the role of overt viral and bacterial infections, the significance of environmental exposure to microbial compounds, and the effect of both on underlying responses of the innate and adaptive immunity. To date, a truly unifying concept has not yet emerged, but various pieces of a complex interplay between immune responses of the host, characteristics of the invading microorganism, the level and variety of the environmental exposure, and the interactions between a genetic background and a range of exposures becomes apparent. These influences are discussed as determinants for a number of complex allergic illnesses in this review, while we attempt to pay attention to the importance of different phenotypes, namely of the asthma syndrome. Even if today practical implications cannot directly be deduced from these findings, there is great potential for the development of novel preventive and therapeutic strategies in the future.	Univ Munich, Univ Childrens Hosp Munich, Dr Haunersches Kinderspital, Pediat Pulm Div, D-80337 Munich, Germany; Univ Zurich, Childrens Hosp, Ctr Allergy Res, Zurich, Switzerland	Schaub, B (reprint author), Univ Munich, Univ Childrens Hosp Munich, Dr Haunersches Kinderspital, Pediat Pulm Div, Lindwurmstr 4, D-80337 Munich, Germany.	bianca.schaub@med.uni-muenchen.de	Lauener, Roger/O-8612-2016	Lauener, Roger/0000-0002-8412-606X; von Mutius, Erika/0000-0002-8893-4515			Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Akdis CA, 2004, ALLERGY, V59, P897, DOI 10.1111/j.1398-9995.2004.00587.x; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Annus T, 2004, ALLERGY, V59, P1068, DOI 10.1111/j.1398-9995.2004.00557.x; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.20001.113081; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Avila PC, 2000, J ALLERGY CLIN IMMUN, V105, P923, DOI 10.1067/mai.2000.106214; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; BEESON PB, 1947, J EXP MED, V86, P29, DOI 10.1084/jem.86.1.29; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Birchler T, 2001, EUR J IMMUNOL, V31, P3131, DOI 10.1002/1521-4141(200111)31:11<3131::AID-IMMU3131>3.0.CO;2-G; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; Brightbill HD, 2000, IMMUNOLOGY, V101, P1, DOI 10.1046/j.1365-2567.2000.00093.x; Calvani M, 2002, EUR RESPIR J, V20, P391, DOI 10.1183/09031936.02.00274502; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241; Cooper PJ, 2004, PARASITE IMMUNOL, V26, P455, DOI 10.1111/j.0141-9838.2004.00728.x; Crellin NK, 2005, J IMMUNOL, V175, P8051; Cullinan P, 2003, EUR RESPIR J, V22, P956, DOI 10.1183/09031936.03.00039102; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Dakhama A, 2005, J IMMUNOL, V175, P1876; Dakhama A., 2005, PEDIATR INFECT DIS J, V24, pS66; Dakhama Azzeddine, 2005, Pediatr Infect Dis J, V24, pS159, DOI 10.1097/01.inf.0000188155.46381.15; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eder Waltraud, 2004, Curr Opin Allergy Clin Immunol, V4, P113, DOI 10.1097/00130832-200404000-00008; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elliott L, 2004, EUR RESPIR J, V24, P938, DOI 10.1183/09031936.04.0006404; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; Garofalo RP, 2005, J MED VIROL, V75, P282, DOI 10.1002/jmv.20268; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gruber C, 2002, PEDIATR ALLERGY IMMU, V13, P177, DOI 10.1034/j.1399-3038.2002.01006.x; Hemmi H, 2000, NATURE, V408, P740; Henderson J, 2005, PEDIATR ALLERGY IMMU, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hoffjan S, 2005, AM J HUM GENET, V76, P696, DOI 10.1086/429418; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jarvis D, 2004, ALLERGY, V59, P1063, DOI 10.1111/j.1398-9995.2004.00539.x; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kaplan G, 1996, EMBO J, V15, P4282; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Krause TG, 2003, JAMA-J AM MED ASSOC, V289, P1012, DOI 10.1001/jama.289.8.1012; Kumar A, 1997, AM J RESP CRIT CARE, V155, P130; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999; Medzhitov R, 1997, NATURE, V388, P394; Mikus LD, 2001, AM J RESP CELL MOL, V24, P74; Muthukkumar S, 2000, J IMMUNOL, V165, P4803; Nafstad P, 2005, PEDIATRICS, V116, P255; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nilsson C, 2005, J ALLERGY CLIN IMMUN, V116, P438, DOI 10.1016/j.jaci.2005.04.027; Nja F, 2003, ARCH DIS CHILD, V88, P566, DOI 10.1136/adc.88.7.566; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos NG, 2002, CLIN EXP ALLERGY, V32, P537, DOI 10.1046/j.0954-7894.2002.01313.x; PAPUDOPOULOS NG, 2004, PAEDIAT RESP REV, V5, P255; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 2003, ALLERGY, V58, P1187, DOI 10.1034/j.1398-9995.2003.00263.x; Racila DM, 2005, J ALLERGY CLIN IMMUN, V116, P1202, DOI 10.1016/j.jaci.2005.08.050; Radon K, 2004, AM J IND MED, V46, P349, DOI 10.1002/ajim.20000; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Rennie Donna C, 2002, Can Respir J, V9, P313; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rosenthal LA, 2004, AM J RESP CELL MOL, V30, P702, DOI 10.1165/rcmb.2003-0181OC; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; SAKAMOTO M, 1984, J IMMUNOL, V132, P2614; Sayers I, 2004, J ALLERGY CLIN IMMUN, V114, P302, DOI 10.1016/j.jaci.2004.03.057; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Smit JJ, 2003, CLIN EXP ALLERGY, V33, P1083, DOI 10.1046/j.1365-2222.2003.01727.x; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Sutmuller RPM, 2006, J CLIN INVEST, V116, P485, DOI 10.1172/JCI25439; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Vogel SN, 2003, BIOCHEM SOC T, V31, P664, DOI 10.1042/BST0310664; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wassall HJ, 2005, J ASTHMA, V42, P737, DOI 10.1080/02770900500306498; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	118	205	221	3	65	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					969	977		10.1016/j.jaci.2006.03.003		9	Allergy; Immunology	Allergy; Immunology	041EM	WOS:000237436300001	16675321	
J	Alvarez-Cuesta, E; Bousquet, J; Canonica, GW; Durham, SR; Mailing, HJ; Valovirta, E				Alvarez-Cuesta, E.; Bousquet, J.; Canonica, G. W.; Durham, S. R.; Mailing, H. -J.; Valovirta, E.			Standards for practical allergen-specific immunotherapy	ALLERGY			English	Article							HYMENOPTERA VENOM ALLERGY; HOUSE-DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; GRASS-POLLEN IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; DOUBLE-BLIND; CONTROLLED TRIAL; ORAL IMMUNOTHERAPY; CLINICAL-EFFICACY; HAY-FEVER									[Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; BAER H, 1978, J ALLERGY CLIN IMMUN, V61, P206, DOI 10.1016/0091-6749(78)90180-X; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 1998, ALLERGY S, V53, P44; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Brown JL, 2001, CLIN EXP ALLERGY, V31, P8, DOI 10.1046/j.1365-2222.2001.01009.x; Brown SGA, 2003, LANCET, V361, P1001, DOI 10.1016/S0140-6736(03)12827-9; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CARREIRA J, 1994, ARB PEI GSH, V87, P155; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; Delacourt C, 2001, AM J RESP CRIT CARE, V164, P1382; Desbordes J, 1975, Dev Biol Stand, V29, P267; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; *EUR COMM, 1991, CPMPBWP24396, V3; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Javeed N, 1996, CATHETER CARDIO DIAG, V39, P383, DOI 10.1002/(SICI)1097-0304(199612)39:4<383::AID-CCD13>3.0.CO;2-E; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; LICHTENSTEIN LM, 1976, NEW ENGL J MED, V295, P1195, DOI 10.1056/NEJM197611182952113; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; MAASCH HJ, 1988, ARB P EHRLICH I BUND, V82, P117; Malling HJ, 2002, CURR OPIN ALLERGY CL, V2, P523, DOI 10.1097/01.all.0000044538.45448.80; Malling HJ, 2000, DRUG SAFETY, V23, P323, DOI 10.2165/00002018-200023040-00005; MALLING HJ, 1993, ALLERGY, V48, P9; Malling HJ, 1998, ALLERGY, V53, P461; MALLING HJ, 1993, ALLERGY, V48, P14; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; MARSH DG, 1970, IMMUNOLOGY, V18, P705; MARSH DG, 1981, J ALLERGY CLIN IMMUN, V68, P449, DOI 10.1016/0091-6749(81)90199-8; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; MULLER U, 1979, ALLERGY, V34, P369, DOI 10.1111/j.1398-9995.1979.tb02006.x; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Muller U, 1993, ALLERGY          S14, V48, P36; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jsci.2004.11.012, 10.1016/j.jaci.2004.11.012]; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nelson Harold S., 2003, Journal of Allergy and Clinical Immunology, V111, pS793, DOI 10.1067/mai.2003.150; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; Niederberger Verena, 2004, Curr Opin Allergy Clin Immunol, V4, P549, DOI 10.1097/00130832-200412000-00013; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Nord-Larsen T, 2002, BIOMASS BIOENERG, V23, P1, DOI 10.1016/S0961-9534(02)00032-6; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; SCHEINMANN P, 2004, ALLERGENS ALLERGEN I, P567; Shekelle PG, 1999, BRIT MED J, V318, P593; Sjoholm I., 1997, ARB P EHRLICH I, V91, P107; Sopo SM, 2004, ARCH DIS CHILD, V89, P620, DOI 10.1136/adc.2003.030411; TABAR AI, 1993, ALLERGY, V48, P450, DOI 10.1111/j.1398-9995.1993.tb00743.x; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; U.S. Health Resources and Services Administration, 1985, FED REG; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; VANDENTOORN LM, 2003, CUR OPIN PULM MED, V9, P5; VARNEY VA, 1991, BRIT MED J, V302, P265; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WANTKE F, 1993, ALLERGY, V48, P552, DOI 10.1111/j.1398-9995.1993.tb01116.x; WEEKE B, 1975, SCAND J IMMUNOL S2, V4, P149; Wells JH, 1996, J ALLERGY CLIN IMMUN, V97, P1030, DOI 10.1016/S0091-6749(96)80081-9; WELSH PW, 1983, J ALLERGY CLIN IMMUN, V71, P454, DOI 10.1016/0091-6749(83)90461-X; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; YUNGINGER JW, 1988, ARB P EHRLICH I BUND, V82, P129	82	205	270	1	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy		2006	61			82			1	20		10.1111/j.1398-9995.2006.01219_1.x		20	Allergy; Immunology	Allergy; Immunology	085SF	WOS:000240624000001	16930249	
J	Spencer, S; Calverley, PMA; Burge, PS; Jones, PW				Spencer, S; Calverley, PMA; Burge, PS; Jones, PW		ISOLDE Study Grp	Health status deterioration in patients with chronic obstructive pulmonary disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							QUALITY-OF-LIFE; GEORGE RESPIRATORY QUESTIONNAIRE; AIR-FLOW LIMITATION; SF-36; ASTHMA; COPD	This study examined health status decline in patients with chronic obstructive pulmonary disease (COPD). Data are from the Inhaled Steroids in Obstructive Lung Disease (ISOLDE) trial. After an 8-wk run-in, 751 patients (566 male), mean age 64 yr, were randomized to receive fluticasone propionate (FP) 500 mug twice daily (376 patients) or placebo (375 patients). Mean baseline postbronchodilator FEV1 was 50 +/- 15% predicted. Patients completed the St George's Respiratory Questionnaire (SGRQ) and the Short-Form 36 (SF-36) at baseline and every 6 mo for 3 yr. FEV1 and smoking status were assessed at baseline and at 3-mo intervals. A total of 387 (212 FP) patients completed the trial. All SGRQ components (p = 0.03 to 0.004) and Physical Function, Mental Health, Energy/Vitality, and Physical Role Limitation scales of the SF-36 (p = 0.05 to 0.005) deteriorated faster in the placebo group. FEV, and SGRQ scores correlated at baseline values (r = -0.25, p < 0.0001), as did change in FEV1 and change in SGRQ (<Delta> r = -0.24, p < 0.0001). At baseline values smokers had worse SGRQ Total, Symptoms, and Impacts scores than ex-smokers. This difference was maintained throughout the study. Smoking status did not influence the rate of decline in health status. The SGRQ Total scores of FP-treated patients took 59% longer than placebo to deteriorate by a clinically significant amount. We conclude that health status decline in moderate to severe COPD can be reduced by high-dose fluticasone.	St George Hosp, Sch Med, Dept Med Physiol, London SW17 0RE, England	Spencer, S (reprint author), St George Hosp, Sch Med, Dept Med Physiol, Cranmer Terrace, London SW17 0RE, England.		Spencer, Sally/D-6963-2013				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Bowling A., 1995, MEASURING HLTH REV Q; BRAZIER JE, 1992, BRIT MED J, V305, P160; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Ferrer M, 1996, EUR RESPIR J, V9, P1160, DOI 10.1183/09031936.96.09061160; Goldstein H., 1995, MULTILEVEL STAT MODE; The Intermittent Positive Pressure Breathing Trial Group, 1983, ANN INTERN MED, V99, P612; Jarad NA, 1999, RESP MED, V93, P161, DOI 10.1016/S0954-6111(99)90001-X; JENKINSON C, 1993, BRIT MED J, V306, P1437; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283; JONES PW, 1989, AM REV RESPIR DIS, V140, P1538; JONES PW, 1995, EUR RESPIR REV, V5, P279; Jones PW, 1994, AM J RESP CRIT CARE, V149, pA211; MAHLER DA, 1995, AM J RESP CRIT CARE, V151, P61; MEECHAMJONES DJ, 1995, AM J RESP CRIT CARE, V152, P538; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467; Okubadejo AA, 1996, THORAX, V51, P44, DOI 10.1136/thx.51.1.44; Osman L. M., 1996, European Respiratory Journal Supplement, V9, p143S; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; SWINBURN CR, 1988, BRIT J CLIN PHARMACO, V26, P709; VANSCHAYCK CP, 1995, CHEST, V107, P1199, DOI 10.1378/chest.107.5.1199; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	25	205	209	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN	2001	163	1					122	128				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	394TV	WOS:000166540100025	11208636	
J	Lee, M; Lee, J; Carroll, MW; Choi, H; Min, S; Song, T; Via, LE; Goldfeder, LC; Kang, E; Jin, B; Park, H; Kwak, H; Kim, H; Jeon, HS; Jeong, I; Joh, JS; Chen, RY; Olivier, KN; Shaw, PA; Follmann, D; Song, SD; Lee, JK; Lee, D; Kim, CT; Dartois, V; Park, SK; Cho, SN; Barry, CE				Lee, Myungsun; Lee, Jongseok; Carroll, Matthew W.; Choi, Hongjo; Min, Seonyeong; Song, Taeksun; Via, Laura E.; Goldfeder, Lisa C.; Kang, Eunhwa; Jin, Boyoung; Park, Hyeeun; Kwak, Hyunkyung; Kim, Hyunchul; Jeon, Han-Seung; Jeong, Ina; Joh, Joon Sung; Chen, Ray Y.; Olivier, Kenneth N.; Shaw, Pamela A.; Follmann, Dean; Song, Sun Dae; Lee, Jong-Koo; Lee, Dukhyoung; Kim, Cheon Tae; Dartois, Veronique; Park, Seung-Kyu; Cho, Sang-Nae; Barry, Clifton E., III			Linezolid for Treatment of Chronic Extensively Drug-Resistant Tuberculosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRACTABLE MULTIDRUG-RESISTANT; MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; OXAZOLIDINONE ANTIBACTERIAL; MURINE MODEL; PHARMACOKINETICS; TOLERABILITY; MOXIFLOXACIN; OFLOXACIN; EFFICACY	BACKGROUND Linezolid has antimycobacterial activity in vitro and is increasingly used for patients with highly drug-resistant tuberculosis. METHODS We enrolled 41 patients who had sputum-culture-positive extensively drug-resistant (XDR) tuberculosis and who had not had a response to any available chemotherapeutic option during the previous 6 months. Patients were randomly assigned to linezolid therapy that started immediately or after 2 months, at a dose of 600 mg per day, without a change in their background regimen. The primary end point was the time to sputum-culture conversion on solid medium, with data censored 4 months after study entry. After confirmed sputum-smear conversion or 4 months (whichever came first), patients underwent a second randomization to continued linezolid therapy at a dose of 600 mg per day or 300 mg per day for at least an additional 18 months, with careful toxicity monitoring. RESULTS By 4 months, 15 of the 19 patients (79%) in the immediate-start group and 7 of the 20 (35%) in the delayed-start group had culture conversion (P = 0.001). Most patients (34 of 39 [87%]) had a negative sputum culture within 6 months after linezolid had been added to their drug regimen. Of the 38 patients with exposure to linezolid, 31 (82%) had clinically significant adverse events that were possibly or probably related to linezolid, including 3 patients who discontinued therapy. Patients who received 300 mg per day after the second randomization had fewer adverse events than those who continued taking 600 mg per day. Thirteen patients completed therapy and have not had a relapse. Four cases of acquired resistance to linezolid have been observed. CONCLUSIONS Linezolid is effective at achieving culture conversion among patients with treatment-refractory XDR pulmonary tuberculosis, but patients must be monitored carefully for adverse events. (Funded by the National Institute of Allergy and Infectious Diseases and the Ministry of Health and Welfare, South Korea; ClinicalTrials.gov number, NCT00727844.)	[Carroll, Matthew W.; Via, Laura E.; Goldfeder, Lisa C.; Barry, Clifton E., III] NIAID, TB Res Sect, NIH, Bethesda, MD 20892 USA; [Lee, Myungsun; Lee, Jongseok; Choi, Hongjo; Min, Seonyeong; Song, Taeksun; Kang, Eunhwa; Jin, Boyoung; Park, Hyeeun; Kwak, Hyunkyung; Kim, Hyunchul; Jeon, Han-Seung; Song, Sun Dae] Int TB Res Ctr, Chang Won, South Korea; [Jeong, Ina; Joh, Joon Sung] Natl Med Ctr, Dept Internal Med, Seoul, South Korea; [Lee, Jong-Koo] Seoul Natl Univ Hosp, Dept Family Med, Seoul 110744, South Korea; [Lee, Dukhyoung] Korea Ctr Dis Control & Prevent, Osong, South Korea; [Kim, Cheon Tae; Park, Seung-Kyu] Natl Masan Hosp, Masan, South Korea; [Cho, Sang-Nae] Yonsei Univ, Coll Med, Dept Microbiol, Seoul, South Korea; [Cho, Sang-Nae] Yonsei Univ, Coll Med, Inst Immunol & Immunol Dis, Seoul, South Korea; [Olivier, Kenneth N.] NIAID, Immunopathol Sect, NIH, Bethesda, MD 20892 USA; [Chen, Ray Y.] NIAID, Lab Clin Infect Dis, Off Global Res, NIH, Bethesda, MD 20892 USA; [Shaw, Pamela A.; Follmann, Dean] NIAID, Biostat Res Branch, NIH, Bethesda, MD 20892 USA; [Dartois, Veronique] Novartis Inst Trop Dis, Singapore, Singapore	Barry, CE (reprint author), NIAID, TB Res Sect, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.	cbarry@niaid.nih.gov	Barry, III, Clifton/H-3839-2012	Via, Laura/0000-0001-6074-9521; Chen, Ray/0000-0001-6344-1442	National Institute of Allergy and Infectious Diseases, National Institutes of Health; Ministry of Health and Welfare, South Korea	Supported by the Intramural Research Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, and by the Ministry of Health and Welfare, South Korea.	Anger HA, 2010, J ANTIMICROB CHEMOTH, V65, P775, DOI 10.1093/jac/dkq017; ASHTEKAR DR, 1991, DIAGN MICR INFEC DIS, V14, P465, DOI 10.1016/0732-8893(91)90002-W; Barbachyn MR, 1996, J MED CHEM, V39, P680, DOI 10.1021/jm950956y; Beckert P, 2012, ANTIMICROB AGENTS CH, V56, P2743, DOI 10.1128/AAC.06227-11; Beekmann SE, 2008, DIAGN MICR INFEC DIS, V62, P407, DOI 10.1016/j.diagmicrobio.2008.08.009; Boselli E, 2005, CRIT CARE MED, V33, P1529, DOI 10.1097/01.CCM.0000168206.59873.80; Carroll MW, 2012, CLIN INFECT DIS, V54, P1624, DOI 10.1093/cid/cis293; Condos Rany, 2008, Chest, V134, P187, DOI 10.1378/chest.07-1988; Conte JE, 2002, ANTIMICROB AGENTS CH, V46, P1475, DOI 10.1128/AAC.46.5.1475-1480.2002; Cynamon MH, 1999, ANTIMICROB AGENTS CH, V43, P1189; Davies GR, 2010, TUBERCULOSIS, V90, P171, DOI 10.1016/j.tube.2010.03.007; Di Paolo A, 2010, CLIN PHARMACOKINET, V49, P439, DOI 10.2165/11319960-000000000-00000; Diacon AH, 2009, NEW ENGL J MED, V360, P2397, DOI 10.1056/NEJMoa0808427; Dietze R, 2008, AM J RESP CRIT CARE, V178, P1180, DOI 10.1164/rccm.200806-892OC; Dorman SE, 2009, AM J RESP CRIT CARE, V180, P273, DOI 10.1164/rccm.200901-0078OC; Fortun J, 2005, J ANTIMICROB CHEMOTH, V56, P180, DOI 10.1093/jac/dki148; HAYBITTL.JL, 1971, BRIT J RADIOL, V44, P793; Hillemann D, 2008, ANTIMICROB AGENTS CH, V52, P800, DOI 10.1128/AAC.01189-07; Ippolito JA, 2008, J MED CHEM, V51, P3353, DOI 10.1021/jm800379d; Koh WJ, 2009, J ANTIMICROB CHEMOTH, V64, P388, DOI 10.1093/jac/dkp171; Guidelines for tuberculosis control, 2010, GUID TUB CONTR 2010; Leach KL, 2011, ANN NY ACAD SCI, V1222, P49, DOI 10.1111/j.1749-6632.2011.05962.x; Lee E, 2003, CLIN INFECT DIS, V37, P1389, DOI 10.1086/379012; McArthur J H, 1998, J Assoc Nurses AIDS Care, V9, P84, DOI 10.1016/S1055-3290(98)80048-4; McGee B, 2009, ANTIMICROB AGENTS CH, V53, P3981, DOI 10.1128/AAC.01378-08; Nagiec EE, 2005, ANTIMICROB AGENTS CH, V49, P3896, DOI 10.1128/AAC.49.9.3896-3902.2005; Park IN, 2006, J ANTIMICROB CHEMOTH, V58, P701, DOI 10.1093/jac/dkl298; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; Richter E, 2007, ANTIMICROB AGENTS CH, V51, P1534, DOI 10.1128/AAC.01113-06; Rodriguez JC, 2004, J ANTIMICROB CHEMOTH, V53, P441, DOI 10.1093/jac/dkh119; Rustomjee R, 2008, INT J TUBERC LUNG D, V12, P128; Sander P, 2002, MOL MICROBIOL, V46, P1295, DOI 10.1046/j.1365-2958.2002.03242.x; Saralaya D, 2004, J ANTIMICROB CHEMOTH, V53, P325, DOI 10.1093/jac/dkh072; Schecter GF, 2010, CLIN INFECT DIS, V50, P49, DOI 10.1086/648675; Singla R, 2012, EUR RESPIR J, V39, P956, DOI 10.1183/09031936.00076811; Stalker DJ, 2003, CLIN PHARMACOKINET, V42, P1129, DOI 10.2165/00003088-200342130-00004; Tato M, 2006, INT J ANTIMICROB AG, V28, P75, DOI 10.1016/j.ijantimicag.2006.02.011; Traunmuller F, 2010, INT J ANTIMICROB AG, V36, P84, DOI 10.1016/j.ijantimicag.2010.03.007; Vinh DC, 2009, J INFECTION, V59, pS59, DOI 10.1016/S0163-4453(09)60009-8; von der Lippe B, 2006, J INFECTION, V52, P92, DOI 10.1016/j.jinf.2005.04.007; Williams KN, 2009, ANTIMICROB AGENTS CH, V53, P1314, DOI 10.1128/AAC.01182-08; Yew WW, 2003, CHEST, V124, P1476, DOI 10.1378/chest.124.4.1476; Zurenko GE, 1996, ANTIMICROB AGENTS CH, V40, P839; [Anonymous], 1948, BMJ, V2, P769; [Anonymous], 1960, TUBERCLE, V41, P83	45	204	213	4	40	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 18	2012	367	16					1508	1518		10.1056/NEJMoa1201964		11	Medicine, General & Internal	General & Internal Medicine	021SA	WOS:000309904500008	23075177	
J	Beckett, WS; Jacobs, DR; Yu, XH; Iribarren, C; Williams, D				Beckett, WS; Jacobs, DR; Yu, XH; Iribarren, C; Williams, D			Asthma is associated with weight gain in females but not males, independent of physical activity	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; obesity; body mass index; African American; physical activity; epidemiology; environmental tobacco smoke; passive smoking; sex differences	BODY-MASS INDEX; RISK; CARDIA; CHILDREN; WOMEN; MEN	We tested whether asthma diagnosis is associated with weight gain and physical activity in 4,547 18 to 30-yr-old African American and white men and women, followed prospectively for up to 10 yr. Baseline asthma was most frequent in African American men. Incident asthma was more frequent in women. Incident asthma was associated with highest and lowest baseline and change in body mass index (BMI), in a J-shaped curve, after adjustment for other factors. When stratified by sex, this association was seen only in females. Subjects on average decreased physical activity and gained weight over time, but there was no significant difference in asthma prevalence by physical activity at baseline or asthma incidence by change in physical activity. Cigarette smoking in females was significantly associated with asthma incidence, but serum cotinine level at baseline among nonsmokers (reflecting environmental tobacco smoke [ETS] exposure) was not significantly associated with asthma. We conclude that gain in BMI predisposes to new asthma diagnosis In female young adults, but decreased physical activity does not explain the association of weight gain with asthma.	Univ Rochester, Sch Med & Dent, Div Pulm & Crit Care, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA; Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55455 USA; Univ Oslo, Inst Nutr Res, Oslo, Norway; Univ Alabama, Div Prevent Med, Birmingham, AL USA; Kaiser Permanente, Div Res, Oakland, CA USA	Beckett, WS (reprint author), Univ Rochester, Sch Med & Dent, Div Pulm & Crit Care, Box EHSC,575 Elmwood Ave, Rochester, NY 14642 USA.		Yu, Xinhua/D-5570-2009		NHLBI NIH HHS [N01-HC-48049, N01-HC-48048, N01-HC-48050, N01-HC-4807]; NIEHS NIH HHS [P30 ES01247]		American College of Sports Medicine position stand, 1990, MED SCI SPORTS EXERC, V22, P265; Anderssen N, 1996, AM J EPIDEMIOL, V143, P351; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; GUERRA S, 2001, AM J RESP CRIT CARE, V163, P138; HIGGINS M, 1991, CHEST, V99, P315, DOI 10.1378/chest.99.2.315; JACOBS DR, 1989, J CARDIOPULMONARY RE, V0009; Litonjua A, 1999, AM J RESP CRIT CARE, V159, pA131; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Platts-Mills TA, 1996, J ALLERGY CLIN IMMUN, V98, P297; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; Sporik R, 1999, THORAX, V54, P675	15	204	208	2	11	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2001	164	11					2045	2050				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	504CA	WOS:000172838600008	11739133	
J	Wong, CA; Walsh, LJ; Smith, CJP; Wisniewski, AF; Lewis, SA; Hubbard, R; Cawte, S; Green, DJ; Pringle, M; Tattersfield, AE				Wong, CA; Walsh, LJ; Smith, CJP; Wisniewski, AF; Lewis, SA; Hubbard, R; Cawte, S; Green, DJ; Pringle, M; Tattersfield, AE			Inhaled corticosteroid use and bone-mineral density in patients with asthma	LANCET			English	Article							BECLOMETHASONE DIPROPIONATE; REFERENCE RANGES; STEROID-THERAPY; WOMEN; RISK; BUDESONIDE; GLUCOCORTICOIDS; FLUTICASONE; METABOLISM; FRACTURE	Background Inhaled corticosteroids are absorbed into the systemic circulation, but the extent to which they have adverse effects on bone is uncertain. The question is important since 3% of the European population take an inhaled corticosteroid regularly and may do so for many years. Methods We studied the dose-response relation between cumulative inhaled corticosteroid dose and bone-mineral density at the lumbar spine and proximal femur in 196 adults (119 women) with asthma aged 20-40 years. Patients had taken an inhaled corticosteroid regularly for at least 6 months, and had had limited exposure to systemic steroids. Cumulative dose of inhaled corticosteroid was calculated from questionnaires and computerised and written general-practice records, and its effect on bone-mineral density was estimated by multiple regression analysis. Findings Median duration of inhaled corticosteroid treatment was 6 years (range 0.5-24), and median cumulative dose was 876 mg (87-4380), There was a negative association between cumulative dose of inhaled corticosteroid and bone-mineral density at the lumbar spine (L2-L4), femoral neck, Ward's triangle, and trochanter, both before and after adjustment for the effects of age and sex. A doubling in dose of inhaled corticosteroid was associated with a decrease in bone-mineral density at the lumbar spine of 0.16 SD (95% CI 0.04-0.28). Similar decreases were found at the femoral neck, Ward's triangle, and trochanter, Adjustment for potential confounding factors including physical activity and past oral, nasal, dermal, and parenteral corticosteroids did not weaken the associations. Interpretation This study provides evidence of a negative relation between total cumulative dose of inhaled corticosteroid and bone-mineral density in patients with asthma.	City Hosp, Div Resp Med, Nottingham NG5 1PB, England; City Hosp, Dept Radiol, Nottingham NG5 1PB, England; Queens Med Ctr, Dept Gen Practice, Nottingham NG7 2UH, England	Wong, CA (reprint author), City Hosp, Div Resp Med, Nottingham NG5 1PB, England.						BALFOURLYNNE L, 1987, PAEDIATRICIAN, V24, P237; BARNES PJ, 1993, AM REV RESPIR DIS, V148, pS1; Bisgaard H, 1996, EUR RESPIR J, V9, pS28; BOULET LP, 1994, J ALLERGY CLIN IMMUN, V94, P796, DOI 10.1016/0091-6749(94)90145-7; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; EASTELL R, 1991, J BONE MINER RES, V6, P207; Ebeling PR, 1998, J BONE MINER RES, V13, P1283, DOI 10.1359/jbmr.1998.13.8.1283; Egan JJ, 1999, EUR RESPIR J, V13, P1267, DOI 10.1183/09031936.99.13612769; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; HERRALA J, 1994, BONE, V15, P621, DOI 10.1016/8756-3282(94)90309-3; Hughes JA, 1999, THORAX, V54, P223; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; JAGLAL SB, 1993, AM J EPIDEMIOL, V138, P107; Lau EMC, 1998, CLIN EXP ALLERGY, V28, P1066; Luengo M, 1997, EUR RESPIR J, V10, P2110, DOI 10.1183/09031936.97.10092110; Marystone JF, 1995, AM J PUBLIC HEALTH, V85, P1693, DOI 10.2105/AJPH.85.12.1693; Mazess RB, 1997, BRIT J RADIOL, V70, P109; Packe GE, 1996, J ROY COLL PHYS LOND, V30, P128; PACKE GE, 1992, THORAX, V47, P414, DOI 10.1136/thx.47.6.414; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Petley GW, 1996, BRIT J RADIOL, V69, P655; RUSELL G, 1993, ARCH DIS CHILD, V69, P694; SAMBROOK P, 1990, J BONE MINER RES, V5, P1211; TOOGOOD JH, 1995, J ALLERGY CLIN IMMUN, V96, P157, DOI 10.1016/S0091-6749(95)70003-X; Truscott JG, 1997, BRIT J RADIOL, V70, P1245; Walsh LJ, 1999, THORAX, V54, P296; WASNICH R, 1993, AM J MED, V95, pS6, DOI 10.1016/0002-9343(93)90374-X; Wisniewski AF, 1997, THORAX, V52, P853; WOLFF AH, 1991, ANN ALLERGY, V67, P117	30	204	212	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 22	2000	355	9213					1399	1403		10.1016/S0140-6736(00)02138-3		5	Medicine, General & Internal	General & Internal Medicine	310LN	WOS:000086829800010	10791523	
J	Lambrecht, BN; Hammad, H				Lambrecht, Bart N.; Hammad, Hamida			Biology of Lung Dendritic Cells at the Origin of Asthma	IMMUNITY			English	Review							HOUSE-DUST MITE; ALLERGIC AIRWAY INFLAMMATION; CD4(+) T-CELLS; RESPIRATORY SYNCYTIAL VIRUS; ANTIGEN-PRESENTING CELLS; BLOOD MONOCYTE SUBSETS; EPITHELIAL-CELLS; IMMUNE-RESPONSES; INHALED ANTIGEN; TH2 RESPONSES	Dendritic cells (DCs) initiate and maintain adaptive T helper 2 (Th2) cell responses to inhaled allergens in asthma. Various functions like antigen uptake, migration to the draining LNs, and induction of tolerance and adaptive immunity are not equally shared by all subsets of DCs, adding considerable complexity to understanding the immunology of allergic sensitization. Whereas the epithelium was initially considered solely as a physical barrier, it is now seen as a central player in controlling the function of lung DCs through release of Th2 cell-promoting cytokines. Although DCs are sufficient and necessary for induction of Th2 cell responses to many antigens, some allergens might require antigen presentation by basophils. Clinically relevant allergens, as well as environmental and genetic risk factors for allergy and asthma, often interfere directly or indirectly with the innate immune functions of airway epithelial cells, basophils, and DCs. This review summarizes the recent progress on our understanding how DCs control Th2 cell immunity in the lung.	[Lambrecht, Bart N.; Hammad, Hamida] Ghent Univ Hosp, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium; [Lambrecht, Bart N.] Erasmus Univ, Med Ctr, Dept Pulm Med, NL-3015 GE Rotterdam, Netherlands	Lambrecht, BN (reprint author), Ghent Univ Hosp, Dept Resp Dis, Lab Immunoregulat & Mucosal Immunol, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Barrett NA, 2009, J IMMUNOL, V182, P1119; Beaty SR, 2007, J IMMUNOL, V178, P1882; Bleck B, 2006, J IMMUNOL, V176, P7431; Cates EC, 2004, J IMMUNOL, V173, P6384; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JC1200216109; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; del Rio ML, 2007, J IMMUNOL, V178, P6861; Dodge IL, 2003, J IMMUNOL, V170, P4457; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fainaru O, 2005, P NATL ACAD SCI USA, V102, P10598, DOI 10.1073/pnas.0504787102; GeurtsvanKessel C H, 2008, Mucosal Immunol, V1, P442, DOI 10.1038/mi.2008.39; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; Gilles S, 2009, J IMMUNOL, V182, P6653, DOI 10.4049/jimmunol.0802613; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grohmann U, 2007, NAT MED, V13, P579, DOI 10.1038/nm1563; Hammad H, 2003, EUR CYTOKINE NETW, V14, P219; Hammad H, 2004, AM J PATHOL, V164, P263, DOI 10.1016/S0002-9440(10)63116-1; Hammad H, 2003, J IMMUNOL, V171, P3936; Hammad H, 2002, J IMMUNOL, V169, P1524; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; Headley MB, 2009, J IMMUNOL, V182, P1641; HOLT PG, 1994, J IMMUNOL, V153, P256; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jahnsen FL, 2006, J IMMUNOL, V177, P5861; Jakubzick C, 2008, J IMMUNOL, V180, P3019; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; KleinJan A, 2006, J ALLERGY CLIN IMMUN, V118, P1117, DOI 10.1016/j.jaci.2006.05.030; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kool M, 2008, J IMMUNOL, V181, P3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Kuipers H, 2009, J LEUKOCYTE BIOL, V85, P64, DOI 10.1189/jlb.0807519; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Landsman L, 2007, J IMMUNOL, V178, P2000; Lewkowich IP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003879; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Li Q, 2008, EUR J IMMUNOL, V38, P2751, DOI 10.1002/eji.200838542; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Matsubara S, 2006, AM J RESP CELL MOL, V34, P426, DOI 10.1165/rcmb.2005-0298OC; Maurer D, 1998, J IMMUNOL, V161, P2731; Medoff BD, 2009, J IMMUNOL, V182, P623; Miyata M, 2009, EUR J IMMUNOL, V39, P3078, DOI 10.1002/eji.200939302; Monick MM, 2003, J BIOL CHEM, V278, P53035, DOI 10.1074/jbc.M308093200; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Naito T, 2008, AM J RESP CELL MOL, V38, P161, DOI 10.1165/rcmb.2007-0237OC; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Nolte MA, 2007, J EXP MED, V204, P1487, DOI 10.1084/jem.20070325; Oriss TB, 2005, J IMMUNOL, V174, P854; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rate A, 2009, J IMMUNOL, V182, P72; RAYMOND M, 2009, J ALLERGY C IN PRESS; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Robays LJ, 2007, J IMMUNOL, V178, P5305; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SERTL K, 1986, J EXP MED, V163, P436, DOI 10.1084/jem.163.2.436; Shao ZF, 2009, J ALLERGY CLIN IMMUN, V123, P917, DOI 10.1016/j.jaci.2009.01.052; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Smits HH, 2009, MUCOSAL IMMUNOL, V2, P331, DOI 10.1038/mi.2009.16; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Sokolovska A, 2007, VACCINE, V25, P4575, DOI 10.1016/j.vaccine.2007.03.045; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Traves SL, 2008, CURR MOL MED, V8, P416, DOI 10.2174/156652408785160998; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Veres TZ, 2009, AM J PATHOL, V174, P808, DOI 10.2353/ajpath.2009.080800; Vermaelen K, 2004, CYTOM PART A, V61A, P170, DOI 10.1002/cyto.a.20064; Vermaelen KY, 2001, J EXP MED, V193, P51; von Garnier C, 2005, J IMMUNOL, V175, P1609; Walzer T, 2005, J ALLERGY CLIN IMMUN, V115, P192, DOI 10.1016/j.jaci.2004.08.046; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Webb DC, 2007, J IMMUNOL, V178, P219; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xanthou G, 2007, NAT MED, V13, P570, DOI 10.1038/nm1580; Xu H, 2008, P NATL ACAD SCI USA, V105, P6690, DOI 10.1073/pnas.0708809105; Yang D, 2008, J EXP MED, V205, P79, DOI 10.1084/jem.20062027; Yerkovich ST, 2009, J ALLERGY CLIN IMMUN, V123, P209, DOI 10.1016/j.jaci.2008.09.009; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhang X, 2009, J IMMUNOL, V182, P5123, DOI 10.4049/jimmunol.0804276; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou WS, 2007, J IMMUNOL, V178, P702	121	202	205	0	17	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613			IMMUNITY	Immunity	SEP 18	2009	31	3					412	424		10.1016/j.immuni.2009.08.008		13	Immunology	Immunology	503IA	WOS:000270525900007	19766084	
J	Gilliland, FD; Li, YF; Dubeau, L; Berhane, K; Avol, E; McConnell, R; Gauderman, WJ; Peters, JM				Gilliland, FD; Li, YF; Dubeau, L; Berhane, K; Avol, E; McConnell, R; Gauderman, WJ; Peters, JM			Effects of glutathione S-transferase M1, maternal smoking during pregnancy, and environmental tobacco smoke on asthma and wheezing in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						In utero exposure; tobacco smoke; GSTM1; asthma; wheeze; children	PARENTAL SMOKING; CHILDHOOD ASTHMA; LUNG-FUNCTION; OXIDATIVE STRESS; FAMILY HISTORY; RESPIRATORY HEALTH; AIR-POLLUTION; RISK-FACTORS; PREVALENCE; EXPOSURE	The rise in childhood asthma prevalence suggests a role for environmental factors in the etiology of this evolving epidemic; however, genetics also influence the occurrence of asthma. Glutathione S-transferase (GST) M1 may play a role in asthma and wheezing occurrence among those exposed to tobacco smoke, as it functions in pathways involved in asthma pathogenesis such as xenobiotic metabolism and antioxidant defenses. Effects of GSTM1 genotype, maternal smoking during pregnancy, and childhood environmental tobacco smoke (ETS) exposure on asthma and wheezing were investigated in 2,950 children enrolled in 4th, 7th, and 10th grade classrooms in 12 Southern California communities. The effects of in utero exposure to maternal smoking on asthma and wheezing occurrence were largely restricted to children with GSTM1 null genotype. Among GSTM1 null children, in utero exposure was associated with increased prevalence of early onset asthma (odds ratio [OR] 1.6, 95% confidence interval [CI] 1.0-2.5), asthma with current symptoms (OR 1.7, 95% Cl 1.1-2.8), persistent asthma (OR 1.6, 95% Cl 1.1-2.4), lifetime history of wheezing (OR 1.8, 95% Cl 1.3-2.5), wheezing with exercise (OR 2.1, 95% Cl 1.3-3.3), wheezing requiring medication (OR 2.2, 95% Cl 1.4-3.4), and emergency room visits in the past year (OR 3.7, 95% Cl 1.9-7.3). Among children with GSTM1 (+) genotype, in utero exposure was not associated with asthma or wheezing. Our findings indicate that there are important long-term effects of in utero exposure in a genetically susceptible group of children.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.		LI, YU-FEN/F-4770-2010; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NHLBI NIH HHS [5R01 HL 61768]; NIEHS NIH HHS [1P50 ES 09581, 2P30 ES 07048]		ANDERSON HR, 1994, BRIT MED J, V308, P1600; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; California Environmental Protection Agency (Cal EPA) Office of Environmental Health Hazard Assessment, 1997, HLTH EFF EXP ENV TOB; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; *COMM ASS ASTHM IN, 2000, CLEAN AIR ASTHM IND; Cook DG, 1999, THORAX, V54, P357; Cook DG, 1997, THORAX, V52, P1081; Cook DG, 1998, THORAX, V53, P295; Cook DG, 1998, THORAX, V53, P884; Cookson WOC, 2000, HUM MOL GENET, V9, P2359, DOI 10.1093/hmg/9.16.2359; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Ebrahim SH, 2000, JAMA-J AM MED ASSOC, V283, P361, DOI 10.1001/jama.283.3.361; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Fryer A A, 1999, IARC Sci Publ, P303; Geisler SA, 2001, AM J EPIDEMIOL, V154, P95, DOI 10.1093/aje/154.2.95; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; Howard DJ, 1998, CANCER EPIDEM BIOMAR, V7, P981; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; Ivaschenko T. E., 2001, Genetika, V37, P107; Joad JP, 1999, TOXICOL APPL PHARM, V155, P253, DOI 10.1006/taap.1998.8612; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Koyama H, 1998, THORAX, V53, pS10; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Mates JM, 1999, CLIN BIOCHEM, V32, P595, DOI 10.1016/S0009-9120(99)00075-2; MENZEL DB, 1992, ANN NY ACAD SCI, V669, P141; Nanavaty U, 2001, AM J MED SCI, V321, P11, DOI 10.1097/00000441-200101000-00003; Onaran I, 2001, TOXICOLOGY, V157, P195, DOI 10.1016/S0300-483X(00)00358-9; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; RAPPAPORT S, 1998, MMWR-MORBID MORTAL W, V47, P1022; Samet JM, 1995, TOXICOL LETT, V82-3, P33, DOI 10.1016/0378-4274(95)03544-3; Sandford AJ, 2000, AM J RESP CRIT CARE, V161, pS202; *SASS I, 2000, SAS STAT US GUID VER; Schunemann HJ, 1997, AM J EPIDEMIOL, V146, P939; Stead LF, 2006, REP SCI COMM TOB HLT, DOI 10.1002/14651858.CD002850.pub2; Shields PG, 2000, J CLIN ONCOL, V18, P2309; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1998, THORAX, V53, P204; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; Tager IB, 1998, AM J RESP CRIT CARE, V158, P349; [Anonymous], 1986, HLTH CONS INV SMOK R; Wacholder S, 2000, J NATL CANCER I, V92, P1151, DOI 10.1093/jnci/92.14.1151; Weiss ST, 1999, CLIN EXP ALLERGY, V29, P96, DOI 10.1046/j.1365-2222.1999.00017.x; World Health Organization, 1999, INT CONS ENV TOB SMO; Whyatt RM, 2000, CANCER EPIDEM BIOMAR, V9, P207; Whyatt RM, 2001, CANCER EPIDEM BIOMAR, V10, P581; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	54	202	207	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2002	166	4					457	463		10.1164/rccm.2112064		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	584BE	WOS:000177446700008	12186820	
J	Kogevinas, M; Zock, JP; Jarvis, D; Kromhout, H; Lillienberg, L; Plana, E; Radon, K; Toren, K; Alliksoo, A; Benke, G; Blanc, PD; Dahlman-Hoglund, A; D'Errico, A; Hery, M; Kennedy, S; Kunzli, N; Leynaert, B; Mirabelli, MC; Muniozguren, N; Norback, D; Olivieri, M; Payo, F; Villani, S; van Sprundel, M; Urrutia, I; Wieslander, G; Sunyer, J; Anto, JM				Kogevinas, Manolis; Zock, Jan-Paul; Jarvis, Debbie; Kromhout, Hans; Lillienberg, Linnea; Plana, Estel; Radon, Katja; Toren, Kjell; Alliksoo, Ada; Benke, Geza; Blanc, Paul D.; Dahlman-Hoglund, Anna; D'Errico, Angelo; Hery, Michel; Kennedy, Susan; Kunzli, Nino; Leynaert, Benedicte; Mirabelli, Maria C.; Muniozguren, Nerea; Norback, Dan; Olivieri, Mario; Payo, Felix; Villani, Simona; van Sprundel, Marc; Urrutia, Isabel; Wieslander, Gundla; Sunyer, Jordi; Anto, Josep M.			Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II)	LANCET			English	Article							OCCUPATIONAL RESPIRATORY-DISEASES; AIRWAYS DYSFUNCTION SYNDROME; WORK-RELATED ASTHMA; REPORTED INCIDENCE; EPIDEMIOLOGY; SURVEILLANCE; LATEX	Background The role of exposure to substances in the workplace in new-onset asthma is not well characterised in population-based studies. We therefore aimed to estimate the relative and attributable risks of new-onset asthma in relation to occupations, work-related exposures, and inhalation accidents. Methods We studied prospectively 6837 participants from 13 countries who previously took part in the European Community Respiratory Health Survey (1990-95) and did not report respiratory symptoms or a history of asthma at the time of the first study. Asthma was assessed by methacholine challenge test and by questionnaire data on asthma symptoms. Exposures were defined by high-risk occupations, an asthma-specific job exposure matrix with additional expert judgment, and through self-report of acute inhalation events. Relative risks for new onset asthma were calculated with log-binomial models adjusted for age, sex, smoking, and study Centre. Findings A significant excess asthma risk was seen after exposure to substances known to cause occupational asthma (Relative risk=1.6, 95% CI 1.1-2.3, p=0.017). Risks were highest for asthma defined by bronchial hyper-reactivity in addition to symptoms (2.4,1.3-4.6, p=0.008). Of common occupations, a significant excess risk of asthma was seen for nursing (2.2,1.3-4.0, p=0.007). Asthma risk was also increased in participants who reported an acute symptomatic inhalation event such as fire, mixing cleaning products, or chemical spills (RR=3.3, 95% CI 1.0-11.1, p=0.051). The population-attributable risk for adult asthma due to occupational exposures ranged from 10% to 25%, equivalent to an incidence of new-onset occupational asthma of 250-300 cases per million people per year. Interpretation Occupational exposures account for a substantial proportion of adult asthma incidence. The increased risk of asthma after inhalation accidents suggests that workers who have such accidents should be monitored closely.	Municipal Inst Med Res, Ctr Res Environm Epidemiol, Barcelona 08003, Spain; Univ Crete, Sch Med, Iraklion, Greece; Univ London Imperial Coll Sci Technol & Med, Resp Epidmeiol & Publ Hlth Grp, Natl Heart & Lung Inst, London, England; Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands; Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden; Univ Munich, Inst Occupat & Environm Med, Unit Occupat & Environm Epidemiol & NetTeaching, Munich, Germany; Tartu Univ Clin, Lung Clin, Tartu, Estonia; Monash Univ, Dept Epidemiol & Prevent Med, Clayton, Vic 3168, Australia; Univ Calif San Francisco, Dept Med, Div Environm & Occupat Med, San Francisco, CA USA; Serv Reg Epidemiol, Turin, Italy; Inst Natl Rech & Secur, F-54501 Vandoeuvre Les Nancy, France; Univ British Columbia, Sch Occupat & Environm Hyg, Vancouver, BC V5Z 1M9, Canada; Univ Paris 07, INSERM, French Inst Hlth & Med Res, Unit Epidemiol 700, Paris, France; Publ Hlth Dept Bizkaia, Epidemiol Unit, Galolatao, Spain; Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; Univ Verona, Dept Med & Publ Hlth, Unit Occupat Med, I-37100 Verona, Italy; Natl Inst Silicosis, Oviedo, Spain; Univ Pavia, Dept Hlth Sci, Sect Epidemiol & Med Stat, I-27100 Pavia, Italy; Univ Antwerp, Dept Epidemiol & Community Hlth, Antwerp, Belgium; Pompeu Fabra Univ, Barcelona, Spain	Kogevinas, M (reprint author), Municipal Inst Med Res, Ctr Res Environm Epidemiol, Barcelona 08003, Spain.	kogevinas@imim.es	; Kromhout, Hans/A-9159-2008; Jarvis, Deborah/E-6494-2011; Kunzli, Nino/F-7195-2014; Sanchez-Ramos, Jose Luis/G-1259-2011; Ciccone, Giovannino/K-3136-2016; Burgos, Felip/E-5734-2015; Kogevinas, Manolis/C-3918-2017; Sunyer, J/G-6909-2014	Mirabelli, Maria/0000-0002-3540-0085; ROMANO, Canzio/0000-0001-5294-9793; Kunzli, Nino/0000-0001-8360-080X; Sanchez-Ramos, Jose Luis/0000-0001-7187-9989; Ciccone, Giovannino/0000-0001-7644-9574; Burgos, Felip/0000-0002-4938-4581; Sunyer, J/0000-0002-2602-4110; Abramson, Michael/0000-0002-9954-0538; Basagana, Xavier/0000-0002-8457-1489; Corsico, Angelo Guido/0000-0002-8716-4694; Rolla, Giovanni/0000-0001-5997-7172; Dalmasso, Paola/0000-0001-6081-6966; /0000-0003-2517-6515	NCRR NIH HHS [2 S07RR05521-28]; NHLBI NIH HHS [1 R01 HL62633-01, R01 HL62633-01]; NIEHS NIH HHS [5P30 ES07048]		Ameille J, 2003, OCCUP ENVIRON MED, V60, P136, DOI 10.1136/oem.60.2.136; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Bernstein DI, 2006, ASTHMA WORKPLACE; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CONTRERAS GR, 1994, OCCUP ENVIRON MED, V51, P710; Elder D, 2004, OCCUP MED-OXFORD, V54, P395, DOI 10.1093/occmed/kqh050; Garabrant DH, 2002, J ALLERGY CLIN IMMUN, V110, pS82, DOI 10.1067/mai.2002.124967; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; International Labour Organization, 1991, INT STAND CLASS OCC; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Orriols R, 2006, OCCUP ENVIRON MED, V63, P255, DOI 10.1136/oem.2005.022525; Pekkanen J, 2006, J CLIN EPIDEMIOL, V59, P281, DOI 10.1016/j.jclinepi.2005.07.013; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Toren K, 1996, OCCUP ENVIRON MED, V53, P757; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; Vandenplas O, 2005, REV MAL RESPIR, V22, P421, DOI 10.1019/200530010; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702	27	201	201	2	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL-AUG	2007	370	9584					336	341		10.1016/S0140-6736(07)61164-7		6	Medicine, General & Internal	General & Internal Medicine	195QG	WOS:000248426100031	17662882	
J	Jahnsen, FL; Lund-Johansen, F; Dunne, JF; Farkas, L; Haye, R; Brandtzaeg, P				Jahnsen, FL; Lund-Johansen, F; Dunne, JF; Farkas, L; Haye, R; Brandtzaeg, P			Experimentally induced recruitment of plasmacytoid (CD123(high)) dendritic cells in human nasal allergy	JOURNAL OF IMMUNOLOGY			English	Article							ENDOTHELIAL ADHESION MOLECULES; T-CELLS; LYMPH-NODE; HUMAN BLOOD; EXPRESSION; INTERFERON; MONOCYTES; ORIGIN; MXA; LYMPHADENITIS	Recent evidence suggests that the previously enigmatic cell type designated plasmacytoid monocytes can function as dendritic cells and contribute substantially to both innate and adaptive immunity. This cell type has previously been described only in bone marrow, blood, and organized lymphoid tissue, but not at effector sites with direct Ag exposure such as the mucosae, Plasmacytoid dendritic cells (P-DCs) matured in vitro can induce T cells to produce allergy-promoting Th2 cytokines; therefore, their possible occurrence in nasal mucosa during experimentally elicited allergic rhinitis was examined. Patients with silent nasal allergy were challenged topically with relevant allergen daily for 7 days. Biopsy specimens as well as blood samples were obtained before and during such provocation, and P-DCs were identified by their high expression of CD123 (IL3R alpha-chain), together with CD45RA, Our results showed that P-DCs were present in low and variable numbers in normal nasal mucosa but increased dramatically during the allergic reaction. This accumulation concurred with the expression of the L-selectin ligand peripheral lymph node addressin on the mucosal vascular endothelium. The latter observation was particularly interesting in view of the high levels of L-selectin on circulating P-DC precursors and of previous reports suggesting that these cells ran enter organized lymphoid tissue via high endothelial venules (which express peripheral lymph node addressin constitutively). Together, our findings suggested that P-DCs are involved in the triggering of airway allergy and that they are directed to allergic lesions by adhesion molecules that normally mediate leukocyte extravasation in organized lymphoid tissue.	Univ Oslo, Rikshosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway; Univ Oslo, Rikshosp, Dept Ear Nose & Throat, N-0027 Oslo, Norway; Becton Dickinson Immunocytometry Syst, San Jose, CA 95131 USA	Brandtzaeg, P (reprint author), Univ Oslo, Rikshosp, Inst Pathol, Lab Immunohistochem & Immunopathol, N-0027 Oslo, Norway.						Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BEISKE K, 1986, J PATHOL, V150, P247, DOI 10.1002/path.1711500404; Berg EL, 1998, AM J PATHOL, V152, P469; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Cella M, 1999, NAT MED, V5, P919; Denburg JA, 1999, IMMUNOL TODAY, V20, P111, DOI 10.1016/S0167-5699(98)01423-6; FACCHETTI F, 1989, J PATHOL, V158, P57, DOI 10.1002/path.1711580112; FACCHETTI F, 1989, HUM PATHOL, V20, P588, DOI 10.1016/0046-8177(89)90248-7; FACCHETTI F, 1989, AM J CLIN PATHOL, V92, P42; FACCHETTI F, 1988, AM J PATHOL, V133, P15; FACCHETTI F, 1988, HUM PATHOL, V19, P1085, DOI 10.1016/S0046-8177(88)80091-1; FAH J, 1995, J HISTOCHEM CYTOCHEM, V43, P47; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1111/j.1365-2222.1996.tb00594.x; Grouard G, 1997, J EXP MED, V185, P1101, DOI 10.1084/jem.185.6.1101; HUITFELDT HS, 1985, HISTOCHEMISTRY, V83, P381, DOI 10.1007/BF00509196; Ito T, 1999, J IMMUNOL, V163, P1409; Jahnsen FL, 1998, AM J RESP CELL MOL, V18, P392; Jahnsen FL, 1999, ALLERGY, V54, P37, DOI 10.1111/j.1398-9995.1999.tb04405.x; Kohrgruber N, 1999, J IMMUNOL, V163, P3250; Lechleitner S, 1999, J INVEST DERMATOL, V113, P410, DOI 10.1046/j.1523-1747.1999.00696.x; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; LENNERT KARL, 1958, ACTA HAEMATOL, V19, P99; MICHIE SA, 1993, AM J PATHOL, V143, P1688; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393; MULLERHERMELINK HK, 1983, AM J SURG PATHOL, V7, P849, DOI 10.1097/00000478-198307080-00013; Olweus J, 1997, P NATL ACAD SCI USA, V94, P12551, DOI 10.1073/pnas.94.23.12551; PICKER LJ, 1994, CURR OPIN IMMUNOL, V6, P394, DOI 10.1016/0952-7915(94)90118-X; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Ronni T, 1997, J IMMUNOL, V158, P2363; ROOS D, 1970, BIOCHIM BIOPHYS ACTA, V222, P565, DOI 10.1016/0304-4165(70)90182-0; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Siegal FP, 1999, SCIENCE, V284, P1835, DOI 10.1126/science.284.5421.1835; SIMON A, 1991, J VIROL, V65, P968; Strobl H, 1998, J IMMUNOL, V161, P740; Svensson H, 1996, SCAND J IMMUNOL, V44, P164, DOI 10.1046/j.1365-3083.1996.d01-289.x; YAMADA T, 1994, NEUROSCI LETT, V181, P61, DOI 10.1016/0304-3940(94)90560-6	36	201	207	0	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	OCT 1	2000	165	7					4062	4068				7	Immunology	Immunology	357AZ	WOS:000089477500066	11034417	
J	Karjalainen, EM; Laitinen, A; Sue-Chu, M; Altraja, A; Bjermer, L; Laitinen, LA				Karjalainen, EM; Laitinen, A; Sue-Chu, M; Altraja, A; Bjermer, L; Laitinen, LA			Evidence of airway inflammation and remodeling in ski athletes with and without bronchial hyperresponsiveness to methacholine	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							CROSS-COUNTRY SKIERS; INHALED HISTAMINE; ASTHMA; RESPONSIVENESS; LYMPHOCYTES; MACROPHAGES; EOSINOPHILS; PREVALENCE; SYMPTOMS; TENASCIN	Asthma-like symptoms, methacholine hyperresponsiveness, and use of asthma medication are prevalent in elite cross-country skiers. We quantitated mucosal inflammatory cell infiltration and tenascin expression in the subepithelial basement membrane in endobronchial biopsy specimens of the proximal airways from 40 elite, competitive skiers (mean: 17.5; range: 16 to 20 yr) without a diagnosis of asthma, in 12 subjects with mild asthma, and in 12 healthy controls, through immunohistochemistry and indirect immunofluorescence, respectively. All of the subjects were nonsmokers. T-lymphocyte, macrophage, and eosinophil counts were, respectively, greater by 43-fold (p < 0.001), 26-fold (p < 0.001), and twofold (p < 0.001) in skiers, and by 70-fold (p < 0.001), 63-fold (p < 0.001), and eightfold (p < 0.001) in asthmatic subjects than in controls. In skiers, neutrophil counts were more than twofold greater than in asthmatic subjects, and mast cell counts were not significantly different than in controls. Tenascin expression (as measured through the thickness of the tenascin-specific immunoreactivity band in the basement membrane) was increased in skiers (median: 6.7 mu m; interquartile range [IQR]: 5.3 to 8.5 mu m, p < 0.001) and asthmatic subjects (mean: 8.8 mu m; IQR: 7.2 to 10.8 mu m, p < 0.001) compared with controls (mean: 0.8 mu m; IQR: 0 to 3.1 mu m) and did not correlate with inflammatory cell counts. Inflammatory changes were present irrespective of asthmalike symptoms, hyperresponsiveness, or atopy. Prolonged repeated exposure of the airways to inadequately conditioned air may induce inflammation and remodeling in competitive skiers.	Univ Helsinki, Cent Hosp, Dept Med, FIN-00290 Helsinki, Finland; Univ Helsinki, Dept Anat, Inst Biomed, Helsinki, Finland; Univ Trondheim Hosp, Dept Lung Med, N-7006 Trondheim, Norway; Univ Tartu, Dept Pulm Med, EE-50090 Tartu, Estonia	Laitinen, LA (reprint author), Univ Helsinki, Cent Hosp, Dept Med, Haartmaninkatu 4, FIN-00290 Helsinki, Finland.						Altraja A, 1996, J ALLERGY CLIN IMMUN, V98, pS58, DOI 10.1016/S0091-6749(96)80130-8; AMIRAV I, 1989, AM REV RESPIR DIS, V140, P1416; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500; Blecker E.R., 1991, J ALLERGY CLIN IMMUN, V88, P808; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P128; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LARSSON K, 1993, BRIT MED J, V307, P1326; MACKIE EJ, 1988, J CELL BIOL, V107, P2757, DOI 10.1083/jcb.107.6.2757; MCFADDEN ER, 1985, J APPL PHYSIOL, V58, P564; OMORI C, 1995, J APPL PHYSIOL, V78, P1043; POWER C, 1993, THORAX, V48, P1125, DOI 10.1136/thx.48.11.1125; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; Richmond I, 1996, AM J RESP CRIT CARE, V153, P899; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; TIKKANEN HO, 1994, BRIT MED J, V309, P1087	22	201	205	0	8	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN	2000	161	6					2086	2091				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	325KV	WOS:000087675500054	10852791	
J	Sicherer, SH; Sampson, HA				Sicherer, Scott H.; Sampson, Hugh A.			Peanut allergy: Emerging concepts and approaches for an apparent epidemic	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						food allergy; food hypersensitivity; peanut allergy; food allergens; anaphylaxis; treatment	TREE NUT ALLERGY; CONTROLLED FOOD CHALLENGES; COWS MILK ALLERGY; SKIN PRICK TESTS; MURINE MODEL; DOUBLE-BLIND; IN-VITRO; ANAPHYLACTIC REACTIONS; IMMUNE-RESPONSE; ORAL TOLERANCE	Peanut allergy is typically lifelong, often severe, and potentially fatal. Because reactions can occur from small amounts, the allergy presents patients with significant obstacles to avoid allergic reactions. In North America and the United Kingdom, prevalence rates among schoolchildren are now in excess of 1%, framing an increasing public health concern and raising research questions about environmental, immunologic, and genetic factors that may influence outcomes of peanut allergy. This review focuses on recent observations that continue to question the influences of maternal and infant diet on outcomes of peanut allergy, and explore how peanut may be uniquely suited to induce an allergic response. We highlight studies that affect current diagnosis, management, and the nature of advice that can be provided to patients, including the utility of diagnostic tests. doses that elicit reactions, characteristics of reactions from exposure, issues of cross-reactivity, concerns about peanut contamination of manufactured goods, and the natural course of the allergy. Clinical, molecular, and immunologic advances are reviewed, highlighting research discoveries that influence strategies for improved diagnosis, prevention, and treatment. Among the therapeutic strategies reviewed are sublingual and oral immunotherapy, anti-IgE, Chinese herbal medicine, and vaccine strategies.	CUNY Mt Sinai Sch Med, Div Allergy Immunol, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY 10029 USA	Sicherer, SH (reprint author), CUNY Mt Sinai Sch Med, Div Allergy Immunol, Dept Pediat, Elliot & Roslyn Jaffe Food Allergy Inst, Box 1198,One Gustave L Levy Pl, New York, NY 10029 USA.	scott.sicherer@mssm.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			AMOLD DM, 2007, ARCH INTERN MED, V167, P853; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; AUDIBERT F, 1975, CR ACAD SCI D NAT, V280, P1629; Baker SS, 2000, PEDIATRICS, V106, P346; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Bashir MEH, 2004, J IMMUNOL, V172, P6978; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, pS288, DOI 10.1016/S0091-6749(02)82015-2; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Boyle RJ, 2006, ALLERGY, V61, P1423, DOI 10.1111/j.1398-9995.2006.01113.x; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Chehade M, 2005, J ALLERGY CLIN IMMUN, V115, P3, DOI 10.1016/j.jaci.2004.11.008; Chung SY, 2003, J AGR FOOD CHEM, V51, P4273, DOI 10.1021/jf02121d; Chung SY, 1999, J AGR FOOD CHEM, V47, P5227, DOI 10.1021/jf9904416; Clark AT, 2005, PEDIATR ALLERGY IMMU, V16, P507, DOI 10.1111/j.1399-3038.2005.00310.x; Cohen BL, 2004, J ALLERGY CLIN IMMUN, V114, P1159, DOI 10.1016/j.jaci.2004.08.007; Creticos PS, 2004, IMMUNOL ALLERGY CLIN, V24, P569, DOI 10.1016/j.iac.2004.06.012; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; de Jonge JD, 2007, METHODS, V41, P99, DOI 10.1016/j.ymeth.2006.09.004; de Leon MP, 2007, MOL IMMUNOL, V44, P463, DOI 10.1016/j.molimm.2006.02.016; de Leon Maria P., 2007, Expert Reviews in Molecular Medicine, V9, P1, DOI 10.1017/S1462399407000208; Dean T, 2007, J HUM NUTR DIET, V20, P95, DOI 10.1111/j.1365-277X.2007.00751.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fleischer DM, 2004, J ALLERGY CLIN IMMUN, V114, P1195, DOI 10.1016/j.jaci.2004.08.035; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; Flinterman AE, 2006, J ALLERGY CLIN IMMUN, V117, P448, DOI 10.1016/j.jaci.2005.11.035; Flinterman AE, 2006, ALLERGY, V61, P370, DOI 10.1111/j.1398-9995.2006.01018.x; Grimshaw KEC, 2003, CLIN EXP ALLERGY, V33, P1581, DOI 10.1046/j.1365-2222.2003.01795.x; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Guarneri F, 2005, INT ARCH ALLERGY IMM, V138, P273, DOI 10.1159/000088864; Hefle SL, 2007, J ALLERGY CLIN IMMUN, V120, P171, DOI 10.1016/j.jaci.2007.04.013; Hinds MJ, 1997, PLANT FOOD HUM NUTR, V50, P269, DOI 10.1007/BF02436073; Ho MHK, 2006, J ALLERGY CLIN IMMUN, V117, P1506, DOI 10.1016/j.jaci.2006.03.029; Hourihane JO, 2005, CLIN EXP ALLERGY, V35, P1227, DOI 10.1111/j.1365-2222.2005.02312.x; Hourihane JO, 2005, ALLERGY, V60, P536, DOI 10.1111/j.1398-9995.2005.00752.x; Hourihane JO, 1998, BRIT MED J, V316, P1271; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Klemola T, 2005, PEDIATR ALLERGY IMMU, V16, P641, DOI 10.1111/j.1399-3038.2005.00326.x; Koppelman SJ, 2003, ALLERGY, V58, P1144, DOI 10.1034/j.1398-9995.2003.00259.x; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; Kopper RA, 2005, INT ARCH ALLERGY IMM, V136, P16, DOI 10.1159/000082580; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 1996, BRIT MED J, V313, P300; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Leung TF, 2002, J ASTHMA, V39, P523, DOI 10.1081/JAS-120004922; Levy Y, 2003, ALLERGY, V58, P1206, DOI 10.1046/j.1398-9995.2003.00307.x; Lewis SA, 2005, CLIN EXP ALLERGY, V35, P767, DOI 10.1111/j.1365-2222.2005.02252.x; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Li XM, 2003, J ALLERGY CLIN IMMUN, V112, P159, DOI 10.1067/mai.2003.1622; Li XM, 2001, J ALLERGY CLIN IMMUN, V108, P639, DOI 10.1067/mai.2001.118787; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; Mansfield L, 2006, ANN ALLERG ASTHMA IM, V97, P266; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Meyer S, 2005, J BIOL CHEM, V280, P37349, DOI 10.1074/jbc.M507100200; Mittag D, 2004, J ALLERGY CLIN IMMUN, V114, P1410, DOI 10.1016/j.jaci.2004.09.014; Mondoulet L, 2005, J AGR FOOD CHEM, V53, P4547, DOI 10.1021/jf050091p; Moneret-Vautrin DA, 1999, J ALLERGY CLIN IMMUN, V104, P883; MORISSET M, 2005, ALLERG IMMUNOL, V37, P54; Mortz CG, 2005, PEDIATR ALLERGY IMMU, V16, P501, DOI 10.1111/j.1399-3038.2005.00302.x; Mouecoucou J, 2004, CLIN EXP ALLERGY, V34, P1429, DOI 10.1111/j.1365-2222.2004.02022.x; Nash SD, 2007, J ALLERGY CLIN IMMUN, V119, pS158, DOI 10.1016/j.jaci.2006.11.558; Nguyen MD, 2001, ALLERGY, V56, P127, DOI 10.1034/j.1398-9995.2001.00937.x; Nolan RC, 2007, PEDIATR ALLERGY IMMU, V18, P224, DOI 10.1111/j.1399-3038.2006.00519.x; Nowak-Wegrzyn A, 2004, IMMUNOL ALLERGY CLIN, V24, P705, DOI 10.1016/j.iac.2004.06.005; Omata N, 2005, J ALLERGY CLIN IMMUN, V115, P822, DOI 10.1016/j.jaci.2004.12.1121; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; Osterballe M, 2005, PEDIATR ALLERGY IMMU, V16, P567, DOI 10.1111/j.1399-3038.2005.00251.x; Palmer GW, 2005, CLIN IMMUNOL, V115, P302, DOI 10.1016/j.clim.2005.02.011; PARTIARCA G, 2006, DIGEST DIS SCI, V51, P471; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; Peeters KABM, 2007, CLIN EXP ALLERGY, V37, P108, DOI 10.1111/j.1365-2222.2006.02628.x; Peeters KABM, 2007, J ALLERGY CLIN IMMUN, V120, P647, DOI 10.1016/j.jaci.2007.05.032; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Pomes A, 2006, CLIN EXP ALLERGY, V36, P824, DOI 10.1111/j.1365-2222.2006.02490.x; Pons L, 2004, J ALLERGY CLIN IMMUN, V114, P915, DOI 10.1016/j.jaci.2004.06.049; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Qu C, 2007, CLIN EXP ALLERGY, V37, P846, DOI 10.1111/j.1365-2222.2007.02718.x; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Restani P, 2005, ANN ALLERG ASTHMA IM, V94, P262; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Ronteltap A, 2004, ALLERGY, V59, P457, DOI 10.1046/j.1398-9995.2003.00329.x; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Roy K, 1999, NAT MED, V5, P387; Sampson HA, 2007, J ALLERGY CLIN IMMUN, V119, pS117, DOI 10.1016/j.jaci.2006.11.440; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Santadusit Sathit, 2005, J Med Assoc Thai, V88 Suppl 8, pS27; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P717, DOI 10.1016/j.jaci.2007.07.027; Shek LPC, 2006, CURR OPIN ALLERGY CL, V6, P197, DOI 10.1097/01.all.0000225160.52650.17; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; Shreffler WG, 2006, J IMMUNOL, V177, P3677; Shreffler WG, 2006, ANN ALLERG ASTHMA IM, V96, P865; Shreffler WG, 2005, J ALLERGY CLIN IMMUN, V116, P893, DOI 10.1016/j.jaci.2005.06.033; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, P1419, DOI 10.1016/j.jaci.2006.01.051; Sicherer SH, 2000, CURR OPIN PEDIATR, V12, P567, DOI 10.1097/00008480-200012000-00010; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V106, P53, DOI 10.1067/mai.2000.108105; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V117, pS470, DOI 10.1016/j.jaci.2005.05.048; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350; Simons F. E. R., 2007, Journal of Allergy and Clinical Immunology, V120, pS1, DOI 10.1016/j.jaci.2007.05.016; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1541, DOI 10.1046/j.1365-2222.2000.00928.x; Srivastava KD, 2005, J ALLERGY CLIN IMMUN, V115, P171, DOI 10.1016/j.jaci.2004.10.003; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Strid J, 2004, IMMUNOLOGY, V113, P293, DOI 10.1111/j.1365-2567.2004.01989.x; Tariq SM, 1996, BRIT MED J, V313, P514; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; Thottingal TB, 2006, J ALLERGY CLIN IMMUN, V118, P905, DOI 10.1016/j.jaci.2006.06.016; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; Untersmayr E, 2005, J ALLERGY CLIN IMMUN, V115, P377, DOI 10.1016/j.jaci.2004.10.029; Wainstein BK, 2007, PEDIATR ALLERGY IMMU, V18, P231, DOI 10.1111/j.1399-3038.2006.00517.x; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; Wensing M, 2003, J ALLERGY CLIN IMMUN, V111, P420, DOI 10.1067/mai.2003.61; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P1225, DOI 10.1046/j.1365-2222.2001.01140.x; Woods RK, 2001, EUR J CLIN NUTR, V55, P298, DOI 10.1038/sj.ejcn.1601159; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	143	200	203	3	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3					491	503		10.1016/j.jaci.2007.07.015		13	Allergy; Immunology	Allergy; Immunology	211DV	WOS:000249505400001	17689596	
J	Kharitonov, SA; Gonio, F; Kelly, C; Meah, S; Barnes, PJ				Kharitonov, SA; Gonio, F; Kelly, C; Meah, S; Barnes, PJ			Reproducibility of exhaled nitric oxide measurements in healthy and asthmatic adults and children	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; exhaled nitric oxide; fractional exhaled nitric oxide measurements	SPUTUM INDUCTION; ATOPIC ASTHMA; FLOW; AIR	Airway inflammation in asthma is not measured routinely in clinical practice. Fractional exhaled nitric oxide (FENO), a marker of airway inflammation, is increasingly used as an outcome measure in asthma intervention studies and yet the reproducibility of FENO measurements is unknown. The reproducibility, day-to-day, diurnal variation and perception of standardised FENO measurements were examined in 59 subjects (40 children aged 7-13 yrs and 19 adults aged 18-60 yrs), both healthy (n=30) and with mild (n=29) asthma. FENO was measured on five consecutive days (four measurements on the same day) for adults and twice on the same day for children. The coefficient of reproducibility expressed as the mean pooled standard deviation (n=59, 675 estimations) was 2.11 parts per billion (ppb) and intraclass correlation coefficient was 0.99 in both children and adults. FENO was significantly higher in asthma subjects (32.3 ppb) than in healthy subjects (16.3 ppb). There was no diurnal or day-to-day variation, or a learning effect, as the result of FEND measurements were identical at results of the beginning and at the end of the study. It was concluded that fractional exhaled nitric oxide measurements are simple, reproducible, free from diurnal and day-to-day variation, and acceptable by both healthy and asthmatic adults and children, as a part of their routine visit to a physician.	Univ London Imperial Coll Sci Technol & Med, Royal Brompton & Harefield NHS Trust, Fac Med,Natl Heart & Lung Inst, Dept Thorac Med, London, England	Kharitonov, SA (reprint author), Univ London Imperial Coll Sci Technol & Med, Dept Thorac Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.						Ames M H, 1996, J Biopharm Stat, V6, P177, DOI 10.1080/10543409608835131; den Otter JJ, 2000, FAM PRACT, V17, P314, DOI 10.1093/fampra/17.4.314; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P1470; Faul JL, 1999, AM J RESP CRIT CARE, V160, P1457; Gannon PFG, 1999, EUR RESPIR J, V14, P28, DOI 10.1034/j.1399-3003.1999.14a07.x; Godfrey S, 2001, RESPIRATION, V68, P637, DOI 10.1159/000050589; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Kamps AWA, 2001, THORAX, V56, P180, DOI 10.1136/thorax.56.3.180; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Kharitonov SA, 2001, AM J RESP CRIT CARE, V164, P727; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; KHARITONOV SA, 1999, EUR RESPIR J, V9, P212; Nightingale JA, 1998, THORAX, V53, P87; O'Neill ME, 2002, BIOMETRICS, V58, P216, DOI 10.1111/j.0006-341X.2002.00216.x; Omland O, 2001, RESP MED, V95, P287, DOI 10.1053/rmed.2001.1036; Philipp L., 2002, PEDIAT ALLERGY IMMUN, V13, P37, DOI 10.1034/j.1399-3038.2002.00066.x; Purokivi M, 2000, EUR RESPIR J, V16, P242, DOI 10.1034/j.1399-3003.2000.16b10.x; Ross R, 2001, THORAX, V56, P500; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Upton MN, 2000, PUBLIC HEALTH, V114, P353, DOI 10.1038/sj.ph.1900683; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953	30	200	207	0	6	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2003	21	3					433	438		10.1183/09031936.03.00066903		6	Respiratory System	Respiratory System	655XP	WOS:000181578200010	12661997	
J	Mishra, A; Hogan, SP; Brandt, EB; Rothenberg, ME				Mishra, A; Hogan, SP; Brandt, EB; Rothenberg, ME			IL-5 promotes eosinophil trafficking to the esophagus	JOURNAL OF IMMUNOLOGY			English	Article							GASTROESOPHAGEAL REFLUX; TISSUE EOSINOPHILIA; CHEMOKINE EOTAXIN; TRANSGENIC MICE; IN-VIVO; INTERLEUKIN-5; ACID; CHILDREN; DISEASE; CORTICOSTEROIDS	Eosinophil infiltration into the esophagus occurs in a wide range of diseases; however, the underlying pathophysiological mechanisms involved are largely unknown. We now report that the Th2 cytokine, IL-5, is necessary and sufficient for the induction of eosinophil trafficking to the esophagus. We show that transgenic mice overexpressing IL-5 under the control of a T cell (CD2) or a small intestinal enterocyte (fatty acid-binding protein) promoter have markedly increased eosinophil numbers in the esophagus. For example, esophageal eosinophil levels are 1.9 +/- 0.9 and 121 +/- 14 eosinophils/mm(2) in wild-type and CD2-IL-5-transgenic mice, respectively. Consistent with this effect being mediated by a systemic mechanism, pharmacological administration of IL-5 via a miniosmotic pump in the peritoneal cavity resulted in blood and esophageal eosinophilia. To examine the role of IL-5 in oral Ag-induced esophageal eosinophilia, eosinophilic esophagitis was induced by allergen exposure in IL-5-deficient and wild-type mice. Importantly, IL-5-deficient mice were resistant to eosinophilic esophagitis. Finally, we examined the role of eotaxin when IL-5 was overproduced in vivo. Esophageal eosinophil levels in CD2-IL-5-transgenic mice were found to decrease 15-fold in the absence of the cotaxin gene; however, esophageal eosinophil numbers in eotaxin-deficient IL-5-transgenic mice still remained higher than wild-type nice. In conclusion, these studies demonstrate a central role for IL-5 in inducing eosinophil trafficking to the esophagus.	Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT, Australia	Rothenberg, ME (reprint author), Childrens Hosp, Med Ctr, Dept Pediat, Div Allergy & Immunol, Cincinnati, OH 45229 USA.				NIAID NIH HHS [AI 42242-03, R01 AI 45898-02]		Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; BROWN LF, 1984, AM J SURG PATHOL, V8, P899, DOI 10.1097/00000478-198412000-00002; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; DISCOMBE G, 1946, Lancet, V1, P195; Faubion WA, 1998, J PEDIATR GASTR NUTR, V27, P90, DOI 10.1097/00005176-199807000-00016; Furuta GT, 1998, J PEDIATR GASTR NUTR, V26, P468, DOI 10.1097/00005176-199804000-00021; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Kelly KJ, 2000, J PEDIATR GASTR NUTR, V30, pS28, DOI 10.1097/00005176-200001001-00005; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; LECKIE MJ, 1999, RESP CRIT CARE MED, V159, pA624; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2000, BLOOD, V96, P1538; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; MISHRA A, 2002, IN PRESS J BIOL CHEM; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Nicholson AG, 1997, J PATHOL, V183, P233, DOI 10.1002/(SICI)1096-9896(199710)183:2<233::AID-PATH936>3.0.CO;2-Z; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 2001, IMMUNOL REV, V179, P139, DOI 10.1034/j.1600-065X.2001.790114.x; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SANDERSON CJ, 1992, BLOOD, V79, P3101; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; SWEETSER DA, 1987, J BIOL CHEM, V262, P16060; Walsh SV, 1999, AM J SURG PATHOL, V23, P390, DOI 10.1097/00000478-199904000-00003; WINTER HS, 1982, GASTROENTEROLOGY, V83, P818	36	199	203	1	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	MAR 1	2002	168	5					2464	2469				6	Immunology	Immunology	524AR	WOS:000173990200049	11859139	
J	Tulic, MK; Wale, JL; Holt, PG; Sly, PD				Tulic, MK; Wale, JL; Holt, PG; Sly, PD			Modification of the inflammatory response to allergen challenge after exposure to bacterial lipopolysaccharide	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							INDUCED BRONCHIAL HYPERRESPONSIVENESS; BROWN-NORWAY RATS; AIRWAY HYPERRESPONSIVENESS; HUMAN-LYMPHOCYTES; VIRAL-INFECTIONS; NITRIC-OXIDE; ASTHMA; ENDOTOXIN; IGE; CHILDHOOD	The potential role of respiratory infections in altering the development of atopy and asthma is complex. Infections have been suggested to be effective in preventing the induction of T-helper 2-polarized allergen-specific immunity in early life, but also to exacerbate asthma in older, sensitized individuals. The mechanism(s) underlying these effects are poorly defined. The aim of this work was to determine the influence of lipopolysaccharide (LPS) exposure on the development of sensitization to allergen and the response to allergen challenge in vivo. Piebald-Virol-Glaxo rats were exposed to a single aerosol of LPS 1 d before or 1, 2, 4, 6, 8, or 10 d after sensitization with ovalbumin (OVA). On Day 11 animals were exposed to 1% OVA and responses to allergen were measured 24 h later, monitoring inflammatory cell influx and microvascular leakage into bronchoalveolar lavage (BAL) fluid as well as pulmonary responses to methacholine using the forced oscillation technique. Histologic analysis was included to complement the BAL results. Single aerosol exposure to LPS 1 d before and up to 4 d after intraperitoneal injection of OVA protected against the development of OVA-specific immunoglobulin tig) E. LPS exposure 6, 8, or 10 d after sensitization further exacerbated the OVA-induced cellular influx, resulting in neutrophilia and increased Evans Blue dye leakage with no effect on serum IgE levels. In addition, LPS abolished the OVA-induced hyperresponsiveness in sensitized animals when given 18 h after OVA challenge. This study demonstrates that exposure to LPS can modify the development of allergic inflammation in vivo by two independent mechanisms. Exposure early in the sensitization process, up to Day 6 after exposure to allergen, prevented allergen sensitization. Exposure to LPS after allergen challenge in sensitized animals abolished the hyperresponsiveness and modified the inflammatory cell influx characteristic of late-phase response to allergen.	TVW Telethon Inst Child Hlth Res, Div Clin Sci, W Perth, WA 6872, Australia; Univ Western Australia, Dept Paediat, Perth, WA 6009, Australia	Tulic, MK (reprint author), TVW Telethon Inst Child Hlth Res, Div Clin Sci, POB 855, W Perth, WA 6872, Australia.		Sly, Peter/F-1486-2010; Holt, Patrick/H-1548-2011; Tulic, Meri/P-6613-2016	Sly, Peter/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935; 			ANDERSSON D, 1998, AM J RESP CRIT CARE, V175, pA823; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.immunol.12.1.881; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Bjorksten B, 1996, Eur Respir J Suppl, V21, p22s; Bjornsson E, 1996, SCAND J INFECT DIS, V28, P63, DOI 10.3109/00365549609027152; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; BUSSE WW, 1994, AM J RESP CRIT CARE, V150, pS77; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; ELWOOD W, 1992, INT ARCH ALLERGY IMM, V99, P91; ELWOOD W, 1991, J ALLERGY CLIN IMMUN, V88, P951, DOI 10.1016/0091-6749(91)90253-K; EVANS TW, 1988, AM REV RESPIR DIS, V138, P140; HANTOS Z, 1992, J APPL PHYSIOL, V73, P427; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471; JOHNSSON P, 1995, J CARDIOTHOR VASC AN, V9, P1; KATO H, 1997, AM J RESP CRIT CARE, V156, P234; KAY AB, 1991, RESP MED, V85, P87, DOI 10.1016/S0954-6111(06)80283-0; KOBAYASHI M, 1989, J EXP MED, V170, P827, DOI 10.1084/jem.170.3.827; LARSEN GL, 1991, AM REV RESPIR DIS, V143, pS64; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MORRIS SC, 1994, J IMMUNOL, V152, P1047; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; PAUWELS RA, 1990, AM REV RESPIR DIS, V141, P540; Peat JK, 1996, EUR RESPIR J, V9, P1545, DOI 10.1183/09031936.96.09071545; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Petak F, 1997, J APPL PHYSIOL, V82, P1479; Rylander R, 1998, MEDIAT INFLAMM, V7, P105; Schuiling M, 1998, BRIT J PHARMACOL, V123, P1450, DOI 10.1038/sj.bjp.0701738; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; SEDGWICK JD, 1983, IMMUNOLOGY, V50, P625; Strachan D, 1996, TOXICOL LETT, V86, P199, DOI 10.1016/0378-4274(96)03691-0; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; vanHalteren AGS, 1997, J ALLERGY CLIN IMMUN, V99, P94; Verhasselt V, 1997, J IMMUNOL, V158, P2919; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P365; WILLIESJACOBO LJ, 1993, J ALLERGY CLIN IMMUN, V92, P630, DOI 10.1016/0091-6749(93)90090-3; YANO T, 1994, AM J RESP CRIT CARE, V149, P1348	45	199	204	0	4	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAY	2000	22	5					604	612				9	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	313EC	WOS:000086986500015	10783133	
J	Riedl, M; Diaz-Sanchez, D				Riedl, M; Diaz-Sanchez, D			Biology of diesel exhaust effects on respiratory function	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						air pollution; diesel exhaust particles; allergy; asthma; oxidative stress; respiratory effects	BRONCHIAL EPITHELIAL-CELLS; GLUTATHIONE-S-TRANSFERASE; PARTICULATE AIR-POLLUTION; PLACEBO-CONTROLLED TRIAL; OXIDATIVE STRESS; IN-VIVO; BRONCHOALVEOLAR LAVAGE; ASTHMATIC-PATIENTS; CHILDHOOD ASTHMA; NASAL CHALLENGE	In recent decades, clinicians and scientists have witnessed a significant increase in the prevalence of allergic rhinitis and asthma. The factors underlying this phenomenon are clearly complex; however, this rapid increase in the burden or atopic disease has undeniably occurred in parallel with rapid industrialization and urbanization in many parts or the world. Consequently, more people are exposed to air pollutants than at any point in human history. Worldwide, increases in allergic respiratory disease have mainly been observed in urban communities. Epidemiologic and clinical investigations have suggested a strong link between particulate air pollution and detrimental health effects, including cardiopulmonary morbidity and mortality. The purpose of this review is to provide an evidence-based summary of the health effects of air pollutants on asthma, focusing on diesel exhaust particles (DEPs) as a model particulate air pollutant. An overview of observational and experimental studies linking DEPs and asthma will be provided, followed by consideration of the mechanisms underlying DEP-induced inflammation and a brief discussion of future research and clinical directions.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol Allergy,Hart & Louis Lyon Lab, Los Angeles, CA 90095 USA	Diaz-Sanchez, D (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Clin Immunol Allergy,Hart & Louis Lyon Lab, 52-175 Ctr Hlth Sci, Los Angeles, CA 90095 USA.	ddiazsa@mednet.ucla.edu			NIAID NIH HHS [AI-40945]		Alam R, 1996, AM J RESP CRIT CARE, V153, P1398; Allam MF, 2004, COCHRANE DB SYST REV, V2004; Arimoto T, 1999, JPN J PHARMACOL, V80, P49, DOI 10.1254/jjp.80.49; Baulig A, 2003, TOXICOL IN VITRO, V17, P567, DOI 10.1016/S0887-2333(03)00115-2; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; Chanez P, 1996, INT ARCH ALLERGY IMM, V111, P83; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; D'Ippoliti D, 2003, EPIDEMIOLOGY, V14, P528, DOI 10.1097/01.ede.0000082046.22919.72; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Dworski R, 2001, CLIN EXP ALLERGY, V31, P387, DOI 10.1046/j.1365-2222.2001.01055.x; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Englert N, 2004, TOXICOL LETT, V149, P235, DOI 10.1016/j.toxlet.2003.12.035; Fahy O, 2000, AM J RESP CELL MOL, V23, P247; Finkelman FD, 2004, J IMMUNOL, V172, P3808; Fogarty A, 2003, CLIN EXP ALLERGY, V33, P1355, DOI 10.1046/j.1365-2222.2003.01777.x; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gluck U, 2003, ENVIRON HEALTH PERSP, V111, P925, DOI 10.1289/ehp.4401; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749; Hasan MMS, 2000, J ASTHMA, V37, P353, DOI 10.3109/02770900009055459; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280; Hiura TS, 1999, J IMMUNOL, V163, P5582; Horvath I, 1998, THORAX, V53, P668; HULSMANN AR, 1994, AM J RESP CRIT CARE, V149, P519; Ichinose T, 2002, TOXICOLOGY, V180, P293, DOI 10.1016/S0300-483X(02)00420-1; Ivaschenko TE, 2002, J MOL MED-JMM, V80, P39, DOI 10.1007/s001090100274; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; JIMINEZ LA, 1999, AM J RESP CRIT CARE, V159, pA27; Kagawa J, 2002, TOXICOLOGY, V181, P349, DOI 10.1016/S0300-483X(02)00461-4; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kobayashi T, 1998, TOXICOL SCI, V45, P106, DOI 10.1093/toxsci/45.1.106; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; LANSING MW, 1993, AM REV RESPIR DIS, V147, P321; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2002, J IMMUNOL, V169, P4531; Li N, 2000, J IMMUNOL, V165, P3393; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Madden MC, 2003, J TOXICOL ENV HEAL A, V66, P2281, DOI 10.1080/15287390390244292; Mann JK, 2002, ENVIRON HEALTH PERSP, V110, P1247; Marr LC, 2004, ENVIRON SCI TECHNOL, V38, P2584, DOI 10.1021/es034962s; Mastrangelo G, 2003, INT ARCH OCC ENV HEA, V76, P63, DOI 10.1007/s00420-002-0373-x; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nemmar A, 2004, CIRCULATION, V110, P1670, DOI 10.1161/01.CIR.0000142053.13921.21; Ng D, 1998, J IMMUNOL, V161, P942; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; Oberdorster G, 2002, ENVIRON HEALTH PERSP, V110, pA440, DOI 10.1289/ehp.110-a440; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Paramesh H., 2002, Indian Journal of Pediatrics, V69, P309, DOI 10.1007/BF02723216; Pearson PJK, 2004, THORAX, V59, P652, DOI 10.1136/thx.2004.022616; Pereira PM, 1995, ENVIRON RES, V69, P96, DOI 10.1006/enrs.1995.1030; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; Rahman Q, 1999, CRIT REV TOXICOL, V29, P543, DOI 10.1080/10408449991349276; Romieu I, 2004, THORAX, V59, P8; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658; Sagai M, 1996, FREE RADICAL BIO MED, V21, P199, DOI 10.1016/0891-5849(96)00032-9; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; SAMAT JA, 2001, NEW ENGL J MED, V344, P1253; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725; Schwartz J, 2004, PEDIATRICS, V113, P1037; Shima M, 2003, J EPIDEMIOL, V13, P108; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Steerenberg PA, 1999, INHAL TOXICOL, V11, P1109; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; STEVENS WHM, 1995, AM J RESP CRIT CARE, V151, P1526; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Takizawa H, 2003, AM J PHYSIOL-LUNG C, V284, pL1055, DOI 10.1152/ajplung.00358.2002; Takizawa H, 1999, J IMMUNOL, V162, P4705; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167; *US EPA, 2003, AIR QUAL CRIT PART M; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; WHO, 2003, HLTH ASP AIR POLL PA; *WHO WORK GROUP, 2003, SYST REV HLTH ASP AI; WJST M, 1993, BRIT MED J, V307, P596; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	110	198	204	4	22	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					221	228		10.1016/j.jaci.2004.11.047		8	Allergy; Immunology	Allergy; Immunology	897YU	WOS:000227043600002	15696072	
J	Johnson, JR; Wiley, RE; Fattouh, R; Swirski, FK; Gajewska, BU; Coyle, AJ; Gutierrez-Ramos, JC; Ellis, R; Inman, MD; Jordana, M				Johnson, JR; Wiley, RE; Fattouh, R; Swirski, FK; Gajewska, BU; Coyle, AJ; Gutierrez-Ramos, JC; Ellis, R; Inman, MD; Jordana, M			Continuous exposure to house dust mite elicits chronic airway inflammation and structural remodeling	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						allergy and immunology; animal; asthma; models	MURINE MODEL; ALLERGEN DER-P-1; LUNG INFLAMMATION; EPITHELIAL-CELLS; GM-CSF; ASTHMA; HYPERRESPONSIVENESS; RESPONSIVENESS; SENSITIZATION; EOSINOPHILIA	It is now fully appreciated that asthma is a disease of a chronic nature resulting from intermittent or continued aeroallergen exposure leading to airway inflammation. To investigate responses to continuous antigen exposure, mice were exposed to either house dust mite extract (HDM) or ovalbumin intranasally for five consecutive days, followed by 2 days of rest, for up to seven consecutive weeks. Continuous exposure to HDM, unlike ovalbumin, elicited severe and persistent eosinophilic airway inflammation. Flow cytometric analysis demonstrated an accumulation of CD4(+) lymphocytes in the lung with elevated expression of inducible costimulator a marker of T cell activation, and of T1/ST2, a marker of helper T Type 2 effector cells. We also detected increased and sustained production of helper T cell Type 2-associated cytokines by splenocytes of HDM-exposecl mice on in vitro HDM recall. Histologic analysis of the lung showed evidence of airway remodeling in mice exposed to HIDM, with goblet cell hyperplasia, collagen deposition, and peribronchial accumulation of contractile tissue. In addition, HDM-exposed mice demonstrated severe airway hyperreactivity to methacholine. Finally, these responses were studied for up to 9 weeks after cessation of HDM exposure. We observed that whereas airway inflammation resolved fully, the remodeling changes did not resolve and airway hyperreactivity resolved only partly.	McMaster Univ, Firestone Inst Resp Hlth, Dept Med, Hamilton, ON, Canada; Millennium Pharmaceut, Ctr Gene Therapeut, Div Resp Dis & Allergy, Cambridge, MA USA; Millennium Pharmaceut, Ctr Gene Therapeut, Dept Pathol & Mol Med, Cambridge, MA USA	Jordana, M (reprint author), McMaster Univ, Ctr Hlth Sci, Dept Pathol & Mol Med, Room 4H17,1200 Main St, Hamilton, ON L8N 3Z5, Canada.	jordanam@mcmaster.ca					Asokananthan N, 2002, J IMMUNOL, V169, P4572; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cates E. C., 2003, Journal of Allergy and Clinical Immunology, V111, pS81, DOI 10.1016/S0091-6749(03)80205-1; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; Ewart SL, 1996, AM J RESP CELL MOL, V14, P487; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; Fernandez-Caldas Enrique, 2002, Curr Allergy Asthma Rep, V2, P424, DOI 10.1007/s11882-002-0077-z; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; John RJ, 2000, CLIN EXP ALLERGY, V30, P784, DOI 10.1046/j.1365-2222.2000.00840.x; JOHNSON JR, 2003, AM J RESP CRIT CARE, V167, pA453; Knight DR, 2001, IMMUNOL CELL BIOL, V79, P160, DOI 10.1046/j.1440-1711.2001.00988.x; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Nahm DH, 2000, ANN ALLERG ASTHMA IM, V85, P129; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Sun G, 2001, J IMMUNOL, V167, P1014; Swirski FK, 2002, J IMMUNOL, V169, P3499; Temelkovski J, 1998, THORAX, V53, P849; Trifilieff A, 2001, CLIN EXP ALLERGY, V31, P934, DOI 10.1046/j.1365-2222.2001.01084.x; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wiley RE, 2003, AM J RESP CELL MOL, V28, P722, DOI 10.1165/rcmb.2002-0220OC	26	198	212	0	8	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 1	2004	169	3					378	385		10.1164/rccm.200308-1094OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	767BA	WOS:000188417800014	14597485	
J	Crystal-Peters, J; Neslusan, C; Crown, WH; Torres, A				Crystal-Peters, J; Neslusan, C; Crown, WH; Torres, A			Treating allergic rhinitis in patients with comorbid asthma: The risk of asthma-related hospitalizations and emergency department visits	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; administrative claims analysis		Background: Although asthma and allergic rhinitis commonly occur together, the nature of the association has yet to be determined. Treatments for one condition could potentially alleviate the coexisting condition. Objective: Patients with both allergic rhinitis and asthma were studied to test the hypothesis that treating allergic rhinitis reduces health care utilization for co-morbid asthma. Methods: A retrospective cohort study was carried out with 1994-1995 MarketScan claims data. The cohort was limited to patients with both allergic rhinitis and asthma, aged 12 to 60 years, who were continuously enrolled and had no evidence of chronic obstructive pulmonary disease. Allergic rhinitis treatment and asthma-related events (hospitalizations and emergency department visits) were identified. An incidence density ratio (IDR) associated with exposure to allergic rhinitis treatment was calculated. A multivariate Poisson regression was estimated, and the parameter estimates were transformed into IDRs for each explanatory variable. An allergic rhinitis treatment indicator was included in all regressions. Results: The study sample population consisted of 4944 patients with allergic asthma, approximately 73% of whom were treated for their allergic rhinitis. Asthma-related events occurred more often for the untreated group compared with the treated group, 6.6 % compared with 1.3 %. An IDR of 0.49 for the treatment group (P =.001) indicates that the risk of an asthma-related event for the treated group was about half that for the untreated group. Conclusion: In summary, those who were treated for allergic rhinitis have a significantly lower risk of subsequent asthma-related events (emergency department visits or hospitalizations) than those who were not treated.	MEDSTAT Grp, Washington, DC 20008 USA	Crystal-Peters, J (reprint author), MEDSTAT Grp, 4401 Connecticut Ave NW,Suite 400, Washington, DC 20008 USA.						ALTEMEIER WA, 2001, PEDIATR ANN, V29, P398; ALTEMEIER WA, 2001, PEDIATR ANN, V29, P391; *AM AC ALL ASTHM I, FAST FACTS STAT ASTH; Busse WW, 1998, J ALLERGY CLIN IMMUN, V101, pS424, DOI 10.1016/S0091-6749(98)70236-2; Bykowsky M, 2000, J S C Med Assoc, V96, P229; Corren J, 1998, J ALLERGY CLIN IMMUN, V101, pS352, DOI 10.1016/S0091-6749(98)70218-0; Fireman P, 2000, ALLERGY ASTHMA PROC, V21, P45, DOI 10.2500/108854100778248935; GRANT JA, 1995, J ALLERGY CLIN IMMUN, V95, P923, DOI 10.1016/S0091-6749(95)70090-0; HALPERN M, 1996, AM J RESP CRIT CARE, V153, pA860; HECKMAN JJ, 1976, ANN ECON SOC MEAS, V5, P475; Hennekens C. H., 1987, EPIDEMIOLOGY MED; HENRIKSEN JM, 1984, AM REV RESPIR DIS, V130, P1014; Lemanske RF, 1998, J ALLERGY CLIN IMMUN, V101, pS392, DOI 10.1016/S0091-6749(98)70228-3; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; RoweJones JM, 1997, ALLERGY, V52, P20; Selvin S, 1996, STAT ANAL EPIDEMIOLO; Skoner DP, 2000, J ALLERGY CLIN IMMUN, V105, pS605; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Stata Corp, 1997, STAT STAT SOFTW REL; WATSON WT, 1993, J ALLERGY CLIN IMM 1, V9, P97; WELSH PW, 1987, MAYO CLIN PROC, V62, P125	21	198	209	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					57	62		10.1067/mai.2002.120554		6	Allergy; Immunology	Allergy; Immunology	519RM	WOS:000173739300009	11799366	
J	Kauffman, HF; Tomee, JFC; van de Riet, MA; Timmerman, AJB; Borger, P				Kauffman, HF; Tomee, JFC; van de Riet, MA; Timmerman, AJB; Borger, P			Protease-dependent activation of epithelial cells by fungal allergens leads to morphologic changes and cytokine production	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungal; proteases; epithelial cells; cytokines; desquamation; protease-activated receptor; asthma; sensitization	VOLUMETRIC AEROBIOLOGICAL SURVEY; HOUSE-DUST MITE; MOLD ALLERGY; NORTHEAST NETHERLANDS; CONIDIAL FUNGI; ASPERGILLUS; ASTHMA; DETACHMENT; DIAGNOSIS; SENSITIZATION	Background: Proteases in extracts of Aspergillus fumigatus cause epithelial cell desquamation and release of proinflammatory cytokines. Objective: We sought to assess protease activity in Alternaria alternata, Cladosporium herbarum, and Aspergillus fumigatus extracts and study the ability of these extracts to cause desquamation and release of proinflammatory cytokines from epithelial cells. Methods: Protease activities of the fungal extracts were quantified, Changes with respect to cell morphology, cell desquamation, and cytokine production (IL-6 and IL-8) were measured in the absence and presence of the fungal extracts in an airway-derived epithelial cell line (A549) and primary epithelial nasal cells. Results: Fungal proteases differentially induced morphologic changes, cell desquamation, and production of IL-6 and IL-8 in a dose- and time-dependent fashion. Alternaria alternata extracts induced cell shrinking and cell desquamation and strongly enhanced the production of IL-6 and IL-8 at higher concentrations. Aspergillus fumigatus extracts caused cell shrinking, cell desquamation, and production of IL-6 and IL-8, even at low concentrations. The Aspergillus fumigatus-derived extract groan on collagen medium induced a strong dose-dependent decline in cytokine production at higher concentrations. Cladosporium herbarum extracts did not induce morphologic changes or cell desquamation but enhanced IL-6 and IL-8 productions at higher concentrations. The dependence of these effects on intact protease activity was shown by their abrogation by protease inhibitors. Conclusion: Proteases present in fungal extracts interact with epithelial cells, leading to morphologic changes, cell desquamation, and induction of proinflammatory cytokines. It is proposed that these fungal proteases may activate epithelial cells through a protease-activated receptor type 2-driven mechanism.	Univ Groningen Hosp, Clin Internal Med, Lab Allergol & Pulmonol, NL-9700 RB Groningen, Netherlands	Kauffman, HF (reprint author), Univ Groningen Hosp, Clin Internal Med, Lab Allergol & Pulmonol, POB 30-001, NL-9700 RB Groningen, Netherlands.						BEAUMONT F, 1985, ALLERGY, V40, P181, DOI 10.1111/j.1398-9995.1985.tb00214.x; BEAUMONT F, 1985, ALLERGY, V40, P173, DOI 10.1111/j.1398-9995.1985.tb00213.x; Bohm SK, 1996, J BIOL CHEM, V271, P22003; Borger P, 1999, J INFECT DIS, V180, P1267, DOI 10.1086/315027; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Davies RJ, 1998, CLIN EXP ALLERGY, V28, P8; ESCH RE, 1991, ARB P EHRLICH I BUND, P171; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; HOARD WA, 1984, MOULD ALLERGY, P147; Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97; KAUFFMAN HF, 1994, AIR QUAL MG, V2, P221; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109; KOIVIKKO A, 1991, ALLERGY, V46, P85, DOI 10.1111/j.1398-9995.1991.tb00549.x; KOLATTUKUDY PE, 1993, INFECT IMMUN, V61, P2357; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; MALLING HJ, 1992, CLIN REV ALLERG, V10, P213; MALLING HJ, 1985, ALLERGY, V40, P108, DOI 10.1111/j.1398-9995.1985.tb02669.x; MONOD M, 1993, FEMS MICROBIOL LETT, V106, P39, DOI 10.1111/j.1574-6968.1993.tb05932.x; MONOD M, 1995, CAN J BOT, V73, pS1081; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; Pearce N, 1999, THORAX, V54, P268; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Sarlo K, 1997, J ALLERGY CLIN IMMUN, V100, P480; Schechter NM, 1998, J CELL PHYSIOL, V176, P365, DOI 10.1002/(SICI)1097-4652(199808)176:2<365::AID-JCP15>3.0.CO;2-2; Shen HD, 1998, INT ARCH ALLERGY IMM, V116, P29, DOI 10.1159/000023921; Shibata Y, 1996, J IMMUNOL, V156, P772; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; TAKATORI K, 1994, AIR QUAL MG, V2, P93; Thompson PJ, 1998, CLIN EXP ALLERGY, V28, P110; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; Tomee JFC, 1997, J INFECT DIS, V176, P300, DOI 10.1086/517272; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; Wilken-Jensen K., 1984, ATLAS MOULDS EUROPE	37	198	208	0	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2000	105	6	1				1185	1193		10.1067/mai.2000.106210		9	Allergy; Immunology	Allergy; Immunology	327EX	WOS:000087781800021	10856154	
J	Shi, HZ; Humbles, A; Gerard, C; Jin, Z; Weller, PF				Shi, HZ; Humbles, A; Gerard, C; Jin, Z; Weller, PF			Lymph node trafficking and antigen presentation by endobronchial eosinophils	JOURNAL OF CLINICAL INVESTIGATION			English	Article							INTERCELLULAR-ADHESION MOLECULE-1; T-CELL CLONES; HLA-DR; DENDRITIC CELLS; ALVEOLAR MACROPHAGES; PRESENTING CELL; INDUCED SPUTUM; EXPRESSION; ASTHMA; LUNG	Because eosinophils recruited into the airways in allergic diseases are exposed to inhaled allergens, we evaluated whether eosinophils within the endobronchial lumen can function in vivo as antigen-presenting cells for inhaled antigens. We recovered eosinophils from the airways after aerosol antigen challenge in sensitized mice or from the peritoneal cavities of IL-5 transgenic mice and fluorescently labeled these cells ex vivo. These labeled cells, instilled intratracheally into normal mice, migrated into draining paratracheal lymph nodes and localized to T cell-rich paracortical areas. The homing of airway eosinophils to lymph nodes was not governed by eotaxin, because CCR3(-/-) and CCR3(+/+) eosinophils migrated identically. Airway eosinophils, recovered after inhalational antigen challenge in sensitized mice, expressed MHC class II and costimulatory CD80 and CD86 proteins and functioned in vitro as CD80- and CD86-dependent, antigen-specific, antigen-presenting cells. Moreover, when instilled into the airways of antigen-sensitized recipient mice, airway eosinophils recovered after inhalational antigen challenge stimulated antigen-specific CD4(+) T cell proliferation within paratracheal lymph nodes. Thus, eosinophils within the lumina of airways can process inhaled antigens, traffic to regional lymph nodes, and function in vivo as antigen-presenting cells to stimulate responses of CD4(+) T cells.	Harvard Univ, Sch Med,Charles A Dana Res Inst, Beth Israel Deaconess Med Ctr,Dept Med, Harvard Thorndike Labs, Boston, MA 02215 USA; Harvard Univ, Childrens Hosp, Sch Med,Med Ctr, Ina Sue Perlmutter Labs,Dept Pediat, Boston, MA 02115 USA	Weller, PF (reprint author), Harvard Univ, Sch Med,Charles A Dana Res Inst, Beth Israel Deaconess Med Ctr,Dept Med, Harvard Thorndike Labs, DA-617,330 Brookline Ave, Boston, MA 02215 USA.				NHLBI NIH HHS [HL46563]; NIAID NIH HHS [R01 AI022571, AI20241, AI22571, R01 AI020241, R37 AI020241]		BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; CHELEN CJ, 1995, J CLIN INVEST, V95, P1415, DOI 10.1172/JCI117796; CROWLEY M, 1990, J EXP MED, V172, P383, DOI 10.1084/jem.172.1.383; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GOSSELIN EJ, 1992, J IMMUNOL, V149, P3477; HANSEL TT, 1992, J IMMUNOL, V149, P2130; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; HAVENITH CEG, 1993, AM J RESP CELL MOL, V9, P484; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Laberge S, 1997, AM J RESP CELL MOL, V17, P193; LACY P, 1997, MEM I OSWALDO CRUZ S, V92, pH125; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; MacLean JA, 1996, AM J PATHOL, V148, P657; MAURER D, 1995, J IMMUNOL, V154, P6285; MAWHORTER SD, 1994, IMMUNOLOGY, V81, P584; McAdam AJ, 1998, IMMUNOL REV, V165, P231; MENGELERS HJ, 1994, AM J RESP CRIT CARE, V149, P345; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; Persson CGA, 1997, LANCET, V350, P1021, DOI 10.1016/S0140-6736(96)02335-5; PIN I, 1992, AM REV RESPIR DIS, V145, P1265; PLATTSMILLS TAE, 1992, AM REV RESPIR DIS, V145, pS44; RESNICK MB, 1995, GASTROENTEROLOGY, V108, P409, DOI 10.1016/0016-5085(95)90067-5; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291; RYTOMAA T, 1960, Acta Pathol Microbiol Scand Suppl, V50(Suppl 140), P1; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; STELLATO C, 1995, J IMMUNOL, V155, P410; Taguchi M, 1998, J EXP MED, V187, P1927, DOI 10.1084/jem.187.12.1927; Tamura N, 1996, SCAND J IMMUNOL, V44, P229, DOI 10.1046/j.1365-3083.1996.d01-303.x; TOMINAGA A, 1991, J EXP MED, V173, P429, DOI 10.1084/jem.173.2.429; van Rooijen N, 1992, Semin Immunol, V4, P237; VANROOIJEN N, 1990, IMMUNOL TODAY, V11, P436, DOI 10.1016/0167-5699(90)90171-5; WELLER PF, 1993, J IMMUNOL, V150, P2554; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; WYSSCORAY T, 1993, EUR J IMMUNOL, V23, P3350, DOI 10.1002/eji.1830231243; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275	41	198	204	3	4	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	APR	2000	105	7					945	953		10.1172/JCI8945		9	Medicine, Research & Experimental	Research & Experimental Medicine	300XW	WOS:000086279900016	10749574	
J	Brandt, EB; Strait, RT; Hershko, D; Wang, Q; Muntel, EE; Scribner, TA; Zimmermann, N; Finkelman, FD; Rothenberg, ME				Brandt, EB; Strait, RT; Hershko, D; Wang, Q; Muntel, EE; Scribner, TA; Zimmermann, N; Finkelman, FD; Rothenberg, ME			Mast cells are required for experimental oral allergen-induced diarrhea	JOURNAL OF CLINICAL INVESTIGATION			English	Article							IMMUNOGLOBULIN-E RECEPTOR; FC-GAMMA RIII; SYSTEMIC-ANAPHYLAXIS; TRICHINELLA-SPIRALIS; TRYPTASE LEVELS; T-CELL; INFLAMMATION; IGE; HISTAMINE; MICE	Gastrointestinal allergic disorders represent a diverse spectrum of inflammatory diseases that are occurring with increasing incidence and severity. An essential question concerning these disorders is to determine the specific cells and mediators responsible for specific clinical manifestations. With this in mind, we developed a murine model of oral allergen-induced intestinal inflammation accompanied by strong Th2-associated humoral and cellular responses and focused on the immunopathogenesis of allergic diarrhea. Exposure of OVA/alum-sensitized mice to repeated doses of intragastric OVA induced genetically restricted, dose-dependent, acute diarrhea associated with increased intestinal permeability, eosinophilia, and mastocytosis. Mice developed limited systemic manifestations of anaphylaxis, even though they developed marked intestinal mucosal mast cell degranulation. Notably, experiments involving mast cell depletion (with anti-c-kit mAb), anti-IgE treatment, and FcepsilonRI-deficient mice indicated a critical effector role for mast cells in mediating allergic diarrhea. Furthermore, allergic diarrhea was dependent upon synergistic signaling induced by serotonin and platelet-activating factor (PAF), but not histamine. These results demonstrate that oral allergen-induced diarrhea associated with experimental Th2 intestinal inflammation is largely mast cell, IgE, serotonin, and PAF dependent.	Cincinnati Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Med Ctr, Cincinnati, OH 45229 USA; Cincinnati Childrens Hosp, Dept Pediat, Div Emergency Med, Med Ctr, Cincinnati, OH 45229 USA; Shriners Hosp Children, Cincinnati, OH USA; Univ Cincinnati, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Internal Med, Div Immunol, Cincinnati, OH USA; Vet Adm Med Ctr, Cincinnati, OH 45220 USA	Rothenberg, ME (reprint author), Cincinnati Childrens Hosp, Dept Pediat, Div Allergy & Immunol, Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NIAID NIH HHS [K08 AI-50006, N01AI50006, R01 AI-42242-05, R01 AI-45898-03, R01 AI045898]		Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Bischoff SC, 1996, BAILLIERE CLIN GASTR, V10, P443, DOI 10.1016/S0950-3528(96)90052-4; Chen CY, 2000, SEX TRANSM DIS, V27, P21, DOI 10.1097/00007435-200001000-00005; Cremonini F, 2003, NEUROGASTROENT MOTIL, V15, P79, DOI 10.1046/j.1365-2982.2003.00389.x; CROWE SE, 1992, GASTROENTEROLOGY, V103, P1075; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; Dombrowicz D, 2001, J EXP MED, V193, P25; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Field M, 2003, J CLIN INVEST, V111, P931, DOI 10.1172/JCI200318326; Friend DS, 1996, J CELL BIOL, V135, P279, DOI 10.1083/jcb.135.1.279; GRENCIS RK, 1993, PARASITE IMMUNOL, V15, P55, DOI 10.1111/j.1365-3024.1993.tb00572.x; GURISH MF, 2001, CURR OPIN IMMUNOL, V194, pF1; Haga K, 1995, OBES RES, V3, pS801; Han L, 1998, LIFE SCI, V62, P715, DOI 10.1016/S0024-3205(97)01170-3; Hogan SP, 2001, NAT IMMUNOL, V2, P353, DOI 10.1038/86365; Ishii S, 1998, J EXP MED, V187, P1779, DOI 10.1084/jem.187.11.1779; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; KANETA S, 1993, RES COMMUN CHEM PATH, V79, P167; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kweon MN, 2000, J CLIN INVEST, V106, P199, DOI 10.1172/JCI8490; Kweon MN, 2003, CURR ALLERGY ASTHM R, V3, P79, DOI 10.1007/s11882-003-0016-7; LEYSEN JE, 1982, MOL PHARMACOL, V21, P301; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Lin RY, 2000, J ALLERGY CLIN IMMUN, V106, P65, DOI 10.1067/mai.2000.107600; LUI E, 2002, J CLIN INVEST, V110, P1021; Makabe-Kobayashi Y, 2002, J ALLERGY CLIN IMMUN, V110, P298, DOI 10.1067/mai.2002.125977; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; MOURAD FH, 1995, GUT, V36, P553, DOI 10.1136/gut.36.4.553; Musch MW, 2002, J CLIN INVEST, V110, P1739, DOI 10.1172/JCI200215695; Ooe M, 1993, Nihon Yakurigaku Zasshi, V101, P299; Piliponsky AM, 2002, MOL IMMUNOL, V38, P1369, DOI 10.1016/S0161-5890(02)00090-1; Piliponsky AM, 2003, BLOOD, V101, P1898, DOI 10.1182/blood-2002-05-1488; Rothenberg ME, 2001, ADV IMMUNOL, V78, P291, DOI 10.1016/S0065-2776(01)78007-8; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A., 2003, Journal of Allergy and Clinical Immunology, V111, pS540; Santos J, 1999, GUT, V45, P553; SCHWARTZ LB, 1987, NEW ENGL J MED, V316, P1622, DOI 10.1056/NEJM198706253162603; Strait RT, 2002, J ALLERGY CLIN IMMUN, V109, P658, DOI 10.1067/mai.2002.123302; TAKAI T, 1994, CELL, V76, P519, DOI 10.1016/0092-8674(94)90115-5; Takatsu K, 1995, Cancer Treat Res, V80, P187; VAZ NM, 1977, INT ARCH ALLER A IMM, V53, P545; Wang C, 2001, J NONLINEAR OPT PHYS, V10, P281, DOI 10.1142/S0218863501000620; Wershil BK, 2000, AM J PHYSIOL-GASTR L, V278, pG343; Xu X, 2002, SCAND J GASTROENTERO, V37, P330, DOI 10.1080/003655202317284246; Yu LCH, 2001, IMMUNOL REV, V179, P61, DOI 10.1034/j.1600-065X.2001.790107.x; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	49	197	206	0	8	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	DEC	2003	112	11					1666	1677		10.1172/JCI19785		12	Medicine, Research & Experimental	Research & Experimental Medicine	751VY	WOS:000187111800011	14660743	
J	Beggs, PJ				Beggs, PJ			Impacts of climate change on aeroallergens: past and future	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review						allergen; carbon dioxide; climate change; distribution; mould; plant; pollen; season; spore; temperature	RAGWEED AMBROSIA-ARTEMISIIFOLIA; OUTDOOR AIR-POLLUTION; BIRCH POLLEN SEASONS; PUBLIC-HEALTH; RESPIRATORY ALLERGY; AIRBORNE POLLEN; CO2 ENRICHMENT; COMMON RAGWEED; WEATHER; EUROPE	Human activities are resulting in increases in atmospheric greenhouse gases, such as carbon dioxide, and changes in global climate. These, in turn, are likely to have had, and will continue to have, impacts on human health. While such impacts have received increasing attention in recent years, the impacts of climate change on aeroallergens and related allergic diseases have been somewhat neglected. Despite this, a number of studies have revealed potential impacts of climate change on aeroallergens that may have enormous clinical and public health significance. The purpose of this review is to synthesize this work and to outline a number of research challenges in this area. There is now considerable evidence to suggest that climate change will have, and has already had, impacts on aeroallergens. These include impacts on pollen amount, pollen allergenicity, pollen season, plant and pollen distribution, and other plant attributes. There is also some evidence of impacts on other aeroallergens, such as mould spores. There are many research challenges along the road to a more complete understanding of the impacts of climate change on aeroallergens and allergic diseases such as asthma and hayfever. It is important that public health authorities and allergy practitioners be aware of these changes in the environment, and that research scientists embrace the challenges that face further work in this area.	Macquarie Univ, Dept Phys Geog, Div Environm & Life Sci, N Ryde, NSW 2109, Australia	Beggs, PJ (reprint author), Macquarie Univ, Dept Phys Geog, Div Environm & Life Sci, N Ryde, NSW 2109, Australia.	paul.beggs@mq.edu.au	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; ALEXANDER JB, 1991, MED VET ENTOMOL, V5, P395, DOI 10.1111/j.1365-2915.1991.tb00567.x; BEGGS P, 1997, ADV ENV CONTROL TECH, P329, DOI 10.1016/B978-088415386-3/50016-3; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; Bernard SM, 2001, ENVIRON HEALTH PERSP, V109, P199, DOI 10.2307/3435010; Buckland SM, 2001, J APPL ECOL, V38, P301, DOI 10.1046/j.1365-2664.2001.00603.x; Bunyavanich S, 2003, AMBUL PEDIATR, V3, P44, DOI 10.1367/1539-4409(2003)003<0044:TIOCCO>2.0.CO;2; Burch M, 2002, INT J BIOMETEOROL, V46, P107, DOI 10.1007/s00484-002-0127-1; Corden JM, 2001, AEROBIOLOGIA, V17, P127, DOI 10.1023/A:1010876917512; Cubasch U, 2001, CLIMATE CHANGE 2001, P525; D'Amato G, 2002, EUR RESPIR J, V20, P763, DOI 10.1183/09031936.02.00401402; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Emberlin J, 1997, GRANA, V36, P29; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Emberlin J, 2003, INT J BIOMETEOROL, V47, P113, DOI 10.1007/s00484-002-0154-y; Folland C K, 2001, CLIMATE CHANGE 2001, P99; Frei T, 1998, GRANA, V37, P172; Frenguelli G, 2002, Monaldi Arch Chest Dis, V57, P141; Harvell CD, 2002, SCIENCE, V296, P2158, DOI 10.1126/science.1063699; HASHIMOTO M, 1990, CLIMATE CHANGE IPCC; HJELMROOS M, 1993, GRANA, V32, P40; HJELMROOS M, 1995, INT ARCH ALLERGY IMM, V108, P368; Huynen M, 2003, WHO M ROM IT 16 17 J; Katial RK, 1997, INT J BIOMETEOROL, V41, P17, DOI 10.1007/s004840050048; Keeling CD, 2004, ATMOSPHERIC CARBON D; Klus DJ, 2001, AM J BOT, V88, P1080, DOI 10.2307/2657091; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; LAST J, 1990, Public Health Reviews, V18, P49; LAST JM, 1993, ANNU REV PUBL HEALTH, V14, P115; Levetin E, 2001, J ALLERGY CLIN IMMUN, V107, pS172; Lindroth RL, 2001, ENVIRON POLLUT, V115, P395, DOI 10.1016/S0269-7491(01)00229-9; McCarthy J.J., 2001, CLIMATE CHANGE 2001; McMichael AJ, 2001, CLIMATE CHANGE 2001, P451; Mc Michael AJ, 2003, CLIMATE CHANGE HUMAN; McMichael A. J., 1996, CLIMATE CHANGE 1995, P561; McMichael AJ, 1996, CLIMATE CHANGE HUMAN; Menzel A, 2000, INT J BIOMETEOROL, V44, P76, DOI 10.1007/s004840000054; Nakicenovic N, 2000, IPCC SPECIAL REPORT; OKOTH SA, 2002, WORLD RESOURCE REV, V14, P223; Partanen J, 1998, TREE PHYSIOL, V18, P811; Patz JA, 2002, BRIT MED J, V325, P1094, DOI 10.1136/bmj.325.7372.1094; Patz JA, 2000, ANNU REV PUBL HEALTH, V21, P271, DOI 10.1146/annurev.publhealth.21.1.271; PEDEN DB, 1999, AIR POLLUTION HLTH, P865, DOI 10.1016/B978-012352335-8/50112-5; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; Yool A., 2001, CLIMATE CHANGE 2001, P183; Rasmussen Alix, 2002, Aerobiologia, V18, P253, DOI 10.1023/A:1021321615254; Rybncek O, 2001, ALLERGY CLIN IMMUNOL, V13, P60, DOI 10.1027/0838-1925.13.2.60; SCHENK U, 1995, J EXP BOT, V46, P987, DOI 10.1093/jxb/46.8.987; SPIEKSMA FTM, 1995, GRANA, V34, P51; Teranishi H, 2000, CLIMATE RES, V14, P65, DOI 10.3354/cr014065; van Ginkel JH, 2000, SOIL BIOL BIOCHEM, V32, P449, DOI 10.1016/S0038-0717(99)00097-8; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Weber RW, 2002, ANN ALLERG ASTHMA IM, V88, P251; WULFF RD, 1985, OECOLOGIA, V66, P458, DOI 10.1007/BF00378315; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53; ZISKA LH, 2000, WORLD RESOURCE REV, V12, P449; 1989, LANCET, V1, P819	61	196	207	12	55	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-7894	1365-2222		CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2004	34	10					1507	1513		10.1111/j.1365-2222.2004.02061.x		7	Allergy; Immunology	Allergy; Immunology	861RB	WOS:000224434800002	15479264	
J	Neugut, AI; Ghatak, AT; Miller, RL				Neugut, AI; Ghatak, AT; Miller, RL			Anaphylaxis in the United States - An investigation into its epidemiology	ARCHIVES OF INTERNAL MEDICINE			English	Review							CONTRAST-MEDIA; ADVERSE REACTIONS; LATEX ALLERGY; PREVALENCE; RISK; HYPERSENSITIVITY; WORKERS; RUBBER; PEANUT; DRUGS	Background: Anaphylaxis is a severe, life-threatening allergic reaction that affects both children and adults in the United States. However, data regarding the incidence and prevalence of anaphylaxis and the number of deaths caused by it are limited. Objective: To provide a better understanding of the magnitude of the problem of anaphylaxis in the United States. Methods: A thorough review of the current medical literature was conducted to obtain prevalence estimates on each of the 4 major subtypes of anaphylaxis (food, drugs, latex, and insect stings). We calculated an overall estimate of the risk of anaphylaxis by using only estimates that are specifically derived from epidemiologic studies measuring anaphylaxis in the general population. Results: Known rates or cases of anaphylaxis were 0.0004% for food, 0.7% to 10% for penicillin, 0.22% to 1% for radiocontrast media, and 0.5% to 5% after insect stings. There were 220 cases after latex exposure. Considering the 1999 US population of 272 million, the population at risk for anaphylaxis from food is 1099, from penicillin is 1.9 million to 27.2 million, from radiocontrast media is 22 000 to 100 000, from latex is 220, and from insect stings is 1.36 million to 13.6 million. These calculations yield a total of 1.29 million to 40.9 million individuals at risk of anaphylaxis. Conclusion: The occurrence of anaphylaxis in the US is not as rare as is generally believed. On the basis of our figures, the problem of anaphylaxis may, in fact, affect 1.21% to 15.04% of the US population.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Joseph L Mailman Sch Publ Hlth, New York, NY 10032 USA; DEY Corp, Napa, CA USA	Neugut, AI (reprint author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St,Room PH18-127, New York, NY 10032 USA.						ANDERSON JA, 1992, JAMA-J AM MED ASSOC, V268, P2845; ANSELL G, 1980, INVESTIGATIVE RADI S, V15, P32; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; BOCHNER BS, 1991, NEW ENGL J MED, V324, P1785; BOCK SA, 1992, J ALLERGY CLIN IMMUN, V90, P683, DOI 10.1016/0091-6749(92)90143-P; *BOST COLL DRUG SU, 1973, JAMA-J AM MED ASSOC, V224, P613; BUSH WH, 1991, AM J ROENTGENOL, V157, P1153; BUSH WH, 1990, UROLOGY, V35, P145, DOI 10.1016/0090-4295(90)80064-T; Centers for Disease Control and Prevention, 1994, DHHS PUBL; Ewan PW, 1998, BRIT MED J, V316, P1442; GREENBERGER PA, 1991, J ALLERGY CLIN IMMUN, V87, P867, DOI 10.1016/0091-6749(91)90135-B; Hollingsworth H, 1997, JAMA-J AM MED ASSOC, V277, P1196; Kagy L, 1998, PEDIATR ANN, V27, P727; KATAYAMA H, 1990, RADIOLOGY, V175, P621; KELLY KJ, 1994, J ALLERGY CLIN IMMUN, V93, P813, DOI 10.1016/0091-6749(94)90370-0; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; LANG DM, 1991, ANN INTERN MED, V115, P270; LIEBERMAN P, 1992, IMMUNOL ALLERGY CLIN, V12, P649; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335; MONERETVAUTRIN DA, 1993, J ALLERGY CLIN IMMUN, V77, P905; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; SAMPSON HA, 1990, J ALLERGY CLIN IMMUN, V86, P1, DOI 10.1016/S0091-6749(05)80115-0; SAMPSON HA, 1992, JAMA-J AM MED ASSOC, V268, P2840, DOI 10.1001/jama.268.20.2840; SHEHADI WH, 1975, AM J ROENTGENOL, V124, P145; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; STARK BJ, 1986, J ALLERGY CLIN IMMUN, V78, P76, DOI 10.1016/0091-6749(86)90117-X; SUE MA, 1988, AM J EMERG MED, V6, P456, DOI 10.1016/0735-6757(88)90245-8; Sullivan TJ., 1993, ALLERGY PRINCIPLES P, P1726; SUSSMAN GL, 1995, ANN INTERN MED, V122, P43; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; VALENTINE M, 1979, ASTHMA OTHER ALLERGI, P467; Valentine M D, 1992, JAMA, V268, P2830; Watts DN, 1998, AM J IND MED, V34, P359, DOI 10.1002/(SICI)1097-0274(199810)34:4<359::AID-AJIM9>3.0.CO;2-N; WEISS ME, 1988, CLIN ALLERGY, V18, P515, DOI 10.1111/j.1365-2222.1988.tb02904.x; World Health Organization, 1977, INT CLASS DIS; Wyatt R, 1996, POSTGRAD MED, V100, P87; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; 1998, J ALLERGY CLIN IMM S, V101, pS465	38	196	202	2	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9926			ARCH INTERN MED	Arch. Intern. Med.	JAN 8	2001	161	1					15	21		10.1001/archinte.161.1.15		7	Medicine, General & Internal	General & Internal Medicine	387LN	WOS:000166124200001	11146694	
J	Bashir, MEH; Louie, S; Shi, HN; Nagler-Anderson, C				Bashir, MEH; Louie, S; Shi, HN; Nagler-Anderson, C			Toll-like receptor 4 signaling by intestinal microbes influences susceptibility to food allergy	JOURNAL OF IMMUNOLOGY			English	Article							MAJOR PEANUT ALLERGEN; ENDOTOXIN EXPOSURE; BALB/C MICE; CD14 GENE; HAY-FEVER; 1ST YEAR; CPG DNA; ASTHMA; RESPONSES; SENSITIZATION	The mechanisms by which signaling by the innate immune system controls susceptibility to allergy are poorly understood. In this report, we show that intragastric administration of a food allergen with a mucosal adjuvant induces allergen-specific IgE, elevated plasma histamine levels, and anaphylactic symptoms in three different strains of mice lacking a functional receptor for bacterial LPS (Toll-like receptor 4 (TLR4)), but not in MHC-matched or congenic controls. Susceptibility to allergy correlates with a Th2-biased cytokine response in both the mucosal (mesenteric lymph node and Peyer's patch) and systemic (spleen) tissues of TLR4-mutant or -deficient mice. TLR4-mutant mice are not inherently impaired in their ability to regulate Th1 cytokine production because they respond to stimulation via TLR9. Coadministration of CpG oligodeoxynucleotides during sensitization of TLR4-mutant mice with allergen plus CT abrogates anaphylactic symptoms and Ag-specific IgE, and results in a Th1-polarized cytokine response. When the composition of the bacterial flora is reduced and altered by antibiotic administration (beginning at 2 wk of age), TLR4 wild-type mice become as susceptible to the induction of allergy as their TLR4-mutant counterparts. Both allergen-specific IgE and Th2 cytokine responses are reduced in antibiotic-treated mice in which the flora has been allowed to repopulate. Taken together, our results suggest that TLR4-dependent signals provided by the intestinal commensal flora inhibit the development of allergic responses to food Ags.	Massachusetts Gen Hosp E, Mucosal Immunol Lab, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Nagler-Anderson, C (reprint author), Massachusetts Gen Hosp E, Mucosal Immunol Lab, Bldg 114,16th St, Charlestown, MA 02129 USA.	nagler_a@helix.mgh.harvard.edu			NIDDK NIH HHS [DK 40561, DK 55678, DK43551]		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Bashir MEH, 2002, J IMMUNOL, V169, P3284; Berg RD, 1996, TRENDS MICROBIOL, V4, P430, DOI 10.1016/0966-842X(96)10057-3; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Burks W, 2003, J CLIN INVEST, V111, P950, DOI 10.1172/JCI200318233; Cebra JJ, 1999, AM J CLIN NUTR, V69, p1046S; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HOMER AA, 2002, ALLERGY S72, V57, P24; Imler JL, 2003, NAT IMMUNOL, V4, P105, DOI 10.1038/ni0203-105; Julia V, 2000, J IMMUNOL, V165, P5637; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kawai T, 2001, J IMMUNOL, V167, P5887; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Koppelman SJ, 1999, J BIOL CHEM, V274, P4770, DOI 10.1074/jbc.274.8.4770; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941; Maleki SJ, 2000, J IMMUNOL, V164, P5844; MARINARO M, 1995, J IMMUNOL, V155, P4621; Matricardi PM, 2003, ALLERGY, V58, P461, DOI 10.1034/j.1398-9995.2003.00175.x; McCluskie MJ, 2000, VACCINE, V19, P413, DOI 10.1016/S0264-410X(00)00208-5; McCluskie MJ, 2000, MOL MED, V6, P867; McCluskie MJ, 1998, J IMMUNOL, V161, P4463; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Morafo V, 2003, J ALLERGY CLIN IMMUN, V111, P1122, DOI 10.1067/mai.2003.1463; Nagler-Anderson C, 2001, NAT REV IMMUNOL, V1, P59, DOI 10.1038/35095573; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Sudo N, 1997, J IMMUNOL, V159, P1739; TOSCHAKOV V, 2002, NAT IMMUNOL, V3, P392	38	195	207	1	16	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUN 1	2004	172	11					6978	6987				10	Immunology	Immunology	822ZN	WOS:000221579600057	15153518	
J	Hanifin, JM; Cooper, KD; Ho, VC; Kang, SW; Krafchik, BR; Margolis, DJ; Schachner, LA; Sidbury, R; Whitmore, SE; Sieck, CK; Van Voorhees, AS				Hanifin, JM; Cooper, KD; Ho, VC; Kang, SW; Krafchik, BR; Margolis, DJ; Schachner, LA; Sidbury, R; Whitmore, SE; Sieck, CK; Van Voorhees, AS		Chair Guidlines Outcomes Task	Guidelines of care for atopic dermatitis	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY			English	Review							PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL; FLUTICASONE PROPIONATE CREAM; CHINESE HERBAL MEDICINE; LONG-TERM EFFICACY; AIR-CONDITIONED PHOTOTHERAPY; ALLERGEN-ANTIBODY COMPLEXES; FUROATE 0.1-PERCENT CREAM; INTERFERON-GAMMA-THERAPY; DOSE UVA1 PHOTOTHERAPY		Amer Acad Dermatol, Schaumburg, IL 60168 USA	Hanifin, JM (reprint author), Amer Acad Dermatol, POB 4014, Schaumburg, IL 60168 USA.			Feldman, Steven/0000-0002-0090-6289			AaltoKorte K, 1997, BRIT J DERMATOL, V136, P172; Abeck D, 2000, J AM ACAD DERMATOL, V42, P254, DOI 10.1016/S0190-9622(00)90134-8; Ainley-Walker PF, 1998, ARCH DIS CHILD, V79, P149; Alaiti S, 1998, J AM ACAD DERMATOL, V38, P69, DOI 10.1016/S0190-9622(98)70541-9; Aliaga A, 1996, INT J DERMATOL, V35, P131, DOI 10.1111/j.1365-4362.1996.tb03280.x; Andersen PH, 1998, ACTA DERM-VENEREOL, V78, P60; BAMFORD JTM, 1985, J AM ACAD DERMATOL, V13, P959, DOI 10.1016/S0190-9622(85)70245-9; Bates DW, 2002, JAMA-J AM MED ASSOC, V288, P1898, DOI 10.1001/jama.288.15.1898; Berberian BJ, 1999, INT J DERMATOL, V38, P145, DOI 10.1046/j.1365-4362.1999.00505.x; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; BerthJones J, 1996, J AM ACAD DERMATOL, V34, P1016, DOI 10.1016/S0190-9622(96)90281-9; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1111/j.1365-2133.1997.tb08750.x; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; BERTHJONES J, 1990, BRIT J DERMATOL, V122, P553, DOI 10.1111/j.1365-2133.1990.tb14733.x; BERTHJONES J, 1993, LANCET, V341, P1557, DOI 10.1016/0140-6736(93)90697-F; BLEEHEN SS, 1995, BRIT J DERMATOL, V133, P592, DOI 10.1111/j.1365-2133.1995.tb02711.x; Boguniewicz M, 1998, J ALLERGY CLIN IMMUN, V102, P637, DOI 10.1016/S0091-6749(98)70281-7; Boguniewicz M, 2001, J ALLERGY CLIN IMMUN, V108, P651, DOI 10.1067/mai.2001.118598; Breneman DL, 2000, CUTIS, V66, P296; BROBERG A, 1990, ACTA DERM-VENEREOL, V70, P495; Bunikowski R, 2001, PEDIATR ALLERGY IMMU, V12, P216, DOI 10.1034/j.1399-3038.2001.012004216.x; Capella GL, 2001, EUR J DERMATOL, V11, P209; Cato A, 2001, INT J DERMATOL, V40, P232, DOI 10.1046/j.1365-4362.2001.01161.x; Chamlin SL, 2001, ARCH DERMATOL, V137, P1110; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; Charman CR, 2000, BRIT J DERMATOL, V142, P931, DOI 10.1046/j.1365-2133.2000.03473.x; Chawla M, 1996, BRIT J DERMATOL, V135, P9, DOI 10.1111/j.1365-2133.1996.tb00703.x; Chinn DJ, 2002, BRIT J DERMATOL, V146, P432, DOI 10.1046/j.1365-2133.2002.04603.x; COLE WC, 1988, J AM ACAD DERMATOL, V18, P286, DOI 10.1016/S0190-9622(88)70041-9; COLLINS P, 1995, BRIT J DERMATOL, V133, P653, DOI 10.1111/j.1365-2133.1995.tb02725.x; COSTA C, 1989, ACTA DERM-VENEREOL, V69, P41; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; Cummings SR, 2002, JAMA-J AM MED ASSOC, V288, P1889, DOI 10.1001/jama.288.15.1889; DOHERTY V, 1989, BRIT MED J, V298, P96; DRAKE LA, 1994, J AM ACAD DERMATOL, V31, P613; EHLERS A, 1995, J CONSULT CLIN PSYCH, V63, P624, DOI 10.1037//0022-006X.63.4.624; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; EWING CI, 1991, EUR J CLIN NUTR, V45, P507; Ewing CI, 1998, BRIT J DERMATOL, V138, P1022; Fairfield KM, 2002, JAMA-J AM MED ASSOC, V287, P3116, DOI 10.1001/jama.287.23.3116; *FDA, 2002, CDER DRUG APPR 1998; Ferguson JE, 1997, BRIT J DERMATOL, V136, P592, DOI 10.1046/j.1365-2133.1997.d01-1241.x; Finlay AY, 1996, BRIT J DERMATOL, V135, P509, DOI 10.1111/j.1365-2133.1996.tb03822.x; Friedlander SF, 2002, J AM ACAD DERMATOL, V46, P387, DOI 10.1067/mjd.2002.118337; Friedmann PS, 1998, ALLERGY, V53, P97; Fung AYP, 1999, INT J DERMATOL, V38, P387, DOI 10.1046/j.1365-4362.1999.00732.x; GEORGE SA, 1993, BRIT J DERMATOL, V128, P49, DOI 10.1111/j.1365-2133.1993.tb00147.x; Gimenez-Arnau A, 1997, ADV EXP MED BIOL, V433, P285; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; GOODMAN CS, 1998, TA101 INTRO HLTH CAR; GRANLUND H, 1995, BRIT J DERMATOL, V132, P106, DOI 10.1111/j.1365-2133.1995.tb08633.x; Griffiths CEM, 2002, BRIT J DERMATOL, V147, P299, DOI 10.1046/j.1365-2133.2002.04894.x; Grundmann-Kollman M, 2001, ARCH DERMATOL, V137, P870; Grundmann-Kollmann Marcella, 1999, Journal of the American Academy of Dermatology, V40, P995, DOI 10.1016/S0190-9622(99)70090-3; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Hanifin J, 2002, BRIT J DERMATOL, V147, P528, DOI 10.1046/j.1365-2133.2002.05006.x; Hanifin JM, 1996, J INVEST DERMATOL, V107, P51, DOI 10.1111/1523-1747.ep12297888; Hanifin JM, 1998, CURR THER RES CLIN E, V59, P227, DOI 10.1016/S0011-393X(98)85076-5; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hanifin JM, 2001, J AM ACAD DERMATOL, V44, pS28, DOI 10.1067/mjd.2001.109810; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; HANNUKSELA M, 1993, ANN ALLERGY, V70, P127; Harper J, 2001, BRIT J DERMATOL, V144, P781, DOI 10.1046/j.1365-2133.2001.04133.x; Harper JI, 2000, BRIT J DERMATOL, V142, P52, DOI 10.1046/j.1365-2133.2000.03241.x; Hederos CA, 1996, ARCH DIS CHILD, V75, P494; Henz BM, 1999, BRIT J DERMATOL, V140, P685; HERZ G, 1991, J AM ACAD DERMATOL, V25, P1166, DOI 10.1016/0190-9622(91)70319-W; HO VC, 2003, J PEDIATR, V143, P23; Hoare C, 2000, Health Technol Assess, V4, P1; Holgate ST, 1997, NEW ENGL J MED, V337, P1690, DOI 10.1056/NEJM199712043372312; Holm L, 2001, ALLERGY, V56, P152, DOI 10.1034/j.1398-9995.2001.056002152.x; HORNE DJD, 1989, BRIT J MED PSYCHOL, V62, P241; HSIEH KH, 1992, ARCH DIS CHILD, V67, P1095; HudsonPeacock MJ, 1996, BRIT J DERMATOL, V135, P332, DOI 10.1111/j.1365-2133.1996.tb01179.x; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Jang IG, 2000, J AM ACAD DERMATOL, V42, P1033, DOI 10.1016/S0190-9622(00)90300-1; JEKLER J, 1991, BRIT J DERMATOL, V125, P569, DOI 10.1111/j.1365-2133.1991.tb14796.x; JOLLES S, 2000, ADJUNCTIVE HIGH DOSE; JORIZZO J, 1995, J AM ACAD DERMATOL, V33, P74, DOI 10.1016/0190-9622(95)90014-4; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; KANG S, 2001, J AM ACAD DERM S1, V44, P558; KAPP A, 2002, J ALLERGY CLIN IMMUN, V110, P3; Keane FM, 1999, BRIT MED J, V318, P563; KELLY JW, 1994, AUSTR J DERMATOL, V32, P85; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Kolmer HL, 1996, J ALLERGY CLIN IMMUN, V98, P702, DOI 10.1016/S0091-6749(96)70106-9; Koo J, 1998, ARCH DERMATOL, V134, P1388, DOI 10.1001/archderm.134.11.1388; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; KORSTANJE MJ, 1991, ACTA DERM-VENEREOL, V71, P356; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; Kubota K, 1997, ACTA DERM-VENEREOL, V77, P452; LANGELAND T, 1994, ALLERGY, V49, P22, DOI 10.1111/j.1398-9995.1994.tb00768.x; LAROSA M, 1994, ANN ALLERGY, V73, P117; Latchman Y, 1996, INT ARCH ALLERGY IMM, V109, P243; Lebwohl M, 1999, INT J DERMATOL, V38, P604, DOI 10.1046/j.1365-4362.1999.00759.x; Leroy B P, 1992, Acta Derm Venereol Suppl (Stockh), V176, P129; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; LEROY BP, 1995, BRIT J DERMATOL, V132, P599; LEROY BP, 1991, DERMATOLOGICA, V182, P98; LEUNG DYM, 1990, J ALLERGY CLIN IMMUN, V85, P927, DOI 10.1016/0091-6749(90)90079-J; LEUNG DYM, 2002, ROLE STAPHYLOCOCCUS, P401; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; Lever R, 1998, PEDIATR ALLERGY IMMU, V9, P13, DOI 10.1111/j.1399-3038.1998.tb00294.x; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; Long CC, 1998, BRIT J DERMATOL, V138, P293, DOI 10.1046/j.1365-2133.1998.02077.x; Lucky AW, 1997, CUTIS, V59, P151; Luger T, 2001, BRIT J DERMATOL, V144, P788, DOI 10.1046/j.1365-2133.2001.04134.x; MABIN DC, 1995, ARCH DIS CHILD, V73, P208; MABIN DC, 1995, BRIT J DERMATOL, V133, P764; MABIN DC, 1995, ARCH DIS CHILD, V73, P202; Maloney JM, 1998, INT J DERMATOL, V37, P142; Marini A, 1996, Acta Paediatr Suppl, V414, P1; Matsuda K, 2000, ANN ALLERG ASTHMA IM, V85, P35; MCMENAMY CJ, 1988, J BEHAV THER EXP PSY, V19, P221, DOI 10.1016/0005-7916(88)90045-6; Meggitt SJ, 2001, CLIN EXP DERMATOL, V26, P369, DOI 10.1046/j.1365-2230.2001.00837.x; Meurer M, 2002, DERMATOLOGY, V205, P271, DOI 10.1159/000065863; MONROE EW, 1992, CLIN THER, V14, P17; Morris AD, 2002, BRIT J DERMATOL, V146, P705, DOI 10.1046/j.1365-2133.2001.46862.x; Moshang T, 2001, CUTIS, V68, P63; MUNKVAD M, 1989, BRIT J DERMATOL, V121, P763, DOI 10.1111/j.1365-2133.1989.tb08219.x; MUNRO CS, 1991, BRIT J DERMATOL, V124, P43; MUNRO CS, 1994, BRIT J DERMATOL, V130, P376, DOI 10.1111/j.1365-2133.1994.tb02936.x; MUSIAL J, 1995, ALLERGY, V50, P520, DOI 10.1111/j.1398-9995.1995.tb01190.x; Neuber K, 2000, BRIT J DERMATOL, V143, P385, DOI 10.1046/j.1365-2133.2000.03667.x; Noh G, 2001, CLIN EXP ALLERGY, V31, P1932, DOI 10.1046/j.1365-2222.2001.01124.x; Odelram H, 1996, ALLERGY, V51, P192, DOI 10.1111/j.1398-9995.1996.tb04587.x; OGAWA H, 1992, PEDIATR DERMATOL, V9, P383, DOI 10.1111/j.1525-1470.1992.tb00638.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Paller A, 2001, J AM ACAD DERMATOL, V44, pS47, DOI 10.1067/mjd.2001.109813; Paller AS, 2003, J AM ACAD DERMATOL, V48, P569, DOI 10.1067/mjd.2003.174; Pei AYS, 2001, PEDIATR ALLERGY IMMU, V12, P154, DOI 10.1034/j.1399-3038.2001.012003154.x; PERHARIC L, 1995, VET HUM TOXICOL, V37, P562; PHERICWALTON L, 1992, LANCET, V340, P673; PRINZ B, 1994, ARCH DERMATOL RES, V287, P48, DOI 10.1007/BF00370718; Prinz B, 1999, J AM ACAD DERMATOL, V40, P577, DOI 10.1016/S0190-9622(99)70440-8; Ramsay CA, 1996, J EUR ACAD DERMAT S1, V7, pS15, DOI 10.1016/0926-9959(96)00032-3; RASMUSSEN JE, 1978, ARCH DERMATOL, V114, P1165, DOI 10.1001/archderm.114.8.1165; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; REINHOLD U, 1993, J AM ACAD DERMATOL, V29, P58; Reitamo S, 2000, ARCH DERMATOL, V136, P999, DOI 10.1001/archderm.136.8.999; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P547, DOI 10.1067/mai.2002.121832; Reitamo S, 2002, J ALLERGY CLIN IMMUN, V109, P539, DOI 10.1067/mai.2002.121831; Reynolds NJ, 2001, LANCET, V357, P2012, DOI 10.1016/S0140-6736(00)05114-X; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; RUZICKA T, 1980, ARCH DERMATOL RES, V269, P109, DOI 10.1007/BF00404466; Ruzicka T, 1997, NEW ENGL J MED, V337, P816, DOI 10.1056/NEJM199709183371203; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SALEK MS, 1993, BRIT J DERMATOL, V129, P422, DOI 10.1111/j.1365-2133.1993.tb03170.x; Sambrook PN, 2000, LANCET, V355, P1385, DOI 10.1016/S0140-6736(00)02134-6; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; Schachner L, 1998, PEDIATR DERMATOL, V15, P390, DOI 10.1046/j.1525-1470.1998.1998015390.x; Schneider LC, 1998, ANN ALLERG ASTHMA IM, V80, P263; Sears HW, 1997, CLIN THER, V19, P710, DOI 10.1016/S0149-2918(97)80095-1; SHAH VP, 1989, ARCH DERMATOL, V125, P1558, DOI 10.1001/archderm.125.11.1558; SHEEHAN MP, 1993, BRIT J DERMATOL, V129, P431, DOI 10.1111/j.1365-2133.1993.tb03171.x; SHEEHAN MP, 1995, CLIN EXP DERMATOL, V20, P136; SHEEHAN MP, 1992, BRIT J DERMATOL, V126, P179, DOI 10.1111/j.1365-2133.1992.tb07817.x; SHEEHAN MP, 1994, BRIT J DERMATOL, V130, P488, DOI 10.1111/j.1365-2133.1994.tb03383.x; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; SHUPACK J, 1991, DERMATOLOGICA, V183, P21; Sidbury R, 2000, CLIN EXP DERMATOL, V25, P559, DOI 10.1046/j.1365-2230.2000.00697.x; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; SLOPER KS, 1991, Q J MED, V80, P677; Soter NA, 2001, J AM ACAD DERMATOL, V44, pS39, DOI 10.1067/mjd.2001.109817; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Stalder J F, 1992, Acta Derm Venereol Suppl (Stockh), V176, P132; STALDER JF, 1993, DERMATOLOGY, V186, P23; Staughton R, 2001, J AM ACAD DERMATOL, V45, pS53, DOI 10.1067/mjd.2001.117014; STEVENS LM, 2002, JAMA, V287; Stevens SR, 1998, ARCH DERMATOL, V134, P799, DOI 10.1001/archderm.134.7.799; STEWART AC, 1995, BRIT J DERMATOL, V132, P778; STILLER MJ, 1994, J AM ACAD DERMATOL, V30, P597; STROUGHTON RB, 1989, ARCH DERMATOL, V125, P1509; STROUGHTON RB, 1987, ARCH DERMATOL, V123, P1312; Sugiura H, 2000, ARCH DERMATOL, V136, P1062, DOI 10.1001/archderm.136.8.1062; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tan MH, 2001, J AM ACAD DERMATOL, V45, P392, DOI 10.1067/mjd.2001.116220; Tharp MD, 1996, CUTIS, V57, P19; Thomas KS, 2002, BRIT MED J, V324, P768, DOI 10.1136/bmj.324.7340.768; TURPEINEN M, 1986, BRIT J DERMATOL, V115, P475, DOI 10.1111/j.1365-2133.1986.tb06242.x; TURPEINEN M, 1988, ACTA DERM-VENEREOL, V68, P331; Tzaneva S, 2001, J AM ACAD DERMATOL, V45, P503, DOI 10.1067/mjd.2001.114743; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Van Leent EJM, 1998, ARCH DERMATOL, V134, P805, DOI 10.1001/archderm.134.7.805; VANJOOST T, 1994, BRIT J DERMATOL, V130, P634; VERNON HJ, 1991, J AM ACAD DERMATOL, V24, P603, DOI 10.1016/0190-9622(91)70092-G; von Kobyletzki G, 1999, J AM ACAD DERMATOL, V41, P931, DOI 10.1016/S0190-9622(99)70249-5; WAHLGREN CF, 1990, BRIT J DERMATOL, V122, P545, DOI 10.1111/j.1365-2133.1990.tb14732.x; WAHLGREN CF, 1990, ACTA DERM-VENEREOL, V70, P323; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; Wakim M, 1998, ANN ALLERG ASTHMA IM, V81, P153; Whitmore SE, 1999, JAMA-J AM MED ASSOC, V281, P791; Willett WC, 2001, NEW ENGL J MED, V345, P1819, DOI 10.1056/NEJMcp010710; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wolkerstorfer A, 1998, J AM ACAD DERMATOL, V39, P226, DOI 10.1016/S0190-9622(98)70080-5; Wolkerstorfer A, 2000, BRIT J DERMATOL, V143, P999, DOI 10.1046/j.1365-2133.2000.03833.x; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Woodmansee DP, 1999, ANN ALLERG ASTHMA IM, V83, P548, DOI 10.1016/S1081-1206(10)62868-2; Worm M, 2000, CLIN EXP ALLERGY, V30, P407, DOI 10.1046/j.1365-2222.2000.00722.x; Yanase DJ, 2001, J AM ACAD DERMATOL, V44, P89, DOI 10.1067/mjd.2001.111352; YAWALKAR SJ, 1991, J AM ACAD DERMATOL, V25, P1163, DOI 10.1016/0190-9622(91)70318-V; Yunginger JW, 2001, CUTIS, V68, P153; Zaki I, 1996, BRIT J DERMATOL, V135, P21, DOI 10.1111/j.1365-2133.1996.tb00705.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zonneveld IM, 1996, BRIT J DERMATOL, V135, P15, DOI 10.1111/j.1365-2133.1996.tb00704.x	211	195	209	3	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0190-9622			J AM ACAD DERMATOL	J. Am. Acad. Dermatol.	MAR	2004	50	3					391	404		10.1016/j.jaad.2003.08.003		14	Dermatology	Dermatology	801EZ	WOS:000220080500011	14988682	
J	Nicolai, T; Carr, D; Weiland, SK; Duhme, H; von Ehrenstein, O; Wagner, C; von Mutius, E				Nicolai, T; Carr, D; Weiland, SK; Duhme, H; von Ehrenstein, O; Wagner, C; von Mutius, E			Urban traffic and pollutant exposure related to respiratory outcomes and atopy in a large sample of children	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; atopy; children; pollutants; respiratory; traffic	DIESEL EXHAUST PARTICLES; AIR-POLLUTION; ALLERGIC SENSITIZATION; LUNG-FUNCTION; ASTHMA; SYMPTOMS; PREVALENCE; INFLAMMATION; GERMANY; POLLEN	Conflicting results have been reported for the relationship between traffic exposure and inception of atopy. The effect of traffic on the prevalence of asthma and atopy at school age was investigated in a representative population. Random samples of schoolchildren (n = 7,509, response rate 83.7%,) were studied using the International Study of Asthma and Allergies in Childhood phase-II protocol with skin-prick tests, measurements of specific immunoglobulin E and lung function. Traffic exposure was assessed via traffic counts and by an emission model which predicted soot, benzene and nitrogen dioxide (NO2). Traffic counts were associated with current asthma, wheeze and cough. In children with tobacco-smoke exposure, traffic volume was additionally associated with a positive skin-prick test. Cough was associated with soot, benzene and NO2, current asthma with soot and benzene, and current wheeze with benzene and NO2. No pollutant was associated with allergic sensitisation. High vehicle traffic was associated with asthma, cough and wheeze, and in children additionally exposed to environmental tobacco smoke, with allergic sensitisation. However, effects of socioeconomic factors associated with living close to busy roads cannot be ruled out.	Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany; Univ Munster, Inst Epidemiol & Social Med, D-4400 Munster, Germany	Nicolai, T (reprint author), Univ Munich, Childrens Hosp, D-8000 Munich, Germany.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BARBEE RA, 1976, ANN INTERN MED, V84, P129; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Carr D, 2002, ENVIRON RES, V90, P111, DOI 10.1006/enrs.2002.4393; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Devalia JL, 1997, ALLERGY, V52, P45; Emberlin J, 1995, CLIN EXP ALLERGY, V25, P33, DOI 10.1111/j.1365-2222.1995.tb00040.x; Gardner RM, 1987, AM REV RESPIR DIS, V136, P1285; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hirsch T, 2000, J ALLERGY CLIN IMMUN, V106, P573, DOI 10.1067/mai.2000.109430; Kabesch M, 1999, EUR RESPIR J, V13, P577, DOI 10.1183/09031936.99.13357799; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; von Ehrenstein OS, 2002, EUR RESPIR J, V19, P1099, DOI 10.1183/09031936.02.00104302; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WILLIAMS PB, 1995, J ALLERGY CLIN IMMUN, V95, P88, DOI 10.1016/S0091-6749(95)70156-7; WJST M, 1993, BRIT MED J, V307, P596; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; ZAPLETAL A, 1977, Zeitschrift fuer Erkrankungen der Atmungsorgane, V149, P343	31	195	198	1	21	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUN	2003	21	6					956	963		10.1183/09031936.03.00041103		8	Respiratory System	Respiratory System	685CH	WOS:000183242900009	12797488	
J	ten Brinke, A; Zwinderman, AH; Sterk, PJ; Rabe, KF; Bel, EH				ten Brinke, A; Zwinderman, AH; Sterk, PJ; Rabe, KF; Bel, EH			Factors associated with persistent airflow limitation in severe asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; severity of illness index; airway obstruction; sputum; eosinophilia	AIR-FLOW OBSTRUCTION; LONG-TERM INFLAMMATION; LUNG-FUNCTION; BRONCHIAL-ASTHMA; FOLLOW-UP; PULMONARY-FUNCTION; NATURAL-HISTORY; RISK-FACTORS; DECLINE; ADULTS	Persistent airflow limitation can develop in nonsmoking patients with asthma. However, the prevalence and risk factors for airways obstruction with incomplete reversibility in asthma are unknown. We assessed the prevalence of persistent airflow limitation (defined as postbronchodilator FEV1 or FEV1/VC < 75% predicted) in 132 nonsmoking outpatients with severe asthma visiting chest physicians in general hospitals in The Netherlands. They had used inhaled corticosteroids (greater than or equal to 1,600 mug/d) and/or daily oral prednisone and long-acting bronchodilators for > 1 yr. In addition, we examined whether persistent airways obstruction in these patients was associated with specific clinical characteristics (age at onset, smoking history, atopic status, bronchodilator reversibility, provocative concentration of histamine causing a 20% decrease in FEV1 [PC(20)histamine]) or markers of inflammation (exhaled nitric oxide [NO], blood eosinophils, total IgE; and eosinophilia or neutrophilia in induced sputum). Multiple logistic regression analyses were used to calculate adjusted odds ratios (OR). Persistent airflow limitation was observed in 49% of the patients in the study, and apart from older age and longer asthma duration, was strongly associated with a sputum eosinophils percent greater than or equal to 2% (OR = 7.7; confidence interval [CI]: 2.4 to 25), PC(20)histamine less than or equal to 1.0 mg/ml (OR = 3.9; CI: 1.2 to 13), and adult onset (greater than or equal to 18 yr) of asthma (OR = 3.3; CI: 1.2 to 9). Only sputum eosinophilia appeared to be independently associated with persistent airflow limitation (OR = 8.9; CI: 1.3 to 59). In conclusion, persistent airflow limitation is common in adult patients with severe asthma, and is associated with adult onset of the disease, airway hyperresponsiveness, and most importantly, sputum eosinophilia. These findings suggest that eosinophilic airway inflammation contributes to persistent airflow limitation in severe asthma. Whether reduction of sputum eosinophils with more vigorous treatment leads to a better prognosis in severe asthma is still an open question.	Leiden Univ, Med Ctr, Dept Pulm Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Dept Med Stat, NL-2300 RA Leiden, Netherlands	ten Brinke, A (reprint author), Leiden Univ, Med Ctr, Dept Pulm Dis, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.						AKHTER J, 1989, ANN ALLERGY, V63, P53; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Belda J, 2000, AM J RESP CRIT CARE, V161, P475; BIRKLAND TP, 1994, ARCH DERMATOL RES, V286, P312, DOI 10.1007/BF00402221; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; Carr DH, 1998, RESP MED, V92, P448, DOI 10.1016/S0954-6111(98)90290-6; Chung KF, 1999, EUR RESPIR J, V13, P1198; COCKCROFT DW, 1992, J ALLERGY CLIN IMMUN, V89, P23, DOI 10.1016/S0091-6749(05)80037-5; COTES JE, 1993, EUR RESPIR J, V6, P41, DOI 10.1183/09041950.041s1693; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; ELIASSON O, 1985, AM REV RESPIR DIS, V132, P858; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267; Homer RJ, 2000, CLIN CHEST MED, V21, P331, DOI 10.1016/S0272-5231(05)70270-7; Ichinose M, 2000, EUR RESPIR J, V15, P248, DOI 10.1034/j.1399-3003.2000.15b05.x; In 'T Veen J. C. C. M., 1996, European Respiratory Journal, V9, P2441, DOI 10.1183/09031936.96.09122441; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Lamblin C, 1999, J ALLERGY CLIN IMMUN, V104, P85, DOI 10.1016/S0091-6749(99)70118-1; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; McFadden ER, 2000, J ALLERGY CLIN IMMUN, V105, pS535, DOI 10.1016/S0091-6749(00)90057-5; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; RIJCKEN B, 1995, AM J RESP CRIT CARE, V151, P1377; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; SHOCK A, 1991, CLIN EXP IMMUNOL, V86, P185; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TENBRINKE A, 2000, IN PRESS AM J RESP C, V164; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Ulrik CS, 1998, ANN ALLERG ASTHMA IM, V80, P487; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001	42	195	196	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2001	164	5					744	748				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	472QQ	WOS:000170996800007	11549526	
J	Abrahamsson, TR; Jakobsson, HE; Andersson, AF; Bjorksten, B; Engstrand, L; Jenmalm, MC				Abrahamsson, Thomas R.; Jakobsson, Hedvig E.; Andersson, Anders F.; Bjorksten, Bengt; Engstrand, Lars; Jenmalm, Maria C.			Low diversity of the gut microbiota in infants with atopic eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic disease; Bacteroides species; diversity; eczema; hygiene hypothesis; infant; microbiota; molecular microbiology; pyrosequencing; Sutterella species	INTESTINAL MICROBIOTA; MOLECULAR ANALYSIS; REDUCED DIVERSITY; MICROFLORA; EXPOSURE; DISEASE; ALLERGY; COHORT; RISK	Background: It is debated whether a low total diversity of the gut microbiota in early childhood is more important than an altered prevalence of particular bacterial species for the increasing incidence of allergic disease. The advent of powerful, cultivation-free molecular methods makes it possible to characterize the total microbiome down to the genus level in large cohorts. Objective: We sought to assess microbial diversity and characterize the dominant bacteria in stool during the first year of life in relation to atopic eczema development. Methods: Microbial diversity and composition were analyzed with barcoded 16S rDNA 454-pyrosequencing in stool samples at 1 week, 1 month, and 12 months of age in 20 infants with IgE-associated eczema and 20 infants without any allergic manifestation until 2 years of age (ClinicalTrials.gov ID NCT01285830). Results: Infants with IgE-associated eczema had a lower diversity of the total microbiota at 1 month (P = .004) and a lower diversity of the bacterial phylum Bacteroidetes and the genus Bacteroides at 1 month (P = .02 and P = .01) and the phylum Proteobacteria at 12 months of age (P = .02). The microbiota was less uniform at 1 month than at 12 months of age, with a high interindividual variability. At 12 months, when the microbiota had stabilized, Proteobacteria, comprising gram-negative organisms, were more abundant in infants without allergic manifestation (Empirical Analysis of Digital Gene Expression in R [edgeR] test: P = .008, q = 0.02). Conclusion: Low intestinal microbial diversity during the first month of life was associated with subsequent atopic eczema. (J Allergy Clin Immunol 2012;129:434-40.)	[Abrahamsson, Thomas R.; Jenmalm, Maria C.] Linkoping Univ, Dept Clin & Expt Med, Div Pediat, S-58183 Linkoping, Sweden; [Jakobsson, Hedvig E.; Engstrand, Lars] Swedish Inst Communicable Dis Control, Dept Preparedness, Solna, Sweden; [Jakobsson, Hedvig E.; Engstrand, Lars] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Andersson, Anders F.] KTH Royal Inst Technol, Sci Life Lab, Sch Biotechnol, Stockholm, Sweden; [Bjorksten, Bengt] Univ Orebro, Sch Hlth & Med Sci, Orebro, Sweden; [Bjorksten, Bengt] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Jenmalm, Maria C.] Linkoping Univ, Dept Clin & Expt Med, Unit Autoimmun & Immune Regulat, Div Clin Immunol, S-58183 Linkoping, Sweden	Abrahamsson, TR (reprint author), Linkoping Univ Hosp, Div Paediat, SE-58185 Linkoping, Sweden.	thomas.abrahamsson@lio.se	Jenmalm, Maria/C-9679-2009	Jenmalm, Maria/0000-0002-2117-5366; Andersson, Anders/0000-0002-3627-6899	BioGaia AB, Stockholm, Sweden; Ekhaga Foundation, the Heart and Lung foundation; Research Council for the South-East Sweden [F2000-106]; Olle Engqvist Foundation; Swedish Asthma and Allergy Association; Swedish Research Council; University Hospital of Linkoping; Soderberg Foundation; Vardal Foundation for Health Care Science and Allergy Research, Sweden; BioGaia AB	Supported by grants from BioGaia AB, Stockholm, Sweden; the Ekhaga Foundation, the Heart and Lung foundation; the Research Council for the South-East Sweden (grant no. F2000-106); the Olle Engqvist Foundation; the Swedish Asthma and Allergy Association; the Swedish Research Council; the University Hospital of Linkoping; the Soderberg Foundation; and the Vardal Foundation for Health Care Science and Allergy Research, Sweden.; B. Bjorksten has received research support from BioGaia AB. M. C. Jenmalm has received lecture honoraria from BioGaia AB. The rest of the authors declare that they have no relevant conflicts of interest.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Andersson AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002836; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, pe5; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; BJORKSTEN B, 1999, CLIN EXP ALLERGY, V29, P1; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Doreswamy V, 2010, CLIN EXP ALLERGY, V41, P9; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Freitas M, 2005, HISTOCHEM CELL BIOL, V124, P423, DOI 10.1007/s00418-005-0004-1; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Hamady M, 2009, GENOME RES, V19, P1141, DOI 10.1101/gr.085464.108; Hayashi H, 2005, J MED MICROBIOL, V54, P1093, DOI 10.1099/jmm.0.45935-0; Hayek, 1996, SURVEYING NATURAL PO; Herlemann DPR, 2011, ISME J, V5, P1571, DOI 10.1038/ismej.2011.41; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; Hooper LV, 2001, SCIENCE, V291, P881, DOI 10.1126/science.291.5505.881; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; MacDonald G., 2003, BIOGEOGRAPHY INTRO S; Maidak BL, 2000, NUCLEIC ACIDS RES, V28, P173, DOI 10.1093/nar/28.1.173; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Prescott Susan L, 2003, Curr Opin Allergy Clin Immunol, V3, P125, DOI 10.1097/00130832-200304000-00006; Quince C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-38; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105	36	194	203	12	85	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2012	129	2					434	U244		10.1016/j.jaci.2011.10.025		9	Allergy; Immunology	Allergy; Immunology	887TC	WOS:000299951700021	22153774	
J	Perera, F; Tang, WY; Herbstman, J; Tang, DL; Levin, L; Miller, R; Ho, SM				Perera, Frederica; Tang, Wan-yee; Herbstman, Julie; Tang, Deliang; Levin, Linda; Miller, Rachel; Ho, Shuk-mei			Relation of DNA Methylation of 5 '-CpG Island of ACSL3 to Transplacental Exposure to Airborne Polycyclic Aromatic Hydrocarbons and Childhood Asthma	PLOS ONE			English	Article								In a longitudinal cohort of similar to 700 children in New York City, the prevalence of asthma (>25%) is among the highest in the US. This high risk may in part be caused by transplacental exposure to traffic-related polycyclic aromatic hydrocarbons (PAHs) but biomarkers informative of PAH-asthma relationships is lacking. We here hypothesized that epigenetic marks associated with transplacental PAH exposure and/or childhood asthma risk could be identified in fetal tissues. Mothers completed personal prenatal air monitoring for PAH exposure determination. Methylation sensitive restriction fingerprinting was used to analyze umbilical cord white blood cell (UCWBC) DNA of 20 cohort children. Over 30 DNA sequences were identified whose methylation status was dependent on the level of maternal PAH exposure. Six sequences were found to be homologous to known genes having one or more 5'-CpG island(s) (5'-CGI). Of these, acyl-CoA synthetase long-chain family member 3 (ACSL3) exhibited the highest concordance between the extent of methylation of its 5'-CGI in UCWBCs and the level of gene expression in matched fetal placental tissues in the initial 20 cohort children. ACSL3 was therefore chosen for further investigation in a larger sample of 56 cohort children. Methylation of the ACSL3 5'-CGI was found to be significantly associated with maternal airborne PAH exposure exceeding 2.41 ng/m(3) (OR = 13.8; p<0.001; sensitivity = 75%; specificity = 82%) and with a parental report of asthma symptoms in children prior to age 5 (OR = 3.9; p<0.05). Thus, if validated, methylated ACSL3 5'CGI in UCWBC DNA may be a surrogate endpoint for transplacental PAH exposure and/or a potential biomarker for environmentally-related asthma. This exploratory report provides a new blueprint for the discovery of epigenetic biomarkers relevant to other exposure assessments and/or investigations of exposure-disease relationships in birth cohorts. The results support the emerging theory of early origins of later life disease development.		Perera, F (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY 10027 USA.	shuk-mei.ho@uc.edu			NIEHS NIH HHS [ES013071, ES006096, ES008977, ES009600, ES015584, ES015905, ES016817, K99 ES016817, P01 ES009600, P01 ES009600-060005, P30 ES006096, P50 ES015905, P50 ES015905-010001, R00 ES016817, R01 ES008977, R01 ES013163, R01 ES015584, R21 ES013071]		Agarwal S, 1998, CURR OPIN IMMUNOL, V10, P345, DOI 10.1016/S0952-7915(98)80174-X; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Aqeilan RI, 2005, CANCER RES, V65, P6764, DOI 10.1158/0008-5472.CAN-05-1150; Beck M, 2000, ACTA PAEDIATR, V89, P279, DOI 10.1080/080352500750028401; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; Bouzigon E, 2007, EUR RESPIR J, V30, P253, DOI 10.1183/09031936.00162206; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Coleman RA, 2004, PROG LIPID RES, V43, P134, DOI 10.1016/S0163-7827(03)00051-1; DAS DK, 1982, LUNG, V160, P207, DOI 10.1007/BF02719294; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Faergeman NJ, 1997, BIOCHEM J, V323, P1; Fujino T, 1996, J BIOL CHEM, V271, P16748; Godschalk RWL, 2003, J BIOCHEM MOL BIOL, V36, P1; Gyorffy E, 2008, MUTAGENESIS, V23, P1, DOI 10.1093/mutage/gem043; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hilakivi-Clarke L, 2006, TRENDS ENDOCRIN MET, V17, P340, DOI 10.1016/j.tem.2006.09.002; Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004; Ho SM, 2006, CANCER RES, V66, P5624, DOI 10.1158/0008-5472.CAN-06-0516; Huang THM, 1997, CANCER RES, V57, P1030; Jedrychowski W, 2005, EUR J EPIDEMIOL, V20, P775, DOI 10.1007/s10654-005-1048-1; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Khaled AR, 2005, J CELL BIOL, V169, P755, DOI 10.1083/jcb.200409099; Kuzmin A, 2008, GENE EXPR PATTERNS, V8, P107, DOI 10.1016/j.modgep.2007.09.005; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Li SF, 2003, ANN NY ACAD SCI, V983, P161; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E4000002-JLR200; Mashima T, 2005, J NATL CANCER I, V97, P765, DOI 10.1093/jnci.dji133; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Minekura H, 2001, GENE, V278, P185, DOI 10.1016/S0378-1119(01)00714-4; Miyazaki M, 2003, PROSTAG LEUKOTR ESS, V68, P113, DOI 10.1016/S0952-3278(02)00261-2; Mori Trevor A, 2004, Curr Atheroscler Rep, V6, P461, DOI 10.1007/s11883-004-0087-5; Nicholas SW, 2005, AM J PUBLIC HEALTH, V95, P245, DOI 10.2105/AJPH.2004.042705; Oddy WH, 2006, PEDIATR ALLERGY IMMU, V17, P4, DOI 10.1111/j.1399-3038.2005.00340.x; Padmanabhan V, 2007, REV ENDOCR METAB DIS, V8, P67, DOI 10.1007/s11154-007-9051-3; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Prins GS, 2007, REPROD TOXICOL, V23, P374, DOI 10.1016/j.reprotox.2006.10.001; Selgrade MK, 2006, ENVIRON HEALTH PERSP, V114, P615, DOI 10.1289/ehp.8376; Stock W, 2000, LANCET, V355, P1351, DOI 10.1016/S0140-6736(00)02125-5; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; TANG WY, 2008, ENDOCRINOLOGY   0731; Tomita Michiyo, 2004, Lipids Health Dis, V3, P1, DOI 10.1186/1476-511X-3-1; Tykocinski LO, 2005, J BIOL CHEM, V280, P28177, DOI 10.1074/jbc.M502038200; Van Horn CG, 2005, BIOCHEMISTRY-US, V44, P1635, DOI 10.1021/bi0477211; Weber P, 2001, BRIT J NUTR, V86, pS93, DOI 10.1079/BJN2001344; Wijga A, 2003, PEDIATR ALLERGY IMMU, V14, P156, DOI 10.1034/j.1399-3038.2003.00022.x; Woods RK, 2004, THORAX, V59, P105, DOI 10.1136/thorax.2003.009498; Wu MC, 2004, ONCOGENE, V23, P250, DOI 10.1038/sj.onc.1207076	51	194	206	3	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	FEB 16	2009	4	2							e4488	10.1371/journal.pone.0004488		14	Multidisciplinary Sciences	Science & Technology - Other Topics	437KF	WOS:000265485700013	19221603	
J	Green, RM; Cusotvic, A; Sanderson, G; Hunter, J; Johnston, SL; Woodcock, A				Green, RM; Cusotvic, A; Sanderson, G; Hunter, J; Johnston, SL; Woodcock, A			Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study	BRITISH MEDICAL JOURNAL			English	Article							MONOCLONAL-ANTIBODIES; INDOOR ALLERGENS; EXPOSURE; CHILDREN; SENSITIZATION; RHINOVIRUS-16; EXACERBATIONS; INFLAMMATION; PURIFICATION; INFECTIONS	Objective To investigate the importance of sensitisation and exposure to allergens and viral infection in precipitating acute asthma in adults resulting in admission to hospital. Design Case-control study. Setting Large district general hospital. Participants 60 patients aged 17-50 admitted to hospital over a year with acute asthma, matched with two controls: patients with stable asthma recruited from die outpatient department and patients admitted to hospital with non-respiratory conditions (inpatient controls). Main outcome measures Atopic status (skin testing and total and specific IgE), presence of common respiratory Viruses and atypical bacteria (polymerase chain reaction), dust samples from homes, and exposure to allergens (enzyme linked immunosorbent assay (ELISA): Der p 1, Fel d 1, Can f 1, and Bla g 2). Results Viruses were detected in 31 of 177 patients. The difference in the frequency of viruses detected between the groups was significant (admitted with asthma 26%, stable asthma 18%, inpatient controls 9%; P=0.04). A significantly higher proportion of patients admitted with asthma (66%) were sensitised and exposed to either mite, cat, or dog allergen than patients with stable asthma (37%) and inpatient controls (15%; P < 0.001). Being sensitised and exposed to allergens was all independent associate of the group admitted to hospital (odds ratio 2.3, 95% confidence interval 1.0 to 5.4; P=0.05), whereas the combination of sensitisation, high exposure to one or more allergens, and viral detection considerably increased the risk of being admitted with asthma (8.4, 2.1 to 32.8; P=0.002). Conclusions Allergens and viruses may act together to exacerbate asthma.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; Southampton Gen Hosp, Univ Med, Southampton SO9 6YD, Hants, England	Cusotvic, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.		Johnston, Sebastian/I-2423-2012; Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578			Busse WW, 1997, J ALLERGY CLIN IMMUN, V100, P147, DOI 10.1016/S0091-6749(97)70216-1; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Campbell MJ, 1997, BRIT MED J, V315, P1012; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHAUHAN AJ, 2001, ASTHMA RESP INFECT, P221; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; DUFF AL, 1993, PEDIATRICS, V92, P535; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; LEMANSKE RF, 1989, J CLIN INVEST, V83, P1, DOI 10.1172/JCI113843; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MILLS TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS1; *NAT ASTHM CAMP, 1999, NAT ASTHM AUD 1999 2, P12; NICHOLSON KG, 1993, BRIT MED J, V307, P982; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499	24	194	199	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAR 30	2002	324	7340					763	766A		10.1136/bmj.324.7340.763		7	Medicine, General & Internal	General & Internal Medicine	538KY	WOS:000174816200016	11923159	
J	Wichmann, HE; Peters, A				Wichmann, HE; Peters, A			Epidemiological evidence of the effects of ultrafine particle exposure	PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY OF LONDON SERIES A-MATHEMATICAL PHYSICAL AND ENGINEERING SCIENCES			English	Article						ultrafine particles; fine particles; short-term effects; mortality; respiratory diseases; cardiovascular diseases	PARTICULATE AIR-POLLUTION; CORONARY HEART-DISEASE; ENVIRONMENTAL AEROSOLS; PLASMA VISCOSITY; DAILY MORTALITY; CHILDREN; ASSOCIATION; EPISODE; COHORT; NUMBER	In epidemiological studies associations have been observed consistently and coherently between ambient concentrations of particulate matter and morbidity and mortality. With improvement of measurement techniques, the effects became clearer when smaller particle sizes were considered. Therefore, it seems worthwhile to look at the smallest size fraction available today, namely ultrafine particles (UPs, diameter below 0.1 mum) and to compare their health effects with those of fine particles (FPs, diameter below 2.5 mum) However, there are only few studies available which allow such a comparison. Four panel studies with asthma patients have been performed in Germany and Finland. A decrease of peak expiratory flow and an increase of daily symptoms and medication use was found for elevated daily particle concentrations, and in three of these studies it was strongest for UPs. One large study on daily mortality is available from Germany. It showed comparable effects of fine and ultrafine particles in all sire classes considered. However, FPs showed more immediate effects while UPs showed more delayed effects with a lag of four days between particulate concentrations and mortality. Furthermore, immediate effects were clearer in respiratory cases, whereas delayed effects were clearer in cardiovascular cases. In total, the limited body of studies suggests that there are health effects, due to both UPs and FPs, which might be independent from each other. If this is confirmed in further investigations, it might have important implications for monitoring and regulation, which until now does not exist for UPs. Data from Germany show that FPs cannot be used as indicator for UPs: the time trends for FPs decreased, while UPs was stable and the smallest size fraction of UPs has continually increased since 1991/92.	GSF, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, LMU, D-85764 Neuherberg, Germany	Wichmann, HE (reprint author), GSF, Inst Epidemiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.		Peters, Annette/A-6117-2011				Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; BRAND P, 1991, ATMOS ENVIRON A-GEN, V25, P581, DOI 10.1016/0960-1686(91)90055-C; BRAND P, 1992, ATMOS ENVIRON A-GEN, V26, P2451, DOI 10.1016/0960-1686(92)90375-U; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DOCKERY DW, 1992, ENVIRON RES, V59, P362, DOI 10.1016/S0013-9351(05)80042-8; DOCKERY DW, 1994, REV PUBLIC HLTH, V15, P107; FERIN J, 1991, J AEROSOL MED, V4, P57, DOI 10.1089/jam.1991.4.57; Fuchs N.A., 1964, MECH AEROSOLS, P288; GOLD DR, 2000, IN PRESS CIRCULATION; *ICRP, 1994, ICRP PUBL, V66, P36; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; Katsouyanni K., 1996, J EPIDEMIOL COMMUN S, V50, pS12; KOENIG W, 1992, ATHEROSCLEROSIS, V94, P93, DOI 10.1016/0021-9150(92)90234-8; Koenig W, 1998, ARTERIOSCL THROM VAS, V18, P768; KREYLING WG, 1999, P 3 COLL PART AIR PO; Liao DP, 1997, AM J EPIDEMIOL, V145, P696; MIRME A, 2000, UNPUB ATMOS ENV; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; PEKKANEN J, 1999, ENV4CT950205 ULTRA; PEKKANEN J, 1999, AM J RESP CRIT CARE, V54, P1027; PENTTINEN P, 2000, IN PRESS AM J RESP C; Peters A, 1999, AM J EPIDEMIOL, V150, P1094; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; PETERS A, 1999, P INT INH S HAN GERM; PETERS A, 1999, P 3 COLL PART AIR PO; PITZ M, 2000, UNPUB CHANGE PARTICL; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 1999, AM J RESP CRIT CARE, V159, P365; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; POPE CA, 2000, IN PRESS ENV HLTH PE; RUSSKANEN J, 2000, IN PRESS ATMOS ENV; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Seaton A, 1999, THORAX, V54, P1027; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; STEARNS RC, 1994, ICEM, V13, P763; Stone PH, 1999, AM HEART J, V138, P804, DOI 10.1016/S0002-8703(99)70002-5; Tuch T, 2000, ATMOS ENVIRON, V34, P139, DOI 10.1016/S1352-2310(99)00248-4; Tuch T, 1997, ATMOS ENVIRON, V31, P4193, DOI 10.1016/S1352-2310(97)00260-4; TUCH T, 2000, UNPUB REDUCTION PART; U. S. Environmental Protection Agency, 1996, AIR QUAL CRIT PART M; UTELL MJ, 1999, J AEROSOL MED, V12, P104; VONKLOT S, 2000, P C AM THOR SOC 2000; WICHMANN H, 2000, DAILY MORTALITY FINE; WICHMANN HE, 1999, HLTH EFFECTS FINE PA, V8, P163; Willeke K., 1993, AEROSOL MEASUREMENTS	52	194	211	3	32	ROYAL SOC LONDON	LONDON	6 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND	1364-503X			PHILOS T ROY SOC A	Philos. Trans. R. Soc. Lond. Ser. A-Math. Phys. Eng. Sci.	OCT 15	2000	358	1775					2751	2768				18	Multidisciplinary Sciences	Science & Technology - Other Topics	368DH	WOS:000090102100025		
J	Hanski, I; von Hertzen, L; Fyhrquist, N; Koskinen, K; Torppa, K; Laatikainen, T; Karisola, P; Auvinen, P; Paulin, L; Makela, MJ; Vartiainen, E; Kosunen, TU; Alenius, H; Haahtela, T				Hanski, Ilkka; von Hertzen, Leena; Fyhrquist, Nanna; Koskinen, Kaisa; Torppa, Kaisa; Laatikainen, Tiina; Karisola, Piia; Auvinen, Petri; Paulin, Lars; Makela, Mika J.; Vartiainen, Erkki; Kosunen, Timo U.; Alenius, Harri; Haahtela, Tari			Environmental biodiversity, human microbiota, and allergy are interrelated	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						biodiversity benefits; hygiene hypothesis; microbial deprivation; civilization diseases	BLOOD MONONUCLEAR-CELLS; GRAM-POSITIVE BACTERIA; IN-VITRO STIMULATION; GUT MICROBIOTA; ATOPIC ECZEMA; INTESTINAL MICROBIOTA; HYGIENE HYPOTHESIS; REDUCED DIVERSITY; IMMUNE-RESPONSES; CHILDHOOD ASTHMA	Rapidly declining biodiversity may be a contributing factor to another global megatrend-the rapidly increasing prevalence of allergies and other chronic inflammatory diseases among urban populations worldwide. According to the "biodiversity hypothesis," reduced contact of people with natural environmental features and biodiversity may adversely affect the human commensal microbiota and its immunomodulatory capacity. Analyzing atopic sensitization (i.e., allergic disposition) in a random sample of adolescents living in a heterogeneous region of 100 x 150 km, we show that environmental biodiversity in the surroundings of the study subjects' homes influenced the composition of the bacterial classes on their skin. Compared with healthy individuals, atopic individuals had lower environmental biodiversity in the surroundings of their homes and significantly lower generic diversity of gammaproteobacteria on their skin. The functional role of the Gram-negative gammaproteobacteria is supported by in vitro measurements of expression of IL-10, a key anti-inflammatory cytokine in immunologic tolerance, in peripheral blood mononuclear cells. In healthy, but not in atopic, individuals, IL-10 expression was positively correlated with the abundance of the gammaproteobacterial genus Acinetobacter on the skin. These results raise fundamental questions about the consequences of biodiversity loss for both allergic conditions and public health in general.	[Hanski, Ilkka; Torppa, Kaisa] Univ Helsinki, Dept Biosci, FI-00014 Helsinki, Finland; [von Hertzen, Leena; Makela, Mika J.; Haahtela, Tari] Univ Helsinki, Cent Hosp, Skin & Allergy Hosp, FI-00029 Helsinki, Finland; [Fyhrquist, Nanna; Karisola, Piia; Alenius, Harri] Finnish Inst Occupat Hlth, FI-00250 Helsinki, Finland; [Koskinen, Kaisa; Auvinen, Petri; Paulin, Lars] Univ Helsinki, Inst Biotechnol, FI-00014 Helsinki, Finland; [Laatikainen, Tiina; Vartiainen, Erkki] Natl Inst Hlth & Welf, FI-00271 Helsinki, Finland; [Kosunen, Timo U.] Univ Helsinki, Haartman Inst, Dept Bacteriol & Immunol, FI-00014 Helsinki, Finland	Hanski, I (reprint author), Univ Helsinki, Dept Biosci, FI-00014 Helsinki, Finland.	ilkka.hanski@helsinki.fi; tari.haahtela@hus.fi	Auvinen, Petri/D-5044-2009; Osborne, Nicholas/N-4915-2015	Auvinen, Petri/0000-0002-3947-4778; Osborne, Nicholas/0000-0002-6700-2284; Fyhrquist, Nanna Theresia/0000-0002-5408-0005; Makela, Mika/0000-0002-2933-3111	European Research Council [232826]; European Commission [261357]; Academy of Finland [131155, 138932]; Helsinki University Hospital [8361]; Juselius Foundation; Liv och Halsa Foundation	We thank T. Vlasoff and S. Lipponen for obtaining DNA and blood samples; E.-M. Turkki, K. Lipponen, and H. Kangas for technical assistance in processing the bacterial samples; and J. Corander, C. Godfray, H. Jacobs, E. von Mutius, and G. Rook for comments on the manuscript. This work was supported by European Research Council Advanced Grant 232826 (to I.H.), European Commission Seventh Framework Programme Grant Agreement 261357, the Finnish CoE Programme 2006-2011, Academy of Finland Grants 131155 and 138932, Helsinki University Hospital Research Grant 8361, the Juselius Foundation, and the Liv och Halsa Foundation.	Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P434, DOI 10.1016/j.jaci.2011.10.025; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Abrahamsson TR, 2012, J ALLERGY CLIN IMMUN, V129, P440; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2009, CURR OPIN IMMUNOL, V21, P700, DOI 10.1016/j.coi.2009.07.012; Ariano R, 2010, ANN ALLERG ASTHMA IM, V104, P215, DOI 10.1016/j.anai.2009.12.005; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Arva E, 1999, SCAND J IMMUNOL, V49, P417; Arva E, 1999, SCAND J IMMUNOL, V49, P411; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V128, P646, DOI 10.1016/j.jaci.2011.04.060; Brand S, 2011, J ALLERGY CLIN IMMUN, V128, P618, DOI 10.1016/j.jaci.2011.04.035; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P269, DOI 10.1067/mai.2001.117455; Conrad ML, 2009, J EXP MED, V206, P2869, DOI 10.1084/jem.20090845; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Doreswamy V, 2011, CLIN EXP ALLERGY, V41, P9, DOI 10.1111/j.1365-2222.2010.03628.x; EDWARDS U, 1989, NUCLEIC ACIDS RES, V17, P7843, DOI 10.1093/nar/17.19.7843; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Gore C, 2008, J ALLERGY CLIN IMMUN, V121, P135, DOI 10.1016/j.jaci.2007.07.061; Graham-Rowe D, 2011, NATURE, V479, pS2; Grice EA, 2011, NAT REV MICROBIOL, V9, P244, DOI 10.1038/nrmicro2537; Grice EA, 2009, SCIENCE, V324, P1190, DOI 10.1126/science.1171700; Haakana M, 2008, REMOTE SENSING ENV M; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; Heydenreich B, 2012, CLIN EXP ALLERGY, V42, P76, DOI 10.1111/j.1365-2222.2011.03888.x; Junker RR, 2011, PLANT BIOLOGY, V13, P918, DOI 10.1111/j.1438-8677.2011.00454.x; Koskinen K, 2011, FEMS MICROBIOL ECOL, V75, P99, DOI 10.1111/j.1574-6941.2010.00987.x; Lane D.J., 1991, NUCL ACID TECHNIQUES, P115; Lee YK, 2010, SCIENCE, V330, P1768, DOI 10.1126/science.1195568; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Maintz L, 2011, J INNATE IMMUN, V3, P131, DOI 10.1159/000323963; Matsuoka RH, 2008, LANDSCAPE URBAN PLAN, V84, P7, DOI 10.1016/j.landurbplan.2007.09.009; Nakayama J, 2011, FEMS IMMUNOL MED MIC, V63, P397, DOI 10.1111/j.1574-695X.2011.00872.x; Napolitani G, 2005, NAT IMMUNOL, V6, P769, DOI 10.1038/ni1223; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Rook GAW, 2010, CLIN EXP IMMUNOL, V160, P70, DOI 10.1111/j.1365-2249.2010.04133.x; Rook GAW, 2009, IMMUNOLOGY, V126, P3, DOI 10.1111/j.1365-2567.2008.03007.x; Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Sjogren YM, 2009, CLIN EXP ALLERGY, V39, P518, DOI 10.1111/j.1365-2222.2008.03156.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; UN, 2008, WORLD URB PROSP 2007; Vael C, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-68; von Hertzen L, 2006, J ALLERGY CLIN IMMUN, V117, P151, DOI 10.1016/j.jaci.2005.07.028; von Hertzen L, 2011, EMBO REP, V12, P1089, DOI 10.1038/embor.2011.195; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; von Mutius E, 2012, J ALLERGY CLIN IMMUN; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Zhang M, 2010, GUT MICROBES, V1, P325, DOI DOI 10.4161/GMIC.1.5.13052	53	193	203	17	192	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	MAY 22	2012	109	21					8334	8339		10.1073/pnas.1205624109		6	Multidisciplinary Sciences	Science & Technology - Other Topics	947QY	WOS:000304445800082	22566627	
J	de Lafaille, MAC; Kutchukhidze, N; Shen, S; Ding, Y; Yee, H; Lafaille, JJ				de Lafaille, Maria A. Curotto; Kutchukhidze, Nino; Shen, Shiqian; Ding, Yi; Yee, Herman; Lafaille, Juan J.			Adaptive Foxp3(+) regulatory T cell-dependent and -independent control of allergic inflammation	IMMUNITY			English	Article							SPONTANEOUS AUTOIMMUNE ENCEPHALOMYELITIS; TRANSCRIPTION FACTOR FOXP3; RECEPTOR TRANSGENIC MICE; MYELIN BASIC-PROTEIN; TGF-BETA; DENDRITIC CELLS; RETINOIC-ACID; IN-VIVO; AIRWAY HYPERRESPONSIVENESS; INDUCTION	Adaptive Foxp3(+) regulatory T (Treg) cells develop during induction of mucosal tolerance and after immunization. Large numbers of Foxp3(+) T cells have been found in inflamed tissues. We investigated the role of adaptive Foxp3(+) Treg cells in mucosal tolerance and in chronic allergic lung inflammation. We used two strains of mice that are devoid of naturally occurring Treg cells; one is capable of generating adaptive Foxp3+ Treg cells upon exposure to antigen, whereas the other is deficient in both naturally occurring and adaptive Foxp3(+) Treg cells. We found that adaptive Foxp3(+) Treg cells were essential for establishing mucosal tolerance and for suppressing IL-4 production and lymphoid neogenesis in chronic inflammation, whereas IL-5 production and eosinophilia. could be controlled by Foxp3-independent IFN-gamma-dependent mechanisms. Thus, whereas adaptive Foxp3(+) Treg cells regulate sensitization to allergens and the severity of chronic inflammation, IFN-gamma-producing cells can play a beneficial role in inflammatory conditions involving eosinophils.	[de Lafaille, Maria A. Curotto; Kutchukhidze, Nino; Shen, Shiqian; Ding, Yi; Lafaille, Juan J.] NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med,Program Mol Pathogenesis, New York, NY 10016 USA; [Ding, Yi] NYU, Sch Med, Sackler Inst Grad Biomed Sci, New York, NY 10016 USA; [de Lafaille, Maria A. Curotto; Yee, Herman; Lafaille, Juan J.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA	de Lafaille, MAC (reprint author), NYU, Sch Med, Skirball Inst, Kimmel Ctr Biol & Med,Program Mol Pathogenesis, New York, NY 10016 USA.	curotto@saturn.med.nyu.edu; lafaille@saturn.med.nyu.edu					Aloisi F, 2006, NAT REV IMMUNOL, V6, P205, DOI 10.1038/nri1786; Annacker O, 2001, J IMMUNOL, V166, P3008; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Bennett CL, 2001, NAT GENET, V27, P20; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Carrier Y, 2007, J IMMUNOL, V178, P179; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Cobbold SP, 2004, J IMMUNOL, V172, P6003; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; Lafaille J. J., 2004, J IMMUNOL, V173, P7259; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Drayton DL, 2006, NAT IMMUNOL, V7, P344, DOI 10.1038/ni1330; Erazo A, 2007, IMMUNITY, V26, P191, DOI 10.1016/j.immuni.2006.12.006; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; IWAMOTO I, 1993, J EXP MED, V177, P573, DOI 10.1084/jem.177.2.573; Iweala OI, 2006, IMMUNOL REV, V213, P82, DOI 10.1111/j.1600-065X.2006.00431.x; Kanangat S, 1996, EUR J IMMUNOL, V26, P161, DOI 10.1002/eji.1830260125; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Klein L, 2003, P NATL ACAD SCI USA, V100, P8886, DOI 10.1073/pnas.1533365100; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; LAFAILLE JJ, 1994, CELL, V78, P399, DOI 10.1016/0092-8674(94)90419-7; Levings MK, 2005, BLOOD, V105, P1162, DOI 10.1182/blood-2004-03-1211; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Moyron-Quiroz J, 2007, ADV EXP MED BIOL, V590, P55; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Olivares-Villagomez D, 1998, J EXP MED, V188, P1883, DOI 10.1084/jem.188.10.1883; Ruprecht CR, 2005, J EXP MED, V201, P1793, DOI 10.1084/jem.20050085; Saruta M, 2007, CLIN IMMUNOL, V125, P281, DOI 10.1016/j.clim.2007.08.003; Sasaki M, 2007, J CLIN PATHOL, V60, P1102, DOI 10.1136/jcp.2006.044776; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shen SQ, 2005, J CLIN INVEST, V115, P3517, DOI 10.1172/JC125463; Shevach EM, 2006, IMMUNOL REV, V212, P60, DOI 10.1111/j.0105-2896.2006.00415.x; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Smyth LJC, 2007, CHEST, V132, P156, DOI 10.1378/chest.07-0083; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; van Amelsfort JMR, 2004, ARTHRITIS RHEUM, V50, P2775, DOI 10.1002/art.20499; Vieira PL, 2004, J IMMUNOL, V172, P5986; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wensky A, 2001, J IMMUNOL, V167, P3074; Williams Luke M, 2007, Nat Immunol, V8, P277; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Zheng SG, 2007, J IMMUNOL, V178, P2018	51	193	195	0	10	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613	1097-4180		IMMUNITY	Immunity	JUL 18	2008	29	1					114	126		10.1016/j.immuni.2008.05.010		13	Immunology	Immunology	329YB	WOS:000257905400015		
J	Verhasselt, V; Milcent, V; Cazareth, J; Kanda, A; Fleury, S; Dombrowicz, D; Glaichenhaus, N; Julia, V				Verhasselt, Valerie; Milcent, Valerie; Cazareth, Julie; Kanda, Akira; Fleury, Sebastien; Dombrowicz, David; Glaichenhaus, Nicolas; Julia, Valerie			Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; T-CELLS; IMMUNE-RESPONSES; INHALED ANTIGEN; ORAL TOLERANCE; MICE; PROTEIN; ABSORPTION; EXPRESSION	Allergic asthma is a chronic disease characterized by airway obstruction in response to allergen exposure. It results from an inappropriate T helper type 2 response to environmental airborne antigens and affects 300 million individuals(1). Its prevalence has increased markedly in recent decades, most probably as a result of changes in environmental factors(2). Exposure to environmental antigens during infancy is crucial to the development of asthma(3). Epidemiological studies on the relationship between breastfeeding and allergic diseases have reached conflicting results(4-8). Here, we have investigated whether the exposure of lactating mice to an airborne allergen affects asthma development in progeny. We found that airborne antigens were efficiently transferred from the mother to the neonate through milk and that tolerance induction did not require the transfer of immunoglobulins. Breastfeeding-induced tolerance relied on the presence of transforming growth factor (TGF)-beta during lactation, was mediated by regulatory CD4(+) T lymphocytes and depended on TGF-beta signaling in T cells. In conclusion, breast milk-mediated transfer of an antigen to the neonate resulted in oral tolerance induction leading to antigen-specific protection from allergic airway disease. This study may pave the way for the design of new strategies to prevent the development of allergic diseases.	[Verhasselt, Valerie; Milcent, Valerie; Glaichenhaus, Nicolas; Julia, Valerie] Univ Nice Sophie Antipolis, U924, INSERM, F-06560 Valbonne, France; [Cazareth, Julie] Univ Nice Sophie Antipolis, UMR 6097, CNRS, F-06560 Valbonne, France; [Kanda, Akira; Fleury, Sebastien; Dombrowicz, David] Univ Lille, Inst Pasteur, INSERM, U547, F-59000 Lille, France	Verhasselt, V (reprint author), Univ Nice Sophie Antipolis, U924, INSERM, 660 Route Lucioles, F-06560 Valbonne, France.	verhasselt@unice.fr; vjulia@unice.fr	Dombrowicz, David/F-7044-2013	Dombrowicz, David/0000-0002-0485-8923			Adkins B, 2004, NAT REV IMMUNOL, V4, P553, DOI 10.1038/nri1394; Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; BENSCH KG, 1967, SCIENCE, V157, P1204, DOI 10.1126/science.157.3793.1204; BRALEY JF, 1978, J CLIN INVEST, V61, P1240, DOI 10.1172/JCI109040; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; Frentsch M, 2005, NAT MED, V11, P1118, DOI 10.1038/nm1292; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Guilbert TW, 2007, AM J RESP CRIT CARE, V176, P843, DOI 10.1164/rccm.200610-1507OC; HANSON DG, 1981, J IMMUNOL, V127, P1518; Holt PG, 2005, NAT IMMUNOL, V6, P957, DOI 10.1038/ni1005-957; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kramer MS, 2007, BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Labbok MH, 2004, NAT REV IMMUNOL, V4, P565, DOI 10.1038/nri1393; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lucas PJ, 2000, J EXP MED, V191, P1187, DOI 10.1084/jem.191.7.1187; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; Palmer DJ, 2006, CURR OPIN CLIN NUTR, V9, P284, DOI 10.1097/01.mco.0000222113.46042.50; Penttila I, 2006, PEDIATR RES, V59, P650, DOI 10.1203/01.pdr.0000203149.75465.74; Penttila IA, 1998, PEDIATR RES, V44, P524, DOI 10.1203/00006450-199810000-00010; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; SAITO S, 1993, CLIN EXP IMMUNOL, V94, P220; STROBEL S, 1984, PEDIATR RES, V18, P588, DOI 10.1203/00006450-198407000-00004; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; WILLOUGHBY JB, 1977, J IMMUNOL, V119, P2137	30	193	199	0	18	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	FEB	2008	14	2					170	175		10.1038/nm1718		6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	259NT	WOS:000252946700025	18223654	
J	Moingeon, P; Batard, T; Fadel, R; Frati, F; Sieber, J; Van Overtvelt, L				Moingeon, P; Batard, T; Fadel, R; Frati, F; Sieber, J; Van Overtvelt, L			Immune mechanisms of allergen-specific sublingual immunotherapy	ALLERGY			English	Review						allergy vaccine; Langerhans cells; regulatory T lymphocyte; sublingual immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; RANDOMIZED CONTROLLED-TRIAL; HOUSE-DUST MITES; PLACEBO-CONTROLLED EVALUATION; MESSENGER-RNA EXPRESSION; BLOCKING IGG ANTIBODIES; DOUBLE-BLIND; DENDRITIC CELLS; HAY-FEVER	Sublingual immunotherapy has been shown in some clinical studies to modulate allergen-specific antibody responses [with a decrease in the immunoglobulin E/immunoglobulin G4 (IgE/IgG4) ratio] and to reduce the recruitment and activation of proinflammatory cells in target mucosa. Whereas a central paradigm for successful immunotherapy has been to reorient the pattern of allergen-specific T-cell responses in atopic patients from a T helper (Th)2 to Th1 profile, there is currently a growing interest in eliciting regulatory T cells, capable of downregulating both Th1 and Th2 responses through the production of interleukin (IL)-10 and/or transforming growth factor (TGF)-beta. We discuss herein immune mechanisms involved during allergen-specific sublingual immunotherapy (SLIT), in comparison with subcutaneous immunotherapy. During SLIT, the allergen is captured within the oral mucosa by Langerhans-like dendritic cells expressing high-affinity IgE receptors, producing IL-10 and TGF-beta, and upregulating indoleamine dioxygenase (IDO), suggesting that such cells are prone to induce tolerance. The oral mucosa contains limited number of proinflammatory cells, such as mast cells, thereby explaining the well-established safety profile of SLIT. In this context, second-generation vaccines based on recombinant allergens in a native conformation formulated with adjuvants are designed to target Langerhans-like cells in the sublingual mucosa, with the aim to induce allergen-specific regulatory T cells. Importantly, such recombinant vaccines should facilitate the identification of biological markers of SLIT efficacy in humans.	Stallergenes, Res & Dev, F-92160 Antony, France; Stallergenes Italia SRL, Milan, Italy; Stallergenes GmbH & Co KG Germany, Kamp Lintfort, Germany	Moingeon, P (reprint author), Stallergenes, Res & Dev, 6 Rue Alexis de Tocqueville, F-92160 Antony, France.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2004, ALLERGY, V59, P897, DOI 10.1111/j.1398-9995.2004.00587.x; Akdis CA, 2001, INT ARCH ALLERGY IMM, V124, P180, DOI 10.1159/000053704; Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; AOYAMAKONDO T, 1992, IMMUNOBIOLOGY, V184, P372; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; BOUSQUET J, 1998, ALLERGY S, V53, P20; Bullens DMA, 2004, CLIN EXP ALLERGY, V34, P879, DOI 10.1111/j.1365-2222.2004.01955.x; Canonica GW, 2004, IMMUNOL ALLERGY CLIN, V24, P685, DOI 10.1016/j.iac.2004.07.001; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; CLEARY JF, 1997, SEMIN ONCOL      S16, V24, pS13; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1998, CLIN EXP ALLERGY, V28, P781; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; EINARSSON R, 1988, ALLERGY, V43, P469, DOI 10.1111/j.1398-9995.1988.tb00921.x; El Biaze M, 2003, ALLERGY, V58, P844, DOI 10.1034/j.1398-9995.2003.00282.x; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; Falagiani P, 1997, ALLERGY, V52, P17; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Faria AMC, 1999, ADV IMMUNOL, V73, P153, DOI 10.1016/S0065-2776(08)60787-7; Fenoglio D, 2005, Eur Ann Allergy Clin Immunol, V37, P147; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Freeman J, 1911, LANCET, V2, P814; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; GARCIA NM, 1995, J INVEST ALLERG CLIN, V5, P8; Gardner LM, 2004, ALLERGY, V59, P1308, DOI 10.1111/j.1398-9995.2004.00584.x; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Gentile DA, 2004, ANN ALLERG ASTHMA IM, V92, P538; GONZALEZESPINOS.C, 2003, J EXP MED, V11, P1453; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Groux H, 1997, NATURE, V389, P737; Guerra F, 2001, J ALLERGY CLIN IMMUN, V107, P647; Hakansson L, 1997, J ALLERGY CLIN IMMUN, V99, P551, DOI 10.1016/S0091-6749(97)70084-8; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HOLSTLARSEN T, 2005, J ALLERGY CLIN IMMUN, V1, P529; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Igea J M, 1994, Allergol Immunopathol (Madr), V22, P55; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JAKOBSEN CG, 2005, CLIN EXP ALLERGY, V36, P193; Jonuleit H, 2003, J IMMUNOL, V171, P6323; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kemper C, 2003, NATURE, V421, P388, DOI 10.1038/nature01315; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Laaksonen K, 2003, J ALLERGY CLIN IMMUN, V112, P1171, DOI 10.1016/j.jaci.2003.08.043; Larche M, 2000, BRIT MED BULL, V56, P1019, DOI 10.1258/0007142001903517; Levings MK, 2001, J IMMUNOL, V166, P5530; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Mahler V, 2004, CLIN EXP ALLERGY, V34, P115, DOI 10.1111/j.1365-2222.2004.01857.x; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; Malling HJ, 2005, J ALLERGY CLIN IMMUN, V115, pS161, DOI 10.1016/j.jaci.2004.12.656; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Marcucci F, 2001, ALLERGY, V56, P1091, DOI 10.1034/j.1398-9995.2001.00226.x; MARCUCCI F, IN PRESS INT J PHARM; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Mavroleon G, 1998, CLIN EXP ALLERGY, V28, P917; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; Michils A, 1998, J ALLERGY CLIN IMMUN, V102, P118, DOI 10.1016/S0091-6749(98)70062-4; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Monteseirin J, 2001, J ALLERGY CLIN IMMUN, V107, P623, DOI 10.1067/mai.2001.113566; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Noirey N, 2000, J ALLERGY CLIN IMMUN, V105, P1194, DOI 10.1067/mai.2000.106545; Noon L, 1911, LANCET, V1, P1572; NOONAN PK, 1985, AM J CARDIOL, V55, P184, DOI 10.1016/0002-9149(85)90325-X; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; OBrien RM, 1997, CLIN EXP ALLERGY, V27, P46, DOI 10.1046/j.1365-2222.1997.d01-424.x; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 2001, ALLERGY, V56, P578, DOI 10.1034/j.1398-9995.2001.056006578.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Pierson-Mullany LK, 2000, ANN ALLERG ASTHMA IM, V84, P241, DOI 10.1016/S1081-1206(10)62761-5; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; Polosa R, 2003, CLIN EXP ALLERGY, V33, P873, DOI 10.1046/j.1365-2222.2003.01676.x; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Senel Sevda, 2001, Current Pharmaceutical Biotechnology, V2, P175, DOI 10.2174/1389201013378734; Silvestri M, 2002, J INVEST ALLERG CLIN, V12, P52; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Sprent J, 2001, CURR OPIN IMMUNOL, V13, P248, DOI 10.1016/S0952-7915(00)00211-9; Stassen M, 2004, EUR J IMMUNOL, V34, P1303, DOI 10.1002/eji.200324656; Svenson M, 2003, MOL IMMUNOL, V39, P603, DOI 10.1016/S0161-5890(02)00198-0; Taams LS, 1999, J IMMUNOL, V162, P1974; Taylor A, 2004, INT ARCH ALLERGY IMM, V135, P73, DOI 10.1159/000080523; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Helvoort JMLM, 2004, ALLERGY, V59, P1211, DOI 10.1111/j.1398-9995.2004.00510.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2004, CLIN EXP ALLERGY, V34, P420, DOI 10.1111/j.1365-2222.2004.01899.x; VANWILSEM EJG, 1995, IMMUNOBIOLOGY, V194, P403; Vieira PL, 2004, J IMMUNOL, V172, P5986; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; von Bubnoff D, 2004, CLIN EXP ALLERGY, V34, P1056, DOI 10.1111/j.1365-2222.2004.01984.x; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Walker GF, 2002, INT J PHARM, V233, P141, DOI 10.1016/S0378-5173(01)00934-6; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Wilson DR, 2003, COCHRANE DB SYST REV, V2; Yamagiwa S, 2001, J IMMUNOL, V166, P7282; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	148	193	212	1	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	FEB	2006	61	2					151	165		10.1111/j.1398-9995.2006.01002.x		15	Allergy; Immunology	Allergy; Immunology	001XJ	WOS:000234575700002	16409190	
J	Nicolaou, N; Poorafshar, M; Murray, C; Simpson, A; Winell, H; Kerry, G; Harlin, A; Woodcock, A; Ahlstedt, S; Custovic, A				Nicolaou, Nicolaos; Poorafshar, Maryam; Murray, Clare; Simpson, Angela; Winell, Henric; Kerry, Gina; Haerlin, Annika; Woodcock, Ashley; Ahlstedt, Staffan; Custovic, Adnan			Allergy or tolerance in children sensitized to peanut: Prevalence and differentiation using component-resolved diagnostics	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Peanut allergy; oral food challenge; component-resolved diagnostics; Ara h 2; microarray; birth cohort	FOOD CHALLENGES; RECOMBINANT ALLERGENS; SKIN PRICK; IGE; POLLEN; IDENTIFICATION; ASSOCIATION; ADOLESCENTS; DERMATITIS; REACTIVITY	Background: Not all peanut-sensitized children develop allergic reactions on exposure. Objective: To establish by oral food challenge the proportion of children with clinical peanut allergy among those considered peanut-sensitized by using skin prick tests and/or IgE measurement, and to investigate whether component-resolved diagnostics using microarray could differentiate peanut allergy from tolerance. Methods: Within a population-based birth cohort, we ascertained peanut sensitization by skin tests and IgE measurement at age 8 years. Among sensitized children, we determined peanut allergy versus tolerance by oral food challenges. We used open challenge among children consuming peanuts (n = 45); others underwent double-blind placebo-controlled challenge (n = 34). We compared sensitization profiles between children with peanut allergy and peanut-tolerant children by using a microarray with 12 pure components (major peanut and potentially cross-reactive components, including grass allergens). Results: Of 933 children, 110 (11.8%) were peanut-sensitized. Nineteen were not challenged (17 no consent). Twelve with a convincing history of reactions on exposure, IgE >= 15 kUA/L and/or skin test >= 8mm were considered allergic without challenge. Of the remaining 79 children who underwent challenge, 7 had >= 2 objective signs and were designated as having peanut allergy. We estimated the prevalence of clinical peanut allergy among sensitized subjects as 22.4% (95% CI, 14.8% to 32.3%). By using component-resolved diagnostics, we detected marked differences in the pattern of component recognition between children with peanut allergy (n = 29; group enriched with 12 children with allergy) and peanut-tolerant children (n = 52). The peanut component Ara h 2 was the most important predictor of clinical allergy. Conclusion: The majority of children considered peanut-sensitized on the basis of standard tests do not have peanut allergy. Component-resolved diagnostics may facilitate the diagnosis of peanut allergy. Q Allergy Clin Immunol 2010;125:191-7.)	[Nicolaou, Nicolaos; Murray, Clare; Simpson, Angela; Kerry, Gina; Woodcock, Ashley; Custovic, Adnan] Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Sch Translat Med, NIHR Translat Res Facil Resp Med, Manchester M23 9LT, Lancs, England; [Poorafshar, Maryam; Winell, Henric; Haerlin, Annika] Phadia AB, Uppsala, Sweden; [Ahlstedt, Staffan] Karolinska Inst, Natl Inst Environm Med, Ctr Allergy Res, Stockholm, Sweden	Custovic, A (reprint author), Univ Manchester, Univ Hosp S Manchester NHS Fdn Trust, Sch Translat Med, NIHR Translat Res Facil Resp Med, Manchester M23 9LT, Lancs, England.	adnan.custovic@manchester.ac.uk	Custovic, Adnan/A-2435-2012; Osborne, Nicholas/N-4915-2015	Custovic, Adnan/0000-0001-5218-7071; Osborne, Nicholas/0000-0002-6700-2284; Simpson, Angela/0000-0003-2733-6666; Woodcock, Ashley/0000-0002-5428-8578	Medical Research Council; Moulton Charitable Foundation; Grand Charity of Freemasons; National Institute for Health Research	A. Harlin, and H. Winell are employees of Phadia AB. S. Ahlstedt is a previous employee of Phadia AB. A. Simpson has received research support from the Medical Research Council, the Moulton Charitable Foundation, and the Grand Charity of Freemasons. A. Custovic has received lecture fees from GlaxoSmithKline and Phadia, is on the advisory board of ALK, and has received research support from the Medical Research Council and the National Institute for Health Research. The rest of the authors have declared that they have no conflict of interest.	Asero R, 2007, MOL NUTR FOOD RES, V51, P135, DOI 10.1002/mnfr.200600132; Astier C, 2006, J ALLERGY CLIN IMMUN, V118, P250, DOI 10.1016/j.jaci.2006.04.053; Avery NJ, 2003, PEDIATR ALLERGY IMMU, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Beyer K, 2003, J ALLERGY CLIN IMMUN, V112, P202, DOI 10.1067/mai.2003.1621; Beyer Kirsten, 2003, Curr Opin Allergy Clin Immunol, V3, P189, DOI 10.1097/00130832-200306000-00007; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; Burks W, 1998, ALLERGY, V53, P725; Clarke MCA, 1998, CLIN EXP ALLERGY, V28, P1251; Custovic A, 2002, PEDIATR ALLERGY IMMU, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743; DEMARTINO M, 1988, ALLERGY, V43, P206; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; HAHSLER M, 2008, J STAT SOFTW, V25; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hourihane JO, 2007, J ALLERGY CLIN IMMUN, V119, P1197, DOI 10.1016/j.jaci.2006.12.670; King JG, 2008, J NUTR, V138, p1736S; Kleber-Janke T, 1999, INT ARCH ALLERGY IMM, V119, P265, DOI 10.1159/000024203; Koppelman SJ, 2004, CLIN EXP ALLERGY, V34, P583, DOI 10.1111/j.1365-2222.2004.1923.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lidholm J, 2006, CURR OPIN ALLERGY CL, V6, P234, DOI 10.1097/01.all.0000225166.90768.d6; Mortz CG, 2005, PEDIATR ALLERGY IMMU, V16, P501, DOI 10.1111/j.1399-3038.2005.00302.x; Niggemenn B, 2007, ALLERGY, V62, P729, DOI 10.1111/j.1398-9995.2007.01396.x; Palmer GW, 2005, CLIN IMMUNOL, V115, P302, DOI 10.1016/j.clim.2005.02.011; R Development Core Team, 2008, R LANG ENV STAT COMP; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P504; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wood RA, 2003, PEDIATRICS, V111, P1631; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	41	192	197	2	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					191	197		10.1016/j.jaci.2009.10.008		7	Allergy; Immunology	Allergy; Immunology	544MG	WOS:000273660500023	20109746	
J	Bieber, T				Bieber, Thomas			Atopic Dermatitis	ANNALS OF DERMATOLOGY			English	Review						Atopic dermatitis; Pathophysiology; Proactive management; Therapy	TOPICAL CALCINEURIN INHIBITORS; RANDOMIZED CONTROLLED-TRIAL; INNATE IMMUNE-RESPONSE; SINGLE NUCLEOTIDE POLYMORPHISMS; REGULATORY T-CELLS; ANTIMICROBIAL PEPTIDES; ALLERGIC INFLAMMATION; FILAGGRIN MUTATIONS; CYTOKINE MILIEU; VACCINIA VIRUS	Atopic dermatitis (AD) is a chronic and relapsing disease affecting an increasing number of patients. Usually starting in early childhood, AD can be the initial step of the so-called atopic march, i.e. followed by allergic rhinitis and allergic asthma. AD is a paradigmatic genetically complex disease involving gene-gene and gene-environment interactions. Genetic linkage analysis as well as association studies have identified several candidate genes linked to either the epidermal barrier function or to the immune system. Stress, bacterial or viral infections, the exposure to aero- or food-allergens as well as hygienic factors are discussed to aggravate symptoms of AD. Athough generalized Th2-deviated immune response is closely linked to the condition of AD, the skin disease itself is a biphasic inflammation with an initial Th2 phase and while chronic lesions harbour Th0/Th1 cells. Regulatory T cells have been shown to be altered in AD as well as the innate immune system in the skin. The main treatment-goals include the elimination of inflammation and infection, preserving and restoring the barrier function and controlling exacerbating factors. The overall future strategy in AD will be aimed to control skin inflammation by a more proactive management in order to potentially prevent the emergence of sensitization as well as to design customized management based on genetic and pathophysiologic information. (Ann Dermatol 22(2) 125 similar to 137, 2010)	Univ Bonn, Dept Dermatol & Allergy, D-53105 Bonn, Germany	Bieber, T (reprint author), Univ Bonn, Dept Dermatol & Allergy, Sigmund Freud Str 25, D-53105 Bonn, Germany.	Thomas.Bieber@ukb.uni-bonn.de					Alomar A, 2004, BRIT J DERMATOL, V151, P3, DOI 10.1111/j.1365-2133.2004.06269.x; Arellano FM, 2007, J INVEST DERMATOL, V127, P808, DOI 10.1038/sj.jid.5700622; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, pe1, DOI DOI 10.1016/J.JACI.2009.11.008; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P30; BECK LA, 2009, J ALLERGY CLIN IMMUN, V124, P269; BECK LA, 2009, J ALLERGY CLIN IMMUN, V124, pE261; Beck LA, 2009, J ALLERGY CLIN IMMUN, V124, P260, DOI 10.1016/j.jaci.2009.05.020; Beissert S, 2006, J INVEST DERMATOL, V126, P15, DOI 10.1038/sj.jid.5700004; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Bieber T, 2007, ALLERGY, V62, P184, DOI 10.1111/j.1398-9995.2006.01269.x; Bieber T, 2005, DERMATOLOGY, V211, P77, DOI 10.1159/000086431; Biedermann T, 2004, J INVEST DERM SYMP P, V9, P5, DOI 10.1111/j.1087-0024.2004.00829.x; Breuer K, 2005, AM J CLIN DERMATOL, V6, P65, DOI 10.2165/00128071-200506020-00001; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Callen J, 2007, BRIT J DERMATOL, V156, P203, DOI 10.1111/j.1365-2133.2006.07538x; Cardona ID, 2006, J ALLERGY CLIN IMMUN, V117, P688, DOI 10.1016/j.jaci.2005.11.037; Cardona ID, 2006, AM J CLIN DERMATOL, V7, P273, DOI 10.2165/00128071-200607050-00001; Cassano N, 2006, INT J IMMUNOPATH PH, V19, P237; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Dawe RS, 2003, BRIT J DERMATOL, V148, P626, DOI 10.1046/j.1365-2133.2003.05261.x; Diepgen TL, 1996, J CLIN EPIDEMIOL, V49, P1031, DOI 10.1016/0895-4356(96)00119-9; Fiset PO, 2006, J ALLERGY CLIN IMMUN, V118, P287, DOI 10.1016/j.jaci.2006.03.046; Forrest S, 1999, J ALLERGY CLIN IMMUN, V104, P1066; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P507, DOI 10.1016/j.jaci.2009.07.034; Gao PS, 2009, J ALLERGY CLIN IMMUN, V124, P513; GAO PS, 2009, J ALLERGY CLIN IMMUN, V124, pE501; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Griffin JW, 2006, NAT CLIN PRACT NEURO, V2, P1, DOI 10.1038/ncpneuro0096; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; HANIFIN JM, 1980, ACTA DERM-VENEREOL, P44; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hijnen DJ, 2007, J EUR ACAD DERMATOL, V21, P85, DOI 10.1111/j.1468-3083.2006.01877.x; Homey B, 2006, J ALLERGY CLIN IMMUN, V118, P178, DOI 10.1016/j.jaci.2006.03.047; HOSOI J, 1993, NATURE, V363, P159, DOI 10.1038/363159a0; Housman TS, 2002, BRIT J DERMATOL, V147, P1192, DOI 10.1046/j.1365-2133.2002.05031.x; Howell MD, 2006, IMMUNITY, V24, P341, DOI 10.1016/j.immuni.2006.02.006; Izadpanah A, 2005, J AM ACAD DERMATOL, V52, P381, DOI 10.1016/j.jaad.2004.08.026; Izadpanah A, 2005, J AM ACAD DERMATOL, V52, P391; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Juenger M, 2006, CURR MED RES OPIN, V22, P739, DOI 10.1185/030079906X99990; Kim BE, 2007, J ALLERGY CLIN IMMUN, V119, P457, DOI 10.1016/j.jaci.2006.10.005; Kimura M, 1998, J ALLERGY CLIN IMMUN, V101, P84, DOI 10.1016/S0091-6749(98)70197-6; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; LARSEN FVS, 1985, ACTA DERM-VENEREOL, P159; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Margolis DJ, 2007, DERMATOLOGY, V214, P289, DOI 10.1159/000100879; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Meggitt SJ, 2006, LANCET, V367, P839, DOI 10.1016/S0140-6736(06)68340-2; Meggitt SJ, 2001, CLIN EXP DERMATOL, V26, P369, DOI 10.1046/j.1365-2230.2001.00837.x; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; Mittermann Irene, 2004, Curr Opin Allergy Clin Immunol, V4, P367, DOI 10.1097/00130832-200410000-00007; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467; Mothes N, 2005, J ALLERGY CLIN IMMUN, V116, P706, DOI 10.1016/j.jaci.2005.06.025; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Nomura I, 2003, J IMMUNOL, V171, P3262; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Novak N, 2005, J AM ACAD DERMATOL, V53, pS171, DOI 10.1016/j.jaad.2005.04.060; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P828, DOI 10.1016/j.jaci.2005.01.030; Novak N, 2002, J INVEST DERMATOL, V119, P870, DOI 10.1046/j.1523-1747.2002.00191.x; Ong PY, 2006, CURR ALLERGY ASTHM R, V6, P384, DOI 10.1007/s11882-996-0008-5; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Park JH, 2006, BRIT J DERMATOL, V155, P778, DOI 10.1111/j.1365-2133.2006.07394.x; Peters EMJ, 2007, HORM METAB RES, V39, P110, DOI 10.1055/s-2007-961812; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Raap U, 2005, CURR OPIN ALLERGY CL, V5, P419, DOI 10.1097/01.all.0000183111.78558.4d; Rieg S, 2005, J IMMUNOL, V174, P8003; RING J, 1991, INT ARCH ALLER A IMM, V94, P194; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Sator PG, 2003, J AM ACAD DERMATOL, V48, P352, DOI 10.1067/mjd.2003.105; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Silva SH, 2006, J EUR ACAD DERMATOL, V20, P1114, DOI 10.1111/j.1468-3083.2006.01748.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Staab D, 2006, BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; STALDER JF, 1994, BRIT J DERMATOL, V131, P536; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Thomas KS, 2002, BRIT MED J, V324, P768, DOI 10.1136/bmj.324.7340.768; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Tzaneva S, 2001, J AM ACAD DERMATOL, V45, P503, DOI 10.1067/mjd.2001.114743; Valenta R, 1998, J INVEST DERMATOL, V111, P1178, DOI 10.1046/j.1523-1747.1998.00413.x; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; WAHLGREN CF, 1990, BRIT J DERMATOL, V122, P545, DOI 10.1111/j.1365-2133.1990.tb14732.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Wilkinson JD, 1998, BRIT J DERMATOL, V139, P37; Williams HC, 2005, NEW ENGL J MED, V352, P2314, DOI 10.1056/NEJMcp042803; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Wohlrab J, 2007, SKIN PHARMACOL PHYS, V20, P71, DOI 10.1159/000097653; Wollenberg A, 2008, ALLERGY, V63, P742, DOI 10.1111/j.1398-9995.2008.01683.x; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1067/mai.2003.1775; Wollenberg A, 2009, ALLERGY, V64, P276, DOI 10.1111/j.1398-9995.2008.01803.x; [Anonymous], 1993, DERMATOLOGY, V186, P23	106	191	206	7	48	KOREAN DERMATOLOGICAL ASSOC	SEOUL	305 SEOCHO NASAN, SUITE OFFICE 1330-16, SEOCHO-2-DONG, SEOCHO-GU, SEOUL, 137-858, SOUTH KOREA	1013-9087			ANN DERMATOL	Ann. Dermatol.	MAY	2010	22	2					125	137		10.5021/ad.2010.22.2.125		13	Dermatology	Dermatology	624AF	WOS:000279787800001	20548901	
J	Gehring, U; Wijga, AH; Brauer, M; Fischer, P; de Jongste, JC; Kerkhof, M; Oldenwening, M; Smit, HA; Brunekreef, B				Gehring, Ulrike; Wijga, Alet H.; Brauer, Michael; Fischer, Paul; de Jongste, Johan C.; Kerkhof, Marjan; Oldenwening, Marieke; Smit, Henriette A.; Brunekreef, Bert			Traffic-related Air Pollution and the Development of Asthma and Allergies during the First 8 Years of Life	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; allergy; air pollution; cohort; traffic	BIRTH COHORT; EXPOSURE; CHILDHOOD; CHILDREN; SYMPTOMS; SENSITIZATION; POLLUTANTS; INFECTIONS; INFANTS; MODELS	Rationale The role of air pollution exposure in the development of asthma, allergies, and related symptoms remains unclear, due in part to the limited number of prospective cohort studies with sufficiently long follow-ups addressing this problem. Objectives: We studied the association between traffic-related air pollution and the development of asthma, allergy, and related symptoms in a prospective birth cohort study with a unique 8-year follow-up. Methods: Annual questionnaire reports of asthma, hay fever, and related symptoms during the first 8 years of life were analyzed for 3,863 children. At age 8, measurements of allergic sensitization and bronchial hyperresponsiveness were performed for subpopulations (n = 1,700 and 936, respectively). Individual exposures to nitrogen dioxide (NO(2)), particulate matter (PM(2.5)), and soot at the birth address were estimated by land-use regression models. Associations between exposure to traffic-related air pollution and repeated measures of health outcomes were assessed by repeated-measures logistic regression analysis. Effects are presented for an interquartile range increase in exposure after adjusting for covariates. Measurements and Main Results: Annual prevalence was 3 to 6% for asthma and 12 to 23% for asthma symptoms. Annual incidence of asthma was 6% at age 1, and 1 to 2% at later ages. PM2.5 levels were associated with a significant increase in incidence of asthma (odds ratio [OR], 1.28; 95% confidence interval [CI], 1.10-1.49), prevalence of asthma (OR, 1.26; 95% CI, 1.04-1.51), and prevalence of asthma symptoms (OR, 1.15; 95% CI, 1.02-1.28). Findings were similar for NO(2) and soot. Associations were stronger for children who had not moved since birth. Positive associations with hay fever were found in nonmovers only. No associations were found with atopic eczema, allergic sensitization, and bronchial hyperresponsiveness. Conclusions: Exposure to traffic-related air pollution may cause asthma in children.	[Gehring, Ulrike; Oldenwening, Marieke; Brunekreef, Bert] Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; [Wijga, Alet H.; Smit, Henriette A.] Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; [Brauer, Michael] Univ British Columbia, Sch Environm Hlth, Vancouver, BC V5Z 1M9, Canada; [Fischer, Paul] Natl Inst Publ Hlth & Environm, Ctr Environm Hlth Res, NL-3720 BA Bilthoven, Netherlands; [de Jongste, Johan C.] Erasmus Univ Med Ctr Sophia Childrens Hosp, Div Resp Med, Dept Pediat, Rotterdam, Netherlands; [Kerkhof, Marjan] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands; [Smit, Henriette A.; Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands	Gehring, U (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80178, NL-3508 TD Utrecht, Netherlands.	u.gehring@uu.nl	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; brunekreef, bert/0000-0001-9908-0060; Gehring, Ulrike/0000-0003-3612-5780; Brauer, Michael/0000-0002-9103-9343	Netherlands Organization for Health Research and Development; Netherlands Organization for Scientific Research (NWO); Netherlands Asthma Fund; Netherlands Ministry of Spatial Planning, Housing, and the Environment; Netherlands Ministry of Health, Welfare, and Sport; German Academic Exchange Service (DAAD)	Supported by The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; The Netherlands Asthma Fund; The Netherlands Ministry of Spatial Planning, Housing, and the Environment; and The Netherlands Ministry of Health, Welfare, and Sport (the PIAMA Study). Ulrike Gehring was supported by research fellowships of the German Academic Exchange Service (DAAD) and the Netherlands Organization for Scientific Research (NWO).	Andersen ZJ, 2008, THORAX, V63, P710, DOI 10.1136/thx.2007.085480; Beijk R., 2008, 680704005 RIVM NAT I; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brauer M, 2006, ENVIRON HEALTH PERSP, V114, P1414, DOI 10.1289/ehp.9089; Brown JS, 2007, J EXPO SCI ENV EPID, V17, pS97, DOI 10.1038/sj.jes.7500632; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; CHEN CM, CLIN EXP DE IN PRESS; Diggle P. J., 1994, ANAL LONGITUDINAL DA; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gehring U, 2009, EPIDEMIOLOGY, V20, pS34; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Hosmer DW, 1989, APPL LOGISTIC REGRES; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Nethery E, 2008, OCCUP ENVIRON MED, V65, P579, DOI 10.1136/oem.2007.035337; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; Ryan PH, 2008, SCI TOTAL ENVIRON, V404, P139, DOI 10.1016/j.scitotenv.2008.05.051; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; Sarnat JA, 2007, CURR OPIN PULM MED, V13, P63, DOI 10.1097/MCP.0b013e3280117d25; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056	29	191	197	5	66	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 15	2010	181	6					596	603		10.1164/rccm.200906-0858OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	632RX	WOS:000280446500013	19965811	
J	Clifton, VL				Clifton, V. L.			Sex and the Human Placenta: Mediating Differential Strategies of Fetal Growth and Survival	PLACENTA			English	Article; Proceedings Paper	Annual Meeting of the International-Federation-of-Placenta-Associations	OCT 06-09, 2009	Adelaide, AUSTRALIA	Int Federat Placenta Assoc, Univ Adelaide, Robinson Inst, NGED		Placenta Sex; Pregnancy; Birthweight	MATERNAL ASTHMA; X-INACTIVATION; FACTOR-I; GLUCOCORTICOID EXPOSURE; ANTENATAL BETAMETHASONE; PRENATAL-DIAGNOSIS; ANDROGEN RECEPTOR; IMMUNE-RESPONSES; BLOOD-PRESSURE; EXPRESSION	There are known sex specific differences in fetal and neonatal morbidity and mortality. There are also known differences in birthweight centile with males generally being larger than females at birth. These differences are generally ignored when studying obstetric complications of pregnancy and the mechanisms that confer these differences between the sexes are unknown. Current evidence suggests sex specific adaptation of the placenta may be central to the differences in fetal growth and survival. Our research examining pregnancies complicated by asthma has reported sexually dimorphic differences in fetal growth and survival with males adapting placental function to allow for continued growth in an adverse maternal environment while females reduce growth in an attempt to survive further maternal insults. We have reported sex differences in placental cytokine expression, insulin-like growth factor pathways and the placental response to cortisol in relation to the complication of asthma during pregnancy. More recently we have identified sex specific alterations in placental function in pregnancies complicated by preterm delivery which were associated with neonatal outcome and survival. We propose the sexually dimorphic differences in growth and survival of the fetus are mediated by the sex specific function of the human placenta. This review will present evidence supporting this hypothesis and will argue that to ignore the sex of the placenta is no longer sound scientific practice. (C) 2010 Published by IFPA and Elsevier Ltd.	Univ Adelaide, Robinson Inst, Dept Paediat & Reprod Hlth, Fac Hlth Sci, Adelaide, SA 5005, Australia	Clifton, VL (reprint author), Univ Adelaide, Robinson Inst, Dept Paediat & Reprod Hlth, Fac Hlth Sci, Med N,Level 6,Frome Rd, Adelaide, SA 5005, Australia.	Vicki.clifton@adelaide.edu.au	Clifton, Vicki/A-1445-2012	Clifton, Vicki/0000-0002-4892-6748			Angele MK, 2003, AM J PHYSIOL-ENDOC M, V285, pE189, DOI 10.1152/ajpendo.00035.2003; Angele MK, 2000, SHOCK, V14, P81, DOI 10.1097/00024382-200014020-00001; ASHTON IK, 1983, EARLY HUM DEV, V8, P135, DOI 10.1016/0378-3782(83)90069-5; BAKER J, 1993, CELL, V75, P73, DOI 10.1016/S0092-8674(05)80085-6; Banjanin S, 2004, J PHYSIOL-LONDON, V558, P305, DOI 10.1113/jphysiol.2004.063669; Barnes Peter J, 2004, Proc Am Thorac Soc, V1, P264, DOI 10.1513/pats.200402-014MS; Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1; Clark JM, 2007, PAEDIATR PERINAT EP, V21, P154, DOI 10.1111/j.1365-3016.2007.00784.x; Clarke Joseph, 1786, PHILOS T ROY SOC LON, V76, P349, DOI DOI 10.1098/RSTL.1786.0017; Clifton VL, 2007, J CHROMATOGR B, V855, P249, DOI 10.1016/j.jchromb.2007.05.041; Clifton VL, 2005, PLACENTA, V26, P773, DOI 10.1016/j.placenta.2004.10.018; Clifton VL, 2004, PLACENTA, V25, pS45, DOI 10.1016/j.placenta.2004.01.004; CLIFTON VL, 2009, GROWTH HORM IGF 0818; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Di Renzo GC, 2007, GENDER MED, V4, P19, DOI 10.1016/S1550-8579(07)80004-0; Engel PJ, 2008, AUST NZ J OBSTET GYN, V48, P375, DOI 10.1111/j.1479-828X.2008.00863.x; FANT M, 1986, J CLIN ENDOCR METAB, V63, P499; Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394; Fowden AL, 1996, J ENDOCRINOL, V151, P97, DOI 10.1677/joe.0.1510097; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; Geary MPP, 2003, J CLIN ENDOCR METAB, V88, P3708, DOI 10.1210/jc.2002-022006; Geifman-Holtzman O, 2008, EXPERT REV MOL DIAGN, V8, P727, DOI 10.1586/14737159.8.6.727; Ghidini A, 2005, ACTA OBSTET GYN SCAN, V84, P547, DOI 10.1111/j.0001-6349.2005.00694.x; Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P1533, DOI 10.1016/j.ajog.2006.05.023; Han VKM, 1996, J CLIN ENDOCR METAB, V81, P2680, DOI 10.1210/jc.81.7.2680; HORIE K, 1992, HUM REPROD, V7, P184; Hsu TY, 2009, TAIWAN J OBSTET GYNE, V48, P262, DOI 10.1016/S1028-4559(09)60301-6; Johnson RF, 2008, J CLIN ENDOCR METAB, V93, P4887, DOI 10.1210/jc.2008-1077; Kovar J, 2001, PEDIATR PULM, V32, P8, DOI 10.1002/ppul.1082; LEE PDK, 1993, P SOC EXP BIOL MED, V204, P4; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/S0092-8674(05)80084-4; Lo YMD, 2007, NAT REV GENET, V8, P71, DOI 10.1038/nrg1982; Looijenga LHJ, 1999, AM J HUM GENET, V64, P1445, DOI 10.1086/302382; Mayhew TM, 2008, PLACENTA, V29, P366, DOI 10.1016/j.placenta.2008.01.011; Migeon BR, 2005, AM J HUM GENET, V77, P355, DOI 10.1086/432815; MONTENEGRO D, 2007, AM J OBSTET GYNECOL, V197, pE1; Murphy VE, 2006, RESPIROLOGY, V11, P41, DOI 10.1111/j.1440-1843.2006.00782.x; Murphy VE, 2005, OBSTET GYNECOL, V106, P1046, DOI 10.1097/01.AOG.0000185281.21716.02; Murphy VE, 2005, J SOC GYNECOL INVEST, V12, P349, DOI 10.1016/j.jsgi.2005.01.024; Murphy VE, 2003, AM J RESP CRIT CARE, V168, P1317, DOI 10.1164/rccm.200303-374OC; Osei-Kumah A, 2008, EXPERT REV CLIN IMMU, V4, P713, DOI 10.1586/1744666X.4.6.713; OSEIKUMAH A, 2009, PLACENTA, pA103; Owen D, 2003, ENDOCRINOLOGY, V144, P2775, DOI 10.1210/en.2002-0145; PAPAGEORGIOU AN, 1981, PEDIATRICS, V67, P614; Pineles BL, 2007, AM J OBSTET GYNECOL, V196, pe1; Reik W, 2005, NAT REV GENET, V6, P403, DOI 10.1038/nrg1602; Ricart W, 2009, J EPIDEMIOL COMMUN H, V63, P64, DOI 10.1136/jech.2008.074542; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; Rosmond R, 1998, INT J OBESITY, V22, P1184; Sakamoto M, 2001, ENVIRON RES, V87, P92, DOI 10.1006/enrs.2001.4293; Scott NM, 2009, J IMMUNOL, V182, P1411; SIMMONS D, 1994, BIOL NEONATE, V65, P287; Sood R, 2006, P NATL ACAD SCI USA, V103, P5478, DOI 10.1073/pnas.0508035103; Stark MJ, 2008, ARCH DIS CHILD-FETAL, V93, pF271, DOI 10.1136/adc.2007.123539; Stark MJ, 2006, J SOC GYNECOL INVEST, V13, P573, DOI 10.1016/jjsgi.2006.06.006; Stark MJ, 2009, AM J PHYSIOL-REG I, V297, pR510, DOI 10.1152/ajpregu.00175.2009; Stark MJ, 2009, PEDIATR RES, V65, P291; Stark MJ, 2008, PEDIATR RES, V63, P415, DOI 10.1203/01.pdr.0000304937.38669.63; STARK MJ, 2009, PLACENTA, pA103; STEVENSON DK, 2000, ARCH DIS CHILD-FETAL, V83, pF782; Vatten LJ, 2004, EARLY HUM DEV, V76, P47, DOI 10.1016/j.earlhumdev.2003.10.006; Vu TT, 2009, REPROD FERT DEVELOP, V21, P599, DOI 10.1071/RD08224; Yeganegi M, 2009, AM J OBSTET GYNECOL, V200, DOI 10.1016/j.ajog.2008.12.032; ZAPF J, 1978, METABOLISM, V27, P1803, DOI 10.1016/0026-0495(78)90267-6; Zeng SM, 2003, PLACENTA, V24, P270, DOI 10.1053/plac.2002.0889	65	191	194	2	23	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0143-4004			PLACENTA	Placenta	MAR	2010	31			A			S33	S39		10.1016/j.placenta.2009.11.010		7	Developmental Biology; Obstetrics & Gynecology; Reproductive Biology	Developmental Biology; Obstetrics & Gynecology; Reproductive Biology	570VS	WOS:000275707000006	20004469	
J	Smith, AD; Cowan, JO; Brassett, KP; Filsell, S; McLachlan, C; Monti-Sheehan, G; Herbison, GP; Taylor, DR				Smith, AD; Cowan, JO; Brassett, KP; Filsell, S; McLachlan, C; Monti-Sheehan, G; Herbison, GP; Taylor, DR			Exhaled nitric oxide - A predictor of steroid response	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; exhaled nitric oxide; inhaled corticosteroid; symptoms; treatment response	AIR-FLOW OBSTRUCTION; INHALED CORTICOSTEROIDS; PULMONARY-DISEASE; MILD ASTHMA; RESPONSIVENESS; INFLAMMATION; CHILDREN; ADULTS; PREDNISOLONE; EOSINOPHILS	Rationale: The initial management of patients who present with persistent respiratory symptoms includes recognizing those with the potential to benefit from inhaled steroid therapy. To date, this has required undertaking a "trial of steroid" to identify responders. There is increasing evidence that steroid response is more likely in patients with eosinophilic airway inflammation, and this can be assessed indirectly using exhaled nitric oxide (FENO) measurements. Objectives: We aimed to assess the predictive accuracy of FENO to identify steroid response in 52 patients presenting with undiagnosed respiratory symptoms in a single-blind, fixed-sequence, placebo-controlled trial of inhaled fluticasone for 4 weeks. Methods: Comparisons of predictive accuracy were made between FENO, and other conventional predictors: peak flows, spirometry, bronchodilator response, and airway hyperresponsiveness measured at baseline. "Steroid response" was defined as change in symptoms, peak flows, spirometry, or airway hyperresponsiveness to adenosin,e based on established guidelines and recommendations. Results: Steroid response was significantly greater in the highest FENO tertile (> 47 ppb) for each endpoint. This outcome was independent of the diagnostic label. The predictive values for FENO were significantly greater than for almost all other baseline predictors, with an optimum cut point of 47 ppb. Conclusions: FENO measurements greater than 47 ppb provide a means of predicting steroid response in patients with undiagnosed respiratory symptoms. Assessing airway inflammation is of more practical value than diagnostic labeling when considering the potential usefulness of inhaled antiinflammatory therapy.	Univ Otago, Sch Med, Otago Resp Res Unit, Dunedin, New Zealand	Taylor, DR (reprint author), Univ Otago, Sch Med, Otago Resp Res Unit, POB 913, Dunedin, New Zealand.	robin.taylor@stonebow.otago.ac.nz					American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; HANLEY JA, 1983, RADIOLOGY, V148, P839; Jatakanon A, 1998, THORAX, V53, P91; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Kelly HW, 2003, J ALLERGY CLIN IMMUN, V112, P469, DOI 10.1067/mai.2003.1718; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Meijer RJ, 2002, CLIN EXP ALLERGY, V32, P1096, DOI 10.1046/j.1365-2222.2002.01412.x; [Anonymous], 2002, NIH PUBL, V01-4913; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376; POLOSA R, 1991, J ALLERGY CLIN IMMUN, V87, P939, DOI 10.1016/0091-6749(91)90415-K; Powell H, 2003, MED J AUSTRALIA, V178, P223; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smith AD, 2005, CURR OPIN ALLERGY CL, V5, P49, DOI 10.1097/00130832-200502000-00010; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; TAYLOR DR, 2001, EVIDENCE BASED ASTHM; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107; WEIR DC, 1990, THORAX, V45, P118, DOI 10.1136/thx.45.2.118; WEIR DC, 1990, THORAX, V45, P112, DOI 10.1136/thx.45.2.112; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	29	191	199	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2005	172	4					453	459		10.1164/rccm.200411-1498OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	953DL	WOS:000231056500016	15901605	
J	Canonica, GW; Passalacqua, G				Canonica, GW; Passalacqua, G			Noninjection routes for immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen immunotherapy; sublingual immunotherapy; local nasal immunotherapy; noninjection routes	LOCAL NASAL IMMUNOTHERAPY; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; HOUSE-DUST-MITE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; SHORT RAGWEED EXTRACT; CD4(+) T-CELLS; PRESEASONAL INTRANASAL IMMUNOTHERAPY	Allergen specific immunotherapy, together with drugs and allergen avoidance, is a cornerstone in the management of respiratory allergy. The traditional subcutaneous route is burdened with the risk of severe adverse events; therefore, safer routes of administration (noninjection or local routes) have been investigated and developed. Controlled trials failed to demonstrate the clinical efficacy and the safety of oral and bronchial administration, and these routes have been abandoned. Local nasal immunotherapy proved effective and safe in 17 of 18 controlled trials; thus it is considered a viable route of immunotherapy. Nevertheless, nasal immunotherapy is effective in rhinitis only and requires a particular administration technique; therefore its use is slowly declining. The sublingual route is supported by numerous controlled trials showing its efficacy in asthma and rhinitis in adults and children. The safety profile, assessed in clinical trials and postmarketing surveillance studies, is satisfactory; the most frequent side effects are gastrointestinal complaints, which can be easily managed by proper dose adjusting. Sublingual immunotherapy is now accepted by the World Health Organization as a valid alternative to the subcutaneous route also in children. Although the long-lasting efficacy has been recently documented for the sublingual route, several points still need to be elucidated, including mechanisms of action, optimal dosage, cost-effectiveness, and adherence.	Univ Genoa, Dept Internal Med, Div Allergy & Resp Dis, I-16126 Genoa, Italy	Canonica, GW (reprint author), DIMI, Allergy & Resp Dis, Lgo R Benzi 10, I-16132 Genoa, Italy.						Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; Andri L, 1993, J ALLERGY CLIN IMMUN, V91, P587; ANDRI L, 1996, J ALLERGY CLIN IMMUN, V97, P37; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; BAGNASCO M, 1997, J ALLERGY CLIN IMMUN, V100, P121; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; BARDARE M, 1996, J INVESTIG ALLERGOL, V97, P34; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bertoni M, 1999, ANN ALLERG ASTHMA IM, V82, P47, DOI 10.1016/S1081-1206(10)62659-2; BJORKSTEN B, 1994, ALLERGY, V49, P299, DOI 10.1111/j.1398-9995.1994.tb02271.x; Black JH, 1927, J LAB CLIN MED, V12, P1156; Black JH, 1928, J LAB CLIN MED, V13, P709; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; BOUSQUET J, 1998, ALLERGY S, V53; BOUSQUET J, 2001, J ALLERGY CLIN IM S5, V108, pS240; Brown JL, 2001, CLIN EXP ALLERGY, V31, P8, DOI 10.1046/j.1365-2222.2001.01009.x; BUCKLE FG, 1975, J ALLERGY CLIN IMMUN, V55, P213, DOI 10.1016/0091-6749(75)90139-6; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Cirla AM, 1996, ALLERGY, V51, P299, DOI 10.1111/j.1398-9995.1996.tb04613.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; Committee on the safety of medicines, 1986, BRIT MED J, V293, P948, DOI 10.1136/bmj.293.6552.948; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; Curtis HH, 1900, MED NEWS, V77, P16; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P141, DOI 10.1111/j.1365-2222.1995.tb01019.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Douglass J, 2002, CLIN EXP ALLERGY, V32, P1, DOI 10.1046/j.0022-0477.2001.01278.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EINARSSON R, 1988, ALLERGY, V43, P469, DOI 10.1111/j.1398-9995.1988.tb00921.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Falagiani P, 1997, ALLERGY, V52, P17; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; FELIZIANI V, 1995, ALLERGOL IMMUNOPATH, V23, P173; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Gabrielsson S, 2001, ALLERGY, V56, P293, DOI 10.1034/j.1398-9995.2001.00472.x; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; GEORGITIS JW, 1983, J ALLERGY CLIN IMMUN, V71, P71, DOI 10.1016/0091-6749(83)90549-3; Giannarini L, 1998, CLIN EXP ALLERGY, V28, P404; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; HASSEUS B, 1995, J ORAL PATHOL MED, V24, P56, DOI 10.1111/j.1600-0714.1995.tb01139.x; Herxeimer H, 1951, INT ARCH ALLER A IMM, V40, P40; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P159; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; HOLT PG, 1987, CELL IMMUNOL, V104, P434, DOI 10.1016/0008-8749(87)90045-1; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P55; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; JOHANSSON SGO, 1979, INT ARCH ALLER A IMM, V60, P447; Kagi MK, 2002, ALLERGY, V57, P379, DOI 10.1034/j.1398-9995.2002.01153.x; KHINCHI S, 2000, ALLERGY S, V55, P24; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LAISSUE JA, 1993, DIGEST DIS, V11, P298, DOI 10.1159/000171421; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Litwin A, 1997, J ALLERGY CLIN IMMUN, V100, P30; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47; Lombardi C, 2000, ALLERGY, V55, P677, DOI 10.1034/j.1398-9995.2000.00687.x; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; Lombardi C, 2001, ALLERGY, V56, P889; LOWER T, 1993, ANN ALLERGY, V70, P480; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Malling HJ, 1998, ALLERGY, V53, P461; MALLING HJ, 1993, ALLERGY S44, V53, P6; Marcucci F, 2002, ALLERGY, V57, P23, DOI 10.1034/j.1398-9995.2002.13149.x; Marcucci F, 2001, ALLERGY, V56, P1091, DOI 10.1034/j.1398-9995.2001.00226.x; METHA SB, 1975, CLIN ALLERGY, V5, P279; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; MISTRELLO G, 1991, ALLERGY, V46, P52, DOI 10.1111/j.1398-9995.1991.tb00543.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOSBECH H, 1987, ALLERGY, V42, P451, DOI 10.1111/j.1398-9995.1987.tb00362.x; Motta G, 2000, LARYNGOSCOPE, V110, P132, DOI 10.1097/00005537-200001000-00024; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; NICKELSEN JA, 1981, J ALLERGY CLIN IMMUN, V68, P33, DOI 10.1016/0091-6749(81)90120-2; Noon L, 1911, LANCET, V1, P1572; ONGARI S, 1995, ALLERGY, V50, P358; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; OSTERGAARD PA, 1986, ALLERGY, V41, P588; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 1996, J INVEST ALLERG CLIN, V6, P81; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; Passalacqua G, 2002, ALLERGY, V57, P275, DOI 10.1034/j.1398-9995.2002.03264.x; Passalacqua G, 2001, ALLERGY, V56, P578, DOI 10.1034/j.1398-9995.2001.056006578.x; PIAZZA I, 1993, ANN ALLERGY, V71, P461; Pocobelli D, 2001, J INVEST ALLERG CLIN, V11, P79; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; REBIEN W, 1980, Allergologie, V3, P101; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; SCHUMACHER MJ, 1981, ALLERGY, V37, P241; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; Silvestri M, 2002, J INVEST ALLERG CLIN, V12, P52; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; SWARBRICK ET, 1979, GUT, V20, P121, DOI 10.1136/gut.20.2.121; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1989, J ALLERGY CLIN IMMUN, V83, P589, DOI 10.1016/0091-6749(89)90070-5; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TAUDORF E, 1983, ALLERGY, V38, P561, DOI 10.1111/j.1398-9995.1983.tb04140.x; Taylor D. R. F., 1997, P 18 INT CART C STOC, V1, P1; TAYLOR G, 1972, Clinical Allergy, V2, P125, DOI 10.1111/j.1365-2222.1972.tb01277.x; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; URBANEK R, 1982, MONATSSCHR KINDERH, V130, P150; VanDeusen MA, 1997, ANN ALLERG ASTHMA IM, V78, P573; VANWILSEM EJ, 1994, IMMUNOLOGY, V93, P128; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Vervloet D, 2002, ALLERGY, V57, P70; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WELSH PW, 1981, J ALLERGY CLIN IMMUN, V67, P237, DOI 10.1016/0091-6749(81)90067-1	137	191	200	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					437	448		10.1067/mai.2003.129		12	Allergy; Immunology	Allergy; Immunology	656YW	WOS:000181639500001	12642818	
J	Lauener, RP; Birchler, T; Adamski, J; Braun-Fahrlander, C; Bufe, A; Herz, U; von Mutius, E; Nowak, D; Riedler, J; Waser, M; Sennhauser, FH				Lauener, RP; Birchler, T; Adamski, J; Braun-Fahrlander, C; Bufe, A; Herz, U; von Mutius, E; Nowak, D; Riedler, J; Waser, M; Sennhauser, FH		ALEX Study Grp	Expression of CD14 and Toll-like receptor 2 in farmers' and nonfarmers' children	LANCET			English	Article							ASTHMA	Children of farmers are at decreased risk of developing allergies. Results of epidemiological studies suggest increased exposure to microbial compounds might be responsible for this reduced risk. Alterations in adaptive immune response are thought to be the underlying mechanism. We measured expression of receptors for microbial compounds known to trigger the innate immune response. We showed that blood cells from farmers' children express significantly higher amounts of CD14 (0.96 vs 0.43, p = 0.0013), and Toll-like receptor 2 (0.11 vs 0.04, p < 0.0001) than those from nonfarmers' children. We propose that the innate immune system responds to the microbial burden in the environment and modulates the development of allergic disease.	Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland; Univ Basel, Inst Social & Prevent Med, CH-4003 Basel, Switzerland; Ruhr Univ Bochum, D-4630 Bochum, Germany; Hosp Philipps Univ, Marburg, Germany; Univ Munich, Dr von Hauner Childrens Hosp, D-80539 Munich, Germany; Univ Munich, Inst Occupat & Environm Med, D-80539 Munich, Germany; Childrens Hosp Salzburg, Salzburg, Austria	Lauener, RP (reprint author), Univ Zurich, Childrens Hosp, CH-8032 Zurich, Switzerland.		Lauener, Roger/O-8612-2016	Lauener, Roger/0000-0002-8412-606X			Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Flo TH, 2001, J LEUKOCYTE BIOL, V69, P474; Martin P, 1999, APPL MICROW WIREL, V11, P12; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3	5	191	196	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	AUG 10	2002	360	9331					465	466		10.1016/S0140-6736(02)09641-1		2	Medicine, General & Internal	General & Internal Medicine	582GZ	WOS:000177342900018	12241724	
J	Kroes, R; Muller, D; Lambe, J; Lowik, MRH; van Klaveren, J; Kleiner, J; Massey, R; Mayer, S; Urieta, I; Verger, P; Visconti, A				Kroes, R; Muller, D; Lambe, J; Lowik, MRH; van Klaveren, J; Kleiner, J; Massey, R; Mayer, S; Urieta, I; Verger, P; Visconti, A			Assessment of intake from the diet	FOOD AND CHEMICAL TOXICOLOGY			English	Review						exposure assessments; risk assessment; food consumption; concentration of chemicals in food; probabilistic modelling	SUBCUTANEOUS ADIPOSE-TISSUE; TERM EXPOSURE DISTRIBUTIONS; VETERINARY DRUG RESIDUES; HEALTH-RISK ASSESSMENT; HABITUAL FOOD-INTAKE; NUTRIENT INTAKE; FATTY-ACIDS; HUMAN-URINE; VITAMIN-E; PLASMA-CONCENTRATIONS	Exposure assessment is one of the key parts of the risk assessment process. Only intake of toxicologically significant amounts can lead to adverse health effects even for a relatively toxic substance. In the case of chemicals in foods this is based on three major aspects: (i) how to determine quantitatively the presence of a chemical in individual foods and diets, including its fate during the processes within the food production chains 60 how to determine the consumption patterns of the individual foods containing the relevant chemicals, (iii) how to integrate both the likelihood of consumers eating large amounts of the given foods and of the relevant chemical being present in these foods at high levels. The techniques used for the evaluation of these three aspects have been critically reviewed in this paper to determine those areas where the current approaches provide a solid basis for assessments and those areas here improvements are needed or desirable. For those latter areas, options for improvements are being suggested, including. for example, the development of a pan-European food composition database, activities to understand better effects of processing on individual food chemicals, harmonisation of food consumption survey methods with the option of a regular pan-European survey, evaluation of probabilistic models and the development of models to assess exposure to food allergens. In all three areas, the limitations of the approaches currently used lead to uncertainties which can either cause an over- or underestimation of real intakes and thus risks, Given these imprecisions, risk assessors tend to build in additional uncertainty factors to avoid health-relevant underestimates. This is partly done by using screening methods designed to look for "worst case" situations. Such worse case assumptions lead to intake estimates that are higher than reality. These screening methods are used to screen all those chemicals with a safe intake distribution. For chemicals with a potential risk, more information is needed to allow more refined screening or even the most accurate estimation. More information and more refined methods however. require more resources. The ultimate aims are: (1) to obtain appropriate estimations for the presence and quantity of a given chemical in a food and in the diet in general: (2) to assess the consumption patterns for the foods containing these Substances, including especially those parts of the population with high consumption and thus potentially high intakes: and (3) to develop and apply tools to predict reliably the likelihood of high end consumption with the presence of high levels of the relevant substances, It has thus been demonstrated that a tiered approach at all three steps can be helpful to optimise the use of the available resources: if relatively crude tools - designed to provide a "worst case" estimate - do not suggest a toxicologically significant exposure (or a relevant deficit of a particular nutrient) it may not be necessary to use more sophisticated tools. These ill be needed if initially high intakes are indicated for at least parts of the Population, Existing pragmatic approaches are a first crude step to model food chemical intake. It is recommended to extend. refine and validate this approach in the near future. This has to result in a cost-effective exposure assessment system to be used for existing and potential categories of chemicals. This system of knowledge (with information on sensitivities. accuracy, etc.) will guide future data collection. (C) 2002 ILSL Published by Elsevier Science Ltd All rights reserved.	Int Life Sci Inst, European Branch, B-1200 Brussels, Belgium; Univ Utrecht, Fac Vet Med, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Procter & Gamble Serv GmbH, D-65823 Schwabach, Germany; Univ Dublin Trinity Coll, Inst European Food Studies, Inst Biotechnol, IRL, Dublin 2, Ireland; TNO, Nutr & Food Res Inst, Dept Nutr Epidemiol, NL-3700 AJ Zeist, Netherlands; DLO, RIKILT, NL-6700 AE Wageningen, Netherlands; CSL, Cent Sci Lab, York YO41 1LZ, N Yorkshire, England; Red Bull GmbH, A-5330 Fuschl Am See, Austria; Gobierno Vasco, Dept Hlth, E-48010 Bilbao, Spain; INRA, Nutr Humaine & Securite Alimentaire, F-75338 Paris 07, France; CNR, Ist Tossine & Micotossine Parassiti Vegetali, I-70126 Bari, Italy	Kleiner, J (reprint author), Int Life Sci Inst, European Branch, 83 Ave E Mounier,Box 6, B-1200 Brussels, Belgium.						ACAR J, 1998, Z LEBENSMITTEL UNT A, V328, P331; Andersen ST, 1970, DANMARKS GEOLOGISKE, V2, P1; ANDERSON W, 2001, FOOD ADDIT CONTAM, P1068; *ANZFA, 1998, AUSTR MARK BASK SURV; ARMSTRONG B, 1999, QUANTITATIVE ESTIMAT, P75; ASCHERIO A, 1992, J NUTR, V122, P1792; BASIOTIS PP, 1987, J NUTR, V117, P1638; BEATON GH, 1979, AM J CLIN NUTR, V32, P2546; BEATON GH, 1982, P S DIET DAT COLL AN, P36; Beemster C. J. M., 2000, Journal of Food Composition and Analysis, V13, P411, DOI 10.1006/jfca.2000.0899; Benfort DJ., 1997, FOOD CHEM RISK ANAL, P21; Bennett GA, 1996, FOOD TECHNOL-CHICAGO, V50, P235; Berg M.V., 1998, ENV HLTH PERSPECT, V106, P775; Berry MR, 1997, J EXPO ANAL ENV EPID, V7, P3; Bier VM, 1999, RISK ANAL, V19, P703, DOI 10.1023/A:1007093805693; Bingham SA, 1997, AM J CLIN NUTR, V65, P1130; BINGHAM SA, 1995, BRIT J NUTR, V73, P531, DOI 10.1079/BJN19950057; Black AE, 2000, BRIT J NUTR, V83, P341; Bousquet J, 1998, ALLERGY, V53, P3; BREITHOLTZ A, 1991, FOOD ADDIT CONTAM, V8, P183; Brera C, 1998, MICROCHEM J, V59, P45, DOI 10.1006/mchj.1998.1583; Briley ME, 1999, J AM DIET ASSOC, V99, P341, DOI 10.1016/S0002-8223(99)00086-3; Brussaard JH, 1997, EUR J CLIN NUTR, V51, pS32; BURMASTER DE, 1994, RISK ANAL, V14, P477, DOI 10.1111/j.1539-6924.1994.tb00265.x; Cadby P, 1996, FOOD ADDIT CONTAM, V13, P453; Carroll YL, 1999, EUR J CLIN NUTR, V53, P644, DOI 10.1038/sj.ejcn.1600827; Cassin MH, 1998, J FOOD PROTECT, V61, P1560; Castelo MM, 1998, J FOOD PROTECT, V61, P1030; Chambolle M, 1999, REGUL TOXICOL PHARM, V30, pS13, DOI 10.1006/rtph.1999.1320; Charmley L. L., 1994, P471; Committee on Biological Markers of the National Research Council, 1987, ENV HLTH PERSPECT, V74, P3; COPELAND TL, 1994, J AIR WASTE MANAGE, V44, P1399; CRESSEY PJ, 2000, NZ TOTAL DIET SURV 1; Cullen AC, 1999, PROBABILISTIC TECHNI; De Girolamo A, 2001, J FOOD PROTECT, V64, P701; DEEHR MS, 1990, AM J CLIN NUTR, V51, P95; DEGROOF LCP, 1991, EUR J CLIN NUTR, V45, pS1; Deharveng G, 1999, EUR J CLIN NUTR, V53, P60, DOI 10.1038/sj.ejcn.1600677; DOUGLAS JS, 1997, ESTIMATION DIETARY I, P195; Driver JH, 1996, RISK ANAL, V16, P763, DOI 10.1111/j.1539-6924.1996.tb00827.x; Dybing E, 2002, FOOD CHEM TOXICOL, V40, P237, DOI 10.1016/S0278-6915(01)00115-6; *EC, 2000, SANCO259700 EUR COMM; *EC, 1997, IMPR KNOWL FOOD CONS; Edler L, 2002, FOOD CHEM TOXICOL, V40, P283, DOI 10.1016/S0278-6915(01)00116-8; *EEC, 1990, OJCE; *EFCOSUM GROUP, 2001, V3766 TNO NUTR FOOD; Eisenbrand G, 2002, FOOD CHEM TOXICOL, V40, P193, DOI 10.1016/S0278-6915(01)00118-1; *EPA, 1996, AC DIAT EXP ASS OFF; *EPA, 2000, 6047 US EPA; EPA Guiding principles for Monte Carlo analysis, 1997, GUID PRINC MONT CARL; Enviromental Protection Agency (EPA), 1992, GUID EXP ASS; *EWG, 1998, OV ORG INS CHILDR FO; FAO/WHO, 1997, WHOFSFFOS975; *FAO WHO, 1999, PEST RES FOOD 1998 E; *FASEB LIF SCI RES, 1989, DHHS PUBL PHS; *FCA, 1997, SIMPL GUID EC FOOD C; FDA, 2000, FOOD DRUG ADM PEST P; Feunekes GIJ, 1999, AM J EPIDEMIOL, V150, P105; FINLEY B, 1994, RISK ANAL, V14, P533, DOI 10.1111/j.1539-6924.1994.tb00269.x; FINLEY B, 1994, RISK ANAL, V14, P53, DOI 10.1111/j.1539-6924.1994.tb00028.x; FORMAN MR, 1993, AM J CLIN NUTR, V58, P519; FREUDENHEIM JL, 1987, AM J EPIDEMIOL, V126, P703; FRIESEN MD, 1982, J ASSOC OFF ANA CHEM, V65, P855; GAN LS, 1988, CARCINOGENESIS, V9, P1323, DOI 10.1093/carcin/9.7.1323; Gilbert J, 2001, FOOD ADDIT CONTAM, V18, P1088, DOI 10.1080/02652030110070030; Goris AHC, 2000, AM J CLIN NUTR, V71, P130; GROOPMAN JD, 1992, CANCER RES, V52, P45; Groten JP, 2000, REGUL TOXICOL PHARM, V31, P77, DOI 10.1006/rtph.1999.1356; Hall RL, 1999, FOOD ADDIT CONTAM, V16, P481, DOI 10.1080/026520399283777; HALLER J, 1991, EUR J CLIN NUTR, V45, P63; Hamey PY, 2000, FOOD ADDIT CONTAM, V17, P601, DOI 10.1080/026520300412519; Hamey PY, 1999, REGUL TOXICOL PHARM, V30, pS34, DOI 10.1006/rtph.1999.1324; HANSEN SC, 1979, J FOOD PROTECT, V42, P429; HARRIES JM, 1969, J SCI FOOD AGR, V20, P242, DOI 10.1002/jsfa.2740200413; Harris CA, 2000, FOOD ADDIT CONTAM, V17, P491, DOI 10.1080/026520300412375; Hill MJ, 1996, INT J EPIDEMIOL, V25, P505, DOI 10.1093/ije/25.3.505; HOFFMAN K, IN PRESS EUROPEAN J; Hoogenboom LAP, 1999, ANALYST, V124, P79, DOI 10.1039/a804950e; Hoover SM, 1999, RISK ANAL, V19, P527, DOI 10.1023/A:1007065032101; HULSHOF KFA, IN PRESS NUTR SURVEI; HULSHOF KFA, 1998, ENCY HUMAN NUTR, P1413; Hulshof KFAM, 1999, EUR J CLIN NUTR, V53, P143, DOI 10.1038/sj.ejcn.1600692; HULT K, 1982, ARCH TOXICOL, V51, P313, DOI 10.1007/BF00317010; *ILSI, 1998, AGGR EXP ASS ILSI RI; *IOMC, 1999, PRINC ASS RISKS HUM; Ireland Jayne D., 2000, Journal of Food Composition and Analysis, V13, P529, DOI 10.1006/jfca.2000.0921; Ito N, 1996, FOOD CHEM TOXICOL, V34, P1091, DOI 10.1016/S0278-6915(97)00079-3; JALON M, 1997, VIGILANCIA CONTAMINA; Jebb SA, 1995, P NUTR SOC, V54, P721, DOI 10.1079/PNS19950071; *JECFA, 1989, JOINT FAO WHO EXP CO; Kaaks R, 1997, INT J EPIDEMIOL, V26, pS15, DOI 10.1093/ije/26.suppl_1.S15; Pate-Cornell ME, 1999, RISK ANAL, V22, P633, DOI 10.1111/j.1539-6924.1999.tb00388.x; Key PE, 1997, J AOAC INT, V80, P895; KIM W W, 1984, American Journal of Clinical Nutrition, V40, P1333; Kroes R, 2000, FOOD CHEM TOXICOL, V38, P255, DOI 10.1016/S0278-6915(99)00120-9; LAMBE J, 2001, FOOD ADDIT CONTAM, V19, P3; Larsen JC, 1998, FOOD ADDIT CONTAM, V15, P1; LIJINSKY W, 1991, MUTAT RES, V259, P251, DOI 10.1016/0165-1218(91)90121-2; LIPTON J, 1995, REGUL TOXICOL PHARM, V21, P192, DOI 10.1006/rtph.1995.1024; LISSNER L, 1989, AM J CLIN NUTR, V49, P320; LIU K, 1978, J CHRON DIS, V31, P399, DOI 10.1016/0021-9681(78)90004-8; LIVINGSTONE MBE, 1990, BRIT MED J, V300, P708; LOFTUS NJ, 1994, FOOD CHEM TOXICOL, V32, P1, DOI 10.1016/0278-6915(84)90029-2; LONDON SJ, 1991, AM J CLIN NUTR, V54, P340; Lowik Michiel R. H., 1994, International Journal of Food Sciences and Nutrition, V45, pS1; Lowik MRH, 1999, REGUL TOXICOL PHARM, V30, pS48, DOI 10.1006/rtph.1999.1326; Lowik MRH, 1996, P NUTR SOC, V55, P705, DOI 10.1079/PNS19960067; LOWIK MRH, 1998, V98593 TNO NUTR FOOD; MACDONALD I, 1991, ILSI MONOGRAPHS, V259; *MAFF, 1996, SURV EST DIET EXP PE; *MAFF, 1996, 49 STEER GROUP CHEM; MALLETT AK, 1988, FOOD CHEM TOXICOL, V26, P831, DOI 10.1016/0278-6915(88)90022-1; Massey RC, 1997, FOOD CHEM, V60, P177, DOI 10.1016/S0308-8146(96)00349-4; MCKONE TE, 1992, REGUL TOXICOL PHARM, V15, P86, DOI 10.1016/0273-2300(92)90087-P; Medlock V. F. P., 1996, SGM Quarterly, V23, P71; MILLER JD, 1996, MYCOTOXINS PHYCOTOXI, P1; MOOLGAVKAR S, 1999, IARC SCI PUBL, V131, P305; NELSON M, 1989, AM J CLIN NUTR, V50, P155; *NRC, 1986, NUTR AD; Nusser SM, 1996, J AM STAT ASSOC, V91, P1440, DOI 10.2307/2291570; Ocke MC, 1997, AM J CLIN NUTR, V65, P1240; ODONNELL MG, 1991, BRIT J NUTR, V66, P3, DOI 10.1079/BJN19910004; PACKER PJ, 1991, NITRATES NITRITES FO, P131, DOI 10.1533/9781855736559.131; *PAL CORP, 1997, RISK ADV RISK AN SPR; Pao EM, 1996, PRESENT KNOWLEDGE NU, P498; Park D.L., 1999, FOOD NUTR AGR, V23, P49; Parmar B, 1997, REGUL TOXICOL PHARM, V26, P44, DOI 10.1006/rtph.1997.1117; PAUSTENBACH DJ, 1991, TOXICOL IND HEALTH, V7, P159; PELUSO M, 1991, CARCINOGENESIS, V12, P713, DOI 10.1093/carcin/12.4.713; PENNINGTON JAT, 1987, J ASSOC OFF ANA CHEM, V70, P772; Petersen B, 1996, FOOD TECHNOL-CHICAGO, V50, P221; Petersen BJ, 2000, FOOD ADDIT CONTAM, V17, P591, DOI 10.1080/026520300412500; Pineiro Maya, 1996, Natural Toxins, V4, P242; POORTVLIET EJ, 1992, EUR J CLIN NUTR, V46, pS9; PRICE P, 1999, BACKGROUND DOCUMENT; Price PS, 1996, RISK ANAL, V16, P339, DOI 10.1111/j.1539-6924.1996.tb01468.x; PRICE SP, 2000, ASSESSING AGGREGATE; Rees NMA, 2000, FOOD ADDIT CONTAM, V17, P575, DOI 10.1080/026520300412483; REES NMA, 1993, SAFETY CHEM FOOD CHE, P157; Reistad R, 1999, BIOMARKERS, V4, P263; Reistad R, 1997, FOOD CHEM TOXICOL, V35, P945, DOI 10.1016/S0278-6915(97)00112-9; RENWICK AG, 1993, REGUL TOXICOL PHARM, V18, P463, DOI 10.1006/rtph.1993.1071; Riboli E, 1997, INT J EPIDEMIOL, V26, pS6, DOI 10.1093/ije/26.suppl_1.S6; Rose MD, 1997, ANALYST, V122, P1095, DOI 10.1039/a702771k; Rose MD, 1998, FOOD ADDIT CONTAM, V15, P157; SCHAFER L, 1990, AM J CLIN NUTR, V52, P486; Scott KJ, 1996, BRIT J NUTR, V75, P409, DOI 10.1079/BJN19960143; SCOTT PM, 1994, J FOOD PROTECT, V47, P490; SEMPOS CT, 1991, ILSI MONOGRAPHS, P99; SEWRAM V, 2000, 10 INT IUPAC S MYC P; Sichert-Hellert W, 1999, INT J FOOD SCI NUTR, V50, P65, DOI 10.1080/096374899101436; Sithisarankul P, 1997, BIOMARKERS, V2, P217; Slimani N, 1999, COMPUT METH PROG BIO, V58, P251, DOI 10.1016/S0169-2607(98)00088-1; SLOB W, 1994, ENVIRON HEALTH PERSP, V102, P78; Slob W, 1996, RISK ANAL, V16, P195; Solfrizzo M, 1997, J CHROMATOGR B, V692, P87, DOI 10.1016/S0378-4347(96)00502-6; STJEOR ST, 1983, J AM DIET ASSOC, V83, P155; STOCKLEY L, 1985, ECOL FOOD NUTR, V17, P263; STRICKLAND PT, 1995, AM J CLIN NUTR, V61, p710S; Sweeney MJ, 1998, INT J FOOD MICROBIOL, V43, P141, DOI 10.1016/S0168-1605(98)00112-3; TENNANT DR, 1997, FOOD CHEM RISK ANAL; Thomas KW, 1997, J EXPO ANAL ENV EPID, V7, P17; THOMPSON FE, 1994, J NUTR, V124, pS2245; TJONNELAND A, 1993, AM J CLIN NUTR, V57, P629; TRICHOPOLOU A, 1997, EUR 17909 COST ACTIO; Turner PC, 1999, MUTAT RES-GEN TOX EN, V443, P81, DOI 10.1016/S1383-5742(99)00012-5; Turner PC, 1998, CANCER EPIDEM BIOMAR, V7, P441; Urieta I, 1996, FOOD ADDIT CONTAM, V13, P29; Vaessen HAMG, 1999, FOOD ADDIT CONTAM, V16, P181, DOI 10.1080/026520399284046; van De Vijver LPL, 1999, J NUTR, V129, P963; van der Westhuizen L, 1999, FOOD CHEM TOXICOL, V37, P1153, DOI 10.1016/S0278-6915(99)00113-1; van Poppel G., 1998, Journal of Food Composition and Analysis, V11, P112, DOI 10.1006/jfca.1998.0568; VANDOKKUM W, 1990, 10 TNOCIVO I; VANDUSSELDORP M, 2000, V3136 TNO NUTR FOOD; VANERPBAART AMJ, 2002, V3452 TNO; VANKLAVEREN JD, 1999, RISK ASSESSMENT FOOD, P145; VANKLAVEREN JD, 1999, QUALITY PROGRAMME AG; Vannoort R, 2000, 1997 98 NZ TOTAL D 2; Verger P, 1999, REGUL TOXICOL PHARM, V30, pS103, DOI 10.1006/rtph.1999.1334; Voit EO, 2000, RISK ANAL, V20, P59, DOI 10.1111/0272-4332.00006; Vose D., 2000, RISK ANAL QUANTITATI; WAGENER DK, 1995, ANNU REV PUBL HEALTH, V16, P105; Wagstaffe PJ, 1996, FOOD ADDIT CONTAM, V13, P397; WALLACE LA, 1994, RISK ANAL, V14, P75, DOI 10.1111/j.1539-6924.1994.tb00029.x; Walsh M, 2000, FOOD ADDIT CONTAM, V17, P637, DOI 10.1080/026520300412564; Wasserbacher B., 2001, Ernahrung, V25, P57; Weigert P, 1997, FOOD ADDIT CONTAM, V14, P399; WHICKER FW, 1990, HEALTH PHYS, V59, P645; WHO (World Health Organization), 1997, WHOFSFFOS977; WHO, 1985, WHO OFFS PUBL; World Health Organization, 1991, FOOD HLTH DAT THEIR; WHO, 1998, WHOFSFFOS983; World Health Organization (WHO), 2000, ENV HLTH CRIT; [WHO] World Health Organization, 1999, JOINT USFDA WHO INT; WILD CP, 1992, CANCER EPIDEM BIOMAR, V1, P229; Ysart G, 1999, FOOD ADDIT CONTAM, V16, P521, DOI 10.1080/026520399283669; ZHU JQ, 1987, CANCER RES, V47, P1848	197	191	207	3	32	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915			FOOD CHEM TOXICOL	Food Chem. Toxicol.	FEB-MAR	2002	40	2-3					327	385	PII S0278-6915(01)00113-2	10.1016/S0278-6915(01)00113-2		59	Food Science & Technology; Toxicology	Food Science & Technology; Toxicology	543LA	WOS:000175102400007	11893401	
J	Burke, H; Leonardi-Bee, J; Hashim, A; Pine-Abata, H; Chen, YL; Cook, DG; Britton, JR; McKeever, TM				Burke, Hannah; Leonardi-Bee, Jo; Hashim, Ahmed; Pine-Abata, Hembadoon; Chen, Yilu; Cook, Derek G.; Britton, John R.; McKeever, Tricia M.			Prenatal and Passive Smoke Exposure and Incidence of Asthma and Wheeze: Systematic Review and Meta-analysis	PEDIATRICS			English	Review						asthma; wheeze; passive smoking exposure; meta-analysis	PROSPECTIVE BIRTH COHORT; ENVIRONMENTAL TOBACCO-SMOKE; BODY-MASS INDEX; MATERNAL SMOKING; EARLY-CHILDHOOD; RISK-FACTORS; PARENTAL SMOKING; 1ST YEAR; ATOPIC-DERMATITIS; SOCIOECONOMIC-STATUS	OBJECTIVES: Exposure to passive smoke is a common and avoidable risk factor for wheeze and asthma in children. Substantial growth in the prospective cohort study evidence base provides an opportunity to generate new and more detailed estimates of the magnitude of the effect. A systematic review and meta-analysis was conducted to provide estimates of the prospective effect of smoking by parents or household members on the risk of wheeze and asthma at different stages of childhood. METHODS: We systematically searched Medline, Embase, and conference abstracts to identify cohort studies of the incidence of asthma or wheeze in relation to exposure to prenatal or postnatal maternal, paternal, or household smoking in subjects aged up to 18 years old. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were estimated by using random effects model. RESULTS: We identified 79 prospective studies. Exposure to pre-or postnatal passive smoke exposure was associated with a 30% to 70% increased risk of incident wheezing (strongest effect from postnatal maternal smoking on wheeze in children aged <= 2 years, OR = 1.70, 95% CI = 1.24-2.35, 4 studies) and a 21% to 85% increase in incident asthma (strongest effect from prenatal maternal smoking on asthma in children aged <= 2 years, OR = 1.85, 95% CI = 1.35-2.53, 5 studies). CONCLUSIONS: Building upon previous findings, exposure to passive smoking increases the incidence of wheeze and asthma in children and young people by at least 20%. Preventing parental smoking is crucially important to the prevention of asthma. Pediatrics 2012;129:735-744	[Burke, Hannah; Leonardi-Bee, Jo; Hashim, Ahmed; Pine-Abata, Hembadoon; Chen, Yilu; Britton, John R.; McKeever, Tricia M.] Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, UK Ctr Tobacco Control Studies, Nottingham NG5 1PB, England; [Cook, Derek G.] St Georges Univ London, Div Populat Hlth Sci & Educ, London, England	McKeever, TM (reprint author), Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, UK Ctr Tobacco Control Studies, Nottingham NG5 1PB, England.	tricia.mckeever@nottingham.ac.uk	Britton, John/G-9705-2011; Cook, Derek/C-3271-2008	McKeever, Tricia/0000-0003-0914-0416	Cancer Research UK [C1512/A11160]; British Heart Foundation; Economic and Social Research Council; Medical Research Council; Department of Health under UK Clinical Research Collaboration; UK Clinical Research Collaboration	Supported by project grant C1512/A11160 from Cancer Research UK and by core funding to the UK Centre for Tobacco Control Studies (http://www.ukctcs.org) from the British Heart Foundation, Cancer Research UK, Economic and Social Research Council, Medical Research Council, and the Department of Health, under the auspices of the UK Clinical Research Collaboration.	Alati R, 2006, EPIDEMIOLOGY, V17, P138, DOI 10.1097/01.ede.0000198148.02347.33; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Bacopoulou F, 2009, J ASTHMA, V46, P171, DOI 10.1080/02770900802553128; Bergmann RL, 2000, CLIN EXP ALLERGY, V30, P1740, DOI 10.1046/j.1365-2222.2000.00927.x; Calam R, 2005, AM J RESP CRIT CARE, V171, P323, DOI 10.1164/rccm.200406-791OC; Chan-Yeung M, 2008, PEDIAT ALLERG IMM-UK, V19, P482, DOI 10.1111/j.1399-3038.2007.00689.x; Darlow BA, 2000, PEDIATR PULM, V30, P291, DOI 10.1002/1099-0496(200010)30:4<291::AID-PPUL3>3.0.CO;2-8; de Bilderling G, 2005, AM J EPIDEMIOL, V162, P513, DOI 10.1093/aje/kwi238; Fergusson D M, 1985, Pediatr Pulmonol, V1, P99, DOI 10.1002/ppul.1950010208; Genuneit J, 2006, THORAX, V61, P572, DOI 10.1136/thx.2005.051227; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Guedes HTV, 2009, PEDIATR ALLERGY IMMU, V20, P30, DOI 10.1111/j.1399-3038.2007.00710.x; Haberg SE, 2007, AM J EPIDEMIOL, V166, P679, DOI 10.1093/aje/kwm134; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Henderson AJ, 2010, THORAX, V65, P897, DOI 10.1136/thx.2009.125856; Henderson AJ, 2001, EUR RESPIR J, V18, P323, DOI 10.1183/09031936.01.00012401; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Jaakkola JJK, 2007, EPIDEMIOLOGY, V18, P573, DOI 10.1097/EDE.0b013e31812001d2; Jedrychowski W, 2008, INT J OCCUP MED ENV, V21, P111, DOI 10.2478/v10001-008-0013-0; Johansson A, 2008, ACTA PAEDIATR, V97, P354, DOI 10.1111/j.1651-2227.2007.00619.x; Kang EM, 2009, OBSTET GYNECOL, V114, P1295, DOI 10.1097/AOG.0b013e3181c225c0; Karmaus W, 2008, J ASTHMA, V45, P688, DOI 10.1080/02770900802178306; Keil T, 2009, ALLERGY, V64, P445, DOI 10.1111/j.1398-9995.2008.01867.x; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Kurukulaaratchy RJ, 2006, ANN ALLERG ASTHMA IM, V97, P84; Kurukulaaratchy RJ, 2005, ACTA PAEDIATR, V94, P553, DOI 10.1080/08035250510027282; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Lannero E, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-3; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Lewis SA, 1998, RESP MED, V92, P1237, DOI 10.1016/S0954-6111(98)90427-9; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Magnusson LL, 2005, CLIN EXP ALLERGY, V35, P1550; Mallol J, 2005, Allergol Immunopathol (Madr), V33, P257, DOI 10.1157/13080928; Mamun AA, 2007, INT J OBESITY, V31, P578, DOI 10.1038/sj.ijo.0803571; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258; McConnell R, 2002, EPIDEMIOLOGY, V13, P288, DOI 10.1097/00001648-200205000-00009; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Menezes AMB, 2007, ANN ALLERG ASTHMA IM, V98, P427; Midodzi WK, 2008, RESPIROLOGY, V13, P537, DOI 10.1111/j.1440-1843.2008.01284.x; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; Nicolaou NC, 2008, J ALLERGY CLIN IMMUN, V122, P500, DOI 10.1016/j.jaci.2008.06.033; Noakes P, 2007, PEDIATR ALLERGY IMMU, V18, P118, DOI 10.1111/j.1399-3038.2006.00490.x; Oberg M, 2011, LANCET, V377, P139, DOI 10.1016/S0140-6736(10)61388-8; Oddy WH, 1999, BRIT MED J, V319, P815; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Ponsonby AL, 2000, EPIDEMIOLOGY, V11, P128, DOI 10.1097/00001648-200003000-00008; Ronmark E, 2002, RESP MED, V96, P1006, DOI 10.1053/rmed.2002.1391; Royal College of Physicians, 2010, PASS SMOK CHILDR REP; Sadeghnejad A, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-2; Sangsupawanich P, 2007, J INVEST ALLERG CLIN, V17, P292; Schroer KT, 2009, J PEDIATR-US, V154, P401, DOI 10.1016/j.jpeds.2008.08.040; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1998, THORAX, V53, P204; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tanaka K, 2008, J ASTHMA, V45, P833, DOI 10.1080/02770900802339742; Tariq SM, 2000, POSTGRAD MED J, V76, P694, DOI 10.1136/pmj.76.901.694; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Taveras EM, 2006, PEDIATR PULM, V41, P643, DOI 10.1002/ppul.20427; Triche EW, 2011, ANN ALLERG ASTHMA IM, V106, P131, DOI 10.1016/j.anai.2010.11.007; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; US Department of Health and Human Services, 2011, HLTH CONS INV EXP TO; Vork KL, 2007, ENVIRON HEALTH PERSP, V115, P1394, DOI 10.1289/ehp.10155; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; Yang KD, 2007, J ALLERGY CLIN IMMUN, V120, P842, DOI 10.1016/j.jaci.2007.07.009; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; Yuan W, 2003, EUR J EPIDEMIOL, V18, P763; Zejda J E, 2003, Cent Eur J Public Health, V11, P149; [Anonymous], NEWCASTLE OTTAWA SCA	88	190	197	4	34	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2012	129	4					735	744		10.1542/peds.2011-2196		10	Pediatrics	Pediatrics	922IX	WOS:000302541700053	22430451	
J	Barnes, PJ; Dweik, RA; Gelb, AF; Gibson, PG; George, SC; Grasemann, H; Pavord, ID; Ratjen, F; Silkoff, PE; Taylor, DR; Zamel, N				Barnes, Peter J.; Dweik, Raed A.; Gelb, Arthur F.; Gibson, Peter G.; George, Steven C.; Grasemann, Hartmut; Pavord, Ian D.; Ratjen, Felix; Silkoff, Philip E.; Taylor, D. Robin; Zamel, Noe			Exhaled Nitric Oxide in Pulmonary Diseases A Comprehensive Review	CHEST			English	Review							RANDOMIZED CONTROLLED-TRIAL; EOSINOPHILIC AIRWAY INFLAMMATION; DOSE-RESPONSE RELATIONSHIP; CYSTIC-FIBROSIS; AXIAL DIFFUSION; ASTHMATIC-PATIENTS; HEALTHY-VOLUNTEERS; EXCHANGE DYNAMICS; CHILDHOOD ASTHMA; REFERENCE VALUES	The upregulation of nitric oxide (NO) by inflammatory cytokines and mediators in central and peripheral airway sites can be monitored easily in exhaled air. It is now possible to estimate the predominant site of increased fraction of exhaled NO (FENO) and its potential pathologic and physiologic role in various pulmonary diseases. In asthma, increased FENO reflects eosinophilic-mediated inflammatory pathways moderately well in central and/or peripheral airway sites and implies increased inhaled and systemic corticosteroid responsiveness. Recently, five randomized controlled algorithm asthma trials reported only equivocal benefits of adding measurements of FENO to usual clinical guideline management including spirometry; however, significant design issues may exist. Overall, FENO measurement at a single expiratory flow rate of 50 mL/s may be an important adjunct for diagnosis and management in selected cases of asthma. This may supplement standard clinical asthma care guidelines, including spirometry, providing a noninvasive window into predominantly large-airway-presumed eosinophilic inflammation. In COPD, large/central airway maximal NO flux and peripheral/small airway/alveolar NO concentration may be normal and the role of FENO monitoring is less clear and therefore less established than in asthma. Furthermore, concurrent smoking reduces FENO. Monitoring FENO in pulmonary hypertension and cystic fibrosis has opened up a window to the role NO may play in their pathogenesis and possible clinical benefits in the management of these diseases. CHEST 2010; 138(3):682-692	[Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Airway Dis Sect, Natl Heart & Lung Inst, London, England; [Pavord, Ian D.] Glenfield Hosp, Univ Hosp Leicester Trust, Dept Resp Med Allergy & Thorac Surg, Leicester, Leics, England; [Dweik, Raed A.] Cleveland Clin Fdn, Div Pulm, Dept Med, Cleveland, OH 44195 USA; [Gelb, Arthur F.] Lakewood Reg Med Ctr, Div Pulm, Dept Med, Lakewood, CA USA; [Gelb, Arthur F.] UCLA Med Ctr, Geffen Sch Med, Los Angeles, CA USA; [George, Steven C.] Univ Calif Irvine, Dept Biomed Engn & Chem Engn & Mat Sci, Irvine, CA USA; [Gibson, Peter G.] John Hunter Hosp, Woolcock Inst Med Res, Dept Resp & Sleep Med, New Lambton, NSW, Australia; [Grasemann, Hartmut; Ratjen, Felix] Hosp Sick Children, Div Resp Med, Dept Pediat & Physiol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Res Inst, Expt Med Program, Toronto, ON M5G 1X8, Canada; [Zamel, Noe] Univ Toronto, Sch Med, Div Resp, Toronto, ON, Canada; [Silkoff, Philip E.] Drexel Univ, Div Pulm, Sch Med, Philadelphia, PA 19104 USA; [Taylor, D. Robin] Univ Otago, Dunedin Sch Med, Dunedin, New Zealand	Gelb, AF (reprint author), 3650 E South St,Ste 308, Lakewood, CA 90712 USA.	afgelb@msn.com	George, Steven/K-9359-2015	George, Steven/0000-0003-2263-1914; silkoff, philip/0000-0001-6018-5199; Pavord, Ian/0000-0002-4288-5973	GE Analytical Instruments, Inc.; Aperion Inc.; Aerocrine, Ltd.; Aerocrine, Ltd. Sweden	The authors have reported to CHEST the following conflicts of interest: Dr George has patents issued and pending that have been licensed in the past by Aerocrine, Ltd., Sweden, and have resulted in royalties. His employer, University of California, Irvine, has received NO analyzers as gifts from Aerocrine, Ltd., and currently holds the rights to the patents. Dr Silkoff has received royalties ($2,000/year) from patents that are currently licensed to GE Analytical Instruments, Inc, and Aperion.ine, manufacturers of exhaled NO monitors. He has also received consultant fees ($10,000) from GE Analytical Instruments, Inc, Aperion Inc, and Aerocrine, Ltd. He anticipates being involved in patent litigation related to measurement of exhaled NO. Dr Zamel has received royalties ($2,000/year) from patents that are currentlylicensed to Aerocrine, Ltd. and Aperion Inc, manufacturers of exhaled NO monitors. Dr Taylor has received research funding ($25,000) and lecture fees ($2,000) from Aerocrine, Ltd., Sweden. Drs Barnes, Dweik, Gelb, Gibson Grasemann, Pavord, and Ratjen have reported that no potential conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article.	American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; Ansarin K, 2001, EUR RESPIR J, V17, P934, DOI 10.1183/09031936.01.17509340; Archer S, 2000, CIRCULATION, V102, P2781; Bacci E, 2006, CHEST, V129, P565, DOI 10.1378/chest.129.3.565; Barnes PJ, 2006, AM J RESP CRIT CARE, V174, P6, DOI 10.1164/rccm.200510-1659PP; Bernareggi M, 1997, AM J RESP CRIT CARE, V155, P869; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brindicci C, 2005, EUR RESPIR J, V26, P52, DOI 10.1183/09031936.05.00125304; Brindicci C, 2007, CHEST, V132, P581, DOI 10.1378/chest.06-3046; Brindicci C, 2007, CHEST, V131, P1353, DOI 10.1378/chest.06-2531; Brindicci C, 2010, AM J RESP CRIT CARE, V181, P21, DOI 10.1164/rccm.200904-0493OC; BROWN HM, 1958, LANCET, V2, P1245; Condorelli P, 2007, J APPL PHYSIOL, V102, P417, DOI 10.1152/japplphysiol.00533.2006; Corradi M, 1999, THORAX, V54, P572; de Jongste JC, 2009, AM J RESP CRIT CARE, V179, P93, DOI 10.1164/rccm.200807-1010OC; de Winter-de Groot Karin M, 2005, J Cyst Fibros, V4 Suppl 2, P25, DOI 10.1016/j.jcf.2005.05.008; Donnelly LE, 2002, AM J RESP CELL MOL, V26, P144; Dressel H, 2008, RESP MED, V102, P962, DOI 10.1016/j.rmed.2008.02.012; Dummer JF, 2009, AM J RESP CRIT CARE, V180, P846, DOI 10.1164/rccm.200905-0685OC; Dweik RA, 2002, LANCET, V360, P886, DOI 10.1016/S0140-6736(02)11067-1; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; Dweik RA, 2007, AM J PHYSIOL-LUNG C, V292, pL15, DOI 10.1152/ajplung.00322.2006; Gaston B, 2002, AM J RESP CRIT CARE, V165, P387; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; Gelb AF, 2004, AM J RESP CRIT CARE, V170, P737, DOI 10.1164/rccm.200403-408OC; Gelb AF, 2010, CHEST, V137, P575, DOI 10.1378/chest.09-1522; George SC, 2004, J APPL PHYSIOL, V96, P831, DOI 10.1152/japplphysiol.00950.2003; Ghamra Ziad W, 2003, Cleve Clin J Med, V70 Suppl 1, pS2; Ghiro L, 2002, EUR RESPIR J, V20, P630, DOI 10.1183/09031936.02.01512002; Gibson PG, 2009, CLIN EXP ALLERGY, V39, P478, DOI 10.1111/j.1365-2222.2009.03226.x; Girgis RE, 2007, ANN RHEUM DIS, V66, P1467, DOI 10.1136/ard.2007.069609; Grasemann H, 2005, AM J RESP CRIT CARE, V172, P1523, DOI 10.1164/rccm.200502-253OC; Grasemann H, 2000, AM J RESP CRIT CARE, V162, P2172; Grasemann H, 2006, RESP RES, V7, P1, DOI 10.1186/1465-9921-7-87; Grasemann H, 2006, AM J RESP CRIT CARE, V174, P208, DOI 10.1164/rccm.200509-1439OC; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Heresi Gustavo A., 2007, Comprehensive Therapy, V33, P150, DOI 10.1007/s12019-007-0014-0; Hewitt RS, 2008, J ASTHMA, V45, P101, DOI 10.1080/02770900701767696; Ho LP, 1998, EUR RESPIR J, V12, P1290, DOI 10.1183/09031936.98.12061290; Hofer M, 2009, LUNG, V187, P307, DOI 10.1007/s00408-009-9160-8; Hogman M, 2000, RESP MED, V94, P985, DOI 10.1053/rmed.2000.0872; Hogman M, 2002, RESP MED, V96, P24, DOI 10.1053/rmed.2001.1204; Holt S, 2001, BRIT MED J, V323, P253, DOI 10.1136/bmj.323.7307.253; Hubert D, 2009, EUR RESPIR J, V34, P117, DOI 10.1183/09031936.00164508; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; Jang AS, 2003, RESPIRATION, V70, P95, DOI 10.1159/000068406; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Jorres RA, 2000, EUR RESPIR J, V16, P555, DOI 10.1034/j.1399-3003.2000.016003555.x; Kaneko FT, 1998, AM J RESP CRIT CARE, V158, P917; Keen C, 2007, CHEST, V131, P1857, DOI 10.1378/chest.06-2635; Kerckx Y, 2008, J APPL PHYSIOL, V104, P918, DOI 10.1152/japplphysiol.01032.2007; Kunisaki Ken M, 2008, Ther Adv Respir Dis, V2, P55, DOI 10.1177/1753465808088902; Lehtimaki L, 2001, EUR RESPIR J, V18, P635, DOI 10.1183/09031936.01.00000201; Lim KG, 2008, CHEST, V133, P1232, DOI 10.1378/chest.07-1712; Maarsingh H, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-6; Machado RF, 2004, FREE RADICAL BIO MED, V37, P1010, DOI 10.1016/j.freeradbiomed.2004.06.039; Mahut B, 2004, CHEST, V125, P1012, DOI 10.1378/chest.125.3.1012; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Michils A, 2008, EUR RESPIR J, V31, P539, DOI 10.1183/09031936.00020407; Moeller A, 2006, THORAX, V61, P514, DOI 10.1136/thx.2005.054643; Olin AC, 2007, CHEST, V131, P1852, DOI 10.1378/chest.06-2928; Olin AC, 2006, CHEST, V130, P1319, DOI 10.1378/chest.130.5.1319; Olivieri M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-94; Osoata GO, 2009, CHEST, V135, P1513, DOI 10.1378/chest.08-2105; Ozkan M, 2001, LUNG, V179, P233, DOI 10.1007/s004080000064; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; Paraskakis E, 2006, AM J RESP CRIT CARE, V174, P260, DOI 10.1164/rccm.200506-962OC; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; Ravi K, 2004, P NATL ACAD SCI USA, V101, P2619, DOI 10.1073/pnas.0300464101; Ricciardolo FLM, 2005, J ALLERGY CLIN IMMUN, V116, P1028, DOI 10.1016/j.jaci.2005.06.034; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Roy K, 2007, EUR RESPIR J, V29, P651, DOI 10.1183/09031936.00149706; Saleh D, 1998, FASEB J, V12, P929; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-14270C; Shin HW, 2006, J APPL PHYSIOL, V100, P623, DOI 10.1152/japplphysiol.00008.2005; Shin HW, 2004, J APPL PHYSIOL, V97, P874, DOI 10.1152/japplphysiol.01297.2003; Shin HW, 2004, J APPL PHYSIOL, V96, P65, DOI 10.1152/japplphysiol.00575.2003; Shin HW, 2002, J APPL PHYSIOL, V93, P2070, DOI 10.1152/japplphysiol.00129.2002; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Singh D, 2007, AM J RESP CRIT CARE, V176, P988, DOI 10.1164/rccm.200704-588OC; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; SMITH AD, 2009, J ALLERGY CLIN IMMUN, V124, pE4; Smith AD, 2009, J ALLERGY CLIN IMMUN, V124, P714, DOI 10.1016/j.jaci.2009.07.020; Suresh V, 2008, J APPL PHYSIOL, V104, P1743, DOI 10.1152/japplphysiol.01355.2007; Szefler S, 2008, LANCET, V372, P1065, DOI 10.1016/S0140-6736(08)61448-8; Taylor DR, 2008, POSTGRAD MED J, V84, P628, DOI 10.1136/pgmj.2008.069864; Travers J, 2007, AM J RESP CRIT CARE, V176, P238, DOI 10.1164/rccm.200609-13460C; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P642; Van Muylem A, 2003, J APPL PHYSIOL, V94, P119, DOI 10.1152/japplphysiol.00044.2002; van Veen IH, 2006, EUR RESPIR J, V27, P951, DOI 10.1183/09031936.06.00087905; WAGNER PD, 1974, J CLIN INVEST, V54, P54, DOI 10.1172/JCI107750; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; Wooldridge JL, 2004, PEDIATR PULM, V37, P338, DOI 10.1002/ppul.10455; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC	111	190	197	2	37	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	SEP	2010	138	3					682	692		10.1378/chest.09-2090		11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	659IZ	WOS:000282561500034	20822990	
J	Robinson, DS; Larche, M; Durham, SR				Robinson, DS; Larche, M; Durham, SR			Tregs and allergic disease	JOURNAL OF CLINICAL INVESTIGATION			English	Review							REGULATORY T-CELLS; GRASS-POLLEN IMMUNOTHERAPY; IMMUNOLOGICAL SELF-TOLERANCE; LATE ASTHMATIC REACTIONS; COWS MILK ALLERGY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; TRANSCRIPTION FACTOR FOXP3; MYELIN BASIC-PROTEIN; HOUSE-DUST MITE; IN-VITRO	Allergic diseases such as asthma, rhinitis, and eczema are increasing in prevalence and affect up to 15% of populations in Westernized countries. The description of Tregs as T cells that prevent development of autoinumme disease led to considerable interest in whether these Tregs were also normally involved in prevention of sensitization to allergens and whether it might be possible to manipulate Tregs for the therapy of allergic disease. Current data suggest that Th2 responses to allergens are normally suppressed by both CD4(+)CD25(+) Tregs and IL-10 Tregs. Furthermore, suppression by these subsets is decreased in allergic individuals. In animal models, Tregs could be induced by high- or low-dose inhaled antigen, and prior induction of such Tregs prevented subsequent development of allergen sensitization and airway inflammation in inhaled challenge models. For many years, allergen-injection immunotherapy has been used for the therapy of allergic disease, and this treatment may induce IL-10 Tregs, leading to both suppression of Th2 responses and a switch from IgE to IgG4 antibody production. Improvements in allergen immunotherapy, such as peptide therapy, and greater understanding of the biology of Tregs hold great promise for the treatment and prevention of allergic disease.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Allergy & Clin Immunol, Natl Heart & Lung Inst, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, Fac Med, Sect Leukocyte Biol, Div Biomed Sci, London SW3 6LY, England	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Allergy & Clin Immunol, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk	Larche, Mark/B-4326-2010				Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; ALEXANDER C, 2004, IN PRESS CLIN EXP AL; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; Baecher-Allan C, 2004, J EXP MED, V200, P273, DOI 10.1084/jem.20040812; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Bluestone JA, 2003, NAT REV IMMUNOL, V3, P253, DOI 10.1038/nri1032; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Burkhart C, 1999, INT IMMUNOL, V11, P1625, DOI 10.1093/intimm/11.10.1625; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CLAYTON JP, 1989, J EXP MED, V169, P1681, DOI 10.1084/jem.169.5.1681; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cosmi L, 2004, BLOOD, V103, P3117, DOI 10.1182/blood-2003-09-3302; Cottrez F, 2000, J IMMUNOL, V165, P4848; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daniel D, 1996, P NATL ACAD SCI USA, V93, P956, DOI 10.1073/pnas.93.2.956; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; Dieckmann D, 2002, J EXP MED, V196, P247, DOI 10.1084/jem.20020642; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; GAUR A, 1992, SCIENCE, V258, P1491, DOI 10.1126/science.1279812; Hadeiba H, 2003, J IMMUNOL, V170, P5502; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Hoyne GF, 2001, IMMUNOL REV, V182, P215, DOI 10.1034/j.1600-065X.2001.1820118.x; Hurst SD, 2001, J IMMUNOL, V166, P4922; Jaffar Z, 2004, J IMMUNOL, V172, P3842; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; JUREL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kay AB, 2001, NEW ENGL J MED, V344, P30; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lloyd CM, 2001, ADV IMMUNOL, V77, P263, DOI 10.1016/S0065-2776(01)77019-8; Malbec O, 1998, J IMMUNOL, V160, P1647; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; METZLER B, 1993, INT IMMUNOL, V5, P1159, DOI 10.1093/intimm/5.9.1159; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; Nguyen XD, 2004, J ALLERGY CLIN IMMUN, V114, P296, DOI 10.1016/j.jaci.2004.04.048; NORMAN PS, 1981, J ALLERGY CLIN IMMUN, V68, P460, DOI 10.1016/0091-6749(81)90200-1; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; O'Garra A, 2003, NAT IMMUNOL, V4, P304, DOI 10.1038/ni0403-304; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Piccirillo CA, 2002, J EXP MED, V196, P237, DOI 10.1084/jem.20020590; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prakken BJ, 2004, P NATL ACAD SCI USA, V101, P4228, DOI 10.1073/pnas.0400061101; Prakken BJ, 1997, P NATL ACAD SCI USA, V94, P3284, DOI 10.1073/pnas.94.7.3284; Rachmilewitz D, 2004, GASTROENTEROLOGY, V126, P520, DOI 10.1053/j.gastro.2003.11.019; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Robinson DS, 2000, BRIT MED BULL, V56, P956, DOI 10.1258/0007142001903625; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Stassen M, 2004, J IMMUNOL, V173, P267; Stephens LA, 2000, J IMMUNOL, V165, P3105; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Suto A, 2001, AM J RESP CRIT CARE, V164, P680; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Thornton AM, 1998, J EXP MED, V188, P287, DOI 10.1084/jem.188.2.287; Tiemessen MM, 2004, J ALLERGY CLIN IMMUN, V113, P932, DOI 10.1016/j.jaci.2003.12.016; Tiemessen MM, 2002, J ALLERGY CLIN IMMUN, V110, P934, DOI 10.1067/mai.2002.128856; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till S, 1997, CLIN EXP IMMUNOL, V110, P114, DOI 10.1111/j.1365-2249.1997.494-ce1392.x; Till Stephen J, 2004, Clin Allergy Immunol, V18, P85; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VARNEY VA, 1991, BRIT MED J, V302, P265; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VERHOEF A, 2004, J ALLERGY CLIN IMM S, V113, P918; Vieira PL, 2004, J IMMUNOL, V172, P5986; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	110	190	209	1	7	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	NOV	2004	114	10					1389	1397		10.1172/JCI200423595		9	Medicine, Research & Experimental	Research & Experimental Medicine	871EU	WOS:000225113200005	15545986	
J	Avery, NJ; King, RM; Knight, S; Hourihane, JO				Avery, NJ; King, RM; Knight, S; Hourihane, JO			Assessment of quality of life in children with peanut allergy	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						quality of life; peanut allergy; children		Children with a peanut allergy (PA) are faced with food and social restrictions due to the potentially life-threatening nature of their disease, for which there is no cure or treatment. This inevitably impacts upon their quality of life (QoL). QoL of 20 children with PA and 20 children with insulin-dependent diabetes mellitus (IDDM) was measured using two disease-specific QoL questionnaires (higher scores correspond to a poorer QoL). One questionnaire was designed by us and the other was adapted from the Vespid Allergy QoL questionnaire. We gave subjects cameras to record how their QoL is affected over a 24-h period. Response rates for both questionnaires were 100%. Mean ages were 9.0 and 10.4 years for PA and IDDM subjects, respectively. Children with a PA reported a poorer quality of life than children with IDDM: mean scores were 54.85 for PA subjects and 46.40 for diabetics (p = 0.004) in questionnaire 1 and 54.30 and 34.50 (pless than or equal to0.001) in questionnaire 2. PA children reported more fear of an adverse event and more anxiety about eating, especially when eating away from home. Photographs fell into seven common categories: food, management, environment, away from home, physical activities, restaurant and people. Most photographs related to food and management issues and revealed difficulties for both groups regarding food restrictions. PA subjects felt more threatened by potential hazards within their environment, felt more restricted by their PA regarding physical activities, and worried more about being away from home. However, they felt safe when carrying epinephrine kits and were positive about eating at familiar restaurants. The QoL in children with PA is more impaired than in children with IDDM. Their anxiety may be considered useful in some situations, promoting better adherence to allergen avoidance advice and rescue plans.	Univ Southampton, Div Infect Inflammat & Repair, Southampton, Hants, England; Southampton Univ Hosp NHS Trust, Wellcome Trust Clin Res Facil, Southampton, Hants, England; Southampton Univ Hosp NHS Trust, Dept Psychol, Southampton, Hants, England	Hourihane, JO (reprint author), Univ Southampton, Southampton Univ Hosp NHS Trust, Div Infect Inflammat & Repair, Mailpoint 218,Tremona Rd, Southampton S016 6YD, Hants, England.						Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V109, P162, DOI 10.1067/mai.2002.120552; Elberink JNGO, 2002, J ALLERGY CLIN IMMUN, V110, P174, DOI 10.1067/mai.2002.125827; Gardiner P., 1997, PRACTICAL DIABETES I, V14, P43, DOI 10.1002/(ISSN)1528-252X; Hourihane JO, 2002, CURR OPIN ALLERGY CL, V2, P227, DOI 10.1097/00130832-200206000-00012; McCabe M, 2001, LANCET, V357, P1531, DOI 10.1016/S0140-6736(00)04687-0; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Sicherer SH, 2001, ANN ALLERG ASTHMA IM, V87, P461; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Thompson AK, 2000, ANN ALLERG ASTHMA IM, V85, P338; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376	12	190	191	5	27	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	OCT	2003	14	5					378	382		10.1034/j.1399-3038.2003.00072.x		5	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	736JR	WOS:000186168100007	14641608	
J	Devereux, G; Barker, RN; Seaton, A				Devereux, G; Barker, RN; Seaton, A			Antenatal determinants of neonatal immune responses to allergens	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; T helper cells; antenatal influences; smoking; birth order; vitamin E	CELL PROLIFERATIVE RESPONSES; UMBILICAL-CORD BLOOD; HOUSE-DUST-MITE; RESPIRATORY SYMPTOMS; ABERDEEN SCHOOLCHILDREN; ASTHMA; ATOPY; GAMMA; LIFE; RESPONSIVENESS	Background The environmental factors responsible for recent increases in the prevalence of asthma and atopic disease have been assumed to act after birth. Their possible effects on fetal immune development in utero have not been investigated systematically, although sensitization to allergens may occur before birth. Objective This prospective study determined whether the risk factors for asthma and atopic disease, namely family history of atopic disease, maternal smoking, birth order, or maternal dietary intake of antioxidant vitamins, exert antenatal effects on the fetal immune system that may predispose to childhood atopy. Methods The T helper (Th) cell proliferative responses of cord blood mononuclear cells (CBMC) from a sample of 223 neonates, representative of children born to a cohort of 2000 pregnant women, were measured and related to family, maternal and environmental factors associated with the pregnancy. Results The magnitude of CBMC-proliferative responses to allergens increased significantly in association with a family history of atopic disease or maternal smoking, and decreased significantly with increasing birth order and high maternal dietary intake of vitamin E. The epidemiological association between birth order and atopy may therefore be a consequence of antenatal influences rather than of protective effects of childhood infections. The association between maternal intake of vitamin E and CBMC responsiveness suggests that diet during pregnancy may influence the fetal immune system in such a way as to modulate the risk of childhood atopy. Conclusion These results provide a new insight into the aetiology of atopic disease by demonstrating that the maternal environmental risk factors for atopy, diet, birth order and smoking, influence the development of the fetal immune system. This raises the prospect of preventative public health interventions during pregnancy.	Univ Aberdeen, Sch Med, Dept Environm & Occupat Med, Aberdeen AB25 2ZD, Scotland; Univ Aberdeen, Sch Med, Dept Med & Therapeut, Aberdeen AB25 2ZD, Scotland	Seaton, A (reprint author), Univ Aberdeen, Sch Med, Dept Environm & Occupat Med, Aberdeen AB25 2ZD, Scotland.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Al MDM, 1997, EUR J CLIN NUTR, V51, P548, DOI 10.1038/sj.ejcn.1600444; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bodner C, 1999, EUR RESPIR J, V13, P22, DOI 10.1183/09031936.99.13102299; Chan-Yeung M, 1999, J ALLERGY CLIN IMMUN, V104, P317, DOI 10.1016/S0091-6749(99)70373-8; Cook DG, 1997, THORAX, V52, P1081; Devereux G, 2000, J IMMUNOL METHODS, V234, P13, DOI 10.1016/S0022-1759(99)00185-4; Devereux G, 1996, THORAX, V51, P169, DOI 10.1136/thx.51.2.169; Fogarty A, 2000, LANCET, V356, P1573, DOI 10.1016/S0140-6736(00)03132-9; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kohut KG, 1997, AM J REPROD IMMUNOL, V37, P257; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1046/j.1365-2222.1996.d01-383.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; NINAN TK, 1992, BRIT MED J, V304, P873; Olesen AB, 1997, BRIT MED J, V314, P1003; Omran M, 1996, BRIT MED J, V312, P34; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; PLEBANSKI M, 1994, J IMMUNOL METHODS, V170, P15, DOI 10.1016/0022-1759(94)90241-0; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Van Duren Schmidt K., 1997, PEDIATR RES, V41, P128; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TOMANY J, 1999, THESIS U ABERDEEN; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Willett W, 1998, NUTR EPIDEMIOLOGY, P273	35	190	198	0	10	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2002	32	1					43	50		10.1046/j.0022-0477.2001.01267.x		8	Allergy; Immunology	Allergy; Immunology	525GV	WOS:000174061300008	12002736	
J	Maddox, L; Schwartz, DA				Maddox, L; Schwartz, DA			The pathophysiology of asthma	ANNUAL REVIEW OF MEDICINE			English	Review						atopy; cytokines; Th-2 cells; airway obstruction; bronchial hyperreactivity; lungs	GENOME-WIDE SEARCH; ENDOTOXIN EXPOSURE-RESPONSE; ALLERGEN-SPECIFIC TH1; RI-BETA GENE; BRONCHIAL HYPERRESPONSIVENESS; BETA(2)-ADRENERGIC RECEPTOR; INNATE IMMUNITY; SEGREGATION ANALYSIS; ATOPIC ASTHMA; COTTON DUST	Asthma is a chronic disorder of the airways that is characterized by reversible airflow obstruction and airway inflammation, persistent airway hyper-reactivity, and airway remodeling. The etiology of asthma is complex and multifactorial. Recent advances have demonstrated the importance of genetics in the development of asthma, particularly atopic asthma. Environmental stimuli, particularly early childhood infections, have also been associated with the development of asthma. Most current data seem to suggest that these factors drive the development of a Th-2 lymphocyte-predominant immune response, which has been associated with atopy and IgE-mediated inflammation. The concept of reversible airflow obstruction has also recently been challenged. It is now clear that chronic airway changes occur, which may contribute to progressive airflow obstruction. We discuss the important influence of genetic and environmental factors on the emergence of the asthmatic phenotype. The significance of Th-1 and Th-2 lymphocyte-mediated immunity are discussed, and the inflammatory processes leading to chronic airway inflammation are detailed.	Duke Univ, Med Ctr, Div Pulm & Crit Care, Durham, NC 27710 USA	Maddox, L (reprint author), Duke Univ, Med Ctr, Div Pulm & Crit Care, Res Dr, Durham, NC 27710 USA.				NHLBI NIH HHS [HL62628]; NIEHS NIH HHS [ES09607, ES06537, ES07498]		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Amelung PJ, 1998, CLIN EXP ALLERGY, V28, P397; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; Bonner JC, 1998, AM J RESP CELL MOL, V19, P672; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919; Busse WW, 2001, NEW ENGL J MED, V344, P350; Castro M, 2000, AM J RESP CELL MOL, V22, P143; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Christiansen SC, 2000, NEW ENGL J MED, V343, P574, DOI 10.1056/NEJM200008243430810; Cookson W, 1999, NATURE, V402, pB5; COOKSON WOC, 1989, LANCET, P1292; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dockery D.W., 1993, NEW ENGL J MED, V329, P1754; DONHAM K, 1989, BRIT J IND MED, V46, P31; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Elias JA, 2000, AM J RESP CRIT CARE, V161, pS168; Evans R, 1987, CHEST S, V91, P65; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Gao PS, 2000, BIOCHEM BIOPH RES CO, V267, P761, DOI 10.1006/bbrc.1999.2030; GAZZINELLI RT, 1993, P NATL ACAD SCI USA, V90, P6115, DOI 10.1073/pnas.90.13.6115; George CLS, 2001, AM J PHYSIOL-LUNG C, V280, pL203; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; GILES GG, 1984, AUST NZ J MED, V14, P631, DOI 10.1111/j.1445-5994.1984.tb05015.x; Gray L, 2000, CLIN EXP ALLERGY, V30, P393; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HAGLIND P, 1984, BRIT J IND MED, V41, P340; Hall IP, 1996, THORAX, V51, P351, DOI 10.1136/thx.51.4.351; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Harris JR, 1997, AM J RESP CRIT CARE, V156, P43; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; HILL MR, 1995, BRIT MED J, V311, P776; Hobbs K, 1998, AM J RESP CRIT CARE, V158, P1958; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Holberg CJ, 1999, AM J RESP CRIT CARE, V160, P1604; Holberg CJ, 1996, AM J RESP CRIT CARE, V154, P144; Holgate ST, 1997, NAT GENET, V15, P227, DOI 10.1038/ng0397-227; Holt PG, 2000, AM J RESP CRIT CARE, V162, pS151; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Israel E, 2000, AM J RESP CRIT CARE, V162, P75; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; KATZ RM, 1976, J ALLERGY CLIN IMMUN, V57, P41, DOI 10.1016/0091-6749(76)90077-4; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; Kishimoto K, 2000, J CLIN INVEST, V106, P63, DOI 10.1172/JCI9586; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620; Koppelman GH, 1999, EUR RESPIR J, V13, P2, DOI 10.1183/09031936.99.13100299; Laitinen T, 1998, AM J RESP CRIT CARE, V157, P1073; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; Lazaro C, 1999, HUM MUTAT, V14, P510, DOI 10.1002/(SICI)1098-1004(199912)14:6<510::AID-HUMU10>3.0.CO;2-O; Liggett SB, 1997, AM J RESP CRIT CARE, V156, pS156; Los H, 1999, EUR RESPIR J, V14, P1210, DOI 10.1183/09031936.99.14512109; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mellor AL, 2000, ANNU REV IMMUNOL, V18, P367, DOI 10.1146/annurev.immunol.18.1.367; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.0.CO;2-V; Moffatt M. F., 1994, Lancet (North American Edition), V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MRAZEK D, 1989, American Journal of Human Genetics, V45, pA245; NAKAYAMA T, 1999, RRD PHOTOCHEM PHOTOB, V3, P103; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; *NIH, 1991, 913042 US DEP HLTH H; *NIH, 1997, 974051 US DEP HLTH H; Noguchi E, 1998, CLIN EXP ALLERGY, V28, P449; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Palmer LJ, 2000, GENOME RES, V10, P1280, DOI 10.1101/gr.143400; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; PEAT JK, 1992, EUR RESPIR J, V5, P921; PEAT JK, 1987, CLIN ALLERGY, V17, P283, DOI 10.1111/j.1365-2222.1987.tb02016.x; PEAT JK, 1987, CLIN ALLERGY, V17, P291, DOI 10.1111/j.1365-2222.1987.tb02017.x; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Randolph DA, 1999, J IMMUNOL, V162, P2375; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981; SAMET JM, 1991, ENVIRON HEALTH PERSP, V95, P71, DOI 10.2307/3431109; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2; Skadhauge LR, 1999, EUR RESPIR J, V13, P8, DOI 10.1183/09031936.99.13100899; SPEIZER FE, 1990, CHEST, V98, pS191; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stafforini DM, 1996, J CLIN INVEST, V97, P2784, DOI 10.1172/JCI118733; STEMPEL DA, 1980, J PEDIATR-US, V97, P185, DOI 10.1016/S0022-3476(80)80471-9; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; TOWNLEY RG, 1986, J ALLERGY CLIN IMMUN, V77, P101, DOI 10.1016/0091-6749(86)90330-1; Trabetti E, 1999, J MED GENET, V36, P323; Trabetti E, 1998, J MED GENET, V35, P680, DOI 10.1136/jmg.35.8.680; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; Wa TCLK, 1999, CLIN EXP ALLERGY, V29, P1204; Wallace PM, 1996, RESTOR ECOL, V4, P33, DOI 10.1111/j.1526-100X.1996.tb00105.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787; WEISS KB, 1990, AM J EPIDEMIOL, V132, pS107; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; Wiener AS, 1936, ANN EUGENIC, V7, P141; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wright SD, 1999, J EXP MED, V189, P605, DOI 10.1084/jem.189.4.605; YOUNG S, 1991, NEW ENGL J MED, V325, P747; Zhiping Wang, 1996, American Journal of Respiratory and Critical Care Medicine, V154, P1261; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; ZIMMERMAN B, 1988, J ALLERGY CLIN IMMUN, V81, P63, DOI 10.1016/0091-6749(88)90221-7; 1995, MORBID MORTAL WKLY R, V43, P952	150	190	194	1	26	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0066-4219			ANNU REV MED	Annu. Rev. Med.		2002	53						477	498		10.1146/annurev.med.53.082901.103921		22	Medicine, General & Internal	General & Internal Medicine	531KL	WOS:000174414500031	11818486	
J	Dayan, AD; Paine, AJ				Dayan, AD; Paine, AJ			Mechanisms of chromium toxicity, carcinogenicity and allergenicity: Review of the literature from 1985 to 2000	HUMAN & EXPERIMENTAL TOXICOLOGY			English	Review						chromium; toxicity; allergenicity; carcinogenicity; genotoxicity; biochemical mechanisms	SINGLE-STRAND BREAKS; HEXAVALENT CHROMIUM; ALVEOLAR MACROPHAGES; ASCORBIC-ACID; CROSS-LINKS; DNA-DAMAGE; IN-VITRO; REDUCTION; GLUTATHIONE; EXPOSURE	Laboratory and clinical reports about the pathogenesis of the carcinogenicity and allergenicity of chromium compounds published between 1985 and 2000 have been reviewed as a basis for consideration of the pathogenetic mechanisms involved. There is good evidence from the clinic and the laboratory that Cr[VI] is the ion responsible for most of the toxic actions, although much of the underlying molecular damage may be due to its intracellular reduction to the even more highly reactive and short-lived chemical species Cr[III] and Cr[V]. Exposure to Cr[VI] can result in various point mutations in DNA and to chromosomal damage, as well as to oxidative changes in proteins and to adduct formation. The relative importance of these effects of chromium ions and of the free oxidising radicals they may generate in the body in causing tumours and allergic sensitisation remain to be demonstrated. Biochemical studies of the DNA-damaging effects and of the pathogenesis of the allergic reactions to chromium ions have not kept up with advances in understanding of the molecular basis of the effects of other carcinogens and allergens.	Kings Coll London, Dept Pharm, IRG Toxicol, London SE1 9NN, England	Paine, AJ (reprint author), Kings Coll London, Dept Pharm, IRG Toxicol, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NN, England.						Aebischer I, 1996, ADV IMMUNOL, V61, P341, DOI 10.1016/S0065-2776(08)60871-8; AESETH J, 1982, ACTA PHARMACOL TOX, V50, P310; AITIO A, 1984, INT ARCH OCC ENV HEA, V54, P241, DOI 10.1007/BF00379053; Aitito A., 1988, BIOL MONITORING TOXI, P369; AIYAR J, 1991, ENVIRON HEALTH PERSP, V92, P53, DOI 10.2307/3431137; *ATSDR, 1993, TP9208 US DHHS; BARANOWSKADUTKIEWICZ B, 1981, ARCH TOXICOL, V47, P47; BARBER LD, 1994, J EXP MED, V180, P1191, DOI 10.1084/jem.180.4.1191; BARNES PJ, 1998, PHARMACOL REV, V50, P517; BESKETTER D, 1999, AM J CONTACT DERMATI, V10, P207; Bigazzi PE, 1999, ENVIRON HEALTH PERSP, V107, P753, DOI 10.2307/3434338; BORGES KM, 1991, CARCINOGENESIS, V12, P551, DOI 10.1093/carcin/12.4.551; Boscolo P, 1997, LIFE SCI, V60, P1319, DOI 10.1016/S0024-3205(96)00669-8; Chen F, 1997, ARCH BIOCHEM BIOPHYS, V338, P165, DOI 10.1006/abbi.1996.9849; CLARKSON TW, 1985, SCAND J WORK ENV HEA, V11, P45; COENRAADS PJ, 2000, EPIDEMIOLOGY WORK RE, P175, DOI 10.1002/9780470695005.ch9; COHEN MD, 1993, CRIT REV TOXICOL, V23, P255, DOI 10.3109/10408449309105012; Cohen MD, 1998, TOXICOL APPL PHARM, V152, P30, DOI 10.1006/taap.1998.8502; CONNETT PH, 1983, STRUCT BOND, V54, P93; COSTA M, 1991, ENVIRON HEALTH PERSP, V92, P45, DOI 10.2307/3431136; Costa M, 1997, CRIT REV TOXICOL, V27, P431, DOI 10.3109/10408449709078442; *CRIT GROUP, 1993, OPAC97, P1; DEFLORA S, 1987, MUTAT RES, V192, P169, DOI 10.1016/0165-7992(87)90051-0; De Flora S, 1989, LIFE CHEM REPORTS, V7, P169; Dillon CT, 1997, CHEM RES TOXICOL, V10, P533, DOI 10.1021/tx970010m; DONALDSON RM, 1966, J LAB CLIN MED, V68, P484; FAIRHURST SC, 1989, TOXIC REV, V21, P1; FOA V, 1988, SCI TOTAL ENVIRON, V71, P389, DOI 10.1016/0048-9697(88)90211-2; FRENKEL K, 1994, ENVIRON HEALTH PERSP, V102, P221, DOI 10.2307/3431790; GLASER U, 1985, ARCH TOXICOL, V57, P250, DOI 10.1007/BF00324787; Granchi D, 1999, BIOMATERIALS, V20, P1079, DOI 10.1016/S0142-9612(99)00004-6; GRAY SJ, 1950, J CLIN INVEST, V29, P1604, DOI 10.1172/JCI102403; GREVATT PC, 1999, TOXICOLOGICAL REV TR, P1; GUENICHE A, 1994, ARCH DERMATOL RES, V286, P466, DOI 10.1007/BF00371573; HAINES AT, 1988, CHROMIUM NATURAL HUM, P497; Huby RDJ, 2000, TOXICOL SCI, V55, P235, DOI 10.1093/toxsci/55.2.235; IARC, 1990, IARC MON EV CARC RIS, V49, P49; Janeway CA, 1999, IMMUNOBIOLOGY IMMUNE, P1; KIILUNEN M, 1983, SCAND J WORK ENV HEA, V9, P265; KITAGAWA S, 1988, INORG CHIM A-BIOINOR, V152, P251, DOI 10.1016/S0020-1693(00)91477-4; Klein C. B., 1996, TOXICOLOGY METALS, P205; KORTENKAMP A, 1994, ENVIRON HEALTH PERSP, V102, P237, DOI 10.2307/3431793; LINDBERG E, 1983, SCAND J WORK ENV HEA, V9, P333; Liu KJ, 1997, MAGNET RESON MED, V38, P524, DOI 10.1002/mrm.1910380403; Maggi E, 1998, IMMUNOTECHNOLOGY, V3, P233, DOI 10.1016/S1380-2933(97)10005-7; MERTZ W, 1969, PHYSIOL REV, V49, P163; MYERS CR, 1999, F296209810079 AFOSR, P1; NOMIYAMA H, 1980, AM IND HYG ASSOC J, V41, P98, DOI 10.1080/15298668091424438; PETRILLI FL, 1986, J CLIN INVEST, V77, P1917, DOI 10.1172/JCI112520; Pingel S, 1999, J EXP MED, V189, P1111, DOI 10.1084/jem.189.7.1111; Polak L., 1983, CHROMIUM METABOLISM, P51; Rogers PR, 1999, J IMMUNOL, V163, P1205; ROITT IM, 1997, BLACKWELL SCI, P1; ROSSI SC, 1989, CARCINOGENESIS, V10, P913; Rycroft RJG, 1995, TXB CONTACT DERMATIT; SHARMA BK, 1978, POSTGRAD MED J, V54, P414; Shi XL, 1999, J TOXICOL ENV HEAL B, V2, P87, DOI 10.1080/109374099281241; SHI XL, 1989, BIOCHEM BIOPH RES CO, V163, P627, DOI 10.1016/0006-291X(89)92183-9; SloanLancaster J, 1996, ANNU REV IMMUNOL, V14, P1, DOI 10.1146/annurev.immunol.14.1.1; STANDEVEN AM, 1992, CARCINOGENESIS, V13, P1319, DOI 10.1093/carcin/13.8.1319; STANDEVEN AM, 1991, CHEM RES TOXICOL, V4, P616, DOI 10.1021/tx00024a003; STEARNS DM, 1994, ENVIRON HEALTH PERSP, V102, P21, DOI 10.2307/3431756; Susa N, 1997, ARCH TOXICOL, V71, P345, DOI 10.1007/s002040050397; SUZUKI Y, 1988, ARCH TOXICOL, V62, P116, DOI 10.1007/BF00570129; TAMINO G, 1981, CHEM-BIOL INTERACT, V37, P309, DOI 10.1016/0009-2797(81)90117-4; TAMINO G, 1980, DEV BIOPHYSICAL RES, P335; Voitkun V, 1998, NUCLEIC ACIDS RES, V26, P2024, DOI 10.1093/nar/26.8.2024; WEIGAND HJ, 1984, TOXICOL LETT, V22, P273; WETTERHAHN KE, 1989, BIOL TRACE ELEM RES, V21, P405, DOI 10.1007/BF02917282; *WHO, 1990, ENV HLTH CRIT, V61; WITMER C, 1994, ENVIRON HEALTH PERSP, V102, P169, DOI 10.2307/3431782; Zhitkovich A, 1998, ENVIRON HEALTH PERSP, V106, P969, DOI 10.2307/3434139	72	190	199	3	37	ARNOLD, HODDER HEADLINE PLC	LONDON	338 EUSTON ROAD, LONDON NW1 3BH, ENGLAND	0960-3271			HUM EXP TOXICOL	Hum. Exp. Toxicol.	SEP	2001	20	9					439	451		10.1191/096032701682693062		13	Toxicology	Toxicology	501DE	WOS:000172666900001	11776406	
J	Underwood, DC; Osborn, RR; Bochnowicz, S; Webb, EF; Rieman, DJ; Lee, JC; Romanic, AM; Adams, JL; Hay, DWP; Griswold, DE				Underwood, DC; Osborn, RR; Bochnowicz, S; Webb, EF; Rieman, DJ; Lee, JC; Romanic, AM; Adams, JL; Hay, DWP; Griswold, DE			SB 239063, a p38 MAPK inhibitor, reduces neutrophilia, inflammatory cytokines, MMP-9, and fibrosis in lung	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						chronic obstructive pulmonary disease; interleukin-6; bleomycin; alveolar macrophage; mitogen-activated protein kinase; matrix metalloproteinase-9	OBSTRUCTIVE PULMONARY-DISEASE; ACTIVATED PROTEIN-KINASE; COR-PULMONALE; ASTHMA; PATHOPHYSIOLOGY; INTERLEUKIN-6; EXPRESSION; MACROPHAGE; RELEASE; STRESS	The effects of a second generation p38 mitogen-activated protein kinase (MAPK) inhibitor, SB 239063 [trans-1-(4-hydroxycyclohexyl)-4-(4-fluorophenyl)-5-(2-methoxypyridimidin-4-yl) imidazole; IC50 = 44 nM vs. p38 alpha], were assessed in models that represent different pathological aspects of chronic obstructive pulmonary disease (COPD) [airway neutrophilia, enhanced cytokine formation and increased matrix metalloproteinase (MMP)-9 activity] and in a model of lung fibrosis. Airway neutrophil infiltration and interleukin (IL)-6 levels, assessed by bronchoalveolar lavage 48 h after lipopolysaccharide (LPS) inhalation, were inhibited dose dependently by 3-30 mg/kg of SB 239063 given orally twice a day. In addition, SB 239063 (30 mg/kg orally) attenuated IL-6 bronchoalveolar lavage fluid concentrations (>90% inhibition) and MMP-9 activity (64% inhibition) assessed 6 h after LPS exposure. In guinea pig cultured alveolar macrophages, SB 239063 inhibited LPS-induced IL-6 production (IC50 of 362 nM). In a bleomycin-induced pulmonary fibrosis model in rats, treatment with SB 239063 (2.4 or 4.8 mg/day via osmotic pump) significantly inhibited bleomycin-induced right ventricular hypertrophy (indicative of secondary pulmonary hypertension) and increases in lung hydroxyproline synthesis (indicative of collagen synthesis and fibrosis). Therefore, SB 239063 demonstrates activity against a range of sequelae commonly associated with COPD and fibrosis, supporting the therapeutic potential of p38 MAPK inhibitors such as SB 239063 in chronic airway disease.	SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Bone & Cartilage Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Cardiovasc Biol, King Of Prussia, PA 19406 USA; SmithKline Beecham Pharmaceut, Dept Med Chem, King Of Prussia, PA 19406 USA	Underwood, DC (reprint author), SmithKline Beecham Pharmaceut, Dept Pulm Pharmacol, UW2532,709 Swedeland Rd, King Of Prussia, PA 19406 USA.						Barnes PJ, 1999, AM J RESP CRIT CARE, V160, pS72; Barnes PJ, 1998, THORAX, V53, P137; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Bochnowicz S, 2000, CLIN EXP HYPERTENS, V22, P471, DOI 10.1081/CEH-100100085; Cuzzocrea S, 1999, J LEUKOCYTE BIOL, V66, P471; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Foltz IN, 1997, J BIOL CHEM, V272, P3296; Force T, 1999, GENE EXPRESSION, V7, P337; Griswold DE, 1996, PHARM COMMUN, V7, P323; Hashimoto S, 1999, AM J RESP CRIT CARE, V159, P634; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; Jeffery PK, 1999, CLIN EXP ALLERGY, V29, P14, DOI 10.1046/j.1365-2222.1999.00004.x-i2; JEFFERY PK, 1994, AM J RESP CRIT CARE, V150, pS6; Johnson JL, 1998, J SURG RES, V76, P91, DOI 10.1006/jsre.1998.5295; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; Kuhn C, 2000, AM J RESP CELL MOL, V22, P289; Lee JC, 1999, PHARMACOL THERAPEUT, V82, P389, DOI 10.1016/S0163-7258(99)00008-X; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Liou TG, 1996, J IMMUNOL, V157, P2624; MACNEE W, 1994, AM J RESP CRIT CARE, V150, P833; MACNEE W, 1994, AM J RESP CRIT CARE, V150, P1158; OLIVERA DL, 1992, CIRC SHOCK, V37, P301; Scott PH, 1998, AM J RESP CRIT CARE, V158, P958; Shapiro SD, 1999, AM J RESP CRIT CARE, V160, pS29; Simon C, 1998, CANCER RES, V58, P1135; SMITH RE, 1994, J IMMUNOL, V153, P4704; Tamura DY, 1998, SURGERY, V124, P403, DOI 10.1067/msy.1998.90483; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Underwood DC, 1996, AM J RESP CRIT CARE, V154, P850; Wanner A, 1999, AM J RESP CRIT CARE, V160, pS1	32	190	202	0	10	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	NOV	2000	279	5					L895	L902				8	Physiology; Respiratory System	Physiology; Respiratory System	367HT	WOS:000090056200015	11053025	
J	Horwell, CJ; Baxter, PJ				Horwell, Claire J.; Baxter, Peter J.			The respiratory health hazards of volcanic ash: a review for volcanic risk mitigation	BULLETIN OF VOLCANOLOGY			English	Review						volcanic ash; respiratory; health; hazard; risk mitigation; review	MOUNT-ST-HELENS; SOUFRIERE HILLS VOLCANO; BRITISH-WEST-INDIES; PARTICULATE AIR-POLLUTION; PULMONARY TOXICITY; NEW-ZEALAND; CRYSTALLINE SILICA; LUNG-FUNCTION; MONTSERRAT; ERUPTION	Studies of the respiratory health effects of different types of volcanic ash have been undertaken only in the last 40 years, and mostly since the eruption of Mt. St. Helens in 1980. This review of all published clinical, epidemiological and toxicological studies, and other work known to the authors up to and including 2005, highlights the sparseness of studies on acute health effects after eruptions and the complexity of evaluating the long-term health risk (silicosis, non-specific pneumoconiosis and chronic obstructive pulmonary disease) in populations from prolonged exposure to ash due to persistent eruptive activity. The acute and chronic health effects of volcanic ash depend upon particle size (particularly the proportion of respirable-sized material), mineralogical composition (including the crystalline silica content) and the physicochemical properties of the surfaces of the ash particles, all of which vary between volcanoes and even eruptions of the same volcano, but adequate information on these key characteristics is not reported for most eruptions. The incidence of acute respiratory symptoms (e.g. asthma, bronchitis) varies greatly after ashfalls, from very few, if any, reported cases to population outbreaks of asthma. The studies are inadequate for excluding increases in acute respiratory mortality after eruptions. Individuals with preexisting lung disease, including asthma, can be at increased risk of their symptoms being exacerbated after falls of fine ash. A comprehensive risk assessment, including toxicological studies, to determine the long-term risk of silicosis from chronic exposure to volcanic ash, has been under-taken only in the eruptions of Mt. St. Helens (1980), USA, and Soufriere Hills, Montserrat (1995 onwards). In the Soufriere Hills eruption, a long-term silicosis hazard has been identified and sufficient exposure and toxicological information obtained to make a probabilistic risk assessment for the development of silicosis in outdoor workers and the general population. A more systematic approach to multi-disciplinary studies in future eruptions is recommended, including establishing an archive of ash samples and a website containing health advice for the public, together with scientific and medical study guidelines for volcanologists and health-care workers.	Univ Cambridge, Dept Earth Sci, Cambridge CB2 3EQ, England; Univ Cambridge, Inst Publ Hlth, Cambridge CB2 2SR, England	Horwell, CJ (reprint author), Univ Cambridge, Dept Earth Sci, Downing St, Cambridge CB2 3EQ, England.	chor05@esc.cam.ac.uk					ADLER KB, 1984, ENVIRON RES, V35, P346, DOI 10.1016/0013-9351(84)90142-7; AKEMATSU T, 1982, ENVIRON RES, V29, P358, DOI 10.1016/0013-9351(82)90037-8; ANDERSON H.R., 1999, AIR POLLUTION HLTH, P461, DOI 10.1016/B978-012352335-8/50096-X; BABOLINI G, 1978, 14 INT C INT MED EXC, V2, P829; Baris Y I, 1979, Ann N Y Acad Sci, V330, P423, DOI 10.1111/j.1749-6632.1979.tb18744.x; BAXTER PJ, 1983, ARCH ENVIRON HEALTH, V38, P138; Baxter PJ, 1999, SCIENCE, V283, P1142, DOI 10.1126/science.283.5405.1142; BAXTER PJ, 1981, JAMA-J AM MED ASSOC, V246, P2585, DOI 10.1001/jama.246.22.2585; BAXTER PJ, 1998, PRELIMINARY ASSESSME, P32; BAXTER PJ, 2002, ERUPTION EL REVENTAD; BECK BD, 1981, EXP LUNG RES, V2, P289, DOI 10.3109/01902148109052324; Beckett WS, 2000, NEW ENGL J MED, V342, P406, DOI 10.1056/NEJM200002103420607; Bernstein R, 1981, GHE80112 DHHS NIOSH; BERNSTEIN RS, 1986, AM J PUBLIC HEALTH, V76, P25, DOI 10.2105/AJPH.76.Suppl.25; BERNSTEIN RS, 1982, MOUNT ST HELENS ONE, P207; Blong R, 1996, MONITORING MITIGATIO, P675; Bonner JC, 1998, AM J RESP CELL MOL, V19, P672; Bradshaw L, 1997, NEW ZEAL MED J, V110, P90; BUIST AS, 1986, AM J PUBLIC HEALTH, V76, P1, DOI 10.2105/AJPH.76.Suppl.1; BUIST AS, 1983, AM REV RESPIR DIS, V127, P714; BUIST AS, 1986, AM REV RESPIR DIS, V133, P526; Burney P, 1999, LANCET, V353, P859, DOI 10.1016/S0140-6736(99)00002-1; CALVERLEY PMA, 2003, LANCET, V352, P1053; CASTRANOVA V, 1982, J TOXICOL ENV HEALTH, V9, P317; Choudhury AH, 1997, ARCH ENVIRON HEALTH, V52, P113; COWIE HA, 2001, TM0201 IOM; COWIE HA, 2001, TM0107 IOM; Cowie H.A., 2003, RISK ASSESSMENT SILI, P49; CRAIGHEAD JE, 1983, LAB INVEST, V48, P5; Cronin SJ, 2000, NEW ZEAL J AGR RES, V43, P295; Cronin SJ, 2003, J VOLCANOL GEOTH RES, V121, P271, DOI 10.1016/S0377-0273(02)00465-1; Cronin SJ, 2002, INT J ENVIRON HEAL R, V12, P109, DOI 10.1080/09603120220129274; Cullen RT, 1998, PRELIMINARY TOXICOLO, P13; Cullen RT, 2002, TOXICITY VOLCANIC AS, P55; Daniels MJ, 2000, AM J EPIDEMIOL, V152, P397, DOI 10.1093/aje/152.5.397; DASHTOYAN AK, 1980, GIG T PROF ZABOL, V2, P36; DAVIS BL, 1981, J APPL METEOROL, V20, P922, DOI 10.1175/1520-0450(1981)020<0922:QAOMSH>2.0.CO;2; DODSON RF, 1982, EXP MOL PATHOL, V37, P406, DOI 10.1016/0014-4800(82)90052-1; DOLLBERG DD, 1986, AM J PUBLIC HEALTH, V76, P53, DOI 10.2105/AJPH.76.Suppl.53; DOLLBERG DD, 1984, 4 ANN S EL MICR XRAY; Donaldson Ken, 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P109; *EXP PAN AIR QUAL, 2001, AIRB PART WHAT APPR; Expert Panel on Air Quality Standards, 1995, PART, P30; FARAONE G, 1958, Acta Med Leg Soc (Liege), V11, P83; FEDAN JS, 1981, ENVIRON RES, V26, P497, DOI 10.1016/0013-9351(81)90225-5; Forbes L, 2003, OCCUP ENVIRON MED, V60, P207, DOI 10.1136/oem.60.3.207; FRAUNFELDER FT, 1983, ARCH OPHTHALMOL-CHIC, V101, P376; FRUCHTER JS, 1980, SCIENCE, V209, P1116, DOI 10.1126/science.209.4461.1116; Fubini B., 1999, ADSORPTION SILICA SU, P645; Fubini Bice, 2001, Journal of Environmental Pathology Toxicology and Oncology, V20, P95; GAGE DR, 1981, ANAL CHEM, V53, P2123, DOI 10.1021/ac00236a041; GILBERT JS, 1991, NATURE, V349, P598, DOI 10.1038/349598a0; Gordian ME, 1996, ENVIRON HEALTH PERSP, V104, P290, DOI 10.2307/3432887; GREEN FHY, 1982, ANN OCCUP HYG, V26, P921, DOI 10.1093/annhyg/26.8.921; GROSE EC, 1985, ENVIRON RES, V37, P84, DOI 10.1016/0013-9351(85)90051-9; HALLIWELL B, 1984, MED BIOL, V62, P71; HANSEN K, 1987, CANCER RES, V47, P1681; HEFFLIN BJ, 1994, ARCH ENVIRON HEALTH, V49, P170; HEIKEN G, 1972, GEOL SOC AM BULL, V83, P1961, DOI 10.1130/0016-7606(1972)83[1961:MAPOVA]2.0.CO;2; Heiken G, 1985, VOLCANIC ASH, P246; HENDRICK DJ, 2002, OCCUPATIONAL DISORDE, P652; Hickling J, 1999, INT J ENVIRON HEAL R, V9, P97; HIGASHI H, 1987, JPN J PUBLIC HLTH, V34, P453; *HLTH SAF EX, 2002, EH754 HLTH SAF EX; *HLTH SAF EX, 2003, EH755 HLTH SAF EX; Hnizdo E, 2003, OCCUP ENVIRON MED, V60, P237, DOI 10.1136/oem.60.4.237; HOLT PF, 1987, INHALED DUST DIS, P325; HORTON RJM, 1964, PUBLIC HEALTH REP, V79, P925, DOI 10.2307/4592281; Horwell CJ, 2003, ENVIRON RES, V93, P202, DOI 10.1016/S0013-9351(03)00044-6; Horwell CJ, 2003, B VOLCANOL, V65, P346, DOI 10.1007/s00445-002-0266-6; Horwell CJ, 2001, J VOLCANOL GEOTH RES, V109, P247, DOI 10.1016/S0377-0273(00)00319-X; HORWELL CJ, UNPUB SCIENCE; HORWELL CJ, UNPUB GRAIN SIZE ANA; Housley DG, 2002, OCCUP ENVIRON MED, V59, P466, DOI 10.1136/oem.59.7.466; Hughes JM, 1998, AM J RESP CRIT CARE, V158, P807; International Agency for Research on Cancer (IARC), 1997, MON EV CARC RISKS HU, V68, P506; JOHNSON KG, 1982, AM REV RESPIR DIS, V126, P1066; KARIYA M, 1992, TOHOKU J EXP MED, V167, P197, DOI 10.1620/tjem.167.197; KORNBRUST DJ, 1984, ENVIRON RES, V35, P140, DOI 10.1016/0013-9351(84)90121-X; KRAEMER MJ, 1985, J ASTHMA, V22, P37, DOI 10.3109/02770908509079882; Lee SH, 2004, TOXICOLOGY, V195, P155, DOI 10.1016/j.tox.2003.09.013; LEHNERT BE, 1993, HLTH EFFECTS MINERAL, P425; LEUS X, 1981, DISASTERS, V5, P67, DOI 10.1111/j.1467-7717.1981.tb01130.x; Malilay J, 1996, Bull Pan Am Health Organ, V30, P218; MARTIN TR, 1983, AM REV RESPIR DIS, V128, P158; MARTIN TR, 1986, AM J PUBLIC HEALTH, V76, P59, DOI 10.2105/AJPH.76.Suppl.59; MARTIN TR, 1983, AM REV RESPIR DIS, V128, P144; MARTIN TR, 1984, AM REV RESPIR DIS, V129, P138; MERCHANT JA, 1982, ANN OCCUP HYG, V26, P911, DOI 10.1093/annhyg/26.8.911; MOSSMAN BT, 1993, HLTH EFFECTS MINERAL, P514; NANIA J, 1982, ANN EMERG MED, V11, P184, DOI 10.1016/S0196-0644(82)80495-2; NEWHALL CG, 1986, AM J PUBLIC HEALTH, V76, P10, DOI 10.2105/AJPH.76.Suppl.10; NIOSH, 2002, HAZ REV HLTH EFF EXP; Norton MR, 1999, AM MINERAL, V84, P1009; OPS, 2000, ERUPC VOLC PROT SAL; Paoletti L, 2000, ARCH ENVIRON HEALTH, V55, P392; Peters A, 2001, CIRCULATION, V103, P2810; Ping C-L, 1999, ENCY VOLCANOES, P461; *QUAL URB AIR REV, 1996, AIRB PART MATT UN KI, V3, P30; RAUB JA, 1985, ENVIRON RES, V37, P72, DOI 10.1016/0013-9351(85)90050-7; *RES COMM VOLC EM, 1982, RES REP HUM EFF VOLC; ROBINSON AV, 1982, VITRO TOXICITY MOUNT; Rojas-Ramos M, 2001, ENVIRON GEOCHEM HLTH, V23, P383; SANDERS CL, 1982, ENVIRON RES, V27, P118, DOI 10.1016/0013-9351(82)90063-9; SANDERS CL, 1983, ENVIRON RES, V32, P188, DOI 10.1016/0013-9351(83)90205-0; SARNAWOJCICKI AM, 1981, 1980 ERUPTION MOUNT; SARNAWOJCIKI AM, 1981, 1980 ERUPTION MOUNT; SCHIFF LJ, 1981, SCAN ELEC MICRO, V11, P169; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; Searl A, 2002, OCCUP ENVIRON MED, V59, P523, DOI 10.1136/oem.59.8.523; Shi X MY, 1995, APPL OCCUP ENV HYG, V10, P1138; SHIRAKAWA M, 1984, Japanese Journal of Industrial Health, V26, P130; SHORE JH, 1986, AM J PUBLIC HEALTH, V76, P76, DOI 10.2105/AJPH.76.Suppl.76; Small C, 2001, ENV HAZARDS, V3, P93, DOI DOI 10.1016/S1464-2867(02)00002-5; SOREM RK, 1982, J VOLCANOL GEOTH RES, V13, P63, DOI 10.1016/0377-0273(82)90019-1; TALVITIE NA, 1951, ANAL CHEM, V23, P623, DOI 10.1021/ac60052a021; Tobin G. A., 2001, APPL GEOGRAPHY C, V24, P183; Uda H, 1999, J Epidemiol, V9, P27; VALLYATHAN V, 1983, ENVIRON RES, V30, P349, DOI 10.1016/0013-9351(83)90220-7; VALLYATHAN V, 1983, ENVIRON RES, V30, P361, DOI 10.1016/0013-9351(83)90221-9; VALLYATHAN V, 1992, AM J RESP CELL MOL, V6, P404; VALLYATHAN V, 1984, J TOXICOL ENV HEALTH, V14, P641; Wakisaka I, 1985, J JPN SOC AIR POLLUT, V20, P120; Wakisaka I, 1978, JPN J PUB HLTH, V25, P455; Wakisaka I, 1983, JPN J PUB HLTH, V30, P101; Wakisaka I, 1984, JPN J PUB HLTH, V31, P548; Wakisaka I, 1983, JPN J PUB HLTH, V30, P109; Wakisaka I, 1986, J JPN SOC AIR POLLUT, V21, P322; Walker GPL, 1973, GEOL RUNDSCH, V62, P431, DOI DOI 10.1007/BF01840108; WEHNER AP, 1986, ENVIRON RES, V40, P499, DOI 10.1016/S0013-9351(86)80125-6; WEHNER AP, 1984, ENVIRON RES, V35, P211, DOI 10.1016/0013-9351(84)90129-4; WHO, 2000, AIR QUAL GUID EUR; WIESTER MJ, 1985, ENVIRON RES, V36, P230, DOI 10.1016/0013-9351(85)90020-9; Williamson BJ, 2001, ATMOS ENVIRON, V35, P3539, DOI 10.1016/S1352-2310(01)00121-2; Wilson MR, 2000, OCCUP ENVIRON MED, V57, P727, DOI 10.1136/oem.57.11.727; YANO E, 1990, ARCH ENVIRON HEALTH, V45, P367; YANO E, 1986, ARCH ENVIRON HEALTH, V41, P94; YANO E, 1985, J TOXICOL ENV HEALTH, V16, P127; Yano E, 1987, JPN J PUBLIC HLTH, V34, P251; Zanobetti A, 2002, EPIDEMIOLOGY, V13, P87, DOI 10.1097/00001648-200201000-00014	140	189	196	7	73	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0258-8900			B VOLCANOL	Bull. Volcanol.	JUL	2006	69	1					1	24		10.1007/s00445-006-0052-y		24	Geosciences, Multidisciplinary	Geology	078MK	WOS:000240107700001		
J	Custovic, A; Simpson, BM; Simpson, A; Kissen, P; Woodcock, A				Custovic, A; Simpson, BM; Simpson, A; Kissen, P; Woodcock, A		NAC Manchester Asthma Allergy Stud	Effect of environmental manipulation in pregnancy and early life on respiratory symptoms and atopy during first year of life: a randomised trial	LANCET			English	Article							ALLERGEN AVOIDANCE; CONFIDENCE-INTERVALS; EARLY EXPOSURE; RISK FACTOR; ASTHMA; SENSITIZATION; CHILDREN; INFANCY; CAT; MITE	Background Asthma places huge demands on healthcare services, and its prevalence is increasing. Reduction of exposure to environmental allergens could offer a realistic chance for primary prevention. Our aim was to ascertain whether or not living in a low-allergen environment reduces the risk of asthma and atopic diseases in infants. Methods We assigned infants to four risk groups according to parental atopic status. We enrolled 291 high-risk couples (both parents atopic, no pets) into a prospective, prenatally randomised, cohort study, and allocated them to environmental manipulation, in which measures to reduce prenatal and postnatal allergen exposure were undertaken (active HRA) (n=145) or no intervention (control HRC) (n=146). Two further prospective groups were studied: 161 high-risk infants with pets in the home (HRP group) and 168 low-risk infants, whose parents were both non-atopic (LR group). The main outcome measures were signs and symptoms of atopic disease at 1 year of age. Findings 103 families dropped out or were lost to follow up. At age 1 year we followed-up 133 HRA, 118 HRC, 140 HRP, and 126 LR infants. Children in the HRA group were less likely to have respiratory symptoms during the first year of life than those in the HRC group. The most pronounced differences were in the relative risks for severe wheeze with shortness of breath (relative risk 0.44 [95% CI 0.20-1.00]), prescribed medication for the treatment of wheezy attacks (0.58 [0.36-0.95]), and wheezing after vigorous playing, crying, or exertion (0.18 [0.04-0.79]). Probability of respiratory symptoms in HRC and HRP infants was similar, whereas it was much lower in the LR than in the HRC group. Cat ownership was significantly associated with sensitisation to cats (24.6 [3.04-199.05]; p=0.003). Interpretation Environmental manipulation reduces some respiratory symptoms in the first year of life in high-risk infants. Further follow up is needed, however, to ascertain whether living in a low-allergen environment reduces allergy and asthma in later life.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Woodcock, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666			ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BULPITT CJ, 1987, LANCET, V1, P494; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Gardner M., 1989, STAT CONFIDENCE CONF; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LANGMAN MJS, 1986, BRIT MED J, V292, P716; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Martin YC, 1998, PERSPECT DRUG DISCOV, V12, P3, DOI 10.1023/A:1017037831628; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V104, pS169, DOI 10.1016/S0091-6749(99)70058-8; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; pidemiology Standardization Project. II, 1978, AM REV RESP DIS S, V118, P7; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79	24	189	195	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUL 21	2001	358	9277					188	193		10.1016/S0140-6736(01)05406-X		6	Medicine, General & Internal	General & Internal Medicine	454HL	WOS:000169967100011	11476835	
J	Finotto, S; De Sanctis, GT; Lehr, HA; Herz, U; Buerke, M; Schipp, M; Bartsch, B; Atreya, R; Schmitt, E; Galle, PR; Renz, H; Neurath, MF				Finotto, S; De Sanctis, GT; Lehr, HA; Herz, U; Buerke, M; Schipp, M; Bartsch, B; Atreya, R; Schmitt, E; Galle, PR; Renz, H; Neurath, MF			Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						GATA-3 antisense DNA; asthma; T cells; Th2 cytokines	TRANSCRIPTION FACTOR GATA-3; CHRONIC INTESTINAL INFLAMMATION; DEVELOPING TH1 CELLS; CD4(+) T-CELLS; MOUSE MODEL; TH2-SPECIFIC EXPRESSION; GENE-EXPRESSION; TRANSGENIC MICE; ATOPIC ASTHMA; MURINE MODEL	Recent studies in transgenic mice have revealed that expression of a dominant negative form of the transcription factor GATA-3 in T cells can prevent T helper cell type 2 (Th2)-mediated allergic airway inflammation in mice. However, it remains unclear whether GATA-3 plays a role in the effector phase of allergic airway inflammation and whether antagonizing the expression and/or function of GATA-3 can be used for the therapy of allergic airway inflammation and hyperresponsiveness. Here, we analyzed the effects of locally antagonizing GATA-3 function in a murine model of asthma. We could suppress GATA-3 expression in interleukin (IL)-4-producing T cells in vitro and in vivo by an antisense phosphorothioate oligonucleotide overlapping the translation start site of GATA-3, whereas nonsense control oligonucleotides were virtually inactive. In a murine model of asthma associated with allergic pulmonary inflammation and hyperresponsiveness in ovalbumin (OVA)-sensitized mice, local intranasal administration of fluorescein isothiocyanate-labeled GATA-3 antisense oligonucleotides led to DNA uptake in lung cells associated with a reduction of intracellular GATA-3 expression. Such intrapulmonary blockade of GATA-3 expression caused an abrogation of signs of lung inflammation including infiltration of eosinophils and Th2 cytokine production. Furthermore, treatment with antisense but not nonsense oligonucleotides induced a significant reduction of airway hyperresponsiveness in OVA-sensitized mice to levels comparable to saline-treated control mice, as assessed by both enhanced pause (PenH) responses and pulmonary resistance determined by body plethysmography. These data indicate a critical role for GATA-3 in the effector phase of a murine asthma model and suggest that local delivery of GATA-3 antisense oligonucleotides may be a novel approach for the treatment of air-way hyperresponsiveness such as in asthma. This approach has the potential advantage of suppressing the expression of various proinflammatory Th2 cytokines simultaneously rather than suppressing the activity of a single cytokine.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Univ Marburg, Inst Lab Med, D-35033 Marburg, Germany; Univ Mainz, Inst Immunol, D-55099 Mainz, Germany; Univ Mainz, Med Clin 2, D-55099 Mainz, Germany; Univ Mainz, Inst Pathol, D-55099 Mainz, Germany; Univ Mainz, Immunol Lab, D-55099 Mainz, Germany	Finotto, S (reprint author), Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care Med, 75 Francis St, Boston, MA 02115 USA.						Atreya R, 2000, NAT MED, V6, P583; Blumenthal SG, 1999, J BIOL CHEM, V274, P12910, DOI 10.1074/jbc.274.18.12910; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Danzig M, 1997, ALLERGY, V52, P787, DOI 10.1111/j.1398-9995.1997.tb02149.x; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Finotto S, 1999, DEVELOPMENT, V126, P2935; Finotto S, 1997, J CLIN INVEST, V99, P1721, DOI 10.1172/JCI119336; Gelfand EW, 1998, ALLERGY ASTHMA PROC, V19, P365, DOI 10.2500/108854198778612744; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hamid QA, 2000, J ALLERGY CLIN IMMUN, V105, P20, DOI 10.1016/S0091-6749(00)90172-6; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Hendriks RW, 1999, EUR J IMMUNOL, V29, P1912, DOI 10.1002/(SICI)1521-4141(199906)29:06<1912::AID-IMMU1912>3.0.CO;2-D; Himmelrich H, 1998, J IMMUNOL, V161, P6156; HO IC, 1991, EMBO J, V10, P1187; Holgate ST, 1999, NATURE, V402, pB2; KALINER MA, 1996, CLIN IMMUNOLOGY, P909; Kon OM, 1999, INT ARCH ALLERGY IMM, V118, P133, DOI 10.1159/000024049; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; Kurata H, 1999, IMMUNITY, V11, P677, DOI 10.1016/S1074-7613(00)80142-9; Lee HJ, 1998, J IMMUNOL, V160, P2343; Miaw SC, 2000, IMMUNITY, V12, P323, DOI 10.1016/S1074-7613(00)80185-5; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; Nakamura Y, 1999, J ALLERGY CLIN IMMUN, V103, P215, DOI 10.1016/S0091-6749(99)70493-8; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pandolfi PP, 1995, NAT GENET, V11, P10; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; Range LM, 1998, J PERS INTERPERS LOS, V3, P161, DOI 10.1080/10811449808414438; Ranger AM, 1998, IMMUNITY, V8, P125, DOI 10.1016/S1074-7613(00)80465-3; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; RODRIGUEZPALMER.M, 1999, EUR J IMMUNOL, V29, P14; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818; TEPPER RI, 1990, CELL, V62, P457, DOI 10.1016/0092-8674(90)90011-3; Teran LM, 1999, AM J RESP CELL MOL B, V20, P1044; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; WAGNER RW, 1994, NATURE, V372, P333, DOI 10.1038/372333a0; WAKATSUKI Y, 1994, J EXP MED, V179, P1099, DOI 10.1084/jem.179.4.1099; Wirtz S, 1999, J IMMUNOL, V162, P1884; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; ZHU YX, 1996, J BIOL CHEM, V271, P26; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	50	189	220	0	11	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	JUN 4	2001	193	11					1247	1260		10.1084/jem.193.11.1247		14	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	440LV	WOS:000169177500004	11390432	
J	Wilson, RH; Whitehead, GS; Nakano, H; Free, ME; Kolls, JK; Cook, DN				Wilson, Rhonda H.; Whitehead, Gregory S.; Nakano, Hideki; Free, Meghan E.; Kolls, Jay K.; Cook, Donald N.			Allergic Sensitization through the Airway Primes Th17-dependent Neutrophilia and Airway Hyperresponsiveness	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; lung; immunity	T-CELLS; EOSINOPHILIC INFLAMMATION; LUNG INFLAMMATION; TH2 RESPONSES; SEVERE ASTHMA; ANTIGEN; INTERLEUKIN-17; DISSOCIATION; CHEMOKINE; MICE	Rationale: In humans, immune responses to inhaled aeroallergens develop in the lung and draining lymph nodes. Many animal models of asthma bypass this route and instead use intraperitoneal injections of allergen using aluminum hydroxide as an adjuvant. Objectives: We investigated whether allergic sensitization through the airway elicits immune responses qualitatively different than those arising in the peritoneum. Methods: Mice were sensitized to allergen through the airway using low-dose LIPS as an adjuvant, or through the peritoneum using aluminum hydroxide as an adjuvant. After a single allergen challenge, ELISA and flow cytometry were used to measure cytokines and leukocyte subsets. Invasive measurements of airway resistance were used to measure allergen-induced airway hyperreactivity (AHR). Measurements and Main Results: Sensitization through the peritoneum primed strong Th2 responses and eosinophilia, but not AHR, after a single allergen challenge. By contrast, allergic sensitization through the airway primed only modest Th2 responses, but strong Th17 responses. Th17 cells homed to the lung and released IL-17 into the airway on subsequent encounter with inhaled allergen. As a result, these mice developed IL-17-dependent airway neutrophilia and AHR. This AHR was neutrophil-dependent because it was abrogated in CXCR2-deficient mice and also in wild-type mice receiving a neutrophil-depleting antibody. Individually, neither IL-17 nor ongoing Th2 responses were sufficient to confer AHR, but together they acted synergistically to promote neutrophil recruitment, eosinophil recruitment and AHR. Conclusions: Allergic sensitization through the airway primes modest Th2 responses but strong Th17 responses that promote airway neutrophilia and acute AHR. These findings support a causal role for neutrophils in severe asthma.	[Cook, Donald N.] Natl Inst Environm Hlth Sci, Div Intramural Res, NIH, Lab Resp Biol, Res Triangle Pk, NC 27709 USA; [Kolls, Jay K.] Childrens Hosp Pittsburgh, Dept Pediat & Immunol, Pittsburgh, PA 15213 USA	Cook, DN (reprint author), Natl Inst Environm Hlth Sci, Div Intramural Res, NIH, Lab Resp Biol, 111 TW Alexander Dr,Bldg 101,Rm E244, Res Triangle Pk, NC 27709 USA.	usa.cookd@niehs.nih.gov			Intramural NIH HHS		Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1063; Birrell MA, 2003, RESPIR RES, V4, DOI 10.1186/rr197; Brewer JM, 1999, J IMMUNOL, V163, P6448; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P1282, DOI 10.1016/j.jaci.2007.02.006; Gereke M, 2009, AM J RESP CRIT CARE, V179, P344, DOI 10.1164/rccm.200804-592OC; Harrington LE, 2005, NAT IMMUNOL, V6, P1123, DOI 10.1038/ni1254; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Holgate ST, 2009, CURR OPIN PULM MED, V15, P63, DOI 10.1097/MCP.0b013e32831da867; Hollingsworth JW, 2006, J IMMUNOL, V176, P5856; Kamachi A, 2002, EUR RESPIR J, V19, P76, DOI 10.1183/09031936.02.00208202; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Laan M, 1999, J IMMUNOL, V162, P2347; Larche M, 2003, J ALLERGY CLIN IMMUN, p[111, 464]; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Ley K, 2006, IMMUNOL RES, V34, P229, DOI 10.1385/IR:34:3:229; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Ouyang WJ, 2008, IMMUNITY, V28, P454, DOI 10.1016/j.immuni.2008.03.004; Park H, 2005, NAT IMMUNOL, V6, P1133, DOI 10.1038/ni1261; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Song CW, 2008, J IMMUNOL, V181, P6117; Taube C, 2004, AM J RESP CELL MOL, V30, P837, DOI 10.1165/rcmb.2003-0395OC; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721; Toy D, 2006, J IMMUNOL, V177, P36; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Whitehead GS, 2007, AM J RESP CRIT CARE, V175, P243, DOI 10.1164/rccm.200606-839OC; XING Z, 1994, AM J RESP CELL MOL, V10, P148; Yang XXO, 2008, J EXP MED, V205, P1063, DOI 10.1084/jem.20071978; Ye P, 2001, J EXP MED, V194, P519, DOI 10.1084/jem.194.4.519	35	188	210	0	11	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2009	180	8					720	730		10.1164/rccm.200904-0573OC		11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	506AB	WOS:000270743100006	19661246	
J	Flores, G; Tomany-Korman, SC				Flores, Glenn; Tomany-Korman, Sandra C.			Racial and ethnic disparities in medical and dental health, access to care, and use of services in US children	PEDIATRICS			English	Article						disparities; minorities; children; race; ethnicity; African Americans; Hispanics; Asians/Pacific islanders; native Americans; multiracial	UNITED-STATES; OVERWEIGHT; ADOLESCENTS; INSURANCE; AMERICAN; TRENDS; PREVALENCE; OBESITY; WEIGHT; IMPACT	BACKGROUND. Not enough is known about the national prevalence of racial/ethnic disparities in children's medical and dental care. OBJECTIVE. The purpose of this work was to examine racial/ethnic disparities in medical and oral health, access to care, and use of services in a national sample. METHODS. The National Survey of Children's Health was a telephone survey in 2003 2004 of a national random sample of parents and guardians of 102 353 children 0 to 17 years old. Disparities in selected medical and oral health and health care measures were examined for white, African American, Latino, Asian/Pacific Islander, Native American, and multiracial children. Multivariate analyses were performed to adjust for primary language at home, age, insurance coverage, income, parental education and employment, and number of children and adults in the household. Forty measures of medical and oral health status, access to care, and use of services were analyzed. RESULTS. Many significant disparities were noted; for example, uninsurance rates were 6% for whites, 21% for Latinos, 15% for Native Americans, 7% for African Americans, and 4% for Asians or Pacific Islanders, and the proportions with a usual source of care were as follows: whites, 90%; Native Americans, 61%; Latinos, 68%; African Americans, 77%; and Asians or Pacific Islanders, 87%. Many disparities persisted for >= 1 minority group in multivariate analyses, including increased odds of suboptimal health status, overweight, asthma, activity limitations, behavioral and speech problems, emotional difficulties, uninsurance, suboptimal dental health, no usual source of care, unmet medical and dental needs, transportation barriers to care, problems getting specialty care, no medical or dental visit in the past year, emergency department visits, not receiving mental health care, and not receiving prescription medications. Certain disparities were particularly marked for specific racial/ethnic groups: for Latinos, suboptimal health status and teeth condition, uninsurance, and problems getting specialty care; for African Americans, asthma, behavior problems, skin allergies, speech problems, and unmet prescription needs; for Native Americans, hearing or vision problems, no usual source of care, emergency department visits, and unmet medical and dental needs; and for Asians or Pacific Islanders, problems getting specialty care and not seeing a doctor in the past year. Multiracial children also experienced many disparities. CONCLUSIONS. Minority children experience multiple disparities in medical and oral health, access to care, and use of services. Certain disparities are particularly marked for specific racial/ethnic groups, and multiracial children experience many disparities.	[Flores, Glenn] Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Gen Pediat, Dallas, TX 75390 USA; [Flores, Glenn] Childrens Med Ctr, Dept Pediat Med, Dallas, TX 75235 USA; [Tomany-Korman, Sandra C.] LLC, Signature Sci, Austin, TX USA	Flores, G (reprint author), Univ Texas SW Med Ctr Dallas, Dept Pediat, Div Gen Pediat, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	glenn.flores@utsouthwestern.edu					*AG HEALTHC RES QU, 2006, 070012 AHRQ PUBL; Akinbami Lara, 2006, Adv Data, P1; Baruffi G, 2004, J AM DIET ASSOC, V104, P1701, DOI 10.1016/j.jada.2004.08.027; Beal AC, 2004, HEALTH AFFAIR, V23, P171, DOI 10.1377/hlthaff.23.5.171; Blumberg SJ, 2005, VITAL HLTH STAT, V1, P1; Burt CW, 2001, VITAL HLTH STAT, V13, P1; *COMM UND ELIM RAC, 2003, UN TREATM CONFR RAC, P285; Denny Clark H, 2003, MMWR Surveill Summ, V52, P1; Edelstein BL, 2002, AMBUL PEDIATR, V2, P141, DOI 10.1367/1539-4409(2002)002<0141:DIOHAA>2.0.CO;2; Eisenmann JC, 2000, INT J OBESITY, V24, P211, DOI 10.1038/sj.ijo.0801116; Elixhauser A, 2002, AMBUL PEDIATR, V2, P419, DOI 10.1367/1539-4409(2002)002<0419:HCFCAY>2.0.CO;2; Flores G, 2005, PEDIATRICS, V116, P1433, DOI 10.1542/peds.2005-0786; Flores G, 1999, AM J PUBLIC HEALTH, V89, P1066, DOI 10.2105/AJPH.89.7.1066; Flores G, 2005, PEDIATRICS, V115; Flores GF, 2005, PUBLIC HEALTH REP, V120, P418; Guevara JP, 2006, HEALTH SERV RES, V41, P532, DOI 10.1111/j.1475-6773.2005.00484.x; Harris KM, 2006, ARCH PEDIAT ADOL MED, V160, P74, DOI 10.1001/archpedi.160.1.74; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Heslin KC, 2006, ARCH OPHTHALMOL-CHIC, V124, P895, DOI 10.1001/archopht.124.6.895; JACKSON MY, 1993, J AM DIET ASSOC, V93, P1136, DOI 10.1016/0002-8223(93)91645-7; Lewis C, 2007, J AM DENT ASSOC, V138, P369; Mendoza FS, 1999, WESTERN J MED, V170, P85; Moore William E, 2006, Prev Chronic Dis, V3, pA114; NeumarkSztainer D, 1997, J AM DIET ASSOC, V97, P598, DOI 10.1016/S0002-8223(97)00154-5; NEWACHECK PW, 1989, PEDIATRICS, V84, P699; NEWACHECK PW, 1995, HEALTH AFFAIR, V14, P244, DOI 10.1377/hlthaff.14.1.244; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.2012.40; Passel JS, 2002, AMBUL PEDIATR, V2, P169, DOI 10.1367/1539-4409(2002)002<0169:DASTAT>2.0.CO;2; Stata Corporation, 2003, STAT SURV DAT REF MA; Weitzman M, 1999, PEDIATRICS, V104, P151; Williams DR, 2000, AM J PUBLIC HEALTH, V90, P1728, DOI 10.2105/AJPH.90.11.1728; Wisen AGM, 2004, CLIN PHYSIOL FUNCT I, V24, P341, DOI 10.1111/j.1475-097X.2004.00576.x; WOOD DL, 1990, PEDIATRICS, V86, P666; Yu SM, 2004, PEDIATRICS, V113, P101, DOI 10.1542/peds.113.1.101; Zephier E, 2006, ARCH PEDIAT ADOL MED, V160, P34, DOI 10.1001/archpedi.160.1.34	35	188	190	4	32	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2008	121	2					E286	E298		10.1542/peds.2007-1243		13	Pediatrics	Pediatrics	258OQ	WOS:000252877600046	18195000	
J	Wigle, DT; Arbuckle, TE; Turner, MC; Berube, A; Yang, QY; Liu, SL; Krewski, D				Wigle, Donald T.; Arbuckle, Tye E.; Turner, Michelle C.; Berube, Annie; Yang, Qiuying; Liu, Shiliang; Krewski, Daniel			Epidemiologic evidence of relationships between reproductive and child health outcomes and environmental chemical contaminants	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS			English	Review							LEVEL LEAD-EXPOSURE; ADVERSE PREGNANCY OUTCOMES; LOW-BIRTH-WEIGHT; PATERNAL OCCUPATIONAL-EXPOSURE; IN-UTERO EXPOSURE; NEURAL-TUBE DEFECTS; HAZARDOUS-WASTE LANDFILL; PORT-PIRIE COHORT; ACUTE LYMPHOBLASTIC-LEUKEMIA; TOBACCO-SMOKE EXPOSURE	This review summarizes the level of epidemiologic evidence for relationships between prenatal and/or early life exposure to environmental chemical contaminants and fetal, child, and adult health. Discussion focuses on fetal loss, intrauterine growth restriction, preterm birth, birth defects, respiratory and other childhood diseases, neuropsychological deficits, premature or delayed sexual maturation, and certain adult cancers linked to fetal or childhood exposures. Environmental exposures considered here include chemical toxicants in air, water, soil/house dust and foods (including human breast milk), and consumer products. Reports reviewed here included original epidemiologic studies (with at least basic descriptions of methods and results), literature reviews, expert group reports, meta-analyses, and pooled analyses. Levels of evidence for causal relationships were categorized as sufficient, limited, or inadequate according to predefined criteria. There was sufficient epidemiological evidence for causal relationships between several adverse pregnancy or child health outcomes and prenatal or childhood exposure to environmental chemical contaminants. These included prenatal high-level methylmercury (CH3Hg) exposure (delayed developmental milestones and cognitive, motor, auditory, and visual deficits), high-level prenatal exposure to polychlorinated biphenyls (PCBs), polychlorinated dibenzofurans (PCDFs), and related toxicants (neonatal tooth abnormalities, cognitive and motor deficits), maternal active smoking (delayed conception, preterm birth, fetal growth deficit [FGD] and sudden infant death syndrome [SIDS]) and prenatal environmental tobacco smoke (ETS) exposure (preterm birth), low-level childhood lead exposure (cognitive deficits and renal tubular damage), high-level childhood CH3Hg exposure (visual deficits), high-level childhood exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) (chloracne), childhood ETS exposure (SIDS, new-onset asthma, increased asthma severity, lung and middle ear infections, and adult breast and lung cancer), childhood exposure to biomass smoke (lung infections), and childhood exposure to outdoor air pollutants (increased asthma severity). Evidence for some proven relationships came from investigation of relatively small numbers of children with high-dose prenatal or early childhood exposures, e. g., CH3Hg poisoning episodes in Japan and Iraq. In contrast, consensus on a causal relationship between incident asthma and ETS exposure came only recently after many studies and prolonged debate. There were many relationships supported by limited epidemiologic evidence, ranging from several studies with fairly consistent findings and evidence of dose-response relationships to those where 20 or more studies provided inconsistent or otherwise less than convincing evidence of an association. The latter included childhood cancer and parental or childhood exposures to pesticides. In most cases, relationships supported by inadequate epidemiologic evidence reflect scarcity of evidence as opposed to strong evidence of no effect. This summary points to three main needs: (1) Where relationships between child health and environmental exposures are supported by sufficient evidence of causal relationships, there is a need for (a) policies and programs to minimize population exposures and (b) population-based biomonitoring to track exposure levels, i.e., through ongoing or periodic surveys with measurements of contaminant levels in blood, urine and other samples. (2) For relationships suported by limited evidence, there is a need for targeted research and policy options ranging from ongoing evaluation of evidence to proactive actions. (3) There is a great need for population-based, multidisciplinary and collaborative research on the many relationships supported by inadequate evidence, as these represent major knowledge gaps. Expert groups faced with evaluating epidemiologic evidence of potential causal relationships repeatedly encounter problems in summarizing the available data. A major driver for undertaking such summaries is the need to compensate for the limited sample sizes of individual epidemiologic studies. Sample size limitations are major obstacles to exploration of prenatal, paternal, and childhood exposures during specific time windows, exposure intensity, exposure-exposure or exposure-gene interactions, and relatively rare health outcomes such as childhood cancer. Such research needs call for investments in research infrastructure, including human resources and methods development (standardized protocols, biomarker research, validated exposure metrics, reference analytic laboratories). These are needed to generate research findings that can be compared and subjected to pooled analyses aimed at knowledge synthesis.	[Wigle, Donald T.; Turner, Michelle C.; Krewski, Daniel] Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada; [Arbuckle, Tye E.] Hlth Canada, Healthy Environm & Consumer Safety Branch, Ottawa, ON K1A 0L2, Canada; [Berube, Annie] Hlth Canada, Vulnerable Populat Div, Safe Environm Program, Ottawa, ON K1A 0L2, Canada; [Yang, Qiuying] Univ Ottawa, Dept Obstet & Gynecol, Fac Med, OMNI Res Grp, Ottawa, ON, Canada; [Yang, Qiuying] Ottawa Hlth Res Inst, Ottawa, ON, Canada; [Liu, Shiliang] Publ Hlth Agcy Canada, Ctr Healthy Human Dev, Ottawa, ON, Canada	Wigle, DT (reprint author), Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Room 318B,1 Stewart St, Ottawa, ON K1N 6N5, Canada.	don.wigle@sympatico.ca					Abadi-Korek I, 2006, J OCCUP ENVIRON MED, V48, P165, DOI 10.1097/01.jom.0000183343.81485.7c; Abell A, 2000, SCAND J WORK ENV HEA, V26, P131; *AG TOX SUBST DIS, 1999, TOX PROF CAD; Agency for Toxic Substances and Disease Registry, 2000, TOX PROF ARS; Agency for Toxic Substances and Disease Registry, 2000, TOX PROF MANG; Agency for Toxic Substances and Disease Registry, 1999, TOX PROF LEAD; Agnesi R, 1997, INT ARCH OCC ENV HEA, V69, P311, DOI 10.1007/s004200050153; Ahlborg G, 1996, INT J EPIDEMIOL, V25, P783, DOI 10.1093/ije/25.4.783; AHLBORG G, 1991, AM J EPIDEMIOL, V133, P338; Ahmad SA, 2001, ENVIRON HEALTH PERSP, V109, P629, DOI 10.2307/3455038; Alaluusua S, 1999, LANCET, V353, P206, DOI 10.1016/S0140-6736(05)77214-7; Alaluusua S, 2002, PEDIATR RES, V52, P652, DOI 10.1203/01.PDR.0000031926.09665.F1; Alaluusua S, 2004, ENVIRON HEALTH PERSP, V112, P1313, DOI 10.1289/ehp.6920; Alderton LE, 2006, AM J EPIDEMIOL, V164, P212, DOI 10.1093/aje/kwj203; Alexander BH, 1996, INT J OCCUP ENV HEAL, V2, P280; Alexander FE, 2001, CANCER RES, V61, P2542; Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; Altmann L, 1998, NEUROTOXICOL TERATOL, V20, P9, DOI 10.1016/S0892-0362(97)00070-6; American Academy of Pediatrics Committee on Environmental Health, 2003, PED ENV HLTH; American Cancer Society, 2006, CANC FACTS FIG 2006; Amin-Zaki L, 1981, J Appl Toxicol, V1, P210, DOI 10.1002/jat.2550010405; AMINZAKI L, 1974, J PEDIATR-US, V85, P81, DOI 10.1016/S0022-3476(74)80291-X; AMINZAKI L, 1979, AM J DIS CHILD, V133, P172; AMINZAKI L, 1978, BRIT MED J, V1, P613; AMINZAKI L, 1974, PEDIATRICS, V54, P587; Anderson HR, 1997, THORAX, V52, P1003; ANDREWS MW, 1994, BEHAV RES METH INSTR, V26, P32, DOI 10.3758/BF03204560; ANNEST JL, 1983, NEW ENGL J MED, V308, P1373, DOI 10.1056/NEJM198306093082301; ANTTILA A, 1995, J OCCUP ENVIRON MED, V37, P915, DOI 10.1097/00043764-199508000-00005; Arbuckle TE, 1998, CRIT REV TOXICOL, V28, P229, DOI 10.1080/10408449891344218; Arbuckle TE, 1999, EPIDEMIOLOGY, V10, P752, DOI 10.1097/00001648-199911000-00017; Arbuckle TE, 2001, ENVIRON HEALTH PERSP, V109, P851, DOI 10.2307/3454830; ARBUCKLE TE, 1988, ARCH ENVIRON HEALTH, V43, P162; Arias Elizabeth, 2003, Natl Vital Stat Rep, V51, P1; ASCHENGRAU A, 1989, ARCH ENVIRON HEALTH, V44, P283; ASCHENGRAU A, 1993, ARCH ENVIRON HEALTH, V48, P105; Atuma SS, 1998, FOOD ADDIT CONTAM, V15, P142; Axmon A, 2004, ENVIRON RES, V96, P186, DOI 10.1016/j.envres.2003.10.002; Axmon A, 2000, INT ARCH OCC ENV HEA, V73, P204, DOI 10.1007/s004200050028; Axtell CD, 1998, ENVIRON HEALTH PERSP, V106, P559, DOI 10.2307/3434230; Axtell CD, 2000, ENVIRON RES, V84, P71, DOI 10.1006/enrs.2000.4082; BAGHURST PA, 1992, NEW ENGL J MED, V327, P1279, DOI 10.1056/NEJM199210293271805; BAGHURST PA, 1991, ENVIRON HEALTH PERSP, V90, P315, DOI 10.2307/3430885; Baibergenova A, 2003, ENVIRON HEALTH PERSP, V111, P1352, DOI 10.1289/ehp.6053; BAIRD DD, 1986, AM J EPIDEMIOL, V124, P470; Ballew C, 1999, J PEDIATR-US, V134, P623, DOI 10.1016/S0022-3476(99)70250-7; Banks EC, 1997, NEUROTOXICOLOGY, V18, P237; Bell EM, 2001, AM J EPIDEMIOL, V154, P702, DOI 10.1093/aje/154.8.702; Bell EM, 2001, EPIDEMIOLOGY, V12, P595, DOI 10.1097/00001648-200109000-00034; Bell EM, 2001, EPIDEMIOLOGY, V12, P148, DOI 10.1097/00001648-200103000-00005; BELLINGER D, 1994, ENVIRON RES, V66, P12, DOI 10.1006/enrs.1994.1041; BELLINGER D, 1991, PEDIATRICS, V87, P219; BELLINGER D, 1991, ENVIRON RES, V54, P151, DOI 10.1016/S0013-9351(05)80097-0; BELLINGER D, 1988, NEUROTOXICOL TERATOL, V10, P497, DOI 10.1016/0892-0362(88)90084-0; Bellinger DC, 2005, BIRTH DEFECTS RES A, V73, P409, DOI 10.1002/bdra.20127; BELLINGER DC, 1984, NEUROBEH TOXICOL TER, V6, P387; Bellinger DC, 2003, NEW ENGL J MED, V349, P500; BELLINGER DC, 1992, PEDIATRICS, V90, P855; Bellinger DC, 2004, PEDIATRICS, V113, P1016; Beral V, 2002, BRIT J CANCER, V87, P1234, DOI 10.1038/sj.bjc.6600596; Berkowitz GS, 2004, ENVIRON HEALTH PERSP, V112, P388, DOI 10.1289/ehp.6414; Berkowitz Z, 2006, INT J HYG ENVIR HEAL, V209, P123, DOI 10.1016/j.ijheh.2005.11.001; Berlin CM, 2002, J TOXICOL ENV HEAL A, V65, P1839, DOI 10.1080/00984100290071748; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Bernard A, 2006, ENVIRON HEALTH PERSP, V114, P1567, DOI 10.1289/ehp.8461; BERNARD AM, 1995, ENVIRON RES, V68, P91, DOI 10.1006/enrs.1995.1012; Bernard SM, 2003, PEDIATRICS, V112, P1308, DOI 10.1542/peds.112.6.1308; Berry M, 1997, ENVIRON HEALTH PERSP, V105, P856, DOI 10.1289/ehp.97105856; BERUBE A, 2006, J TOXICOL ENV HEAL B, V10, P131; Bhatia R, 2005, ENVIRON HEALTH PERSP, V113, P220, DOI 10.1289/ehp.7382; Binkova B, 2005, EFFECTS AIR POLLUTIO; BIRNBAUM LS, 1995, ENVIRON HEALTH PERSP, V103, P89, DOI 10.2307/3432515; Blanck HM, 2000, EPIDEMIOLOGY, V11, P641, DOI 10.1097/00001648-200011000-00005; Blanck HM, 2002, EPIDEMIOLOGY, V13, P205; Blatter BM, 1996, OCCUP ENVIRON MED, V53, P80; Blatter BM, 1996, EPIDEMIOLOGY, V7, P188, DOI 10.1097/00001648-199603000-00014; Blatter BM, 1997, AM J IND MED, V32, P283, DOI 10.1002/(SICI)1097-0274(199709)32:3<283::AID-AJIM15>3.0.CO;2-R; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; Bolumar F, 1996, AM J EPIDEMIOL, V143, P578; Bonde JP, 2002, OCCUP ENVIRON MED, V59, P234, DOI 10.1136/oem.59.4.234; Borja-Aburto VH, 1999, AM J EPIDEMIOL, V150, P590; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; BORZSONYI M, 1992, ARCH TOXICOL, V66, P77, DOI 10.1007/BF02307274; Bound JP, 1997, ARCH DIS CHILD, V76, P107; Bove F, 2002, ENVIRON HEALTH PERSP, V110, P61; BOVE FJ, 1995, AM J EPIDEMIOL, V141, P850; Boyle E, 2004, Ir Med J, V97, P16; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brauer M, 2006, ENVIRON HEALTH PERSP, V114, P1414, DOI 10.1289/ehp.9089; Brender J, 2002, J OCCUP ENVIRON MED, V44, P650, DOI 10.1097/01.jom.0000023382.41727.7b; Brender JD, 2006, ENVIRON RES, V101, P132, DOI 10.1016/j.envres.2005.08.003; BRENDER JD, 1990, AM J EPIDEMIOL, V131, P517; Brender JD, 2004, EPIDEMIOLOGY, V15, P330, DOI 10.1097/01.ede.0000121381.79831.7b; Briggs NC, 2003, AM J PUBLIC HEALTH, V93, P1748, DOI 10.2105/AJPH.93.10.1748; Brouwer A, 1998, CHEMOSPHERE, V37, P1627, DOI 10.1016/S0045-6535(98)00230-6; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; Brown Rebecca C., 2006, Toxicological and Environmental Chemistry, V88, P423, DOI 10.1080/02772240600741411; Bruce N., 2002, WHOSDEOEH0205; BUCKLEY JD, 1989, CANCER RES, V49, P4030; Buckley JD, 2000, CANCER, V89, P2315, DOI 10.1002/1097-0142(20001201)89:11<2315::AID-CNCR21>3.0.CO;2-G; Budtz-Jorgensen E, 2000, TOXICOL LETT, V112, P193, DOI 10.1016/S0378-4274(99)00283-0; Buffler PA, 2005, CANCER INVEST, V23, P60, DOI 10.1081/CNV-200046402; Bukowski J, 2001, J OCCUP ENVIRON MED, V43, P377, DOI 10.1097/00043764-200104000-00016; Bull N, 1999, OCCUP MED-OXFORD, V49, P371, DOI 10.1093/occmed/49.6.371; BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197; BUNIN GR, 1990, CANCER RES, V50, P7129; Burns JM, 1999, AM J EPIDEMIOL, V149, P740; Byers RK, 1943, AM J DIS CHILD, V66, P471; California Environmental Protection Agency, 2005, PROP ID ENV TOB SMOK; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Calderon J, 2001, ENVIRON RES, V85, P69, DOI 10.1006/enrs.2000.4106; Campbell JR, 2000, ENVIRON HEALTH PERSP, V108, P1099, DOI 10.2307/3434965; Can A, 2005, MOL HUM REPROD, V11, P389, DOI 10.1093/molehr/gah179; Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; Carbone P, 2007, INT J ANDROL, V30, P3, DOI 10.1111/j.1365-2605.2006.00703.x; Carpenter RG, 2004, LANCET, V363, P185, DOI 10.1016/S0140-6736(03)15323-8; *CDC, 1989, CTR DIS CONTR VIETN, V5; Centers for Disease Control and Prevention, 2004, MMWR-MORBID MORTAL W, V53, P529; *CDCP, 2006, LEAD QUEST ANSW; Centers for Disease Control and Prevention, 2005, 3 CDCP; *CDCP, 2005, METR ATL CONG DEF PR; Cedergren MI, 2002, ENVIRON RES, V89, P124, DOI 10.1006/enrs.2001.4362; Chaix B, 2006, J EPIDEMIOL COMMUN H, V60, P234, DOI 10.1136/jech.2005.038190; Chang JS, 2006, AM J EPIDEMIOL, V163, P1091, DOI 10.1093/aje/kwj143; Chao WY, 1997, ARCH ENVIRON HEALTH, V52, P257; Chen AM, 2005, ENVIRON HEALTH PERSP, V113, P597, DOI 10.1289/ehp.7625; Chen L, 2002, INHAL TOXICOL, V14, P141, DOI 10.1080/089583701753403962; Chen PC, 2006, AM J IND MED, V49, P417, DOI 10.1002/ajim.20313; Chen PC, 2002, EPIDEMIOLOGY, V13, P191, DOI 10.1097/00001648-200203000-00014; CHEN YCJ, 1994, AM J PUBLIC HEALTH, V84, P415, DOI 10.2105/AJPH.84.3.415; CHEN YJ, 1994, DEV MED CHILD NEUROL, V36, P312; Chen Z, 2006, INT J HYG ENVIR HEAL, V209, P31, DOI 10.1016/j.ijheh.2005.08.001; Chen Z, 2005, AM J EPIDEMIOL, V162, P858, DOI 10.1093/aje/kwi294; Chen Z, 2005, CANCER, V103, P1064, DOI 10.1002/cncr.20894; Chia SE, 2004, NEUROTOXICOL TERATOL, V26, P285, DOI 10.1016/j.ntt.2003.10.009; Chiodo LM, 2004, NEUROTOXICOL TERATOL, V26, P359, DOI 10.1016/j.ntt.2004.01.010; Cho S I, 1999, Int J Occup Environ Health, V5, P164; Clarkson TW, 2002, ENVIRON HEALTH PERSP, V110, P11; Clavel J, 2005, EUR J CANCER PREV, V14, P531, DOI 10.1097/00008469-200512000-00007; Cocco P, 2005, ENVIRON RES, V98, P120, DOI 10.1016/j.envres.2004.09.007; Cohn BA, 2003, LANCET, V361, P2205, DOI 10.1016/S0140-6736(03)13776-2; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Colt JS, 1998, ENVIRON HEALTH PERSP, V106, P909, DOI 10.2307/3434208; *COMM ENV COOP, 2002, N AM REG ACT PLAN EN; Commission for Environmental Cooperation, 2006, CHILDR HLTH ENV N AM; Cook DG, 1999, THORAX, V54, P357; COONEY GH, 1989, NEUROTOXICOL TERATOL, V11, P95, DOI 10.1016/0892-0362(89)90047-0; COONEY GH, 1989, DEV MED CHILD NEUROL, V31, P640; Cooney MA, 2007, ENVIRON HEALTH PERSP, V115, P134, DOI 10.1289/ehp.9298; Cordier S, 2001, CANCER CAUSE CONTROL, V12, P865, DOI 10.1023/A:1012277703631; Cordier S, 2004, OCCUP ENVIRON MED, V61, P8; Cordier S, 1997, CANCER CAUSE CONTROL, V8, P688, DOI 10.1023/A:1018419118841; Cordier S, 1997, EPIDEMIOLOGY, V8, P355, DOI 10.1097/00001648-199707000-00002; Cordier S, 2002, ENVIRON RES, V89, P1, DOI 10.1006/enrs.2002.4349; CORDIER S, 1994, INT J CANCER, V59, P776, DOI 10.1002/ijc.2910590612; CORDIER S, 1992, SCAND J WORK ENV HEA, V18, P11; Correa A, 1996, AM J EPIDEMIOL, V143, P707; CORREAVILLASENOR A, 1991, TERATOLOGY, V44, P415, DOI 10.1002/tera.1420440408; CORREAVILLASENOR A, 1993, J EXPO ANAL ENV EPID, V3, P173; Counter SA, 1997, J NEUROL SCI, V152, P85; Counter SA, 2003, J OCCUP ENVIRON MED, V45, P87, DOI 10.1097/01.jom.0000048165.87707.fd; Counter SA, 1998, NEUROTOXICOLOGY, V19, P185; COX C, 1989, ENVIRON RES, V49, P318, DOI 10.1016/S0013-9351(89)80075-1; Croen LA, 2001, AM J EPIDEMIOL, V153, P325, DOI 10.1093/aje/153.4.325; Croen LA, 1997, EPIDEMIOLOGY, V8, P347, DOI 10.1097/00001648-199707000-00001; Crosignani P, 2004, INT J CANCER, V108, P596, DOI 10.1002/ijc.11597; Crump KS, 1998, RISK ANAL, V18, P701, DOI 10.1023/B:RIAN.0000005917.52151.e6; Curtis KM, 1997, AM J EPIDEMIOL, V146, P32; Curtis KM, 1999, EPIDEMIOLOGY, V10, P112, DOI 10.1097/00001648-199903000-00005; Dahl R, 1996, NEUROTOXICOL TERATOL, V18, P413, DOI 10.1016/0892-0362(96)00031-1; Dallaire F, 2004, ENVIRON HEALTH PERSP, V112, P1359, DOI 10.1289/ehp.7255; Dallaire F, 2006, ENVIRON HEALTH PERSP, V114, P1301, DOI 10.1289/ehp.8683; Damgaard IN, 2006, ENVIRON HEALTH PERSP, V114, P1133, DOI 10.1289/ehp.8741; DANIELL WE, 1988, BRIT J IND MED, V45, P193; Daniels JL, 2004, EPIDEMIOLOGY, V15, P394, DOI 10.1097/01.ede.0000129514.46451.ce; Daniels JL, 2003, AM J EPIDEMIOL, V157, P485, DOI 10.1093/aje/kwg010; Daniels JL, 2001, EPIDEMIOLOGY, V12, P20, DOI 10.1097/00001648-200101000-00005; Darvill T, 2000, NEUROTOXICOLOGY, V21, P1029; Davidson PW, 2004, PEDIATRICS, V113, P1023; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; Davidson PW, 1995, NEUROTOXICOLOGY, V16, P677; Davidson PW, 2000, ENVIRON RES, V84, P1, DOI 10.1006/enrs.2000.4084; DAVIS JR, 1993, ARCH ENVIRON CON TOX, V24, P87; Dawson EB, 1999, AM J PERINAT, V16, P373, DOI 10.1055/s-2007-993887; de Burbure C, 2006, ENVIRON HEALTH PERSP, V114, P584, DOI 10.1289/ehp.8202; de Burbure C, 2003, J TOXICOL ENV HEAL A, V66, P783, DOI 10.1080/15287390390156182; De Roos AJ, 2001, AM J EPIDEMIOL, V154, P106, DOI 10.1093/aje/154.2.106; Debes F, 2006, NEUROTOXICOL TERATOL, V28, P363, DOI 10.1016/j.ntt.2006.02.004; DECOCK J, 1994, OCCUP ENVIRON MED, V51, P693; Dejin-Karlsson E, 2003, EUR J PUBLIC HEALTH, V13, P210, DOI 10.1093/eurpub/13.3.210; Dejmek J, 2002, ENVIRON HEALTH PERSP, V110, P601; Dejmek J, 2000, ENVIRON HEALTH PERSP, V108, P647, DOI 10.2307/3434886; Del Corno G, 1985, Eur J Epidemiol, V1, P139; Den Hond E, 2002, ENVIRON HEALTH PERSP, V110, P771; DeSesso JM, 1998, REPROD TOXICOL, V12, P385, DOI 10.1016/S0890-6238(98)00021-5; Dewailly E, 2000, ENVIRON HEALTH PERSP, V108, P205, DOI 10.2307/3454435; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; DIETRICH KN, 1992, NEUROTOXICOL TERATOL, V14, P51, DOI 10.1016/0892-0362(92)90028-9; DIETRICH KN, 1990, ENVIRON HEALTH PERSP, V89, P13, DOI 10.2307/3430891; Dietrich KN, 2001, NEUROTOXICOL TERATOL, V23, P511, DOI 10.1016/S0892-0362(01)00184-2; DiFranza JR, 2004, PEDIATRICS, V113, P1007; DimichWard H, 1996, SCAND J WORK ENV HEA, V22, P267; Dodds L, 1999, EPIDEMIOLOGY, V10, P233, DOI 10.1097/00001648-199905000-00007; Dodds L, 2004, EPIDEMIOLOGY, V15, P179, DOI 10.1097/01.ede.0000112209.47765.d9; Dodds L, 2001, CAN J PUBLIC HEALTH, V92, P331; Dodds L, 2001, OCCUP ENVIRON MED, V58, P443, DOI 10.1136/oem.58.7.443; Dolk H, 2000, ARCH ENVIRON HEALTH, V55, P26; Dolk H, 2003, BRIT MED BULL, V68, P25, DOI 10.1093/bmb/ldg024; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; DORSCH MM, 1984, AM J EPIDEMIOL, V119, P473; Doyle P, 1997, OCCUP ENVIRON MED, V54, P848; DUGANDZIC R, 2006, ENV HLTH, V5, P1, DOI DOI 10.1186/1476-069X-5-3; Dulout FN, 1996, MUTAT RES-GENET TOX, V370, P151; Dummer TJB, 2003, PAEDIATR PERINAT EP, V17, P250, DOI 10.1046/j.1365-3016.2003.00495.x; Dummer TJB, 2003, J EPIDEMIOL COMMUN H, V57, P456, DOI 10.1136/jech.57.6.456; Efird JT, 2003, PAEDIATR PERINAT EP, V17, P201, DOI 10.1046/j.1365-3016.2003.00484.x; EIBEN B, 1990, AM J HUM GENET, V47, P656; Elghany NA, 1997, OCCUP MED-OXFORD, V47, P333, DOI 10.1093/occmed/47.6.333; Elliott P, 2001, BRIT MED J, V323, P363, DOI 10.1136/bmj.323.7309.363; Elliott RC, 1999, AM J IND MED, V36, P557, DOI 10.1002/(SICI)1097-0274(199911)36:5<557::AID-AJIM8>3.0.CO;2-Q; Ellish NJ, 1996, HUM REPROD, V11, P406; ELWOOD JM, 1981, AM J EPIDEMIOL, V113, P681; Emory E, 2003, AM J OBSTET GYNECOL, V188, pS26, DOI 10.1067/mob.2003.244; Engel LS, 2000, SCAND J WORK ENV HEA, V26, P193; ERICKSON JD, 1984, JAMA-J AM MED ASSOC, V252, P903, DOI 10.1001/jama.252.7.903; ERNHART CB, 1988, SCI TOTAL ENVIRON, V71, P453, DOI 10.1016/0048-9697(88)90218-5; ERNHART CB, 1989, NEUROTOXICOL TERATOL, V11, P161, DOI 10.1016/0892-0362(89)90055-X; Eskenazi B, 2003, ENVIRON HEALTH PERSP, V111, P947, DOI 10.1289/ehp.6080; Eskenazi B, 2006, PEDIATRICS, V118, P233, DOI 10.1542/peds.2005-3117; ESKENAZI B, 1995, AM J EPIDEMIOL, V142, pS10; *EUR ENV AG WHO RE, 2002, CHILDR HLTH ENV REV; FABIA J, 1974, BRIT J PREV SOC MED, V28, P98; Factor-Litvak P, 1999, ENVIRON HEALTH PERSP, V107, P9, DOI 10.2307/3434284; FACTORLITVAK P, 1991, INT J EPIDEMIOL, V20, P722, DOI 10.1093/ije/20.3.722; Falcon M, 2003, TOXICOLOGY, V185, P59, DOI 10.1016/S0300-483X(02)00589-9; Fan AM, 1996, REGUL TOXICOL PHARM, V23, P35, DOI 10.1006/rtph.1996.0006; Faustman EM, 2000, ENVIRON HEALTH PERSP, V108, P13, DOI 10.2307/3454629; FEINGOLD L, 1992, CANCER CAUSE CONTROL, V3, P161, DOI 10.1007/BF00051656; Fell JME, 1996, LANCET, V347, P1218, DOI 10.1016/S0140-6736(96)90735-7; Fels LM, 1998, NEPHROL DIAL TRANSPL, V13, P2248, DOI 10.1093/ndt/13.9.2248; Fenske RA, 2005, ENVIRON HEALTH PERSP, V113, P1651, DOI 10.1289/ehp.8022; Fenster L, 2006, ENVIRON HEALTH PERSP, V114, P597, DOI 10.1289/ehp.8423; Feychting M, 1998, SCAND J WORK ENV HEA, V24, P8; Feychting M, 2001, ENVIRON HEALTH PERSP, V109, P193, DOI 10.2307/3434775; Figa-Talamanca I, 2000, REPROD TOXICOL, V14, P325, DOI 10.1016/S0890-6238(00)00083-6; Filippini G, 2002, INT J CANCER, V100, P206, DOI 10.1002/ijc.10465; Fleming LE, 1999, J OCCUP ENVIRON MED, V41, P279, DOI 10.1097/00043764-199904000-00010; Flores-Luevano S, 2003, SALUD PUBLICA MEXICO, V45, P431, DOI [10.1590/S0036-36342003000600002, 10.1590/s0036-36342003000600002]; Flower KB, 2004, ENVIRON HEALTH PERSP, V112, P631; Ford AM, 1998, P NATL ACAD SCI USA, V95, P4584, DOI 10.1073/pnas.95.8.4584; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Foster W, 2000, J CLIN ENDOCR METAB, V85, P2954, DOI 10.1210/jc.85.8.2954; Freedman DM, 2001, AM J PUBLIC HEALTH, V91, P564, DOI 10.2105/AJPH.91.4.564; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gallagher MD, 1998, EPIDEMIOLOGY, V9, P484, DOI 10.1097/00001648-199809000-00003; GarciaRodriguez J, 1996, ENVIRON HEALTH PERSP, V104, P1090, DOI 10.2307/3433122; GARDNER MJ, 1990, BRIT MED J, V300, P423; Garry VF, 1996, ENVIRON HEALTH PERSP, V104, P394, DOI 10.2307/3432683; Garry VF, 2002, ENVIRON HEALTH PERSP, V110, P441; Garry VF, 2002, J TOXICOL ENV HEAL A, V65, P769, DOI 10.1080/00984100290071333; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gemmel A, 2002, ENVIRON HEALTH PERSP, V110, pA625; George L, 2006, EPIDEMIOLOGY, V17, P500, DOI 10.1097/01.ede.0000229984.53726.33; GESCHWIND SA, 1992, AM J EPIDEMIOL, V135, P1197; Gilboa SM, 2005, AM J EPIDEMIOL, V162, P238, DOI 10.1093/aje/kwi189; Gilbreath S, 2006, INT J CIRCUMPOL HEAL, V65, P133; Gilbreath S, 2006, AM J EPIDEMIOL, V164, P518, DOI 10.1093/aje/kwj241; Gladen BC, 2004, ENVIRON HEALTH PERSP, V112, P1761, DOI 10.1289/ehp.7287; Gladen BC, 2000, J PEDIATR-US, V136, P490, DOI 10.1016/S0022-3476(00)90012-X; Gladen BC, 2003, ANN EPIDEMIOL, V13, P151, DOI 10.1016/S1047-2797(02)00268-5; GLADEN BC, 1988, J PEDIATR-US, V113, P991, DOI 10.1016/S0022-3476(88)80569-9; GLADEN BC, 1991, J PEDIATR-US, V119, P58, DOI 10.1016/S0022-3476(05)81039-X; Glinianaia SV, 2004, ENVIRON HEALTH PERSP, V112, P1365, DOI 10.1289/ehp.6857; Glinianaia SV, 2004, EPIDEMIOLOGY, V15, P36, DOI 10.1097/01.ede.0000101023.41844.ac; Gocmen A, 1989, Biomed Environ Sci, V2, P36; Goel P, 2004, J Postgrad Med, V50, P12; GOLD E, 1979, AM J EPIDEMIOL, V109, P309; GOLDBERG MS, 1995, ENVIRON RES, V69, P37, DOI 10.1006/enrs.1995.1023; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Golub MS, 1998, J TOXICOL ENV HEAL B, V1, P199; Gomaa A, 2002, PEDIATRICS, V110, P110, DOI 10.1542/peds.110.1.110; GonzalezCossio T, 1997, PEDIATRICS, V100, P856, DOI 10.1542/peds.100.5.856; GOTELLI CA, 1985, SCIENCE, V227, P638, DOI 10.1126/science.2857500; Gouveia N, 2004, J EPIDEMIOL COMMUN H, V58, P11, DOI 10.1136/jech.58.1.11; GOYER RA, 1990, ENVIRON HEALTH PERSP, V86, P177, DOI 10.2307/3430951; GRANDJEAN P, 1995, NEUROTOXICOLOGY, V16, P27; Grandjean P, 2003, FASEB J, V17, P699, DOI 10.1096/fj.02-0661fje; Grandjean P, 2003, AMBUL PEDIATR, V3, P18, DOI 10.1367/1539-4409(2003)003<0018:NRCBSA>2.0.CO;2; Grandjean P, 1999, ENVIRON HEALTH PERSP, V107, P587, DOI 10.2307/3434402; Grandjean P, 2001, NEUROTOXICOL TERATOL, V23, P305, DOI 10.1016/S0892-0362(01)00155-6; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Grandjean P, 1999, AM J EPIDEMIOL, V150, P301; Grandjean P, 2001, INT J EPIDEMIOL, V30, P1272, DOI 10.1093/ije/30.6.1272; Grandjean P, 2001, NEUROTOXICOL TERATOL, V23, P141, DOI 10.1016/S0892-0362(01)00134-9; Graves CG, 2001, REGUL TOXICOL PHARM, V34, P103, DOI 10.1006/rtph.2001.1494; Gray KA, 2005, AM J EPIDEMIOL, V162, P17, DOI 10.1093/aje/kwi158; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; GREENE T, 1991, NEUROTOXICOL TERATOL, V13, P417, DOI 10.1016/0892-0362(91)90091-A; GRESIEBRUSIN DF, 2006, INT ARCH OCCUP ENV H; GUO YL, 1994, J TOXICOL ENV HEALTH, V41, P83; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P715, DOI 10.2307/3434656; GUO YLL, 1994, CHEMOSPHERE, V29, P2395, DOI 10.1016/0045-6535(94)90408-1; Guo YLL, 2004, INT ARCH OCC ENV HEA, V77, P153, DOI 10.1007/s00420-003-0487-9; GUO YLL, 1995, ENVIRON HEALTH PERSP, V103, P117, DOI 10.2307/3432359; Ha E, 2002, ARCH ENVIRON HEALTH, V57, P207; Halfon N, 1999, J AM ACAD CHILD PSY, V38, P600, DOI 10.1097/00004583-199905000-00023; Hanke W, 2004, INT ARCH OCC ENV HEA, V77, P47, DOI 10.1007/s00420-003-0475-0; Hansen C, 2006, BJOG-INT J OBSTET GY, V113, P935, DOI 10.1111/j.1471-0528.2006.01010.x; HANSEN ES, 1992, AM J IND MED, V21, P651, DOI 10.1002/ajim.4700210505; HANSEN ON, 1989, NEUROTOXICOL TERATOL, V11, P205, DOI 10.1016/0892-0362(89)90060-3; HARADA M, 1978, TERATOLOGY, V18, P285, DOI 10.1002/tera.1420180216; Harada M, 1999, SCI TOTAL ENVIRON, V234, P59, DOI 10.1016/S0048-9697(99)00255-7; HARADA M, 1995, CRIT REV TOXICOL, V25, P1, DOI 10.3109/10408449509089885; Harada M., 1977, MINIMATA DIS METHYLM, P209; Hardell L, 2006, INT J ANDROL, V29, P228, DOI 10.1111/j.1365-2605.2005.00622.x; Hardell L, 2003, ENVIRON HEALTH PERSP, V111, P930, DOI 10.1289/ehp.5816; Harrison RM, 1999, OCCUP ENVIRON MED, V56, P774; HARVEY PG, 1988, BRIT J DEV PSYCHOL, V6, P145; Hassan MAM, 2004, FERTIL STERIL, V81, P384, DOI 10.1016/j.fertnstert.2003.06.027; He P, 1994, Zhonghua Yu Fang Yi Xue Za Zhi, V28, P216; Heacock H, 2000, ENVIRON HEALTH PERSP, V108, P499, DOI 10.2307/3454610; Heinrich J, 2002, EPIDEMIOLOGY, V13, P394, DOI 10.1097/01.EDE.00000016977.59359.B6; HEMMINKI K, 1985, J EPIDEMIOL COMMUN H, V39, P141, DOI 10.1136/jech.39.2.141; HERRSTROM P, 1995, ARCH ENVIRON HEALTH, V50, P103; Hertz-Picciotto I, 2005, EPIDEMIOLOGY, V16, P648, DOI 10.1097/01.ede.0000173043.85834.f3; Hertz-Picciotto I, 2000, AM J IND MED, V38, P300, DOI 10.1002/1097-0274(200009)38:3<300::AID-AJIM9>3.0.CO;2-C; HERY M, 1995, ANN OCCUP HYG, V39, P427, DOI 10.1016/0003-4878(95)00013-5; Hewitt J B, 1998, J Obstet Gynecol Neonatal Nurs, V27, P521, DOI 10.1111/j.1552-6909.1998.tb02618.x; Hinckley AF, 2005, ENVIRON HEALTH PERSP, V113, P1808, DOI 10.1289/ehp.8282; Hing Esther, 2006, Adv Data, P1; Hjollund NHI, 1998, REPROD TOXICOL, V12, P29, DOI 10.1016/S0890-6238(97)00097-X; Hjollund NHI, 2000, SCAND J WORK ENV HEA, V26, P187; Health Canada, 2003, CAN PER HLTH REP 200; Holly EA, 1998, CANCER EPIDEM BIOMAR, V7, P797; HOLLY EA, 1992, AM J EPIDEMIOL, V135, P122; Hong YC, 2003, J OCCUP ENVIRON MED, V45, P492, DOI 10.1097/01.jom.0000063627.37065.a1; Hopenhayn C, 2003, EPIDEMIOLOGY, V14, P593, DOI 10.1097/01.ede.0000072104.65240.69; Hopenhayn-Rich C, 2000, ENVIRON HEALTH PERSP, V108, P667, DOI 10.2307/3434889; Hoppin JA, 1999, EPIDEMIOLOGY, V10, P300, DOI 10.1097/00001648-199905000-00019; Hosie S, 2000, EUR J PEDIATR SURG, V10, P304, DOI 10.1055/s-2008-1072381; HOWE GR, 1989, CANCER RES, V49, P4349; Hruba D, 2000, Cent Eur J Public Health, V8, P249; HSU MML, 1995, BRIT J DERMATOL, V132, P427, DOI 10.1111/j.1365-2133.1995.tb08677.x; HU H, 1991, AM J PUBLIC HEALTH, V81, P1070, DOI 10.2105/AJPH.81.8.1070; Hu H, 2006, ENVIRON HEALTH PERSP, V114, P1730, DOI 10.1289/ehp.9067; HUEL G, 1981, ARCH ENVIRON HEALTH, V36, P221; HUISMAN M, 1995, EARLY HUM DEV, V41, P111, DOI 10.1016/0378-3782(94)01611-R; Huisman M, 1995, EARLY HUM DEV, V43, P165, DOI 10.1016/0378-3782(95)01674-0; Hull MGR, 2000, FERTIL STERIL, V74, P725, DOI 10.1016/S0015-0282(00)01501-6; Hum L, 1998, INT J EPIDEMIOL, V27, P766, DOI 10.1093/ije/27.5.766; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Huynh M, 2006, PAEDIATR PERINAT EP, V20, P454, DOI 10.1111/j.1365-3016.2006.00759.x; Hwang BF, 2003, ARCH ENVIRON HEALTH, V58, P83, DOI 10.3200/AEOH.58.2.83-91; Hwang BF, 2002, AM J EPIDEMIOL, V156, P374, DOI 10.1093/aje/kwf038; Idrovo AJ, 2005, INT ARCH OCC ENV HEA, V78, P493, DOI 10.1007/s00420-005-0615-9; Ihrig MM, 1998, EPIDEMIOLOGY, V9, P290, DOI 10.1097/00001648-199805000-00013; Infante-Rivard C, 2005, ENVIRON HEALTH PERSP, V113, P787, DOI 10.1289/ehp.7707; Infante-Rivard C, 1999, LANCET, V354, P1819, DOI 10.1016/S0140-6736(05)70586-9; Infante-Rivard C, 2001, EPIDEMIOLOGY, V12, P13, DOI 10.1097/00001648-200101000-00004; Infante-Rivard C, 2002, ENVIRON HEALTH PERSP, V110, P591; Infante-Rivard C, 1999, EPIDEMIOLOGY, V10, P481, DOI 10.1097/00001648-199909000-00004; Infante-Rivard C, 2000, CANCER CAUSE CONTROL, V11, P547, DOI 10.1023/A:1008976116512; Infante-Rivard C, 2007, J TOXICOL ENV HEAL B, V10, P81, DOI 10.1080/10937400601034589; INFANTERIVARD C, 1991, J EPIDEMIOL COMMUN H, V45, P11, DOI 10.1136/jech.45.1.11; *INT AG RES CANC, 1989, IARC MON EV CARC RSK, V46; *INT CLEAR BIRTH D, 2000, ANN REP 2000; Irgens A, 2000, ACTA OBSTET GYN SCAN, V79, P465, DOI 10.1034/j.1600-0412.2000.079006465.x; Irgens A, 1998, AM J IND MED, V34, P431, DOI 10.1002/(SICI)1097-0274(199811)34:5<431::AID-AJIM3>3.0.CO;2-T; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P557, DOI 10.2307/3455027; Jaakkola JJK, 2001, OCCUP ENVIRON MED, V58, P437, DOI 10.1136/oem.58.7.437; Jackson LW, 2004, BIRTH DEFECTS RES A, V70, P185, DOI 10.1002/bdra.20014; JACOBSON JL, 1990, J PEDIATR-US, V116, P38, DOI 10.1016/S0022-3476(05)81642-7; JACOBSON JL, 1990, NEUROTOXICOL TERATOL, V12, P319, DOI 10.1016/0892-0362(90)90050-M; Jacobson JL, 2003, J PEDIATR-US, V143, P780, DOI 10.1067/S0022-3476(03)00577-8; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Jacobson JL, 1996, TOXICOL IND HEALTH, V12, P435; JACOBSON SW, 1985, CHILD DEV, V56, P853, DOI 10.1111/j.1467-8624.1985.tb00158.x; Jan J, 2000, CARIES RES, V34, P469, DOI 10.1159/000016625; Jarrell J, 1998, REPROD TOXICOL, V12, P469, DOI 10.1016/S0890-6238(98)00019-7; Jarup L, 2002, BRIT J CANCER, V86, P1732, DOI 10.1038/sj.bjc.6600311; Jedrychowski W, 2006, ANN EPIDEMIOL, V16, P439, DOI 10.1016/j.annepidem.2005.06.059; Jedrychowski W, 2004, ENVIRON HEALTH PERSP, V112, P1398, DOI 10.1289/ehp.7065; Jelliffe-Pawlowski LL, 2006, J PERINATOL, V26, P154, DOI 10.1038/sj.jp.7211453; Joffe M, 2005, AM J EPIDEMIOL, V162, P115, DOI 10.1093/aje/kwi172; Joffe M, 2003, OCCUP ENVIRON MED, V60, P752, DOI 10.1136/oem.60.10.752; Johnson BL, 1995, TOXICOLOGY, V105, P145, DOI 10.1016/0300-483X(95)03208-W; JOHNSON CC, 1990, INT ARCH OCC ENV HEA, V62, P513, DOI 10.1007/BF00381182; JOHNSON CC, 1987, AM J EPIDEMIOL, V126, P605; Kafourou A, 1997, ARCH ENVIRON HEALTH, V52, P377; Kaiser R, 2004, ENV HLTH, V3, P1, DOI DOI 10.1186/1476-069X-3-4; Kallen BAJ, 2000, REPROD TOXICOL, V14, P303, DOI 10.1016/S0890-6238(00)00086-1; Karmaus W, 2003, PAEDIATR PERINAT EP, V17, P212, DOI 10.1046/j.1365-3016.2003.00488.x; Karmaus W, 2002, J PEDIATR-US, V140, P33, DOI 10.1067/mpd.2002.120764; Karmaus W, 2001, ARCH ENVIRON HEALTH, V56, P485; Karmaus W, 1995, ENVIRON HEALTH PERSP, V103, P1120, DOI 10.2307/3432608; Karmaus Wilfried, 2004, Environ Health, V3, P1, DOI 10.1186/1476-069X-3-1; Karpati AM, 2004, ENVIRON HEALTH PERSP, V112, P1183, DOI 10.1289/ehp.6946; Kasim K, 2005, EPIDEMIOLOGY, V16, P672, DOI 10.1097/01.ede.0000173039.79207.80; KEOLIVEIRA LM, 2002, REV SAUDE PUBL, V36, P81; Kerr MA, 2000, CANCER CAUSE CONTROL, V11, P635, DOI 10.1023/A:1008951632482; Khanjani N, 2007, J EXPO SCI ENV EPID, V17, P191, DOI 10.1038/sj.jes.7500495; Khanjani N, 2006, SCI TOTAL ENVIRON, V368, P557, DOI 10.1016/j.scitotenv.2006.03.029; Kharrazi M, 2004, EPIDEMIOLOGY, V15, P660, DOI 10.1097/01.ede.0000142137.39619.60; Kharrazi M, 1997, TOXICOL IND HEALTH, V13, P299; Khattak S, 1999, JAMA-J AM MED ASSOC, V281, P1106, DOI 10.1001/jama.281.12.1106; King WD, 2000, ENVIRON HEALTH PERSP, V108, P883, DOI 10.1289/ehp.00108883; Kogevinas M, 1997, AM J EPIDEMIOL, V145, P1061; Koller K, 2004, ENVIRON HEALTH PERSP, V112, P987, DOI 10.1289/ehp.6941; Kolstad HA, 2000, SCAND J WORK ENV HEA, V26, P353; Komaki H, 1999, BRAIN DEV-JPN, V21, P122, DOI 10.1016/S0387-7604(98)00074-6; Komulainen H, 2004, TOXICOLOGY, V198, P239, DOI 10.1016/j.tox.2004.01.031; KoopmanEsseboom C, 1996, PEDIATRICS, V97, P700; Korrick SA, 2001, ANN EPIDEMIOL, V11, P491, DOI 10.1016/S1047-2797(01)00239-3; KRAMER MD, 1992, EPIDEMIOLOGY, V3, P407, DOI 10.1097/00001648-199209000-00005; Krewski D, 2007, HUM ECOL RISK ASSESS, V13, P1288, DOI 10.1080/10807030701655798; Kristensen P, 1997, Epidemiology, V8, P537, DOI 10.1097/00001648-199709000-00011; Kristensen P, 1996, INT J CANCER, V65, P39, DOI 10.1002/(SICI)1097-0215(19960103)65:1<39::AID-IJC8>3.0.CO;2-2; Kristensen P, 1997, AM J EPIDEMIOL, V146, P329; Kristensen P, 1996, CANCER EPIDEM BIOMAR, V5, P3; KRISTENSEN P, 1993, AM J EPIDEMIOL, V137, P134; KUHNERT BR, 1987, AM J OBSTET GYNECOL, V157, P1247; KUIJTEN RR, 1992, CANCER RES, V52, P782; Lacasana M, 2006, OCCUP ENVIRON MED, V63, P649, DOI 10.1136/oem.2005.023333; Lai T J, 2001, Br J Psychiatry Suppl, V40, ps49; LAI TJ, 1994, CHEMOSPHERE, V29, P2405, DOI 10.1016/0045-6535(94)90409-X; Lamb MR, 2006, ENVIRON HEALTH PERSP, V114, P779, DOI 10.1289/ehp.8488; LAN SJ, 1989, B ENVIRON CONTAM TOX, V42, P931; Landgren O, 1996, ACTA PAEDIATR, V85, P1361, DOI 10.1111/j.1651-2227.1996.tb13926.x; Landrigan PJ, 2002, ENVIRON HEALTH PERSP, V110, P721; LANDRIGAN PJ, 1975, LANCET, V1, P708; Landrigan PJ, 1999, ANN NY ACAD SCI, V895, P1, DOI 10.1111/j.1749-6632.1999.tb08073.x; Langholz B, 2002, ANN EPIDEMIOL, V12, P482, DOI 10.1016/S1047-2797(01)00317-9; Lanphear BP, 2000, PUBLIC HEALTH REP, V115, P521, DOI 10.1093/phr/115.6.521; Lanphear BP, 2005, ENVIRON HEALTH PERSP, V113, P894, DOI 10.1289/ehp.7688; LANSDOWN R, 1986, INT ARCH OCC ENV HEA, V57, P225, DOI 10.1007/BF00405790; Lanting CI, 1998, EARLY HUM DEV, V50, P283, DOI 10.1016/S0378-3782(97)00066-2; Lanting CI, 1998, ARCH ENVIRON CON TOX, V35, P135; Larsen SB, 1998, OCCUP ENVIRON MED, V55, P278; Laslo-Baker D, 2004, ARCH PEDIAT ADOL MED, V158, P956, DOI 10.1001/archpedi.158.10.956; Laumon B, 1996, REPROD TOXICOL, V10, P15, DOI 10.1016/0890-6238(95)02013-6; Law DCG, 2005, AM J EPIDEMIOL, V162, P523, DOI 10.1093/aje/kwi240; Lawson CC, 2004, ENVIRON HEALTH PERSP, V112, P1403, DOI 10.1289/ehp.7051; Lee BE, 2003, HUM REPROD, V18, P638, DOI 10.1093/humrep/deg102; Leem JH, 2006, ENVIRON HEALTH PERSP, V114, P905, DOI 10.1289/ehp.8733; LEISS JK, 1995, AM J PUBLIC HEALTH, V85, P249, DOI 10.2105/AJPH.85.2.249; Levario-Carrillo M, 2004, CHEMOSPHERE, V55, P1421, DOI 10.1016/j.chemosphere.2003.11.027; LEVITON A, 1993, ENVIRON RES, V60, P30, DOI 10.1006/enrs.1993.1003; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; Lin MC, 2001, J TOXICOL ENV HEAL A, V63, P565, DOI 10.1080/152873901316857743; Lin MC, 2001, J TOXICOL ENV HEAL A, V64, P637, DOI 10.1080/152873901753246232; LIN S, 1994, SCAND J WORK ENV HEA, V20, P166; Lin S, 1998, AM J EPIDEMIOL, V148, P173; Lindbohm ML, 2002, SCAND J WORK ENV HEA, V28, P84; LINDBOHM ML, 1991, SCAND J WORK ENV HEA, V17, P95; LINDBOHM ML, 1991, AM J PUBLIC HEALTH, V81, P1029, DOI 10.2105/AJPH.81.8.1029; Linet MS, 1999, J NATL CANCER I, V91, P1051, DOI 10.1093/jnci/91.12.1051; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; Loffredo CA, 2001, AM J EPIDEMIOL, V153, P529, DOI 10.1093/aje/153.6.529; LoghmanAdham M, 1997, ENVIRON HEALTH PERSP, V105, P928; Logman JFS, 2005, AM J IND MED, V47, P37, DOI 10.1002/ajim.20102; LOIACONO NJ, 1992, ARCH ENVIRON HEALTH, V47, P250; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; Longnecker MP, 2005, ENVIRON RES, V97, P127, DOI 10.1016/S0013-9351(03)00108-7; Longnecker MP, 2004, NEUROTOXICOL TERATOL, V26, P629, DOI 10.1016/j.ntt.2004.04.007; Longnecker MP, 2002, AM J EPIDEMIOL, V155, P313, DOI 10.1093/aje/155.4.313; Longnecker MP, 2001, LANCET, V358, P110, DOI 10.1016/S0140-6736(01)05329-6; Longnecker MP, 2003, ENVIRON HEALTH PERSP, V111, P65, DOI 10.1289/ehp.5463; Longnecker MP, 2005, EPIDEMIOLOGY, V16, P641, DOI 10.1097/01.ede.0000172137.45662.85; Lorente C, 2000, SCAND J WORK ENV HEA, V26, P137; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; Luderer U, 2004, AM J IND MED, V46, P614, DOI 10.1002/ajim.20100; Lund KE, 2005, EUR J PUBLIC HEALTH, V15, P123, DOI 10.1093/eurpub/cki075; Lynge E, 1998, ENVIRON HEALTH PERSP, V106, P683, DOI 10.2307/3433820; Ma SK, 1999, HEMATOL ONCOL, V17, P91, DOI 10.1002/(SICI)1099-1069(199909)17:3<91::AID-HON643>3.0.CO;2-Y; Ma XM, 2002, ENVIRON HEALTH PERSP, V110, P955; *MASS DEP PUBL HLT, 1997, WOB CHILDH LEUK FOLL, V1; *MASS DEP PUBL HLT, 1998, FIN REP WOB ENV BIRT; National Academy of Sciences, 2000, TOX EFF METH; National Academy of Sciences, 2000, SCI FRONT DEV TOX RI; National Academy of Science, 2000, CLEAR AIR ASTHM IND; *NAT AC SCI, 2003, VET AG OR; National Academy of Sciences, 1993, PEST DIETS INF CHILD; *NAT I CHILD HLTH, 2002, NAT CHILDR STUD; *PUBL HLTH AG CAN, 2005, PRET BIRTH; United Nations Environment Programme, 2002, GLOB MERC ASS; US Department of Health and Human Services, 2001, WOM SMOK REP SURG GE; U.S. Department of Health Education and Welfare Public Health Service, 1964, PUBL HLTH SERV PUBL, V1103; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; *US DEP HHS, 2003, CHILD HLTH US 2003; United States Department of Health and Human Services, 2004, HLTH CONS SMOK REP S; *US EPA, 2001, CHEM TEST INF HOM PA; World Health Organization, 1999, INT CONS ENV TOB SMO; WHO, 2000, FOOD ADDIT CONTAM, V17, P223; World Health Organization, 1990, ENV HLTH CRIT, V101; MAGNANI C, 1990, TUMORI, V76, P413; Magnus P, 1999, EPIDEMIOLOGY, V10, P513, DOI 10.1097/00001648-199909000-00008; Maia AT, 2004, GENE CHROMOSOME CANC, V39, P335, DOI 10.1002/gcc.20003; Maisonet M, 2004, ENVIRON RES, V95, P106, DOI 10.1016/j.envres.2004.01.001; Malik S, 2004, ARCH ENVIRON HEALTH, V59, P177, DOI 10.3200/AEOH.59.4.177-181; Maroziene L., 2002, ENV HLTH, V1, P1; Marrett Loraine D, 2002, Chronic Dis Can, V23, P58; MARSH DO, 1981, CLIN TOXICOL, V18, P1311; MARSH DO, 1980, ANN NEUROL, V7, P348, DOI 10.1002/ana.410070412; Marsh DO, 1995, NEUROTOXICOLOGY, V16, P717; MARSH DO, 1987, ARCH NEUROL-CHICAGO, V44, P1017; Marshall EG, 1997, ARCH ENVIRON HEALTH, V52, P416; Masuda Y, 2001, CHEMOSPHERE, V43, P925, DOI 10.1016/S0045-6535(00)00452-5; Matsubara F, 2000, J Epidemiol, V10, P335; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; MCCREDIE M, 1994, INT J CANCER, V56, P6; MCCREDIE M, 1994, INT J CANCER, V56, P11; MCDONALD AD, 1988, BRIT J IND MED, V45, P148; McGready R, 2001, AM J TROP MED HYG, V65, P285; McKee RH, 2004, ENVIRON HEALTH PERSP, V112, pA541; McKinney PA, 2003, OCCUP ENVIRON MED, V60, P901, DOI 10.1136/oem.60.12.901; McMartin KI, 1998, AM J IND MED, V34, P288, DOI 10.1002/(SICI)1097-0274(199809)34:3<288::AID-AJIM12>3.0.CO;2-Q; MCMICHAEL AJ, 1986, J EPIDEMIOL COMMUN H, V40, P18, DOI 10.1136/jech.40.1.18; Meinert R, 2000, AM J EPIDEMIOL, V151, P639; Meinert R, 1996, EUR J CANCER, V32A, P1943, DOI 10.1016/0959-8049(96)00231-6; Meironyte D, 1999, J TOXICOL ENV HEAL A, V58, P329, DOI 10.1080/009841099157197; Mendell MJ, 2007, INDOOR AIR, V17, P259, DOI 10.1111/j.1600-0668.2007.00478.x; Mendelsohn A.L., 1998, PEDIATRICS, V101, P1; Mendola P, 2002, MENT RETARD DEV D R, V8, P188, DOI 10.1002/mrdd.10033; Menegaux F, 2005, CANCER DETECT PREV, V29, P487, DOI 10.1016/j.cdp.2005.06.008; Menegaux F, 2006, OCCUP ENVIRON MED, V63, P131, DOI 10.1136/oem.2005.023036; MES J, 1995, CHEMOSPHERE, V30, P789, DOI 10.1016/0045-6535(94)00408-M; Meyer KJ, 2006, ENVIRON HEALTH PERSP, V114, P1589, DOI 10.1289/ehp.9146; Michalek JE, 1998, EPIDEMIOLOGY, V9, P161, DOI 10.1097/00001648-199803000-00010; Millar W J, 1998, Health Rep, V10, P9; Modigh CM, 2002, SCAND J WORK ENV HEA, V28, P418; Mol NM, 2002, EUR J ENDOCRINOL, V146, P357, DOI 10.1530/eje.0.1460357; Moller H, 1997, CANCER EPIDEM BIOMAR, V6, P141; Moore LE, 2005, INT J CANCER, V114, P472, DOI 10.1002/ijc.20734; Moore LE, 2002, ARCH ENVIRON HEALTH, V57, P201; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Morris SE, 2003, SCOT MED J, V48, P105; MORRISEY RE, 1987, FUND APPL TOXICOL, V8, P571, DOI 10.1016/0272-0590(87)90142-4; Moss ME, 1999, JAMA-J AM MED ASSOC, V281, P2294, DOI 10.1001/jama.281.24.2294; Moya J, 2004, PEDIATRICS, V113, P996; Mueller BA, 2004, INT J EPIDEMIOL, V33, P1209, DOI 10.1093/ije/dyh215; Mueller BA, 2001, ENVIRON HEALTH PERSP, V109, P551, DOI 10.2307/3455026; Munger R, 1997, ENVIRON HEALTH PERSP, V105, P308, DOI 10.1289/ehp.97105308; Munoz JB, 2005, PUBLIC HEALTH REP, V120, P39; Murata K, 1999, NEUROTOXICOL TERATOL, V21, P471, DOI 10.1016/S0892-0362(99)00026-4; Murata K, 2004, J PEDIATR-US, V144, P177, DOI 10.1016/j.jpeds.2003.10.059; Murata K, 2002, RISK ANAL, V22, P465, DOI 10.1111/0272-4332.00034; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; Myers GJ, 1998, NEUROTOXICOLOGY, V19, P313; Myers GJ, 1997, NEUROTOXICOLOGY, V18, P819; Myers GJ, 1995, NEUROTOXICOLOGY, V16, P653; Myers GJ, 2003, LANCET, V361, P1686, DOI 10.1016/S0140-6736(03)13371-5; Myers GJ, 2000, ENVIRON RES, V83, P275, DOI 10.1006/enrs.2000.4065; Myers GJ, 2000, ENVIRON RES, V84, P12, DOI 10.1006/enrs.2000.4085; Myers GJ, 2000, ENVIRON HEALTH PERSP, V108, P413, DOI 10.2307/3454530; NEEDLEMAN HL, 1990, NEW ENGL J MED, V322, P83, DOI 10.1056/NEJM199001113220203; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; Needleman HL, 1996, JAMA-J AM MED ASSOC, V275, P363, DOI 10.1001/jama.275.5.363; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; Needleman HL, 2002, NEUROTOXICOL TERATOL, V24, P711, DOI 10.1016/S0892-0362(02)00269-6; Needleman HL, 1997, ENVIRON RES, V74, P95, DOI 10.1006/enrs.1997.3767; Neri M, 2006, MUTAT RES-REV MUTAT, V612, P14, DOI 10.1016/j.mrrev.2005.04.003; Newland MC, 2002, ENVIRON TOXICOL PHAR, V12, P119, DOI 10.1016/S1382-6689(02)00030-3; Nickmilder M, 2007, OCCUP ENVIRON MED, V64, P37, DOI 10.1136/oem.2005.025452; Nielsen SS, 2005, ENVIRON HEALTH PERSP, V113, P909, DOI 10.1289/ehp.7680; Nieuwenhuijsen MJ, 2002, EPIDEMIOLOGY, V13, P725, DOI 10.1097/01.EDE.0000030722.16351.91; Nieuwenhuijsen MJ, 2000, OCCUP ENVIRON MED, V57, P73, DOI 10.1136/oem.57.2.73; Nishijo M, 2004, ARCH ENVIRON HEALTH, V59, P22, DOI 10.3200/AEOH.59.1.22-25; Nishijo M, 2002, OCCUP ENVIRON MED, V59, P394, DOI 10.1136/oem.59.6.394; Noonan CW, 2002, ENVIRON HEALTH PERSP, V110, P151; Nordlinder R, 1997, INT ARCH OCC ENV HEA, V70, P57, DOI 10.1007/s004200050186; NURMINEN T, 1995, EPIDEMIOLOGY, V6, P23, DOI 10.1097/00001648-199501000-00006; O'Sullivan BCY, 2005, AM J EMERG MED, V23, P463, DOI 10.1016/j.ajem.2004.12.017; Odland Jon Oyvind, 2004, Int J Circumpolar Health, V63, P169; Oken E, 2005, ENVIRON HEALTH PERSP, V113, P1376, DOI 10.1289/ehp.8041; OLSEN J, 1990, SCAND J WORK ENV HEA, V16, P163; Olshan AF, 1999, CANCER CAUSE CONTROL, V10, P539, DOI 10.1023/A:1008998925889; Olshan Andrew F, 2003, Adv Exp Med Biol, V518, P147; Orr M, 2002, INT J HYG ENVIR HEAL, V205, P19, DOI 10.1078/1438-4639-00126; Osman K, 1999, ENVIRON RES, V80, P1, DOI 10.1006/enrs.1998.3886; Osman K, 2000, CLIN BIOCHEM, V33, P131, DOI 10.1016/S0009-9120(00)00052-7; OTTO DA, 1993, NEUROTOXICOLOGY, V14, P191; Pahwa P, 2003, J OCCUP ENVIRON MED, V45, P857, DOI 10.1097/01.jom.0000083033.56116.c1; Pang D, 2003, BRIT J CANCER, V88, P373, DOI 10.1038/sj.bjc.6600774; Pastore LM, 1997, OCCUP ENVIRON MED, V54, P511; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; Patandin S, 1998, PEDIATR RES, V44, P538, DOI 10.1203/00006450-199810000-00012; Pearce MS, 2000, PEDIATR HEMAT ONCOL, V17, P223, DOI 10.1080/088800100276398; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P626, DOI 10.1289/ehp.6617; Perera FP, 2002, ENVIRON HEALTH PERSP, V110, P197; Perera FP, 2006, ENVIRON HEALTH PERSP, V114, P1287, DOI 10.1289/ehp.9084; PESATORI AC, 1993, INT J EPIDEMIOL, V22, P1010, DOI 10.1093/ije/22.6.1010; Petrelli G, 2001, EUR J EPIDEMIOL, V17, P675, DOI 10.1023/A:1015511625099; Petrelli G, 2000, EUR J EPIDEMIOL, V16, P391, DOI 10.1023/A:1007630610911; Petrelli Grazia, 2003, Environ Health Prev Med, V8, P77, DOI 10.1007/BF02897919; Petridou E, 2000, EPIDEMIOLOGY, V11, P230, DOI 10.1097/00001648-200003000-00027; Pichini S, 2003, J EXPO ANAL ENV EPID, V13, P144, DOI 10.1038/sj.jea.7500264; Pierik FH, 2004, ENVIRON HEALTH PERSP, V112, P1570, DOI 10.1289/ehp.7234; Pinkerton KE, 2000, ENVIRON HEALTH PERSP, V108, P457, DOI 10.2307/3454537; Pirkle JL, 2006, ENVIRON HEALTH PERSP, V114, P853, DOI 10.1289/ehp.8850; Plenge-Bonig A, 1999, OCCUP ENVIRON MED, V56, P443; POCOCK SJ, 1994, BRIT MED J, V309, P1189; Pogoda JM, 1997, ENVIRON HEALTH PERSP, V105, P1214, DOI 10.1289/ehp.971051214; Raaschou-Nielsen O, 2006, INT J CANCER, V118, P2920, DOI 10.1002/ijc.21787; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Rais-Bahrami K, 2004, ENVIRON HEALTH PERSP, V112, P1339, DOI 10.1289/ehp.6901; Regidor E, 2004, OCCUP ENVIRON MED, V61, P334, DOI 10.1136/oem.2003.009043; RESTREPO M, 1990, SCAND J WORK ENV HEA, V16, P239; RESTREPO M, 1990, SCAND J WORK ENV HEA, V16, P232; Reynolds P, 2004, EPIDEMIOLOGY, V15, P6, DOI 10.1097/01.ede.0000101749.28283.de; Reynolds P, 2003, ENVIRON HEALTH PERSP, V111, P663, DOI 10.1289/ehp.5986; Reynolds P, 2002, ENVIRON HEALTH PERSP, V110, P319; Reynolds P, 2005, EPIDEMIOLOGY, V16, P93, DOI 10.1097/01.ede.0000147119.32704.5c; Reynolds P, 2005, SCAND J WORK ENV HEA, V31, P46; Reynolds P, 2002, CANCER CAUSE CONTROL, V13, P665, DOI 10.1023/A:1019579430978; Ribas-Fito N, 2003, PEDIATRICS, V111, pE580, DOI 10.1542/peds.111.5.e580; Ribas-Fito N, 2001, J EPIDEMIOL COMMUN H, V55, P537, DOI 10.1136/jech.55.8.537; Ribas-Fito N, 2002, PEDIATR RES, V52, DOI 10.1023/01.PDR.0000023171.89966.8B; Ris MD, 2004, J INT NEUROPSYCH SOC, V10, P261, DOI 10.1017/S1355617704102154; RITTER WF, 1990, J ENVIRON SCI HEAL B, V25, P1, DOI 10.1080/03601239009372674; Ritz B, 2002, AM J EPIDEMIOL, V155, P17, DOI 10.1093/aje/155.1.17; ROAN CC, 1984, ARCH ENVIRON HEALTH, V39, P56; Robin LF, 1996, PEDIATR INFECT DIS J, V15, P859, DOI 10.1097/00006454-199610000-00006; Rodvall Y, 2003, OCCUP ENVIRON MED, V60, P798, DOI 10.1136/oem.60.10.798; Rogan W J, 1991, Ann Epidemiol, V1, P407; ROGAN WJ, 1987, AM J PUBLIC HEALTH, V77, P1294, DOI 10.2105/AJPH.77.10.1294; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3; Romieu I, 2002, J OCCUP ENVIRON MED, V44, P640, DOI 10.1097/01.jom.0000023383.41727.32; Rothenberg SJ, 2000, NEUROTOXICOL TERATOL, V22, P503, DOI 10.1016/S0892-0362(00)00079-9; ROTHENBERG SJ, 1994, NEUROTOXICOLOGY, V15, P695; Rothenberg SJ, 2005, ENVIRON HEALTH PERSP, V113, P1190, DOI 10.1289/ehp.7691; Rowland AS, 1996, EPIDEMIOLOGY, V7, P363, DOI 10.1097/00001648-199607000-00005; Ruckart PZ, 2004, ENVIRON HEALTH PERSP, V112, P46, DOI 10.1289/ehp.6430; Rull RP, 2006, AM J EPIDEMIOL, V163, P743, DOI 10.1093/aje/kwj101; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; RUPA DS, 1991, ENVIRON RES, V55, P123, DOI 10.1016/S0013-9351(05)80168-9; Rylander L, 2000, CHEMOSPHERE, V40, P1255, DOI 10.1016/S0045-6535(99)00377-X; Rylander L, 1998, AM J EPIDEMIOL, V147, P493; Rylander L, 2007, CHEMOSPHERE, V67, P498, DOI 10.1016/j.chemosphere.2006.09.089; Sagiv SK, 2005, ENVIRON HEALTH PERSP, V113, P602, DOI 10.1289/ehp.7646; Saint-Amour D, 2006, NEUROTOXICOLOGY, V27, P567, DOI 10.1016/j.neuro.2006.02.008; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Salameh PR, 2003, EUR RESPIR J, V22, P507, DOI 10.1183/09031936.03.00107403; Salazar-Garcia F, 2004, ENVIRON HEALTH PERSP, V112, P542, DOI 10.1289/ehp.6759; Sallmen M, 2006, OCCUP ENVIRON MED, V63, P469, DOI 10.1136/oem.2005.021337; Sallmen M, 2003, SCAND J WORK ENV HEA, V29, P85; Sallmen M, 1998, OCCUP ENVIRON MED, V55, P24; Salpietro CD, 2002, J PERINAT MED, V30, P395, DOI 10.1515/JPM.2002.061; SAVITZ DA, 1989, AM J EPIDEMIOL, V129, P1201; Savitz DA, 1997, AM J EPIDEMIOL, V146, P1025; Savitz DA, 1997, ANN EPIDEMIOL, V7, P509, DOI 10.1016/S1047-2797(97)00078-1; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360; SAVITZ DA, 1989, PUBLIC HEALTH REP, V104, P473; Schantz SL, 2003, ENVIRON HEALTH PERSP, V111, P357, DOI 10.1289/ehp.5461; Schantz SL, 1996, NEUROTOXICOL TERATOL, V18, P217, DOI 10.1016/S0892-0362(96)90001-X; SCHEELE J, 1992, EUR J PEDIATR, V151, P802, DOI 10.1007/BF01957928; SCHENKER MB, 1995, AM J IND MED, V28, P639; Schnaas L, 2006, ENVIRON HEALTH PERSP, V114, P791, DOI 10.1289/ehp.8552; Schnaas L, 2000, NEUROTOXICOL TERATOL, V22, P805, DOI 10.1016/S0892-0362(00)00101-X; Schneider D, 2004, ARCH ENVIRON HEALTH, V59, P4, DOI 10.3200/AEOH.59.1.4-13; Schnorr TM, 2001, ENVIRON HEALTH PERSP, V109, P1127, DOI 10.2307/3454859; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Schreinemachers DM, 2003, ENVIRON HEALTH PERSP, V111, P1259, DOI 10.1289/ehp.5830; Schuz J, 2000, CANCER EPIDEM BIOMAR, V9, P835; Schuz J, 2001, MED PEDIATR ONCOL, V36, P274, DOI 10.1002/1096-911X(20010201)36:2<274::AID-MPO1065>3.0.CO;2-D; Schuz J, 2001, EUR J PEDIATR, V160, P333, DOI 10.1007/PL00008443; SCHWARTZ DA, 1988, AM J PUBLIC HEALTH, V78, P654, DOI 10.2105/AJPH.78.6.654; SCHWARTZ J, 1991, ARCH ENVIRON HEALTH, V46, P300; Schwartz J, 2004, PEDIATRICS, V113, P1037; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; SCHWARTZ J, 1987, ARCH ENVIRON HEALTH, V42, P153; SCHWARTZ J, 1994, ENVIRON RES, V65, P42, DOI 10.1006/enrs.1994.1020; SCHWARTZ J, 1993, NEUROTOXICOLOGY, V14, P237; Seidler A, 1999, AM J IND MED, V36, P213, DOI 10.1002/(SICI)1097-0274(199907)36:1<213::AID-AJIM30>3.0.CO;2-A; Selevan SG, 2003, NEW ENGL J MED, V348, P1527, DOI 10.1056/NEJMoa020880; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; Sever LE, 1997, OCCUP MED, V12, P305; Shapiro GG, 2002, PEDIATR PULM, V33, P47, DOI 10.1002/ppul.10029; SHARPE CR, 1995, AM J EPIDEMIOL, V141, P210; Shaw GM, 2003, AM J EPIDEMIOL, V157, P475, DOI 10.1093/aje/kwg013; Shaw GM, 2003, EPIDEMIOLOGY, V14, P191, DOI 10.1097/00001648-200303000-00013; Shaw GM, 1999, EPIDEMIOLOGY, V10, P60, DOI 10.1097/00001648-199901000-00011; Shen XM, 1998, ENVIRON RES, V79, P1, DOI 10.1006/enrs.1998.3851; Shi L, 2001, OCCUP MED-OXFORD, V51, P230, DOI 10.1093/occmed/51.4.230; Shiau CY, 2004, OCCUP ENVIRON MED, V61, P915, DOI 10.1136/oem.2004.014944; Shima M, 2003, J EPIDEMIOL, V13, P108; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; Shu XO, 1999, CANCER EPIDEM BIOMAR, V8, P783; Shu XO, 2004, CANCER EPIDEM BIOMAR, V13, P1230; SHU XO, 1988, CANCER, V62, P635, DOI 10.1002/1097-0142(19880801)62:3<635::AID-CNCR2820620332>3.0.CO;2-3; SHU XO, 1995, CANCER CAUSE CONTROL, V6, P187, DOI 10.1007/BF00051790; SHUKLA R, 1991, PEDIATRICS, V88, P886; SHUKLA R, 1989, PEDIATRICS, V84, P604; SILVA PA, 1988, J CHILD PSYCHOL PSYC, V29, P43, DOI 10.1111/j.1469-7610.1988.tb00687.x; SMALL CM, 2007, ENV RES; Smith AH, 2006, ENVIRON HEALTH PERSP, V114, P1293, DOI 10.1289/ehp.8832; Sonnenfeld N, 2001, AM J EPIDEMIOL, V154, P902, DOI 10.1093/aje/154.10.902; SOSNIAK WA, 1994, ARCH ENVIRON HEALTH, V49, P251; Spinelli A, 1997, INT J EPIDEMIOL, V26, P601; Staessen JA, 2001, LANCET, V357, P1660, DOI 10.1016/S0140-6736(00)04822-4; Steffen C, 2004, OCCUP ENVIRON MED, V61, P773, DOI 10.1136/oem.2003.010868; Steliarova-Foucher E, 2004, LANCET, V364, P2097, DOI 10.1016/S0140-6736(04)17550-8; Steuerwald U, 2000, J PEDIATR-US, V136, P599, DOI 10.1067/mpd.2000.102774; Stewart P, 2000, NEUROTOXICOL TERATOL, V22, P21, DOI 10.1016/S0892-0362(99)00056-2; Stewart PW, 2003, NEUROTOXICOL TERATOL, V25, P11, DOI 10.1016/S0892-0362(02)00320-3; Steyn K, 2006, PAEDIATR PERINAT EP, V20, P90, DOI 10.1111/j.1365-3016.2006.00707.x; STILES KM, 1993, NEUROTOXICOL TERATOL, V15, P27, DOI 10.1016/0892-0362(93)90042-M; STOCKBAUER JW, 1988, AM J EPIDEMIOL, V128, P410; Stokes L, 1998, OCCUP ENVIRON MED, V55, P507; Storgaard L, 2006, REPROD TOXICOL, V21, P4, DOI 10.1016/j.reprotox.2005.05.006; Strachan DP, 1998, THORAX, V53, P50; Strachan DP, 1998, THORAX, V53, P204; Suarez L, 2005, INT J OCCUP ENV HEAL, V11, P233; Sugiura-Ogasawara M, 2003, AM J REPROD IMMUNOL, V50, P485, DOI 10.1046/j.8755-8920.2003.00106.x; Sugiura-Ogasawara M, 2005, HUM REPROD, V20, P2325, DOI 10.1093/humrep/deh888; Suh HH, 2000, ENVIRON HEALTH PERSP, V108, P625, DOI 10.2307/3454398; Sunyer J, 2005, ENVIRON HEALTH PERSP, V113, P1787, DOI 10.1289/ehp.8127; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; SWAN SH, 1995, AM J IND MED, V28, P751; Sweeney MH, 2000, FOOD ADDIT CONTAM, V17, P303, DOI 10.1080/026520300283379; TAHA TE, 1993, B WORLD HEALTH ORGAN, V71, P317; Tajimi M, 2005, CHEMOSPHERE, V61, P383, DOI 10.1016/j.chemosphere.2005.02.085; Takser L, 2003, NEUROTOXICOLOGY, V24, P667, DOI 10.1016/S0161-813X(03)00058-5; Tango T, 2004, J EPIDEMIOL, V14, P83, DOI 10.2188/jea.14.83; TASKINEN H, 1989, SCAND J WORK ENV HEA, V15, P345; TASKINEN H, 1994, J OCCUP ENVIRON MED, V36, P311, DOI 10.1097/00043764-199403000-00008; Taskinen HK, 1999, AM J IND MED, V36, P206, DOI 10.1002/(SICI)1097-0274(199907)36:1<206::AID-AJIM29>3.0.CO;2-D; Taub JW, 2004, LEUKEMIA LYMPHOMA, V45, P19, DOI 10.1080/1042819031000149403; TAYLOR PR, 1989, AM J EPIDEMIOL, V129, P395; Tellez-Rojo M. M., 2006, PEDIATRICS, V118, P323, DOI DOI 10.1542/PEDS.2005-3123; THACKER SB, 1992, ARCH ENVIRON HEALTH, V47, P336; THATCHER RW, 1982, ARCH ENVIRON HEALTH, V37, P159; THOMAS DC, 1992, EPIDEMIOLOGY, V3, P32, DOI 10.1097/00001648-199201000-00007; Thonneau P, 1999, AM J EPIDEMIOL, V150, P157; Thorpe N, 2005, J ENVIRON SCI HEAL C, V23, P261, DOI 10.1080/10590500500235001; TIKKANEN J, 1992, EUR J EPIDEMIOL, V8, P48; TIKKANEN J, 1991, TERATOLOGY, V43, P591, DOI 10.1002/tera.1420430614; TIKKANEN J, 1992, INT ARCH OCC ENV HEA, V64, P59, DOI 10.1007/BF00625952; Tilson HA, 1997, NEUROTOXICOLOGY, V18, P727; Toft G, 2004, REPROD TOXICOL, V19, P5, DOI 10.1016/j.reprotox.2004.05.006; Toledano MB, 2005, ENVIRON HEALTH PERSP, V113, P225, DOI 10.1289/ehp.7111; Tong S, 1998, JAMA-J AM MED ASSOC, V280, P1915, DOI 10.1001/jama.280.22.1915; Tong SL, 2004, PAEDIATR PERINAT EP, V18, P327, DOI 10.1111/j.1365-3016.2004.00565.x; Tong SL, 1996, BRIT MED J, V312, P1569; TORCHIO P, 1994, SCI TOTAL ENVIRON, V149, P183, DOI 10.1016/0048-9697(94)90178-3; Torres-Arreola L, 2003, ANN EPIDEMIOL, V13, P158, DOI 10.1016/S1047-2797(02)00424-6; Torres-Sanchez LE, 1999, ENVIRON RES, V81, P297, DOI 10.1006/enrs.1999.3984; Tryphonas H, 1998, CAN J PUBLIC HEALTH, V89, pS49; Tsai J, 2006, INT J HYG ENVIR HEAL, V209, P57, DOI 10.1016/j.ijheh.2005.09.003; Tsai SS, 2004, ARCH ENVIRON HEALTH, V59, P478; Tsai SS, 2003, J TOXICOL ENV HEAL A, V66, P987, DOI 10.1080/15287390390212783; TYSHENKO M, 2006, J TOXICOL ENV HEAL B, V10, P143; UDINA MJC, 2004, AN PEDIATR, V60, P133; Valery PC, 2002, CANCER CAUSE CONTROL, V13, P263, DOI 10.1023/A:1015036109130; van Wijngaarden E, 2003, AM J EPIDEMIOL, V157, P989, DOI 10.1093/aje/kwg082; van Wijngaarden E, 2006, NEUROTOXICOLOGY, V27, P702, DOI 10.1016/j.neuro.2006.05.016; VANSTEENSELMOLL HA, 1985, AM J EPIDEMIOL, V121, P216; Vartiainen T, 1998, ENVIRON HEALTH PERSP, V106, P61, DOI 10.1289/ehp.9810661; Vasiliu O, 2004, HUM REPROD, V19, P1506, DOI 10.1093/humrep/deh292; Venners SA, 2005, AM J EPIDEMIOL, V162, P709, DOI 10.1093/aje/kwi275; Verberk MM, 1996, ARCH ENVIRON HEALTH, V51, P83; Villeneuve PJ, 2004, CAN J PUBLIC HEALTH, V95, P32; Vinceti M, 2001, SCI TOTAL ENVIRON, V278, P23, DOI 10.1016/S0048-9697(00)00885-8; VINEIS P, 1987, SCAND J WORK ENV HEA, V13, P9; VIVOLI G, 1993, J EXPO ANAL ENV EPID, V3, P201; Vreugdenhil HJI, 2004, DEV MED CHILD NEUROL, V46, P398, DOI 10.1017/S0012162204000647; Vreugdenhil HJI, 2004, NEUROPSYCHOLOGY, V18, P185, DOI 10.1037/0894-4105.18.1.185; Vreugdenhil HJI, 2002, J PEDIATR-US, V140, P48, DOI 10.1067/mpd.2002.119625; Vrijheid M, 2003, OCCUP ENVIRON MED, V60, P543, DOI 10.1136/oem.60.8.543; Vrijheid M, 2002, LANCET, V359, P320, DOI 10.1016/S0140-6736(02)07531-1; Vrijheid M, 2002, OCCUP ENVIRON MED, V59, P768, DOI 10.1136/oem.59.11.768; Vrijheid M, 2000, ENVIRON HEALTH PERSP, V108, P101, DOI 10.2307/3454635; Walkowiak J, 2001, LANCET, V358, P1602, DOI 10.1016/S0140-6736(01)06654-5; Walkowiak J, 1998, NEUROTOXICOL TERATOL, V20, P511, DOI 10.1016/S0892-0362(98)00010-5; Wang SL, 2003, ENVIRON RES, V93, P131, DOI 10.1016/S0013-9351(03)00040-9; Wang XB, 2003, FERTIL STERIL, V79, P577, DOI 10.1016/S0015-0282(02)04694-0; WASSERMAN G, 1992, J PEDIATR-US, V121, P695, DOI 10.1016/S0022-3476(05)81895-5; Wasserman GA, 2000, J PEDIATR-US, V137, P555, DOI 10.1067/mpd.2000.109111; Wasserman GA, 1997, ENVIRON HEALTH PERSP, V105, P956; Wasserman GA, 2000, NEUROTOXICOL TERATOL, V22, P811, DOI 10.1016/S0892-0362(00)00106-9; Wasserman GA, 1998, AM J PUBLIC HEALTH, V88, P481, DOI 10.2105/AJPH.88.3.481; WASSERMAN GA, 2003, NEUROPSYCHOL DEV COG, V9, P22; Weidner IS, 1998, ENVIRON HEALTH PERSP, V106, P793, DOI 10.1289/ehp.98106793; Weihe Pal, 2002, Int J Circumpolar Health, V61, P41; Weisglas-Kuperus N, 2000, ENVIRON HEALTH PERSP, V108, P1203, DOI 10.2307/3434834; Weisglas-Kuperus N, 2004, TOXICOL LETT, V149, P281, DOI 10.1016/j.toxlet.2003.12.039; Weisskopf MG, 2005, ENVIRON RES, V97, P149, DOI 10.1016/j.envres.2004.01.014; Wennborg H, 2001, OCCUP ENVIRON MED, V58, P225, DOI 10.1136/oem.58.4.225; Wennborg H, 2000, J OCCUP ENVIRON MED, V42, P438, DOI 10.1097/00043764-200004000-00022; WESELAK M, 2006, J TOXICOL ENV HEAL B, V10, P41; Weselak M, 2007, ENVIRON RES, V103, P79, DOI 10.1016/j.envres.2006.09.001; Whyatt RM, 2004, ENVIRON HEALTH PERSP, V112, P1125, DOI 10.1289/ehp.6641; WIGG NR, 1988, J EPIDEMIOL COMMUN H, V42, P213, DOI 10.1136/jech.42.3.213; Wigle DT, 2003, CHILD HLTH ENV; WIGLE DT, 2008, CHILD HLTH ENV S; Wigle DT, 2006, J TOXICOL ENV HEAL B, V10, P3; WIKLUND K, 1988, J OCCUP ENVIRON MED, V30, P801, DOI 10.1097/00043764-198810000-00010; Wilhelm M, 2005, ENVIRON HEALTH PERSP, V113, P1212, DOI 10.1289/ehp.7751; Wilhelm M, 2003, ENVIRON HEALTH PERSP, V111, P207, DOI 10.1289/ehp.5688; WILKINS JR, 1988, AM J IND MED, V14, P299; WILKINS JR, 1990, AM J EPIDEMIOL, V132, P275; WILLIS WO, 1993, J OCCUP ENVIRON MED, V35, P943, DOI 10.1097/00043764-199309000-00019; Windham GC, 2000, EPIDEMIOLOGY, V11, P427, DOI 10.1097/00001648-200007000-00011; WINDHAM GC, 1991, AM J IND MED, V20, P241, DOI 10.1002/ajim.4700200210; WINNEKE G, 1983, INT ARCH OCC ENV HEA, V51, P231, DOI 10.1007/BF00377755; WINNEKE G, 1990, NEUROTOXICOL TERATOL, V12, P553, DOI 10.1016/0892-0362(90)90022-5; WINNEKE G, 1994, NEUROTOXICOLOGY, V15, P705; Winneke Gerhard, 1998, Toxicology Letters (Shannon), V102-103, P423, DOI 10.1016/S0378-4274(98)00334-8; WOLFE WH, 1995, EPIDEMIOLOGY, V6, P17, DOI 10.1097/00001648-199501000-00005; Wollins DS, 2001, TERATOLOGY, V64, P229, DOI 10.1002/tera.1069; WOOD A, 2007, COMPENDIUM PESTICIDE; Woodruff TJ, 2006, ENVIRON HEALTH PERSP, V114, P786, DOI 10.1289/ehp.8484; Wright JM, 2004, ENVIRON HEALTH PERSP, V112, P920, DOI 10.1289/ehp.6779; Wright JM, 2002, ENVIRON HEALTH PERSP, V110, P157; Wu TJ, 2003, ENVIRON HEALTH PERSP, V111, P737, DOI 10.1289/ehp.6008; Wu XC, 2005, CANCER CAUSE CONTROL, V16, P309, DOI 10.1007/s10552-004-4026-0; WULFF M, 1995, SCAND J WORK ENV HEA, V21, P277; Wulff M, 1999, J OCCUP ENVIRON MED, V41, P678, DOI 10.1097/00043764-199908000-00010; Wulff M, 1996, PAEDIATR PERINAT EP, V10, P22, DOI 10.1111/j.1365-3016.1996.tb00022.x; Wulff M, 2002, AM J IND MED, V41, P131, DOI 10.1002/ajim.10036; Yanez L, 2003, ENVIRON RES, V93, P231, DOI 10.1016/j.envres.2003.07.005; Yang CY, 2000, ENVIRON HEALTH PERSP, V108, P765, DOI 10.1289/ehp.00108765; Yang CY, 2004, TOXICOLOGY, V198, P249, DOI 10.1016/j.tox.2004.01.032; Yang CY, 2003, ARCH ENVIRON HEALTH, V58, P649, DOI 10.3200/AEOH.58.10.649-654; Yang CY, 2003, J TOXICOL ENV HEAL A, V66, P807, DOI 10.1080/15287390390156236; Yang CY, 2003, ENVIRON RES, V92, P64, DOI 10.1016/S0013-9351(02)00055-5; Yang CY, 2002, ARCH ENVIRON HEALTH, V57, P461; Yang CY, 2003, ENVIRON RES, V91, P29, DOI 10.1016/S0013-9351(02)00015-4; Yolton K, 2005, ENVIRON HEALTH PERSP, V113, P98; Young JG, 2005, NEUROTOXICOLOGY, V26, P199, DOI 10.1016/j.neuro.2004.10.004; Yu CL, 2006, AM J EPIDEMIOL, V164, P200, DOI 10.1093/aje/kwj182; Yu ML, 2000, INT J EPIDEMIOL, V29, P672, DOI 10.1093/ije/29.4.672; Yu ML, 1998, CHEMOSPHERE, V37, P1855, DOI 10.1016/S0045-6535(98)00251-3; Zahm SH, 1998, ENVIRON HEALTH PERSP, V106, P893, DOI 10.2307/3434207; ZAHM SH, 1988, SCAND J WORK ENV HEA, V14, P224; ZHANG J, 1992, American Journal of Industrial Medicine, V21, P397, DOI 10.1002/ajim.4700210312; Zhang YL, 2004, J ENVIRON SCI HEAL A, V39, P2507, DOI 10.1081/lesa-200026331; Zhu JL, 2006, J OCCUP ENVIRON MED, V48, P347, DOI 10.1097/01.jom.0000201566.42186.5f; ZIERLER S, 1988, INT J EPIDEMIOL, V17, P589, DOI 10.1093/ije/17.3.589; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18; Zou CC, 2003, CHINESE MED J-PEKING, V116, P565	851	188	196	6	96	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1093-7404	1521-6950		J TOXICOL ENV HEAL B	J. Toxicol. Env. Health-Pt b-Crit. Rev.		2008	11	5-6					373	517		10.1080/10937400801921320		145	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	319EK	WOS:000257146700001	18470797	
J	Dragonieri, S; Schot, R; Mertens, BJA; Le Cessie, S; Gauw, SA; Spanevello, A; Resta, O; Willard, NP; Vink, TJ; Rabe, KF; Bel, EH; Sterk, PJ				Dragonieri, Silvano; Schot, Robert; Mertens, Bart J. A.; Le Cessie, Saskia; Gauw, Stefanie A.; Spanevello, Antonio; Resta, Onofrio; Willard, Nico P.; Vink, Teunis J.; Rabe, Klaus F.; Bel, Elisabeth H.; Sterk, Peter J.			An electronic nose in the discrimination of patients with asthma and controls	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma mild; asthma severe; biomarkers; diagnosis; electronic nose; exhaled breath; volatile organic compounds	VOLATILE ORGANIC-COMPOUNDS; COMPOSITE VAPOR DETECTORS; LUNG-CANCER; EXHALED BREATH; CLINICAL-APPLICATION; PULMONARY-DISEASE; MARKERS; TECHNOLOGY; PNEUMONIA; DIAGNOSIS	Background: Exhaled breath contains thousands of volatile organic compounds (VOCs) that could serve as biomarkers of lung disease. Electronic noses can distinguish VOC mixtures by pattern recognition. Objective: We hypothesized that an electronic nose can discriminate exhaled air of patients with asthma from healthy controls, and between patients with different disease severities. Methods: Ten young patients with mild asthma (25.1 +/- 5.9 years; FEV1, 99.9 +/- 7.7% predicted), 10 young controls (26.8 +/- 6.4 years; FEV1, 101.9 +/- 10.3), 10 older patients with severe asthma (49.5 +/- 12.0 years; FEV1, 62.3 +/- 23.6), and 10 older controls (57.3 +/- 7.1 years; FEV1, 108.3 +/- 14.7) joined a cross-sectional study with duplicate sampling of exhaled breath with an interval of 2 to 5 minutes. Subjects inspired VOC-filtered air by tidal breathing for 5 minutes, and a single expiratory vital capacity was collected into a Tedlar bag that was sampled by electronic nose (Cyranose 320) within 10 minutes. Smellprints were analyzed by linear discriminant analysis on principal component reduction. Cross-validation values (CVVs) were calculated. Results: Smellprints of patients with mild asthma were fully separated from young controls (CVV, 100%; Mahalanobis distance [M-distance], 5.32), and patients with severe asthma could be distinguished from old controls (CVV, 90%; M-distance, 2.77). Patients with mild and severe asthma could be less well discriminated (CVV, 65%; M-distance, 1.23), whereas the 2 control groups were indistinguishable (CVV, 50%; M-distance, 1.56). The duplicate samples replicated these results. Conclusion: An electronic nose can discriminate exhaled breath of patients with asthma from controls but is less accurate in distinguishing asthma severities. Clinical implication: These findings warrant validation of electronic noses in diagnosing newly presented patients with asthma.	Univ Amsterdam, Acad Med Ctr, Dept Resp Dis, NL-1100 DE Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Pulmonol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Med Stat, NL-2300 RA Leiden, Netherlands; Univ Bari, Dept Resp Dis, I-70121 Bari, Italy; Philips Res, Eindhoven, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Resp Dis, NL-1012 WX Amsterdam, Netherlands	Sterk, PJ (reprint author), Univ Amsterdam, Acad Med Ctr, Dept Resp Dis, F5-259,POB 22700, NL-1100 DE Leiden, Netherlands.	p.j.sterk@amc.nl					American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; Bossuyt PM, 2003, ANN INTERN MED, V138, pW1, DOI DOI 10.7326/0003-4819-138-1-200301070-00010; BRIGHHTLING CE, 2006, CHEST, V129, P1444; Briglin SM, 2002, SENSOR ACTUAT B-CHEM, V82, P54, DOI 10.1016/S0925-4005(01)00991-1; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; Busse William W., 2003, Journal of Allergy and Clinical Immunology, V111, pS799, DOI 10.1067/mai.2003.158; Corradi M, 2004, EUR RESPIR J, V24, P1011, DOI 10.1183/09031936.04.00002404; Crameri R, 2005, ALLERGY, V60, P1227, DOI 10.1111/j.1398-9995.2005.00873.x; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; De Maesschalck R, 2000, CHEMOMETR INTELL LAB, V50, P1, DOI 10.1016/S0169-7439(99)00047-7; DRAGONIERI S, 2007, AM J RESP CRIT CARE, V175, pA330; Dutta Ritaban, 2002, Biomed Eng Online, V1, P4, DOI 10.1186/1475-925X-1-4; Fend R, 2006, J CLIN MICROBIOL, V44, P2039, DOI 10.1128/JCM.01591-05; GORDON SM, 1985, CLIN CHEM, V31, P1278; Hanson CW, 2005, ANESTHESIOLOGY, V102, P63, DOI 10.1097/00000542-200501000-00013; Hockstein NG, 2004, LARYNGOSCOPE, V114, P1701, DOI 10.1097/00005537-200410000-00005; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; Knottnerus JA, 2003, J CLIN EPIDEMIOL, V56, P1118, DOI 10.1016/S0895-4356(03)00206-3; Lai SY, 2002, LARYNGOSCOPE, V112, P975, DOI 10.1097/00005537-200206000-00007; Lewis NS, 2004, ACCOUNTS CHEM RES, V37, P663, DOI 10.1021/ar030120m; Lex C, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-63; Machado RF, 2005, AM J RESP CRIT CARE, V171, P1286, DOI 10.1164/rccm.200409-1184OC; Mertens BJA, 2006, J COMPUT BIOL, V13, P1591, DOI 10.1089/cmb.2006.13.1591; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moser B, 2005, RESP PHYSIOL NEUROBI, V145, P295, DOI 10.1016/j.resp.2004.02.002; Paredi P, 2000, AM J RESP CRIT CARE, V162, P369; PAULING L, 1971, P NATL ACAD SCI USA, V68, P2374, DOI 10.1073/pnas.68.10.2374; Phillips M, 1999, LANCET, V353, P1930, DOI 10.1016/S0140-6736(98)07552-7; Phillips M, 2003, CHEST, V123, P2115, DOI 10.1378/chest.123.6.2115; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Thaler ER, 2005, EXPERT REV MED DEVIC, V2, P559, DOI 10.1586/17434440.5.5.559; *WHO, 2006, GLOB IN ASTHM; WOLD S, 1987, CHEMOMETR INTELL LAB, V2, P37, DOI 10.1016/0169-7439(87)80084-9	35	188	191	2	44	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2007	120	4					856	862		10.1016/j.jaci.2007.05.043		7	Allergy; Immunology	Allergy; Immunology	220LH	WOS:000250157700020	17658592	
J	Krieger, JW; Takaro, TK; Song, L; Weaver, M				Krieger, JW; Takaro, TK; Song, L; Weaver, M			The Seattle-King County Healthy Homes Project: A randomized, controlled trial of a community health worker intervention to decrease exposure to indoor asthma triggers	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							LOW-INCOME CHILDREN; INNER-CITY CHILDREN; QUALITY-OF-LIFE; URBAN CHILDREN; MITE ALLERGEN; COST; CARE; OUTREACH; PROGRAM; AVOIDANCE	Objectives. We assessed the effectiveness of a community health worker intervention focused on reducing exposure to indoor asthma triggers. Methods. We conducted a randomized controlled trial with 1-year follow-up among 274 low-income households containing a child aged 4-12 years who had asthma. Community health workers provided in-home environmental assessments, education, support for behavior change, and resources. Participants were assigned to either a high-intensity group receiving 7 visits and a full set of resources or a low-intensity group receiving a single visit and limited resources. Results. The high-intensity group improved significantly more than the low-intensity group in its pediatric asthma caregiver quality-of-life score (P=.005) and asthma-related urgent health services use (P=.026). Asthma symptom days declined more in the high-intensity group, although the across-group difference did not reach statistical significance (P=.138). Participant actions to reduce triggers generally increased in the high-intensity group. The projected 4-year net savings per participant among the high-intensity group relative to the low-intensity group were $189-$721. Conclusions. Community health workers reduced asthma symptom days and urgent health services use while improving caregiver quality-of-life score. Improvement was greater with a higher-intensity intervention.	Publ Hlth Seattle & King Cty, Seattle, WA 98104 USA; Univ Washington, Sch Med, Seattle, WA USA; Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA	Krieger, JW (reprint author), Publ Hlth Seattle & King Cty, 999 3rd Ave,Suite 1200, Seattle, WA 98104 USA.	james.krieger@metrokc.gov			NIEHS NIH HHS [5 R21 ES09095]; ODCDC CDC HHS [U48/CCU009654-07]		Baier C, 1999, CHEST, V116, p204S, DOI 10.1378/chest.116.suppl_2.204S; Balas EA, 1998, JAMA-J AM MED ASSOC, V279, P54, DOI 10.1001/jama.279.1.54; Baranowski T., 1997, HLTH BEHAV HLTH ED; BUTZ AM, 1994, CLIN PEDIATR, V33, P135, DOI 10.1177/000992289403300302; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; CLARK NM, 1986, J ALLERGY CLIN IMMUN, V78, P108, DOI 10.1016/0091-6749(86)90122-3; *COMM ENV HLTH, 1999, HDB PED ENV HLTH; Custovic A, 2001, CLIN EXP ALLERGY, V31, P670, DOI 10.1046/j.1365-2222.2001.01092.x; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439; Eggleston PA, 1998, IMMUNOL ALLERGY CLIN, V18, P75, DOI 10.1016/S0889-8561(05)70348-9; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS403, DOI 10.1067/mai.2001.113673; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Emanuel EJ, 2001, NEW ENGL J MED, V345, P915, DOI 10.1056/NEJM200109203451211; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Gotzsche PC, 2001, COCHRANE DB SYST REV, V3; Greineder DK, 1998, AM J MANAG CARE, V4, P196; GUEVARA JP, 2003, BRIT MED J, V326, P308; Guyatt GH, 1998, BRIT MED J, V316, P690; Hardin J. W., 2003, GENERALIZED ESTIMATI; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Krieger J, 1999, AM J PUBLIC HEALTH, V89, P856, DOI 10.2105/AJPH.89.6.856; Krieger J, 2002, ENVIRON HEALTH PERSP, V110, P311; Krieger J, 2002, HEALTH EDUC BEHAV, V29, P361, DOI 10.1177/109019810202900307; Krieger J, 2002, AM J PUBLIC HEALTH, V92, P758, DOI 10.2105/AJPH.92.5.758; Leung R, 1997, ENVIRON HEALTH PERSP, V105, P1132; LEWIS CE, 1984, PEDIATRICS, V74, P478; Love MB, 1997, HEALTH EDUC BEHAV, V24, P510, DOI 10.1177/109019819702400409; Lozano P, 1997, PEDIATRICS, V99, P757, DOI 10.1542/peds.99.6.757; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; National Asthma Education and Prevention Program, 1997, 2 NAT ASTHM ED PREV; *NAT I ENV HLTH SC, COMM BAS PART RES EN; NELSON H, 1995, PROVOCATIVE CHALLENG; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; Prochaska JO, 1997, HLTH BEHAV HLTH ED; Sarpong SB, 1997, ANN ALLERG ASTHMA IM, V79, P455; SCHNEIDER D, 2000, CHILDRENS ENV HLTH R; Stout JW, 1998, J ASTHMA, V35, P119, DOI 10.3109/02770909809055413; Stroupe KT, 1999, J ASTHMA, V36, P645, DOI 10.3109/02770909909055416; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Swider SM, 2002, PUBLIC HEALTH NURS, V19, P11, DOI 10.1046/j.1525-1446.2002.19003.x; TAKARO T, IN PRESS J EXPO ANAL; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; *US BUR LAB STAT, CONS PRIC IND URB CO; *US EPA, ASTHM ED OUTR PROGR; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; Wilson SR, 2001, CHEST, V120, P1709, DOI 10.1378/chest.120.5.1709; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; HLTH HOMES HLTH KIDS; HLTH HOUSE	52	188	192	4	33	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	APR	2005	95	4					652	659		10.2105/AJPH.2004.042994		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	911JP	WOS:000227998700025	15798126	
J	Khinchi, MS; Poulsen, LK; Carat, F; Andre, C; Hansen, AB; Malling, HJ				Khinchi, MS; Poulsen, LK; Carat, F; Andre, C; Hansen, AB; Malling, HJ			Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study	ALLERGY			English	Article						allergen-specific immunotherapy; clinical efficacy; controlled study; randomized; rhinitis; side-effects; subcutaneous; sublingual	HOUSE-DUST-MITE; STANDARDIZED 5-GRASS-POLLEN EXTRACT; PARIETARIA-JUDAICA EXTRACT; HEALTH SURVEY SF-36; GRASS-POLLEN; SWALLOW IMMUNOTHERAPY; CONTROLLED TRIAL; ORAL IMMUNOTHERAPY; HAY-FEVER; RHINITIS	Background: Both sublingual allergen-specific immunotherapy (SLIT) and subcutaneous immunotherapy (SCIT) have a documented clinical efficacy, but only few comparative studies have been performed. Objective: To investigate the clinical efficacy of SLIT vs SCIT and secondary to compare SLIT and SCIT with placebo and to evaluate the relative clinical efficacy in relation to systemic side-effects. Methods: A 3-year randomized, placebo-controlled, double-blind, double-dummy study including 71 adult birch pollen hay fever patients treated for two consecutive years after a baseline year. Allocation to treatment groups was based on disease severity in the baseline season, gender and age. Results: Clinical efficacy was estimated in 58 patients completing the first treatment year by subtracting baseline data and by calculating the ratio first treatment season vs baseline. SLIT diminished the median disease severity to one-half and SCIT to one-third of placebo treatment. No statistical significant difference between the two groups was observed. Both for symptoms and medication scores actively treated patients showed statistically significant and clinical relevant efficacy compared with placebo. SLIT treatment only resulted in local mild side-effects, while SCIT resulted in few serious systemic side-effects. Conclusion: Based on the limited number of patients the clinical efficacy of SLIT was not statistically different from SCIT, and both treatments are clinically effective compared with placebo in the treatment of birch pollen rhinoconjunctivitis. The lack of significant difference between the two treatments does not indicate equivalent efficacy, but to detect minor differences necessitates investigation of larger groups. Due to the advantageous safety profile SLIT may be favored.	Natl Univ Hosp, Allergy Clin, Copenhagen, Denmark; Stallergenes SA, Antony, France	Malling, HJ (reprint author), Natl Univ Hosp, Allergy Clin 4222, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.						Andri L, 1996, J ALLERGY CLIN IMMUN, V97, P34, DOI 10.1016/S0091-6749(96)70280-4; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Balda BR, 1998, ALLERGY, V53, P740; BJORKSTEN B, 1986, ALLERGY, V41, P290, DOI 10.1111/j.1398-9995.1986.tb02031.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; CAMPBELL MJ, 1995, BRIT MED J, V311, P1145; Cirla AM, 1996, ALLERGY, V51, P299, DOI 10.1111/j.1398-9995.1996.tb04613.x; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Frew AJ, 1999, J ALLERGY CLIN IMMUN, V104, P267, DOI 10.1016/S0091-6749(99)70362-3; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Malling HJ, 1998, ALLERGY, V53, P461; Malling HJ, 1993, ALLERGY          S14, V48, P7; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua G, 2001, BIODRUGS, V15, P509, DOI 10.2165/00063030-200115080-00003; Pedersen B. V., 1993, Aerobiologia, V9, P15, DOI 10.1007/BF02311366; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VARNEY VA, 1991, BRIT MED J, V302, P265; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x	54	188	202	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JAN	2004	59	1					45	53		10.1046/j.1398-9995.2003.00387.x		9	Allergy; Immunology	Allergy; Immunology	753QY	WOS:000187243100008	14674933	
J	Rundell, KW; Im, JH; Mayers, LB; Wilber, RL; Szmedra, L; Schmitz, HR				Rundell, KW; Im, JH; Mayers, LB; Wilber, RL; Szmedra, L; Schmitz, HR			Self-reported symptoms and exercise-induced asthma in the elite athlete	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						bronchospasm; cold weather; exercise-induced asthma; exercise; pulmonary function	CROSS-COUNTRY SKIERS; INDUCED BRONCHOSPASM; AIRWAY RESPONSIVENESS; FIGURE SKATERS; COLD-AIR; CHALLENGE; CHILDREN; RUNNERS; ADULTS	Purpose: The purpose of this study was to compare self-reported symptoms for exercise-induced asthma (EIA) to postexercise challenge pulmonary function test results in elite athletes. Methods: Elite athletes (N = 158; 83 men and 75 women; age: 22 +/- 4.4 yr) performed pre- and post-exercise spirometry and were grouped according to postexercise pulmonary function decrements (PFT-positive, PFT-borderline. and PFT-normal for EIA). Before the sport/environment specific exercise challenge, subjects completed an EIA symptoms-specific questionnaire. Results: Resting FEV1 values were above predicted values (114-121%) and not different between groups. Twenty-six percent of the study population demonstrated >10% postexercise drop in FEV1 and 29% reported two or more symptoms. However, the proportion of PFT-positive and PFT-normal athletes reporting two or more symptoms was nor different (39% vs. 41%). Postrace cough was the most reported symptom, reported significantly more frequently for PFT-positive athletes (P < 0.05). Sensitivity/specificity analysis demonstrated a lack of effectiveness of self-reported symptoms to identify PFT-positive or exclude PFT-normal athletes. Postexercise lower limit reference ranges (MN-2SDs) were determined from normal athletes for FEV1, FEF25-75% and PEF to be -7%, -12.5%, and -18%, respectively. Conclusion: Although questionnaires provide reasonable estimates of ELA prevalence among elite cold-weather athletes, the use of self-reported symptoms for EIA diagnosis in this population will likely yield high frequencies Of both false positive and false negative results. Diagnosis should include spirometry using an exercise/environment specific challenge in combination with the athlete's history of asthma symptoms.	US Olymp Comm Lake Placid, Sports Sci & Technol Div, Lake Placid, NY 12946 USA	Rundell, KW (reprint author), US Olymp Comm Lake Placid, Sports Sci & Technol Div, 421 Old Mil Rd, Lake Placid, NY 12946 USA.						American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; ANDERSON SD, 1971, THORAX, V26, P396, DOI 10.1136/thx.26.4.396; AVITAL A, 1995, THORAX, V50, P511, DOI 10.1136/thx.50.5.511; BAROR O, 1983, PHYSL PRINCIPLES CLI, P88; BECK KC, 1994, AM J RESP CRIT CARE, V149, P352; CHARPIN D, 1988, ALLERGY, V43, P481, DOI 10.1111/j.1398-9995.1988.tb01624.x; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; HABY MM, 1995, EUR RESPIR J, V8, P729; HABY MM, 1994, EUR RESPIR J, V7, P431; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P128; Heir T., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P134; Helenius IJ, 1996, THORAX, V51, P628, DOI 10.1136/thx.51.6.628; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; KNUDSON RJ, 1976, AM REV RESPIR DIS, V113, P587; Larsson L., 1994, Scandinavian Journal of Medicine and Science in Sports, V4, P124; MAHLER DA, 1993, MED SCI SPORT EXER, V25, P554; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; MORRIS JF, 1976, WESTERN J MED, V125, P110; Nystad W, 2000, MED SCI SPORT EXER, V32, P266, DOI 10.1097/00005768-200002000-00003; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; RUPP NT, 1992, AM J DIS CHILD, V146, P941; SEARS MR, 1991, ASTHMA ITS PATHOLOGY, V49, P1; SMITH L, 1999, LUNG BIOL HEALTH DIS, V130, P235; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Tan RA, 1998, SPORTS MED, V25, P1, DOI 10.2165/00007256-199825010-00001; Tikkanen H. O., 1999, Medicine and Science in Sports and Exercise, V31, pS99, DOI 10.1097/00005768-199905001-00335; VOY RO, 1986, MED SCI SPORT EXER, V18, P328, DOI 10.1249/00005768-198606000-00013; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WILBER RL, IN PRESS MED SCI SPO	32	188	193	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0195-9131			MED SCI SPORT EXER	Med. Sci. Sports Exerc.	FEB	2001	33	2					208	213				6	Sport Sciences	Sport Sciences	399PV	WOS:000166822300006	11224807	
J	Commins, SP; Satinover, SM; Hosen, J; Mozena, J; Borish, L; Lewis, BD; Woodfolk, JA; Platts-Mills, TAE				Commins, Scott P.; Satinover, Shama M.; Hosen, Jacob; Mozena, Jonathan; Borish, Larry; Lewis, Barrett D.; Woodfolk, Judith A.; Platts-Mills, Thomas A. E.			Delayed anaphylaxis, angioedema, or urticaria after consumption of red meat in patients with IgE antibodies specific for galactose-alpha-1,3-galactose	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Anaphylaxis; urticaria; food allergy; galactose-alpha-1,3-galactose; cross-reactive carbohydrate determinant	CROSS-REACTIVE IGE; ALPHA-GAL EPITOPE; CLINICAL-RELEVANCE; CARBOHYDRATE DETERMINANTS; LINKED OLIGOSACCHARIDES; IMMUNOGLOBULIN-E; FOOD ALLERGY; SOLID-PHASE; GLYCOPROTEINS; CETUXIMAB	Background: Carbohydrate moieties are frequently encountered in food and can elicit IgE responses, the clinical significance of which has been unclear. Recent work, however, has shown that IgE antibodies to galactose-alpha-1,3-galactose (alpha-gal), a carbohydrate commonly expressed on nonprimate mammalian proteins, are capable of eliciting serious, even fatal, reactions. Objective: We sought to determine whether IgE antibodies to alpha-gal are present in sera from patients who report anaphylaxis or urticaria after eating beef, pork, or lamb. Methods: Detailed histories were taken from patients presenting to the University of Virginia Allergy Clinic. Skin prick tests (SPTs), intradermal skin tests, and serum IgE antibody analysis were performed for common indoor, outdoor, and food allergens. Results: Twenty-four patients with IgE antibodies to alpha-gal were identified. These patients described a similar history of anaphylaxis or urticaria 3 to 6 hours after the ingestion of meat and reported fewer or no episodes when following an avoidance diet. SPTs to mammalian meat produced wheals of usually less than 4 mm, whereas intradermal or fresh-food SPTs provided larger and more consistent wheal responses. CAP-RAST testing revealed specific IgE antibodies to beef, pork, lamb, cow's milk, cat, and dog but not turkey, chicken, or fish. Absorption experiments indicated that this pattern of sensitivity was explained by an IgE antibody specific for alpha-gal. Conclusion: We report a novel and severe food allergy related to IgE antibodies to the carbohydrate epitope alpha-gal. These patients experience delayed symptoms of anaphylaxis, angioedema, or urticaria associated with eating beef, pork, or lamb. (J Allergy Clin Immunol 2009;123:426-33.)	[Platts-Mills, Thomas A. E.] Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; [Mozena, Jonathan] Allergy & Asthma Associates Fredericksburg, Fredericksburg, VA USA	Platts-Mills, TAE (reprint author), Univ Virginia Hlth Syst, Div Allergy, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu	Hosen, Jacob/F-9224-2013; Osborne, Nicholas/N-4915-2015	Hosen, Jacob/0000-0003-2559-0687; Osborne, Nicholas/0000-0002-6700-2284	National Institutes of Health [RO1 AI-20565]; American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline [T32 A1007496-14];  [AI-AADCRC-U19-070364]	Supported by National Institutes of Health grant RO1 AI-20565, by AI-AADCRC-U19-070364, and by an American Academy of Allergy, Asthma & Immunology/GlaxoSmithKline fellow career development award and T32 A1007496-14 to S.P.C.	AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Adedoyin J, 2007, J ALLERGY CLIN IMMUN, V119, P640, DOI 10.1016/j.jaci.2006.11.637; Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Cavalier E, 2006, ANN BIOL CLIN-PARIS, V64, P91; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; FIOCCHI A, 1995, J AM COLL NUTR, V14, P239; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Galili U, 2005, IMMUNOL CELL BIOL, V83, P674, DOI 10.1111/j.1440-1711.2005.01366.x; GALILI U, 1984, J EXP MED, V160, P1519, DOI 10.1084/jem.160.5.1519; KEMP SF, 1995, ARCH INTERN MED, V155, P1749, DOI 10.1001/archinte.155.16.1749; Kochuyt AM, 2005, CLIN EXP ALLERGY, V35, P441, DOI 10.1111/j.1365-2222.2005.00217.x; Macher BA, 2008, BBA-GEN SUBJECTS, V1780, P75, DOI 10.1016/j.bbagen.2007.11.003; Mamikoglu B, 2005, OTOLARYNG HEAD NECK, V133, P534, DOI 10.1016/j.otohns.2005.07.016; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812; OWERA R, 2008, J CLIN IMMUNOL S, V26; Paschinger K, 2005, ACTA BIOCHIM POL, V52, P629; PRENNER C, 1992, BIOCHEM J, V284, P377; Qian J, 2007, ANAL BIOCHEM, V364, P8, DOI 10.1016/j.ab.2007.01.023; Reefer AJ, 2007, J ALLERGY CLIN IMMUN, V120, P156, DOI 10.1016/j.jaci.2007.03.042; Sabbah A, 1994, Allerg Immunol (Paris), V26, P259; Sampson HA, 1996, J ALLERGY CLIN IMMUN, V98, P714, DOI 10.1016/S0091-6749(96)70111-2; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Simon PM, 1998, TRANSPLANTATION, V65, P346, DOI 10.1097/00007890-199802150-00009; SPIRO RG, 1984, J BIOL CHEM, V259, P9858; THALL A, 1990, BIOCHEMISTRY-US, V29, P3959, DOI 10.1021/bi00468a024; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; van Nunen SA, 2007, INTERN MED J, V37, pA132; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; VERDAGUER J, 1993, ALLERGY, V48, P542, DOI 10.1111/j.1398-9995.1993.tb01112.x; Werfel SJ, 1997, J ALLERGY CLIN IMMUN, V99, P293, DOI 10.1016/S0091-6749(97)70045-9; YOCUM MW, 1994, MAYO CLIN PROC, V69, P16	34	187	188	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					426	433		10.1016/j.jaci.2008.10.052		8	Allergy; Immunology	Allergy; Immunology	409GU	WOS:000263495000022	19070355	
J	Beasley, R; Clayton, T; Crane, J; von Mutius, E; Lai, CKW; Montefort, S; Stewart, A				Beasley, Richard; Clayton, Tadd; Crane, Julian; von Mutius, Erika; Lai, Christopher K. W.; Montefort, Stephen; Stewart, Alistair		ISAAC Phase Three Study Grp	Association between paracetamol use in infancy and childhood, and risk of asthma, rhinoconjunctivitis, and eczema in children aged 6-7 years: analysis from Phase Three of the ISAAC programme	LANCET			English	Article							WORLDWIDE VARIATIONS; ALLERGIC RHINOCONJUNCTIVITIS; ACETAMINOPHEN USE; LUNG-FUNCTION; EARLY-LIFE; DRUG-USE; PREVALENCE; SYMPTOMS; ASPIRIN; IBUPROFEN	Background Exposure to paracetamol during intrauterine life, childhood, and adult life may increase the risk of developing asthma. We studied 6-7-year-old children from Phase Three of the International Study of Asthma and Allergies in Childhood (ISAAC) programme to investigate the association between paracetamol consumption and asthma. Methods As part of Phase Three of ISAAC, parents or guardians of children aged 6-7 years completed written questionnaires about symptoms of asthma, rhinoconjunctivitis, and eczema, and several risk factors, including the use of paracetamol for fever in the child's first year of life and the frequency of paracetamol use in the past 12 months. The primary outcome variable was the odds ratio (OR) of asthma symptoms in these children associated with the use of paracetamol for fever in the first year of life, as calculated by logistic regression. Findings 205 487 children aged 6-7 years from 73 centres in 31. countries were included in the analysis. In the multivariate analyses, use of paracetamol for fever in the first year of life was associated with an increased risk of asthma symptoms when aged 6-7 years (OR 1.46 [95% Cl 1.36-1.56]). Current use of paracetamol was associated with a dose-dependent increased risk of asthma symptoms (1.61 [1.46-1.77] and 3.23 [2.9]-3.60] for medium and high use vs no use, respectively). Use of paracetamol was similarly associated with the risk of severe asthma symptoms, with population-attributable risks between 22% and 38%. Paracetamol use, both in the first year of life and in children aged 6-7 years, was also associated with an increased risk of symptoms of rhinoconjunctivitis and eczema. Interpretation Use of paracetamol in the first year of life and in later childhood, is associated with risk of asthma, rhinoconjunctivitis, and eczema at age 6 to 7 years. We suggest that exposure to paracetamol might be a risk factor for the development of asthma in childhood. Funding The BUPA Foundation, the Health Research Council of New Zealand, the Asthma and Respiratory Foundation of New Zealand, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, Glaxo Wellcome New Zealand, the New Zealand Lottery Board, Astra Zeneca New Zealand, and Glaxo Wellcome international Medical Affairs.	[Beasley, Richard] Med Res Inst New Zealand, Wellington 6143, New Zealand; [Clayton, Tadd] Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand; [Crane, Julian] Univ Otago, Dept Med, Wellington, New Zealand; [von Mutius, Erika] Univ Munich, Dr Von Haunerschen Kinderspital, D-80337 Munich, Germany; [Lai, Christopher K. W.] Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Peoples R China; [Montefort, Stephen] Univ Malta, Dept Med, Msida, Malta; [Stewart, Alistair] Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand	Beasley, R (reprint author), Med Res Inst New Zealand, POB 10055, Wellington 6143, New Zealand.	Richard.Beasley@mrinz.ac.nz	Clayton, Tadd/B-7914-2009; MARTINEZ-GIMENO, ANTONIO/A-9416-2010; Ellwood, Philippa/G-7555-2015	MARTINEZ-GIMENO, ANTONIO/0000-0003-4051-1860; Ellwood, Philippa/0000-0002-1994-4023; brunekreef, bert/0000-0001-9908-0060; Masjedi, Mohammadreza/0000-0003-4964-3851; Beasley, Richard/0000-0003-0337-406X	ISAAC International Data Centre (IIDC) is The BUPA Foundation	We thank the children and parents who participated in ISAAC Phase Three, and the school staff for their coordination and assistance. The authors also acknowledge and thank die many funding bodies throughout the world that supported the individual ISAAC centres, collaborators, and their meetings. Currently, the main source of funding for the ISAAC International Data Centre (IIDC) is The BUPA Foundation. Many funding bodies in New Zealand have contributed to support the IIDC during the periods of fieldwork arid data compilation: the Health Research Council of New Zealand, the Asthma arid Respiratory Foundation of New Zealand, the Child Health Research Foundation, the Hawke's Bay Medical Research Foundation, the Waikato Medical Research Foundation, GlaxoWellcome New Zealand, the New Zealand Lottery Board, and Astra Zeneca New Zealand. GlaxoWellcome International Medical Affairs supported the regional coordination for Phase Three and the IIDC.	AGYEPONG IA, 1994, ACTA TROP, V58, P317, DOI 10.1016/0001-706X(94)90025-6; Ajayi I O, 2006, Afr J Med Med Sci, V35, P85; Allmers H, 2005, J ALLERGY CLIN IMMUN, V116, P859, DOI 10.1016/j.jaci.2005.07.019; Anderson HR, 2008, INT J EPIDEMIOL, V37, P573, DOI 10.1093/ije/dyn039; ARROWSMITH JB, 1987, PEDIATRICS, V79, P858; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barr RG, 2004, AM J RESP CRIT CARE, V169, P836, DOI 10.1164/rccm.200304-596OC; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Benichou J, 2001, STAT METHODS MED RES, V10, P195, DOI 10.1191/096228001680195157; Benoni Giuseppina, 2005, Pediatr Med Chir, V27, P67; Bertolini A, 2006, CNS DRUG REV, V12, P250, DOI 10.1111/j.1527-3458.2006.00250.x; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Davey G, 2005, J ALLERGY CLIN IMMUN, V116, P863, DOI 10.1016/j.jaci.2005.05.045; Del-Rio-Navarro BE, 2007, J INVEST ALLERG CLIN, V17, P77; Dodge R, 1996, J ALLERGY CLIN IMMUN, V98, P48, DOI 10.1016/S0091-6749(96)70225-7; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ellwood P, 2005, INT J TUBERC LUNG D, V9, P10; Eneli I, 2005, CHEST, V127, P604, DOI 10.1378/chest.127.2.604; Fawole O I, 2001, West Afr J Med, V20, P152; GARCIAMARCOS L, 2008, INT ARCH ALLERGY IMM; Koniman R, 2007, PEDIATR ALLERGY IMMU, V18, P128, DOI 10.1111/j.1399-3038.2006.00484.x; Kuschnir FC, 2007, PEDIATR ALLERGY IMMU, V18, P142, DOI 10.1111/j.1399-3038.2006.00477.x; Lagerlov Per, 2004, Tidsskr Nor Laegeforen, V124, P1620; Lesko SM, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e20; Li SF, 2000, PEDIATR EMERG CARE, V16, P394, DOI 10.1097/00006565-200012000-00003; Maison P, 1998, EUR J CLIN PHARMACOL, V54, P659, DOI 10.1007/s002280050530; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 2002, ASTHMA: CRITICAL DEBATES, P3; McKeever TM, 2005, AM J RESP CRIT CARE, V171, P966, DOI 10.1164/rccm.200409-1269OC; Newson RB, 2000, EUR RESPIR J, V16, P817, DOI 10.1183/09031936.00.16581700; Nuttall SL, 2003, J CLIN PHARM THER, V28, P289, DOI 10.1046/j.1365-2710.2003.00493.x; Nuttall SL, 2003, J CLIN PHARM THER, V28, P251, DOI 10.1046/j.1365-2710.2003.00492.x; OLOUGHLIN EV, 1995, J PAEDIATR CHILD H, V31, P189, DOI 10.1111/j.1440-1754.1995.tb00783.x; Pandolfini C, 2005, EUR J PEDIATR, V164, P552, DOI 10.1007/s00431-005-1698-8; REBORDOSA C, 2007, AM J RESP CRIT CARE, V175, pA80; SETTIPANE GA, 1983, AM J MED, V74, P102, DOI 10.1016/0002-9343(83)90537-5; Shaheen SO, 2005, CLIN EXP ALLERGY, V35, P18, DOI 10.1111/j.1365-2222.2005.02151.x; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Taddio A, 2007, PEDIATRICS, V120, pE637, DOI 10.1542/peds.2006-3351; Taylor BJ, 1996, J PAEDIATR CHILD H, V32, P316, DOI 10.1111/j.1440-1754.1996.tb02561.x; Varner AE, 1998, ANN ALLERG ASTHMA IM, V81, P347; VEDANTHAN PK, 1977, J ALLERGY CLIN IMMUN, V60, P8, DOI 10.1016/0091-6749(77)90077-X; Vennemann MMT, 2005, ARCH DIS CHILD, V90, P520, DOI 10.1136/adc.2004.065581; Vlaski E, 2007, IRAN J ALLERGY ASTHM, V6, P143; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WILLIAMS LA, 1991, ASHP MIDY CLIN M, V26; Wong GWK, 2007, CLIN EXP ALLERGY, V37, P174, DOI 10.1111/j.1365-2222.2007.02649.x; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x	54	187	193	2	27	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 20	2008	372	9643					1039	1048		10.1016/S0140-6736(08)61445-2		10	Medicine, General & Internal	General & Internal Medicine	354OI	WOS:000259648500030	18805332	
J	Di Rienzo, V; Marcucci, F; Puccinelli, P; Parmiani, S; Frati, F; Sensi, L; Canonica, GW; Passalacqua, G				Di Rienzo, V; Marcucci, F; Puccinelli, P; Parmiani, S; Frati, F; Sensi, L; Canonica, GW; Passalacqua, G			Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; children; long-lasting effect; respiratory allergy; rhinitis; sublingual immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; CONTROLLED TRIAL; ALLERGOID IMMUNOTHERAPY; MESSENGER-RNA; FOLLOW-UP; PLACEBO; RHINITIS; SENSITIZATIONS	Background Subcutaneous immunotherapy for respiratory allergy has shown a long-lasting efficacy after its discontinuation, whereas this evidence is still lacking for sublingual immunotherapy, despite the fact that it is widely used. Objective We aimed to evaluate whether a long-lasting effect of SLIT occurs, in a prospective parallel group controlled study. Methods Sixty children (mean age 8.5 years) suffering from allergic asthma/rhinitis due to mites were subdivided into two matched groups: 35 underwent a 4- to 5-year course of SLIT with standardized extract and 25 received only drug therapy. The patients were evaluated at three time points (baseline, end of SLIT and 4 to 5 years after SLIT discontinuation) regarding presence of asthma, use of anti-asthma drugs, skin prick tests and specific IgE. Results We found that in the SLIT group there was a significant difference vs. baseline for the presence of asthma (P less than or equal to 0.001) and the use of asthma medications (P less than or equal to 0.01), whereas no difference was observed in the control group. The mean peak expiratory flow result was significantly higher in the active group than in the control group after 10 years. No change was seen as far as new sensitizations were concerned. Specific IgE showed a near-significant increase (baseline vs. 10 years, P = 0.06) only in the control group. Conclusion Our study demonstrates that sublingual immunotherapy is effective in children and that it maintains the clinical efficacy for 4 to 5 years after discontinuation.	Univ Genoa, DIMI, Padigl Maragliano, I-16132 Genoa, Italy; Clin Villa Benedetta, Rome, Italy; Univ Perugia, Pediat Clin, I-06100 Perugia, Italy; ALK Abello, Milan, Italy	Passalacqua, G (reprint author), Univ Genoa, DIMI, Padigl Maragliano, Largo R Benzi 10, I-16132 Genoa, Italy.						Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 1998, ALLERGY S52, V54, P20; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Frew AJ, 2001, J ALLERGY CLIN IMMUN, V107, P441, DOI 10.1067/mai.2001.113525; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; JOHNSTON.DE, 1968, AM J DIS CHILD, V115, P213; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lombardi C, 2001, ALLERGY, V56, P889; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; National Institutes of Health, 1997, NIH PUBL; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Silvestri M, 2002, J INVEST ALLERG CLIN, V12, P52; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633	31	187	196	0	7	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2003	33	2					206	210		10.1046/j.1365-2222.2003.01587.x		5	Allergy; Immunology	Allergy; Immunology	644PN	WOS:000180927400011	12580913	
J	Mostafalou, S; Abdollahi, M				Mostafalou, Sara; Abdollahi, Mohammad			Pesticides and human chronic diseases: Evidences, mechanisms, and perspectives	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Review						Pesticides; Systematic review; Chronic diseases; Cancer; Birth defects; Reproductive toxicity; Parkinson; Alzheimer; Amyotrophic lateral sclerosis; Diabetes; Asthma; Cardiovascular disease; Nephropathy; Genetic damage; Epigenetics; Endocrine disruption; Mitochondrial dysfunction; Oxidative stress; Endoplasmic reticulum stress; Proteotoxicity	NON-HODGKINS-LYMPHOMA; AMYOTROPHIC-LATERAL-SCLEROSIS; ENDOPLASMIC-RETICULUM STRESS; ENVIRONMENTAL RISK-FACTORS; SISTER-CHROMATID EXCHANGES; SOFT-TISSUE SARCOMA; EPIGENETIC TRANSGENERATIONAL ACTIONS; PARENTAL OCCUPATIONAL-EXPOSURE; PERSISTENT ORGANIC POLLUTANTS; INDUCED OXIDATIVE STRESS	Along with the wide use of pesticides in the world, the concerns over their health impacts are rapidly growing. There is a huge body of evidence on the relation between exposure to pesticides and elevated rate of chronic diseases such as different types of cancers, diabetes, neurodegenerative disorders like Parkinson, Alzheimer, and amyotrophic lateral sclerosis (ALS), birth defects, and reproductive disorders. There is also circumstantial evidence on the association of exposure to pesticides with some other chronic diseases like respiratory problems, particularly asthma and chronic obstructive pulmonary disease (COPD), cardiovascular disease such as atherosclerosis and coronary artery disease, chronic nephropathies, autoimmune diseases like systemic lupus erythematous and rheumatoid arthritis, chronic fatigue syndrome, and aging. The common feature of chronic disorders is a disturbance in cellular homeostasis, which can be induced via pesticides' primary action like perturbation of ion channels, enzymes, receptors, etc., or can as well be mediated via pathways other than the main mechanism. In this review, we present the highlighted evidence on the association of pesticide's exposure with the incidence of chronic diseases and introduce genetic damages, epigenetic modifications, endocrine disruption, mitochondrial dysfunction, oxidative stress, endoplasmic reticulum stress and unfolded protein response (UPR), impairment of ubiquitin proteasome system, and defective autophagy as the effective mechanisms of action. (C) 2013 Elsevier Inc. All rights reserved.	[Abdollahi, Mohammad] Univ Tehran Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Tehran, Iran; Univ Tehran Med Sci, Pharmaceut Sci Res Ctr, Tehran, Iran	Abdollahi, M (reprint author), Univ Tehran Med Sci, Fac Pharm, Dept Pharmacol & Toxicol, Tehran, Iran.	Mohammad.Abdollahi@UToronto.Ca	Tuomisto, Jouko/J-7450-2012; Abdollahi, Mohammad/B-9232-2008; Mostafalou, Sara/I-3151-2017	Abdollahi, Mohammad/0000-0003-0123-1209; 			Abdollahi M, 2004, COMP BIOCHEM PHYS C, V137, P29, DOI 10.1016/j.cca.2003.11.002; Abdollahi M, 2004, COMP BIOCHEM PHYS C, V137, P343, DOI 10.1016/j.cca.2004.03.009; Abdollahi M, 2004, MED SCI MONITOR, V10, P141; Abdul-Ghani MA, 2008, CURR DIABETES REP, V8, P173, DOI 10.1007/s11892-008-0030-1; Abele D, 2012, OXIDATIVE STRESS IN AQUATIC ECOSYSTEMS, P1; Ahmad R, 2010, SINGAP MED J, V51, P110; Alavanja MCR, 2004, AM J EPIDEMIOL, V160, P876, DOI 10.1093/aje/kwh290; Alavanja MCR, 2003, AM J EPIDEMIOL, V157, P800, DOI 10.1093/aje/kwg040; ALAVANJA MCR, 1990, J NATL CANCER I, V82, P840, DOI 10.1093/jnci/82.10.840; Alavanja MCR, 2012, J TOXICOL ENV HEAL B, V15, P238, DOI 10.1080/10937404.2012.632358; Alderton LE, 2006, AM J EPIDEMIOL, V164, P212, DOI 10.1093/aje/kwj203; Alexander FE, 2001, CANCER RES, V61, P2542; Alguacil J, 2000, ANN OCCUP HYG, V44, P391, DOI 10.1016/S0003-4878(99)00119-2; Andreotti G, 2009, INT J CANCER, V124, P2495, DOI 10.1002/ijc.24185; Antov G, 1980, Probl Khig, V5, P58; Anway MD, 2006, ENDOCRINOLOGY, V147, pS43, DOI 10.1210/en.2005-1058; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Arifkhanova S I, 2007, Probl Tuberk Bolezn Legk, P29; Ascherio A, 2006, ANN NEUROL, V60, P197, DOI 10.1002/ana.20904; Back SH, 2012, EXP DIABETES RES, DOI 10.1155/2012/618396; Baldi I, 2003, NEUROEPIDEMIOLOGY, V22, P305, DOI 10.1159/000071194; Baldi I, 2003, AM J EPIDEMIOL, V157, P409, DOI 10.1093/aje/kwf216; Baldi Isabelle, 2007, Rev Prat, V57, P40; Band PR, 2011, PROSTATE, V71, P168, DOI 10.1002/pros.21232; Band PR, 2000, J OCCUP ENVIRON MED, V42, P284, DOI 10.1097/00043764-200003000-00010; BARBEAU A, 1987, CAN J NEUROL SCI, V14, P36; Barczyk Adam, 2006, Wiad Lek, V59, P596; Barlow BK, 2005, NEUROTOXICOLOGY, V26, P63, DOI 10.1016/j.neuro.2004.07.004; Barlow BK, 2004, DEV NEUROSCI-BASEL, V26, P11, DOI 10.1159/000080707; BARTHEL E, 1981, J TOXICOL ENV HEALTH, V8, P1027; Beard J, 2003, ENVIRON HEALTH PERSP, V111, P724, DOI 10.1289/ehp.5885; Begum K, 2011, CHEM-BIOL INTERACT, V193, P240, DOI 10.1016/j.cbi.2011.07.003; Behan P.O., 1994, CLIN INFECT DIS   S1, V18, pS54; Benachour N, 2009, CHEM RES TOXICOL, V22, P97, DOI 10.1021/tx800218n; BLAIR A, 1983, J NATL CANCER I, V71, P31; Bolognesi C, 2003, MUTAT RES-REV MUTAT, V543, P251, DOI 10.1016/S1383-5742(03)00015-2; BOLOGNESI C, 1993, J TOXICOL ENV HEALTH, V40, P405; Bonetta L, 2002, NAT MED, V8, P1050, DOI 10.1038/nm1002-1050; Bonner MR, 2010, CANCER CAUSE CONTROL, V21, P871, DOI 10.1007/s10552-010-9514-9; Bonvicini F, 2010, ANN I SUPER SANITA, V46, P284, DOI 10.4415/ANN_10_03_10; Braconi D, 2010, FREE RADICAL RES, V44, P891, DOI 10.3109/10715762.2010.489111; Brender JD, 2010, ANN EPIDEMIOL, V20, P16, DOI 10.1016/j.annepidem.2009.09.011; Brophy JT, 2002, INT J OCCUP ENV HEAL, V8, P346; BROWN LM, 1990, CANCER RES, V50, P6585; BROWNSON RC, 1993, CANCER CAUSE CONTROL, V4, P449, DOI 10.1007/BF00050864; Brucker-Davis F, 2008, HUM REPROD, V23, P1708, DOI 10.1093/humrep/den186; BUCKLEY JD, 1994, LEUKEMIA, V8, P856; BUCKLEY JD, 1989, CANCER RES, V49, P4030; Buckley JD, 2000, CANCER, V89, P2315, DOI 10.1002/1097-0142(20001201)89:11<2315::AID-CNCR21>3.0.CO;2-G; Bull S, 2006, MUTAGENESIS, V21, P93, DOI 10.1093/mutage/gel011; Bumroongkit K, 2008, CANCER GENET CYTOGEN, V185, P20, DOI 10.1016/j.cancergencyto.2008.04.009; BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197; BURMEISTER LF, 1983, AM J EPIDEMIOL, V118, P72; Burns CJ, 2001, OCCUP ENVIRON MED, V58, P24, DOI 10.1136/oem.58.1.24; Burrell AM, 2011, DISCOV MED, V11, P187; BUTTERFIELD PG, 1993, NEUROLOGY, V43, P1150; Buzio L, 2002, Med Lav, V93, P303; Caboni P, 2004, CHEM RES TOXICOL, V17, P1540, DOI 10.1021/tx049867r; CANTOR KP, 1992, CANCER RES, V52, P2447; Cantor KP, 1999, AM J IND MED, V36, P239, DOI 10.1002/(SICI)1097-0274(199908)36:2<239::AID-AJIM3>3.3.CO;2-M; CANTOR KP, 1982, INT J CANCER, V29, P239, DOI 10.1002/ijc.2910290303; CARBONELL E, 1990, MUTAGENESIS, V5, P403, DOI 10.1093/mutage/5.4.403; CARBONELL E, 1993, MUTAGENESIS, V8, P511, DOI 10.1093/mutage/8.6.511; Carozza SE, 2008, ENVIRON HEALTH PERSP, V116, P559, DOI 10.1289/ehp.9967; Caudle WM, 2005, NEUROTOXICOLOGY, V26, P721, DOI 10.1016/j.neuro.2004.09.003; Cavieres MF, 2004, REV MED CHILE, V132, P873, DOI 10.4067/S0034-98872004000700014; Cavieres MF, 2002, ENVIRON HEALTH PERSP, V110, P1081; Cerhan JR, 1998, CANCER CAUSE CONTROL, V9, P311, DOI 10.1023/A:1008877204830; Chakraborty S, 2009, J OCCUP HEALTH, V51, P488; Chamie K, 2008, CANCER, V113, P2464, DOI 10.1002/cncr.23695; Chan DKY, 1998, J NEUROL NEUROSUR PS, V65, P781, DOI 10.1136/jnnp.65.5.781; Chen YW, 2010, TOXICOL LETT, V199, P333, DOI 10.1016/j.toxlet.2010.09.016; Chen YY, 2008, BIOCHEM PHARMACOL, V76, P128, DOI 10.1016/j.bcp.2008.04.010; Chevrier C, 2011, ENVIRON HEALTH PERSP, V119, P1034, DOI 10.1289/ehp.1002775; Chinta SJ, 2008, NEUROMOL MED, V10, P333, DOI 10.1007/s12017-008-8047-9; Chiu BCH, 2006, BLOOD, V108, P1363, DOI 10.1182/blood-2005-12-008755; Chou AP, 2010, NEUROTOXICOLOGY, V31, P367, DOI 10.1016/j.neuro.2010.04.006; Chou AP, 2008, J BIOL CHEM, V283, P34696, DOI 10.1074/jbc.M802210200; Choy S, 2011, KOREAN J OCCUP ENV M, V23, P480; Chrisman JD, 2009, INT J HYG ENVIR HEAL, V212, P310, DOI 10.1016/j.ijheh.2008.07.006; CICCONE G, 1993, CANCER GENET CYTOGEN, V68, P135, DOI 10.1016/0165-4608(93)90010-J; Ciobica A, 2011, PSYCHIAT DANUB, V23, P237; Clavel J, 1996, SCAND J WORK ENV HEA, V22, P285; Cocco Pierluigi, 2002, Cad. Saúde Pública, V18, P379, DOI 10.1590/S0102-311X2002000200003; Cooper GS, 2004, J RHEUMATOL, V31, P1928; CORDIER S, 1994, INT J CANCER, V59, P776, DOI 10.1002/ijc.2910590612; Cory-Slechta DA, 2005, ENVIRON HEALTH PERSP, V113, P1263, DOI 10.1289/ehp.7570; Costa C, 2011, J TOXICOL ENV HEAL A, V74, P960, DOI 10.1080/15287394.2011.582024; Costa LG, 2008, FRONT BIOSCI-LANDMRK, V13, P1240, DOI 10.2741/2758; Costello S, 2009, AM J EPIDEMIOL, V169, P919, DOI 10.1093/aje/kwp006; Crisp TM, 1998, ENVIRON HEALTH PERSP, V106, P11, DOI 10.2307/3433911; CUNEO A, 1992, LEUKEMIA RES, V16, P789, DOI 10.1016/0145-2126(92)90158-4; Daniels JL, 2001, EPIDEMIOLOGY, V12, P20, DOI 10.1097/00001648-200101000-00005; Das Kamalesh, 2012, N Am J Med Sci, V4, P350, DOI 10.4103/1947-2714.99517; DAVIS JR, 1993, ARCH ENVIRON CON TOX, V24, P87; De Roos AJ, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.9.e11; de Siqueira MT, 2010, B ENVIRON CONTAM TOX, V84, P647, DOI 10.1007/s00128-010-0027-8; de Souza A, 2011, CIENC SAUDE COLETIVA, V16, P3519; DEFERRARI M, 1991, MUTAT RES, V260, P105, DOI 10.1016/0165-1218(91)90086-2; DELZELL E, 1985, AM J EPIDEMIOL, V121, P391; Dennis LK, 2010, ENVIRON HEALTH PERSP, V118, P812, DOI 10.1289/ehp.0901518; Dhawan A, 2009, CELL BIOL TOXICOL, V25, P5, DOI 10.1007/s10565-008-9072-z; Dich J, 1998, PROSTATE, V34, P100, DOI 10.1002/(SICI)1097-0045(19980201)34:2<100::AID-PROS4>3.0.CO;2-O; Dick FD, 2007, OCCUP ENVIRON MED, V64, P666, DOI 10.1136/oem.2006.027003; Dickhout JG, 2011, CIRC RES, V108, P629, DOI 10.1161/CIRCRESAHA.110.226803; Doi H, 2006, NEUROLOGY, V67, P1894, DOI 10.1212/01.wnl.0000244489.65670.9f; Dolapsakis G, 2001, EUR J CANCER, V37, P1531, DOI 10.1016/S0959-8049(01)00159-9; DONNA A, 1989, SCAND J WORK ENV HEA, V15, P47; DOSEMECI M, 1994, J NATL CANCER I, V86, P1718, DOI 10.1093/jnci/86.22.1718; Doyle KM, 2011, J CELL MOL MED, V15, P2025, DOI 10.1111/j.1582-4934.2011.01374.x; Draper A, 2003, OCCUP ENVIRON MED, V60, P76, DOI 10.1136/oem.60.1.76; Duell EJ, 2000, EPIDEMIOLOGY, V11, P523, DOI 10.1097/00001648-200009000-00007; Dugas J, 2010, OCCUP ENVIRON MED, V67, P196, DOI 10.1136/oem.2009.047373; DULOUT FN, 1985, MUTAT RES, V143, P237, DOI 10.1016/0165-7992(85)90087-9; Dutheil F, 2010, ARCH NEUROL-CHICAGO, V67, P739, DOI 10.1001/archneurol.2010.101; Dwivedi RS, 2011, KIDNEY INT, V79, P23, DOI 10.1038/ki.2010.335; Efird JT, 2003, PAEDIATR PERINAT EP, V17, P201, DOI 10.1046/j.1365-3016.2003.00484.x; Elbaz A, 2009, ANN NEUROL, V66, P494, DOI 10.1002/ana.21717; Enoch RR, 2007, ENVIRON HEALTH PERSP, V115, P541, DOI 10.1289/ehp.9612; Ergene S, 2007, ENVIRON INT, V33, P877, DOI 10.1016/j.envint.2007.04.003; Eriksson M, 2008, INT J CANCER, V123, P1657, DOI 10.1002/ijc.23589; Everett CJ, 2010, ENVIRON INT, V36, P398, DOI 10.1016/j.envint.2010.02.010; Fall PA, 1999, MOVEMENT DISORD, V14, P28, DOI 10.1002/1531-8257(199901)14:1<28::AID-MDS1007>3.0.CO;2-O; Faria NMX, 2005, REV SAUDE PUBL, V39, P973, DOI 10.1590/S0034-89102005000600016; Fear NT, 1998, BRIT J CANCER, V77, P825, DOI 10.1038/bjc.1998.134; Fei XL, 2005, ENDOCRINOLOGY, V146, P3445, DOI 10.1210/en.2005-0341; Fendri C, 2006, ENCEPHALE, V32, P244; Feychting M, 2001, ENVIRON HEALTH PERSP, V109, P193, DOI 10.2307/3434775; Figa-Talamanca I, 2001, OCCUP MED-OXFORD, V51, P174, DOI 10.1093/occmed/51.3.174; FIGATALAMANCA I, 1993, INT J EPIDEMIOL, V22, P579, DOI 10.1093/ije/22.4.579; Firestone JA, 2005, ARCH NEUROL-CHICAGO, V62, P91, DOI 10.1001/archneur.62.1.91; Fleming LE, 1999, J OCCUP ENVIRON MED, V41, P279, DOI 10.1097/00043764-199904000-00010; Flower KB, 2004, ENVIRON HEALTH PERSP, V112, P631; Fokina K V, 1978, Vrach Delo, P19; Fong CS, 2007, CLIN CHIM ACTA, V378, P136, DOI 10.1016/j.cca.2006.11.006; FORASTIERE F, 1993, SCAND J WORK ENV HEA, V19, P382; Fortes C, 2007, EUR J CANCER, V43, P1066, DOI 10.1016/j.ejca.2007.01.013; Frazier Linda M, 2007, J Agromedicine, V12, P27, DOI 10.1300/J096v12n01_04; Freedman M, 2001, OCCUP ENVIRON MED, V58, P609; Freeman LEB, 2005, AM J EPIDEMIOL, V162, P1070, DOI 10.1093/aje/kwi321; Freire C, 2012, NEUROTOXICOLOGY, V33, P947, DOI 10.1016/j.neuro.2012.05.011; Frigerio R, 2006, MOVEMENT DISORD, V21, P1688, DOI 10.1002/mds.21009; GARABRANT DH, 1992, J NATL CANCER I, V84, P764, DOI 10.1093/jnci/84.10.764; Garaj-Vrhovac V, 2002, J APPL TOXICOL, V22, P249, DOI 10.1002/jat.855; Garry VF, 2001, ENVIRON HEALTH PERSP, V109, P495, DOI 10.2307/3454708; Garry VF, 1996, ENVIRON HEALTH PERSP, V104, P394, DOI 10.2307/3432683; Gatto NM, 2009, ENVIRON HEALTH PERSP, V117, P1912, DOI 10.1289/ehp.0900852; George J, 2011, J PROTEOMICS, V74, P2713, DOI 10.1016/j.jprot.2011.09.024; Gies E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014410; Giordano F, 2006, Int J Immunopathol Pharmacol, V19, P61; GOLD E, 1979, AM J EPIDEMIOL, V109, P309; Gold LS, 2007, ARTHRITIS RHEUM, V56, P3189, DOI 10.1002/art.22880; Gomez C, 2007, FRONT BIOSCI, V12, P1079, DOI 10.2741/2128; Gomez-Arroyo S, 2000, MUTAT RES-GEN TOX EN, V466, P117, DOI 10.1016/S1383-5718(99)00231-4; Gonzalez CD, 2011, AUTOPHAGY, V7, P2, DOI 10.4161/auto.7.1.13044; Gonzalez-Polo RA, 2007, TOXICOL SCI, V97, P448, DOI 10.1093/toxsci/kfm040; Gorell JM, 1998, NEUROLOGY, V50, P1346; Gravina S, 2010, PFLUG ARCH EUR J PHY, V459, P247, DOI 10.1007/s00424-009-0730-7; Gray LE, 1999, TOXICOL IND HEALTH, V15, P48, DOI 10.1191/074823399678846646; Greenlee AR, 2004, ENVIRON HEALTH PERSP, V112, P703, DOI 10.1289/ehp.6774; Greenlee AR, 2003, EPIDEMIOLOGY, V14, P429, DOI 10.1097/01.EDE.0000071407.15670.aa; Grosicka-Maciag E, 2011, POSTEP HIG MED DOSW, V65, P357; Grover P, 2003, MUTAGENESIS, V18, P201, DOI 10.1093/mutage/18.2.201; Guerrero-Bosagna C, 2010, PLOS ONE, V5; Guy R.C., 2005, ENCY TOXICOLOGY; Habibi E, 2011, FUNCT INTEGR GENOMIC, V11, P523, DOI 10.1007/s10142-011-0246-z; Hamlin HJ, 2010, SYST BIOL REPROD MED, V56, P113, DOI 10.3109/19396360903244598; Hancock DB, 2008, BMC NEUROL, V8, DOI 10.1186/1471-2377-8-6; Hardell L, 1999, CANCER, V85, P1353, DOI 10.1002/(SICI)1097-0142(19990315)85:6<1353::AID-CNCR19>3.0.CO;2-1; Hardell L, 2002, LEUKEMIA LYMPHOMA, V43, P1043, DOI 10.1080/10428190290021560; Hayden KM, 2010, NEUROLOGY, V74, P1524, DOI 10.1212/WNL.0b013e3181dd4423; Hernandez AF, 2011, CURR OPIN ALLERGY CL, V11, P90, DOI 10.1097/ACI.0b013e3283445939; HERTZMAN C, 1994, MOVEMENT DISORD, V9, P69, DOI 10.1002/mds.870090111; HOAR SK, 1986, JAMA-J AM MED ASSOC, V256, P1141, DOI 10.1001/jama.256.9.1141; Holly EA, 1998, CANCER EPIDEM BIOMAR, V7, P797; HOLLY EA, 1992, AM J EPIDEMIOL, V135, P122; Hoppin JA, 2002, AM J RESP CRIT CARE, V165, P683, DOI 10.1164/rccm.2106074; Hoppin JA, 2007, AM J IND MED, V50, P969, DOI 10.1002/ajim.20523; Hoppin JA, 2008, AM J RESP CRIT CARE, V177, P11, DOI 10.1164/rccm.200706-821OC; Hossain MM, 2011, TOXICOL SCI, V122, P512, DOI 10.1093/toxsci/kfr111; Hou LF, 2006, EPIDEMIOLOGY, V17, P302, DOI 10.1097/01.ede.0000201398.82658.50; Hu J, 2002, OCCUP MED-OXFORD, V52, P157, DOI 10.1093/occmed/52.3.157; HUBBLE JP, 1993, NEUROLOGY, V43, P1693; Hubble JP, 1998, NEUROEPIDEMIOLOGY, V17, P96, DOI 10.1159/000026159; ILIVICKY J, 1969, BIOCHEM PHARMACOL, V18, P1389, DOI 10.1016/0006-2952(69)90252-4; Infante-Rivard C, 1999, EPIDEMIOLOGY, V10, P481, DOI 10.1097/00001648-199909000-00004; JABLONICKA A, 1989, MUTAT RES, V224, P143, DOI 10.1016/0165-1218(89)90148-1; Jaga Kushik, 2005, Reviews on Environmental Health, V20, P15; Jamshidi HR, 2009, PESTIC BIOCHEM PHYS, V93, P23, DOI 10.1016/j.pestbp.2008.09.002; Jansson C, 2006, OCCUP ENVIRON MED, V63, P107, DOI 10.1136/oem.2005.022467; Ji BT, 2001, AM J IND MED, V39, P92, DOI 10.1002/1097-0274(200101)39:1<92::AID-AJIM9>3.3.CO;2-G; Jia Z, 2007, NEUROTOXICOLOGY, V28, P727, DOI 10.1016/j.neuro.2007.04.003; Johnson FO, 2009, NEUROTOXICOLOGY, V30, P761, DOI 10.1016/j.neuro.2009.07.010; Johri A, 2012, J PHARMACOL EXP THER, V342, P619, DOI 10.1124/jpet.112.192138; Jones Nick, 2010, Nat Rev Neurol, V6, P353, DOI 10.1038/nrneurol.2010.80; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Joshi C.S., 2011, TOXICOL ENVIRON CHEM, V93, P593; Jungmann G, 1966, Landarzt, V42, P1244; Kamel F, 2007, AM J EPIDEMIOL, V165, P364, DOI 10.1093/aje/kwk024; Kamel F, 2012, NEUROTOXICOLOGY, V33, P457, DOI 10.1016/j.neuro.2012.04.001; Kanavouras K, 2011, TOXICOL APPL PHARM, V256, P399, DOI 10.1016/j.taap.2011.07.022; Kang D, 2008, ENVIRON RES, V107, P271, DOI 10.1016/j.envres.2008.01.010; Kanthasamy A, 2002, J NEUROCHEM, V81, P76; Karami S, 2008, CARCINOGENESIS, V29, P1567, DOI 10.1093/carcin/bgn153; Karami-Mohajeri S, 2011, HUM EXP TOXICOL, V30, P1119, DOI 10.1177/0960327110388959; KAUPPINEN T, 1995, EPIDEMIOLOGY, V6, P498, DOI 10.1097/00001648-199509000-00006; KellerByrne JE, 1997, AM J IND MED, V31, P580, DOI 10.1002/(SICI)1097-0274(199705)31:5<580::AID-AJIM13>3.0.CO;2-V; Khuder SA, 1998, SCAND J WORK ENV HEA, V24, P255; Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472; Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131; Kim MK, 2012, EXP DIABETES RES, DOI 10.1155/2012/509437; KOGEVINAS M, 1995, EPIDEMIOLOGY, V6, P396, DOI 10.1097/00001648-199507000-00012; Kojima H, 2010, J HEALTH SCI, V56, P374; KOLLER W, 1990, NEUROLOGY, V40, P1218; KOLMODINHEDMAN B, 1982, ARCH TOXICOL, V50, P27, DOI 10.1007/BF00569234; Koumenis C, 2006, CURR MOL MED, V6, P55, DOI 10.2174/156652406775574604; Koutros S, 2009, INT J CANCER, V124, P1206, DOI 10.1002/ijc.24020; Kouznetsova M, 2007, ENVIRON HEALTH PERSP, V115, P75, DOI 10.1289/ehp.9223; Kristensen P, 1996, SCAND J WORK ENV HEA, V22, P14; Kristensen P, 1996, INT J CANCER, V65, P39, DOI 10.1002/(SICI)1097-0215(19960103)65:1<39::AID-IJC8>3.0.CO;2-2; Kross BC, 1996, AM J IND MED, V29, P501; Kumar S, 2004, J OCCUP HEALTH, V46, P1, DOI 10.1539/joh.46.1; Kwok JBJ, 2010, EPIGENOMICS-UK, V2, P671, DOI [10.2217/epi.10.43, 10.2217/EPI.10.43]; LaFiura KM, 2007, PEDIATR BLOOD CANCER, V49, P624, DOI 10.1002/pbc.21283; Lander B F, 2000, Scand J Work Environ Health, V26, P436; Landgren O, 2009, BLOOD, V113, P6386, DOI 10.1182/blood-2009-02-203471; Langston JW, 1996, NEUROLOGY, V47, pS153; Laurent C, 1996, INT ARCH OCC ENV HEA, V68, P399; LAVAL G, 1988, BRIT J IND MED, V45, P843; Lebailly P, 1998, CANCER EPIDEM BIOMAR, V7, P929; Lee AS, 2006, CANCER BIOL THER, V5, P721, DOI 10.4161/cbt.5.7.3120; Lee DH, 2010, ENVIRON HEALTH PERSP, V118, P1235, DOI 10.1289/ehp.0901480; Lee Hong Kyu, 2011, Diabetes and Metabolism Journal, V35, P207, DOI 10.4093/dmj.2011.35.3.207; Lee W J, 2005, Occup Environ Med, V62, P786, DOI 10.1136/oem.2005.020230; Lee WJ, 2004, J NATL CANCER I, V96, P1781, DOI 10.1093/jnci/djh324; Lee WJ, 2004, AM J EPIDEMIOL, V159, P373, DOI 10.1093/aje/kwh040; Lee WJ, 2007, INT J CANCER, V121, P339, DOI 10.1002/ijc.22635; LEISS JK, 1995, AM J PUBLIC HEALTH, V85, P249, DOI 10.2105/AJPH.85.2.249; Lemaire G, 2005, TOXICOL APPL PHARM, V202, P38, DOI 10.1016/j.taap.2004.06.004; LESSENGER JE, 1992, J TOXICOL ENV HEALTH, V35, P261; LeVan TD, 2006, AM J EPIDEMIOL, V163, P1118, DOI 10.1093/aje/kwj144; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Lim S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005186; Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292; Lindholm D, 2006, CELL DEATH DIFFER, V13, P385, DOI 10.1038/sj.cdd.4401778; LITTORIN M, 1993, INT ARCH OCC ENV HEA, V65, P163, DOI 10.1007/BF00381152; Lo AC, 2007, PANCREAS, V35, P120, DOI 10.1097/mpa.0b013e318053e7d3; Lo AC, 2010, DIS COLON RECTUM, V53, P830, DOI 10.1007/DCR.0b013e3181d320b1; Lope V, 2008, CANCER EPIDEM BIOMAR, V17, P3123, DOI 10.1158/1055-9965.EPI-08-0343; Lowell BB, 2005, SCIENCE, V307, P384, DOI 10.1126/science.1104343; LOWENGART RA, 1987, J NATL CANCER I, V79, P39; Lund G, 2011, CURR ATHEROSCLER REP, V13, P208, DOI 10.1007/s11883-011-0174-3; Lynch SM, 2009, ENVIRON RES, V109, P860, DOI 10.1016/j.envres.2009.06.006; Ma XM, 2002, ENVIRON HEALTH PERSP, V110, P955; Ma ZA, 2012, EXP DIABETES RES, DOI 10.1155/2012/703538; MacLennan PA, 2002, J OCCUP ENVIRON MED, V44, P1048, DOI 10.1097/01.jom.0000038322.36316.59; MAGNANI C, 1990, TUMORI, V76, P413; MAGNANI C, 1989, TUMORI, V75, P396; Mahajan R, 2006, ENVIRON HEALTH PERSP, V114, P1838, DOI 10.1289/ehp.9301; Mahajan R, 2007, INT J CANCER, V121, P1799, DOI 10.1002/ijc.22836; Manthripragada AD, 2010, EPIDEMIOLOGY, V21, P87, DOI 10.1097/EDE.0b013e3181c15ec6; Martin LJ, 2012, PROG MOL BIOL TRANSL, V107, P355, DOI 10.1016/B978-0-12-385883-2.00005-9; MASLANSKY CJ, 1981, J TOXICOL ENV HEALTH, V8, P121; McDuffie HH, 2001, CANCER EPIDEM BIOMAR, V10, P1155; McGuire V, 1997, AM J EPIDEMIOL, V145, P1076; McKinlay R, 2008, ENVIRON INT, V34, P168, DOI 10.1016/j.envint.2007.07.013; Meeker JD, 2006, EPIDEMIOLOGY, V17, P61, DOI 10.1097/01.ede.0000190602.14691.70; Meinert R, 2000, AM J EPIDEMIOL, V151, P639; Meinert R, 1996, EUR J CANCER, V32A, P1943, DOI 10.1016/0959-8049(96)00231-6; MELLEMGAARD A, 1994, SCAND J WORK ENV HEA, V20, P160; Menegaux F, 2006, OCCUP ENVIRON MED, V63, P131, DOI 10.1136/oem.2005.023036; Menegon A, 1998, LANCET, V352, P1344, DOI 10.1016/S0140-6736(98)03453-9; Merhi M, 2007, CANCER CAUSE CONTROL, V18, P1209, DOI 10.1007/s10552-007-9061-1; Merletti F, 2006, INT J CANCER, V118, P721, DOI 10.1002/ijc.21388; Meyer TE, 2007, OCCUP ENVIRON MED, V64, P155, DOI 10.1136/oem.2006.027383; Miligi L, 2006, ANN NY ACAD SCI, V1076, P366, DOI 10.1196/annals.1371.036; Mills PK, 2007, ENVIRON RES, V104, P282, DOI 10.1016/j.envres.2007.11.008; Mills PK, 1998, ARCH ENVIRON HEALTH, V53, P410; Mills PK, 2005, INT J OCCUP ENV HEAL, V11, P123; Mills PK, 2003, J OCCUP ENVIRON MED, V45, P249, DOI 10.1097/01.jom.0000058339.05741.0c; MILLS PK, 1984, LANCET, V1, P207; Monge P, 2007, SCAND J WORK ENV HEA, V33, P293; Montgomery MP, 2008, AM J EPIDEMIOL, V167, P1235, DOI 10.1093/aje/kwn028; Moore LE, 2005, INT J CANCER, V114, P472, DOI 10.1002/ijc.20734; Morahan JM, 2006, NEUROEPIDEMIOLOGY, V27, P130, DOI 10.1159/000095552; MORETTO A, 1991, B WORLD HEALTH ORGAN, V69, P591; MORRISON H, 1993, AM J EPIDEMIOL, V137, P270; MORRISON HI, 1994, SCAND J WORK ENV HEA, V20, P42; MORTON WE, 1975, J OCCUP ENVIRON MED, V17, P182; Mostafalou S, 2012, INT J PHARMACOL, V8, P473, DOI 10.3923/ijp.2012.473.474; Mostafalou S., 2012, CLIN EXP PHARMACOL P, V2; Mostafalou Sara, 2012, Adv Pharm Bull, V2, P79, DOI 10.5681/apb.2012.011; Mostafalou S, 2012, TOXICOL IND HEALTH, V28, P840, DOI 10.1177/0748233711425073; Mostafalou S, 2012, INT J PHARMACOL, V8, P139, DOI 10.3923/ijp.2012.139.140; MULDER YM, 1994, J EPIDEMIOL COMMUN H, V48, P161, DOI 10.1136/jech.48.2.161; Multigner L, 2010, J CLIN ONCOL, V28, P3457, DOI 10.1200/JCO.2009.27.2153; MUSICCO M, 1988, AM J EPIDEMIOL, V128, P778; Nassar N, 2010, OCCUP ENVIRON MED, V67, P585, DOI 10.1136/oem.2009.048272; Nassif M, 2010, ANTIOXID REDOX SIGN, V13, P1955, DOI 10.1089/ars.2009.2991; Nathan FM, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-382; Ngo AD, 2006, INT J EPIDEMIOL, V35, P1220, DOI 10.1093/ije/dyl038; Nielsen SS, 2010, ENVIRON HEALTH PERSP, V118, P144, DOI 10.1289/ehp.0901226; Niso-Santano M, 2011, TOXICOL SCI, V119, P156, DOI 10.1093/toxsci/kfq313; Nordstrom M, 1998, BRIT J CANCER, V77, P2048, DOI 10.1038/bjc.1998.341; Oates N, 2007, AMYOTROPH LATERAL SC, V8, P83, DOI 10.1080/1748290601149160; Olgun S, 2006, MOL CELL BIOCHEM, V290, P137, DOI 10.1007/s11010-006-9178-7; Oliva A, 2001, HUM REPROD, V16, P1768, DOI 10.1093/humrep/16.8.1768; OLSHAN AF, 1993, CANCER, V72, P938, DOI 10.1002/1097-0142(19930801)72:3<938::AID-CNCR2820720345>3.0.CO;2-C; Orsi L, 2007, J OCCUP ENVIRON MED, V49, P1339, DOI 10.1097/JOM.0b013e3181569a49; Jacome GPO, 2010, J TOXICOL ENV HEAL A, V73, P858, DOI 10.1080/15287391003744773; Orton F, 2011, ENVIRON HEALTH PERSP, V119, P794, DOI [10.1289/ehp.1002895, 10.1289/ehp.1002897]; Pamphlett R, 2012, EUR J NEUROL, V19, P1343, DOI 10.1111/j.1468-1331.2012.03769.x; PAN, 2009, LIST LISTS CAT LISTS; Parks CG, 2011, ARTHRIT CARE RES, V63, P184, DOI 10.1002/acr.20335; Parron T, 2011, TOXICOL APPL PHARM, V256, P379, DOI 10.1016/j.taap.2011.05.006; PARTANEN T, 1994, AM J IND MED, V25, P851, DOI 10.1002/ajim.4700250609; Pasquini Rossana Giuseppina Scassellati-Sforzolini, 1996, Journal of Environmental Pathology Toxicology and Oncology, V15, P29; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Paul S, 2008, BIOESSAYS, V30, P1172, DOI 10.1002/bies.20852; PEARCE NE, 1985, AM J EPIDEMIOL, V121, P225; Peiris-John R. J., 2006, Ceylon Medical Journal, V51, P42; Peluso M, 1996, CANCER EPIDEM BIOMAR, V5, P361; Penel N, 2007, B CANCER, V94, P15; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; PERSSON B, 1993, CANCER, V72, P1773, DOI 10.1002/1097-0142(19930901)72:5<1773::AID-CNCR2820720542>3.0.CO;2-6; PESATORI AC, 1994, CANCER CAUSE CONTROL, V5, P310, DOI 10.1007/BF01804981; Pesonen M, 2012, TOXICOL LETT, V211, P239, DOI 10.1016/j.toxlet.2012.04.002; Petit C, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-71; Petrovitch H, 2002, ARCH NEUROL-CHICAGO, V59, P1787, DOI 10.1001/archneur.59.11.1787; Pogoda JM, 1997, ENVIRON HEALTH PERSP, V105, P1214, DOI 10.1289/ehp.971051214; Poovala VS, 1998, TOXICOL SCI, V46, P403, DOI 10.1093/toxsci/46.2.403; Pournourmohammadi S., 2011, ANTICHOLINESTERASE P; Pournourmohammadi S, 2007, PESTIC BIOCHEM PHYS, V88, P346, DOI 10.1016/j.pestbp.2007.02.001; Priyadarshi A, 2001, ENVIRON RES, V86, P122, DOI 10.1006/enrs.2001.4264; Priyadarshi A, 2000, NEUROTOXICOLOGY, V21, P435; Provost D, 2007, OCCUP ENVIRON MED, V64, P509, DOI 10.1136/oem.2006.028100; Purdue MP, 2007, INT J CANCER, V120, P642, DOI 10.1002/ijc.22258; Purisai MG, 2007, NEUROBIOL DIS, V25, P392, DOI 10.1016/j.nbd.2006.10.008; Qiao D, 2001, ENVIRON HEALTH PERSP, V109, P909, DOI 10.2307/3454991; Qureshi MM, 2006, AMYOTROPH LATERAL SC, V7, P173, DOI 10.1080/14660820600640596; Rahimi R, 2007, PESTIC BIOCHEM PHYS, V88, P115, DOI 10.1016/j.pestbp.2006.10.003; Rakitsky VN, 2000, TERATOGEN CARCIN MUT, V20, P229, DOI 10.1002/1520-6866(2000)20:4<229::AID-TCM5>3.0.CO;2-M; Ranjbar A, 2010, HUM EXP TOXICOL, V29, P851, DOI 10.1177/0960327110363836; Rau ATK, 2012, INDIAN PEDIATR, V49, P113, DOI 10.1007/s13312-012-0025-5; Rauch SA, 2012, ENVIRON HEALTH PERSP, V120, P1055, DOI 10.1289/ehp.1104615; Ren AG, 2011, P NATL ACAD SCI USA, V108, P12770, DOI 10.1073/pnas.1105209108; Reynolds P, 2005, EPIDEMIOLOGY, V16, P93, DOI 10.1097/01.ede.0000147119.32704.5c; Richard S, 2005, ENVIRON HEALTH PERSP, V113, P716, DOI 10.1289/ehp.7728; Richardson JR, 2006, FASEB J, V20, P1695, DOI 10.1096/fj.06-5684fje; Richardson JR, 2009, ARCH NEUROL-CHICAGO, V66, P870, DOI 10.1001/archneurol.2009.89; Ritter L, 1990, Med Lav, V81, P499; Ritz B, 2000, INT J EPIDEMIOL, V29, P323, DOI 10.1093/ije/29.2.323; Ritz BR, 2009, ENVIRON HEALTH PERSP, V117, P964, DOI 10.1289/ehp.0800277; Rocheleau CM, 2009, J PEDIATR UROL, V5, P17, DOI 10.1016/j.jpurol.2008.08.006; Rodvall Y, 1996, OCCUP ENVIRON MED, V53, P526; Rogers J.M., 2008, CASARETT DOULLS TOXI; Rosso A, 2008, CANCER CAUSE CONTROL, V19, P1201, DOI 10.1007/s10552-008-9189-7; ROTH F, 1958, VIRCHOWS ARCH A, V331, P119, DOI 10.1007/BF00955191; Rudant J, 2007, ENVIRON HEALTH PERSP, V115, P1787, DOI 10.1289/ehp.10596; Ruder A M, 2006, J Agric Saf Health, V12, P255; Rull RP, 2009, ENVIRON RES, V109, P891, DOI 10.1016/j.envres.2009.07.014; RUPA DS, 1991, ENVIRON MOL MUTAGEN, V18, P136, DOI 10.1002/em.2850180209; RUPA DS, 1988, HUM TOXICOL, V7, P333; Rusiecki JA, 2006, INT J CANCER, V118, P3118, DOI 10.1002/ijc.21758; Rusiecki JA, 2008, ENVIRON HEALTH PERSP, V116, P1547, DOI 10.1289/ehp.11338; Rusiecki JA, 2009, ENVIRON HEALTH PERSP, V117, P581, DOI 10.1289/ehp.11318; Saadi HS, 2012, INT J PHARMACOL, V8, P708, DOI 10.3923/ijp.2012.708.710; Saiyed H, 2003, ENVIRON HEALTH PERSP, V111, P1958, DOI 10.1289/ehp.6271; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Salameh PR, 2003, EUR RESPIR J, V22, P507, DOI 10.1183/09031936.03.00107403; Saldana TM, 2007, DIABETES CARE, V30, P529, DOI 10.2337/dc06-1832; Samanic C, 2006, ENVIRON HEALTH PERSP, V114, P1521, DOI 10.1289/ehp.9204; Samanic CM, 2008, AM J EPIDEMIOL, V167, P976, DOI 10.1093/aje/kwm401; Scheuner D, 2008, ENDOCR REV, V29, P317, DOI 10.1210/er.2007-0039; Schreinemachers DM, 2003, ENVIRON HEALTH PERSP, V111, P1259, DOI 10.1289/ehp.5830; Schroeder JC, 2001, EPIDEMIOLOGY, V12, P701, DOI 10.1097/00001648-200111000-00020; Schulte PA, 1996, AM J PUBLIC HEALTH, V86, P1281, DOI 10.2105/AJPH.86.9.1281; Seidler A, 1996, NEUROLOGY, V46, P1275; SEMCHUK KM, 1992, NEUROLOGY, V42, P1328; Settimi L, 2003, INT J CANCER, V104, P458, DOI 10.1002/ijc.10955; Shadnia S, 2005, HUM EXP TOXICOL, V24, P439, DOI 10.1191/0960327105ht549oa; Shah MD, 2010, FOOD CHEM TOXICOL, V48, P3345, DOI 10.1016/j.fct.2010.09.003; Sharma H, 2010, NEUROTOXICOLOGY, V31, P215, DOI 10.1016/j.neuro.2009.12.007; Sharma-Wagner S, 2000, J OCCUP ENVIRON MED, V42, P517, DOI 10.1097/00043764-200005000-00010; SHARPE CR, 1995, AM J EPIDEMIOL, V141, P210; Sherman JD, 1996, ARCH ENVIRON HEALTH, V51, P5; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; SHU XO, 1988, CANCER, V62, P635, DOI 10.1002/1097-0142(19880801)62:3<635::AID-CNCR2820620332>3.0.CO;2-3; Siddharth M, 2012, J BIOCHEM MOL TOXIC, V26, P241, DOI 10.1002/jbt.21416; Simmons Rebecca A, 2007, Curr Opin Endocrinol Diabetes Obes, V14, P13, DOI 10.1097/MED.0b013e328013da5b; Singh C, 2007, CELL MOL BIOL, V53, P19, DOI 10.1170/T815; Skandrani D, 2006, TOXICOL IN VITRO, V20, P1378, DOI 10.1016/j.tiv.2006.06.001; Skandrani D, 2006, BBA-GEN SUBJECTS, V1760, P95, DOI 10.1016/j.bbagen.2005.09.015; Skinner Michael K., 2007, Critical Reviews in Oncogenesis, V13, P75; Slager RE, 2009, OCCUP ENVIRON MED, V66, P718, DOI 10.1136/oem.2008.041798; Slaninova A, 2009, NEUROENDOCRINOL LETT, V30, P2; Smith-Rooker J L, 1992, J Neurosci Nurs, V24, P260; Snijder CA, 2011, FERTIL STERIL, V95, P2067, DOI 10.1016/j.fertnstert.2011.02.017; Soldin OP, 2009, THER DRUG MONIT, V31, P495, DOI 10.1097/FTD.0b013e3181aae982; Soltaninejad K, 2009, MED SCI MONITOR, V15, pRA75; Song C, 2010, MOL PHARMACOL, V77, P621, DOI 10.1124/mol.109.062174; Spinelli JJ, 2007, INT J CANCER, V121, P2767, DOI 10.1002/ijc.23005; Stanko JP, 2010, REPROD TOXICOL, V30, P540, DOI 10.1016/j.reprotox.2010.07.006; Stephenson J, 2000, JAMA-J AM MED ASSOC, V283, P3055, DOI 10.1001/jama.283.23.3055; Sun F, 2005, J PHARMACOL EXP THER, V315, P69, DOI 10.1124/jpet.105.084632; Sutedja NA, 2009, AMYOTROPH LATERAL SC, V10, P302, DOI 10.3109/17482960802455416; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P1478, DOI 10.1289/ehp.6417; Swan SH, 2003, ENVIRON HEALTH PERSP, V111, P414, DOI 10.1289/ehp.5927; t Mannetje A, 2008, OCCUP ENVIRON MED, V65, P354, DOI 10.1136/oem.2007.035014; Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766; Tanner CM, 2011, ENVIRON HEALTH PERSP, V119, P866, DOI 10.1289/ehp.1002839; Tanner CM, 2009, ARCH NEUROL-CHICAGO, V66, P1106, DOI 10.1001/archneurol.2009.195; Tao LH, 2000, CANCER LETT, V158, P185, DOI 10.1016/S0304-3835(00)00518-8; Tao LH, 2000, TOXICOL SCI, V54, P399, DOI 10.1093/toxsci/54.2.399; Tarvainen L, 2008, INT J CANCER, V123, P653, DOI 10.1002/ijc.23286; Teimouri F, 2006, HUM EXP TOXICOL, V25, P697, DOI 10.1177/0960327106075064; Teitelbaum SL, 2007, AM J EPIDEMIOL, V165, P643, DOI 10.1093/aje/kwk046; Thayer KA, 2012, ENVIRON HEALTH PERSP, V120, P779, DOI 10.1289/ehp.1104597; THIERS H, 1967, ANN DERMATOL SYPHIL, V94, P133; Tiemann U, 2008, REPROD TOXICOL, V25, P316, DOI 10.1016/j.reprotox.2008.03.002; Tiido T, 2006, ENVIRON HEALTH PERSP, V114, P718, DOI 10.1289/ehp.8668; Tiido T, 2005, HUM REPROD, V20, P1903, DOI 10.1093/humrep/deh855; Tisch M, 2002, EUR ARCH OTO-RHINO-L, V259, P150, DOI 10.1007/s004050100406; Tomita M, 2006, ARCH TOXICOL, V80, P687, DOI 10.1007/s00204-006-0092-2; Tsai J, 2006, INT J HYG ENVIR HEAL, V209, P57, DOI 10.1016/j.ijheh.2005.09.003; Tuchsen F, 2000, SCAND J WORK ENV HEA, V26, P359; Turner MC, 2010, ENVIRON HEALTH PERSP, V118, P33, DOI 10.1289/ehp.0900966; Tyas SL, 2001, INT J EPIDEMIOL, V30, P590, DOI 10.1093/ije/30.3.590; Ubaidullaeva K M, 2006, Probl Tuberk Bolezn Legk, P21; Vajdic CM, 2007, INT J CANCER, V120, P2271, DOI 10.1002/ijc.22602; Valcin M, 2007, J OCCUP ENVIRON MED, V49, P574, DOI 10.1097/JOM.0b013e3180577768; van Balen E, 2006, OCCUP ENVIRON MED, V63, P663, DOI 10.1136/oem.2005.024026; van Bemmel DM, 2008, ENVIRON HEALTH PERSP, V116, P1541, DOI 10.1289/ehp.11371; van der Mark M, 2012, ENVIRON HEALTH PERSP, V120, P340, DOI 10.1289/ehp.1103881; Van Leeuwen JA, 1999, INT J EPIDEMIOL, V28, P836, DOI 10.1093/ije/28.5.836; van Maele-Fabry G, 2006, CANCER CAUSE CONTROL, V17, P353, DOI 10.1007/s10552-005-0443-y; Van Maele-Fabry G, 2008, ENVIRON RES, V106, P121, DOI 10.1016/j.envres.2007.09.002; Van Maele-Fabry G, 2007, CANCER CAUSE CONTROL, V18, P457, DOI 10.1007/s10552-007-0122-2; Van Maele-Fabry G, 2012, ENVIRON INT, V46, P30, DOI 10.1016/j.envint.2012.05.004; van Wijngaarden E, 2003, AM J EPIDEMIOL, V157, P989, DOI 10.1093/aje/kwg082; Vandenplas O, 2000, ALLERGY, V55, P417, DOI 10.1034/j.1398-9995.2000.00599.x; van Gelder M.M., 2010, HUM REPROD UPDATE, V16, P378; Viel JF, 1998, ARCH ENVIRON HEALTH, V53, P65; Vinceti Marco, 2012, Reviews on Environmental Health, V27, P19, DOI 10.1515/reveh-2012-0002; Wagner S, 2000, WESTERN J MED, V173, P86, DOI 10.1136/ewjm.173.2.86; Walker K M, 2007, J Agric Saf Health, V13, P9; Wang A, 2011, EUR J EPIDEMIOL, V26, P547, DOI 10.1007/s10654-011-9574-5; Wang H, 2011, ENVIRON TOXICOL, V26, P382, DOI 10.1002/tox.20566; Wang XF, 2006, NEUROBIOL DIS, V23, P198, DOI 10.1016/j.nbd.2006.02.012; Wanigasuriya KP, 2007, T ROY SOC TROP MED H, V101, P1013, DOI 10.1016/j.trstmh.2007.05.006; Ward MH, 2010, EPIDEMIOLOGY, V21, P389, DOI 10.1097/EDE.0b013e3181d6201d; Weichenthal S, 2010, ENVIRON HEALTH PERSP, V118, P1117, DOI 10.1289/ehp.0901731; Weiner B P, 1969, Hawaii Med J, V28, P283; Weinhold B, 2006, ENVIRON HEALTH PERSP, V114, pA160; Weselak M, 2007, J TOXICOL ENV HEAL B, V10, P41, DOI 10.1080/10937400601034571; Wesseling C, 1999, INT J EPIDEMIOL, V28, P365, DOI 10.1093/ije/28.3.365; WIKLUND K, 1983, CANCER, V51, P566, DOI 10.1002/1097-0142(19830201)51:3<566::AID-CNCR2820510334>3.0.CO;2-D; WILKINS JR, 1988, AM J IND MED, V14, P299; WILKINS JR, 1990, AM J EPIDEMIOL, V132, P275; Winchester PD, 2009, ACTA PAEDIATR, V98, P664, DOI 10.1111/j.1651-2227.2008.01207.x; WOODS JS, 1987, J NATL CANCER I, V78, P899; Xu CY, 2005, J CLIN INVEST, V115, P2656, DOI 10.1172/JC126373; Yang W, 2007, HUM MOL GENET, V16, P2900, DOI 10.1093/hmg/ddm249; Yang W, 2007, J TOXICOL ENV HEAL A, V70, P1849, DOI 10.1080/15287390701459262; Yang W, 2009, TOXICOL LETT, V191, P203, DOI 10.1016/j.toxlet.2009.08.024; Zahm S H, 1990, Epidemiology, V1, P349, DOI 10.1097/00001648-199009000-00004; ZAHM SH, 1993, ARCH ENVIRON HEALTH, V48, P353; Zama AM, 2009, ENDOCRINOLOGY, V150, P4681, DOI 10.1210/en.2009-0499; Zamzila A.N., 2011, CHRONIC ORGANOPHOSPH; Zeljezic D, 2002, CHEMOSPHERE, V46, P295, DOI 10.1016/S0045-6535(01)00073-X; Zeljezic D, 2001, MUTAGENESIS, V16, P359, DOI 10.1093/mutage/16.4.359; Zheng TZ, 2001, J OCCUP ENVIRON MED, V43, P317, DOI 10.1097/00043764-200104000-00005; Zhong Y, 1996, INT J EPIDEMIOL, V25, P1117, DOI 10.1093/ije/25.6.1117; Ziech D, 2010, CHEM-BIOL INTERACT, V188, P340, DOI 10.1016/j.cbi.2010.06.012; Zorzon M, 2002, ACTA NEUROL SCAND, V105, P77, DOI 10.1034/j.1600-0404.2002.1o040.x; Zucchini-Pascal N, 2009, TOXICOLOGY, V256, P32, DOI 10.1016/j.tox.2008.11.004	476	186	195	25	284	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	APR 15	2013	268	2					157	177		10.1016/j.taap.2013.01.025		21	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	117UN	WOS:000316978700008	23402800	
J	Kuitunen, M; Kukkonen, K; Juntunen-Backman, K; Korpela, R; Poussa, T; Tuure, T; Haahtela, T; Savilahti, E				Kuitunen, Mikael; Kukkonen, Kaarina; Juntunen-Backman, Kaisu; Korpela, Riitta; Poussa, Tuija; Tuure, Tuula; Haahtela, Tari; Savilahti, Erkki			Probiotics prevent IgE-associated allergy until age 5 years in cesarean-delivered children but not in the total cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; prevention; high-risk infants; probiotic; prebiotic; eczema; allergic rhinitis; asthma; cesarean	PLACEBO-CONTROLLED TRIAL; 1ST 6 MONTHS; ATOPIC-DERMATITIS; DOUBLE-BLIND; INTESTINAL MICROFLORA; ECZEMA; INFANTS; RISK; LIFE; OLIGOSACCHARIDES	Background: Less microbial exposure in early childhood is associated with more allergic disease later. Allergic children have a different fecal microflora, with less lactobacilli and bifidobacteria. Beneficial effects regarding the development of allergy have been suggested to come through probiotic supplementation. Objective: We sought to study the effect of probiotic and prebiotic supplementation in preventing allergies. Methods: In a double-blinded, placebo-controlled study we randomized 1223 mothers with infants at high risk for allergy to receive a probiotic mixture (2 lactobacilli, bifidobacteria, and propionibacteria) or placebo during the last month of pregnancy and their infants to receive it from birth until age 6 months. Infants also received a prebiotic galactooligosaccharide or placebo. At 5 years, we evaluated the cumulative incidence of allergic diseases (eczema, food allergy, allergic rhinitis, and asthma) and IgE sensitization. Results: Of the 1018 intent-to-treat infants, 891 (88%) attended the 5-year visit. Frequencies of allergic and IgE-associated allergic disease and sensitization in the probiotic and placebo groups were similar: 52.6% versus 54.9% and 29.5% versus 26.6%, respectively, and 41.3% in both. No significant difference appeared in frequencies of eczema (39.3% vs 43.3%), atopic eczema (24.0% vs 25.1%), allergic rhinitis (20.7% vs 19.1%), or asthma (13.0% vs 14.1%) between groups. However, less IgE-associated allergic disease occurred in cesarean-delivered children receiving probiotics (24.3% vs 40.5%; odds ratio, 0.47; 95% CI, 0.23% to 0.96%; P = .035). Conclusions: No allergy-preventive effect that extended to age 5 years was achieved with perinatal supplementation of probiotic bacteria to high-risk mothers and children. It conferred protection only to cesarean-delivered children. (J Allergy Clin Immunol 2009;123:335-41.)	[Kuitunen, Mikael; Kukkonen, Kaarina; Juntunen-Backman, Kaisu; Haahtela, Tari] Helsinki Univ Cent Hosp, Skin & Allergy Hosp, Helsinki, Finland; [Savilahti, Erkki] Helsinki Univ Cent Hosp, Hosp Children & Adolescents, Helsinki, Finland; [Korpela, Riitta] Univ Helsinki, Inst Biomed, Helsinki, Finland; [Korpela, Riitta; Tuure, Tuula] Valio Ltd, Res & Dev, Helsinki, Finland; [Poussa, Tuija] STAT Consulting, Tampere, Finland	Kuitunen, M (reprint author), Helsinki Univ Cent Hosp, Skin & Allergy Hosp, POB 160, FIN-00029 Helsinki, Finland.	mikael.kuitunen@hus.fi					Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; [Anonymous], 1993, ALLERGY, V48, P48; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Hamilton BE, 2007, PEDIATRICS, V119, P345, DOI 10.1542/peds.2006-3226; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Lund VJ, 1994, ALLERGY S19, V49, P1; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Marschan E, 2008, CLIN EXP ALLERGY, V38, P611, DOI 10.1111/j.1365-2222.2008.02942.x; Moro G, 2006, ARCH DIS CHILD, V91, P814, DOI 10.1136/adc.2006.098251; Renz-Polster H, 2005, CLIN EXP ALLERGY, V35, P1466, DOI 10.1111/j.1365-2222.2005.02356.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sato A, 2003, J IMMUNOL, V171, P3684; Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x; Sudo N, 1997, J IMMUNOL, V159, P1739; SUVILAHTI E, 2008, CURR OPIN ALLERGY CL, V8, P243; Suzuki S, 2007, CLIN EXP ALLERGY, V37, P506, DOI 10.1111/j.1365-2222.2007.02676.x; Taylor AL, 2007, J ALLERGY CLIN IMMUN, V119, P184, DOI 10.1016/j.jaci.2006.08.036; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; Viljanen M, 2005, J ALLERGY CLIN IMMUN, V115, P1254, DOI 10.1016/j.jaci.2005.03.047; Viljanen M, 2005, PEDIATR ALLERGY IMMU, V16, P65, DOI 10.1111/j.1399-3038.2005.00224.x; Villar J, 2007, BRIT MED J, V335, P1025, DOI 10.1136/bmj.39363.706956.55; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x	32	186	198	6	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					335	341		10.1016/j.jaci.2008.11.019		7	Allergy; Immunology	Allergy; Immunology	409GU	WOS:000263495000007	19135235	
J	Bush, RK; Portnoy, JM; Saxon, A; Terr, AI; Wood, RA				Bush, RK; Portnoy, JM; Saxon, A; Terr, AI; Wood, RA			The medical effects of mold exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mold; fungi; hypersensitivity; allergy; asthma	ATOPIC-DERMATITIS; FUNGAL ALLERGENS; 1ST YEAR; SYMPTOMS; HEALTH; ASTHMA; MYCOTOXINS; RISK; IGE; SPORES	Exposure to molds can cause human disease through several well-defined mechanisms. In addition, many new mold-related illnesses have been hypothesized in recent years that remain largely or completely unproved. Concerns about mold exposure and its effects are so common that all health care providers, particularly allergists and immunologists, are frequently faced with issues regarding these real and asserted mold-related illnesses. The purpose of this position paper is to provide a state-of-the-art review of the role that molds are known to play in human disease, including asthma, allergic rhinitis, allergic bronchopulmonary aspergillosis, sinusitis, and hypersensitivity pneumonitis. In addition, other purported mold-related illnesses and the data that currently exist to support them are carefully reviewed, as are the currently available approaches for the evaluation of both patients and the environment.	Univ Wisconsin, Madison, WI USA; Childrens Mercy Hosp, Kansas City, KS USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; Johns Hopkins Med Ctr, Dept Pediat, Baltimore, MD USA	Wood, RA (reprint author), Johns Hopkins Univ Hosp, CMSC 1102,600 N Wolfe St, Baltimore, MD 21287 USA.	rwood@jhmi.edu					*ACOEM COUNC SCI A, 2002, ADV HLTH EFF ASS MOL; Andersson M, 2003, PEDIATR ALLERGY IMMU, V14, P100, DOI 10.1034/j.1399-3038.2003.00031.x; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Bush RK, 2005, J ALLERGY CLIN IMMUN, V115, P123, DOI 10.1016/j.jaci.2004.10.025; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Campbell AW, 2004, ADV APPL MICROBIOL, V55, P375, DOI 10.1016/S0065-2164(04)55015-3; *CDCP, CAS DEF CHEM POIS; McCammon J., 2001, AIR SAMPLING INSTRUM; Committee on the Assessment of Asthma and Indoor Air Division of Health Promotion and Disease Prevention IOM, 2002, CLEAR AIR ASTHM IND; Committee on Damp Indoor Spaces and Health, 2004, DAMP IND SPAC HLTH; *CTR FOOD SAF APPL, 2004, TITL 21 FOOD DRUGS; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; FEIGIN RD, 2003, TXB PEDIAT INFECT DI; Fung F, 2004, J TOXICOL-CLIN TOXIC, V42, P217, DOI 10.1081/CLT-120030947; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gray MR, 2003, ARCH ENVIRON HEALTH, V58, P410; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Helbling A, 1998, J ALLERGY CLIN IMMUN, V102, P853, DOI 10.1016/S0091-6749(98)70028-4; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; Huang SW, 1997, CLIN PEDIATR, V36, P695, DOI 10.1177/000992289703601205; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; Kelman BJ, 2004, INT J TOXICOL, V23, P3, DOI 10.1080/10915810490265423; Lander F, 2001, INFLAMM RES, V50, P227, DOI 10.1007/s000110050748; Luong A, 2004, CURR ALLERGY ASTHM R, V4, P465, DOI 10.1007/s11882-004-0013-5; Macher J, 1999, BIOAEROSOLS ASSESSME; Mandell GL, 2004, PRINCIPLES PRACTICE; Monaci L, 2004, ANAL BIOANAL CHEM, V378, P96, DOI 10.1007/s00216-003-2364-5; Montealegre F, 2004, CLIN EXP ALLERGY, V34, P51, DOI 10.1111/j.1365-2222.2004.01855.x; *OSHA US DEP LAB, BRIEF GUID MOLD WORK; Pasanen AL, 1996, ANALYST, V121, P1949, DOI 10.1039/an9962101949; Pasanen AL, 1998, ENVIRON INT, V24, P703, DOI 10.1016/S0160-4120(98)00065-8; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Reijula K, 2003, ANN ALLERG ASTHMA IM, V91, P280; Roponen M, 2002, INHAL TOXICOL, V14, P541, DOI 10.1080/089583701753678616; ROWE MS, 1986, J ALLERGY CLIN IMMUN, V77, P714, DOI 10.1016/0091-6749(86)90416-1; SALVAGGIO JE, 1994, J ALLERGY CLIN IMMUN, V94, P380; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Taskinen TM, 2002, ALLERGY, V57, P9, DOI 10.1034/j.1398-9995.2002.13154.x; Trout DB, 2004, ANN ALLERG ASTHMA IM, V92, P483; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; 2005, NATURE, V437, P452; [Anonymous], 2005, MMWR MORB MORTAL WKL, V54, P1018	44	186	189	0	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2					326	333		10.1016/j.jaci.2005.12.001		8	Allergy; Immunology	Allergy; Immunology	017IM	WOS:000235687300015	16514772	
J	Matricardi, PM; Rosmini, F; Panetta, V; Ferrigno, L; Bonini, S				Matricardi, PM; Rosmini, F; Panetta, V; Ferrigno, L; Bonini, S			Hay fever and asthma in relation to markers of infection in the United States	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; hay fever; hepatitis A virus; hygiene; infection; epidemiology; National Health and Nutrition Examination Survey III	ANTHROPOSOPHIC LIFE-STYLE; ATOPY; PREVALENCE; CHILDREN; CHILDHOOD; SIBLINGS; EXPOSURE; INCREASE; ALLERGY; HYGIENE	Background: The hygiene hypothesis proposes that declining exposure to infections is implicated in the rising trend of allergy, and asthma. Objective: We sought to test this hypothesis by examining the relationship of hay fever, asthma, and atopic sensitization with markers of infection in a large general population sample of the United States. Methods: We analyzed the data of 33,994 US residents recorded in a public database of a nationally representative cross-sectional survey (Third National Health and Nutrition Examination Survey, 1988-1994). The variables examined were sociodemographic information, lifetime diagnosis and age at first diagnosis of hay fever or asthma, current skin sensitization to 9 airborne allergens and peanut, and current serology for Toxoplasma gondii, herpes simplex viruses type 1 and 2, and hepatitis A, B, and C viruses. Results: Hay fever (adjusted odds ratio, 0.27; 95% CI, 0.18-0.41; P<.001) and asthma (adjusted odds ratio, 0.45; 95% CI, 0.31-0.66; P<.001) were less frequent in subjects seropositive for hepatitis A virus (HAV), T gondii, and herpes simplex virus 1 versus seronegative subjects after adjusting for age, sex, race, urban residence, census region, family size, income, an education. Skin sensitization to peanut and to all the airborne allergens examined, except for cockroach, was less frequent among HAV-seropositive versus HAV-seronegative subjects younger than 40 years of age. The prevalence of hay fever and asthma diagnosed at or before 18 years of age in HAV-seronegative subjects increased progressively from 2.7% (95% CI, 0.71%-4.7%) and 0.4% (95% CI, 0.1%-1.6%), respectively, in cohorts born before 1920 to 8.5% (95% CI, 7.3%-9.7%) and 5.8% (95% CI, 4.8%-6.8%), respectively, in cohorts born in the 1960s, whereas they remained constant at around 2% in all cohorts of HAV-seropositive subjects. Conclusion: In the United States serologic evidence of acquisition of certain infections, mainly food-borne and orofecal infection, is associated with a lower probability of having hay, fever and asthma. Third National Health and Nutrition Examination Survey data support the hypothesis that hygiene is a major factor contributing to the increase in hay fever, asthma, and atopic sensitization in westernized countries.	CNR, Inst Neurobiol & Mol Med, Rome, Italy; Ist Super Sanita, Epidemiol & Biostat Lab, I-00161 Rome, Italy	Matricardi, PM (reprint author), WHO, Chron Resp Dis & Arthrit Unit, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.			Bonini, Sergio/0000-0003-0079-3031			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Behrendt H, 1995, PROG ALLER CLIN IMM, V3, P83; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Busse WW, 2001, NEW ENGL J MED, V344, P350; GUNTER EW, 1996, NCHS CDC PUBLICATION; Holgate ST, 2000, BRIT MED J, V320, P231, DOI 10.1136/bmj.320.7229.231; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Matricardi PM, 1997, BRIT MED J, V314, P999; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; *PLAN OP 3 NAT HLT, 1994, VITAL HLTH STAT, V32, P1; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Snedecor G.W., 1967, STAT METHODS, p[246, 349]; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Weiss ST, 1997, CIBA F SYMP, V206, P244; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	29	186	196	2	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2002	110	3					381	387		10.1067/mai.2002.126658		7	Allergy; Immunology	Allergy; Immunology	592KM	WOS:000177936900006	12209083	
J	Gilliland, FD; Berhane, K; McConnell, R; Gauderman, WJ; Vora, H; Rappaport, EB; Avol, E; Peters, JM				Gilliland, FD; Berhane, K; McConnell, R; Gauderman, WJ; Vora, H; Rappaport, EB; Avol, E; Peters, JM			Maternal smoking during pregnancy, environmental tobacco smoke exposure and childhood lung function	THORAX			English	Article						maternal smoking; pregnancy; environmental tobacco smoke; lung function; children	PULMONARY-FUNCTION; PARENTAL SMOKING; FUNCTION GROWTH; CHILDREN; ASTHMA; LIFE	Background-Exposure to environmental tobacco smoke (ETS) during childhood and in utero exposure to maternal smoking are associated with adverse effects on lung growth and development. Methods-A study was undertaken of the associations between maternal smoking during pregnancy, exposure to ETS, and pulmonary function in 3357 school children residing in 12 Southern California communities. Current and past exposure to household ETS and exposure to maternal smoking in utero were assessed by at self-administered questionnaire completed by parents of 4th,7th; and 10th grade students in 1993. Standard linear regression techniques were used to estimate the effects of in utero and ETS exposure on lung function, adjusting for age, sex, race, Hispanic ethnicity, height, weight, asthma, personal smoking, and selected household characteristics. Results-In utero exposure to maternal smoking was associated with reduced peak expiratory flow rate (PEFR) (-3.0%, 95% CI -4.4 to -1.4), mean mid expiratory flow (MMEF) (-4.6%, 95% CI -7.0 to -2.3), and forced expiratory flow (FEF75) (-6.2%, 95% CI -9.1 to -3.1), but not forced expiratory volume in one second (FEV1). Adjusting for household ETS exposure did not substantially change these estimates. The reductions in flows associated with in utero exposure did not significantly vary with sex, race, grade, income, parental education, or personal smoking. Exposure to two or more current household smokers was associated with reduced MMEF (-4.1%, 95% CI -7.6 to -0.4) and FEF75 (-4.4%, 95% CI -9.0 to 0.4). Current or past maternal smoking was associated with reductions in PEFR and MMEF; however, after adjustment for in utero exposure, deficits in MMEF and FEF75 associated with all measurements of ETS were substantially reduced and were not statistically significant. Conclusions-In utero exposure to maternal smoking is independently associated with decreased lung function in children of school age, especially for small airway flows.	Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA.				NHLBI NIH HHS [R01 HL/ES61768-01]; NIEHS NIH HHS [1PO1ESO939581-05, 5P30ES07048-02]		American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; BURROWS B, 1980, AM REV RESPIR DIS, V122, P813; California Environmental Protection Agency, 1997, HLTH EFF EXP ENV TOB; *CDC, 1997, MMWR-MORBID MORTAL W, V46, P1038; Cook DG, 1998, THORAX, V53, P884; COULTAS DB, 1989, AM J EPIDEMIOL, V130, P338; COULTAS DB, 1990, AM REV RESPIR DIS, V142, P602; CUNNINGHAM J, 1995, AM J RESP CRIT CARE, V152, P565; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Dezateux C, 1997, BRIT MED BULL, V53, P40; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172; Hanrahan J P, 1998, Eur Respir J Suppl, V27, p46s; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Jedrychowski W, 1997, Pneumonol Alergol Pol, V65, P605; Lodrup Carlsen K C, 1997, Eur Respir J, V10, P1774, DOI 10.1183/09031936.97.10081774; ORYSZCZYN MP, 1991, J ALLERGY CLIN IMMUN, V87, P1169, DOI 10.1016/0091-6749(91)92163-U; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; RONCHETTI R, 1994, EUR RESPIR J, V7, P472, DOI 10.1183/09031936.94.07030472; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TAGER IB, 1987, AM REV RESPIR DIS, V136, P1366; *US DHHS, 1986, 878398 US DHHS; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420; Wypij D, 1996, AM J RESP CRIT CARE, V154, pS223	32	186	198	1	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	APR	2000	55	4					271	276		10.1136/thorax.55.4.271		6	Respiratory System	Respiratory System	299FK	WOS:000086185800006	10722765	
J	Thorne, PS; Kulhankova, K; Yin, M; Cohn, R; Arbes, SJ; Zeldin, DC				Thorne, PS; Kulhankova, K; Yin, M; Cohn, R; Arbes, SJ; Zeldin, DC			Endotoxin exposure is a risk factor for asthma - The National Survey of Endotoxin in United States Housing	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway inflammation; house dust; lipopolysaccharide; wheeze	LOWER RESPIRATORY-TRACT; DUST-INDUCED INFLAMMATION; GRAIN DUST; COTTON DUST; AIRBORNE ENDOTOXIN; ALLERGIC DISEASES; BIRTH COHORT; CHILDREN; FARM; LIPOPOLYSACCHARIDE	Background: Although research has shown that early life exposure to household endotoxin protects against development of allergies, studies are less clear on the relationship between household endotoxin exposure and prevalence of wheezing and asthma. We assayed 2,552 house dust samples in a representative nationwide sample to explore relationships between endotoxin exposures and risk factors for asthma, asthma symptoms, and medication use. Methods: House dust was vacuum-sampled from five locations within homes and assayed for endotoxin. Health, demographic, and housing information was assessed through questionnaire and on-site evaluation of 2,456 residents of 831 homes selected to represent the demographics of the United States. Results: Endotoxin concentration (EU/mg) and load (EU/m(2)) were highly correlated (r = 0.73-0.79). Geometric mean endotoxin concentrations were as follows (in EU/mg): bedroom floors, 35.3 (5th-95th percentile, 5.0-260); bedding, 18.7 (2.0-142); family room floors, 63.9 (11.5-331); sofas, 44.8 (6.4-240); and kitchen floors, 80.5 (9.8-512). Multivariate analysis demonstrated significant relationships between increasing endotoxin levels and diagnosed asthma, asthma symptoms in the past year, current use of asthma medications, and wheezing among residents of the homes. These relationships were strongest for bedroom floor and bedding dust and were observed in adults only. Modeling the joint effect of bedding and bedroom floor endotoxin on recent asthma symptoms yielded an adjusted odds ratio of 2.83 (95% confidence interval, 1.01-7.87). When stratified by allergy status, allergic subjects with higher endotoxin exposure were no more likely to have diagnosed asthma or asthma symptoms than nonallergic subjects. Conclusion: This study demonstrates that household endotoxin exposure is a significant risk factor for increased asthma prevalence.	Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Environm Hlth Sci Res Ctr, Iowa City, IA 52242 USA; Constella Grp Inc, Durham, NC USA; NIEHS, Div Intramural Res, Res Triangle Pk, NC 27709 USA	Thorne, PS (reprint author), Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Environm Hlth Sci Res Ctr, 100 Oakdale Campus,176 IREH, Iowa City, IA 52242 USA.	peter-thorne@uiowa.edu			Intramural NIH HHS; NIEHS NIH HHS [P30 ES05605, Z01 ES025041-08]		Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; CASTELLAN RM, 1984, ANN INTERN MED, V101, P157; CAVAGNA G, 1969, BRIT J IND MED, V26, P314; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; CINKOTAI FF, 1977, AM IND HYG ASSOC J, V38, P554, DOI 10.1080/0002889778507669; CLAPP WD, 1994, AM J RESP CRIT CARE, V150, P611; Deetz DC, 1997, AM J RESP CRIT CARE, V155, P254; Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gioannini TL, 2003, J ENDOTOXIN RES, V9, P401, DOI 10.1179/096805103225002773; Jagielo PJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1052; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Merchant JA, 2005, ENVIRON HEALTH PERSP, V113, P350, DOI 10.1289/ehp.7240; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Mueller-Anneling L, 2004, ENVIRON HEALTH PERSP, V112, P583, DOI 10.1289/ehp.6552; National Center for Health Statistics, 2002, ASTHM PREV HLTH CAR; Nomura F, 2000, J IMMUNOL, V164, P3476; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; PERNIS B, 1960, Med Lav, V51, P780; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; RYLANDER R, 1987, AM J IND MED, V12, P687, DOI 10.1002/ajim.4700120607; SCHWARTZ DA, 1994, AM J PHYSIOL-LUNG C, V267, pL609; Thorne PS, 1999, AM J RESP CELL MOL, V20, P1155; THORNE PS, 2000, TOXICOLOGY, V152, P627; THORNE PS, 2003, AM J RESP CRIT CARE, V167, pA470; THORNE PS, 1999, ORGANIC INDOOR AIR P, P275, DOI 10.1002/9783527613663.ch20; Tobias PS, 1999, CLIN INFECT DIS, V28, P476, DOI 10.1086/515163; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000	41	185	190	0	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2005	172	11					1371	1377		10.1164/rccm.200505-758OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	989TR	WOS:000233697300006	16141442	
J	Pijnenburg, MW; Hofhuis, W; Hop, WC; De Jongste, JC				Pijnenburg, MW; Hofhuis, W; Hop, WC; De Jongste, JC			Exhaled nitric oxide predicts asthma relapse in children with clinical asthma remission	THORAX			English	Article							AIRWAY INFLAMMATION; INHALED BUDESONIDE; CHILDHOOD ASTHMA; MILD ASTHMA; MARKERS; CORTICOSTEROIDS; REPRODUCIBILITY; BECLOMETHASONE; ADULTS	Background: Nitric oxide in exhaled air (FENO) is a marker of eosinophilic airway inflammation. A study was undertaken to determine whether FENO predicts asthma relapse in asymptomatic asthmatic children in whom inhaled corticosteroids are discontinued. Methods: Forty children ( 21 boys) of mean age 12.2 years on a median dose of 400 mg budesonide or equivalent ( range 100 - 400) were included. FENO was measured before and 2, 4, 12, and 24 weeks after withdrawal of steroids. A relapse was defined as more than one exacerbation per month, or need for beta agonist treatment on 4 days per week for at least 2 weeks, or diurnal peak flow variability of >20%. FENO measurements were performed online with an expiratory flow of 50 ml/s. Results: Nine patients relapsed. Two and 4 weeks after withdrawal of steroids geometric mean FENO in children who were about to relapse was higher than in those who did not relapse: 35.3 ppb v 15.7 ppb at 2 weeks ( ratio 2.3; 95% CI 1.2 to 4.1; p = 0.01) and 40.8 ppb v 15.9 ppb at 4 weeks ( ratio 2.6; 95% CI 1.3 to 5.1). An FENO value of 49 ppb at 4 weeks after discontinuation of steroids had the best combination of sensitivity ( 71%) and specificity ( 93%) for asthma relapse. Conclusion: FENO 2 and 4 weeks after discontinuation of steroids in asymptomatic asthmatic children may be an objective predictor of asthma relapse.	Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat Paediat Resp Med, NL-3000 CB Rotterdam, Netherlands; Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Biostat & Epidemiol, Rotterdam, Netherlands	De Jongste, JC (reprint author), Sophia Childrens Univ Hosp, Erasmus Med Ctr, Dept Paediat Paediat Resp Med, POB 2060, NL-3000 CB Rotterdam, Netherlands.	j.c.dejongste@erasmusmc.nl					Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Baraldi E, 1997, J PEDIATR-US, V131, P381, DOI 10.1016/S0022-3476(97)80062-5; Barbee RA, 1998, J ALLERGY CLIN IMMUN, V102, pS65, DOI 10.1016/S0091-6749(98)70006-5; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; COX DR, 1972, J R STAT SOC B, V34, P187; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hoekstra M O, 1997, Ned Tijdschr Geneeskd, V141, P2223; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; LIM TK, 2001, AM J RESP CRIT CARE, V163, pA48; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Strachan DP, 1999, ALLERGY, V54, P7, DOI 10.1111/j.1398-9995.1999.tb04381.x; Verberne AAPH, 1998, AM J RESP CRIT CARE, V158, P213; Zapletal A, 1987, PROGR RESPIRATION RE, V22, P114	21	185	193	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2005	60	3					215	218		10.1136/thx.2004.023374		4	Respiratory System	Respiratory System	904BR	WOS:000227470700011	15741438	
J	Guilbert, TW; Morgan, WJ; Zeiger, RS; Bacharier, LB; Boehmer, SJ; Krawiec, M; Larsen, G; Lemanske, RF; Liu, A; Mauger, DT; Sorkness, C; Szefler, SJ; Strunk, RC; Taussig, LM; Martinez, FD				Guilbert, TW; Morgan, WJ; Zeiger, RS; Bacharier, LB; Boehmer, SJ; Krawiec, M; Larsen, G; Lemanske, RF; Liu, A; Mauger, DT; Sorkness, C; Szefler, SJ; Strunk, RC; Taussig, LM; Martinez, FD			Atopic characteristics of children with recurrent wheezing at high risk for the development of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; aeroallergen and food sensitization; asthma predictive index; atopy; clinical trials; earIv childhood asthma; fluticasone; glucocorticoids; intermittent wheezing; prevention of asthma; research network; skin prick test	MANAGEMENT PROGRAM CAMP; INNER-CITY ASTHMA; HOUSE-DUST MITE; BRONCHIAL HYPERRESPONSIVENESS; NATURAL-HISTORY; IGE ANTIBODIES; ALLERGENS; SENSITIZATION; EXPOSURE; DESIGN	Background: Few studies have characterized the atopic profile of toddler-aged children with recurrent wheezing at high risk of the development of persistent asthma. Objective: We sought to determine the atopic profile of toddler-aged children with frequent wheeze at high risk for the development of persistent asthma who either had a parental history of asthma, a personal history of atopic dermatitis, or both. Methods: Participants enrolled in the Prevention of Early Asthma in Kids study (n = 285) on the basis of a modified Asthma Predictive Index were characterized on the basis of allergy and asthma questionnaire responses and allergy skin puncture test results. Results: The majority of the children (60.7%, n = 148) were sensitized to either food or aeroallergens. Male children were significantly more likely to be sensitized to aeroallergens (P =.03) and to have a blood eosinophil level of 4% or greater (P =.03) and a total serum IgE level of greater than 100 IU/mL (P =.0004). Additionally, eosinophilia and total serum IgE level had the strongest correlation with aeroallergen sensitization. Conclusion: The high prevalence of aeroallergen sensitization in this high-risk cohort suggests that aeroallergens might have an important role in the early development of asthma. As such, the Prevention of Early Asthma in Kids cohort appears to he an appropriate cohort in which to test whether early intervention with an inhaled corticosteroid can significantly attenuate, or perhaps even prevent, the allergic march from the initial stages of allergic sensitization to the subsequent development of asthma in toddlers with episodic wheezing.	Univ Arizona, Div Pediat Pulm Med, Arizona Resp Ctr, Tucson, AZ 85724 USA; Univ Calif San Diego, San Diego, CA 92103 USA; Kaiser Permanente, San Diego, CA USA; Washington Univ, St Louis, MO USA; Penn State Univ, Hershey, PA USA; Univ Wisconsin, Madison, WI USA; Natl Jewish Med & Res Ctr, Denver, CO USA	Guilbert, TW (reprint author), Univ Arizona, Div Pediat Pulm Med, Arizona Resp Ctr, 1501 N Campbell Ave,POB 245073, Tucson, AZ 85724 USA.	Guilbert@arc.arizona.edu		Guilbert, Theresa/0000-0002-6932-712X	NHLBI NIH HHS [HL64313, HL004519-04, HL071742-01]		Air pollution and respiratory health Br NCEH CDC, 1996, MMWR MORB MORTAL WKL, V45, P350; Amr S, 2003, ANN ALLERG ASTHMA IM, V90, P34; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arlian LG, 2001, ANN ALLERG ASTHMA IM, V87, P296; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; *CHILD ASTH MAN PR, 1994, CHILDH ASTHM MAN PRO; DUFF AL, 1993, PEDIATRICS, V92, P535; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HILL DJ, 1994, CLIN EXP ALLERGY, V24, P1137; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mitchell H, 1997, PEDIATR PULM, V24, P237; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; NELSON HS, 1995, ANN ALLERG ASTHMA IM, V75, P337; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Pao CS, 2002, AM J RESP CRIT CARE, V166, P945, DOI 10.1164/rccm.200203-265OC; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Platts-Mills TA, 2000, J ALLERGY CLIN IMMUN, V105, P503; PRICE GW, 1995, J ALLERGY CLIN IMMUN, V96, P266, DOI 10.1016/S0091-6749(95)70020-X; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Song CH, 1997, ANN ALLERG ASTHMA IM, V79, P273; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050; Stein RT, 1997, THORAX, V52, P946; Strunk RC, 2002, J ALLERGY CLIN IMMUN, V110, P395, DOI 10.1067/mai.2002.127433; SULLIVAN S, 1996, AM J RESP CRIT CAR S, V154, P84; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4; 1992, MMWR MORB MORTAL WKL, V41, P733	39	185	200	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2004	114	6					1282	1287		10.1016/j.jaci.2004.09.020		6	Allergy; Immunology	Allergy; Immunology	877NN	WOS:000225577400005	15577824	
J	Venn, AJ; Lewis, SA; Cooper, M; Hubbard, R; Britton, J				Venn, AJ; Lewis, SA; Cooper, M; Hubbard, R; Britton, J			Living near a main road and the risk of wheezing illness in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; wheezing; children; vehicular emissions	CHRONIC RESPIRATORY SYMPTOMS; TRAFFIC DENSITY; AIR-POLLUTION; ASTHMA; PREVALENCE; MOTORWAYS; EXPOSURE; EXHAUST	The effect of road vehicle traffic pollution on asthma is still not clearly understood. However, any effect is likely to be most marked among those who live within 150 m of a main road, because this is the distance within which concentrations of primary vehicle traffic pollutants are raised above ambient background levels. We have investigated the relation between proximity of the family home to the nearest main road, estimated objectively using geographical information system software, and the risk of wheeze in the past year in a case-control sample of 6,147 primary schoolchildren (age 4 to I I yr) and a random cross-sectional sample of 3,709 secondary schoolchildren (age I I to 16 yr) in Nottingham, United Kingdom. Among children living within 150 m of a main road, the risk of wheeze increased with increasing proximity by an odds ratio (OR) of 1.08 (95% confidence interval [CI] 1.00 to 1.16) per 30-m increment in primary schoolchildren, and 1.16 (1.02 to 1.32) in secondary schoolchildren. Most of the increased risk was localized to within 90 m of the roadside. Among primary schoolchildren, effects were stronger in girls than boys (P-interaction = 0.02). Living within approximately 90 m of a main road is associated with a proximity-related increase in the risk of wheezing illness in children.	Univ Nottingham, Div Resp Med, Nottingham NG7 2RD, England	Venn, AJ (reprint author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.		Britton, John/G-9705-2011; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; CARSTAIRS V, 1989, COMMUNITY MED, V11, P364; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; *DEP TRANSP SCOTT, 1994, DES MAN ROADS BRIDG, V11; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; FORASTIERE F, 1994, AM J RESP CRIT CARE, V149, P365; Livingstone AE, 1996, BRIT MED J, V312, P676; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 1998, EUR RESPIR J, V11, P1324, DOI 10.1183/09031936.98.11061324; Venn A, 1998, BRIT MED J, V316, P1945; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilkinson P, 1999, THORAX, V54, P1070	18	185	188	1	14	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2001	164	12					2177	2180		10.1164/rccm2106126		4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	528XX	WOS:000174271400011	11751183	
J	Wolkoff, P; Nielsen, GD				Wolkoff, P; Nielsen, GD			Organic compounds in indoor air - their relevance for perceived indoor air quality?	ATMOSPHERIC ENVIRONMENT			English	Article						airway irritation; indoor air quality; OCIA; odour annoyance; TVOC; volatile organic compounds (VOCs)	SICK BUILDING SYNDROME; ENVIRONMENTAL TOBACCO-SMOKE; BIOLOGICAL EVALUATION; MATERIAL EMISSIONS; INHALED ALLERGEN; RISK-ASSESSMENT; OFFICE WORKERS; EYE IRRITATION; VOC EMISSIONS; OZONE	It is generally believed that indoor air pollution, one way or another may cause indoor air complaints. However, any association between volatile organic compounds (VOCs) concentrations and increase of indoor climate complaints, like the sick-building syndrome symptoms, is not straightforward. The reported symptom rates of, in particular, eye and upper airway irritation cannot generally be explained by our present knowledge of common chemically non-reactive VOCs measured indoors. Recently, experimental evidence has shown those chemical reactions between ozone (either with or without nitrogen dioxide) and unsaturated organic compounds (e.g. from citrus and pine oils) produce strong eye and airway irritating species. These have not yet been well characterised by conventional sampling and analytical techniques. The chemical reactions can occur indoors, and there is indirect evidence that they are associated with eye and airway irritation. However, many other volatile and non-volatile organic compounds have not generally been measured which could equally well have potent biological effects and cause an increase of complaint rates, and posses a health/comfort risk. As a consequence, it is recommended to use a broader analytical window of organic compounds than the classic VOC window as defined by the World Health Organisation. It may include hitherto not yet sampled or identified intermediary species (e.g., radicals, hydroperoxides and ionic compounds like detergents) as well as species deposited onto particles. Additionally, sampling strategies including emission testing of building products should carefully be linked to the measurement of organic compounds that are expected, based on the best available toxicological knowledge, to have biological effects at indoor concentrations. (C) 2001 Elsevier Science Ltd. All rights reserved.	Natl Inst Occupat Hlth, DK-2100 Copenhagen O, Denmark	Wolkoff, P (reprint author), Natl Inst Occupat Hlth, Lerso Parkalle 105, DK-2100 Copenhagen O, Denmark.	pwo@ami.dk		Wolkoff, Peder/0000-0003-1933-7351			Alarie Y, 1996, SAR QSAR Environ Res, V5, P151, DOI 10.1080/10629369608032986; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Becher R, 1996, TOXICOL LETT, V86, P155, DOI 10.1016/0378-4274(96)03685-5; Bergeron P, 1996, J ENDOVASC SURG, V3, P1, DOI 10.1583/1074-6218(1996)003<0001:SSOCDT>2.0.CO;2; BERNHARD CA, 1995, P HLTH BUILD 95 MIL, V3, P1347; BORNEHAG CG, 2001, UNPUB INDOOR AIR, V11; BORNEHAG CG, 2000, P HLTH BUILD 2000 WO, V25, P117; Bornehag CG, 2000, P HLTH BUILD 2000 ES, V1, P437; Bourbeau J, 1997, OCCUP ENVIRON MED, V54, P49; BRIGHTMAN HS, 2000, INDOOR AIR QUALITY H, pCH3; Brown SK, 1999, INDOOR AIR, V9, P259, DOI 10.1111/j.1600-0668.1999.00005.x; Brown S.K., 1999, ORGANIC INDOOR AIR P, P171; BROWN V, 1996, IEH ASSESSMENT INDOO, P152; CAIN WS, 1987, ATMOS ENVIRON, V21, P347, DOI 10.1016/0004-6981(87)90011-4; Cain WS, 1986, IAQ 86 MANAGING INDO, P126; Calogirou A, 1996, ANAL CHEM, V68, P1499, DOI 10.1021/ac950803i; Clausen PA, 1998, J CHROMATOGR A, V814, P161, DOI 10.1016/S0021-9673(98)00397-5; Eriksson KA, 1997, SCAND J WORK ENV HEA, V23, P114; *EUR COLL ACT ECA, 1997, 19 EUR COMM; Fenske JD, 1999, J AIR WASTE MANAGE, V49, P594; Fisk WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; Girman JR, 1999, P 8 INT C IND AIR QU, V2, P460; GROES L, 1996, P 6 INT C IND AIR QU, V4, P237; GUNNARSEN L, 1992, ENVIRON INT, V18, P43, DOI 10.1016/0160-4120(92)90209-M; Hempel-Jorgensen A, 1999, ARCH ENVIRON HEALTH, V54, P86; Hodgson AT, 2000, INDOOR AIR, V10, P178, DOI 10.1034/j.1600-0668.2000.010003178.x; HOLCOMB LC, 1995, INDOOR ENVIRON, V4, P7, DOI 10.1177/1420326X9500400103; Hoppe P, 1995, ENVIRON RES, V71, P109, DOI 10.1006/enrs.1995.1072; HUDNELL HK, 1993, INDOOR AIR 93, V1, P567; HUMMEL T, 2000, CHEM SENSES, V25, P788; Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223; JAKAB GJ, 1994, J TOXICOL ENV HEALTH, V41, P221; JENSEN B, 1995, INDOOR AIR, V5, P44, DOI 10.1111/j.1600-0668.1995.t01-3-00007.x; JENSEN B, 1996, VOCBASE ODOR MUCOUS; KANE LE, 1978, AM IND HYG ASSOC J, V39, P270, DOI 10.1080/0002889778507758; KNUDSEN HK, 2000, P HLTH BUILD 2000, V1, P217; Knudsen HN, 1999, ATMOS ENVIRON, V33, P1217, DOI 10.1016/S1352-2310(98)00278-7; KOREN HS, 1992, ARCH ENVIRON HEALTH, V47, P39; KRZYZANOWSKI M, 1992, ARCH ENVIRON HEALTH, V47, P107; Leovic KW, 1996, J AIR WASTE MANAGE, V46, P821; Massold E., 2000, P HLTH BUILD 2000, V4, P67; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Molhave L, 2000, INDOOR AIR, V10, P315, DOI 10.1034/j.1600-0668.2000.010004315.x; Nielsen GD, 1997, INDOOR AIR, V7, P8, DOI 10.1111/j.1600-0668.1997.t01-3-00003.x; Nielsen GD, 1997, INDOOR AIR, V7, P17; NIELSEN GD, 1995, SCAND J WORK ENV HEA, V21, P165; OPPL R, 2000, INNENRAUMLUFT TVOC, V43, P513; Pasanen AL, 1998, ENVIRON INT, V24, P703, DOI 10.1016/S0160-4120(98)00065-8; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Prah JD, 1998, ENVIRON HEALTH PERSP, V106, P739, DOI 10.1289/ehp.98106739; Purohit A, 2000, INT ARCH OCC ENV HEA, V73, P423, DOI 10.1007/s004200000162; RAMAZZINI B, 1991, ARBETSMILJOFORLAGET, P176; Reitzig M, 1998, INDOOR AIR, V8, P91, DOI 10.1111/j.1600-0668.1998.t01-2-00004.x; Rodes C, 1991, INDOOR AIR, V2, P123, DOI 10.1111/j.1600-0668.1991.03-12.x; ROFZKAMP E, 2001, GEFAHRSTOFFE REINHAL, V61, P41; ROTHWEILER H, 1993, TOXICOL ENVIRON CHEM, V40, P93, DOI 10.1080/02772249309357934; SAARELA K, 1999, P IND AIR 99, V4, P405; SALTHAMMER T, 1998, ATMOS ENVIRON, V32, P75; Sanderson WT, 1999, SCAND J WORK ENV HEA, V25, P227; SCHLEIBINGER H, 2000, GEFAHRSTOFFE REINHAL, V61, P26; SEIFE C, 1999, NEW SCI         0731, P5; SEIFERT B, 1995, SCI TOTAL ENVIRON, V168, P101, DOI 10.1016/0048-9697(95)04613-6; Shields HC, 1996, INDOOR AIR, V6, P2, DOI 10.1111/j.1600-0668.1996.t01-3-00002.x; SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286; STEPHENS ER, 1961, INT J AIR WATER POLL, V4, P79; Subramanian P, 2000, J ENVIRON SCI HEAL A, V35, P999; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; Sundell J., 1993, INDOOR AIR, V3, P82, DOI 10.1111/j.1600-0668.1993.t01-2-00003.x; Thuerauf N, 2000, J CLIN PSYCHOPHARM, V20, P472, DOI 10.1097/00004714-200008000-00012; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Tuomainen M, 2001, ATMOS ENVIRON, V35, P305, DOI 10.1016/S1352-2310(00)00157-6; VEJRUP KV, 1999, 8 INT C IND AIR QUAL, V4, P244; Walker JC, 1997, INDOOR AIR, V7, P173, DOI 10.1111/j.1600-0668.1997.t01-1-00003.x; Weschler CJ, 2000, INDOOR AIR, V10, P92, DOI 10.1034/j.1600-0668.2000.010002092.x; Weschler CJ, 1997, ATMOS ENVIRON, V31, P3487, DOI 10.1016/S1352-2310(97)00219-7; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x; WHO, 1989, EURO REP STUD, V111; Wilkins CK, 1998, PHARMACOL TOXICOL, V83, P112; Wilkins C. K., 1993, INDOOR AIR, V3, P283, DOI 10.1111/j.1600-0668.1993.00010.x; Wolkoff P, 1997, INDOOR AIR, V7, P92, DOI 10.1111/j.1600-0668.1997.t01-2-00003.x; Wolkoff P, 1999, SCI TOTAL ENVIRON, V227, P197, DOI 10.1016/S0048-9697(99)00019-4; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Wolkoff P, 1995, INDOOR AIR, P1, DOI 10.1111/j.1600-0668.1995.tb00017.x; Wolkoff P, 1996, ATMOS ENVIRON, V30, P2679, DOI 10.1016/1352-2310(95)00323-1; Wolkoff P, 2000, INDOOR AIR, V10, P82, DOI 10.1034/j.1600-0668.2000.010002082.x; Wolkoff P., 1992, J EXPOSURE ANAL EN S, V1, P71; Wolkoff P., 1991, INDOOR AIR, V1, P389, DOI 10.1111/j.1600-0668.1991.00003.x	87	185	191	12	73	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	SEP	2001	35	26					4407	4417		10.1016/S1352-2310(01)00244-8		11	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	471MK	WOS:000170933000004		
J	Kramer, U; Koch, T; Ranft, U; Ring, J; Behrendt, H				Kramer, U; Koch, T; Ranft, U; Ring, J; Behrendt, H			Traffic-related air pollution is associated with atopy in children living in urban areas	EPIDEMIOLOGY			English	Article						air pollution; traffic; atopy; child; nitrogen dioxide; living conditions; urban environment; gender	CHRONIC RESPIRATORY SYMPTOMS; NITROGEN-DIOXIDE EXPOSURE; DIESEL EXHAUST PARTICLES; AUTOMOBILE EXHAUST; ASTHMATIC-PATIENTS; ALLERGIC RHINITIS; INHALED ALLERGEN; LUNG-FUNCTION; HEALTH; PREVALENCE	Traffic emissions are a major source of air pollution in Western industrialized countries. To investigate the association between traffic-related air pollution and parameters of atopy, we studied 317 children 9 years of age living near major roads in two urban areas and one suburban area of a city in West Germany. Atopic sensitization was analyzed by skin-prick testing and determination of allergen-specific serum immunoglobulin E. Parents recorded allergic symptoms in a symptom diary, and physicians assessed allergic diseases. Personal NO2 exposure and NO2 concentrations in front of each child's home were measured. Outdoor NO2 was a good predictor for traffic exposure but a poor predictor for NO2 exposure at the personal level. Atopy was found to be related to outdoor NO2 (odds ratio for the association between symptoms of allergic rhinitis and outdoor NO2 = 1.81; 95% confidence interval = 1.02-3.21) but not to personal NO2 (odds ratio for the association between symptoms of allergic rhinitis and personal NO2 = 0.99; 95% confidence interval = 0.55-1.79). When the analysis was restricted to urban areas, we found that hay fever, symptoms of allergic rhinitis, wheezing, sensitization against pollen, house dust mites or cats, and milk or eggs were associated with outdoor NO2. The results indicate that traffic-related air pollution leads to increased prevalence of atopic sensitizations, allergic symptoms, and diseases.	Univ Dusseldorf, Med Inst Environm Hyg, D-40225 Dusseldorf, Germany; Tech Univ Munich, Dept Dermatol & Allergol, Munich, Germany; Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergol, Munich, Germany	Kramer, U (reprint author), Univ Dusseldorf, Med Inst Environm Hyg, Hennekamp 50, D-40225 Dusseldorf, Germany.						Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; Behrendt H, 1995, PROG ALLER CLIN IMM, V3, P83; Blomberg A, 1997, AM J RESP CRIT CARE, V156, P418; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; KRAMER U, 1997, NEW TRENDS ALLERGY, V4, P21; LUTTMANN H, 1994, ZBL HYG UMWELTMED, V196, P114; NAKAI S, 1995, J EXPO ANAL ENV EPID, V5, P125; NAKATSUKA H, 1991, ENVIRON INT, V17, P51, DOI 10.1016/0160-4120(91)90337-P; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; RaaschouNielsen O, 1997, ENVIRON HEALTH PERSP, V105, P964; RAFT U, 1996, P C ENV EP EUR 1995, P340; RANFT U, 1992, P 9 WORLD CLEAN AIR, V5; SCHUPP A, 1994, ALLERGOLOGIE, V17, P591; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; *UMW STADT DUSS, 1997, LUFTB DUSS MESSB 199; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; WANG JH, 1995, J ALLERGY CLIN IMMUN, V96, P669, DOI 10.1016/S0091-6749(95)70266-0; WANG JH, 1995, INT ARCH ALLERGY IMM, V107, P103; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; World Health Organization, 1997, ENV HLTH CRIT, V188; WJST M, 1993, BRIT MED J, V307, P596	35	185	193	0	28	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	JAN	2000	11	1					64	70		10.1097/00001648-200001000-00014		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	266TH	WOS:000084316000014	10615846	
J	Clark, NA; Demers, PA; Karr, CJ; Koehoorn, M; Lencar, C; Tamburic, L; Brauer, M				Clark, Nina Annika; Demers, Paul A.; Karr, Catherine J.; Koehoorn, Mieke; Lencar, Cornel; Tamburic, Lillian; Brauer, Michael			Effect of Early Life Exposure to Air Pollution on Development of Childhood Asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						administrative data; air pollution; asthma; children's health; in utero; respiratory; traffic	LAND-USE REGRESSION; RESPIRATORY HEALTH; SOUTHERN CALIFORNIA; BIRTH COHORT; PARTICULATE MATTER; PULMONARY-FUNCTION; CHILDREN; SYMPTOMS; WOODSMOKE; OUTCOMES	BACKGROUND: There is increasing recognition of the importance of early environmental exposures in the development of childhood asthma. Outdoor air pollution is a recognized asthma trigger, but it is unclear whether exposure influences incident disease. We investigated the effect of exposure to ambient air pollution in utero and during the first year of life oil risk of subsequent asthma diagnosis in a population-based nested case-control study. METHODS: We assessed all children born in southwestern British Columbia in 1999 and 2000 (n = 37,401) for incidence of asthma diagnosis tip to 3-4 years of age using outpatient and hospitalization records. Asthma cases were age- and sex-matched to five randomly chosen controls from the eligible cohort. We estimated each individual's exposure to ambient air pollution for the gestational period and first year of life using high-resolution pollution surfaces derived from regulatory monitoring data as well as land use regression models adjusted for temporal variation. We used logistic regression analyses to estimate effects of carbon monoxide, nitric oxide, nitrogen dioxide, particulate matter <= 10 mu m and < 2.5 mu m in aerodynamic diameter (PM(10) and PM(2.5)), ozone, sulfur dioxide, black carbon, woodsmoke, and proximity to roads and point sources on asthma diagnosis. RESULTS: A total of 3,482 children (9%) were classified as asthma cases. We observed a statistically significantly increased risk of asthma diagnosis with increased earl), life exposure to CO, NO, NO(2), PM(10), SO(2), and black carbon and proximity to point sources. Traffic-related pollutants were associated with the highest risks: adjusted odds ratio = 1.08 (95% confidence interval, 1.04-1.12) for a 10-mu g/m(3) increase of NO, 1.12 (1.07-1.17) for a 10-mu g/m(3) increase in NO(2), and 1.10 (1.06-1.13) for a 100-mu g/m(3) increase in CO. These data support the hypothesis that early childhood exposure to air pollutants plays a role in development of asthma.	[Demers, Paul A.; Koehoorn, Mieke; Lencar, Cornel; Brauer, Michael] Univ British Columbia, Sch Environm Hlth, Vancouver, BC V6T 1Z3, Canada; [Clark, Nina Annika; Demers, Paul A.; Koehoorn, Mieke] Univ British Columbia, Sch Populat & Publ Hlth, Vancouver, BC V6T 1Z3, Canada; [Karr, Catherine J.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Tamburic, Lillian] Univ British Columbia, Ctr Hlth Serv & Policy Res, Vancouver, BC V6T 1Z3, Canada	Brauer, M (reprint author), Univ British Columbia, Sch Environm Hlth, 2206 East Mall, Vancouver, BC V6T 1Z3, Canada.	brauer@interchange.ubc.ca	Wang, Linden/M-6617-2014; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Brauer, Michael/0000-0002-9103-9343	Health Canada; Centre for Health and Environment Research at the University of British Columbia; Michael Smith Foundation	The research was supported in part by Health Canada via all agreement with the British Columbia Centre for Disease Control to the Border Air Quality Study. Additional support was provided by the Centre for Health and Environment Research at the University of British Columbia, funded by the Michael Smith Foundation for Health Research. N.A.C. Was supported by the Michael Smith Foundation for Health Research Junior Graduate Trainee Award, the Canadian Institutes for Health Research Master's Award, and the Bridge Program fellowship (a Canadian Institutes for Health Research Strategic Training Program). M.K. was supported by a Michael Smith Foundation for Health Research Scholar Award.	Allen RW, 2008, INHAL TOXICOL, V20, P423, DOI 10.1080/08958370801903826 ; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; BRAUER M, 2008, AIR POLLUTION MODELL, V19, P589; Brauer M, 2008, ENVIRON HEALTH PERSP, V116, P680, DOI 10.1289/ehp.10952; *BRIT COL MIN HLTH, 2009, HLTH CAR HLTH SERV D; *BRIT COL PER HLTH, 2009, PER DAT REG; *BRIT COL VIT STAT, 2009, VIT STAT AG; CICCONE G, 1998, ROAD TRAFFIC ADVERSE; Derauf C, 2003, AM J EPIDEMIOL, V158, P705, DOI 10.1093/aje/kwg215; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Haberg SE, 2007, AM J EPIDEMIOL, V166, P679, DOI 10.1093/aje/kwm134; Hanley GE, 2008, BMC HEALTH SERV RES, V8, DOI 10.1186/1472-6963-8-79; Henderson SB, 2007, ENVIRON SCI TECHNOL, V41, P2422, DOI 10.1021/es0606780; *I MED, 2000, CLEAR AIR ASTH IND A; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Larson T, 2007, ENVIRON SCI TECHNOL, V41, P2429, DOI 10.1021/es0614060; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Marshall JD, 2008, ATMOS ENVIRON, V42, P1359, DOI 10.1016/j.atmosenv.2007.08.012; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Ries FJ, 2009, ENVIRON SCI TECHNOL, V43, P4701, DOI 10.1021/es803127d; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Salam MT, 2005, ENVIRON HEALTH PERSP, V113, P1638, DOI 10.1289/ehp.8111; Slama R, 2007, ENVIRON HEALTH PERSP, V115, P1283, DOI 10.1289/ehp.10047; To T, 2006, PEDIATR ALLERGY IMMU, V17, P69, DOI 10.1111/j.1399-3038.2005.00346.x; To T, 2007, ARCH PEDIAT ADOL MED, V161, P1197, DOI 10.1001/archpedi.161.12.1197; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Wang Lei, 2007, Birth Defects Research, V81, P144, DOI 10.1002/bdrc.20097; *WHO, 2006, 307 WHO; World Health Organization, 1975, INT CLASS DIS; WJST M, 1993, BRIT MED J, V307, P596; Zelikoff JT, 2002, J TOXICOL ENV HEAL B, V5, P269, DOI 10.1080/10937400290070062; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	52	184	190	9	94	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	FEB	2010	118	2					284	290		10.1289/ehp.0900916		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	555BQ	WOS:000274482400032	20123607	
J	Castells, MC; Tennant, NM; Sloane, DE; Hsu, FI; Barrett, NA; Hong, DI; Laidlaw, TM; Legere, HJ; Nallamshetty, SN; Palis, RI; Rao, JJ; Berlin, ST; Campos, SM; Matulonis, UA				Castells, Mariana C.; Tennant, Nichole M.; Sloane, David E.; Hsu, F. Ida; Barrett, Nora A.; Hong, David I.; Laidlaw, Tanya M.; Legere, Henry J.; Nallamshetty, Samridhi N.; Palis, Ross I.; Rao, Jayanti J.; Berlin, Suzanne T.; Campos, Susana M.; Matulonis, Ursula A.			Hypersensitivity reactions to chemotherapy: Outcomes and safety of rapid desensitization in 413 cases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; chemotherapy agents; monoclonal antibodies; rapid desensitization; hypersensitivity reactions; carboplatin; paclitaxel; adverse drug reactions	CARBOPLATIN HYPERSENSITIVITY; OVARIAN-CANCER; PROTOCOL; PACLITAXEL; SKIN; CISPLATIN; ALLERGY; TAXOL; EXPERIENCE	Background: Hypersensitivity reactions (HSRs) to chemotherapeutic drugs, including mAbs, often require that the provoking medication be discontinued, thus raising a dilemma for the caregiver: further use could precipitate a severe, even fatal, allergic reaction on re-exposure, but alternative drugs might be poorly tolerated or much less effective compared with the preferred agent. Objective: We have developed a standardized rapid desensitization protocol for achieving temporary tolerization to drug allergens. In this study we evaluate the safety and efficacy of this protocol. Methods: Ninety-eight patients who had HSRs in response to treatment with carboplatin, cisplatin, oxaliplatin, paclitaxel, liposomal doxorubicin, doxorubicin, or rituximab received rapid desensitization to these agents. A standardized 12-step protocol was used, with treatment given intravenously or intraperitoneally. Initial desensitizations occurred in the medical intensive care unit, whereas most subsequent infusions took place in an outpatient setting. Safety and efficacy of the protocol were assessed by review of treatment records. Results: Of the 413 desensitizations performed, 94% induced mild or no reactions. No life-threatening HSRs or deaths occurred during the procedure, and all patients received their full target dose. Most reactions occurred during the first desensitization. Reactions were most commonly reported at the last step of the protocol. Desensitizations through the intravenous and intraperitoneal routes were equally effective. Conclusions: Our standardized 12-step protocol for rapid drug desensitization is safe and effective and has been adopted as the standard of care at our institutions in treating patients with HSRs to chemotherapeutic drugs, including mAbs.	[Castells, Mariana C.; Tennant, Nichole M.; Sloane, David E.; Hsu, F. Ida; Barrett, Nora A.; Hong, David I.; Laidlaw, Tanya M.; Legere, Henry J.; Nallamshetty, Samridhi N.; Palis, Ross I.; Rao, Jayanti J.] Brigham & Womens Hosp, Dept Med, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA; [Berlin, Suzanne T.; Campos, Susana M.; Matulonis, Ursula A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA	Castells, MC (reprint author), 1 Jimmy Fund Way,Smith Bldg,Room 626D, Boston, MA 02115 USA.	mcastells@partners.org			Ovations for the Cure Desensitization Program; American Academy of Allergy, Asthma Immunology; National Institutes of Health; GlaxoSmithKline; Genentech; Novartis; Ortho-Biotechnology	Supported by the Ovations for the Cure Desensitization Program.; Disclosure of potential conflict of interest: D. E. Sloane has received honoraria front Genentech F. I. Hsu has served as a coinvestigator for Dyax Corporation and has received a research grant front the American Academy of Allergy, Asthma & Immunology. N. A. Barrett has served as a coinvestigator for the National Institutes of Health and has served as a primary investigator for the American Academy of Allergy, Asthma & Immunology and Altana. D. I. Hong and T M. Laidlaw have received training grant salary from the National Institutes of Health. S. N. Nallamshetty has received training grant salary front the National Institutes of Health and research grants from the American Academy of Allergy, Asthma & Immunology and GlaxoSmithKline. S. M, Campos has served as a research consultant for Genentech and has received research support from Genentech, Novartis. and Ortho-Biotechnology. The rest of the authors have declared that they have no conflict of interest.	Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985; BALSARI A, 1989, J CHEMOTHERAPY, V1, P324; Castells Mariana, 2007, P413, DOI 10.1159/000104218; Choi J, 2004, ANN ALLERG ASTHMA IM, V93, P137; Dizon DS, 2002, GYNECOL ONCOL, V84, P378, DOI 10.1006/gyno.2001.6519; Feldweg AM, 2005, GYNECOL ONCOL, V96, P824, DOI 10.1016/j.ygyno.2004.11.043; Garufi C, 2003, ANN ONCOL, V14, P497, DOI 10.1093/annonc/mdg092; Goldberg A, 1996, J ALLERGY CLIN IMMUN, V98, P841, DOI 10.1016/S0091-6749(96)70134-3; Lee CW, 2005, GYNECOL ONCOL, V99, P393, DOI 10.1016/j.ygyno.2005.06.028; Lee CW, 2004, GYNECOL ONCOL, V95, P370, DOI 10.1016/j.ygyno.2004.08.002; Markman M, 1999, J CLIN ONCOL, V17, P1141; Markman M, 2003, J CLIN ONCOL, V21, P4611, DOI 10.1200/JCO.2003.05.539; Markman M, 2000, J CLIN ONCOL, V18, P102; Morales AR, 2005, ANN ALLERG ASTHMA IM, V94, P575; Mullins DW, 1999, J IMMUNOL, V162, P6811; Perera PY, 2001, J IMMUNOL, V166, P574; Rosique-Robles D, 2007, INT J CLIN PHARM TH, V45, P606; Sehn LH, 2007, BLOOD, V109, P4171, DOI 10.1182/blood-2006-11-059469; SHEFFER AL, 2006, ALLERGY, P167, DOI 10.1016/B978-0-323-03227-8.50014-7; SYKES E, 1994, BRIT J CANCER, V70, P401, DOI 10.1038/bjc.1994.317; WEISS RB, 1990, J CLIN ONCOL, V8, P1263; WENDEL GD, 1985, NEW ENGL J MED, V312, P1229, DOI 10.1056/NEJM198505093121905; Zanotti KM, 2001, J CLIN ONCOL, V19, P3126; ZWEIZIG S, 1994, GYNECOL ONCOL, V53, P121, DOI 10.1006/gyno.1994.1098	24	184	191	1	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					574	580		10.1016/j.jaci.2008.02.044		7	Allergy; Immunology	Allergy; Immunology	348TW	WOS:000259234000020	18502492	
J	Rumchev, K; Spickett, J; Bulsara, M; Phillips, M; Stick, S				Rumchev, K; Spickett, J; Bulsara, M; Phillips, M; Stick, S			Association of domestic exposure to volatile organic compounds with asthma in young children	THORAX			English	Article							CHILDHOOD ASTHMA; INDOOR AIR; PREVALENCE; FORMALDEHYDE; POPULATION; ALLERGY; HEALTH	Aim: To investigate the association between domestic exposure to volatile organic compounds (VOCs) and asthma in young children. Methods: A population based case-control study was conducted in Perth, Western Australia in children aged between 6 months and 3 years. Cases ( n = 88) were children recruited at Princess Margaret Hospital accident and emergency department and discharged with asthma as the primary diagnosis; 104 controls consisted of children from the same age group without an asthma diagnosis identified through the Health Department of Western Australia. Information regarding the health status of the study children and characteristics of the home was collected using a standardised questionnaire. Exposure to VOCs, average temperature and relative humidity were measured in winter and summer in the living room of each participating household. Results: Cases were exposed to significantly higher VOC levels (mug/m(3)) than controls (p< 0.01). Most of the individual VOCs appeared to be significant risk factors for asthma with the highest odds ratios for benzene followed by ethylbenzene and toluene. For every 10 unit increase in the concentration of toluene and benzene (mu g/m(3)) the risk of having asthma increased by almost two and three times, respectively. Conclusions: Domestic exposure to VOCs at levels below currently accepted recommendations may increase the risk of childhood asthma. Measurement of total VOCs may underestimate the risks associated with individual compounds.	Curtin Univ Technol, Sch Publ Hlth, Perth, WA 6845, Australia; Univ Western Australia, Sch Populat Hlth, Fac Med & Dent, Crawley, WA 6009, Australia; Princess Margaret Hosp Children, Dept Resp Med, Perth, WA 6001, Australia	Rumchev, K (reprint author), Curtin Univ Technol, Sch Publ Hlth, GPO Box U1987, Perth, WA 6845, Australia.	k.rumchev@curtin.edu.au	Bulsara, Max/A-5966-2008; Stick, Stephen/O-5683-2014; Osborne, Nicholas/N-4915-2015	Bulsara, Max/0000-0002-8033-6123; Osborne, Nicholas/0000-0002-6700-2284; Stick, Stephen/0000-0002-5386-8482			ANDERSON HR, 1994, BRIT MED J, V308, P1600; *AUSTR BUR STAT, 1998, N20390 AUSTR BUR STA; BROWN SK, 1994, INDOOR AIR, V4, P123, DOI 10.1111/j.1600-0668.1994.t01-2-00007.x; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; HARVING H, 1991, AM REV RESPIR DIS, V143, P751; Holt PG, 1999, NATURE, V402, pB12; HYNDMAN SJ, 1994, Q J MED, V87, P367; Karol MH, 2002, TOXICOLOGY, V181, P305, DOI 10.1016/S0300-483X(02)00298-6; KOREN HS, 1992, ARCH ENVIRON HEALTH, V47, P39; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Maroni M., 1995, INDOOR AIR QUALITY C; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; *NHMRC, 1995, 115 NHMRC SESS AUSTR; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; PEAT JK, 1994, BRIT MED J, V308, P1591; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; SAMET J, 1990, AM REV RESPIR DIS, V142, P915; WALLACE LA, 1986, TOXICOL ENVIRON CHEM, V12, P215, DOI 10.1080/02772248609357160; WALLACE LA, 1989, CELL BIOL TOXICOL, V5, P297, DOI 10.1007/BF01795358; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; Weislander G., 1997, INT ARCH OCC ENV HEA, V69, P115; Wolkoff P, 1997, INDOOR AIR, V7, P92, DOI 10.1111/j.1600-0668.1997.t01-2-00003.x; Wolkoff P, 1995, INDOOR AIR, P1, DOI 10.1111/j.1600-0668.1995.tb00017.x; Yuan W, 2003, EUR J EPIDEMIOL, V18, P763	27	184	195	4	50	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	SEP	2004	59	9					746	751		10.1136/thx.2003.013680		6	Respiratory System	Respiratory System	849OV	WOS:000223549100008	15333849	
J	Kheradmand, F; Kiss, A; Xu, J; Lee, SH; Kolattukudy, PE; Corry, DB				Kheradmand, F; Kiss, A; Xu, J; Lee, SH; Kolattukudy, PE; Corry, DB			A protease-activated pathway underlying Th cell type 2 activation and allergic lung disease	JOURNAL OF IMMUNOLOGY			English	Article							DUST-MITE ALLERGEN; INDUCED AIRWAY HYPERREACTIVITY; MURINE MODEL; IFN-GAMMA; PROTEOLYTIC ACTIVITY; CYSTEINE PROTEASE; GUINEA-PIG; PHYSICOCHEMICAL CHARACTERIZATION; ASPERGILLUS-FUMIGATUS; DETERGENT ENZYMES	The respiratory allergens that induce experimental. Th cell type 2-dependent allergic lung inflammation may be grouped into two functional classes. One class of allergens, in this study termed type I, requires priming with adjuvants remote from the lung to overcome airway tolerogenic mechanisms that ordinarily preclude allergic responses to inhaled Ags. In contrast, the other, or type II, allergen class requires neither remote priming nor additional adjuvants to overcome airway tolerance and elicit robust allergic lung disease. In this study, we show in an experimental model that diverse type II allergens share in common proteolytic activity that is both necessary and sufficient for overcoming airway tolerance and induction of pulmonary allergic disease. Inactivated protease and protease-free Ag fragments showed no allergenic potency, demonstrating that only active protease acting on endogenous substrates was essential. Furthermore, induction of airway tolerance could be aborted and allergic lung disease established by simply adding purified protease to a type I allergen. Thus, exogenous proteases are common to type II allergens and may be generally required to overcome the innate resistance of the airway to Th cell type 2 activation and allergic inflammation, raising concern for their potential contribution to diseases such as asthma.	Baylor Coll Med, Biol Inflammat Ctr, Houston, TX 77030 USA; Baylor Coll Med, Dept Med, Houston, TX 77030 USA; Baylor Coll Med, Dept Immunol, Houston, TX 77030 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA; Ohio State Univ, Dept Biochem, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol & Cellular Biochem, Columbus, OH 43210 USA; Semmelweis Univ, Dept Resp Med, H-1085 Budapest, Hungary	Corry, DB (reprint author), Baylor Coll Med, Biol Inflammat Ctr, 1 Baylor Plaza,Suite 520B, Houston, TX 77030 USA.	dcorry@bcm.tmc.edu	kolattukudy, pappachan/A-1350-2012; Lee, Seung-Hyo/B-9922-2015	Lee, Seung-Hyo/0000-0003-0010-4072	NHLBI NIH HHS [K08 HL 03344, K08 HL 03732, R01 HL 64061]		Bagarozzi DA, 1998, PHYTOCHEMISTRY, V47, P593, DOI 10.1016/S0031-9422(97)00634-1; Bannwarth S, 1998, J BIOL CHEM, V273, P1911, DOI 10.1074/jbc.273.4.1911; BAUR X, 1994, CLIN EXP ALLERGY, V24, P465, DOI 10.1111/j.1365-2222.1994.tb00935.x; Blease K, 2001, J IMMUNOL, V166, P5219; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Cohn L, 1999, J IMMUNOL, V162, P6178; Comoy EE, 1998, J IMMUNOL, V160, P2456; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Drouin SM, 2001, J IMMUNOL, V167, P4141; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289; FINKELMAN FD, 1989, CIBA F SYMP, V147, P3; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FLINDT MLH, 1969, LANCET, V1, P1177; Ford JG, 2001, J IMMUNOL, V167, P1769; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4<1211::AID-IMMU1211>3.0.CO;2-R; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263; Hadeiba H, 2000, J IMMUNOL, V164, P4933; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hole AM, 2000, OCCUP ENVIRON MED, V57, P840, DOI 10.1136/oem.57.12.840; Hurst SD, 2001, J IMMUNOL, V166, P4922; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053; Kania SA, 2001, VET IMMUNOL IMMUNOP, V78, P83, DOI 10.1016/S0165-2427(00)00256-7; KANNY G, 1995, J ALLERGY CLIN IMMUN, V95, P132, DOI 10.1016/S0091-6749(95)70161-3; Kanwar S, 2001, AM J RESP CELL MOL, V25, P170; KOLATTUKUDY PE, 1993, INFECT IMMUN, V61, P2357; KURUP VP, 1994, J LEUKOCYTE BIOL, V56, P593; Kurup VP, 1997, INT ARCH ALLERGY IMM, V112, P270; LAKE FR, 1991, INT ARCH ALLER A IMM, V94, P357; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; Lilly CM, 1996, AM J PHYSIOL-LUNG C, V270, pL368; LOCKSLEY RM, 1987, ANN INST PASTEUR IMM, V138, P744; MARIKOVSKY M, 1988, J IMMUNOL, V141, P273; MARKARYAN A, 1994, INFECT IMMUN, V62, P2149; MATHESON N, 1995, AM J RESP CELL MOL, V12, P441; Mattes J, 2001, J IMMUNOL, V167, P1683; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MOSER M, 1994, INFECT IMMUN, V62, P936; PEPYS J, 1973, P ROY SOC MED, V66, P930; PEPYS J, 1973, Clinical Allergy, V3, P143, DOI 10.1111/j.1365-2222.1973.tb01318.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; RAMEZANI CA, 1995, J AGR RESOUR ECON, V20, P165; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Ring PC, 2000, CLIN EXP ALLERGY, V30, P1085; Sarlo K, 1997, FUND APPL TOXICOL, V39, P44, DOI 10.1006/faat.1997.2356; Sarlo K, 1997, J ALLERGY CLIN IMMUN, V100, P480; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; SNAPPER CM, 1988, J EXP MED, V167, P183, DOI 10.1084/jem.167.1.183; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; Tomkinson A, 2001, J IMMUNOL, V166, P5792; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; vanHalteren AG, 1997, J IMMUNOL, V159, P3009; Walter DM, 2001, J IMMUNOL, V167, P4668; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Wan GH, 1999, EUR J IMMUNOL, V29, P2491, DOI 10.1002/(SICI)1521-4141(199908)29:08<2491::AID-IMMU2491>3.3.CO;2-I; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WATANABE A, 1995, AM J RESP CRIT CARE, V152, P64; Widmer F, 2000, CLIN EXP ALLERGY, V30, P571, DOI 10.1046/j.1365-2222.2000.00784.x; YAMAKAMI K, 1995, EUR J BIOCHEM, V233, P490, DOI 10.1111/j.1432-1033.1995.490_2.x; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661; Zhaoming Wen, 1996, Journal of Investigational Allergology and Clinical Immunology, V6, P144	76	184	192	0	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	NOV 15	2002	169	10					5904	5911				8	Immunology	Immunology	614CG	WOS:000179170300067	12421974	
J	Wu, WJ; Samoszuk, MK; Comhair, SAA; Thomassen, MJ; Farver, CF; Dweik, RA; Kavuru, MS; Erzurum, SC; Hazen, SL				Wu, WJ; Samoszuk, MK; Comhair, SAA; Thomassen, MJ; Farver, CF; Dweik, RA; Kavuru, MS; Erzurum, SC; Hazen, SL			Eosinophils generate brominating oxidants in allergen-induced asthma	JOURNAL OF CLINICAL INVESTIGATION			English	Article							HUMAN NEUTROPHILS EMPLOY; HYDROGEN-PEROXIDE; AMINO-ACIDS; SCHISTOSOMA-MANSONI; REACTIVE ALDEHYDES; MOLECULAR-CLONING; ANTIGEN CHALLENGE; SINGLET OXYGEN; GUINEA-PIG; MYELOPEROXIDASE	Eosinophils promote tissue injury and contribute to the pathogenesis of allergen-triggered diseases like asthma, but the chemical basis of damage to eosinophil targets is unknown. We now demonstrate that eosinophil activation in vivo results in oxidative damage of proteins through bromination of tyrosine residues, a heretofore unrecognized pathway for covalent modification of biologic targets in human tissues. Mass spectrometric studies demonstrated that 3-bromotyrosine serves as a specific "molecular fingerprint" for proteins modified through the eosinophil peroxidase-H2O2 system in the presence of plasma levels of halides. We applied a localized allergen challenge to model the effects of eosinophils and brominating oxidants in human lung injury. Endobronchial biopsy specimens from allergen-challenged lung segments of asthmatic, but not healthy control, subjects demonstrated significant enrichments in eosinophils and eosinophil peroxidase, Baseline levels of 3-bromotyrosine in bronchoalveolar lavage (BAL) proteins from mildly allergic asthmatic individuals were modestly but not statistically significantly elevated over those in control subjects. After exposure to segmental allergen challenge, lung segments of asthmatics, but not healthy control subjects, exhibited a >10-fold increase in BAL 3-bromotyrosine content, but only two- to threefold increases in 3-chlorotyrosine, a specific oxidation product formed by neutrophil- and monocyte-derived myeloperoxidase. These results identify reactive brominating species produced by eosinophils as a distinct class of oxidants formed in vivo. They also reveal eosinophil peroxidase as a potential therapeutic target for allergen-triggered inflammatory tissue injury in humans.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Quest Diagnost Inc, San Juan Capistrano, CA USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Anat Pathol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA	Hazen, SL (reprint author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.				NHLBI NIH HHS [R01 HL061878, HL-62526]		AGOSTI JM, 1987, J ALLERGY CLIN IMMUN, V79, P496, DOI 10.1016/0091-6749(87)90368-X; BABIOR BM, 1973, J CLIN INVEST, V52, P741, DOI 10.1172/JCI107236; BEISSNER RS, 1981, BIOCHEMISTRY-US, V20, P3724, DOI 10.1021/bi00516a009; BOS AJ, 1981, INFECT IMMUN, V32, P427; Brottman GM, 1996, PEDIATR PULM, V21, P159, DOI 10.1002/(SICI)1099-0496(199603)21:3<159::AID-PPUL2>3.0.CO;2-L; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; CARNEY JR, 1995, J NAT PRODUCTS, V58, P971, DOI 10.1021/np50121a001; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; DECHATELET LR, 1977, BLOOD, V50, P525; Faulkner DJ, 1998, NAT PROD REP, V15, P113; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; FUERST DE, 1965, NATURE, V205, P1333, DOI 10.1038/2051333a0; GLEICH GJ, 1989, INT ARCH ALLER A IMM, V88, P59; GUNASEKERA SP, 1992, J NAT PROD, V55, P509, DOI 10.1021/np50082a020; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; HAMANN KJ, 1993, AM J PHYSIOL, V265, pL301; HANSEL TT, 1989, J IMMUNOL METHODS, V122, P97, DOI 10.1016/0022-1759(89)90339-6; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, FREE RADICAL BIO MED, V23, P909, DOI 10.1016/S0891-5849(97)00084-1; Hazen SL, 1998, J BIOL CHEM, V273, P4997, DOI 10.1074/jbc.273.9.4997; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; Hazen SL, 1996, J BIOL CHEM, V271, P1861; Heinecke JW, 1999, METHOD ENZYMOL, V300, P124; Holt PG, 1999, NATURE, V402, pB12; JAMES DM, 1991, J NAT PROD, V54, P1137, DOI 10.1021/np50076a040; Jarjour NN, 1997, AM J RESP CRIT CARE, V155, P1515; JONG EC, 1981, J IMMUNOL, V126, P468; JONG EC, 1980, J IMMUNOL, V124, P1949; JONG EC, 1980, J IMMUNOL, V124, P1378; KANOFSKY JR, 1989, ARCH BIOCHEM BIOPHYS, V274, P229, DOI 10.1016/0003-9861(89)90434-7; KANOFSKY JR, 1988, J BIOL CHEM, V263, P9692; KAZURA JW, 1981, J CLIN INVEST, V67, P93, DOI 10.1172/JCI110037; KLEBANOFF SJ, 1983, CIBA F SYMP, V99, P92; KLEBANOFF SJ, 1989, J IMMUNOL, V143, P239; MANTHEY JA, 1984, METHOD ENZYMOL, V107, P439; MAYENO AN, 1989, J BIOL CHEM, V264, P5660; MCCORD TJ, 1975, J MED CHEM, V18, P26, DOI 10.1021/jm00235a006; MIERZWA R, 1994, J NAT PROD, V57, P175, DOI 10.1021/np50103a029; MINNICOZZI M, 1994, J IMMUNOL, V153, P2664; *NAT HEART LUNG BL, 1997, 2 NAT HEART LUNG BLO, P1; PRETOLANI M, 1994, AM J RESP CRIT CARE, V149, P1167; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; SAKAMAKI K, 1989, J BIOL CHEM, V264, P16828; SAMOSZUK MK, 1986, AM J PATHOL, V125, P426; SAMOSZUK MK, 1994, CANCER RES, V54, P2650; SAMOSZUK MK, 1987, BLOOD, V70, P597; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; SLUNGAARD A, 1991, J EXP MED, V173, P117, DOI 10.1084/jem.173.1.117; SLUNGAARD A, 1991, J BIOL CHEM, V266, P4903; SLUNGAARD A, 1990, J EXP MED, V171, P2025, DOI 10.1084/jem.171.6.2025; SMITH HR, 1992, J ALLERGY CLIN IMMUN, V89, P1076, DOI 10.1016/0091-6749(92)90291-9; Someya A, 1997, ARCH BIOCHEM BIOPHYS, V345, P207, DOI 10.1006/abbi.1997.0252; TEITZ NW, 1999, TEITZ TXB CLIN CHEM, P1097; TEITZ NW, 1999, TEITZ TXB CLIN CHEM, P2216; TEN RM, 1989, J EXP MED, V169, P1757, DOI 10.1084/jem.169.5.1757; THOMAS EL, 1995, J BIOL CHEM, V270, P2906; Thomassen MJ, 1999, J ALLERGY CLIN IMMUN, V104, P1174; Thurau AM, 1996, CYTOMETRY, V23, P150, DOI 10.1002/(SICI)1097-0320(19960201)23:2<150::AID-CYTO8>3.3.CO;2-3; vanDalen CJ, 1997, BIOCHEM J, V327, P487; Wajon J. E., 1980, WATER CHLORINATION E, V3, P171; WEIL GJ, 1981, BLOOD, V57, P1099; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l; YOSHIKAWA S, 1993, AM REV RESPIR DIS, V147, P914	67	184	186	0	7	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	MAY	2000	105	10					1455	1463		10.1172/JCI9702		9	Medicine, Research & Experimental	Research & Experimental Medicine	314UE	WOS:000087075300017	10811853	
J	Silkoff, PE; Sylvester, JT; Zamel, N; Permutt, S				Silkoff, PE; Sylvester, JT; Zamel, N; Permutt, S			Airway nitric oxide diffusion in asthma - Role in pulmonary function and bronchial responsiveness	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							EXHALED AIR; MILD ASTHMA; SYNTHASE; HYPERREACTIVITY; INHIBITION; INDUCTION; HUMANS; LIVER; LUNG	If the nitric oxide (NO) diffusing capacity of the airways (DNO) is the quantity of NO diffusing per unit time into exhaled gas ((q) over dot) divided by the difference between the concentration of NO in the airway wall (C-w) and lumen, then DNO and C-w can be estimated from the relationship between exhaled NO concentration and expiratory flow, in 10 normal subjects and 25 asthmatic patients before and after treatment with inhaled beclomethasone, DNO averaged 6.8 +/- 1.2, 25.5 +/- 3.8, and 22.3 +/- 2.7 nl/s/ppb x 10(-3) respectively; C-w averaged 149 +/- 31.9, 255.3 +/- 46.4 and 108.3 +/- 14.3 ppb, respectively; and DNOCw (the maximal q from diffusion) averaged 1,020 +/- 157.5, 6,512 +/- 866, and 2416 +/- 208.5 nl/s x 10-3, respectively. DNO and DNOCw in the asthmatic subjects before and after steroids were greater than in normal subjects (p < 0.0001), but C-w was not different. Within asthmatic subjects, steroids caused C-w and DNOCw to fall (p < 0.0001), but DNO was Unchanged, DNOCw after steroids, presumably reflecting maximal diffusion of constitutive NO, was positively correlated with methacholine PC20 and FEV1/FVC before or after steroids. The increased DNO measured in asthmatic patients may reflect upregulation of nonadrenergic, noncholinergic, NO-producing nerves in airways in compensation for decreased sensitivity of airway smooth muscle to the relaxant effects of endogenous NO.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD 21224 USA; Univ Toronto, Div Respirol, Toronto, ON, Canada	Silkoff, PE (reprint author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA.						ALVING K, 1993, EUR RESPIR J, V6, P1368; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; BLAND JM, 1995, LANCET, V346, P1085, DOI 10.1016/S0140-6736(95)91748-9; DAgostino B, 1997, LIFE SCI, V60, pPL353; deBoer J, 1996, BRIT J PHARMACOL, V119, P1109; DEFRONZO RA, 1988, DIABETES, V37, P667; Dupont LJ, 1998, AM J RESP CRIT CARE, V157, P894; Dweik RA, 1998, J CLIN INVEST, V101, P660, DOI 10.1172/JCI1378; ELLIS JL, 1992, AM REV RESPIR DIS, V146, P1543; Fischer A, 1996, AM J RESP CRIT CARE, V154, P209; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hogman M, 1999, AM J RESP CRIT CARE, V159, pA862; Jatakanon A, 1998, THORAX, V53, P91; Jia YL, 1996, J APPL PHYSIOL, V80, P404; JIA YL, 1995, AM J PHYSIOL-LUNG C, V269, pL85; JORRES RA, 1998, AM J RESP CRIT CARE, V157, pA612; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KNOWLES RG, 1990, BIOCHEM BIOPH RES CO, V172, P1042, DOI 10.1016/0006-291X(90)91551-3; Mehta S, 1997, AM J PHYSIOL-LUNG C, V273, pL656; Miura M, 1997, AM J RESP CRIT CARE, V156, P217; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; ROHSENOW WM, 1961, HEAT MASS MOMENTUM T, P132; Schuiling M, 1998, AM J RESP CRIT CARE, V158, P1442; Silkoff PE, 1998, RESP PHYSIOL, V113, P33, DOI 10.1016/S0034-5687(98)00033-4; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Taylor DA, 1998, THORAX, V53, P483; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P642; Weibel E, 1963, MORPHOMETRY HUMAN LU; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247	31	184	184	0	0	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR	2000	161	4					1218	1228				11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	306AF	WOS:000086573400026	10764315	
J	Caceres, AI; Brackmann, M; Elia, MD; Bessac, BF; del Camino, D; D'Amours, M; Witek, JS; Fanger, CM; Chong, JA; Hayward, NJ; Homer, RJ; Cohn, L; Huang, XZ; Moran, MM; Jordt, SE				Caceres, Ana I.; Brackmann, Marian; Elia, Maxwell D.; Bessac, Bret F.; del Camino, Donato; D'Amours, Marc; Witek, JoAnn S.; Fanger, Chistopher M.; Chong, Jayhong A.; Hayward, Neil J.; Homer, Robert J.; Cohn, Lauren; Huang, Xiaozhu; Moran, Magdalene M.; Jordt, Seven-Eric			A sensory neuronal ion channel essential for airway inflammation and hyperreactivity in asthma	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						airway hyperreactivity; TRP channel; TRPA1	NEUROGENIC INFLAMMATION; TRPA1; PAIN; RECEPTOR; NOCICEPTION; ACTIVATION; MECHANISMS; SENSATION; DISEASES; FIBERS	Asthma is an inflammatory disorder caused by airway exposures to allergens and chemical irritants. Studies focusing on immune, smooth muscle, and airway epithelial function revealed many aspects of the disease mechanism of asthma. However, the limited efficacies of immune-directed therapies suggest the involvement of additional mechanisms in asthmatic airway inflammation. TRPA1 is an irritant-sensing ion channel expressed in airway chemosensory nerves. TRPA1-activating stimuli such as cigarette smoke, chlorine, aldehydes, and scents are among the most prevalent triggers of asthma. Endogenous TRPA1 agonists, including reactive oxygen species and lipid peroxidation products, are potent drivers of allergen-induced airway inflammation in asthma. Here, we examined the role of TRPA1 in allergic asthma in the murine ovalbumin model. Strikingly, genetic ablation of TRPA1 inhibited allergen-induced leukocyte infiltration in the airways, reduced cytokine and mucus production, and almost completely abolished airway hyperreactivity to contractile stimuli. This phenotype is recapitulated by treatment of wild-type mice with HC-030031, a TRPA1 antagonist. HC-030031, when administered during airway allergen challenge, inhibited eosinophil infiltration and prevented the development of airway hyperreactivity. Trpa1(-/-) mice displayed deficiencies in chemically and allergen-induced neuropeptide release in the airways, providing a potential explanation for the impaired inflammatory response. Our data suggest that TRPA1 is a key integrator of interactions between the immune and nervous systems in the airways, driving asthmatic airway inflammation following inhaled allergen challenge. TRPA1 may represent a promising pharmacological target for the treatment of asthma and other allergic inflammatory conditions.	[del Camino, Donato; D'Amours, Marc; Witek, JoAnn S.; Fanger, Chistopher M.; Chong, Jayhong A.; Hayward, Neil J.; Moran, Magdalene M.] Hydra Biosci Inc, Cambridge, MA 02139 USA; [Caceres, Ana I.; Brackmann, Marian; Elia, Maxwell D.; Bessac, Bret F.; Jordt, Seven-Eric] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; [Homer, Robert J.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06520 USA; [Cohn, Lauren] Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; [Huang, Xiaozhu] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA	Moran, MM (reprint author), Hydra Biosci Inc, 790 Mem Dr, Cambridge, MA 02139 USA.	mmoran@hydrabiosciences.com; sven.jordt@yale.edu	Caceres, Ana/E-5542-2012		NIEHS NIH HHS [R01 ES015056, ES015056, ES017218, U54 ES017218]; NIGMS NIH HHS [5T32GM07205, T32 GM007205]		Andersson DA, 2008, J NEUROSCI, V28, P2485, DOI 10.1523/JNEUROSCI.5369-07.2008; Andre E, 2008, J CLIN INVEST, V118, P2574, DOI 10.1172/JCI34886; Bandell M, 2004, NEURON, V41, P849, DOI 10.1016/S0896-6273(04)00150-3; Basbaum AI, 2006, SCI AM, V294, P60; Bautista DM, 2006, CELL, V124, P1269, DOI 10.1016/j.cell.2006.02.023; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Bessac BF, 2009, FASEB J, V23, P1102, DOI 10.1096/fj.08-117812; Bessac BF, 2008, PHYSIOLOGY, V23, P360, DOI 10.1152/physiol.00026.2008; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cruz-Orengo L, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-30; Dai Y, 2007, J CLIN INVEST, V117, P1979, DOI 10.1172/JCI3095; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/rccm.2109058; DAVIS B, 1982, J APPL PHYSIOL, V53, P985; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eid SR, 2008, MOL PAIN, V4, DOI 10.1186/1744-8069-4-48; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Groneberg DA, 2004, ALLERGY, V59, P1139, DOI 10.1111/j.1398-9995.2004.00665.x; Heaney LG, 1998, THORAX, V53, P357; Jia YL, 2007, BBA-MOL BASIS DIS, V1772, P915, DOI 10.1016/j.bbadis.2007.01.013; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; McLeod Robbie L, 2006, Cough, V2, P10, DOI 10.1186/1745-9974-2-10; McNamara CR, 2007, P NATL ACAD SCI USA, V104, P13525, DOI 10.1073/pnas.0705924104; Petrus M, 2007, MOL PAIN, V3, DOI 10.1186/1744-8069-3-40; Redlich CA, 2002, INT IMMUNOPHARMACOL, V2, P213, DOI 10.1016/S1567-5769(01)00174-6; Shakeri MS, 2008, OCCUP MED-OXFORD, V58, P205, DOI 10.1093/occmed/kqn013; TAYLORCLARK TE, 2008, AM J RESP CELL MOL B; Trevisani M, 2007, P NATL ACAD SCI USA, V104, P13519, DOI 10.1073/pnas.0705923104; Undem Bradley J, 2002, Curr Allergy Asthma Rep, V2, P159, DOI 10.1007/s11882-002-0011-4; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; White FA, 2008, CURR OPIN ANESTHESIO, V21, P580, DOI 10.1097/ACO.0b013e32830eb69d	32	183	188	3	16	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUN 2	2009	106	22					9099	9104		10.1073/pnas.0900591106		6	Multidisciplinary Sciences	Science & Technology - Other Topics	452ZU	WOS:000266580500058	19458046	
J	Akdis, CA; Akdis, M; Bieber, T; Bindslev-Jensen, C; Boguniewicz, M; Eigenmann, P; Hamid, Q; Kapp, A; Leung, DYM; Lipozencic, J; Luger, TA; Muraro, A; Novak, N; Platts-Mills, TAE; Rosenwasser, L; Scheynius, A; Simons, FER; Spergel, J; Turjanmaa, K; Wahn, U; Weidinger, S; Werfel, T; Zuberbier, T				Akdis, C. A.; Akdis, M.; Bieber, T.; Bindslev-Jensen, C.; Boguniewicz, M.; Eigenmann, P.; Hamid, Q.; Kapp, A.; Leung, D. Y. M.; Lipozencic, J.; Luger, T. A.; Muraro, A.; Novak, N.; Platts-Mills, T. A. E.; Rosenwasser, L.; Scheynius, A.; Simons, F. E. R.; Spergel, J.; Turjanmaa, K.; Wahn, U.; Weidinger, S.; Werfel, T.; Zuberbier, T.		European Acad Allergology Clinical; Amer Acad Allergy Asthma Immunol; PRACTALL Consensus Grp	Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/PRACTALL consensus report	ALLERGY			English	Review						atopic dermatitis; children; adults; risk factors; immunopathology; diagnosis; systemic treatment; topical treatment	RANDOMIZED CONTROLLED-TRIAL; STAPHYLOCOCCUS-AUREUS COLONIZATION; TOPICAL CALCINEURIN INHIBITORS; PIMECROLIMUS CREAM 1-PERCENT; PLASMACYTOID DENDRITIC CELLS; PLACEBO-CONTROLLED TRIAL; DUST-MITE ALLERGENS; REGULATORY T-CELLS; LONG-TERM EFFICACY; DOUBLE-BLIND	There are remarkable differences in the diagnostic and therapeutic management of atopic dermatitis practiced by dermatologists and pediatricians in different countries. Therefore, the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma and Immunology nominated expert teams who were given the task of finding a consensus to serve as a guideline for clinical practice in Europe as well as in North America. The consensus report is part of the PRACTALL initiative, which is endorsed by both academies.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Univ Bonn, D-5300 Bonn, Germany; Odense Univ, Odense, Denmark; Natl Jewish Med & Res Ctr, Denver, CO USA; Univ Colorado, Sch Med, Denver, CO 80202 USA; Univ Geneva, Childrens Hosp, Geneva, Switzerland; McGill Univ, Montreal, PQ, Canada; Hannover Med Sch, Hannover, Germany; Univ Zagreb, Ctr Hosp, Zagreb 41000, Croatia; Univ Zagreb, Sch Med, Zagreb 41000, Croatia; Univ Munster, D-4400 Munster, Germany; Univ Padua, Padua, Italy; Asthma & Allerg Dis Ctr, Charlottesville, VA USA; Karolinska Univ Hosp Solna, Stockholm, Sweden; Univ Manitoba, Winnipeg, MB R3T 2N2, Canada; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Philadelphia, PA 19104 USA; Tampere Univ Hosp, Tampere, Finland; Charite Univ Berlin, Berlin, Germany; Tech Univ Munich, D-8000 Munich, Germany; Hannover Med Sch, D-3000 Hannover, Germany	Wahn, U (reprint author), Charite Univ Med Berlin, Augustenburger Pl 1, D-13353 Berlin, Germany.		Weidinger, Stephan/C-8461-2011; Bindslev-Jensen, Carsten/H-1877-2011; Eigenmann, Philippe/A-6569-2017	Bindslev-Jensen, Carsten/0000-0002-8940-038X; Eigenmann, Philippe/0000-0003-1738-1826			Abeck D, 1998, BRIT J DERMATOL, V139, P13; Abeck D, 2000, J AM ACAD DERMATOL, V42, P254, DOI 10.1016/S0190-9622(00)90134-8; Ainley-Walker PF, 1998, ARCH DIS CHILD, V79, P149; Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akhavan A, 2003, CLIN DERMATOL, V21, P225, DOI 10.1016/S0738-081X(02)00362-0; Anstey AV, 2004, BRIT J DERMATOL, V151, P1123, DOI 10.1111/j.1365-2133.2004.06323.x; Arikawa J, 2002, J INVEST DERMATOL, V119, P433, DOI 10.1046/j.1523-1747.2002.01846.x; Ashcroft DM, 2005, BRIT MED J, V330, P516, DOI 10.1136/bmj.38376.439653.D3; *AST PHARM MAN INC, 2006, PROT PACK INS; Aylett S E, 1992, Acta Derm Venereol Suppl (Stockh), V176, P123; BAECK O, 2001, J EUR ACAD DERMATOL, V15, P34; Baud O, 2001, NEW ENGL J MED, V344, P1758, DOI 10.1056/NEJM200106073442304; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Berth-Jones J, 2002, BRIT J DERMATOL, V147, P324, DOI 10.1046/j.1365-2133.2002.04989.x; BerthJones J, 1996, J AM ACAD DERMATOL, V34, P1016, DOI 10.1016/S0190-9622(96)90281-9; BerthJones J, 1997, BRIT J DERMATOL, V136, P76, DOI 10.1111/j.1365-2133.1997.tb08750.x; Bhargava HN, 1996, AM J INFECT CONTROL, V24, P209, DOI 10.1016/S0196-6553(96)90017-6; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; Bloch AM, 2002, ACTA PAEDIATR, V91, P275, DOI 10.1080/08035250252833914; Boguniewicz M, 2002, IMMUNOL ALLERGY CLIN, V22, P107, DOI 10.1016/S0889-8561(03)00072-9; Boguniewicz M, 2001, J ALLERGY CLIN IMMUN, V108, P651, DOI 10.1067/mai.2001.118598; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; BRATTON DL, 1995, J CLIN INVEST, V95, P211, DOI 10.1172/JCI117642; Breuer K, 2005, AM J CLIN DERMATOL, V6, P65, DOI 10.2165/00128071-200506020-00001; Breuer K, 2002, BRIT J DERMATOL, V147, P55, DOI 10.1046/j.1365-2133.2002.04872.x; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; Breuer K, 2004, CLIN EXP ALLERGY, V34, P817, DOI [10.1111/j.1365-2222.2004.1953.x, 10.1111/j.1365-2222.2004.01953.x]; BROBERG A, 1990, ACTA DERM-VENEREOL, V70, P495; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; Capristo C, 2004, ALLERGY, V59, P53, DOI 10.1111/j.1398-9995.2004.00652.x; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Chan LS, 2001, J INVEST DERMATOL, V117, P977, DOI 10.1046/j.0022-202x.2001.01484.x; Chatila TA, 2005, J ALLERGY CLIN IMMUN, V116, P949, DOI 10.1016/j.jaci.2005.08.047; Chinn DJ, 2002, BRIT J DERMATOL, V146, P432, DOI 10.1046/j.1365-2133.2002.04603.x; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Darsow U, 2005, J EUR ACAD DERMATOL, V19, P286, DOI 10.1111/j.1468-3083.2005.01249.x; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Diepgen TL, 2002, PEDIATR ALLERGY IMMU, V13, P278, DOI 10.1034/j.1399-3038.2002.01047.x; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; DIMITROFF CJ, 2004, J CLIN INVEST, V112, P1008; Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Eigenmann P.A., 1998, PEDIATRICS, V101, P8; Ellis C, 2003, BRIT J DERMATOL, V148, P3, DOI 10.1046/j.1365-2133.148.s63.1.x; Faergemann J, 1999, ALLERGY, V54, P413, DOI 10.1034/j.1398-9995.1999.00089.x; Foelster-Holst R, 2006, DERMATOLOGY, V212, P66, DOI 10.1159/000089025; Gauger A, 2003, DERMATOLOGY, V207, P15, DOI 10.1159/000070935; Giustizieri ML, 2001, J ALLERGY CLIN IMMUN, V107, P871, DOI 10.1067/mai.2001.114707; Grewe M, 1998, J IMMUNOL, V161, P415; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Haagerup A, 2004, ACTA DERM-VENEREOL, V84, P346, DOI 10.1080/00015550410034426; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halken Susanne, 2004, Pediatr Allergy Immunol, V15 Suppl 16, P4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Harper J, 2001, BRIT J DERMATOL, V144, P781, DOI 10.1046/j.1365-2133.2001.04133.x; Hauk PJ, 2001, J ALLERGY CLIN IMMUN, V107, P391, DOI 10.1067/mai.2001.112848; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Hoeger PH, 2004, PEDIATR ALLERGY IMMU, V15, P474, DOI 10.1111/j.1399-3038.2004.00182.x; Hoetzenecker W, 2005, J ALLERGY CLIN IMMUN, V115, P1276, DOI 10.1016/j.jaci.2005.02.011; Hoffjan S, 2005, J MOL MED-JMM, V83, P682, DOI 10.1007/s00109-005-0672-2; Howell MD, 2006, J ALLERGY CLIN IMMUN, V117, P836, DOI 10.1016/j.jaci.2005.12.1345; Hultsch T, 2005, DERMATOLOGY, V211, P174, DOI 10.1159/000086739; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jappe U, 2003, BRIT J DERMATOL, V149, P87, DOI 10.1046/j.1365-2133.2003.05290.x; Johnke H, 2005, BRIT J DERMATOL, V153, P352, DOI 10.1111/j.1365-2133.2005.06491.x; KAPP A, 1993, ALLERGY, V48, P1, DOI 10.1111/j.1398-9995.1993.tb02167.x; KAY J, 1994, J AM ACAD DERMATOL, V30, P35; Kempers S, 2004, J AM ACAD DERMATOL, V51, P515, DOI 10.1016/j.jaad.2004.01.051; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P195, DOI 10.1067/mai.2003.1; KERSCHER MJ, 1995, INT J CLIN PHARM TH, V33, P187; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Klunker S, 2003, J IMMUNOL, V171, P1078; KOBLENZER CS, 1988, ARCH DERMATOL, V124, P1673, DOI 10.1001/archderm.124.11.1673; KORTING HC, 1992, J AM ACAD DERMATOL, V27, P87, DOI 10.1016/0190-9622(92)70162-9; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Lear JT, 1996, J AM ACAD DERMATOL, V35, P642, DOI 10.1016/S0190-9622(96)90701-X; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leo HL, 2004, J ALLERGY CLIN IMMUN, V114, P691, DOI 10.1016/j.jaci.2004.05.037; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Leung DYM, 2003, CURR OPIN PEDIATR, V15, P399; LEUNG DYM, 1983, J ALLERGY CLIN IMMUN, V71, P47, DOI 10.1016/0091-6749(83)90546-8; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; LEYDEN JJ, 1977, BRIT J DERMATOL, V96, P179, DOI 10.1111/j.1365-2133.1977.tb12541.x; LIN W, 2006, J ALLERGY CLIN IMMUN, V116, P1106; Lintu P, 2001, ALLERGY, V56, P512, DOI 10.1034/j.1398-9995.2001.056006512.x; Loden M, 2003, AM J CLIN DERMATOL, V4, P771; Lubbe J, 2003, AM J CLIN DERMATOL, V4, P641; Luger T, 2001, BRIT J DERMATOL, V144, P788, DOI 10.1046/j.1365-2133.2001.04134.x; Mallon E, 1994, J DERMATOL TREAT, V5, P97, DOI 10.3109/09546639409084540; Mastrandrea F, 2004, AM J CLIN DERMATOL, V5, P281, DOI 10.2165/00128071-200405050-00001; MCHENRY PM, 1995, BRIT MED J, V310, P843; McSkimming J, 1984, Australas J Dermatol, V25, P8; Meggitt SJ, 2001, CLIN EXP DERMATOL, V26, P369, DOI 10.1046/j.1365-2230.2001.00837.x; MITCHELL EB, 1982, LANCET, V1, P127; MORREN MA, 1994, J AM ACAD DERMATOL, V31, P467; MOTHES N, 2005, CLIN IMMUNOL, V116, P706; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P196, DOI 10.1111/j.1399-3038.2004.00128.x; NATTER S, 1998, FASEB J, V12, P1569; Nikkels AF, 2003, DERMATOLOGY, V206, P398, DOI 10.1159/000069968; NILSSON EJ, 1992, J AM ACAD DERMATOL, V27, P29, DOI 10.1016/0190-9622(92)70151-5; Nomura I, 2003, J IMMUNOL, V171, P3262; *NOV PHARM CORP, 2006, EL PACK INS; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P252, DOI 10.1067/mai.2003.1595; Novak N, 2005, J ALLERGY CLIN IMMUN, V115, P828, DOI 10.1016/j.jaci.2005.01.030; Novak N, 2004, J ALLERGY CLIN IMMUN, V114, P364, DOI 10.1016/j.jaci.2004.05.038; Novak N, 2004, J ALLERGY CLIN IMMUN, V113, P949, DOI 10.1016/j.jaci.2004.02.005; Novak N, 2003, J ALLERGY CLIN IMMUN, V112, P215, DOI 10.1067/mai.2003.1590; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Novak Natalija, 2003, Journal of Allergy and Clinical Immunology, V112, pS128, DOI 10.1016/j.jaci.2003.09.032; Novembre E, 2001, ALLERGY, V56, P452, DOI 10.1034/j.1398-9995.2001.056005452.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oranje AP, 1999, J DERMATOL TREAT, V10, P73, DOI 10.3109/09546639909055916; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Ou LS, 2004, J ALLERGY CLIN IMMUN, V113, P756, DOI 10.1016/j.jaci.2004.01.772; Ozkaya E, 2005, J AM ACAD DERMATOL, V52, P579, DOI 10.1016/j.jaad.2004.11.037; Pastore S, 1998, J ALLERGY CLIN IMMUN, V101, P538, DOI 10.1016/S0091-6749(98)70361-6; Paul C, 2006, PEDIATRICS, V117, P118; Peeters KABM, 2004, INT J DERMATOL, V43, P235, DOI 10.1111/j.1365-4632.2004.02172.x; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Plaut M, 2003, J ALLERGY CLIN IMMUN, V112, P683, DOI 10.1067/mai.2003.1776; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Queille-Roussel C, 2001, BRIT J DERMATOL, V144, P507, DOI 10.1046/j.1365-2133.2001.04076.x; Raap U, 2005, J ALLERGY CLIN IMMUN, V115, P1268, DOI 10.1016/j.jaci.2005.02.007; Ravenscroft JC, 2000, CLIN EXP DERMATOL, V25, P327, DOI 10.1046/j.1365-2230.2000.00654.x; Ravenscroft JC, 2003, BRIT J DERMATOL, V148, P1010, DOI 10.1046/j.1365-2133.2003.05292.x; Reynolds NJ, 2001, LANCET, V357, P2012, DOI 10.1016/S0140-6736(00)05114-X; Ricci G, 2004, BRIT J DERMATOL, V150, P127, DOI 10.1111/j.1365-2133.2004.05705.x; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Rudolph R, 2004, CONTACT DERMATITIS, V50, P354, DOI 10.1111/j.0105-1873.2004.00368.x; Sampson HA, 2005, ALLERGY, V60, P19, DOI 10.1111/j.1398-9995.2005.00853.x; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Sator PG, 2003, J AM ACAD DERMATOL, V48, P352, DOI 10.1067/mjd.2003.105; Sayama K, 2005, EUR J IMMUNOL, V35, P1886, DOI 10.1002/eji.20425827; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schafer T, 2005, HAUTARZT, V56, P232, DOI 10.1007/s00105-004-0884-3; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Scheinfeld NS, 2003, CLIN DERMATOL, V21, P241, DOI 10.1016/S0738-081X(02)00364-4; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Schmid-Grendelmeier P, 2006, CHEM IMMUNOL ALLERGY, V91, P98; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; SCHMIDGRENDELEM.P, 2005, J ALLLERGY CLIN IMMU, V115, P1868; SEIDENARI S, 1996, ACTA DERM-VENEREOL, V79, P429; Simon D, 2004, ALLERGY, V59, P561, DOI 10.1111/j.1398-9995.2004.00476.x; SNOW JL, 1995, ARCH DERMATOL, V131, P193, DOI 10.1001/archderm.131.2.193; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Sporik R, 1997, J ALLERGY CLIN IMMUN, V99, P861, DOI 10.1016/S0091-6749(97)80029-2; Staab D, 2006, BRIT MED J, V332, P933, DOI 10.1136/bmj.332.7547.933; Staab D, 2000, DERMATOL PSYCHOSOM, V1, P173, DOI 10.1159/000057973; STALDER JF, 1994, BRIT J DERMATOL, V131, P536; Subramanyan Kumar, 2004, Dermatol Ther, V17 Suppl 1, P26, DOI 10.1111/j.1396-0296.2004.04S1003.x; Taha RA, 2000, J ALLERGY CLIN IMMUN, V105, P1002, DOI 10.1067/mai.2000.106483; Takaoka A, 2005, EUR J PHARMACOL, V516, P180, DOI 10.1016/j.ejphar.2005.04.040; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tan BB, 1997, BRIT J DERMATOL, V136, P351, DOI 10.1111/j.1365-2133.1997.tb14942.x; THOMAS KS, 2003, BRIT MED J, V30, P768; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Toyoda M, 2002, BRIT J DERMATOL, V147, P71, DOI 10.1046/j.1365-2133.2002.04803.x; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; Turjanmaa K, 2005, CURR OPIN ALLERGY CL, V5, P425, DOI 10.1097/01.all.0000182538.63273.a3; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Valenta R, 2000, J ALLERGY CLIN IMMUN, V105, P432, DOI 10.1067/mai.2000.104783; Van der Meer JB, 1999, BRIT J DERMATOL, V140, P1114; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; VERBIST L, 1990, J ANTIMICROB CHEMOTH, V25, P1; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; WAHLGREN CF, 1990, BRIT J DERMATOL, V122, P545, DOI 10.1111/j.1365-2133.1990.tb14732.x; Wahn U, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.1.e2; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Wedi B, 1997, J ALLERGY CLIN IMMUN, V100, P536; Weidinger S, 2005, J ALLERGY CLIN IMMUN, V116, P177, DOI 10.1016/j.jaci.2005.02.034; Weidinger S, 2005, ALLERGY, V60, P1256, DOI 10.1111/j.1398-9995.2005.00879.x; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Werfel Thomas, 2004, Curr Opin Allergy Clin Immunol, V4, P379, DOI 10.1097/00130832-200410000-00009; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Wojnarowska F, 2002, BRIT J DERMATOL, V147, P214, DOI 10.1046/j.1365-2133.2002.04835.x; Wollenberg A, 2003, J AM ACAD DERMATOL, V49, P198, DOI 10.1067/S0190-9622(03)00896-X; Wollenberg A, 2002, J INVEST DERMATOL, V119, P1096, DOI 10.1046/j.1523-1747.2002.19515.x; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zaki I, 1996, BRIT J DERMATOL, V135, P21, DOI 10.1111/j.1365-2133.1996.tb00705.x	200	183	200	1	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	AUG	2006	61	8					969	987		10.1111/j.1398-9995.2006.01153.x		19	Allergy; Immunology	Allergy; Immunology	061NZ	WOS:000238880600013	16867052	
J	Noverr, MC; Huffnagle, GB				Noverr, MC; Huffnagle, GB			The 'microflora hypothesis' of allergic diseases	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							CHAIN FATTY-ACIDS; PLACEBO-CONTROLLED TRIAL; ANTHROPOSOPHIC LIFE-STYLE; ORAL TOLERANCE INDUCTION; REGULATORY T-CELLS; INTESTINAL MICROFLORA; DENDRITIC CELLS; CANDIDA-ALBICANS; EARLY-CHILDHOOD; ATOPIC DISEASE	Increasingly, epidemiologic and clinical data support the hypothesis that perturbations in the gastrointestinal (GI) microbiota because of antibiotic use and dietary differences in 'industrialized' countries have disrupted the normal microbiota-mediated mechanisms of immunological tolerance in the mucosa, leading to an increase in the incidence of allergic airway disease. The data supporting this 'microflora hypothesis' includes correlations between allergic airway disease and (1) antibiotic use early in life, (2) altered fecal microbiota and (3) dietary changes over the past two decades. Our laboratory has recently demonstrated that mice can develop allergic airway responses to allergens if their endogenous microbiota is altered at the time of first allergen exposure. These experimental and clinical observations are consistent with other studies demonstrating that the endogenous microbiota plays a significant role in shaping the development of the immune system. Data are beginning to accumulate that a 'balanced' microbiota plays a positive role in maintaining mucosal immunologic tolerance long after post-natal development. Other studies have demonstrated that even small volumes delivered to the nasopharynx largely end up in the GI tract, suggesting that airway tolerance and oral tolerance may operate simultaneously. The mechanism of microbiota modulation of host immunity is not known; however, host and microbial oxylipins are one potential set of immunomodulatory molecules that may control mucosal tolerance. The cumulative data are beginning to support the notion that probiotic and prebiotic strategies be considered for patients coming off of antibiotic therapy.	Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA	Huffnagle, GB (reprint author), Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA.	ghuff@umich.edu					ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Alm JS, 2002, PEDIATR ALLERGY IMMU, V13, P402, DOI 10.1034/j.1399-3038.2002.01062.x; Alpan O, 2001, Curr Allergy Asthma Rep, V1, P572, DOI 10.1007/s11882-001-0067-6; Andoh A, 1999, JPEN-PARENTER ENTER, V23, pS70; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; ASSEMAN C, 2000, AM J RESP CRIT CARE, V162, P185; BANDEIRA A, 1990, J EXP MED, V172, P239, DOI 10.1084/jem.172.1.239; BAUER H, 1963, AM J PATHOL, V42, P471; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Black PN, 1999, J ALLERGY CLIN IMMUN, V103, P351, DOI 10.1016/S0091-6749(99)70513-0; Bohmig GA, 1997, IMMUNOLOGY, V92, P234, DOI 10.1046/j.1365-2567.1997.00337.x; Bos NA, 2000, CURR TOP MICROBIOL, V252, P211; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Cavaglieri CR, 2003, LIFE SCI, V73, P1683, DOI 10.1016/S0024-3205(03)00490-9; Chung Y, 2002, IMMUNOBIOLOGY, V206, P408, DOI 10.1078/0171-2985-00190; Cooper M D, 1974, Adv Exp Med Biol, V45, P13; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; Dixon RA, 2001, NATURE, V411, P843, DOI 10.1038/35081178; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; DUBOS R, 1963, J EXP MED, V117, P231, DOI 10.1084/jem.117.2.231; DUBOS R, 1971, MAN ADAPTING; Eldeirawi K, 2004, CHEST, V125, P1685, DOI 10.1378/chest.125.5.1685; Eyles JE, 2001, J PHARM PHARMACOL, V53, P601, DOI 10.1211/0022357011775929; EYSSEN H, 1972, J NUTR, V102, P1501; EYSSEN H, 1974, AM J CLIN NUTR, V27, P1329; EYSSEN H, 1973, P NUTR SOC, V32, P59, DOI 10.1079/PNS19730016; Fanaro S, 2003, ACTA PAEDIATR, V92, P48; Farooqi IS, 1998, THORAX, V53, P927; Fogarty A, 2000, Curr Opin Pulm Med, V6, P86, DOI 10.1097/00063198-200001000-00015; GIBSON GR, 1995, GASTROENTEROLOGY, V108, P975, DOI 10.1016/0016-5085(95)90192-2; GIULIANO M, 1987, ANTIMICROB AGENTS CH, V31, P202; Greene LS, 1999, NUTRITION, V15, P899, DOI 10.1016/S0899-9007(99)00209-9; GUGGENBICHLER JP, 1985, INFECTION, V13, pS137, DOI 10.1007/BF01644235; Hall G, 2003, VACCINE, V21, P549, DOI 10.1016/S0264-410X(02)00394-8; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; HOBERG KA, 1983, ANTIMICROB AGENTS CH, V24, P401; Hogan DA, 2004, MOL MICROBIOL, V54, P1212, DOI 10.1111/j.1365-2958.2004.04349.x; Hooper LV, 2004, TRENDS MICROBIOL, V12, P129, DOI 10.1016/j.tim.2004.01.001; Huang Min-Yi, 2003, Journal of Microbiology Immunology and Infection, V36, P123; Hunt JRF, 2005, CLIN EXP ALLERGY, V35, P685, DOI 10.1111/j.1365-2222.2005.02239.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jonuleit H, 2001, TRENDS IMMUNOL, V22, P394, DOI 10.1016/S1471-4906(01)01952-4; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Kirjavainen PV, 2003, J PEDIATR GASTR NUTR, V36, P223, DOI 10.1097/00005176-200302000-00012; Kirjavainen PV, 2001, FEMS IMMUNOL MED MIC, V32, P1, DOI 10.1016/S0928-8244(01)00272-3; La Vecchia C, 1998, EPIDEMIOLOGY, V9, P208; Laiho K, 2002, BRIT J NUTR, V88, pS19, DOI 10.1079/BJNBJN2002581; LEFRANCOIS L, 1989, SCIENCE, V243, P1716, DOI 10.1126/science.2564701; LIDBECK A, 1993, CLIN INFECT DIS, V16, pS181; Lodinova-Zadnikova R, 2003, INT ARCH ALLERGY IMM, V131, P209, DOI 10.1159/000071488; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Maeda Y, 2001, IMMUNOBIOLOGY, V204, P442, DOI 10.1078/0171-2985-00054; Magnusson J, 2003, FEMS MICROBIOL LETT, V219, P129, DOI 10.1016/S0378-1097(02)01207-7; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Majamaa H, 1996, CLIN EXP ALLERGY, V26, P181, DOI 10.1111/j.1365-2222.1996.tb00078.x; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Maraki S, 2003, J CHEMOTHERAPY, V15, P369; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; Mastrandrea F., 2004, ALLERG IMMUNOL PARIS, V36, P118; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; MOROTOMI M, 1976, APPL ENVIRON MICROB, V31, P475; MULLIGAN ME, 1982, ANTIMICROB AGENTS CH, V22, P226; Noverr MC, 2005, INFECT IMMUN, V73, P30, DOI 10.1128/IAI.73.1.30-38.2005; Noverr MC, 2004, INFECT IMMUN, V72, P6206, DOI 10.1128/IAI.72.11.6206-6210.2004; Noverr MC, 2004, INFECT IMMUN, V72, P4996, DOI 10.1128/IAI.72.9.4996-5003.2004; Noverr MC, 2003, CLIN MICROBIOL REV, V16, P517, DOI 10.1128/CMR.16.3.517-533.2003; Noverr MC, 2002, INFECT IMMUN, V70, P400, DOI 10.1128/IAI.70.1.400-402.2002; Noverr MC, 2001, INFECT IMMUN, V69, P2957, DOI 10.1128/IAI.69.5.2957-2963.2001; Orrhage K, 2000, DRUG EXP CLIN RES, V26, P95; Panwala CM, 1998, J IMMUNOL, V161, P5733; Payne Samantha, 2003, Curr Issues Intest Microbiol, V4, P1; Pickett TE, 2000, INFECT IMMUN, V68, P205; RETTGER LF, 1914, CENTRALBL BAKTERIOL, V73, P362; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Rook GAW, 2005, CLIN EXP ALLERGY, V35, P841, DOI 10.1111/j.1365-2222.2005.02112.x; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Russo M, 2001, AM J RESP CELL MOL, V24, P518; Russo M, 1998, IMMUNOL LETT, V61, P15, DOI 10.1016/S0165-2478(97)00155-7; Saemann MD, 2000, FASEB J, V14, P2380; Saemann MD, 2002, WIEN KLIN WOCHENSCHR, V114, P289; SAMONIS G, 1993, ANTIMICROB AGENTS CH, V37, P51; Sellon RK, 1998, INFECT IMMUN, V66, P5224; Sjogren J, 2003, APPL ENVIRON MICROB, V69, P7554, DOI 10.1128/AEM.69.12.7554-7557.2003; SJOVALL J, 1988, SCAND J INFECT DIS S, V49, P73; Smith KM, 2000, AM J RESP CRIT CARE, V162, pS175; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Stagg AJ, 2003, GUT, V52, P1522, DOI 10.1136/gut.52.10.1522; Steinman RM, 2000, J EXP MED, V191, P411, DOI 10.1084/jem.191.3.411; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strom K, 1996, Monaldi Arch Chest Dis, V51, P16; Stumbles PA, 2003, APMIS, V111, P741, DOI 10.1034/j.1600-0463.2003.11107806.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Sullivan A, 2001, Lancet Infect Dis, V1, P101, DOI 10.1016/S1473-3099(01)00066-4; Takabayashi K, 2003, J IMMUNOL, V170, P3898; Tannock G, 1995, NORMAL MICROFLORA; Tannock GW, 2002, EUR J CLIN NUTR, V56, pS44, DOI 10.1038/sj.ejcn.1601661; TAUROG JD, 1994, J EXP MED, V180, P2359, DOI 10.1084/jem.180.6.2359; Umesaki Y, 2000, MICROBES INFECT, V2, P1343, DOI 10.1016/S1286-4579(00)01288-0; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; VANDERWAAIJ D, 1989, ANNU REV MICROBIOL, V43, P69, DOI 10.1146/annurev.micro.43.1.69; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Weiner HL, 2001, MICROBES INFECT, V3, P947, DOI 10.1016/S1286-4579(01)01456-3; Wheeler JG, 1997, ANN ALLERG ASTHMA IM, V79, P229; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Xu J, 2004, TRENDS MICROBIOL, V12, P21, DOI 10.1016/j.tim.2003.11.007; Yamanaka T, 2003, J IMMUNOL, V170, P816	119	183	197	1	29	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	DEC	2005	35	12					1511	1520		10.1111/j.1365-2222.2005.02379.x		10	Allergy; Immunology	Allergy; Immunology	990XT	WOS:000233777400002	16393316	
J	Dobie, DJ; Kivlahan, DR; Maynard, C; Bush, KR; Davis, TM; Bradley, KA				Dobie, DJ; Kivlahan, DR; Maynard, C; Bush, KR; Davis, TM; Bradley, KA			Posttraumatic stress disorder in female veterans - Association with self-reported health problems and functional impairment	ARCHIVES OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; MALE VIETNAM VETERANS; PTSD CHECKLIST; PRIMARY-CARE; SCREENING INSTRUMENT; SEXUAL VICTIMIZATION; TRAUMATIC EVENTS; AFFAIRS PATIENTS; BREAST-CANCER; DESERT-STORM	Background: The purpose of this report is to identify self-reported health problems and functional impairment associated with screening positive for posttraumatic stress disorder (PTSD) in women seen for care at a Department of Veterans Affairs (VA) medical center. Methods: A survey was mailed to all women (N = 1935) who received care at the VA Puget Sound Health Care System between October 1996 and January 1998. The survey inquired about health history and habits. It included the PTSD Checklist-Civilian Version (PCL-C) and validated screening measures for other psychiatric disorders. The veteran's version of the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36-V) was included to assess health-related quality of life. Results: Of the 1259 eligible women who completed the survey, 266 women (21%) screened positive for current PTSD (PCL-C score greater than or equal to50). In age-adjusted bivariate analyses, women who screened positive for PTSD reported more psychiatric problems, substance abuse, and lifetime exposure to domestic violence. They were significantly more likely to endorse physical health problems including obesity, smoking, irritable bowel syndrome, fibromyalgia, chronic pelvic pain, polycystic ovary disease, asthma, cervical cancer, and stroke. In fully adjusted multivariate models, a PCL-C score of 50 or greater was independently associated with scoring in the lowest quartile on SF-36-V subscales and composite scales. Conclusions: Symptoms of PTSD are common in women treated at VA facilities. In addition, PTSD is associated with self-reported mental and physical health problems and poor health-related quality of life in these patients. These findings have implications for the design of VA primary care services for the growing population of female veterans.	Univ Washington, Sch Med, Dept Psychiat, Seattle, WA USA; Univ Washington, Sch Med, Dept Behav Sci, Seattle, WA USA; Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; Ctr Excellence Subst Abuse Treatment & Educ, Seattle, WA USA; Hlth Serv Res & Dev, Seattle, WA USA; VA Puget Sound Hlth Care Syst, Seattle, WA USA	Dobie, DJ (reprint author), S-116 VA PSHCS,1660 S Columbian Way, Seattle, WA 98108 USA.	djdobie@u.washington.edu	Maynard, Charles/N-3906-2015	Maynard, Charles/0000-0002-1644-7814			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037//0022-006X.66.3.586; Andrykowski MA, 1998, J TRAUMA STRESS, V11, P189, DOI 10.1023/A:1024490718043; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; Beckham JC, 1998, AM J PSYCHIAT, V155, P1565; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Boscarino JA, 1999, ANN BEHAV MED, V21, P227, DOI 10.1007/BF02884839; Bradley KA, 1998, JAMA-J AM MED ASSOC, V280, P166, DOI 10.1001/jama.280.2.166; Bradley KA, 2001, PSYCHOL ADDICT BEHAV, V15, P297, DOI 10.1037//0893-164X.15.4.297; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; Brown RL, 1997, J FAM PRACTICE, V44, P151; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; ENGEL CC, 1993, J NERV MENT DIS, V181, P683, DOI 10.1097/00005053-199311000-00006; FELITTI VJ, 1991, SOUTHERN MED J, V84, P328; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fontana A, 1998, PSYCHIATR SERV, V49, P658; Freund KM, 1996, J GEN INTERN MED, V11, P44, DOI 10.1007/BF02603485; Friedman M.J., 1995, NEUROBIOLOGICAL CLIN; Grossman LS, 1997, PSYCHIATR SERV, V48, P393; Hankin CS, 1999, AM J PSYCHIAT, V156, P1924; Hankin CS, 1999, J TRAUMA STRESS, V12, P601, DOI 10.1023/A:1024760900213; Hoff RA, 1998, MED CARE, V36, P1524, DOI 10.1097/00005650-199811000-00002; Kazis LE, 1998, ARCH INTERN MED, V158, P626, DOI 10.1001/archinte.158.6.626; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kimerling R, 2000, J TRAUMA STRESS, V13, P115, DOI 10.1023/A:1007729116133; KOSS MP, 1990, J CONSULT CLIN PSYCH, V58, P147, DOI 10.1037//0022-006X.58.2.147; LISSAU I, 1994, LANCET, V343, P324, DOI 10.1016/S0140-6736(94)91163-0; Manne SL, 1998, J PEDIATR PSYCHOL, V23, P357, DOI 10.1093/jpepsy/23.6.357; MCFALL ME, 1992, J STUD ALCOHOL, V53, P357; MCFARLANE AC, 1994, J PSYCHOSOM RES, V38, P715, DOI 10.1016/0022-3999(94)90024-8; Montrey J. S., 2000, VETERANS HLTH SYSTEM, V5, P32; NORRIS FH, 1992, J CONSULT CLIN PSYCH, V60, P409, DOI 10.1037/0022-006X.60.3.409; RESNICK HS, 1993, J CONSULT CLIN PSYCH, V61, P984, DOI 10.1037/0022-006X.61.6.984; RUSSELL M, 1994, ALCOHOL CLIN EXP RES, V18, P1156, DOI 10.1111/j.1530-0277.1994.tb00097.x; Sadler AG, 2000, OBSTET GYNECOL, V96, P473, DOI 10.1016/S0029-7844(00)00919-4; Schnurr PP, 2000, J NERV MENT DIS, V188, P496, DOI 10.1097/00005053-200008000-00004; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238; Shalev AY, 1998, AM J PSYCHIAT, V155, P630; SIBAI AM, 1989, AM J EPIDEMIOL, V130, P623; Skinner K, 1999, WOMEN HEALTH, V29, P17, DOI 10.1300/J013v29n04_02; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; SPRINGS FE, 1992, MAYO CLIN PROC, V67, P527; *SPSS INC, 1989, SPSS SPSS 10 0 7; Stein MB, 2000, GEN HOSP PSYCHIAT, V22, P261, DOI 10.1016/S0163-8343(00)00080-3; Stein MB, 2000, BEHAV RES THER, V38, P619, DOI 10.1016/S0005-7967(99)00098-4; Stein MB, 1997, AM J PSYCHIAT, V154, P1114; vanderKolk BA, 1996, AM J PSYCHIAT, V153, P83; Wagner AW, 2000, J TRAUMA STRESS, V13, P41, DOI 10.1023/A:1007716813407; WALKER EA, 1995, PSYCHOSOMATICS, V36, P531; WALKER EA, 1993, AM J PSYCHIAT, V150, P1502; Ware JE, 1993, SF36 HLTH SURVEY MAN; WEATHERS F, 1996, MEASURMENT STRESS TR; WOLFE J, 1992, AM J PSYCHIAT, V149, P676; WOLFE J, 1994, J CONSULT CLIN PSYCH, V62, P1235, DOI 10.1037/0022-006X.62.6.1235; Zatzick DF, 1997, MIL MED, V162, P661; Zatzick DF, 1997, AM J PSYCHIAT, V154, P1690; Zoellner LA, 2000, J TRAUMA STRESS, V13, P635, DOI 10.1023/A:1007810200460	60	183	188	5	17	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0003-9926			ARCH INTERN MED	Arch. Intern. Med.	FEB 23	2004	164	4					394	400		10.1001/archinte.164.4.394		7	Medicine, General & Internal	General & Internal Medicine	776ZE	WOS:000189148600006	14980990	
J	Samee, S; Altes, T; Powers, P; de Lange, EE; Knight-Scott, J; Rakes, G; Mugler, JP; Ciambotti, JM; Alford, BA; Brookeman, JR; Platts-Mills, TAE				Samee, S; Altes, T; Powers, P; de Lange, EE; Knight-Scott, J; Rakes, G; Mugler, JP; Ciambotti, JM; Alford, BA; Brookeman, JR; Platts-Mills, TAE			Imaging the lungs in asthmatic patients by using hyperpolarized helium-3 magnetic resonance: Assessment of response to methacholine and exercise challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; helium; magnetic resonance imaging; imaging; ventilation; lungs	COMPUTED-TOMOGRAPHY; HE-3 GAS; DISEASE; AIRWAYS; HEALTH	Background: Imaging of gas distribution in the lungs of patients with asthma has been restricted because of the lack of a suitable gaseous contrast agent. Hyperpolarized helium-3 (HHe3) provides a new technique for magnetic resonance imaging of lung diseases. Objective: We sought to investigate the use of HHe3 gas to image the lungs of patients with moderate or severe asthma and to assess changes in gas distribution after methacholine and exercise challenge. Methods: Magnetic resonance imaging was performed in asthmatic patients immediately after inhalation of HHe3 gas. In addition, images were obtained before and after methacholine challenge and a standard exercise test. Results: Areas of the lung with no signal or sharply reduced HHe3 signal (ventilation defects) are common in patients with asthma, and the number of defects was inversely related to the percent predicted FEV1 (r = 0.71, P < .002). After methacholine challenge (n = 3), the number of defects increased. Similarly, imaging of the lungs after exercise (n = 6) showed increased ventilation defects in parallel with decreases in FEV1. The increase in defects after challenge in these 9 asthmatic patients was significant both for the number (P < .02) and extent (P < .02) of the defects. The variability and speed of changes in ventilation and the complete lack of signal in many areas is in keeping with a model in which the defects result from airway closure. Conclusion: HHe3 magnetic resonance provides a new technique for imaging the distribution of inhaled air in the lungs. The technique is suitable for following responses to treatment of asthma and changes after methacholine or exercise challenge.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Dept Internal Med,Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Radiol, Charlottesville, VA 22903 USA; Univ Virginia, Dept Biomed Engn, Charlottesville, VA 22903 USA	Platts-Mills, TAE (reprint author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Dept Internal Med,Div Asthma Allergy & Immunol, POB 801355, Charlottesville, VA 22908 USA.		Mugler, John/B-9432-2013	Mugler, John/0000-0002-4140-308X	NHLBI NIH HHS [R44 HL 59022, R01 HL 66479]; NIAID NIH HHS [AI 20565]; NIEHS NIH HHS [P01 ES/AI 50989]		Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crater SE, 1999, AM J RESP CRIT CARE, V159, P806; de Lange EE, 1999, RADIOLOGY, V210, P851; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215; ENRIGHT PL, 1994, AM J RESP CRIT CARE, V149, pS9; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179; Kauczor HU, 1997, JMRI-J MAGN RESON IM, V7, P538, DOI 10.1002/jmri.1880070314; King GG, 1999, AM J RESP CRIT CARE, V159, P992; MCFALL J, 1996, RADIOLOGY, V200, P553; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; National Asthma Education and Prevention Program, 1997, NIH PUBL, V97-4051; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Parker JA, 1996, J NUCL MED, V37, P1906; WOOLCOCK AJ, 1972, AM REV RESPIR DIS, V106, P692; WOOLCOCK AJ, 1972, AUST NZ J MED, V2, P294, DOI 10.1111/j.1445-5994.1972.tb03078.x	19	183	188	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2003	111	6					1205	1211		10.1067/mai.2003.1544		7	Allergy; Immunology	Allergy; Immunology	688FZ	WOS:000183424700006	12789218	
J	Remes, ST; Castro-Rodriguez, JA; Holberg, CJ; Martinez, FD; Wright, AL				Remes, ST; Castro-Rodriguez, JA; Holberg, CJ; Martinez, FD; Wright, AL			Dog exposure in infancy decreases the subsequent risk of frequent wheeze but not of atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; wheezing; atopy; allergy; epidemiology; risk; children; cat; dog; pets; IgE	HAY-FEVER; ALLERGIC SENSITIZATION; CHILDREN; ASTHMA; ENVIRONMENT; PREVALENCE; CHILDHOOD; COMMUNITY; FARMERS; COHORT	Background: Influence of household pets in the development of childhood asthma or atopy has been controversial. Objective: The purpose of this study was to investigate whether pet exposure in early life decreases the subsequent risk of frequent wheezing and/or allergic sensitization. Methods: This was a prospective observational birth cohort study. The setting was a large health maintenance organization in Tucson, Ariz; the subjects were a population sample of 1246 newborns enrolled at birth and followed prospectively to age 13 years. The main outcome measures were as follows: time to first report of frequent wheezing (>3 episodes in the past year), skin prick test reactivity at 6 years and 11 years of age, an total serum IgE at 9 months, 6 years, and 11 years of age. Results: Children living in households with greater than or equal to1 indoor dogs at birth were less likely to develop frequent wheeze than those not having indoor dogs (P = .004). This inverse association was confined to children without parental asthma (hazard ratio = 0.47; P < .001 [Cox regression]) and was not evident for children with parental asthma (hazard ratio = 0.96; P = .87). Adjustment by potential confounders did not change the results. Indoor cat exposure was not significantly associated with the risk of frequent wheezing. Neither cat exposure in early life nor dog exposure in early life was associated with skin prick test reactivity or total serum IgE at any age. Conclusion: Dog exposure in early life might prevent the development of asthmalike symptoms, at least in low-risk children with no family history of asthma. Nevertheless, early pet exposure does not seem to significantly influence the development of allergic sensitization.	Univ Arizona, Arizona Hlth Sci Ctr, Resp Sci Ctr, Tucson, AZ 85724 USA; Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland	Wright, AL (reprint author), Univ Arizona, Arizona Hlth Sci Ctr, Resp Sci Ctr, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL 56177, HL 14136]		ARSHAD SH, 1991, BRIT J CLIN PRACT, V45, P88; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; HAAHTELA T, 1990, BRIT MED J, V301, P266; HALONEN M, 1991, CLIN EXP ALLERGY, V21, P235, DOI 10.1111/j.1365-2222.1991.tb00836.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; Martinez FD, 1999, LANCET S2, V354, pSII12; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Peat J, 1998, EUR RESPIR J, V12, p28S; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; SIGURS N, 1995, PEDIATRICS, V95, P500; StataCorp, 1999, STAT STAT SOFTW REL; Strachan D, 1998, Eur Respir J Suppl, V27, p23s; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; vonMutius E, 1997, LANCET, V350, P14; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	30	183	189	2	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2001	108	4					509	515		10.1067/mai.2001.117797		7	Allergy; Immunology	Allergy; Immunology	485NK	WOS:000171760300006	11590373	
J	Stern, DA; Morgan, WJ; Halonen, M; Wright, AL; Martinez, FD				Stern, Debra A.; Morgan, Wayne J.; Halonen, Marilyn; Wright, Anne L.; Martinez, Fernando D.			Wheezing and bronchial hyper-responsiveness in early childhood as predictors of newly diagnosed asthma in early adulthood: a longitudinal birth-cohort study	LANCET			English	Article							YOUNG-ADULTS; RISK-FACTORS; FOLLOW-UP; POPULATION; LIFE; CHILDREN; ILLNESS; ALLERGEN; RATIO	Background Incidence of asthma increases during early adulthood. We aimed to estimate the contributions of sex and early life factors to asthma diagnosed in young adults. Methods 1246 healthy newborn babies were enrolled in the Tucson Children's Respiratory Study. Parental characteristics, early-life wheezing phenotypes, airway function, and bronchial hyper-responsiveness to cold dry air and sensitisation to Alternaria alternata were determined before age 6 years. Physician-diagnosed asthma, both chronic and newly diagnosed, and airway function were recorded at age 22 years. Findings Of 1246 babies enrolled, 849 had follow-up data at 22 years. Average incidence of asthma at age 16-22 years was 12.6 per thousand person-years. 49 (27%) of all 181 cases of active asthma at 22 years were newly diagnosed, of which 35 (71%) were women. Asthma remittance by 22 years was higher in men than in women (multinomial odds ratio [M-OR] 2.0, 95% CI 1.2-3.2, p=0 . 008). Age at diagnosis was linearly associated with the ratio of forced expiratory volume at 1 s to forced vital capacity at age 22 years. Factors independently associated with chronic asthma at 22 years included onset at 6 years (7.4, 3 . 9-14. 0) and persistent wheezing (14.0, 6.8-28 . 0) in early life, sensitisation to A alternata (3.6, 2.1-6.4), low airway function at age 6 years (2.1, 1.1-3.9.), and bronchial hyper-responsiveness at 6 years (4 . 5, 1.9-10 . 0). Bronchial hyper-responsiveness (6.9, 2.3-21 . 0), low airway function at 6 years (2.8, 1.1-6.9), and late-onset (4 . 6, 1.7-12 . 0) and persistent wheezing (4 . 0, 1.2-14. 0) predicted newly diagnosed asthma at age 22 years. Interpretation Asthma with onset in early adulthood has its origins in early childhood. Funding National Heart Lung and Blood Institute.	[Stern, Debra A.; Morgan, Wayne J.; Halonen, Marilyn; Wright, Anne L.; Martinez, Fernando D.] Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Morgan, Wayne J.; Wright, Anne L.] Univ Arizona, Dept Pediat, Tucson, AZ USA	Martinez, FD (reprint author), Univ Arizona, Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA.	fernando@arc.arizona.edu			National Heart Lung and Blood Institute [HL-56177]	This work is supported by grant HL-56177 from the National Heart Lung and Blood Institute. We gratefully acknowledge the contributions of Lynn Taussig who started the Tucson Children's Respiratory Study in 1980 We thank Bruce Saul for data management and our study nurses, Marilyn Lindell and Lydia de la Ossa, for data collection and participant follow-LIP.	Anderson HR, 2007, THORAX, V62, P85, DOI 10.1136/thx.2006.066407; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; Avila L, 2005, J ASTHMA, V42, P543, DOI 10.1080/02770900500214791; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; King ME, 2004, PANMINERVA MED, V46, P97; LARSSON L, 1995, THORAX, V50, P260, DOI 10.1136/thx.50.3.260; Lombardi E, 1997, AM J RESP CRIT CARE, V156, P1863; Martinez FD, 2003, NEW ENGL J MED, V349, P1473, DOI 10.1056/NEJMe030041; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moore YF, 2004, IMMUNOGENETICS, V56, P1, DOI 10.1007/s00251-004-0661-6; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nicolai T, 2003, PEDIATR ALLERGY IMMU, V14, P280, DOI 10.1034/j.1399-3038.2003.00047.x; Ownby DR, 1996, ANN ALLERG ASTHMA IM, V77, P304; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stein RT, 1997, THORAX, V52, P946; Strachan DP, 1996, BRIT MED J, V312, P1195; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; Wright AL, 2006, PEDIATR PULM, V41, P318, DOI 10.1002/ppul.20373; Xuan W, 2000, AM J RESP CRIT CARE, V161, P1820	27	182	187	2	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 20	2008	372	9643					1058	1064		10.1016/S0140-6736(08)61447-6		7	Medicine, General & Internal	General & Internal Medicine	354OI	WOS:000259648500032	18805334	
J	Haland, G; Carlsen, KCL; Sandvik, L; Devulapalli, CS; Munthe-Kaas, MC; Pettersen, M; Carlsen, KH				Haland, Geir; Carlsen, Karin C. Lodrup; Sandvik, Leiv; Devulapalli, Chandra Sekhar; Munthe-Kaas, Monica Cheng; Pettersen, Morten; Carlsen, Kai-Hakon		ORAACLE	Reduced lung function at birth and the risk of asthma at 10 years of age	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EXPIRATORY FLOW PATTERNS; BRONCHIAL OBSTRUCTION; AIRWAY FUNCTION; EARLY-LIFE; INFANTS; CHILDREN; MECHANICS; EXPOSURE; WHEEZE	BACKGROUND Reduced lung function in early infancy has been associated with later obstructive airway diseases. We assessed whether reduced lung function shortly after birth predicts asthma 10 years later. METHODS We conducted a prospective birth cohort study of healthy infants in which we measured lung function shortly after birth with the use of tidal breathing flow-volume loops (the fraction of expiratory time to peak tidal expiratory flow to total expiratory time [t(sub PTEF)/t(sub E)]) in 802 infants and passive respiratory mechanics, including respiratory-system compliance, in 664 infants. At 10 years of age, 616 children (77%) were reassessed by measuring lung function, exercise-induced bronchoconstriction, and bronchial hyperresponsiveness (by means of a methacholine challenge) and by conducting a structured interview to determine whether there was a history of asthma or current asthma. RESULTS As compared with children whose t(sub PTEF)/t(sub E) shortly after birth was above the median, children whose t(sub PTEF)/t(sub E) was at or below the median were more likely at 10 years of age to have a history of asthma (24.3% vs. 16.2%, P=0.01), to have current asthma (14.6% vs. 7.5%, P=0.005), and to have severe bronchial hyperresponsiveness, defined as a methacholine dose of less than 1.0 micromol causing a 20% fall in the forced expiratory volume in 1 second (FEV(sub 1)) (9.1% vs. 4.9%, P=0.05). As compared with children whose respiratory-system compliance was above the median, children with respiratory compliance at or below the median more often had a history of asthma (27.4% vs. 14.8%; P=0.001) and current asthma (15.0% vs. 7.7%, P=0.009), although this measure was not associated with later measurements of lung function. At 10 years of age, t(sub PTEF)/t(sub E) at birth correlated weakly with the maximal midexpiratory flow rate (r=0.10, P=0.01) but not with FEV(sub 1) or forced vital capacity. CONCLUSIONS Reduced lung function at birth is associated with an increased risk of asthma by 10 years of age.	Rigshosp Radiumhosp Med Ctr, Dept Pediat, Voksentoppen, N-0491 Oslo, Norway; Ullevaal Univ Hosp, Dept Pediat, Div Woman & Child, Oslo, Norway; Ullevaal Univ Hosp, Clin Res Ctr, Oslo, Norway; Univ Oslo, Fac Med, Oslo, Norway	Haland, G (reprint author), Rigshosp Radiumhosp Med Ctr, Dept Pediat, Voksentoppen, Ullveien 14, N-0491 Oslo, Norway.	haland@medisin.uio.no	Devulapalli, Chandra Sekhar/B-6170-2008				BANOVCIN P, 1995, PEDIATR RES, V38, P218, DOI 10.1203/00006450-199508000-00014; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; Carlsen KCL, 2006, ALLERGY, V61, P454, DOI 10.1111/j.1398-9995.2005.00938.x; CARLSEN KCL, 1997, EUR RESP MON, V5, P27; Carlsen KH, 2000, RESP MED, V94, P750, DOI 10.1053/rmed.2000.0809; Carlsen L, 1999, PEDIATR ALLERGY IMMU, V10, P89; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CUTRERA R, 1991, PEDIATR PULM, V10, P6, DOI 10.1002/ppul.1950100103; LESOUEF PN, 1984, AM REV RESPIR DIS, V129, P552; Lodrup Carlsen K C, 1994, Eur Respir J, V7, P1660, DOI 10.1183/09031936.94.07091660; LODRUP KC, 1992, PEDIATR PULM, V12, P99, DOI 10.1002/ppul.1950120208; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; MORRIS MJ, 1981, THORAX, V36, P135, DOI 10.1136/thx.36.2.135; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; Nystad W, 2001, EUR J EPIDEMIOL, V17, P209, DOI 10.1023/A:1017926403763; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Seddon PC, 1996, AM J RESP CRIT CARE, V153, P1248; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; vanderEnt CK, 1996, AM J RESP CRIT CARE, V153, P1253; YOUNG S, 1994, J PEDIATR-US, V124, P681, DOI 10.1016/S0022-3476(05)81355-1; Young S, 2000, EUR RESPIR J, V15, P151, DOI 10.1034/j.1399-3003.2000.15a28.x; Yuksel B, 1996, THORAX, V51, P815, DOI 10.1136/thx.51.8.815	25	182	190	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 19	2006	355	16					1682	1689		10.1056/NEJMoa052885		8	Medicine, General & Internal	General & Internal Medicine	096DN	WOS:000241357300009	17050892	
J	Viegi, G; Pistelli, F; Sherrill, DL; Maio, S; Baldacci, S; Carrozzi, L				Viegi, G.; Pistelli, F.; Sherrill, D. L.; Maio, S.; Baldacci, S.; Carrozzi, L.			Definition, epidemiology and natural history of COPD	EUROPEAN RESPIRATORY JOURNAL			English	Review						air pollution; chronic obstructive pulmonary disease clinical/basic investigations; cor pulmonale; epidemiology of asthma/chronic obstructive pulmonary disease; smoking; spirometry	OBSTRUCTIVE PULMONARY-DISEASE; GENERAL-POPULATION SAMPLE; PARTICULATE AIR-POLLUTION; PERCUTANEOUS CORONARY INTERVENTION; DOMICILIARY OXYGEN-THERAPY; PROPORTIONAL VENN-DIAGRAM; FORCED EXPIRATORY VOLUME; PHYSICIAN-DIAGNOSED COPD; HEALTH-CARE UTILIZATION; LUNG-FUNCTION DECLINE	Chronic obstructive pulmonary disease (COPD) is the fifth cause of morbidity and mortality in the developed world and represents a substantial economic and social burden. Patients experience a progressive deterioration up to end-stage COPD, characterised by very severe airflow limitation, severely limited and declining performance status with chronic respiratory failure, advanced age, multiple comorbidities and severe systemic manifestations/ complications. COPD is frequently underdiagnosed and under-treated. Today, COPD develops earlier in life and is less gender specific. Tobacco smoking is the major risk factor for COPD, followed by occupation and air pollution. Severe deficiency for alpha(1)-antitrypsin is rare; several phenotypes are being associated with elevated risk for COPD in the presence of risk factor exposure. Any patient presenting with cough, sputum production or dyspnoea should be assessed by standardised spirometry. Continued exposure to noxious agents promotes a more rapid decline in lung function and increases the risk for repeated exacerbations, eventually leading to end-stage disease. Without major efforts in prevention, there will be an increasing proportion of end-stage patients who can live longer through long-term oxygen therapy and assisted ventilation, but with elevated suffering and huge costs. Smoking prevention and smoking cessation are the most important epidemiological measurements to counteract chronic obstructive pulmonary disease epidemics.	CNR, Inst Clin Physiol, Pulm Environm Unit, I-56126 Pisa, Italy; Univ Pisa, Cardiothorac Dept, Pisa, Italy; Univ Arizona, Arizona Clin Res Traning Program, Tucson, AZ USA; Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ USA	Viegi, G (reprint author), CNR, Inst Clin Physiol, Pulm Environm Unit, Via Trieste 41, I-56126 Pisa, Italy.	viegig@ifc.cnr.it	Maio, Sara/K-4065-2016	Maio, Sara/0000-0001-6363-8544			Adcock IM, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-21; Ai-Ping Chua, 2005, Chest, V128, P518, DOI 10.1378/chest.128.2.518; *AM MED ASS, 1984, GUID EV PERM IMP, P85; American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P665; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; *ASS NAT TRAIT DOM, 1998, OBS; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BATES DV, 1979, LUNG TRANSITION HLTH, V12, P1; Bednarek M, 2006, THORAX, V61, P869, DOI 10.1136/thx.2006.059071; Bergdahl IA, 2004, EUR RESPIR J, V23, P402, DOI 10.1183/09031936.04.00034304; Berger JS, 2004, AM J CARDIOL, V94, P649, DOI 10.1016/j.amjcard.2004.05.034; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bestall JC, 1999, THORAX, V54, P581; Bilde L, 2007, RESP MED, V101, P539, DOI 10.1016/j.rmed.2006.06.020; Bleecker Eugene R, 2004, Chest, V126, p93S, DOI 10.1378/chest.126.2_suppl_1.93S; Bousquet J, 2007, EUR RESPIR J, V29, P233, DOI 10.1183/09031936.00138606; Boutin-Forzano S, 2007, INT J TUBERC LUNG D, V11, P695; Brusasco V, 2005, EUR RESPIR J, V26, P1, DOI 10.1183/09031936.05.00034205; Burchfiel CM, 1996, ANN EPIDEMIOL, V6, P217, DOI 10.1016/1047-2797(96)00007-5; BURROWS B, 1965, AM REV RESPIR DIS, V91, P665; CALVERLEY PMA, 2006, EUR RESP MON, V38, P7; Garrido PC, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-31; Celli BR, 2003, EUR RESPIR J, V22, P268, DOI 10.1183/09031936.03.00075102; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Cerveri I, 2003, EUR RESPIR J, V22, P413, DOI 10.1183/09031936.03.00121103; Chailleux E, 1996, CHEST, V109, P741, DOI 10.1378/chest.109.3.741; Chan-Yeung M, 2004, INT J TUBERC LUNG D, V8, P2; Chapman KR, 2006, EUR RESPIR J, V27, P188, DOI 10.1183/09031936.06.00024505; Chapman RS, 2005, BRIT MED J, V331, P1050, DOI 10.1136/bmj.38628.676088.55; Chen Y, 1996, GENET EPIDEMIOL, V13, P35, DOI 10.1002/(SICI)1098-2272(1996)13:1<35::AID-GEPI4>3.0.CO;2-5; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Claessens MT, 2000, J AM GERIATR SOC, V48, pS146; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; Clini E, 2002, EUR RESPIR J, V20, P529, DOI 10.1183/09031936.02.02162001; Clotet J, 2004, ARCH BRONCONEUMOL, V40, P155, DOI 10.1157/13058850; COHEN BH, 1980, AM J EPIDEMIOL, V112, P274; Confalonieri M, 2005, EUR RESPIR J, V25, P348, DOI 10.1183/09031936.05.00085304; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959; COULTAS DB, 1991, AM REV RESPIR DIS, V144, P770; Cricelli C, 2003, J PUBLIC HEALTH MED, V25, P254, DOI 10.1093/pubmed/fdg060; Croxton TL, 2006, AM J RESP CRIT CARE, V174, P373, DOI 10.1164/rccm.200507-1161WS; Croxton TL, 2003, AM J RESP CRIT CARE, V167, P1142, DOI 10.1164/rccm.200207-756WS; Dahl M, 2007, AM J RESP CRIT CARE, V175, P250, DOI 10.1164/rccm.200605-713OC; Dal Negro R, 2003, RESP MED, V97, pS43, DOI 10.1016/S0954-6111(03)80024-0; de Marco R, 2004, THORAX, V59, P120, DOI 10.1136/thorax.2003.011163; Detournay B, 2004, VALUE HEALTH, V7, P168, DOI 10.1111/j.1524-4733.2004.72329.x; Doll R, 2004, BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Driscoll T, 2005, AM J IND MED, V48, P432, DOI 10.1002/ajim.20210; Eagan TML, 2004, EUR RESPIR J, V23, P589, DOI 10.1183/09031936.04.00041204; Eisner Mark D, 2006, BMC Pulm Med, V6, P12, DOI 10.1186/1471-2466-6-12; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Ekberg-Aronsson M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-98; Ekici A, 2005, ENVIRON RES, V99, P93, DOI 10.1016/j.envres.2005.01.004; Elkington H, 2004, RESP MED, V98, P439, DOI 10.1016/j.rmed.2003.11.006; ERIKSSON S, 1964, ACTA MED SCAND, V175, P197; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; FLETCHER C, 1977, BRIT MED J, V1, P1645; FREW AJ, 1992, AM REV RESPIR DIS, V146, P878; Fuhrman C, 2006, THORAX, V61, P930, DOI 10.1136/thx.2006.061267; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Geijer RMM, 2005, FAM PRACT, V22, P485, DOI 10.1093/fampra/cmi049; GERVAIS R, 1993, LANCET, V342, P997, DOI 10.1016/0140-6736(93)92046-V; GIBSON GJ, 2006, EUR RESP MON, V38, P24; Givelber RJ, 1998, AM J RESP CRIT CARE, V157, P1445; Gorecka D, 2003, CHEST, V123, P1916, DOI 10.1378/chest.123.6.1916; Gryparis A, 2004, AM J RESP CRIT CARE, V170, P1080, DOI 10.1164/rccm.200403-333OC; Gudmundsson G, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-109; Guerra S, 2005, ALLERGY, V60, P343, DOI 10.1111/j.1398-9995.2005.00717.x; Guyatt GH, 2005, AM J RESP CRIT CARE, V172, P573, DOI 10.1164/rccm.200412.1692OC; Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605; Halbert RJ, 2003, CHEST, V123, P1684, DOI 10.1378/chest.123.5.1684; Hansell AL, 2003, EUR RESPIR J, V22, P809, DOI 10.1183/09031936.03.00031403; Hardie JA, 2002, EUR RESPIR J, V20, P1117, DOI 10.1183/09031936.02.00023202; He J, 2005, NEW ENGL J MED, V353, P1124, DOI 10.1056/NEJMsa050467; HE J, 2006, NEW ENGL J MED, V354, P874; Henley SJ, 2004, J NATL CANCER I, V96, P853, DOI 10.1093/jnci/djh144; Hersh CP, 2004, CHEST, V126, P1443, DOI 10.1378/chest.126.5.1443; Hersh CP, 2005, AM J RESP CELL MOL, V33, P71, DOI 10.1165/rcmb.2005-0073OC; HIGGINS M, 1975, J CHRON DIS, V28, P239, DOI 10.1016/0021-9681(75)90053-3; Hill AT, 1998, RESP MED, V92, P156, DOI 10.1016/S0954-6111(98)90088-9; Hnizdo Eva, 2006, COPD, V3, P95, DOI 10.1080/15412550600651552; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Holberg CJ, 1998, AM J RESP CRIT CARE, V158, P162; Holguin F, 2005, CHEST, V128, P2005, DOI 10.1378/chest.128.4.2005; Hozawa A, 2006, CHEST, V130, P1642, DOI 10.1378/chest.130.6.1642; Huiart L, 2005, CHEST, V128, P2640, DOI 10.1378/chest.128.4.2640; Hurst JR, 2006, AM J RESP CRIT CARE, V174, P867, DOI 10.1164/rccm.200604-506OC; Iversen L, 2005, CHEST, V128, P2059, DOI 10.1378/chest.128.4.2059; Jaakkola MS, 2006, EUR RESPIR J, V28, P397, DOI 10.1183/09031936.06.00001306; Janssens JP, 2003, CHEST, V123, P67, DOI 10.1378/chest.123.1.67; Jansson SA, 2002, CHEST, V122, P1994, DOI 10.1378/chest.122.6.1994; Jensen HH, 2006, EUR RESPIR J, V28, P781, DOI 10.1183/09031936.06.00152205; Jimemez-Ruiz CA, 2004, NICOTINE TOB RES, V6, P649, DOI 10.1080/14622200410001727948; Jimenez-Ruiz CA, 2001, CHEST, V119, P1365, DOI 10.1378/chest.119.5.1365; Johannessen A, 2006, AM J RESP CRIT CARE, V173, P1316, DOI 10.1164/rccm.200601-023OC; Johannessen A, 2005, THORAX, V60, P842, DOI 10.1136/thx.2005.043943; Johannessen A, 2005, INT J TUBERC LUNG D, V9, P926; Jorgensen NR, 2007, RESP MED, V101, P177, DOI 10.1016/j.rmed.2006.03.029; KALSHEKER NA, 1990, DIS MARKERS, V8, P151; KAUFFMANN F, 1989, AM J EPIDEMIOL, V129, P1289; Kjoller E, 2004, EUR J HEART FAIL, V6, P71, DOI 10.1016/j.ejheart.2003.09.008; KLIMATHIANAKI M, 2006, EUR RESP MON, V38, P430; Kornmann O, 2003, RESPIRATION, V70, P67, DOI 10.1159/000068417; Kriegsman DMW, 2004, J CLIN EPIDEMIOL, V57, P55, DOI 10.1016/S0895-4356(03)00258-0; Kurzius-Spencer M, 2001, AM J RESP CRIT CARE, V164, P1261; Laden F, 2006, AM J RESP CRIT CARE, V173, P667, DOI 10.1164/rccm.200503-443OC; LIEBERMAN J, 1986, CHEST, V89, P370, DOI 10.1378/chest.89.3.370; Lindberg A, 2006, CHEST, V129, P879, DOI 10.1378/chest.129.4.879; Lindberg A, 2006, RESP MED, V100, P264, DOI 10.1016/j.rmed.2005.04.029; Lindberg A, 2005, CHEST, V127, P1544, DOI 10.1378/chest.127.5.1544; Lloyd-Owen SJ, 2005, EUR RESPIR J, V25, P1025, DOI 10.1183/09031936.05.00066704; Loddenkemper R, 2003, EUROPEAN LUNG WHITE, P34; Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802; Lopez AD, 2006, LANCET, V367, P1747, DOI 10.1016/S0140-6736(06)68770-9; Lundback B, 2003, RESP MED, V97, P115, DOI 10.1053/rmed.2003.1446; Lynn J, 2000, J AM GERIATR SOC, V48, pS91; MacIntyre N, 2005, EUR RESPIR J, V26, P720, DOI 10.1183/09031936.05.00034905; MacNee W, 2007, EUR RESPIR J, V29, P223, DOI 10.1183/09031936.00159006; Mannino David M, 2003, Respir Care, V48, P1185; Mannino DM, 2006, EUR RESPIR J, V27, P627, DOI 10.1183/09031936.06.00024605; Mapel Douglas W, 2005, COPD, V2, P35; Mapel DW, 2000, ARCH INTERN MED, V160, P2653, DOI 10.1001/archinte.160.17.2653; Marti S, 2006, EUR RESPIR J, V27, P689, DOI 10.1183/09031936.06.00076405; Masa JF, 2004, ARCH BRONCONEUMOL, V40, P72, DOI 10.1157/13056712; Matheson MC, 2005, THORAX, V60, P645, DOI 10.1136/thx.2004.035170; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; Mikkelsen RL, 2004, NORD J PSYCHIAT, V58, P65, DOI 10.1080/08039480310000824; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Miller MR, 2005, EUR RESPIR J, V26, P153, DOI 10.1183/09031936.05.00034505; Miravitlles M, 2000, RESPIRATION, V67, P495, DOI 10.1159/000067462; Miravitlles M, 2006, RESP MED, V100, P1973, DOI 10.1016/j.rmed.2006.02.024; MITROUSKA I, 2006, EUR RESP MON, V38, P302; MIYAMOTO K, 1995, AM J RESP CRIT CARE, V152, P972; Mohangoo AD, 2006, EUR J PUBLIC HEALTH, V16, P101, DOI 10.1093/eurpub/cki043; Mokhlesi B, 2001, CHEST, V119, P1043, DOI 10.1378/chest.119.4.1043; Molfino NA, 2004, CHEST, V125, P1929, DOI 10.1378/chest.125.5.1929; Molfino NA, 2007, CURR OPIN PULM MED, V13, P107, DOI 10.1097/MCP.0b013e328013e97d; Moran JL, 1998, CRIT CARE MED, V26, P71, DOI 10.1097/00003246-199801000-00019; Murphy BR, 1997, B WORLD HEALTH ORGAN, V75, P307; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murtagh E, 2005, EUR J EPIDEMIOL, V20, P443, DOI 10.1007/s10654-005-1248-8; Neri M, 2006, RESP MED, V100, P795, DOI 10.1016/j.rmed.2005.09.018; Niederlander E., 2006, EUROSTAT EUROPEAN CO, V101, P1; Nizet TAC, 2005, CHEST, V127, P1904, DOI 10.1378/chest.127.6.1904; PAOLETTI P, 1989, EUR RESPIR J, V2, P428; Patil SP, 2003, ARCH INTERN MED, V163, P1180, DOI 10.1001/archinte.163.10.1180; Pelkonen M, 2006, CHEST, V130, P1129, DOI 10.1378/chest.130.4.1129; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Perez-Padilla Rogelio, 2007, COPD, V4, P113, DOI 10.1080/15412550701341012; Pistelli F, 2000, RESPIRATION, V67, P491, DOI 10.1159/000067460; Pistelli F, 2007, RESP MED, V101, P814, DOI 10.1016/j.rmed.2006.06.032; POLLER W, 1992, LANCET, V339, P1538, DOI 10.1016/0140-6736(92)91301-N; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Purdue MP, 2007, THORAX, V62, P51, DOI 10.1136/thx.2006.064196; Rabow MW, 2004, ARCH INTERN MED, V164, P83, DOI 10.1001/archinte.164.1.83; Ramirez-Venegas A, 2006, AM J RESP CRIT CARE, V173, P393, DOI 10.1164/rccm.200504-568OC; REDLINE S, 1989, AM J EPIDEMIOL, V129, P827; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; RIBARREN C, 1999, NEW ENGL J MED, V340, P1773; RYBICKI BA, 1990, J CLIN EPIDEMIOL, V43, P667, DOI 10.1016/0895-4356(90)90037-P; Sakao S, 2001, AM J RESP CRIT CARE, V163, P420; SANDVIK L, 1995, BRIT MED J, V311, P715; Scanlon PD, 2000, AM J RESP CRIT CARE, V161, P381; Schellenberg D, 1998, AM J RESP CRIT CARE, V157, P957; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; Schirnhofer L, 2007, CHEST, V131, P29, DOI 10.1378/chest.06-0365; Selvaraj CL, 2005, AM J CARDIOL, V96, P756, DOI 10.1016/j.amjcard.2005.05.016; SHERMAN CB, 1992, AM REV RESPIR DIS, V146, P855; Sherrill D, 2003, EUR RESPIR J, V21, P95, DOI 10.1183/09031936.03.00017103; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SIAFAKAS NM, 2006, EUR RESP MON, V38, P1; Sidney S, 2005, CHEST, V128, P2068, DOI 10.1378/chest.128.4.2068; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V115, P337, DOI 10.1016/j.jaci.2004.11.035; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Silverman EK, 2002, CHEST, V121-3, P1; Simoni M, 2003, EUR RESPIR J, V21, p15S, DOI 10.1183/09031936.03.00403603; Simoni M, 2007, RESP MED, V101, P531, DOI 10.1016/j.rmed.2006.06.021; Smith CAD, 1997, LANCET, V350, P630, DOI 10.1016/S0140-6736(96)08061-0; Soriano JB, 2000, THORAX, V55, P789, DOI 10.1136/thorax.55.9.789; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Soriano JB, 2005, CHEST, V128, P2099, DOI 10.1378/chest.128.4.2099; Sprenkle MD, 2004, CHEST, V126, P81, DOI 10.1378/chest.126.1.81; Stapleton RD, 2005, CHEST, V127, P328, DOI 10.1378/chest.127.1.328; Stratelis G, 2004, BRIT J GEN PRACT, V54, P201; STROM K, 1988, EUR RESPIR J, V1, P952; Stuart B, 1996, MED GUIDELINES DETER; Sunyer J, 2006, OCCUP ENVIRON MED, V63, P836, DOI 10.1136/oem.2006.027995; Sunyer J, 2005, AM J RESP CRIT CARE, V172, P1139, DOI 10.1164/rccm.200504-648OC; TAGER IB, 1976, AM REV RESPIR DIS, V114, P485; Tonnesen P, 2007, EUR RESPIR J, V29, P390, DOI 10.1183/09031936.00060806; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; United States Department of Health and Human Services, 2004, HLTH CONS SMOK REP S; van Schayck CP, 2002, BRIT MED J, V324, P1370, DOI 10.1136/bmj.324.7350.1370; Varma MG, 2006, DIS COLON RECTUM, V49, P841, DOI 10.1007/s10350-006-0535-0; Vermeeren MAP, 2006, RESP MED, V100, P1349, DOI 10.1016/j.rmed.2005.11.023; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; Viegi G, 1999, INT J TUBERC LUNG D, V3, P1034; Viegi G, 2004, INT J TUBERC LUNG D, V8, P1401; Viegi G, 2004, CHEST, V126, P1093, DOI 10.1378/chest.126.4.1093; VIEGI G, 1991, ENVIRON HEALTH PERSP, V94, P95, DOI 10.2307/3431299; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510; Viegi G, 2000, CHEST, V117, p339S; Viegi G, 2006, RESPIROLOGY, V11, P523, DOI 10.1111/j.1400-1843.2006.00886.x; Wagena EJ, 2004, EUR J EPIDEMIOL, V19, P147; Wagner PD, 2006, NEW ENGL J MED, V354, P874; Wanger J, 2005, EUR RESPIR J, V26, P511, DOI 10.1183/09031936.05.00035005; WATERHOUSE JC, 1994, EUR RESPIR J, V7, P2021; Weerasuriya N, 2006, DIS ESOPHAGUS, V19, P189, DOI 10.1111/j.1442-2050.2006.00563.x; WOUTERS EFM, 2003, EUR RESPIR J, V22, P46; Xu F, 2005, CHEST, V128, P2818, DOI 10.1378/chest.128.4.2818; Yang QY, 2005, ENVIRON RES, V99, P99, DOI 10.1016/j.envres.2004.09.014; Zielinski J, 2006, EUR RESPIR J, V27, P833, DOI 10.1183/09031936.06.00025905; Zock JP, 2001, AM J RESP CRIT CARE, V163, P1572; Zoia MC, 2005, RESP MED, V99, P1568, DOI 10.1016/j.rmed.2005.03.032; MORTALITY DATA COPD; 1995, AM J RESP CRIT CARE, V152, pS77; 2006, GLOBAL INITIATIVE CH	221	181	188	5	40	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	NOV	2007	30	5					993	1013		10.1183/09031936.00082507		21	Respiratory System	Respiratory System	229PU	WOS:000250817300028	17978157	
J	Kirkpatrick, B; Fleming, LE; Squicciarini, D; Backer, LC; Clark, R; Abraham, W; Benson, J; Cheng, YS; Johnson, D; Pierce, R; Zaias, J; Bossart, GD; Baden, DG				Kirkpatrick, B; Fleming, LE; Squicciarini, D; Backer, LC; Clark, R; Abraham, W; Benson, J; Cheng, YS; Johnson, D; Pierce, R; Zaias, J; Bossart, GD; Baden, DG			Literature review of Florida red tide: implications for human health effects	HARMFUL ALGAE			English	Review						Florida red tide; red tide; neurotoxic shellfish poisoning; NSP; brevetoxins; harmful algal bloom; HAB; karenia brevis; shellfish poisoning; respiratory irritation; marine toxin diseases	NEUROTOXIC SHELLFISH TOXINS; FORMERLY GYMNODINIUM-BREVE; SENSITIVE SODIUM-CHANNELS; RAT-BRAIN SYNAPTOSOMES; MARINE ALGAL TOXINS; PTYCHODISCUS-BREVIS; NEW-ZEALAND; DINOFLAGELLATE TOXINS; CRASSOSTREA-GIGAS; MOUSE BIOASSAY	Florida red tides are a natural phenomenon caused by dense aggregations of single cell or several species Of unicellular organisms. Patches of discolored water, dead or dying fish, and respiratory irritants in the air often characterize these algal blooms. In humans, two distinct clinical entities, depending on the route of exposure, are associated with exposure to the Florida red tide toxins (particularly the brevetoxins). With the ingestion of brevetoxin-contaminated shellfish, neurotoxic shellfish poisoning (NSP) presents as a milder gastroenteritis with neurologic symptoms compared with other marine toxin diseases such as paralytic shellfish poisoning (PSP) or ciguatera fish poisoning. With the inhalation of the aerosolized red tide toxins (especially the brevetoxins) from the sea spray, respiratory irritation and possibly other health effects are reported in both humans and other mammals [Nat. Toxins Drugs (1995) 141; Fleming, L.E., Baden, D.G., 1988. Neurotoxic shellfish poisoning: public health and human health effects. White Paper for the Proceedings of the Texas Conference on Neurotoxic Shellfish Poisoning. In: Proceedings of the Texas NSP Conference, Corpus Christi, TX, pp. 27-34; Travel Med, 2 (10) (1998b) 1: Travel Med. 3 (10) (1999a) 1; Toxins Pathol. 26 (2) (1998) 276; J. Allergy Clin. Imunol. 69 (1982) 418; Arch. Intern. Med. 149 (1989) 1735; Toxicon 24 (1986) 955; Florida Med. J. 60 (11) (1773) 27; J. Nat. Toxins 4 (1995) 181; J. Nat. Toxins 4 (1995) 18 1: Sci. Ani. 271 (4) (1994) 62]. This paper reviews the literature on the known and possible human health effects of exposure to the Florida red tides and their toxins. The review includes discussion of the red tide organisms and their toxins, as well as the effects of these toxins on both wild and laboratory animals as they relate to possible human health effects and exposures. (C) 2004 Elsevier B.V. All rights reserved.	Mote Marine Lab, Sarasota, FL 34236 USA; Univ Miami, NIEHS, Marine & Freshwater Biomed Sci Ctr, Miami, FL 33149 USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA; Florida Dept Hlth, Tallahassee, FL 32399 USA; Lovelace Resp Inst, Albuquerque, NM 87108 USA; Univ N Carolina, Ctr Marine Sci, Wilmington, NC 28409 USA	Kirkpatrick, B (reprint author), Mote Marine Lab, 1600 Ken Thompson Pkwy, Sarasota, FL 34236 USA.	bkirkpat@mote.org			NIEHS NIH HHS [P01 ES010594, P01 ES010594-04]		ABRAHAM WM, 2001, INT SOC EXPOSURE ANA, V126; AHLES MD, 1974, PUBLIC HLTH BRIEFS, V64, P807; AHMED FE, 1993, ENVIRON TOXIC WATER, V8, P141, DOI 10.1002/tox.2530080203; ANDERSON DM, 1994, SCI AM, V271, P62; Anderson DM, 1993, 9302 WHOI; Anderson D. M., 2000, ESTIMATED ANN EC IMP; APLAND JP, 1993, BRAIN RES BULL, V31, P201, DOI 10.1016/0361-9230(93)90026-8; Asai JS, 1984, J ALLERGY CLIN IMMUN, V73, P824; ASAI S, 1982, J ALLERGY CLIN IMMUN, V69, P418, DOI 10.1016/0091-6749(82)90116-6; BACKER LC, 2003, UNPUB RECREATIONAL E; Baden D., 1995, HDB CLIN NEUROLOGY 2, P141; Baden Daniel G., 1993, P49; BADEN DG, 1983, INT REV CYTOL, V82, P99, DOI 10.1016/S0074-7696(08)60824-4; BADEN DG, 1982, TOXICON, V20, P457, DOI 10.1016/0041-0101(82)90009-5; BADEN DG, 1989, FASEB J, V3, P1807; BADEN DG, 1982, TOXICON, V20, P929, DOI 10.1016/0041-0101(82)90081-2; BENSON JM, 1999, J TOXICOL ENV HLTH, V56, P345; BLOGOSLAWSKI WJ, 1975, ENVIRON LETT, V9, P209; BLYTHE DG, 2001, MED MANAGEMENT SEAFO, P311; BORISON HL, 1980, BRIT J PHARMACOL, V70, P249; BORISON HL, 1985, TOXICON, V23, P517, DOI 10.1016/0041-0101(85)90036-4; Bossart GD, 1998, TOXICOL PATHOL, V26, P276; CATTET M, 1993, TOXICON, V31, P1483, DOI 10.1016/0041-0101(93)90214-4; Chang DC, 2002, TAIWAN J MATH, V6, P1; CHENG YS, UNPUB CHARACTERIZATI; Cortes-Altamirano Roberto, 1995, Revista Latinoamericana de Microbiologia, V37, P343; CUMMINS JM, 1971, T AM FISH SOC, V100, P112, DOI 10.1577/1548-8659(1971)100<112:OOTBMD>2.0.CO;2; Davis R., 1994, J AM ACAD PHYS ASSIS, V7, P485; DEMBERT ML, 1981, AM FAM PHYSICIAN, V24, P103; Dickey R, 1999, NAT TOXINS, V7, P157, DOI 10.1002/(SICI)1522-7189(199907/08)7:4<157::AID-NT52>3.3.CO;2-R; EASTAUGH J, 1989, ARCH INTERN MED, V149, P1735, DOI 10.1001/archinte.149.8.1735; ELLIS S, 1985, TOXICON, V23, P469, DOI 10.1016/0041-0101(85)90030-3; Epstein PR, 1998, MARINE ECOSYSTEMS EM; EPSTEIN PR, 1994, HLTH CLIMATE CHANGE, P14; Fairey ER, 1997, ANAL BIOCHEM, V251, P129, DOI 10.1006/abio.1997.2264; FLEMING LE, 2001, MED MANAGEMENT SEAFO, P311; FLEMING LE, 1988, P TEX NSP C CORP CHR, P27; Fleming L.E., 1998, TRAVEL MED, V2, P1; FLEMING LE, 1999, VID C FLOR HARMF ALG; FLEMING LE, 1997, TRAVEL MED MONTHLY, V1, P1; Fleming L. E., 1998, HARMFUL ALGAE, P245; FLEMING LE, 1995, UNESCO IOC MANUAL HA, V33, P475; Fletcher GC, 1998, J SHELLFISH RES, V17, P1637; FORRESTER DJ, 1977, J WILDLIFE DIS, V13, P160; FRANZ DR, 1989, TOXICON, V27, P647, DOI 10.1016/0041-0101(89)90015-9; Gallagher P., 1980, BRIT J PHARMACOL, V69, P367; Garthwaite I, 1996, ACS SYM SER, V621, P404; Geraci J.R., 1989, CLIN INVESTIGATION 1, P1; Halstead BW., 1988, POISONOUS VENOMOUS M; HANNAH DJ, 1996, P NZMAF MAR BIOT WOR; Hopkins R S, 1997, J Fla Med Assoc, V84, P441; HORSTMAN DA, 1991, T ROY SOC S AFR, V47, P611; HUA YS, 1995, ANAL CHEM, V67, P1815, DOI 10.1021/ac00107a010; HUGHES JM, 1976, NEW ENGL J MED, V295, P1117, DOI 10.1056/NEJM197611112952006; *ICRP, 1994, PUBL ICRP, V66, P24; *ILO UNEP WHO, 1984, ENV HLTH CRIT, V37; Ishida H, 1996, TOXICON, V34, P1050, DOI 10.1016/0041-0101(96)00076-1; Jeglitsch G, 1998, J PHARMACOL EXP THER, V284, P516; JESSUP DA, 1998, P INT ASS AQ AN MED; KEMPPAINEN BW, 1991, TOXICOLOGY, V66, P1, DOI 10.1016/0300-483X(91)90174-Y; KENNEDY CJ, 1992, AQUAT TOXICOL, V22, P3, DOI 10.1016/0166-445X(92)90032-I; Kerr DS, 1999, TOXICON, V37, P1803, DOI 10.1016/S0041-0101(99)00124-5; Keynes R.D., 1979, SCI AM, V240, P125; Khan S, 1997, AQUAC RES, V28, P9, DOI 10.1111/j.1365-2109.1997.tb01309.x; KINCHUNG H, 1991, ASIAN MARINE BIOL, P5; Henry M., 2001, HARMFUL ALGAL BLOOMS, P447; KOLEY J, 1995, EUR J PHARM-ENVIRON, V293, P483, DOI 10.1016/S0014-2999(95)80107-3; Kreuder C., 1998, P WILDL DIS ASS MAD; Kusek Kristen M., 1999, Contributions in Marine Science, V34, P1; Laverty R, 1993, R SOC NZ, V24, P31; MACLEAN JL, 1979, P 2 INT C TOX DIN BL, P173; MANGER RL, 1995, J AOAC INT, V78, P521; Martin Dean F., 1998, Florida Scientist, V61, P10; MARTIN DF, 1976, J CHEM EDUC, V53, P614; Martius Christopher, 1996, Ecotropica, V2, P1; Mattei Cesar, 1999, Journal de la Societe de Biologie, V193, P329; Mazumder P. K., 1997, Indian Journal of Experimental Biology, V35, P650; McFARREN E. F., 1965, TOXICON, V3, P111, DOI 10.1016/0041-0101(65)90005-X; MCKEE D, 2000, HARMFUL ALGAL BLOOMS; MEHTA M, 1991, TOXICOL LETT, V55, P185, DOI 10.1016/0378-4274(91)90133-Q; MELINEK R, 1994, TOXICON, V32, P883, DOI 10.1016/0041-0101(94)90367-0; Morohashi A, 1999, NAT TOXINS, V7, P45, DOI 10.1002/(SICI)1522-7189(199903/04)7:2<45::AID-NT34>3.0.CO;2-H; MORRISON SJ, 1991, J CONTAM HYDROL, V8, P1, DOI 10.1016/0169-7722(91)90006-M; MORSE EV, 1977, J AM VET MED ASSOC, V171, P1178; Music S I, 1973, JFMA, V60, P27; Naar J, 2002, ENVIRON HEALTH PERSP, V110, P179; NOBLE RC, 1990, PERSPECT BIOL MED, V33, P313; *NRC, 1999, MONS MICR; OSHEA TJ, 1991, MAR MAMMAL SCI, V7, P165, DOI 10.1111/j.1748-7692.1991.tb00563.x; PALAFOX NA, 1988, JAMA-J AM MED ASSOC, V259, P2740, DOI 10.1001/jama.259.18.2740; PARK DL, 1995, FOOD ADDIT CONTAM, V12, P361; PIERCE R, 1989, CLIMATE AND HEALTH IMPLICATIONS OF BUBBLE-MEDIATED SEA-AIR EXCHANGE, P27; PIERCE RH, 1986, TOXICON, V24, P955, DOI 10.1016/0041-0101(86)90001-2; PIERCE RH, 1990, TOXIC MARINE PHYTOPLANKTON, P397; PIERCE RH, 1992, B ENVIRON CONTAM TOX, V49, P479; Pierce RH, 2001, ENVIRON TOXICOL CHEM, V20, P107, DOI 10.1897/1551-5028(2001)020<0107:ITFHAT>2.0.CO;2; Pierce R., 2001, HARMFUL ALGAL BLOOMS, P421; POLI MA, 1990, TOXICON, V28, P903, DOI 10.1016/0041-0101(90)90020-8; POLI MA, 1995, J AOAC INT, V78, P538; Poli MA, 2000, TOXICON, V38, P981, DOI 10.1016/S0041-0101(99)00191-9; POLI MA, 1990, ACS SYM SER, V418, P176; POLI MA, 1988, J ASSOC OFF ANA CHEM, V71, P1000; POLI MA, 1986, MOL PHARMACOL, V30, P129; Purkerson SL, 1999, NEUROTOXICOLOGY, V20, P909; Purkerson-Parker SL, 2000, CHEM BIOL, V7, P385, DOI 10.1016/S1074-5521(00)00119-8; RHEINSTEIN PH, 1993, AM FAM PHYSICIAN, V47, P1837; RODERICK GE, 1997, J SHELLFISH RES, V16, P322; Rodriguez-Rodriguez F A, 1996, P R Health Sci J, V15, P261; Rogers R.L., 1984, TOXINS APPL PHARM, V76, P296; SAKAMOTO Y, 1985, J ALLERGY CLIN IMMUN, V76, P117, DOI 10.1016/0091-6749(85)90814-0; SAKAMOTO Y, 1987, SOUTHERN MED J, V80, P866, DOI 10.1097/00007611-198707000-00016; SAMPAYO MAD, 1997, PUBL ESPEC I EXP OCE, V23, P35; SHEA D, 1997, ELECTROPHORESIS, V18, P217; SHIMODA T, 1988, J ALLERGY CLIN IMMUN, V81, P1187, DOI 10.1016/0091-6749(88)90889-5; Sierra-Beltran AP, 1998, TOXICON, V36, P1493, DOI 10.1016/S0041-0101(98)00139-1; Singer LJ, 1998, AM J RESP CRIT CARE, V157, pA158; SMAYDA TJ, 1990, TOXIC MARINE PHYTOPLANKTON, P516; Steidinger K.A., 1984, P201; Steidinger K.A., 1983, Progress phycol. Res., V2, P147; STEIDINGER KA, 1972, ENVIRON LETT, V3, P271; STEIDINGER KA, 1999, HARMFUL ALGAL BOOMS; *SUBC LAB METH EX, 1970, REC PROC EX SEAW SHE, P61; SUDARSANAM S, 1992, J COMPUT AID MOL DES, V6, P223, DOI 10.1007/BF00123378; SUMMERSON HC, 1990, ESTUARIES, V13, P322, DOI 10.2307/1351923; TEMPLE WA, 1995, J NAT TOXINS, V4, P181; TEMPLETON CB, 1989, TOXICON, V27, P1389, DOI 10.1016/0041-0101(89)90070-6; TEMPLETON CB, 1989, TOXICON, V27, P1043, DOI 10.1016/0041-0101(89)90155-4; TEMPLETON CB, 1988, GOV REP ANNOUNCE IND, V88, P155; TESTER P, 1997, LIMNOL OCEANOGR, V45, P1039; TESTER PA, 1991, LIMNOL OCEANOGR, V36, P1053; Tibbetts J, 1998, ENVIRON HEALTH PERSP, V106, pA326, DOI 10.2307/3434060; TOMMASI L R, 1983, Ciencia e Cultura (Sao Paulo), V35, P225; Trainer VL, 1999, AQUAT TOXICOL, V46, P139, DOI 10.1016/S0166-445X(98)00125-8; TRAINER VL, 1991, MOL PHARMACOL, V40, P988; Tsai M C, 1991, J Formos Med Assoc, V90, P431; Van Dolah F. M., 1994, Natural Toxins, V2, P189, DOI 10.1002/nt.2620020407; Van Dolah FM, 2000, ENVIRON HEALTH PERSP, V108, P133; Villareal T. A., 2001, P 9 INT C HARMF ALG, P153; VIVIANI R, 1992, SCIENCE OF THE TOTAL ENVIRONMENT, SUPPLEMENT 1992, P631; Walsh JJ, 2001, J GEOPHYS RES-OCEANS, V106, P11597, DOI 10.1029/1999JC000123; WASHBURN BS, 1994, TOXICON, V32, P799, DOI 10.1016/0041-0101(94)90005-1; Washburn BS, 1996, AQUAT TOXICOL, V35, P1, DOI 10.1016/0166-445X(95)00050-E; WATANABE T, 1988, ALLERGY PRACT, V10, P185; WELLER PF, 1984, J ALLERGY CLIN IMMUN, V73, P1, DOI 10.1016/0091-6749(84)90474-3; Whitney Philip L., 1997, Natural Toxins, V5, P193; WOODCOCK AH, 1948, J MAR RES, V7, P56; Yeh HC, 1996, AEROSOL SCI TECH, V25, P134, DOI 10.1080/02786829608965386	147	181	186	9	75	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1568-9883			HARMFUL ALGAE	Harmful Algae	APR	2004	3	2					99	115		10.1016/j.hal.2003.08.005		17	Marine & Freshwater Biology	Marine & Freshwater Biology	813RY	WOS:000220925400001	20411030	
J	Kreiss, K; Gomaa, A; Kullman, G; Fedan, K; Simoes, EJ; Enright, PL				Kreiss, K; Gomaa, A; Kullman, G; Fedan, K; Simoes, EJ; Enright, PL			Clinical bronchiolitis obliterans in workers at a microwave-popcorn plant	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POPULATION; VALUES; SAMPLE	Background In May 2000, eight persons who had formerly worked at a microwave-popcorn production plant were reported to have severe bronchiolitis obliterans. No recognized cause was identified in the plant. Therefore, we medically evaluated current employees and assessed their occupational exposures. Methods Questionnaire responses and spirometric findings in participating workers were compared with data from the third National Health and Nutrition Examination Survey, after adjustment for age and smoking status. We evaluated the relation between exposures and health-related outcomes by analyzing the rates of symptoms and abnormalities according to current and cumulative exposure to diacetyl, the predominant ketone in artificial butter flavoring and in the air at the plant. Results Of the 135 current workers at the plant, 117 (87 percent) completed the questionnaire. These 117 workers had 2.6 times the expected rates of chronic cough and shortness of breath, according to comparisons with the national data, and twice the expected rates of physician-diagnosed asthma and chronic bronchitis. Overall, the workers had 3.3 times the expected rate of airway obstruction; those who had never smoked had 10.8 times the expected rate. Workers directly involved in the production of microwave popcorn had higher rates of shortness of breath on exertion and skin problems that had developed since they started work than workers in other parts of the plant. There was a strong relation between the quartile of estimated cumulative exposure to diacetyl and the frequency and extent of airway obstruction. Conclusions The excess rates of lung disease and lung-function abnormalities and the relation between exposure and outcomes in this working population indicate that they probably had occupational bronchiolitis obliterans caused by the inhalation of volatile butter-flavoring ingredients.	NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA; Missouri Dept Hlth & Senior Serv, Off Epidemiol, Jefferson City, MO USA	Kreiss, K (reprint author), NIOSH, Div Resp Dis Studies, H2800,1095 Willowdale Rd, Morgantown, WV 26505 USA.			Simoes, Eduardo/0000-0003-4371-4305			AKPINARELCI M, 2002, AM J RESP CRIT CARE, V165, pA526; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P2185; Eller PM, 1994, DHHS NIOSH PUBLICATI; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; HUBBS AF, 2002, TOXICOL SCI S, V66, P194; *INT BAK SERV INC, 1986, DHHS NIOSH PUBL; International Labour Office, 1980, OCC SAF HLTH SER, V22; KING TE, 1998, FISHMANS PULMONARY D, P825; Lockey J, 2002, AM J RESP CRIT CARE, V165, pA461; MILLER A, 1983, AM REV RESPIR DIS, V127, P270; MONSON RR, 1990, OCCUPATIONAL EPIDEMI, P114; MORGAN RH, 1979, AM J ROENTGENOL, V132, P803; National Center for Health Statistics, 1996, 3 NAT HLTH NUTR EX S; Parmet AJ, 2002, J OCCUP ENVIRON MED, V44, P216, DOI 10.1097/00043764-200203000-00002; SAS Institute, 1990, SAS STAT US GUID VER; [Anonymous], 2002, MMWR MORB MORTAL WKL, V51, P345	19	181	184	5	15	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 1	2002	347	5					330	338		10.1056/NEJMoa020300		9	Medicine, General & Internal	General & Internal Medicine	587WC	WOS:000177665900005	12151470	
J	Huss, K; Adkinson, NF; Eggleston, PA; Dawson, C; Van Natta, ML; Hamilton, RG				Huss, K; Adkinson, NF; Eggleston, PA; Dawson, C; Van Natta, ML; Hamilton, RG			House dust mite and cockroach exposure are strong risk factors for positive allergy skin test responses in the Childhood Asthma Management Program	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; childhood asthma; cockroach allergy; Childhood Asthma Management Program; allergy sensitization; indoor allergens; atopy; risk factors for asthma; allergen exposure	INNER-CITY CHILDREN; CAT ALLERGEN; SENSITIZATION; HOMES; AUSTRALIA; ANTIGEN; SCHOOL; DOG	Background: Children with asthma have a high prevalence of environmental allergies, especially to indoor allergens. The relationships of exposure to indoor allergens (dust mites, cat, dog, cockroach, and molds) and other host factors to allergy sensitization have not been evaluated simultaneously in a large cohort. Objectives: We studied 1041 children aged 5 to 12 years with mild-to-moderate asthma to determine risk factors associated with having positive allergy skin test responses to indoor allergens. Also, we described, compared, and contrasted 6 allergens in the home environments of these children from 8 North American cities. Methods: Data were used from baseline visits of the Childhood Asthma Management Program. Patients' sensitivities to house dust mites (Dermatophagoides farinae and Dermatophagoides pteronyssinus), cats, dogs, cockroaches, and molds were examined for relationships to demographic variables, home dust allergen exposures, number of other positive allergy skin test responses, total serum IgE levels, and smoking in the home. Results: San Diego (78.5%) and Toronto (59.3%) had the topmost percentages of homes with moderate-to-high house dust mite levels. Boston (21.5%), St Louis (16.3%), and Baltimore (13.4%) had the highest percentages of homes with detectable levels of cockroach allergen. For house dust mites, the higher the level of allergen exposure, the more likely patients were to have positive allergy skin test responses, with relative odds of 9.0 (95% confidence interval, 5.4-15.1) for those exposed to high mite levels: (>10.0 mug/g dust) relative to those unexposed. Even exposure to low levels of mite allergen (0.020-2.0 mug/g) was found to be a significant risk factor for sensitization. For cockroach allergen, those with detectable home exposure were more likely to have positive skin test responses (relative odds, 2.2; 95% confidence interval, 1.3-3.8) than those with undetectable exposure. In contrast, levels of exposure to cat, dog, and mold allergens were not related to sensitization rates. For cat allergen, this may reflect lower rates of cat ownership among highly sensitized subjects. Furthermore, the number of allergy skin test responses that were positive, excluding the test for the outcome of interest for each model, and total serum IgE levels were strong independent predictors of sensitization. Conclusions: Levels of exposure determined by house dust analysis are important determinants of sensitization for dust mite and cockroach allergen. This relationship was not demonstrable for cat, dog, or mold allergens, possibly because of confounding factors. For all allergens studied, the degree of atopy; determined by the total number of positive skin test responses or by total serum IgE levels, is an important contributing risk factor for sensitization.	Johns Hopkins Univ, Sch Hyg & Publ Hlth, Baltimore, MD 21205 USA; Johns Hopkins Asthma & Allergy Ctr, DACI Reference Lab, Baltimore, MD USA	Huss, K (reprint author), Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St,Room 416, Baltimore, MD 21205 USA.						ADINOFF AD, 1990, J ALLERGY CLIN IMMUN, V86, P766, DOI 10.1016/S0091-6749(05)80181-2; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; BACKER V, 1992, ALLERGY, V47, P484, DOI 10.1111/j.1398-9995.1992.tb00669.x; BURR ML, 1993, ARCH DIS CHILD, V68, P724; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805; CHAPMAN MD, 1995, PEDIATR ALLERGY IMMU, V6, P8, DOI 10.1111/j.1399-3038.1995.tb00378.x; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; COULTAS DB, 1988, AM REV RESPIR DIS, V135, P1386; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; HAMILTON RG, 1997, MANUAL CLIN LAB IMMU, P881; HAMILTON S, 1992, NEW ENGL REV-MIDDLEB, V14, P96; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OWNBY DR, 1984, J ALLERGY CLIN IMMUN, V73, P466, DOI 10.1016/0091-6749(84)90356-7; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SAS Institute, 1989, SAS STAT US GUID VER, V1; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	32	181	194	3	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					48	54		10.1067/mai.2001.111146		7	Allergy; Immunology	Allergy; Immunology	394PW	WOS:000166533300009	11149990	
J	Calamita, Z; Saconato, H; Pela, AB; Atallah, AN				Calamita, Z.; Saconato, H.; Pela, A. B.; Atallah, A. N.			Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane Collaboration method	ALLERGY			English	Review						asthma; immunotherapy; meta-analysis; review; sublingual	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; GRASS-POLLEN EXTRACT; HOUSE-DUST MITES; STANDARDIZED 5-GRASS-POLLEN EXTRACT; SWALLOW IMMUNOTHERAPY; ALLERGIC RHINOCONJUNCTIVITIS; RESPIRATORY ALLERGY; BRONCHIAL HYPERREACTIVITY; PEDIATRIC-PATIENTS	Background: Sublingual immunotherapy (SLIT) is effective and safe in the treatment of allergic rhinitis. However, there is no meta-analysis in asthma treatment. Methods: The clinical efficacy of SLIT for asthma was evaluated through a systematic review with meta-analysis. MEDLINE (1966-2005), EMBASE (1974-2005), LILACS (1982-2005), and the Cochrane Library were searched for related literature in any language. Randomized-controlled clinical trials (RCT) on SLIT in asthma treatment for adults and children were selected. From 119 citations, 25 studies with 1706 patients were included in this meta-analysis. For each report, quality scores were assigned and data were extracted in relation to the outcomes analyzed: asthmatic symptoms, use of asthma medications, lung function, and bronchial provocation. Results: According to the Jadad quality method, 64% of the studies were assigned scores of 4 or 5. Immunotherapy was seen to significantly reduce asthma severity when parameter compositions were all analyzed by categorical outcomes. There was a nonsignificant reduction in asthma symptoms when analyzed using standardized mean differences. No severe reactions were observed. Conclusions: This meta-analysis found that SLIT is beneficial for asthma treatment albeit the magnitude of the effect is not very large. Moreover, it is a safe alternative to the subcutaneous route. More RCT with standardization of symptom scores and medications are needed in order to contribute further to this subject.	Med Sch Marilia, Div Internal Med & Allergy & Immunol, Marilia, SP, Brazil; Univ Fed Sao Paulo, Div Internal Med Urgency & Therapeut, Sch Med, Sao Paulo, Brazil; Med Sch Marilia, Div Internal Med & Allergy & Immunol, Marilia, SP, Brazil	Calamita, Z (reprint author), Med Sch Marilia, Div Internal Med & Allergy & Immunol, 648 Vicente Ferreira, Marilia, SP, Brazil.		Atallah, Alvaro/K-7182-2013				Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ABRAMSON MJ, 2005, COCHRANE LIB, P1; Akdis CA, 2000, ALLERGY, V55, P522, DOI 10.1034/j.1398-9995.2000.00120.x; Allen-Diaz B, 1998, J SOIL WATER CONSERV, V53, P42; Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Arena A, 2003, INT J IMMUNOPATH PH, V16, P277; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; ARIANO R, 2005, ALLERG IMMUNOL PARIS, V37, P103; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; BELLINGHAUSEN I, 2000, ALLERGY CLIN IMMUNOL, V12, P20, DOI 10.1027/0838-1925.12.1.20; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Cirla A M, 2003, Allergol Immunopathol (Madr), V31, P31, DOI 10.1157/13042841; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Drachenberg KJ, 2001, ALLERGOLOGIE, V24, P525; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Feliziani V, 1993, Allergol Immunopathol (Madr), V21, P173; Gozalo F, 1997, Allergol Immunopathol (Madr), V25, P219; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; HIGGINS JPT, 2005, COCHRANE HDB SYSTEM, P265; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; LIMI A, 2005, REVMAN COMPUTER PROG; Lombardi C, 2001, J INVEST ALLERG CLIN, V11, P41; MALLING HJ, 2004, ALLERGY CLIN IMMUNOL, V16, P92, DOI 10.1027/0838-1925.16.3.92; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; MAROGNA M, 2003, ALLERG IMMUNOL PARIS, V35, P133; Mauro M., 2004, Journal of Allergy and Clinical Immunology, V113, pS108, DOI 10.1016/j.jaci.2003.12.378; Melaranci C., 2004, Journal of Allergy and Clinical Immunology, V113, pS111, DOI 10.1016/j.jaci.2003.12.388; MITSCH A, 1996, TW PADIATRIE, V9, P628; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Mungan D., 1996, European Respiratory Journal Supplement, V9, p210S; Niu C., 2004, Journal of Allergy and Clinical Immunology, V113, pS108, DOI 10.1016/j.jaci.2003.12.377; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; NOVEMBRE E, 1991, RIV ITAL PED, V17, P75; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Orefice U., 2004, Journal of Allergy and Clinical Immunology, V113, pS111, DOI 10.1016/j.jaci.2003.12.390; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2005, CLIN EXP ALLERGY, V35, P551, DOI 10.1111/j.1365-2222.2005.02256.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PASSALACQUA G, 2005, ALLERGY CLIN IMMUNOL, V17, P181, DOI 10.1027/0838-1925.17.5.181; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P31, DOI 10.1097/00130832-200402000-00007; Patriarca G, 2002, ANESTH ANALG, V95, P956, DOI 10.1213/01.ANE.0000028849.92989.84; PEREIRA MG, 1995, EPIDEMIOLOGIA TEORIA, P358; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; PURELLODAMBROSI.F, 1996, ALLERGOL IMMUNOPATH, V24, P146; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Rakoski J, 2001, INT ARCH ALLERGY IMM, V126, P185, DOI 10.1159/000049512; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Sambugaro R, 2003, Allergol Immunopathol (Madr), V31, P329, DOI 10.1157/13055212; SANTOS OR, 2004, REV ALERG MEX, V51, P177; SCHEINMANN P, 2002, ALLERG IMMUNOL PARIS, V34, P60; Silvestri M, 2002, J INVEST ALLERG CLIN, V12, P52; Sopo SM, 2004, ARCH DIS CHILD, V89, P620, DOI 10.1136/adc.2003.030411; Tari M G, 1994, Allergol Immunopathol (Madr), V22, P209; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TePas EC, 2004, ANN ALLERG ASTHMA IM, V92, P25; Vervloet D, 2002, ALLERGY, V57, P70; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wessner D, 2003, CHEM IMMUNOL, V82, P53; WILSON DC, 2005, EARTHQUAKE PREDICTIO, P1; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	87	180	195	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	OCT	2006	61	10					1162	1172		10.1111/j.1395-9995.2006.01205.x		11	Allergy; Immunology	Allergy; Immunology	079WK	WOS:000240208400003	16942563	
J	Li, YF; Langholz, B; Salam, MT; Gilliland, FD				Li, YF; Langholz, B; Salam, MT; Gilliland, FD			Maternal and grandmaternal smoking patterns are associated with early childhood asthma	CHEST			English	Article						asthma; in utero exposure to maternal smoking; smoking cessation; transgenerational association	ENVIRONMENTAL TOBACCO-SMOKE; SOUTHERN CALIFORNIA COMMUNITIES; PARENTAL SMOKING; ALLERGIC RHINOCONJUNCTIVITIS; RESPIRATORY-FUNCTION; DIFFERING LEVELS; FAMILY-HISTORY; AIR-POLLUTION; ATOPIC ECZEMA; UNITED-STATES	Objective: To investigate the associations of maternal and grandmaternal smoking before, during, and after pregnancy with childhood asthma. Design, setting, and participants: We conducted a case-control study nested within the Children's Health Study in southern California. The case patients consisted of 338 children with asthma that had been diagnosed in the first 5 years of life, and 570 control subjects were countermatched on in utero exposure to maternal smoking within grade, sex, and community of residence. Measurements: Detailed maternal and household smoking histories and other asthma risk factor information was obtained by telephone interview. Results: The participation rates were 72.3% and S2.5%, respectively, for control subjects and case patients. In utero exposure to maternal smoking was associated with increased risk for asthma diagnosed in the first 5 years of life (odds ratio [OR], 1.5; 95% confidence interval [CI] 1.0 to 2.3), and for persistent asthma (OR, 1.5; 95% CI, 1.0 to 2.3). The associations did not differ in children with early transient asthma compared to those with early persistent asthma. Relative to never-smokers, children whose mothers smoked throughout the pregnancy had an elevated risk of asthma in the first 5 years of life (OR, 1.6; 95% CI, 1.0 to 2.6). Children of mothers who quit smoking prior to the pregnancy showed no increased risk (OR, 0.9; 95% CI, 0.5 to 1.5). We were unable to assess the association of smoking cessation during pregnancy because very few mothers were reported to have done so (15%). Asthma risk did not increase in a monotonic pattern with smoking intensity during pregnancy. Postnatal secondhand smoke exposure was not independently associated with asthma. Grandmaternal smoking during the mother's fetal period was associated with increased asthma risk in her grandchildren (OR, 2.1; 95% CI, 1.4 to 3.2). Conclusions: Maternal and grandmaternal smoking during pregnancy may increase the risk of childhood asthma.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [1R01HL61768]; NIEHS NIH HHS [1P01 ES09581, 5P30 ES07048]		*AM LUNG ASS, 2003, TRENDS ASTHM MORB MO; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; Asher MI, 1998, EUR RESPIR J, V12, P315; Asher MI, 2001, NEW ZEAL MED J, V114, P114; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BOTTO F, 1994, BIOCHEM BIOPH RES CO, V205, P1086, DOI 10.1006/bbrc.1994.2777; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; *CDHS TOB CONTR SE, 2000, AD SMOK TRENDS CAL; CHEN Y, 1994, AM J RESP CRIT CARE, V150, P54; Cook DG, 1999, THORAX, V54, P357; Cook DG, 1998, THORAX, V53, P884; Csonka P, 2000, PEDIATR ALLERGY IMMU, V11, P225, DOI 10.1034/j.1399-3038.2000.00088.x; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Ebrahim SH, 2000, JAMA-J AM MED ASSOC, V283, P361, DOI 10.1001/jama.283.3.361; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Finette BA, 1998, NAT MED, V4, P1144, DOI 10.1038/2640; Floreani A A, 1999, Curr Opin Pulm Med, V5, P38, DOI 10.1097/00063198-199901000-00007; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; HANRAHAN JP, 1998, EUR RESP J S, V27; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; Huberman M, 1999, AM J EPIDEMIOL, V150, P1340; Landau L I, 2001, Paediatr Respir Rev, V2, P202, DOI 10.1053/prrv.2001.0141; LANGHOLZ B, 1995, BIOMETRIKA, V82, P69; Langholz B., 2001, BIOSTATISTICS, V2, P63, DOI 10.1093/biostatistics/2.1.63; Lannero E, 2002, PEDIATR ALLERGY IMMU, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Pierce JP, 2001, TOB CONTROL, V10, P145, DOI 10.1136/tc.10.2.145; Pluth JM, 2000, MUTAT RES-GEN TOX EN, V465, P101, DOI 10.1016/S1383-5718(99)00217-X; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557; Sole D, 2001, J INVEST ALLERG CLIN, V11, P123; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; STORB U, 1983, P NATL ACAD SCI-BIOL, V80, P6642, DOI 10.1073/pnas.80.21.6642; Strachan DP, 1998, THORAX, V53, P204; U.S. Environmental Protection Agency, 1992, EPA600690006F; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Young S, 2000, PEDIATR PULM, V29, P331, DOI 10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A	44	180	181	0	11	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	APR	2005	127	4					1232	1241		10.1378/chest.127.4.1232		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	915ZG	WOS:000228349900029	15821200	
J	Brunekreef, B; Smit, J; de Jongste, J; Neijens, H; Gerritsen, J; Postma, D; Aalberse, R; Koopman, L; Kerkhof, M; Wijga, A; van Strien, R				Brunekreef, B; Smit, J; de Jongste, J; Neijens, H; Gerritsen, J; Postma, D; Aalberse, R; Koopman, L; Kerkhof, M; Wijga, A; van Strien, R			The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study: Design and first results	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article; Proceedings Paper	Congress of the European-Academy-of-Allergy-and-Clinical-Immunology	JUN, 2001	BERLIN, GERMANY	European Acad Allergy & Clin Immunol		allergy; asthma; intervention; natural history; dust mites	HOUSE-DUST MITE; SENSITIZATION; EXPOSURE; CHILDREN; ENVIRONMENT; AVOIDANCE; CHILDHOOD; INFANCY; LIFE; RISK	The Prevention and Incidence of Asthma and Mite Allergy (PIAMA) birth cohort study was initiated in 1996. Children born to allergic mothers were enrolled in a double-blind placebo-controlled trial for evaluating the use of mite-impermeable mattress and pillow covers. Children born to allergic and non-allergic mothers were enrolled in a 'natural history' study to assess the role of environmental and dietary risk factors for the development of allergic disease in childhood. Recruitment started by distributing a validated screening questionnaire among >10,000 pregnant women during their first visit to a prenatal health clinic. Allergic mothers-to-be were invited to participate in the intervention study. Allergic, and a random sample of non-allergic, mothers-to-be were invited to participate in the 'natural history' arm of the study. In the intervention study, homes were visited before birth, 3 months after birth, and 12 months after birth for the collection of dust samples from floors and mattresses. In addition, the homes of about one-third of the children in the 'natural history' part of the study were visited for dust collection when the children were 3 months of age. The intervention study started with 855 participants and the 'natural history' study with 3,291 participants. Follow-up at 3 years of age has now been completed with satisfactory compliance (>90%,). A medical investigation and home visit at 4 years of age are nearing completion. Preliminary results show that mite-allergen levels were lower than found in previous Dutch studies, and that the intervention measure had a significant effect on mite-allergen levels, without important clinical benefits up to age 2 years old. The allergic families lived in homes with fewer 'triggers' such as pets, smoking and carpets than the non-allergic families, regardless of the intervention. The ongoing PIAMA cohort study will probably reveal useful information concerning effects of allergen load and reduction in the setting of a relatively low mite-allergen exposure, as well as other variables on the development of allergic manifestions and asthma.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Paediat, Rotterdam, Netherlands; Univ Groningen, Univ Groningen Hosp, Dept Paediat Resp Med, Groningen, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen, Univ Groningen Hosp, Dept Epidemiol & Stat, Groningen, Netherlands; Netherlands Red Cross, Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands	Brunekreef, B (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.	b.brunekreef@iras.uu.nl	Kerkhof, Marjan/A-8846-2008	brunekreef, bert/0000-0001-9908-0060			ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; van Strien R.T., 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; STRIEN RTV, 1995, CLIN EXP ALLERGY, V25, P1184, DOI 10.1111/j.1365-2222.1995.tb03042.x; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693; van Moerbeke D, 1997, EUROPEAN ALLERGY WHI; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner JA, 1996, PEDIATR ALLERGY IMMU, V7, P98, DOI 10.1111/j.1399-3038.1996.tb00406.x; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x	17	180	181	2	15	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0905-6157	1399-3038		PEDIAT ALLERG IMM-UK	Pediatr. Allergy Immunol.		2002	13			15			55	60		10.1034/j.1399-3038.13.s.15.1.x		6	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	638KW	WOS:000180571000012	12688626	
J	Beasley, R; Crane, J; Lai, CKW; Pearce, N				Beasley, R; Crane, J; Lai, CKW; Pearce, N			Prevalence and etiology of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; prevalence; atopic disorders; ISAAC; etiology	RESPIRATORY-HEALTH-SURVEY; CHILDHOOD ASTHMA; INCREASING PREVALENCE; WRITTEN QUESTIONNAIRE; VIDEO QUESTIONNAIRE; CHANGING PREVALENCE; RISK FACTOR; NEW-ZEALAND; CHILDREN; ATOPY	An increased understanding of the causes of asthma is coming from the international comparisons of asthma prevalence particularly those from the European Community Respiratory Health Survey of asthma prevalence in adults and the International Study of Asthma and Allergies in Childhood. From these and other studies of asthma prevalence, it is possible to draw some tentative conclusions as to the patterns of asthma prevalence worldwide, There are five striking patterns: first, asthma prevalence is increasing worldwide; second, asthma is generally more common in Western countries and less common in developing countries; third, asthma is more prevalent in English-speaking countries; fourth, asthma prevalence is increasing in developing countries as they become more Westernized or communities become urbanized: and fifth, the prevalence of other allergic disorders may also be increasing worldwide. These five key features of the international patterns of asthma prevalence raise major questions about the role of "established" risk factors for the development of asthma, As a result, recent research has expanded to include the study of novel factors that may "program" the initial susceptibility to sensitization or contribute to the development of asthma independent of atopic sensitization. These include various exposures in utero, which are reflected in various perinatal factors measured at birth, and exposures (or lack of exposures) in the early years of life that may make the infant more susceptible to the subsequent development of asthma, These issues are now the focus of an intensive research effort worldwide, and the next few gears are likely to see exciting advances in our understanding of the causes of asthma.	Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, Wellington S, New Zealand; Chinese Univ Hong Kong, Dept Med, Shatin, Hong Kong, Peoples R China	Beasley, R (reprint author), Wellington Sch Med, Dept Med, Wellington Asthma Res Grp, POB 7343, Wellington S, New Zealand.						ALBERG N, 1989, CLIN EXP ALLERGY, V19, P59; ANDERSON HR, 1989, ARCH DIS CHILD, V64, P172; ANDERSON HR, 1994, BRIT MED J, V308, P1600; ASHER I, 1996, EUR RESPIR J, V9, pS410; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; AUERBACH I, 1993, THORAX, V48, P139, DOI 10.1136/thx.48.2.139; BALFE D, 1996, S AFR MED J CME, V14, P433; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; BURR ML, 1987, J EPIDEMIOL COMMUN H, V41, P185, DOI 10.1136/jech.41.3.185; Clark S, 1996, LANCET, V348, P811, DOI 10.1016/S0140-6736(05)65212-9; Crane J., 1996, European Respiratory Journal Supplement, V9, p230S; Doll R, 1966, CANC INCIDENCE 5 CON, VI; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; HAAHTELA T, 1990, BRIT MED J, V301, P266; HSIEH HH, 1992, PROGR ALLERGOLOGY CL, V2, P223; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; INFANTERIVARD C, 1987, J ASTHMA, V24, P283, DOI 10.3109/02770908709070953; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; Kemp T, 1997, EPIDEMIOLOGY, V8, P678, DOI 10.1097/00001648-199710000-00011; Lai CKW, 1997, CLIN EXP ALLERGY, V27, P540, DOI 10.1046/j.1365-2222.1997.520869.x; LAI CKW, 1997, P 5 W PAC ALL S JUN; LAI CKW, 1997, INCREASING PREVALENC; LAI CKW, 1996, EUR RESPIR J, V9, pA411; LEE BW, 1997, 5 W PAC ALL S 7 KOR; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; LIARD R, 1988, J EPIDEMIOL COMMUN H, V42, P149, DOI 10.1136/jech.42.2.149; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Matricardi PM, 1997, BRIT MED J, V314, P999; MITCHELL EA, 1983, NEW ZEAL MED J, V96, P463; NEUTRA RR, 1990, AM J EPIDEMIOL, V132, P1; NINAN TK, 1992, BRIT MED J, V304, P873; Nishima S, 1993, Arerugi, V42, P192; Nystad W, 1997, EUR RESPIR J, V10, P1046, DOI 10.1183/09031936.97.10051046; PEARCE N, 1993, EUR RESPIR J, V6, P1455; PEARCE N, 1994, P INT S NEW EP OCC H, P214; PEAT JK, 1994, BRIT MED J, V308, P1591; PERDRIZET S, 1987, CHEST, V91, pS104, DOI 10.1378/chest.91.6.104S; REID DD, 1975, AM J EPIDEMIOL, V102, P469; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; ROSE G., 1992, STRATEGY PREVENTIVE; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; SHAW R, 1994, NEW ZEAL MED J, V107, P387; SHAW R, 1995, INT J EPIDEMIOL, V24, P597, DOI 10.1093/ije/24.3.597; SHAW RA, 1992, CLIN EXP ALLERGY, V22, P561, DOI 10.1111/j.1365-2222.1992.tb00166.x; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; STRACHAN D, 1995, CLIN EXP ALLERGY, V26, P791; STRACHAN DP, 1989, BRIT MED J, V299, P1259; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VONMUTIUS E, 1994, BRIT MED J, V308, P692; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WHINCUP PH, 1993, ARCH DIS CHILD, V68, P729; WILLIAMS HC, 1992, CLIN EXP DERMATOL, V17, P385, DOI 10.1111/j.1365-2230.1992.tb00244.x; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	65	180	189	4	16	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	2	S			S466	S472		10.1016/S0091-6749(00)90044-7		7	Allergy; Immunology	Allergy; Immunology	286JG	WOS:000085439600002	10669525	
J	Tarlo, SM; Balmes, J; Balkissoon, R; Beach, J; Beckett, W; Bernstein, D; Blanc, PD; Brooks, SM; Cowl, CT; Daroowalla, F; Harber, P; Lemiere, C; Liss, GM; Pacheco, KA; Redlich, CA; Rowe, B; Heitzer, J				Tarlo, Susan M.; Balmes, John; Balkissoon, Ronald; Beach, Jeremy; Beckett, William; Bernstein, David; Blanc, Paul D.; Brooks, Stuart M.; Cowl, Clayton T.; Daroowalla, Feroza; Harber, Philip; Lemiere, Catherine; Liss, Gary M.; Pacheco, Karin A.; Redlich, Carrie A.; Rowe, Brian; Heitzer, Julia			Diagnosis and management of work-related asthma: American College of Chest Physicians Consensus Statement	CHEST			English	Review						asthma; occupational lung; preventive medicine	EXHALED NITRIC-OXIDE; PEAK EXPIRATORY FLOW; NATURAL-RUBBER LATEX; HEALTH-CARE WORKERS; INDUCED OCCUPATIONAL ASTHMA; DIISOCYANATE-INDUCED ASTHMA; IRRITANT-INDUCED ASTHMA; VOCAL CORD DYSFUNCTION; RED CEDAR ASTHMA; NONSPECIFIC BRONCHIAL HYPERRESPONSIVENESS	Background: A previous American College of Chest Physicians Consensus Statement on asthma in the workplace was published in 1995. The current Consensus Statement updates the previous one based on additional research that has been published since then, including findings relevant to preventive measures and work-exacerbated asthma (WEA). Methods: A panel of experts, including allergists, pulmonologists, and occupational medicine physicians, was convened to develop this Consensus Document on the diagnosis and management of work-related asthma (WRA), based in part on a systematic review, that was performed by the University of Alberta/Capital Health Evidence-Based Practice and was supplemented by additional published studies to 2007. Results: The Consensus Document defined WRA to include occupational asthma (ie, asthma induced by sensitizer or irritant work exposures) and WEA (ie, preexisting or concurrent asthma worsened by work factors). The Consensus Document focuses on the diagnosis and management of NIMA (including diagnostic tests, and work and compensation issues), as well as preventive measures. WRA should be considered in all individuals with new-onset or worsening asthma, and a careful occupational history should be obtained. Diagnostic tests such as serial peak flow recordings, methacholine challenge tests, immunologic tests, and specific inhalation challenge tests, (if available), can increase diagnostic certainty. Since the prognosis is better with early diagnosis and appropriate intervention, effective preventive measures for other workers with exposure should be addressed. Conclusions: The substantial prevalence of WRA supports consideration of the diagnosis in all who present with new-onset or worsening asthma, followed by appropriate investigations and intervention including consideration of other exposed workers.	[Balmes, John; Blanc, Paul D.] Univ Calif San Francisco, San Francisco, CA 94143 USA; [Balkissoon, Ronald; Pacheco, Karin A.] Natl Jewish Med & Res Ctr, Denver, CO USA; [Beach, Jeremy; Rowe, Brian] Univ Alberta, Calgary, AB, Canada; [Beckett, William] Univ Rochester, Sch Med & Dent, Rochester, NY USA; [Bernstein, David] Univ Cincinnati, Cincinnati, OH USA; [Brooks, Stuart M.] Univ S Florida, Tampa, FL USA; [Cowl, Clayton T.] Mayo Clin, Rochester, MN USA; [Daroowalla, Feroza] SUNY Stony Brook, Stony Brook, NY 11794 USA; [Harber, Philip] Univ Calif Los Angeles, Los Angeles, CA USA; [Lemiere, Catherine] Univ Montreal, Montreal, PQ, Canada; [Redlich, Carrie A.] Yale Univ, Sch Med, New Haven, CT USA; [Heitzer, Julia] Amer Coll Chest Phys, Northbrook, IL USA; [Tarlo, Susan M.; Liss, Gary M.] Univ Toronto, Toronto, ON, Canada	Tarlo, SM (reprint author), Toronto Western Hosp, EW7-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	susan.tarlo@utoronto.ca					Adisesh LA, 1998, CLIN EXP ALLERGY, V28, P876; Allmers H, 2000, INT ARCH OCC ENV HEA, V73, P181, DOI 10.1007/s004200050025; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Allmers H, 1996, DEUT MED WOCHENSCHR, V121, P823, DOI 10.1055/s-2008-1043073; Alvarez MJ, 2001, ALLERGY, V56, P185, DOI 10.1034/j.1398-9995.2001.056002185.x; ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Ameille J, 2005, CURR OPIN ALLERGY CL, V5, P125, DOI 10.1097/01.all.0000162303.59363.b4; Ameille J, 1997, EUR RESPIR J, V10, P55, DOI 10.1183/09031936.97.10010055; ANDERTON RC, 1979, J ALLERGY CLIN IMMUN, V63, P315, DOI 10.1016/0091-6749(79)90125-8; Andreoli R, 2003, RAPID COMMUN MASS SP, V17, P637, DOI 10.1002/rcm.960; Andrianopoulos MV, 2000, J VOICE, V14, P607, DOI 10.1016/S0892-1997(00)80016-8; Anees W, 2006, THORAX, V61, P751, DOI 10.1136/thx.2005.054080; Anees W, 2002, THORAX, V57, P231, DOI 10.1136/thorax.57.3.231; Antczak Adam, 2002, Int J Occup Med Environ Health, V15, P317; ARMENTIA A, 1992, ANN ALLERGY, V69, P441; ARMENTIA A, 1990, ANN ALLERGY, V65, P265; Bachert C, 2006, CURR OPIN ALLERGY CL, V6, P29, DOI 10.1097/01.all.0000200504.54425.0e; Bagnato GF, 2000, RESPIRATION, V67, P507, DOI 10.1159/000067464; Bahima AC, 2004, J INVEST ALLERG CLIN, V14, P17; Baldwin DR, 2002, THORAX, V57, P860, DOI 10.1136/thorax.57.10.860; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BALMES JR, 1991, OCCUP MED, V6, P101; Banks Daniel E, 2003, Curr Opin Allergy Clin Immunol, V3, P101, DOI 10.1097/00130832-200304000-00003; BANKS DE, 1990, CHEST, V97, P121, DOI 10.1378/chest.97.1.121; BANKS DE, 1986, CHEST, V89, P389, DOI 10.1378/chest.89.3.389; Banks DE, 1996, CHEST, V109, P1370, DOI 10.1378/chest.109.5.1370; Barbinova L, 2006, INT ARCH OCC ENV HEA, V79, P387, DOI 10.1007/s00420-005-0051-x; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; BAUR X, 1995, J ALLERGY CLIN IMMUN, V96, P489, DOI 10.1016/S0091-6749(95)70292-X; Baur X, 2005, INT ARCH OCC ENV HEA, V78, P593, DOI 10.1007/s00420-005-0613-y; Baur X, 2005, EUR RESPIR J, V25, P309, DOI 10.1183/09031936.05.00021504; Baur X, 2003, ANN ALLERG ASTHMA IM, V90, P11; BEACH J, 2005, PUBLICATION AGENCY H; Beach J, 2007, CHEST, V131, P569, DOI 10.1378/chest.06-0492; Bello D, 2007, ENVIRON HEALTH PERSP, V115, P328, DOI 10.1289/ehp.9557; Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; Bernstein I. Leonard, 1993, P1; Bernstein IL, 2006, ASTHMA WORKPLACE REL; BERNSTEIN IL, 2003, ASTHMA WORKPLACE REL, P1; BERUBE D, 1991, CHEST, V99, P831, DOI 10.1378/chest.99.4.831; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; Blanc PD, 1996, CHEST, V109, P688, DOI 10.1378/chest.109.3.688; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Bolen AR, 2007, OCCUP ENVIRON MED, V64, P343, DOI 10.1136/oem.028662; Brant A, 2006, CLIN EXP ALLERGY, V36, P483, DOI 10.1111/j.1365-2222.2006.02465.x; Brant A, 2005, OCCUP ENVIRON MED, V62, P395, DOI 10.1136/oem.2004.014639; BRITTON J, 1986, THORAX, V41, P128, DOI 10.1136/thx.41.2.128; BROOKS SM, 1990, CHEST, V97, P1401, DOI 10.1378/chest.97.6.1401; BROOKS SM, 1990, J ALLERGY CLIN IMMUN, V85, P17, DOI 10.1016/0091-6749(90)90216-Q; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Burge P S, 1982, Eur J Respir Dis Suppl, V123, P47; Burge PS, 1999, OCCUP ENVIRON MED, V56, P758; BURGE PS, 1979, THORAX, V34, P300, DOI 10.1136/thx.34.3.300; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; Busse W, 2004, AM J RESP CRIT CARE, V170, P683, DOI 10.1164/rccm.200311-1539WS; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661; CANNON J, 1995, BRIT MED J, V311, P602; Cap P, 2004, THORAX, V59, P465, DOI 10.1136/thx.2003.011866; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P1185, DOI 10.1016/0091-6749(86)90270-8; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P823, DOI 10.1016/0091-6749(89)90346-1; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434; Chan-Yeung Moira, 2003, Am J Respir Crit Care Med, V167, P450; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; Chatkin JM, 1999, CHEST, V116, P1780, DOI 10.1378/chest.116.6.1780; Chladkova J, 2006, RESPIRATION, V73, P173, DOI 10.1159/000088050; Choudat D, 1999, EUR RESPIR J, V14, P328; Christopher KL, 2006, CHEST, V129, P842, DOI 10.1378/chest.129.4.842; COCKCROFT DW, 1990, AM REV RESPIR DIS, V142, P497; Corradi M, 2003, AM J RESP CRIT CARE, V167, P1380, DOI 10.1164/rccm.200210-1253OC; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crescioli S, 1996, ANN ALLERG ASTHMA IM, V77, P106; Currie GP, 2003, ANN ALLERG ASTHMA IM, V90, P194; Curwick CC, 2006, ANN ALLERG ASTHMA IM, V97, P546; DALES RE, 1988, CHEST, V93, P984, DOI 10.1378/chest.93.5.984; de Jong NW, 1999, ALLERGY, V54, P980, DOI 10.1034/j.1398-9995.1999.00158.x; De Marzo N, 1988, Pulm Pharmacol, V1, P15, DOI 10.1016/0952-0600(88)90005-1; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; DIJKMAN JH, 1981, INT ARCH ALLER A IMM, V64, P422; Effros RM, 2003, AM J RESP CRIT CARE, V168, P1500, DOI 10.1164/rccm.200307-920OC; Effros RM, 2004, AM J PHYSIOL-LUNG C, V287, P1073; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Escudero C, 2003, ALLERGY, V58, P616, DOI 10.1034/j.1398-9995.2003.00201.x; Esterhuizen TM, 2001, S AFR MED J, V91, P509; European Respiratory Society, 1993, EUR RESPIR J, V16, P1; Fernandez C, 2007, CLIN EXP ALLERGY, V37, P391, DOI 10.1111/j.1365-2222.2007.02659.x; Fishwick D, 2007, OCCUP ENVIRON MED, V64, P185, DOI 10.1136/oem.2006.027722; Fletcher AM, 2006, J OCCUP ENVIRON MED, V48, P1203, DOI 10.1097/01.jom.0000245920.87676.7b; Francis H C, 2007, Occup Environ Med, V64, P361; Ganas K, 2001, RESP MED, V95, P649, DOI 10.1053/rmed.2001.1117; GANNON PFG, 1993, BRIT J IND MED, V50, P491; Gassert TH, 1998, J OCCUP ENVIRON MED, V40, P481, DOI 10.1097/00043764-199805000-00011; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Global Initiative for asthma, 2008, GLOB STRAT ASTHM MAN; Goe SK, 2004, OCCUP ENVIRON MED, V61, P512, DOI 10.1136/oem.2003.008177; GOLDEN DBK, 1986, J ALLERGY CLIN IMMUN, V77, P727, DOI 10.1016/0091-6749(86)90418-5; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298; Goldstein MF, 2001, CHEST, V119, P1001, DOI 10.1378/chest.119.4.1001; Gong H, 1997, ARCH ENVIRON HEALTH, V52, P34; Gordon SB, 1998, OCCUP MED-OXFORD, V48, P455, DOI 10.1093/occmed/48.7.455; Gordon SB, 1997, OCCUP MED-OXFORD, V47, P361, DOI 10.1093/occmed/47.6.361; Grammer LC, 2002, CHEST, V121, P1317, DOI 10.1378/chest.121.4.1317; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; Guyatt G, 2006, CHEST, V129, P174, DOI 10.1378/chest.129.1.174; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; HARBER P, 1995, CHEST, V107, P1156, DOI 10.1378/chest.107.4.1156; Henneberger PK, 2006, OCCUP ENVIRON MED, V63, P551, DOI 10.1136/oem.2005.024786; Henneberger PK, 2003, ARCH ENVIRON HEALTH, V58, P781; Henneberger PK, 2002, INT J OCCUP ENV HEAL, V8, P291; HENNEBERGER PK, 1991, CHEST, V100, P1515, DOI 10.1378/chest.100.6.1515; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Jaakkola JJK, 2006, CURR OPIN ALLERGY CL, V6, P85, DOI 10.1097/01.all.0000216849.64828.55; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Johannesson G, 2001, CLIN EXP ALLERGY, V31, P1021, DOI 10.1046/j.1365-2222.2001.01109.x; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Juniper EF, 1991, HISTAMINE METHACHOLI; Karanicolas PJ, 2007, EVIDENCE BASED LAB M; Karjalainen A, 2003, CHEST, V123, P283, DOI 10.1378/chest.123.1.283; Kay AB, 2004, SPRINGER SEMIN IMMUN, V25, P391, DOI 10.1007/s00281-003-0146-y; Kennedy P, 2000, SOCIOL RES ONLINE, V5, P1; KILLIAN D, 1976, CLIN ALLERGY, V6, P219, DOI 10.1111/j.1365-2222.1976.tb01900.x; KIPPEN HM, 1998, AM J PUBLIC HEALTH, V85, P575; Kolbeck KG, 2000, RESP MED, V94, P1065, DOI 10.1053/rmed.2000.0885; Koskela H, 2003, CHEST, V124, P383, DOI 10.1378/chest.124.1.383; Kraft M, 2006, J ALLERGY CLIN IMMUN, V117, P1197, DOI 10.1016/j.jaci.2006.03.001; Kraw M, 1999, AM J IND MED, V35, P87, DOI 10.1002/(SICI)1097-0274(199901)35:1<87::AID-AJIM12>3.0.CO;2-X; Kreutzer R, 1999, AM J EPIDEMIOL, V150, P1; Kurtz KM, 2001, J ALLERGY CLIN IMMUN, V107, P178, DOI 10.1067/mai.2001.112125; LaMontagne A D, 2005, Occup Environ Med, V62, P741, DOI 10.1136/oem.2005.022236; LaMontagne AD, 2006, OCCUP ENVIRON MED, V63, P359, DOI 10.1136/oem.2005.025221; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202; Leggit J, 2004, AM FAM PHYSICIAN, V69, P1045; Leigh R, 1999, Can Respir J, V6, P194; Lemanske RF, 2006, J ALLERGY CLIN IMMUN, V117, pS456, DOI 10.1016/j.jaci.2005.07.006; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329; Lemiere C, 2004, CLIN EXP ALLERGY, V34, P1684, DOI 10.1111/j.1365-2222.2004.02102.x; Lemiere C, 2002, J ALLERGY CLIN IMMUN, V110, P641, DOI 10.1067/mai.2002.128806; Lemiere C, 1996, CHEST, V109, P1631, DOI 10.1378/chest.109.6.1631; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Leroyer C, 1998, AM J RESP CRIT CARE, V158, P827; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585; Leynadier F, 2004, J ALLERGY CLIN IMMUN, V113, P360, DOI 10.1016/j.jaci.2003.11.020; Linnett PJ, 2005, OCCUP MED-OXFORD, V55, P595, DOI 10.1093/occmed/kqi183; LISS GM, 1993, J ALLERGY CLIN IMMUN, V92, P237, DOI 10.1016/0091-6749(93)90167-E; LISS GM, 1991, CHEST, V100, P63, DOI 10.1378/chest.100.1.63; Liu YC, 2006, J OCCUP ENVIRON HYG, V3, P234, DOI 10.1080/15459620600628704; LOZEWICZ S, 1987, BRIT J DIS CHEST, V81, P14, DOI 10.1016/0007-0971(87)90103-3; Lund MB, 2000, OCCUP ENVIRON MED, V57, P274, DOI 10.1136/oem.57.4.274; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MACCIA CA, 1976, AM REV RESPIR DIS, V113, P701; MAESTRELLI P, 1993, AM REV RESPIR DIS, V148, P407; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; MALO JL, 1993, THORAX, V48, P1211, DOI 10.1136/thx.48.12.1211; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; Maniscalco M, 2004, OCCUP MED-OXFORD, V54, P404, DOI 10.1093/occmed/kqh082; MAPP C, 1987, AM REV RESPIR DIS, V136, P1403; MAPP CE, 1986, EUR J RESPIR DIS, V68, P89; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; McDonald JC, 2005, OCCUP ENVIRON MED, V62, P836, DOI 10.1136/oem.2004.019489; Medina-Ramon M, 2006, EUR RESPIR J, V27, P1196, DOI 10.1183/09031936.06.00085405; Meggs WJ, 1996, ARCH ENVIRON HEALTH, V51, P275; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; MERGET R, 1988, CLIN ALLERGY, V18, P569, DOI 10.1111/j.1365-2222.1988.tb02908.x; MERGET R, 1993, J ALLERGY CLIN IMMUN, V92, P264, DOI 10.1016/0091-6749(93)90170-K; MERGET R, 1991, BRIT J IND MED, V48, P830; Merget R, 2001, J ALLERGY CLIN IMMUN, V107, P707; MILLER MR, 1992, THORAX, V47, P904, DOI 10.1136/thx.47.11.904; Millqvist E, 2000, ALLERGY, V55, P546, DOI 10.1111/j.1398-9995.2000.all2513.x; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Montuschi P, 2002, J ALLERGY CLIN IMMUN, V109, P615, DOI 10.1067/mai.2002.122461; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; Moscato Gianna, 2003, Curr Opin Allergy Clin Immunol, V3, P109, DOI 10.1097/00130832-200304000-00004; MULLAN RJ, 1991, AM J IND MED, V19, P775, DOI 10.1002/ajim.4700190610; Muller UR, 2005, CURR OPIN ALLERGY CL, V5, P343; Munoz X, 2004, OCCUP ENVIRON MED, V61, P861, DOI 10.1136/oem.2004.013177; Munoz X, 2003, CHEST, V123, P2124, DOI 10.1378/chest.123.6.2124; Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731; Nicholson PJ, 2001, OCCUP MED-OXFORD, V51, P81, DOI 10.1093/occmed/51.2.081; Nowak D, 2001, FREE RADICAL BIO MED, V30, P178, DOI 10.1016/S0891-5849(00)00457-3; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; OBYRNE P, 2000, ASTHMA, P92; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; Olin AC, 2004, EUR RESPIR J, V23, P87, DOI 10.1183/09031936.03.00044402; Olin AC, 1999, EUR RESPIR J, V14, P828, DOI 10.1034/j.1399-3003.1999.14d18.x; Ortega HG, 2002, CHEST, V121, P1323, DOI 10.1378/chest.121.4.1323; Padoan M, 2003, EUR RESPIR J, V21, P637, DOI 10.1183/09031936.03.00060703; PAGGIARO P, 1987, AM REV RESPIR DIS, V136, P1237; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847; Park HS, 1998, CLIN EXP ALLERGY, V28, P724; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; Park JW, 2001, OCCUP ENVIRON MED, V58, P411, DOI 10.1136/oem.58.6.411; Patriarca G, 2002, ANESTH ANALG, V95, P956, DOI 10.1213/01.ANE.0000028849.92989.84; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; Pereira C, 1999, ALLERGY, V54, P291, DOI 10.1034/j.1398-9995.1999.00954.x; PEREIRA C, 2003, ALLERG IMMUNOL PARIS, V35, P217; Perkner JJ, 1998, J OCCUP ENVIRON MED, V40, P136, DOI 10.1097/00043764-199802000-00009; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Petsonk EL, 2002, ENVIRON HEALTH PERSP, V110, P569; PETSONK EL, 1995, OCCUP ENVIRON MED, V52, P745; Piipari R, 2002, EUR RESPIR J, V20, P1532, DOI 10.1183/09031936.02.0041802; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; Pontes Paulo, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P138, DOI 10.1097/01.moo.0000193193.09602.51; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323; Quirce S, 2003, J ALLERGY CLIN IMMUN, V111, P788, DOI 10.1067/mai.2003.166; Quirce S, 2001, ALLERGY, V56, P446, DOI 10.1034/j.1398-9995.2001.056005446.x; Quirce S, 2000, J ASTHMA, V37, P267, DOI 10.3109/02770900009055449; Quirce Santiago, 2004, Curr Opin Allergy Clin Immunol, V4, P87, DOI 10.1097/00130832-200404000-00003; Rachiotis G, 2007, THORAX, V62, P147, DOI 10.1136/thx.2006.061952; Rahman I, 2003, FREE RADICAL RES, V37, P1253, DOI 10.1080/10715760310001623331; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; Saarinen K, 2003, EUR RESPIR J, V22, P305, DOI 10.1183/09031936.03.00100102; Sama SR, 2006, J OCCUP ENVIRON MED, V48, P400, DOI 10.1097/01.jom.0000199437.33100.cf; Sander I, 2004, ALLERGY, V59, P95, DOI 10.1046/j.1398-9995.2003.00349.x; Sarlo K, 2003, ANN ALLERG ASTHMA IM, V90, P32; Sastre J, 2006, CURR OPIN ALLERGY CL, V6, P96, DOI 10.1097/01.all.0000216851.10571.64; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Sastre J, 2003, CHEST, V123, P1276, DOI 10.1378/chest.123.4.1276; Schwaiblmair M, 1997, INT ARCH OCC ENV HEA, V70, P419, DOI 10.1007/s004200050239; Schweigert MK, 2000, CLIN EXP ALLERGY, V30, P1511, DOI 10.1046/j.1365-2222.2000.00893.x; Shirai T, 2003, CLIN EXP ALLERGY, V33, P1252, DOI 10.1046/j.1365-2222.2003.01744.x; Sparer J, 2004, J OCCUP ENVIRON HYG, V1, P570, DOI 10.1080/15459620490485909; STENTON SC, 1993, OCCUP MED-OXFORD, V43, P203, DOI 10.1093/occmed/43.4.203; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; Stern A, 2000, ALLERGY, V55, P88, DOI 10.1034/j.1398-9995.2000.00202.x; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; Tan K, 2001, ALLERGY, V56, P627, DOI 10.1034/j.1398-9995.2001.00975.x; Tanaka H, 2002, CHEST, V122, P1080, DOI 10.1378/chest.122.3.1080; Tarlo S M, 1998, Can Respir J, V5, P289; Tarlo SA, 2003, ANN ALLERG ASTHMA IM, V90, P19; Tarlo SM, 2006, EUR RESPIR J, V27, P607, DOI 10.1183/09031936.06.00062105; Tarlo SM, 2006, CHEST, V129, p186S, DOI 10.1378/chest.129.1_suppl.186S; TARLO SM, 1991, CHEST, V100, P329, DOI 10.1378/chest.100.2.329; Tarlo SM, 2003, J ALLERGY CLIN IMMUN, V111, P692, DOI 10.1067/mai.2003.1374; Tarlo SM, 2002, OCCUP ENVIRON MED, V59, P58, DOI 10.1136/oem.59.1.58; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; TARLO SM, 1995, CHEST, V107, P634, DOI 10.1378/chest.107.3.634; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; Taylor AJN, 2005, THORAX, V60, P364, DOI 10.1136/thx.2004.032367; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; Ternesten-Hasseus E, 2002, ALLERGY, V57, P501, DOI 10.1034/j.1398-9995.2002.23380.x; TOWNLEY R G, 1975, Journal of Allergy and Clinical Immunology, V56, P429, DOI 10.1016/0091-6749(75)90061-5; Tufvesson E, 2006, RESP MED, V100, P34, DOI 10.1016/j.med.2005.04.007; Tunnicliffe WS, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.11.e15; ULRIK CS, 1994, J ASTHMA, V31, P35, DOI 10.3109/02770909409056767; Ulvestad B, 2001, EUR RESPIR J, V17, P416, DOI 10.1183/09031936.01.17304160; van Beurden WJC, 2002, RESP MED, V96, P197, DOI 10.1053/rmed.2001.1240; Van Hoydonck PGA, 2004, EUR RESPIR J, V23, P189, DOI 10.1183/09031936.03.00049403; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.0.CO;2-2; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; Vandenplas O, 2005, EUR RESPIR J, V26, P1056, DOI 10.1183/09031936.05.00024705; Vandenplas O, 2003, EUR RESPIR J, V22, P689, DOI 10.1183/09031936.03.00053203; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; VANDENPLAS O, 1992, AM REV RESPIR DIS, V145, P582; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VENABLES KM, 1985, BRIT J IND MED, V42, P517; Vinuya RZ, 2002, ANN ALLERG ASTHMA IM, V88, P8; WARREN CPW, 1985, CAN MED ASSOC J, V133, P851; Wild D M, 2005, Occup Environ Med, V62, P743, DOI 10.1136/oem.2004.016147; Wisnewski AV, 2004, J ALLERGY CLIN IMMUN, V113, P1178, DOI 10.1016/j.jaci.2004.03.009; WOITOWITZ HJ, 1972, RESPIRATION, V29, P549; Wong CH, 2006, ALIMENT PHARM THERAP, V23, P1321, DOI 10.1111/j.1365-2036.2006.02888.x; Yacoub MR, 2007, EUR RESPIR J, V29, P889, DOI 10.1183/09031936.00127206; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; Yang X, 2001, DRUGS, V61, P365, DOI 10.2165/00003495-200161030-00005; Ye YM, 2006, J ALLERGY CLIN IMMUN, V118, P885, DOI 10.1016/j.jaci.2006.06.026; ZEISS CR, 1977, J ALLERGY CLIN IMMUN, V60, P96, DOI 10.1016/0091-6749(77)90033-1; Zock JP, 2004, J EXPO ANAL ENV EPID, V14, P397, DOI 10.1038/sj.jea.7500337	304	179	183	4	14	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	SEP	2008	134	3		S			1S	41S		10.1378/chest.08-0201		41	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	349OQ	WOS:000259290600001	18779187	
J	Pichavant, M; Goya, S; Meyer, EH; Johnston, RA; Kim, HY; Matangkasombut, P; Zhu, M; Iwakura, Y; Savage, PB; DeKruyff, RH; Shore, SA; Umetsu, DT				Pichavant, Muriel; Goya, Sho; Meyer, Everett H.; Johnston, Richard A.; Kim, Hye Y.; Matangkasombut, Ponpan; Zhu, Ming; Iwakura, Yoichiro; Savage, Paul B.; DeKruyff, Rosemarie H.; Shore, Stephanie A.; Umetsu, Dale T.			Ozone exposure in a mouse model induces airway hyperreactivity that requires the presence of natural killer T cells and IL-17	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							NKT CELLS; EPITHELIAL-CELLS; ASTHMATIC-PATIENTS; BRONCHIAL-ASTHMA; ALLERGIC-ASTHMA; INFLAMMATION; MICE; HYPERRESPONSIVENESS; LUNG; RESPONSES	Exposure to ozone, which is a major component of air pollution, induces a form of asthma that occurs in the absence of adaptive immunity. Although ozone-induced asthma is characterized by airway neutrophilia, and not eosinophilia, it is nevertheless associated with airway hyperreactivity (AHR), which is a cardinal feature of asthma. Because AHR induced by allergens requires the presence of natural killer T (NKT) cells, we asked whether ozone-induced AHR had similar requirements. We found that repeated exposure of wild-type (WT) mice to ozone induced severe AHR associated with an increase in airway NKT cells, neutrophils, and macrophages. Surprisingly, NKT cell-deficient (CD1d(-/-) and J alpha 18(-/-)) mice failed to develop ozone-induced AHR. Further, treatment of WT mice with an anti-CD1d mAb blocked NKT cell activation and prevented ozone-induced AHR. Moreover, ozone-induced, but not allergen-induced, AHR was associated with NKT cells producing interleukin (IL)-17, and failed to occur in IL-17(-/-) mice nor in WT mice treated with anti-IL-17 mAb. Thus, ozone exposure induces AHR that requires the presence of NKT cells and IL-17 production. Because NKT cells are required for the development of two very disparate forms of AHR (ozone- and allergen-induced), our results strongly suggest that NKT cells mediate a unifying pathogenic mechanism for several distinct forms of asthma, and represent a unique target for effective asthma therapy.	[Pichavant, Muriel; Goya, Sho; Meyer, Everett H.; Kim, Hye Y.; Matangkasombut, Ponpan; DeKruyff, Rosemarie H.; Umetsu, Dale T.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA; [Johnston, Richard A.; Zhu, Ming; Shore, Stephanie A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Iwakura, Yoichiro] Univ Tokyo, Ctr Med Expt, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; [Savage, Paul B.] Brigham Young Univ, Provo, UT 84604 USA; [Meyer, Everett H.] Stanford Univ, Stanford Immunol Program, Stanford, CA 94305 USA	Umetsu, DT (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA 02115 USA.	dale.umetsu@childrens.harvard.edu	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775	NHLBI NIH HHS [HL062348, R01 HL062348]; NIAID NIH HHS [AI054456, P01 AI054456, T32 AI007290]		Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363; Babin SM, 2007, ENVIRON HEALTH-UK, V6, DOI 10.1186/1476-096X-6-9; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Behar SM, 1999, J EXP MED, V189, P1973, DOI 10.1084/jem.189.12.1973; Bendelac A, 2007, ANNU REV IMMUNOL, V25, P297, DOI 10.1146/annurev.immunol.25.022106.141711; Brutkiewicz RR, 2006, J IMMUNOL, V177, P769; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; Ferretti S, 2003, J IMMUNOL, V170, P2106; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Hamzaoui A, 2006, MEDIAT INFLAMM, DOI 10.1155/MI/2006/71214; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL390, DOI 10.1152/ajplung.00007.2004; Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346; Kronenberg M, 2002, NAT REV IMMUNOL, V2, P557, DOI 10.1038/nri854; Kronenberg M, 2005, ANNU REV IMMUNOL, V23, P877, DOI 10.1146/annurev.immunol.23.021704.115742; Li N, 2004, J IMMUNOL, V173, P3467; Linden A, 2005, EUR RESPIR J, V25, P159, DOI 10.1183/09031936.04.00032904; Lisbonne M, 2003, J IMMUNOL, V171, P1637; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; Mercer JC, 2005, INT J BIOCHEM CELL B, V37, P1337, DOI 10.1016/j.biocel.2004.11.019; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Michel ML, 2007, J EXP MED, V204, P995, DOI 10.1084/jem.20061551; Miyamoto M, 2003, J IMMUNOL, V170, P4665; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nieuwenhuis EES, 2002, NAT MED, V8, P588, DOI 10.1038/nm0602-588; Park JW, 2004, AM J RESP CELL MOL, V30, P830, DOI 10.1165/rcmb.2003.0373OC; Park SH, 2000, EUR J IMMUNOL, V30, P620, DOI 10.1002/1521-4141(200002)30:2<620::AID-IMMU620>3.0.CO;2-4; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Sen Yang, 2005, J Immunol, V175, P4914; Shore SA, 2002, J APPL PHYSIOL, V92, P1019, DOI 10.1152/japplphysiol.00381.2001; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Smiley ST, 1997, SCIENCE, V275, P977, DOI 10.1126/science.275.5302.977; Todokoro M, 2004, INFLAMMATION, V28, P105, DOI 10.1023/B:IFLA.0000033026.91221.ed; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; VanderLaan PA, 2007, AM J PATHOL, V170, P1100, DOI 10.2353/ajpath.2007.060188; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yu M, 2002, TOXICOL SCI, V68, P488, DOI 10.1093/toxsci/68.2.488	52	179	192	0	6	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	FEB 18	2008	205	2					385	393		10.1084/jem.20071507		9	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	263XR	WOS:000253250300016	18250191	
J	Van dn Berge, M; Meijer, RJ; Kerstjens, HAM; de Reus, DM; Koeter, GH; Kauffman, HF; Postma, DS				Van dn Berge, M; Meijer, RJ; Kerstjens, HAM; de Reus, DM; Koeter, GH; Kauffman, HF; Postma, DS			PC20 adenosine 5 '-monophosphate is more closely associated with airway inflammation in asthma than PC20 methacholine	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							EXHALED NITRIC-OXIDE; BRONCHIAL HYPERRESPONSIVENESS; ALLERGIC RHINITIS; INDUCED BRONCHOCONSTRICTION; SPUTUM EOSINOPHILS; SMOOTH-MUSCLE; DISEASE; BLOOD; RESPONSIVENESS; HYPERREACTIVITY	Inhalation of a direct stimulus such as histamine or methacholine is generally used to measure bronchial hyperresponsiveness (BHR). Provocation with adenosine 5'-monophosphate (AMP), an indirect airway challenge, has been suggested to be a better marker of airway inflammation than direct challenges. However, so far little information on this subject is available. The aim of our study was to assess whether the concentration of AMP causing the FEV1 to drop by 20% (PC20) is more closely associated with inflammatory parameters in asthma than PC20 methacholine. In 120 patients with atopic asthma (median FEV1 81% predicted [pred], median age 27 yr), PC20 methacholine and PC20 AMP as well as sputum induction, blood sampling, and measurement of nitric oxide in exhaled air were performed. PC20 methacholine was predominantly predicted by FEV1 %pred (explained variance [ev] = 18%) with the percentage of peripheral blood monocytes being a weak additional independent predictor (total ev = 23%). By contrast, PC20 AMP was predominantly predicted by the percentage of eosinophils in sputum (ev = 25%), while FEV1 %pred was only an additional independent predictor (total ev = 36%). PC20 AMP reflects more closely the extent of airway inflammation due to asthma than PC20 methacholine.	Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen Hosp, Dept Allergol, Groningen, Netherlands	Postma, DS (reprint author), Univ Groningen Hosp, Dept Pulm Dis, Hanzepl 1, NL-9700 RB Groningen, Netherlands.						Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; ALVING K, 1993, EUR RESPIR J, V6, P1368; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; BRAND PLP, 1991, AM REV RESPIR DIS, V143, P916; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; CRIMI N, 1992, EUR RESPIR J, V5, P560; DAHL R, 1993, ALLERGY, V48, P77, DOI 10.1111/j.1398-9995.1993.tb04704.x; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126; FINNEY MJB, 1985, BRIT J PHARMACOL, V85, P29; FRETTE C, 1991, AM REV RESPIR DIS, V143, P987; Grunberg K, 1997, AM J RESP CRIT CARE, V156, P609; Ichinose M, 2000, EUR RESPIR J, V15, P248, DOI 10.1034/j.1399-3003.2000.15b05.x; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64; Jatakanon A, 1998, THORAX, V53, P91; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Meijer RJ, 1999, THORAX, V54, P894; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560; PAUWELS RA, 1987, AM REV RESPIR DIS, V136, P374; PHILLIPS GD, 1987, THORAX, V42, P939, DOI 10.1136/thx.42.12.939; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1183/09031936.00.15103000; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; Schmidt D, 2000, J ALLERGY CLIN IMMUN, V105, P673, DOI 10.1067/mai.2000.105705; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; STERK PJ, 1989, EUR RESPIR J, V2, P267; TAYLOR KJ, 1987, THORAX, V42, P452, DOI 10.1136/thx.42.6.452; ULRIK CS, 1995, CLIN EXP ALLERGY, V25, P820, DOI 10.1111/j.1365-2222.1995.tb00024.x; Viksman MY, 1997, AM J RESP CRIT CARE, V155, P858; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241	33	179	181	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN	2001	163	7					1546	1550				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	443JE	WOS:000169337400011	11401871	
J	Rogge, L; Bianchi, E; Biffi, M; Bono, E; Chang, SYP; Alexander, H; Santini, C; Ferrari, G; Sinigaglia, L; Seiler, M; Neeb, M; Mous, J; Sinigaglia, F; Certa, U				Rogge, L; Bianchi, E; Biffi, M; Bono, E; Chang, SYP; Alexander, H; Santini, C; Ferrari, G; Sinigaglia, L; Seiler, M; Neeb, M; Mous, J; Sinigaglia, F; Certa, U			Transcript imaging of the development of human T helper cells using oligonucleotide arrays	NATURE GENETICS			English	Article							REGULATORY FACTOR-I; SELECTIVE EXPRESSION; IMMUNE-RESPONSES; P-SELECTIN; INTERLEUKIN-12; T-HELPER-1; CYTOKINE; RECEPTOR; TYPE-1; LYMPHOCYTES	Many pathological processes, including those causing allergies and autoimmune diseases, are associated with the presence of specialized subsets of T helper cells at the site of inflammation(1) Understanding the genetic program that controls the functional properties of T helper type 1 (Th1) versus T helper type 2 (Th2) cells may provide insight into the pathophysiology of inflammatory diseases. We compared the gene-expression profiles of human Th1 and Th2 cells using high-density oligonucleotide arrays with the capacity to display transcript levels of 6,000 human genes'. Here we analyse the data sets derived from five independent experiments using statistical algorithms. This approach resulted in the identification of 215 differentially expressed genes, encoding proteins involved in transcriptional regulation, apoptosis, proteolysis, and cell adhesion and migration. A-subset of these genes was further upregulated by exposure of differentiated Th1 cells to interleukin-12 (IL-12), as confirmed by kinetic PCR analysis, indicating that IL-12 modulates the effector functions of Th1 cells in the absence of antigenic stimulation. Functional assays and in vivo expression of selected genes have validated the biological relevance of our study. Our results provide new insight into the transcriptional program controlling the functional diversity of subsets of T helper cells.	Roche Milano Ric, Milan, Italy; Ist Sci San Raffaele, DIBIT, Milan, Italy; Roche Mol Syst, Alameda, CA USA; TIGET HS Raffaele, Milan, Italy; Ist Ortoped Gaetano Pini, Chair Rheumatol, Milan, Italy; F Hoffmann La Roche & Co Ltd, PRPZB, CH-4002 Basel, Switzerland; F Hoffmann La Roche & Co Ltd, Roche Genet, CH-4002 Basel, Switzerland	Rogge, L (reprint author), Roche Milano Ric, Milan, Italy.				Telethon [TGT06S01]		Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Coccia EM, 1999, J BIOL CHEM, V274, P6698, DOI 10.1074/jbc.274.10.6698; Colantonio L, 1999, BLOOD, V94, P2981; Coligan J., 1991, CURRENT PROTOCOLS IM; Dolhain RJEM, 1996, ARTHRITIS RHEUM, V39, P1961, DOI 10.1002/art.1780391204; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; HIGUCHI R, 1999, PCR APPL PROTOCOLS F, P263, DOI 10.1016/B978-012372185-3/50017-1; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Rogge L, 1997, J EXP MED, V185, P825, DOI 10.1084/jem.185.5.825; Rogge L, 1998, J IMMUNOL, V161, P6567; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; SIMON AK, 1994, P NATL ACAD SCI USA, V91, P8562, DOI 10.1073/pnas.91.18.8562; Taki S, 1997, IMMUNITY, V6, P673, DOI 10.1016/S1074-7613(00)80443-4; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Verzeletti S, 1998, HUM GENE THER, V9, P2243, DOI 10.1089/hum.1998.9.15-2243; Xu DM, 1998, J EXP MED, V188, P1485, DOI 10.1084/jem.188.8.1485; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	29	179	187	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1061-4036			NAT GENET	Nature Genet.	MAY	2000	25	1					96	101		10.1038/75671		6	Genetics & Heredity	Genetics & Heredity	311KU	WOS:000086884000025	10802665	
J	Kouzaki, H; Iijima, K; Kobayashi, T; O'Grady, SM; Kita, H				Kouzaki, Hideaki; Iijima, Koji; Kobayashi, Takao; O'Grady, Scott M.; Kita, Hirohito			The Danger Signal, Extracellular ATP, Is a Sensor for an Airborne Allergen and Triggers IL-33 Release and Innate Th2-Type Responses	JOURNAL OF IMMUNOLOGY			English	Article							RECEPTOR ACCESSORY PROTEIN; MAST-CELLS; DENDRITIC CELLS; AIRWAY HYPERRESPONSIVENESS; INFLAMMATORY RESPONSE; ADAPTIVE IMMUNITY; TYPE-2 IMMUNITY; CYTOKINE IL-33; NK CELLS; IN-VIVO	The molecular mechanisms underlying the initiation of innate and adaptive proallergic Th2-type responses in the airways are not well understood. IL-33 is a new member of the IL-1 family of molecules that is implicated in Th2-type responses. Airway exposure of naive mice to a common environmental aeroallergen, the fungus Alternaria alternata, induces rapid release of IL-33 into the airway lumen, followed by innate Th2-type responses. Biologically active IL-33 is constitutively stored in the nuclei of human airway epithelial cells. Exposing these epithelial cells to A. alternata releases IL-33 extracellularly in vitro. Allergen exposure also induces acute extracellular accumulation of a danger signal, ATP; autocrine ATP sustains increases in intracellular Ca(2+) concentration and releases IL-33 through activation of P2 purinergic receptors. Pharmacological inhibitors of purinergic receptors or deficiency in the P2Y2 gene abrogate IL-33 release and Th2-type responses in the Alternaria-induced airway inflammation model in naive mice, emphasizing the essential roles for ATP and the P2Y2 receptor. Thus, ATP and purinergic signaling in the respiratory epithelium are critical sensors for airway exposure to airborne allergens, and they may provide novel opportunities to dampen the hypersensitivity response in Th2-type airway diseases such as asthma. The Journal of Immunology, 2011, 186: 4375-4387.	[Kita, Hirohito] Mayo Clin, Div Allerg Dis, Dept Immunol, Rochester, MN 55905 USA; [Kouzaki, Hideaki; Iijima, Koji; Kobayashi, Takao; Kita, Hirohito] Mayo Clin, Div Allerg Dis, Dept Internal Med, Rochester, MN 55905 USA; [Kouzaki, Hideaki] Shiga Univ Med Sci, Dept Otorhinolaryngol, Shiga 5250072, Japan; [O'Grady, Scott M.] Univ Minnesota, Dept Integrat Biol & Physiol, St Paul, MN 55108 USA; [O'Grady, Scott M.] Univ Minnesota, Dept Anim Sci, St Paul, MN 55108 USA	Kita, H (reprint author), Mayo Clin, Div Allerg Dis, Dept Immunol, 200 1st St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			National Institutes of Health [AI34486, AI49235, DK074010, HL095811]; Mayo Foundation	This work was supported in part by National Institutes of Health Grants AI34486 and AI49235 (to H.K.) and DK074010 and HL095811 (to S.M.O.), as well as by the Mayo Foundation.	Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Bodin P, 2001, NEUROCHEM RES, V26, P959, DOI 10.1023/A:1012388618693; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Bourgeois E, 2009, EUR J IMMUNOL, V39, P1046, DOI 10.1002/eji.200838575; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Burnstock G, 2006, PHARMACOL REV, V58, P58, DOI 10.1124/pr.58.1.5; Burnstock G, 2004, INT REV CYTOL, V240, P31, DOI 10.1016/S0074-7696(04)40002-3; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Chackerian AA, 2007, J IMMUNOL, V179, P2551; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Diehl S, 2002, J EXP MED, V196, P39, DOI 10.1084/jem.20020026; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Gudipaty L, 2003, AM J PHYSIOL-CELL PH, V285, pC286, DOI 10.1152/ajpcell.00070.2003; Ho LH, 2007, J LEUKOCYTE BIOL, V82, P1481, DOI 10.1189/jlb.0407200; Holt PG, 1999, NATURE, V402, pB12; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; James G, 2001, CELL CALCIUM, V30, P251, DOI 10.1054/ceca.2001.0232; Kim HY, 2010, NAT IMMUNOL, V11, P577, DOI 10.1038/ni.1892; Kobayashi T, 2003, J IMMUNOL, V170, P5756; Komai-Koma M, 2007, EUR J IMMUNOL, V37, P2779, DOI 10.1002/eji.200737547; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kreda SM, 2010, J PHYSIOL-LONDON, V588, P2255, DOI 10.1113/jphysiol.2009.186643; Kuchler AM, 2008, AM J PATHOL, V173, P1229, DOI 10.2353/ajpath.2008.080014; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; LAMBRECHT G, 1992, EUR J PHARMACOL, V217, P217, DOI 10.1016/0014-2999(92)90877-7; Lamkanfi M, 2009, IMMUNITY, V31, P5, DOI 10.1016/j.immuni.2009.06.011; Lazarowski ER, 2003, MOL PHARMACOL, V64, P785, DOI 10.1124/mol.64.4.785; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moulin D, 2007, CYTOKINE, V40, P216, DOI 10.1016/j.cyto.2007.09.013; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Myrtek D, 2007, PURINERG SIGNAL, V3, P5, DOI 10.1007/s11302-006-9032-0; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x; O'Neill LAJ, 2007, NAT REV IMMUNOL, V7, P353, DOI 10.1038/nri2079; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Piccini A, 2008, P NATL ACAD SCI USA, V105, P8067, DOI 10.1073/pnas.0709684105; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; PUTNEY JW, 1993, SCIENCE, V262, P676, DOI 10.1126/science.8235587; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rock KL, 2008, ANNU REV PATHOL-MECH, V3, P99, DOI 10.1146/annurev.pathol.3.121806.151456; Rock KL, 2010, ANNU REV IMMUNOL, V28, P321, DOI 10.1146/annurev-immunol-030409-101311; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Talabot-Ayer D, 2009, J BIOL CHEM, V284, P19420, DOI 10.1074/jbc.M901744200; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Yegutkin G, 2000, BRIT J PHARMACOL, V129, P921, DOI 10.1038/sj.bjp.0703136; Zhu P, 1998, BIOCHEM J, V330, P975	76	178	183	2	18	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	APR 1	2011	186	7					4375	4387		10.4049/jimmunol.1003020		13	Immunology	Immunology	739WH	WOS:000288751200065	21357533	
J	Wright, RJ; Mitchell, H; Visness, CM; Cohen, S; Stout, J; Evans, R; Gold, DR				Wright, RJ; Mitchell, H; Visness, CM; Cohen, S; Stout, J; Evans, R; Gold, DR			Community violence and asthma morbidity: The inner-city asthma study	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							POSTTRAUMATIC-STRESS-DISORDER; COCKROACH ALLERGEN; POLITICAL VIOLENCE; URBAN COMMUNITIES; AFRICAN-AMERICAN; LIFE EVENTS; CHILDREN; EXPOSURE; POPULATION; DISTRESS	Objectives. We examined the association between exposure to violence and asthma among urban children. Methods. We obtained reports from caretakers (n=851) of violence, negative life events, unwanted memories (rumination), caretaker-perceived stress, and caretaker behaviors (keeping children indoors, smoking, and medication adherence). Outcomes included caretaker-reported wheezing, sleep disruption, interference with play because of asthma, and effects on the caretaker (nights caretaker lost sleep because of child's asthma). Results. Increased exposure to violence predicted higher number of symptom days (P=.0008) and more nights that caretakers lost sleep (P=.02) in a graded fashion after control for socioeconomic status, housing deterioration, and negative life events. Control for stress and behaviors partially attenuated this gradient, although these variables had little effect on the association between the highest level of exposure to morbidity, which suggests there are other mechanisms. Conclusions. Mechanisms linking violence and asthma morbidity need to be further explored.	Beth Israel Deaconess Med Ctr, Div Pulm & Crit Care, Boston, MA USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA USA; Rho Inc, Fed Syst Div, Chapel Hill, NC USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; Northwestern Univ, Sch Med, Dept Pediat & Med, Chicago, IL USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Cambridge, MA 02138 USA	Wright, RJ (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	rosalind.wright@channing.harvard.edu		Cohen, Sheldon/0000-0003-2248-4600	NHLBI NIH HHS [K08 HL07427, T32 HL007427]; NIAID NIH HHS [AI-39900, AI-39761, AI-39769, AI-39776, AI-39785, AI-39789, AI-39901, AI-39902, U01 AI039761, U01 AI039769, U01 AI039776, U01 AI039902]		Acierno R, 1996, BEHAV MODIF, V20, P363, DOI 10.1177/01454455960204001; ATTAR BK, 1994, J CLIN CHILD PSYCHOL, V23, P391, DOI 10.1207/s15374424jccp2304_5; Augustyn M., 1995, CONT PEDIAT, V12, P35; BAUM A, 1990, HEALTH PSYCHOL, V9, P653, DOI 10.1037//0278-6133.9.6.653; BECKHAM JC, 1995, J TRAUMA STRESS, V8, P461, DOI 10.1007/BF02102970; BONEYMCCOY S, 1995, J CONSULT CLIN PSYCH, V63, P726, DOI 10.1037//0022-006X.63.5.726; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P216; Camargo CA, 1999, AM J RESP CRIT CARE, V159, pA150; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; COHEN S, 1988, CLAR SYMP, P31; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S., 1995, MEASURING STRESS GUI; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; FINKELHOR D, 1994, PEDIATRICS, V94, P413; FITZPATRICK KM, 1993, J AM ACAD CHILD PSY, V32, P424, DOI 10.1097/00004583-199303000-00026; FONG RL, 1995, J NATL MED ASSOC, V87, P203; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; Henderson S., 1981, NEUROSIS SOCIAL ENV; HERMAN AA, 1988, AM J PUBLIC HEALTH, V78, P767, DOI 10.2105/AJPH.78.7.767; ISAACS MR, 1992, VIOLENCE IMPACT COMM; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Kennedy BP, 1998, SOC SCI MED, V47, P7, DOI 10.1016/S0277-9536(98)00097-5; KESSLER RC, 1979, J HEALTH SOC BEHAV, V20, P259, DOI 10.2307/2136450; Kleinbaum D. G., 1998, APPL REGRESSION ANAL; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Lochner K, 1999, HEALTH PLACE, V5, P259, DOI 10.1016/S1353-8292(99)00016-7; Lyubomirsky S, 1999, J PERS SOC PSYCHOL, V77, P1041, DOI 10.1037/0022-3514.77.5.1041; Macintyre S, 2003, NEIGHBORHOODS HLTH, P20; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6_Supplement.426S; MARTINEZ P, 1993, PSYCHIATRY, V56, P22; MATTHEWS K A, 1988, Annals of Behavioral Medicine, V10, P71, DOI 10.1207/s15324796abm1002_5; MCLEOD JD, 1990, J HEALTH SOC BEHAV, V31, P162, DOI 10.2307/2137170; Nolen-Hoeksema S, 2000, J ABNORM PSYCHOL, V109, P504, DOI 10.1037/0021-843X.109.3.504; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323; ROBICSEK R, 1993, NC MED J, V54, P578; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RUTTER M, 1982, PEDIATRICS, V70, P883; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sampson R. J., 1992, FACTS FRAMEWORKS FOR, P63; SCHUBINER H, 1993, J ADOLESCENT HEALTH, V14, P214, DOI 10.1016/1054-139X(93)90008-D; Sheehan K, 1997, ARCH PEDIAT ADOL MED, V151, P502; Smith P, 2001, J CHILD PSYCHOL PSYC, V42, P395, DOI 10.1017/S0021963001007065; STEELE GP, 1980, PSYCHOL MED, V10, P301; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Thomson CC, 2002, ARCH PEDIAT ADOL MED, V156, P818; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; VALLEE M, 1997, J NEUROSCI, V17, P626; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Walters V, 1997, SOC SCI MED, V45, P1729, DOI 10.1016/S0277-9536(97)00105-6; Wilson W. J, 1987, TRULY DISADVANTAGED; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; WRIGHT RJ, 2001, ALLERGY, P203; Wright RJ, 2003, NEIGHBORHOODS HLTH, P233; ZAPATA BC, 1992, AM J PUBLIC HEALTH, V82, P685, DOI 10.2105/AJPH.82.5.685	59	178	183	1	5	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	APR	2004	94	4					625	632		10.2105/AJPH.94.4.625		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	807IC	WOS:000220494200028	15054016	
J	Chafen, JJS; Newberry, SJ; Riedl, MA; Bravata, DM; Maglione, M; Suttorp, MJ; Sundaram, V; Paige, NM; Towfigh, A; Hulley, BJ; Shekelle, PG				Chafen, Jennifer J. Schneider; Newberry, Sydne J.; Riedl, Marc A.; Bravata, Dena M.; Maglione, Margaret; Suttorp, Marika J.; Sundaram, Vandana; Paige, Neil M.; Towfigh, Ali; Hulley, Benjamin J.; Shekelle, Paul G.			Diagnosing and Managing Common Food Allergies A Systematic Review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							COWS MILK ALLERGY; PLACEBO-CONTROLLED TRIAL; HIGH-RISK INFANTS; ATOPY PATCH TEST; BREAST-FED INFANTS; RANDOMIZED CONTROLLED-TRIAL; BRIEF NEONATAL EXPOSURE; DOUBLE-BLIND TRIAL; SKIN-PRICK TESTS; 1ST 2 YEARS	Context There is heightened interest in food allergies but no clear consensus exists regarding the prevalence or most effective diagnostic and management approaches to food allergies. Objective To perform a systematic review of the available evidence on the prevalence, diagnosis, management, and prevention of food allergies. Data Sources Electronic searches of PubMed, Cochrane Database of Systematic Reviews, Cochrane Database of Abstracts of Reviews of Effects, and Cochrane Central Register of Controlled Trials. Searches were limited to English-language articles indexed between January 1988 and September 2009. Study Selection Diagnostic tests were included if they had a prospective, defined study population, used food challenge as a criterion standard, and reported sufficient data to calculate sensitivity and specificity. Systematic reviews and randomized controlled trials (RCTs) for management and prevention outcomes were also used. For foods where anaphylaxis is common, cohort studies with a sample size of more than 100 participants were included. Data Extraction Two investigators independently reviewed all titles and abstracts to identify potentially relevant articles and resolved discrepancies by repeated review and discussion. Quality of systematic reviews and meta-analyses was assessed using the AMSTAR criteria, the quality of diagnostic studies using the QUADAS criteria most relevant to food allergy, and the quality of RCTs using the Jadad criteria. Data Synthesis A total of 12 378 citations were identified and 72 citations were included. Food allergy affects more than 1% to 2% but less than 10% of the population. It is unclear if the prevalence of food allergies is increasing. Summary receiver operating characteristic curves comparing skin prick tests (area under the curve [AUC], 0.87; 95% confidence interval [CI], 0.81-0.93) and serum food-specific IgE (AUC, 0.84; 95% CI, 0.78-0.91) to food challenge showed no statistical superiority for either test. Elimination diets are the mainstay of therapy but have been rarely studied. Immunotherapy is promising but data are insufficient to recommend use. In high-risk infants, hydrolyzed formulas may prevent cow's milk allergy but standardized definitions of high risk and hydrolyzed formula do not exist. Conclusion The evidence for the prevalence and management of food allergy is greatly limited by a lack of uniformity for criteria for making a diagnosis. JAMA. 2010; 303(18): 1848-1856	[Chafen, Jennifer J. Schneider; Bravata, Dena M.; Sundaram, Vandana] Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, Stanford, CA 94305 USA; [Chafen, Jennifer J. Schneider; Sundaram, Vandana] VA Palo Alto Healthcare Syst, Palo Alto, CA USA; [Newberry, Sydne J.; Maglione, Margaret; Suttorp, Marika J.; Paige, Neil M.; Towfigh, Ali; Hulley, Benjamin J.; Shekelle, Paul G.] Rand Hlth, So Calif Evidence Based Practice Ctr, Santa Monica, CA USA; [Riedl, Marc A.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Paige, Neil M.; Towfigh, Ali; Shekelle, Paul G.] W Los Angeles VA Med Ctr, Los Angeles, CA USA	Chafen, JJS (reprint author), Stanford Univ, Sch Med, Ctr Primary Care & Outcomes Res, 117 Encina Commons, Stanford, CA 94305 USA.	jjschnei@stanford.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	National Institutes of Health [HHSN272200800065C]; National Institute of Allergy and Infectious Diseases	Funding/Support: This work was funded in part by contract HHSN272200800065C from the National Institutes of Health. This work was commissioned by National Institute of Allergy and Infectious Diseases in support of the development of practice guidelines.	Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; AGATA H, 1993, J ALLERGY CLIN IMMUN, V91, P668, DOI 10.1016/0091-6749(93)90273-I; Arslanoglu S, 2008, J NUTR, V138, P1091; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; BARDARE M, 1993, ANN ALLERGY, V71, P366; Ben-Shoshan M, 2009, J ALLERGY CLIN IMMUN, V123, P783, DOI 10.1016/j.jaci.2009.02.004; BINDSLEVJENSEN C, 1991, ALLERGY, V46, P610, DOI 10.1111/j.1398-9995.1991.tb00631.x; BIRD JA, 2010, ANN M AM AC ALL ASTH; Bollinger ME, 2006, ANN ALLERG ASTHMA IM, V96, P415; Branum AM, 2008, NCHS DATA BRIEF, P1; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P417, DOI 10.1016/0091-6749(88)90910-4; BURR ML, 1993, ARCH DIS CHILD, V68, P724; BUSINCO L, 1990, ALLERGOL IMMUNOPATH, V18, P339; Calvani Mauro, 2007, Pediatr Allergy Immunol, V18, P583; Canani RB, 2007, ALLERGY, V62, P738, DOI 10.1111/j.1398-9995.2007.01351.x; CANT AJ, 1986, BRIT MED J, V293, P231; CAVAGNI G, 1989, IMMUNOPHARM IMMUNOT, V11, P131; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; Cudowska B, 2005, Rocz Akad Med Bialymst, V50, P261; de Boissieu D, 2003, J PEDIATR-US, V142, P203, DOI 10.1067/mpd.2003.92; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; Dieguez MC, 2008, PEDIAT ALLERG IMM-UK, V19, P319, DOI 10.1111/j.1399-3038.2007.00652.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Estelle F, 2001, J ALLERGY CLIN IMMUN, V107, P703, DOI 10.1067/mai.2001.113866; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.01; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Garzi A, 2002, Allergol Immunopathol (Madr), V30, P36; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halmerbauer G, 2002, PEDIATR ALLERGY IMMU, V13, P47, DOI 10.1034/j.1399-3038.13.s.15.11.x; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Hill DJ, 2005, PEDIATRICS, V116, pE709, DOI 10.1542/peds.2005-0147; Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x; Iacono G, 1998, NEW ENGL J MED, V339, P1100, DOI 10.1056/NEJM199810153391602; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Jarvinen KM, 2003, CLIN EXP ALLERGY, V33, P1060, DOI 10.1046/j.1365-2222.2003.01741.x; Jirapinyo P, 2007, ASIA PAC J CLIN NUTR, V16, P711; Juvonen P, 1996, ACTA PAEDIATR, V85, P1047, DOI 10.1111/j.1651-2227.1996.tb14215.x; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; Keskin O, 2005, ANN ALLERG ASTHMA IM, V94, P553; Klemola T, 2002, J PEDIATR-US, V140, P219, DOI 10.1067/mpd.2002.121935; Koplin J, 2008, PEDIAT ALLERG IMM-UK, V19, P682, DOI 10.1111/j.1399-3038.2008.00731.x; Kramer MS, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD000133.PUB2; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Kvenshagen B, 2008, ACTA PAEDIATR, V97, P196, DOI 10.1111/j.1651-2227.2007.00599.x; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lijmer JG, 1999, JAMA-J AM MED ASSOC, V282, P1061, DOI 10.1001/jama.282.11.1061; LILJA G, 1991, CLIN EXP ALLERGY, V21, P195, DOI 10.1111/j.1365-2222.1991.tb00830.x; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408; LIU H, 2009, ANN M AM AC ALL ASTH; LOVEGROVE JA, 1994, BRIT J NUTR, V71, P223, DOI 10.1079/BJN19940129; Marini A, 1996, Acta Paediatr Suppl, V414, P1; Mehl A, 2006, J ALLERGY CLIN IMMUN, V118, P923, DOI 10.1016/j.jaci.2006.07.003; Monti G, 2002, CLIN EXP ALLERGY, V32, P1515, DOI 10.1046/j.1365-2745.2002.01454.x; Morisset M, 2007, Eur Ann Allergy Clin Immunol, V39, P12; MUDD KE, 2010, ANN M AM AC ALL ASTH; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nentwich I, 2001, ALLERGY, V56, P1144, DOI 10.1111/j.1398-9995.2001x.00926.x; Niggemann B, 2008, PEDIAT ALLERG IMM-UK, V19, P348, DOI 10.1111/j.1399-3038.2007.00653.x; Odelram H, 1996, ALLERGY, V51, P192, DOI 10.1111/j.1398-9995.1996.tb04587.x; Osborn DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003741.pub4; Osborn DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003664.pub3; Osterballe M, 2004, J AM ACAD DERMATOL, V51, P556, DOI 10.1016/j.jaad.2004.03.025; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; PERRY TT, 2009, ANN M AM AC ALL ASTH; POYSA L, 1988, ACTA PAEDIATR SCAND, V77, P563, DOI 10.1111/j.1651-2227.1988.tb10701.x; POYSA L, 1991, ALLERGY PROC, V12, P107, DOI 10.2500/108854191779011800; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, ADV EXP MED BIOL, V478, P121; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; Salpietro C D, 2005, Minerva Pediatr, V57, P173; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Savino F, 2005, ACTA PAEDIATR, V94, P115, DOI 10.1080/08035320510043664; Schoetzau A, 2002, PEDIATR ALLERGY IMMU, V13, P234, DOI 10.1034/j.1399-3038.2002.01050.x; Shea BJ, 2007, BMC MED RES METHODOL, V7, DOI 10.1186/1471-2288-7-10; SHEKELLE P, FOOD ALLERGY EVIDENC; SIGURS N, 1992, PEDIATRICS, V89, P735; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Szajewska H, 2007, J PEDIATR GASTR NUTR, V45, P247, DOI 10.1097/MPG.0b013e31804c505b; Szajewska H, 2004, ACTA PAEDIATR, V93, P1159, DOI 10.1080/08035250410026554; TAINIO VM, 1990, ALLERGY, V45, P189, DOI 10.1111/j.1398-9995.1990.tb00482.x; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Vita D, 2007, PEDIATR ALLERGY IMMU, V18, P594, DOI 10.1111/j.1399-3038.2007.00567.x; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Wainstein BK, 2007, PEDIATR ALLERGY IMMU, V18, P231, DOI 10.1111/j.1399-3038.2006.00517.x; Wananukul S, 2005, ASIAN PAC J ALLERGY, V23, P175; Whiting Penny, 2003, BMC Med Res Methodol, V3, P25, DOI 10.1186/1471-2288-3-25; WILLEMS R, 1993, ANN ALLERGY, V71, P147; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	113	177	185	10	45	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAY 12	2010	303	18					1848	1856		10.1001/jama.2010.582		9	Medicine, General & Internal	General & Internal Medicine	594DK	WOS:000277513900026	20460624	
J	Radauer, C; Bublin, M; Wagner, S; Mari, A; Breiteneder, H				Radauer, Christian; Bublin, Merima; Wagner, Stefan; Mari, Adriano; Breiteneder, Heimo			Allergens are distributed into few protein families and possess a restricted number of biochemical functions	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; protein families; allergen structures; allergen databases	PLANT FOOD ALLERGENS; STRUCTURAL BIOLOGY; CROSS-REACTIVITY; POLLEN ALLERGENS; SEQUENCE; HOMOLOGS; TOOLS	Background: Existing allergen databases classify their entries by source and route of exposure, thus lacking an evolutionary, structural, and functional classification of allergens. Objective: We sought to build AllFam, a database of allergen families, and use it to extract common structural and functional properties of allergens. Methods: Allergen data from the Allergome database and protein family definitions from the Pfam database were merged into AllFam, a database that is freely accessible on the Internet at: http://www.meduniwien.ac.at/allergens/allfam/. A structural classification of allergens was established by matching Pfam families with families from the Structural Classification of Proteins database. Biochemical functions of allergens were extracted from the Gene Ontology Annotation database. Results: Seven hundred seven allergens were classified by sequence into 134 AllFam families containing 184 Pfam domains (2% of 9318 Pfam families). A random set of 707 sequences with the same taxonomic distribution contained a significantly higher number of different Pfam domains (479 +/- 17). Classifying allergens by structure revealed that 5% of 3012 Structural Classification of Proteins families contained allergens. The biochemical functions of allergens most frequently found were limited to hydrolysis of proteins, polysaccharides, and lipids; binding of metal ions and lipids; storage; and cytoskeleton association. Conclusion: The small number of protein families that contain allergens and the narrow functional distribution of most allergens confirm the existence of yet unknown factors that render proteins allergenic.	[Radauer, Christian; Bublin, Merima; Wagner, Stefan; Breiteneder, Heimo] Med Univ Vienna, Dept Pathophysiol, Ctr Physiol Pathophysiol & Immunol, A-1090 Vienna, Austria; [Mari, Adriano] IDI IRCCS, Ctr Clin & Expt Allergol, Rome, Italy; [Mari, Adriano] Allergy Data Labs, Latina, Italy	Breiteneder, H (reprint author), Med Univ Vienna, Dept Pathophysiol, Ctr Physiol Pathophysiol & Immunol, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	Heimo.Breiteneder@meduniwien.ac.at	Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335; Radauer, Christian/0000-0001-9920-4449			Aalberse RC, 2006, CHEM IMMUNOL ALLERGY, V91, P134; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; Breiteneder H, 2005, J ALLERGY CLIN IMMUN, V115, P14, DOI 10.1016/j.jaci.2004.10.022; Breiteneder H, 2004, J ALLERGY CLIN IMMUN, V113, P821, DOI 10.1016/j.jaci.2004.01.079; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; de Leon MP, 2007, MOL IMMUNOL, V44, P463, DOI 10.1016/j.molimm.2006.02.016; Emanuelsson C, 2007, MOL IMMUNOL, V44, P3256, DOI 10.1016/j.molimm.2007.01.019; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Jenkins JA, 2007, J ALLERGY CLIN IMMUN, V120, P1399, DOI 10.1016/j.jaci.2007.08.019; Jeong KY, 2006, PROTEIN PEPTIDE LETT, V13, P835; Keber MM, 2005, J ENDOTOXIN RES, V11, P186, DOI 10.1179/096805105X35206; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Mari A, 2006, CELL IMMUNOL, V244, P97, DOI 10.1016/j.cellimm.2007.02.012; Marin-Rodriguez MC, 2002, J EXP BOT, V53, P2115, DOI 10.1093/jxb/erf089; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Menu-Bouaouiche L, 2003, BIOCHIMIE, V85, P123, DOI 10.1016/S0300-9084(03)00058-0; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Radauer C, 2006, CLIN EXP ALLERGY, V36, P920, DOI 10.1111/j.1365-2222.2006.02521.x; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Radauer C, 2007, J ALLERGY CLIN IMMUN, V120, P518, DOI 10.1016/j.jaci.2007.07.024; Robotham JM, 2005, J ALLERGY CLIN IMMUN, V115, P1284, DOI 10.1016/j.jaco.2005.02.028; Stadler MB, 2003, FASEB J, V17, P1141, DOI 10.1096/fj.02-1052fje; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844	29	177	182	1	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					847	852		10.1016/j.jaci.2008.01.025		6	Allergy; Immunology	Allergy; Immunology	286YY	WOS:000254884000006	18395549	
J	Weinmayr, G; Weiland, SK; Bjorksten, B; Brunekreef, B; Buchele, G; Cookson, WOC; Garcia-Marcos, L; Gotua, M; Gratziou, C; van Hage, M; von Mutius, E; Riikjarv, MA; Rzehak, P; Stein, RT; Strachan, DP; Tsanakas, J; Wickens, K; Wong, GW				Weinmayr, Gudrun; Weiland, Stephan K.; Bjorksten, Bengt; Brunekreef, Bert; Buechele, Gisela; Cookson, William O. C.; Garcia-Marcos, Luis; Gotua, Maia; Gratziou, Christina; van Hage, Marianne; von Mutius, Erika; Riikjarv, Mall-Anne; Rzehak, Peter; Stein, Renato T.; Strachan, David P.; Tsanakas, John; Wickens, Kristin; Wong, Gary W.		ISAAC Phase Two Study Grp	Atopic sensitization and the international variation of asthma symptom prevalence in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						wheeze; ISAAC Phase Two; IgE; population attributable risk; gross national income per capita	CHILDHOOD ISAAC; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; ESTONIAN CHILDREN; ALLERGEN EXPOSURE; DIFFERENT PATTERN; SCHOOL-CHILDREN; SEMIRURAL AREA; RISK-FACTORS; WHEEZE	Rationale: Atopic sensitization has long been known to be related to asthma in children, but its role in determining asthma prevalence remains to be elucidated further. Objectives: To Investigate the role of atopic sensitization in the large international variation in the prevalence of childhood asthma. Methods: Cross-sectional studies of random samples of 8- to 12-yearold children (n = 1,000 per center) were performed according to the standardized methodology of Phase Two of the International Study of Asthma and Allergy in Childhood (ISAAC). Thirty study centers in 22 countries worldwide participated and reflect a wide range of living conditions, from rural Africa to urban Europe. Data were collected by parental questionnaires (n = 54,439), skin prick tests (n = 311,759), and measurements of allergen-specific IgE levels in serum (n = 8,951). Economic development was assessed by gross national income per capita (GNI). Measurements and Main Results: The prevalence of current wheeze (i.e., during the past year) ranged from 0.8% in Pichincha (Ecuador) to 25.6% in Uruguaiana (Brazil). The fraction of current wheeze attributable to atopic sensitization ranged from 0% in Ankara (Turkey) to 93.8% in Guangzhou (China). There were no correlations between prevalence rates of current wheeze and atopic sensitization, and only weak correlations of both with GNI. However, the fractions and prevalence rates of wheeze attributable to skin test reactivity correlated strongly with GNI (Spearman rank-order coefficient p = 0.50, P = 0.006, and p = 0.74, P < 0.0001, respectively). In addition, the strength of the association between current wheeze and skin test reactivity, assessed by odds ratios, increased with GNI (p = 0.47, P = 0.01). Conclusions: The link between atopic sensitization and asthma symptoms in children differs strongly between populations and increases with economic development.	Univ Ulm, Inst Epidemiol, D-89075 Ulm, Germany; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; Univ Murcia, Murcia, Spain; Ctr Allergy & Immunol, Tbilisi, Rep of Georgia; Univ Athens, Sch Med, Evgenidio Hosp, GR-11527 Athens, Greece; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Univ Munich, Childrens Hosp, Dr Von Haunerschen Univ, D-8000 Munich, Germany; Tallinn Childrens Hosp, Tallinn, Estonia; Pontificia Univ Catolica Rio Grande do Sul, Porto Alegre, RS, Brazil; St Georges Univ London, London, England; Hippokrateion Hosp, Paediat Resp Unit, Thessaloniki, Greece; Wellington Sch Med & Hlth Sci, Wellington Asthma Res Grp, Wellington, New Zealand; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, Hong Kong, Peoples R China	Weinmayr, G (reprint author), Univ Ulm, Inst Epidemiol, Helmholzstr 22, D-89075 Ulm, Germany.	gudrun.weinmayr@uni-ulm.de	van Hage, Marianne/A-9678-2017; Hatziagorou, Elpis/D-3247-2012; MARTINEZ-GIMENO, ANTONIO/A-9416-2010; Stein, Renato/K-2568-2014; Ellwood, Philippa/G-7555-2015; De sario, Manuela/K-1932-2016; Forastiere, Francesco/J-9067-2016	van Hage, Marianne/0000-0003-3091-1596; Pearce, Neil/0000-0002-9938-7852; brunekreef, bert/0000-0001-9908-0060; Braback, Lennart/0000-0001-9930-7755; MARTINEZ-GIMENO, ANTONIO/0000-0003-4051-1860; Ellwood, Philippa/0000-0002-1994-4023; De sario, Manuela/0000-0002-1117-2735; Forastiere, Francesco/0000-0002-9162-5684; Beasley, Richard/0000-0003-0337-406X; von Mutius, Erika/0000-0002-8893-4515			Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Calvert J, 2005, J ALLERGY CLIN IMMUN, V116, P773, DOI 10.1016/j.jaci.2005.05.025; CHAMBLESS LE, 1985, COMMUN STAT-THEOR M, V14, P1377, DOI 10.1080/03610928508828982; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Court CS, 2002, THORAX, V57, P951, DOI 10.1136/thorax.57.11.951; Custovic A, 2004, THORAX, V59, P825, DOI 10.1136/thx.2004.027334; EDER W, 2006, NEW ENGL J MED, V355, P226; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Garcia-Marcos L, 2005, PEDIATR ALLERGY IMMU, V16, P471, DOI 10.1111/j.1399-3038.2005.00318.x; Julge K, 2001, CLIN EXP ALLERGY, V31, P1854, DOI 10.1046/j.1365-2222.2001.01235.x; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; Mackenney J, 2005, INT J TUBERC LUNG D, V9, P1288; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; Martinez FD, 2002, PEDIATRICS, V109, P362; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Pearce N, 1999, THORAX, V54, P268; Penny ME, 2001, THORAX, V56, P607, DOI 10.1136/thorax.56.8.607; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; PFEFFERMANN D, 1993, INT STAT REV, V61, P317, DOI 10.2307/1403631; Riikjarv MA, 1995, CLIN EXP ALLERGY, V25, P1198; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Saraclar Y, 2003, ANN ALLERG ASTHMA IM, V91, P477; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sepp E, 2005, CLIN EXP ALLERGY, V35, P1141, DOI 10.1111/j.1365-2222.2005.02315.x; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stewart AW, 2001, INT J EPIDEMIOL, V30, P173, DOI 10.1093/ije/30.1.173; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Voor T, 2005, CLIN EXP ALLERGY, V35, P153, DOI 10.1111/j.1365-2222.2005.02157.x; WEILAND S, 2006, EUR RESP J S50, V28, pS835; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; WEINMAYR G, 2006, ALLERGO J, P1514; WEINMAYR G, 2004, EUR RESP J S48, V24, pS169; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Wong GWK, 2006, INT J TUBERC LUNG D, V10, P242; *WORLD BANK GROUP, 2006, WORLD BANK ATL METH; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	50	177	184	3	25	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 15	2007	176	6					565	574		10.1164/rccm.200607-994OC		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	213DK	WOS:000249646100006	17575099	
J	Gilmour, M; Jaakkola, MS; London, SJ; Nel, AE; Rogers, CA				Gilmour, M; Jaakkola, MS; London, SJ; Nel, AE; Rogers, CA			How exposure to environmental tobacco smoke, outdoor air pollutants, and increased pollen burdens influences the incidence of asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; cigarette smoke; climate change; diesel exhaust; environment; inflammation; mechanisms; ozone; particulate matter; pollen	EXHAUST PARTICLE CHEMICALS; LOWER RESPIRATORY ILLNESS; DIESEL EXHAUST; PARENTAL SMOKING; OXIDATIVE STRESS; ATMOSPHERIC CO2; ELEVATED CO2; CARBON-DIOXIDE; CLIMATE-CHANGE; HEALTH	Asthma is a multifactorial airway disease that arises from a relatively common genetic background interphased with exposures to allergens and airborne irritants. The rapid rise in asthma over the past three decades in Western societies has been attributed to numerous diverse factors, including increased awareness of the disease, altered lifestyle and activity patterns, and ill-defined changes in environmental exposures. It is well accepted that persons with asthma are more sensitive than persons without asthma to air pollutants such as cigarette smoke, traffic emissions, and photochemical smog components. It has also been demonstrated that exposure to a mix of allergens and irritants can at times promote the development phase (induction) of the disease. Experimental evidence suggests that complex organic molecules from diesel exhaust may act as allergic adjuvants through the production of oxidative stress in airway cells. It also seems that climate change is increasing the abundance of aeroallergens Such as pollen, which may result in greater incidence or severity of allergic diseases. In this review we illustrate how environmental tobacco smoke, outdoor air pollution, and climate change may act as environmental risk factors for the development of asthma and provide mechanistic explanations for how some of these effects can occur.	US EPA, Res Triangle Pk, NC 27711 USA; Univ Birmingham, Inst Occupat & Environm Med, Birmingham, AL USA; NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90024 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Gilmour, M (reprint author), US EPA, Res Triangle Pk, NC 27711 USA.	gilmour.ian@epa.gov	Rogers, Christine/A-2189-2008; Nel, Andre/J-2808-2012; Osborne, Nicholas/N-4915-2015	Rogers, Christine/0000-0003-0887-9606; Osborne, Nicholas/0000-0002-6700-2284; London, Stephanie/0000-0003-4911-5290			AAAAI, 2000, ALL REP; ABBEY DE, 1995, ARCH ENVIRON HEALTH, V50, P139; ALSBERG T, 1985, ENVIRON SCI TECHNOL, V19, P43, DOI 10.1021/es00131a003; BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123; Bornehag CG, 2001, INDOOR AIR, V11, P72; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; California Environmental Protection Agency (Cal EPA) Office of Environmental Health Hazard Assessment, 1997, HLTH EFF EXP ENV TOB; CDC (Centers for Disease Control), 2004, MMWR-MORBID MORTAL W, V53, P145; Clot Bernard, 2003, Aerobiologia, V19, P227, DOI 10.1023/B:AERO.0000006572.53105.17; Cook DG, 1997, THORAX, V52, P1081; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; Diaz-Sanchez D, 2003, CURR ALLERGY ASTHM R, V3, P146, DOI 10.1007/s11882-003-0027-4; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Drake BG, 1997, ANNU REV PLANT PHYS, V48, P609, DOI 10.1146/annurev.arplant.48.1.609; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Frei T, 1998, GRANA, V37, P172; Frenguelli Giuseppe, 2002, Aerobiologia, V18, P223, DOI 10.1023/A:1021320128458; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; HEINRICH J, 2004, CURR OPIN ALLERGY CL, P341; Heloma A, 2003, ADDICTION, V98, P1111, DOI 10.1046/j.1360-0443.2003.00429.x; HISADA T, 2000, EUR J PHARMACOL, V399, P299; Hiura TS, 1999, J IMMUNOL, V163, P5582; IOM. The National Institute of Medicine, 2000, CLEAR AIR ASTHM IND; IOM (Institute of Medicine), 2004, DAMP IND SPAC HLTH; IPCC, 2001, 3 ASS REP; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; JAAKKOLA JJK, 2004, AM J PUBLIC HEALTH, V94, P134; JAAKKOLA JJK, 2000, EUR RESP MONOGR, V15, P322; Jaakkola MS, 1997, EUR RESPIR J, V10, P2384, DOI 10.1183/09031936.97.10102384; Jaakkola MS, 2003, AM J PUBLIC HEALTH, V93, P2055, DOI 10.2105/AJPH.93.12.2055; Jaakkola MS, 2002, SCAND J WORK ENV HEA, V28, P52; Jaakkola MS, 2004, ADV APPL MICROBIOL, V55, P309, DOI 10.1016/S0065-2164(04)55012-8; Jaakkola N, 2001, AM J PUBLIC HEALTH, V91, P284, DOI 10.2105/AJPH.91.2.284; JAAKKOLA N, 1994, SCAND J SOC MED, V22, P107; Jablonski LM, 2002, NEW PHYTOL, V156, P9, DOI 10.1046/j.1469-8137.2002.00494.x; Klironomos JN, 2005, NATURE, V433, P621, DOI 10.1038/nature03268; Klironomos JN, 1997, CAN J BOT, V75, P1670; LaDeau SL, 2001, SCIENCE, V292, P95, DOI 10.1126/science.1057547; Li N, 2004, J IMMUNOL, V173, P3467; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2000, J IMMUNOL, V165, P3393; LI N, 2003, CLIN IMMUNOL, V3, P250; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; MONKS TJ, 1992, TOXICOL APPL PHARM, V112, P2, DOI 10.1016/0041-008X(92)90273-U; *NCS, 2005, NAT CHILDR STUD HOM; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; NRC (National Research Council), 1998, RES PRIOR AIRB PART; Owen L, 1998, BRIT MED J, V317, P728; PEDEN DB, 2003, MIDDLETONS ALLERGY P, V1, P529; Penning TM, 1999, CHEM RES TOXICOL, V12, P1, DOI 10.1021/tx980143n; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; Rasmussen Alix, 2002, Aerobiologia, V18, P253, DOI 10.1023/A:1021321615254; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; ROGERS CA, 2006, ENV HLTH PERSPECT; SPIEKSMA FTM, 1995, GRANA, V34, P51; Stiling P, 2004, GLOBAL CHANGE BIOL, V10, P228, DOI 10.1111/j.1529-8817.2003.00728.x; Strachan DP, 1997, THORAX, V52, P905; Strachan DP, 1998, THORAX, V53, P204; Tarlo SA, 2003, ANN ALLERG ASTHMA IM, V90, P19; Treseder KK, 2003, ECOSYSTEMS, V6, P786, DOI 10.1007/s10021-003-0182-4; *US EPA, 2005, 6 PRINC POLL; Van Vliet AJH, 2002, INT J CLIMATOL, V22, P1757, DOI 10.1002/joc.820; Wang MY, 2005, ELECTROPHORESIS, V26, P2092, DOI 10.1002/elps.200410428; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; Wolf J, 2003, NEW PHYTOL, V157, P579, DOI 10.1046/j.1469-8137.2003.00696.x; Xia T, 2004, ENVIRON HEALTH PERSP, V112, P1347, DOI 10.1289/ehp.7167; Xiao Gary Guishan, 2005, Electrophoresis, V26, P280, DOI 10.1002/elps.200406145; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Ziska LH, 2003, J EXP BOT, V54, P395, DOI 10.1093/jxb/erg027; ZISKA LH, 2000, AUST J PLANT PHYSL, V27, P1	77	177	179	4	42	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2006	114	4					627	633		10.1289/ehp.8380		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	030QX	WOS:000236650500052	16581557	
J	Woodcock, A; Forster, L; Matthews, E; Martin, J; Letley, L; Vickers, M; Britton, J; Strachan, D; Howarth, P; Altmann, D; Frost, C; Custovic, A				Woodcock, A; Forster, L; Matthews, E; Martin, J; Letley, L; Vickers, M; Britton, J; Strachan, D; Howarth, P; Altmann, D; Frost, C; Custovic, A		Med Res Council Gen Practice Res	Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED STEROIDS; CONTROLLED TRIAL; OCCUPATIONAL ASTHMA; INDOOR ALLERGENS; AVOIDANCE; CHILDREN; ENCASEMENT; REDUCTION; MATTRESS	Background: The effectiveness of avoidance of house-dust-mite allergen (Dermatophagoides pteronyssinus 1 [Der p1]) in the management of asthma is uncertain. Methods: We conducted a double-blind, randomized, placebo-controlled study of allergen-impermeable bed covers involving 1122 adults with asthma. The primary outcomes were the mean morning peak expiratory flow rate over a four-week period during the run-in phase and at six months and the proportion of patients who discontinued inhaled corticosteroid therapy as part of a phased-reduction program during months 7 through 12. Der p1 was measured in mattress dust in a 10 percent random subsample of homes at entry and at 6 and 12 months. Results: The prevalence of sensitivity to dust-mite allergen was 65.4 percent in the group supplied with allergen-impermeable bed covers (active-intervention group) and 65.1 percent in the control group supplied with non-impermeable bed covers. The concentration of Der p1 in mattress dust was significantly lower in the active-intervention group at 6 months (geometric mean, 0.58 mug per gram vs. 1.71 mug per gram in the control group; P=0.01) but not at 12 months (1.05 mug per gram vs. 1.64 mug per gram; P=0.74). The mean morning peak expiratory flow rate improved significantly in both groups (from 410.7 to 419.1 liters per minute in the active-intervention group, P<0.001 for the change; and from 417.8 to 427.4 liters per minute in the control group, P<0.001 for the change). After adjustment for base-line differences (by analysis of covariance), there was no significant difference between the groups in the peak expiratory flow rate at six months (difference in means, active-intervention group vs. control group, -1.6 liters per minute [95 percent confidence interval, -5.9 to 2.7] among all patients [P=0.46] and -1.5 liters per minute [95 percent confidence interval, -6.9 to 3.9] among mite-sensitive patients [P=0.59]). There was no significant difference between the groups in the proportion in whom complete cessation of inhaled corticosteroid therapy was achieved (17.4 percent in the active-intervention group and 17.1 percent in the control group) or in the mean reduction in steroid dose, either among all patients or among mite-sensitive patients. Conclusions: Allergen-impermeable covers, as a single intervention for the avoidance of exposure to dust-mite allergen, seem clinically ineffective in adults with asthma.	Univ Manchester, NW Lung Ctr, Wythenshawe Hosp, S Manchester Acad Grp, Manchester M23 9LT, Lancs, England; MRC, Gen Practice Res Framework, London, England; Univ Nottingham, City Hosp, Div Epidemiol & Publ Hlth, Nottingham NG5 1PB, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; Univ Southampton, Gen Hosp, London, England; London Sch Hyg & Trop Med, Med Stat Unit, London WC1, England	Woodcock, A (reprint author), Univ Manchester, NW Lung Ctr, Wythenshawe Hosp, S Manchester Acad Grp, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578			BURR ML, 1976, LANCET, V1, P333; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2002, ANN ALLERG ASTHMA IM, V88, P432; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V108, P685, DOI 10.1067/mai.2001.119569; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Green R, 2002, BRIT MED J, V324, P1131; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Paganelli R, 1998, ALLERGY, V53, P763; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; Strachan DP, 1998, BRIT MED J, V317, P1096; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; WONG CS, 1993, CLIN EXP ALLERGY, V23, P370, DOI 10.1111/j.1365-2222.1993.tb00341.x	25	177	185	1	9	MASSACHUSETTS MEDICAL SOC/NEJM	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 17	2003	349	3					225	236		10.1056/NEJMoa023175		12	Medicine, General & Internal	General & Internal Medicine	701KA	WOS:000184165700006	12867606	
J	Perzanowski, MS; Ronmark, E; Platts-Mills, TAE; Lundback, B				Perzanowski, MS; Ronmark, E; Platts-Mills, TAE; Lundback, B			Effect of cat and dog ownership on sensitization and development of asthma among preteenage children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						allergy; asthma; cat; dog; tolerance	HOUSE-DUST MITE; INNER-CITY CHILDREN; COCKROACH ALLERGEN; NORTHERN SWEDEN; RISK-FACTORS; EXPOSURE; MORBIDITY; SCHOOLS; HOMES; IGE	An inverse relationship has been proposed between exposure to high quantities of cat allergen at home and both asthma and cat allergy. First- and second-grade children from Lule (a) over circle, Kiruna, and Pite (a) over circle, Sweden participated in an asthma questionnaire study (n = 3,431) and incidence was evaluated over the next 3 years. Skin testing was performed on the children in Lule (a) over circle and Kiruna (n = 2,149). The strongest risk factor for incident cases of asthma was Type 1 allergy (relative risk [RR], 4.9 [2.9-8.4]), followed by a family history of asthma (RR, 2.83 [1.8-4.5]). Living with a cat was inversely related both to having a positive skin test to cat (1111, 0.62 [0.47-0.83]) and incidence of physician-diagnosed asthma (1111, 0.49 [0.28-0.83]). This effect on incident asthma was most pronounced among the children with a family history of asthma (RR, 0.25 [0.08-0.80]). The evidence also suggests that many of the children exposed to cats at home can develop an immune response that does not include immunoglobulin E. Weaker protective trends were seen with dog ownership. The traditional thinking that not owning cats can provide protection against developing allergy and asthma among those with a family history of allergy needs to be re-evaluated. In a community where cat sensitization was strongly associated with asthma, owning a cat was protective against both prevalent and incident asthma.	Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Med, Charlottesville, VA 22908 USA; Sunderby Cent Hosp Norrbotten, Dept Med, OLIN Studies, Lulea, Sweden; Umea Univ, Dept Resp Med & Allergy, S-90187 Umea, Sweden; Karolinska Inst, Natl Inst Environm Med, Unit Lung & Allergy Res, S-10401 Stockholm, Sweden	Perzanowski, MS (reprint author), Univ Virginia, Hlth Sci Ctr, Asthma & Allerg Dis Ctr, Dept Med, POB 801355, Charlottesville, VA 22908 USA.				NIAID NIH HHS [R01 AI-20565, P01 AI50989]		Aalberse RC, 2000, AM J RESP CRIT CARE, V162, pS124; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; ANDERSON HR, 1992, THORAX, V47, P537, DOI 10.1136/thx.47.7.537; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Burney P, 1996, EUR RESPIR J, V9, P687; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Crater DD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e97; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1046/j.1365-2222.1996.d01-278.x; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Dotterud LK, 1997, CLIN EXP ALLERGY, V27, P252; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842; EVANS R, 1987, CHEST, V91, pS65; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; LAU S, 2000, LANCET, V356, P1368; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; OWNBY DR, 2001, AM J RESP CRIT CARE, V163, pA722; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1978, J IMMUNOL, V120, P1201; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SEARS MR, 1987, J ALLERGY CLIN IMMUN, V80, P383, DOI 10.1016/0091-6749(87)90055-8; SEARS MR, 2000, EUR RESP J S31, V16, pS555; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Woolcock AJ, 2001, MED J AUSTRALIA, V175, P141	36	177	183	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2002	166	5					696	702		10.1164/rccm.2201035		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	588ZZ	WOS:000177734100016	12204868	
J	Wright, RJ; Cohen, S; Carey, V; Weiss, ST; Gold, DR				Wright, RJ; Cohen, S; Carey, V; Weiss, ST; Gold, DR			Parental stress as a predictor of wheezing in infancy - A prospective birth-cohort study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						caregiver stress; wheeze; infancy; birth cohort	PSYCHOLOGICAL STRESS; BEHAVIORAL-RESPONSE; RESPIRATORY ILLNESS; ALLERGEN LEVELS; EARLY-CHILDHOOD; IMMUNE-SYSTEM; COMMON COLD; 1ST YEAR; ASTHMA; LIFE	The role of stress in the pathogenesis of childhood wheeze remains controversial. Caretaker stress might influence wheeze through stress-induced behavioral changes In caregivers (e.g., smoking, breast-feeding) or biologic processes impacting infant development (e.g., immune response, susceptibility to lower respiratory infections). The influence of caregiver stress on wheeze in infancy was studied in a genetically predisposed prospective birth-cohort (n = 496). Caregiver-perceived stress and wheeze in the children were ascertained bimonthly from the first 2 to 3 mo of life. Greater levels of caregiver-perceived stress at 2 to 3 mo was associated with increased risk of subsequent repeated wheeze among the children during the first 14 mo of life (RR, 1.6; 95% Cl, 1.3 to 1.9). Caregiver-perceived stress remained significant (RR, 1.4; 9S% Cl, 1.1 to 1.9) when controlling for factors potentially associated with both stress and wheeze (parental asthma, socioeconomic status, birth weight, and race/ethnicity) as well as mediators through which stress might influence wheeze (maternal smoking, breast-feeding, indoor allergen exposures, and lower respiratory infections). Furthermore, caregiver stress prospectively predicted wheeze In the infants, whereas wheeze In the children did not predict subsequent caregiver stress. The effect of caregiver stress on early childhood wheeze was independent of caregiver smoking and breast-feeding behaviors, as well as allergen exposure, birth weight, and lower respiratory Infections. These findings suggest a more direct mechanism may be operating between stress and wheeze In early childhood. Stress may contribute significantly to the population burden of preventable childhood respiratory illness.	Brigham & Womens Hosp, Channing Lab, Dept Med, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Dept Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Carnegie Mellon Univ, Dept Psychol, Pittsburgh, PA 15213 USA	Wright, RJ (reprint author), Brigham & Womens Hosp, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	rosalind.wright@channing.harvard.edu		Cohen, Sheldon/0000-0003-2248-4600	NHLBI NIH HHS [K08 HL 04187]; NIAID NIH HHS [R01 AI/EH S35786]		ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; Anisman H, 1998, INT J DEV NEUROSCI, V16, P149, DOI 10.1016/S0736-5748(98)00025-2; Boyce WT, 1995, PSYCHOSOM MED, V57, P411; BUSSE WE, 1994, AM J RESP CRIT CARE, V151, P249; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; CLOVER RD, 1989, J FAM PRACTICE, V28, P535; Coe CL, 1999, BIOL NEONATE, V76, P301, DOI 10.1159/000014172; Coe CL, 1996, BRAIN BEHAV IMMUN, V10, P221, DOI 10.1006/brbi.1996.0020; Cohen S, 1999, PSYCHOSOM MED, V61, P175; COHEN S, 1990, HEALTH PSYCHOL, V9, P466, DOI 10.1037/0278-6133.9.4.466; COHEN S, 1988, CLAR SYMP, P31; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 1998, HEALTH PSYCHOL, V17, P214, DOI 10.1037//0278-6133.17.3.214; Cohen S., 1989, ADV INVESTIGATION PS, P235; Cohen S, 1995, MEASURING STRESS GUI, P3; CRONBACH LJ, 1951, PSYCHOMETRIKA, V16, P297; Elenkov IJ, 1999, BEST PRACT RES CL EN, V13, P583, DOI 10.1053/beem.1999.0045; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Folkerts G, 1998, AM J RESP CRIT CARE, V157, P1708; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; GUSTAFSSON PA, 1994, J PEDIATR-US, V125, P493, DOI 10.1016/S0022-3476(05)83306-2; Holgate ST, 1997, CIBA F SYMP, V206, P5; Holt PG, 1997, CIBA F SYMP, V206, P35; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; Leserman J, 1998, PSYCHOSOM MED, V60, P175; LEWIS M, 1995, DEV PSYCHOBIOL, V28, P419, DOI 10.1002/dev.420280804; LEWIS M, 1995, CHILDREN FAMILIES ST, P35; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; Martin YC, 1998, PERSPECT DRUG DISCOV, V12, P3, DOI 10.1023/A:1017037831628; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1997, ASTHMA, P121; MATTHEWS K A, 1988, Annals of Behavioral Medicine, V10, P71, DOI 10.1207/s15324796abm1002_5; McEwen BS, 1998, NEW ENGL J MED, V338, P171; MCLEAN DE, 1993, AM J PREV MED, V9, P39; MINUCHIN S, 1975, ARCH GEN PSYCHIAT, V32, P1031; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; PATTERSON JM, 1995, CHILDREN FAMILIES ST, P11; PEARCE N, 1998, ASTHMA EPIDEMIOLOGY, P75; PRIEL B, 1999, J PEDIATR PSYCHOL, V15, P197; RAMSAY DS, 1994, CHILD DEV, V65, P1491, DOI 10.1111/j.1467-8624.1994.tb00831.x; Reyes TM, 1997, BRAIN RES, V769, P29, DOI 10.1016/S0006-8993(97)00687-2; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83; SILVERMAN M, 1995, CHILDHOOD ASTHMA OTH, P141; Sobrian SK, 1997, ENVIRON RES, V73, P227, DOI 10.1006/enrs.1997.3734; VALLEE M, 1997, J NEUROSCI, V17, P626; Warner JA, 1996, ALLERGY, V51, P447, DOI 10.1111/j.1398-9995.1996.tb04650.x; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; Wright RJ, 1998, THORAX, V53, P1066; WRIGHT RJ, 2000, ALLERGY, P203; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZUCKERMAN B, 1995, CHILDREN FAMILIES ST, P164	55	177	177	1	16	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 1	2002	165	3					358	365				8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	517PA	WOS:000173618100011	11818321	
J	Kinney, PL; Aggarwal, M; Northridge, ME; Janssen, NAH; Shepard, P				Kinney, PL; Aggarwal, M; Northridge, ME; Janssen, NAH; Shepard, P			Airborne concentrations of PM2.5 and diesel exhaust particles on Harlem sidewalks: A community-based pilot study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						diesel exhaust; Harlem; outdoor air pollution; PM2.5 urban	PARTICULATE AIR-POLLUTION; RESPIRATORY HOSPITAL ADMISSIONS; ELEMENTAL CARBON; EPITHELIAL-CELLS; ASTHMA; CHILDREN; MORTALITY; EXPOSURE; AEROSOL; HYDROCARBONS	Residents of the dense urban core neighborhoods of New York City (NYC) have expressed increasing concern about the potential human health impacts of diesel vehicle emissions. We measured concentrations of particulate matter less than or equal to 2.5 mu m in aerodynamic diameter (PM2.5) and diesel exhaust particles (DEP) on sidewalks in Harlem, NYC, and tested whether spatial variations in concentrations were related to local diesel traffic density. Eight-hour (1000-1800 hr) air samples for PM2.5 and elemental carbon (EC) were collected for 5 days in July 1996 on sidewalks adjacent to four geographically distinct Harlem intersections. Samples were taken using portable monitors worn by study staff. Simultaneous traffic counts for diesel trucks, buses, cars, and pedestrians were carried out at each intersection on greater than or equal to 2 of the 5 sampling days. Eight-hour diesel vehicle counts ranged from 61 to 2,467 across the four sires. Mean concentrations of PM2.5 exhibited only modest site-to-site variation (37-47 mu g/m(3)), reflecting the importance of broader regional sources of PM2.5. In contrast, EC concentrations varied 4-fold across sites (from 1.5 to 6 mu g/m(3)), and were associated with bus and truck counts on adjacent streets and, at one site, with the presence of a bus depot. A high correlation (r = 0.95) was observed between EC concentrations measured analytically and a blackness measurement based on PM2.5 filter reflectance, suggesting the utility of the tatter as a surrogate measure of DEP in future community-based studies. These results show that local diesel sources in Harlem create spatial variations in sidewalk concentrations of DEP. The study also demonstrates the feasibility of a new paradigm for community-based research involving full and active partnership between academic scientists and community-based organizations.	Columbia Univ, JL Mailman Sch Publ Hlth, Div Environm Hlth Sci, New York, NY 10032 USA; Harlem Ctr Hlth Promot & Dis Prevent, New York, NY USA; Wageningen Univ Agr, Dept Environm Sci, Environm & Occupat Hlth Grp, Wageningen, Netherlands; W Harlem Environm Act Inc, New York, NY USA	Kinney, PL (reprint author), Columbia Univ, JL Mailman Sch Publ Hlth, Div Environm Hlth Sci, 60 Haven Ave,Floor B 1, New York, NY 10032 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Bhatia R, 1998, EPIDEMIOLOGY, V9, P84, DOI 10.1097/00001648-199801000-00017; Birch ME, 1996, AEROSOL SCI TECH, V25, P221, DOI 10.1080/02786829608965393; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Burton RM, 1996, ENVIRON SCI TECHNOL, V30, P400, DOI 10.1021/es950030f; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CASS GR, 1995, DIESEL EXHAUST CRITI; CHOW JC, 1994, ATMOS ENVIRON, V28, P2061, DOI 10.1016/1352-2310(94)90474-X; DELUMYEA RG, 1980, ATMOS ENVIRON, V14, P647, DOI 10.1016/0004-6981(80)90047-5; DiazSanchez D, 1997, ALLERGY, V52, P52; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; GODLEE F, 1993, BRIT MED J, V303, P1539; GRAY HA, 1986, ENVIRON SCI TECHNOL, V20, P580, DOI 10.1021/es00148a006; Jacobs J., 1961, DEATH LIFE GREAT AM; KEELER GJ, 1990, ATMOS ENVIRON A-GEN, V24, P2795, DOI 10.1016/0960-1686(90)90166-K; Kobayashi T, 1997, FUND APPL TOXICOL, V38, P166, DOI 10.1006/faat.1997.2347; Nielsen T, 1996, ATMOS ENVIRON, V30, P3481, DOI 10.1016/1352-2310(96)00096-9; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; OSTRO BD, 1987, J ENVIRON ECON MANAG, V14, P87, DOI 10.1016/0095-0696(87)90008-8; PETERSON B, 1996, ANN ALLERG ASTHMA IM, V77, P262; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Suh HH, 1997, ENVIRON HEALTH PERSP, V105, P826, DOI 10.2307/3433700; Suzuki T, 1996, J CLIN LAB IMMUNOL, V48, P187; Terada N, 1997, INT ARCH ALLERGY IMM, V114, P167; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; ULRICH E, 1992, J AEROSOL SCI, V23, pS925; *US EPA, 1999, NAT AMB AIR QUAL STA; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; *WHO, 1996, ENV HLTH CRIT, V171; WJST M, 1993, BRIT MED J, V307, P596	36	177	180	1	38	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2000	108	3					213	218		10.2307/3454436		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	296NX	WOS:000086031400029	10706526	
J	Kudo, M; Melton, AC; Chen, C; Engler, MB; Huang, KE; Ren, X; Wang, YL; Bernstein, X; Li, JT; Atabai, K; Huang, XZ; Sheppard, D				Kudo, Makoto; Melton, Andrew C.; Chen, Chun; Engler, Mary B.; Huang, Katherine E.; Ren, Xin; Wang, Yanli; Bernstein, Xin; Li, John T.; Atabai, Kamran; Huang, Xiaozhu; Sheppard, Dean			IL-17A produced by alpha beta T cells drives airway hyper-responsiveness in mice and enhances mouse and human airway smooth muscle contraction	NATURE MEDICINE			English	Article							GROWTH-FACTOR-BETA; ROR-GAMMA-T; ALLERGIC-ASTHMA; GENE POLYMORPHISMS; T(H)17 CELLS; RHO-KINASE; RECEPTOR; INFLAMMATION; INTERLEUKIN-17; ASSOCIATION	Emerging evidence suggests that the T helper 17 (T(H)17) subset of alpha beta T cells contributes to the development of allergic asthma. In this study, we found that mice lacking the alpha v beta 8 integrin on dendritic cells did not generate T(H)17 cells in the lung and were protected from airway hyper-responsiveness in response to house dust mite and ovalbumin sensitization and challenge. Because loss of T(H)17 cells inhibited airway narrowing without any obvious effects on airway inflammation or epithelial morphology, we examined the direct effects of T(H)17 cytokines on mouse and human airway smooth muscle function. Interleukin-17A (IL-17A), but not IL-17F or IL-22, enhanced contractile force generation of airway smooth muscle through an IL-17 receptor A (IL-17RA)-IL-17RC, nuclear factor kappa light-chain enhancer of activated B cells (NF-kappa B)-ras homolog gene family, member A (RhoA)-Rho-associated coiled-coil containing protein kinase 2 (ROCK2) signaling cascade. Mice lacking integrin alpha v beta 8 on dendritic cells showed impaired activation of this pathway after ovalbumin sensitization and challenge, and the diminished contraction of the tracheal rings in these mice was reversed by IL-17A. These data indicate that the IL-17A produced by T(H)17 cells contributes to allergen-induced airway hyper-responsiveness through direct effects on airway smooth muscle.	[Kudo, Makoto; Melton, Andrew C.; Chen, Chun; Huang, Katherine E.; Ren, Xin; Wang, Yanli; Bernstein, Xin; Li, John T.; Atabai, Kamran; Huang, Xiaozhu; Sheppard, Dean] Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA; [Kudo, Makoto] Yokohama City Univ, Grad Sch Med, Dept Internal Med & Clin Immunol, Kanazawa Ku, Yokohama, Kanagawa 232, Japan; [Engler, Mary B.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA USA; [Li, John T.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA; [Atabai, Kamran] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Sheppard, D (reprint author), Univ Calif San Francisco, Dept Med, Lung Biol Ctr, San Francisco, CA 94143 USA.	dean.sheppard@ucsf.edu			US National Institutes of Health (NIH) [HL64353, HL53949, HL083950, AI024674, U19 AI077439]; NIH Ruth L. Kirschstein National Research Service [HL095314]; American Lung Association of California; University of California, San Francisco (UCSF) Strategic Asthma Basic Research Center	This work was supported by US National Institutes of Health (NIH) grants HL64353, HL53949, HL083950, AI024674 and U19 AI077439 (to D.S.), a NIH Ruth L. Kirschstein National Research Service Award HL095314 (to A.C.M.), an American Lung Association of California Research Training Fellowship Award (to A.C.M.) and funds from the University of California, San Francisco (UCSF) Strategic Asthma Basic Research Center. Deidentified human lung was kindly provided by M. Matthay (UCSF) and P. Wolters (UCSF). IL-17RC knockout mice were kindly provided by W. Ouyang (Genentech).	Alcorn JF, 2010, ANNU REV PHYSIOL, V72, P495, DOI 10.1146/annurev-physiol-021909-135926; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Atarashi K, 2008, NATURE, V455, P808, DOI 10.1038/nature07240; Bai Y, 2006, AM J PHYSIOL-LUNG C, V291, pL208, DOI 10.1152/ajplung.00494.2005; BARNES PJ, 1985, BRIT J PHARMACOL, V86, P685; BARNETT K, 1988, AM REV RESPIR DIS, V138, P780; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Blaho VA, 2009, J IMMUNOL, V183, P5644, DOI 10.4049/jimmunol.0901499; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Chen XY, 2009, PHARMACOLOGY, V83, P67, DOI 10.1159/000178814; Chiba Yoshihiko, 2004, Journal of Smooth Muscle Research, V40, P155, DOI 10.1540/jsmr.40.155; de Faria ICJ, 2008, J PEDIAT, V84, P203, DOI [10.2223/JPED.1783, 10.1590/S0021-75572008000300004]; Ely LK, 2009, NAT IMMUNOL, V10, P1245, DOI 10.1038/ni.1813; Finkelman FD, 2010, J IMMUNOL, V184, P1663, DOI 10.4049/jimmunol.0902185; Fossiez F, 1996, J EXP MED, V183, P2593, DOI 10.1084/jem.183.6.2593; Goto K, 2010, PHARMACOL RES, V61, P466, DOI 10.1016/j.phrs.2009.12.001; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Khromov A, 2009, J BIOL CHEM, V284, P21569, DOI 10.1074/jbc.M109.019729; Kolls JK, 2004, IMMUNITY, V21, P467, DOI 10.1016/j.immuni.2004.08.018; Korn T, 2007, NATURE, V448, P484, DOI 10.1038/nature05970; Lajoie S, 2010, NAT IMMUNOL, V11, P928, DOI 10.1038/ni.1926; Lin YY, 2009, IMMUNITY, V31, P799, DOI 10.1016/j.immuni.2009.08.025; Littman DR, 2010, CELL, V140, P845, DOI 10.1016/j.cell.2010.02.021; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Manel N, 2008, NAT IMMUNOL, V9, P641, DOI 10.1038/ni.1610; Mangan PR, 2006, NATURE, V441, P231, DOI 10.1038/nature04754; McKinley L, 2008, J IMMUNOL, V181, P4089; Melton AC, 2010, J CLIN INVEST, V120, P4436, DOI 10.1172/JCI43786; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Oda N, 2005, AM J RESP CRIT CARE, V171, P12, DOI 10.1164/rccm.200406-778OC; Ohama T, 2003, J BIOL CHEM, V278, P48794, DOI 10.1074/jbc.M310166200; Parris JRM, 1999, J PHYSIOL-LONDON, V518, P561, DOI 10.1111/j.1469-7793.1999.0561p.x; Patil SB, 2006, AM J PHYSIOL-GASTR L, V290, pG83, DOI 10.1152/ajpgi.00178.2005; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Settin A, 2008, INDIAN J PEDIATR, V75, P1019, DOI [10.1007/s12098-008-0161-z, 10.1007/S12098-008-0161-2]; Shimada H, 2010, J BIOL CHEM, V285, P12536, DOI 10.1074/jbc.M109.099630; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Somlyo AP, 2000, J PHYSIOL-LONDON, V522, P177, DOI 10.1111/j.1469-7793.2000.t01-2-00177.x; Sonder SU, 2011, J BIOL CHEM, V286, P12881, DOI 10.1074/jbc.M110.199547; Song CW, 2008, J IMMUNOL, V181, P6117; Souwer Y, 2010, CURR OPIN IMMUNOL, V22, P821, DOI 10.1016/j.coi.2010.10.013; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; Travis MA, 2007, NATURE, V449, P361, DOI 10.1038/nature06110; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Volpe E, 2008, NAT IMMUNOL, V9, P650, DOI 10.1038/ni.1613; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Yang XXO, 2007, J BIOL CHEM, V282, P9358, DOI 10.1074/jbc.C600321200; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Zeyrek D, 2008, ALLERGY ASTHMA PROC, V29, P468, DOI 10.2500/aap.2008.29.3154; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	55	176	186	3	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	APR	2012	18	4					547	554		10.1038/nm.2684		8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	923KI	WOS:000302617800031	22388091	
J	Bouzigon, E; Corda, E; Aschard, H; Dizier, MH; Boland, A; Bousquet, J; Chateigner, N; Gormand, F; Just, J; Le Moual, N; Scheinmann, P; Siroux, V; Vervloet, D; Zelenika, D; Pin, I; Kauffmann, F; Lathrop, M; Demenais, F				Bouzigon, Emmanuelle; Corda, Eve; Aschard, Hugues; Dizier, Marie-Helene; Boland, Anne; Bousquet, Jean; Chateigner, Nicolas; Gormand, Frederic; Just, Jocelyne; Le Moual, Nicole; Scheinmann, Pierre; Siroux, Valerie; Vervloet, Daniel; Zelenika, Diana; Pin, Isabelle; Kauffmann, Francine; Lathrop, Mark; Demenais, Florence			Effect of 17q21 Variants and Smoking Exposure in Early-Onset Asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; ORMDL3 EXPRESSION; CHILDRENS HEALTH; LUNG-FUNCTION; GENE; ASSOCIATION; LIFE; POLYMORPHISM	Background: A genomewide association study has shown an association between variants at chromosome 17q21 and an increased risk of asthma. To elucidate the relationship between this locus and disease, we examined a large, family-based data set that included extensive phenotypic and environmental data from the Epidemiological Study on the Genetics and Environment of Asthma. Methods: We tested 36 single-nucleotide polymorphisms (SNPs) in the 17q21 region in 1511 subjects from 372 families for an association with asthma. We also tested for genetic heterogeneity according to the age at the onset of asthma and exposure to environmental tobacco smoke in early life. Results: Eleven SNPs were significantly associated with asthma (P<0.01), of which three (rs8069176, rs2305480, and rs4795400) were strongly associated (P<0.001). Ordered-subset regression analysis led us to select an onset at 4 years of age or younger to classify patients as having early-onset asthma. Association with early-onset asthma was highly significant (P<10(-5) for four SNPs), whereas no association was found with late-onset asthma. With respect to exposure to environmental tobacco smoke in early life, we observed a significant association with early-onset asthma only in exposed subjects (P<5 x 10(-5) for six SNPs). Under the best-fitting recessive model, homozygous status (GG) at the most strongly associated SNP (rs8069176) conferred an increase in risk by a factor of 2.9, as compared with other genotypes (AG and AA) in the group exposed to environmental tobacco smoke (P=2.8 x 10(-6); P=0.006 for the test for heterogeneity of the SNP effect on early-onset asthma between groups with tobacco exposure and those without such exposure). Conclusions: This study shows that the increased risk of asthma conferred by 17q21 genetic variants is restricted to early-onset asthma and that the risk is further increased by early-life exposure to environmental tobacco smoke. These findings provide a greater understanding of the functional role of the 17q21 variants in the pathophysiology of asthma.	[Bouzigon, Emmanuelle; Corda, Eve; Aschard, Hugues; Chateigner, Nicolas; Lathrop, Mark; Demenais, Florence] Fdn Jean Dausset, CEPH, INSERM, U794, F-75010 Paris, France; [Bouzigon, Emmanuelle; Aschard, Hugues; Chateigner, Nicolas; Demenais, Florence] Univ Evry, Evry, France; [Dizier, Marie-Helene] INSERM, U535, Villejuif, France; [Dizier, Marie-Helene; Le Moual, Nicole; Kauffmann, Francine] Univ Paris 11, Villejuif, France; [Boland, Anne; Zelenika, Diana; Lathrop, Mark] Ctr Natl Genotypage, CEA, Inst Genom, Evry, France; [Bousquet, Jean] Hop Arnaud de Villeneuve, Montpellier, France; [Gormand, Frederic] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France; [Just, Jocelyne] Hop Enfants Armand Trousseau, Paris, France; [Le Moual, Nicole; Kauffmann, Francine] INSERM, U780, Villejuif, France; [Scheinmann, Pierre] Hop Necker Enfants Malad, Paris, France; [Siroux, Valerie; Pin, Isabelle] INSERM, U823, Grenoble, France; [Vervloet, Daniel] Hop St Marguerite, Marseille, France; [Pin, Isabelle] CHU Grenoble, F-38043 Grenoble, France	Demenais, F (reprint author), Fdn Jean Dausset, CEPH, INSERM, U794, 27 Rue Juliette Dodu, F-75010 Paris, France.	demenais@inserm.fr	PIN, Isabelle/N-3020-2013; Demenais, Florence/G-3298-2013; LeMoual, Nicole/R-8976-2016; siroux, valerie/N-1865-2013	Demenais, Florence/0000-0001-8361-0936; LeMoual, Nicole/0000-0002-2723-5569; 	INSERM; French Ministry of Higher Education and Research; University of Evry; French Agency for Environmental and Occupational Health Safety; Afsset-APR-SE-2004; French National Agency for Research [ANR 05-SEST-020-02/05-9-97, ANR 06-CEBS]; European Commission as part of the Global Allergy and Asthma European Network [FOOD-CT-2004-506378]; GABRIEL consortium; Glaxo SmithKline; Stallergenes; Allerbio; Astra Zeneca; UCB	Supported by INSERM, the French Ministry of Higher Education and Research, and the University of Evry and by grants from the French Agency for Environmental and Occupational Health Safety (Afsset-APR-SE-2004), the French National Agency for Research (ANR 05-SEST-020-02/05-9-97 and ANR 06-CEBS), and the European Commission as part of the Global Allergy and Asthma European Network (FOOD-CT-2004-506378) and the GABRIEL consortium (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community; HEALTH-LSH-2005-018996). Dr. Vervloet reports receiving lecture fees from Glaxo SmithKline, Stallergenes, and Allerbio and consulting fees from Astra Zeneca, GlaxoSmithKline, Allerbio, and UCB. No other potential conflict of interest relevant to this article was reported.	Barrett R, 2008, J MOTOR BEHAV, V40, P62, DOI 10.3200/JMBR.40.1.62-70; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Dizier MH, 2007, EUR J HUM GENET, V15, P810, DOI 10.1038/sj.ejhg.5201830; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Hashimoto Shu, 2008, Allergol Int, V57, P21, DOI 10.2332/allergolint.R-07-156; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; Hjelmqvist L, 2002, GENOME BIOL, V3; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Katoh M, 2003, INT J MOL MED, V12, P399; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Kurukulaaratchy RJ, 2003, CLIN EXP ALLERGY, V33, P573, DOI 10.1046/j.1365-2222.2003.01657.x; Li MY, 2006, AM J HUM GENET, V78, P778, DOI 10.1086/503711; Li MY, 2005, AM J HUM GENET, V76, P934, DOI 10.1086/430277; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; Madore AM, 2008, HUM GENET, V123, P93, DOI 10.1007/s00439-007-0444-x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Pattaro C, 2007, J CLIN EPIDEMIOL, V60, P704, DOI 10.1016/j.jclinepi.2006.10.010; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Schmitt C, 2002, APOPTOSIS, V7, P277, DOI 10.1023/A:1015372322419; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Siroux V, 2004, EUR J EPIDEMIOL, V19, P841; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Tamura M, 2007, GENOMICS, V89, P618, DOI 10.1016/j.ygeno.2007.01.003; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Toren K, 2006, J CLIN EPIDEMIOL, V59, P90, DOI 10.1016/j.jclinepi.2005.03.019; Wang JH, 1998, IMMUNITY, V9, P543, DOI 10.1016/S1074-7613(00)80637-8; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404; Wenzel SE, 2006, LANCET, V368, P804, DOI 10.1016/S0140-6736(06)69290-8; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	38	176	187	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 6	2008	359	19					1985	1994		10.1056/NEJMoa0806604		10	Medicine, General & Internal	General & Internal Medicine	368OW	WOS:000260632700003	18923164	
J	Holgate, ST				Holgate, Stephen T.			The sentinel role of the airway epithelium in asthma pathogenesis	IMMUNOLOGICAL REVIEWS			English	Review						asthma; epithelium; inflammation; remodeling; environmental injury; origins; progression; phenotypes	EPIDERMAL-GROWTH-FACTOR; THYMIC STROMAL LYMPHOPOIETIN; RETICULAR BASEMENT-MEMBRANE; GOBLET CELL HYPERPLASIA; CHEMOKINE RECEPTOR 4; BRONCHIAL-ASTHMA; DENDRITIC CELLS; INCREASED EXPRESSION; CHILDHOOD ASTHMA; TIGHT JUNCTIONS	The adoption of the concept that asthma is primarily a disease most frequently associated with elaboration of T-helper 2 (Th2)-type inflammation has led to the widely held concept that its origins, exacerbation, and persistence are allergen driven. Taking aside the asthma that is expressed in non-allergic individuals leaves the great proportion of asthma that is associated with allergy (or atopy) and that often has its onset in early childhood. Evidence is presented that asthma is primarily an epithelial disorder and that its origin as well as its clinical manifestations have more to do with altered epithelial physical and functional barrier properties than being purely linked to allergic pathways. In genetically susceptible individuals, impaired epithelial barrier function renders the airways vulnerable to early life virus infection, and this in turn provides the stimulus to prime immature dendritic cells toward directing a Th2 response and local allergen sensitization. Continued epithelial susceptibility to environmental insults such as viral, allergen, and pollutant exposure and impaired repair responses leads to asthma persistence and provides the mediator and growth factor microenvironment for persistence of inflammation and airway wall remodeling. Increased deposition of matrix in the epithelial lamina reticularis provides evidence for ongoing epithelial barrier dysfunction, while physical distortion of the epithelium consequent upon repeated bronchoconstriction provides additional stimuli for remodeling. This latter response initially serves a protective function but, if exaggerated, may lead to fixed airflow obstruction associated with more severe and chronic disease. Dual pathways in the origins, persistence, and progression of asthma help explain why anti-inflammatory treatments fail to influence the natural history of asthma in childhood and only partially does so in chronic severe disease. Positioning the airway epithelium as fundamental to the origins and persistence of asthma provides a rationale for pursuit of therapeutics that increase the resistance of the airways to environmental insults rather than concentrating all effort on suppressing inflammation.	[Holgate, Stephen T.] Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Immun, Southampton SO16 6YD, Hants, England; [Holgate, Stephen T.] Univ Southampton, Div Infect Inflammat & Immun, Sch Med, Southampton, Hants, England	Holgate, ST (reprint author), Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Immun, MP810,Level F,South Block, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk			MSD; Novartis	Stephen Holgate is an occasional paid consultant for Novartis, MSD, Almiral, Boehringer Ingelheim and Synairgen. He was a Founder of Synairgen and serves as a non-executive board member. He has also received honoraria for lectures supported by MSD and Novartis.	Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907; Antoniu SA, 2010, CURR OPIN MOL THER, V12, P770; Bai TR, 2005, CLIN SCI, V108, P463; Baraldo S, 2011, EUR RESPIR J, V38, P575, DOI 10.1183/09031936.00168210; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Batzer G, 2007, IMMUNOBIOLOGY, V212, P491, DOI 10.1016/j.imbio.2007.03.004; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Bertorelli G, 1998, CLIN EXP ALLERGY, V28, P551; Biswas SK, 2009, MOL ASPECTS MED, V30, P60, DOI 10.1016/j.mam.2008.07.001; Blanchard C, 2009, ADV IMMUNOL, V101, P81, DOI 10.1016/S0065-2776(08)01003-1; Boggaram V., 2003, FRONT BIOSCI, V8, P751; Bonner K, 2010, J ALLERGY CLIN IMMUN, V126, P1277, DOI 10.1016/j.jaci.2010.08.013; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Bousquet J, 2000, ALLERGY, V55, P1194, DOI 10.1034/j.1398-9995.2000.00923.x; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Broekema M, 2011, AM J RESP CRIT CARE, V183, P310, DOI 10.1164/rccm.201003-0494OC; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Cakebread JA, 2011, J ALLERGY CLIN IMMUN, V127, P1148, DOI 10.1016/j.jaci.2011.01.023; Chen G, 2010, J IMMUNOL, V184, P6133, DOI 10.4049/jimmunol.1000223; Chen G, 2009, J CLIN INVEST, V119, P2914, DOI 10.1172/JCI39731; Chen QS, 2005, J IMMUNOL, V174, P2305; Chetty A, 2004, PEDIATR PULM, V37, P128, DOI 10.1002/ppul.10415; Chokki M, 2006, LIFE SCI, V78, P3051, DOI 10.1016/j.lfs.2005.12.023; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Comhair SAA, 2010, ANTIOXID REDOX SIGN, V12, P93, DOI 10.1089/ARS.2008.2425; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Coward William R, 2010, Ther Adv Respir Dis, V4, P367, DOI 10.1177/1753465810379801; Crosby LM, 2010, AM J PHYSIOL-LUNG C, V298, pL715, DOI 10.1152/ajplung.00361.2009; Crystal Ronald G, 2008, Proc Am Thorac Soc, V5, P772, DOI 10.1513/pats.200805-041HR; Davies Donna E, 2009, Proc Am Thorac Soc, V6, P678, DOI 10.1513/pats.200907-067DP; de Blic J, 2007, J ALLERGY CLIN IMMUN, V119, P808, DOI 10.1016/j.jaci.2006.12.657; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI 10.1139/y08-004; De Luca G, 2010, J MATERN-FETAL NEO M, V23, P80, DOI 10.3109/14767058.2010.509931; De Silva D, 2006, J MED VIROL, V78, P666, DOI 10.1002/jmv.20591; Descalzi Desideria, 2007, Recent Pat Inflamm Allergy Drug Discov, V1, P237; Detoraki A, 2010, ALLERGY, V65, P946, DOI 10.1111/j.1398-9995.2010.02372.x; Doull IJM, 1997, BRIT MED J, V315, P858; Esnault S, 2002, ARCH IMMUNOL THER EX, V50, P121; Fahy JV, 2010, NEW ENGL J MED, V363, P2233, DOI 10.1056/NEJMra0910061; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Fitzpatrick AM, 2009, J ALLERGY CLIN IMMUN, V123, P146, DOI 10.1016/j.jaci.2008.10.047; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; FLOODPAGE PT, 2001, AM J RESP CRIT CARE, V67, P199; Foley SC, 2007, J ALLERGY CLIN IMMUN, V119, P863, DOI 10.1016/j.jaci.2006.12.665; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Freishtat RJ, 2011, AM J RESP CELL MOL, V44, P863, DOI 10.1165/rcmb.2010-0029OC; Furuse M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002907; Gelfand Erwin W, 2009, Proc Am Thorac Soc, V6, P278, DOI 10.1513/pats.200808-090RM; GRAINGE CL, 2011, N ENG J MED IN PRESS; Green FHY, 2010, THORAX, V65, P32, DOI 10.1136/thx.2008.111435; Greenberger PA, 2010, J ALLERGY CLIN IMMUN, V125, P305, DOI 10.1016/j.jaci.2009.11.038; Gupta S, 2009, CHEST, V136, P1521, DOI 10.1378/chest.09-0174; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hahn C, 2006, J ALLERGY CLIN IMMUN, V117, P787, DOI 10.1016/j.jaci.2005.12.1339; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565; Halwani R, 2010, CURR OPIN PHARMACOL, V10, P236, DOI 10.1016/j.coph.2010.06.004; Hamilton LM, 2005, EUR RESPIR J, V25, P978, DOI 10.1183/09031936.05.00098604; Han SW, 2006, ONCOGENE, V25, P4341, DOI 10.1038/sj.onc.1209460; He R, 2010, ANN NY ACAD SCI, V1183, P13, DOI 10.1111/j.1749-6632.2009.05128.x; Heijink IH, 2010, AM J RESP CELL MOL, V42, P69, DOI 10.1165/rcmb.2008-0449OC; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Holgate ST, 2010, DISCOV MED, V9, P439; Holgate Stephen T, 2009, Proc Am Thorac Soc, V6, P655, DOI 10.1513/pats.200907-072DP; Hoshino M, 1998, THORAX, V53, P21; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jartti T, 2010, PEDIAT ALLERG IMM-UK, V21, P1008, DOI 10.1111/j.1399-3038.2010.01059.x; Jeffery P, 2002, NOVART FDN SYMP, V248, P51; Jeffery P., 2002, NOVART FDN SYMP, V248, P68; Jeffery P., 2002, NOVART FDN SYMP, V248, P277; Kariyawasam HH, 2007, CURR OPIN IMMUNOL, V19, P681, DOI 10.1016/j.coi.21007.07.021; Kato A, 2007, J IMMUNOL, V179, P1080; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Kay AB, 2001, NEW ENGL J MED, V344, P109; Keeley Ellen C, 2011, Fibrogenesis Tissue Repair, V4, P2, DOI 10.1186/1755-1536-4-2; Kicic A, 2006, AM J RESP CRIT CARE, V174, P1110, DOI 10.1164/rccm.200603-392OC; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Kim JY, 2005, INFECT IMMUN, V73, P7107, DOI 10.1128/IAI.73.11.7107-7112-2005; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Kizkin O, 2002, INT ARCH OCC ENV HEA, V75, P441, DOI 10.1007/s00420-002-0326-4; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; KRAFT M, 1996, AM J RESP CRIT CARE, V1541, P505; Kuwano K, 2007, CELL MOL IMMUNOL, V4, P419; Lai H, 2010, J AEROSOL MED PULM D, V23, P219, DOI 10.1089/jamp.2009.0802; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Lambrecht BN, 2010, LANCET, V376, P835, DOI 10.1016/S0140-6736(10)61226-3; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JY, 2006, AM J RESP CRIT CARE, V173, P729, DOI 10.1164/rccm.2005409-1175OC; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Liu LY, 2002, J IMMUNOL, V169, P6459; Liu LY, 2002, J IMMUNOL, V169, P6452; MAEDA Y, 2011, J IMMUNOL IN PRESS; Makinde T, 2007, IMMUNOL CELL BIOL, V85, P348, DOI 10.1038/sj.icb.7100044; Malmstrom K, 2011, THORAX, V66, P157, DOI 10.1136/thx.2010.139246; Mapp Cristina E, 2005, Acta Biomed, V76 Suppl 2, P15; Matsumoto M, 2011, REV MED VIROL, V21, P67, DOI 10.1002/rmv.680; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Michalik M, 2009, MED SCI MONITOR, V15, P194; Miller EK, 2010, IMMUNOL ALLERGY CLIN, V30, P541, DOI 10.1016/j.iac.2010.08.007; MISHIMA T, 2011, AM J PHYSIOL-HEART C, V300, P431; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Papadopoulos NG, 2011, ALLERGY, V66, P458, DOI 10.1111/j.1398-9995.2010.02505.x; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Park KS, 2007, J CLIN INVEST, V117, P978, DOI 10.1172/JCI29176; Pearce N, 1999, THORAX, V54, P268; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Perl AKT, 2011, AM J RESP CRIT CARE, V183, P511, DOI 10.1164/rccm.201005-0744OC; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Pini L, 2007, EUR RESPIR J, V29, P71, DOI 10.1183/09031936.00047905; Pohunek P, 2005, PEDIAT ALLERG IMM-UK, V16, P43, DOI 10.1111/j.1399-3038.2005.00239.x; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Puxeddu I, 2008, J ALLERGY CLIN IMMUN, V121, P1400, DOI 10.1016/j.jaci.2008.03.003; Rate A, 2009, J IMMUNOL, V182, P72; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Richter A, 2001, AM J RESP CELL MOL, V25, P385; ROCHE WR, 1989, LANCET, V1, P520; Rossmann MG, 2000, VIROLOGY, V269, P239, DOI 10.1006/viro.2000.0258; Rousseau K, 2007, ANN HUM GENET, V71, P561, DOI 10.1111/j.1469-1809.2007.00374.x; Sackesen C, 2008, J ALLERGY CLIN IMMUN, V122, P78, DOI 10.1016/j.jaci.2008.03.035; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Savla U, 2001, AM J PHYSIOL-LUNG C, V280, pL421; Schultz EN, 2010, J ASTHMA, V47, P1049, DOI [10.1080/02770903.2010.508856, 10.3109/02770903.2010.508856]; Sharma S, 2010, AM J RESP CRIT CARE, V181, P328, DOI 10.1164/rccm.200907-1009OC; Shaw TJ, 2004, EUR RESPIR J, V23, P813, DOI 10.1183/09031936.04.00119904; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Sly PD, 2010, J ALLERGY CLIN IMMUN, V125, P1202, DOI 10.1016/j.jaci.2010.01.024; Snyder JC, 2009, AM J RESP CELL MOL, V40, P633, DOI 10.1165/rcmb.2008-0334OC; Steed E, 2010, TRENDS CELL BIOL, V20, P142, DOI 10.1016/j.tcb.2009.12.002; Swartz MA, 2001, P NATL ACAD SCI USA, V98, P6180, DOI 10.1073/pnas.111133298; Swindle EJ, 2009, J ALLERGY CLIN IMMUN, V124, P23, DOI 10.1016/j.jaci.2009.05.037; Takai T, 2011, INT ARCH ALLERGY IMM, V154, P3, DOI 10.1159/000319202; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Tanjore H, 2009, AM J RESP CRIT CARE, V180, P657, DOI 10.1164/rccm.200903-0322OC; Thai P, 2005, AM J RESP CELL MOL, V33, P523, DOI 10.1165/rcmb.2004-0220RC; Thompson HGR, 2006, AM J PHYSIOL-LUNG C, V291, pL1277, DOI 10.1152/ajplung.00057.2006; Truong-Tran AQ, 2003, BIOCHEM PHARMACOL, V66, P1459, DOI 10.1016/S0006-2952(03)00498-2; Tschumperlin DJ, 2002, AM J PHYSIOL-LUNG C, V282, pL904, DOI 10.1152/ajplung.00270.2001; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Uddin M, 2008, EUR RESPIR J, V31, P714, DOI 10.1183/09031936.00144307; Uddin M, 2010, THORAX, V65, P684, DOI 10.1136/thx.2009.120741; Vijayanand P, 2010, J IMMUNOL, V184, P4568, DOI 10.4049/jimmunol.0901342; Voynow JA, 2009, CHEST, V135, P505, DOI 10.1378/chest.08-0412; Walters EH, 2008, CURR OPIN ALLERGY CL, V8, P39, DOI 10.1097/ACI.0b013e3282f42696; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Ward C, 2005, J HEART LUNG TRANSPL, V24, P533, DOI 10.1016/j.healun.2004.02.018; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; Westergren-Thorsson G, 2010, CLIN RESPIR J, V4, P1, DOI 10.1111/j.1752-699X.2010.00190.x; Willart Monique A. M., 2010, Allergology International, V59, P95, DOI 10.2332/allergolint.09-RAI-0162; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261; Yang IA, 2009, POSTGRAD MED J, V85, P428, DOI 10.1136/thx.2007.079426; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; Zhang SL, 1999, LAB INVEST, V79, P395; ZIEGLER SF, 2010, NAT IMMUNOL, V1, P289; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	176	174	181	4	50	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-2896			IMMUNOL REV	Immunol. Rev.	JUL	2011	242				SI		205	219		10.1111/j.1600-065X.2011.01030.x		15	Immunology	Immunology	822AR	WOS:000295016200013	21682747	
J	Simpson, A; John, SL; Jury, F; Niven, R; Woodcock, A; Ollier, WER; Custovic, A				Simpson, Angela; John, Sally L.; Jury, Francine; Niven, Rob; Woodcock, Ashley; Ollier, William E. R.; Custovic, Adrian			Endotoxin exposure, CD14, and allergic disease - An interaction between genes and the environment	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						allergy; asthma; genetics	SERUM IMMUNOGLOBULIN-E; HOUSE-DUST; PROMOTER POLYMORPHISM; SOLUBLE CD14; MANCHESTER ASTHMA; RECEPTOR CD14; IGE LEVELS; EARLY-LIFE; HAY-FEVER; ATOPY	Rationale: High endotoxin exposure may reduce the risk of allergic sensitization. Objective: To determine the relationship between a promoter polymorphism in the CD14 gene (CD14/-159 C to T) and endotoxin exposure in relation to the development of allergic sensitization, eczema, and wheeze within the setting of a birth cohort. Methods: We genotyped 442 children (CD14/-159 C to T; rs2569190). We assessed children for allergic sensitization (IgE > 0.2 kU/L to at least one of seven allergens), eczema (physical examination), and parentally reported wheeze. Endotoxin was measured in house dust. Main Results: Genotype frequencies were consistent with other populations (TT, 25%; CT, 47%; CC, 28%). Sensitization (present in 33% of children) was not associated with genotype. For children with TT and CT genotypes, there was no association between endo toxin and sensitization (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.71-1.23; p = 0.7; and OR, 0.90; 95% CI, 0.77-1.04; p = 0.16, respectively) or endotoxin and eczema (OR, 0.99; 95% CI, 0.81-1.20; p = 0.89; and OR, 1.38; 95% CI, 0.83-2.30; p = 0.22, respectively). In children with the genotype CC, increasing endotoxin load was associated with a marked and significant reduction in the risk of sensitization (OR, 0.70; 95% CI, 0.55-0.89; p = 0.004) and eczema (OR, 0.73; 95% CI, 0.56-0.95; p = 0.02). However, we observed an increased risk of nonatopic wheeze with increasing endotoxin exposure in children with the CC genotype (OR, 1.42; 95% CI, 1.01-1.99; p = 0.04) but not other genotypes. No effect was seen for atopic wheeze. Conclusions: Increasing enclotoxin exposure is associated with reduced risk of allergic sensitization and eczema but with increased risk of nonatopic wheeze in children with the CC genotype at -159 of the CD14 gene. The impact of environmental enclotoxin may be enhanced in individuals with this genotype.	Wythenshawe Hosp, NW Lung Ctr, Acad Div Med & Surg S, Manchester M23 9LT, Lancs, England; Univ Manchester, Ctr Integrated Genom Med Res, Manchester, Lancs, England	Custovic, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Acad Div Med & Surg S, Manchester M23 9LT, Lancs, England.	adnan.custovic@manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Niven, Robert/0000-0003-2249-960X; Jury, Francine/0000-0003-0683-4041; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666			Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Baldini M, 2002, ALLERGY, V57, P188, DOI 10.1034/j.1398-9995.2002.1r152.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; BURR ML, 1993, ARCH DIS CHILD, V68, P724; Custovic A, 2002, PEDIATR ALLERGY IMMU, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Gao PS, 1999, CLIN GENET, V56, P164; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Heesen M, 2001, INTENS CARE MED, V27, P1770, DOI 10.1007/s001340101106; HEINZEL FP, 1994, INFECT IMMUN, V62, P4244; Hubacek JA, 1999, CIRCULATION, V99, P3218; Ito D, 2000, STROKE, V31, P2661; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2001, J IMMUNOL, V167, P5838; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P1056, DOI 10.1016/j.jaci.2005.02.006; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Manukyan M, 2005, EUR J IMMUNOL, V35, P911, DOI 10.1002/eji.200425336; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Sharma M, 2004, IMMUNOGENETICS, V56, P544, DOI 10.1007/s00251-004-0721-y; Simpson A, 2003, CLIN EXP ALLERGY, V33, P1183, DOI 10.1046/j.1365-2745.2003.01679.x; SIMPSON A, 2004, AM J HUM GENET S, V75, P24; SIMPSON A, 2005, J ALLERGY CLIN IMMUN, V115, pS61, DOI 10.1016/j.jaci.2004.12.257; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, THORAX S1, V55, pS2; Tavernier GOG, 2005, INDOOR AIR, V15, P25, DOI 10.1111/j.1600-0668.2005.00354.x; Topp R, 2003, CLIN EXP ALLERGY, V33, P1659, DOI 10.1111/j.1365-2222.2003.01807.x; Trinchieri Giorgio, 1992, Progress in Growth Factor Research, V4, P355, DOI 10.1016/0955-2235(92)90016-B; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Viriyakosol S, 2000, J BIOL CHEM, V275, P3144, DOI 10.1074/jbc.275.5.3144; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Williams HC, 1996, BRIT J DERMATOL, V135, P12; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	50	174	175	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2006	174	4					386	392		10.1164/rccm.200509-1380OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	074FG	WOS:000239797500007	16614348	
J	Konig, A; Cockburn, A; Crevel, RWR; Debruyne, E; Grafstroem, R; Hammerling, U; Kimber, I; Knudsen, I; Kuiper, HA; Peijnenburg, AACM; Penninks, AH; Poulsen, M; Schauzu, M; Wal, JM				Konig, A; Cockburn, A; Crevel, RWR; Debruyne, E; Grafstroem, R; Hammerling, U; Kimber, I; Knudsen, I; Kuiper, HA; Peijnenburg, AACM; Penninks, AH; Poulsen, M; Schauzu, M; Wal, JM			Assessment of the safety of foods derived from genetically modified (GM) crops	FOOD AND CHEMICAL TOXICOLOGY			English	Article; Proceedings Paper	Conference of the European-Network-on-Safety-Assessment-of-Genetically-Modified-Food-Crops	MAY 29-30, 2003	Rome, ITALY	European Network Safety Assessment Genetically Modified Food Crops		food; plant biotechnology; genetic modification; genetic engineering; genetic manipulation; transgenic crops; novel foods; recombinant proteins; plant metabolism; regulation; safety assessment; risk analysis; molecular characterisation; toxicology; allergy; substantial equivalence; unintended effects; bioinformatics; in vitro test methods; in vivo test methods; animal testing; post market monitoring; estimated consumption; exposure assessment; compositional analysis; advanced analytical methods; profiling	SELECTABLE MARKER GENES; IN-VITRO TOXICOLOGY; BETA-LACTOGLOBULIN; RICE GENOME; INTRACHROMOSOMAL RECOMBINATION; POTENTIAL ALLERGENICITY; CONVENTIONAL COTTONSEED; SUBSTANTIAL EQUIVALENCE; PROTEIN ALLERGENICITY; CONSUMPTION SURVEYS	This paper provides guidance on how to assess the safety of foods derived from genetically modified crops (GM crops); it summarises conclusions and recommendations of Working Group I of the ENTRANSFOOD project. The paper provides an approach for adapting the test strategy to the characteristics of the modified crop and the introduced trait, and assessing potential unintended effects from the genetic modification. The proposed approach to safety assessment starts with the comparison of the new GM crop with a traditional counterpart that is generally accepted as safe based on a history of human food use (the concept of substantial equivalence). This case-focused approach ensures that foods derived from GM crops that have passed this extensive test-regime are as safe and nutritious as currently consumed plant-derived foods. The approach is suitable for current and future GM crops with more complex modifications. First, the paper reviews test methods developed for the risk assessment of chemicals, including food additives and pesticides, discussing which of these methods are suitable for the assessment of recombinant proteins and whole foods. Second, the paper presents a systematic approach to combine test methods for the safety assessment of foods derived from a specific GM crop. Third, the paper provides an overview on developments in this area that may prove of use in the safety assess-merit of GM crops, and recommendations for research priorities. It is concluded that the combination of existing test methods provides a sound test-regime to assess the safety of GM crops. Advances in our understanding of molecular biology, biochemistry, and nutrition may in future allow further improvement of test methods that will over time render the safety assessment of foods even more effective and informative. (C) 2004 Elsevier Ltd. All rights reserved.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02115 USA; Monsanto Serv Int, Sci Affairs, Agr Sector, B-1150 Brussels, Belgium; Unilever Res Colworth, SEAC Toxicol Dept, Sharnbrook MK44 1LQ, Beds, England; Bayer CropSci, Regulatory Toxicol Herbicides & Biotechnol, F-06903 Sophia Antipolis, France; Karolinska Inst, Inst Environm Med, SE-17177 Stockholm, Sweden; Swedish Natl Food Adm, SE-751 Uppsala, Sweden; Syngenta UK, Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England; Danish Vet & Food Adm, Inst Food Safety & Toxicol, DK-2860 Soborg, Denmark; Univ Wageningen & Res Ctr, Inst Food Safety, RIKILT, NL-6700 AE Wageningen, Netherlands; TNO, Nutr & Food Res, NL-3700 AJ Zeist, Netherlands; Fed Inst Risk Assessment, Ctr Novel Foods & Genet Engn, D-14195 Berlin, Germany; CEA Saclay, Serv Pharmacol & Immunol, Lab Associe INRA, CEA Immuno Allergie Alimentaire, F-91191 Gif Sur Yvette, France	Konig, A (reprint author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, 718 Huntington Ave, Boston, MA 02115 USA.	ariane_koenig@harvard.edu					Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Adel-Patient K, 2003, CLIN EXP ALLERGY, V33, P376, DOI 10.1046/j.1365-2222.2003.01613.x; Adel-Patient K, 2000, J IMMUNOL METHODS, V235, P21, DOI 10.1016/S0022-1759(99)00210-0; *ALLERGEST, 2003, QLK1CT200101239 ALLE; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Barlow SM, 2002, FOOD CHEM TOXICOL, V40, P145, DOI 10.1016/S0278-6915(01)00117-X; Barratt MD, 1998, ENVIRON HEALTH PERSP, V106, P459, DOI 10.2307/3433795; Bennetzen J, 2002, SCIENCE, V296, P60, DOI 10.1126/science.1071402; Berberich SA, 1996, J AGR FOOD CHEM, V44, P365, DOI 10.1021/jf950304i; Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; Brake J, 1998, POULTRY SCI, V77, P648; Bredehorst R, 2001, J CHROMATOGR B, V756, P33, DOI 10.1016/S0378-4347(01)00069-X; Bufe A, 1998, INT ARCH ALLERGY IMM, V117, P215, DOI 10.1159/000024013; CBAC (Canadian Biotechnology Advisory Committee), 2002, IMPR REG GEN MOD FOO; CELLINI F, 2004, FOOD CHEM TOXICOLOGY; *CFIA, 1998, D9613 CAN FOOD INSP; CHAN MT, 1992, PLANT CELL PHYSIOL, V33, P577; CHASSY BM, 2002, BIOTECHNOLOGY SAFETY; Clark J. H., 2001, Journal of Dairy Science, V84, pE9; Cockburn A, 2002, J BIOTECHNOL, V98, P79, DOI 10.1016/S0168-1656(02)00088-3; [Anonymous], 2003, JOINT FAO WHO FOOD S; *COMA, 1996, 47 COMA; Culver KW, 1999, NAT BIOTECHNOL, V17, P989, DOI 10.1038/13684; *DAFNE, 2003, DAFNE DAT FOOD NETW; DALE EC, 1991, P NATL ACAD SCI USA, V88, P10558, DOI 10.1073/pnas.88.23.10558; De Groot AS, 2002, IMMUNOL CELL BIOL, V80, P255, DOI 10.1046/j.1440-1711.2002.01092.x; Dearman RJ, 2001, TOXICOL LETT, V120, P181, DOI 10.1016/S0378-4274(01)00276-4; Dearman RJ, 2001, TOXICOLOGY, V167, P217, DOI 10.1016/S0300-483X(01)00462-0; DEFRAMOND AJ, 1986, MOL GEN GENET, V202, P125; DEPICKER A, 1985, MOL GEN GENET, V201, P477, DOI 10.1007/BF00331342; DUKE JA, 1977, CRC CR REV TOXICOL, V5, P189, DOI 10.3109/10408447709082600; Eisenbrand G, 2002, FOOD CHEM TOXICOL, V40, P193, DOI 10.1016/S0278-6915(01)00118-1; Ermel RW, 1997, LAB ANIM SCI, V47, P40; Eurostat, 2002, EUR YB 2002; European Commission, 1997, OFFICIAL J EUROPEA L, VL253, P1; *EUR COMM, 2003, SCI STEER COMM JOINT; European Commission, 2001, OFFICIAL J EUROPEA L, V106, P1; *EUR COMM, 2000, SCI STEER COMM HLTH; *EUR COMM, 2000, 1999 COM; European Commission, 2003, OFF J EUR UNION L, V268, P1; European Commission, 2003, OFF J EUR UNION L, V1268, P24; European Parliament and the Council, 1997, OFFICIAL J EUROPEA L, V43, P1; European Commission, 1990, OFFICIAL J EUROPEA L, V117, P15; European Communities, 2002, OFFICIAL J EUROPEA L, VL31, P1; *FAO, 2002, FAO FOOD BAL SHEET C; *FAO, 1995, REP FAO TECHN CONS; FAO/WHO, 2000, JOINT FAO WHO EXP CO; Food and Agriculture Organization/World Health Organisation, 1995, JOINT FAO WHO EXP CO; *FAO WHO, 1991, JOINT FAO WHO EXP CO; FAO/WHO, 1996, JOINT FAO WHO CONS R; FAO/WHO, 2001, JOINT FAO WHO EXP CO; *FAO WHO, 1997, JOINT FAO WHO CONS R; FAUST RM, 1974, J INVERTEBR PATHOL, V24, P365, DOI 10.1016/0022-2011(74)90145-1; FRITSCHE R, 1990, INT ARCH ALLER A IMM, V93, P289; *FSA, 2002, G01021 SURV POST MAR; *FSANZ, 2000, STAND 1 5 2 FOOD PRO; *FSANZ, 2001, A18 FSANZ; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Gelvin SB, 2000, ANNU REV PLANT PHYS, V51, P223, DOI 10.1146/annurev.arplant.51.1.223; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P45, DOI 10.1016/S1043-4526(08)60092-3; Gendel SM, 1998, ADV FOOD NUTR RES, V42, P63, DOI 10.1016/S1043-4526(08)60093-5; Goff SA, 2002, SCIENCE, V296, P92, DOI 10.1126/science.1068275; Gregory J, 2000, NATL DIET NUTR SURVE, VI; Gregory J, 1990, DIETARY NUTR SURVEY; HADDAD ZH, 1979, ANN ALLERGY, V42, P368; Hammond B, 1996, FOOD SAFETY EVALUATI, P85; HARBORNE JB, 1996, DICT PLANT TOXINS, V1; Hellens R, 2000, TRENDS PLANT SCI, V5, P446, DOI 10.1016/S1360-1385(00)01740-4; Helm RM, 2002, J ALLERGY CLIN IMMUN, V109, P136, DOI 10.1067/mai.2002.120551; Hileman RE, 2002, INT ARCH ALLERGY IMM, V128, P280, DOI 10.1159/000063861; Health Canada, 2000, NOV FOOD INF FOOD BI; *HLTH CAN, 1994, GUID SAF ASS NOV HLT, V1; Hoffmann A, 1997, J ALLERGY CLIN IMMUN, V99, P227, DOI 10.1016/S0091-6749(97)70101-5; Hollingworth RM, 2003, TOXICOL SCI, V71, P2; Huby RDJ, 2000, TOXICOL SCI, V55, P235, DOI 10.1093/toxsci/55.2.235; International Food Biotechnology Council (IFBC), 1990, REGUL TOXICOL PHARM, V12, pS1; *ILSI HESI, 2001, ALL ASS FOODS DER GE; *INFORMALL, 2003, QLRT200102284 INFORM; *INVITTOX, 2003, IN VITR TECHN TOX; Ireland J, 2002, EUR J CLIN NUTR, V56, pS33, DOI 10.1038/sj/ejcn/1601427; JAMES C, 2002, 27 ISAAA; James Ph., 1999, EUROPEAN FOOD PUBLIC; *JAP MAFF, 1995, GUID APPL REC DNA OR; *JAP MHLW, 2000, PROC APPL SAF ASS FO; Jasanoff S., 2000, J RISK RES, V3, P277, DOI 10.1080/13669870050043161; Jasanoff S., 1990, 5 BRANCH SCI ADV POL; Jonas DA, 1996, FOOD CHEM TOXICOL, V34, P931, DOI 10.1016/S0278-6915(96)00061-0; Kauppinen J, 1999, CLIN EXP ALLERGY, V29, P989; KESSLER DA, 1992, SCIENCE, V256, P1747, DOI 10.1126/science.1615315; KILBY NJ, 1995, PLANT J, V8, P637, DOI 10.1046/j.1365-313X.1995.08050637.x; Kimber I., 2001, Nutrition Bulletin, V26, P127, DOI 10.1046/j.1467-3010.2001.00125.x; Kimber I, 2002, TOXICOL SCI, V68, P4, DOI 10.1093/toxsci/68.1.4; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224; Kleter Gijs A, 2002, BMC Struct Biol, V2, P8, DOI 10.1186/1472-6807-2-8; Knippels LMJ, 1998, CLIN EXP ALLERGY, V28, P368, DOI 10.1046/j.1365-2222.1998.00242.x; Knoblauch M, 1999, NAT BIOTECHNOL, V17, P906, DOI 10.1038/12902; Konig A, 2003, NAT BIOTECHNOL, V21, P1274, DOI 10.1038/nbt1103-1274; KONIG A, 2000, P 6 INT S BIOS GEN M, P171; KOSCHATZKY K, 1994, TOXICOL LETT, V127, P43; Kuiper HA, 2001, PLANT J, V27, P503, DOI 10.1046/j.1365-313X.2001.01119.x; KUIPER HA, 2000, EVALUATING SUBSTANTI, P69; Majumdar A, 1998, NAT GENET, V20, P212, DOI 10.1038/2530; MARTINEAU B, 1994, PLANT CELL, V6, P1032; Maynard F, 1997, INT ARCH ALLERGY IMM, V113, P478; Metcalfe D. D., 1996, CRITICAL REV FOOD SC, V36S, P165; Miller HI, 1999, NAT BIOTECHNOL, V17, P1042, DOI 10.1038/14987; Millstone E, 1999, NATURE, V401, P525, DOI 10.1038/44006; NAS, 1987, INTR REC DNA ENG ORG; NCHS, 2001, NAT HLTH NUTR EX SUR; Nida DL, 1996, J AGR FOOD CHEM, V44, P1967, DOI 10.1021/jf950565s; Nordic Council of Ministers, 1998, SAF ASS NOV FOOD PLA; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Noteborn HPJM, 1995, ACS SYM SER, V605, P134; NRC National Research Council, 1994, SCI JUDG RISK ASS; *NRC, 1996, UND RISK INF DEC DEM; NRC, 2000, GEN MOD PEST PROT PL; *NRC, 1989, FIELD TEDST GEN MOD; *OECD, 1997, SER HARM REG OV BIOT, V8; OECD, 1996, FOOD SAF EV; [Anonymous], 2001, SER SAF NOV FOODS FE, P2; OECD, 2011, SER SAF NOV FOODS FE, V1; OECD, 2002, SER SAF NOV FOODS FE, V4; *OECD, 2002, SER SAF NOV FOODS FE, V3; *OECD, 1993, SAF EV FOODS DER MO; OECD, 1993, GUID TEST CHEM; [Anonymous], 2002, SER SAF NOV FOODS FE, P6; OECD, 1998, OECD WORKSH TOX NUTR; *OECD, 2002, SER SAF NOV FOODS FE, V5; *OECD, 1986, RECOMB DNA SAF CONS; OECD, 2003, BIOT REG DEV OECD ME; OECD, 2000, COMP NAT FOOD SAF SY; ONOUCHI H, 1991, NUCLEIC ACIDS RES, V19, P6373, DOI 10.1093/nar/19.23.6373; Padgette SR, 1996, J NUTR, V126, P702; PARIZA MW, 1983, J FOOD PROTECT, V46, P453; Pariza MW, 2001, REGUL TOXICOL PHARM, V33, P173, DOI 10.1006/rtph.2001.1466; PARIZA MW, 1996, PRESENT KNOWLEDGE NU, P563; Penninks AH, 2001, TOXICOL LETT, V120, P171, DOI 10.1016/S0378-4274(01)00275-2; PETERHANS A, 1990, EMBO J, V9, P3437; Pres./Congr. Comm. Risk Assess. Risk Manag, 1997, RISK ASS RISK MAN RE; Puchta H, 2000, TRENDS PLANT SCI, V5, P273, DOI 10.1016/S1360-1385(00)01684-8; Reiss B, 1996, P NATL ACAD SCI USA, V93, P3094, DOI 10.1073/pnas.93.7.3094; Rice MC, 2001, NAT BIOTECHNOL, V19, P321, DOI 10.1038/86701; Riechmann JL, 2000, SCIENCE, V290, P2105, DOI 10.1126/science.290.5499.2105; Rost B, 2001, J STRUCT BIOL, V134, P204, DOI 10.1006/jsbi.2000.4336; *ROY SOC, 1998, GEN MOD PLANTS FOODS; Royal Society, 2002, GEN MOD PLANTS FOOD; Royal Society of Canada, 2001, EL PREC REC REG FOOD; *SBC, 2001, GM FOOD CROPS APPL S; SCHAUZU M, 2000, 44 AGBIOTECHNET; SCHLOTKE F, 2000, EUROFOODS RECOMMENDA; Sidhu RS, 2000, J AGR FOOD CHEM, V48, P2305, DOI 10.1021/jf000172f; SIMANI N, 2002, EUROPEAN J CLIN NUTR, V56, pS63; Singh MB, 1999, INT ARCH ALLERGY IMM, V119, P75, DOI 10.1159/000024181; SJOBLAD RD, 1992, REGUL TOXICOL PHARM, V15, P3, DOI 10.1016/0273-2300(92)90078-N; Slimani N, 2000, EUR J CLIN NUTR, V54, P900, DOI 10.1038/sj.ejcn.1601107; Snow CD, 2002, NATURE, V420, P102, DOI 10.1038/nature01160; Spuergin P, 1996, ALLERGY, V51, P306, DOI 10.1111/j.1398-9995.1996.tb04614.x; Tait J., 2001, J RISK RES, V4, P175, DOI DOI 10.1080/13669870010027640; Taylor NB, 1999, J AGR FOOD CHEM, V47, P4469, DOI 10.1021/jf990056g; Taylor SL, 2002, J ALLERGY CLIN IMMUN, V109, P24, DOI 10.1067/mai.2002.120564; *UK ACRE, 2001, GUID PRINC BEST PRAC; *UK DEP HLTH, 1991, 38 UK DEP HLTH; *US ACRE, 2002, GUID BEST PRACT PRES; Vance V, 2001, SCIENCE, V292, P2277, DOI 10.1126/science.1061334; VANDENEEDE G, 2004, FOOD CHEM TOXICOLOGY; Verger P, 2002, EUR J CLIN NUTR, V56, pS18, DOI 10.1038/sj/ejcn/1601425; VOELKER T, 1997, RECENT ADV PHYTOCHEM, V31, P223; Wal JM, 2003, REGUL TOXICOL PHARM, V38, P98, DOI 10.1016/S0273-2300(03)00079-5; Walum E, 1998, ENVIRON HEALTH PERSP, V106, P497, DOI 10.2307/3433801; WATZL B, 1995, BIOKTIVE SUBSTANZEN; Wensing M, 2002, CLIN EXP ALLERGY, V32, P1757, DOI 10.1046/j.1365-2222.2002.01555.x; WENSING M, 2002, J ALLERGY CLIN IMMUN, V10, P915; *WHO, 1998, FEMS FOOD REG DIETS; *WHO, 1999, PRINC RISKS HUM HLTH, V210; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; Yu J, 2002, SCIENCE, V296, P79, DOI 10.1126/science.1068037; Zhu T, 2000, NAT BIOTECHNOL, V18, P555; Zorzet Anna, 2002, In Silico Biology, V2, P525; Zubko E, 2000, NAT BIOTECHNOL, V18, P442; Zuo JR, 2001, NAT BIOTECHNOL, V19, P157, DOI 10.1038/84428; [Anonymous], 1992, FED REG, V57, p[22, 984, 988, 991]; [Anonymous], 1986, FED REG, V51	183	174	192	31	276	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915			FOOD CHEM TOXICOL	Food Chem. Toxicol.	JUL	2004	42	7					1047	1088		10.1016/j.fct.2004.02.019		42	Food Science & Technology; Toxicology	Food Science & Technology; Toxicology	827TW	WOS:000221924900003	15123382	
J	Delfino, RJ				Delfino, RJ			Epidemiologic evidence for asthma and exposure to air toxics: Linkages between occupational, indoor, and community air pollution research	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						asthma; diesel; epidemiology; toxic air pollutants; volatile organic compounds	DIESEL EXHAUST PARTICLES; ENVIRONMENTAL TOBACCO-SMOKE; VOLATILE ORGANIC-COMPOUNDS; CHRONIC RESPIRATORY SYMPTOMS; LUNG-FUNCTION GROWTH; TERM AMBIENT CONCENTRATIONS; NITROGEN-DIOXIDE EXPOSURE; BUS GARAGE WORKERS; CHILDHOOD ASTHMA; AUTOMOBILE EXHAUST	Outdoor ambient air pollutant exposures in communities are relevant to the acute exacerbation and possibly the onset of asthma. However, the complexity of pollutant mixtures and etiologic heterogeneity of asthma has made it difficult to identify causal components in those mixtures. Occupational exposures associated with asthma may yield clues to causal components in ambient air pollution because such exposures are often identifiable as single-chemical agents (e.g., metal compounds). However, translating occupational to community exposure-response relationships is limited. Of the air toxics found to cause occupational asthma, only formaldehyde has been frequently investigated in epidemiologic studies of allergic respiratory responses to indoor air, where general consistency can be shown despite lower ambient exposures. The specific volatile organic compounds (VOCs) identified in association with occupational asthma are generally not the same as those in studies showing respiratory effects of VOC mixtures on nonoccupational adult and pediatric asthma. In addition, experimental evidence indicates that airborne polycyclic aromatic hydrocarbon (PAH) exposures linked to diesel exhaust particles (DEPs) have proinflammatory effects on airways, but there is insufficient supporting evidence from the occupational literature of effects of DEPs on asthma or lung function. In contrast, nonoccupational epidemiologic studies have frequently shown associations between allergic responses or asthma with exposures to ambient air pollutant mixtures with PAH components, including black smoke, high home or school traffic density (particularly truck traffic), and environmental tobacco smoke. Other particle-phase and gaseous co-pollutants are likely causal in these associations as well. Epidemiologic research on the relationship of both asthma onset and exacerbation to air pollution is needed to disentangle effects of air toxics; from monitored criteria air pollutants such as particle mass. Community studies should focus on air toxics expected to have adverse respiratory effects based on biological mechanisms, particularly irritant and immunological pathways to asthma onset and exacerbation.	Univ Calif Irvine, Dept Med, Div Epidemiol, Irvine, CA 92697 USA	Delfino, RJ (reprint author), Univ Calif Irvine, Dept Med, Div Epidemiol, 224 Irvine Hall, Irvine, CA 92697 USA.						ABBEY DE, 1991, ENVIRON HEALTH PERSP, V94, P43, DOI 10.2307/3431291; Abbey DE, 1998, AM J RESP CRIT CARE, V158, P289; ABBEY DE, 1993, J EXPO ANAL ENV EPID, V3, P99; American Thoracic Scciety Workshop, 1999, AM J RESP CRIT CAR 1, V160, P1778; AMES RG, 1982, AM REV RESPIR DIS, V125, P39; AMES RG, 1984, ARCH ENVIRON HEALTH, V39, P389; ATTFIELD MD, 1982, ANN OCCUP HYG, V26, P817, DOI 10.1093/annhyg/26.8.817; AYRES SM, 1973, ARCH ENVIRON HEALTH, V27, P168; BALMES JR, 1997, 78 HLTH EFF I; Barfknecht T R, 1982, Dev Toxicol Environ Sci, V10, P277; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; BARNES PJ, 1992, J ASTHMA, V29, P165, DOI 10.3109/02770909209099025; Barnes PJ, 1996, J ALLERGY CLIN IMMUN, V98, pS73, DOI 10.1016/S0091-6749(96)80132-1; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; Berglund DJ, 1999, CHEST, V115, P49, DOI 10.1378/chest.115.1.49; Bernstein IL, 1999, ASTHMA WORKPLACE; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; BUSSE W, 1995, AM J RESP CRIT CARE, V151, P1635; Busse WW, 2001, NEW ENGL J MED, V344, P350; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Cook DG, 1997, THORAX, V52, P1081; CORRIGAN CJ, 1998, LUNG BIOL HLTH DIS I, V117; Coultas DB, 1998, THORAX, V53, P381; CRIQUI MH, 1990, ANN ALLERGY, V64, P308; Cullinan P, 1997, CIBA F SYMP, V206, P160; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; Dubowsky SD, 1999, J EXPO ANAL ENV EPID, V9, P312, DOI 10.1038/sj.jea.7500034; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; DUSSER DJ, 1989, J CLIN INVEST, V84, P900, DOI 10.1172/JCI114251; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; EERENS HC, 1993, ATMOS ENVIRON B-URB, V27, P389, DOI 10.1016/0957-1272(93)90016-Y; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Eisner MD, 1998, AM J RESP CRIT CARE, V158, P170; EMANUEL MB, 1988, CLIN ALLERGY, V18, P295, DOI 10.1111/j.1365-2222.1988.tb02872.x; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; GAMBLE J, 1987, ENVIRON RES, V42, P201, DOI 10.1016/S0013-9351(87)80022-1; GAMBLE J, 1987, ENVIRON RES, V44, P6, DOI 10.1016/S0013-9351(87)80082-8; GAMBLE J, 1983, AM J IND MED, V4, P435, DOI 10.1002/ajim.4700040305; GAMBLE JF, 1983, AM REV RESPIR DIS, V128, P389; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Glovsky MM, 1997, ALLERGY ASTHMA PROC, V18, P163, DOI 10.2500/108854197778984392; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Grant EN, 1999, J ALLERGY CLIN IMMUN, V104, pS1, DOI 10.1016/S0091-6749(99)70268-X; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; HARVING H, 1991, AM REV RESPIR DIS, V143, P751; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; *HLTH EFF I, 1995, EX SUMM DIES EXH CRI; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; JENSEN EJ, 1992, J ALLERGY CLIN IMMUN, V90, P224, DOI 10.1016/0091-6749(92)90075-D; JORGENSEN H, 1970, JOM-J OCCUP MED, V12, P348; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; KAHN G, 1988, AM J IND MED, V13, P405, DOI 10.1002/ajim.4700130309; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KOREN HS, 1992, ARCH ENVIRON HEALTH, V47, P39; KOTO H, 1995, AM J RESP CRIT CARE, V151, P1763; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; Larsen GL, 2000, J ALLERGY CLIN IMMUN, V106, pS153; LEIKAUF GD, 1995, ENVIRON HEALTH PERSP, V103, P253, DOI 10.2307/3432382; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; Macaubas C, 2000, PEDIATR ALLERGY IMMU, V11, P9, DOI 10.1034/j.1399-3038.2000.00502.x; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Mannino DM, 2000, OCCUP MED, V15, P359; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; MEGGS WJ, 1993, ENVIRON HEALTH PERSP, V101, P234, DOI 10.2307/3431548; MIDDLETON DC, 2001, AM J RESP CRIT CARE, V163, pA561; Miguel AG, 1996, ENVIRON HEALTH PERSP, V104, P1180, DOI 10.2307/3432911; Miller CS, 2001, ADDICTION, V96, P115, DOI 10.1046/j.1360-0443.2001.9611159.x; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; MONTNEMERY P, 2000, RESP MED, V95, P744; Nakai S, 1999, ARCH ENVIRON HEALTH, V54, P26; NAKAI S, 1995, J EXPO ANAL ENV EPID, V5, P125; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; *OCMM ASS ASTHM IN, 2000, CLEAR AIR ASTHM IND; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241; PAZDRAK K, 1993, INT ARCH OCC ENV HEA, V64, P515, DOI 10.1007/BF00381101; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Purdham JT, 1987, APPL IND HYG, V2, P133; REGER R, 1982, ANN OCCUP HYG, V26, P799, DOI 10.1093/annhyg/26.8.799; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; ROBBINS AS, 1993, INT J EPIDEMIOL, V22, P809, DOI 10.1093/ije/22.5.809; ROBERTSON A, 1984, BRIT J IND MED, V41, P214; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; RUFFIN J, 1986, CYTOBIOS, V46, P119; [Anonymous], 2000, MULT AIR TOX EXP STU; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Schwartz J, 2000, AM J RESP CRIT CARE, V161, P802; SHEPPARD D, 1988, J CLIN INVEST, V81, P1111, DOI 10.1172/JCI113424; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; SPEIZER FE, 1973, ARCH ENVIRON HEALTH, V26, P313; SPEIZER FE, 1973, ARCH ENVIRON HEALTH, V26, P319; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1998, THORAX, V53, P204; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; TOLLERUD DJ, 1983, ARCH ENVIRON HEALTH, V38, P334; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; ULFVARSON U, 1987, SCAND J WORK ENV HEA, V13, P505; Ulvestad B, 2000, THORAX, V55, P277, DOI 10.1136/thorax.55.4.277; *US DEP TRANSP BUR, 2001, NAT TRNASP STAT 2000; VanLoveren H, 1996, TOXICOL LETT, V86, P163; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; WADE JF, 1993, J OCCUP ENVIRON MED, V35, P149, DOI 10.1097/00043764-199302000-00015; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; Wallace L, 1991, J Expo Anal Environ Epidemiol, V1, P157; Wantke F, 1996, CLIN EXP ALLERGY, V26, P276; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; Warner JO, 2000, PEDIATR ALLERGY IMMU, V11, P6, DOI 10.1034/j.1399-3038.2000.00501.x; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; WEISEL CP, 1992, J EXPO ANAL ENV EPID, V2, P79; Weiss ST, 1999, ENVIRON HEALTH PERSP, V107, P891, DOI 10.2307/3434571; Wernette D.R., 1992, EPA J, V18, P16; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Wilkinson P, 1999, THORAX, V54, P1070; Williams RW, 1999, J EXPO ANAL ENV EPID, V9, P158, DOI 10.1038/sj.jea.7500028; WILSON NK, 1991, INDOOR AIR, V4, P513; WIXTROM RN, 1992, J EXPO ANAL ENV EPID, V2, P23; WJST M, 1993, BRIT MED J, V307, P596; Woolcock AJ, 1996, MED J AUSTRALIA, V165, P358; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835	156	174	183	6	42	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2002	110			4			573	589				17	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	586ER	WOS:000177572100012	12194890	
J	Hogan, SP; Mishra, A; Brandt, EB; Royalty, MP; Pope, SM; Zimmermann, N; Foster, PS; Rothenberg, ME				Hogan, SP; Mishra, A; Brandt, EB; Royalty, MP; Pope, SM; Zimmermann, N; Foster, PS; Rothenberg, ME			A pathological function for eotaxin and eosinophils in eosinophilic gastrointestinal inflammation	NATURE IMMUNOLOGY			English	Article							MAJOR BASIC-PROTEIN; IN-VIVO; MUCOSAL EOSINOPHILS; TISSUE EOSINOPHILIA; CHEMOKINE EOTAXIN; INTERFERON-GAMMA; FOOD ALLERGY; GASTROENTERITIS; DISEASE; INTERLEUKIN-5	Although eosinophils have been implicated in the pathogenesis of gastrointestinal disorders, their function has not been established. Using a murine model of oral antigen-induced eosinophil-associated gastrointestinal disease, we report the pathological consequences of eosinophilic inflammation and the involvement of eotaxin and eosinophils, Exposure of mice to enteric-coated antigen promotes an extensive T helper 2-associated eosinophilic inflammatory response involving the esophagus, stomach, small intestine and Peyer's patches as well as the development of gastric dysmotility, gastromegaly and cachexia. Electron microscopy shows eosinophils in proximity to damaged axons, which indicated that eosinophils were mediating a pathologic response. In addition, mice deficient in eotaxin have impaired eosinophil recruitment and are protected from gastromegaly and cachexia. These results establish a critical pathological function for eotaxin and eosinophils in gastrointestinal allergic hypersensitivity.	Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Biochem & Mol Biol, Canberra, ACT 0200, Australia	Rothenberg, ME (reprint author), Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA.		Foster, Paul/G-5057-2013		NIAID NIH HHS [R01 AI42242-02, R01 AI45898-01]		ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Adamko DJ, 1999, J EXP MED, V190, P1465, DOI 10.1084/jem.190.10.1465; CELLO JP, 1979, AM J MED, V67, P1097, DOI 10.1016/0002-9343(79)90652-1; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886; DOBBINS JW, 1977, GASTROENTEROLOGY, V72, P1312; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V102, P33; Erjefalt JS, 2000, AM J RESP CRIT CARE, V161, P2074; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gleich GJ, 1997, P NATL ACAD SCI USA, V94, P2101, DOI 10.1073/pnas.94.6.2101; GLEICH GJ, 1993, ANNU REV MED, V44, P85, DOI 10.1146/annurev.med.44.1.85; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846; Gutierrez-Ramos JC, 1999, IMMUNOL TODAY, V20, P500, DOI 10.1016/S0167-5699(99)01522-4; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; JAFFE JS, 1994, J CLIN IMMUNOL, V14, P299, DOI 10.1007/BF01540983; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; Kelly KJ, 2000, J PEDIAT GASTROENT S, V30, P28; KESHAVARZIAN A, 1985, GASTROENTEROLOGY, V88, P1041; KLEIN NC, 1970, MEDICINE, V49, P299; LEE RG, 1985, AM J SURG PATHOL, V9, P475, DOI 10.1097/00000478-198507000-00002; Lin S, 1997, DIGEST DIS SCI, V42, P907, DOI 10.1023/A:1018808329603; Litwin A, 1998, BIODRUGS, V9, P261, DOI 10.2165/00063030-199809040-00001; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Lowichik A, 1996, MODERN PATHOL, V9, P110; MESTECKY J, 1978, J CLIN INVEST, V61, P71; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2000, BLOOD, V96, P1538; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Stelts D, 1998, AM J RESP CELL MOL, V18, P463; TALLEY NJ, 1990, GUT, V31, P54, DOI 10.1136/gut.31.1.54; TALLEY NJ, 1992, GASTROENTEROLOGY, V103, P137; TORPIER G, 1988, CLIN EXP IMMUNOL, V74, P404; van den Bos GAM, 1995, EUR J PUBLIC HEALTH, V5, P29, DOI 10.1093/eurpub/5.1.29; Weller P F, 1996, Eur Respir J Suppl, V22, p109s; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487	47	174	180	0	4	NATURE AMERICA INC	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	APR	2001	2	4					353	360		10.1038/86365		8	Immunology	Immunology	420AZ	WOS:000167982900017	11276207	
J	Bell, ML; Peng, RD; Dominici, F				Bell, ML; Peng, RD; Dominici, F			The exposure-response curve for ozone and risk of mortality and the adequacy of current ozone regulations	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						mortality; ozone; regulations; threshold	DISTRIBUTED LAG MODELS; LARGEST US CITIES; AIR-POLLUTION; PARTICULATE MATTER; AMBIENT OZONE; HEALTH; CHILDREN; ASTHMA	Time-series analyses have shown that ozone is associated with increased risk of premature mortality, but little is known about how O-3 affects health at low concentrations. A critical scientific and policy question is whether a threshold level exists below which O-3 does not adversely affect mortality. We developed and applied several statistical models to data on air pollution, weather, and mortality for 98 U.S. urban communities for the period 1987-2000 to estimate the exposure-response curve for tropospheric O-3 and risk of mortality and to evaluate whether a "safe" threshold level exists. Methods included a linear approach and subset, threshold, and spline models. All results indicate that any threshold would exist at very low concentrations, far below current U.S. and international regulations and nearing background levels. For example, under a scenario in which the U.S. Environmental Protection Agency's 8-hr regulation is met every day in each community, there was still a 0.30% increase in mortality per 10-ppb increase in the average of the same and previous days' O-3 levels (95% posterior interval, 0.15-0.45%). Our findings indicate that even low levels of tropospheric O-3 are associated with increased risk of premature mortality. Interventions to further reduce O-3 pollution would benefit public health, even in regions that meet current regulatory standards and guidelines.	Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA	Bell, ML (reprint author), Yale Univ, Sch Forestry & Environm Studies, 205 Prospect St, New Haven, CT 06511 USA.	michelle.bell@yale.edu			NIEHS NIH HHS [ES 012054-01, P30 ES 03819, P30 ES003819, R01 ES012054, R01 ES015028]		Akaike H., 1973, INT S INF THEOR, P267, DOI DOI 10.2307/2334537; American Thoracic Society, 2000, AM J RESP CRIT CARE, V161, P665; Anderson HR, 2004, META ANAL TIME SERIE; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; BELL ML, 2005, EPIDEMIOLOGY, V4, P436; Broeckaert F, 1999, LANCET, V353, P900, DOI 10.1016/S0140-6736(99)00540-1; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; *CAL ENV PROT AG, 2005, CAL AD NEW OZ STAND; Canadian Council of Ministers of the Environment CCME, 2000, CAN WID STAND PART M; Chan CC, 2005, ENVIRON HEALTH PERSP, V113, P735, DOI 10.1289/ehp.7636; Daniels MJ, 2000, AM J EPIDEMIOL, V152, P397, DOI 10.1093/aje/152.5.397; DANIELS MJ, 2004, NATL MORBIDITY MORTA; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2002, J AM STAT ASSOC, V97, P100, DOI 10.1198/016214502753479266; *EUR COMM, 2002, DIR 2002 3 EC EUR PA; Everson PJ, 2000, J ROY STAT SOC B, V62, P399, DOI 10.1111/1467-9868.00239; FIORE A, 2004, J GEOPHYS RES ATMOS; Fiore A.M., 2003, J GEOPHYS RES ATMOS; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Hoek G, 1997, ARCH ENVIRON HEALTH, V52, P455; Huang Y, 2005, ENVIRONMETRICS, V16, P547, DOI 10.1002/env.721; Hubbell BJ, 2005, ENVIRON HEALTH PERSP, V113, P73; *IHAPSS, 2006, INT BAS HLTH AIR POL; ITO K, 2005, EPIDEMIOLOGY, V4, P446; Kim SY, 2004, ENVIRON RES, V94, P113, DOI 10.1016/j.envres.2003.09.006; Knowlton K, 2004, ENVIRON HEALTH PERSP, V112, P1557, DOI 10.1289/ehp.7163; LEVY JI, 2005, EPIDEMIOLOGY, V4, P458; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McCullagh P, 1989, GENERALIZED LINEAR M; Peng RD, 2005, AM J EPIDEMIOL, V161, P585, DOI 10.1093/aje/kwi075; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SAMET JM, 2000, HLTH EFFECTS I, V94, P1; Samet J.M., 2000, NATL MORBIDITY MORTA; *SAN JAOQ VALL AIR, 2006, OZONE; *TLNISE, 2006, 2 LEV NORM IND SAMPL; Review of the National Ambient Air Quality Standards for Particulate Matter, 2005, EPA452R05005; EPA, 2004, EPA454K04001; US EPA, 1997, FED REGISTER, V62, P38855; *US EPA, 1996, EPA600P93004ACF; Welty LJ, 2005, AM J EPIDEMIOL, V162, P80, DOI 10.1093/aje/kwi157; World Health Organization, 2000, WHO REG PUBL EUR SER, V91; World Health Organization, 1978, INT CLASS DIS; World Health Organization, 1993, INT CLASS DIS	43	173	177	6	44	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2006	114	4					532	536		10.1289/ehp.8816		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	030QX	WOS:000236650500036	16581541	
J	Gauvreau, GM; O'Byrne, PM; Boulet, LP; Wang, Y; Cockcroft, D; Bigler, J; FitzGerald, JM; Boedigheimer, M; Davis, BE; Dias, C; Gorski, KS; Smith, L; Bautista, E; Comeau, MR; Leigh, R; Parnes, JR				Gauvreau, Gail M.; O'Byrne, Paul M.; Boulet, Louis-Philippe; Wang, Ying; Cockcroft, Donald; Bigler, Jeannette; FitzGerald, J. Mark; Boedigheimer, Michael; Davis, Beth E.; Dias, Clapton; Gorski, Kevin S.; Smith, Lynn; Bautista, Edgar; Comeau, Michael R.; Leigh, Richard; Parnes, Jane R.			Effects of an Anti-TSLP Antibody on Allergen-Induced Asthmatic Responses	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							THYMIC STROMAL LYMPHOPOIETIN; INDUCED AIRWAY RESPONSES; HUMAN EPITHELIAL-CELLS; MAST-CELLS; INFLAMMATION; SPUTUM; REPRODUCIBILITY; RESPONSIVENESS; MEPOLIZUMAB; EXPRESSION	BACKGROUND Thymic stromal lymphopoietin (TSLP) is an epithelial-cell-derived cytokine that may be important in initiating allergic inflammation. AMG 157 is a human anti-TSLP monoclonal immunoglobulin G2 lambda that binds human TSLP and prevents receptor interaction. METHODS In this double-blind, placebo-controlled study, we randomly assigned 31 patients with mild allergic asthma to receive three monthly doses of AMG 157 (700 mg) or placebo intravenously. We conducted allergen challenges on days 42 and 84 to evaluate the effect of AMG 157 in reducing the maximum percentage decrease in the forced expiratory volume in 1 second (FEV1). We also measured the fraction of nitric oxide in exhaled air, blood and sputum eosinophils, and airway hyperresponsiveness. The primary end point was the late asthmatic response, as measured 3 to 7 hours after the allergen challenge. RESULTS AMG 157 attenuated most measures of allergen-induced early and late asthmatic responses. The maximum percentage decrease in the FEV1 during the late response was 34.0% smaller in the AMG-157 group than in the placebo group on day 42 (P=0.09) and 45.9% smaller on day 84 (P=0.02). In addition, patients receiving AMG 157 had significant decreases in levels of blood and sputum eosinophils before and after the allergen challenge and in the fraction of exhaled nitric oxide. There were 15 adverse events in the AMG-157 group, as compared with 12 in the placebo group; there were no serious adverse events. CONCLUSIONS Treatment with AMG 157 reduced allergen-induced bronchoconstriction and indexes of airway inflammation before and after allergen challenge. These findings are consistent with a key role for TSLP in allergen-induced airway responses and persistent airway inflammation in patients with allergic asthma. Whether anti-TSLP therapeutics will have clinical value cannot be determined from these data. (Funded by Amgen; ClinicalTrials.gov number, NCT01405963.)	[Gauvreau, Gail M.; O'Byrne, Paul M.] McMaster Univ, Dept Med, Firestone Inst Resp Hlth, Hamilton, ON L8N 3Z5, Canada; [Boulet, Louis-Philippe] Univ Laval, Inst Univ Cardiol & Pneumol Quebec, Quebec City, PQ, Canada; [Cockcroft, Donald; Davis, Beth E.] Univ Saskatchewan, Div Respirol Crit Care & Sleep Med, Saskatoon, SK, Canada; [FitzGerald, J. Mark] Univ British Columbia, Inst Heart & Lung Hlth, Vancouver, BC V5Z 1M9, Canada; [Leigh, Richard] Univ Calgary, Fac Med, Snyder Inst Chron Dis, Calgary, AB, Canada; [Wang, Ying; Boedigheimer, Michael; Dias, Clapton; Gorski, Kevin S.; Smith, Lynn; Bautista, Edgar; Parnes, Jane R.] Amgen Inc, Thousand Oaks, CA USA; [Bigler, Jeannette; Comeau, Michael R.] Amgen Inc, Seattle, WA USA	O'Byrne, PM (reprint author), McMaster Univ, Dept Med, HSC 3W10,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	obyrnep@mcmaster.ca		O'Byrne, Paul/0000-0003-0979-281X	Amgen; AllerGen Network of Centers of Excellence	Supported by Amgen. The AllerGen Network of Centers of Excellence provided administrative funding for the study centers.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Allakhverdi Z, 2009, J ALLERGY CLIN IMMUN, V123, P472, DOI 10.1016/j.jaci.2008.10.022; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; Bates JHT, 2009, AM J PHYSIOL-LUNG C, V297, pL401, DOI 10.1152/ajplung.00027.2009; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; Bunyavanich Supinda, 2011, Clin Mol Allergy, V9, P1, DOI 10.1186/1476-7961-9-1; COCKCROFT DW, 1987, AM REV RESPIR DIS, V135, P264; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; Corrigan CJ, 2009, ALLERGY, V64, P1014, DOI 10.1111/j.1398-9995.2009.01947.x; Dahlen B, 2009, EUR RESPIR J, V33, P747, DOI 10.1183/09031936.00095508; Davis BE, 2009, EUR RESPIR J, V33, P1302, DOI 10.1183/09031936.00169008; Diamant Z, 2013, J ALLERGY CLIN IMMUN, V132, P1045, DOI 10.1016/j.jaci.2013.08.023; Ferreira MA, 2013, J ALLERGY CLIN IMMUN; Gauvreau GM, 2014, CLIN EXP ALLERGY, V44, P29, DOI 10.1111/cea.12235; Gauvreau GM, 2011, AM J RESP CRIT CARE, V183, P1007, DOI 10.1164/rccm.201008-1210OC; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640; Gauvreau GM, 1999, J ALLERGY CLIN IMMUN, V104, P66, DOI 10.1016/S0091-6749(99)70115-6; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473; Gavala ML, 2013, CURR ALLERGY ASTHM R, V13, P298, DOI 10.1007/s11882-013-0344-1; Green R, 2002, BRIT MED J, V324, P1131; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Haldar P, 2011, NEW ENGL J MED, V364, P588; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; He JQ, 2009, J ALLERGY CLIN IMMUN, V124, P222, DOI 10.1016/j.jaci.2009.04.018; INMAN MD, 1995, J ALLERGY CLIN IMMUN, V95, P1191, DOI 10.1016/S0091-6749(95)70075-7; Kato A, 2007, J IMMUNOL, V179, P1080; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nolte H, 2013, RESP MED, V107, P656, DOI 10.1016/j.rmed.2013.02.010; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; Reche PA, 2001, J IMMUNOL, V167, P336; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Ying S, 2005, J IMMUNOL, V174, P8183; Ying S, 2008, J IMMUNOL, V181, P2790; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247	42	172	181	0	15	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 29	2014	370	22					2102	2110		10.1056/NEJMoa1402895		9	Medicine, General & Internal	General & Internal Medicine	AH9BM	WOS:000336434000008	24846652	
J	Landrigan, PJ; Lioy, PJ; Thurston, G; Berkowitz, G; Chen, LC; Chillrud, SN; Gavett, SH; Georgopoulos, PG; Geyh, AS; Levin, S; Perera, F; Rappaport, SM; Small, C				Landrigan, PJ; Lioy, PJ; Thurston, G; Berkowitz, G; Chen, LC; Chillrud, SN; Gavett, SH; Georgopoulos, PG; Geyh, AS; Levin, S; Perera, F; Rappaport, SM; Small, C		NIEHS World Trade Ctr Working Grp	Health and environmental consequences of the world trade center disaster	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; airway hyperresponsiveness; asbestos; occupational lung disease; PM2.5; PM10; small for gestational age (SGA)	NEW-YORK-CITY; FINE PARTICULATE MATTER; 11TH TERRORIST ATTACKS; CENTER SITE; MALIGNANT MESOTHELIOMA; LOWER MANHATTAN; AIR-POLLUTION; FETAL-GROWTH; CENTER COUGH; GROUND-ZERO	The attack on the World Trade Center (WTC) created an acute environmental disaster of enormous magnitude. This study characterizes the environmental exposures resulting from destruction of the WTC and assesses their effects on health. Methods include ambient air sampling; analyses of outdoor and indoor settled dust; high-altitude imaging and modeling of the atmospheric plume; inhalation studies of WTC dust in mice; and clinical examinations, community surveys, and prospective epidemiologic studies of exposed populations. WTC dust was found to consist predominantly (95%) of coarse particles and contained pulverized cement, glass fibers, asbestos, lead, polycyclic aromatic hydrocarbons (PAHs), polychlorinated biphenyls (PCBs), and polychlorinated furans and dioxins. Airborne particulate levels were highest immediately after the attack and declined thereafter. Particulate levels decreased sharply with distance from the WTC. Dust pH was highly alkaline (pH 9.0-11.0). Mice exposed to WTC dust showed only moderate pulmonary inflammation but marked bronchial hyperractivity. Evaluation of 10,116 firefighters showed exposure-related. P increases in cough and bronchial hyperreactivity. Evaluation of 183 cleanup workers showed new-onset cough (33%), wheeze (18%), and phlegm production (24%). Increased frequency of new-onset cough, wheeze, and shortness of breath were also observed in community residents. Follow-up of 182 pregnant women who were either inside or near the WTC on I I September showed a 2-fold increase in small-for-gestational-age (SGA) infants. In summary, environmental exposures after the WTC disaster were associated with significant adverse effects on health. The high alkalinity of WTC dust produced bronchial hyperreactivity, persistent cough, and increased risk of asthma. Plausible causes of the observed increase in SGA infants include maternal exposures to PAH and particulates. Future risk of mesothelioma may be increased, particularly among workers and volunteers exposed occupationally to asbestos. Continuing follow-up of all exposed populations is required to document the long-term consequences of the disaster.	CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Environm & Occupat Hlth Sci Inst New Jersey, New Brunswick, NJ USA; NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; US EPA, Off Res & Dev, Res Triangle Pk, NC 27711 USA; Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA; Univ N Carolina, Sch Publ Hlth, Chapel Hill, NC USA	Landrigan, PJ (reprint author), CUNY Mt Sinai Sch Med, 1 Gustave L Levy Pl,Box 1057, New York, NY 10029 USA.	phil.landrigan@mssm.edu	Lioy, Paul/F-6148-2011; Cjem, Lung-Chi/H-5030-2012		NIEHS NIH HHS [P30 ES03819, P30 ES00260, P30 ES009089, P30 ES05022, P30ES09089-04S, P42ES05948, P42ES07384]		*AM THOR SOC, 1994, STAND SPIR 1994 UPD; Anderson H.A., 1982, P WORLD S ASB MONT M, P349; Bayley N., 1993, BAYLEY SCALES INFANT; Beckett WS, 2002, AM J RESP CRIT CARE, V166, P785, DOI 10.1164/rccm.2208001; Berkowitz GS, 2003, JAMA-J AM MED ASSOC, V290, P595, DOI 10.1001/jama.290.5.595-b; Bobak M, 2001, EPIDEMIOLOGY, V12, P358, DOI 10.1097/00001648-200105000-00018; Boscarino Joseph A, 2002, Int J Emerg Ment Health, V4, P143; BRENNER WE, 1976, AM J OBSTET GYNECOL, V126, P555; Camus M, 1998, NEW ENGL J MED, V338, P1565, DOI 10.1056/NEJM199805283382201; Canfield RL, 2001, INFANCY, V2, P197, DOI 10.1207/S15327078IN0202_5; Brezsnyak M. P., 1997, MONOGRAPHS SOC RES C, V62; CDC. Centers for Disease Control and Prevention, 2002, MMWR-MORBID MORTAL W, V51, P1; Chen LC, 2002, LANCET, V360, pS37, DOI 10.1016/S0140-6736(02)11814-9; CLARK RN, 2004, ENV STUDIES WORLD TR; CLAUDIO L, 2001, ENV HLTH PERSPECT, V109, P528; *COL U, 2003, WORLD TRAD CTR ENV C; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; DODSON RF, 1991, ANN NY ACAD SCI, V643, P53, DOI 10.1111/j.1749-6632.1991.tb24443.x; Edelman P, 2003, ENVIRON HEALTH PERSP, V111, P1906, DOI 10.1289/ehp.6315; Fairbrother G, 2003, AMBUL PEDIATR, V3, P304, DOI 10.1367/1539-4409(2003)003<0304:PSRINY>2.0.CO;2; Galea S, 2002, J URBAN HEALTH, V79, P340, DOI 10.1093/jurban/79.3.340; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P981, DOI 10.1289/ehp.5931; JACOBSON SW, 1992, CHILD DEV, V63, P711; Kogevinas M, 2001, HUM REPROD UPDATE, V7, P331, DOI 10.1093/humupd/7.3.331; Landrigan PJ, 2001, ENVIRON HEALTH PERSP, V109, pA514, DOI 10.1289/ehp.109-a514; LEBOUFFANT L, 1973, ARC SCI PUBL, V8, P249; Levin S, 2002, AM J IND MED, V42, P545, DOI 10.1002/ajim.10154; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; Lippy BE, 2002, AM J IND MED, V42, P539, DOI 10.1002/ajim.10152; Magnani C, 2001, Environ Health Perspect, V109, P915; Malievskaya E, 2002, AM J IND MED, V42, P548, DOI 10.1002/ajim.10149; McCurdy T, 2000, J EXPO ANAL ENV EPID, V10, P566, DOI 10.1038/sj.jea.7500114; McGee JK, 2003, ENVIRON HEALTH PERSP, V111, P972, DOI 10.1289/ehp.5930; NICHOLSON WJ, 1971, P 2 INT CLEAN AIR C, P36; NICHOLSON WJ, 1996, CURRENT ISSUES PUBLI, V2, P118; Offenberg JH, 2003, ENVIRON SCI TECHNOL, V37, P502, DOI 10.1021/es025730g; Perera FP, 1998, AM J EPIDEMIOL, V147, P309; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; REIBMAN J, 2003, AM J RESP CRIT CARE, V167, pA335; REITZE WB, 1972, AM IND HYG ASSOC J, V33, P178, DOI 10.1080/0002889728506628; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Rom WN, 2002, AM J RESP CRIT CARE, V166, P797, DOI 10.1164/rccm.200206-576OC; Scanlon PD, 2002, NEW ENGL J MED, V347, P840, DOI 10.1056/NEJMe020100; Schlenger WE, 2002, JAMA-J AM MED ASSOC, V288, P581, DOI 10.1001/jama.288.5.581; SHEPHERD PA, 1987, FAGAN TEST INFANT IN; Spadafora R, 2002, AM J IND MED, V42, P532, DOI 10.1002/ajim.10153; Stuber J, 2002, PSYCHIATR SERV, V53, P815, DOI 10.1176/appi.ps.53.7.815; Suzuki Y, 2002, ANN NY ACAD SCI, V982, P160; Thurston G, 2003, EPIDEMIOLOGY, V14, pS87, DOI 10.1097/00001648-200309001-00205; Thurston GD, 2002, AM J IND MED, V42, P543, DOI 10.1002/ajim.10163; *US DEP LAB, 2003, ASB; *US EPA, 2003, FACT SHEET REL REP R; *US EPA, 1986, ASB HAZ EM RESP ACT; *US EPA, 2004, EPA RESP SEPT 11; *US EPA, 2002, EPA600P2002A; Vlahov D, 2002, J URBAN HEALTH, V79, P2, DOI 10.1093/jurban/79.1.2; Vlahov D, 2002, AM J EPIDEMIOL, V155, P988, DOI 10.1093/aje/155.11.988	58	172	177	9	48	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2004	112	6					731	739		10.1289/ehp.6702		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	822DD	WOS:000221514400040	15121517	
J	Mannino, DM				Mannino, DM			COPD - Epidemiology, prevalence, morbidity and mortality, and disease heterogeneity	CHEST			English	Article; Proceedings Paper	COPD 2001 International Symposium	APR, 2001	LUND, SWEDEN			COPD; epidemiology; mortality; prevalence; risk factors	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; UNITED-STATES; LUNG-DISEASE; ASTHMA; AIRWAYS; HEALTH; BURDEN; HYPERRESPONSIVENESS; NUTRITION	COPD continues to cause a heavy health and economic burden both in the United states and around the world. Some of the risk factors for COPD are well-known and include smoking, occupational exposures, air pollution, airway hyperresponsiveness, asthma, and certain genetic variations, although many questions, such as why <20% of smokers develop significant airway obstruction, remain. Precise definitions of COPD vary and are frequently dependent on an accurate diagnosis of the problem by a physician. These differences in the definition of COPD can have large effects on the estimates of COPD in the population. Furthermore, evidence that COPD represents several different disease processes with potentially different interventions continues to emerge. In most 4 the world, COPD prevalence and mortality are still increasing and likely will continue to rise in response to increases in smoking, particularly by women and adolescents. Resources aimed at smoking cessation and prevention, COPD education and early detection, and better treatment will be of the most benefit in our continuing efforts against this important cause of morbidity and mortality.	Ctr Dis Control & Prevent, Air Pollut Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA	Mannino, DM (reprint author), Ctr Dis Control & Prevent, Air Pollut Resp Hlth Branch, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, 1600 Clifton Rd,MS E-17, Atlanta, GA 30333 USA.			Mannino, David/0000-0003-3646-7828			[Anonymous], 1994, VITAL HLTH STAT, V32, P1; AGUILANIU B, 1992, JPEN-PARENTER ENTER, V16, P248, DOI 10.1177/0148607192016003248; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; BECKLAKE MR, 1989, AM REV RESPIR DIS, V140, pS85; Bestall JC, 1999, THORAX, V54, P581; CAMILLI AE, 1991, AM J EPIDEMIOL, V133, P795; Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P908; CHANG JT, 1995, CHEST, V108, P736, DOI 10.1378/chest.108.3.736; Dennison C, 2000, VITAL HLTH STAT 1, V39, P1; DIRKSEN A, 1991, DAN MED BULL, V38, P486; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267; HEGELE RG, 1995, AM J RESP CRIT CARE, V151, P1659; Hogg J C, 2000, Semin Respir Infect, V15, P32; Hurd SS, 2000, CHEST, V117, p336S, DOI 10.1378/chest.117.5_suppl_2.336S; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956; KEELECARD G, 1993, PUBLIC HEALTH NURS, V10, P245, DOI 10.1111/j.1525-1446.1993.tb00060.x; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Mannino DM, 1997, AM J RESP CRIT CARE, V156, P814; McCaig LF, 2000, ADV DATA, V313, P1; Michaud CM, 2001, JAMA-J AM MED ASSOC, V285, P535, DOI 10.1001/jama.285.5.535; Murphy S L, 2000, Natl Vital Stat Rep, V48, P1; National Center for Health Statistics, 1999, VITAL HLTH STAT 2, V126, P1; Piccioni P, 1998, J CLIN EPIDEMIOL, V51, P547, DOI 10.1016/S0895-4356(98)00022-5; Popover JR, 2000, VITAL HLTH STAT 13, V148, P1; Rennard SI, 1998, CHEST, V113, p235S, DOI 10.1378/chest.113.4_Supplement.235S; Rennard SI, 2000, CHEST, V117, p360S, DOI 10.1378/chest.117.5_suppl_2.360S; SHEFFER AL, 1993, MED CARE, V31, pMS20; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Silverman EK, 1996, MED CLIN N AM, V80, P501; SLUSARCICK AL, 2000, ADV DATA, V317, P1; Snider G L, 1995, Monaldi Arch Chest Dis, V50, P3; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P942; Sullivan SD, 2000, CHEST, V117, P5; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; World Health Organization, 2001, GOLD GLOB STRAT MAN	41	172	183	1	12	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2002	121	5		S			121S	126S		10.1378/chest.121.5_suppl.121S		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	554HV	WOS:000175730500003	12010839	
J	Salimi, M; Barlow, JL; Saunders, SP; Xue, LZ; Gutowska-Owsiak, D; Wang, XW; Huang, LC; Johnson, D; Scanlon, ST; McKenzie, ANJ; Fallon, PG; Ogg, GS				Salimi, Maryam; Barlow, Jillian L.; Saunders, Sean P.; Xue, Luzheng; Gutowska-Owsiak, Danuta; Wang, Xinwen; Huang, Li-Chieh; Johnson, David; Scanlon, Seth T.; McKenzie, Andrew N. J.; Fallon, Padraic G.; Ogg, Graham S.			A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							IMMUNE DEFECTS; E-CADHERIN; HUMAN EOSINOPHILS; T-CELLS; INFLAMMATION; EXPRESSION; DISEASE; KERATINOCYTES; FILAGGRIN; INSIGHTS	Type 2 innate lymphoid cells (ILC2s, nuocytes, NHC) require RORA and GATA3 for their development. We show that human ILC2s express skin homing receptors and infiltrate the skin after allergen challenge, where they produce the type 2 cytokines IL-5 and IL-13. Skin-derived ILC2s express the IL-33 receptor ST2, which is up-regulated during activation, and are enriched in lesional skin biopsies from atopic patients. Signaling via IL-33 induces type 2 cytokine and amphiregulin expression, and increases ILC2 migration. Furthermore, we demonstrate that E-cadherin ligation on human ILC2 dramatically inhibits IL-5 and IL-13 production. Interestingly, down-regulation of E-cadherin is characteristic of filaggrin insufficiency, a cardinal feature of atopic dermatitis (AD). ILC2 may contribute to increases in type 2 cytokine production in the absence of the suppressive E-cadherin ligation through this novel mechanism of barrier sensing. Using Rag1(-/-) and ROR alpha-deficient mice, we confirm that ILC2s are present in mouse skin and promote AD-like inflammation. IL-25 and IL-33 are the predominant ILC2-inducing cytokines in this model. The presence of ILC2s in skin, and their production of type 2 cytokines in response to IL-33, identifies a role for ILC2s in the pathogenesis of cutaneous atopic disease.	[Salimi, Maryam; Xue, Luzheng; Gutowska-Owsiak, Danuta; Huang, Li-Chieh; Ogg, Graham S.] Univ Oxford, Human Immunol Unit, MRC, Inst Hlth Res Biomed Res Ctr,Radcliffe Dept Med, Oxford OX3 9DS, England; [Barlow, Jillian L.; Scanlon, Seth T.; McKenzie, Andrew N. J.] Univ Cambridge, Mol Biol Lab, MRC, Cambridge CB2 0QH, England; [Saunders, Sean P.; Fallon, Padraic G.] Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin 2, Ireland; [Fallon, Padraic G.] St James Hosp, Inst Mol Med, Dublin 2, Ireland; [Fallon, Padraic G.] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin 12, Ireland; [Johnson, David] Oxford Univ Hosp Natl Hlth Serv Trust, John Radcliffe Hosp, Dept Plast & Reconstruct Surg, Oxford OX3 9DU, England; [Wang, Xinwen] Fourth Mil Med Univ, Sch Stomatol, Dept Periodontol & Oral Med, Xian 710032, Shaanxi, Peoples R China	McKenzie, ANJ (reprint author), Univ Cambridge, Mol Biol Lab, MRC, Cambridge CB2 0QH, England.	anm@mrc-lmb.cam.ac.uk		Scanlon, Seth Thomas/0000-0002-1792-6382; Fallon, Padraic/0000-0002-8401-7293; Saunders, Sean/0000-0003-1689-3598; Gutowska-Owsiak, Danuta/0000-0003-4503-2279	MRC; Barrie Trust; National Institute of Health Research Biomedical Research Centre Program; Comprehensive Local Research Network; Wellcome Trust; Science Foundation Ireland; National Children's Research Centre; American Asthma Foundation	We are grateful for funding from the MRC, Barrie Trust, National Institute of Health Research Biomedical Research Centre Program and Comprehensive Local Research Network. P. G. Fallon is supported by the Wellcome Trust, Science Foundation Ireland, and National Children's Research Centre. J.L. Barlow, S. T. Scanlon, and A.N.J. McKenzie were supported by the MRC and the American Asthma Foundation.	Averdam A, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000688; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Crack LR, 2012, CLIN EXP DERMATOL, V37, P266, DOI 10.1111/j.1365-2230.2011.04227.x; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Grundemann C, 2006, J IMMUNOL, V176, P1311; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hofmann M, 2012, EUR J IMMUNOL, V42, P2484, DOI 10.1002/eji.201142357; Hoyler T, 2012, IMMUNITY, V37, P634, DOI 10.1016/j.immuni.2012.06.020; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Imai Y, 2013, P NATL ACAD SCI USA, V110, P13921, DOI 10.1073/pnas.1307321110; Iordanov MS, 2005, J INVEST DERMATOL, V125, P134, DOI 10.1111/j.0022-202X.2005.23804.x; Islam SA, 2012, NAT MED, V18, P705, DOI 10.1038/nm.2760; Jiang A, 2007, IMMUNITY, V27, P610, DOI 10.1016/j.immuni.2007.08.015; Kim B.S., 2013, SCI TRANSL MED, V5; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; McCully ML, 2012, BLOOD, V120, P4591, DOI 10.1182/blood-2012-05-433037; McGirt LY, 2006, J ALLERGY CLIN IMMUN, V118, P202, DOI 10.1016/j.jaci.2006.04.033; Miller AM, 2011, J INFLAMM-LOND, V8, DOI 10.1186/1476-9255-8-22; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Mun SH, 2010, CELL MOL LIFE SCI, V67, P3883, DOI 10.1007/s00018-010-0410-y; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland RB, 2001, EXP CELL RES, V270, P199, DOI 10.1006/excr.2001.5348; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; RAND TH, 1991, J CLIN INVEST, V88, P825, DOI 10.1172/JCI115383; Roediger B, 2013, NAT IMMUNOL, V14, P564, DOI 10.1038/ni.2584; Rosshart S, 2008, EUR J IMMUNOL, V38, P3354, DOI 10.1002/eji.200838690; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Shiohara T, 2011, CURR PROBL DERMATOL, V41, P125, DOI 10.1159/000323306; Siddiqui KRR, 2010, IMMUNITY, V32, P557, DOI 10.1016/j.immuni.2010.03.017; Spits H, 2013, NAT REV IMMUNOL, V13, P145, DOI 10.1038/nri3365; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Trautmann A, 2001, J INVEST DERMATOL, V117, P927, DOI 10.1046/j.0022-202x.2001.01474.x; WAHL SM, 1987, J IMMUNOL, V139, P1342; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Wong SH, 2012, NAT IMMUNOL, V13, P229, DOI 10.1038/ni.2208	44	171	175	5	32	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007	1540-9538		J EXP MED	J. Exp. Med.	DEC 16	2013	210	13					2939	2950		10.1084/jem.20130351		12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	276ID	WOS:000328742600012	24323357	
J	Bartemes, KR; Iijima, K; Kobayashi, T; Kephart, GM; McKenzie, AN; Kita, H				Bartemes, Kathleen R.; Iijima, Koji; Kobayashi, Takao; Kephart, Gail M.; McKenzie, Andrew N.; Kita, Hirohito			IL-33-Responsive Lineage(-)CD25(+)CD44(hi) Lymphoid Cells Mediate Innate Type 2 Immunity and Allergic Inflammation in the Lungs	JOURNAL OF IMMUNOLOGY			English	Article							AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; MAST-CELLS; T-CELLS; ASTHMA; IL-33; RESPONSES; RECEPTOR; FAMILY; ST2	Innate immunity provides the first line of response to invading pathogens and a variety of environmental insults. Recent studies identified novel subsets of innate lymphoid cells that are capable of mediating immune responses in mucosal organs. In this paper, we describe a subset of lymphoid cells that is involved in innate type 2 immunity in the lungs. Airway exposure of naive BALB/c or C57BL/6J mice to IL-33 results in a rapid (<12 h) production of IL-5 and IL-13 and marked airway eosinophilia independently of adaptive immunity. In the lungs of nonsensitized naive mice, IL-33-responsive cells were identified that have a lymphoid morphology, lack lineage markers, highly express CD25, CD44, Thy1.2, ICOS, Sca-1, and IL-7R alpha (i.e., Lin(-)CD25(+)D44(hi) lymphoid cells), and require IL-7Ra for their development. Airway exposure of naive mice to a clinically relevant ubiquitous fungal allergen, Alternaria alternata, increases bronchoalveolar lavage levels of IL-33, followed by IL-5 and IL-13 production and airway eosinophilia without T or B cells. This innate type 2 response to the allergen is nearly abolished in mice deficient in IL-33R (i.e., ST2), and the Lin(-)CD25(+)CD44(hi) lymphoid cells in the lungs are required and sufficient to mediate the response. Thus, a subset of innate immune cells that responds to IL-33 and vigorously produces Th2-type cytokines is present in mouse lungs. These cells may provide a novel mechanism for type 2 immunity in the airways and induction of allergic airway diseases such as asthma. The Journal of Immunology, 2012, 188: 1503-1513.	[Bartemes, Kathleen R.; Iijima, Koji; Kobayashi, Takao; Kephart, Gail M.; Kita, Hirohito] Mayo Clin, Div Allerg Dis, Dept Internal Med, Rochester, MN 55905 USA; [Bartemes, Kathleen R.; Kita, Hirohito] Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; [McKenzie, Andrew N.] MRC, Mol Biol Lab, Cambridge CB2 0QH, England	Kita, H (reprint author), Mayo Clin, Div Allerg Dis, Dept Internal Med, 200 1st St SW, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			National Institutes of Health [AI34486, AI49235]; Mayo Foundation	This work was supported by R01 grants (AI34486 and AI49235) from the National Institutes of Health and the Mayo Foundation.	Ali M, 2009, TISSUE ANTIGENS, V73, P206, DOI 10.1111/j.1399-0039.2008.01185.x; Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051; Baekkevold ES, 2003, AM J PATHOL, V163, P69, DOI 10.1016/S0002-9440(10)63631-0; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Buonocore S, 2010, NATURE, V464, P1371, DOI 10.1038/nature08949; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Kephart GM, 2010, AM J GASTROENTEROL, V105, P298, DOI 10.1038/ajg.2009.584; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kouzaki H, 2011, J IMMUNOL, V186, P4375, DOI 10.4049/jimmunol.1003020; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lamkanfi M, 2009, IMMUNITY, V31, P5, DOI 10.1016/j.immuni.2009.06.011; Liu XJ, 2009, BIOCHEM BIOPH RES CO, V386, P181, DOI 10.1016/j.bbrc.2009.06.008; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Louten J, 2011, INT IMMUNOL, V23, P307, DOI 10.1093/intimm/dxr006; Luthi AU, 2009, IMMUNITY, V31, P84, DOI 10.1016/j.immuni.2009.05.007; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Sakashita M, 2008, CLIN EXP ALLERGY, V38, P1875, DOI 10.1111/j.1365-2222.2008.03114.x; Satoh-Takayama N, 2010, J EXP MED, V207, P273, DOI 10.1084/jem.20092029; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Spits H, 2011, NAT IMMUNOL, V12, P21, DOI 10.1038/ni.1962; SUGAMURA K, 1995, ADV IMMUNOL, V59, P225, DOI 10.1016/S0065-2776(08)60632-X; Suzukawa M, 2008, J IMMUNOL, V181, P5981; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wang YH, 2009, CLIN EXP ALLERGY, V39, P798, DOI 10.1111/j.1365-2222.2009.03241.x; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	50	171	180	1	25	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 1	2012	188	3					1503	1513		10.4049/jimmunol.1102832		11	Immunology	Immunology	884FL	WOS:000299690200065	22198948	
J	Kogan, MD; Strickland, BB; Blumberg, SJ; Singh, GK; Perrin, JM; van Dyck, PC				Kogan, Michael D.; Strickland, Bonnie B.; Blumberg, Stephen J.; Singh, Gopal K.; Perrin, James M.; van Dyck, Peter C.			A National Profile of the Health Care Experiences and Family Impact of Autism Spectrum Disorder Among Children in the United States, 2005-2006	PEDIATRICS			English	Article						autism spectrum disorder; children with special health care needs; disability; national estimates; access to health care	PERVASIVE DEVELOPMENTAL DISORDERS; PARENTAL REPORT; MEDICAL HOME; NEEDS; PREVALENCE; EXPENDITURES; ACCESS; SERVICES; SUPPORT; ASTHMA	OBJECTIVES. We sought to examine the health care experiences of children with autism spectrum disorder and the impact of autism spectrum disorder on the family and to assess whether having a medical home is associated with less family impact. METHODS. We used the 2005-2006 National Survey of Children With Special Health Care Needs to compare 2088 children with special health care needs, aged 3 to 17 years, reported by their parents to have autism spectrum disorder, with children with special health care needs with "other emotional, developmental, or behavioral problems" (excluding autism spectrum disorder; n = 9534) and 26 751 other children with special health care needs. We used weighted logistic regression to examine unmet needs for specific health care and support services, delayed care, no usual care source or personal physician, difficulty receiving referrals, and financial, employment, or time problems because of child's care. RESULTS. Nationally, an estimated 535 000 children have special health care needs and autism spectrum disorder, a prevalence of 86 per 10 000 children aged 3 to 17 years. Among children with special health care needs, 5.6% have autism spectrum disorder. Compared with other children with special health care needs without emotional, developmental, or behavioral problems, children with special health care needs with autism spectrum disorder were more likely to have unmet needs for specific health care services, family support services, delayed or foregone care, difficulty receiving referrals, and care that is not family centered. Children with special health care needs with autism spectrum disorder were more likely to live in families that report financial problems, need additional income for the child's medical care, reduce or stop work because of the child's condition, spend >= 10 hours per week providing or coordinating care, and paid more than $1000 in the previous year for the child's care. The financial impacts of autism spectrum disorder were significantly more burdensome when children with special health care needs did not have a medical home. CONCLUSIONS. Children with special health care needs with autism spectrum disorder are significantly more likely to have problems regarding access to care and unmet needs, and their families have greater financial, employment, and time burdens compared with other children with special health care needs. Receipt of primary care in a medical home may reduce these burdens. Pediatrics 2008; 122: e1149-e1158	[Kogan, Michael D.; Strickland, Bonnie B.; Singh, Gopal K.; van Dyck, Peter C.] US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD 20857 USA; [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA; [Perrin, James M.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA	Kogan, MD (reprint author), US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, 5600 Fishers Lane,Room 18-41, Rockville, MD 20857 USA.	mkogan@hrsa.gov					AAFP AAP ACP AOA, 2007, JOINT PRINC PAT CTR; American Academy of Pediatrics A, 2004, PEDIATRICS, V113, P1545; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; *AUT SPEAKS, ARG SUPP PRIV INS CO; Barbaresi WJ, 2006, ARCH PEDIAT ADOL MED, V160, P1167, DOI 10.1001/archpedi.160.11.1167; Beal A. C., 2007, CLOSING DIVIDE MED H; Bethell CD, 2002, AMBUL PEDIATR, V2, P38, DOI 10.1367/1539-4409(2002)002<0038:ICWSHC>2.0.CO;2; Blacher J, 2006, J INTELL DISABIL RES, V50, P184, DOI 10.1111/j.1365-2788.2005.00768.x; Blaxill MF, 2004, PUBLIC HEALTH REP, V119, P536, DOI 10.1016/j.phr.2004.09.003; BLUMBERG SJ, 2008, VITAL HLTH IN PRESS, V1; Brachlow AE, 2007, ARCH PEDIAT ADOL MED, V161, P399, DOI 10.1001/archpedi.161.4.399; BURD L, 1987, J AM ACAD CHILD PSY, V26, P700, DOI 10.1097/00004583-198709000-00014; Canitano R, 2005, J CHILD NEUROL, V20, P27, DOI 10.1177/08830738050200010401; Centers for Disease Control and Prevention, 2007, PROGR IMPL COMM BAS; Chakrabarti S, 2001, JAMA-J AM MED ASSOC, V285, P3093, DOI 10.1001/jama.285.24.3093; Croen LA, 2006, PEDIATRICS, V118; Denboba D, 2006, PEDIATRICS, V118, P1607, DOI 10.1542/peds.2006-0383; Duarte CS, 2005, AUTISM, V9, P416, DOI 10.1177/1362361305056081; Fombonne E, 2005, J CLIN PSYCHIAT, V66, P3; Ganz ML, 2006, UNDERSTANDING AUTISM, P475; Ghaziuddin M, 2002, J AUTISM DEV DISORD, V32, P299, DOI 10.1023/A:1016330802348; Gurney JG, 2006, ARCH PEDIAT ADOL MED, V160, P825, DOI 10.1001/archpedi.160.8.825; Gurney JG, 2003, ARCH PEDIAT ADOL MED, V157, P622, DOI 10.1001/archpedi.157.7.622; Herring S, 2006, J INTELL DISABIL RES, V50, P874, DOI 10.1111/j.1365-2788.2006.00904.x; Higgins DJ, 2005, AUTISM, V9, P125, DOI 10.1177/1362361305051403; Institute of Medicine, 2001, CROSS QUAL CHASM NEW; Johnson CP, 2007, PEDIATRICS, V120, P1183, DOI 10.1542/peds.2007-2361; Krauss MW, 2003, MENT RETARD, V41, P329, DOI 10.1352/0047-6765(2003)41<329:ATSMCF>2.0.CO;2; Landrigan PJ, 2002, ENVIRON HEALTH PERSP, V110, P721; Leslie DL, 2007, ARCH PEDIAT ADOL MED, V161, P350, DOI 10.1001/archpedi.161.4.350; LIMB S, 2001, PEDIAT PROVIDER CAPA; Liptak Gregory S, 2006, J Pediatr Health Care, V20, P245, DOI 10.1016/j.pedhc.2005.12.008; Liptak GS, 2006, J AUTISM DEV DISORD, V36, P871, DOI 10.1007/s10803-006-0119-9; Lord C., 2001, ED CHILDREN AUTISM; Lotter V., 1966, SOC PSYCHIAT, V1, P124, DOI DOI 10.1007/BF00584048; Mandell DS, 2007, AUTISM, V11, P111, DOI 10.1177/1362361307077506; Mangione-Smith R, 2007, NEW ENGL J MED, V357, P1515, DOI 10.1056/NEJMsa064637; McConachie H, 2006, CHILD CARE HLTH DEV, V32, P553, DOI 10.1111/j.1365-2214.2006.00672.x; McPherson M, 1998, PEDIATRICS, V102, P137, DOI 10.1542/peds.102.1.137; Molloy CA, 2003, AUTISM, V7, P165, DOI 10.1177/1362361303007002004; MONTES G, 2007, PEDIATRICS, V119; Myers SM, 2007, PEDIATRICS, V120, P1162, DOI 10.1542/peds.2007-2362; Newacheck PW, 2005, ARCH PEDIAT ADOL MED, V159, P10, DOI 10.1001/archpedi.159.1.10; NEWSCHAFFER CJ, 2005, PEDIATRICS, V115; Olley JG, 2005, HDB AUTISM PERVASIVE, P863; Pedlow S., 2007, MULTIPLE IMPUTATION; Peele PB, 2002, PSYCHIATR SERV, V53, P591, DOI 10.1176/appi.ps.53.5.591; Renty J, 2006, CHILD CARE HLTH DEV, V32, P371, DOI 10.1111/j.1365-2214.2006.00584.x; [Anonymous], 2004, SUDAAN EX MAN REL 9; Rickards AL, 2007, J DEV BEHAV PEDIATR, V28, P308, DOI 10.1097/DBP.0b013e318032792e; RITVO ER, 1989, AM J PSYCHIAT, V146, P194; Ruble LA, 2005, J AUTISM DEV DISORD, V35, P3, DOI 10.1007/s10803-004-1026-6; Schieve L. A., 2006, Morbidity and Mortality Weekly Report, V55, P481; SCHOENBAUM SC, 2006, NO PLACE HOME; Shimabukuro TT, 2008, J AUTISM DEV DISORD, V38, P546, DOI 10.1007/s10803-007-0424-y; Strickland B, 2004, PEDIATRICS, V113, P1485; Thomas KC, 2007, J AUTISM DEV DISORD, V37, P1902, DOI 10.1007/s10803-006-0323-7; *US BUR CENS, 1997, GLOSS DEC CENS TERMS; Williams JG, 2006, ARCH DIS CHILD, V91, P8, DOI 10.1136/adc.2004.062083; Yeargin-Allsopp M, 2003, JAMA-J AM MED ASSOC, V289, P49, DOI 10.1001/jama.289.1.49; [Anonymous], 2007, MMWR SURVEILL SUMM, V56, P1	61	171	171	2	22	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	DEC	2008	122	6					E1149	E1158		10.1542/peds.2008-1057		10	Pediatrics	Pediatrics	377NP	WOS:000261258200005	19047216	
J	Menzies, D; Nair, A; Williamson, PA; Schembri, S; Al-Khairalla, MZH; Barnes, M; Fardon, TC; McFarlane, L; Magee, GJ; Lipworth, BJ				Menzies, Daniel; Nair, Arun; Williamson, Peter A.; Schembri, Stuart; Al-Khairalla, Mudher Z. H.; Barnes, Martyn; Fardon, Tom C.; McFarlane, Lesley; Magee, Gareth J.; Lipworth, Brian J.			Respiratory symptoms, pulmonary function, and markers of inflammation among bar workers before and after a legislative ban on smoking in public places	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; EXHALED NITRIC-OXIDE; SECONDHAND SMOKE; LUNG-FUNCTION; PASSIVE SMOKING; BRONCHIAL RESPONSIVENESS; AIRWAY INFLAMMATION; PARENTAL SMOKING; EXPOSURE; ASTHMA	Context Scotland prohibited smoking in confined public places on March 26, 2006. Objective To investigate the association of smoke-free legislation with symptoms, pulmonary function, and markers of inflammation of bar workers. Design, Setting, and Participants This prospective observational study was conducted in Tayside, Scotland from February-June 2006. One hundred five nonasthmatic and asthmatic nonsmoking bar workers were initially enrolled, of whom 77 completed the study per protocol. Main Outcome Measures Respiratory and sensory symptoms, spirometry measurements, serum cotinine levels, peripheral inflammatory cell count, asthma qualityof-life scores, and exhaled nitric oxide levels were evaluated before and after introduction of the smoking ban. Results For the per-protocol analysis, the percentage of bar workers with respiratory and sensory symptoms decreased from 79.2% (n = 61) before the smoke-free policy to 53.2% (n = 41) (total change, -26%; 95% confidence interval [CI], -13.8% to -38.1%; P < .001) and 46.8% (n = 38) (-32.5%; 95% CI, -19.8% to -45.2%; P < .001) 1 and 2 months afterward. Forced expiratory volume in the first second increased from 96.6% predicted to 104.8% (change, 8.2%; 95% CI, 3.9% to 12.4%; P , .001) and then 101.7% (change, 5.1%; 95% CI, 2.1% to 8.0%; P = .002), and serum cotinine levels decreased from 5.15 ng/mL to 3.22 ng/mL (change, -1.93 ng/mL; 95% CI, -2.83 to -1.03 ng/mL; P < .001) and then 2.93 ng/mL (-2.22 ng/mL; 95% CI, -3.10 to -1.34 ng/ mL; P < .001). The total white blood cell and neutrophil count was reduced from 7610 to 6980 cells/mu L at 2 months (-630 cells/mu L; 95% CI, - 1010 to - 260 cells/mu L; P = .002) and from 4440 to 4030 cells/mu L (-410 cells/mu L; 95% CI, - 740 to - 90 cells/mu L; P = .03), respectively. Asthmatic bar workers also had less airway inflammation, with a reduction in exhaled nitric oxide from 34.3 parts per billion (ppb) to 27.4 ppb 1 month after the ban (0.8-fold change; 95% CI, 0.67 to 0.96 ppb; P = .04), and Juniper quality-of-life scores increased from 80.2 to 87.5 points (7.3 points; 95% CI, 0.1 to 14.6 points; P = .049). Conclusions Smoke-free legislation was associated with significant early improvements in symptoms, spirometry measurements, and systemic inflammation of bar workers. Asthmatic bar workers also had reduced airway inflammation and improved quality of life.	Univ Dundee, Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med & Therapeut, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Resp Med, Dundee DD1 9SY, Scotland	Menzies, D (reprint author), Univ Dundee, Ninewells Hosp & Med Sch, Asthma & Allergy Res Grp, Dept Med & Therapeut, Dundee DD1 9SY, Scotland.	d.menzies@dundee.ac.uk					Allwright S, 2005, BRIT MED J, V331, P1117, DOI 10.1136/bmj.38636.499225.55; Alving K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-67; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST.PUBMED:15817806; Barnoya J, 2005, CIRCULATION, V111, P2684, DOI 10.1161/CIRCULATIONAHA.104.492215; Berry M, 2005, EUR RESPIR J, V25, P986, DOI 10.1183/09031936.05.00132404; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Chinn S, 2005, AM J RESP CRIT CARE, V172, P956, DOI 10.1164/rccm.200503-3230C; Cook DG, 1998, THORAX, V53, P884; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crook MA, 2000, EUR J CLIN INVEST, V30, P861, DOI 10.1046/j.1365-2362.2000.00738.x; Eisner MD, 1998, JAMA-J AM MED ASSOC, V280, P1909, DOI 10.1001/jama.280.22.1909; Eisner MD, 2005, THORAX, V60, P814, DOI 10.1136/thx.2004.037283; Eisner MD, 2001, ENVIRON HEALTH PERSP, V109, P809, DOI 10.2307/3454823; Fardon TC, 2004, ANN ALLERG ASTHMA IM, V93, P365; Farrelly MC, 2005, TOB CONTROL, V14, P236, DOI 10.1136/tc.2004.008839; Frohlich M, 2003, EUR HEART J, V24, P1365, DOI 10.1016/S0195-668X(03)00260-4; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Houston TK, 2006, BRIT MED J, V332, P1064, DOI 10.1136/bmj.38779.584028.55; Inman MD, 1998, J ALLERGY CLIN IMMUN, V101, P342; Iribarren C, 2004, NEUROEPIDEMIOLOGY, V23, P38, DOI 10.1159/000073973; Janson C, 2001, LANCET, V358, P2103, DOI 10.1016/S0140-6736(01)07214-2; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Juniper EF, 1999, EUR RESPIR J, V14, P32, DOI 10.1034/j.1399-3003.1999.14a08.x; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Mulcahy M, 2005, TOB CONTROL, V14, P384, DOI 10.1136/tc.2005.011635; *NIH, 1995, PUBL NIH; *OFF SMOK HLTH, 2006, HLTH CONS INV EXP TO; Panagiotakos DB, 2004, AM J MED, V116, P145, DOI 10.1016/j.amjmed.2003.07.019; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Sargent RP, 2004, BRIT MED J, V328, P977, DOI 10.1136/bmj.38055.715683.55; Sasco AJ, 2004, LUNG CANCER-J IASLC, V45, pS3, DOI 10.1016/j.lungcan.2004.07.000; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; Ward C, 2005, CLIN EXP ALLERGY, V35, P1565, DOI 10.1111/j.1365-2222.2005.02365.x; Willemse BWM, 2004, EUR RESPIR J, V23, P464, DOI 10.1183/09031936.01.00012704; Yates DH, 2001, AM J RESP CRIT CARE, V164, P1043	36	171	178	1	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 11	2006	296	14					1742	1748		10.1001/jama.296.14.1742		7	Medicine, General & Internal	General & Internal Medicine	092NH	WOS:000241103400022	17032987	
J	Hysi, P; Kabesch, M; Moffatt, MF; Schedel, M; Carr, D; Zhang, YM; Boardman, B; von Mutius, E; Weiland, SK; Leupold, W; Fritzsch, C; Klopp, N; Musk, AW; James, A; Nunez, G; Inohara, N; Cookson, WOC				Hysi, P; Kabesch, M; Moffatt, MF; Schedel, M; Carr, D; Zhang, YM; Boardman, B; von Mutius, E; Weiland, SK; Leupold, W; Fritzsch, C; Klopp, N; Musk, AW; James, A; Nunez, G; Inohara, N; Cookson, WOC			NOD1 variation, immunoglobulin E and asthma	HUMAN MOLECULAR GENETICS			English	Article							QUANTITATIVE TRAITS; FOUNDER POPULATION; CROHNS-DISEASE; ASSOCIATION; GENE; SUSCEPTIBILITY; POLYMORPHISMS; LOCUS; IGE; RESPONSIVENESS	Asthma is a familial inflammatory disease of the airways of the lung. Microbial exposures in childhood protect against asthma through unknown mechanisms. The innate immune system is able to identify microbial components through a variety of pattern-recognition receptors (PRRs). NOD1 is an intracellular PRR that initiates inflammation in response to bacterial diaminopimelic acid (iE-DAP). The NOD1 gene is on chromosome 7p14, in a region that has been genetically linked to asthma. We carried out a systematic search for polymorphism in the gene. We found an insertion-deletion polymorphism (ND1+32656) near the beginning of intron IX that accounted for similar to 7% of the variation in IgE in two panels of families (P < 0.0005 in each). Allele*2 (the insertion) was associated with high IgE levels. The same allele was strongly associated with asthma in an independent study of 600 asthmatic children and 1194 super-normal controls [odds ratio (OR) 6.3; 95% confidence interval (CI) 1.4-28.3, dominant model]. Differential binding of the two ND1+32656 alleles was observed to a protein from nuclei of the Calu 3 epithelial cell line. In an accompanying study, the deletion allele (ND1+32656*1) was found to be associated with inflammatory bowel disease. The results indicate that intracellular recognition of specific bacterial products affects the presence of childhood asthma.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Environm Change Inst, Oxford OX3 7BN, England; Univ Childrens Hosp, Munich, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany; Univ Childrens Hosp Dresden, Dresden, Germany; Univ Childrens Hosp Leipzig, Leipzig, Germany; GSF Res Ctr Environm & Hlth, Neuherberg, Germany; Sir Charles Gairdner Hosp, Dept Resp Med & Pulm Physiol, Perth, WA, Australia; Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA	Cookson, WOC (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	wocc@well.ox.ac.uk		von Mutius, Erika/0000-0002-8893-4515			Abecasis GR, 2000, AM J HUM GENET, V66, P279, DOI 10.1086/302698; Abecasis GR, 2002, NAT GENET, V30, P97, DOI 10.1038/ng786; Abecasis GR, 2000, BIOINFORMATICS, V16, P182, DOI 10.1093/bioinformatics/16.2.182; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; DANIELS SE, 1996, NATURE, V383, P250; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; Dixon MS, 1998, PLANT CELL, V10, P1915, DOI 10.1105/tpc.10.11.1915; DIZIER MH, 1995, GENET EPIDEMIOL, V12, P93, DOI 10.1002/gepi.1370120109; FRECH K, 1993, NUCLEIC ACIDS RES, V21, P1655, DOI 10.1093/nar/21.7.1655; HILL MR, 1995, BRIT MED J, V311, P776; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1067/mai.2003.1815; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kruglyak L, 2001, NAT GENET, V27, P234, DOI 10.1038/85776; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; Lund O, 1997, PROTEIN ENG, V10, P1241, DOI 10.1093/protein/10.11.1241; MCGOVERN DPB, 2004, IN PRESS ASS COMPLEX; Moffatt MF, 2001, EUR J HUM GENET, V9, P341, DOI 10.1038/sj.ejhg.5200636; Monks SA, 1998, AM J HUM GENET, V63, P1507, DOI 10.1086/302104; Noel L, 1999, PLANT CELL, V11, P2099, DOI 10.1105/tpc.11.11.2099; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; SHERRILL DL, 1995, AM J RESP CRIT CARE, V152, P98; STRACHAN DP, 1989, BRIT MED J, V299, P1259; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x	34	171	178	1	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0964-6906			HUM MOL GENET	Hum. Mol. Genet.	APR 1	2005	14	7					935	941		10.1093/hmg/ddi087		7	Biochemistry & Molecular Biology; Genetics & Heredity	Biochemistry & Molecular Biology; Genetics & Heredity	911BJ	WOS:000227975800006	15718249	
J	Woerly, G; Honda, K; Loyens, M; Papin, JP; Auwerx, J; Staels, B; Capron, M; Dombrowicz, D				Woerly, G; Honda, K; Loyens, M; Papin, JP; Auwerx, J; Staels, B; Capron, M; Dombrowicz, D			Peroxisome proliferator-activated receptors alpha and gamma down-regulate allergic inflammation and eosinophil activation	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						nuclear receptors; asthma; eosinophils; IgE; ADCC	STEM-CELL FACTOR; FC-EPSILON-RI; NF-KAPPA-B; PPAR-GAMMA; GENE-EXPRESSION; AIRWAY HYPERRESPONSIVENESS; ENDOTHELIAL-CELLS; T-LYMPHOCYTES; MAST-CELLS; DENDRITIC CELLS	Allergic asthma is characterized by airway hyperresponsiveness, eosinophilia, and mucus accumulation and is associated with increased IgE concentrations. We demonstrate here that peroxisome proliferator-activated receptors (PPARs), PPAK-alpha and PPAR-gamma, which have been shown recently to be involved in the regulation of various cell types within the immune system, decrease antigen-induced air-way hyperresponsiveness, lung inflammation, eosinophilia, cytokine production, and GATA-3 expression as well as serum levels of antigen-specific IgE in a murine model of human asthma. In addition, we demonstrate that PPAR-alpha and -gamma are expressed in eosinophils and their activation inhibits in vitro chemotaxis and antibody-dependent cellular cytotoxicity. Thus, PPAR-alpha and -gamma (co)agonists might be of therapeutic interest for the regulation of allergic or inflammatory reactions by targeting both regulatory and effector cells involved in the immune response.	Inst Pasteur, INSERM, U547, IFR17, F-59019 Lille, France; Univ Lille 2, INSERM, U545, Inst Pasteur, F-59019 Lille, France; Univ Lille 2, Fac Pharm, F-59019 Lille, France; Univ Strasbourg 1, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67401 Illkirch Graffenstaden, France	Dombrowicz, D (reprint author), Inst Pasteur, INSERM, U547, IFR17, 1 Rue Prof Calmette BP 245, F-59019 Lille, France.		Dombrowicz, David/F-7044-2013	Dombrowicz, David/0000-0002-0485-8923			Adachi T, 1998, AM J PHYSIOL-CELL PH, V275, pC623; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Angeli W, 2001, EUR J IMMUNOL, V31, P2751; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487; CAPRON M, 1994, SCIENCE, V264, P1876, DOI 10.1126/science.8009216; Capron M, 1998, INT ARCH ALLERGY IMM, V116, P140, DOI 10.1159/000023937; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Clark RB, 2000, J IMMUNOL, V164, P1364; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Daynes RA, 2002, NAT REV IMMUNOL, V2, P748, DOI 10.1038/nri912; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Desreumaux P, 2001, J EXP MED, V193, P827, DOI 10.1084/jem.193.7.827; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Dombrowicz D, 2000, J IMMUNOL, V165, P1266; Dombrowicz D, 2001, CURR OPIN IMMUNOL, V13, P716, DOI 10.1016/S0952-7915(01)00284-9; Faveeuw C, 2000, FEBS LETT, V486, P261, DOI 10.1016/S0014-5793(00)02319-X; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Foster PS, 2001, IMMUNOL REV, V179, P173, DOI 10.1034/j.1600-065X.2001.790117.x; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Gosset P, 2001, EUR J IMMUNOL, V31, P2857, DOI 10.1002/1521-4141(2001010)31:10<2857::AID-IMMU2857>3.0.CO;2-X; GREZEL D, 1993, EUR J IMMUNOL, V23, P454, DOI 10.1002/eji.1830230223; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Hatae T, 2001, J BIOL CHEM, V276, P46260, DOI 10.1074/jbc.M107180200; Huang JT, 1999, NATURE, V400, P378; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Jones DC, 2002, P NUTR SOC, V61, P363, DOI 10.1079/PNS2002173; Jones DC, 2002, J BIOL CHEM, V277, P6838, DOI 10.1074/jbc.M106908200; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL302; Kampen GT, 2000, BLOOD, V95, P1911; Kayaba H, 2001, J IMMUNOL, V167, P995; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee H, 2000, CIRC RES, V87, P516; Lee JH, 2001, AM J RESP CELL MOL, V25, P474; LEE SST, 1995, MOL CELL BIOL, V15, P3012; Lewis JD, 2001, AM J GASTROENTEROL, V96, P3323; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Miyazaki Y, 2002, BIOCHEM BIOPH RES CO, V295, P547, DOI 10.1016/S0006-291X(02)00709-X; Moore KJ, 2001, NAT MED, V7, P41; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Patel HJ, 2003, J IMMUNOL, V170, P2663; Pelletier C, 1998, J IMMUNOL, V161, P4768; Poynter ME, 1998, J BIOL CHEM, V273, P32833, DOI 10.1074/jbc.273.49.32833; RAZIN E, 1994, P NATL ACAD SCI USA, V91, P7722, DOI 10.1073/pnas.91.16.7722; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Setoguchi K, 2001, J CLIN INVEST, V108, P1667; STANDIFORD TJ, 1995, J IMMUNOL, V155, P1515; Su CG, 1999, J CLIN INVEST, V104, P383, DOI 10.1172/JCI7145; Sugiyama H, 2000, EUR J IMMUNOL, V30, P3363, DOI 10.1002/1521-4141(2000012)30:12<3363::AID-IMMU3363>3.0.CO;2-B; Tan NS, 2001, GENE DEV, V15, P3263, DOI 10.1101/gad.207501; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; TSAI M, 1993, EUR J IMMUNOL, V23, P867, DOI 10.1002/eji.1830230415; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; Woerly G, 2002, J LEUKOCYTE BIOL, V72, P769; Yang XY, 2000, J BIOL CHEM, V275, P4541, DOI 10.1074/jbc.275.7.4541; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu X, 1999, J ELECTROMAGNET WAVE, V13, P3, DOI 10.1163/156939399X01573	68	171	180	2	3	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	AUG 4	2003	198	3					411	421		10.1084/jem.20021384		11	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	712TQ	WOS:000184813700005	12900517	
J	Romieu, I; Sienra-Monge, JJ; Ramirez-Aguilar, M; Tellez-Rojo, MM; Moreno-Macias, H; Reyes-Ruiz, NI; del Rio-Navarro, BE; Ruiz-Navarro, MX; Hatch, G; Slade, R; Hernandez-Avila, M				Romieu, I; Sienra-Monge, JJ; Ramirez-Aguilar, M; Tellez-Rojo, MM; Moreno-Macias, H; Reyes-Ruiz, NI; del Rio-Navarro, BE; Ruiz-Navarro, MX; Hatch, G; Slade, R; Hernandez-Avila, M			Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						childhood asthma; antioxidants; air pollution; Mexico	OZONE EXPOSURE; VITAMIN-E; LIPID-PEROXIDATION; PULMONARY-FUNCTION; ALPHA-TOCOPHEROL; RHESUS-MONKEYS; ASCORBIC-ACID; MILD ASTHMA; MEXICO-CITY; GLUTATHIONE	To evaluate whether acute effects of ozone, nitrogen dioxide, and particulates with mass median diameter less than 10 mum could be attenuated by antioxidant vitamin supplementation, we conducted a randomized trial using a double-blinded design. Children with asthma (n = 158) who were residents of Mexico City were randomly given a daily supplement of vitamins (50 mg/day of vitamin E and 250 mg/day of vitamin Q or a placebo and were followed from October 1998 to April 2000. Pulmonary function tests were carried out twice a week in the morning. During the follow-up observation period, the mean 1-hour maximum ozone level was 102 ppb (SD = 47), and the mean 24-hour average PM10 level was 56.7 mug/m(3) (SD = 27.4). In children with moderate and severe asthma, ozone levels 1 day before spirometry were inversely associated significantly with forced expiratory flow (FEF25-75) (-13.32 ml/ second/10 ppb; p = 0.000), FEV1 (-4.59 ml/10 ppb; p = 0.036), and peak expiratory flow (PEF) (-15.01 ml/second/10 ppb; p = 0.04) in the placebo group after adjusting for potential confounding factors. No association between ozone and lung functions was observed in the supplement group. We observed significant differences in lung function decrements between groups for FEF25-75 and PEF. Our results suggest that supplementation with antioxidants might modulate the impact of ozone exposure on the small airways of children with moderate to severe asthma.	Inst Nacl Salud Publ, Cuernavaca 62508, Morelos, Mexico; Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico; US EPA, Durham, NC USA	Romieu, I (reprint author), Inst Nacl Salud Publ, 655 Avenida Univ,Col Santa Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.						American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Blomberg A, 1999, EUR RESPIR J, V13, P1418, DOI 10.1183/09031936.99.13614299; Blomberg A, 2000, CLIN EXP ALLERGY, V30, P310; Castillejos M, 1992, AM REV RESPIR DIS, V145, P278; CASTLEMAN WL, 1980, AM J PATHOL, V98, P811; CHATHAM MD, 1987, ANN NY ACAD SCI, V498, P269, DOI 10.1111/j.1749-6632.1987.tb23767.x; Duan XZ, 1996, AM J RESP CELL MOL, V14, P70; ELSAYED NM, 1990, ARCH BIOCHEM BIOPHYS, V282, P263, DOI 10.1016/0003-9861(90)90115-F; *FOOD NUTR BOARD, 1989, NAT RES COUNC REC DI, P284; Frank R, 2001, AM J RESP CRIT CARE, V164, P1253; FREI B, 1991, BIOCHEM J, V277, P133; FREI B, 1990, ADV EXP MED BIOL, V264, P155; Grievink L., 1997, European Respiratory Journal Supplement, V10, p229S; Grievink L, 1999, AM J EPIDEMIOL, V149, P306; Hatch GE, 1995, AM J CLIN NUTR S, V61, p625S; HERNANDEZAVILA M, 1998, SALUD PUBLICA MEXICO, V39, P133; Kalayci O, 2000, TURKISH J PEDIATR, V42, P17; KELLY FJ, 1995, RESP MED, V89, P647, DOI 10.1016/0954-6111(95)90131-0; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; MCCAY PB, 1985, ANNU REV NUTR, V5, P323; MOHSENIN V, 1987, AM REV RESPIR DIS, V136, P1408; Mudway I. S., 2000, Molecular Aspects of Medicine, V21, P1, DOI 10.1016/S0098-2997(00)00003-0; NIKI E, 1982, CHEM LETT, P789, DOI 10.1246/cl.1982.789; *OFF MEX NORM, 1993, ENV HLTH CRIT EV AMB; Paige R., 1999, AIR POLLUTION HLTH, P531, DOI 10.1016/B978-012352335-8/50099-5; PLOPPER C, 1990, TROPOSPHERIC OZONE E, P137; Plopper CG, 1998, AM J RESP CELL MOL, V19, P387; PRYOR WA, 1991, AM J CLIN NUTR, V53, P702; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Romieu I, 1998, AM J RESP CRIT CARE, V158, P226; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819; SHARMA MK, 1993, FREE RADICAL BIO MED, V14, P649, DOI 10.1016/0891-5849(93)90146-L; *STAT, 1996, STAT SOFTW REL 5 0; Tekin D, 2000, J ASTHMA, V37, P59, DOI 10.3109/02770900009055428; TRABER MG, 1998, MODERN NUTR HLTH DIS, P347; Trenga CA, 2001, ARCH ENVIRON HEALTH, V56, P242; [National Instittites of Health National Heart Lung and Blood Institute US Department of Health and Human Services], 1998, NIH PUBL; U.S. Environmental Protection Agency, 1992, EPA600690006F; VANDEWOUDE M, 1984, J CHROMATOGR, V311, P176, DOI 10.1016/S0378-4347(00)84706-4; WEINMANN GG, 1995, AM J RESP CRIT CARE, V152, P1175; Wood LG, 2000, LIPIDS, V35, P967, DOI 10.1007/s11745-000-0607-x; Zar JH, 1996, BIOSTATISTICAL ANAL	46	171	174	0	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2002	166	5					703	709		10.1164/rccm.2112074		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	588ZZ	WOS:000177734100017	12204869	
J	Chung, KF; Pavord, ID				Chung, Kian Fan; Pavord, Ian D.			Chronic cough 1 - Prevalence, pathogenesis, and causes of chronic cough	LANCET			English	Review							GASTROESOPHAGEAL-REFLUX DISEASE; CHRONIC NONPRODUCTIVE COUGH; CHRONIC PERSISTENT COUGH; POSTNASAL-DRIP-SYNDROME; CRYPTOGENIC FIBROSING ALVEOLITIS; SOLE PRESENTING MANIFESTATION; OBSTRUCTIVE PULMONARY-DISEASE; BRONCHOALVEOLAR LAVAGE FLUID; INTERSTITIAL LUNG-DISEASE; CAPSAICIN-INDUCED COUGH	Cough is a reflex action of the respiratory tract that is used to clear the upper airways. Chronic cough lasting for more than 8 weeks is common in the community. The causes include cigarette smoking, exposure to cigarette smoke, and exposure to environmental pollution, especially particulates. Diseases causing chronic cough include asthma, eosinophilic bronchitis, gastro-oesophageal reflux disease, postnasal drip syndrome or rhinosinusitis, chronic obstructive pulmonary disease, pulmonary fibrosis, and bronchiectasis. Doctors should always work towards a clear diagnosis, considering common and rare illnesses. In some patients, no cause is identified, leading to the diagnosis of idiopathic cough. Chronic cough is often associated with an increased response to tussive agents such as capsaicin. Plastic changes in intrinsic and synaptic excitability in the brainstem, spine, or airway nerves can enhance the cough reflex, and can persist in the absence of the initiating cough event. Structural and inflammatory airway mucosal changes in non-asthmatic chronic cough could represent the cause or the traumatic response to repetitive coughing. Effective control of cough requires not only controlling the disease causing the cough but also desensitisation of cough pathways.	[Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, London SW3 6LY, England; [Chung, Kian Fan] Royal Brompton Hosp, London SW3 6LY, England; [Pavord, Ian D.] Univ Hosp Leicester NHS Trust, Glenfield Gen Hosp, Dept Resp Med Allergy & Thorac Surg, Inst Lung Hlth, Leicester, Leics, England	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Airway Dis Sect, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk		Pavord, Ian/0000-0002-4288-5973; Chung, Kian Fan/0000-0001-7101-1426			BALUK P, 1992, J COMP NEUROL, V319, P586, DOI 10.1002/cne.903190408; Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; BARBEE RA, 1991, CHEST, V99, P20, DOI 10.1378/chest.99.1.20; Bayer-Oglesby L, 2006, AM J EPIDEMIOL, V164, P1190, DOI 10.1093/aje/kwj338; Benini L, 2000, GUT, V46, P762, DOI 10.1136/gut.46.6.762; BERKIN KE, 1988, BRIT MED J, V296, P1279; Birkebaek NH, 1999, CLIN INFECT DIS, V29, P1239, DOI 10.1086/313448; Birring SS, 2004, EUR RESPIR J, V23, P199, DOI 10.1183/09031936.03.00066403; Birring SS, 2004, AM J RESP CRIT CARE, V169, P15, DOI 10.1164/rccm.200308-10920C; Birring SS, 2003, THORAX, V58, P1066, DOI 10.1136/thorax.58.12.1066; Bonham AC, 2006, RESP PHYSIOL NEUROBI, V152, P312, DOI 10.1016/j.resp.2006.02.010; BONNET R, 1995, CHEST, V108, P581, DOI 10.1378/chest.108.2.581; BOULET LP, 1994, AM J RESP CRIT CARE, V149, P482; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Brightling CE, 2000, EUR RESPIR J, V15, P682, DOI 10.1034/j.1399-3003.2000.15d10.x; Brightling CE, 2002, J ALLERGY CLIN IMMUN, V110, P899, DOI 10.1067/mai.2002.129698; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brightling Christopher E., 2000, American Journal of Respiratory and Critical Care Medicine, V162, P878; BUCCA C, 1995, J ALLERGY CLIN IMMUN, V95, P52, DOI 10.1016/S0091-6749(95)70152-4; Canning BJ, 2004, J PHYSIOL-LONDON, V557, P543, DOI 10.1113/jphysio.2003.057885; Canning BJ, 2006, RESP PHYSIOL NEUROBI, V152, P223, DOI 10.1016/j.resp.2006.03.001; Carney IK, 1997, AM J RESP CRIT CARE, V156, P211; Carter Edward R, 2006, Cough, V2, P11, DOI 10.1186/1745-9974-2-11; Caterina MJ, 2001, ANNU REV NEUROSCI, V24, P487, DOI 10.1146/annurev.neuro.24.1.487; Cerveri I, 2003, EUR RESPIR J, V22, P413, DOI 10.1183/09031936.03.00121103; CHOUDRY NB, 1989, AM REV RESPIR DIS, V140, P137; CHOUDRY NB, 1992, EUR RESPIR J, V5, P296; Chung KF, 2006, EUR RESPIR J, V27, P230, DOI 10.1183/09031936.06.00089405; Cook DG, 1999, THORAX, V54, P357; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372; Coyle Michael A, 2005, Cough, V1, P3, DOI 10.1186/1745-9974-1-3; CULLINAN P, 1993, J EPIDEMIOL COMMUN H, V47, P27, DOI 10.1136/jech.47.1.27; CULLINAN P, 1992, RESP MED, V86, P143, DOI 10.1016/S0954-6111(06)80231-3; David GL, 2005, THORAX, V60, P1052, DOI 10.1136/thx.2005.042960; DAVIS SF, 1995, CLIN INFECT DIS, V20, P621; de Jongste JC, 2003, THORAX, V58, P998, DOI 10.1136/thorax.58.11.998; DEMARCO R, 2006, AM J RESP CRIT CARE, V175, P32; Doherty MJ, 2000, THORAX, V55, P1028, DOI 10.1136/thorax.55.12.1028; Doherty MJ, 2000, THORAX, V55, P643, DOI 10.1136/thorax.55.8.643; Eccles R, 2003, COUGH: CAUSES, MECHANISMS AND THERAPY, P259, DOI 10.1002/9780470755846.ch25; FERRARI M, 1995, AM J RESP CRIT CARE, V151, P557; Ford AC, 2006, THORAX, V61, P975, DOI 10.1136/thx.2006.060087; Ford CN, 2005, JAMA-J AM MED ASSOC, V294, P1534, DOI 10.1001/jama.294.12.1534; Fox AJ, 1996, NAT MED, V2, P814, DOI 10.1038/nm0796-814; French CL, 1998, ARCH INTERN MED, V158, P1657, DOI 10.1001/archinte.158.15.1657; Fujimura M, 2005, RESPIROLOGY, V10, P201, DOI 10.1111/j.1440-1843.2005.00686.x; Fujimura M, 2003, THORAX, V58, P14, DOI 10.1136/thorax.58.1.14; Fujimura M, 2000, CLIN EXP ALLERGY, V30, P41; Fujimura M, 1997, J ASTHMA, V34, P119, DOI 10.3109/02770909709075656; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gibson PG, 2002, THORAX, V57, P178, DOI 10.1136/thorax.57.2.178; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V101, P320; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; Gilberg S, 2002, J INFECT DIS, V186, P415, DOI 10.1086/341511; Gordon SB, 1998, OCCUP MED-OXFORD, V48, P455, DOI 10.1093/occmed/48.7.455; Gordon SB, 1997, AM J RESP CRIT CARE, V156, P206; Groneberg DA, 2004, AM J RESP CRIT CARE, V170, P1276, DOI 10.1164/rccm.200402-1740C; Harnden A, 2006, BRIT MED J, V333, P174, DOI 10.1136/bmj.38870.655405.AE; HEINO M, 1990, AM REV RESPIR DIS, V141, P428; HO SY, 2006, ANN EPIDEMIOL, V17, P126; HOFFSTEIN V, 1994, CAN RESP J, V1, P40; Hope-Gill BDM, 2003, AM J RESP CRIT CARE, V168, P995, DOI 10.1164/rccm/200304-597OC; HSU JY, 1994, EUR RESPIR J, V7, P1246, DOI 10.1183/09031936.94.07071246; HUTCHINGS HA, 1993, RESP MED, V87, P379, DOI 10.1016/0954-6111(93)90052-2; ING AJ, 1994, AM J RESP CRIT CARE, V149, P160; Ing AJ, 2004, PULM PHARMACOL THER, V17, P403, DOI 10.1016/j.pupt.2004.09.023; Irwin RS, 2006, CHEST, V130, P362, DOI 10.1378/chest.130.2.362; IRWIN RS, 1993, CHEST, V104, P1511, DOI 10.1378/chest.104.5.1511; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640; IRWIN RS, 1989, AM REV RESPIR DIS, V140, P1294; Irwin RS, 2006, CHEST, V129, P1, DOI 10.1378/chest.129.1.1; Irwin RS, 2002, CHEST, V121, P1132, DOI 10.1378/chest.121.4.1132; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; Irwin RS, 1998, CHEST S, V114, P133; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234; JACK CIA, 1995, THORAX, V50, P201, DOI 10.1136/thx.50.2.201; Jacoby DB, 2004, PULM PHARMACOL THER, V17, P333, DOI 10.1016/j.pupt.2004.09.014; Janson C, 2001, EUR RESPIR J, V18, P647, DOI 10.1183/09031936.01.00098701; Jatakanon A, 1999, THORAX, V54, P234; Joad JP, 2004, AM J RESP CRIT CARE, V169, P499, DOI 10.1164/rccm.200308-1139OC; KAMEI RK, 1991, PEDIATR CLIN N AM, V38, P593; Kastelik JA, 2005, EUR RESPIR J, V25, P235, DOI 10.1183/09031936.05.00140803; KATSUMATA U, 1989, TOHOKU J EXP MED, V158, P105, DOI 10.1620/tjem.158.105; Kimber J, 1998, J NEUROL NEUROSUR PS, V65, P583, DOI 10.1136/jnnp.65.4.583; Kohno S, 2006, RESPIROLOGY, V11, pS135, DOI 10.1111/j.1400-1843.2006.00920.x; Kok C, 2003, AM J HUM GENET, V73, P632, DOI 10.1086/377591; Kollarik M, 2006, RESP PHYSIOL NEUROBI, V152, P243, DOI 10.1016/j.resp.2005.12.008; Kwon NH, 2006, CHEST, V129, P1142, DOI 10.1378/chest.129.5.1142; Kwong K, 2005, J PHYSIOL-LONDON, V564, P437, DOI 10.1113/jphysiol.2004.078725; Kwong K, 2002, J APPL PHYSIOL, V93, P1419, DOI 10.1152/japplphysiol.00382.2002; Lalloo UG, 1998, EUR RESPIR J, V11, P702; Lee SY, 2001, CHEST, V120, P1114, DOI 10.1378/chest.120.4.1114; Ludviksdottir D, 1996, CHEST, V109, P1262, DOI 10.1378/chest.109.5.1262; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; Madison JM, 2005, CURR OPIN PULM MED, V11, P412, DOI 10.1097/01.mcp.0000174249.07762.37; Mazzone SB, 2007, AM J RESP CRIT CARE, V176, P327, DOI 10.1164/rccm.200612-1856OC; McGarvey LPA, 1998, THORAX, V53, P738; McGarvey LPA, 1999, EUR RESPIR J, V13, P59; McLeod Robbie L, 2006, Cough, V2, P10, DOI 10.1186/1745-9974-2-10; Mello CJ, 1996, ARCH INTERN MED, V156, P997, DOI 10.1001/archinte.156.9.997; Moayyedi P, 2006, LANCET, V367, P2086, DOI 10.1016/S0140-6736(06)68932-0; Morice AH, 2004, EUR RESPIR J, V24, P481, DOI 10.1183/09031936.04.00027804; Morice AH, 2004, PULM PHARMACOL THER, V17, P343, DOI 10.1016/j.pupt.2004.09.005; Morice AH, 2002, PULM PHARMACOL THER, V15, P253, DOI 10.1006/pupt.2002.0352; MORICE AH, 2006, THORAX, V61, pS21; Mund E, 2005, CHEST, V127, P1714, DOI 10.1378/chest.127.5.1714; Mund E, 2001, THORAX, V56, P450, DOI 10.1136/thorax.56.6.450; NICHOL G, 1990, THORAX, V45, P694, DOI 10.1136/thx.45.9.694; Niimi A, 2000, LANCET, V356, P564, DOI 10.1016/S0140-6736(00)02584-8; Niimi A, 2005, J ALLERGY CLIN IMMUN, V116, P565, DOI 10.1016/j.jaci.2005.07.010; Niimi A, 2004, THORAX, V59, P608, DOI 10.1136/thx.2003.012906; Niimi A, 1998, EUR RESPIR J, V11, P1064, DOI 10.1183/09031936.98.11051064; NIIMI A, 2006, PULM PHARMACOL THER, V20, P383; Novitsky YW, 2002, SURG ENDOSC, V16, P567, DOI 10.1007/s00464-001-8328-y; O'Hara J, 2005, J LARYNGOL OTOL, V119, P507; OCONNELL F, 1994, AM J RESP CRIT CARE, V150, P374; Ojoo JC, 2003, LANCET, V361, P674, DOI 10.1016/S0140-6736(03)12603-7; Osman LM, 2001, THORAX, V56, P138, DOI 10.1136/thorax.56.2.138; Ours TM, 1999, AM J GASTROENTEROL, V94, P3131; Palombini BC, 1999, CHEST, V116, P279, DOI 10.1378/chest.116.2.279; Pierse N, 2006, THORAX, V61, P216, DOI 10.1136/thx.2004.036418; POE RH, 1989, CHEST, V95, P723, DOI 10.1378/chest.95.4.723; POWER JT, 1984, AM REV RESPIR DIS, V130, P999; PRATTER MR, 1993, ANN INTERN MED, V119, P977; Pratter MR, 2006, CHEST, V129, p63S, DOI 10.1378/chest.129.1_suppl.63S; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; SANTAMBROGIO F, 1987, ANNU REV PHYSIOL, V49, P622; Schelegle ES, 2001, RESP PHYSIOL, V125, P17, DOI 10.1016/S0034-5687(00)00202-4; Segala C, 2004, ARCH ENVIRON HEALTH, V59, P669; Sekizawa S, 2003, J PHYSIOL-LONDON, V552, P547, DOI 10.1113/jphysiol.2003.051326; Shannon R, 1998, J APPL PHYSIOL, V84, P2020; Shirahata K, 2005, RESPIROLOGY, V10, P354, DOI 10.1111/j.1440-1843.2005.00709.x; Smith J, 2006, CHEST, V130, P379, DOI 10.1378/chest.130.2.379; SMYRNIOS NA, 1995, CHEST, V108, P991, DOI 10.1378/chest.108.4.991; Suwanprathes P, 2003, AM J MED, V115, p31S, DOI 10.1016/S0002-9343(03)00190-6; Torrego A, 2006, THORAX, V61, P706, DOI 10.1136/thx.2005.049767; TURNERWARWICK M, 1980, THORAX, V35, P171, DOI 10.1136/thx.35.3.171; Undem BJ, 2004, J PHYSIOL-LONDON, V556, P905, DOI 10.1113/jphysiol.2003.060079; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Weinfeld D, 2002, ANN ALLERG ASTHMA IM, V89, P419; Widdicombe J, 2006, EUR RESPIR J, V28, P10, DOI 10.1183/09031936.06.00096905; Widdicombe JG, 1998, RESP PHYSIOL, V114, P5, DOI 10.1016/S0034-5687(98)00076-0; WIDDICOMBE JG, 1954, J PHYSIOL-LONDON, V123, P55; Widdicombe J, 2006, RESP PHYSIOL NEUROBI, V152, P320, DOI 10.1016/j.resp.2006.02.018; Wong CH, 1999, THORAX, V54, P62; Wu DN, 2002, CHEST, V122, P505, DOI 10.1378/chest.122.2.505; Zemp E, 1999, AM J RESP CRIT CARE, V159, P1257	151	170	193	1	19	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR 19	2008	371	9621					1364	1374		10.1016/S0140-6736(08)60595-4		11	Medicine, General & Internal	General & Internal Medicine	291PE	WOS:000255208500027	18424325	
J	Marks, GB; Mihrshahi, S; Kemp, AS; Tovey, ER; Webb, K; Almqvist, C; Ampon, RD; Crisafulli, D; Belousova, EG; Mellis, CM; Peat, JK; Leeder, SR				Marks, Guy B.; Mihrshahi, Seema; Kemp, Andrew S.; Tovey, Euan R.; Webb, Karen; Almqvist, Catarina; Ampon, Rosario D.; Crisafulli, Daniel; Belousova, Elena G.; Mellis, Craig M.; Peat, Jennifer K.; Leeder, Stephen R.		Childhood Asthma Prevention Study	Prevention of asthma during the first 5 years of life: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen avoidance; omega-3 fatty acids; prevention; birth cohort; house dust mite	DUST-MITE ALLERGEN; FATTY-ACID MODIFICATION; CHILDHOOD ASTHMA; ATOPIC ECZEMA; MATTRESS ENCASINGS; PREVALENCE; CHILDREN; SYMPTOMS; RISK; EXPOSURE	Background: Early life exposures may be important in the development of asthma and allergic disease. Objective: To test house dust mite (HDM) avoidance and dietary fatty acid modification, implemented throughout the first 5 years of life, as interventions to prevent asthma and allergic disease. Methods: We recruited newborns with a family history of asthma antenatally and randomized them, separately, to HDM avoidance or control and to dietary modification or control. At age 5 years, they were assessed for asthma and eczema and had skin prick tests for atopy. Results: Of 616 children randomized, 516 (84%) were evaluated at age 5 years. The HDM avoidance intervention resulted in a 61% reduction in HDM allergen concentrations (mu g/g dust) in the child's bed but no difference in the prevalence of asthma, wheeze, or atopy (P > .1). The prevalence of eczema was higher in the active HDM avoidance group (26% vs 19%; P = .06). The ratio of omega-6 to omega-3 fatty acids in plasma was lower in the active diet group (5.8 vs 7.4; P < .0001). However, the prevalence of asthma, wheezing, eczema, or atopy did not differ between the diet groups (P > .1). Conclusion: Further research is required to establish whether other interventions can be recommended for the prevention of asthma and allergic disease. Clinical implications: House dust mite avoidance measures and dietary fatty acid modification, as implemented in this trial during infancy and early childhood, did not prevent the onset of asthma, eczema, or atopy in high-risk children.	Woolcock Inst Med Res, Camperdown, NSW 2050, Australia; Univ Sydney, Sydney, NSW 2006, Australia; Childrens Hosp, Westmead, NSW, Australia	Marks, GB (reprint author), Woolcock Inst Med Res, POB M77,Missenden Rd PO, Camperdown, NSW 2050, Australia.	g.marks@unsw.edu.au	Mihrshahi, Seema/A-9877-2009; Tovey, Euan/G-8604-2017	Mihrshahi, Seema/0000-0001-6567-9884; Tovey, Euan/0000-0002-1802-7266			Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; JENKINS MA, 1994, BRIT MED J, V309, P90; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; KORSGAARD J, 1983, AM REV RESPIR DIS, V128, P231; MENEGHINI CL, 1982, CONTACT DERMATITIS, V8, P285, DOI 10.1111/j.1600-0536.1982.tb04231.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2003, ALLERGY, V58, P784, DOI 10.1034/j.1398-9995.2003.00194.x; Mihrshahi S, 2002, RESPIROLOGY, V7, P147, DOI 10.1046/j.1440-1843.2002.00384.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; PEAT JK, 1994, BRIT MED J, V308, P1591; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; Tovey ER, 2003, ALLERGY, V58, P790, DOI 10.1034/j.1398-9995.2003.00228.x; Tovey Euan R, 2003, N Engl J Med, V349, P1668; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; Warner JO, 1998, PEDIATR PULM, V25, P1; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC	35	170	175	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2006	118	1					53	61		10.1016/j.jaci.2006.04.004		9	Allergy; Immunology	Allergy; Immunology	065UH	WOS:000239184800006	16815138	
J	Gehring, U; Cyrys, J; Sedlmeir, G; Brunekreef, B; Bellander, T; Fischer, P; Bauer, CP; Reinhardt, D; Wichmann, HE; Heinrich, J				Gehring, U; Cyrys, J; Sedlmeir, G; Brunekreef, B; Bellander, T; Fischer, P; Bauer, CP; Reinhardt, D; Wichmann, HE; Heinrich, J			Traffic-related air pollution and respiratory health during the first 2 yrs of life	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; geographic information systems; infants; respiratory symptoms; traffic	NITROGEN-DIOXIDE; EAST-GERMANY; CHILDREN; SYMPTOMS; ASTHMA; EXPOSURE; POLLUTANTS; PREVALENCE; PARTICLES; DENSITY	As part of an international collaborative study on the impact of Traffic-Related Air Pollution on Childhood Asthma (TRAPCA), the health effects associated with long-term exposure to particles with a 50% cut-off aerodynamic diameter of 2.5 mum (PM2.5), PM2.5 absorbance, and nitrogen dioxide (NO2) were analysed. The German part of the TRAPCA study used data from subpopulations of two ongoing birth cohort studies (German Infant Nutrition Intervention Programme (GIN I) and Influences of Lifestyle Related Factors on the Human Immune System and Development of Allergies in Children (LISA)) based in the city of Munich. Geographic information systems (GIS)-based exposure modelling was used to estimate traffic-related air pollutants at the birth addresses of 1,756 infants. Logistic regression was used to analyse possible health effects and potential confounding factors were adjusted for. The ranges in estimated exposures to PM2.5, PM2.5 absorbance, and NO2 were 11.9-21.9 mug.m(-3), 1.38-4.39x10(-5) m(-1), and 19.5-66.9 mug.m(3), respectively. Significant associations between these pollutants and cough without infection (odds ratio (OR) (95% confidence interval (CI): 1.34 (1.11-1.61), 1.32 (1.10-1.59), and 1.40 (1.12-1.75), respectively) and dry cough at night (OR (95% Cl): 1.31 (1.07-1.60), 1.27 (1.04-1.55), and 1.36 (1.07-1.74), respectively) in the first year of life were found. In the second year of life, these effects were attenuated. There was some indication of an association between traffic-related air pollution and symptoms of cough. Due to the very young age of the infants, it was too early to draw definitive conclusions from this for the development of asthma.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Chair Epidemiol, D-80539 Munich, Germany; City Munich Dept Environm & Hlth, Munich, Germany; Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Grp, Utrecht, Netherlands; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; RIVM Natl Inst Publ Hlth & Environm, Bilthoven, Netherlands; Tech Univ Munich, Dept Paediat, D-8000 Munich, Germany; Univ Munich, Dept Pediat, Munich, Germany	Gehring, U (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Cyrys, Josef/B-5359-2014	brunekreef, bert/0000-0001-9908-0060; Gehring, Ulrike/0000-0003-3612-5780; Cyrys, Josef/0000-0002-2105-8696			BEYER U, 1998, EUR RESPIR REV, V8, P61; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1989, SCHWEIZ MED WSCHR, V119, P1424; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; de Marco R, 2000, AM J RESP CRIT CARE, V162, P68; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; DOERSHUK CF, 1974, AM REV RESPIR DIS, V109, P452; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Farrow A, 1997, ARCH ENVIRON HEALTH, V52, P189; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; *I RISK ASS SCI UT, RISK ASS EXP TRAFF R; Kunzli N, 2000, ENVIRON HEALTH PERSP, V108, P915, DOI 10.2307/3435048; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Magnus P, 1998, INT J EPIDEMIOL, V27, P995, DOI 10.1093/ije/27.6.995; MARPLE VA, 1987, JAPCA J AIR WASTE MA, V37, P1303; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Samet J M, 1993, Res Rep Health Eff Inst, P1; *STAT AMT LAND MUE, BAS JAH VERSCH BER K; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; THURLBECK WM, 1982, THORAX, V37, P564, DOI 10.1136/thx.37.8.564; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; VONMUTIUS E, 1995, EUR RESPIR J, V8, P723; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilkinson P, 1999, THORAX, V54, P1070; WJST M, 1993, BRIT MED J, V307, P596	36	170	176	5	25	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	APR	2002	19	4					690	698		10.1183/09031936.02.01182001		9	Respiratory System	Respiratory System	541RB	WOS:000174996600017	11998999	
J	Warner, JO				Warner, JO		ETAC Study Grp	A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months' treatment and 18 months' posttreatment follow-up	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; asthma; prevention; house dust mite; grass pollen; cetirizine; antihistamine; children	ALLERGIC AIRWAY DISEASE; YOUNG-CHILDREN; CAT ALLERGEN; RISK; RECRUITMENT; CHALLENGE; CHILDHOOD	Background: Because asthma is not a curable condition, the development of strategies for prevention of the disease has a high priority. Atopic dermatitis is a common precursor to the development of asthma, and 2 studies have suggested that the use of an H-1 receptor antagonist might reduce the development of asthma while the treatment is being administered, at least in subgroups with evidence of high IgE levels. However, no trial to date has conducted follow-up after the initial treatment has been stopped to establish whether the intervention has merely suppressed symptoms or truly prevented disease. Objective: We sought to establish whether the use of cetirizine compared with placebo for 18 months in infants with atopic dermatitis suppressed or truly delayed the onset of asthma, even after cessation of therapy. Methods: The Early Treatment of the Atopic Child study was a double-blinded, parallel-group, randomized trial of 0.25 mg/kg body weight cetirizine administered twice daily compared with placebo given to infants between I and 2 years of age with atopic dermatitis. After 18 months of treatment, follow-up continued for a further 18 months. This article reports the outcome over the full 3 years of follow-up and relates the outcomes to the allergic status on the basis of IgE antibody measurements at recruitment. Results: Although there was no difference in cumulative prevalence of asthma between active and placebo treatment in the intention-to-treat population (P = .7), those infants with evidence of sensitivity to house dust mite, grass pollen, or both who were treated with cetirizine were significantly less likely to have asthma compared with those treated with placebo over the 18 months of treatment (P = .005 and .002, respectively), and this effect was sustained for the grass pollen-sensitized infants over the full 36 months (P = .008). In the house dust mite-sensitized group there was a gradual narrowing of the difference between active and placebo treatment in terms of cumulative prevalence of asthma at the end of 36 months but no evidence of a rebound immediately after the treatment stopped (P = .04). In the placebo population there was a significantly higher risk of development of asthma in those sensitized at baseline to egg (relative risk, 1.4 [95% CI, 1.1-1.7]), house dust mite (relative risk, 1.6 [95% CI, 1.3-1.9%]), grass pollen (relative risk, 1.7 [95% CI, 1.4-2.1]), or cat (relative risk, 1.5 [95% CI, 1.2-1.9]). Early and persistent sensitization conferred a higher risk than transient or later sensitization. Conclusions: Cetirizine compared with placebo truly delays or, in some cases, prevents the development of asthma in a subgroup of infants with atopic dermatitis sensitized to grass pollen and, to a lesser extent, house dust mite. Further studies are required focusing specifically on sensitized groups to substantiate this finding. The study also highlights risk factors for asthma in infants with atopic dermatitis and indicates that early and persistent aeroallergen sensitization confers a higher risk than later development of sensitivity.	Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton S016 6YD, Hants, England	Warner, JO (reprint author), Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Southampton S016 6YD, Hants, England.						Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arnold R, 1999, CLIN EXP ALLERGY, V29, P1681, DOI 10.1046/j.1365-2222.1999.00630.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; Eriksson Nils E., 1998, Allergology International, V47, P187, DOI 10.2332/allergolint.47.187; Estelle F, 2001, J ALLERGY CLIN IMMUN, V107, P703, DOI 10.1067/mai.2001.113866; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325; IIKURA Y, 1992, ANN ALLERGY, V68, P233; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Marguet C, 2001, PEDIATR ALLERGY IMMU, V12, P27, DOI 10.1034/j.1399-3038.2001.012001027.x; National Heart Lung and Blood Institute, 1995, NIH PUBL, V95-3803; Orange AP, 1997, PEDIATR ALLERGY IMMU, V8, P28, DOI 10.1111/j.1399-3038.1997.tb00139.x; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; REDIER H, 1992, J ALLERGY CLIN IMMUN, V90, P215, DOI 10.1016/0091-6749(92)90074-C; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P433, DOI 10.1016/S0091-6749(99)70389-1; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; WARNER JO, 1998, CLIN EXP ALLERGY, V28, P179; WOOD RA, 1993, CLIN EXP ALLERGY, V23, P733, DOI 10.1111/j.1365-2222.1993.tb00360.x	20	170	186	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2001	108	6					929	937		10.1067/mai.2001.120015		9	Allergy; Immunology	Allergy; Immunology	505WK	WOS:000172938400008	11742270	
J	Chapman, KR; Tashkin, DP; Pye, DJ				Chapman, KR; Tashkin, DP; Pye, DJ			Gender bias in the diagnosis of COPD	CHEST			English	Article						asthma; misdiagnosis; physician decision making; spirometry; underdiagnosis	OBSTRUCTIVE PULMONARY-DISEASE; INHALED CORTICOSTEROID USE; ASTHMA; DIFFERENCE; DENSITY; CARE; RISK	Background: COPD is thought to be more prevalent among men than women, a finding usually attributed to higher smoking rates and more frequent occupational exposures of significance for men. However, smoking prevalence has increased among women and there is evidence that women may be more susceptible to the adverse pulmonary function effects of smoking than men. There may also be underdiagnosis and misdiagnosis of COPD in both sexes because objective measures of lung function are underused, Objectives: We undertook the present study to determine if there is gender bias in the diagnosis of COPD, such that women are less likely than men to receive a diagnosis of COPD, We also attempted to determine if underuse of I;ng function measurements was a factor in any bias detected. Methods: We surveyed a random sample of 192 primary-care physicians (96 American and 96 Canadian; 154 men and 38 women) using a hypothetical case presentation and a structured interview. The case of cough and dyspnea in a smoker was presented in six versions differing only in the age and sex of the patient. After presentation of the history and physical findings, physicians were asked to state the most probable diagnosis and to choose the diagnostic studies needed, Physicians were then presented with spirometric findings of moderate or severe obstruction without significant bronchodilator response, and the questions repeated. Finally, the negative outcome of an oral steroid trial was described. Results: Initially, COPD was given as the most probable diagnosis significantly more often for men than women (58% vs 42%; p < 0,05), The likelihood of a COPD diagnosis increased significantly and initial differences between sexes decreased as objective information was provided. After spirometry, COPD diagnosis rates for men and women were 74% vs 66% (p = not significant); after the steroid trial 85% vs 79% (p = not significant). Only 22% of physicians would have requested spirometry after the initial presentation, Conclusions: In North America, primary-care physicians underdiagnose COPD, particularly in women. Spirometry reduces the risk of underdiagnosis and gender bias but is underused.	Univ Toronto, Dept Med, Div Resp Med, Toronto, ON, Canada; Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; Westmount Res Consultants, Toronto, ON, Canada	Chapman, KR (reprint author), Univ Hlth Network, Asthma Ctr, Suite 4-011 ECW,399 Bathurst St, Toronto, ON M5T 2S8, Canada.						AYANIAN JZ, 1991, NEW ENGL J MED, V325, P221, DOI 10.1056/NEJM199107253250401; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; FRANKS P, 1995, ANN INTERN MED, V123, P548; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; HANANIA NA, 1995, J ALLERGY CLIN IMMUN, V96, P571, DOI 10.1016/S0091-6749(95)70254-7; IP M, 1994, CHEST, V105, P1722, DOI 10.1378/chest.105.6.1722; Jackevicius C, 1997, CHEST, V111, P296, DOI 10.1378/chest.111.2.296; Jackevicius CA, 1997, ANN PHARMACOTHER, V31, P160; Joyce DP, 1996, CHEST, V109, P697, DOI 10.1378/chest.109.3.697; KANNER RE, 1994, AM J RESP CRIT CARE, V150, P956; KESTEN S, 1993, CHEST, V104, P254, DOI 10.1378/chest.104.1.254; KUHN CE, 1995, PEDIATR PULM, V19, P156, DOI 10.1002/ppul.1950190303; Prescott E, 1997, EUR RESPIR J, V10, P822; REA HH, 1991, ANN ALLERGY, V66, P48; SHEFFER SL, 1992, PUBLICATION	15	170	172	1	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2001	119	6					1691	1695		10.1378/chest.119.6.1691		5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	441NB	WOS:000169235500014	11399692	
J	Kouzaki, H; O'Grady, SM; Lawrence, CB; Kita, H				Kouzaki, Hideaki; O'Grady, Scott M.; Lawrence, Christopher B.; Kita, Hirohito			Proteases Induce Production of Thymic Stromal Lymphopoietin by Airway Epithelial Cells through Protease-Activated Receptor-2	JOURNAL OF IMMUNOLOGY			English	Article							NF-KAPPA-B; DUST MITE ALLERGEN; DENDRITIC CELLS; CYTOKINE PRODUCTION; ADAPTIVE IMMUNITY; HUMAN EOSINOPHILS; TYPE-2 RESPONSES; INHALED ANTIGEN; IFN-GAMMA; ASTHMA	Thymic stromal lymphopoietin (TSLP) is produced by epithelial cells and triggers dendritic cell-mediated Th2-type inflammation. Although TSLP is up-regulated in epithelium of patients with asthma, the factors that control TSLP production have not been studied extensively. Because mouse models suggest roles for protease(s) in Th2-type immune responses, we hypothesized that proteases from airborne allergens may induce TSLP production in a human airway epithelial cell line, BEAS-2B. TSLP mRNA and protein were induced when BEAS-2B cells were exposed to prototypic proteases, namely, trypsin and papain. TSLP induction by trypsin required intact protease activity and also a protease-sensing G protein-coupled receptor, protease-activated receptor (PAR)-2; TSLP induction by papain was partially dependent on PAR-2. In humans, exposure to ubiquitous airborne fungi, such as Alternaria, is implicated in the development and exacerbation of asthma. When BEAS-2B cells or normal human bronchial epithelial cells were exposed to Alternaria extract, TSLP was potently induced. The TSLP-inducing activity of Alternaria was partially blocked by treating the extract with a cysteine protease inhibitor, E-64, or by infecting BEAS-2B cells with small interfering RNA for PAR-2. Protease-induced TSLP production by BEAS-2B cells was enhanced synergistically by IL-4 and abolished by IFN-gamma. These findings demonstrate that TSLP expression is induced in airway epithelial cells by exposure to allergen-derived proteases and that PAR-2 is involved in the process. By promoting TSLP production in the airways, proteases associated with airborne allergens may facilitate the development and/or exacerbation of Th2-type airway inflammation, particularly in allergic individuals. The Journal of Immunology, 2009, 183: 1427-1434.	[Kouzaki, Hideaki; Kita, Hirohito] Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA; [Kouzaki, Hideaki] Shiga Univ Med Sci, Dept Otorhinolaryngol, Shiga, Japan; [O'Grady, Scott M.] Univ Minnesota, Dept Integrated Biol, St Paul, MN 55108 USA; [O'Grady, Scott M.] Univ Minnesota, Dept Physiol & Anim Sci, St Paul, MN 55108 USA; [Lawrence, Christopher B.] Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA; [Lawrence, Christopher B.] Virginia Polytech Inst & State Univ, Dept Biol Sci, Blacksburg, VA 24061 USA	Kita, H (reprint author), Mayo Clin, Dept Internal Med, Div Allerg Dis, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			National Institutes of Health; National Institute of Allergy and Infectious Diseases [AI49235]; Mayo Foundation	This work was supported in part by the National Institutes of Health, National Institute of Allergy and Infectious Diseases (Grant AI49235) and the Mayo Foundation.	Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Alexander J, 1998, J IMMUNOL, V161, P6794; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; Chapman MD, 2007, CURR ALLERGY ASTHM R, V7, P363, DOI 10.1007/s11882-007-0055-6; Comoy EE, 1998, J IMMUNOL, V160, P2456; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; Ebeling C, 2007, J IMMUNOL, V179, P2910; Goh FG, 2008, CELL SIGNAL, V20, P1267, DOI 10.1016/j.cellsig.2008.02.015; Gottar M, 2006, CELL, V127, P1425, DOI 10.1016/j.cell.2006.10.046; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hayashi T, 2007, J IMMUNOL, V178, P7385; Hong JH, 2008, AM J RESP CELL MOL, V39, P530, DOI 10.1165/rcmb.2007-0410OC; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Kato A, 2007, CURR OPIN IMMUNOL, V19, P711, DOI 10.1016/j.coi.2007.08.004; Kato A, 2007, J IMMUNOL, V179, P1080; Kato A, 2006, J IMMUNOL, V177, P7164; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kheradmand F, 2002, J IMMUNOL, V169, P5904; King C, 1998, J IMMUNOL, V161, P3645; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; McGlade JP, 2007, J IMMUNOL, V178, P2794; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; Miike S, 2001, J IMMUNOL, V167, P6615; Nathan AT, 2009, J ALLERGY CLIN IMMUN; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ossovskaya VS, 2004, PHYSIOL REV, V84, P579, DOI 10.1152/physrev.00028.2003; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Rallabhandi P, 2008, J BIOL CHEM, V283, P24314, DOI 10.1074/jbc.M804800200; Ramachandran R, 2008, BRIT J PHARMACOL, V153, pS263, DOI 10.1038/sj.bjp.0707507; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Roche N, 2003, J ALLERGY CLIN IMMUN, V111, P367, DOI 10.1067/mai.2003.6; Romani Luigina, 2004, Nat Rev Immunol, V4, P1; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Schmidlin F, 2002, J IMMUNOL, V169, P5315; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-03880C; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sun A Y, 2001, Neurotox Res, V3, P167; Temkin V, 2002, J IMMUNOL, V169, P2662; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Wang H, 2002, AM J PHYSIOL-CELL PH, V283, P1351; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Ying S, 2005, J IMMUNOL, V174, P8183; Zhao AP, 2005, J IMMUNOL, V175, P2563; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	57	169	174	0	5	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUL 15	2009	183	2					1427	1434		10.4049/jimmunol.0900904		8	Immunology	Immunology	468JD	WOS:000267812600071	19561109	
J	Passalacqua, G; Durham, SR				Passalacqua, Giovanni; Durham, Stephen R.		Global Allergy Asthma	Allergic rhinitis and its impact on asthma update: Allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						injection immunotherapy; sublingual immunotherapy; efficacy; safety; mechanisms	GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; MONOPHOSPHORYL-LIPID-A; PRESEASONAL-SPECIFIC IMMUNOTHERAPY; SYSTEMIC IMMUNOLOGICAL CHANGES; MESSENGER-RNA EXPRESSION; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND	The Allergic Rhinitis and its Impact on Asthma document was first published in 2001. Since then, new data on specific immunotherapy have appeared. This review is intended as an update to the original document. MedLine (2001 to June 2006) was searched with appropriate key words, and panelists were asked to identify further relevant articles. Randomized controlled trials were considered for the evaluation of efficacy. For the evaluation of safety, and additional effects, studies with lower grades of evidence were included. The clinical efficacy of injection immunotherapy in rhinitis and asthma was confirmed, as well as the safety, provided that recommendations are followed. Studies have demonstrated the long-term efficacy and the preventive effect of immunotherapy in reducing the onset of new sensitizations. One randomized open trial demonstrated that in children with allergic rhinitis, injection immunotherapy may reduce the risk of developing asthma. There is strong evidence that sublingual immunotherapy is effective in allergic rhinitis in adults. Recent meta-analyses demonstrated its efficacy in allergic rhinitis in children and in asthma, although more definitive trials are required. Current data indicate that sublingual immunotherapy is safe and the rate of adverse reactions is not greater below 5 years of age. One randomized open trial showed that in children with allergic rhinitis, sublingual immunotherapy reduced the onset of asthma. Further studies are needed to identify the optimal maintenance dose and to elucidate the mechanism of action. Novel approaches for immunotherapy are currently under evaluation, including the use of adjuvants, peptides. and DNA-conjugated and recombinant allergens.	Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Passalacqua, G (reprint author), Univ Genoa, Dept Internal Med, Padiglione Maragliano,Lgo R Benzi 10, I-16132 Genoa, Italy.	passalacqua@unige.it	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	Medical Research Council [G9805965]		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Alvarez-Cuesta E, 2005, CLIN EXP ALLERGY, V35, P572, DOI 10.1111/j.1365-2222.2005.02245.x; Ameal A, 2005, ALLERGY, V60, P1178, DOI 10.1111/j.1398-9995.2005.00862.x; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Arifhodzic N, 2003, INT ARCH ALLERGY IMM, V132, P258, DOI 10.1159/000074307; Arvidsson MB, 2004, ALLERGY, V59, P74, DOI 10.1046/j.1398-9995.2003.00334.x; Asero R, 2003, ALLERGY, V58, P435, DOI 10.1034/j.1398-9995.2003.00139.x; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI [10.1111/j.1365-2222.2004.1939.x, 10.1111/j.1365-2222.2004.01939.x]; Bonini S, 2006, ALLERGY, V61, P681, DOI 10.1111/j.1398-9995.2006.01080.x; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS146; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Calderon MA, 2007, COCHRANE DB SYST REV, V1, DOI DOI 10.1002/14651858.CD001936.PUB2; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Custovic A, 2005, ALLERGY, V60, P1112, DOI 10.1111/j.1398-9995.2005.00934.x; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Harvey SM, 2004, ANN ALLERG ASTHMA IM, V92, P414; Horner AA, 2002, ALLERGY, V57, P24, DOI 10.1034/j.1398-9995.57.s72.12.x; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; KHINCHI MS, 2004, ALLERGY, V59, P33; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Limb SL, 2006, INT ARCH ALLERGY IMM, V140, P245, DOI 10.1159/000093250; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j/jaci.2004.03.013; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Marcucci F, 2005, PEDIATR ALLERGY IMMU, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nettis E, 2002, CLIN EXP ALLERGY, V32, P1745, DOI 10.1046/j.1365-2222.2002.01544.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niggemann B, 2006, ALLERGY, V61, P865; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1395-9995.2006.01098.x; Passalacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P1054, DOI 10.1016/j.jaci.2005.12.1308; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Passlacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; PITNER M, 2004, CLIN EXP ALLERGY, V34, P597; Polosa R, 2003, CLIN EXP ALLERGY, V33, P873, DOI 10.1046/j.1365-2222.2003.01676.x; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Rak S, 2005, ALLERGY, V60, P643, DOI 10.1111/j.1398-9995.2005.00763.x; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Schadlich PK, 2000, PHARMACOECONOMICS, V17, P37; Shekelle PG, 1999, BRIT MED J, V318, P593; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Strait RT, 2006, J CLIN INVEST, V116, P833, DOI 10.1172/JCI25575; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Walker Ross F., 2000, Limnology, V1, P107, DOI 10.1007/s102010070016; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Watanabe Hiroshi, 2004, Allergology International, V53, P255, DOI 10.1111/j.1440-1592.2004.00342.x; *WHO, 1998, ALLERGY S54, V53, pS3; Wilcock LK, 2004, CLIN EXP ALLERGY, V34, P1373, DOI 10.1111/j.1365-2222.2004.02052.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Wilson DR, 2005, ALLERGY, V60, P3; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Zan H, 1998, J IMMUNOL, V161, P5217; Zhu DC, 2002, NAT MED, V8, P518, DOI 10.1038/nm0502-518	144	169	187	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					881	891		10.1016/j.jaci.2007.01.045		11	Allergy; Immunology	Allergy; Immunology	157OK	WOS:000245729500016	17418661	
J	Johnston, NW; Johnston, SL; Duncan, JM; Greene, JM; Kebadze, T; Keith, PK; Roy, M; Waserman, S; Sears, MR				Johnston, NW; Johnston, SL; Duncan, JM; Greene, JM; Kebadze, T; Keith, PK; Roy, M; Waserman, S; Sears, MR			The September epidemic of asthma exacerbations in children: A search for etiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; children; viral infections; rhinovirus; school return; inhaled corticosteroid; leukotriene receptor antagonist	RESPIRATORY-INFECTIONS; RHINOVIRUS INFECTIONS; HOSPITAL ADMISSION; CHILDHOOD ASTHMA; AIR-POLLUTION; ALLERGENS; FREQUENCY; EXPOSURE; VIRUSES; SCHOOL	Background: Predictable peaks of asthma exacerbation requiring hospital treatment, of greatest magnitude in children and of uncertain etiology, occur globally after school returns. Objective: We wished to determine whether asthmatic children requiring emergency department treatment for exacerbations after school return in September were more likely to have respiratory viruses present and less likely to have prescriptions for control medications than children with equally severe asthma not requiring emergent treatment. Methods: Rates of viral detection and characteristics of asthma management in 57 (of 60) children age 5 to 15 years presenting to emergency departments with asthma in 2 communities in Canada between September 10 and 30, 2001, (cases) were compared with those in 157 age-matched volunteer children with asthma of comparable severity studied simultaneously (controls). Results: Human picornaviruses were detected in 52% of cases and 29% of controls (P=.002) and viruses of any type in 62% of cases and 41% of controls (P =.011). Cases were less likely to have been prescribed controller medication (inhaled corticosteroid, 49% vs 85%; P <.0001; leukotriene receptor antagonist, 9% vs 21%; P =.04). Conclusion: Respiratory viruses were detected in the majority of children presenting to emergency departments with asthma during the September epidemic of the disease and in a significant minority of children with asthma in the community. The latter were more likely to have anti-inflammatory medication prescriptions than children requiring emergent treatment. Such medication may reduce the risk of emergency department treatment for asthma during the September epidemic.	St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 4A6, Canada; Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Resp Med, London, England; Brant Community Healthcare Syst, Brantford, ON, Canada	Johnston, NW (reprint author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	njohnsto@sympatico.ca	Johnston, Sebastian/I-2423-2012				Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arruda E, 1997, J CLIN MICROBIOL, V35, P2864; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; Blaisdell CJ, 2002, J ASTHMA, V39, P567, DOI 10.1081/JAS-120014921; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; DEKLUIJVER J, 2002, AM J RESP CRIT CARE, V168, P1174; Fleming DM, 2000, THORAX, V55, P657, DOI 10.1136/thorax.55.8.657; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gergen PJ, 2002, J PEDIATR-US, V141, P631, DOI 10.1067/mpd.2002.127510; Gern JE, 1999, CLIN MICROBIOL REV, V12, P9; Gern JE, 2002, AM J MED, V112, p19S; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; Habbick BF, 1999, CAN MED ASSOC J, V160, P1824; Harju T, 1997, EUR J PEDIATR, V156, P436, DOI 10.1007/s004310050632; JOHNSTON NW, 2001, AM J RESP CRIT CARE, V163, pA359; Johnston SL, 2003, AM J RESP CRIT CARE, V168, P1145, DOI 10.1164/rccm.2309004; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; LONGINI IM, 1984, INT J EPIDEMIOL, V13, P99, DOI 10.1093/ije/13.1.99; Makela MJ, 2003, J ALLERGY CLIN IMMUN, V112, P861, DOI 10.1067/mai.2003.1768; MAO Y, 1990, CAN J PUBLIC HEALTH, V81, P226; MELETH S, 1997, CAN RESP J, V4, P263; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; Monteil MA, 2000, J ASTHMA, V37, P677, DOI 10.3109/02770900009087306; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; POTTER PC, 1984, S AFR MED J, V15, P397; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; STORR J, 1989, ARCH DIS CHILD, V64, P103; STRACHAN D, 2002, COLLATION COMPAR DAT; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323	36	169	172	0	10	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					132	138		10.1016/j.jaci.2004.09.025		7	Allergy; Immunology	Allergy; Immunology	886XS	WOS:000226267000019	15637559	
J	Bornehag, CG; Sundell, J; Bonini, S; Custovic, A; Malmberg, P; Skerfving, S; Sigsgaard, T; Verhoeff, A				Bornehag, CG; Sundell, J; Bonini, S; Custovic, A; Malmberg, P; Skerfving, S; Sigsgaard, T; Verhoeff, A			Dampness in buildings as a risk factor for health effects, EUROEXPO: a multidisciplinary review of the literature (1998-2000) on dampness and mite exposure in buildings and health effects	INDOOR AIR			English	Review						indoor environment; damp buildings; mite exposure; health effects; review	HOUSE-DUST-MITE; INDOOR ALLERGEN LEVELS; RESPIRATORY SYMPTOMS; ATOPIC-DERMATITIS; SCHOOL-CHILDREN; CHILDHOOD ASTHMA; AIR-POLLUTION; NASAL LAVAGE; BRONCHIAL HYPERRESPONSIVENESS; SYSTEMIC SYMPTOMS	The scientific literature on health effects from dampness in buildings, including mite exposure over the period 1998-2000 has been reviewed by a European group (EUROEXPO) of eight scientists in experience from medicine, epidemiology, toxicology and engineering. Forty studies deemed relevant have been the foundation for the conclusions. Dampness in buildings is a risk factor for health effects among atopics and non-atopics both in domestic and in public environments. However, the literature is not conclusive in respect of causative agents, e.g. mites, microbiological agents and organic chemicals from degraded building materials. There is a strong need for more multidisciplinary studies including expertise from all relevant areas. A general conclusion from the work was that there is a strong need for multidisciplinary reviews in scientific journals of articles dealing with associations between indoor environmental factors and health effects.	Swedish Natl Testing & Res Inst, Boras, Sweden; Tech Univ Denmark, Int Ctr Indoor Environm & Energy, Kongens Lyngby, Denmark; Italian Natl Res Council, Inst Neurobiol & Mol Med, Rome, Italy; Univ Naples 2, Naples, Italy; Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England; Natl Inst Working Life, Stockholm, Sweden; Lund Univ, Environm & Occupat Med Sect, Lund, Sweden; Univ Aarhus, Dept Environm & Occupat Med, Aarhus, Denmark; Municipal Hlth Serv Amsterdam, Dept Epidemiol & Hlth Promot, Amsterdam, Netherlands; Karlstad Univ, SE-65188 Karlstad, Sweden	Bornehag, CG (reprint author), Karlstad Univ, SE-65188 Karlstad, Sweden.	carl-qustaf.bornehaq@kau.se	Sundell, Jan/B-2857-2012; Verhoeff, Arnoud/F-7924-2013; Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Sigsgaard, Torben/0000-0002-2043-7571; Bonini, Sergio/0000-0003-0079-3031			Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Ahman M, 2000, INDOOR AIR, V10, P57, DOI 10.1034/j.1600-0668.2000.010001057.x; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Atkinson W, 1999, EUR RESPIR J, V13, P583, DOI 10.1183/09031936.99.13358599; Attena F, 1999, EUR J EPIDEMIOL, V15, P569, DOI 10.1023/A:1007564323390; Bornehag CG, 2001, INDOOR AIR, V11, P72; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Brown CW, 1999, ANN ALLERG ASTHMA IM, V83, P240, DOI 10.1016/S1081-1206(10)62647-6; Burr ML, 1999, THORAX, V54, P27; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Chan-Yeung M, 1999, CLIN EXP ALLERGY, V29, P762; Charpin D, 1999, CLIN EXP ALLERGY, V29, P1474; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Couper D, 1998, CLIN EXP ALLERGY, V28, P715; de Almeida M M, 1999, Pediatr Pulmonol Suppl, V18, P49; De Boer R, 1998, J MED ENTOMOL, V35, P905; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Fielder HMP, 1999, ARCH DIS CHILD, V80, P253; Flappan SM, 1999, ENVIRON HEALTH PERSP, V107, P927; Friedmann PS, 1998, ALLERGY, V53, P97; Frosh AC, 1999, CLIN EXP ALLERGY, V29, P457; Gaig P, 1999, ANN ALLERG ASTHMA IM, V82, P531, DOI 10.1016/S1081-1206(10)63160-2; GARETT MH, 1998, CLIN EXP ALLERGY, V28, P459; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Gutgesell C, 1999, CLIN EXP ALLERGY, V29, P920, DOI 10.1046/j.1365-2222.1999.00553.x; Hallas TE, 1998, ALLERGY, V53, P101; Hansen SK, 1998, ACTA DERM-VENEREOL, V78, P139; Haverinen U, 1999, ENVIRON HEALTH PERSP, V107, P509; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hirsch Thomas, 1999, Reviews on Environmental Health, V14, P159; Hirvonen MR, 1999, AM J RESP CRIT CARE, V160, P1943; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; Holm L, 1999, ALLERGY, V54, P708, DOI 10.1034/j.1398-9995.1999.00010.x; Ichikawa K, 1999, CLIN EXP ALLERGY, V29, P754; Jalaludin B, 1998, J ALLERGY CLIN IMMUN, V102, P382, DOI 10.1016/S0091-6749(98)70124-1; Jedrychowski W, 1998, Int J Occup Med Environ Health, V11, P19; Julge K, 1998, ALLERGY, V53, P388, DOI 10.1111/j.1398-9995.1998.tb03910.x; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261; Kane MP, 1999, J ASTHMA, V36, P371, DOI 10.3109/02770909909068230; Karaman O, 1999, PEDIATR INT, V41, P147; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; Klanova K, 2000, Cent Eur J Public Health, V8, P59; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; Korsgaard J, 1998, ALLERGY, V53, P36; Korsgaard J, 1998, ALLERGY, V53, P77; Koskinen OM, 1999, EUR RESPIR J, V14, P1363, DOI 10.1183/09031936.99.14613639; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Krieger JW, 2000, J URBAN HEALTH, V77, P50, DOI 10.1007/BF02350962; Kroidl RF, 1998, ALLERGY, V53, P435, DOI 10.1111/j.1398-9995.1998.tb03919.x; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; Lonnkvist K, 1999, PEDIATR ALLERGY IMMU, V10, P45, DOI 10.1034/j.1399-3038.1999.101001.x; Montefort S, 1998, CLIN EXP ALLERGY, V28, P1089; Moon JS, 1999, YONSEI MED J, V40, P238; Nahm DH, 1998, ANN ALLERG ASTHMA IM, V80, P411; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Nicolai T, 1998, THORAX, V53, P1035; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Nriagu J, 1999, EUR J EPIDEMIOL, V15, P747, DOI 10.1023/A:1007653709188; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Ooi PL, 1998, OCCUP ENVIRON MED, V55, P188; Parameswaran K, 1999, J ASTHMA, V36, P613, DOI 10.3109/02770909909087299; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Plaschke P, 1999, ALLERGY, V54, P843, DOI 10.1034/j.1398-9995.1999.00162.x; Ponsonby AL, 2000, EPIDEMIOLOGY, V11, P128, DOI 10.1097/00001648-200003000-00008; Puybasset L, 1998, AM J RESP CRIT CARE, V158, P1644; Ramadan F, 1998, EUR J EPIDEMIOL, V14, P687, DOI 10.1023/A:1007454505983; Rangel A, 1998, CLIN EXP ALLERGY, V28, P1100; Ricci G, 1999, BRIT J DERMATOL, V140, P651; Ring J, 1999, INT ARCH ALLERGY IMM, V118, P403, DOI 10.1159/000024148; RONNMARK E, 1999, ALLERGY, V54, P926; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Schafer T, 1999, ENVIRON RES, V81, P151, DOI 10.1006/enrs.1999.3964; Schafer T, 1999, ALLERGY ASTHMA PROC, V20, P23, DOI 10.2500/108854199778681477; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18; Smith AM, 1998, CLIN IMMUNOL IMMUNOP, V86, P102, DOI 10.1006/clin.1997.4454; Sporik R, 1999, THORAX, V54, P675; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; van der Heide S, 1998, ALLERGY, V53, P104; Vervloet D, 1999, EUR RESPIR J, V13, P983, DOI 10.1034/j.1399-3003.1999.13e09.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P58; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Warner A, 1999, ALLERGY, V54, P681, DOI 10.1034/j.1398-9995.1999.00850.x; Warner A, 1998, ALLERGY, V53, P698, DOI 10.1111/j.1398-9995.1998.tb03956.x; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8; Wever-Hess J, 2000, PEDIATR PULM, V29, P250, DOI 10.1002/(SICI)1099-0496(200004)29:4<250::AID-PPUL3>3.0.CO;2-4; Wickens K, 1999, PEDIATR ALLERGY IMMU, V10, P199, DOI 10.1034/j.1399-3038.1999.00033.x; Wieslander G, 1999, INT ARCH OCC ENV HEA, V72, P507, DOI 10.1007/s004200050408; Wieslander G, 1999, INT ARCH OCC ENV HEA, V72, P451, DOI 10.1007/s004200050398; Yang CY, 1998, CHEST, V114, P393, DOI 10.1378/chest.114.2.393; Yang CY, 1998, PEDIATR PULM, V26, P120, DOI 10.1002/(SICI)1099-0496(199808)26:2<120::AID-PPUL8>3.0.CO;2-Q; Yazicioglu M, 1998, Allergol Immunopathol (Madr), V26, P5; Yu CK, 1999, CLIN EXP ALLERGY, V29, P414; Zacharasiewicz A, 1999, WIEN KLIN WOCHENSCHR, V111, P882	107	169	177	4	31	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air	AUG	2004	14	4					243	257		10.1111/j.1600-0668.2004.00240.x		15	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	832SY	WOS:000222288600003	15217478	
J	Black, PN; Udy, AA; Brodie, SM				Black, PN; Udy, AA; Brodie, SM			Sensitivity to fungal allergens is a risk factor for life-threatening asthma	ALLERGY			English	Article						asthma; fungal allergens	FATAL ASTHMA	Background: Previous studies have suggested that sensitivity to Alternaria and Cladosporium may be risk factors for life-threatening asthma. We have investigated this by studying the relationship between skin tests for fungal spores and admission to atl intensive care unit (ICU) for asthma. Methods: Skin prick tests for fungal spores (Alternaria tenuis, Cladosporium cladosporoides, Helminthosporium maydis, and Epicoccum nigrum), cat dander, house-dust mite (Dermatophagoides pteronyssinus), and a seven-grass mix were performed in three groups of patients: patients admitted to an ICU with an attack of asthma; those who had received emergency treatment for asthma but had not been admitted to an ICU, and those who had never required emergency treatment for their asthma. Results: Twenty of 37 patients (54%) admitted to the ICU had a positive skin test for one or more fungal allergens compared with 15/50 patients (30%) in each of the other groups (P=0.005). The ICU patients were no more likely to have positive skin tests for the grass mix, cat dander, or house-dust mite than the other patients. Conclusions: a positive skin test for fungal allergens is a risk factor for admission to an ICU with an acute attack of asthma.	Univ Auckland, Dept Med, Auckland, New Zealand	Black, PN (reprint author), Auckland Hosp, Dept Med, Private Bag 92024, Auckland, New Zealand.		Udy, Andrew /G-2538-2010	Udy, Andrew /0000-0002-6284-2022			ABRAMSON M, 1995, AUST N Z MED J, V25, P424; BENATAR SR, 1986, NEW ENGL J MED, V314, P423, DOI 10.1056/NEJM198602133140706; BROWN HM, 1978, CLIN ALLERGY, V7, P611; CAREY MJ, 1986, BRIT MED J, V293, P843; *COMM SKIN TEST ST, 1988, CLIN ALLERGY, V18, P305; Derrick EH, 1972, AUSTR NZ J MEDICINE, V3, P235; HASNAIN SM, 1985, NEW ZEAL MED J, V98, P342; LI DW, 1995, INT J BIOMETEOROL, V39, P74, DOI 10.1007/BF01212584; MOLFINO NA, 1994, EUR RESPIR J, V7, P981; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; RICHARDS GN, 1993, THORAX, V48, P1105, DOI 10.1136/thx.48.11.1105; Richerson HB, 1986, ASTHMA CLIN PHARM TH, P23; ROUX P, 1993, S AFR MED J, V83, P177; SOLOMON WR, 1993, ALLERGY PRINCIPLES P, P469; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1	16	169	175	0	6	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	MAY	2000	55	5					501	504		10.1034/j.1398-9995.2000.00293.x		4	Allergy; Immunology	Allergy; Immunology	308KT	WOS:000086710800013	10843433	
J	Xiao, C; Puddicombe, SM; Field, S; Haywood, J; Broughton-Head, V; Puxeddu, I; Haitchi, HM; Vernon-Wilson, E; Sammut, D; Bedke, N; Cremin, C; Sones, J; Djukanovic, R; Howarth, PH; Collins, JE; Holgate, ST; Monk, P; Davies, DE				Xiao, Chang; Puddicombe, Sarah M.; Field, Sarah; Haywood, Joel; Broughton-Head, Victoria; Puxeddu, Ilaria; Haitchi, Hans Michael; Vernon-Wilson, Elizabeth; Sammut, David; Bedke, Nicole; Cremin, Catherine; Sones, Jody; Djukanovic, Ratko; Howarth, Peter H.; Collins, Jane E.; Holgate, Stephen T.; Monk, Phillip; Davies, Donna E.			Defective epithelial barrier function in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Tight junction; epidermal growth factor; cigarette smoke; asthma; epithelial barrier	EPIDERMAL-GROWTH-FACTOR; TIGHT JUNCTIONS; BRONCHIAL EPITHELIUM; ULCERATIVE-COLITIS; FACTOR RECEPTOR; ERBB RECEPTORS; HEGF LEVELS; DISEASE; CELLS; EXPRESSION	Background: Asthma is a complex disease involving gene and environment interactions. Although atopy is a strong predisposing risk factor for asthma, local tissue susceptibilities are required for disease expression. The bronchial epithelium forms the interface with the external environment and is pivotally involved in controlling tissue homeostasis through provision of a physical barrier controlled by tight junction (TJ) complexes. Objectives: To explain the link between environment exposures and airway vulnerability, we hypothesized that epithelial TJs are abnormal in asthma, leading to increased susceptibility to environmental agents. Methods: Localization of TJs in bronchial biopsies and differentiated epithelial cultures was assessed by electron microscopy or immunostaining. Baseline permeability and the effect of cigarette smoke and growth factor were assessed by measurement of transepithelial electrical resistance and passage of fluorescently labeled dextrans. Results: By using immunostaining, we found that bronchial biopsies from asthmatic subjects displayed patchy disruption of TJs. In differentiated bronchial epithelial cultures, TJ formation and transepithelial electrical resistance were significantly lower (P < .05) in cultures from asthmatic donors (n = 43) than from normal controls (n = 40) and inversely correlated with macromolecular permeability. Cultures from asthmatic donors were also more sensitive to disruption by cigarette smoke extract. Epidermal growth factor enhanced basal TJ formation in cultures from asthmatic subjects (P < .01) and protected against cigarette smoke-induced barrier disruption (P < .01). Conclusions: Our results show that the bronchial epithelial barrier in asthma is compromised. This defect may facilitate the passage of allergens and other agents into the airway tissue, leading to immune activation and may thus contribute to the end organ expression of asthma. (J Allergy Clin Immunol 2011;128:549-56.)	[Davies, Donna E.] Univ Southampton, Div Infect Inflammat & Immun, Sir Henry Wellcome Labs, Sch Med,Southampton Gen Hosp, Southampton SO16 6YD, Hants, England; [Puxeddu, Ilaria; Haitchi, Hans Michael; Sammut, David; Bedke, Nicole; Djukanovic, Ratko; Howarth, Peter H.; Collins, Jane E.; Holgate, Stephen T.; Davies, Donna E.] Univ Southampton, Sch Med,Southampton Gen Hosp, Southampton NIHR Resp Biomed Res Unit, Southampton SO16 6YD, Hants, England	Davies, DE (reprint author), Univ Southampton, Div Infect Inflammat & Immun, Sir Henry Wellcome Labs, Sch Med,Southampton Gen Hosp, Level F,S Block,Mailpoint 810, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna/H-2993-2012; Haywood, Joel/G-8311-2016	Djukanovic, Ratko/0000-0001-6039-5612	Synairgen Research Ltd; University of Southampton; National Institute of Health Research (United Kingdom); Medical Research Council; Synairgen	This work was funded by Synairgen Research Ltd and the University of Southampton. Stephen T. Holgate is a Medical Research Council Clinical Professor.; Disclosure of potential conflict of interest: C. Xiao, S. Field, J. Haywood, V. Broughton-Head, J. Sones, and P. Monk are employees of Synairgen Research Limited. R. Djukanovic is a cofounder and shareholder of and a consultant for Synairgen. P. H. Howarth has received research support from the National Institute of Health Research (United Kingdom). S. T. Holgate owns shares in and consults for Synairgen; is vice president of the British Lung Foundation; and has received research support from the Medical Research Council. D. E. Davies is a cofounder and shareholder of, is a consultant for, and has received research support from Synairgen. The rest of the authors have declared that they have no conflict of interest.	Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029; Van Itallie CM, 2009, CSH PERSPECT BIOL, V1, DOI DOI 10.1101/cshperspect.a002584; Basuroy S, 2006, BIOCHEM J, V393, P69; BOSKABADY MH, 1992, AM REV RESPIR DIS, V145, P756; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; BRITTEN KM, 1993, BIOTECH HISTOCHEM, V68, P271, DOI 10.3109/10520299309105629; Bruewer M, 2006, ANN NY ACAD SCI, V1072, P242, DOI 10.1196/annals.1326.017; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; CEREIJIDO M, 1988, AM REV RESPIR DIS, V138, pS17; Davies DE, 1999, ALLERGY, V54, P771; BA De, 2011, J ALLERGY CLIN IMMUN, V127, P773; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI 10.1139/y08-004; DJUKANOVIC R, 1991, AM REV RESPIR DIS, V143, P772; DRAGSTEN PR, 1981, NATURE, V294, P718, DOI 10.1038/294718a0; Ehrhardt C, 2002, CELL TISSUE RES, V308, P391, DOI 10.1007/s00441-002-0548-5; Evans SM, 2002, AM J RESP CELL MOL, V27, P446, DOI 10.1165/rcmb.4776; Farrell RJ, 2003, NEW ENGL J MED, V349, P395, DOI 10.1056/NEJMe030075; Furuse M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002907; Gray TE, 1996, AM J RESP CELL MOL, V14, P104; HAYASHI T, 1988, J PHARMACOBIO-DYNAM, V11, P146; Heyman M, 2005, EUR J GASTROEN HEPAT, V17, P1279, DOI 10.1097/00042737-200512000-00003; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Ma L, 2000, AM J PHYSIOL-GASTR L, V278, pG10; O'Donnell RA, 2004, THORAX, V59, P1032, DOI 10.1136/thx.2004.028043; Oxford GE, 2000, J DIABETES COMPLICAT, V14, P140, DOI 10.1016/S1056-8727(00)00073-8; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Polosa R, 1999, AM J RESP CELL MOL, V20, P914; Prasad S, 2005, LAB INVEST, V85, P1139, DOI 10.1038/labinvest.3700316; Puddicombe SM, 2006, P AM THORAC SOC, V3, pA424; Shin CE, 2000, J PEDIATR SURG, V35, P173, DOI 10.1016/S0022-3468(00)90005-8; Sinha A, 2003, NEW ENGL J MED, V349, P350, DOI 10.1056/NEJMoa013136; Spears M, 2010, EXPERT REV CLIN IMMU, V6, P257, DOI 10.1586/ECI.09.85; Steed E, 2010, TRENDS CELL BIOL, V20, P142, DOI 10.1016/j.tcb.2009.12.002; SWEETENHAM JW, 1990, BRIT J CANCER, V62, P459, DOI 10.1038/bjc.1990.318; Terakado M, 2011, AM J PHYSIOL-LUNG C, V300, pL56, DOI 10.1152/ajplung.00159.2010; Thomason HA, 2010, BIOCHEM J, V429, P419, DOI 10.1042/BJ20100567; Tillie-Leblond I, 2007, EUR RESPIR J, V30, P31, DOI 10.1183/09031936.00011606; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; VAN MEER G, 1986, EMBO J, V5, P1455; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Xiao C, 2007, AM J RESP CRIT CARE, V175, pA886; Xiao C, 2008, AM J RESP CRIT CARE, V177, pA57	43	168	173	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2011	128	3					549	U177		10.1016/j.jaci.2011.05.038		20	Allergy; Immunology	Allergy; Immunology	812HS	WOS:000294283400013	21752437	
J	Saarinen, KM; Pelkonen, AS; Makela, M; Savilahti, E				Saarinen, KM; Pelkonen, AS; Makela, M; Savilahti, E			Clinical course and prognosis of cow's milk allergy are dependent on milk-specific IgE status	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cow's milk allergy; IgE; sensitization; skin test; tolerance; atopy	FOLLOW-UP; ATOPIC-DERMATITIS; EGG ALLERGY; 4 REGIONS; CHILDREN; AGE; INFANTS; SENSITIZATION; TOLERANCE; FOOD	Background: Large, prospective population-based studies on clinical course, development of tolerance, and risk for other atopy in children with cow's milk allergy (CMA) are lacking. Objective: We investigated the development of tolerance and the risk for asthma, rhinoconjunctivitis, atopic dermatitis, and sensitization in children with CMA followed to school age. Methods: We followed 118 children with CMA until recovery and repeatedly measured their sensitization to cow's milk (CM). At age 8.6 years, 94 allergic subjects and 80 control subjects from the same cohort were studied for atopic diseases and sensitization. In addition, the parents of 12 allergic subjects and 26 control children returned a questionnaire on atopy, respectively. Results: IgE-mediated CMA was detected in 86 (73%) children; at age 8.6 years, 13 (15%) had persistent CMA. All children with IgE-negative CMA were tolerant by age 5.0 years (P < .0001). Risk factors for persistent CMA at age 2.0 years were sensitization to CM at age 1.6 years (odds ratio, 6.3; 95% CI, 2.6-15.2), urticaria at diagnostic challenge (odds ratio, 3.3; 95% CI, 1.4-7.8), CM exposure at the maternity hospital (odds ratio, 3.2; 95% CI, 1.4-7.8), and early sensitization to egg (odds ratio, 2.8; 95% CI, 1.2-6.6). By age 8.6 years, children with IgE-positive CMA more frequently had asthma (31% vs 13%, P <= .01), rhinoconjunctivitis (66% vs 21%, P <= .001), atopic eczema (81% vs 26%, P <= .001), and sensitization to any allergen (88% vs 39%, P <= .001) than control subjects. CMA and family history of atopy were independent risk factors for atopic diseases, and CMA was also a risk factor for sensitization to inhalant allergens. Conclusion: IgE-mediated CMA often persists to school age and is a risk factor for other atopy; non-IgE-mediated CMA, by contrast, is a benign infantile condition.	Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Allergol Skin & Allergy Hosp, Helsinki, Finland	Savilahti, E (reprint author), Univ Helsinki, Hosp Children & Adolescents, POB 281, FIN-00029 Helsinki, Finland.	erkki.savilahti@hus.fi		Makela, Mika/0000-0002-2933-3111			Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; DANNAEUS A, 1979, ACTA PAEDIATR SCAND, V68, P377, DOI 10.1111/j.1651-2227.1979.tb05023.x; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Gustafsson D, 2003, PEDIATR ALLERGY IMMU, V14, P448, DOI 10.1046/j.0905-6157.2003.00093.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; HILL DJ, 1993, CLIN EXP ALLERGY, V23, P124, DOI 10.1111/j.1365-2222.1993.tb00307.x; Host A, 2002, PEDIATR ALLERGY IMMU, V13, P23, DOI 10.1034/j.1399-3038.13.s.15.7.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Pekkanen J, 1997, EUR RESPIR J, V10, P1787, DOI 10.1183/09031936.97.10081787; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; SCHRANDER JJP, 1992, EUR J PEDIATR, V151, P783, DOI 10.1007/BF01959091; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Vanto T, 2004, J PEDIATR-US, V144, P218, DOI 10.1016/j.jpeds.2003.10.063; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0	28	168	178	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2005	116	4					869	875		10.1016/j.jaci.2005.06.018		7	Allergy; Immunology	Allergy; Immunology	017IF	WOS:000235686600023	16210063	
J	Mapp, CE; Boschetto, P; Maestrelli, P; Fabbri, LM				Mapp, CE; Boschetto, P; Maestrelli, P; Fabbri, LM			Occupational asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review						asthma; management; risk; susceptibility; workplace	NATURAL-RUBBER LATEX; EXHALED NITRIC-OXIDE; WORK-RELATED ASTHMA; AIRWAYS DYSFUNCTION SYNDROME; DIISOCYANATE-INDUCED ASTHMA; HEALTH-CARE WORKERS; WESTERN RED CEDAR; EXPOSURE-RESPONSE RELATIONSHIPS; LABORATORY-ANIMAL WORKERS; ISOCYANATE-INDUCED ASTHMA	Substantial epidemiologic and clinical evidence indicates that agents inhaled at work can induce asthma. In industrialized countries, occupational factors have been implicated in 9 to 15% of all cases of adult asthma. Work-related asthma includes (1) immunologic occupational asthma (OA), characterized by a latency period before the onset of symptoms; (2) nonimmunologic OA, which occurs after single or multiple exposures to high concentrations of irritant materials; (3) work-aggravated asthma, which is preexisting or concurrent asthma exacerbated by workplace exposures; and (4) variant syndromes. Assessment of the work environment has improved, making it possible to measure concentrations of several high- and low-molecular-weight agents in the workplace. The identification of host factors, polymorphisms, and candidate genes associated with OA is in progress and may improve our understanding of mechanisms involved in OA. A reliable diagnosis of OA should be confirmed by objective testing early after its onset. Removal of the worker from exposure to the causal agent and treatment with inhaled glucocorticoids lead to a better outcome. Finally, strategies for preventing OA should be implemented and their cost-effectiveness examined.	Univ Ferrara, Sect Hyg & Occupat Med, Dept Clin & Expt Med, I-44100 Ferrara, Italy; Univ Padua, Dept Environm Med & Publ Hlth, Padua, Italy; Univ Modena, Dept Hematol & Oncol, Sect Resp Dis, I-41100 Modena, Italy	Mapp, CE (reprint author), Univ Ferrara, Sect Hyg & Occupat Med, Dept Clin & Expt Med, Via Fossato di Mortara 64-B, I-44100 Ferrara, Italy.	mapp@unipd.it	Fabbri, Leonardo/I-4055-2012	Fabbri, Leonardo/0000-0001-8894-1689			Adisesh LA, 1998, CLIN EXP ALLERGY, V28, P876; Akpinar-Elci M, 2004, CHEST, V125, P2336, DOI 10.1378/chest.125.6.2336; Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; Allmers H, 2000, INT ARCH OCC ENV HEA, V73, P181, DOI 10.1007/s004200050025; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; ALVING K, 1993, EUR RESPIR J, V6, P1368; Alwis K U, 1999, Appl Occup Environ Hyg, V14, P598; American Medical Association, 2000, GUIDES EVALUATION PE; Ameille J, 2003, OCCUP ENVIRON MED, V60, P136, DOI 10.1136/oem.60.2.136; Ameille J, 1997, EUR RESPIR J, V10, P55, DOI 10.1183/09031936.97.10010055; Andersson E, 2003, AM J IND MED, V43, P532, DOI 10.1002/ajim.10203; Anees W, 2004, EUR RESPIR J, V23, P730, DOI 10.1183/09031936.04.00027304; Anees W, 2003, ANN ALLERG ASTHMA IM, V90, P47; Anees W, 2002, THORAX, V57, P231, DOI 10.1136/thorax.57.3.231; Antczak Adam, 2002, Int J Occup Med Environ Health, V15, P317; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P938, DOI 10.1067/mai.2003.1417; Arif AA, 2002, OCCUP ENVIRON MED, V59, P505, DOI 10.1136/oem.59.8.505; Arnaiz NO, 2003, ARCH ENVIRON HEALTH, V58, P197, DOI 10.3200/AEOH.58.4.197-200; Arts JHE, 2004, INHAL TOXICOL, V16, P259, DOI 10.1080/08958370490427932; BAI TR, 2001, AIRWAY REMODELING, P147; Baldwin DR, 2002, THORAX, V57, P860, DOI 10.1136/thorax.57.10.860; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; Banks D E, 2001, Curr Opin Allergy Clin Immunol, V1, P163, DOI 10.1097/01.all.0000011002.72912.c8; Banks Daniel E, 2003, Curr Opin Allergy Clin Immunol, V3, P101, DOI 10.1097/00130832-200304000-00003; Banks DE, 1996, CHEST, V109, P1370, DOI 10.1378/chest.109.5.1370; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Barbee RA, 1998, J ALLERGY CLIN IMMUN, V102, pS65, DOI 10.1016/S0091-6749(98)70006-5; BARDANA EJ, 2003, J ALLERGY CLIN IMMUN, V11, pS530; Barker RD, 1998, OCCUP ENVIRON MED, V55, P684; BARNES PJ, 2003, EUR RESP MONOGR, V2, P84; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; BAUR X, 1995, J ALLERGY CLIN IMMUN, V96, P489, DOI 10.1016/S0091-6749(95)70292-X; Baur X, 2005, EUR RESPIR J, V25, P309, DOI 10.1183/09031936.05.00021504; Baur X, 2003, ANN ALLERG ASTHMA IM, V90, P11; Baur X, 1998, AM J IND MED, V33, P114; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BECKLAKE MR, 1999, EPIDEMIOLOGICAL APPR, P27; Beghe B, 2004, ALLERGY, V59, P61, DOI 10.1046/j.1398-9995.2003.00352.x; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Bernstein DI, 1997, JAMA-J AM MED ASSOC, V278, P1907, DOI 10.1001/jama.278.22.1907; Bernstein DI, 2002, AM J RESP CRIT CARE, V166, P445, DOI 10.1164/rccm.2109018; Bernstein DI, 2003, IMMUNOL ALLERGY CLIN, V23, P221, DOI 10.1016/S0889-8561(02)00084-X; Bernstein DI, 2003, ANN ALLERG ASTHMA IM, V90, P209; BERNSTEIN DI, 1999, ASTHMA WORKPLACE, P1451; Bernstein IL, 1999, ASTHMA WORKPLACE, P1; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; Bernstein JA, 1999, J ALLERGY CLIN IMMUN, V103, P1153, DOI 10.1016/S0091-6749(99)70192-2; Berry MA, 2004, J ALLERGY CLIN IMMUN, V114, P1106, DOI 10.1016/j.jaci.2004.08.032; BIAGINI RE, 1985, J ALLERGY CLIN IMMUN, V76, P794, DOI 10.1016/0091-6749(85)90750-X; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; BLANC P, 1997, CHEST, V110, P3; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; Blanc PD, 2003, CHEST, V124, P1153, DOI 10.1378/chest.124.3.1153; Boulay Marie-Eve, 2003, Curr Opin Allergy Clin Immunol, V3, P51, DOI 10.1097/00130832-200302000-00009; BOULET LP, 1994, EUR RESPIR J, V7, P1567, DOI 10.1183/09031936.94.07091567; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Brant A, 2005, EUR RESPIR J, V25, P303, DOI 10.1183/09031936.05.00054004; Bresnitz EA, 2004, AM J RESP CRIT CARE, V169, P873, DOI 10.1164/rccm.169.7.873; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brisman J, 2000, OCCUP ENVIRON MED, V57, P335, DOI 10.1136/oem.57.5.335; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Brown William E, 2002, Appl Occup Environ Hyg, V17, P840, DOI 10.1080/10473220290107039; Brusasco V, 2001, ALLERGY, V56, P1114, DOI 10.1034/j.1398-9995.2001.00148.x; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; Burke W, 2003, NEW ENGL J MED, V349, P969; Burton WN, 2003, J OCCUP ENVIRON MED, V45, P610, DOI 10.1097/01.jom0000069244.06498.01; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661; Campo P, 2004, CURR OPIN PULM MED, V10, P142, DOI 10.1097/00063198-200403000-00009; CANNON J, 1995, BRIT MED J, V311, P602; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; Cartier A, 1998, Can Respir J, V5 Suppl A, p71A; CARTIER A, 1999, ASTHMA WORKPLACE, P211; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434; Chan-Yeung Moira, 2004, Can Respir J, V11, P21; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1994, AM J IND MED, V25, P13, DOI 10.1002/ajim.4700250106; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHANYEUNG M, 1978, J OCCUP ENVIRON MED, V20, P323; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CHANYEUNG M, 1988, CLIN ALLERGY, V18, P359, DOI 10.1111/j.1365-2222.1988.tb02883.x; CHANYEUNG M, 1999, ASTHMA WORKPLACE, P617; Chan-Yeung M., 1999, ASTHMA WORKPLACE, P129; Chan-Yeung M, 1999, ASTHMA WORKPLACE, P683; CHANYEUNG M, 1990, CHEST S, V98, P148; Charous BL, 2002, METHODS, V27, P15, DOI 10.1016/S1046-2023(02)00047-6; Charous BL, 2002, J ALLERGY CLIN IMMUN, V109, P31, DOI 10.1067/mai.2002.120953; Chatkin JM, 1999, CHEST, V116, P1780, DOI 10.1378/chest.116.6.1780; Cherry NM, 2000, OCCUP MED-OXFORD, V50, P496; Choi JH, 2004, ANN ALLERG ASTHMA IM, V93, P293; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; Clayton EW, 2003, NEW ENGL J MED, V349, P562; CONE JE, 1994, CHEST, V106, P500, DOI 10.1378/chest.106.2.500; CONTRERAS GR, 1994, OCCUP ENVIRON MED, V51, P710; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; COTE J, 1990, AM REV RESPIR DIS, V141, P373; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Cullinan P, 1997, CLIN EXP ALLERGY, V27, P41, DOI 10.1111/j.1365-2222.1997.tb01825.x; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Cullinan P, 2001, ANN OCCUP HYG, V45, P97, DOI 10.1016/S0003-4878(00)00028-4; Cullinan P, 2003, EUR RESPIR J, V22, P853, DOI 10.1183/09031936.03.00119502; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; D'Ambrosio D, 2003, J IMMUNOL METHODS, V273, P3, DOI 10.1016/S0022-1759(02)00414-3; D'Ambrosio D, 2001, AM J RESP CRIT CARE, V164, P1266; Danuser B, 2001, AM J IND MED, V39, P410, DOI 10.1002/ajim.1032.abs; de Meer G, 2003, CLIN EXP ALLERGY, V33, P789, DOI 10.1046/j.1365-2222.2003.01677.x; de Meer Gea, 2004, Environ Health, V3, P6; Dearman RJ, 2003, J APPL TOXICOL, V23, P199, DOI 10.1002/jat.907; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; DESJARDINS A, 1994, AM J RESP CRIT CARE, V150, P1714; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; Di Franco A, 1998, RESP MED, V92, P550; Di Lorenzo G, 2002, J INVEST ALLERG CLIN, V12, P114; DISTEFANO F, 2004, ALLERG IMMUNOL, V36, P56; Drake-Lee A, 2002, J LARYNGOL OTOL, V116, P580; Droste J, 2003, J OCCUP ENVIRON MED, V45, P648, DOI 10.1097/01.jom.0000071501.96740.f7; Dykewicz Mark S., 2003, Journal of Allergy and Clinical Immunology, V111, pS520; Eagan TML, 2002, AM J RESP CRIT CARE, V166, P933, DOI 10.1164/rccm.200203-238OC; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; EHRLICH RI, 1994, AM J IND MED, V26, P799, DOI 10.1002/ajim.4700260608; El-Zein M, 2003, EUR RESPIR J, V22, P513, DOI 10.1183/09031936.03.00000903; El-Zein M, 2003, OCCUP ENVIRON MED, V60, P655, DOI 10.1136/oem.60.9.655; Elder D, 2004, OCCUP MED-OXFORD, V54, P395, DOI 10.1093/occmed/kqh050; Esterhuizen TM, 2001, S AFR MED J, V91, P509; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36; FABBRI LM, 1999, ASTHMA WORKPLACE, P81; Fransman W, 2003, ANN OCCUP HYG, V47, P287, DOI 10.1093/annhyg/meg046; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; Frew AJ, 2004, J ALLERGY CLIN IMMUN, V113, P1161, DOI 10.1016/j.jaci.2004.03.039; Frew AJ, 2003, ANN ALLERG ASTHMA IM, V90, P7; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS824, DOI 10.1067/mai.2003.151; Gallefoss F, 2003, PATIENT EDUC COUNS, V49, P91, DOI 10.1016/S0738-3991(02)00051-4; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; Gautrin D, 2003, EUR RESPIR J, V22, P551, DOI 10.1183/09031936.03.00047803; Gautrin D, 2003, ALLERGY, V58, P608, DOI 10.1034/j.1398-9995.2003.00197.x; Gautrin D, 2002, EUR RESPIR J, V19, P96, DOI 10.1183/09031936.02.00230202; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899; Gautrin D, 1999, ASTHMA WORKPLACE, P565; Gibson PG, 2002, THORAX, V57, P178, DOI 10.1136/thorax.57.2.178; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32; GILBERT R, 1990, CHEST, V97, P562, DOI 10.1378/chest.97.3.562; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Goe SK, 2004, OCCUP ENVIRON MED, V61, P512, DOI 10.1136/oem.2003.008177; Goodno LE, 2002, J OCCUP ENVIRON MED, V44, P1143, DOI 10.1097/01.jom.0000044117.59147.2d; Gordon S, 2003, OCCUP MED-OXFORD, V53, P371, DOI 10.1093/occmed/kqg117; Grad R, 2000, LANCET, V356, P1369, DOI 10.1016/S0140-6736(00)02834-8; Graham C, 1997, REGUL TOXICOL PHARM, V26, P296, DOI 10.1006/rtph.1997.1170; Grammer L, 1998, CHEST, V114, P1199, DOI 10.1378/chest.114.4.1199; Grammer LC, 2002, J OCCUP ENVIRON MED, V44, P1179, DOI 10.1097/01.jom.0000044121.59147.44; Hallsworth MP, 2003, J ALLERGY CLIN IMMUN, V111, P251, DOI 10.1067/mai.2003.40; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Harber P, 1996, AM J RESP CRIT CARE, V154, P1153; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Heederik D, 2002, ANN OCCUP HYG, V46, P439, DOI 10.1093/annhyg/mef062; Heederik D, 2001, ANN OCCUP HYG, V45, P175, DOI 10.1016/S0003-4878(00)00044-2; Heederik D, 1999, OCCUP ENVIRON MED, V56, P735; Hendrick DJ, 2002, AM J RESP CRIT CARE, V166, P436, DOI 10.1164/rccm.2205021; HENDRICK DJ, 2002, DISORDERS AIRWAYS PA, P33; Henneberger P K, 1999, Int J Occup Environ Health, V5, P1; Henneberger PK, 2003, J OCCUP ENVIRON MED, V45, P360, DOI 10.1097/01.jom.0000063620.37065.6f; Herrick CA, 2003, J ALLERGY CLIN IMMUN, V111, P1087, DOI 10.1067/mai.2003.1413; Hirschhorn JN, 2002, GENET MED, V4, P45, DOI 10.1097/00125817-200203000-00002; HOLGATE ST, 1993, EUR RESPIR J, V6, P1507; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562; Horne C., 2000, European Respiratory Journal, V15, P911, DOI 10.1034/j.1399-3003.2000.15e17.x; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499; Houba R, 1996, AM J RESP CRIT CARE, V154, P130; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Jaakkola JJK, 2003, AM J EPIDEMIOL, V158, P981, DOI 10.1093/aje/kwg238; Jaakkola MS, 1999, ENVIRON HEALTH PERSP, V107, P823, DOI 10.2307/3434560; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Johnson Victor J, 2004, Curr Opin Allergy Clin Immunol, V4, P105, DOI 10.1097/00130832-200404000-00006; Jones KP, 2004, ANN OCCUP HYG, V48, P455, DOI 10.1093/annhyg/mch038; Jones MG, 2004, CLIN EXP ALLERGY, V34, P812, DOI 10.1111/j.1365-2222.2004.01956.x; JOOS G, 2003, EUR RESP MONOG, V23, P138; Jung K S, 1999, Respirology, V4, P303, DOI 10.1046/j.1440-1843.1999.00196.x; Kanazawa H, 2004, AM J RESP CRIT CARE, V169, P1125, DOI 10.1164/rccm.200401-123OC; Karjalainen A, 2003, CHEST, V123, P283, DOI 10.1378/chest.123.1.283; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; KERN DG, 1991, AM REV RESPIR DIS, V144, P1058; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; Kimber I, 2003, ANN ALLERG ASTHMA IM, V90, P28; Kips JC, 2003, EUR RESP MON, V23, P164; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; KONGERUD J, 1992, THORAX, V47, P292, DOI 10.1136/thx.47.4.292; KONGERUD J, 1994, EUR RESPIR J, V7, P165, DOI 10.1183/09031936.94.07010165; Krakowiak Anna, 2003, Int J Occup Med Environ Health, V16, P125; Kraw M, 1999, AM J IND MED, V35, P87, DOI 10.1002/(SICI)1097-0274(199901)35:1<87::AID-AJIM12>3.0.CO;2-X; Kristiansson MH, 2004, RAPID COMMUN MASS SP, V18, P1592, DOI 10.1002/rcm.1527; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lantz RC, 2001, TOXICOL SCI, V60, P348, DOI 10.1093/toxsci/60.2.348; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Le Moual N, 2004, AM J EPIDEMIOL, V160, P1108, DOI 10.1093/aje/kwh316; Lee YC, 2001, J ALLERGY CLIN IMMUN, V108, P1021, DOI 10.1067/mai.2001.120132; Leigh JP, 2003, SCAND J WORK ENV HEA, V29, P304; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976; Lemiere C, 1997, J ALLERGY CLIN IMMUN, V100, P852, DOI 10.1016/S0091-6749(97)70286-0; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329; Lemiere C, 2003, ANN ALLERG ASTHMA IM, V90, P52; Lemiere C, 2002, J ALLERGY CLIN IMMUN, V110, P641, DOI 10.1067/mai.2002.128806; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; Lemiere Catherine, 2002, Curr Opin Allergy Clin Immunol, V2, P109, DOI 10.1097/00130832-200204000-00005; Leroyer C, 1998, AM J RESP CRIT CARE, V158, P827; Leroyer C, 1998, THORAX, V53, P152; LESAGE J, 1999, ASTHMA WORKPLACE, P257; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585; Lieutier-Colas F, 2002, CLIN EXP ALLERGY, V32, P1424, DOI 10.1046/j.1365-2745.2002.01502.x; Liss GM, 2003, OCCUP ENVIRON MED, V60, P254, DOI 10.1136/oem.60.4.254; LISS GM, 1984, J ALLERGY CLIN IMMUN, V73, P348, DOI 10.1016/0091-6749(84)90407-X; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Lund MB, 2000, OCCUP ENVIRON MED, V57, P274, DOI 10.1136/oem.57.4.274; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; Maestrelli P, 2004, AM J RESP CRIT CARE, V169, P331, DOI 10.1164/rccm.2312012; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V151, P607; MAESTRELLI P, 1999, EUR RESP MONOGR, V11, P124; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1291; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Malmberg Per, 2001, Scandinavian Journal of Work Environment and Health, V27, P422; Malo J L, 1998, Can Respir J, V5, P66; Malo Jean-Luc, 2003, American Journal of Respiratory and Critical Care Medicine, V167, P463; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; MALO JL, 1994, AM J RESP CRIT CARE, V150, P1697; Malo JL, 2004, EUR RESPIR J, V23, P300, DOI 10.1183/09031936.03.00055003; Malo JL, 2004, CURR OPIN PULM MED, V10, P57, DOI 10.1097/00063198-200401000-00010; MALO JL, 1990, J ALLERGY CLIN IMMUN, V86, P562, DOI 10.1016/S0091-6749(05)80213-1; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; MALO JL, 1999, AM J IND MED, V35, pL207; MALO JL, 2003, AM J RESP CRIT CARE, V167, P452; MALO JL, 1999, EUR RESP MON, V11, P106; Mannino DM, 2000, OCCUP MED, V15, P359; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; MAPP CE, 1988, EUR RESPIR J, V1, P273; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Mapp CE, 2003, EUR RESPIR J, V22, P173, DOI 10.1183/09031939.03.00011003; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326; MAPP CE, 1985, J ALLERGY CLIN IMMUN, V75, P568, DOI 10.1016/0091-6749(85)90031-4; Mapp CE, 2001, OCCUP ENVIRON MED, V58, P354, DOI 10.1136/oem.58.5.354; MAPP CE, 1994, EUR RESPIR J, V7, P1559, DOI 10.1183/09031936.94.07091559; MAPP CE, 2003, AM J RESP CRIT CARE, V167, P454; MAPP CE, 1996, EUR RESPIR J, V68, P89; MAPP CE, 1999, EUROPEAN RESP MONOGR, V11, P255; MAPP CE, 2003, EUR RESP MONOGR, V23, P249; Marabini A, 2003, CHEST, V124, P2372, DOI 10.1378/chest.124.6.2372; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; MARKS GB, 1991, AM REV RESPIR DIS, V144, P1065; Martin JG, 2003, AM J RESP CRIT CARE, V168, P568, DOI 10.1164/rccm.200201-021OC; Mastrangelo G, 1995, Med Lav, V86, P503; MATTE TD, 1990, CHEST, V98, P173; MATTHEWS JNS, 1990, BRIT MED J, V300, P230; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; Meijer E, 2004, OCCUP ENVIRON MED, V61, P831, DOI 10.1136/oem.2003.011593; Mendonca EMC, 2003, AM J IND MED, V43, P611, DOI 10.1002/ajim.10210; Meredith S, 1996, THORAX, V51, P435, DOI 10.1136/thx.51.4.435; Meredith SK, 2000, OCCUP ENVIRON MED, V57, P830, DOI 10.1136/oem.57.12.830; MERGET R, 1991, BRIT J IND MED, V48, P830; Merget R, 2000, J ALLERGY CLIN IMMUN, V105, P364, DOI 10.1016/S0091-6749(00)90089-7; MERGET R, 2003, J ALLERGY CLIN IMMUN, V107, P707; Meyer JD, 2001, OCCUP MED-OXFORD, V51, P204, DOI 10.1093/occmed/51.3.204; Milton DK, 1998, AM J IND MED, V33, P1, DOI 10.1002/(SICI)1097-0274(199801)33:1<1::AID-AJIM1>3.0.CO;2-2; Miralles JC, 2003, J INVEST ALLERG CLIN, V13, P133; MOSCATO G, 1995, EUR RESPIR J, V8, P1605; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; Moscato G, 2003, EUR RESPIR J, V21, P879, DOI 10.1183/09031936.03.00000403; Moscato G, 2002, ALLERGY, V57, P236, DOI 10.1034/j.1398-9995.2002.1o3337.x; Moscato Gianna, 2003, Curr Opin Allergy Clin Immunol, V3, P109, DOI 10.1097/00130832-200304000-00004; Murphy E, 2002, OCCUP MED-OXFORD, V52, P497, DOI 10.1093/occmed/52.8.497; Nemery B, 2003, AM J RESP CRIT CARE, V168, P2, DOI 10.1164/rccm.2304005; Nicholson P, 2004, GUIDELINES PREVENTIO; NEWMAN TA, 2001, ANN OCCUP HYG, V46, P563; NEWMAN TAJ, 2003, ANN ALLERG ASTHMA IM, V90, P24, DOI 10.1016/S1081-1206(10)61644-4; NEWMAN TAJ, 2002, ANN OCCUP HYG, V46, P563; Newman Taylor AJ, 1999, AM J RESP CRIT CARE, V160, P435; Nguyen B, 2003, J ALLERGY CLIN IMMUN, V111, P807, DOI 10.1067/mai.2003.1341; Nieuwenhuijsen MJ, 2003, OCCUP ENVIRON MED, V60, P104, DOI 10.1136/oem.60.2.104; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211.1268OC; Obase Y, 2000, OCCUP ENVIRON MED, V57, P62, DOI 10.1136/oem.57.1.62; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; Olin AC, 2004, CLIN EXP ALLERGY, V34, P221, DOI 10.1111/j.1365-2222.2004.01888.x; Olin AC, 1999, EUR RESPIR J, V14, P828, DOI 10.1034/j.1399-3003.1999.14d18.x; Omland O, 2002, ANN AGR ENV MED, V9, P119; Ortega HG, 2002, CHEST, V121, P1323, DOI 10.1378/chest.121.4.1323; Ortega HG, 2002, AM J IND MED, V42, P50, DOI 10.1002/ajim.10088; Ortega HG, 2001, AM J IND MED, V39, P598, DOI 10.1002/ajim.1059; *OSHA SAF HLTH STA, 1983, OCC SAF HLTH ADM; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; Padoan M, 2003, EUR RESPIR J, V21, P637, DOI 10.1183/09031936.03.00060703; PAGGIARO P, 1990, CHEST, V98, P536, DOI 10.1378/chest.98.3.536; PAGGIARO PL, 1987, B EUR PHYSIOPATH RES, V23, P565; Panzer SE, 2003, J ALLERGY CLIN IMMUN, V111, P308, DOI 10.1067/mai.2003.65; Park Hae Sim, 2002, Korean J Intern Med, V17, P249; Park Hae-Sim, 1996, Journal of Korean Medical Science, V11, P314; PARK HS, 1991, CLIN EXP ALLERGY, V21, P357, DOI 10.1111/j.1365-2222.1991.tb01668.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847; Park HS, 1998, CLIN EXP ALLERGY, V28, P724; Park HS, 2003, CLIN EXP ALLERGY, V33, P113, DOI 10.1046/j.1365-2222.2003.01563.x; Park HS, 2002, J ALLERGY CLIN IMMUN, V109, P774, DOI 10.1067/mai.2002.124664; Park HS, 2002, CLIN EXP ALLERGY, V32, P198, DOI 10.1046/j.1365-2222.2002.01290.x; Park HS, 2002, CLIN EXP ALLERGY, V32, P551, DOI 10.1046/j.0954-7894.2002.01349.x; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; PARK HS, 2000, J KOREAN MED SCI, V16, P57; PARK HS, 1998, J KOREAN MED SCI, V13, P12; Park SW, 2004, CHEST, V125, P1998, DOI 10.1378/chest.125.6.1998; Patino CM, 2001, ALLERGY, V56, P279, DOI 10.1034/j.1398-9995.2001.00135.x; Pauli Gabrielle, 2003, Curr Opin Allergy Clin Immunol, V3, P95, DOI 10.1097/00130832-200304000-00002; Pavord ID, 1997, THORAX, V52, P498; PEAT JK, 1994, J CLIN EPIDEMIOL, V47, P1099, DOI 10.1016/0895-4356(94)90096-5; Perfetti L, 2003, AM J IND MED, V44, P325, DOI 10.1002/ajim.10262; Perfetti L, 1998, CLIN EXP ALLERGY, V28, P66; PERRAULT G, 2003, AM J RESP CRIT CARE, V167, P458; Petrick MM, 2003, IMMUNOL ALLERGY CLIN, V23, P193, DOI 10.1016/S0889-8561(02)00082-6; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Piipari R, 2002, EUR RESPIR J, V20, P1532, DOI 10.1183/09031936.02.0041802; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Provencher S, 1997, OCCUP ENVIRON MED, V54, P272; Quirce S, 2003, J ALLERGY CLIN IMMUN, V111, P788, DOI 10.1067/mai.2003.166; Quirce S, 2001, J ALLERGY CLIN IMMUN, V108, P143, DOI 10.1067/mai.2001.116120; Quirce S, 2000, J ASTHMA, V37, P267, DOI 10.3109/02770900009055449; Quirce Santiago, 2004, Curr Opin Allergy Clin Immunol, V4, P87, DOI 10.1097/00130832-200404000-00003; RAMSDELL JW, 1982, AM REV RESPIR DIS, V126, P829; Redlich CA, 1997, SCAND J WORK ENV HEA, V23, P227; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; REED CE, 1999, ASTHMA WORKPLACE, P235; Rees D, 1998, S AFR MED J, V88, P1110; REIJULA K, 1994, ALLERGY PROC, V15, P163, DOI 10.2500/108854194778702919; Reijula K, 1996, CHEST, V110, P58, DOI 10.1378/chest.110.1.58; Reinisch F, 2001, AM J IND MED, V39, P72; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.3.CO;2-T; Rihs HP, 2002, J ALLERGY CLIN IMMUN, V110, P507, DOI 10.1067/mai.2002.127282; Rodford R, 2003, ENVIRON TOXICOL CHEM, V22, P1855, DOI 10.1897/01-438; Rodier F, 2003, J ALLERGY CLIN IMMUN, V112, P1105, DOI 10.1016/j.jaci.2003.08.011; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Ross DJ, 1999, CLIN EXP ALLERGY, V29, P750; Saarinen K, 2003, EUR RESPIR J, V22, P305, DOI 10.1183/09031936.03.00100102; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489; Sastre J, 2003, EUR RESPIR J, V22, P364, DOI 10.1183/09031936.03.00045103; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Sastre J, 2003, CHEST, V123, P1276, DOI 10.1378/chest.123.4.1276; SASTRE J, 1990, J ALLERGY CLIN IMMUN, V85, P567, DOI 10.1016/0091-6749(90)90094-K; Scanlon PD, 2002, NEW ENGL J MED, V347, P840, DOI 10.1056/NEJMe020100; SETA JA, 1999, ASTHMA WORKPLACE, P721; Sjaheim T, 2004, OCCUP ENVIRON MED, V61, P779, DOI 10.1136/oem.2003.011627; Slavin RG, 2003, ANN ALLERG ASTHMA IM, V90, P2; Smith TA, 2004, OCCUP MED-OXFORD, V54, P21, DOI 10.1093/occmed/kqg122; Son Minsik, 1998, Journal of Korean Medical Science, V13, P147; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; SOYSETH V, 1994, THORAX, V49, P984, DOI 10.1136/thx.49.10.984; SOYSETH V, 1992, EUR RESPIR J, V5, P829; STENTON SC, 1994, EUR RESPIR J, V7, P806, DOI 10.1183/09031936.94.07040806; Stenton SC, 2000, OCCUP MED, V15, P431; STENTON SC, 1995, RESP MED, V89, P181, DOI 10.1016/0954-6111(95)90245-7; SWANSON MC, 2003, AM J RESP CRIT CARE, V167, P456; Taivainen AI, 1998, SCAND J WORK ENV HEA, V24, P503; Tan RA, 2003, IMMUNOL ALLERGY CLIN, V23, P251, DOI 10.1016/S0889-8561(02)00080-2; TARLO S, 2003, AM J RESP CRIT CARE, V167, P460; Tarlo S M, 1998, Can Respir J, V5, P289; Tarlo SA, 2003, ANN ALLERG ASTHMA IM, V90, P19; Tarlo SM, 2003, J ALLERGY CLIN IMMUN, V111, P692, DOI 10.1067/mai.2003.1374; Tarlo SM, 2003, CAN MED ASSOC J, V168, P867; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V107, P583; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; Tarlo SM, 2000, OCCUP MED, V15, P471; Tarlo Susan M, 2002, Appl Occup Environ Hyg, V17, P902, DOI 10.1080/10473220290107101; Tarlo Susan M, 2003, Curr Opin Allergy Clin Immunol, V3, P91, DOI 10.1097/00130832-200304000-00001; Taylor A N, 2001, Curr Opin Allergy Clin Immunol, V1, P157, DOI 10.1097/00130832-200104000-00007; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; Testud F, 2004, Rev Pneumol Clin, V60, P154; Toren K, 1996, OCCUP ENVIRON MED, V53, P757; Toren K, 1999, EUR RESPIR J, V13, P496, DOI 10.1183/09031936.99.13349699; Turato G, 2000, OCCUP MED, V15, P445; *US DEP HHS, 2002, NAT I HLTH NAT HEART; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.0.CO;2-2; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; VENABLES KM, 1990, J ALLERGY CLIN IMMUN, V85, P55, DOI 10.1016/0091-6749(90)90221-O; VENABLES KM, 1985, BRIT MED J, V290, P201; VENABLES KM, 1989, BRIT MED J, V299, P939; Vermeulen Roel, 2002, Environ Health, V1, P5, DOI 10.1186/1476-069X-1-5; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510; Vignola A M, 2002, Eur Respir J Suppl, V37, p51s; Wagner GR, 1998, AM J IND MED, V33, P427, DOI 10.1002/(SICI)1097-0274(199805)33:5<427::AID-AJIM1>3.0.CO;2-P; Wai Y, 2003, EUR RESP MONOGR, V25, P131; Walls C, 2000, NEW ZEAL MED J, V113, P491; Welinder H, 2001, ALLERGY, V56, P506, DOI 10.1034/j.1398-9995.2001.056006506.x; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Wild LG, 2003, IMMUNOL ALLERGY CLIN, V23, P235, DOI 10.1016/S088908561(02)00083-8; Wisnewski AV, 2004, J ALLERGY CLIN IMMUN, V113, P1178, DOI 10.1016/j.jaci.2004.03.009; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330; YOKATA K, 1998, CLIN EXP ALLERGY, V28, P694; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139; ZOCCA E, 1990, J APPL PHYSIOL, V68, P1576; Zock JP, 1996, CLIN EXP ALLERGY, V26, P542, DOI 10.1046/j.1365-2222.1996.d01-344.x; Zock JP, 2004, J EXPO ANAL ENV EPID, V14, P397, DOI 10.1038/sj.jea.7500337	435	168	171	1	11	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2005	172	3					280	305		10.1164/rccm.200311-1575SO		26	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	949IM	WOS:000230778600006	15860754	
J	Ziska, LH; Gebhard, DE; Frenz, DA; Faulkner, S; Singer, BD; Straka, JG				Ziska, LH; Gebhard, DE; Frenz, DA; Faulkner, S; Singer, BD; Straka, JG			Cities as harbingers of climate change: Common ragweed, urbanization, and public health	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						global change; seasonal allergenic rhinitis; Amb a 1; common ragweed	CO2 CONCENTRATION; UNITED-STATES; PROTEIN; ALLERGY; AEROALLERGENS; QUANTITATION; NUTRITION; PROGRAM; ASSAY; USA	Background: Although controlled laboratory experiments have been conducted to demonstrate the sensitivity of allergenic pollen production to future climatic change tie, increased CO2 and temperature), no in situ data are available. Objective: The purpose of this investigation was to assess, under realistic conditions, the impact of climatic change on pollen production of common ragweed, a ubiquitous weed occurring in disturbed sites and the principal source of pollen associated with seasonal allergenic rhinitis. Methods: We used an existing temperature/CO2 gradient between urban and rural areas to examine the quantitative and qualitative aspects of ragweed growth and pollen production. Results: For 2000 and 200 1, average daily (24-hour) values of CO2 concentration and air temperature within an urban environment were 30% to 31% and 1.8degrees to 2.0degreesC (3.4degrees to 3.6degreesF) higher than those at a rural site. This result is consistent with most global change scenarios. Ragweed grew faster, flowered earlier, and produced significantly greater above-ground biomass and ragweed pollen at urban locations than at rural locations. Conclusions: Here we show that 2 aspects of future global environmental change, air temperature and atmospheric CO2, are already significantly higher in urban relative to rural areas. In general, we show that regional urbanization-induced temperature/CO2 increases similar to those associated with projected global climatic change might already have public health consequences; we suggest that urbanization, per se, might provide a low-cost alternative to current experimental methods evaluating plant responses to climate change. (J Allergy Clin Immunol 2003;111:290-5.).	USDA ARS, Alternate Crop & Syst Lab, Beltsville, MD 20705 USA; Surveillance Data Inc, St Louis Pk, MN USA; Bethesda Clin, St Paul, MN USA; Macalester Coll, Dept Biol, St Paul, MN 55105 USA	Ziska, LH (reprint author), USDA ARS, Alternate Crop & Syst Lab, 10300 Baltimore Ave, Beltsville, MD 20705 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Singer, Benjamin/0000-0001-5775-8427			BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; CHAPMAN JA, 1986, GRANA, V25, P235; Cifuentes L, 2001, SCIENCE, V293, P1257, DOI 10.1126/science.1063357; CONROY JP, 1992, AUST J BOT, V40, P445, DOI 10.1071/BT9920445c; DRAKE BG, 1989, FUNCT ECOL, V3, P363, DOI 10.2307/2389377; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Engvall E, 1980, Methods Enzymol, V70, P419; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Frenz DA, 1996, ANN ALLERG ASTHMA IM, V76, P245; Frenz DA, 1999, ANN ALLERG ASTHMA IM, V82, P41, DOI 10.1016/S1081-1206(10)62658-0; Frenz DA, 2000, ANN ALLERG ASTHMA IM, V84, P481; Frenz DA, 2001, ANN ALLERG ASTHMA IM, V87, P390; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; HENDREY GR, 1994, AGR FOREST METEOROL, V70, P3, DOI 10.1016/0168-1923(94)90044-2; Idso CD, 2001, ATMOS ENVIRON, V35, P995, DOI 10.1016/S1352-2310(00)00412-X; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; McCarthy J., 2001, CLIMATE CHANGE 2001, P1032; PATTERSON DT, 1995, WEED SCI, V43, P685; POORTER H, 1993, VEGETATIO, V104, P77, DOI 10.1007/BF00048146; RAYNOR GS, 1970, BNL PUBLICATION; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STRAKA JG, 1991, AM J HUM GENET, V48, P72; TSANG VCW, 1983, METHOD ENZYMOL, V92, P391; United States Environmental Protection Agency (EPA), AIR QUAL PLANN STAND; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Wodehouse R, 1971, HAYFEVER PLANTS; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; ZISKA LH, 2002, FUNCTIONAL PLANT BIO, V29, P1	28	168	179	3	45	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					290	295		10.1067/mai.2003.53		6	Allergy; Immunology	Allergy; Immunology	644WF	WOS:000180942700011	12589347	
J	Rothenberg, ME; Mishra, A; Brandt, EB; Hogan, SP				Rothenberg, ME; Mishra, A; Brandt, EB; Hogan, SP			Gastrointestinal eosinophils	IMMUNOLOGICAL REVIEWS			English	Review							MAJOR BASIC-PROTEIN; COLONY-STIMULATING FACTOR; ACCUMULATION IN-VIVO; HUMAN CC-CHEMOKINE; AIRWAY HYPERRESPONSIVENESS; GASTROESOPHAGEAL REFLUX; TISSUE EOSINOPHILIA; ENDOTHELIAL-CELLS; CATIONIC PROTEIN; FOOD ALLERGY	The gut-associated lymphoid tissue (GALT) is composed of lymphocytes residing in Peyer's patches, lamina propria, and intraepithelial compartments. In addition to these features which distinguish GALT from other peripheral sites of the immune system, the gastrointestinal immune system is also composed of resident eosinophils. Eosinophils are generally considered to be peripheral blood leukocytes that have an important proinflammatory role in various immune disorders. Although most research concerning this cell has focused on understanding its trafficking and function in the blood and lung, recent studies have also started to elucidate its regulation and function in the gastrointestinal tract. Interestingly, eosinophil numbers in the gastrointestinal tract are substantially higher than in other tissues. At baseline (healthy conditions), most eosinophils reside in the lamina propria in the stomach and intestine. Eosinophil homing to these sites occurs during embryonic development and their levels in perinatal mice are comparable to those in adults, indicating that their homing is not dependent upon the presence of intestinal flora. Furthermore, eosinophil localization to the lamina propria at baseline is critically regulated by eotaxin, a chemokine constitutively expressed throughout the gastrointestinal tract. Although eotaxin is required for eosinophil homing, its expression in the esophagus is not sufficient for eosinophil accumulation, since this organ is devoid of eosinophils at baseline. During Th2-associated inflammatory conditions (e.g. interleukin (IL)-5 overexpression or oral allergen challenge), marked increases of eosinophils occur not only in the lamina propria but also in Peyer's patches. The accumulation of Peyer's patch eosinophils, which mainly occurs in the outer cortex and interfollicular regions, is critically regulated by IL-5 and less significantly by eotaxin, suggesting the involvement of other eosinophil chemokines in this lymphoid compartment. Preliminary investigations have shown that gastrointestinal eosinophils express the alpha4 beta7 integrin and that this molecule is responsible, in part, for eosinophil homing. In summary, eosinophils are resident cells of the gastrointestinal immune system whose levels can be induced by antigen exposure under Th2 conditions, in a manner that is critically regulated by eotaxin and IL-5. We propose that eosinophils are integral members of the gastrointestinal immune system and are likely to be important in innate, regulatory and inflammatory immune responses.	Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, Cincinnati, OH 45229 USA	Rothenberg, ME (reprint author), Childrens Hosp, Med Ctr, Dept Pediat, Div Pulm Med Allergy & Clin Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.				NIAID NIH HHS [R01 AI45898]		ANWAR ARF, 1993, J EXP MED, V177, P839, DOI 10.1084/jem.177.3.839; Artis D, 2000, EUR J IMMUNOL, V30, P1656, DOI 10.1002/1521-4141(200006)30:6<1656::AID-IMMU1656>3.0.CO;2-Z; Behm CA, 2000, PARASITOL TODAY, V16, P202, DOI 10.1016/S0169-4758(99)01620-8; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BJERKE K, 1993, GUT, V34, P1357, DOI 10.1136/gut.34.10.1357; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BROWN LF, 1984, AM J SURG PATHOL, V8, P899, DOI 10.1097/00000478-198412000-00002; Butterworth A E, 1977, Curr Top Microbiol Immunol, V77, P127; BUTTERWORTH AE, 1984, ADV PARASIT, V23, P143; CALDWELL JH, 1975, NEW ENGL J MED, V292, P1388, DOI 10.1056/NEJM197506262922608; CELLO JP, 1979, AM J MED, V67, P1097, DOI 10.1016/0002-9343(79)90652-1; Challacombe SJ, 1997, VACCINE, V15, P169, DOI 10.1016/S0264-410X(96)00159-4; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Desreumaux P, 1996, GASTROENTEROLOGY, V110, P768, DOI 10.1053/gast.1996.v110.pm8608886; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; DVORAK AM, 1993, INT ARCH ALLERGY IMM, V102, P33; DVORAK AM, 1980, J IMMUNOL, V125, P460; FERGUSON A, 1976, CLIN GASTROENTEROL, V5, P271; FERGUSON A, 1972, CLIN EXP IMMUNOL, V12, P477; FERGUSON A, 1972, J PATHOL, V106, P95, DOI 10.1002/path.1711060205; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Friend DS, 2000, J IMMUNOL, V165, P344; FRIGAS E, 1980, LAB INVEST, V42, P35; FURUTA GT, 1995, CURR OPIN GASTROEN, V11, P541, DOI 10.1097/00001574-199511000-00013; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177, DOI 10.1016/S0065-2776(08)60351-X; Gleich GJ, 2000, J ALLERGY CLIN IMMUN, V105, P651, DOI 10.1067/mai.2000.105712; Gouon-Evans V, 2000, DEVELOPMENT, V127, P2269; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; HILL SM, 1990, ARCH DIS CHILD, V65, P132; Hogan SP, 2000, P NATL ACAD SCI USA, V97, P6681, DOI 10.1073/pnas.97.12.6681; Hogan SP, 1998, J IMMUNOL, V161, P1501; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; HOGAN SP, 1999, J ALLERGY CLIN IMMUN, V105, pS379; HSU CK, 1976, NATURE, V262, P397, DOI 10.1038/262397a0; Iacono G, 1996, J ALLERGY CLIN IMMUN, V97, P822; JACOBY DB, 1993, J CLIN INVEST, V91, P1314, DOI 10.1172/JCI116331; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1; KATZ AJ, 1984, J ALLERGY CLIN IMMUN, V74, P72, DOI 10.1016/0091-6749(84)90090-3; Kelly KJ, 2000, J PEDIATR GASTR NUTR, V30, pS28, DOI 10.1097/00005176-200001001-00005; KELLY KJ, 1995, GASTROENTEROLOGY, V109, P1503, DOI 10.1016/0016-5085(95)90637-1; KESHAVARZIAN A, 1985, GASTROENTEROLOGY, V88, P1041; Kita H, 1996, J ALLERGY CLIN IMMUN, V97, P889, DOI 10.1016/S0091-6749(96)80061-3; Kitaura M, 1999, J BIOL CHEM, V274, P27975, DOI 10.1074/jbc.274.39.27975; KLEIN NC, 1970, MEDICINE, V49, P299; KORENAGA M, 1991, IMMUNOLOGY, V72, P502; KURUP VP, 1992, J IMMUNOL, V148, P3783; KURUP VP, 1994, J ALLERGY CLIN IMMUN, V93, P1013, DOI 10.1016/S0091-6749(94)70050-8; Lacy P, 1998, BLOOD, V91, P2508; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; LARSON KA, 1995, J IMMUNOL, V155, P3002; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Liacouras CA, 1998, J PEDIATR GASTR NUTR, V26, P380, DOI 10.1097/00005176-199804000-00004; Litwin A, 1998, BIODRUGS, V9, P261, DOI 10.2165/00063030-199809040-00001; LOPEZ AF, 1986, J EXP MED, V163, P1085, DOI 10.1084/jem.163.5.1085; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; MALUENDA C, 1984, J PEDIATR GASTR NUTR, V3, P349, DOI 10.1097/00005176-198406000-00008; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Mayer L, 1996, ANN NY ACAD SCI, V778, P28, DOI 10.1111/j.1749-6632.1996.tb21111.x; MESTECKY J, 1978, J CLIN INVEST, V61, P731, DOI 10.1172/JCI108986; MICHAEL JG, 1989, IMMUNOL INVEST, V18, P1049, DOI 10.3109/08820138909030606; MILLER A, 1992, J NEUROIMMUNOL, V39, P243, DOI 10.1016/0165-5728(92)90258-M; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Mishra A, 2000, BLOOD, V96, P1538; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; MOON A, 1995, ANN ALLERG ASTHMA IM, V74, P5; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; NAKAJIMA H, 1992, AM REV RESPIR DIS, V146, P374; ODZE RD, 1995, J PEDIATR-US, V126, P163, DOI 10.1016/S0022-3476(95)70540-6; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; OWEN WF, 1987, J EXP MED, V166, P129, DOI 10.1084/jem.166.1.129; OYAIZU N, 1985, ACTA PATHOL JAPON, V35, P759; Palframan RT, 1998, BLOOD, V91, P2240; Pinto A, 1996, BLOOD, V88, P3299; ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460; ROSENBERG HF, 1995, NAT GENET, V10, P219, DOI 10.1038/ng0695-219; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; ROTHENBERG ME, 1988, J CLIN INVEST, V81, P1986, DOI 10.1172/JCI113547; Rothenberg ME, 1999, AM J RESP CELL MOL, V21, P291; ROTHENBERG ME, 1995, J EXP MED, V181, P1211, DOI 10.1084/jem.181.3.1211; ROTHENBERG ME, 1995, P NATL ACAD SCI USA, V92, P8960, DOI 10.1073/pnas.92.19.8960; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Rothenberg ME, 1996, MOL MED, V2, P334; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592; Ruchelli E, 1999, PEDIATR DEVEL PATHOL, V2, P15, DOI 10.1007/s100249900084; RUITENBERG EJ, 1977, IMMUNOLOGY, V33, P581; SAAVEDRADELGADO AM, 1985, ANN ALLERGY, V55, P694; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SANDERSON CJ, 1992, BLOOD, V79, P3101; SARIN SK, 1987, DIGEST DIS SCI, V32, P363, DOI 10.1007/BF01296289; SCUDAMORE HH, 1982, J ALLERGY CLIN IMMUN, V70, P129, DOI 10.1016/0091-6749(82)90241-X; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; SHERMAN MP, 1982, J PEDIATR-US, V100, P587, DOI 10.1016/S0022-3476(82)80760-9; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Shinkai A, 1999, J IMMUNOL, V163, P1602; SILBERSTEIN DS, 1989, HEMATOL ONCOL CLIN N, V3, P511; SILBERSTEIN DS, 1995, CRIT REV ONCOL HEMAT, V19, P47, DOI 10.1016/1040-8428(94)00127-F; SLIFMAN NR, 1986, J IMMUNOL, V137, P2913; STEAD R H, 1992, Regional Immunology, V4, P91; TAI PC, 1984, BRIT MED J, V289, P400; Tajima K, 1996, DIGEST DIS SCI, V41, P282, DOI 10.1007/BF02093816; TALLEY NJ, 1990, GUT, V31, P54, DOI 10.1136/gut.31.1.54; Tamura N, 1996, SCAND J IMMUNOL, V44, P229, DOI 10.1046/j.1365-3083.1996.d01-303.x; Teixeira MM, 1995, TRENDS PHARMACOL SCI, V16, P418; TORPIER G, 1988, CLIN EXP IMMUNOL, V74, P404; Venge P, 1980, EOSINOPHIL HLTH DIS, P1131; WALSH RE, 1991, SCAND J GASTROENTERO, V26, P1217, DOI 10.3109/00365529108998617; WATKINS SG, 1976, EXPERIENTIA, V32, P1339, DOI 10.1007/BF01953127; Weiner HL, 1996, ANN NY ACAD SCI, V778, pR13, DOI 10.1111/j.1749-6632.1996.tb21109.x; WELLER PF, 1991, NEW ENGL J MED, V324, P1110; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; WINTER HS, 1982, GASTROENTEROLOGY, V83, P818; Woerly G, 1999, J EXP MED, V190, P487, DOI 10.1084/jem.190.4.487; WOODBURY RG, 1978, BIOCHEMISTRY-US, V17, P4298, DOI 10.1021/bi00613a029; Ying S, 1999, J IMMUNOL, V163, P6321; YOUNG JD, 1986, NATURE, V321, P613, DOI 10.1038/321613a0; Zimmermann N, 2000, J IMMUNOL, V165, P5839	130	168	171	2	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-2896			IMMUNOL REV	Immunol. Rev.	FEB	2001	179						139	155		10.1034/j.1600-065X.2001.790114.x		17	Immunology	Immunology	404VY	WOS:000167123800014	11292017	
J	Ciencewicki, J; Trivedi, S; Kleeberger, SR				Ciencewicki, Jonathan; Trivedi, Shweta; Kleeberger, Steven R.			Oxidants and the pathogenesis of lung diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						oxidative stress; antioxidant; genetics; susceptibility; infant; reproductive outcome; premature; children; elderly; asthma; chronic obstructive pulmonary disease; ozone; pollutants; particulates; PM; acute respiratory distress syndrome; hyperoxia; SNP; single nucleotide polymorphism	OBSTRUCTIVE PULMONARY-DISEASE; RESPIRATORY-DISTRESS-SYNDROME; LOW-BIRTH-WEIGHT; EXHALED BREATH CONDENSATE; DIESEL EXHAUST PARTICLES; AMBIENT AIR-POLLUTION; SURFACTANT PROTEIN-A; ACUTE OZONE EXPOSURE; LIPID OZONATION PRODUCTS; GLUTATHIONE-S-TRANSFERASE	The increasing number of population-based and epiderniologic associations between oxidant pollutant exposures and cardiopulmonary disease exacerbation, decrements in pulmonary function, and mortality underscores the important detrimental effects of oxidants on public health. Because inhaled oxidants initiate a number of pathologic processes, including inflammation of the airways, which may contribute to the pathogenesis and/or exacerbation of airways disease, it is critical to understand the mechanisms through which exogenous and endogenous oxidants interact with molecules in the cells, tissues, and epithelial lining fluid of the lung. Furthermore, it is clear that interindividual variation in response to a given exposure also exists across an individual lifetime. Because of the potential impact that oxidant exposures may have on reproductive outcomes and infant, child, and adult health, identification of the intrinsic and extrinsic factors that may influence susceptibility to oxidants remains an important issue. In this review, we discuss mechanisms of oxidant stress in the lung, the role of oxidants in lung disease pathogenesis and exacerbation (eg, asthma, chronic obstructive pulmonary disease, and acute respiratory distress syndrome), and the potential risk factors (eg, age, genetics) for enhanced susceptibility to oxidant-induced disease.	[Ciencewicki, Jonathan; Trivedi, Shweta; Kleeberger, Steven R.] NIEHS, Lab Resp Biol, NIH, Res Triangle Pk, NC 27709 USA	Kleeberger, SR (reprint author), NIEHS, Lab Resp Biol, NIH, 111 TW Alexander Dr,Bldg 101,Rm D240, Res Triangle Pk, NC 27709 USA.	kleeber1@niehs.nih.gov			National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services.	Supported by the Division of Intramural Research at the National Institute of Environmental Health Sciences, National Institutes of Health, Department of Health and Human Services.	Abraham E, 2000, AM J PHYSIOL-LUNG C, V279, P1137; AKBARALY TN, BR J NUTR IN PRESS; Aldridge RE, 2002, FREE RADICAL BIO MED, V33, P847, DOI 10.1016/S0891-5849(02)00976-0; ALEXEEFF SE, J OCCUP ENV IN PRESS; Alexeeff SE, 2007, AM J RESP CRIT CARE, V176, P742, DOI 10.1164/rccm.200705-6560C; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Anderson H R, 2003, Eur Respir J Suppl, V40, p39s; Antonicelli F, 2002, FREE RADICAL BIO MED, V32, P492, DOI 10.1016/S0891-5849(01)00820-6; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363; Ballinger CA, 2005, FREE RADICAL BIO MED, V38, P515, DOI 10.1016/j.freeradbiomed.2004.11.009; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; BARNES PJ, 2004, ALVEOLAR MACROPHAGES, P159; Bateson TF, 2004, EPIDEMIOLOGY, V15, P143, DOI 10.1097/01.ede.0000112210.68754.fa; Bateson TF, 2008, J TOXICOL ENV HEAL A, V71, P238, DOI 10.1080/15287390701598234; Bauer AK, 2004, AM J PHYSIOL-LUNG C, V287, pL685, DOI 10.1152/ajplung.00223.2003; BECKMAN JS, 1994, METHOD ENZYMOL, V233, P229; Behrman R, 2006, PRETERM BIRTH CAUSES; Bell ML, 2007, ENVIRON HEALTH PERSP, V115, P1118, DOI 10.1289/ehp.9759; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bhatia M, 2004, J PATHOL, V202, P145, DOI 10.1002/path.1491; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Brauer M, 2008, ENVIRON HEALTH PERSP, V116, P680, DOI 10.1289/ehp.10952; Bridges JP, 2000, J BIOL CHEM, V275, P38848, DOI 10.1074/jbc.M005322200; British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Cantin AM, 2006, AM J PHYSIOL-CELL PH, V290, pC262, DOI 10.1152/ajpcell.00070.2005; Cardoso WV, 2004, LUNG DEV AGING ENV, P3, DOI 10.1016/B978-012324751-3/50035-8; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; Chen C, 2007, EUR RESPIR J, V30, P677, DOI 10.1183/09031936.00160806; Chen C, 2007, ENVIRON HEALTH PERSP, V115, P1732, DOI 10.1289/ehp.10294; Cheng TJ, 2003, ENVIRON RES, V93, P279, DOI 10.1016/S0013-9351(03)00041-0; Cho HY, 2002, AM J RESP CELL MOL, V26, P175; Churg A, 2005, TOXICOL APPL PHARM, V208, P37, DOI 10.1016/j.aap.2005.01.013; Ciencewicki J, 2007, INHAL TOXICOL, V19, P1121, DOI 10.1080/08958370701665426; Connor LM, 2004, AM J PHYSIOL-LUNG C, V286, pL1169, DOI 10.1152/ajplung.00397.2003; Corradi M, 2003, AM J RESP CRIT CARE, V167, P1380, DOI 10.1164/rccm.200210-1253OC; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; Cowley EA, 2002, J PHYSIOL-LONDON, V543, P201, DOI 10.1113/jphysiol.2002.022400; Cuzzocrea S, 1998, SHOCK, V9, P336, DOI 10.1097/00024382-199805000-00004; Dagher Z, 2007, J APPL TOXICOL, V27, P284, DOI 10.1002/jat.1211; Dauletbaev N, 2001, THORAX, V56, P13, DOI 10.1136/thorax.56.1.13; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; de Burbure CY, 2007, J TOXICOL ENV HEAL A, V70, P284, DOI 10.1080/15287390600884875; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P550, DOI 10.1289/ehp.10911; Dellinger B, 2001, CHEM RES TOXICOL, V14, P1371, DOI 10.1021/tx010050x; Dick CAJ, 2003, INHAL TOXICOL, V15, P39, DOI 10.1080/08958370304454; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Dworski R, 2001, CLIN EXP ALLERGY, V31, P387, DOI 10.1046/j.1365-2222.2001.01055.x; Eichenwald EC, 2008, NEW ENGL J MED, V358, P1700, DOI 10.1056/NEJMra0707601; Elsayed NM, 2002, TOXICOL APPL PHARM, V184, P1, DOI 10.1006/taap.2002.9487; Emelyanov A, 2001, CHEST, V120, P1136, DOI 10.1378/chest.120.4.1136; Ergonul Z, 2007, INHAL TOXICOL, V19, P161, DOI 10.1080/08958370601051883; Etzel RA, 2003, PEDIATRICS, V112, P233; Foos B, 2008, J TOXICOL ENV HEAL A, V71, P149, DOI 10.1080/15287390701597871; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gerritsen WBM, 2005, RESP MED, V99, P84, DOI 10.1016/j.rmed.2004.04.017; Gessner BD, 2007, THORAX, V62, P231, DOI 10.1136/thx.2005.053363; Gilboa SM, 2005, AM J EPIDEMIOL, V162, P238, DOI 10.1093/aje/kwi189; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Hamilton RF, 1996, AM J RESP CELL MOL, V15, P275; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; Hanta I, 2006, LUNG, V184, P51, DOI 10.1007/s00408-005-2561-4; Haque R, 2007, TOXICOL APPL PHARM, V220, P72, DOI 10.1016/j.taap.2006.12.017; Hollingsworth JW, 2007, J IMMUNOL, V179, P4367; Inoue KI, 2007, IMMUNOPHARM IMMUNOT, V29, P403, DOI 10.1080/08923970701675002; Ito K, 2005, MUTAT RES-GEN TOX EN, V585, P60, DOI 10.1016/j.mrgentox.2005.04.004; Jaakkola JJK, 2006, J ALLERGY CLIN IMMUN, V118, P823, DOI 10.1016/j.jaci.2006.06.043; Jang AS, 2005, J KOREAN MED SCI, V20, P759; Jones KL, 2000, PEDIATR PULM, V30, P79, DOI 10.1002/1099-0496(200008)30:2<79::AID-PPUL1>3.0.CO;2-1; Kafoury RM, 1999, AM J RESP CRIT CARE, V160, P1934; Kafoury RM, 1998, TOXICOL APPL PHARM, V150, P338, DOI 10.1006/taap.1998.8418; KASSMANN M, 2008, PFLUGERS AR IN PRESS; KELLER JN, 1997, NEUROSCIENCE, V806, P85; Kelly FJ, 2005, P NUTR SOC, V64, P510, DOI 10.1079/PNS2005457; Kelly FJ, 2003, AMINO ACIDS, V25, P375, DOI 10.1007/s00726-003-0024-x; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kettle AJ, 2004, AM J RESP CRIT CARE, V170, P1317, DOI 10.1164/rccm.200311-15160C; KIENAST K, 1994, ARCH ENVIRON HEALTH, V49, P246; Kierstein S, 2008, ALLERGY, V63, P438, DOI 10.1111/j.1398-9995.2007.01587.x; Kierstein S, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-85; KIETZMANN D, 1993, INTENS CARE MED, V19, P78, DOI 10.1007/BF01708366; Kirichenko A, 1996, TOXICOL APPL PHARM, V141, P416, DOI 10.1006/taap.1996.0307; Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.025; Kirsch M, 2000, J BIOL CHEM, V275, P16702, DOI 10.1074/jbc.M909228199; Kleeberger SR, 2005, AM J RESP CRIT CARE, V171, P804, DOI 10.1164/rccm.2501002; Kleeberger SR, 2005, ANNU REV MED, V56, P383, DOI 10.1146/annurev/med.56.062904.144908; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620; KLEEBERGER SR, 1990, AM J PHYSIOL, V258, pL313; Ko FWS, 2007, CLIN EXP ALLERGY, V37, P1312, DOI 10.1111/j.1365-2222.2007.02791.x; Lehnig M, 1999, ARCH BIOCHEM BIOPHYS, V368, P303, DOI 10.1006/abbi.1999.1268; LEIKAUF GD, 1993, AM J RESP CELL MOL, V9, P594; Li L, 1996, TOXICOL APPL PHARM, V139, P135, DOI 10.1006/taap.1996.0152; Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; Liu XL, 2005, INHAL TOXICOL, V17, P467, DOI 10.1080/08958370590964467; Lundborg M, 2007, ENVIRON RES, V104, P250, DOI 10.1016/j.envres.2007.01.002; MacPherson JC, 2001, J IMMUNOL, V166, P5763; Maisonet M, 2001, ENVIRON HEALTH PERSP, V109, P351, DOI 10.2307/3434782; Mak JCW, 2004, J ALLERGY CLIN IMMUN, V114, P260, DOI 10.1016/j.jaci.2004.05.013; MANZANARES D, 2007, BIOCHEMISTRY-US, V465, P60604; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCDONNELL WF, 1985, AM REV RESPIR DIS, V131, P36; Mikerov AN, 2008, AM J PHYSIOL-LUNG C, V294, pL121, DOI 10.1152/ajplung.00288.2007; MILLER LA, 2004, LUNG DEV AGING ENV, P169, DOI 10.1016/B978-012324751-3/50045-0; MONTESEIRIN J, 2001, J ALLERGY CLIN IMMUN, V1007, P62623; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Morrison D, 1999, AM J RESP CRIT CARE, V159, P473; Morrow JD, 1997, PROG LIPID RES, V36, P1, DOI 10.1016/S0163-7827(97)00001-5; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nowak D, 1999, RESP MED, V93, P389, DOI 10.1053/rmed.1999.0574; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Paredi P, 2000, AM J RESP CRIT CARE, V162, P1450; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; Pinkerton KE, 2006, CLIN EXP PHARMACOL P, V33, P269, DOI 10.1111/j.1440-1681.2006.04357.x; Prahalad AK, 2000, CHEM RES TOXICOL, V13, P1011, DOI 10.1021/tx000110j; Prahalad AK, 2001, CHEM RES TOXICOL, V14, P879, DOI 10.1021/tx010022e; PRYOR WA, 1995, FREE RADICAL BIO MED, V19, P935, DOI 10.1016/0891-5849(95)02033-7; QUINLAN GJ, 1994, FREE RADICAL RES, V21, P95, DOI 10.3109/10715769409056561; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Rahman I, 1996, FREE RADICAL BIO MED, V21, P669, DOI 10.1016/0891-5849(96)00155-4; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; RAHMAN I, 1996, AM J RESP CRIT CARE, V159, P11055; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Reynolds WF, 2006, MEDIAT INFLAMM, DOI 10.1155/MI/2006/36735; Riedl MA, 2008, CURR OPIN ALLERGY CL, V8, P49, DOI 10.1097/ACI.0b013e3282f3d913; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 2002, AM J EPIDEMIOL, V155, P17, DOI 10.1093/aje/155.1.17; Rogers JF, 2006, PEDIATRICS, V118, P156, DOI 10.1542/peds.2005-2432; ROGERS JF, 2000, AM J EPIDEMIOL, V151, P60601; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Romieu I, 2004, THORAX, V59, P8; Rosias PPR, 2006, FREE RADICAL RES, V40, P901, DOI 10.1080/10715760500522648; ROUMEN RMH, 1994, BRIT J SURG, V81, P1300, DOI 10.1002/bjs.1800810913; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304; Sahin U., 2001, Journal of Basic and Clinical Physiology and Pharmacology, V12, P59; SILER TM, 1989, EXP LUNG RES, V15, P881, DOI 10.3109/01902148909069633; Slama R, 2007, ENVIRON HEALTH PERSP, V115, P1283, DOI 10.1289/ehp.10047; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; SRAM RJ, 2005, ENV HLTH PERSPECT, V113, P37375; Su WY, 1996, J APPL PHYSIOL, V80, P1560; Suc I, 1998, FASEB J, V12, P665; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; SUZUKI M, 2008, AM J RESP C IN PRESS; Taggart C, 2000, J BIOL CHEM, V275, P27258; Tjalkens RB, 1999, ADV EXP MED BIOL, V463, P123; Tokiwa H, 1999, FREE RADICAL BIO MED, V27, P1251, DOI 10.1016/S0891-5849(99)00156-2; Tomaki M, 2007, PULM PHARMACOL THER, V20, P596, DOI 10.1016/j.pupt.2006.06.006; Tsukagoshi H, 2002, TOXICOL APPL PHARM, V184, P127, DOI 10.1006/taap.2002.9514; Uchida K, 1999, J BIOL CHEM, V274, P2234, DOI 10.1074/jbc.274.4.2234; Uhlson C, 2002, CHEM RES TOXICOL, V15, P896, DOI 10.1021/tx010183i; Upton RL, 2003, EUR RESPIR J, V22, P335, DOI 10.1183/09031936.03.00075302; Valacchi G, 2004, FREE RADICAL BIO MED, V36, P673, DOI 10.1016/j.freeradbiomed.2003.12.005; Velsor LW, 2006, AM J RESP CELL MOL, V35, P579, DOI 10.1165/rcmb.2005-04730C; Velsor LW, 1997, AM J PHYSIOL-LUNG C, V273, pL1265; WAN J, 2007, INHAL TOXICOL S1, V19, P17177; Wang Lei, 2007, Birth Defects Research, V81, P144, DOI 10.1002/bdrc.20097; Ware LB, 2006, SEMIN RESP CRIT CARE, V27, P337, DOI 10.1055/s-2006-948288; WEINMANN GG, 1995, AM J RESP CRIT CARE, V151, P33; Williams AS, 2007, J PHARMACOL EXP THER, V322, P351, DOI 10.1124/jpet.107.121624; Winterton DL, 2001, ANN ALLERG ASTHMA IM, V86, P232; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Xie JF, 2007, INHAL TOXICOL, V19, P759, DOI 10.1080/08958370701399885; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Yargicoglu P, 2007, NEUROTOXICOL TERATOL, V29, P211, DOI 10.1016/j.ntt.2006.11.002; Yin XJJ, 2004, TOXICOL SCI, V77, P263, DOI 10.1093/toxsci/kfh035; Young RP, 2007, EUR RESPIR J, V30, P616, DOI 10.1183/09031936.00021707; Zhang HQ, 2006, AM J RESP CELL MOL, V34, P174, DOI 10.1165/rcmb.2005-0280OC	182	167	171	1	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2008	122	3					456	468		10.1016/j.jaci.2008.08.004		13	Allergy; Immunology	Allergy; Immunology	348TW	WOS:000259234000002	18774381	
J	Jacobson, MZ				Jacobson, Mark Z.			Effects of ethanol (E85) versus gasoline vehicles on cancer and mortality in the United States	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Article							EMISSIONS; FUEL; ENERGY; AIR	Ethanol use in vehicle fuel is increasing worldwide, but the potential cancer risk and ozone-related health consequences of a large-scale conversion from gasoline to ethanol have not been examined. Here, a nested global-through-urban air pollution/weather forecast model is combined with high-resolution future emission inventories, population data, and health effects data to examine the effect of converting from gasoline to E85 on cancer, mortality, and hospitalization in the United States as a whole and Los Angeles in particular. Under the base-case emission scenario derived, which accounted for projected improvements in gasoline and E85 vehicle emission controls, it was found that E85 (85% ethanol fuel, 15% gasoline) may increase ozone-related mortality, hospitalization, and asthma by about 9% in Los Angeles and 4% in the United States as a whole relative to 100% gasoline. Ozone increases in Los Angeles and the northeast were partially offset by decreases in the southeast. E85 also increased peroxyacetyl nitrate (PAN) in the U.S. but was estimated to cause little change in cancer risk. Due to its ozone effects, future E85 may be a greater overall public health risk than gasoline. However, because of the uncertainty in future emission regulations, it can be concluded with confidence only that E85 is unlikely to improve air quality over future gasoline vehicles. Unburned ethanol emissions from E85 may result in a global-scale source of acetaldehyde larger than that of direct emissions.	Stanford Univ, Dept Civil & Environm Engn, Stanford, CA 94305 USA	Jacobson, MZ (reprint author), Stanford Univ, Dept Civil & Environm Engn, Stanford, CA 94305 USA.	jacobson@stanford.edu					BARRETT R, 2004, 14 CRC ON ROAD VEH E; Black F, 1998, J AIR WASTE MANAGE, V48, P578; BLACK F, 1991, EPA600D91239; *CA AIR RES BOARD, 2004, POP VEH TRENDS REP; *CA AIR RES BOARD, 2003, ARB ALM 2003 TOX AIR; Delucchi M., 2006, LIFECYCLE ANAL BIOFU; DELUCCHI M, 1996, UCDITSRR9612; DESERVES C, 2005, 5509 AVL MTC SWED RO; *DOE, ETH 2006 RES SUMM; Energy Information Administration, 2005, HOUS VEH EN US LAT D; Farrell AE, 2006, SCIENCE, V311, P506, DOI 10.1126/science.1121416; *GEN MOT CORP, 2007, 2007 OD YEAR E8K GAS; Hammerschlag R, 2006, ENVIRON SCI TECHNOL, V40, P1744, DOI 10.1021/es052024h; Jacobson MZ, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL027838; Jacobson MZ, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004945; Jacobson MZ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018448; Jacobson MZ, 2005, SCIENCE, V308, P1901, DOI 10.1126/science.1109157; Jacobson MZ, 2001, J GEOPHYS RES-ATMOS, V106, P5385, DOI 10.1029/2000JD900560; KARMAN D, 1998, ETHANOL FUELED MOTOR; Kim S, 2005, BIOMASS BIOENERG, V28, P475, DOI 10.1016/j.biombioe.2004.11.005; Lipman TE, 2002, CLIMATIC CHANGE, V53, P477, DOI 10.1023/A:1015235211266; MACDONALD T, 2005, 15 INT S ALC FUELS S; Magnusson R, 2002, ENVIRON SCI TECHNOL, V36, P1656, DOI 10.1021/es010262g; *NREL, FACT SHEET FORD TAUR; Patzek TW, 2005, CRIT REV PLANT SCI, V24, P327, DOI 10.1080/07352680500316029; PATZEK TW, 2006, RAEL BIOFUEL CYCLE; PIMENTEL D, 2005, NAT RESOUR RES, V14, P67; Shapouri H, 2003, T ASAE, V46, P959; Thurston GD, 2001, J EXPO ANAL ENV EPID, V11, P286, DOI 10.1038/sj.jea.7500169; WHO, 2002, WORLD HLTH REP; Winebrake JJ, 2001, J AIR WASTE MANAGE, V51, P1073	31	167	172	4	53	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X	1520-5851		ENVIRON SCI TECHNOL	Environ. Sci. Technol.	JUN 1	2007	41	11					4150	4157		10.1021/es062085v		8	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	172ZM	WOS:000246843300052	17612204	
J	Olin, AC; Rosengren, A; Thelle, DS; Lissner, L; Bake, B; Toren, K				Olin, Anna-Carin; Rosengren, Annika; Thelle, Dag S.; Lissner, Lattren; Bake, Bjorn; Toren, Kjell			Height, age, and atopy are associated with fraction of exhaled nitric oxide in a large adult general population sample	CHEST			English	Article						asthma; epidemiology; exhaled nitric oxide; gender	AIRWAY RESPONSIVENESS; HEALTHY-CHILDREN; REFERENCE VALUES; ASTHMA; SYMPTOMS; SMOKING; SEX; SCHOOLCHILDREN; COMMUNITY; EXPOSURE	Study objectives: The fraction of exhaled nitric oxide (FENO) is elevated in subjects with asthma and atopy, and it has been proposed to be a noninvasive marker of airway inflammation. In addition to asthma and atopy, there is limited information about the determinants of FENO in a general population. Design: Cross-sectional. Setting: A random adult general population sample. Participants: A total of 2,200 subjects, 1, 111 women and 1,089 men, aged 25 to 75 years. Interventions: The subjects were examined with regard to FENO, pulmonary function, anthropometric variables, and blood samples for Ig E, and completed a respiratory questionnaire. The associations between different determinants and FENO were analyzed with multiple linear regression models. Results: The median value of FENO was 16.0 parts per billion (ppb), ranging from 2.4 to 199 ppb. Height, age, atopy, reporting of asthma symptoms in the last month, and reported use of inhaled steroids were positively associated with FENO. Current smokers had lower values of FENO. Gender was not associated with FENO. Conclusions: In this random adult population sample, height, but not gender, was associated with FENO. Furthermore, asthma symptoms in the last month, reported use of inhaled steroids, and atopy were positively and independently associated with FENO, while there was a negative association with smoking.	Sahlgrens Univ Hosp, Dept Occupat & Environm Med, SE-40530 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Resp Med & Allergol, Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden; Univ Gothenburg, Sahlgrenska Acad, Dept Community Hlth & Publ Hlth, Gothenburg, Sweden; Univ Oslo, Akerhus Univ Hosp, Oslo, Norway	Olin, AC (reprint author), Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Box 414, SE-40530 Gothenburg, Sweden.	Anna-Carin.Olin@amm.gu.se					Adamkiewicz G, 2004, THORAX, V59, P204, DOI 10.1136/thorax.2003.006445; ALVING K, 1993, EUR RESPIR J, V6, P1368; Avital A, 2003, PEDIATR PULM, V36, P433, DOI 10.1002/ppul.10377; Baraldi E, 1999, PEDIATR PULM, V27, P54, DOI 10.1002/(SICI)1099-0496(199901)27:1<54::AID-PPUL10>3.0.CO;2-V; Berg CM, 2005, EUR J CARDIOV PREV R, V12, P115, DOI 10.1097/00149831-200504000-00005; Berry MA, 2005, CLIN EXP ALLERGY, V35, P1175, DOI 10.1111/j.1365-2222.2005.02314.x; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; D'Angelo E, 2005, J APPL PHYSIOL, V99, P433, DOI 10.1152/japplphysiol.01368.2004; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69; Franklin PJ, 2004, CHEST, V126, P1540, DOI 10.1378/chest.126.5.1540; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Gratziou C, 1999, EUR RESPIR J, V14, P897, DOI 10.1034/j.1399-3003.1999.14d28.x; Hellgren J, 2002, AM J IND MED, V42, P23, DOI 10.1002/ajim.10083; Ho LP, 2000, CHEST, V118, P1327, DOI 10.1378/chest.118.5.1327; Jilma B, 1996, LIFE SCI, V58, P469, DOI 10.1016/0024-3205(95)02311-9; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KIISSOON N, 2000, AM J RESP CRIT CARE, V162, P539; Langhammer A, 2001, EUR RESPIR J, V18, P770, DOI 10.1183/09031936.01.00255301; Ludviksdottir D, 1999, RESP MED, V93, P552, DOI 10.1016/S0954-6111(99)90154-3; Malmberg LP, 2005, ALLERGY, V60, P464, DOI 10.1111/j.1398-9995.2005.00740.x; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Olin AC, 2004, CLIN EXP ALLERGY, V34, P221, DOI 10.1111/j.1365-2222.2004.01888.x; Olin AC, 2001, RESP MED, V95, P153, DOI 10.1053/rmed.2000.1010; Pedroletti C, 2003, PEDIATR RES, V54, P496, DOI 10.1203/01.PDR.0000081761.33822.36; RIISE GC, 2005, P AM THORAC SOC, V2, pA930; S. American Thoracic and S. European Respiratory, 2005, AM J RESP CRIT CARE, V171, P912; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Toren K, 1999, INT J TUBERC LUNG D, V3, P192; Toren K, 2004, EUR RESPIR J, V24, P942, DOI 10.1183/09031936.04.00044804; Tsang KW, 2001, LUNG, V179, P83, DOI 10.1007/s004080000050; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953; Warke TJ, 2002, THORAX, V57, P383, DOI 10.1136/thorax.57.5.383	33	167	177	0	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2006	130	5					1319	1325		10.1378/chest.130.5.1319		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	106OH	WOS:000242109800009	17099006	
J	Martinez, FD				Martinez, FD			Development of wheezing disorders and asthma in preschool children	PEDIATRICS			English	Article						asthma expression; phenotypes; wheezing; atopy	MID-ADULT LIFE; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; LUNG-FUNCTION; ATOPY; SMOKING; EXPOSURE; INFANTS; DISEASE	Recent longitudinal studies have shed light on the pathogenesis and progression of asthma. The patterns of expression of childhood asthma that persist into adult life have been explored. Distinct asthma phenotypes (transient wheezing, nonatopic wheezing, and atopy-associated asthma) have been identified. Defining which children are at risk for persistent asthma could allow for better management and, potentially, for reduced morbidity and mortality.	Univ Arizona, Tucson, AZ USA	Martinez, FD (reprint author), Arizona Resp Ctr, Box 245030,1501 N Campbell Ave,Room 2349, Tucson, AZ 85724 USA.						Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BARBEE RA, 1985, CHEST S, V87, P21; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hanrahan JP, 1996, AM J RESP CRIT CARE, V154, P670; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; KELLY WJW, 1988, AM REV RESPIR DIS, V138, P26; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1999, CLIN EXP ALLERGY, V29, P53; MORGAN W J, 1991, American Review of Respiratory Disease, V143, pA508; National Asthma Education Prevention Program (NAEPP), 1997, NIH PUBL; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; OSWALD H, 1994, BRIT MED J, V309, P95; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; Speer C P, 1998, Eur Respir J Suppl, V27, p13s; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1997, THORAX, V52, P946; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stern DA, 1999, AM J RESP CRIT CARE, V159, pA148; Szefler S, 2000, NEW ENGL J MED, V343, P1054; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	26	167	187	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2002	109			S			362	367				6	Pediatrics	Pediatrics	517FW	WOS:000173601300003	11826251	
J	Durham, SR; Emminger, W; Kapp, A; Colombo, G; de Monchy, JGR; Rak, S; Scadding, GK; Andersen, JS; Riis, B; Dahl, R				Durham, Stephen R.; Emminger, Waltraud; Kapp, Alexander; Colombo, Giselda; de Monchy, Jan G. R.; Rak, Sabina; Scadding, Glenis K.; Andersen, Jens S.; Riis, Bente; Dahl, Ronald			Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy tablet; disease modification; grass pollen; immunotherapy; sublingual; sustained efficacy; rhinoconjunctivitis; placebo controlled; Phleum pratense	6-YEAR FOLLOW-UP; HOUSE-DUST MITE; SUBLINGUAL IMMUNOTHERAPY; IMMUNOLOGICAL CHANGES; CONTROLLED-TRIAL; RHINITIS; SAFETY; CHILDREN; PERFORMANCE; BURDEN	Background: Sustained and disease-modifying effects of sublingual immunotherapy have never before been confirmed in a large-scale randomized, double-blind, placebo-controlled trial. Objective: We sought to investigate sustained efficacy I year after a 3-year period of daily treatment with the SQ-standardized grass allergy immunotherapy tablet Grazax (Phleum pratense 75,000 SQ-T/2,800 BAU; ALK-Abello, Horsholm, Denmark). Methods: A randomized, double-blind, placebo-controlled, phase III trial including adults with a history of moderate-to-severe grass pollen induced rhinoconjunctivitis inadequately controlled by symptomatic medications. The analysis set comprised 257 subjects at the follow-up. Efficacy end points were rhinoconjunctivitis symptom and medication scores, quality of life, and percentages of symptom and medication free days. Immunologic end points included grass pollen-specific serum IgG4 and IgE-blocking factor. Safety was assessed based on adverse events. Results: Significant improvements in efficacy were consistently shown during 3 years' treatment. One year after treatment, the active group showed sustained reductions in mean rhinoconjunctivitis symptom scores (26%, P < .001) and medication scores (29%, P = .022) when compared with placebo. This level was similar to the efficacy observed during the 3-year treatment period. The differences in percentages of symptom- and medication-free days were significant during and I year after treatment. The active group also reported sustained and significant improvements in quality of life. Sustained clinical benefit was accompanied by immunologic changes. No safety issues were identified. Conclusion: Three years of treatment with the SQ-standardized grass allergy immunotherapy tablet resulted in consistent clinical improvement and accompanying immunologic changes that were sustained I year after treatment, which is indicative of disease modification and associated long-term benefits. (J Allergy Clin Immunol 2010;125:131-38.)	[Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, London SW3 6LY, England; [Durham, Stephen R.] Royal Brompton Hosp, London SW3 6LY, England; [Emminger, Waltraud] Allergie Ambulatorium Rennweg, Vienna, Austria; [Kapp, Alexander] Hannover Med Sch, Dept Dermatol & Allergol, Hannover, Germany; [Colombo, Giselda] Sci Univ Inst San Raffaele Monte Tabor, Sect Allergy, Milan, Italy; [de Monchy, Jan G. R.] Univ Groningen, Univ Med Ctr Groningen, Sect Allergol Internal Med, Groningen, Netherlands; [Rak, Sabina] Sahlgrens Univ Hosp, Sect Allergy, Gothenburg, Sweden; [Scadding, Glenis K.] Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England; [Andersen, Jens S.; Riis, Bente] ALK Abello AS, Res & Dev, Horsholm, Denmark; [Dahl, Ronald] Aarhus Univ Hosp, Dept Resp Dis, Aarhus, Denmark	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Sect Allergy & Clin Immunol, Natl Heart & Lung Inst, Guy Scadding Bldg,Royal Brompton Campus,Dovehouse, London SW3 6LY, England.	s.durham@imperial.ac.uk	Dahl, Ronahl/F-8170-2013		Medical Research Council [G0601303]		Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Ciprandi G, 2007, ALLERGY ASTHMA PROC, V28, P40, DOI 10.2500/aap.2007.28.2974; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2004, RESP MED, V98, P398, DOI 10.1016/j.rmed.2003.11.015; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2008, CURR OPIN ALLERGY CL, V8, P577, DOI 10.1097/ACI.0b013e3283196764; European Interoperability Framework, 2004, COAST ER EV NEED ACT, P1; *EUR MED AG, 2008, CHMPEWP185042006FINA; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Madonini E, 2003, INT J IMMUNOPATH PH, V16, P73; Malling HJ, 2006, J INVEST ALLERG CLIN, V16, P162; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; MOSBECH H, 1988, ALLERGY, V43, P523, DOI 10.1111/j.1398-9995.1988.tb01631.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Ott H, 2009, ALLERGY, V64, P179, DOI 10.1111/j.1398-9995.2008.01875.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Petersen AB, 2004, CLIN BIOCHEM, V37, P882, DOI 10.1016/j.clinbiochem.2004.06.010; Plaut M, 2005, NEW ENGL J MED, V353, P1934, DOI 10.1056/NEJMcp044141; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Sundberg R, 2007, J ADOLESCENT HEALTH, V40, P581, DOI 10.1016/j.jadohealth.2007.01.003; Valovirta E, 2008, CURR OPIN ALLERGY CL, V8, P1, DOI 10.1097/ACI.0b013e3282f3f42f; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Walker S, 2007, J ALLERGY CLIN IMMUN, V120, P381, DOI 10.1016/j.jaci.2007.03.034; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; World Medical Association, 1996, DECL HELS ETH PRINC	39	166	172	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2010	125	1					131	138		10.1016/j.jaci.2009.10.035		8	Allergy; Immunology	Allergy; Immunology	544MG	WOS:000273660500015	20109743	
J	Mendell, MJ				Mendell, M. J.			Indoor residential chemical emissions as risk factors for-respiratory and allergic effects in children: a review	INDOOR AIR			English	Review							VOLATILE ORGANIC-COMPOUNDS; INTERIOR SURFACE MATERIALS; PEAK EXPIRATORY FLOW; 3.0 PPM FORMALDEHYDE; YOUNG-CHILDREN; HOUSE-DUST; ASTHMA SYMPTOMS; AIRWAY SYMPTOMS; MITE ALLERGEN; BUILDING CHARACTERISTICS	Most research into effects of residential exposures on respiratory health has focused on allergens, moisture/mold, endotoxin, or combustion products. A growing body of research from outside the US; however, has associated chemical emissions from common indoor materials with risk of asthma, allergies, and pulmonary infections. This review summarizes 21 studies in the epidemiologic literature on associations between indoor residential chemical emissions, or emission-related materials or activities, and respiratory health or allergy in infants or children. Associations, some strong, were reported between many risk factors and respiratory or allergic effects. Risk factors identified most frequently included formaldehyde or particleboard, phthalates or plastic materials, and recent painting. Findings for other risk factors, such as aromatic and aliphatic chemical compounds, were limited but suggestive. Elevated risks were also reported for renovation and cleaning activities, new furniture, and carpets or textile wallpaper. Reviewed studies were entirely observational, limited in size, and variable in quality, and specific risk factors identified may only be indicators for correlated, truly causal exposures. Nevertheless, overall evidence suggests a new class of residential risk factors for adverse respiratory effects, ubiquitous in modern residences, and distinct from those currently recognized. It is important to confirm and quantify any risks, to motivate and guide necessary preventive actions.	Lawrence Berkeley Natl Lab, Indoor Environm Dept, Berkeley, CA 94720 USA	Mendell, MJ (reprint author), Lawrence Berkeley Natl Lab, Indoor Environm Dept, 1 Cyclotron Rd MS 90-3058, Berkeley, CA 94720 USA.	mjmendell@lbl.gov	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Arts JHE, 2006, REGUL TOXICOL PHARM, V44, P144, DOI 10.1016/j.yrtph.2005.11.006; Baumann MGD, 2000, FOREST PROD J, V50, P75; Becher R, 1996, TOXICOL LETT, V86, P155, DOI 10.1016/0378-4274(96)03685-5; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2005, INDOOR AIR, V15, P275, DOI 10.1111/j.1600-0668.2005.00372.x; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; BROWN SK, 1994, INDOOR AIR, V4, P123, DOI 10.1111/j.1600-0668.1994.t01-2-00007.x; Brown SK, 2002, INDOOR AIR, V12, P55, DOI 10.1034/j.1600-0668.2002.120107.x; Brunekreef B, 2004, THORAX, V59, P729, DOI 10.1136/thx.2004.024091; BURGE PS, 1985, THORAX, V40, P255, DOI 10.1136/thx.40.4.255; Casset A, 2006, ALLERGY, V61, P1344, DOI 10.1111/j.1398-9995.2006.01174.x; Chan-Yeung M, 2006, CURR OPIN ALLERGY CL, V6, P146, DOI 10.1097/01.all.0000225150.91661.34; Copas J, 2000, Biostatistics, V1, P247, DOI 10.1093/biostatistics/1.3.247; Dales R, 2004, J ASTHMA, V41, P259, DOI 10.1081/JAS-120026082; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Delfino RJ, 2003, J EXPO ANAL ENV EPID, V13, P348, DOI 10.1038/sj.jea.7500287; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; DIAMOND RC, 2000, INDOOR AIR QUALITY H, P6; Diez U, 2003, INT J HYG ENVIR HEAL, V206, P173, DOI 10.1078/1438-4639-00218; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; Emenius G, 2004, ACTA PAEDIATR, V93, P899, DOI 10.1080/08035250410025582; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757; Frosh AC, 1999, CLIN EXP ALLERGY, V29, P457; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; George WO, 2005, CHEM WORLD-UK, V2, P26; GREEN DJ, 1987, AM REV RESPIR DIS, V135, P1261; HARVING H, 1986, BRIT MED J, V293, P310; Hodgson AT, 2002, INDOOR AIR, V12, P235, DOI 10.1034/j.1600-0668.2002.01129.x; Hoppin JA, 2004, ENVIRON HEALTH PERSP, V112, P571; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; Institute of Medicine Committee on Damp Indoor Spaces and Health, 2004, DAMP IND SPAC HLTH; JAAKKOLA JJK, 1994, ARCH ENVIRON HEALTH, V49, P175; Jaakkola JJK, 2006, CURR OPIN ALLERGY CL, V6, P85, DOI 10.1097/01.all.0000216849.64828.55; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P560, DOI 10.2105/AJPH.94.4.560; Jaakkola JJK, 2006, AM J EPIDEMIOL, V164, P742, DOI 10.1093/aje/kwj249; Johnson CC, 2002, EPIDEMIOL REV, V24, P154, DOI 10.1093/epirev/mxf013; Kita T, 2003, CLIN EXP ALLERGY, V33, P1747, DOI 10.1111/j.1365-2222.2003.01826.x; KRIEBEL D, 1993, AM REV RESPIR DIS, V148, P1509; Kriebel D, 2001, ARCH ENVIRON HEALTH, V56, P11; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; LAGERCRANTZ L, 2005, P IND AIR 2005 10 IN, V5, P3855; Lehmann I, 2001, INT J HYG ENVIR HEAL, V204, P211, DOI 10.1078/1438-4639-00100; Lehmann I, 2002, ENVIRON TOXICOL, V17, P203, DOI 10.1002/tox.10055; Lehmann I, 2002, ALLERGY, V57, P129, DOI 10.1046/j.0105-4538.2002.00001.x; LEHMANN I, 2002, 14 INT C INT SOC ENV; Leikauf GD, 2002, ENVIRON HEALTH PERSP, V110, P505; LIU KS, 1991, ENVIRON HEALTH PERSP, V94, P91, DOI 10.2307/3431298; MATTHEWS TG, 1986, JAPCA J AIR WASTE MA, V36, P1244; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; Mills S, 2002, NEW ZEAL MED J, V115, P151; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Norback D, 2000, INT J TUBERC LUNG D, V4, P1016; Norback D, 2000, ALLERGY, V55, P163, DOI 10.1034/j.1398-9995.2000.00353.x; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Otake T, 2004, J EXPO ANAL ENV EPID, V14, P524, DOI 10.1038/sj.jea.7500352; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; PAZDRAK K, 1993, INT ARCH OCC ENV HEA, V64, P515, DOI 10.1007/BF00381101; Ponsonby AL, 2004, PEDIATRICS, V113, P1216, DOI 10.1542/peds.113.5.1216; Ponsonby AL, 2003, EPIDEMIOLOGY, V14, P37, DOI 10.1097/00001648-200301000-00012; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; QUACKENBOSS JJ, 1989, ENVIRON INT, V15, P169, DOI 10.1016/0160-4120(89)90023-8; Rains N, 1999, CLIN EXP ALLERGY, V29, P182; Reitzig M, 1998, INDOOR AIR, V8, P91, DOI 10.1111/j.1600-0668.1998.t01-2-00004.x; Richardson G, 2005, J ADV NURS, V52, P328, DOI 10.1111/j.1365-2648.2005.03591.x; Riedel F, 1996, ALLERGY, V51, P94, DOI 10.1111/j.1398-9995.1996.tb04564.x; Rolle-Kampczyk UE, 2002, ARCH ENVIRON HEALTH, V57, P326; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; Sadakane Kaori, 2002, Journal of Environmental Pathology Toxicology and Oncology, V21, P267; Saijo Y, 2004, INT ARCH OCC ENV HEA, V77, P461, DOI 10.1007/s00420-004-0535-0; SAUDER LR, 1987, TOXICOL IND HEALTH, V3, P569; SHEPPARD D, 1984, ENVIRON RES, V35, P133, DOI 10.1016/0013-9351(84)90120-8; Sherriff A, 2005, THORAX, V60, P45, DOI 10.1136/thx.2004.021154; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; STRACHAN DP, 1995, BRIT MED J, V311, P1053; SWIECICHOWSKI AL, 1993, ENVIRON RES, V61, P185, DOI 10.1006/enrs.1993.1063; Tavernier G, 2006, J ALLERGY CLIN IMMUN, V117, P656, DOI 10.1016/j.jaci.2005.12.1311; Trevillian LF, 2005, AM J PUBLIC HEALTH, V95, P2238, DOI 10.2105/AJPH.2004.047191; Trevillian LF, 2004, PAEDIATR PERINAT EP, V18, P281, DOI 10.1111/j.1365-3016.2004.00563.x; Trevillian LF, 2003, CLIN EXP ALLERGY, V33, P483, DOI 10.1046/j.1365-2222.2003.01642.x; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; Viegi G, 2004, INT J TUBERC LUNG D, V8, P1401; Wantke F, 1996, CLIN EXP ALLERGY, V26, P276; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; Weisel CP, 2002, ENVIRON HEALTH PERSP, V110, P527; Wensing M, 2005, SCI TOTAL ENVIRON, V339, P19, DOI 10.1016/j.scitotenv.2004.10.028; WEXCHLER CJ, 2005, P IND AIR 2005 10 IN, V2, P1636; Wichmann G, 2005, TOXICOL IN VITRO, V19, P685, DOI 10.1016/j.tiv.2005.03.012; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Wieslander G, 1997, ANN OCCUP HYG, V41, P155, DOI 10.1016/S0003-4878(96)00039-7; WIESLANDER G, 1994, INT ARCH OCC ENV HEA, V66, P261, DOI 10.1007/BF00454365; Zacharasiewicz A, 2000, ALLERGY, V55, P945, DOI 10.1034/j.1398-9995.2000.00575.x; Zhu JP, 2005, ENVIRON SCI TECHNOL, V39, P3964, DOI 10.1021/es050173u; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	103	166	172	10	61	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	AUG	2007	17	4					259	277		10.1111/j.1600-0668.2007.00478.x		19	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	201QX	WOS:000248848800002	17661923	
J	Chanan-Khan, A; Szebeni, J; Savay, S; Liebes, L; Rafique, NM; Alving, CR; Muggia, FM				Chanan-Khan, A; Szebeni, J; Savay, S; Liebes, L; Rafique, NM; Alving, CR; Muggia, FM			Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions	ANNALS OF ONCOLOGY			English	Article						allergy; anaphylatoxins; cancer chemotherapy; doxorubicin; liposomes; hypersensitivity reactions	PHASE-II; ANTITUMOR-ACTIVITY; OVARIAN-CANCER; CHEMOTHERAPY; PHARMACOKINETICS; PACLITAXEL; MECHANISM; TOXICITY; DISEASE	Background: Pegylated liposomal doxorubicin (Doxil(R)) has been reported to cause immediate hypersensitivity reactions (HSRs) that cannot be explained as IgE-mediated (type I) allergy. Previous in vitro and animal studies indicated that activation of the complement (C) system might play a causal role in the process, a proposal that has not been tested in humans to date. Patients and methods: Patients with solid tumors (n=29) treated for the first time with Doxil were evaluated for HSRs and concurrent C activation. HSRs were classified from mild to severe, while C activation was estimated by serial measurement of plasma C terminal complex (SC5b-9) levels. Increases in SC5b-9 were compared in patients with or without reactions, and were correlated with Doxil dose rate. Results: Moderate to severe HSRs occurred in 45% of patients. Plasma SC5b-9 at 10 min after infusion was significantly elevated in 92% of reactor patients versus 56% in the non-reactor group, and the rise was greater in reactors than in non-reactors. We found significant association between C activation and HSRs, both showing direct correlation with the initial Doxil dose rate. Conclusions: C activation may play a key role in HSRs to Doxil. However, low-level C activation does not necessarily entail clinical symptoms, highlighting the probable involvement of further, as yet unidentified, amplification factors.	Kaplan Comprehens Canc Ctr, New York, NY USA; Walter Reed Army Med Ctr, Walter Reed Army Inst Res, Dept Membrane Biochem, Washington, DC 20307 USA	Chanan-Khan, A (reprint author), Roswell Pk Canc Inst, Elm & Carlton St, Buffalo, NY 14263 USA.						*ALZA PHARM, 2000, DOX PACK INS; Brouwers AH, 2000, J DRUG TARGET, V8, P225, DOI 10.3109/10611860008997901; BUYON JP, 1992, ARTHRITIS RHEUM, V35, P1028, DOI 10.1002/art.1780350907; deMarie S, 1996, LEUKEMIA, V10, pS93; Dezube BJ, 1996, DOXIL CLIN SERIES, V1, P1; GABIZON A, 1994, CANCER RES, V54, P987; GABIZON A, 1994, ACTA ONCOL, V33, P779; Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV-100103136; Gabizon AA, 1998, LONG CIRCULATING LIP, P165; Gordon AN, 2000, J CLIN ONCOL, V18, P3093; Hubert A, 2000, ANTI-CANCER DRUG, V11, P123, DOI 10.1097/00001813-200002000-00009; Koukourakis MI, 1999, J CLIN ONCOL, V17, P3512; Lyass O, 2001, CLIN CANCER RES, V7, P3040; Lyass O, 2000, CANCER, V89, P1037, DOI 10.1002/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z; Muggia F M, 2001, Curr Oncol Rep, V3, P156, DOI 10.1007/s11912-001-0016-5; Muggia FM, 2002, J CLIN ONCOL, V20, P2360, DOI 10.1200/JCO.2002.08.171; Muggia FM, 1997, J CLIN ONCOL, V15, P987; MULLEREBERHARD HJ, 1984, SPRINGER SEMIN IMMUN, V7, P93, DOI 10.1007/BF01893017; Northfelt DW, 1997, J CLIN ONCOL, V15, P653; ROSNER B, 1986, FUNDAMENTALS BIOSTAT, P424; SCULIER JP, 1986, J CLIN ONCOL, V4, P789; Skubitz KM, 1998, ANTI-CANCER DRUG, V9, P45, DOI 10.1097/00001813-199801000-00005; Szebeni J, 1998, CRIT REV THER DRUG, V15, P57; Szebeni J, 2001, INT IMMUNOPHARMACOL, V1, P721, DOI 10.1016/S1567-5769(01)00006-6; Szebeni J, 1998, J NATL CANCER I, V90, P300; Szebeni J, 1999, CIRCULATION, V99, P2302; Szebeni J, 2000, AM J PHYSIOL-HEART C, V279, pH1319; Szebeni J., 2000, J LIPOSOME RES, V10, P347; UZIELY B, 1995, J CLIN ONCOL, V13, P1777	29	166	173	5	23	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0923-7534			ANN ONCOL	Ann. Oncol.	SEP	2003	14	9					1430	1437		10.1093/annonc/mdg374		8	Oncology	Oncology	723NA	WOS:000185437400015	12954584	
J	Barnes, PJ				Barnes, PJ			New concepts in chronic obstructive pulmonary disease	ANNUAL REVIEW OF MEDICINE-SELECTED TOPICS IN THE CLINICAL SCIENCES			English	Review						emphysema; bronchitis; inflammation; proteases; macrophage	RANDOMIZED CONTROLLED TRIAL; BRONCHOALVEOLAR LAVAGE FLUID; SPUTUM INFLAMMATORY MARKERS; CYSTIC-FIBROSIS SPUTUM; EXHALED NITRIC-OXIDE; AIR-FLOW LIMITATION; CHRONIC-BRONCHITIS; ALVEOLAR MACROPHAGES; LUNG-FUNCTION; INHALED BUDESONIDE	Chronic obstructive pulmonary disease (COPD) is a leading cause of death and disability but has only recently been explored from a cellular and molecular perspective. In COPD, chronic inflammation leads to fixed narrowing of small airways and alveolar wall destruction (emphysema). This is characterized by increased numbers of alveolar macrophages, neutrophils, and cytotoxic T lymphocytes, and the release of multiple inflammatory mediators (lipids, chemokines, cytokines, growth factors). There is also a high level of oxidative stress, which may amplify this inflammation. There is increased elastolysis and probable involvement of matrix metalloproteinases. The inflammation and proteolysis in COPD is an amplification of the normal inflammatory response to cigarette smoke. Unlike asthma, this inflammation appears to be resistant to corticosteroids, prompting a search for novel anti-inflammatory therapies that may prevent the relentless progression of the disease.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London, England.						Aaron SD, 2001, AM J RESP CRIT CARE, V163, P349; Agusti AGN, 1999, EUR RESPIR J, V14, P523, DOI 10.1034/j.1399-3003.1999.14c08.x; Altose MD, 2000, NEW ENGL J MED, V343, P1902; Balbi B, 1997, EUR RESPIR J, V10, P846; Barnes Peter J., 2000, Chest, V117, p10S, DOI 10.1378/chest.117.2_suppl.10S; Barnes Peter J., 2001, Current Opinion in Pharmacology, V1, P217, DOI 10.1016/S1471-4892(01)00039-X; Barnes PJ, 1999, THORAX, V54, P245; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Barnes PJ, 2001, EUR RESPIR J, V18, p67S, DOI 10.1183/09031936.01.00229901; Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820; Barnes PJ, 2000, AM J RESP CRIT CARE, V161, P342; Bernard S, 1998, AM J RESP CRIT CARE, V158, P629; Betsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Capelli A, 1999, EUR RESPIR J, V14, P160, DOI 10.1034/j.1399-3003.1999.14a27.x; CASOLARI P, 2002, AM J RESP CRIT CARE, V165, pA597; Chalmers GW, 1999, EUR RESPIR J, V13, P1288, DOI 10.1183/09031936.99.13612939; Compton CH, 2001, LANCET, V358, P265, DOI 10.1016/S0140-6736(01)05481-2; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951; deGodoy I, 1996, AM J RESP CRIT CARE, V153, P633; Dekhuijzen PNR, 1996, AM J RESP CRIT CARE, V154, P813; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803; DISTEFANO A, 2002, IN PRESS EUR RESP J, V18; Donaldson GC, 1999, EUR RESPIR J, V13, P844, DOI 10.1034/j.1399-3003.1999.13d25.x; Eid AA, 2001, AM J RESP CRIT CARE, V164, P1414; Fabbri L, 1998, THORAX, V53, P803; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666; Finlay GA, 1997, AM J RESP CRIT CARE, V156, P240; GIAID A, 1993, NEW ENGL J MED, V328, P1732, DOI 10.1056/NEJM199306173282402; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V154, P1290; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P237; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hill AT, 1999, AM J RESP CRIT CARE, V160, P893; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; ITO K, 2001, EUR RESPIR J, V18, pS316; Ito K, 2001, FASEB J, V15, P1100; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Langen RCJ, 2001, FASEB J, V15, P1169, DOI 10.1096/fj.00-0463; Lim S, 2000, AM J RESP CRIT CARE, V162, P1355; Liu H, 1999, AM J PHYSIOL-LUNG C, V276, pL28; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; Loppow D, 2001, RESP MED, V95, P115, DOI 10.1053/rmed.2000.0960; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Meagher LC, 1996, J IMMUNOL, V156, P4422; Meshi B, 2002, AM J RESP CELL MOL, V26, P52; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Nightingale JA, 2000, AM J RESP CRIT CARE, V161, P479; Noguera A, 1998, AM J RESP CRIT CARE, V158, P1664; Ohnishi K, 1998, LAB INVEST, V78, P1077; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; Paredi P, 2000, AM J RESP CRIT CARE, V162, P369; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pesci A, 1998, EUR RESPIR J, V12, P380, DOI 10.1183/09031936.98.12020380; Punturieri A, 2000, J EXP MED, V192, P789, DOI 10.1084/jem.192.6.789; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341; Roland M, 2001, THORAX, V56, P30, DOI 10.1136/thorax.56.1.30; Russell REK, 2002, AM J RESP CELL MOL, V26, P602; Russell REK, 2002, AM J PHYSIOL-LUNG C, V283, pL867, DOI 10.1152/ajplung.00020.2002; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1046/j.1365-2222.1996.d01-386.x; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304; Schols AMWJ, 1999, AM J RESP CRIT CARE, V160, P1220; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791; Schols AMWJ, 1996, THORAX, V51, P819, DOI 10.1136/thx.51.8.819; SCHOLS AMWJ, 1995, AM J RESP CRIT CARE, V152, P1268; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100; Stockley RA, 1999, AM J RESP CRIT CARE, V160, pS49; Takizawa H, 2001, AM J RESP CRIT CARE, V163, P1476; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802; Tomita K, 2002, AM J RESP CRIT CARE, V166, P724, DOI 10.1164/rccm.2104010; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; Turato G, 2001, RESPIRATION, V68, P117, DOI 10.1159/000050478; TURATO G, 1995, AM J RESP CRIT CARE, V152, P1262; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vukmanovic-Stejic M, 2000, BLOOD, V95, P231; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729; Yamada K, 2002, J ALLERGY CLIN IMMUN, V109, P35, DOI 10.1067/mai.2002.120525; Yamamoto C, 1997, CHEST, V112, P505, DOI 10.1378/chest.112.2.505; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	103	166	177	0	8	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0066-4219			ANNU REV MED	Annu. Rev. Med.		2003	54						113	129		10.1146/annurev.med.54.101601.152209		17	Medicine, General & Internal	General & Internal Medicine	670WV	WOS:000182433600007	12359824	
J	Kharitonov, SA; Barnes, PJ				Kharitonov, SA; Barnes, PJ			Biomarkers of some pulmonary diseases in exhaled breath	BIOMARKERS			English	Review						airway inflammation; oxidative stress; nitric oxide; carbon monoxide; exhaled breath condensate; non-invasive markers; asthma; chronic obstructive pulmonary disease; cystic fibrosis; bronchiectasis; interstitial lung diseases; hydrogen peroxide; eicosanoids; products of lipid peroxidation; proteins; cytokines	NITRIC-OXIDE SYNTHASE; INCREASED CARBON-MONOXIDE; RESPIRATORY-DISTRESS SYNDROME; LEUKOTRIENE RECEPTOR ANTAGONIST; KAPPA-B ACTIVATION; CYSTIC-FIBROSIS; ASTHMATIC-PATIENTS; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; AIRWAY INFLAMMATION	Analysis of various biomarkers in exhaled breath allows completely non-invasive monitoring of inflammation and oxidative stress in the respiratory tract in inflammatory lung diseases, including asthma, chronic obstructive pulmonary disease (COPD), cystic firbrosis (CF), bronchiectasis and interstitial lung diseases. The technique is simple to perform, may be repeated frequently, and can be applied to children, including neonates, and patients with severe disease in whom more invasive procedures are not possible. Several volatile chemicals can be measured in the breath (nitric oxide, carbon monoxide, ammonia), and many non-volatile molecules (mediators, oxidation and nitration products, proteins) may be measured in exhaled breath condensate. Exhaled breath analysis may be used to quantify inflammation and oxidative stress in the respiratory tract, in differential diagnosis of airway disease and in the monitoring of therapy. Most progress has been made with exhaled nitric oxide (NO), which is increased in atopic asthma, is correlated with other inflammatory indices and is reduced by treatment with corticosteroids and antileukotrienes, but not (beta (2)-agonists. In contrast, exhaled NO is normal in COPD, reduced in CF and diagnostically low in primary ciliary dyskinesia. Exhaled carbon monoxide (CO) is increased in asthma, COPD and CF. Increased concentrations of 8-isoprostane, hydrogen peroxide, nitrite and 3-nitrotyrosine are found in exhaled breath condensate in inflammatory lung diseases. Furthermore, increased levels of lipid mediators are found in these diseases, with a differential pattern depending on the nature of the disease process. In the future it is likely that smaller and more sensitive analysers will extend the discriminatory value of exhaled breath analysis and that these techniques may be available to diagnose and monitor respiratory diseases in the general practice and home setting.	Royal Brompton Hosp, Imperial Coll, Fac Med, Natl Heart & Lung Inst,Dept Thorac Med, London SW3 6LY, England	Kharitonov, SA (reprint author), Royal Brompton Hosp, Imperial Coll, Fac Med, Natl Heart & Lung Inst,Dept Thorac Med, Dovehouse St, London SW3 6LY, England.						Adisesh LA, 1998, CLIN EXP ALLERGY, V28, P876; Andersson JA, 2000, J ALLERGY CLIN IMMUN, V105, P269, DOI 10.1016/S0091-6749(00)90075-7; Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; Antuni JD, 2000, THORAX, V55, P138, DOI 10.1136/thorax.55.2.138; Antuni JD, 1999, AM J RESP CRIT CARE, V159, pA51; ANTUNI JD, 1999, AM J RESP CRIT CARE, V159, pA86; ARESE M, 1995, NEPHROL DIAL TRANSPL, V10, P1386; Artlich A, 2001, BIOL NEONATE, V79, P21, DOI 10.1159/000047061; Aziz I, 2000, CHEST, V118, P1049, DOI 10.1378/chest.118.4.1049; BALDWIN SR, 1986, LANCET, V1, P11; BalfourLynn IM, 1996, ARCH DIS CHILD, V75, P319; Balint B, 2001, EUR RESPIR J, V17, P1201, DOI 10.1183/09031936.01.00072501; Ballal SG, 1998, INT J TUBERC LUNG D, V2, P330; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262; Baraldi E, 1997, J PEDIATR-US, V131, P381, DOI 10.1016/S0022-3476(97)80062-5; Baraldi E, 1999, PEDIATR PULM, V27, P54, DOI 10.1002/(SICI)1099-0496(199901)27:1<54::AID-PPUL10>3.0.CO;2-V; Baraldi E, 2000, AM J RESP CRIT CARE, V162, P1828; Bartley J, 1999, AM J RHINOL, V13, P401, DOI 10.2500/105065899781367528; Becher G, 1997, Pneumologie, V51 Suppl 2, P456; Bellocq A, 1998, J BIOL CHEM, V273, P5086, DOI 10.1074/jbc.273.9.5086; BERK PD, 1974, J LAB CLIN MED, V83, P29; Biernacki W, 1999, AM J RESP CRIT CARE, V159, pA631; Biernacki W., 1998, European Respiratory Journal, V12, p345S; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; Brett SJ, 1998, AM J RESP CRIT CARE, V157, P993; Bush A, 2000, Acta Otorhinolaryngol Belg, V54, P317; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810; Clini E, 2000, AM J RESP CRIT CARE, V162, P446; Collins CE, 1999, LIPIDS, V34, P551, DOI 10.1007/s11745-999-0397-1; Corradi M, 2001, AM J RESP CRIT CARE, V163, P854; Cox GM, 2000, INFECT IMMUN, V68, P443, DOI 10.1128/IAI.68.2.443-448.2000; CULPITT SV, 1998, AM J RESP CRIT CARE, V157, pA787; D'Acquisto F, 1998, FEBS LETT, V440, P76, DOI 10.1016/S0014-5793(98)01407-0; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Dekhuijzen PNR, 1996, AM J RESP CRIT CARE, V154, P813; Delen FM, 2000, CHEST, V117, P695, DOI 10.1378/chest.117.3.695; Deykin A, 2000, AM J RESP CRIT CARE, V161, P1237; DOHLMAN AW, 1993, AM REV RESPIR DIS, V148, P955; Dupont LJ, 1999, AM J RESP CRIT CARE, V159, pA861; DZHANGOZINA DM, 1999, MED T PROM EKOL, V8, P13; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Ekroos H, 2000, CLIN PHYSIOL, V20, P434, DOI 10.1046/j.1365-2281.2000.00277.x; EMELYANOV AV, 1995, TERAPEVT ARKH, V67, P45; EVANS TG, 1994, CLIN EXP IMMUNOL, V97, P83; Ferguson EA, 1997, ACTA OTO-LARYNGOL, V117, P614, DOI 10.3109/00016489709113447; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032; Fujimoto K, 1999, CHEST, V115, P697, DOI 10.1378/chest.115.3.697; Gabazza EC, 2000, CLIN SCI, V98, P291, DOI 10.1042/CS19990176; GAREY KW, 2000, AM J RESP CRIT CARE, V161, pA175; GICHKA SG, 1998, KLINICHESKAIA LAB DI, V11, P5; Gomez FP, 1998, EUR RESPIR J, V12, P865, DOI 10.1183/09031936.98.12040865; Goncharova V A, 1996, Klin Med (Mosk), V74, P46; GONCHAROVA VA, 1989, SOV MEDITISINA, V5, P22; Grasemann H, 1997, EUR J PEDIATR, V156, P575, DOI 10.1007/s004310050667; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Griese M, 2000, Eur J Med Res, V5, P334; Guo FH, 2000, J IMMUNOL, V164, P5970; Gustafsson L E, 1998, Eur Respir J Suppl, V26, p49S; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; Hanazawa T., 2000, AM J RESP CRIT CARE, V161, pA919; Heard SO, 1999, ANESTH ANALG, V89, P353, DOI 10.1097/00000539-199908000-00020; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; Ho LP, 1998, THORAX, V53, P680; Holden WE, 1999, J APPL PHYSIOL, V87, P1260; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042; Horvath I, 1998, THORAX, V53, P867; HUNT J, 1995, LANCET, V346, P1235, DOI 10.1016/S0140-6736(95)92947-9; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701; Ignatova GL, 1998, TERAPEVT ARKH, V70, P36; Ishibe Y, 2000, CRIT CARE MED, V28, P3823, DOI 10.1097/00003246-200012000-00012; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Jobsis Q, 1998, EUR RESPIR J, V12, P483, DOI 10.1183/09031936.98.12020483; Jobsis Q, 2000, EUR RESPIR J, V16, P95, DOI 10.1034/j.1399-3003.2000.16a17.x; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, CLIN SCI, V88, P135; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 1998, AM J RESP CRIT CARE, V158, P1374; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; Kharitonov SA, 1997, THORAX, V52, P540; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609; KHARITONOV SA, 1994, BRIT HEART J, V72, P243; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Kharitonov SA, 2000, EUR RESPIR J, V16, P781, DOI 10.1183/09031936.00.16478100; Kharitonov SA, 1997, THORAX, V52, P1051; KHARITONOV SA, 1999, EUR RESPIR J, V9, P212; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, pA799; Kharitinov SA, 2000, AM J RESP CRIT CARE, V161, pA186; Kharitonov SA, 1998, AM J RESP CRIT CARE, V157, pA613; KHARITONOV SA, 2000, AM J RESP CRIT CARE, V161, pA307; Kharitonov SA, 1999, EUR RESPIR J, V9, P223; Kharitonov SA, 2000, AM J RESP CRIT CARE, V161, pA584; Khyshiktuev B. S., 1994, Voprosy Onkologii (St. Petersburg), V40, P161; KHYSHIKTUEV BS, 1996, KLINICHESKAIA LAB DI, V3, P13; KHYSHITKUYEVA NA, 1998, KLIN LAB DIAGN, V1, P21; Kirsch EA, 1999, AM J RESP CELL MOL, V20, P658; Kobayashi H, 1999, JPN J PHYSIOL, V49, P541, DOI 10.2170/jjphysiol.49.541; KOMAR SI, 1996, KLINICHESKAIA LAB DI, V6, P24; Kurik MV, 1987, VRACHEBNOE DELO, V7, P37; Lanz MJ, 1999, ANN ALLERG ASTHMA IM, V82, P161, DOI 10.1016/S1081-1206(10)62591-4; Larfars G, 1999, BLOOD, V93, P1399; Lases EC, 2000, CHEST, V117, P999, DOI 10.1378/chest.117.4.999; Leff AR, 2000, AM J RESP CRIT CARE, V161, pS125; Lehtimaki L, 2000, ANN MED, V32, P417, DOI 10.3109/07853890008995949; Lim S, 2000, AM J RESP CRIT CARE, V162, P1912; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; Lipworth BJ, 2000, AM J MED, V109, P114, DOI 10.1016/S0002-9343(00)00454-X; Little SA, 2000, THORAX, V55, P232, DOI 10.1136/thorax.55.3.232; Liu CY, 1998, BRIT J CANCER, V78, P534, DOI 10.1038/bjc.1998.528; Long R, 1999, ANTIMICROB AGENTS CH, V43, P403; Loukides S, 1998, LANCET, V352, P371, DOI 10.1016/S0140-6736(05)60471-0; Loukides S, 1998, AM J RESP CRIT CARE, V158, P991; Loveless MO, 1997, THORAX, V52, P185; Ludviksdottir D, 1999, RESP MED, V93, P552, DOI 10.1016/S0954-6111(99)90154-3; Lund MB, 2000, OCCUP ENVIRON MED, V57, P274, DOI 10.1136/oem.57.4.274; Lundberg JON, 1999, THORAX, V54, P947; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; McKnight GM, 1997, GUT, V40, P211; Montuschi P, 2000, THORAX, V55, P205, DOI 10.1136/thorax.55.3.205; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Montuschi P, 1998, AM J RESP CRIT CARE, V158, P1524; Montuschi P, 2000, AM J RESP CRIT CARE, V162, P1175; Moodley YP, 1999, EUR RESPIR J, V14, P822, DOI 10.1034/j.1399-3003.1999.14d17.x; Moody A, 2000, J ALLERGY CLIN IMMUN, V105, P895, DOI 10.1067/mai.2000.105318; Mozalevsky A. F., 1997, Ukrainskii Biokhimicheskii Zhurnal, V69, P162; Mullen L, 1998, AM BOOK REV, V19, P5; Murphy AW, 1998, CHEST, V114, P452, DOI 10.1378/chest.114.2.452; Nightingale JA, 1999, THORAX, V54, P1061; Nightingale JA, 1998, THORAX, V53, P87; NIKBERG I I, 1972, Vrachebnoe Delo, V12, P112; NORWOOD DM, 1992, ARCH ENVIRON HEALTH, V47, P309; Nowak D, 1996, EUR RESPIR J, V9, P652, DOI 10.1183/09031936.96.09040652; Nowak D, 1998, Monaldi Arch Chest Dis, V53, P268; ODonnell DM, 1997, AM J RESP CRIT CARE, V156, P1892; Olin AC, 1999, EUR RESPIR J, V14, P828, DOI 10.1034/j.1399-3003.1999.14d18.x; Palm J, 2000, ACTA OTO-LARYNGOL, V120, P420, DOI 10.1080/000164800750000676; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; Parameswaran K, 2000, EUR RESPIR J, V15, P486, DOI 10.1034/j.1399-3003.2000.15.10.x; Paredi P, 2000, AM J RESP CRIT CARE, V161, P1247; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Paredi P, 1998, THORAX, V53, P775; Paredi P, 1999, THORAX, V54, P917; Paredi P, 1999, CHEST, V116, P1007, DOI 10.1378/chest.116.4.1007; PERSSON MG, 1992, EUR J PHARMACOL, V224, P99, DOI 10.1016/0014-2999(92)94826-H; Phillips CR, 1996, J APPL PHYSIOL, V80, P1865; Piacentini GL, 2000, PEDIATR PULM, V29, P430, DOI 10.1002/(SICI)1099-0496(200006)29:6<430::AID-PPUL3>3.0.CO;2-0; Piacentini GL, 2000, EUR RESPIR J, V15, P730, DOI 10.1034/j.1399-3003.2000.15d17.x; PROKHOROVA MN, 1998, KLINICHESKAIA LAB DI, V7, P13; Purokivi M, 2000, EUR RESPIR J, V16, P242, DOI 10.1034/j.1399-3003.2000.16b10.x; Reinhold P, 1999, BERL MUNCH TIERARZTL, V112, P254; Robbins RA, 1996, AM J RESP CRIT CARE, V153, P1631; Rolla G, 2000, J RHEUMATOL, V27, P1693; Rutgers SR, 1999, THORAX, V54, P576; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Saleh D, 1998, FASEB J, V12, P929; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763; Sapienza MA, 1998, THORAX, V53, P172; Saura M, 1999, IMMUNITY, V10, P21, DOI 10.1016/S1074-7613(00)80003-5; Scharte M, 2000, BIOCHEM BIOPH RES CO, V267, P423, DOI 10.1006/bbrc.1999.1936; SCHEIDELER L, 1993, AM REV RESPIR DIS, V148, P778; Sheu FS, 2000, BIOPHYS J, V78, P1216; SIDORENKO GI, 1980, TERAPEVT ARKH, V52, P65; Silkoff PE, 1998, J ASTHMA, V35, P473, DOI 10.3109/02770909809071000; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45; Sippel JM, 1999, SLEEP, V22, P786; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Sovijarvi A. R. A., 1998, European Respiratory Journal, V12, p431S; Spanel P, 1998, RAPID COMMUN MASS SP, V12, P763, DOI 10.1002/(SICI)1097-0231(19980630)12:12<763::AID-RCM229>3.0.CO;2-S; Stamler J S, 1995, Curr Top Microbiol Immunol, V196, P19; Steerenberg PA, 1999, EUR RESPIR J, V13, P334, DOI 10.1034/j.1399-3003.1999.13b19.x; STEWART TE, 1995, AM J RESP CRIT CARE, V151, P713; Stirling RG, 1998, THORAX, V53, P1030; Stirling RG, 2000, AM J RESP CRIT CARE, V161, pA922; Su YC, 1998, AM J RESP CELL MOL, V19, P819; Takahashi H, 2000, AM J RESP CRIT CARE, V162, P258; Tamaoki J, 2000, J AEROSOL MED, V13, P239, DOI 10.1089/jam.2000.13.239; ten Hacken NHT, 1998, AM J RESP CRIT CARE, V158, P902; Thomas SR, 2000, CHEST, V117, P1085, DOI 10.1378/chest.117.4.1085; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; Uasuf CG, 1999, J PEDIATR-US, V135, P569, DOI 10.1016/S0022-3476(99)70054-5; van Amsterdam JGC, 1999, INT ARCH OCC ENV HEA, V72, P404, DOI 10.1007/s004200050392; Van Amsterdam JGC, 1999, ARCH ENVIRON HEALTH, V54, P331; Van Amsterdam JGC, 2000, ARCH ENVIRON HEALTH, V55, P418; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; van Rensen ELJ, 1999, THORAX, V54, P403; Verleden GM, 1999, CHEST, V116, P59, DOI 10.1378/chest.116.1.59; VOLOZHIN AI, 1998, PATOLOGICHESKAIA FIZ, V4, P20; Von Essen SG, 1998, J TOXICOL-CLIN TOXIC, V36, P557; VONPOHLE WR, 1992, CHEST, V101, P1601, DOI 10.1378/chest.101.6.1601; Vreman HJ, 1996, CLIN CHEM, V42, P50; VYSOTSKII VG, 1975, KOSM BIOL AVIAK MED+, V9, P23; Wang CH, 1998, EUR RESPIR J, V11, P809, DOI 10.1183/09031936.98.11040809; Wechsler ME, 2000, AM J RESP CRIT CARE, V162, P2043; Wilson AM, 2000, AM J RESP CRIT CARE, V162, P1297; Withers N. J., 1998, European Respiratory Journal, V12, p393S; Yamaya M, 1998, AM J RESP CRIT CARE, V158, P311; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; Yates DH, 1997, EUR RESPIR J, V10, P1483, DOI 10.1183/09031936.97.10071483; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247; Yates DH, 1996, EUR RESPIR J, V9, P1130, DOI 10.1183/09031936.96.09061130; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140; Zervas E, 2000, EUR RESPIR J, V16, P621, DOI 10.1034/j.1399-3003.2000.16d09.x; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x	217	166	176	2	31	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	1354-750X			BIOMARKERS	Biomarkers	JAN-FEB	2002	7	1					1	32		10.1080/13547500110104233		32	Biotechnology & Applied Microbiology; Toxicology	Biotechnology & Applied Microbiology; Toxicology	505FD	WOS:000172902000001	12101782	
J	Wan, H; Winton, HL; Soeller, C; Taylor, GW; Gruenert, DC; Thompson, PJ; Cannell, MB; Stewart, GA; Garrod, DR; Robinson, C				Wan, H; Winton, HL; Soeller, C; Taylor, GW; Gruenert, DC; Thompson, PJ; Cannell, MB; Stewart, GA; Garrod, DR; Robinson, C			The transmembrane protein occludin of epithelial tight junctions is a functional target for serine peptidases from faecal pellets of Dermatophagoides pteronyssinus	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; house dust mite allergens; tight junctions; serine peptidases; adherens junctions; allergic sensitization; occludin; claudins	HOUSE-DUST MITE; DER-P-I; MEMBRANE-PROTEINS; ALLERGEN; PERMEABILITY; ASTHMA; CHILDHOOD; CLEAVAGE; RECEPTOR; DER-P-1	Background There have been only a few studies of how allergens cross the airway epithelium to cause allergic sensitization. House dust mite fecal pellets (HDMFP) contain several proteolytic enzymes. Group I allergens are cysteine peptidases, whilst those of groups 3, 6 and 9 have catalytic sites indicative of enzymes that mechanistically behave as serine peptidases. We have previously shown that the group 1 allergen Der p 1 leads to cleavage of tight junctions (TJs), allowing allergen delivery to antigen presenting cells. Objective In this study we determined whether HDMFP serine peptidases similarly compromise the airway epithelium by attacking TJs, desmosomes and adherens junctions. Methods Experiments were performed in monolayers of MDCK, Calu-3 or 16HBE14o-epithelial cells. Cell junction morphology was examined by 2-photon molecular excitation microscopy and digital image analysis. Barrier function was measured as mannitol permeability. Cleavage of cell adhesion proteins was studied by immunoblotting and mass spectrometry. Results HDMFP serine peptidases led to a progressive cleavage of TJs and increased epithelial permeability. Desmosomal puncta became more concentrated. Cleavage of TJs involved proteolysis of the TJ proteins, occludin and ZO-1. This was associated with activation of intracellular proteolysis of ZO-1. In contrast to occludin, E-cadherin of adherens junctions was cleaved less extensively. Although Calu-3 and 16HBE14o-cells expressed tethered ligand receptors for serine peptidases, these were not responsible for transducing the changes in TJs. Conclusion HDMFP serine peptidases cause cleavage of TJs. This study identifies a second general class of HDM peptidase capable of increasing epithelial permeability and thereby creating conditions that would favour transepithelial delivery of allergens.	Univ London St Georges Hosp, Sch Med, Dept Pharmacol & Clin Pharmacol, London SW17 0RE, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Clin Pharmacol Sect, London, England; Univ Calif San Francisco, Dept Lab Med, Cardiovasc Res Inst, Gene Therapy Core Ctr, San Francisco, CA 94143 USA; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Med, Nedlands, WA 6009, Australia; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Microbiol, Nedlands, WA 6009, Australia; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England	Robinson, C (reprint author), Univ London St Georges Hosp, Sch Med, Dept Pharmacol & Clin Pharmacol, Cranmer Terrace, London SW17 0RE, England.		Soeller, Christian/G-5525-2011	Robinson, Clive/0000-0001-6253-7864			ANDERSON JM, 1995, AM J PHYSIOL-GASTR L, V269, pG467; ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; CARVER JE, 1999, BRIT J PHARMACOL, V126, P1119; Comoy EE, 1998, J IMMUNOL, V160, P2456; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; HERBERT CA, 1990, LANCET, V336, P1132, DOI 10.1016/0140-6736(90)92611-K; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hirokawa T, 1998, BIOINFORMATICS, V14, P378, DOI 10.1093/bioinformatics/14.4.378; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; King C, 1998, J IMMUNOL, V161, P3645; LYNCH RD, 1995, EUR J CELL BIOL, V66, P259; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; PARRISH EP, 1987, J PATHOL, V153, P265, DOI 10.1002/path.1711530311; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; ROBINSON C, 1995, IMMUNOPHARMACOLOGY R, P187, DOI 10.1016/B978-012352325-9/50012-5; Sakakibara A, 1997, J CELL BIOL, V137, P1393, DOI 10.1083/jcb.137.6.1393; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SMITH PK, 1987, ANAL BIOCHEM, V163, P279; Soeller C, 1996, PFLUG ARCH EUR J PHY, V432, P555, DOI 10.1007/s004240050169; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEWART GA, 1989, LANCET, V2, P154; VanItallie CM, 1997, J CELL SCI, V110, P1113; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Winton HL, 1998, CLIN EXP ALLERGY, V28, P1273; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Wong V, 1997, J CELL BIOL, V136, P399, DOI 10.1083/jcb.136.2.399; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859; Xu WF, 1998, P NATL ACAD SCI USA, V95, P6642, DOI 10.1073/pnas.95.12.6642	37	166	175	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2001	31	2					279	294		10.1046/j.1365-2222.2001.00970.x		16	Allergy; Immunology	Allergy; Immunology	417HF	WOS:000167828900013	11251630	
J	Wang, H; Feng, Z; Shu, Y; Yu, H; Zhou, L; Zu, RQ; Huai, Y; Dong, J; Bao, CJ; Wen, LY; Wang, H; Yang, P; Zhao, W; Dong, LB; Zhou, MH; Liao, QH; Yang, HT; Wang, M; Lu, XJ; Shi, ZY; Wang, W; Gu, L; Zhu, FC; Li, Q; Yin, WD; Yang, WZ; Li, DX; Uyeki, TM; Wang, Y				Wang, Hua; Feng, Zijian; Shu, Yuelong; Yu, Hongjie; Zhou, Lei; Zu, Rongqiang; Huai, Yang; Dong, Jie; Bao, Changjun; Wen, Leying; Wang, Hong; Yang, Peng; Zhao, Wei; Dong, Libo; Zhou, Minghao; Liao, Qiaohong; Yang, Haitao; Wang, Min; Lu, Xiaojun; Shi, Zhiyang; Wang, Wei; Gu, Ling; Zhu, Fengcai; Li, Qun; Yin, Weidong; Yang, Weizhong; Li, Dexin; Uyeki, Timothy M.; Wang, Yu			Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China	LANCET			English	Article							HEALTH-CARE WORKERS; RECEPTOR SPECIFICITY; ANTI-H5 ANTIBODY; HONG-KONG; INFECTION; HEMAGGLUTININ; DISEASE; EPIDEMIOLOGY; RISK	Bankground in December, 2007, family cluster of two individuals infected with highly pathogenic avian influenza A (H5N1) virus was identified in Jiangsu Province, China. Field and laboratory investigations were implemented immediately by public-health authorities. Methods Epidemiological, clinical, and virological data were collected and analysed. Respiratory specimens from the patients were tested by reverse transcriptase (RT) PCR and by viral culture for the presence of H5N1 virus. Contacts of cases were monitored for symptoms of illness for 10 days. Any contacts who became ill had respiratory specimens collected for H5N1 testing by RT PCR. Sera were obtained from contacts for H5N1 serological testing by microneutralisation and horse red-blood-cell haemagglutinin inhibition assays. Findings The 24-year-old index case died, and the second case, his 52-year-old father, survived after receiving early antiviral treatment and post-vaccination plasma from a participant in an H5N1 vaccine trial. The index case's only plausible exposure to H5N1 virus was a poultry market visit 6 days before the onset of illness. The second case had substantial unprotected close exposure to his ill son. 91 contacts with close exposure to one or both cases without adequate protective equipment provided consent for serological investigation. Of these individuals, 78 (86%) received oseltamivir chemoprophylaxis and two had mild illness. Both ill contacts tested negative for H5N1 by RT PCR. All 91 close contacts tested negative for H5N1 antibodies. HSN1 viruses isolated from the two cases were genetically identical except for one non-synonymous nucleotide substitution. Interpretation Limited, non-sustained person-to-person transmission of H5N1 virus probably occurred in this family cluster. Funding Chinese Ministry of Science and Technology; US National Institute of Allergy and infectious Diseases, National Institutes of Health; China-US Collaborative Program on Emerging and Re-emerging Infectious Diseases.	[Feng, Zijian; Yu, Hongjie; Zhou, Lei; Huai, Yang; Yang, Peng; Liao, Qiaohong; Li, Qun; Yang, Weizhong; Wang, Yu] Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, Beijing 100050, Peoples R China; [Wang, Hua; Zu, Rongqiang; Bao, Changjun; Zhou, Minghao; Yang, Haitao; Shi, Zhiyang; Gu, Ling; Zhu, Fengcai] Jiangsu Prov Ctr Dis Control & Prevent, Nanjing, Peoples R China; [Shu, Yuelong; Dong, Jie; Wen, Leying; Dong, Libo; Wang, Min; Wang, Wei; Li, Dexin] China CDC, State Key Lab Infect Dis Prevent & Control, Natl Inst Viral Dis Control & Prevent, Beijing, Peoples R China; [Wang, Hong] Jiangsu Prov Peoples Hosp, Nanjing, Peoples R China; [Zhao, Wei] Nanjing Secondary Peoples Hosp, Nanjing, Peoples R China; [Lu, Xiaojun] Nanjing Ctr Dis Control & Prevent, Nanjing, Peoples R China; [Yin, Weidong] Sinovac Biotech Co, Beijing, Peoples R China; [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA	Wang, Y (reprint author), Chinese Ctr Dis Control & Prevent, Off Dis Control & Emergency Response, 27 Nanwei Rd, Beijing 100050, Peoples R China.	wangyu@chinacdc.cn			NIAID NIH HHS [U19 AI51915]		Abdel-Ghafar AN, 2008, NEW ENGL J MED, V358, P261; Apisarnthanarak A, 2005, CLIN INFECT DIS, V40, pE16, DOI 10.1086/427034; Auewarakul P, 2007, J VIROL, V81, P9950, DOI 10.1128/JVI.00468-07; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Chassagne P, 1996, AM J MED, V100, P65, DOI 10.1016/S0002-9343(96)90013-3; Chiu CH, 2004, CLIN MICROBIOL REV, V17, P311, DOI 10.1128/CMR.17.2.311-322.2004; Gu J, 2007, LANCET, V370, P1137, DOI 10.1016/S0140-6736(07)61515-3; Jong M. D. de, 2006, Nature Medicine, V12, P1203, DOI 10.1038/nm1477; Kandun IN, 2006, NEW ENGL J MED, V355, P2186, DOI 10.1056/NEJMoa060930; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Liem NT, 2005, EMERG INFECT DIS, V11, P210; Mounts AW, 1999, J INFECT DIS, V180, P505, DOI 10.1086/314903; Olsen SJ, 2005, EMERG INFECT DIS, V11, P1799; Oner AF, 2006, NEW ENGL J MED, V355, P2179, DOI 10.1056/NEJMoa060601; Peiris JSM, 2004, LANCET, V363, P617, DOI 10.1016/S0140-6736(04)15595-5; Pitzer VE, 2007, EMERG INFECT DIS, V13, P1074, DOI 10.3201/eid1307.061538; Rowe T, 1999, J CLIN MICROBIOL, V37, P937; Schultsz C, 2005, EMERG INFECT DIS, V11, P1158; Scientific Panel on Biological Hazards, 2006, EUR FOOD SAFETY AUTH, V74, P1; Sedyaningsih ER, 2007, J INFECT DIS, V196, P522, DOI 10.1086/519692; Songserm T, 2006, EMERG INFECT DIS, V12, P1744; Spackman E, 2002, J CLIN MICROBIOL, V40, P3256, DOI 10.1128/JCM.40.9.3256-3260.2002; Stephenson I, 2003, J MED VIROL, V70, P391, DOI 10.1002/jmv.10408; Stevens J, 2006, SCIENCE, V312, P404, DOI 10.1126/science.1124513; Ungchusak K, 2005, NEW ENGL J MED, V352, P333, DOI 10.1056/NEJMoa044021; Webster RG, 2004, LANCET, V363, P234, DOI 10.1016/S0140-6736(03)15329-9; WHO, CLIN MAN HUM INF AV; *WHO, WHO MAN AN INFL DIAG; World Health Organization, 2007, AV INFL SIT IND UPD; World Health Organization, WHO CAS DEF HUM INF; WHO, REC LAB PROC DET AV; WHO, WHO GUID INV HUM CAS; World Health Organization (WHO), COLL PRES SHIPP SPEC; WHO, 2016, CUM NUMB CONF HUM CA; World Health Organization, 2006, WKLY EPIDEMIOL REC, V5, p[81, 183]; Yamada S, 2006, NATURE, V444, P378, DOI 10.1038/nature05264; Yu HJ, 2007, EMERG INFECT DIS, V13, P1061, DOI 10.3201/eid1307.061557; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9; Zhou BP, 2007, NEW ENGL J MED, V357, P1450, DOI 10.1056/NEJMc070359	39	165	186	3	29	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	APR-MAY	2008	371	9622					1427	1434		10.1016/S0140-6736(08)60493-6		8	Medicine, General & Internal	General & Internal Medicine	294XW	WOS:000255440600023	18400288	
J	Johnston, SL; Blasi, F; Black, PN; Martin, RJ; Farrell, DJ; Nieman, RB				Johnston, SL; Blasi, F; Black, PN; Martin, RJ; Farrell, DJ; Nieman, RB		TELICAST Investigators	The effect of telithromycin in acute exacerbations of asthma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IN-VITRO ACTIVITY; MYCOPLASMA-PNEUMONIAE; CHLAMYDIA-PNEUMONIAE; HMR 3647; KETOLIDE; INFECTION; TRIAL	BACKGROUND: We conducted a double-blind, randomized, placebo-controlled study to evaluate the efficacy of telithromycin in patients with acute exacerbations of asthma. METHODS: A total of 278 adults with diagnosed asthma were enrolled within 24 hours after an acute exacerbation of asthma requiring short-term medical care. The patients were randomly assigned to receive 10 days of oral treatment with telithromycin (at a dose of 800 mg daily) or placebo in addition to usual care. Primary efficacy end points were a change from baseline over the treatment period in symptoms (as recorded by patients in a diary card) and in the peak expiratory flow in the morning at home. The presence of Chlamydophila pneumoniae or Mycoplasma pneumoniae was ascertained by serologic analysis, polymerase chain reaction, and culture. RESULTS: Of the two prespecified primary outcomes, only asthma symptoms showed a significantly greater reduction among patients receiving telithromycin than among those receiving placebo. Mean (+/-SD) scores on a test of asthma symptoms (on a 7-point scale, with 0 denoting no symptoms and 6 denoting severe symptoms) were 3.0+/-1.4 at baseline and 1.7+/-1.1 at the end of treatment for the telithromycin group and 2.8+/-1.3 at baseline and 2.0+/-1.0 at the end of treatment for the placebo group. The mean decrease in symptom scores during the treatment period was 1.3 for telithromycin and 1.0 for placebo (mean difference, -0.3; 95 percent confidence interval, -0.5 to -0.1; P=0.004). There was no significant treatment effect on the other primary outcome measure, a change in morning peak expiratory flow. Nausea was more common among patients in the telithromycin group than in the placebo group (P=0.01). Although 61 percent of patients had evidence of infection with C. pneumoniae, M. pneumoniae, or both, there was no relationship between bacteriologic status and the response to asthma treatment. CONCLUSIONS: This study provides evidence of the benefit of telithromycin in patients with acute exacerbations of asthma; the mechanisms of benefit remain unclear.	Natl Heart & Lung Inst, Imperial Coll London, London W2 1PG, England; GR Micro, London, England; Univ Milan, Ist Ric & Cura Carattere Sci Policlin, Milan, Italy; Univ Auckland, Auckland 1, New Zealand; Natl Jewish Med & Res Ctr, Denver, CO USA; Sanofi Aventis, Bridgewater, NJ USA	Johnston, SL (reprint author), Natl Heart & Lung Inst, Imperial Coll London, Norfolk Pl, London W2 1PG, England.	s.johnston@imperial.ac.uk	Johnston, Sebastian/I-2423-2012	Blasi, Francesco/0000-0002-2285-9970			Ackermann G, 2003, J ANTIMICROB CHEMOTH, V51, P497, DOI 10.1093/jac/dkg123; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; Araujo FG, 2002, ANTIMICROB AGENTS CH, V46, P3327, DOI 10.1128/AAC.46.10.3327-3330.2002; Biscione GL, 2004, EUR RESPIR J, V24, P745, DOI 10.1183/09031936.04.00049004; Black PN, 2001, AM J RESP CRIT CARE, V164, P536; Carbon C, 2003, INFECTION, V31, P308, DOI 10.1007/s15010-003-3142-1; CLAY KD, IN PRESS ANN INTERN; Daxboeck F, 2003, CLIN MICROBIOL INFEC, V9, P263, DOI 10.1046/j.1469-0691.2003.00590.x; Dowell SF, 2001, CLIN INFECT DIS, V33, P492, DOI 10.1086/322632; *FDA, 2003, IN PRESS FDA ANT DRU, P96; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; *FOOD DRUG ADM, QUEST ANSW TEL MARK; Graham V, 2001, COCHRANE DB SYST REV, V3; Hammerschlag MR, 2001, J ANTIMICROB CHEMOTH, V48, P25; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Johnston SL, 2005, AM J RESP CRIT CARE, V172, P1078, DOI 10.1164/rccm.200412-1743PP; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; National Asthma Education and Prevention Program. National Asthma Education and Prevention Program, 2002, J ALLERGY CLIN IMMUN, V110, pS141; NICOLAU DP, 2003, CLIN MICROBIOL INFEC, V9, P397; Roblin PM, 1998, ANTIMICROB AGENTS CH, V42, P1515; Santanello NC, 1997, EUR RESPIR J, V10, P646; Wark PAB, 2002, EUR RESPIR J, V20, P834, DOI 10.1183/09031936.02.00192002; Yamaguchi T, 2000, ANTIMICROB AGENTS CH, V44, P1381, DOI 10.1128/AAC.44.5.1381-1382.2000	23	165	178	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	APR 13	2006	354	15					1589	1600		10.1056/NEJMoa044080		12	Medicine, General & Internal	General & Internal Medicine	031WW	WOS:000236736900007	16611950	
J	Srinivasan, S; O'Fallon, LR; Dearry, A				Srinivasan, S; O'Fallon, LR; Dearry, A			Creating healthy communities, healthy homes, healthy people: Initiating a research agenda on the built environment and public health	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							PHYSICAL-ACTIVITY; UNITED-STATES; CHILDREN; POPULATION; COCKROACH; ASTHMA; RISK; CITY	Mounting evidence suggests physical and mental health problems relate to the built environment, including human-modified places such as homes, schools, workplaces, parks, industrial areas, farms, roads and highways. The public health relevance of the built environment requires examination. Preliminary research demonstrates the health benefits of sustainable communities. However, the impact of mediating and moderating factors within the built environment on health must be explored further. Given the complexity of the built environment, understanding its influence on human health requires a community-based, multilevel, interdisciplinary research approach. The authors offer recommendations, based upon a recent conference sponsored by the National Institute of Environmental Health Sciences (NIEHS), for research and policy approaches, and suggest interagency research alliances for greater public health impact.	Natl Inst Environm Hlth Sci, Div Extramural Res, Res Triangle Pk, NC 27709 USA	Srinivasan, S (reprint author), Natl Inst Environm Hlth Sci, Div Extramural Res, 111 TW Alexander Dr,POB 12233,MD EC-21, Res Triangle Pk, NC 27709 USA.						Adler NE, 1999, ANN NY ACAD SCI, V896, P3, DOI 10.1111/j.1749-6632.1999.tb08101.x; Bashir SA, 2002, AM J PUBLIC HEALTH, V92, P733, DOI 10.2105/AJPH.92.5.733; Bell ML, 2002, ENVIRON HEALTH PERSP, V110, P1163, DOI 10.1289/ehp.021101163; BENEDICT MA, 2000, SPRAWL WATCH CLEARIN; CAPPON D, 1991, CAN J PUBLIC HEALTH, V82, P249; CLINTON WJ, 1993, EXECUTIVE ORDER 1285; Corvalan CF, 1999, EPIDEMIOLOGY, V10, P656, DOI 10.1097/00001648-199909000-00036; Cummins SK, 2001, PEDIATR CLIN N AM, V48, P1241, DOI 10.1016/S0031-3955(05)70372-2; EWING R, 2002, MEASURING SPRAWL IMP; FE K, 2001, ENVIRON BEHAV, V33, P343; Frumkin H, 2002, PUBLIC HEALTH REP, V117, P201, DOI 10.1016/S0033-3549(04)50155-3; Fullilove M T, 1998, J Am Med Womens Assoc (1972), V53, P72; Fullilove MT, 2000, AM J PUBLIC HEALTH, V90, P183, DOI 10.2105/AJPH.90.2.183; Goran MI, 2001, PEDIATR CLIN N AM, V48, P931, DOI 10.1016/S0031-3955(05)70349-7; Halpern D., 1995, MORE BRICKS MORTAR M; HANCOCK T, 2002, PUBLIC HLTH REP, V115, P151; Hancock T., 2002, CAN J PUBLIC HLTH, V93, P45; Handy SL, 2002, AM J PREV MED, V23, P64, DOI 10.1016/S0749-3797(02)00475-0; Hawe P, 2000, SOC SCI MED, V51, P871, DOI 10.1016/S0277-9536(00)00067-8; Hedge A, 2000, ERGONOMICS, V43, P1019, DOI 10.1080/001401300409198; *HLTH CAN DIV CHIL, 2002, NAT BUILT ENV; Hodgson M, 2002, ENVIRON HEALTH PERSP, V110, P663; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; KILLINGSWORTH RE, 2001, URBAN LAND       JUL, P12; King AC, 2000, HEALTH PSYCHOL, V19, P354, DOI 10.1037//0278-6133.19.4.354; Kjellstrom Tord, 1995, World Health Statistics Quarterly, V48, P144; Kreiger J, 2002, AM J PUBLIC HEALTH, V92, P758; LABONTE R, 1996, AUST J PUBLIC HLTHK, V17, P4; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; Lehmann I, 2002, ALLERGY, V57, P129, DOI 10.1046/j.0105-4538.2002.00001.x; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Morland K, 2002, AM J PREV MED, V22, P23, DOI 10.1016/S0749-3797(01)00403-2; *NAT I ENV HLTH SC, 2003, ENV JUST PARTN COMM; OLDEN K, 1998, SCIENTIST       0216; Pederson R M, 2000, Rev Environ Health, V15, P231; POPE CA, 2002, JAMA-J AM MED ASSOC, V287, P1131; PORRAS C, 2003, SO CALIFORNIA ENV HL; Raffestine C, 1990, J SOCIOLOGY SOCIAL W, V17, P143; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557; Sharfstein J, 2001, AM J PUBLIC HEALTH, V91, P1191, DOI 10.2105/AJPH.91.8.1191; SHEPARD P, 2003, NO MANHATTAN ENV JUS; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665; Taylor Ralph B., 1996, PHYSICAL ENV CRIME; Thomson H, 2001, BRIT MED J, V323, P187, DOI 10.1136/bmj.323.7306.187; *US DEP HHHS, 2001, HLTH PEOPL 2010 UND; VONSCHIRNDING YE, 2002, CAN J PUBLIC HLTH, V93, P9; Wang G, 2002, PEDIATRICS, V109, P81; Weich S, 2002, BRIT J PSYCHIAT, V180, P428, DOI 10.1192/bjp.180.5.428; Wilson A., 1998, GREEN DEV INTEGRATIN; Zein SR, 1997, TRANSPORT RES REC, V1578, P3, DOI 10.3141/1578-01	51	165	167	3	41	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	SEP	2003	93	9					1446	1450		10.2105/AJPH.93.9.1446		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	716KL	WOS:000185027300024	12948961	
J	Simpson, A; Tan, VYF; Winn, J; Svensen, M; Bishop, CM; Heckerman, DE; Buchan, I; Custovic, A				Simpson, Angela; Tan, Vincent Y. F.; Winn, John; Svensen, Markus; Bishop, Christopher M.; Heckerman, David E.; Buchan, Iain; Custovic, Adnan			Beyond Atopy Multiple Patterns of Sensitization in Relation to Asthma in a Birth Cohort Study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; atopy; unsupervised clustering; Bayesian inference; machine learning in epidemiology	AGE 3 YEARS; LUNG-FUNCTION; RESPIRATORY SYMPTOMS; REVISED NOMENCLATURE; PRESCHOOL-CHILDREN; MANCHESTER ASTHMA; EARLY-LIFE; ALLERGY; CHILDHOOD; PREVALENCE	Rationale: The pattern of IgE response (over time or to specific allergens) may reflect different atopic vulnerabilities which are related to the presence of asthma in a fundamentally different way from current definition of atopy. Objectives: To redefine the atopic phenotype by identifying latent structure within a complex dataset, taking into account the timing and type of sensitization to specific allergens, and relating these novel phenotypes to asthma. Methods: In a population-based birth cohort in which multiple skin and IgE tests have been taken throughout childhood, we used a machine learning approach to cluster children into multiple atopic classes in an unsupervised way. We then investigated the relation between these classes and asthma (symptoms, hospitalizations, lung function and airway reactivity). Measurements and Main Results: A five-class model indicated a complex latent structure, in which children with atopic vulnerability were clustered into four distinct classes (Multiple Early [112/1053, 10.6%]; Multiple Late [171/1053, 16.2%]; Dust Mite [47/1053,4.5%]; and Non-dust Mite [100/1053, 9.5%]), with a fifth class describing children with No Latent Vulnerability (623/1053, 59.2%). The association with asthma was considerably stronger for Multiple Early compared with other classes and conventionally defined atopy (odds ratio [95% Cl]: 29.3 [11.1-77.2] versus 12.4 [4.8-32.2] versus 11.6 [4.8-27.9] for Multiple Early class versus Ever Atopic versus Atopic age 8). Lung function and airway reactivity were significantly poorer among children in Multiple Early class. Cox regression demonstrated a highly significant increase in risk of hospital admissions for wheeze/asthma after age 3 yr only among children in the Multiple Early class (HR 9.2 [3.5-24.0], P < 0.001). Conclusions: IgE antibody responses do not reflect a single phenotype of atopy, but several different atopic vulnerabilities which differ in their relation with asthma presence and severity.	[Simpson, Angela; Custovic, Adnan] Univ Manchester, Manchester Acad Hlth Sci Ctr, NIHR Translat Res Facil Resp Med, Univ Hosp S Manchester NHS Fdn Trust, Manchester M23 9LT, Lancs, England; [Tan, Vincent Y. F.] MIT, Stochast Syst Grp, Lab Informat & Decis Syst, Cambridge, MA 02139 USA; [Winn, John; Svensen, Markus; Bishop, Christopher M.] Microsoft Res Cambridge, Cambridge, England; [Heckerman, David E.] Microsoft Res, eSci Res Grp, Redmond, WA USA; [Buchan, Iain] Univ Manchester, NW Inst Biohlth Informat, Manchester M23 9LT, Lancs, England	Simpson, A (reprint author), Univ Manchester, Wythenshawe Hosp, ERC Bldg,2nd Floor, Manchester M23 9LT, Lancs, England.	angela.simpson@manchester.ac.uk	Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Simpson, Angela/0000-0003-2733-6666; Buchan, Iain/0000-0003-3392-1650	Asthma UK [04/014]; Moulton Charitable Trust; James Trust; Microsoft Research; GlaxoSmithKline; Phadia Research in industry; Pfizer; UCB Pharma; ALK; Phadia; Novartis	Supported by Asthma UK Grant 04/014, Moulton Charitable Trust, the James Trust, and Microsoft Research.; A.S. received up to $1,000 in lecture fees for CME activity from GlaxoSmithKline and $5,001 $10,000 from Phadia Research in industry-sponsored grants for collaborative research. V.Y.F.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.W. is a full-time employee of Microsoft Research and has various patents through normal course of work within Microsoft Research. M.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C.M.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. D.E.H.'s dependent is an employee of Microsoft, has received or is pending a patent from Microsoft in algorithm patents, and holds more than $100,001 in stock ownership or options in Microsoft. I.B, received more than $100,001 from Microsoft in funding to develop methods for genetic epidemiology. A.C. received 81,001 $5,000 from Pfizer and $1,001 $5,000 from UCB Pharma in consultancy fees, $1,001 $5,000 from ALK and $1,001 $5,000 from GlaxoSmithKline in advisory board fees, $5,001 $10,000 from GlaxoSmithKline in promotional lecture fees, $1,001 $5,000 from AstraZeneca, up to $1,000 from Phadia, up to $1,000 from ALK, and up to $1,000 from Novartis in lecture fees, and $5,001 $10,000 from Phadia in collaborative industry-sponsored grants.	Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Chapman Martin D, 2008, Clin Allergy Immunol, V21, P47; Chinn S, 1996, J APPL STAT, V23, P395, DOI 10.1080/02664769624134; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Custovic A, 2003, J ALLERGY CLIN IMMUN, V111, P402, DOI 10.1067/mai.2003.55; Custovic A, 2002, PEDIATR ALLERGY IMMU, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic Adnan, 2004, Pediatr Pulmonol Suppl, V26, P12; DUFFY DL, 1992, CHEST, V102, P654, DOI 10.1378/chest.102.2.654; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Litonjua AA, 1997, AM J RESP CRIT CARE, V156, P23; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; Matricardi PM, 2009, ALLERGY, V64, P1093, DOI 10.1111/j.1398-9995.2009.02055.x; Moore WC, 2009, AM J RESP CRIT CARE, V181, P315; NICOLAOU NC, 2008, J ALLERGY CLIN IMMUN, V122; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; RABINER LR, 1985, AT&T TECH J, V64, P1251; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; Smith JA, 2008, AM J RESP CRIT CARE, V177, P1358, DOI 10.1164/rccm.200709-1419OC; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Winn J, 2005, J MACH LEARN RES, V6, P661; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; WOOLCOCK AJ, 1983, EUR J RESPIR DIS, V64, P571	35	164	168	1	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2010	181	11					1200	1206		10.1164/rccm.200907-1101OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	609NN	WOS:000278663600009	20167852	
J	Penagos, M; Passalacqua, G; Compalati, E; Baena-Cagnani, CE; Orozco, S; Pedroza, A; Canonica, GW				Penagos, Martin; Passalacqua, Giovanni; Compalati, Enrico; Baena-Cagnani, Carlos E.; Orozco, Socorro; Pedroza, Alvaro; Canonica, Giorgio Walter			Metaanalysis of the efficacy of sublingual immunotherapy in the treatment of allergic asthma in pediatric patients, 3 to 18 years of age	CHEST			English	Article						asthma; children; efficacy; metaanalysis; randomized controlled trials; sublingual immunotherapy	RANDOMIZED CONTROLLED-TRIALS; HOUSE-DUST MITE; DOUBLE-BLIND; CLINICAL-TRIALS; GRASS-POLLEN; SWALLOW IMMUNOTHERAPY; STATISTICAL POWER; RESPIRATORY ALLERGY; DOUBLE-DUMMY; CHILDREN	Background: Recent studies have documented the efficacy and safety of sublingual immunotherapy (SLIT) in patients with rhinitis, but the value of this treatment in those with asthma is still debated. We evaluated the efficacy of SLIT in the treatment of allergic asthma in children by a metaanalysis of randomized, double-blind, and placebo-controlled (DBPC) clinical trials. Methods: Electronic databases were searched up to May 31, 2006, for randomized DBPC trials assessing SLIT in pediatric cases of asthma. Effects on primary outcomes (ie, symptom scores and concomitant use of rescue medication) were calculated with standardized mean differences (SMDs) using the random-effects model. We performed the metaanalysis using a statistical software package (RevMan, 4.2.8; The Cochrane Collaboration; Oxford, UK), and we followed the recommendations of the Cochrane Collaboration and the Quality of Reporting of Metaanalyses guidelines. Results: Seventy-three articles were identified and reviewed. Nine studies, all published after 1990, fulfilled the selection criteria. A total of 441 patients had a final assessment and were included in the analysis. Two hundred thirty-two patients received SLIT, and 209 patients received placebo. The results of the present analysis demonstrated a relevant heterogeneity due to widely differing scoring systems. Overall, there was a significant reduction in both symptoms (SMD 1.14; 95% confidence interval [CI], -2.10 to -0.18; p = 0.02) and medication use (SMD, 1.63; 95% CI, -2.83 to -0.44; p = 0.007) following SLIT. Conclusion: SLIT with standardized extracts reduces both symptom scores and rescue medication use in children with allergic asthma compared with placebo.	[Penagos, Martin; Passalacqua, Giovanni; Compalati, Enrico; Canonica, Giorgio Walter] Univ Genoa, Dept Internal Med, Div Allergy & Respiratory Dis, Genoa, Italy; [Baena-Cagnani, Carlos E.] Univ Cordoba, Cordoba, Argentina; [Orozco, Socorro; Pedroza, Alvaro] Natl Pediat Inst, Mexico City, DF, Mexico	Canonica, GW (reprint author), DIMI, Largo R Benzi 10, I-16132 Genoa, Italy.	canonica@unige.it					Abramson MJ, 2003, COCHRANE DATABASE SY; Akobeng AK, 2005, ARCH DIS CHILD, V90, P837, DOI 10.1133/adc.2005.071761; Alderson P., 2002, COCHRANE COLLABORATI; *AM AC PED COUNC C, 1972, PEDIATRICS, V49, P463; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Battle M. V., 2000, IEEE Transactions on Professional Communication, V43, DOI 10.1109/47.888810; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; BLAND JM, 1986, LANCET, V1, P307; *BORM, 2003, DIG 1 5 7 PROGR; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS146; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; CAMARACLARK OA, 2002, INT J EPIDEMIOL, V31, P112; Canonica GW, 2007, ALLERGY, V62, P317, DOI 10.1111/j.1398-9995.2006.01312.x; Ciprandi G, 2006, ALLERGY, V61, P511, DOI 10.1111/j.1398-9995.2006.01046.x; RevMan Analyses, 2002, REV MAN REVMAN 4 2; Cohen J., 1988, STAT POWER ANAL BEHA; Cohn LD, 2003, PSYCHOL METHODS, V8, P243, DOI 10.1037/1082-989X.8.3.243; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; DAWSON B, 2004, BASIC CLIN BIOSTATIS, V118; Deeks J, 2001, SYSTEMATIC REV HLTH, P285, DOI 10.1002/9780470693926.ch15; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DerSimonian R, 2007, CONTEMP CLIN TRIALS, V28, P105, DOI 10.1016/j.cct.2006.04.004; Di Rienzo V, 2005, CLIN EXP ALLERGY, V35, P560, DOI 10.1111/j.1365-2222.2005.02219.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Dupont WD, PS POWER SAMPLE SIZE; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Egger M, 1997, BRIT MED J, V315, P1533; Egger M, 2003, Health Technol Assess, V7, P1; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HIGGINS JPT, 2006, COCHRANE DATABASE SY; Higgins Julian, 2002, J Health Serv Res Policy, V7, P51, DOI 10.1258/1355819021927674; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Holmgren J, 2005, NAT MED, V11, pS45, DOI 10.1038/nm1213; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Laczo RM, 2005, J APPL PSYCHOL, V90, P758, DOI 10.1037/0021-9010.90.4.758; Litt IF, 1998, PEDIATRICS, V102, P249; LITT IF, 1972, PEDIATRICS, V49, P463; *MEDCALC SOFTW, 2006, MEDCALC WIND VERS 8; MOHER D, 1994, JAMA-J AM MED ASSOC, V272, P122, DOI 10.1001/jama.272.2.122; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Moher D, 1999, HEALTH TECHNOL ASSES, V3, p[i, 1], DOI DOI 10.3310/HTA3120; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Passalacqua G, 2006, CURR OPIN ALLERGY CL, V6, P449, DOI 10.1097/01.all.0000246617.41871.40; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Robinson KA, 2002, INT J EPIDEMIOL, V31, P150, DOI 10.1093/ije/31.1.150; Rodriguez Santos Olimpio, 2004, Rev Alerg Mex, V51, P177; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Sackett DL, 2002, J CLIN EPIDEMIOL, V55, P1161, DOI 10.1016/S0895-4356(02)00521-8; Shekelle PG, 1999, BRIT MED J, V318, P593; *SPSS INC, SPSS VERS 14 0 WIND; Stenning SP, 2002, ANN ONCOL, V13, P131, DOI 10.1093/annonc/mdf650; Sterne JAC, 2001, J CLIN EPIDEMIOL, V54, P1046, DOI 10.1016/S0895-4356(01)00377-8; Sutton AJ, 2008, STAT MED, V27, P625, DOI 10.1002/sim.2934; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; US Food and Drug Administration, 2000, GUID IND ALL RHIN CL; VELARDE T, 2002, REV SANID MILIT MEX, V56, P10; Viera AJ, 2005, FAM MED, V37, P360; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wang MC, 1998, PSYCHOL METHODS, V3, P46, DOI 10.1037//1082-989X.3.1.46; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	76	164	175	0	6	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAR	2008	133	3					599	609		10.1378/chest.06-1425		11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	273LV	WOS:000253933300006	17951626	
J	Linneberg, A; Nielsen, NH; Frolund, L; Madsen, F; Dirksen, A; Jorgensen, T				Linneberg, A; Nielsen, NH; Frolund, L; Madsen, F; Dirksen, A; Jorgensen, T			The link between allergic rhinitis and allergic asthma: A prospective population-based study. The Copenhagen Allergy Study	ALLERGY			English	Article						allergic asthma; allergic rhinitis; epidemiology; IgE antibody; respiratory hypersensitivity	8 YEARS APART; DANISH ADULTS; SKIN-TEST; IMMUNOTHERAPY; PREVALENCE	Background: It has been hypothesized that allergic rhinitis and allergic asthma are manifestations of the same disease entity. We aimed to investigate the relationship between allergic rhinitis and allergic asthma. Methods: Participants in a population-based study of 15-69-year-olds in 1990 were invited to a follow-up in 1998. A total of 734 subjects were examined on two occasions eight years apart. Allergic rhinitis to pollen was defined as a history of nasal symptoms on exposure to pollens and IgE specific to pollen. Allergic asthma to pollen was defined as a history of lower airway symptoms on exposure to pollens and IgE specific to pollen. Similarly, diagnoses of allergic rhinitis and allergic asthma to animals or mite were defined. Results: At follow-up, all subjects with allergic asthma to pollen (n = 52) had in addition allergic rhinitis to pollen. In the longitudinal analysis, there were a total of 28 new (incident) cases of allergic asthma to pollen. They all had allergic rhinitis to pollen at baseline, or had developed allergic rhinitis to pollen at follow-up. Accordingly, allergic rhinitis to animals and mite were ubiquitous in subjects with allergic asthma to animals and mite, respectively. Conclusions: The results support the hypothesis that allergic rhinitis and allergic asthma are manifestations of the same disease entity.	Glostrup Univ Hosp, Dept Internal Med M, Ctr Prevent Med, Glostrup, Denmark; Bispebjerg Univ Hosp, Dept Dermatol, Copenhagen, Denmark; Frederiksberg Univ Hosp, Dept Internal Med B, Frederiksberg, Denmark; Gentofte Univ Hosp, Dept Resp Med Y, Gentofte, Denmark	Linneberg, A (reprint author), Glostrup Cty Hosp, Ctr Prevent Med, 57 Ndr Ringvej,Entrance 8,7th Floor, DK-2600 Glostrup, Denmark.						ABRAHAMSON MJ, 1998, COCHRANE LIB; Annesi-Maesano I, 1999, ALLERGY, V54, P7; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Ciprandi G, 1996, Int Arch Allergy Immunol, V111, P278; CORREN J, 1998, J ALLERGY CLIN IMMUN, V101, P352; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P185, DOI 10.2500/108854198778557836; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; Grossman J, 1997, CHEST, V111, P11; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kapsali T, 1997, J ALLERGY CLIN IMMUN, V99, P138; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Leynaert B., 2000, J ALLERGY CLIN IMMUN, V106, P201; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Linneberg A, 2001, RESP MED, V95, P258, DOI 10.1053/rmed.2001.1031; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; LINNEBERG A, 2001, ALLERGY, V54, P328; NIELSEN NH, 1993, ALLERGY, V48, P319, DOI 10.1111/j.1398-9995.1993.tb02400.x; Passalacqua G, 2000, THORAX, V55, P26; PEDERSEN PA, 1983, ALLERGY, V38, P25, DOI 10.1111/j.1398-9995.1983.tb00852.x; Rachelefsky GS, 1999, ANN ALLERG ASTHMA IM, V82, P296, DOI 10.1016/S1081-1206(10)62612-9; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; Spector S. L., 1997, J ALLERGY CLIN IMMUN, V99, P773; Townley RG, 1998, ANN ALLERG ASTHMA IM, V80, P137; Valovirta E, 1997, J INVEST ALLERG CLIN, V7, P369; Vignola AM, 2001, CLIN EXP ALLERGY, V31, P674, DOI 10.1046/j.1365-2222.2001.01115.x	27	164	171	0	3	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	NOV	2002	57	11					1048	1052		10.1034/j.1398-9995.2002.23664.x		5	Allergy; Immunology	Allergy; Immunology	599PC	WOS:000178343400011	12359002	
J	DeRijk, RH; Schaaf, M; de Kloet, ER				DeRijk, RH; Schaaf, M; de Kloet, ER			Glucocorticoid receptor variants: clinical implications	JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Review						glucocorticoid receptor variants; clinical implications; hypothalamic-pituitary-adrenal axis	PRIMARY CORTISOL RESISTANCE; FRAGMENT-LENGTH-POLYMORPHISM; HORMONE-BINDING DOMAIN; HUMAN MULTIPLE-MYELOMA; BETA-ISOFORM; DNA-BINDING; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVATION; RESPONSE ELEMENT; CUSHINGS-DISEASE	Following exposure to stress, cortisol is secreted from the adrenal cortex under the control of the hypothalamic-pituitary-adrenal axis (HPA-axis). Central in the regulation of the HPA-axis is a two tied corticosteroid-receptor system, comprised of high and low affinity receptors, the mineralocorticoid receptor (MR) and the glucocorticoid receptor (GR), respectively. In addition, these corticosteroid receptors mediate the effects of cortisol during stress on both central and peripheral targets. Cortisol modulates gene-expression of corticosteroid-responsive genes, with the effect lasting from hours to days. Mutations in the GR-gene are being associated with corticosteroid resistance and haematological malignancies, although these mutations are relatively rare and probably not a common cause of these diseases. However, several GR-gene variants and single nucleotide polymorphisms (SNP) in the GR-gene have been identified which are relatively common in the human population. The GRbeta-variant, for example, has been proposed to influence corticosteroid-sensitivity and most evidence has been derived from the immune system and in particular asthma. With respect to polymorphisms, a BclI restriction fragment polymorphism and a Asp363Ser have been described, which not only influence the regulation of the HPA-axis, but are also associated with changes in metabolism and cardiovascular control. These associations of a GR-gene polymorphism with metabolism and cardivascular control, and also with the regulation of the HPA-axis, indicates an important underlying role of cortisol in the etiology of these complex disorders. Therefore, we propose that a common underlying defect in these complex disorders is a disregulation of the HPA-axis, especially during stress. The clinical implication is that the regulation of the HPA-axis should be envisioned as a primary target of new drugs for the treatment of stress-related disorders. (C) 2002 Elsevier Science Ltd. All rights reserved.	Rijngeestgroep LUMC, Hosp Psychiat, Dept Psychiat, NL-2342 AJ Oesgstsgeest, Netherlands; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC USA; LUMC, Dept Med Pharmacol, Oesgstsgeest, Netherlands	DeRijk, RH (reprint author), Rijngeestgroep LUMC, Hosp Psychiat, Dept Psychiat, Endegeesterstr Weg 5, NL-2342 AJ Oesgstsgeest, Netherlands.						Almlof T, 1997, MOL CELL BIOL, V17, P934; ASHRAF J, 1993, MOL ENDOCRINOL, V7, P631, DOI 10.1210/me.7.5.631; Bamberger CM, 1997, MOL CELL ENDOCRINOL, V136, P23, DOI 10.1016/S0303-7207(97)00209-8; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; Bamberger CM, 1997, J STEROID BIOCHEM, V60, P43, DOI 10.1016/S0960-0760(96)00167-7; BAUMANN H, 1993, BIOCHEMISTRY-US, V32, P13463, DOI 10.1021/bi00212a011; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; Bjorntorp P, 1993, Obes Res, V1, P206; Bodwell JE, 1998, J STEROID BIOCHEM, V65, P91, DOI 10.1016/S0960-0760(97)00185-4; Breslin MB, 1998, J STEROID BIOCHEM, V67, P369, DOI 10.1016/S0960-0760(98)00138-1; BRESLIN MB, 2001, MOL ENDOCRINOL, V15, P1395; BRINK M, 1992, ENDOCRINOLOGY, V130, P3575, DOI 10.1210/en.130.6.3575; Brogan IJ, 1999, MOL CELL ENDOCRINOL, V157, P95, DOI 10.1016/S0303-7207(99)00156-2; Buemann B, 1997, OBES RES, V5, P186; CADEPOND F, 1992, EXP CELL RES, V201, P99, DOI 10.1016/0014-4827(92)90352-9; CADEPOND F, 1991, J BIOL CHEM, V266, P5834; CAIRNS W, 1991, J BIOL CHEM, V266, P11221; Catts VS, 2001, LEUKEMIA, V15, P929, DOI 10.1038/sj.leu.2402128; Checkley S, 1996, BRIT MED BULL, V52, P597; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Christodoulopoulos P, 2000, J ALLERGY CLIN IMMUN, V106, P479; CHROUSOS GP, 1983, J STEROID BIOCHEM, V19, P567, DOI 10.1016/0022-4731(83)90219-4; Chu JW, 2001, J CLIN ENDOCR METAB, V86, P3568, DOI 10.1210/jc.86.8.3568; COLE TJ, 1995, GENE DEV, V9, P1608, DOI 10.1101/gad.9.13.1608; CRAINS C, 1993, DNA CELL BIOL, V12, P695; Dahia PLM, 1997, J CLIN ENDOCR METAB, V82, P1088, DOI 10.1210/jc.82.4.1088; de Kloet ER, 1999, TRENDS NEUROSCI, V22, P422, DOI 10.1016/S0166-2236(99)01438-1; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; de Lange P, 1999, MOL CELL ENDOCRINOL, V153, P163, DOI 10.1016/S0303-7207(99)00072-6; de Lange P, 2001, CANCER RES, V61, P3937; deCastro M, 1996, MOL MED, V2, P597; DEKLOET ER, 1994, PSYCHONEUROENDOCRINO, V19, P121, DOI 10.1016/0306-4530(94)90002-7; De Kloet E. R., 1997, STRESS, V2, P13; deLange P, 1997, MOL ENDOCRINOL, V11, P1156, DOI 10.1210/me.11.8.1156; Derijk RH, 2001, J RHEUMATOL, V28, P2383; [Anonymous], 2001, PHYSICAL CONSEQUENCE; DESOUSA AR, 2000, J ALLERGY CLIN IMMUN, V105, P943; DETERAWADLEIGH SD, 1991, NUCLEIC ACIDS RES, V19, P1960, DOI 10.1093/nar/19.8.1960-a; Dobson MG, 2001, J CLIN ENDOCR METAB, V86, P2270, DOI 10.1210/jc.86.5.2270; ENCIO IJ, 1991, J BIOL CHEM, V266, P7182; Feng JO, 2000, AM J MED GENET, V96, P412, DOI 10.1002/1096-8628(20000612)96:3<412::AID-AJMG33>3.0.CO;2-C; Fryer CJ, 1998, NATURE, V393, P88; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7; GAITAN D, 1995, MOL ENDOCRINOL, V9, P1193, DOI 10.1210/me.9.9.1193; Giangrande PH, 1999, RECENT PROG HORM RES, V54, P291; GIGUERE V, 1986, CELL, V46, P645, DOI 10.1016/0092-8674(86)90339-9; GODOWSKI PJ, 1987, NATURE, V325, P365, DOI 10.1038/325365a0; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600; Hamilos DL, 2001, J ALLERGY CLIN IMMUN, V108, P59; Hauk PJ, 2000, J ALLERGY CLIN IMMUN, V105, P782, DOI 10.1067/mai.2000.105807; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; Hillmann AG, 2000, CANCER RES, V60, P2056; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; Holsboer F, 2000, NEUROPSYCHOPHARMACOL, V23, P477, DOI 10.1016/S0893-133X(00)00159-7; Honda M, 2000, GASTROENTEROLOGY, V118, P859, DOI 10.1016/S0016-5085(00)70172-7; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P917, DOI 10.1210/jc.83.3.917; Huizenga NATM, 1998, J CLIN ENDOCR METAB, V83, P144, DOI 10.1210/jc.83.1.144; Huizenga NATM, 2000, J CLIN ENDOCR METAB, V85, P2076, DOI 10.1210/jc.85.5.2076; HURLEY DM, 1991, J CLIN INVEST, V87, P680, DOI 10.1172/JCI115046; Jenkins BD, 2001, TRENDS ENDOCRIN MET, V12, P122, DOI 10.1016/S1043-2760(00)00357-X; JONAT C, 1990, CELL, V62, P1189, DOI 10.1016/0092-8674(90)90395-U; KAM JC, 1993, J IMMUNOL, V151, P3460; Karkera JD, 1997, BRIT J HAEMATOL, V99, P372, DOI 10.1046/j.1365-2141.1997.4123227.x; Karl M, 1996, P ASSOC AM PHYSICIAN, V108, P296; KARL M, 1993, J CLIN ENDOCR METAB, V76, P683, DOI 10.1210/jc.76.3.683; Karl M, 1996, J CLIN ENDOCR METAB, V81, P124, DOI 10.1210/jc.81.1.124; Karst H, 2000, NAT NEUROSCI, V3, P977; KING LB, 1995, IMMUNITY, V3, P647, DOI 10.1016/1074-7613(95)90135-3; Koper JW, 1997, HUM GENET, V99, P663, DOI 10.1007/s004390050425; KRETT NL, 1995, CANCER RES, V55, P2727; LAMBERTS SWJ, 1992, J CLIN ENDOCR METAB, V74, P313, DOI 10.1210/jc.74.2.313; Lamberts SWJ, 1996, STEROIDS, V61, P157, DOI 10.1016/0039-128X(96)00005-0; LANE SJ, 1994, AM J RESP CELL MOL, V11, P42; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Leung DYM, 2000, AM J RESP CRIT CARE, V162, P1; Lin RCY, 1999, BRIT MED J, V319, P1337; LIN RCY, 1999, HYPERTENSION, V34, P1192; Lind U, 1996, MOL ENDOCRINOL, V10, P1358, DOI 10.1210/me.10.11.1358; Lind U, 1999, J BIOL CHEM, V274, P18515, DOI 10.1074/jbc.274.26.18515; Lind U, 2000, J BIOL CHEM, V275, P19041, DOI 10.1074/jbc.M000228200; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MALCHOFF DM, 1993, J CLIN INVEST, V91, P1918, DOI 10.1172/JCI116410; MANN J, 2001, THAKORE J, V5, P87; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; McEwen BS, 1998, NEW ENGL J MED, V338, P171; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Meijer OC, 1998, ENDOCRINOLOGY, V139, P1789, DOI 10.1210/en.139.4.1789; MOALLI PA, 1993, CANCER RES, V53, P3877; Moutsatsou P, 2000, MOL PSYCHIATR, V5, P196, DOI 10.1038/sj.mp.4000646; Mu YM, 1998, CLIN ENDOCRINOL, V49, P301, DOI 10.1046/j.1365-2265.1998.00520.x; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NAKAI Y, 1991, J STEROID BIOCHEM, V40, P301, DOI 10.1016/0960-0760(91)90195-B; NOBUKUNI Y, 1995, BIOCHEMISTRY-US, V34, P8207, DOI 10.1021/bi00025a028; Oakley RH, 1996, J BIOL CHEM, V271, P9550; Oakley RH, 1999, STEROIDS, V64, P742, DOI 10.1016/S0039-128X(99)00059-8; Oakley RH, 1999, J BIOL CHEM, V274, P27857, DOI 10.1074/jbc.274.39.27857; Oakley RH, 1997, ENDOCRINOLOGY, V138, P5028, DOI 10.1210/endo.138.11.5501; Oitzl MS, 1997, EUR J NEUROSCI, V9, P2284, DOI 10.1111/j.1460-9568.1997.tb01646.x; Oitzl MS, 2001, P NATL ACAD SCI USA, V98, P12790, DOI 10.1073/pnas.231313998; Otto C, 1997, J BIOL CHEM, V272, P26665, DOI 10.1074/jbc.272.42.26665; PALMER LA, 1992, CANCER RES, V52, P6612; Panarelli M, 1998, J CLIN ENDOCR METAB, V83, P1846, DOI 10.1210/jc.83.6.1846; [Anonymous], 2001, MOL CELL ENDOCRINOL; PEPIN MC, 1992, NATURE, V355, P725, DOI 10.1038/355725a0; PFOHL B, 1991, J NERV MENT DIS, V179, P44, DOI 10.1097/00005053-199101000-00009; PICARD D, 1987, EMBO J, V6, P3333; POWERS JH, 1993, CANCER RES, V53, P4059; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Pujols L, 2001, AM J RESP CELL MOL, V24, P49; Ray DW, 1996, CANCER RES, V56, P3276; Ray DW, 1999, MOL ENDOCRINOL, V13, P1855, DOI 10.1210/me.13.11.1855; Reichardt HM, 1998, CELL, V93, P531, DOI 10.1016/S0092-8674(00)81183-6; Rivers C, 1999, J CLIN ENDOCR METAB, V84, P4283, DOI 10.1210/jc.84.11.4283; Robin-Jagerschmidt C, 2000, MOL ENDOCRINOL, V14, P1028, DOI 10.1210/me.14.7.1028; Rogatsky I, 1998, P NATL ACAD SCI USA, V95, P2050, DOI 10.1073/pnas.95.5.2050; Rogatsky I, 1998, J BIOL CHEM, V273, P14315, DOI 10.1074/jbc.273.23.14315; Rosmond P, 2000, METABOLISM, V49, P1197; Rosmond R, 2000, OBES RES, V8, P211, DOI 10.1038/oby.2000.24; Rosmond R, 2001, BRIT MED J, V322, P652, DOI 10.1136/bmj.322.7287.652; Rosmond R, 1998, J CLIN ENDOCR METAB, V83, P1853, DOI 10.1210/jc.83.6.1853; Ruiz M, 2001, CLIN ENDOCRINOL, V55, P363, DOI 10.1046/j.1365-2265.2001.01323.x; SAVORY JG, 2001, MOL CELL BIOL, V22, P781; Seckl JR, 2001, ENDOCRINOLOGY, V142, P1371, DOI 10.1210/endo.142.4.8114; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SOUFI M, 1995, EXP CLIN ENDOCR DIAB, V103, P175; SPAHN JD, 1995, AM J RESP CRIT CARE, V151, P1709; STRASSERWOZAK EMC, 1995, CANCER RES, V55, P348; Strickland I, 2001, J EXP MED, V193, P585, DOI 10.1084/jem.193.5.585; Takami S, 1999, AM J PHYSIOL-HEART C, V276, pH1379; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Turney MK, 2001, J MOL ENDOCRINOL, V26, P43, DOI 10.1677/jme.0.0260043; Ukkola O, 2001, ATHEROSCLEROSIS, V157, P221, DOI 10.1016/S0021-9150(00)00712-7; VELDHUIS JD, 1990, J CLIN ENDOCR METAB, V71, P452; VINGERHOEDS ACM, 1976, J CLIN ENDOCR METAB, V43, P1128; Vottero A, 1999, TRENDS ENDOCRIN MET, V10, P333, DOI 10.1016/S1043-2760(99)00179-4; WARRIAR N, 1994, J BIOL CHEM, V269, P29010; WATT GCM, 1992, J HYPERTENS, V10, P473, DOI 10.1097/00004872-199205000-00011; WEAVER JU, 1992, J MOL ENDOCRINOL, V9, P295; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Webster JC, 1997, J BIOL CHEM, V272, P9287; WEINBERGER C, 1985, NATURE, V318, P670, DOI 10.1038/318670a0; Whorwood CB, 2001, J CLIN ENDOCR METAB, V86, P2296, DOI 10.1210/jc.86.5.2296; Wickert L, 2000, J NEUROENDOCRINOL, V12, P867, DOI 10.1046/j.1365-2826.2000.00535.x; [Anonymous], 1997, IMMUNOL TODAY; Windle RJ, 1998, ENDOCRINOLOGY, V139, P4044, DOI 10.1210/en.139.10.4044; WRANGE O, 1989, J BIOL CHEM, V264, P5253; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Yudt MR, 2001, MOL ENDOCRINOL, V15, P1093, DOI 10.1210/me.15.7.1093	151	164	171	1	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0960-0760			J STEROID BIOCHEM	J. Steroid Biochem. Mol. Biol.	JUN	2002	81	2					103	122	PII S0960-0760(02)00062-6	10.1016/S0960-0760(02)00062-6		20	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	592MT	WOS:000177942000001	12137800	
J	O'Brien, C; Guest, PJ; Hill, SL; Stockley, RA				O'Brien, C; Guest, PJ; Hill, SL; Stockley, RA			Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care	THORAX			English	Article						chronic obstructive pulmonary disease; bronchiectasis; lung function tests; radiology	CHRONIC SPUTUM PRODUCTION; COMPUTED-TOMOGRAPHY; FUNCTION TESTS; LUNG; CHEST; EXACERBATIONS; MANAGEMENT; EMPHYSEMA; SMOKERS; COPD	Background-Chronic obstructive pulmonary disease (COPD) is common although often poorly characterised, particularly in primary care. However, application of guidelines to the management of such patients needs a clear understanding of the phenotype. In particular, the British guidelines for the management of COPD recommend that the diagnosis is based on appropriate symptoms and evidence of airflow obstruction as determined by a forced expiratory volume in one second (FEV1) of <80% of the predicted value and an FEV1/VC ratio of <70%. Methods-A study was undertaken of 110 patients aged 40-80 years who had presented to their general practitioner with an acute exacerbation of COPD. The episode was treated at home and, when patients had recovered to the stable state (two months later), they were characterised by full lung function tests and a high resolution computed tomographic (HRCT) scan of the chest. Results-There was a wide range of impairment of FEV1 which was in the normal range (greater than or equal to 80%) in 30%, mildly impaired (60-79%) in 18%, moderately impaired (40-59%) in 33%, and severely impaired (<40%) in 19% of patients. A reduced FEV1/VC ratio was present in all patients with an FEV1 of <80% predicted but also in 41% of those with an FEV1 of greater than or equal to 80% predicted. Only 5% of patients had a substantial bronchodilator response suggesting a diagnosis of asthma. Emphysema was present in 51% of patients and confined to the upper lobes in most (73% of these patients). HRCT evidence of bronchiectasis was noted in 29% of patients and was predominantly tubular; most (81%) were current or ex-smokers. A solitary pulmonary nodule was seen on 9% of scans and unsuspected lung malignancy was diagnosed in two patients. Conclusions-This study confirms that COPD in primary care is a heterogeneous condition. Some patients do not fulfil the proposed diagnostic criteria with FEV1 of greater than or equal to 80% predicted but they may nevertheless have airflow obstruction. Bronchiectasis is common in this group of patients, as is unsuspected malignancy. These findings should be considered when developing recommendations for the investigation and management of COPD in the community.	Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England; Queen Elizabeth Hosp, Dept Radiol, Birmingham B15 2TH, W Midlands, England	Stockley, RA (reprint author), Queen Elizabeth Hosp, Dept Med, Birmingham B15 2TH, W Midlands, England.						American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P14; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; Bergin C J, 1986, J Thorac Imaging, V1, P94, DOI 10.1097/00005382-198603000-00010; Britton PD, 1999, BREAST, V8, P1, DOI 10.1016/S0960-9776(99)90329-6; Cole PJ, 1995, RESP MED, P1286; [Anonymous], 1997, THORAX S5, V52, pS1; CURRIE DC, 1987, THORAX, V42, P278, DOI 10.1136/thx.42.4.278; Eller J, 1998, CHEST, V113, P1542, DOI 10.1378/chest.113.6.1542; GURNEY JW, 1992, RADIOLOGY, V183, P457; HANSELL DM, 1998, IMAGING OBSTRUCTIVE, P107; KESTEN S, 1993, CHEST, V104, P254, DOI 10.1378/chest.104.1.254; Kubo K, 1999, EUR RESPIR J, V13, P252, DOI 10.1034/j.1399-3003.1999.13b06.x; Miravitlles M, 1999, RESP MED, V93, P173, DOI 10.1016/S0954-6111(99)90004-5; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; NAIDICH DP, 1982, J COMPUT ASSIST TOMO, V6, P437, DOI 10.1097/00004728-198206000-00001; NISAR M, 1990, THORAX, V45, P190, DOI 10.1136/thx.45.3.190; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542; Office of Population Census and Surveys, 1995, MORB STAT GEN PRACT; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Smith IE, 1996, THORAX, V51, P914, DOI 10.1136/thx.51.9.914; SNIDER GL, 1989, AM REV RESPIR DIS, V140, pS3; SNIDER GL, 1995, CHRONIC OBSTRUCTIVE, P1; STERN EJ, 1994, AM J ROENTGENOL, V162, P791; STOCKLEY RA, 1991, ANN NY ACAD SCI, V624, P257, DOI 10.1111/j.1749-6632.1991.tb17024.x; Tantucci C, 1998, EUR RESPIR J, V12, P799, DOI 10.1183/09031936.98.12040799; TRAVER GA, 1979, AM REV RESPIR DIS, V119, P895; WOLKOVE N, 1989, CHEST, V96, P1247, DOI 10.1378/chest.96.6.1247; Yankelevitz DF, 1997, AM J ROENTGENOL, V168, P325	29	164	164	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	AUG	2000	55	8					635	642		10.1136/thorax.55.8.635		8	Respiratory System	Respiratory System	339TU	WOS:000088494600003	10899238	
J	Hart, PH; Gorman, S; Finlay-JonesO, JJ				Hart, Prue H.; Gorman, Shelley; Finlay-JonesO, John J.			Modulation of the immune system by UV radiation: more than just the effects of vitamin D?	NATURE REVIEWS IMMUNOLOGY			English	Review							REGULATORY-T-CELLS; ULTRAVIOLET-RADIATION; MULTIPLE-SCLEROSIS; UROCANIC ACID; INDUCED IMMUNOSUPPRESSION; HUMAN SKIN; ANTIMICROBIAL PEPTIDES; INDUCED SUPPRESSION; MAST-CELLS; INFECTIOUS-DISEASES	Humans obtain most of their vitamin D through the exposure of skin to sunlight. The immunoregulatory properties of vitamin D have been demonstrated in studies showing that vitamin D deficiency is associated with poor immune function and increased disease susceptibility. The benefits of moderate ultraviolet (UV) radiation exposure and the positive latitude gradients observed for some immune-mediated diseases may therefore reflect the activities of UV-induced vitamin D. Alternatively, other mediators that are induced by UV radiation may be more important for UV-mediated immunomodulation. Here, we compare and contrast the effects of UV radiation and vitamin D on immune function in immunopathological diseases, such as psoriasis, multiple sclerosis and asthma, and during infection.	[Hart, Prue H.; Gorman, Shelley] Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6872, Australia; [Finlay-JonesO, John J.] Edith Cowan Univ, Perth, WA, Australia	Hart, PH (reprint author), Univ Western Australia, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, POB 855, Perth, WA 6872, Australia.	prueh@ichr.uwa.edu.au	Finlay-Jones, John/C-2421-2013; Gorman, Shelley/E-1649-2013; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Gorman, Shelley/0000-0002-7111-6735	Australian National Health and Medical Research Council; Cancer Council Western Australia; Asthma Foundation of Western Australia; Raine Foundation; Brightspark Foundation	The authors would like to thank M. Norval for valuable analysis of this Review and D. Damian for assistance with TABLE 1. Our research has been supported by the Australian National Health and Medical Research Council, the Cancer Council Western Australia, the Asthma Foundation of Western Australia, the Raine Foundation and the Brightspark Foundation.	Adams JS, 2009, J IMMUNOL, V182, P4289, DOI 10.4049/jimmunol.0803736; Agar NS, 2004, P NATL ACAD SCI USA, V101, P4954, DOI 10.1073/pnas.0401141101; Albert E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013676; Baeke F, 2011, J IMMUNOL, V186, P132, DOI 10.4049/jimmunol.1000695; Baeke F, 2010, CURR OPIN PHARMACOL, V10, P482, DOI 10.1016/j.coph.2010.04.001; Barresi C, 2011, J INVEST DERMATOL, V131, P188, DOI 10.1038/jid.2010.231; Beard JA, 2011, J CLIN VIROL, V50, P194, DOI 10.1016/j.jcv.2010.12.006; Becklund BR, 2010, P NATL ACAD SCI USA, V107, P6418, DOI 10.1073/pnas.1001119107; Bhan I, 2011, J ALLERGY CLIN IMMUN, V127, P1302, DOI 10.1016/j.jaci.2010.12.1097; Biggs L, 2010, J EXP MED, V207, P455, DOI 10.1084/jem.20091725; Bikle D, 2009, J CLIN ENDOCR METAB, V94, P26, DOI 10.1210/jc.2008-1454; Bilu Donna, 2003, Br J Dermatol, V149 Suppl 66, P5; Bogh MKB, 2010, J INVEST DERMATOL, V130, P546, DOI 10.1038/jid.2009.323; Bouillon R, 2008, ENDOCR REV, V29, P726, DOI 10.1210/er.2008-0004; Bruce D, 2010, EXP BIOL MED, V235, P921, DOI 10.1258/ebm.2010.010061; Burton JM, 2010, NEUROLOGY, V74, P1852, DOI 10.1212/WNL.0b013e3181e1cec2; Camouse MM, 2009, EXP DERMATOL, V18, P522, DOI 10.1111/j.1600-0625.2008.00818.x; Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175; Cantorna MT, 2011, ANN NY ACAD SCI, V1217, P77, DOI 10.1111/j.1749-6632.2010.05823.x; Chacon-Salinas R, 2011, J IMMUNOL, V186, P25, DOI 10.4049/jimmunol.1001657; Chang JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012925; Dahl MV, 2010, PHOTODERMATOL PHOTO, V26, P303, DOI 10.1111/j.1600-0781.2010.00550.x; Damian DL, 2011, BRIT J DERMATOL, V164, P657, DOI 10.1111/j.1365-2133.2010.10161.x; Damian DL, 2010, EXP DERMATOL, V19, pE23, DOI 10.1111/j.1600-0625.2009.00955.x; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Edfeldt K, 2010, P NATL ACAD SCI USA, V107, P22593, DOI 10.1073/pnas.1011624108; Egan KM, 2009, ANN EPIDEMIOL, V19, P455, DOI 10.1016/j.annepidem.2009.01.005; Enioutina EY, 2009, J IMMUNOL, V182, P4296, DOI 10.4049/jimmunol.0804344; Enioutina EY, 2002, VACCINE, V20, P2116, DOI 10.1016/S0264-410X(02)00060-9; Field S, 2011, MOL ONCOL, V5, P197, DOI 10.1016/j.molonc.2011.01.007; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Garland CF, 2011, ANTICANCER RES, V31, P607; Ghoreishi M, 2009, J IMMUNOL, V182, P6071, DOI 10.4049/jimmunol.0804064; Gibbs NK, 2008, PHOTOCH PHOTOBIO SCI, V7, P655, DOI 10.1039/b717398a; Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043; GORMAN S, PEDIAT ALLE IN PRESS; Gorman S, 2010, J STEROID BIOCHEM, V121, P247, DOI 10.1016/j.jsbmb.2010.02.034; Gorman S, 2010, IMMUNOLOGY, V130, P181, DOI 10.1111/j.1365-2567.2009.03222.x; Gorman S, 2010, PHOTOCH PHOTOBIO SCI, V9, P571, DOI 10.1039/b9pp00136k; Hagenau T, 2009, OSTEOPOROSIS INT, V20, P133, DOI 10.1007/s00198-008-0626-y; Halliday GM, 2004, PHOTOCH PHOTOBIO SCI, V3, P736, DOI 10.1039/b313199h; Hanneman KK, 2006, ARCH DERMATOL, V142, P1332, DOI 10.1001/archderm.142.10.1332; Hart PH, 2002, METHODS, V28, P79, DOI 10.1016/S1046-2023(02)00201-3; Hart PH, 1998, J EXP MED, V187, P2045, DOI 10.1084/jem.187.12.2045; Hewison M, 2011, NAT REV ENDOCRINOL, V7, P336, DOI 10.1038/nrendo.2010.226; Hewison M, 2010, MOL CELL ENDOCRINOL, V321, P103, DOI 10.1016/j.mce.2010.02.013; Hollams EM, 2011, EUR RESPIR J, V38, P1320, DOI 10.1183/09031936.00029011; Holt PG, 2011, CHEST, V139, P1165, DOI 10.1378/chest.10-2397; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Howes RA, 2006, J DERMATOL SCI, V44, P113, DOI 10.1016/j.jdermsci.2006.07.005; Johnson-Huang LM, 2010, J INVEST DERMATOL, V130, P2654, DOI 10.1038/jid.2010.166; Kaneko K, 2008, J IMMUNOL, V181, P217; Kelly DA, 2000, J EXP MED, V191, P561, DOI 10.1084/jem.191.3.561; Khoo AL, 2011, CYTOKINE, V55, P294, DOI 10.1016/j.cyto.2011.04.016; Kreindler JL, 2010, J CLIN INVEST, V120, P3242, DOI 10.1172/JCI42388; Kriegel MA, 2011, SEMIN ARTHRITIS RHEU, V40, P512, DOI 10.1016/j.semarthrit.2010.07.009; KRIPKE ML, 1974, J NATL CANCER I, V53, P1333; Krstic G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018492; Kuchel JM, 2005, PHOTOCH PHOTOBIO SCI, V4, P577, DOI 10.1039/b504068j; Lagishetty V, 2010, ENDOCRINOLOGY, V151, P2423, DOI 10.1210/en.2010-0089; Lehmann B, 2003, ARCH DERMATOL RES, V295, P24, DOI 10.1007/s00403-003-0387-6; Lehrer RI, 2002, CURR OPIN HEMATOL, V9, P18, DOI 10.1097/00062752-200201000-00004; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518; Lucas RM, 2011, NEUROLOGY, V76, P540, DOI 10.1212/WNL.0b013e31820af93d; Majak P, 2011, J ALLERGY CLIN IMMUN, V127, P1294, DOI 10.1016/j.jaci.2010.12.016; Martin PE, 2011, J ALLERGY CLIN IMMUN, V127, P1473, DOI 10.1016/j.jaci.2011.02.041; Martineau AR, 2011, LANCET, V377, P242, DOI 10.1016/S0140-6736(10)61889-2; Mason RS, 2010, J STEROID BIOCHEM, V121, P164, DOI 10.1016/j.jsbmb.2010.03.082; MEHTA BK, 2010, J NEUROL SCI, V192, P5; Mowry EM, 2011, MULT SCLER J, V17, P666, DOI 10.1177/1352458510394398; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Munger KL, 2004, NEUROLOGY, V62, P60; Ng RLX, 2010, J IMMUNOL, V185, P7207, DOI 10.4049/jimmunol.1001693; Norval M, 2006, PROG BIOPHYS MOL BIO, V92, P108, DOI 10.1016/j.pbiomolbio.2006.02.009; Norval M, 2011, PHOTOCH PHOTOBIO SCI, V10, P199, DOI 10.1039/c0pp90044c; Norval M, 2008, PHOTOCHEM PHOTOBIOL, V84, P19, DOI 10.1111/j.1751-1097.2007.00239.x; Norval M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1495, DOI 10.1562/2006-07-28-IR-987; Norval M, 2010, PHOTOCH PHOTOBIO SCI, V9, P11, DOI 10.1039/b9pp00012g; Penna G, 2007, J IMMUNOL, V178, P145; Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318; Reeve VE, 2009, J INVEST DERMATOL, V129, P2702, DOI 10.1038/jid.2009.121; Rhodes LE, 2010, J INVEST DERMATOL, V130, P1411, DOI 10.1038/jid.2009.417; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Roux C, 2008, CURR MED RES OPIN, V24, P1363, DOI 10.1185/030079908X301857 ; Schwarz A, 2010, J INVEST DERMATOL, V130, P1914, DOI 10.1038/jid.2010.59; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Sleijffers A, 2003, PHOTOCHEM PHOTOBIOL, V77, P271, DOI 10.1562/0031-8655(2003)077<0271:ECUALC>2.0.CO;2; Sleijffers A, 2002, METHODS, V28, P111, DOI 10.1016/S1046-2023(02)00215-3; SMOLDERS J, 2009, PLOS ONE, V13, pE6635; Sreevidya CS, 2010, J INVEST DERMATOL, V130, P1428, DOI 10.1038/jid.2009.329; Staples J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1640; Stein P, 2011, J INVEST DERMATOL, V131, P211, DOI 10.1038/jid.2010.254; Taher YA, 2008, J IMMUNOL, V180, P5211; Ullrich SE, 2005, MUTAT RES-FUND MOL M, V571, P185, DOI 10.1016/j.mrfmmm.2004.06.059; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; van der Aar AMG, 2011, J ALLERGY CLIN IMMUN, V127, P1532, DOI 10.1016/j.jaci.2011.01.068; van der Mei IAF, 2011, NEUROL CLIN, V29, P233, DOI 10.1016/j.ncl.2010.12.007; Veldhoen M, 2010, CURR OPIN IMMUNOL, V22, P747, DOI 10.1016/j.coi.2010.09.001; Wallace AM, 2010, STEROIDS, V75, P477, DOI 10.1016/j.steroids.2010.02.012; Webb AR, 2011, PHOTOCHEM PHOTOBIOL, V87, P741, DOI 10.1111/j.1751-1097.2011.00898.x; Weiss ST, 2011, J ALLERGY CLIN IMMUN, V127, P1128, DOI 10.1016/j.jaci.2011.02.025; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Yamshchikov AV, 2009, ENDOCR PRACT, V15, P438, DOI 10.4158/EP09101.ORR; Yiasemides E, 2009, CARCINOGENESIS, V30, P101, DOI 10.1093/carcin/bgn248; Yu C, 2011, INT J BIOCHEM CELL B, V43, P41, DOI [10.1016/j.biocel.2010.10.011, 10.1016/j.bioce1.2010.10.011]; Yu SH, 2011, J IMMUNOL, V186, P1384, DOI 10.4049/jimmunol.1002545; Zosky GR, 2011, AM J RESP CRIT CARE, V183, P1336, DOI 10.1164/rccm.201010-1596OC	111	163	165	7	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1733	1474-1741		NAT REV IMMUNOL	Nat. Rev. Immunol.	SEP	2011	11	9					584	596		10.1038/nri3045		13	Immunology	Immunology	811XB	WOS:000294250400002	21852793	
J	Koplin, JJ; Osborne, NJ; Wake, M; Martin, PE; Gurrin, LC; Robinson, MN; Tey, D; Slaa, M; Thiele, L; Miles, L; Anderson, D; Tan, T; Dang, TD; Hill, DJ; Lowe, AJ; Matheson, MC; Ponsonby, AL; Tang, MLK; Dharmage, SC; Allen, KJ				Koplin, Jennifer J.; Osborne, Nicholas J.; Wake, Melissa; Martin, Pamela E.; Gurrin, Lyle C.; Robinson, Marnie N.; Tey, Dean; Slaa, Marjolein; Thiele, Leone; Miles, Lucy; Anderson, Deborah; Tan, Tina; Dang, Thanh D.; Hill, David J.; Lowe, Adrian J.; Matheson, Melanie C.; Ponsonby, Anne-Louise; Tang, Mimi L. K.; Dharmage, Shyamali C.; Allen, Katrina J.			Can early introduction of egg prevent egg allergy in infants? A population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Egg allergy; food allergy; solids; breast-feeding; infant diet; weaning	ATOPIC DISEASE; ORAL TOLERANCE; PEANUT ALLERGY; FOOD ALLERGY; BIRTH COHORT; CHILDREN; RISK; LIFE; SENSITIZATION; CONSUMPTION	Background: Infant feeding guidelines have long recommended delaying introduction of solids and allergenic foods to prevent allergy in high-risk infants, despite a paucity of evidence. Objective: We aimed to determine whether confirmed egg allergy in 12-month-old infants is associated with (1) duration of breast-feeding and (2) ages of introducing egg and solids. Methods: In a population-based cross-sectional study (HealthNuts) parents reported on infant feeding and potential confounding factors before skin prick testing for egg white. Egg-sensitized infants were then offered an egg oral food challenge. Multiple logistic regression was used to investigate associations between diet and egg allergy adjusted for possible confounding factors. Results: A total of 2589 infants (73% response) participated. Compared with introduction at 4 to 6 months, introducing egg into the diet later was associated with higher risks of egg allergy (adjusted odds ratios [ORs], 1.6 [95% CI, 1.0-2.6] and 3.4 [95% CI, 1.8-6.5] for introduction at 10-12 and after 12 months, respectively). These findings persisted even in children without risk factors (OR, 3.3 [95% CI, 1.1-9.9]; 10-12 months). At age 4 to 6 months, first exposure as cooked egg reduced the risk of egg allergy compared with first exposure as egg in baked goods (OR, 0.2 [95% CI, 0.06-0.71]). Duration of breast-feeding and age at introduction of solids were not associated with egg allergy. Conclusions: Introduction of cooked egg at 4 to 6 months of age might protect against egg allergy. Changes in infant feeding guidelines could have a significant effect on childhood egg allergy and possibly food allergy more generally. (J Allergy Clin Immunol 2010;126:807-13.)	[Allen, Katrina J.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Koplin, Jennifer J.; Osborne, Nicholas J.; Wake, Melissa; Martin, Pamela E.; Tan, Tina; Dang, Thanh D.; Ponsonby, Anne-Louise; Tang, Mimi L. K.; Allen, Katrina J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Osborne, Nicholas J.; Gurrin, Lyle C.; Lowe, Adrian J.; Matheson, Melanie C.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; [Robinson, Marnie N.; Tey, Dean; Tang, Mimi L. K.; Allen, Katrina J.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia	Allen, KJ (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Wake, Melissa/J-1396-2012; Osborne, Nicholas/D-2086-2011; Matheson, Melanie/O-4721-2015; Osborne, Nicholas/N-4915-2015	Wake, Melissa/0000-0001-7501-9257; Osborne, Nicholas/0000-0002-6700-2284; Matheson, Melanie/0000-0002-5822-3499; Osborne, Nicholas/0000-0002-6700-2284; Tan, Hern-Tze Tina/0000-0002-8289-7573; Lowe, Adrian/0000-0002-4691-8162; Dharmage, Shyamali/0000-0001-6063-1937; Allen, Katrina/0000-0002-1921-4493	Australian National Health & Medical Research Council; Ilhan Food Allergy Foundation; AnaphylaxiStop; National Health and Medical Research Council Award; Australian Egg Corporation Limited; Australian National Health and Medical Research Council; Clifford Craig Trust; Sypkes Trust	Supported by the Australian National Health & Medical Research Council, the Ilhan Food Allergy Foundation, and AnaphylaxiStop. K. J. A. is a Viertel Senior Medical Research Fellow, and L. C. G., M. W., M. C. M., A. J. L., A.-L. P., and S. C. D. hold National Health and Medical Research Council Awards. J. J. K., P. E. M., and T. D. are Australian Postgraduate Award scholars. T. T. is a recipient of a Malaysian Government Scholarship.; Disclosure of potential conflict of interest: N. J. Osborne and K. J. Allen have received research support from the Australian Egg Corporation Limited. M. Wake and L. C. Gurrin have received research support from the Australian National Health and Medical Research Council. M. L. K. Tang is on the Medical Advisory Board for Nestle. S. C. Dharmage has received research support from the Clifford Craig Trust and the Sypkes Trust. The rest of the authors have declared that they have no conflict of interest.	Baker SS, 2000, PEDIATRICS, V106, P346; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; CHALLACOMBE DN, 1983, ARCH DIS CHILD, V58, P326; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Grimshaw KEC, 2009, ALLERGY, V64, P1407, DOI 10.1111/j.1398-9995.2009.02172.x; Gupta R, 2007, THORAX, V62, P91, DOI 10.1136/thx.2004.038844; HARRIS LE, 1969, AM J DIS CHILD, V117, P483; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; JONES KM, 1964, GUT, V5, P248, DOI 10.1136/gut.5.3.248; Konstantinou GN, 2008, J ALLERGY CLIN IMMUN, V122, P414, DOI 10.1016/j.jaci.2008.05.032; Koplin J, 2008, J ALLERGY CLIN IMMUN, V121, P1455, DOI 10.1016/j.jaci.2008.03.017; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Marklund B, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-48; Nwaru BI, 2010, PEDIATRICS, V125, P50, DOI 10.1542/peds.2009-0813; OSBORNE NJ, 2010, CLIN EXP ALLERGY; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Poulos LM, 2007, J ALLERGY CLIN IMMUN, V120, P878, DOI 10.1016/j.jaci.2007.07.040; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; [Anonymous], 2008, VICT IMM STRAT 2009; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Venter C, 2008, ALLERGY, V63, P354, DOI 10.1111/j.1398-9995.2007.01570.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	29	163	169	3	28	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2010	126	4					807	813		10.1016/j.jaci.2010.07.028		7	Allergy; Immunology	Allergy; Immunology	658SP	WOS:000282510000019	20920771	
J	Bernstein, JA; Alexis, N; Bacchus, H; Bernstein, IL; Fritz, P; Horner, E; Li, N; Mason, S; Nel, A; Oullette, J; Reijula, K; Reponen, T; Seltzer, J; Smith, A; Tarlo, SM				Bernstein, Jonathan A.; Alexis, Neil; Bacchus, Hyacinth; Bernstein, I. Leonard; Fritz, Pat; Horner, Elliot; Li, Ning; Mason, Stephany; Nel, Andre; Oullette, John; Reijula, Kari; Reponen, Tina; Seltzer, James; Smith, Alisa; Tarlo, Susan M.			The health effects of nonindustrial indoor air pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						indoor air pollutants; ozone; particulate matter; nitrogen dioxide; carbon monoxide; sulfur dioxide; health effects; volatile organic compounds; tobacco smoke; passive smoke exposure; cotinine; fungal allergens	ENVIRONMENTAL TOBACCO-SMOKE; VOLATILE ORGANIC-COMPOUNDS; NITROGEN-DIOXIDE EXPOSURE; RESPIRATORY SYMPTOMS; STACHYBOTRYS-CHARTARUM; PARTICULATE MATTER; OZONE EXPOSURE; SENSORY IRRITATION; INHALED ALLERGEN; OXIDATIVE STRESS	Background: There is growing public awareness regarding the risk associated with poor indoor air quality in the home and workplace. Because Americans spend approximately 22 hours every day indoors, susceptible individuals are at much greater risk of adverse health effects from chronic low levels of exposure to indoor air pollutants over time. Along with particulate matter, gases such as ozone, nitrogen dioxide, carbon monoxide, and sulfur dioxide; microbial and chemical volatile organic compounds; passive smoke; and outdoor ambient air are the most common types of air pollutants encountered indoors. Objective: To provide the allergists with necessary information that will assist them in making useful recommendations to patients seeking advice regarding indoor environmental triggers beyond traditional perennial allergens. Methods: Review of the literature pertaining to indoor exposure and health effects of gaseous and particular matter. Results: Indoor pollutants act as respiratory irritants, toxicants, and adjuvants or carriers of allergens. Conclusion: The allergist should be prepared to evaluate patient exposure to allergic and nonallergic triggers and understand how outdoor air pollution is affecting indoor environments. This requires being familiar with methodologies for monitoring and interpreting indoor air quality and interpreting results in the context of the patients exposure history and advising patients about rational environmental control interventions.	[Bernstein, Jonathan A.; Bernstein, I. Leonard] Univ Cincinnati, Div Immunol, Dept Internal Med, Allergy Sect, Cincinnati, OH 45221 USA; [Alexis, Neil] Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC USA; [Fritz, Pat] Rensselaer Polytech Inst, Troy, NY USA; [Horner, Elliot; Mason, Stephany] Air Qual Sci Inc, Atlanta, GA USA; [Li, Ning; Nel, Andre] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA; [Oullette, John] Adult Allergy Clin, Madison, WI USA; [Reijula, Kari] Finnish Inst Occupat Hlth, Helsinki, Finland; [Reponen, Tina] Univ Cincinnati, Ctr Environm Hlth, Cincinnati, OH 45221 USA; [Seltzer, James] Sharp Mission Pk Med Grp, Vista, CA USA; [Smith, Alisa] US EPA, Washington, DC 20460 USA; [Tarlo, Susan M.] Toronto Western Hosp, Toronto, ON, Canada	Bernstein, JA (reprint author), 231 Albert Sabin Way ML 563, Cincinnati, OH 45267 USA.	Jonathan.Bernstein@uc.edu	Nel, Andre/J-2808-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Alexis NE, 2004, CLIN IMMUNOL, V111, P126, DOI 10.1016/j.clim.2003.12.002; *AM C GOV IND HYG, 2004, BIOAER ASS CONTR; BECKETT WS, 1995, ENVIRON HEALTH PERSP, V103, P372, DOI 10.2307/3432291; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; BERNSTEIN JA, 2004, J ALLERGY ASTHMA CLI, V114, P116; Bluyssen PM, 1996, INDOOR AIR, V6, P221, DOI 10.1111/j.1600-0668.1996.00002.x; Bobbitt RC, 2005, ANN ALLERG ASTHMA IM, V94, P39; Brasel TL, 2005, APPL ENVIRON MICROB, V71, P114, DOI 10.1128/AEM.71.1.114-122.2005; Brownson RC, 2002, ONCOGENE, V21, P7341, DOI 10.1038/sj.onc.1205809; Burge HA, 2001, ANN ALLERG ASTHMA IM, V87, P52; Burnett RT, 1997, EPIDEMIOLOGY, V8, P162, DOI 10.1097/00001648-199703000-00007; Bush RK, 2006, J ALLERGY CLIN IMMUN, V117, P326, DOI 10.1016/j.jaci.2005.12.001; CDC (Centers for Disease Control and Prevention), 2000, MMWR-MORBID MORTAL W, V49, P180; Cho SH, 2005, ATMOS ENVIRON, V39, P5454, DOI 10.1016/j.atmosenv.2005.05.042; Chriqui JF, 2002, TOB CONTROL, V11, P26, DOI 10.1136/tc.11.1.26; Cometto-Muniz JE, 2004, INDOOR AIR, V14, P108, DOI 10.1111/j.1600-0668.2004.00297.x; Cook DG, 1998, THORAX, V53, P884; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Donaldson K, 2002, J AEROSOL MED, V15, P213, DOI 10.1089/089426802320282338; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; FLANNIGAN B, 1995, FUNGI BACTERIA INDOO, P123; Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; HORSTMAN D, 1986, Toxicology and Industrial Health, V2, P289; Hubbard HF, 2005, INDOOR AIR, V15, P432, DOI 10.1111/j.1600-0668.2005.00388.x; IOM (Institute of Medicine), 2004, DAMP IND SPAC HLTH; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Jaakkola MS, 2002, SCAND J WORK ENV HEA, V28, P52; JAAKKOLA MS, 2002, SCAND J WORK ENV S2, V28, P71; Janson C, 2004, INT J TUBERC LUNG D, V8, P510; Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; Korpi A, 1998, APPL ENVIRON MICROB, V64, P2914; Larsen FO, 1998, INFLAMM RES, V47, pS5; Leaderer Brian P., 1999, Environmental Health Perspectives, V107, P223, DOI 10.2307/3434513; Leem JH, 2005, J ASTHMA, V42, P463, DOI 10.1080/02770900500200733; Leung TF, 2002, J ASTHMA, V39, P323, DOI 10.1081/JAS-120002289; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; McDonnell WF, 2004, ARCH ENVIRON HEALTH, V59, P76; Menzies D, 2003, LANCET, V362, P1785, DOI 10.1016/S0140-6736(03)14897-0; Moglia D, 2006, ENVIRON HEALTH PERSP, V114, P141, DOI 10.1289/ehp.7881; Molhave L, 2005, INDOOR AIR, V15, P383, DOI 10.1111/j.1600-0668.2005.00366.x; NEVALAINEN A, 1991, ENVIRON INT, V17, P299, DOI 10.1016/0160-4120(91)90015-I; Ogulei D, 2006, INDOOR AIR, V16, P204, DOI 10.1111/j.1600-0668.2006.00418.x; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Park JH, 2004, INDOOR AIR, V14, P425, DOI 10.1111/j.1600-0668.2004.00291.x; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; Portnoy JM, 2005, ANN ALLERG ASTHMA IM, V94, P313; Pouli AE, 2003, FREE RADICAL BIO MED, V34, P345, DOI 10.1016/S0891-5849(02)01289-3; Rao CY, 2000, MYCOPATHOLOGIA, V149, P27, DOI 10.1023/A:1007239017018; Rushton Lesley, 2004, Reviews on Environmental Health, V19, P291; Rylander R, 2005, TOXICOLOGY OF 1- 3-BETA-GLUCANS: GLUCANS AS A MARKER FOR FUNGAL EXPOSURE, P53, DOI 10.1201/9780203020814.ch3; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Simoni M, 2002, ARCH ENVIRON HEALTH, V57, P130; Smedje G., 1996, P INDOOR AIR 96, V1, P611; Spengler J, 2006, INDOOR AIR, V16, P2; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; Thorn A, 1998, SOC SCI MED, V47, P1307, DOI 10.1016/S0277-9536(98)00206-8; Triche EW, 2005, EPIDEMIOLOGY, V16, P377, DOI 10.1097/01.ede.0000158225.44414.85; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; TUNNICLIFFE WS, 2003, OCCUP ENVIRON MED, V60, pE1; van Strien RT, 2004, EPIDEMIOLOGY, V15, P471, DOI 10.1097/01.ede.0000129511.61698.d8; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Walinder R, 2005, ENVIRON HEALTH PERSP, V113, P1775, DOI 10.1289/ehp.8193; Walinder R, 1998, INT J TUBERC LUNG D, V2, P1037; Walinder R, 2001, ARCH ENVIRON HEALTH, V56, P30; Weaver LK, 2002, NEW ENGL J MED, V347, P1057, DOI 10.1056/NEJMoa013121; Weichenthal S., 2006, J EXPO SCI ENV EPID, V17, P288; Weisel CP, 2002, ENVIRON HEALTH PERSP, V110, P527; WILKIE DJ, 1995, CANCER NURS, V18, P7; Wolkoff P, 2006, INDOOR AIR, V16, P7, DOI 10.1111/j.1600-0668.2005.00393.x	76	163	168	18	70	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					585	591		10.1016/j.jaci.2007.10.045		7	Allergy; Immunology	Allergy; Immunology	273GR	WOS:000253918900005	18155285	
J	Clark, S; Bock, SA; Gaeta, TJ; Brenner, BE; Cydulka, RK; Camargo, CA				Clark, S; Bock, SA; Gaeta, TJ; Brenner, BE; Cydulka, RK; Camargo, CA			Multicenter study of emergency department visits for food allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; emergency department; epinephrine	ANAPHYLACTIC REACTIONS; EPIDEMIOLOGY; ROOM	Background: Relatively little is known about the characteristics of patients who visit the emergency department (ED) for an acute allergic reaction. Although anaphylaxis guidelines suggest treatment with epinephrine, teaching about self-injectable epinephrine, and referral to an allergist, current ED management remains uncertain. Objective: The objective of this study was to describe the management of food-related acute allergic reactions. Methods: The Multicenter Airway Research Collaboration performed a chart review study in 21 North American EDs. Investigators reviewed a random sample of 678 charts of patients who presented with food allergy (International Classification of Diseases-ninth revision codes 693.1, 995.0, 995.3, and 995.60-995.69). Results: Patients had an average age of 29 years; the cohort was 57% female and 40% white. A variety of foods provoked the allergic reaction, including nuts (21%), crustaceans (19%), fruit (12%), and fish (10%). Although exposure to these foods can be life threatening, only 18% of patients came to the ED by ambulance. In the ED, 72% of patients received antihistamines, 48% received systemic corticosteroids, and 16% received epinephrine; 33% received respiratory treatments such as inhaled albuterol. Among patients with severe reactions (55% of total), 24% received epinephrine. Overall, 97% of patients were discharged to home. At ED discharge, 16% of patients were prescribed self-injectable epinephrine, and 12% were referred to an allergist. Conclusions: Although guidelines suggest specific approaches for the management of acute allergic reactions, ED concordance for food allergy appears low. These findings support a new collaboration between professional organizations in allergy and emergency medicine and the development of educational programs and materials for ED patients and staff.	Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Natl Jewish Med & Res Ctr, Denver, CO USA; New York Methodist Hosp, Dept Emergency Med, Brooklyn, NY USA; Univ Arkansas Med Sci, Dept Emergency Med, Little Rock, AR 72204 USA; Metrohlth Med Ctr, Dept Emergency Med, Cleveland, OH USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab,Dept Med, Boston, MA USA	Clark, S (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 55 Fruit St,Clin Bldg 397, Boston, MA 02114 USA.				NIEHS NIH HHS [T32 ES07069]		Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; Burks AW, 1999, CLIN REV ALLERG IMMU, V17, P339, DOI 10.1007/BF02737615; GAETA TJ, 2001, ACAD EMERG MED, V8, P449; Hosmer DW, 1989, APPL LOGISTIC REGRES; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; KRAUSE RS, 1999, ANAPHYLAXIS; Matasar MJ, 2003, CURR ALLERGY ASTHM R, V3, P30, DOI 10.1007/s11882-003-0007-8; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SCHWARTZ HJ, 1995, ALLERGY PROC, V16, P247, DOI 10.2500/108854195778702639; Shimamoto SR, 2002, CURR OPIN ALLERGY CL, V2, P211, DOI 10.1097/00130832-200206000-00010; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; *STAT, 1985, STAT REF MAN; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859; Yocum MW, 1999, J ALLERGY CLIN IMMUN, V104, P452, DOI 10.1016/S0091-6749(99)70392-1; 2000, FOOD ALLERGY ANAPHYL; 2000, SOURCEBOOK ZIP CODE; 1996, FEDERAL CENSUS DATA	18	163	164	0	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					347	352		10.1016/j.jaci.2003.10.053		6	Allergy; Immunology	Allergy; Immunology	773EX	WOS:000188885700026	14767453	
J	Suissa, S; Ernst, P				Suissa, S; Ernst, P			Inhaled corticosteroids: Impact on asthma morbidity and mortality	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; case-control studies; cohort studies; ecologic studies; epidemiologic studies; hospitalization; inhaled glucocorticoids; mortality; registries	NEW-ZEALAND; PRESCRIBED FENOTEROL; HOSPITAL ADMISSION; CHILDHOOD ASTHMA; BETA-AGONISTS; UNITED-STATES; YOUNG-ADULTS; RISK-FACTORS; MILD ASTHMA; DEATH	Inhaled corticosteroids are now recommended as first-line therapy for asthma, Although these drugs clearly improve the symptoms of the disease and the associated physiologic abnormalities, epidemiologic studies provide important information on their effectiveness in preventing asthma morbidity and mortality. We review the evidence regarding the role of inhaled corticosteroids in the prevention of asthma fatality and hospitalization. In the process, we discuss the methodologic complexities of the nonexperimental studies and the implications of the methodologic issues on the evaluation of the impart of these drugs. Eight of the cohort and ecologic studies conducted to date strongly suggest that inhaled corticosteroids. when taken regularly, decrease the number of hospitalizations for asthma by up to 80%. For asthma death, the results of 11 investigations appear less consistent, especially those of several cohort and case-control studies whose principal objective was to examine not the benefit of inhaled corticosteroids but the adverse effects of other drug classes, Much of the inconsistency in the results, however, can be explained by weaknesses in study design and analysis-in particular, the failure to consider exposure in terms of regular use of inhaled corticosteroids. When the most recent study involving the use of the Saskatchewan databases is considered, it is evident that regular treatment with conventional or low-dose inhaled corticosteroids results in a significant reduction in fatalities due to asthma, In all, the evidence to date strongly indicates that regular use of inhaled corticosteroids, even at low doses, would prevent the major portion of asthma hospitalizations and deaths.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, Montreal, PQ H3A 1A1, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Ctr Hlth, Div Resp Med, Montreal, PQ, Canada	Suissa, S (reprint author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Div Clin Epidemiol, 687 Pine Ave W,Ross 4-29, Montreal, PQ H3A 1A1, Canada.						ADELROTH E, 1988, LANCET, V1, P476; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Barnes PJ, 1998, J ALLERGY CLIN IMMUN, V101, pS427, DOI 10.1016/S0091-6749(98)70154-X; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blais L, 1998, THORAX, V53, P1025; Blais L, 1998, AM J RESP CRIT CARE, V158, P126; Boulet LP, 1999, CAN MED ASSOC J, V161, pS1; Bousquet J, 2000, CLIN EXP ALLERGY, V30, P2; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Campbell MJ, 1997, BRIT MED J, V314, P1439; Centers for Disease Control and Prevention (CDC), 1996, JAMA-J AM MED ASSOC, V275, P1535; Cochrane GM, 1996, DRUGS, V52, P12, DOI 10.2165/00003495-199600526-00004; CRANE J, 1989, LANCET, V1, P917; CRANE J, 1992, INT J EPIDEMIOL, V21, P737, DOI 10.1093/ije/21.4.737; DEVOY MAB, 1995, CHEST, V108, P1768, DOI 10.1378/chest.108.6.1768-a; Donahue JG, 1997, JAMA-J AM MED ASSOC, V277, P887, DOI 10.1001/jama.277.11.887; ERNST P, 1992, EUR RESPIR J, V5, P773; ERNST P, 1992, JAMA-J AM MED ASSOC, V268, P3462, DOI 10.1001/jama.268.24.3462; GARRETT J, 1995, THORAX, V50, P303, DOI 10.1136/thx.50.3.303; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERSTMAN BB, 1993, J ALLERGY CLIN IMMUN, V91, P838, DOI 10.1016/0091-6749(93)90340-L; GODFREY S, 1977, BRIT J CLIN PHARMACO, V4, pS273; Goldman M, 2000, J ALLERGY CLIN IMMUN, V105, P71, DOI 10.1016/S0091-6749(00)90180-5; GRAINGER J, 1991, THORAX, V46, P105, DOI 10.1136/thx.46.2.105; GREENLAND S, 1994, AM J EPIDEMIOL, V139, P747; Haahtela T, 1998, THORAX, V53, P1005; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HARGREAVE FE, 1990, J ALLERGY CLIN IMMUN, V85, P1098, DOI 10.1016/0091-6749(90)90056-A; Hessel PA, 1999, ANN ALLERG ASTHMA IM, V83, P362, DOI 10.1016/S1081-1206(10)62832-3; HORWITZ RI, 1990, AM J MED, V89, P630, DOI 10.1016/0002-9343(90)90182-D; HORWOOD LJ, 1991, NEW ZEAL MED J, V104, P277; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; JANSONBJERKLIE S, 1992, HEART LUNG, V21, P265; Konig P, 1996, J ALLERGY CLIN IMMUN, V98, P1103, DOI 10.1016/S0091-6749(96)80198-9; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; LI D, 1995, AM J RESP CRIT CARE, V151, P647; MAHR TA, 1993, ANN ALLERGY, V71, P115; MIETTINEN OS, 1989, J CLIN EPIDEMIOL, V42, P325, DOI 10.1016/0895-4356(89)90037-1; MITCHELL EA, 1994, THORAX, V49, P33, DOI 10.1136/thx.49.1.33; MORGENSTERN H, 1982, AM J PUBLIC HEALTH, V72, P1336, DOI 10.2105/AJPH.72.12.1336; National Asthma and Prevention Program, 1997, NIH PUBL, V97-4051; *NATL HEART LONG B, 1991, NAT ASTHM ED PROGR G; NINAN TK, 1992, BRIT MED J, V304, P873; PEARCE N, 1995, LANCET, V345, P41, DOI 10.1016/S0140-6736(95)91159-6; PEARCE N, 1990, THORAX, V45, P170, DOI 10.1136/thx.45.3.170; REA HH, 1986, THORAX, V41, P833, DOI 10.1136/thx.41.11.833; Sears M R, 1991, Bull Int Union Tuberc Lung Dis, V66, P79; SEARS MR, 2001, EVIDENCE BASED ASTHM, P112; Sears MR, 1996, CAN RESP J, V3, P261; SENTHILSELVAN A, 1995, J CLIN EPIDEMIOL, V48, P1277, DOI 10.1016/0895-4356(95)00019-Z; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; SILVERSTEIN MD, 1994, NEW ENGL J MED, V331, P1537, DOI 10.1056/NEJM199412083312301; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STRACHAN DP, 1992, BRIT MED J, V304, P819; STROM BL, 1984, AM J MED, V77, P703, DOI 10.1016/0002-9343(84)90369-3; Suissa S, 1997, J CLIN EPIDEMIOL, V50, P1079, DOI 10.1016/S0895-4356(97)00158-3; SUISSA S, 1994, AM J RESP CRIT CARE, V149, P604; Suissa S, 2000, NEW ENGL J MED, V343, P332, DOI 10.1056/NEJM200008033430504; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; Tasche MJA, 2000, THORAX, V55, P913, DOI 10.1136/thorax.55.11.913; Tough SC, 1996, J ASTHMA, V33, P179, DOI 10.3109/02770909609054550; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Wennergren G, 1996, J ALLERGY CLIN IMMUN, V97, P742, DOI 10.1016/S0091-6749(96)80150-3; WILKINS K, 1993, CAN MED ASSOC J, V148, P185	71	163	172	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					937	944		10.1067/mai.2001.115653		8	Allergy; Immunology	Allergy; Immunology	445JR	WOS:000169454800001	11398069	
J	Flaherman, V; Rutherford, GW				Flaherman, V; Rutherford, GW			A meta-analysis of the effect of high weight on asthma	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							BODY-MASS INDEX; UNITED-STATES; BIRTH-WEIGHT; FETAL-GROWTH; RISK-FACTORS; NUTRITION EXAMINATION; CHILDHOOD ASTHMA; NATIONAL-HEALTH; LUNG-FUNCTION; YOUNG-ADULTS	Background: Prevalence rates for both overweight and asthma have been increasing among children in developed countries over the past two decades. Some recent studies have postulated a causal relation between these but have lacked power to form a definitive conclusion. Aim: To estimate the effect of high body weight in childhood on the future risk of asthma. Methods: Medline search ( 1966 to October 2004), supplemented by manual search of reference lists and grey literature. Cohort studies that examined high body weight at birth or during childhood and future outcome of asthma were included. Data from each study were extracted on exposure status, clinical outcome, and study characteristics. Results: A total of 402 studies were initially identified, of which 12 met the inclusion criteria. The combined results from four studies that examined the effect of high body weight during middle childhood on the outcome of subsequent asthma showed a 50% increase in relative risk (RR 1.5, 95% CI 1.2 to 1.8). The combined results from nine studies that examined the effect of high birth weight on subsequent asthma had a pooled RR of 1.2 ( 95% CI 1.1 to 1.3). There was consistency among the results in sensitivity analyses examining studies containing only estimates of odds ratios, studies containing only the outcome of physician diagnosis of asthma, and studies including all definitions of high body weight. Conclusions: Children with high body weight, either at birth or later in childhood, are at increased risk for future asthma. Potential biological mechanisms include diet, gastro-oesophageal reflux, mechanical effects of obesity, atopy, and hormonal influences. Further research might elucidate the causal pathway, which could improve our understanding of the pathophysiology of asthma and perhaps lead to knowledge of potential preventive interventions.	Univ Calif San Francisco, Dept Family & Community Med, Sch Med, San Francisco, CA 94143 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Flaherman, V (reprint author), Univ Calif San Francisco, Dept Family & Community Med, Sch Med, 3333 Calif St,Box 0503, San Francisco, CA 94143 USA.	FlahermanV@peds.ucsf.edu					Arif AA, 2003, EUR RESPIR J, V21, P827, DOI 10.1183/09031936.03.00054103; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bolte G, 2004, CLIN EXP ALLERGY, V34, P381, DOI 10.1111/j.1365-2222.2004.01890.x; Brenner JS, 2001, J ASTHMA, V38, P509, DOI 10.1081/JAS-100105872; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Chinn S, 2003, J ASTHMA, V40, P1, DOI 10.1081/JAS-120017202; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; Dietz WH, 2004, NEW ENGL J MED, V350, P855, DOI 10.1056/NEJMp048008; Egger M, 1997, BRIT MED J, V315, P629; Epstein LH, 2000, OBES RES, V8, P575, DOI 10.1038/oby.2000.74; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Katz KA, 2003, CLIN EXP ALLERGY, V33, P737, DOI 10.1046/j.1365-2222.2003.01670.x; Laerum BN, 2004, RESP MED, V98, P611, DOI 10.1016/j.rmed.2004.01.003; Lau J, 1997, ANN INTERN MED, V127, P820; LAU J, 1992, NEW ENGL J MED, V327, P248, DOI 10.1056/NEJM199207233270406; Leadbitter P, 1999, THORAX, V54, P905; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.2012.40; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V105, pS503, DOI 10.1016/S0091-6749(00)90051-4; Rasanen M, 2000, THORAX, V55, P25, DOI 10.1136/thorax.55.1.25; Redd SC, 2002, ENVIRON HEALTH PERSP, V110, P557; Rothman KJ, 2002, MODERN EPIDEMIOLOGY; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SEIDELL JC, 1986, AM J PUBLIC HEALTH, V76, P264, DOI 10.2105/AJPH.76.3.264; Shaheen SO, 1999, THORAX, V54, P396; Sin DD, 2004, ARCH PEDIAT ADOL MED, V158, P60, DOI 10.1001/archpedi.158.1.60; Theodoropoulos Demetrios S, 2002, Am J Respir Med, V1, P133; Thomas EJ, 2003, CLIN IMAG, V27, P333, DOI 10.1016/S0899-7071(02)00555-7; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; WELLS G, NEWCASLTE OTTAWA SCA; Wood RA, 2002, JAMA-J AM MED ASSOC, V288, P745, DOI 10.1001/jama.288.6.745; Woods RK, 2003, AM J CLIN NUTR, V78, P414; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166; Young SYN, 2001, ARCH INTERN MED, V161, P1605, DOI 10.1001/archinte.161.13.1605; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240	48	162	171	5	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	APR	2006	91	4					334	339		10.1136/adc.2005.080390		6	Pediatrics	Pediatrics	023UO	WOS:000236151900015	16428358	
J	Marsland, BJ; Soos, TJ; Spath, G; Littman, DR; Kopf, M				Marsland, BJ; Soos, TJ; Spath, G; Littman, DR; Kopf, M			Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						PKC-theta; asthma; Leishmania; nippostrongylus; Th2 cell	NF-KAPPA-B; ALLERGIC AIRWAY INFLAMMATION; PKC-THETA; IMMUNOLOGICAL SYNAPSE; INTERFERON-GAMMA; CUTANEOUS LEISHMANIASIS; T(H)2 DIFFERENTIATION; ACTIVATION; INTERLEUKIN-4; EXPRESSION	The serine/threonine-specific protein kinase C (PKC)-theta is predominantly expressed in T cells and localizes to the center of the immunological synapse upon T cell receptor (TCR) and CD28 signaling. T cells deficient in PKC-theta exhibit reduced interleukin (IL)-2 production and proliferative responses in vitro, however, its significance in vivo remains unclear. We found that pkc-theta(-/-) mice were protected from pulmonary allergic hypersensitivity responses such as air-way hyperresponsiveness, eosinophilia, and immunoglobulin E production to inhaled allergen. Furthermore, T helper (Th)2 cell immune responses against Nippostrongylus brasiliensis were severely impaired in pkc-theta(-/-) mice. In striking contrast, pkc-theta(-/-) mice on both the C57BL/6 background and the normally susceptible BALB/c background mounted protective Th1 immune responses and were resistant against infection with Leishmania major. Using in vitro TCR transgenic T cell-dendritic cell coculture systems and antigen concentration-dependent Th polarization, PKC-theta-deficient T cells were found to differentiate into Th1 cells after activation with high concentrations of specific peptide, but to have compromised Th2 development at low antigen concentration. The addition of IL-2 partially reconstituted Th2 development in pkc-theta(-/-) T cells, consistent with an important role for this cytokine in Th2 polarization. Taken together, our results reveal a central role for PKC-theta signaling during Th2 responses.	Swiss Fed Inst Technol, CH-8952 Zurich, Switzerland; NYU, Sch Med, Howard Hughes Med Inst, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA; NYU, Sch Med, Dept Med & Mol Parasitol, New York, NY 10016 USA	Kopf, M (reprint author), Swiss Fed Inst Technol, Wagistr 27, CH-8952 Zurich, Switzerland.	Manfred.Kopf@ethz.ch	Spaeth, Gerald/B-1393-2014		NIAID NIH HHS [T32-AI0732, Z01 AI000732]		Altman A, 2000, IMMUNOL TODAY, V21, P567, DOI 10.1016/S0167-5699(00)01749-7; Artis D, 2002, J IMMUNOL, V169, P4481; Baier G, 2003, IMMUNOL REV, V192, P64, DOI 10.1034/j.1600-065X.2003.00018.x; BAIER G, 1993, J BIOL CHEM, V268, P4997; Bauer B, 2001, J BIOL CHEM, V276, P31627, DOI 10.1074/jbc.M103098200; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; Bi K, 2001, NAT IMMUNOL, V2, P556, DOI 10.1038/88765; Bromley SK, 2001, ANNU REV IMMUNOL, V19, P375, DOI 10.1146/annurev.immunol.19.1.375; Cote-Sierra J, 2004, P NATL ACAD SCI USA, V101, P3880, DOI 10.1073/pnas.0400339101; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; DENT LA, 1990, J EXP MED, V172, P1425, DOI 10.1084/jem.172.5.1425; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Grakoui A, 1999, SCIENCE, V285, P221, DOI 10.1126/science.285.5425.221; HEINZEL FP, 1989, J EXP MED, V169, P59, DOI 10.1084/jem.169.1.59; HEINZEL FP, 1993, J IMMUNOL, V150, P3924; Huang JY, 2002, P NATL ACAD SCI USA, V99, P9369, DOI 10.1073/pnas.142298399; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Korn T, 2003, J NEUROIMMUNOL, V139, P17, DOI 10.1016/S0165-5728(03)00128-0; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Liu YH, 2000, J BIOL CHEM, V275, P3603, DOI 10.1074/jbc.275.5.3603; Monks CRF, 1998, NATURE, V395, P82; Pfeifhofer C, 2003, J EXP MED, V197, P1525, DOI 10.1084/jem.20020234; POWERS GD, 1988, J IMMUNOL, V140, P3352; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.immunol.13.1.151; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; Ruedl C, 2000, EUR J IMMUNOL, V30, P2056, DOI 10.1002/1521-4141(200007)30:7<2056::AID-IMMU2056>3.0.CO;2-S; SADICK MD, 1986, J IMMUNOL, V136, P655; SCOTT P, 1988, J EXP MED, V168, P1675, DOI 10.1084/jem.168.5.1675; Sica A, 1997, J BIOL CHEM, V272, P30412, DOI 10.1074/jbc.272.48.30412; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TITUS RG, 1985, PARASITE IMMUNOL, V7, P545, DOI 10.1111/j.1365-3024.1985.tb00098.x; Villalba M, 2000, IMMUNITY, V12, P151, DOI 10.1016/S1074-7613(00)80168-5; Walter DM, 2001, J IMMUNOL, V167, P4668; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739; YAO L, 1994, P NATL ACAD SCI USA, V91, P9175, DOI 10.1073/pnas.91.19.9175; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1; Yoshimoto T, 1997, EUR J IMMUNOL, V27, P3461, DOI 10.1002/eji.1830271247	40	162	171	0	0	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	JUL 19	2004	200	2					181	189		10.1084/jem.20032229		9	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	841JL	WOS:000222926000006	15263025	
J	Dabbagh, K; Dahl, ME; Stepick-Biek, P; Lewis, DB				Dabbagh, K; Dahl, ME; Stepick-Biek, P; Lewis, DB			Toll-like receptor 4 is required for optimal development of Th2 immune responses: Role of dendritic cells	JOURNAL OF IMMUNOLOGY			English	Article							LEISHMANIA-MAJOR INFECTION; HOUSE-DUST ENDOTOXIN; IFN-GAMMA PRODUCTION; T-CELLS; ADAPTIVE IMMUNITY; SIGNALING PATHWAY; ALLERGIC-ASTHMA; CUTTING EDGE; MAST-CELLS; B7-2 CD86	LPS potently induces dendritic cell maturation and the production of proinflammatory cytokines, such as IL-12, by activation of Toll-like receptor 4 (TLR4). Since IL-12 is important for the generation and maintenance of Th1 responses and may also inhibit Th2 cell generation from naive CD4 T cell precursors, it has been inferred that TLR4 signaling would have similar effects via the induction of IL-12 secretion. Surprisingly, we found that TLR4-defective mice subjected to sensitization and pulmonary challenge with a protein allergen had reductions in airway inflammation with eosinophils, allergen-specific IgE levels, and Th2 cytokine production, compared with wild-type mice. These reduced responses were attributable, at least in part, to decreased dendritic cell function: Dendritic cells from TLR4-defective mice expressed lower levels of CD86, a costimulatory molecule important for The responses. They also induced less Th2 cytokine production by antigenically naive CD4 T cells in vitro and mediated diminished CD4 T cell Ag-specific pulmonary inflammation in vivo. These results indicate that TLR4 is required for optimal Th2 responses to Ags from nonpathogenic sources and suggest a role for TLR4 ligands, such as LPS derived from commensal bacteria or endogenously derived ligands, in maturation of the innate immune system before pathogen exposure.	Stanford Univ, Sch Med, Dept Pediat & Immunol Program, Palo Alto, CA 94304 USA	Lewis, DB (reprint author), Stanford Univ, Sch Med, Dept Pediat & Immunol Program, Ctr Clin Sci Res Bldg Rm 2115b 269 Campus Dr, Palo Alto, CA 94304 USA.				NIAID NIH HHS [R01-AI44699]		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akashi S, 2000, J IMMUNOL, V164, P3471; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Arbour NC, 2000, NAT GENET, V25, P187; Asnagli H, 2001, CURR OPIN IMMUNOL, V13, P242, DOI 10.1016/S0952-7915(00)00210-7; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Breloer M, 2001, EUR J IMMUNOL, V31, P2051, DOI 10.1002/1521-4141(200107)31:7<2051::AID-IMMU2051>3.0.CO;2-H; Busse WW, 2001, NEW ENGL J MED, V344, P350; Dabbagh K, 2000, J IMMUNOL, V165, P3418; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HEINZEL FP, 1994, INFECT IMMUN, V62, P4244; Hubacek JA, 1999, CIRCULATION, V99, P3218; Jiang GZ, 1998, FEMS IMMUNOL MED MIC, V21, P303, DOI 10.1016/S0928-8244(98)00085-6; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KAYE J, 1989, NATURE, V341, P746, DOI 10.1038/341746a0; Keane-Myers A, 1998, J IMMUNOL, V161, P919; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; Kitchens RL, 2001, J CLIN INVEST, V108, P485, DOI 10.1172/JCI13139; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; LASKAY T, 1995, EUR J IMMUNOL, V25, P2220, DOI 10.1002/eji.1830250816; Liu YJ, 2001, CELL, V106, P259, DOI 10.1016/S0092-8674(01)00456-1; Matsuguchi T, 2000, BLOOD, V95, P1378; Medzhitov R, 1997, NATURE, V388, P394; MELLMAN L, 2001, CELL, V106, P255; Morel PA, 1998, CRIT REV IMMUNOL, V18, P275; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Muzio M, 2000, BIOCHEM SOC T, V28, P563; Ohashi K, 2000, J IMMUNOL, V164, P558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Park AY, 2000, J IMMUNOL, V165, P896; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ranger AM, 1996, INT IMMUNOL, V8, P1549, DOI 10.1093/intimm/8.10.1549; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Rempel JD, 2000, EUR J IMMUNOL, V30, P347, DOI 10.1002/1521-4141(200002)30:2<347::AID-IMMU347>3.0.CO;2-H; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Smiley ST, 2001, J IMMUNOL, V167, P2887; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; Stassen M, 2001, J IMMUNOL, V166, P4391; Stobie L, 2000, P NATL ACAD SCI USA, V97, P8427, DOI 10.1073/pnas.160197797; Strohmeier GR, 2001, J IMMUNOL, V166, P2063; Supajatura V, 2001, J IMMUNOL, V167, P2250; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; VANNIER E, 1991, J CLIN INVEST, V87, P1936, DOI 10.1172/JCI115219; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Wang SH, 2001, J IMMUNOL, V166, P2741; Weinmann AS, 2001, NAT IMMUNOL, V2, P51, DOI 10.1038/83168; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Yap G, 2000, J IMMUNOL, V165, P628; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837; Zhang Y, 1996, J EXP MED, V184, P1507, DOI 10.1084/jem.184.4.1507; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661	63	162	175	1	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	MAY 1	2002	168	9					4524	4530				7	Immunology	Immunology	546FP	WOS:000175263000036	11970998	
J	Durham, SR; Emminger, W; Kapp, A; de Monchy, JGR; Rak, S; Scadding, GK; Wurtzen, PA; Andersen, JS; Tholstrup, B; Riis, B; Dahl, R				Durham, Stephen R.; Emminger, Waltraud; Kapp, Alexander; de Monchy, Jan G. R.; Rak, Sabina; Scadding, Glenis K.; Wurtzen, Peter A.; Andersen, Jens S.; Tholstrup, Bente; Riis, Bente; Dahl, Ronald			SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy immunotherapy tablet; disease modification; grass pollen; immunotherapy; sublingual; sustained efficacy; placebo-controlled; Phleum pratense; rhinoconjunctivitis; rhinoconjunctivitis quality of life	ALLERGIC RHINITIS; FOLLOW-UP; RHINOCONJUNCTIVITIS; EFFICACY; TABLET; CHILDREN; ASTHMA; SAFETY; PREVALENCE; MECHANISMS	Background: The main aim of specific immunotherapy is sustained effect due to changes in the immune system that can be demonstrated only in long-term trials. Objective: To investigate sustained efficacy and disease modification in a 5-year double-blind, placebo-controlled trial, including 2 years of blinded follow-up after completion of a 3-year period of treatment, with the SQ-standardized grass allergy immunotherapy tablet, Grazax (Phleum pratense 75,000 SQ-T/2,800 BAU,* ALK, Denmark) or placebo. Methods: A randomized, double-blind, placebo-controlled, multinational, phase III trial included adults with a history of moderate-to-severe grass pollen-induced allergic rhinoconjunctivitis, with or without asthma, inadequately controlled by symptomatic medications. Two hundred thirty-eight participants completed the trial. End points included rhinoconjunctivitis symptom and medication scores, combined scores, asthma symptom and medication scores, quality of life, days with severe symptoms, immunologic end points, and safety parameters. Results: The mean rhinoconjunctivitis daily symptom score was reduced by 25% to 36% (P <= .004) in the grass allergy immunotherapy tablet group compared with the placebo group over the 5 grass pollen seasons covered by the trial. The rhinoconjunctivitis DMS was reduced by20% to45%(P <= .022 for seasons 1-4; P = .114 for season 5), and the weighted rhinoconjunctivitis combined score was reduced by 27% to 41% (P <= .003) in favor of active treatment. The percentage of days with severe symptoms during the peak grass pollen exposure was in all seasons lower in the active group than in the placebo group, with relative differences of 49% to 63% (P <= .0001). Efficacy was supported by long-lasting significant effects on the allergen-specific antibody response. No safety issues were identified. Conclusion: The results confirm disease modification by SQ-standardized grass allergy immunotherapy tablet in addition to effective symptomatic treatment of allergic rhinoconjunctivitis. (J Allergy Clin Immunol 2012; 129: 717-25.)	[Durham, Stephen R.] Univ London Imperial Coll Sci Technol & Med, Allergy & Clin Immunol Sect, Natl Heart & Lung Inst, London SW3 6LY, England; [Durham, Stephen R.] Royal Brompton Hosp, London SW3 6LY, England; [Emminger, Waltraud] Allergie Ambulatorium Rennweg, Vienna, Austria; [Kapp, Alexander] Hannover Med Sch, Dept Dermatol & Allergy, D-3000 Hannover, Germany; [de Monchy, Jan G. R.] Univ Groningen, Univ Med Ctr Groningen, Sect Allergol Internal Med, NL-9713 AV Groningen, Netherlands; [Rak, Sabina] Sahlgrens Univ Hosp, Sect Allergy, Gothenburg, Sweden; [Scadding, Glenis K.] Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England; [Wurtzen, Peter A.; Andersen, Jens S.; Tholstrup, Bente; Riis, Bente] ALK, Res & Dev, Horsholm, Denmark; [Dahl, Ronald] Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Allergy & Clin Immunol Sect, Natl Heart & Lung Inst, Guy Scadding Bldg,Royal Brompton Campus,Dovehouse, London SW3 6LY, England.	s.durham@imperial.ac.uk	Dahl, Ronahl/F-8170-2013		ALK; Novartis; Astellas; UCB; DPC; Swedish Asthma and Allergy Association; GlaxoSmithKline; Boehringer Ingelheim; AstraZeneca; Stallergenes; Pfizer; ALK, Denmark; AllergoPharma; Allergenes; Airsonett; MSD; Vectura; Elevation; Roche; Norpharma	The trial was sponsored by ALK, Denmark. S. R. D. has received consultancy and lecture fees and grant support from ALK. A. Kapp has consultant arrangements with DPC; has received grant support from Novartis, Astellas, UCB, ALK, and DPC; and is on the speakers' bureau for Novartis, Astellas, UCB, and ALK. J. G. R. d. M. has received a grant from ALK. S. R. has received grant support from the Swedish Asthma and Allergy Association. R. D. has been on advisory boards for Nycomed, Boehringer Ingelheim, Novartis, TEVA, Oxagen, and Vectura and has received grant support from GlaxoSmithKline, Boehringer Ingelheim, Novartis, AstraZeneca, ALK, Stallergenes, and Pfizer. G. K. S. has been on advisory boards and is on the speakers' bureau for ALK and is advisor and speaker for Merck. P. A. W., J. S. A., B. T., and B. R. are employed by ALK.; S. R. Durham has received honoraria for lectures and consulting from ALK, Denmark, and Merck; has received research support from ALK, Denmark; and is head of the Allergy Consortium Immune Tolerance Network/National Institute of Allergy and Infectious Disease. W. Emminger, J. G. R. de Monchy, and G. K. Scadding have received research support from ALK. A. Kapp has provided consultation services for ALK. S. Rak has received consultation fees from AllergoPharma, lecture honoraria from Stallergenes, and research support from AllergoPharma and Allergenes, and has provided consultation services/expert witness testimony on the topic of sublingual immunotherapy. P. A. Wurtzen is a shareholder in ALK and a member of the Lundbeck Foundation Board of Directors. B. Tholstrup is a shareholder in ALK. B. Riis is a shareholder in ALK Abello. R. Dahl has received lecture fees or is on the advisory board for Boehringer-Ingelheim, AstraZeneca, ALK, Airsonett, MSD, Novartis, Vectura, Elevation, Roche, and Norpharma; has received research support from ALK, Stalleren, Pfizer, Boehringer Ingelheim, AstraZeneca, Novartis, Airsonett, and GlaxoSmithKline; is Chairman of the Danish Respiratory Society; is Vice-chair of the Global Alliance against Chronic Respiratory Diseases; and is past president of Interasma. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis CA, 2011, J ALLERGY CLIN IMMUN, V127, P18, DOI 10.1016/j.jaci.2010.11.030; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Blaiss M, 2011, J ALLERGY CLIN IMMUN, V127, P64, DOI 10.1016/j.jaci.2010.11.034; Bourdin A, 2009, THORAX, V64, P999, DOI 10.1136/thx.2008.112862; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Canonica G Walter, 2009, World Allergy Organ J, V2, P233, DOI 10.1097/WOX.0b013e3181c6c379; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; Chehregani A, 2004, ECOTOX ENVIRON SAFE, V58, P267, DOI 10.1016/j.ecoenv.2003.12.004; Corren J, 2007, CURR OPIN PULM MED, V13, P13, DOI 10.1097/MCP.0b013e328010d0db; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2004, RESP MED, V98, P398, DOI 10.1016/j.rmed.2003.11.015; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Durham S, 2010, ALLERGY, V65, P689; Durham SR, 2011, ALLERGY, V66, P120, DOI 10.1111/j.1398-9995.2010.02434.x; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Emberlin JC., 1997, ALLERGY ALLERGIC DIS, V2, P835; European Medicine Agency (EMEA), 2008, CHMPEWP185042006 EME; Frolund L, 2010, ALLERGY, V65, P753, DOI 10.1111/j.1398-9995.2009.02238.x; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nelson HS, 2011, J ALLERGY CLIN IMMUN, V127, P72, DOI 10.1016/j.jaci.2010.11.035; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Roches Anne Des, 1997, Journal of Allergy and Clinical Immunology, V99, P450; Scadding G, 2011, IMMUNOL ALLERGY CLIN, V31, P191, DOI 10.1016/j.iac.2011.02.005; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Shamji MH, 2006, J IMMUNOL METHODS, V317, P71, DOI 10.1016/j.jim.2006.09.004; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Valovirta E, 2010, ALLERGY, V65, P309; World Medical Association, 2008, DECL HELS ETH PRINC; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x	36	161	163	0	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2012	129	3					717	U184		10.1016/j.jaci.2011.12.973		14	Allergy; Immunology	Allergy; Immunology	904IW	WOS:000301189300017	22285278	
J	Conrad, ML; Ferstl, R; Teich, R; Brand, S; Blumer, N; Yildirim, AO; Patrascan, CC; Hanuszkiewicz, A; Akira, S; Wagner, H; Holst, O; von Mutius, E; Pfefferle, PI; Kirschning, CJ; Garn, H; Renz, H				Conrad, Melanie L.; Ferstl, Ruth; Teich, Rene; Brand, Stephanie; Bluemer, Nicole; Yildirim, Ali Oe.; Patrascan, Cecilia C.; Hanuszkiewicz, Anna; Akira, Shizuo; Wagner, Hermann; Holst, Otto; von Mutius, Erika; Pfefferle, Petra I.; Kirschning, Carsten J.; Garn, Holger; Renz, Harald			Maternal TLR signaling is required for prenatal asthma protection by the nonpathogenic microbe Acinetobacter lwoffii F78	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							ALLERGIC SENSITIZATION; AIRWAY INFLAMMATION; DENDRITIC CELLS; EXPOSURE; CHILDREN; RISK; FARM; LIPOPOLYSACCHARIDE; RECOGNITION; EXPRESSION	The pre- and postnatal environment may represent a window of opportunity for allergy and asthma prevention, and the hygiene hypothesis implies that microbial agents may play an important role in this regard. Using the cowshed-derived bacterium Acinetobacter lwoffii F78 together with a mouse model of experimental allergic airway inflammation, this study investigated the hygiene hypothesis, maternal (prenatal) microbial exposure, and the involvement of Toll-like receptor (TLR) signaling in prenatal protection from asthma. Maternal intranasal exposure to A. lwoffii F78 protected against the development of experimental asthma in the progeny. Maternally, A. lwoffii F78 exposure resulted in a transient increase in lung and serum proinflammatory cytokine production and up-regulation of lung TLR messenger RNA. Conversely, suppression of TLRs was observed in placental tissue. To investigate further, the functional relevance of maternal TLR signaling was tested in TLR2/3/4/7/9(-/-) knockout mice. The asthma-preventive effect was completely abolished in heterozygous offspring from A. lwoffii F78-treated TLR2/3/4/7/9(-/-) homozygous mother mice. Furthermore, the mild local and systemic inflammatory response was also absent in these A. lwoffii F78-exposed mothers. These data establish a direct relationship between maternal bacterial exposures, functional maternal TLR signaling, and asthma protection in the progeny.	[Conrad, Melanie L.; Teich, Rene; Brand, Stephanie; Bluemer, Nicole; Yildirim, Ali Oe.; Patrascan, Cecilia C.; Pfefferle, Petra I.; Garn, Holger; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35043 Marburg, Germany; [Ferstl, Ruth; Wagner, Hermann] Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; [Hanuszkiewicz, Anna; Holst, Otto] Leibniz Ctr Med & Biosci, Res Ctr Borstel, Div Struct Biochem, D-23845 Borstel, Germany; [Akira, Shizuo] Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Suita, Osaka 5650871, Japan; [von Mutius, Erika] Univ Munich, Univ Childrens Hosp, D-80337 Munich, Germany; [Kirschning, Carsten J.] Univ Duisburg Essen, Inst Med Microbiol, D-45147 Essen, Germany	Renz, H (reprint author), Univ Marburg, Dept Clin Chem & Mol Diagnost, D-35043 Marburg, Germany.	renzh@med.uni-marburg.de	Akira, Shizuo/C-3134-2009	Yildirim, Ali Onder/0000-0003-1969-480X; von Mutius, Erika/0000-0002-8893-4515	Deutsche Forschungsgemeinschaft [SFB/TR22]; Stiftung P. E. Kempkes, Marburg [10/07]	This work was supported by the Deutsche Forschungsgemeinschaft (SFB/TR22) and Stiftung P. E. Kempkes, Marburg (10/07).	Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Brewer JM, 1999, J IMMUNOL, V163, P6448; Conrad ML, 2009, CLIN EXP ALLERGY, V39, P1246, DOI 10.1111/j.1365-2222.2009.03260.x; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Entrican G, 2002, J COMP PATHOL, V126, P79, DOI 10.1053/jcpa.2001.0539; Gon Yasuhiro, 2008, Allergol Int, V57, P33, DOI 10.2332/allergolint.R-07-157; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Harju K, 2005, PEDIATR RES, V57, P644, DOI 10.1203/01.PDR.0000156212.03459.A9; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740; Holgate ST, 2008, NAT REV IMMUNOL, V8, P218, DOI 10.1038/nri2262; Honda K, 2003, P NATL ACAD SCI USA, V100, P10872, DOI 10.1073/pnas.1934678100; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kawai T, 2009, INT IMMUNOL, V21, P317, DOI 10.1093/intimm/dxp017; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; LIVAK KJ, 2001, METHOD METHODS, V4, P402; Majkowska-Wojciechowska BM, 2007, ALLERGY, V62, P1044, DOI 10.1111/j.1398-9995.2007.01457.x; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Midodzi WK, 2007, RESPIROLOGY, V12, P692, DOI 10.1111/j.1440-1843.2007.01134.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Neuhaus-Steinmetz U, 2000, INT ARCH ALLERGY IMM, V121, P57, DOI 10.1159/000024298; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Sel S, 2008, J ALLERGY CLIN IMMUN, V121, P910, DOI 10.1016/j.jaci.2007.12.1175; Spiller S, 2007, J BIOL CHEM, V282, P13190, DOI 10.1074/jbc.M610340200; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, pS493, DOI 10.1016/S0091-6749(00)90049-6; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002	32	161	163	0	22	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	DEC 21	2009	206	13					2869	2877		10.1084/jem.20090845		9	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	535RE	WOS:000272987500004	19995952	
J	Lloyd, CM; Hawrylowicz, CM				Lloyd, Clare M.; Hawrylowicz, Catherine M.			Regulatory T Cells in Asthma	IMMUNITY			English	Review							INDUCED AIRWAY HYPERREACTIVITY; VITAMIN-D SUPPLEMENTATION; TGF-BETA; IMMUNE DYSREGULATION; INHALED ANTIGEN; ALLERGIC-ASTHMA; DENDRITIC CELLS; IN-VIVO; PEPTIDE IMMUNOTHERAPY; ALVEOLAR MACROPHAGES	Asthma is characterized by T helper cell 2 (Th2) type inflammation, leading to airway hyperresponsiveness and tissue remodeling. Th2 cell-driven inflammation is likely to represent an abnormal response to harmless airborne particles. These reactions are normally suppressed by regulatory T cells, which maintain airway tolerance. The anti-inflammatory cytokine IL-10 is likely to play a central role. The role of the cytokine transforming growth factor beta (TGF-beta) is more complex, with evidence for immune suppression and remodeling in the airways. In asthmatic individuals there is a breakdown in these regulatory mechanisms. There is emerging evidence that early life events, including exposure to allergen and infections, are critical in programming effective regulatory pathways to maintain pulmonary homeostasis. In this review we examine the clinical and experimental evidence for T regulatory cell function in the lung and discuss the events that might influence the functioning of these cells. Ultimately, the ability to enhance regulatory function in affected individuals may represent an effective treatment for asthma.	[Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, MRC, London SW7 2AZ, England; [Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Asthma UK Ctr Allerg Mech Asthma, NHLI, London SW7 2AZ, England; [Hawrylowicz, Catherine M.] Kings Coll London, MRC, London SE1 9RT, England; [Hawrylowicz, Catherine M.] Kings Coll London, Asthma UK Ctr Allerg Mech Asthma, London SE1 9RT, England	Lloyd, CM (reprint author), Univ London Imperial Coll Sci Technol & Med, MRC, London SW7 2AZ, England.	c.lloyd@imperial.ac.uk; catherine.hawrylowicz@kcl.ac.uk		Lloyd, Clare/0000-0001-8977-6726; Hawrylowicz, Catherine/0000-0002-2337-7463	Wellcome Trust [057704, 087618]		Adams JS, 2008, NAT CLIN PRACT ENDOC, V4, P80, DOI 10.1038/ncpendmet0716; Adorini L, 2008, NAT CLIN PRACT RHEUM, V4, P404, DOI 10.1038/ncprheum0855; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; Bacchetta R, 2006, J CLIN INVEST, V116, P1713, DOI 10.1172/JCI25112; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barnes MJ, 2009, IMMUNITY, V31, P401, DOI 10.1016/j.immuni.2009.08.011; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Barrett NA, 2009, IMMUNITY, V31, P425, DOI 10.1016/j.immuni.2009.08.014; Blumenthal RL, 2001, J ALLERGY CLIN IMMUN, V107, P258, DOI 10.1067/mai.2001.112845; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Caudy AA, 2007, J ALLERGY CLIN IMMUN, V119, P482, DOI 10.1016/j.jaci.2006.10.007; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; Deniz G, 2008, J IMMUNOL, V180, P850; Doherty T, 2007, CURR OPIN IMMUNOL, V19, P676, DOI 10.1016/j.coi.2007.07.017; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Gambineri E, 2003, CURR OPIN RHEUMATOL, V15, P430, DOI 10.1097/00002281-200307000-00010; Gereke M, 2009, AM J RESP CRIT CARE, V179, P344, DOI 10.1164/rccm.200804-592OC; Gerhold K, 2006, J ALLERGY CLIN IMMUN, V118, P666, DOI 10.1016/j.jaci.2006.05.022; Goswami S, 2009, NAT IMMUNOL, V10, P496, DOI 10.1038/ni.1719; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; Haddeland U, 2005, PEDIATR ALLERGY IMMU, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hawrylowicz C, 2002, J ALLERGY CLIN IMMUN, V109, P369, DOI 10.1067/mai.2002.121455; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Higgins SC, 2003, J IMMUNOL, V171, P3119; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; HOLT PG, 1981, IMMUNOLOGY, V42, P409; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Joetham A, 2007, J IMMUNOL, V178, P1433; John M, 1998, AM J RESP CRIT CARE, V157, P256; Karagiannidis C, 2006, J ALLERGY CLIN IMMUN, V117, P111, DOI 10.1016/j.jaci.2005.09.017; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kariyawasam HH, 2008, AM J RESP CRIT CARE, V177, P1074, DOI 10.1164/rccm.200709-1376OC; Kearley J, 2005, J EXP MED, V202, P1539, DOI 10.1084/jem.20051166; Kearley J, 2008, J ALLERGY CLIN IMMUN, V122, P617, DOI 10.1016/j.jaci.2008.05.048; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Leech MD, 2007, J IMMUNOL, V179, P7050; Leggat JA, 2008, J ALLERGY CLIN IMMUN, V122, P1014, DOI 10.1016/j.jaci.2008.08.011; lellem A, 2001, J EXP MED, V194, P847; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lim S, 1998, LANCET, V352, P113, DOI 10.1016/S0140-6736(98)85018-6; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Lloyd CM, 2007, CURR ALLERGY ASTHM R, V7, P231; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Lund JM, 2008, SCIENCE, V320, P1220, DOI 10.1126/science.1155209; Mahon BD, 2003, J NEUROIMMUNOL, V134, P128, DOI 10.1016/S0165-5728(02)00396-X; Makinde T, 2007, IMMUNOL CELL BIOL, V85, P348, DOI 10.1038/sj.icb.7100044; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McMillan SJ, 2005, J IMMUNOL, V174, P5774; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Message SD, 2008, P NATL ACAD SCI USA, V105, P13562, DOI 10.1073/pnas.0804181105; Miller RL, 2008, J CLIN INVEST, V118, P3265, DOI 10.1172/JCI37171; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nakao A, 2000, J EXP MED, V192, P151, DOI 10.1084/jem.192.2.151; Novak N, 2001, J IMMUNOL, V167, P797; O'Garra A, 2008, IMMUNOL REV, V223, P114, DOI 10.1111/j.1600-065X.2008.00635.x; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Penna G, 2005, BLOOD, V106, P3490, DOI 10.1182/blood-2005-05-2044; Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x; Polte T, 2008, J ALLERGY CLIN IMMUN, V122, P1022, DOI 10.1016/j.jaci.2008.09.014; PROVOOST S, 2009, ALLERGY IN PRESS, DOI DOI 10.1111/J.1398-9995.2009.02056.X; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Rao A, 2007, BLOOD, V109, P383, DOI 10.1182/blood-2006-05-025072; Riley JL, 2009, IMMUNITY, V30, P656, DOI 10.1016/j.immuni.2009.04.006; Roifman CM, 2000, PEDIATR RES, V48, P6, DOI 10.1203/00006450-200007000-00004; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Rubtsov YP, 2008, IMMUNITY, V28, P546, DOI 10.1016/j.immuni.2008.02.017; Ryanna K, 2009, ALLERGY, V64, P335, DOI 10.1111/j.1398-9995.2009.01972.x; Saglani S, 2007, AM J RESP CRIT CARE, V176, P858, DOI 10.1164/rccm.200702-212OC; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Scherf W, 2005, EUR J IMMUNOL, V35, P198, DOI 10.1002/eji.200425209; Schleithoff SS, 2006, AM J CLIN NUTR, V83, P754; Seidel MG, 2009, BLOOD, V113, P5689, DOI 10.1182/blood-2009-02-206359; Semitekolou M, 2009, J EXP MED, V206, P1769, DOI 10.1084/jem.20082603; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Stampfli MR, 1999, AM J RESP CELL MOL, V21, P586; Stelmach I, 2002, CLIN EXP ALLERGY, V32, P264, DOI 10.1046/j.1365-2222.2002.01286.x; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Sun J, 2009, NAT MED, V15, P277, DOI 10.1038/nm.1929; Sutmuller RPM, 2006, TRENDS IMMUNOL, V27, P387, DOI 10.1016/j.it.2006.06.005; Szefler SJ, 2005, AM J RESP CRIT CARE, V171, P672, DOI 10.1164/rccm.2501001; Taher YA, 2008, J IMMUNOL, V180, P5211; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Torgerson TR, 2007, J ALLERGY CLIN IMMUN, V120, P744, DOI 10.1016/j.jaci.2007.08.044; Urry Z, 2009, J CLIN INVEST, V119, P387, DOI 10.1172/JCI32354; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Verhasselt V, 2008, NAT MED, V14, P170, DOI 10.1038/nm1718; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Vignali DAA, 2008, NAT REV IMMUNOL, V8, P523, DOI 10.1038/nri2343; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	117	161	173	2	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613			IMMUNITY	Immunity	SEP 18	2009	31	3					438	449		10.1016/j.immuni.2009.08.007		12	Immunology	Immunology	503IA	WOS:000270525900009	19766086	
J	Homer, CJ; Klatka, K; Romm, D; Kuhlthau, K; Bloom, S; Newacheck, P; Van Cleave, J; Perrin, JM				Homer, Charles J.; Klatka, Kirsten; Romm, Diane; Kuhlthau, Karen; Bloom, Sheila; Newacheck, Paul; Van Cleave, Jeanne; Perrin, James M.			A review of the evidence for the medical home for children with special health care needs	PEDIATRICS			English	Review						medical home; special needs children; systematic review; family-centered care	PEDIATRIC-ASTHMA-CARE; OUTCOMES-RESEARCH-TEAM; QUALITY IMPROVEMENT; PATIENT-OUTCOMES; CHRONIC ILLNESS; COORDINATED CARE; NATIONAL-SURVEY; FAMILY; EMERGENCY; ACCESS	CONTEXT. The receipt of health care in a medical home is increasingly touted as a fundamental basis for improved care for persons with chronic conditions, yet the evidence for this claim has not been systematically assessed. OBJECTIVE. Our goal was to determine the evidence for the federal Maternal and Child Health Bureau recommendation that children with special health care needs receive ongoing comprehensive care within a medical home. METHODS. We searched the nursing and medical literature, references of selected articles, and requested expert recommendations. Search terms included children with special health care needs, medical home-related interventions, and health-related outcomes. Articles that met defined criteria (eg, children with special health care needs, United States-based, quantitative) were selected. We extracted data, including design, population characteristics, sample size, intervention, and findings from each article. RESULTS. We selected 33 articles that reported on 30 distinct studies, 10 of which were comparison-group studies. None of the studies examined the medical home in its entirety. Although tempered by weak designs, inconsistent definitions and extent of medical home attributes, and inconsistent outcome measures, the preponderance of evidence supported a positive relationship between the medical home and desired outcomes, such as better health status, timeliness of care, family centeredness, and improved family functioning. CONCLUSIONS. The evidence provides moderate support for the hypothesis that medical homes provide improved health-related outcomes for children with special health care needs. Additional studies with comparison groups encompassing all or most of the attributes of the medical home need to be undertaken.	[Klatka, Kirsten; Romm, Diane; Kuhlthau, Karen; Bloom, Sheila] Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA; [Homer, Charles J.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Homer, Charles J.] Natl Initiat Childrens Healthcare Qual, Cambridge, MA USA; [Kuhlthau, Karen; Van Cleave, Jeanne; Perrin, James M.] Harvard Univ, Sch Med, Boston, MA USA; [Newacheck, Paul; Van Cleave, Jeanne; Perrin, James M.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; [Newacheck, Paul; Van Cleave, Jeanne; Perrin, James M.] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA	Klatka, K (reprint author), Massachusetts Gen Hosp, Ctr Child & Adolescent Hlth Policy, 50 Staniford St,Suite 901, Boston, MA 02114 USA.	kklatka@partners.org	eshaghian, azam/Q-8826-2016	eshaghian, azam/0000-0001-7918-2895	MCHB [U53MC04473-03-00]	We thank our funders at the MCHB (Cooperative Agreement 5 U53MC04473-03-00) for support.	Agency for Healthcare Research and Quality, 2005, NAT HEALTHC QUAL REP; Agency for Healthcare Research and Quality, 2005, NAT HEALTHC DISP REP; American Academy of Pediatrics A, 2004, PEDIATRICS, V113, P1545; Baruffi G, 2005, MATERN CHILD HLTH J, V9, pS99, DOI 10.1007/s10995-005-3861-2; Berman S, 2005, PEDIATRICS, V115; Broyles RS, 2000, JAMA-J AM MED ASSOC, V284, P2070, DOI 10.1001/jama.284.16.2070; Christakis DA, 1999, PEDIATRICS, V103, P738, DOI 10.1542/peds.103.4.738; Christakis DA, 2003, AMBUL PEDIATR, V3, P82, DOI 10.1367/1539-4409(2003)003<0082:COCIAW>2.0.CO;2; Christakis DA, 2001, PEDIATRICS, V107, P524, DOI 10.1542/peds.107.3.524; CHRISTAKIS DA, 2002, PEDIATRICS, V109; Clark NM, 2000, EUR RESPIR J, V16, P15, DOI 10.1034/j.1399-3003.2000.16a04.x; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Criscione T, 1995, MENT RETARD, V33, P364; DAMIANO PC, 2006, PEDIATRICS, V118; Denboba D, 2006, PEDIATRICS, V118, P1607, DOI 10.1542/peds.2006-0383; DICKENS MD, 1992, PEDIATRICS, V90, P774; Dinkevich EI, 1998, J ASTHMA, V35, P63, DOI 10.3109/02770909809055406; Farmer JE, 2005, PEDIATRICS, V116, P649, DOI 10.1542/peds.2004-0647; Farmer JE, 2004, J PEDIATR PSYCHOL, V29, P355, DOI 10.1093/jpepsy/jsh039; Ferris TG, 2001, PEDIATRICS, V107, P143, DOI 10.1542/peds.107.1.143; Finkelstein JA, 2005, HEALTH SERV RES, V40, P1737, DOI 10.1111/j.1475-6773.2005.00451.x; FINKELSTEIN JA, 1996, AMBUL CHILD HLTH, V2, P129; Freeman Katherine, 2004, J Pediatr Oncol Nurs, V21, P87, DOI 10.1177/1043454203262691; Gavin LA, 1999, J PEDIATR PSYCHOL, V24, P355, DOI 10.1093/jpepsy/24.4.355; Gill JM, 2005, J HEALTH CARE POOR U, V16, P515, DOI 10.1353/hpu.2005.0050; Heslin KC, 2006, ARCH OPHTHALMOL-CHIC, V124, P895, DOI 10.1001/archopht.124.6.895; Homer CJ, 2005, ARCH PEDIAT ADOL MED, V159, P464, DOI 10.1001/archpedi.159.5.464; JESSOP DJ, 1994, PEDIATRICS, V93, P602; Kelley M A, 1991, J Community Health, V16, P213, DOI 10.1007/BF01324389; Kieckhefer Gail M, 2005, J Pediatr Health Care, V19, P285, DOI 10.1016/j.pedhc.2005.05.009; Lafata JE, 2002, AMBUL PEDIATR, V2, P268, DOI 10.1367/1539-4409(2002)002<0268:RFFEDU>2.0.CO;2; Landon BE, 2007, NEW ENGL J MED, V356, P921, DOI 10.1056/NEJMsa062860; LEATHERMAN S, 2004, QUALITY CARE CHILDRE; Liptak GS, 1998, ARCH PEDIAT ADOL MED, V152, P1003; Lotstein DS, 2005, PEDIATRICS, V115, P1562, DOI 10.1542/peds.2004-1262; Lozano P, 2004, ARCH PEDIAT ADOL MED, V158, P875, DOI 10.1001/archpedi.158.9.875; Mangione-Smith R, 2005, AMBUL PEDIATR, V5, P75, DOI 10.1367/A04-106R.1; Nash DR, 1999, PEDIATRICS, V104, P310, DOI 10.1542/peds.104.2.310; Newacheck PW, 1998, PEDIATRICS, V102, P117, DOI 10.1542/peds.102.1.117; Ngui EM, 2006, PEDIATRICS, V117, P1184, DOI 10.1542/peds.2005-1088; ORR DP, 1984, J PEDIATR-US, V104, P152, DOI 10.1016/S0022-3476(84)80616-2; Palfrey JS, 2004, PEDIATRICS, V113, P1507; Perry D F, 2001, Matern Child Health J, V5, P15, DOI 10.1023/A:1011341700765; PLESS IB, 1978, CHILD CARE HLTH DEV, V4, P9, DOI 10.1111/j.1365-2214.1978.tb00067.x; PLESS IB, 1976, PEDIATRICS, V58, P37; RICHARD WC, 2001, CROSSING QUALITY CHA; Scal P, 2005, PEDIATRICS, V115, P1607, DOI 10.1542/peds.2004-0458; Sia C, 2004, PEDIATRICS, V113, P1473; SIA CCJ, 1992, PEDIATRICS, V90, P419; Silver EJ, 2001, AMBUL PEDIATR, V1, P314, DOI 10.1367/1539-4409(2001)001<0314:ATCUHN>2.0.CO;2; Smaldone A, 2005, MATERN CHILD HLTH J, V9, pS75, DOI 10.1007/s10995-005-3859-9; SMITH K, 1994, CHILD HEALTH CARE, V23, P251, DOI 10.1207/s15326888chc2304_2; Starfield B, 2004, PEDIATRICS, V113, P1493; STEIN REK, 1991, PEDIATRICS, V88, P490; Strickland B, 2004, PEDIATRICS, V113, P1485; Van Riper M, 1999, RES NURS HEALTH, V22, P357, DOI 10.1002/(SICI)1098-240X(199910)22:5<357::AID-NUR2>3.0.CO;2-Q; Wang C, 2005, PEDIATRICS, V116, P1075, DOI 10.1542/peds.2004-2093; WILLIAMS J, 1995, CHILD HEALTH CARE, V24, P235, DOI 10.1207/s15326888chc2404_3	58	161	164	3	16	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	OCT	2008	122	4					E922	E937		10.1542/peds.2007-3762		16	Pediatrics	Pediatrics	356YD	WOS:000259812600062	18829788	
J	Israel, BA; Parker, EA; Rowe, Z; Salvatore, A; Minkler, M; Lopez, J; Butz, A; Mosley, A; Coates, L; Lambert, G; Potito, PA; Brenner, B; Rivera, M; Romero, H; Thompson, B; Coronado, G; Halstead, S				Israel, BA; Parker, EA; Rowe, Z; Salvatore, A; Minkler, M; Lopez, J; Butz, A; Mosley, A; Coates, L; Lambert, G; Potito, PA; Brenner, B; Rivera, M; Romero, H; Thompson, B; Coronado, G; Halstead, S			Community-based participatory research: Lessons learned from the Centers for Children's Environmental Health and Disease Prevention Research	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						children's health; collaborative research; community-based participatory research; partnership	PARTICULATE AIR-POLLUTION; INNER-CITY CHILDREN; PUBLIC-HEALTH; PESTICIDE EXPOSURE; TOBACCO-SMOKE; ASTHMA; PARTNERSHIP; ASSOCIATION; POPULATION; POLLUTANTS	Over the past several decades there has been growing evidence of the increase in incidence rates, morbidity, and mortality for a number of health problems experienced by children. The causation and aggravation of these problems are complex and multifactorial. The burden of these health problems and environmental exposures is borne disproportionately by children from low-income communities and communities of color. Researchers and funding institutions have called for increased attention to the complex issues that affect the health of children living in marginalized communities-and communities more broadly and have suggested greater community involvement in processes that shape research and intervention approaches, for example, through community-based participatory research (CBPR) partnerships among academic, health services, public health, and community-based organizations. Centers for Children's Environmental Health and Disease Prevention Research (Children's Centers) funded by the National Institute of Environmental Health Sciences and U.S. Environmental Protection Agency, were required to include a CBPR project. The purpose of this article is to provide a definition and set of CBPR principles, to describe the rationale for and major benefits of using this approach, to draw on the experiences of six of the Children's Centers in using CBPR, and to provide lessons learned and recommendations for how to successfully establish and maintain CBPR partnerships aimed at enhancing our understanding and addressing the multiple determinants of children's health.	Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Calif Rural Legal Assistance, Salinas, CA USA; Johns Hopkins Univ, Sch Med, Dept Gen Pediat, Baltimore, MD USA; Off Commun Hlth, Baltimore, MD USA; Dr Bernard Harris Sr Elementary Sch, Baltimore, MD USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Ctr Childhood Neurotoxicol & Exposure Assessment, Piscataway, NJ 08854 USA; COSAC, Ewing, NJ USA; Mt Sinai Sch Med, Mt Sinai Ctr Childrens Environm Hlth & Dis Preven, Dept Community & Prevent Med, New York, NY USA; Boriken Neighborhood Hlth Ctr, New York, NY USA; Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA; US EPA, Prosser, WA USA	Israel, BA (reprint author), Univ Michigan, Sch Publ Hlth, 1420 Washington Heights, Ann Arbor, MI 48109 USA.	samanj@umich.edu			NIEHS NIH HHS [P01 ES011256, ES009584, ES009601, ES009605, ES009606, ES011256, ES09589, P01 ES009584, P01 ES009589, P01 ES009601, P01 ES009605, P01 ES009606]		ARNSTEIN SR, 1969, J AM I PLANNERS, V35, P216, DOI 10.1080/01944366908977225; Balcazar FE, 2004, APA DECADE BEHAV VOL, P17, DOI 10.1037/10726-001; Baldi I, 2001, ENVIRON HEALTH PERSP, V109, P839, DOI 10.2307/3454828; Barone S, 2000, NEUROTOXICOLOGY, V21, P15; Becker A, 2005, METHODS COMMUNITY BA, P52; Buchdahl R, 2000, OCCUP ENVIRON MED, V57, P86, DOI 10.1136/oem.57.2.86; Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; Daniels JL, 1997, ENVIRON HEALTH PERSP, V105, P1068, DOI 10.1289/ehp.971051068; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Edgren Katherine K, 2005, Health Promot Pract, V6, P263, DOI 10.1177/1524839903260696; Eggleston PA, 2000, CLIN REV ALLERG IMMU, V18, P311, DOI 10.1385/CRIAI:18:3:311; Eng E, 1990, Int Q Community Health Educ, V11, P93, DOI 10.2190/W8MU-5H9X-PQW1-LV38; Eskenazi B, 2004, ENVIRON HEALTH PERSP, V112, P1116, DOI 10.1289/ehp.6789; Evans GW, 2002, ANNU REV PUBL HEALTH, V23, P303, DOI 10.1146/annurev.publhealth.23.112001.112349; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Green LW, 2001, AM J PUBLIC HEALTH, V91, P1926, DOI 10.2105/AJPH.91.12.1926; GREEN LW, 2003, COMMUNITY BASED PART, P27; Heron J., 2001, HDB ACTION RES PARTI, P179; Israel B A, 2001, J Public Health Manag Pract, V7, P1; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Israel B. A., 2003, COMMUNITY BASED PART, P56; Jason L. A., 2004, PARTICIPATORY COMMUN; Johnson DH, 2003, JOINING TOGETHER GRO; McTaggart R., 2000, HDB QUALITATIVE RES, P567; Kone A, 2000, PUBLIC HEALTH REP, V115, P243, DOI 10.1093/phr/115.2.243; Landrigan PJ, 2002, ENVIRON HEALTH PERSP, V110, P721; Lantz PM, 2001, J URBAN HEALTH, V78, P495, DOI 10.1093/jurban/78.3.495; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Minkler M, 2004, HEALTH EDUC BEHAV, V31, P684, DOI 10.1177/1090198104269566; Minkler M, 2003, COMMUNITY BASED PART; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; O'Fallon Liam R., 2000, Environmental Epidemiology and Toxicology, V2, P201; O'Fallon LR, 2000, SUCCESSFUL MODELS CO, P1; Parker EA, 2003, J GEN INTERN MED, V18, P558, DOI 10.1046/j.1525-1497.2003.20322.x; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schantz SL, 2003, ENVIRON HEALTH PERSP, V111, P357, DOI 10.1289/ehp.5461; Schulz AJ, 2003, EVAL PROGRAM PLANN, V26, P249, DOI 10.1016/S0149-7189(03)00029-6; Schulz AJ, 2002, MILBANK Q, V80, P677, DOI 10.1111/1468-0009.00028; Schulz A. J., 1998, RES STRATEGIES COMMU, P83; Sporik R, 1999, THORAX, V54, P675; Steuart GW, 1993, HLTH ED S1, V20, P99; Thompson B, 2001, ENVIRON HEALTH PERSP, V109, P443, DOI 10.2307/3434793; Wallerstein NB, 2003, COMMUNITY BASED PART, P27; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025	47	161	162	1	30	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2005	113	10					1463	1471		10.1289/ehp.7675		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	970GF	WOS:000232292600058	16203263	
J	Trasande, L; Thurston, GD				Trasande, L; Thurston, GD			The role of air pollution in asthma and other pediatric morbidities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; particulate matter; lead; sulfur dioxide; carbon monoxide; nitrogen oxides; children's environmental health	DIESEL EXHAUST PARTICLES; LOW-BIRTH-WEIGHT; EMERGENCY-ROOM VISITS; TRADE-CENTER DISASTER; SOUTHERN CALIFORNIA; CHILDHOOD ASTHMA; INFANT-MORTALITY; SULFUR-DIOXIDE; RESPIRATORY SYMPTOMS; HOSPITAL ADMISSIONS	A growing body of research supports the role of outdoor air pollutants in acutely aggravating chronic diseases in children, and suggests that the pollutants may have a role in the development of these diseases. This article reviews the biologic basis of children's unique vulnerability to highly prevalent outdoor air pollutants, with a special focus on ozone, respirable particulate matter (PM2.5 [< 2.5 mu m in diameter] and PM10 [< 10 mu m in diameter]), lead, sulfur dioxide, carbon monoxide, and nitrogen oxides. We also summarize understanding regarding health effects and molecular mechanisms of action. Practitioners can significantly reduce morbidity in children and other vulnerable populations by advising families to minimize pollutant exposures to children with asthma, or at a broader level by educating policymakers about the need to act to reduce pollutant emissions. Management of children with asthma must expand beyond preventing exposures to agents that directly cause allergic reactions (and therefore can be diagnosed by means of skin tests) and must focus more attention on agents that cause a broad spectrum of nonspecific, generalized inflammation, such as air pollution.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Dept Community & Prevent Med, Ctr Childs Hlth & Environm, New York, NY USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Thurston, GD (reprint author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	thurston@env.med.nyu.edu		Trasande, Leonardo/0000-0002-1928-597X	NIEHS NIH HHS [P42 ES 07384, ES 00260]		Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; ANDERSON H.R., 1999, AIR POLLUTION HLTH, P461, DOI 10.1016/B978-012352335-8/50096-X; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Bates D. V., 2002, CITIZENS GUIDE AIR P; Berkowitz GS, 2003, JAMA-J AM MED ASSOC, V290, P595, DOI 10.1001/jama.290.5.595-b; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; BOBAK M, 1992, LANCET, V340, P1010, DOI 10.1016/0140-6736(92)93017-H; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; Bobak M, 2001, EPIDEMIOLOGY, V12, P358, DOI 10.1097/00001648-200105000-00018; BOBAK M, 2000, ENV HLTH PERSPECT, V108, P539; Cloutier MM, 2002, CHEST, V122, P1571, DOI 10.1378/chest.122.5.1571; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; DUGGAN M J, 1985, Public Health Reviews, V13, P1; DUNNILL M. S., 1962, THORAX, V17, P329, DOI 10.1136/thx.17.4.329; Ekbom A, 1997, J NATL CANCER I, V89, P71, DOI 10.1093/jnci/89.1.71; [Anonymous], NAT SCAL AIR TOX ASS; Fanucchi MV, 2000, AM J RESP CRIT CARE, V161, pA615; FANUCCHI MV, 1997, COMPREHENSIVE TOXICO, V8, P203; Feychting M, 1998, SCAND J WORK ENV HEA, V24, P8; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Goldman LR, 2001, PEDIATRICS, V108, P197, DOI 10.1542/peds.108.1.197; GRAY R, 1991, CANCER RES, V51, P6470; GRISCOM NT, 1978, RADIOL CLIN N AM, V16, P367; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Hajat S, 1999, THORAX, V54, P597; Holt PG, 1998, ENVIRON HEALTH PERSP, V106, P795, DOI 10.2307/3434191; IARC, 1989, IARC MON EV CARC RIS, V46, P458; Janssen NAH, 1998, AM J EPIDEMIOL, V147, P537; Janssen NAH, 1997, OCCUP ENVIRON MED, V54, P888; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; KAVLOCK R, 1979, TOXICOL APPL PHARM, V48, P19, DOI 10.1016/S0041-008X(79)80004-6; KIMBROUGH R, 1995, PEDIATRICS, V95, P550; KOENIG JQ, 1992, J ALLERGY CLIN IMMUN, V89, P789, DOI 10.1016/0091-6749(92)90432-2; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lanphear BP, 1998, ENVIRON RES, V79, P51, DOI 10.1006/enrs.1998.3859; Lanphear BP, 1997, ENVIRON RES, V74, P67, DOI 10.1006/enrs.1997.3726; Lederman SA, 2004, ENVIRON HEALTH PERSP, V112, P1772, DOI 10.1289/ehp.7348; LI N, 2003, CLIN IMMUNOL, V3, P250; LIN MC, 2001, J TOXICOL ENV HEAL A, V64, P37; LINN WS, 1990, ARCH ENVIRON HEALTH, V45, P24; LINN WS, 1988, ARCH ENVIRON HEALTH, V43, P399; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCDONNELL WF, 1990, LONG TERM AMBIENT OZ, pA80; MOLFINO NA, 1992, CLIN EXP ALLERGY, V22, P667, DOI 10.1111/j.1365-2222.1992.tb00189.x; Mudway IS, 1999, OCCUP ENVIRON MED, V56, P473; *NAT AC SCI, 1984, TOX TEST NEEDS PRIOR; *NAT ASTHM ED PREV, 1996, AM REV RESPIR CRIT 2, V154, pS119; National Research Council, 1993, PEST DIETS INF CHILD; *NAT RES DEF COUNC, 2001, NO BREATH AISL DIES; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Pereira LAA, 1998, ENVIRON HEALTH PERSP, V106, P325, DOI 10.1289/ehp.98106325; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 1997, EUR RESPIR J, V10, P872; Petroeschevsky A, 2001, ARCH ENVIRON HEALTH, V56, P37; Plopper CG, 2000, ENVIRON HEALTH PERSP, V108, pA252, DOI 10.1289/ehp.108-a252; PLUNKETT LM, 1992, SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS : IMPLICATIONS FOR RISK ASSESSMENT, P79; PORNSCHEIN RL, 1987, TRACE SUBSTANCES ENV, V20, P322; PRYOR WA, 1991, OXIDATIVE DAMAGE & REPAIR, P496; *PUBL HLTH SERV, 1952, 95 PUBL HLTH SERV; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Saintot M, 1999, ARCH ENVIRON HEALTH, V54, P34; SALDIVA PHN, 1994, ENVIRON RES, V65, P218, DOI 10.1006/enrs.1994.1033; Schwartz J, 2004, PEDIATRICS, V113, P1037; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Shannon MW, 2004, PEDIATRICS, V114, P1699, DOI 10.1542/peds.2004-2166; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; SPIELBERG SP, 1992, SIMILARITIES AND DIFFERENCES BETWEEN CHILDREN AND ADULTS : IMPLICATIONS FOR RISK ASSESSMENT, P104; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; TRASANDE L, 2005, IN PRESS ENV HLTH PE; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; *US EPA, 1998, CHEM COMM INF SYST C; *US EPA, 2003, 410R97002 EPA; *US EPA, 2004, AIR TOX HLTH EC EFF; *US EPA, 2001, 454K02001 EPA; *US EPA, 2002, EPA6008909057F; U.S. EPA, 2003, EPA454R03005; U.S. Environmental Protection Agency, 1998, CHEM HAZ DAT AV STUD; *US EPA, 2001, 454K01002 EPA; *US EPA, 2003, 410R99001 EPA; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Wiley J. A., 1991, STUDY CHILDRENS ACTI; Wiley J.A., 1991, ACTIVITY PATTERNS CA; Windham GC, 1999, PAEDIATR PERINAT EP, V13, P35; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407	102	161	164	3	44	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					689	699		10.1016/j.jaci.2005.01.056		11	Allergy; Immunology	Allergy; Immunology	916GM	WOS:000228373400005	15805986	
J	Gehring, U; Bischof, W; Fahlbusch, B; Wichmann, HE; Heinrich, J				Gehring, U; Bischof, W; Fahlbusch, B; Wichmann, HE; Heinrich, J			House dust endotoxin and allergic sensitization in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						endotoxin; house dust; atopy; school children	HAY-FEVER; EARLY-LIFE; EXPOSURE; ASTHMA; ATOPY; CHILDHOOD; FARM; RISK; CAT; ENVIRONMENT	A higher exposure to endotoxin was hypothesized to contribute to lower prevalence of allergic sensitization and hay fever in children growing up on a farm. We studied the association between house dust endotoxin and allergic sensitization. We randomly selected 740 children, aged between 5 and 10 years, from a group of children who participated in two cross-sectional surveys performed in Saxony-Anhalt, Germany, from 1992 to 1993 and from 1995 to 1996, such that 50% of the children were atopic or had a diagnosis of asthma. From 1996 to 1998, we collected living-room floor dust in the homes of 454 of these children (61%). The content of endotoxin in house dust was quantified using a chromogenic kinetic limulus amoebocyte lysate test and was related with health outcomes measured in the preceding cross-sectional surveys. Multiple logistic regression analyses adjusted for place of residence, sex, age, parental education, parental atopy, and pet ownership showed a negative association between exposure to endotoxin and sensitization to one or more allergens (aOR [95% CI] 0.95 [0.83; 1.10]) and two or more allergens (aOR [95% CI] 0.80 [0.67, 0.97]) using 0.35 kU/L as the cutoff value for sensitization. The protective effect was strengthened with increasing degree of sensitization. In conclusion, exposure to higher levels of house dust endotoxin is associated with lower prevalence of allergic sensitization in children.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Chair Epidemiol, D-80539 Munich, Germany; Univ Jena, Inst Occupat Social & Environm Med, Dept Indoor Climatol Ark, Erfurt, Germany; Univ Jena, Inst Clin Immunol, D-6900 Jena, Germany	Gehring, U (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.			Gehring, Ulrike/0000-0003-3612-5780			Bischof W, 2000, P HLTH BUILDINGS, V1, P251; Braback L, 2001, PEDIATR ALLERGY IMMU, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fahlbusch B, 1999, ALLERGY, V54, P1215, DOI 10.1034/j.1398-9995.1999.00196.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hastie T, 1990, GEN ADDITIVE MODELS; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hosmer DW, 1989, APPL LOGISTIC REGRES; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Martinez FD, 1999, LANCET S2, V354, pSII12; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 2001, AM J RESP CRIT CARE, V164, P116	35	161	166	0	10	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2002	166	7					939	944		10.1164/rccm.200203-256OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	599YJ	WOS:000178362600010	12359650	
J	Eggesbo, M; Botten, G; Halvorsen, R; Magnus, P				Eggesbo, M; Botten, G; Halvorsen, R; Magnus, P			The prevalence of allergy to egg: a population-based study in young children	ALLERGY			English	Article						adverse reactions; DBPCFC; egg; egg hypersensitivity; epidemiology; food hypersensitivity; prevalence; prospective	COWS MILK ALLERGY; CONTROLLED FOOD CHALLENGES; SKIN-TEST REACTIVITY; DOUBLE-BLIND; CLINICAL MANIFESTATIONS; ATOPIC-DERMATITIS; ADVERSE REACTIONS; HYPERSENSITIVITY; CHILDHOOD; INFANCY	Background: The aim of the present study was to estimate the prevalence of adverse reactions to egg, as population-based prevalence estimates based on objective diagnostic procedures are lacking. Methods: The parents of 2721 children in a population-based birth cohort completed questionnaires on the occurrence of any reaction to food at 12, 18, and 24 months of age. Children with parentally reported reactions to eggs at the age of 2 years were selected for further examination. A stepwise diagnostic procedure was developed that included diet trials at home, skin prick tests, and open and double-blind, placebo-controlled food challenges. The mean age of the children at the time of the examination was 2.5 years (CI 2.5-2.6). A sample of children without perceived reactions to egg was also selected for assessment of unrecognized reactions. Results: The estimated point prevalence of allergy to egg in children aged 2 1/2 years was 1.6% (CI 1.3-2.0%), with an upper estimate of the cumulative incidence by this age calculated roughly at 2.6% (CI 1.6-3.6). Almost all reactions were IgE mediated. In general, two-thirds of the parentally perceived reactions were verified. However, the positive predictive value of a parentally perceived reaction depended on the number of times it had been reported, and increased from 50% to 100%, for reactions reported one and three times, respectively. Unrecognized reactions were infrequent. Conclusions: This study confirms that allergy to egg is frequent in a child population.	Natl Inst Publ Hlth, Dept Populat Hlth Sci, Epidemiol Sect, N-0403 Oslo, Norway; Univ Oslo, Natl Hosp, Ctr Hlth Adm, Oslo 3, Norway; Univ Hosp Oslo, Voksentoppen Ctr Asthma Allergy & Chron Lung Dis, Oslo, Norway	Eggesbo, M (reprint author), Natl Inst Publ Hlth, Dept Populat Hlth Sci, Epidemiol Sect, Post Box 4404, N-0403 Oslo, Norway.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Eggesbo, Merete/0000-0002-0006-5336			AAS K, 1973, INT ARCH ALLER A IMM, V45, P57; Altman DO, 1993, PRACTICAL STAT MED R; Baehler P, 1996, CLIN EXP ALLERGY, V26, P254, DOI 10.1046/j.1365-2222.1996.d01-310.x; BOCK SA, 1987, PEDIATRICS, V79, P683; BOCK SA, 1985, J ALLERGY CLIN IMMUN, V75, P528; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; BOCK SA, 1990, J PEDIATR-US, V117, P561, DOI 10.1016/S0022-3476(05)80689-4; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; Efron B., 1993, INTRO BOOTSTRAP; Eggesbo M, 1999, PEDIATR ALLERGY IMMU, V10, P122, DOI 10.1034/j.1399-3038.1999.00022.x; EGGESBO M, 2000, IN PRESS ALLERGY, V56; FORD RPK, 1980, ARCH DIS CHILD, V55, P608; HALPERN SR, 1973, J ALLERGY CLIN IMMUN, V51, P139, DOI 10.1016/0091-6749(73)90019-5; Hill DJ, 1999, ANN MED, V31, P272, DOI 10.3109/07853899908995890; HILL DJ, 1988, CLIN ALLERGY, V18, P469, DOI 10.1111/j.1365-2222.1988.tb02897.x; HILL DJ, 1988, CLIN ALLERGY, V18, P481, DOI 10.1111/j.1365-2222.1988.tb02898.x; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; KAJOSAARI M, 1982, ACTA PAEDIATR SCAND, V71, P815, DOI 10.1111/j.1651-2227.1982.tb09525.x; KAPLAN MS, 1994, CLIN EXP ALLERGY, V24, P291, DOI 10.1111/j.1365-2222.1994.tb00234.x; KUITUNEN P, 1975, ARCH DIS CHILD, V50, P351; LEE YH, 1992, J PEDIATR-US, V121, pS47, DOI 10.1016/S0022-3476(05)81406-4; MAY CD, 1978, ALLERGY, V33, P166, DOI 10.1111/j.1398-9995.1978.tb01532.x; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; MAY CD, 1985, J ALLERGY CLIN IMMUN, V75, P329, DOI 10.1016/0091-6749(85)90067-3; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; MENARDO JL, 1985, J ALLERGY CLIN IMMUN, V75, P646, DOI 10.1016/0091-6749(85)90088-0; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Newcombe RG, 1998, STAT MED, V17, P857, DOI 10.1002/(SICI)1097-0258(19980430)17:8<857::AID-SIM777>3.0.CO;2-E; Niggemann B, 1999, CLIN EXP ALLERGY, V29, P91; Reibel S, 2000, ALLERGY, V55, P940, DOI 10.1034/j.1398-9995.2000.00689.x; SAMPSON HA, 1988, ANN ALLERGY, V60, P262; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; SKASSABROCIEK W, 1987, J ALLERGY CLIN IMMUN, V80, P711, DOI 10.1016/0091-6749(87)90292-2; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Wilson EB, 1927, J AM STAT ASSOC, V22, P209, DOI 10.2307/2276774	36	161	172	1	6	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	MAY	2001	56	5					403	411		10.1034/j.1398-9995.2001.056005403.x		9	Allergy; Immunology	Allergy; Immunology	437BW	WOS:000168971200006	11350303	
J	Sunyer, J; Schwartz, J; Tobias, A; Macfarlane, D; Garcia, J; Anto, JM				Sunyer, J; Schwartz, J; Tobias, A; Macfarlane, D; Garcia, J; Anto, JM			Patients with chronic obstructive pulmonary disease are at increased risk of death associated with urban particle air pollution: A case-crossover analysis	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						air pollution; lung diseases; obstructive; mortality	EMERGENCY ROOM ADMISSIONS; HOSPITAL ADMISSIONS; PARTICULATE MATTER; EUROPEAN CITIES; APHEA PROJECT; MORTALITY; ASTHMA; DEPOSITION; GENDER	The authors assessed the acute association between particulate air pollution and mortality among subjects suffering from chronic obstructive pulmonary disease by using a case-crossover analysis. This design avoided the common concerns about the methods used to assess the acute effects of air pollution. The 1,845 men and the 460 women included were residents of Barcelona, Spain, who were over age 35 years, had died during the period 1990-1995, and had visited emergency rooms because of a chronic obstructive pulmonary disease exacerbation during the period 1985-1989. Particle levels (measured as black smoke at the city monitoring stations) were associated with mortality for all causes (odds ratio (OR) for an increase of 20 mu g/m(3), the interquartile change, adjusted for temperature, humidity, and influenza = 1.112, 95 percent confidence interval (CI): 1.017, 1.215). The association was stronger for respiratory causes (OR = 1.182, 95 percent CI: 1.025, 1.365), but was not significant for cardiovascular causes (OR = 1.077, 95 percent CI: 0.917, 1.264). Older women, patients admitted to intensive care units, and patients with a higher rate of emergency room visits were at greater risk of dying associated with black smoke. The results reinforced the deleterious role of urban pollution and provided information on factors possibly conferring susceptibility to the acute role of air pollution.	Inst Municipal Invest Med, Unit Resp & Environm Res, E-08003 Barcelona, Catalonia, Spain; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Environm Epidemiol Program, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA	Sunyer, J (reprint author), Inst Municipal Invest Med, Unit Resp & Environm Res, E-08003 Barcelona, Catalonia, Spain.		Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110			Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; ANTO JM, 1990, CHEST, V98, pS185, DOI 10.1378/chest.98.5_Supplement.185S; AYRES JG, 1998, EUR RESPIR REV, V8, P135; AYRES JG, 1998, EUR RESPIR REV, V8, P53; Bagley S. T., 1996, RES REP HLTH EFF I, V76, P1; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATESON T, 1999, EPIDEMIOLOGY, V54, P596; Bennett WD, 1996, AM J RESP CRIT CARE, V153, P1641; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; de Hartog J J, 1997, Ned Tijdschr Geneeskd, V141, P1814; Gilmour PS, 1996, OCCUP ENVIRON MED, V53, P817; GOLD DR, 1998, AM J RESP CRIT CARE, V157, P261; HIGGINS MW, 1989, CLIN EPIDEMIOLOGY CH; Katsouyanni K, 1997, BMJ-BRIT MED J, V314, P1658; Kim CS, 1997, AM J RESP CRIT CARE, V155, P899; LAWTHER PJ, 1970, THORAX, V25, P525, DOI 10.1136/thx.25.5.525; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144; MARTINEZ F, 1993, EUR RESPIR J, V6, P337; Ministry of Health, 1954, MORT MORB LOND FOG D; NEAS LM, 1995, EPIDEMIOLOGY, V6, pS56; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055; SALVI S, 1997, AM J RESP CRIT CARE, V155, P425; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; SCHWARTZ J, 1998, AM J RESP CRIT CARE, V157, P879; STYER P, 1995, ENVIRON HEALTH PERSP, V103, P490, DOI 10.2307/3432588; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701; Sunyer J, 1998, AM J RESP CRIT CARE, V158, P851; *WHO, 1977, INT CLASS DIS MAN IN; XU X, 1994, EUR RESPIR J, V7, P1056	35	161	170	0	7	JOHNS HOPKINS UNIV SCHOOL HYGIENE PUB HEALTH	BALTIMORE	111 MARKET PLACE, STE 840, BALTIMORE, MD 21202-6709 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JAN 1	2000	151	1					50	56				7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	271KV	WOS:000084593500005	10625173	
J	Lambrecht, BN; Hammad, H				Lambrecht, Bart N.; Hammad, Hamida			The immunology of asthma	NATURE IMMUNOLOGY			English	Review							INNATE LYMPHOID-CELLS; ALLERGIC AIRWAY INFLAMMATION; HOUSE-DUST MITE; PLASMACYTOID DENDRITIC CELLS; REGULATORY T-CELLS; FC-EPSILON-RI; NATURAL HELPER-CELLS; THYMIC STROMAL LYMPHOPOIETIN; RESPIRATORY VIRAL-INFECTION; AFFINITY IGE RECEPTOR	Asthma is a common disease that affects 300 million people worldwide. Given the large number of eosinophils in the airways of people with mild asthma, and verified by data from murine models, asthma was long considered the hallmark T helper type 2 (T(H)2) disease of the airways. It is now known that some asthmatic inflammation is neutrophilic, controlled by the T(H)17 subset of helper T cells, and that some eosinophilic inflammation is controlled by type 2 innate lymphoid cells (ILC2 cells) acting together with basophils. Here we discuss results from in-depth molecular studies of mouse models in light of the results from the first clinical trials targeting key cytokines in humans and describe the extraordinary heterogeneity of asthma.	[Lambrecht, Bart N.; Hammad, Hamida] Univ Ghent, VIB, Inflammat Res Ctr, B-9000 Ghent, Belgium; [Lambrecht, Bart N.; Hammad, Hamida] Univ Hosp Ghent, Dept Resp Med, Ghent, Belgium; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Lambrecht, BN (reprint author), Univ Ghent, VIB, Inflammat Res Ctr, B-9000 Ghent, Belgium.	bart.lambrecht@ugent.be; hamida.hammad@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834	European Union European Research Council; European Union Framework Programme 7 (MedALL and EUBIOPRED); University of Ghent Multidisciplinary Research Platform (Group-ID); Fonds Wetenschappelijk Onderzoek Vlaanderen	Supported by the European Union European Research Council (B.N.L.), the European Union Framework Programme 7 (MedALL and EUBIOPRED to B.N.L.), the University of Ghent Multidisciplinary Research Platform (Group-ID, to B.N.L.) and Fonds Wetenschappelijk Onderzoek Vlaanderen (B.N.L. and H.H.).	Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Barczyk A, 2014, J INFLAMM-LOND, V11, DOI 10.1186/1476-9255-11-22; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barnig C., 2013, SCI TRANSL MED, V5, DOI DOI 10.1126/SCITRANSLMED.3004812; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Bartemes KR, 2012, J IMMUNOL, V188, P1503, DOI 10.4049/jimmunol.1102832; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Bel EH, 2014, NEW ENGL J MED, V371, P1189, DOI 10.1056/NEJMoa1403291; Bell BD, 2013, NAT IMMUNOL, V14, P364, DOI 10.1038/ni.2541; Bellini A., 2011, MUCOSAL IMMUNOLOGY, V5, P140; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Besnard AG, 2011, AM J RESP CRIT CARE, V183, P1153, DOI 10.1164/rccm.201008-1383OC; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brandt EB, 2013, J ALLERGY CLIN IMMUN, V132, P1194, DOI 10.1016/j.jaci.2013.06.048; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Brusselle GG, 2013, NAT MED, V19, P977, DOI 10.1038/nm.3300; Brusselle GG, 2011, LANCET, V378, P1015, DOI 10.1016/S0140-6736(11)60988-4; Busse WW, 2013, AM J RESP CRIT CARE, V188, P1294, DOI 10.1164/rccm.201212-2318OC; Caliskan M, 2013, NEW ENGL J MED, V368, P1398, DOI 10.1056/NEJMoa1211592; Chang H.C., 2011, NAT IMMUNOL, V11, P527; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Cheng D, 2014, AM J RESP CRIT CARE, V190, P639, DOI 10.1164/rccm.201403-0505OC; Chu DK, 2014, J EXP MED, V211, P1657, DOI 10.1084/jem.20131800; Chu DK, 2013, J ALLERGY CLIN IMMUN, V131, P187, DOI 10.1016/j.jaci.2012.08.002; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1999, J IMMUNOL, V162, P6178; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Collison A, 2013, NAT MED, V19, P232, DOI 10.1038/nm.3049; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, J CLIN INVEST, V95, P1735, DOI 10.1172/JCI117850; COYLE AJ, 1994, J CLIN INVEST, V94, P2301, DOI 10.1172/JCI117594; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Djukanovic R, 2014, AM J RESP CRIT CARE, V190, P145, DOI 10.1164/rccm.201312-2235OC; Doherty TA, 2013, J ALLERGY CLIN IMMUN, V132, P205, DOI 10.1016/j.jaci.2013.03.048; Doherty TA, 2012, AM J PHYSIOL-LUNG C, V303, pL577, DOI 10.1152/ajplung.00174.2012; Doherty TA, 2009, AM J PHYSIOL-LUNG C, V296, pL229, DOI 10.1152/ajplung.90543.2008; Dougherty RH, 2010, J ALLERGY CLIN IMMUN, V125, P1046, DOI 10.1016/j.jaci.2010.03.003; Durrani SR, 2012, J ALLERGY CLIN IMMUN, V130, P489, DOI 10.1016/j.jaci.2012.05.023; Dworski R, 2011, J ALLERGY CLIN IMMUN, V127, P1260, DOI 10.1016/j.jaci.2010.12.1103; Edwards MR, 2013, MUCOSAL IMMUNOL, V6, P797, DOI 10.1038/mi.2012.118; Elyaman W, 2012, IMMUNITY, V36, P623, DOI 10.1016/j.immuni.2012.01.020; Erpenbeck VJ, 2003, J ALLERGY CLIN IMMUN, V111, P1319, DOI 10.1067/mai.2003.1485; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fattouh R, 2011, AM J RESP CRIT CARE, V183, P179, DOI 10.1164/rccm.200905-0736OC; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Ford JG, 2001, J IMMUNOL, V167, P1769; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gauvreau GM, 2014, NEW ENGL J MED, V370, P2102, DOI 10.1056/NEJMoa1402895; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gold MJ, 2014, J ALLERGY CLIN IMMUN, V133, P1142, DOI 10.1016/j.jaci.2014.02.033; Gorski SA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003615; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Halim TYF, 2014, IMMUNITY, V40, P425, DOI 10.1016/j.immuni.2014.01.011; Halim TYF, 2012, IMMUNITY, V37, P463, DOI 10.1016/j.immuni.2012.06.012; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Heger K, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001762; Herre J, 2013, J IMMUNOL, V191, P1529, DOI 10.4049/jimmunol.1300284; Hessel EM, 1997, AM J RESP CELL MOL, V16, P325; Holgate S, 2009, ALLERGY, V64, P1728, DOI 10.1111/j.1398-9995.2009.02201.x; Hong JY, 2014, J ALLERGY CLIN IMMUN, V134, P429, DOI 10.1016/j.jaci.2014.04.020; Huang MT, 2009, J IMMUNOL, V183, P4745, DOI 10.4049/jimmunol.0804371; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Irvin C, 2014, J ALLERGY CLIN IMMUN, V134, P1175, DOI 10.1016/j.jaci.2014.05.038; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Joller N, 2014, IMMUNITY, V40, P569, DOI 10.1016/j.immuni.2014.02.012; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Juncadella IJ, 2013, NATURE, V493, P547, DOI 10.1038/nature11714; Kabata H, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3675; Kaiko GE, 2013, J ALLERGY CLIN IMMUN, V131, P1331, DOI 10.1016/j.jaci.2013.02.041; Kang ZZ, 2012, IMMUNITY, V36, P821, DOI 10.1016/j.immuni.2012.03.021; Kearley J, 2011, AM J RESP CRIT CARE, V183, P865, DOI 10.1164/rccm.200909-1462OC; Kennedy JL, 2014, AM J RESP CRIT CARE, V189, P532, DOI 10.1164/rccm.201310-1767OC; Kerzerho J, 2013, J ALLERGY CLIN IMMUN, V131, P1048, DOI 10.1016/j.jaci.2012.09.027; Khan SH, 2010, J ALLERGY CLIN IMMUN, V125, P265, DOI 10.1016/j.jaci.2009.09.038; Khare A, 2013, J IMMUNOL, V191, P25, DOI 10.4049/jimmunol.1300193; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Krug N, 1996, AM J RESP CELL MOL, V14, P319; Kudo M, 2012, NAT MED, V18, P547, DOI 10.1038/nm.2684; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Lambrecht BN, 2012, ANNU REV IMMUNOL, V30, P243, DOI 10.1146/annurev-immunol-020711-075021; Laviolette M, 2013, J ALLERGY CLIN IMMUN, V132, P1086, DOI 10.1016/j.jaci.2013.05.020; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Liao W, 2014, P NATL ACAD SCI USA, V111, P3508, DOI 10.1073/pnas.1301138111; Mamessier E, 2008, ALLERGY, V63, P1202, DOI 10.1111/j.1398-9995.2008.01687.x; Manni ML, 2014, MUCOSAL IMMUNOL, V7, P1186, DOI 10.1038/mi.2014.8; Mathur SK, 2013, ANN ALLERG ASTHMA IM, V111, P25, DOI 10.1016/j.anai.2013.05.010; Maurer D, 1996, J IMMUNOL, V157, P607; Maurer D, 1998, J IMMUNOL, V161, P2731; McKinley L, 2008, J IMMUNOL, V181, P4089; McSorley HJ, 2014, MUCOSAL IMMUNOL, V7, P1068, DOI 10.1038/mi.2013.123; Millien VO, 2013, SCIENCE, V341, P792, DOI 10.1126/science.1240342; Mjosberg J, 2012, IMMUNITY, V37, P649, DOI 10.1016/j.immuni.2012.08.015; Mjosberg JM, 2011, NAT IMMUNOL, V12, P1055, DOI 10.1038/ni.2104; Monticelli LA, 2011, NAT IMMUNOL, V12, P1045, DOI [10.1031/ni.2131, 10.1038/ni.2131]; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Motomura Y, 2014, IMMUNITY, V40, P758, DOI 10.1016/j.immuni.2014.04.013; Norimoto A, 2014, AM J RESP CELL MOL, V51, P201, DOI 10.1165/rcmb.2013-0522OC; Novak N, 2001, J IMMUNOL, V167, P797; O'Garra A, 2008, NAT IMMUNOL, V9, P588, DOI 10.1038/ni0608-588; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Oliphant CJ, 2014, IMMUNITY, V41, P283, DOI 10.1016/j.immuni.2014.06.016; Ortega HG, 2014, NEW ENGL J MED, V371, P1198, DOI 10.1056/NEJMoa1403290; Osborne LC, 2014, SCIENCE, V345, P578, DOI 10.1126/science.1256942; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Papi A, 2013, J ALLERGY CLIN IMMUN, V132, P1075, DOI 10.1016/j.jaci.2013.05.028; Parker JM, 2011, BMC PULM MED, V11, DOI 10.1186/1471-2466-11-14; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Platzer B, 2014, MUCOSAL IMMUNOL, DOI [10.1038/mi.2014.85, DOI 10.1038/MI.2014.85]; Porter PC, 2014, J ALLERGY CLIN IMMUN, V134, P325, DOI 10.1016/j.jaci.2014.04.028; Porter PC, 2011, INFECT IMMUN, V79, P4459, DOI 10.1128/IAI.05209-11; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallmann E, 2011, J IMMUNOL, V187, P164, DOI 10.4049/jimmunol.1003392; SCHMITT E, 1994, J IMMUNOL, V153, P3989; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Semmrich M, 2012, MUCOSAL IMMUNOL, V5, P150, DOI 10.1038/mi.2011.61; Shaw DE, 2007, CHEST, V132, P1871, DOI 10.1378/chest.07-1047; Simpson A, 2010, AM J RESP CRIT CARE, V181, P1200, DOI 10.1164/rccm.200907-1101OC; Smyth LJC, 2010, CHEST, V138, P905, DOI 10.1378/chest.09-3079; Song DJ, 2009, J IMMUNOL, V183, P5333, DOI 10.4049/jimmunol.0801421; Spann KM, 2014, THORAX, V69, P918, DOI 10.1136/thoraxjnl-2013-204908; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Staudt V, 2010, IMMUNITY, V33, P192, DOI 10.1016/j.immuni.2010.07.014; Sugimoto T, 2004, J EXP MED, V199, P535, DOI 10.1084/jem.20031368; Sutherland TE, 2014, NAT IMMUNOL, V15, P1116, DOI 10.1038/ni.3023; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Thornton EE, 2012, J EXP MED, V209, P1183, DOI 10.1084/jem.20112667; Turner JE, 2013, J EXP MED, V210, P2951, DOI 10.1084/jem.20130071; Tversky JR, 2008, CLIN EXP ALLERGY, V38, P781, DOI 10.1111/j.1365-2222.2008.02954.x; Ullah MA, 2014, J ALLERGY CLIN IMMUN, V134, P440, DOI 10.1016/j.jaci.2013.12.1035; Van Dyken SJ, 2014, IMMUNITY, V40, P414, DOI 10.1016/j.immuni.2014.02.003; van Rijt LS, 2011, AM J RESP CRIT CARE, V184, P303, DOI 10.1164/rccm.201101-0019OC; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2003, J IMMUNOL, V171, P3372; Wakahara K, 2013, ALLERGY, V68, P180, DOI 10.1111/all.12072; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Walker JA, 2013, NAT REV IMMUNOL, V13, P75, DOI 10.1038/nri3349; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weiss JM, 2012, J EXP MED, V209, P1723, DOI 10.1084/jem.20120914; Wenzel S, 2013, NEW ENGL J MED, V368, P2455, DOI 10.1056/NEJMoa1304048; Wenzel SE, 2012, NAT MED, V18, P716, DOI 10.1038/nm.2678; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Whitehead GS, 2012, J ALLERGY CLIN IMMUN, V129, P207, DOI 10.1016/j.jaci.2011.08.009; Wilhelm C, 2011, NAT IMMUNOL, V12, P1071, DOI 10.1038/ni.2133; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams JW, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3990; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wolterink RGJK, 2012, EUR J IMMUNOL, V42, P1106, DOI 10.1002/eji.201142018; Woodruff PG, 2007, P NATL ACAD SCI USA, V104, P15858, DOI 10.1073/pnas.0707413104; Woodruff PG, 2009, AM J RESP CRIT CARE, V180, P388, DOI 10.1164/rccm.200903-0392OC; Wu W, 2014, J ALLERGY CLIN IMMUN, V133, P1280, DOI 10.1016/j.jaci.2013.11.042; Xiao X, 2012, NAT IMMUNOL, V13, P981, DOI 10.1038/ni.2390; Xue LZ, 2014, J ALLERGY CLIN IMMUN, V133, P1184, DOI 10.1016/j.jaci.2013.10.056; Yang XXO, 2013, NAT IMMUNOL, V14, P732, DOI 10.1038/ni.2633; Yao WG, 2013, IMMUNITY, V38, P360, DOI 10.1016/j.immuni.2013.01.007; Yasuda K, 2012, P NATL ACAD SCI USA, V109, P3451, DOI 10.1073/pnas.1201042109; Yousefi S, 2012, CURR OPIN IMMUNOL, V24, P736, DOI 10.1016/j.coi.2012.08.010; Yu M, 2011, J CLIN INVEST, V121, P3133, DOI 10.1172/JCI43598; Zaiss DM, 2006, SCIENCE, V314, P1746, DOI 10.1126/science.1133715; Zhao J, 2012, MUCOSAL IMMUNOL, V6, P335; Zhu J, 2014, CHEST, V145, P1219, DOI 10.1378/chest.13-1567	185	160	166	32	129	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1529-2908	1529-2916		NAT IMMUNOL	Nat. Immunol.	JAN	2015	16	1					45	56		10.1038/ni.3049		12	Immunology	Immunology	AW8ET	WOS:000346494200008	25521684	
J	Karner, AA; Eisinger, DS; Niemeier, DA				Karner, Alex A.; Eisinger, Douglas S.; Niemeier, Deb A.			Near-Roadway Air Quality: Synthesizing the Findings from Real-World Data	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Review							CHILDRENS RESPIRATORY HEALTH; AIRBORNE PARTICULATE MATTER; SCALE SPATIAL VARIABILITY; ULTRAFINE PARTICLES; SIZE DISTRIBUTION; NITROGEN-DIOXIDE; CHILDHOOD ASTHMA; MAJOR HIGHWAY; TRAFFIC DENSITY; LOS-ANGELES	Despite increasing regulatory attention and literature linking roadside air pollution to health outcomes, studies on near roadway air quality have not yet been well synthesized. We employ data collected from 1978 as reported in 41 roadside monitoring studies, encompassing more than 700 air pollutant concentration measurements, published as of June 2008. Two types of normalization, background and edge-of-road, were applied to the observed concentrations. Local regression models were specified to the concentration-distance relationship and analysis of variance was used to determine the statistical significance of trends. Using an edge-of-road normalization, almost all pollutants decay to background by 115-570 m from the edge of road; using the more standard background normalization, almost all pollutants decay to background by 160-570 m from the edge of road. Differences between the normalization methods arose due to the likely bias inherent in background normalization, since some reported background values tend to underpredict (be lower than) actual background. Changes in pollutant concentrations with increasing distance from the road fell into one of three groups: at least a 50% decrease in peak/edge-of-road concentration by 150 m, followed by consistent but gradual decay toward background (e.g., carbon monoxide, some uttrafine particulate matter number concentrations); consistent decay or change over the entire distance range (e.g., benzene, nitrogen dioxide); or no trend with distance (e.g., particulate matter mass concentrations).	[Karner, Alex A.; Eisinger, Douglas S.; Niemeier, Deb A.] Univ Calif Davis, Dept Civil & Environm Engn, UC Davis Caltrans Air Qual Project, Davis, CA 95616 USA	Niemeier, DA (reprint author), Univ Calif Davis, Dept Civil & Environm Engn, UC Davis Caltrans Air Qual Project, 1 Shields Ave, Davis, CA 95616 USA.	dniemeier@ucdavis.edu			UC Davis-Caltrans Air Quality Project; Caltrans Division of Research and Innovation	Support for this research was partially provided by the UC Davis-Caltrans Air Quality Project (http://AQP.engr.ucdavis.edu/) and the Caltrans Division of Research and Innovation. Dr. Song Bai provided valuable statistical assistance.	Ashbaugh L., 1996, TRAFFIC GENERATED PM; Baldauf R, 2008, ATMOS ENVIRON, V42, P7502, DOI 10.1016/j.atmosenv.2008.05.051; Barzyk TM, 2009, ATMOS ENVIRON, V43, P787, DOI 10.1016/j.atmosenv.2008.11.002; Beckerman B, 2008, ATMOS ENVIRON, V42, P275, DOI 10.1016/j.atmosenv.2007.09.042; Brugge D, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-23; Buonanno G, 2009, ATMOS ENVIRON, V43, P1100, DOI 10.1016/j.atmosenv.2008.11.011; CAHILL T, 1994, EMISSIONS CALIFORNIA; CARB, 2005, AIR QUAL LAND US HDB; CLEMENTS A, 2008, AIR WASTE MANAGEMENT; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; Donaldson K, 2001, OCCUP ENVIRON MED, V58, P211, DOI 10.1136/oem.58.3.211; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; *FED HIGHW ADM FHW, FED HIGHW ADM FHWA M; FINLAYSONPITTS BJ, 1997, SCIENCE, V276, P1095; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gidhagen L, 2004, ENVIRON SCI TECHNOL, V38, P6730, DOI 10.1021/es0498134; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Gramotnev G, 2004, ATMOS ENVIRON, V38, P1767, DOI 10.1016/j.atmosenv.2003.12.028; Green RS, 2009, ENVIRON HEALTH PERSP, V117, P1939, DOI 10.1289/ehp.0900943; Hagler GSW, 2009, ATMOS ENVIRON, V43, P1229, DOI 10.1016/j.atmosenv.2008.11.024; HAGLER GSW, 2008, AIR WASTE MANAGEMENT; Harrison RM, 2003, ATMOS ENVIRON, V37, P2391, DOI 10.1016/S1352-2310(03)00122-5; Hitchins J, 2000, ATMOS ENVIRON, V34, P51, DOI 10.1016/S1352-2310(99)00304-0; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; Hu SS, 2009, ATMOS ENVIRON, V43, P2541, DOI 10.1016/j.atmosenv.2009.02.033; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Janssen NAH, 1997, ATMOS ENVIRON, V31, P1185, DOI 10.1016/S1352-2310(96)00291-9; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kuhn T, 2005, AEROSOL SCI TECH, V39, P347, DOI 10.1080/027868290930024; KUHN T, 2005, ATMOS ENVIRON, V39, P7159; Lena TS, 2002, ENVIRON HEALTH PERSP, V110, P1009; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Molnar P, 2002, ATMOS ENVIRON, V36, P4115, DOI 10.1016/S1352-2310(02)00183-8; Monn C, 1997, ATMOS ENVIRON, V31, P2243, DOI 10.1016/S1352-2310(97)00030-7; MYERS LL, 1991, RES DESIGN STAT ANAL; Nanzetta MK, 2004, J AIR WASTE MANAGE, V54, P540; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; Ntziachristos L, 2007, ENVIRON SCI TECHNOL, V41, P2223, DOI 10.1021/es062590s; O'Donoghue RT, 2007, TRANSPORT RES D-TR E, V12, P589, DOI 10.1016/j.trd.2007.07.003; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175; Pedersen CB, 2004, ATMOS ENVIRON, V38, P3733, DOI 10.1016/j.atmosenv.2004.04.011; PETERS A, 2004, NEW ENGL J MED, V351, P1861; Pirjola L, 2004, ATMOS ENVIRON, V38, P3625, DOI 10.1016/j.atmosenv.2004.03.047; Pleijel H, 2004, SCI TOTAL ENVIRON, V332, P261, DOI 10.1016/j.scitotenv.2004.03.020; R Development Core Team, 2008, R LANG ENV STAT COMP; Reponen T, 2003, J ENVIRON MONITOR, V5, P557, DOI 10.1039/b303557c; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; RODES CE, 1981, ATMOS ENVIRON, V15, P243, DOI 10.1016/0004-6981(81)90024-X; Roemer WH, 2001, ENVIRON HEALTH PERSP, V109, P151, DOI 10.2307/3434768; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Sabin LD, 2006, ATMOS ENVIRON, V40, P7528, DOI 10.1016/j.atmosenv.2006.07.004; Sarkar D, 2008, USE R, P1; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360; Sexton K, 1988, AIR POLLUTION AUTOMO, P207; Shi JP, 1999, SCI TOTAL ENVIRON, V235, P51, DOI 10.1016/S0048-9697(99)00189-8; Singer BC, 2004, ATMOS ENVIRON, V38, P393, DOI 10.1016/j.atmosenv.2003.10.005; Smargiassi A, 2005, SCI TOTAL ENVIRON, V338, P243, DOI 10.1016/j.scitotenv.2004.07.013; Tiitta P, 2002, ATMOS ENVIRON, V36, P4057, DOI 10.1016/S1352-2310(02)00309-6; Vardoulakis S, 2005, ATMOS ENVIRON, V39, P2725, DOI 10.1016/j.atmosenv.2004.05.067; Weijers EP, 2004, ATMOS ENVIRON, V38, P2993, DOI 10.1016/j.atmosenv.2004.02.045; WJST M, 1993, BRIT MED J, V307, P596; Wu Y, 2003, SCI TOTAL ENVIRON, V317, P159, DOI 10.1016/S0048-9697(03)00331-0; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Zhang KM, 2004, ATMOS ENVIRON, V38, P6655, DOI 10.1016/j.atmosenv.2004.06.044; Zhou Y, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-89; ZHU Y, 2002, AMOS ENV, V36, P9323; ZHU Y, 2008, AIR WASTE MANAGEMENT; Zhu YF, 2006, ENVIRON SCI TECHNOL, V40, P2531, DOI 10.1021/es0516514; Zhu YF, 2004, AEROSOL SCI TECH, V38, P5, DOI 10.1080/02786820390229156; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18; 2001, FED REG, V66, P17230	74	160	162	11	105	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X			ENVIRON SCI TECHNOL	Environ. Sci. Technol.	JUL 15	2010	44	14					5334	5344		10.1021/es100008x		11	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	623NF	WOS:000279747100008	20560612	
J	Fox, AT; Sasieni, P; du Toit, G; Syed, H; Lack, G				Fox, Adam T.; Sasieni, Peter; du Toit, George; Syed, Huma; Lack, Gideon			Household peanut consumption as a risk factor for the development of peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; children; food allergy; peanut allergy; sensitization; peanut consumption; cutaneous exposure; environmental exposure	FOOD CHALLENGES; NUT ALLERGY; FOLLOW-UP; CHILDREN; EXPOSURE; ANTIGEN; IGE; AVOIDANCE; CHILDHOOD; FEATURES	Background: Most children with peanut allergy (PA) react on first known oral exposure to peanut. Recent data suggest cutaneous exposure as a route of sensitization. Objectives: This study aimed to establish the relevant route of peanut exposure in the development of allergy. Methods: Questionnaires were administered to children with PA and to high-risk controls (with egg allergy) and controls without allergy. Questionnaires were completed before subjects were aware of their PA status, avoiding recall bias. Questionnaires recorded maternal peanut consumption during pregnancy, breast-feeding, and the first year of life. Peanut consumption was determined among all household members, allowing quantification of environmental household exposure (household peanut). Results: Median weekly household peanut in the 133 PA cases was significantly elevated (18.8 g) compared with 150 controls without allergy (6.9 g) and 160 high-risk controls (1.9 g). There were no differences in infant peanut consumption between groups. Differences in maternal peanut consumption during pregnancy (and lactation) were significant but become nonsignificant after adjusting for household peanut. A dose-response relationship was observed between environmental (nonoral) peanut exposure and the development of PA, which was strongest for peanut butter. Early oral exposure to peanut in infants with high environmental peanut exposure may have had a protective effect against the development of PA. Conclusions: High levels of environmental exposure to peanut during infancy appear to promote sensitization, whereas low levels may be protective in atopic children. No effect of maternal peanut consumption during pregnancy or lactation is observed, supporting the hypothesis that peanut sensitization occurs as a result of environmental exposure. (J Allergy Clin Immunol 2009;123:417-23.)	[Fox, Adam T.; du Toit, George; Lack, Gideon] Kings Coll London, MRC, London, England; [Sasieni, Peter; Syed, Huma] Queen Mary Univ London, Wolfson Inst Prevent Med, Barts & London Sch Med, London, England	Lack, G (reprint author), St Thomas Hosp, Dept Pediat Allergy, Lambeth Palace Rd, London SE1 7EH, England.	gideon.lack@kel.ac.uk	Osborne, Nicholas/N-4915-2015; Fox, Adam/O-3547-2015	Osborne, Nicholas/0000-0002-6700-2284; Fox, Adam/0000-0002-3533-9798	Food Standards Agency [T07043]; Aimwell Foundation	Supported by it research grant from the Food Standards Agency (United Kingdom; T07043). This grant supported the project costs, including the salary of A.T.F. over the study duration. G.L.'s salary was supported in part by the Aimwell Foundation.	Baker SS, 2000, PEDIATRICS, V106, P346; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Committee on Toxicity of Chemicals in Food Consumer Products and the Environment, 1998, PEAN ALL; DUTOIT G, 2008, J ALLERGY CLIN IMMUN, V122, P986; Ewan PW, 1996, BRIT MED J, V312, P1074; Fox A. T., 2006, SAJCN - South African Journal of Clinical Nutrition, V19, P154; Frank L, 1999, PEDIATR ALLERGY IMMU, V10, P27, DOI 10.1034/j.1399-3038.1999.101010.x; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Hsieh KY, 2003, CLIN EXP ALLERGY, V33, P1067, DOI 10.1046/j.1365-2222.2003.01724.x; HUSBY S, 1994, J IMMUNOL, V152, P4663; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Maloney JM, 2006, J ALLERGY CLIN IMMUN, V118, P719, DOI 10.1016/j.jaci.2006.05.017; NGAN J, 1978, J IMMUNOL, V120, P861; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; SALOGA J, 1994, AM J RESP CRIT CARE, V149, P65; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Strid J, 2004, EUR J IMMUNOL, V34, P2100, DOI 10.1002/eji.200324843; Vadas P, 2001, JAMA-J AM MED ASSOC, V285, P1746, DOI 10.1001/jama.285.13.1746; Venter C, 2006, J HUM NUTR DIET, V19, P129, DOI 10.1111/j.1365-277X.2006.00677.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	30	160	163	0	20	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2009	123	2					417	423		10.1016/j.jaci.2008.12.014		7	Allergy; Immunology	Allergy; Immunology	409GU	WOS:000263495000020	19203660	
J	Weidinger, S; Gieger, C; Rodriguez, E; Baurecht, H; Mempel, M; Klopp, N; Gohlke, H; Wagenpfeil, S; Ollert, M; Ring, J; Behrendt, H; Heinrich, J; Novak, N; Bieber, T; Kraemer, U; Berdel, D; von Berg, A; Bauer, CP; Herbarth, O; Koletzko, S; Prokisch, H; Mehta, D; Meitinger, T; Depner, M; von Mutius, E; Liang, L; Moffatt, M; Cookson, W; Kabesch, M; Wichmann, HE; Illig, T				Weidinger, Stephan; Gieger, Christian; Rodriguez, Elke; Baurecht, Hansjoerg; Mempel, Martin; Klopp, Norman; Gohlke, Henning; Wagenpfeil, Stefan; Ollert, Markus; Ring, Johannes; Behrendt, Heidrun; Heinrich, Joachim; Novak, Natalija; Bieber, Thomas; Kraemer, Ursula; Berdel, Dietrich; von Berg, Andrea; Bauer, Carl Peter; Herbarth, Olf; Koletzko, Sibylle; Prokisch, Holger; Mehta, Divya; Meitinger, Thomas; Depner, Martin; von Mutius, Erika; Liang, Liming; Moffatt, Miriam; Cookson, William; Kabesch, Michael; Wichmann, H. -Erich; Illig, Thomas			Genome-Wide Scan on Total Serum IgE Levels Identifies FCER1A as Novel Susceptibility Locus	PLOS GENETICS			English	Article							IMMUNOGLOBULIN-E CONCENTRATIONS; TH2 CYTOKINE LOCUS; EPSILON-RI-BETA; CONTROL REGION; JAPANESE POPULATION; ATOPIC-DERMATITIS; ASTHMA; ASSOCIATION; GENE; DISEASE	High levels of serum IgE are considered markers of parasite and helminth exposure. In addition, they are associated with allergic disorders, play a key role in anti-tumoral defence, and are crucial mediators of autoimmune diseases. Total IgE is a strongly heritable trait. In a genome-wide association study (GWAS), we tested 353,569 SNPs for association with serum IgE levels in 1,530 individuals from the population-based KORA S3/F3 study. Replication was performed in four independent population-based study samples (total n = 9,769 individuals). Functional variants in the gene encoding the alpha chain of the high affinity receptor for IgE (FCER1A) on chromosome 1q23 (rs2251746 and rs2427837) were strongly associated with total IgE levels in all cohorts with P values of 1.85 x 10(-20) and 7.08 x 10(-19) in a combined analysis, and in a post-hoc analysis showed additional associations with allergic sensitization (P = 7.78 x 10(-4) and P = 1.95 x 10(-3)). The "top'' SNP significantly influenced the cell surface expression of FCER1A on basophils, and genome-wide expression profiles indicated an interesting novel regulatory mechanism of FCER1A expression via GATA-2. Polymorphisms within the RAD50 gene on chromosome 5q31 were consistently associated with IgE levels (P values 6.28 x 10(-7) -4.46 x 10(-8)) and increased the risk for atopic eczema and asthma. Furthermore, STAT6 was confirmed as susceptibility locus modulating IgE levels. In this first GWAS on total IgE FCER1A was identified and replicated as new susceptibility locus at which common genetic variation influences serum IgE levels. In addition, variants within the RAD50 gene might represent additional factors within cytokine gene cluster on chromosome 5q31, emphasizing the need for further investigations in this intriguing region. Our data furthermore confirm association of STAT6 variation with serum IgE levels.	[Weidinger, Stephan; Mempel, Martin; Ollert, Markus; Ring, Johannes] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany; [Weidinger, Stephan; Rodriguez, Elke; Baurecht, Hansjoerg; Mempel, Martin] Helmholtz Zentrum Munchen, Div Environm Dermatol & Allergy, Neuherberg, Germany; [Weidinger, Stephan; Rodriguez, Elke; Baurecht, Hansjoerg; Mempel, Martin] Tech Univ Munich, ZAUM Ctr Allergy & Environm, Munich, Germany; [Gieger, Christian; Klopp, Norman; Gohlke, Henning; Heinrich, Joachim; Wichmann, H. -Erich] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Epidemiol, Neuherberg, Germany; [Gieger, Christian; Wichmann, H. -Erich] Univ Munich, Inst Med Informat Biometry & Epidemiol, Munich, Germany; [Baurecht, Hansjoerg; Wagenpfeil, Stefan] Tech Univ Munich, Inst Med Stat & Epidemiol, Munich, Germany; [Wagenpfeil, Stefan] Tech Univ Munich, GSISH, Munich, Germany; [Novak, Natalija; Bieber, Thomas] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Kraemer, Ursula] Univ Dusseldorf, IUF, Dusseldorf, Germany; [Berdel, Dietrich; von Berg, Andrea] Marien Hosp, Wesel, Germany; [Bauer, Carl Peter] Tech Univ Munich, Dept Pediat, Munich, Germany; [Herbarth, Olf] UFZ Helmholtz Ctr Environm Res, Dept Human Exposure Res & Epidemiol, Leipzig, Germany; [Koletzko, Sibylle] Univ Munich, Univ Childrens Hosp, Munich, Germany; [Prokisch, Holger; Mehta, Divya; Meitinger, Thomas] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Inst Human Genet, Neuherberg, Germany; [Prokisch, Holger; Mehta, Divya; Meitinger, Thomas] Tech Univ Munich, Klinikum Rechts Isar, Inst Human Genet, D-8000 Munich, Germany; [Liang, Liming] Univ Michigan, Sch Publ Hlth, Dept Biostat, Ctr Stat Genet, Ann Arbor, MI 48109 USA; [Moffatt, Miriam; Cookson, William] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Weidinger, S (reprint author), Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany.	weidinger@lrz.tum.de	Rodriguez, Elke/C-4259-2013; Prokisch, Holger/N-8964-2013; Meitinger, Thomas/O-1318-2015; Weidinger, Stephan/C-8461-2011; Baurecht, Hansjoerg/C-4035-2013	Mehta, Divya/0000-0001-7971-7255; Gieger, Christian/0000-0001-6986-9554; von Mutius, Erika/0000-0002-8893-4515; Meitinger, Thomas/0000-0002-8838-8403; 	German Ministry of Education and Research (BMBF); National Genome Research Network (NGFN); Wellcome Trust; European Commission; Genetic Epidemiological Modelling Center Munich (GEM Munich); Helmholtz Zentrum Munchen; German Research Center for Environmental Health, Neuherberg, Germany; German Federal Ministry of Education and Research (BMBF); Munich Center of Health Sciences (MC Health); BMU (for IUF) [FKZ 20462296]; Federal Ministry for Education, Science, Research, and Technology [01 EG 9705/2, 01EG9732, 01 EE 9401-4]; Stiftung Kindergesundheit (Child Health Foundation); University Hospital Rechts der Isar [KKF-07/04]; Technische Universitat Munchen [KKF-27/05]; Wilhelm-Vaillant-Stiftung	The study was funded by the German Ministry of Education and Research (BMBF) as part of the National Genome Research Network (NGFN), the Wellcome Trust, the German Ministry of Education and Research (BMBF), and the European Commission as part of GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community). Furthermore the study was supported by the Genetic Epidemiological Modelling Center Munich (GEM Munich). The MONICA/KORA Augsburg studies were financed by the Helmholtz Zentrum Munchen, German Research Center for Environmental Health, Neuherberg, Germany and supported by grants from the German Federal Ministry of Education and Research (BMBF). The research was supported within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. The GINI/LISA studies were funded by grants of the BMU (for IUF, FKZ 20462296), and Federal Ministry for Education, Science, Research, and Technology (No. 01 EG 9705/2 and 01EG9732; No. 01 EE 9401-4) and additional financial support from the Stiftung Kindergesundheit (Child Health Foundation). S. Weidinger and S. Wagenpfeil are supported by research grants KKF-07/04 and KKF-27/05 of the University Hospital Rechts der Isar, Technische Universitat Munchen. The first author in addition is supported by a grant from the Wilhelm-Vaillant-Stiftung.	BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; Cooper PJ, 2008, ALLERGY, V63, P409, DOI 10.1111/j.1398-9995.2007.01601.x; Dimson OG, 2003, J INVEST DERMATOL, V120, P784, DOI 10.1046/j.1523-1747.2003.12146.x; DIZIER MH, 1995, GENET EPIDEMIOL, V12, P93, DOI 10.1002/gepi.1370120109; Fields PE, 2004, IMMUNITY, V21, P865, DOI 10.1016/j.immuni.2004.10.015; Gould HJ, 2008, NAT REV IMMUNOL, V8, P205, DOI 10.1038/nri2273; Gould HJ, 1999, EUR J IMMUNOL, V29, P3527, DOI 10.1002/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5; Hasegawa M, 2003, J IMMUNOL, V171, P1927; Hizawa N, 2001, J ALLERGY CLIN IMMUN, V108, P74, DOI 10.1067/mai.2001.116119; Hizawa N, 2000, AM J RESP CRIT CARE, V161, P906; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Jacobsen HP, 2001, J ALLERGY CLIN IMMUN, V107, P659; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; LEBOWITZ MD, 1984, J ALLERGY CLIN IMMUN, V73, P259, DOI 10.1016/S0091-6749(84)80017-2; Lee DU, 2004, P NATL ACAD SCI USA, V101, P16010, DOI 10.1073/pnas.0407031101; Lee GR, 2005, NAT IMMUNOL, V6, P42, DOI 10.1038/ni1148; Lee GR, 2003, IMMUNITY, V19, P145, DOI 10.1016/S1074-7613(03)00179-1; Limb SL, 2005, J ALLERGY CLIN IMMUN, V115, P61, DOI 10.1016/j.jaci.2004.09.032; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Moffatt MF, 1997, AM J RESP CRIT CARE, V156, pS110; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Palmer LJ, 1999, CLIN EXP ALLERGY, V29, P1555; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836; Schedel M, 2004, J ALLERGY CLIN IMMUN, V114, P1100, DOI 10.1016/j.jaci.2004.07.048; Shikanai T, 2002, J APPL PHYSIOL, V93, P37, DOI 10.1152/japplphysiol.00993.2001; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Traherne JA, 2003, HUM MOL GENET, V12, P2577, DOI 10.1093/hmg/ddg290; Ulbrecht M, 1997, J ALLERGY CLIN IMMUN, V99, P828, DOI 10.1016/S0091-6749(97)80018-8; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; von Berg A, 2007, J ALLERGY CLIN IMMUN, V119, P718, DOI 10.1016/j.jaci.2006.11.017; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521	41	160	169	1	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1553-7404			PLOS GENET	PLoS Genet.	AUG	2008	4	8							e1000166	10.1371/journal.pgen.1000166		9	Genetics & Heredity	Genetics & Heredity	365MN	WOS:000260410800016	18846228	
J	Kielhorn, J; Melber, C; Keller, D; Mangelsdorf, I				Kielhorn, J; Melber, C; Keller, D; Mangelsdorf, I			Palladium - A review of exposure and effects to human health	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Review						palladium; exposure; health effects; dental alloys; sensitization; nickel; allergy; auto catalytic converters; catalysts; lewellery	PLATINUM-GROUP ELEMENTS; DENTAL-CASTING ALLOYS; CELL-CULTURE MEDIUM; CONTACT-DERMATITIS; CROSS-REACTIVITY; IN-VITRO; ALLERGY DIAGNOSIS; METAL-COMPOUNDS; NICKEL SULFATE; EXHAUST FUMES	Palladium is a metal the output and use of which has more than doubled in the past ten years. It is used in dental appliances, chemical catalysts, electrical appliances and jewellery, but the greatest increase in I'd demand has been in automotive emission control catalysts. Studies on I'd concentrations in ancient ice and recent snow samples reflect the increase in mining, smelting and use of palladium in the last decades. Increases of palladium in the environment have been shown in air and dust samples. There is no data as yet available to assess the effect of this exposure. A major source of health concern is the sensitization risk of Pd as very low doses are sufficient to cause allergic reactions in susceptible individuals. Persons with known nickel allergy may be especially susceptible. Workers occupationally exposed to Pd include miners, dental technicians and chemical workers. The latter are exposed mainly to I'd salts several of which may cause primary skin and eye irritations. It. is advised that persons with known Pd allergy should not work with I'd compounds. The general population may come into contact with palladium mainly through mucosal contact with dental restorations and jewellery containing palladium and possibly via emissions from Pd catalysts. Protection of the public from related adverse effects may be achieved by the use of alloys with high corrosion stability and thus minimal release of palladium. In general, in dental patients who are sensitive to Pd, restorations using Pd-containing materials should not be used although I'd has been used without allergic effects in some of these individuals. Further, those patients who have an allergy to nickel should be informed that use of Pd-containing dental materials may cause I'd allergy, though this risk appears to be low.	Fraunhofer Inst Toxicol& Aerosol Res Drug Res & C, D-30625 Hannover, Germany; Beiersdorf AG, Hamburg, Germany	Fraunhofer Inst Toxicol& Aerosol Res Drug Res & C, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	kielhorn@ita.fhg.de					ABBASI SA, 1987, ANAL LETT, V20, P1013; ABERER W, 1993, CONTACT DERMATITIS, V28, P163, DOI 10.1111/j.1600-0536.1993.tb03379.x; Adachi Atsuko, 1997, Journal of Dermatology (Tokyo), V24, P12; Akiya Osamu, 1996, Bulletin of Tokyo Dental College, V37, P35; Augthun M, 1991, Dtsch Zahnarztl Z, V46, P519; Augthun M, 1990, Dtsch Zahnarztl Z, V45, P480; Barbante C, 2001, ENVIRON SCI TECHNOL, V35, P835, DOI 10.1021/es000146y; Begerow J, 1997, ANAL CHIM ACTA, V340, P277, DOI 10.1016/S0003-2670(96)00486-2; Begerow J, 1997, FRESEN J ANAL CHEM, V359, P427, DOI 10.1007/s002160050603; Begerow J, 1999, BIOMARKERS, V4, P27, DOI 10.1080/135475099230976; Begerow J, 1999, ZBL HYG UMWELTMED, V202, P411; Begerow J., 1998, UMWELTMEDIZIN FORSCH, V3, P257; BIAGINI RE, 1985, J ALLERGY CLIN IMMUN, V76, P794, DOI 10.1016/0091-6749(85)90750-X; BOMAN A, 1990, Contact Dermatitis, V23, P256, DOI 10.1111/j.1600-0536.1990.tb05056.x; Bunger J, 1996, INT ARCH OCC ENV HEA, V69, P33; CASTELAIN PY, 1987, CONTACT DERMATITIS, V16, P46, DOI 10.1111/j.1600-0536.1987.tb02624.x; CHOUDAT D, 1994, TUBERCLE LUNG DIS, V75, P99, DOI 10.1016/0962-8479(94)90037-X; Daenen M, 1999, EUR RESPIR J, V13, P213, DOI 10.1034/j.1399-3003.1999.13a39.x; DAUNDERER M, 1993, ECOMED, P1; DISSANAYAKE CB, 1984, INT J ENVIRON STUD, V22, P109, DOI 10.1080/00207238408710108; DOWNEY D, 1989, CONTACT DERMATITIS, V21, P54, DOI 10.1111/j.1600-0536.1989.tb04688.x; DRAPAL S, 1993, J DENT RES, V72, P587, DOI 10.1177/00220345930720030601; Fernandez-Redondo V, 1998, CONTACT DERMATITIS, V38, P178, DOI 10.1111/j.1600-0536.1998.tb05696.x; Flint GN, 1998, CONTACT DERMATITIS, V39, P213, DOI 10.1111/j.1600-0536.1998.tb05912.x; FUCHS WA, 1974, ECON GEOL, V69, P332; FUHRMANN R, 1992, THESIS PHILIPPS U MA; Fujita S., 1971, SHIKA IGAKU, V34, P918; GAILHOFER G, 1990, ALLERGOLOGIE, V13, P250; Gebel T, 1997, MUTAT RES-GEN TOX EN, V389, P183, DOI 10.1016/S1383-5718(96)00145-3; GERTLER AW, 1994, ISRAEL J CHEM, V34, P425; Gregurek D, 1999, ATMOS ENVIRON, V33, P3281, DOI 10.1016/S1352-2310(98)00434-8; HACKEL H, 1991, Contact Dermatitis, V24, P131, DOI 10.1111/j.1600-0536.1991.tb01665.x; Hansen P A, 1997, J Prosthodont, V6, P144, DOI 10.1111/j.1532-849X.1997.tb00080.x; Hay IC, 1998, CONTACT DERMATITIS, V38, P216, DOI 10.1111/j.1600-0536.1998.tb05713.x; Helmers E, 1998, ENVIRON SCI POLLUT R, V5, P44, DOI 10.1007/BF02986373; HODGE VF, 1986, ENVIRON SCI TECHNOL, V20, P1058, DOI 10.1021/es00152a018; HOLBROOK D J JR, 1975, Environmental Health Perspectives, V10, P95, DOI 10.2307/3428413; HOLBROOK DJ, 1976, J TOXICOL ENV HEALTH, V1, P1067; Jappe U, 1999, CONTACT DERMATITIS, V40, P111, DOI 10.1111/j.1600-0536.1999.tb06003.x; Jarvis KE, 2001, ENVIRON SCI TECHNOL, V35, P1031, DOI 10.1021/es0001512; JOHNSON D, 1976, EPA600176019 SW RES, P1; Kanerva L, 1996, CONTACT DERMATITIS, V34, P39, DOI 10.1111/j.1600-0536.1996.tb02110.x; Katoh N, 1999, CONTACT DERMATITIS, V40, P226, DOI 10.1111/j.1600-0536.1999.tb06051.x; Kobayashi H, 1989, Shikwa Gakuho, V89, P1679; Koch P, 1996, CONTACT DERMATITIS, V34, P253; KOCH P, 1995, CONTACT DERMATITIS, V33, P323, DOI 10.1111/j.1600-0536.1995.tb02046.x; Koch P, 1999, J AM ACAD DERMATOL, V41, P422, DOI 10.1016/S0190-9622(99)70116-7; KOLPAKOV VI, 1980, GIGIENA TRUDA PROFES, V4, P52; KOTHNY EL, 1979, PLANT SOIL, V53, P547, DOI 10.1007/BF02140726; KRANKE B, 1995, WIEN KLIN WOCHENSCHR, V107, P323; KRATZENSTEIN B, 1988, DEUT ZAHNAERZTL Z, V43, P419; KRATZENSTEIN B, 1988, DEUT ZAHNAERZTL Z, V43, P343; Kulig J., 1995, ARCH DERMATOL RES, V287, P389; KUTTING B, 1994, HAUTARZT, V45, P176, DOI 10.1007/s001050050059; LEE DS, 1983, NATURE, V305, P47, DOI 10.1038/305047a0; LIDEN C, 1994, ACTA DERM-VENEREOL, V74, P341; LOTTERMOSER BG, 1995, AMBIO, V24, P354; Lu Z., 1994, P ANN M AIR WAST MAN, V7, P1; *MAFF FSIS, 1998, 1994 TOT DIET STUD 2; *MAFF UK, 1997, 1994 TOT DIET STUD M, P131; Marcusson JA, 1996, CONTACT DERMATITIS, V34, P320, DOI 10.1111/j.1600-0536.1996.tb02215.x; MARX H, 1987, ZAHNARZTLICHE MITT, V3, P211; MATTHEY J, 1997, TETRAAMMINE PALLADIU, P1; MAYER T, 1989, THESIS U HAUTKLINIK, P1, DOI 10.1017/CBO9780511522703.001; MENCK HR, 1976, J OCCUP ENVIRON MED, V18, P797, DOI 10.1097/00043764-197612000-00005; MERGET R, 1991, ASTHMA BRONCHIALE ME, P1; Mizoguchi S, 1998, DERMATOLOGY, V196, P268, DOI 10.1159/000017891; Moldovan M, 1999, J ANAL ATOM SPECTROM, V14, P1163, DOI 10.1039/a901516g; MOORE W, 1974, ENVIRON RES, V8, P234, DOI 10.1016/0013-9351(74)90055-3; MOORE W, 1975, Environmental Health Perspectives, V10, P63, DOI 10.2307/3428410; MUNROASHMAN D, 1969, DERMATOL SOC, V55, P196; MURDOCH RD, 1986, BRIT J IND MED, V43, P37; MURDOCH RD, 1987, ANN ALLERGY, V59, P464; OLIVARIUS FD, 1992, CONTACT DERMATITIS, V27, P71; Palacios M, 2000, SCI TOTAL ENVIRON, V257, P1, DOI 10.1016/S0048-9697(00)00464-2; PANOVA AI, 1978, GIGIENA T PROFESSION, V22, P45; Pfeiffer P., 1995, DTSCH ZAHNAERZTL Z, V50, P136; Phielepeit T, 1989, Arch Toxicol Suppl, V13, P357; Purt R, 1991, Quintessenz Zahntech, V17, P329; REBANDEL P, 1990, CONTACT DERMATITIS, V23, P121, DOI 10.1111/j.1600-0536.1990.tb03241.x; RENCZ AN, 1992, J GEOCHEM EXPLOR, V43, P265, DOI 10.1016/0375-6742(92)90111-K; REULING N, 1992, DTSCH ZAHNARZTL Z, V47, P747; Richter G, 1996, HAUTARZT, V47, P844, DOI 10.1007/s001050050518; Richter G, 1996, HAUTARZT, V47, P839, DOI 10.1007/s001050050517; Roshchin A V, 1984, J Hyg Epidemiol Microbiol Immunol, V28, P17; RUELING N, 1992, BIOCOMPATIBILITY DEN; Santucci B, 1995, Exp Dermatol, V4, P207, DOI 10.1111/j.1600-0625.1995.tb00246.x; Schafer J, 1998, SCI TOTAL ENVIRON, V215, P59, DOI 10.1016/S0048-9697(98)00115-6; Schafer J, 1999, ENVIRON SCI TECHNOL, V33, P3166, DOI 10.1021/es990033i; SCHAFER J, 1996, J C ABSTR, V1, P536; Schaffran R M, 1999, Am J Contact Dermat, V10, P201, DOI 10.1016/S1046-199X(99)90069-6; Schramel P, 1997, INT ARCH OCC ENV HEA, V69, P219, DOI 10.1007/s004200050140; SCHROEDER HA, 1971, J NUTR, V101, P1431; SCHULTZ I, 1997, DTSCH ZAHNARZTL Z, V52, P355; Schuppe HC, 1998, CLIN DERMATOL, V16, P149, DOI 10.1016/S0738-081X(97)00194-6; Schuster M, 2000, ANTHROPOGENIC PLATINUM-GROUP ELEMENT EMISSIONS, P173; Schwickerath H, 1989, Phillip J, V6, P357; SCHWICKERATH H, 1998, VERTRAGLICHKEIT DENT, P15; STEJSKAL VDM, 1994, TOXICOL IN VITRO, V8, P991, DOI 10.1016/0887-2333(94)90233-X; STRIETZEL R, 1992, DTSCH ZAHNARZTLIEHE, V47, P535; STUMKE M, 1992, ULLMANNS ENCY IND CH, P260; Suhonen R, 2001, CONTACT DERMATITIS, V44, P257; SURAIKINA T I, 1979, Cytology and Genetics, V13, P50; Sures B, 2001, ENVIRON POLLUT, V113, P341, DOI 10.1016/S0269-7491(00)00185-8; TAUBLER JH, 1977, EPA600177039; TIBBLING L, 1995, INT J OCCUP MED TOX, V4, P285; Tilch J, 2000, FRESEN J ANAL CHEM, V367, P450, DOI 10.1007/s002160000380; TODD DJ, 1992, CONTACT DERMATITIS, V26, P327; TOMILETS VA, 1979, FARMAKOL TOKSIKOL, V42, P170; UNO Y, 1993, MUTAT RES, V298, P269, DOI 10.1016/0165-1218(93)90006-Y; UTER W, 1995, CONTACT DERMATITIS, V32, P135, DOI 10.1111/j.1600-0536.1995.tb00802.x; VANJOOST T, 1990, CONTACT DERMATITIS, V22, P227; VANKETEL WG, 1981, CONTACT DERMATITIS, V7, P331; VANLOON LAJ, 1988, J ORAL PATHOL MED, V17, P129; VANLOON LAJ, 1986, CONTACT DERMATITIS, V14, P158, DOI 10.1111/j.1600-0536.1986.tb01196.x; VANLOON LAJ, 1984, CONTACT DERMATITIS, V11, P294; VILAPLANA J, 1991, CONTACT DERMATITIS, V25, P145, DOI 10.1111/j.1600-0536.1991.tb01819.x; Vilaplana J, 1998, CONTACT DERMATITIS, V39, P55, DOI 10.1111/j.1600-0536.1998.tb05832.x; VINCENZI C, 1995, AM J CONTACT DERMATI, V6, P110, DOI 10.1016/1046-199X(95)90108-6; WAAHA JC, 1999, J PROSTHODONT, V8, P245; WAHLBERG JE, 1992, ACTA DERM-VENEREOL, V72, P95; Wahlberg JE, 1999, CONTACT DERMATITIS, V41, P145, DOI 10.1111/j.1600-0536.1999.tb06106.x; Wahlberg J E, 1990, AM J CONTACT DERMATI, V1, P112; WATAHA JC, 1992, J DENT RES, V71, P1417, DOI 10.1177/00220345920710071101; Wataha JC, 1996, J ORAL REHABIL, V23, P309, DOI 10.1111/j.1365-2842.1996.tb00858.x; Wataha JC, 1998, DENT MATER, V14, P158, DOI 10.1016/S0109-5641(98)00023-2; WATAHA JC, 1991, J DENT RES, V70, P1014, DOI 10.1177/00220345910700060301; WATAHA JC, 1994, DENT MATER, V10, P298, DOI 10.1016/0109-5641(94)90037-X; *WHO, 2002, IPCS ENV HLTH CRIT E, V226; WHYTE JNC, 1991, CAN J FISH AQUAT SCI, V48, P382, DOI 10.1139/f91-050; WIRZ J, 1993, KLIN MAT WERKSTOFFKU, P67; YANG JS, 1989, HEAV METALS ENV, V2, P1; Yoshida S, 1999, J ALLERGY CLIN IMMUN, V103, P1211, DOI 10.1016/S0091-6749(99)70201-0; Ysart G, 1999, FOOD ADDIT CONTAM, V16, P391, DOI 10.1080/026520399283876; Zereini F., 1997, Umweltwissenschaften und Schadstoff-Forschung, V9, P193, DOI 10.1007/BF02937649; ZEREINI F, 2000, ANTHROPOGENIC PLATIN, P308; ZINKE T, 1992, BUNDESGESUNDHBL, V11, P579	137	160	164	2	30	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1438-4639	1618-131X		INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.	OCT	2002	205	6					417	432		10.1078/1438-4639-00180		16	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	612YV	WOS:000179103800001	12455264	
J	Gareau, MG; Wine, E; Rodrigues, DM; Cho, JH; Whary, MT; Philpott, DJ; MacQueen, G; Sherman, PM				Gareau, Melanie G.; Wine, Eytan; Rodrigues, David M.; Cho, Joon Ho; Whary, Mark T.; Philpott, Dana J.; MacQueen, Glenda; Sherman, Philip M.			Bacterial infection causes stress-induced memory dysfunction in mice	GUT			English	Article							IRRITABLE-BOWEL-SYNDROME; CITROBACTER-RODENTIUM INFECTION; MURINE COLONIC HYPERPLASIA; CHRONIC PSYCHOLOGICAL STRESS; INTESTINAL BARRIER FUNCTION; MATERNAL SEPARATION; ESCHERICHIA-COLI; SYNAPTIC PLASTICITY; SPATIAL MEMORY; C-FOS	Background The brainegut axis is a key regulator of normal intestinal physiology; for example, psychological stress is linked to altered gut barrier function, development of food allergies and changes in behaviour. Whether intestinal events, such as enteric bacterial infections and bacterial colonisation, exert a reciprocal effect on stress-associated behaviour is not well established. Objective To determine the effects of either acute enteric infection or absence of gut microbiota on behaviour, including anxiety and non-spatial memory formation. Methods Behaviour was assessed following infection with the non-invasive enteric pathogen, Citrobacter rodentium in both C57BL/6 mice and germ-free Swiss-Webster mice, in the presence or absence of acute water avoidance stress. Whether daily treatment with probiotics normalised behaviour was assessed, and potential mechanisms of action evaluated. Results No behavioural abnormalities were observed, either at the height of infection (10 days) or following bacterial clearance (30 days), in C rodentium-infected C57BL/6 mice. When infected mice were exposed to acute stress, however, memory dysfunction was apparent after infection (10 days and 30 days). Memory dysfunction was prevented by daily treatment of infected mice with probiotics. Memory was impaired in germ-free mice, with or without exposure to stress, in contrast to conventionally reared, control Swiss-Webster mice with an intact intestinal microbiota. Conclusions The intestinal microbiota influences the ability to form memory. Memory dysfunction occurs in infected mice exposed to acute stress, while in the germ-free setting memory is altered at baseline.	[Sherman, Philip M.] Univ Toronto, Hosp Sick Children, Res Inst, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Wine, Eytan] Univ Alberta, Div Gastroenterol & Nutr, Dept Pediat, Edmonton, AB T6G 2M7, Canada; [Cho, Joon Ho; Philpott, Dana J.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Whary, Mark T.] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [MacQueen, Glenda] Univ Calgary, Dept Psychiat, Calgary, AB T2N 1N4, Canada	Sherman, PM (reprint author), Univ Toronto, Hosp Sick Children, Res Inst, Cell Biol Program, 555 Univ Ave,Rm 8409, Toronto, ON M5G 1X8, Canada.	philip.sherman@sickkids.ca		Sherman, Philip/0000-0002-4733-6690	Crohn's and Colitis Foundation of Canada St. Clair Avenue East Toronto [ON M4T 1N5]; Crohn's and Colitis Foundation of Canada; CCFC/CAG/CIHR; Canada Research Chair in Gastrointestinal Disease; Institut-Rosell Lallemand Inc, Montreal, Quebec, Canada	Crohn's and Colitis Foundation of Canada 600-60 St. Clair Avenue East Toronto, ON M4T 1N5. This work was provided by a Faye Shapiro Cutler Grant-In-Aid from the Crohn's and Colitis Foundation of Canada (PMS). CCFC/CAG/CIHR fellowship (MGG); Canada Research Chair in Gastrointestinal Disease (PMS).; Portions of this work were funded by a research contract with Institut-Rosell Lallemand Inc, Montreal, Quebec, Canada.	Ahn HJ, 2008, LEARN MEMORY, V15, P539, DOI 10.1101/lm.866408; Antoniou K, 2008, BEHAV BRAIN RES, V187, P462, DOI 10.1016/j.bbr.2007.10.010; Barman M, 2008, INFECT IMMUN, V76, P907, DOI 10.1128/IAI.01432-07; Borenshtein D, 2008, CURR OPIN GASTROEN, V24, P32; Bourin M, 2003, EUR J PHARMACOL, V463, P55, DOI 10.1016/S0014-2999(03)01274-3; Bry L, 2006, INFECT IMMUN, V74, P673, DOI 10.1158/IAI.74.1.673-681.2006; Cameron HL, 2005, J PHARMACOL EXP THER, V314, P214, DOI 10.1124/jpet.105.085373; Castelhano-Carlos MJ, 2009, LAB ANIM-UK, V43, P311, DOI 10.1258/la.2009.0080098; Chen Y, 2006, MOL PSYCHIATR, V11, P992, DOI 10.1038/sj.mp.4001863; Countryman RA, 2005, NEUROBIOL LEARN MEM, V84, P175, DOI 10.1016/j.nlm.2005.07.005; De Kloet ER, 2004, ANN NY ACAD SCI, V1032, P14, DOI 10.1193/annals.1314.003; Deacon RMJ, 2006, NAT PROTOC, V1, P7, DOI 10.1038/nprot.2006.2; Eaton KA, 2008, INFECT IMMUN, V76, P3054, DOI 10.1128/IAI.01626-07; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Eutamene H, 2007, J NUTR, V137, P1901; Floch MH, 2008, J CLIN GASTROENTEROL, V42, pS104, DOI 10.1097/MCG.0b013e31816b903f; Friswell MK, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008584; Gareau MG, 2008, CURR MOL MED, V8, P274, DOI 10.2174/156652408784533760; Gareau MG, 2007, GUT, V56, P1522, DOI 10.1136/gut.2006.117176; Gareau MG, 2010, J INFECT DIS, V201, P81, DOI 10.1086/648614; Gareau MG, 2006, PEDIATR RES, V59, P83, DOI 10.1203/01.pdr.0000190577.62426.45; Gaykema RPA, 2004, BRAIN BEHAV IMMUN, V18, P238, DOI 10.1016/j.bbi.2003.08.002; Girard SA, 2009, BR J NUTR, V29, P1; Goehler LE, 2007, BRAIN BEHAV IMMUN, V21, P721, DOI 10.1016/j.bbi.2007.02.005; GOMBORONE JE, 1993, GUT, V34, P1230, DOI 10.1136/gut.34.9.1230; Hammerle CW, 2008, WORLD J GASTROENTERO, V14, P2639, DOI 10.3748/wjg.14.2639; Hayakawa Y, 2010, GASTROENTEROLOGY, V138, P1055, DOI 10.1053/j.gastro.2009.11.015; Heldt SA, 2007, MOL PSYCHIATR, V12, P656, DOI 10.1038/sj.mp.4001957; Higgins LM, 1999, INFECT IMMUN, V67, P3031; Hirst WD, 2008, J PHARMACOL EXP THER, V325, P134, DOI 10.1124/jpet.107.133082; Hoffmann C, 2009, INFECT IMMUN, V77, P4668, DOI 10.1128/IAI.00493-09; Johnson-Henry KC, 2005, J INFECT DIS, V191, P2106, DOI 10.1086/430318; Katayama A, 2004, CLIN CANCER RES, V10, P634, DOI 10.1158/1078-0432.CCR-0864-02; KAWAHITO Y, 1995, GUT, V37, P544, DOI 10.1136/gut.37.4.544; Kuc KA, 2006, GENES BRAIN BEHAV, V5, P355, DOI 10.1111/j.1601-183X.2005.00168.x; Kumar NSN, 2008, J GASTROEN HEPATOL, V23, P1834, DOI 10.1111/j.1440-1746.2008.05723.x; Li W, 2009, PHYSIOL BEHAV, V96, P557, DOI 10.1016/j.physbeh.2008.12.004; Luperchio SA, 2001, MICROBES INFECT, V3, P333, DOI 10.1016/S1286-4579(01)01387-9; Luperchio SA, 2000, J CLIN MICROBIOL, V38, P4343; Lupien SJ, 2005, PSYCHONEUROENDOCRINO, V30, P225, DOI 10.1016/j.psyneuen.2004.08.003; Lyte M, 2006, PHYSIOL BEHAV, V89, P350, DOI 10.1016/j.physbeh.2006.06.019; Maes M, 2008, NEUROENDOCRINOL LETT, V29, P117; Mangell P, 2002, DIGEST DIS SCI, V47, P511, DOI 10.1023/A:1017947531536; Mayer EA, 2008, NEW ENGL J MED, V358, P1692, DOI 10.1056/NEJMcp0801447; Millecamps M, 2004, PAIN, V109, P214, DOI 10.1016/j.pain.2003.12.028; Mumby DG, 2002, LEARN MEMORY, V9, P49, DOI 10.1101/lm.41302; Mundy R, 2005, CELL MICROBIOL, V7, P1697, DOI 10.1111/j.1462-5822.2005.00625.x; O'Hara JR, 2006, CELL MICROBIOL, V8, P646, DOI 10.1111/j.1462-5822.2005.00657.x; Oprica M, 2005, BRAIN BEHAV IMMUN, V19, P223, DOI 10.1016/j.bbi.2004.07.006; Petnicki-Ocwieja T, 2009, P NATL ACAD SCI USA, V106, P15813, DOI 10.1073/pnas.0907722106; Petri WA, 2008, J CLIN INVEST, V118, P1277, DOI 10.1172/JCI34005; Richwine AF, 2009, BRAIN BEHAV IMMUN, V23, P794, DOI 10.1016/j.bbi.2009.02.020; Ruigomez A, 2007, CLIN GASTROENTEROL H, V5, P465, DOI 10.1016/j.cgh.2007.02.008; Saunders PR, 2002, DIGEST DIS SCI, V47, P208, DOI 10.1023/A:1013204612762; Schaaf M J, 1999, Stress, V3, P173, DOI 10.3109/10253899909001121; Sherman PM, 2009, NUTR CLIN PRACT, V24, P10, DOI 10.1177/0884533608329231; Skorzewska A, 2006, PHARMACOL BIOCHEM BE, V85, P522, DOI 10.1016/j.pbb.2006.10.001; Soderholm JD, 2002, AM J PHYSIOL-GASTR L, V283, pG1257, DOI 10.1152/ajpgi.00314.2002; Soderholm JD, 2002, GASTROENTEROLOGY, V123, P1099, DOI 10.1053/gast.2002.36019; Spiller R, 2006, CURR OPIN GASTROEN, V22, P13, DOI 10.1097/01.mog.0000194792.36466.5c; Stasi C, 2008, DIGEST DIS, V26, P156, DOI 10.1159/000116774; Sudo N, 2004, J PHYSIOL-LONDON, V558, P263, DOI 10.1113/jphysiol.2004.063388; Tsien JZ, 1996, CELL, V87, P1327, DOI 10.1016/S0092-8674(00)81827-9; Walker FR, 2008, J PSYCHIATR RES, V42, P1094, DOI 10.1016/j.jpsychires.2007.12.006; Wu X, 2008, AM J PHYSIOL-GASTR L, V294, pG295, DOI 10.1152/ajpgi.00173.2007; Yang PC, 2006, AM J PATHOL, V168, P104, DOI 10.2353/ajpath.2006.050575; Zareie M, 2006, GUT, V55, P1553, DOI 10.1136/gut.2005.080739; Zheng Y, 2008, NAT MED, V14, P282, DOI 10.1038/nm1720	68	159	171	5	51	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0017-5749			GUT	Gut	MAR	2011	60	3					307	317		10.1136/gut.2009.202515		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	716LJ	WOS:000286969800007	20966022	
J	Henderson, J; Northstone, K; Lee, SP; Liao, HH; Zhao, YW; Pembrey, M; Mukhopadhyay, S; Smith, GD; Palmer, CNA; McLean, WHI; Irvine, AD				Henderson, John; Northstone, Kate; Lee, Simon P.; Liao, Haihui; Zhao, Yiwei; Pembrey, Marcus; Mukhopadhyay, Somnath; Smith, George Davey; Palmer, Colin N. A.; McLean, W. H. Irwin; Irvine, Alan D.			The burden of disease associated with filaggrin mutations: A population-based, longitudinal birth cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						eczema; atopic dermatitis; asthma; skin barrier; filaggrin; birth cohort; atopy	ATOPIC-DERMATITIS; BRONCHIAL RESPONSIVENESS; BARRIER; METHODOLOGY; PHENOTYPES; CHILDREN; ALSPAC; ASTHMA; ECZEMA; GENE	Background: Atopic disease is a major health problem. Mutations in the filaggrin gene (FLG) confer major susceptibility to eczema and related asthma. Objective: We sought to determine the natural history and burden of atopic disease conferred by the 2 most common FLG mutations in a large, population-based birth cohort study. Methods: We analyzed the effect of the most common null alleles (R501X and 2282del4) on several atopic phenotypes in a cohort of approximately 7000 English children born in 1990-1991. Results: FLG null alleles associated strongly with eczema; eczema associated with these mutations presents in early life and is more persistent (hazard ratio for eczema resolution for those with FLG mutations to FLG wild type, 0.67; 95% CI, 0.58-0.77; P = 5 x 10(-8)). FLG mutations conferred a population asthma risk of 1.80 (95% CI, 1.34-2.41; P = .00019); asthma risk was especially high in the context of eczema (odds ratio, 3.16; 95% CI, 2.25-4.43; P = 1.4 x 10(-11)). Strong associations were identified with sensitization to grass, house dust mite, and cat dander and sensitization to multiple allergens (odds ratio, 2.12; 95% CI, 1.03-4.37; P = 5.42 x 10(-27)). Conclusion: FLG mutations are strong genetic determinants of eczema, early wheeze, asthma in the context of eczema, and atopic sensitization. They confer risk of a particular trajectory for eczema, with increased duration of disease and greater risk of asthma and multiple allergic sensitizations. FLG alleles help define the risk profile of children with eczema and help define the "eczema plus early wheeze" and "eczema plus asthma" phenotypes.	[Irvine, Alan D.] Our Ladys Childrens Hosp Crumlin, Dept Paediat Dermatol, Dublin 12, Ireland; [Henderson, John] Univ Bristol, Dept Community Based Med, Bristol BS8 1TH, Avon, England; [Northstone, Kate] Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England; [Smith, George Davey] Univ Bristol, MRC, Ctr Causal Anal Translat Epidemiol, Bristol BS8 1TH, Avon, England; [Lee, Simon P.; Palmer, Colin N. A.] Univ Dundee, Populat Pharmacogenet Grp, Biomed Res Ctr, Dundee DD1 4HN, Scotland; [Mukhopadhyay, Somnath] Univ Dundee, Childrens Asthma & Allergy Res Unit, Dundee DD1 4HN, Scotland; [Liao, Haihui; Zhao, Yiwei; McLean, W. H. Irwin] Univ Dundee, Epithelial Genet Grp, Human Genet Unit, Div Pathol & Neurosci, Dundee DD1 4HN, Scotland; [Pembrey, Marcus] UCL, Inst Child Hlth, London WC1E 6BT, England	Irvine, AD (reprint author), Our Ladys Childrens Hosp Crumlin, Dept Paediat Dermatol, Dublin 12, Ireland.	irvinea@tcd.ie	Palmer, Colin/C-7053-2008; McLean, William/C-6352-2009; Northstone, Kate/A-8165-2011; Osborne, Nicholas/N-4915-2015; Davey Smith, George/A-7407-2013	Palmer, Colin/0000-0002-6415-6560; Northstone, Kate/0000-0002-0602-1983; Osborne, Nicholas/0000-0002-6700-2284; Davey Smith, George/0000-0002-1407-8314; McLean, William Henry Irwin/0000-0001-5539-5757; Monsalve, Beatriz Elena/0000-0002-5994-866X; Irvine, Alan/0000-0002-9048-2044	Medical Research Council [G0700314, G0600705, G9815508]; Wellcome Trust		ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chinn S, 1998, THORAX, V53, P984; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Jones RW, 2000, EUR J HUM GENET, V8, P653, DOI 10.1038/sj.ejhg.5200502; Kondo H, 1998, EUR J IMMUNOL, V28, P769, DOI 10.1002/(SICI)1521-4141(199803)28:03<769::AID-IMMU769>3.0.CO;2-H; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Virtanen H, 2007, J ALLERGY CLIN IMMUN, V120, P1464, DOI 10.1016/j.jaci.2007.08.021; Wadonda-Kabondo N, 2003, BRIT J DERMATOL, V149, P1023, DOI 10.1111/j.1365-2133.2003.05605.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	20	159	165	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					872	877		10.1016/j.jaci.2008.01.026		6	Allergy; Immunology	Allergy; Immunology	286YY	WOS:000254884000010	18325573	
J	Guarner, F; Bourdet-Sicard, R; Brandtzaeg, P; Gill, HS; McGuirk, P; van Eden, W; Versalovic, J; Weinstock, JV; Rook, GAW				Guarner, Francisco; Bourdet-Sicard, Raphaelle; Brandtzaeg, Per; Gill, Harsharnjit S.; McGuirk, Peter; van Eden, Willem; Versalovic, James; Weinstock, Joel V.; Rook, Graham A. W.			Mechanisms of disease: the hygiene hypothesis revisited	NATURE CLINICAL PRACTICE GASTROENTEROLOGY & HEPATOLOGY			English	Review						microbiota; probiotics; prebiotics; regulatory T cells; tolerance	REGULATORY T-CELLS; INFLAMMATORY-BOWEL-DISEASE; ACTIVE ULCERATIVE-COLITIS; PLACEBO-CONTROLLED TRIAL; TRICHURIS-SUIS THERAPY; BORDETELLA-PERTUSSIS; MULTIPLE-SCLEROSIS; CROHNS-DISEASE; TRANSCRIPTIONAL REGULATION; INTESTINAL MICROFLORA	In industrialized countries the incidence of diseases caused by immune dysregulation has risen. Epidemiologic studies initially suggested this was connected to a reduction in the incidence of infectious diseases; however, an association with defects in immunoregulation is now being recognized. Effector T(H)1 and T(H)2 cells are controlled by specialized subsets of regulatory T cells. Some pathogens can induce regulatory cells to evade immune elimination, but regulatory pathways are homeostatic and mainly triggered by harmless microorganisms. Helminths, saprophytic mycobacteria, bifidobacteria and lactobacilli, which induce immunoregulatory mechanisms in the host, ameliorate aberrant immune responses in the setting of allergy and inflammatory bowel disease. These organisms cause little, if any, harm, and have been part of human microecology for millennia; however, they are now less frequent or even absent in the human environment of westernized societies. Deficient exposure to these 'old friends' might explain the increase in immunodysregulatory disorders. The use of probiotics, prebiotics, helminths or microbe-derived immunoregulatory vaccines might, therefore, become a valuable approach to disease prevention.	Univ Hosp Valle Hebron, Digest Syst Res Unit, E-08035 Barcelona, Spain; Danone Vitapole, Palaiseau, France; Univ Oslo, LIIPAT Inst Pathol, Oslo, Norway; Univ Dublin Trinity Coll, Immune Regulat Res Grp, Dublin 2, Ireland; Dept Infect Dis & Immunol, Utrecht, Netherlands; Baylor Coll Med, Houston, TX 77030 USA; Texas Childrens Hosp, Houston, TX 77030 USA; Tufts Univ New England Med Ctr, Boston, MA USA; UCL Royal Free Univ Coll, Sch Med, Ctr Infect Dis & Int Hlth, Windeyer Inst Med Sci, London, England	Guarner, F (reprint author), Univ Hosp Valle Hebron, Digest Syst Res Unit, Passeig Vall Hebron 119-129, E-08035 Barcelona, Spain.	fguarnera@medynet.com		Guarner, Francisco/0000-0002-4051-0836; Rook, Graham/0000-0002-8041-8110			Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659; Arif S, 2004, J CLIN INVEST, V113, P451, DOI 10.1172/JCI200419585; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bartosch S, 2004, APPL ENVIRON MICROB, V70, P3575, DOI 10.1128/AEM.70.6.3575-3581.2004; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Benn CS, 2004, BRIT MED J, V328, P1223, DOI 10.1136/bmj.38069.512245.FE; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Borruel N, 2002, GUT, V51, P659, DOI 10.1136/gut.51.5.659; Braat H, 2004, GASTROENTEROLOGY, V126, pA284; Brandtzaeg P, 2005, IMMUNOL REV, V206, P32, DOI 10.1111/j.0105-2896.2005.00283.x; BRANDTZAEG P, 1984, NATURE, V311, P71, DOI 10.1038/311071a0; Bron PA, 2004, J BACTERIOL, V186, P5721, DOI 10.1128/JB.186.17.5721-5729.2004; Chapat L, 2004, EUR J IMMUNOL, V34, P2520, DOI 10.1002/eji.200425139; Christensen HR, 2002, J IMMUNOL, V168, P171; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; CRABBE PA, 1970, LAB INVEST, V22, P448; de Kleer IM, 2004, J IMMUNOL, V172, P6435; Derrien M, 2004, INT J SYST EVOL MICR, V54, P1469, DOI 10.1099/ijs.0.2873-0; Di Giacinto C, 2005, J IMMUNOL, V174, P3237; Elliott DE, 2004, EUR J IMMUNOL, V34, P2690, DOI 10.1002/eji.200324833; Elliott DE, 2003, AM J PHYSIOL-GASTR L, V284, pG385, DOI 10.1152/ajpgi.00049.2002; Gale EAM, 2002, DIABETES, V51, P3353, DOI 10.2337/diabetes.51.12.3353; GENT AE, 1994, LANCET, V343, P766, DOI 10.1016/S0140-6736(94)91841-4; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Haddeland U, 2005, PEDIATR ALLERGY IMMU, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; Helgeland L, 2000, MICROBIOL ECOL HL S2, V12, pS110; Higgins SC, 2003, J IMMUNOL, V171, P3119; Johansen FE, 2004, TRENDS IMMUNOL, V25, P150, DOI 10.1016/j.it.2004.01.001; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kato K, 2004, ALIMENT PHARM THERAP, V20, P1133, DOI 10.1111/j.1365-2036.2004.02268.x; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Kleessen B, 2002, SCAND J GASTROENTERO, V37, P1034, DOI 10.1080/003655202320378220; KORENBLAT PE, 1968, J ALLERGY, V41, P226, DOI 10.1016/0021-8707(68)90046-4; Kraus TA, 2004, GASTROENTEROLOGY, V126, P1771, DOI 10.1053/j.gastro.2004.03.076; La Flamme AC, 2003, INFECT IMMUN, V71, P4996, DOI 10.1128/IAI.71.9.4996-5004.2003; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Marshall AL, 2004, DIABETIC MED, V21, P1035, DOI 10.1111/j.1464-5491.2004.01282.x; Marteau P, 2004, ALIMENT PHARM THERAP, V20, P18, DOI 10.1111/j.1365-2036.2004.02062.x; McGuirk P, 1998, EUR J IMMUNOL, V28, P153, DOI 10.1002/(SICI)1521-4141(199801)28:01<153::AID-IMMU153>3.0.CO;2-#; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; McKee AS, 2004, J IMMUNOL, V173, P1224; Menard S, 2004, GUT, V53, P821, DOI 10.1136/gut.2003.026252; Moreels TG, 2004, GUT, V53, P99, DOI 10.1136/gut.53.1.99; Mowat AM, 2003, NAT REV IMMUNOL, V3, P331, DOI 10.1038/nri1057; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; Nielsen HE, 1999, J RHEUMATOL, V26, P1600; Ponsonby AL, 2005, JAMA-J AM MED ASSOC, V293, P463, DOI 10.1001/jama.293.4.463; POSER S, 1989, NEUROEPIDEMIOLOGY, V8, P207, DOI 10.1159/000110184; Qiao L, 1996, EUR J IMMUNOL, V26, P922, DOI 10.1002/eji.1830260430; Rook GAW, 2004, SPRINGER SEMIN IMMUN, V25, P237, DOI 10.1007/s00281-003-0148-9; SALAS SD, 1990, ARCH INTERN MED, V150, P1514, DOI 10.1001/archinte.150.7.1514; Sawczenko A, 2001, LANCET, V357, P1093, DOI 10.1016/S0140-6736(00)04309-9; Schwiertz A, 2003, PEDIATR RES, V54, P393, DOI 10.1203/01.PDR.0000078274.74607.7A; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Seksik P, 2003, GUT, V52, P237, DOI 10.1136/gut.52.2.237; Sonnenburg JL, 2004, NAT IMMUNOL, V5, P569, DOI 10.1038/ni1079; STANWELLSMITH R, 2004, INT SCI FOR HOM HYG; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Suau A, 1999, APPL ENVIRON MICROB, V65, P4799; Summers RW, 2005, GASTROENTEROLOGY, V128, P825, DOI 10.1053/j.gastro.2005.01.005; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Telford G, 1998, INFECT IMMUN, V66, P36; Uhlig T, 2005, ANN RHEUM DIS, V64, P7, DOI 10.1136/ard.2004.023044; van Amelsfort JMR, 2004, ARTHRITIS RHEUM, V50, P2775, DOI 10.1002/art.20499; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; van Eden W, 2005, NAT REV IMMUNOL, V5, P318, DOI 10.1038/nri1593; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; von der Weid T, 2001, CLIN DIAGN LAB IMMUN, V8, P695, DOI 10.1128/CDLI.8.4.695-701.2001; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yamanaka T, 2003, J IMMUNOL, V170, P816; Zaccone P, 2003, EUR J IMMUNOL, V33, P1439, DOI 10.1002/eji.200323910; Zoetendal Erwin G., 2001, Microbial Ecology in Health and Disease, V13, P129, DOI 10.1080/089106001750462669; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	82	159	173	3	57	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1743-4378			NAT CLIN PRACT GASTR	Nat. Clin. Pract. Gastroenterol. Hepatol.	MAY	2006	3	5					275	284		10.1038/ncpgasthep0471		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	046KI	WOS:000237810100010	16673007	
J	Wenzel, S				Wenzel, S			Severe asthma in adults	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review						asthma; inflammation; physiology; phenotypes; remodeling; treatment	NEAR-FATAL ASTHMA; STEROID-RESISTANT ASTHMA; LIFE-THREATENING ASTHMA; AIR-FLOW OBSTRUCTION; GLUCOCORTICOID-RECEPTOR; PERSISTENT ASTHMA; LUNG-FUNCTION; CLINICAL CHARACTERISTICS; CHILDHOOD ASTHMA; BRONCHIAL-ASTHMA	Severe asthma remains poorly understood and frustrating to care for, partly because it is a heterogeneous disease. Patients with severe asthma disproportionately consume health care resources related to asthma. Severe asthma may develop over time, or shortly after onset of the disease. The genetic and environmental elements that may be most important in the development of severe disease are poorly understood, but likely include both allergic and nonallergic elements. Physiologically, these patients often have air trapping, airway collapsibility, and a high degree of methacholine hyper-responsiveness. Specific phenotypes of severe asthma are only beginning to be defined. However, describing severe asthma by age at onset (early- vs. late-onset) appears to describe two phenotypes that differ at immunologic, physiologic, epidemiologic, and pathologic levels. In particular, early-onset severe asthma is a more allergic-associated disease than late-onset severe asthma. In addition, patients with severe asthma can be defined on the basis of presence and type of inflammation. Severe asthma with persistent eosinophilia (of either early or late onset) is more symptomatic and has more near-fatal events. However, at least 50% of patients with severe asthma have very little identifiable inflammation. Thus, "steroid resistance" may occur at numerous levels, not all of which are caused by a lack of effect of steroids on inflammation. Treatment remains problematic, with corticosteroids remaining the most effective therapy. However, 5-lipoxygenase inhibitors, anti-IgE, and immunomodulatory drugs are also likely to have a place in treatment. Improving therapy in this disease will require a better understanding of the phenotypes involved.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA	Wenzel, S (reprint author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	wenzels@njc.org					Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Antonicelli L, 2004, EUR RESPIR J, V23, P723, DOI 10.1183/09031936.04.00004904; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.020.0261102; Barreiro E, 2004, EUR RESPIR J, V24, P219, DOI 10.1183/09031936.04.00074703; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648; Bukstein DA, 2003, ANN ALLERG ASTHMA IM, V90, P543; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594; Chaudhuri R, 2003, AM J RESP CRIT CARE, V168, P1308, DOI 10.1164/rccm.200304-503OC; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Chu HW, 2000, J ALLERGY CLIN IMMUN, V106, P1115; Chung KF, 1999, EUR RESPIR J, V13, P1198; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; COX G, 1995, J IMMUNOL, V154, P4719; Cundall M, 2003, J ALLERGY CLIN IMMUN, V112, P1064, DOI 10.1016/j.jaci.2003.08.013; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; Gagliardo R, 2003, AM J RESP CRIT CARE, V168, P1190, DOI 10.1164/rccm.200205-479OC; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7; GARDEN GMF, 1993, THORAX, V48, P501, DOI 10.1136/thx.48.5.501; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; GIBBS R, 2002, AM J RESP CRIT CARE, V165, pA119; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Guyer B, 2002, J ALLERGY CLIN IMMUN, V109, pS244, DOI 10.1016/S0091-6749(02)81879-6; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Howat WJ, 2002, AM J PHYSIOL-LUNG C, V282, pL115; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Jensen SP, 2002, CLIN RADIOL, V57, P1078, DOI 10.1053/crad.2002.1104; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.01938.x; KAM JC, 1993, J IMMUNOL, V151, P3460; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; Kolbe J, 2002, THORAX, V57, P317, DOI 10.1136/thorax.57.4.317; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Lemjabbar H, 1999, AM J RESP CRIT CARE, V159, P1298; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Lock SH, 1996, AM J RESP CRIT CARE, V153, P509; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; Lynd LD, 2004, CHEST, V126, P1161, DOI 10.1378/chest.126.4.1161; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Mauad Thais, 1999, American Journal of Respiratory and Critical Care Medicine, V160, P968; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; *NAEPP, 1997, 974051 NAEPP; *NATL I HLTH NATL, 2002, GLOB IN ASTHM GLOB S; Nightingale JA, 2002, CHEST, V121, P1401, DOI 10.1378/chest.121.5.1401; NOONAN M, 1995, AM J RESP CRIT CARE, V152, P1467; OGIRALA RG, 1995, AM J RESP CRIT CARE, V152, P1461; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376; Perkins PJ, 2002, CHEST, V122, P1988, DOI 10.1378/chest.122.6.1988; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Rackeman FM, 1947, AM J MED, V33, P601; Rosa-Rosa L, 1999, J ALLERGY CLIN IMMUN, V104, P1008; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Roth M, 2004, NEW ENGL J MED, V351, P560, DOI 10.1056/NEJMoa021660; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SILKOFF PE, 2004, AM J RESP CRIT CARE, V169, pA298; Silverman RA, 2003, CHEST, V123, P1472, DOI 10.1378/chest.123.5.1472; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Stoloff SW, 2004, J ALLERGY CLIN IMMUN, V113, P245, DOI 10.1016/j.jaci.2003.10.011; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Szalai C, 2001, J ALLERGY CLIN IMMUN, V108, P375, DOI 10.1067/mai.2001.117930; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; ten Brinke A, 2001, AM J RESP CRIT CARE, V163, P1093; ten Brinke A, 2001, J PSYCHOSOM RES, V50, P7, DOI 10.1016/S0022-3999(00)00203-8; Thomas PS, 1999, THORAX, V54, P352; Turner MO, 1998, AM J RESP CRIT CARE, V157, P1804; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; Veen JC, 2000, AM J RESP CRIT CARE, V161, P1902; Veen JCCMI, 1998, AM J RESP CRIT CARE, V158, P1134; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; WEISS S, 2002, AM J RESP CRIT CARE, V165, pA435; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50; WENZEL S, 2002, AM J RESP CRIT CARE, V165, pA730; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Wenzel SE, 2002, J IMMUNOL, V169, P4613; Wenzel SE, 2002, AM J MED, V112, P627, DOI 10.1016/S0002-9343(02)01095-1; Wenzel S, 2000, AM J RESP CRIT CARE, V162, P2341; WENZEL SE, 2004, COLL INT ALL BORN DE; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788; WOOLCOCK AJ, 1971, AM REV RESPIR DIS, V104, P703; Wraight JM, 2002, RESPIROLOGY, V7, P133, DOI 10.1046/j.1440-1843.2002.00374.x	120	159	166	0	10	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2005	172	2					149	160		10.1164/rccm.200409-1181PP		12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	943QG	WOS:000230368400002	15849323	
J	Chalupa, DC; Morrow, PE; Oberdorster, G; Utell, MJ; Frampton, MW				Chalupa, DC; Morrow, PE; Oberdorster, G; Utell, MJ; Frampton, MW			Ultrafine particle deposition in subjects with asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; deposition; dosimetry; inhalation; ultrafine particles	PARTICULATE AIR-POLLUTION; BREATHING PATTERNS; RESPIRATORY-TRACT; LUNG DEPOSITION; FINE PARTICLES; DISEASE; HEALTHY; MORTALITY; EXPOSURE; NUMBER	Ambient air particles in the ultrafine size range (diameter < 100 nm) may contribute to the health effects of particulate matter. However, there are few data on ultrafine particle deposition during spontaneous breathing, and none in people with asthma. Sixteen subjects with mild to moderate asthma were exposed for 2 hr, by mouthpiece, to ultrafine carbon particles with a count median diameter (CMD) of 23 nm and a geometric standard deviation of 1.6. Deposition was measured during spontaneous breathing at rest (minute ventilation, 13.3 +/- 2.0 L/min) and exercise (minute ventilation, 41.9 +/- 9.0 L/min). The mean SD fractional deposition was 0.76 +/- 0.05 by particle number and 0.69 +/- 0.07 by particle mass concentration. The number deposition fraction increased as particle size decreased, reaching 0.84 +/- 0.03 for the smallest particles (midpoint CMD = 8.7 nm). No differences between sexes were observed. The deposition fraction increased during exercise to 0.86 +/- 0.04 and 0.79 +/- 0.05 by particle number and mass concentration, respectively, and reached 0.93 +/- 0.02 for the smallest particles. Experimental deposition data exceeded model predictions during exercise. The deposition at rest was greater in these subjects with asthma than in previously studied healthy subjects (0.76 +/- 0.05 vs. 0.65 +/- 0.10, p < 0.001). The efficient respiratory deposition of ultrafine particles increases further in subjects with asthma.	Univ Rochester, Sch Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY 14642 USA	Frampton, MW (reprint author), Univ Rochester, Sch Med, 601 Elmwood Ave,Box 692, Rochester, NY 14642 USA.	mark_frampton@urmc.rochester.edu			NCRR NIH HHS [RR 00044]; NIEHS NIH HHS [P30 ES 01247]		ANDERSON PJ, 1990, CHEST, V97, P1115, DOI 10.1378/chest.97.5.1115; Bennett WD, 1997, INHAL TOXICOL, V9, P1; BROWN BW, 1980, BIOMETRICS, V36, P69, DOI 10.2307/2530496; Brown JS, 2002, AM J RESP CRIT CARE, V166, P1240, DOI 10.1164/rccm.00205-399OC; Chalupa DC, 2002, CRUCIAL ISSUES INHAL, P241; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370390205065; de Hartog JJ, 2003, AM J EPIDEMIOL, V157, P613, DOI 10.1093/aje/kwg021; DEVLIN RB, 2000, RELATONSHIPS ACUTE C, P159; Frampton MW, 2001, ENVIRON HEALTH PERSP, V109, P529, DOI 10.2307/3454664; FRAMPTON MW, 2000, PARTICLE LUNG INTERA, P653; Gavett SH, 2001, INT ARCH ALLERGY IMM, V124, P109, DOI 10.1159/000053685; International Commission on Radiological Protection, 1994, ICRP PUBL, V66; Jaques PA, 2000, INHAL TOXICOL, V12, P715; Karol MH, 2002, TOXICOLOGY, V181, P305, DOI 10.1016/S0300-483X(02)00298-6; Kim CS, 1997, AM J RESP CRIT CARE, V155, P899; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; *NCRP, 1997, 125 NCRP NAT COUNC R; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; PAEK D, 1992, J APPL PHYSIOL, V73, P887; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Roth C., 1994, ANN OCCUP HYG     S1, V38, P101; Schiller C. F., 1988, ANN OCCUP HYG, V32, P41; SVARTENGREN M, 1991, J APPL PHYSIOL, V71, P2238; TOBIN MJ, 1983, CHEST, V84, P286, DOI 10.1378/chest.84.3.286; Utell MJ, 2000, INHAL TOXICOL, V12, P37, DOI 10.1080/089583700196365; WICHMANN HE, 2000, 98 HEI, P1; WILSON FJ, 1985, J APPL PHYSIOL, V58, P223	29	159	165	3	23	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2004	112	8					879	882		10.1289/ehp.6851		4	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	829BO	WOS:000222018200037	15175176	
J	Fujiwara, D; Inoue, S; Wakabayashi, H; Fujii, T				Fujiwara, D; Inoue, S; Wakabayashi, H; Fujii, T			The anti-allergic effects of lactic acid bacteria are strain dependent and mediated by effects on both Th1/Th2 cytokine expression and balance	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						lactic acid bacteria; IgE; Th1; Th2; Lactobacillus paracasei strain KW3110	LIPOTEICHOIC ACID; DENDRITIC CELLS; INTERFERON-GAMMA; STAPHYLOCOCCUS-AUREUS; IFN-GAMMA; INTERLEUKIN-12; ACTIVATION; INDUCTION; RECEPTOR; IL-12	Background: There is growing interest in the immune-stimulating effect and in particular, the anti-allergic effect, of lactic acid bacteria (LAB). However, no comprehensive studies have been done that compare the immune-stimulating potential of LAB strains. Methods: The in vitro immune-stimulating effects on Th1/Th2 balance of more than 100 LAB strains were compared in splenocytes from ovalbumin-sensitized Th2-polarized mice. The in vivo anti-allergic ability of strain KW3110 was studied in the Th2-polarized model by detecting serum IgE concentration, Th1/Th2 cytokine secretion from splenocytes, and the expression of co-stimulatory molecules on macrophages. Results: In vitro studies from Th2-polarized splenocytes, using IL-12 as a Th1 parameter and IL-4 secretion as a Th2 parameter revealed a wide variety of IL-12- inducing and IL-4-repressing activities, depending on the strain of LAB, not depending on the species. However, evaluation of individual strains in vivo revealed that after exposure to Lactobacillus paracasei KW3110 strain, the serum IgE elevation elicited by repeated OVA injection of mice was strongly inhibited. Cytokine secretion from splenocytes 20 weeks after KW3110 administration showed increased IL-12 and decreased IL-4 expression. Both CD40 and B7-1 expression on macrophages was upregulated by administration of KW3110. Conclusions: Improving the consequences of the Th1/Th2 imbalance by administration of LAB was dependent upon the LAB strain rather than the LAB species. Oral KW3110 administration in the mouse allergy model directed the Th1/Th2 balance toward Th1 through the maturation of APCs and inhibition of serum IgE elevation. Copyright (C) 2004 S. Karger AG, Basel.	Kirin Brewery Co Ltd, Cent Lab Key Technol, Kanagawa 2360004, Japan	Fujiwara, D (reprint author), Kirin Brewery Co Ltd, Cent Lab Key Technol, 1-13-5 Fukuura, Kanagawa 2360004, Japan.	d-fujiwara@kirin.co.jp					Ahrne S, 1998, J APPL MICROBIOL, V85, P88; BHAKDI S, 1991, INFECT IMMUN, V59, P4614; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Chiaramonte MG, 2000, J IMMUNOL, V164, P973; Christensen HR, 2002, J IMMUNOL, V168, P171; Fujimoto T, 1997, J IMMUNOL, V158, P5619; Ginsburg I, 2002, LANCET INFECT DIS, V2, P171, DOI 10.1016/S1473-3099(02)00226-8; Gupta D, 1999, J BIOL CHEM, V274, P14012, DOI 10.1074/jbc.274.20.14012; Haller D, 2000, GUT, V47, P79, DOI 10.1136/gut.47.1.79; HATCHER GE, 1993, J DAIRY SCI, V76, P2485; Kato I, 1999, INT J IMMUNOPHARMACO, V21, P121, DOI 10.1016/S0192-0561(98)00072-1; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Maassen CBM, 2000, VACCINE, V18, P2613, DOI 10.1016/S0264-410X(99)00378-3; MACATONIA SE, 1993, INT IMMUNOL, V5, P1119, DOI 10.1093/intimm/5.9.1119; McDyer JF, 1998, J IMMUNOL, V160, P1701; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Nagura T, 2002, BRIT J NUTR, V88, P421, DOI [10.1079/BJN2002666, 10.1079/BJNBJN2002561]; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PEREYRA BS, 1993, NUTR RES, V13, P1127; Platts-Mills T. A., 2001, AM J RESP CRIT CARE, V164, P1; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Schroder NWJ, 2003, J BIOL CHEM, V278, P15587, DOI 10.1074/jbc.M212829200; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SELDEN RF, 1995, SHORT PROTOCOLS MOL; SHAHANI KM, 1983, J FOOD PROTECT, V46, P385; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Takagi A, 2001, CARCINOGENESIS, V22, P599, DOI 10.1093/carcin/22.4.599; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Veckman V, 2003, J LEUKOCYTE BIOL, V74, P395, DOI 10.1189/jlb.0402212	31	159	170	1	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.		2004	135	3					205	215		10.1159/000081305		11	Allergy; Immunology	Allergy; Immunology	880CD	WOS:000225765100003	15467373	
J	Norman, GR; Sridar, FG; Guyatt, GH; Walter, SD				Norman, GR; Sridar, FG; Guyatt, GH; Walter, SD			Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life	MEDICAL CARE			English	Article						effect size; NNT (number needed to treat)	OBSTRUCTIVE PULMONARY-DISEASE; OF-LIFE; IMPORTANT DIFFERENCE; RHEUMATOID-ARTHRITIS; CLINICAL-TRIALS; REHABILITATION; QUESTIONNAIRE; ASTHMA; HOME	Background. Approaches to interpretation of quality of life changes in clinical trials have fallen into two camps: those that rely on the distribution of changes and the Effect Size (ES), and those that use some external anchor, such as patient judgments of change, which is then used to compute a Minimally Important Difference (MID), the proportion benefiting from treatment, p(B), and the Number Needed to Treat (NNT). OBJECTIVE. To examine the relationship between the ES and p(B), and the impact of the MID on this relationship. METHODS. Simulation was used based on a normal distribution to compute the proportion of patients benefiting in both parallel group and crossover designs, for various values of the ES and the MID. The agreement of the simulation with empirical data from four studies of asthma and respiratory disease was assessed. The effect of skewness in the distributions of change scores on the relationship between ES and p(B) was also examined. RESULTS. The simulation showed a near-linear relationship between ES and p(B), which was nearly independent of the value of the MID. Agreement of the simulation with the empirical data were excellent. Although the curves differed for crossover and parallel group designs, the general form was similar. Introducing moderate skew into the distributions had minimal impact on the relationship. CONCLUSIONS. The proportion of patients who will benefit from treatment can be directly estimated from the ES, and is nearly independent of the choice of MID. Effect size and anchor based approaches provide equivalent information in this situation.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada	Norman, GR (reprint author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Room 2C14,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.						Cohen J., 1969, STAT POWER ANAL BEHA; Dalton GW, 2000, PHYS THER, V80, P1214; GOLDSMITH CH, 1993, J RHEUMATOL, V20, P561; GOLDSTEIN RS, 1994, LANCET, V344, P1394, DOI 10.1016/S0140-6736(94)90568-1; Guell R, 1998, EUR RESPIR J, V11, P55, DOI 10.1183/09031936.98.11010055; Guyatt GH, 1998, BRIT MED J, V316, P690; GUYATT GH, 1987, THORAX, V42, P773, DOI 10.1136/thx.42.10.773; GUYATT GH, 1993, ANN INTERN MED, V118, P622; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037//0022-006X.59.1.12; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KAZIS LE, 1989, MED CARE, V27, pS178, DOI 10.1097/00005650-198903001-00015; Norman GR, 1997, J CLIN EPIDEMIOL, V50, P869, DOI 10.1016/S0895-4356(97)00097-8; Redelmeier DA, 1996, J CLIN EPIDEMIOL, V49, P1215, DOI 10.1016/S0895-4356(96)00206-5; SENN S, 1998, BRIT MED J, V316, P690; Stratford PW, 1998, PHYS THER, V78, P1186; WELLS GA, 1993, J RHEUMATOL, V20, P557; WIJKSTRA PJ, 1994, EUR RESPIR J, V7, P269, DOI 10.1183/09031936.94.07020269; WIJKSTRA PJ, 1995, THORAX, V50, P824, DOI 10.1136/thx.50.8.824; Wyrwich KW, 1999, MED CARE, V37, P469, DOI 10.1097/00005650-199905000-00006	21	159	160	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0025-7079			MED CARE	Med. Care	OCT	2001	39	10					1039	1047		10.1097/00005650-200110000-00002		9	Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	477KT	WOS:000171283300002	11567167	
J	Plaschke, PP; Janson, C; Norrman, E; Bjornsson, E; Ellbjar, S; Jarvholm, B				Plaschke, PP; Janson, C; Norrman, E; Bjornsson, E; Ellbjar, S; Jarvholm, B			Onset and remission of allergic rhinitis and asthma and the relationship with atopic sensitization and smoking	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SWEDISH SCHOOLCHILDREN; CHRONIC-BRONCHITIS; CAT; SYMPTOMS; IGE; SWEDEN; ADULTS; AREAS; HOMES; PETS	The aim of this study was to assess the influence of some risk factors for onset and remission of allergic rhinitis and asthma in Swedish adults. A random sample of 1,370 subjects, age 20 to 44 yr was investigated by means of postal questionnaires in 1990 and 1993. Skin prick tests were conducted in 1991-1992. The association between risk factors and onset or remission of allergic rhinitis and asthma was estimated using multivariate logistic regression analysis. Onset of allergic rhinitis was associated with sensitization to birch (odds ratio [OR] = 6.5), Parietaria (OR = 7.4); and pets (OR = 3.0) and with female sex (OR = 1.9). Onset of asthma was associated with allergic rhinitis (OR = 4.9), sensitization to pets (OR = 2.4); and with smoking (OR = 3.0). Onset of asthma was strongly associated with allergic rhinitis among atopics (OR = 5.7), but onset of asthma and rhinitis also tended to be related among nonatopics (OR = 3.5). A strong association between smoking and onset of asthma was found among nonatopics (OR = 5.7). In conclusion, sensitization to pollens and pets were risk factors for onset of allergic rhinitis, whereas allergic rhinitis, sensitization to pets, and smoking were risk factors for onset of asthma.	Copenhagen Univ Hosp, Amager Hosp, Dept Med, DK-2300 Copenhagen S, Denmark; Sahlgrens Univ Hosp, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden; Akad Sjukhuset, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; Akad Sjukhuset, Asthma Res Ctr, Uppsala, Sweden; Univ Hosp No Sweden, Dept Pulm Med & Allergol, Umea, Sweden; Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden	Plaschke, PP (reprint author), Copenhagen Univ Hosp, Amager Hosp, Dept Med, Italiensvej 1, DK-2300 Copenhagen S, Denmark.						ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; AUGUSTO A, 1997, AM J RESP CRIT CARE, V156, P23; BELIN L, 1985, ALLERGY S4, V40, P60; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; BERGGREN B, 1993, POLLENSASONGEN 1993; BJORNSSON E, 1994, EUR RESPIR J, V7, P2146, DOI 10.1183/09031936.94.07122146; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1992, ASTHMA, P254; BURNEY PGJ, 1987, CHEST, V91, P79; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; Dreborg S, 1989, ALLERGY S10, V44, P1; Egmar AC, 1998, PEDIATR ALLERGY IMMU, V9, P31, DOI 10.1111/j.1399-3038.1998.tb00297.x; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; HIGGINS MW, 1977, AM REV RESPIR DIS, V116, P403; Kaplan BA, 1997, J ASTHMA, V34, P219, DOI 10.3109/02770909709068192; KRZYANOWSKI M, 1992, EUR RESPIR J, V5, P1; LARSSON L, 1995, THORAX, V50, P260, DOI 10.1136/thx.50.3.260; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; LIN RY, 1993, ANN ALLERGY, V71, P33; Norrman E, 1998, ALLERGY, V53, P28, DOI 10.1111/j.1398-9995.1998.tb03770.x; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Plaschke P, 1996, ALLERGY, V51, P461, DOI 10.1111/j.1398-9995.1996.tb04652.x; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)81050-0; Strachan DP, 1996, BRIT MED J, V312, P1195; Sunyer J., 1997, European Respiratory Journal, V10, P2490, DOI 10.1183/09031936.97.10112490; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534	32	159	164	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP	2000	162	3					920	924				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	355AM	WOS:000089363500029	10988106	
J	Arnold, IC; Dehzad, N; Reuter, S; Martin, H; Becher, B; Taube, C; Muller, A				Arnold, Isabelle C.; Dehzad, Nina; Reuter, Sebastian; Martin, Helen; Becher, Burkhard; Taube, Christian; Mueller, Anne			Helicobacter pylori infection prevents allergic asthma in mouse models through the induction of regulatory T cells	JOURNAL OF CLINICAL INVESTIGATION			English	Article							AIRWAY INFLAMMATION; PROTECT; MICE	Atopic asthma is a chronic disease of the airways that has taken on epidemic proportions in the industrialized world. The increase in asthma rates has been linked epidemiologically to the rapid disappearance of Helicobacter pylori, a bacterial pathogen that persistently colonizes the human stomach, from Western societies. In this study, we have utilized mouse models of allergic airway disease induced by ovalbumin or house dust mite allergen to experimentally examine a possible inverse correlation between H. pylori and asthma. H. pylori infection efficiently protected mice from airway hyperresponsiveness, tissue inflammation, and goblet cell metaplasia, which are hallmarks of asthma, and prevented allergen-induced pulmonary and bronchoalveolar infiltration with eosinophils, Th2 cells, and Th17 cells. Protection against asthma was most robust in mice infected neonatally and was abrogated by antibiotic eradication of H. pylori. Asthma protection was further associated with impaired maturation of lung-infiltrating dendritic cells and the accumulation of highly suppressive Tregs in the lungs. Systemic Treg depletion abolished asthma protection; conversely, the adoptive transfer of purified Treg populations was sufficient to transfer protection from infected donor mice to uninfected recipients. Our results thus provide experimental evidence for a beneficial effect of H. pylori colonization on the development of allergen-induced asthma.	[Arnold, Isabelle C.; Mueller, Anne] Univ Zurich, Inst Mol Canc Res, CH-8057 Zurich, Switzerland; [Dehzad, Nina; Reuter, Sebastian; Martin, Helen; Taube, Christian] Johannes Gutenberg Univ Mainz, Med Clin 3, D-55101 Mainz, Germany; [Becher, Burkhard] Univ Zurich, Inst Expt Immunol, CH-8057 Zurich, Switzerland	Muller, A (reprint author), Univ Zurich, Inst Mol Canc Res, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	taube@3-med.klinik.uni-mainz.de; mueller@imcr.uzh.ch	Reuter, Sebastian/L-1804-2013	Becher, Burkhard/0000-0002-1541-7867	Swiss National Science Foundation; Zurich University; Deutsches Forschungsgemeinschaft (DFG) [Ta 275/4-1, Ta 275/5-1]; Research Center for Immunology of the University of Mainz	This study was funded by grants from Swiss National Science Foundation and the Zurich University Research Priority Program - Systems Biology to A. Muller. Additional funding was obtained from Deutsches Forschungsgemeinschaft (DFG) (Ta 275/4-1 and Ta 275/5-1) and the Research Center for Immunology of the University of Mainz (to C. Taube).	Arnold IC, 2011, GASTROENTEROLOGY, V140, P199, DOI 10.1053/j.gastro.2010.06.047; BANATVALA N, 1993, J INFECT DIS, V168, P219; Blaser MJ, 2008, GUT, V57, P561, DOI 10.1136/gut.2007.133462; Blaser MJ, 2009, NAT REV MICROBIOL, V7, P887, DOI 10.1038/nrmicro2245; Busse WW, 2001, NEW ENGL J MED, V344, P350; Chang YJ, 2011, J CLIN INVEST, V121, P57, DOI 10.1172/JCI44845; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; Chen Y, 2007, ARCH INTERN MED, V167, P821, DOI 10.1001/archinte.167.8.821; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Harris PR, 2008, GASTROENTEROLOGY, V134, P491, DOI 10.1053/j.gastro.2007.11.006; Kitagaki K, 2006, J IMMUNOL, V177, P1628; Onishi Y, 2008, P NATL ACAD SCI USA, V105, P10113, DOI 10.1073/pnas.0711106105; Reibman J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004060; Reuter S, 2008, EUR RESPIR J, V31, P773, DOI 10.1183/09031936.00058907; Robinson DS, 2009, CLIN EXP ALLERGY, V39, P1314, DOI 10.1111/j.1365-2222.2009.03301.x; Steinman RM, 2003, ANN NY ACAD SCI, V987, P15; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572	19	158	174	4	23	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	AUG	2011	121	8					3088	3093		10.1172/JCI45041		6	Medicine, Research & Experimental	Research & Experimental Medicine	802FU	WOS:000293495500019	21737881	
J	Weiland, SK; Husing, A; Strachan, DP; Rzehak, P; Pearce, N				Weiland, SK; Husing, A; Strachan, DP; Rzehak, P; Pearce, N		ISAAC Phase One Study Grp	Climate and the prevalence of symptoms of asthma, allergic rhinitis, and atopic eczema in children	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							HOUSE-DUST MITES; CHILDHOOD ISAAC; WORLDWIDE VARIATIONS; RESPIRATORY HEALTH; EXPOSURE; SENSITIZATION; AREAS; HOME; RHINOCONJUNCTIVITIS; ADOLESCENTS	Aims: To investigate the association between climate and atopic diseases using worldwide data from 146 centres of the International Study of Asthma and Allergies in Childhood (ISAAC). Methods: Between 1992 and 1996, each centre studied random samples of children aged 13 - 14 and 6 - 7 years (approx. 3000 per age group and centre) using standardised written and video questionnaires on symptoms of asthma, allergic rhinoconjunctivitis, and atopic eczema during the past 12 months. Data on long term climatic conditions in the centres were abstracted from one standardised source, and mixed linear regression models calculated to take the clustering of centres within countries into account. Results: In Western Europe ( 57 centres in 12 countries), the prevalence of asthma symptoms, assessed by written questionnaire, increased by 2.7% ( 95% CI 1.0% to 4.5%) with an increase in the estimated annual mean of indoor relative humidity of 10%. Similar associations were seen for the video questionnaire and the younger age group. Altitude and the annual variation of temperature and relative humidity outdoors were negatively associated with asthma symptoms. The prevalence of eczema symptoms correlated with latitude ( positively) and mean annual outdoor temperature ( negatively). Conclusions: Results suggest that climate may affect the prevalence of asthma and atopic eczema in children.	Univ Ulm, Dept Epidemiol, D-89081 Ulm, Germany; Ruhr Univ Bochum, Dept Med Informat Biometr & Epidemiol, Bochum, Germany; Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; Massey Univ, Wellington, New Zealand	Weiland, SK (reprint author), Univ Ulm, Dept Epidemiol, Helmholzstr 22, D-89081 Ulm, Germany.	stephan.weiland@medizin.uni-ulm.de	Clayton, Tadd/B-7914-2009; Ellwood, Philippa/G-7555-2015	Ellwood, Philippa/0000-0002-1994-4023; Pearce, Neil/0000-0002-9938-7852			ALLEGRA L, 1995, EUR RESPIR J, V8, P1842, DOI 10.1183/09031936.95.08111842; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BJORNSSON E, 1994, EUR RESPIR J, V7, P2146, DOI 10.1183/09031936.94.07122146; CAREY MJ, 1986, BRIT MED J, V293, P843; Celenza A, 1996, BRIT MED J, V312, P604; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; CULLEN KJ, 1972, BRIT MED J, V4, P65; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; EberleinKonig B, 1996, ACTA DERM-VENEREOL, V76, P447; ECHECHIPIA S, 1995, ALLERGY, V50, P478, DOI 10.1111/j.1398-9995.1995.tb01182.x; Epton MJ, 1997, THORAX, V52, P528; Gibson PG, 2000, CLIN EXP ALLERGY, V30, P1181; GOLDSTEIN H, 1995, KENDALLS ADV THEORY; Hales S, 1998, ENVIRON HEALTH PERSP, V106, P607, DOI 10.1289/ehp.98106607; Harju T, 1998, EUR RESPIR J, V12, P1362, DOI 10.1183/09031936.98.12061362; LARSSON K, 1993, BRIT MED J, V307, P1326; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Little RC, 1996, SAS SYSTEM MIXED MOD; McNally NJ, 2000, BRIT J DERMATOL, V142, P712, DOI 10.1046/j.1365-2133.2000.03416.x; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; Newson R, 1997, THORAX, V52, P680; Newson R, 1998, EUR RESPIR J, V11, P694; Nicolai T, 1998, THORAX, V53, P1035; PATZ JA, 2002, BRIT MED J, V25, P1094; Pearce E. A., 1984, WORLD WEATHER GUIDE; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; POYSA L, 1991, ALLERGY, V46, P161, DOI 10.1111/j.1398-9995.1991.tb00564.x; ROEDEL W, 1994, PHYS UNSERER UMWELT, P186; Schultz Larsen F, 1996, J Am Acad Dermatol, V34, P760; Stewart AW, 2001, INT J EPIDEMIOL, V30, P173, DOI 10.1093/ije/30.1.173; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Tanaka H, 1998, EUR RESPIR J, V11, P1301, DOI 10.1183/09031936.98.11061301; Tromp S W, 1968, Rev Allergy, V22, P1027; Verlato G, 2002, ARCH ENVIRON HEALTH, V57, P48; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1	45	158	168	3	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2004	61	7					609	615		10.1136/oem.2002.006809		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	830QC	WOS:000222136700007	15208377	
J	ten Brinke, A; Grootendorst, DC; Schmidt, JT; de Bruine, FT; van Buchem, MA; Sterk, PJ; Rabe, KF; Bel, EH				ten Brinke, A; Grootendorst, DC; Schmidt, JT; de Bruine, FT; van Buchem, MA; Sterk, PJ; Rabe, KF; Bel, EH			Chronic sinusitis in severe asthma is related to sputum eosinophilia	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity-of-illness index; age of onset; inflammation; nasal mucosa; eosinophils; sputum; computed tomography; human	NASAL; INFLAMMATION; RHINITIS; AIRWAYS	Background: Chronic rhinosinusitis and asthma are conditions that frequently coexist, particularly in severe asthma. The precise mechanism of the relationship between upper and lower airway, inflammation is still a matter of debate. We hypothesized that the extent of inflammation in the nasal mucosa is related to lung function and inflammation in the bronchial mucosa in patients with severe asthma. Objective: We sought to investigate the relationship between sinonasal inflammation as assessed on computed tomography (CT) scanning, lung function, sputum eosinophilia, and nitric oxide (NO) in exhaled air in patients with severe asthma. Methods: Eighty-nine nonsmoking outpatients with severe asthma (29 men and 60 women; mean age 45 years; age range, 18-74 years) were included in this study. CT scans were scored (0-30) by a blinded investigator using a validated method. Lung function, NO in exhaled air, and sputum eosinophils were measured by using standard procedures. Results: CT scans showed abnormalities in 84% of patients. Extensive sinus disease (score 12-30) was found in 24% of patients. There was a significant positive correlation between CT scores and eosinophils in peripheral blood (R-s = 0.46) and induced sputum (R-s = 0.40) and level of exhaled NO (R-s = 0.45, P < .01). CT scores were also positively related to functional residual capacity and inversely, related to diffusion capacity, particularly in patients with adult-onset asthma (R-s = 0.47 and R-s = -0.53, respectively). Conclusions: The results of this study show a direct relationship between sinonasal mucosa thickness and bronchial inflammation in severe asthma, particularly in patients with adult-onset disease. Whether sinus disease directly affects the intensity of bronchial inflammation is still an unanswered question.	Leiden Univ, Med Ctr, Dept Pulm Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Otorhinolaryngol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Radiol, NL-2300 RC Leiden, Netherlands; Med Ctr Leeuwarden, Dept Pulm Dis, Leeuwarden, Netherlands	Bel, EH (reprint author), Leiden Univ, Med Ctr, Dept Pulm Dis, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.						American Thoracic Society Workshop, 1999, AM J RESP CRIT CARE, V160, P1778; Armitage P, 1987, STAT METHODS MED RES; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; BRUGMAN SM, 1993, AM REV RESPIR DIS, V147, P314; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588; Chung KF, 1999, EUR RESPIR J, V13, P1198; COTES JE, 1995, EUR RESPIR J, V16, P41; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; Gaga M, 2000, CLIN EXP ALLERGY, V30, P663; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; In 'T Veen J. C. C. M., 1996, European Respiratory Journal, V9, P2441, DOI 10.1183/09031936.96.09122441; in 't Veen Johannes C. C. M., 2000, American Journal of Respiratory and Critical Care Medicine, V161, P1902; Kepley CL, 2001, AM J RESP CRIT CARE, V164, P1053; Leynaert Benedicte, 2000, Journal of Allergy and Clinical Immunology, V106, pS201; MCFADDEN ER, 1986, J ALLERGY CLIN IMMUN, V78, P1, DOI 10.1016/0091-6749(86)90106-5; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683; Nakamura H, 1999, ACTA OTO-LARYNGOL, V119, P592; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Senior BA, 1996, ANN ALLERG ASTHMA IM, V77, P6; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; SZEZCKLIK A, 2000, THORAX S2, V55, pS42; TAHA RA, 1999, J ALLERGY CLIN IMMUN, V10, P47; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P749; TENBRINKE A, 2001, EUR RESPIR J, V18, pS66; ZINREICH SJ, 1990, OTOLARYNG HEAD NECK, V103, P863	33	158	162	3	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2002	109	4					621	626		10.1067/mai.2002.122458		6	Allergy; Immunology	Allergy; Immunology	543YZ	WOS:000175132600008	11941310	
J	Soukup, JM; Becker, S				Soukup, JM; Becker, S			Human alveolar macrophage responses to air pollution particulates are associated with insoluble components of coarse material, including particulate endotoxin	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						human macrophage; endotoxin; air pollution PM10 and PM2.5; phagocytosis; apoptosis; cytokines	NECROSIS-FACTOR-ALPHA; FINE PARTICLES; HOSPITAL ADMISSIONS; RESPIRATORY HEALTH; OXIDATIVE BURST; BLOOD MONOCYTES; CHILDREN; ASTHMA; LIPOPOLYSACCHARIDE; PHAGOCYTOSIS	Inhalation of particulate matter in the ambient air has been shown to cause pulmonary morbidity and exacerbate asthma. Alveolar macrophage (AIM) are essential for effective removal of inhaled particles and microbes in the lower airways. While some particles minimally effect AM function others inhibit antimicrobial activity or cause cytokine and growth factor production leading to inflammation and tissue remodeling. This study has investigated the effects of water soluble (s) and insoluble (is) components of Chapel Hill, North Carolina ambient particulate matter in the size ranges 0.1-2.5 Ccm (PM2.5) and 2.5-10 mum (PM10) diameter, on human AM IL-6, TNF alpha, and MCP-1 cytokine production and host defense mechanisms including phagocytosis and oxidant production. Cytokines were found to be induced by isPM10 to a much higher extent (>50-fold) than sPM10, which in turn stimulated production better than isPM2.5, while sPM2.5 was inactive. Previous studies have indicated that endotoxin (ETOX) is a component of sPM10 responsible for cytokine production. Here, it is shown that inhibition of isPM10-induced cytokine production was partially achieved with polymyxin B and LPS-binding protein (LBP), but not with a metal chelator, implicating ETOX as a cytokine-inducing moiety also in isPM10. In addition to inducing cytokines, exposure to isPM10, but not the other PM fractions, also inhibited phagocytosis and oxidant generation in response to yeast. This inhibition was ETOX independent. The decrease in host defenses may be the result of apoptosis in the AM population, which was also found to be specifically caused by isPM10. These results show that the functional capacity of AM is selectively modulated by insoluble components of coarse PM, including the biocontaminant ETOX.	US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	Soukup, JM (reprint author), US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.						Becker S, 1998, J TOXICOL ENV HEAL A, V55, P455, DOI 10.1080/009841098158278; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BECKER S, 1994, AM J PHYSIOL, V266, P278; BRACH MA, 1992, MOL PHARMACOL, V42, P63; CHUNG KF, 1988, EUR RESPIR J, V1, P890; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; DELFINO RJ, 1994, ENVIRON RES, V67, P1, DOI 10.1006/enrs.1994.1061; DELUCCA AJ, 1984, AM IND HYG ASSOC J, V45, P336; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dong WM, 1996, EXP LUNG RES, V22, P577, DOI 10.3109/01902149609046043; FOGELMARK B, 1994, INT J EXP PATHOL, V75, P85; Gamble JF, 1998, ENVIRON HEALTH PERSP, V106, P535, DOI 10.1289/ehp.98106535; GERSCHENSON LE, 1992, FASEB J, V6, P2450; HEPPLESTON AG, 1984, ENVIRON HEALTH PERSP, V55, P111, DOI 10.2307/3429696; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; HOFFMAN OA, 1993, IMMUNOL LETT, V37, P19, DOI 10.1016/0165-2478(93)90127-N; Holian A, 1998, ENVIRON HEALTH PERSP, V106, P127; Imrich A, 1999, TOXICOL APPL PHARM, V159, P117, DOI 10.1006/taap.1999.8731; Jakab G J, 1990, Environ Health Perspect, V89, P169; Jakab GJ, 1996, TOXICOL LETT, V88, P243, DOI 10.1016/0378-4274(96)03745-9; Kim CS, 1996, J APPL PHYSIOL, V81, P2203; Kim CS, 1997, AM J RESP CRIT CARE, V155, P899; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; KREYLING WG, 1992, ENVIRON HEALTH PERSP, V97, P121, DOI 10.2307/3431339; LAITINEN S, 1994, AM IND HYG ASSOC J, V55, P1055; Larsson BM, 1999, INFLAMMATION, V23, P217; LAUBE BL, 1986, AM REV RESPIR DIS, V133, P740; LIEBLER JM, 1994, J IMMUNOL, V152, P241; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Monn C, 1999, TOXICOL APPL PHARM, V155, P245, DOI 10.1006/taap.1998.8591; MORGAN A, 1980, ENVIRON RES, V22, P1, DOI 10.1016/0013-9351(80)90113-9; NEAS LM, 1994, AM J EPIDEMIOL, V139, P1088; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Slight J, 1996, THORAX, V51, P389, DOI 10.1136/thx.51.4.389; Soltys J, 1999, INFECT IMMUN, V67, P244; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tseng P, 1992, SIAM J OPTIMIZ, V2, P425, DOI 10.1137/0802021; Wilson WE, 1997, J AIR WASTE MANAGE, V47, P1238; ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49	47	158	163	4	28	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	FEB 15	2001	171	1					20	26		10.1006/taap.2000.9096		7	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	407JE	WOS:000167267800003	11181108	
J	Nurmatov, U; Devereux, G; Sheikh, A				Nurmatov, Ulugbek; Devereux, Graham; Sheikh, Aziz			Nutrients and foods for the primary prevention of asthma and allergy: Systematic review and meta-analysis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy; antioxidants; asthma; atopy; diet; foods; nutrients	VITAMIN-D INTAKE; MEDITERRANEAN DIET; CHILDHOOD ASTHMA; SCHOOL-CHILDREN; 5-YEAR-OLD CHILDREN; RISK-FACTORS; RESPIRATORY SYMPTOMS; ANTIOXIDANT VITAMINS; FRUIT CONSUMPTION; WHEEZING SYMPTOMS	Background: Epidemiologic studies suggest that deficiencies of the nutrients selenium; zinc; vitamins A, C, D, and E; and low fruit and vegetable intake may be associated with the development of asthma and allergic disorders. Objectives: To investigate the evidence that nutrient and food intake modifies the risk of children developing allergy. Methods: We systematically searched 11 databases. Studies were critically appraised, and meta-analyses were undertaken. Results: We identified 62 eligible reports. There were no randomized controlled trials. Studies used cohort (n = 21), case-control (n 5 15), or cross-sectional (n 5 26) designs. All studies were judged to be at moderate to substantial risk of bias. Meta-analysis revealed that serum vitamin A was lower in children with asthma compared with controls (odds ratio [OR], 0.25; 95% CI, 0.10-0.40). Meta-analyses also showed that high maternal dietary vitamin D and E intakes during pregnancy were protective for the development of wheezing outcomes (OR, 0.56, 95% CI, 0.42-0.73; and OR, 0.68, 95% CI, 0.52-0.88, respectively). Adherence to a Mediterranean diet was protective for persistent wheeze (OR, 0.22; 95% CI, 0.08-0.58) and atopy (OR, 0.55; 95% CI, 0.31-0.97). Seventeen of 22 fruit and vegetable studies reported beneficial associations with asthma and allergic outcomes. Results were not supportive for other allergic outcomes for these vitamins or nutrients, or for any outcomes in relation to vitamin C and selenium. Conclusion: The available epidemiologic evidence is weak but nonetheless supportive with respect to vitamins A, D, and E; zinc; fruits and vegetables; and a Mediterranean diet for the prevention of asthma. Experimental studies of these exposures are now warranted. (J Allergy Clin Immunol 2011;127:724-33.)	[Nurmatov, Ulugbek; Sheikh, Aziz] Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh EH8 9AG, Midlothian, Scotland; [Devereux, Graham] Univ Aberdeen, Royal Aberdeen Childrens Hosp, Dept Child Hlth, Aberdeen, Scotland	Sheikh, A (reprint author), Univ Edinburgh, Sch Med, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.	aziz.sheikh@ed.ac.uk	Sheikh, Aziz /D-2818-2009	Sheikh, Aziz /0000-0001-7022-3056	Chief Scientist's Office of the Scottish Government Health Department [CZG/2/396]	This project was supported in its entirety by a project grant awarded by the Chief Scientist's Office of the Scottish Government Health Department (CZG/2/396).	Allen S, 2009, THORAX, V64, P610, DOI 10.1136/thx.2008.101469; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Anandan C, 2009, ALLERGY, V64, P840, DOI 10.1111/j.1398-9995.2009.02042.x; Antova T, 2003, THORAX, V58, P231, DOI 10.1136/thorax.58.3.231; Arora P, 2002, PEDIATR ALLERGY IMMU, V13, P223, DOI 10.1034/j.1399-3038.2002.00010.x; Awasthi Shally, 2004, Indian Pediatr, V41, P1205; Back O, 2009, ACTA DERM-VENEREOL, V89, P28, DOI 10.2340/00015555-0541; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Burney P, 2008, ALLERGY, V63, P865, DOI 10.1111/j.1398-9995.2008.01716.x; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Castro-Rodriguez JA, 2008, J PEDIATR, V152, P823, DOI 10.1016/j.jpeds.2008.01.003; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; Chatzi L, 2007, PEDIATR ALLERGY IMMU, V18, P480, DOI 10.1111/j.1399-3038.2007.00596.x; Cook DG, 1997, THORAX, V52, P628; Covar R, 2010, CLIN EXP ALLERGY, V40, P1163, DOI 10.1111/j.1365-2222.2010.03523.x; de Batlle J, 2008, ALLERGY, V63, P1310, DOI 10.1111/j.1398-9995.2008.01722.x; Devenny A, 2004, BRIT MED J, V329, P489, DOI 10.1136/bmj.38139.666447.F7; Devereux G, 2007, CLIN EXP ALLERGY, V37, P1000, DOI 10.1111/j.1365-2222.2007.02757.x; Devereux G, 2007, AM J CLIN NUTR, V85, P853; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; el-Kholy M S, 1990, J Egypt Public Health Assoc, V65, P657; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Ermis B., 2004, European Journal of General Medicine, V1, P4; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Fitzsimon N, 2007, Ir Med J, V100, P27; Forastiere F, 2000, THORAX, V55, P283, DOI 10.1136/thorax.55.4.283; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Gao JM, 2008, RESPIROLOGY, V13, P528, DOI 10.1111/j.1440-1843.2008.01286.x; Garcia E, 2008, PEDIAT ALLERG IMM-UK, V19, P307, DOI 10.1111/j.1399-3038.2007.00650.x; Garcia-Marcos L, 2007, THORAX, V62, P503, DOI 10.1136/thx.2006.060020; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P577; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Hozyasz Kamil K, 2004, Med Wieku Rozwoj, V8, P963; Hozyasz KK, 2005, PEDIATR POL, V80, P6; Huang SL, 2001, CLIN EXP ALLERGY, V31, P1875, DOI 10.1046/j.1365-2222.2001.01222.x; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Jenner Nicole, 2004, Australas J Dermatol, V45, P16, DOI 10.1111/j.1440-0960.2004.00046.x; Kalayci O, 2000, TURKISH J PEDIATR, V42, P17; Kocabas CN, 2006, TURKISH J PEDIATR, V48, P308; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059; Liberati A, 2009, PLOS MED, V6, DOI [10.1371/journal.pmed.1000100, 10.1016/j.jclinepi.2009.06.006]; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Litonjua AA, 2006, AM J CLIN NUTR, V84, P903; Martindale S, 2005, AM J RESP CRIT CARE, V171, P121, DOI 10.1164/rccm.200402-220OC; McKeever TM, 2004, J ALLERGY CLIN IMMUN, V114, P1398, DOI 10.1016/j.jaci.2004.08.006; Milner JD, 2004, PEDIATRICS, V114, P27, DOI 10.1542/peds.114.1.27; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Miyake Y, 2010, ALLERGY, V65, P758, DOI 10.1111/j.1398-9995.2009.02267.x; Mizuno Y, 2006, PEDIATR INT, V48, P261, DOI 10.1111/j.1442-200X.2006.02200.x; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Murr C, 2005, MED HYPOTHESES, V64, P973, DOI 10.1016/j.mehy.2004.11.011; Murray CS, 2006, ALLERGY, V61, P438, DOI 10.1111/j.1398-9995.2005.00927.x; Nja F, 2005, ACTA PAEDIATR, V94, P147, DOI 10.1080/08035250410023638; Okoko BJ, 2007, EUR RESPIR J, V29, P1161, DOI 10.1183/09031936.00097806; Omata N, 2001, LIFE SCI, V69, P223, DOI 10.1016/S0024-3205(01)01124-9; Pastorino AC, 2006, J ASTHMA, V43, P695, DOI 10.1080/02770900600925544; Pesonen M, 2007, CLIN EXP ALLERGY, V37, P54, DOI 10.1111/j.1365-2222.2006.02630.x; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; Romieu I, 2004, PEDIATR PULM, V38, P31, DOI 10.1002/ppul.20042; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; Sala-Vila A, 2008, CLIN EXP ALLERGY, V38, P1432, DOI 10.1111/j.1365-2222.2008.03072.x; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; Shaheen SO, 2009, THORAX, V64, P411, DOI 10.1136/thx.2008.104703; Shaheen SO, 2004, EUR RESPIR J, V24, P292, DOI 10.1183/09031936.04.00117803; SHAW R, 1994, NEW ZEAL MED J, V107, P387; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; Tabak C, 2006, THORAX, V61, P1048, DOI 10.1136/thx.2005.043034; Tagiyeva N, 2008, PEDIATR ALLERGY IMMU, V19, P7, DOI 10.1111/j.1399-3038.2007.00594.x; Tahan F, 2006, PEDIATR PULM, V41, P630, DOI 10.1002/ppul.20413; Tamay Z, 2007, INT J PEDIATR OTORHI, V71, P463, DOI 10.1016/j.ijporl.2006.11.013; Tricon S., 2006, Clinical and Experimental Allergy Reviews, V6, P117, DOI 10.1111/j.1365-2222.2006.00114.x; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401; Tsai HJ, 2007, J ASTHMA, V44, P599, DOI 10.1080/02770900701539509; Ushiyama Y, 2002, J NUTR SCI VITAMINOL, V48, P345; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; Weiss ST, 2007, THORAX, V62, P745; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Wjst M, 1999, ALLERGY, V54, P757, DOI 10.1034/j.1398-9995.1999.00193.x; Wong GWK, 2004, BRIT MED J, V329, P486, DOI 10.1136/bmj.329.7464.486; Wood LG, 2005, J AM COLL NUTR, V24, P448	85	157	165	4	56	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					724	U359		10.1016/j.jaci.2010.11.001		40	Allergy; Immunology	Allergy; Immunology	730FG	WOS:000288018400027	21185068	
J	Spergel, JM				Spergel, Jonathan M.			From atopic dermatitis to asthma: the atopic march	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Review							OF-FUNCTION MUTATIONS; MAJOR RISK-FACTOR; FOLLOW-UP; INHALED CORTICOSTEROIDS; AIRWAY INFLAMMATION; RUSSIAN KARELIA; YOUNG-CHILDREN; PEANUT ALLERGY; PHASE-III; FILAGGRIN	Objective: To examine the mechanisms whereby allergen exposure through the epidermis could initiate systemic allergy and predispose individuals to the development of 1 or more atopic diseases via the so-called atopic march. Data Sources: PubMed databases from 1950 to the present were searched for relevant articles pertaining to epidemiologic and genetic evidence of the progression of the atopic march. Study Selection: Articles concerning pathophysiologic conditions that link atopic dermatitis, allergic rhinitis, and asthma were examined. Results: The data suggest that a sequence of atopic manifestations occurs, typically atopic dermatitis in infancy followed by allergic rhinitis and/or asthma in later stages. Reduced filaggrin expression is implicated as a major predisposing factor for atopy in multiple lines of evidence, including genome-wide analysis and microarray investigations. Other gene products have an important role. Cross-sectional and longitudinal studies provide preliminary epidemiologic support for the sequential development of allergic diseases. Conclusion: The mechanisms by which allergen exposure through the epidermis can initiate systemic allergy and predispose individuals to atopic dermatitis, allergic rhinitis, and asthma have become clearer in recent years. Longitudinal studies of individuals carrying loss-of-function filaggrin gene mutations are needed to further define the risks associated with epidermal barrier dysfunction and potentially identify specific targets for barrier repair and prevention of atopic dermatitis and other atopic disease. The effects of preventive and treatment strategies have been inconsistent across studies, and further research is warranted before any definitive recommendations can be made. Ann Allergy Asthma Immunol. 2010; 105:99-106.	Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Allergy & Immunol, Philadelphia, PA 19104 USA	Spergel, JM (reprint author), Univ Penn, Sch Med, Childrens Hosp Philadelphia, Div Allergy & Immunol, Wood 5314,34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.	spergel@email.chop.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Spergel, Jonathan/0000-0002-4658-5353	Novartis Pharmaceuticals Corporation; Ception Therapeutics; AstraZeneca Pharmaceuticals LP; GlaxoSmithKline; Astellas Pharma US Inc.; National Institute of Allergy and Infectious Disease [R01-AI062698]	Dr Spergel has indicated that in the last 12 months he has received grant support and speaker fees from Novartis Pharmaceuticals Corporation, grant support from Ception Therapeutics, and consultant and speaking fees from AstraZeneca Pharmaceuticals LP, GlaxoSmithKline, and Astellas Pharma US Inc.; Funding for editorial assistance was provided by Novartis Pharmaceuticals Corporation. This study was supported by National Institute of Allergy and Infectious Disease grant R01-AI062698.	Akei HS, 2006, J ALLERGY CLIN IMMUN, V118, P62, DOI 10.1016/j.jaci.2006.04.046; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Barnetson RS, 2002, BRIT MED J, V324, P1376, DOI 10.1136/bmj.324.7350.1376; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Beyer K, 2000, J INVEST DERMATOL, V115, P906, DOI 10.1046/j.1523-1747.2000.00096.x; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bjorksten B, 2008, PEDIATR ALLERGY IMMU, V19, P110, DOI 10.1111/j.1399-3038.2007.00601.x; Boguniewicz M, 2007, J ALLERGY CLIN IMMUN, V119, pS209, DOI 10.1016/j.jaci.2006.12.188; Clark AT, 2009, ALLERGY, V64, P1218, DOI 10.1111/j.1398-9995.2009.01982.x; [Anonymous], 2009, SAF EFF PRIM CREAM 1; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Hanifin JM, 2009, J INVEST DERMATOL, V129, P320, DOI 10.1038/jid.2008.252; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Kapoor R, 2008, J AM ACAD DERMATOL, V58, P68, DOI 10.1016/j.jaad.2007.06.041; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lee GR, 2004, INT IMMUNOL, V16, P1155, DOI 10.1093/intimm/dxh117; Lee J, 2008, J ALLERGY CLIN IMMUN, V121, P116, DOI 10.1016/j.jaci.2007.10.043; Li J, 2005, IMMUNOLOGY, V114, P386, DOI 10.1111/j.1365-2567.2005.02109.x; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; National Institute of Allergy and Infectious Diseases (NIAID) Immune Tolerance Network, 2009, PROM TOL COMM ALL HI; Nicolaou N, 2005, ALLERGY, V60, P1357, DOI 10.1111/j.1398-9995.2005.00961.x; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Ohshima Y, 2002, ANN ALLERG ASTHMA IM, V89, P265; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Pommerencke T, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-473; Ricci G, 2006, J AM ACAD DERMATOL, V55, P765, DOI 10.1016/j.jaad.2006.04.064; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schleimer RP, 2007, J ALLERGY CLIN IMMUN, V120, P1279, DOI 10.1016/j.jaci.2007.08.046; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; Seiskari T, 2007, CLIN EXP IMMUNOL, V148, P47, DOI 10.1111/j.1365-2249.2007.03333.x; Simons FE, 2007, PEDIAT ALLERGY IMMUN, V18, P535, DOI 10.1111/j.1399-3038.2007.00558.x; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 2003, J ALLERGY CLIN IMMUN, V112; Tse K, 2008, CURR ALLERGY ASTHM R, V8, P475, DOI 10.1007/s11882-008-0088-5; van der Hulst AE, 2007, J ALLERGY CLIN IMMUN, V120, P565, DOI 10.1016/j.jaci.2007.05.042; von Hertzen L, 2007, ALLERGY, V62, P288, DOI 10.1111/j.1398-9995.2006.01281.x; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Williams H, 2008, J ALLERGY CLIN IMMUN, V121, P947, DOI 10.1016/j.jaci.2007.11.004; [Anonymous], 2009, GLOBAL PREVENTION AS	54	157	163	1	18	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	AUG	2010	105	2					99	107		10.1016/j.anai.2009.10.002		9	Allergy; Immunology	Allergy; Immunology	701PI	WOS:000285832800002	20674819	
J	Agarwal, R				Agarwal, Ritesh			Allergic Bronchopulmonary Aspergillosis	CHEST			English	Review						allergic bronchopulmonary aspergillosis; Aspergillus; bronchial asthma; cystic fibrosis; prevalence	CYSTIC-FIBROSIS PATIENTS; TERM FOLLOW-UP; INVASIVE PULMONARY ASPERGILLOSIS; REGULATOR GENE-MUTATIONS; HIGH-ATTENUATION MUCUS; FUNGAL DISEASE; RECOMBINANT ALLERGENS; FUMIGATUS ALLERGENS; ASTHMATIC-PATIENTS; SERUM IGE	Allergic bronchopulmonary aspergillosis (ABPA) is air immunologic pulmonary disorder caused by hypersensitivity to Aspergillus fumigatus. Clinically, a patient presents with chronic asthma, recurrent pulmonary infiltrates, and bronchiectasis. The population prevalence of ABPA is not clearly known, but the prevalence in asthma clinics is reported to be around 13%. The disorder needs to be detected before bronchiectasis has developed because the occurrence of bronchiectasis is associated with poorer outcomes. Because many patients with ABPA may be minimally symptomatic or asymptomatic, a high index of suspicion for ABPA should be maintained while managing any patient with bronchial asthma whatever the severity or the level of control. This underscores the need for routine screening of all patients with asthma with an Aspergillus skin test. Finally, there is a need to update and revise the criteria for the diagnosis of ABPA. This review summarizes the advances in the diagnosis and management of ABPA using a systematic search methodology. (CHEST 2009; 135:805-826)	Postgrad Inst Med Educ & Res, Dept Pulm Med, Chandigarh 160012, India	Agarwal, R (reprint author), Postgrad Inst Med Educ & Res, Dept Pulm Med, Sector 12, Chandigarh 160012, India.	riteshpgi@gmail.com		Agarwal, Ritesh/0000-0003-2547-7668			Agarwal R, 2006, AM J ROENTGENOL, V186, P904, DOI 10.2214/AJR.05.0125; Agarwal R, 2008, Monaldi Arch Chest Dis, V69, P32; AGARWAL R, 2009, MYCOSES IN PRESS; AGARWAL R, 2009, BJR IN PRESS; AGARWAL R, 2009, ASPERGILLOS IN PRESS; Agarwal R, 2006, LUNG INDIA, V23, P90; AGARWAL R, 2009, INDIAN J CHEST DIS, V51, P377; AGARWAL R, 2009, INT J TUBER IN PRESS; Agarwal R, 2008, MYCOSES, V51, P83, DOI 10.1111/j.1439-0507.2007.01432.x; Agarwal R, 2006, CHEST, V130, P442, DOI 10.1378/chest.130.2.442; Agarwal R, 2007, CHEST, V132, P1183, DOI 10.1378/chest.07-0808; Agarwal R, 2008, RESP CARE, V53, P1744; AKIYAMA K, 1984, CHEST, V85, P699, DOI 10.1378/chest.85.5.699; Al-Mobeireek AF, 2001, RESP MED, V95, P341, DOI 10.1053/rmed.2001.1047; Allan J D, 1975, Clin Allergy, V5, P255, DOI 10.1111/j.1365-2222.1975.tb01860.x; Allmers H, 2000, AM J IND MED, V37, P438, DOI 10.1002/(SICI)1097-0274(200004)37:4<438::AID-AJIM14>3.3.CO;2-1; Almeida Marina B., 2006, J. Pediatr. (Rio J.), V82, P215, DOI 10.1590/S0021-75572006000300011; ANGUS RM, 1994, THORAX, V49, P586, DOI 10.1136/thx.49.6.586; Aron Y, 1999, J ALLERGY CLIN IMMUN, V104, P891; ATTAPATTU M C, 1991, Ceylon Medical Journal, V36, P45; BACKMAN KS, 1995, AM J RESP CRIT CARE, V152, P1379; BAHOUS J, 1985, CLIN ALLERGY, V15, P571, DOI 10.1111/j.1365-2222.1985.tb02311.x; BALTER MS, 1992, RESP MED, V86, P441, DOI 10.1016/S0954-6111(06)80013-2; BARDANA EJ, 1981, CRC CR REV CL LAB SC, V13, P21; BATEMAN ED, 1994, RESP MED, V88, P325, DOI 10.1016/0954-6111(94)90035-3; BAUR X, 1989, J ALLERGY CLIN IMMUN, V83, P839, DOI 10.1016/0091-6749(89)90023-7; Beamis JF, 2001, NEW ENGL J MED, V345, P443, DOI 10.1056/NEJM200108093450608; Becker JW, 1996, CHEST, V109, P1536, DOI 10.1378/chest.109.6.1536; Behera D, 1994, Indian J Chest Dis Allied Sci, V36, P173; BENATAR SR, 1980, THORAX, V35, P515, DOI 10.1136/thx.35.7.515; BERKIN KE, 1982, BRIT MED J, V285, P552; BHAGAT R, 1993, J ALLERGY CLIN IMMUN, V91, P1094, DOI 10.1016/0091-6749(93)90224-4; BODEY GP, 1993, CHEST, V103, P299, DOI 10.1378/chest.103.1.299; Bondue B, 2005, RESP MED EXTRA, V1, P39, DOI 10.1016/j.rmedx.2005.04.002; Brouard J, 2005, J INFECT DIS, V191, P1988, DOI 10.1086/429964; CAMPBELL MJ, 1964, AM REV RESPIR DIS, V89, P186; Carvalho A, 2008, J INFECT DIS, V197, P618, DOI 10.1086/526500; Chakrabarti A, 2002, MYCOSES, V45, P295, DOI 10.1046/j.1439-0507.2002.00738.x; CHANYEUN.M, 1971, CHEST, V59, P33, DOI 10.1378/chest.59.1.33; Chauhan B, 1997, J IMMUNOL, V159, P4072; Chauhan B, 2000, J ALLERGY CLIN IMMUN, V106, P723, DOI 10.1067/mai.2000.109913; Chauhan B, 1996, J CLIN INVEST, V97, P2324, DOI 10.1172/JCI118675; Chotirmall SH, 2008, RESP CARE, V53, P1035; CHUNG Y, 1994, PEDIATR PULM, V17, P131, DOI 10.1002/ppul.1950170210; Cimon B, 2000, J MYCOL MED, V10, P128; Coop CPTC, 2004, ALLERGY ASTHMA PROC, V25, P263; Cote CG, 1998, CHEST, V114, P1465, DOI 10.1378/chest.114.5.1465; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1996, CLIN EXP ALLERGY, V26, P1411, DOI 10.1046/j.1365-2222.1996.d01-296.x; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; Cunningham S, 2001, ARCH DIS CHILD, V84, P89; de Almeida MB, 2006, PAEDIATR RESPIR REV, V7, P67, DOI 10.1016/j.prrv.2005.09.003; DEBEULE K, 1988, MYCOSES, V31, P476; Denning DW, 2003, CLIN INFECT DIS, V37, pS265, DOI 10.1086/376526; DENNING DW, 1991, CHEST, V100, P813, DOI 10.1378/chest.100.3.813; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; DOLAN CT, 1970, AM J CLIN PATHOL, V53, P235; DONNELLY SC, 1991, IRISH J MED SCI, V160, P288; Eaton T, 2000, CHEST, V118, P66, DOI 10.1378/chest.118.1.66; Eaton TE, 2002, CLIN EXP ALLERGY, V32, P756, DOI 10.1046/j.1365-2222.2002.01361.x; EIN ME, 1979, AM REV RESPIR DIS, V119, P811; ELDAHR JM, 1994, AM J RESP CRIT CARE, V150, P1513; Eppinger TM, 1999, J ALLERGY CLIN IMMUN, V104, P1265, DOI 10.1016/S0091-6749(99)70023-0; Erwin GE, 2007, J ASTHMA, V44, P891, DOI 10.1080/02770900701750197; FEANNY S, 1988, ANN ALLERGY, V60, P64; Ferrari M, 2004, RESPIRATION, V71, P289, DOI 10.1159/000077429; GANASSINI A, 1995, RESP MED, V89, P143, DOI 10.1016/0954-6111(95)90198-1; GEHA RS, 2001, IMMUNOBIOLOGY, P517; Geiser DM, 2007, STUD MYCOL, P1, DOI 10.3114/sim.2007.59.01; Geller DE, 1999, CHEST, V116, P639, DOI 10.1378/chest.116.3.639; GERMAUD P, 1995, CHEST, V107, P883, DOI 10.1378/chest.107.3.883; Gimeno RB, 2007, ARCH BRONCONEUMOL, V43, P49, DOI 10.1016/S1579-2129(07)60021-4; GLANCY JJ, 1981, THORAX, V36, P345, DOI 10.1136/thx.36.5.345; Otero Gonzalez I, 2000, ARCH BRONCONEUMOL, V36, P351; GOYAL R, 1992, J COMPUT ASSIST TOMO, V16, P649; GREENBERGER PA, 1984, J ALLERGY CLIN IMMUN, V74, P645, DOI 10.1016/0091-6749(84)90223-9; GREENBERGER PA, 1993, ANN ALLERGY, V70, P333; Greenberger PA, 2002, J ALLERGY CLIN IMMUN, V110, P685, DOI 10.1067/mai.2002.130179; GREENBERGER PA, 1988, J ALLERGY CLIN IMMUN, V81, P646, DOI 10.1016/0091-6749(88)91034-2; GREENBERGER PA, 1980, J ALLERGY CLIN IMMUN, V66, P327, DOI 10.1016/0091-6749(80)90029-9; Greenberger PA, 2003, FRONT BIOSCI, V8, pS119, DOI 10.2741/943; GREENBERGER PA, 1982, J LAB CLIN MED, V99, P288; HALWIG JM, 1984, J ALLERGY CLIN IMMUN, V74, P738, DOI 10.1016/0091-6749(84)90238-0; HANSON G, 1977, J ALLERGY CLIN IMMUN, V59, P83, DOI 10.1016/0091-6749(77)90182-8; HEINIG JH, 1988, ALLERGY, V43, P24, DOI 10.1111/j.1398-9995.1988.tb02040.x; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.3.CO;2-Y; HENDERSON AH, 1968, THORAX, V23, P513, DOI 10.1136/thx.23.5.513; HINSON KFW, 1952, THORAX, V7, P317, DOI 10.1136/thx.7.4.317; Hogaboam CM, 2003, FRONT BIOSCI, V8, pE147, DOI 10.2741/979; Hoshino H, 1999, RESPIRATION, V66, P369, DOI 10.1159/000029392; Hutcheson PS, 1996, CHEST, V110, P363, DOI 10.1378/chest.110.2.363; HUTCHESON PS, 1991, J ALLERGY CLIN IMMUN, V88, P390, DOI 10.1016/0091-6749(91)90102-T; IMBEAU SA, 1978, J ALLERGY CLIN IMMUN, V62, P91, DOI 10.1016/0091-6749(78)90084-2; IMBEAULT B, 1993, CHEST, V103, P1614, DOI 10.1378/chest.103.5.1614; ISRAEL RH, 1980, AM J MED SCI, V280, P41, DOI 10.1097/00000441-198007000-00007; JAQUES D, 1995, INT ARCH ALLERGY IMM, V106, P263; KAGEN SL, 1983, J ALLERGY CLIN IMMUN, V71, P389, DOI 10.1016/0091-6749(83)90067-2; KAMEI K, 1994, CLIN INFECT DIS, V18, P305; Karunaratne Nishantha, 2003, Australas Radiol, V47, P336, DOI 10.1046/j.1440-1673.2003.01192.x; Kauffman HF, 2003, FRONT BIOSCI, V8, pE190, DOI 10.2741/990; Kauffman HF, 1998, IMMUNOL ALLERGY CLIN, V18, P619, DOI 10.1016/S0889-8561(05)70025-4; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kino T, 1983, Nihon Kyobu Shikkan Gakkai Zasshi, V21, P896; KIRSTEN D, 1993, MED KLIN, V88, P353; Knutsen Alan P, 2006, Clin Mol Allergy, V4, P3, DOI 10.1186/1476-7961-4-3; Knutsen Alan P, 2002, J Cyst Fibros, V1, P76, DOI 10.1016/S1569-1993(02)00033-4; KNUTSEN AP, 1990, J LAB CLIN MED, V116, P724; Knutsen A.P., 2006, MED MYCOL S1, V44, P61, DOI 10.1080/13693780600789178; KO WK, 1999, TUBERC RESP DIS, V46, P260; Kradin RL, 2008, ARCH PATHOL LAB MED, V132, P606, DOI 10.1043/1543-2165(2008)132[606:TPOPDD]2.0.CO;2; Kraemer R, 2006, AM J RESP CRIT CARE, V174, P1211, DOI 10.1164/rccm.200603-423OC; KRAMER MN, 1989, AM REV RESPIR DIS, V140, P1086; Kumar R, 2000, ASIAN PAC J ALLERGY, V18, P181; Kumar R, 2003, CHEST, V124, P890, DOI 10.1378/chest.124.3.890; Kumar R, 2003, SAUDI MED J, V24, P546; Kumar Raj, 2002, J Asthma, V39, P473; Kurup VP, 2000, CLIN EXP ALLERGY, V30, P988, DOI 10.1046/j.1365-2222.2000.00837.x; Kurup VP, 2005, MED MYCOL, V43, pS189, DOI 10.1080/13693780500064763; LAHAM MN, 1981, ANN ALLERGY, V46, P74; LAKE FR, 1990, THORAX, V45, P489, DOI 10.1136/thx.45.6.489; LAKE FR, 1991, AUST NZ J MED, V21, P871, DOI 10.1111/j.1445-5994.1991.tb01410.x; Laoudi Y, 2008, EUR RESPIR J, V31, P908, DOI 10.1183/09031936.00146707; LAUFER P, 1984, J ALLERGY CLIN IMMUN, V73, P44, DOI 10.1016/0091-6749(84)90482-2; Lebrun-Vignes B, 2001, BRIT J CLIN PHARMACO, V51, P443, DOI 10.1046/j.1365-2125.2001.01372.x; LEE TM, 1987, ARCH INTERN MED, V147, P319, DOI 10.1001/archinte.147.2.319; LESER C, 1992, J ALLERGY CLIN IMMUN, V90, P589, DOI 10.1016/0091-6749(92)90131-K; Logan PM, 1996, CAN ASSOC RADIOL J, V47, P374; LONGBOTTOM JL, 1964, J PATHOL BACTERIOL, V88, P141, DOI 10.1002/path.1700880119; Lynch DA, 1998, RADIOL CLIN N AM, V36, P129, DOI 10.1016/S0033-8389(05)70010-5; Main KM, 2002, ACTA PAEDIATR, V91, P1008, DOI 10.1080/080352502760272759; Malde B, 2004, ALLERGY ASTHMA PROC, V25, pS38; MALO JL, 1977, THORAX, V32, P254, DOI 10.1136/thx.32.3.254; MALO JL, 1979, CLIN ALLERGY, V9, P377, DOI 10.1111/j.1365-2222.1979.tb02496.x; MANNES GPM, 1993, LANCET, V341, P492, DOI 10.1016/0140-6736(93)90244-B; Marchand E, 2001, CHEST, V119, P762, DOI 10.1378/chest.119.3.762; MARCHANT JL, 1994, THORAX, V49, P1002, DOI 10.1136/thx.49.10.1002; Mastella G, 2000, EUR RESPIR J, V16, P464, DOI 10.1034/j.1399-3003.2000.016003464.x; Maurya V, 2005, CHEST, V127, P1252, DOI 10.1378/chest.127.4.1252; MCALEER R, 1981, THORAX, V36, P338, DOI 10.1136/thx.36.5.338; MCCARTHY D S, 1970, Clinical Radiology, V21, P366, DOI 10.1016/S0009-9260(70)80070-8; McCarthy D S, 1971, Clin Allergy, V1, P415, DOI 10.1111/j.1365-2222.1971.tb00793.x; McCarthy DS, 1971, CLIN ALLERGY, V1, P261, DOI 10.1111/j.1365-2222.1971.tb00779.x; MEARNS M, 1965, THORAX, V20, P385, DOI 10.1136/thx.20.5.385; MEARNS M, 1967, LANCET, V1, P538; Miller PW, 1996, AM J HUM GENET, V59, P45; MINTZER RA, 1978, RADIOLOGY, V127, P301; Molinari M, 2004, Monaldi Arch Chest Dis, V61, P62; MorenoAncillo A, 1996, J ALLERGY CLIN IMMUN, V97, P714, DOI 10.1016/S0091-6749(96)70321-4; MORIMOTO T, 2003, J CHEST DIS, V62, P55; Morozov A, 2007, PEDIATR RADIOL, V37, P592, DOI 10.1007/s00247-007-0471-8; MROUEH S, 1994, CHEST, V105, P32, DOI 10.1378/chest.105.1.32; Mulliez P, 2006, REV MAL RESPIR, V23, P93, DOI 10.1019/200530211; MURPHY D, 1981, BRIT J DIS CHEST, V75, P91, DOI 10.1016/S0007-0971(81)80013-7; MUSCAT I, 1988, LANCET, V1, P1341; NEELD DA, 1990, AM REV RESPIR DIS, V142, P1200; NELSON LA, 1979, AM REV RESPIR DIS, V120, P863; Nepomuceno IB, 1999, CHEST, V115, P364, DOI 10.1378/chest.115.2.364; NICHOLS D, 1979, AM J MED, V67, P631, DOI 10.1016/0002-9343(79)90246-8; NICOLAI T, 1990, PEDIATR PULM, V8, P12, DOI 10.1002/ppul.1950080106; Nikaido Y, 1998, RESP MED, V92, P118, DOI 10.1016/S0954-6111(98)90042-7; NIKOLAIZIK WH, 1995, AM J RESP CRIT CARE, V152, P634; Nikolaizik WH, 2002, AM J RESP CRIT CARE, V165, P916, DOI 10.1164/rccm.2109008; Novey HS, 1998, IMMUNOL ALLERGY CLIN, V18, P641, DOI 10.1016/S0889-8561(05)70026-6; NOVEY HS, 1978, AM J CLIN PATHOL, V70, P840; O'Connor T M, 2001, Respirology, V6, P361, DOI 10.1046/j.1440-1843.2001.00342.x; Ogasawara Takashi, 2003, Nihon Kokyuki Gakkai Zasshi, V41, P905; Ogawa H, 2004, J ASTHMA, V41, P223, DOI 10.1081/JAS-120026080; Ownby DR, 2007, ALLERGIC DIS DIAGNOS, P27, DOI 10.1007/978-1-59745-382-0_3; PACHECO A, 1993, CHEST, V103, P980; Panchal N, 1997, RESP MED, V91, P213, DOI 10.1016/S0954-6111(97)90041-X; PATTERSON R, 1986, ARCH INTERN MED, V146, P916, DOI 10.1001/archinte.146.5.916; PATTERSON R, 1982, ANN INTERN MED, V96, P286; PATTERSON R, 1987, J ALLERGY CLIN IMMUN, V80, P663, DOI 10.1016/0091-6749(87)90285-5; PATTERSON R, 1982, INT ARCH ALLER A IMM, V69, P30; Patterson R., 1998, FISHMANS PULMONARY D, P777; PHELAN MS, 1984, CLIN RADIOL, V35, P385, DOI 10.1016/S0009-9260(84)80200-7; PRASAD R, 2008, INTERNET J PULMONARY, V9; Rajan TV, 2003, TRENDS IMMUNOL, V24, P376, DOI 10.1016/S1471-4906(03)00142-X; RAPAKA RR, 2008, MED MYCOL, P1; RICKETTI AJ, 1984, J ALLERGY CLIN IMMUN, V74, P68, DOI 10.1016/0091-6749(84)90089-7; RICKETTI AJ, 1984, INT ARCH ALLER A IMM, V73, P283; RILEY DJ, 1975, AM REV RESPIR DIS, V111, P232; Ritz N, 2005, EUR J PEDIATR, V164, P577, DOI 10.1007/s00431-005-1701-4; ROSENBERG IL, 1984, CHEST, V85, P123, DOI 10.1378/chest.85.1.123; ROSENBERG M, 1977, ANN INTERN MED, V86, P405; ROSENBERG M, 1978, AM J MED, V64, P599, DOI 10.1016/0002-9343(78)90579-X; SAFIRSTEIN BH, 1973, AM REV RESPIR DIS, V108, P940; SAHN SA, 1973, CHEST, V63, P286, DOI 10.1378/chest.63.2.286; Salez F, 1999, CHEST, V116, P1665, DOI 10.1378/chest.116.6.1665; Sambatakou H, 2006, INT J IMMUNOGENET, V33, P297, DOI 10.1111/j.1744-313X.2006.00616.x; Sanchez-Alarcos JMF, 2001, ALLERGY, V56, P80, DOI 10.1034/j.1398-9995.2001.00840.x; Saravanan K, 2006, ARCH OTOLARYNGOL, V132, P173, DOI 10.1001/archotol.132.2.173; Saxena S, 2003, J ALLERGY CLIN IMMUN, V111, P1001, DOI 10.1067/mai.2003.1395; SCADDING JG, 1967, SCAND J RESPIR DIS, V48, P372; SCHONHEYDER H, 1988, INT ARCH ALLER A IMM, V85, P472; Schuyler M, 1998, J LAB CLIN MED, V131, P194, DOI 10.1016/S0022-2143(98)90089-0; SCHWARTZ HJ, 1991, J LAB CLIN MED, V117, P138; SEATON A, 1994, Q J MED, V87, P529; Shah A, 2006, ANN ALLERG ASTHMA IM, V96, P874; Shah A, 2004, ALLERGY, V59, P236, DOI 10.1046/j.1398-9995.2003.00372.x; Shah A, 2001, CLIN EXP ALLERGY, V31, P1896, DOI 10.1046/j.1365-2222.2001.01159.x; Shah A, 2003, FRONT BIOSCI, V8, pE138, DOI 10.2741/944; SHAH A, 1989, J ASTHMA, V26, P109, DOI 10.3109/02770908909073239; Shah A, 1993, INDIAN J TUBERC, V40, P39; Shah A, 1999, INDIAN J RADIOL IMAG, V9, P107; Shah A, 2008, ANN ALLERG ASTHMA IM, V101, P363, DOI 10.1016/S1081-1206(10)60311-0; Shah A, 2007, PEDIATR PULM, V42, P747, DOI 10.1002/ppul.20639; Shah TS, 2003, POSTGRAD MED J, V79, P710, DOI 10.1136/pgmj.2002.003095q; SHALE DJ, 1987, THORAX, V42, P26, DOI 10.1136/thx.42.1.26; Sharma Bhavneesh, 2005, MedGenMed, V7, P25; Sharma P, 1998, Indian J Chest Dis Allied Sci, V40, P269; Sharma T N, 1985, J Assoc Physicians India, V33, P748; SILVERMAN M, 1978, ARCH DIS CHILD, V53, P873; SIMMONDS EJ, 1990, ARCH DIS CHILD, V65, P507; Skov M, 2002, EUR RESPIR J, V20, P127, DOI 10.1183/09031936.02.00248002; Skov M, 2005, RESP MED, V99, P887, DOI 10.1016/j.rmed.2004.11.018; Skov M, 2002, ALLERGY, V57, P723, DOI 10.1034/j.1398-9995.2002.23583.x; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V81, P718, DOI 10.1016/0091-6749(88)91044-5; Soubani AO, 2002, CHEST, V121, P1988, DOI 10.1378/chest.121.6.1988; STARKE ID, 1980, BRIT J DIS CHEST, V74, P301, DOI 10.1016/0007-0971(80)90061-3; Stevens DA, 2000, NEW ENGL J MED, V342, P756, DOI 10.1056/NEJM200003163421102; Stevens DA, 2003, CLIN INFECT DIS, V37, pS225, DOI 10.1086/376525; SUZUKI M, 1999, J CHEST DIS, V58, P770; Taccetti G, 2000, EUR J EPIDEMIOL, V16, P837, DOI 10.1023/A:1007670717619; Thomson JM, 2006, PEDIATR PULM, V41, P164, DOI 10.1002/ppul.20333; Tillie-Leblond I, 2005, ALLERGY, V60, P1004, DOI 10.1111/j.1398-9995.2005.00887.x; Tomee JFC, 1997, J INFECT DIS, V176, P300, DOI 10.1086/517272; TOMEE JFC, 1994, J ALLERGY CLIN IMMUN, V93, P768, DOI 10.1016/0091-6749(94)90257-7; TSIMIKAS S, 1994, J ALLERGY CLIN IMMUN, V94, P264, DOI 10.1016/0091-6749(94)90051-5; TUCKER RM, 1990, J ANTIMICROB CHEMOTH, V26, P561, DOI 10.1093/jac/26.4.561; Vaid M, 2007, CLIN CHEM LAB MED, V45, P183, DOI 10.1515/CCLM.2007.033; van der Ent CK, 2007, THORAX, V62, P276, DOI 10.1136/thx.2004.035519; Vlahakis NE, 2001, MAYO CLIN PROC, V76, P930; Walsh TJ, 2008, CLIN INFECT DIS, V46, P327, DOI 10.1086/525258; WANG JLF, 1978, AM REV RESPIR DIS, V117, P917; WANG JLF, 1979, AM REV RESPIR DIS, V120, P87; Ward S, 1999, AM J ROENTGENOL, V173, P937; WARK PA, 2004, COCHRANE DATABASE SY; Wark PAB, 2003, J ALLERGY CLIN IMMUN, V111, P952, DOI 10.1067/mai.2003.1388; Yoshida N, 1992, Nihon Kyobu Shikkan Gakkai Zasshi, V30, P2123; ZEASKE R, 1988, J ALLERGY CLIN IMMUN, V82, P73, DOI 10.1016/0091-6749(88)90054-1; [Anonymous], 1979, BR J DIS CHEST, V73, P349	242	157	176	1	15	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAR	2009	135	3					805	826		10.1378/chest.08-2586		22	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	420SW	WOS:000264310500030	19265090	
J	Barnett, AG; Williams, GM; Schwartz, J; Neller, AH; Best, TL; Petroeschevsky, AL; Simpson, RW				Barnett, AG; Williams, GM; Schwartz, J; Neller, AH; Best, TL; Petroeschevsky, AL; Simpson, RW			Air pollution and child respiratory health - A case-crossover study in Australia and new Zealand	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollutants; Australasia; meta-analysis; respiration disorders	INFANT-MORTALITY; UTAH VALLEY; ASSOCIATION; DISEASE; METAANALYSIS; POLLUTANTS; ADMISSIONS; PARTICLES; SELECTION; ASTHMA	Rationale: The strength of the association between outdoor air pollution and hospital admissions in children has not yet been well defined. Objectives: To estimate the impact of outdoor air pollution on respiratory morbidity in children after controlling for the confounding effects of weather, season, and other pollutants. Methods: The study used data on respiratory hospital admissions in children (three age groups: < 1, 1-4, and 5-14years) for five cities in Australia and two in New Zealand. Time series of daily numbers of hospital admissions were analyzed using the case-crossover method; the results from cities were combined using a random-effects meta-analysis. Measurements and Main Results: Significant increases across the cities were observed for hospital admissions in children for pneumonia and acute bronchitis (0, 1-4 years), respiratory disease (0, 1-4, 5-14 years), and asthma (5-14 years). These increases were found for particulate matter with a diameter less than 2.5 mu m (PM2.5) and less than 10 mu m (PM10), nephelometry, NO2, and SO2. The largest association found was a 6.0% increase in asthma admissions (5-14years) in relation to a 5.1-ppb increase in 24-hour NO2. Conclusions: This study found strong and consistent associations between outdoor air pollution and short-term increases in childhood hospital admissions. A number of different pollutants showed significant associations, and these were distinct from any temperature (warm or cool) effects.	Univ Sunshine Coast, Fac Sci Hlth & Educ, Maroochydore DC, Qld 4558, Australia; Univ Queensland, Sch Populat Hlth, Herston, Qld, Australia; Harvard Univ, Sch Publ Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA	Simpson, RW (reprint author), Univ Sunshine Coast, Fac Sci Hlth & Educ, Maroochydore DC, Qld 4558, Australia.	rsimpson@usc.edu.au	Barnett, Adrian/I-9850-2012; Wang, Linden/M-6617-2014	Barnett, Adrian/0000-0001-6339-0374			ANDERSON H, 2004, EUR045042688; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Bateson TF, 2001, EPIDEMIOLOGY, V12, P654, DOI 10.1097/00001648-200111000-00013; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Binkova B, 2004, EFFECTS AIR POLLUTIO; Braga A. L. F., 1999, Journal of Environmental Medicine, V1, P95, DOI 10.1002/(SICI)1099-1301(199904/06)1:2<95::AID-JEM16>3.0.CO;2-S; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Chauhan AJ, 2003, BRIT MED BULL, V68, P95, DOI 10.1093/bmb/ldg022; Chew FT, 1999, ALLERGY, V54, P320, DOI 10.1034/j.1398-9995.1999.00012.x; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Ha EH, 2003, PEDIATRICS, V111, P284, DOI 10.1542/peds.111.2.284; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Katsouyanni K, 2003, BRIT MED BULL, V68, P143, DOI 10.1093/bmb/ldg028; Levy D, 2001, EPIDEMIOLOGY, V12, P186, DOI 10.1097/00001648-200103000-00010; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144; Mathieu-Nolf M, 2002, J TOXICOL-CLIN TOXIC, V40, P483; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Neas LM, 1999, ENVIRON HEALTH PERSP, V107, P629, DOI 10.2307/3434453; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Ostro BD, 1999, ENVIRON HEALTH PERSP, V107, P69, DOI 10.2307/3434291; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; Schwartz J, 2004, ENVIRON HEALTH PERSP, V112, P557; Schwartz J, 2004, PEDIATRICS, V113, P1037; SIMPSON R, 2004, EPIDEMIOLOGY, V106, pS54; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608	30	157	168	3	43	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2005	171	11					1272	1278		10.1164/rccm.200411-1586OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	930JB	WOS:000229410800013	15764722	
J	Muraro, A; Dreborg, S; Halken, S; Host, A; Niggemann, B; Aalberse, R; Arshad, SH; von Berg, A; Carlsen, KH; Duschen, K; Eigenmann, P; Hill, D; Jones, C; Mellon, M; Oldeus, G; Oranje, A; Pascual, C; Prescott, S; Sampson, H; Svartengren, M; Vandenplas, Y; Wahn, U; Warner, JA; Warner, JO; Wickman, M; Zeiger, RS				Muraro, A; Dreborg, S; Halken, S; Host, A; Niggemann, B; Aalberse, R; Arshad, SH; von Berg, A; Carlsen, KH; Duschen, K; Eigenmann, P; Hill, D; Jones, C; Mellon, M; Oldeus, G; Oranje, A; Pascual, C; Prescott, S; Sampson, H; Svartengren, M; Vandenplas, Y; Wahn, U; Warner, JA; Warner, JO; Wickman, M; Zeiger, RS			Dietary prevention of allergic diseases in infants and small children - Part III: Critical review of published peer-reviewed observational and interventional studies and final recommendations	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						breast feeding; cow's milk allergy; food allergy; prevention; review; statements of evidence	HIGH-RISK INFANTS; PARTIAL WHEY HYDROLYSATE; BRIEF NEONATAL EXPOSURE; BREAST-FED INFANTS; COWS MILK FORMULA; ATOPIC DISEASE; FOLLOW-UP; 1ST YEAR; CONTROLLED-TRIAL; PRETERM INFANTS	The role of primary prevention of allergic diseases has been a matter of debate for the last 40 years. In order to shed some light on this issue, a group of experts of the Section of Pediatrics EAACI reviewed critically the existing literature on the subject. An analysis of published peer-reviewed observational and interventional studies was performed following the statements of evidence as defined by WHO. The results of the analysis indicate that breastfeeding is highly recommended for all infants irrespective of atopic heredity. A dietary regimen is unequivocally effective in the prevention of allergic diseases in high-risk children. In these patients breastfeeding combined with avoidance of solid food and cow's milk for at least 4-6 months is the most effective preventive regimen. In the absence of breast milk, formulas with documented reduced allergenicity for at least 4-6 months should be used.	Univ Padua, Dept Pediat, I-35128 Padua, Italy; ESPACI, Lerum, Sweden; Sonderborg Hosp, Dept Pediat, Sonderborg, Denmark; Odense Univ Hosp, Dept Pediat, DK-5000 Odense, Denmark; Humboldt Univ, Univ Childrens Hosp Charite, Dept Pneumol & Immunol, Berlin, Germany; Dept Allergy CLB, Amsterdam, Netherlands; St Marys Hosp, Clin Allergy Res Unit, Newport, Isle Of Wight, England; Marien Hosp, Abt Kinderheilkunde, Wesel, Germany; Voksentoppen Natl Ctr Asthma Allergy & Chron Lung, Oslo, Norway; Linkoping Univ Hosp, Dept Paediat, S-58185 Linkoping, Sweden; Univ Geneva, Geneva, Switzerland; Royal Childrens Hosp, Dept Allergy, Melbourne, Vic, Australia; Southampton Gen Hosp, Southampton SO9 4XY, Hants, England; Kaiser Permanente San Diego, San Diego, CA USA; Cty Hosp Ryhov, Dept Paediat, Jonkoping, Sweden; Univ Hosp Sophia Rotterdam, Dept Dermatol & Venerol, Rotterdam, Netherlands; Hosp Infantil Univ La Paz, Serv Alergia, Madrid, Spain; Univ Western Australia, Dept Paediat, Subiaco, WA, Australia; Mt Sinai Sch Med, Div Allergy & Immunol, Dept Pediat, New York, NY USA; Karolinska Hosp, Dept Publ Hlth Sci, Div Occupat Med, S-10401 Stockholm, Sweden; Free Univ Brussels, AZ Kinderen, Brussels, Belgium; Karolinska Hosp, Dept Environm Hlth, S-10401 Stockholm, Sweden	Muraro, A (reprint author), Univ Padua, Dept Pediat, Via Giustiniani 3, I-35128 Padua, Italy.	muraro@pediatria.unipd.it	Prescott, Susan/H-5665-2014; Osborne, Nicholas/N-4915-2015; Eigenmann, Philippe/A-6569-2017	Osborne, Nicholas/0000-0002-6700-2284; Eigenmann, Philippe/0000-0003-1738-1826			Arato A, 1995, Orv Hetil, V136, P1433; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; BARDARE M, 1993, ANN ALLERGY, V71, P366; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bloch AM, 2002, ACTA PAEDIATR, V91, P275, DOI 10.1080/08035250252833914; Bottcher MF, 2000, PEDIATR RES, V47, P157; BURR ML, 1993, ARCH DIS CHILD, V68, P724; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; Businco L, 1993, Pediatr Allergy Immunol, V4, P101, DOI 10.1111/j.1399-3038.1993.tb00077.x; BUSINCO L, 1983, ANN ALLERGY, V51, P296; BUSINCO L., 1992, J PEDIATR, V121, P21; Chan YH, 2002, J PAEDIATR CHILD H, V38, P84, DOI 10.1046/j.1440-1754.2002.00725.x; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; CHANDRA RK, 1985, CLIN ALLERGY, V15, P517, DOI 10.1111/j.1365-2222.1985.tb02304.x; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; Duchen K, 1998, PEDIATR RES, V44, P478, DOI 10.1203/00006450-199810000-00003; Duchen K, 1999, ACTA PAEDIATR, V88, P1338, DOI 10.1080/080352599750030040; Elder DE, 1996, ARCH DIS CHILD, V74, pF165, DOI 10.1136/fn.74.3.F165; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; GRULEE C, 1936, J PEDIATR, V72, P411; GRUSKAY FL, 1982, CLIN PEDIATR, V21, P486, DOI 10.1177/000992288202100807; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halken S, 1995, ALLERGY S, V26, P49; Hattevig G, 1999, ACTA PAEDIATR, V88, P7; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135; Host A, 1999, ARCH DIS CHILD, V81, P80; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; JOHANSSON SGO, 2003, IN PRESS J ALLERGY C; JOHNSTONE DE, 1966, NEW ENGL J MED, V274, P715, DOI 10.1056/NEJM196603312741305; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kerner JA, 1997, J PEDIATR GASTR NUTR, V24, P442, DOI 10.1097/00005176-199704000-00016; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; KRAMER MS, 2000, COCHRANE DATABASE SY, V2, DOI UNSP CD000132; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; LINDFORS A, 1988, ALLERGY, V43, P11, DOI 10.1111/j.1398-9995.1988.tb02038.x; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; LUCAS A, 1990, BRIT MED J, V300, P837; MALLET E, 1992, J PEDIATR, V121, P95; Marini A, 1996, Acta Paediatr Suppl, V414, P1; Matejek N, 1998, NUTR RES, V18, P1389, DOI 10.1016/S0271-5317(98)00117-1; MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388; MOORE WJ, 1985, ARCH DIS CHILD, V60, P722; Nentwich I, 2001, ALLERGY, V56, P1144, DOI 10.1111/j.1398-9995.2001x.00926.x; Oddy W H, 2000, Breastfeed Rev, V8, P5; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 1999, BRIT MED J, V319, P815; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Oddy WH, 2000, ADV EXP MED BIOL, V478, P393; Odelram H, 1996, ALLERGY, V51, P192, DOI 10.1111/j.1398-9995.1996.tb04587.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; Porch MC, 1998, NUTR RES, V18, P1413, DOI 10.1016/S0271-5317(98)00119-5; PRATT HF, 1984, EARLY HUM DEV, V9, P283, DOI 10.1016/0378-3782(84)90039-2; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAARINEN UM, 1979, LANCET, V2, P163; SCHMITZ J, 1992, J PEDIATR-US, V121, pS85, DOI 10.1016/S0022-3476(05)81413-1; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; WILLEMS R, 1993, ANN ALLERGY, V71, P147; Wilson AC, 1998, BRIT MED J, V316, P21; WRIGHT AL, 1995, ARCH PEDIAT ADOL MED, V149, P758; WRIGHT AL, 1989, BRIT MED J, V299, P946; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; ZIEGER RS, 1992, PEDIATR ALLERGY IMMU, V3, P110	83	157	168	4	19	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	AUG	2004	15	4					291	307		10.1111/j.1399-3038.2004.00127.x		17	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	843RE	WOS:000223101400002	15305938	
J	Bush, RK; Prochnau, JJ				Bush, RK; Prochnau, JJ			Alternaria-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						alternaria; asthma; allergens; aerobiology	HUMANIZED MONOCLONAL-ANTIBODY; NUTRITION EXAMINATION SURVEY; SCHOOL-AGE-CHILDREN; 2ND NATIONAL-HEALTH; HOUSE-DUST MITE; FUNGAL ALLERGENS; CHILDHOOD ASTHMA; MOLECULAR-CLONING; IGE ANTIBODY; RISK-FACTOR	Acute, severe asthma attacks can be precipitated by a variety of stimuli including exposure to aeroallergens, viral respiratory infections, pollutants, and occupational chemicals. Alternaria is a major aeroallergen in many parts of the world. Sensitivity to Alternaria has been increasingly recognized as a risk factor for the development and persistence of asthma, asthma severity, and potentially fatal asthma exacerbations. We present the case of a patient with IgE-mediated sensitivity to Alternaria who developed an acute, life-threatening asthma attack during the peak Alternaria season. We describe the aerobiology, pathophysiobiology, diagnosis, and treatment options for patients with Alternaria-induced asthma.	William S Middleton VA Hosp, Madison, WI 53705 USA; Univ Wisconsin, Dept Med, Madison, WI 53706 USA	Bush, RK (reprint author), William S Middleton VA Hosp, 2500 Overlook Terrace, Madison, WI 53705 USA.						ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; Bush RK, 2002, MED CLIN N AM, V86, P1113, DOI 10.1016/S0025-7125(02)00036-6; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; Bush RK, 1999, J ALLERGY CLIN IMMUN, V104, P665, DOI 10.1016/S0091-6749(99)70340-4; BUSH RK, 2001, ENV ASTHMA, P69; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Busse WW, 2003, MIDDLETONS ALLERGY P, P1175; CANTANI A, 1988, ALLERGOL IMMUNOPATH, V16, P1; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Esch R, 2003, MIDDLETONS ALLERGY P, P539; Floyer J., 1745, VIOLENT ASTHMA VISIT; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hopkins JG, 1930, J AMER MED ASSOC, V94, P6; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; JARJOUR NN, 2003, MIDDLETONS ALLERGY P, P1257; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kenyon N, 2001, CLIN REV ALLERG IMMU, V20, P271, DOI 10.1385/CRIAI:20:3:271; Kheradmand F, 2002, J IMMUNOL, V169, P5904; LOPEZ M, 1985, CLIN REV ALLERG, V3, P183, DOI 10.1007/BF02992982; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; Seear M, 1997, AM J RESP CRIT CARE, V155, P364; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; VIJAY HM, 1999, ALLERGENS ALLERGEN I, P113; Wan GH, 1999, EUR J IMMUNOL, V29, P2491, DOI 10.1002/(SICI)1521-4141(199908)29:08<2491::AID-IMMU2491>3.3.CO;2-I; Werner HA, 2001, CHEST, V119, P1913, DOI 10.1378/chest.119.6.1913	51	157	161	0	11	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					227	234		10.1016/j.jaci.2003.11.023		8	Allergy; Immunology	Allergy; Immunology	773EX	WOS:000188885700007	14767434	
J	Trupin, L; Earnest, G; San Pedro, M; Balmes, JR; Eisner, MD; Yelin, E; Katz, PP; Blanc, PD				Trupin, L; Earnest, G; San Pedro, M; Balmes, JR; Eisner, MD; Yelin, E; Katz, PP; Blanc, PD			The occupational burden of chronic obstructive pulmonary disease	EUROPEAN RESPIRATORY JOURNAL			English	Article						Airflow limitation; chronic bronchitis; chronic obstructive pulmonary disease; emphysema; occupational health; work-related	CHRONIC RESPIRATORY SYMPTOMS; LUNG-FUNCTION; CHRONIC-BRONCHITIS; GENERAL-POPULATION; EXPOSURES; ADULTS; PREVALENCE; COMMUNITY; ASTHMA; MINERS	Although chronic obstructive pulmonary disease (COPD) is attributed predominantly to tobacco smoke, occupational exposures are also suspected risk factors for COPD. Estimating the proportion of COPD attributable to occupation is thus an important public health need. A randomly selected sample of 2,061 US residents aged 55-75 yrs completed telephone interviews covering respiratory health, general health status and occupational history. Occupational exposure during the longest-held job was determined by self-reported exposure to vapours, gas, dust or fumes and through a job exposure matrix. COPD was defined by self-reported physician's diagnosis. After adjusting for smoking status and demography, the odds ratio for COPD related to self-reported occupational exposure was 2.0 (95% confidence interval (Cl) 1.6-2.5), resulting in an adjusted population attributable risk (PAR) of 20% (95% Cl 13-27%). The adjusted odds ratio based on the job exposure matrix was 1.6 (95% Cl 1.1-2.5) for high and 1.4 (95% Cl 1.1-1.9) for intermediate probability of occupational dust exposure; the associated PAR was 9% (95% Cl 3-15%). A narrower definition of COPD, excluding chronic bronchitis, was associated with a PAR based on reported occupational exposure of 31% (95% Cl 19-41%). Past occupational exposures significantly increased the likelihood of chronic obstructive pulmonary disease, independent of the effects of smoking. Given that one in five cases of chronic obstructive pulmonary disease may be attributable to occupational exposures, clinicians and health policy-makers should address this potential avenue of chronic obstructive pulmonary disease causation and its prevention.	Univ Calif San Francisco, Div Rheumatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Environm & Occupat Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Div Pulm & Crit Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Trupin, L (reprint author), Univ Calif San Francisco, Div Rheumatol, Box 0920, San Francisco, CA 94143 USA.				NHLBI NIH HHS [HL677438, K23 HL04201]		Anto JM, 2001, EUR RESPIR J, V17, P982, DOI 10.1183/09031936.01.17509820; BAKKE PS, 1991, THORAX, V46, P863, DOI 10.1136/thx.46.12.863; Barr RG, 2002, AM J EPIDEMIOL, V155, P965, DOI 10.1093/aje/155.10.965; BECKLAKE MR, 1958, AM REV TUBERC PULM, V77, P400; BECKLAKE MR, 1989, AM REV RESPIR DIS S, V140, P85; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; Bobadilla A, 2002, CHEST, V122, P1234, DOI 10.1378/chest.122.4.1234; Fishwick D, 1997, AM J RESP CRIT CARE, V156, P1440; FLETCHER C M, 1958, AMA Arch Ind Health, V18, P368; GOODMAN N, 1953, BRIT MED J, V4830, P237; Greenhow E, 1868, CHRONIC BRONCHITIS E; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; HNIZDO E, 1990, SCAND J WORK ENV HEA, V16, P411; HUMERFELT S, 1993, EUR RESPIR J, V6, P1095; KIM J, 1998, ATLAS RESP DIS MORTA, P23; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298; KOVAR M, 1985, VITAL HLTH STAT 1, V18, P82; KRZYZANOWSKI M, 1988, INT J EPIDEMIOL, V17, P397, DOI 10.1093/ije/17.2.397; KRZYZANOWSKI M, 1990, INT ARCH OCC ENV HEA, V62, P311, DOI 10.1007/BF00640839; LEBOWITZ MD, 1977, ENVIRON RES, V14, P59, DOI 10.1016/0013-9351(77)90066-4; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; National Center for Health Statistics,, 1994, PLAN OP 3 NAT HLTH N; *NAT HEART LUNG BL, 2001, GLOB IN CHRON OBSTR; STOECKLE JD, 1962, J CHRON DIS, V15, P887, DOI 10.1016/0021-9681(62)90058-9; Stratton JD, 2002, NEPHROL DIAL TRANSPL, V17, P684, DOI 10.1093/ndt/17.4.684; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512; *UN MED DENT SCH G, 1993, PROT EUR COMM RESP H; *US BUR CENS, 1993, CURR POP SURV TECHN; *US BUR CENS, 2000, IND OCC CLASS SYST; U. S. Department of Health and Human Services, 1984, HLTH CONS SMOK CHRON; Viegi Giovanni, 2002, Curr Opin Allergy Clin Immunol, V2, P115, DOI 10.1097/00130832-200204000-00006; Zock JP, 2001, AM J RESP CRIT CARE, V163, P1572	34	157	165	0	13	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2003	22	3					462	469		10.1183/09031936.03.00094203		8	Respiratory System	Respiratory System	721VP	WOS:000185339400014	14516136	
J	Ayuso, R; Reese, G; Leong-Kee, S; Plante, M; Lehrer, SB				Ayuso, R; Reese, G; Leong-Kee, S; Plante, M; Lehrer, SB			Molecular basis of arthropod cross-reactivity: IgE-binding cross-reactive epitopes of shrimp, house dust mite and cockroach tropomyosins	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						shrimp; dust mite; cockroach; allergens; cross-reactivity	MUSCLE PROTEIN TROPOMYOSIN; MAJOR ALLERGEN; FOOD HYPERSENSITIVITY; OCCUPATIONAL ASTHMA; MUTATIONAL ANALYSIS; IDENTIFICATION; IMMUNOTHERAPY; POLLEN; LOBSTER; SENSITIZATION	Background. Shrimp may cross-react with other crustaceans and mollusks and nonedible arthropods such as insects (cockroach and chironomids), arachnids (house dust mites) and even nematodes. Since the muscle protein tropomyosin has been implicated as a possible cross-reacting allergen, this study characterized the IgE-binding epitopes in shrimp tropomyosin, Pen a 1, that cross-react with other allergenic invertebrate tropomyosins in house dust mites (Der p 10, Der f 10) and cockroaches (Per a 7). Pen a 1-reactive sera from shrimp-allergic subjects were used to evaluate the effect on IgE binding of different amino acid substitutions in Pen a 1 epitopes based on homologous sequences in Per a 7 and Der p 10/Der f 10. Methods: Peptides were synthesized spanning the length of Pen a 1 IgE-binding epitopes and amino acid substitutions were performed based on homologous amino acid sequences from Per a 7 and Der p 10/Der f 10. Results: 7/8 individually recognized Pen a 1 epitopes (2, 3a, 3b, 4, 5a, 5b and 56 had an identical amino acid sequence with lobster allergen, Hom a 1, 4/8 (3a, 3b, 4 and 5a) with Der p 10 and Derf 10, and 5/8 (2, 3a, 3b, 4 and 5a) with Per a 7. In addition, even homologous regions of other arthropod tropomyosins that differ in one or more amino acids from the sequences of Pen a 1 epitopes are still recognized by shrimp-allergic IgE antibodies. In total, shrimp-allergic sera recognize 6/8 peptides homologous to Pen a 1 epitopes in Per a 7, 7/8 in Der p 10/Der f 10, and 7/8 epitopes in Hom a 1. Conclusions: The IgE recognition by shrimp-allergic individuals of identified and/or similar amino acid sequences homologous to Pen a 1 epitopes in mite, cockroach and lobster tropomyosins are the basis of the in vitro cross-reactivity among invertebrate species. Based on amino acid sequence similarity and epitope reactivity, lobster tropomyosin has the strongest and cockroach the least cross-reactivity with shrimp. The clinical relevance of these cross-reactivities in developing allergic reactions to different arthropods needs to be determined. Copyright (C) 2002 S. Karger AG, Basel.	Tulane Univ, Sch Med, Allergy & Clin Immunol Sect, New Orleans, LA 70112 USA	Lehrer, SB (reprint author), Tulane Univ, Sch Med, Allergy & Clin Immunol Sect, 1700 Perdido St, New Orleans, LA 70112 USA.						AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; Ayuso R, 1999, J ALLERGY CLIN IMMUN, V103, pS66; AYUSO R, IN PRESS INT ARCH AL; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; BANZET ML, 1992, REV FR ALLERGOL, V32, P198, DOI 10.1016/S0335-7457(05)80359-4; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P433, DOI 10.1016/0091-6749(87)90359-9; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; CARRILLO T, 1994, ANN ALLERGY, V73, P504; CHU KH, 2000, MAR BIOTECHNOL, V5, P499; CRESPO JF, 1995, ALLERGY, V50, P918, DOI 10.1111/j.1398-9995.1995.tb02499.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; *FDA, 1996, REP FDA AH HOC COMM; FERNANDES J, IN PRESS J ALLERGY C; Ferreira F, 1998, FASEB J, V12, P231; Goetz DW, 2000, ANN ALLERG ASTHMA IM, V85, P461; Helbling A, 1999, ANN ALLERG ASTHMA IM, V83, P517, DOI 10.1016/S1081-1206(10)62862-1; Ishikawa M, 1998, J FOOD SCI, V63, P44, DOI 10.1111/j.1365-2621.1998.tb15672.x; Ishikawa M, 1998, BIOSCI BIOTECH BIOCH, V62, P1337, DOI 10.1271/bbb.62.1337; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; Lehrer SB, 1998, REV FR ALLERGOL, V38, P846, DOI 10.1016/S0335-7457(98)80154-8; Lemiere C, 1996, ALLERGY, V51, P272, DOI 10.1111/j.1398-9995.1996.tb04606.x; Leung PSC, 1998, J ALLERGY CLIN IMMUN, V102, P847, DOI 10.1016/S0091-6749(98)70027-2; Leung PSC, 1998, MOL MAR BIOL BIOTECH, V7, P12; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V92, P837; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Mykles DL, 1998, J MUSCLE RES CELL M, V19, P105, DOI 10.1023/A:1005352410725; ONEIL CE, 1985, ANN ALLERGY, V55, P374; Petrus M, 1999, ARCH PEDIATRIE, V6, P1075, DOI 10.1016/S0929-693X(00)86982-1; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; REESE G, UNPUB EPITOPE MAPPIN; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V103, pS122; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Swoboda I, 2001, INT ARCH ALLERGY IMM, V124, P380, DOI 10.1159/000053763; TAYLOR SL, 1987, ANN ALLERGY, V59, P93; TAYLOR SL, 1988, MARINE TOXINS VENOMS, V3, P149; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97; vanRee R, 1996, ALLERGY, V51, P108; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56; WUTRICH B, 1985, SHWEIZ MED WOCHENSCH, V115, P258	57	157	173	3	9	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	SEP	2002	129	1					38	48		10.1159/000065172		11	Allergy; Immunology	Allergy; Immunology	605YA	WOS:000178703600004	12372997	
J	Milgrom, H; Berger, W; Nayak, A; Gupta, N; Pollard, S; McAlary, M; Taylor, AF; Rohane, P				Milgrom, H; Berger, W; Nayak, A; Gupta, N; Pollard, S; McAlary, M; Taylor, AF; Rohane, P			Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab)	PEDIATRICS			English	Article						asthma; child; omalizumab; rhuMAb-E25; anti-IgE; beclomethasone dipropionate; steroid-sparing; inhaled corticosteroid; asthma exacerbation	IGE MONOCLONAL-ANTIBODY; AIRWAY HYPERRESPONSIVENESS; FLUTICASONE PROPIONATE; PULMONARY-FUNCTION; ALLERGIC RHINITIS; COMPLEX-FORMATION; SENSITIZATION; ASSOCIATION; CHILDREN; EXPOSURE	Background and Objective. There seems to be a strong causal relationship between allergy and the origins of asthma. Susceptibility to both is determined by a combination of genetics and environment acting through a complex network of cytokines. Nearly 90% of affected children have positive skin tests indicating the presence of specific immunoglobulin E (IgE), with sensitivity to house dust mite, Alternaria, cockroach, cat, and dog most closely linked to the disease. Greater exposure to house dust mite during infancy leads to earlier onset of wheezing, and elevated serum IgE levels correlate with the appearance of asthma symptoms. Specific IgE binds to high-affinity (Fc epsilon RI) receptors on mast cells and basophils. The IgE-mediated reactions that follow exposure of sensitized mast cells to an allergen are designated early- and late-phase asthmatic responses (EAR and LAR). EAR is characterized by release of histamine and other preformed mediators within 1 hour of allergen exposure. It is often followed by LAR, an infiltration of the airways by inflammatory cells associated with an episode of more prolonged, and usually more severe airflow obstruction, 4 to 8 hours after antigen exposure. Chronic airway symptoms result from persistent LAR caused by continuous allergen exposure. IgE antibodies are capable of passive transfer of both EAR and LAR sensitivity. IgE-mediated mast cell activation contributes to chronic tissue eosinophilia and airway remodeling, with permanent loss in pulmonary function. Omalizumab (rhuMAb-E25) is a recombinant, humanized, monoclonal anti-IgE antibody of mouse origin developed for the treatment of IgE-mediated diseases. Omalizumab binds to free IgE at the same site as the high-affinity receptor. Although it attaches to free IgE, it does not bind to IgA, IgG, or cell-bound IgE. It therefore does not induce cross-linking of cell-bound IgE, which would lead to the release of allergic mediators. It has been reported to decrease serum IgE levels in a dose-dependent manner, inhibit EAR and LAR, and cause a down-regulation of Fc epsilon RI receptors on basophils. Omalizumab has been reported to be safe and effective in improving asthma control and reducing the requirement for oral and inhaled corticosteroids. This double-blind, randomized, placebo-controlled study evaluated the safety, steroid-sparing effects, and impact on disease exacerbations of omalizumab in the treatment of childhood asthma. Methods. Participants were 334 males and premenarchal females aged 6 to 12 years, with moderate to severe allergic asthma requiring treatment with inhaled corticosteroids. During a run-in phase, all children were switched to equivalent doses of beclomethasone dipropionate (BDP), and the dose was adjusted to assure maintenance of asthma control achieved with previous corticosteroid treatment. Children were randomized to subcutaneously administered placebo (N = 109) or omalizumab (N = 225) at a dose based on body weight and initial serum IgE (0.016 mg/kg/IgE [IU/mL] per 4 weeks). BDP dose (initial range 168-420 mug/d) was kept stable for 16 weeks (stable-steroid phase), reduced over 8 weeks to the minimum effective dose (steroid-reduction phase), and maintained constant for the final 4 weeks. Results. More participants in the omalizumab group decreased their BDP dose, and their reduction was greater than that of the placebo group (median reduction 100% vs 66.7%). BDP was withdrawn completely in 55% of the omalizumab group versus 39% of the placebo group. The incidence and the frequency of asthma exacerbations requiring treatment with doubling of BDP dose or systemic corticosteroids were lower in the omalizumab group. The treatment differences were statistically significant during the steroid-reduction phase, during which fewer participants in the omalizumab group had asthma exacerbation episodes (18.2% vs 38.5%), and the mean number of episodes per patient was smaller than with placebo (0.42 vs 2.72). Five asthma exacerbations requiring hospitalization all occurred in the placebo group. Participants' and investigators' global evaluations of treatment effectiveness were more favorable for omalizumab than placebo. Investigators rated effectiveness excellent for 31.5% of the omalizumab group versus 16.3% of the placebo group and good for 44.7% of the omalizumab group versus 32.7% of the placebo group. There was little change in asthma symptom scores or spirometry measurements during either the stable-steroid or steroid dose-reduction phase, with minimal differences between the treatment groups. The requirement for rescue medication in the omalizumab group during both the stable-steroid and steroid dose-reduction phases was consistently lower than at baseline. At week 28, the median number of puffs of rescue medication taken daily was 0 in the omalizumab group and 0.46 in the placebo group. The change from baseline was significant in favor of omalizumab. Over the entire treatment period, patients in the omalizumab group missed a mean of 0.65 school days, compared with a mean of 1.21 days in the placebo group. The mean number of unscheduled medical contacts attributable to asthma-related medical problems was significantly smaller in the omalizumab group than in the placebo group throughout the treatment period (0.15 vs 5.35). Median reduction in serum free IgE was 95% to 99% among omalizumab patients. Median free IgE ranged from 133 to 790 IU/mL at baseline and was in the range of 6 to 9 IU/mL during the treatment period. The dosing scheme used in the trial therefore effectively reduced serum IgE in patients with initial concentrations as high as 1300 IU/mL. There was no reduction in free IgE in the placebo group. Omalizumab treatment was well tolerated. There were no serious treatment-related adverse events. The frequency and types of all adverse events were similar in the omalizumab and placebo groups. The majority of adverse events were mild to moderate in severity. No adverse events suggestive of serum sickness or immune complex formation were observed. Study-drug-related adverse events occurred more frequently in the omalizumab group than in the placebo group (6.2% vs 0.9%). Urticaria was reported in 9 omalizumab patients (4%) compared with 1 (0.9%) placebo patient and was mild or moderate in nearly all cases. Conclusion. Treatment with omalizumab is safe in children with asthma. It reduces the requirement for inhaled corticosteroids while protecting against disease exacerbation.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; So Calif Res Ctr, Mission Viejo, CA USA; Univ Illinois, Peoria, IL USA; Novartis Pharmaceut, E Hanover, NJ USA; Allergy & Asthma Res Inst, Louisville, KY USA; Schering Plough Corp, Kenilworth, NJ 07033 USA	Milgrom, H (reprint author), Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.						Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; BAZARAL M, 1972, J ALLERGY CLIN IMMUN, V49, P189, DOI 10.1016/0091-6749(72)90113-3; Bisberg D, 1996, J CLIN PHARMACOL, V36, P859; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; Breslow NE, 1980, IARC SCI PUBL, V32, P5; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; Chang TW, 2000, NAT BIOTECHNOL, V18, P157, DOI 10.1038/72601; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Fox JA, 1996, J PHARMACOL EXP THER, V279, P1000; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; GERRITSEN J, 1989, AM REV RESPIR DIS, V140, P1325; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; Holgate ST, 1996, CLIN EXP ALLERGY, V26, P1; Holgate ST, 1993, ALLERGY PRINCIPLES P, P267; Lemanske RF, 1993, ALLERGY PRINCIPLES P, P320; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MERRETT J, 1993, J CLIN IMMUNOASSAY, V16, P164; Metzger WJ, 1998, J ALLERGY CLIN IMMUN, V101, P231; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; *NAT ASTHM ED PREV, 1997, PUBL US DEP HHS PHS; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; Oettgen HC, 1999, J CLIN INVEST, V104, P829, DOI 10.1172/JCI8205; Overbeek SE, 1996, EUR RESPIR J, V9, P2256, DOI 10.1183/09031936.96.09112256; PLATTSMILLS T, 1999, ASTHMA A LINK ENV IM; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; PRESTA L, 1994, J BIOL CHEM, V269, P26368; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P308; Spahn JD, 1998, J ASTHMA, V35, P307, DOI 10.3109/02770909809075664; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TURKELTAUB PC, 1992, ARB PEI GSH, V85, P59; U.S. Department of Education, 1999, ATSDR TOX PROF MERC, P1; VANELTEREN P, 1960, B INT STATIST INST, V37, P351; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wohl MEB, 2000, NEW ENGL J MED, V343, P1113, DOI 10.1056/NEJM200010123431509; ZWEIMAN B, 1993, CURR OPIN IMMUNOL, V5, P950, DOI 10.1016/0952-7915(93)90111-5	45	157	166	2	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2001	108	2					art. no.	e36		10.1542/peds.108.2.e36		10	Pediatrics	Pediatrics	458TZ	WOS:000170211800017	11483846	
J	Papi, A; Romagnoli, M; Baraldo, S; Braccioni, F; Guzzinati, I; Saetta, M; Ciaccia, A; Fabbri, LM				Papi, A; Romagnoli, M; Baraldo, S; Braccioni, F; Guzzinati, I; Saetta, M; Ciaccia, A; Fabbri, LM			Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							ENDOGENOUS NITRIC-OXIDE; CORTICOSTEROID-THERAPY; RESPIRATORY-TRACT; SINGLE-BREATH; ASTHMA; COPD; INFLAMMATION; AIRWAY; BRONCHITIS	We investigated the relationship between the reversibility of airflow limitation, the concentration of nitric oxide (NO) in exhaled air, and the inflammatory cells in the sputum of patients with stable chronic obstructive pulmonary disease (COPD). We examined nine normal healthy control subjects and 20 nonatopic patients with COPD. Ten patients had no reversibility of airflow limitation (increase in FEV1 of < 12% and < 200 ml after 200 mug of inhaled salbutamol), and 10 patients had partial reversibility of airflow limitation (increase in FEV1 of < 12% but > 200 ml after 200 mug of inhaled salbutamol). Exhaled NO levels were higher in COPD patients with partial reversibility of airflow limitation than in those with no reversibility of airflow limitation (median 24 [interquartile range 15.3 to 32] ppb versus 8.9 [4.6 to 14.7] ppb; p < 0.01). Compared with healthy control subjects, only COPD patients with partial reversibility of airflow limitation had increased concentrations of sputum eosinophils. We conclude that, in patients with stable COPD, even a partial bronchodilator response to inhaled salbutamol is associated with increased exhaled NO and sputum eosinophilia, suggesting that these patients may have a different response to treatment than do those without reversible airflow limitation.	Univ Modena, Dept Pulm Dis, I-41100 Modena, Italy; Univ Ferrara, Res Ctr Asthma, I-44100 Ferrara, Italy; Univ Ferrara, COPD, I-44100 Ferrara, Italy; Univ Padua, Inst Occupat Med, Padua, Italy	Fabbri, LM (reprint author), Univ Modena, Dept Pulm Dis, Via Pozzo 71, I-41100 Modena, Italy.		Fabbri, Leonardo/I-4055-2012	Fabbri, Leonardo/0000-0001-8894-1689; PAPI, ALBERTO/0000-0002-6924-4500			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ANTHONISEN NR, 1986, AM REV RESPIR DIS, V133, P814; Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; CALLAHAN CM, 1991, ANN INTERN MED, V114, P216; CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; Clini E, 1998, THORAX, V53, P881; Corradi M, 1999, THORAX, V54, P572; CRAPO RO, 1991, AM REV RESPIR DIS, V143, P1212; Fujimoto K, 1999, CHEST, V115, P697, DOI 10.1378/chest.115.3.697; Hedenstierna G, 1998, EUR RESPIR J, V12, P1248, DOI 10.1183/09031936.98.12061248; Hogman M, 1997, ACTA PHYSIOL SCAND, V159, P345, DOI 10.1046/j.1365-201X.1997.00101.x; Jatakanon A, 1998, THORAX, V53, P91; Kanazawa H, 1998, CLIN EXP ALLERGY, V28, P1244; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P1773; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V152, P1926; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; *NAT I HLTH, 1997, PUBLICATION; Peleman RA, 1999, EUR RESPIR J, V13, P839, DOI 10.1034/j.1399-3003.1999.13d24.x; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Robbins RA, 1996, AM J RESP CRIT CARE, V153, P1631; RODRIGUEZROISIN R, 1998, MANAGEMENT CHRONIC O, P107; Rogge L, 1999, J IMMUNOL, V162, P3926; Rutgers SR, 1998, EUR RESPIR J, V12, P816, DOI 10.1183/09031936.98.12040816; Rutgers SR, 1999, THORAX, V54, P576; Saetta M, 1997, EUR RESPIR REV, V7, P29; Saetta M, 1998, MANAGEMENT CHRONIC O, P92; Saleh D, 1998, FASEB J, V12, P929; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; van Rensen ELJ, 1999, THORAX, V54, P403	35	157	165	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV	2000	162	5					1773	1777				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	371WU	WOS:000165202900031	11069811	
J	Hunninghake, GM; Cho, MH; Tesfaigzi, Y; Soto-Quiros, ME; Avila, L; Lasky-Su, J; Stidley, C; Melen, E; Soderhall, C; Hallberg, J; Kull, I; Kere, J; Svartengren, M; Pershagen, G; Wickman, M; Lange, C; Demeo, DL; Hersh, CP; Klanderman, BJ; Raby, BA; Sparrow, D; Shapiro, SD; Silverman, EK; Litonjua, AA; Weiss, ST; Celedon, JC				Hunninghake, Gary M.; Cho, Michael H.; Tesfaigzi, Yohannes; Soto-Quiros, Manuel E.; Avila, Lydiana; Lasky-Su, Jessica; Stidley, Chris; Melen, Erik; Soderhall, Cilla; Hallberg, Jenny; Kull, Inger; Kere, Juha; Svartengren, Magnus; Pershagen, Goran; Wickman, Magnus; Lange, Christoph; Demeo, Dawn L.; Hersh, Craig P.; Klanderman, Barbara J.; Raby, Benjamin A.; Sparrow, David; Shapiro, Steven D.; Silverman, Edwin K.; Litonjua, Augusto A.; Weiss, Scott T.; Celedon, Juan C.			MMP12, Lung Function, and COPD in High-Risk Populations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; CHILDHOOD ASTHMA; POLYMORPHISMS; EMPHYSEMA; GENE; SMOKERS; DECLINE; GROWTH; ASSOCIATION	BACKGROUND Genetic variants influencing lung function in children and adults may ultimately lead to the development of chronic obstructive pulmonary disease ( COPD), particularly in high-risk groups. METHODS We tested for an association between single-nucleotide polymorphisms (SNPs) in the gene encoding matrix metalloproteinase 12 (MMP12) and a measure of lung function (prebronchodilator forced expiratory volume in 1 second [FEV(1)]) in more than 8300 subjects in seven cohorts that included children and adults. Within the Normative Aging Study (NAS), a cohort of initially healthy adult men, we tested for an association between SNPs that were associated with FEV(1) and the time to the onset of COPD. We then examined the relationship between MMP12 SNPs and COPD in two cohorts of adults with COPD or at risk for COPD. RESULTS The minor allele ( G) of a functional variant in the promoter region of MMP12 (rs2276109 [-82A -> G]) was positively associated with FEV1 in a combined analysis of children with asthma and adult former and current smokers in all cohorts (P=2x10(-6)). This allele was also associated with a reduced risk of the onset of COPD in the NAS cohort (hazard ratio, 0.65; 95% confidence interval [CI], 0.46 to 0.92; P = 0.02) and with a reduced risk of COPD in a cohort of smokers ( odds ratio, 0.63; 95% CI, 0.45 to 0.88; P = 0.005) and among participants in a family-based study of early-onset COPD (P = 0.006). CONCLUSIONS The minor allele of a SNP in MMP12 (rs2276109) is associated with a positive effect on lung function in children with asthma and in adults who smoke. This allele is also associated with a reduced risk of COPD in adult smokers.	[Hunninghake, Gary M.; Cho, Michael H.; Lasky-Su, Jessica; Melen, Erik; Lange, Christoph; Demeo, Dawn L.; Hersh, Craig P.; Klanderman, Barbara J.; Raby, Benjamin A.; Silverman, Edwin K.; Litonjua, Augusto A.; Weiss, Scott T.; Celedon, Juan C.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Hunninghake, Gary M.; Cho, Michael H.; Lasky-Su, Jessica; Melen, Erik; Lange, Christoph; Demeo, Dawn L.; Hersh, Craig P.; Klanderman, Barbara J.; Raby, Benjamin A.; Silverman, Edwin K.; Litonjua, Augusto A.; Weiss, Scott T.; Celedon, Juan C.] Brigham & Womens Hosp, Ctr Genom Med, Boston, MA 02115 USA; [Hunninghake, Gary M.; Cho, Michael H.; Demeo, Dawn L.; Hersh, Craig P.; Raby, Benjamin A.; Silverman, Edwin K.; Litonjua, Augusto A.; Celedon, Juan C.] Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; [Hunninghake, Gary M.; Cho, Michael H.; Lasky-Su, Jessica; Melen, Erik; Demeo, Dawn L.; Hersh, Craig P.; Klanderman, Barbara J.; Raby, Benjamin A.; Silverman, Edwin K.; Litonjua, Augusto A.; Weiss, Scott T.; Celedon, Juan C.] Harvard Univ, Sch Med, Boston, MA USA; [Lange, Christoph] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Sparrow, David] Boston Univ, Sch Med, VA Normat Aging Study, VA Healthcare Syst, Boston, MA 02118 USA; [Sparrow, David] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; [Tesfaigzi, Yohannes; Stidley, Chris] Lovelace Resp Res Inst, Albuquerque, NM USA; [Soto-Quiros, Manuel E.; Avila, Lydiana] Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica; [Melen, Erik; Kull, Inger; Pershagen, Goran; Wickman, Magnus] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Soderhall, Cilla; Kere, Juha] Karolinska Inst, Novum, Dept Biosci, S-10401 Stockholm, Sweden; [Svartengren, Magnus] Karolinska Inst, Dept Publ Hlth Sci, S-10401 Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Ctr Allergy Res, S-10401 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Hallberg, Jenny; Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden; [Shapiro, Steven D.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	Celedon, JC (reprint author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu	Kere, Juha/A-9179-2008; Soderhall, Cilla/E-3940-2012	Kere, Juha/0000-0003-1974-0271; Soderhall, Cilla/0000-0002-8397-3080; Litonjua, Augusto/0000-0003-0422-5875; Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771	National Heart, Lung, and Blood Institute (NHLBI) [K08 HL092222, K12 HL089990, K08 HL72918, K08 HL074193, R37 HL66289, K01 HL04370, U01 HL065899, U01 HL075419, P01 HL083069, R01 HL086601, R01 HL075478, N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110]; Swedish Research Council, Stockholm County Council, Center for Allergy Research, Karolinska Institutet; State of New Mexico; Cooperative Studies Program-Epidemiology Research and Information Center of the U. S. Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center, Boston; Medical Research Council [G0000934]; Wellcome Trust [068545/Z/02]; AstraZeneca; Merck; Johnson Johnson; Golden Helix; Novartis Pharmaceuticals; GlaxoSmithKline; Sandvik Hard Materials; Sepracor; Genentech; Phadia; Merck Sweden	Supported by grants from the National Heart, Lung, and Blood Institute (NHLBI) (K08 HL092222, to Dr. Hunninghake; K12 HL089990, to Dr. Cho; K08 HL72918, to Dr. Demeo; and K08 HL074193, to Dr. Raby). The Genetics of Asthma in Costa Rica Study (GACRS) was supported by grants from the NHLBI (R37 HL66289 and K01 HL04370); the Childhood Asthma Management Program ( CAMP) Genetics Ancillary Study was supported by grants from the NHLBI (U01 HL065899, U01 HL075419, P01 HL083069, and R01 HL086601); the Children, Allergy, Milieu, Stockholm, Epidemiological Survey (BAMSE) was supported by the Swedish Research Council, Stockholm County Council, Center for Allergy Research, Karolinska Institutet, and Swedish Heart Lung Foundation; the Boston Early- Onset COPD (eoCOPD) study was supported by a grant from the NHLBI (R01 HL075478); the National Emphysema Treatment Trial ( NETT) was supported by contracts from the NHLBI (N01HR76101, N01HR76102, N01HR76103, N01HR76104, N01HR76105, N01HR76106, N01HR76107, N01HR76108, N01HR76109, N01HR76110, N01HR76111, N01HR76112, N01HR76113, N01HR76114, N01HR76115, N01HR76116, N01HR76118, and N01HR76119), Centers for Medicare and Medicaid Services, and Agency for Healthcare Research and Quality, and the NETT Genetics Ancillary Study was supported by grants from the NHLBI ( R01 HL71393 and R01 HL084323); the Lovelace Smokers Cohort was supported by funding from the State of New Mexico; and the Normative Aging Study (NAS) was supported by the Cooperative Studies Program-Epidemiology Research and Information Center of the U. S. Department of Veterans Affairs and is a component of the Massachusetts Veterans Epidemiology Research and Information Center, Boston. The British 1958 Birth Cohort DNA collection, from which genotype data were used, was funded by grants from the Medical Research Council (G0000934) and the Wellcome Trust (068545/Z/02). Dr. Avila reports receiving lecture fees from AstraZeneca and Merck; Dr. Kere, grant support from Johnson & Johnson; Dr. Lange, consulting fees from Golden Helix; Dr. Raby, lecture fees from Novartis Pharmaceuticals; Dr. Silverman, consulting and lecture fees from AstraZeneca and consulting fees and grant support from GlaxoSmithKline; Dr. Soto-Quiros, lecture fees from AstraZeneca, GlaxoSmithKline, and Merck; Dr. Svartengren, lecture fees from Sandvik Hard Materials; Dr. Tesfaigzi, grant support from Sepracor; Dr. Weiss, consulting fees from Genentech; and Dr. Wickman, lecture fees from Phadia and Merck Sweden. No other potential conflict of interest relevant to this article was reported.	Adam E, 2006, J BIOL CHEM, V281, P6910, DOI 10.1074/jbc.M507140200; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BELL B, 1972, AGING HUM DEVELOP, V3, P5; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Espada R, 1999, CHEST, V116, P1750; Fletcher C, 1976, NATURAL HIST CHRONIC; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; He JQ, 2002, AM J RESP CRIT CARE, V166, P323, DOI 10.1164/rccm.2111059; Hersh CP, 2005, AM J RESP CELL MOL, V33, P71, DOI 10.1165/rcmb.2005-0073OC; Houghton AM, 2006, J CLIN INVEST, V116, P753, DOI 10.1172/JCI25617; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; HUNNINGHAKE GW, 1981, SCIENCE, V212, P925, DOI 10.1126/science.7233186; Joos L, 2002, HUM MOL GENET, V11, P569, DOI 10.1093/hmg/11.5.569; Jormsjo S, 2000, CIRC RES, V86, P998; Juul K, 2006, AM J RESP CRIT CARE, V173, P858, DOI 10.1164/rccm.200509-1387OC; Kenchaiah S, 2002, NEW ENGL J MED, V347, P305, DOI 10.1056/NEJMoa020245; Lange C, 2004, AM J HUM GENET, V74, P367, DOI 10.1086/381563; Lange C., 2004, STAT APPL GENET MOL, V3, DOI 10.2202/1544-6115.1067; Lettre G, 2008, NAT GENET, V40, P584, DOI 10.1038/ng.125; Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; ORIE N G, 1961, Ned Tijdschr Geneeskd, V105, P2136; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Sadeghnejad A, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-21; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Silverman EK, 1998, AM J RESP CRIT CARE, V157, P1770; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Sood A, 2008, COPD, V5, P274, DOI 10.1080/15412550802363345; *STGEORG U LOND, GEN INF BRIT 1958 BI; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Woodruff PG, 2005, AM J RESP CRIT CARE, V172, P1383, DOI 10.1164/rccm.200505-686OC; Wu LH, 2003, GENES CELLS, V8, P225, DOI 10.1046/j.1365-2443.2003.00628.x; Yun K, 2007, BIOCHEM BIOPH RES CO, V364, P1009, DOI 10.1016/j.bbrc.2007.10.121; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	40	156	161	4	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 31	2009	361	27					2599	2608		10.1056/NEJMoa0904006		10	Medicine, General & Internal	General & Internal Medicine	538JV	WOS:000273181300007	20018959	
J	Mothes, N; Heinzkill, M; Drachenberg, KJ; Sperr, WR; Krauth, MT; Majlesi, Y; Semper, H; Valent, P; Niederberger V; Kraft, D; Valenta, R				Mothes, N; Heinzkill, M; Drachenberg, KJ; Sperr, WR; Krauth, MT; Majlesi, Y; Semper, H; Valent, P; Niederberger, V; Kraft, D; Valenta, R			Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						blocking antibodies; immunotherapy; recombinant grass pollen allergens	GRASS-POLLEN ALLERGEN; HEPATITIS-B-VACCINE; IGE; IGG2; IMMUNOGENICITY; IMMUNIZATION; EPITOPES; EFFICACY; DEFECTS; SAFETY	Background Allergen-specific immunotherapy represents a causal form of treatment for IgE-mediated allergies. The allergen extract-based analyses of immunotherapy-induced effects yielded highly controversial results regarding a beneficial role of therapy-induced IgG antibodies. Objective We analysed allergen-specific IgE, IgG subclass, and IgM responses in patients treated with a grass pollen allergy vaccine adjuvanted with monophosphoryl lipid A (MPL), a Th1-inducing agent, and in a placebo group using recombinant timothy grass pollen allergen molecules (rPhl p 1, rPhl p 2, rPhl p 5). Results The strong induction of allergen-specific IgG(1) and IgG(4) antibodies observed only in the actively treated group was associated with significant clinical improvement. Therapy-induced allergen-specific IgM and IgG(2) responses were also noted in several actively treated patients. An inhibition of allergen-dependent basophil histamine release was only obtained with sera containing therapy-induced allergen-specific IgG, but not with sera obtained before therapy or from placebo-treated patients. Moreover, patients with therapy-induced allergen-specific IgG antibodies showed a reduced induction of allergen-specific IgE responses during seasonal grass pollen exposure. Conclusion Successful immunotherapy with the MPL-adjuvanted grass pollen allergy vaccine is associated with the production of allergen-specific IgG antibodies. These blocking antibodies may have protective effects by inhibiting immediate-type reactions and systemic increases of IgE responses caused by seasonal allergen exposure.	Univ Vienna, Sch Med, Vienna Gen Hosp,Mol Immunopathol Grp, Dept Pathophysiol,Div Immunopathol, A-1090 Vienna, Austria; Bencard Allergie GmbH, Munich, Germany; Univ Vienna, Vienna Gen Hosp, Div Hematol & Hemostaseol, Vienna, Austria; Univ Vienna, Vienna Gen Hosp, Dept Otorhinolaryngol, Vienna, Austria	Valenta, R (reprint author), Univ Vienna, Sch Med, Vienna Gen Hosp,Mol Immunopathol Grp, Dept Pathophysiol,Div Immunopathol, Waehringer Gurtel 18-20, A-1090 Vienna, Austria.						Ball T, 1999, FASEB J, V13, P1277; Boluda L, 1997, J INVEST ALLERG CLIN, V7, P205; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bufe A, 1998, AM J RESP CRIT CARE, V157, P1269; CLINTON PM, 1989, INT ARCH ALLER A IMM, V89, P43; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282; Ebner C, 1999, INT ARCH ALLERGY IMM, V119, P1, DOI 10.1159/000024168; Flicker S, 2000, J IMMUNOL, V165, P3849; HENDERSON LL, 1975, J ALLERGY CLIN IMMUN, V55, P10, DOI 10.1016/S0091-6749(75)80003-0; Heppner DG, 1996, J INFECT DIS, V174, P361; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; INOUE R, 1995, SCAND J IMMUNOL, V41, P130, DOI 10.1111/j.1365-3083.1995.tb03544.x; KAWANO Y, 1994, J IMMUNOL, V153, P4948; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; MORAN DM, 1977, INT ARCH ALLER A IMM, V54, P315; Noon L, 1911, LANCET, V1, P1572; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Sehra S, 1998, CLIN EXP ALLERGY, V28, P1530; ServetDelprat C, 1996, INT IMMUNOL, V8, P1495, DOI 10.1093/intimm/8.10.1495; Thoelen S, 1998, VACCINE, V16, P708, DOI 10.1016/S0264-410X(97)00254-5; Thoelen S, 2000, ACTA GASTRO-ENT BELG, V63, P185; Ulrich J., 1995, VACCINE DESIGN SUBUN, P495; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902; Vrtala S, 1998, J IMMUNOL, V160, P6137; VRTALA S, 1993, J IMMUNOL, V151, P4773; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V97, P781, DOI 10.1016/S0091-6749(96)80156-4; Wheeler AW, 2001, INT ARCH ALLERGY IMM, V126, P135, DOI 10.1159/000049504	35	156	162	1	6	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2003	33	9					1198	1208		10.1046/j.1365-2222.2003.01699.x		11	Allergy; Immunology	Allergy; Immunology	727UC	WOS:000185678400006	12956739	
J	Rumchev, KB; Spickett, JT; Bulsara, MK; Phillips, MR; Stick, SM				Rumchev, KB; Spickett, JT; Bulsara, MK; Phillips, MR; Stick, SM			Domestic exposure to formaldehyde significantly increases the risk of asthma in young children	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; children; formaldehyde; indoor air quality	VOLATILE ORGANIC-COMPOUNDS; LONGITUDINAL DATA-ANALYSIS; CHILDHOOD; ASSOCIATION; ALLERGENS; DIOXIDE	Concern has arisen in recent years about indoor air pollution as a risk factor for asthma. Formaldehyde exposure vas examined in relation to asthma among young children (between 6 months and 3 yrs old) in a population-based control study carried out in Perth, Western Australia, between 1997-1999. An association between exposure to formaldehyde and asthma in young children has been suggested. Cases (n=88), whose parents were recruited at Princess Margaret Hospital Accident and Emergency Dept (Perth, Western Australia), were children discharged with asthma as the primary diagnosis. Controls (n=104), who were children in the same age group without asthma diagnosed by a doctor, were identified from birth records through the Health Dept of Western Australia (Perth, Western Australia). Health outcomes for the children were studied using a respiratory questionnaire and skin-prick tests. Formaldehyde, average temperature and relative humidity were measured on two occasions, winter (July-September 1998) and summer (December 1998-March 1999) in the child's bedroom and in the living room. The study found seasonal differences in formaldehyde levels in the children's bedrooms and living rooms with significantly greater formaldehyde exposure during the summer period for case and control subjects. The generalised estimating equation model showed that children exposed to formaldehyde levels of greater than or equal to60 mug.m(-3) are at increased risk of having asthma. The results suggest that domestic exposure to formaldehyde increases the risk of childhood asthma.	Curtin Univ Technol, Sch Publ Hlth, Perth, WA 6001, Australia; Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia	Rumchev, KB (reprint author), Curtin Univ Technol, Sch Publ Hlth, GPO Box U1987, Perth, WA 6001, Australia.		Bulsara, Max/A-5966-2008; Stick, Stephen/O-5683-2014; Osborne, Nicholas/N-4915-2015	Bulsara, Max/0000-0002-8033-6123; Osborne, Nicholas/0000-0002-6700-2284; Stick, Stephen/0000-0002-5386-8482			Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; CZAP C, 1993, EUR RESPIR J, V6, pS235; FERRIS BG, 1978, AM REV RESPIR DIS, V188, P1; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757; Garrett M.H., 1996, P 7 INT C IND AIR QU, V1, P617; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662; HELWIG H, 1977, DEUT MED WOCHENSCHR, V102, P1612; Hosmer DW, 1989, APPL LOGISTIC REGRES; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; LEVIN JO, 1985, ANAL CHEM, V57, P1032, DOI 10.1021/ac00283a016; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Magnus P, 1997, BRIT MED J, V314, P1795; Maroni M., 1995, AIR QUALITY MONOGRAP, V3; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; *NAT HLTH MRC, 1995, 115 NHMRC SESS 1995; *NAT HLTH MRC AUST, 1996, AUSTR 93 SESS NAT HL; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Pendergast JF, 1996, INT STAT REV, V64, P89, DOI 10.2307/1403425; QUACKENBOSS JJ, 1989, ENVIRON INT, V15, P169, DOI 10.1016/0160-4120(89)90023-8; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; WHO, 1989, FORM ENV HLTH CRIT; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Woodcock A, 1998, BRIT MED J, V316, P1075; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	30	156	169	2	22	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	AUG	2002	20	2					403	408		10.1183/09031936.02.00245002		6	Respiratory System	Respiratory System	587LE	WOS:000177641400026	12212974	
J	Pastuszka, JS; Paw, UKT; Lis, DO; Wlazlo, A; Ulfig, K				Pastuszka, JS; Paw, UKT; Lis, DO; Wlazlo, A; Ulfig, K			Bacterial and fungal aerosol in indoor environment in Upper Silesia, Poland	ATMOSPHERIC ENVIRONMENT			English	Article						bioaerosol; bacteria; fungi; indoor air; mold problem	RESPIRATORY SYMPTOMS; MOLD PROBLEMS; AIR-QUALITY; HOMES; PREVALENCE; KATOWICE; DAMP; SCHOOLCHILDREN; BIOAEROSOLS; PARTICLES	The purpose of this study was to find the typical concentration levels of bacterial and fungal bioaerosol in healthy and moldy homes as well as in office rooms in Upper Silesia Industrial Zone. Airborne bacteria and fungi were collected using the 6-stage Andersen impactor inside and outside of buildings. It was found that the typical level of bacterial aerosol indoors is about 10(3) CFU m(-3) in horncs and 10(2) CFU m(-3) in offices, Only Micrococcus spp was present in all homes studied, constituting 36% of the bacterial genera. The second most common was Staphylococcus epidermidis, present in 76% of homes and constituting 14% of the total. The concentration of fungal aerosol in winter ranged from 10 to 102 CFU m-3 in healthy homes and from 10 to 103 CFU m-3 in homes with mold problems. In summer these values were elevated reaching 10(3) CFU m(-3) in healthy homes and 10(3)-10(4) CFU m-3 in moldy buildings. In healthy homes the relative concentration of observed species, including Penicillium, ranged from 3 to about 50% while in moldy homes the highest concentration of Penicillium accounted for 90% of the total fungi. However, the differences between viable fungal species as well as concentrations observed in moldy and healthy homes seem to be too small to be a reason of significantly higher risk for allergic asthma symptoms in any group of buildings. Comparison of the respirable fraction of airborne bacteria and Fungi with literature data suggests that the percentage of respirable fungi and bacteria is generally not dependent on the type of home, building material, geographical factors and particulate air pollution. (C) 2000 Elsevier Science Ltd. All rights reserved.	Univ Calif Davis, Davis, CA 95616 USA; Inst Occupat Med & Enviromm Hlth, PL-41200 Sosnowiec, Poland; Inst Ecol Ind Areas, PL-40832 Katowice, Poland	Pastuszka, JS (reprint author), Univ Calif Davis, Hoagland Hall,1 Shields Ave, Davis, CA 95616 USA.		Lis, Danuta/H-9921-2013	Lis, Danuta/0000-0002-9657-7650			ACGIH, 1989, GUID ASS BIOAER IND; Atlas R M, 1981, MICROBIAL ECOLOGY FU; AYLOR DE, 1980, MYCOLOGIA, V72, P1213, DOI 10.2307/3759577; Braback L, 1991, PEDIATR ALLERGY IMMU, V2, P14, DOI 10.1111/j.1399-3038.1991.tb00174.x; BURGE H, 1990, J ALLERGY CLIN IMMUN, V86, P687, DOI 10.1016/S0091-6749(05)80170-8; CEC, 1993, 12 CEC; Chanda S, 1996, ANN AGR ENV MED, V3, P157; CHATIGNY MA, 1989, AIR SAMPLING INSTRUM, P200; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; DeKoster J. A., 1995, AM IND HYG ASSOC J, V56, P576; Dotterud LK, 1996, INDOOR AIR, V6, P71, DOI 10.1111/j.1600-0668.1996.t01-2-00002.x; Dutkiewicz J., 1997, Annals of Agricultural and Environmental Medicine, V4, P11; FAIRCHILD CI, 1982, ATMOS ENVIRON, V16, P229, DOI 10.1016/0004-6981(82)90437-1; FLANNIGAN B, 1994, P INT C FUNG BACT IN, P123; Flannigan B., 1991, J APPL BACTERIOL S, V70, p61S; GALLI A, 1993, J NEURAL TRANSM-GEN, V93, P167, DOI 10.1007/BF01244994; GALLUP J, 1987, ADV AEROBIOL, V51, P139; GOLDFARB AA, 1968, ANN ALLERGY, V26, P321; GRAVESEN S, 1978, ALLERGY, V33, P268, DOI 10.1111/j.1398-9995.1978.tb01547.x; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; Gravesen S, 1994, MICROFUNGI MUNKSGAAR; Horak B, 1996, ANN ALLERG ASTHMA IM, V76, P41; HUSMAN T, 1993, P IND AIR 93 HELS FI, V4, P171; Hyvarinen A., 1993, INDOOR AIR, V3, P337, DOI 10.1111/j.1600-0668.1993.00017.x; KOSKINEN O, 1995, INDOOR AIR, V5, P3, DOI 10.1111/j.1600-0668.1995.t01-3-00002.x; KUO YM, 1994, ATMOS ENVIRON, V28, P3125, DOI 10.1016/1352-2310(94)E0069-V; LACEY J, 1988, ANN OCCUP HYG, V32, P515, DOI 10.1093/annhyg/32.4.515; LACEY J, 1994, J AEROSOL SCI, V25, P1371, DOI 10.1016/0021-8502(94)90215-1; LACEY J, 1989, AIRBORNE DETERIOGENS, P13; LI CS, 1993, ENVIRON INT, V19, P233, DOI 10.1016/0160-4120(93)90084-U; Lis D. O, 1997, J AEROSOL SCI     S1, V28, P665; Maroni M, 1993, P IND AIR 93 HELS FI, V4, P137; NEVALAINEN A, 1991, ENVIRON INT, V17, P299, DOI 10.1016/0160-4120(91)90015-I; NEVALAINEN A, 1992, ATMOS ENVIRON A-GEN, V26, P531, DOI 10.1016/0960-1686(92)90166-I; Nevalainen A, 1989, BACTERIAL AEROSOLS I; NEVALAINEN A, 1994, HLTH IMPLICATIONS FU, P155; Nevalainen A., 1993, AEROSOL MEASUREMENT, P471; NINAN TK, 1992, BRIT MED J, V304, P873; OWEN MK, 1992, ATMOS ENVIRON A-GEN, V26, P2149, DOI 10.1016/0960-1686(92)90403-8; PASTUSZKA J, 1993, ATMOS ENVIRON B-URB, V27, P59, DOI 10.1016/0957-1272(93)90045-8; PASTUSZKA JS, 1989, J AEROSOL SCI, V20, P1265, DOI 10.1016/0021-8502(89)90813-6; Pastuszka JS, 1995, SCI TOTAL ENVIRON, V175, P179, DOI 10.1016/0048-9697(95)04789-1; PASTUSZKA JS, 1996, P WORKSH AIR POLL EP, P85; PASTUSZKA JS, 1998, PROBLEMY EKOLOGII, V5, P171; Pitt J. I., 1979, GENUS PENICILLIUM IT; PLATT SD, 1989, BRIT MED J, V298, P1673; Raper K B, 1977, GENUS ASPERGILLUS; REN J, 1993, P INDOOR AIR 93, V4, P207; Reponen T, 1992, INDOOR AIR, V2, P26, DOI DOI 10.1111/J.1600-0668.1992.03-21.X; Rietmeijer FJM, 1997, ATMOS ENVIRON, V31, P1941, DOI 10.1016/S1352-2310(96)00357-3; Rosas I, 1997, AEROBIOLOGIA, V13, P23, DOI 10.1007/BF02694787; SELTZER JM, 1995, OCCUP MED, V10, P1; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P46, DOI 10.1016/0091-6749(76)90078-6; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; VERHOEFF AP, 1992, ALLERGY, V47, P83	55	156	175	4	30	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.		2000	34	22					3833	3842		10.1016/S1352-2310(99)00527-0		10	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	338XP	WOS:000088448800017		
J	Finkelman, FD; Hogan, SP; Hershey, GKK; Rothenberg, ME; Wills-Karp, M				Finkelman, Fred D.; Hogan, Simon P.; Hershey, Gurjit K. Khurana; Rothenberg, Marc E.; Wills-Karp, Marsha			Importance of Cytokines in Murine Allergic Airway Disease and Human Asthma	JOURNAL OF IMMUNOLOGY			English	Review							NECROSIS-FACTOR-ALPHA; IL-5 MESSENGER-RNA; THYMIC STROMAL LYMPHOPOIETIN; RECEPTOR ANTAGONIST GENE; SINGLE-NUCLEOTIDE POLYMORPHISM; DENDRITIC CELL MATURATION; COLONY-STIMULATING FACTOR; CHILDHOOD ATOPIC ASTHMA; DUST-MITE EXPOSURE; SERUM IGE LEVELS	Asthma is a common, disabling inflammatory respiratory disease that has increased in frequency and severity in developed nations. We review studies of murine allergic airway disease (MAAD) and human asthma that evaluate the importance of Th2 cytokines, Th2 response-promoting cytokines, IL-17, and proinflammatory and anti-inflammatory cytokines in MAAD and human asthma. We discuss murine studies that directly stimulate airways with specific cytokines or delete, inactivate, neutralize, or block specific cytokines or their receptors, as well as controversial issues including the roles of IL-5, IL-17, and IL-13R alpha 2 in MAAD and IL-4R alpha expression by specific cell types. Studies of human asthmatic cytokine gene and protein expression, linkage of cytokine polymorphisms to asthma, cytokine responses to allergen stimulation, and clinical responses to cytokine antagonists are discussed as well. Results of these analyses establish the importance of specific cytokines in MAAD and human asthma and have therapeutic implications. The journal of Immunology, 2010, 184: 1663-1674.	[Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH 45220 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Immunol, Cincinnati, OH 45267 USA; [Finkelman, Fred D.; Wills-Karp, Marsha] Cincinnati Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Hogan, Simon P.; Rothenberg, Marc E.] Cincinnati Childrens Hosp, Med Ctr, Div Allergy Res, Cincinnati, OH 45229 USA; [Hershey, Gurjit K. Khurana] Cincinnati Childrens Hosp, Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA	Finkelman, FD (reprint author), Cincinnati Vet Author Med Ctr, 3200 Vine St, Cincinnati, OH 45220 USA.	ffinkelman@pol.net		Khurana Hershey, Gurjit/0000-0001-6663-977X	U.S. Department for Veterans Affairs; National Institutes of Health [P01 HL076383, R01 HL097360]	The work was supported by the U.S. Department for Veterans Affairs and the National Institutes of Health (P01 HL076383 and R01 HL097360).	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akiho H, 2005, GASTROENTEROLOGY, V129, P131, DOI 10.1053/j.gastro.2005.03.049; Akiho H, 2002, AM J PHYSIOL-GASTR L, V282, pG226; Akinbami Lara, 2006, Adv Data, P1; Akpinarli A, 2002, J ASTHMA, V39, P159, DOI 10.1081/JAS-120002197; Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; American Academy of Allergy Asthma and Immunology, 2009, ASTHM STAT; Aschard H, 2009, GENES IMMUN, V10, P559, DOI 10.1038/gene.2009.46; Aytekin Caner, 2009, Tuberk Toraks, V57, P62; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Bates JHT, 2009, AM J PHYSIOL-LUNG C, V297, pL401, DOI 10.1152/ajplung.00027.2009; Beghe B, 2003, CLIN EXP ALLERGY, V33, P1111, DOI 10.1046/j.1365-2222.2003.01731.x; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bertorelli G, 2000, ALLERGY, V55, P449, DOI 10.1034/j.1398-9995.2000.055005449.x; Bierbaum S, 2006, ALLERGY, V61, P576, DOI 10.1111/j.1398-9995.2006.01059.x; Borger P, 1999, CLIN EXP ALLERGY, V29, P772; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Brasier AR, 2008, J ALLERGY CLIN IMMUN, V121, P30, DOI 10.1016/j.jaci.2007.10.015; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; Chae SC, 2007, J HUM GENET, V52, P355, DOI 10.1007/s10038-007-0123-8; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278; Chaouche-Drider N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005396; Chatterjee R, 2005, CLIN EXP ALLERGY, V35, P914, DOI 10.1111/j.1365-2222.2005.02273.x; Chatterjee R, 2009, INT ARCH ALLERGY IMM, V148, P137, DOI 10.1159/000155744; Chen WG, 2009, J IMMUNOL, V183, P7870, DOI 10.4049/jimmunol.0901028; Chen WG, 2004, J ALLERGY CLIN IMMUN, V114, P553, DOI 10.1016/j.jaci.2004.04.044; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; Chiang CH, 2007, RESPIROLOGY, V12, P42, DOI 10.1111/j.1440-1843.2006.00960.x; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Cho SH, 2005, AM J RESP CRIT CARE, V171, P224, DOI 10.1164/rccm.200310-1416OC; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; Chung K.F., 2001, EUR RESPIR J, V34, P50; COFFMAN RL, 1989, SCIENCE, V245, P308, DOI 10.1126/science.2787531; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1998, MOL MED, V4, P344; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; Coyle AJ, 1996, J IMMUNOL, V156, P2680; Cui Tianpen, 2003, J Huazhong Univ Sci Technolog Med Sci, V23, P134; de Faria ICJ, 2008, J PEDIAT, V84, P203, DOI [10.2223/JPED.1783, 10.1590/S0021-75572008000300004]; Devos S, 2006, CLIN EXP ALLERGY, V36, P174, DOI 10.1111/j.1365-2222.2006.02422.x; Dittrich AM, 2008, J IMMUNOL, V181, P7307; Durrant DM, 2009, J IMMUNOL, V183, P5293, DOI 10.4049/jimmunol.0803109; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; Erin EM, 2006, AM J RESP CRIT CARE, V174, P753, DOI 10.1164/rccm.200601-072OC; Eum SY, 2005, AM J PHYSIOL-LUNG C, V288, pL576, DOI 10.1152/ajplung.00380.2003; Farghaly HSM, 2008, MOL PHARMACOL, V73, P1530, DOI 10.1124/mol.108.045419; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Fichtner-Feigl S, 2006, NAT MED, V12, P99, DOI 10.1038/nm1332; FINKELMAN F, 2001, SAMTERS IMMUNOLOGIC, P111; Finkelman FD, 1999, CURR OPIN IMMUNOL, V11, P420, DOI 10.1016/S0952-7915(99)80070-3; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Finkelman FD, 2000, J IMMUNOL, V164, P2303; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Finkelman FD, 2008, J ALLERGY CLIN IMMUN, V121, P603, DOI 10.1016/j.jaci.2008.01.008; Finotto S, 2005, INT IMMUNOL, V17, P993, DOI 10.1093/intimm/dxh281; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fu CL, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-72; Fujiwara M, 2007, J ALLERGY CLIN IMMUN, V119, P662, DOI 10.1016/j.jaci.2006.12.643; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gervaziev YV, 2006, INT ARCH ALLERGY IMM, V141, P257, DOI 10.1159/000095295; Gohlke H, 2004, AM J RESP CRIT CARE, V169, P1217, DOI 10.1164/rccm.200302-281OC; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V118, P90, DOI 10.1159/000024037; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; Hamid Q, 2009, ANNU REV PHYSIOL, V71, P489, DOI 10.1146/annurev.physiol.010908.163200; Hang LW, 2003, J CLIN LAB ANAL, V17, P168, DOI 10.1002/jcla.10088; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Harada M, 2009, AM J RESP CRIT CARE, V180, P1048, DOI 10.1164/rccm.200905-0652OC; Hatsushika K, 2007, CLIN EXP ALLERGY, V37, P1165, DOI 10.1111/j.1365-2222.2007.02768.x; He JQ, 2009, J ALLERGY CLIN IMMUN, V124, P222, DOI 10.1016/j.jaci.2009.04.018; Heinzmann A, 2005, PEDIATR ALLERGY IMMU, V16, P310, DOI 10.1111/j.1399-3038.2005.00287.x; Heinzmann A, 2004, ALLERGY, V59, P845, DOI 10.1111/j.1398-9995.2004.00538.x; Heller NM, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164795; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Henderson WR, 2000, J IMMUNOL, V164, P1086; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Higa S, 2003, CLIN EXP ALLERGY, V33, P1097, DOI 10.1046/j.1365-2222.2003.01739.x; Hirota T, 2005, J ALLERGY CLIN IMMUN, V116, P789, DOI 10.1016/j.jaci.2005.06.010; Ho LP, 2002, CHEST, V121, P1421, DOI 10.1378/chest.121.5.1421; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, EUR J IMMUNOL, V28, P413; Hogan SP, 1998, J IMMUNOL, V161, P1501; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; Hosseini-Farahabadi S, 2007, IRAN J ALLERGY ASTHM, V6, P9; Howard TD, 2001, AM J RESP CELL MOL, V25, P377; Huang Jian, 2008, Proceedings of the American Association for Cancer Research Annual Meeting, V49, P34; HUANG SK, 1995, J IMMUNOL, V155, P2688; Huang TJ, 2001, J IMMUNOL, V166, P207; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Imboden M, 2006, CLIN EXP ALLERGY, V36, P211, DOI 10.1111/j.1365-2222.2006.02424.x; Ishikawa Y, 2006, INT IMMUNOL, V18, P847, DOI 10.1093/intimm/dxl021; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Jones TG, 2009, J IMMUNOL, V183, P5251, DOI 10.4049/jimmunol.0901471; Junttila IS, 2008, J EXP MED, V205, P2595, DOI 10.1084/jem.20080452; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL1066, DOI 10.1152/ajplung.00195.2001; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V112, P893, DOI 10.1067/mai.2003.1815; Kamali-Sarvestani E, 2007, J INVEST ALLERG CLIN, V17, P361; Kanda A, 2009, J ALLERGY CLIN IMMUN, V124, P573, DOI 10.1016/j.jaci.2009.04.031; Karras JG, 2007, AM J RESP CELL MOL, V36, P276, DOI 10.1165/rcmb.2005-0456OC; Kawaguchi M, 2006, J ALLERGY CLIN IMMUN, V117, P795, DOI 10.1016/j.jaci.2005.12.1346; Kellner J, 2007, INT ARCH ALLERGY IMM, V142, P199, DOI 10.1159/000097022; Khodoun M, 2007, J IMMUNOL, V179, P6429; Kim HB, 2008, CLIN EXP ALLERGY, V38, P774, DOI 10.1111/j.1365-2222.2008.02965.x; Kim SH, 2009, ALLERGY, V64, P1221, DOI 10.1111/j.1398-9995.2009.01989.x; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535; Koch M, 2006, AM J RESP CELL MOL, V35, P211, DOI 10.1165/rcmb.2005-0293OC; Kodama T, 2000, J ALLERGY CLIN IMMUN, V105, P45, DOI 10.1016/S0091-6749(00)90176-3; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Krug N, 1998, AM J RESP CRIT CARE, V158, P754; Kumar A, 2008, GENES IMMUN, V9, P294, DOI 10.1038/gene.2008.17; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuperman DA, 2005, J IMMUNOL, V175, P3746; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kuribayashi K, 2002, CLIN EXP ALLERGY, V32, P641, DOI 10.1046/j.0954-7894.2002.01346.x; Laan M, 1999, J IMMUNOL, V162, P2347; Lachheb J, 2008, INT J IMMUNOGENET, V35, P63, DOI 10.1111/j.1744-313X.2007.00738.x; LaPorte SL, 2008, CELL, V132, P259, DOI 10.1016/j.cell.2007.12.030; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEE CC, 2009, J CLIN LAB ANAL, V22, P39; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; LEWIS CC, 2009, J ALLERGY CLIN IMMUN, V123, pE8; Lewis Christina C, 2009, J Allergy Clin Immunol, V123, P795, DOI 10.1016/j.jaci.2009.01.003; Li YF, 2007, RESP MED, V101, P1977, DOI 10.1016/j.rmed.2007.04.006; Liebhart J, 2008, INT J IMMUNOGENET, V35, P417, DOI 10.1111/j.1744-313X.2008.00771.x; Linden A, 2000, EUR RESPIR J, V15, P973, DOI 10.1034/j.1399-3003.2000.15e28.x; Liu XJ, 2009, BIOCHEM BIOPH RES CO, V386, P181, DOI 10.1016/j.bbrc.2009.06.008; Liu YJ, 2007, J ALLERGY CLIN IMMUN, P245; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Lutz MB, 2002, J IMMUNOL, V169, P3574; Lyon H, 2004, GENET EPIDEMIOL, V26, P155, DOI 10.1002/gepi.10298; Mahdaviani SA, 2009, J CLIN IMMUNOL, V29, P57, DOI 10.1007/s10875-008-9232-1; Mak JCW, 2006, J ALLERGY CLIN IMMUN, V117, P92, DOI 10.1016/j.jaci.2005.08.049; Mak JCW, 2007, INT ARCH ALLERGY IMM, V144, P114, DOI 10.1159/000103222; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; Melen E, 2006, CLIN EXP ALLERGY, V36, P1391, DOI 10.1111/j.1365-2222.2006.02577.x; Menzies-Gow AN, 2007, CLIN EXP ALLERGY, V37, P1023, DOI 10.1111/j.1365-2222.2007.02735.x; Morjaria JB, 2008, THORAX, V63, P584, DOI 10.1136/thx.2007.086314; Morris SC, 2006, J IMMUNOL, V176, P5299; Movahedi M, 2008, J ASTHMA, V45, P790, DOI 10.1080/02770900802207261; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832; Munitz A, 2008, P NATL ACAD SCI USA, V105, P7240, DOI 10.1073/pnas.0802465105; Nagai H, 1996, ANN NY ACAD SCI, V796, P91, DOI 10.1111/j.1749-6632.1996.tb32570.x; Nagpal K, 2005, J ALLERGY CLIN IMMUN, V115, P527, DOI 10.1016/j.jaci.2004.11.048; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; Nembrini C, 2009, J ALLERGY CLIN IMMUN, P995; Nembrini C, 2009, J ALLERGY CLIN IMMUN, V123, P986, DOI 10.1016/j.jaci.2009.03.033; Nishikubo K, 2003, GENE THER, V10, P2119, DOI 10.1038/sj.gt.3302131; Noguchi E, 2002, AM J RESP CRIT CARE, V166, P43, DOI 10.1164/rccm.2110052; Noguchi E, 2001, HUM IMMUNOL, V62, P1251, DOI 10.1016/S0198-8859(01)00338-X; Noguchi E, 2001, GENES IMMUN, V2, P401, DOI 10.1038/sj.gene.6363790; O'Toole M, 2008, CLIN EXP ALLERGY, V38, P594, DOI 10.1111/j.1365-2222.2007.02921.x; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Oda N, 2005, AM J RESP CRIT CARE, V171, P12, DOI 10.1164/rccm.200406-778OC; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Ohkusa T, 2009, J MED MICROBIOL, V58, P535, DOI 10.1099/jmm.0.005801-0; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Ohta Y, 2008, J IMMUNOL, V180, P4191; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; Onari Y, 2009, CLIN EXP ALLERGY, V39, P290, DOI 10.1111/j.1365-2222.2008.03131.x; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Pala P, 2002, CLIN EXP ALLERGY, V32, P1739, DOI 10.1046/j.1365-2222.2002.01548.x; Pawlik A, 2007, TISSUE ANTIGENS, V70, P314, DOI 10.1111/j.1399-0039.2007.00908.x; Perkins C, 2006, J ALLERGY CLIN IMMUN, V118, P410, DOI 10.1016/j.jaci.2006.06.004; Phelan JD, 2008, J IMMUNOL, V180, P44; Presser K, 2008, J IMMUNOL, V181, P7751; Pulleyn LJ, 2001, HUM GENET, V109, P623, DOI 10.1007/s00439-001-0617-y; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Ramalingam TR, 2008, NAT IMMUNOL, V9, P25, DOI 10.1038/ni1544; Ramsey CD, 2005, GENES IMMUN, V6, P236, DOI 10.1038/sj.gene.6364170; Randolph AG, 2004, AM J HUM GENET, V75, P709, DOI 10.1086/424886; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Rickel EA, 2008, J IMMUNOL, V181, P4299; Riffo-Vasquez Y, 2002, PHARMACOL THERAPEUT, V94, P185, DOI 10.1016/S0163-7258(02)00217-6; Risma KA, 2002, J IMMUNOL, V169, P1604; Ritz SA, 2002, AM J RESP CELL MOL, V27, P428, DOI 10.1165/rcmb.4824; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Rosenwasser L. J, 1995, CLIN EXP ALLERGY S2, V25, P95; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; Rovina N, 2009, RESP MED, V103, P1919, DOI 10.1016/j.rmed.2009.05.023; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135; Sanford AN, 2002, COMPARATIVE MED, V52, P429; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Schroeder JT, 2001, J ALLERGY CLIN IMMUN, V107, P265, DOI 10.1067/mai.2001.112846; Settin A, 2008, INDIAN J PEDIATR, V75, P1019, DOI [10.1007/s12098-008-0161-z, 10.1007/S12098-008-0161-2]; Shannon J, 2008, CHEST, V133, P420, DOI 10.1378/chest.07-1881; Sharkhuu T, 2006, CLIN EXP ALLERGY, V36, P1575, DOI 10.1111/j.1365-2222.2006.02595.x; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P1818; Shi HZ, 1998, AM J RESP CRIT CARE, V157, P204; Shi LY, 2008, CLIN IMMUNOL, V129, P202, DOI 10.1016/j.clim.2008.07.015; Shore SA, 2002, CLIN EXP PHARMACOL P, V29, P859, DOI 10.1046/j.1440-1681.2002.03756.x; Silverman ES, 2004, AM J RESP CRIT CARE, V169, P214, DOI 10.1164/rccm.200307-973OC; Smithgall MD, 2008, INT IMMUNOL, V20, P1019, DOI 10.1093/intimm/dxn060; Song CW, 2008, J IMMUNOL, V181, P6117; Song ZM, 1996, J IMMUNOL, V156, P424; Steenwinckel V, 2007, J IMMUNOL, V178, P3244; Su YC, 2008, J IMMUNOL, V180, P2600; Tabata Y, 2006, J IMMUNOL, V177, P7905; Tachdjian R, 2009, J EXP MED, V206, P2191, DOI 10.1084/jem.20091480; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Tanaka H, 2004, AM J RESP CELL MOL, V31, P62, DOI 10.1165/rcmb.2003-0305OC; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tliba O, 2003, BRIT J PHARMACOL, V140, P1159, DOI 10.1038/sj.bjp.0705558; Tomkinson A, 2001, J IMMUNOL, V166, P5792; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; Toy D, 2006, J IMMUNOL, V177, P36; Trifilieff A, 2001, CLIN EXP ALLERGY, V31, P934, DOI 10.1046/j.1365-2222.2001.01084.x; URBAN JF, 1993, J IMMUNOL, V151, P7086; van Rensen ELJ, 2001, THORAX, V56, P935, DOI 10.1136/thorax.56.12.935; van Scott MR, 2000, AM J PHYSIOL-LUNG C, V278, pL667; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; Vladich FD, 2005, J CLIN INVEST, V115, P747, DOI 10.1172/JCI200522818; Wa TCLK, 1999, CLIN EXP ALLERGY, V29, P1204; Walsh ER, 2008, J EXP MED, V205, P1285, DOI 10.1084/jem.20071836; Wang TN, 2006, CLIN EXP ALLERGY, V36, P1147, DOI 10.1111/j.1365-2222.2006.02551.x; Webb DC, 2000, J IMMUNOL, V165, P108; Webb DC, 2003, EUR J IMMUNOL, V33, P3377, DOI 10.1002/eji.200324178; Webb DC, 2007, J IMMUNOL, V178, P219; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson MS, 2007, J CLIN INVEST, V117, P2941, DOI 10.1172/JCI31546; Wilson RH, 2009, AM J RESP CRIT CARE, V180, P720, DOI 10.1164/rccm.200904-0573OC; Witte JS, 2002, EUR J HUM GENET, V10, P82, DOI 10.1038/sj/ejhg/5200746; Yamagata S, 2008, CLIN EXP IMMUNOL, V154, P295, DOI 10.1111/j.1365-2249.2008.03772.x; Yanagibashi T, 2009, BIOSCI BIOTECH BIOCH, V73, P372, DOI 10.1271/bbb.80612; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Zeyrek D, 2008, ALLERGY ASTHMA PROC, V29, P468, DOI 10.2500/aap.2008.29.3154; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou BH, 2008, J IMMUNOL, V181, P6557; Zhou YF, 2002, CHINESE MED J-PEKING, V115, P1624; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	264	155	163	1	13	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 15	2010	184	4					1663	1674		10.4049/jimmunol.0902185		12	Immunology	Immunology	556IU	WOS:000274585100001	20130218	
J	Frohlich-Nowoisky, J; Pickersgill, DA; Despres, VR; Poschl, U				Froehlich-Nowoisky, Janine; Pickersgill, Daniel A.; Despres, Viviane R.; Poeschl, Ulrich			High diversity of fungi in air particulate matter	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						atmospheric aerosol; bioaerosol; DNA analysis; fungal spores	HIGH-ALPINE AIR; ENVIRONMENTAL-SAMPLES; ATMOSPHERIC PROCESSES; ENDOPHYTIC FUNGI; DNA-POLYMERASES; AIRBORNE FUNGI; AEROSOLS; SPORES; URBAN; PRECIPITATION	Fungal spores can account for large proportions of air particulate matter, and they may potentially influence the hydrological cycle and climate as nuclei for water droplets and ice crystals in clouds, fog, and precipitation. Moreover, some fungi are major pathogens and allergens. The diversity of airborne fungi is, however, not well-known. By DNA analysis we found pronounced differences in the relative abundance and seasonal cycles of various groups of fungi in coarse and fine particulate matter, with more plant pathogens in the coarse fraction and more human pathogens and allergens in the respirable fine particle fraction (<3 mu m). Moreover, the ratio of Basidiomycota to Ascomycota was found to be much higher than previously assumed, which might also apply to the biosphere.	[Froehlich-Nowoisky, Janine; Pickersgill, Daniel A.; Despres, Viviane R.; Poeschl, Ulrich] Max Planck Inst Chem, Biogeochem Dept, D-55128 Mainz, Germany; [Froehlich-Nowoisky, Janine] Johannes Gutenberg Univ Mainz, Inst Geosci, D-55128 Mainz, Germany; [Despres, Viviane R.] Johannes Gutenberg Univ Mainz, Inst Gen Bot, D-55128 Mainz, Germany	Despres, VR (reprint author), Max Planck Inst Chem, Biogeochem Dept, Johann Joachim Becher Weg 27, D-55128 Mainz, Germany.	despres@mpch-mainz.mpg.de; poeschl@mpch-mainz.mpg.de	Poschl, Ulrich/A-6263-2010; Froehlich, Janine/D-6227-2015	Poschl, Ulrich/0000-0003-1412-3557; Froehlich, Janine/0000-0002-1278-0054; Pickersgill, Daniel/0000-0002-3983-506X	Max Planck Society; German Research Foundation [DE1161/2-1]; Landesexzellenzcluster Geocycles [494]	We thank J. Cimbal and I. Germann for technical assistance; M. O. Andreae, W. Elbert, H. Paulsen, and D. Begerow for helpful discussions and support; U. Kampe for providing air quality data; and the Max Planck Institute for Plant Breeding Research for DNA sequencing. This work was supported by the Max Planck Society, German Research Foundation Grant DE1161/2-1, and Landesexzellenzcluster Geocycles Contribution No. 494.	Adhikari A, 2006, ENVIRON POLLUT, V140, P16, DOI 10.1016/j.envpol.2005.07.004; Adhikari A, 2004, SCI TOTAL ENVIRON, V326, P123, DOI 10.1016/j.scitotenv.2003.12.007; Andreae MO, 2008, EARTH-SCI REV, V89, P13, DOI 10.1016/j.earscirev.2008.03.001; Andreae MO, 1997, SCIENCE, V276, P1052, DOI 10.1126/science.276.5315.1052; Arnold A. Elizabeth, 2007, Fungal Biology Reviews, V21, P51, DOI 10.1016/j.fbr.2007.05.003; Bauer H, 2002, ATMOS RES, V64, P109, DOI 10.1016/S0169-8095(02)00084-4; Bauer H, 2008, ATMOS ENVIRON, V42, P588, DOI 10.1016/j.atmosenv.2007.10.013; Boreson J, 2004, ATMOS ENVIRON, V38, P6029, DOI 10.1016/j.atmosenv.2004.06.040; Bridge P, 2001, PLANT SOIL, V232, P147, DOI 10.1023/A:1010346305799; Brown JKM, 2002, SCIENCE, V297, P537, DOI 10.1126/science.1072678; CHAO A, 1984, SCAND J STAT, V11, P265; Christner BC, 2008, SCIENCE, V319, P1214, DOI 10.1126/science.1149757; de Meeus T, 2002, TRENDS PARASITOL, V18, P247, DOI 10.1016/S1471-4922(02)02269-9; Deguillaume L, 2008, BIOGEOSCIENCES, V5, P1073; Despres VR, 2007, BIOGEOSCIENCES, V4, P1127; Eichmann R, 2008, J PLANT PHYSIOL, V165, P5, DOI 10.1016/j.jplph.2007.05.004; Elbert W, 2007, ATMOS CHEM PHYS, V7, P4569; Fierer N, 2008, APPL ENVIRON MICROB, V74, P200, DOI 10.1128/AEM.01467-07; Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002; Green Brett J, 2006, Med Mycol, V44 Suppl 1, pS245, DOI 10.1080/13693780600776308; Griffin Dale W., 2004, Aerobiologia, V20, P135, DOI 10.1023/B:AERO.0000032948.84077.12; Griffin D.W., 2004, ECOHEALTH, V1, P284, DOI DOI 10.1007/S10393-004-0120-8; Guo LD, 2008, J INTEGR PLANT BIOL, V50, P997, DOI 10.1111/j.1744-7909.2008.00394.x; Hata Kunihiko, 2002, Mycoscience, V43, P369, DOI 10.1007/s102670200054; Held A, 2008, ATMOS ENVIRON, V42, P8502, DOI 10.1016/j.atmosenv.2008.06.015; Hibbett DS, 2007, MYCOL RES, V111, P1001, DOI 10.1016/j.mycres.2007.01.012; Hibbett DS, 2007, MYCOL RES, V111, P509, DOI 10.1016/j.mycres.2007.03.004; Hill TCJ, 2003, FEMS MICROBIOL ECOL, V43, P1, DOI 10.1111/j.1574-6941.2003.tb01040.x; Hock N, 2008, ATMOS CHEM PHYS, V8, P603; Hoss M, 1996, NUCLEIC ACIDS RES, V24, P1304, DOI 10.1093/nar/24.7.1304; Hunt J, 2004, MICROBIAL ECOL, V47, P385, DOI 10.1007/s00248-003-2018-3; Jaenicke R, 2005, SCIENCE, V308, P73, DOI 10.1126/science.1106335; James TY, 2006, NATURE, V443, P818, DOI 10.1038/nature05110; KEOHAVONG P, 1989, P NATL ACAD SCI USA, V86, P9253, DOI 10.1073/pnas.86.23.9253; Klironomos JN, 1997, CAN J BOT, V75, P1670; Kurup VP, 2000, MICROBES INFECT, V2, P1101, DOI 10.1016/S1286-4579(00)01264-8; Lee T, 2006, ATMOS ENVIRON, V40, P2902, DOI 10.1016/j.atmosenv.2006.01.011; Levetin E., 1990, Aerobiologia, V6, P177, DOI 10.1007/BF02539111; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ling L L, 1991, PCR Methods Appl, V1, P63; Lugauskas A, 2003, ANN AGR ENV MED, V10, P233; Maria GL, 2002, CURR SCI INDIA, V83, P1573; Marshall WA, 1997, APPL ENVIRON MICROB, V63, P2240; Mohler O, 2007, BIOGEOSCIENCES, V4, P1059; O'Brien HE, 2005, APPL ENVIRON MICROB, V71, P5544, DOI 10.1128/AEM.71.9.5544-5550.2005; PAABO S, 1989, P NATL ACAD SCI USA, V86, P1939, DOI 10.1073/pnas.86.6.1939; Poschl U, 2005, ANGEW CHEM INT EDIT, V44, P7520, DOI 10.1002/anie.200501122; POULEUR S, 1992, APPL ENVIRON MICROB, V58, P2960; Pratt KA, 2009, NAT GEOSCI, V2, P397, DOI 10.1038/NGEO521; Prenni AJ, 2009, NAT GEOSCI, V2, P401, DOI 10.1038/NGEO517; Reddy SR, 2005, CURR SCI INDIA, V89, P1699; Richard F, 2004, CAN J BOT, V82, P1711, DOI 10.1139/B04-128; Rosenfeld D, 2008, SCIENCE, V321, P1309, DOI 10.1126/science.1160606; SCOTT PM, 1971, J ANTIBIOT, V24, P747; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; SOLOMON PA, 1983, AEROSOL SCI TECH, V2, P455, DOI 10.1080/02786828308958649; SWANN E, 2007, BASIDIOMYCOTA CLUB F; TAYLOR JW, 2006, ASCOMYCOTA SAC FUNGI; THORN RG, 1999, HDB SOIL SCI, pC22; von Wintzingerode F, 1997, FEMS MICROBIOL REV, V21, P213; Wang CS, 2007, NAT BIOTECHNOL, V25, P1455, DOI 10.1038/nbt1357; Womiloju TO, 2003, ATMOS ENVIRON, V37, P4335, DOI 10.1016/S1352-2310(03)00577-6	62	155	157	9	67	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	AUG 4	2009	106	31					12814	12819		10.1073/pnas.0811003106		6	Multidisciplinary Sciences	Science & Technology - Other Topics	479NT	WOS:000268667600047	19617562	
J	Nicholson, PJ; Cullinan, P; Taylor, AJN; Burge, PS; Boyle, C				Nicholson, PJ; Cullinan, P; Taylor, AJN; Burge, PS; Boyle, C			Evidence based guidelines for the prevention, identification, and management of occupational asthma	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Review							PEAK EXPIRATORY FLOW; DIISOCYANATE-INDUCED ASTHMA; LABORATORY-ANIMAL ALLERGY; NATURAL-RUBBER LATEX; ISOCYANATE-INDUCED ASTHMA; WORK-RELATED SYMPTOMS; HEALTH-CARE WORKERS; EXPOSURE-RESPONSE RELATIONSHIPS; IMMUNOLOGICAL LUNG-DISEASE; CRAB-PROCESSING WORKERS	Background: Occupational asthma is the most frequently reported work related respiratory disease in many countries. This work was commissioned by the British Occupational Health Research Foundation to assist the Health and Safety Executive in achieving its target of reducing the incidence of occupational asthma in Great Britain by 30% by 2010. Aim: The guidelines aim to improve the prevention, identification, and management of occupational asthma by providing evidence based recommendations on which future practice can be based. Methods: The literature was searched systematically using Medline and Embase for articles published in all languages up to the end of June 2004. Evidence based statements and recommendations were graded according to the Royal College of General Practitioner's star system and the revised Scottish Intercollegiate Guidelines Network grading system. Results: A total of 474 original studies were selected for appraisal from over 2500 abstracts. The systematic review produced 52 graded evidence statements and 22 recommendations based on 223 studies. Discussion: Evidence based guidelines have become benchmarks for practice in healthcare and the process used to prepare them is well established. This evidence review and its recommendations focus on interventions and outcomes to provide a robust approach to the prevention, identification, and management of occupational asthma, based on and using the best available medical evidence. The most important action to prevent cases of occupational asthma is to reduce exposure at source. Thereafter surveillance should be performed for the early identification of symptoms, including occupational rhinitis, with additional functional and immunological tests where appropriate. Effective management of workers suspected to have occupational asthma involves the identification and investigation of symptoms suggestive of asthma immediately they occur. Those workers who are confirmed to have occupational asthma should be advised to avoid further exposure completely and early in the course of their disease to offer the best chance of recovery.	British Occupat Hlth Res Fdn, London NW1 4LB, England; Procter & Gamble Co, Surrey, England; Natl Heart & Lung Inst, London, England; Birmingham Heartlands Hosp, Birmingham B9 5ST, W Midlands, England; Hlth & Safety Execut, Bootle, England	Nicholson, PJ (reprint author), British Occupat Hlth Res Fdn, 6 St Andrews Pl,Regents Pk, London NW1 4LB, England.	nicholson.pj@pg.com					AGRUP G, 1986, BRIT J IND MED, V43, P192; ALLARD C, 1989, CHEST, V96, P1046, DOI 10.1378/chest.96.5.1046; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Ameille J, 2003, OCCUP ENVIRON MED, V60, P136, DOI 10.1136/oem.60.2.136; Ameille J, 1997, EUR RESPIR J, V10, P55, DOI 10.1183/09031936.97.10010055; Anees W, 2002, THORAX, V57, P231, DOI 10.1136/thorax.57.3.231; AXON EJ, 1995, OCCUP MED-OXFORD, V45, P109, DOI 10.1093/occmed/45.2.109; BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; Baldwin DR, 2002, THORAX, V57, P860, DOI 10.1136/thorax.57.10.860; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Barker RD, 1998, J ALLERGY CLIN IMMUN, V101, P717, DOI 10.1016/S0091-6749(98)70401-4; BARSELA S, 1984, J ALLERGY CLIN IMMUN, V73, P271, DOI 10.1016/S0091-6749(84)80019-6; BAUR X, 1995, J ALLERGY CLIN IMMUN, V96, P489, DOI 10.1016/S0091-6749(95)70292-X; Baur X, 1998, J ALLERGY CLIN IMMUN, V102, P984, DOI 10.1016/S0091-6749(98)70337-9; Baur X, 1998, AM J IND MED, V33, P114; Beghe B, 2004, ALLERGY, V59, P61, DOI 10.1046/j.1398-9995.2003.00352.x; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Bernstein DI, 2003, ANN ALLERG ASTHMA IM, V90, P209; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BOTHAM PA, 1987, BRIT J IND MED, V44, P627; Brhel P, 2003, IND HEALTH, V41, P121, DOI 10.2486/indhealth.41.121; Bright P, 2001, Monaldi Arch Chest Dis, V56, P281; Brisman J, 2003, INT ARCH OCC ENV HEA, V76, P167, DOI 10.1007/s00420-002-0396-3; Brisman J, 2000, OCCUP ENVIRON MED, V57, P335, DOI 10.1136/oem.57.5.335; Brooks S M, 1981, Chest, V80, P30; Burge P S, 1982, Eur J Respir Dis Suppl, V123, P91; BURGE PS, 1981, THORAX, V36, P828, DOI 10.1136/thx.36.11.828; BURGE PS, 1979, THORAX, V34, P308, DOI 10.1136/thx.34.3.308; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; BURGE PS, 1982, THORAX, V37, P348, DOI 10.1136/thx.37.5.348; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661; CANNON J, 1995, BRIT MED J, V311, P602; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; Cathcart M, 1997, OCCUP MED-OXFORD, V47, P473, DOI 10.1093/occmed/47.8.473; CHANYEUNG M, 1982, AM J MED, V72, P411, DOI 10.1016/0002-9343(82)90497-1; CHANYEUNG M, 1987, J ALLERGY CLIN IMMUN, V79, P792, DOI 10.1016/0091-6749(87)90212-0; Chatkin JM, 1999, CHEST, V116, P1780, DOI 10.1378/chest.116.6.1780; COCKCROFT A, 1981, LANCET, V1, P827; Cortona G, 2001, G Ital Med Lav Ergon, V23, P64; COTE J, 1993, THORAX, V48, P48, DOI 10.1136/thx.48.1.48; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; COUTTS II, 1984, BRIT MED J, V288, P1418; Cullen MR, 1996, OCCUP MED-OXFORD, V46, P197; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Cullinan P, 2001, ANN OCCUP HYG, V45, P97, DOI 10.1016/S0003-4878(00)00028-4; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P579; de Bono J, 1999, OCCUP MED-OXFORD, V49, P217, DOI 10.1093/occmed/49.4.217; De Zotti R, 1997, Med Lav, V88, P155; De Zotti R, 2000, OCCUP ENVIRON MED, V57, P58, DOI 10.1136/oem.57.1.58; DEZOTTI R, 1994, OCCUP ENVIRON MED, V51, P548; Di Stefano F, 1999, ALLERGY, V54, P1105, DOI 10.1034/j.1398-9995.1999.00239.x; DOCKER A, 1987, BRIT J IND MED, V44, P534; DOUGLAS JDM, 1995, LANCET, V346, P737, DOI 10.1016/S0140-6736(95)91505-2; Drexler H, 1999, OCCUP ENVIRON MED, V56, P202; Droste J, 2003, J OCCUP ENVIRON MED, V45, P648, DOI 10.1097/01.jom.0000071501.96740.f7; El-Zein M, 2003, EUR RESPIR J, V22, P513, DOI 10.1183/09031936.03.00000903; Fisher R, 1998, J OCCUP ENVIRON MED, V40, P609, DOI 10.1097/00043764-199807000-00005; FLOOD DFS, 1985, BRIT J IND MED, V42, P43; GANNON PFG, 1993, BRIT J IND MED, V50, P791; Gannon PFG, 1996, THORAX, V51, P484, DOI 10.1136/thx.51.5.484; GANNON PFG, 1993, BRIT J IND MED, V50, P491; Gautrin D, 2001, EUR RESPIR J, V17, P904, DOI 10.1183/09031936.01.17509040; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899; Glasziou P, 2004, BRIT MED J, V328, P39, DOI 10.1136/bmj.328.7430.39; Gordon SB, 1997, OCCUP MED-OXFORD, V47, P361, DOI 10.1093/occmed/47.6.361; Grammer L, 1998, CHEST, V114, P1199, DOI 10.1378/chest.114.4.1199; GRAMMER LC, 1993, AM REV RESPIR DIS, V148, P54; Grammer LC, 1996, J LAB CLIN MED, V127, P443, DOI 10.1016/S0022-2143(96)90061-X; Grammer LC, 2002, J OCCUP ENVIRON MED, V44, P1179, DOI 10.1097/01.jom.0000044121.59147.44; Grammer LC, 2002, CHEST, V121, P1317, DOI 10.1378/chest.121.4.1317; Grammer LC, 2000, ALLERGY ASTHMA PROC, V21, P355, DOI 10.2500/108854100778249178; GRAMMER LC, 1994, J OCCUP ENVIRON MED, V36, P642; GREENBERG M, 1970, BMJ-BRIT MED J, V2, P629; HAGMAR L, 1984, AM J IND MED, V6, P347, DOI 10.1002/ajim.4700060505; HARGREAVE FE, 1984, AM REV RESPIR DIS, V130, P513; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Heederik D, 2001, ANN OCCUP HYG, V45, P175, DOI 10.1016/S0003-4878(00)00044-2; HENNEBERGER PK, 1991, CHEST, V100, P1515, DOI 10.1378/chest.100.6.1515; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; Hollander A, 1998, EUR RESPIR J, V11, P929, DOI 10.1183/09031936.98.11040929; Horne C., 2000, European Respiratory Journal, V15, P911, DOI 10.1034/j.1399-3003.2000.15e17.x; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499; Houba R, 1996, AM J RESP CRIT CARE, V154, P130; HOWE W, 1983, J ALLERGY CLIN IMMUN, V7, P5; HUDSON P, 1985, J ALLERGY CLIN IMMUN, V76, P682, DOI 10.1016/0091-6749(85)90671-2; Jaakkola JJK, 2003, AM J EPIDEMIOL, V158, P981, DOI 10.1093/aje/kwg238; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Johnsen CR, 1997, OCCUP ENVIRON MED, V54, P671; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; JUNIPER CP, 1984, J SOC OCCUP MED, V34, P126; Karjalainen A, 2003, CHEST, V123, P283, DOI 10.1378/chest.123.1.283; Karjalainen A, 2002, SCAND J WORK ENV HEA, V28, P49; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; Kim YK, 1999, ANN ALLERG ASTHMA IM, V82, P223, DOI 10.1016/S1081-1206(10)62601-4; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kor A. C., 2001, SMJ Singapore Medical Journal, V42, P373; Koskela H, 2003, CHEST, V124, P383, DOI 10.1378/chest.124.1.383; Krakowiak A, 1997, Int J Occup Med Environ Health, V10, P31; Krakowiak A, 2002, INT ARCH OCC ENV HEA, V75, pS113, DOI 10.1007/s00420-002-0346-0; Kraw M, 1999, AM J IND MED, V35, P87, DOI 10.1002/(SICI)1097-0274(199901)35:1<87::AID-AJIM12>3.0.CO;2-X; Kruize H, 1997, OCCUP ENVIRON MED, V54, P830; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202; Lemiere C, 2000, AM J RESP CRIT CARE, V162, P976; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329; Leroyer C, 1998, AM J RESP CRIT CARE, V158, P827; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; LIN FJ, 1995, OCCUP ENVIRON MED, V52, P54; LISS GM, 1993, J ALLERGY CLIN IMMUN, V92, P237, DOI 10.1016/0091-6749(93)90167-E; LISS GM, 1991, CHEST, V100, P63, DOI 10.1378/chest.100.1.63; LOZEWICZ S, 1987, BRIT J DIS CHEST, V81, P14, DOI 10.1016/0007-0971(87)90103-3; Maghni K, 2004, AM J RESP CRIT CARE, V169, P367, DOI 10.1164/rccm.200309-1238OC; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1995, J ALLERGY CLIN IMMUN, V96, P601, DOI 10.1016/S0091-6749(95)70258-X; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; Malo JL, 1996, J ALLERGY CLIN IMMUN, V98, P1132, DOI 10.1016/S0091-6749(96)80207-7; MALO JL, 1993, THORAX, V48, P1211, DOI 10.1136/thx.48.12.1211; MALO JL, 1993, REV MAL RESPIR, V10, P313; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; Marabini A, 1994, Med Lav, V85, P134; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; MCSHARRY C, 1994, CLIN EXP IMMUNOL, V97, P499; Meijer E, 2002, OCCUP ENVIRON MED, V59, P189, DOI 10.1136/oem.59.3.189; Meredith SK, 2000, OCCUP ENVIRON MED, V57, P830, DOI 10.1136/oem.57.12.830; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; MERGET R, 1994, AM J RESP CRIT CARE, V150, P1146; MERGET R, 1988, CLIN ALLERGY, V18, P569, DOI 10.1111/j.1365-2222.1988.tb02908.x; MERGET R, 1991, BRIT J IND MED, V48, P830; Merget R, 2000, J ALLERGY CLIN IMMUN, V105, P364, DOI 10.1016/S0091-6749(00)90089-7; Merget R, 1996, EUR RESPIR J, V9, P211, DOI 10.1183/09031936.96.09020211; Meyer JD, 1999, OCCUP MED-OXFORD, V49, P485, DOI 10.1093/occmed/49.8.485; Meyer JD, 2001, OCCUP MED-OXFORD, V51, P204, DOI 10.1093/occmed/51.3.204; Michie S, 2004, BRIT MED J, V328, P343, DOI 10.1136/bmj.328.7435.343; Milton DK, 1998, AM J IND MED, V33, P1, DOI 10.1002/(SICI)1097-0274(199801)33:1<1::AID-AJIM1>3.0.CO;2-2; MOLLER DR, 1986, CHEST, V90, P494, DOI 10.1378/chest.90.4.494; MOSCATO G, 1991, J OCCUP ENVIRON MED, V33, P720, DOI 10.1097/00043764-199106000-00014; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; Muller-Wening D, 1998, EUR RESPIR J, V12, P569, DOI 10.1183/09031936.98.12030569; MUNOZ X, 2003, CHEST, V123, P124; MUSK AW, 1989, BRIT J IND MED, V46, P636; NEWHOUSE ML, 1970, LANCET, V1, P689; NEWILL CA, 1986, J OCCUP ENVIRON MED, V28, P1158; Nielsen J, 2001, SCAND J WORK ENV HEA, V27, P327; Nieuwenhuijsen MJ, 1999, OCCUP ENVIRON MED, V56, P197; Niezborala M, 1996, OCCUP ENVIRON MED, V53, P252; Obase Y, 2000, OCCUP ENVIRON MED, V57, P62, DOI 10.1136/oem.57.1.62; ODONNELL TV, 1989, AM J IND MED, V15, P43, DOI 10.1002/ajim.4700150106; Ortega HG, 2001, AM J IND MED, V39, P598, DOI 10.1002/ajim.1059; OSTERMAN K, 1982, ALLERGY, V37, P313, DOI 10.1111/j.1398-9995.1982.tb01917.x; Padoan M, 2003, EUR RESPIR J, V21, P637, DOI 10.1183/09031936.03.00060703; PAGGIARO PL, 1984, CLIN ALLERGY, V14, P463, DOI 10.1111/j.1365-2222.1984.tb02230.x; PAGGIARO PL, 1993, CHEST, V103, P1123, DOI 10.1378/chest.103.4.1123; PARK H S, 1989, Yonsei Medical Journal, V30, P298; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Park JW, 2001, OCCUP ENVIRON MED, V58, P411, DOI 10.1136/oem.58.6.411; PERRIN B, 1992, EUR RESPIR J, V5, P40; PETSONK EL, 2000, CHEST, V118, P183; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; PISATI G, 1993, BRIT J IND MED, V50, P60; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PRICHARD MG, 1984, BRIT J IND MED, V41, P450; Provencher S, 1997, OCCUP ENVIRON MED, V54, P272; QUIRCE S, 1995, AM J RESP CRIT CARE, V152, P1100; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; Reijula K, 1996, CHEST, V110, P58, DOI 10.1378/chest.110.1.58; RENSTROM A, 1994, ALLERGY, V49, P548, DOI 10.1111/j.1398-9995.1994.tb01127.x; REVSBECH P, 1989, BRIT J IND MED, V46, P566; Ricciardi L, 2003, ANN ALLERG ASTHMA IM, V91, P393; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.3.CO;2-T; ROMANO C, 1995, CLIN EXP ALLERGY, V25, P643, DOI 10.1111/j.1365-2222.1995.tb01112.x; ROSENBERG N, 1987, CLIN ALLERGY, V17, P55, DOI 10.1111/j.1365-2222.1987.tb02319.x; Ross DJ, 1998, OCCUP MED-OXFORD, V48, P219, DOI 10.1093/occmed/48.4.219; SALLIE BA, 1994, OCCUP MED-OXFORD, V44, P177, DOI 10.1093/occmed/44.4.177; Schlunssen V, 2004, OCCUP ENVIRON MED, V61, P504, DOI 10.1136/oem.2003.007815; Sjostedt L, 1996, AM J IND MED, V30, P415; SJOSTEDT L, 1989, AM J IND MED, V16, P199, DOI 10.1002/ajim.4700160211; SJOSTEDT L, 1993, AM J IND MED, V24, P459, DOI 10.1002/ajim.4700240410; SLOVAK AJM, 1981, THORAX, V36, P906, DOI 10.1136/thx.36.12.906; SLOVAK AJM, 1985, AM IND HYG ASSOC J, V46, P411, DOI 10.1202/0002-8894(1985)046<0411:EOTHRI>2.3.CO;2; STENTON SC, 1993, OCCUP MED-OXFORD, V43, P203, DOI 10.1093/occmed/43.4.203; Taivainen AI, 1998, SCAND J WORK ENV HEA, V24, P503; Talini D, 2002, RESP MED, V96, P236, DOI 10.1053/rmed.2001.1259; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; TARLO SM, 1991, CHEST, V100, P329, DOI 10.1378/chest.100.2.329; Tarlo SM, 2002, OCCUP ENVIRON MED, V59, P58, DOI 10.1136/oem.59.1.58; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628; TARLO SM, 1995, CHEST, V107, P634, DOI 10.1378/chest.107.3.634; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756; Taylor AJN, 1999, AM J RESP CRIT CARE, V160, P435; Newman Taylor AJ, 2004, GUIDELINES PREVENTIO; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; Toren K, 1999, SCAND J WORK ENV HEA, V25, P430; Ucgun I, 1998, ALLERGY, V53, P1096, DOI 10.1111/j.1398-9995.1998.tb03822.x; Valentino M, 2002, G Ital Med Lav Ergon, V24, P26; VALENTINO M, 1994, OCCUP MED-OXFORD, V44, P161, DOI 10.1093/occmed/44.3.161; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; Vandenplas O, 2002, J ALLERGY CLIN IMMUN, V109, P125, DOI 10.1067/mai.2002.120760; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; Vanhanen M, 1997, SCAND J WORK ENV HEA, V23, P385; VEDAL S, 1986, J ALLERGY CLIN IMMUN, V78, P1103, DOI 10.1016/0091-6749(86)90257-5; VENABLES KM, 1987, J ALLERGY CLIN IMMUN, V80, P212, DOI 10.1016/0091-6749(87)90131-X; VENABLES KM, 1988, BRIT J IND MED, V45, P660; VENABLES KM, 1985, BRIT J IND MED, V42, P517; VENABLES KM, 1985, BRIT MED J, V290, P201; VENABLES KM, 1989, BRIT MED J, V299, P939; VENABLES KM, 1989, RESP MED, V83, P437, DOI 10.1016/S0954-6111(89)80078-2; VENABLES KM, 1988, BRIT J IND MED, V45, P667; Waddell G, 2000, OCCUPATIONAL HLTH GU; WEILL H, 1971, J AMER MED ASSOC, V217, P425, DOI 10.1001/jama.217.4.425; WERNFORS M, 1986, INT ARCH ALLER A IMM, V79, P77; Winck JC, 2004, INT ARCH OCC ENV HEA, V77, P296, DOI 10.1007/s00420-003-0494-x; WITMEUR O, 1973, ACTA ALLERGOL, V28, P250, DOI 10.1111/j.1398-9995.1973.tb01445.x; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219; Zentner A, 1997, ALLERGY, V52, P928, DOI 10.1111/j.1398-9995.1997.tb01253.x; Zock JP, 1998, J OCCUP ENVIRON MED, V40, P969, DOI 10.1097/00043764-199811000-00006	230	155	156	2	9	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	MAY	2005	62	5					290	299		10.1136/oem.2004.016287		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	917KV	WOS:000228461300007	15837849	
J	Kull, I; Almqvist, C; Lilja, G; Pershagen, G; Wickman, M				Kull, I; Almqvist, C; Lilja, G; Pershagen, G; Wickman, M			Breast-feeding reduces the risk of asthma during the first 4 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; asthma; sensitization; breast-fieeding; children; primary prevention; prospective studies; BAMSE	BIRTH COHORT; ATOPIC DISEASE; NONALLERGIC MOTHERS; FOLLOW-UP; CHILDREN; CHILDHOOD; PREVALENCE; MILK; ASSOCIATION; CONTROVERSY	Background: The evidence for a preventive effect of breast-feeding on asthma and other allergic diseases in childhood is inconclusive. Objective: The aim of this study was to investigate the effect of breast-feeding on asthma and sensitization to airborne allergens among children up to 4 years of age. Methods: A birth cohort of 4089 children was followed. Exposure data were collected at 2 months and 1 year of age. The total dose of breast milk was estimated by combining periods of exclusive and partial breast-feeding. Outcomes data were collected at 1, 2, and 4 years of age. The response rate at 4 years was 90%, and 73% participated in a clinical investigation, including blood sampling for analysis of specific IgE and lung function testing. Children with onset of wheeze during lactation (n = 217) were excluded in some of the analyses to avoid disease-related modification of exposure. Results: Exclusive breast-feeding for 4 months or more reduced the risk of asthma at the age of 4 years (odds ratio [OR], 0.72; 95% CI, 0.53-0.97), irrespective of sensitization to common airborne allergens (P = .72). Excluding children with wheeze during lactation tended to strengthen the risk estimate (OR, 0.64; 95% CI, 0.46-0.88). A duration of 3 months or more of partial breast-feeding seemed to offer additional protection; exclusive breast-feeding for 3 to 4 months combined with partial breast-feeding for 3 months or more resulted in an OR of 0.44 (95% CI, 0.21-0.87). The effects tended to be stronger in children without heredity for allergy (P interaction = .36). Conclusion: Breast-feeding reduces the risk of asthma during the first 4 years of life.	Stockholm Cty Council, Dept Environm & Occupat Hlth, S-10726 Stockholm, Sweden; Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Women & Child Hlth, Stockholm, Sweden; Sachs Childrens Hosp, Inst Sodersjukhuset, Karolinska Inst, Stockholm, Sweden; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Kull, I (reprint author), Karolinska Hosp, Dept Environm & Occupat Hlth, SE-17176 Stockholm, Sweden.	inger.kull@smd.sll.se		Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771			ALMQVIST C, 2003, J ALLERGY CLIN IMMUN, V11, P800; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; Bottcher MF, 2000, PEDIATR RES, V47, P157; Chulada PC, 2003, J ALLERGY CLIN IMMUN, V111, P328, DOI 10.1067/mai.2003.127; FIDLER N, 2000, EUR J NUTR, V39, P321; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Hanson LA, 2003, ANN ALLERG ASTHMA IM, V90, P59; Hoppu U, 2001, ALLERGY, V56, P23, DOI 10.1034/j.1398-9995.2001.00908.x; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miyake Y, 2003, CLIN EXP ALLERGY, V33, P312, DOI 10.1046/j.1365-2222.2003.t01-1-01607.x; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oddy WH, 1999, BRIT MED J, V319, P815; Peat JK, 2003, PEDIATR PULM, V35, P331, DOI 10.1002/ppul.10276; Quanjer PH, 1997, EUR RESPIR J, V10, pS2; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Rust GS, 2001, J NATL MED ASSOC, V93, P139; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Siltanen M, 2003, ALLERGY, V58, P524, DOI 10.1034/j.1398-9995.2003.00150.x; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wijga A, 2003, PEDIATR ALLERGY IMMU, V14, P156, DOI 10.1034/j.1399-3038.2003.00022.x; Wilson AC, 1998, BRIT MED J, V316, P21; Wright AL, 2001, ADV EXP MED BIOL, V501, P249; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192	31	155	158	1	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2004	114	4					755	760		10.1016/j.jaci.2004.07.036		6	Allergy; Immunology	Allergy; Immunology	861SO	WOS:000224439100006	15480312	
J	Dakin, CJ; Numa, AH; Wang, H; Morton, JR; Vertzyas, CC; Henry, RL				Dakin, CJ; Numa, AH; Wang, H; Morton, JR; Vertzyas, CC; Henry, RL			Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						cystic fibrosis; infants; respiratory function tests	1ST 5 YEARS; BRONCHOALVEOLAR LAVAGE; PSEUDOMONAS-AERUGINOSA; RESPIRATORY MECHANICS; AIRWAY INFLAMMATION; VENTILATED INFANTS; LUNG INFLAMMATION; RESIDUAL CAPACITY; WASHOUT; RESPONSIVENESS	Our aim was to study the effect of lower airway infection on clinical parameters, pulmonary function tests, and inflammation in clinically stable infants and young children with cystic fibrosis (CF). To accomplish this goal, a prospective cohort of screened CF patients under 4 years of age were studied, using elective anesthesia and intubation for: passive respiratory mechanics (single breath occlusion passive deflation) and lung volumes (nitrogen washout), under neuromuscular blockade; and bronchoalveolar lavage (BAL) of 3 main bronchi for cytology, cytokine interleukin (IL)-8, and quantitative microbiology. There were 22 children studied, with a mean age of 23.2 months (6.7-44 months). A greater relative risk of lower airway pathogens was associated with prior respiratory admission (3.60, 95% confidence interval [CI] 2.87-4.51), history of asthma (1.75, 95% Cl 1.52-2.03), and chronic symptoms (1.50, 95% Cl 1.23-1.83), especially wheeze (1.88, 95% Cl 1.61-2.19). Lower respiratory pathogens (greater than or equal to 10 cfu/ml BAL) were found in 14 out of 22, and greater than 10(5) cfu/ml in 8 out of 22 subjects. The level of pathogens in BAL (log(10) cfu/ml) explained 78% of the variability in percent neutrophils and 34% of the variability in IL-8 levels. Pathogen level also correlated with pulmonary function tests of specific respiratory system compliance (r -0.49, p = 0.02) and functional residual capacity over total lung capacity (r 0.49, p = 0.03). We conclude that the presence of pathogens in the lower airways correlated with levels of inflammation, respiratory system compliance, and degree of air trapping.	Sydney Childrens Hosp, Dept Resp Med, Sydney, NSW, Australia; Sydney Childrens Hosp, Intens Care Unit, Sydney, NSW, Australia; Univ New S Wales, Sch Pediat, Sydney, NSW, Australia; S Eastern Area Lab Serv, Dept Microbiol, Sydney, NSW, Australia	Dakin, CJ (reprint author), Starship Childrens Hosp, Level 6,Pk Rd,Private Bag 92024, Auckland 1, New Zealand.		Wang, He/C-6141-2011; Dakin, Carolyn/D-2857-2012				ALLEN JL, 1993, AM REV RESPIR DIS, V147, P474; ANDERSON JR, 1980, MUIRS TXB PATHOLOGY, P174; Armstrong D, 1998, PEDIATR PULM, V26, P371, DOI 10.1002/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.0.CO;2-N; Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197; Armstrong DS, 1996, PEDIATR PULM, V21, P267, DOI 10.1002/(SICI)1099-0496(199605)21:5<267::AID-PPUL1>3.0.CO;2-K; BALOUGH K, 1995, PEDIATR PULM, V20, P63, DOI 10.1002/ppul.1950200203; BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650; BEARDSMORE CS, 1994, ARCH DIS CHILD, V71, P133; BEARDSMORE CS, 1988, THORAX, V43, P545, DOI 10.1136/thx.43.7.545; BERGER M, 1991, CLIN REV ALLERG, V9, P119; BIRRER P, 1994, AM J RESP CRIT CARE, V150, P207; Boat T., 1989, CYSTIC FIBROSIS, P2649; Braggion C, 1998, PEDIATR PULM, V25, P213, DOI 10.1002/(SICI)1099-0496(199803)25:3<213::AID-PPUL12>3.0.CO;2-9; CANTIN A, 1995, AM J RESP CRIT CARE, V151, P939; Clayton RG, 1998, J PEDIATR-US, V132, P405, DOI 10.1016/S0022-3476(98)70010-1; FITZSIMMONS SC, 1993, J PEDIATR-US, V122, P1, DOI 10.1016/S0022-3476(05)83478-X; Fletcher ME, 1996, INFANT RESP FUNCTION, P283; FRIEDERIKSEN B, 1997, PEDIAT PULMONOL, V23, P330; GERHARDT T, 1987, PEDIATR PULM, V3, P309, DOI 10.1002/ppul.1950030506; GODFREY S, 1978, ARCH DIS CHILD, V53, P83; Hammer J, 1998, AM J RESP CRIT CARE, V158, P526; HAMMER J, 1995, J PEDIATR-US, V127, P485, DOI 10.1016/S0022-3476(95)70088-9; Haslam PL, 1999, EUR RESPIR J, V14, P245, DOI 10.1034/j.1399-3003.1999.14b01.x; HIATT P, 1988, AM REV RESPIR DIS, V137, P119; HOIBY N, 1990, THORAX, V45, P881, DOI 10.1136/thx.45.11.881; Hoiby N, 1987, Antibiot Chemother (1971), V39, P60; JARRIEL WS, 1993, PEDIATR PULM, V15, P175, DOI 10.1002/ppul.1950150309; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; Kirchner KK, 1996, AM J RESP CRIT CARE, V154, P1426; LESOUEF PN, 1984, AM REV RESPIR DIS, V129, P552; LeSouef PN, 1996, INFANT RESP FUNCTION, P379; LITTLEWOOD JM, 1985, LANCET, V1, P865; LUCIDI V, 1996, PEDIAT PULMONOL, V22, pS299; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533; Meyer KC, 1997, AM J RESP CRIT CARE, V156, P1536; MOHON RT, 1993, PEDIAT PULMONOL, V22, P550; Muhlebach MS, 1999, AM J RESP CRIT CARE, V160, P186; NAKAYAMA DK, 1991, J PEDIATR-US, V118, P793, DOI 10.1016/S0022-3476(05)80048-4; Newth CJL, 1997, EUR RESPIR J, V10, P2174, DOI 10.1183/09031936.97.10092174; Noah TL, 1997, J INFECT DIS, V175, P638; Numa AH, 2001, AM J RESP CRIT CARE, V164, P86; RABBETTE PS, 1991, J APPL PHYSIOL, V71, P474; RAMSEY BW, 1991, AM REV RESPIR DIS, V144, P331; Roske K, 1998, J CLIN MONITOR COMP, V14, P413, DOI 10.1023/A:1009993916980; Shields MD, 2000, AM J RESP CRIT CARE, V162, pS15; SIVAN Y, 1990, PEDIATR RES, V28, P451, DOI 10.1203/00006450-199011000-00006; SIVAN Y, 1990, PEDIATR RES, V28, P446, DOI 10.1203/00006450-199011000-00005; SLY PD, 1988, PEDIATR PULM, V4, P39, DOI 10.1002/ppul.1950040109; TOMASHEFSKI HF, 1993, PATHOLOGY CYSTIC FIB, P435; VALERIUS NH, 1991, LANCET, V338, P725, DOI 10.1016/0140-6736(91)91446-2; WALTERS EH, 1991, THORAX, V46, P613, DOI 10.1136/thx.46.9.613; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365	52	155	159	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2002	165	7					904	910		10.1164/rccm.2010139		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	536ZA	WOS:000174730700006	11934712	
J	McKeever, TM; Lewis, SA; Smith, C; Collins, J; Heatlie, H; Frischer, M; Hubbard, R				McKeever, TM; Lewis, SA; Smith, C; Collins, J; Heatlie, H; Frischer, M; Hubbard, R			Early exposure to infections and antibiotics and the incidence of allergic disease: A birth cohort study with the West Midlands General Practice Research Database	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; eczema; hay fever; infections; siblings; antibiotics; cohort	RESPIRATORY SYNCYTIAL VIRUS; HAY-FEVER; ATOPIC DISORDER; GUINEA-BISSAU; FAMILY-SIZE; ASTHMA; CHILDREN; MEASLES; RISK; PREVALENCE	Background: It has been suggested that the rise in prevalence of allergic disease in westernized countries is due in part to a decrease in exposure to infections and an increase in the use of antibiotics early in life. Objective: The purpose of this investigation was to quantify the relationships between (1) exposure to personal infections, infections in siblings, and use of antibiotics in early life and (2) the incidence of allergic disease. Methods: Using the West Midlands section of the UK General Practice Research Database, we established a historical birth cohort of children (N = 29,238). For each child, we identified all personal infections and infections in siblings and determined the use of antibiotics in early life; we also noted incident diagnoses of asthma, eczema, and hay fever. The data were analyzed through use of Cox regression. Results: There was no clear protective effect of exposure to either personal infections or infections in siblings with respect to the incidence of allergic disease. Antibiotic exposure was associated with an increased risk of developing allergic disease in a dose-related manner: having 4 or more courses of antibiotics in the first year of life was associated with an increased incidence of asthma (hazard ratio [HR), 3.13; 95% CI, 2.75-3.57), eczema (HR, 1.48; 95% CI, 1.31-1.68), and hay fever (HR, 2.12; 95% CI, 1.68-2.66). However, adjusting for consulting behavior reduced these effects (adjusted HR [95% CI]: asthma, 1.99 [1.72-2.31]; eczema, 1.01 [0.88-1.17]; hay fever, 1.14 [0.88-1.47]). Conclusions: We found no evidence that exposure to infections reduced the incidence of allergic disease, and infections did not explain the previous findings of a strong birth order effect in this cohort. The use of antibiotics might be associated with early diagnoses of allergic disease.	Univ Nottingham, Div Resp Med, Nottingham NG7 2RD, England; Univ Keele, Dept Med Management, Keele ST5 5BG, Staffs, England	McKeever, TM (reprint author), City Hosp, Div Resp Med, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.		Research Datalink, Clinical Practice/H-2477-2013	McKeever, Tricia/0000-0003-0914-0416			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bodner C, 1998, THORAX, V53, P28; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Farooqi IS, 1998, THORAX, V53, P927; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Lewis SA, 1998, CLIN EXP ALLERGY, V28, P1493; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1997, BRIT MED J, V314, P999; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; *OFF NAT STAT, 1996, GEN PRACT RES DAT IN; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shaheen SO, 1996, BRIT MED J, V313, P969; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Sudo N, 1997, J IMMUNOL, V159, P1739; von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Walley T, 1997, LANCET, V350, P1097, DOI 10.1016/S0140-6736(97)04248-7; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009	25	155	163	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					43	50		10.1067/mai.2002.121016		8	Allergy; Immunology	Allergy; Immunology	519RM	WOS:000173739300007	11799364	
J	Jakobsson, HE; Abrahamsson, TR; Jenmalm, MC; Harris, K; Quince, C; Jernberg, C; Bjorksten, B; Engstrand, L; Andersson, AF				Jakobsson, Hedvig E.; Abrahamsson, Thomas R.; Jenmalm, Maria C.; Harris, Keith; Quince, Christopher; Jernberg, Cecilia; Bjoerksten, Bengt; Engstrand, Lars; Andersson, Anders F.			Decreased gut microbiota diversity, delayed Bacteroidetes colonisation and reduced Th1 responses in infants delivered by Caesarean section	GUT			English	Article							INTESTINAL MICROBIOTA; IMMUNE-RESPONSES; FECAL SAMPLES; T-CELLS; BACTERIA; ALLERGY; ASTHMA; CHILDREN; ECZEMA; MODE	important stimuli for immune development, and a reduced microbial exposure as well as caesarean section (CS) has been associated with the development of allergic disease. Here we address how microbiota development in infants is affected by mode of delivery, and relate differences in colonisation patterns to the maturation of a balanced Th1/Th2 immune response. Design The postnatal intestinal colonisation pattern was investigated in 24 infants, born vaginally (15) or by CS (nine). The intestinal microbiota were characterised using pyrosequencing of 16S rRNA genes at 1 week and 1, 3, 6, 12 and 24 months after birth. Venous blood levels of Th1- and Th2-associated chemokines were measured at 6, 12 and 24 months. Results Infants born through CS had lower total microbiota diversity during the first 2 years of life. CS delivered infants also had a lower abundance and diversity of the Bacteroidetes phylum and were less often colonised with the Bacteroidetes phylum. Infants born through CS had significantly lower levels of the Th1-associated chemokines CXCL10 and CXCL11 in blood. Conclusions CS was associated with a lower total microbial diversity, delayed colonisation of the Bacteroidetes phylum and reduced Th1 responses during the first 2 years of life.	[Jakobsson, Hedvig E.; Jernberg, Cecilia] Swedish Inst Communicable Dis Control, Dept Preparedness, Solna, Sweden; [Jakobsson, Hedvig E.; Engstrand, Lars] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, Stockholm, Sweden; [Abrahamsson, Thomas R.] Linkoping Univ, Div Pediat, Dept Clin & Expt Med, Linkoping, Sweden; [Jenmalm, Maria C.] Linkoping Univ, Div Inflammat Med, Dept Clin & Expt Med, Linkoping, Sweden; [Harris, Keith; Quince, Christopher] Univ Glasgow, Sch Engn, Glasgow, Lanark, Scotland; [Bjoerksten, Bengt] Karolinska Inst, Inst Environm Med, Stockholm, Sweden; [Bjoerksten, Bengt] Univ Orebro, Sch Hlth & Med Sci, SE-70182 Orebro, Sweden; [Andersson, Anders F.] KTH Royal Inst Technol, Sci Life Lab, Sch Biotechnol, Div Gene Technol, SE-17121 Solna, Sweden	Andersson, AF (reprint author), KTH Royal Inst Technol, Sci Life Lab, Sch Biotechnol, Div Gene Technol, POB 1031, SE-17121 Solna, Sweden.	lars.engstrand@ki.se; andersson@scilifelab.se	Jenmalm, Maria/C-9679-2009	Jenmalm, Maria/0000-0002-2117-5366; Andersson, Anders/0000-0002-3627-6899	Ekhaga Foundation and the Soderbergs Foundation; Swedish Research Council [K2011-56X-21854-01-06]; Research Council for the South-East Sweden; Swedish Asthma and Allergy Association; Olle Engkvist Foundation; Vardal Foundation-for Health Care Sciences and Allergy Research; Swedish Research Councils VR [621-2011-5689]; FORMAS [215-2009-1174]; Unilever	This work was supported by the Ekhaga Foundation and the Soderbergs Foundation to LE and by the Swedish Research Council (K2011-56X-21854-01-06), the Research Council for the South-East Sweden, the Swedish Asthma and Allergy Association, the Olle Engkvist Foundation, the Vardal Foundation-for Health Care Sciences and Allergy Research to MJ and by the Swedish Research Councils VR (621-2011-5689) and FORMAS (215-2009-1174) to AA. KH was funded through a direct grant from Unilever.	Abrahamsson TR, 2011, CLIN EXP ALLERGY, V41, P1729, DOI 10.1111/j.1365-2222.2011.03827.x; Abrahamsson TR, 2007, J ALLERGY CLIN IMMUN, V119, P1174, DOI 10.1016/j.jaci.2007.01.007; ABRAHAMSSON TR, J ALLERGY CLIN IMMUN; Adlerberth I, 2006, PEDIATR RES, V59, P96, DOI 10.1203/01.pdr.0000191137.12774.b2; ADLERBERTH I, J ALLERGY CLIN IMMUN; Andersson AF, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002836; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bahl MI, 2012, FEMS MICROBIOL LETT, V329, P193, DOI 10.1111/j.1574-6968.2012.02523.x; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; BJORKSTEN B, 1999, CLIN EXP ALLERGY, V29, P1; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1690, DOI 10.1046/j.1365-2222.2002.01463.x; CHAO A, 1984, SCAND J STAT, V11, P265; de Jager W, 2005, J IMMUNOL METHODS, V300, P124, DOI 10.1016/j.jim.2005.03.009; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Eggesbo M, 2003, J ALLERGY CLIN IMMUN, V112, P420, DOI 10.1067/mai.2003.1610; Eggesbo M, 2011, APMIS, V119, P17, DOI 10.1111/j.1600-0463.2010.02688.x; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Hamady M, 2010, ISME J, V4, P17, DOI 10.1038/ismej.2009.97; Hayek L.-A. C., 1996, SURVEYING NATURAL PO; Herlemann DPR, 2011, ISME J, V5, P1571, DOI 10.1038/ismej.2011.41; Huurre A, 2008, NEONATOLOGY, V93, P236, DOI 10.1159/000111102; Jenmalm MC, 2011, AM J REPROD IMMUNOL, V66, P75, DOI 10.1111/j.1600-0897.2011.01036.x; Kelly D, 2004, NAT IMMUNOL, V5, P104, DOI 10.1038/ni1018; Klindworth A, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks808; Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107; Ley RE, 2006, CELL, V124, P837, DOI 10.1016/j.cell.2006.02.017; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Maidak BL, 2000, NUCLEIC ACIDS RES, V28, P173, DOI 10.1093/nar/28.1.173; Martin R, 2003, J PEDIATR-US, V143, P754, DOI 10.1016/j.jpeds.2003.09.028; Maukonen J, 2012, FEMS MICROBIOL ECOL, V79, P697, DOI 10.1111/j.1574-6941.2011.01257.x; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; PIELOU EC, 1966, J THEOR BIOL, V13, P131, DOI 10.1016/0022-5193(66)90013-0; Prescott Susan L, 2003, Curr Opin Allergy Clin Immunol, V3, P125, DOI 10.1097/00130832-200304000-00006; Quince C, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-38; ROTIMI VO, 1981, J MED MICROBIOL, V14, P51; Salam MT, 2006, ANN EPIDEMIOL, V16, P341, DOI 10.1016/j.annepidem.2005.06.054; Singh N, 2005, INFECT CONT HOSP EP, V26, P646, DOI 10.1086/502595; Sufang G, 2007, B WORLD HEALTH ORGAN, V85, P755, DOI 10.2471/BLT.06.035808; TANNOCK GW, 1990, J CLIN MICROBIOL, V28, P1225; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Turroni F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036957; Vaishampayan PA, 2010, GENOME BIOL EVOL, V2, P53, DOI 10.1093/gbe/evp057; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Wang M, 2008, J ALLERGY CLIN IMMUN, V121, P129, DOI 10.1016/j.jaci.2007.09.011; Watanabe S, 2003, J ALLERGY CLIN IMMUN, V111, P587, DOI 10.1067/mai.2003.105; Yatsunenko T, 2012, NATURE, V486, P222, DOI 10.1038/nature11053	53	154	162	4	65	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0017-5749	1468-3288		GUT	Gut	APR	2014	63	4					559	566		10.1136/gutjnl-2012-303249		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AC1PC	WOS:000332267500006	23926244	
J	Sundell, J; Levin, H; Nazaroff, WW; Cain, WS; Fisk, WJ; Grimsrud, DT; Gyntelberg, F; Li, Y; Persily, AK; Pickering, AC; Samet, JM; Spengler, JD; Taylor, ST; Weschler, CJ				Sundell, J.; Levin, H.; Nazaroff, W. W.; Cain, W. S.; Fisk, W. J.; Grimsrud, D. T.; Gyntelberg, F.; Li, Y.; Persily, A. K.; Pickering, A. C.; Samet, J. M.; Spengler, J. D.; Taylor, S. T.; Weschler, C. J.			Ventilation rates and health: multidisciplinary review of the scientific literature	INDOOR AIR			English	Article						Outdoor air supply rate; Indoor air quality; Offices; Schools; Homes	SICK-BUILDING-SYNDROME; INDOOR AIR-QUALITY; SYNDROME SBS SYMPTOMS; HOUSE-DUST MITES; OFFICE BUILDINGS; CO2 CONCENTRATIONS; EXCHANGE-RATE; RESPIRATORY-DISEASES; CARBON-DIOXIDE; YOUNG-CHILDREN	P>The scientific literature through 2005 on the effects of ventilation rates on health in indoor environments has been reviewed by a multidisciplinary group. The group judged 27 papers published in peer-reviewed scientific journals as providing sufficient information on both ventilation rates and health effects to inform the relationship. Consistency was found across multiple investigations and different epidemiologic designs for different populations. Multiple health endpoints show similar relationships with ventilation rate. There is biological plausibility for an association of health outcomes with ventilation rates, although the literature does not provide clear evidence on particular agent(s) for the effects. Higher ventilation rates in offices, up to about 25 l/s per person, are associated with reduced prevalence of sick building syndrome (SBS) symptoms. The limited available data suggest that inflammation, respiratory infections, asthma symptoms and short-term sick leave increase with lower ventilation rates. Home ventilation rates above 0.5 air changes per hour (h-1) have been associated with a reduced risk of allergic manifestations among children in a Nordic climate. The need remains for more studies of the relationship between ventilation rates and health, especially in diverse climates, in locations with polluted outdoor air and in buildings other than offices. Practical Implications Ventilation with outdoor air plays an important role influencing human exposures to indoor pollutants. This review and assessment indicates that increasing ventilation rates above currently adopted standards and guidelines should result in reduced prevalence of negative health outcomes. Building operators and designers should avoid low ventilation rates unless alternative effective measures, such as source control or air cleaning, are employed to limit indoor pollutant levels.	[Levin, H.] Bldg Ecol Res Grp, Santa Cruz, CA USA; [Sundell, J.] Tsinghua Univ, Beijing 100084, Peoples R China; [Cain, W. S.] Univ Calif San Diego, San Diego, CA 92103 USA; [Fisk, W. J.] Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA; [Gyntelberg, F.] Bispebjerg Hosp, DK-2400 Copenhagen, Denmark; [Li, Y.] Univ Hong Kong, Hong Kong, Hong Kong, Peoples R China; [Persily, A. K.] Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA; [Samet, J. M.] Univ So Calif, Los Angeles, CA USA; [Spengler, J. D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Taylor, S. T.] Taylor Engineers, Alameda, CA USA; [Weschler, C. J.] Rutgers State Univ, Piscataway, NJ USA; [Weschler, C. J.] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA; [Sundell, J.] Tech Univ Denmark, DK-2800 Lyngby, Denmark; [Grimsrud, D. T.] Univ Minnesota, Minneapolis, MN 55455 USA; [Pickering, A. C.] Wythenshawe Hosp, Manchester M23 9LT, Lancs, England	Levin, H (reprint author), Bldg Ecol Res Grp, Santa Cruz, CA USA.	hal.levin@buildingecology.com	Sanders, Susan/G-1957-2011; Sundell, Jan/B-2857-2012; Li, Yuguo/A-9469-2010; Nazaroff, William/C-4106-2008; Weschler, Charles/A-9788-2009	Li, Yuguo/0000-0002-2281-4529; Nazaroff, William/0000-0001-5645-3357; Weschler, Charles/0000-0002-9097-5850	American Society of Heating, Refrigerating, and Air-Conditioning Engineers, Inc. (ASHRAE); National Center for Energy Management and Building Technology (NCEMBT)	The authors gratefully acknowledge the assistance of Gina Bendy and Shela Ray of the Indoor Air Institute, Inc., for their assistance in the literature review. Funding was provided by the American Society of Heating, Refrigerating, and Air-Conditioning Engineers, Inc. (ASHRAE) and the National Center for Energy Management and Building Technology (NCEMBT). The Indoor Air Institute was the project contractor.	Apte MG, 2000, INDOOR AIR, V10, P246, DOI 10.1034/j.1600-0668.2000.010004246.x; *ASHRAE INC, 1981, 621981 ASHRAE INC; ASHRAE, 2004, 6212004 ASHRAE INC; *ASHRAE INC, 1973, 6273 ASHRAE INC; *ASHRAE INC, 2004, 6222004 ASHRAE INC; *ASHRAE INC, 1989, 621989 ASHRAE INC; Bell ML, 2006, ENVIRON HEALTH PERSP, V114, P532, DOI 10.1289/ehp.8816; Billings John S., 1893, VENTILATION HEATING; Bornehag CG, 2005, INDOOR AIR, V15, P275, DOI 10.1111/j.1600-0668.2005.00372.x; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; CEN, 1998, 1752 CEN CR EUR COMM; Chao HJ, 2003, ENVIRON HEALTH PERSP, V111, P1242, DOI 10.1289/ehp.5697; *CIBSE, 1978, ENV CRIT DES CIBSE G; *DCA, 1992, 11 ECA; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; Erdmann CA, 2004, INDOOR AIR, V14, P127, DOI 10.1111/j.1600-0668.2004.00298.x; Fisk WJ, 1997, INDOOR AIR, V7, P158, DOI 10.1111/j.1600-0668.1997.t01-1-00002.x; Godish T, 1996, INDOOR AIR, V6, P135, DOI 10.1111/j.1600-0668.1996.00010.x; HARVING H, 1993, ALLERGY, V48, P106, DOI 10.1111/j.1398-9995.1993.tb00694.x; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; JAAKKOLA JJK, 1991, ENVIRON INT, V17, P371, DOI 10.1016/0160-4120(91)90025-L; JAAKKOLA JJK, 1995, OCCUP ENVIRON MED, V52, P709; JAAKKOLA JJK, 1994, AM J PUBLIC HEALTH, V84, P422, DOI 10.2105/AJPH.84.3.422; Jaakkola JJK, 1991, INDOOR AIR, V1, P111; Janssen JE, 1999, ASHRAE J, V41, P48; Jennings BH, 1971, ASHRAE T, V77, P50; KLAUSS AK, 1970, ASHRAE JOURNAL, V12, P51; MARMOR M, 1978, ENVIRON RES, V17, P102, DOI 10.1016/0013-9351(78)90065-8; Mendell MJ, 2002, AM J PUBLIC HEALTH, V92, P1430, DOI 10.2105/AJPH.92.9.1430; Mendell MJ, 1993, INDOOR AIR, V3, P227, DOI 10.1111/j.1600-0668.1993.00003.x; Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107; Menzies D, 2000, ANN INTERN MED, V133, P779; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; Milton DK, 2000, INDOOR AIR, V10, P212, DOI 10.1034/j.1600-0668.2000.010004212.x; Myatt TA, 2004, AM J RESP CRIT CARE, V169, P1187, DOI 10.1164/rccm.200306-760OC; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; *NY STAT COMM VENT, 1931, SCH VENT PRINC PRACT; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Pettenkofer M., 1858, BESPRECHUNG ALLGEMEI; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106; Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; Shendell DG, 2004, INDOOR AIR, V14, P333, DOI 10.1111/j.1600-0668.2004.00251.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18; Stanke D, 1999, ASHRAE J, V41, P40; STENBERG B, 1994, INT J EPIDEMIOL, V23, P1190, DOI 10.1093/ije/23.6.1190; SUNDELL J, 1994, ENVIRON INT, V20, P239, DOI 10.1016/0160-4120(94)90141-4; SUNDELL J, 1995, ALLERGY, V50, P106; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; Tredgold T, 1836, PRINCIPLES WARMING V; Walinder R, 1997, INDOOR AIR, V7, P198, DOI 10.1111/j.1600-0668.1997.t01-1-00005.x; Walinder R, 1997, ACTA OTO-LARYNGOL, V117, P724, DOI 10.3109/00016489709113467; Walinder R, 1998, INT ARCH OCC ENV HEA, V71, P479, DOI 10.1007/s004200050309; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wargocki P, 2004, INDOOR AIR, V14, P7, DOI 10.1111/j.1600-0668.2004.00304.x; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x; Wargocki P, 1999, INDOOR AIR, V9, P165, DOI 10.1111/j.1600-0668.1999.t01-1-00003.x; Weschler CJ, 2006, ENVIRON HEALTH PERSP, V114, P1489, DOI 10.1289/ehp.9256; Yaglou C.P., 1936, ASHRAE T, V42, P133	61	154	157	25	160	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0905-6947			INDOOR AIR	Indoor Air	JUN	2011	21	3					191	204		10.1111/j.1600-0668.2010.00703.x		14	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	762OW	WOS:000290490300004	21204989	
J	Stenfors, N; Nordenhall, C; Salvi, SS; Mudway, I; Soderberg, M; Blomberg, A; Helleday, R; Levin, JO; Holgate, ST; Kelly, FJ; Frew, AJ; Sandstrom, T				Stenfors, N; Nordenhall, C; Salvi, SS; Mudway, I; Soderberg, M; Blomberg, A; Helleday, R; Levin, JO; Holgate, ST; Kelly, FJ; Frew, AJ; Sandstrom, T			Different airway inflammatory responses in asthmatic and healthy humans exposed to diesel	EUROPEAN RESPIRATORY JOURNAL			English	Article						airway inflammation; asthma; cytokines; diesel; pollution	EXHAUST PARTICLES; POLLUTION; INTERLEUKIN-10; CELLS	Particulate matter (PM) pollution adversely affects the airways, with asthmatic subjects thought to be especially sensitive. The authors hypothesised that exposure to diesel exhaust (DE), a major source of PM, would induce airway neutrophilia in healthy subjects, and that either these responses would be exaggerated in subjects with mild allergic asthma, or DE would exacerbate pre-existent allergic airways. Healthy and mild asthmatic subjects were exposed for 2 h to ambient levels of DE (particles with a 50% cut-off aerodynamic diameter of 10 mum (PM10) 108 mug(.)m(-3)) and lung function and airway inflammation were assessed. Both groups showed an increase in airway resistance of similar magnitude after DE exposure. Healthy subjects developed airway inflammation 6 h after DE exposure, with airways neutrophilia and lymphocytosis together with an increase in interleukin-8 (IL-8) protein in lavage fluid, increased IL-8 messenger ribonucleic acid expression in the bronchial mucosa and upregulation of the endothelial adhesion molecules. In asthmatic subjects, DE exposure did not induce a neutrophilic response or exacerbate their preexisting eosinophilic airway inflammation. Epithelial staining for the cytokine IL-10 was increased after DE in the asthmatic group. Differential effects on the airways of healthy subjects and asthmatics of particles with a 50% cut-off aerodynamic diameter of 10 mum at concentrations below current World Health Organisation air quality standards have been observed in this study. Further work is required to elucidate the significance of these differential responses.	Umea Univ Hosp, Dept Resp Med & Allergy, SE-90185 Umea, Sweden; Southampton Gen Hosp, Resp Cell & Mol Biol Res Div, Southampton SO9 4XY, Hants, England; St Thomas Hosp, Rayne Inst, London SE1 7EH, England; Natl Inst Working Life, Umea, Sweden	Sandstrom, T (reprint author), Umea Univ Hosp, Dept Resp Med & Allergy, SE-90185 Umea, Sweden.	Thomas.sandstrom@lung.umu.se	Kelly, Frank/C-6125-2009	Kelly, Frank/0000-0003-2558-8392; Blomberg, Anders/0000-0002-2452-7347; Stenfors, Nikolai/0000-0002-1684-1301			Barnes PJ, 1998, MOL MED TODAY, V4, P452, DOI 10.1016/S1357-4310(98)01335-5; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Boezen M, 1998, AM J RESP CRIT CARE, V158, P1848; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; DiazSanchez D, 1997, ALLERGY, V52, P52; Jeannin P, 1998, J IMMUNOL, V160, P3555; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; *NIH NAT HEART LAB, 1995, GLOB STRAT ASTHM MAN; RUDELL B, 1994, INT ARCH OCC ENV HEA, V66, P77, DOI 10.1007/BF00383361; Rudell B, 1990, J AEROSOL SCI     S1, V21, P411; Salvi S, 1999, AM J RESP CELL MOL, V20, P984; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; Sanchez-Guerrero I, 1997, Allergol Immunopathol (Madr), V25, P98; SCHROEDER WH, 1987, JAPCA J AIR WASTE MA, V37, P1267; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Takanashi S, 1999, EUR RESPIR J, V14, P309, DOI 10.1034/j.1399-3003.1999.14b12.x; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507	20	154	159	2	10	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JAN	2004	23	1					82	86		10.1183/09031936.03.00004603		5	Respiratory System	Respiratory System	763KA	WOS:000188083000017	14738236	
J	Untersmayr, E; Scholl, I; Swoboda, I; Beil, WJ; Forster-Waldl, E; Walter, F; Riemer, A; Kraml, G; Kinaciyan, T; Spitzauer, S; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E				Untersmayr, E; Scholl, I; Swoboda, I; Beil, WJ; Forster-Waldl, E; Walter, F; Riemer, A; Kraml, G; Kinaciyan, T; Spitzauer, S; Boltz-Nitulescu, G; Scheiner, O; Jensen-Jarolim, E			Antacid medication inhibits digestion of dietary proteins and causes food allergy: A fish allergy model in Balb/c mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						food allergy; caviar; parvalbumin; IgE; nutrition; antacids; digestion; animal model	PEANUT; HYPERSENSITIVITY; DIGESTIBILITY; EPIDEMIOLOGY; INTOLERANCE; PREVALENCE; POPULATION; RESPONSES; EPITOPES; EXPOSURE	Background: Digestible proteins were supposed to be irrelevant for oral sensitization and induction of food allergy. Approximately 10% of the adult population uses antacids for the treatment of dyspeptic disorders, drugs that hinder peptic digestion. In these patients, proteins that are normally degradable might act as food allergens. Objective: We aimed to study the influence of antacid intake on the allergenicity of dietary proteins, taking sturgeon caviar and parvalbumin, the major fish allergen, as examples. Methods: Caviar proteins and recombinant parvalbumin from carp, rCyp c 1, were applied for intragastric feedings with or without the antacids sucralfate, ranitidine or omeprazole, using a Balb/c mouse model. Results: Both caviar proteins and parvalbumin were rapidly degraded in an in vitro digestion assay at pH 2.0, but not at pH 5.0, imitating the effect of antacids. The groups fed with caviar in combination with ranitidine hydrochloride intramuscularly or sucralfate orally had significant levels of caviar-specific IgE antibodies (P < .01), T-cell reactivity, and elevated counts of gastrointestinal eosinophils and mast cells. Food allergy in these groups was further evidenced by oral provocation tests and positive immediate-type skin reactivity. In contrast, feedings with caviar alone led to antigen-specific T-cell tolerance. None of the groups showed immune reactivity against the daily mouse diet. As a proof of the principle, feeding mice with parvalbumin in combination with ranitidine or omeprazole intramuscularly induced allergen-specific IgE antibodies (P < .05). Conclusions: When antacid medication impairs the gastric digestion, IgE synthesis toward novel dietary proteins is promoted, leading to food allergy.	Univ Vienna, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Dept Clin Chem & Lab Med, Vienna, Austria; Univ Vienna, Dept Pathol, Vienna, Austria; Univ Vienna, Dept Pediat & Juvenile Med, Vienna, Austria; Univ Vienna, Dept Dermatol, Vienna, Austria; Tech Univ Vienna, A-1060 Vienna, Austria	Jensen-Jarolim, E (reprint author), Univ Vienna, Dept Pathophysiol, AKH-3Q,Waehringer Guertel 18-20, A-1090 Vienna, Austria.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; AMLOT PL, 1987, CLIN ALLERGY, V17, P33, DOI 10.1111/j.1365-2222.1987.tb02317.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Beil Waltraud J., 1997, Histochemical Journal, V29, P759, DOI 10.1023/A:1026421303260; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Bindslev-Jensen C, 2001, ALLERGY, V56, P75, DOI 10.1034/j.1398-9995.2001.00922.x; Bischoff SC, 1997, GUT, V40, P745; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Brewer JM, 1999, J IMMUNOL, V163, P6448; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Dearman RJ, 2002, FOOD CHEM TOXICOL, V40, P625, DOI 10.1016/S0278-6915(01)00132-6; Dearman RJ, 2001, TOXICOLOGY, V167, P217, DOI 10.1016/S0300-483X(01)00462-0; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Furu K, 1999, J CLIN EPIDEMIOL, V52, P509, DOI 10.1016/S0895-4356(99)00020-7; GARNETT W R, 1982, Clinical Pharmacy, V1, P307; Hong SJ, 1999, J ALLERGY CLIN IMMUN, V104, P473, DOI 10.1016/S0091-6749(99)70396-9; JANSEN JJN, 1994, J ALLERGY CLIN IMMUN, V93, P446; Jensen-Jarolim E, 1999, FASEB J, V13, P1586; Jensen-Jarolim E, 1999, CLIN EXP ALLERGY, V29, P1075, DOI 10.1046/j.1365-2222.1999.00592.x; JensenJarolim E, 1997, CLIN EXP ALLERGY, V27, P1299, DOI 10.1046/j.1365-2222.1997.1580956.x; Kelly KJ, 2000, J PEDIAT GASTROENT S, V30, P28; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maleki SJ, 2000, J IMMUNOL, V164, P5844; PEDEN NR, 1979, LANCET, V1, P690; PRICHARD PJ, 1985, GASTROENTEROLOGY, V88, P64; Sampson HA, 1996, PEDIAT ALLERG IMM-UK, V7, P42, DOI 10.1111/j.1399-3038.1996.tb00394.x; Schafer T, 2001, ALLERGY, V56, P1172, DOI 10.1034/j.1398-9995.2001.00196.x; SCHOLL I, 2002, CLIN EXP ALLERGY, V323, P1583; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; Straumann A, 2001, J ALLERGY CLIN IMMUN, V108, P954, DOI 10.1067/mai.2001.119917; Svensson L, 2003, IMMUNOLOGY, V108, P98, DOI 10.1046/j.1365-2567.2003.01561.x; Swoboda I, 2002, J IMMUNOL, V168, P4576; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Untersmayr E, 2002, J ALLERGY CLIN IMMUN, V109, P1034, DOI 10.1067/mai.2002.124893; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Yagami T, 2000, J ALLERGY CLIN IMMUN, V106, P752, DOI 10.1067/mai.2000.109171; Zivny JH, 2001, CLIN IMMUNOL, V101, P158, DOI 10.1006/clim.2001.5103	38	154	159	1	17	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2003	112	3					616	623		10.1016/mai.2003.1681		8	Allergy; Immunology	Allergy; Immunology	719XW	WOS:000185231200024	13679824	
J	Gehring, U; Bolte, G; Borte, M; Bischof, W; Fahlbusch, B; Wichmann, HE; Heinrich, J				Gehring, U; Bolte, G; Borte, M; Bischof, W; Fahlbusch, B; Wichmann, HE; Heinrich, J		LISA Study Grp	Exposure to endotoxin decreases the risk of atopic eczema in infancy: A cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; house dust; atopic eczema; infections; wheezing; infancy	HOUSE-DUST; HAY-FEVER; ALLERGIC SENSITIZATION; ASTHMA; CHILDREN; DERMATITIS; CHILDHOOD; ENVIRONMENT; COMMUNITY; SYMPTOMS	Background: Previous studies have shown a protective effect of early exposure to cats and dogs on the development of atopic eczema, asthma, allergic rhinitis, and atopic sensitization in later life. In particular, a higher microbial exposure to endotoxin in early childhood might contribute to this effect. Objective: We examined the associations between bacterial endotoxin in house dust and atopic eczema, infections, and wheezing during the first year of life in an ongoing birth cohort study (LISA). Methods: Data of 1884 term and normal-weight neonates with complete information on exposure to biocontaminants and confounding variables were analyzed. House dust from the mothers' and the children's mattresses was sampled 3 months after birth. Endotoxin content was quantified by using a chromogenic kinetic limulus amoebocyte lysate test. Results: During the first 6 months of life, the risk of atopic eczema was significantly decreased by endotoxin exposure in dust from mothers' mattresses in the fifth quintile (odds ratio [OR], 0.50; 95% CI, 0.28-0.88), whereas the risk was increased for respiratory infections (OR, 1.69; 95% CI, 1.25-2.28) and cough with respiratory infection, bronchitis, or both (OR, 1.73; 95% CI, 1.28-2.33). The risk of wheezing was also significantly increased during the first 6 months of life (OR, 2.37; 95% CI, 1.40-4.03). For the entire first year of life, these associations attenuated, except for the risk of wheezing, which remained significant (OR, 1.60; 95% CI, 1.10-2.30). Conclusion: Our findings support the hygiene hypothesis that exposure to high concentrations of endotoxin very early in life might protect against the development of atopic eczema within the first 6 months of life, along with an increased prevalence of nonspecific respiratory diseases.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Chair Epidemiol, Munich, Germany; Univ Leipzig, Dept Pediat, D-7010 Leipzig, Germany; Univ Jena, Inst Clin Immunol, D-6900 Jena, Germany; Univ Jena, Inst Occupat Social & Enviornm Med, Dept Indoor Climatol Ark, Erfurt, Germany	Gehring, U (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.			Gehring, Ulrike/0000-0003-3612-5780			Asher MI, 1998, EUR RESPIR J, V12, P315; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bischof W, 2000, P HLTH BUILDINGS, V1, P251; Bjorksten B, 1999, P NUTR SOC, V58, P729, DOI 10.1017/S0029665199000956; Bonifazi E, 1989, Acta Derm Venereol Suppl (Stockh), V144, P20; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burney P, 1996, EUR RESPIR J, V9, P687; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Fahlbusch B, 1999, ALLERGY, V54, P1215, DOI 10.1034/j.1398-9995.1999.00196.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; GUILLET G, 1992, ARCH DERMATOL, V128, P187, DOI 10.1001/archderm.128.2.187; HEINRICH J, IN PRESS CLIN EXP AL; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holgate ST, 1999, NATURE, V402, pB2; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kaliomaki M, 2001, LANCET, V357, P1076; Kimpen JLL, 2000, AM J RESP CRIT CARE, V162, pS108; KJELLMAN B, 1994, ACTA PAEDIATR, V83, P229, DOI 10.1111/j.1651-2227.1994.tb13057.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 1999, LANCET S2, V354, pSII12; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Queille-Roussel C, 1985, Acta Derm Venereol Suppl (Stockh), V114, P87; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; YATES VM, 1983, BRIT J DERMATOL, V108, P633, DOI 10.1111/j.1365-2133.1983.tb01074.x	36	154	155	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					847	854		10.1067/mai.2001.119026		8	Allergy; Immunology	Allergy; Immunology	498RG	WOS:000172523800029	11692114	
J	Miller, RL; Ho, SM				Miller, Rachel L.; Ho, Shuk-mei			Environmental epigenetics and asthma - Current concepts and call for studies	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						epigenetics; asthma; DNA methylation; gene-environment interactions	SCHOOL-AGE-CHILDREN; LOW-BIRTH-WEIGHT; SERUM IGE LEVELS; IFN-GAMMA GENE; CHILDHOOD ASTHMA; LUNG-FUNCTION; TOBACCO-SMOKE; ALLERGIC DISEASE; MATERNAL SMOKING; DNA METHYLATION	Recent studies suggest that epigenetic regulation (heritable changes in gene expression that occur in the absence of alterations in DNA sequences) may in part mediate the complex gene-by-environment interactions that can lead to asthma. The variable natural history of asthma (i.e., incidence and remission of symptoms) may be a result of epigenetic changes, such as DNA methylation, covalent histone modifications, microRNA changes, and chromatin alterations, after early or later environmental exposures. Findings from multiple epidemiologic and experimental studies indicate that asthma risk may be modified by epigenetic regulation. One study suggested that the transmission of asthma risk may occur across multiple generations. Experimental studies provide substantial in vitro data indicating that DNA methylation of genes critical to T-helper cell differentiation may induce polarization toward or away from an allergic phenotype. Despite this initial progress, fundamental questions remain that need to be addressed by well-designed research studies. Data generated from controlled experiments using in vivo models and/or clinical specimens collected after environmental exposure monitoring are limited. Importantly, cohort-driven epigenetic research has the potential to address key questions, such as those concerning the influence of timing of exposure, dose of exposure, diet, and ethnicity on susceptibility to asthma development. There is immense promise that the study of environmental epigenetics will help us understand a theoretically preventable environmental disease.	[Miller, Rachel L.] Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA; [Ho, Shuk-mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Ho, Shuk-mei] Univ Cincinnati, Coll Med, Ctr Canc, Cincinnati, OH 45267 USA	Miller, RL (reprint author), Columbia Univ Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, PH8E,630 W 168th St, New York, NY 10032 USA.	rlm14@columbia.edu			NIEHS NIH HHS [ES006096, ES013071, ES013163, ES015584, ES015905, P30 ES006096, P50 ES015905, P50 ES015905-010001, R01 ES013163, R01 ES013163-01A1, ES013063, R01 ES013163-05]		Agarwal S, 1998, IMMUNITY, V9, P765, DOI 10.1016/S1074-7613(00)80642-1; Alati R, 2006, EPIDEMIOLOGY, V17, P138, DOI 10.1097/01.ede.0000198148.02347.33; Anand D, 2003, ARCH DIS CHILD, V88, P135, DOI 10.1136/adc.88.2.135; BARKER DJP, 1991, BRIT MED J, V303, P671; Barr RG, 2001, CHEST, V120, P1474, DOI 10.1378/chest.120.5.1474; Bernstein DI, 2006, ANN ALLERG ASTHMA IM, V97, P800; Blumenthal MN, 2006, J ALLERGY CLIN IMMUN, V117, P79, DOI 10.1016/j.jaci.2005.09.038; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Callinan PA, 2006, HUM MOL GENET, V15, pR95, DOI 10.1093/hmg/ddl095; Carroll WD, 2005, PEDIATR ALLERGY IMMU, V16, P32, DOI 10.1111/j.1399-3038.2005.00249.x; Chan C, 2005, J IMMUNOL, V175, P461; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Cooney CA, 2002, J NUTR, V132, p2393S; Devereux G, 2006, AM J RESP CRIT CARE, V174, P499, DOI 10.1164/rccm.200512-1946OC; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Dizier MH, 2007, EUR J HUM GENET, V15, P810, DOI 10.1038/sj.ejhg.5201830; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Elliot JG, 2003, AM J RESP CRIT CARE, V167, P45, DOI 10.1164/rccm.2110005; Falls JG, 1999, AM J PATHOL, V154, P635, DOI 10.1016/S0002-9440(10)65309-6; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Finch CE, 2004, SCIENCE, V305, P1736, DOI 10.1126/science.1092556; Fitzsimon N, 2007, Ir Med J, V100, P27; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; HALES CN, 1991, BRIT MED J, V303, P1019; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Ho SM, 2007, REPROD TOXICOL, V23, P267, DOI 10.1016/j.reprotox.2007.01.004; Hoppin AA, 2004, AM J RESP CRIT CARE, V169, P1308, DOI 10.1164/rccm.200309-1228OC; Hunt JS, 2005, FASEB J, V19, P681, DOI 10.1096/fj.04-2078rev; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Jedrychowski Wieslaw, 2006, International Journal of Occupational Medicine and Environmental Health, V19, P70, DOI 10.2478/v10001-006-0010-0; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Krebs JE, 2007, MOL BIOSYST, V3, P590, DOI 10.1039/b703923a; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Lau Christopher, 2004, Birth Defects Res C Embryo Today, V72, P300, DOI 10.1002/bdrc.20029; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1067/mai.2003.1812; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/1369052012191; Magnusson LL, 2005, CLIN EXP ALLERGY, V35, P1550; Mandhane PJ, 2005, AM J RESP CRIT CARE, V172, P45, DOI 10.1164/rccm.200412-1738OC; MARCO RD, 2002, J ALLERGY CLIN IMMUN, V110, P228; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Mone SM, 2004, PEDIATRICS, V113, P1058; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Nightingale KP, 2006, CURR OPIN GENET DEV, V16, P125, DOI 10.1016/j.gde.2006.02.015; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Pessi T, 2005, INT ARCH ALLERGY IMM, V137, P282, DOI 10.1159/000086421; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1544, DOI 10.1046/j.1365-2222.2001.01163.x; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Ramadas RA, 2007, EUR RESPIR J, V29, P502, DOI 10.1183/09031936.00029506; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Sarraf SA, 2004, MOL CELL, V15, P595, DOI 10.1016/j.molcel.2004.06.043; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Traherne JA, 2003, HUM MOL GENET, V12, P2577, DOI 10.1093/hmg/ddg290; Tykocinski LO, 2005, J BIOL CHEM, V280, P28177, DOI 10.1074/jbc.M502038200; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weaver ICG, 2006, P NATL ACAD SCI USA, V103, P3480, DOI 10.1073/pnas.0507526103; White GP, 2002, J IMMUNOL, V168, P2820; Williams LK, 2006, J ALLERGY CLIN IMMUN, V118, P851, DOI 10.1016/j.jaci.2006.07.007; Windham GC, 2000, EPIDEMIOLOGY, V11, P427, DOI 10.1097/00001648-200007000-00011; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	91	153	163	2	17	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 15	2008	177	6					567	573		10.1164/rccm.200710-1511PP		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	272IB	WOS:000253852000004	18187692	
J	Chauhan, AJ; Inskip, HM; Linaker, CH; Smith, S; Schreiber, J; Johnston, SL; Holgate, ST				Chauhan, AJ; Inskip, HM; Linaker, CH; Smith, S; Schreiber, J; Johnston, SL; Holgate, ST			Personal exposure to nitrogen dioxide (NO2) and the severity of virus-induced asthma in children	LANCET			English	Article							RESPIRATORY SYMPTOMS; AIR-POLLUTION; RISK-FACTORS; IN-VITRO; ASSOCIATION; INFECTION; COOKING; ADULTS; CELLS; GAS	Background A link between exposure to the air pollutant nitrogen dioxide (NO2) and respiratory disease has been suggested. Viral infections are the major cause of asthma exacerbations. We aimed to assess whether there is a relation between NO2 exposure and the severity of asthma exacerbations caused by proven respiratory viral infections in children. Methods A cohort of 114 asthmatic children aged between 8 and 11 years recorded daily upper and lower respiratory-tract symptoms, peak expiratory flow (PEF), and measured personal NO2 exposures every week for up to 13 months. We took nasal aspirates during reported episodes of upper respiratory-tract illness and tested for infection by common respiratory viruses and atypical bacteria with RT-PCR assays. We used generalised estimating equations to assess the relation between low (<7.5 &mu;g/m(3) medium (7.5-14 &mu;g/m(3)), and high (>14 mug/m(3)) tertiles of NO2 exposure in the week before or after upper respiratory-tract infection and the severity of asthma exacerbation in the week after the start of an infection. Findings One or more viruses were detected in 78% of reported infection episodes, and the medians of NO2 exposure were 5 (IQR 3.6-6.3), 10 (8.7-12.0), and 21 mug/m(3) (16.8-42.9) for low, medium, and high tertiles, respectively. There were significant increases in the severity of lower respiratory-tract symptom scores across the three tertiles (0.6 for all viruses [p=0.05] and >2 for respiratory syncytial virus [p=0.01]) and a reduction in PEF of more than 12 L/min for picornavirus (p=0.04) for high compared with low NO2 exposure before the start of the virus-induced exacerbation. Interpretation High exposure to NO2 in the week before the start of a respiratory viral infection, and at levels within current air quality standards, is associated with an increase in the severity of a resulting asthma exacerbation.	Univ Southampton, Resp Cell & Mol Biol Res Div, Southampton, Hants, England; Univ Southampton, MRC, Environm Epidemiol Unit, Southampton, Hants, England; Natl Heart & Lung Inst, London, England; Univ London Imperial Coll Sci Technol & Med, Wright Fleming Inst Infect & Immun, London, England	Chauhan, AJ (reprint author), St Marys Hosp, Portsmouth PO3 6AD, Hants, England.		Johnston, Sebastian/I-2423-2012	Inskip, Hazel/0000-0001-8897-1749			*ADV GROUP MED ASP, 1993, 3 DEP HLTH ADV GROUP, P29; Ando M, 2001, ARCH ENVIRON HEALTH, V56, P227; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BRUNEKREEF B, 1982, INT ARCH OCC ENV HEA, V50, P299, DOI 10.1007/BF00378091; CARSON JL, 1993, AM J RESP CELL MOL, V9, P264; Chauhan A. J., 1998, Reviews on Environmental Health, V13, P73; CLAUSING P, 1986, Environment International, V12, P413, DOI 10.1016/0160-4120(86)90056-5; Dennekamp M, 2001, OCCUP ENVIRON MED, V58, P511, DOI 10.1136/oem.58.8.511; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271; DEVALIA JL, 1993, EUR RESPIR J, V6, P1308; EHRLICH R, 1966, BACTERIOL REV, V30, P604; FRAMPTON MW, 1989, ENVIRON RES, V48, P179, DOI 10.1016/S0013-9351(89)80033-7; Frampton MW, 2002, AM J PHYSIOL-LUNG C, V282, pL155; GOINGS SAJ, 1989, AM REV RESPIR DIS, V139, P1075; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; JAKAB GJ, 1987, ENVIRON RES, V42, P215, DOI 10.1016/S0013-9351(87)80023-3; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; KAWAMOTO T, 1993, ARCH ENVIRON CON TOX, V25, P534; KOO LC, 1990, AM REV RESPIR DIS, V141, P1119; Linaker CH, 2000, OCCUP ENVIRON MED, V57, P472, DOI 10.1136/oem.57.7.472; Linaker CH, 1996, OCCUP ENVIRON MED, V53, P200; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; NOY D, 1990, ATMOS ENVIRON A-GEN, V24, P2903, DOI 10.1016/0960-1686(90)90470-8; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258; SANDSTROM T, 1992, EUR RESPIR J, V5, P1092; SCHENKER MB, 1983, AM REV RESPIR DIS, V128, P1038; Siegel PD, 1997, TOXICOL APPL PHARM, V144, P356, DOI 10.1006/taap.1997.8148; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; World Health Organization, 2000, EUR SER, V91; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	35	153	160	4	23	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 7	2003	361	9373					1939	1944		10.1016/S0140-6736(03)13582-9		6	Medicine, General & Internal	General & Internal Medicine	687DB	WOS:000183359700009	12801737	
J	Tomioka, S; Bates, JHT; Irvin, CG				Tomioka, S; Bates, JHT; Irvin, CG			Airway and tissue mechanics in a murine model of asthma: alveolar capsule vs. forced oscillations	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						airway resistance; tissue elastance; lung impedance; antigen challenge; inflammation	RESPIRATORY SYSTEM MECHANICS; INDUCED CONSTRICTION; LUNG-MECHANICS; DRY AIR; RATS; BRONCHOCONSTRICTION; HISTAMINE; IMPEDANCE; PRESSURE; BEHAVIOR	To better address the functional consequences of inflammation on bronchial responsiveness, we studied two groups of BALB/c mice: a nonimmunized control group (n = 8) and a group immunized and challenged with inhaled ovalbumin (n = 8). An alveolar capsule (AC) measured airway resistance (Raw(AC)) and lung elastance (EL). A forced oscillation (FO) technique independently estimated airway resistance (RawFO) and a parameter H-ti related to tissue elastance. Ovalbumin-immunized and -challenged mice had increased numbers of eosinophils in bronchoalveolar lavage and increased responsiveness to methacholine (MCh). Corresponding parameters from the AC and FO techniques were correlated: RawAC vs. RawFO (r = 0.76) and EL vs. H-ti (r = 0.88, P < 0.0001 in all cases). AC and FO techniques showed significant increases in tissue elastance in response to MCh but no significant increases in airway resistance. These results demonstrated that the AC and FO techniques yield essentially equivalent results in mice, even when the lung is inhomogeneous, and that the bronchoconstrictive responses to MCh and inflammation in mice are predominantly located in the lung periphery.	Univ Vermont, Dept Med, Fletcher Allen Hlth Care, Vermont Lung Ctr, Burlington, VT 05405 USA	Irvin, CG (reprint author), Univ Vermont, Dept Med, Fletcher Allen Hlth Care, Vermont Lung Ctr, Burlington, VT 05405 USA.				NHLBI NIH HHS [HL-62746, HL-67273]; PHS HHS [P01 15557]		CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; FREDBERG JJ, 1984, J APPL PHYSIOL, V57, P788; FREDBERG JJ, 1985, J APPL PHYSIOL, V58, P1914; Gomes RFM, 2000, J APPL PHYSIOL, V89, P908; HANTOS Z, 1987, J APPL PHYSIOL, V63, P36; HANTOS Z, 1995, J APPL PHYSIOL, V79, P1440; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; Hirai T, 1999, J APPL PHYSIOL, V86, P16; Homma T, 1999, EUR RESPIR J, V13, P313, DOI 10.1034/j.1399-3003.1999.13b16.x; IRVIN CG, 1984, J APPL PHYSIOL, V57, P168; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053; KAMINSKY DA, 1995, AM J RESP CRIT CARE, V152, P1784; Kaminsky DA, 1997, AM J RESP CRIT CARE, V155, P1260; Kaminsky DA, 2000, AM J RESP CRIT CARE, V162, P179; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; LAUZON AM, 1991, J APPL PHYSIOL, V71, P1159; LAUZON AM, 1995, RESP PHYSIOL, V99, P139, DOI 10.1016/0034-5687(94)00087-G; LUDWIG MS, 1987, J APPL PHYSIOL, V62, P807; LUDWIG MS, 1989, J APPL PHYSIOL, V67, P1220; Lutchen KR, 1996, J APPL PHYSIOL, V80, P1841; LUTCHEN KR, 1994, J APPL PHYSIOL, V77, P373; MISHIMA M, 1994, J APPL PHYSIOL, V77, P2140; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; NAGASE T, 1994, J APPL PHYSIOL, V76, P830; Nagase T, 1996, J APPL PHYSIOL, V81, P2373; NAGASE T, 1994, AM J RESP CRIT CARE, V150, P218; NAGASE T, 1992, J APPL PHYSIOL, V73, P1900; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; Petak F, 1998, J APPL PHYSIOL, V84, P1680; Petak F, 1997, J APPL PHYSIOL, V82, P1479; PETAK F, 1993, J APPL PHYSIOL, V75, P513; Phillips CG, 1995, RESP PHYSIOL, V102, P303, DOI 10.1016/0034-5687(95)00056-9; RODARTE JR, 1985, J APPL PHYSIOL, V58, P164; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; SHARDONOFSKY FR, 1993, J APPL PHYSIOL, V75, P2506; SIMILOWSKI T, 1991, EUR RESPIR J, V4, P353; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TU YP, 1995, EUR RESPIR REV, V5, P224	39	153	157	0	5	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	JUL	2002	93	1					263	270		10.1152/japplphysiol.01129.2001		8	Physiology; Sport Sciences	Physiology; Sport Sciences	563JV	WOS:000176253300034	12070213	
J	Wargocki, P; Sundell, J; Bischof, W; Brundrett, G; Fanger, PO; Gyntelberg, F; Hanssen, SO; Harrison, P; Pickering, A; Seppanen, O; Wouters, P				Wargocki, P; Sundell, J; Bischof, W; Brundrett, G; Fanger, PO; Gyntelberg, F; Hanssen, SO; Harrison, P; Pickering, A; Seppanen, O; Wouters, P			Ventilation and health in non-industrial indoor environments: report from a European Multidisciplinary Scientific Consensus Meeting (EUROVEN)	INDOOR AIR			English	Review						ventilation; outdoor air supply rate; ventilation system; non-industrial indoor environments; offices; schools; homes; health; EUROVEN	SICK-BUILDING-SYNDROME; AIR-EXCHANGE-RATE; VOLATILE ORGANIC-COMPOUNDS; SYNDROME SBS SYMPTOMS; FACIAL SKIN SYMPTOMS; OFFICE BUILDINGS; PERSONAL FACTORS; CASE-REFERENT; CO2 CONCENTRATIONS; RISK INDICATORS	Scientific literature on the effects of ventilation on health, comfort, and productivity in non-industrial indoor environments (offices, schools, homes, etc.) has been reviewed by a multidisciplinary group of European scientists, called EUROVEN, with expertise in medicine, epidemiology, toxicology, and engineering. The group reviewed 105 papers published in peer-reviewed scientific journals and judged 30 as conclusive, providing sufficient information on ventilation, health effects, data processing, and reporting, 14 as providing relevant background information on the issue, 43 as relevant but non-informative or inconclusive, and 18 as irrelevant for the issue discussed. Based on the data in papers judged conclusive, the group agreed that ventilation is strongly associated with comfort (perceived air quality) and health [Sick Building Syndrome (SBS) symptoms, inflammation, infections, asthma, allergy, short-term sick leave], and that an association between ventilation and productivity (performance of office work) is indicated. The group also concluded that increasing outdoor air supply rates in non-industrial environments improves perceived air quality; that outdoor air supply rates below 25 l/s per person increase the risk of SBS symptoms, increase short-term sick leave, and decrease productivity among occupants of office buildings; and that ventilation rates above 0.5 air changes per hour (h(-1) ) in homes reduce infestation of house dust mites in Nordic countries. The group concluded additionally that the literature indicates that in buildings with air-conditioning systems there may be an increased risk of SBS symptoms compared with naturally or mechanically ventilated buildings, and that improper maintenance, design, and functioning of air-conditioning systems contributes to increased prevalence of SBS symptoms.	Tech Univ Denmark, Int Ctr Indoor Environm & Energy, DK-2800 Lyngby, Denmark; Univ Jena, Erfurt, Germany; Royal Soc Hlth, London, England; Bispebjerg Hosp, DK-2400 Copenhagen, Denmark; Norwegian Univ Sci & Technol, N-7034 Trondheim, Norway; MRC, Inst Environm & Hlth, Leicester, Leics, England; Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; Helsinki Univ Technol, FIN-02150 Espoo, Finland; Belgian Bldg Res Inst, Brussels, Belgium	Wargocki, P (reprint author), Tech Univ Denmark, Int Ctr Indoor Environm & Energy, Bldg 402, DK-2800 Lyngby, Denmark.		Sundell, Jan/B-2857-2012; Wargocki, Pawel/B-4632-2017	Wargocki, Pawel/0000-0003-3865-3560			ABBRITTI G, 1992, ARCH ENVIRON HEALTH, V47, P16; ANDERSEN I, 1986, Environment International, V12, P121, DOI 10.1016/0160-4120(86)90022-X; Apte MG, 2000, INDOOR AIR, V10, P246, DOI 10.1034/j.1600-0668.2000.010004246.x; ASHRAE, 1993, ASHRAE HDB; *ASHRAE, 1989, 6289 ASHRAE; BACHMANN MO, 1995, OCCUP MED-OXFORD, V45, P11, DOI 10.1093/occmed/45.1.11; BECK HI, 1989, ACTA DERM-VENEREOL, V69, P162; BERARDI BM, 1991, INT ARCH OCC ENV HEA, V63, P233, DOI 10.1007/BF00386371; BERG-MUNCH B, 1986, Environment International, V12, P195, DOI 10.1016/0160-4120(86)90030-9; BJORKROTH M, 1998, DESIGN CONSTRUCTION, P47; Bluyssen PM, 1996, INDOOR AIR, V6, P221, DOI 10.1111/j.1600-0668.1996.00002.x; Bourbeau J, 1996, OCCUP ENVIRON MED, V53, P204; Bourbeau J, 1997, OCCUP ENVIRON MED, V54, P49; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; CAIN WS, 1983, ATMOS ENVIRON, V17, P1183, DOI 10.1016/0004-6981(83)90341-4; CEN, 1998, 1752 CEN CR EUR COMM; *CIBSE, 1978, CIBSE GUID; DALE HCA, 1985, ENERGY RES, V9, P431; Drinka PJ, 1996, J AM GERIATR SOC, V44, P910; *EUR COLL ACT IND, 1992, 11EUR14449EN OFF PUB; EVERETT WD, 1991, AM J INFECT CONTROL, V19, P277, DOI 10.1016/0196-6553(91)90173-A; FANGER PO, 1988, ENERG BUILDINGS, V12, P7, DOI 10.1016/0378-7788(88)90052-7; FANGER PO, 1988, ENERG BUILDINGS, V12, P1, DOI 10.1016/0378-7788(88)90051-5; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573; Fisk WJ, 1997, INDOOR AIR, V7, P158, DOI 10.1111/j.1600-0668.1997.t01-1-00002.x; Fisk WJ, 1998, INDOOR AIR, V8, P301; Fisk WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; GIBERT I, 1992, INDOOR ENVIRON, V1, P279, DOI 10.1177/1420326X9200100505; Godish T, 1996, INDOOR AIR, V6, P135, DOI 10.1111/j.1600-0668.1996.00010.x; Gunnarsen L, 1997, INDOOR AIR, V7, P116, DOI 10.1111/j.1600-0668.1997.t01-2-00005.x; Gustafsson D, 1996, ALLERGY, V51, P789, DOI 10.1111/j.1398-9995.1996.tb04468.x; Haghighat F, 1999, BUILD ENVIRON, V34, P479, DOI 10.1016/S0360-1323(98)00034-1; HARRISON J, 1992, RESP MED, V86, P225, DOI 10.1016/S0954-6111(06)80060-0; HARVING H, 1993, ALLERGY, V48, P106, DOI 10.1111/j.1398-9995.1993.tb00694.x; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HEDGE A, 1989, ENVIRON INT, V15, P143, DOI 10.1016/0160-4120(89)90020-2; Hedge A, 1996, ENVIRON INT, V22, P3, DOI 10.1016/0160-4120(95)00099-2; HEDGE A, 1995, INDOOR AIR, V5, P10, DOI 10.1111/j.1600-0668.1995.t01-3-00003.x; HEDGE A, 1984, J ARCHIT PLAN RES, V1, P163; Hill B. A., 1992, APPL OCCUPATIONAL EN, V7, P101; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOSEIN HR, 1989, INT J EPIDEMIOL, V18, P390, DOI 10.1093/ije/18.2.390; IHENACHO HNC, 1990, CENT AFR J MED, V36, P147; IVERSEN M, 1986, Environment International, V12, P161, DOI 10.1016/0160-4120(86)90026-7; Iwashita G., 1990, J ARCHITECTURAL PLAN, V410, P9; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755; JAAKKOLA JJK, 1991, ENVIRON INT, V17, P371, DOI 10.1016/0160-4120(91)90025-L; JAAKKOLA JJK, 1995, OCCUP ENVIRON MED, V52, P709; JAAKKOLA JJK, 1994, AM J PUBLIC HEALTH, V84, P422, DOI 10.2105/AJPH.84.3.422; Jaakkola JJK, 1991, INDOOR AIR, V1, P111, DOI 10.1111/j.1600-0668.1991.02-12.x; Kelland P, 1992, INDOOR ENVIRON, V1, P335, DOI 10.1177/1420326X9200100604; Knudsen HN, 1997, INDOOR AIR, V7, P107, DOI 10.1111/j.1600-0668.1997.t01-2-00004.x; Knudsen HN, 1998, INDOOR AIR, V8, P264, DOI 10.1111/j.1600-0668.1998.00007.x; KODAMA AM, 1986, ARCH ENVIRON HEALTH, V41, P306; KROELING P, 1988, ENERG BUILDINGS, V11, P277, DOI 10.1016/0378-7788(88)90043-6; MARMOR M, 1978, ENVIRON RES, V17, P102, DOI 10.1016/0013-9351(78)90065-8; MCDONALD JC, 1993, ARCH ENVIRON HEALTH, V48, P298; Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; Mendell MJ, 1993, INDOOR AIR, V3, P227, DOI 10.1111/j.1600-0668.1993.00003.x; Menzies D, 1997, ARCH ENVIRON HEALTH, V52, P360; Menzies D, 1996, AM J PUBLIC HEALTH, V86, P1629, DOI 10.2105/AJPH.86.11.1629; Menzies D, 1997, NEW ENGL J MED, V337, P1524, DOI 10.1056/NEJM199711203372107; MENZIES R, 1993, NEW ENGL J MED, V328, P821, DOI 10.1056/NEJM199303253281201; Merrill J. L., 1989, ASHRAE T, V95, P405; Milton DK, 2000, INDOOR AIR, V10, P212, DOI 10.1034/j.1600-0668.2000.010004212.x; Muzi G, 1998, INT ARCH OCC ENV HEA, V71, P372, DOI 10.1007/s004200050295; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302; NELSON NA, 1995, SCAND J WORK ENV HEA, V21, P51; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121; Norback D, 1995, INDOOR AIR, V5, P237, DOI 10.1111/j.1600-0668.1995.00003.x; NORBACK D, 1990, BRIT J IND MED, V47, P733; NORBACK D, 1991, BRIT J IND MED, V48, P451; NORDSTROM K, 1995, OCCUP ENVIRON MED, V52, P170; NORDSTROM K, 1995, INDOOR ENVIRON, V4, P37, DOI 10.1177/1420326X9500400105; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; PAUL WS, 1993, J INFECT DIS, V167, P1053; Pejtersen J, 2001, INDOOR AIR, V11, P10, DOI 10.1034/j.1600-0668.2001.011001010.x; RICHARDS AL, 1993, AM J PUBLIC HEALTH, V83, P1326, DOI 10.2105/AJPH.83.9.1326; ROBERTSON AS, 1989, ANN OCCUP HYG, V33, P47, DOI 10.1093/annhyg/33.1.47; ROBERTSON AS, 1985, BRIT MED J, V291, P373; ROGOT E, 1992, AM J EPIDEMIOL, V136, P106; ROWE DM, 1993, INDOOR ENVIRON, V2, P276, DOI 10.1177/1420326X9300200504; RUOTSALAINEN R, 1994, ENVIRON INT, V20, P731, DOI 10.1016/0160-4120(94)90305-0; Ruotsalainen R, 1991, INDOOR AIR, V1, P428, DOI 10.1111/j.1600-0668.1991.00007.x; SALISBURY SA, 1984, ANN AM C GOVT IND HY, V10, P129; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; Shigematsu I, 1985, Tokai J Exp Clin Med, V10, P407; Sieber W.K., 1996, APPL OCCUP ENV HYG, V11, P1387; SKOV P, 1987, ENVIRON INT, V13, P339, DOI 10.1016/0160-4120(87)90190-5; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363; Smedje G, 1997, INDOOR AIR, V7, P143, DOI 10.1111/j.1600-0668.1997.00009.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18; STENBERG B, 1994, INT J EPIDEMIOL, V23, P1190, DOI 10.1093/ije/23.6.1190; STENBERG B, 1995, INT J EPIDEMIOL, V24, P796, DOI 10.1093/ije/24.4.796; STERLING E, 1983, CAN J PUBLIC HEALTH, V74, P385; SULLIVANBOLYAI JZ, 1979, PUBLIC HEALTH REP, V94, P466; SUNDELL J, 1994, ENVIRON INT, V20, P239, DOI 10.1016/0160-4120(94)90141-4; SUNDELL J, 1995, ALLERGY, V50, P106; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; SUNDELL J, 1999, P IND AIR 99 ED 8 IN, V1, P177; TAMBLYN RM, 1992, J CLIN EPIDEMIOL, V45, P603, DOI 10.1016/0895-4356(92)90132-7; Teculescu DB, 1998, INT ARCH OCC ENV HEA, V71, P353, DOI 10.1007/s004200050292; TURIEL I, 1983, ATMOS ENVIRON, V17, P51, DOI 10.1016/0004-6981(83)90007-0; Vincent D, 1997, ENVIRON RES, V75, P100, DOI 10.1006/enrs.1997.3764; Walinder R, 1997, INDOOR AIR, V7, P198, DOI 10.1111/j.1600-0668.1997.t01-1-00005.x; Walinder R, 1997, ACTA OTO-LARYNGOL, V117, P724, DOI 10.3109/00016489709113467; Walinder R, 1998, INT ARCH OCC ENV HEA, V71, P479, DOI 10.1007/s004200050309; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wargocki P, 1999, INDOOR AIR, V9, P165, DOI 10.1111/j.1600-0668.1999.t01-1-00003.x; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; World Health Organization, 1948, CONST WHO; Wieslander G, 1999, INT ARCH OCC ENV HEA, V72, P507, DOI 10.1007/s004200050408; WYON DP, 1992, ENVIRON TECHNOL, V13, P313; Yaglou C.P., 1936, ASHRAE T, V42, P133; YAGLOU CP, 1955, ASHAE T, V61, P25; ZWEERS T, 1990, ENERG BUILDINGS, V14, P175, DOI 10.1016/0378-7788(90)90038-K; Zweers T, 1992, INDOOR AIR, V2, P127, DOI 10.1111/j.1600-0668.1992.00001.x	121	153	156	3	57	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air	JUN	2002	12	2					113	128		10.1034/j.1600-0668.2002.01145.x		16	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	566TA	WOS:000176443300005	12216467	
J	Wayne, P; Foster, S; Connolly, J; Bazzaz, F; Epstein, P				Wayne, P; Foster, S; Connolly, J; Bazzaz, F; Epstein, P			Production of allergenic pollen by ragweed (Ambrosia artemisiifolia L.) is increased in CO2-enriched atmospheres	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							ELEVATED CO2; GROWTH; CLIMATE; PLANTS; REPRODUCTION; METAANALYSIS; ASTERACEAE; BIOLOGY; GENDER; HEALTH	Background: The potential effects of global climate change on allergenic pollen production are still poorly understood. Objective: To study the direct impact of rising atmospheric CO2 concentrations on ragweed (Ambrosia artemisiifolia L.) pollen production and growth. Methods: In environmentally controlled greenhouses, stands of ragweed plants were grown from seed through flowering stages at both ambient and twice-ambient CO2 levels (350 vs 700 muL L-1). Outcome measures included stand-level total pollen production and end-of-season measures of plant mass,, height, and seed production. Results: A doubling of the atmospheric CO2 concentration stimulated ragweed-pollen production by 61% (P = 0.005). Conclusions: These results suggest that there may be significant increases in exposure to allergenic pollen under the present scenarios of global warming. Further studies may enable public health groups to more accurately evaluate the future risks of hay fever and respiratory diseases (eg, asthma) exacerbated by allergenic pollen, and to develop strategies to mitigate them.	Harvard Univ, Dept Organism & Evolutionary Biol, Cambridge, MA 02138 USA; Univ Coll Dublin, Dept Stat, Dublin 2, Ireland; Harvard Univ, Sch Med, Ctr Hlth & Global Environm, Boston, MA USA	Wayne, P (reprint author), New England Sch Acupuncture, Dept Res, Watertown, MA 02472 USA.	pwayne@nesa.edu					ABULFATIH HA, 1979, NEW PHYTOL, V83, P829, DOI 10.1111/j.1469-8137.1979.tb02314.x; ACKERLY DD, 1995, GLOB CHANGE BIOL, V1, P199, DOI 10.1111/j.1365-2486.1995.tb00021.x; ACKERLY DD, 1990, OECOLOGIA, V82, P474, DOI 10.1007/BF00319788; Amthor J. S., 1997, Advances in carbon dioxide effects research. Proceedings of a symposium, Cincinnati, Ohio, USA, 7-12 November 1993., P35; ARRIGHI HM, 1995, ANN ALLERG ASTHMA IM, V74, P321; BASSETT IJ, 1975, CAN J PLANT SCI, V55, P463; BAZZAZ FA, 1982, OECOLOGIA, V54, P313, DOI 10.1007/BF00379999; BAZZAZ FA, 1990, ANNU REV ECOL SYST, V21, P167, DOI 10.1146/annurev.es.21.110190.001123; CONROY JP, 1994, AUST J PLANT PHYSIOL, V21, P741; Curtis PS, 1998, OECOLOGIA, V113, P299, DOI 10.1007/s004420050381; Curtis PS, 1996, PLANT CELL ENVIRON, V19, P127, DOI 10.1111/j.1365-3040.1996.tb00234.x; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P566, DOI 10.1111/j.1365-2222.1994.tb00954.x; Emberlin J, 1997, GRANA, V36, P29; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Epstein PR, 1999, SCIENCE, V285, P347, DOI 10.1126/science.285.5426.347; EPSTEIN PR, 1995, AM J PUBLIC HEALTH, V85, P168, DOI 10.2105/AJPH.85.2.168; FARNSWORTH EJ, 1995, OECOLOGIA, V104, P454, DOI 10.1007/BF00341343; Fitzpatrick Thomas B., 1996, Journal of Dermatology (Tokyo), V23, P816; GRIFFITH IJ, 1991, INT ARCH ALLER A IMM, V96, P296; Houghton JT, 1996, CLIMATE CHANGE 1995; HUNTLEY B, 1991, ANN BOT-LONDON, V67, P15; Jaeger S, 1996, GRANA, V35, P171, DOI [10.1080/00173139609429078, DOI 10.1080/00173139609429078]; Lewis W. H., 1983, AIRBORNE ALLERGENIC; LOEVINSOHN ME, 1994, LANCET, V343, P714, DOI 10.1016/S0140-6736(94)91586-5; MCKONE MJ, 1986, OECOLOGIA, V70, P63, DOI 10.1007/BF00377111; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; NICHOLLS N, 1993, LANCET, V342, P1284, DOI 10.1016/0140-6736(93)92368-4; [Anonymous], 1993, NIH PUBL; PAYNE WW, 1963, AM J BOT, V50, P872, DOI 10.2307/2439774; POORTER H, 1993, VEGETATIO, V104, P77, DOI 10.1007/BF00048146; RAYNAL DJ, 1973, ECOLOGY, V54, P1335, DOI 10.2307/1934196; REEKIE JYC, 1994, CAN J BOT, V72, P533; TYREE MT, 1993, VEGETATIO, V104, P47, DOI 10.1007/BF00048144; WUTHRICH B, 1991, ALLERGY CLIN IMMUNOL, V3, P41; ZISKA LH, 2000, WORLD RESOURCE REV, V12, P449	35	153	159	0	21	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	MAR	2002	88	3					279	282				4	Allergy; Immunology	Allergy; Immunology	532ZX	WOS:000174505900006	11926621	
J	Pajno, GB; Morabito, L; Barberio, G; Parmiani, S				Pajno, GB; Morabito, L; Barberio, G; Parmiani, S			Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study	ALLERGY			English	Article						asthma; dust-mite allergy; sublingual immunotherapy (SLIT)	HOUSE-DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; CONTROLLED TRIAL; POLLEN EXTRACT; SWALLOW IMMUNOTHERAPY; EFFICACY; RHINITIS; RHINOCONJUNCTIVITIS; INFLAMMATION	Background: Immunotherapy through local routes is thought to be a valuable therapeutic option for respiratory allergy. We investigated the clinical efficacy and immunologic effects of sublingual immunotherapy (SLIT) in asthmatic children with mite-induced respiratory allergy. Methods: Twenty-four patients (age range 8-15 years), suffering from mild to moderate asthma, with single sensitization to mite allergen, were enrolled. After a 1-year observation phase, patients were randomly allocated to one of two groups, and were given SLIT (sublingual-spit) as drops for 2 years according to a double-blind, placebo-controlled (DBPC) design. Symptoms/medication scores (diary card), visual analog scale, and immunologic parameters (house-dust-mite [HDM]-specific IgE, and total HDM-specific IgG and IgG4) were determined during the observation phase and during the DBPC treatment period. Results: Twenty-one patients completed the study. At the beginning of the treatment, no difference in environmental allergenic pressure could be shown between the groups. After 2 years of therapy, there was a significant decrease ill asthmatic symptoms (P = 0.0001) and medication use (P = 0.0001) in the active group compared to the placebo group. The visual analog score on overall asthma symptoms improved in the SLIT group (P = 0.0001), but not in the placebo group. Nevertheless, the immunologic results did not show significant differences in HDM-specific IgE and total HDM-specific IgG or IgG4 between the active and placebo groups (P = NS). No relevant side-effects were recorded throughout the study. Conclusions: Our results suggest that treatment for 2 years with SLIT is clinically safe and effective in significantly decreasing respiratory symptoms in children with mild to moderate asthma sensitized to HDM. On the other hand, the lack of changes of the immunologic parameters calls for further investigations with special reference to kinetics and mechanism(s) of action of this mode of treatment.	Univ Messina, Policlin Univ, Ist Clin Pediat, I-98124 Messina, Italy; ALK Abello SpA, Milan, Italy	Pajno, GB (reprint author), Univ Messina, Policlin Univ, Ist Clin Pediat, Via Consolare Valeria,Gazzi, I-98124 Messina, Italy.						Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; BLOCK JH, 1927, J LAB CLIN MED, V12, P1156; BOUSQUET J, 1994, DRUG SAFETY, V10, P5; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; CARREIRA J, 1984, CLIN ALLERGY, V14, P503, DOI 10.1111/j.1365-2222.1984.tb02236.x; CARREIRA J, 1994, NEW DEV IN VITRO MET; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; DELACOURT C, 1994, ALLERGY, V49, P843, DOI 10.1111/j.1398-9995.1994.tb00785.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Malling HJ, 1996, CLIN EXP ALLERGY, V26, P1228, DOI 10.1111/j.1365-2222.1996.tb00517.x; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Malling HJ, 1993, ALLERGY          S14, V48, P7; MALLING HJ, 1987, ALLERGY, V43, P60; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; *NHLBI, 1995, PUBL NAT HEART LUNG; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Ventas P, 1990, REV ESP ALERGOL IMMU, V5, P71; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WARNER JO, 1978, LANCET, V2, P912; ZIMMERMANN B, 1998, J ALLERGY CLIN IMMUN, V81, P71; [Anonymous], 1991, J ALLERGY CLIN IMMUN, V88, P425	35	153	158	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	SEP	2000	55	9					842	849		10.1034/j.1398-9995.2000.00495.x		8	Allergy; Immunology	Allergy; Immunology	348FP	WOS:000088975100007	11003448	
J	Cabana, MD; Ebel, BE; Cooper-Patrick, L; Powe, NR; Rubin, HR; Rand, CS				Cabana, MD; Ebel, BE; Cooper-Patrick, L; Powe, NR; Rubin, HR; Rand, CS			Barriers pediatricians face when using asthma practice guidelines	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article; Proceedings Paper	Annual Conference of the Society-for-Medical-Decision-Making	OCT 24-28, 1998	BOSTON, MASSACHUSETTS	Soc Med Decis Making			CLINICAL-PRACTICE GUIDELINES; INNER-CITY CHILDREN; PHYSICIANS ATTITUDES; RANDOMIZED TRIAL; CARE; IMPLEMENTATION; EDUCATION; INTERVENTION; MANAGEMENT; PARENTS	Objective: To describe barriers to the successful use of the 1997 National Heart, Lung, and Blood Institute (NHLBI) asthma guidelines. Methods; We conducted 3 focus groups to understand barriers to the use of 4 recommendations within the NHLBI guidelines (prescription of inhaled corticosteroids, recommendation of daily peak flowmeter use, smoking cessation screening and counseling, and allergen exposure counseling). Participants: Twenty-one pediatricians and 1 nurse practitioner, who each followed an average of 47 patients with asthma, participated. Six participants (27%) had a faculty or adjunct appointment at a medical school. Nineteen (90%) of the 21 pediatricians were board certified. Results: We identified 171 comments about barriers to adherence. Type of recommendation and physician year of graduation from medical school were related to which barrier was prominent. For corticosteroid prescription, senior physicians mentioned lack of agreement, whereas younger physicians described lack of confidence in dosing or recognizing contraindications. For peak flowmeter use, senior physicians emphasized lack of training. Only senior physicians described the inertia of previous practice as a barrier. All groups mentioned time limitations. Conclusions: Efforts to improve adherence to asthma guidelines should consider the range of barriers that pediatricians face, such as lack of awareness, familiarity, or agreement, and external barriers owing to environmental, guideline, or patient factors. In addition, this study documents barriers not previously considered, such as lack of self-efficacy, lack of outcome expectancy, and inertia of previous practice, that prevent adherence, Be cause type of recommendation and physician demographics are related to which barriers are prominent, interventions to improve NHLBI guideline adherence should be tailored to these factors.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD USA	Cabana, MD (reprint author), Univ Michigan, Dept Pediat & Communicable Dis, Div Gen Pediat, D3202 Med Profess Bldg,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.		Ebel, Beth/F-4544-2014	Ebel, Beth/0000-0001-9310-8325			BANDURA A, 1986, SOCIAL FDN THOUGHT A; BROWN JB, 1995, JOINT COMM J QUAL IM, V21, P5; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Christakis DA, 1998, PEDIATRICS, V101, P825, DOI 10.1542/peds.101.5.825; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; CLARK NM, 1986, PATIENT EDUC COUNS, V8, P27, DOI 10.1016/0738-3991(86)90024-8; CRAIN EF, 1995, ARCH PEDIAT ADOL MED, V149, P893; CUMMINGS SR, 1989, JAMA-J AM MED ASSOC, V261, P75, DOI 10.1001/jama.261.1.75; DAVIS TC, 1994, PEDIATRICS, V93, P460; Doerschug KC, 1999, AM J RESP CRIT CARE, V159, P1735; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; FLEID MJ, 1990, CLIN PRACTICE GUIDEL; FLORES G, 1998, ANN M AMB PED ASS MA; Goodman DC, 1999, PEDIATRICS, V104, P187, DOI 10.1542/peds.104.2.187; Greer A L, 1988, Int J Technol Assess Health Care, V4, P5; GROL R, 1990, BRIT J GEN PRACT, V40, P361; GROSS CP, 1999, MED DECIS MAKING, V19, P521; Hayward RSA, 1997, CAN MED ASSOC J, V156, P1715; HENDRICSON WD, 1994, ARCH PEDIAT ADOL MED, V148, P595; Homer CJ, 1997, NEW ENGL J MED, V337, P1461, DOI 10.1056/NEJM199711133372010; HUDAK BB, 1995, PEDIATRICS, V50, P649; JACOBY I, 1986, JAMA-J AM MED ASSOC, V255, P1328, DOI 10.1001/jama.255.10.1328; James PA, 1997, J FAM PRACTICE, V45, P341; Krueger R. A., 1994, FOCUS GROUPS PRACTIC; Lagoe RJ, 1996, HEALTH CARE MANAGE R, V21, P61; LENFANT C, 1995, CIRCULATION, V91, P617; LOMAS J, 1989, NEW ENGL J MED, V321, P1306, DOI 10.1056/NEJM198911093211906; MAIMAN LA, 1988, AM J DIS CHILD, V142, P773; MAIN DS, 1995, AM J PREV MED, V11, P54; Massett HA, 1996, HEALTH EDUC RES, V11, P231, DOI 10.1093/her/11.2.231; Mittman B S, 1992, QRB Qual Rev Bull, V18, P413; *NAT HEART BLOOD L, 1997, NIH PUBL; Pathman DE, 1996, MED CARE, V34, P873, DOI 10.1097/00005650-199609000-00002; Picken HA, 1998, J GEN INTERN MED, V13, P659, DOI 10.1046/j.1525-1497.1998.00200.x; Pololi LH, 1996, J GEN INTERN MED, V11, P545, DOI 10.1007/BF02599603; POPE C, 1995, BRIT MED J, V311, P42; Premaratne UN, 1999, BRIT MED J, V318, P1251; Shye D, 1998, INT J QUAL HEALTH C, V10, P83, DOI 10.1093/intqhc/10.2.83; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; STAVISH S, 1998, PEDIAT NEWS      MAR, P38; Stone TT, 1999, AM J MED QUAL, V14, P170, DOI 10.1177/106286069901400404; TUNIS SR, 1994, ANN INTERN MED, V120, P956; Warman KL, 1999, PEDIATRICS, V103, P422, DOI 10.1542/peds.103.2.422; WEINBERG AD, 1981, J MED EDUC, V56, P174; WILSON DM, 1988, JAMA-J AM MED ASSOC, V260, P1570, DOI 10.1001/jama.260.11.1570; ZWIEFLER J, 1998, ACAD MED, V73, P1056	46	153	153	4	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	JUL	2000	154	7					685	693				9	Pediatrics	Pediatrics	332LE	WOS:000088075100007	10891020	
J	Darsow, U; Laifaoui, J; Kerschenlohr, K; Wollenberg, A; Przybilla, B; Wuthrich, B; Borelli, S; Giusti, F; Seidenari, S; Drzimalla, K; Simon, D; Disch, R; Borelli, S; Devillers, ACA; Oranje, AP; De Raeve, L; Hachem, JP; Dangoisse, C; Blondeel, A; Song, M; Breuer, K; Wulf, A; Werfel, T; Roul, S; Taieb, A; Bolhaar, S; Bruijnzeel-Koomen, C; Bronnimann, M; Braathen, LR; Didierlaurent, A; Andre, C; Ring, J				Darsow, U; Laifaoui, J; Kerschenlohr, K; Wollenberg, A; Przybilla, B; Wuthrich, B; Borelli, S; Giusti, F; Seidenari, S; Drzimalla, K; Simon, D; Disch, R; Borelli, S; Devillers, ACA; Oranje, AP; De Raeve, L; Hachem, JP; Dangoisse, C; Blondeel, A; Song, M; Breuer, K; Wulf, A; Werfel, T; Roul, S; Taieb, A; Bolhaar, S; Bruijnzeel-Koomen, C; Bronnimann, M; Braathen, LR; Didierlaurent, A; Andre, C; Ring, J			The prevalence of positive reactions in the atopy patch test with aeroallergens and food allergens in subjects with atopic eczema: a European multicenter study	ALLERGY			English	Article						aeroallergens; atopic eczema; atopy patch test; European multicenter	HOUSE-DUST MITE; EPIDERMAL LANGERHANS CELLS; DERMATITIS PATIENTS; DOUBLE-BLIND; SKIN; FREQUENCY; AVOIDANCE; INDUCTION; EXTRACTS; CHILDREN	Background: The atopy patch test (APT) was proposed to evaluate IgE-mediated sensitizations in patients with atopic eczema (AE). Objective: The prevalence and agreement with clinical history and specific IgE (sIgE) of positive APT reactions was investigated in six European countries using a standardized method. Methods: A total of 314 patients with AE in remission were tested in 12 study centers on clinically uninvolved, non-abraded back skin with 200 index of reactivity (IR)/g of house dust mite Dermatophagoides pteronyssinus, cat dander, grass, and birch pollen allergen extracts with defined major allergen contents in petrolatum. Extracts of egg white, celery and wheat flour with defined protein content were also patch tested. APT values were evaluated at 24, 48, and 72 h according to the European Task Force on Atopic Dermatitis (ETFAD) guidelines. In addition, skin-prick test (SPT) and sIgE and a detailed history on allergen-induced eczema flares were obtained. Results: Previous eczema flares, after contact with specific allergens, were reported in 1% (celery) to 34% (D. pteronyssinus) of patients. The frequency of clear-cut positive APT reactions ranged from 39% with D. pteronyssinus to 9% with celery. All ETFAD intensities occured after 48 and 72 h. Positive SPT (16-57%) and elevated sIgE (19-59%) results were more frequent. Clear-cut positive APT with all SPT and sIgE testing negative was seen in 7% of the patients, whereas a positive APT without SPT or sIgE for the respective allergen was seen in 17% of the patients. APT, SPT and sIgE results showed significant agreement with history for grass pollen and egg white (two-sided Pr > \Z\ less than or equal to 0.01). In addition, SPT and sIgE showed significant agreement with history for the other aeroallergens. With regard to clinical history, the APT had a higher specificity (64-91% depending on the allergen) than SPT (50-85%) or sIgE (52-85%). Positive APT were associated with longer duration of eczema flares and showed regional differences. In 10 non-atopic controls, no positive APT reaction was seen. Conclusion: Aeroallergens and food allergens are able to elicit eczematous skin reactions after epicutaneous application. As no gold standard for aeroallergen provocation in AE exists, the relevance of aeroallergens for AE flares may be evaluated by APT in addition to SPT and sIgE. The data may contribute to the international standardization of the APT.	Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; GSF TUM, Div Environm Dermatol & Allergy, Munich, Germany; Univ Munich, Dept Dermatol & Allergy, Munich, Germany; Univ Zurich Hosp, Dept Dermatol, CH-8091 Zurich, Switzerland; Univ Modena & Reggio Emilia, Dept Dermatol, Modena, Italy; Clin Dermatol & Allergy Davos, Davos, Switzerland; Ersamus MC Sophia Childrens Hosp, Rotterdam, Netherlands; Free Univ Brussels, Dept Dermatol, Brussels, Belgium; Queen Fabiola Childrens Univ Hosp, Brussels, Belgium; Hannover Med Sch, Dept Dermatol, D-3000 Hannover, Germany; Childrens Hosp Pellegrin, Dept Pediat Dermatol, Bordeaux, France; Univ Utrecht Hosp, Dept Dermatol, Utrecht, Netherlands; Univ Bern, Dept Dermatol, Bern, Switzerland; Stallergenes SA, Antony, France	Darsow, U (reprint author), Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.						BIEBER T, 1989, J EXP MED, V170, P309, DOI 10.1084/jem.170.1.309; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; BRUIJNZEELKOOME.C, 1988, BRIT J DERMATOL, V118, P229; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; Darsow U, 1999, J AM ACAD DERMATOL, V40, P187, DOI 10.1016/S0190-9622(99)70186-6; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; de Bruin-Weller MS, 1999, ALLERGY, V54, P784; GONDO A, 1986, BRIT J DERMATOL, V115, P485, DOI 10.1111/j.1365-2133.1986.tb06243.x; Heinemann C, 2002, ALLERGY, V57, P641, DOI 10.1034/j.1398-9995.2002.23438.x; Ingordo V, 2002, J EUR ACAD DERMATOL, V16, P450, DOI 10.1046/j.1468-3083.2002.00525.x; Johansson C, 2003, BRIT J DERMATOL, V148, P479, DOI 10.1046/j.1365-2133.2003.05093.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KAUFMAN HS, 1974, ANN ALLERGY, V32, P321; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P869, DOI 10.1067/mai.2003.1347; Kerschenlohr K, 2003, J ALLERGY CLIN IMMUN, V111, P195, DOI 10.1067/mai.2003.1; Langeveld-Wildschut EG, 2000, J ALLERGY CLIN IMMUN, V105, P1008, DOI 10.1067/mai.2000.106544; MAEDA K, 1992, Journal of Dermatological Science, V3, P73, DOI 10.1016/0923-1811(92)90038-D; MANZINI BM, 1995, CONTACT DERMATITIS, V33, P243, DOI 10.1111/j.1600-0536.1995.tb00475.x; MITCHELL EB, 1982, LANCET, V1, P127; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; NORRIS PG, 1988, BRIT J DERMATOL, V118, P435, DOI 10.1111/j.1365-2133.1988.tb02440.x; Oosting AJ, 2002, J ALLERGY CLIN IMMUN, V110, P500, DOI 10.1067/mai.2002.126791; RAJKA G, 1989, ESSENTIAL ASPECTS AT; Ring J, 1996, DERMATOL THER, V1, P51; Ring J, 1989, J ALLERGY CLIN IMMUN, V82, P195; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Rostenberg A, 1937, ARCH DERMATOL SYPH, V35, P433; Ruzicka T, 1991, HDB ATOPIC ECZEMA; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Seidenari S, 2003, ALLERGY, V58, P426, DOI 10.1034/j.1398-9995.2003.00142.x; SEIDENARI S, 1992, ANN ALLERGY, V69, P201; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; TANAKA Y, 1990, Journal of Dermatological Science, V1, P361, DOI 10.1016/0923-1811(90)90593-3; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; VADER PCV, 1991, ACTA DERM-VENEREOL, V71, P301; VANREIJSEN FC, 1992, J ALLERGY CLIN IMMUN, V90, P184, DOI 10.1016/0091-6749(92)90070-I; WOLLENBERG A, 1993, J EXP MED, V178, P777, DOI 10.1084/jem.178.3.777; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596	39	152	158	1	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	DEC	2004	59	12					1318	1325		10.1111/j.1398-9995.2004.00556.x		8	Allergy; Immunology	Allergy; Immunology	865WV	WOS:000224735800011	15507101	
J	Kagawa, J				Kagawa, J			Health effects of diesel exhaust emissions - a mixture of air pollutants of worldwide concern	TOXICOLOGY			English	Article; Proceedings Paper	9th International Congress of Toxicology (ICT IX)	JUL 08-12, 2001	QUEENSLAND, AUSTRALIA			health effects; diesel exhaust; diesel particles		Diesel exhaust is a mixture of particles and gases. It contains more than several hundred different organic and inorganic components, including many chemicals that have been designated as toxic air pollutants. Because mutagens and carcinogens are present in both the gaseous and particulate components, lung cancer has been the focus of attention as a health risk in animal and human research. Moreover, since the epidemiologic data suggest carcinogenicity in humans, and the diesel exhaust exposure data in evaluations in rats by NIOSH, IARC, WHO, and the California EPA, are said to demonstrate or support carcinogenicity, agencies have designated them as latent occupational carcinogens (NIOSH) or toxic air pollutants (California EPA). In regard to their non-carcinogenic effects, a contribution to airway inflammation and allergies, and in relation to disease, the possibility of contracting asthma and chronic bronchitis, have been investigated both experimentally and epidemiologically, and concern has increased about their health effects, particularly in children. (C) 2002 Published by Elsevier Science Ireland Ltd.	Tokyo Womens Med Univ, Sch Med, Dept Hyg & Publ Hlth, Shinjuku Ku, Tokyo 1628666, Japan	Kagawa, J (reprint author), Tokyo Womens Med Univ, Sch Med, Dept Hyg & Publ Hlth, Shinjuku Ku, 8-1 Kawada Cho, Tokyo 1628666, Japan.						*HEI, 1999, PROGR SUMM RES DIES; *HEI, 1995, DIES EXH CRIT AN EM; International Agency for Research on Cancer, 1989, MON EV CARC RISKS HU, V46; *JAP AUT RES I, 1994, REP AUT EM CHRON OBS; *JAP ENV AG DEP EN, 1999, STUD REP RES METH HL; *JAP ENV AG HLTH R, 2000, INT REP HLTH RISK AS; Kato A, 2000, INHAL TOXICOL, V12, P469, DOI 10.1080/089583700402879; Mauderly JL, 1996, INHAL TOXICOL S, V8, P1; McClellan R.O., 1996, INHAL TOXICOL S, V8, P193; National Institute for Occupational Safety and Health, 1988, NIOSH CURR INT B, V50; *OFF ENV HLTH HAZ, 1998, HLTH RISK ASS DIES E; *US EPA, 1999, EPA600890057D NAT CT; *WHO, 1996, ENV HLTH CRIT, V171	13	84	89	1	21	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-483X			TOXICOLOGY	Toxicology	DEC 27	2002	181						349	353	PII S0300-483X(02)00461-4	10.1016/S0300-483X(02)00461-4		5	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	639TX	WOS:000180646400060	12505335	
J	Hermiz, O; Comino, E; Marks, G; Daffurn, K; Wilson, S; Harris, M				Hermiz, O; Comino, E; Marks, G; Daffurn, K; Wilson, S; Harris, M			Randomised controlled trial of home based care of patients with chronic obstructive pulmonary disease	BRITISH MEDICAL JOURNAL			English	Article							AIR-FLOW LIMITATION; RESPIRATORY QUESTIONNAIRE; COPD; EXACERBATIONS; PROGRAM; ASTHMA	Objectives To evaluate usefulness of limited community based care for patients with chronic obstructive pulmonary disease after discharge from hospital. Design Randomised controlled trial. Setting Liverpool Health Service and Macarthur Health Service in outer metropolitan Sydney between September 1999 and July 2000. Participants 177 patients randomised into an intervention group (84 patients) and a control group (93 patients) which received current usual care. Interventions Home visits by community nurse at one and four weeks after discharge and preventive general practitioner care. Main outcome measures Frequency of patients' presentation and admission to hospital; changes in patients' disease-specific quality of life, measured with St George's respiratory questionnaire, over three months after discharge; patients' knowledge of illness, self management, and satisfaction with care at discharge and three months later; frequency of general practitioner and nurse visits and their satisfaction with care. Results Intervention and control groups showed no differences in presentation or admission to hospital or in overall functional status. However, the intervention group improved their activity scores and the control group worsened their symptom scores. While intervention group patients received more visits from community nurses and were more satisfied with their care, involvement of general practitioners was much less (with only 31% (22) remembering receiving a care plan). Patients in the intervention group had higher knowledge scores and were more satisfied. There were no differences in general practitioner visits or management. Conclusions This brief intervention after acute care improved patients' knowledge and some aspects of quality of life. However, it failed to prevent presentation and readmission to hospital.	Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia; Liverpool Hlth Serv, Div Crit Care, Sydney, NSW, Australia; SW Sydney Area Hlth Serv, Macarthur Hlth Serv, Sydney, NSW, Australia	Harris, M (reprint author), Univ New S Wales, Sch Community Med, Sydney, NSW 2052, Australia.						Blakeman T, 2001, Aust Fam Physician, V30, P75; Crockett AJ, 1996, QUAL LIFE RES, V5, P330, DOI 10.1007/BF00433917; Crockett AJ, 2000, INT J QUAL HEALTH C, V12, P41, DOI 10.1093/intqhc/12.1.41; Farrero E, 2001, CHEST, V119, P364, DOI 10.1378/chest.119.2.364; Fried TR, 1998, J GEN INTERN MED, V13, P522, DOI 10.1046/j.1525-1497.1998.00162.x; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812; Gibson P G, 1998, J Qual Clin Pract, V18, P125; GIBSON PG, 1988, J QUAL CLIN PRACT, V18, P125; Gravil JH, 1998, LANCET, V351, P1853, DOI 10.1016/S0140-6736(97)11048-0; JONES PW, 1991, RESP MED, V85, P25, DOI 10.1016/S0954-6111(06)80166-6; Keenan SP, 2000, CRIT CARE MED, V28, P2094, DOI 10.1097/00003246-200006000-00072; Ketelaars CAJ, 1998, HEART LUNG, V27, P109, DOI 10.1016/S0147-9563(98)90018-8; Madison JM, 1998, LANCET, V352, P467, DOI 10.1016/S0140-6736(97)11081-9; Rutten-van Molken M, 1999, THORAX, V54, P995; *S W SYDN AR HLTH, 1998, EP UN REP COPD ASTHM; Skwarska E, 2000, THORAX, V55, P907, DOI 10.1136/thorax.55.11.907; SMITH B, 2000, COCHRANE DATABASE SY, DOI UNSP CD000994; Smith BJ, 1999, AUST NZ J MED, V29, P718, DOI 10.1111/j.1445-5994.1999.tb01621.x; Strijbos JH, 1996, CHEST, V109, P366, DOI 10.1378/chest.109.2.366; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; TRAVER GA, 1988, HEART LUNG, V17, P689; [Anonymous], 1987, AM REV RESP DIS, V136, P225	22	84	85	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	OCT 26	2002	325	7370					938	940C		10.1136/bmj.325.7370.938		6	Medicine, General & Internal	General & Internal Medicine	610XB	WOS:000178986300017	12399344	
J	Hammad, H; Lambrecht, BN; Pochard, P; Gosset, P; Marquillies, P; Tonnel, AB; Pestel, J				Hammad, H; Lambrecht, BN; Pochard, P; Gosset, P; Marquillies, P; Tonnel, AB; Pestel, J			Monocyte-derived dendritic cells induce a house dust mite-specific Th2 allergic inflammation in the lung of humanized SCID mice: Involvement of CCR7	JOURNAL OF IMMUNOLOGY			English	Article							EOSINOPHILIC AIRWAY INFLAMMATION; LYMPH-NODES; INHALED ANTIGEN; INTRATRACHEAL INSTILLATION; LACKING EXPRESSION; RESPIRATORY-TRACT; RESPONSES; CHEMOKINE; ASTHMA; MODEL	In rodents, airway dendritic cells (DCs) capture inhaled Ag, undergo maturation, and migrate to the draining mediastinal lymph nodes (MLN) to initiate the Ag-specific T cell response. However, the role of human DCs in the pathogenesis of the Th2 cell-mediated disease asthma remains to be clarified. Here, by using SCID mice engrafted with T cells from either house dust mite (HDM)-allergic patients or healthy donors, we show that DCs pulsed with Der p 1, one of the major allergens or HDM, and injected intratracheally into naive animals migrated into the MLN. In the NILN, Der p I-pulsed DCs from allergic patients induced the proliferation of IL-4-producing CD4(+) T cells, whereas those from healthy donors induced IFN-gamma-secreting cells. In reconstituted human PBM C-reconstituted SCID mice primed with pulsed DCs from allergic patients, repeated exposure to aerosols of HDM induced 1) a strong pulmonary inflammatory reaction rich in T cells and eosinophils, 2) an increase in IL-4 and IL-5 production in the lung lavage fluid, and 3) increased IgE production compared with that in mice primed with unpulsed DCs. All these effects were reduced following in vivo neutralization of the CCR7 ligand secondary lymphoid tissue chemokine. These data in human PBMC-reconstituted SCID mice show that monocyte-derived DCs might play a key role in the pathogenesis of the pulmonary allergic response by inducing Th2 effector function following migration to the MLN.	Inst Pasteur, Inst Natl Sante & Rech Med, Unit 416, Lille, France; Erasmus Univ, Dept Pulm & Crit Care Med, Rotterdam, Netherlands; Ctr Hosp Reg Univ Lille, Hop Calmette, Clin Malad Respiratoires, Lille, France	Pestel, J (reprint author), Inst Pasteur, Inst Natl Sante & Rech Med, Unit 416, 1 Rue Prof Clamette,BP 24559019, Lille, France.		Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834			Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bellinghausen I, 2000, J ALLERGY CLIN IMMUN, V105, P988, DOI 10.1067/mai.2000.105526; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Cochand L, 1999, AM J RESP CELL MOL, V21, P547; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; De Wit D, 2000, J ALLERGY CLIN IMMUN, V105, P346, DOI 10.1016/S0091-6749(00)90086-1; Duez C, 1996, EUR J IMMUNOL, V26, P1088, DOI 10.1002/eji.1830260520; Duez C, 1998, SCAND J IMMUNOL, V47, P110; Engeman TM, 2000, J IMMUNOL, V164, P5207; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2000, LAB INVEST, V80, P605; HAVENITH CEG, 1993, AM J RESP CELL MOL, V9, P484; HOLT PG, 1994, J IMMUNOL, V153, P256; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Iezzi G, 1999, EUR J IMMUNOL, V29, P4092, DOI 10.1002/(SICI)1521-4141(199912)29:12<4092::AID-IMMU4092>3.3.CO;2-1; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kellermann SA, 1999, J IMMUNOL, V162, P3859; KUEZ C, 2000, AM J RESP CRIT CARE, V161, P200; Lambrecht B N, 2001, Curr Opin Allergy Clin Immunol, V1, P51, DOI 10.1097/00130832-200102000-00010; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 2000, CLIN EXP ALLERGY, V30, P214; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; LYONS AB, 1994, J IMMUNOL METHODS, V171, P131, DOI 10.1016/0022-1759(94)90236-4; MACKAY CR, 1990, J EXP MED, V171, P801, DOI 10.1084/jem.171.3.801; MANZ R, 1995, P NATL ACAD SCI USA, V92, P1921, DOI 10.1073/pnas.92.6.1921; Mori S, 2001, J EXP MED, V193, P207, DOI 10.1084/jem.193.2.207; PESTEL J, 1994, J IMMUNOL, V153, P3804; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Vermaelen KY, 2001, J EXP MED, V193, P51; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275	40	84	86	0	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2002	169	3					1524	1534				11	Immunology	Immunology	576UV	WOS:000177025100048	12133980	
J	Woessner, KM; Simon, RA; Stevenson, DD				Woessner, KM; Simon, RA; Stevenson, DD			The safety of celecoxib in patients with aspirin-sensitive asthma	ARTHRITIS AND RHEUMATISM			English	Article							CYCLOOXYGENASE-2 INHIBITOR; INTOLERANT PATIENTS; CROSS-SENSITIVITY; COX-2; PATHOGENESIS; EXPRESSION; DRUGS	Objective. To determine whether celecoxib, a selective cyclooxygenase 2 (COX-2) inhibitor, cross-reacts in patients with aspirin-exacerbated respiratory disease (AERD) with asthma. Methods. Sixty patients with asthma underwent double-blinded, placebo-controlled oral challenges with celecoxib (100 mg, 200 mg, and 2 placebos) over 48 hours in our General Clinical Research Center. The next day, sensitivity to acetylsalicylic acid (ASA) was proven in all patients with the use of single-blinded ASA challenges. Results. None of the 60 patients experienced any symptoms, changes in nasal examinations, or declines in forced expiratory volume in 1 second during the celecoxib challenges. All 60 patients experienced oculo-nasal and/or asthmatic reactions to ASA, with a mean provoking dose of 69 mg. The exact 1-sided confidence interval for the probability of celecoxib inducing cross-reactions in AERD patients was calculated to be between 0% and 5%. Conclusion. Cross-reactivity between ASA and celecoxib does not occur in patients with AERD. These results do not preclude the possibility of other types of immune reactions occurring with celecoxib after prior exposure. Our results add to the growing body of evidence that inhibition of COX-1 is a critical initiating event in the precipitation of respiratory reactions in AERD patients following ingestion of nonsteroidal anti-inflammatory drugs.	Scripps Clin, Div Allergy Asthma & Immunol, La Jolla, CA 92037 USA	Woessner, KM (reprint author), Scripps Clin, Div Allergy Asthma & Immunol, 10666 N Torrey Pines Rd,W-205, La Jolla, CA 92037 USA.	woessner@scripps.edu			NCRR NIH HHS [M01-RR-0883]		ANDRI L, 1994, ANN ALLERGY, V72, P29; Dahlen B, 2001, NEW ENGL J MED, V344, P142, DOI 10.1056/NEJM200101113440215; Demoly P, 1997, AM J RESP CRIT CARE, V155, P670; FISCHER AR, 1994, J ALLERGY CLIN IMMUN, V94, P1046, DOI 10.1016/0091-6749(94)90123-6; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; HAMBERG M, 1974, P NATL ACAD SCI USA, V71, P3400, DOI 10.1073/pnas.71.9.3400; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Kosnik M, 1998, ALLERGY, V53, P1231, DOI 10.1111/j.1398-9995.1998.tb03854.x; Lehman E. L., 1986, TESTING STAT HYPOTHE; Levy MB, 2001, ANN ALLERG ASTHMA IM, V87, P72; *MED EC, 2001, PHYSICIANS DESK REFE; NIZANKOWSKA E, 1989, ANN ALLERGY, V63, P159; Pauls JD, 2000, ANN ALLERG ASTHMA IM, V85, P40; Schellenberg RR, 2001, NEW ENGL J MED, V345, P1856, DOI 10.1056/NEJM200112203452518; SETTIPANE RA, 1989, J ALLERGY CLIN IMMUN, V84, P26, DOI 10.1016/0091-6749(89)90174-7; Sousa AR, 1997, THORAX, V52, P940; SPECTOR SL, 1979, J ALLERGY CLIN IMMUN, V64, P500, DOI 10.1016/0091-6749(79)90059-9; Stevenson DD, 2000, J ALLERGY CLIN IMMUN, V105, pS273, DOI 10.1016/S0091-6749(00)91234-X; Stevenson DD, 2000, ANN ALLERG ASTHMA IM, V85, P477; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; STEVENSON DD, 1990, J ALLERGY CLIN IMMUN, V86, P749, DOI 10.1016/S0091-6749(05)80179-4; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2001, ANN ALLERG ASTHMA IM, V87, P177; Stevenson DD, 1998, ALLERGY PRINCIPLES P, P1225; SZCZEKLIK A, 1979, THORAX, V34, P654, DOI 10.1136/thx.34.5.654; Szczeklik A, 1999, J ALLERGY CLIN IMMUN, V104, P5, DOI 10.1016/S0091-6749(99)70106-5; SZCZEKLIK A, 1977, J ALLERGY CLIN IMMUN, V60, P276, DOI 10.1016/0091-6749(77)90106-3; SZCZEKLIK A, 1990, EUR RESPIR J, V3, P588; Szczeklik A, 2001, CLIN EXP ALLERGY, V31, P219, DOI 10.1046/j.1365-2222.2001.01075.x; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692; Yoshida S, 2000, J ALLERGY CLIN IMMUN, V106, P1201	32	84	85	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0004-3591			ARTHRITIS RHEUM	Arthritis Rheum.	AUG	2002	46	8					2201	2206		10.1002/art.10426		6	Rheumatology	Rheumatology	583WB	WOS:000177432800029	12209526	
J	Hogman, M; Holmkvist, T; Wegener, T; Emtner, M; Andersson, M; Hedenstrom, H; Merilainen, P				Hogman, M; Holmkvist, T; Wegener, T; Emtner, M; Andersson, M; Hedenstrom, H; Merilainen, P			Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis	RESPIRATORY MEDICINE			English	Article						nitric oxide; asthma; allergic rhinitis; smoker; COPD; airway inflammation; method	EXHALED NITRIC-OXIDE; RESPONSIVENESS; DISEASE; AIRWAYS; AIR	The recommended method to measure exhaled nitric oxide (NO) cannot reveal the source of NO production. We applied a model based on the classical Fick's first law of diffusion to partition NO in the lungs. The aim was to develop a simple and robust solution algorithm with a data quality control feature, and apply it to patients with known alterations in exhaled NO. Subjects with allergic rhinitis, allergic asthma, chronic obstructive pulmonary disease (COPD) smokers and controls were investigated. NO was measured at three expiratory flow rates. An iteration method was developed to partition NO. The airway tissue content of NO was increased in asthma, 144 +/- 80 ppb (P = 0(.)04) and decreased in smokers, 56 +/- 36 ppb (P = 0(.)02). There was no difference between subjects with rhinitis, 98 +/- 40 ppb and controls, 98 +/- 44 ppb. The airway transfer rate was increased in allergic asthma and allergic rhinithis, 12 +/- 4 vs. 12 +/- 5 ml sec(-1), compared to controls, 8 +/- 2 ml sec(-1) (P < 0(.)001). The alveolar levels were no different from controls, 2 +/- 1 ppb. In COPD the alveolar levels were increased, 4 +/- 2 ppb (P < 0(.)001). Extended NO analysis reveals from where in the respiratory system NO is generated. Hence, this new test can be added to the tools the physician has for the diagnosis and treatment of patients with respiratory disorders. (C) 2001 Harcourt Publishers Ltd.	Univ Uppsala, Dept Med Sci, SE-75123 Uppsala, Sweden	Hogman, M (reprint author), Univ Uppsala, Dept Med Cell Biol, Sect Integrat Physiol, Box 571, SE-75123 Uppsala, Sweden.						ALVING K, 1993, EUR RESPIR J, V6, P1368; ASSREUY J, 1993, BRIT J PHARMACOL, V108, P833; BLAND JM, 1986, LANCET, V1, P307; Clini E, 1998, THORAX, V53, P881; Corradi M, 1999, THORAX, V54, P572; FICK A, 1856, MED PHYSIK; Gow AJ, 1999, P NATL ACAD SCI USA, V96, P9027, DOI 10.1073/pnas.96.16.9027; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Hogman M, 2000, RESP MED, V94, P985, DOI 10.1053/rmed.2000.0872; Hogman M, 1997, ACTA PHYSIOL SCAND, V159, P345, DOI 10.1046/j.1365-201X.1997.00101.x; Hogman M, 1999, AM J RESP CRIT CARE, V159, pA862; Jorres RA, 2000, EUR RESPIR J, V16, P555, DOI 10.1034/j.1399-3003.2000.016003555.x; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Ludviksdottir D, 1999, RESP MED, V93, P552, DOI 10.1016/S0954-6111(99)90154-3; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653	18	84	84	1	8	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0954-6111			RESP MED	Respir. Med.	JAN	2002	96	1					24	30		10.1053/rmed.2001.1204		7	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	521YY	WOS:000173870000005	11863206	
J	Ma, JYC; Ma, JKH				Ma, JYC; Ma, JKH			The dual effect of the particulate and organic components of diesel exhaust particles on the alteration of pulmonary immune/inflammatory responses and metabolic enzymes	JOURNAL OF ENVIRONMENTAL SCIENCE AND HEALTH PART C-ENVIRONMENTAL CARCINOGENESIS & ECOTOXICOLOGY REVIEWS			English	Review						diesel exhaust particles (DEP); particulate; organic extract; reactive oxygen species (ROS); metabolic enzymes; th1 and th2 immune responses; cytokines; infection; allergy; lung tumors	TUMOR-NECROSIS-FACTOR; CYTOCHROME P450 REDUCTASE; RAT ALVEOLAR MACROPHAGES; CELL-MEDIATED-IMMUNITY; OXIDATIVE DNA-DAMAGE; CARBON-BLACK; NITRIC-OXIDE; LISTERIA-MONOCYTOGENES; HEME OXYGENASE-1; IN-VIVO	Exposure to diesel exhaust particles (DEP) is an environmental and occupational health concern. This review examines the cellular actions of the organic and the particulate components of DEP in the development of various lung diseases. Both the organic and the particulate components cause oxidant lung injury. The particulate component is known to induce alveolar epithelial damage, alter thiol levels in alveolar macrophages (AM) and lymphocytes, and activate AM in the production of reactive oxygen species (ROS) and pro-inflammatory cytokines. The organic component, on the other hand, is shown to generate intracellular ROS, leading to a variety of cellular responses including apoptosis. There are a number of differences between the biological actions exerted by these two components. The organic component is responsible-for DEP induction of cytochrome P450 family 1 enzymes that are critical to the polycyclic aromatic hydrocarbons (PAH) and nitro-PAH metabolism in the lung as well as in the liver. The particulate component, on the other hand, causes a sustained down-regulation of CYP2B1 in the rat lung. The significance of this effect on pulmonary metabolism of xenobiotics and endobiotics remains to be seen, but may prove to be an important factor governing the interplay of the pulmonary metabolic and inflammatory systems. Long-term exposures to various particles including DEP, carbon black (CB), TiO(2), and washed DEP devoid of the organic content, have been shown to produce similar tumorigenic responses in rodents. There is a lack of correlation between tumor development and DEP chemical-derived DNA adduct formation. But the organic component has been shown to generate ROS that produce 8-hydroxydeoxyguanosine (8-OHdG) in cell culture. The organic, but not the particulate, component of DEP suppresses the production of pro-inflammatory cytokines by AM and the development of Th1 cell-mediated immunity. The mechanism for this effect is not yet clear, but may involve the induction of heme oxygenase-1 (HO-1), a cellular genetic response to oxidative stress. Both the organic and the particulate components of DEP enhance respiratory allergic sensitization. Part of the DEP effects may be due to a depletion of glutathione in lymphocytes. The organic component, which is shown to induce IL-4 and IL-10 productions, may skew the immunity toward Th2 response, whereas the particulate component may stimulate both the Th1 and Th2 responses. In conclusion, the literature shows that the particulate and organic components of DEP exhibit different biological actions but both involve the induction of cellular oxidative stress. Together, these effects inhibit cell-mediated immunity toward infectious agents, exacerbate respiratory allergy, cause DNA damage, and under long-term exposure, induce the development of lung tumors.	W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA; NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Ma, JKH (reprint author), W Virginia Univ, Sch Pharm, Morgantown, WV 26506 USA.	jma@hsc.wvu.edu			NHLBI NIH HHS [R01 HL-62630]		Al-Humadi NH, 2002, ENVIRON HEALTH PERSP, V110, P349; Al-Humadi NH, 2002, EXP LUNG RES, V28, P333, DOI 10.1080/01902140290091976; American Thoracic Society Workshop, 1999, AM J RESP CRIT CARE, V160, P1778; Arimoto T, 1999, JPN J PHARMACOL, V80, P49, DOI 10.1254/jjp.80.49; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; Bhagwat SV, 1999, TOXICOL APPL PHARM, V156, P231, DOI 10.1006/taap.1999.8646; BOND JA, 1990, ENVIRON MOL MUTAGEN, V16, P64, DOI 10.1002/em.2850160203; BOND JA, 1990, TOXICOLOGY, V60, P127, DOI 10.1016/0300-483X(90)90167-F; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515; Bouton C, 2000, J BIOL CHEM, V275, P32688, DOI 10.1074/jbc.275.42.32688; Campbell P A, 1994, Immunol Ser, V60, P313; Castranova V, 2001, ENVIRON HEALTH PERSP, V109, P609, DOI 10.2307/3454678; CASTRANOVA V, 1985, ENVIRON RES, V36, P405, DOI 10.1016/0013-9351(85)90034-9; CHRISTOU M, 1987, ARCH BIOCHEM BIOPHYS, V258, P519, DOI 10.1016/0003-9861(87)90374-2; CONNEY AH, 1982, CANCER RES, V42, P4874; Czekaj P, 2000, ACTA BIOCHIM POL, V47, P1115; Demple B, 1999, BRAZ J MED BIOL RES, V32, P1417; *DEP LAB, 1998, FED REGISTER, V63, P58104; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dinsdale D, 2001, BIOCHEM PHARMACOL, V61, P493, DOI 10.1016/S0006-2952(00)00572-4; DONG CY, 1998, THESIS W VIRGINIA U; DRAPER WM, 1986, CHEMOSPHERE, V15, P437, DOI 10.1016/0045-6535(86)90537-0; DRISCOLL KE, 1990, AM J RESP CELL MOL, V2, P381; EAGLESTON PA, 1999, ENVIRON HEALTH PER S, V107, P439; Fahy O, 2000, AM J RESP CELL MOL, V23, P247; Ferrari L, 2001, MOL PHARMACOL, V60, P209; Fleming SD, 1999, J LEUKOCYTE BIOL, V66, P961; Foster PS, 1997, MEM I OSWALDO CRUZ, V92, P55, DOI 10.1590/S0074-02761997000800009; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; Furman GM, 1998, J TOXICOL ENV HEAL A, V54, P633; GALLAGHER J, 1994, CARCINOGENESIS, V15, P1291, DOI 10.1093/carcin/15.7.1291; GERMOLEC DR, 1995, BIOCHEM PHARMACOL, V50, P1495, DOI 10.1016/0006-2952(95)02062-4; Ghanayem BI, 2000, TOXICOL PATHOL, V28, P839, DOI 10.1177/019262330002800613; GMUNDER H, 1990, CELL IMMUNOL, V129, P32, DOI 10.1016/0008-8749(90)90184-S; GMUNDER H, 1991, CELL IMMUNOL, V138, P229, DOI 10.1016/0008-8749(91)90147-4; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; HAHON N, 1982, ENVIRON RES, V28, P443, DOI 10.1016/0013-9351(82)90141-4; HAMILOS DL, 1991, INT J IMMUNOL PHARM, V13, P79; HANDA T, 1983, ENVIRON INT, V9, P335, DOI 10.1016/0160-4120(83)90123-X; Hatanaka N, 2001, CARCINOGENESIS, V22, P2033, DOI 10.1093/carcin/22.12.2033; HEINRICH U, 1994, ILSI MONOGR, P57; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hiura TS, 2000, J IMMUNOL, V165, P2703; Hossain A, 1998, J BIOL CHEM, V273, P19853, DOI 10.1074/jbc.273.31.19853; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Ichinose T, 1997, CARCINOGENESIS, V18, P185, DOI 10.1093/carcin/18.1.185; Inoue S, 2001, HUM GENE THER, V12, P967, DOI 10.1089/104303401750195926; Ito T, 2000, ENVIRON TOXICOL PHAR, V9, P1, DOI 10.1016/S1382-6689(00)00053-3; Iwai K, 2000, ENVIRON RES, V84, P255, DOI 10.1006/enrs.2000.4072; Iwai K, 1997, EXP TOXICOL PATHOL, V49, P393; JAKAB GJ, 1990, ENVIRON HEALTH PERSP, V86, P337, DOI 10.2307/3430973; JOSEPH P, 1994, P NATL ACAD SCI USA, V91, P8413, DOI 10.1073/pnas.91.18.8413; KAUFMANN SHE, 1993, ANNU REV IMMUNOL, V11, P129, DOI 10.1146/annurev.immunol.11.1.129; Kawabata Y, 1986, Dev Toxicol Environ Sci, V13, P213; Khatsenko OG, 1997, TOXICOL LETT, V90, P207, DOI 10.1016/S0378-4274(96)03857-X; Koike E., 2002, TOXICOL SCI, V67, P242; Koren HS, 1997, ENVIRON HEALTH PERSP, V105, P534, DOI 10.1289/ehp.97105534; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; LE JM, 1987, LAB INVEST, V56, P234; LEE MJ, 1995, BIOCHEM PHARMACOL, V49, P1387, DOI 10.1016/0006-2952(95)00056-6; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Lei W, 1998, CANCER RES, V58, P2102; Li N, 2002, INHAL TOXICOL, V14, P459, DOI 10.1080/089583701753678571; Li N, 2000, J IMMUNOL, V165, P3393; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; MAUDERLY JL, 1987, FUND APPL TOXICOL, V9, P208, DOI 10.1016/0272-0590(87)90044-3; Mori Y, 1996, J TOXICOL ENV HEALTH, V47, P125, DOI 10.1080/009841096161834; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NAGASHIMA M, 1995, CARCINOGENESIS, V16, P1441, DOI 10.1093/carcin/16.6.1441; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Ng D, 1998, J IMMUNOL, V161, P942; NIKULA KJ, 1995, FUND APPL TOXICOL, V25, P80, DOI 10.1006/faat.1995.1042; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; PAIRON JC, 1994, AM J RESP CELL MOL, V11, P386; Park AY, 2001, SCAND J IMMUNOL, V53, P529, DOI 10.1046/j.1365-3083.2001.00917.x; Park JYK, 1996, P NATL ACAD SCI USA, V93, P2322, DOI 10.1073/pnas.93.6.2322; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; Pons F, 2001, PHARMACOL TOXICOL, V88, P40, DOI 10.1034/j.1600-0773.2001.088001040.x; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; Redpath S, 2001, TRENDS MICROBIOL, V9, P86, DOI 10.1016/S0966-842X(00)01919-3; RENGASAMY A, 2002, IN PRESS J TOXICOL E; RICCI M, 1994, J INVEST ALLERG CLIN, V4, P214; ROSENKRANZ HS, 1993, MUTAT RES, V303, P91, DOI 10.1016/0165-7992(93)90100-A; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; Rudell B, 1999, OCCUP ENVIRON MED, V56, P527; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sato H, 2000, CARCINOGENESIS, V21, P653, DOI 10.1093/carcin/21.4.653; Saxon A, 2000, IMMUNOPHARMACOLOGY, V48, P325, DOI 10.1016/S0162-3109(00)00234-4; SCHUETZLE D, 1983, ENVIRON HEALTH PERSP, V47, P65, DOI 10.2307/3429500; SETHI JM, 2002, REDOX SIGNAL, V4, P241; Shen H, 1998, CURR OPIN IMMUNOL, V10, P450, DOI 10.1016/S0952-7915(98)80120-9; SHEN H, 1991, ARCH BIOCHEM BIOPHYS, V286, P178, DOI 10.1016/0003-9861(91)90025-E; Shukla A, 2000, AM J RESP CELL MOL, V23, P182; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471; STICKNEY JA, 1991, XENOBIOTICA, V21, P641; TAKAHASHI Y, 1994, TOXICOL APPL PHARM, V128, P207, DOI 10.1006/taap.1994.1199; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Takano H, 2002, ARCH TOXICOL, V76, P146, DOI 10.1007/s00204-002-0323-0; TALALAY P, 1987, CHEM SCRIPTA, V27A, P61; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; Villard PH, 1998, TOXICOL APPL PHARM, V148, P195, DOI 10.1006/taap.1997.8332; VILLARD PH, 1994, BIOCHEM BIOPH RES CO, V202, P1731, DOI 10.1006/bbrc.1994.2135; VOGL G, 1989, TOXICOL LETT, V47, P17, DOI 10.1016/0378-4274(89)90082-9; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; Whitlock JP, 1996, FASEB J, V10, P809; Yamazaki H, 2000, MUTAT RES-GEN TOX EN, V472, P129, DOI 10.1016/S1383-5718(00)00138-8; Yang HM, 2001, ENVIRON HEALTH PERSP, V109, P515, DOI 10.2307/3454711; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372; Yang HM, 1999, J TOXICOL ENV HEAL A, V58, P261, DOI 10.1080/009841099157232; YIN X, 2002, IN PRESS ENV HLTH PE; YIN X, 2002, ENV HLTH PERSPECT; YIN X, UNPUB ROLE ORGANIC C; Yoshino S, 1999, J PHARMACOL EXP THER, V290, P524; ZHAO HY, COMMUNICATION	121	84	85	5	16	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1059-0501			J ENVIRON SCI HEAL C	J. Environ. Sci. Health Pt. C-Environ. Carcinog. Ecotoxicol. Rev.		2002	20	2					117	147		10.1081/GNC-120016202		31	Oncology; Environmental Sciences; Toxicology	Oncology; Environmental Sciences & Ecology; Toxicology	621VY	WOS:000179612800002	12515672	
J	Wachholz, PA; Nouri-Aria, KT; Wilson, DR; Walker, SM; Verhoef, A; Till, SJ; Durham, SR				Wachholz, PA; Nouri-Aria, KT; Wilson, DR; Walker, SM; Verhoef, A; Till, SJ; Durham, SR			Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1 : Th2 cytokine ratios	IMMUNOLOGY			English	Article							MESSENGER-RNA EXPRESSION; SEASONAL ALLERGIC RHINITIS; CD4+ T-CELLS; IMMUNOLOGICAL CHANGES; INTERFERON-GAMMA; ANTIBODY-LEVELS; PRIMARY CULTURE; IL-4 PRODUCTION; LYMPHOCYTES-T; IN-VITRO	Grass pollen immunotherapy is the only treatment for hayfever that is both effective and confers long-term benefit. Immunotherapy may act by altering the local nasal mucosal T helper type 2 (Th2) to type 1 (Th1) cytokine balance either by down-regulation and/or immune deviation of T-lymphocyte responses. There is controversy as to whether these changes are detectable in peripheral blood. We therefore examined both local nasal and peripheral T-cell responses to allergen exposure in the same subjects before and after immunotherapy. In a double-blind trial of grass pollen immunotherapy, nasal biopsies were obtained at baseline and during the peak pollen season following 2 years of immunotherapy. Placebo-treated patients showed a seasonal increase in CD3(+) T cells (P=0.02) and in interleukin-5 (IL-5) mRNA(+) cells (P=0.03) and no change in interferon-gamma (IFN-gamma) mRNA(+) cells (P=0.2) in the nasal mucosa. In contrast, in the immunotherapy-treated group, there were no changes in the number of CD3(+) T cells (P=0.3) and IL-5 mRNA(+) cells (P=0.2) but a significant increase in the number of IFN-gamma mRNA(+) cells (P=0.03). Furthermore, clinical improvement in the immunotherapy-treated group was accompanied by a seasonal increase in the ratio of IFN-gamma to IL-5 mRNA(+) cells in the nasal mucosa (P=0.03). In contrast, there were no significant changes in peripheral T-cell proliferative responses or cytokine production for IFN-gamma or IL-5 in response to grass pollen either within or between the two treatment groups. We conclude that successful grass pollen immunotherapy was associated with an increase in the ratio of IFN-gamma to IL-5 mRNA(+) cells in the nasal mucosa, whereas these changes were not reflected by alterations in peripheral blood T-cell proliferative responses or cytokine production before/after treatment.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258			Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1999, FASEB J, V13, P603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DEL PG, 1988, J IMMUNOL, V140, P4193; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FREW AJ, 1988, J IMMUNOL, V141, P4158; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; GAGA M, 1991, J IMMUNOL, V147, P816; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; IMADA M, 1995, IMMUNOLOGY, V85, P373; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kay AB, 2001, NEW ENGL J MED, V344, P109; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Lu FM, 1998, ANN ALLERG ASTHMA IM, V80, P419; Magnan A, 2000, ALLERGY, V55, P286, DOI 10.1034/j.1398-9995.2000.00425.x; Moverare R, 2000, IMMUNOL LETT, V73, P51, DOI 10.1016/S0165-2478(00)00199-1; Moverare R, 2000, SCAND J IMMUNOL, V52, P200; Ohashi Y, 1997, SCAND J IMMUNOL, V46, P67, DOI 10.1046/j.1365-3083.1997.d01-87.x; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Till S, 1997, CLIN EXP IMMUNOL, V110, P114, DOI 10.1111/j.1365-2249.1997.494-ce1392.x; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Varga EM, 2000, J IMMUNOL, V165, P2877; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170; VARNEY VA, 1991, BRIT MED J, V302, P265; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VOLLENWEIDER S, 1991, J ALLERGY CLIN IMMUN, V87, P1088, DOI 10.1016/0091-6749(91)92154-S; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; WILSON DR, 2001, IN PRESS CLIN EXP AL; YING S, 1993, AM J RESP CELL MOL, V9, P356	44	84	90	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0019-2805			IMMUNOLOGY	Immunology	JAN	2002	105	1					56	62		10.1046/j.1365-2567.2002.01338.x		7	Immunology	Immunology	516FX	WOS:000173544200007	11849315	
J	Lester, LA; Rich, SS; Blumenthal, MN; Togias, A; Murphy, S; Malveaux, F; Miller, ME; Dunston, GM; Solway, J; Wolf, RL; Samet, JM; Marsh, DG; Meyers, DA; Ober, C; Bleecker, ER				Lester, LA; Rich, SS; Blumenthal, MN; Togias, A; Murphy, S; Malveaux, F; Miller, ME; Dunston, GM; Solway, J; Wolf, RL; Samet, JM; Marsh, DG; Meyers, DA; Ober, C; Bleecker, ER		Collaborative Study Genetics Asthm	Ethnic differences in asthma and associated phenotypes: Collaborative Study on the Genetics of Asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; bronchial hyperresponsiveness; atopy; ethnic differences	SKIN-TEST REACTIVITY; GENOME-WIDE SEARCH; SERUM IGE LEVELS; SOCIOECONOMIC-STATUS; COCKROACH ALLERGEN; CHILDHOOD ASTHMA; INDOOR ALLERGENS; CHILDREN; RACE; SEVERITY	Background: In the Collaborative Study on the Genetics of Asthma, 314 families with 2584 subjects were characterized for asthma and allergy. Objective: The purpose of this investigation was to examine clinical heterogeneity observed in asthma and allergic characteristics among 3 ethnic groups (African American, white, and Hispanic family members). Methods: pulmonary function parameters and asthma-associated phenotypes were compared among the ethnic groups. Results: In comparison with the other groups, African American sibling pairs had a significantly lower baseline FEV, percent of predicted (P = .0001) and a higher rate of skin test reactivity to cockroach allergen (P = .0001); Hispanic sibling pairs had significantly more skin reactivity overall (P = .001); and white sibling pairs had significantly lower total serum IgE (P < .05). In addition, there were significantly more relatives with asthma among the African American families than among the white and the Hispanic families (P = .001). Conclusion: Although different environmental backgrounds should be considered, these clinical differences could be due to differences in genetic susceptibility among the ethnic groups, such as those suggested by our previous genome screen.	Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Winston Salem, NC 27157 USA; Univ Chicago, Chicago, IL 60637 USA; Univ Minnesota, Minneapolis, MN 55455 USA; Johns Hopkins Univ, Baltimore, MD 21218 USA; Univ New Mexico, Albuquerque, NM 87131 USA; Howard Univ, Washington, DC 20059 USA; Univ Maryland, College Pk, MD 20742 USA	Bleecker, ER (reprint author), Wake Forest Univ, Bowman Gray Sch Med, Ctr Human Genom, Med Ctr Blvd, Winston Salem, NC 27157 USA.		Solway, Julian/B-1116-2008	Solway, Julian/0000-0002-0898-8530	NCRR NIH HHS [M01-RR00400, MR1 RR00055]; NHLBI NIH HHS [UO1 HL/AI49596, HL/AI 49609, U01 HL/AI 49612, U01 HL/AI49602, UO1 HL 58977]		ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BLUMENTHAL M, 1992, J IMMUNOL, V148, P411; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198; HOLGATE ST, 1997, NAT GENET, V15, P389; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P393; Liang K. Y., 1992, BIOMETRIKA, V73, P12; LIGGETT S, 1996, LUNG BIOL HLTH DIS; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339; RICH SS, 1992, CLIN EXP ALLERGY, V22, P1070, DOI 10.1111/j.1365-2222.1992.tb00132.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; TASKIN DP, 1992, AM REV RESPIR DIS, V145, P301; TAUSSIG LM, 1989, AM J EPIDEMIOL, V129, P1219; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; Winer BJ, 1971, STAT PRINCIPLES EXPT; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; 1987, AM J RESP CRIT CARE, V136, P1285	35	84	85	2	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					357	362		10.1067/mai.2001.117796		6	Allergy; Immunology	Allergy; Immunology	476FK	WOS:000171215400005	11544453	
J	Mihrshahi, S; Peat, JK; Webb, K; Tovey, ER; Marks, GB; Mellis, CM; Leeder, SR				Mihrshahi, S; Peat, JK; Webb, K; Tovey, ER; Marks, GB; Mellis, CM; Leeder, SR		CAPS Team	The Childhood Asthma Prevention Study (CAPS): Design and research protocol of a randomized trial for the primary prevention of asthma	CONTROLLED CLINICAL TRIALS			English	Article						Asthma; atopy; allergen avoidance; benzyl benzoate; fatty acid supplementation; house dust mite; primary prevention of asthma	FOOD-ALLERGEN AVOIDANCE; DUST MITE ALLERGENS; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; POPULATION-SAMPLE; FATTY-ACIDS; CHILDREN; INFANCY; ATOPY; RISK	The Childhood Asthma Prevention Study is a randomized controlled trial to measure whether the incidence of atopy and asthma can be reduced by house dust mite allergen reduction, a diet supplemented with omega-3 fatty acids, or a combination of both interventions. Six hundred and sixteen pregnant women whose unborn children were at high risk of developing asthma because of a family history were randomized prenatally. Study groups are as follows: Group A (placebo diet intervention, no house dust mite reduction), Group B (placebo diet intervention, active house dust mite reduction), Group C (active diet intervention, no house dust mite reduction), and Group D (active diet intervention, active house dust mite reduction). The house dust mite reduction intervention comprises use of physical and chemical methods to reduce allergen contact. The dietary intervention comprises use of a daily oil supplement from 6 months or at onset of bottle-feeding, and use of margarine and cooking oils based on sunflower or canola oils to increase omega-3 dietary intake. Data is collected quarterly until the infant is 1 year old and then half yearly until age 5 years. Questionnaires are used ti, collect respiratory illness history and information about diet and home environment. Dust is collected from the child's bed and bedroom and playroom floors. Blinded assessments are conducted at 18 months, 3 years, and 5 years. Skin prick tests to common allergens, blood tests, and detailed illness, medication use, and vaccination histories are collected. Primary outcomes will be the development of allergic sensitization and the presence and severity of asthma. This study is designed to measure the effectiveness of allergen reduction and dietary supplementation, both separately and in combination, for the primary prevention of atopy and asthma. The results of this study may have important implications for public health policies to reduce the incidence of childhood asthma. (C) Elsevier Science Inc. 2001.	Childrens Hosp, Clin Epidemiol Unit, Westmead, NSW 2145, Australia; Univ Sydney, Dept Paediat & Child Hlth, Sydney, NSW 2006, Australia; Univ Sydney, Dept Biochem, Fac Med, Sydney, NSW 2006, Australia; Univ Sydney, Dept Publ Hlth & Community Med, Sydney, NSW 2006, Australia; Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia	Mihrshahi, S (reprint author), Childrens Hosp, Clin Epidemiol Unit, Locked Bag 4001, Westmead, NSW 2145, Australia.		Mihrshahi, Seema/A-9877-2009; Tovey, Euan/G-8604-2017	Mihrshahi, Seema/0000-0001-6567-9884; Tovey, Euan/0000-0002-1802-7266			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; ARM J P, 1988, Thorax, V43, P84, DOI 10.1136/thx.43.2.84; Asher MI, 1998, EUR RESPIR J, V12, P315; BITTINER SB, 1988, LANCET, V1, P3; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1046/j.1365-2222.1996.d01-380.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DRY J, 1991, INT ARCH ALLER A IMM, V95, P156; ENHERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135; GRAY EJ, 1994, AUST NZ J MED, V24, P168, DOI 10.1111/j.1445-5994.1994.tb00553.x; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; HAMMARQUIST C, 2000, COCHRANE DATABASE SY, V2; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; KREMER J, 1995, LANCET, P184; Kremer JM, 2000, AM J CLIN NUTR, V71, p349S; LANDS WEM, 1991, ANNU REV NUTR, V11, P41; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MAKRIDES M, 1995, LIPIDS, V30, P941, DOI 10.1007/BF02537486; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MUNIR AKM, 1995, ALLERGY, V50, P55, DOI 10.1111/j.1398-9995.1995.tb02483.x; *NAT ASTHM CAMP, 1996, NAT ASTHM MAN HDB; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; PEAT JK, 1992, EUR RESPIR J, V5, P921; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442; PISTELLI R, 1993, EUR RESPIR J, V6, P517; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; Soutar A, 1997, THORAX, V52, P166; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; THIEN FCK, 1993, AM REV RESPIR DIS, V147, P1138; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Warner J, 1990, PEDIATR ALLERGY IMMU, V1, P79, DOI 10.1111/j.1399-3038.1990.tb00015.x; WOODS RK, 2000, COCHRANE LIB; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	42	84	84	2	6	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0197-2456			CONTROL CLIN TRIALS	Controlled Clin. Trials	JUN	2001	22	3					333	354		10.1016/S0197-2456(01)00112-X		22	Medicine, Research & Experimental; Pharmacology & Pharmacy	Research & Experimental Medicine; Pharmacology & Pharmacy	435PW	WOS:000168890700010	11384793	
J	Tsang, KW; Ip, SK; Leung, R; Tipoe, GL; Chan, SL; Shum, IH; Ip, MS; Yan, C; Fung, PC; Chan-Yeung, M; Lam, W				Tsang, KW; Ip, SK; Leung, R; Tipoe, GL; Chan, SL; Shum, IH; Ip, MS; Yan, C; Fung, PC; Chan-Yeung, M; Lam, W			Exhaled nitric oxide: The effects of age, gender and body size	LUNG			English	Article						exhaled nitric oxide; aging; gender; body mass index; body surface area	OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC-FIBROSIS; AIR; CHILDREN; BRONCHIECTASIS; MARKERS; ASTHMA; LUNGS; NASAL; NO	Since little is known of the effects of age, gender, and body size on exhaled nitric oxide (NO) production, we have conducted a prospective study to examine these factors in a healthy nonsmoking women (mean age +/- SD 47.7 +/- 15.8, range 20-79 years). Exhaled NO was measured by an automatic chemiluminescence analyzer (Sievers NO Analyser 280) at steady expiration. Men had significantly higher exhaled NO levels than women (p = 0.001). Although exhaled NO levels did not correlate with age (r = 0.12, p = 0.17), it correlated significantly with height (r = 0.23,p = 0.02), weight (r = 0.34,p < 0.001), body mass index (r = 0.25,p = 0.009), and body surface area (r = 0.42,p < 0.001) for the entire cohort. After making adjustment for age, height, weight, body mass index, and body surface area, exhaled NO levels were still significantly higher for men than for women (p = 0.004). Our data, therefore, could help explain the discrepancy in results of previous studies on exhaled NO production, which had not taken these parameters into account. Our findings should help researchers design future studies on evaluation of exhaled NO levels.	Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Queen Mary Hosp, Dept Anat, Hong Kong, Hong Kong, Peoples R China	Tsang, KW (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.						BalfourLynn IM, 1996, ARCH DIS CHILD, V75, P319; Baraldi E, 1999, PEDIATR PULM, V27, P54, DOI 10.1002/(SICI)1099-0496(199901)27:1<54::AID-PPUL10>3.0.CO;2-V; Becklake MR, 1999, THORAX, V54, P1119; Chambers DC, 1998, THORAX, V53, P677; Corradi M, 1999, THORAX, V54, P572; CREMONA G, 1995, J APPL PHYSIOL, V78, P59; Delen FM, 2000, CHEST, V117, P695, DOI 10.1378/chest.117.3.695; Du Bois D, 1916, ARCH INTERN MED, V17, P863; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; Grasemann H, 1997, PEDIATR PULM, V24, P173, DOI 10.1002/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O; Ho LP, 1998, EUR RESPIR J, V12, P1290, DOI 10.1183/09031936.98.12061290; JANGHORBANI M, 1993, INT J EPIDEMIOL, V22, P1056, DOI 10.1093/ije/22.6.1056; Jilma B, 1996, LIFE SCI, V58, P469, DOI 10.1016/0024-3205(95)02311-9; Karadag B, 1999, EUR RESPIR J, V13, P1402, DOI 10.1183/09031936.99.13614069; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889; Ludviksdottir D, 1999, EUR RESPIR J, V13, P739, DOI 10.1034/j.1399-3003.1999.13d07.x; MANCINELLI RL, 1983, APPL ENVIRON MICROB, V46, P198; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; MONCADA S, 1991, PHARMACOL REV, V43, P109; Murphy AW, 1998, CHEST, V114, P452, DOI 10.1378/chest.114.2.452; NATHAN CF, 1991, CURR OPIN IMMUNOL, V3, P65, DOI 10.1016/0952-7915(91)90079-G; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Piacentini GL, 2000, EUR RESPIR J, V15, P730, DOI 10.1034/j.1399-3003.2000.15d17.x; Rutgers SR, 1999, THORAX, V54, P576; Steerenberg PA, 1999, EUR RESPIR J, V13, P334, DOI 10.1034/j.1399-3003.1999.13b19.x	30	84	87	1	4	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0341-2040			LUNG	Lung	MAR-APR	2001	179	2					83	91		10.1007/s004080000050		9	Respiratory System	Respiratory System	489TL	WOS:000172007700002	11733851	
J	Trifilieff, A; Fujitani, Y; Mentz, F; Dugas, B; Fuentes, M; Bertrand, C				Trifilieff, A; Fujitani, Y; Mentz, F; Dugas, B; Fuentes, M; Bertrand, C			Inducible nitric oxide synthase inhibitors suppress airway inflammation in mice through down-regulation of chemokine expression	JOURNAL OF IMMUNOLOGY			English	Article							CELL-ADHESION MOLECULE-1; LUNG EPITHELIAL-CELLS; IN-VITRO; GENE-EXPRESSION; RAT LUNG; ASTHMATIC-PATIENTS; MURINE MODEL; EXHALED AIR; MODULATION; INDUCTION	Growing evidence demonstrates that inducible NO synthase (iNOS) is induced in the airways of asthmatic patients. However, the precise role of NO in the lung inflammation is unknown. This study investigated the effect of both selective and nonselective iNOS inhibitors in an allergen-driven murine lung inflammation model. OVA challenge resulted in an accumulation of eosinophils and neutrophils in the airways. Expression of iNOS immunostaining in lung sections together with an increase in calcium-independent NOS activity in lung homogenates was also observed after OVA challenge. Treatment with iNOS inhibitors from the day of challenge to the day of sacrifice resulted in an inhibition of the inflammatory cell influx together with a down-regulation of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1 production. In contrast, eosinophilic and neutrophilic inhibition was not observed with treatment during the sensitization. Both treatments induced an increased production of Th2-type cytokines (IL-4 and IL-5) with a concomitant decrease in production of Thl-type cytokine (IFN-gamma). In vitro exposure of primary cultures of murine lung fibroblasts to a NO donor, hydroxylamine, induced a dose-dependent release of macrophage inflammatory protein-2 and monocyte chemoattractant protein-1. Our results suggest that lung inflammation after allergen challenge in mice is partially dependent on NO produced mainly by iNOS. NO appears to increase lung chemokine expression and, thereby, to facilitate influx of inflammatory cells into the airways.	Novartis Horsham Res Ctr, Horsham RH12 5AB, W Sussex, England; Hop La Pitie Salpetriere, Immunohematol Grp, Paris, France; Roche Biosci, Palo Alto, CA USA	Trifilieff, A (reprint author), Novartis Horsham Res Ctr, Wimblehurst Rd, Horsham RH12 5AB, W Sussex, England.						ALVING K, 1993, EUR RESPIR J, V6, P1368; ANDERSON GP, 1994, TRENDS PHARMACOL SCI, V15, P324, DOI 10.1016/0165-6147(94)90027-2; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; BARNES PJ, 1995, IMMUNOL TODAY, V16, P128, DOI 10.1016/0167-5699(95)80128-6; BEAUVAIS F, 1995, FEBS LETT, V361, P229, DOI 10.1016/0014-5793(95)00188-F; BEAUVAIS F, 1995, J CELL PHYSIOL, V165, P610, DOI 10.1002/jcp.1041650319; Campbell EM, 1998, J IMMUNOL, V161, P7047; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; DRISCOLL KE, 1993, AM J RESP CELL MOL, V8, P311; Feder LS, 1997, AM J RESP CELL MOL, V17, P436; Ferreira HHA, 1996, EUR J PHARMACOL, V310, P201, DOI 10.1016/0014-2999(96)00379-2; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; GROULS V, 1981, STAIN TECHNOL, V56, P323; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hogaboam C M, 1999, J Immunol, V163, P2193; Iadecola C., 1995, AM J PHYSIOL, V268, P286; IANARO A, 1994, IMMUNOLOGY, V82, P370; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; Kallmann BA, 1999, LIFE SCI, V65, P1787, DOI 10.1016/S0024-3205(99)00431-2; Kawachi S, 1999, AM J PHYSIOL-GASTR L, V277, pG572; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KUO HP, 1992, EUR J PHARMACOL, V221, P385; LEDERMANN F, 1991, J IMMUNOL METHODS, V141, P263, DOI 10.1016/0022-1759(91)90153-7; LIEW FY, 1995, CURR OPIN IMMUNOL, V7, P396, DOI 10.1016/0952-7915(95)80116-2; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Miyamasu M, 1999, CYTOKINE, V11, P751, DOI 10.1006/cyto.1999.0487; NAGAKI M, 1995, RESP PHYSIOL, V102, P89, DOI 10.1016/0034-5687(95)00042-C; NAKANE M, 1995, MOL PHARMACOL, V47, P831; NATHAN C, 1992, FASEB J, V6, P3051; NIJKAMP FP, 1993, AM REV RESPIR DIS, V148, P727; Peng HB, 1998, J IMMUNOL, V161, P1970; PHAN SH, 1985, J CLIN INVEST, V76, P241, DOI 10.1172/JCI111953; REES DD, 1995, BRIT J PHARMACOL, V114, P689; RESNICK MB, 1993, AM J RESP CELL MOL, V8, P349; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V198, P835, DOI 10.1006/bbrc.1994.1119; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; TRACEY WR, 1995, CAN J PHYSIOL PHARM, V73, P665; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; VanUffelen BE, 1996, J LEUKOCYTE BIOL, V60, P94; Villarete LH, 1997, SHOCK, V7, P29, DOI 10.1097/00024382-199701000-00003; VONVLIET E, 1986, J HISTOCHEM CYTOCHEM, V34, P883; WARD JK, 1993, J CLIN INVEST, V92, P736, DOI 10.1172/JCI116644; WELLER PF, 1991, P NATL ACAD SCI USA, V88, P7430, DOI 10.1073/pnas.88.16.7430; WHITTLE BJR, 1989, BRIT J PHARMACOL, V98, P646; Wolyniec WW, 1998, AM J RESP CELL MOL, V18, P777; Xiong YL, 1999, J IMMUNOL, V162, P445; Xue C, 1996, HYPERTENSION, V28, P743; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247; YEADON M, 1995, BRIT J PHARMACOL, V116, P2545; Zingarelli B, 1999, GUT, V45, P199	53	84	90	0	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2000	165	3					1526	1533				8	Immunology	Immunology	337CV	WOS:000088340600048	10903760	
J	Ledogar, RJ; Penchaszadeh, A; Garden, CCI; Acosta, LG				Ledogar, RJ; Penchaszadeh, A; Garden, CCI; Acosta, LG			Asthma and Latino cultures: Different prevalence reported among groups sharing the same environment	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							PUERTO-RICAN CHILDREN; NEW-YORK-CITY; MEXICAN-AMERICAN; HEALTH; ALPHA-1-ANTITRYPSIN; VARIANTS; RISK	Objectives. This 1999 study measured asthma prevalence among Latinos of different cultural traditions who live on the same streets and in the same buildings. Methods. Health promoters from El Puente in North Brooklyn, New York City, surveyed 3015 people in 946 households, asking standard asthma prevalence questions. Results. Some 46%, of households identified themselves as Dominican, 42% as Puerto Rican, 6% as other Latino, and 6% as other. Reported asthma period prevalence was 5.3% (93 of 1749) among Dominicans and other Latinos, compared with 13.2% (147 of 1115)among Puerto Ricans (odds ratio = 0.37; 95% confidence interval = 0.28, 0.49), a difference not explained by location (cluster or building), household size, use of home remedies, educational attainment, or country where education was completed. Differences were least detectable among 13- to 24-year-olds of both sexes and sharpest among women aged 45 years and older and girls from birth to 12 years. Conclusions, Further research oil gene-environment interactions is needed among Puerto Ricans and Dominicans, but asthma's associations with low income and unhealthy environment, which more recent immigrants seem better able to withstand, should not be overlooked.	CIETintl, New York, NY 10011 USA; EI Puente, Brooklyn, NY USA	Ledogar, RJ (reprint author), CIETintl, 511 Ave Amer, Suite 132, New York, NY 10011 USA.						ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; BOURNIGAL EC, 1985, ARCH DOMINICANOS PED, V21, P9; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; COLP C, 1990, ARCH INTERN MED, V150, P2349, DOI 10.1001/archinte.150.11.2349; COLP C, 1993, CHEST, V103, P812, DOI 10.1378/chest.103.3.812; CRAIN EF, 1994, PEDIATRICS, V94, P356; Lara M, 1999, WESTERN J MED, V170, P75; Ledogar RJ, 1999, AM J PUBLIC HEALTH, V89, P1795, DOI 10.2105/AJPH.89.12.1795; Mendoza FS, 1999, WESTERN J MED, V170, P85; MENDOZA FS, 1991, JAMA-J AM MED ASSOC, V265, P227, DOI 10.1001/jama.265.2.227; MICHELE MA, 1996, J RESP CRIT CARE MED, V153, P1285; Miller RL, 1999, AM J PUBLIC HEALTH, V89, P819, DOI 10.2105/AJPH.89.6.819; Montealegre F, 1996, P R Health Sci J, V15, P113; *NY CIT DEP HLTH O, 1991, SUMM VIT STAT, V20; ORENGO JC, 1996, CAT WORKSH PUERT RIC; Pelkonen AS, 1997, AM J RESP CRIT CARE, V156, P1178; RIOS L, 1982, J LATIN COMMUNITY HL, V1, P25; SCHWARZ K, 1992, RIGHT BREATHE RIGHT	20	84	85	0	4	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	JUN	2000	90	6					929	935		10.2105/AJPH.90.6.929		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	319HQ	WOS:000087335800019	10846511	
J	Soyka, MB; Wawrzyniak, P; Eiwegger, T; Holzmann, D; Treis, A; Wanke, K; Kast, JI; Akdis, CA				Soyka, Michael B.; Wawrzyniak, Paulina; Eiwegger, Thomas; Holzmann, David; Treis, Angela; Wanke, Kerstin; Kast, Jeannette I.; Akdis, Cezmi A.			Defective epithelial barrier in chronic rhinosinusitis: The regulation of tight junctions by IFN-gamma and IL-4	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Chronic rhinosinusitis; chronic sinusitis; tight junctions; occludin; claudin; zonula occludens; regulation; cytokines; leaky epithelium	HUMAN AIRWAY EPITHELIA; NASAL POLYPOSIS; CHRONIC SINUSITIS; CELLS; EXPRESSION; DISEASES; ASTHMA; DIFFERENTIATION; EPIDEMIOLOGY; INFLAMMATION	Background: Chronic rhinosinusitis (CRS) is a common disease with still unclear pathophysiologic mechanisms. Epithelial tight junctions (TJs) have been shown to be involved in different chronic disorders, including bronchial asthma, inflammatory bowel diseases, and skin disorders. The regulation of epithelial barrier function and TJ expression has not been extensively studied in patients with CRS and in the paranasal sinus epithelium thus far. Objective: We sought to elucidate the TJ expression pattern in the epithelium of the sinonasal mucosa and its regulation in patients with CRS. Methods: Trans-tissue resistance was measured in biopsy specimens from healthy control subjects and patients with CRS with and without nasal polyps. TJ protein expression was determined by using immunofluorescence, Western blotting, and real-time PCR. Primary epithelial cell cultures from patients with CRS and control subjects were used in air-liquid interface (ALI) cultures for the measurement of transepithelial resistance (TER) and TJ expression. The effect of IFN-gamma, IL-4, and IL-17 on ALI cultures was assessed. Results: A decreased trans-tissue resistance was found in biopsy specimens from patients with CRS with nasal polyps along with an irregular, patchy, and decreased expression of the TJ molecules occludin and zonula occludens 1. TER was reduced in ALI cultures from patients with CRS with nasal polyps. The cytokines IFN-gamma and IL-4 decreased TER, whereas IL-17 did not have any influence on epithelial integrity. Conclusion: A defective epithelial barrier was found in patients with CRS with nasal polyps along with a decreased expression of TJ proteins. The disruption of epithelial integrity by IFN-gamma and IL-4 in vitro indicates a possible role for these proinflammatory cytokines in the pathogenesis of patients with CRS. (J Allergy Clin Immunol 2012;130:1087-96.)	[Soyka, Michael B.; Wawrzyniak, Paulina; Eiwegger, Thomas; Treis, Angela; Wanke, Kerstin; Kast, Jeannette I.; Akdis, Cezmi A.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, CH-7270 Davos, Switzerland; [Soyka, Michael B.; Holzmann, David] Univ Zurich Hosp, Dept Otorhinolaryngol Head & Neck Surg, Zurich, Switzerland; [Eiwegger, Thomas] Med Univ Vienna, Dept Pediat, Vienna, Austria	Akdis, CA (reprint author), Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Obere Str 22,7270 Davos Pl, CH-7270 Davos, Switzerland.	akdisac@siaf.uzh.ch	Kast, Jeannette/I-2397-2013		European Allergy and Asthma Center Davos (EACD); Swiss National Science Foundation [32-132899, 32-112306]; Christine Kuhne Center for Allergy Research and Education (CK-CARE); Muller-Gierok-Foundation; University Hospital Zurich; Muller-Gierok Foundation; European Allergy and Asthma Center Davos; Swiss National Foundation; CK-CARE; Novartis; PREDICTA; Swiss National Science Foundation; MeDALL; Global Allergy and Asthma European Network	The laboratory of C.A.A. is supported by the European Allergy and Asthma Center Davos (EACD), Swiss National Science Foundation grants 32-132899 and 32-112306, the Christine Kuhne Center for Allergy Research and Education (CK-CARE), the Muller-Gierok-Foundation, and University Hospital Zurich.; Disclosure of potential conflict of interest: M. B. Soyka has received research support from the Muller-Gierok Foundation, the European Allergy and Asthma Center Davos, the Swiss National Foundation, University Hospital Zurich, and CK-CARE and is employed by University Hospital Zurich. C. A. Akdis has received research support from Novartis, PREDICTA, the Swiss National Science Foundation, MeDALL, the Global Allergy and Asthma European Network, and CK-CARE; has provided legal consultation/expert witness testimony on the topics of Acellion T<INF>H</INF>2-specific receptors, Aventis T-cell Bell regulation, and allergen-specific immunotherapy (for Stallergenes and Allergopharma); is president of the European Academy of Allergy and Clinical Immunology, a GA <SUP>2</SUP>LEN ex-committee member, director of CK-CARE, and a fellow and interest group member for the American Academy of Allergy, Asthma & Immunology. The rest of the authors declare that they have no relevant conflicts of interest.	Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Akdis M, 2011, J ALLERGY CLIN IMMUN, V127, P701, DOI 10.1016/j.jaci.2010.11.050; Asgrimsson V, 2006, ANTIMICROB AGENTS CH, V50, P1805, DOI 10.1128/AAC.50.5.1805-1812.2006; Bachert C, 2009, ALLERGY, V64, P520, DOI 10.1111/j.1398-9995.2009.01964.x; Holzmann D, 2009, J ALLERGY CLIN IMMUN, V124, pe1, DOI 10.1016/Haci.2009; Basinski TM, 2009, J ALLERGY CLIN IMMUN, V124, P74, DOI 10.1016/j.jaci.2009.04.019; Bernstein JM, 1997, J ALLERGY CLIN IMMUN, V99, P165, DOI 10.1016/S0091-6749(97)70091-5; Capaldo CT, 2009, BBA-BIOMEMBRANES, V1788, P864, DOI 10.1016/j.bbamem.2008.08.027; Chiba H, 2008, BBA-BIOMEMBRANES, V1778, P588, DOI 10.1016/j.bbamem.2007.08.017; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI 10.1139/y08-004; Rafaels NM, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Dejima K, 2006, ARCH OTOLARYNGOL, V132, P1352, DOI 10.1001/archotol.132.12.1352; Fokkens W, 2007, RHINOLOGY, V45, P97; Fujita H, 2011, J ALLERGY CLIN IMMUN, V127, P1612, DOI 10.1016/j.jaci.2011.03.039; Guttman JA, 2009, BBA-BIOMEMBRANES, V1788, P832, DOI 10.1016/j.bbamem.2008.10.028; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate ST, 2010, CLIN SCI, V118, P439, DOI 10.1042/CS20090474; Jang YJ, 2002, EUR ARCH OTO-RHINO-L, V259, P465, DOI 10.1007/s00405-002-0500-z; Kanai K, 2004, Eur Respir J, V23, P671, DOI 10.1183/09031936.04.00057104; Kirschner N, 2010, EUR J CELL BIOL, V89, P839, DOI 10.1016/j.ejcb.2010.07.010; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Koizumi JI, 2007, J MEMBRANE BIOL, V218, P1, DOI 10.1007/s00232-007-9029-9; Lischper M, 2010, BRAIN RES, V1326, P114, DOI 10.1016/j.brainres.2010.02.054; Marchiando AM, 2010, ANNU REV PATHOL-MECH, V5, P119, DOI 10.1146/annurev.pathol.4.110807.092135; Marple BF, 2009, POSTGRAD MED, V121, P121, DOI 10.3810/pgm.2009.11.2081; Masaki T, 2011, MOL BIOL CELL, V22, P2144, DOI 10.1091/mbc.E10-11-0875; Meyer N, 2010, J ALLERGY CLIN IMMUN, V125, P858, DOI 10.1016/j.jaci.2010.01.016; Naclerio Robert M, 2010, Int J Gen Med, V3, P47; NASH S, 1987, J CLIN INVEST, V80, P1104, DOI 10.1172/JCI113167; Runswick S, 2007, RESPIROLOGY, V12, P834, DOI 10.1111/j.1440-1843.2007.01175.x; Sachse F, 2010, ALLERGY, V65, P1430, DOI 10.1111/j.1398-9995.2010.02381.x; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Schulzke JD, 2009, ANN NY ACAD SCI, V1165, P294, DOI 10.1111/j.1749-6632.2009.04062.x; Settipane GA, 1996, ALLERGY ASTHMA PROC, V17, P231, DOI 10.2500/108854196778662246; Sun DI, 2009, EUR ARCH OTO-RHINO-L, V266, P981, DOI 10.1007/s00405-008-0872-9; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, P1435, DOI 10.1016/j.jaci.2008.02.018; Van Cauwenberge P, 2000, THORAX, V55, pS20, DOI 10.1136/thorax.55.suppl_2.S20; Van Zele T, 2006, ALLERGY, V61, P1280, DOI 10.1111/j.1398-9995.2006.01225.x; Van Bruaene N, 2008, J ALLERGY CLIN IMMUN, V121, pe1; Vermeer PD, 2009, AM J PHYSIOL-LUNG C, V296, pL751, DOI 10.1152/ajplung.90578.2008; Watelet JB, 2004, ALLERGY, V59, P54, DOI 10.1046/j.1398-9995.2003.00364.x; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, pe1, DOI DOI 10.1016/J.JACI.2011.05.038; Xiao C, 2011, J ALLERGY CLIN IMMUN, V128, P549, DOI 10.1016/j.jaci.2011.05.038; Zhang XH, 2012, AM J RESP CRIT CARE, V185, P140, DOI 10.1164/rccm.201103-0456OC; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, pe1, DOI [10.1016/j.jaci.2010, DOI 10.1016/J.JACI.2010]; Zimmermann M, 2011, J ALLERGY CLIN IMMUN, V127, P200, DOI 10.1016/j.jaci.2010.11.005; Zuckerman JD, 2008, AM J RHINOL, V22, P589, DOI 10.2500/ajr.2008.22.3235	49	83	92	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2012	130	5					1087	+		10.1016/j.jaci.2012.05.052		20	Allergy; Immunology	Allergy; Immunology	030LE	WOS:000310571400009	22840853	
J	Peiser, M; Tralau, T; Heidler, J; Api, AM; Arts, JHE; Basketter, DA; English, J; Diepgen, TL; Fuhlbrigge, RC; Gaspari, AA; Johansen, JD; Karlberg, AT; Kimber, I; Lepoittevin, JP; Liebsch, M; Maibach, HI; Martin, SF; Merk, HF; Platzek, T; Rustemeyer, T; Schnuch, A; Vandebriel, RJ; White, IR; Luch, A				Peiser, M.; Tralau, T.; Heidler, J.; Api, A. M.; Arts, J. H. E.; Basketter, D. A.; English, J.; Diepgen, T. L.; Fuhlbrigge, R. C.; Gaspari, A. A.; Johansen, J. D.; Karlberg, A. T.; Kimber, I.; Lepoittevin, J. P.; Liebsch, M.; Maibach, H. I.; Martin, S. F.; Merk, H. F.; Platzek, T.; Rustemeyer, T.; Schnuch, A.; Vandebriel, R. J.; White, I. R.; Luch, A.			Allergic contact dermatitis: epidemiology, molecular mechanisms, in vitro methods and regulatory aspects Current knowledge assembled at an international workshop at BfR, Germany	CELLULAR AND MOLECULAR LIFE SCIENCES			English	Review						Contact allergy; Dermatitis; Epidemiology; Molecular mechanisms; Regulatory aspects	LYMPH-NODE ASSAY; OCCUPATIONAL SKIN-DISEASE; HUMAN DENDRITIC CELLS; RECEPTOR ACCESSORY PROTEIN; PIG MAXIMIZATION TEST; NECROSIS-FACTOR-ALPHA; N-ACETYLTRANSFERASE 1; TOLL-LIKE RECEPTOR; EFFECTOR T-CELLS; TEST H-CLAT	Contact allergies are complex diseases, and one of the important challenges for public health and immunology. The German 'Federal Institute for Risk Assessment' hosted an 'International Workshop on Contact Dermatitis'. The scope of the workshop was to discuss new discoveries and developments in the field of contact dermatitis. This included the epidemiology and molecular biology of contact allergy, as well as the development of new in vitro methods. Furthermore, it considered regulatory aspects aiming to reduce exposure to contact sensitisers. An estimated 15-20% of the general population suffers from contact allergy. Workplace exposure, age, sex, use of consumer products and genetic predispositions were identified as the most important risk factors. Research highlights included: advances in understanding of immune responses to contact sensitisers, the importance of autoxidation or enzyme-mediated oxidation for the activation of chemicals, the mechanisms through which hapten-protein conjugates are formed and the development of novel in vitro strategies for the identification of skin-sensitising chemicals. Dendritic cell cultures and structure-activity relationships are being developed to identify potential contact allergens. However, the local lymph node assay (LLNA) presently remains the validated method of choice for hazard identification and characterisation. At the workshop the use of the LLNA for regulatory purposes and for quantitative risk assessment was also discussed.	[Peiser, M.; Tralau, T.; Heidler, J.; Platzek, T.; Luch, A.] German Fed Inst Risk Assessment BfR, Dept Prod Safety, D-14195 Berlin, Germany; [Api, A. M.] Res Inst Fragrance Mat, Hackensack, NJ USA; [Arts, J. H. E.] AkzoNobel NV, Arnhem, Netherlands; [Basketter, D. A.] DABMEB Consultancy Ltd, Sharnbrook, Beds, England; [English, J.] Univ Nottingham Hosp, Nottingham NG7 2UH, England; [Diepgen, T. L.] Univ Heidelberg, Dept Social Med Occupat & Environm Dermatol, Heidelberg, Germany; [Fuhlbrigge, R. C.] Harvard Skin Dis Res Ctr, Boston, MA USA; [Gaspari, A. A.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA; [Johansen, J. D.] Univ Copenhagen, Dept Dermaallergol, Gentofte Hosp, Copenhagen, Denmark; [Karlberg, A. T.] Univ Gothenburg, Dept Chem Dermatochem & Skin Allergy, Gothenburg, Sweden; [Kimber, I.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Lepoittevin, J. P.] Univ Strasbourg, Strasbourg, France; [Liebsch, M.; Luch, A.] German Fed Inst Risk Assessment BfR, Dept Expt Toxicol, D-14195 Berlin, Germany; [Liebsch, M.; Luch, A.] German Fed Inst Risk Assessment BfR, ZEBET, Ctr Alternat Anim Testing, D-14195 Berlin, Germany; [Maibach, H. I.] Univ Calif San Francisco, Dept Dermatol, San Francisco, CA 94143 USA; [Martin, S. F.] Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, Freiburg, Germany; [Merk, H. F.] Univ Hosp Aachen, Dept Dermatol & Allergol, Aachen, Germany; [Rustemeyer, T.] Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands; [Schnuch, A.] Univ Gottingen, Dept Dermatol, Gottingen, Germany; [Vandebriel, R. J.] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands; [White, I. R.] St Thomas Hosp, St Johns Inst Dermatol, London, England	Tralau, T (reprint author), German Fed Inst Risk Assessment BfR, Dept Prod Safety, Thielallee 88-92, D-14195 Berlin, Germany.	Tewes.Tralau@bfr.bund.de; Andreas.Luch@bfr.bund.de					Ade Nadege, 2006, J Immunotoxicol, V3, P189, DOI 10.1080/15476910600978038; Ade N, 2007, TOXICOL SCI, V99, P488, DOI 10.1093/toxsci/kfm178; Ade N, 2009, TOXICOL SCI, V107, P451, DOI 10.1093/toxsci/kfn243; Agner T, 2002, CONTACT DERMATITIS, V47, P253, DOI 10.1034/j.1600-0536.2002.470501.x; Albanesi C, 2000, J INVEST DERMATOL, V115, P81, DOI 10.1046/j.1523-1747.2000.00041.x; Alcaide P, 2007, J INVEST DERMATOL, V127, P1964, DOI 10.1038/sj.jid.5700805; Ale IS, 2008, DERMATOTOXICOLOGY, P159; Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Aliahmadi E, 2009, EUR J IMMUNOL, V39, P1221, DOI 10.1002/eji.200838742; Allen MH, 2000, IMMUNOGENETICS, V51, P201, DOI 10.1007/s002510050032; Antonopoulos C, 2008, J LEUKOCYTE BIOL, V83, P361, DOI 10.1189/jlb.0604352; Api AM, 2008, REGUL TOXICOL PHARM, V52, P3, DOI 10.1016/j.yrtph.2007.10.008; Arts JHE, 2008, TOXICOL SCI, V106, P423, DOI 10.1093/toxsci/kfn199; Ashikaga T, 2006, TOXICOL IN VITRO, V20, P767, DOI 10.1016/j.tiv.2005.10.012; Balato A, 2009, J INVEST DERMATOL, V129, P1628, DOI 10.1038/jid.2009.30; Ball N, 2011, REGUL TOXICOL PHARM, V60, P389, DOI 10.1016/j.yrtph.2011.05.007; Baron JM, 2008, CURR MED CHEM, V15, P2258, DOI 10.2174/092986708785747535; Baron JM, 2001, J INVEST DERMATOL, V116, P541, DOI 10.1046/j.1523-1747.2001.01298.x; Basketter DA, 2009, CONTACT DERMATITIS, V60, P65, DOI 10.1111/j.1600-0536.2008.01444.x; BERARDESCA E, 1989, ACTA DERM-VENEREOL, V69, P431; Bergstrom MA, 2007, J INVEST DERMATOL, V127, P1145, DOI 10.1038/sj.jid.5700638; Blomeke B, 2009, BRIT J DERMATOL, V161, P1130, DOI 10.1111/j.1365-2133.2009.09352.x; Braendstrup P, 2008, CONTACT DERMATITIS, V59, P187, DOI 10.1111/j.1600-0536.2008.01397.x; Brasch J, 1997, CONTACT DERMATITIS, V37, P286, DOI 10.1111/j.1600-0536.1997.tb02466.x; Brasch J, 2006, ALLERGY, V61, P364, DOI 10.1111/j.1398-9995.2006.00998.x; BUEHLER EV, 1965, ARCH DERMATOL, V91, P171; Burns R, 2005, J ALLERGY CLIN IMMUN, V115, P383, DOI 10.1016/j.jaci.2004.11.019; Campos RA, 2003, J EXP MED, V198, P1785, DOI 10.1084/jem.20021562; Campos RA, 2006, J IMMUNOL, V177, P3686; Carbone T, 2010, J IMMUNOL, V184, P1102, DOI 10.4049/jimmunol.0902518; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Cavani A, 2003, J IMMUNOL, V171, P5760; Chackerian AA, 2007, J IMMUNOL, V179, P2551; Chatila TA, 2008, J ALLERGY CLIN IMMUN, V121, P812, DOI 10.1016/j.jaci.2008.02.025; Christensson JB, 2010, CONTACT DERMATITIS, V62, P32, DOI 10.1111/j.1600-0536.2009.01657.x; Christensson JB, 2009, CONTACT DERMATITIS, V60, P32, DOI 10.1111/j.1600-0536.2008.01471.x; Church LD, 2008, NAT CLIN PRACT RHEUM, V4, P34, DOI 10.1038/ncprheum0681; CUMBERBATCH M, 1992, IMMUNOLOGY, V75, P257; Dardalhon V, 2008, NAT IMMUNOL, V9, P1347, DOI 10.1038/ni.1677; De Jong WH, 2002, TOXICOL SCI, V66, P226, DOI 10.1093/toxsci/66.2.226; De Jong WH, 2007, J IMMUNOTOXICOL, V4, P239, DOI 10.1080/15476910701507967; de Jongh CM, 2008, BRIT J DERMATOL, V159, P621, DOI 10.1111/j.1365-2133.2008.08730.x; de Padua MCA, 2005, PHARMACOEPIDEM DR S, V14, P725; Dickel H, 2003, J INVEST DERMATOL, V121, P37, DOI 10.1046/j.1523-1747.2003.12323.x; Dickel H, 2002, BRIT MED J, V324, P1422, DOI 10.1136/bmj.324.7351.1422; Dickel H, 2001, BRIT J DERMATOL, V145, P453, DOI 10.1046/j.1365-2133.2001.04377.x; Dickel H, 2010, CONTACT DERMATITIS, V63, P215, DOI 10.1111/j.1600-0536.2010.01769.x; Diepgen TL, 2003, INT ARCH OCC ENV HEA, V76, P331, DOI 10.1007/s00420-002-0418-1; Diepgen TL, 1999, INT ARCH OCC ENV HEA, V72, P496, DOI 10.1007/s004200050407; Diepgen TL, 2002, ARBEITSMED SOZIALMED, V37, P477; Dubois B, 2003, BLOOD, V102, P3295, DOI 10.1182/blood-2003-03-0727; Dudda JC, 2005, EUR J IMMUNOL, V35, P1056, DOI 10.1002/eji.200425817; Dudda JC, 2004, J IMMUNOL, V172, P857; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; EC, 2008, OFF J EUR UNION L, VL353, P1; EC, 2003, OFF J EUR UNION L, V178, P24; Edele F, 2008, J IMMUNOL, V181, P3745; Elahi EN, 2004, CHEM RES TOXICOL, V17, P301, DOI 10.1021/tx0341456; Franot C, 1993, Bioorg Med Chem, V1, P389, DOI 10.1016/S0968-0896(00)82146-X; FRANOT C, 1994, CHEM RES TOXICOL, V7, P297, DOI 10.1021/tx00039a005; FRIEDMANN PS, 1983, CLIN EXP IMMUNOL, V53, P709; Fuhlbrigge RC, 2006, BLOOD, V107, P1421, DOI 10.1182/blood-2005-05-2112; Funke U, 2001, CONTACT DERMATITIS, V44, P166, DOI 10.1034/j.1600-0536.2001.044003166.x; Gaspari AA, 1998, INFECT IMMUN, V66, P4440; Geier J, 2000, DERMATOL BERUF UMWEL, V48, P4; Geier J, 2011, INT ARCH OCC ENV HEA, V84, P403, DOI 10.1007/s00420-010-0581-8; Gerberick F. G., 2007, METHODS, V41, P54; Gerberick GF, 2007, TOXICOL SCI, V97, P417, DOI 10.1093/toxsci/kfm064; Gerberick GF, 2004, TOXICOL SCI, V81, P332, DOI 10.1093/toxsci/kfh213; Gerberick GF, 2001, CONTACT DERMATITIS, V45, P333, DOI 10.1034/j.1600-0536.2001.450603.x; Gober MD, 2008, J INVEST DERMATOL, V128, P1460, DOI 10.1038/sj.jid.5701199; Gober Michael D., 2008, V10, P1, DOI 10.1159/000131410; GOH CL, 1986, CONTACT DERMATITIS, V14, P237, DOI 10.1111/j.1600-0536.1986.tb01232.x; Griffiths CEM, 2005, CYTOKINE, V32, P67, DOI 10.1016/j.cyto.2005.07.011; Hagvall L, 2008, CONTACT DERMATITIS, V59, P143, DOI 10.1111/j.1600-0536.2008.01402.x; Hagvall L, 2007, CHEM RES TOXICOL, V20, P807, DOI 10.1021/tx700017v; Hagvall L, 2008, TOXICOL APPL PHARM, V233, P308, DOI 10.1016/j.taap.2008.08.014; Haraldsen G, 2009, TRENDS IMMUNOL, V30, P227, DOI 10.1016/j.it.2009.03.003; He DG, 2006, J IMMUNOL, V177, P6852; Hermann-Kunz E, 2000, BUNDESGESUNDHEITSBLA, V43, P400, DOI 10.1007/s001030070045; Hilton J, 1998, Am J Contact Dermat, V9, P29, DOI 10.1016/S1046-199X(98)90142-7; Ho SGY, 2005, BRIT J DERMATOL, V153, P364, DOI 10.1111/j.1365-2133.2005.06742.x; Honda T, 2011, J DERMATOL SCI, V63, P75, DOI 10.1016/j.jdermsci.2011.06.004; Honda T, 2011, J DERMATOL SCI, V61, P144, DOI 10.1016/j.jdermsci.2010.11.001; Hooyberghs J, 2008, TOXICOL APPL PHARM, V231, P103, DOI 10.1016/j.taap.2008.03.014; IRVINE C, 1994, OCCUP MED-OXFORD, V44, P17, DOI 10.1093/occmed/44.1.17; Itakura A, 2005, J IMMUNOL, V175, P7170; Jacobs JJL, 2004, TOXICOL IN VITRO, V18, P681, DOI 10.1016/j.tiv.2004.03.007; Jadassohn J, 1896, VERHANDLUNGEN DTSCH, P129; Jensen CS, 2002, BRIT J DERMATOL, V146, P636, DOI 10.1046/j.1365-2133.2002.04666.x; Johansen JD, 2008, CONTACT DERMATITIS, V59, P48, DOI 10.1111/j.1600-0536.2008.01364.x; Johansson H, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-399; Kalergis AM, 1997, J INVEST DERMATOL, V108, P57, DOI 10.1111/1523-1747.ep12285632; Kaplan DH, 2005, IMMUNITY, V23, P611, DOI 10.1016/j.immuni.2005.10.008; Karlberg AT, 2008, CHEM RES TOXICOL, V21, P53, DOI 10.1021/tx7002239; Kielar D, 2003, J INVEST DERMATOL, V121, P465, DOI 10.1046/j.1523-1747.2003.12404.x; Kim BS, 2009, J INVEST DERMATOL, V129, P2805, DOI 10.1038/jid.2009.176; KIMBER I, 1989, ARCH TOXICOL, V63, P274, DOI 10.1007/BF00278640; Kimber I, 2007, ATLA-ALTERN LAB ANIM, V35, P243; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kohl L, 2002, DERMATOLOGY, V204, P334, DOI 10.1159/000063379; Komai-Koma M, 2011, J IMMUNOL, V186, P2584, DOI 10.4049/jimmunol.1002103; Krautheim A, 2010, CONTACT DERMATITIS, V63, P262, DOI 10.1111/j.1600-0536.2010.01753.x; Kutting B, 2008, DEUT MED WOCHENSCHR, V133, P201, DOI 10.1055/s-2008-1017498; KWANGSUKSTITH C, 1995, CONTACT DERMATITIS, V33, P289, DOI 10.1111/j.1600-0536.1995.tb02041.x; Lambrechts N, 2010, TOXICOL SCI, V116, P122, DOI 10.1093/toxsci/kfq108; LAMMINTAUSTA K, 1982, CONTACT DERMATITIS, V8, P327, DOI 10.1111/j.1600-0536.1982.tb04239.x; Landsteiner K, 1936, J EXP MED, V64, P625, DOI 10.1084/jem.64.4.625; Lehe CL, 2006, EXP DERMATOL, V15, P421, DOI 10.1111/j.0906-6705.2006.00415.x; Lepoittevin JP, 2006, CONTACT DERMATITIS, V54, P73, DOI 10.1111/j.0105-1873.2006.00795.x; Lerbaek A, 2007, BRIT J DERMATOL, V157, P1199, DOI 10.1111/j.1365-2133.2007.08252.x; Lerbaek A, 2007, BRIT J DERMATOL, V157, P552, DOI 10.1111/j.1365-2133.2007.08088.x; Liden C, 2008, CONTACT DERMATITIS, V58, P347, DOI 10.1111/j.1600-0536.2008.01326.x; Lindberg M, 2007, CONTACT DERMATITIS, V56, P205, DOI 10.1111/j.1600-0536.2006.01063.x; Lunder T, 2000, CONTACT DERMATITIS, V43, P107, DOI 10.1034/j.1600-0536.2000.043002107.x; MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martin SF, 2011, ALLERGY, V66, P1152, DOI 10.1111/j.1398-9995.2011.02652.x; Martin SF, 2008, J EXP MED, V205, P2151, DOI 10.1084/jem.20070509; Martin Stefan F., 2007, P34, DOI 10.1159/000104187; Martin SF, 2010, CELL MOL LIFE SCI, V67, P4171, DOI 10.1007/s00018-010-0495-3; Martinon F, 2004, CELL, V117, P561, DOI 10.1016/j.cell.2004.05.004; Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x; Matura M, 2002, J AM ACAD DERMATOL, V47, P709, DOI 10.1067/mjd.2002.124817; Maxwell G, 2011, ALTEX-ALTERN ANIM EX, V28, P50; Menne T, 2002, CONTACT DERMATITIS, V46, P189, DOI 10.1034/j.1600-0536.2002.460401.x; Mortz CG, 2002, ACTA DERM-VENEREOL, V82, P352, DOI 10.1080/000155502320624087; Mutyambizi K, 2009, CELL MOL LIFE SCI, V66, P831, DOI 10.1007/s00018-008-8470-y; Nacak M, 2007, BASIC CLIN PHARMACOL, V101, P101, DOI 10.1111/j.1742-7843.2007.00077.x; Nakae S, 2002, IMMUNITY, V17, P375, DOI 10.1016/S1074-7613(02)00391-6; Nguyen SH, 2008, CONTACT DERMATITIS, V58, P101, DOI 10.1111/j.1600-0536.2007.01281.x; O'Leary JG, 2006, NAT IMMUNOL, V7, P507, DOI 10.1038/ni1332; OECD, 2002, OECD GUID 429 SKIN S; Ott H, 2010, SKIN PHARMACOL PHYS, V23, P213, DOI 10.1159/000313897; Ott H, 2009, CHEM RES TOXICOL, V22, P399, DOI 10.1021/tx8003642; Patlewicz GY, 2004, CONTACT DERMATITIS, V50, P91, DOI 10.1111/j.0105-1873.2004.00322.x; Patlewicz GY, 2002, CONTACT DERMATITIS, V47, P219, DOI 10.1034/j.1600-0536.2002.470406.x; Paust S, 2010, NAT IMMUNOL, V11, P1127, DOI 10.1038/ni.1953; Python F, 2007, TOXICOL APPL PHARM, V220, P113, DOI 10.1016/j.taap.2006.12.026; Reduta T, 2011, FOLIA HISTOCHEM CYTO, V49, P255, DOI 10.5603/FHC.2011.0035; REED JT, 1995, ARCH DERMATOL, V131, P1134, DOI 10.1001/archderm.131.10.1134; REES JL, 1989, BRIT J DERMATOL, V120, P371, DOI 10.1111/j.1365-2133.1989.tb04162.x; Reich K, 2003, J ALLERGY CLIN IMMUN, V112, P1191, DOI 10.1016/j.jaci.2003.09.012; Ring S, 2006, EUR J IMMUNOL, V36, P2981, DOI 10.1002/eji.200636207; Ring S, 2010, J IMMUNOL, V184, P3408, DOI 10.4049/jimmunol.0901751; Ring S, 2010, J ALLERGY CLIN IMMUN, V125, P237, DOI 10.1016/j.jaci.2009.10.025; Ring S, 2009, J ALLERGY CLIN IMMUN, V123, P1287, DOI 10.1016/j.jaci.2009.03.022; Sakaguchi H, 2006, TOXICOL IN VITRO, V20, P774, DOI 10.1016/j.tiv.2005.10.014; Sakaguchi S, 1996, J AUTOIMMUN, V9, P211, DOI 10.1006/jaut.1996.0026; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schiffer R, 2003, J INVEST DERMATOL, V120, P285, DOI 10.1046/j.1523-1747.2003.12031.x; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schnuch A, 2008, BRIT J DERMATOL, V159, P379, DOI 10.1111/j.1365-2133.2008.08644.x; Schnuch A, 2003, CONTACT DERMATITIS, V49, P107, DOI 10.1111/j.0105-1873.2003.0128f.x; Schnuch A, 1998, CONTACT DERMATITIS, V38, P209, DOI 10.1111/j.1600-0536.1998.tb05709.x; Schnuch A, 2006, HDB ATOPIC ECZEMA, P178, DOI 10.1007/3-540-29856-8_17; Schnuch A, 2007, CONTACT DERMATITIS, V57, P1, DOI 10.1111/j.1600-0536.2007.01088.x; Schnuch A, 2007, CONTACT DERMATITIS, V56, P331, DOI 10.1111/j.1600-0536.2007.01116.x; Schnuch A, 2011, CONTACT DERMATITIS, V64, P142, DOI 10.1111/j.1600-0536.2010.01841.x; Schnuch A, 2011, CONTACT DERMATITIS, V64, P2, DOI 10.1111/j.1600-0536.2010.01800.x; Schnuch A, 2011, CONTACT DERMATITIS, FIFTH EDITION, P13, DOI 10.1007/978-3-642-03827-3_2; [Anonymous], 2006, MEM HAIR DYE SUBST T; [Anonymous], 2007, OP SENS HAIR DYES CO; [Anonymous], 2005, 086305 SCCP; SINIGAGLIA F, 1985, J IMMUNOL, V135, P3929; Skazik C, 2008, EXP DERMATOL, V17, P739, DOI 10.1111/j.1600-0625.2008.00745.x; Skazik C, 2011, ARCH BIOCHEM BIOPHYS, V508, P212, DOI 10.1016/j.abb.2011.01.013; Skold M, 2002, CONTACT DERMATITIS, V46, P267, DOI 10.1034/j.1600-0536.2002.460504.x; Skold M, 2008, CONTACT DERMATITIS, V58, P9; Sosted H, 2006, CONTACT DERMATITIS, V54, P87, DOI 10.1111/j.0105-1873.2006.00746.x; Thyssen JP, 2008, CONTACT DERMATITIS, V59, P238, DOI 10.1111/j.1600-0536.2008.01418.x; Thyssen JP, 2008, CONTACT DERMATITIS, V59, P38, DOI 10.1111/j.1600-0536.2008.01350.x; Thyssen JP, 2007, CONTACT DERMATITIS, V57, P287, DOI 10.1111/j.1600-0536.2007.01220.x; Thyssen JP, 2007, CONTACT DERMATITIS, V57, P265, DOI 10.1111/j.1600-0536.2007.01218.x; Thyssen JP, 2007, CONTACT DERMATITIS, V56, P185, DOI 10.1111/j.1600-0536.2006.01058.x; Thyssen JP, 2008, CONTACT DERMATITIS, V59, P327, DOI 10.1111/j.1600-0536.2008.01427.x; Toebak MJ, 2009, CONTACT DERMATITIS, V60, P2, DOI 10.1111/j.1600-0536.2008.01443.x; Toebak MJ, 2006, TOXICOL IN VITRO, V20, P117, DOI 10.1016/j.tiv.2005.06.039; Tomura M, 2010, J CLIN INVEST, V120, P883, DOI 10.1172/JCI40926; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Uter W, 2007, J EUR ACAD DERMATOL, V21, P374, DOI 10.1111/j.1468-3083.2006.01973.x; Uter W, 2006, CONTACT DERMATITIS, V55, P54, DOI 10.1111/j.0105-1873.2006.0847b.x; Uter W, 2003, CONTACT DERMATITIS, V48, P33, DOI 10.1034/j.1600-0536.46.s4.29_102.x; Uter W, 2002, DERMATOLOGY, V204, P266, DOI 10.1159/000063356; Uter W, 2010, CONTACT DERMATITIS, V63, P277, DOI 10.1111/j.1600-0536.2010.01768.x; Uter W, 2010, CONTACT DERMATITIS, V63, P254, DOI 10.1111/j.1600-0536.2010.01759.x; van Och FMM, 2003, TOXICOLOGY, V184, P23, DOI 10.1016/S0300-483X(02)00550-4; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Vocanson M, 2009, ALLERGY, V64, P1699, DOI 10.1111/j.1398-9995.2009.02082.x; Vocanson M, 2008, J INVEST DERMATOL, V128, P2119, DOI 10.1038/jid.2008.15; Vocanson M, 2010, J ALLERGY CLIN IMMUN, V126, P280, DOI 10.1016/j.jaci.2010.05.022; Vocanson M, 2009, J INVEST DERMATOL, V129, P1185, DOI 10.1038/jid.2008.352; Wakem P, 2000, J INVEST DERMATOL, V114, P1085, DOI 10.1046/j.1523-1747.2000.00997.x; Wang BJ, 2007, CONTACT DERMATITIS, V57, P309, DOI 10.1111/j.1600-0536.2007.01242.x; Wang LC, 2008, J IMMUNOL, V180, P4722; Watanabe H, 2007, J INVEST DERMATOL, V127, P1956, DOI 10.1038/sj.jid.5700819; Weber FC, 2010, J EXP MED, V207, P2609, DOI 10.1084/jem.20092489; WEDIG JH, 1981, J AM ACAD DERMATOL, V5, P433, DOI 10.1016/S0190-9622(81)70105-1; Westphal GA, 2000, INT ARCH OCC ENV HEA, V73, P384, DOI 10.1007/s004200000159; Westphal GA, 2003, CONTACT DERMATITIS, V48, P93, DOI 10.1034/j.1600-0536.2003.480208.x; Westphal GA, 2000, BRIT J DERMATOL, V142, P1121, DOI 10.1046/j.1365-2133.2000.03536.x; Wohrl S, 2001, J EUR ACAD DERMATOL, V15, P470, DOI 10.1046/j.1468-3083.2001.00317.x; Yoshiki R, 2009, J INVEST DERMATOL, V129, P705, DOI 10.1038/jid.2008.304; [Anonymous], 2003, OFF J EUR UNION L, V66, P26; [Anonymous], 2009, OFF J EUR UNION L, V342, P59; [Anonymous], 2004, OFF J EUR UNION L, VL-104, P1; 1994, OFF J EUR UNION L, V188, P1	210	83	86	0	23	SPRINGER BASEL AG	BASEL	PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND	1420-682X			CELL MOL LIFE SCI	Cell. Mol. Life Sci.	MAR	2012	69	5					763	781		10.1007/s00018-011-0846-8		19	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	898IR	WOS:000300736400007	21997384	
J	Chung, KF				Chung, Kian Fan			p38 Mitogen-Activated Protein Kinase Pathways in Asthma and COPD	CHEST			English	Article							AIRWAY SMOOTH-MUSCLE; NF-KAPPA-B; RELATIVE CORTICOSTEROID INSENSITIVITY; OBSTRUCTIVE PULMONARY-DISEASE; HUMAN ALVEOLAR MACROPHAGES; HEAT-SHOCK-PROTEIN; MAP-KINASE; GLUCOCORTICOID-RECEPTOR; CELL-MIGRATION; CYTOKINE RELEASE	The mitogen-activated protein kinase (MAPK) family includes the p38 kinases, which consist of highly conserved proline-directed serine-threonine protein kinases that are activated in response to inflammatory signals. Of the four isoforms, p38 alpha is the most abundant in inflammatory cells and has been the most studied through mainly the availability of small molecule inhibitors. The p38 substrates include transcription factors; other protein kinases, which in turn phosphorylate transcription factors; cytoskeletal proteins and translational components; and other enzymes. Both asthma and COPD are characterized by chronic airflow obstruction, airway and lung remodeling, and chronic inflammation. p38 is involved in the inflammatory responses induced by cigarette smoke exposure, endotoxin, and oxidative stress through activation and release of proinflammatory cytokines/chemokines, posttranslational regulation of these genes, and activation of inflammatory cell migration. Inhibition of p38 MAPK prevented allergen-induced pulmonary eosinophilia, mucus hypersecretion, and airway hyperresponsiveness, effects that may partly result from p38 activation on eosinophil apoptosis and on airway smooth muscle cell production of cytokines/chemokines. In addition, p38 regulates the augmented contractile response induced by oxidative stress. The activation of p38 observed in epithelial cells and macrophages also may underlie corticosteroid insensitivity of severe asthma and COPD. Therefore, p38 inhibitors present a potential attractive treatment of these conditions. Second-generation p38 inhibitors have been disappointing in the treatment of rheumatoid arthritis. In two 6-week studies in patients with COPD, the results were encouraging. Side effects such as liver toxicity remain a possibility, and whether the beneficial effects of p38 inhibitors are clinically significant and sustained need to be determined. CHEST 2011; 139(6):1470-1479	[Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Chung, Kian Fan] Royal Brompton Hosp, Biomed Res Unit, London SW3 6LY, England	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk		Chung, Kian Fan/0000-0001-7101-1426	Wellcome Trust; Asthma UK; Medical Research Council; Biomedical Research Unit of Royal Brompton Hospital; National Heart and Lung Institute, Imperial College	Dr Chung is supported by grants from the Wellcome Trust, Asthma UK, and Medical Research Council and by the Biomedical Research Unit of Royal Brompton Hospital and National Heart and Lung Institute, Imperial College.	Abraham SM, 2006, J EXP MED, V203, P1883, DOI 10.1084/jem.20060336; Adachi T, 2000, J IMMUNOL, V165, P2198; Adcock IM, 2006, EUR J PHARMACOL, V533, P118, DOI 10.1016/j.ejphar.2005.12.054; Alfaro-Moreno E, 2002, ENVIRON HEALTH PERSP, V110, P715; Amrani Y, 2001, MOL PHARMACOL, V60, P646; Arrighi JF, 2001, J IMMUNOL, V166, P3837; Barnes N, 2009, EUR RESP J S53, V34, p648s; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Bhavsar P, 2010, EUR RESPIR J, V35, P750, DOI 10.1183/09031936.00071309; Birrell MA, 2008, J CELL PHYSIOL, V214, P27, DOI 10.1002/jcp.21158; Branger J, 2002, J IMMUNOL, V168, P4070; Cheng SE, 2009, FREE RADICAL BIO MED, V46, P948, DOI 10.1016/j.freeradbiomed.2009.01.006; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Chung KF, 2000, EUR RESPIR J, V15, P961, DOI 10.1034/j.1399-3003.2000.15e26.x; Chung KF, 2009, EUR J CLIN PHARMACOL, V65, P853, DOI 10.1007/s00228-009-0682-z; Cohen SB, 2009, ARTHRITIS RHEUM, V60, P335, DOI 10.1002/art.24266; Cosio BG, 2004, AM J RESP CRIT CARE, V170, P141, DOI 10.1164/rccm.200305-659OC; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Damjanov N, 2009, ARTHRITIS RHEUM, V60, P1232, DOI 10.1002/art.24485; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408; Eckert RL, 2003, J INVEST DERMATOL, V120, P823, DOI 10.1046/j.1523-1747.2003.12120.x; Gerthoffer WT, 2003, RESP PHYSIOL NEUROBI, V137, P237, DOI 10.1016/S1569-9048(03)00150-2; Godl K, 2003, P NATL ACAD SCI USA, V100, P15434, DOI 10.1073/pnas.2535024100; Goncharova EA, 2002, BIOL CHEM, V383, P115, DOI 10.1515/BC.2002.012; Haddad J J, 2001, Curr Opin Investig Drugs, V2, P1070; Hall DJ, 2005, J IMMUNOL, V174, P8056; Hallsworth MP, 2001, AM J RESP CRIT CARE, V164, P688; Hammaker D, 2010, ANN RHEUM DIS, V69, P77, DOI 10.1136/ard.2009.119479; Hayashi S, 2008, RESPIROLOGY, V13, P203, DOI 10.1111/j.1440-1843.2007.01204.x; Hedges JC, 2000, AM J RESP CELL MOL, V23, P86; Hedges JC, 1999, J BIOL CHEM, V274, P24211, DOI 10.1074/jbc.274.34.24211; Heit B, 2002, J CELL BIOL, V159, P91, DOI 10.1083/jcb.200202114; Henness S, 2006, AM J PHYSIOL-LUNG C, V290, pL1283, DOI 10.1152/ajplung.00367.2005; Henness S, 2004, J ALLERGY CLIN IMMUN, V114, P958, DOI 10.1016/j.jaci.2004.06.023; Heuertz RM, 1999, J BIOL CHEM, V274, P17968, DOI 10.1074/jbc.274.25.17968; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Hu JH, 2007, CELL SIGNAL, V19, P393, DOI 10.1016/j.cellsig.2006.07.010; Huot J, 1997, CIRC RES, V80, P383; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Ishizuka T, 2001, J IMMUNOL, V167, P2298; Issa R, 2007, J IMMUNOL, V178, P7366; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Jang MK, 2010, BIOCHEM BIOPH RES CO, V393, P137, DOI 10.1016/j.bbrc.2010.01.102; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; Koch A, 2004, EUR RESPIR J, V23, P805, DOI 10.1183/09031936.04.00104304; Koch A, 2004, AM J RESP CELL MOL, V30, P342, DOI 10.1165/rcmb.2003-0122OC; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lakser OJ, 2002, AM J PHYSIOL-LUNG C, V282, pL1117, DOI 10.1152/ajplung.00230.2000; Langlois A, 2009, J LEUKOCYTE BIOL, V85, P656, DOI 10.1189/jlb.0808492; Larsen JK, 1997, AM J PHYSIOL-LUNG C, V273, pL930; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Leigh R, 2008, J ALLERGY CLIN IMMUN, V121, P1238, DOI 10.1016/j.jaci.2008.01.067; Li F, 2011, EUR RESPIR J, V37, P933, DOI 10.1183/09031936.00021110; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Macedo P, 2009, CLIN EXP ALLERGY, V39, P1668, DOI 10.1111/j.1365-2222.2009.03319.x; MacNee W, 2010, EUR RESP J S54, V36, p718s; Medicherla S, 2008, J PHARMACOL EXP THER, V324, P921, DOI 10.1124/jpet.107.127092; Meja KK, 2000, BRIT J PHARMACOL, V131, P1143, DOI 10.1038/sj.bjp.0703684; Miller AL, 2005, MOL ENDOCRINOL, V19, P1569, DOI 10.1210/me.2004-0528; Mirzapoiazova T, 2005, J CELL PHYSIOL, V203, P520, DOI 10.1002/jcp.20244; Moretto N, 2009, AM J PHYSIOL-LUNG C, V296, pL839, DOI 10.1152/ajplung.90570.2008; Mourey RJ, 2010, J PHARMACOL EXP THER, V333, P797, DOI 10.1124/jpet.110.166173; Nath P, 2006, EUR J PHARMACOL, V544, P160, DOI 10.1016/j.ejphar.2006.06.031; Nguyen J, 2006, IMMUNOL LETT, V106, P34, DOI 10.1016/j.imlet.2006.04.003; O'Shea JM, 2008, BIOCHEM SOC T, V36, P603, DOI 10.1042/BST0360603; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; Piotrowicz RS, 1998, FASEB J, V12, P1481; Pramanik R, 2003, J BIOL CHEM, V278, P4831, DOI 10.1074/jbc.M207732200; Qi XM, 2007, J BIOL CHEM, V282, P31398, DOI 10.1074/jbc.M703857200; Quante T, 2008, AM J RESP CELL MOL, V39, P208, DOI 10.1165/rcmb.2007-0014OC; Renda T, 2008, EUR RESPIR J, V31, P62, DOI 10.1183/09031936.00036707; Rincon M, 2003, IMMUNOL REV, V192, P131, DOI 10.1034/j.1600-065X.2003.00019.x; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Rousseau S, 2006, CELL SIGNAL, V18, P1897, DOI 10.1016/j.cellsig.2006.02.006; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Schreiber S, 2006, CLIN GASTROENTEROL H, V4, P325, DOI 10.1016/j.cgh.2005.11.013; Singh D, 2010, J CLIN PHARMACOL, V50, P94, DOI 10.1177/0091270009347873; Smith SJ, 2006, BRIT J PHARMACOL, V149, P393, DOI 10.1038/sj.bjp.0706885; Spahn JD, 1996, J IMMUNOL, V157, P2654; Szatmary Z, 2004, J BIOL CHEM, V279, P43708, DOI 10.1074/jbc.M406568200; Tudor C, 2009, FEBS LETT, V583, P1933, DOI 10.1016/j.febslet.2009.04.039; Underwood DC, 2000, AM J PHYSIOL-LUNG C, V279, pL895; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Wang X, 2004, MOL PSYCHIATR, V9, P65, DOI 10.1038/sj.mp.4001339; Williams AS, 2008, EUR J PHARMACOL, V600, P117, DOI 10.1016/j.ejphar.2008.09.031; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Wong CK, 2003, AM J RESP CELL MOL, V29, P133, DOI 10.1165/rcmb.2002-0289OC; Woo CH, 2004, J IMMUNOL, V173, P6973; Xing L, 2009, BIOCHEMISTRY-US, V48, P6402, DOI 10.1021/bi900655f; Zhai WW, 2004, BRIT J PHARMACOL, V143, P1042, DOI 10.1038/sj.bjp.0705971; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007	94	83	93	0	23	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2011	139	6					1470	1479		10.1378/chest.10-1914		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	776CC	WOS:000291511100034	21652557	
J	Morello-Frosch, R; Zuk, M; Jerrett, M; Shamasunder, B; Kyle, AD				Morello-Frosch, Rachel; Zuk, Miriam; Jerrett, Michael; Shamasunder, Bhavna; Kyle, Amy D.			Understanding The Cumulative Impacts Of Inequalities In Environmental Health: Implications For Policy	HEALTH AFFAIRS			English	Article							SELF-RATED HEALTH; ADVERSE BIRTH OUTCOMES; AMBIENT AIR-POLLUTION; UNITED-STATES; CARDIOVASCULAR-DISEASE; CHILDHOOD ASTHMA; HAZARDOUS-WASTE; RISK-ASSESSMENT; OLDER-ADULTS; DISPARITIES	Racial or ethnic minority groups and low-income communities have poorer health outcomes than others. They are more frequently exposed to multiple environmental hazards and social stressors, including poverty, poor housing quality, and social inequality. Researchers are grappling with how best to characterize the cumulative effects of these hazards and stressors in order to help regulators and decision makers craft more-effective policies to address health and environmental disparities. In this article we synthesize the existing scientific evidence regarding the cumulative health implications of higher rates of exposure to environmental hazards, along with individual biological susceptibility and social vulnerability. We conclude that current environmental policy, which is focused narrowly on pollutants and their sources, should be broadened to take into account the cumulative impact of exposures and vulnerabilities encountered by people who live in neighborhoods consisting largely of racial or ethnic minorities or people of low socioeconomic status.	[Morello-Frosch, Rachel; Shamasunder, Bhavna] Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; [Jerrett, Michael; Kyle, Amy D.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA	Morello-Frosch, R (reprint author), Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA.	rmf@berkeley.edu		Morello-Frosch, Rachel/0000-0003-1153-7287	California Environmental Protection Agency, Office of Environmental Health Hazard Assessment [07-E0009]; National Institute of Environmental Health Sciences	This work was funded in part by the California Environmental Protection Agency, Office of Environmental Health Hazard Assessment (07-E0009, Understanding and Acting on Cumulative Impacts on California Communities) and the Superfund Research Program of the National Institute of Environmental Health Sciences. The authors thank Valerie Tran for assistance with preparing this manuscript.	Adler NE, 2008, ANNU REV PUBL HEALTH, V29, P235, DOI 10.1146/annurev.publhealth.29.020907.090852; Bhatia R, 2009, GUIDE HLTH IMPACT AS; Brody JG, 2009, AM J PUBLIC HLTH S3, V99, pS600; Brook RD, 2008, J OCCUP ENVIRON MED, V50, P32, DOI 10.1097/JOM.0b013e31815dba70; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; California Air Resource Board, 2005, AIR QUAL LAND US HDB; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Clougherty JE, 2009, ENVIRON HEALTH PERSP, V117, P1351, DOI 10.1289/ehp.0900612; Cole BL, 2004, J HEALTH POLIT POLIC, V29, P1153, DOI 10.1215/03616878-29-6-1153; Corburn J, 2007, J ENVIRON PLANN MAN, V50, P323, DOI 10.1080/09640560701260283; Dahmann N, 2009, HEALTH PLACE, V16, P431; deFur PL, 2007, ENVIRON HEALTH PERSP, V115, P817, DOI 10.1289/ehp.9332; DiezRoux AV, 1997, AM J EPIDEMIOL, V146, P48; Do DP, 2008, SOC SCI MED, V67, P1258, DOI 10.1016/j.socscimed.2008.06.018; Downey L, 2005, J HEALTH SOC BEHAV, V46, P289; Environmental Protection Agency, 2003, FRAM CUM RISK ASS; Environmental Protection Agency, 2011, ENV JUST STRAT ENF A; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409; Faustman EM, 2000, ENVIRON HEALTH PERSP, V108, P13, DOI 10.2307/3454629; Finkelstein MM, 2003, CAN MED ASSOC J, V169, P397; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gavidia TG, 2009, BMC PEDIATR, V9, DOI 10.1186/1471-2431-9-10; Gee G, 2004, ENV HLTH PERSPECT, V112, P645; Giscombe CL, 2005, PSYCHOL BULL, V131, P662, DOI 10.1037/0033-2909.131.5.662; Goodman E, 2005, PSYCHOSOM MED, V67, P9, DOI 10.1097/01.psy.0000149254.36133.1a; Gordon CJ, 2003, ENVIRON RES, V92, P1, DOI 10.1016/S0013-9351(02)00008-7; Gordon-Larsen P, 2006, PEDIATRICS, V117, P417, DOI 10.1542/peds.2005-0058; Gunier RB, 2003, J EXPO ANAL ENV EPID, V13, P240, DOI 10.1038/sj.jea.7500276; Hartig T, 2008, LANCET, V372, P1614, DOI 10.1016/S0140-6736(08)61669-4; Huynh M, 2005, INT J EPIDEMIOL, V34, P888, DOI 10.1093/ije/dyi092; Idler EL, 1997, J HEALTH SOC BEHAV, V38, P21, DOI 10.2307/2955359; Jerrett M, 2001, ENVIRON PLANN A, V33, P955, DOI 10.1068/a33137; Jerrett M, 2009, ENVIRON HEALTH PERSP, V117, P772, DOI 10.1289/ehp.11533; Jones RL, 2009, PEDIATRICS, V123, pe376, DOI 10.1542/peds.2007-3608; KAPLAN GA, 1993, CIRCULATION, V88, P1973; Krieger N, 2005, AM J PUBLIC HEALTH, V95, P2155, DOI 10.2105/AJPH.2005.067108; Kunzli N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009096; Kuzawa CW, 2009, AM J HUM BIOL, V21, P2, DOI 10.1002/ajhb.20822; Kwate NOA, 2009, HEALTH PLACE, V15, P364, DOI 10.1016/j.healthplace.2008.07.003; Levy JI, 2008, RISK ANAL, V28, P1507, DOI 10.1111/j.1539-6924.2008.01121.x; McEwen BS, 1998, NEW ENGL J MED, V338, P171; Mensah GA, 2005, CIRCULATION, V111, P1233, DOI 10.1161/01.CIR.0000158136.76824.04; Mohai P, 2007, SOC PROBL, V54, P343, DOI 10.1525/sp.2007.54.3.343; Mohai Paul, 2009, Am J Public Health, V99 Suppl 3, pS649, DOI 10.2105/AJPH.2007.131383; Morello-Frosch R, 2002, ENVIRON HEALTH PERSP, V110, P149; Morello-Frosch RA, 2002, ENVIRON PLANN C, V20, P477, DOI 10.1068/c03r; Morello-Frosch R, 2006, ENVIRON HEALTH PERSP, V114, P1150, DOI 10.1289/ehp.8930; Morello-Frosch R, 2010, ENVIRON HEALTH-GLOB, V9, DOI 10.1186/1476-069X-9-44; Morland K, 2007, PUBLIC HEALTH NUTR, V10, P1481, DOI 10.1017/S1368980007000079; Mustillo S, 2004, AM J PUBLIC HEALTH, V94, P2125, DOI 10.2105/AJPH.94.12.2125; National Environmental Justice Advisory Council, 2004, ENS RISK RED COMM MU; National Environmental Justice Advisory Council, 2010, NAT CONS ENV JUST SC; Natl. Res. Counc. Comm. Improv. Risk Anal. Approaches Used by the U. S. EPA Board Environ. Stud. Toxicol. Div. Earth Life Stud, 2009, SCI DEC ADV RISK ASS; Navas-Acien A, 2007, ENVIRON HEALTH PERSP, V115, P472, DOI 10.1289/ehp.9785; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Office of Environmental Health Hazard Assessment, 2007, ENV JUST ACT OEHHA C; Osborn B, 2011, LIBERTY HILL    0121; Sadd J., 2010, AIR POLLUTION ENV JU; Pastor M., 2000, REGIONS WORK CITIES; Ponce NA, 2005, AM J EPIDEMIOL, V162, P140, DOI 10.1093/aje/kwi173; Pope CA, 2009, CIRCULATION, V120, P941, DOI 10.1161/CIRCULATIONAHA.109.857888; Sahagun L, 2011, LOS ANGELES TIM 0121; Sandstrom T, 2003, Eur Respir J Suppl, V40, p92s; Shankardass K, 2009, P NATL ACAD SCI USA, V106, P12406, DOI 10.1073/pnas.0812910106; Su JG, 2009, ENVIRON SCI TECHNOL, V43, P7626, DOI 10.1021/es901041p; Subramanian SV, 2005, SOC SCI MED, V60, P1667, DOI 10.1016/j.socscimed.2004.08.040; Teutsch SM, 2011, HEALTH AFFAIR, V30, P349, DOI 10.1377/hlthaff.2010.0593; Vrijheid M, 2000, ENVIRON HEALTH PERSP, V108, P101, DOI 10.2307/3454635; Wang Y, 2007, EPIDEMIOL REV, V29, P6, DOI 10.1093/epirev/mxm007; Wen M, 2006, SOC SCI MED, V63, P2575, DOI 10.1016/j.socscimed.2006.06.025; Wilhelm M, 2003, ENVIRON HEALTH PERSP, V111, P207, DOI 10.1289/ehp.5688; Woodruff TJ, 2003, ENVIRON HEALTH PERSP, V111, P942, DOI 10.1289/ehp.5317; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yao L, 2008, RES AGING, V30, P251, DOI 10.1177/0164027507311155; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991; Zanobetti A, 2001, AM J RESP CRIT CARE, V164, P831	77	83	84	9	52	PROJECT HOPE	BETHESDA	7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA	0278-2715			HEALTH AFFAIR	Health Aff.	MAY	2011	30	5					879	887		10.1377/hlthaff.2011.0153		9	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	761WD	WOS:000290430800011	21555471	
J	McPherson, EG; Simpson, JR; Xiao, QF; Wu, CX				McPherson, E. Gregory; Simpson, James R.; Xiao, Qingfu; Wu, Chunxia			Million trees Los Angeles canopy cover and benefit assessment	LANDSCAPE AND URBAN PLANNING			English	Article						Ecosystem services; Urban forestry; Tree canopy cover; Tree benefits	URBAN FOREST; CALIFORNIA; VEGETATION; HEALTH; ASTHMA; COSTS; AREAS	The Million Trees LA initiative intends to improve Los Angeles's environment through planting and stewardship of 1 million trees. The purpose of this study was to measure Los Angeles's existing tree canopy cover (TCC), determine if space exists for 1 million additional trees, and estimate future benefits from the planting. High-resolution QuickBird remote sensing data, aerial photographs, and geographic information systems were used to classify land cover types, measure TCC, and identify potential tree planting sites. Benefits were forecast for planting of 1 million trees between 2006 and 2010, and their growth and mortality were projected until 2040. Two scenarios reflected low (17%) and high (56%) mortality rates. Numerical models were used with geographic data and tree size information for coastal and inland climate zones to calculate annual benefits and their monetary value. Los Angeles's existing TCC was 21%, and ranged from 7 to 37% by council district. There was potential to add 2.5 million additional trees to the existing population of approximately 10.8 million, but only 1.3 million of the potential tree sites are deemed realistic to plant. Benefits for the 1-million-tree planting for the 35-year period were $1.33 billion and $1.95 billion for the high- and low-mortality scenarios, respectively. Average annual benefits were $38 and $56 per tree planted. Eighty-one percent of total benefits were aesthetic/other, 8% were stormwater runoff reduction, 6% energy savings, 4% air quality improvement, and less than 1% atmospheric carbon reduction. Published by Elsevier B.V.	[McPherson, E. Gregory; Simpson, James R.] US Forest Serv, USDA, Pacific SW Res Stn, Ctr Urban Forest Res, Davis, CA 95618 USA; [Xiao, Qingfu; Wu, Chunxia] Univ Calif Davis, Dept Land Air & Water Resources, Davis, CA 95616 USA	McPherson, EG (reprint author), US Forest Serv, USDA, Pacific SW Res Stn, Ctr Urban Forest Res, 1731 Res Pk Dr, Davis, CA 95618 USA.	gmcpherson@fs.fed.us; jrsimpson@fs.fed.us; qxiao@ucdavis.edu; chelseawu2@gmail.com			City of Los Angeles, California	This research was supported by funds provided by the city of Los Angeles, California, and we thank Paula Daniels, George Gonzalez, Lisa Sarno, and Lillian Kawasaki for their support. We wish to acknowledge Patrice Gin, Randy Price. and Kirk Bishop (Public Works/Bureau of Engineering/Mapping Division, city of Los Angeles) for sharing their GIS data and aerial imagery with us. Rebecca Drayse, Edith Ben-Horin, and David O'Donnell of TreePeople led the survey of field plots. Thanks to Dan Knapp, Los Angeles Conservation Corp, who assisted with development of the planting scenarios. Kelaine Vargas and Paula Peper at the U.S. Forest Service Center for Urban Forest Research provided technical and editorial assistance throughout the course of the study.	*AM FOR, 2002, PROJ BEN COMM TREE P; *AM FOR, 2002, URB EC AN WASH DC ME; Anderson L. M., 1985, Southern Journal of Applied Forestry, V9, P162; Benjamin MT, 1998, ATMOS ENVIRON, V32, P53, DOI 10.1016/S1352-2310(97)00176-3; BRENZEL KN, 2001, SUNSET W GARDEN BOOK; *CAL ASS REALT, 2006, MED HOM SAL PRIC LOS; City of Los Angeles, 2007, GREEN LA ACT PLAN LE; Condon R, 1999, 2 NATURE ADAPTING LA; Galvin MF, 2006, REPORT BALTIMORE CIT; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; GIDOLFGUNNARSSO.A, 2007, LANDSCAPE URBAN PLAN, V3, P115; Given S, 2006, ENVIRON SCI TECHNOL, V40, P4851, DOI 10.1021/es060679s; Goetz SJ, 2003, REMOTE SENS ENVIRON, V88, P195, DOI 10.1016/j.rse.2003.07.010; Grove J.M., 2006, REPORT NEW YORK CITY; HYMON S, 2006, LA BE REMADE SHADE; IRANI FW, 2003, TECHNOLOGY CONVERGIN, P85; *JON STOK ASS INC, 1998, COST BEN AN TREES PR; KALER D, 2005, CITY VANCOUVER CANOP; Kaplan R., 1989, EXPERIENCE NATURE PS; Kollin C., 2006, STORMWATER, V7, P138; Larsen K, 2009, AM J PUBLIC HEALTH, V99, P520, DOI 10.2105/AJPH.2008.135319; Lovasi GS, 2008, J EPIDEMIOL COMMUN H, V62, P647, DOI 10.1136/jech.2007.071894; Maas J, 2006, J EPIDEMIOL COMMUN H, V60, P587, DOI 10.1136/jech.2005.043125; Maco Scott E., 2003, Journal of Arboriculture, V29, P84; McPherson E. Gregory, 2003, Urban Forestry & Urban Greening, V2, P73, DOI 10.1078/1618-8667-00025; McPherson E. Gregory, 2005, Journal of Arboriculture, V31, P303; McPherson E. Gregory, 1998, Journal of Arboriculture, V24, P174; MCPHERSON EG, 1992, LANDSCAPE URBAN PLAN, V22, P41; McPherson EG, 2001, LANDSCAPE URBAN PLAN, V57, P105, DOI 10.1016/S0169-2046(01)00196-7; McPherson E. G., 2001, TREE GUIDELINES INLA; McPherson E. G., 1993, ELECT J, V6, P57, DOI 10.1016/1040-6190(93)90078-Y; McPherson E.G, 2000, TREE GUIDELINES COAS; McPherson E.G., 1999, PSW171 USDA FOR SERV; McPherson E. G., 2005, J FOREST, V103, P411; McPherson E. G., 2008, PSW207 USDA FOR SERV; Myeong Soojeong, 2001, Urban Ecosystems, V5, P243, DOI 10.1023/A:1025687711588; Parsons R, 1998, J ENVIRON PSYCHOL, V18, P113, DOI 10.1006/jevp.1998.0086; Payton S, 2008, J ENVIRON PLANN MAN, V51, P717, DOI 10.1080/09640560802423509; Pearce D, 2003, OXFORD REV ECON POL, V19, P362, DOI 10.1093/oxrep/19.3.362; Peper Paula J., 2001, Journal of Arboriculture, V27, P169; Peper Paula J., 2003, Urban Forestry & Urban Greening, V2, P019, DOI 10.1078/1618-8667-00020; Peper Paula J., 2001, Journal of Arboriculture, V27, P306; Pillsbury N, 1998, 7 CAL POL STAT U URB; PORACSKY J, 2004, URBAN FOREST CANOPY; Rosenfeld AH, 1998, ENERG BUILDINGS, V28, P51, DOI 10.1016/S0378-7788(97)00063-7; Rosenzweig C., 2006, MITIGATING NEW YORK; Scott Klaus I., 1998, Journal of Arboriculture, V24, P224; Taha H, 1996, ATMOS ENVIRON, V30, P3423, DOI 10.1016/1352-2310(96)00035-0; ULRICH RS, 1986, LANDSCAPE URBAN PLAN, V13, P29, DOI 10.1016/0169-2046(86)90005-8; *US BUR CENS, 2000, POP FIND CENS 2000; Wang M. Q., 1995, TRANSPORT RES REC, V1475, P33; Wolf KL, 2005, J FOREST, V103, P396; Wu Chunxia, 2008, Urban Forestry & Urban Greening, V7, P65, DOI 10.1016/j.ufug.2008.01.002; Xiao Q, 2004, INT J REMOTE SENS, V25, P5637, DOI [10.1080/01431160412331291224, 10.1080/01431160410001735094]; Xiao QF, 2000, HYDROL PROCESS, V14, P763, DOI 10.1002/(SICI)1099-1085(200003)14:4<763::AID-HYP971>3.3.CO;2-Z; Xiao Qingfu, 2002, Urban Ecosystems, V6, P291, DOI 10.1023/B:UECO.0000004828.05143.67	57	83	89	8	98	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-2046			LANDSCAPE URBAN PLAN	Landsc. Urban Plan.	JAN 30	2011	99	1					40	50		10.1016/j.landurbplan.2010.08.011		11	Ecology; Environmental Studies; Geography; Geography, Physical; Urban Studies	Environmental Sciences & Ecology; Geography; Physical Geography; Urban Studies	692UB	WOS:000285179500005		
J	Chang, C				Chang, Christopher			The immune effects of naturally occurring and synthetic nanoparticles	JOURNAL OF AUTOIMMUNITY			English	Article; Proceedings Paper	7th International Congress on Autoimmunity	MAY 05-09, 2010	Ljubljana, SLOVENIA			Ultrafine particles; Nanoparticles; Nanotechnology; Air pollution; Climate change; Diesel exhaust particles; Asthma; Anthropogenic; Environmental tobacco smoke; Particulate matter; PM(2.5); PM(10); Oxidative stress; Adjuvants; Reactive oxygen species; Carbon nanotubes; Autoimmunity	DIESEL EXHAUST PARTICLES; INHALED ULTRAFINE PARTICLES; COLLAGEN-INDUCED ARTHRITIS; BLOOD MONONUCLEAR-CELLS; OXIDATIVE STRESS; AIR-POLLUTION; PARTICULATE MATTER; TITANIUM-DIOXIDE; IN-VIVO; EPITHELIAL-CELLS	Ultrafine particles and engineered nanoparticles have unique aerodynamic and biochemical properties that affect the immune system and human health in ways that are different from or exceed those seen with gases or larger particulates. These effects result from a unique set of physical characteristics and surface moieties, which generate an ability of UFPs to enter tissues and cells, interact with proteins and DNA at a molecular level and directly and indirectly modulate the immune system by novel mechanisms. In recent years, a new field known as nanotechnology has impacted multiple industries by taking advantage of the special qualities of these small "atomic-sized" particles. Nanomedicine has already opened up a new avenue of research in cancer therapy, drug delivery and immune regulation. While the benefits of this new science to human civilization are seemingly immeasurable, it is also important to appreciate that these particles can also lead to harmful effects on human health. In vitro and animal studies are showing that nanoparticles and UFPs are capable of activating proinflammatory cytokines, chemokines and adhesion molecules, with recruitment of inflammatory cells including basophils, macrophages, dendritic cells, T cells, neutrophils and eosinophils. These changes may have an impact on immune defense, but also on the Th1/Th2 balance, and even on non-immunologic function. Resulting immune system derangement can lead to increases in incidence of autoimmune, allergic and even neoplastic diseases. Cardiorespiratory effects have been observed to occur in humans. Much further research is needed to establish safe exposure levels for this important new class of particulates. (C) 2009 Elsevier Ltd. All rights reserved.	Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA	Chang, C (reprint author), Univ Calif Davis, Div Rheumatol Allergy & Clin Immunol, 451 Hlth Sci Dr,Suite 6510, Davis, CA 95616 USA.	c3chang@yahoo.com					Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833; Araujo JA, 2008, CIRC RES, V102, P589, DOI 10.1161/CIRCRESAHA.107.164970; Asgharian B, 2007, INHAL TOXICOL, V19, P1045, DOI 10.1080/08958370701626501; Augustin MA, 2009, ADV FOOD NUTR RES, V58, P183, DOI 10.1016/S1043-4526(09)58005-9; BAINTON DF, 1989, AM J PATHOL, V134, P15; Bartra J, 2007, J INVEST ALLERG CLIN, V17, P3; Becker S, 2003, J TOXICOL ENV HEAL A, V66, P847, DOI 10.1080/15287390390156227; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Bhattacharya K, 2008, J TOXICOL ENV HEAL A, V71, P976, DOI 10.1080/15287390801989218; Bleck B, 2006, J IMMUNOL, V176, P7431; Borchers AT, 2006, CLIN REV ALLERG IMMU, V31, P1, DOI 10.1385/CRIAI:31:1:1; Brauner EV, 2007, ENVIRON HEALTH PERSP, V115, P1177, DOI 10.1289/ehp.9984; Brown DM, 2007, AM J PHYSIOL-LUNG C, V292, pL1444, DOI 10.1152/ajplung.00162.2006; Brugge D, 2007, ENVIRON HEALTH-GLOB, V6, DOI 10.1186/1476-069X-6-23; BUREK CL, 2009, J AUTOIMMUN; Campen Matthew J, 2003, Cardiovasc Toxicol, V3, P353, DOI 10.1385/CT:3:4:353; Carmichael GR, 2009, ENVIRON SCI TECHNOL, V43, P5811, DOI 10.1021/es8036803; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; Chan VSW, 2006, REGUL TOXICOL PHARM, V46, P218, DOI 10.1016/j.yrtph.2006.04.009; Churg A, 2000, ULTRASTRUCT PATHOL, V24, P353; Dahlgren J, 2007, ENVIRON HEALTH-UK, V6, DOI 10.1186/1476-069X-6-8; Dai H, 2006, INT J NANOMED, V1, P507, DOI 10.2147/nano.2006.1.4.507; de Haar C, 2008, J ALLERGY CLIN IMMUN, V121, P1246, DOI 10.1016/j.jaci.2008.01.010; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dinauer N, 2005, BIOMATERIALS, V26, P5898, DOI 10.1016/j.biomaterials.2005.02.038; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dong CC, 2005, TOXICOL SCI, V88, P202, DOI 10.1093/toxsci/kfi280; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Fahy O, 2000, AM J RESP CELL MOL, V23, P247; Finkelman FD, 2004, J IMMUNOL, V172, P3808; Folkmann JK, 2007, TOXICOLOGY, V237, P134, DOI 10.1016/j.tox.2007.05.009; Gillespie MN, 2009, ANN NY ACAD SCI, V1177, P140, DOI 10.1111/j.1749-6632.2009.05036.x; Gomez-Mejiba SE, 2009, MUTAT RES-GEN TOX EN, V674, P62, DOI 10.1016/j.mrgentox.2008.09.016; Gong H, 2008, INHAL TOXICOL, V20, P533, DOI 10.1080/08958370801911340 ; Goto Y, 2004, AM J RESP CRIT CARE, V170, P891, DOI 10.1164/rccm.200402-235OC; Granum B, 2001, TOXICOLOGY, V156, P149, DOI 10.1016/S0300-483X(00)00375-9; Hathout Eba H, 2002, Pediatr Diabetes, V3, P184, DOI 10.1034/j.1399-5448.2002.30403.x; Hathout EH, 2006, PEDIATR DIABETES, V7, P81, DOI 10.1111/j.1399-543X.2006.00150.x; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Hewagama A, 2009, J AUTOIMMUN, V33, P3, DOI 10.1016/j.jaut.2009.03.007; Hoet PHM, 1999, TOXICOL SCI, V52, P209, DOI 10.1093/toxsci/52.2.209; Holgate ST, 2003, RES REP HLTH EFF I, P51; Holgate Stephen T, 2003, Res Rep Health Eff Inst, P1; Inoue K, 2006, ARCH TOXICOL, V80, P275, DOI 10.1007/s00204-005-0040-6; Inoue K, 2004, J APPL TOXICOL, V24, P415, DOI 10.1002/jat.984; Invernizzi P, 2009, J AUTOIMMUN, V33, P1, DOI 10.1016/j.jaut.2009.03.001; Jaques PA, 2000, INHAL TOXICOL, V12, P715; Jin CY, 2008, CHEM RES TOXICOL, V21, P1871, DOI 10.1021/tx800179f; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Khandoga A, 2004, CIRCULATION, V109, P1320, DOI 10.1161/01.CIR.0000118524.62298.E8; Kim J, 2009, ENVIRON SCI TECHNOL, V43, P5488, DOI 10.1021/es900342q; Kleinman MT, 2008, TOXICOL LETT, V178, P127, DOI 10.1016/j.toxlet.2008.03.001; Kuroda Y, 2006, TOXICOLOGY, V218, P186, DOI 10.1016/j.tox.2005.10.011; LARSEN ST, 2009, BASIC CLIN PHARM TOX; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Liu Q, 2004, P NATL ACAD SCI USA, V101, P4302, DOI 10.1073/pnas.0300265101; Lleo A, 2008, J AUTOIMMUN, V31, P257, DOI 10.1016/j.jaut.2008.04.009; LOFROTH G, 1989, MUTAT RES, V222, P73, DOI 10.1016/0165-1218(89)90021-9; Lomer MCE, 2000, ANALYST, V125, P2339, DOI 10.1039/b006285p; Lomer MCE, 2002, P NUTR SOC, V61, P123, DOI 10.1079/PNS2001134; Lucking AJ, 2008, EUR HEART J, V29, P3043, DOI 10.1093/eurheartj/ehn464; Mackay IR, 2008, J AUTOIMMUN, V30, P5, DOI 10.1016/j.jaut.2007.11.009; MACKAY IR, 2009, J AUTOIMMUN; Moller W, 2008, AM J RESP CRIT CARE, V177, P426, DOI 10.1164/rccm.200602-301OC; Monteiller C, 2007, OCCUP ENVIRON MED, V64, P609, DOI 10.1136/oem.2005.024802; Morahan G, 2008, J AUTOIMMUN, V31, P233, DOI 10.1016/j.jaut.2008.04.011; Nahrendorf M, 2006, CIRCULATION, V114, P1504, DOI 10.1161/CIRCULATIONAHA.106.646380; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Nemmar A, 2003, AM J RESP CRIT CARE, V168, P1366, DOI 10.1164/rccm.200306-801OC; Nemmar A, 2003, CIRCULATION, V107, P1202, DOI 10.1161/01.CIR.0000053568.13058.67; Ning Z, 2008, PART FIBRE TOXICOL, V5, DOI 10.1186/1743-8977-5-15; Noyes PD, 2009, ENVIRON INT, V35, P971, DOI 10.1016/j.envint.2009.02.006; Nygaard UC, 2009, TOXICOL SCI, V109, P113, DOI 10.1093/toxsci/kfp057; Park EJ, 2008, TOXICOLOGY, V245, P90, DOI 10.1016/j.tox.2007.12.022; Poland CA, 2008, NAT NANOTECHNOL, V3, P423, DOI 10.1038/nnano.2008.111; Poletaev AB, 2008, J AUTOIMMUN, V30, P68, DOI 10.1016/j.jaut.2007.11.012; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Powell JJ, 2000, J AUTOIMMUN, V14, P99, DOI 10.1006/jaut.1999.0342; Ramanathan V, 2008, P NATL ACAD SCI USA, V105, P14245, DOI 10.1073/pnas.0803838105; RITZ SA, 2009, MED HYPOTHESES; Ryan JJ, 2007, J IMMUNOL, V179, P665; Salunga TL, 2007, J AUTOIMMUN, V29, P78, DOI 10.1016/j.jaut.2007.04.002; Sanchez-Pernaute O, 2008, J AUTOIMMUN, V30, P12, DOI 10.1016/j.jaut.2007.11.006; Sandhiya S, 2009, FUND CLIN PHARMACOL, V23, P263, DOI 10.1111/j.1472-8206.2009.00692.x; Schmid O, 2009, BIOMARKERS, V14, P67, DOI 10.1080/13547500902965617; Sedlik C, 1997, INT IMMUNOL, V9, P91, DOI 10.1093/intimm/9.1.91; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Shoenfeld Y, 2008, ISR MED ASSOC J, V10, P8; Shoenfeld Y, 2008, ISR MED ASSOC J, V10, P3; Siddiqi TA, 2008, ANN NY ACAD SCI, V1140, P22, DOI 10.1196/annals.1454.023; Stranges PB, 2007, IMMUNITY, V26, P629, DOI 10.1016/j.immuni.2007.03.016; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Takizawa Hajime, 2004, Curr Opin Allergy Clin Immunol, V4, P355, DOI 10.1097/00130832-200410000-00005; Tomer Y, 2009, J AUTOIMMUN, V32, P231, DOI 10.1016/j.jaut.2009.02.007; Tyner KM, 2009, NANOMEDICINE-UK, V4, P145, DOI 10.2217/17435889.4.2.145; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; van Zlverden M, 2000, TOXICOLOGY, V152, P69, DOI 10.1016/S0300-483X(00)00293-6; Verstraelen S, 2005, TOXICOL IN VITRO, V19, P903, DOI 10.1016/j.tiv.2005.06.017; Vidard L, 1996, J IMMUNOL, V156, P2809; Vinzents PS, 2005, ENVIRON HEALTH PERSP, V113, P1485, DOI 10.1289/ehp.7562; Wang JJ, 2007, MUTAT RES-GEN TOX EN, V628, P99, DOI 10.1016/j.mrgentox.2006.12.003; West JL, 2003, ANNU REV BIOMED ENG, V5, P285, DOI 10.1146/annurev.bioeng.5.011303.120723; Wokovich A, 2009, DRUG DEV IND PHARM, V35, P1180, DOI 10.1080/03639040902838043; Xia Tian, 2006, Clin Occup Environ Med, V5, P817; Yanagisawa R, 2006, CLIN EXP ALLERGY, V36, P386, DOI 10.1111/j.1365-2222.2006.02452.x; Yoshino S, 2002, INT J IMMUNOPATH PH, V15, P13; Yoshino S, 2002, AUTOIMMUNITY, V35, P57, DOI 10.1080/08916930290005936; Yoshino S, 1999, CELL IMMUNOL, V192, P72, DOI 10.1006/cimm.1998.1427; Yoshino S, 1999, J PHARMACOL EXP THER, V290, P524; Zhang Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006348	113	83	84	2	30	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0896-8411			J AUTOIMMUN	J. Autoimmun.	MAY	2010	34	3			SI		J234	J246		10.1016/j.jaut.2009.11.009		13	Immunology	Immunology	585IJ	WOS:000276818300007	19995678	
J	Pergola, C; Werz, O				Pergola, Carlo; Werz, Oliver			5-Lipoxygenase inhibitors: a review of recent developments and patents	EXPERT OPINION ON THERAPEUTIC PATENTS			English	Review						arachidonic acid; asthma; inflammation; inhibitors; leukotriene; 5-lipoxygenase	PROSTAGLANDIN E-2 SYNTHASE-1; CYTOSOLIC PHOSPHOLIPASE A(2); PHARMACOPHORE BIOLOGICAL EVALUATION; HUMAN POLYMORPHONUCLEAR LEUKOCYTES; COACTOSIN-LIKE PROTEIN; DUAL INHIBITORS; LEUKOTRIENE B-4; ANTIINFLAMMATORY ACTIVITY; ARACHIDONATE 5-LIPOXYGENASE; PHARMACOLOGICAL PROFILE	Importance to the field: Leukotrienes (LTs) are pivotal lipid mediators of inflammation and allergy and results from recent studies also suggest roles of LTs in cardiovascular diseases, cancer and osteoporosis. 5-Lipoxygenase (5-LO) catalyzes the first step in the biosynthesis of LTs from arachidonic acid, and based on the multiple potent pathophysiological actions of LTs, the pharmacological intervention with 5-LO is a challenge in the development of therapeutics. Areas covered in this review: We first summarize the biochemical regulation of 5-LO and the general pharmacological concepts in 5-LO inhibition by currently available compounds, and subsequently we report recent developments deduced from recent scientific publications and patents. What the reader will gain: A comprehensive overview about the different molecular pharmacological strategies to inhibit 5-LO and the most successful previous 5-LO inhibitors. The review also gives insights into novel concepts, for example, dual prostaglandin/LT synthesis inhibition and reveals novel compounds patented or developed within the past 5 years. Take home message: Despite the increasing therapeutic indications of anti-LT therapy, the progress in the development of novel 5-LO inhibitors is moderate. However, novel molecular concepts in the intervention with LT biosynthesis seem promising.	[Pergola, Carlo; Werz, Oliver] Univ Tubingen, Inst Pharmaceut, Dept Pharmaceut Analyt, D-72076 Tubingen, Germany	Werz, O (reprint author), Univ Tubingen, Inst Pharmaceut, Dept Pharmaceut Analyt, Morgenstelle 8, D-72076 Tubingen, Germany.	oliver.werz@uni-tuebingen.de					Albert D, 2002, BIOCHEM PHARMACOL, V64, P1767, DOI 10.1016/S0006-2952(02)01387-4; Araico A, 2007, LIFE SCI, V80, P2108, DOI 10.1016/j.lfs.2007.03.017; Araico A, 2006, LIFE SCI, V78, P2911, DOI 10.1016/j.lfs.2005.11.017; Austen KF, 2007, PROSTAG OTH LIPID M, V83, P182, DOI 10.1016/j.prostaglandins.2007.01.004; Back M, 2005, P NATL ACAD SCI USA, V102, P17501, DOI 10.1073/pnas.0505845102; Back M, 2007, PROSTAG OTH LIPID M, V83, P209, DOI 10.1016/j.prostaglandins.2007.01.008; Back M, 2007, CIRC RES, V100, P946, DOI 10.1161/01.RES.0000264498.60702.0d; Back M, 2009, CURR PHARM DESIGN, V15, P3116; Bannenberg GL, 2009, CURR OPIN DRUG DISC, V12, P644; Bellido-Reyes YA, 2006, TRANSPLANTATION, V81, P1700, DOI 10.1097/01.tp.0000226065.82066.21; Berg C, 2006, THROMB HAEMOSTASIS, V96, P652, DOI 10.1160/TH06-02-0069; Brink C, 2003, PHARMACOL REV, V55, P195, DOI 10.1124/pr.55.1.8; BROOKS CDW, 1995, J MED CHEM, V38, P4768, DOI 10.1021/jm00024a004; Celotti F, 2001, PHARMACOL RES, V43, P429, DOI 10.1006/phrs.2000.0784; Chen M, 2006, J EXP MED, V203, P837, DOI 10.1084/jem.20052371; Chen QH, 2006, BIOORGAN MED CHEM, V14, P7898, DOI 10.1016/j.bmc.2006.07.047; CHEN XS, 1994, NATURE, V372, P179, DOI 10.1038/372179a0; Chowdhury MA, 2009, J MED CHEM, V52, P1525, DOI 10.1021/jm8015188; Chowdhury MA, 2008, BIOORG MED CHEM LETT, V18, P6138, DOI 10.1016/j.bmcl.2008.10.009; Chowdhury MA, 2008, BIOORG MED CHEM LETT, V18, P4195, DOI 10.1016/j.bmcl.2008.05.071; Chowdhury MA, 2009, BIOORG MED CHEM LETT, V19, P584, DOI 10.1016/j.bmcl.2008.12.066; Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d; Claesson HE, 1999, J INTERN MED, V245, P205, DOI 10.1046/j.1365-2796.1999.00418.x; ClinicalTrial Database, 2007, NCT01968733, Patent No. [2007012464, WO2007012464]; Cortes-Burgos LA, 2009, EUR J PHARMACOL, V617, P59, DOI 10.1016/j.ejphar.2009.06.058; Doiron J, 2009, BIOORG MED CHEM LETT, V19, P1118, DOI 10.1016/j.bmcl.2008.12.108; ESSER J, 2009, BIOCH J; Evans JF, 2008, TRENDS PHARMACOL SCI, V29, P72, DOI 10.1016/j.tips.2007.11.006; Feisst C, 2009, CELL MOL LIFE SCI, V66, P2759, DOI 10.1007/s00018-009-0078-3; Ferguson AD, 2007, SCIENCE, V317, P510, DOI 10.1126/science.1144346; Fischer L, 2007, BRIT J PHARMACOL, V152, P471, DOI 10.1038/sj.bjp.0707416; Fischer L, 2004, BRIT J PHARMACOL, V142, P861, DOI 10.1038/sj.bjp.0705860; Flamand N, 2009, J BIOL CHEM, V284, P306, DOI 10.1074/jbc.M805593200; Folco G, 2006, PHARMACOL REV, V58, P375, DOI 10.1124/pr.58.3.8; FORDHUTCHINSON AW, 1994, ANNU REV BIOCHEM, V63, P383, DOI 10.1146/annurev.bi.63.070194.002123; Grant GE, 2009, PROSTAG OTH LIPID M, V89, P98, DOI 10.1016/j.prostaglandins.2009.05.002; Grimm EL, 2006, BIOORG MED CHEM LETT, V16, P2528, DOI 10.1016/j.bmcl.2006.01.085; Hamano N, 1998, ALLERGY ASTHMA PROC, V19, P263, DOI 10.2500/108854198778557773; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; HELGADOTTIR A, 2004, NAT GENET, V8, P8; Hemak J, 2002, J MOL MODEL, V8, P102, DOI 10.1007/s00894-002-0076-y; Ikonomovic MD, 2008, J HISTOCHEM CYTOCHEM, V56, P1065, DOI 10.1369/jhc.2008.951855; Karg EM, 2009, J MED CHEM, V52, P3474, DOI 10.1021/jm900212y; KOEBERLE A, 2009, CURR MED CHEM, V16, P7924; Koeberle A, 2008, J PHARMACOL EXP THER, V326, P975, DOI 10.1124/jpet.108.139444; Koeberle A, 2009, BIOORGAN MED CHEM, V17, P7924, DOI 10.1016/j.bmc.2009.10.025; Koeberle A, 2009, MOL CANCER THER, V8, P2348, DOI 10.1158/1535-7163.MCT-09-0290; Koeberle A, 2009, BIOCHEM BIOPH RES CO, V388, P350, DOI 10.1016/j.bbrc.2009.08.005; Koeberle A, 2009, EUR J PHARMACOL, V608, P84, DOI 10.1016/j.ejphar.2009.02.023; Koeberle A, 2008, J MED CHEM, V51, P8068, DOI 10.1021/jm801085s; Kulkarni Shrinivas K, 2008, Curr Rheumatol Rep, V10, P43, DOI 10.1007/s11926-008-0008-7; Landwehr J, 2006, J MED CHEM, V49, P4327, DOI 10.1021/jm05080li; LAUFER S, 1994, ARZNEIMITTEL-FORSCH, V44-1, P629; Lehnigk B, 1998, EUR RESPIR J, V11, P617; Lepley RA, 1996, J BIOL CHEM, V271, P6179; Li LW, 2009, EUR J PHARMACOL, V607, P244, DOI 10.1016/j.ejphar.2009.02.032; Liedtke AJ, 2009, J MED CHEM, V52, P4968, DOI 10.1021/jm900481c; Lorrain DS, 2009, J PHARMACOL EXP THER, V331, P1042, DOI 10.1124/jpet.109.158089; Luo M, 2004, J BIOL CHEM, V279, P41512, DOI 10.1074/jbc.M312568200; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Mahshid Y, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-2; Maier TJ, 2008, BIOCHEM PHARMACOL, V76, P862, DOI 10.1016/j.bcp.2008.07.009; Mano T, 2005, CHEM PHARM BULL, V53, P965, DOI 10.1248/cpb.53.965; MCMILLAN RM, 1992, TRENDS PHARMACOL SCI, V13, P323, DOI 10.1016/0165-6147(92)90100-K; Nagase T, 2003, AM J PHYSIOL-LUNG C, V284, pL720, DOI 10.1152/ajplung.00396.2002; Nicosia S, 2001, PULM PHARMACOL THER, V14, P3, DOI 10.1006/pupt.2000.0262; OCHI K, 1983, J BIOL CHEM, V258, P5754; Osman M, 2003, ARCH DIS CHILD, V88, P587, DOI 10.1136/adc.88.7.587; Pergola C, 2008, P NATL ACAD SCI USA, V105, P19881, DOI 10.1073/pnas.0809120105; Peters-Golden M, 2008, CURR ALLERGY ASTHM R, V8, P367, DOI 10.1007/s11882-008-0057-z; Peters-Golden M, 2007, NEW ENGL J MED, V357, P1841, DOI 10.1056/NEJMra071371; Poeckel D, 2009, J BIOL CHEM, V284, P21077, DOI 10.1074/jbc.M109.000901; Provost P, 2001, J BIOL CHEM, V276, P16520, DOI 10.1074/jbc.M011205200; Radmark O, 2003, ARTERIOSCL THROM VAS, V23, P1140, DOI 10.1161/01.ATV.0000082460.58448.01; RADMARK O, 1995, J LIPID MEDIAT CELL, V12, P171, DOI 10.1016/0929-7855(95)00017-K; Radmark O, 2007, TRENDS BIOCHEM SCI, V32, P332, DOI 10.1016/j.tibs.2007.06.002; Rakonjac M, 2006, P NATL ACAD SCI USA, V103, P13150, DOI 10.1073/pnas.0605150103; Rao PNP, 2006, J MED CHEM, V49, P1668, DOI 10.1021/jm0510474; Riccioni G, 2008, J LEUKOCYTE BIOL, V84, P1374, DOI 10.1189/jlb.0808476; ROUZER CA, 1986, FEBS LETT, V204, P293, DOI 10.1016/0014-5793(86)80831-6; SAFAYHI H, 1992, J PHARMACOL EXP THER, V261, P1143; Sampson AP, 2009, CURR OPIN INVEST DR, V10, P1163; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Scholz M, 2009, BIOORGAN MED CHEM, V17, P558, DOI 10.1016/j.bmc.2008.11.074; Sengupta K, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2461; Serhan CN, 2008, NAT REV IMMUNOL, V8, P349, DOI 10.1038/nri2294; Shirumalla RK, 2008, INFLAMM RES, V57, P135, DOI 10.1007/s00011-007-7149-4; Shirumalla RK, 2006, INFLAMM RES, V55, P517, DOI 10.1007/s00011-006-6032-z; Siemoneit U, 2009, EUR J PHARMACOL, V606, P246, DOI 10.1016/j.ejphar.2009.01.044; Spanbroek R, 1998, P NATL ACAD SCI USA, V95, P663, DOI 10.1073/pnas.95.2.663; Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099; Sud'ina GF, 2008, PROSTAG LEUKOTR ESS, V78, P99, DOI 10.1016/j.plefa.2007.12.006; Tai N, 2010, INFLAMM RES, V59, P53, DOI 10.1007/s00011-009-0069-8; Tries S, 2002, INFLAMM RES, V51, P135, DOI 10.1007/PL00000285; Uozumi N, 1997, NATURE, V390, P618; Uz T, 1999, J NEUROCHEM, V73, P693, DOI 10.1046/j.1471-4159.1999.0730693.x; Vannella KM, 2007, J IMMUNOL, V179, P7883; Wan M, 2007, FASEB J, V21, P2897, DOI 10.1096/fj.06-7974com; WEITZEL F, 1993, J BIOL CHEM, V268, P6288; Werz O, 2005, P NATL ACAD SCI USA, V102, P13164, DOI 10.1073/pnas.0505991102; Werz O, 2005, BIOCHEM PHARMACOL, V70, P327, DOI 10.1016/j.bcp.2005.04.018; Werz O, 2005, EXPERT OPIN THER PAT, V15, P505, DOI 10.1517/13543776.15.5.505; Werz O, 2000, P NATL ACAD SCI USA, V97, P5261, DOI 10.1073/pnas.050588997; Werz O, 2002, FASEB J, V16, P1441, DOI 10.1096/fj.01-0909fje.; Werz O, 2002, J BIOL CHEM, V277, P14793, DOI 10.1074/jbc.M111945200; Werz O, 2002, BLOOD, V99, P1044, DOI 10.1182/blood.V99.3.1044; Werz O, 2001, BLOOD, V97, P2487, DOI 10.1182/blood.V97.8.2487; Werz O, 2001, J LEUKOCYTE BIOL, V70, P830; Werz O, 2008, J MED CHEM, V51, P5449, DOI 10.1021/jm800588x; Werz O, 2006, PHARMACOL THERAPEUT, V112, P701, DOI 10.1016/j.pharmthera.2006.05.009; Werz Oliver, 2002, Current Drug Targets - Inflammation and Allergy, V1, P23, DOI 10.2174/1568010023344959; Xu GL, 2009, BASIC CLIN PHARMACOL, V105, P350, DOI 10.1111/j.1742-7843.2009.00463.x; Xu GL, 2009, EUR J PHARMACOL, V611, P100, DOI 10.1016/j.ejphar.2009.03.062; Zheng MY, 2006, BIOORGAN MED CHEM, V14, P3428, DOI 10.1016/j.bmc.2005.12.062; TAOGOSEI CO LTD, 2005, Patent No. 2005229100; [Anonymous], 2009, [No title captured], Patent No. [WO/2009/027077, 2009027077]; ANALYTICON DISCOVERY, 2007, Patent No. 2007115836; CERMA AK, 2007, Patent No. 1834953; LOGIGAL THERAPEUTICS, 2009, Patent No. 2009012425; TAHITIAN NONI INT, 2008, Patent No. 2008067410; Ducharme Y., 2007, PCT Int. Appl., Patent No. [WO 2007038865 A1, 2007038865]; PFIZER INC, 2008, Patent No. 2008065493; Alvira E., 2009, PCT Int. Appl., Patent No. [WO 2009069044 A1, 2009069044, 2,009,069,044]; BERTHELETTE C, 2007, Patent No. 2007016784; MERCK CO, 2009, Patent No. 2009042098; EWHA FDN UIC, 2008, Patent No. 2008035956	126	83	83	0	27	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	1354-3776			EXPERT OPIN THER PAT	Expert Opin. Ther. Patents	MAR	2010	20	3					355	375		10.1517/13543771003602012		21	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	572DQ	WOS:000275807900004	20180620	
J	Martino, DJ; Prescott, SL				Martino, D. J.; Prescott, S. L.			Silent mysteries: epigenetic paradigms could hold the key to conquering the epidemic of allergy and immune disease	ALLERGY			English	Review						acetylation; allergic disease; epigenetics; methylation; susceptibility	IFN-GAMMA PROMOTER; DNA METHYLATION CHANGES; T-CELL DIFFERENTIATION; FOXP3 GENE-EXPRESSION; AIRWAY INFLAMMATION; IN-UTERO; HISTONE DEACETYLASES; TH2 DIFFERENTIATION; LINEAGE COMMITMENT; CYTOKINE RESPONSES	P>Epigenetic mechanisms provide new insights into how environmental changes may mediate the increasing propensity for complex immune diseases such as allergic disease. There is now strong evidence that early environmental exposures play a key role in activating or silencing genes by altering DNA and histone methylation, histone acetylation and chromatin structure. These modifications determine the degree of DNA compaction and accessibility for gene transcription, altering gene expression, phenotype and disease susceptibility. While there is already evidence that a number of early environmental exposures are associated with an increased risk of allergic disease, several new studies indicate in utero microbial and dietary exposures can modify gene expression and allergic disease propensity through epigenetic modification. This review explores the evidence that immune development is under clear epigenetic regulation, including the pattern of T helper (Th)1 and Th2 cell differentiation, regulatory T cell differentiation, and more recently, Th17 development. It also considers the mechanisms of epigenetic regulation and early immune defects in allergy prone neonates. The inherent plasticity conferred by epigenetic mechanisms clearly also provides opportunities for environmental strategies that can re-programme gene expression for disease prevention. Identifying genes that are differentially silenced or activated in relation to subsequent disease will not only assist in identifying causal pathways, but may also help identify the contributing environmental factors.	[Martino, D. J.; Prescott, S. L.] Univ Western Australia, Sch Pediat & Child Hlth Res, Perth, WA 6001, Australia	Martino, DJ (reprint author), Univ Western Australia, Sch Pediat & Child Hlth Res, Perth, WA 6001, Australia.		Prescott, Susan/H-5665-2014	Martino, David/0000-0001-6823-4696			Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Akimzhanov AM, 2007, J BIOL CHEM, V282, P5969, DOI 10.1074/jbc.C600322200; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baek YS, 2009, BMC IMMUNOL, V10, DOI 10.1186/1471-2172-10-18; BARKER DJP, 1989, LANCET, V2, P577; Barker DJP, 1998, CLIN SCI, V95, P115, DOI 10.1042/CS19980019; BARKER DJP, 1993, BRIT MED J, V307, P1524; Bernstein E, 2005, GENE DEV, V19, P1635, DOI 10.1101/gad.1324305; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1591, DOI 10.1046/j.1365-2222.2000.00982.x; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Cedar H, 2009, NAT REV GENET, V10, P295, DOI 10.1038/nrg2540; Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170; Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108; Djupedal I, 2009, CELL RES, V19, P282, DOI 10.1038/cr.2009.13; Dolinoy DC, 2007, PEDIATR RES, V61, p30R, DOI 10.1203/pdr.0b013e31804575f7; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fagerudd J, 2004, HYPERTENSION, V44, P832, DOI 10.1161/01.HYP.0000147272.10646.e6; Fields PE, 2002, J IMMUNOL, V169, P647; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Fujimaki W, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/305859; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Janson PCJ, 2009, BBA-GEN SUBJECTS, V1790, P906, DOI 10.1016/j.bbagen.2008.12.003; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lee GR, 2006, IMMUNITY, V24, P369, DOI 10.1016/j.immuni.2006.03.007; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Mattick JS, 2007, J EXP BIOL, V210, P1526, DOI 10.1242/jeb.005017; Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046; Miller RL, 2008, J CLIN INVEST, V118, P3265, DOI 10.1172/JCI37171; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Nie M, 2005, J BIOL CHEM, V280, P2550, DOI 10.1074/jbc.M410616200; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Pfeifer K, 2000, AM J HUM GENET, V67, P777, DOI 10.1086/303101; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; PRESCOTT S, 1999, STUDIES EARLY POSTNA; Prescott SL, 2000, ALLERGY, V55, P470; PRESCOTT SL, 1998, DEV ALLERGEN T CELL; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI [10.1016/j.jaci.2008.04.042, 10.1016/j.jaci.2008.04.0422]; Prescott Susan L, 2003, Curr Opin Allergy Clin Immunol, V3, P125, DOI 10.1097/00130832-200304000-00006; Sanders VM, 2006, BRAIN BEHAV IMMUN, V20, P317, DOI 10.1016/j.bbi.2005.08.005; Santangelo S, 2002, J IMMUNOL, V169, P1893; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Shaheen S, 2008, EUR RESPIR J, V32, P1231, DOI 10.1183/09031936.00039208; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Shin HJ, 2005, J IMMUNOL, V175, P7143; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Song F, 2009, GENOMICS, V93, P130, DOI 10.1016/j.ygeno.2008.09.003; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, P57, DOI 10.1016/j.jaci.2007.09.004; Sudo N, 1997, J IMMUNOL, V159, P1739; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; Waterland RA, 2007, FASEB J, V21, P3380, DOI 10.1096/fj.07-8229com; White GP, 2002, J IMMUNOL, V168, P2820; White GP, 2006, PEDIATR ALLERGY IMMU, V17, P557, DOI 10.1111/j.1399-3038.2006.00465.x; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Winders BR, 2004, J IMMUNOL, V173, P7377; Wolff GL, 1998, FASEB J, V12, P949; Xu CR, 2009, J IMMUNOL, V182, P1362; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; Yang YW, 2008, J ALLERGY CLIN IMMUN, V121, P1393, DOI 10.1016/j.jaci.2008.02.031; Yano S, 2003, J IMMUNOL, V171, P2510; Zhu JF, 2003, IMMUNITY, V19, P739, DOI 10.1016/S1074-7613(03)00292-9	81	83	85	1	9	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	JAN	2010	65	1					7	15		10.1111/j.1398-9995.2009.02186.x		9	Allergy; Immunology	Allergy; Immunology	530YZ	WOS:000272630200002	19796189	
J	Aguilera-Aguirre, L; Bacsi, A; Saavedra-Molina, A; Kurosky, A; Sur, S; Boldogh, I				Aguilera-Aguirre, Leopoldo; Bacsi, Attila; Saavedra-Molina, Alfredo; Kurosky, Alexander; Sur, Sanjiv; Boldogh, Istvan			Mitochondrial Dysfunction Increases Allergic Airway Inflammation	JOURNAL OF IMMUNOLOGY			English	Article							ELECTRON-TRANSPORT CHAIN; OXIDATIVELY DAMAGED PROTEINS; CYTOCHROME BC(1) COMPLEX; GEL-ELECTROPHORESIS; CORE PROTEINS; ASTHMA; STRESS; POLLEN; CELLS; IDENTIFICATION	The prevalence of allergies and asthma among the world's population has been steadily increasing due to environmental factors. It has been described that exposure to ozone, diesel exhaust particles, or tobacco smoke exacerbates allergic inflammation in the lungs. These environmental oxidants increase the levels of cellular reactive oxygen species (ROS) and induce mitochondrial dysfunction in the airway epithelium. In this study, we investigated the involvement of preexisting mitochondrial dysfunction in the exacerbation of allergic airway inflammation. After cellular oxidative insult induced by ragweed pollen extract (RWE) exposure, we have identified nine oxidatively damaged mitochondrial respiratory chain-complex and associated proteins. Out of these, the ubiquinol-cytochrome c reductase core II protein (UQCRC2) was found to be implicated in mitochondrial ROS generation from respiratory complex III. Mitochondrial dysfunction induced by deficiency of UQCRC2 in airway epithelium of sensitized BALB/c mice prior the RWE challenge increased the Ag-induced accumulation of eosinophils, mucin levels in the airways, and bronchial hyperresponsiveness. Deficiency of UQCRC1, another oxidative damage-sensitive complex III protein, did not significantly alter cellular ROS levels or the intensity of RWE-induced airway inflammation. These observations suggest that preexisting mitochondrial dysfunction induced by oxidant environmental pollutants is responsible for the severe symptoms in allergic airway inflammation. These data also imply that mitochondrial defects could be risk factors and may be responsible for severe allergic disorders in atopic individuals. The Journal of Immunology, 2009, 183: 5379-5387.	[Aguilera-Aguirre, Leopoldo; Bacsi, Attila; Boldogh, Istvan] Univ Texas Galveston, Med Branch, Dept Microbiol & Immunol, Galveston, TX 77555 USA; [Kurosky, Alexander] Univ Texas Galveston, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Sur, Sanjiv] Univ Texas Galveston, Med Branch, Dept Internal Med, Galveston, TX 77555 USA; [Aguilera-Aguirre, Leopoldo; Saavedra-Molina, Alfredo] Univ Michoacana, Inst Invest Quim Biol, Morelia, Michoacan, Mexico; [Bacsi, Attila] Univ Debrecen, Fac Med, Med & Hlth Sci Ctr, Inst Immunol, H-4012 Debrecen, Hungary	Boldogh, I (reprint author), Univ Texas Galveston, Med Branch, Dept Microbiol & Immunol, 301 Univ Blvd, Galveston, TX 77555 USA.	sboldogh@utmb.edu		Aguilera-Aguirre, Leopoldo/0000-0001-7964-7402	National Institute of Allergy and Infectious Diseases [P01 A1062885-01]; National Institutes of Health [HL071163, NO1HV-28184]; National Institute on Environmental Health Sciences Center [EOS 006677]; Hungarian Scientific Research Fund [73347]	This work was supported by National Institute of Allergy and Infectious Diseases Grant P01 A1062885-01 (to I.B. and S.S.), National Institutes of Health Grant HL071163 (to S.S. and I.B.), National Institutes of Health, National Heart. Lung, and Blood Institute Proteornics Initiative NO1HV-28184 (to A.K.), National Institute on Environmental Health Sciences Center Grant EOS 006677 (to I.B. and A.K.), and the Hungarian Scientific Research Fund 73347 (to A.B.).	Adam-Vizi V, 2005, ANTIOXID REDOX SIGN, V7, P1140, DOI 10.1089/ars.2005.7.1140; Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Aguilera-Aguirre L, 2002, MITOCHONDRION, V1, P413, DOI 10.1016/S1567-7249(02)00002-8; Bacsi A, 2005, J ALLERGY CLIN IMMUN, V116, P836, DOI 10.1016/j.jaci.2005.06.002; Bacsi A, 2006, MITOCHONDRION, V6, P235, DOI 10.1016/j.mito.2006.07.008; Bacsi A, 2006, J ALLERGY CLIN IMMUN, V118, P844, DOI 10.1016/j.jaci.2006.07.006; Batinic-Haberle I, 1998, J BIOL CHEM, V273, P24521, DOI 10.1074/jbc.273.38.24521; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Boldogh I, 2008, INT ARCH ALLERGY IMM, V146, P298, DOI 10.1159/000121464; Bowler RR, 2004, CURR ALLERGY ASTHM R, V4, P116, DOI 10.1007/s11882-004-0056-7; Bulteau AL, 2006, EXP GERONTOL, V41, P653, DOI 10.1016/j.exger.2006.03.013; Chang LY, 2002, FREE RADICAL BIO MED, V33, P379, DOI 10.1016/S0891-5849(02)00919-X; Chen Q, 2003, J BIOL CHEM, V278, P36027, DOI 10.1074/jbc.M304854200; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Choksi KB, 2008, FREE RADICAL BIO MED, V45, P826, DOI [10.1016/j.freeradbiomed.2008.06.006, 10.1016/j.freeradbiomed.2008.06.06]; Choksi KB, 2007, FREE RADICAL BIO MED, V43, P1423, DOI 10.1016/j.freeradbiomed.2007.07.027; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Cocco T, 1998, BIOCHEMISTRY-US, V37, P2037, DOI 10.1021/bi9724164; COLES CJ, 1979, J BIOL CHEM, V254, P5161; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; Degli Esposti M, 1993, Biochem Biophys Res Commun, V190, P1090; Del Prete A, 2008, FREE RADICAL BIO MED, V44, P1443, DOI 10.1016/j.freeradbiomed.2007.12.037; Deng K, 2001, J BIOL CHEM, V276, P6499, DOI 10.1074/jbc.M007128200; Dharajiya N, 2007, J ALLERGY CLIN IMMUN, V119, P646, DOI 10.1016/j.jaci.2006.11.634; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; Estabrook R., 1967, METHOD ENZYMOL, V10, P41; Fahn HJ, 1998, AM J RESP CELL MOL, V19, P901; Forbus J, 2006, PROTEOMICS, V6, P2656, DOI 10.1002/pmic.200500652; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; Hauser R, 2003, ENVIRON HEALTH PERSP, V111, P472, DOI 10.1289/ehp.5862; Hittel DS, 2005, J APPL PHYSIOL, V98, P168, DOI 10.1152/japplphysiol.00331.2004; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; Jung T, 2008, IUBMB LIFE, V60, P743, DOI 10.1002/iub.114; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kurukulaaratchy RJ, 2006, ANN ALLERG ASTHMA IM, V97, P84; Lad SP, 2008, MOL IMMUNOL, V45, P2277, DOI 10.1016/j.molimm.2007.11.018; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; LOSCHEN G, 1974, FEBS LETT, V42, P68, DOI 10.1016/0014-5793(74)80281-4; Mabalirajan U, 2008, J IMMUNOL, V181, P3540; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2; Raby BA, 2005, AM J RESP CRIT CARE, V172, P552, DOI 10.1164/rccm.200501.010OC; Raby BA, 2007, J ALLERGY CLIN IMMUN, V120, P351, DOI 10.1016/j.jaci.2007.05.029; Riedl MA, 2008, CURR OPIN ALLERGY CL, V8, P49, DOI 10.1097/ACI.0b013e3282f3d913; Romieu I, 2003, AM J EPIDEMIOL, V158, P165, DOI 10.1093/aje/kwg131; SAAVEDRAMOLINA A, 1990, BIOCHEM BIOPH RES CO, V167, P148, DOI 10.1016/0006-291X(90)91743-C; Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007; Schagger H, 2001, METHOD CELL BIOL, V65, P231, DOI 10.1016/S0091-679X(01)65014-3; Servais S, 2005, FREE RADICAL RES, V39, P305, DOI 10.1080/10715760400011098; Shringarpure R, 2001, CELL MOL LIFE SCI, V58, P1442, DOI 10.1007/PL00000787; Spasojevic I, 2007, FREE RADICAL BIO MED, V42, P1193, DOI 10.1016/j.freeradbiomed.2007.01.019; Sur S, 1999, J IMMUNOL, V162, P6284; TANIZAKI Y, 1993, J ASTHMA, V30, P257, DOI 10.3109/02770909309054525; Thornton DJ, 1996, BIOCHEM J, V316, P967; Trinidad JC, 2006, MOL CELL PROTEOMICS, V5, P914, DOI 10.1074/mcp.T500041-MCP200; Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020; VanGestelen P, 1997, PLANT PHYSIOL, V115, P543; Wen JJ, 2004, FREE RADICAL BIO MED, V37, P2072, DOI 10.1016/j.freeradbiomed.2004.09.011; Xia T, 2007, FRONT BIOSCI, V12, P1238, DOI 10.2741/2142	61	83	87	1	9	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	OCT 15	2009	183	8					5379	5387				9	Immunology	Immunology	507DC	WOS:000270830300065	19786549	
J	Douwes, J; Cheng, S; Travier, N; Cohet, C; Niesink, A; McKenzie, J; Cunningham, C; Le Gros, G; von Mutius, E; Pearce, N				Douwes, J.; Cheng, S.; Travier, N.; Cohet, C.; Niesink, A.; McKenzie, J.; Cunningham, C.; Le Gros, G.; von Mutius, E.; Pearce, N.			Farm exposure in utero may protect against asthma, hay fever and eczema	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; farming; hygiene hypothesis; prenatal; timing	ALLERGY	The aim of the present study was to assess which factors contribute to the lower prevalence of allergic diseases in farmers' children, and the importance of timing of exposure. In a cross-sectional questionnaire survey, asthma symptoms, hay fever and eczema were assessed, as well as current, early and prenatal farm-related exposures in 1,333 farmers' children and 566 reference children aged 5-17 yrs. Farmers' children had a lower incidence of asthma symptoms and eczema. Current and maternal exposure during pregnancy to animals and/or grain and hay reduced the risk of asthma symptoms, hay fever and eczema. The exposure-response association for maternal exposure was nonlinear for most outcomes. After mutual adjustment, the effects of prenatal exposure remained unchanged whereas current exposure remained protective only for asthma medication, asthma ever and hay fever. Exposure during the first 2 yrs was not associated with symptoms, after controlling for prenatal exposure. A combination of prenatal and current exposure was most strongly associated with wheeze (odds ratio (OR) 0.48, 95% confidence interval (CI) 0.28-0.80), asthma medication (OR 0.50, 95% Cl 0.30-0.82), asthma ever (OR 0.50, 95% Cl 0.33-0.76), hay fever (OR 0.47, 95% Cl 0.30-0.73) and eczema (OR 0.46, 95% Cl 0.30-0.70). Prenatal exposure may contribute to the low prevalence of asthma, hay fever and eczema in farmers' children, but continued exposure may be required to maintain optimal protection.	[Douwes, J.; Cheng, S.; Travier, N.; Cohet, C.; Niesink, A.; Pearce, N.] Massey Univ, Res Sch Publ Hlth, Res Ctr Maori Hlth & Dev, Palmerston North, New Zealand; [Cunningham, C.] Massey Univ, Res Sch Publ Hlth, Res Ctr Maori Hlth & Dev, Palmerston North, New Zealand; [Le Gros, G.] Victoria Univ, Malaghan Inst Med Res, Wellington, New Zealand; [McKenzie, J.] Massey Univ, Inst Vet Anim & Biomed Sci, Epictr, Palmerston North, New Zealand; [von Mutius, E.] Univ Munich, Dr Von Hauner Childrens Hosp, Munich, Germany	Douwes, J (reprint author), Private Box 756, Wellington, New Zealand.	j.douwes@massey.ac.nz	Le Gros, Graham/C-6725-2011	Pearce, Neil/0000-0002-9938-7852; Douwes, Jeroen/0000-0003-3599-4036	Centre for Public Health Research; Sir Charles Hercus Research; Health Research Council of New Zealand	The Centre for Public Health Research is supported by a Programme Grant that includes funding for the current study and J. Douwes is supported by a Sir Charles Hercus Research Fellowship, both from the Health Research Council of New Zealand.	Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008	2	83	86	1	13	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2008	32	3					603	611		10.1183/09031936.00033707		9	Respiratory System	Respiratory System	351OG	WOS:000259433100012	18448493	
J	Purohit, A; Niederberger, V; Kronqvist, M; Horak, F; Gronneberg, R; Suck, R; Weber, B; Fiebig, H; van Hage, M; Pauli, G; Valenta, R; Cromwell, O				Purohit, A.; Niederberger, V.; Kronqvist, M.; Horak, F.; Gronneberg, R.; Suck, R.; Weber, B.; Fiebig, H.; van Hage, M.; Pauli, G.; Valenta, R.; Cromwell, O.			Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergen variants; allergic rhinitis; allergy; Bet v 1; birch pollen; immunotherapy; recombinant allergens	BET V 1; ALLERGEN-SPECIFIC IMMUNOTHERAPY; QUANTITATIVE IGE INHIBITION; LATE ASTHMATIC REACTIONS; WILD-TYPE; VACCINATION; SENSITIVITY; TRANSITION; POPULATION; CANDIDATES	Background Birch pollen and pollen from related trees of the Fagales order are a major cause of allergic rhinitis, conjunctivitis, and asthma through the spring season in northern and central Europe. Objective To investigate the clinical effects of injection immunotherapy with genetically modified derivatives of major birch pollen allergen Bet v 1 on pollen-induced allergic symptoms. Methods A three-arm double-blind placebo-controlled immunotherapy study was conducted with one pre-seasonal course of treatment using two derivatives of Bet v 1, namely a recombinant Bet v 1 trimer and an equimolar mixture of two recombinant Bet v 1 fragments together representing the whole protein sequence. Analysis of local and systemic adverse events was performed for 124 patients who had received at least one dose of medication. Clinical efficacy was monitored by symptom medication scores and interval scoring in the per protocol-treated population (n=84). In addition, skin and nasal provocation responses and allergen-specific antibodies were assessed. Results There were trends towards improvement in the subjects' well-being and clinical symptoms (nasal scores), although comparisons with a placebo group did not show statistical significance in the main end-point, the combined symptom medication score. Reductions in skin and nasal sensitivity were observed for some subjects with a trend for the Bet v 1 trimer to be more effective than the fragments. Treatment induced strong IgG1 and IgG4 allergen-specific antibody responses. Local injection-site reactions were most frequent in the trimer group affecting 59.5% of patients as opposed to 37.8% and 30.6% in the fragment and placebo groups, respectively. Systemic reactions were elicited more frequently by fragments. A large proportion of adverse side-effects appeared hours following injections, and might be attributable to concurrent exposure to related pollens. Conclusion Single courses of injection immunotherapy with Bet v 1 allergen derivatives showed trends towards improved well-being and reduced reactivity to specific allergen provocation, but did not yield significant improvement in the combined symptom medication score in this study.	[Purohit, A.; Pauli, G.] Hop Univ Strasbourg, Serv Pneumol, Strasbourg, France; [Niederberger, V.; Kronqvist, M.; Horak, F.] Med Univ Vienna, Dept Otorhinolaryngol, Vienna, Austria; [Kronqvist, M.; van Hage, M.] Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; [Kronqvist, M.; Gronneberg, R.; van Hage, M.] Univ Hosp, Stockholm, Sweden; [Gronneberg, R.] Karolinska Inst, Dept Med, Resp Med Unit, Stockholm, Sweden; [Suck, R.; Weber, B.; Fiebig, H.; Cromwell, O.] Allergopharma Joachim Ganzer KG, Reinbek, Germany; [Valenta, R.] Med Univ Vienna, Dept Pathophysiol, Div Immunopathol, Christian Doppler Lab Allergy Res, Vienna, Austria	Valenta, R (reprint author), Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Lab Allergy Res, Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596	Swedish Research Council; Swedish Foundation for Health Care Sciences and Allergy Research; Swedish Asthma and Allergy Association's Research Foundation; Swedish Cancer- and Allergy Foundation; Hesselman Foundation; King Gustaf V 80th Birthday Foundation; Swedish Heart-Lung Foundation [F1815, F01818, L214-B13]; Christian Doppler Research Association	Supported by the Swedish Research Council, the Swedish Foundation for Health Care Sciences and Allergy Research, the Swedish Asthma and Allergy Association's Research Foundation, the Swedish Cancer- and Allergy Foundation, the Hesselman Foundation, King Gustaf V 80th Birthday Foundation, the Swedish Heart-Lung Foundation, grants TRP, F1815, F01818 and L214-B13 of the Austrian Science Fund and by the Christian Doppler Research Association.	Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bousquet J, 1998, ALLERGY S, V53, P44; BREITENEDER H, 1989, EMBO J, V8, P1935; Cromwell O, 2004, METHODS, V32, P300, DOI 10.1016/j.ymeth.2003.08.009; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Global Initiative for Asthma (GINA), 2002, GLOB STRAT ASTHM MAN; HoffmannSommergruber K, 1997, PROTEIN EXPRES PURIF, V9, P33, DOI 10.1006/prep.1996.0671; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kay AB, 2007, ALLERGY, V62, P495, DOI 10.1111/j.1398-9995.2007.01342.x; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kleine-Tebbe J, 2001, Pneumologie, V55, P438, DOI 10.1055/s-2001-16954; KLIMEK L, 2005, ALLERGY CLIN IMMUN S, P1; Mothes N, 2004, INT ARCH ALLERGY IMM, V135, P357, DOI 10.1159/000082332; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 2006, 25 C EUR AC ALL CLIN, P28; Pree I, 2007, J IMMUNOL, V179, P5309; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; ROHAC M, 1991, MOL IMMUNOL, V28, P897, DOI 10.1016/0161-5890(91)90054-N; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; SWOBODA I, 1995, J BIOL CHEM, V270, P2607; Tryba M, 1994, ALLERGO J, V3, P211; Valenta R, 1996, J ALLERGY CLIN IMMUN, V97, P893, DOI 10.1016/S0091-6749(96)80062-5; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; van Hage-Hamsten M, 2002, CLIN EXP ALLERGY, V32, P1448, DOI 10.1046/j.1365-2745.2002.01495.x; Vrtala S, 1999, INT ARCH ALLERGY IMM, V118, P218, DOI 10.1159/000024075; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; WEIHRAUCH TR, 1996, PHARM MED, V10, P125; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x	41	83	87	1	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2008	38	9					1514	1525		10.1111/j.1365-2222.2008.03042.x		12	Allergy; Immunology	Allergy; Immunology	341PS	WOS:000258727400014	18564326	
J	Gotzsche, PC; Johansen, HK				Gotzsche, P. C.; Johansen, H. K.			House dust mite control measures for asthma: systematic review	ALLERGY			English	Review						asthma; house dust mites; systematic review	RANDOMIZED CONTROLLED-TRIAL; IMPERMEABLE BED COVERS; SENSITIVE ADULT ASTHMA; DOUBLE-BLIND TRIAL; ALLERGEN-AVOIDANCE; BENZYL-BENZOATE; HIGH-EFFICIENCY; MATTRESS ENCASINGS; CHILDHOOD ASTHMA; BRONCHIAL HYPERREACTIVITY	The major allergen in house dust comes from mites. We performed a systematic review of the randomized trials that had assessed the effects of reducing exposure to house dust mite antigens in the homes of people with mite-sensitive asthma, and had compared active interventions with placebo or no treatment. Fifty-four trials (3002 patients) were included. Thirty-six trials assessed physical methods (26 mattress covers), 10 chemical methods and eight a combination of chemical and physical methods. Despite the fact that many trials were of poor quality and would be expected to exaggerate the reported effect, we did not find an effect of the interventions. For the most frequently reported outcome, peak flow in the morning (1565 patients), the standardized mean difference was 0.00 (95% confidence interval (CI) -0.10 to 0.10). There were no statistically significant differences in number of patients improved (relative risk 1.01, 95% CI 0.80-1.27), asthma symptom scores (standardized mean difference -0.04, 95% CI -0.15 to 0.07) or in medication usage (standardized mean difference -0.06, 95% CI -0.18 to 0.07). Chemical and physical methods aimed at reducing exposure to house dust mite allergens cannot be recommended.	[Gotzsche, P. C.; Johansen, H. K.] Rigshosp, Nordic Cochrane Ctr, DK-2100 Copenhagen, Denmark	Gotzsche, PC (reprint author), Rigshosp, Nordic Cochrane Ctr, Dept 3343 Blegdamsvej 9, DK-2100 Copenhagen, Denmark.						ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bahir A, 1997, ANN ALLERG ASTHMA IM, V78, P506; Bland JM, 1996, BRIT MED J, V313, P106; BURR ML, 1980, THORAX, V35, P513, DOI 10.1136/thx.35.7.513; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; BURR ML, 1976, LANCET, V1, P333; Carswell F., 1996, Allergy (Copenhagen), V51, P38; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; CARSWELL F, 1995, EUROPEAN RESP J S19, V8, pS572; CARSWELL F, 1994, ANN ALLERGY, V72, P74; Chan AW, 2004, JAMA-J AM MED ASSOC, V291, P2457, DOI 10.1001/jama.291.20.2457; Chang JH, 1996, ANN ALLERG ASTHMA IM, V77, P187; CHARPIN D, 1990, REV FR ALLERGOL, V30, P149, DOI 10.1016/S0335-7457(05)80229-1; Chen Chih-Chang, 1996, Acta Paediatrica Sinica, V37, P420; Cinti C, 1996, LOTTA CONTRO TUBERCU, V6, P131; Cloosterman S. G. M., 1996, European Respiratory Journal Supplement, V9, p394S; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 1998, THORAX, V53, P63; CUSTOVIC A, 2002, THORAX, V57, P45; de Vries MP, 2007, BRIT J GEN PRACT, V57, P184; Dharmage S, 2006, INT ARCH ALLERGY IMM, V139, P132, DOI 10.1159/000090388; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DIETEMANN A, 1992, ALLERGY          S12, V47, P251; DIETEMANN A, 1991, REV MALADIES RESP S1, V8, pR16; DORWARD AJ, 1988, THORAX, V43, P98, DOI 10.1136/thx.43.2.98; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Fang Zongjun, 2001, Zhonghua Jiehe He Huxi Zazhi, V24, P685; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Geller-Bernstein C, 1995, Allerg Immunol (Paris), V27, P147; Ghazala L, 2004, ALLERGOLOGIE, V27, P26; GILLIES DRN, 1987, CLIN ALLERGY, V17, P105, DOI 10.1111/j.1365-2222.1987.tb02327.x; Gotzsche PC, 2003, J ALLERGY CLIN IMMUN, V112, P220, DOI 10.1067/mai.2003.1555; Gotzsche PC, 1998, BRIT MED J, V317, P1105; GOTZSCHE PC, 1990, DAN MED BULL, V37, P329; GOTZSCHE PC, 2008, COCHRANE DB SYST REV, V1, P89; Gotzsche PC, 2007, LANCET, V370, P2100, DOI 10.1016/S0140-6736(07)61899-6; Gotzsche PC, 2006, BRIT MED J, V333, P231, DOI 10.1136/bmj.38895.410451.79; Halken S, 2003, J ALLERGY CLIN IMMUN, V112, P220, DOI 10.1067/mai.2003.1556; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Halken S., 1997, Journal of Allergy and Clinical Immunology, V99, pS320; HAMMARQUIST C, 1998, COCHRANE DATABASE SY; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; HOWARTH PH, 1992, CLIN EXP ALLERGY, V22, P140; Htut T., 1998, European Respiratory Journal, V12, p69S; Htut T, 1999, THORAX, V54, pA28; Htut T, 2001, J ALLERGY CLIN IMMUN, V107, P55, DOI 10.1067/mai.2001.111240; HTUT T, 1999, MITE ERADICATION TRI, pS334; HUSS K, 1992, J ALLERGY CLIN IMMUN, V89, P836, DOI 10.1016/0091-6749(92)90439-9; IHRE E, 1988, CLIN ALLERGY, V18, P557, DOI 10.1111/j.1365-2222.1988.tb02907.x; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; JOOMA OF, 1995, S AFR MED J, V85, P1002; KORSGAARD J, 1983, ALLERGY, V38, P93, DOI 10.1111/j.1398-9995.1983.tb01592.x; Kroidl RF, 1998, ALLERGY, V53, P435, DOI 10.1111/j.1398-9995.1998.tb03919.x; Lee IS, 2003, YONSEI MED J, V44, P313; LEE IS, 2006, INT J NURS STUD; Luczynska C, 2003, CLIN EXP ALLERGY, V33, P1648, DOI 10.1111/j.1365-2222.2003.01729.x; Maesen F P, 1977, Acta Tuberc Pneumol Belg, V68, P133; MANJRA A, 1994, S AFR MED J, V84, P278; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; Matthys H., 1996, European Respiratory Journal Supplement, V9, p350S; MITCHELL EA, 1980, LANCET, V2, P559; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; MURRAY AB, 1983, PEDIATRICS, V71, P418; Naspitz CK, 1997, LANCET, V349, P404, DOI 10.1016/S0140-6736(97)80026-8; *NAT HEART LUNG BL, 2007, 3 US DEP HLTH NAT HE; *NORD COCHR CTR CO, 2003, REV MAN REVMAN COMP; Pildal J, 2007, INT J EPIDEMIOL, V36, P847, DOI 10.1093/ije/dym087; Popplewell EJ, 2000, PEDIATR ALLERGY IMMU, V11, P142, DOI 10.1034/j.1399-3038.2000.00058.x; REISER J, 1990, CLIN EXP ALLERGY, V20, P561, DOI 10.1111/j.1365-2222.1990.tb03150.x; Rijssenbeek-Nouwens LHM, 2002, CLIN EXP ALLERGY, V32, P117, DOI 10.1046/j.0022-0477.2001.01256.x; Rijssenbeek-Nouwens LHM, 2002, THORAX, V57, P784, DOI 10.1136/thorax.57.9.784; Schmidt LM, 2005, J FAM PRACTICE, V54, P334; SETTE L, 1994, PEDIATR PULM, V18, P218, DOI 10.1002/ppul.1950180405; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Sheikh Aziz, 2002, BMC Fam Pract, V3, P12, DOI 10.1186/1471-2296-3-12; SOOLTANGOS S, 1992, J ALLERGY CLIN IMMUN, V89, P259; Thiam DGY, 1999, ASIAN PAC J ALLERGY, V17, P169; TOVEY ER, 1992, EXP APPL ACAROL, V16, P181, DOI 10.1007/BF01201500; van den Bemt L, 2004, J ALLERGY CLIN IMMUN, V114, P858, DOI 10.1016/j.jaci.2004.05.069; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; van Schayck OCP, 2007, J ALLERGY CLIN IMMUN, V119, P1323, DOI 10.1016/j.jaci.2007.02.024; VANDENBEMT L, 2000, EUR RESPIR J, V16, pS468; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; vanderHeide S, 1997, ALLERGY, V52, P921; VERRALL B, 1988, ANN ALLERGY, V61, P117; WALSHAW MJ, 1986, Q J MED, V58, P199; WARBURTON CJ, 1994, RESP MED, V88, P771, DOI 10.1016/S0954-6111(05)80200-8; WARNER JA, 1993, THORAX, V48, P330, DOI 10.1136/thx.48.4.330; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; ZWEMER RJ, 1973, ANN ALLERGY, V31, P284; [Anonymous], 1989, J ALLERGY CLIN IMMUN, V83, P416	94	83	85	2	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JUN	2008	63	6					646	659		10.1111/j.1398-9995.2008.01690.x		14	Allergy; Immunology	Allergy; Immunology	292SB	WOS:000255285300003	18445182	
J	Chu, HW; Thaikoottathil, J; Rino, JG; Zhang, G; Wu, Q; Moss, T; Refaeli, Y; Bowler, R; Wenzel, SE; Chen, Z; Zdunek, J; Breed, R; Young, R; Allaire, E; Martin, RJ				Chu, Hong Wei; Thaikoottathil, Jyoti; Rino, John G.; Zhang, Gongyi; Wu, Qun; Moss, Taylor; Refaeli, Yosef; Bowler, Russell; Wenzel, Sally E.; Chen, Zhongzhou; Zdunek, Jeffrey; Breed, Rachel; Young, Ryan; Allaire, Erin; Martin, Richard J.			Function and regulation of SPLUNC1 protein in mycoplasma infection and allergic inflammation	JOURNAL OF IMMUNOLOGY			English	Article							NASAL LAVAGE FLUID; CHLAMYDIA-PNEUMONIAE; BRONCHIAL HYPERRESPONSIVENESS; COLLAGEN DEPOSITION; AIRWAY INFLAMMATION; MUCIN EXPRESSION; MURINE MODEL; LUNG; ASTHMA; PLUNC	Respiratory infections, including Mycoplasma pneumoniae (Mp), contribute to asthma pathobiology. To date, the mechanisms underlying the increased susceptibility of asthmatics to airway Mp infection remain unclear. Short palate, lung, and nasal epithelium clone 1 (SPLUNC1) protein is a recently described large airway epithelial cell-derived molecule that was predicted to exert host defense activities. However, SPLUNC1 function and regulation in an infectious or allergic milieu are still unknown. We determined host defense and anti-inflammatory functions of SPLUNC1 protein in Mp infection and the regulation of SPLUNC1 by Mp and allergic inflammation (e.g., IL-13). SPLUNC1 function was examined in Mp or human airway epithelial cell cultures by using SPLUNC1 recombinant protein, overexpression and RNA interference. Human and mouse bronchial epithelial SPLUNC1 was examined using immunostaining, Western blotting, ELISA, laser capture microdissection, and real-time PCR. Mouse models of Mp infection and allergic inflammation and air-liquid interface cultures of normal human primary bronchial epithelial cells were used to study SPLUNC1 regulation by Mp and IL-13. We found that: 1) SPLUNC1 protein decreased Mp levels and inhibited epithelial IL-8 production induced by Mp-derived lipoproteins; 2) normal human and mouse large airway epithelial cells expressed high levels of SPLUNC1; and 3) although Mp infection increased SPLUNC1, IL-13 significantly decreased SPLUNC1 expression and Mp clearance. Our results suggest that SPLUNC1 serves as a novel host defense protein against Mp and that an allergic setting markedly reduces SPLUNC1 expression, which may in part contribute to the persistent nature of bacterial infections in allergic airways.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80206 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA	Chu, HW (reprint author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,Room A639, Denver, CO 80206 USA.	chuhw@njc.org	chen, zhong/E-3900-2015	chen, zhong/0000-0003-1319-9664	NHLBI NIH HHS [P01 HL073907]		Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; Bingle CD, 2002, HUM MOL GENET, V11, P937, DOI 10.1093/hmg/11.8.937; Blasi F, 2002, THORAX, V57, P672, DOI 10.1136/thorax.57.8.672; Campos MA, 2004, AM J RESP CELL MOL, V30, P184, DOI 10.1165/rcmb.2003-01420C; Cartner SC, 1996, INFECT IMMUN, V64, P5326; Chen WE, 2005, WIREL NETW MOB COMP, V1, P3; Chen ZZ, 2006, CELL, V125, P691, DOI 10.1016/j.cell.2006.04.024; Chu H. W., 2002, Clinical and Experimental Allergy, V32, P1558, DOI 10.1046/j.1365-2222.2002.01477.x; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; Chu HW, 2005, AM J PHYSIOL-LUNG C, V289, pL125, DOI 10.1152/ajplung.00167.2004; Chu HW, 2005, J IMMUNOL, V174, P5713; Chu HW, 2004, AM J PATHOL, V165, P1097, DOI 10.1016/S0002-9440(10)63371-8; Chu HW, 2004, J INFECT DIS, V189, P1119, DOI 10.1086/382050; Chu HW, 2003, INFECT IMMUN, V71, P1520, DOI 10.1128/IAI.71.3.1520-1526.2003; Ghafouri B, 2006, J PROTEOME RES, V5, P330, DOI 10.1021/pr050341h; Ghafouri B, 2004, BBA-PROTEINS PROTEOM, V1699, P57, DOI 10.1016/j.bbapap.2004.01.001; Ghafouri B, 2003, BIOCHEM SOC T, V31, P810, DOI 10.1042/BST0310810; Ghafouri B, 2002, PROTEOMICS, V2, P112, DOI 10.1002/1615-9861(200201)2:1<112::AID-PROT112>3.0.CO;2-N; Hardy RD, 2003, ANTIMICROB AGENTS CH, V47, P1614, DOI 10.1128/AAC.47.5.1614-1620.2003; Kelly MM, 2005, AM J RESP CELL MOL, V32, P99, DOI 10.1165/rcmb.2004-0190OC; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; LeClair EE, 2003, BIOCHEM SOC T, V31, P801, DOI 10.1042/BST0310801; LeClair EE, 2003, J DENT RES, V82, P944; LEVY O, 1995, J IMMUNOL, V154, P5403; Li RG, 2003, J BACTERIOL, V185, P4219, DOI 10.1128/JB.185.14.4219-4225.2003; Lindahl M, 2001, ELECTROPHORESIS, V22, P1795, DOI 10.1002/1522-2683(200105)22:9<1795::AID-ELPS1795>3.0.CO;2-J; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595; Matta H, 2003, CANCER BIOL THER, V2, P206; Moraes TJ, 2006, AM J RESP CELL MOL, V34, P364, DOI 10.1165/rcmb.2005-0146OC; Nomura I, 2003, J IMMUNOL, V171, P3262; Refaeli Y, 2005, P NATL ACAD SCI USA, V102, P4097, DOI 10.1073/pnas.0409832102; Refaeli Y, 2002, J EXP MED, V196, P999, DOI 10.1084/JEM.20020666; ten Brinke A, 2001, J ALLERGY CLIN IMMUN, V107, P449, DOI 10.1067/mai.2001.113047; TRUDEAU J, 2006, ALLERGY CLIN IMMUNOL, V117, P1446; Weston WM, 1999, J BIOL CHEM, V274, P13698, DOI 10.1074/jbc.274.19.13698; Wu L, 2000, AM J RESP CRIT CARE, V162, P1148; Yang J, 2002, INFECT IMMUN, V70, P3649, DOI 10.1128/IAI.70.7.3649-3655.2002; Zhu Z, 2001, AM J RESP CRIT CARE, V164, pS67	38	83	92	1	6	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	SEP 15	2007	179	6					3995	4002				8	Immunology	Immunology	210ON	WOS:000249465600071	17785838	
J	Thyssen, JP; Johansen, JD; Menne, T				Thyssen, Jacob Pontoppidan; Johansen, Jeanne Duus; Menne, Torkil			Contact allergy epidemics and their controls	CONTACT DERMATITIS			English	Review						chromium; contact allergy; contact dermatitis; epidemic; formaldehyde; isothiazolinone; methyldibromo glutaronitrile; nickel; para-phenylenediamine; risk assessment	RINSE-OFF PRODUCTS; PATCH TEST; KATHON-CG; NICKEL-EXPOSURE; RISK-ASSESSMENT; METHYLDIBROMO GLUTARONITRILE; FERROUS SULFATE; GUINEA-PIG; HAIR-DYES; DERMATITIS	Contact dermatitis can be severe and lead to sick leave as well as significant healthcare expenses. The aim of this review is to present the published knowledge on 6 historical epidemics of contact allergy to apply this knowledge on the prevention and control of future contact allergy epidemics. A historical review is performed on nickel, chromium, methylchloroisothiazolinone/methylisothiazolinone, methyldibromo glutaronitrile, formaldehyde, and para-phenylenediamine. The first cases of contact dermatitis are mostly occupational, whereas consumer cases appear later. There is often a latency period from the first cases are observed until an epidemic occurs, and the problem is recognized. Finally, no one seems to take responsibility of dealing with the situation, and there are no attempts of regulation until an epidemic is consolidated among consumers for many years. Steps should be taken to prevent contact allergy epidemics. It is essential that dermatologist, scientists, administrators, and consumers organize and structure known methods to accelerate the control of emerging contact allergens.	Gentofte Univ Hosp, Dept Dermatovenerol, Natl Allery Res Ctr, DK-2820 Gentofte, Denmark	Thyssen, JP (reprint author), Gentofte Univ Hosp, Dept Dermatovenerol, Natl Allery Res Ctr, Ledreborg Alle 40,1, DK-2820 Gentofte, Denmark.	jacpth01@gentoftehosp.kbhamt.dk					AGNER T, 2006, CONTACT DERMATITIS, P127, DOI 10.1007/3-540-31301-X_9; Armstrong DKB, 1999, CONTACT DERMATITIS, V41, P348, DOI 10.1111/j.1600-0536.1999.tb06191.x; AVNSTORP C, 1989, CONTACT DERMATITIS, V20, P365, DOI 10.1111/j.1600-0536.1989.tb03174.x; AZUA J, 1910, ACTAS DERMO SIF, V2, P220; BELSITO DV, 2006, 8 C EUR SOC CONT DER; BJORKNER B, 1986, CONTACT DERMATITIS, V14, P85, DOI 10.1111/j.1600-0536.1986.tb01166.x; BLASCHKO A, 1989, DEUT MED WOCHENSCHR, V15, P925; BONNEVIE P, 1936, ACTA DERM-VENEREOL, V17, P376; BOSS A, 1982, CONTACT DERMATITIS, V8, P211, DOI 10.1111/j.1600-0536.1982.tb04191.x; BRANDRUP F, 1979, CONTACT DERMATITIS, V5, P148, DOI 10.1111/j.1600-0536.1979.tb04827.x; BRUZE M, 1988, CONTACT DERMATITIS, V18, P37, DOI 10.1111/j.1600-0536.1988.tb05487.x; Bryld LE, 2004, J INVEST DERMATOL, V123, P1025, DOI 10.1111/j.0022-202X.2004.23452.x; Bulmer FM, 1926, J IND HYG, V8, P517; Cathelineau H., 1898, B SOC FRANC SYPH, V9, P28; *CDC, 2006, GLOSS TERMS; CHAN PK, 1983, J INVEST DERMATOL, V81, P409, DOI 10.1111/1523-1747.ep12522544; Conde-Salazar L, 1995, AM J CONTACT DERMATI, V6, P19, DOI 10.1016/1046-199X(95)90064-0; Cosmetic Ingredient Review Expert panel of The Cosmetics Toiletry and Fragrance Association, 1992, J AM COLL TOXICOL, V11, P75; *CRAIN COMM INC, 2006, ADV CENT; deGroot AC, 1996, CONTACT DERMATITIS, V34, P118; DEGROOT AC, 1985, CONTACT DERMATITIS, V12, P76; Dillarstone A, 1997, CONTACT DERMATITIS, V37, P190, DOI 10.1111/j.1600-0536.1997.tb00205.x; DUBOIS C, 1931, SCHWEIZ MED WOCHENSC, V12, P278; Englehardt W E, 1931, ARCH GEWERBEPATH HYG, V2, P140; *EUR COMM, 2003, OFFICIAL J EUROPEAN, P28; European Commission, 2004, OFFICIAL J EUROPEAN; European Communities, 1994, OFFICIAL J EUR COMMU, V37, P1; Felter SP, 2003, REGUL TOXICOL PHARM, V37, P1, DOI 10.1016/S0273-2300(02)00021-1; Fewings J, 1999, CONTACT DERMATITIS, V41, P1, DOI 10.1111/j.1600-0536.1999.tb06200.x; Fischer LA, 2005, CONTACT DERMATITIS, V52, P57, DOI 10.1111/j.0105-1873.2005.00523.x; Flint GN, 1998, CONTACT DERMATITIS, V39, P213, DOI 10.1111/j.1600-0536.1998.tb05912.x; Flyvholm MA, 2005, CONTACT DERMATITIS, V53, P27, DOI 10.1111/j.0105-1873.2005.00629.x; Flyvholm MA, 1997, CONTACT DERMATITIS, V36, P26, DOI 10.1111/j.1600-0536.1997.tb00918.x; FORSCH P, 2006, CONTACT DERMATITIS; FOUSSEREAU J, 1990, CONTACT DERMATITIS, V22, P68, DOI 10.1111/j.1600-0536.1990.tb01519.x; Fransway A. F., 1991, AM J CONTACT DERMATI, V2, P6; FREGERT S, 1972, HAUTARZT, V23, P393; FREGERT S, 1979, CONTACT DERMATITIS, V5, P39, DOI 10.1111/j.1600-0536.1979.tb05533.x; FROSCH PJ, 1993, CONTACT DERMATITIS, V28, P180, DOI 10.1111/j.1600-0536.1993.tb03383.x; Galeotti N, 2005, BEHAV BRAIN RES, V164, P165, DOI 10.1016/j.bbr.2005.06.011; Geier J, 2000, DERMATOL BERUF UMWEL, V48, P4; Gruvberger B, 1998, ACTA DERM-VENEREOL, V78, P52; GRUVBERGER B, 2006, 8 C EUR SOC CONT DER; GRUVBERGER B, 1997, METHYLISOTHIAZOLINON, P9; GUERRA L, 1992, CONTACT DERMATITIS, V26, P101, DOI 10.1111/j.1600-0536.1992.tb00892.x; HANNUKSELA M, 1986, CONTACT DERMATITIS, V15, P211, DOI 10.1111/j.1600-0536.1986.tb01338.x; Hansen MB, 2002, CONTACT DERMATITIS, V47, P127, DOI 10.1034/j.1600-0536.2002.470301.x; HAUSEN BM, 1993, CONTACT DERMATITIS, V28, P149, DOI 10.1111/j.1600-0536.1993.tb03376.x; Hindsen M, 1999, Am J Contact Dermat, V10, P62, DOI 10.1016/S1046-199X(99)90001-5; *HLTH SAF EX, 2006, HLTH EX STAT DERM OT; Isaksson Marlene, 2004, Dermatitis, V15, P201, DOI 10.2310/6620.2004.04017; Jadassohn W, 1929, ARCH DERMATOL SYPH-G, V157, P572, DOI 10.1007/BF01833373; JAEGER H., 1950, DERMATOLOGICA [BASEL], V100, P207; Jensen CD, 2004, BRIT J DERMATOL, V150, P90, DOI 10.1111/j.1365-2133.2004.05727.x; Jensen CS, 2002, BRIT J DERMATOL, V146, P636, DOI 10.1046/j.1365-2133.2002.04666.x; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; Johansen J D, 2006, CONTACT DERMATITIS, P189, DOI 10.1007/3-540-31301-X_13; JORDAN WP, 1979, J AM ACAD DERMATOL, V1, P44, DOI 10.1016/S0190-9622(79)70003-X; Kist JM, 2004, ARCH DERMATOL, V140, P1448, DOI 10.1001/archderm.140.12.1448; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P393, DOI 10.1038/jid.1966.160; Law A.B., 1984, COSMETIC DRUG PRESER, P129; Lind ML, 2005, ANN OCCUP HYG, V49, P457, DOI 10.1093/annhyg/mei032; LOVELL CR, 1984, CONTACT DERMATITIS, V11, P187, DOI 10.1111/j.1600-0536.1984.tb00970.x; Maibach H, 1983, FORMALDEHYDE TOXICIT, P166; MARCUSSEN P V, 1959, Acta Derm Venereol, V39, P348; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; Martial R, 1908, PRESSE MED, V64, P507; MARZULLI FN, 1974, FOOD COSMET TOXICOL, V12, P219, DOI 10.1016/0015-6264(74)90367-8; MATHIAS CGT, 1983, CONTACT DERMATITIS, V9, P418, DOI 10.1111/j.1600-0536.1983.tb04440.x; MCALESTER AW, 1931, AM J OPHTHALMOL, V14, P925; MENNE T, 1987, CONTACT DERMATITIS, V16, P255, DOI 10.1111/j.1600-0536.1987.tb01448.x; Menne T, 2002, CONTACT DERMATITIS, V46, P189, DOI 10.1034/j.1600-0536.2002.460401.x; Menne T, 1979, Derm Beruf Umwelt, V27, P37; MENNE T, 1990, CONTACT DERMATITIS, V23, P57, DOI 10.1111/j.1600-0536.1990.tb00093.x; Miller HE, 1925, J AMER MED ASSOC, V84, P1999; *MUS FUN CUST, 2006, FORM ITS DEV HIST SI; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; ODONOVAN WJ, 1925, LANCET, V21, P599; ODRISCOLL JB, 1988, CONTACT DERMATITIS, V19, P63, DOI 10.1111/j.1600-0536.1988.tb02872.x; PEDERSEN NB, 1974, ACTA DERM-VENEREOL, V54, P231; PETERS KP, 1994, DERMATOS BER UMWELT, V42, P50; Reinhardi E, 2001, CONTACT DERMATITIS, V45, P257, DOI 10.1034/j.1600-0536.2001.450501.x; Robinson MK, 2000, CONTACT DERMATITIS, V42, P251, DOI 10.1034/j.1600-0536.2000.042005251.x; Schafer T, 2001, ALLERGY, V56, P1192, DOI 10.1034/j.1398-9995.2001.00086.x; SCHITTENHELM A, 1925, Z GES EXP MED, V45, P58, DOI 10.1007/BF02626025; Schnuch A, 2002, CONTACT DERMATITIS, V47, P32, DOI 10.1034/j.1600-0536.2002.470107.x; SCHNUCH A, 1995, DERMATOS BER UMWELT, V43, P29; Schnuch A, 2003, CONTACT DERMATITIS, V49, P107, DOI 10.1111/j.0105-1873.2003.0128f.x; *SCI COMM COSM PRO, 2002, SCCNFP DUR 20 PLEN M; SENFF H, 1989, CONTACT DERMATITIS, V20, P381, DOI 10.1111/j.1600-0536.1989.tb03180.x; Sosted H, 2005, BRIT J DERMATOL, V153, P132, DOI 10.1111/j.1365-2133.2005.06588.x; Thyssen JP, 2006, CONTACT DERMATITIS, V54, P322, DOI 10.1111/j.0105-1873.2006.00850.x; TOSTI A, 1988, CONTACT DERMATITIS, V18, P173, DOI 10.1111/j.1600-0536.1988.tb04509.x; Tosti A, 2000, CONTACT DERMATITIS, V42, P64, DOI 10.1034/j.1600-0536.2000.042002064.x; Uter W, 2005, CONTACT DERMATITIS, V53, P136, DOI 10.1111/j.0105-1873.2005.00673.x; Uter W, 2000, DERMATOLOGY, V200, P132, DOI 10.1159/000018346; Uter W, 2003, CONTACT DERMATITIS, V49, P236, DOI 10.1111/j.0105-1873.2003.0233.x; Uter W, 2004, ANN OCCUP HYG, V48, P21, DOI 10.1093/annhyg/meg080; UTER W, 2006, CONTACT DERMATITIS, P893, DOI 10.1007/3-540-31301-X_47; Wahlberg J, 2002, OCCUP ENV DERMATOL, V50, P51; Wahlkvist H, 1999, CONTACT DERMATITIS, V41, P330, DOI 10.1111/j.1600-0536.1999.tb06182.x; Westphal GA, 2003, CONTACT DERMATITIS, V48, P93, DOI 10.1034/j.1600-0536.2003.480208.x; Wikipedia the free encyclopedia, 2006, FREE ENC; Wilkinson JD, 2002, CONTACT DERMATITIS, V46, P207, DOI 10.1034/j.1600-0536.2002.460404.x; Zachariae C, 2005, CONTACT DERMATITIS, V53, P268, DOI 10.1111/j.0105-1873.2005.00712.x; Zachariae C, 2006, CONTACT DERMATITIS, V55, P160, DOI 10.1111/j.1600-0536.2006.00895.x; Zachariae COC, 1996, CONTACT DERMATITIS, V35, P83, DOI 10.1111/j.1600-0536.1996.tb02295.x; 2006, HAIR COLOR; 1976, OFFICIAL J EEC L, V262, P169	109	83	87	1	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-1873			CONTACT DERMATITIS	Contact Dermatitis		2007	56	4					185	195		10.1111/j.1600-0536.2006.01058.x		11	Allergy; Dermatology	Allergy; Dermatology	141WF	WOS:000244609000001	17343617	
J	Pincus-Knackstedt, MK; Joachim, RA; Blois, SM; Douglas, AJ; Orsal, AS; Klapp, BF; Wahn, U; Hamelmann, E; Arck, PC				Pincus-Knackstedt, Maike K.; Joachim, Ricarda A.; Blois, Sandra M.; Douglas, Alison J.; Orsal, Arif S.; Klapp, Burghard F.; Wahn, Ulrich; Hamelmann, Eckard; Arck, Petra C.			Prenatal stress enhances susceptibility of murine adult offspring toward airway inflammation	JOURNAL OF IMMUNOLOGY			English	Article							PULMONARY EOSINOPHILIA; ASTHMA; CELLS; RAT; HYPERRESPONSIVENESS; PREGNANCY; CYTOKINES; ENDOTOXIN; EXPOSURE; CORTISOL	Allergic asthma is one of the most prevalent and continuously increasing diseases in developed countries. Its clinical features include airway hyperresponsiveness and inflammation upon allergen contact. Furthermore, an emerging area of research subsumed as fetal programming evaluates the impact of environmental insults in utero on the incidence of diseases in later life. The aim of this study was to identify whether prenatal exposure to stress, which constitutes a severe environmental insult, perpetuates airway inflammation in later life. Our experiments were performed in mice and revealed that prenatally stressed adult offspring indeed show an increased vulnerability toward airway hyperresponsiveness and inflammation. Furthermore, we provide persuasive insights on dysregulated pathways of the cellular and humoral immune response upon Ag challenge in prenatally stressed adult offspring, reflected by a Th2 greater Th1 adaptive immune response and increased CCR3 and IgE levels in vivo. Additionally, APCs derived from prenatally stressed offspring trigger clonal expansion of Th2 cells in vitro. We also deliver experimental evidence for a reduced corticotrophin-releasing hormone expression in the paraventricular nucleus of adult offspring in response to prenatal stress. Furthermore, behavioral analyses indicate an increase in anxiety in these mice. In conclusion, our data will facilitate future research aiming to identify the individual impact, hierarchy, and redundancy of multiple key protagonists in airway inflammation in an interdisciplinary context. This will foster the substantiation of disease-prevention strategies, such as asthma, during the prenatal period.	Univ Med Berlin, Charite, Dept Internal Med Psychosomat, Div Psychoneuroimmunol, Berlin, Germany; Univ Med Berlin, Charite, Dept Pediat, Div Pneumol & Immunol, Berlin, Germany; Univ Med Berlin, Charite, Neurosci Program, Berlin, Germany; Univ Edinburgh, Ctr Integrat Physiol, Edinburgh EH8 9YL, Midlothian, Scotland	Arck, PC (reprint author), Univ Med Berlin, Charite, Dept Internal Med Psychosomat, Div Psychoneuroimmunol, Berlin, Germany.	petra.arck@charite.de	Arck, Petra/D-7094-2013				ABBAS AK, 2004, CELLULAR MOL IMMUNOL, P449; ARCK PC, 1995, BIOL REPROD, V53, P814, DOI 10.1095/biolreprod53.4.814; BARKER DJP, 1995, MOL MED TODAY, V1, P418, DOI 10.1016/S1357-4310(95)90793-9; Blois S, 2005, J IMMUNOL, V174, P1820; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bousquet J, 2000, ALLERGY, V55, P1194, DOI 10.1034/j.1398-9995.2000.00923.x; BOUSQUET J, 2004, ALLERGY, V59, P38; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURNEY P, 2002, THORAX, V57, P1136; Coe CL, 2002, J CLIN ENDOCR METAB, V87, P675, DOI 10.1210/jc.87.2.675; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; Douglas AJ, 2003, ENDOCRINOLOGY, V144, P5268, DOI 10.1210/en.2003-0461; Franklin KBJ, 1997, MOUSE BRAIN STEREOTA; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V118, P90, DOI 10.1159/000024037; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; JINGAMI H, 1985, FEBS LETT, V191, P63, DOI 10.1016/0014-5793(85)80994-7; Joachim RA, 2003, PSYCHOSOM MED, V65, P811, DOI 10.1097/01.PSY.0000088582.50468.A3; Karrow NA, 2006, BRAIN BEHAV IMMUN, V20, P144, DOI 10.1016/j.bbi.2005.05.003; Kovacs KJ, 2004, ANN NY ACAD SCI, V1018, P466, DOI 10.1196/annals.1296.057; LANNERO E, 2006, RESP RES, V5, P7; Lesage J, 2004, J ENDOCRINOL, V181, P291, DOI 10.1677/joe.0.1810291; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Matricardi PM, 2001, ANN ALLERG ASTHMA IM, V87, P24; Mitchell B, 2005, EMBRYOLOGY, P25; MURPHY BEP, 1974, AM J OBSTET GYNECOL, V118, P538; Nepomnaschy PA, 2006, P NATL ACAD SCI USA, V103, P3938, DOI 10.1073/pnas.0511183103; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Pope SM, 2005, J IMMUNOL, V175, P5341; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; van Rijt LS, 2003, J IMMUNOL, V171, P3372; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Warburton D, 2000, MECH DEVELOP, V92, P55, DOI 10.1016/S0925-4773(99)00325-1; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032	39	83	86	0	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	DEC 15	2006	177	12					8484	8492				9	Immunology	Immunology	125BP	WOS:000243416800025	17142746	
J	Mi, YH; Norback, D; Tao, J; Mi, YL; Ferm, M				Mi, Y-H.; Norback, D.; Tao, J.; Mi, Y-L.; Ferm, M.			Current asthma and respiratory symptoms among pupils in Shanghai, China: influence of building ventilation, nitrogen dioxide, ozone, and formaldehyde in classrooms	INDOOR AIR			English	Article							INDOOR AIR-QUALITY; SCHOOL ENVIRONMENT; DIFFUSION TUBES; HEALTH-SURVEY; HONG-KONG; EXPOSURE; POLLUTION; SCHOOLCHILDREN; PREVALENCE; CHILDREN	We investigated 10 naturally ventilated schools in Shanghai, in winter. Pupils (13-14 years) in 30 classes received a questionnaire, 1414 participated (99%). Classroom temperatures were 13-21 degrees C (mean 17 degrees C), relative air humidity was 36-82% (mean 56%). The air exchange rate was 2.9-29.4 ac/h (mean 9.1), because of window opening. Mean CO(2) exceeded 1000 ppm in 45% of the classrooms. NO(2) levels were 33-85 mu g/m(3) indoors, and 45-80 mu g/m(3) outdoors. Ozone were 1-9 mu g/m(3) indoors and 17-28 mu g/m(3) outdoors. In total, 8.9% had doctors' diagnosed asthma, 3.1% wheeze, 23.0% daytime breathlessness, 2.4% current asthma, and 2.3% asthma medication. Multiple logistic regression was applied. Observed indoor molds was associated with asthma attacks [odds ratio (OR) = 2.40: P < 0.05]. Indoor temperature was associated with daytime breathlessness (OR = 1.26 for 1 C; P < 0.001), and indoor CO(2) with current asthma (OR = 1.18 for 100 ppm; P < 0.01) and asthma medication (OR = 1.15 for 100 ppm; P < 0.05). Indoor NO(2) was associated with current asthma (OR = 1.51 for 10 mu g/m(3); P < 0.01) and asthma medication (OR = 1.45 for 10 mu g/m(3); P < 0.01). Outdoor NO(2) was associated with current asthma (OR = 1.44 for 10 mu g/m(3); P < 0.05). Indoor and outdoor ozone was negatively associated with daytime breathlessness. In conclusion, asthma symptoms among pupils in Shanghai can be influenced by lack of ventilation and outdoor air pollution from traffic.	Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden; Univ Uppsala Hosp, SE-75185 Uppsala, Sweden; Jiao Tong Univ, Shanghai 200030, Peoples R China; Shanghai Teachers Univ, Shanghai, Peoples R China; IVL Swedish Environm Res Inst, Gothenburg, Sweden	Norback, D (reprint author), Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden.	dan.norback@medsci.uu.se		Norback, Dan/0000-0002-5174-6668			Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694; ANDERSSON K, 1981, SCAND J WORK ENV HEA, V7, P282; Baker M, 2000, SCIENCE, V288, P1317; Belsley DA, 1991, CONDITIONING DIAGNOS; Bornehag CG, 2001, INDOOR AIR, V11, P72; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; CALDER IC, 1993, B ENVIRON CONTAM TOX, V51, P185; CAMPBELL GW, 1994, ATMOS ENVIRON, V28, P477, DOI 10.1016/1352-2310(94)90125-2; Carmichael GR, 2003, ATMOS ENVIRON, V37, P1293, DOI 10.1016/S1352-2310(02)01009-9; Chen Yu-zhi, 2004, Zhonghua Jiehe He Huxi Zazhi, V27, P112; Chen Y Z, 1998, CHINESE J PEDIAT, V36, P353; Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; ELLIOT L, 1991, APPL OCCUP ENV HYG, V6, P836; Ferm M, 1997, J ATMOS CHEM, V27, P17, DOI 10.1023/A:1005816621522; Ferm M, 1998, ATMOS ENVIRON, V32, P1377, DOI 10.1016/S1352-2310(97)00170-2; FERM M, 2001, P INT C MEAS AIR POL, P31; FERM M, 2001, P INT C MEAS AIR POL, P298; GEBSKI V, 1992, SPIDA USERS MANUAL V; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Godish T, 1996, INDOOR AIR, V6, P135, DOI 10.1111/j.1600-0668.1996.00010.x; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662; Heal MR, 1999, ATMOS ENVIRON, V33, P513, DOI 10.1016/S1352-2310(98)00290-8; HEYMAN E, 1880, NORD MED ARK, V12, P1; Immonen J, 2001, PEDIATR ALLERGY IMMU, V12, P87, DOI 10.1034/j.1399-3038.2001.012002087.x; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Kan HD, 2003, ARCH ENVIRON HEALTH, V58, P360; Lee SC, 2000, CHEMOSPHERE, V41, P109, DOI 10.1016/S0045-6535(99)00396-3; Mendell MJ, 2005, INDOOR AIR, V15, P27, DOI 10.1111/j.1600-0668.2004.00320.x; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; NORBACK D, 1990, BRIT J IND MED, V47, P733; Norback Dan, 1992, INDOOR AIR, V2, P58, DOI 10.1111/j.1600-0668.1992.07-21.x; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; Qian ZM, 2000, ARCH ENVIRON HEALTH, V55, P126; Ramadour M, 2000, ALLERGY, V55, P1163, DOI 10.1034/j.1398-9995.2000.00637.x; Salo PM, 2004, ANN EPIDEMIOL, V14, P543, DOI 10.1016/j.annepidem.2003.09.015; SESLINE D, 1994, ARCH ENVIRON HEALTH, V49, P439; SJOBERG K, 2001, P INT C MEAS AIR POL, P116; Smedje G, 1997, INDOOR AIR, V7, P143, DOI 10.1111/j.1600-0668.1997.00009.x; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; Su HJJ, 2001, ARCH ENVIRON HEALTH, V56, P144; Sundell J, 1996, SCAND J WORK ENV HEA, V22, P5; Taskinen TM, 2002, ALLERGY, V57, P9, DOI 10.1034/j.1398-9995.2002.13154.x; THORNE PS, 1993, VET HUM TOXICOL, V35, P141; Wainman T, 2000, ENVIRON HEALTH PERSP, V108, P1139, DOI 10.2307/3434825; World Health Organization (WHO), 1987, EUR SER WHO, V23; WHO, 2005, WHO AIR QUAL GUID GL; Wieslander G, 1997, J OCCUP HEALTH, V39, P331, DOI 10.1539/joh.39.331; Wilkins CK, 2001, ENVIRON HEALTH PERSP, V109, P937, DOI 10.2307/3454995; Wong CM, 1998, J EPIDEMIOL COMMUN H, V52, P571; ZHAO R, 1991, ZHONGHUA YU FANG YI, V56, P149; 1993, VENTILATION QUALITY, P5	57	83	86	8	41	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0905-6947			INDOOR AIR	Indoor Air	DEC	2006	16	6					454	464		10.1111/j.1600-0668.2006.00439.x		11	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	102SC	WOS:000241832600006	17100666	
J	Bousquet, J; Flahault, A; Vandenplas, O; Ameille, J; Duron, JJ; Pecquet, C; Chevrie, K; Annesi-Maesano, I				Bousquet, Jean; Flahault, Antoine; Vandenplas, Olivier; Ameille, Jacques; Duron, Jean-Jacques; Pecquet, Corine; Chevrie, Karine; Annesi-Maesano, Isabella			Natural rubber latex allergy among health care workers: A systematic review of the evidence	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						latex allergy; health care workers; IgE; skin test; exposure-response relationship; meta-analysis	APPRENTICES STARTING EXPOSURE; OPERATING-ROOM NURSES; IN-HOSPITAL PERSONNEL; POWDER-FREE GLOVES; IGE ANTIBODIES; DENTAL STUDENTS; BLOOD-DONORS; OCCUPATIONAL EPIDEMIOLOGY; RESPIRATORY SYMPTOMS; NURSING STAFF	Background: Natural rubber latex is a recognized allergen, but a recent meta-analysis failed to find any association between latex exposure and allergy in health care workers (HCWs). Objectives: A meta-analysis was carried out under the auspices of the French National Regulatory Authority to assess the allergic risk induced by latex gloves in HCWs. Methods: The risk of work-related exposure to latex for the development of latex allergy was assessed. Prevalence and incidence rates of latex sensitization or allergy were compared in HCWs and in the general population. Exposure-response relationships were assessed in HCWs. Results: Latex allergy was found in 4.32% (range, 4.01% to 4.63%) of HCWs and in 1.37% (range, 0.43% to 2.31%) of the general population. Latex-positive skin prick test responses ranged from 2.1% to 3.7% in the general population and from 6.9% to 7.8% for the HCWs. HCWs exposed to latex showed an increased risk of hand dermatitis (odds ratio [OR], 2.46; 95% CI, 2.11-2.86), asthma or wheezing (OR, 1.55; 95% CI, 1.15-2.08), rhinoconjunctivitis (OR, 2.73; 95% CI, 1.97-3.81), and at least one generic symptom (OR, 1.27; 95% CI, 1.09-1.47). Sensitization to latex was significantly associated with asthma and rhinoconjunctivitis. By contrast, exposure to latex was not associated with a significantly increased risk of positive skin prick test responses to latex (OR, 1.47; 95% CI, 0.94-2.30). Conclusion: HCWs have an increased risk of sensitization and allergic symptoms to latex. Clinical implications: Prevention of latex allergy in HCWs is needed.	Univ Hosp, Clin Malad Resp, INSERM, U454,Hop Arnaud Villeneuve, F-34295 Montpellier 5, France; Univ Paris 06, INSERM, U707, Med Sch St Antoine, Paris, France; Clin Univ UCL Montgodinne, Serv Pneumol, Yvoir, France; Hop Raymond Poincare, Assistance Publ Hop Paris, Unit Occupat Hlth, Paris, France; CHU Pitie Salpetriere, Serv Chirurg Digest & Gen, Paris, France; Hop Tenon, Ctr Allergol, F-75970 Paris, France	Bousquet, J (reprint author), Univ Hosp, Clin Malad Resp, INSERM, U454,Hop Arnaud Villeneuve, F-34295 Montpellier 5, France.	jean.bousquet@wanadoo.fr	Annesi-Maesano, Isabella/D-9173-2016				Ahmed DDF, 2003, IMMUNOL ALLERGY CLIN, V23, P205, DOI 10.1016/S0889-8561(02)00079-6; Aichane A, 1997, REV MAL RESPIR, V14, P451; AKASAWA A, 1993, INT ARCH ALLERGY IMM, V101, P177; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Allmers H, 2002, J ALLERGY CLIN IMMUN, V110, P318, DOI 10.1067/mai.2002.126461; Amin A, 1998, INT DENT J, V48, P77; Archambault S, 2001, J ALLERGY CLIN IMMUN, V107, P921; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Baur X, 2003, J ALLERGY CLIN IMMUN, V111, P652, DOI 10.1067/mai.2003.109; BEAUDOUIN E, 1990, REV FR ALLERGOL, V30, P157, DOI 10.1016/S0335-7457(05)80230-8; Bernstein DI, 2003, ANN ALLERG ASTHMA IM, V90, P209; BLETTNER M, 1990, STAT MED, V9, P1339, DOI 10.1002/sim.4780091111; Bollinger ME, 2002, ANN ALLERG ASTHMA IM, V88, P560; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; Brown RH, 1998, ANESTHESIOLOGY, V89, P292, DOI 10.1097/00000542-199808000-00004; Charous BL, 2002, J ALLERGY CLIN IMMUN, V109, P31, DOI 10.1067/mai.2002.120953; Chen YH, 2002, J FORMOS MED ASSOC, V101, P622; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; CORMIO L, 1993, CLIN EXP ALLERGY, V23, P618, DOI 10.1111/j.1365-2222.1993.tb00903.x; de Groot H, 1998, CONTACT DERMATITIS, V38, P159; Di Lorenzo G, 2002, J INVEST ALLERG CLIN, V12, P114; Dixon-Woods Mary, 2005, J Health Serv Res Policy, V10, P45, DOI 10.1258/1355819052801804; Douglas R, 1997, AUST NZ J MED, V27, P165, DOI 10.1111/j.1445-5994.1997.tb00933.x; Fein JA, 1996, PEDIATR EMERG CARE, V12, P6, DOI 10.1097/00006565-199602000-00002; Filon FL, 2001, INT ARCH OCC ENV HEA, V74, P219, DOI 10.1007/s004200000208; Galobardes B, 2001, DERMATOLOGY, V203, P226, DOI 10.1159/000051754; Garabrant DH, 2002, J ALLERGY CLIN IMMUN, V110, pS82, DOI 10.1067/mai.2002.124967; Garabrant DH, 2001, AM J EPIDEMIOL, V153, P515, DOI 10.1093/aje/153.6.515; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; Grzybowski M, 2002, ANN EMERG MED, V40, P411, DOI 10.1067/mem.2002.128144; Hack ME, 2001, ANAESTH INTENS CARE, V29, P43; HADJILIADIS D, 1995, J ALLERGY CLIN IMMUN, V96, P431, DOI 10.1016/S0091-6749(95)70067-6; Hamann CP, 1998, J AM DENT ASSOC, V129, P43; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Hamilton RG, 1999, J ALLERGY CLIN IMMUN, V103, P925, DOI 10.1016/S0091-6749(99)70440-9; Harmanci E, 2000, J INVEST ALLERG CLIN, V10, P162; Holter G, 2002, DERMATOLOGY, V205, P28, DOI 10.1159/000063146; Hunt LW, 2002, J ALLERGY CLIN IMMUN, V110, pS96, DOI 10.1067/mai.2002.125442; Jackson EM, 2000, J EMERG MED, V18, P241, DOI 10.1016/S0736-4679(99)00202-4; Kaczmarek RG, 1996, ANN ALLERG ASTHMA IM, V76, P51; Kibby T, 1997, ANN ALLERG ASTHMA IM, V78, P41; Kim KT, 1999, ALLERGY ASTHMA PROC, V20, P387, DOI 10.2500/108854199778251780; Konrad C, 1997, ANESTH ANALG, V84, P629, DOI 10.1097/00000539-199703000-00031; KUJALA VM, 1995, AM J IND MED, V28, P89, DOI 10.1002/ajim.4700280108; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Levy Y, 2000, ISRAEL MED ASSOC J, V2, P154; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; Lindberg M, 2000, CONTACT DERMATITIS, V43, P4, DOI 10.1034/j.1600-0536.2000.043001004.x; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335; Lonnroth EC, 1998, SWED DENT J, V22, P23; Mace SR, 1998, ANN ALLERG ASTHMA IM, V80, P252; McElvenny DM, 2004, OCCUP MED-OXFORD, V54, P336, DOI 10.1093/occmed/kqh049; Merrett TG, 1999, CLIN EXP ALLERGY, V29, P1572; Mizutari Kumiko, 1995, Journal of Dermatology (Tokyo), V22, P19; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; Nettis E, 2002, CLIN EXP ALLERGY, V32, P441, DOI 10.1046/j.1365-2222.2002.01308.x; Nielsen PS, 2000, ANN ALLERG ASTHMA IM, V85, P489; Nolte H, 2002, ANN ALLERG ASTHMA IM, V89, P452; Ownby DR, 1996, J ALLERGY CLIN IMMUN, V97, P1188, DOI 10.1016/S0091-6749(96)70183-5; Page EH, 2000, J OCCUP ENVIRON MED, V42, P613, DOI 10.1097/00043764-200006000-00010; Palczynski C, 2000, ALLERGY, V55, P34, DOI 10.1034/j.1398-9995.2000.00037.x; Porri F, 1997, CLIN EXP ALLERGY, V27, P413; Potter PC, 2001, SAMJ S AFR MED J, V91, P760; Rueff F, 2001, ALLERGY, V56, P889, DOI 10.1034/j.1398-9995.2001.00021.x; Ryan M, 2001, Health Technol Assess, V5, P1; Saary MJ, 2002, J ALLERGY CLIN IMMUN, V109, P131, DOI 10.1067/mai.2002.120557; Safadi GS, 1996, ANN ALLERG ASTHMA IM, V77, P39; Safadi GS, 1996, J AM DENT ASSOC, V127, P83; SALKIE ML, 1993, ARCH PATHOL LAB MED, V117, P897; Saxon A, 2000, ANN ALLERG ASTHMA IM, V84, P199, DOI 10.1016/S1081-1206(10)62756-1; Schmid K, 2002, CONTACT DERMATITIS, V47, P103, DOI 10.1034/j.1600-0536.2002.470209.x; Sener O, 2000, J INVEST ALLERG CLIN, V10, P30; Shahnaz M, 1999, Med J Malaysia, V54, P26; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171; Tarlo S M, 2001, Curr Opin Pulm Med, V7, P27, DOI 10.1097/00063198-200101000-00005; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; Verna N, 2003, ANN CLIN LAB SCI, V33, P184; Vila L, 1999, J INVEST ALLERG CLIN, V9, P356; Vyas A, 2000, OCCUP ENVIRON MED, V57, P752, DOI 10.1136/oem.57.11.752; Watts DN, 1998, AM J IND MED, V34, P359, DOI 10.1002/(SICI)1097-0274(199810)34:4<359::AID-AJIM9>3.0.CO;2-N; WRANGSJO K, 1994, CONTACT DERMATITIS, V30, P139, DOI 10.1111/j.1600-0536.1994.tb00694.x; YASSIN MS, 1994, ANN ALLERGY, V72, P245; Zaza S, 1994, AORN J, V60, P806, DOI 10.1016/S0001-2092(07)63329-8	89	83	91	0	15	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					447	454		10.1016/j.jaci.2006.03.048		8	Allergy; Immunology	Allergy; Immunology	075IH	WOS:000239877700022	16890771	
J	Cates, CJ; Crilly, JA; Rowe, BH				Cates, CJ; Crilly, JA; Rowe, BH			Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							METERED-DOSE INHALER; RANDOMIZED CONTROLLED-TRIAL; AIR-FLOW OBSTRUCTION; BRONCHODILATOR DELIVERY METHODS; HAND-HELD NEBULIZER; PEAR-SHAPED SPACER; YOUNG-CHILDREN; JET NEBULIZER; WET NEBULIZER; HOSPITALIZED-PATIENTS	Background In acute asthma inhaled beta 2-agonists are often administered to relieve bronchospasm by wet nebulisation, but some have argued that metered-dose inhalers with a holding chamber (spacer) can be equally effective. Nebulisers require a power source and need regular maintenance, and are more expensive in the community setting. Objectives To assess the effects of holding chambers (spacers) compared to nebulisers for the delivery of beta 2-agonists for acute asthma. Search strategy We last searched the Cochrane Airways Group trials register in January 2006 and the Cochrane Central Register of Controlled Trials (The Cochrane Library, Issue 4, 2005). Selection criteria Randomised trials in adults and children (from two years of age) with asthma, where spacer beta 2-agonist delivery was compared with wet nebulisation. Data collection and analysis Two reviewers independently applied study inclusion criteria (one reviewer for the first version of the review), extracted the data and assessed trial quality. Missing data were obtained from the authors or estimated. Results are reported with 95% confidence intervals (CI). Main results This review has been updated in January 2006 and four new trials have been added. 2066 children and 614 adults are now included in 25 trials from emergency room and community settings. In addition, six trials on in-patients with acute asthma (213 children and 28 adults) have been reviewed. Method of delivery of beta 2-agonist did not appear to affect hospital admission rates. In adults, the relative risk of admission for spacer versus nebuliser was 0.97 (95% CI 0.63 to 1.49). The relative risk for children was 0.65 (95% CI: 0.4 to 1.06). In children, length of stay in the emergency department was significantly shorter when the spacer was used, with a mean difference of -0.47 hours (95% CI: -0.58 to -0.37). Length of stay in the emergency department for adults was similar for the two delivery methods. Peak flow and forced expiratory volume were also similar for the two delivery methods. Pulse rate was lower for spacer in children, mean difference -7.6% baseline (95% CI: -9.9 to -5.3% baseline). Authors' conclusions Metered-dose inhalers with spacer produced outcomes that were at least equivalent to nebuliser delivery. Spacers may have some advantages compared to nebulisers for children with acute asthma.	Bushey Hlth Ctr, Watford WD23 2NN, Herts, England	Cates, CJ (reprint author), Bushey Hlth Ctr, London Rd, Watford WD23 2NN, Herts, England.	Chris.cates@nhs.net					BA M, 1989, J ASTHMA, V26, P355; Batra V, 1997, Indian Pediatr, V34, P497; BEASLEY CRW, 1985, NEW ZEAL MED J, V98, P854; Benton G, 1989, ANN DIS CHILDHOOD, V43, P678; BERENBERG MJ, 1985, J ASTHMA, V22, P87, DOI 10.3109/02770908509079893; BLAKE KV, 1992, CHEST, V101, P309, DOI 10.1378/chest.101.2.309; *BTS, 2003, THORAX S, V58; Burrows T, 2004, THORAX, V59, P20; CAMPBELL IA, 1995, THORAX, V50, P79, DOI 10.1136/thx.50.1.79; CHONGNETO JHJ, 2005, J PEDIAT J PEDIAT, V81, P298; CHOU KJ, 1995, ARCH PEDIAT ADOL MED, V149, P201; Coker M, 1995, TURKISH J MED SCI, V23, P293; COLACONE A, 1993, CHEST, V104, P835, DOI 10.1378/chest.104.3.835; Vazquez Cordero C, 1992, AN ESP PEDIATR, V36, P359; Deerojanawong J, 2005, PEDIATR PULM, V39, P466, DOI 10.1002/ppul.20204; Dewar AL, 1999, ARCH DIS CHILD, V80, P421; Duarte M, 2002, ACTA PAEDIATR, V91, P909, DOI 10.1080/080352502760272579; FREELANDER M, 1984, BRIT MED J, V288, P1873; FUGLSANG G, 1986, EUR J RESPIR DIS, V69, P109; FUGLSANG G, 1988, EUROPEAN RESP J, V94, P53; GLEESON JGA, 1988, BRIT J DIS CHEST, V82, P172, DOI 10.1016/0007-0971(88)90039-3; HDODER RV, 1988, CHEST S, V94, P53; HUSSEIN ZM, 2002, EUR RESP SOC ANN C; IDRIS AH, 1993, CHEST, V103, P665, DOI 10.1378/chest.103.3.665; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JAMES RW, 1990, PEDIATR PULM, V8, P263, DOI 10.1002/ppul.1950080410; JASPER AC, 1987, CHEST, V91, P614, DOI 10.1378/chest.91.4.614; KEREM E, 1993, J PEDIATR-US, V123, P313, DOI 10.1016/S0022-3476(05)81710-X; Leversha AM, 2000, J PEDIATR-US, V136, P497, DOI 10.1016/S0022-3476(00)90013-1; LEVITT MA, 1995, ANN EMERG MED, V26, P273, DOI 10.1016/S0196-0644(95)70071-4; LIN YZ, 1995, ARCH DIS CHILD, V72, P214; Lipworth BJ, 1997, THORAX, V52, P1036; MADSEN EM, 1982, EUROPEAN J CLIN PHAR, V23; MAGUIRE GP, 1991, CHEST, V100, P1300, DOI 10.1378/chest.100.5.1300; Maldano-Alanis M, 1997, B MED HOSP INFANT M, V54, P374; Mandelberg A, 2000, CHEST, V117, P1309, DOI 10.1378/chest.117.5.1309; Mandelberg A, 1997, CHEST, V112, P1501, DOI 10.1378/chest.112.6.1501; MORGAN MDL, 1982, BRIT MED J, V285, P849; MORLEY TF, 1988, CHEST, V94, P1205, DOI 10.1378/chest.94.6.1205; Morrone N, 1990, Rev Paul Med, V108, P83; Newman KB, 2002, CHEST, V121, P1036, DOI 10.1378/chest.121.4.1036; NEWMAN SP, 1984, THORAX, V39, P935, DOI 10.1136/thx.39.12.935; PARKIN PC, 1995, ARCH DIS CHILD, V72, P239; PENDERGAST J, 1989, MED J AUSTRALIA, V151, P406; Ploin D, 2001, REV FR ALLERGOL, V41, P155, DOI 10.1016/S0335-7457(01)00011-9; Ploin D, 2000, PEDIATRICS, V106, P311; Powell CVE, 2001, ARCH DIS CHILD, V84, P142, DOI 10.1136/adc.84.2.142; Raimondi AC, 1997, CHEST, V112, P24, DOI 10.1378/chest.112.1.24; Rao NA, 2002, JCPSP-J COLL PHYSICI, V12, P579; Robertson CF, 1998, J PAEDIATR CHILD H, V34, P142, DOI 10.1046/j.1440-1754.1998.00184.x; Robertson J, 2003, NAT REV GENET, V4, P6, DOI 10.1038/nrg984; Rodrigo C, 1998, AM J EMERG MED, V16, P637, DOI 10.1016/S0735-6757(98)90164-4; Rodrigo G, 1996, AM J EMERG MED, V14, P144, DOI 10.1016/S0735-6757(96)90121-7; RODRIGO G, 1993, CURR THER RES CLIN E, V54, P797, DOI 10.1016/S0011-393X(05)80709-X; Rodriguez IS, 1999, NEBULIZER VERSUS INH; ROWE BH, 2001, COCHRANE DATABASE SY, V1; Rubilar L, 2000, PEDIATR PULM, V29, P264, DOI 10.1002/(SICI)1099-0496(200004)29:4<264::AID-PPUL5>3.0.CO;2-S; SALZMAN GA, 1989, CHEST, V95, P1017, DOI 10.1378/chest.95.5.1017; SCHUH S, 1989, PEDIATRICS, V83, P513; Shaikh GP, 2001, IND PRACT, V54, P619; SHIM CS, 1984, J ALLERGY CLIN IMMUN, V73, P387, DOI 10.1016/0091-6749(84)90413-5; SUMMER W, 1989, ARCH INTERN MED, V149, P618, DOI 10.1001/archinte.149.3.618; TARALA RA, 1980, BRIT J CLIN PHARMACO, V10, P393; TURNER JR, 1988, CHEST, V93, P476, DOI 10.1378/chest.93.3.476; Turner MO, 1997, ARCH INTERN MED, V157, P1736, DOI 10.1001/archinte.157.15.1736; Valencia ML, 1999, IATREIA, V12, P130; Vilarinho Liana Consuelo Santana, 2003, J. Pediatr. (Rio J.), V79, P403, DOI 10.1590/S0021-75572003000500007; Vivek P, 2003, THORAX, V58, P44; Wildhaber JH, 1999, J PEDIATR-US, V135, P28, DOI 10.1016/S0022-3476(99)70323-9; Williams JR, 1996, PEDIATR EMERG CARE, V12, P263, DOI 10.1097/00006565-199608000-00007	70	83	83	0	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1469-493X			COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2006		2							CD000052	10.1002/14651858.CD000052.pub2		70	Medicine, General & Internal	General & Internal Medicine	034MC	WOS:000236932100074		
J	Osborn, DA; Sinn, J				Osborn, D. A.; Sinn, J.			Formulas containing hydrolysed protein for prevention of allergy and food intolerance in infants	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review							COWS MILK ALLERGY; HIGH-RISK INFANTS; AMINO-ACID-CONCENTRATIONS; LOW-BIRTH-WEIGHT; AUSTRALIAN ABORIGINAL CHILDREN; DIETARY INTERVENTION PROGRAM; DIFFERENT FEEDING REGIMENS; PARTIAL WHEY HYDROLYSATE; BRIEF NEONATAL EXPOSURE; PROSPECTIVE FOLLOW-UP	Background Allergies and food reactions are common and may be associated with foods including adapted cow's milk formula. Formulas containing hydrolysed proteins have been used to treat infants with allergy or food intolerance. However, it is unclear whether hydrolysed formula can be advocated for prevention of allergy and food intolerance in infants without evidence of allergy or food intolerance. Objectives To determine the effect of feeding hydrolysed formulas on allergy and food intolerance in infants and children compared to adapted cow's milk or human breast milk. If hydrolysed formulas are effective, to determine what type of hydrolysed formula is most effective including extensively and partially hydrolysed formulas. To determine which infants benefit, including infants at low or high risk of allergy and infants receiving early, short term or prolonged formula feeding. Search strategy The standard search strategy of the Cochrane Neonatal Review Group was used. The review was updated with searches of the Cochrane Central Register of Controlled Trials (CENTRAL, The Cochrane Library, Issue 1, 2006), MEDLINE (1966 - March 2006), EMBASE (1980 - March 2006) and CINAHL (1982 - March 2006) and previous reviews including cross references. Selection criteria Randomised and quasi-randomised trials that compare the use of a hydrolysed infant formula to human milk or cow's milk formula. Trials with > 80% follow up of participants were eligible for inclusion. Data collection and analysis Eligibility of studies for inclusion, methodological quality and data extraction were assessed independently by each review author. Primary outcomes included clinical allergy, specific allergies and food intolerance. Meta-analysis was conducted using a fixed effects model. Main results Two trials compared early, short termhydrolysed formula to human milk feeding. No significant difference in infant allergy or childhood cow's milk allergy (CMA) were reported. No eligible trial compared prolonged hydrolysed formula to human milk feeding. Two trials compared early, short term hydrolysed formula to cow's milk formula feeding. No significant benefits were reported. One large quasi-random study reported a reduction in infant CMA of borderline significance in low risk infants (RR 0.62, 95% CI 0.38, 1.00). Ten eligible studies compared prolonged feeding with hydrolysed formula versus cow's milk formula in high risk infants. Meta-analysis found a significant reduction in infant allergy (seven studies, 2514 infants; typical RR 0.79, 95% CI 0.66, 0.94), but not in the incidence of childhood allergy (two studies, 950 infants; typical RR 0.85, 95% CI 0.69, 1.05). There was no significant difference in infant eczema (eight studies, 2558 infants, typical RR 0.84, 95% CI 0.68, 1.04), childhood eczema incidence (two studies, 950 infants, typical RR 0.83, 95% CI 0.63, 1.10), childhood eczema prevalence (one study, 872 infants; RR 0.66, 95% CI 0.43, 1.02), or infant or childhood asthma, rhinitis and food allergy. One study reported a significant reduction in infants with CMA with confirmed atopy (RR 0.36, 95% CI 0.15, 0.89). Subgroup analysis of trials blinded to formula found no significant difference in infant allergy (four studies, 2156 infants; typical RR 0.87, 95% CI 0.69, 1.08) or childhood allergy incidence (one study, 872 infants; RR 0.91, 95% CI 0.73, 1.14). No eligible trial examined the effect of prolonged hydrolysed formula feeding on allergy beyond early childhood. There is evidence that preterm or low birthweight infants fed a hydrolysed preterm formula have significantly reduced weight gain, but not in other growth parameters (head circumference or length). Studies in term infants report no adverse effects on growth. Subgroup analysis of trials of partially hydrolysed versus cow's milk formula found a significant reduction in infant allergy (six studies, 1391 infants; typical RR 0.79, 95% CI 0.65, 0.97) but not childhood allergy, or infant or childhood asthma, eczema or rhinitis. Methodological concerns were the same as for the overall analysis. Analysis of trials of extensively hydrolysed formula versus cow's milk formula found no significant differences in allergy or food intolerance. Infants fed extensively hydrolysed formula compared with partially hydrolysed formula had a significant reduction in food allergy (two studies, 341 infants; typical RR 0.43, 95% CI 0.19, 0.99), but there was no significant difference in all allergy or any other specific allergy incidence. Comparing extensively hydrolysed casein containing formula with cow's milk formula, one study (431 infants) reported a significant reduction in childhood allergy incidence (RR 0.72, 95% CI 0.53, 0.97). Meta- analysis found a significant reduction in infant eczema (three studies, 1237 infants; typical RR 0.71, 95% CI 0.51, 0.97). One study reported a significant reduction in childhood eczema incidence (RR 0.66, 95% CI 0.44, 0.98) and prevalence (RR 0.50, 95% CI 0.27, 0.92). Authors' conclusions There is no evidence to support feeding with a hydrolysed formula for the prevention of allergy compared to exclusive breast feeding. In high risk infants who are unable to be completely breast fed, there is limited evidence that prolonged feeding with a hydrolysed formula compared to a cow's milk formula reduces infant and childhood allergy and infant CMA. In view of methodological concerns and inconsistency of findings, further large, well designed trials comparing formulas containing partially hydrolysed whey, or extensively hydrolysed casein to cow's milk formulas are needed.	Westmead Hosp, Neonatal Unit, Westmead, NSW 2145, Australia	Sinn, J (reprint author), Westmead Hosp, Neonatal Unit, Hawkesbury Rd, Westmead, NSW 2145, Australia.	johnsinn@westgate.wh.usyd.edu.au					Agosti M., 2003, Acta Paediatrica, V91, P34; Akimoto K, 1997, Arerugi, V46, P1044; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; ATHERTON DJ, 1978, LANCET, V1, P401; Austin JB, 1999, ARCH DIS CHILD, V81, P225; Baker SS, 2000, PEDIATRICS, V106, P346; Barbee RA, 1998, J ALLERGY CLIN IMMUN, V102, pS65, DOI 10.1016/S0091-6749(98)70006-5; BARBERI I, 1993, 2 WORLD C PER MED; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Bellioni-Businco B, 1999, J ALLERGY CLIN IMMUN, V103, P1191, DOI 10.1016/S0091-6749(99)70198-3; Bergmann R, 1998, Eur Respir J Suppl, V27, p9s; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Bergmann RL, 1996, MONATSSCHR KINDERH, V144, P152; BRAND JC, 1977, MED J AUSTRALIA, V2, P10; Bruno G, 1996, Minerva Pediatr, V48, P413; BURKS AW, 1988, J ALLERGY CLIN IMMUN, V81, P1135, DOI 10.1016/0091-6749(88)90881-0; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; BURR ML, 1993, ARCH DIS CHILD, V68, P724; BUSINCO L, 1987, ANN ALLERGY, V59, P183; BUSINCO L, 1983, ANN ALLERGY, V51, P296; Campbell J P, 1993, Cesk Pediatr, V48, P199; CAMPBELL JPM, 1989, J ROY COLL GEN PRACT, V39, P11; Carroccio A, 2000, ALLERGY, V55, P574, DOI 10.1034/j.1398-9995.2000.00417.x; CARROCCIO A, 2000, CLIN EXPT ALLERGY, V31, P1597; Carroll PR, 2003, EUR UROL SUPPL, V2, P7, DOI 10.1016/j.eursup.2003.10.002; Chan YH, 2002, J PAEDIATR CHILD H, V38, P84, DOI 10.1046/j.1440-1754.2002.00725.x; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; CHANDRA RK, 1989, BMJ-BRIT MED J, V299, P228; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; CHANDRA RK, 1986, CLIN ALLERGY, V16, P563, DOI 10.1111/j.1365-2222.1986.tb01995.x; Chirico G, 1997, ALLERGY, V52, P82, DOI 10.1111/j.1398-9995.1997.tb02549.x; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; D'Agata A, 1996, Pediatr Med Chir, V18, P469; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; David TJ, 2000, BRIT MED BULL, V56, P34, DOI 10.1258/0007142001902950; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; de Seta L, 1994, Pediatr Med Chir, V16, P251; Decsi T, 1998, J PEDIATR GASTR NUTR, V27, P12, DOI 10.1097/00005176-199807000-00003; DONNELLY A, 2003, COCHRANE DATABASE SY, V1; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Exl BM, 1998, NUTR RES, V18, P1443, DOI 10.1016/S0271-5317(98)00121-3; Exl BM, 2000, EUR J NUTR, V39, P145, DOI 10.1007/s003940070018; Exl BM, 2000, EUR J NUTR, V39, P89, DOI 10.1007/s003940070024; Fukushima Y, 1997, J NUTR SCI VITAMINOL, V43, P397; Giampietro PG, 2001, PEDIATR ALLERGY IMMU, V12, P83, DOI 10.1034/j.1399-3038.2001.012002083.x; GIOVANNINI M, 1994, J AM COLL NUTR, V13, P357; GOTZSCHE PC, 2001, COCHRANE DATABASE SY, V3; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; GRUSKAY FL, 1982, CLIN PEDIATR, V21, P486, DOI 10.1177/000992288202100807; GUSTAFSSON D, 1992, ARCH DIS CHILD, V67, P1008; Habbick BF, 1999, CAN MED ASSOC J, V160, P1824; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Halken S, 1994, Ugeskr Laeger, V156, P308; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; HARTMAN CT, 1994, J ALLERGY CLIN IMMUN, P210; Hattevig G, 1999, ACTA PAEDIATR, V88, P7; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; HATTEVIG G, 1990, J ALLERGY CLIN IMMUN, V85, P108, DOI 10.1016/0091-6749(90)90231-R; Hauser B, 1997, JPEN-PARENTER ENTER, V21, P27, DOI 10.1177/014860719702100127; HAUSER B, 1993, CLIN PEDIATR, V32, P433, DOI 10.1177/000992289303200708; Hernell O, 2003, AM J CLIN NUTR, V78, P296; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; HILL D, 2000, REPORT ANAL MELBOURN; Hill DJ, 2000, J PEDIATR-US, V137, P475, DOI 10.1067/mpd.2000.108207; Hill DJ, 1999, J PEDIATR-US, V135, P118, DOI 10.1016/S0022-3476(99)70341-0; HILL DJ, 1995, J ALLERGY CLIN IMMUN, V96, P386, DOI 10.1016/S0091-6749(95)70058-7; Hill DJ, 1995, J ALLERGY CLIN IMMUN, V96, P886, DOI 10.1016/S0091-6749(95)70224-5; Hill DJ, 2000, J PEDIATR-US, V136, P641, DOI 10.1067/mpd.2000.104774; HOST A, 1995, EUR J CLIN NUTR, V49, pS13; Host A, 1994, Pediatr Allergy Immunol, V5, P1; HOST A, 1988, ALLERGY, V43, P113, DOI 10.1111/j.1398-9995.1988.tb00404.x; HOST A, 1991, ALLERGY PROC, V12, P227, DOI 10.2500/108854191778879287; Huovinen E, 1999, CHEST, V115, P928, DOI 10.1378/chest.115.4.928; Iacono G, 1998, NEW ENGL J MED, V339, P1100, DOI 10.1056/NEJM199810153391602; IIKURA Y, 1995, NESTLE NUTR WORKS SE, V34, P269; ISOLAURI E, 1995, J PEDIATR-US, V127, P550, DOI 10.1016/S0022-3476(95)70111-7; JUVONEN P, 1994, J PEDIATR GASTR NUTR, V18, P344, DOI 10.1097/00005176-199404000-00016; Juvonen P, 1999, PEDIATR ALLERGY IMMU, V10, P191, DOI 10.1034/j.1399-3038.1999.00030.x; Juvonen P, 1996, ACTA PAEDIATR, V85, P1047, DOI 10.1111/j.1651-2227.1996.tb14215.x; Keller KM, 1996, EUR J PEDIATR, V155, P331; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Klemola T, 2002, J PEDIATR-US, V140, P219, DOI 10.1067/mpd.2002.121935; KRAMER MS, 2001, COCHRANE DATABASE SY, V3; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; LAM BCC, 1992, EFFECT BREAST MILK I; Laubereau B, 2004, ARCH DIS CHILD, V89, P993, DOI 10.1136/adc.2003.043265; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; LILJA G, 1991, CLIN EXP ALLERGY, V21, P195, DOI 10.1111/j.1365-2222.1991.tb00830.x; LILJA G, 1989, CLIN EXP ALLERGY, V19, P473, DOI 10.1111/j.1365-2222.1989.tb02416.x; LINDFORS A, 1988, ALLERGY, V43, P11, DOI 10.1111/j.1398-9995.1988.tb02038.x; LOTHE L, 1982, PEDIATRICS, V70, P7; LUCAS A, 1984, ARCH DIS CHILD, V59, P722; LUCAS A, 1984, BRIT MED J, V289, P1254; LUCAS A, 1990, ARCH DIS CHILD, V65, P411; LUCAS A, 1990, BRIT MED J, V300, P837; Lucassen PLBJ, 2000, PEDIATRICS, V106, P1349, DOI 10.1542/peds.106.6.1349; Maggio L, 2005, ACTA PAEDIATR, V94, P75, DOI 10.1080/08035250410023188; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; Manfreda J, 2001, CAN MED ASSOC J, V164, P995; Marini A, 1996, Acta Paediatr Suppl, V414, P1; MARTINENEZVALVE.A, 1993, THESIS U MALAGA SPAI; MCLEISH CM, 1995, ARCH DIS CHILD, V73, P211; MEDJADGUILLOU N, 1992, ANN PEDIATR-PARIS, V39, P202; MERRETT TG, 1988, ANN ALLERGY, V61, P13; Mihatsch WA, 2002, PEDIATRICS, V110, P1199, DOI 10.1542/peds.110.6.1199; Mihatsch WA, 2001, ACTA PAEDIATR, V90, P196, DOI 10.1080/080352501300049442; Mihatsch WA, 1999, J PEDIATR GASTR NUTR, V29, P406, DOI 10.1097/00005176-199910000-00007; MISKELLY FG, 1988, ARCH DIS CHILD, V63, P388; MITCHELL JD, 1977, LANCET, V1, P500; MORAN JR, 1992, J PEDIATR-US, V121, pS90, DOI 10.1016/S0022-3476(05)81414-3; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; Nentwich I, 2003, KLIN PADIATR, V215, P275; Nentwich I, 2001, ALLERGY, V56, P1144, DOI 10.1111/j.1398-9995.2001x.00926.x; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1417, DOI 10.1046/j.1365-2222.2000.00913.x; Niggemann B, 2001, PEDIATR ALLERGY IMMU, V12, P78, DOI 10.1034/j.1399-3038.2001.012002078.x; Oddy WH, 1999, BRIT MED J, V319, P815; Odelram H, 1996, ALLERGY, V51, P192, DOI 10.1111/j.1398-9995.1996.tb04587.x; Ogawa A, 2000, J Nutr Sci Vitaminol (Tokyo), V46, P271; OGGERO R, 1994, ACTA PAEDIATR, V83, P222, DOI 10.1111/j.1651-2227.1994.tb13055.x; Oldaeus G, 1999, ALLERGY, V54, P352, DOI 10.1034/j.1398-9995.1999.00661.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; OSBORN DA, 2003, COCHRANE DATABASE SY, V4; PALMA M, 1996, REV INVESTIGACION CO, V48, pS25; Paronen J, 1996, PEDIATR RES, V40, P276, DOI 10.1203/00006450-199608000-00014; Paronen J, 2000, DIABETES, V49, P1657, DOI 10.2337/diabetes.49.10.1657; Paronen J, 2000, J ALLERGY CLIN IMMUN, V106, P302, DOI 10.1067/mai.2000.108110; PAULS J, 1996, J PEDIAT GASTROENTER, V22, P450, DOI 10.1097/00005176-199605000-00177; Peat JK, 2001, THORAX, V56, P406, DOI 10.1136/thorax.56.5.406; Peat JK, 2000, J ALLERGY CLIN IMMUN, V106, pS144, DOI 10.1067/mai.2000.109420; Picaud JC, 2001, J PEDIATR GASTR NUTR, V32, P555, DOI 10.1097/00005176-200105000-00012; Polberger S, 1999, J PEDIATR GASTR NUTR, V29, P332, DOI 10.1097/00005176-199909000-00017; RAUPP P, 1995, MONATSSCHR KINDERH, V143, pS140; Ravault C, 1986, J TUBERCULOSIS LUNG, V5, P191; REY S, 1996, THESIS MADRID SPAIN; Riezzo G, 2001, J PEDIATR GASTR NUTR, V33, P290, DOI 10.1097/00005176-200109000-00012; Rigo J, 1994, Acta Paediatr Suppl, V405, P98; RIGO J, 1995, EUR J CLIN NUTR, V49, pS26; Rigo J, 1994, Acta Paediatr Suppl, V402, P100; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; Saarinen KM, 2000, CLIN EXP ALLERGY, V30, P400, DOI 10.1046/j.1365-2222.2000.00732.x; Saarinen KM, 2000, ADV EXP MED BIOL, V478, P121; Saarinen KM, 2001, CLIN EXP ALLERGY, V31, P423, DOI 10.1046/j.1365-2222.2001.01015.x; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SACK RB, 1994, ACTA PAEDIATR, V83, P819, DOI 10.1111/j.1651-2227.1994.tb13152.x; SAMPSON HA, 1991, J PEDIATR-US, V118, P520; Savino F., 2003, Acta Paediatrica, V91, P86; Schmelzle H, 2003, J PEDIATR GASTR NUTR, V36, P343, DOI 10.1097/00005176-200303000-00008; SCHMIDT E, 1995, NESTLE NUTR WORKS SE, V34, P231; SCHMITZ J, 1992, J PEDIATR-US, V121, pS85, DOI 10.1016/S0022-3476(05)81413-1; Schoetzau A, 2002, ARCH DIS CHILD, V86, P180, DOI 10.1136/adc.86.3.180; Schoetzau A, 2002, PEDIATR ALLERGY IMMU, V13, P234, DOI 10.1034/j.1399-3038.2002.01050.x; SCHRANDER JJP, 1993, EUR J PEDIATR, V152, P640, DOI 10.1007/BF01955238; Sears MR, 1996, ARCH DIS CHILD, V75, P392; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sears MR, 1998, CLIN EXP ALLERGY, V28, P82; Seppo L, 2005, AM J CLIN NUTR, V82, P140; Sicherer SH, 2001, J PEDIATR-US, V138, P688, DOI 10.1067/mpd.2001.113007; SIGURS N, 1992, PEDIATRICS, V89, P735; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; Strachan DP, 1996, BRIT MED J, V312, P1195; Szajewska H, 2004, ACTA PAEDIATR, V93, P1159, DOI 10.1080/08035250410026554; Szajewska H, 2001, J PEDIATR GASTR NUTR, V32, P303, DOI 10.1097/00005176-200103000-00013; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; TAUBMAN B, 1988, PEDIATRICS, V81, P756; Terheggen-Lagro Suzanne W J, 2002, BMC Pediatr, V2, P10, DOI 10.1186/1471-2431-2-10; Tikkanen S, 2000, ACTA PAEDIATR, V89, P1174, DOI 10.1080/080352500750027529; TSAI Y-T, 1991, Acta Paediatrica Sinica, V32, P137; UNICEF, 2001, STAT WORLDS CHILDR; Vaarala O, 1995, J ALLERGY CLIN IMMUN, V96, P917, DOI 10.1016/S0091-6749(95)70229-6; VANDENPLAS Y, 1993, J PEDIATR GASTR NUTR, V17, P92, DOI 10.1097/00005176-199307000-00014; VANDENPLAS Y, 1992, LANCET, V339, P1118, DOI 10.1016/0140-6736(92)90716-G; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; VANDENPLAS Y, 1988, EUR J PEDIATR, V148, P274, DOI 10.1007/BF00441420; Vandenplas Y, 1989, IMMUNOL ALLERGY PRAC, VXI, P430; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; WILLEMS R, 1993, ANN ALLERGY, V71, P147; Williams HC, 1998, BRIT J DERMATOL, V139, P834; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; Zeiger RS, 1999, J PEDIATR-US, V134, P614, DOI 10.1016/S0022-3476(99)70249-0; ZEIGER RS, 1993, J ALLERGY CLIN IMMUN, V91, P723, DOI 10.1016/0091-6749(93)90191-H; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zeiger R, 1992, PEDIATR ALLERGY IMMU, V3, P110, DOI 10.1111/j.1399-3038.1992.tb00035.x	197	83	86	5	32	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	1469-493X			COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2006		4							CD003664	10.1002/14651858.CD003664.pub3		127	Medicine, General & Internal	General & Internal Medicine	096OF	WOS:000241386000148		
J	Nelson, DI; Concha-Barrientos, M; Driscoll, T; Steenland, K; Fingerhut, M; Punnett, L; Pruss-Ustun, A; Leigh, J; Corvalan, C				Nelson, DI; Concha-Barrientos, M; Driscoll, T; Steenland, K; Fingerhut, M; Punnett, L; Pruss-Ustun, A; Leigh, J; Corvalan, C			The global burden of selected occupational diseases and injury risks: Methodology and summary	AMERICAN JOURNAL OF INDUSTRIAL MEDICINE			English	Article						burden of disease; occupational health; DALYs; comparative risk assessment; health impact assessment	OBSTRUCTIVE PULMONARY-DISEASE; DUST EXPOSURE; UNITED-STATES; ASTHMA; DISABILITY; POPULATION; MORTALITY; HEALTH; CARCINOGENS; PREVALENCE	Background A round the globe, work has a heavy impact on health. To better advise policy makers, we assessed the global burden of disease and injury due to selected occupational hazards. This article presents an overview, and describes the methodology employed in the companion studies. Methods Using the World Health Organization (WHO) Comparative Risk Assessment methodology, we applied relative risk measures to the proportions of the population exposed to selected occupational hazards to estimate attributable fractions, deaths, and disability-adjusted life years (DALYs). Numerous occupational risk factors had to be excluded due to inadequate global data. Results In 2000, the selected risk factors were responsible worldwide for 37% of back pain, 16% of hearing loss, 13% of chronic obstructive. pulmonary disease (COPD), 11% of asthma, 8% of injuries, 9% of lung cancer, and 2% of leukemia. These risks at work caused 850, 000 deaths worldwide and resulted in the loss of about 24 million years of healthy life. Needlesticks accounted for about 40% of Hepatitis B and Hepatitis C infections and 4.4% of HIV infections in health care workers. Conclusions Exposure to occupational hazards accounts for a significant proportion of the global burden of disease and injury, which could be substantially reduced through application of proven risk prevention strategies. Am. J. Ind. Med. 48:400-418, 2005. (c) 2005 Wiley-Liss, Inc.	Geol Soc Amer, Boulder, CO 80301 USA; WHO, CH-1211 Geneva, Switzerland; Asociac Chilena Seguridad, Santiago, Chile; ELMATOM Pty Ltd, Sydney, NSW, Australia; Emory Univ, Atlanta, GA 30322 USA; NIOSH, Washington, DC USA; Univ Massachusetts, Lowell, MA USA; Univ Sydney, Sch Publ Hlth, Ctr Environm & Occupat Hlth, Sydney, NSW 2006, Australia	Nelson, DI (reprint author), Geol Soc Amer, PO 9140, Boulder, CO 80301 USA.	dnelson@geosociety.org					BADLEY EM, 1994, J RHEUMATOL, V21, P505; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BECKLAKE MR, 1989, AM REV RESPIR DIS, V140, pS85; BEIR V, 1990, HLTH EFF EXP LOW LEV; BUTLER S, 1979, SOCIOL ABSTR, V27; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; Concha-Barrientos M, 2005, AM J IND MED, V48, P470, DOI 10.1002/ajim.20226; DAVIS AC, 1989, INT J EPIDEMIOL, V18, P911, DOI 10.1093/ije/18.4.911; Desai MA, 2004, WHO ENV BURDEN DIS S, V4; Dosemeci M, 1995, SCAND J WORK ENV HEA, V21, P39; Driscoll T, 2005, AM J IND MED, V48, P419, DOI 10.1002/ajim.20209; Driscoll T, 2005, AM J IND MED, V48, P432, DOI 10.1002/ajim.20210; Driscoll T, 2005, AM J IND MED, V48, P491, DOI 10.1002/aijm.20194; *EIU, 1995, BUS OP REP IND 4 Q; *EIU, 1996, CHIN HAND, pCH13; *EIU, 2001, COUNTR FOR AFR; Ezzati M, 2004, COMP QUANTIFICATION; *FINN I OCC HLTH, 1999, CAR DAT; Hendrick DJ, 1996, THORAX, V51, P947, DOI 10.1136/thx.51.9.947; Hewett P, 1996, OCCUP MED, V11, P561; IARC, 1994, SOM IND CHEM; *INT LAB ORG, 1995, ILO YB LAB STAT 1995; *INT LAB ORG, 2001, LAB LAB STAT DAT; International Labour Organisation, 2002, INT LAB C; *INT LAB ORG, 1995, SECT ACT PROGR REC D; *INT LAB ORG, 2001, ILO YB LAB STAT; *INT LAB ORG, 2002, EC ACT POP 1950 2010; JOHNSON AG, 1977, IND LABOR RELATIONS, V11, P18; JUENGPRASERT W, 1997, ASIAN PACIFIC REGION, V4; Karjalainen A, 2002, SCAND J WORK ENV HEA, V28, P49; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Kauppinen T, 2000, OCCUP ENVIRON MED, V57, P10, DOI 10.1136/oem.57.1.10; KOCH JL, 1981, J VOCAT BEHAV, V18, P145, DOI 10.1016/0001-8791(81)90003-8; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298; Leigh J, 1999, EPIDEMIOLOGY, V10, P626, DOI 10.1097/00001648-199909000-00032; Leigh JP, 2003, SCAND J WORK ENV HEA, V29, P304; Leigh JP, 1997, ARCH INTERN MED, V157, P1557, DOI 10.1001/archinte.157.14.1557; LEIGH JP, 1989, BRIT J IND MED, V46, P651; Loewenson R, 1999, EPIDEMIOLOGY, V10, P632, DOI 10.1097/00001648-199909000-00033; Lucifora C, 1998, INT J IND ORGAN, V16, P353, DOI 10.1016/S0167-7187(96)01055-7; Lynge E, 1997, CANCER CAUSE CONTROL, V8, P406, DOI 10.1023/A:1018461406120; Mathers C, 2002, 50 WHO; MOFFETT M, 2002, NEW MEXICO LABOR MAR; Murray CJL, 1997, J HEALTH ECON, V16, P703, DOI 10.1016/S0167-6296(97)00004-0; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray C., 1996, GLOBAL BURDEN DIS CO, P1; MYERS JE, 1989, SCAND J WORK ENV HEA, V15, P180; *NAT I ENV HLTH SC, 1999, ENV HLTH PERSPECTIVE, V107; *NAT I OCC SAF HLT, 1995, SUMM CRIT REC STAND; *NAT I OCC SAF HLT, 1999, WORK REL LUNG DIS SU; National Institute for Occupational Safety and Health, 1998, CRIT REC STAND OCC N; National Institute of Occupational Safety and Health, 2000, INJ ILLN HAZ EXP MIN; Nelson DI, 2005, AM J IND MED, V48, P446, DOI 10.1002/aijm.20223; Nurminen M, 2001, SCAND J WORK ENV HEA, V27, P161; OLEINICK A, 1993, AM J IND MED, V23, P231, DOI 10.1002/ajim.4700230202; Partanen T, 1995, SCAND J WORK ENV HEA, V21, P84; Pearce N, 1994, IARC SCI PUBLICATION, V129; Pope MH, 1991, OCCUPATIONAL LOW BAC; Prince MM, 1997, J ACOUST SOC AM, V101, P950, DOI 10.1121/1.418053; Pruss-Ustun A, 2003, ENV BURDEN DIS SERIE, V1; Punnett L, 2005, AM J IND MED, V48, P459, DOI 10.1002/ajim.20232; QUINLAN M, 2002, GLOBAL OCCUPATIONAL; REES D, 1992, BRIT J IND MED, V49, P459; Riihimaki Hilkka, 1995, P207; ROACH S, 1992, HLTH RISKS HAZARDOUS; SON PH, 1999, USE GEOGRAPHICAL INF; Steenland K, 1996, AM J IND MED, V29, P474, DOI 10.1002/(SICI)1097-0274(199605)29:5<474::AID-AJIM6>3.0.CO;2-M; Steenland K, 2003, AM J IND MED, V43, P461, DOI 10.1002/ajim.10216; Takala J, 1999, EPIDEMIOLOGY, V10, P640, DOI 10.1097/00001648-199909000-00034; THI N, 2001, COMMUNICATION   0831; UN (United Nations), 2000, INT STAND IND CLASS; *USDHHS, 2001, NATL VITAL STAT SYST, V49; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; World Health Organization, 2004, GLOB BURD DIS EST; World Health Organization, 2002, WORLD HLTH REP RED R; World Bank, 2001, WORLD DEV IND 2001; YIN SN, 1987, BRIT J IND MED, V44, P192; ZOU CQ, 1997, MINERAL DUSTS PREVEN, V4	80	83	90	1	11	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0271-3586			AM J IND MED	Am. J. Ind. Med.	DEC	2005	48	6					400	418		10.1002/ajim.20211		19	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	991KA	WOS:000233811700002	16299700	
J	Bailey, M; Haverson, K; Inman, C; Harris, C; Jones, P; Corfield, G; Miller, B; Stokes, C				Bailey, M; Haverson, K; Inman, C; Harris, C; Jones, P; Corfield, G; Miller, B; Stokes, C			The development of the mucosal immune system pre- and post-weaning: balancing regulatory and effector function	PROCEEDINGS OF THE NUTRITION SOCIETY			English	Article						oral tolerance; immune development; weaning; pig; allergy	GROWTH-FACTOR-BETA; INFLAMMATORY-BOWEL-DISEASE; RESIDENT INTESTINAL FLORA; ORAL TOLERANCE; T-CELL; LAMINA PROPRIA; PEYERS-PATCHES; SPLEEN-CELLS; BREAST-MILK; B-CELL	The mucosal immune system fulfils the primary function of defence against potential pathogens that may enter across vulnerable surface epithelia. However, a secondary function of the intestinal immune system is to discriminate between pathogen-associated and 'harmless' antigens, expressing active responses against the former and tolerance to the latter. Control of immune responses appears to be an active process, involving local generation of IgA and of regulatory and/or regulated T lymphocytes. Two important periods of maximum exposure to novel antigens occur in the young animal, immediately after birth and at weaning. In both cases the antigenic composition of the intestinal contents can shift suddenly, as a result of a novel diet and of colonisation by novel strains and species of bacteria. Changes in lifestyles of man, and husbandry of animals, have resulted in weaning becoming much more abrupt than previously in evolution, increasing the number of antigens that must be simultaneously evaluated by neonates. Thus, birth and weaning are likely to represent hazard and critical control points in the development of appropriate responses to pathogens and harmless dietary and commensal antigens. Neonates are born with relatively undeveloped mucosal immune systems. At birth this factor may prevent both expression of active immune responses and development of tolerance. However, colonisation by intestinal flora expands the mucosal immune system in antigen-specific and non-specific ways. At weaning antibody to fed proteins can be detected, indicating active immune responses to fed proteins. It is proposed that under normal conditions the ability of the mucosal immune system to mount active responses to foreign antigens develops simultaneously with the ability to control and regulate such responses. Problems arise when one or other arm of the immune system develops inappropriately, resulting in inappropriate effector responses to harmless food proteins (allergy) or inadequate responses to pathogens (disease susceptibility).	Univ Bristol, Sch Clin Vet Sci, Bristol BS4 5SU, Avon, England	Bailey, M (reprint author), Univ Bristol, Sch Clin Vet Sci, Langford House, Bristol BS4 5SU, Avon, England.	mick.bailey@bristol.ac.uk	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Inman, Charlotte/0000-0002-0801-4779			Adkins B, 2004, EUR J IMMUNOL, V34, P1901, DOI 10.1002/eji.200324271; Bailey M, 2004, CLIN DIAGN LAB IMMUN, V11, P337, DOI 10.1128/CDLI.11.2.337-343.2004; BAILEY M, 1993, INT ARCH ALLERGY IMM, V101, P266; BAILEY M., 2001, P NUTR SOC, V60, P1; BAILEY M, 2005, IN PRESS VET IMMUNOL; Beutler B, 2002, CURR TOP MICROBIOL, V270, P1; BIANCHI ATJ, 1992, VET IMMUNOL IMMUNOP, V33, P201, DOI 10.1016/0165-2427(92)90182-P; Borsutzky S, 2004, J IMMUNOL, V173, P3305; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; BROWN TA, 1984, J IMMUNOL, V132, P780; Bu P, 2001, J IMMUNOL, V166, P6399; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Butler JE, 2000, IMMUNOLOGY, V100, P119, DOI 10.1046/j.1365-2567.2000.00013.x; CHALLACOMBE SJ, 1980, J EXP MED, V152, P1459, DOI 10.1084/jem.152.6.1459; Chun SK, 2004, J MICROBIOL BIOTECHN, V14, P1267; Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448; Duchmann R, 1996, EUR J IMMUNOL, V26, P934, DOI 10.1002/eji.1830260432; Flajnik Martin F., 2004, Trends in Immunology, V25, P640, DOI 10.1016/j.it.2004.10.001; Fujihashi K, 2001, P NATL ACAD SCI USA, V98, P3310, DOI 10.1073/pnas.061412598; Helm RM, 2000, CURR OPIN IMMUNOL, V12, P647, DOI 10.1016/S0952-7915(00)00157-6; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Johansen FE, 2001, J IMMUNOL, V167, P5185; Kalliomaki M, 1999, J ALLERGY CLIN IMMUN, V104, P1251, DOI 10.1016/S0091-6749(99)70021-7; Kunkel EJ, 2002, IMMUNITY, V16, P1, DOI 10.1016/S1074-7613(01)00261-8; Levine AD, 2001, SEMIN IMMUNOL, V13, P195, DOI 10.1006/smim.2001.0309; Litman GF, 1999, ANNU REV IMMUNOL, V17, P109, DOI 10.1146/annurev.immunol.17.1.109; Luo CH, 2000, IMMUNOGENETICS, V51, P92, DOI 10.1007/s002510050017; MacPherson AJ, 2004, ANN NY ACAD SCI, V1029, P36, DOI 10.1196/annals.1309.005; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Manzano M, 2002, J NUTR, V132, P2757; MCDERMOTT MR, 1979, J IMMUNOL, V122, P1892; MILLER BG, 1994, BRIT J NUTR, V71, P615, DOI 10.1079/BJN19940167; Mowat AM, 2004, ANN NY ACAD SCI, V1029, P1, DOI 10.1196/annals.1309.001; Ogawa J, 2004, EARLY HUM DEV, V77, P67, DOI 10.1016/j.earlhumdev.2004.01.005; Oz HS, 2004, J AM COLL NUTR, V23, P220; PENG HJ, 1989, PEDIATR RES, V26, P486, DOI 10.1203/00006450-198911000-00025; Peng YF, 2004, P NATL ACAD SCI USA, V101, P4572, DOI 10.1073/pnas.0400810101; PHILLIPSQUAGLIA.JM, 2002, FOOD ALLERGY INTOLER, pCH4; Prioult G, 2003, CLIN DIAGN LAB IMMUN, V10, P787, DOI 10.1128/CDLI.10.5.787-792.2003; ROTHKOTTER HJ, 1991, PEDIATR RES, V29, P237, DOI 10.1203/00006450-199103000-00004; Sait L, 2003, APPL ENVIRON MICROB, V69, P2100, DOI 10.1128/AEM.69.4.2100-2109.2003; Samsom JN, 2004, CRIT REV IMMUNOL, V24, P157, DOI 10.1615/CritRevImmunol.v24.i3.10; Schroder HC, 2003, J BIOL CHEM, V278, P32810, DOI 10.1074/jbc.M304116200; Spahn TW, 2001, EUR J IMMUNOL, V31, P1278, DOI 10.1002/1521-4141(200104)31:4<1278::AID-IMMU1278>3.0.CO;2-A; Stagg AJ, 2002, EUR J IMMUNOL, V32, P1445, DOI 10.1002/1521-4141(200205)32:5<1445::AID-IMMU1445>3.0.CO;2-E; STOKES CR, 1983, CLIN EXP IMMUNOL, V52, P678; STOKES CR, 1983, CLIN EXP IMMUNOL, V52, P399; Talham GL, 1999, INFECT IMMUN, V67, P1992; Teillet F, 2005, J IMMUNOL, V174, P2870; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VEGALOPEZ MA, 1993, VET IMMUNOL IMMUNOP, V37, P49, DOI 10.1016/0165-2427(93)90015-V; VEGALOPEZ MA, 1995, VET IMMUNOL IMMUNOP, V44, P319, DOI 10.1016/0165-2427(94)05309-G; Wilson AD, 1996, IMMUNOLOGY, V88, P98, DOI 10.1046/j.1365-2567.1996.d01-640.x; Xu RJ, 1999, BIOL NEONATE, V75, P59, DOI 10.1159/000014078; Zapata A. G., 1990, IMMUNE SYSTEM COMP H	55	83	84	3	17	CABI PUBLISHING	WALLINGFORD	C/O PUBLISHING DIVISION, NOSWORTHY WAY, WALLINGFORD OX10 8DE, OXON, ENGLAND	0029-6651			P NUTR SOC	Proc. Nutr. Soc.	NOV	2005	64	4					451	457		10.1079/PNS2005452		7	Nutrition & Dietetics	Nutrition & Dietetics	987YM	WOS:000233553700005	16313686	
J	von Leupoldt, A; Dahme, B				von Leupoldt, A; Dahme, B			Cortical substrates for the perception of dyspnea	CHEST			English	Review						asthma; brain; breathlessness; COPD; dyspnea; emission-CT; MRI; pain; perception	POSITRON-EMISSION-TOMOGRAPHY; CEREBRAL BLOOD-FLOW; INSULAR CORTEX; AIR HUNGER; RESPIRATORY SENSATIONS; LUNG-VOLUME; CHEMORECEPTOR AFFERENTS; VOLITIONAL INSPIRATION; SOMATOSENSORY CORTEX; SYMPTOM PERCEPTION	Dyspnea is a common, unpleasant, and impairing symptom in various respiratory diseases and other diseases. Despite growing understanding of the multiple peripheral mechanisms giving rise to dyspnea, little is known about the cortical mechanisms underlying its perception. The results of neuroiniaging studies have shown that distinct brain areas process the dyspneic sensation, among which the anterior insular seems to be the most important. Based on the findings of the first relevant neuroimaging studies, this review describes the cortical structures associated with the perception of dyspnea. Moreover, similarities to the perception of pain are discussed, and implications for future research are provided.	Univ Hamburg, Psychol Inst 3, D-20146 Hamburg, Germany	von Leupoldt, A (reprint author), Univ Hamburg, Psychol Inst 3, Von Melle Pk 5, D-20146 Hamburg, Germany.	andreas.vonleupoldt@uni-hamburg.de	Frank, David/E-8213-2012				Augustine JR, 1996, BRAIN RES REV, V22, P229, DOI 10.1016/S0165-0173(96)00011-2; BANZETT RB, 1990, RESP PHYSIOL, V81, P1, DOI 10.1016/0034-5687(90)90065-7; Banzett RB, 2000, NEUROREPORT, V11, P2117, DOI 10.1097/00001756-200007140-00012; Banzett RB, 2000, AM J RESP CRIT CARE, V162, P1178; BANZETT RB, 1996, LUNG BIOL HEALTH DIS, V90, P155; Banzett RB, 2001, APS B, V11, P1; BARNES PJ, 1994, NEW ENGL J MED, V330, P1383, DOI 10.1056/NEJM199405123301910; Bauldoff GS, 2002, CHEST, V122, P948, DOI 10.1378/chest.122.3.948; BINDER JR, 1994, LOCALIZATION NEUROIM, V1, P185; Birbaumer N, 2003, BIOL PSYCHOL, P328; Bornhovd K, 2002, BRAIN, V125, P1326, DOI 10.1093/brain/awf137; Brannan S, 2001, P NATL ACAD SCI USA, V98, P2029, DOI 10.1073/pnas.98.4.2029; BUSHNELL MC, 2002, CAN J ANAESTH, V49, pR1; Casey KL, 1999, P NATL ACAD SCI USA, V96, P7668, DOI 10.1073/pnas.96.14.7668; CHEN Z, 1991, J PHYSIOL-LONDON, V437, P305; CHEN ZB, 1992, RESP PHYSIOL, V90, P99, DOI 10.1016/0034-5687(92)90137-L; CHERTKOW H, 1994, LOCALIZATION NEUROIM, P152; Chetta A, 1998, AM J RESP CRIT CARE, V157, P116; COLEBATCH JG, 1991, J PHYSIOL-LONDON, V443, P91; CORFIELD DR, 1995, J PHYSIOL-LONDON, V488, P77; DAHME B, 2000, ASTHMA BRONCHIALE, P99; Damasio AR, 2000, NAT NEUROSCI, V3, P1049, DOI 10.1038/79871; Davenport PW, 2000, AM J RESP CRIT CARE, V161, P1830; DAVENPORT PW, 1985, BRAIN RES, V328, P150, DOI 10.1016/0006-8993(85)91334-4; DAVENPORT PW, 1986, J APPL PHYSIOL, V60, P1843; Davenport PW, 1995, REGULATION BREATHING, P365; Dawson SL, 1999, J APPL PHYSIOL, V86, P675; De Peuter S, 2004, CLIN PSYCHOL REV, V24, P557, DOI 10.1016/j.cpr.2004.05.001; Demoule A, 2003, J APPL PHYSIOL, V94, P453, DOI 10.1152/japplphysiol.00581.2002; Denton D, 1999, P NATL ACAD SCI USA, V96, P5304, DOI 10.1073/pnas.96.9.5304; Evans KC, 2002, J NEUROPHYSIOL, V88, P1500, DOI 10.1152/jn.00957.2001; Evans KC, 1999, J PHYSIOL-LONDON, V520, P383, DOI 10.1111/j.1469-7793.1999.00383.x; Feldman JM, 2002, PSYCHOSOM MED, V64, P294; Fink GR, 1996, J APPL PHYSIOL, V81, P1295; Fritz GK, 1996, J AM ACAD CHILD PSY, V35, P1033, DOI 10.1097/00004583-199608000-00014; GANDEVIA SC, 1993, J PHYSIOL-LONDON, V470, P85; GANDEVIA SC, 1987, J PHYSIOL-LONDON, V384, P109; GANDEVIA SC, 1989, RESP PHYSIOL, V77, P203, DOI 10.1016/0034-5687(89)90007-8; Gaytan SP, 1998, BRAIN RES BULL, V47, P625, DOI 10.1016/S0361-9230(98)00125-7; Gehlbach BK, 2004, CHEST, V125, P669, DOI 10.1378/chest.125.2.669; GEISSNER E, 1992, PSYCHOL SCHMERZES DI, P25; Geissner E., 1996, SCHMERZEMPFINDUNGS S; GOZAL D, 1994, J APPL PHYSIOL, V76, P2076; GOZAL D, 1995, P NATL ACAD SCI USA, V92, P6607, DOI 10.1073/pnas.92.14.6607; Guz A, 1997, RESP PHYSIOL, V109, P197, DOI 10.1016/S0034-5687(97)00050-9; HALLOWITZ RA, 1977, BRAIN RES, V130, P271, DOI 10.1016/0006-8993(77)90275-X; Hanamori T, 1997, CHEM SENSES, V22, P399, DOI 10.1093/chemse/22.4.399; Hanamori T, 1998, J NEUROPHYSIOL, V79, P2535; Harver A, 2000, CHEST, V118, P679, DOI 10.1378/chest.118.3.679; Harver A., 1998, SELF MANAGEMENT ASTH, P35; Henderson LA, 2003, J APPL PHYSIOL, V94, P1063, DOI 10.1152/japplphysiol.00702.2002; Isaev G, 2002, J PHYSIOL-LONDON, V539, P935, DOI 10.1013/jphysiol.2001.012957; Isenberg S, 1997, J BEHAV MED, V20, P461, DOI 10.1023/A:1025551532756; KIKUCHI Y, 1994, NEW ENGL J MED, V330, P1329, DOI 10.1056/NEJM199405123301901; KILLIAN KJ, 1984, J APPL PHYSIOL, V57, P686; KINOMURA S, 1994, BRAIN RES, V659, P263, DOI 10.1016/0006-8993(94)90890-7; Knafelc M, 1997, J APPL PHYSIOL, V83, P918; Lavietes MH, 2001, CHEST, V120, P409, DOI 10.1378/chest.120.2.409; LEHRER P, 2002, J CONSULT CLIN PSYCH, V7, P691; LEHRER PM, 1993, J PSYCHOSOM RES, V37, P515, DOI 10.1016/0022-3999(93)90007-3; Liotti M, 2001, P NATL ACAD SCI USA, V98, P2035, DOI 10.1073/pnas.98.4.2035; Magadle R, 2002, CHEST, V121, P329, DOI 10.1378/chest.121.2.329; MANNING HL, 1991, J APPL PHYSIOL, V71, P175; MANNING HL, 1995, NEW ENGL J MED, V333, P1547; Manning HL, 2001, J ASTHMA, V38, P447, DOI 10.1081/JAS-100105865; MASKILL D, 1991, J PHYSIOL-LONDON, V443, P105; McKay LC, 2003, J APPL PHYSIOL, V95, P1170, DOI 10.1152/japplphysiol.00641.2002; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; MELZACK R, 1975, PAIN, V1, P277, DOI 10.1016/0304-3959(75)90044-5; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Moosavi SH, 2003, J APPL PHYSIOL, V94, P141, DOI 10.1152/japplphysiol.00594.2002; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; *NAT ASTHM ED PREV, 1997, PUBL; *NAT ASTHM ED PREV, 2001, PUBL; *NAT ASTHM ED PREV, 2002, PUBL; Nishino T, 1999, ANESTHESIOLOGY, V91, P1633, DOI 10.1097/00000542-199912000-00014; OBRIEN JH, 1971, ELECTROEN CLIN NEURO, V31, P7, DOI 10.1016/0013-4694(71)90285-9; OGAWA S, 1990, P NATL ACAD SCI USA, V87, P9868, DOI 10.1073/pnas.87.24.9868; Parsons LM, 2001, P NATL ACAD SCI USA, V98, P2041, DOI 10.1073/pnas.98.4.2041; Peiffer C, 2001, AM J RESP CRIT CARE, V163, P951; Peyron R, 2000, NEUROPHYSIOL CLIN, V30, P263, DOI 10.1016/S0987-7053(00)00227-6; Price DD, 2000, SCIENCE, V288, P1769, DOI 10.1126/science.288.5472.1769; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; RAMSAY SC, 1993, J PHYSIOL-LONDON, V461, P85; Rao AB, 2003, POSTGRAD MED J, V79, P681; Reiman EM, 1997, AM J PSYCHIAT, V154, P918; REVELETTE WR, 1990, J APPL PHYSIOL, V68, P282; Rietveld S, 1998, PSYCHOL MED, V28, P407, DOI 10.1017/S0033291797006387; Rietveld Simon, 2003, Adv Psychosom Med, V24, P115, DOI 10.1159/000073784; Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081; RUBINFELD AR, 1976, LANCET, V1, P882; Ruoss M, 1998, VERHALTENSTHERAPIE, V8, P14, DOI 10.1159/000030626; SCHWARTZSTEIN RM, 1989, AM REV RESPIR DIS, V139, P1231; Shea SA, 1995, REGULATION BREATHING, P923; SIMON PM, 1990, AM REV RESPIR DIS, V142, P1009; SIMON PM, 1991, AM REV RESPIR DIS, V144, P419; TAGUCHI O, 1991, J APPL PHYSIOL, V71, P2183; Tataranni PA, 1999, P NATL ACAD SCI USA, V96, P4569, DOI 10.1073/pnas.96.8.4569; Thornton JM, 2001, J PHYSIOL-LONDON, V533, P823, DOI 10.1111/j.1469-7793.2001.00823.x; Treede RD, 1999, PAIN, V79, P105, DOI 10.1016/S0304-3959(98)00184-5; Valet M, 2004, PAIN, V109, P399, DOI 10.1016/j.pain.2004.02.033; VandenBergh O, 1997, PSYCHOSOM MED, V59, P13; Villemure C, 2002, PAIN, V95, P195, DOI 10.1016/S0304-3959(02)00007-6; Webster KE, 2002, AM J RESP CRIT CARE, V166, P47, DOI 10.1164/rccm.2012006; WHITELAW WA, 1987, J APPL PHYSIOL, V62, P1962; Williamson JW, 1999, J APPL PHYSIOL, V87, P1213; Williamson JW, 2003, J APPL PHYSIOL, V94, P1726, DOI 10.1152/japplphysiol.01152.2002; WILSON RC, 1991, CLIN SCI, V80, P65	108	83	85	2	6	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUL	2005	128	1					345	354		10.1378/chest.128.1.345		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	945VN	WOS:000230530500054	16002956	
J	Di Lorenzo, G; Pacor, ML; Pellitteri, ME; Morici, G; Di Gregoli, A; Lo Bianco, C; Ditta, V; Martinelli, N; Candore, G; Mansueto, P; Rini, GB; Corrocher, R; Caruso, C				Di Lorenzo, G; Pacor, ML; Pellitteri, ME; Morici, G; Di Gregoli, A; Lo Bianco, C; Ditta, V; Martinelli, N; Candore, G; Mansueto, P; Rini, GB; Corrocher, R; Caruso, C			Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						cetirizine; eosinophil cationic protein; eosinophils; fluticasone propionate; montelukast; nasal lavage; Parietaria; pollen season	LEUKOTRIENE RECEPTOR ANTAGONISTS; POLLEN SEASON; GRASS-POLLEN; DOUBLE-BLIND; PROPIONATE; CORTICOSTEROIDS; ASTHMA; ANTILEUKOTRIENE; LEVOCABASTINE; EOSINOPHILS	Background Corticosteroids are considered to be particularly effective in reducing nasal congestion and are therefore recommended as first-line treatment in allergic rhinitis patients with moderate to severe and/or persistent symptoms. Objective We compared the clinical efficacy of fluticasone propionate aqueous nasal spray (FPANS) 200 mug given once daily, administered in mono-therapy or combined therapy with a H-1 receptor antagonist (cetirizine, CTZ) or with a leukotriene antagonist (montelukast, MSK), and the combined therapy of CTZ plus MSK in the treatment of patients affected by allergic rhinitis to Parietaria during natural pollen exposure. In addition, we examined the effect of the treatment on eosinophil counts and eosinophil cationic protein (ECP) in nasal lavage performed at beginning of season, during season and at the end of the season. Methods One hundred patients aged 12-50 years (mean+/-SD 31.8+/-9.6) with a history of moderate to severe Parietaria pollen-induced seasonal allergic rhinitis were selected. A randomized, double-blind, double dummy, placebo (PLA)-controlled, parallel-group study design was used. Patients were treated FPANS 200 mug once daily (n=20) or with FPANS 200 mug once daily, plus CTZ (10 mg) in the morning (n=20), or with FPANS 200 mug once daily, plus MSK (10 mg) in the evening (n=20) or with CTZ (10 mg) in the morning plus MSK in the evening (n=20) or matched PLA (n=20). Assessment of efficacy was based on scores of daily nasal symptoms and on eosinophil counts and ECP in nasal lavage. Results All treatments showed significant differences (P<0.001) compared with PLA in terms of total symptom, rhinorrhea, sneezing and nasal itching scores. Concerning nasal congestion on waking and daily only the groups treated with FPANS in mono-therapy or in combined therapy showed significant differences compared with PLA. Comparing the group treated with FPANS alone and the groups treated with FPANS plus CTZ, we found significant differences for total symptom score (P=0.04) and for nasal itching (P=0.003). The comparison between FPANS plus CTZ and FPANS plus MSK showed significant difference for nasal itching (P=0.003). Finally, there were significant differences between the group treated with FPANS and the group treated with CTZ plus MSK for total symptom score (P=0.009), for nasal congestion on waking (P<0.001) and nasal congestion daily (P<0.001). Also the comparisons between the group treated with FPANS plus CTZ and the group treated with CTZ plus MSK demonstrated significant differences (P<0.001) for total symptom, for nasal congestion on waking and for nasal congestion on daily, for rhinorrhea (P=0.04) and for nasal itching (P=0.003) scores. Concerning the comparison between the group treated with FPANS plus MSK and the group treated with CTZ plus MSK we found significant differences for total symptom score (P=0.005), for nasal congestion on waking (P<0.001) and for nasal congestion on daily (P<0.001). No other differences were observed between the groups. Concerning blood eosinophil counts, significant differences were found between the treatments with FPANS in mono-therapy or in combined therapy with PLA group during and at the end of the season (P=0.0003 and P<0.0001, respectively). Concerning eosinophils and ECP in nasal lavage, all treatments showed significant differences (P<0.001) compared with PLA. Besides, there were significant differences (P<0.001) between the groups treated with FPANS alone or in combined therapy and the group treated with CTZ plus MSK. Conclusion The results of this comparative study demonstrate that FPANS is highly effective for treating patients affected by allergic rhinitis, with efficacy exceeding that of CTZ plus MSK in combined therapy. In addition, the regular combined therapy of FPANS plus CTZ or plus MSK would not seem to offer substantial advantage with respect to FPANS in mono-therapy in patients affected by seasonal allergic rhinitis.	Univ Palermo, Dipartimento Med Clin & Patol Emergenti, I-90127 Palermo, Italy; Univ Verona, Dipartimento Med Clin & Med Sperimentale, I-37100 Verona, Italy; Univ Palermo, Dipartimento Biopatol & Metodol Biomed, I-90133 Palermo, Italy	Di Lorenzo, G (reprint author), Univ Palermo, Dipartimento Med Clin & Patol Emergenti, Via Vespro 141, I-90127 Palermo, Italy.	dilo601@unipa.it	Martinelli, Nicola/J-5622-2016; Mansueto, Pasquale/K-3458-2016	Martinelli, Nicola/0000-0001-6465-5119; Mansueto, Pasquale/0000-0002-0406-0583; Di Lorenzo, Gabriele/0000-0002-0197-5665			Barnes PJ, 2001, ALLERGY, V56, P928, DOI 10.1034/j.1398-9995.2001.00001.x; Barnes PJ, 1998, AM J RESP CRIT CARE, V157, P1; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; D'Ambrosio F P, 1998, Allergol Immunopathol (Madr), V26, P277; DACIE JV, 1984, PRACTICAL HAEMATOLOG, P42; DARNELL R, 1994, CLIN EXP ALLERGY, V24, P1144; Di Lorenzo G, 1997, J ALLERGY CLIN IMMUN, V100, P832, DOI 10.1016/S0091-6749(97)70281-1; Di Lorenzo G, 2002, MEDIAT INFLAMM, V11, P187, DOI 10.1080/09622935020138226; Di Lorenzo G, 1999, CLIN EXP ALLERGY, V29, P1367; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; DiLorenzo G, 1997, CLIN EXP ALLERGY, V27, P1052; DILORENZO G, 2001, INT ARCH ALLERGY IMM, V25, P164; Ducharme FM, 2000, COCHRANE DB SYST REV, V3; DUJUKANOVIC R, 1996, CLIN EXP ALLERGY  S3, V26, P44; Erdfelder E, 1996, BEHAV RES METH INSTR, V28, P1, DOI 10.3758/BF03203630; GODTHELP T, 1995, ALLERGY, V50, P21, DOI 10.1111/j.1398-9995.1995.tb02737.x; Grossman J., 1997, Journal of Allergy and Clinical Immunology, V99, pS443; HOWARTH PH, 1995, ALLERGY, V50, P6, DOI 10.1111/j.1398-9995.1995.tb02734.x; Jordana G, 1996, J ALLERGY CLIN IMMUN, V97, P588, DOI 10.1016/S0091-6749(96)70303-2; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357; Mygind N, 1996, CLIN EXP ALLERGY, V26, P2, DOI 10.1111/j.1365-2222.1996.tb00652.x; Nielsen LP, 2001, DRUGS, V61, P1563, DOI 10.2165/00003495-200161110-00004; OKUDA M, 1988, ANN ALLERGY, V60, P537; Ortolani C, 1999, ALLERGY, V54, P1173, DOI 10.1034/j.1398-9995.1999.00200.x; Palczynski C, 1996, Allergol Immunopathol (Madr), V24, P237; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Smith LJ, 2001, BIODRUGS, V15, P239, DOI 10.2165/00063030-200115040-00004; Sorkness CA, 2001, PHARMACOTHERAPY, V21, p34S, DOI 10.1592/phco.21.4.34S.34262; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Weiner JM, 1998, BRIT MED J, V317, P1624; Wilson AM, 2001, ANN ALLERG ASTHMA IM, V87, P344; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x	35	83	89	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2004	34	2					259	267		10.1111/j.1365-2222.2004.01877.x		9	Allergy; Immunology	Allergy; Immunology	779KL	WOS:000189293900016	14987306	
J	Taube, C; Dakhama, A; Gelfand, EW				Taube, C; Dakhama, A; Gelfand, EW			Insights into the pathogenesis of asthma utilizing murine models	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Review						asthma; mouse model; airway hyperresponsiveness	DELTA-T-CELLS; ALLERGIC AIRWAY DISEASE; RESPIRATORY SYNCYTIAL VIRUS; ACTIVATED MAST-CELLS; NF-KAPPA-B; MOUSE MODEL; PULMONARY EOSINOPHILIA; MUCUS PRODUCTION; BRONCHIAL HYPERREACTIVITY; ANTIGEN EXPOSURE	Asthma is a common syndrome in children and adults. Despite the increasing prevalence and socioeconomic burden, the underlying pathophysiology remains poorly defined in a large percentage of asthmatics. Animal models and, in particular, murine models of allergic airway disease have helped to reveal some of the potential underlying mechanisms and have played an important role in identifying the importance of T cells and T(H)2 cytokines in development of allergen-induced inflammation and airway hyperresponsiveness. In addition, other cell types including mast cells and eosinophils have been implicated in the development of some aspects of the disease. To further understand this complex syndrome, the development of animal models which mimic elements of this chronic airway disease is essential. Copyright (C) 2004 S. Karger AG, Basel.	Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, Denver, CO 80206 USA	Gelfand, EW (reprint author), Natl Jewish Med & Res Ctr, Div Cell Biol, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org					Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Bautsch W, 2000, J IMMUNOL, V165, P5401; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Blackburn MR, 2003, J CLIN INVEST, V112, P332, DOI 10.1172/JCI200316815; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Busse WW, 2001, NEW ENGL J MED, V344, P350; Chapoval SP, 2001, J ALLERGY CLIN IMMUN, V108, P764; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1999, J IMMUNOL, V162, P6178; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Colasurdo GN, 1998, AM J RESP CRIT CARE, V157, P1506; Cookson W, 1999, NATURE, V402, pB5; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; CROFT M, 1994, J EXP MED, V180, P1715, DOI 10.1084/jem.180.5.1715; Crosby JR, 2002, J IMMUNOL, V168, P4050; Cui ZH, 2003, AM J RESP CRIT CARE, V168, P1324, DOI 10.1164/rccm.200305-634OC.R1; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/rccm.2109058; DAKHAMA A, 2002, BIOTHERAPEUTIC APPRO, P247; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Elias JA, 2003, CHEST, V123, p339S, DOI 10.1378/chest.123.3_suppl.339S-a; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Evans MJ, 2003, AM J PHYSIOL-LUNG C, V285, pL931, DOI 10.1152/ajplung.00175.2003; FAIRBAIRN SM, 1993, CLIN EXP ALLERGY, V23, P821, DOI 10.1111/j.1365-2222.1993.tb00259.x; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Gelfand EW, 2004, J IMMUNOL, V173, P1298; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GONZALEZ MC, 1987, AM REV RESPIR DIS, V136, P600; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunstein MM, 2002, AM J PHYSIOL-LUNG C, V282, pL520; Hahn C, 2003, J ALLERGY CLIN IMMUN, V111, P1361, DOI 10.1067/mai.2003.1527; Hahn YS, 2004, J IMMUNOL, V172, P2894; Hahn YS, 2003, J IMMUNOL, V171, P3170; Haile S, 1999, AM J RESP CELL MOL, V20, P891; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; Henderson WR, 2000, J IMMUNOL, V164, P1086; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Herz U, 1999, EUR J IMMUNOL, V29, P1021, DOI 10.1002/(SICI)1521-4141(199903)29:03<1021::AID-IMMU1021>3.0.CO;2-3; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; Holtzman MJ, 2003, AM J RESP CELL MOL, V29, P163, DOI 10.1165/rcmb.F276; Hoshino T, 1999, J Immunol, V162, P51; Ikeda RK, 2003, J IMMUNOL, V171, P4860; Ikeda RK, 2003, AM J RESP CELL MOL, V28, P655, DOI 10.1165/rcmb.4853; JARVIS D, 2000, EPIDEMIOLOGY ASTHMA; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Johnson Victor J, 2004, Curr Opin Allergy Clin Immunol, V4, P105, DOI 10.1097/00130832-200404000-00006; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL1066, DOI 10.1152/ajplung.00195.2001; Kanehiro A, 2001, AM J RESP CRIT CARE, V164, P2229, DOI 10.1164/rccm2012059; Kanehiro A, 2002, J IMMUNOL, V169, P4190; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173; Kips JC, 2003, EUR RESPIR J, V22, P374, DOI 10.1183/09031936.03.00026403; Komai M, 2003, BRIT J PHARMACOL, V138, P912, DOI 10.1038/sj.bjp.0705105; Kraneveld AD, 2002, J IMMUNOL, V169, P2044; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404; Kuo CT, 1999, ANNU REV IMMUNOL, V17, P149, DOI 10.1146/annurev.immunol.17.1.149; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lahn M, 1998, J IMMUNOL, V160, P5221; Lahn M, 2002, P NATL ACAD SCI USA, V99, P8850, DOI 10.1073/pnas.132519299; Lahn M, 1999, NAT MED, V5, P1150; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lazaar AL, 2003, AM J MED, V115, P652, DOI 10.1016/j.amjmed.2003.07.010; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Leigh R, 2004, AM J RESP CRIT CARE, V169, P860, DOI 10.1164/rccm.200305-706OC; Lemanske Robert F. Jr., 2003, Journal of Allergy and Clinical Immunology, V111, pS502; Magnussen H, 1998, CLIN EXP ALLERGY, V28, P187; Magnussen H., 1998, CLIN EXP ALLERGY, V28, P203; Manjunath N, 2001, J CLIN INVEST, V108, P871, DOI 10.1172/JCI13296; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Masopust D, 2001, SCIENCE, V291, P2413, DOI 10.1126/science.1058867; Masuda A, 2002, J IMMUNOL, V169, P3801; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2001, J IMMUNOL, V167, P1683; Mayr SI, 2002, J IMMUNOL, V169, P2061; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1995, J IMMUNOL, V154, P4390; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Mestas J, 2004, J IMMUNOL, V172, P2731; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Miyahara N, 2004, J IMMUNOL, V172, P2549; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mould AW, 2000, J IMMUNOL, V164, P2142; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Nelms K, 1999, ANNU REV IMMUNOL, V17, P701, DOI 10.1146/annurev.immunol.17.1.701; NOGAMI M, 1990, AM REV RESPIR DIS, V141, P1289; O'Byrne PM, 2001, J ALLERGY CLIN IMMUN, V108, P503; Ogawa K, 1999, INT ARCH ALLERGY IMM, V120, P15, DOI 10.1159/000053586; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Persson CGA, 2002, AM J RESP CRIT CARE, V166, P6, DOI 10.1164/rccm.2204001; Pitchford SC, 2004, BLOOD, V103, P639, DOI 10.1182/blood-2003-05-1707; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; RENZ H, 1993, J IMMUNOL, V151, P1907; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rothenberg ME, 1999, J CLIN IMMUNOL, V19, P250, DOI 10.1023/A:1020531322556; Sakai K, 2001, INT ARCH ALLERGY IMM, V126, P126, DOI 10.1159/000049503; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Schneider T, 1997, AM J RESP CELL MOL, V17, P702; Schramm CM, 2004, AM J PATHOL, V164, P295, DOI 10.1016/S0002-9440(10)63119-7; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SEDER RA, 1992, J IMMUNOL, V148, P1652; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; SIM GK, 1994, INT IMMUNOL, V6, P1287, DOI 10.1093/intimm/6.9.1287; Stassen M, 2001, J IMMUNOL, V166, P4391; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2004, J IMMUNOL, V172, P6398; Taube C, 2003, J IMMUNOL, V170, P4301; Taube C, 2002, J IMMUNOL, V169, P6482; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temelkovski J, 1998, THORAX, V53, P849; Tomaki M, 2000, J IMMUNOL, V165, P4040; Tomkinson A, 2001, J IMMUNOL, V166, P5792; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283; Tomkinson A, 2001, AM J RESP CRIT CARE, V163, P721; Turner H, 1999, NATURE, V402, P24, DOI 10.1038/35037021; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Walter DM, 2001, J IMMUNOL, V167, P4668; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Webb DC, 2000, J IMMUNOL, V165, P108; Webb DC, 2004, J IMMUNOL, V172, P1092; Weninger W, 2001, J EXP MED, V194, P953, DOI 10.1084/jem.194.7.953; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yiamouyiannis CA, 1999, AM J PATHOL, V154, P1911, DOI 10.1016/S0002-9440(10)65449-1; Yu CK, 1999, J ALLERGY CLIN IMMUN, V104, P228, DOI 10.1016/S0091-6749(99)70140-5; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; Zimmermann N, 2000, J IMMUNOL, V165, P5839	161	83	85	0	7	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.		2004	135	2					173	186		10.1159/000080899		14	Allergy; Immunology	Allergy; Immunology	861HB	WOS:000224405600012	15375327	
J	Mishra, V				Mishra, V			Indoor air pollution from biomass combustion and acute respiratory illness in preschool age children in Zimbabwe	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						indoor air pollution; biomass; smoke; respiratory tract infections; child; Zimbabwe	ENVIRONMENTAL TOBACCO-SMOKE; DEVELOPING-COUNTRIES; CHRONIC-BRONCHITIS; IMMUNE-RESPONSE; LUNG IMMUNITY; BONE-MARROW; EXPOSURE; DISEASE; WOMEN; ASTHMA	Background Reliance on biomass for cooking and heating exposes many women and young children in developing countries to high levels of air pollution indoors. This study investigated the association between household use of biomass fuels for cooking and acute respiratory infections (ARI) in preschool age children (<5 years) in Zimbabwe. Methods Analysis is based on 3559 children age 0-59 months included in the 1999 Zimbabwe Demographic and Health Survey (ZDHS). Children who suffered from cough accompanied by short, rapid breathing during the 2 weeks preceding the survey were defined as having suffered from ARI. Logistic regression was used to estimate the odds of suffering from ARI among children from households using biomass fuels (wood, dung, or straw) relative to children from households using cleaner fuels (liquid petroleum gas [LPG]/natural gas, or electricity), after controlling for potentially confounding factors. Results About two-thirds (66%) of children lived in households using biomass fuels and 16% suffered from ARI during the 2 weeks preceding the survey interview. After adjusting for child's age, sex, birth order, nutritional status, mother's age at childbirth, education, religion, household living standard, and region of residence, children in households using wood, dung, or straw for cooking were more than twice as likely to have suffered from ARI as children from households using LPG/natural gas or electricity (OR = 2.20; 95% CI: 1.16, 4.19). Conclusions Household use of high pollution biomass fuels is associated with ARI in children in Zimbabwe. The relationship needs to be further investigated using more direct measures of smoke exposure and clinical measures of ARI.	East West Ctr, Honolulu, HI 96848 USA	Mishra, V (reprint author), East West Ctr, 1601 East West Rd, Honolulu, HI 96848 USA.						Albalak R, 1999, THORAX, V54, P1004; Albalak R, 1997, THESIS U MICHIGAN; Aldous MB, 1996, AM J EPIDEMIOL, V143, P423; ANDERSON HR, 1978, INT J EPIDEMIOL, V7, P63, DOI 10.1093/ije/7.1.63; ARMSTRONG JRM, 1991, INT J EPIDEMIOL, V20, P424, DOI 10.1093/ije/20.2.424; AZIZI BHO, 1991, INT J EPIDEMIOL, V20, P144, DOI 10.1093/ije/20.1.144; BEHERA D, 1991, CHEST, V100, P385, DOI 10.1378/chest.100.2.385; BEHERA D, 1988, INDIAN J MED RES, V88, P522; Bruce N, 1998, INT J EPIDEMIOL, V27, P454, DOI 10.1093/ije/27.3.454; Bruce N., 2000, B WORLD HEALTH ORGAN, V78, P1080; CABARABAN MC, 1993, RURAL MOTHERS MANAGE; CHANG JCC, 1990, TOXICOL APPL PHARM, V102, P514, DOI 10.1016/0041-008X(90)90046-W; COLLINGS DA, 1990, TROP DOCT, V20, P151; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; Ezzati M, 2001, LANCET, V358, P1104; Fujii T, 2001, AM J RESP CELL MOL, V25, P265; GREEN GM, 1977, AM REV RESPIR DIS, V115, P479; HARDIN JA, 1992, TOXICOL APPL PHARM, V117, P155, DOI 10.1016/0041-008X(92)90232-H; HERSEY P, 1983, MED J AUSTRALIA, V2, P425; JACOB CV, 1980, IMMUNOLOGY, V40, P621; Janet S.M.L., 1999, PEDIAT PULMONOL, V27, P5; JOHNSON JD, 1990, CRIT REV TOXICOL, V20, P369, DOI 10.3109/10408449009089870; KONG LY, 1994, AM J RESP CRIT CARE, V150, P1123; KOSSOVE D, 1982, S AFR MED J, V61, P622; Malik S K, 1985, Indian J Chest Dis Allied Sci, V27, P171; MEHNTA S, 2002, 9 INT C IND AIR QUAL; MIKA L, 2002, 9 INT C IND AIR QUAL; Mishra V, 2003, ENVIRON HEALTH PERSP, V111, P71, DOI 10.1289/ehp.5559; Mishra V K, 1999, Int J Infect Dis, V3, P119, DOI 10.1016/S1201-9712(99)90032-2; MISHRA VK, 2000, BOILING POINT, V44, P11; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; Mukae H, 2001, AM J RESP CRIT CARE, V163, P201; PANDEY MR, 1989, LANCET, V1, P427; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701; Perez-Padilla R, 2001, INT J TUBERC LUNG D, V5, P1; Pistelly R, 1997, AM J RESP CRIT CARE, V155, pA941; Robin LF, 1996, PEDIATR INFECT DIS J, V15, P859, DOI 10.1097/00006454-199610000-00006; SAMET JM, 1990, TOXICOL IND HEALTH, V6, P247; Samet J.M., 1993, RES REP HLTH EFF I, V58, P1; Samet J.M., 1991, INDOOR AIR POLLUTION; SAMET JM, 1993, RES REP HLTH EFF I, V58, P51; SAS Institute Inc, 2001, SAS SYST WIND REL 8; SCHEI MA, 2002, 9 INT C IND AIR QUAL; SCHNIZLEIN CT, 1982, ARCH ENVIRON HEALTH, V37, P201; Smith GR, 2002, J ROY ASIATIC SOC, V12, P1; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; SMITH KR, 1994, LUNG BIOL HEALTH DIS, V74, P151; SOPORI ML, 1989, TOXICOL APPL PHARM, V97, P489, DOI 10.1016/0041-008X(89)90254-8; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213; Taszakowski W, 1992, Pol Tyg Lek, V47, P763; THOMAS P, AIR POLLUTION HLTH; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; TUTHILL RW, 1984, AM J EPIDEMIOL, V120, P952; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; Wang Jin, 1992, Chinese Journal of Preventive Medicine, V26, P86; WHO, 2001, WORLD HLTH REP 2001; World Health Organization (WHO), 1997, HLTH ENV SUST DEV 5; Xu X, 1996, INT J OCCUP ENV HEAL, V2, P172; ZELIKOFF JT, 1994, CIAR CURR        NOV, P1; *ZIMB MACR INT INC, 2000, ZIMB DEM HLTH SURV 1	61	83	86	0	7	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	OCT	2003	32	5					847	853		10.1093/ije/dyg240		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	735ZY	WOS:000186146300036	14559763	
J	Fernandes, J; Reshef, A; Patton, L; Ayuso, R; Reese, G; Lehrer, SB				Fernandes, J; Reshef, A; Patton, L; Ayuso, R; Reese, G; Lehrer, SB			Immunoglobulin E antibody reactivity to the major shrimp allergen, tropomyosin, in unexposed Orthodox Jews	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergen cross-reactivity; cockroaches; dust mites; Orthodox Jews; shrimp reactivity; tropomyosin	HOUSE-DUST MITE; CROSS-REACTIVITY; DERMATOPHAGOIDES-PTERONYSSINUS; IDENTIFICATION; NITROCELLULOSE; HYPERSENSITIVITY; PROTEINS; BINDING; SNAILS	Background Assessment of allergic (IgE antibody-mediated) reactions to foods may become complicated by cross-reactivity that can occur among certain food families and between foods and seemingly unrelated allergens. Objective The allergenic properties of tropomyosin (muscle-derived protein) have been recently demonstrated in invertebrates such as cockroaches, dust mites, and shrimp. In view of a possible cross-reactivity between food allergens and related allergens from animal sources, we designed a study to assess IgE antibody reactivity to the major shrimp allergen, Pen a 1, in an unexposed population of Orthodox Jews, who observe Kosher dietary laws that prohibit eating shellfish. Methods Nine subjects, who reacted positively by skin tests to shrimp (Penaeus setiferous ), were selected for the study. Subjects (two females, seven males) ranged in age from 14 to 32 years (mean 20.4). All subjects were strictly observant of Jewish tradition and had no prior exposure to seafood (regarded as a non-Kosher food). Serum was obtained from all the subjects and tested for IgE antibody reactivity to shrimp and dust mite. Results All subjects reported symptoms of perennial allergic rhinitis, five had history of asthma, atopic dermatitis, and/or sinusitis. All had positive skin prick tests to shrimp and house dust mite (HDM) (Dermatophagoides farinae, D. pteronyssinus , or both); 2/7 subjects were positive to cockroach mix (Blattella germanica and Periplaneta americana ). Sera of 4/9 subjects demonstrated specific IgE antibodies by RAST to shrimp (7.0-20.0%), 3/9 to Pen a 1 (6.3-24.1%), and 3/9 to shrimp or Pen a 1 by immunoblot. IgE binding to Pen a 1 was inhibited with either mite or cockroach extracts as demonstrated by RAST and/or immunoblot inhibition analysis. Conclusions These studies indicate that IgE antibody reactivity to a major food allergen, shrimp, can occur in an unexposed population of individuals; some subjects allergic to HDM and/or cockroach show substantial IgE antibody reactivity to the major shrimp allergen Pen a 1 (tropomyosin). Based on inhibition with cockroach and/or dust mite extracts, this reactivity appears to be due to cross-reacting tropomyosins.	Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70112 USA; Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel	Lehrer, SB (reprint author), Tulane Univ, Hlth Sci Ctr, 1700 Perdido St SL-57, New Orleans, LA 70112 USA.						AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; BANZET ML, 1992, REV FR ALLERGOL, V32, P198, DOI 10.1016/S0335-7457(05)80359-4; BARLETTA B, 2002, J ALLERGY CLIN IMMUN, V109, P383; BARNETT D, 1987, J ALLERGY CLIN IMMUN, V79, P438; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Caballero T, 1998, J INVEST ALLERG CLIN, V8, P6; CARRILLO T, 1994, ANN ALLERGY, V73, P504; CESKA M, 1972, IMMUNOCHEMISTRY, V9, P1921; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; DAUL CB, 1987, J ALLERGY CLIN IMMUN, V80, P716, DOI 10.1016/0091-6749(87)90293-4; DEMAATBLEEKER F, 1995, ALLERGY, V50, P438; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; Ebner C, 1996, MONOGR ALLERGY, V32, P73; HALMEPURO L, 1987, INT ARCH ALLER A IMM, V82, P213; JEONG KY, 2002, J ALLERGY CLIN IMMUN, V109, P380; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; Lehrer SB, 1998, REV FR ALLERGOL, V38, P846, DOI 10.1016/S0335-7457(98)80154-8; LEHRER SB, 1986, ANN ALLERGY, V57, P267; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Petrus M, 1999, ARCH PEDIATRIE, V6, P1075, DOI 10.1016/S0929-693X(00)86982-1; RAME JM, 2002, J ALLERGY CLIN IMMUN, V109, P654; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Reese G, 2002, J ALLERGY CLIN IMMUN, V109, pS307, DOI 10.1016/S0091-6749(02)82078-4; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V103, pS122; SHANTI KN, 1993, J IMMUNOL, V151, P5354; TAYLOR SL, 1988, MARINE TOXINS VENOMS, V3, P149; vanRee R, 1996, ALLERGY, V51, P108; Vuitton DA, 1998, ALLERGY, V53, P144, DOI 10.1111/j.1398-9995.1998.tb03862.x	32	83	90	1	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUL	2003	33	7					956	961		10.1046/j.1365-2222.2003.01722.x		6	Allergy; Immunology	Allergy; Immunology	702AM	WOS:000184202400016	12859453	
J	Eichenfield, LF; Hanifin, JM; Beck, LA; Lemanske, RF; Sampson, HA; Weiss, ST; Leung, DYM				Eichenfield, LF; Hanifin, JM; Beck, LA; Lemanske, RF; Sampson, HA; Weiss, ST; Leung, DYM			Atopic dermatitis and asthma: Parallels in the evolution of treatment	PEDIATRICS			English	Article						allergy; asthma; atopic dermatitis; treatment guidelines	DENDRITIC CELLS; EARLY-LIFE; CHILDHOOD; PREVALENCE; ALLERGY; EPIDEMIOLOGY; POPULATION; EXPOSURE; LINKAGE; INTERVENTION	Objectives. To review epidemiologic correlations between asthma and atopic dermatitis (AD), identify common features in disease pathophysiology, and review steps involved in the development of asthma therapy guidelines to assess the appropriateness of a similar process and approach for AD. Methods. A 7-member panel representing specialists in dermatology, allergy, asthma, immunology, and pediatrics from around the United States convened to review the current literature and evolving data on AD. Participants presented reviews to the panel on the epidemiology of asthma and AD, the genetic predisposition to allergic disease, the current understanding of the immunopathophysiology of AD, interrelationships between the pathologic pathways of asthma and AD, evolving treatment concepts and options in AD, and the applicability of the asthma treatment model and how it may be adapted for guideline development for AD. Commentary and criticism were recorded for use in document preparation. Results. There are clear epidemiologic parallels in asthma and AD. Importantly, AD frequently is the first manifestation of an atopic diathesis, which occurs in genetically predisposed individuals and also includes asthma and allergic rhinitis. Up to 80% of children with AD will eventually develop allergic rhinitis or asthma later in childhood. This classic "atopic triad" has numerous pathophysiologic elements in common, including cyclic nucleotide regulatory abnormalities, immune cell alterations, and inflammatory mediators and allergic triggers. New therapeutic options that target underlying immune mechanisms are available, and their place among treatments for AD is becoming established. Guidelines of care have been developed for asthma. The panel noted that the National Institutes of Health/National Heart, Lung, and Blood Institute guidelines for diagnosis and management of asthma, first issued in 1991, had a tremendous positive impact on many aspects of asthma treatment. It not only created a heightened awareness that asthma is a disease of chronic inflammation, but it also provided unified approaches for therapy and opened new areas of basic science and clinical research. In addition, the guidelines spurred interactions among physicians of various specialties and stimulated a great quantity of research in asthma therapy. It is anticipated that AD therapy guidelines would have similar positive outcomes. Conclusions. The panel concluded that, on the basis of current information and evolving therapeutic options, a clear rationale exists to support AD guideline development. The many parallels between AD and asthma suggest that processes and approaches used for the asthma therapy guidelines would be appropriate for AD.	Childrens Hosp, San Diego, CA 92123 USA; Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA; Oregon Hlth Sci Univ, Dermatol Clin, Portland, OR 97201 USA; Johns Hopkins Asthma & Allergy Ctr, Baltimore, MD USA; Univ Wisconsin, Sch Med, Madison, WI USA; CUNY Mt Sinai Sch Med, New York, NY 10029 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Natl Jewish Med & Res Ctr, Denver, CO USA	Eichenfield, LF (reprint author), Childrens Hosp, 8010 Frost St,Ste 602, San Diego, CA 92123 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [R01 AI045839]		ADINOFF AD, 1988, J ALLERGY CLIN IMMUN, V81, P736, DOI 10.1016/0091-6749(88)91047-0; *AM AC DERM, 1992, J AM ACAD DERMATOL 2, V26, P485; Asher MI, 1998, CLIN EXP ALLERGY, V28, P52; Asher MI, 1998, CLIN EXP ALLERGY, V28, P90; Bavandi A, 1992, Exp Dermatol, V1, P199, DOI 10.1111/j.1600-0625.1992.tb00189.x; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Beyer K, 2000, J INVEST DERMATOL, V115, P906, DOI 10.1046/j.1523-1747.2000.00096.x; Brinkman L, 1997, EUR RESPIR J, V10, P1033, DOI 10.1183/09031936.97.10051033; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, pS65, DOI 10.1067/mai.2001.116436; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Diepgen TL, 2001, J AM ACAD DERMATOL, V45, pS44, DOI 10.1067/mjd.2001.117016; Eichenfield LF, 2002, J AM ACAD DERMATOL, V46, P495, DOI 10.1067/mjd.2002.122187; Eigenmann PA, 1998, PEDIATRICS, V101; Folster-Holst R, 1998, HUM GENET, V102, P236, DOI 10.1007/s004390050685; Gern JE, 2000, JAMA-J AM MED ASSOC, V283, P394, DOI 10.1001/jama.283.3.394; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; HANIFIN J, 2002, BRIT J DERMATOL, V147, P1; HANIFIN JM, 1995, J INVEST DERMATOL, V105, pS84, DOI 10.1111/1523-1747.ep12316116; Hanifin JM, 2001, J AM ACAD DERMATOL, V44, pS28, DOI 10.1067/mjd.2001.109810; HANIFIN JM, 1999, DERMATOL NURS, V11, P4; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; Howarth PH, 1998, CLIN EXP ALLERGY, V28, P2; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kang S, 2001, J AM ACAD DERMATOL, V44, pS58, DOI 10.1067/mjd.2001.109812; KAY J, 1994, J AM ACAD DERMATOL, V30, P35; Laughter D, 2000, J AM ACAD DERMATOL, V43, P649, DOI 10.1067/mjd.2000.107773; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Lever R, 2001, J AM ACAD DERMATOL, V45, pS57, DOI 10.1067/mjd.2001.117012; Luger T, 2001, BRIT J DERMATOL, V144, P788, DOI 10.1046/j.1365-2133.2001.04134.x; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; *NAT CTR HLTH STAT, 2001, NEW ASTHM EST TRACK; *NAT HEART BLOOD I, 1999, PUBL NAT HEART BLOOD; Nevot S, 1997, Allergol Immunopathol (Madr), V25, P203; [Anonymous], 1997, PUBL NIH; Oppel T, 2000, BRIT J DERMATOL, V143, P1193, DOI 10.1046/j.1365-2133.2000.03887.x; Paller A, 2001, J AM ACAD DERMATOL, V44, pS47, DOI 10.1067/mjd.2001.109813; PALLER AS, 2002, AM AC DERM ANN M FEB; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; Schultz Larsen F, 1996, J Am Acad Dermatol, V34, P760; Schultz-Larsen F, 1986, J AM ACAD DERMATOL, V15, P487, DOI 10.1016/S0190-9622(86)70198-9; Schultz-Larsen F, 2002, IMMUNOL ALLERGY CLIN, V22, P1; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Tofte SJ, 2001, J AM ACAD DERMATOL, V44, pS13, DOI 10.1067/mjd.2001.109811; Van Leent EJM, 1998, ARCH DERMATOL, V134, P805, DOI 10.1001/archderm.134.7.805; von Hertzen LC, 2000, ANN MED, V32, P397, DOI 10.3109/07853890008995946; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; Wollenberg A, 2001, J ALLERGY CLIN IMMUN, V107, P519, DOI 10.1067/mai.2001.112942; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Woolcock AJ, 1997, CIBA F SYMP, V206, P134; Woolcock AJ, 1997, CIBA F SYMP, V206, P157; Wuthrich B, 1999, ANN ALLERG ASTHMA IM, V83, P464, DOI 10.1016/S1081-1206(10)62852-9; Young SYN, 2001, ARCH INTERN MED, V161, P1605, DOI 10.1001/archinte.161.13.1605	63	83	87	1	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2003	111	3					608	616		10.1542/peds.111.3.608		9	Pediatrics	Pediatrics	650ZD	WOS:000181294000042	12612244	
J	Martin, RJ				Martin, RJ			Therapeutic significance of distal airway inflammation in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; distal airway inflammation; nocturnal asthma; inhaled corticosteroids; chlorofluorocarbon-based preparations; hydrofluoroalkane propellants	INHALED BECLOMETHASONE DIPROPIONATE; OBSTRUCTIVE PULMONARY-DISEASE; METERED-DOSE INHALER; LONG-TERM TREATMENT; NOCTURNAL ASTHMA; PSEUDOPHYSIOLOGIC EMPHYSEMA; EOSINOPHILIC INFLAMMATION; TRIAMCINOLONE ACETONIDE; FLUTICASONE PROPIONATE; PERIPHERAL AIRWAYS	Inflammation In asthma is not merely confined to the large central airways but also extends to the small peripheral airways. Distal lung inflammation can be observed even In patients with asthma with mild disease and normal spirometric readings. Subjects with asymptomatic asthma can exhibit significant Increases In peripheral airway resistance, likely the result of distal lung inflammation. As determined from measurements of eosinophilic and other cellular infiltrates, the inflammatory response in the distal lung can exceed that in the large airways. Nocturnal asthma, a natural model of cyclic asthma worsening, is associated with an increase in nighttime distal lung inflammation, as evidenced by the accumulation of alveolar tissue eosinophils. Distal lung disease appears to Increase the risk of recurrent asthma exacerbation, whereas disease-related anatomic changes in the small airways of the distal lung are prominent in fatal asthma. The clinical significance of distal lung disease makes this region an important therapeutic target. Chlorofluorocarbon (CFC)-based preparations of inhaled corticosteroids used to treat airway inflammation produce aerosols of relatively large particle size (similar to4 mum); such aerosols have poor access to the distal lung. New formulations of Inhaled corticosteroids that use hydrofluoroalkane (HFA) propellants can have smaller particle sizes (similar to1 mum). Extrafine HFA aerosols have better access to the distal lung, with less oropharyngeal deposition. Imaging studies suggest that anti-inflammatory medication delivered as an extrafine aerosol produces beneficial changes in distal lung function. In one study, an HFA formulation of an inhaled corticosteroid reduced air trapping to a greater degree than a CFC formulation of the same corticosteroid. By extending the delivery of anti-inflammatory medication to the distal lung, the new HFA-based corticosteroids have the potential to treat asthma more effectively and at reduced steroid doses.	Natl Jewish Med & Res Ctr, Dept Med, Div Pulm, Denver, CO 80206 USA	Martin, RJ (reprint author), Natl Jewish Med & Res Ctr, Dept Med, Div Pulm, 1400 Jackson St, Denver, CO 80206 USA.						AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; ALLEN DB, 1994, J ALLERGY CLIN IMMUN, V93, P967, DOI 10.1016/S0091-6749(94)70043-5; ALMIND M, 1992, DAN MED BULL, V39, P561; Awadh N, 1998, THORAX, V53, P248; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; Barnes NC, 2000, THORAX, V55, P478, DOI 10.1136/thorax.55.6.478; Berman AR, 1996, AM J RESP CRIT CARE, V154, P418; BOGUNIEWICZ M, 2001, WORLD ASTHM M JUL 13; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; British Thoracic Society, 1997, THORAX S5, V52, P1; Busse WW, 1999, J ALLERGY CLIN IMMUN, V104, P1215; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Casale TB, 2001, CLIN DRUG INVEST, V21, P755, DOI 10.2165/00044011-200121110-00003; CHAPLIN MD, 1980, CLIN PHARMACOL THER, V27, P402; Corren J, 2001, ANN ALLERG ASTHMA IM, V87, P405; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; Gelb AF, 2000, AM J RESP CRIT CARE, V162, P1778; Gelb AF, 1998, AM J RESP CRIT CARE, V158, P815; Goldin JG, 1998, RADIOLOGY, V208, P321; GOLDIN JG, 1999, J ALLERGY CLIN IMM S, V104, P258; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; HARDING SM, 1990, RESP MED, V84, P25, DOI 10.1016/S0954-6111(08)80004-2; Howarth P, 1998, Int J Clin Pract Suppl, V96, P15; in 't Veen Johannes C. C. M., 2000, American Journal of Respiratory and Critical Care Medicine, V161, P1902; Irvin CG, 2000, AM J RESP CRIT CARE, V161, P50; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laurent F, 2000, EUR RADIOL, V10, P1404, DOI 10.1007/s003300000504; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Leach CL, 1998, RESP MED, V92, P3, DOI 10.1016/S0954-6111(98)90211-6; MARTIN RJ, 1991, AM REV RESPIR DIS, V143, P351; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; National Asthma Education and Prevention Program, 1997, NIH PUBL, V97-4051; NEWMAN SP, 1981, THORAX, V36, P52, DOI 10.1136/thx.36.1.52; PATEL P, 1990, AM REV RESPIR DIS, V141, P357; PAVORD I, 1993, CLIN PHARMACOKINET, V25, P126; PEDERSEN S, 1994, EUR RESPIR REV, V17, P33; Pickering H, 2000, CLIN THER, V22, P1483, DOI 10.1016/S0149-2918(00)83046-5; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Richards J, 2001, J AEROSOL MED, V14, P197, DOI 10.1089/08942680152484126; Rohatagi S, 1996, J CLIN PHARMACOL, V36, P938; Rohatagi S, 1995, J CLIN PHARMACOL, V35, P1187; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138; Selvadurai H, 2000, Paediatr Drugs, V2, P367, DOI 10.2165/00128072-200002050-00004; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Soria I, 1998, BIOPHARM DRUG DISPOS, V19, P297, DOI 10.1002/(SICI)1099-081X(199807)19:5<297::AID-BDD105>3.0.CO;2-I; Storms W, 2001, CLIN EXP ALLERGY, V31, P77, DOI 10.1046/j.1365-2222.2001.00969.x; Synek M, 1996, AM J RESP CRIT CARE, V154, P224; TAKISHIMA T, 1988, TOHOKU J EXP MED, V156, P99, DOI 10.1620/tjem.156.99; Thien F, 2000, Aust Fam Physician, V29, P547; Thompson PJ, 1998, AM J RESP CRIT CARE, V157, pS199; TINKELMAN DG, 1993, PEDIATRICS, V92, P64; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403; Villareal MS, 1996, ANN ALLERG ASTHMA IM, V76, P369; Virchow JC, 2000, AM J RESP CRIT CARE, V162, P578; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; Wilson AM, 2001, CHEST, V119, P1021, DOI 10.1378/chest.119.4.1021; ZANEN P, 1995, INT J PHARM, V114, P111, DOI 10.1016/0378-5173(94)00224-S; 2000, RESP CARE, V45, P586	71	83	87	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2002	109	2		S			S447	S460		10.1067/mai.2002.121409		14	Allergy; Immunology	Allergy; Immunology	529VQ	WOS:000174322000001	11842317	
J	Tanaka, H; Masuda, T; Tokuoka, S; Komai, M; Nagao, K; Takahashi, Y; Nagai, H				Tanaka, H; Masuda, T; Tokuoka, S; Komai, M; Nagao, K; Takahashi, Y; Nagai, H			The effect of allergen-induced airway inflammation on airway remodeling in a murine model of allergic asthma	INFLAMMATION RESEARCH			English	Article						airway inflammation; bronchial hyperresponsiveness; goblet cells; subepithelial fibrosis; TGF-beta 1	GROWTH-FACTOR-BETA; BRONCHIAL HYPERRESPONSIVENESS; PULMONARY FIBROSIS; CELL HYPERPLASIA; EXPRESSION; MICE; COLLAGEN; EXPOSURE; RESPONSIVENESS; METHACHOLINE	Objective and design: We examined the effect of airway inflammation on airway remodeling and bronchial responsiveness in a mouse model of allergic asthma. Materials and methods: BALB/c mice were sensitized to ovalbumin (OA), and exposed to aerosolized OA (0.01, 0.1 and 1%). Twenty-four hours after the final antigen challenge, bronchial responsiveness was measured, and bronchoalveolar lavage (BAL) and histological examinations were carried out. Results: Repeated antigen exposure induced airway inflammation, IgE/IgG1 responses, epithelial changes, collagen deposition in the lungs, subepithelial fibrosis associated with increases in the amount of transforming growth factor (TGF)-beta1 in BAL fluid (BALF), and bronchial hyperresponsiveness to acetylcholine. The number of eosinophils in BALF was significantly correlated with TGF-beta1 production in BALF and the amount of hydroxyproline. Furthermore, significant correlations were found between these fibrogenic parameters and the bronchial responsiveness. Conclusion: These findings demonstrated that in this murine model airway eosinophilic inflammation is responsible for the development of airway remodeling as well as bronchial hyperresponsiveness in allergic bronchial asthma.	Gifu Pharmaceut Univ, Dept Pharmacol, Gifu 5028585, Japan	Nagai, H (reprint author), Gifu Pharmaceut Univ, Dept Pharmacol, 5-6-1 Mitahora Higashi, Gifu 5028585, Japan.						AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; Cui ZH, 1999, ALLERGY, V54, P1074, DOI 10.1034/j.1398-9995.1999.00133.x; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; EBINA M, 1973, AM REV RESPIR DIS, V48, P720; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; GAULDIE J, 1993, THORAX, V48, P931, DOI 10.1136/thx.48.9.931; Haneda K, 1999, AM J RESP CELL MOL, V21, P268; HEARD BE, 1973, J PATHOL, V110, P319, DOI 10.1002/path.1711100406; Hoshino M, 1998, THORAX, V53, P21; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; KIVIRIKKO KI, 1967, ANAL BIOCHEM, V19, P249, DOI 10.1016/0003-2697(67)90160-1; LAIHO M, 1989, CANCER RES, V49, P2533; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; MAGNAN A, 1994, THORAX, V49, P789, DOI 10.1136/thx.49.8.789; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; MORI H, 1995, JPN J PHARMACOL, V67, P279, DOI 10.1254/jjp.67.279; Nagai H, 1997, CLIN EXP ALLERGY, V27, P218; Nagai Hiroichi, 1993, Life Sciences, V53, P243; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; PADRID P, 1995, AM J RESP CRIT CARE, V151, P184; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; ROCHE WR, 1989, LANCET, V1, P520; Tanaka H, 1998, LIFE SCI, V62, P169; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temelkovski J, 1998, THORAX, V53, P849; VARGA J, 1987, BIOCHEM J, V247, P597; YAMAGUCHI S, 1994, LIFE SCI, V54, P471; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	36	83	86	0	2	BIRKHAUSER VERLAG AG	BASEL	VIADUKSTRASSE 40-44, PO BOX 133, CH-4010 BASEL, SWITZERLAND	1023-3830			INFLAMM RES	Inflamm. Res.	DEC	2001	50	12					616	624		10.1007/PL00000243		9	Cell Biology; Immunology	Cell Biology; Immunology	508WB	WOS:000173111800007	11822788	
J	Walters, DM; Breysse, PN; Wills-Karp, M				Walters, DM; Breysse, PN; Wills-Karp, M			Ambient urban Baltimore particulate-induced airway hyperresponsiveness and inflammation in mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollution; allergy; asthma; inflammation	DIESEL EXHAUST PARTICLES; RESPIRATORY-DISEASE; LUNG INJURY; POLLUTION; METALS; HYPERREACTIVITY; EXPRESSION	Airborne particulate matter (PM) is hypothesized. to play a role in increases in asthma prevalence, although a causal relationship has yet to be established. To investigate the effects of real-world PM exposure on airway reactivity (AHR) and bronchoalveolar lavage (BAL) cellularity, we exposed naive mice to a single dose (0.5 mg/ mouse) of ambient PM, coal fly ash, or diesel PM. We found that ambient PM exposure induced increases in AHR and BAL cellularity, whereas diesel PM induced significant increases in BAL cellularity, but not AHR. On the other hand, coal fly ash exposure did not elicit significant changes in either of these parameters. We further examined ambient PM-induced temporal changes in AHR, BAL cells, and lung cytakine levels over a 2-wk period. Ambient PM-induced AHR was sustained over 7 d. The increase in AHR was preceded by dramatic increases in BAL eosinophils, whereas a decline in AHR was associated with increases. in macrophages. A Th2 cytokine pattern (IL-5, IL-13, eotaxin) was observed early on with a shift toward a Th1 pattern (IFN-gamma). In additional studies, we found that the active component(s) of ambient PM are not water-soluble and that ambient PM-induced AHR and inflammation are dose-dependent. We conclude that ambient PM can induce asthmalike parameters in naive mice, suggesting that PM exposure may be an important factor in increases in asthma prevalence.	Childrens Hosp, Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; Johns Hopkins Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Wills-Karp, M (reprint author), Childrens Hosp, Med Ctr, Div Immunobiol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.			Walters, Dianne/0000-0003-3888-2646	NIEHS NIH HHS [P01 ES-09606, P30 ES-03819]		ABBEY DE, 1993, ARCH ENVIRON HEALTH, V48, P33; AUST S D, 1985, Journal of Free Radicals in Biology and Medicine, V1, P3, DOI 10.1016/0748-5514(85)90025-X; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DREHER KL, 1997, TOXICOL ENV HLTH, V50, P285; Evans R, 1987, CHEST S, V91, P65; Foster WM, 2001, J APPL PHYSIOL, V90, P1111; Gavett SH, 1997, ENVIRON RES, V72, P162, DOI 10.1006/enrs.1997.3732; Ghio AJ, 1999, INHAL TOXICOL, V11, P37, DOI 10.1080/089583799197258; HINDS WC, 1982, AEROSOL TECHNOLOGY P, P83; LEVITT RC, 1988, FASEB J, V2, P2605; MOORE ME, 1993, ENVIRON SCI TECHNOL, V27, P1842, DOI 10.1021/es00046a012; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; OBERDORSTER G, 1992, EXP LUNG RES, V18, P87, DOI 10.3109/01902149209020653; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263; Pritchard RJ, 1996, INHAL TOXICOL, V8, P457, DOI 10.3109/08958379609005440; SCHWARTZ J, 1993, ENVIRON RES, V62, P7, DOI 10.1006/enrs.1993.1083; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; WILLSKARP MA, 1909, IN VIVO MODELS INFLA, P137	24	83	83	0	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 15	2001	164	8					1438	1443				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	494WW	WOS:000172309700022	11704592	
J	Malo, JL; Chan-Yeung, M				Malo, JL; Chan-Yeung, M			Occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						asthma; occupational asthma; irritant-induced asthma; reactive airways dysfunction syndrome	WESTERN RED CEDAR; AIRWAYS DYSFUNCTION SYNDROME; ISOCYANATE-INDUCED ASTHMA; TOLUENE DIISOCYANATE TDI; MOLECULAR-WEIGHT AGENTS; EXHALED NITRIC-OXIDE; HLA CLASS-II; BRONCHIAL-MUCOSA; IGE ANTIBODIES; ADULT ASTHMA	The workplace can be responsible for approximately one in 10 cases of adult-onset asthma. Two types of occupational asthma (OA) are distinguished by whether they arise after a latency period that is necessary for acquiring sensitization or as a result of acute exposure to irritant materials (irritant-induced asthma). The pathophysiology of OA with a latency period is similar to that of nonoccupational asthma, whereas the mechanism of irritant-induced asthma is still uncertain. HLA haplotypes and other genetic polymorphisms have been found to be associated with OA. According to various sources of data, the overall frequency of OA has remained stable in the last 10 years, although the frequency of causal agents vary. Registers of causal occupations and agents have been issued on Web sites (eg, www.asmanet.com). Improved sampling methods have shown that the degree of exposure plays a key role in the onset of the disease, whereas prospective data collected in high-risk workplaces have also identified personal risk factors (eg, atopy, smoking, and rhinoconjunctivitis). A diagnosis of OA should no longer be based on a compatible history only but should be confirmed by means of objective testing. Once the diagnosis is confirmed, the worker should be removed from exposure, and satisfactory compensation programs should be offered, the most important being retraining programs with financial compensations because affected workers are generally young. The cost-effectiveness of prevention programs in high-risk workforces should be assessed.	Hop Sacre Coeur, Dept Resp Med, Montreal, PQ H4J 1C5, Canada; Univ British Columbia, Vancouver Gen Hosp, Dept Med, Vancouver, BC V5Z 1M9, Canada	Malo, JL (reprint author), Hop Sacre Coeur, Dept Resp Med, 5400 W Gouin Blvd, Montreal, PQ H4J 1C5, Canada.						AGLUS RM, 1991, ANN OCCUP HYG, V35, P129; ARCHAMBAULT S, IN PRESS JALLERGY CL; Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; Becklake M, 1999, ASTHMA WORKPLACE, P27; BENTLEY A M, 1991, Journal of Allergy and Clinical Immunology, V87, P246, DOI 10.1016/0091-6749(91)91710-B; BERNSTEIN DI, 1999, ASTHMA WORKPLACE, P145; Bernstein IL, 1999, ASTHMA WORKPLACE; Bernstein JA, 1999, J ALLERGY CLIN IMMUN, V103, P1153, DOI 10.1016/S0091-6749(99)70192-2; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BOULET LP, 1994, EUR RESPIR J, V7, P1567, DOI 10.1183/09031936.94.07091567; Burge PS, 1999, ASTHMA WORKPLACE, P193; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BUTCHER BT, 1979, J ALLERGY CLIN IMMUN, V64, P655, DOI 10.1016/0091-6749(79)90031-9; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CARTIER A, 1999, ASTHMA WORKPLACE, P211; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434; CHANYEUNG M, 1993, AM REV RESPIR DIS, V147, P1056; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CHANYEUNG M, 1980, J ALLERGY CLIN IMMUN, V65, P333, DOI 10.1016/0091-6749(80)90209-2; Chan-Yeung M., 1999, ASTHMA WORKPLACE, P129; CHITANO P, 1994, EUR J PHARM-ENVIRON, V270, P167, DOI 10.1016/0926-6917(94)90059-0; COTE J, 1990, AM REV RESPIR DIS, V141, P373; DALFONSO S, 1997, 12 INT HIST WORKSH C, P167; DEWITTE JD, 1994, EUR RESPIR J, V7, P969; FABBRI LM, 1988, AM REV RESPIR DIS, V137, P1494; FINOTTO S, 1991, BRIT J IND MED, V48, P116; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340; FREW AJ, 1993, J ALLERGY CLIN IMMUN, V91, P219; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899; Gautrin D, 1999, ASTHMA WORKPLACE, P565; GAUTRIN D, IN PRESS EUR RESP J; Graham C, 1997, REGUL TOXICOL PHARM, V26, P296, DOI 10.1006/rtph.1997.1170; Grammer L, 1998, CHEST, V114, P1199, DOI 10.1378/chest.114.4.1199; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; Heederik D, 1999, OCCUP ENVIRON MED, V56, P735; HEEDERIK D, 1999, ASTHMA WORKPLACE, P377; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P323; Horne C., 2000, European Respiratory Journal, V15, P911, DOI 10.1034/j.1399-3003.2000.15e17.x; Houba R, 1998, AM J IND MED, V34, P529, DOI 10.1002/(SICI)1097-0274(199812)34:6<529::AID-AJIM1>3.0.CO;2-I; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; KAROL MH, 1980, CLIN ALLERGY, V10, P101, DOI 10.1111/j.1365-2222.1980.tb02086.x; KERWIN EM, 1993, J ALLERGY CLIN IMMUN, V91, P235; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; LESAGE J, 1999, ASTHMA WORKPLACE, P257; Liss GM, 2000, AM J RESP CRIT CARE, V162, P112; LOW B, 1988, TISSUE ANTIGENS, V32, P224; MAESTRELLI P, 1993, J ALLERGY CLIN IMMUN, V91, P220; Malo JL, 2000, CHEST, V118, P1232, DOI 10.1378/chest.118.5.1232; Malo JL, 1996, AM J RESP CRIT CARE, V153, P953; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1988, AM REV RESPIR DIS, V138, P807; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P1121, DOI 10.1016/0091-6749(93)90313-5; MAPP CE, 1990, EUR J PHARMACOL, V180, P113, DOI 10.1016/0014-2999(90)90598-Z; MAPP CE, 2000, EUR RES J S31, V16, pS329; McDonald JC, 2000, OCCUP ENVIRON MED, V57, P823, DOI 10.1136/oem.57.12.823; MCDONALD JC, 1995, BRIT MED J, P325; Meredith S, 1996, THORAX, V51, P435, DOI 10.1136/thx.51.4.435; Monso E, 2000, AM J RESP CRIT CARE, V161, P1508; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; Newman Taylor Anthony J., 1999, American Journal of Respiratory and Critical Care Medicine, V160, P435; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; PEPYS J, 1999, ASTHMA WORKPLACE, P5; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; REED CE, 1999, ASTHMA WORKPLACE, P235; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.3.CO;2-T; SAETTA M, 1992, AM REV RESPIR DIS, V145, P169; SHIRAKAWA T, 1990, THORAX, V45, P267, DOI 10.1136/thx.45.4.267; Tarlo S M, 1998, Can Respir J, V5, P289; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; TARLO SM, 1989, CHEST, V96, P297, DOI 10.1378/chest.96.2.297; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; TSE KS, 1982, CLIN ALLERGY, V12, P249, DOI 10.1111/j.1365-2222.1982.tb02525.x; VENABLES KM, 1994, EUR RESPIR J, V7, P768, DOI 10.1183/09031936.94.07040768; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219	91	83	85	3	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2001	108	3					317	328		10.1067/mai.2001.116432		12	Allergy; Immunology	Allergy; Immunology	476FK	WOS:000171215400001	11544449	
J	Troutt, C; Levetin, E				Troutt, C; Levetin, E			Correlation of spring spore concentrations and meteorological conditions in Tulsa, Oklahoma	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						aerobiology; Cladosporium; basidiospores; ascospores; multiple regression	ENVIRONMENTAL-FACTORS; AIRBORNE; POPULATIONS; ALTERNARIA; RELEASE; ASTHMA	Different spore types are abundant in the atmosphere depending on the weather conditions. Ascospores generally follow precipitation, while spore types such as Atternaria and Cladosporium are abundant in dry conditions. This project attempted to correlate fungal spore concentrations with meteorological data from Tulsa, Oklahoma during May 1998 and May 1999, Air samples were collected and analyzed by the 12-traverse method. The spore types included were Cladosporium, Alternaria, Epicoccum, Curvularia, Pithomyces, Drechslera. smut spores, ascospores, basidiospores, and other spores. Weather variables included precipitation levels, temperature, dew point, air pressure. wind speed, wind direction and wind gusts. There were over 242.57 mm of rainfall in May 1999 and only 64.01 mm in May 1998. The most abundant spore types during May 1998 and May 1999 were Cladosporium, ascospores, and basidiospores. Results showed that there were significant differences in the dry-air spora between May 1998 and May 1999. There were twice as many Cladosporium in May 1998 as in May 1999; both ascospores and basidiospores showed little change. Multiple regression analysis was used to determine which meteorological variables influenced spore concentrations. Results showed that there was no single model for all spore types. Different combinations of factors were predictors of concentration for the various fungi examined: however. temperature and dew point seemed to be the most important meteorological factors.	Univ Tulsa, Fac Biol Sci, Tulsa, OK 74104 USA	Levetin, E (reprint author), Univ Tulsa, Fac Biol Sci, 600 S Coll Ave, Tulsa, OK 74104 USA.						BURGE HA, 1986, GRANA, V25, P143; Bush R K, 1989, J Allergy Clin Immunol, V84, P1120, DOI 10.1016/0091-6749(89)90167-X; Crotzer V., 1996, Aerobiologia, V12, P177, DOI 10.1007/BF02248147; CUTTEN AEC, 1988, NEW ZEAL MED J, V101, P361; Epton MJ, 1997, THORAX, V52, P528; Gadoury DM, 1998, PHYTOPATHOLOGY, V88, P902, DOI 10.1094/PHYTO.1998.88.9.902; Gottwald TR, 1997, PHYTOPATHOLOGY, V87, P1078, DOI 10.1094/PHYTO.1997.87.10.1078; HASNAIN SM, 1993, GRANA, V32, P184; HJELMROOS M, 1993, GRANA, V32, P40; HORNER WE, 1992, CLIN REV ALLERG, V10, P191; Katial RK, 1997, INT J BIOMETEOROL, V41, P17, DOI 10.1007/s004840050048; LEVETIN E, 1991, GRANA, V30, P123; LEVETIN E, 1998, 13 C BIOM AER AM MET, P335; Levestin E., 1995, BIOAEROSOLS, P87; LI DW, 1994, GRANA, V33, P166; Richardson MJ, 1996, MYCOL RES, V100, P213; TARLO SM, 1979, J ALLERGY CLIN IMMUN, V64, P43, DOI 10.1016/0091-6749(79)90082-4; Timmer LW, 1998, PHYTOPATHOLOGY, V88, P1218, DOI 10.1094/PHYTO.1998.88.11.1218; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x	19	83	89	0	7	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0020-7128			INT J BIOMETEOROL	Int. J. Biometeorol.	JUL	2001	45	2					64	74		10.1007/s004840100087		11	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	457DX	WOS:000170122800003	11513049	
J	Cullinan, P; Cook, A; Nieuwenhuijsen, MJ; Sandiford, C; Tee, RD; Venables, KM; McDonald, JC; Taylor, AJN				Cullinan, P; Cook, A; Nieuwenhuijsen, MJ; Sandiford, C; Tee, RD; Venables, KM; McDonald, JC; Taylor, AJN			Allergen and dust exposure as determinants of work-related symptoms and sensitization in a cohort of flour-exposed workers; a case-control analysis	ANNALS OF OCCUPATIONAL HYGIENE			English	Article						sensitization; asthma; flour; alpha-amylase; bakers' asthma	BAKERS ASTHMA; MILLS	Objectives: To estimate the incidence of specific IgE sensitization and allergic respiratory symptoms among UK bakery and flour mill workers; and to examine the roles of flour aeroallergen and total dust exposures in determining these outcomes. Methods: A cohort of 300 new employees, without previous occupational exposure to flour, were followed prospectively for a median (range) of 40 (1-91) months. Cases-defined as those developing work-related symptoms or a positive skin prick test to hour or alpha -amylase during follow up-were compared with controls, matched for duration of employment. Exposures to hour aeroallergen and total inhalable dust were estimated using a questionnaire and personal sampling techniques. Results: Incidence rates for work-related eye/nose and chest symptoms were 11.8 and 4.1 cases per 100 person years (py), respectively. Few er employees developed positive skin prick tests to hour (2.2 cases per 100 py) or alpha -amylase (2.5 cases per 100 py), Positive skin tests to occupational allergens were more common among those with new work-related symptoms. There were clear relationships between the risks of developing work-related symptoms or a positive skin prick test and three categories of estimated exposure to total dust or hour aeroallergen. Atopic employees were more likely to develop a positive skin prick test-but not work-related symptoms, These findings were unaffected by age, sex or cigarette smoking. Conclusions: In this population, many work-related symptoms which develop after first employment in modern UK bakeries or hour mills were not accompanied by evidence of IgE sensitization to flour or alpha -amylase, Although average dust exposures were within current occupational standards, the risks of development of upper and lower respiratory symptoms and of specific sensitization were clearly related to total dust and/or flour aeroallergen exposure. The incidence of work-related chest symptoms in the presence of a positive skin test to flour or alpha -amylase in this setting was approximately 1 case per 100 py, (C) 2001 British Occupational Hygiene Society. Published by Elsevier Science Ltd, All rights reserved.	Univ London Imperial Coll Sci Technol & Med, NHLI, Dept Occupat & Environm Med, London SW3 6LR, England	Cullinan, P (reprint author), Univ London Imperial Coll Sci Technol & Med, NHLI, Dept Occupat & Environm Med, London SW3 6LR, England.		Nieuwenhuijsen, Mark/C-3914-2017	Nieuwenhuijsen, Mark/0000-0001-9461-7981			CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P579; Gordon SB, 1997, OCCUP MED-OXFORD, V47, P361, DOI 10.1093/occmed/47.6.361; HERXHEIMER H, 1973, ACTA ALLERGOL, V28, P42, DOI 10.1111/j.1398-9995.1973.tb02564.x; Houba R, 1996, AM J RESP CRIT CARE, V154, P130; HOUBA R, 1996, THESIS LANDBOUWUNIVE; MCDONALD JC, 2000, UNPUB OCCUPATIONAL E; NIEUWENHUIJSEN MJ, 1994, OCCUP ENVIRON MED, V51, P584; NIEUWENHUIJSEN MJ, 1995, ANN OCCUP HYG, V39, P291, DOI 10.1016/0003-4878(94)00127-M; Nieuwenhuijsen MJ, 1999, OCCUP ENVIRON MED, V56, P197; QUIRCE S, 1992, J ALLERGY CLIN IMMUN, V90, P970, DOI 10.1016/0091-6749(92)90470-M; Ross DJ, 1997, OCCUP MED-OXFORD, V47, P377, DOI 10.1093/occmed/47.6.377	11	83	84	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0003-4878			ANN OCCUP HYG	Ann. Occup. Hyg.	MAR	2001	45	2					97	103		10.1016/S0003-4878(00)00028-4		7	Public, Environmental & Occupational Health; Toxicology	Public, Environmental & Occupational Health; Toxicology	409HU	WOS:000167378900003	11182423	
J	Huang, TJ; MacAry, PA; Eynott, P; Moussavi, A; Daniel, KC; Askenase, PW; Kemeny, DM; Chung, KF				Huang, TJ; MacAry, PA; Eynott, P; Moussavi, A; Daniel, KC; Askenase, PW; Kemeny, DM; Chung, KF			Allergen-specific Th1 cells counteract efferent Th2 cell-dependent bronchial hyperresponsiveness and eosinophilic inflammation partly via IFN-gamma	JOURNAL OF IMMUNOLOGY			English	Article							BROWN-NORWAY RATS; INDUCED AIRWAY HYPERRESPONSIVENESS; CD4+ T-CELLS; INTERFERON-GAMMA; IGE PRODUCTION; ATOPIC ASTHMA; SMOOTH-MUSCLE; MESSENGER-RNA; CUTTING EDGE; MURINE MODEL	Th2 T cell immune-driven inflammation plays an important role in allergic asthma, We studied the effect of counterbalancing Th1 T cells in an asthma model in Brown Norway rats that favors Th2 responses. Rats received i.v. transfers of syngeneic allergen-specific Th1 or Th2 cells, 24 h before aerosol exposure to allergen, and were studied 18-24 h later. Adoptive transfer of OVA-specific Th2 cells, but not Th1 cells, and OVA, but not BSA exposure, induced bronchial hyperresponsiveness (BHR) to acetylcholine and eosinophilia in a cell number-dependent manner. Importantly, cotransfer of OVA-specific Th1 cells dose-dependently reversed BHR and bronchoalveolar lavage (BAL) eosinophilia, but not mucosal eosinophilia, OVA-specific Th1 cells transferred alone induced mucosal eosinophilia, but neither BHR nor BAL eosinophilia. Th1 suppression of BHR and BAL eosinophilia was allergen specific, since cotransfer of BSA-specific Th1 cells with the OVA-specific Th2 cells was not inhibitory when OVA aerosol alone was used, but was suppressive with OVA and BSA challenge, Furthermore, recipients of Th1 cells alone had increased gene expression for IFN-gamma in the Lungs, while those receiving Th2 cells alone showed increased IL-4 mRNA, Importantly, induction of these Th2 cytokines was inhibited in recipients of combined Th1 and Th2 tells. Anti-IFN-gamma treatment attenuated the down-regulatory effect of Th1 cells. Allergen-specific Th1 cells down-regulate efferent Th2 cytokine-dependent BHR and BAL eosinophilia in an asthma model via mechanisms that depend on IFN-gamma, Therapy designed to control the efferent phase of established asthma by augmenting down-regulatory Th1 counterbalancing mechanisms should be effective.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; Chang Gung Mem Hosp, Keelung, Taiwan; Univ London Kings Coll, Sch Med & Dent, Dept Immunol, London, England	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BARNES PJ, 1986, LANCET, V1, P242; Broide D, 1998, J IMMUNOL, V161, P7054; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cohn L, 1998, J IMMUNOL, V161, P3813; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; COYLE AJ, 1995, AM J RESP CELL MOL, V13, P54; DIJKEMA R, 1985, EMBO J, V4, P761; ELWOOD W, 1992, AM REV RESPIR DIS, V145, P1289; ELWOOD W, 1991, J ALLERGY CLIN IMMUN, V88, P951, DOI 10.1016/0091-6749(91)90253-K; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; FLAVAHAN NA, 1988, AM REV RESPIR DIS, V138, P685; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GOODMAN RE, 1992, BIOCHEM BIOPH RES CO, V189, P1, DOI 10.1016/0006-291X(92)91516-S; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HACZKU A, 1995, IMMUNOLOGY, V85, P598; Haczku A, 1997, IMMUNOLOGY, V91, P176, DOI 10.1046/j.1365-2567.1997.d01-2221.x; Haczku A, 1996, IMMUNOLOGY, V88, P247, DOI 10.1111/j.1365-2567.1996.tb00011.x; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Hogan SP, 1997, IMMUNOL CELL BIOL, V75, P284, DOI 10.1038/icb.1997.43; Huang TJ, 1999, IMMUNOLOGY, V98, P280; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kim G, 1998, J IMMUNOL, V161, P6993; Kim TS, 1997, J IMMUNOL, V158, P4137; Kline JN, 1998, J IMMUNOL, V160, P2555; Kumar V, 1998, J IMMUNOL, V161, P6585; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Li L, 1998, J IMMUNOL, V161, P3128; MacAry PA, 1998, J IMMUNOL, V160, P580; MCKNIGHT AJ, 1991, EUR J IMMUNOL, V21, P1187, DOI 10.1002/eji.1830210514; Mishima H, 1998, AM J RESP CRIT CARE, V158, P1863; NOBLE A, 1993, IMMUNOLOGY, V79, P562; NOBLE A, 1995, J IMMUNOL, V155, P2928; NOBLE A, 1993, IMMUNOLOGY, V80, P326; PAUWELS R, 1979, IMMUNOLOGY, V36, P151; PROUVOSTDANON A, 1981, J IMMUNOL, V126, P699; Randolph DA, 1999, J IMMUNOL, V162, P2375; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; SIEGLING A, 1994, J IMMUNOL METHODS, V177, P23, DOI 10.1016/0022-1759(94)90139-2; SUN J, 1994, INT ARCH ALLERGY IMM, V104, P291; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; VANTOORENENBERGEN AW, 1983, SCAND J IMMUNOL, V17, P13; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yeung VP, 1998, J IMMUNOL, V161, P4146; YI Q, 1994, J IMMUNOL, V153, P3353	52	83	90	0	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JAN 1	2001	166	1					207	217				11	Immunology	Immunology	385PG	WOS:000166012400027	11123294	
J	Cullinan, P; Harris, JM; Taylor, AJN; Hole, AM; Jones, M; Barnes, F; Jolliffe, G				Cullinan, P; Harris, JM; Taylor, AJN; Hole, AM; Jones, M; Barnes, F; Jolliffe, G			An outbreak of asthma in a modern detergent factory	LANCET			English	Article							ENZYMES	The striking decrease in the occurrence of protease-induced occupational asthma in the detergent industry has been attributed to enzyme encapsulation. We report an outbreak of asthma, at least equal in sire to those reported in the 1960s, in a modern European factory which has exclusively used encapsulated enzymes. A survey revealed that enzyme sensitisation and work-related respiratory symptoms were positively correlated with airborne enzyme exposure. We suggest that encapsulation alone is insufficient to prevent enzyme-induced allergy and asthma.	Imperial Coll Sch Med, Dept Occupat & Environm Med, London SW3 6LR, England	Cullinan, P (reprint author), Imperial Coll Sch Med, Dept Occupat & Environm Med, London SW3 6LR, England.						BELIN L, 1970, LANCET, V2, P1153; FLINDT MLH, 1969, LANCET, V1, P1177; JUNIPER CP, 1977, J SOC OCCUP MED, V27, P3; PERDU D, 1992, REV MAL RESPIR, V9, P443; Sarlo K, 1997, J ALLERGY CLIN IMMUN, V100, P480	5	83	83	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1899	1900		10.1016/S0140-6736(00)03264-5		2	Medicine, General & Internal	General & Internal Medicine	379WD	WOS:000165665400016	11130389	
J	Platts-Mills, TAE; Vaughan, JW; Carter, MC; Woodfolk, JA				Platts-Mills, TAE; Vaughan, JW; Carter, MC; Woodfolk, JA			The role of intervention in established allergy: Avoidance of indoor allergens in the treatment of chronic allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; indoor allergens; intervention	HOUSE-DUST MITE; FEL-D-I; PARTICLE-SIZE DISTRIBUTION; PLACEBO-CONTROLLED TRIAL; AIRBORNE CAT ALLERGEN; INNER-CITY CHILDREN; ASTHMATIC-CHILDREN; COCKROACH ALLERGEN; VACUUM CLEANERS; REDUCE ALLERGEN	Avoidance of exposure to indoor allergens is an important element in the treatment of allergic disease. The results of several studies provide strong evidence in support of a role for allergen avoidance; however, strategies that optimize allergen reduction in houses have not been determined. Complex issues regarding the efficacy of physical and chemical measures that target house dust mite, pet, and cockroach allergens in the home are discussed. The greatest challenge is to educate allergic patients so that they can play an important role in controlling their own disease.	Univ Virginia, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA 22908 USA	Platts-Mills, TAE (reprint author), Univ Virginia, Dept Med, Div Asthma Allergy & Immunol, POB 801355, Charlottesville, VA 22908 USA.						AALBERSE RC, 1983, J IMMUNOL, V130, P722; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; Arlian LG, 1999, J MED ENTOMOL, V36, P457; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; BERMAN AR, 1995, J APPL PHYSIOL, V78, P1844; BERNTON H S, 1972, British Journal of Diseases of the Chest, V66, P61, DOI 10.1016/S0007-0971(72)80008-1; BONER AL, 1993, ALLERGY, V48, P119, DOI 10.1111/j.1398-9995.1993.tb04713.x; Bruijnzeel-Koomen CAFM, 1986, ARCH DERMATOL RES, V278, P199; BURR ML, 1980, THORAX, V35, P506, DOI 10.1136/thx.35.7.506; Butland BK, 1997, THORAX, V52, P618; Butland BK, 1997, BRIT MED J, V315, P717; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARTER MC, 1998, J ALLERGY CLIN IMMUN, V101, pS4; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; COCKRAN DG, 1995, EXPERIENTIA, V51, P561; Colloff M. J., 1990, Pesticide Outlook, V1, P3; COLLOFF MJ, 1986, CLIN ALLERGY, V16, P41, DOI 10.1111/j.1365-2222.1986.tb01952.x; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53; Custovic A, 1999, CLIN EXP ALLERGY, V29, P144; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DANA H, 1986, 2 YEARS MAST; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; Eggleston PA, 1999, J ALLERGY CLIN IMMUN, V104, P842; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Fitzharris P, 1999, CLIN EXP ALLERGY, V29, P429; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gotzsche PC, 1998, BRIT MED J, V317, P1105; GREEN WF, 1984, LANCET, V2, P160; GREEN WF, 1989, CLIN EXP ALLERGY, V19, P203, DOI 10.1111/j.1365-2222.1989.tb02365.x; HANLEY JT, 1994, INDOOR AIR, V4, P169, DOI 10.1111/j.1600-0668.1994.t01-1-00005.x; HAYDEN ML, 1992, J ALLERGY CLIN IMMUN, V89, P536, DOI 10.1016/0091-6749(92)90320-2; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hodson T, 1999, J ALLERGY CLIN IMMUN, V103, P581, DOI 10.1016/S0091-6749(99)70227-7; Horak F, 1995, Wien Med Wochenschr, V145, P1; Horsfield Margaret, 1997, BITING DUST JOYS HOU; Hughes A. M., 1976, MITES STORED FOOD HO; HULETT AC, 1979, ANN ALLERGY, V42, P160; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; KANG BC, 1988, J ASTHMA, V25, P205; Kern R., 1921, MED CLIN N AM, V5, P751; KERREBIJN KF, 1970, BRONCHITIS, V3, P38; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; KLUCKA CV, 1995, J ALLERGY CLIN IMMUN, V95, P1164, DOI 10.1016/S0091-6749(95)70072-2; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; KORSGAARD J, 1982, J ALLERGY CLIN IMMUN, V38, P93; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361; MACDONALD L, 1992, J ALLERGY CLIN IMMUN, V90, P599; Mason K, 1999, J ALLERGY CLIN IMMUN, V104, P499, DOI 10.1016/S0091-6749(99)70400-8; MCGREGOR PG, 1996, P NZ SOC PAR C 25 JU; Miller J. D., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81180-8; MITCHELL EB, 1982, LANCET, V1, P127; MITCHELL EB, 1985, CLIN ALLERGY, V15, P235, DOI 10.1111/j.1365-2222.1985.tb02280.x; MITCHELL EB, 1984, J INVEST DERMATOL, V83, P290, DOI 10.1111/1523-1747.ep12340423; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Munir A K, 1994, Pediatr Allergy Immunol, V5, P32, DOI 10.1111/j.1399-3038.1994.tb00216.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; NIH (National Institutes of Health), 1997, NIH PUBLICATION, V97-3981; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Perzanowski MS, 1997, J ALLERGY CLIN IMMUN, V100, P428, DOI 10.1016/S0091-6749(97)70261-6; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P441; Platts-Mills TAE, 1999, BRIT MED J, V318, P870; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Platts-Mills TAE, 1984, ASTHMA PHYSL IMMUNOP, P297; PLATTSMILLS TAE, 2000, J ALLERGY CLIN IMMUN, V105, P363; Prescott SL, 1998, J IMMUNOL, V160, P4730; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Ransom J. H., 1996, Journal of Allergy and Clinical Immunology, V97, P223, DOI 10.1016/S0091-6749(96)80382-4; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROST GA, 1932, ARCH DERMATOL SYPHIL, V155, P297; ROWNTREE S, 1985, ARCH DIS CHILD, V60, P727; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442; SHAW J, 1991, OVERWORKED AM UNEXPE, P83; SIMON HU, 1994, PEDIATR PULM, V17, P304, DOI 10.1002/ppul.1950170507; SLY RM, 1985, ANN ALLERGY, V54, P209; SMITH TF, 1985, J ALLERGY CLIN IMMUN, V76, P782, DOI 10.1016/0091-6749(85)90748-1; Spivacke CA, 1925, J IMMUNOL, V10, P465; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; Valles SM, 1999, COMP BIOCHEM PHYS C, V124, P227, DOI 10.1016/S0742-8413(99)00076-6; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; VANLEUWEN S, 1927, LANCET, V1, P1287; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; VOORHORST R, 1969, DERMATOPHAGOIDES PTE; VYSZENSKIMOHER DL, 2000, ANN ALLERG ASTHMA IM, V84, P136; WALSHAW MJ, 1986, Q J MED, V58, P199; WHARTON E, 1984, HOUSE MIRTH; WHARTON G W, 1977, Acarologia (Paris), V19, P112; WICKMAN M, 1993, AM REV RESPIR DIS, V148, P58; Williams LW, 1999, J ALLERGY CLIN IMMUN, V104, P702, DOI 10.1016/S0091-6749(99)70346-5; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115; WOODFOLK JA, 1995, J ALLERGY CLIN IMMUN, V96, P325, DOI 10.1016/S0091-6749(95)70051-X; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3; WOODFOLK JA, 1993, J ALLERGY CLIN IMMUN, V91, P829, DOI 10.1016/0091-6749(93)90339-H; YASUEDA H, 1990, INT ARCH ALLER A IMM, V90, P182	117	83	88	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					787	804		10.1067/mai.2000.110548		18	Allergy; Immunology	Allergy; Immunology	417ZK	WOS:000167865200001	11080699	
J	Nordenhall, C; Pourazar, J; Blomberg, A; Levin, JO; Sandstrom, T; Adelroth, E				Nordenhall, C; Pourazar, J; Blomberg, A; Levin, JO; Sandstrom, T; Adelroth, E			Airway inflammation following exposure to diesel exhaust: a study of time kinetics using induced sputum	EUROPEAN RESPIRATORY JOURNAL			English	Article						airway inflammation; diesel exhaust; induced sputum; neutrophils	EPITHELIAL-CELLS; HEALTHY-SUBJECTS; DAILY MORTALITY; POLLUTION; PARTICLES; INDUCTION; COUNTS; ASTHMA; INTERLEUKIN-6; ASSOCIATION	The adverse health effects of particulate matter pollution are of increasing concern. In a recent bronchoscopic study in healthy volunteers, pronounced airway inflammation was detected following exposure to diesel exhaust (DE), The present study was conducted in order to evaluate the time kinetics of the inflammatory response following exposure to DE using induced sputum from healthy volunteers. Fifteen healthy nonsmoking volunteers were exposed to DE particles,vith a 50% cut-off aerodynamic diameter of 10 mu m 300 mu g.m(-3) and air for 1 h on two separate occasions. Sputum induction with hypertonic saline was performed 6 and 24 h after each exposure. Analyses of sputum differential cell counts and soluble protein concentrations were performed. Six hours after exposure to DE, a significant increase was found in the percentage of sputum neutrophils (37.7 versus 26.2% p=0.002) together with increases in the concentrations of interleukin-6 (12.0 versus 6.3 pg.mL(-1), p=0.006) and methylhistamine (0.11 versus 0.12 mu g.L-1, p=0.024). Irrespective of exposure, a significant increase was found in the percentage of sputum neutrophils at 24 as compared to 6 h. indicating that the procedure of sputum induction itself may change the composition of sputum. This study demonstrates that exposure to diesel exhaust induces inflammatory response in healthy human airways, represented by an early increase in interleukin-6 and methylhistamine concentration and the percentage of neutrophils. Induced sputum provides a safe tool for the investigation of the inflammatory effects of diesel exhaust, but care must be taken when interpreting results from repeated sputum inductions.	Umea Univ Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden; Inst Working Life, Dept Occupat Chem, Umea, Sweden	Adelroth, E (reprint author), Umea Univ Hosp, Dept Resp Med & Allergy, S-90185 Umea, Sweden.						BARRY CC, 1994, ENVIRONMENT, V36, P5; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; CLENCHAAS J, 1996, QUANTIFICATION HLTH; DiazSanchez D, 1997, ALLERGY, V52, P52; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53; FAHY JV, 1994, J ALLERGY CLIN IMMUN, V93, P1031, DOI 10.1016/S0091-6749(94)70052-4; Fahy JV, 1995, ENVIRON RES, V70, P77, DOI 10.1006/enrs.1995.1051; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126; FLOREANI AA, 1995, AM J RESP CRIT CARE, V151, pA704; GAMBLE J, 1987, ENVIRON RES, V42, P201, DOI 10.1016/S0013-9351(87)80022-1; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1046/j.1365-2222.1997.890900.x; Holz O, 1998, THORAX, V53, P83; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; Nightingale JA, 1998, THORAX, V53, P87; OSTRO B, 1993, ARCH ENVIRON HEALTH, V48, P336; Pavord ID, 1997, THORAX, V52, P498; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; Pizzichini MMM, 1996, AM J RESP CRIT CARE, V154, P866; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; *QUAL URB AIR REV, 1996, SOURC EM PRIM PART M, P37; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; REGER R, 1982, ANN OCCUP HYG, V26, P799, DOI 10.1093/annhyg/26.8.799; RUDELL B, 1994, INT ARCH OCC ENV HEA, V66, P77, DOI 10.1007/BF00383361; Rudell B, 1999, OCCUP ENVIRON MED, V56, P527; Rudell B, 1996, OCCUP ENVIRON MED, V53, P658; Rudell B, 1990, J AEROSOL SCI     S1, V21, P411; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12; SCHWARTZ J, 1993, AM J EPIDEMIOL, V137, P1136; Steerenberg PA, 1998, EXP LUNG RES, V24, P85; ULFVARSON U, 1991, AM J IND MED, V19, P283, DOI 10.1002/ajim.4700190303; Vagaggini B, 1996, EUR RESPIR J, V9, P1852, DOI 10.1183/09031936.96.09091852; VISTAL JJ, 1980, B NY ACAD MED, V56, P914	36	83	88	1	6	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUN	2000	15	6					1046	1051		10.1034/j.1399-3003.2000.01512.x		6	Respiratory System	Respiratory System	327KA	WOS:000087792000012	10885423	
J	D'Amato, G				D'Amato, G			Urban air pollution and plant-derived respiratory allergy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							DIESEL EXHAUST PARTICLES; POLLEN-RELATED ALLERGY; GRASS-POLLEN; EPITHELIAL-CELLS; OZONE EXPOSURE; IN-VITRO; MEDITERRANEAN AREA; PARIETARIA-JUDAICA; ASTHMA EPIDEMICS; NITROGEN-DIOXIDE		Azienda Osped Alta Special, Dept Chest Dis, Div Pneumol & Allergol, Naples, Italy	D'Amato, G (reprint author), Hosp A Cardarelli, Div Pneumol & Allergol, Via Rione Sirignano 10, I-80121 Naples, Italy.						ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; ANTO JM, 1986, LANCET, V2, P1096; Ball BA, 1996, J ALLERGY CLIN IMMUN, V98, P563, DOI 10.1016/S0091-6749(96)70090-8; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; COMTOIS P, 1991, AEROBIOLOGIA, V8, P144; COTTON P, 1993, JAMA-J AM MED ASSOC, V269, P3087, DOI 10.1001/jama.269.24.3087; D'Amato G, 1994, Monaldi Arch Chest Dis, V49, P406; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 1998, PULM PHARMACOL THER, V11, P369, DOI 10.1006/pupt.1999.0159; DAmato G, 1996, ANN ALLERG ASTHMA IM, V77, P147; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P566, DOI 10.1111/j.1365-2222.1994.tb00954.x; DAMATO G, 1989, J ALLERGY CLIN IMMUN, V83, P116, DOI 10.1016/0091-6749(89)90485-5; DAMATO G, 1991, ANN ALLERGY, V67, P421; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P210, DOI 10.1111/j.1365-2222.1994.tb00222.x; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; DAmato G, 1991, ALLERGENIC POLLEN PO; DAMATO G, 1998, CLIN ASTHMA REV, V2, P175; *DEP HLTH, 1995, COMEAP COMM MED EFF, P29; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; Devalia JL, 1997, ALLERGY, V52, P45; DiazSanchez D, 1997, ALLERGY, V52, P52; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; *DIES WORK GROUP, 1995, DIES EXH CRIT AN EM; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; FARRELL BP, 1979, AM REV RESPIR DIS, V119, P725; FEDER WA, 1990, ENVIRON EXP BOT, V30, P451, DOI 10.1016/0098-8472(90)90024-X; FOLINSBEE LJ, 1980, AM REV RESPIR DIS, V121, P431; Frew AJ, 1997, CLIN EXP ALLERGY, V27, P237; GarciaOrtega P, 1997, MED CLIN-BARCELONA, V108, P677; HACKNEY JD, 1977, J APPL PHYSIOL, V43, P82; HERNANDO L, 1989, LANCET, V1, P502; HOLGATE ST, 1998, AIR POLLUTION HLTH; HORVATH SM, 1981, AM REV RESPIR DIS, V123, P496; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KREIT JW, 1989, J APPL PHYSIOL, V66, P217; LLOYD W, 1907, HAY FEVER ITS CAUSES; Miyamoto T, 1991, NEW TRENDS ALLERGY, P459; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; *NIH, 1995, PUBL NIH; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; PELTRE G, 1991, GRANA, V30, P425; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; PLINIUS YOUNGER, COMMUNICATION; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; RING J, 1994, PROGR ALLERGY CLIN I, P174; RUDELL B, 1990, J AEROSOL SCI, V21, pS411; Salter HH, 1868, ASTHMA ITS PATHOLOGY; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; SCHENKER M, 1993, NEW ENGL J MED, V329, P1807, DOI 10.1056/NEJM199312093292410; Schwartz J, 1992, PUBLIC HLTH REV, V19, P39; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; Steerenberg PA, 1998, EXP LUNG RES, V24, P85; STOKINGER H E, 1956, AMA Arch Ind Health, V14, P158; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Thomas P., 1996, Journal of Allergy and Clinical Immunology, V97, P218, DOI 10.1016/S0091-6749(96)80361-7; *UN ENV PROGR WHO, 1994, ENVIRONMENT, V36, P5; VIEGI G, 1998, EUR RESPIR REV, V8, P1; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; Wallis D. N., 1995, European Respiratory Journal, V8, p500S; White MC, 1997, AM J EPIDEMIOL, V145, P432; Wichmann HE, 1996, CLIN EXP ALLERGY, V26, P621, DOI 10.1111/j.1365-2222.1996.tb00587.x; Woolcock AJ, 1997, CIBA F SYMP, V206, P122	84	83	85	0	12	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2000	30	5					628	636				9	Allergy; Immunology	Allergy; Immunology	314CU	WOS:000087037700005	10792353	
J	Eberlein-Konig, B; Schafer, T; Huss-Marp, J; Darsow, U; Mohrenschlager, M; Herbert, O; Abeck, D; Kramer, U; Behrendt, H; Ring, J				Eberlein-Konig, B; Schafer, T; Huss-Marp, J; Darsow, U; Mohrenschlager, M; Herbert, O; Abeck, D; Kramer, U; Behrendt, H; Ring, J			Skin surface pH, stratum corneum hydration, trans-epidermal water loss and skin roughness related to atopic eczema and skin dryness in a population of primary school children	ACTA DERMATO-VENEREOLOGICA			English	Article						skin morphology; epidemiological study; MIRIAM (Multicentre International Study for Risk Assessment of Indoor and Outdoor-Air Pollution on Allergy and Eczema Morbidity); non-invasive technologies; cutaneous properties	CLINICALLY UNINVOLVED SKIN; LOSS TEWL; DRY SKIN; DERMATITIS; PROFILOMETRY; CAPACITANCE; PARAMETERS	Non-invasive investigations of skin morphology and function are standard tools to study the pathophysiology of several cutaneous disorders, yet they have not been used in population-based epidemiological studies. Here we examined skin surface pH, stratum corneum hydration, trans-epidermal water loss (TEWL) and skin roughness by profilometry in a study population comprising 377 primary school children (8-9 years old) as part of a multicentre survey on risk factors for allergic diseases in school children. Skin surface pH showed significant higher values (p=0.029) in the group with atopic eczema (n=45) compared with the group without atopic eczema; all other parameters did not differ significantly between children,vith and without atopic eczema. With increasing skin dryness there was a significant increase in pH values (p = 0.004). Stratum corneum hydration showed a significant decrease with increasing dryness (p<0.001). Measurement of skin roughness also revealed a significant linear relationship with skin dryness (p = 0.02). It is concluded that measurement of skin surface pH, corneometry and profilometry are useful non-invasive techniques to objectively assess skin dryness in epidemiological studies regarding atopic skin disease.	Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Dept Dermatol & Allergy Biederstein, D-80802 Munich, Germany; GSF, TUM, Div Environm Dermatol & Allergol, Neuherberg, Germany	Eberlein-Konig, B (reprint author), Tech Univ Munich, Klin & Poliklin Dermatol & Allergol Biederstein, Dept Dermatol & Allergy Biederstein, Biedersteiner Str 29, D-80802 Munich, Germany.						ABE T, 1978, Journal of Dermatology (Tokyo), V5, P223; ABECK D, 1997, NEW TRENDS ALLERGY, V4, P213; BERARDESCA E, 1990, ACTA DERM-VENEREOL, V70, P400; BRAUNFALCO O, 1986, HAUTARZT, V37, P126; COOK TH, 1985, J SOC COSMET CHEM, V36, P143; Dikstein S, 1994, Acta Derm Venereol Suppl (Stockh), V185, P18; Eberlein-Konig B, 1998, J ALLERGY CLIN IMMUN, V101, P141, DOI 10.1016/S0091-6749(98)70212-X; EberleinKonig B, 1996, ACTA DERM-VENEREOL, V76, P447; Gfatter R, 1997, DERMATOLOGY, V195, P258; GLOOR M, 1985, J SOC COSMET CHEM, V36, P153; GOLLHAUSEN R, 1991, HDB ATOPIC ECZEMA, P306; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; HUSSMARP J, 1999, ALLERGO J, V8, P356; Leveque JL, 1987, J SOC COSMET CHEM, V82, P171; Linde Y W, 1992, Acta Derm Venereol Suppl (Stockh), V177, P9; LINDE YW, 1989, ACTA DERM-VENEREOL, V69, P315; LODEN M, 1992, BRIT J DERMATOL, V126, P137, DOI 10.1111/j.1365-2133.1992.tb07810.x; Marchionini A, 1938, KLIN WOCHENSCHR, V17, P663, DOI 10.1007/BF01778645; OHMAN H, 1994, ACTA DERM-VENEREOL, V74, P375; PINNAGODA J, 1990, CONTACT DERMATITIS, V22, P164, DOI 10.1111/j.1600-0536.1990.tb01553.x; PRZYBILLA B, 1991, ACTA DERM-VENEREOL, V71, P407; Ring J, 1998, ALLERGY AND ALLERGIC DISEASES, P481; RING J, 1992, ALLERGY, V47, P265, DOI 10.1111/j.1398-9995.1992.tb02051.x; Schafer T, 1997, BRIT J DERMATOL, V137, P558, DOI 10.1111/j.1365-2133.1997.tb03786.x; SCHIAVI ME, 1992, G INT DERM PED, V3, P119; Seidenari S, 1995, ACTA DERM-VENEREOL, V75, P429; TUPKER RA, 1990, BRIT J DERMATOL, V123, P199, DOI 10.1111/j.1365-2133.1990.tb01847.x; WERNER Y, 1986, ACTA DERM-VENEREOL, V66, P281; WERNER Y, 1985, ACTA DERM-VENEREOL, V65, P102; YAMAMOTO A, 1991, ARCH DERMATOL RES, V283, P219, DOI 10.1007/BF01106105	30	83	94	0	12	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0001-5555			ACTA DERM-VENEREOL	Acta Derm.-Venereol.	MAY	2000	80	3					188	191				4	Dermatology	Dermatology	338BW	WOS:000088399100008	10954209	
J	Bailey, LC; Forrest, CB; Zhang, PX; Richards, TM; Livshits, A; DeRusso, PA				Bailey, L. Charles; Forrest, Christopher B.; Zhang, Peixin; Richards, Thomas M.; Livshits, Alice; DeRusso, Patricia A.			Association of Antibiotics in Infancy With Early Childhood Obesity	JAMA PEDIATRICS			English	Article							INFECTIOUS-DISEASES SOCIETY; GUT MICROBIOME; OTITIS-MEDIA; BODY-MASS; MANAGEMENT; CHILDREN; DIAGNOSIS; AMERICA	IMPORTANCE Obesity in children and adults is associated with significant health burdens, making prevention a public health imperative. Infancy may be a critical period when environmental factors exert a lasting effect on the risk for obesity; identifying modifiable factors may help to reduce this risk. OBJECTIVE To assess the impact of antibiotics prescribed in infancy (ages 0-23 months) on obesity in early childhood (ages 24-59 months). DESIGN, SETTING, AND PARTICIPANTS We conducted a cohort study spanning 2001-2013 using electronic health records. Cox proportional hazard models were used to adjust for demographic, practice, and clinical covariates. The study spanned a network of primary care practices affiliated with the Children's Hospital of Philadelphia including both teaching clinics and private practices in urban Philadelphia, Pennsylvania, and the surrounding region. All children with annual visits at ages 0 to 23 months, as well 1 or more visits at ages 24 to 59 months, were enrolled. The cohort comprised 64 580 children. EXPOSURES Treatment episodes for prescribed antibiotics were ascertained up to 23 months of age. MAIN OUTCOMES AND MEASURES Obesity outcomes were determined directly from anthropometric measurements using National Health and Nutrition Examination Survey 2000 body mass index norms. RESULTS Sixty-nine percent of children were exposed to antibiotics before age 24 months, with a mean (SD) of 2.3 (1.5) episodes per child. Cumulative exposure to antibiotics was associated with later obesity (rate ratio [RR], 1.11; 95% CI, 1.02-1.21 for >= 4 episodes); this effect was stronger for broad-spectrum antibiotics (RR, 1.16; 95% CI, 1.06-1.29). Early exposure to broad-spectrum antibiotics was also associated with obesity (RR, 1.11; 95% CI, 1.03-1.19 at 0-5 months of age and RR, 1.09; 95% CI, 1.04-1.14 at 6-11 months of age) but narrow-spectrum drugs were not at any age or frequency. Steroid use, male sex, urban practice, public insurance, Hispanic ethnicity, and diagnosed asthma or wheezing were also predictors of obesity; common infectious diagnoses and antireflux medications were not. CONCLUSIONS AND RELEVANCE Repeated exposure to broad-spectrum antibiotics at ages 0 to 23 months is associated with early childhood obesity. Because common childhood infections were the most frequent diagnoses co-occurring with broad-spectrum antibiotic prescription, narrowing antibiotic selection is potentially a modifiable risk factor for childhood obesity.	[Bailey, L. Charles; Forrest, Christopher B.; Zhang, Peixin; Richards, Thomas M.; Livshits, Alice; DeRusso, Patricia A.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; [Bailey, L. Charles; Forrest, Christopher B.; DeRusso, Patricia A.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Richards, Thomas M.] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA	Bailey, LC (reprint author), Childrens Hosp Philadelphia, Div Oncol, CTRB 10407, 34th St & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	baileyc@email.chop.edu			American Beverage Foundation	Funding was provided by an unrestricted donation from the American Beverage Foundation for a Healthy America to the Children's Hospital of Philadelphia to support the Healthy Weight Program.	Ajslev TA, 2011, INT J OBESITY, V35, P522, DOI 10.1038/ijo.2011.27; Arnold SR, 2005, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD003539.PUB2; Bailey LC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066192; Bradley JS, 2011, CLIN INFECT DIS, V53, pE25, DOI 10.1093/cid/cir531; Cho I, 2012, NATURE, V488, P621, DOI 10.1038/nature11400; Cox LM, 2014, CELL, V158, P705, DOI 10.1016/j.cell.2014.05.052; Perez-Cobas AE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080201; Perez-Cobas AE, 2013, GUT, V62, P1591, DOI 10.1136/gutjnl-2012-303184; Institute of Medicine, 2011, EARL CHILDH OB PREV; Kuczmarski RJ, 2002, VITAL HLTH STAT, V11, P1; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Lieberthal AS, 2004, PEDIATRICS, V113, P1451; Ogden CL, 2002, JAMA-J AM MED ASSOC, V288, P1728, DOI 10.1001/jama.2012.40; Rosenfeld RM, 2004, PEDIATRICS, V113, P1412; Shulman ST, 2012, CLIN INFECT DIS, V55, P1279, DOI 10.1093/cid/cis847; Steinberger J, 2003, CIRCULATION, V107, P1448, DOI 10.1161/01.CIR.0000060923.07573.F2; Trasande L, 2013, INT J OBESITY, V37, P16, DOI 10.1038/ijo.2012.132; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vael C., 2011, GUT PATHOG, V23, P8, DOI DOI 10.1186/1757-4749-3-8	20	82	85	7	50	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2168-6203	2168-6211		JAMA PEDIATR	JAMA Pediatr.	NOV	2014	168	11					1063	1069		10.1001/jamapediatrics.2014.1539		7	Pediatrics	Pediatrics	AT1NS	WOS:000344701500021	25265089	
J	Hinds, DA; McMahon, G; Kiefer, AK; Do, CB; Eriksson, N; Evans, DM; St Pourcain, B; Ring, SM; Mountain, JL; Francke, U; Davey-Smith, G; Timpson, NJ; Tung, JY				Hinds, David A.; McMahon, George; Kiefer, Amy K.; Do, Chuong B.; Eriksson, Nicholas; Evans, David M.; St Pourcain, Beate; Ring, Susan M.; Mountain, Joanna L.; Francke, Uta; Davey-Smith, George; Timpson, Nicholas J.; Tung, Joyce Y.			A genome-wide association meta-analysis of self-reported allergy identifies shared and allergy-specific susceptibility loci	NATURE GENETICS			English	Article							DISEASE SUSCEPTIBILITY; ATOPIC-DERMATITIS; GENOTYPE DATA; RISK LOCI; T-CELLS; ASTHMA; POPULATION; VARIANTS; GENE; DIFFERENTIATION	Allergic disease is very common and carries substantial public-health burdens. We conducted a meta-analysis of genome-wide associations with self-reported cat, dust-mite and pollen allergies in 53,862 individuals. We used generalized estimating equations to model shared and allergy-specific genetic effects. We identified 16 shared susceptibility loci with association P < 5 x 10(-8), including 8 loci previously associated with asthma, as well as 4p14 near TLR1, TLR6 and TLR10 (rs2101521, P = 5.3 x 10(-21)); 6p21.33 near HLA-C and MICA (rs9266772, P = 3.2 x 10(-12)); 5p13.1 near PTGER4 (rs7720838, P = 8.2 x 10(-11)); 2q33.1 in PLCL1 (rs10497813, P = 6.1 x 10(-10)), 3q28 in LPP (rs9860547, P = 1.2 x 10(-9)); 20q13.2 in NFATC2 (rs6021270, P = 6.9 x 10(-9)), 4q27 in ADAD1 (rs17388568, P = 3.9 x 10(-8)); and 14q21.1 near FOXA1 and TTC6 (rs1998359, P = 4.8 x 10(-8)). We identified one locus with substantial evidence of differences in effects across allergies at 6p21.32 in the class II human leukocyte antigen (HLA) region (rs17533090, P = 1.7 x 10(-12)), which was strongly associated with cat allergy. Our study sheds new light on the shared etiology of immune and autoimmune disease.	[Hinds, David A.; Kiefer, Amy K.; Do, Chuong B.; Eriksson, Nicholas; Mountain, Joanna L.; Francke, Uta; Tung, Joyce Y.] 23andMe Inc, Mountain View, CA USA; [McMahon, George; Evans, David M.; Davey-Smith, George; Timpson, Nicholas J.] Univ Bristol, MRC, Ctr Causal Anal Translat Epidemiol, Sch Social & Community Med, Bristol, Avon, England; [St Pourcain, Beate; Ring, Susan M.] Univ Bristol, Sch Social & Community Med, Bristol, Avon, England	Hinds, DA (reprint author), 23andMe Inc, Mountain View, CA USA.	dhinds@23andMe.com	Fox, Laura /C-6249-2016; Osborne, Nicholas/N-4915-2015; Davey Smith, George/A-7407-2013	Osborne, Nicholas/0000-0002-6700-2284; Davey Smith, George/0000-0002-1407-8314; St Pourcain, Beate/0000-0002-4680-3517; Timpson, Nicholas/0000-0002-7141-9189; Evans, David/0000-0003-0663-4621	National Heart, Lung, and Blood Institute of the US National Institutes of Health [1R43HL115873-01]; UK MRC [74882]; Wellcome Trust [092731]	We thank the customers of 23andMe who answered surveys, as well as the employees of 23andMe, who together made this research possible. We also thank K. Nadeau for assistance in survey development and S. Nelson and R. Altman for reviewing surveys. This work was supported in part by the National Heart, Lung, and Blood Institute of the US National Institutes of Health under grant 1R43HL115873-01.; We are extremely grateful to all the families who took part in ALSPAC, to the midwives for their help in recruiting them and to the whole ALSPAC team, which includes interviewers, computer and laboratory technicians, clerical workers, research scientists, volunteers, managers, receptionists and nurses. The UK MRC (grant 74882), the Wellcome Trust (grant 092731) and the University of Bristol provide core support for ALSPAC.	Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534; Anderson CA, 2011, NAT GENET, V43, P246, DOI 10.1038/ng.764; Andiappan AK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019719; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bauer S, 1999, SCIENCE, V285, P727, DOI 10.1126/science.285.5428.727; Bonnelykke K, 2013, NAT GENET, V45, P902, DOI 10.1038/ng.2694; Browning SR, 2007, AM J HUM GENET, V81, P1084, DOI 10.1086/521987; Dubois PCA, 2010, NAT GENET, V42, P295, DOI 10.1038/ng.543; Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eriksson N, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000993; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Evans DM, 2011, NAT GENET, V43, P761, DOI 10.1038/ng.873; Fagnani C, 2008, TWIN RES HUM GENET, V11, P121, DOI 10.1375/twin.11.2.121; Falush D, 2003, GENETICS, V164, P1567; Ferreira MAR, 2011, LANCET, V378, P1006, DOI 10.1016/S0140-6736(11)60874-X; Ferrell PB, 2008, PHARMACOGENOMICS, V9, P1543, DOI 10.2217/14622416.9.10.1543; FISHER R. A., 1932, STAT METHODS RES WOR; Franke A, 2010, NAT GENET, V42, P1118, DOI 10.1038/ng.717; Fraser A, 2013, INT J EPIDEMIOL, V42, P97, DOI 10.1093/ije/dys066; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Halekoh U, 2006, J STAT SOFTW, V15, P1; Harris MB, 1999, MOL CELL BIOL, V19, P7264; Henn BM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034267; Hermann-Kleiter N, 2010, BLOOD, V115, P2989, DOI 10.1182/blood-2009-10-233585; Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, 2009, P NATL ACAD SCI USA, V106, P9362, DOI 10.1073/pnas.0903103106; Hinrichs AS, 2006, NUCLEIC ACIDS RES, V34, pD590, DOI 10.1093/nar/gkj144; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; HOWELL WM, 1995, THORAX, V50, P815, DOI 10.1136/thx.50.8.815; Howie B, 2012, NAT GENET, V44, P955, DOI 10.1038/ng.2354; Hunt KA, 2008, NAT GENET, V40, P395, DOI 10.1038/ng.102; Jin Y, 2010, NEW ENGL J MED, V362, P1686, DOI 10.1056/NEJMoa0908547; Kabashima K, 2003, NAT MED, V9, P744, DOI 10.1038/nm872; Karwot R, 2008, J ALLERGY CLIN IMMUN, V121, P992, DOI 10.1016/j.jaci.2007.12.1172; Karwot R, 2012, IMMUNOBIOLOGY, V217, P905, DOI 10.1016/j.imbio.2012.01.004; Kormann MSD, 2008, J ALLERGY CLIN IMMUN, V122, P86, DOI 10.1016/j.jaci.2008.04.039; Kurz T, 2006, J ALLERGY CLIN IMMUN, V118, P396, DOI 10.1016/j.jaci.2006.04.036; Kusam S, 2003, J IMMUNOL, V170, P2435; Li Y, 2010, GENET EPIDEMIOL, V34, P816, DOI 10.1002/gepi.20533; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Liao W, 2011, NAT IMMUNOL, V12, P551, DOI 10.1038/ni.2030; Libioulle C, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030058; LIn XN, 2005, J BIOL CHEM, V280, P12820, DOI 10.1074/jbc.M411591200; Martin AM, 2004, P NATL ACAD SCI USA, V101, P4180, DOI 10.1073/pnas.0307067101; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Park SW, 2009, AM J RESP CRIT CARE, V180, P603, DOI 10.1164/rccm.200811-1768OC; Paternoster L, 2012, NAT GENET, V44, P187, DOI 10.1038/ng.1017; Pereyra FP, 2010, SCIENCE, V330, P1551, DOI 10.1126/science.1195271; Plagnol V, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002216; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Ramasamy A, 2011, J ALLERGY CLIN IMMUN, V128, P996, DOI 10.1016/j.jaci.2011.08.030; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Schatz M, 1997, CLIN PERINATOL, V24, P407; Sleiman PMA, 2010, NEW ENGL J MED, V362, P36, DOI 10.1056/NEJMoa0901867; Smith HE, 2009, J ALLERGY CLIN IMMUN, V123, P646, DOI 10.1016/j.jaci.2008.11.005; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Strange A, 2010, NAT GENET, V42, P985, DOI 10.1038/ng.694; Sun LD, 2011, NAT GENET, V43, P690, DOI 10.1038/ng.851; Tantisira K, 2004, GENES IMMUN, V5, P343, DOI 10.1038/sj.gene.6364096; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Voorman A, 2012, BIOINFORMATICS, V28, P1818, DOI 10.1093/bioinformatics/bts291; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wan Yize I, 2011, J Allergy Clin Immunol, V127, P223, DOI 10.1016/j.jaci.2010.10.006; Ward LD, 2012, NUCLEIC ACIDS RES, V40, pD930, DOI 10.1093/nar/gkr917; Willemsen G, 2008, TWIN RES HUM GENET, V11, P132, DOI 10.1375/twin.11.2.132; Willer CJ, 2010, BIOINFORMATICS, V26, P2190, DOI 10.1093/bioinformatics/btq340; Yao CC, 2009, NAT MED, V15, P633, DOI 10.1038/nm.1968; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; Zeller T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010693	72	82	82	3	26	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1061-4036	1546-1718		NAT GENET	Nature Genet.	AUG	2013	45	8					907	U292		10.1038/ng.2686		7	Genetics & Heredity	Genetics & Heredity	190WW	WOS:000322374900014	23817569	
J	Rondon, C; Campo, P; Togias, A; Fokkens, WJ; Durham, SR; Powe, DG; Mullol, J; Blanca, M				Rondon, Carmen; Campo, Paloma; Togias, Alkis; Fokkens, Wytske J.; Durham, Stephen R.; Powe, Desmond G.; Mullol, Joaquim; Blanca, Miguel			Local allergic rhinitis: Concept, pathophysiology, and management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; eosinophil cationic protein; entopy; local allergic rhinitis; local specific IgE; nasal polyps; nonallergic rhinitis; nasal allergen provocation test; tryptase	PERSISTENT NONALLERGIC RHINITIS; IDIOPATHIC RHINITIS; PROVOCATION TEST; NASAL POLYPOSIS; IGE ANTIBODIES; MESSENGER-RNA; MAST-CELLS; ABSENCE; ASTHMA; ATOPY	Local allergic rhinitis (LAR) is a localized nasal allergic response in the absence of systemic atopy characterized by local production of specific IgE (sIgE) antibodies, a T(H)2 pattern of mucosal cell infiltration during natural exposure to aeroallergens, and a positive nasal allergen provocation test response with release of inflammatory mediators (tryptase and eosinophil cationic protein). Although the prevalence remains to be established, a number of patients previously given a diagnosis of nonallergic rhinitis or idiopathic rhinitis are now being classified as having LAR. Culprit allergens responsible include house dust mite, grass and olive pollens, and many others. For the diagnosis of LAR, neither skin prick testing nor determination of the presence of serum sIgE antibodies is useful, and a nasal allergen provocation test is needed to identify the culprit allergen or allergens. In a certain proportion of cases, local sIgE can be detected, and conjunctivitis, asthma, or both can be associated. Whether patients with LAR will have systemic atopy in the future is a matter of debate. Further studies are needed for examine the prevalence of this phenomenon in different areas, to improve the diagnostic methods to better identify these patients, and to develop therapeutic approaches, including the use of immunotherapy. (J Allergy Clin Immunol 2012;129:1460-7.)	[Rondon, Carmen; Campo, Paloma; Blanca, Miguel] Carlos Haya Hosp, Allergy Serv, Malaga, Spain; [Togias, Alkis] NIAID, Asthma Allergy & Inflammat Branch, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; [Fokkens, Wytske J.] Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, NL-1105 AZ Amsterdam, Netherlands; [Durham, Stephen R.] Imperial Coll Sch Med, Natl Heart & Lung Inst, London, England; [Powe, Desmond G.] Nottingham Trent Univ, John Van Geest Canc Res Ctr, Nottingham, England; [Powe, Desmond G.] Nottingham Trent Univ, Nottingham Univ Hosp NHS Trust, Queens Med Ctr, Dept Cellular Pathol, Nottingham, England; [Mullol, Joaquim] CIBERES, Hosp Clin IDIBAPS, ENT Dept, Rhinol Unit, Barcelona, Spain; [Mullol, Joaquim] CIBERES, Hosp Clin IDIBAPS, ENT Dept, Smell Clin, Barcelona, Spain	Rondon, C (reprint author), Hosp Civil, Lab Invest, Pabellon 5,Plaza Hosp Civil, Malaga 29009, Spain.	carmenrs61@gmail.com			GlaxoSmithKline; Medtronic	W. J. Fokkens has received research support from GlaxoSmithKline and Medtronic and has served as an advisor to GlaxoSmith Kline, MSD, and Stallergenes. The rest of the authors declare that they have no relevant conflicts of interest.	BLOM HM, 1995, EUR ARCH OTO-RHINO-L, V252, pS33, DOI 10.1007/BF02484432; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Campo P, 2011, J ALLERGY CLIN IMMUN, V127, pAB6, DOI 10.1016/j.jaci.2010.12.038; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Coker HA, 2003, J IMMUNOL, V171, P5601; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; HUGGINS KG, 1975, LANCET, V2, P148; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Lopez S, 2010, CLIN EXP ALLERGY, V40, P1007, DOI 10.1111/j.1365-2222.2010.03492.x; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Powe DG, 2010, J ALLERGY CLIN IMMUN, V125, P139, DOI 10.1016/j.jaci.2009.07.025; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; Powe DG, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Rondon C, 2008, ALLERGY, V63, P1352, DOI 10.1111/j.1398-9995.2008.01695.x; Rondon C, 2010, J INVEST ALLERG CLIN, V20, P364; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Rondon C, 2011, J ALLERGY CLIN IMMUN, V128, P1192, DOI 10.1016/j.jaci.2011.06.012; Rondon C, 2011, J ALLERGY CLIN IMMUN, V127, P1069, DOI 10.1016/j.jaci.2010.12.013; Rondon C, 2009, J ALLERGY CLIN IMMUN, V124, P1005, DOI 10.1016/j.jaci.2009.07.018; Rondon C, 2009, J ALLERGY CLIN IMMUN, V123, P1098, DOI 10.1016/j.jaci.2009.02.018; Sabirov A, 2008, LARYNGOSCOPE, V118, P4, DOI 10.1097/MLG.0b013e3181567a7a; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; van Rijswijk JB, 2003, RHINOLOGY, V41, P25; Van Zele T, 2007, CLIN EXP ALLERGY, V37, P1840, DOI 10.1111/j.1365-2222.2007.02838.x; Wedback A, 2005, RHINOLOGY, V43, P86	27	82	86	2	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1460	1467		10.1016/j.jaci.2012.02.032		8	Allergy; Immunology	Allergy; Immunology	952BL	WOS:000304764600004	22516477	
J	Royer, PJ; Emara, M; Yang, CX; Al-Ghouleh, A; Tighe, P; Jones, N; Sewell, HF; Shakib, F; Martinez-Pomares, L; Ghaemmaghami, AM				Royer, Pierre-Joseph; Emara, Mohamed; Yang, Chaoxing; Al-Ghouleh, Abeer; Tighe, Paddy; Jones, Nick; Sewell, Herb F.; Shakib, Farouk; Martinez-Pomares, Luisa; Ghaemmaghami, Amir M.			The Mannose Receptor Mediates the Uptake of Diverse Native Allergens by Dendritic Cells and Determines Allergen-Induced T Cell Polarization through Modulation of IDO Activity	JOURNAL OF IMMUNOLOGY			English	Article							INDOLEAMINE 2,3-DIOXYGENASE IDO; TRYPTOPHAN-METABOLITES; ANTIGEN PRESENTATION; EXPERIMENTAL ASTHMA; TH2 POLARIZATION; IL-4 PRODUCTION; RESPONSES; SUPPRESSION; INHIBITION; MATURATION	The mannose receptor (MR) is a C-type lectin expressed by dendritic cells (DCs). We have investigated the ability of MR to recognize glycosylated allergens. Using a gene silencing strategy, we have specifically inhibited the expression of MR on human monocyte-derived DCs. We show that MR mediates internalization of diverse allergens from mite (Der p 1 and Der p 2), dog (Can f 1), cockroach (Bla g 2), and peanut (Ara h 1) through their carbohydrate moieties. All of these allergens bind to the C-type lectin-like carbohydrate recognition domains 4-7 of MR. We have also assessed the contribution of MR to T cell polarization after allergen exposure. We show that silencing MR expression on monocyte-derived DCs reverses the Th2 cell polarization bias, driven by Der p 1 allergen exposure, through upregulation of IDO activity. In conclusion, our work demonstrates a major role for MR in glycoallergen recognition and in the development of Th2 responses. The Journal of Immunology, 2010, 185: 1522-1531.	[Royer, Pierre-Joseph; Emara, Mohamed; Yang, Chaoxing; Al-Ghouleh, Abeer; Tighe, Paddy; Sewell, Herb F.; Shakib, Farouk; Martinez-Pomares, Luisa; Ghaemmaghami, Amir M.] Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, Nottingham NG7 2UH, England; [Jones, Nick] Univ Nottingham, Queens Med Ctr, Div Otorhinolaryngol, Sch Clin Sci, Nottingham NG7 2UH, England; [Shakib, Farouk; Martinez-Pomares, Luisa; Ghaemmaghami, Amir M.] Univ Nottingham, Queens Med Ctr, Resp Biomed Res Unit, Nottingham NG7 2UH, England	Ghaemmaghami, AM (reprint author), Univ Nottingham, Queens Med Ctr, Sch Mol Med Sci, A Floor,West Block, Nottingham NG7 2UH, England.	luisa.m@nottingham.ac.uk; amg@nottingham.ac.uk	Emara, Mohamed/C-8220-2013; Royer, Pierre-Joseph/D-4768-2015	Royer, Pierre-Joseph/0000-0001-5534-7982; Emara, Mohamed/0000-0001-7708-9435; Martinez-Pomares, Luisa/0000-0002-2331-127X	Asthma U.K. [06/001]; Faculty of Pharmacy, Helwan University, Egypt	This work was supported by an Asthma U.K. Research Grant (06/001). M.E. is a recipient of a Ph.D. scholarship from the Faculty of Pharmacy, Helwan University, Egypt.	Braun D, 2005, BLOOD, V106, P2375, DOI 10.1182/blood-2005-03-0979; Burgdorf S, 2006, J IMMUNOL, V176, P6770; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Chieppa M, 2003, J IMMUNOL, V171, P4552; Chung DJ, 2009, BLOOD, V114, P555, DOI 10.1182/blood-2008-11-191197; Deslee G, 2002, J ALLERGY CLIN IMMUN, V110, P763, DOI 10.1067/mai.2002.129121; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gazi U, 2009, IMMUNOBIOLOGY, V214, P554, DOI 10.1016/j.imbio.2008.11.004; Guermonprez P, 2002, ANNU REV IMMUNOL, V20, P621, DOI 10.1146/annurev.immunol.20.100301.064828; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hattori T, 2009, IMMUNOGENETICS, V61, P731, DOI 10.1007/s00251-009-0403-x; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Hayashi T, 2007, P NATL ACAD SCI USA, V104, P18619, DOI 10.1073/pnas.0709261104; Hilmenyuk T, 2010, IMMUNOLOGY, V129, P437, DOI 10.1111/j.1365-2567.2009.03199.x; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Lamhamedi-Cherradi SE, 2008, J IMMUNOL, V180, P6000; Lee SJ, 2002, SCIENCE, V295, P1898, DOI 10.1126/science.1069540; Leteux C, 2000, J EXP MED, V191, P1117, DOI 10.1084/jem.191.7.1117; Li X, 2007, DNA SEQUENCE, V18, P190, DOI 10.1080/10425170701207166; MacDonald AS, 2008, J EXP MED, V205, P13, DOI 10.1084/jem.20072665; Maneachotesuwan K, 2009, J ALLERGY CLIN IMMUN, V123, P239, DOI 10.1016/j.jaci.2008.10.018; Mariani V, 2007, J IMMUNOL, V178, P7623; Martinez-Pomares Luisa, 2009, V531, P103, DOI 10.1007/978-1-59745-396-7_8; Mellor A, 2005, BIOCHEM BIOPH RES CO, V338, P20, DOI 10.1016/j.bbrc.2005.08.232; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Muller AJ, 2005, NAT MED, V11, P312, DOI 10.1038/nm1196; Nigou J, 2001, J IMMUNOL, V166, P7477; Odemuyiwa SO, 2009, ALLERGY, V64, P488, DOI 10.1111/j.1398-9995.2008.01809.x; Okamoto T, 2007, CYTOTECHNOLOGY, V54, P107, DOI 10.1007/s10616-007-9081-4; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Raitala A, 2006, MOL IMMUNOL, V43, P1054, DOI 10.1016/j.molimm.2005.06.022; Rubio MT, 2005, INT IMMUNOL, V17, P1561, DOI 10.1093/intimm/dxh335; Shakib F, 2008, TRENDS IMMUNOL, V29, P633, DOI 10.1016/j.it.2008.08.007; Shreffler WG, 2006, J IMMUNOL, V177, P3677; SMEDSROD B, 1990, BIOCHEM J, V271, P345; SMEDSROD B, 1990, THROMB HAEMOSTASIS, V63, P60; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Sun J, 2007, J IMMUNOL, V178, P1635; Taher YA, 2008, J ALLERGY CLIN IMMUN, V121, P983, DOI 10.1016/j.jaci.2007.11.021; TAKIKAWA O, 1988, J BIOL CHEM, V263, P2041; Tan MCAA, 1997, EUR J IMMUNOL, V27, P2426, DOI 10.1002/eji.1830270942; TAYLOR ME, 1992, J BIOL CHEM, V267, P1719; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Terness P, 2006, TRENDS IMMUNOL, V27, P68, DOI 10.1016/j.it.2005.12.006; Traidl-Hoffmann C, 2009, J ALLERGY CLIN IMMUN, V123, P558, DOI 10.1016/j.jaci.2008.12.003; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Xu H, 2008, P NATL ACAD SCI USA, V105, P6690, DOI 10.1073/pnas.0708809105; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737	49	82	84	2	14	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2010	185	3					1522	1531		10.4049/jimmunol.1000774		10	Immunology	Immunology	629EI	WOS:000280177400028	20610655	
J	Li, J; Sun, B; Huang, Y; Lin, X; Zhao, D; Tan, G; Wu, J; Zhao, H; Cao, L; Zhong, N				Li, J.; Sun, B.; Huang, Y.; Lin, X.; Zhao, D.; Tan, G.; Wu, J.; Zhao, H.; Cao, L.; Zhong, N.		CARRAD	A multicentre study assessing the prevalence of sensitizations in patients with asthma and/or rhinitis in China	ALLERGY			English	Article						aeroallergens; asthma; epidemiology; rhinitis; sensitization; skin prick test	DERMATOPHAGOIDES-PTERONYSSINUS; BLOMIA-TROPICALIS; ALLERGIC RHINITIS; INDOOR ALLERGENS; DUST MITES; EPITHELIAL-CELLS; RISK-FACTOR; CHILDREN; SEVERITY; EXPOSURE	The prevalence of sensitization in patients with asthma and rhinitis in mainland China remains unclear. Our aim was to estimate the prevalence of allergy in patients with respiratory allergic diseases such as asthma and/or rhinitis attending respiratory clinics within mainland China. The study also investigated regional and annual differences in the prevalence and pattern of sensitization among the patients in China. A cross-sectional survey was performed in 6304 patients suffering from asthma and/or rhinitis in 17 cities from 4 regions of China. Patients completed a standardized questionnaire asking for the presence of respiratory and allergic symptoms. They also underwent skin prick tests with 13 common aeroallergens. Among the 6304 patients, 4545 (72.1%) had at least one positive skin prick reaction. The overall prevalence of positive skin prick responses was 59.0% for Dermatophagoides farinae, 57.6% for Dermatophagoides pteronyssinus, 40.7% for Blomia tropicalis, 16.1% for American cockroach, 14.0% for dog, 11.5% for Blatella germanica, 11.3% for Artemisia vulgaris, 10.3% for cat, 6.5% for Ambrosia artemisifolia, 6.3% for mixed mould I, 4.4% for mixed mould IV, 3.5% for mixed grass pollen and 2.2% for mixed tree pollen. Sensitizations to common allergens varied widely between geographical areas and demonstrated unique pattern in patients by stratification with age groups, with asthma and/or rhinitis. Severity of rhinitis and asthma was significantly correlated with skin index of reactivity to Artemisia vulgaris, Ambrosia artemisifolia and to D. pteronyssinus, D. farinae and Blomia tropicalis respectively (P < 0.001). Positive reactivity to the tested allergens and concomitant reactivity to multiple allergens including to house dust mites and Blomia tropicalis was markedly increased in patients with both asthma and rhinitis. House dust mites were the most prevalent allergens in patients with asthma and/or rhinitis in China. There were significant differences in patterns of sensitizations in patients from different geographical areas, age groups as well as asthma and/or rhinitis.	[Li, J.; Sun, B.; Zhong, N.] Guangzhou Med Coll, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou 510120, Guangdong, Peoples R China; [Huang, Y.] Chongqing Univ Med Sci, Childrens Hosp, Chongqing, Peoples R China; [Lin, X.] Gen Hosp Shenyang Mil Command, Shenyang, Liaoning, Peoples R China; [Zhao, D.] Nanjing Childrens Hosp, Nanjing, Jiangsu, Peoples R China; [Tan, G.] Xiangya Med Univ, Hosp 3, Changsha, Hunan, Peoples R China; [Wu, J.] First Hosp Xiamen, Xiamen, Fujian, Peoples R China; [Zhao, H.] Shanxi Med Univ, Hosp 2, Taiyuan, Shanxi, Peoples R China; [Cao, L.] Capital Inst Pediat, Beijing, Peoples R China	Zhong, N (reprint author), Guangzhou Med Coll, Affiliated Hosp 1, State Key Lab Resp Dis, Guangzhou 510120, Guangdong, Peoples R China.				ALK-Abello A/S [FC409(10441)-ALK]	This study was supported by ALK-Abello A/S (FC409(10441)-ALK).	ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; BAI YLZ, 2007, CHINESE J ZOONOSES, V23, P227; Baker SF, 2003, MOL MEMBR BIOL, V20, P71, DOI 10.1080/0968768021000061150; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; BILIOTTI G, 1972, Clinical Allergy, V2, P109, DOI 10.1111/j.1365-2222.1972.tb01275.x; Bousquet J, 2003, ALLERGY, V58, P192, DOI 10.1034/j.1398-9995.2003.00054.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Casas R, 1999, ALLERGY, V54, P392, DOI 10.1034/j.1398-9995.1999.00875.x; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; [Deng Yun 邓韫], 2002, [古生物学报, Acta Palaeontologica Sinica], V41, P508; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Gioulekas D, 2004, ALLERGY, V59, P174, DOI 10.1046/j.1398-9995.2003.00312.x; Kidon MI, 2005, CLIN EXP ALLERGY, V35, P434, DOI 10.1111/j.1365-2222.2005.02208.x; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; Lemanske Robert F. Jr., 2003, Journal of Allergy and Clinical Immunology, V111, pS502; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; LEUNG R, 1994, CLIN EXP ALLERGY, V24, P353, DOI 10.1111/j.1365-2222.1994.tb00246.x; Li J, 2005, IMMUNOLOGY, V114, P386, DOI 10.1111/j.1365-2567.2005.02109.x; LIND P, 1988, J IMMUNOL, V140, P4256; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Munir AKM, 1998, ALLERGY, V53, P64; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Puccio FA, 2004, ALLERGY, V59, P753, DOI 10.1111/j.1398-9995.2004.00454.x; Puerta Llerena L, 1991, J Allergy Clin Immunol, V88, P943; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Ronmark E, 2003, PEDIATR ALLERGY IMMU, V14, P91, DOI 10.1034/j.1399-3038.2003.00042.x; Sarpong SB, 1998, ANN ALLERG ASTHMA IM, V80, P303; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Stach A, 2007, J INVEST ALLERG CLIN, V17, P39; Sun Hai-Lun, 2000, Journal of Microbiology Immunology and Infection, V33, P233; [孙会忠 SUN Huizhong], 2006, [环境与健康杂志, Journal of Environment and Health], V23, P283; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8; Wijnhoven HAH, 2001, CHEST, V119, P1034, DOI 10.1378/chest.119.4.1034; Witteman AM, 1999, ALLERGY, V54, P366, DOI 10.1034/j.1398-9995.1999.00962.x; Wong GWK, 2004, BRIT MED J, V329, P486, DOI 10.1136/bmj.329.7464.486; Wong GWK, 2002, EUR RESPIR J, V19, P288, DOI 10.1183/09031936.02.002319.02; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402; Yasueda H, 1996, CLIN EXP ALLERGY, V26, P171, DOI 10.1111/j.1365-2222.1996.tb00076.x	49	82	124	1	16	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	JUL	2009	64	7					1083	1092		10.1111/j.1398-9995.2009.01967.x		10	Allergy; Immunology	Allergy; Immunology	453FN	WOS:000266595800014	19210346	
J	Bryant-Stephens, T				Bryant-Stephens, Tyra			Asthma disparities in urban environments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Asthma; disparities; children; community-based; asthma morbidity; asthma interventions	INNER-CITY CHILDREN; INSURANCE PROGRAM SCHIP; COCKROACH ALLERGEN; MANAGEMENT PROGRAM; HEALTH-CARE; AFRICAN-AMERICAN; CHILDHOOD ASTHMA; CONTROLLED-TRIAL; SELF-MANAGEMENT; UNITED-STATES	Asthma continues to disproportionately affect minority and low-income groups, with African American and Latino children who live in low-socioeconomic-status urban environments experiencing higher asthma morbidity and mortality than white children. This uneven burden in asthma morbidity has been ever increasing despite medical advancement. Many factors have contributed to these disparities in the areas of health care inequities, which result in inadequate treatment; poor housing, which leads to increased exposure to asthma allergens; and social and psychosocial stressors, which are often unappreciated. Interventions to reduce individual areas of disparities have had varying successes. Because asthma is a complex disease that affects millions of persons, multifaceted comprehensive interventions that combine all evidence-based successful strategies are essential to finally closing the gap in asthma morbidity. (J Allergy Clin Immunol 2009;123:1199-206.)	Univ Penn, Childrens Hosp Philadelphia, Community Asthma Prevent Program, Dept Gen Pediat,Sch Med, Philadelphia, PA 19104 USA	Bryant-Stephens, T (reprint author), Univ Penn, Childrens Hosp Philadelphia, Community Asthma Prevent Program, Dept Gen Pediat,Sch Med, 3535 Market St,Suite 1032, Philadelphia, PA 19104 USA.	stephenst@email.chop.edu					AKINBAMI LJ, 1980, STATE CHILDHOOD ASTH; Apter AJ, 1998, AM J RESP CRIT CARE, V157, P1810; Bartholomew LK, 2006, J SCHOOL HEALTH, V76, P283; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Bryant-Stephens T, 2004, J NATL MED ASSOC, V96, P954; Bryant-Stephens T, 2008, J NATL MED ASSOC, V100, P306; Cabana MD, 2006, PEDIATRICS, V117, P2149, DOI 10.1542/peds.2005-1055; Canino G, 2008, J ALLERGY CLIN IMMUN, V121, P665, DOI 10.1016/j.jaci.2007.10.022; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; CHRISTIAANSE ME, 1989, J DEV BEHAV PEDIATR, V10, P75; Clark NM, 2000, EUR RESPIR J, V16, P15, DOI 10.1034/j.1399-3003.2000.16a04.x; Cloutier MM, 2008, ANN ALLERG ASTHMA IM, V100, P545, DOI 10.1016/S1081-1206(10)60058-0; Coffman JM, 2008, PEDIATRICS, V121, P575, DOI 10.1542/peds.2007-0113; Curtin-Brosnan J, 2008, ANN ALLERG ASTHMA IM, V101, P517, DOI 10.1016/S1081-1206(10)60291-8; de Oliveira MA, 1999, EUR RESPIR J, V14, P908, DOI 10.1034/j.1399-3003.1999.14d30.x; Diette GB, 2007, CHEST, V132, p802S, DOI 10.1378/chest.07-1909; Eggleston PA, 2007, CHEST, V132, p782S, DOI 10.1378/chest.07-1906; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Ford ES, 2004, J ASTHMA, V41, P327, DOI 10.1081/JAS-120026090; Fox P, 2007, PEDIATRICS, V120, pE902, DOI 10.1542/peds.2006-1805; Friedman Amy R, 2006, Health Promot Pract, V7, p140S, DOI 10.1177/1524839906287058; Gendo K, 2003, ANN ALLERG ASTHMA IM, V91, P251; Gerald LB, 2006, J SCHOOL HEALTH, V76, P291, DOI 10.1111/j.1746-1561.2006.00114.x; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Gotzsche PC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001187.pub3; Greek AA, 2006, J ASTHMA, V43, P61, DOI 10.1080/02770900500448639; Gupta RS, 2006, J ALLERGY CLIN IMMUN, V117, P351, DOI 10.1016/j.jaci.2005.11.047; Hardie GE, 2000, CHEST, V117, P935, DOI 10.1378/chest.117.4.935; Haselkorn T, 2008, ANN ALLERG ASTHMA IM, V101, P256, DOI 10.1016/S1081-1206(10)60490-5; HOWDENCHAPMAN P, 2008, BRIT MED J, V33, P208; Institute of Medicine, 2001, CROSS QUAL CHASM NEW; *I MED REP, 2003, UN TREATM CONFR ETH; Johnson RL, 2004, AM J PUBLIC HEALTH, V94, P2084, DOI 10.2105/AJPH.94.12.2084; Kamble S, 2009, J ASTHMA, V46, P73, DOI 10.1080/02770900802503107; Krieger JW, 2005, AM J PUBLIC HEALTH, V95, P652, DOI 10.2105/AJPH.2004.042994; Lee Jung-Ahn, 2006, Korean Journal of Internal Medicine, V21, P33; Levy Jonathan I, 2004, Environ Health, V3, P13, DOI 10.1186/1476-069X-3-13; Levy M, 2006, J SCHOOL HEALTH, V76, P320, DOI 10.1111/j.1746-1561.2006.00120.x; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Magzamen S, 2008, J SCHOOL HEALTH, V78, P655, DOI 10.1111/j.1746-1561.2008.00362.x; MATHER M, KIDS COUNT      0206; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; MCMANUS MA, 1993, PEDIATRICS, V91, P1040; Mitchell DK, 2005, J ASTHMA, V42, P425, DOI 10.1081/JAS-200067936; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray MD, 1997, J CLIN EPIDEMIOL, V50, P167, DOI 10.1016/S0895-4356(96)00333-2; *NAT HEART LUNG BL, 2007, NAT ASTHM ED PROGR E; *OFF ACT CTR MED M, NAT HLTH EXP FOR SUM; Okelo SO, 2007, J GEN INTERN MED, V22, P976, DOI 10.1007/s11606-007-0209-1; Paasche-Orlow MK, 2005, AM J RESP CRIT CARE, V172, P980, DOI 10.1164/rccm.200409-0191OC; Peters JL, 2007, J ASTHMA, V44, P455, DOI 10.1080/02770900701421971; Pilotto LS, 2004, INT J EPIDEMIOL, V33, P208, DOI 10.1093/ije/dyh018; Riekert KA, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e214; Robinson LD, 2008, J NATL MED ASSOC, V100, P892; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Saenz R, NEW ORLEANS SOCIAL E; Saha S, 1999, ARCH INTERN MED, V159, P997, DOI 10.1001/archinte.159.9.997; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SHIELDS A, 2008, CHEST, V132, P818; Shone LP, 2003, PEDIATRICS, V112, pE521; Simons E, 2007, J URBAN HEALTH, V84, P577, DOI 10.1007/s11524-007-9205-3; Smith LA, 2008, PEDIATRICS, V122, P760, DOI 10.1542/peds.2007-2750; STRACHAN DP, 1999, THORAX, V54, P469; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; Szilagyi PG, 2004, PEDIATRICS, V113, pE395, DOI 10.1542/peds.113.5.e395; van Ryn M, 2000, SOC SCI MED, V50, P813, DOI 10.1016/S0277-9536(99)00338-X; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Wang JL, 2005, J ALLERGY CLIN IMMUN, V115, P1076, DOI 10.1016/j.jaci.2005.02.014; Williams MV, 1998, CHEST, V114, P1008, DOI 10.1378/chest.114.4.1008; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60; Wright RJ, 2007, CHEST 2007 S5, V132, p757S, DOI DOI 10.1378/CHEST.07-1904	74	82	82	2	19	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1199	1206		10.1016/j.jaci.2009.04.030		8	Allergy; Immunology	Allergy; Immunology	455WO	WOS:000266799100007	19501229	
J	Glasser, R; Navid, F; Schuller, W; Jantschitsch, C; Harder, J; Schroder, JM; Schwarz, A; Schwarz, T				Glaesser, Regine; Navid, Fatemeh; Schuller, Winfried; Jantschitsch, Christian; Harder, Juergen; Schroeder, Jens M.; Schwarz, Agatha; Schwarz, Thomas			UV-B radiation induces the expression of antimicrobial peptides in human keratinocytes in vitro and in vivo	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						UV radiation; immunosuppression; adaptive immune response; innate immune response; antimicrobial peptides; skin; keratinocytes	NORMAL HUMAN SKIN; ULTRAVIOLET-RADIATION; ATOPIC-DERMATITIS; PSORIASIN S100A7; GENE-EXPRESSION; MESSENGER-RNA; T-CELLS; INNATE; PHOTOTHERAPY; INFECTION	Background: Suppression of the adaptive immune system by UV radiation plays an important role in photocarcinogenesis. Exacerbation of skin infections has been proposed as a further consequence of UV-induced immunosuppression. Clinically bacterial infections are not a problem. For defense against bacteria, the innate immune response including the release of antimicrobial peptides is much more relevant than the adaptive immune response. Keratinocytes; have the capacity to release antimicrobial peptides. Objective: We asked whether UV radiation induces antimicrobial peptides in vitro and in vivo. Methods: Antimicrobial peptide expression by normal human keratinocytes was measured by real-time PCR and fluorescence-activated cell sorting analysis. Biopsies taken from human volunteers and skin explants were studied with immunohistochemistry. Results: Real-time PCR of normal human keratinocytes revealed a dose-dependent increase of human beta-defensin-2, -3, ribonuclease 7, and psoriasin (S100A7) after UV radiation. This was confirmed at the protein level by intracellular fluorescence-activated cell sorting and in vitro immunofluorescence analysis. Immunohistochemistry of biopsies taken from healthy volunteers exposed to different UV radiation doses revealed enhanced epidermal expression of antimicrobial peptides after UV exposure. This was also confirmed by exposing human skin explants to UV radiation. Conclusion: UV radiation exerts diverse effects on the immune system, suppressing the adaptive but inducing the innate immune response. This may explain why T-cell-mediated immune reactions are suppressed on UV exposure but not host defense reactions against bacterial attacks. (J Allergy Clin Immunol 2009;123:1117-23.)	[Glaesser, Regine; Navid, Fatemeh; Schuller, Winfried; Jantschitsch, Christian; Harder, Juergen; Schroeder, Jens M.; Schwarz, Agatha; Schwarz, Thomas] Univ Kiel, Dept Dermatol & Allergol, D-24105 Kiel, Germany	Schwarz, T (reprint author), Univ Kiel, Dept Dermatol & Allergol, Schittenhelmstr 7, D-24105 Kiel, Germany.	tschwarz@dermatology.uni-kiel.de	Harder, Juergen/B-3162-2010; Glaser, Regine/B-3168-2010; Schwarz, Thomas/A-9148-2010		German Research Foundation [SFB 617, A21]; Federal Ministry of Education and Research	Supported by grants front the German Research Foundation (SFB 617, A21) to T.S. and from the Federal Ministry of Education and Research (Bundesministerium fur Bildung und Forschung, SkinSlaph) to R.G.	Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; CASCIOLAROSEN LA, 1994, J EXP MED, V179, P1317, DOI 10.1084/jem.179.4.1317; CHAPMAN RS, 1995, PHOTOCHEM PHOTOBIOL, V61, P223; Di Nuzzo S, 2000, PHOTOCHEM PHOTOBIOL, V72, P374; Euvrard S, 2003, NEW ENGL J MED, V348, P1681, DOI 10.1056/NEJMra022137; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gambichler T, 2006, BRIT J DERMATOL, V155, P1275, DOI 10.1111/j.1365-2133.2006.07481.x; Glaser R, 2009, J INVEST DERMATOL, V129, P641, DOI 10.1038/jid.2008.268; Glaser R, 2005, NAT IMMUNOL, V6, P57, DOI 10.1038/ni1142; Harder J, 2002, J BIOL CHEM, V277, P46779, DOI 10.1074/jbc.M20758200; Harder J, 2000, AM J RESP CELL MOL, V22, P714; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Harder J, 2007, J ENDOTOXIN RES, V13, P317, DOI 10.1177/0968051907088275; Hong SP, 2008, J INVEST DERMATOL, V128, P2880, DOI 10.1038/jid.2008.169; Jiang SJ, 2006, J DERMATOL SCI, V44, P29, DOI 10.1016/j.jdermsci.2006.05.012; Lande R, 2007, NATURE, V449, P564, DOI 10.1038/nature06116; Lee PL, 2008, PHOTOCHEM PHOTOBIOL, V84, P1528, DOI 10.1111/j.1751-1097.2008.00380.x; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Mallbris L, 2005, J INVEST DERMATOL, V125, P1072, DOI 10.1111/j.0022-202X.2005.23872.x; Mehling A, 2001, J EXP MED, V194, P615, DOI 10.1084/jem.194.5.615; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Norval M, 2006, PHOTOCHEM PHOTOBIOL, V82, P1495, DOI 10.1562/2006-07-28-IR-987; Reddy KVR, 2004, INT J ANTIMICROB AG, V24, P536, DOI 10.1016/j.ijantimicag.2004.09.005; RUNGER TM, 2008, DERMATOLOGY, P1321; Schauber J, 2008, J ALLERGY CLIN IMMUN, V122, P261, DOI 10.1016/j.jaci.2008.03.027; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schittek Birgit, 2008, Infectious Disorders - Drug Targets, V8, P135; Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0; SCHWARZ T, 2008, DERMATOLOGY, P63; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Schwarz Thomas, 2005, Keio Journal of Medicine, V54, P165, DOI 10.2302/kjm.54.165; Seo SJ, 2001, J DERMATOL SCI, V27, P183, DOI 10.1016/S0923-1811(01)00135-9; Silva SH, 2006, J EUR ACAD DERMATOL, V20, P1114, DOI 10.1111/j.1468-3083.2006.01748.x; Sorensen O, 1997, BLOOD, V90, P2796; Termorshuizen F, 2002, INT IMMUNOPHARMACOL, V2, P263, DOI 10.1016/S1567-5769(01)00178-3; Wang TT, 2004, J IMMUNOL, V173, P2909; Weichenthal M, 2005, PHOTODERMATOL PHOTO, V21, P260, DOI 10.1111/j.1600-0781.2005.00173.x; Wollenberg A, 2007, CLIN REV ALLERG IMMU, V33, P35, DOI 10.1007/s12016-007-0032-9; YOSHIKAWA T, 1990, J INVEST DERMATOL, V95, P530, DOI 10.1111/1523-1747.ep12504877	42	82	83	3	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2009	123	5					1117	1123		10.1016/j.jaci.2009.01.043		7	Allergy; Immunology	Allergy; Immunology	449CW	WOS:000266309400021	19342087	
J	Maestrelli, P; Boschetto, P; Fabbri, LM; Mapp, CE				Maestrelli, Piero; Boschetto, Piera; Fabbri, Leonardo M.; Mapp, Cristina E.			Mechanisms of occupational asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Workplace exposure; asthma; airway hyperresponsiveness; antigen; chemical; genetics; mechanisms; inflammation	DIISOCYANATE-INDUCED ASTHMA; AIRWAYS DYSFUNCTION SYNDROME; ISOCYANATE-INDUCED ASTHMA; SERUM-ALBUMIN CONJUGATE; TUMOR-NECROSIS-FACTOR; GENE-ENVIRONMENT INTERACTIONS; LABORATORY-ANIMAL WORKERS; WESTERN RED CEDAR; HLA CLASS-II; TOLUENE DIISOCYANATE	Inhalation of agents in the workplace can induce asthma in a relatively small proportion of exposed workers. Like nonoccupational asthma, occupational asthma is probably the result of multiple genetic, environmental, and behavioral influences. It is important that occupational asthma be recognized clinically because it has serious medical and socioeconomic consequences. Environmental factors that can affect the initiation of occupational asthma include the intrinsic characteristics of causative agents as well as the influence of the level and route of exposure at the workplace. The identification of host factors, polymorphisms, and candidate genes associated with occupational asthma may improve our understanding of mechanisms involved in asthma. High-molecular-weight compounds from biological sources and low-molecular-weight chemicals cause occupational asthma after a latent period of exposure. Although the clinical, functional, and pathologic features of occupational asthma caused by low-molecular-weight agents resemble those of allergic asthma, the failure to detect specific IgE antibodies against most low-molecular-weight agents has resulted in a search for alternative or complementary physiopathologic mechanisms leading to airway sensitization. Recent advances have been made in the characterization of the immune response to low-molecular-weight agents. In contrast, the mechanism of the type of occupational asthma that occurs without latency after high-level exposure to irritants remains undetermined. (J Allergy Clin Immunol 2009;123:531-42.)	[Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Policlin Modena, I-41100 Modena, Italy; [Maestrelli, Piero] Univ Padua, Dept Environm Med & Publ Hlth, I-35100 Padua, Italy; [Boschetto, Piera; Mapp, Cristina E.] Univ Ferrara, Dept Clin & Expt Med, Sect Hyg & Occupat Med, I-44100 Ferrara, Italy	Fabbri, LM (reprint author), Univ Modena & Reggio Emilia, Dept Oncol Hematol & Resp Dis, Policlin Modena, Largo Pozzo 71, I-41100 Modena, Italy.	leonardo.fabbri@unimore.it	Fabbri, Leonardo/I-4055-2012	Fabbri, Leonardo/0000-0001-8894-1689	Ministry of University and Scientific Research; University of Padova; University of Ferrara; Consorzio Ferrara Ricerche; Associazione per la Ricerca e Cara dell' Asma, Padova; Associazione per to Studio dei Tumori e delle Malattie Polmonari, Padova	Supported by the Ministry of University and Scientific Research: University of Padova; University of Ferrara; Consorzio Ferrara Ricerche; the Associazione per la Ricerca e Cara dell' Asma, Padova; and the Associazione per to Studio dei Tumori e delle Malattie Polmonari, Padova.	Akdis CA, 1999, FASEB J, V13, P603; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Aul DJ, 1999, J ALLERGY CLIN IMMUN, V103, P749, DOI 10.1016/S0091-6749(99)70415-X; BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Ban M, 2006, TOXICOLOGY, V218, P39, DOI 10.1016/j.tox.2005.09.013; Bardana EJ, 2008, J ALLERGY CLIN IMMUN, V121, pS408, DOI 10.1016/j.jaci.2007.08.005; BAUR X, 1995, J ALLERGY CLIN IMMUN, V96, P489, DOI 10.1016/S0091-6749(95)70292-X; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; Beghe B, 2004, ALLERGY, V59, P61, DOI 10.1046/j.1398-9995.2003.00352.x; Bello D, 2008, ANN OCCUP HYG, V52, P117, DOI 10.1093/annhyg/mem066; BENAUCH GI, 2005, CRIT CARE MED, V33, pS102; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; Bernstein DI, 2006, ANN ALLERG ASTHMA IM, V97, P800; BERNSTEIN DI, 1984, J ALLERGY CLIN IMMUN, V74, P794, DOI 10.1016/0091-6749(84)90181-7; Bernstein IL, 2006, ASTHMA WORKPLACE, P1; BERODE M, 1991, BIOCHEM INT, V24, P947; Berode M, 2005, INT ARCH OCC ENV HEA, V78, P158, DOI 10.1007/s00420-004-0568-4; BIAGINI RE, 1985, J ALLERGY CLIN IMMUN, V76, P794, DOI 10.1016/0091-6749(85)90750-X; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Carosella ED, 2008, TRENDS IMMUNOL, V29, P125, DOI 10.1016/j.it.2007.11.005; Casset A, 2006, ALLERGY, V61, P1344, DOI 10.1111/j.1398-9995.2006.01174.x; Ceyhan BB, 2004, J INVEST ALLERG CLIN, V14, P80; Chan-Yeung Moira, 2004, Can Respir J, V11, P21; Christiani DC, 2008, OCCUP ENVIRON MED, V65, P430, DOI 10.1136/oem.2007.033977; CLEARE MJ, 1976, CLIN ALLERGY, V6, P183, DOI 10.1111/j.1365-2222.1976.tb01897.x; Cullinan P, 2000, LANCET, V356, P1899, DOI 10.1016/S0140-6736(00)03264-5; Cunningham AR, 2005, SAR QSAR ENVIRON RES, V16, P273, DOI 10.1080/10659360500036976; DEARMAN RJ, 1991, IMMUNOLOGY, V72, P563; Dearman RJ, 2000, J APPL TOXICOL, V20, P221, DOI 10.1002/(SICI)1099-1263(200005/06)20:3<221::AID-JAT651>3.3.CO;2-R; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Farrall M, 2004, HUM MOL GENET, V13, pR1, DOI 10.1093/hmg/ddh084; Feger U, 2007, BLOOD, V110, P568, DOI 10.1182/blood-2006-11-057125; Fent KW, 2008, J ENVIRON MONITOR, V10, P500, DOI 10.1039/b715605g; FREW A, 1993, J ALLERGY CLIN IMMUN, V92, P466, DOI 10.1016/0091-6749(93)90126-Z; Frew A, 1998, J ALLERGY CLIN IMMUN, V101, P841, DOI 10.1016/S0091-6749(98)70313-6; Frew AJ, 2004, J ALLERGY CLIN IMMUN, V113, P1161, DOI 10.1016/j.jaci.2004.03.039; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P12, DOI 10.1016/0091-6749(94)90228-3; HENDRICK DJ, 2002, DISORDERS AIRWAYS PA, P33; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Herrick CA, 2003, J ALLERGY CLIN IMMUN, V111, P1087, DOI 10.1067/mai.2003.1413; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Horne C., 2000, European Respiratory Journal, V15, P911, DOI 10.1034/j.1399-3003.2000.15e17.x; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499; Jame AJ, 2007, CLIN EXP ALLERGY, V37, P880, DOI 10.1111/j.1365-2222.2007.02733.x; Jarvis J, 2005, OCCUP ENVIRON MED, V62, P243, DOI 10.1136/oem.2004.016402; Jeal H, 2006, AM J RESP CRIT CARE, V174, P21, DOI 10.1164/rccm.200506-946OC; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Jiang YH, 2004, ANNU REV GENOM HUM G, V5, P479, DOI 10.1146/annurev.genom.5.061903.180014; Jones MG, 2008, CURR OPIN ALLERGY CL, V8, P110, DOI 10.1097/ACI.0b013e3282f4b5f1; Jones MG, 2006, J ALLERGY CLIN IMMUN, V117, P663, DOI 10.1016/j.jaci.2005.09.053; Jones MG, 2004, CLIN EXP ALLERGY, V34, P812, DOI 10.1111/j.1365-2222.2004.01956.x; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611; KAROL MH, 1978, AM IND HYG ASSOC J, V39, P454, DOI 10.1080/0002889778507789; Kim SH, 2006, ALLERGY, V61, P891, DOI 10.1111/j.1398-9995.2006.01023.x; Kimber I, 2005, CURR OPIN ALLERGY CL, V5, P119, DOI 10.1097/01.all.0000162302.82233.93; Kimber I, 1997, CLIN REV ALLERG IMMU, V15, P145, DOI 10.1007/BF02826584; Kimber I, 2007, ATLA-ALTERN LAB ANIM, V35, P243; Klein J, 2000, NEW ENGL J MED, V343, P702; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lee CT, 2005, TOXICOL APPL PHARM, V205, P53, DOI 10.1016/j.taap.2004.09.015; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; Liu Q, 2003, ANN ALLERG ASTHMA IM, V90, P35; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376; MAESTRELLI P, 2006, ASTHMA WORKPLACE REL, V5, P109; Magnusson LL, 2006, OCCUP ENVIRON MED, V63, P640, DOI 10.1136/oem.2005.024422; Malo JL, 2004, CURR OPIN PULM MED, V10, P57, DOI 10.1097/00063198-200401000-00010; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; Mamessier E, 2007, ALLERGY, V62, P162, DOI 10.1111/j.1398-9995.2006.01288.x; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Mapp CE, 2001, OCCUP ENVIRON MED, V58, P354, DOI 10.1136/oem.58.5.354; MAPP CE, 2009, CLIN EXP AL IN PRESS; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Matheson JM, 2002, AM J RESP CELL MOL, V27, P396, DOI 10.1165/rcmb.4614; Matsui EC, 2006, CLIN EXP ALLERGY, V36, P1097, DOI 10.1111/j.1365-2222.2006.02534.x; Matsui EC, 2005, CLIN EXP ALLERGY, V35, P1347, DOI 10.1111/j.1365-2222.2005.02331.x; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; NIELSEN J, 1989, SCAND J WORK ENV HEA, V15, P154; Nieuwenhuijsen MJ, 2003, OCCUP ENVIRON MED, V60, P104, DOI 10.1136/oem.60.2.104; Ober C, 2005, CURR OPIN IMMUNOL, V17, P670, DOI 10.1016/j.coi.2005.09.009; Pacheco K, 2008, J ALLERGY CLIN IMMUN, V122, P896, DOI 10.1016/j.jaci.2008.08.025; Park Hae Sim, 2002, Korean J Intern Med, V17, P249; Park Hae-Sim, 1996, Journal of Korean Medical Science, V11, P314; PARK HS, 1991, CLIN EXP ALLERGY, V21, P357, DOI 10.1111/j.1365-2222.1991.tb01668.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847; Park HS, 2001, J KOREAN MED SCI, V16, P57; PEPYS J, 1979, CLIN ALLERGY, V9, P99, DOI 10.1111/j.1365-2222.1979.tb01528.x; Perfetti L, 2003, AM J IND MED, V44, P325, DOI 10.1002/ajim.10262; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prezant DJ, 2008, MT SINAI J MED, V75, P89, DOI 10.1002/msj.20028; Prezant DJ, 2008, LUNG, V186, pS94, DOI 10.1007/s00408-007-9051-9; Pronk A, 2006, OCCUP ENVIRON MED, V63, P624, DOI 10.1136/oem.2005.023226; Redlich CA, 2008, CURR OPIN ALLERGY CL, V8, P115, DOI 10.1097/ACI.0b013e3282f85a31; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.3.CO;2-T; Rizzo R, 2005, J ALLERGY CLIN IMMUN, V115, P508, DOI 10.1016/j.jaci.2004.11.031; Sastre J, 2003, EUR RESPIR J, V22, P364, DOI 10.1183/09031936.03.00045103; Seed MJ, 2008, CURR OPIN ALLERGY CL, V8, P103, DOI 10.1097/ACI.0b013e3282f4cadd; Shiina T, 2004, TISSUE ANTIGENS, V64, P631, DOI 10.1111/j.1399-0039.2004.00327.x; Sigsgaard T, 2000, EUR RESPIR J, V16, P50, DOI 10.1034/j.1399-3003.2000.16a09.x; Son Minsik, 1998, Journal of Korean Medical Science, V13, P147; Tarlo SA, 2003, ANN ALLERG ASTHMA IM, V90, P19; Tarlo SM, 2006, EUR RESPIR J, V27, P607, DOI 10.1183/09031936.06.00062105; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Taylor A N, 2001, Curr Opin Allergy Clin Immunol, V1, P157, DOI 10.1097/00130832-200104000-00007; Taylor AJN, 2003, ANN ALLERG ASTHMA IM, V90, P24; Taylor AJN, 1999, AM J RESP CRIT CARE, V160, P435; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; Tomita K, 2002, CLIN IMMUNOL, V102, P258, DOI 10.1006/clim.2001.5176; Valdar W, 2006, GENETICS, V174, P959, DOI 10.1534/genetics.106.060004; Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155; Vanoirbeek JAJ, 2008, J ALLERGY CLIN IMMUN, V121, P456, DOI 10.1016/j.jaci.2007.09.006; VENABLES KM, 1989, BRIT MED J, V299, P939; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; Wikman H, 2002, PHARMACOGENETICS, V12, P227, DOI 10.1097/00008571-200204000-00007; Wisnewski AV, 2008, CLIN EXP ALLERGY, V38, P957, DOI 10.1111/j.1365-2222.2008.02982.x; Wisnewski AV, 2007, CURR OPIN ALLERGY CL, V7, P138, DOI 10.1097/ACI.0b013e3280895d22; Wisnewski AV, 2003, J ALLERGY CLIN IMMUN, V112, P538, DOI 10.1067/mai.2003.1713; Wisnewski AV, 2005, CLIN EXP ALLERGY, V35, P352, DOI 10.1111/j.1365-2222.2005.02185.x; Wisnewski AV, 2001, AM J RESP CELL MOL, V24, P332; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330; Xue AL, 2005, CLIN IMMUNOL, V117, P302, DOI 10.1016/j.clim.2005.08.003; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Ye YM, 2006, CLIN EXP ALLERGY, V36, P1153, DOI 10.1111/j.1365-2222.2006.02547.x; YOKATA K, 1998, CLIN EXP ALLERGY, V28, P694; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219; Zhang XD, 1997, TOXICOLOGY, V118, P223, DOI 10.1016/S0300-483X(96)03605-0; Zock JP, 1996, CLIN EXP ALLERGY, V26, P542, DOI 10.1046/j.1365-2222.1996.d01-344.x	144	82	82	2	9	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					531	542		10.1016/j.jaci.2009.01.057		12	Allergy; Immunology	Allergy; Immunology	426TQ	WOS:000264731200008	19281901	
J	Weghofer, M; Thomas, WR; Kronqvist, M; Mari, A; Purohit, A; Pauli, G; Horak, F; Gronlund, H; Van Hage, M; Valenta, R; Vrtala, S				Weghofer, M.; Thomas, W. R.; Kronqvist, M.; Mari, A.; Purohit, A.; Pauli, G.; Horak, F.; Gronlund, H.; van Hage, M.; Valenta, R.; Vrtala, S.			Variability of IgE reactivity profiles among European mite allergic patients	EUROPEAN JOURNAL OF CLINICAL INVESTIGATION			English	Article						Diagnosis; HDM allergy; IgE prevalence; recombinant allergens; storage mite allergy	HOUSE-DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS; CROSS-REACTIVITY; LEPIDOGLYPHUS-DESTRUCTOR; TYROPHAGUS-PUTRESCENTIAE; RECOMBINANT ALLERGENS; SWEDISH FARMERS; STORAGE MITES; P 7; RESPONSES	House dust mites (HDM) Dermatophagoides pteronyssinus are a frequent indoor allergen source. Our aim was to determine the frequencies of IgE reactivity to purified HDM allergen molecules in mite allergic patients from different parts of Europe in order to establish an allergen panel for diagnosis of HDM allergy. Populations of D. pteronyssinus-allergic patients from Austria (n = 56), France (n = 55), Italy (n = 67) and Sweden (n = 65) and storage mite allergic patients from Sweden (n = 31) were analysed for IgE reactivity to eight purified natural (n) and recombinant (r) D. pteronyssinus allergens (nDer p 1, rDer p 2, nDer p 4, rDer p 5, rDer p 7, rDer p 8, rDer p 10 and rDer p 14) in RAST-based dot blot assays. Using a combination of Der p 1 and Der p 2, at least 97% of the D. pteronyssinus-allergic patients could be diagnosed in each of the HDM allergic populations. However, more than 50% of the patients also reacted with other allergens and significant variabilities regarding the frequencies of IgE reactivity to individual allergen molecules were found. Patients with a predominant storage mite allergy showed none or only very weak IgE reactivity to purified D. pteronyssinus allergens. Purified Der p 1 and Der p 2 are sufficient for the diagnosis of >= 97% of D. pteronyssinus allergic patients in Europe, but other allergens may also play an important role for the diagnosis and treatment of HDM allergy. Eur J Clin Invest 2008; 38 (12): 959-965.	[Vrtala, S.] Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, A-1090 Vienna, Austria; [Kronqvist, M.; Gronlund, H.; van Hage, M.] Karolinska Inst, Stockholm, Sweden; [Kronqvist, M.; Gronlund, H.; van Hage, M.] Univ Hosp, Stockholm, Sweden; [Mari, A.] IDI IRCCS, Rome, Italy; [Purohit, A.; Pauli, G.] Strasbourg Univ Hosp, Strasbourg, France	Vrtala, S (reprint author), Med Univ Vienna, Div Immunopathol, Dept Pathophysiol, Ctr Physiol & Pathophysiol, Wachringer Guertel 18-20, A-1090 Vienna, Austria.	susanne.vrtala@meduniwien.ac.at	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596	Austrian Science Fund [F1803, F1815]; Christian Doppler Research Association, Biomay, Vienna, Austria; Swedish Asthma and Allergy Association's Research Foundation; Swedish Research Council	This work was supported by grants F1803 and F1815 of the Austrian Science Fund, the Christian Doppler Research Association, Biomay, Vienna, Austria, the Swedish Asthma and Allergy Association's Research Foundation and the Swedish Research Council.	Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P399, DOI 10.1097/01.all.0000182536.55650.d0; Asturias JA, 2000, ALLERGY, V55, P898, DOI 10.1034/j.1398-9995.2000.00734.x; Epton MJ, 1999, INT ARCH ALLERGY IMM, V120, P185, DOI 10.1159/000024266; Erwin EA, 2007, J ALLERGY CLIN IMMUN, V119, P359, DOI 10.1016/j.jaci.2006.12.648; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Gafvelin G, 2001, J ALLERGY CLIN IMMUN, V107, P511, DOI 10.1067/mai.2001.112264; Hales BJ, 2007, CLIN EXP ALLERGY, V37, P1357, DOI 10.1111/j.1365-2222.2007.02786.x; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P934, DOI 10.1046/j.1365-2222.2000.00901.x; Hales BJ, 2002, CLIN EXP ALLERGY, V32, P1461, DOI 10.1046/j.1365-2745.2002.01500.x; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Kronqvist M, 1999, CLIN EXP ALLERGY, V29, P35; Kronqvist M, 1999, ALLERGY, V54, P1142, DOI 10.1034/j.1398-9995.1999.00115.x; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; Lynch NR, 1997, INT ARCH ALLERGY IMM, V114, P59; MEYER CH, 1994, CLIN EXP ALLERGY, V24, P1041, DOI 10.1111/j.1365-2222.1994.tb02741.x; Musken H, 2002, J INVEST ALLERG CLIN, V12, P177; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Schram-Bijkerk D, 2006, ALLERGY, V61, P640, DOI 10.1111/j.1398-9995.2006.01079.x; TEE RD, 1992, CLIN EXP ALLERGY, V22, P233, DOI 10.1111/j.1365-2222.1992.tb03078.x; Thomas WR, 2007, PROTEIN PEPTIDE LETT, V14, P943, DOI 10.2174/092986607782541169; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; van der Heide S, 1998, ALLERGY, V53, P426; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P23; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; Vieths S, 2001, ALLERGY, V56, P78, DOI 10.1034/j.1398-9995.2001.00923.x; Weghofer M, 2008, ALLERGY, V63, P758, DOI 10.1111/j.1398-9995.2008.01647.x; Weghofer M, 2005, CLIN EXP ALLERGY, V35, P1384, DOI 10.1111/j.1365-2222.2005.02345.x; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Westritschnig K, 2003, CLIN EXP ALLERGY, V33, P22, DOI 10.1046/j.1365-2222.2003.01540.x	33	82	83	1	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0014-2972			EUR J CLIN INVEST	Eur. J. Clin. Invest.	DEC	2008	38	12					959	965		10.1111/j.1365-2362.2008.02048.x		7	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	375GT	WOS:000261102800012	19021722	
J	Ghadimi, D; Folster-Holst, R; de Vrese, M; Winkler, P; Heller, KJ; Schrezenmeir, J				Ghadimi, Darab; Foelster-Holst, Regina; de Vrese, Michael; Winkler, Petra; Heller, Knut J.; Schrezenmeir, Juergen			Effects of probiotic bacteria and their genomic DNA on T(H)1/T(H)2-cytokine production by peripheral blood mononuclear cells (PBMCs) of healthy and allergic subjects	IMMUNOBIOLOGY			English	Article						T(H)1/T(H)2-cytokines; Immune system; Allergy; Probiotics; Lactobacilli; Bifidobacteria	LACTIC-ACID BACTERIA; RANDOMIZED CONTROLLED-TRIAL; PLACEBO-CONTROLLED TRIAL; COMMON COLD EPISODES; IFN-GAMMA PRODUCTION; CPG OLIGODEOXYNUCLEOTIDES; LACTOBACILLUS-RHAMNOSUS; ATOPIC-DERMATITIS; AIRWAY INFLAMMATION; INTERFERON-GAMMA	Among the factors potentially involved in the increased prevalence of allergic diseases, modification of the intestinal flora or lack of microbial exposure during childhood has been proposed. TH2-cytokines increase the production of IgE and stimulate mast cells and eosinophils, whereas T(H)1-cytokines, Such Lis IFN-gamma, may suppress IgE synthesis and Stimulate the expression of the secretory piece of IgA. Thus, a dysregulation In the expression of T(H)1- and T(H)2-cytokines may contribute to the initiation and maintenance of allergic diseases. Lactobacilli belonging to the natural intestinal rnicroflora were reported to reduce the incidence of atopic dermatitis and the severity of allergic manifestations and to modulate T(H)1/T(H)2 responses. The mechanisms still remain to be elucidated. We Sought to assess the effect of different probiotics, Lactobacillus rhamnosus GG, Lactobacillus gasseri (PA 16/8) Bifidobacterium bifidum (MP20/5), and B Bifidobacterium longum (SP07/3), on the T(H)1 I and T(H)2 responses of peripheral blood mononuclear cells (PBMCs) from healthy subjects and from patients with allergy against house dust mite to Staphylococcus enterotoxin A (SEA) and Dermatophagoides pteronyssinus (Dpt). To elucidate the Molecular basis of these effects, the effects of bacterial genomic DNA were compared with the effects of viable bacteria. PBMCs from allergic patients and from healthy donors were incubated for 24 or 48h, respectively, With Or Without SEA and Dpt allergens. The effects of preincubation with live probiotic bacteria and the effect of their genomic DNA, Lidded Simultaneously to Cultures and incubated for 24h, were assessed by measuring T(H)1/T(H)2-cytokine production. The tested live Gram-positive probiotic bacteria and their genomic DNA inhibited SEA- and Dpt-stimulated secretion of T(H)2-cytokines (IL-4 and IL-5) and enhanced the Stimulation of IFN-gamma. This effect was dose-dependent with a dosage-optimum, which was identical for all lactic acid producing bacteria (LAB) tested (10 bacteria per (PBMC) and their DNA (75 ng/rnl). Based on the maximal effects achieved with LAB and their DNA, more than 50% of the effects seem to be contributed by DNA. No significant effect was induced by the control, Gram-negative Escherichia coli TGl. Lactobacilli and bifidobacteria reduced SEA-stimulated IL-4 and IL-5 production more effectively in PBMCs from healthy subjects than from allergic patients. In contrast to this, inhibition of Dpt-stimulated IL-4- and IL-5-secretion was more pronounced in cells from allergic subjects. Compared with living LAB, bacterial DNA inhibited IL-4- and IL-5-secretion in a similar manner. SEA- and even more so Dpt-stimulated IFN-gamma stimulation by living LAB was less pronounced in allergic than in healthy Subjects, whereas IFN-gamma Stimulation by their DNA was more Pronounced in allergic subjects. The tested probiotic bacteria as well as their genomic DNA modulated the T(H)1/T(H)2 response to some allergens dose-dependently. DNA seems to contribute to 50% of the effect exerted by living bacteria in this in vitro model. The magnitude of the probiotic effects differed between healthy and allergic subjects. Whether the modulation found for the tested strains might be useful for the prevention and treatment of allergic diseases has to be assessed In clinical trials. (C) 2008 Published by Elsevier GmbH.	[Ghadimi, Darab; de Vrese, Michael; Winkler, Petra; Schrezenmeir, Juergen] Fed Res Ctr Nutr & Food, Inst Physiol & Biochem Nutr, D-24103 Kiel, Germany; [Foelster-Holst, Regina] Univ Hosp Schleswig Holstein, Dermatol Clin, D-24105 Kiel, Germany; [Heller, Knut J.] Fed Res Ctr Nutr & Food, Inst Microbiol, D-24103 Kiel, Germany	Schrezenmeir, J (reprint author), Fed Res Ctr Nutr & Food, Inst Physiol & Biochem Nutr, Hermann Weigmann Str 1, D-24103 Kiel, Germany.	pbe.kiel@bfel.de	Folster-Holst, Regina/A-9560-2010; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Behera AK, 2002, HUM GENE THER, V13, P1697, DOI 10.1089/104303402760293547; Bjorksten B, 1997, CLIN REV ALLERG IMMU, V15, P125, DOI 10.1007/BF02826583; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Broide DH, 2001, J ALLERGY CLIN IMMUN, V108, P759; CAYZER C, 2001, J GASTROEN HEPATOL, V16, P36, DOI 10.1111/j.1440-1746.2001.ca01-36.x; de Vrese M, 2005, EUR J NUTR, V44, P406, DOI 10.1007/s00394-004-0541-8; de Vrese M, 2005, CLIN NUTR, V24, P481, DOI 10.1016/j.clnu.2005.02.006; de Vrese M, 2006, VACCINE, V24, P6670, DOI 10.1016/j.vaccine.2006.05.048; Flinterman AE, 2007, INT ARCH ALLERGY IMM, V143, P237, DOI 10.1159/000099467; Folster-Holst R, 2006, BRIT J DERMATOL, V155, P1256, DOI 10.1111/j.1365-2133.2006.07558.x; Foligne B, 2007, WORLD J GASTROENTERO, V13, P236; Helin T, 2002, ALLERGY, V57, P243, DOI 10.1034/j.1398-9995.2002.1s3299.x; Helwig U, 2006, WORLD J GASTROENTERO, V12, P5978; Hessel EM, 2005, J EXP MED, V202, P1563, DOI 10.1084/jem.20050631; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Hussain I, 2002, LARYNGOSCOPE, V112, P1819, DOI 10.1097/00005537-200210000-00021; Iliev ID, 2005, CELL MICROBIOL, V7, P403, DOI 10.1111/j.1462-5822.2004.00470.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kitagaki K, 2002, CLIN DIAGN LAB IMMUN, V9, P1260, DOI 10.1128/CDLI.9.6.1260-1269.2002; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; Lammers KM, 2003, FEMS IMMUNOL MED MIC, V38, P165, DOI 10.1016/S0928-8244(03)00144-5; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Martinez FD, 1999, LANCET, V354, pSII12; Matsuguchi T, 2003, CLIN DIAGN LAB IMMUN, V10, P259, DOI 10.1128/CDLI.10.2.259.266.2003; Matsuzaki T, 1998, J DAIRY SCI, V81, P48; Medina M, 2007, CLIN EXP IMMUNOL, V150, P531, DOI 10.1111/j.1365-2249.2007.03522.x; Meier R, 2005, CURR OPIN CRIT CARE, V11, P318, DOI 10.1097/01.ccx.0000166396.42894.60; Miettinen M, 1998, INFECT IMMUN, V66, P6058; MullerAlouf H, 1996, INFECT IMMUN, V64, P1450; O'Byrne PM, 2006, CHEST, V130, P244, DOI 10.1378/chest.130.1.244; O'Mahony L, 2006, AM J PHYSIOL-GASTR L, V290, pG839, DOI 10.1152/ajpgi.00112.2005; Pena JA, 2003, CELL MICROBIOL, V5, P277, DOI 10.1046/j.1462-5822.2003.t01-1-00275.x; Peng GC, 2005, PEDIATR ALLERGY IMMU, V16, P433, DOI 10.1111/j.1399-3038.2005.00284.x; Pochard P, 2005, J ALLERGY CLIN IMMUN, V116, P198, DOI 10.1016/j.jaci.2005.02.037; Pochard P, 2002, J ALLERGY CLIN IMMUN, V110, P617, DOI 10.1067/mai.2002.128528; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Sambrook J., 2001, MOL CLONING; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; van der Velden VHJ, 2001, CLIN EXP ALLERGY, V31, P997, DOI 10.1046/j.1365-2222.2001.01176.x; Wang MF, 2004, PEDIATR ALLERGY IMMU, V15, P152, DOI 10.1111/j.1399-3038.2004.00156.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Winkler P, 2007, J NUTR, V137, p756S	50	82	90	2	14	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	0171-2985			IMMUNOBIOLOGY	Immunobiology		2008	213	8					677	692		10.1016/j.imbio.2008.02.001		16	Immunology	Immunology	359YY	WOS:000260025400008	18950596	
J	Salvi, S				Salvi, Sundeep			Health effects of ambient air pollution in children	PAEDIATRIC RESPIRATORY REVIEWS			English	Article						air pollution; particulate matter; nitrogen oxides; oxidative stress	DIESEL EXHAUST PARTICLES; LUNG-FUNCTION GROWTH; LOW-BIRTH-WEIGHT; RESPIRATORY SYMPTOMS; ANTIOXIDANT SUPPLEMENTATION; ALLERGIC SENSITIZATION; ASTHMATIC-CHILDREN; PARTICULATE MATTER; PULMONARY-FUNCTION; INFANT-MORTALITY	Children seem to be most vulnerable to the harmful effects of ambient air air pollution; pollutants because their defence mechanisms are still evolving and because they inhale a particulate matter; higher volume of air per body weight than adults. Air pollutants can also harm the foetus if nitrogen oxides; the mother is exposed to high levels of air pollution during pregnancy. An increase in oxidative stress respiratory neonatal mortality has been associated with ambient levels of air pollutants. Exposure to fine particles has been shown to increase allergen sensitisation, increase the risk of worsening asthma and decrease lung function. Lung growth, as measured by lung function, seems to be adversely affected in children exposed to various oxidant air pollutants. Oxidative stress is the main underlying mechanism responsible for the harmful effects of air pollutants and preliminary studies have indicated that antioxicant supplementation can offer some protection. (c) 2007 Elsevier Ltd. All rights reserved.	Chest Res Fdn, Pune 411014, Maharashtra, India	Salvi, S (reprint author), Chest Res Fdn, Marigold Complex, Pune 411014, Maharashtra, India.	ssalvi@crfindia.com					Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; Behrens T, 2004, PEDIATR ALLERGY IMMU, V15, P331, DOI 10.1111/j.1399-3038.2004.00157.x; Bennett WD, 2004, J APPL PHYSIOL, V97, P821, DOI 10.1152/japplphysiol.01403.2003; Bobak M, 1999, EPIDEMIOLOGY, V10, P666, DOI 10.1097/00001648-199911000-00004; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Calderon-Garciduenas L, 2001, AM J RESP CELL MOL, V24, P132; CHATHAM MD, 1987, ANN NY ACAD SCI, V498, P269, DOI 10.1111/j.1749-6632.1987.tb23767.x; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Dales R, 2004, PEDIATRICS, V113, pE628, DOI 10.1542/peds.113.6.e628; Dales RE, 2006, ENVIRON HEALTH PERSP, V114, P1751, DOI 10.1289/ehp.9044; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1982, JAPCA J AIR WASTE MA, V32, P937; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Environmental Working Group, 2005, BOD BURD POLL NEWB B; Frew AJ, 1997, CLIN EXP ALLERGY, V27, P237; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kulkarni N, 2006, NEW ENGL J MED, V355, P21, DOI 10.1056/NEJMoa052972; Lacasana M, 2005, EUR J EPIDEMIOL, V20, P183, DOI 10.1007/s10654-004-3005-9; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Lee YL, 2004, CLIN EXP ALLERGY, V34, P1707, DOI 10.1111/j.1365-2222.2004.02099.x; Lipfert FW, 2000, J AIR WASTE MANAGE, V50, P1350; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Moya J, 2004, PEDIATRICS, V113, P996; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Pino P, 2004, EPIDEMIOLOGY, V15, P702, DOI 10.1097/01.ede.0000142153.28496.d0; Rogers JF, 2000, AM J EPIDEMIOL, V151, P602; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Salvi S, 2001, Curr Opin Allergy Clin Immunol, V1, P35; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819; SCHWARTZ DA, 1994, AM J RESP CRIT CARE, V150, P1243; Schwartz J, 2004, PEDIATRICS, V113, P1037; STROM KA, 1990, J TOXICOL ENV HEALTH, V29, P377; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; Tang CS, 2007, SCI TOTAL ENVIRON, V382, P43, DOI 10.1016/j.scitotenv.2007.04.016; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Trenga CA, 2001, ARCH ENVIRON HEALTH, V56, P242; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Xu XP, 1995, ARCH ENVIRON HEALTH, V50, P407	65	82	87	3	19	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1526-0542			PAEDIATR RESPIR REV	Paediatr. Respir. Rev.	DEC	2007	8	4					275	280		10.1016/j.prrv.2007.08.008		6	Pediatrics; Respiratory System	Pediatrics; Respiratory System	241XA	WOS:000251687900002	18005894	
J	Nielsen, GD; Larsen, ST; Olsen, O; Lovik, M; Poulsen, LK; Glue, C; Wolkoff, P				Nielsen, G. D.; Larsen, S. T.; Olsen, O.; Lovik, M.; Poulsen, L. K.; Glue, C.; Wolkoff, P.			Do indoor chemicals promote development of airway allergy?	INDOOR AIR			English	Review						volatile organic compounds; quaternary ammonium compounds; cleaning agents; surfactants; phthalates; adjuvant	VOLATILE ORGANIC-COMPOUNDS; SUSPENDED PARTICULATE MATTER; SUBTILISIN CARLSBERG ALCALASE; QUATERNARY AMMONIUM-COMPOUNDS; SUBCUTANEOUS INJECTION MODEL; OZONE OXIDATION-PRODUCTS; WORK-RELATED ASTHMA; IN-HOUSE DUST; YOUNG-CHILDREN; OCCUPATIONAL EXPOSURES	Allergic asthma has increased worldwide in the industrialized countries. This review evaluates whether the major groups of indoor chemical exposures possess allergy-promoting (adjuvant) effects; formaldehyde was excluded, because of the size of the literature. Volatile organic compounds (VOCs) are used as an example of gases and vapors. The precipitation of asthmatic symptoms by VOC exposures is probably because of VOC levels considerably above typical indoor levels, or VOCs may be a surrogate for exposure to allergens, combustion products or dampness. Indoor particles possessed adjuvant effects in animal studies and allergy-promoting effects in humans. Quaternary ammonium compounds may possess adjuvant effects in animal studies and promoted sensitization in humans in occupational settings. The use of cleaning agents, anionic and non-ionic surfactants are not considered to possess an important adjuvant effect in the general population. Regarding phthalate exposures, results from animal and epidemiological studies were found to be discordant. There is little evidence that the indoor chemicals evaluated possess important adjuvant effects. If buildings are kept clean, dry and free of combustion products, the important question may be would it be profitable to look for lifestyle factors and non-chemical indoor exposures in order to abate airway allergy?	Natl Inst Occupat Hlth Denmark, DK-2100 Copenhagen O, Denmark; Norwegian Inst Publ Hlth, Dept Environm Immunol, Div Environm Med, Oslo, Norway; Natl Univ Hosp, Allergy Clin, Copenhagen, Denmark	Nielsen, GD (reprint author), Natl Inst Occupat Hlth Denmark, Lerso Parkalle 105, DK-2100 Copenhagen O, Denmark.	gdn@ami.dk		Wolkoff, Peder/0000-0003-1933-7351			Ameille J, 2003, OCCUP ENVIRON MED, V60, P136, DOI 10.1136/oem.60.2.136; Arif AA, 2003, AM J IND MED, V44, P368, DOI 10.1002/ajim.10291; Becher R, 1996, TOXICOL LETT, V86, P155, DOI 10.1016/0378-4274(96)03685-5; Blanc PD, 2005, J OCCUP ENVIRON MED, V47, P362, DOI 10.1097/01.jom.0000158708.32491.9d; Bluyssen PM, 1996, INDOOR AIR, V6, P221, DOI 10.1111/j.1600-0668.1996.00002.x; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2005, INDOOR AIR, V15, P275, DOI 10.1111/j.1600-0668.2005.00372.x; Bornehag CG, 2004, INDOOR AIR, V14, P243, DOI 10.1111/j.1600-0668.2004.00240.x; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, pA152; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bosgra S, 2005, REGUL TOXICOL PHARM, V43, P104, DOI 10.1016/j.yrtph.2005.06.008; Branis M, 2002, INDOOR BUILT ENVIRON, V11, P184, DOI 10.1159/000066018; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Brown S.K., 1999, ORGANIC INDOOR AIR P, P171; Brugge D, 2003, INDOOR AIR, V13, P18, DOI 10.1034/j.1600-0668.2003.01130.x; Butala JH, 2004, TOXICOLOGY, V201, P77, DOI 10.1016/j.tox.2004.04.004; Cain WS, 2005, INDOOR AIR, V15, P445, DOI 10.1111/j.1600-0668.2005.00390.x; Calzavara Thomas S, 2003, Appl Occup Environ Hyg, V18, P358, DOI 10.1080/10473220301366; Carlsen KCL, 2002, PEDIATR ALLERGY IMMU, V13, P29; Clausen PA, 2001, ENVIRON INT, V26, P511, DOI 10.1016/S0160-4120(01)00035-6; Clausen PA, 1998, J CHROMATOGR A, V814, P161, DOI 10.1016/S0021-9673(98)00397-5; Clausen SK, 2000, FOOD CHEM TOXICOL, V38, P1065, DOI 10.1016/S0278-6915(00)00092-2; Clausen SK, 2003, TOXICOLOGY, V184, P51, DOI 10.1016/S0300-483X(02)00583-8; CUMBERBATCH M, 1993, TOXICOLOGY, V77, P181, DOI 10.1016/0300-483X(93)90148-L; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; Dales R, 2004, J ASTHMA, V41, P259, DOI 10.1081/JAS-120026082; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Delfino RJ, 2003, J EXPO ANAL ENV EPID, V13, P348, DOI 10.1038/sj.jea.7500287; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; Erwin EA, 2005, INDOOR AIR, V15, P33, DOI 10.1111/j.1600-0668.2005.00355.x; Ferro AR, 2004, J EXPO ANAL ENV EPID, V14, pS34, DOI 10.1038/sj.jea.7500356; Ferro AR, 2004, ENVIRON SCI TECHNOL, V38, P1759, DOI 10.1021/es0263893; Fiedler N, 2005, ENVIRON HEALTH PERSP, V113, P1542, DOI 10.1289/ehp.8132; Flyvholm MA, 2005, CONTACT DERMATITIS, V53, P27, DOI 10.1111/j.0105-1873.2005.00629.x; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Fromme H, 2004, INDOOR AIR, V14, P188, DOI 10.1046/j.1600-0668.2003.00223.x; Granum B, 2002, TOXICOL SCI, V65, P7, DOI 10.1093/toxsci/65.1.7; Granum B, 2001, TOXICOL LETT, V118, P171, DOI 10.1016/S0378-4274(00)00292-7; Harrison RM, 2004, SCI TOTAL ENVIRON, V334, P3, DOI 10.1016/j.scitotenv.2004.04.059; HARVING H, 1991, AM REV RESPIR DIS, V143, P751; He CR, 2004, ATMOS ENVIRON, V38, P3405, DOI 10.1016/j.atmosenv.2004.03.027; Hersoug LG, 2005, INDOOR AIR, V15, P363, DOI 10.1111/j.1600-0668.2005.00382.x; HILGERS LAT, 1992, RES IMMUNOL, V143, P494, DOI 10.1016/0923-2494(92)80060-X; Hodgson AT, 2000, INDOOR AIR, V10, P178, DOI 10.1034/j.1600-0668.2000.010003178.x; *ICRP, 1981, 23 ICRP, P345; Isaksson Marlene, 2002, Contact Dermatitis, V47, P312, DOI 10.1034/j.1600-0536.2002.4705104.x; Ito Y, 2005, ARCH TOXICOL, V79, P147, DOI 10.1007/s00204-004-0615-7; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jarand Curtis W, 2002, Appl Occup Environ Hyg, V17, P491, DOI 10.1080/10473220290035705; Jones AP, 2000, J ASTHMA, V37, P103, DOI 10.3109/02770900009055434; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; Kawabata TT, 1996, FUND APPL TOXICOL, V29, P238, DOI 10.1006/faat.1996.0027; Kelly TJ, 1999, ENVIRON SCI TECHNOL, V33, P81, DOI 10.1021/es980592+; Kildeso J, 1999, ATMOS ENVIRON, V33, P699, DOI 10.1016/S1352-2310(98)00258-1; Kildeso J, 1998, INDOOR AIR, V8, P12, DOI 10.1111/j.1600-0668.1998.t01-3-00003.x; KLIMISCH HJ, 1992, FOOD CHEM TOXICOL, V30, P915, DOI 10.1016/0278-6915(92)90175-K; Klimisch HJ, 1998, FOOD CHEM TOXICOL, V36, P165, DOI 10.1016/S0278-6915(97)00134-8; Klinguer-Hamour C, 2002, VACCINE, V20, P2743, DOI 10.1016/S0264-410X(02)00193-7; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; Krone CA, 2004, ARCH ENVIRON HEALTH, V59, P306; Landau L I, 2001, Paediatr Respir Rev, V2, P202, DOI 10.1053/prrv.2001.0141; Larsen ST, 2004, BASIC CLIN PHARMACOL, V95, P94; Larsen ST, 2004, TOXICOL LETT, V151, P389, DOI 10.1016/j.toxlet.2004.03.008; Larsen ST, 2003, FOOD CHEM TOXICOL, V41, P439, DOI 10.1016/S0278-6915(02)00248-X; Larsen ST, 2001, TOXICOL LETT, V125, P11; Larsen ST, 2001, TOXICOLOGY, V169, P37, DOI 10.1016/S0300-483X(01)00484-X; LARSEN ST, 2004, MILJO SUNDHED, V10, P13; Laumbach RJ, 2005, J OCCUP ENVIRON MED, V47, P1182, DOI 10.1097/01.jom.0000183338.95778.f0; Le Moual N, 2004, AM J EPIDEMIOL, V160, P1108, DOI 10.1093/aje/kwh316; Leong KP, 2001, ANN ALLERG ASTHMA IM, V87, P96; Lewis RG, 1999, ENVIRON HEALTH PERSP, V107, P721, DOI 10.2307/3434657; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P969; Long CM, 2000, J AIR WASTE MANAGE, V50, P1236; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Lynch RM, 2000, ENVIRON HEALTH PERSP, V108, P911, DOI 10.1289/ehp.00108911; Mapp CE, 2000, EUR RESPIR J, V16, P570, DOI 10.1034/j.1399-3003.2000.016003570.x; MARKHAM RJF, 1976, INT ARCH ALLER A IMM, V51, P529; McCusker Christine T, 2004, Curr Opin Allergy Clin Immunol, V4, P11, DOI 10.1097/00130832-200402000-00004; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; MOLHAVE L, 1995, INDOOR AIR, V5, P104, DOI 10.1111/j.1600-0668.1995.t01-2-00002.x; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Nazaroff WW, 2004, ATMOS ENVIRON, V38, P2841, DOI 10.1016/j.atmosenv.2004.02.040; Nielsen GD, 2005, TOXICOLOGY, V216, P87, DOI 10.1016/j.tox.2005.07.022; Nielsen GD, 2002, PHARMACOL TOXICOL, V90, P231, DOI 10.1034/j.1600-0773.2002.900502.x; Nielsen GD, 1997, INDOOR AIR, V7, P17; NIELSEN GD, 1991, CRIT REV TOXICOL, V21, P183, DOI 10.3109/10408449109089879; Nilsson A, 2005, ENVIRON INT, V31, P1141, DOI 10.1016/j.envint.2005.04.003; NORDBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Ormstad H, 1998, TOXICOLOGY, V129, P227, DOI 10.1016/S0300-483X(98)00079-1; Ormstad H, 1997, SCI TOTAL ENVIRON, V193, P185, DOI 10.1016/S0048-9697(96)05337-5; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; Pasanen AL, 1998, ENVIRON INT, V24, P703, DOI 10.1016/S0160-4120(98)00065-8; Petrovsky N, 2004, IMMUNOL CELL BIOL, V82, P488, DOI 10.1111/j.1440-1711.2004.01272.x; PIERSON WE, 1989, WESTERN J MED, V151, P339; Post WK, 1998, OCCUP ENVIRON MED, V55, P119; Poulsen LK, 2000, TOXICOLOGY, V152, P79, DOI 10.1016/S0300-483X(00)00294-8; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; Purohit A, 2000, INT ARCH OCC ENV HEA, V73, P423, DOI 10.1007/s004200000162; Putus T, 2004, ARCH ENVIRON HEALTH, V59, P194, DOI 10.3200/AEOH.59.4.194-201; Robinson MK, 1996, FUND APPL TOXICOL, V34, P15, DOI 10.1006/faat.1996.0171; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; SALTHAMMER T, 1995, INDOOR AIR, V5, P120, DOI 10.1111/j.1600-0668.1995.t01-2-00003.x; Schneider T, 2003, INDOOR AIR, V13, P38, DOI 10.1034/j.1600-0668.2003.02025.x; Sherriff A, 2005, THORAX, V60, P45, DOI 10.1136/thx.2004.021154; Silvestri Michela, 2004, Paediatr Respir Rev, V5 Suppl A, pS81, DOI 10.1016/S1526-0542(04)90016-4; Soderholm S. C., 1993, APPL OCCUP ENV HYG, V8, P453; STENTON SC, 1990, BRIT J IND MED, V47, P405; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1; TEERLINK T, 1987, VACCINE, V5, P307, DOI 10.1016/0264-410X(87)90157-5; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Tuomainen Anneli, 2004, Int Arch Occup Environ Health, V77, P222, DOI 10.1007/s00420-003-0481-2; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.0.CO;2-2; van Thriel C, 2005, ENVIRON TOXICOL PHAR, V19, P589, DOI 10.1016/j.etap.2004.12.024; Vejrup KV, 2002, SCI TOTAL ENVIRON, V300, P51, DOI 10.1016/S0048-9697(02)00280-2; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Vogelzang PFJ, 2000, CHEST, V117, P1488, DOI 10.1378/chest.117.5.1488; Wallace LA, 2004, ENVIRON SCI TECHNOL, V38, P2304, DOI 10.1021/es0306260; WALLACE LA, 1989, ENVIRON HEALTH PERSP, V82, P165; WALTER SD, 1978, INT J EPIDEMIOL, V7, P175, DOI 10.1093/ije/7.2.175; Weisel CP, 2002, ENVIRON HEALTH PERSP, V110, P527; Weschler CJ, 2003, ATMOS ENVIRON, V37, P5455, DOI 10.1016/j.atmosenv.2003.09.022; Weschler CJ, 2000, INDOOR AIR, V10, P269, DOI 10.1034/j.1600-0668.2000.010004269.x; *WHO, 1989, EURO REP STUD, V111, P1; *WHO, 1983, ENV HLTH CRIT, V27, P39; World Health Organization, 2000, EM OTH COMM DIS STRA, P1; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Wieslander G, 1997, ANN OCCUP HYG, V41, P155, DOI 10.1016/S0003-4878(96)00039-7; Wilson Nicola M, 2003, Paediatr Respir Rev, V4, P184, DOI 10.1016/S1526-0542(03)00052-6; Wirts M, 2002, ENVIRON SCI TECHNOL, V36, P1827, DOI 10.1021/es015538z; Wolkoff P, 2006, INDOOR AIR, V16, P7, DOI 10.1111/j.1600-0668.2005.00393.x; WOLKOFF P, 1994, INDOOR AIR, V4, P248, DOI 10.1111/j.1600-0668.1994.00005.x; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Wolkoff P, 1995, INDOOR AIR, P1, DOI 10.1111/j.1600-0668.1995.tb00017.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zhang GC, 2005, PEDIATR ALLERGY IMMU, V16, P587, DOI 10.1111/j.1399-3038.2005.00325.x; Zhang JF, 2003, BRIT MED BULL, V68, P209, DOI 10.1093/bmb/ldg029; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	151	82	83	6	25	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	JUN	2007	17	3					236	255		10.1111/j.1600-0668.2006.00468.x		20	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	183VM	WOS:000247600500007	17542836	
J	Chan, DS; Callahan, CW; Hatch-Pigott, VB; Lawless, A; Proffitt, HL; Manning, NE; Schweikert, M; Malone, FJ				Chan, Debora S.; Callahan, Charles W.; Hatch-Pigott, Virginia B.; Lawless, Annette; Proffitt, H. Lorraine; Manning, Nola E.; Schweikert, Mary; Malone, Francis J.			Internet-based home monitoring and education of children with asthma is comparable to ideal office-based care: Results of a 1-year asthma in-home monitoring trial	PEDIATRICS			English	Article						telemedicine; home; telehealth; telemonitoring; store-and-forward; clinic; case management; pediatric	METERED-DOSE INHALER; MANAGEMENT; TELEMEDICINE; IMPROVEMENT; PREVENTION; DEPOSITION; QUALITY; THERAPY; PROGRAM	OBJECTIVE. The goal was to determine whether home asthma telemonitoring with store- and- forward technology improved outcomes, compared with in- person, office- based visits. METHODS. A total of 120 patients, 6 to 17 years of age, with persistent asthma were assigned randomly to the office- based or virtual group. The 2 groups followed the same ambulatory clinical pathway for 12 months. Office- based group patients received traditional in- person education and case management. Virtual group patients received computers, Internet connections, and in- home, Internet- based case management and received education through the study Web site. Disease control outcome measures included quality of life, utilization of services, and symptom control. RESULTS. A total of 120 volunteers ( 45 female) were enrolled. The groups were clinically comparable ( office- based: 22 female/ 38 male; mean age: 9.0 +/- 3.0 years; virtual: 23 female/ 37 male; mean age: 10.2 +/- 3.1 years). Virtual patients had higher metered- dose inhaler with valved holding chamber technique scores than did the office- based group at 52 weeks ( 94% vs 89%), had greater adherence to daily asthma symptom diary submission ( 35.4% vs 20.8%), had less participant time ( 636 vs 713 patient- months), and were older. Caregivers in both groups perceived an increase in quality of life and an increase in asthma knowledge scores from baseline. There were no other differences in therapeutic or disease control outcome measures. CONCLUSIONS. Virtual group patients achieved excellent asthma therapeutic and disease control outcomes. Compared with those who received standardized officebased care, they were more adherent to diary submission and had better inhaler scores at 52 weeks. Store- and- forward telemedicine technology and case management provide additional tools to assist in the management of children with persistent asthma.	Tripler Army Med Ctr, Dept Pediat, MCHK PE, Honolulu, HI 96859 USA	Chan, DS (reprint author), Tripler Army Med Ctr, Dept Pediat, MCHK PE, 1 Jarrett White Rd, Honolulu, HI 96859 USA.	debora.chan@haw.tamc.amedd.army.mil					Barry E, 1998, Telemed Virtual Real, V3, P61; Blais L, 1998, AM J RESP CRIT CARE, V158, P126; Bynum A, 2001, TELEMED J E-HEALTH, V7, P207, DOI 10.1089/153056201316970902; Callahan CW, 2000, CHEST, V117, P1226, DOI 10.1378/chest.117.5.1226; Chan DS, 2001, AM J HEALTH-SYST PH, V58, P1413; CHAN DS, 2003, AM J HEALTH-SYST PH, V60, P1; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; Eliasson AH, 1998, MIL MED, V163, P530; Finkelstein J, 1998, Proc AMIA Symp, P336; FINKELSTEIN J, 2000, CHEST, V117, P147; Greenberger PA, 1996, AM J MED, V100, P381, DOI 10.1016/S0002-9343(97)89511-3; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; Headrick L, 1996, AM J RESP CRIT CARE, V154, pS96; Institute of Medicine, 2001, CROSS QUAL CHASM NEW; Karp WB, 2000, PEDIATRICS, V105, P843, DOI 10.1542/peds.105.4.843; Kokubu F, 2000, Arerugi, V49, P19; Malone F, 2004, TELEMED J E-HEALTH, V10, P138, DOI 10.1089/1530562041641192; MCQUESTON JA, 1996, DOD ASTHMA OUTCOMES; National Heart Lung and Blood Institute National Asthma Education Program, 1997, NIH PUBL; Person D A, 2000, Pac Health Dialog, V7, P29; Reddel HK, 1998, EUR RESPIR J, V12, P853, DOI 10.1183/09031936.98.12040853; Romano MJ, 2001, TELEMED J E-HEALTH, V7, P281, DOI 10.1089/15305620152814683; Tal A, 1996, J PEDIATR-US, V128, P479, DOI 10.1016/S0022-3476(96)70357-8; *US DEP HHS NAT HE, 2002, GUID DIAGN MAN ASTHM; Wildhaber JH, 1999, J PEDIATR-US, V135, P28, DOI 10.1016/S0022-3476(99)70323-9; Wojtczak H, 1999, AM J RESP CRIT CARE, V159, pA756	26	82	85	2	19	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2007	119	3					569	578		10.1542/peds.2006-1884		10	Pediatrics	Pediatrics	141LK	WOS:000244579800017	17332210	
J	Lienhardt, C; Fielding, K; Sillah, JS; Bah, B; Gustafson, P; Warndorff, D; Palayew, M; Lisse, I; Donkor, S; Diallo, S; Manneh, K; Adegbola, R; Aaby, P; Bah-Sow, O; Bennett, S; McAdam, K				Lienhardt, C; Fielding, K; Sillah, JS; Bah, B; Gustafson, P; Warndorff, D; Palayew, M; Lisse, I; Donkor, S; Diallo, S; Manneh, K; Adegbola, R; Aaby, P; Bah-Sow, O; Bennett, S; McAdam, K			Investigation of the risk factors for tuberculosis: a case-control study in three countries in West Africa	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						tuberculosis; risk factors; epidemiology; developing countries	SUB-SAHARAN AFRICA; PULMONARY TUBERCULOSIS; SOCIOECONOMIC-STATUS; NORTHERN MALAWI; BCG SCARS; SUSCEPTIBILITY; SMOKING; HIV; EPIDEMIOLOGY; DEPRIVATION	Background Host-related and environment-related factors have been shown to play a role in the development of tuberculosis (TB), but few studies were carried out to identify their respective roles in resource-poor countries. Methods A multicentre case-control study was conducted in Guinee, Guinea Bissau, and The Gambia, from January 1999 to March 2001. Cases were newly detected smear positive TB patients. TWO controls were recruited for each case, one within the household of the case, and one in the community. Results Regarding host-related factors, univariate analysis by conditional logistic regression of 687 matched pairs of cases and household controls showed that TB was associated with male sex, family history of TB, absence of a BCG scar, smoking, alcohol, anaemia, HIV infection, and history and treatment of worm infection. In a multivariable model based on 601 matched pairs, male sex, family history of TB, smoking, and HIV infection were independent risk factors of TB. The investigation of environmental factors based on the comparison of 816 cases/community control pairs showed that the risk of TB was associated with single marital status, family history of TB, adult crowding, and renting the house. In a final model assessing the combined effect of host and environmental factors, TB was associated with male sex, HIV infection, smoking (with a dose-effect relationship), history of asthma, family history of TB, marital status, adult crowding, and renting the house. Conclusion TB is a multifactorial disorder, in which environment interacts with host-related factors. This study provided useful information for the assessment of host and environmental factors of TB for the improvement of TB control activities in developing countries.	Inst Rech Dev, Dakar, Senegal; MRC Labs, Fajara, Gambia; London Sch Hyg & Trop Med, London WC1, England; CHU Ignace Deen, Programme Natl Lutte AntiTuberculeuse, Serv Pneumol, Conakry, Guinea; Danish Epidemiol Sci Ctr, Projecto Saude Bandim, Bissau, Guinea Bissau; McGill Univ, Jewish Gen Hosp, Div Pulm Med, Montreal, PQ H3A 2T5, Canada	Lienhardt, C (reprint author), Inst Rech Dev, UR 36,BP 1386, Dakar, Senegal.	lienhardt@dakar.ird.sn					Alcaide J, 1996, TUBERCLE LUNG DIS, V77, P112, DOI 10.1016/S0962-8479(96)90024-6; ANDERSEN S, 1960, Bull World Health Organ, V22, P39; Aubry MC, 2000, CLIN CHEST MED, V21, P11, DOI 10.1016/S0272-5231(05)70005-8; Bellamy R, 2000, P NATL ACAD SCI USA, V97, P8005, DOI 10.1073/pnas.140201897; Bennett S, 2002, AM J EPIDEMIOL, V155, P1074, DOI 10.1093/aje/155.11.1074; BHATTI N, 1995, BRIT MED J, V310, P967; Bornman L, 2004, J INFECT DIS, V190, P1631, DOI 10.1086/424462; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; BRUDNEY K, 1991, AM REV RESPIR DIS, V144, P7415; BUSKIN SE, 1994, AM J PUBLIC HEALTH, V84, P1750, DOI 10.2105/AJPH.84.11.1750; Cantwell MF, 1998, AM J RESP CRIT CARE, V157, P1016; COMSTOCK GW, 1982, AM REV RESPIR DIS, V125, P8; Corbett EL, 2003, ARCH INTERN MED, V163, P1009, DOI 10.1001/archinte.163.9.1009; DECOCK KM, 1994, TUBERCULOSIS BACK FU; Diwan VK, 1999, LANCET, V353, P1000, DOI 10.1016/S0140-6736(99)01318-5; DRUCKER E, 1994, LANCET, V343, P1482, DOI 10.1016/S0140-6736(94)92588-7; Dubos R, 1987, WHITE PLAGUE TUBERCU; FINE PEM, 1981, INT J LEPROSY, V49, P437; Fine PEM, 1996, LANCET, V348, P17; FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35; Floyd S, 2000, INT J TUBERC LUNG D, V4, P1133; Frost WH, 1933, AM J PUBLIC HEALTH N, V23, P426, DOI 10.2105/AJPH.23.5.426; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Glynn JR, 2000, T ROY SOC TROP MED H, V94, P500, DOI 10.1016/S0035-9203(00)90065-8; Gustafson P, 2004, INT J EPIDEMIOL, V33, P163, DOI 10.1093/ije/dyh026; Harper M, 2003, T ROY SOC TROP MED H, V97, P506, DOI 10.1016/S0035-9203(03)80007-X; Holmes CB, 1998, INT J TUBERC LUNG D, V2, P96; Hudelson P, 1996, TUBERCLE LUNG DIS, V77, P391, DOI 10.1016/S0962-8479(96)90110-0; KASS EH, 1971, J INFECT DIS, V123, P110; Kolappan C, 2002, THORAX, V57, P964, DOI 10.1136/thorax.57.11.964; Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC; Lienhardt C, 2002, EUR J IMMUNOL, V32, P1605, DOI 10.1002/1521-4141(200206)32:6<1605::AID-IMMU1605>3.0.CO;2-6; Lienhardt C, 2001, EPIDEMIOL REV, V23, P288; Lienhardt C, 2002, AM J EPIDEMIOL, V155, P1066, DOI 10.1093/aje/155.11.1066; MANGTANI P, 1995, BRIT MED J, V310, P963; Mukadi YD, 1997, AIDS, V11, P1151, DOI 10.1097/00002030-199709000-00011; Rieder HL, 1999, EPIDEMIOLOGICAL BASI; SCHOEMAN JH, 1991, INT J EPIDEMIOL, V20, P435, DOI 10.1093/ije/20.2.435; SHIRAKAWA T, 1997, SCIENCE, V275, P7; SPENCE DPS, 1993, BRIT MED J, V307, P759; Stein L, 1952, BR J SOC MED, V6, P1; Tocque K, 1998, INT J TUBERC LUNG D, V2, P213; Van Rie A, 1999, NEW ENGL J MED, V341, P1174, DOI 10.1056/NEJM199910143411602; von Mutius E, 2000, THORAX, V55, P449, DOI 10.1136/thorax.55.6.449; World Health Organization, 2001, WHOCDSTB2001287; World Health Organization, 2003, WHO FRAM CONV TOB CO	46	82	88	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	AUG	2005	34	4					914	923		10.1093/ije/dyi100		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	957HG	WOS:000231360300038	15914505	
J	Russo, C; Polosa, R				Russo, C; Polosa, R			TNF-alpha as a promising therapeutic target in chronic asthma: a lesson from rheumatoid arthritis	CLINICAL SCIENCE			English	Review						asthma; biological therapy; cytokine; inflammation; rheumatoid arthritis; TNF-alpha (turnout necrosis factor-alpha)	TUMOR-NECROSIS-FACTOR; ADHESION MOLECULE EXPRESSION; EPIDERMAL-GROWTH-FACTOR; LUNG MAST-CELLS; NF-KAPPA-B; ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MESSENGER-RNA; SMOOTH-MUSCLE; IN-VITRO	TNF-alpha (tumour necrosis factor-alpha) is known to play a critical role in the pathogenic mechanisms of a number of chronic inflammatory diseases, including RA (rheumatoid arthritis), Crohn's disease and psoriasis. The notion that TNF-alpha is released in allergic responses from both mast cells and macrophages via IgE-dependent mechanisms, the demonstration that elevated levels of TNF-a are frequently observed in bronchoalveolar fluid of asthmatic subjects undergoing allergen challenge and the results from exposure studies of TNF-alpha in vivo showing increases in airway responsiveness in both normal and asthmatic subjects emphasize the importance of TNF-alpha in the initiation of allergic asthmatic airway inflammation and the generation of airway hyper-responsiveness. Drugs targeting TNF-alpha have been developed to neutralize the deleterious effects of this inflammatory cytokine and have proved to be safe and effective in the treatment of patients with RA, Crohn's disease and psoriasis refractory to conventional treatments. Biological therapies blocking TNF-alpha are likely to constitute a considerable advance in the management of those difficult cases of asthma that are particularly resistant to typical treatment modalities. In this review article, we intend to address the potential role of TNF-alpha in asthma and to put forward the idea that drugs that have been developed to neutralize the deleterious effects of TNF-alpha may also be useful in the management of chronic severe asthma.	Catania Univ, Ascoli Tomaselli Hosp, Dipartimento Med Interna & Specialistica, I-95125 Catania, Italy	Polosa, R (reprint author), Catania Univ, Ascoli Tomaselli Hosp, Dipartimento Med Interna & Specialistica, Via Passo Gravina 187, I-95125 Catania, Italy.	rp5@soton.ac.uk					ABDELAZIZ MM, 1995, AM J RESP CELL MOL, V13, P728; Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Amrani Y, 2000, Respir Res, V1, P49, DOI 10.1186/rr12; Babu K., 2003, Journal of Allergy and Clinical Immunology, V111, pS277, DOI 10.1016/S0091-6749(03)80997-1; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Bazzoni F, 1996, NEW ENGL J MED, V334, P1717; BAZZONI F, 1996, NEW ENGL J MED, V334, pS1; Bodey KJ, 1999, ALLERGY, V54, P1083, DOI 10.1034/j.1398-9995.1999.00889.x; Brown SL, 2002, ARTHRITIS RHEUM, V46, P3151, DOI 10.1002/art.10679; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Busse WW, 2001, NEW ENGL J MED, V344, P350; CEMBRZYNSKANOWAK M, 1993, AM REV RESPIR DIS, V147, P291; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278; Chung KF, 1999, EUR RESPIR J, V13, P1198; Coward WR, 2002, J IMMUNOL, V169, P5287; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Ellerin T, 2003, ARTHRITIS RHEUM, V48, P3013, DOI 10.1002/art.11301; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; FINOTTO S, 1994, J IMMUNOL, V153, P2278; GOSSET P, 1992, AM REV RESPIR DIS, V146, P768; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; Grant EN, 1999, J ALLERGY CLIN IMMUN, V104, pS1, DOI 10.1016/S0091-6749(99)70268-X; Hamilos DL, 1999, J ALLERGY CLIN IMMUN, V103, P79, DOI 10.1016/S0091-6749(99)70529-4; Idriss HT, 2000, MICROSC RES TECHNIQ, V50, P184, DOI 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H; Jobanputra P, 2002, Health Technol Assess, V6, P1; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; KHALILSAADEH C, 2002, J ALLERGY CLIN IM S1, V109, pS243; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332; Kobelt G, 2003, RHEUMATOLOGY, V42, P326, DOI 10.1093/rheumatology/keg107; LASSALLE P, 1993, CLIN EXP IMMUNOL, V94, P105; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196; Li Kam Wa TC, 1999, CLIN EXP ALLERGY, V29, P1204, DOI 10.1046/j.1365-2222.1999.00638.x; Lorenz HM, 2002, ARTHRITIS RES THER, V4, pS17, DOI 10.1186/ar564; Louis R, 2000, EUR RESPIR J, V16, P604, DOI 10.1034/j.1399-3003.2000.16d06.x; Mariette X, 2002, BLOOD, V99, P3909, DOI 10.1182/blood.V99.11.3909; Matheson JM, 2002, AM J RESP CELL MOL, V27, P396, DOI 10.1165/rcmb.4614; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; Moffatt MF, 1999, THORAX, V54, P757; Mohan N, 2001, ARTHRITIS RHEUM, V44, P2862, DOI 10.1002/1529-0131(200112)44:12<2862::AID-ART474>3.0.CO;2-W; Moreland LW, 2001, J RHEUMATOL, V28, P1238; Nakamura Y, 2004, J IMMUNOL, V172, P1945; [Anonymous], 1997, NIH PUBL; OHKAWARA Y, 1992, AM J RESP CELL MOL, V7, P385; PALOMBELLA VJ, 1988, J CELL PHYSIOL, V135, P23, DOI 10.1002/jcp.1041350104; Panettieri Reynold A. Jr., 2002, Journal of Allergy and Clinical Immunology, V110, pS269, DOI 10.1067/mai.2002.129429; PAULSSON Y, 1989, EXP CELL RES, V180, P490, DOI 10.1016/0014-4827(89)90075-X; Pennings HJ, 1998, EUR RESPIR J, V12, P45, DOI 10.1183/09031936.98.12010045; Polosa R, 2004, J ALLERGY CLIN IMMUN, V113, P120, DOI 10.1016/j.jaci.2003.09.040; Renzetti LM, 1996, J PHARMACOL EXP THER, V278, P847; Schwingshackl A, 1999, J ALLERGY CLIN IMMUN, V104, P983; Scichilone N, 2004, CLIN EXP ALLERGY, V34, P1168, DOI 10.1111/j.1365-2222.2004.02020.x; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; Thomas PS, 2001, IMMUNOL CELL BIOL, V79, P132, DOI 10.1046/j.1440-1711.2001.00980.x; Thomas PS, 2002, THORAX, V57, P774, DOI 10.1136/thorax.57.9.774; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76; Toussirot E, 2004, EXPERT OPIN PHARMACO, V5, P581, DOI 10.1517/eoph.5.3.581.27357; Trabetti E, 1999, J MED GENET, V36, P323; Wajant H, 2001, CELL SIGNAL, V13, P389, DOI 10.1016/S0898-6568(01)00160-7; Weisman MH, 2002, J RHEUMATOL, V29, P33; Wilson SJ, 2001, AM J RESP CRIT CARE, V164, P1047; Witte JS, 2002, EUR J HUM GENET, V10, P82, DOI 10.1038/sj/ejhg/5200746; XING Z, 1993, AM J PATHOL, V143, P1009; Yamamoto H, 1998, J IMMUNOL, V161, P971	65	82	83	0	2	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	0143-5221			CLIN SCI	Clin. Sci.	AUG	2005	109	2					135	142				8	Medicine, Research & Experimental	Research & Experimental Medicine	954FC	WOS:000231138500002	16033328	
J	Bradley, JP; Bacharier, LB; Bonfiglio, J; Schechtman, KB; Strunk, R; Storch, G; Castro, M				Bradley, JP; Bacharier, LB; Bonfiglio, J; Schechtman, KB; Strunk, R; Storch, G; Castro, M			Severity of respiratory syncytial virus bronchiolitis is affected by cigarette smoke exposure and atopy	PEDIATRICS			English	Article						RSV; bronchiolitis; asthma	ENVIRONMENTAL TOBACCO-SMOKE; MATERNAL SMOKING; LUNG-FUNCTION; RISK-FACTORS; CHILDHOOD ASTHMA; MECHANICAL VENTILATION; ALLERGIC SENSITIZATION; CHILDREN; INFECTION; PREGNANCY	Objective. Respiratory syncytial virus (RSV) bronchiolitis is a common cause of hospitalizations in children and has been increasingly identified as a risk factor in the development of asthma. Little is known about what determines the severity of RSV bronchiolitis, which may be helpful in the initial assessment of these children. Design. We evaluated a variety of environmental and host factors that may contribute to the severity of RSV bronchiolitis in the RSV Bronchiolitis in Early Life prospective cohort study. Severity of bronchiolitis was based on the quantization of lowest O-2 saturation and the length of stay. These factors included the child's and family's demographics, presence of household allergens (dust mite, cat, dog, and cockroach), peripheral blood eosinophil count, immunoglobulin E level, infant feeding, prior illnesses, exposure to intrauterine and postnatal cigarette smoke, and family history of atopy. Patients. We prospectively enrolled 206 hospitalized infants, all under 12 months old (4.0 +/- 3.3 months old), with their first episode of severe RSV bronchiolitis (mean O-2 saturation: 91.6 +/- 7.3%; length of stay: 2.5 +/- 2.5 days; presence of radiographic opacities: 75%). Patients were excluded for a variety of reasons including previous wheezing, regular use of bronchodilator or antiinflammatory medications, any preexisting lung disease including asthma, chronic lung disease of prematurity/bronchopulmonary dysplasia, or cystic fibrosis; gastroesophageal reflux disease on medical therapy; or congenital anomalies of the chest or lung. Results. Age was found to be a significant factor in the severity of infection. The younger an infant was, the more severe the infection tended to be as measured by the lowest oxygen (O-2) saturation. We also found that infants exposed to postnatal cigarette smoke from the mother had a lower O-2 saturation than those not exposed. However, there was no significant difference in RSV bronchiolitis severity between infants exposed only to intrauterine smoke and those infants never exposed to cigarette smoke. Infants with a family history of atopy, especially a maternal history of asthma or hay fever, had a higher O-2 saturation. Although a history of maternal atopy seemed to be protective, there was no association between allergens and bronchiolitis severity, although 25% of households had elevated allergen levels. Black infants demonstrated less severe RSV bronchiolitis than their white counterparts. Multivariate analysis revealed age, race, maternal atopy, and smoking to be associated with severity of RSV bronchiolitis. Conclusion. The severity of RSV bronchiolitis early in life seems modified by postnatal maternal cigarette smoke exposure and atopy and age of the infant, not by levels of allergens in the home environment.	Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA	Castro, M (reprint author), Washington Univ, Sch Med, Dept Internal Med, Campus Box 8052,660 S Euclid Ave, St Louis, MO 63110 USA.	castrom@wustl.edu		Bradley, Joseph/0000-0001-6408-9700	NHLBI NIH HHS [HL61895]		Aligne CA, 1997, ARCH PEDIAT ADOL MED, V151, P648; Castro M, 2001, J ASTHMA, V38, P625, DOI 10.1081/JAS-100107540; Corbo GM, 1996, AM J RESP CRIT CARE, V154, P695; COULTAS DB, 1993, AM J RESP CRIT CARE, V149, pS93; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; EVERARD ML, 1992, EUR J PEDIATR, V151, P638, DOI 10.1007/BF01957564; FRANKEL LR, 1986, PEDIATR PULM, V2, P307, DOI 10.1002/ppul.1950020511; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; GREEN M, 1989, PEDIATR INFECT DIS J, V8, P601, DOI 10.1097/00006454-198909000-00007; Gurkan F, 2000, EUR J EPIDEMIOL, V16, P465, DOI 10.1023/A:1007658411953; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Hofhuis W, 2003, ARCH DIS CHILD, V88, P1086, DOI 10.1136/adc.88.12.1086; Infante-Rivard C, 1999, AM J EPIDEMIOL, V150, P528; Lanari M, 2002, PEDIATR PULM, V33, P458, DOI 10.1002/ppul.10052; Larsson ML, 2001, CHEST, V120, P711, DOI 10.1378/chest.120.3.711; LAVIA WV, 1993, CLIN PEDIATR, V32, P450, DOI 10.1177/000992289303200801; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Martinez FD, 2001, J ALLERGY CLIN IMMUN, V107, pS449, DOI 10.1067/mai.2001.114993; Moler FW, 1999, AM J RESP CRIT CARE, V159, P1234; Robinson PJ, 1997, J ALLERGY CLIN IMMUN, V100, P492; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Singh SP, 2003, AM J RESP CRIT CARE, V168, P342, DOI 10.1164/rccm.200211.1262OC; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strannegard O, 1997, PEDIATR ALLERGY IMMU, V8, P1, DOI 10.1111/j.1399-3038.1997.tb00134.x; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; TISSING WJE, 1993, EUR J PEDIATR, V152, P125, DOI 10.1007/BF02072488; Weiss ST, 2001, J ALLERGY CLIN IMMUN, V107, P634, DOI 10.1067/mai.2001.113869	30	82	84	1	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JAN	2005	115	1					E7	E14		10.1542/peds.2004-0059		8	Pediatrics	Pediatrics	884KN	WOS:000226083700002	15629968	
J	Rolinck-Werninghaus, C; Wolf, H; Liebke, C; Baars, JC; Lange, J; Kopp, MV; Hammermann, J; Leupold, W; Bartels, P; Gruebl, A; Bauer, CP; Schnitker, J; Wahn, U; Niggemann, B				Rolinck-Werninghaus, C; Wolf, H; Liebke, C; Baars, JC; Lange, J; Kopp, MV; Hammermann, J; Leupold, W; Bartels, P; Gruebl, A; Bauer, CP; Schnitker, J; Wahn, U; Niggemann, B			A prospective, randomized, double-blind, placebo-controlled multi-centre study on the efficacy and safety of sublingual immunotherapy (SLIT) in children with seasonal allergic rhinoconjunctivitis to grass pollen	ALLERGY			English	Article						children; conjunctival provocation test; grass pollen; immunoglobulin E; immunoglobulin G(4); rye pollen; skin prick test; specific immunotherapy; sublingual immunotherapy	STANDARDIZED 5-GRASS-POLLEN EXTRACT; HOUSE-DUST MITE; CONTROLLED TRIAL; SWALLOW IMMUNOTHERAPY; CLINICAL-EFFICACY; HAY-FEVER; RHINITIS; ASTHMA; SENSITIZATIONS	Background: Especially in childhood, sublingual immunotherapy (SLIT) could offer advantages over subcutaneous therapy. However, limited data on its efficacy is available. Methods: In four German centres 97 children (age 3-14 years) with allergic rhinoconjunctivitis to grass pollen were enrolled in a prospective, double-blind trial comparing SLIT (Pangramin SLIT(R); ALK-SCHERAX, 0.5 mug major allergens, three times per week, 32 months) with placebo. Primary endpoint was a multiple symptom-medication score for changes in seasonal diary entries between the first and third year of the study (SLIT n = 39; placebo n = 38). Results: The multiple symptom-medication score was significantly reduced by SLIT to 77.3% of the placebo group (P = 0.0498). The subsequent analysis of the single endpoints did not reveal significant differences for symptom scores in favour of SLIT (85.1% of placebo group; P = 0.22). However, the medication score improved significantly (67.1% of placebo group; P = 0.0025). Furthermore, secondary endpoints assessing in vivo immune responses did not differ significantly between the groups. However, retrospective analysis showed some inhomogeneity for clinical and in vitro parameters at the beginning of the study. Allergic side effects with possible relation to the study drug were reported in both groups (SLIT 49%, placebo 27%, P = 0.026). Conclusion: Our study indicates that SLIT had a positive effect on the reduction of a multiple symptom-medication score, mainly by significantly reducing rescue medication use, but had no significant effect on symptoms alone in children with rhinoconjunctivitis to grass pollen compared with a placebo.	Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; ALK SCHERAX Arzneimittel GmbH, Clin Res, Hamburg, Germany; Univ Freiburg, Dept Pediat & Adolescent Med, Freiburg, Germany; Univ Childrens Hosp, Dresden, Germany; Tech Univ, Childrens Hosp, Munich, Germany; Inst Appl Stat Dr Joerg Schnitker GmbH, Bielefeld, Germany	Niggemann, B (reprint author), Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						Adkinson NF, 1999, NEW ENGL J MED, V341, P522, DOI 10.1056/NEJM199908123410710; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bousquet J., 2002, Allergy (Copenhagen), V57, P841, DOI 10.1034/j.1398-9995.2002.23625.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Joint Task Force, 1996, J ALLERGY CLIN IMMUN, V98, P1001; KHINCHI M, 2004, ALLERGY, V58, P45; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LEHMACHER W, 1991, BIOMETRICS, V47, P511, DOI 10.2307/2532142; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Malling HJ, 2002, CURR OPIN ALLERGY CL, V2, P523, DOI 10.1097/01.all.0000044538.45448.80; Malling HJ, 1998, ALLERGY, V53, P461; Malling HJ, 1993, ALLERGY          S14, V48, P7; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Noon L, 1911, LANCET, V1, P1572; OBRIEN PC, 1984, BIOMETRICS, V40, P1079, DOI 10.2307/2531158; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2004, ALLERGY, V59, P37, DOI 10.1046/j.1398-9995.2003.00397.x; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; STALDER JF, 1993, DERMATOLOGY, V186, P23; VARNEY VA, 1991, BRIT MED J, V302, P265; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WILSON D, 2003, COCHRANE LIB, V2	34	82	85	1	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	DEC	2004	59	12					1285	1293		10.1111/j.1398-9995.2004.00627.x		9	Allergy; Immunology	Allergy; Immunology	865WV	WOS:000224735800007	15507097	
J	Viegi, G; Simoni, M; Scognamiglio, A; Baldacci, S; Pistelli, F; Carrozzi, L; Annesi-Maesano, I				Viegi, G; Simoni, M; Scognamiglio, A; Baldacci, S; Pistelli, F; Carrozzi, L; Annesi-Maesano, I			Indoor air pollution and airway disease	INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE			English	Review						indoor pollution; biomass; ETS; particles; nitrogen oxides; VOC; epidemiology; asthma; COPD; respiratory health; prevention	VOLATILE ORGANIC-COMPOUNDS; ENVIRONMENTAL TOBACCO-SMOKE; EXPOSURE ASSESSMENT SURVEY; RESPIRATORY HEALTH SURVEY; NONCANCER END-POINTS; DEVELOPING-COUNTRIES; BRONCHIAL RESPONSIVENESS; PARTICULATE MATTER; PULMONARY-FUNCTION; CHILDHOOD ASTHMA	Scientific interest in indoor pollution has been increasing since the second half of the 1980s. Growing scientific evidence has shown that because people generally spend the majority of their time indoors, indoor pollution plays a significant role in affecting health and is thus an important health issue. Indoor environments include dwellings, workplaces, schools and day care centres, bars, discotheques and vehicles. Common indoor pollutants are environmental tobacco smoke, particulate matter, nitrogen dioxide, carbon monoxide, volatile organic compounds and biological allergens. In developing countries, relevant sources of indoor pollution include biomass and coal burning for cooking and heating. Concentrations of these pollutants can be many times higher indoors than outdoors. Indoor air pollution may increase the risk of irritation phenomena, allergic sensitisation, acute and chronic respiratory disorders and lung function impairment. Recent conservative estimates have shown that 1.5-2 million deaths per year worldwide could be attributed to indoor air pollution. Approximately I million of these deaths occur in children aged tinder 5 years due to acute respiratory infections and significant proportions of deaths occur due to chronic obstructive pulmonary disease and lung cancer in women. Today, indoor air pollution ranks tenth among preventable risk factors contributing to the global burden of disease. Further research is necessary to better evaluate the respiratory health effects of indoor pollution and to implement protective programmes for public health.	CNR, Inst Clin Physiol, Pulm Environm Epidemiol Unit, I-56126 Pisa, Italy; INSERM, U472, Epidemiol Allerg & Resp Dis Dept, Villejuif, France; Univ Hosp Pisa, Cardiothorac Dept, Pisa, Italy	Viegi, G (reprint author), CNR, Inst Clin Physiol, Pulm Environm Epidemiol Unit, Via Trieste 41, I-56126 Pisa, Italy.	viegig@ifc.cnr.it	Annesi-Maesano, Isabella/D-9173-2016				ALBERTS WM, 1994, J ALLERGY CLIN IMMUN, V94, P289, DOI 10.1016/0091-6749(94)90088-4; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1167, DOI 10.1046/j.1365-2222.2003.t01-1-01759.x; *AM THOR SOC, 1997, J RESP CRIT CARE M 2, V156, pS33; Annesi-Maesano I, 2003, EUR RESPIR J, V21, p57S, DOI 10.1183/09031936.03.00402103; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; BALDACCI S, 2001, EUR RESPIR J, V18, pS274; Bardana EJ, 2001, ANN ALLERG ASTHMA IM, V87, P33; Battistini A, 2000, Acta Biomed Ateneo Parmense, V71, P27; Billings C G, 1998, Monaldi Arch Chest Dis, V53, P43; BLANC PD, 2003, EUR RESP MON, V8, P118; Briggs D, 2003, BRIT MED BULL, V68, P1, DOI 10.1093/bmb/ldg019; BROOKS BO, 1991, J TOXICOL-CLIN TOXIC, V29, P315; BROWN VM, 2002, P INDOOR AIR, V4, P477; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; BRUNEKREEF B, 2000, EUR RESP MON, V5, P384; Carrer P, 2000, INDOOR AIR, V10, P258, DOI 10.1034/j.1600-0668.2000.010004258.x; Chan-Yeung M, 2004, INT J TUBERC LUNG D, V8, P2; CHEN B H, 1990, World Health Statistics Quarterly, V43, P127; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; De Vera MJ, 2003, ANN ALLERG ASTHMA IM, V91, P455; del Giudice MM, 2002, ALLERGY, V57, P169, DOI 10.1034/j.1398-9995.2002.1s3252.x; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; EHRLICH R, 1992, AM REV RESPIR DIS, V145, P594; *EUR COMM, EUR IFN SYST CHEM RI; European Federation of Allergy and Airways Diseases Patients' Associations, 2004, HLTH AIR DWELL EUR; Ezzati M, 2002, ENVIRON HEALTH PERSP, V110, P1057; Ezzati M, 2001, LANCET, V358, P1104; Ezzati M, 2001, LANCET, V358, P619, DOI 10.1016/S0140-6736(01)05777-4; FORASTIERE F, 1993, ARCH ENVIRON HEALTH, V48, P230; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; GILMOUR PS, 2002, EUR RESP MON, V7, P241; Golshan M, 2002, RESP MED, V96, P382, DOI 10.1053/rmed.2002.1288; Harris AG, 2002, EUR J MED RES, V7, P117; HELEN E, 2001, ALLERGY, V56, P646; Hong CJ, 1995, GLOBAL BURDEN DIS AI; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Jaakkola MS, 2002, EUR RESPIR J, V19, P172, DOI 10.1183/09031936.02.00270702; Jaakkola MS, 2000, EUR RESP MONOGR, V15, P322; Jacob B, 2002, ENVIRON HEALTH PERSP, V110, P647; Jaen A, 2002, CLIN EXP ALLERGY, V32, P1713, DOI 10.1046/j.1365-2222.2002.01539.x; JARVIS MJ, 1991, INT J EPIDEMIOL, V20, P126, DOI 10.1093/ije/20.1.126; KIM CS, 2002, P INDOOR AIR, V1, P492; Kiraz K, 2003, CLIN INVEST MED, V26, P243; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; LANGONE JJ, 1988, J IMMUNOL METHODS, V114, P73, DOI 10.1016/0022-1759(88)90156-1; Lanphear BP, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e98; LEBOWITZ MD, 1995, J EXPO ANAL ENV EPID, V5, P297; LEVESQUE B, 2001, SCI TOTAL ENVIRON, V281, P46; LICCARDI G, 2002, EUR RESP MON, V7, P226; Lin YC, 2002, CHEST, V121, P347, DOI 10.1378/chest.121.2.347; Lioy P J, 1991, J Expo Anal Environ Epidemiol, V1, P45; LIREPLO RG, 2003, J TOXICOL ENV HTLH B, V6, P85; Loan R, 2003, INDOOR AIR, V13, P232, DOI 10.1034/j.1600-0668.2003.00180.x; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MANNINO DM, 1995, INT ARCH OCC ENV HEA, V67, P59, DOI 10.1007/BF00383134; Maroni M, 2002, P IND AIR 2002, V4, P455; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; MURRAY CS, 2002, EUR RESP MONOGR, V7, P133; Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; NEAS LM, 1994, AM J EPIDEMIOL, V139, P1088; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Oberle D, 2003, ALLERGY, V58, P1033, DOI 10.1034/j.1398-9995.2003.00285.x; OCONNOR GT, 1987, AM REV RESPIR DIS, V135, P800; Oryszczyn MP, 2003, ALLERGY, V58, P1136, DOI 10.1046/j.1398-9995.2003.00314.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; PAN XC, 2002, P INDOOR AIR, V4, P982; Payne-Sturges DC, 2004, ENVIRON HEALTH PERSP, V112, P589; PELLIZZARI E, 1995, J EXPO ANAL ENV EPID, V5, P327; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; PIERSON TK, 1991, ENVIRON HEALTH PERSP, V95, P121; PIRKLE JL, 1995, ENVIRON HEALTH PERSP, V103, P45, DOI 10.2307/3432559; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Quackenboss J J, 1991, J Expo Anal Environ Epidemiol, V1, P83; QUACKENBOSS JJ, 1989, ENVIRON INT, V15, P353, DOI 10.1016/0160-4120(89)90048-2; Raw GJ, 2004, J EXPO ANAL ENV EPID, V14, pS85, DOI 10.1038/sj.jea.7500363; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rojas-Bracho L, 2000, J EXPO ANAL ENV EPID, V10, P294, DOI 10.1038/sj.jea.7500092; Rollin HB, 2004, INDOOR AIR, V14, P208, DOI 10.1111/j.1600-0668.2004.00238.x; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P465; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486; Samet JM, 2003, AM J PUBLIC HEALTH, V93, P1489, DOI 10.2105/AJPH.93.9.1489; SAMET JM, 1991, JAMA-J AM MED ASSOC, V266, P670, DOI 10.1001/jama.266.5.670; Sarinho E, 2004, BRAZ J MED BIOL RES, V37, P503, DOI 10.1590/S0100-879X2004000400007; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184; SATERI J, 2000, P INDOOR AIR, V3, P512; Schneider P, 2001, SCI TOTAL ENVIRON, V267, P41, DOI 10.1016/S0048-9697(00)00766-X; Schwela D, 1997, People Planet, V6, P24; SHOAF CR, 1991, ENVIRON HEALTH PERSP, V95, P111, DOI 10.2307/3431117; Simoni M, 2004, J EXPO ANAL ENV EPID, V14, pS144, DOI 10.1038/sj.jea.7500368; Simoni M, 2003, EUR RESPIR J, V21, p15S, DOI 10.1183/09031936.03.00403603; Simoni M, 1998, INDOOR AIR, V8, P70, DOI 10.1111/j.1600-0668.1998.t01-2-00002.x; Simoni M, 2002, ARCH ENVIRON HEALTH, V57, P130; Smith KR, 2000, P NATL ACAD SCI USA, V97, P13286, DOI 10.1073/pnas.97.24.13286; Smith KR, 2002, INDOOR AIR, V12, P198, DOI 10.1034/j.1600-0668.2002.01137.x; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; Smith KR, 2003, INT J HYG ENVIR HEAL, V206, P279, DOI 10.1078/1438-4639-00224; Spengler J.D., 2002, P INDOOR AIR, V4, P461; Stelmach I, 2002, ALLERGY, V57, P701, DOI 10.1034/j.1398-9995.2002.23561.x; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; US Environmental Protection Agency, 1997, FED REG, V62, P38651; *US EPA, 1992, EPA60069000F OFF RES; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; VIEGI G, 1992, ARCH ENVIRON HEALTH, V47, P64; VIEGI G, 1999, EUR RESP MONOGR, V4, P214; Wahlgren DR, 1997, CHEST, V111, P81, DOI 10.1378/chest.111.1.81; Wakefield MA, 2000, BRIT MED J, V321, P333, DOI 10.1136/bmj.321.7257.333; Wakefield MA, 2000, BRIT MED J, V31, P623; WALLANDER JL, 1987, CLIN PSYCHOL REV, V7, P203; WHITAKER DA, 1995, J EXPO ANAL ENV EPID, V5, P89; *WHO, 1997, NITR OX ENV HLTH CRI; WHO, 2000, WHO SER, V91; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Wong GWK, 2002, EUR RESPIR J, V19, P288, DOI 10.1183/09031936.02.002319.02; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	126	82	83	0	46	INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)	PARIS	68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE	1027-3719			INT J TUBERC LUNG D	Int. J. Tuberc. Lung Dis.	DEC	2004	8	12					1401	1415				15	Infectious Diseases; Respiratory System	Infectious Diseases; Respiratory System	881VV	WOS:000225898400003	15636485	
J	Seppanen, OA; Fisk, WJ				Seppanen, OA; Fisk, WJ			Summary of human responses to ventilation	INDOOR AIR			English	Article						ventilation; ventilation rate; HVAC-system SBS symptoms; productivity; sick leave; CO2; air-conditioning; infectious disease; cleanliness	INDOOR AIR-QUALITY; SICK BUILDING SYNDROME; HOUSE-DUST MITES; MECHANICAL VENTILATION; OFFICE ENVIRONMENT; AEROSOL FRACTION; SBS SYMPTOMS; HEALTH; POLLEN; POLLUTION	It is known that ventilation is necessary to remove indoor-generated pollutants from indoor air or dilute their concentration to acceptable levels. But as the limit values of all pollutants are not known the exact determination of required ventilation rates based on pollutant concentrations is seldom possible. The selection of ventilation rates has to be based also on epidemiological research, laboratory and field experiments and experience. The existing literature indicates that ventilation has a significant impact on several important human outcomes including: (1) communicable respiratory illnesses; (2) sick building syndrome symptoms; (3) task performance and productivity, and (4) perceived air quality (PAQ) among occupants or sensory panels (5) respiratory allergies and asthma. In many studies, prevalence of sick building syndrome symptoms has also been associated with characteristics of HVAC-systems. Often the prevalence of SBS symptoms is higher in air-conditioned buildings than in naturally ventilated buildings. The evidence suggests that better hygiene, commissioning, operation and maintenance of air handling systems may be particularly important for reducing the negative effects of HVAC systems. Ventilation may also have harmful effects on indoor air quality and climate if not properly designed, installed, maintained and operated. Ventilation may bring indoors harmful substances or deteriorate indoor environment. Ventilation interacts also with the building envelope and may deteriorate the structures of the building. Ventilation changes the pressure differences across the structures of building and may cause or prevent infiltration of pollutants from structures or adjacent spaces. Ventilation is also in many cases used to control the thermal environment or humidity in buildings. The paper summarises the current knowledge on positive and negative effects of ventilation on health and other human responses. The focus is on office-type working environment and residential buildings.	Helsinki Univ Technol, FIN-02015 Espoo, Finland; Univ Calif Berkeley, Lawrence Berkeley Lab, Indoor Environm Dept, Berkeley, CA 94720 USA	Seppanen, OA (reprint author), Helsinki Univ Technol, POB 4100, FIN-02015 Espoo, Finland.	Olli.seppanen@hut.fi					Airaksinen M, 2004, INDOOR AIR, V14, P92, DOI 10.1046/j.1600-0668.2003.00215.x; Angell WJ, 1997, P HLTH BUILD 97 WASH, V1, P143; Apte MG, 2000, INDOOR AIR, V10, P246, DOI 10.1034/j.1600-0668.2000.010004246.x; [Anonymous], 2001, 622001 ANSIASHRAE; BERGIUND B, 1989, GUIDELINES COMMUNITY; BERGMUNCH B, 1980, P INT C BUILD EN MAN; BJORKROTH M, 2002, P IND AIR 2002; BLUYSSEN P, 2001, P CLIMA 2000 NAPL; BLUYSSEN P, 1996, INT J INDOOR AIR QUA, V6; Bornehag CG, 2001, INDOOR AIR, V11, P72; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; Burge PS, 1990, INDOOR AIR 90, V1, P479; BURR ML, 2001, INDOOR AIR QUALITY H, pCH29; BYRD R, 1996, P IND AIR 96, P3203; *CA EPA, 1997, HLTH EFF EXP ENV TOB; *CA EPA, 2003, IN PRESS PROP ID ENV; *CEN, 1996, 1752 CEN CR EUR COMM; *CEN, 2003, 13779 CEN PREN EUR C; Chivato T, 1997, Allergol Immunopathol (Madr), V25, P67; CRANDALL M, 1996, P IAQ 1996, P103; Crane J, 1998, ALLERGY, V53, P755; DORGAN CB, 1999, P IAW EN AM SOC HEAT, P47; Drinka PJ, 1996, J AM GERIATR SOC, V44, P910; *ECA, 2003, 23 ECA; Engdahl F, 1998, BUILD ENVIRON, V33, P197, DOI 10.1016/S0360-1323(97)00040-1; Erdmarm CA, 2002, P 9 INT C IND AIR QU, V3, P443; Fang L, 1998, INDOOR AIR, V8, P80, DOI 10.1111/j.1600-0668.1998.t01-2-00003.x; FANG L, 1997, P HLTH BUILD 97 HLTH, V2, P231; FANGER PO, 1988, ENERG BUILDINGS, V12, P1, DOI 10.1016/0378-7788(88)90051-5; *FISIAQ, 2001, FISIAQ PUBL E, V5; FISK WJ, 2003, P HLTH BUILD 2003 NA, P361; FISK WJ, 2002, INDOOR AIR J, P223; Flannigan B, 1996, ISIAQ GUIDELINE TASK; GOLD DR, 1992, CLIN CHEST MED, V13, P215; HARVING H, 1993, ALLERGY, V48, P106, DOI 10.1111/j.1398-9995.1993.tb00694.x; HEDGE A, 1984, J ARCHIT PLAN RES, V1, P163; *HMG, 2003, WIND OFF STUD WORK P; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; HOWIESON S, 2002, P 9 INT C IND AIR QU, V1, P113; HUMPHREYS MA, 2002, P 9 INT C IND AIR QU, V5, P86; *IOM, 2000, CLEARING AIR ASTHMA; Jones AP, 1999, ATMOS ENVIRON, V33, P4535, DOI 10.1016/S1352-2310(99)00272-1; Kajtar L., 2003, P HLTH BUILD C SING, V3, P176; LEADERER B, 1983, ASHRAE T, P601; Mendell MJ, 2003, AM J IND MED, V43, P630, DOI 10.1002/ajim.10211; MENDELL MJ, 2003, LBNL51567; Mendell MJ, 1993, INDOOR AIR, V3, P227, DOI 10.1111/j.1600-0668.1993.00003.x; Menzies D, 2003, LANCET, V362, P1785, DOI 10.1016/S0140-6736(03)14897-0; MILTON K, 2000, INT J INDOOR AIR QUA, V10, P211; Morrison GC, 1998, J AIR WASTE MANAGE, V48, P941, DOI 10.1080/10473289.1998.10463740; MORRISON GC, 1996, P IND AIR 96 JAP SEE, V3, P585; MYATT TA, 2002, P IND AIR 2002, V1, P778; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302; NEVALAINEN A, 2002, P 9 INT C IND AIR QU, V3, P1; NIEMELA R, 2003, P HLTH BUILD C SING, V3, P251; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; REPACE JL, 1993, RISK ANAL, V13, P463, DOI 10.1111/j.1539-6924.1993.tb00747.x; *RTS, 2002, PROT CLEANL TEST AIR; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x; SEPPANEN O, 1989, ASTM STP, V1002; SEPPANEN O, 2003, P HLTH BUILD 2003 SI, V3; SEPPANEN O, 2003, P HLTH BUILD C SING, V1, P9; Seppanen OA, 1999, INDOOR AIR, V9, P252; SHENDELL DG, 2004, IN PRESS INDOOR AIR; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363; SPIEKSMA FTM, 1991, GRANA, V30, P98; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; SUNDELL J, 1994, INDOOR AIR S, V2, P1; THAM KW, 2003, P HLTH BUILD 2003 C, V1, P182; Tham K., 2003, P HLTH BUILD 2003 C, V3, P280; *VER DTSCH ING, 1997, 6022 VDI; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x; Wargocki P, 2002, ENERG BUILDINGS, V34, P775, DOI 10.1016/S0378-7788(02)00096-8; WARGOCKI P, 2003, P HLTH BUILD 2003 SI, V3, P213; Wargocki P, 2000, P COLD CLIM HVAC 200, P445; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Wolkoff P, 2000, INDOOR AIR, V10, P82, DOI 10.1034/j.1600-0668.2000.010002082.x; Zweers T, 1992, INDOOR AIR, V2, P127, DOI 10.1111/j.1600-0668.1992.00001.x	81	82	83	5	59	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air	AUG	2004	14			7			102	118		10.1111/j.1600-0668.2004.00279.x		17	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	850DF	WOS:000223590700013	15330778	
J	Sutherland, ER; Martin, RJ				Sutherland, ER; Martin, RJ			Airway inflammation in chronic obstructive pulmonary disease: Comparisons with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						inflammation; chronic obstructive pulmonary disease; small airway; asthma; lymphocyte	CHRONIC-BRONCHITIS; PERIPHERAL AIRWAYS; LUNG-FUNCTION; MACROPHAGE METALLOELASTASE; STRUCTURAL-CHANGES; CIGARETTE SMOKERS; FLOW OBSTRUCTION; ALVEOLAR TISSUE; T-LYMPHOCYTES; EMPHYSEMA	Chronic obstructive pulmonary disease (COPD) is a progressive syndrome of expiratory airflow limitation caused by chronic inflammation of the airways and lung parenchyma. The airway inflammatory response in COPD is initiated by smoking in the overwhelming majority of cases, and chronic exposure to cigarette smoke initiates a series of events that causes damage to central airways, peripheral airways, and terminal airspaces, leading to physiologic and clinical abnormalities. Although COPD shares some clinical features with asthma, another prevalent airway inflammatory disease, there are distinct differences in the phenotypic characteristics of airway inflammation between COPD and asthma. The eosinophil is the most prominent inflammatory cell in asthma, with mast cells, lymphocytes, and macrophages playing important but less prominent roles. In COPD the cellular composition of the airway inflammatory infiltrate differs, with neutrophils, macrophages, and lymphocytes assuming prominence and the eosinophil playing a minor role, except in the setting of exacerbations. The contrasting inflammatory phenotypes of asthma and COPD have important implications for clinical and physiologic manifestations of disease, as well as for therapy.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA; Univ Colorado, Hlth Sci Ctr, Boulder, CO 80309 USA	Martin, RJ (reprint author), 1400 Jackson St, Denver, CO 80206 USA.		Sutherland, Everett/B-7666-2008				American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Amin K, 2003, THORAX, V58, P135, DOI 10.1136/thorax.58.2.135; Anthonisen NR, 2002, AM J RESP CRIT CARE, V166, P675, DOI 10.1164/rccm.2112096; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Arias Elizabeth, 2003, Natl Vital Stat Rep, V51, P1; BOSKEN CH, 1990, AM REV RESPIR DIS, V142, P563; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666; FLETCHER C, 1977, BRIT MED J, V1, P1645; Fujimoto K, 1999, CHEST, V115, P697, DOI 10.1378/chest.115.3.697; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hogg JC, 2002, THORAX, V57, P830, DOI 10.1136/thorax.57.9.830; HUNNINGHAKE GW, 1983, AM REV RESPIR DIS, V128, P833; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; Lams BEA, 1998, AM J RESP CRIT CARE, V158, P1518; Lopez AD, 1998, NAT MED, V4, P1241, DOI 10.1038/3218; LUSUARDI M, 1994, THORAX, V49, P1211, DOI 10.1136/thx.49.12.1211; Majo J, 2001, EUR RESPIR J, V17, P946, DOI 10.1183/09031936.01.17509460; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; O'Donnell DE, 1999, AM J RESP CRIT CARE, V160, P542; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511; Retamales I, 2001, AM J RESP CRIT CARE, V164, P469; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Shapiro SD, 1999, AM J RESP CRIT CARE, V160, pS29; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802; TASHKIN DP, 1992, AM REV RESPIR DIS, V145, P301; Turato G, 2002, AM J RESP CRIT CARE, V166, P105, DOI 10.1164/rccm.2111084; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584; WRIGHT JL, 1983, AM REV RESPIR DIS, V127, P474	42	82	86	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2003	112	5					819	827		10.1067/mai.2003.1760		9	Allergy; Immunology	Allergy; Immunology	743BV	WOS:000186553300001	14610463	
J	Hamscher, G; Pawelzick, HT; Sczesny, S; Nau, H; Hartung, J				Hamscher, G; Pawelzick, HT; Sczesny, S; Nau, H; Hartung, J			Antibiotics in dust originating from a pig-fattening farm: A new source of health hazard for farmers?	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						antibiotics; dust; farmer; liquid chromatography; mass spectrometry; pig fattening; veterinary drugs	ALLERGIC CONTACT-DERMATITIS; LIVESTOCK BUILDINGS; LIQUID MANURE; ENVIRONMENT; PHARMACEUTICALS; CONTAMINANTS; SUBSTANCES; POLLUTANTS; EMISSIONS; RESIDUES	Pig-house dust originates from feed, bedding, feces, and the animals themselves. If the animals receive drugs such as antibiotics, residues of these substances may occur in manure, in the air, or on surfaces of the respective animal house. In a retrospective study, we investigated dust samples collected during two decades from the same piggery for the occurrence of various antibiotics. In 90% of these samples, we detected up to five different antibiotics, including tylosin, various tetra-cyclines, sulfamethazine, and chloramphenicol, in total amounts up to 12.5 mg/kg dust. High dust exposure in animal confinement buildings is believed to be a respiratory health hazard because of the high content of microorganisms, endotoxins, and allergens. Further risks may arise from the inhalation of dust contaminated with a cocktail of antibiotics. Apart from that, our data provide first evidence for a new route of entry for veterinary drugs in the environment.	Tierarztlichen Hsch Hannover, Dept Food Toxicol, Ctr Food Sci, D-30173 Hannover, Germany; Tierarztlichen Hsch Hannover, Inst Anim Hyg Anim Welf & Behav Farm Anim, D-30173 Hannover, Germany	Hamscher, G (reprint author), Tierarztlichen Hsch Hannover, Dept Food Toxicol, Ctr Food Sci, Bischofsholer Damm 15, D-30173 Hannover, Germany.		Hamscher, Gerd/B-2100-2012				BARBERA E, 1989, CONTACT DERMATITIS, V20, P308, DOI 10.1111/j.1600-0536.1989.tb03155.x; BERGER K, 1986, ARCH LEBENSMITTELHYG, V37, P99; CARAFFINI S, 1994, CONTACT DERMATITIS, V5, P327; Choquet-Kastylevsky Genevieve, 2002, Curr Allergy Asthma Rep, V2, P16, DOI 10.1007/s11882-002-0033-y; DANESE P, 1994, CONTACT DERMATITIS, V30, P122, DOI 10.1111/j.1600-0536.1994.tb00587.x; Daughton CG, 1999, ENVIRON HEALTH PERSP, V107, P907, DOI 10.2307/3434573; DONHAM KJ, 1993, SEMIN RESPIR MED, V14, P49, DOI 10.1055/s-2007-1006308; Halling-Sorensen B, 1998, CHEMOSPHERE, V36, P357, DOI 10.1016/S0045-6535(97)00354-8; Hamscher G, 2000, DEUT TIERARZTL WOCH, V107, P332; Hamscher G, 2002, ANAL CHEM, V74, P1509, DOI 10.1021/ac015588m; Hartung J, 1998, DEUT TIERARZTL WOCH, V105, P213; HARTUNG J, 1995, DEUT TIERARZTL WOCH, V102, P283; HARTUNG J, 1997, ZENTRALBL ARBEITSMED, V47, P65; Heberer T, 2002, TOXICOL LETT, V131, P5, DOI 10.1016/S0378-4274(02)00041-3; HJORTH N, 1980, CONTACT DERMATITIS, V6, P27, DOI 10.1111/j.1600-0536.1980.tb03885.x; HOLT D, 1993, ADVERSE DRUG REACT T, V12, P83; Iversen M, 2000, J Agric Saf Health, V6, P283; *JECFA, 1994, WHO FOOD ADD SER, V33; Kolpin DW, 2002, ENVIRON SCI TECHNOL, V36, P1202, DOI 10.1021/es011055j; Kummerer K, 2001, PHARM ENV SOURCES FA; LANGHAMMER IP, 1988, TIERARZTL UMSCHAU, V43, P375; Lindsey ME, 2001, ANAL CHEM, V73, P4640, DOI 10.1021/ac010514w; Nowak D, 1998, DEUT TIERARZTL WOCH, V105, P225; Nwosu VC, 2001, RES MICROBIOL, V152, P421, DOI 10.1016/S0923-2508(01)01215-3; Pedersen S, 2000, J Agric Saf Health, V6, P261; PLATZ S, 1995, ZBL HYG UMWELTMED, V196, P399; Radon K, 2002, ANN AGR ENV MED, V9, P41; SEEDORF J, 2002, DUST MICRO ORGANISMS; Takai H, 1998, J AGR ENG RES, V70, P59, DOI 10.1006/jaer.1997.0280; Winckler C., 2001, Journal of Soils and Sediments, V1, P66, DOI 10.1007/BF02987711; Witte W, 1998, SCIENCE, V279, P996, DOI 10.1126/science.279.5353.996; 2001, DEUT TIERARZTEBLATT, V8, P841	32	82	88	2	24	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2003	111	13					1590	1594		10.1289/ehp.6288		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	732JU	WOS:000185940800023	14527837	
S	Hanson, LA; Korotkova, M; Lundin, S; Haversen, L; Silfverdal, SA; Mattsby-Baltzer, I; Strandvik, B; Telemo, E		Chiorazzi, N; Lahita, RG; Capra, JD; Ferrarini, M; Zabriskie, JB		Hanson, LA; Korotkova, M; Lundin, S; Haversen, L; Silfverdal, SA; Mattsby-Baltzer, I; Strandvik, B; Telemo, E			The transfer of immunity from mother to child	IMMUNE MECHANISMS AND DISEASE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Immune Mechanisms and Disease	APR 14-17, 2002	ST GEORGES, W IND ASSOC ST	Henry Kunkel Soc, NY Acad Sci		anti-idiotypic; secretory IgA; lactoferrin; Bramwell receptor; immune system; breastfeeding	BREAST-FED INFANTS; ANTIBODY-RESPONSE; HUMAN-MILK; IGG ANTIBODIES; MICE; PROTECTION; DIARRHEA; CELLS; COLONIZATION; IMMUNIZATION	The newborn's immune system grows fast from a small size at birth by exposure primarily to the intestinal microflora normally obtained from the mother at and after birth. While building up its immune system, the infant is supported by the transplacental IgG antibodies, which also contain anti-idiotypic antibodies, possibly also actively priming the offspring. The second mode of transfer of immunity occurs via the milk. Numerous major protective components, including secretory IgA (SIgA) antibodies and lactoferrin, are present. The breastfed infant is better protected against numerous common infections than the non-breastfed. Breastfeeding also seems to actively stimulate the infant's immune system by anti-idiotypes, uptake of milk lymphocytes, cytokines, etc. Therefore, the breastfed child continues to be better protected against various infections for some years. Vaccine responses are also often enhanced in breastfed infants. Long-lasting protection against certain immunological diseases such as allergies and celiac disease is also noted.	Univ Gothenburg, Dept Clin Immunol, SE-41346 Gothenburg, Sweden; Univ Gothenburg, Dept Med Microbiol & Immunol, SE-41346 Gothenburg, Sweden; Univ Gothenburg, Dept Clin Bacteriol, SE-41346 Gothenburg, Sweden; Univ Gothenburg, Dept Pediat, SE-41346 Gothenburg, Sweden; Orebro Med Ctr Hosp, Dept Pediat, S-70185 Orebro, Sweden	Hanson, LA (reprint author), Univ Gothenburg, Dept Clin Immunol, Guldheosgatan 10, SE-41346 Gothenburg, Sweden.						Adkins B, 1999, IMMUNOL TODAY, V20, P330, DOI 10.1016/S0167-5699(99)01473-5; ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Adlerberth I, 1999, DEV GASTROINTESTINAL, P279; ANDERSSON B, 1986, J INFECT DIS, V153, P232; Arvola M, 2000, BIOL REPROD, V63, P1817, DOI 10.1095/biolreprod63.6.1817; AUGUSTIN A, 1976, EUR J IMMUNOL, V6, P497, DOI 10.1002/eji.1830060710; Avanzini MA, 1998, ACTA PAEDIATR, V87, P180, DOI 10.1080/08035259850157633; Barbier M, 1998, GUT, V43, P783; CAMPBELL DA, 1984, TRANSPLANTATION, V37, P340, DOI 10.1097/00007890-198404000-00004; CERNY J, 1983, EUR J IMMUNOL, V13, P244, DOI 10.1002/eji.1830130313; COUTINHO A, 1987, EUR J IMMUNOL, V17, P821, DOI 10.1002/eji.1830170614; CRABBE PA, 1970, LAB INVEST, V22, P448; CRUZ JR, 1988, ACTA PAEDIATR SCAND, V77, P658, DOI 10.1111/j.1651-2227.1988.tb10726.x; Davis MK, 2001, PEDIATR CLIN N AM, V48, P125, DOI 10.1016/S0031-3955(05)70289-3; Elass E, 2002, INFECT IMMUN, V70, P1860, DOI 10.1128/IAI.70.4.1860-1866.2002; GLASS RI, 1983, NEW ENGL J MED, V308, P1389, DOI 10.1056/NEJM198306093082304; Goldblum R.M., 1996, IMMUNOLOGIC DISORDER, P159; HAHNZORIC M, 1992, PEDIATR RES, V32, P150, DOI 10.1203/00006450-199208000-00005; HAHNZORIC M, 1990, ACTA PAEDIATR SCAND, V79, P1137; HAHNZORIC M, 1993, PEDIATR RES, V33, P475, DOI 10.1203/00006450-199305000-00011; Hanson L A, 2000, Nutr Rev, V58, pS31; Hanson LA, 1998, ANN ALLERG ASTHMA IM, V81, P523, DOI 10.1016/S1081-1206(10)62704-4; HANSON LA, 2002, RES AGENDA MILLENIUM, P99; Hanson LA, 1998, MUCOSAL IMMUNOLOGY; Hasselbalch H, 1996, ACTA PAEDIATR, V85, P1029, DOI 10.1111/j.1651-2227.1996.tb14211.x; Haversen LA, 2000, INFECT IMMUN, V68, P5816, DOI 10.1128/IAI.68.10.5816-5823.2000; HAVERSEN LA, UNPUB ANTIINFLAMMATO; HAVERSEN LA, UNPUB LACTOFERRIN IN; HAYANI KC, 1992, J PEDIATR-US, V121, P852, DOI 10.1016/S0022-3476(05)80327-0; HORSFALL DJ, 1978, AUST J EXP BIOL MED, V56, P727, DOI 10.1038/icb.1978.79; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; Karlsson MR, 1999, EUR J IMMUNOL, V29, P109, DOI 10.1002/(SICI)1521-4141(199901)29:01<109::AID-IMMU109>3.3.CO;2-J; KOIS WE, 1984, J SURG RES, V37, P89, DOI 10.1016/0022-4804(84)90166-5; KOROTKOVA M, UNPUB MODULATION NEO; LARSON BL, 1985, HUMAN LACTATION, V1, P33; LUCAS GP, 1991, INFECT IMMUN, V59, P3651; Lundin BS, 1999, SCAND J IMMUNOL, V50, P651; LUNDIN BS, 1998, THESIS GOTEBORG U GO; LUNDKVIST I, 1989, P NATL ACAD SCI USA, V86, P5074, DOI 10.1073/pnas.86.13.5074; MARTINEZ C, 1985, NATURE, V317, P721, DOI 10.1038/317721a0; MATA LJ, 1969, AM J DIS CHILD, V117, P142; Matthews P, 1996, SIGHT SOUND, V6, P40; MELLANDER L, 1986, CLIN EXP IMMUNOL, V63, P555; OKAMOTO Y, 1989, J IMMUNOL, V142, P2507; Pabst HF, 1997, ACTA PAEDIATR, V86, P1291, DOI 10.1111/j.1651-2227.1997.tb14900.x; PABST HF, 1989, LANCET, V1, P295; RETH M, 1981, NATURE, V290, P257, DOI 10.1038/290257a0; RUIZPALACIOS GM, 1990, J PEDIATR-US, V116, P707, DOI 10.1016/S0022-3476(05)82652-6; Schelonka RL, 1998, SEMIN PERINATOL, V22, P2, DOI 10.1016/S0146-0005(98)80003-7; Seeger M, 1998, EUR J IMMUNOL, V28, P2124, DOI 10.1002/(SICI)1521-4141(199807)28:07<2124::AID-IMMU2124>3.0.CO;2-A; Silfverdal SA, 2002, PEDIATR INFECT DIS J, V21, P816, DOI 10.1097/01.inf.0000027668.74570.96; SOTO H, 1979, AM J DIS CHILD, V133, P1240; STEIN KE, 1984, J EXP MED, V160, P1001, DOI 10.1084/jem.160.4.1001; TUBOLY S, 1995, ACTA VET HUNG, V43, P105; VANODIJK J, 1966, UNPUB BREAST FEEDING; VARELA FJ, 1991, IMMUNOL TODAY, V12, P159, DOI 10.1016/S0167-5699(05)80046-5; WALTERSPIEL JN, 1994, PEDIATRICS, V93, P28; WIKLER M, 1980, J EXP MED, V152, P1024, DOI 10.1084/jem.152.4.1024; ZHANG L, 1991, TRANSPLANTATION, V52, P914	60	82	89	4	22	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-434-X	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2003	987						199	206				8	Cell Biology; Immunology; Multidisciplinary Sciences	Cell Biology; Immunology; Science & Technology - Other Topics	BW84D	WOS:000183319000023	12727640	
J	Skold, M; Borje, A; Matura, M; Karlberg, AT				Skold, M; Borje, A; Matura, M; Karlberg, AT			Studies on the autoxidation and sensitizing capacity of the fragrance chemical linalool, identifying a linalool hydroperoxide	CONTACT DERMATITIS			English	Article						autoxidation; fragrance allergy; FCAT; gas chromatographic analysis; guinea pigs; hydroperoxide; linalool; NMR; sensitization studies; terpene	OXIDIZED D-LIMONENE; CONTACT ALLERGENS; 15-HYDROPEROXYABIETIC ACID; CITRUS SOLVENT; ESSENTIAL OILS; COLOPHONY; DERMATITIS	Fragrances are among the most common causes of allergic contact dermatitis. The two monoterpenes linalool and d -limonene are the most frequently incorporated fragrance chemicals in scented products. Previous studies on d -limonene show that this monoterpene oxidizes on air exposure (autoxidation) and that allergenic oxidation products are formed. Due to structural similarities, linalool might also form allergenic oxidation products on air exposure. The aim of the present study was to study the autoxidation of linalool and to investigate the sensitizing potential of linalool before and after air exposure. Linalool was oxidized for 10 weeks and gas chromatographic analyses showed that the content of linalool decreased to about 80%. The chromatograms revealed the formation of other compounds during oxidation. One of the major oxidation products was isolated and identified as 7-hydroperoxy-3,7-dimethyl-octa-1,5-diene-3-ol. This substance is, to the best of our knowledge, described for the first time. In sensitization studies in guinea pigs, linalool of high purity gave no reactions, while linalool that had been oxidized for 10 weeks sensitized the animals. It is concluded that autoxidation of linalool is essential for its sensitizing potential.	Univ Gothenburg, Dept Chem Med Chem Dermatochem & Skin Allergy, SE-41296 Gothenburg, Sweden; Natl Inst Working Life, Stockholm, Sweden	Karlberg, AT (reprint author), Univ Gothenburg, Dept Chem Med Chem Dermatochem & Skin Allergy, SE-41296 Gothenburg, Sweden.		Borje, Anna/A-7581-2010; Karlberg, Ann-Therese/A-7706-2010				Bezard M, 1997, CHEM RES TOXICOL, V10, P987, DOI 10.1021/tx970014r; BOMAN A, 1988, CONTACT DERMATITIS, V18, P25, DOI 10.1111/j.1600-0536.1988.tb05485.x; Casabianca H, 1998, HRC-J HIGH RES CHROM, V21, P107, DOI 10.1002/(SICI)1521-4168(19980201)21:2<107::AID-JHRC107>3.0.CO;2-A; DeGroot AC, 1997, CONTACT DERMATITIS, V36, P57; DEGROOT AC, 1983, CONTACT DERMATITIS, V9, P230; DEGROOT AC, 1994, UNWANTED EFFECTS COS, P579; Fielder S, 1998, TETRAHEDRON, V54, P12907, DOI 10.1016/S0040-4020(98)00782-0; Fregert S, 1969, CONTACT DERMATITIS N, V5, P85; GAFVERT E, 1994, CHEM RES TOXICOL, V7, P260, DOI 10.1021/tx00038a020; Greif N., 1967, AM PERFUM COSMET, V82, P54; KARLBERG AT, 1994, ARCH DERMATOL RES, V286, P97, DOI 10.1007/BF00370734; KARLBERG AT, 1994, ANN OCCUP HYG, V38, P199, DOI 10.1093/annhyg/38.2.199; KARLBERG AT, 1985, CONTACT DERMATITIS, V13, P209, DOI 10.1111/j.1600-0536.1985.tb02552.x; KARLBERG AT, 1988, J PHARM PHARMACOL, V40, P42; KARLBERG AT, 1992, CONTACT DERMATITIS, V26, P332, DOI 10.1111/j.1600-0536.1992.tb00129.x; KARLBERG AT, 1991, ANN OCCUP HYG, V35, P419, DOI 10.1093/annhyg/35.4.419; Karlberg AT, 1997, CONTACT DERMATITIS, V36, P201, DOI 10.1111/j.1600-0536.1997.tb00270.x; Andersen KE, 1985, CONTACT ALLERGY PRED, V14, P152; MATURA M, IN PRESS J AM DERMAT; Mutterer V, 2000, CHEM RES TOXICOL, V13, P1028, DOI 10.1021/tx9901433; Opdyke D. L., 1975, FOOD COSMET TOXICO S, V13, P827; PORTER NA, 1976, J AM CHEM SOC, V98, P6000, DOI 10.1021/ja00435a037; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; Ryan CA, 2000, CONTACT DERMATITIS, V43, P95, DOI 10.1034/j.1600-0536.2000.043002095.x; SCHALLER M, 1995, CLIN EXP DERMATOL, V20, P143; WILKINS AL, 1993, J AGR FOOD CHEM, V41, P873, DOI 10.1021/jf00030a006	27	82	82	4	27	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	MAY	2002	46	5					267	272		10.1034/j.1600-0536.2002.460504.x		6	Allergy; Dermatology	Allergy; Dermatology	568AY	WOS:000176521300004	12084079	
J	Wilson, SR; Yamada, EG; Sudhakar, R; Roberto, L; Mannino, D; Mejia, C; Huss, N				Wilson, SR; Yamada, EG; Sudhakar, R; Roberto, L; Mannino, D; Mejia, C; Huss, N			A controlled trial of an environmental tobacco smoke reduction intervention in low-income children with asthma	CHEST			English	Article						asthma; behavior change; children; controlled trial; cotinine; education; environmental tobacco smoke; low-income	COTININE-ASSISTED INTERVENTION; PASSIVE SMOKING; RELAPSE PREVENTION; YOUNG-CHILDREN; BODY-FLUIDS; EXPOSURE; PREGNANCY; PROGRAM; PARENTS; POSTPARTUM	Study objectives: To determine the effectiveness of a cotinine-feedback, behaviorally based education intervention in reducing environmental tobacco smoke (ETS) exposure and health-care utilization of children with asthma. Design: Randomized controlled trial of educational intervention vs usual care. Setting: The pediatric pulmonary service of a regional pediatric hospital. Participants: ETS-exposed, Medicaid/Niedi-Cal-eligible, predominantly minority children who were 3 to 12 years old and who were seen for asthma in the hospital's emergency, inpatient, and outpatient services departments (n = 87). Intervention: Three nurse-led sessions employing behavior-changing strategies and basic asthma education and that incorporated repeated feedback on the child's urinary cotinine level. Measurements: The primary measurements were the urinary cotinine/creatinine ratio (CCR) and the number of acute asthma medical visits. The secondary measurements were number of hospitalizations, smoking restrictions in home, amount smoked, reported exposures of children, and asthma control. Results: The intervention was associated with a significantly lower odds ratio (OR) for more than one acute asthma medical visit in the follow-up year, after adjusting for baseline visits (total visits, 87; OR, 0.32; p = 0.03), and a comparably sized but nonsignificant OR for one or more hospitalization (OR, 0.34; p = 0.14). The follow-up CCR measurement and the determination of whether smoking was prohibited inside the home strongly favored the intervention group (n = 51) (mean difference in CCR adjusted for baseline, -0.38; p = 0.26; n = 51) (60; OR [for proportion of subjects prohibiting smoking], 0.24; p = 0.11; n = 60). Conclusions: This intervention significantly reduced asthma health-care utilization in ETS-exposed, low-income, minority children. Effects sizes for urine cotinine and proportion prohibiting smoking were moderate to large but not statistically significant, possibly the result of reduced precision due to the loss of patients to active follow-up. Improving ETS reduction interventions and understanding their mechanism of action on asthma outcomes requires further controlled trials that measure ETS exposure and behavioral and disease outcomes concurrently.	Palo Alto Med Fdn, Res Inst, Dept Hlth Serv Res, Palo Alto, CA 94301 USA; Calif Dept Hlth Serv, Chron Dis Control Branch, Sacramento, CA USA; Valley Childrens Hosp, Pediat Pulm Dept, Madera, CA USA; US Ctr Dis Control & Prevent, Atlanta, GA USA	Wilson, SR (reprint author), Palo Alto Med Fdn, Res Inst, Dept Hlth Serv Res, 795 El Camino Real,Ames Bldg, Palo Alto, CA 94301 USA.			Mannino, David/0000-0003-3646-7828	PHS HHS [U60/CCU912212]		*AM AC OT, 1995, 4763355 AM AC OT HEA; Benowitz NL, 1999, ENVIRON HEALTH PERSP, V107, P349, DOI 10.2307/3434427; BENOWITZ NL, 1994, CLIN PHARMACOL THER, V56, P483; BUTZ AM, 1992, J ASTHMA, V29, P265, DOI 10.3109/02770909209048941; California Environmental Protection Agency, 1997, HLTH EFF EXP ENV TOB; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Centers for Disease Control and Prevention (CDC), 1998, MMWR-MORBID MORTAL W, V47, P1022; CHILMONCZYK BA, 1992, AM J DIS CHILD, V146, P357; Cook DG, 1999, THORAX, V54, P357; DOLANMULLEN P, 1994, AM J OBSTET GYNECOL, V171, P1328; Efron B., 1993, INTRO BOOTSTRAP; Eriksen W, 1996, ACTA PAEDIATR, V85, P209, DOI 10.1111/j.1651-2227.1996.tb13994.x; ERSHOFF DH, 1995, AM J PREV MED, V11, P178; FINGERHUT LA, 1990, AM J PUBLIC HEALTH, V80, P541, DOI 10.2105/AJPH.80.5.541; Fish L, 1996, AM J PUBLIC HEALTH, V86, P246, DOI 10.2105/AJPH.86.2.246; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GREENBERG RA, 1994, J BEHAV MED, V17, P273, DOI 10.1007/BF01857953; HADDOW JE, 1991, BRIT J OBSTET GYNAEC, V98, P859, DOI 10.1111/j.1471-0528.1991.tb13506.x; HOVELL MF, 1994, CHEST, V106, P440, DOI 10.1378/chest.106.2.440; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; Irvine L, 1999, BRIT MED J, V318, P1456; JARVIS MJ, 1988, AM J PUBLIC HEALTH, V78, P696, DOI 10.2105/AJPH.78.6.696; JARVIS MJ, 1984, EUR J RESPIR DIS S, V133, P68; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MCBRIDE CM, 1992, HEALTH EDUC RES, V7, P381, DOI 10.1093/her/7.3.381; MCINTOSH NA, 1994, J ASTHMA, V31, P453, DOI 10.3109/02770909409089487; MULLEN PD, 1990, AM J PUBLIC HEALTH, V80, P992, DOI 10.2105/AJPH.80.8.992; National Asthma Education and Prevention Program, 1997, NIH PUBL, V97-4051; Ockene Judith K., 1993, Annals of Behavioral Medicine, V15, P135; Polgar G, 1971, PULMONARY FUNCTION T; Prochaska JO, 1997, AM J HEALTH PROMOT, V12, P38; *SCI COMM TOB HLTH, 1999, REP SCI COMM TOB HLT; Secker-Walker RH, 1998, AM J PREV MED, V15, P25, DOI 10.1016/S0749-3797(98)00029-4; *U CAL, 1998, CANC PREV CONTR PROG; U. S. Environmental Protection Agency, 1992, EPA600690006F OFF HL; VINEIS P, 1993, TUMORI, V79, P183; Wahlgren DR, 1997, CHEST, V111, P81, DOI 10.1378/chest.111.1.81; WALL MA, 1995, PEDIATRICS, V96, P622; WATTS RR, 1990, ENVIRON HEALTH PERSP, V84, P173, DOI 10.2307/3430719; World Health Organization, 1999, WHO LAB MAN EX HUM S, P11; Wilson SR, 1996, J ASTHMA, V33, P239, DOI 10.3109/02770909609055365; WOODWARD A, 1987, PEDIATR PULM, V3, P173, DOI 10.1002/ppul.1950030311	42	82	85	1	5	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2001	120	5					1709	1722		10.1378/chest.120.5.1709		14	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	494GW	WOS:000172274300049	11713157	
J	Miller, RL; Chew, GL; Bell, CA; Biedermann, SA; Aggarwal, M; Kinney, PL; Tsai, WY; Whyatt, RM; Perera, FP; Ford, JG				Miller, RL; Chew, GL; Bell, CA; Biedermann, SA; Aggarwal, M; Kinney, PL; Tsai, WY; Whyatt, RM; Perera, FP; Ford, JG			Prenatal exposure, maternal sensitization,, and sensitization in utero to indoor allergens in an inner-city cohort	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						in utero sensitization; indoor antigens; lymphocyte proliferation	HOUSE-DUST MITE; T-CELL RESPONSES; DER-P-I; DERMATOPHAGOIDES-PTERONYSSINUS; ENVIRONMENTAL ALLERGENS; ASTHMA; CHILDREN; LIFE; COCKROACH; IGE	Primary sensitization to antigens may occur prenatally. We hypothesized that high prenatal exposure to indoor antigens increases the risk for sensitization in newborns in New York City populations with increased risk for asthma. We also investigated whether maternal sensitization is required for in utero sensitization to occur. One hundred sixty-seven pregnant African American or Dominican women residing in northern Manhattan were recruited and antigen was measured from home dust. After delivery, newborn cord and maternal blood were assayed for IgE and mononuclear cell proliferation and cytokine production in response to antigen. Cockroach, mouse, but not dust mite antigens, were commonly elevated in the kitchens and pregnant mothers' beds. Increased mononuclear cell proliferation occurred in 54% of newborns in response to cockroach, 25% in response to dust mite Dermatophagoides pteronyssinus, 40% in response to dust mite D. farinae, and 34% in response to mouse protein extracts. Antigen-induced mononuclear cell proliferation occurred in cord blood even in the absence of antigen-induced mononuclear cell proliferation in the mother. Proliferation in response to antigens did not correlate with IgE levels, but proliferation in response to dust mite extracts correlated with interluekin-5 (IL-5) production in cord blood. These results suggest that (1) high prenatal exposures to cockroach and mouse antigens are prevalent; (2) in utero sensitization to multiple indoor antigens is common, occurs to a different degree than maternal sensitization, and may involve IL-5 uprequlation.	Columbia Univ Coll Phys & Surg, Harlem Hosp Ctr, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Div Biostat, Columbia Ctr Childrens Environm Hlth, Joseph L Mailman Sch Publ Hlth, New York, NY 10032 USA	Miller, RL (reprint author), Columbia Univ Coll Phys & Surg, Div Pulm Allergy Crit Care, Dept Med, 630 W 168th St, New York, NY 10032 USA.	rim14@columbia.edu			NCRR NIH HHS [RR00645]; NIEHS NIH HHS [5 R01 ES08977, P50 ES09600]		Boyum A, 1968, Scand J Clin Lab Invest Suppl, V97, P77; CARR W, 1992, AM J PUBLIC HEALTH, V82, P58; Curriculum Development Council (CDC), 1998, SEX TRANSM DIS TREAT; Chan-Yeung M, 1999, J ALLERGY CLIN IMMUN, V104, P317, DOI 10.1016/S0091-6749(99)70373-8; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; ELOISANTOS SM, 1989, J CLIN INVEST, V84, P1028, DOI 10.1172/JCI114225; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Fleiss J. L., 1986, DESIGN ANAL CLIN EXP; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Grant EN, 1999, J ALLERGY CLIN IMMUN, V104, pS1, DOI 10.1016/S0091-6749(99)70268-X; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; LIN H, 1993, J IMMUNOL, V151, P4562; Malhotra I, 1999, J IMMUNOL, V162, P6843; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1046/j.1365-2222.1996.d01-383.x; MIZUNO M, 1994, AM J REPROD IMMUNOL, V31, P180; Munir AKM, 1998, ALLERGY, V53, P84; NOELLE R, 1984, P NATL ACAD SCI-BIOL, V81, P6149, DOI 10.1073/pnas.81.19.6149; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OHEHIR RE, 1990, INT IMMUNOL, V2, P885, DOI 10.1093/intimm/2.9.885; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V105, pS79, DOI 10.1016/S0091-6749(00)90671-7; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75; Prescott SL, 1998, J IMMUNOL, V160, P4730; RAWLE FC, 1984, J IMMUNOL, V133, P195; RONCAROLO MG, 1994, BLOOD CELLS, V20, P573; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Schroeder H, 2000, J ALLERGY CLIN IMMUN, V105, pS164, DOI 10.1016/S0091-6749(00)90929-1; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Sorg RV, 1999, BLOOD, V93, P2302; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stephan V, 1999, CLIN EXP ALLERGY, V29, P1049, DOI 10.1046/j.1365-2222.1999.00610.x; van Strien R.T., 1994, CLIN EXP ALLERGY, V24, P843, DOI 10.1111/j.1365-2222.1994.tb01807.x; STRIEN RTV, 1995, CLIN EXP ALLERGY, V25, P1184, DOI 10.1111/j.1365-2222.1995.tb03042.x; Wickens K, 1997, J ALLERGY CLIN IMMUN, V99, P587, DOI 10.1016/S0091-6749(97)70017-4; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4	41	82	84	0	2	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 15	2001	164	6					995	1001				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	480DD	WOS:000171446000018	11587985	
J	Juncadella, IJ; Kadl, A; Sharma, AK; Shim, YM; Hochreiter-Hufford, A; Borish, L; Ravichandran, KS				Juncadella, Ignacio J.; Kadl, Alexandra; Sharma, Ashish K.; Shim, Yun M.; Hochreiter-Hufford, Amelia; Borish, Larry; Ravichandran, Kodi S.			Apoptotic cell clearance by bronchial epithelial cells critically influences airway inflammation	NATURE			English	Article							DUST MITE ALLERGEN; ASTHMA; RESPONSES; FAMILY; ENGULFMENT; MECHANISM; MIMICRY; PROTEIN; INNATE; MOUSE	Lung epithelial cells can influence immune responses to airway allergens(1,2). Airway epithelial cells also undergo apoptosis after encountering environmental allergens(3); yet, relatively little is known about how these are cleared, and their effect on airway inflammation. Here we show that airway epithelial cells efficiently engulf apoptotic epithelial cells and secrete anti-inflammatory cytokines, dependent upon intracellular signalling by the small GTPase Rac1. Inducible deletion of Rac1 expression specifically in airway epithelial cells in a mouse model resulted in defective engulfment by epithelial cells and aberrant anti-inflammatory cytokine production. Intranasal priming and challenge of these mice with house dust mite extract or ovalbumin as allergens led to exacerbated inflammation, augmented Th2 cytokines and airway hyper-responsiveness, with decreased interleukin (IL)-10 in bronchial lavages. Rac1-deficient epithelial cells produced much higher IL-33 upon allergen or apoptotic cell encounter, with increased numbers of nuocyte-like cells(1,4,5). Administration of exogenous IL-10 'rescued' the airway inflammation phenotype in Rac1-deficient mice, with decreased IL-33. Collectively, these genetic and functional studies suggest a new role for Rac1-dependent engulfment by airway epithelial cells and in establishing the anti-inflammatory environment, and that defects in cell clearance in the airways could contribute to inflammatory responses towards common allergens.	[Juncadella, Ignacio J.; Hochreiter-Hufford, Amelia; Borish, Larry; Ravichandran, Kodi S.] Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; [Juncadella, Ignacio J.; Hochreiter-Hufford, Amelia; Ravichandran, Kodi S.] Univ Virginia, Dept Microbiol, Charlottesville, VA 22908 USA; [Juncadella, Ignacio J.; Hochreiter-Hufford, Amelia; Ravichandran, Kodi S.] Univ Virginia, Ctr Cell Clearance, Charlottesville, VA 22908 USA; [Kadl, Alexandra; Shim, Yun M.; Borish, Larry] Univ Virginia, Dept Med, Charlottesville, VA 22908 USA; [Sharma, Ashish K.] Univ Virginia, Dept Surg, Charlottesville, VA 22908 USA; [Borish, Larry] Univ Virginia, Ctr Asthma & Allerg Dis, Charlottesville, VA 22908 USA	Ravichandran, KS (reprint author), Univ Virginia, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA.	Ravi@virginia.edu			Immunology Training Grant; NHLBI; American Asthma Foundation; National Institutes of Health	We thank the members of the Ravichandran laboratory for their suggestions, especially J. Kinchen and P. Trampont. We thank J. Whitsett for the rtTA-CCSP/Cre mice, X. Liu for the TGF-beta responsive cell line PE25, and J. Steinke and J. Kennedy for providing human nasal epithelial cells. This work was supported by an Immunology Training Grant (I. J. J.), a F32 postdoctoral fellowship from the NHLBI (I. J. J.), and grants from the American Asthma Foundation and the National Institutes of Health (K. S. R.). K. S. R. has been a William Benter Senior Fellow of the American Asthma Foundation.	Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Cates EC, 2004, J IMMUNOL, V173, P6384; Daidoji T, 2008, J VIROL, V82, P11294, DOI 10.1128/JVI.01192-08; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Elliott MR, 2010, ANN NY ACAD SCI, V1209, P30, DOI 10.1111/j.1749-6632.2010.05764.x; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fahy JV, 2011, AM J RESP CRIT CARE, V184, P390, DOI 10.1164/rccm.201107-1258ED; Glogauer M, 2003, J IMMUNOL, V170, P5652; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Jyonouchi H, 1999, APOPTOSIS, V4, P407, DOI 10.1023/A:1009607607603; Kirsch T, 2007, BLOOD, V109, P2854, DOI 10.1182/blood-2006-06-026187; Lambrecht BN, 2012, NAT MED, V18, P684, DOI 10.1038/nm.2737; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Lloyd CM, 2010, CURR OPIN IMMUNOL, V22, P800, DOI 10.1016/j.coi.2010.10.006; Locksley RM, 2010, CELL, V140, P777, DOI 10.1016/j.cell.2010.03.004; Monks J, 2005, CELL DEATH DIFFER, V12, P107, DOI 10.1038/sj.cdd.4401517; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; Park D, 2011, NATURE, V477, P220, DOI 10.1038/nature10340; Park D, 2009, CURR BIOL, V19, P346, DOI 10.1016/j.cub.2009.01.042; Perl AKT, 2002, TRANSGENIC RES, V11, P21; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; Ravichandran KS, 2011, IMMUNITY, V35, P445, DOI 10.1016/j.immuni.2011.09.004; Shutes A, 2007, J BIOL CHEM, V282, P35666, DOI 10.1074/jbc.M703571200; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Thomas WR, 2010, TRENDS MOL MED, V16, P321, DOI 10.1016/j.molmed.2010.04.008; Thomas WR, 2009, EXPERT REV CLIN IMMU, V5, P233, DOI [10.1586/eci.09.5, 10.1586/ECI.09.5]; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; White SR, 2011, J ALLERGY CAIRO, V2011, DOI DOI 10.1155/2011/948406; Yamada Y, 2004, PEDIATR ALLERGY IMMU, V15, P159, DOI 10.1111/j.1399-3038.2004.00155.x	30	81	83	6	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JAN 24	2013	493	7433					547	+		10.1038/nature11714		7	Multidisciplinary Sciences	Science & Technology - Other Topics	075GF	WOS:000313871400041	23235830	
J	Chu, DK; Llop-Guevara, A; Walker, TD; Flader, K; Goncharova, S; Boudreau, JE; Moore, CL; In, TS; Waserman, S; Coyle, AJ; Kolbeck, R; Humbles, AA; Jordana, M				Chu, Derek K.; Llop-Guevara, Alba; Walker, Tina D.; Flader, Kristin; Goncharova, Susanna; Boudreau, Jeanette E.; Moore, Cheryl Lynn; In, Tracy Seunghyun; Waserman, Susan; Coyle, Anthony J.; Kolbeck, Roland; Humbles, Alison A.; Jordana, Manel			IL-33, but not thymic stromal lymphopoietin or IL-25, is central to mite and peanut allergic sensitization	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						T(H)2; allergy; asthma; house dust mite; peanut; thymic stromal lymphopoietin; IL-25; IL-33; OX40 ligand; innate lymphoid cells	AIRWAY INFLAMMATION; DENDRITIC CELLS; IMMUNE-RESPONSES; IN-VIVO; TH2 RESPONSES; OX40 LIGAND; TSLP; ASTHMA; RECEPTOR; INNATE	Background: Allergen exposure at lung and gut mucosae can lead to aberrant T(H)2 immunity and allergic disease. The epithelium-associated cytokines thymic stromal lymphopoietin (TSLP), IL-25, and IL-33 are suggested to be important for the initiation of these responses. Objective: We sought to investigate the contributions of TSLP, IL-25, and IL-33 in the development of allergic disease to the common allergens house dust mite (HDM) or peanut. Methods: Neutralizing antibodies or mice deficient in TSLP, IL-25, or IL-33 signaling were exposed to HDM intranasally or peanut intragastrically, and immune inflammatory and physiologic responses were evaluated. In vitro assays were performed to examine specific dendritic cell (DC) functions. Results: We showed that experimental HDM-induced allergic asthma and food allergy and anaphylaxis to peanut were associated with TSLP production but developed independently of TSLP, likely because these allergens functionally mimicked TSLP inhibition of IL-12 production and induction of OX40 ligand (OX40L) on DCs. Blockade of OX40L significantly lessened allergic responses to HDM or peanut. Although IL-25 and IL-33 induced OX40L on DCs in vitro, only IL-33 signaling was necessary for intact allergic immunity, likely because of its superior ability to induce DC OX40L and expand innate lymphoid cells in vivo. Conclusion: These data identify a nonredundant, IL-33-driven mechanism initiating T(H)2 responses to the clinically relevant allergens HDM and peanut. Our findings, along with those in infectious and transgenic/surrogate allergen systems, favor a paradigm whereby multiple molecular pathways can initiate T(H)2 immunity, which has implications for the conceptualization and manipulation of these responses in health and disease. (J Allergy Clin Immunol 2013;131:187-200.)	[Chu, Derek K.; Llop-Guevara, Alba; Walker, Tina D.; Flader, Kristin; Goncharova, Susanna; Boudreau, Jeanette E.; Moore, Cheryl Lynn; In, Tracy Seunghyun; Coyle, Anthony J.; Jordana, Manel] McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, Hamilton, ON L8N 3Z5, Canada; [Waserman, Susan] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada; [Coyle, Anthony J.] Pfizer, Cambridge, MA USA; [Kolbeck, Roland; Humbles, Alison A.] MedImmune LLC, Dept Resp Inflammat & Autoimmun, Gaithersburg, MD USA	Jordana, M (reprint author), McMaster Univ, McMaster Immunol Res Ctr, Dept Pathol & Mol Med, MDCL 4013,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	jordanam@mcmaster.ca			CIHR; Anaphylaxis Canada; MedImmune LLC; Fundacion Caja Madrid doctoral scholarship (Spain); NSERC Doctoral Canada Graduate Scholarship; Canadian Institutes of Health Research	Supported by CIHR, Anaphylaxis Canada, and grants from MedImmune LLC. D.K.C. is a CIHR Vanier Scholar. A.L.-G. is supported by a Fundacion Caja Madrid doctoral scholarship (Spain). J.E.B. holds an NSERC Doctoral Canada Graduate Scholarship. M.J. holds a Senior Canada Research Chair in Immunobiology of Respiratory Diseases and Allergy.; Disclosure of potential conflict of interest: S. Waserman has received research support from Anaphylaxis Canada and is employed by McMaster University. A. J. Coyle was an employee of MedImmune LLC and is now an employee of Pfizer. R. Kolbeck is employed by and has stock options in MedImmune LLC. A. A. Humbles is employed by MedImmune LLC and has stock options in MedImmune (AZ). M. Jordana has received research support from MedImmune LLC, Anaphylaxis Canada, and the Canadian Institutes of Health Research and is employed by McMaster University. The rest of the authors declare that they have no relevant conflicts of interest.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Arias K, 2011, J ALLERGY CLIN IMMUN, V127, P1552, DOI 10.1016/j.jaci.2011.03.044; Arias K, 2009, J ALLERGY CLIN IMMUN, V124, P307, DOI 10.1016/j.jaci.2009.03.012; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barlow JL, 2012, J ALLERGY CLIN IMMUN, V129, P191, DOI 10.1016/j.jaci.2011.09.041; Barlow JL, 2009, BIOFACTORS, V35, P178, DOI 10.1002/biof.24; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Blazquez AB, 2008, J IMMUNOL, V180, P4441; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Boudreau J, 2008, J VIS EXP, V17, P769; Boudreau JE, 2009, MOL THER, V17, P1465, DOI 10.1038/mt.2009.95; Bulek K, 2010, IMMUNOL CELL BIOL, V88, P257, DOI 10.1038/icb.2009.113; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Cates EC, 2004, J IMMUNOL, V173, P6384; Cates Elizabeth C., 2007, V14, P42; Chafen JJS, 2010, JAMA-J AM MED ASSOC, V303, P1848, DOI 10.1001/jama.2010.582; Claudio E, 2009, J IMMUNOL, V182, P1617; Corrigan CJ, 2011, P NATL ACAD SCI USA, V108, P1579, DOI 10.1073/pnas.1014241108; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Damayanti T, 2010, AM J RESP CRIT CARE, V181, P688, DOI 10.1164/rccm.200910-1598OC; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Gratchev A, 2004, SCAND J IMMUNOL, V60, P233, DOI 10.1111/j.0300-9475.2004.01443.x; Gregory LG, 2010, AM J RESP CRIT CARE, V182, P143, DOI 10.1164/rccm.200905-0725OC; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2012, ALLERGOL INT, V61, P35, DOI 10.2332/allergolint.11-RAI-0376; Jessup HK, 2008, J IMMUNOL, V181, P4311; Johnson JR, 2007, AM J PHYSIOL-LUNG C, V293, pL730, DOI 10.1152/ajplung.00056.2007; Kashyap M, 2011, J IMMUNOL, V187, P1207, DOI 10.4049/jimmunol.1100355; Kool M, 2011, IMMUNITY, V34, P527, DOI 10.1016/j.immuni.2011.03.015; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Llop-Guevara A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002426; Massacand JC, 2009, P NATL ACAD SCI USA, V106, P13968, DOI 10.1073/pnas.0906367106; Nakanishi K, 2010, CURR OPIN IMMUNOL, V22, P814, DOI 10.1016/j.coi.2010.10.018; Nishikado H, 2011, J IMMUNOL, V186, P5766, DOI 10.4049/jimmunol.1100370; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Ramalingam TR, 2009, J IMMUNOL, V182, P6452, DOI 10.4049/jimmunol.0900181; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rickel EA, 2008, J IMMUNOL, V181, P4299; Rona RJ, 2007, J ALLERGY CLIN IMMUN, V120, P638, DOI 10.1016/j.jaci.2007.05.026; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Senn KA, 2000, EUR J IMMUNOL, V30, P1929, DOI 10.1002/1521-4141(200007)30:7<1929::AID-IMMU1929>3.0.CO;2-1; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Spits H, 2012, ANNU REV IMMUNOL, V30, P647, DOI 10.1146/annurev-immunol-020711-075053; Sun JF, 2007, J IMMUNOL, V179, P6696; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590; Zhou BH, 2008, J IMMUNOL, V181, P6557; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Ziegler SF, 2010, CURR OPIN IMMUNOL, V22, P795, DOI 10.1016/j.coi.2010.10.020; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	63	81	83	4	30	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2013	131	1					187	U283		10.1016/j.jaci.2012.08.002		22	Allergy; Immunology	Allergy; Immunology	062YR	WOS:000312961200024	23006545	
J	Wisnivesky, JP; Teitelbaum, SL; Todd, AC; Boffetta, P; Crane, M; Crowley, L; de la Hoz, RE; Dellenbaugh, C; Harrison, D; Herbert, R; Kim, H; Jeon, Y; Kaplan, J; Katz, C; Levin, S; Luft, B; Markowitz, S; Moline, JM; Ozbay, F; Pietrzak, RH; Shapiro, M; Sharma, V; Skloot, G; Southwick, S; Stevenson, LA; Udasin, I; Wallenstein, S; Landrigan, PJ				Wisnivesky, Juan P.; Teitelbaum, Susan L.; Todd, Andrew C.; Boffetta, Paolo; Crane, Michael; Crowley, Laura; de la Hoz, Rafael E.; Dellenbaugh, Cornelia; Harrison, Denise; Herbert, Robin; Kim, Hyun; Jeon, Yunho; Kaplan, Julia; Katz, Craig; Levin, Stephen; Luft, Ben; Markowitz, Steven; Moline, Jacqueline M.; Ozbay, Fatih; Pietrzak, Robert H.; Shapiro, Moshe; Sharma, Vansh; Skloot, Gwen; Southwick, Steven; Stevenson, Lori A.; Udasin, Iris; Wallenstein, Sylvan; Landrigan, Philip J.			Persistence of multiple illnesses in World Trade Center rescue and recovery workers: a cohort study	LANCET			English	Article							POSTTRAUMATIC STRESS SYMPTOMS; CENTER DISASTER; LUNG-FUNCTION; HEALTH; FIREFIGHTERS; ASTHMA; STRATEGIES; EXPOSURE; COLLAPSE; ATTACKS	Background More than 50000 people participated in the rescue and recovery work that followed the Sept 11, 2001 (9/11) attacks on the World Trade Center (WTC). Multiple health problems in these workers were reported in the early years after the disaster. We report incidence and prevalence rates of physical and mental health disorders during the 9 years since the attacks, examine their associations with occupational exposures, and quantify physical and mental health comorbidities. Methods In this longitudinal study of a large cohort of WTC rescue and recovery workers, we gathered data from 27 449 participants in the WTC Screening, Monitoring, and Treatment Program. The study population included police officers, firefighters, construction workers, and municipal workers. We used the Kaplan-Meier procedure to estimate cumulative and annual incidence of physical disorders (asthma, sinusitis, and gastro-oesophageal reflux disease), mental health disorders (depression, post-traumatic stress disorder [PTSD], and panic disorder), and spirometric abnormalities. Incidence rates were assessed also by level of exposure (days worked at the WTC site and exposure to the dust cloud). Findings 9-year cumulative incidence of asthma was 27.6% (number at risk: 7027), sinusitis 42.3% (5870), and gastro-oesophageal reflux disease 39.3% (5650). In police officers, cumulative incidence of depression was 7.0% (number at risk: 3648), PTSD 9.3% (3761), and panic disorder 8.4% (3780). In other rescue and recovery workers, cumulative incidence of depression was 27.5% (number at risk: 4200), PTSD 31.9% (4342), and panic disorder 21.2% (4953). 9-year cumulative incidence for spirometric abnormalities was 41.8% (number at risk: 5769); three-quarters of these abnormalities were low forced vital capacity. Incidence of most disorders was highest in workers with greatest WTC exposure. Extensive comorbidity was reported within and between physical and mental health disorders. Interpretation 9 years after the 9/11 WTC attacks, rescue and recovery workers continue to have a substantial burden of physical and mental health problems. These findings emphasise the need for continued monitoring and treatment of the WTC rescue and recovery population.	[Wisnivesky, Juan P.] Mt Sinai Sch Med, Dept Med, Div Gen Internal Med, New York, NY 10029 USA; [Wisnivesky, Juan P.; Skloot, Gwen] Mt Sinai Sch Med, Div Pulm & Crit Care Med, New York, NY 10029 USA; [Teitelbaum, Susan L.; Todd, Andrew C.; Crane, Michael; Crowley, Laura; de la Hoz, Rafael E.; Dellenbaugh, Cornelia; Herbert, Robin; Jeon, Yunho; Kaplan, Julia; Levin, Stephen; Shapiro, Moshe; Stevenson, Lori A.; Wallenstein, Sylvan; Landrigan, Philip J.] Mt Sinai Sch Med, Dept Prevent Med, New York, NY 10029 USA; [Boffetta, Paolo] Mt Sinai Sch Med, Inst Translat Epidemiol, New York, NY 10029 USA; [Katz, Craig; Ozbay, Fatih; Sharma, Vansh] Mt Sinai Sch Med, Dept Psychiat, New York, NY 10029 USA; [Harrison, Denise] NYU, Bellevue Hosp Ctr, Sch Med, Dept Med, New York, NY 10016 USA; [Kim, Hyun; Moline, Jacqueline M.] Hofstra N Shore LIJ Sch Med, Dept Populat Hlth, Great Neck, NY USA; [Luft, Ben] SUNY Stony Brook, Dept Med, Port Jefferson, NY USA; [Markowitz, Steven] CUNY Queens Coll, Flushing, NY 11367 USA; [Pietrzak, Robert H.; Southwick, Steven] Yale Univ, Sch Med, Dept Psychiat, West Haven, CT 06516 USA; [Pietrzak, Robert H.; Southwick, Steven] Vet Adm Connecticut Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA; [Udasin, Iris] Univ Med & Dent New Jersey, Piscataway, NJ 08854 USA	Wisnivesky, JP (reprint author), Mt Sinai Sch Med, Dept Med, Div Gen Internal Med, 1 Gustave L Pl,Box 1087, New York, NY 10029 USA.	juan.wisnivesky@mssm.edu		Luft, Benjamin/0000-0001-9008-7004; de la Hoz, Rafael E./0000-0002-8949-9279	Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health [200-2002-0038, 5U1O 0H008232]; American Red Cross Liberty Fund; September 11th Recovery Program; Bear Stearns Charitable Foundation; September 11th Fund; Robin Hood Foundation	We thank the staff of the World Trade Center (WTC) Worker and Volunteer Medical Screening, Medical Monitoring, and Treatment programmes; the labour, community, and volunteer organisation stake-holders; and the WTC rescue and recovery workers, who gave of themselves so readily in response to the WTC attacks and to whom the WTC programmes are dedicated. This work was supported by the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health (contract 200-2002-0038 and grant 5U1O 0H008232), the American Red Cross Liberty Fund, The September 11th Recovery Program, The Bear Stearns Charitable Foundation, The September 11th Fund, The Robin Hood Foundation Relief Fund, and many others. The contents of this report are solely the responsibility of the authors and do not necessarily represent the official views of Centers for Disease Control or the National Institute for Occupational Safety and Health.	Aldrich TK, 2010, NEW ENGL J MED, V362, P1263, DOI 10.1056/NEJMoa0910087; Brackbill RM, 2009, JAMA-J AM MED ASSOC, V302, P502, DOI 10.1001/jama.2009.1121; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CHOI BC, 1992, OCCUP MED, V34, P979; Crowley LE, 2011, AM J IND MED, V54, P175, DOI 10.1002/ajim.20924; DiGrande L, 2011, AM J EPIDEMIOL, V173, P271, DOI 10.1093/aje/kwq372; Feldman DM, 2004, CHEST, V125, P1256, DOI 10.1378/chest.125.4.1256; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P981, DOI 10.1289/ehp.5931; Herbert R, 2006, ENVIRON HEALTH PERSP, V114, P1853, DOI 10.1289/ehp.9592; Hoge CW, 2004, NEW ENGL J MED, V351, P13, DOI 10.1056/NEJMoa040603; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; Lombardo LJ, 2000, ENVIRON HEALTH PERSP, V108, P697, DOI 10.2307/3454406; Mann JM, 2005, AM J IND MED, V48, P225, DOI 10.1002/ajim.20196; Mauer MP, 2010, OCCUP MED-OXFORD, V60, P145, DOI 10.1093/occmed/kqp176; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; MOLINE IM, 2008, MT SINAI J MED, V75, P67; Murphy J, 2007, STAT MED, V26, P1688, DOI 10.1002/sim.2806; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Perrin MA, 2007, AM J PSYCHIAT, V164, P1385, DOI 10.1176/appi.apj.2007.06101645; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Renck B, 2002, NORD J PSYCHIAT, V56, P7, DOI 10.1080/08039480252803855; Safirstein BH, 2003, CHEST, V123, P301, DOI 10.1378/chest.123.1.301; Savitz DA, 2008, MT SINAI J MED, V75, P77, DOI 10.1002/msj.20023; Spitzer RL, 1999, JAMA-J AM MED ASSOC, V282, P1737, DOI 10.1001/jama.282.18.1737; Stellman JM, 2008, ENVIRON HEALTH PERSP, V116, P1248, DOI 10.1289/ehp.11164; Tapp LC, 2005, AM J IND MED, V47, P475, DOI 10.1002/aijm.20177; Udasin I, 2011, J OCCUP ENVIRON MED, V53, P49, DOI 10.1097/JOM.0b013e3182028e5c; Weathers FW, 1993, ANN CONV INT SOC TRA; Weiden MD, 2010, CHEST, V137, P566, DOI 10.1378/chest.09-1580; ZHAN J, 1997, JASA, V92, P945	32	81	82	1	16	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	SEP 3	2011	378	9794					888	897				10	Medicine, General & Internal	General & Internal Medicine	818XZ	WOS:000294791300029	21890053	
J	Ziegler, SF				Ziegler, Steven F.			The role of thymic stromal lymphopoietin (TSLP) in allergic disorders	CURRENT OPINION IN IMMUNOLOGY			English	Review							RESPIRATORY SYNCYTIAL VIRUS; AIRWAY EPITHELIAL-CELLS; IGM(+) B-CELLS; ATOPIC-DERMATITIS; EOSINOPHILIC ESOPHAGITIS; NETHERTON-SYNDROME; IN-VITRO; INFLAMMATION; EXPRESSION; RECEPTOR	The importance of the epithelium in initiating and controlling immune responses is becoming more appreciated. For example, allergen contact first occurs at mucosal sites exposed to the external environment, such as the skin, airways and gastrointestinal tract. This exposure leads to the production of a variety of cytokines and chemokines that are involved in driving allergic inflammatory responses. One such product is thymic stromal lymphopoietin (TSLP). Recent studies, in both humans and mouse models, have implicated TSLP in the development and progression of atopy and atopic diseases. This review will discuss this work and place TSLP in the inflammatory cascade that leads to allergic disease.	Benaroya Res Inst, Program Immunol, Seattle, WA 98101 USA	Ziegler, SF (reprint author), Benaroya Res Inst, Program Immunol, Seattle, WA 98101 USA.	sziegler@benaroyaresearch.org			NIAID NIH HHS [R01 AI068731-05, R01 AI044259, R01 AI044259-01A1, R01 AI044259-02, R01 AI044259-03, R01 AI044259-04, R01 AI044259-05A1, R01 AI068731, R01 AI068731-01, R01 AI068731-02, R01 AI068731-03, R01 AI068731-04]; NIAMS NIH HHS [R01 AR055695, R01 AR055695-01A2, R01 AR055695-02, R01 AR055695-03, R01 AR056113, R01 AR056113-01A1, R01 AR056113-02, R01 AR056113-03]		Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Blazquez AB, 2010, GASTROENTEROLOGY; Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Chavanas S, 2000, NAT GENET, V25, P141; Corrigan CJ, 2009, ALLERGY, V64, P1014, DOI 10.1111/j.1398-9995.2009.01947.x; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Fang CL, 2010, ARCH IMMUNOL THER EX, V58, P81, DOI 10.1007/s00005-010-0064-3; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Hall CB, 2001, NEW ENGL J MED, V344, P1917, DOI 10.1056/NEJM200106213442507; Harada H, 2010, AM J RESP C IN PRESS; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Headley MB, 2009, J IMMUNOL, V182, P1641; Holt PG, 2002, J EXP MED, V196, P1271, DOI 10.1084/jem.20021572; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Hunninghake G. M., 2010, ALLERGY; Isaksen DE, 2002, J IMMUNOL, V168, P3288; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Kato A, 2007, J IMMUNOL, V179, P1080; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Levin SD, 1999, J IMMUNOL, V162, P677; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; Matsuda A, 2010, INVEST OPHTH VIS SCI, V51, P151, DOI 10.1167/iovs.09-4183; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Mou ZL, 2009, ACTA OTO-LARYNGOL, V129, P297, DOI 10.1080/00016480802225884; Pandey A, 2000, NAT IMMUNOL, V1, P59; PARK LS, 1990, J EXP MED, V171, P1073, DOI 10.1084/jem.171.4.1073; Qiao J, 2010, IMMUNOL CELL BIOL; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Reche PA, 2001, J IMMUNOL, V167, P336; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shigeno T, 2009, IMMUNOLOGY, V128, pe849, DOI 10.1111/j.1365-2567.2009.03094.x; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spergel JM, 2003, J ALLERGY CLIN IMMUN, V112; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Ying S, 2005, J IMMUNOL, V174, P8183; Ying S, 2008, J IMMUNOL, V181, P2790; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Zheng XF, 2010, INVEST OPHTH VIS SCI, V51, P3076, DOI 10.1167/iovs.09-4122; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu DD, 2009, CHINESE MED J-PEKING, V122, P2303, DOI 10.3760/cma.j.issn.0366-6999.2009.19.021	55	81	90	1	6	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2010	22	6					795	799		10.1016/j.coi.2010.10.020		5	Immunology	Immunology	701HP	WOS:000285809300016	21109412	
J	DeKruyff, RH; Bu, X; Ballesteros, A; Santiago, C; Chim, YLE; Lee, HH; Karisola, P; Pichavant, M; Kaplan, GG; Umetsu, DT; Freeman, GJ; Casasnovas, JM				DeKruyff, Rosemarie H.; Bu, Xia; Ballesteros, Angela; Santiago, Cesar; Chim, Yee-Ling E.; Lee, Hyun-Hee; Karisola, Piia; Pichavant, Muriel; Kaplan, Gerardo G.; Umetsu, Dale T.; Freeman, Gordon J.; Casasnovas, Jose M.			T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells	JOURNAL OF IMMUNOLOGY			English	Article							TIM GENE FAMILY; IMMUNE-RESPONSES; IN-VIVO; PERIPHERAL TOLERANCE; AIRWAY INFLAMMATION; AUTOIMMUNE-DISEASE; ACTIVATION; RECEPTOR; MECHANISMS; EXPOSURE	T cell/transmembrane, Ig, and mucin (TIM) proteins, identified using a congenic mouse model of asthma, critically regulate innate and adaptive immunity. TIM-1 and TIM-4 are receptors for phosphatidylserine (PtdSer), exposed on the surfaces of apoptotic cells. Herein, we show with structural and biological studies that TIM-3 is also a receptor for PtdSer that binds in a pocket on the N-terminal IgV domain in coordination with a calcium ion. The TIM-3/PtdSer structure is similar to that of TIM-4/PtdSer, reflecting a conserved PtdSer binding mode by TIM family members. Fibroblastic cells expressing mouse or human TIM-3 bound and phagocytosed apoptotic cells, with the BALB/c allelic variant of mouse TIM-3 showing a higher capacity than the congenic C.D2 Es-Hba-allelic variant. These functional differences were due to structural differences in the BC loop of the IgV domain of the TIM-3 polymorphic variants. In contrast to fibroblastic cells, T or B cells expressing TIM-3 formed conjugates with but failed to engulf apoptotic cells. Together these findings indicate that TIM-3-expressing cells can respond to apoptotic cells, but the consequence of TIM-3 engagement of PtdSer depends on the polymorphic variants of and type of cell expressing TIM-3. These findings establish a new paradigm for TIM proteins as PtdSer receptors and unify the function of the TIM gene family, which has been associated with asthma and autoimmunity and shown to modulate peripheral tolerance. The Journal of Immunology, 2010,184: 1918-1930.	[Freeman, Gordon J.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [DeKruyff, Rosemarie H.; Chim, Yee-Ling E.; Lee, Hyun-Hee; Karisola, Piia; Pichavant, Muriel; Umetsu, Dale T.] Harvard Univ, Sch Med, Div Immunol, Childrens Hosp Boston, Cambridge, MA 02138 USA; [DeKruyff, Rosemarie H.; Chim, Yee-Ling E.; Lee, Hyun-Hee; Karisola, Piia; Pichavant, Muriel; Umetsu, Dale T.] Harvard Univ, Sch Med, Dept Pediat, Cambridge, MA 02138 USA; [Bu, Xia; Freeman, Gordon J.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; [Ballesteros, Angela; Santiago, Cesar; Casasnovas, Jose M.] Consejo Super Invest Cient, Ctr Nacl Biotecnol, Madrid, Spain; [Kaplan, Gerardo G.] US FDA, Ctr Biol Evaluat & Res, Bethesda, MD 20892 USA	Freeman, GJ (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	gordon_freeman@dfci.harvard.edu	Casasnovas, Jose/L-6299-2014; Santiago, Cesar/K-4240-2014	Casasnovas, Jose/0000-0002-2873-6410; Santiago, Cesar/0000-0002-5149-1722	National Institutes of Health [P01 AI054456, HL069507]; Ministerio de Ciencia e Innovacion [BFU2005-05972, BFU2008-00971]	This work was supported by National Institutes of Health Grants P01 AI054456 (to D.T.U., G.J.F., R.H.D., and G.G.K.) and HL069507 (to R.H.D.) and Ministerio de Ciencia e Innovacion Grants BFU2005-05972 and BFU2008-00971 (to J.M.C.).	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Anderson AC, 2007, SCIENCE, V318, P1141, DOI 10.1126/science.1148536; Cao EH, 2007, IMMUNITY, V26, P311, DOI 10.1016/j.immuni.2007.01.016; Chakravarti S, 2005, J EXP MED, V202, P437, DOI 10.1084/jem.20050308; Chan A, 2003, GLIA, V43, P231, DOI 10.1002/glia.10258; de Souza AJ, 2005, P NATL ACAD SCI USA, V102, P17113, DOI 10.1073/pnas.0508643102; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Hanayama R, 2004, SCIENCE, V304, P1147, DOI 10.1126/science.1094359; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Ichimura T, 2008, J CLIN INVEST, V118, P1657, DOI 10.1172/JCI34487; Kearley J, 2007, J EXP MED, V204, P1289, DOI 10.1084/jem.20062093; Kinchen JM, 2008, CURR BIOL, V18, pR521, DOI 10.1016/j.cub.2008.04.058; Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206; McIntire JJ, 2003, NATURE, V425, P576, DOI 10.1038/425576a; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Miyanishi M, 2007, NATURE, V450, P435, DOI 10.1038/nature06307; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Nakae S, 2007, BLOOD, V110, P2565, DOI 10.1182/blood-2006-11-058800; Nakae S, 2007, J LEUKOCYTE BIOL, V81, P1258, DOI 10.1186/jlb.1006610; Nakayama M, 2009, BLOOD, V113, P3821, DOI 10.1182/blood-2008-10-185884; Ohler B, 2004, BBA-MOL BASIS DIS, V1688, P10, DOI 10.1016/j.bbadis.2003.10.001; Ravichandran KS, 2007, NAT REV IMMUNOL, V7, P964, DOI 10.1038/nri2214; Rennert PD, 2006, J IMMUNOL, V177, P4311; Rodriguez-Manzanet R, 2009, IMMUNOL REV, V229, P259, DOI 10.1111/j.1600-065X.2009.00772.x; RUSCETTI S, 1985, J EXP MED, V162, P1579, DOI 10.1084/jem.162.5.1579; Sabatos CA, 2003, NAT IMMUNOL, V4, P1102, DOI 10.1038/ni988; Sanchez-Fueyo A, 2003, NAT IMMUNOL, V4, P1093, DOI 10.1038/ni987; Santiago C, 2007, IMMUNITY, V27, P941, DOI 10.1016/j.immuni.2007.11.008; Santiago C, 2007, IMMUNITY, V26, P299, DOI 10.1016/j.immuni.2007.01.014; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schwende H, 1996, J LEUKOCYTE BIOL, V59, P555; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; Sizing Irene D, 2007, J Immunol, V178, P2249; STOCKINGER B, 1994, INT IMMUNOL, V6, P247, DOI 10.1093/intimm/6.2.247; Su EW, 2008, CYTOKINE, V44, P9, DOI 10.1016/j.cyto.2008.06.013; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; VERHOVEN B, 1995, J EXP MED, V182, P1597, DOI 10.1084/jem.182.5.1597; Wu QW, 2009, INT ARCH ALLERGY IMM, V150, P252, DOI 10.1159/000222677; Xiao S, 2007, J EXP MED, V204, P1691, DOI 10.1084/jem.20062498; Zhu C, 2005, NAT IMMUNOL, V6, P1245, DOI 10.1038/ni1271	46	81	87	0	11	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 15	2010	184	4					1918	1930		10.4049/jimmunol.0903059		13	Immunology	Immunology	556IU	WOS:000274585100028	20083673	
J	Inoue, K; Koike, E; Yanagisaw, R; Hirano, S; Nishikawa, M; Takano, H				Inoue, Ken-ichiro; Koike, Eiko; Yanagisaw, Rie; Hirano, Seishiro; Nishikawa, Masataka; Takano, Hirohisa			Effects of multi-walled carbon nanotubes on a murine allergic airway inflammation model	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						Multi-walled carbon nanotubes; Allergic airway inflammation; Antigen-presenting cells; Dendritic cells; Th immunity	DIESEL EXHAUST PARTICLES; ANTIGEN-PRESENTING CELLS; MOUSE BONE-MARROW; DENDRITIC CELLS; LUNG INFLAMMATION; INTRATRACHEAL INSTILLATION; BACTERIAL-ENDOTOXIN; CYTOKINE EXPRESSION; PARTICULATE MATTER; PULMONARY TOXICITY	The development of nanotechnology has increased the risk of exposure to types of particles other than combustion-derived particles in the environment, namely, industrial nanomaterials. On the other hand, patients with bronchial asthma are sensitive to inhaled substances including particulate matters. This Study examined the effects of pulmonary exposure to a type of nano-sized carbon nanotube (multi-walled nanotubes: MWCNT) on allergic airway inflammation in vivo and their cellular mechanisms in vitro. In vivo, ICR mice were divided into 4 experimental groups. Vehicle, MWCNT (50 mu g/animal), ovalbumin (OVA), and OVA + MWCNT were repeatedly administered intratracheally. Bronchoalveolar lavage (BAL) cellularity, lung histology, levels of cytokines related to allergic inflammation in lung homogenates/BAL fluids (BALF's), and serum immunoglobulin levels were Studied. Also, we evaluated the impact of MWCNT (0.1-1 mu g/ml) on the phenotype and function of bone marrow-derived dendritic cells (DC) in vitro. MWCNT aggravated allergen-induced airway inflammation characterized by the infiltration of eosinophils, neutrophils, and mononuclear cells in the lung, and an increase in the number of goblet cells in the bronchial epithelium. MWCNT with allergen amplified lung protein levels of Th cytokines and chemokines compared with allergen alone. MWCNT exhibited adjuvant activity for allergen-specific IgG(1) and IgE. MWCNT significantly increased allergen (OVA)-specific syngeneic T-cell proliferation, particularly at a lower concentration in vitro. Taken together, MWCNT can exacerbate murine allergic airway inflammation, at least partly, via the promotion of a Th-dominant milieu. In addition, the exacerbation may be partly through the inappropriate activation of antigen-presenting cells including DC. (C) 2009 Elsevier Inc. All rights reserved.	[Inoue, Ken-ichiro; Koike, Eiko; Yanagisaw, Rie; Takano, Hirohisa] Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki 3058506, Japan; [Hirano, Seishiro] Natl Inst Environm Studies, Res Ctr Environm Risk, Tsukuba, Ibaraki 3058506, Japan; [Nishikawa, Masataka] Natl Inst Environm Studies, Div Environm Chem, Tsukuba, Ibaraki 3058506, Japan	Inoue, K (reprint author), Natl Inst Environm Studies, Environm Hlth Sci Div, 16-2 Onogawa, Tsukuba, Ibaraki 3058506, Japan.	inoue.kenichirou@nies.go.jp			Japan Society for the Promotion of Science [18390188, 19510037]	This study was supported by Grants-in-Aid for Scientific Research (B) 18390188 (to H. Takano) and (C) 19510037 (to K. Inoue) from the Japan Society for the Promotion of Science. The authors thank Naoko Ueki, Satomi Abe, and Rieko Shibahara for their assistance throughout the work.	Boezen M, 1998, AM J RESP CRIT CARE, V158, P1848; Borm PJA, 2002, INHAL TOXICOL, V14, P311, DOI 10.1080/08958370252809086; Cacciotti P, 2005, CANCER RES, V65, P5256, DOI 10.1158/0008-5472.CAN-05-0127; Chen HW, 2006, FASEB J, V20, P2393, DOI 10.1096/fj.06-6485fje; Cherukuri P, 2004, J AM CHEM SOC, V126, P15638, DOI 10.1021/ja0466311; Choi M, 2008, TOXICOL LETT, V182, P97, DOI 10.1016/j.toxlet.2008.08.019; Chou CC, 2008, NANO LETT, V8, P437, DOI 10.1021/nl0723634; Colvin VL, 2003, NAT BIOTECHNOL, V21, P1166, DOI 10.1038/nbt875; de Haar C, 2006, CLIN EXP ALLERGY, V36, P1469, DOI 10.1111/j.1365-2222.2006.02586.x; de Haar C, 2005, TOXICOL SCI, V87, P409, DOI 10.1093/toxsci/kfi255; de Jong EC, 2005, SPRINGER SEMIN IMMUN, V26, P289, DOI 10.1007/s00281-004-0167-1; de Jonge N, 2004, PHILOS T R SOC A, V362, P2239, DOI 10.1098/rsta.2004.1438; Dong CC, 2005, TOXICOL SCI, V88, P202, DOI 10.1093/toxsci/kfi280; Guzman KAD, 2006, ENVIRON SCI TECHNOL, V40, P1401, DOI 10.1021/es0515708; Hamilton RF, 2004, EXP LUNG RES, V30, P147, DOI 10.1080/01902140490266439; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1067/mai.2003.1780; Hayashi N, 2007, P NATL ACAD SCI USA, V104, P14765, DOI 10.1073/pnas.0706378104; Hirano S, 2008, TOXICOL APPL PHARM, V232, P244, DOI 10.1016/j.taap.2008.06.016; Inoue K, 2007, INT J IMMUNOPATH PH, V20, P737; Inoue K, 2007, EUR RESPIR J, V29, P259, DOI 10.1183/09031936.00033106; Inoue K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-106; Inoue KI, 2006, EXP BIOL MED, V231, P1626; Inoue KI, 2006, ENVIRON HEALTH PERSP, V114, P1325, DOI 10.1289/ehp.8903; Inoue K, 2006, ARCH TOXICOL, V80, P614, DOI 10.1007/s00204-006-0075-3; Inoue K, 2009, EXP BIOL MED, V234, P200, DOI 10.3181/0809-RM-285; Inoue K, 2009, TOXICOL APPL PHARM, V234, P68, DOI 10.1016/j.taap.2008.09.012; Kato T, 2006, EUR J IMMUNOL, V36, P1199, DOI 10.1002/eji.200535140; Kim YA, 2005, CARBON, V43, P2243, DOI 10.1016/j.carbon.2005.03.039; Koike E, 2008, INT J IMMUNOPATH PH, V21, P35; Koike E, 2008, CHEMOSPHERE, V73, P371, DOI 10.1016/j.chemosphere.2008.05.054; Koike E, 2008, INT IMMUNOPHARMACOL, V8, P1737, DOI 10.1016/j.intimp.2008.08.006; Lam CW, 2004, TOXICOL SCI, V77, P126, DOI 10.1093/toxsci/kfg243; Lange A, 1995, ANN NY ACAD SCI, V762, P435; Larsen ST, 2004, TOXICOL LETT, V151, P389, DOI 10.1016/j.toxlet.2004.03.008; Larsen ST, 2002, PHARMACOL TOXICOL, V91, P264, DOI 10.1034/j.1600-0773.2002.910508.x; Leikauf GD, 2002, ENVIRON HEALTH PERSP, V110, P505; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Manna SK, 2005, NANO LETT, V5, P1676, DOI 10.1021/nl0507966; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Matsumoto A, 2006, CLIN IMMUNOL, V121, P227, DOI 10.1016/j.clim.2006.08.003; Mitchell LA, 2007, TOXICOL SCI, V100, P203, DOI 10.1093/toxsci/kfm196; Mossman BT, 1997, ENVIRON HEALTH PERSP, V105, P1121, DOI 10.2307/3433519; Muller J, 2005, TOXICOL APPL PHARM, V207, P221, DOI 10.1016/j.taap.2005.01.008; Murr L E, 2005, Int J Environ Res Public Health, V2, P31, DOI 10.3390/ijerph2005010031; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Okamoto K, 1987, ANAL SC, V3, P191, DOI 10.2116/analsci.3.191; Pacurari M, 2008, ENVIRON HEALTH PERSP, V116, P1211, DOI 10.1289/ehp.10924; Rossi M, 2005, J IMMUNOL, V175, P1373; Ryman-Rasmussen JP, 2009, AM J RESP CELL MOL, V40, P349, DOI 10.1165/rcmb.2008-0276OC; Sabo-Attwood T, 2005, AM J PATHOL, V167, P1243, DOI 10.1016/S0002-9440(10)61212-6; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Shvedova AA, 2005, AM J PHYSIOL-LUNG C, V289, pL698, DOI 10.1152/ajplung.00084.2005; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Takano H, 2002, AM J RESP CRIT CARE, V165, P1329, DOI 10.1164/rccm20108122; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Upham JW, 2003, RESPIROLOGY, V8, P140, DOI 10.1046/j.1440-1843.2003.00465.x; Warheit DB, 2006, TOXICOL SCI, V91, P227, DOI 10.1093/toxsci/kfj140; Warheit DB, 2004, TOXICOL SCI, V77, P117, DOI 10.1093/toxsci/kfg228; Wick P, 2007, TOXICOL LETT, V168, P121, DOI 10.1016/j.toxlet.2006.08.019; Yanagisawa R, 2006, CLIN EXP ALLERGY, V36, P386, DOI 10.1111/j.1365-2222.2006.02452.x	62	81	82	1	9	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	JUN 15	2009	237	3					306	316		10.1016/j.taap.2009.04.003		11	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	454NS	WOS:000266689800007	19371758	
J	Smit, LAM; Siroux, V; Bouzigon, E; Oryszczyn, MP; Lathrop, M; Demenais, F; Kauffmann, F				Smit, Lidwien A. M.; Siroux, Valerie; Bouzigon, Emmanuelle; Oryszczyn, Marie-Pierre; Lathrop, Mark; Demenais, Florence; Kauffmann, Francine		Epidemiological Study Genetics	CD14 and Toll-like Receptor Gene Polymorphisms, Country Living, and Asthma in Adults	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; atopy; epidemiology; gene-environment interaction; hygiene hypothesis	YOUNG DANISH FARMERS; BRONCHIAL HYPERRESPONSIVENESS; C-159T POLYMORPHISM; ENDOTOXIN EXPOSURE; IMMUNOGLOBULIN-E; ATOPY; ASSOCIATION; ENVIRONMENT; CHILDREN; EGEA	Rationale It has been shown that country living protects against asthma, which may be explained by microbial exposures. Objectives: To study whether single nucleotide polymorphisms (SNPs) in CD 14 and Toll-like receptor (TLR) 2, TLR4 and TLR9 genes are associated with asthma in adults, and whether these SNPs modify associations between country living and asthma. Methods: Twenty-five SNPs in CD14, TLR2, TLR4, and TLR9 genes were genotyped in adult subjects from the French Epidemiological study on the Genetics and Environment of Asthma, Bronchial Hyperresponsiveness, and Atopy (EGEA). We conducted a case-control analysis on unrelated subjects (239 with asthma and 596 without asthma), and a family-based association test (FBAT) in 192 families ascertained through probands with asthma. Measurements and Main Results: The TLR2/+596 C allele was associated with an increased risk for asthma in both case-control and family-based analyses (under a dominant model, odds ratio [OR] 1.91 and 95% confidence interval [CI] 1.34-2.72, P = 0.0003; Z statistics from FBAT = 2.48, P = 0.01). In skin prick test (SPT) positive subjects, the CD14/-260 C allele was negatively associated with asthma (additive model, OR 0.66; CI 0.48-0.91). Significant gene-environment interactions between variation in CD14 and TLR genes and country living during childhood were found for ten SNPs. In SPT positive subjects carrying CD14/-260 CC, country living protected against asthma (OR, 0.32; 95% CI, 0.12-0.85), whereas country living was not associated with asthma in subjects who were atopic and carrying CD14/-260 T (OR, 1.11; 95% CI, 0.65-1.90) (gene-environment interaction, P < 0.05). Conclusions: TLR2 and CD14 SNPs were associated with asthma and atopic asthma respectively. In addition, CD14, TLR2, TLR4, and TLR9 SNPs modified associations between country living and asthma.	[Smit, Lidwien A. M.; Oryszczyn, Marie-Pierre; Kauffmann, Francine] INSERM, U780, F-94807 Villejuif, France; [Smit, Lidwien A. M.] Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands; [Siroux, Valerie] Ctr Rech Albert Bonniot, INSERM, U823, La Tronche, France; [Siroux, Valerie] Univ Grenoble 1, Grenoble, France; [Bouzigon, Emmanuelle; Demenais, Florence] INSERM, U794, Paris, France; [Bouzigon, Emmanuelle; Demenais, Florence] Univ Evry, Evry, France; [Bouzigon, Emmanuelle; Demenais, Florence] Fdn Jean Dausset, CEPH, Paris, France; [Oryszczyn, Marie-Pierre; Kauffmann, Francine] Univ Paris 11, IFR69, Villejuif, France; [Lathrop, Mark] Ctr Natl Genotypage, Inst Genom, Commissariat Energie Atom, Evry, France	Kauffmann, F (reprint author), INSERM, U780, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	francine.kauffmann@.inserm.fr	siroux, valerie/N-1865-2013; Demenais, Florence/G-3298-2013; LeMoual, Nicole/R-8976-2016	Demenais, Florence/0000-0001-8361-0936; LeMoual, Nicole/0000-0002-2723-5569; Smit, Lidwien AM/0000-0003-0292-0946	French Agency for Environmental and Occupational Health Safety [Afsset-APR-SE-2004]; French National Agency for Research [ANR 05-SEST-020-02/05-9-97]; European Academy of Allergology and Clinical Immunology-Global Allergy; Asthma European Network	Supported by the French Agency for Environmental and Occupational Health Safety (grant Afsset-APR-SE-2004), and the French National Agency for Research (grants ANR 05-SEST-020-02/05-9-97). Lidwien Smit is supported by a European Academy of Allergology and Clinical Immunology-Global Allergy and Asthma European Network (EAACI-GA<SUP>2</SUP>LEN) exchange fellowship award.	Baldini M, 1999, AM J RESP CELL MOL, V20, P976; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Berghofer B, 2005, CLIN EXP ALLERGY, V35, P1147, DOI 10.1111/j.1365-2222.2005.02325.x; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Kauffmann F, 1997, AM J RESP CRIT CARE, V156, pS123; Kauffmann F, 2002, CLIN EXP ALLERGY, V32, P379, DOI 10.1046/j.1365-2222.2002.01325.x; KAUFFMANN F, 1995, CLIN EXP ALLERGY, V25, P19, DOI 10.1111/j.1365-2222.1995.tb00413.x; Kauffmann F, 2001, REV EPIDEMIOL SANTE, V49, P343; Kedda MA, 2005, THORAX, V60, P211, DOI 10.1136/thx.2004.028449; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Lazarus R, 2003, GENOMICS, V81, P85, DOI 10.1016/S0888-7543(02)00022-8; LeVan TD, 2001, J IMMUNOL, V167, P5838; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Maccario J, 2003, J ALLERGY CLIN IMMUN, V111, P750, DOI 10.1067/mai.2003.1386; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Noguchi E, 2004, CLIN EXP ALLERGY, V34, P177, DOI 10.1111/j.1365-2222.2004.01839.x; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2008, EUR RESPIR J, V31, P1241, DOI 10.1183/09031936.00090607; Smit LAM, 2007, CLIN EXP ALLERGY, V37, P1602, DOI 10.1111/j.1365-2222.2007.02831.x; SMIT LAM, 2008, EUR RESPIR J, V32, pS481; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Zhang G, 2008, ALLERGY, V63, P1411, DOI 10.1111/j.1398-9995.2008.01804.x	42	81	85	1	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 1	2009	179	5					363	368		10.1164/rccm.200810-1533OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	413BG	WOS:000263767300005	19096003	
J	Willart, MAM; Lambrecht, BN				Willart, M. A. M.; Lambrecht, B. N.			The danger within: endogenous danger signals, atopy and asthma	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							TOLL-LIKE RECEPTORS; REGULATORY T-CELLS; EOSINOPHILIC AIRWAY INFLAMMATION; NOD-LIKE RECEPTORS; DENDRITIC CELLS; INHALED ANTIGEN; NONATOPIC ASTHMA; TH2 RESPONSES; P2X RECEPTORS; MOUSE MODEL	In allergic asthmatics, airway inflammation is triggered by specific (inhalation of allergen such as house dust mite allergen and pollen spores) or non-specific triggers (such as air pollutants and viral infection). Most of these inhaled particles are immunologically inert. Dendritic cells (DCs) are essential for priming and T helper-2 differentiation of naive T cells towards aeroallergens. Contamination of antigens with pattern-associated molecular patterns (PAMPs), such as lipopolysaccharide (LPS), is required to activate DCs to mount an immune response. Damage-associated molecular patterns (DAMPs), such as uric acid and adenosine triphosphate (ATP), also contribute to the induction of inflammation by activation and recruitment of various inflammatory cells. Compelling evidence suggests that a tight collaboration between PAMPs and DAMPs is needed to start an immune response to allergens. Several studies have recently demonstrated an important role of endogenous danger signals at the inception and maintenance phase of allergic disease. Further research into this area should focus on the possible role of these factors in maintenance of chronic disease and induction of airway remodelling.	[Willart, M. A. M.; Lambrecht, B. N.] Univ Ghent, Dept Pulm Med, Lab Immunoregulat & Mucosal Immun, B-9000 Ghent, Belgium	Willart, MAM (reprint author), Univ Ghent, Dept Pulm Med, Lab Immunoregulat & Mucosal Immun, 0 Block B,Pintelaan 185, B-9000 Ghent, Belgium.	Monique.willart@ugent.be	Lambrecht, Bart/K-2484-2014	Lambrecht, Bart/0000-0003-4376-6834			ABBRACCHIO MP, 1994, PHARMACOL THERAPEUT, V64, P445, DOI 10.1016/0163-7258(94)00048-4; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295; Aswad F, 2005, J IMMUNOL, V175, P3075; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Behrens MD, 2008, BLOOD, V111, P1472, DOI 10.1182/blood-2007-10-117184; Bodin P, 2001, J CARDIOVASC PHARM, V38, P900, DOI 10.1097/00005344-200112000-00012; BORTOLATTO J, 2008, CLIN EXP AL IN PRESS; Bours MJL, 2006, PHARMACOL THERAPEUT, V112, P358, DOI 10.1016/j.pharmthera.2005.04.013; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brewer JM, 1998, IMMUNOLOGY, V93, P41; Brewer JM, 1999, J IMMUNOL, V163, P6448; BURNSTOCK G, 1978, EUR J PHARMACOL, V49, P145, DOI 10.1016/0014-2999(78)90070-5; Christodoulopoulos P, 2001, J ALLERGY CLIN IMMUN, V107, P586, DOI 10.1067/mai.2001.114883; D'hulst AI, 2005, EUR RESPIR J, V26, P204, DOI 10.1183/09031936.05.00095204; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; DAVIS CW, 2008, RESP PHYSL IN PRESS; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Di Virgilio F, 2007, TRENDS PHARMACOL SCI, V28, P465, DOI 10.1016/j.tips.2007.07.002; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Ferrari D, 2000, FEBS LETT, V486, P217, DOI 10.1016/S0014-5793(00)02306-1; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hansel NN, 2008, ALLERGY, V63, P366, DOI 10.1111/j.1398-9995.2007.01540.x; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Hussl S, 2007, PURINERG SIGNAL, V3, P367, DOI 10.1007/s11302-007-9062-2; Iandiev I, 2007, PURINERG SIGNAL, V3, P423, DOI 10.1007/s11302-007-9061-3; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kaiko GE, 2008, IMMUNOLOGY, V123, P326, DOI 10.1111/j.1365-2567.2007.02719.x; Kanneganti TD, 2007, IMMUNITY, V27, P549, DOI 10.1016/j.immuni.2007.10.002; Kanneganti TD, 2007, IMMUNITY, V26, P433, DOI 10.1016/j.immuni.2007.03.008; Kay AB, 2001, NEW ENGL J MED, V344, P109; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kolosova IA, 2008, AM J PHYSIOL-LUNG C, V294, pL319, DOI 10.1152/ajplung.00283.2007; Kool M, 2008, J IMMUNOL, V181, P3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kool M, 2007, CURR OPIN IMMUNOL, V19, P701, DOI 10.1016/j.coi.2007.09.003; Kotsimbos ATC, 1997, J ALLERGY CLIN IMMUN, V99, P666, DOI 10.1016/S0091-6749(97)70029-0; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; la Sala A, 2003, J LEUKOCYTE BIOL, V73, P339, DOI 10.1189/jlb.0802418; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Li HF, 2007, J IMMUNOL, V178, P5271; LUTZ MB, 2006, HDB DENDRITIC CELLS; Mariani V, 2007, J IMMUNOL, V178, P7623; Mariathasan S, 2007, NAT REV IMMUNOL, V7, P31, DOI 10.1038/nri1997; Martinon F, 2008, J LEUKOCYTE BIOL, V83, P507, DOI 10.1189/jlb.0607362; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; McDermott MF, 2007, TRENDS MOL MED, V13, P381, DOI 10.1016/j.molmed.2007.07.005; Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012; Mohanty JG, 2001, J ALLERGY CLIN IMMUN, V107, P849, DOI 10.1067/mai.2001.114658; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Novak I, 2003, NEWS PHYSIOL SCI, V18, P12, DOI 10.1152/nips.01409.2002; Oguma T, 2007, CLIN EXP ALLERGY, V37, P893, DOI 10.1111/j.1365-2222.2007.02719.x; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; Pelegrin P, 2006, EMBO J, V25, P5071, DOI 10.1038/sj.emboj.7601378; Pelleg Amir, 2002, Am J Ther, V9, P454, DOI 10.1097/00045391-200209000-00014; Petrilli V, 2007, CURR OPIN IMMUNOL, V19, P615, DOI 10.1016/j.coi.2007.09.002; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Sousa CR, 2006, NAT REV IMMUNOL, V6, P476, DOI 10.1038/nri1845; Robson SC, 2005, SEMIN THROMB HEMOST, V31, P217, DOI 10.1055/s-2005-869527; Rubartelli A, 2007, TRENDS IMMUNOL, V28, P429, DOI 10.1016/j.it.2007.08.004; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schnurr M, 2003, BLOOD, V102, P613, DOI 10.1182/blood-2002-12-3745; Schulman ES, 1999, AM J RESP CELL MOL, V20, P530; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289; Shaw MH, 2008, CURR OPIN IMMUNOL, V20, P377, DOI 10.1016/j.coi.2008.06.001; Shi Y, 2003, NATURE, V425, P516, DOI 10.1038/nature01991; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Tsan MF, 2007, J ENDOTOXIN RES, V13, P6, DOI 10.1177/0968051907078604; van der Kleij HPM, 2004, INFLAMMATION, V28, P115, DOI 10.1023/B:IFLA.0000039557.33267.65; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Verghese MW, 1996, J BIOL CHEM, V271, P15597; Vermaelen K, 2003, AM J RESP CELL MOL, V29, P405, DOI 10.1165/rcmb.2003-0008OC; Vermaelen KY, 2001, J EXP MED, V193, P51	82	81	84	1	3	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2009	39	1					12	19		10.1111/j.1365-2222.2008.03118.x		8	Allergy; Immunology	Allergy; Immunology	392DE	WOS:000262282300005	19016800	
J	Le Moual, N; Kauffmann, F; Eisen, EA; Kennedy, SM				Le Moual, Nicole; Kauffmann, Francine; Eisen, Ellen A.; Kennedy, Susan M.			The healthy worker effect in asthma - Work may cause asthma, but asthma may also influence work	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						epidemiology; asthma; occupational exposure; healthy worker effect	MARGINAL STRUCTURAL MODELS; BODY SHOP WORKERS; RESPIRATORY SYMPTOMS; OCCUPATIONAL EPIDEMIOLOGY; AIRWAY RESPONSIVENESS; METALWORKING FLUIDS; UNITED-STATES; FOLLOW-UP; SELECTION; POPULATION	Despite the increasing attention to the relationship between asthma and work exposures, occupational asthma remains underrecognized and its population burden underestimated. This may be due, in part, to the fact that traditional approaches to studying asthma in populations cannot adequately take into account the healthy worker effect (HWE). The HWE is the potential bias caused by the phenomenon that sicker individuals may choose work environments in which exposures are low, they may be excluded from being hired; or once hired, they may seek transfer to less exposed jobs or leave work. This article demonstrates that population- and workplace-based asthma studies are particularly subject to HWE bias, which leads to underestimates of relative risks. Our objective is to describe the HWE as it relates to asthma research, and to discuss the significance of taking HWE bias into account in designing and interpreting asthma studies. We also discuss the importance of understanding HWE bias for public health practitioners and for clinicians. Finally, we emphasize the timeliness of this review in light of the many longitudinal "child to young adult" asthma cohort studies currently underway. These prospective studies will soon provide an ideal opportunity to examine the impact of early workplace environments on asthma in young adults. We urge occupational and childhood asthma epidemiologists collaborate to ensure that this opportunity is not lost.	[Le Moual, Nicole; Kauffmann, Francine] INSERM U780, F-94807 Villejuif, France; [Le Moual, Nicole; Kauffmann, Francine] Univ Paris Sud, Fac Med, IFR69, Villejuif, France; [Eisen, Ellen A.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Eisen, Ellen A.] Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; [Kennedy, Susan M.] Univ British Columbia, Sch Occupat & Environm Hygiene, Vancouver, BC V5Z 1M9, Canada	Le Moual, N (reprint author), INSERM U780, 16 Ave Paul Vaillant Couturier, F-94807 Villejuif, France.	lemoual@vjf.inserm.fr	LeMoual, Nicole/R-8976-2016	LeMoual, Nicole/0000-0002-2723-5569			Arif AA, 2002, OCCUP ENVIRON MED, V59, P505, DOI 10.1136/oem.59.8.505; ARRIGHI HM, 1994, EPIDEMIOLOGY, V5, P189, DOI 10.1097/00001648-199403000-00009; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Baillargeon J, 2001, OCCUP MED-STATE ART, V16, P359; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; BECKLAKE MR, 1990, RESPIRATION, V57, P137; Blanc PD, 1999, CHEST, V115, P1259, DOI 10.1378/chest.115.5.1259; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; Blanc PD, 2001, J CLIN EPIDEMIOL, V54, P610, DOI 10.1016/S0895-4356(00)00349-8; Chan-Yeung Moira, 2003, Am J Respir Crit Care Med, V167, P450; Checkoway H, 1998, EPIDEMIOL REV, V20, P100; Chen R, 1996, OCCUP MED-OXFORD, V46, P345; Copilevitz C, 2003, IMMUNOL ALLERGY CLIN, V23, P155, DOI 10.1016/S0889-8561(03)00018-3; DAHL E, 1993, SOC SCI MED, V36, P1077, DOI 10.1016/0277-9536(93)90126-O; DOSMAN JA, 1991, J OCCUP ENVIRON MED, V33, P1007; Drexler H, 1999, OCCUP ENVIRON MED, V56, P202; Eisen E A, 1995, Med Lav, V86, P125; Eisen EA, 1997, AM J IND MED, V31, P671; ERNST P, 1989, THORAX, V44, P116, DOI 10.1136/thx.44.2.116; FOX AJ, 1976, BRIT J PREV SOC MED, V30, P225; Greaves IA, 1997, AM J IND MED, V32, P450, DOI 10.1002/(SICI)1097-0274(199711)32:5<450::AID-AJIM4>3.0.CO;2-W; Henneberger PK, 2003, ARCH ENVIRON HEALTH, V58, P781; Hernan MA, 2000, EPIDEMIOLOGY, V11, P561, DOI 10.1097/00001648-200009000-00012; Iwatsubo Y, 2003, OCCUP ENVIRON MED, V60, P831, DOI 10.1136/oem.60.11.831; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; KAUFFMANN F, 1982, BRIT J IND MED, V39, P221; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; Kennedy SM, 1999, AM J RESP CRIT CARE, V159, P87; KIVITY S, 1995, CHEST, V108, P24, DOI 10.1378/chest.108.1.24; Le Moual N, 2005, AM J RESP CRIT CARE, V172, P440, DOI 10.1164/rccm.200501-111OC; Le Moual N, 2004, AM J EPIDEMIOL, V160, P1108, DOI 10.1093/aje/kwh316; Lea CS, 1999, AM J EPIDEMIOL, V150, P1099; Li CY, 1999, OCCUP MED-OXFORD, V49, P225, DOI 10.1093/occmed/49.4.225; MARABINI A, 1993, CHEST, V104, P821, DOI 10.1378/chest.104.3.821; MCMICHAEL AJ, 1976, J OCCUP ENVIRON MED, V18, P165, DOI 10.1097/00043764-197603000-00009; Monso E, 2000, AM J RESP CRIT CARE, V161, P1508; MONSON RR, 1986, J OCCUP ENVIRON MED, V28, P425, DOI 10.1097/00043764-198606000-00009; OSTLIN P, 1989, SCAND J SOC MED, V17, P265; Pearce N, 2007, OCCUP ENVIRON MED, V64, P562, DOI 10.1136/oem.2006.026690; Radon K, 2006, EUR RESPIR J, V27, P774, DOI 10.1183/09031936.06.00093005; RAMAZZINI B, 1990, MALADIES TRAVAIL; Redlich CA, 2002, AM J IND MED, V42, P511, DOI 10.1002/ajim.10143; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; Reijula K, 1996, CHEST, V110, P58, DOI 10.1378/chest.110.1.58; Robins JM, 2000, EPIDEMIOLOGY, V11, P550, DOI 10.1097/00001648-200009000-00011; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; SIRACUSA A, 1995, AM J IND MED, V28, P411, DOI 10.1002/ajim.4700280310; STEENLAND K, 1991, EPIDEMIOLOGY, V2, P418, DOI 10.1097/00001648-199111000-00005; Toren K, 1999, EUR RESPIR J, V13, P496, DOI 10.1183/09031936.99.13349699; Turner S, 2005, OCCUP MED-OXFORD, V55, P287, DOI 10.1093/occmed/kqi055; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Zock JP, 1998, OCCUP ENVIRON MED, V55, P823	53	81	83	1	10	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 1	2008	177	1					4	10		10.1164/rccm.200703-415PP		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	246BN	WOS:000251982600003	17872490	
J	Singh, D; Richards, D; Knowles, RG; Schwartz, S; Woodcock, A; Langley, S; O'Connor, BJ				Singh, Dave; Richards, Duncan; Knowles, Richard G.; Schwartz, Sheila; Woodcock, Ashley; Langley, Steve; O'Connor, Brian J.			Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						nitric oxide; bronchial hyperreactivity	REACTIVE NITROGEN; AIRWAY RESPONSIVENESS; EXHALED AIR; MILD ASTHMA; RESPIRATORY-TRACT; IN-VITRO; INFLAMMATION; GW274150; MONTELUKAST; POTENT	Rationale Exhaled breath nitric oxide (F-ENO) is increased in asthma. NO is produced predominantly by inducible nitric oxide synthase (NOS). Objectives: We evaluated the selective and potent NOS inhibitor GW274150 in asthma. Methods: Twenty-eight steroid-naive patients with asthma participated in a double-blind, randomized, double-dummy, placebo-controlled, three-period cross-over study. Subjects received GW274150 (90 mg), montelukast (10 mg), or placebo once daily for 14 days. FENO was assessed predose on Days 1, 7, 10, and 14. Adenosine 5 '-monophosphate (AMP) challenge was performed on Day 10, allergen challenge on Day 14 followed by methacholine challenge (MCh) 24 hours later, and then bronchoscopy. Measurements and Main Results: GW274150 reduced predose FENO by 73, 75, and 71% on Days 7, 10, and 14, respectively, compared with placebo. Montelukast did not reduce FENO. GW274150 did not inhibit AMP reactivity whereas for montelukast there was a trend toward inhibition: the mean doubling dose difference versus placebo was 0.64 (95% confidence interval [95% Cl], 0 to 1.28). GW274150 did not inhibit early (EAR) and late (LAR) asthmatic responses to allergen, or MCh reactivity, despite reduced FEND levels. Montelukast inhibited EAR and LAIR FEV1; the mean difference versus placebo for minimal FEV1 was 0.37 L (95% Cl, 0.19 to 0.55) and 0.18 L (95% Cl, 0.04 to 0.32), respectively. MCh reactivity was inhibited by montelukast (mean doubling dose difference vs. placebo, 0.51; 95% Cl, 0.02 to 1.01). GW271540 also had no effect on inflammatory cell numbers in bronchoalveolar lavage fluid after allergen challenge. Conclusions: Selective iNOS inhibition effectively reduces FENO but does not affect airway hyperreactivity or airway inflammatory cell numbers after allergen challenge in subjects with asthma.	Univ Manchester, S Manchester Univ Hosp Trust, Med Evaluat Unit, Manchester M23 9LT, Lancs, England; GlaxoSmithKline Inc, Stevenage, Herts, England; Kings Coll Hosp, Guys Kings & St Thomas Sch Med, Dept Asthma Allergy & Respirat Sci, London, England	Singh, D (reprint author), Univ Manchester, S Manchester Univ Hosp Trust, Med Evaluat Unit, Southmoor Rd, Manchester M23 9LT, Lancs, England.	dsingh@meu.org.uk		Woodcock, Ashley/0000-0002-5428-8578			Alderton WK, 2005, BRIT J PHARMACOL, V145, P301, DOI 10.1038/sj.bjp.0706168; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; ALVING K, 1993, EUR RESPIR J, V6, P1368; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Borrill Z, 2006, RESP MED, V100, P1392, DOI 10.1016/j.rmed.2005.11.018; Chatterjee PK, 2003, KIDNEY INT, V63, P853, DOI 10.1046/j.1523-1755.2003.00802.x; Cuzzocrea S, 2002, EUR J PHARMACOL, V453, P119, DOI 10.1016/S0014-2999(02)02338-5; De Alba J, 2006, PAIN, V120, P170, DOI 10.1016/j.pain.2005.10.028; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Dugo L, 2004, BRIT J PHARMACOL, V141, P979, DOI 10.1038/sj.bjp.0705683; Folkerts G, 2001, EUR J PHARMACOL, V429, P251, DOI 10.1016/S0014-2999(01)01324-3; Garvey EP, 1997, J BIOL CHEM, V272, P4959; Gaston B, 2006, AM J RESP CRIT CARE, V173, P1186, DOI 10.1164/rccm.200510-1584PP; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hansel TT, 2003, FASEB J, V17, P1298, DOI 10.1096/fj.02-0633fje; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P906, DOI 10.1067/mai.2000.105709; Ichinose M, 2000, AM J RESP CRIT CARE, V162, P701; Kanniess F, 2002, EUR RESPIR J, V20, P853, DOI 10.1183/09031936.02.00244602; Ketchell RI, 2002, J ALLERGY CLIN IMMUN, V110, P603, DOI 10.1067/mai.2002.128486; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kidney JC, 1997, J ALLERGY CLIN IMMUN, V100, P65; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; KNOWLES RG, 1994, BIOCHEM J, V298, P249; Knowles RG, 2007, P AM THOR SOC, V4, pA487; Koarai A, 2000, PULM PHARMACOL THER, V13, P267, DOI 10.1006/pupt.2000.0254; Koopmans JG, 2005, J ALLERGY CLIN IMMUN, V116, P1007, DOI 10.1016/j.jaci.2005.08.016; Laszlo F, 1997, EUR J PHARMACOL, V334, P99, DOI 10.1016/S0014-2999(97)01163-1; MONCADA S, 1995, FASEB J, V9, P1319; Muijsers RBR, 2001, BRIT J PHARMACOL, V134, P434, DOI 10.1038/sj.bjp.0704235; Palmqvist M, 2005, ALLERGY, V60, P65, DOI 10.1111/j.1398-9995.2005.00633.x; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; Prado CM, 2006, AM J RESP CELL MOL, V35, P457, DOI 10.1165/rcmb.2005-0391OC; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Ricciardolo FLM, 2006, EUR J PHARMACOL, V533, P240, DOI 10.1016/j.cjphar.2005.12.057; Saleh D, 1998, FASEB J, V12, P929; Sandrini A, 2003, CHEST, V124, P1334, DOI 10.1378/chest.124.4.1334; SCHWARTZ S, 2007, P AM THOR SOC, V4, pA485; SINGH SD, 2007, P AM THOR SOC, V4, pA483; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Taylor DA, 1998, AM J RESP CRIT CARE, V158, P99; Taylor DA, 1998, THORAX, V53, P483; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; Young RJ, 2000, BIOORG MED CHEM LETT, V10, P597, DOI 10.1016/S0960-894X(00)00055-X	44	81	81	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2007	176	10					988	993		10.1164/rccm.200704-588OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	230PW	WOS:000250889400008	17717202	
J	Yang, PC; Xing, Z; Berin, CM; Soderholm, JD; Feng, BS; Wu, L; Yeh, C				Yang, Ping-Chang; Xing, Zhou; Berin, Cecilia M.; Soderholm, Johan D.; Feng, Bai-Sui; Wu, Linda; Yeh, Calvin			TIM-4 expressed by mucosal dendritic cells plays a critical role in food antigen-specific Th2 differentiation and intestinal allergy	GASTROENTEROLOGY			English	Article							MURINE MODEL; MOUSE MODEL; T-CELLS; TRANSPORT; PROTEINS; MICE; IGE; SENSITIZATION; ANTIBODIES; TOLERANCE	Background & Aims: Food allergy accounts for Significant morbidity. The etiology and immune mechanisms of food allergy, however, have remained poorly understood. In this study, we aimed to determine the role of T-cell immunoglobulin-domain and mucin-domain (TIM)-4, a recently identified member of cell surface molecules, in the pathogenesis of intestinal allergy in a murine model. Methods: We report that TIM-4 as well as costimulatory molecules were up-regulated in intestinal mucosal dendritic cells by in vitro or in vivo exposure to Staphylococcus enterotoxin B (SEB). SEB-conditioned intestinal dendritic cells loaded with a food macromolecule ovalbumin (OVA) induced potent OVA-specific T-helper (Th)2 lymphocyte responses in vitro and such Th2 responses were inhibited completely by TIM-4 blockade. Results: In vivo exposure to both SEB and OVA resulted in OVA-specific Th2 differentiation and intestinal allergic responses including increased serum immunoglobulin E and Th2 cytokine levels, activation of OVA-specific Th2 cells detected both ex vivo and in situ, and mast cell degranulation. Of importance, in vivo abrogation of TIM-4 or its cognate ligand TIM-1 by using a polyclonal antibody remarkably dampened Th2 differentiation and intestinal allergy. Conclusions: Our study thus identifies TIM-4 as a novel molecule critically required for the development of intestinal allergy.	McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; CUNY Mt Sinai Sch Med, Dept Med, Div Clin Immunol, New York, NY 10029 USA; Linkoping Univ Hosp, Dept Surg, Colorectal Surg Unit, S-58185 Linkoping, Sweden	Yang, PC (reprint author), St Josephs Hosp, Room T3330,50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	yangp@mcmaster.ca					Becker Y, 2006, VIRUS GENES, V33, P235, DOI 10.1007/s11262-006-0064-x; Berin MC, 2006, ALLERGY, V61, P64, DOI 10.1111/j.1398-9995.2006.01012.x; BOSCHOFF SC, 2006, CURR GASTROENTEROL R, V8, P374; Chirdo FG, 2005, EUR J IMMUNOL, V35, P1831, DOI 10.1002/eji.200425882; Encinas JA, 2005, J ALLERGY CLIN IMMUN, V116, P1343, DOI 10.1016/j.jaci.2005.08.031; Fischer R, 2005, AM J PATHOL, V167, P1621, DOI 10.1016/S0002-9440(10)61246-1; Fukushima A, 2007, BIOCHEM BIOPH RES CO, V353, P211, DOI 10.1016/j.bbrc.2006.12.023; Gomez-Garcia L, 2006, PARASITOL RES, V99, P440, DOI 10.1007/s00436-006-0159-2; Kis Z, 2004, INFLAMM RES, V53, P413, DOI 10.1007/s00011-004-1274-0; LIU T, 2006, BMC GASTROENTEROL, V18, P6; Mandron M, 2006, J ALLERGY CLIN IMMUN, V117, P1141, DOI 10.1016/j.jaci.2005.12.1360; Mendoza L, 2006, BIOSYSTEMS, V84, P101, DOI 10.1016/j.biosystems.2005.10.004; Meyers JH, 2005, NAT IMMUNOL, V6, P455, DOI 10.1038/ni1185; Okano M, 2005, CLIN EXP ALLERGY, V35, P506, DOI 10.1111/j.1365-2222.2005.02195.x; Rey J, 2004, J IMMUNOL, V172, P3026; Savinko T, 2005, J IMMUNOL, V175, P8320; Sicherer SH, 2006, J ALLERGY CLIN IMMUN, V118, P170, DOI 10.1016/j.jaci.2006.04.018; Strobel S, 2006, CURR OPIN ALLERGY CL, V6, P207, DOI 10.1097/01.all.0000225162.98391.81; Umetsu SE, 2005, NAT IMMUNOL, V6, P447, DOI 10.1038/ni1186; Verdu EF, 2004, GASTROENTEROLOGY, V127, P826, DOI 10.1053/j.gastro.2004.06.007; Vesterlund S, 2006, MICROBIOL-SGM, V152, P1819, DOI 10.1099/mic.0.28522-0; Webb RA, 2007, PARASITE IMMUNOL, V29, P11, DOI 10.1111/j.1365-3024.2006.00908.x; Yang PC, 2000, J CLIN INVEST, V106, P879, DOI 10.1172/JCI9258; Yu LCH, 2001, GASTROENTEROLOGY, V121, P370, DOI 10.1053/gast.2001.26470	24	81	86	0	11	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085			GASTROENTEROLOGY	Gastroenterology	NOV	2007	133	5					1522	1533		10.1053/j.gastro.2007.08.006		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	229QV	WOS:000250820100020	17915221	
J	Chapman, MD; Wunschmann, S; Pomes, A				Chapman, Martin D.; Wuenschmann, Sabina; Pomes, Anna			Proteases as Th2 adjuvants	CURRENT ALLERGY AND ASTHMA REPORTS			English	Review							HOUSE-DUST MITE; COCKROACH ALLERGEN BLA-G-2; DERMATOPHAGOIDES-PTERONYSSINUS; CRYSTAL-STRUCTURE; EPITHELIAL-CELLS; SERINE-PROTEASE; MOLECULAR CHARACTERIZATION; RECOMBINANT PRO-DER-P-1; PROTEOLYTIC ACTIVITY; ANTIBODY-RESPONSE	Several cysteine and serine protease allergens have been cloned from house dust mites, including Der p 1, Der p 3, Der p 6, and Der p 9. A significant body of evidence suggests that these allergens mimic helper T (Th) 2 cell adjuvants. Der p 1 cleaves CD23 from activated B cells and CD25 from T cells. Der p I proteolytically degrades tight junctions in lung epithelium and causes release of proinflammatory cytokines from bronchial epithelial cells, mast cells, and basophils. These synergistic effects of mite enzyme allergens may promote IgE synthesis and have direct inflammatory effects on lung epithelium, which could explain why mite allergens are associated with asthma. The crystal structures of the proenzyme and mature forms of Der p 1 have been determined, as have the structures of other indoor allergens that are not enzymes (eg, Der p 2, Fel d 1, and Bla g 2). Cockroach allergens are strongly associated with asthma in US inner cities, yet none of the cockroach allergens that have been cloned are proteolytic enzymes. Thus although mite proteases allergens may act as Th2 adjuvants, a paradoxical effect is that other allergens may elicit strong Th2 responses in the absence of enzyme activity.	INDOOR Biotechnol Inc, Charlottesville, VA 22903 USA	Chapman, MD (reprint author), INDOOR Biotechnol Inc, 1216 Harris St, Charlottesville, VA 22903 USA.	mdc@inbio.com					Allen GR, 2000, ETHOLOGY, V106, P409, DOI 10.1046/j.1439-0310.2000.00550.x; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Bennett BJ, 1996, CLIN EXP ALLERGY, V26, P1150, DOI 10.1046/j.1365-2222.1996.d01-268.x; Best EA, 2000, PROTEIN EXPRES PURIF, V20, P462, DOI 10.1006/prep.2000.1327; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Fan Y, 2005, INSECT MOL BIOL, V14, P45, DOI 10.1111/j.1365-2583.2004.00530.x; Flores I, 2003, INT ARCH ALLERGY IMM, V130, P12, DOI 10.1159/000068375; Gore JC, 2007, ANNU REV ENTOMOL, V52, P439, DOI 10.1146/annurev.ento.52.110405.091313; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Gruber A, 2004, J BIOL CHEM, V279, P28475, DOI 10.1074/jbc.M400993200; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Gustchina A, 2005, J MOL BIOL, V348, P433, DOI 10.1016/j.jmb.2005.02.062; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Kikuchi Y, 2006, J IMMUNOL, V177, P1609; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; King C, 1998, J IMMUNOL, V161, P3645; Machado DC, 1996, EUR J IMMUNOL, V26, P2972, DOI 10.1002/eji.1830261224; Meno K, 2005, J IMMUNOL, V175, P3835; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nishiyama C, 1995, FEBS LETT, V377, P62, DOI 10.1016/0014-5793(95)01291-5; Pomes A, 2002, AM J RESP CRIT CARE, V165, P391; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Sun G, 2001, J IMMUNOL, V167, P1014; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; Tomee JFC, 1998, J ALLERGY CLIN IMMUN, V102, P75, DOI 10.1016/S0091-6749(98)70057-0; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wunschmann S, 2005, J ALLERGY CLIN IMMUN, V116, P140, DOI 10.1016/j.jaci.2005.04.024	41	81	84	0	4	CURRENT SCIENCE INC	PHILADELPHIA	400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA	1529-7322			CURR ALLERGY ASTHM R	Curr. Allergy Asthma Rep.	SEP	2007	7	5					363	367		10.1007/s11882-007-0055-6		5	Allergy; Immunology	Allergy; Immunology	205LQ	WOS:000249115500011	17697645	
J	Rowe, J; Kusel, M; Holt, BJ; Suriyaarachchi, D; Serralha, M; Hollams, E; Yerkovich, ST; Subrata, LS; Ladyman, C; Sadowska, A; Gillett, J; Fisher, E; Loh, R; Soderstrom, L; Ahistedt, S; Sly, PD; Holt, PG				Rowe, Julie; Kusel, Merci; Holt, Barbara J.; Suriyaarachchi, Devinda; Serralha, Michael; Hollams, Elysia; Yerkovich, Stephanie T.; Subrata, Lily S.; Ladyman, Claire; Sadowska, Agata; Gillett, Jamie; Fisher, Elizabeth; Loh, Richard; Soderstrom, Lars; Ahistedt, Staffan; Sly, Peter D.; Holt, Patrick G.			Prenatal versus postnatal sensitization to environmental allergens in a high-risk birth cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; cytokines; IgE; IgG(4); T-cell memory; T(H)2	HOUSE-DUST MITE; T-CELL RESPONSES; CORD-BLOOD; INHALANT ALLERGENS; INDOOR ALLERGENS; MATERNAL INTAKE; EARLY-CHILDHOOD; GRASS-POLLEN; DIETARY EGG; CHILDREN	Background: The timing of allergen sensitization is controversial, with conflicting evidence suggesting transplacental priming versus exclusively postnatal priming. Resolution of this question is important in relation to rational design of allergy prevention strategies, particularly the issue of allergen avoidance during pregnancy. Objective: To elucidate the kinetics of sensitization in high-risk children during their first 2 years of life. Methods: We prospectively studied house dust mite (HDM)specific IgE and IgG(4) antibody production and associated T-cell immunity in a cohort of 200 high-risk infants. Parallel antibody studies tracked responses against a broader panel of inhalant and dietary allergens including peanut. Results: HDM-induced T-H(2) responses in PBMC from 6 months onward, particularly IL-4 and IL-5, correlated increasingly strongly with sensitization outcomes at 2 years, and a I contrasting negative relationship was observed with IFN-T response capacity. HDM-induced T-cell responses in cord blood, although common, were unrelated to subsequent sensitization. Transient HDM-IgE (and IgG4) production frequently peaked at 6 or 12 months before returning to baseline, which suggests the onset of protective tolerance. This finding contrasted wi th progressively increasing HDM titers in children sensitized by 2 years of age. Comparably contrasting patterns were observed in peanut-specific responses in sensitized versus nonsensitized children. Conclusion: Priming of T-H(2) responses associated with persistent HDM-IgE production occurs entirely postnatally, as HDM reactivity in cord blood seems nonspecific and is unrelated to subsequent development of allergen-specific T-H(2) memory or TgE. Clinical implications: These findings question the scientific basis for existing recommendations for allergen avoidance by high-risk women during pregnancy.	Univ Western Australia, Telethon Inst Child Hlth Res, Div Cell Biol, Ctr Child Hlth Res, Perth, WA 6009, Australia; Princess Margaret Hosp Children, Subiaco, WA, Australia; Phadia AB, Uppsala, Sweden; Karolinska Inst, Stockholm, Sweden	Holt, PG (reprint author), Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.	patrick@ichr.uwa.edu.au	Sly, Peter/F-1486-2010; Holt, Patrick/H-1548-2011; Yerkovich, Stephanie/A-9004-2011; Osborne, Nicholas/N-4915-2015	Sly, Peter/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935; Osborne, Nicholas/0000-0002-6700-2284; Soderstrom, Lars/0000-0002-6474-6501; Hollams, Elysia/0000-0002-3481-6396			AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; Baker SS, 2000, PEDIATRICS, V106, P346; Ballardini N, 2006, ALLERGY, V61, P337, DOI 10.1111/j.1398-9995.2005.00936.x; Bjorksten B, 1996, CLIN EXP ALLERGY, V26, P775, DOI 10.1046/j.1365-2222.1996.d01-380.x; BJORKSTEN F, 1976, CLIN ALLERGY, V6, P165, DOI 10.1111/j.1365-2222.1976.tb01894.x; BUSINCO L, 1988, CLIN ALLERGY, V18, P269, DOI 10.1111/j.1365-2222.1988.tb02869.x; Cain TW, 2006, ALLERGY CLIN IMMUNOL, V18, P1; Casas R, 2004, CLIN EXP ALLERGY, V34, P591, DOI 10.1111/j.1365-2222.2004.1924.x; Committee on Toxicity of Chemicals in Food Consumer Products and the Environment, 1998, PEAN ALL; Cressy I, 2006, P 25 C EUR AC ALL CL, P296; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Department of Health, 1998, PEAN ALL; Evans G, 2000, IMMUNOASSAY HDB; Gavin MA, 1995, IMMUNITY, V3, P793, DOI 10.1016/1074-7613(95)90068-3; GILL TJ, 1983, J CLIN INVEST, V72, P987, DOI 10.1172/JCI111071; Hagendorens MM, 2004, PEDIATR ALLERGY IMMU, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; HANNAH ML, 2000, NZ MED MED DEVICES S, P22; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; Herrmann ME, 1996, EUR J PEDIATR, V155, P770, DOI 10.1007/BF02002904; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; HOLT PG, 1987, IMMUNOL TODAY, V8, P14, DOI 10.1016/0167-5699(87)90825-5; HOLT PG, 2006, PROPHYLAXIS ATOPY AS; Julge K, 2001, CLIN EXP ALLERGY, V31, P1854, DOI 10.1046/j.1365-2222.2001.01235.x; Kihlstrom A, 2003, ALLERGY, V58, P871, DOI 10.1034/j.1398-9995.2003.00232.x; KONDO N, 1992, ARCH DIS CHILD, V67, P1003; KORSGAARD J, 1983, CLIN ALLERGY, V13, P529, DOI 10.1111/j.1365-2222.1983.tb02634.x; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kusel MMH, 2005, J ALLERGY CLIN IMMUN, V116, P1067, DOI 10.1016/j.jaci.2005.06.038; Malhotra I, 2006, J INFECT DIS, V193, P1005, DOI 10.1086/500472; Marchant A, 2003, J CLIN INVEST, V111, P1747, DOI 10.1172/JCI200317470; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358; Platts-Mills TAE, 2000, AM J RESP CRIT CARE, V162, pS128; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rowe J, 2004, VACCINE, V22, P3986, DOI 10.1016/j.vaccine.2004.03.052; Sasai K, 1996, J PEDIATR-US, V128, P834, DOI 10.1016/S0022-3476(96)70337-2; Strickland DH, 2006, J EXP MED, V203, P2649, DOI 10.1084/jem.20060155; Szepfalusi Z, 2000, PEDIATR RES, V48, P404; Thornton CA, 2004, J IMMUNOL, V173, P3084; Turke J, 2005, PEDIATR ALLERGY IMMU, V16, P512, DOI 10.1111/j.1399-3038.2005.00305.x; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; Vance GHS, 2004, CLIN EXP ALLERGY, V34, P1855, DOI 10.1111/j.1365-2222.2004.02111.x; WOOD RA, 2007, IN PRESS ANN ALLERGY; YMAN L, 2000, IMMUNOASSAY HDB; ZEIGER R, 1995, J ALLERGY CLIN IMMUN, V96, P1179	49	81	83	2	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2007	119	5					1164	1173		10.1016/j.jaci.2007.02.016		10	Allergy; Immunology	Allergy; Immunology	167CB	WOS:000246427200017	17412403	
J	Wenzel, S; Holgate, ST				Wenzel, Sally; Holgate, Stephen T.			The mouse trap - It still yields few answers in asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Editorial Material							FATAL ASTHMA; MURINE MODEL; UNRESTRAINED PLETHYSMOGRAPHY; AIRWAY HYPERRESPONSIVENESS; MONOCLONAL-ANTIBODY; ALLERGEN EXPOSURE; ATOPIC ASTHMA; SMOOTH-MUSCLE; TGF-BETA; MICE		Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; Univ Southampton, Southampton SO9 5NH, Hants, England	Wenzel, S (reprint author), Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA.				Medical Research Council [G0800766]		Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.020.0261102; Bates J, 2004, AM J RESP CELL MOL, V31, P373; BERKART JJB, 1889, ASTHMA ITS PATHOLOG; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241; Borish LC, 1999, AM J RESP CRIT CARE, V160, P1816; Boyce JA, 2005, J EXP MED, V201, P1869, DOI 10.1084/jem.20050584; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brown V, 2003, THORAX, V58, P311, DOI 10.1136/thorax.58.4.311; Lodrup Carlsen K., 2001, CURR OPIN ALLERGY CL, V1, P139; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Collins RA, 2003, RESP PHYSIOL NEUROBI, V139, P51, DOI 10.1016/j.resp.2003.09.003; Fulkerson PC, 2005, CLIN EXP ALLERGY, V35, P1251, DOI 10.1111/j.1365-2222.2005.02354.x; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; Greenough A, 2004, EUR RESPIR J, V24, P731, DOI 10.1183/09031936.04.00060304; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Harris JR, 2003, J VIROL, V77, P4773, DOI 10.1128/JVI.77.8.4773-4780.2003; Hauber HP, 2003, THORAX, V58, P519, DOI 10.1136/thorax.58.6.519; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Howarth PH, 2005, THORAX, V60, P1012, DOI 10.1136/thx.2005.045260; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; James A, 2000, EUR RESPIR J, V15, P782, DOI 10.1034/j.1399-3003.2000.15d25.x; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Kaviratne M, 2004, J IMMUNOL, V173, P4020; Kenyon NJ, 2000, ANN ALLERG ASTHMA IM, V85, P115; Kenyon NJ, 2003, TOXICOL APPL PHARM, V186, P90, DOI 10.1016/S0041-008X(02)00025-X; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lilly CM, 2005, AM J RESP CRIT CARE, V171, P579, DOI 10.1164/rccm.200404-532C; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; McMillan SJ, 2005, CLIN EXP ALLERGY, V35, P388, DOI 10.1111/j.1365-2222.2005.02193.x; Norris V, 2005, J ALLERGY CLIN IMMUN, V116, P761, DOI 10.1016/j.jaci.2005.04.045; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pearce N, 1999, THORAX, V54, P268; Persson CGA, 1997, TRENDS PHARMACOL SCI, V18, P465; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Tormanen KR, 2005, AM J RESP CRIT CARE, V171, P19, DOI 10.1164/rccm.200406-498OC; Tumas DB, 2001, J ALLERGY CLIN IMMUN, V107, P1025, DOI 10.1067/mai.2001.115625; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 2002, J IMMUNOL, V169, P4613; Xisto DG, 2005, AM J RESP CRIT CARE, V171, P829, DOI 10.1164/rccm.200408-997OC; Yang GY, 2005, J PHARMACOL EXP THER, V313, P8, DOI 10.1124/jpet.104.076133	49	81	82	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2006	174	11					1173	1176		10.1164/rccm.2609002		4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	109BU	WOS:000242283700005	17110654	
J	Li, YF; Gauderman, WJ; Avol, E; Dubeau, L; Gilliland, FD				Li, YF; Gauderman, WJ; Avol, E; Dubeau, L; Gilliland, FD			Associations of tumor necrosis factor G-308A with childhood asthma and wheezing	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						child; genetic epidemiology; lung	GLUTATHIONE-S-TRANSFERASE; GENE-ENVIRONMENT INTERACTIONS; SOUTHERN CALIFORNIA COMMUNITIES; AIR-POLLUTION; FACTOR-ALPHA; TNF-ALPHA; ATOPIC ASTHMA; INDUCED INFLAMMATION; ALLERGIC RESPONSES; DIFFERING LEVELS	Rationale: Tumor necrosis factor (TNF) mediates a spectrum of airway inflammatory responses, including those to air pollutants, and is an asthma candidate gene. One TNF promoter variant (G-308A) affects expression of TNF and has been associated with inflammatory diseases; however, studies of asthma have been inconsistent. Because ozone produces oxidative stress, increased airway TNF, and inflammation, the associations of the -308 TNF polymorphism with asthma may vary by ozone exposure and variants of oxidant defense genes glutathione-S-transferase (GST) M1 and GSTP1. Objectives: To investigate the association of TNF G-308A with asthma and wheezing and to determine whether these associations vary with ozone exposure and GSTM1 and GSTP1 genotype. Methods: We studied associations of TNF-308 genotype with lifetime and current wheezing and asthma among 3,699 children in the Children's Health Study. We examined differences in associations with community ozone and by GSTM1 null and GSTP1 105 Ile/Val (A105G) genotype. Results: Children with TNF-308 GG had decreased risk of asthma (odds ratio, 0.8; 95% confidence interval, 0.7-0.9) and lifetime wheezing (odds ratio, 0.8; 95% confidence interval, 0.7-0.9). The protective effects of GG genotype on wheezing outcomes were of greater magnitude in lower compared with higher ozone communities. These findings were replicated in the two cohorts of fourth-grade children recruited in 1993 and 1996. The reduction of the protective effect from the -308 GG genotype with higher ozone exposure was most marked in the GSTM1 null and GSTP1 Ile/Ile groups. Conclusions: The TNF-308 GG genotype may have a protective role in asthma pathogenesis, depending on airway oxidative stress levels.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; China Med Univ, Inst Environm Hlth, Taichung, Taiwan	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazer St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [5R01HL076647, 5R01HL61768]; NIEHS NIH HHS [5P01ES009581, 5P01ES011627, 5P30ES007048]		Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Allcock RJN, 2004, HUM MUTAT, V24, P517, DOI 10.1002/humu.20100; Babu KS, 2004, IMMUNOL ALLERGY CLIN, V24, P583, DOI 10.1016/j.iac.2004.06.010; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Bilolikar H, 2005, EUR RESPIR J, V26, P637, DOI 10.1183/09031936.05.0007104; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471; Buckova D, 2002, J INVEST ALLERG CLIN, V12, P192; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; California Environmental Protection Agency, 1997, HLTH EFF EXP ENV TOB; CARROLL MC, 1987, P NATL ACAD SCI USA, V84, P8535, DOI 10.1073/pnas.84.23.8535; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278; Choi IW, 2005, J ALLERGY CLIN IMMUN, V116, P537, DOI 10.1016/j.jaci.2005.05.034; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Di Somma C, 2003, HUM IMMUNOL, V64, P359, DOI 10.1016/S0198-8859(02)00819-4; FINOTTO S, 1994, J IMMUNOL, V153, P2278; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Gauderman W J, 1999, J Natl Cancer Inst Monogr, P31; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; GILLILAND FD, 2003, AM J RESP CRIT CARE, V167, pA580; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Hiltermann JTN, 1999, FREE RADICAL BIO MED, V27, P1448, DOI 10.1016/S0891-5849(99)00191-4; Huang SL, 1997, AM J RESP CRIT CARE, V156, P1436; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Kleeberger SR, 2005, ANNU REV MED, V56, P383, DOI 10.1146/annurev/med.56.062904.144908; Lee YL, 2004, CLIN EXP ALLERGY, V34, P1707, DOI 10.1111/j.1365-2222.2004.02099.x; Li Kam Wa TC, 1999, CLIN EXP ALLERGY, V29, P1204, DOI 10.1046/j.1365-2222.1999.00638.x; Liebhart J, 2002, J INVEST ALLERG CLIN, V12, P182; Lin YC, 2002, ALLERGY, V57, P831, DOI 10.1034/j.1398-9995.2002.23719.x; Louis R, 2000, EUR RESPIR J, V16, P604, DOI 10.1034/j.1399-3003.2000.16d06.x; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Miller RL, 1999, AM J PUBLIC HEALTH, V89, P819, DOI 10.2105/AJPH.89.6.819; Millstein J, 2006, AM J HUM GENET, V78, P15, DOI 10.1086/498850; Mitsuta K, 2003, ALLERGY ASTHMA PROC, V24, P19; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 1999, THORAX, V54, P757; Noguchi E, 2002, AM J RESP CRIT CARE, V166, P43, DOI 10.1164/rccm.2110052; PAULESU L, 1991, LYMPHOKINE CYTOK RES, V10, P409; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Randolph AG, 2005, AM J RESP CRIT CARE, V172, P687, DOI 10.1164/rccm.200501.122OC; Romieu I, 2004, THORAX, V59, P8; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; SHAH A, 1995, CLIN EXP ALLERGY, V25, P1038; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Strange RC, 2000, TOXICOL LETT, V112, P357, DOI 10.1016/S0378-4274(99)00230-1; Talalay P, 1995, TOXICOL LETT, V82-3, P173, DOI 10.1016/0378-4274(95)03553-2; U. S. Environmental Protection Agency, 1992, RESP HLTH EFF PASS S; Wilson A. G., 1992, Human Molecular Genetics, V1, P353, DOI 10.1093/hmg/1.5.353; Winchester EC, 2000, HUM GENET, V107, P591, DOI 10.1007/s004390000410; Witte JS, 2002, EUR J HUM GENET, V10, P82, DOI 10.1038/sj/ejhg/5200746; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Zhang J, 2002, EXP BIOL MED, V227, P823	60	81	83	1	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY 1	2006	173	9					970	976		10.1164/rccm.200508-1256OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	039UI	WOS:000237332400008	16456144	
J	Alessandrini, F; Schulz, H; Takenaka, S; Lentner, B; Karg, E; Behrendt, H; Jakob, T				Alessandrini, F; Schulz, H; Takenaka, S; Lentner, B; Karg, E; Behrendt, H; Jakob, T			Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						particulate matter; elemental carbon ultrafine particles; allergic inflammation	PARTICULATE AIR-POLLUTION; EMERGENCY-ROOM VISITS; DIESEL EXHAUST PARTICLES; FINE PARTICLES; IN-VIVO; RESPIRATORY HEALTH; ADJUVANT ACTIVITY; OXIDATIVE STRESS; ASTHMA; MICE	Background: Epidemiologic studies show that exposure to particulate air pollution is associated with asthma exacerbation. Ultrafine particles (diameter <100 nm) may contribute to these adverse effects. Objective: To investigate potential adjuvant activity of inhaled elemental carbon ultrafine particles (EC-UFPs) on allergic airway inflammation. Methods: The effects of ultrafine particle inhalation on allergic airway inflammation was analyzed in ovalbumin-sensitized mice and nonsensitized controls. Particle exposure (526 mu g/m(3), 24 hours) was performed 24, 96, or 168 hours before or 24 or 72 hours after ovalbumin aerosol challenge. Allergic inflammation was analyzed at different time points after allergen challenge by means of bronchoalveolar lavage cell count and cytokine/total protein assays, lung histology, and airway hyperresponsiveness. Results: In sensitized mice, inhalation of ultrafine particles 24 hours before allergen challenge caused a significant increase of bronchoalveolar lavage inflammatory cell infiltrate, protein, IL-4, IL-5, and IL-13 compared with relevant controls. These adjuvant effects were dose- and time-dependent and were still present when particle exposure was performed 4 days before allergen challenge. The adjuvant effect of ultrafine particles was also documented by increased mucus production, peribronchiolar and perivascular inflammation, and enhanced airway hyperresponsiveness. In contrast, particle exposure in sensitized mice after allergen challenge caused only moderate effects, such as a delay of inflammatory infiltrate and a reduction of cytokines in bronchoalveolar lavage fluid. Conclusion: Exposure to ultrafine carbon particles before allergen challenge exerts strong adjuvant effects on the manifestation of allergic airway inflammation. Allergen-sensitized individuals may therefore be more susceptible to detrimental health effects of ultrafine particles.	GSF, Div Environm Dermatol Allergy, Natl Res Ctr Environm Hlth, TUM,ZAUM Ctr Allergy Environm, D-85764 Neuherberg, Germany; GSF, Div Environm Dermatol Allergy, Natl Res Ctr Environm Hlth, TUM,ZAUM Ctr Allergy Environm, Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Focus Network Aerosols & Hlth, Neuherberg, Germany; Tech Univ Munich, Dept Dermatol & Allergy Biederstein, D-8000 Munich, Germany	Alessandrini, F (reprint author), GSF, Div Environm Dermatol Allergy, Natl Res Ctr Environm Hlth, TUM,ZAUM Ctr Allergy Environm, Bldg 34,Room 0340, D-85764 Neuherberg, Germany.	Franci@gsf.de	Jakob, Thilo/J-1621-2012; Karg, Erwin/E-1441-2013; Schulz, Holger/J-5643-2015	Schulz, Holger/0000-0002-1157-200X			Anjilvel S, 1999, MULTIPLE PATH PARTIC; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Barrett EG, 2003, INHAL TOXICOL, V15, P151, DOI 10.1080/08958370390168210; BIRCH ME, 1999, ELEMENTAL CARBON DIE; Bochner BS, 2005, J ALLERGY CLIN IMMUN, V115, P953, DOI 10.1016/j.jaci.2005.02.032; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Cyrys J, 2003, SCI TOTAL ENVIRON, V305, P143, DOI 10.1016/S0048-9697(02)00494-1; de Haar C, 2005, TOXICOL SCI, V87, P409, DOI 10.1093/toxsci/kfi255; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dick CAJ, 2003, INHAL TOXICOL, V15, P39, DOI 10.1080/08958370304454; Dockery D. W., 1996, AM J RESP CRIT CAR S, V154, pS250; DRORBAUGH JE, 1955, PEDIATRICS, V16, P81; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P1471, DOI 10.1289/ehp.6300; Goldsmith CAW, 1999, INHAL TOXICOL, V11, P981; Granum B, 2001, TOXICOL LETT, V118, P171, DOI 10.1016/S0378-4274(00)00292-7; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; HILDEMANN LM, 1994, ENVIRON SCI TECHNOL, V28, P1565, DOI 10.1021/es00058a006; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; KITTELSON DB, 2001, MNRC200112 MINN DEP; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Maejima K, 1997, J TOXICOL ENV HEALTH, V52, P231, DOI 10.1080/009841097159674; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Oberdorster G, 2000, RES REP HLTH EFF I, V96, P5; Peden DB, 1997, ALLERGY, V52, P37; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; Roth C, 2004, AEROSOL SCI TECH, V38, P228, DOI 10.1080/02786820490247632; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Takano H, 1998, TOXICOL APPL PHARM, V150, P328, DOI 10.1006/taap.1998.8437; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Timonen KL, 2004, OCCUP ENVIRON MED, V61, P908, DOI 10.1136/oem.2004.012849; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032	50	81	83	1	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2006	117	4					824	830		10.1016/j.jaci.2005.11.046		7	Allergy; Immunology	Allergy; Immunology	033QB	WOS:000236862800016	16630940	
J	Lee, SA; Adhikari, A; Grinshpun, SA; McKay, R; Shukla, R; Reponen, T				Lee, SA; Adhikari, A; Grinshpun, SA; McKay, R; Shukla, R; Reponen, T			Personal exposure to airborne dust and microorganisms in agricultural environments	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL HYGIENE			English	Article						agricultural farms; bacteria; dust; fungi	N95 FILTERING FACEPIECE; ORGANIC DUST; URINARY ALLERGEN; AIR; FUNGI; BUILDINGS; PARTICLES; FARMS; BARNS; BIOAEROSOLS	Airborne dust and microorganisms are associated with respiratory diseases and increased mortality, and morbidity. Farmers are at high risk of exposure to both of these hazards. Very limited information, however is available on the combined exposures to both hazards on different types of farms. Moreover most of the previous studies have measured the mass concentration of particles ignoring the particle size. In this study, farmers' exposure to airborne dust and microorganisms was studied using our newly developed personal sampling system. Particle number concentration and size distribution were measured with an optical particle counter Simultaneously, particles were collected on a filter and analyzed for microorganisms. The field measurements were conducted in animal confinements (swine, poultry, and dairy) and during grain harvesting (corn and soybean). The ye concentrations on the results show the following avera workers' breathing zone.- 1. 7 x 10(6) to 2.9 x 10(7) particles/m(3) for total dust, 0.9 x 10(3) to 3.9 x 10(4) spores/m(3) for total fungal spores, 0.3 x 10(3) to 3.6 x 10(4) CFU/m(3) for culturable fungal spores, 0.3 x 10(4) to 3.3 x 10(8) CFU/m(3) for culturable bacteria, and limit of detection (LOD) to 2.8 x 103 CFU/m(3) for culturable actinomycetes in animal confinements. The respective concentrations were 4.4 x 10(6) to 5.8 x 10(7) particles/m(3), 3.4 x 10(4) to 6.1 x 10(6) spores/m(3), 8.2 x 10(4) to 7.4 x 10(6) CFU/m(3), 0.4 x 10(5) to 1.4 x 10(6) CFU/m(3), and LOD to 2.6 x 10(4) CFU/m(3) during grain harvesting. The highest contribution of large particles (3-10 mu m) in total particles was found during grain harvesting, whereas the size distribution was dominated by smaller particles (< 3 mu m) in animal confinements. High fraction (up to 37%) of particles between 2-10 mu m was found to be fungal spores. The results indicate that an increase in the concentration of large dust particles (2-10 mu m) during grain harvesting was partially, attributed to the increase in the concentration of the fungal spores. Overall, the combined exposure to airborne dust and microorganisms was found to be more severe during harvesting than in animal confinements.	Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA	Reponen, T (reprint author), Univ Cincinnati, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	reponeta@ucmail.uc.edu			NIOSH CDC HHS [R01 OH04085]		Adhikari A, 2004, ANN AGR ENV MED, V11, P269; Adhikari A, 2003, ATMOS ENVIRON, V37, P4723, DOI 10.1016/j.atmosenv.2003.08.021; Adhikari A, 2004, SCI TOTAL ENVIRON, V326, P121; Bakutis B, 2004, ACTA VET BRNO, V73, P283, DOI 10.2754/avb200473020283; Baron PA, 2001, AEROSOL MEASUREMENT, P45; Baur X, 2003, Pneumologie, V57, P335; Beard M, 1996, APPL OCCUP ENV HYG, V11, P1409; Bisht V, 2002, ANN ALLERG ASTHMA IM, V89, P285; Chang CW, 2001, APPL ENVIRON MICROB, V67, P155, DOI 10.1128/AEM.67.1.155-161.2001; DOSMAN JA, 2005, EUR RESPIR J, V24, P698; DOUWES J, 1999, ANN OCCUP HYG, V47, P187; Duchaine C, 1999, AM IND HYG ASSOC J, V60, P89, DOI 10.1080/00028899908984426; Flannigan B, 1997, J AEROSOL SCI, V28, P381, DOI 10.1016/S0021-8502(96)00441-7; FUCHS NA, 1964, MECH AEROSOLS, P62; GORDON S, 1994, CLIN EXP ALLERGY, V24, P1070, DOI 10.1111/j.1365-2222.1994.tb02745.x; Hameed AAA, 2001, J ENVIRON MONITOR, V3, P206, DOI 10.1039/b007159p; HANHELA R, 1995, SCAND J WORK ENV HEA, V21, P223; Hinds W. C., 1999, AEROSOL TECHNOLOGY P, P52; Hollander A, 1998, SCAND J WORK ENV HEA, V24, P228; Jaenicke R, 2005, SCIENCE, V308, P73, DOI 10.1126/science.1106335; Kullman GJ, 1998, AM IND HYG ASSOC J, V59, P403, DOI 10.1202/0002-8894(1998)059<0403:ODEFWI>2.0.CO;2; Lappalainen S, 1996, ATMOS ENVIRON, V30, P3059, DOI 10.1016/1352-2310(95)00449-1; Lee K, 2004, J OCCUP ENVIRON HYG, V1, P505, DOI [10.1080/15459620490471616, 10.1080/1545559620490471616]; Lee SA, 2005, ANN OCCUP HYG, V49, P245, DOI 10.1093/annhyg/meh097; Lee SA, 2005, J OCCUP ENVIRON HYG, V2, P577, DOI 10.1080/15459620500330583; Lee S. A., 2004, AEROSOL AIR QUAL RES, V4, P56; MCDEVITT TJ, 1997, ANN ALLERGY, V38, P12; Melbostad E, 2001, AM J IND MED, V39, P209, DOI 10.1002/1097-0274(200102)39:2<209::AID-AJIM1008>3.0.CO;2-5; Molocznik A, 2002, ANN AGR ENV MED, V9, P71; *NIOSH, 1994, NIOSH MAN AN METH NM; Pandit T, 1995, AEROBIOLOGIA, V11, P177, DOI 10.1007/BF02450036; Predicala Bernardo Z, 2003, Appl Occup Environ Hyg, V18, P694, DOI 10.1080/10473220301375; Radon K, 2003, Pneumologie, V57, P510; Radon K, 2002, ANN AGR ENV MED, V9, P41; Rautiala S, 2003, AIHA J, V64, P673, DOI 10.1202/471.1; Rautiala S, 1998, AM IND HYG ASSOC J, V59, P455; Reponen T, 2001, GRANA, V40, P119, DOI 10.1080/00173130152625851; Roy CJ, 2003, AIHA J, V64, P487, DOI 10.1202/351.1; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Schneider T, 2003, INDOOR AIR, V13, P38, DOI 10.1034/j.1600-0668.2003.02025.x; Skaug MA, 2001, MYCOPATHOLOGIA, V151, P93, DOI 10.1023/A:1010953401173; Swan JRM, 1998, ANN AGR ENV MED, V5, P7; *SWED NAT BOARD OC, 1994, STAT BOOK SWED WORK; Toivola M, 2002, J ENVIRON MONITOR, V4, P166, DOI 10.1039/b108682k; VONESSEN S, 1999, CHEST, V116, P1157; Wang Z, 2001, J AEROSOL SCI, V32, P661, DOI 10.1016/S0021-8502(00)00108-7; Wilson SC, 2002, APPL ENVIRON MICROB, V68, P3238, DOI 10.1128/AEM.68.7.3238-3242.2002; Womiloju TO, 2003, ATMOS ENVIRON, V37, P4335, DOI 10.1016/S1352-2310(03)00577-6	48	81	83	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1545-9624			J OCCUP ENVIRON HYG	J. Occup. Environ. Hyg.	MAR	2006	3	3					118	130		10.1080/15459620500524607		13	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	019YK	WOS:000235874400004	16484176	
J	Hunninghake, GM; Weiss, ST; Celedon, JC				Hunninghake, GM; Weiss, ST; Celedon, JC			Asthma in Hispanics	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review						asthma; genetics; Hispanics; risk factors	BODY-MASS INDEX; GENOME-WIDE SEARCH; ETHNICALLY DIVERSE POPULATIONS; INNER-CITY CHILDREN; HOUSE-DUST MITE; BETA(2)-ADRENERGIC RECEPTOR POLYMORPHISMS; COMMUNITY RESPIRATORY HEALTH; REFERENCE SPIROMETRIC VALUES; IMMUNOGLOBULIN-E LEVELS; PUERTO-RICAN CHILDREN	Hispanic individuals trace their ancestry to countries that were previously under Spanish rule, including Mexico, large parts of Central and South America, and some Caribbean islands. Most-but not all-Hispanics have variable proportions of European, Amerindian, and African ancestry. Hispanics are diverse with regard to many factors, including racial ancestry, country of origin, area of residence, socioeconomic status, education, and access to health care. Recent findings suggest that there is marked variation in the prevalence, morbidity, and mortality of asthma in Hispanics in the United States and in Hispanic America. The reasons for differences in asthma and asthma morbidity among and within Hispanic subgroups are poorly understood but are likely due to the interaction between yet-unidentified genetic variants and other factors, including environmental tobacco smoke exposure, obesity, allergen exposure, and availability of health care. Barriers to optimal management of asthma in Hispanics in the United States and in Hispanic America include inadequate access to health care, suboptimal use of antiinflammatory medications, and lack of reference values for spirometric measures of lung function in many subgroups (e.g., Puerto Ricans). Future studies of asthma in Hispanics should include large samples of subgroups that are well characterized with regard to self-reported ethnicity, country of origin, place of birth, area of residence, and indicators of socioeconomic status. Because Hispanics are disproportionately represented among the poor in the United States, implementation of adequate access to health care and social reforms (e.g., improving housing conditions) would likely have a major impact on reducing asthma morbidity in this population.	Harvard Univ, Sch Med, Channing Lab, Dept Med, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Resp Disorders Program, Boston, MA 02115 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Pulm & Crit Care Med, Boston, MA 02115 USA	Celedon, JC (reprint author), Harvard Univ, Sch Med, Channing Lab, Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu			NHLBI NIH HHS [HL 004370, HL 073373]		Adams RJ, 2002, J ALLERGY CLIN IMMUN, V110, P58, DOI 10.1067/mai.2002.125489; Ahluwalia Indu B, 2003, MMWR Surveill Summ, V52, P1; Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Alvarez C, 2004, REV MED CHILE, V132, P1205, DOI 10.4067/S0034-98872004001000007; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arif AA, 2004, J PAEDIATR CHILD H, V40, P189, DOI 10.1111/j.1440-1754.2004.00335.x; Arif AA, 2003, EUR RESPIR J, V21, P827, DOI 10.1183/09031936.03.00054103; Asher MI, 1998, EUR RESPIR J, V12, P315; Avila L, 2005, J ASTHMA, V42, P543, DOI 10.1080/02770900500214791; BACAB MAB, 2003, REV ALERG MEX, V50, P208; Bacanu SA, 2000, AM J HUM GENET, V66, P1933, DOI 10.1086/302929; Bamshad M, 2004, NAT REV GENET, V5, P598, DOI 10.1038/nrg1401; Basagana X, 2004, AM J EPIDEMIOL, V160, P178, DOI 10.1093/aje/kwh186; Basehore MJ, 2004, J ALLERGY CLIN IMMUN, V114, P80, DOI 10.1016/j.jaci.2004.05.035; Bayona Manuel, 2002, P R Health Sci J, V21, P213; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; Bertoni B, 2003, HUM BIOL, V75, P1, DOI 10.1353/hub.2003.0016; Binaei S, 2003, CHEST, V123, p375S, DOI 10.1378/chest.123.3_suppl.375S; Bleecker ER, 1999, AM J RESP CRIT CARE, V159, pA645; Blumenthal MN, 2004, HUM GENET, V114, P157, DOI 10.1007/s00439-003-1030-5; Bonner S, 2002, J ASTHMA, V39, P167; Borrell LN, 2005, AM J PUBLIC HEALTH, V95, P379, DOI 10.2105/AJPH.2004.058172; Boudreaux ED, 2003, CHEST, V124, P803, DOI 10.1378/chest.124.3.803; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; BUCHARD EG, 2003, AM J RESP CRIT CARE, V169, P386; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Bustos P, 2005, INT J OBESITY, V29, P804, DOI 10.1038/sj.ijo.0802958; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Caraballo L, 1998, J INVEST ALLERG CLIN, V8, P281; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARRASCO E, 1987, CHEST, V91, pS93, DOI 10.1378/chest.91.6.93S; Carrasquillo O, 2000, AM J PUBLIC HEALTH, V90, P917, DOI 10.2105/AJPH.90.6.917; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Carvajal-Carmona LG, 2003, HUM GENET, V112, P534, DOI 10.1007/s00439-002-0899-8; CASTILLEJOS M, 1992, AM REV RESPIR DIS, V145, P276; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Centers for Disease Control and Prevention, 2004, MMWR-MORBID MORTAL W, V53, P145; Celedon JC, 2001, CHEST, V120, P785, DOI 10.1378/chest.120.3.785; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835; Celedon JC, 2002, PEDIATR ALLERGY IMMU, V13, P91, DOI 10.1034/j.1399-3038.2002.00083.x; Celedon JC, 2004, CHEST, V125, P85, DOI 10.1378/chest.125.1.85; CELEDON JC, 2003, CLIN EXP ALLER, V32, P387; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; ChenMok M, 1997, SALUD PUBLICA MEXICO, V39, P11, DOI 10.1590/S0036-36341997000100003; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Choudhry S, 2005, AM J RESP CRIT CARE, V172, P173, DOI 10.1164/rccm.200409-1232OC; CHOUDHRY S, 2004, AM J RESP CRIT CARE, V171, P563; Christiansen SC, 1997, J ALLERGY CLIN IMMUN, V100, P613, DOI 10.1016/S0091-6749(97)70164-7; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; Christiansen SC, 1996, J ASTHMA, V33, P17, DOI 10.3109/02770909609077759; Cloutier MM, 2005, J PEDIATR-US, V146, P591, DOI 10.1016/j.jpeds.2004.12.017; Cook DG, 1997, THORAX, V52, P1081; Cooper PJ, 2004, J INFECT DIS, V190, P1338, DOI 10.1086/423944; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2004, CLIN EXP ALLERGY, V34, P845, DOI 10.1111/j.1365-2222.2004.01958.x; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Corzo-Alvarez G R, 1998, Invest Clin, V39, P3; Coultas DB, 1998, THORAX, V53, P381; COULTAS DB, 1988, AM REV RESPIR DIS, V138, P1386; CRAIN EF, 1994, PEDIATRICS, V94, P356; Crane J, 2003, EUR RESPIR J, V21, P455, DOI 10.1183/09031936.03.00041403; CRAPO RO, 1990, CHEST, V98, P1435, DOI 10.1378/chest.98.6.1435; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; D'Amato M, 1998, AM J RESP CRIT CARE, V158, P1968; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Davey G, 2005, CLIN EXP ALLERGY, V35, P301, DOI 10.1111/j.1365-2222.2005.02181.x; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; David MMA, 1996, AM J RESP CRIT CARE, V153, P1285; Del-Rio-Navarro BE, 2003, J INVEST ALLERG CLIN, V13, P118; Dennis R, 2004, ANN ALLERG ASTHMA IM, V93, P568; Devlin B, 1999, BIOMETRICS, V55, P997, DOI 10.1111/j.0006-341X.1999.00997.x; Dewar JC, 1997, J ALLERGY CLIN IMMUN, V100, P261, DOI 10.1016/S0091-6749(97)70234-3; Dhabuwala A, 2000, OBES SURG, V10, P428, DOI 10.1381/096089200321594291; Diaz T, 2000, PEDIATRICS, V105, P1188, DOI 10.1542/peds.105.6.1188; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812; DOCKERY DW, 1985, AM REV RESPIR DIS, V131, P511; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Drysdale CM, 2000, P NATL ACAD SCI USA, V97, P10483, DOI 10.1073/pnas.97.19.10483; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Etzel RA, 2003, PEDIATRICS, V112, P233; FERNANDEZCALDAS E, 1993, CLIN EXP ALLERGY, V23, P292, DOI 10.1111/j.1365-2222.1993.tb00325.x; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; FernandezCaldas E, 1996, J INVEST ALLERG CLIN, V6, P98; Fernandez-Cobo M., 2001, HUM BIOL, V73, P385, DOI 10.1353/hub.2001.0032; Ferrandiz R, 1996, ALLERGY, V51, P501, DOI 10.1111/j.1398-9995.1996.tb04656.x; Filozof C, 2001, Obes Rev, V2, P99, DOI 10.1046/j.1467-789x.2001.00029.x; Findley S, 2003, J ASTHMA, V40, P557, DOI 10.1081/JAS-120019028; Flores G, 2000, J PEDIATR-US, V136, P14, DOI 10.1016/S0022-3476(00)90043-X; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Foster MW, 2004, NAT REV GENET, V5, P790, DOI 10.1038/nrg1452; Freeman NCG, 2003, AM J PUBLIC HEALTH, V93, P1316, DOI 10.2105/AJPH.93.8.1316; Freeman NCG, 2003, J EXPO ANAL ENV EPID, V13, P169, DOI 10.1038/sj.jea.7500266; Galindez F, 1998, MEDICINA-BUENOS AIRE, V58, P141; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gold DR, 2003, PEDIATR PULM, V36, P514, DOI 10.1002/ppul.10376; Goldstein DB, 2004, NAT GENET, V36, P1243, DOI 10.1038/ng1204-1243; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; GREALLY M, 1982, IRISH MED J, V75, P403; Gutierrez M, 1996, REV MED CHILE, V124, P1295; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; HALL IP, 1995, LANCET, V345, P1213, DOI 10.1016/S0140-6736(95)91994-5; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Halterman JS, 2000, PEDIATRICS, V105, P272; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; Hancox RJ, 2004, THORAX, V59, P376, DOI 10.1136/thx.2003.010363; HANIS CL, 1991, DIABETES CARE, V14, P618, DOI 10.2337/diacare.14.7.618; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Harrell J, 2003, JAMA-J AM MED ASSOC, V289, P1167, DOI 10.1001/jama.289.9.1167; Hedley AA, 2004, JAMA-J AM MED ASSOC, V291, P2847, DOI 10.1001/jama.291.23.2847; Hernandez-Cadena L, 2000, SALUD PUBLICA MEXICO, V42, P288, DOI 10.1590/S0036-36342000000400003; Himmelgreen DA, 2004, AM J PHYS ANTHROPOL, V125, P90, DOI 10.1002/ajpa.10367; Hoffjan S, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-14; Holguin F, 2005, AM J RESP CRIT CARE, V171, P103, DOI 10.1164/rccm.200402-143OC; Holloway JW, 2000, CLIN EXP ALLERGY, V30, P1097; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504; Hopes E, 1998, BRIT MED J, V316, P664; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; Hovell MF, 2002, PEDIATRICS, V110, P946, DOI 10.1542/peds.110.5.946; Howard TD, 2003, J ALLERGY CLIN IMMUN, V112, P717, DOI 10.1067/mai.2003.1745; Huang SK, 2003, HUM GENET, V113, P71, DOI 10.1007/s00439-003-0934-4; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Huang SL, 2002, CLIN EXP ALLERGY, V32, P1029, DOI 10.1046/j.1365-2745.2002.01424.x; Institute of Medicine Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Ioannidis JPA, 2004, NAT GENET, V36, P1312, DOI 10.1038/ng1474; *ISAAC, 1998, LANCET, V351, P12251; Israel E, 2000, AM J RESP CRIT CARE, V162, P75; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Jimenez-Espinel C A, 2001, Pediatr Pulmonol, VSuppl 23, P127; Kim SH, 2002, J ALLERGY CLIN IMMUN, V109, P630, DOI 10.1067/mai.2002.122842; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Klinnert MD, 2002, AM J PUBLIC HEALTH, V92, P792, DOI 10.2105/AJPH.92.5.792; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Koeppen-Schomerus G, 2001, ARCH DIS CHILD, V85, P398, DOI 10.1136/adc.85.5.398; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Kotani Y, 1999, J ASTHMA, V36, P583, DOI 10.3109/02770909909087295; Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Lara M, 2005, ANNU REV PUBL HEALTH, V26, P367, DOI 10.1146/annurev.publhealth.26.021304.144615; Lara M, 1999, WESTERN J MED, V170, P75; Last JM, 1995, DICT EPIDEMIOLOGY; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; Ledogar RJ, 2000, AM J PUBLIC HEALTH, V90, P929, DOI 10.2105/AJPH.90.6.929; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Lewis SA, 2002, AM J RESP CRIT CARE, V165, P961, DOI 10.1164/rccm.2103044; Lieu TA, 2004, PEDIATRICS, V114, pE102, DOI 10.1542/peds.114.1.e102; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Lind DL, 2003, AM J RESP CRIT CARE, V168, P1312, DOI 10.1164/rccm.200306-877OC; LISKER R, 1986, AM J PHYS ANTHROPOL, V71, P203, DOI 10.1002/ajpa.1330710207; LISKER R, 1986, REV INVEST CLIN, V38, P145; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; LONGO G, 1987, AM J DIS CHILD, V141, P331; Lopez Campos Celsa, 2003, Rev Alerg Mex, V50, P129; LUBS ML, 1972, J PEDIATR-US, V80, P26, DOI 10.1016/S0022-3476(72)80448-7; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; LYNCH NR, 1992, J INVEST ALLERG CLIN, V2, P97; Mallol J, 2004, Allergol Immunopathol (Madr), V32, P100; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Marsh DG, 1997, NAT GENET, V15, P389; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez J, 2005, REV MED CHILE, V133, P195, DOI 10.4067/S0034-98872005000200007; Martinez-Cruzado JC, 2001, HUM BIOL, V73, P491, DOI 10.1353/hub.2001.0056; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; Medeiros M, 2004, PEDIATR ALLERGY IMMU, V15, P142, DOI 10.1046/j.1399-3038.2003.00119.x; Melen E, 2005, AM J RESP CRIT CARE, V171, P1089, DOI 10.1164/rccm.200410-13170C; Mendoza-Mendoza A, 2001, Gac Med Mex, V137, P397; Rojas Molina N, 2001, REV ALERG MEX, V48, P115; Montealegre F, 2004, ANN ALLERG ASTHMA IM, V93, P472; Montealegre F, 2004, J ASTHMA, V41, P485, DOI 10.1081/JAS-120033993; Montealegre F, 2004, CLIN EXP ALLERGY, V34, P51, DOI 10.1111/j.1365-2222.2004.01855.x; Montealegre F, 1997, P R Health Sci J, V16, P359; Montealegre F, 1996, P R Health Sci J, V15, P113; MONTEALEGRE F, 1993, J ASTHMA, V30, P219, DOI 10.3109/02770909309054520; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nazario S, 2004, PEDIATR PULM, V37, P453, DOI 10.1002/ppul.20022; Neffen H, 2005, REV PANAM SALUD PUBL, V17, P191; Neffen H, 1997, J INVEST ALLERG CLIN, V7, P249; Neffen HE, 1996, J INVEST ALLERG CLIN, V6, P278; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; NIEMINEN MM, 1991, CHEST, V100, P70, DOI 10.1378/chest.100.1.70; National Institutes of Health, 1997, NIH PUBL; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Ober C, 1999, CLIN EXP ALLERGY, V29, P11; Ordaz V A, 1998, Rev Alerg Mex, V45, P106; Ortega AN, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e1; Pachter LM, 2002, J ASTHMA, V39, P119, DOI 10.1081/JAS-120002193; PACHTER LM, 1995, ARCH PEDIAT ADOL MED, V149, P982; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; PAMIES RJ, 1992, PRIMARY CARE, V19, P443; Pearce N, 1999, THORAX, V54, P268; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Penny ME, 2001, THORAX, V56, P607, DOI 10.1136/thorax.56.8.607; Perez-Padilla JR, 2001, SALUD PUBLICA MEXICO, V43, P113; Perez-Padilla R, 2003, PEDIATR PULM, V35, P177, DOI 10.1002/ppul.10232; Perez-Perdomo R, 2003, J ASTHMA, V40, P465, DOI 10.1081/JAS-120018713; Perez-Stable EJ, 2001, AM J PUBLIC HEALTH, V91, P1424, DOI 10.2105/AJPH.91.9.1424; PEREZPERDOMO P, 1999, B ASOC MED P R, V91, P91; Phipatanakul W, 2005, ALLERGY, V60, P697, DOI 10.1111/j.1398-9995.2005.00825.x; Pino P, 2004, EPIDEMIOLOGY, V15, P702, DOI 10.1097/01.ede.0000142153.28496.d0; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; PROCTOR BD, 2001, POVERTY US; Puccio FA, 2004, ALLERGY, V59, P753, DOI 10.1111/j.1398-9995.2004.00454.x; Puerta L, 1996, J ALLERGY CLIN IMMUN, V97, P689, DOI 10.1016/S0091-6749(96)70315-9; PUERTA L, 1993, J INVEST ALLERG CLIN, V3, P198; Quintero C, 1996, AM J IND MED, V29, P41, DOI 10.1002/(SICI)1097-0274(199601)29:1<41::AID-AJIM6>3.0.CO;2-1; Rabe KF, 2000, EUR RESPIR J, V16, P802, DOI 10.1183/09031936.00.16580200; Raby BA, 2001, CURR OPIN MOL THER, V3, P554; Raby BA, 2004, J ALLERGY CLIN IMMUN, V113, P1071, DOI 10.1016/j.jaci.2004.03.035; Ramirez R., 2004, WE PEOPLE HISPANICS; Ramsey CD, 2005, PEDIATR PULM, V39, P268, DOI 10.1002/ppul.20177; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334; Risch N, 2002, GENOME BIOL, V3; Rodriguez MA, 2002, ARCH PEDIAT ADOL MED, V156, P269; Romero Linda J., 2001, Ethnicity and Disease, V11, P263; Romero-Placeres M, 2004, SALUD PUBLICA MEXICO, V46, P222, DOI 10.1590/s0036-36342004000300012; ROMIEU I, 1992, AM J EPIDEMIOL, V136, P1524; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; SAMET JM, 1982, AM REV RESPIR DIS, V125, P152; Sanchez-Borges M, 2003, ANN ALLERG ASTHMA IM, V90, P664; Sans M, 2000, HUM BIOL, V72, P155; Sans M, 1997, HUM BIOL, V69, P161; Santillan AA, 2003, J ALLERGY CLIN IMMUN, V112, P1095, DOI 10.1016/j.jaci.2003.09.029; Santillan AA, 2003, INT J OBESITY, V27, P1430, DOI 10.1038/sj.ijo.0802395; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Schei MA, 2004, J EXPO ANAL ENV EPID, V14, pS110, DOI 10.1038/sj.jea.7500365; SCOTT G, 2004, ADV DATA, V344, P1; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SHAFFER BA, 1993, AM REV RESPIR DIS, V147, P1349; Shaheen SO, 1999, THORAX, V54, P396; SIBBALD B, 1980, THORAX, V35, P671, DOI 10.1136/thx.35.9.671; Slutsky AS, 1997, AM J RESP CRIT CARE, V156, pS130; Smith LA, 2005, PUBLIC HEALTH REP, V120, P109; Soto-Quiros ME, 2002, PEDIATR ALLERGY IMMU, V13, P342, DOI 10.1034/j.1399-3038.2002.02035.x; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; Soto-Quiros ME, 1998, ALLERGY, V53, P499, DOI 10.1111/j.1398-9995.1998.tb04087.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Stewart AW, 2001, INT J EPIDEMIOL, V30, P173, DOI 10.1093/ije/30.1.173; Strachan DP, 1998, THORAX, V53, P204; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; Summerhill E, 2000, AM J RESP CRIT CARE, V162, P599; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Tan S, 1997, LANCET, V350, P995, DOI 10.1016/S0140-6736(97)03211-X; THERRIEN M, P20535 US CENS BUR; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; TURKI J, 1995, J CLIN INVEST, V95, P1635, DOI 10.1172/JCI117838; Ulbrecht M, 2000, AM J RESP CRIT CARE, V161, P469; US Census Bureau, US INT PROJ AG SEX R; *US DEP COMM, 2001, 200 GEN DEM CHAR BER; *US DEP COMM NEWS, 1991, CENS BUR COMPL DISTR; Valdivieso R, 1997, J INVEST ALLERG CLIN, V7, P46; Valdivieso R, 1999, J INVEST ALLERG CLIN, V9, P288; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vargas MH, 2004, CHEST, V125, P1993, DOI 10.1378/chest.125.6.1993; Villarreal AB, 2003, J ASTHMA, V40, P413, DOI 10.1081/JAS-120018711; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; Wickens K, 2004, PEDIATR ALLERGY IMMU, V15, P55, DOI 10.1046/j.0905-6157.2003.00100.x; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; WOOD PR, 1993, PEDIATRICS, V91, P62; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; WORLD FACTBOOK CIA	309	81	81	4	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 15	2006	173	2					143	163		10.1164/rccm.200508-1232SO		21	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	001GC	WOS:000234520600004	16210666	
J	Kummeling, I; Thijs, C; Penders, J; Snijders, BEP; Stelma, F; Reimerink, J; Koopmans, M; Dagnelie, PC; Huber, M; Jansen, MCJF; de Bie, R; van den Brandt, PA				Kummeling, I; Thijs, C; Penders, J; Snijders, BEP; Stelma, F; Reimerink, J; Koopmans, M; Dagnelie, PC; Huber, M; Jansen, MCJF; de Bie, R; van den Brandt, PA			Etiology of atopy in infancy: The KOALA Birth Cohort Study	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						allergy; etiology; infant; risk factors; lifestyle; breast feeding; human milk; infections; gene-environment; diet; intestinal microbiota; cohort studies	PARTY DIAGNOSTIC-CRITERIA; ANTHROPOSOPHIC LIFE-STYLE; INTESTINAL MICROFLORA; FATTY-ACIDS; BREAST-MILK; ASTHMA; DERMATITIS; ENVIRONMENT; CHILDREN; ALLERGY	The aim of the KOALA Birth Cohort Study in the Netherlands is to identify factors that influence the clinical expression of atopic disease with a main focus on lifestyle (e.g., anthroposophy, vaccinations, antibiotics, dietary habits, breastfeeding and breast milk composition, intestinal microflora composition, infections during the first year of life, and gene-environment interaction). The recruitment of pregnant women started in October 2000. First, participants with 'conventional lifestyles' (n = 2343) were retrieved from an ongoing prospective cohort study (n = 7020) on pregnancy-related pelvic girdle pain. In addition, pregnant women (n = 491) with 'alternative lifestyles' with regard to child rearing practices, dietary habits (organic, vegetarian), vaccination schemes and/or use of antibiotics, were recruited through organic food shops, anthroposophic doctors and midwives, Steiner schools, and dedicated magazines. All participants were enrolled between 14 and 18 wk of gestation and completed an intake questionnaire on family history of atopy and infant care intentions. Documentation of other relevant variables started in the pregnant mother and covered the first and third trimester as well as early childhood by repeated questionnaires at 14-18, 30, and 34 wk of gestation and 3, 7, 12, and 24 months postpartum. A subgroup of participants, including both conventional and alternative lifestyles, was asked to consent to maternal blood sampling, breast milk and a faecal sample of the infant at I month post-partum, capillary blood at age 1 yr, venous blood and observation of manifestation of atopic dermatitis during home visits at the age of 2 yr (using the UK working party criteria and the severity scoring of atopic dermatitis index), and buccal swabs for DNA isolation from child-parent trios. From the start, ethical approval and informed consent procedures included gene-environment interaction studies. Follow-up at 3 and 7 months post-partum was completed with high response rates (respectively 90% and 88% in the conventional group, and 97% and 97% in the alternative group). The home visits at 2 yr of age will be completed in 2005. Preliminary results show that we have succeeded in recruiting a large population with various lifestyle choices with a fairly large contrast with regard to dietary habits (including organic foods, vegetarian diet), vaccination schemes and/or use of antibiotics. We have also been able to collect a large number of faecal samples (n = 1176) and capillary blood samples at age 1 yr (n = 956). Furthermore, a large proportion of the participants have consented with genetic studies. Mid 2006 we expect to report our first results on the relationship between the various exposures in early life and childhood atopy. An outline of the focus and design of the KOALA Birth Cohort Study is presented.	Maastricht Univ, Dept Epidemiol, Care & Publ Hlth Res Inst Caphri, NL-6200 MD Maastricht, Netherlands; TNO, Nutr & Food Res, NL-3700 AJ Zeist, Netherlands; Louis Bolk Inst, Driebergen, Netherlands; Natl Inst Publ Hlth & Environm, Diagnost Lab Infect Dis, NL-3720 BA Bilthoven, Netherlands; Univ Hosp Maastricht, Dept Med Microbiol, Maastricht, Netherlands; Maastricht Univ, Dept Epidemiol, Nutr & Toxicol Res Inst Maastricht, Maastricht, Netherlands	Kummeling, I (reprint author), Maastricht Univ, Dept Epidemiol, Care & Publ Hlth Res Inst Caphri, POB 616, NL-6200 MD Maastricht, Netherlands.	ischa.kummeling@epid.unimaas.nl	Penders, John/A-1280-2011				Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Alm JS, 2002, PEDIATR ALLERGY IMMU, V13, P402, DOI 10.1034/j.1399-3038.2002.01062.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bastiaanssen JM, 2005, BMC PUBLIC HEALTH, V5, DOI 10.1186/1471-2458-5-1; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bleecker ER, 1997, CIBA F SYMP, V206, P90; Duffy DL, 1997, EPIDEMIOL REV, V19, P129; Hanson LA, 2002, PEDIATR INT, V44, P347, DOI 10.1046/j.1442-200X.2002.t01-1-01592.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Kramer MS, 2003, COCHRANE DB SYST REV, V4; McNally NJ, 1998, SOC SCI MED, V46, P729, DOI 10.1016/S0277-9536(97)00174-3; Pershagen G, 2000, PEDIATR ALLERGY IMMU, V11, P26, DOI 10.1034/j.1399-3038.2000.00507.x; STALDER JF, 1993, DERMATOLOGY, V186, P23; Thijs C, 2000, EUR J CLIN NUTR, V54, P234, DOI 10.1038/sj.ejcn.1600926; van Gool CJAW, 2003, AM J CLIN NUTR, V77, P943; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams Joan C., 1994, VA J SOC POLY L, V1, P383; Wright AL, 2000, ADV EXP MED BIOL, V478, P131; WRIGHT S, 1989, BRIT J NUTR, V62, P693, DOI 10.1079/BJN19890069	24	81	81	1	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	DEC	2005	16	8					679	684		10.1111/j.1399-3038.2005.00333.x		6	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	990MG	WOS:000233746800011	16343090	
J	Gyan, K; Henry, W; Lacaille, S; Laloo, A; Lamsee-Ebanks, C; McKay, S; Antoine, RM; Monteil, MA				Gyan, K; Henry, W; Lacaille, S; Laloo, A; Lamsee-Ebanks, C; McKay, S; Antoine, RM; Monteil, MA			African dust clouds are associated with increased paediatric asthma accident and emergency admissions on the Caribbean island of Trinidad	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						Saharan dust; paediatric; asthma; accident and emergency; Caribbean	WEST-INDIES	A retrospective ecological study of paediatric asthma patients who attended the Accident and Emergency (A&E) department of the Paediatric Priority Care Facility at the Eric Williams Medical Sciences Complex in relation to Saharan dust visibility and other climatic variables for the period 23 May 2001 to 13 May 2002 was undertaken to determine if there is an association between paediatric A&E asthma visits and Saharan dust cloud cover. A Poisson regression model was used to determine the statistical relationship between acute paediatric asthma A&E visits and Saharan dust cover with and without other variables such as climatic parameters and month. During the study period, there were 2,655 A&E visits for acute asthma. There was an association between increased paediatric asthma admissions and increased Saharan dust cover. The best fitting model estimated that in one month, such as June, a deterioration of visibility due to increased Saharan dust cover from no dust (visibility =16 km) to very dusty (visibility =7 km) would increase a daily admission rate of 7.8 patients to 9.25 when climate variables such as barometric pressure and humidity were kept constant.	Univ W Indies, Fac Med Sci, Sch Basic Sci, St Augustine, Trinid & Tobago		mmonteil@tstt.net.tt					Blades E, 1998, W INDIAN MED J S2, V47, P34; DEPRADINE C, 1995, W INDIAN MED J S2, V44, P17; Howitt ME, 1997, AM J RESP CRIT CARE, V157, pA642; Ivey MA, 2003, CLIN EXP ALLERGY, V33, P1526, DOI 10.1046/j.1365-2222.2003.01801.x; Ivey Marsha A., 2001, Allergology International, V50, P29, DOI 10.1046/j.1440-1592.2001.00198.x; LENFANT C, 1993, NHLBI WHO WORKSH REP, P13; McCarthy M, 2001, LANCET, V358, P478, DOI 10.1016/S0140-6736(01)05677-X; Monteil MA, 2000, J ASTHMA, V37, P677, DOI 10.3109/02770900009087306; PEARSON R S B, 1973, Clinical Allergy, V3, P289, DOI 10.1111/j.1365-2222.1973.tb01336.x; Prospero JM, 1999, J GEOPHYS RES-ATMOS, V104, P15917, DOI 10.1029/1999JD900072; Rajkumar WS, 2000, ATMOS ENVIRON, V34, P1181, DOI 10.1016/S1352-2310(99)00381-7; SCHLATTER T, 1995, WEATHERWISE, V48, P38; Shinn EA, 2000, GEOPHYS RES LETT, V27, P3029, DOI 10.1029/2000GL011599; TAM HBT, 1998, W INDIAN MED J S2, V47, P22	14	81	85	3	10	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0020-7128			INT J BIOMETEOROL	Int. J. Biometeorol.	JUL	2005	49	6					371	376		10.1007/s00484-005-0257-3		6	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	946GE	WOS:000230559600003	15692817	
J	Kamradt, T; Goggel, R; Erb, KJ				Kamradt, T; Goggel, R; Erb, KJ			Induction, exacerbation and inhibition of allergic and autoimmune diseases by infection	TRENDS IN IMMUNOLOGY			English	Review							RESPIRATORY SYNCYTIAL VIRUS; INFLAMMATORY-BOWEL-DISEASE; CALMETTE-GUERIN VACCINATION; HELPER TYPE-1 RESPONSES; CENTRAL-NERVOUS-SYSTEM; BIRCH-POLLEN ALLERGY; REGULATORY T-CELLS; AIRWAY INFLAMMATION; DENDRITIC CELLS; MURINE MODEL	Epidemiological and experimental data suggest that infections or the exposure to non-pathogenic bacteria protect individuals from developing some autoimmune and atopic disorders. Generally, these findings support the 'hygiene hypothesis', which attributes the rise in autoimmune and atopic disorders to a lack of infections that normally keep the immune system balanced by inducing immunoregulation. The suspected key players for infection-mediated immune suppression of autoimmunity and atopy are T regulatory cells and dendritic cells, which produce immunosuppressive cytokines, such as interleukin-10 and transforming growth factor-beta. However, there is also solid evidence suggesting that infections can exacerbate or even directly cause autoimmune and allergic disorders. In this Review, we discuss which type of infections induce, exacerbate or inhibit allergic and autoimmune diseases and point at infection-induced immunological mechanisms influencing the development of autoimmunity and atopy.	Klinikum Univ Jena, Inst Immunol, D-07740 Jena, Germany; Boehringer Ingelheim Pharma GmbH & Co KG, Dept Pulm Res, D-88397 Biberach, Germany	Kamradt, T (reprint author), Klinikum Univ Jena, Inst Immunol, D-07740 Jena, Germany.	Immunologie@mti.uni-jena.de; Klaus.Erb@bc.boehringer-ingelheim.com		Kamradt, Thomas/0000-0001-8443-5893			Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659; Allen HF, 1999, DIABETES CARE, V22, P1703, DOI 10.2337/diacare.22.10.1703; Arkwright PD, 2003, BRIT J DERMATOL, V149, P1029, DOI 10.1111/j.1365-2133.2003.05557.x; Audicana MT, 2002, TRENDS PARASITOL, V18, P20, DOI 10.1016/S1471-4922(01)02152-3; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bashir MEH, 2002, J IMMUNOL, V169, P3284; Benoist C, 2001, NAT IMMUNOL, V2, P797, DOI 10.1038/ni0901-797; Blasi F, 2004, EUR RESPIR J, V24, P171, DOI 10.1183/09031936.04.00135703; Bouma G, 2003, NAT REV IMMUNOL, V3, P521, DOI 10.1038/nri1132; Brennan FM, 2002, ARTHRITIS RHEUM, V46, P31, DOI 10.1002/1529-0131(200201)46:1<31::AID-ART10029>3.0.CO;2-5; Camporota L, 2003, EUR RESPIR J, V21, P287, DOI 10.1183/09031936.03.00042103; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dahl ME, 2004, NAT IMMUNOL, V5, P337, DOI 10.1038/ni1041; DECUNHA SS, 2004, ALLERGY, V59, P857; Demirci M, 2003, J DERMATOL, V30, P777; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Elliott DE, 2004, EUR J IMMUNOL, V34, P2690, DOI 10.1002/eji.200324833; Elliott JF, 1998, DIABETES CARE, V21, P1691, DOI 10.2337/diacare.21.10.1691; Ennis DP, 2004, CLIN EXP ALLERGY, V34, P1488, DOI 10.1111/j.1365-2222.2004.02042.x; Geginat J, 2001, J EXP MED, V194, P1711, DOI 10.1084/jem.194.12.1711; Gionchetti P, 2003, GASTROENTEROLOGY, V124, P1202, DOI 10.1016/S0016-5085(03)00171-9; Grunewald SM, 2002, J INVEST DERMATOL, V118, P645, DOI 10.1046/j.1523-1747.2002.01732.x; Han XB, 2004, EUR J IMMUNOL, V34, P981, DOI 10.1002/eji.200324387; Hardy RD, 2002, INFECT IMMUN, V70, P649, DOI 10.1128/IAI.70.2.649-654.2002; Hashimoto K, 2004, AM J RESP CRIT CARE, V170, P306, DOI 10.1164/rccm.200301-030OC; Helin T, 2002, ALLERGY, V57, P243, DOI 10.1034/j.1398-9995.2002.1s3299.x; Herfarth H, 2002, GUT, V50, P146, DOI 10.1136/gut.50.2.146; Herz U, 2000, CURR OPIN IMMUNOL, V12, P632, DOI 10.1016/S0952-7915(00)00155-2; Hurst SD, 2001, J IMMUNOL, V166, P4922; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; John AE, 2003, EUR J IMMUNOL, V33, P1677, DOI 10.1002/eji.200323930; Kamradt T, 2002, ARTHRITIS RES, V4, P20, DOI 10.1186/ar379; Kamradt T, 2001, NEW ENGL J MED, V344, P655; Kamradt T, 2004, MOL DIVERS, V8, P271, DOI 10.1023/B:MODI.0000036236.11774.1b; Kondo Y, 2004, CLIN EXP ALLERGY, V34, P1307, DOI 10.1111/j.1365-2222.2004.02033.x; La Flamme AC, 2003, INFECT IMMUN, V71, P4996, DOI 10.1128/IAI.71.9.4996-5004.2003; Le Bon A, 2002, CURR OPIN IMMUNOL, V14, P432, DOI 10.1016/S0952-7915(02)00354-0; Lieberman D, 2003, AM J RESP CRIT CARE, V167, P406, DOI 10.1164/rccm.200209-996OC; Loftus EV, 2004, GASTROENTEROLOGY, V126, P1504, DOI 10.1053/j.gastro.2004.01.063; Lukacs NW, 2001, J IMMUNOL, V167, P1060; Madsen KL, 1999, GASTROENTEROLOGY, V116, P1107, DOI 10.1016/S0016-5085(99)70013-2; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Marks GB, 2003, J ALLERGY CLIN IMMUN, V111, P541, DOI 10.1067/mai.2003.171; Marsland BJ, 2004, CLIN EXP ALLERGY, V34, P1299, DOI 10.1111/j.1365-2222.2004.02021.x; Marsland BJ, 2004, P NATL ACAD SCI USA, V101, P6116, DOI 10.1073/pnas.0401582101; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Mittrucker HW, 2004, EUR J IMMUNOL, V34, P306, DOI 10.1002/eji.200324578; Moreels TG, 2004, GUT, V53, P99, DOI 10.1136/gut.53.1.99; Moudgil KD, 2001, J IMMUNOL, V166, P4237; Negrao-Correa D, 2003, INFECT IMMUN, V71, P2607, DOI 10.1128/IAI.71.5.2607-2614.2003; Ponsonby AL, 2005, JAMA-J AM MED ASSOC, V293, P463, DOI 10.1001/jama.293.4.463; QIN HY, 1993, J IMMUNOL, V150, P2072; Reardon C, 2001, INFECT IMMUN, V69, P4417, DOI 10.1128/IAI.69.7.4417-4423.2001; Repa A, 2003, VACCINE, V22, P87, DOI 10.1016/S0264-410X(03)00528-0; Ristori G, 1999, NEUROLOGY, V53, P1588; Sayers I, 2004, J ALLERGY CLIN IMMUN, V114, P302, DOI 10.1016/j.jaci.2004.03.057; Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012; Sewell DL, 2003, CLIN DIAGN LAB IMMUN, V10, P564, DOI 10.1128/CDLi.10.4.564-572.2003; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Shirtcliffe PM, 2004, CLIN EXP ALLERGY, V34, P207, DOI 10.1111/j.1365-2222.2004.01861.x; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Summers RW, 2003, AM J GASTROENTEROL, V98, P2034, DOI 10.1016/S0002-9270(03)00623-3; Trujillo C, 2003, INT J MED MICROBIOL, V293, P123, DOI 10.1078/1438-4221-00257; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; Van der Kleij D, 2002, J INFECT DIS, V185, P531, DOI 10.1086/338574; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Walzl G, 2000, J EXP MED, V192, P1317, DOI 10.1084/jem.192.9.1317; Wang CC, 2001, CLIN EXP ALLERGY, V31, P495, DOI 10.1046/j.1365-2222.2001.01044.x; Wark PAB, 2002, EUR RESPIR J, V19, P68, DOI 10.1183/09031936.02.00226302; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Wohlleben G, 2003, J IMMUNOL, V170, P4601; Yang JF, 2001, NAT IMMUNOL, V2, P157, DOI 10.1038/84264; Zaccone P, 2004, EUR J IMMUNOL, V34, P3246, DOI 10.1002/eji.200425285; Zaccone P, 2003, EUR J IMMUNOL, V33, P1439, DOI 10.1002/eji.200323910	78	81	87	1	6	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4906			TRENDS IMMUNOL	Trends Immunol.	MAY	2005	26	5					260	267		10.1016/j.it.2005.03.009		8	Immunology	Immunology	928CY	WOS:000229249900007	15866239	
J	Anderson, SD; Kippelen, P				Anderson, SD; Kippelen, P			Exercise-induced bronchoconstriction: Pathogenesis	CURRENT ALLERGY AND ASTHMA REPORTS			English	Review							CANINE PERIPHERAL AIRWAYS; THERMALLY-INDUCED ASTHMA; CROSS-COUNTRY SKIERS; MAST-CELL; BRONCHIAL HYPERRESPONSIVENESS; INDUCED BRONCHOSPASM; BETA(2)-ADRENOCEPTOR-MEDIATED RESPONSES; NONASTHMATIC SUBJECTS; ISOCAPNIC HYPERPNEA; ALLERGIC RHINITIS	There is still active debate on the acute mechanism of exercise-induced bronchoconstriction (EIB). Although it is unlikely that vasoconstriction and hyperemia of the bronchial vasculature are essential events for EIB, it is likely that this vasculature enhances the airway response to dehydration and contributes to the pathogenesis of EIB, particularly in elite athletes. Accumulating evidence suggests that airway smooth muscle (ASM) becomes more sensitive as a result of repeated exposure to bulk plasma in response to airway injury from dehydration. Recent evidence also demonstrates sufficient concentrations of mediators that could affect ASM. Paradoxically, mediator release from mast cells may be enhanced and their contractile effects greater when beta(2)-receptor agonists are taken daily. The effect of drugs that have the potential to reduce microvascular leak and reduce or inhibit release or action of these mediators needs to be investigated in elite athletes.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, 11 West,Missenden Rd, Camperdown, NSW 2050, Australia.	sandya@mail.med.usyd.edu.au		Anderson, Sandra/0000-0002-6308-8770			Aldridge RE, 2000, AM J RESP CRIT CARE, V161, P1459; Anderson Sandra D, 2004, Paediatr Drugs, V6, P161, DOI 10.2165/00148581-200406030-00003; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; Anderson SD, 2003, CLIN REV ALLERG IMMU, V24, P63; Anderson S, 2003, J ALLERGY CLIN IMMUN, V111, P44; Bonsignore MR, 2001, AM J PHYSIOL-LUNG C, V281, pL668; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403; BRANNAN JD, 2004, J ALLERGY CLIN IMMUN, V113; Caillaud C, 2003, CAN J APPL PHYSIOL, V28, P793; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chong LK, 2003, BRIT J PHARMACOL, V138, P512, DOI 10.1038/sj.bjp.0705050; Crummy F, 2004, J ALLERGY CLIN IMMUN, V114, P34, DOI 10.1016/j.jaci.2004.03.006; Davis MS, 2003, J APPL PHYSIOL, V94, P2545, DOI 10.1152/japplphysiol.00018.2003; Davis MS, 2001, AM J RESP CRIT CARE, V164, P785; DAVISKAS E, 1995, EUR RESPIR J, V8, P742; Evans DW, 1997, THORAX, V52, P136; Freed AN, 1999, AM J RESP CRIT CARE, V159, P1101; HALLSTRAND TS, 2004, AM J RESP CRIT CARE, pA817; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/rccm.200111-091BC; Helenius IJ, 1998, BRIT J SPORT MED, V32, P125; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Johnson PRA, 2004, CURR ALLERGY ASTHM R, V4, P102, DOI 10.1007/s11882-004-0054-9; Kalra S, 1996, CHEST, V109, P953, DOI 10.1378/chest.109.4.953; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086; Koskela H, 2000, CLIN EXP ALLERGY, V30, P1627; Kotaru C, 2003, J APPL PHYSIOL, V94, P227, DOI 10.1152/japplphysiol.00551.2002; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479; Larsson K, 1998, EUR RESPIR J, V12, P825, DOI 10.1183/09031936.98.12040825; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; OBASE Y, 2004, EUR RESP J S48, V24; OMORI C, 1995, J APPL PHYSIOL, V78, P2169; OMORI C, 1995, J APPL PHYSIOL, V78, P1043; Page S, 2001, AM J PHYSIOL-LUNG C, V281, pL1313; PERSSON CGA, 1997, LUNG, P2611; PLISS LB, 1990, AM REV RESPIR DIS, V142, P73; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1183/09031936.00.15103000; Rundell KW, 2004, CHEST, V125, P909, DOI 10.1378/chest.125.3.909; Rundell KW, 2003, INHAL TOXICOL, V15, P237, DOI 10.1080/08958370390168256; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Scola AM, 2004, BRIT J PHARMACOL, V141, P163, DOI 10.1038/sj.bjp.0705599; Sue-Chu M, 1999, EUR RESPIR J, V13, P626, DOI 10.1183/09031936.99.13362699; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; SUECHU M, 2002, EUR RESP J; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57	54	81	83	0	3	CURRENT SCIENCE INC	PHILADELPHIA	400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA	1529-7322			CURR ALLERGY ASTHM R	Curr. Allergy Asthma Rep.	MAR	2005	5	2					116	122		10.1007/s11882-005-0084-y		7	Allergy; Immunology	Allergy; Immunology	949SW	WOS:000230809400004	15683611	
J	Peden, DB				Peden, DB			The epidemiology and genetics of asthma risk associated with air pollution	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						air pollution; asthma; genetics; antioxidants	S-TRANSFERASE M1; ENVIRONMENTAL TOBACCO-SMOKE; DIESEL EXHAUST PARTICLES; INDOOR NITROGEN-DIOXIDE; CHILDHOOD ASTHMA; RESPIRATORY SYMPTOMS; ANTIOXIDANT SUPPLEMENTATION; MEXICO-CITY; OZONE EXPOSURE; LUNG-FUNCTION	The occurrence of asthma and allergic diseases has continued to increase in the United States and worldwide, despite general improvements in air quality over the past 40 years. This observation has led many to question whether air quality is truly a significant risk factor in the development and exacerbation of asthma and whether further improvement in air quality is likely to result in improved health outcomes. However, epidemiologic studies have shown that levels of pollutants of less than the current ambient air quality standards still result in exacerbations of asthma and are associated with other morbidities as well. Specific locations, such as living near a roadway, might pose a special exposure risk. Genetic factors almost certainly play a role in determining susceptibility to pollutants, such as including those involved with antioxidant defenses. The best studied of these in the context of air pollution risks are glutathione-S-transferase polymorphisms. Irrespective of whether pollutants contribute to the development of asthma or the well-documented increases in asthma results in more people having pollutant-induced disease, poor air quality in many places remains a significant problem for patients with asthma and allergic disease. A number of public health, pharmaceutical, and nutriceutical interventions might mitigate the effects of pollutant exposure and deserve further study.	Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC 27599 USA	Peden, DB (reprint author), Univ N Carolina, Sch Med, Ctr Environm Med Asthma & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.	peden@mcd.unc.edu					Alexis NE, 2001, J ALLERGY CLIN IMMUN, V108, P577; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Clancy L, 2002, LANCET, V360, P1210, DOI 10.1016/S0140-6736(02)11281-5; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Davies RJ, 1997, ALLERGY, V52, P59; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Garshick E, 2003, EPIDEMIOLOGY, V14, P728, DOI 10.1097/01.ede.0000082045.50073.66; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823; Gergen PJ, 2001, RESP PHYSIOL, V128, P39, DOI 10.1016/S0034-5687(01)00263-8; GERGEN PJ, 1998, PEDIATRICS, V101, P2; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; HATCH GE, 1995, AM J CLIN NUTR, V61, p625S; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Kalayci O, 2000, TURKISH J PEDIATR, V42, P17; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kongerud J, 2003, INHAL TOXICOL, V15, P101, DOI [10.1080/08958370390168184, 10.1080/08958370304477]; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Mudway IS, 1999, EUR RESPIR J, V13, P1429, DOI 10.1183/09031936.99.13614399; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nightingale JA, 2000, AM J RESP CRIT CARE, V161, P479; Peden DB, 2003, MIDDLETONS ALLERGY P, P515; Peters A, 1996, AM J EPIDEMIOL, V144, P570; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Romieu I, 1998, AM J RESP CRIT CARE, V158, P226; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu I, 2001, EPIDEMIOL REV, V23, P268; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Trapp JF, 1998, CHEST, V113, P505, DOI 10.1378/chest.113.2.505; Trenga CA, 2001, ARCH ENVIRON HEALTH, V56, P242; Vagaggini B, 2001, AM J RESP CRIT CARE, V164, P2172, DOI 10.1164/rccm2009090; van Strien RT, 2004, EPIDEMIOLOGY, V15, P471, DOI 10.1097/01.ede.0000129511.61698.d8; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Whitekus MJ, 2002, J IMMUNOL, V168, P2560	62	81	83	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					213	219		10.1016/j.jaci.2004.12.003		7	Allergy; Immunology	Allergy; Immunology	897YU	WOS:000227043600001	15696070	
J	Singer, BD; Ziska, LH; Frenz, DA; Gebhard, DE; Straka, JG				Singer, BD; Ziska, LH; Frenz, DA; Gebhard, DE; Straka, JG			Increasing Amb a 1 content in common ragweed (Ambrosia artemisiifolia) pollen as a function of rising atmospheric CO2 concentration	FUNCTIONAL PLANT BIOLOGY			English	Article						allergenicity; climate change; public health	PUBLIC-HEALTH; CLIMATE-CHANGE; AEROALLERGENS; ALLERGY; PREVALENCE; MISSOURI; PROTEINS; ANTIGEN; ASTHMA	Although the impact of increasing atmospheric carbon dioxide concentration ([CO2]) on production of common ragweed ( Ambrosia artemisiifolia L.) pollen has been examined in both indoor and outdoor experiments, the relationship between allergen expression and [CO2] is not known. An enzyme-linked immunosorbent assay ( ELISA) was used to quantify Amb a 1, ragweed's major allergen, in protein extracted from pollen of A. artemisiifolia grown at different [CO2] values in a previous experiment. The concentrations used approximated atmospheric pre-industrial conditions (i.e. at the end of the 19th century), current conditions, and the CO2 concentration projected for the middle of the 21st century ( 280, 370 and 600 mu mol mol(-1) CO2, respectively). Although total pollen protein remained unchanged, significant increases in Amb a 1 allergen were observed between pre-industrial and projected future [CO2] and between current and projected future [CO2] (1.8 and 1.6 times, respectively). These data suggest that recent and projected increases in [CO2] could directly increase the allergenicity of ragweed pollen and consequently the prevalence and / or severity of seasonal allergic disease. However, genetic and abiotic factors governing allergen expression will need to be better established to fully understand these data and their implications for public health.	ARS, Crop Syst & Global Change Lab, USDA, Beltsville, MD 20705 USA; Macalester Coll, Dept Biol, St Paul, MN 55105 USA; Multidata LLC, St Louis Pk, MN 55416 USA	ARS, Crop Syst & Global Change Lab, USDA, 10 300 Baltimore Ave, Beltsville, MD 20705 USA.	lziska@asrr.arsusda.gov	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Singer, Benjamin/0000-0001-5775-8427			Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Beggs PJ, 1998, ATMOS ENVIRON, V32, P1777, DOI 10.1016/S1352-2310(97)00466-4; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; CHAPMAN JA, 1986, GRANA, V25, P235; Coca AF, 1922, J IMMUNOL, V7, P163; Engvall E, 1980, Methods Enzymol, V70, P419; Frenz DA, 2001, ANN ALLERG ASTHMA IM, V86, P150; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GOLDFARB AR, 1967, J ALLERGY, V40, P237, DOI 10.1016/0021-8707(67)90086-X; HJELMROOS M, 1995, INT ARCH ALLERGY IMM, V108, P368; Kerim T, 2003, FUNCT PLANT BIOL, V30, P843, DOI 10.1071/FP03100; KNOX RB, 1971, CYTOBIOS, V4, P49; LEE YS, 1979, J ALLERGY CLIN IMMUN, V63, P336, DOI 10.1016/0091-6749(79)90128-3; LEWIS WH, 1975, ANN ALLERGY, V35, P180; MAASCH HJ, 1987, ANN ALLERGY, V58, P429; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; STRAKA JG, 1991, AM J HUM GENET, V48, P72; TSANG VCW, 1983, METHOD ENZYMOL, V92, P391; Wan SQ, 2002, AM J BOT, V89, P1843, DOI 10.3732/ajb.89.11.1843; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Wodehouse R, 1971, HAYFEVER PLANTS; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	24	81	83	3	12	CSIRO PUBLISHING	CLAYTON	UNIPARK, BLDG 1, LEVEL 1, 195 WELLINGTON RD, LOCKED BAG 10, CLAYTON, VIC 3168, AUSTRALIA	1445-4408	1445-4416		FUNCT PLANT BIOL	Funct. Plant Biol.		2005	32	7					667	670		10.1071/FP05039		4	Plant Sciences	Plant Sciences	942TJ	WOS:000230305100009		
J	Sunyer, J; Jarvis, D; Pekkanen, J; Chinn, S; Janson, C; Leynaert, B; Luczynska, C; Garcia-Esteban, R; Burney, P; Anto, JM				Sunyer, J; Jarvis, D; Pekkanen, J; Chinn, S; Janson, C; Leynaert, B; Luczynska, C; Garcia-Esteban, R; Burney, P; Anto, JM		European Comm Resp Health	Geographic variations in the effect of atopy on asthma in the European Community Respiratory Health Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; asthma; attributable fraction; house dust mite; allergens	HOUSE-DUST MITE; BRONCHIAL RESPONSIVENESS; INDIVIDUAL ALLERGENS; SERUM IGE; SENSITIZATION; EXPOSURE; RISK; ASSOCIATION; PREVALENCE; SYMPTOMS	Background: Atopy has long been related to asthma. The prevalences of both atopy and asthma have shown substantial variation. Objective: We sought to assess geographic variations in the fraction of asthma attributable to IgE sensitization to specific allergens in the European Community Respiratory Health Survey. Methods: A cross-sectional study was undertaken during the years 1991 and 1992 on 13,558 individuals in 36 centers in 16 countries. Asthma was defined in several ways, variously incorporating reported symptoms, bronchial responsiveness to methacholine, and physician diagnosis. Specific IgE against house dust mite (Dermatophagoides pteronyssinus), cat, timothy grass, Cladosporium herbarum, and a local allergen (birch, Parietaria judaica, or ragweed) were measured. Results: The overall attributable fraction (AF) of asthma symptoms caused by atopy was 30% but varied widely between centers, ranging from 4% to 61%. The overall AF increased to 43% when asthma was based on wheezing and bronchial responsiveness, to 45% with a physician diagnosis of asthma, and to 48% when the patient reported more than 12 attacks in the last year. Between centers, the AF for atopy was significantly correlated with the prevalence of atopy among the asthmatic patients (r = 0.91) and with the sensitization to house dust mite (r = 0.64), as well as with the prevalence of asthma among atopic individuals (r = 0.43) and the prevalence of asthma among nonatopic individuals (r = -0.51). Conclusion: The effect of atopy on the prevalence of asthma varies widely between centers, probably because of variations in factors related to the expression of asthma and to the prevalence of sensitization, particularly to house dust mite.	UPF, IMIM, Environm Resp Res Unit, Barcelona 08003, Spain; Kings Coll London, Dept Publ Hlth Sci, London, England; Nacl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland; Uppsala Univ, Dept Med Sci Resp Med & Allergol, Uppsala, Sweden; INSERM, Paris, France	Sunyer, J (reprint author), UPF, IMIM, Environm Resp Res Unit, C Doctor Aiguader 80, Barcelona 08003, Spain.	jsunyer@imim.es	Jarvis, Deborah/E-6494-2011; Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110			Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Chinn S, 1999, EUR RESPIR J, V14, P876, DOI 10.1034/j.1399-3003.1999.14d25.x; Chinn S, 1998, THORAX, V53, P662; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Pearce N, 1999, THORAX, V54, P268; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Rockhill B, 1998, AM J PUBLIC HEALTH, V88, P15, DOI 10.2105/AJPH.88.1.15; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, V2nd, P53; Soriano JB, 1999, INT J EPIDEMIOL, V28, P728, DOI 10.1093/ije/28.4.728; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; Sunyer J, 2000, AM J RESP CRIT CARE, V162, P930; WACHOLDER S, 1994, AM J EPIDEMIOL, V140, P303; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460; Zocchetti C, 1997, INT J EPIDEMIOL, V26, P220, DOI 10.1093/ije/26.1.220; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	26	81	81	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2004	114	5					1033	1039		10.1016/j.jaci.2004.05.072		7	Allergy; Immunology	Allergy; Immunology	870HI	WOS:000225047800006	15536406	
J	Ainsworth, DM; Grunig, G; Matychak, MB; Young, J; Wagner, B; Erb, HN; Antczak, DF				Ainsworth, DM; Grunig, G; Matychak, MB; Young, J; Wagner, B; Erb, HN; Antczak, DF			Recurrent airway obstruction (RAO) in horses is characterized by IFN-gamma and IL-8 production in bronchoalveolar lavage cells	VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY			English	Article						cytokine horse; RAO; heaves; t-bet; IFN-gamma	PULMONARY-DISEASE COPD; INTERFERON-GAMMA; PHENOTYPIC ANALYSIS; ANTIBODY-RESPONSES; FLUID LYMPHOCYTES; PERIPHERAL-BLOOD; MESSENGER-RNA; HEAVES HORSES; T-BET; CHEMOKINES	In horses prone to developing recurrent airway obstruction (RAO), we tested the hypotheses that the cytokine profile in the bronchoalveolar lavage (BAL) cells of affected horses would reflect a polarized Th-2 response; that cytokine and chemokine alterations would occur within 24 h of allergen exposure; and that allergen exposure would induce alterations in the expression of the transcription factor t-bet (t-box-expressed in T-cells). The expression levels of interleukin-4 (IL-4), IL-13, Interferongamma (IFN-gamma). t-bet, IL-8 and granulocyte-macrophage colony stimulating factor (GM-CSF) were measured in BAL cells obtained from control and RAO-susceptible horses during an asymptomatic phase and at 24 It and 5 weeks post-stabling and hay exposure. At each sampling time, BAL neutrophil percentages in the RAO-group exceeded controls. In the RAO-group, only IL-13 expression was decreased 2-fold during the asymptomatic phase. No differences in cytokine or chemokine expression were detected during the acute exposure phase. During the chronic phase, IFN-gamma and IL-8 expression levels were 2.5- and 3-fold greater, respectively, in the RAO-group. No other differences in gene expression were detected. We conclude that the cytokine profile of the airway cells does not reflect a polarized Th-2 response; that increases in IFN-gamma result from a t-bet independent pathway and that chemokines from epithelial or interstitial cells may contribute to early neutrophil influx. (C) 2003 Elsevier B.V. All rights reserved.	Cornell Univ, Dept Clin Sci, Coll Vet Med, Ithaca, NY 14853 USA; Columbia Univ, Dept Pathol, New York, NY USA; Cornell Univ, James A Baker Inst Anim Hlth, Coll Vet Med, Ithaca, NY USA; Cornell Univ, Dept Populat Med & Diagnost Sci, Coll Vet Med, Ithaca, NY USA	Ainsworth, DM (reprint author), Cornell Univ, Dept Clin Sci, Coll Vet Med, Ithaca, NY 14853 USA.						Ainsworth DM, 2002, VET IMMUNOL IMMUNOP, V84, P169, DOI 10.1016/S0165-2427(01)00400-7; Ainsworth DM, 2003, VET IMMUNOL IMMUNOP, V91, P61, DOI 10.1016/S0165-2427(02)00274-X; COLOTTA F, 1992, BLOOD, V80, P2012; Davies D E, 2001, Curr Opin Allergy Clin Immunol, V1, P67, DOI 10.1097/00130832-200102000-00012; DERKSEN FJ, 1985, J APPL PHYSIOL, V58, P598; DERKSEN FJ, 1988, AM J VET RES, V49, P933; Eder C, 2000, VET IMMUNOL IMMUNOP, V73, P241, DOI 10.1016/S0165-2427(00)00154-9; Giguere S, 2002, VET IMMUNOL IMMUNOP, V85, P147, DOI 10.1016/S0165-2427(01)00420-2; Grogan JL, 2002, CURR OPIN IMMUNOL, V14, P366, DOI 10.1016/S0952-7915(02)00340-0; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; HALLIWELL REW, 1993, VET IMMUNOL IMMUNOP, V38, P201, DOI 10.1016/0165-2427(93)90081-E; Joubert P, 2001, EQUINE VET J, V33, P730, DOI 10.2746/042516401776249246; Kleiber C, 1999, J VET MED A, V46, P177, DOI 10.1046/j.1439-0442.1999.00210.x; Lavoie JP, 2001, AM J RESP CRIT CARE, V164, P1410; Lukacs NW, 2000, IMMUNOL REV, V177, P21, DOI 10.1034/j.1600-065X.2000.17707.x; MCGORUM BC, 1993, EQUINE VET J, V25, P261; MCGORUM BC, 1993, VET IMMUNOL IMMUNOP, V36, P207, DOI 10.1016/0165-2427(93)90020-5; MCPHERSON EA, 1979, EQUINE VET J, V11, P159; Nelson KM, 1998, VACCINE, V16, P1306, DOI 10.1016/S0264-410X(98)00009-7; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Pirie RS, 2002, EQUINE VET J, V34, P337, DOI 10.2746/042516402776249074; Pirie RS, 2001, EQUINE VET J, V33, P311, DOI 10.2746/042516401776249732; Robinson DS, 2002, IMMUNITY, V16, P755, DOI 10.1016/S1074-7613(02)00331-X; Robinson DS, 2002, CURR BIOL, V12, pR322, DOI 10.1016/S0960-9822(02)00830-8; Robinson N E, 2001, Equine Vet J, V33, P5, DOI 10.2746/042516401776767412; Rush BR, 1998, AM J VET RES, V59, P1033; Schmallenbach KH, 1998, VET IMMUNOL IMMUNOP, V66, P245, DOI 10.1016/S0165-2427(98)00202-5; Sherwood ER, 2001, CLIN SCI, V101, P541, DOI 10.1042/CS20010074; SNAPPER JR, 1986, AM REV RESPIR DIS, V133, P351; Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543; Turlej RK, 2001, THORAX, V56, P696, DOI 10.1136/thorax.56.9.696; Varma TK, 2002, CLIN DIAGN LAB IMMUN, V9, P530, DOI 10.1128/CDLI.9.3.530-543.2002; Watson DB, 1997, IEEE T DIELECT EL IN, V4, P108, DOI 10.1109/94.590877	33	81	81	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-2427			VET IMMUNOL IMMUNOP	Vet. Immunol. Immunopathol.	NOV 15	2003	96	1-2					83	91		10.1016/S0165-2427(03)00142-9		9	Immunology; Veterinary Sciences	Immunology; Veterinary Sciences	733CX	WOS:000185983300009	14522137	
J	Heinrich, J; Holscher, B; Douwes, J; Richter, K; Koch, A; Bischof, W; Fahlbusch, B; Kinne, RW; Wichmann, HE				Heinrich, J; Holscher, B; Douwes, J; Richter, K; Koch, A; Bischof, W; Fahlbusch, B; Kinne, RW; Wichmann, HE		INGA Study Grp	Reproducibility of allergen, endotoxin and fungi measurements in the indoor environment	JOURNAL OF EXPOSURE ANALYSIS AND ENVIRONMENTAL EPIDEMIOLOGY			English	Article						reproducibility; house dust mite; cat; allergen; endotoxin; house dust; fungi	HOUSE-DUST MITE; RESPIRATORY SYMPTOMS; EXTRACELLULAR POLYSACCHARIDES; CULTURABLE FUNGI; 2 CITIES; EXPOSURE; ASTHMA; SENSITIZATION; CHILDREN; GERMANY	Measurements of biocontaminants in settled house dust once a year are commonly used to assess long-term exposure. To examine stability over time and seasonal variation, we measured concentrations of mite and cat allergens, endotoxin and mold spores in living room floor dust in 745 German homes collected twice a year in two different seasons. The study population consisted of adults and children living in five different areas in Germany. All dust samples were collected in a standardized manner from the living room floor and taken during the years 1995 to 1998. The median interval between the two dust samplings was approximately 7 months. Mite and cat allergens were measured in settled house dust by monoclonal antibodies, endotoxin by the limulus amebocyte lysate method, and total spore counts by cultural methods. Crude Pearson's correlation coefficients between log-transformed concentrations in the first and second dust samples ranged between 0.65 and 0.75 for allergens, 0.59 for endotoxin and only 0.06 for total spore counts. The strongest and most consistent seasonal effects were observed for fungi with highest levels in July-September. Cat allergen concentrations were found consistently to be increased in January-March. Mite allergens did not show a strong and consistent seasonal pattern. We conclude that repeated measurements of mite and cat allergens and endotoxin in settled house dust improve the estimate for annual mean concentrations. However, even a single observation of these biocontaminants may be a good proxy for a 1-year exposure since repeated measures were highly correlated. However, repeated measurements of fungi levels were only weakly correlated and thus repeated observations for assessment of annual means of total spore counts are needed.	GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, D-85758 Neuherberg, Germany; Univ Utrecht, Inst Risk Assessment Sci, Div Environm & Occupat Hlth, Utrecht, Netherlands; Grosshansdorf Hosp, Ctr Pneumol & Thorac Surg, Hamburg, Germany; Univ Jena, Dept Indoor Climatol, Erfurt, Germany; Univ Jena, Inst Immunol, D-6900 Jena, Germany; Univ Munich, Dept Epidemiol, Neuherberg, Germany	Heinrich, J (reprint author), GSF, Inst Epidemiol, Natl Res Ctr Environm & Hlth, Ingolstadter Landstr 1, D-85758 Neuherberg, Germany.			Douwes, Jeroen/0000-0003-3599-4036			Altman DG, 1991, PRACTICAL STAT MED R; BISCHOF W, 2002, INDOOR AIR, V121, P2; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; Chew GL, 2001, INDOOR AIR, V11, P171, DOI 10.1034/j.1600-0668.2001.011003171.x; Diggle P. J., 1994, ANAL LONGITUDINAL DA; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Efron B., 1993, INTRO BOOTSTRAP; Fahlbusch B, 1999, ALLERGY, V54, P1215, DOI 10.1034/j.1398-9995.1999.00196.x; FAHLBUSCH B, 2002, J INVEST ALLERG CLIN, V12, P11; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Hastie T, 1990, GEN ADDITIVE MODELS; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; Hirsch T, 1998, ENVIRON HEALTH PERSP, V106, P659; Jacob B, 2002, ENVIRON HEALTH PERSP, V110, P647; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Marks GB, 1995, CLIN EXP ALLERGY, V25, P1190, DOI 10.1111/j.1365-2222.1995.tb03043.x; Martinez FD, 1999, LANCET S2, V354, pSII12; Miyazawa N, 1996, Nihon Rinsho, V54, P2914; MUNIR AKM, 1993, ALLERGY, V48, P158, DOI 10.1111/j.1398-9995.1993.tb00706.x; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Peterson EL, 1999, J ALLERGY CLIN IMMUN, V104, P348, DOI 10.1016/S0091-6749(99)70378-7; PLANSMILLS TA, 1987, J ALLERGY CLIN IMMUN, V79, P781; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Richter K, 2000, RESP MED, V94, P668, DOI 10.1053/rmed.2000.0795; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Su HJ, 2001, ENVIRON RES, V85, P135, DOI 10.1006/enrs.2000.4113	39	81	82	0	1	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1053-4245			J EXPO ANAL ENV EPID	J. Expo. Anal. Environ. Epidemiol.	MAR	2003	13	2					152	160		10.1038/sj.jea.7500267		9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	676HD	WOS:000182744500007	12679795	
J	Webb, JAW; Stacul, F; Thomsen, HS; Morcos, SK				Webb, JAW; Stacul, F; Thomsen, HS; Morcos, SK		Contrast Media Safety Comm ESUR	Late adverse reactions to intravascular iodinated contrast media	EUROPEAN RADIOLOGY			English	Review						iodinated contrast media; late adverse reactions	ALLERGY-LIKE REACTIONS; DELAYED-REACTIONS; INTERLEUKIN-2; HYPERSENSITIVITY; IMMEDIATE; UROGRAPHY; IOPAMIDOL; VASCULITIS; IOXAGLATE; IODIXANOL	Late adverse reactions to intravascular iodinated contrast media are defined as reactions occurring 1 h to 1 week after contrast medium injection. They have received increasing interest over the past decade, but their prevalence remains uncertain and their pathophysiology is not fully understood. The Contrast Media Safety Committee of the European Society of Urogenital Radiology decided to review the literature and to issue guidelines. An extensive literature search was carried out and summarized in a report. Based on the available information, simple guidelines have been drawn up. The report and guidelines were discussed at the 8th European Symposium on Urogenital Radiology in Genoa. Late adverse reactions after intravascular iodinated contrast medium include symptoms such as nausea, vomiting, headache, itching, skin rash, musculoskeletal pain, and fever. A significant proportion of these reactions is unrelated to the contrast medium; however, allergy-like skin reactions are well-documented side effects of contrast media with an incidence of approximately 2%. Late reactions appear to be commoner after nonionic dimers. The majority of late skin reactions after contrast medium exposure are probably T cell-mediated allergic reactions. Patients at increased risk of late skin reactions are those with a history of previous contrast medium reaction and those on interluekin-2 treatment. Most skin reactions are self-limiting and resolve within a week. Management is symptomatic and similar to the management of other drug-induced skin reactions.	Univ Copenhagen, Herlev Hosp, Dept Diagnost Radiol 54E2, DK-2730 Herlev, Denmark; Univ London St Bartholomews Hosp Med Coll, Dept Diagnost Imaging, London EC1A 7BE, England; Osped Cattinara, Inst Radiol, I-34149 Trieste, Italy; No Gen Hosp, Sheffield Teaching Hosp NHS Trust, Dept Diagnost Imaging, Sheffield S5 7AU, S Yorkshire, England	Thomsen, HS (reprint author), Univ Copenhagen, Herlev Hosp, Dept Diagnost Radiol 54E2, DK-2730 Herlev, Denmark.						AKIYAMA M, 1998, ACAD RADIOL S, V5, P159; Bartolucci F, 2000, Radiol Med, V100, P273; BERTRAND P, 1995, ACAD RADIOL, V2, P683, DOI 10.1016/S1076-6332(05)80436-2; BEYERENKE SA, 1993, EUR RADIOL, V3, P237, DOI 10.1007/BF00425901; BIGBY M, 1986, JAMA-J AM MED ASSOC, V256, P3358; Brockow K, 1999, J ALLERGY CLIN IMMUN, V104, P1107; CHOYKE PL, 1992, RADIOLOGY, V183, P111; Christiansen C, 2000, EUR RADIOL, V10, P1965, DOI 10.1007/s003300000543; COCHRAN ST, 1993, ADV XRAY CONTRAST, V1, P61; CONROY RM, 1994, CLIN RADIOL, V49, P337, DOI 10.1016/S0009-9260(05)81801-X; Courvoisier S, 1998, ALLERGY, V53, P1221, DOI 10.1111/j.1398-9995.1998.tb03846.x; FISHMAN JE, 1991, AM J ROENTGENOL, V156, P833; Fransson SG, 1996, ACTA RADIOL, V37, P218; Gall H, 1999, CONTACT DERMATITIS, V40, P248, DOI 10.1111/j.1600-0536.1999.tb06058.x; GOODFELLOW T, 1986, BRIT J RADIOL, V59, P620; HIIGASHI TS, 1990, NIPPON IGAKU HOSHASE, V50, P1359; Hosoya T, 2000, Radiat Med, V18, P39; Kanny G, 2001, EUR J DERMATOL, V11, P134; MCCULLOUGH M, 1989, BRIT J RADIOL, V62, P260; MIKKONEN R, 1995, ACTA RADIOL, V36, P72; Mikkonen R, 2000, ACTA RADIOL, V41, P390; MUNECHIKA H, 1999, EUR RADIOL, V9, P440; NIENDORF HP, 1996, EUR RADIOL S, V6, P8; OLDHAM RK, 1990, J CLIN ONCOL, V8, P942; PANTO PN, 1986, BRIT J RADIOL, V59, P41; Pedersen SH, 1998, ACTA RADIOL, V39, P344; REYNOLDS NJ, 1993, BRIT J DERMATOL, V129, P82, DOI 10.1111/j.1365-2133.1993.tb03317.x; Rosado A, 2001, AM J ROENTGENOL, V176, P262; Rydberg J, 1998, ACTA RADIOL, V39, P219; Sadi Al Muktafi, 1995, Journal of Dermatology (Tokyo), V22, P594; SAVILL JS, 1988, POSTGRAD MED J, V64, P392; Schick E, 1996, CONTACT DERMATITIS, V35, P312, DOI 10.1111/j.1600-0536.1996.tb02403.x; Schild H., 1996, EUR RADIOL, V6, P9; Sedano E, 2001, ALLERGY, V56, P1015, DOI 10.1034/j.1398-9995.2001.00250.x; SHULMAN KL, 1993, J IMMUNOTHER, V13, P208, DOI 10.1097/00002371-199304000-00008; Sutton AGC, 2001, AM HEART J, V141, P677, DOI 10.1067/mhj.2001.113570; UEDA S, 2001, EUR RADIOL, V11, P377; Watanabe H, 1999, DERMATOLOGY, V198, P291, DOI 10.1159/000018133; Yamaguchi Koichi, 1992, Nippon Acta Radiologica, V52, P1565; Yamanouchi K, 1997, J BONE MINER METAB, V15, P23, DOI 10.1007/BF02439451; Yasuda R, 1998, INVEST RADIOL, V33, P1, DOI 10.1097/00004424-199801000-00001; YOSHIKAWA H, 1992, RADIOLOGY, V183, P737; ZUKIWSKI AA, 1990, CANCER, V65, P1521, DOI 10.1002/1097-0142(19900401)65:7<1521::AID-CNCR2820650712>3.0.CO;2-Y	43	81	90	0	2	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.	JAN	2003	13	1					181	184		10.1007/s00330-002-1650-5		4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	643YK	WOS:000180891000026	12541128	
J	Gent, JF; Ren, P; Belanger, K; Triche, E; Bracken, MB; Holford, TR; Leaderer, BP				Gent, JF; Ren, P; Belanger, K; Triche, E; Bracken, MB; Holford, TR; Leaderer, BP			Levels of household mold associated with respiratory symptoms in the first year of life in a cohort at risk for asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; fungi; indoor air; infants; mold; Penicillium; wheezing	FUNGAL EXTRACELLULAR POLYSACCHARIDES; CULTURABLE FUNGI; DUST MITES; INDOOR-AIR; HEALTH; CHILDREN; EXPOSURE; HOMES; DAMP; PREVALENCE	We assessed prospectively the risk of increased incidence of respiratory symptoms after exposure to particular fungal genera in a susceptible population-namely, infants (n = 880) at high risk for developing asthma. Days of wheeze or persistent cough, information on maternal allergy and asthma, socioeconomic variables, and housing characteristics were collected over the course of the infant's first year of life. Exposure to mold was assessed by airborne samples collected at one time early in the infant's life. Fungi were identified to genus level, recorded as colony-forming units per cubic meter (CFU/m(3)), and then categorized into four levels: 0 (undetectable), 1-499 CFU/m(3) (low), 500-999 CFU/m(3) (medium), and 1,000 CFU/m(3) (high). Effects of mold on wheeze and persistent cough, adjusting for potential confounding factors, were examined with Poisson regression analyses. The two most commonly found genera were Cladosporium (in 62% of the homes) and Penicillium (41%). Cladosporium was associated with reported mold (p < 0.02) and water leaks (p < 0.003). Rate of persistent cough was associated with reported mold [Rate ratio (RR) = 1.49; 95% CI, 1.18-1.88]. The highest level of Penicillium was associated with higher rates of wheeze (RR = 2.15; 95% CI, 1.34-3.46) and persistent cough (RR = 2.06; 95% CI, 1.31-3.24) in models controlling for maternal history of asthma and allergy, socioeconomic status, season of mold sample, and certain housing characteristics. We conclude that infants in this high-risk group who are exposed to high levels of Penicillium are at significant risk for wheeze and persistent cough.	Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Yale Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT 06510 USA; New York State Dept Hlth, Albany, NY USA	Gent, JF (reprint author), Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, Yale Ctr Perinatal Pediat & Environm Epidemiol, 1 Church St,6th Floor, New Haven, CT 06510 USA.		Triche, Elizabeth/I-4986-2014		NIEHS NIH HHS [ES05410, ES07456]		Al-Doory Y., 1984, MOULD ALLERGY; Allison PD, 1999, LOGISTIC REGRESSION; BEAUMONT F, 1984, ANN ALLERGY, V53, P486; *CEC, 1994, 12 CEC COMM EUR COMM; Chew GL, 2001, INDOOR AIR, V11, P171, DOI 10.1034/j.1600-0668.2001.011003171.x; Dales RE, 1999, MYCOPATHOLOGIA, V147, P21, DOI 10.1023/A:1007096704217; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65; Dill I, 1996, PEDIATR ALLERGY IMMU, V7, P151, DOI 10.1111/j.1399-3038.1996.tb00123.x; Dillon HK, 1999, ENVIRON HEALTH PERSP, V107, P473; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; Larone D. H., 1987, MED IMPORTANT FUNGI; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; Ortega AN, 2001, ANN ALLERG ASTHMA IM, V86, P405; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; PLATT SD, 1989, BRIT MED J, V298, P1673; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; *SAS I INC, 2001, VERS 8; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; Su HJ, 2001, ENVIRON RES, V85, P135, DOI 10.1006/enrs.2000.4113; Su HJJ, 2001, ARCH ENVIRON HEALTH, V56, P144; VANDERWERFF PJ, 1958, MOULD FUNGI BRONCHIA; VERHOEFF AP, 1990, ALLERGY, V45, P275, DOI 10.1111/j.1398-9995.1990.tb00496.x; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x	31	81	82	1	5	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	DEC	2002	110	12					A781	A786				6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	625HG	WOS:000179810600034	12460818	
J	Booth, BW; Adler, KB; Bonner, JC; Tournier, F; Martin, LD				Booth, BW; Adler, KB; Bonner, JC; Tournier, F; Martin, LD			Interleukin-13 induces proliferation of human airway epithelial cells in vitro via a mechanism mediated by transforming growth factor-alpha	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							FACTOR-RECEPTOR; IN-VITRO; EGF-RECEPTOR; EXPRESSION; INJURY; RATS; ASTHMA; LUNG	Remodeling of the airways, as occurs in asthmatic patients, is associated with the continual presence of inflammatory mediators and Th2 cytokines, especially interleukin (IL)-13, during cycles of epithelial injury and repair. In this study, we examined the effect of IL-13 on well-differentiated normal human bronchial epithelial (NHBE) cells maintained in air-liquid interface culture. IL-13 induced proliferation of NHBE cells after 24 h exposure, as reflected by [H-3]thymidine uptake and cell counts. The effects of IL-13 were mediated through the epidermal growth factor receptor (EGFR), as proliferation was attenuated by AG1478, an EGFR tyrosine kinase inhibitor. Proliferation appeared to be mediated by transforming growth factor (TGF)-alpha, a potent ligand for EGFR, which was released rapidly from NHBE cells in response to IL-13. Neutralizing antibody to TGF-alpha, but not antibodies against other potentially important growth factors (EGF, heparin binding epidermal growth factor-like growth factor [HB-EGF], platelet-derived growth factor [PDGF]), inhibited the mitogenic response to IL-13. This study provides the first experimental evidence that IL-13 can initiate a proliferative response of human airway epithelium in the absence of inflammatory cells or other cell types. The results are consistent with a mechanism whereby IL-13 induces release of TGF-alpha from the epithelial cells, which in turn binds via an autocrine/paracrine-type action to the EGFR, initiating proliferation. IL-13-induced airway remodeling in vivo may involve this epithelium-driven response.	N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA; NIEHS, Res Triangle Pk, NC 27709 USA; Univ Paris 07, Lab Cytophysiol & Toxicol Cellulaire, Paris, France	Martin, LD (reprint author), N Carolina State Univ, Coll Vet Med, Dept Anat Physiol Sci & Radiol, Raleigh, NC 27606 USA.				NHLBI NIH HHS [HL66236, HL36982]		Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253; Barth PJ, 2000, VIRCHOWS ARCH, V437, P648, DOI 10.1007/s004280000316; BATES SE, 1990, ENDOCRINOLOGY, V126, P596; BOOTH B, 2001, AM J RESP CRIT CARE, V163, pA738; COFFEY RJ, 1992, YALE J BIOL MED, V65, P693; Dignass AU, 1996, GUT, V38, P687, DOI 10.1136/gut.38.5.687; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747; Farbman AI, 1996, J NEUROBIOL, V30, P267, DOI 10.1002/(SICI)1097-4695(199606)30:2<267::AID-NEU8>3.0.CO;2-3; Fischer BM, 1999, AM J RESP CELL MOL, V20, P413; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HAUGEN DRF, 1993, INT J CANCER, V55, P37, DOI 10.1002/ijc.2910550108; Huang ZW, 1996, FOLD DES, V1, P13, DOI 10.1016/S1359-0278(96)00007-7; JANKOWSKI J, 1993, DIGEST DIS, V11, P1, DOI 10.1159/000171396; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685; Longphre M, 1999, J APPL PHYSIOL, V86, P341; MADTES DK, 1994, AM J RESP CELL MOL, V11, P540; MARTIN L, 2000, AM J RESP CRIT CARE, V161, pA779; Partik G, 1999, J CANCER RES CLIN, V125, P379, DOI 10.1007/s004320050290; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Rice AB, 1999, AM J PATHOL, V155, P213, DOI 10.1016/S0002-9440(10)65115-2; Riese DJ, 1996, J BIOL CHEM, V271, P20047; SHERWOOD E, 1993, WORLD J UROL, V13, P290; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134; STRANDJORD TP, 1995, PEDIATR RES, V38, P851, DOI 10.1203/00006450-199512000-00005; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Vesely KR, 1999, AM J RESP CELL MOL, V20, P699; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Winkle LS, 1997, AM J PATHOL, V151, P443; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; ZIOBER BL, 1993, J BIOL CHEM, V268, P691	31	81	83	0	3	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	DEC	2001	25	6					739	743				5	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	505MD	WOS:000172915800013	11726400	
J	McCall, C; Hunter, S; Stedman, K; Weber, E; Hillier, A; Bozic, C; Rivoire, B; Olivry, T				McCall, C; Hunter, S; Stedman, K; Weber, E; Hillier, A; Bozic, C; Rivoire, B; Olivry, T			Characterization and cloning of a major high molecular weight house dust mite allergen (Der f 15) for dogs	VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY			English	Article						atopic dermatitis; mite allergen; allergen; dog; IgE	DERMATOPHAGOIDES-FARINAE; IGE; CANINE; REACTIVITY; CHITINASES; EXTRACTS; PROTEIN; FAMILY; SITES	Although house dust mites (HDM(s)) are important elicitors of canine allergy, the low molecular weight molecules defined as major allergens for humans do not appear to be major allergens for dogs. Western blotting of Dermatophagoides farinae (D. farinae) extracts with sera from sensitized dogs showed that the majority of animals had IgE antibodies specific for two proteins of apparent molecular weights of 98 and 109 kDa (98/109 kDa). The N-terminal sequences of these two proteins were identical, suggesting they were very closely related, and sequencing of internal peptides showed the protein(s) to have homology with insect chitinases. A purified preparation of 98/109 kDa proteins elicited positive intradermal skin tests (IDST(s)) in a group of well-characterized atopic dogs sensitized to D. farinae, but not in normal dogs. A rabbit polyclonal antiserum raised against the purified proteins was used to immunoscreen a D. farinae cDNA library. The mature coding region of the isolated chitinase cDNA predicts a protein of 63.2 kDa; sequence analysis and glycan detection blotting suggest that the molecule is extensively O-glycosylated. Monoclonal antibodies made against the purified native protein were used to localize the chitinase in sections of whole D. farinae mites. The protein displayed an intracellular distribution in the proventriculus and intestine of the mite, suggesting that it has a digestive, rather than a moulting-related, function. The high prevalence of IgE antibodies to this antigen in canine atopic dermatitis makes it a major HDM allergen for dogs, and the protein has been formally designated Der f 15. (C) 2001 Elsevier Science B.V. All rights reserved.	Heska Corp, Ft Collins, CO 80525 USA; Ohio State Univ, Coll Vet Med, Dept Vet Clin Sci, Columbus, OH 43210 USA; N Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC USA	McCall, C (reprint author), Heska Corp, 1825 Sharp Point Dr, Ft Collins, CO 80525 USA.		Hillier, Andrew/C-9159-2012; Olivry, Thierry/E-3289-2013				ATTSCHUL SF, 1990, J MOL BIOL, V215, P403; Baldo B.A., 1989, Advances in the Biosciences, V74, P13; Bard J., 1992, P 2 WORLD C VET DERM; BEVIER DE, 1997, CLIN ADV SUPPLEMENT, V3, P10; CHARACH M, 1993, P 9 ANN M AAVD ACVD, P50; CODNER EC, 1995, J AM VET MED ASSOC, V206, P812; de la Vega H, 1998, INSECT MOL BIOL, V7, P233; Esch RE, 1997, P ANN M AM AC VET DE, P87; Fujimura K, 1996, IEEE ROBOT AUTOM MAG, V3, P33, DOI 10.1109/100.486659; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HANSEN JE, 1995, BIOCHEM J, V308, P801; Kramer KJ, 1997, INSECT BIOCHEM MOLEC, V27, P887, DOI 10.1016/S0965-1748(97)00078-7; Lian TM, 1998, VET IMMUNOL IMMUNOP, V66, P203, DOI 10.1016/S0165-2427(98)00199-8; Le Mao J, 1998, J ALLERGY CLIN IMMUN, V102, P631; Masuda K, 1999, VET IMMUNOL IMMUNOP, V72, P303, DOI 10.1016/S0165-2427(99)00142-7; MCCALL CA, 1997, CLIN ADV SUPPLEMENT, V3, P24; Noli C, 1996, VET IMMUNOL IMMUNOP, V52, P147, DOI 10.1016/0165-2427(96)05550-X; Reedy LM, 1997, ALLERGIC SKIN DIS DO; Rodriguez J.G., 1987, P345; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STURE GH, 1995, VET IMMUNOL IMMUNOP, V44, P293, DOI 10.1016/0165-2427(94)05306-D; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; TOVEY ER, 1987, J ALLERGY CLIN IMMUN, V79, P93, DOI 10.1016/S0091-6749(87)80022-2; Tsai LC, 1998, J ALLERGY CLIN IMMUN, V102, P295, DOI 10.1016/S0091-6749(98)70099-5; Wassom DL, 1998, VET DERMATOL, V9, P173; Watanabe T, 1997, ZOOL SCI, V14, P65, DOI 10.2108/zsj.14.65	26	81	84	1	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-2427			VET IMMUNOL IMMUNOP	Vet. Immunol. Immunopathol.	FEB 10	2001	78	3-4					231	247		10.1016/S0165-2427(00)00258-0		17	Immunology; Veterinary Sciences	Immunology; Veterinary Sciences	423FL	WOS:000168164700002	11292526	
J	Reijonen, TM; Kotaniemi-Syrjanen, A; Korhonen, K; Korppi, M				Reijonen, TM; Kotaniemi-Syrjanen, A; Korhonen, K; Korppi, M			Predictors of asthma three years after hospital admission for wheezing in infancy	PEDIATRICS			English	Article						asthma; atopy; budesonide; child; cromlyn sodium; follow-up study; infant; immunoglobulin E; respiratory syncytial virus; risk factors; sensitization; wheezing; virus diseases	RESPIRATORY SYNCYTIAL VIRUS; ENVIRONMENTAL RISK-FACTORS; ACUTE VIRAL BRONCHIOLITIS; FOLLOW-UP; LUNG-FUNCTION; BRONCHIAL-ASTHMA; CHILDHOOD ASTHMA; IMMUNOGLOBULIN-E; HAY-FEVER; CHILDREN	Objective. To evaluate the influence of early antiinflammatory therapy in the development of asthma 3 years after hospitalization for wheezing in infancy. In addition, the effects of allergic sensitization and respiratory syncytial virus (RSV) infection on the development of asthma were investigated. Design and Setting. A randomized, controlled follow-up study in a university hospital that provides primary hospital care for all pediatric patients in a defined area. Patients. Eighty-nine infants under 2 years of age who had been hospitalized for infection associated with wheezing and followed up for 3 years. Intervention. Early antiinflammatory therapy was given for 16 weeks; 29 patients received cromolyn sodium and 31 received budesonide. Twenty-nine control patients received no therapy. Outcome Measures. Clinical diagnosis of current asthma, defined as having at least 3 episodes of physician-diagnosed wheezing and either a wheezing episode during the preceding year or ongoing antiinflammatory medication for asthma. Results. Fourteen (48%) patients in the former cromolyn group, 15 (48%) in the former budesonide group, and 16 (55%) in the control group had current asthma. The significant predictors of asthma were age over 12 months (risk ratio [RR] 4.1; 95% confidence interval [CI] = 1.59-10.35), history of wheezing (RR 6.8; CI = 1.35-34.43), and atopic dermatitis on study entry (RR 3.4; CI = 1.17-9.39). Skin prick test positivity at the age of 16 months significantly predicted asthma (RR 9.5; CI = 2.45-36.72). In addition, all of the 18 (20%) children sensitized with furred pet developed asthma. RSV identification (RR 0.3; CI = 0.08-0.80) and early furred pet contact at home (RR 0.3; CI 0.10-0.79) were associated with the decreased occurrence of asthma. Conclusions. Antiinflammatory therapy for 4 months has no influence on the occurrence of asthma 3 years after wheezing in infancy. Early sensitization to indoor allergens, especially to pets, and atopic dermatitis predict subsequent development of asthma. RSV infection in wheezing infants may have a better outcome than other infections.	Kuopio Univ Hosp, Dept Pediat, FIN-70211 Kuopio, Finland	Reijonen, TM (reprint author), Kuopio Univ Hosp, Dept Pediat, Box 1777, FIN-70211 Kuopio, Finland.						Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; DELACOURT C, 1994, ALLERGY, V49, P837; [Anonymous], 1993, ALLERGY, V48, P48; Fox GF, 1999, ARCH DIS CHILD, V80, P343; GERN JE, 1994, J CLIN INVEST, V94, P2200; HALKEN S, 1991, ALLERGY, V46, P507, DOI 10.1111/j.1398-9995.1991.tb00613.x; HENRY RL, 1983, ARCH DIS CHILD, V58, P713; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Korhonen K, 1999, EUR RESPIR J, V13, P82; KORPPI M, 1993, AM J DIS CHILD, V147, P628; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079; KUIKKA L, 1994, ACTA PAEDIATR, V83, P744, DOI 10.1111/j.1651-2227.1994.tb13131.x; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Merth IT, 1996, AM J RESP CRIT CARE, V154, P689; NORMAN E, 1994, ALLERGY, V49, P808; PRICE GW, 1995, J ALLERGY CLIN IMMUN, V96, P266, DOI 10.1016/S0091-6749(95)70020-X; Rakes CP, 1999, AM J RESP CRIT CARE, V159, P785; Reijonen T, 1996, ARCH PEDIAT ADOL MED, V150, P512; Reijonen TM, 1997, PEDIATR PULM, V24, P35, DOI 10.1002/(SICI)1099-0496(199707)24:1<35::AID-PPUL6>3.0.CO;2-I; Reijonen TM, 1998, PEDIATR PULM, V26, P113, DOI 10.1002/(SICI)1099-0496(199808)26:2<113::AID-PPUL7>3.0.CO;2-N; REIJONEN TM, 1997, EARLY CHILDHOOD WHEE, V135, P57; SAARINEN UM, 1982, ACTA PAEDIATR SCAND, V71, P489, DOI 10.1111/j.1651-2227.1982.tb09457.x; SIGURS N, 1995, PEDIATRICS, V95, P500; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stevenson EC, 1997, CLIN EXP ALLERGY, V27, P1027, DOI 10.1111/j.1365-2222.1997.tb01254.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; WENNERGREN G, 1992, ACTA PAEDIATR, V81, P40, DOI 10.1111/j.1651-2227.1992.tb12076.x; WILSON NM, 1992, ARCH DIS CHILD, V67, P491; Wilson NM, 1997, EUR RESPIR J, V10, P346, DOI 10.1183/09031936.97.10020346; YOUNG S, 1995, ARCH DIS CHILD, V72, P16; ZAR JH, 1984, BIOSTAT ANAL, P402; ZWEIMAN B, 1966, J ALLERGY, V37, P48, DOI 10.1016/0021-8707(66)90109-2	35	81	86	0	1	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	DEC	2000	106	6					1406	1412		10.1542/peds.106.6.1406		7	Pediatrics	Pediatrics	383ZP	WOS:000165914800030	11099596	
J	Petsonk, EL; Wang, ML; Lewis, DM; Siegel, PD; Husberg, BJ				Petsonk, EL; Wang, ML; Lewis, DM; Siegel, PD; Husberg, BJ			Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate	CHEST			English	Article						asthma; diisocyanates; occupational asthma; respiratory protection; skin exposure; wood products	OCCUPATIONAL ASTHMA; SURVEILLANCE SYSTEM; ISOCYANATES; METHACHOLINE; POPULATION; CHALLENGE; RESPONSES; DISEASES; MDI	Background: Diisocyanates, a group of highly reactive chemicals, have frequently been associated with occupational asthma. We evaluated respiratory health in workers at a new wood products manufacturing plant that uses methylene diphenyl diisocyanate (MDI), and was designed and operated with a goal of minimizing worker exposures, Methods: Health surveys using standardized respiratory questionnaires were done prior to the initial use of diisocyanates in the plant, and semiannually thereafter for a period of 2 years. Other testing included occupational and work practice histories, serial peak flow measurements, spirometry, methacholine challenge, and measurement of specific IgE antibodies to MDI-albumin conjugate. Results: Of 214 plant employees who participated in at least one health survey, a follow-up survey was also available from 178 employees (83%). New-onset asthma-like symptoms (NAS) were reported by 15 of 56 workers (27%) in areas with the highest potential for exposures to liquid MDI monomer and prepolymer, vs 0 of 43 workers in the lowest potential exposure areas (p = 0.001). In the areas with high potential exposure, NAS developed in 47% of workers who had noted MDI skin staining, vs 19% without skin stains (p = 0.07), Working around and cleaning up liquid MDI represented a significant risk for asthma-like symptoms in both current smokers and nonsmokers; work with finished wood products did not. Asthma-like symptoms were associated with variable airflow limitation (odds ratio [OR], 5.0; confidence interval [CI], 1.4 to 18.7) and specific IgE to MDI-albumin (OR, 3.2; CI, 1.1 to 9.0), but not with skin prick tests to common aeroallergens (OR, 1.1; CI, 0.5 to 2.7), Conclusions: During the first 2 years of operation, in a plant designed and operated to control exposure to diisocyanates, the development of asthma-like symptoms was reported in a relatively high proportion of the employees who worked with liquid MDI. To prevent asthma symptoms among workers, careful control of respiratory tract exposures associated with liquid MDI is important, especially during cleanup activities. Strict limitation of skin contact with diisocyanates may also be necessary.	NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA; NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA	Petsonk, EL (reprint author), NIOSH, Div Resp Dis Studies, 1095 Willowdale Rd, Morgantown, WV 26505 USA.						American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Baur X, 1998, AM J IND MED, V33, P114; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Bernstein JA, 1996, TOXICOLOGY, V111, P181, DOI 10.1016/0300-483X(96)03375-6; BURGE PS, 1992, BRIT MED BULL, V48, P221; BURNEY PGJ, 1987, CHEST, V91, P79; CHATHAM M, 1982, CHEST, V82, P15, DOI 10.1378/chest.82.1.15; Deschamps F, 1998, ANN OCCUP HYG, V42, P33, DOI 10.1016/S0003-4878(97)00047-1; Fabri G, 1997, J INVEST ALLERG CLIN, V7, P377; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; GANNON PFG, 1993, BRIT J IND MED, V50, P791; HAMILTON RG, 1992, MANUAL CLIN LAB IMMU, P689; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Lebowitz MD, 1997, EUR RESPIR J, V24, p49S; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MALO JL, 1995, OCCUPATIONAL ENV RES, P420; MUSK AW, 1982, J OCCUP ENVIRON MED, V24, P746; *NAT I OCC SAF HLT, 1996, DHEW PUBL NAT I OCC; *NAT I OCC SAF HLT, 1978, DHEW PUBL NAT I OCC; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; Provencher S, 1997, OCCUP ENVIRON MED, V54, P272; QUACKENBOSS JJ, 1991, AM REV RESPIR DIS, V143, P323; RATTRAY NJ, 1994, TOXICOLOGY, V88, P15, DOI 10.1016/0300-483X(94)90108-2; Raulf-Heimsoth N, 1998, AM J IND MED, V34, P137; Redlich CA, 1996, CHEST, V109, pS6, DOI 10.1378/chest.109.3_Supplement.6S; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; TARLO SM, 1995, CHEST, V107, P634, DOI 10.1378/chest.107.3.634; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P1287; Woellner RC, 1997, AM J IND MED, V31, P56	33	81	81	1	5	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	OCT	2000	118	4					1183	1193		10.1378/chest.118.4.1183		15	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	366MC	WOS:000090008300047	11035694	
J	Hofstra, WB; Neijens, HJ; Duiverman, EJ; Kouwenberg, JM; Mulder, PGH; Kuethe, MC; Sterk, PJ				Hofstra, WB; Neijens, HJ; Duiverman, EJ; Kouwenberg, JM; Mulder, PGH; Kuethe, MC; Sterk, PJ			Dose-responses over time to inhaled fluticasone propionate treatment of exercise- and methacholine-induced bronchoconstriction in children with asthma	PEDIATRIC PULMONOLOGY			English	Article						exercise-induced asthma; bronchial hyperresponsiveness; inhaled corticosteroids; fluticasone propionate; eosinophil cationic protein; randomized clinical trial; children	WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; CATIONIC PROTEIN ECP; BRONCHIAL HYPERRESPONSIVENESS; LUNG-FUNCTION; AIRWAY RESPONSIVENESS; OFFICIAL STATEMENT; TERM TREATMENT; MILD ASTHMA; BUDESONIDE	When treating bronchial hyperresponsiveness to so-called direct and indirect stimuli, distinct pathophysiological mechanisms might require differences in dose and duration of inhaled corticosteroid therapy. To test this hypothesis in children with asthma, we investigated the time- and dose-dependent effects of 2 doses of fluticasone propionate (FP, 100 or 250 mu g bid.) in improving exercise- (EIB) and methacholine-induced bronchoconstriction during 6 months of treatment, using a placebo-controlled parallel group study design. Thirty-seven children with asthma (aged 6 to 14 years; forced expired volume in 1 sec (FEV1) greater than or equal to 70% predicted; EIB greater than or equal to 20% fall in FEV1 from baseline; no inhaled steroids during the past 4 months) participated in a double-blind, placebo-controlled, 3-arm parallel study. Children receiving placebo were rerandomized to active treatment after 6 weeks. Standardized dry air treadmill exercise testing (EIB expressed as %fall in FEV1 from baseline) and methacholine challenge using a dosimetric technique (expressed as PD20) were performed repeatedly during the study. During FP-treatment, the severity of EIB decreased significantly as compared to placebo within 3 weeks, the geometric mean % fall in FEV1 being reduced from 34.1% to 9.9% for 100 mu g FP bid, and from 35.9% to 7.6% for 250 mu g FP bid (P < 0.05). These reductions in EIB did not differ between the 2 doses and were sustained throughout the treatment period. PD20 methacholine improved significantly during the first 6 weeks as compared to placebo (P < 0.04) and steadily increased with time in both treatment limbs (P = 0.04), the difference in improvement between doses (100 mu g FP bid, 1.6 dose steps; 250 mu g FP bid, 3.3 dose steps) approaching significance after 24 weeks (P = 0.06). We conclude that in childhood asthma, the protection afforded by inhaled fluticasone propionate against methacholine-induced bronchoconstriction is time- and dose-dependent, whereas protection against EIB is not. This suggests different modes of action of inhaled steroids in protecting against these pharmacological and physiological stimuli. This has to be taken into account when monitoring asthma treatment. (C) 2000 Wiley-Liss, Inc.	Univ Groningen Hosp, Beatrix Childrens Hosp, Acad Hosp, Dept Pediat Pulm, NL-9700 RB Groningen, Netherlands; Juliana Childrens Hosp, Dept Pulm Pediat, The Hague, Netherlands; Sophia Childrens Hosp, Rotterdam, Netherlands; Erasmus Univ, Sch Med, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; T Lange Land Ziekenhuis Zoetermeer, Dept Pediat, Zoetermeer, Netherlands; Leiden Univ, Med Ctr, Dept Pulm Dis, Leiden, Netherlands	Duiverman, EJ (reprint author), Univ Groningen Hosp, Beatrix Childrens Hosp, Acad Hosp, Dept Pediat Pulm, POB 30-001, NL-9700 RB Groningen, Netherlands.						BARNES PJ, 1998, J ALLERGY CLIN IMMUN, V101, P427; Benckhuijsen J, 1996, PEDIATR PULM, V22, P147, DOI 10.1002/(SICI)1099-0496(199609)22:3<147::AID-PPUL2>3.0.CO;2-M; Calpin C, 1997, J ALLERGY CLIN IMMUN, V100, P452; Carlsen KH, 1996, CLIN EXP ALLERGY, V26, P8, DOI 10.1111/j.1365-2222.1996.tb00662.x; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910; DUIVERMAN EJ, 1986, B EUR PHYSIOPATH RES, V22, P433; EGGLESTON PA, 1976, J ALLERGY CLIN IMMUN, V58, P414, DOI 10.1016/0091-6749(76)90122-6; FERGUSON AC, 1992, J ALLERGY CLIN IMMUN, V90, P609, DOI 10.1016/0091-6749(92)90133-M; FITCH KD, 1986, ANN ALLERGY, V57, P90; GODFREY S, 1993, RESP MED, V87, P331, DOI 10.1016/0954-6111(93)90046-3; GREIFF L, 1994, EUR RESPIR J, V7, P1120; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; Hoekx JCM, 1996, EUR RESPIR J, V9, P2263, DOI 10.1183/09031936.96.09112263; Hofstra WB, 1997, THORAX, V52, P739; Holgate ST, 1996, CLIN EXP ALLERGY, V26, P1; Jonasson G, 1998, EUR RESPIR J, V12, P1099, DOI 10.1183/09031936.98.12051099; KERSTJENS HAM, 1992, NEW ENGL J MED, V327, P1413, DOI 10.1056/NEJM199211123272003; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; MAKKER HK, 1994, EUR J CLIN INVEST, V24, P571, DOI 10.1111/j.1365-2362.1994.tb01109.x; MERKUS PJFM, 1992, THORAX, V47, P355, DOI 10.1136/thx.47.5.355; *NHBLI WHO, 1995, NIH PUBL; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864; PAUWELS R, 1988, CLIN ALLERGY, V18, P317, DOI 10.1111/j.1365-2222.1988.tb02878.x; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; Pedersen S, 1997, CLIN EXP ALLERGY, V27, P995, DOI 10.1111/j.1365-2222.1997.tb01247.x; PETERSON CGB, 1991, CLIN EXP ALLERGY, V21, P561, DOI 10.1111/j.1365-2222.1991.tb00847.x; QUANJER PH, 1993, EUR RESPIR J, V6, P5; Selroos O, 1996, CLIN IMMUNOTHER, V6, P273; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; Turktas I, 1996, ARCH DIS CHILD, V75, P314; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; VENGE P, 1991, J ALLERGY CLIN IMMUN, V88, P699, DOI 10.1016/0091-6749(91)90175-N; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879; Zapletal A, 1987, PROG RESPIR RES, V22, P83	41	81	82	2	6	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	JUN	2000	29	6					415	423		10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7		9	Pediatrics; Respiratory System	Pediatrics; Respiratory System	317EZ	WOS:000087214200001	10821721	
J	Jaakkola, JJK; Verkasalo, PK; Jaakkola, N				Jaakkola, JJK; Verkasalo, PK; Jaakkola, N			Plastic wall materials in the home and respiratory health in young children	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							BRONCHIAL OBSTRUCTION; SYMPTOMS; ASTHMA	Objectives, The relation between the presence of plastic wall materials in the home and respiratory health in children was assessed. Methods. This population-based cross-sectional study involved 2568 Finnish children aged 1 to 7 years. Results. In logistic regression models, lower respiratory tract symptoms-persistent wheezing (adjusted odds ratio [OR] = 3.42, 95% confidence interval [CI] = 1.13, 10.36), cough (OR=2.41, 95% CI = 1.04, 5.63), and phlegm (OR= 2.76, 95% Cf = 1.03, 7.41)-were strongly related to the presence of plastic wall materials, whereas upper respiratory symptoms were not. The risk of asthma (OR = 1.52, 95% CI = 0.35, 6.71) and pneumonia (OR= 1.81, 95% CI = 0.62, 5.29) was also increased in children exposed to such materials. Conclusions. Emissions from plastic materials indoors may have adverse effects on the lower respiratory tracts of small children.	Nord Sch Publ Hth, SE-402421 Gothenburg, Sweden; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Univ Oxford, Imperial Canc Res Fund, Canc Epidemiol Unit, Oxford, England; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, FIN-00014 Helsinki, Finland	Jaakkola, JJK (reprint author), Nord Sch Publ Hth, Box 12133, SE-402421 Gothenburg, Sweden.	jouni.jaakkola@nhv.se	Jaakkola, Jouni/G-4314-2012				Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; SAARELA K, 1989, INT CONGR SER, V860, P329; TIMONEN KL, 1995, EUR RESPIR J, V8, P1155, DOI 10.1183/09031936.95.08071155	7	81	83	0	6	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	MAY	2000	90	5					797	799		10.2105/AJPH.90.5.797		3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	308VN	WOS:000086733700025	10800434	
J	Thornton, EE; Looney, MR; Bose, O; Sen, D; Sheppard, D; Locksley, R; Huang, XZ; Krummel, MF				Thornton, Emily E.; Looney, Mark R.; Bose, Oishee; Sen, Debasish; Sheppard, Dean; Locksley, Richard; Huang, Xiaozhu; Krummel, Matthew F.			Spatiotemporally separated antigen uptake by alveolar dendritic cells and airway presentation to T cells in the lung	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							TIGHT JUNCTION PROTEINS; DUST MITE ALLERGEN; IN-VIVO; IMMUNE-SYSTEM; LYMPH-NODE; 2-PHOTON MICROSCOPY; RESPIRATORY-TRACT; CHRONIC ASTHMA; ATOPIC ASTHMA; MOUSE	Asthma pathogenesis is focused around conducting airways. The reasons for this focus have been unclear because it has not been possible to track the sites and timing of antigen uptake or subsequent antigen presentation to effector T cells. In this study, we use two-photon microscopy of the lung parenchyma and note accumulation of CD11b(+) dendritic cells (DCs) around the airway after allergen challenge but very limited access of these airway-adjacent DCs to the contents of the airspace. In contrast, we observed prevalent transepithelial uptake of particulate antigens by alveolar DCs. These distinct sites are temporally linked, as early antigen uptake in alveoli gives rise to DC and antigen retention in the airway-adjacent region. Antigen-specific T cells also accumulate in the airway-adjacent region after allergen challenge and are activated by the accumulated DCs. Thus, we propose that later airway hyperreactivity results from selective retention of allergen-presenting DCs and antigen-specific T cells in airway-adjacent interaction zones, not from variation in the abilities of individual DCs to survey the lung.	[Thornton, Emily E.; Bose, Oishee; Sen, Debasish; Krummel, Matthew F.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA; [Looney, Mark R.] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Sheppard, Dean; Huang, Xiaozhu] Univ Calif San Francisco, Lung Biol Ctr, San Francisco, CA 94143 USA; [Looney, Mark R.; Sheppard, Dean; Huang, Xiaozhu] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Locksley, Richard] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	Krummel, MF (reprint author), Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94143 USA.	matthew.krummel@ucsf.edu		Sen, Debasish/0000-0001-9879-8345; Thornton, Emily/0000-0002-0068-2502	National Science Foundation; Strategic Asthma Basic Research; American Asthma Foundation; National Institutes of Health [P01 HL024136]	This work was supported by the National Science Foundation graduate research fellowship program, the Strategic Asthma Basic Research, the American Asthma Foundation, and the National Institutes of Health (grant P01 HL024136).	AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Ballesteros-Tato A, 2010, NAT IMMUNOL, V11, P216, DOI 10.1038/ni.1838; Belz GT, 2004, P NATL ACAD SCI USA, V101, P8670, DOI 10.1073/pnas.0402644101; Bergner A, 2003, J APPL PHYSIOL, V95, P1325, DOI 10.1152/japplphysiol.00272.2003; Bergner A, 2002, J GEN PHYSIOL, V119, P187, DOI 10.1085/jgp.119.2.187; Blank F, 2007, AM J RESP CELL MOL, V36, P669, DOI 10.1165/rcmb.2006-0234OC; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Bullen A, 2009, CURR TOP MICROBIOL, V334, P1, DOI 10.1007/978-3-540-93864-4_1; Byersdorfer CA, 2001, J IMMUNOL, V167, P6756; Cahalan MD, 2008, ANNU REV IMMUNOL, V26, P585, DOI 10.1146/annurev.immunol.24.021605.090620; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; DANDURAND RJ, 1993, J APPL PHYSIOL, V75, P364; Delmotte P, 2006, AM J RESP CELL MOL, V35, P110, DOI 10.1165/rcmb.2005-0417OC; Desch AN, 2011, J EXP MED, V208, P1789, DOI 10.1084/jem.20110538; Germain RN, 2006, NAT REV IMMUNOL, V6, P497, DOI 10.1038/nri1884; Grayson MH, 2007, J IMMUNOL, V179, P1438; Hadjantonakis Anna-Katerina, 2002, BMC Biotechnol, V2, P11, DOI 10.1186/1472-6750-2-11; HAMILTONEASTON A, 1995, J VIROL, V69, P6359; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Holt Patrick G, 2005, Proc Am Thorac Soc, V2, P116, DOI 10.1513/pats.200502-017AW; Jahnsen FL, 2006, J IMMUNOL, V177, P5861; Jakubzick C, 2008, J IMMUNOL METHODS, V337, P121, DOI 10.1016/j.jim.2008.07.005; Jakubzick C, 2006, J IMMUNOL, V176, P3578; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998; Kreisel D, 2010, P NATL ACAD SCI USA, V107, P18073, DOI 10.1073/pnas.1008737107; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lindquist RL, 2004, NAT IMMUNOL, V5, P1243, DOI 10.1038/ni1139; Looney MR, 2011, NAT METHODS, V8, P91, DOI [10.1038/nmeth.1543, 10.1038/NMETH.1543]; Lukens MV, 2009, J VIROL, V83, P7235, DOI 10.1128/JVI.00452-09; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P403, DOI 10.1513/pats.200508-090JS; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Miller MJ, 2003, P NATL ACAD SCI USA, V100, P2604, DOI 10.1073/pnas.2628040100; Miller MJ, 2002, SCIENCE, V296, P1869, DOI 10.1126/science.1070051; Pedroza-Gonzalez A, 2004, INT J EXP PATHOL, V85, P135, DOI 10.1111/j.0959-9673.2004.00381.x; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sasmono RT, 2003, BLOOD, V101, P1155, DOI 10.1182/blood-2002-02-1569; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/4A6539.2005; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Veiga-Fernandes H, 2007, NATURE, V446, P547, DOI 10.1038/nature05597; Vermaelen KY, 2001, J EXP MED, V193, P51; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; von Garnier C, 2005, J IMMUNOL, V175, P1609; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039	54	80	80	2	11	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	JUN 4	2012	209	6					1183	1199		10.1084/jem.20112667		17	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	953XT	WOS:000304907800012	22585735	
J	Shamji, MH; Durham, SR				Shamji, M. H.; Durham, S. R.			Mechanisms of immunotherapy to aeroallergens	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							GRASS-POLLEN IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; REGULATORY T-CELLS; FC-EPSILON-RI; SEASONAL ALLERGIC RHINOCONJUNCTIVITIS; MESSENGER-RNA EXPRESSION; HOUSE-DUST MITES; LYMPHOCYTIC ACTIVATION MOLECULE; SYSTEMIC IMMUNOLOGICAL CHANGES; BASOPHIL HISTAMINE-RELEASE	Allergen immunotherapy is allergen-specific, allergen dose-and time-dependent and is associated with long-term clinical and immunological tolerance that persists for years after discontinuation. Successful immunotherapy is accompanied by the suppression of numbers of T-helper 2 (Th2) effector cells, eosinophils, basophils, c-kit + mast cells and neutrophils infiltration in target organs, induction of IL-10 and/or TGF-beta + Treg cells and increases in 'protective' non-inflammatory blocking antibodies, particularly IgG4 and IgA2 subclasses with inhibitory activity. These events are accompanied by a reduction and/or a redirection of underlying antigen-specific Th2-type T cell-driven hypersensitivity to the allergen(s) used for therapy. This suppression occurs within weeks or months as a consequence of the appearance of a population of regulatory T cells that exert their effects by mechanisms involving cell-cell contact, but also by the release of cytokines such as IL-10 (increases IgG4) and TGF-beta (increases specific IgA). The more delayed-in-time appearance of antigen-specific T-helper 1 responses and alternative mechanisms such as Th2 cell anergy and/or apoptosis may also be involved. The mechanisms of sublingual immunotherapy are similar to those following a subcutaneous administration of allergen, whereas it is likely that additional events following antigen presentation in the sublingual mucosa and regional lymph nodes are involved. These insights have resulted in novel approaches and portend future biomarkers that may be surrogate or predictive of the clinical response to treatment.	[Shamji, M. H.] Univ London Imperial Coll Sci Technol & Med, MRC, Allergy & Clin Immunol Sect, London SW7 2AZ, England; [Shamji, M. H.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Asthma UK Ctr Allerg Mech Asthma, London SW7 2AZ, England	Shamji, MH (reprint author), Univ London Imperial Coll Sci Technol & Med, MRC, Allergy & Clin Immunol Sect, Room 365,3rd Floor,Sir Alexander Fleming Bldg,S K, London SW7 2AZ, England.	m.shamji99@imperial.ac.uk			Immune Tolerance Network; National Institutes of Health USA; Biotechnology and Biological Sciences Research Council UK (BBSRC); ALK-Abello, Horsholm, Denmark; ALK-Abello	This work was supported by grants from the Immune Tolerance Network, National Institutes of Health USA, a Biotechnology and Biological Sciences Research Council UK (BBSRC) studentship case award and ALK-Abello, Horsholm, Denmark.; Disclosure of potential conflict of interest: S. R. Durham is a member of the Immune Tolerance Network Steering Committee and has consulting arrangements with ALK-Abello and has received research support from ALK-Abello.	Agresti A, 1999, INT ARCH ALLERGY IMM, V118, P279, DOI 10.1159/000024099; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Allam JP, 2008, J ALLERGY CLIN IMMUN, V121, P368, DOI 10.1016/j.jaci.2007.09.045; Allam JP, 2010, J ALLERGY CLIN IMMUN, V126, P638, DOI 10.1016/j.jaci.2010.04.039; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Arvidsson MB, 2004, ALLERGY, V59, P74, DOI 10.1046/j.1398-9995.2003.00334.x; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Bellinghausen I, 2001, INT ARCH ALLERGY IMM, V126, P97, DOI 10.1159/000049499; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Campbell JD, 2009, J EXP MED, V206, P1535, DOI 10.1084/jem.20082901; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Ciprandi G, 2009, INT J IMMUNOPATH PH, V22, P1089; Ciprandi G, 2006, INT IMMUNOPHARMACOL, V6, P1370, DOI 10.1016/j.intimp.2006.03.007; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dreschler K, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Dreschler K, 2011, J ALLERGY CLIN IMMUN, V127, P487, DOI 10.1016/j.jaci.2010.12.003; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Durham SR., 2010, J ALLERGY CLIN IMMUN, V125, pe1; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eifan AO, 2010, CLIN EXP ALLERGY, V40, P922, DOI 10.1111/j.1365-2222.2009.03448.x; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Fantini MC, 2004, J IMMUNOL, V172, P5149; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P19; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Gorelik L, 2002, J EXP MED, V195, P1499, DOI 10.1084/jem.20012076; Gorelik L, 2000, J IMMUNOL, V165, P4773; Grindebacke H, 2009, J CLIN IMMUNOL, V29, P752, DOI 10.1007/s10875-009-9312-x; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JABARA HH, 1993, J IMMUNOL, V151, P4528; JAMES LK, 2011, J ALLERGY CLIN IMMUN, V16, pE1; James LK, 2011, J ALLERGY CLIN IMMUN, V127, P509, DOI 10.1016/j.jaci.2010.12.1080; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kepley CL, 2004, J BIOL CHEM, V279, P35139, DOI 10.1074/jbc.M404318200; Laaksonen K, 2003, J ALLERGY CLIN IMMUN, V112, P1171, DOI 10.1016/j.jaci.2003.08.043; LAMBIN P, 1993, J IMMUNOL METHODS, V165, P99, DOI 10.1016/0022-1759(93)90111-J; Larche M, 2011, CLIN EXP ALLERGY; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Mobs C, 2010, J IMMUNOL, V184, P2194, DOI 10.4049/jimmunol.0901379; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Moverare R, 2001, ANN ALLERG ASTHMA IM, V86, P337; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nieminen K, 2009, INT ARCH ALLERGY IMM, V150, P370, DOI 10.1159/000226238; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novak N, 2001, J IMMUNOL, V167, P797; Oida T, 2006, J IMMUNOL, V177, P2331; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Piconi S, 2010, J IMMUNOL, V185, P7723, DOI 10.4049/jimmunol.1002465; PIENKOWSKI MM, 1985, J ALLERGY CLIN IMMUN, V76, P729, DOI 10.1016/0091-6749(85)90679-7; Pilette C, 2007, J IMMUNOL, V178, P4658; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Puggioni F, 2005, ALLERGY, V60, P678, DOI 10.1111/j.1398-9995.2005.00762.x; PUNNONEN J, 1993, BLOOD, V82, P2781; Radulovic S, 2010, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD002893.PUB2; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Satoguina JS, 2005, J IMMUNOL, V174, P4718; Savolainen J, 2007, ALLERGY, V62, P949, DOI 10.1111/j.1398-9995.2007.01426.x; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Scadding GW, 2010, CLIN EXP ALLERGY, V40, P598, DOI 10.1111/j.1365-2222.2010.03462.x; Scadding G, 2009, J ASTHMA, V46, P322, DOI 10.1080/02770900902785729; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Tsai YG, 2010, J IMMUNOL, V184, P7229, DOI 10.4049/jimmunol.1000083; Tversky JR, 2010, CLIN EXP ALLERGY, V40, P94, DOI 10.1111/j.1365-2222.2009.03388.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Varga EM, 2009, CLIN EXP ALLERGY, V39, P1353, DOI 10.1111/j.1365-2222.2009.03303.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; von Bubnoff D, 2002, J IMMUNOL, V169, P1810; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Wachholz Petra A, 2004, Curr Opin Allergy Clin Immunol, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WARNER JO, 1978, LANCET, V2, P912; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Wurtzen PA, 2008, CLIN EXP ALLERGY, V38, P1290, DOI 10.1111/j.1365-2222.2008.03020.x; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	125	80	81	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2011	41	9			SI		1235	1246		10.1111/j.1365-2222.2011.03804.x		12	Allergy; Immunology	Allergy; Immunology	808SO	WOS:000293998900008	21762223	
J	McGwin, G; Lienert, J; Kennedy, JI				McGwin, Gerald, Jr.; Lienert, Jeffrey; Kennedy, John I., Jr.			Formaldehyde Exposure and Asthma in Children: A Systematic Review	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						asthma; children; epidemiology; formaldehyde; meta-analysis	VOLATILE ORGANIC-COMPOUNDS; RISK-FACTORS; SCHOOL ENVIRONMENT; AIR-POLLUTANTS; UNITED-STATES; INDOOR; SYMPTOMS; SCHOOLCHILDREN; SENSITIZATION; ALLERGY	OBJECTIVE: Despite multiple published studies regarding the association between formaldehyde exposure and childhood asthma, a consistent association has not been identified. Here we report the results of a systematic review of published literature in order to provide a more comprehensive picture of this relationship. DATA SOURCES: After a comprehensive literature search, we identified seven peer-reviewed studies providing quantitative results regarding the association between formaldehyde exposure and asthma in children. Studies were heterogeneous with respect to the definition of asthma (e.g., self-report, physician diagnosis). Most of the studies were cross-sectional. DATA EXTRACTION: For each study, an odds ratio (OR) and 95% confidence interval (CI) for asthma were either abstracted from published results or calculated based on the data provided. Characteristics regarding the study design and population were also abstracted. DATA SYNTHESIS: We used fixed- and random-effects models to calculate pooled ORs and 95% Cls; measures of heterogeneity were also calculated. A fixed-effects model produced an OR of 1.03 (95% Cl, 1.02-1.04), and random effects model produced an OR of 1.17 (95% Cl, 1.01-1.36), both reflecting an increase of 10 mu g/m(3) of formaldehyde. Both the Q and I(2) statistics indicated a moderate amount of heterogeneity. CONCLUSIONS: Results indicate a significant positive association between formaldehyde exposure and childhood asthma. Given the largely cross-sectional nature of the studies underlying this meta-analysis, further well-designed prospective epidemiologic studies are needed.	[McGwin, Gerald, Jr.] Univ Alabama, Sch Publ Hlth, Dept Epidemiol, Birmingham, AL 35294 USA; [Lienert, Jeffrey] Franklin & Marshall Coll, Lancaster, PA 17604 USA; [Kennedy, John I., Jr.] Dept Vet Affairs Med Ctr, Birmingham, AL USA; [Kennedy, John I., Jr.] Univ Alabama, Dept Med, Div Pulm Allergy & Crit Care Med, Tuscaloosa, AL 35487 USA	McGwin, G (reprint author), 1922 7th Ave S,Suite 120, Birmingham, AL 35294 USA.	mcgwin@uab.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Burr M L, 1999, Pediatr Pulmonol Suppl, V18, P3; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Doi S, 2003, ALLERGY, V58, P668, DOI 10.1034/j.1398-9995.2003.00044.x; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Erdei E, 2003, ARCH ENVIRON HEALTH, V58, P337; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; Mendell MJ, 2007, INDOOR AIR, V17, P259, DOI 10.1111/j.1600-0668.2007.00478.x; Mi YH, 2006, INDOOR AIR, V16, P454, DOI 10.1111/j.1600-0668.2006.00439.x; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; National library of medicine, 2009, PUBMED; *OSHA, 2005, THRESH LIM VAL BIOL; Pati S, 2005, EPIDEMIOLOGY, V16, pS132, DOI 10.1097/00001648-200509000-00335; Paustenbach D, 1997, J TOXICOL ENV HEALTH, V50, P217; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008; SYMINGTON P, 1991, BRIT J IND MED, V48, P588; Tavernier G, 2006, J ALLERGY CLIN IMMUN, V117, P656, DOI 10.1016/j.jaci.2005.12.1311; Thompson CM, 2008, TOXICOL APPL PHARM, V233, P355, DOI 10.1016/j.taap.2008.09.011; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; Wantke F, 1996, CLIN EXP ALLERGY, V26, P276; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Zhao ZH, 2008, ENVIRON HEALTH PERSP, V116, P90, DOI 10.1289/ehp.10576	29	80	83	4	40	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2010	118	3					313	317		10.1289/ehp.0901143		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	567LX	WOS:000275449500019	20064771	
J	Balloy, V; Chignard, M				Balloy, Viviane; Chignard, Michel			The innate immune response to Aspergillus fumigatus	MICROBES AND INFECTION			English	Review						Aspergillus fumigatus; Innate defense; Lung; Infection	INVASIVE PULMONARY ASPERGILLOSIS; COLONY-STIMULATING FACTOR; TOLL-LIKE RECEPTORS; HOST-DEFENSE; IN-VITRO; ANTIFUNGAL ACTIVITY; CANDIDA-ALBICANS; BINDING LECTIN; SYSTEMIC ASPERGILLOSIS; IMMUNOSUPPRESSED MICE	Despite the development of new treatments, the mortality due to invasive pulmonary aspergillosis remains above 50%, reaching 95% in certain situations. The battle against Aspergillus fumigatus involves several components of the pulmonary innate immune system: cells, mediators, and natural antifungal molecules involved in the recognition and elimination of the fungus, thereby preventing colonization of the respiratory system. With the 10,000-15,000 1 of air we inhale each day, the lungs are constantly exposed to a wide range of microorganisms, such as A. fumigatus. This fungus is ubiquitous in the environment and can release large numbers of spores able, due to their small size, to penetrate the respiratory tract. The spores of A. fumigatus, like any other pathogen, are then confronted with the innate immune system, a constitutive defense system that is permanently active and tightly regulated. The various elements of the pulmonary innate immune system-physical and cellular barriers and soluble mediators-are involved in the recognition and elimination of pathogens, thereby preventing colonization of the respiratory system. Consequently, the presence of spores in immunocompetent hosts is completely innocuous, because these spores are normally eliminated. However, changes in one of the components of the defense system may lead to the development of pulmonary infections. Thus, in immunocompromised individuals, the spores are able to develop and cause pulmonary mycoses. These mycoses, known as aspergillosis, are highly variable, with the range of presentations extending from an allergy-type illness, allergic bronchopulmonary aspergilloses, to a very serious generalized and frequently fatal infection: invasive pulmonary aspergillosis (IPA). (C) 2009 Elsevier Masson SAS. All rights reserved.	[Balloy, Viviane; Chignard, Michel] Inst Pasteur, Unite Def Innee & Inflammat, F-75015 Paris, France; [Balloy, Viviane; Chignard, Michel] INSERM, U874, F-75015 Paris, France	Chignard, M (reprint author), Inst Pasteur, Unite Def Innee & Inflammat, 25 Rue Dr Roux, F-75015 Paris, France.	chignard@pasteur.fr	Chignard, Michel/B-4351-2008	Chignard, Michel/0000-0003-3810-6575			AMITANI R, 1995, INFECT IMMUN, V63, P3266; Aratani Y, 2002, MED MYCOL, V40, P557, DOI 10.1080/714031156; Balloy V, 2005, INFECT IMMUN, V73, P5420, DOI 10.1128/IAI.73.9.5420-5425.2005; Balloy V, 2005, INFECT IMMUN, V73, P494, DOI 10.1128/IAI.73.1.494-503.2005; BALLOY V, 2008, J BIOL CHEM, V7, P30513; Baranger K, 2008, FEBS J, V275, P2008, DOI 10.1111/j.1742-4658.2008.06355.x; Behnsen J, 2008, INFECT IMMUN, V76, P820, DOI 10.1128/IAI.01037-07; Bellocchio S, 2004, J IMMUNOL, V172, P3059; Bochud PY, 2008, NEW ENGL J MED, V359, P1766, DOI 10.1056/NEJMoa0802629; Botterel F, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-97; BOUCHARA JP, 1994, PATHOL BIOL, V42, P640; Braedel S, 2004, BRIT J HAEMATOL, V125, P392, DOI 10.1111/j.1365-2141.2004.04922.x; Brouard J, 2005, J INFECT DIS, V191, P1988, DOI 10.1086/429964; Cenci E, 1998, J INFECT DIS, V178, P1750, DOI 10.1086/314493; Centeno-Lima S, 2002, FEMS IMMUNOL MED MIC, V32, P167, DOI 10.1111/j.1574-695X.2002.tb00549.x; Chen L, 2009, CLIN EXP DERMATOL, V34, P55, DOI 10.1111/j.1365-2230.2008.03092.x; Chignard M, 2009, ASPERGILLUS FUMIGATU, P229; Chignard M, 2007, CLIN IMMUNOL, V124, P238, DOI 10.1016/j.clim.2007.05.004; Clemons KV, 2000, CLIN EXP IMMUNOL, V122, P186, DOI 10.1046/j.1365-2249.2000.01382.x; Da Silva CA, 2008, J IMMUNOL, V181, P4279; Dubourdeau M, 2006, J IMMUNOL, V177, P3994; Duong M, 1998, J INFECT DIS, V178, P1472, DOI 10.1086/314425; Garlanda C, 2002, NATURE, V420, P182, DOI 10.1038/nature01195; Gersuk GM, 2006, J IMMUNOL, V176, P3717; Hamilton AJ, 1999, MED MYCOL, V37, P375, DOI 10.1046/j.1365-280X.1999.00208.x; HECTOR RF, 1990, INFECT IMMUN, V58, P1476; Hogaboam CM, 2004, J LEUKOCYTE BIOL, V75, P805, DOI 10.1189/jlb.0703325; Kaur S, 2007, CLIN EXP IMMUNOL, V148, P382, DOI 10.1111/j.1365-2249.2007.03351.x; LEVITZ SM, 1985, J INFECT DIS, V152, P33; Lupetti A, 2008, EUR J CLIN MICROBIOL, V27, P1125, DOI 10.1007/s10096-008-0553-z; Luther K, 2007, CELL MICROBIOL, V9, P368, DOI 10.1111/j.1462-5822.2006.00796.x; Madan T, 2001, INFECT IMMUN, V69, P2728, DOI 10.1128/IAI.69.4.2728-2731.2001; Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200; Mehrad B, 2002, AM J RESP CRIT CARE, V166, P1263, DOI 10.1164/rccm.200204-367OC; Mehrad B, 1999, J IMMUNOL, V162, P1633; Meier A, 2003, CELL MICROBIOL, V5, P561, DOI 10.1046/j.1462-5822.2003.00301.x; Netea MG, 2003, J INFECT DIS, V188, P320, DOI 10.1086/376456; Neth O, 2000, INFECT IMMUN, V68, P688, DOI 10.1128/IAI.68.2.688-693.2000; Paris S, 1997, INFECT IMMUN, V65, P1510; Persat F, 2003, CLIN EXP IMMUNOL, V133, P370, DOI 10.1046/j.1365-2249.2003.02222.x; Philippe B, 2003, INFECT IMMUN, V71, P3034, DOI 10.1128/IAI.71.6.3034-3042.2003; POLAKWYSS A, 1991, MYCOSES, V34, P205; Ramaprakash H, 2009, INFECT IMMUN, V77, P108, DOI 10.1128/IAI.00998-08; Ramirez-Ortiz ZG, 2008, INFECT IMMUN, V76, P2123, DOI 10.1128/IAI.00047-08; ROBERTSON MD, 1989, J MED VET MYCOL, V27, P295; Rodriguez-Adrian LJ, 1998, CLIN INFECT DIS, V26, P1270; ROILIDES E, 1993, INFECT IMMUN, V61, P4870; Roilides E, 2001, J INFECT DIS, V183, P518, DOI 10.1086/318077; Saijo S, 2007, NAT IMMUNOL, V8, P39, DOI 10.1038/ni1425; Sainz J, 2007, IMMUNOL LETT, V109, P76, DOI 10.1016/j.imlet.2007.01.005; SCHAFFNER A, 1983, INFECT IMMUN, V42, P1109; Schelenz S, 1999, MED MYCOL, V37, P183, DOI 10.1046/j.1365-280X.1999.00219.x; Serrano-Gomez D, 2004, J IMMUNOL, V173, P5635; Simon A, 2008, ANTIMICROB AGENTS CH, V52, P1407, DOI 10.1128/AAC.00155-07; STEELE C, 2005, PLOS PATHOG, V1, P42; STURTEVANT JE, 1992, INFECT IMMUN, V60, P1913; Taylor PR, 2007, NAT IMMUNOL, V8, P31, DOI 10.1038/ni1408; Tkalcevic J, 2000, IMMUNITY, V12, P201, DOI 10.1016/S1074-7613(00)80173-9; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; WASHBURN RG, 1990, INFECT IMMUN, V58, P3508; Wasylnka JA, 2003, J CELL SCI, V116, P1579, DOI 10.1242/jcs.00329; Wasylnka JA, 2002, INFECT IMMUN, V70, P3156, DOI 10.1128/IAI.70.6.3156-3163.2002; Zarember KA, 2007, J IMMUNOL, V178, P6367; Zhang HJ, 2008, ACTA PHARMACOL SIN, V29, P1202, DOI 10.1111/j.1745-7254.2008.00860.x	64	80	88	0	9	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1286-4579			MICROBES INFECT	Microbes Infect.	OCT	2009	11	12					919	927		10.1016/j.micinf.2009.07.002		9	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	504QI	WOS:000270631700003	19615460	
J	Litonjua, AA				Litonjua, Augusto A.			Childhood asthma may be a consequence of vitamin D deficiency	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergies; asthma; sun exposure; vitamin D; wheeze	REGULATORY T-CELLS; NUTRITION EXAMINATION SURVEY; IMR-90 HUMAN FIBROBLASTS; 3RD NATIONAL-HEALTH; SMOOTH-MUSCLE-CELLS; RAT LUNG EXPLANTS; D-RECEPTOR GENE; 1,25-DIHYDROXYVITAMIN D-3; 1-ALPHA,25-DIHYDROXYVITAMIN D-3; 25-HYDROXYVITAMIN D	Purpose of review Vitamin D deficiency has been rediscovered as a public-health problem worldwide. It has been postulated that vitamin D deficiency may explain a portion of the asthma epidemic. The purpose of this review is to present the evidence for a role of vitamin D in asthma. Recent findings Both animal models and studies in human fetal tissues show that vitamin D plays a role in fetal lung growth and maturation. Epidemiologic studies have also suggested that higher prenatal vitamin D intakes have a protective role against wheezing illnesses in young children. Vitamin D may protect against wheezing illnesses through its role in upregulating antimicrobial proteins or through its multiple immune effects. In addition, vitamin D may play a therapeutic role in steroid resistant asthmatics, and lower vitamin D levels have recently been associated with higher risks for asthma exacerbations. Summary Improving vitamin D status holds promise in primary prevention of asthma, in decreasing exacerbations of disease, and in treating steroid resistance. However, the appropriate level of circulating vitamin D for optimal immune functioning remains unclear. Because vitamin D deficiency is prevalent even in sun-replete areas, clinical trials are needed to definitively answer questions about the role of vitamin D in asthma.	[Litonjua, Augusto A.] Harvard Univ, Sch Med, Channing Lab, Brigham & Womens Hosp, Boston, MA 02115 USA; [Litonjua, Augusto A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02115 USA	Litonjua, AA (reprint author), 181 Longwood Ave, Boston, MA 02115 USA.	augusto.litonjua@channing.harvard.edu		Litonjua, Augusto/0000-0003-0422-5875	NHLBI NIH HHS [R21 HL089842-01, R21 HL089842]		Adorini L, 2004, J STEROID BIOCHEM, V89-90, P437, DOI 10.1016/j.jsbmb.2004.03.013; Akeno N, 1997, ENDOCRINOLOGY, V138, P2233, DOI 10.1210/endo.138.6.5170; Aloia JF, 2007, EPIDEMIOL INFECT, V135, P1097; Aloia JF, 2007, EPIDEMIOL INFECT, V135, P1095; Annesi-Maesano I, 2002, PEDIATR RES, V52, P3, DOI 10.1023/01.PDR/0000017228.29635.EF; Banerjee A, 2008, BRIT J PHARMACOL, V155, P84, DOI 10.1038/bjp.2008.232; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Boonstra A, 2001, J IMMUNOL, V167, P4974; Bosse Y, 2007, PHYSIOL GENOMICS, V29, P161, DOI 10.1152/physiolgenomics.00134.2006; BREHM JM, 2009, AM J RESP CRIT CARE; BRUN P, 1987, PEDIATR RES, V21, P362, DOI 10.1203/00006450-198704000-00008; BURRI PH, 1984, ANNU REV PHYSIOL, V46, P617, DOI 10.1146/annurev.ph.46.030184.003153; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Cantorna MT, 2004, AM J CLIN NUTR, V80, p1717S; Cantorna MT, 1998, J IMMUNOL, V160, P5314; Chatenoud L, 2001, IMMUNOL REV, V182, P149, DOI 10.1034/j.1600-065X.2001.1820112.x; Cippitelli M, 1998, EUR J IMMUNOL, V28, P3017, DOI 10.1002/(SICI)1521-4141(199810)28:10<3017::AID-IMMU3017>3.3.CO;2-Y; Come JM, 2002, LANCET, V359, P831; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Devereux G, 2007, AM J CLIN NUTR, V85, P853; DICKSON I, 1987, NATURE, V325, P18, DOI 10.1038/325018a0; ERKKOLA M, 2009, CLIN EXP AL IN PRESS; GALE CR, 2007, EUR J CLIN NUTR; GAULTIER C, 1984, AM REV RESPIR DIS, V130, P1108; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Grant WB, 2008, PHOTOCHEM PHOTOBIOL, V84, P356, DOI 10.1111/j.1751-1097.2007.00266.x; Gregori S, 2002, DIABETES, V51, P1367, DOI 10.2337/diabetes.51.5.1367; Gregori S, 2001, J IMMUNOL, V167, P1945; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Heine G, 2002, EUR J IMMUNOL, V32, P3395, DOI 10.1002/1521-4141(200212)32:12<3395::AID-IMMU3395>3.0.CO;2-#; Herr C, 2007, EXPERT OPIN BIOL TH, V7, P1449, DOI 10.1517/14712598.7.9.1449; Holick MF, 2006, MAYO CLIN PROC, V81, P353; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Hollis BW, 2007, J STEROID BIOCHEM, V103, P631, DOI 10.1016/j.jsbmb.2006.12.066; Hollis BW, 2006, AM J CLIN NUTR, V84, P273; Hollis BW, 2006, CAN MED ASSOC J, V174, P1287, DOI 10.1503/cmaj.060149; Hollis BW, 2004, AM J CLIN NUTR, V79, P717; HYATTSVILLE MD, 2004, ASTHMA PREVALENCE HE; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; IHO S, 1985, IMMUNOL LETT, V11, P331, DOI 10.1016/0165-2478(85)90116-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Lamberg-Allardt C, 2006, PROG BIOPHYS MOL BIO, V92, P33, DOI 10.1016/j.pbiomolbio.2006.02.017; Lee JM, 2007, CLIN PEDIATR, V46, P42, DOI 10.1177/0009922806289311; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Liu PT, 2007, J IMMUNOL, V179, P2060; Lunghi B, 1995, MOL CELL ENDOCRINOL, V115, P141, DOI 10.1016/0303-7207(95)03681-4; Mahon BD, 2003, J CELL BIOCHEM, V89, P922, DOI 10.1002/jcb.10580; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; MARIN L, 1990, BIOL NEONATE, V57, P257; MARIN L, 1993, AM J PHYSIOL, V265, pL45; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI 10.1037/mai.2003.1703; McGlade JP, 2007, CLIN EXP ALLERGY, V37, P1267, DOI 10.1111/j.1365-2222.2007.02750.x; MEEHAN MA, 1992, CELL IMMUNOL, V140, P400, DOI 10.1016/0008-8749(92)90206-5; MINGHETTI PP, 1988, FASEB J, V2, P3043; Nesby-O'Dell S, 2002, AM J CLIN NUTR, V76, P187; NGUYEN M, 1987, BIOL NEONATE, V52, P232; Nguyen M. N., 2003, Neural, Parallel & Scientific Computations, V11, P1; Nguyen TM, 1996, AM J PHYSIOL-LUNG C, V271, pL392; Pichler J, 2002, PEDIATR RES, V52, P12, DOI 10.1023/01.PDR.0000017267.23950.48; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Ramsey CD, 2005, CURR OPIN PULM MED, V11, P14, DOI 10.1097/01.mcp.0000145791.13714.ae; Rehan VK, 2002, MOL GENET METAB, V76, P46, DOI 10.1016/S1096-7192(02)00022-7; REICHSTEINER M, 1987, ANN REV CELL BIOL, V3, P1; Sahota H, 2008, CANCER EPIDEM BIOMAR, V17, P232, DOI 10.1158/1055-9965.EPI-07-0632; Sanchez PA, 1997, J NATL MED ASSOC, V89, P805; Schwartz RH, 2005, NAT IMMUNOL, V6, P327, DOI 10.1038/ni1184; Stio M, 1997, BIOCHEM MOL BIOL INT, V43, P1173; Stio M, 1996, MECH AGEING DEV, V91, P23, DOI 10.1016/0047-6374(96)01761-7; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Taback SP, 2007, J ALLERGY CLIN IMMUN, V120, P128, DOI 10.1016/j.jaci.2007.05.020; TAHER YA, 2008, J IMMUNOL, V108, P5211; Topilski I, 2004, EUR J IMMUNOL, V34, P1068, DOI 10.1002/eji.200324532; *US EPA, 1989, 400189001C EPA; van der Mei IAF, 2006, CANCER EPIDEM BIOMAR, V15, P1538, DOI 10.1158/1055-9965.EPI-05-0969; Vieth R, 2007, AM J CLIN NUTR, V85, P649; Vollmert C, 2004, CLIN EXP ALLERGY, V34, P1841, DOI 10.1111/j.1365-2222.2004.02047.x; Webb AR, 2006, PROG BIOPHYS MOL BIO, V92, P17, DOI 10.1016/j.pbiomolbio.2006.02.004; Wittke A, 2004, J IMMUNOL, V173, P3432; Wittke A, 2007, ARCH BIOCHEM BIOPHYS, V460, P306, DOI 10.1016/j.abb.2006.12.011; Wjst M, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-2; Wjst M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-60; Xing NZ, 2002, BIOCHEM BIOPH RES CO, V297, P645, DOI 10.1016/S0006-291X(02)02262-3; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; YU XP, 1995, P NATL ACAD SCI USA, V92, P10990, DOI 10.1073/pnas.92.24.10990	87	80	88	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1528-4050			CURR OPIN ALLERGY CL	Curr. Opin. Allergy Clin. Immunol.	JUN	2009	9	3					202	207		10.1097/ACI.0b013e32832b36cd		6	Allergy; Immunology	Allergy; Immunology	452YU	WOS:000266577900004	19365260	
J	Ozdemir, C; Akdis, M; Akdis, CA				Ozdemir, C.; Akdis, M.; Akdis, C. A.			T regulatory cells and their counterparts: masters of immune regulation	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							GROWTH-FACTOR-BETA; IMMUNOLOGICAL SELF-TOLERANCE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; TRANSCRIPTION FACTOR FOXP3; LATE ASTHMATIC REACTIONS; BEE VENOM IMMUNOTHERAPY; DENDRITIC CELLS; IN-VIVO; NK CELLS; CUTTING EDGE	The interaction of environmental and genetic factors with the immune system can lead to the development of allergic diseases. The essential step in this progress is the generation of allergen-specific CD4(+) T-helper (Th) type 2 cells that mediate several effector functions. The influence of Th2 cytokines leads to the production of allergen-specific IgE antibodies by B cells, development and recruitment of eosinophils, mucus production and bronchial hyperreactivity, as well as tissue homing of other Th2 cells and eosinophils. Meanwhile, Th1 cells may contribute to chronicity and the effector phases. T cells termed T regulatory (Treg) cells, which have immunosuppressive functions and cytokine profiles distinct from that of either Th1 or Th2 cells, have been intensely investigated during the last 13 years. Treg cell response is characterized by an abolished allergen-specific T cell proliferation and the suppressed secretion of Th1 and Th2-type cytokines. Treg cells are able to inhibit the development of allergen-specific Th2 and Th1 cell responses and therefore play an important role in a healthy immune response to allergens. In addition, Treg cells potently suppress IgE production and directly or indirectly suppress the activity of effector cells of allergic inflammation, such as eosinophils, basophils and mast cells. Currently, Treg cells represent an exciting area of research, where understanding the mechanisms of peripheral tolerance to allergens may soon lead to more rational and safer approaches for the prevention and cure of allergic diseases.	[Ozdemir, C.] Marmara Univ, Div Pediat Allergy & Immunol, Istanbul, Turkey; [Akdis, M.; Akdis, C. A.] Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Ozdemir, C (reprint author), Obere Str 22, CH-7270 Davos, Switzerland.	akdisac@siaf.unizh.ch			Swiss National Science Foundation [SNF-32-112306/1, 32-118226]; Global Allergy; Asthma European Network (GA<SUP>2</SUP>LEN)	The authors' laboratories are funded by the Swiss National Science Foundation (grant no. SNF-32-112306/1, 32-118226) and Global Allergy and Asthma European Network (GA<SUP>2</SUP>LEN).	Adler HS, 2008, CELL CYCLE, V7, P169; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2006, NEW ENGL J MED, V354, P1117, DOI 10.1056/NEJMoa053614; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Akdis M, 2006, CURR OPIN IMMUNOL, V18, P738, DOI 10.1016/j.coi.2006.06.003; Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Asano M, 1996, J EXP MED, V184, P387, DOI 10.1084/jem.184.2.387; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bellinghausen I, 2006, CLIN EXP ALLERGY, V36, P1546, DOI 10.1111/j.1365-2222.2006.02601.x; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bettelli E, 2008, NATURE, V453, P1051, DOI 10.1038/nature07036; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Bousquet J, 2004, J ALLERGY CLIN IMMUN, V113, P43, DOI 10.1016/j.jaci.2003.09.047; Brusko TM, 2005, DIABETES, V54, P1407, DOI 10.2337/diabetes.54.5.1407; Cella M, 2009, NATURE, V457, P722, DOI 10.1038/nature07537; Chatila TA, 2000, J CLIN INVEST, V106, pR75, DOI 10.1172/JCI11679; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Deniz G, 2002, EUR J IMMUNOL, V32, P879, DOI 10.1002/1521-4141(200203)32:3<879::AID-IMMU879>3.0.CO;2-2; Deniz G, 2008, J IMMUNOL, V180, P850; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; Duvernelle C, 2003, PULM PHARMACOL THER, V16, P181, DOI 10.1016/S1094-5539(03)00051-8; Ehrenstein MR, 2004, J EXP MED, V200, P277, DOI 10.1084/jem.20040165; Fattorossi A, 2005, IMMUNOLOGY, V116, P134, DOI 10.1111/j.1365-2567.2005.02220.x; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Frossard CP, 2004, J ALLERGY CLIN IMMUN, V114, P377, DOI 10.1016/j.jaci.2004.03.040; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Groux H, 1997, NATURE, V389, P737; Harrison LC, 1996, J EXP MED, V184, P2167, DOI 10.1084/jem.184.6.2167; Hartl D, 2007, J ALLERGY CLIN IMMUN, V119, P1258, DOI 10.1016/j.jaci.2007.02.023; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HERBERMAN RB, 1986, ANNU REV IMMUNOL, V4, P651, DOI 10.1146/annurev.immunol.4.1.651; Hodi FS, 2003, P NATL ACAD SCI USA, V100, P4712, DOI 10.1073/pnas.0830997100; Hori S, 2002, P NATL ACAD SCI USA, V99, P8213, DOI 10.1073/pnas.122224799; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hori S, 2003, ADV IMMUNOL, V81, P331, DOI 10.1016/S0065-2776(03)81008-8; Huber S, 2004, J IMMUNOL, V173, P6526; Ito S, 1999, BLOOD, V93, P1456; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 1996, CLIN EXP ALLERGY, V26, P1112, DOI 10.1046/j.1365-2222.1996.d01-259.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Kashyap M, 2008, J IMMUNOL, V180, P2039; Kay A B, 1991, Clin Exp Allergy, V21 Suppl 1, P17, DOI 10.1111/j.1365-2222.1991.tb01700.x; Ke Y, 1997, J IMMUNOL, V158, P3610; Ke Y, 1996, J IMMUNOL, V156, P916; Ko K, 2005, J EXP MED, V202, P885, DOI 10.1084/jem.20050940; Kohm AP, 2002, J IMMUNOL, V169, P4712; Kon OM, 1999, INT ARCH ALLERGY IMM, V118, P133, DOI 10.1159/000024049; Kukreja A, 2002, J CLIN INVEST, V109, P131, DOI 10.1172/JCI13605; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; Larche M, 2005, PHARMACOL THERAPEUT, V108, P353, DOI 10.1016/j.pharmthera.2005.05.004; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larche M, 2006, CURR OPIN IMMUNOL, V18, P745, DOI 10.1016/j.coi.2006.09.013; Lin W, 2005, J ALLERGY CLIN IMMUN, V116, P1106, DOI 10.1016/j.jaci.2005.08.046; Lin YL, 2008, ALLERGY, V63, P67, DOI 10.1111/j.1398-9995.2007.01526.x; Lindley S, 2005, DIABETES, V54, P92, DOI 10.2337/diabetes.54.1.92; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Loser K, 2006, NAT MED, V12, P1372, DOI 10.1038/nm1518; Lutz MB, 2000, EUR J IMMUNOL, V30, P1813, DOI 10.1002/1521-4141(200007)30:7<1813::AID-IMMU1813>3.0.CO;2-8; MacKenzie DA, 2007, J BIOL CHEM, V282, P9696, DOI 10.1074/jbc.M604192200; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; MALEFYT RD, 1991, J EXP MED, V174, P1209; Mamura M, 2004, BLOOD, V103, P4594, DOI 10.1182/blood-2003-08-2897; Manavalan JS, 2004, INT IMMUNOL, V16, P1055, DOI 10.1093/intimm/dxh107; Mantel PY, 2007, PLOS BIOL, V5, P2847, DOI 10.1371/journal.pbio.0050329; Mayerova D, 2004, IMMUNITY, V21, P391, DOI 10.1016/j.immuni.2004.07.019; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Meiler F, 2008, ALLERGY, V63, P1455, DOI 10.1111/j.1398-9995.2008.01774.x; Meiler F, 2008, J EXP MED, V205, P2887, DOI 10.1084/jem.20080193; Mengel J, 1995, IMMUNOL LETT, V48, P97, DOI 10.1016/0165-2478(95)02451-4; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Mirmonsef P, 1999, J IMMUNOL, V163, P2530; Miyara M, 2005, J IMMUNOL, V175, P8392; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1046/j.1365-2222.1996.d01-337.x; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mottet C, 2003, J IMMUNOL, V170, P3939; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; MUDDE GC, 1990, IMMUNOL TODAY, V11, P440, DOI 10.1016/0167-5699(90)90172-6; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Nelson HS, 2005, J ALLERGY CLIN IMMUN, V115, P676, DOI 10.1016/j.jaci.2005.01.037; Noble A, 1998, J IMMUNOL, V160, P566; Nonaka M, 2008, CLIN EXP ALLERGY, V38, P812, DOI 10.1111/j.1365-2222.2008.02959.x; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Onizuka S, 1999, CANCER RES, V59, P3128; Oral HB, 2006, EUR J IMMUNOL, V36, P380, DOI 10.1002/eji.200425523; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Ozdemir C, 2003, CLIN EXP ALLERGY, V33, P266, DOI 10.1046/j.1365-2222.2003.01595.x; Peek EJ, 2005, AM J RESP CELL MOL, V33, P105, DOI 10.1165/rcmb.2005-0100OC; Pereira-Santos MC, 2008, CLIN EXP ALLERGY, V38, P291, DOI 10.1111/j.1365-2222.2007.02887.x; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; PUNNONEN J, 1993, BLOOD, V82, P2781; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; Romagnani S, 2006, CLIN EXP ALLERGY, V36, P1357, DOI 10.1111/j.1365-2222.2006.02606.x; ROMANI N, 1989, J EXP MED, V169, P1169, DOI 10.1084/jem.169.3.1169; Roncarolo MG, 2007, NAT REV IMMUNOL, V7, P585, DOI 10.1038/nri2138; Ronchetti S, 2004, EUR J IMMUNOL, V34, P613, DOI 10.1002/eji.200324804; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009; Sasaki Y, 2004, MOL HUM REPROD, V10, P347, DOI 10.1093/molehr/gah044; Satoguina JS, 2005, J IMMUNOL, V174, P4718; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Schmidt-Weber CB, 2004, CURR OPIN IMMUNOL, V16, P709, DOI 10.1016/j.coi.2004.09.008; Seo N, 1999, J IMMUNOL, V163, P242; Shevach EM, 2001, J EXP MED, V193, pF41, DOI 10.1084/jem.193.11.F41; Shim JY, 2003, CLIN EXP ALLERGY, V33, P52, DOI 10.1046/j.1365-2222.2003.01567.x; Shimizu J, 1999, J IMMUNOL, V163, P5211; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Singh B, 2001, IMMUNOL REV, V182, P190, DOI 10.1034/j.1600-065X.2001.1820115.x; Somerset DA, 2004, IMMUNOLOGY, V112, P38, DOI 10.1111/j.1365-2567.2004.01869.x; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Strober S, 1996, IMMUNOL REV, V149, P217, DOI 10.1111/j.1600-065X.1996.tb00906.x; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Tang QZ, 2004, J EXP MED, V199, P1455, DOI 10.1084/jem.20040139; Tarbell KV, 2007, J EXP MED, V204, P191, DOI 10.1084/jem.20061631; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Taylor A, 2007, J ALLERGY CLIN IMMUN, V120, P76, DOI 10.1016/j.jaci.2007.04.004; Taylor A, 2009, MOL IMMUNOL, V46, P622, DOI 10.1016/j.molimm.2008.07.031; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; Thunberg S, 2007, CLIN EXP ALLERGY, V37, P1127, DOI 10.1111/j.1365-2222.2007.02739.x; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Treter S, 2000, CELL IMMUNOL, V206, P116, DOI 10.1006/cimm.2000.1739; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1111/j.1365-2222.1996.tb00591.x; Van Rijt LS, 2005, CLIN EXP ALLERGY, V35, P1125, DOI 10.1111/j.1365-2222.2005.02321.x; VERCELLI D, 1989, INT ARCH ALLER A IMM, V88, P119; Vermaelen KY, 2001, J EXP MED, V193, P51; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; Wang HY, 2005, J IMMUNOL, V174, P2661; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Yanaba K, 2008, IMMUNITY, V28, P639, DOI 10.1016/j.immuni.2008.03.017; YANAGIDA M, 1995, BLOOD, V86, P3705; Zeiser R, 2008, CELL CYCLE, V7, P458; Zenclussen AC, 2005, AM J PATHOL, V166, P811, DOI 10.1016/S0002-9440(10)62302-4; Zhu Y, 2001, MOL PHARMACOL, V59, P434	155	80	88	2	11	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2009	39	5					626	639		10.1111/j.1365-2222.2009.03242.x		14	Allergy; Immunology	Allergy; Immunology	430ZX	WOS:000265032200003	19422105	
J	Islam, T; Berhane, K; McConnell, R; Gauderman, WJ; Avol, E; Peters, JM; Gilliland, FD				Islam, T.; Berhane, K.; McConnell, R.; Gauderman, W. J.; Avol, E.; Peters, J. M.; Gilliland, F. D.			Glutathione-S-transferase (GST) P1, GSTM1, exercise, ozone and asthma incidence in school children	THORAX			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; SOUTHERN CALIFORNIA COMMUNITIES; AIR-POLLUTION; BRONCHIAL HYPERRESPONSIVENESS; CHILDHOOD ASTHMA; RISK-FACTORS; SUSCEPTIBILITY GENE; OXIDATIVE STRESS; DIFFERING LEVELS; DIOL EPOXIDES	Background: Because asthma has been associated with exercise and ozone exposure, an association likely mediated by oxidative stress, we hypothesised that glutathione-S-transferase (GST) P1, GSTM1, exercise and ozone exposure have interrelated effects on the pathogenesis of asthma. Methods: Associations of the well characterised null variant of GSTM1 and four single nucleotide polymorphisms (SNPs) that characterised common variation in the GSTP1 locus with new onset asthma in a cohort of 1610 school children were examined. Children's exercise and ozone exposure were classified using participation in team sports and community annual average ozone levels, respectively. Results: A two SNP model involving putatively functional variants (rs6591255, rs1695 (Ile105Va)) best captured the association between GSTP1 and asthma. The risk of asthma was lower for those with the Val allele of Ile105Val (hazard ratio (HR) 0.60, 95% CI 0.4 to 0.8) and higher for the variant allele of rs6591255 (HR 1.40, 95% CI 1.1 to 1.9). The risk of asthma increased with level of exercise among ile(105) homozygotes but not among those with at least one val(105) allele (interaction p value= 0.02). The risk was highest among ile(105) homozygotes who participated in >= 3 sports in the high ozone communities (HR 6.15, 95% CI 2.2 to 7.4). GSTM1 null was independently associated with an increased risk of asthma and showed little variation with air pollution or GSTP1 genotype. These results were consistent in two independent fourth grade cohorts recruited in 1993 and 1996. Conclusion: Children who inherit a val105 variant allele may be protected from the increased risk of asthma associated with exercise, especially in high ozone communities. GSTM1 null genotype was associated with an increased risk of asthma.	[Islam, T.; Berhane, K.; McConnell, R.; Gauderman, W. J.; Avol, E.; Peters, J. M.; Gilliland, F. D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@usc.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	National Institute of Environmental Health Sciences [5P30ES007048, 5P01ES009581, R826708-01, RD831861-01, 5P01ES011627]; Environmental Protection Agency; National Heart, Lung and Blood Institute [5R01HL061768, 5R01HL076647]; Hastings Foundation	Funding: This work was supported by the Southern California Environmental Health Sciences Center (grant No 5P30ES007048) funded by the National Institute of Environmental Health Sciences; the Children's Environmental Health Center (grant Nos 5P01ES009581, R826708-01 and RD831861-01) funded by the National Institute of Environmental Health Sciences and the Environmental Protection Agency; the National Institute of Environmental Health Sciences (grant No 5P01ES011627); the National Heart, Lung and Blood Institute (grant Nos 5R01HL061768 and 5R01HL076647); and the Hastings Foundation.	Aynacioglu AS, 2004, BRIT J CLIN PHARMACO, V57, P213, DOI 10.1046/j.1365-2125.2003.01975.x; Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074; Cauchi S, 2006, CANCER RES, V66, P6439, DOI 10.1158/0008-5472.CAN-05-4457; Ercan H, 2006, J ALLERGY CLIN IMMUN, V118, P1097, DOI 10.1016/j.jaci.2006.08.012; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; GREENE LS, 1995, J AM COLL NUTR, V14, P317; Hayes JD, 1999, FREE RADICAL RES, V31, P273, DOI 10.1080/10715769900300851; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hemmingsen A, 2001, Respir Res, V2, P255, DOI 10.1186/rr64; HENENE C, 2007, MEDIAT INFLAMM, P19564; Hu X, 1997, BIOCHEM BIOPH RES CO, V238, P397, DOI 10.1006/bbrc.1997.7311; Imboden M, 2008, THORAX, V63, P322, DOI 10.1136/thx.2007.085555; Islam T, 2008, AM J RESP CRIT CARE, V177, P388, DOI 10.1164/rccm.200706-863OC; Kamada F, 2007, INT ARCH ALLERGY IMM, V144, P275, DOI 10.1159/000106316; Kolonel LN, 2000, AM J EPIDEMIOL, V151, P346; Lee YL, 2005, CHEST, V128, P1156, DOI 10.1378/chest.128.3.1156; Lee YL, 2004, CLIN EXP ALLERGY, V34, P1707, DOI 10.1111/j.1365-2222.2004.02099.x; Lenney W, 2007, CLIN EXP ALLERGY, V37, P1124, DOI 10.1111/j.1365-2222.2007.02772.x; Li YF, 2008, ENVIRON HEALTH PERSP, V116, P409, DOI 10.1289/ehp.10655; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; Mak JCW, 2007, CLIN EXP ALLERGY, V37, P1150, DOI 10.1111/j.1365-2222.2007.02704.x; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MUSTAFA MG, 1990, FREE RADICAL BIO MED, V9, P245, DOI 10.1016/0891-5849(90)90035-H; Nickel R, 2005, PEDIATR ALLERGY IMMU, V16, P539, DOI 10.1111/j.1399-3038.2005.00307.x; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433; Tamer L, 2004, RESPIROLOGY, V9, P493, DOI 10.1111/j.1440-1843.2004.00657.x	35	80	83	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2009	64	3					197	202		10.1136/thx.2008.099366		6	Respiratory System	Respiratory System	413KW	WOS:000263793000005	18988661	
J	Holguin, F; Flores, S; Ross, Z; Cortez, M; Molina, M; Molina, L; Rincon, C; Jerrett, M; Berhane, K; Granados, A; Romieu, I				Holguin, Fernando; Flores, Silvia; Ross, Zev; Cortez, Marlene; Molina, Mario; Molina, Luisa; Rincon, Carlos; Jerrett, Michael; Berhane, Kiros; Granados, Alfredo; Romieu, Isabelle			Traffic-related exposures, airway function, inflammation, and respiratory symptoms in children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollution; traffic; asthma; exhaled nitric oxide	EXHALED NITRIC-OXIDE; CHILDHOOD ASTHMA; RESIDENTIAL EXPOSURE; NITROGEN-DIOXIDE; YOUNG-CHILDREN; POLLUTION; ROAD; HEALTH; CANADA; HOSPITALIZATION	Rationale: Traffic-related emissions have been associated with respiratory symptoms in some studies. However, there is limited information on how traffic-related emissions relate to lung function and airway inflammation. Objectives: To determine the differential association of traffic-related exposures with exhaled nitric oxide (NO) and lung volumes and symptoms in children with and without asthma. Methods: We performed a longitudinal study of 200 children from ages 6 to 12 years of whom half had physician-diagnosed asthma. Two-week NO(2) and 48-hour average levels of elemental carbon and particulate matter of less than 2.5 mu m (PM(2.5)) were measured at participating schools. Road and traffic densities were determine at schools and at each participant's house. Measurements and Main Results: In children with asthma, an inter-quartile increase in road density within the 50-, 100-, and 200-m home buffer areas was associated with increased exhaled NO (50 m: 28%; P = 0.03; 95% confidence interval [CI], 3-60; 100 m: 27%; P = 0.005; 95% Cl, 8-49; 200 m: 17%, P = 0.09, 95% Cl, -2 to 40), and reduced FEV(1) (50 m: -0.091 L; P = 0.038; 95% Cl, -0.174 to -0.007; 100 m: -0.072 L, P = -0.028, 95% Cl, -0.134 to -0.009; 200 in: -0.106L, P= 0.002,95%Cl, -0.171 to -0.041]). Exposure to NO(2) at schools was marginally associated with reduced FEV(1) (-0.020; P = 0.060; 95% Cl, -0.042 to 0.001). We did not observe significant associations with PM(2.5) or elemental carbon on exhaled NO. We did not observe significant reductions in lung volumes or changes in exhaled NO among healthy children. Conclusions: Vehicular traffic exposures are associated with increased levels of exhaled NO and reduced lung volumes in children with asthma.	[Holguin, Fernando] Emory Univ, Atlanta, GA 30322 USA; [Flores, Silvia; Cortez, Marlene; Romieu, Isabelle] Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; [Ross, Zev] Zev Ross Spat Anal, Ithaca, NY USA; [Molina, Mario] Univ Calif San Diego, San Diego, CA 92103 USA; [Molina, Luisa] MIT, Cambridge, MA 02139 USA; [Rincon, Carlos] US EPA, Washington, DC 20460 USA; [Jerrett, Michael] Univ Calif Berkeley, Berkeley, CA 94720 USA; [Berhane, Kiros] Univ So Calif, Los Angeles, CA USA; [Granados, Alfredo] Univ Autonoma Ciudad Juarez, Juarez, Mexico	Holguin, F (reprint author), 550 Peachtree St,NE,Room 2331, Atlanta, GA 30308 USA.	fch@cdc.gov					American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Cesaroni G, 2003, EUR RESPIR J, V22, P619, DOI 10.1183/09031936.03.00091202; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Dinakar C, 2004, CURR ALLERGY ASTHM R, V4, P454, DOI 10.1007/s11882-004-0011-7; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Fritz GJ, 2001, INT J HYG ENVIR HEAL, V203, P235, DOI 10.1078/S1438-4639(04)70034-6; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; GINA, 2004, GLOB STRAT ASTHM MAN; Green RS, 2004, ENVIRON HEALTH PERSP, V112, P61, DOI 10.1289/ehp.6566; Ising H, 2004, Noise Health, V6, P21; Ising H, 2003, Noise Health, V5, P41; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lewis SA, 2005, AM J EPIDEMIOL, V161, P406, DOI 10.1093/aje/kwi059; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Lwebuga-Mukasa JS, 2004, J ASTHMA, V41, P289, DOI 10.1081/JAS-120026086; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Meng Ying-Ying, 2006, Policy Brief UCLA Cent Health Policy Res, P1; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Oyana TJ, 2004, AM J PUBLIC HEALTH, V94, P1250, DOI 10.2105/AJPH.94.7.1250; Oyana Tonny J, 2005, Int J Health Geogr, V4, P14, DOI 10.1186/1476-072X-4-14; Reponen T, 2003, J ENVIRON MONITOR, V5, P557, DOI 10.1039/b303557c; Sahsuvaroglu T, 2006, J AIR WASTE MANAGE, V56, P1059; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smargiassi A, 2006, J EPIDEMIOL COMMUN H, V60, P507, DOI 10.1136/jech.2005.037044; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167; Trenga CA, 2006, CHEST, V129, P1614, DOI 10.1378/chest.129.6.1614; *US EPA, 2006, US MEX BORD ENV PROG; Venables W. N., 2002, MODERN APPL STAT S; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Wilkinson P, 1999, THORAX, V54, P1070; Witten A, 2005, J OCCUP ENVIRON MED, V47, P1250, DOI 10.1097/01.jom.0000177081.62204.8d	36	80	83	2	19	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2007	176	12					1236	1242		10.1164/rccm.200611-1616OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	243PZ	WOS:000251811100011	17641154	
J	Bernard, A; Carbonnelle, S; Dumont, X; Nickmilder, M				Bernard, Alfred; Carbonnelle, Sylviane; Dumont, Xavier; Nickmilder, Marc			Infant swimming practice, pulmonary epithelium integrity, and the risk of allergic and respiratory diseases later in childhood	PEDIATRICS			English	Article						chlorine; trichloramine; nitrogen trichloride; baby swimming; Clara cell protein; CC16; childhood asthma; recurrent bronchitis	CLARA CELL PROTEIN; EXHALED NITRIC-OXIDE; POOL ATTENDANCE; SERUM PNEUMOPROTEINS; ASTHMA; LUNG; CHILDREN; CC16; EXPOSURE; EXERCISE	Objective. Irritant gases and aerosols contaminating the air of indoor swimming pools can affect the lung epithelium and increase asthma risk in children. We evaluated the impact of infant swimming practice on allergic status and respiratory health later in childhood. Methods. Clara cell protein, surfactant-associated protein D, and total and aeroallergen-specific immunoglobulin E were measured in the serum of 341 schoolchildren aged 10 to 13 years, among whom 43 had followed an infant swimming program. Asthma was defined as doctor-diagnosed asthma and/or positive exercise-induced bronchoconstriction (15% decrease in postexercise forced expiratory volume). Results. There were no significant differences between the infant swimming group and the other children regarding the levels of exhaled nitric oxide and total or aeroallergen-specific serum immunoglobulin E. Children who swam as infants showed, by contrast, a significant decrease of serum Clara cell protein and of the serum Clara cell protein/surfactant-associated protein D ratio integrating Clara cell damage and permeability changes of the lung epithelial barrier. These effects were associated with higher risks of asthma and of recurrent bronchitis. Passive exposure to tobacco alone had no effect on these outcomes but seemed to interact with infant swimming practice to increase the risk of asthma or of recurrent bronchitis. Conclusions. Our data suggest that infant swimming practice in chlorinated indoor swimming pools is associated with airways changes that, along with other factors, seem to predispose children to the development of asthma and recurrent bronchitis.	Univ Catholique Louvain, Fac Med, Toxicol Unit, Dept Publ Hlth, B-1200 Brussels, Belgium	Bernard, A (reprint author), Univ Catholique Louvain, Fac Med, Toxicol Unit, Dept Publ Hlth, Ave 3 Mounier 53, B-1200 Brussels, Belgium.	alfred.bernard@uclouvain.be	Nickmilder, Marc/A-9060-2010; BERNARD, Alfred/A-6511-2010	BERNARD, Alfred/0000-0003-3171-3743			AGIBATI N, 2001, OCCUP ENVIRON MED, V58, P399; Anderson SJ, 2000, PEDIATRICS, V105, P868; BENNETT HJ, 1983, PEDIATRICS, V72, P125; BERNARD A, 1992, EUR RESPIR J, V5, P1231; Bernard A, 2005, TOXICOL APPL PHARM, V206, P185, DOI 10.1016/j.taap.2004.10.022; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; BERNARD A, 1992, LANCET, V339, P1620, DOI 10.1016/0140-6736(92)91891-B; Bernard A, 2006, ENVIRON HEALTH PERSP, V114, P1567, DOI 10.1289/ehp.8461; BERNARD AM, 1994, ENVIRON RES, V66, P96, DOI 10.1006/enrs.1994.1047; BERNARD AM, 1994, EUR RESPIR J, V7, P1932; Bonetto G, 2006, AM J RESP CRIT CARE, V174, P545, DOI 10.1164/rccm.200509-1392OC; Broeckaert F, 2000, CLIN EXP ALLERGY, V30, P469; Burgess JL, 2003, AM J IND MED, V44, P246, DOI 10.1002/ajim.10269; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Cardinale F, 2005, PEDIATR ALLERGY IMMU, V16, P236, DOI 10.1111/j.1399-3038.2005.00265.x; Finkelstein JN, 2004, PEDIATRICS, V113, P1092; FREEDMAN FB, 2003, WATER BABIES; GOLDBERG GN, 1982, PEDIATRICS, V70, P599; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hermans C, 1998, CLIN CHIM ACTA, V272, P101, DOI 10.1016/S0009-8981(98)00006-0; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; HERY M, 1995, ANN OCCUP HYG, V39, P427, DOI 10.1016/0003-4878(95)00013-5; *IUSE, 2004, MEAS CHLOR AIR SWIMM; JESSEN HJ, 1988, Z GESAMTE HYG, V34, P248; Johnston CJ, 1997, AM J RESP CELL MOL, V17, P147; JONES A, 1994, THORAX, V49, P757, DOI 10.1136/thx.49.8.757; Kohlhammer Y, 2006, ALLERGY, V61, P1305, DOI 10.1111/j.1398-9995.2006.01229.x; Lagerkvist BJ, 2004, ENVIRON HEALTH PERSP, V112, P1768, DOI 10.1289/ehp.7027; Lesur O, 2006, INTENS CARE MED, V32, P1167, DOI 10.1007/s00134-006-0235-1; Malinovschi A, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-92; Mattsson J, 2005, TRANSPLANTATION, V79, P1411, DOI 10.1097/01.TP.0000158354.39635.AB; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Nickmilder M, 2007, OCCUP ENVIRON MED, V64, P37, DOI 10.1136/oem.2005.025452; Nystad W, 2003, ACTA PAEDIATR, V92, P905, DOI 10.1080/08035250310003587; Parimon Tanyalak, 2004, Respir Care, V49, P291; Porsbjerg C, 2005, ANN ALLERG ASTHMA IM, V95, P137; Rasmussen F, 1999, THORAX, V54, P587; Robin M, 2002, EUR RESPIR J, V20, P1152, DOI 10.1183/09031936.02.02042001; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Shijubo N, 1999, AM J RESP CRIT CARE, V160, P930; Silkoff PE, 2004, J ALLERGY CLIN IMMUN, V114, P1241, DOI 10.1016/j.jaci.2004.08.042; Stav D, 2005, NEW ENGL J MED, V353, P1635, DOI 10.1056/NEJMc050955; Vohra R, 2006, PEDIATR EMERG CARE, V22, P254, DOI 10.1097/01.pec.0000210173.56010.c1; WHO, 2006, GUID SAF RECR WAT EN, V2	44	80	83	1	12	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2007	119	6					1095	1103		10.1542/peds.2006-3333		9	Pediatrics	Pediatrics	174NL	WOS:000246948900008	17545376	
J	Jacobs, JH; Spaan, S; van Rooy, GBGJ; Meliefste, C; Zaat, VAC; Rooyackers, JM; Heederik, D				Jacobs, J. H.; Spaan, S.; van Rooy, G. B. G. J.; Meliefste, C.; Zaat, V. A. C.; Rooyackers, J. M.; Heederik, D.			Exposure to trichloramine and respiratory symptoms in indoor swimming pool workers	EUROPEAN RESPIRATORY JOURNAL			English	Article						occupational asthma; swimming pools; trichloramines	NITROGEN TRICHLORIDE; ASTHMA; CHLORAMINES; CHLORINE; WATER; AIR	The association between swimming pool characteristics and activities of employees and respiratory symptoms in employees was studied. Trichloramine levels were measured to evaluate relationships with pool characteristics and to estimate long-term exposure levels. Questionnaires were available from 624 pool workers and 38 swimming facilities. Chloramine levels were measured by area sampling over 2-h periods and analysed using ion chromatography. Work-related and general respiratory symptoms, and symptoms indicatiive of atopy and bronchial hyperresponsiveness were considered. Respiratory symptom prevalence among pool workers was compared with symptoms in a Dutch population sample. Chloramine levels were modelled with regression analysis. This model was used to estimate long-term average chloramine levels for each pool studied. Employees with higher exposure reported upper respiratory symptoms with greater frequency. Upper respiratory symptoms were statistically significantly associated with cumulative chloramine levels (odds ratio (OR) >1.4 for hoarseness, lost voice, sinusitis). General respiratory symptoms were significantly elevated compared with a Dutch population sample (OR ranged 1.4-7.2). An excess risk for respiratory symptoms indicative of asthma was observed in swimming pool employees. Aggravation of existing respiratory disease or interactions between irritants and allergen exposures are the most likely explanations for the observed associations.	Univ Utrecht, Div Environm Epidemiol, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Netherlands Expertise Ctr Occupat Resp Disorders, Utrecht, Netherlands; Univ Utrecht, Univ Med Ctr Utrecht, Utrecht, Netherlands	Jacobs, JH (reprint author), Univ Utrecht, Div Environm Epidemiol, Inst Risk Assessment Sci, POB 80-178, NL-3508 TD Utrecht, Netherlands.	j.h.jacobs@iras.uu.nl					Armstrong B, 2004, OCCUP ENVIRON MED, V61, P475, DOI 10.1136/oem.2003.011205; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; CHARLIER G, 2003, ETUDE QUALITE ATMOSP; DEJOODE BV, 2004, OCCUPATIONAL DREAM D; GAGNAIRE F, 1994, J APPL TOXICOL, V14, P405, DOI 10.1002/jat.2550140604; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; HERY M, 1995, ANN OCCUP HYG, V39, P427, DOI 10.1016/0003-4878(95)00013-5; LAHL U, 1981, WATER RES, V15, P803, DOI 10.1016/0043-1354(81)90133-0; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; Medina-Ramon M, 2005, OCCUP ENVIRON MED, V62, P598, DOI 10.1136/oem.2004.017640; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; Nemery B, 2002, EUR RESPIR J, V19, P790, DOI 10.1183/09031936.02.00308602; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; PRELLER L, 1995, RESP HLTH EFFECTS PI; RIJCKEN B, 1996, EUROPEES LUCHTWEG ON; SPAAN S, 2004, BLOOTSTELLING ENDOTO; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; WHO, 2000, GUID SAF RECR WAT EN, V2; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702	20	80	81	1	12	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	APR	2007	29	4					690	698		10.1183/09031936.00024706		9	Respiratory System	Respiratory System	156QC	WOS:000245663100012	17107995	
J	Lu, FL; Johnston, RA; Flynt, L; Theman, TA; Terry, RD; Schwartzman, IN; Lee, A; Shore, SA				Lu, FL; Johnston, RA; Flynt, L; Theman, TA; Terry, RD; Schwartzman, IN; Lee, A; Shore, SA			Increased pulmonary responses to acute ozone exposure in obese db/db mice	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						leptin; interleukin-1 beta; airway responsiveness; macrophage inflammatory protein-2; neutrophil; ventilation	BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; LEPTIN RECEPTOR; AIRWAY HYPERRESPONSIVENESS; INSULIN-RESISTANCE; WEIGHT-REDUCTION; SPLICE VARIANTS; ASTHMA SEVERITY; TNF-ALPHA; IN-VITRO	Epidemiological studies indicate the incidence of asthma is increased in obese and overweight humans. Responses to ozone (O-3), an asthma trigger, are increased in obese (ob/ob) mice lacking the satiety hormone leptin. The long form of leptin receptor (Ob-Rb) is required for satiety; mice lacking this receptor (db/db mice) are also substantially obese. Here, wild-type (WT) and db/db mice were exposed to air or O-3 (2 ppm) for 3 h. Airway responsiveness, measured by the forced oscillation technique, was greater in db/db than WT mice after air exposure. O-3-induced increases in pulmonary resistance and airway responsiveness were also greater in db/db mice. BALF eotaxin, IL-6, KC, and MIP-2 increased 4 h after O-3 exposure and subsided by 24 h, whereas protein and neutrophils continued to increase through 24 h. For each outcome, the effect of O-3 was significantly greater in db/db than WT mice. Previously published results obtained in ob/ob mice were similar except for O-3-induced neutrophils and MIP-2, which were not different from WT mice. O-3 also induced pulmonary IL-1 beta and TNF-alpha mRNA expression in db/db but not ob/ob mice. Leptin was increased in serum of db/db mice, and pulmonary mRNA expression of short form of leptin receptor (Ob-R-a) was similar in db/db and WT mice. These data confirm obese mice have innate airway hyperresponsiveness and increased pulmonary responses to O-3. Differences between ob/ob mice, which lack leptin, and db/db mice, which lack Ob-Rb but not Ob-R-a, suggest leptin, acting through Ob-R-a, can modify some pulmonary responses to O-3.	Harvard Univ, Sch Publ Hlth, Physiol Program, Dept Environm Hlth, Boston, MA 02115 USA; Natl Taiwan Univ, Natl Taiwan Univ Hosp & Med Coll, Dept Pediat, Taipei, Taiwan	Shore, SA (reprint author), Harvard Univ, Sch Publ Hlth, Physiol Program, Dept Environm Hlth, Bldg 1,Rm 311,665 Huntington Ave, Boston, MA 02115 USA.	sshore@hsph.harvard.edu	Lu, Frank/G-6196-2012	Lu, Frank/0000-0002-5225-7751	NHLBI NIH HHS [HL 33009]; NIEHS NIH HHS [ES 00002, ES 013307]		Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; ARSALANE K, 1995, AM J RESP CELL MOL, V13, P60; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Bergen HT, 2002, AM J RESP CELL MOL, V27, P71; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Bruno A, 2005, J IMMUNOL, V174, P8090; Brusasco V, 1998, THORAX, V53, P992; Bruun JM, 2003, EUR J ENDOCRINOL, V148, P535, DOI 10.1530/eje.0.1480535; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537; COHEN MP, 1995, J CLIN INVEST, V95, P2338, DOI 10.1172/JCI117926; Considine RV, 1997, INT J BIOCHEM CELL B, V29, P1255, DOI 10.1016/S1357-2725(97)00050-2; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; Faggioni R, 1997, AM J PHYSIOL-REG I, V273, pR181; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; Hamada K, 2003, J IMMUNOL, V170, P1683; Hoggard N, 1997, BIOCHEM BIOPH RES CO, V232, P383, DOI 10.1006/bbrc.1997.6245; Hosoi T, 2002, BRAIN RES, V949, P139, DOI 10.1016/S0006-8993(02)02974-8; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; Hu E, 1996, J BIOL CHEM, V271, P10697; HUANG J, 1992, DIS MARKERS, V10, P81; Inigo C, 2004, J PHYSIOL BIOCHEM, V60, P93; Johnston RA, 2006, AM J PHYSIOL-REG I, V290, pR126, DOI 10.1152/ajpregu.00306.2005; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL61, DOI 10.1152/ajplung.00101.2004; JOHNSTON RA, 2005, AM J PHYSIOL-LUNG C, V288, pL3908; Kellerer M, 1997, DIABETOLOGIA, V40, P1358, DOI 10.1007/s001250050832; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Loffreda S, 1998, FASEB J, V12, P57; Lollmann B, 1997, BIOCHEM BIOPH RES CO, V238, P648, DOI 10.1006/bbrc.1997.7205; Luttmann-Gibson H, 2004, AM J RESP CRIT CARE, V169, pA19; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Ouchi N, 2003, CURR OPIN LIPIDOL, V14, P561, DOI 10.1097/01.mol.0000103609.38789.96; Park JW, 2004, AM J RESP CELL MOL, V30, P830, DOI 10.1165/rcmb.2003.0373OC; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; Sahai A, 2004, AM J PHYSIOL-GASTR L, V287, pG1035, DOI 10.1152/ajpgi.00199.2004; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; SHORE SA, IN PRESS PHARM THER; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tankersley CG, 1998, J APPL PHYSIOL, V85, P2261; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Varraso R, 2005, AM J RESP CRIT CARE, V171, P334, DOI 10.1164/rccm.200405-674OC; Weister MJ, 1987, Toxicol. Appl. Pharmacol, V89, P429; Zarkesh-Esfahani H, 2004, J IMMUNOL, V172, P1809; ZHANG LY, 1995, EXP LUNG RES, V21, P503, DOI 10.3109/01902149509031755	62	80	83	0	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	MAY	2006	290	5					L856	L865		10.1152/ajplung.00386.2005		10	Physiology; Respiratory System	Physiology; Respiratory System	030VU	WOS:000236664000009	16373670	
J	Effros, RM; Casaburi, R; Su, J; Dunning, M; Torday, J; Biller, J; Shaker, R				Effros, RM; Casaburi, R; Su, J; Dunning, M; Torday, J; Biller, J; Shaker, R			The effects of volatile salivary acids and bases on exhaled breath condensate pH	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						acetate; ammonium; bicarbonate; buffer; exhaled breath condensate	CYSTIC-FIBROSIS; AIR-POLLUTION; ASTHMA; ACIDIFICATION; INFLAMMATION; DILUTION; CHILDREN; AMMONIA; DISEASE; COUGH	Rationale: Recent studies have reported acidification of exhaled breath condensate (EBC) in inflammatory lung diseases. This phenomenon, designated "acidopnea," has been attributed to airway inflammation. Objectives: To determine whether salivary acids and bases can influence EBC pH in chronic obstructive pulmonary disease (COPD). Methods: Measurements were made of pH, electrolytes, and volatile bases and acids in saliva and EBC equilibrated with air in 10 healthy subjects and 10 patients. Results: The average EBC pH in COPD was reduced (normal, 7.24 +/- 0.24 SEM; range, 6.11-8.34; COPD, 6.67 +/- 0.18; range, 5.74-7.64; p = 0.079). EBCs were well buffered by NH4+/NH3 and CO2/HCO3- in all but four patients, who had NH4+ concentrations under 60 mu mol/L, and acetate concentrations that approached or exceeded those of NH4+. Saliva contained high concentrations of acetate (similar to 6,000 mu mol/L) and NH4+ (similar to 12,000 mu mol/L). EBC acetate increased and EBC NH4+ decreased when salivary pH was low, consistent with a salivary source for these volatile constituents. Nonvolatile acids did not play a significant role in determining pH of condensates because of extreme dilution of respiratory droplets by water vapor (similar to 1:12,000). Transfer of both acetic acid and NH3 from the saliva to the EBC was in the gas phase rather than droplets. bConclusions: EBC acidification in COPD can be affected by the balance of volatile salivary acids and bases, suggesting that EBC pH may not be a reliable marker of airway acidification. Salivary acidification may play an important role in acidopnea.	Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Inst Biomed Res, LABiomed, Torrance, CA 90502 USA; Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA	Effros, RM (reprint author), Univ Calif Los Angeles, Los Angeles Cty Harbor Med Ctr, Inst Biomed Res, LABiomed, 1124 W Carson St,RB2, Torrance, CA 90502 USA.	reffros@labiomed.org		Torday, John/0000-0001-9071-3052	NHLBI NIH HHS [HL074407, HL55268]; NIDDK NIH HHS [DK25731]		Borrill Z, 2005, EUR RESPIR J, V25, P269, DOI 10.1183/09031936.05.00085804; BRIDGES SR, 1992, AM J CLIN NUTR, V56, P455; Carpagnano GE, 2004, CHEST, V125, P2005, DOI 10.1378/chest.125.6.2005; Chen ZF, 2004, ARCH ORAL BIOL, V49, P863, DOI 10.1016/j.archoralbio.2004.05.002; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; Dwyer TM, 2004, LUNG, V182, P241, DOI 10.1007/s00408-004-2506-3; Effros RM, 2002, AM J RESP CRIT CARE, V165, P663, DOI 10.1164/rccm.2101078; Effros RM, 2003, AM J RESP CRIT CARE, V168, P1500, DOI 10.1164/rccm.200307-920OC; Effros RM, 2005, J APPL PHYSIOL, V99, P1286, DOI 10.1152/japplphysiol.00362.2005; Effros RM, 2004, AM J PHYSIOL-LUNG C, V287, pL1073, DOI 10.1152/ajplung.00069.2004; EFFROS RM, 2003, AM J MED, V115, P137, DOI 10.1016/S0002-9343(03)00212-2; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gessner C, 2003, RESP MED, V97, P1188, DOI 10.1016/S0954-6111(03)00225-7; HARDING SM, 2003, AM J MED, V115, P137; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Hunt JF, 2002, AM J RESP CRIT CARE, V165, P101; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; MITSUHASHI M, 1985, PEDIATRICS, V75, P855; Moloney ED, 2004, AM J RESP CRIT CARE, V169, P64, DOI 10.1164/rccm.200307.105OC; Niimi A, 2004, THORAX, V59, P608, DOI 10.1136/thx.2003.012906; NORWOOD DM, 1992, ARCH ENVIRON HEALTH, V47, P309; OJOOJC, 2005, THORAX, V60, P22; Ricciardolo FLM, 2004, J ALLERGY CLIN IMMUN, V113, P610, DOI 10.1016/j.jaci.2003.12.034; Tate S, 2002, THORAX, V57, P926, DOI 10.1136/thorax.57.11.926; Vass G, 2003, AM J RESP CRIT CARE, V167, P850, DOI 10.1164/rccm.200207-716BC; VAUGHAN J, 2003, EUR RESPIR J, V322, P889; VAUGHAN W, 2001, EUR RESPIR J, V18, pS463; Wells K, 2005, THORAX, V60, P27, DOI 10.1136/thx.2003.020602	29	80	81	1	10	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 15	2006	173	4					386	392		10.1164/rccm.200507-1059OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	012GU	WOS:000235327100006	16284109	
J	Belanger, K; Gent, JF; Triche, EW; Bracken, MB; Leaderer, BP				Belanger, K; Gent, JF; Triche, EW; Bracken, MB; Leaderer, BP			Association of indoor nitrogen dioxide exposure with respiratory symptoms in children with asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; children; gas stoves; indoor environment; nitrogen dioxide; respiratory symptoms	1ST YEAR; PERSONAL EXPOSURE; PRESCHOOL-CHILDREN; AIR CONTAMINANTS; GAS COOKING; LIFE; NO2; POLLUTION; RISK; SCHOOLCHILDREN	Rationale: Chronic exposure to indoor nitrogen dioxide (NO2) is a public health concern. Over half of U.S. households have a source of NO2, and experimental data suggest potential for adverse respiratory effects. Objective: To examine associations of indoor NO2 exposure with respiratory symptoms among children with asthma. Methods: NO2 was measured using Palmes tubes, and respiratory symptoms in the month before sampling were collected during home interviews of mothers of 728 children with active asthma. All were younger than 12 yr, lived at the sampled home for at least 2 mo, and had asthma symptoms or used maintenance medication within the previous year. Measurements: Respiratory symptoms (wheeze, persistent cough, shortness of breath, chest tightness). Results: Mean (SD) NO2 was 8.6 (9.1) ppb in homes with electric ranges and 25.9 (18.1) ppb in homes with gas stoves. In models stratified by housing type (a factor associated with socioeconomic status), gas stove presence and elevated NO2 were each significantly associated with respiratory symptoms, controlling for age, ethnicity, medication, mold/mildew, water leaks, and season of sampling. Among children in multifamily housing, exposure to gas stoves increased likelihood of wheeze (odds ratio [OR], 2.27; 95% confidence interval [95% Cl], 1.15, 4.47), shortness of breath (OR, 2.33; 95% Cl, 1.12, 5.06), and chest tightness (OR, 4.34; 95% Cl, 1.76, 10.69), whereas each 20-ppb increase in NO2 increased both likelihood of any wheeze (OR, 1.52; 95% Cl, 1.04, 2.21) or chest tightness (OR, 1.61; 95% Cl, 1.04, 2.49), and days of wheeze (rate ratio (RR), 1.33; 95% Cl, 1.05, 1.68) or chest tightness (RR, 1.51; 95% Cl, 1.18, 1.91). Conclusion: Exposure to indoor NO2 at levels well below the Environmental Protection Agency outdoor standard (53 ppb) is associated with respiratory symptoms among children with asthma in multifamily housing.	Yale Univ, Sch Med, Yale Ctr Perinatal Pediat & Environm Epidemiol, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA	Belanger, K (reprint author), Yale Univ, Sch Med, Yale Ctr Perinatal Pediat & Environm Epidemiol, Dept Epidemiol & Publ Hlth, 1 Church St,6th Floor, New Haven, CT 06510 USA.	kathleen.belanger@yale.edu	Triche, Elizabeth/I-4986-2014; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIEHS NIH HHS [R01 ES005410, ES07456, ES11013, ES05410, R01 ES007456, R01 ES011013]		Basu R., 1999, J ENV MED, V1, P173, DOI DOI 10.1002/JEM.28; BAUER MA, 1986, AM REV RESPIR DIS, V134, P1203; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; BERGLUND M, 1993, SKANDINAVIAN J WO S2, V19, P37; BREYSSE PN, 2005, ENVIRON RES, V95, P167; Brunekreef B, 2001, CLIN EXP ALLERGY, V31, P1170, DOI 10.1046/j.1365-2222.2001.01208.x; BRUNEKREEF B, 1987, AM J EPIDEMIOL, V125, P892; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Chauhan AJ, 1999, CLIN EXP ALLERGY, V29, P1009, DOI 10.1046/j.1365-2222.1999.00648.x; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; FOLINSBEE LJ, 1992, TOXICOL IND HEALTH, V8, P273; FUHLBRIGGE A, 1997, THORAX S3, V52, P58; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781; GENT JF, 2004, AM J RESP CRIT CARE, V170, pA162; HASSELBLAD V, 1992, J AIR WASTE MANAGE, V42, P662; HOEK G, 1984, INT ARCH OCC ENV HEA, V55, P79, DOI 10.1007/BF00378070; Jarvis D, 1999, THORAX, V54, P1054; KUHR J, 1991, SOZ PRAVENTIV MED, V36, P67, DOI 10.1007/BF01846044; LEADERER BP, 1986, AM J EPIDEMIOL, V124, P275; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Liard R, 1999, ENVIRON RES, V81, P339, DOI 10.1006/enrs.1999.3993; Linaker CH, 2000, THORAX, V55, P930, DOI 10.1136/thorax.55.11.930; Linaker CH, 2000, OCCUP ENVIRON MED, V57, P472, DOI 10.1136/oem.57.7.472; Magnus P, 1998, INT J EPIDEMIOL, V27, P995, DOI 10.1093/ije/27.6.995; Mukala K, 2000, ARCH ENVIRON HEALTH, V55, P431; Nitschke M, 1999, INT J ENVIRON HEAL R, V9, P39, DOI 10.1080/09603129973344; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; PILOTTO LS, 2003, INT J EPIDEMIOL, V33, P208; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1205, DOI 10.1046/j.1365-2222.2001.01168.x; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258; Samet JM, 2004, INT J EPIDEMIOL, V33, P215, DOI 10.1093/ije/dyh045; SAMET JM, 1990, TOXICOL IND HEALTH, V6, P247; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; Smith BJ, 2000, EUR RESPIR J, V16, P879, DOI 10.1183/09031936.00.16587900; Spengler J. D., 1996, RES REP HLTH EFFECTS, V58, P1; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; Sunyer J, 2004, INT J EPIDEMIOL, V33, P116, DOI 10.1093/ije/dyh037; *US CENS BUR, 2000, CENS POP HOUS SUMM; U.S. Environmental Protection Agency, 2005, NAT AMB AIR QUAL STA; Utell M, 1997, COMPREHENSIVE TOXICO, P303; van Strien RT, 2004, EPIDEMIOLOGY, V15, P471, DOI 10.1097/01.ede.0000129511.61698.d8; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; WHO, 2000, AIR QUAL GUID EUR	45	80	84	2	15	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 1	2006	173	3					297	303		10.1164/rccm.200408-1123OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	007IJ	WOS:000234962000009	16254270	
J	Eisner, MD; Klein, J; Hammond, SK; Koren, G; Lactao, G; Iribarren, C				Eisner, MD; Klein, J; Hammond, SK; Koren, G; Lactao, G; Iribarren, C			Directly measured second hand smoke exposure and asthma health outcomes	THORAX			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; QUALITY-OF-LIFE; PASSIVE SMOKING; WORK DISABILITY; NEONATAL HAIR; BETA-AGONISTS; ADULT ASTHMA; NICOTINE; RISK; COTININE	Background: Because they have chronic airway inflammation, adults with asthma could have symptomatic exacerbation after exposure to second hand smoke (SHS). Surprisingly, data on the effects of SHS exposure in adults with asthma are quite limited. Most previous epidemiological studies used self-reported SHS exposure which could be biased by inaccurate reporting. In a prospective cohort study of adult nonsmokers recently admitted to hospital for asthma, the impact of SHS exposure on asthma health outcomes was examined. Methods: Recent SHS exposure during the previous 7 days was directly measured using a personal nicotine badge (n = 189) and exposure during the previous 3 months was estimated using hair nicotine and cotinine levels (n = 138). Asthma severity and health status were ascertained during telephone interviews, and subsequent admission to hospital for asthma was determined from computerised utilisation databases. Results: Most of the adults with asthma were exposed to SHS, with estimates ranging from 60% to 83% depending on the time frame and methodology. The highest level of recent SHS exposure, as measured by the personal nicotine badge, was related to greater asthma severity (mean score increment for highest tertile of nicotine level 1.56 points; 95% CI 0.18 to 2.95), controlling for sociodemographic covariates and previous smoking history. Moreover, the second and third tertiles of hair nicotine exposure during the previous month were associated with a greater baseline prospective risk of hospital admission for asthma (HR 3.73; 95% CI 1.04 to 13.30 and HR 3.61; 95% CI 1.0 to 12.9, respectively). Conclusions: Directly measured SHS exposure appears to be associated with poorer asthma outcomes. In public health terms, these results support efforts to prohibit smoking in public places.	Univ Calif San Francisco, Dept Med, Div Environm & Occupat Med, San Francisco, CA 94117 USA; Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94117 USA; Kaiser Permanente, Div Res, Oakland, CA USA; Hosp Sick Children, Motherisk, Fetal Toxicol Lab, Toronto, ON M5G 1X8, Canada; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Eisner, MD (reprint author), Univ Calif San Francisco, Dept Med, Div Environm & Occupat Med, 350 Parnassus Ave,Ste 609, San Francisco, CA 94117 USA.	eisner@itsa.ucsf.edu	Travers, Mark/C-7832-2011		NHLBI NIH HHS [K23 HL04201]		Allison P. D., 1995, SURVIVAL ANAL USING; Blanc P, 2000, CHEST, V118, P564, DOI 10.1378/chest.118.2.564; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; California Environmental Protection Agency, 1997, HLTH EFF EXP ENV TOB; Chan D, 2004, CLIN BIOCHEM, V37, P429, DOI 10.1016/j.clinbiochem.2004.01.01; COGHLIN J, 1989, AM J EPIDEMIOL, V130, P696; Coultas DB, 1998, THORAX, V53, P381; DimichWard H, 1997, J OCCUP ENVIRON MED, V39, P946, DOI 10.1097/00043764-199710000-00006; Eisner MD, 1998, MED CARE, V36, P1567, DOI 10.1097/00005650-199811000-00006; Eisner MD, 2002, AM J PUBLIC HEALTH, V92, P1506, DOI 10.2105/AJPH.92.9.1506; Eisner MD, 2002, THORAX, V57, P973, DOI 10.1136/thorax.57.11.973; Eisner MD, 2002, CHEST, V122, P826, DOI 10.1378/chest.122.3.826; Eisner MD, 2001, ENVIRON HEALTH PERSP, V109, P809, DOI 10.2307/3454823; Eisner MD, 2001, EUR RESPIR J, V17, P233, DOI 10.1183/09031936.01.17202330; EISNER MD, 2002, AM J RESP CRIT CARE, V165, pA121; Eliopoulos C, 1996, CLIN INVEST MED, V19, P231; ELIOPOULOS C, 1994, JAMA-J AM MED ASSOC, V271, P621, DOI 10.1001/jama.271.8.621; HAMMOND SK, 1987, ENVIRON SCI TECHNOL, V21, P494, DOI 10.1021/es00159a012; HAMMOND SK, 1995, JAMA-J AM MED ASSOC, V274, P956, DOI 10.1001/jama.274.12.956; Iribarren C, 2001, J EPIDEMIOL COMMUN H, V55, P721, DOI 10.1136/jech.55.10.721; Jaakkola MS, 1997, EUR RESPIR J, V10, P2384, DOI 10.1183/09031936.97.10102384; JINDAL SK, 1994, CHEST, V106, P746, DOI 10.1378/chest.106.3.746; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Katz PP, 1999, J CLIN EPIDEMIOL, V52, P667, DOI 10.1016/S0895-4356(99)00026-8; KLEIN J, 1994, THER DRUG MONIT, V16, P67, DOI 10.1097/00007691-199402000-00011; KLEIN J, 1993, NEW ENGL J MED, V328, P66, DOI 10.1056/NEJM199301073280116; Klein J, 1999, HUM EXP TOXICOL, V18, P279, DOI 10.1191/096032799678840048; Knight JM, 1998, J ASTHMA, V35, P113, DOI 10.3109/02770909809055412; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lieu TA, 1999, J ASTHMA, V36, P359, DOI 10.3109/02770909909068229; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; Nafstad P, 1998, AM J PUBLIC HEALTH, V88, P120, DOI 10.2105/AJPH.88.1.120; National Heart Lung and Blood Institute, 1991, J ALLERGY CLIN IMMUN, V88, P425; NILSEN T, 1994, PHARMACOL TOXICOL, V75, P136; OSBORNE ML, 1992, J CLIN EPIDEMIOL, V45, P403, DOI 10.1016/0895-4356(92)90041-K; Osman LM, 2000, AM J RESP CRIT CARE, V161, P498; OSTRO BD, 1994, AM J RESP CRIT CARE, V149, P1400; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sippel JM, 1999, CHEST, V115, P691, DOI 10.1378/chest.115.3.691; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weiss ST, 1999, ENVIRON HEALTH PERSP, V107, P891, DOI 10.2307/3434571; Zahlsen K, 1996, PHARMACOL TOXICOL, V79, P183; 1999, MMWR, V48, P993	45	80	81	1	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	OCT	2005	60	10					814	821		10.1136/thx.2004.037283		8	Respiratory System	Respiratory System	968QS	WOS:000232177800009	16192366	
J	Comhair, SAA; Ricci, KS; Arroliga, M; Lara, AR; Dweik, RA; Song, W; Hazen, SL; Bleecker, ER; Busse, WW; Chung, KF; Gaston, B; Hastie, A; Hew, M; Jarjour, N; Moore, W; Peters, S; Teague, WG; Wenzel, SE; Erzurum, SC				Comhair, SAA; Ricci, KS; Arroliga, M; Lara, AR; Dweik, RA; Song, W; Hazen, SL; Bleecker, ER; Busse, WW; Chung, KF; Gaston, B; Hastie, A; Hew, M; Jarjour, N; Moore, W; Peters, S; Teague, WG; Wenzel, SE; Erzurum, SC		Severe Asthma Res Program National	Correlation of systemic superoxide dismutase deficiency to airflow obstruction in asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							EOSINOPHIL PEROXIDASE; IN-VIVO; OXIDATIVE STRESS; GLUTATHIONE-PEROXIDASE; ANTIOXIDANT ENZYMES; ENHANCED PRODUCTION; TYROSINE NITRATION; OXYGEN RADICALS; LUNG-DISEASES; MILD ASTHMA	Rationale: Increased oxidative stress and decreased superoxide dismutase (SOD) activity in the asthmatic airway are correlated to airflow limitation and hyperreactivity. We hypothesized that asthmatic individuals with higher levels of oxidative stress may have greater loss of SOD activity, which would be reflected systemically in loss of circulating SOD activity and clinically by development of severe asthma and/or worsening airflow limitation. Methods: To investigate this, serum SOD activity and proteins, the glutathione peroxidase/glutathione antioxidant system, and oxidatively modified amino acids were measured in subjects with asthma and healthy control subjects. Results: SOD activity, but not Mn-SOD or Cu,Zn-SOD protein, was lower in asthmatic serum as compared with control, and activity loss was significantly related to airflow limitation. Further, serum SOD activity demonstrated an inverse correlation with circulating levels of 3-bromotyrosine, a posttranslational modification of proteins produced by the eosinophil peroxidase system of eosinophils. Exposure of purified Cu,Zn-SOD to physiologically relevant levels of eosinophil peroxidase-generated reactive brominating species reactive nitrogen species, or tyrosyl radicals in vitro confirmed that eosinophil-derived oxidative pathways promote enzyme inactivation. Conclusion: These findings are consistent with greater oxidant stress in asthma leading to greater inactivation of SOD, which likely amplifies inflammation and progressive airflow obstruction.	Cleveland Clin Fdn, Dept Pathobiol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pulm, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Allergy, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Crit Care Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Lerner Res Inst, Cleveland, OH 44195 USA	Comhair, SAA (reprint author), Cleveland Clin Fdn, Dept Pathobiol, 9500 Euclid Ave,NB40, Cleveland, OH 44195 USA.	comhais@ccf.org		Chung, Kian Fan/0000-0001-7101-1426	NCRR NIH HHS [M01 RR018390]; NHLBI NIH HHS [HL 07649, HL04265, HL61878, HL69116, HL69130, HL69155, HL69167, HL69170, HL69174, HL69349, P01/U01HL67663, U10HL74225]; NIAID NIH HHS [AI70649]		Alvarez B, 2004, FREE RADICAL BIO MED, V37, P813, DOI 10.1016/j.freeradbiomed.2004.06.006; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; BRACCI R, 1970, BIOL NEONATE, V15, P135; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317; Chang LY, 2002, FREE RADICAL BIO MED, V33, P379, DOI 10.1016/S0891-5849(02)00919-X; Comhair SAA, 1999, AM J RESP CRIT CARE, V159, P1824; Comhair SAA, 2005, AM J PATHOL, V166, P663, DOI 10.1016/S0002-9440(10)62288-2; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; Comhair SAA, 2002, AM J PHYSIOL-LUNG C, V283, pL246, DOI 10.1152/ajplung.00491.2001; Comhair SAA, 2001, FASEB J, V15, P70, DOI 10.1096/fj.00-0085com; COMHAIR SAA, 2005, P AM THORAC SOC, V2, pA240; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V93, P108, DOI 10.1016/0091-6749(94)90239-9; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; ERZURUM SC, 1993, J APPL PHYSIOL, V75, P1256; FLATT A, 1990, THORAX, V45, P95, DOI 10.1136/thx.45.2.95; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; Guo W, 2003, AM J PHYSIOL-HEART C, V285, pH1396, DOI 10.1152/ajpheart.00096.2003; Haahtela T, 1997, CLIN EXP ALLERGY, V27, P351; HASS MA, 1989, J CLIN INVEST, V83, P1241, DOI 10.1172/JCI114007; JARJOUR NN, 1994, J LAB CLIN MED, V123, P131; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905; Joseph-Bowen J, 2004, J ALLERGY CLIN IMMUN, V114, P1040, DOI 10.1016/j.jaci.2004.07.051; KARLSSON K, 1988, BIOCHIM BIOPHYS ACTA, V967, P110, DOI 10.1016/0304-4165(88)90195-X; Kelly FK, 1999, LANCET, V354, P482, DOI 10.1016/S0140-6736(99)01812-7; Kinnula VL, 2003, AM J RESP CRIT CARE, V167, P1600, DOI 10.1164/rccm.200212-1479SO; LARSEN GL, 2000, AM J PHYSIOL-LUNG C, V279, P350; MacMillan-Crow LA, 2001, FREE RADICAL BIO MED, V31, P1603, DOI 10.1016/S0891-5849(01)00750-X; MacMillan-Crow LA, 1999, ARCH BIOCHEM BIOPHYS, V366, P82, DOI 10.1006/abbi.1999.1202; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; MacPherson JC, 2001, J IMMUNOL, V166, P5763; Majori M, 1998, EUR RESPIR J, V11, P133, DOI 10.1183/09031936.98.11010133; Mak JCW, 2004, J ALLERGY CLIN IMMUN, V114, P260, DOI 10.1016/j.jaci.2004.05.013; Mamo LB, 2004, AM J RESP CRIT CARE, V170, P313, DOI 10.1164/rccm.200309-1282OC; MASINI EVA, 2001, AM J RESP CRIT CARE, V163, pA813; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; NEBOT C, 1993, ANAL BIOCHEM, V214, P442, DOI 10.1006/abio.1993.1521; PerrinNadif R, 1996, OCCUP ENVIRON MED, V53, P41; Rahman I, 2000, THORAX, V55, P189, DOI 10.1136/thorax.55.3.189; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; SALO DC, 1990, J BIOL CHEM, V265, P11919; SANDSTROM J, 1994, J BIOL CHEM, V269, P19163; Sanz ML, 1997, ALLERGY, V52, P417, DOI 10.1111/j.1398-9995.1997.tb01021.x; Schunemann HJ, 2001, AM J RESP CRIT CARE, V163, P1246; SHARONOV BP, 1992, BIOCHEM BIOPH RES CO, V189, P1129, DOI 10.1016/0006-291X(92)92321-N; SHULL S, 1991, J BIOL CHEM, V266, P24398; Smith LJ, 1997, FREE RADICAL BIO MED, V22, P1301, DOI 10.1016/S0891-5849(96)00550-3; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461; VACHIER I, 1992, AM REV RESPIR DIS, V146, P1161; Wood LG, 2000, LIPIDS, V35, P967, DOI 10.1007/s11745-000-0607-x; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l	58	80	82	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2005	172	3					306	313		10.1164/rccm.200502-180OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	949IM	WOS:000230778600007	15883124	
J	Green, BJ; Sercombe, JK; Tovey, ER				Green, BJ; Sercombe, JK; Tovey, ER			Fungal fragments and undocumented conidia function as new aeroallergen sources	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; Alternaria species; antigen; conidia; fragment; fungal; hyphae; germination; immunoassay; mold	ALTERNARIA; ASTHMA; GERMINATION; ALLERGENS; EXPOSURE; SPORES	Background: More than 100 genera of fungal conidia are currently recognized as sources of allergens. The contribution of other fungal genera plus airborne fungal hyphae and fragmented conidia to allergic diseases is poorly understood. Objective: We sought to investigate the expression of allergens from airborne wild-type fungi using the Halogen immunoassay, which uses allergic serum IgE to immunostain immobilized allergens extracted from individual fungal particles. Methods: Airborne fungi were collected onto mixed cellulose ester protein-binding membranes for 2.5 hours with volumetric air pumps. Collected fungi were incubated overnight in a humid chamber to promote the germination of conidia. The membranes were laminated with an adhesive cover slip and immunostained with an Altentaria species-sensitive serum IgE pool. The samples were examined by means of light microscopy, and positively immunostained fungal particles were classified and counted. Results: All air samples contained fungal hyphae that expressed soluble allergens and were significantly higher in concentration than counts of conidia of individual well-ebaracterized allergenic genera (P &LT; .05). Resultant immunostaining of fungal hyphae was heterogeneous, and approximately 25% of all hyphae expressed detectable allergen compared with nonstained hyphae (P &LT; .05). Fungal conidia of 10 genera that were previously uncharacterized as allergen sources were shown to demonstrate IgE binding to expressed antigens and accounted for 8% of the total airborne conidia count. Conclusions: Our analysis of wild-type fungi collected indoors presents a new paradigm of natural fungal exposure, which, in addition to commonly recognized species, implicates airborne hyphae, fragmented conidia, and the conidia of a much more diverse range of genera as airborne allergens.	Univ Sydney, Dept Med, Woolcock Allergen Unit, Sydney, NSW 2006, Australia	Green, BJ (reprint author), Univ Sydney, Dept Med, Woolcock Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.	brettg@mail.med.usyd.edu.au	Tovey, Euan/G-8604-2017	Tovey, Euan/0000-0002-1802-7266			Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002; Gots RE, 2003, AIHA J-J SCI OCCUP E, V64, P427, DOI 10.1202/396.1; Green BJ, 2003, J ALLERGY CLIN IMMUN, V111, P285, DOI 10.1067/mai.2003.57; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; Levestin E., 1995, BIOAEROSOLS, P87; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; Li ZJ, 2002, BIOTECHNOL LETT, V24, P1, DOI 10.1023/A:1013848325193; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; MARFENINA OE, 1994, MICROBIOLOGY+, V63, P603; MARK D, 1986, ANN OCCUP HYG, V30, P89, DOI 10.1093/annhyg/30.1.89; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; PAUL GC, 1994, BIOTECHNOL BIOENG, V44, P655, DOI 10.1002/bit.260440513	17	80	82	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1043	1048		10.1016/j.jaci.2005.02.009		6	Allergy; Immunology	Allergy; Immunology	925LR	WOS:000229055100022	15867864	
J	Korppi, M; Piippo-Savolainen, E; Korhonen, K; Remes, S				Korppi, M; Piippo-Savolainen, E; Korhonen, K; Remes, S			Respiratory morbidity 20 years after RSV infection in infancy	PEDIATRIC PULMONOLOGY			English	Article						respiratory syncytial virus; bronchiolitis; pneumonia; lung function; asthma; atopy; childhood; adulthood	SYNCYTIAL VIRUS BRONCHIOLITIS; BRONCHIAL-ASTHMA; AGE; CHILDHOOD; CHILDREN; ALLERGY; HISTORY; ILLNESS; ATOPY; RISK	Epidemiological data suggest that respiratory syncytial virus (RSV) infection in early life is a risk factor for later asthma. There are no prospective studies on RSV infection starting from infancy progressing through childhood into adulthood. We followed up a cohort of children, hospitalized for RSV bronchiolitis or RSV pneumonia before age 24 months, until age 18-20 years. The aim of the study was to evaluate early RSV infection as a risk factor for asthma, bronchial reactivity, and lung function abnormalities in young adults. The participants filled in a questionnaire on asthma and asthma-like symptoms. The clinical study included flow-volume spirometry (FVS), methacholine inhalation challenge (MIC), home PEF (peak expiratory flow) monitoring, and skin prick tests (SPT) to common allergens. Asthma was present in 17-22% of 36 index subjects, depending on asthma definition, compared to 11% of 45 controls. Furthermore, FEV% and MEF25 were lower, and MEF50 tended to be lower, in index than in control subjects. One or more abnormal lung function results were found in 16 (44%) index subjects, but only in 5 (11%) controls (P < 0.01). Bronchial reactivity (PD20 <4,900 mug methacholine) was demonstrated in 16 (46%) index subjects and 14 (32%) controls (NS). At least one positive SPT result was present in 21 (60%) index subjects; 6 (29%) had asthma (NS vs. nonatopic index subjects); 13 (62%) had abnormal lung function (P < 0.05); and 14 (67%) had bronchial reactivity (P < 0.01). In the logistic regression adjusted for atopy, as defined by SPT positivity, RSV infection in infancy was an independent risk factor for lung function abnormality (one or more abnormal results in FVS; OR, 5.27; 95% Cl, 1.6017.36), and also for decreased FEV% and MEF50 when these were analyzed separately. However, RSV infection in infancy was not a significant risk factor for asthma or bronchial reactivity. In young adults, lung function abnormalities may be associated with RSV infection which required hospitalization in infancy. (C) 2004 Wiley-Liss, Inc.	Univ Kuopio, Dept Pediat, FIN-70210 Kuopio, Finland; Kuopio Univ Hosp, SF-70210 Kuopio, Finland	Korppi, M (reprint author), Univ Kuopio, Dept Pediat, FIN-70210 Kuopio, Finland.	matti.korppi@uku.fi					[Anonymous], 1993, ALLERGY, V48, P48; GASTRORODRIQUEZ J, 2000, AM J RESP CRIT CARE, V159, P1891; Guilbert T, 2003, PEDIATR CLIN N AM, V50, P523, DOI 10.1016/S0031-3955(03)00044-0; HAAHTELA T, 1979, ALLERGY, V34, P413, DOI 10.1111/j.1398-9995.1979.tb02011.x; Kneyber M, 2000, ACTA PAEDIATR, V89, P654, DOI 10.1080/080352500750043945; KORPPI M, 1993, AM J DIS CHILD, V147, P628; KORPPI M, 1986, ACTA PAEDIATR SCAND, V75, P457, DOI 10.1111/j.1651-2227.1986.tb10230.x; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079; KUIKKA L, 1994, ACTA PAEDIATR, V83, P744, DOI 10.1111/j.1651-2227.1994.tb13131.x; MACINTOSH K, 1987, PEDIAT REV, V9, P191; Martinez Fernando D, 2002, Paediatr Respir Rev, V3, P193, DOI 10.1016/S1526-0542(02)00188-4; MOK JYQ, 1982, BRIT MED J, V285, P333; MURRAY M, 1992, ARCH DIS CHILD, V67, P482; POYSA L, 1989, ACTA PAEDIATR SCAND, V78, P902, DOI 10.1111/j.1651-2227.1989.tb11172.x; PULLAN CR, 1982, BRIT MED J, V284, P1165; Remes ST, 1996, ACTA PAEDIATR, V85, P59, DOI 10.1111/j.1651-2227.1996.tb13891.x; SAMET JM, 1983, AM REV RESPIR DIS, V127, P508; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; SIMS DG, 1978, BRIT MED J, V1, P11; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stein RT, 1997, THORAX, V52, P946; Strachan DP, 1996, AM J RESP CRIT CARE, V154, P1629; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Turner SW, 2002, ARCH DIS CHILD, V87, P417, DOI 10.1136/adc.87.5.417; Viljanen A A, 1982, Scand J Clin Lab Invest Suppl, V159, P5; Welliver R C, 1999, J Pediatr, V135, P14; Welliver RC, 2000, PEDIATR INFECT DIS J, V19, P780, DOI 10.1097/00006454-200008000-00030	28	80	85	0	3	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	AUG	2004	38	2					155	160		10.1002/ppul.20058		6	Pediatrics; Respiratory System	Pediatrics; Respiratory System	840KM	WOS:000222857500010	15211700	
J	Shaheen, SO; Newson, RB; Henderson, AJ; Emmett, PM; Sherriff, A; Cooke, M				Shaheen, SO; Newson, RB; Henderson, AJ; Emmett, PM; Sherriff, A; Cooke, M		ALSPAC Study Team	Umbilical cord trace elements and minerals and risk of early childhood wheezing and eczema	EUROPEAN RESPIRATORY JOURNAL			English	Article						birth cohort; eczema; prenatal/foetal nutrition; trace elements/minerals; wheezing	CYTOKINE PRODUCTION; ATOPIC-DERMATITIS; IRON-DEFICIENCY; IMMUNE FUNCTION; FETAL-GROWTH; DISEASE; BIRTH; CHILDREN; ASTHMA; PREGNANCY	It has been suggested that foetal nutrition might influence the inception of wheezing and atopic disorders in childhood but specific nutrients have not been implicated. In the Avon Longitudinal Study of Parents and Children umbilical cord samples were assayed for trace elements and minerals, and mothers were asked about wheezing and eczema in their children. Associations of cord concentrations of selenium, zinc, copper, manganese, magnesium, iron, lead and mercury with wheezing at 30-42 months, with wheezing patterns defined by the presence or absence of transient infant, later onset or persistent wheezing at 0-6 months and 30-42 months, respectively (n=2,044), and with eczema at 18-30 months (n=2,173), were analysed. Cord selenium was negatively associated with persistent wheeze (adjusted odds ratio (OR) per doubling concentration: 0.67). Cord iron was negatively associated with later onset wheeze (OR: 0.86) and with eczema (OR: 0.90). Children with high cord concentrations of selenium and iron were less likely than those with low concentrations to wheeze transiently in infancy. The level of foetal exposure to selenium and iron may possibly influence the risk of wheezing and eczema in early childhood although, in view of the multiple analyses carried out, it is possible that the main findings occurred by chance.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England; Univ London, Royal Holloway & Bedford New Coll, Ctr Chem Sci, London SE1 3QD, England; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England	Shaheen, SO (reprint author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, Capital House,42 Weston St, London SE1 3QD, England.	seif.shaheen@kcl.ac.uk		Henderson, Alexander John/0000-0001-9650-231X; Emmett, Pauline/0000-0003-1076-4779			Akagi H, 1998, ENVIRON RES, V77, P98, DOI 10.1006/enrs.1997.3822; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BRITTON J, 1994, LANCET, V344, P357, DOI 10.1016/S0140-6736(94)91399-4; Brock JH, 2000, P NUTR SOC, V59, P537, DOI 10.1017/S002966510000077X; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Gambling L, 2002, BIOL REPROD, V66, P516, DOI 10.1095/biolreprod66.2.516; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; Harding JE, 2001, INT J EPIDEMIOL, V30, P15, DOI 10.1093/ije/30.1.15; Heo Y, 1996, TOXICOL APPL PHARM, V138, P149, DOI 10.1006/taap.1996.0108; Jason J, 2001, CLIN EXP IMMUNOL, V126, P466, DOI 10.1046/j.1365-2249.2001.01707.x; KIM HY, 1991, PEDIATR RES, V29, P440, DOI 10.1203/00006450-199105010-00006; Klesges LM, 1998, AM J EPIDEMIOL, V147, P127; Kugelmas V, 2000, J TRACE ELEM EXP MED, V13, P327; Langley-Evans S, 1997, CLIN EXP ALLERGY, V27, P1377, DOI 10.1046/j.1365-2222.1997.1690965.x; Leadbitter P, 1999, THORAX, V54, P905; Levander OA, 1986, J AM COLL TOXICOL, V5, P37; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mathews F, 1998, J HUM NUTR DIET, V11, P151; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Miller TE, 1998, TOXICOL SCI, V42, P129, DOI 10.1006/toxs.1998.2424; Myers GJ, 2003, LANCET, V361, P1686, DOI 10.1016/S0140-6736(03)13371-5; NISHIGAKI S, 1975, NATURE, V258, P324, DOI 10.1038/258324a0; Olesen AB, 1997, BRIT MED J, V314, P1003; Oryszczyn MP, 1999, CLIN EXP ALLERGY, V29, P334; Paeratakul S, 1998, EUR J CLIN NUTR, V52, P722, DOI 10.1038/sj.ejcn.1600633; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rayman MP, 1997, BRIT MED J, V314, P387; Rogers I, 1998, EUR J CLIN NUTR, V52, P246, DOI 10.1038/sj.ejcn.1600543; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Sprietsma JE, 1999, MED HYPOTHESES, V53, P6, DOI 10.1054/mehy.1999.0867; Stata, 2001, STAT STAT SOFTW REL; THIBAULT H, 1993, EUR J PEDIATR, V152, P120, DOI 10.1007/BF02072487; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Weiss G, 2002, EUR J CLIN INVEST, V32, P70, DOI 10.1046/j.1365-2362.2002.0320s1070.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Zhang ZW, 1999, EUR J CLIN NUTR, V53, P226, DOI 10.1038/sj.ejcn.1600711	40	80	81	3	8	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	AUG	2004	24	2					292	297		10.1183/09031936.04.00117803		6	Respiratory System	Respiratory System	842WG	WOS:000223034600019	15332400	
J	Gangloff, M; Gay, NJ				Gangloff, M; Gay, NJ			MD-2: the Toll 'gatekeeper' in endotoxin signalling	TRENDS IN BIOCHEMICAL SCIENCES			English	Editorial Material							DUST-MITE ALLERGEN; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; N-LINKED GLYCOSYLATIONS; LPS BINDING-PROTEIN; CRYSTAL-STRUCTURE; DROSOPHILA TOLL; GM2-ACTIVATOR PROTEIN; ANGSTROM RESOLUTION; ESCHERICHIA-COLI; INNATE IMMUNITY	Lipopolysaccharide (LPS) from the outer cell wall of Gram-negative bacteria is a potent stimulator of the mammalian innate immune system. The Toll-like receptor 4 (TLR4) pathway triggers the inflammatory responses induced by LPS in a process that requires the interaction of LPS-bound myeloid differentiation-2 (MD-2) with TLR4. Here we propose two possible mechanisms for LPS recognition and signalling that take into account both the structural information available for TLR4 and MD-2, and the determinants of endotoxicity, namely, the acylation and phosphorylation patterns of LIPS. In our first model, LPS induces the association of two TLR4-MD-2 heterodimers by binding to two different molecules of MD-2 through the acyl chains of lipid A. In our second model, the binding of LPS to a single TLR4-MD-2 complex facilitates the recruitment of a second TLR4-MD-2 heterodimer. These models contrast with the activation of Drosophila Toll, where the receptor is crosslinked by a dimeric protein ligand.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	Gangloff, M (reprint author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.	njg11@mole.bio.cam.ac.uk		Gangloff, Monique/0000-0001-6131-0115	Medical Research Council [G0400007, G1000133]		Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Beamer LJ, 1997, SCIENCE, V276, P1861, DOI 10.1126/science.276.5320.1861; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Buchanan SGS, 1996, PROG BIOPHYS MOL BIO, V65, P1, DOI 10.1016/S0079-6107(96)00003-X; Correia JD, 2002, J BIOL CHEM, V277, P1845, DOI 10.1074/jbc.M109910200; DeLotto Y, 1998, MECH DEVELOP, V72, P141, DOI 10.1016/S0925-4773(98)00024-0; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.0000/S0022-2836(02)00027-X; DIN ZZ, 1993, BIOCHEMISTRY-US, V32, P4579, DOI 10.1021/bi00068a014; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCT FOLD DES, V8, P585; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Gangloff M, 2003, BIOCHEM SOC T, V31, P659, DOI 10.1042/BST0310659; Golenbock DT, 2001, NAT IMMUNOL, V2, P286, DOI 10.1038/86289; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; HOESS A, 1993, EMBO J, V12, P3351; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; Imler JL, 2001, TRENDS CELL BIOL, V11, P304, DOI 10.1016/S0962-8924(01)02004-9; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Jack RS, 1997, NATURE, V389, P742, DOI 10.1038/39622; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Liang J, 1998, PROTEIN SCI, V7, P1884; LUGTENBERG B, 1983, BIOCHIM BIOPHYS ACTA, V737, P51, DOI 10.1016/0304-4157(83)90014-X; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 1997, NATURE, V388, P394; Mizuguchi K, 1998, TRENDS BIOCHEM SCI, V23, P239, DOI 10.1016/S0968-0004(98)01216-X; MORISATO D, 1994, CELL, V76, P677, DOI 10.1016/0092-8674(94)90507-X; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2001, J IMMUNOL, V167, P3354; Parker JS, 2001, PROTEINS, V45, P71, DOI 10.1002/prot.1125; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Weber ANR, 2003, NAT IMMUNOL, V4, P794, DOI 10.1038/ni955; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; WRIGHT SD, 1989, J EXP MED, V170, P1231, DOI 10.1084/jem.170.4.1231; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311	52	80	85	0	1	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0968-0004			TRENDS BIOCHEM SCI	Trends Biochem.Sci.	JUN	2004	29	6					294	300		10.1016/j.tibs.2004.04.008		7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	834KR	WOS:000222410500006	15276183	
J	Harik-Khan, RI; Muller, DC; Wise, RA				Harik-Khan, RI; Muller, DC; Wise, RA			Serum vitamin levels and the risk of asthma in children	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						adolescent; antioxidants; ascorbic acid; asthma; child	NUTRITION-EXAMINATION-SURVEY; NATIONAL-HEALTH; ASCORBIC-ACID; PULMONARY-FUNCTION; BRONCHIAL-ASTHMA; ALPHA-TOCOPHEROL; RESPONSIVENESS; ANTIOXIDANTS; CONSUMPTION; HISTAMINE	Dietary intake, especially of antioxidant vitamins A, C, E, and the carotenoids, has been linked with the presence and severity of asthma. From the Third National Health and Nutrition Examination Survey (NHANES III), conducted in the United States between 1988 and 1994, the authors selected 4,093 children (aged 6-17 years) for whom relevant medical, socioeconomic, and anthropometric data were complete. The children were 50.6% female, and 9.7% reported a diagnosis of asthma. Bivariate analyses showed that asthma diagnosis was associated with lower levels of serum vitamin C, alpha-carotene, beta-carotene, and beta-cryptoxanthin. However, antioxidant levels may be surrogate markers for socioeconomic variables such as race, poverty, tobacco exposure, or general nutritional status. In logistic models that included age, body mass index, socioeconomic variables, antioxidant levels, parental asthma, and household smoking, the only antioxidants significantly associated with asthma were vitamin C (odds ratio = 0.72 per mg/dl, 95% confidence interval = 0.55, 0.95) and alpha-carotene (odds ratio = 0.95 per mug/dl, 95% confidence interval = 0.90, 0.99). The odds ratio for asthma in the highest quintile of serum vitamin C relative to the lowest was 0.65 (p < 0.05), whereas it was 0.74 for &alpha;-carotene (p = 0.066). The authors concluded that low vitamin C and &alpha;-carotene intakes are associated with asthma risk in children.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA; NIA, Clin Res Branch, NIH, Baltimore, MD USA	Wise, RA (reprint author), Johns Hopkins Univ, Sch Med, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	rwise@jhmi.edu		Wise, Robert/0000-0002-8353-2349			ADERELE W I, 1985, African Journal of Medicine and Medical Sciences, V14, P115; BIELORY L, 1994, ANN ALLERGY, V73, P89; BUCCA C, 1990, ANN ALLERGY, V65, P311; BUCCA C, 1989, EUR RESPIR J, V2, P229; CHYTIL F, 1992, AM J PHYSIOL, V262, P517; Cook DG, 1997, THORAX, V52, P628; Forastiere F, 2000, THORAX, V55, P283, DOI 10.1136/thorax.55.4.283; Gray T, 2001, TOXICOLOGY, V160, P35, DOI 10.1016/S0300-483X(00)00455-8; Gunter EW, 1996, LAB PROCEDURES USED; Hatch GE, 1995, AM J CLIN NUTR S, V61, p625S; Hu GZ, 2000, AM J EPIDEMIOL, V151, P975; Kalayci O, 2000, TURKISH J PEDIATR, V42, P17; Kaur B, 2001, COCHRANE DB SYST REV; Knutsen SF, 2001, ANN EPIDEMIOL, V11, P406, DOI 10.1016/S1047-2797(01)00224-1; Mainous AG, 2000, ARCH FAM MED, V9, P241, DOI 10.1001/archfami.9.3.241; MOHSENIN V, 1983, AM REV RESPIR DIS, V127, P143; Monteleone CA, 1997, ARCH INTERN MED, V157, P23, DOI 10.1001/archinte.157.1.23; Mudway IS, 2001, FREE RADICAL BIO MED, V31, P962, DOI 10.1016/S0891-5849(01)00671-2; OGILVY CS, 1981, J ALLERGY CLIN IMMUN, V67, P363, DOI 10.1016/0091-6749(81)90081-6; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Picado C, 2001, ALLERGY, V56, P43, DOI 10.1034/j.1398-9995.2001.00793.x; POWELL CVE, 1994, PEDIATR PULM, V18, P34, DOI 10.1002/ppul.1950180109; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Schock BC, 2001, PEDIATR RES, V49, P155, DOI 10.1203/00006450-200102000-00005; SCHWARTZ J, 1994, AM J CLIN NUTR, V59, P110; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; SEATON A, 2000, PEDIAT ALLERGY IMM S, V13, P37; Soutar A, 1997, THORAX, V52, P166; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weiss ST, 1997, CIBA F SYMP, V206, P244; WinklhoferRoob BM, 1997, AM J CLIN NUTR, V65, P1858; [Anonymous], 1994, VITAL HLTH STAT 1, V1, P1	32	80	83	0	0	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	FEB 15	2004	159	4					351	357		10.1093/aje/kwh053		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	774GQ	WOS:000188971800004	14769638	
J	Lehrer, SB; Ayuso, R; Reese, G				Lehrer, SB; Ayuso, R; Reese, G			Seafood allergy and allergens: A review	MARINE BIOTECHNOLOGY			English	Review						seafood; shrimp; allergy; tropomyosin; epitopes; IgE antibody reactivity	IGE-BINDING EPITOPES; GRASS-POLLEN IMMUNOTHERAPY; MUSCLE PROTEIN TROPOMYOSIN; CROSS-REACTIVE ALLERGEN; CRAB-PROCESSING WORKERS; CULTURE-OYSTER WORKERS; MAJOR SHRIMP ALLERGEN; SALMON SALMO-SALAR; OCCUPATIONAL ASTHMA; CONTACT URTICARIA	Seafoods are composed of diverse sea organisms and humans are allergic to many of them. Tropomyosin is a major allergen in many shellfish, especially crustacea and mollusks. Interestingly, tropomyosin has also been identified as an important allergen in other invertebrates including dust mites and cockroaches, and it has been proposed by some to be an invertebrate pan allergen. Different regions of shrimp tropomyosin bind IgE; 5 major IgE-binding regions have been identified in shrimp tropomyosin containing 8 epitopes. Mutations of these shrimp allergenic epitopes can reduce seafood allergenicity; methods utilizing such mutations will provide safer vaccines for more effective treatment of seafood-allergic patients, and in the future less-allergenic seafood products for consumption.	Tulane Univ, Hlth Sci Ctr, Dept Med, Clin Immunol Sect, New Orleans, LA 70112 USA	Lehrer, SB (reprint author), Tulane Univ, Hlth Sci Ctr, Dept Med, Clin Immunol Sect, Allergy & Rheumatol 1700 Perdido St,SL-57, New Orleans, LA 70112 USA.						AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Asturias JA, 1999, J IMMUNOL, V162, P4342; Ayuso R, 2002, INT ARCH ALLERGY IMM, V127, P27, DOI 10.1159/000048166; Ayuso R, 1999, J ALLERGY CLIN IMMUN, V103, pS866; Baur X, 2000, ALLERGY, V55, P96, DOI 10.1034/j.1398-9995.2000.00462.x; BECK HI, 1983, ACTA DERM-VENEREOL, V63, P257; BURCHES E, 1992, CONTACT DERMATITIS, V26, P277, DOI 10.1111/j.1600-0536.1992.tb00255.x; Carino M, 1985, Med Lav, V76, P471; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CARTIER A, 1986, J ALLERGY CLIN IMMUN, V78, P344, DOI 10.1016/S0091-6749(86)80087-2; CDC (Centre for Disease Control and Prevention), 1982, MMWR-MORBID MORTAL W, V31, P95; Chu KH, 2000, MAR BIOTECHNOL, V2, P499; CRONIN E, 1987, CONTACT DERMATITIS, V17, P265, DOI 10.1111/j.1600-0536.1987.tb01475.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; DAUL CB, 1993, MOLECULAR BIOLOGY AND IMMUNOLOGY OF ALLERGENS, P291; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; DAUL CB, 1993, CLIN REV ALLERG, V11, P201; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; DROSZCZ W, 1981, INT ARCH OCC ENV HEA, V49, P13, DOI 10.1007/BF00380804; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; ELSAYED S, 1972, IMMUNOCHEMISTRY, V9, P647, DOI 10.1016/0019-2791(72)90250-9; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; Ferreira F, 1998, FASEB J, V12, P231; Fisher A A, 1988, Cutis, V42, P388; Freeman J, 1911, LANCET, V2, P814; GADDIE J, 1980, LANCET, V2, P1350; Goetz DW, 2000, ANN ALLERG ASTHMA IM, V85, P461; GORANSSON K, 1981, CONTACT DERMATITIS, V7, P282; Hjorth N, 1976, Contact Dermatitis, V2, P28, DOI 10.1111/j.1600-0536.1976.tb02975.x; Ishikawa M, 1998, J FOOD SCI, V63, P44, DOI 10.1111/j.1365-2621.1998.tb15672.x; Ishikawa M, 1998, BIOSCI BIOTECH BIOCH, V62, P1337, DOI 10.1271/bbb.62.1337; IYO T, 1974, ALLERGY IMMUNOL, V20, P435; KAVLI G, 1987, CONTACT DERMATITIS, V17, P153, DOI 10.1111/j.1600-0536.1987.tb02696.x; Kim W H, 1982, Yonsei Med J, V23, P123; Lehrer SB, 1999, CLIN REV ALLERG IMMU, V17, P361, DOI 10.1007/BF02737616; LEHRER SB, 1998, FOOD ALLERGENS IMPLI; Lemiere C, 1996, ALLERGY, V51, P272, DOI 10.1111/j.1398-9995.1996.tb04606.x; Leung PSC, 1998, J ALLERGY CLIN IMMUN, V102, P847, DOI 10.1016/S0091-6749(98)70027-2; Leung PSC, 1998, MOL MAR BIOL BIOTECH, V7, P12; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V92, P837; Lindstrom CDV, 1996, SCAND J IMMUNOL, V44, P335, DOI 10.1046/j.1365-3083.1996.d01-314.x; Lopata AL, 1997, J ALLERGY CLIN IMMUN, V100, P642, DOI 10.1016/S0091-6749(97)70168-4; MAIBACH HI, 1986, CONTACT DERMATITIS, V15, P100, DOI 10.1111/j.1600-0536.1986.tb01292.x; Marshall GD, 1997, NAT BIOTECHNOL, V15, P718; McSharry C, 1987, Adv Exp Med Biol, V216A, P865; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; MORGAN J E, 1990, Journal of Allergy and Clinical Immunology, V85, P170; Mykles DL, 1998, J MUSCLE RES CELL M, V19, P105, DOI 10.1023/A:1005352410725; NAKASHIMA T, 1969, HIROSHIMA J MED SCI, V18, P141; NEWHOUSE ML, 1966, P ROY SOC MED, V59, P1119; Noon L, 1911, LANCET, V1, P1572; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; ONEILL CE, 1996, FOOD ALLERGY ADVERSE, P311; ORFORD RR, 1985, AM J IND MED, V7, P155, DOI 10.1002/ajim.4700070207; PATEL PC, 1992, ANN ALLERGY, V68, P360; RASHEIAKOTELBA B, 1979, PRZEGL DERMATOL, V66, P367; RASHEIAKOTELBA B, 1979, VESTN DERMATOL VENER, V5, P46; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Reese G, 1999, INT ARCH ALLERGY IMM, V118, P300, DOI 10.1159/000024108; Rodriguez J, 1997, ALLERGY, V52, P866, DOI 10.1111/j.1398-9995.1997.tb02159.x; Sabatini C, 1969, Folia Med (Napoli), V52, P109; SAMPSON HA, 1991, FOOD ALLERGY ADVERSE, P99; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V103, pS122; SECRIST H, 1995, J EXP MED, V181, P1081, DOI 10.1084/jem.181.3.1081; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; Tas J, 1972, Isr J Med Sci, V81, P630; TAYLOR SL, 1988, MARINE TOXINS VENOMS, V3, P149; Van Do T, 1999, SCAND J IMMUNOL, V50, P619; WADA S, 1967, HIROSHIMA J MED SCI, V16, P255; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Yamura T, 1966, Arerugi, V15, P813; Zhoutyi VR, 1973, VESTN DERMATIL VENER, V47, P71	75	80	112	1	18	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	1436-2228			MAR BIOTECHNOL	Mar. Biotechnol.	JUL-AUG	2003	5	4					339	348		10.1007/s10126-002-0082-1		10	Biotechnology & Applied Microbiology; Marine & Freshwater Biology	Biotechnology & Applied Microbiology; Marine & Freshwater Biology	724XG	WOS:000185513100003	14719162	
J	Packard, KA; Khan, MM				Packard, KA; Khan, MM			Effects of histamine on Th1/Th2 cytokine balance	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Review						Th1/Th2; histamine; asthma	PROTEIN-KINASE-A; RECOMBINANT INTERFERON-GAMMA; ALLERGIC AIRWAY INFLAMMATION; NATURAL SUPPRESSOR CELLS; NITRIC-OXIDE SYNTHASE; HUMAN T-CELLS; IFN-GAMMA; TH2 CELLS; SIGNAL-TRANSDUCTION; IMMUNE-RESPONSE	Atopic asthma is a chronic inflammatory disorder of the airways where upon exposure to allergens, the body mounts an immune response. This disease is associated with an increase in the number of Th2 (T helper type 2) cells and Th2 cytokines and a decrease in the number of Th1 (T helper type 1) cells and Th1 cytokines. Histamine plays an important role in the pathogenesis of atopic asthma through differential regulation of T helper lymphocytes. Histamine enhances the secretion of Th2 cytokines such as IL-4 (interleukin-4), IL-5, IL-10 and IL-13 and inhibits the production of Th1 cytokines IL-2 and IFNgamma (interferon-gamma)and monokine IL-12. It has been shown that histamine can modulate the cytokine network through upregulation of PGE(2) (prostaglandin E-2) and NO (nitric oxide). Histamine also affects cytokine production via H2 receptors and through the activation of PKA (protein kinase A). We have also demonstrated that the Jak-STAT (Janus kinase-signal transducers and activators of transcription) pathway is involved in histamine-mediated regulation of Th2 cytokines IL-5, IL-10, IL-13 and Th1 cytokine IFNgamma. While standard treatment of asthma consists of beta-receptor agonists and inhaled corticosteroids, the elucidation of histamine's control over the cytokine network and the Th1/Th2 balance provides a basis for the potential use of antihistamines in the prevention and treatment of atopic asthma. Several other anti-allergic agents to modulate the Th1/Th2 balance are under current investigation based on this paradigm. These include cytokines, cytokine antagonists, anti-IgE, and vaccinations. As more advances are made in our understanding of histamine and its control over the Th1/Th2 balance, the use of new therapeutic targets such as these will play a prominent role in disease management. (C) 2003 Published by Elsevier Science B.V.	Creighton Univ, Dept Pharm Sci, Omaha, NE 68178 USA	Khan, MM (reprint author), Creighton Univ, Dept Pharm Sci, Omaha, NE 68178 USA.						*AM LUNG ASS WEBS, 2001, TRENDS ASTHM MORB MO; Arad G, 1996, CELL IMMUNOL, V170, P149, DOI 10.1006/cimm.1996.0145; Babe KS, 1996, GOODMAN GILMANS PHAR, P581; Benbernou N, 1997, IMMUNOLOGY, V91, P361, DOI 10.1046/j.1365-2567.1997.00260.x; BETZ M, 1991, J IMMUNOL, V146, P108; BOGUNIEWICZ M, 1993, CLIN EXP ALLERGY, V23, P785, DOI 10.1111/j.1365-2222.1993.tb00367.x; BORISH LC, 2001, J ALLERGY CLIN IMMUN, V107, P63; Brune M, 1996, EUR J HAEMATOL, V57, P312; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CARLSSON R, 1985, CELL IMMUNOL, V96, P104, DOI 10.1016/0008-8749(85)90343-0; Caron G, 2001, J IMMUNOL, V167, P3682; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; DEVRIES JE, 1995, INT ARCH ALLERGY IMM, V106, P175; DOHLSTEN M, 1986, CELL IMMUNOL, V101, P493, DOI 10.1016/0008-8749(86)90160-7; Eigler A, 1998, J LEUKOCYTE BIOL, V63, P101; ELENKOV I, 1998, J IMMUNOL, V161, P2583; Elliott KA, 2001, INT IMMUNOPHARMACOL, V1, P1923, DOI 10.1016/S1567-5769(01)00117-5; Essayan DM, 1999, J ALLERGY CLIN IMMUN, V103, P451, DOI 10.1016/S0091-6749(99)70470-7; Girdlestone J, 1996, EUR J IMMUNOL, V26, P704, DOI 10.1002/eji.1830260329; GOODWIN JS, 1977, J EXP MED, V146, P1719, DOI 10.1084/jem.146.6.1719; GOODWIN JS, 1983, J CLIN IMMUNOL, V3, P295, DOI 10.1007/BF00915791; GOTO T, 1983, J IMMUNOL, V130, P1350; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Haque SJ, 1998, SEMIN ONCOL, V25, P14; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Kato Y, 1999, J IMMUNOL, V162, P7470; KENT TH, 1993, ASTHMA INTRO HUMAN D, P227; KHAN M M, 1985, Clinical Immunology Reviews, V4, P1; KHAN MM, 1986, J IMMUNOL, V137, P308; KHAN MM, 1985, J IMMUNOL, V134, P4100; KHAN MM, 1989, CELL IMMUNOL, V121, P60, DOI 10.1016/0008-8749(89)90005-1; KHAN MM, 1985, J CLIN INVEST, V75, P1578, DOI 10.1172/JCI111863; KHAN MM, 1988, HDB EXPT PHARM, V85, P363; Kips JC, 1996, AM J RESP CRIT CARE, V153, P535; Kirken RA, 1999, J LEUKOCYTE BIOL, V65, P891; Knol K, 2000, ALLERGY, V55, P31, DOI 10.1034/j.1398-9995.2000.00005.x; Krouwels FH, 1998, AM J RESP CELL MOL, V18, P721; Kuo ML, 2001, ANN ALLERG ASTHMA IM, V86, P272; Lack G, 1996, J IMMUNOL, V157, P1432; Lagier B, 1997, CLIN EXP IMMUNOL, V108, P545, DOI 10.1046/j.1365-2249.1997.3791276.x; Levy F, 1997, INT ARCH ALLERGY IMM, V112, P49; Li Y, 1998, J IMMUNOL, V161, P7007; LIEW FY, 1991, EUR J IMMUNOL, V21, P2489, DOI 10.1002/eji.1830211027; Liu CL, 2001, J PHARMACOL EXP THER, V299, P121; LOHMANN SM, 1984, ADV CYCLIC NUCL PROT, V18, P63; Moriggl R, 1998, J IMMUNOL, V160, P3385; Munakata Y, 1999, CLIN EXP ALLERGY, V29, P1281; NAKAJIMA H, 1993, AM REV RESPIR DIS, V148, P1102; *NAT I ENV HLTH SC, 1997, 9 NAT I ENV HLTH SCI; Nguyen T, 2001, MOL PHARMACOL, V59, P427; *NHLBI, 1997, PUBL US DEP HLTH HUM; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Oda T, 2001, Nihon Yakurigaku Zasshi, V118, P36; Ohmori Y, 1997, J IMMUNOL, V159, P5474; OSHIMA Y, 2001, J BIOL CHEM, V276, P11585; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P759, DOI 10.1016/S1567-5769(01)00009-1; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; OSNA N, 2001, INT IMMUNOPHARMACOL, V1, P125; Pauwels RA, 1998, CLIN EXP ALLERGY, V28, P1; Poluektova LY, 1998, IMMUNOPHARMACOLOGY, V39, P9, DOI 10.1016/S0162-3109(97)00093-3; Poluektova LY, 1999, IMMUNOPHARMACOLOGY, V41, P77, DOI 10.1016/S0162-3109(98)00057-5; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Ramshaw HS, 2001, IMMUNOL CELL BIOL, V79, P154, DOI 10.1046/j.1440-1711.2001.00987.x; Ransohoff RM, 1998, NEW ENGL J MED, V338, P616, DOI 10.1056/NEJM199802263380911; SANSONI P, 1985, J CLIN INVEST, V75, P650, DOI 10.1172/JCI111743; SCHMIDT J, 1994, AGENTS ACTIONS, V42, P81, DOI 10.1007/BF01983469; Schmidt-Weber CB, 1999, J IMMUNOL, V162, P238; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Shin HCK, 1999, CYTOKINE, V11, P257, DOI 10.1006/cyto.1998.0433; Siegmund B, 1998, INT J IMMUNOPHARMACO, V20, P57, DOI 10.1016/S0192-0561(98)00014-9; Sirois J, 2000, J IMMUNOL, V164, P2964; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; Spinozzi F, 2001, INT ARCH ALLERGY IMM, V124, P497, DOI 10.1159/000053785; Stirling RG, 2000, EUR RESPIR J, V16, P1158, DOI 10.1034/j.1399-3003.2000.16f24.x; TAYLORROBINSON AW, 1994, EUR J IMMUNOL, V24, P980, DOI 10.1002/eji.1830240430; Teschendorf C, 1996, SCAND J IMMUNOL, V44, P150, DOI 10.1046/j.1365-3083.1996.d01-295.x; Testa B, 2001, LARYNGOSCOPE, V111, P236, DOI 10.1097/00005537-200102000-00009; Till S, 1997, IMMUNOLOGY, V91, P53, DOI 10.1046/j.1365-2567.1997.00218.x; Tournoy KG, 2001, J ALLERGY CLIN IMMUN, V107, P483, DOI 10.1067/mai.2001.112693; TOURNOY KG, 1998, AM J RESP CRIT CARE, V157, pA701; Walker C, 1999, PULM PHARMACOL THER, V12, P73, DOI 10.1006/pupt.1999.0186; Wang LH, 1999, J IMMUNOL, V162, P3897; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116; WELTMAN JK, 2000, ALLERGY ASTHMA P MAY, P125; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265	85	80	87	1	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769			INT IMMUNOPHARMACOL	Int. Immunopharmacol.	JUL	2003	3	7					909	920		10.1016/S1567-5769(02)00235-7		12	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	697MQ	WOS:000183947300001	12810348	
J	Chew, JL; Wolfowicz, CB; Mao, HQ; Leong, KW; Chua, KY				Chew, JL; Wolfowicz, CB; Mao, HQ; Leong, KW; Chua, KY			Chitosan nanoparticles containing plasmid DNA encoding house dust mite allergen, Der p 1 for oral vaccination in mice	VACCINE			English	Article						oral; chitosan nanoparticles; Der p 1	HIV ENVELOPE GLYCOPROTEIN; SYSTEMIC IMMUNE-RESPONSES; MURINE PEYERS-PATCHES; IN-VIVO UPTAKE; DER-P-I; GENE-TRANSFER; DERMATOPHAGOIDES-PTERONYSSINUS; BIODEGRADABLE MICROPARTICLES; MUCOSAL IMMUNIZATION; ANTIBODY-RESPONSES	Our previous studies indicated that intramuscular (i.m.) immunisation with full length Der p 1 cDNA induced significant humoral response to the left domain (approximately corresponding to amino acids 1-116) but not to the right domain (approximately corresponding to amino acids 117-222) of Der p I allergen. This study explored the use of chitosan-DNA nanoparticles for oral immunisation to induce immune responses specific to both the left and right domains of Der p 1. DNA constructs pDer p 1 (1-222) and pDer p 1 (114-222) were complexed with chitosan and delivered orally followed by an i.m. injection of pDer p 1 (1-222) 13 weeks later. Such approach has successfully primed Th1-skewed immune responses against both domains of Der p 1. This strategy could be further optimised for more efficacious gene vaccination for full length Der p 1. (C) 2003 Elsevier Science Ltd. All rights reserved.	Natl Univ Singapore, Fac Med, Dept Paediat, Singapore 119074, Singapore; Johns Hopkins Singapore, Tissue & Therapeut Engn Lab, Singapore 117597, Singapore; Natl Univ Singapore, Dept Mat Sci, Singapore 117543, Singapore; Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA	Chua, KY (reprint author), Natl Univ Singapore, Fac Med, Dept Paediat, Lower Kent Ridge Rd, Singapore 119074, Singapore.		Mao, Hai-Quan/A-3350-2010; Leong, Kam/A-7270-2009	Leong, Kam/0000-0002-8133-4955			Beier R, 1998, AM J PHYSIOL-GASTR L, V275, pG130; Borchard G, 2001, ADV DRUG DELIVER REV, V52, P145, DOI 10.1016/S0169-409X(01)00198-3; Bowersock TL, 1999, VACCINE, V17, P1804, DOI 10.1016/S0264-410X(98)00437-X; CHALLACOMBE SJ, 1992, IMMUNOLOGY, V76, P164; Chen CJ, 1998, APPL PHYS LETT, V72, P7, DOI 10.1063/1.120629; CHUA KY, 1992, J ALLERGY CLIN IMMUN, V89, P95, DOI 10.1016/S0091-6749(05)80045-4; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Collins SP, 1996, CLIN EXP ALLERGY, V26, P36, DOI 10.1111/j.1365-2222.1996.tb00054.x; Dodane V, 1999, INT J PHARM, V182, P21, DOI 10.1016/S0378-5173(99)00030-7; Duchateau J, 1997, CLIN EXP ALLERGY, V27, P296; ELDRIDGE JH, 1990, J CONTROL RELEASE, V11, P205, DOI 10.1016/0168-3659(90)90133-E; Eo SK, 2001, J IMMUNOL, V166, P5473; Etchart N, 1997, J GEN VIROL, V78, P1577; Ferrari F, 1997, FARMACO, V52, P493; Filipovic-Grcic J, 2001, J MICROENCAPSUL, V18, P3; GREENE WK, 1991, J IMMUNOL, V147, P3768; Herrmann JE, 1999, VIROLOGY, V259, P148, DOI 10.1006/viro.1999.9751; Hershberg RM, 2000, IMMUNOL TODAY, V21, P123, DOI 10.1016/S0167-5699(99)01575-3; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Huang SK, 1997, CURR OPIN IMMUNOL, V9, P800, DOI 10.1016/S0952-7915(97)80181-1; Illum L, 1998, PHARMACEUT RES, V15, P1326; Jarnicki AG, 2002, CLIN EXP ALLERGY, V32, P942, DOI 10.1046/j.1365-2745.2002.01407.x; Jones DH, 1998, DEV BIOL STAND, V92, P149; Jones DH, 1997, VACCINE, V15, P814, DOI 10.1016/S0264-410X(96)00266-6; Kaneko H, 2000, VIROLOGY, V267, P8, DOI 10.1006/viro.1999.0093; Mao HQ, 2001, J CONTROL RELEASE, V70, P399, DOI 10.1016/S0168-3659(00)00361-8; Mathiowitz E, 1997, NATURE, V386, P410, DOI 10.1038/386410a0; OBRIEN RM, 1994, J ALLERGY CLIN IMMUN, V93, P628, DOI 10.1016/S0091-6749(94)70074-5; OHAGAN DT, 1993, VACCINE, V11, P149, DOI 10.1016/0264-410X(93)90011-L; Ranaldi G, 2002, J NUTR BIOCHEM, V13, P157, DOI 10.1016/S0955-2863(01)00208-X; Richardson SCW, 1999, INT J PHARMACEUT, V178, P231, DOI 10.1016/S0378-5173(98)00378-0; Roy K, 1999, NAT MED, V5, P387; Singh M, 2001, VACCINE, V20, P594, DOI 10.1016/S0264-410X(01)00321-8; Singla AK, 2001, J PHARM PHARMACOL, V53, P1047, DOI 10.1211/0022357011776441; Takeuchi H, 2001, ADV DRUG DELIVER REV, V47, P39, DOI 10.1016/S0169-409X(00)00120-4; THOMAS WR, 1988, INT ARCH ALLER A IMM, V85, P127; THOMAS WR, 1992, EXP APPL ACAROL, V16, P153, DOI 10.1007/BF01201498; van der Lubben IM, 2001, EUR J PHARM SCI, V14, P201, DOI 10.1016/S0928-0987(01)00172-5; van der Lubben IM, 2001, BIOMATERIALS, V22, P687, DOI 10.1016/S0142-9612(00)00231-3; Van der Lubben IM, 2001, J DRUG TARGET, V9, P39; Wierzbicki A, 2002, VACCINE, V20, P1295, DOI 10.1016/S0264-410X(01)00480-7; Wikingsson LD, 2002, VACCINE, V20, P3355, DOI 10.1016/S0264-410X(02)00288-8; WOLFF JA, 1990, SCIENCE, V247, P1465, DOI 10.1126/science.1690918; WOLFOWICZ CB, 2002, VACCINE, V21, P1195; YSSEL H, 1992, J IMMUNOL, V148, P738	46	80	99	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0264-410X			VACCINE	Vaccine	JUN 20	2003	21	21-22					2720	2729		10.1016/S0264-410X(03)00228-7		10	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	693GT	WOS:000183709300006	12798609	
J	Anderson, SD; Brannan, JD				Anderson, SD; Brannan, JD			Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea, and hypertonic aerosols	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY			English	Review						exercise; dry air hyperpnea; mannitol; hypertonic saline	ULTRASONICALLY NEBULIZED SOLUTIONS; INHALED CORTICOSTEROID BUDESONIDE; HYPERVENTILATION-INDUCED ASTHMA; WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; COLD-AIR HYPERVENTILATION; THERMALLY-INDUCED ASTHMA; LONG-TERM TREATMENT; INDUCED BRONCHOCONSTRICTION; BRONCHIAL RESPONSIVENESS	Bronchial provocation tests that use stimuli that act indirectly to cause airway narrowing have a high specificity for identifying people with active asthma who have the potential to respond to treatment with antiinflammatory drugs. The first test to be developed was exercise and it was used to assess the efficacy of drugs such as sodium cromoglycate. Eucapnic voluntary hyperpnea was developed later, as a surrogate test for exercise. Hypertonic aerosols were introduced to mimic the dehydrating effects of evaporative water loss that occurs during hyperpnea. A wet aerosol of 4.5% saline or a dry powder formulation of mannitol is used. At present the indirect challenge tests are becoming increasingly recognised as appropriate for monitoring treatment with inhaled steroids. Indirect tests identify those with potential for exercise-induced bronchoconstriction, an important problem for some occupations, such as the defence forces, fire fighters and the police force and for some athletic activities. The advantage in using an indirect challenges, over a direct challenge with a single pharmacological agonist, is that a positive response indicates that inflammatory cells and their mediators (prostaglandins, leukotrienes and histamine) are present in the airways in sufficient numbers and concentration to indicate that asthma is active at the time of testing. The corollary to this is that a negative test in a known asthmatic indicates good control or mild disease. Another advantage is that healthy subjects do not have significant airway narrowing to indirect challenge tests. The protocols used for challenge with indirectly acting stimuli are presented in detail.	Royal Prince Alfred Hosp, Dept Resp Med, Camperdown, NSW 2050, Australia	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp Med, E11S,Missenden Rd, Camperdown, NSW 2050, Australia.	sandya@mail.med.usyd.edu.au		Anderson, Sandra/0000-0002-6308-8770			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ANDERSON S, 1979, J ALLERGY CLIN IMMUN, V64, P612, DOI 10.1016/0091-6749(79)90024-1; ANDERSON SD, 1991, CHEST, V100, P1254, DOI 10.1378/chest.100.5.1254; ANDERSON SD, 1994, CHEST, V105, P673, DOI 10.1378/chest.105.3.673; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; ANDERSON SD, 1983, THORAX, V38, P284, DOI 10.1136/thx.38.4.284; ANDERSON SD, 1975, BRIT J DIS CHEST, V69, P1; ANDERSON SD, 1982, EUR J RESPIR DIS, V63, P459; Anderson SD, 1996, J ALLERGY CLIN IMMUN, V98, pS124, DOI 10.1016/S0091-6749(96)80140-0; Anderson SD, 1997, AM J RESP CRIT CARE, V156, P758; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1984, AUST NZ J MED, V14, P803, DOI 10.1111/j.1445-5994.1984.tb04941.x; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; Anderson SD, 1995, PROVOCATION CHALLENG, P249; ANDERSON SD, 1985, CHEST, V87, P191; Anderson SD, 1985, AIRWAY RESPONSIVENES, P39; Anderson SD, 1995, SPUMS, V25, P233; ARGYROS GJ, 1995, CHEST, V108, P419, DOI 10.1378/chest.108.2.419; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; ARGYROS GJ, 1993, AM REV RESPIR DIS, V147, P1419; ASSOUFI BK, 1986, B EUR PHYSIOPATH RES, V22, P349; AVITAL A, 1995, THORAX, V50, P511, DOI 10.1136/thx.50.5.511; BACKER V, 1991, J ALLERGY CLIN IMMUN, V88, P68, DOI 10.1016/0091-6749(91)90302-5; Baki A, 2002, ARCH DIS CHILD, V86, P38, DOI 10.1136/adc.86.1.38; BARBEN J, 2001, EUR RESPIR J, V18, pS493; BARDAGI S, 1993, AM REV RESPIR DIS, V147, P1112; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; BARYISHAY E, 1983, AM REV RESPIR DIS, V127, P572; BELCHER NG, 1987, AM REV RESPIR DIS, V135, P822; BJORCK T, 1992, AM REV RESPIR DIS, V145, P1087; BLACKIE SP, 1990, AM REV RESPIR DIS, V142, P1133; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Brannan JD, 2000, AM J RESP CRIT CARE, V161, P2096; Brannan JD, 2002, RESPIROLOGY, V7, P37, DOI 10.1046/j.1440-1843.2002.00357.x; Brannan JD, 2001, AM J RESP CRIT CARE, V163, P1420; BRANNAN JD, 2002, RESPIROLOGY, V7, pA16; BRANNAN JD, 2001, EUR RESPIR J, V18, pS102; BRANNAN JD, 1998, AM J RESP CRIT CARE, V157, pA407; BRUDNO DS, 1994, ANN ALLERGY, V73, P227; Carlsen KH, 1998, RESP MED, V92, P308, DOI 10.1016/S0954-6111(98)90114-7; Carlsen KH, 2000, RESP MED, V94, P750, DOI 10.1053/rmed.2000.0809; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CUSHLEY MJ, 1983, BRIT J CLIN PHARMACO, V15, P161; Dahlen B, 2002, J ALLERGY CLIN IMMUN, V109, P789, DOI 10.1067/mai.2002.123306; Dahlen B, 2001, EUR RESPIR J, V17, P581, DOI 10.1183/09031936.01.17405810; DAXUN Z, 1989, J ALLERGY CLIN IMMUN, V83, P152, DOI 10.1016/0091-6749(89)90490-9; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEAL EC, 1979, J APPL PHYSIOL, V46, P476; Dessanges JF, 1999, J ALLERGY CLIN IMMUN, V104, P1155; Doull IJM, 1997, PEDIATR PULM, V23, P404, DOI 10.1002/(SICI)1099-0496(199706)23:6<404::AID-PPUL2>3.0.CO;2-I; duToit JI, 1997, ALLERGY ASTHMA PROC, V18, P7, DOI 10.2500/108854197778612817; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; EGGLESTON PA, 1979, J ALLERGY CLIN IMMUN, V64, P642, DOI 10.1016/0091-6749(79)90028-9; ELIASSON AH, 1992, CHEST, V102, P347, DOI 10.1378/chest.102.2.347; FINNERTY JP, 1990, EUR RESPIR J, V3, P540; Folgering H, 1997, EUR RESP MON, V6, P51; GANDEVIA B., 1957, THORAX, V12, P290, DOI 10.1136/thx.12.4.290; Gibson PG, 1998, CLIN EXP ALLERGY, V28, P1081; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; Gibson PG, 2000, J ALLERGY CLIN IMMUN, V105, P752, DOI 10.1067/mai.2000.105319; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Godfrey S., 1974, EXERCISE TESTING CHI; GONDA I, 1986, PHARM TECH JAPAN, V2, P883; HABY MM, 1995, EUR RESPIR J, V8, P729; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/rccm.200111-091BC; HENRIKSEN JM, 1983, AM REV RESPIR DIS, V128, P993; Hofstra WB, 1997, THORAX, V52, P739; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; HOLZER K, 2002, AM J RESP CRIT  1127; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; In 'T Veen J. C. C. M., 1996, European Respiratory Journal, V9, P2441, DOI 10.1183/09031936.96.09122441; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; Jones NL, 1997, CLIN EXERCISE TESTIN; JOOS GF, 1993, RESP MED, V87, P31, DOI 10.1016/S0954-6111(06)80351-3; JOOS GF, 2002, IN PRESS EUR RESP J; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; Koskela HO, 1997, RESP MED, V91, P470, DOI 10.1016/S0954-6111(97)90112-8; LATIMER KM, 1983, AM REV RESPIR DIS, V128, P440; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406; LIDE DR, 1997, CRC HDB CHEM PHYSICS, P24; LIM TK, 1988, THORAX, V43, P599, DOI 10.1136/thx.43.8.599; Lis G, 1998, PEDIATR PULM, V25, P375, DOI 10.1002/(SICI)1099-0496(199806)25:6<375::AID-PPUL4>3.0.CO;2-G; MALO JL, 1986, B EUR PHYSIOPATH RES, V22, P473; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; NISH WA, 1992, ANN ALLERGY, V69, P239; O'Sullivan S, 1998, EUR RESPIR J, V12, P345, DOI 10.1183/09031936.98.12020345; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875; OCONNOR BJ, 1992, AM REV RESPIR DIS, V146, P560; OCONNOR G, 1991, AM REV RESPIR DIS, V144, P663; OHICKEY SP, 1989, J ALLERGY CLIN IMMUN, V83, P472, DOI 10.1016/0091-6749(89)90136-X; PEAT JK, 1992, AM REV RESPIR DIS, V146, P860; PEDERSEN S, 1995, J ALLERGY CLIN IMMUN, V95, P29, DOI 10.1016/S0091-6749(95)70149-4; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9; PHILLIPS YY, 1985, AM REV RESPIR DIS, V131, P31; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; Polosa R, 1997, THORAX, V52, P919; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; QUANJER PH, 1993, EUR RESPIR J, V6, P5; Rabone SJ, 1996, OCCUP MED-OXFORD, V46, P177; RAFFERTY P, 1987, AM REV RESPIR DIS, V136, P369; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; Reddel HK, 2000, EUR RESPIR J, V16, P226, DOI 10.1034/j.1399-3003.2000.16b08.x; Reiss TF, 1997, THORAX, V52, P1030; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; RIEDLER J, 1994, PEDIATR PULM, V18, P330, DOI 10.1002/ppul.1950180511; Riedler J, 1998, EUR RESPIR J, V11, P355, DOI 10.1183/09031936.98.11020355; RIEDLER J, 1994, EUR RESPIR J, V7, P998; Roca J, 1997, EUR RESPIR J, V10, P2662; RODWELL LT, 1992, EUR RESPIR J, V5, P953; RODWELL LT, 1993, EUR RESPIR J, V6, P855; RODWELL LT, 1991, EUR RESPIR J, V4, P1126; RODWELL LT, 1992, AM REV RESPIR DIS, V146, P1149; RODWELL LT, 1993, EUR J RESP DIS S17, V6, pS200; Rorke S, 2002, THORAX, V57, P323, DOI 10.1136/thorax.57.4.323; ROSENTHAL RR, 1984, J ALLERGY CLIN IMMUN, V73, P676, DOI 10.1016/0091-6749(84)90304-X; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; SCHOEFFEL RE, 1981, BRIT MED J, V283, P1285; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882; SINCLAIR DG, 1995, EUR RESPIR J, V8, P1314, DOI 10.1183/09031936.95.08081314; SMITH CM, 1989, EUR RESPIR J, V2, P36; SMITH CM, 1986, J ALLERGY CLIN IMMUN, V77, P729, DOI 10.1016/0091-6749(86)90419-7; SMITH CM, 1989, AM REV RESPIR DIS, V140, P598; SMITH CM, 1988, CHEST, V94, P709, DOI 10.1378/chest.94.4.709; SMITH CM, 1989, J ALLERGY CLIN IMMUN, V84, P781, DOI 10.1016/0091-6749(89)90309-6; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Soto M E, 1985, Pediatr Pulmonol, V1, P80, DOI 10.1002/ppul.1950010205; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Subbarao P, 2000, PEDIATR PULM, V29, P291, DOI 10.1002/(SICI)1099-0496(200004)29:4<291::AID-PPUL9>3.0.CO;2-A; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127; Van Schoor J, 2000, EUR RESPIR J, V16, P514, DOI 10.1034/j.1399-3003.2000.016003514.x; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; WAALKENS JH, 1993, EUR RESPIR J, V6, P652; WEISS ST, 1984, AM REV RESPIR DIS, V129, P898; WILSON NM, 1995, THORAX, V50, P339, DOI 10.1136/thx.50.4.339; WOOLLEY M, 1990, CHEST, V97, P39, DOI 10.1378/chest.97.1.39; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016; ZEBALLOS RJ, 1978, AM REV RESPIR DIS, V118, P877	153	80	83	0	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1080-0549			CLIN REV ALLERG IMMU	Clin. Rev. Allergy Immunol.	FEB	2003	24	1					27	54		10.1385/CRIAI:24:1:27		28	Allergy; Immunology	Allergy; Immunology	658GV	WOS:000181714000004	12644717	
J	Matsuoka, H; Maki, N; Yoshida, S; Arai, M; Wang, J; Oikawa, Y; Ikeda, T; Hirota, N; Nakagawa, H; Ishii, A				Matsuoka, H; Maki, N; Yoshida, S; Arai, M; Wang, J; Oikawa, Y; Ikeda, T; Hirota, N; Nakagawa, H; Ishii, A			A mouse model of the atopic eczema/dermatitis syndrome by repeated application of a crude extract of house-dust mite Dermatophagoides farinae	ALLERGY			English	Article						atopic eczema/dermatitis syndrome; Dermatophagoides farinae; IgE; mast cell; mouse model	EPIDERMAL LANGERHANS CELLS; REGIONAL LYMPH-NODES; IGE HYPERPRODUCTION; NC/NGA MICE; DERMATITIS; SENSITIZATION; ANTIBODIES; POPULATION; ALLERGENS; ANTIGEN	Background: We cultured Dermatophagoides farinae (Df), one of the most common mites in house dust and the most important allergen among natural allergens. With this material, we attempted to produce an animal model of the atopic eczema/dermatitis syndrome (AEDS). Methods: We cultured Df mites in high density and prepared a crude extract of Df (DfE) together with the culture medium. We applied the extract to the back skin of NC/Nga and BALB/c mice three times per week for 8 weeks. Results: In the NC/Nga group, dryness or scaling appeared on the skin, and scratching behavior increased at the second week in the DfE-treated group. Skin erosion and hemorrhage occurred at the fourth week. The epidermis thickened and deepened into the upper dermis, in which mast cells were highly accumulated, corresponding with the skin lesion of AEDS patients. Specific IgE and IgG to DfE and total IgE were elevated in the sera. Mice treated with an extract of mite culture medium did not develop skin lesions. In the BALB/c group, mice developed specific IgE and IgG to DfE, however, no typical skin lesions appeared. Mast cells in the upper dermis did not increase. Conclusions: Repeated painting of Dermatophagoides extract produced IgE-associated AEDS-like lesions on the skin of NC mice.	Jichi Med Sch, Dept Med Zool, Minami Kawachi, Tochigi 3290498, Japan; Kanazawa Med Sch, Dept Med Zool, Kanazawa, Ishikawa, Japan; Jichi Med Sch, Dept Dermatol, Minami Kawachi, Tochigi, Japan	Matsuoka, H (reprint author), Jichi Med Sch, Dept Med Zool, 3311-1 Yakushiji, Minami Kawachi, Tochigi 3290498, Japan.			Matsuoka, Hiroyuki/0000-0001-8839-0012			ALANI M, 1970, ACTA ALLERGOL, V25, P41, DOI 10.1111/j.1398-9995.1970.tb01379.x; Bellinghausen I, 1996, J INVEST DERMATOL, V107, P582, DOI 10.1111/1523-1747.ep12582825; Bellinghausen I, 1999, J ALLERGY CLIN IMMUN, V103, P298, DOI 10.1016/S0091-6749(99)70505-1; Breuer K, 2001, ALLERGY, V56, P1034, DOI 10.1034/j.1398-9995.2001.00146.x; CARSWELL F, 1986, LANCET, V2, P13; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; FUJUI M, 1961, JIKKEN DOBUTSU, V10, P83; Iijima OT, 2000, COMPARATIVE MED, V50, P225; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KRIPKE ML, 1990, J IMMUNOL, V145, P2833; LALTOO H, 1979, IMMUNOL COMMUN, V8, P1, DOI 10.3109/08820137909044702; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; MATSUOKA H, 1995, JPN J MED SCI BIOL, V48, P103; Morita E, 1999, J DERMATOL SCI, V19, P37, DOI 10.1016/S0923-1811(98)00047-4; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Okudaira H, 1989, Arerugi, V38, P296; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Saloga J, 2000, ALLERGY, V55, P905, DOI 10.1034/j.1398-9995.2000.00126.x; SASA M, 1970, Japanese Journal of Experimental Medicine, V40, P367; Sugiura H, 1998, ACTA DERM-VENEREOL, V78, P293; Suto H, 1999, INT ARCH ALLERGY IMM, V120, P70, DOI 10.1159/000053599; TANAKA Y, 1990, Journal of Dermatological Science, V1, P361, DOI 10.1016/0923-1811(90)90593-3; THOMPSON SJ, 1988, IMMUNOLOGY, V64, P311; YAMASHITA K, 1994, MICROBIOL IMMUNOL, V38, P567	25	80	86	0	4	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	FEB	2003	58	2					139	145		10.1034/j.1398-9995.2003.23790.x		7	Allergy; Immunology	Allergy; Immunology	652AA	WOS:000181355500007	12622745	
J	Lehtimaki, L; Kankaanranta, H; Saarelainen, S; Turjanmaa, V; Moilanen, E				Lehtimaki, L; Kankaanranta, H; Saarelainen, S; Turjanmaa, V; Moilanen, E			Inhaled fluticasone decreases bronchial but not alveolar nitric oxide output in asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; eosinophil cationic protein; eosinophil protein X; exhaled nitric oxide; inflammation; inhaled glucocorticoids	EXHALED AIR; SPUTUM EOSINOPHILS; MILD ASTHMA; INDUCTION; SYNTHASE; AIRWAYS; RESPONSIVENESS; INFLAMMATION	Exhaled nitric oxide (NO) concentration is a noninvasive measure of airway inflammation and is increased in asthma. Inhaled glucocorticoids decrease exhaled NO concentration, but the relative contributions of alveolar and bronchial levels to the decrease in exhaled NO concentration are unknown. Alveolar NO concentration and bronchial NO flux can be separately approximated by measuring exhaled NO at several exhalation flow rates. The effect of steroid treatment on alveolar and bronchial NO output in asthma was studied. Alveolar NO concentration and bronchial NO flux were assessed in 16 patients with asthma before and during treatment with inhaled fluticasone for 8 weeks and in 16 healthy controls. Before the treatment, asthmatics had increased bronchial NO flux (mean +/- SEM: 3.6 +/-0.4 versus 0.7 +/-0.1 nL.s(-1), p<0.001) but normal alveolar NO concentration (1.2<plus/minus>0.5 versus 1.0 +/-0.2 parts per billion (ppb), p>0.05) compared with controls Inhaled fluticasone decreased bronchial NO flux from 3.6 +/-0.4 to 0.7 +/-0.1 nL.s(-1)(p<0.01) but had no effect on alveolar NO concentration (before: 1.2<plus/minus>0.5; after: 1.2 +/-0.1 ppb, p>0.05). The forced expiratory volume in one second improved, whereas asthma symptom score and serum levels of eosinophil cationic protein and eosinophil protein X decreased during the treatment. In conclusion, inhaled fluticasone decreases bronchial but not alveolar nitric oxide output simultaneously with clinical improvement in patients with asthma.	Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33014 Tampere, Finland; Tampere Univ Hosp, Dept Clin Chem, FIN-33521 Tampere, Finland; Tampere Univ Hosp, Dept Resp Med, Tampere, Finland; Tampere Univ Hosp, Dept Clin Physiol, Tampere, Finland	Moilanen, E (reprint author), Univ Tampere, Sch Med, Immunopharmacol Res Grp, FIN-33014 Tampere, Finland.			Kankaanranta, Hannu/0000-0001-5258-0906			ALVING K, 1993, EUR RESPIR J, V6, P1368; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Ho LP, 2000, CHEST, V118, P1327, DOI 10.1378/chest.118.5.1327; Hogman M, 2000, RESP MED, V94, P985, DOI 10.1053/rmed.2000.0872; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 1998, THORAX, V53, P91; Jorres RA, 2000, EUR RESPIR J, V16, P555, DOI 10.1034/j.1399-3003.2000.016003555.x; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Kharitonov SA, 2000, EUR RESPIR J, V16, P781, DOI 10.1183/09031936.00.16478100; Kleinert H, 1996, MOL PHARMACOL, V49, P15; Lehtimaki L, 2000, ANN MED, V32, P417, DOI 10.3109/07853890008995949; Lehtimaki L, 2001, AM J RESP CRIT CARE, V163, P1557; Moilanen E, 1999, INFLAMMATION BASIC P, P787; Saleh D, 1998, FASEB J, V12, P929; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Silkoff PE, 2000, CLIN CHEST MED, V21, P345, DOI 10.1016/S0272-5231(05)70271-9; Sippel JM, 2000, J ALLERGY CLIN IMMUN, V106, P645, DOI 10.1067/mai.2000.1096618; Tsoukias NM, 1998, J APPL PHYSIOL, V85, P653; van Rensen ELJ, 1999, THORAX, V54, P403	20	80	80	0	0	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2001	18	4					635	639		10.1183/09031936.01.00000201		5	Respiratory System	Respiratory System	495EM	WOS:000172327300005	11716167	
J	Carbonell-Estrany, X; Quero, J				Carbonell-Estrany, X; Quero, J		IRIS Study Grp	Hospitalization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons	PEDIATRIC INFECTIOUS DISEASE JOURNAL			English	Article						respiratory syncytial virus; premature infants; hospitalization; epidemiology	REHOSPITALIZATION; GESTATION; CHILDREN	Objective. To collect data on hospitalization rates for respiratory syncytial virus (RSV) illness during the season of 1999 to 2000 in nonprophylaxed premature infants less than or equal to 32 weeks gestational age (GA) in Spain and compare this with previously published data collected in the season of 1998 to 1999. Methods. Children born at less than or equal to 32 weeks GA between April 1, 1999, and April 31, 2000, and discharged from the hospital before April 31, 2000, were included. Neonatal and demographic data were obtained at the initial visit. Study subjects were followed at monthly intervals throughout the respiratory season. RSV status and morbidity data were collected on patients rehospitalized for respiratory illness. Results. The 999 evaluable patients in the 2000 season were comparable to the 1999 sample, except for higher rates of family allergy history and number of multiple deliveries and a lower rate of neonatal morbidity. The hospitalization rate for RSV illness was 13.4% in the 1999 season and 13.1% in the 2000 season; 10 (8%) were RSV reinfections in the 2000 season. Significant independent prognostic variables for high risk of RSV hospital admission included: lower gestational age; chronologic age <3 months at onset of the RSV season; living with school age siblings; and exposure to tobacco smoke. Conclusions. Hospitalization rates for RSV disease in nonprophylaxed preterm infants less than or equal to 32 weeks GA were high in Spain and comparable during two consecutive RSV seasons (13%). Readmission for a second RSV infection was also common.	Hosp Clin Barcelona, Inst Clin Ginecol Obstet & Neonatol, Serv Neonatol, Unitat Integrada, Barcelona 08034, Spain; Hosp La Paz, Madrid, Spain	Carbonell-Estrany, X (reprint author), Hosp Clin Barcelona, Inst Clin Ginecol Obstet & Neonatol, Serv Neonatol, Unitat Integrada, C-Sabino Arana 1, Barcelona 08034, Spain.						ANDERSON LJ, 1991, J INFECT DIS, V163, P687; Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Boyce TG, 2000, J PEDIATR-US, V137, P865, DOI 10.1067/mpd.2000.110531; Carbonell-Estrany X, 2000, PEDIATR INFECT DIS J, V19, P592, DOI 10.1097/00006454-200007000-00002; Chew FT, 1998, EPIDEMIOL INFECT, V121, P121, DOI 10.1017/S0950268898008905; COCKBURN F, 1993, LANCET, V342, P193; CUNNINGHAM CK, 1991, PEDIATRICS, V88, P527; DUCOFFRE G, 1998, IPH EPIDEMIOLOGY NOV; FARSTAD T, 2000, 18 ANN M EUR SOC PAE; Gellida Royo M J, 1999, An Esp Pediatr, V50, P21; *GREEK RSV STUD GR, 2000, 18 ANN M EUR SOC PAE; Law B, 1998, Paediatr Child Health, V3, P402; LOWTHER SA, 2000, PED AC SOC AM AC PED; NAVAS L, 1992, J PEDIATR-US, V121, P348, DOI 10.1016/S0022-3476(05)90000-0; Null D, 1998, PEDIATRICS, V102, P531; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Simoes EAF, 1999, LANCET, V354, P847, DOI 10.1016/S0140-6736(99)80040-3; Simoes EAF, 1999, INFECT MED, V16, P11; WANG EEL, 1995, J PEDIATR-US, V126, P212, DOI 10.1016/S0022-3476(95)70547-3; WEIGL JAI, 2000, 18 ANN M EUR SOC PAE	20	80	81	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0891-3668			PEDIATR INFECT DIS J	Pediatr. Infect. Dis. J.	SEP	2001	20	9					874	879		10.1097/00006454-200109000-00010		6	Immunology; Infectious Diseases; Pediatrics	Immunology; Infectious Diseases; Pediatrics	472CW	WOS:000170966500009	11734767	
J	Larsson, ML; Frisk, M; Hallstrom, J; Kiviloog, J; Lundback, B				Larsson, ML; Frisk, M; Hallstrom, J; Kiviloog, J; Lundback, B			Environmental tobacco smoke exposure during childhood is associated with increased prevalence of asthma in adults	CHEST			English	Article						asthma; environmental tobacco smoke; respiratory symptoms	PASSIVE SMOKING; DISEASE; LIFE; RISK	Objective: To examine if exposure to environmental tobacco smoke (ETS) during childhood has an impact on asthma prevalence in adults, and to identify the amount of nuisance from ETS and other lower airway irritants (LAWIs) in a city population. Design: A postal survey. Setting: The municipality of Orebro, Sweden. Participants: A total of 8,008 randomly selected inhabitants aged 15 to 69 years. Measurements: Exposures, airway symptoms, and respiratory history were assessed using a questionnaire. Results: The response rate was 84%. In never-smokers with childhood ETS exposure, the prevalence of physician-diagnosed asthma was 7.6% vs 5.9% in nonexposed subjects (p = 0.036). In never-smokers without a family history of asthma, the prevalence of physician-diagnosed asthma in subjects reporting childhood ETS exposure was 6.8% vs 3.8% in nonexposed subjects (p < 0.001). Subjects with childhood ETS exposure were more likely to start smoking in adulthood. The prevalence of ever-smokers was 54.5% vs 33.8% (p < 0.0001) in nonexposed subjects. ETS was the most commonly reported LAWI in the total sample (21%), followed by exercise in cold air (20%); dust (19%), exercise (16%), perfume (15%), cold air (12%), pollen (10%), and pets (8%). All LAWIs were more frequently reported by women. Conclusions: Childhood exposure to ETS is associated with an increased prevalence of asthma among adult never-smokers, especially in nonatopic subjects. Children exposed to ETS are also more likely to become smokers. ETS is as a major LAWI.	Orebro Med Ctr Hosp, Dept Lung Med, SE-70185 Orebro, Sweden; Univ Uppsala, Dept Publ Hlth & Caring Sci, S-75105 Uppsala, Sweden; Natl Inst Working Life, Dept Occupat Med, Resp Unit, Stockholm, Sweden	Larsson, ML (reprint author), Orebro Med Ctr Hosp, Dept Lung Med, SE-70185 Orebro, Sweden.						Becklake MR, 1999, THORAX, V54, P1119; *COMM PASS SMOK BO, 1983, ENV TOB SMOK MEAS EX; Coultas DB, 1998, THORAX, V53, P381; *DEP HHS, 1994, PREV TOB US AM YOUNG; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; JINOT J, 1994, J CLIN EPIDEMIOL, V47, P339, DOI 10.1016/0895-4356(94)90154-6; KIVILOOG J, 1974, SCAND J RESPIR DIS, V55, P262; KNIGHT A, 1985, MED J AUSTRALIA, V142, P194; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; Medical Research Council, 1960, BRIT MED J, V2, P1665; NIELSEN P, 1993, PASSIV RYGNING OVERF; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; Ramstrom Lars M., 1997, V28, P64; Reid DJ, 1995, TOB CONTROL, V4, P266, DOI 10.1136/tc.4.3.266; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; Steenland K, 1996, CIRCULATION, V94, P622; Strachan DP, 1998, THORAX, V53, P204; Thoren K, 1993, CHEST, V104, P600; WEBER A, 1984, EUR J RESPIR DIS, V68, P98; WEINBERGER M, 1997, CIGARETTES WHAT WARN, P69; WILLERS S, 1991, ALLERGY, V46, P330, DOI 10.1111/j.1398-9995.1991.tb00595.x; ZETTERSTROM O, 1981, BRIT MED J, V283, P1215	23	80	82	0	2	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	SEP	2001	120	3					711	717		10.1378/chest.120.3.711		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	472EN	WOS:000170970700009	11555497	
J	Huss, K; Naumann, PL; Mason, PJ; Nanda, JP; Huss, RW; Smith, CM; Hamilton, RG				Huss, K; Naumann, PL; Mason, PJ; Nanda, JP; Huss, RW; Smith, CM; Hamilton, RG			Asthma severity, atopic status, allergen exposure, and quality of life in elderly persons	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							INNER-CITY CHILDREN; DUST MITE ALLERGENS; INDOOR ALLERGENS; INTERNATIONAL WORKSHOP; RISK FACTOR; OF-LIFE; SENSITIZATION; ADULTS; POPULATION; CHILDHOOD	Background: Although asthma can be associated with significant airflow obstruction in those over the age of 65, it is often underdiagnosed and undertreated. Objective: To describe severity of asthma, allergy skin test sensitivities, indoor allergen exposures, and the impact on quality of life (QOL) and health status in elderly persons with asthma. Methods: A cross-sectional data analysis with 80 elderly persons with asthma recruited from medical, geriatric, and allergy/immunology tertiary care centers. Asthma severity was determined by symptoms and measurements of lung function. House dust specimens were collected from mattresses and bedroom carpets and analyzed separately for the major allergens of house dust, using monoclonal antibody-based immunoenzymetric assays. QOL was measured using Juniper's Asthma Quality of Life Questionnaire. Health status was measured using the Short Form Health Survey Medical Outcome Questionnaire which included Ferrans and Powers' Quality of Life Index subscales. Results: Two-thirds of participants had either moderate or severe persistent asthma. Skin tests to a battery of common airborne allergens were positive to at least one allergen in 56 of the 75 participants tested (74.7%). Reservoir dust allergen levels were often high enough to place participants at risk of symptoms or at risk of developing sensitization. Increased asthma severity was associated with significantly lower QOL and a trend toward decreased health status. Conclusions: Asthma is a significant chronic problem in the elderly. Atopy was common. Asthma severity impacts on these participants' QOL and health status. Results support interventions aimed at identifying allergens precipitating attacks and reducing them in the home.	Johns Hopkins Univ, Sch Nursing, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA; Johns Hopkins Asthma & Allergy Ctr, Serum Repository, DACI Reference Lab, Baltimore, MD USA	Huss, K (reprint author), Johns Hopkins Univ, Sch Nursing, 525 N Wolfe St, Baltimore, MD 21205 USA.						BURROWS B, 1991, CHEST, V100, P935, DOI 10.1378/chest.100.4.935; *CDC, 1998, MMWR CDC SURVEILLANC, V47; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805; CHAPMAN MD, 1995, PEDIATR ALLERGY IMMU, V6, P8, DOI 10.1111/j.1399-3038.1995.tb00378.x; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; Dyer CAE, 1999, EUR RESPIR J, V14, P39, DOI 10.1034/j.1399-3003.1999.14a09.x; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; FERRANS CE, 1985, ADV NURS SCI, V8, P15; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; HAMILTON RG, 1997, MANUAL CLIN LAB IMMU, P881; HUSS K, 1992, J ALLERGY CLIN IMMUN, V89, P836, DOI 10.1016/0091-6749(92)90439-9; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832; KIVITY S, 1993, J ALLERGY CLIN IMMUN, V91, P844, DOI 10.1016/0091-6749(93)90341-C; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; Marks GB, 1998, ALLERGY, V53, P108; *NAT ASTHM ED PREV, 1997, NIH PUB; NIEMEIJER NR, 1992, ALLERGY, V47, P431, DOI 10.1111/j.1398-9995.1992.tb02084.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; PRICE JA, 1990, LANCET, V336, P895, DOI 10.1016/0140-6736(90)92268-M; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; Weiner P, 1998, EUR RESPIR J, V12, P564, DOI 10.1183/09031936.98.12030564; Weiss ST, 1998, J ALLERGY CLIN IMMUN, V101, P720, DOI 10.1016/S0091-6749(98)70300-8	31	80	83	1	5	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	MAY	2001	86	5					524	530				7	Allergy; Immunology	Allergy; Immunology	433UW	WOS:000168779900006	11379803	
J	Best, NG; Ickstadt, K; Wolpert, RL				Best, NG; Ickstadt, K; Wolpert, RL			Spatial Poisson regression for health and exposure data measured at disparate resolutions	JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION			English	Article						air pollution; Bayesian hierarchical models; continuous random fields; ecological regression; environmental epidemiology; respiratory illness	AIR-POLLUTION; RESPIRATORY HEALTH; ASTHMA; CHILDREN; PREVALENCE; STATISTICS; MOTORWAYS; MORTALITY; SYMPTOMS; MODELS	Ecological regression studies are widely used to examine relationships between disease rates for small geographical areas and exposure to environmental risk factors. The raw data for such studies, including disease cases, environmental pollution concentrations, and the reference population at risk, are typically measured at various levels of spatial aggregation but are accumulated to a common geographical scale to facilitate statistical analysis. In this traditional approach, heterogeneous exposure distributions within the aggregate areas may lead to biased inference, whereas individual attributes such as age, gender, and smoking habits must either be summarized to provide area-level covariate values or used to stratify the analysis. This article presents a spatial regression analysis of the effect of traffic pollution on respiratory disorders in children. The analysis features data measured at disparate, nonnested scales, including spatially varying covariates, latent spatially varying risk factors, and case-specific individual attributes. The problem of disparate discretizations is overcome by relating all spatially varying quantities to a continuous underlying random field model. Case-specific individual attributes are accommodated by treating cases as a marked point process. Inference in these hierarchical Poisson/gamma models is based on simulated samples drawn from Bayesian posterior distributions, using Markov chain Monte Carlo methods with data augmentation.	Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, Small Area Stat Unit, London W2 1PG, England; Duke Univ, Inst Stat & Decis Sci, Durham, NC 27708 USA	Best, NG (reprint author), Imperial Coll Sch Med, Dept Epidemiol & Publ Hlth, Small Area Stat Unit, St Marys Campus, London W2 1PG, England.						Bernardinelli L, 1997, STAT MED, V16, P741, DOI 10.1002/(SICI)1097-0258(19970415)16:7<741::AID-SIM501>3.0.CO;2-1; BESAG J, 1991, ANN I STAT MATH, V43, P1, DOI 10.1007/BF00116466; BEST NG, 2000, SPATIAL EPIDEMIOLOGY, pCH22; Breslow N. E, 1980, STAT METHODS CANC RE, V1; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; CARLIN BP, 1999, BAYESIAN STAT, V6, P131; Carstairs V, 1991, DEPRIVATION HLTH SCO; CLAYTON D, 1987, BIOMETRICS, V43, P671, DOI 10.2307/2532003; Committee on the Medical Effects of Air Pollutants, 1995, NONB PART HLTH; *COMM MED EFF AIR, 1995, ASTHM OUTD AIR POLL; CRESSIE N, 1989, J AM STAT ASSOC, V84, P393, DOI 10.2307/2289922; DIGGLE PJ, 1990, J ROY STAT SOC A STA, V153, P349, DOI 10.2307/2982977; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; ELLIOTT P, 1997, SMALL AREA VARIATION; Fischer PH, 1998, INDOOR AIR, V8, P244, DOI 10.1111/j.1600-0668.1998.00005.x; FLOREY C, 1973, METHODS COHORT STUDI; FOTHERINGHAM AS, 1991, ENVIRON PLANN A, V23, P1025, DOI 10.1068/a231025; GREENLAND S, 1992, STAT MED, V11, P1209, DOI 10.1002/sim.4780110907; *HER MAJ GOV DEP H, 1996, UK NAT ENV HLTH ACT; Ickstadt K, 1999, BAYESIAN STAT, V6, P323; Lawson AB, 1999, DISEASE MAPPING AND RISK ASSESSMENT FOR PUBLIC HEALTH, P119; Lawson AB, 1996, ENVIRONMETRICS, V7, P471, DOI 10.1002/(SICI)1099-095X(199609)7:5<471::AID-ENV223>3.0.CO;2-S; Livingstone AE, 1996, BRIT MED J, V312, P676; Martuzzi M, 1996, STAT MED, V15, P1867; Morgenstern H, 1998, MODERN EPIDEMIOLOGY, P459; Mugglin AS, 2000, J AM STAT ASSOC, V95, P877; MURAKAMI M, 1990, Journal of Human Ergology, V19, P101; Openshaw S., 1984, MODIFIABLE AREAL UNI; Osterlee A., 1996, OCCUP ENVIRON MED, V53, P241; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Richardson S., 1992, GEOGRAPHICAL ENV EPI, P181; Robinson WS, 1950, AM SOCIOL REV, V15, P351, DOI 10.2307/2087176; RODRIGUEZ G, 1995, J ROY STAT SOC A STA, V158, P73, DOI 10.2307/2983404; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; SHAW RA, 1992, CLIN EXP ALLERGY, V22, P561, DOI 10.1111/j.1365-2222.1992.tb00166.x; Spiegelhalter DJ, 1998, J ROY STAT SOC C-APP, V47, P115, DOI 10.1111/1467-9876.00101; Spiegelhalter D.J., 1998, WINBUGS BAYESIAN INF; SPIEGELHALTER DJ, 2000, BAYESIAN MEASURES MO; STRACHAN DP, 1995, BRIT MED J, V311, P1053; TIERNEY L, 1994, ANN STAT, V22, P1701, DOI 10.1214/aos/1176325750; WALDRON G, 1995, J PUBLIC HEALTH MED, V17, P85; Waller LA, 1997, J AM STAT ASSOC, V92, P607, DOI 10.2307/2965708; WARDLAW AJ, 1992, J ALLERGY CLIN IMMUN, V90, P358; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilkinson P, 1999, THORAX, V54, P1070; WJST M, 1993, BRIT MED J, V307, P596; Wolpert RL, 1998, BIOMETRIKA, V85, P251, DOI 10.1093/biomet/85.2.251	51	80	80	2	14	AMER STATISTICAL ASSOC	ALEXANDRIA	1429 DUKE ST, ALEXANDRIA, VA 22314 USA	0162-1459			J AM STAT ASSOC	J. Am. Stat. Assoc.	DEC	2000	95	452					1076	1088		10.2307/2669744		13	Statistics & Probability	Mathematics	376RJ	WOS:000165470300006		
J	Siracusa, A; Desrosiers, M; Marabini, A				Siracusa, A; Desrosiers, M; Marabini, A			Epidemiology of occupational rhinitis: prevalence, aetiology and determinants	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							LABORATORY-ANIMAL ALLERGY; WORK-RELATED SYMPTOMS; EXPOSURE-RESPONSE RELATIONSHIPS; IGE-MEDIATED SENSITIZATION; RESPIRATORY SYMPTOMS; METHYLTETRAHYDROPHTHALIC ANHYDRIDE; ACOUSTIC RHINOMETRY; PROCESSING WORKERS; TEXTILE WORKERS; GREEN COFFEE		Univ Perugia, Dept Clin & Expt Med, I-06100 Perugia, Italy; Ctr Hosp Univ Montreal, Dept Otorhinolaryngol, Montreal, PQ, Canada	Siracusa, A (reprint author), Via E dai Pozzo, I-06126 Perugia, Italy.						AGIUS RM, 1991, ANN OCCUP HYG, V35, P129, DOI 10.1093/annhyg/35.2.129; AGRUP G, 1986, BRIT J IND MED, V43, P192; AHMAN M, 1992, ACTA OTO-LARYNGOL, V112, P839, DOI 10.3109/00016489209137482; AOYAMA K, 1992, BRIT J IND MED, V49, P41; BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; BAROODY FM, 1993, J APPL PHYSIOL, V74, P2661; BAUR X, 1995, INT ARCH OCC ENV HEA, V67, P395, DOI 10.1007/BF00381052; Baur X, 1998, CLIN EXP ALLERGY, V28, P537; BEESON MF, 1983, CLIN ALLERGY, V13, P433, DOI 10.1111/j.1365-2222.1983.tb02619.x; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Bernstein JA, 1999, J ALLERGY CLIN IMMUN, V103, P1153, DOI 10.1016/S0091-6749(99)70192-2; BIAGINI RE, 1985, J ALLERGY CLIN IMMUN, V76, P794, DOI 10.1016/0091-6749(85)90750-X; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; BLANC P, 1991, CHEST, V99, P27, DOI 10.1378/chest.99.1.27; BRODER I, 1985, J OCCUP ENVIRON MED, V27, P873; BROUWER R, 1986, AM J IND MED, V10, P283, DOI 10.1002/ajim.4700100314; Burches E, 1996, CLIN EXP ALLERGY, V26, P1262, DOI 10.1046/j.1365-2222.1996.d01-286.x; BURGE PS, 1980, CLIN ALLERGY, V10, P355, DOI 10.1111/j.1365-2222.1980.tb02119.x; Bush RK, 1998, J ALLERGY CLIN IMMUN, V102, P99, DOI 10.1016/S0091-6749(98)70060-0; CARRILLO T, 1995, J ALLERGY CLIN IMMUN, V96, P699, DOI 10.1016/S0091-6749(95)70273-3; CARTIER A, 1984, J ALLERGY CLIN IMMUN, V74, P261, DOI 10.1016/0091-6749(84)90256-2; CHANYEUNG M, 1980, AM REV RESPIR DIS, V121, P329; CHANYEUNG M, 1994, EUR RESPIR J, V7, P346, DOI 10.1183/09031936.94.07020346; CLARKE RW, 1994, CLIN OTOLARYNGOL, V19, P502, DOI 10.1111/j.1365-2273.1994.tb01277.x; Clement P A, 1984, Rhinology, V22, P151; COCKCROFT A, 1981, LANCET, V1, P827; Cole P, 1997, AM J RHINOL, V11, P415, DOI 10.2500/105065897780914901; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P579; CUTHBERT OD, 1984, CLIN ALLERGY, V14, P197, DOI 10.1111/j.1365-2222.1984.tb02653.x; DAVIES GE, 1983, BRIT J IND MED, V40, P442; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; DESROSIERS M, 1998, J ALLERGY CLIN IMMUN, V101, pS86; DESROSIERS MY, 1999, OTOLARYNGOL HEAD NEC, V121, pP141, DOI 10.1016/S0194-5998(99)80241-1; DEZOTTI R, 1988, INT ARCH OCC ENV HEA, V61, P7; DEZOTTI R, 1994, OCCUP ENVIRON MED, V51, P548; DOCKER A, 1987, BRIT J IND MED, V44, P534; DOPICO GA, 1983, AM REV RESPIR DIS, V128, P399; DOPICO GA, 1977, AM REV RESPIR DIS, V115, P915; Feo F, 1997, ALLERGY, V52, P633, DOI 10.1111/j.1398-9995.1997.tb01042.x; FISHWICK D, 1994, OCCUP ENVIRON MED, V51, P744; GADDIE J, 1980, LANCET, V2, P1350; GAFFURI E, 1968, FOLIA MED, V51, P569; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P437, DOI 10.1016/0091-6749(94)90352-2; GROSS NJ, 1980, J ALLERGY CLIN IMMUN, V66, P158, DOI 10.1016/0091-6749(80)90064-0; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; Hennekens C. H., 1987, EPIDEMIOLOGY MED; HILBERG O, 1989, J APPL PHYSIOL, V66, P295; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562; Hollander A, 1996, J ALLERGY CLIN IMMUN, V98, P545, DOI 10.1016/S0091-6749(96)70088-X; HOLNESS DL, 1987, AM J IND MED, V11, P571, DOI 10.1002/ajim.4700110509; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499; Hytonen Maija, 1996, Rhinology (Utrecht), V34, P86; Hytonen ML, 1996, AM J RHINOL, V10, P393, DOI 10.2500/105065896781794798; Ishizaki T, 1973, J Occup Med, V15, P580; Johnsen CR, 1997, OCCUP ENVIRON MED, V54, P671; KAUFMAN GL, 1989, BRIT J IND MED, V46, P473; KREMER AM, 1994, AM J IND MED, V26, P655, DOI 10.1002/ajim.4700260508; Kruize H, 1997, OCCUP ENVIRON MED, V54, P830; Kujala VM, 1996, AM J IND MED, V30, P164, DOI 10.1002/(SICI)1097-0274(199608)30:2<164::AID-AJIM7>3.0.CO;2-0; Larese F, 1998, AM J IND MED, V34, P623, DOI 10.1002/(SICI)1097-0274(199812)34:6<623::AID-AJIM11>3.0.CO;2-R; Leino T, 1998, SCAND J WORK ENV HEA, V24, P398; Leroyer C, 1999, OCCUP ENVIRON MED, V56, P334; LIEBERS V, 1993, ALLERGY, V48, P236, DOI 10.1111/j.1398-9995.1993.tb00722.x; LISS GM, 1993, J ALLERGY CLIN IMMUN, V92, P237, DOI 10.1016/0091-6749(93)90167-E; LOSADA E, 1992, J ALLERGY CLIN IMMUN, V89, P118, DOI 10.1016/S0091-6749(05)80048-X; LOVE RG, 1988, BRIT J IND MED, V45, P727; LUGO G, 1994, INT ARCH OCC ENV HEA, V65, P291, DOI 10.1007/BF00405691; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1988, THORAX, V43, P371, DOI 10.1136/thx.43.5.371; MALO JL, 1990, AM REV RESPIR DIS, V142, P1359; MALO JL, 1990, J ALLERGY CLIN IMMUN, V86, P562, DOI 10.1016/S0091-6749(05)80213-1; MARKS GB, 1991, AM REV RESPIR DIS, V144, P1065; MCCONNOCHIE K, 1990, CLIN EXP ALLERGY, V20, P199, DOI 10.1111/j.1365-2222.1990.tb02668.x; MCGRATH KG, 1984, J OCCUP ENVIRON MED, V26, P671; MEGGS WJ, 1994, J TOXICOL-CLIN TOXIC, V32, P487; Meggs WJ, 1997, ENVIRON HEALTH PERSP, V105, P473, DOI 10.2307/3433355; Merget R, 1996, OCCUP ENVIRON MED, V53, P422; Muir DCF, 1997, AM J IND MED, V31, P570, DOI 10.1002/(SICI)1097-0274(199705)31:5<570::AID-AJIM11>3.0.CO;2-W; MUSK AW, 1989, BRIT J IND MED, V46, P636; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NELSON WL, 1987, J OCCUP ENVIRON MED, V29, P497; NIELSEN J, 1994, ALLERGY, V49, P281, DOI 10.1111/j.1398-9995.1994.tb02661.x; NOVEY HS, 1980, CLIN ALLERGY, V10, P721, DOI 10.1111/j.1365-2222.1980.tb02157.x; PARK HS, 1991, J ALLERGY CLIN IMMUN, V87, P639, DOI 10.1016/0091-6749(91)90382-X; Patussi V, 1994, Med Lav, V85, P402; Pirila T, 1998, CLIN EXP ALLERGY, V28, P468; Pisati G, 1998, J ALLERGY CLIN IMMUN, V101, P327; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; PLAVEC D, 1993, AM J IND MED, V24, P525, DOI 10.1002/ajim.4700240504; QUIRCE S, 1994, J ALLERGY CLIN IMMUN, V93, P44, DOI 10.1016/0091-6749(94)90231-3; ROBERTSON AS, 1985, BRIT MED J, V291, P373; ROMANO C, 1995, CLIN EXP ALLERGY, V25, P643, DOI 10.1111/j.1365-2222.1995.tb01112.x; Salamone L, 1969, Folia Med (Napoli), V52, P427; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; SCHUMACHER MJ, 1989, J ALLERGY CLIN IMMUN, V83, P711, DOI 10.1016/0091-6749(89)90001-8; SHERSON D, 1989, ALLERGY, V44, P336, DOI 10.1111/j.1398-9995.1989.tb00455.x; Siracusa A, 1997, Monaldi Arch Chest Dis, V52, P434; Siracusa A, 1997, AM J RESP CRIT CARE, V155, P1168; SLOVAK AJM, 1981, BRIT J IND MED, V38, P38; Smedley J, 1996, OCCUP ENVIRON MED, V53, P450; SPIEKSMA FTM, 1986, J ALLERGY CLIN IMMUN, V77, P108, DOI 10.1016/0091-6749(86)90331-3; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; TEE R D, 1988, Journal of Allergy and Clinical Immunology, V81, P517, DOI 10.1016/0091-6749(88)90188-1; Ucgun I, 1998, ALLERGY, V53, P1096, DOI 10.1111/j.1398-9995.1998.tb03822.x; ULVESTAD B, 1999, EUR RESP J S30, V14, pS492; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; VENABLES KM, 1988, BRIT J IND MED, V45, P660; VIEGI G, 1986, BRIT J IND MED, V43, P802; Vignola AM, 1998, ALLERGY, V53, P833, DOI 10.1111/j.1398-9995.1998.tb03988.x; VOGELZANG PFJ, 1993, AM J IND MED, V24, P261, DOI 10.1002/ajim.4700240218; WELCH AR, 1995, J LARYNGOL OTOL, V109, P104; WELINDER H, 1990, CLIN EXP ALLERGY, V20, P639, DOI 10.1111/j.1365-2222.1990.tb02702.x; WILHELMSSON B, 1984, ALLERGY, V39, P586, DOI 10.1111/j.1398-9995.1984.tb01978.x; Yokota K, 1998, ALLERGY, V53, P803; Zuskin E, 1997, AM J IND MED, V31, P344, DOI 10.1002/(SICI)1097-0274(199703)31:3<344::AID-AJIM11>3.0.CO;2-0; Zuskin E, 1997, AM J IND MED, V31, P50; Zuskin E, 1998, AM J IND MED, V33, P24, DOI 10.1002/(SICI)1097-0274(199801)33:1<24::AID-AJIM4>3.0.CO;2-W; Zuskin E, 1996, ANN ALLERG ASTHMA IM, V77, P417; Zuskin E, 1998, AM J IND MED, V33, P263, DOI 10.1002/(SICI)1097-0274(199803)33:3<263::AID-AJIM8>3.0.CO;2-X	124	80	86	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-7894	1365-2222		CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2000	30	11					1519	1534		10.1046/j.1365-2222.2000.00946.x		16	Allergy; Immunology	Allergy; Immunology	383WH	WOS:000165907100005	11069559	
J	Chung, KF				Chung, KF			Airway smooth muscle cells: contributing to and regulating airway mucosal inflammation?	EUROPEAN RESPIRATORY JOURNAL			English	Article						airway smooth muscle; asthma; bronchial hyperresponsiveness; chemokines; proliferation	INTERCELLULAR-ADHESION MOLECULE-1; REPEATED ALLERGEN EXPOSURE; BROWN-NORWAY RATS; GROWTH-FACTOR; DNA SYNTHESIS; BRONCHOALVEOLAR LAVAGE; PASSIVE SENSITIZATION; T-HELPER-2 CYTOKINES; ASTHMATIC SUBJECTS; ICAM-1 EXPRESSION	In addition to its contractile properties, airway smooth muscle may contribute to the pathogenesis of asthma by increased proliferation, and by the expression and secretion of pro-inflammatory cytokines and mediators. Studies of airway smooth muscle cells in culture have shown that many mitogenic mediators can induce proliferation, and that these may therefore, contribute to the increase in airway smooth muscle mass observed in asthma. Other mechanisms for airway smooth muscle proliferation include the interaction with inflammatory cells such as T-cells and eosinophils. Airway smooth muscle cells may also be a source of inflammatory mediators and cytokines, in particular chemokines, thus implicating airway smooth muscle cells as contributors to the inflammatory mechanisms of asthma. The pro-activating signals for converting airway smooth muscle cells into a proliferative and secretory cell in asthma are unknown, but may include viruses and immunoglobulin E. Airway smooth muscle contractility may also be altered in response to inflammation. Airway smooth muscle cells may play an important interactive role with inflammatory and other structural cells, contributing to inflammation, injury and repair of the airways. Such a recognition makes it imperative to consider the airway smooth muscle as a target of therapeutic drugs for suppressing not only the contractile but also the proliferative and secretory effects of asthma.	Imperial Coll Sch Med & Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England	Chung, KF (reprint author), Imperial Coll Sch Med & Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England.			Chung, Kian Fan/0000-0001-7101-1426			Amrani Y, 1996, AM J RESP CELL MOL, V15, P55; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Belvisi MG, 1997, BRIT J PHARMACOL, V120, P910, DOI 10.1038/sj.bjp.0700963; BENTLEY AM, 1993, J ALLERGY CLIN IMMUN, V92, P857, DOI 10.1016/0091-6749(93)90064-M; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804; Brar SS, 1999, J BIOL CHEM, V274, P20017, DOI 10.1074/jbc.274.28.20017; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; DE S, 1993, AM J RESP CELL MOL, V9, P645; De S, 1996, AM J PHYSIOL-LUNG C, V270, pL795; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; Elias JA, 1997, AM J PHYSIOL-LUNG C, V273, pL648; Emala CW, 1997, AM J PHYSIOL-LUNG C, V272, pL644; Fernandes D, 1999, AM J RESP CELL MOL, V21, P77; Frid MG, 1997, CIRC RES, V81, P940; Ghaffar O, 1999, AM J RESP CRIT CARE, V159, P1933; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; Hakonarson H, 1998, AM J RESP CRIT CARE, V158, pS115; HAKONARSON H, 1995, AM J PHYSIOL-LUNG C, V269, pL645; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hakonarson H, 1996, J CLIN INVEST, V97, P2593, DOI 10.1172/JCI118708; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; Hakonarson H, 1997, J CLIN INVEST, V99, P117, DOI 10.1172/JCI119122; Hakonarson H, 1999, AM J RESP CRIT CARE, V159, pA401; Hakonarson H, 1999, J ALLERGY CLIN IMMUN, V104, P575, DOI 10.1016/S0091-6749(99)70326-X; Halayko AJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1040; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197; HALL IP, 1995, AM J PHYSIOL-LUNG C, V268, pL1; Hallsworth MP, 1998, AM J RESP CELL MOL, V19, P910; Hirst SJ, 1996, AM J PHYSIOL-LUNG C, V270, pL415; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574; HIRST SJ, 1996, EUR RESPIR J, V9, P908; Hotta K, 1999, AM J PHYSIOL-LUNG C, V276, pL405; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; John M, 1998, AM J RESP CELL MOL, V18, P84; John M, 1997, J IMMUNOL, V158, P1841; JOHNSON PRA, 1995, AM J PHYSIOL-LUNG C, V269, pL514; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; KONG SK, 1990, AM J PHYSIOL, V259, pL53; Koto H, 1996, J CLIN INVEST, V98, P1780, DOI 10.1172/JCI118977; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Laporte JD, 1998, AM J PHYSIOL-LUNG C, V275, pL491; Lazaar AL, 1997, AM J RESP CELL MOL, V16, P38; Lazaar AL, 1998, J IMMUNOL, V161, P3120; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Ma XF, 1998, AM J PHYSIOL-CELL PH, V274, pC1206; Ma XF, 1997, RESP PHYSIOL, V110, P57, DOI 10.1016/S0034-5687(97)00066-2; Mitchell RW, 1997, J APPL PHYSIOL, V83, P1276; MITCHELL RW, 1994, AM J PHYSIOL, V267, pL218; MONTEFORT S, 1992, EUR RESPIR J, V5, P815; NOVERAL JP, 1994, AM J PHYSIOL-LUNG C, V267, pL761; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453; Panettieri RA, 1996, BRIT J PHARMACOL, V118, P191; Panettieri RA, 1998, AM J RESP CRIT CARE, V158, pS133; PANETTIERI RA, 1990, AM J PHYSIOL, V259, pL365; PANETTIERI RA, 1995, J IMMUNOL, V154, P2358; Panettieri Reynold Jr., 1998, American Journal of Physiology, V274, pL417; Pang LH, 1998, J IMMUNOL, V161, P2509; Pang LH, 1997, AM J PHYSIOL-LUNG C, V273, pL1132; Patel HJ, 1999, FASEB J, V13, P1810; Pype JL, 1999, AM J RESP CELL MOL, V21, P528; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014; Rajah R, 1999, AM J RESP CELL MOL, V20, P199; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SALMON M, 2000, IN PRESS AM J RESP C; SANDERS M, 1994, PHARMACOL THERAPEUT, V61, P109, DOI 10.1016/0163-7258(94)90060-4; Saunders MA, 1997, BRIT J PHARMACOL, V120, P545, DOI 10.1038/sj.bjp.0700998; Seow CY, 1998, AM J RESP CRIT CARE, V158, pS179; Shore SA, 1997, AM J RESP CELL MOL, V16, P702; Stephens NL, 1998, AM J RESP CRIT CARE, V158, pS80; STEWART AG, 1994, CLIN EXP PHARMACOL P, V21, P277, DOI 10.1111/j.1440-1681.1994.tb02513.x; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219; THYBERG J, 1994, CELL TISSUE RES, V276, P263, DOI 10.1007/BF00306112; Vadas P, 1996, EUR J BIOCHEM, V235, P557, DOI 10.1111/j.1432-1033.1996.t01-1-00557.x; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689; WANG CG, 1993, AM REV RESPIR DIS, V148, P413; Watson ML, 1998, CYTOKINE, V10, P346, DOI 10.1006/cyto.1997.0350; Whelchel A, 1997, AM J RESP CELL MOL, V16, P589; YAMAMOTO M, 1993, EXP CELL RES, V204, P121, DOI 10.1006/excr.1993.1016; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; ZEPEDA EAG, 1996, NAT MED, V2, P449	85	80	84	0	2	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAY	2000	15	5					961	968		10.1034/j.1399-3003.2000.15e26.x		8	Respiratory System	Respiratory System	317JH	WOS:000087221900026	10853867	
J	Robinson, MK; Gerberick, GF; Ryan, CA; McNamee, P; White, IR; Basketter, DA				Robinson, MK; Gerberick, GF; Ryan, CA; McNamee, P; White, IR; Basketter, DA			The importance of exposure estimation in the assessment of skin sensitization risk	CONTACT DERMATITIS			English	Review						skin; contact allergy; exposure; risk assessment; cosmetics; household products; dose per unit area	LYMPH-NODE ASSAY; ALLERGIC CONTACT SENSITIZATION; SODIUM LAURYL SULFATE; DOSE-RESPONSE ASSESSMENTS; KATHON BIOCIDE; GUINEA-PIGS; PATCH TESTS; AREA; PRETREATMENT; SENSITIVITY	The development of new ingredients and products for the consumer market requires a thorough assessment of their potential for skin sensitization and the possible clinical manifestation of allergic contact dermatitis. The process by which low molecular weight chemicals induce and elicit skin sensitization reactions is complex and dependent on many factors relevant to the ability of the chemical to penetrate the skin, react with protein, and trigger the cell-mediated immune response. These major factors include inherent potency, chemical dose, duration and frequency of exposure, vehicle or product matrix, and occlusion. The fact that a chemical is a contact allergen does not mean that it cannot be formulated into a consumer product at levels well tolerated by most individuals. Many common ingredients (e.g., fragrances, preservatives) are known skin allergens. However, all allergens show dose-response and threshold characteristics. Therefore, one should be able to incorporate these chemicals into products at levels that produce acceptably low incidences of skin sensitization under foreseeable conditions of exposure. The critical exposure determinant for evaluating skin sensitization risk is dose per unit area of skin exposed. Use of this parameter allows for comparative assessments from different types of skin sensitization tests (including cross-species comparisons), and, at least for known potent allergens, there is remarkable similarity in threshold dose/unit area determinations across species. The dose/unit area calculation enables a judgment of the sensitization risk for different product types. This is illustrated using the chemical preservative methylchloroisothiazoline/methylisothiazolinone (MCI/MI) as a case study.	Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH 45253 USA; Rusham Pk Tech Ctr, Egham, Surrey, England; St Thomas Hosp, St Johns Inst Dermatol, London, England; Unilever, SEAC Toxicol Unit, Sharnbrook, Beds, England	Robinson, MK (reprint author), Procter & Gamble Co, Miami Valley Labs, POB 538707, Cincinnati, OH 45253 USA.			Robinson, Michael/0000-0002-6914-8543			BARRATT MD, 1992, CONTACT DERMATITIS, V27, P98, DOI 10.1111/j.1600-0536.1992.tb05217.x; Basketter D. A., 1998, International Journal of Cosmetic Science, V20, P141, DOI 10.1046/j.1467-2494.1998.171746.x; Basketter DA, 1997, FOOD CHEM TOXICOL, V35, P417, DOI 10.1016/S0278-6915(97)00129-4; Basketter DA, 1999, CONTACT DERMATITIS, V40, P150, DOI 10.1111/j.1600-0536.1999.tb06013.x; Basketter DA, 1999, TOXICOLOGY CONTACT D; Robinson M., 1996, TOXICOLOGY CONTACT H, P152; BAY PHS, 1985, J AM OIL CHEM SOC, V62, P646; BELSITO DV, 1989, J AM ACAD DERMATOL, V21, P822, DOI 10.1016/S0190-9622(89)70257-7; BOTHAM PA, 1991, CONTACT DERMATITIS, V25, P172, DOI 10.1111/j.1600-0536.1991.tb01823.x; Buehler E V, 1985, Curr Probl Dermatol, V14, P39; BUEHLER EV, 1994, FOOD CHEM TOXICOL, V32, P97, DOI 10.1016/0278-6915(94)90169-4; CARDIN CW, 1986, CONTACT DERMATITIS, V15, P10, DOI 10.1111/j.1600-0536.1986.tb01254.x; CHAN PK, 1983, J INVEST DERMATOL, V81, P409, DOI 10.1111/1523-1747.ep12522544; CUMBERBATCH M, 1993, TOXICOLOGY, V77, P181, DOI 10.1016/0300-483X(93)90148-L; DANNEMAN PJ, 1983, FOOD CHEM TOXICOL, V21, P721, DOI 10.1016/0278-6915(83)90203-X; European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), 1994, 58 ECETOC; Effendy I, 1996, BRIT J DERMATOL, V135, P428; Environmental Protection Agency (EPA), 1999, EXP FACT HDB; *EPA, 1992, USEPA PUBL; *EPA, 1998, USEPA PUBL; Fewings J, 1999, CONTACT DERMATITIS, V41, P1, DOI 10.1111/j.1600-0536.1999.tb06200.x; FORD RA, 1988, FOOD CHEM TOXICOL, V26, P921, DOI 10.1016/0278-6915(88)90090-7; FREIDMANN PS, 1994, IMMUNOTOXICOLOGY IMM, P589; Friedmann P S, 1990, Adv Dermatol, V5, P175; FRIEDMANN PS, 1983, CLIN EXP IMMUNOL, V53, P709; FRIEDMANN PS, 1983, BR J DERMATOL S109, V25, P86; FROSCH PJ, 1995, CONTACT DERMATITIS, V32, P210, DOI 10.1111/j.1600-0536.1995.tb00671.x; FUNK JO, 1994, CONTACT DERMATITIS, V31, P236, DOI 10.1111/j.1600-0536.1994.tb01995.x; GERBERICK GF, 1993, AM J CONTACT DERMATI, V4, P205; GERBERICK GF, 2000, IN PRESS AM J CONTAC, P43; HANNUKSELA M, 1986, CONTACT DERMATITIS, V15, P211, DOI 10.1111/j.1600-0536.1986.tb01338.x; Heylings JR, 1996, TOXICOLOGY, V109, P57, DOI 10.1016/0300-483X(96)03304-5; INNIS JD, 1989, FUNDAM APPL TOXICOL, V9, P242; KIMBER I, 1994, TOXICOLOGY, V93, P13, DOI 10.1016/0300-483X(94)90193-7; Kimber I, 1996, TOXICOLOGY CONTACT H, P4; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P393, DOI 10.1038/jid.1966.160; Loveless SE, 1996, TOXICOLOGY, V108, P141, DOI 10.1016/0300-483X(95)03279-O; MARZULLI FN, 1974, FOOD COSMET TOXICOL, V12, P219, DOI 10.1016/0015-6264(74)90367-8; McFadden JP, 1998, CONTACT DERMATITIS, V39, P79, DOI 10.1111/j.1600-0536.1998.tb05837.x; REES JL, 1990, BRIT J DERMATOL, V122, P29, DOI 10.1111/j.1365-2133.1990.tb08236.x; Ritz H. L., 1980, CURRENT CONCEPTS CUT, P25; Robinson MK, 1996, FOOD CHEM TOXICOL, V34, P495, DOI 10.1016/0278-6915(96)87361-3; ROBINSON MK, 1990, TOXICOL APPL PHARM, V104, P106, DOI 10.1016/0041-008X(90)90286-4; ROBINSON MK, 1989, FOOD CHEM TOXICOL, V27, P479, DOI 10.1016/0278-6915(89)90036-7; ROBINSON MK, 1991, FUND APPL TOXICOL, V17, P103, DOI 10.1016/0272-0590(91)90243-W; ROBINSON MK, 1990, TOXICOLOGY, V61, P91, DOI 10.1016/0300-483X(90)90012-6; SEIDENARI S, 1995, CONTACT DERMATITIS, V33, P152, DOI 10.1111/j.1600-0536.1995.tb00536.x; Seidenari S, 1996, CONTACT DERMATITIS, V34, P88, DOI 10.1111/j.1600-0536.1996.tb02136.x; Stotts J., 1980, CURRENT CONCEPTS CUT, P41; TOSTI A, 1988, CONTACT DERMATITIS, V18, P173, DOI 10.1111/j.1600-0536.1988.tb04509.x; WEAVER JE, 1985, CONTACT DERMATITIS, V12, P141, DOI 10.1111/j.1600-0536.1985.tb01083.x; WEITLAUFF M, 1996, Z KIRCHENGESCH, V107, P141; WHITE SI, 1986, BRIT J DERMATOL, V115, P663, DOI 10.1111/j.1365-2133.1986.tb06646.x	53	80	81	0	5	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	MAY	2000	42	5					251	259		10.1034/j.1600-0536.2000.042005251.x		9	Allergy; Dermatology	Allergy; Dermatology	306FE	WOS:000086586000001	10789838	
J	Young, S; Sherrill, DL; Arnott, J; Diepeveen, D; LeSouef, PN; Landau, LI				Young, S; Sherrill, DL; Arnott, J; Diepeveen, D; LeSouef, PN; Landau, LI			Parental factors affecting respiratory function during the first year of life	PEDIATRIC PULMONOLOGY			English	Article						infant lung function; maternal tobacco smoking; in utero tobacco smoke exposure; maternal inheritance; infant gender; predictive equations; asthma	FLOW-VOLUME CURVES; FORCED EXPIRATORY FLOWS; PULMONARY-FUNCTION; MATERNAL SMOKING; LUNG-FUNCTION; 1ST YEAR; PASSIVE SMOKING; NORMAL INFANTS; LONGITUDINAL DATA; NEWBORN-INFANTS	In a prospective, longitudinal, population-based cohort study of familial and environmental influences on the development of wheezing respiratory illness in early childhood, we identified infant length, weight, gender, and exposure to maternal cigarette smoking as significant determinants of lung function during the first year of life. A cohort of 237 infants (106 females: 131 males) was evaluated, and 496 lung function measurements were made between the ages of 1-12 months. Respiratory function was assessed using the rapid thoracic compression technique to obtain maximum expiratory flow at functional residual capacity (V'maxFRC). Parental history of asthma and smoking habits during pregnancy were obtained by questionnaire. Data were analyzed using a longitudinal random effects model. infants with a parental history of asthma and/or in utero passive smoke exposure were compared to a reference group of infants who had no parental history of asthma and in whom neither parent smoked pre- or postnatally. Boys were found to have a consistently lower V'maxFRC (-21.05 mL.s(-1)) throughout the first year of life in comparison to girls (P < 0.05). Maternal smoking during pregnancy was associated with a lower V'maxFRG in both genders in comparison to unexposed infants (P < 0.05). V'maxFRC was unaffected by parental history of asthma. Gender-specific normative equations for V'maxFRC throughout the first year of life were derived for the infant cohort as a whole and also for subgroups of infants, based on parental asthma and smoking history. We conclude that lung function during the first year of life differs between genders and is adversely affected by in utero passive tobacco smoke exposure. Gender-specific predictive equations for V'maxFRG should be used during infancy. Pediatr Pulmonol. 2000; 29:331-340, (C) 2000 Wiley-Liss, Inc.	Princess Margaret Hosp Children, Dept Resp Med, Perth, WA, Australia; Univ Arizona, Div Resp Sci, Tucson, AZ USA	Landau, LI (reprint author), Univ Western Australia, Fac Med & Dent, Nedlands, WA 6907, Australia.						ADLER SM, 1978, PEDIATRICS, V61, P636; BASSI JA, 1984, PEDIATR RES, V18, P127, DOI 10.1203/00006450-198402000-00002; BROWN RW, 1995, PEDIATR PULM, V19, P23, DOI 10.1002/ppul.1950190105; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; CATLIN EA, 1990, AM REV RESPIR DIS, V141, P466; CHEN MF, 1987, PEDIATR PULM, V3, P51, DOI 10.1002/ppul.1950030113; COLLEY JRT, 1974, LANCET, V2, P1031; COLLINS MH, 1985, PEDIATR RES, V19, P408; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; DIVERS WA, 1981, AM J OBSTET GYNECOL, V141, P625; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; FERGUSSON DM, 1980, ARCH DIS CHILD, V55, P358; FERGUSSON DM, 1981, J EPIDEMIOL COMMUN H, V35, P180, DOI 10.1136/jech.35.3.180; Ferris B., 1978, AM REV RESPIR DIS, V118, P7; GARDNER G, 1984, J EPIDEMIOL COMMUN H, V38, P42, DOI 10.1136/jech.38.1.42; GREEN M, 1974, J APPL PHYSIOL, V37, P67; HANRAHAN JP, 1990, AM REV RESPIR DIS, V141, P1127; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; HAPPLE R, 1982, INT ARCH ALLER A IMM, V68, P90; HARLAP S, 1974, LANCET, V1, P529; HORWOOD LJ, 1985, PEDIATRICS, V75, P859; JONES RH, 1991, BIOMETRICS, V47, P161, DOI 10.2307/2532504; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LANDAU LI, 1973, THESIS U MELBOURNE; LEBOWITZ MD, 1988, AM J EPIDEMIOL, V128, P589; LEBOWITZ MD, 1976, CHEST, V69, P48, DOI 10.1378/chest.69.1.48; LEEDER SR, 1976, BRIT J PREV SOC MED, V30, P203; LESOUEF PN, 1989, AM REV RESPIR DIS, V139, P62; LIEBERMAN E, 1992, OBSTET GYNECOL, V79, P564; MAGNUSSON CGM, 1988, ALLERGY, V43, P241, DOI 10.1111/j.1398-9995.1988.tb00896.x; MAN SFP, 1976, J APPL PHYSIOL, V41, P874; MASTERS IB, 1987, PEDIATR PULM, V3, P3, DOI 10.1002/ppul.1950030104; MEAD J, 1980, AM REV RESPIR DIS, V121, P339; MICHEL FB, 1980, J ALLERGY CLIN IMMUN, V65, P422, DOI 10.1016/0091-6749(80)90234-1; PATTISHALL EN, 1989, PEDIATR PULM, V7, P22, DOI 10.1002/ppul.1950070107; PHELAN PD, 1974, RESP ILLN CHILDR, P24; PHILIPP K, 1984, GYNECOL OBSTET INVES, V17, P179; REDLINE S, 1987, AM REV RESPIR DIS, V135, P217; REESE AC, 1992, AM REV RESPIR DIS, V146, P66; SCHILLING RSF, 1977, AM J EPIDEMIOL, V106, P274; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136; SILVERMAN M, 1986, B EUR PHYSIOPATH RES, V22, P257; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TASHKIN DP, 1984, AM REV RESPIR DIS, V129, P891; TAUSSIG LM, 1982, J APPL PHYSIOL, V53, P1220; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786; TEPPER RS, 1986, AM REV RESPIR DIS, V134, P513; TEPPER RS, 1993, PEDIATR PULM, V15, P357, DOI 10.1002/ppul.1950150608; TURNER DJ, 1990, PEDIATR PULM, V8, P289, DOI 10.1002/ppul.1950080414; VEDAL S, 1984, AM REV RESPIR DIS, V130, P187; WANG NS, 1983, LUNG, V161, P27, DOI 10.1007/BF02713839; WEISS ST, 1980, AM REV RESPIR DIS, V122, P697; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; ZAPLETAL A, 1976, J APPL PHYSIOL, V40, P953	56	80	82	3	3	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	MAY	2000	29	5					331	340		10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A		10	Pediatrics; Respiratory System	Pediatrics; Respiratory System	308AA	WOS:000086685300001	10790244	
J	Miravitlles, M; Calle, M; Soler-Cataluna, JJ				Miravitlles, Marc; Calle, Myriam; Jose Soler-Cataluna, Juan			Clinical Phenotypes of COPD: Identification, Definition and Implications for Guidelines	ARCHIVOS DE BRONCONEUMOLOGIA			Spanish	Article						COPD; Phenotype; Asthma; Emphysema; Exacerbation; Treatment	OBSTRUCTIVE PULMONARY-DISEASE; INHALED CORTICOSTEROID TREATMENT; RESOLUTION COMPUTED-TOMOGRAPHY; RANDOMIZED CONTROLLED-TRIAL; VOLUME REDUCTION SURGERY; LUNG-FUNCTION DECLINE; AIR-FLOW OBSTRUCTION; QUALITY-OF-LIFE; DYNAMIC HYPERINFLATION; RISK-FACTORS	The term phenotype in the field of COPD is defined as "a single or combination of disease attributes that describe differences between individuals with COPD as they relate to clinically meaningful outcomes". Among all phenotypes described, there are three that are associated with prognosis and especially are associated with a different response to currently available therapies. There phenotypes are: the exacerbator, the overlap COPD-asthma and the emphysema-hyperinflation. The exacerbator is characterised by the presence of, at least, two exacerbations the previous year, and on top of long-acting bronchodilators, may require the use of antiinflammatory drugs. The overlap phenotype presents symptoms of increased variability of airflow and incompletely reversible airflow obstruction. Due to the underlying inflammatory profile, it uses to have a good therapeutic response to inhaled corticosteroids in addition to bronchodilators. Lastly, the emphysema phenotype presents a poor therapeutic response to the existing antiinflammatory drugs and long-acting bronchodilators together with rehabilitation are the treatments of choice. Identifying the peculiarities of the different phenotypes of COPD will allow us to implement a more personalised treatment, in which the characteristics of the patients, together with their severity will be key to choose the best treatment option. (c) 2011 SEPAR. Published by Elsevier Espana, S.L. All rights reserved.	[Miravitlles, Marc] Hosp Clin Barcelona, IDIBAPS, Ciber Enfermedades Resp CIBERES, Barcelona, Spain; [Calle, Myriam] Hosp Clin San Carlos, Serv Neumol, Madrid, Spain; [Jose Soler-Cataluna, Juan] Hosp Requena, Med Interna Serv, Unidad Neumol, Valencia, Spain	Miravitlles, M (reprint author), Hosp Clin Barcelona, IDIBAPS, Ciber Enfermedades Resp CIBERES, Barcelona, Spain.	marcm@separ.es	Calle Rubio, Myriam/B-9780-2017	Calle Rubio, Myriam/0000-0002-3890-2742; Miravitlles, Marc/0000-0002-9850-9520			Abroug F, 2006, AM J RESP CRIT CARE, V174, P990, DOI 10.1164/rccm.200603-380OC; Albert RK, 2011, NEW ENGL J MED, V365, P689, DOI 10.1056/NEJMoa1104623; Alfageme Inmaculada, 2010, Chron Respir Dis, V7, P135, DOI 10.1177/1479972310368692; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P77; Anderson David, 2009, Int J Chron Obstruct Pulmon Dis, V4, P321; Martinez-Garcia MA, 2011, CHEST, V140, P1130, DOI 10.1378/chest.10-1758; Barr RG, 2010, NEW ENGL J MED, V362, P217, DOI 10.1056/NEJMoa0808836; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; Bleecker ER, 2008, PULM PHARMACOL THER, V21, P682, DOI 10.1016/j.pupt.2008.04.003; Boschetto P, 2006, THORAX, V61, P1037, DOI 10.1136/thx.2006058321; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; Bourbeau J, 2007, EUR RESPIR J, V30, P907, DOI 10.1183/09031936.00166606; Brightling CE, 2005, THORAX, V60, P193, DOI 10.1136/thx.2004.032516; Burgel PR, 2010, EUR RESPIR J, V36, P531, DOI 10.1183/09031936.00175109; Burgel PR, 2009, CHEST, V135, P975, DOI 10.1378/chest.08-2062; Calverley PMA, 2007, AM J RESP CRIT CARE, V176, P154, DOI 10.1164/rccm.200610-1563OC; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Casaburi R, 2009, NEW ENGL J MED, V360, P1329, DOI 10.1056/NEJMct0804632; Casanova C, 2005, AM J RESP CRIT CARE, V171, P591, DOI 10.1164/rrcm.200407-867OC; Celli B, 2009, AM J RESP CRIT CARE, V180, P948, DOI 10.1164/rccm.200906-0876OC; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Chalmers GW, 2001, CHEST, V120, P1917, DOI 10.1378/chest.120.6.1917; Cho MH, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-30; Cote CG, 2007, CHEST, V131, P696, DOI 10.1378/chest.06-1610; Dal Negro R, 2008, ADV THER, V25, P1019, DOI [10.1007/s12325-008-0105-2, 10.1007/s12325-008-0105-z]; de Marco R, 2007, AM J RESP CRIT CARE, V175, P32, DOI 10.1164/rccm.200603-381OC; Decramer M, 1997, EUR RESPIR J, V10, P417, DOI 10.1183/09031936.97.10020417; Dewan NA, 2000, CHEST, V117, P662, DOI 10.1378/chest.117.3.662; Diaz O, 2000, EUR RESPIR J, V16, P269, DOI 10.1034/j.1399-3003.2000.16b14.x; Doll H, 2005, PHARMACOECONOMICS, V23, P345, DOI 10.2165/00019053-200523040-00005; Donaldson GC, 2010, CHEST, V137, P1091, DOI 10.1378/chest.09-2029; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Dummer JF, 2009, AM J RESP CRIT CARE, V180, P846, DOI 10.1164/rccm.200905-0685OC; Eisen DP, 2010, J INNATE IMMUN, V2, P114, DOI 10.1159/000228159; Esteban C, 2008, J GEN INTERN MED, V23, P1829, DOI 10.1007/s11606-008-0783-x; Fabbri LM, 2009, LANCET, V374, P695, DOI 10.1016/S0140-6736(09)61252-6; Ferguson Gary T, 2006, Proc Am Thorac Soc, V3, P176, DOI 10.1513/pats.200508-094DO; Foreman MG, 2007, EUR RESPIR J, V30, P1124, DOI 10.1183/09031936.00009307; Fujimoto K, 2006, RESPIROLOGY, V11, P731, DOI 10.1111/j.1440-1843.2006.00930.x; Garcia-Aymerich J, 2006, THORAX, V61, P772, DOI 10.1136/thx.2006.060145; Garcia-Aymerich J, 2003, THORAX, V58, P100, DOI 10.1136/thorax.58.2.100; Garcia-Aymerich J, 2011, THORAX, V66, P430, DOI 10.1136/thx.2010.154484; Garcia-Aymerich J, 2009, ARCH BRONCONEUMOL, V45, P129, DOI 10.1016/j.arbres.2008.10.001; Garcia-Rio F, 2009, AM J RESP CRIT CARE, V180, P506, DOI 10.1164/rccm.200812-1873OC; GELB AF, 1993, AM REV RESPIR DIS, V147, P1157; Gevenois PA, 1996, RADIOLOGY, V199, P825; GEVENOIS PA, 1995, AM J RESP CRIT CARE, V152, P653; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Grydeland TB, 2011, RESP MED, V105, P343, DOI 10.1016/j.rmed.2010.10.018; Han MK, 2010, AM J RESP CRIT CARE, V182, P598, DOI 10.1164/rccm.200912-1843CC; Hannink JDC, 2010, CHEST, V137, P1116, DOI 10.1378/chest.09-1847; Haruna A, 2010, CHEST, V138, P635, DOI 10.1378/chest.09-2836; Harvey Martyn G, 2004, Emerg Med Australas, V16, P212, DOI 10.1111/j.1742-6723.2004.00589.x; Hoesein FAAM, 2011, EUR RESPIR J, V38, P1012, DOI 10.1183/09031936.00050711; HOGG JC, 1994, THORAX, V49, P473, DOI 10.1136/thx.49.5.473; Hurst JR, 2010, NEW ENGL J MED, V363, P1128, DOI 10.1056/NEJMoa0909883; Hurst JR, 2005, EUR RESPIR J, V26, P846, DOI 10.1183/09031936.05.00043405; Jo KW, 2010, INT J TUBERC LUNG D, V14, P1481; Jorgensen K, 2007, CHEST, V131, P1050, DOI 10.1378/chest.06-2245; Soler-Cataluna JJ, 2010, COPD, V7, P276, DOI 10.3109/15412555.2010.496817; Soler-Cataluna JJ, 2009, RESP MED, V103, P692, DOI 10.1016/j.rmed.2008.12.005; Kardos P, 2007, AM J RESP CRIT CARE, V175, P144, DOI 10.1164/rccm.2006.02-244OC; KERSTJENS HAM, 1993, EUR RESPIR J, V6, P868; Kim WJ, 2011, EUR RESPIR J, V37, P39, DOI 10.1183/09031936.00173009; Kitaguchi Y, 2006, RESP MED, V100, P1742, DOI 10.1016/j.rmed.2006.02.003; KNUDSON RJ, 1991, CHEST, V99, P1357, DOI 10.1378/chest.99.6.1357; Kunisaki Ken M, 2008, Ther Adv Respir Dis, V2, P55, DOI 10.1177/1753465808088902; Lee JH, 2010, RESP MED, V104, P542, DOI 10.1016/j.rmed.2009.10.024; Lehtimaki L, 2010, EUR RESPIR J, V35, P72, DOI 10.1183/09031936.00177508; Leigh R, 2006, EUR RESPIR J, V27, P964, DOI 10.1183/09031936.06.00072105; Lopez-Campos JL, 2010, ARCH BRONCONEUMOL, V46, P617, DOI 10.1016/j.arbres.2010.06.003; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; Mair G, 2010, RESP MED, V104, P1683, DOI 10.1016/j.rmed.2010.04.021; Makita H, 2007, THORAX, V62, P932, DOI 10.1136/thx.2006.072777; Makris D, 2007, RESP MED, V101, P1305, DOI 10.1016/j.rmed.2006.10.012; Man WDC, 2004, THORAX, V59, P471, DOI 10.1136/thx.2003.019620; Marin JM, 2001, AM J RESP CRIT CARE, V163, P1395; Marquez-Martin E, 2011, INT J CHRONIC OBSTR, V6, P105, DOI 10.2147/COPD.S16646; Marsh SE, 2008, THORAX, V63, P761, DOI 10.1136/thx.2007.089193; Martinez FJ, 2006, AM J RESP CRIT CARE, V173, P1326, DOI 10.1164/rccm.200510-1677OC; Miravitlles M, 2000, RESPIRATION, V67, P495, DOI 10.1159/000067462; Miravitlles M, 2004, THORAX, V59, P387, DOI 10.1136/thx.2003.008730; Miravitlles M, 2002, EUR RESPIR J, V20, p9S, DOI 10.1183/09031936.02.00400302; Miravitlles M, 2009, EUR RESPIR J, V34, P1066, DOI 10.1183/09031936.00195608; Miravitlles M, 2009, THORAX, V64, P863, DOI 10.1136/thx.2009.115725; Miravitlles M, 2011, ARCH BRONCONEUMOL, V47, P379, DOI 10.1016/j.arbres.2011.05.008; Miravitlles M, 2011, ARCH BRONCONEUMOL, V47, P271, DOI [10.1016/j.arbr.2011.01.003, 10.1016/j.arbres.2011.01.016]; Miravitlles M, 2011, RESP MED, V105, P1118, DOI 10.1016/j.rmed.2011.02.003; Miravitlles Marc, 2009, Arch Bronconeumol, V45 Suppl 5, P27, DOI 10.1016/S0300-2896(09)72952-7; Miravitlles M, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-58; Newton MF, 2002, CHEST, V121, P1042, DOI 10.1378/chest.121.4.1042; Niewoehner DE, 2007, CHEST, V131, P20, DOI 10.1378/chest.06-1316; Nishimura K, 2002, CHEST, V121, P1434, DOI 10.1378/chest.121.5.1434; O'Donnell DE, 2001, AM J RESP CRIT CARE, V164, P770; O'Donnell Denis E, 2006, Proc Am Thorac Soc, V3, P180, DOI 10.1513/pats.200508-093DO; O'Donnell, 2004, EUR RESPIR J, V23, P832; ODONNELL DE, 1993, AM REV RESPIR DIS, V148, P1351; Oga T, 2003, AM J RESP CRIT CARE, V167, P544, DOI 10.1164/rccm.200206-583OC; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; Patel BD, 2008, AM J RESP CRIT CARE, V178, P500, DOI 10.1164/rccm.200801-059OC; Patel IS, 2004, AM J RESP CRIT CARE, V170, P400, DOI 10.1164/rccm.200305-648OC; Patel IS, 2002, THORAX, V57, P759, DOI 10.1136/thorax.57.9.759; Peces-Barba G, 2008, ARCH BRONCONEUMOL, V44, P271, DOI 10.1016/S1579-2129(08)60043-9; Pillai SG, 2010, AM J RESP CRIT CARE, V182, P1498, DOI 10.1164/rccm.201002-0151OC; Pinto-Plata VM, 2004, EUR RESPIR J, V23, P28, DOI 10.1183/09031936.03.00034603; Pistolesi M, 2008, RESP MED, V102, P367, DOI 10.1016/j.rmed.2007.10.019; Pomares X, 2011, INT J CHRONIC OBSTR, V6, P449, DOI 10.2147/COPD.S23655; PRESCOTT E, 1995, EUR RESPIR J, V8, P1333, DOI 10.1183/09031936.95.08081333; Quint JK, 2008, EUR RESPIR J, V32, P53, DOI 10.1183/09031936.00120107; Rabe KF, 2008, CHEST, V134, P255, DOI 10.1378/chest.07-2138; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rennard SI, 2008, CHEST, V134, P623, DOI 10.1378/chest.07-3059; Rennard SI, 2011, RESP RES, V12, DOI 10.1186/1465-9921-12-18; Garcia Rio F, 2007, ARCH BRONCONEUMOL S3, V43, P8; Roy K, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-41; Calle Rubio M, 2007, MED CLIN MONOGR, V8, P22; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; Seemungal TAR, 2008, AM J RESP CRIT CARE, V178, P1139, DOI 10.1164/rccm.200801-145OC; Sethi S, 2008, NEW ENGL J MED, V359, P2355, DOI 10.1056/NEJMra0800353; Sethi S, 2007, AM J RESP CRIT CARE, V176, P356, DOI 10.1164/rccm.200703-417OC; Sethi S, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-10; Sevilla-Sanchez D, 2010, ARCH BRONCONEUMOL, V46, P244, DOI 10.1016/j.arbres.2009.10.008; Siva R, 2007, EUR RESPIR J, V29, P906, DOI 10.1183/09031936.00146306; Snoeck-Stroband JB, 2008, EUR RESPIR J, V31, P70, DOI 10.1183/09031936.00137006; Soejima K, 2000, AM J RESP CRIT CARE, V161, P1264; Soler JJ, 2004, RESP MED, V98, P318, DOI 10.1016/j.rmed.2003.04.001; Soler JJ, 2001, ARCH BRONCONEUMOL, V37, P375; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; Stolk J, 2007, EUR RESPIR J, V29, P1138, DOI 10.1183/09031936.00056206; Suissa S, 2008, EUR RESPIR J, V31, P927, DOI 10.1183/09031936.00098307; Suzuki T, 2001, CHEST, V120, P730, DOI 10.1378/chest.120.3.730; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Takabatake N, 2006, AM J RESP CRIT CARE, V174, P875, DOI 10.1164/rccm.200603-443OC; Tashkin DP, 2008, EUR RESPIR J, V31, P742, DOI 10.1183/09031936.00129607; Tashkin DP, 2010, NEW ENGL J MED, V363, P1183, DOI 10.1056/NEJMe1008184; Tashkin DP, 2004, CHEST, V125, P249, DOI 10.1378/chest.125.1.249; Terada K, 2008, THORAX, V63, P951, DOI 10.1136/thx.2007.092858; Terada K, 2010, CHEST, V137, P326, DOI 10.1378/chest.09-0482; Tumkaya M, 2007, RESP MED, V101, P729, DOI 10.1016/j.rmed.2006.08.020; van Noord JA, 2005, EUR RESPIR J, V26, P214, DOI 10.1183/09031936.05.00140404; Vassaux C, 2008, EUR RESPIR J, V32, P1275, DOI 10.1183/09031936.00151707; Vidal R, 2006, ARCH BRONCONEUMOL, V42, P645, DOI 10.1157/13095974; Vogelmeier C, 2011, NEW ENGL J MED, V364, P1093, DOI 10.1056/NEJMoa1008378; Wan ES, 2011, RESP MED, V105, P588, DOI 10.1016/j.rmed.2010.11.015; Wardlaw AJ, 2005, CLIN EXP ALLERGY, V35, P1254, DOI 10.1111/j.1365-2222.2005.02344.x; Washko GR, 2008, AM J RESP CRIT CARE, V177, P164, DOI 10.1164/rccm.200708-1194OC; Watz H, 2010, CHEST, V138, P32, DOI 10.1378/chest.09-2810; Weatherall M, 2009, EUR RESPIR J, V34, P812, DOI 10.1183/09031936.00174408; WEINER P, 1995, CHEST, V108, P1568, DOI 10.1378/chest.108.6.1568; Yang IA, 2003, GENES IMMUN, V4, P269, DOI 10.1038/sj.gene.6363961; Yuan R, 2009, THORAX, V64, P944, DOI 10.1136/thx.2008.112433; Zhang M, 2010, EUR J CLIN MICROBIOL, V29, P1487, DOI 10.1007/s10096-010-1027-7; Zvezdin B, 2009, CHEST, V136, P329	155	79	88	0	23	EDICIONES DOYMA S A	BARCELONA	TRAV DE GRACIA 17-21, 08021 BARCELONA, SPAIN	0300-2896			ARCH BRONCONEUMOL	Arch. Bronconeumol.	MAR	2012	48	3					86	98		10.1016/j.arbres.2011.10.007		13	Respiratory System	Respiratory System	907DP	WOS:000301398300005	22196477	
J	Rothers, J; Wright, AL; Stern, DA; Halonen, M; Camargo, CA				Rothers, Janet; Wright, Anne L.; Stern, Debra A.; Halonen, Marilyn; Camargo, Carlos A., Jr.			Cord blood 25-hydroxyvitamin D levels are associated with aeroallergen sensitization in children from Tucson, Arizona	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; IgE; aeroallergen; allergic rhinitis; asthma; children	VITAMIN-D INTAKE; CHILDHOOD ASTHMA; ALLERGIC RHINITIS; D SUPPLEMENTATION; PREGNANCY; DISEASES; RISK; IGE; DEFICIENCY; INFANTS	Background: The association between vitamin D status at birth and childhood allergic outcomes is uncertain. The desert climate of Tucson offers a unique setting for studying the health effects of higher exposure to vitamin D. Objective: To assess the relationship between cord blood 25-hydroxyvitamin D (25[OH]D) levels and allergic outcomes through age 5 years. Methods: Cord blood 25(OH)D levels were measured in 219 participants in the Tucson Infant Immune Study, a population-based birth cohort. Plasma total IgE and specific IgE levels to 6 aeroallergens were measured at 1, 2, 3, and 5 years. Skin prick test (SPT) positivity (wheal diameter >= 3 mm) and physician-diagnosed active allergic rhinitis and asthma were assessed at age 5 years. Longitudinal models were used to assess the relationship between 25(OH)D and IgE levels. Logistic regression models were used to assess the relationship of 25(OH)D level with SPT positivity, allergic rhinitis, and asthma. Results: The median cord blood 25(OH)D level was 64 nmol/L (interquartile range, 49-81 nmol/L). Relative to the reference group (50-74.9 nmol/L), both low (<50 nmol/L) and high (>= 100 nmol/L) levels were associated with increased total IgE (coefficient = 0.27, P = .006 and coefficient = 0.27, P = .04, respectively) and detectable inhalant allergen-specific IgE (odds ratio = 2.4, P = .03 and odds ratio = 4.0, P = .01, respectively) through age 5 years. High 25(OH)D levels were also associated with increased SPT positivity (odds ratio = 4.0, P = .02). By contrast, the 25(OH)D level was not significantly associated with allergic rhinitis or asthma. Conclusion: Both low and high levels of cord blood 25(OH)D were associated with increased aeroallergen sensitization. The association between vitamin D status and actual allergic diseases merits further study. (J Allergy Clin Immunol 2011;128:1093-9.)	[Wright, Anne L.] Univ Arizona, Arizona Hlth Sci Ctr, Arizona Resp Ctr, Tucson, AZ 85724 USA; [Rothers, Janet] Univ Arizona, Mel & Enid Zuckerman Coll Publ Hlth, Tucson, AZ 85724 USA; [Wright, Anne L.] Univ Arizona, Dept Pediat, Tucson, AZ 85724 USA; [Halonen, Marilyn] Univ Arizona, Dept Pharmacol, Tucson, AZ 85724 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA; [Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA	Wright, AL (reprint author), Univ Arizona, Arizona Hlth Sci Ctr, Arizona Resp Ctr, 1501 N Campbell Ave, Tucson, AZ 85724 USA.	awright@arc.arizona.edu			National Institutes of Health [AI 42268, AI 61811]	This study was funded by National Institutes of Health grants AI 42268 and AI 61811 and the Massachusetts General Hospital Center for D-receptor Activation Research.; Disclosure of potential conflict of interest: J. Rothers, A.L. Wright, and M. Halonen receive research support from the National Institutes of Health. The rest of the authors have declared that they have no conflict of interest.	Back O, 2009, ACTA DERM-VENEREOL, V89, P28, DOI 10.2340/00015555-0541; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Brockow I, 2009, J INVEST ALLERG CLIN, V19, P180; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Camargo CA, 2011, PEDIATRICS, V127, pE180, DOI 10.1542/peds.2010-0442; Camargo CA, 2010, BRIT J NUTR, V104, P1051, DOI 10.1017/S0007114510001674; Devereux G, 2007, AM J CLIN NUTR, V85, P853; Erkkola M, 2009, CLIN EXP ALLERGY, V39, P875, DOI 10.1111/j.1365-2222.2009.03234.x; Freishtat RJ, 2010, J PEDIATR-US, V156, P948, DOI 10.1016/j.jpeds.2009.12.033; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; GALLO S, 2007, PAEDIAT CHILD HLTH, V12, P583; Hypponen E, 2009, ALLERGY, V64, P613, DOI 10.1111/j.1398-9995.2008.01865.x; Hypponen E, 2004, ANN NY ACAD SCI, V1037, P84, DOI 10.1196/annals.1337.013; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Litonjua AA, 2009, CURR OPIN ALLERGY CL, V9, P202, DOI 10.1097/ACI.0b013e32832b36cd; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matheu V, 2003, J ALLERGY CLIN IMMUN, V112, P585, DOI 10.1037/mai.2003.1703; Miyake Y, 2010, EUR RESPIR J, V35, P1228, DOI 10.1183/09031936.00100609; Ross AC, 2011, J CLIN ENDOCR METAB, V96, P53, DOI 10.1210/jc.2010-2704; Roth HJ, 2008, ANN CLIN BIOCHEM, V45, P153, DOI 10.1258/acb.2007.007091; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Singh RJ, 2006, J CLIN ENDOCR METAB, V91, P3055, DOI 10.1210/jc.2006-0710; Sunyer J, 1996, EUR RESPIR J, V9, P1880, DOI 10.1183/09031936.96.09091880; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Weiss ST, 2008, CLIN EXP ALLERGY, V38, P385, DOI 10.1111/j.1365-2222.2007.02920.x; Wintergerst ES, 2007, ANN NUTR METAB, V51, P301, DOI 10.1159/000107673; Wittke A, 2004, J IMMUNOL, V173, P3432; Wjst M, 2007, ALLERGY, V62, P1085, DOI 10.1111/j.1398-9995.2007.01437.x; Wjst M, 1999, ALLERGY, V54, P757, DOI 10.1034/j.1398-9995.1999.00193.x; [Anonymous], 2007, J ALLERGY CLIN IMMUN, V120, pS94	33	79	79	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					1093	U275		10.1016/j.jaci.2011.07.015		12	Allergy; Immunology	Allergy; Immunology	842FJ	WOS:000296578200024	21855975	
J	Van den Abbeele, P; Van de Wiele, T; Verstraete, W; Possemiers, S				Van den Abbeele, Pieter; Van de Wiele, Tom; Verstraete, Willy; Possemiers, Sam			The host selects mucosal and luminal associations of coevolved gut microorganisms: a novel concept	FEMS MICROBIOLOGY REVIEWS			English	Review						microbial communities; colon; symbiotic bacteria; Crohn's disease; gastrointestinal	HUMAN INTESTINAL MICROBIOTA; INFLAMMATORY-BOWEL-DISEASE; INNATE IMMUNE-SYSTEM; 16S RIBOSOMAL-RNA; GRADIENT GEL-ELECTROPHORESIS; BUTYRATE-PRODUCING BACTERIA; LACTOBACILLUS-RHAMNOSUS GG; ILEAL CROHNS-DISEASE; TOLL-LIKE RECEPTOR-3; T-CELL POLARIZATION	Along the human gastrointestinal tract, microorganisms are confronted with multiple barriers. Besides selective physical conditions, the epithelium is regularly replaced and covered with a protective mucus layer trapping immune molecules. Recent insights into host defense strategies show that the host selects the intestinal microbiota, particularly the mucosa-associated microbial community. In this context, humans coevolved with thousands of intestinal microbial species that have adapted to provide host benefits, while avoiding pathogenic behavior that might destabilize their host interaction. While mucosal microorganisms would be crucial for immunological priming, luminal microorganisms would be important for nutrient digestion. Further, we propose that the intestinal microorganisms also coevolved with each other, leading to coherently organized, resilient microbial associations. During disturbances, functionally redundant members become more abundant and are crucial for preserving community functionality. The outside of the mucus layer, where host defense molecules are more diluted, could serve as an environment where microorganisms are protected from disturbances in the lumen and from where they can recolonize the lumen after perturbations. This might explain the remarkable temporal stability of microbial communities. Finally, commensals that become renegade or a decreased exposure to essential coevolved microorganisms may cause particular health problems such as inflammatory bowel diseases, obesity or allergies.	[Van den Abbeele, Pieter; Van de Wiele, Tom; Verstraete, Willy; Possemiers, Sam] Univ Ghent, Lab Microbial Ecol & Technol LabMET, B-9000 Ghent, Belgium	Verstraete, W (reprint author), Univ Ghent, Lab Microbial Ecol & Technol LabMET, Coupure Links 653, B-9000 Ghent, Belgium.	willy.verstraete@ugent.be			FWO-Vlaanderen (Research Foundation of Flanders, Belgium); Ghent University [BOF07/GOA/002]	T.V.d.W. and S. P. are Postdoctoral Fellows and P.V.d.A. is a PhD student, all supported by FWO-Vlaanderen (Research Foundation of Flanders, Belgium). We acknowledge Erwin Zoetendal, Sahar El Aidy, Nico Boon and David van der Ha for their critical review of the manuscript. Finally, this work was financially supported by GOA (BOF07/GOA/002) project from Ghent University.	Adlercreutz H, 2007, CRIT REV CL LAB SCI, V44, P483, DOI 10.1080/10408360701612942; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Alander M, 1999, APPL ENVIRON MICROB, V65, P351; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Armelagos GJ, 2005, EVOL ANTHROPOL, V14, P109, DOI 10.1002/evan.20048; Atuma C, 2001, AM J PHYSIOL-GASTR L, V280, pG922; Ayabe T, 2004, TRENDS MICROBIOL, V12, P394, DOI 10.1016/j.tim.2004.06.007; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Barnes PJ, 2001, RESPIR RES, V2, P64, DOI 10.1186/rr39; Bates JM, 2007, CELL HOST MICROBE, V2, P371, DOI 10.1016/j.chom.2007.10.010; Belenguer A, 2006, APPL ENVIRON MICROB, V72, P3593, DOI 10.1128/AEM.72.5.3593-3599.2006; Benson AK, 2010, P NATL ACAD SCI USA, V107, P18933, DOI 10.1073/pnas.1007028107; BERNET MF, 1994, GUT, V35, P483, DOI 10.1136/gut.35.4.483; Biedermann T, 1999, SPRINGER SEMIN IMMUN, V21, P295, DOI 10.1007/BF00812259; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Blaser MJ, 2008, GUT, V57, P561, DOI 10.1136/gut.2007.133462; Blaser MJ, 2007, NATURE, V449, P843, DOI 10.1038/nature06198; Blaser MJ, 2006, EMBO REP, V7, P956, DOI 10.1038/sj.embor.7400812; Bomba A, 1996, BERL MUNCH TIERARZTL, V109, P428; BORNSIDE GH, 1976, P SOC EXP BIOL MED, V151, P437; Boyden ED, 2006, NAT GENET, V38, P240, DOI 10.1038/ng1724; Brandtzaeg P, 2004, TRENDS IMMUNOL, V25, P570, DOI 10.1016/j.it.2004.09.005; BUHNIK K, 2010, P INT SCI C PROB PRE; Busch R, 2000, CURR OPIN IMMUNOL, V12, P99, DOI 10.1016/S0952-7915(99)00057-6; Cani PD, 2009, GUT, V58, P1091, DOI 10.1136/gut.2008.165886; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cario E, 2000, INFECT IMMUN, V68, P7010, DOI 10.1128/IAI.68.12.7010-7017.2000; Carneiro LAM, 2008, J PATHOL, V214, P136, DOI 10.1002/path.2271; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Cheesman SE, 2007, RES MICROBIOL, V158, P2, DOI 10.1016/j.resmic.2006.10.005; Cho JH, 2008, NAT REV IMMUNOL, V8, P458, DOI 10.1038/nri2340; Claesson MJ, 2010, P NATL ACAD SCI US; Clavel T, 2006, NUTR RES REV, V19, P187, DOI [10.1017/S0954422407249704, 10.1017/NRR2006129]; Collado MC, 2005, INT J ANTIMICROB AG, V25, P385, DOI 10.1016/j.ijantimicag.2005.01.017; Cooper MD, 2006, CELL, V124, P815, DOI 10.1016/j.cell.2006.02.001; Dabbagh K, 2002, J IMMUNOL, V168, P4524; DANINPOLEG Y, 2010, P INT SCI C PROB PRE; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; De La Cochetiere MF, 2005, J CLIN MICROBIOL, V43, P5588, DOI 10.1128/JCM.43.11.5588-5592.2005; Derrien M, 2004, INT J SYST EVOL MICR, V54, P1469, DOI 10.1099/ijs.0.2873-0; Dethlefsen L, 2006, TRENDS ECOL EVOL, V21, P517, DOI 10.1016/j.tree.2006.06.013; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Didierlaurent A, 2002, CELL MICROBIOL, V4, P61, DOI 10.1046/j.1462-5822.2002.00177.x; Duncan SH, 2008, INT J OBESITY, V32, P1720, DOI 10.1038/ijo.2008.155; Duncan SH, 2002, INT J SYST EVOL MICR, V52, P2141, DOI 10.1099/ijs.0.02241-0; Duncan SH, 2004, APPL ENVIRON MICROB, V70, P5810, DOI 10.1128/AEM.70.10.5810-5817.2004; Duncan SH, 2007, APPL ENVIRON MICROB, V73, P1073, DOI 10.1128/AEM.02340-06; EBERSBACH T, 2009, INT J FOOD MICROBIOL, V140, P218; Eckburg PB, 2005, SCIENCE, V308, P1635, DOI 10.1126/science.1110591; Egert M, 2006, TRENDS MICROBIOL, V14, P86, DOI 10.1016/j.tim.2005.12.007; Epstein J, 1996, CURR OPIN IMMUNOL, V8, P29, DOI 10.1016/S0952-7915(96)80101-4; Falony G, 2006, APPL ENVIRON MICROB, V72, P7835, DOI 10.1128/AEM.01296-06; Flint HJ, 2008, NAT REV MICROBIOL, V6, P121, DOI 10.1038/nrmicro1817; Frank DN, 2007, P NATL ACAD SCI USA, V104, P13780, DOI 10.1073/pnas.0706625104; Fritz JH, 2007, IMMUNITY, V26, P445, DOI 10.1016/j.immuni.2007.03.009; Fritz JH, 2006, NAT IMMUNOL, V7, P1250, DOI 10.1038/ni1412; Gaboriau-Routhiau V, 2009, IMMUNITY, V31, P677, DOI 10.1016/j.immuni.2009.08.020; GARIMA G, 2007, BIOESSAYS, V29, P452; Garrett WS, 2007, CELL, V131, P33, DOI 10.1016/j.cell.2007.08.017; Garrett WS, 2010, CELL HOST MICROBE, V8, P292, DOI 10.1016/j.chom.2010.08.004; Gaskins H. R., 1997, GASTROINTESTINAL MIC, V2, P537; Gewirtz AT, 2001, J IMMUNOL, V167, P1882; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Glimcher LH, 2007, NAT IMMUNOL, V8, P448, DOI 10.1038/ni0507-448; Gutcher I, 2007, J CLIN INVEST, V117, P1119, DOI 10.1172/JC131720; HACKSTEIN JHP, 1994, P NATL ACAD SCI USA, V91, P5441, DOI 10.1073/pnas.91.12.5441; Hackstein JHP, 1996, EVOLUTION, V50, P559, DOI 10.2307/2410831; Harrington SM, 2009, INFECT IMMUN, V77, P2465, DOI 10.1128/IAI.01494-08; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hemmi H, 2000, NATURE, V408, P740; Holmes E, 2008, NATURE, V453, P396, DOI 10.1038/nature06882; Hooper LV, 2009, NAT REV MICROBIOL, V7, P367, DOI 10.1038/nrmicro2114; Hooper LV, 1999, P NATL ACAD SCI USA, V96, P9833, DOI 10.1073/pnas.96.17.9833; Hooper LV, 2003, NAT IMMUNOL, V4, P269, DOI 10.1038/ni888; Hooper LV, 2002, ANNU REV NUTR, V22, P283, DOI 10.1146/annurev.nutr.22.011602.092259; Hopkins MJ, 2001, GUT, V48, P198, DOI 10.1136/gut.48.2.198; Hoshino K, 1999, J IMMUNOL, V162, P3749; Infante-Duarte C, 1999, SPRINGER SEMIN IMMUN, V21, P317, DOI 10.1007/BF00812260; Ivanov II, 2008, CELL HOST MICROBE, V4, P337, DOI 10.1016/j.chom.2008.09.009; Ivanov II, 2006, CELL, V126, P1121, DOI 10.1016/j.cell.2006.07.035; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Johansson MEV, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012238; Johansson MEV, 2008, P NATL ACAD SCI USA, V105, P15064, DOI 10.1073/pnas.0803124105; Kankainen M, 2009, P NATL ACAD SCI USA, V106, P17193, DOI 10.1073/pnas.0908876106; Kaparakis M, 2007, IMMUNOL CELL BIOL, V85, P495, DOI 10.1038/sj.icb.7100105; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Karasov W. H., 2007, PHYSL ECOLOGY ANIMAL; KIRK E, 1949, GASTROENTEROLOGY, V12, P782; Koeppel A, 2008, P NATL ACAD SCI USA, V105, P2504, DOI 10.1073/pnas.0712205105; Konstantinov SR, 2008, P NATL ACAD SCI USA, V105, P19474, DOI 10.1073/pnas.0810305105; Kovatcheva-Datchary P, 2009, ENVIRON MICROBIOL, V11, P914, DOI 10.1111/j.1462-2920.2008.01815.x; Le Poul E, 2003, J BIOL CHEM, V278, P25481, DOI 10.1074/jbc.M301403200; Lederberg J, 2000, SCIENCE, V288, P287, DOI 10.1126/science.288.5464.287; Lepage P, 2005, INFLAMM BOWEL DIS, V11, P473, DOI 10.1097/01.MIB.0000159662.62651.06; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a; Li M, 2008, P NATL ACAD SCI USA, V105, P2117, DOI 10.1073/pnas.0712038105; Lievin-Le Moal Vanessa, 2006, Clin Microbiol Rev, V19, P315, DOI 10.1128/CMR.19.2.315-337.2006; Louis P, 2007, J APPL MICROBIOL, V102, P1197, DOI 10.1111/j.1365-2672.2007.03322.x; Louis P, 2009, FEMS MICROBIOL LETT, V294, P1, DOI 10.1111/j.1574-6968.2009.01514.x; LUCKEY TD, 1972, AM J CLIN NUTR, V25, P1292; Macfarlane GT, 1997, SCAND J GASTROENTERO, V32, P3, DOI 10.1080/00365521.1997.11720708; Macfarlane S, 2003, P NUTR SOC, V62, P67, DOI 10.1079/PNS2002207; Macpherson AJ, 2004, SCIENCE, V303, P1662, DOI 10.1126/science.1091334; Mandel MJ, 2009, NATURE, V458, P215, DOI 10.1038/nature07660; MARGARITA MM, 2006, INFLAMM BOWEL DIS, V12, P1136; Mariathasan S, 2006, NATURE, V440, P228, DOI 10.1038/nature04515; Martens EC, 2008, CELL HOST MICROBE, V4, P447, DOI 10.1016/j.chom.2008.09.007; Martens EC, 2009, J BIOL CHEM, V284, P24673, DOI 10.1074/jbc.R109.022848; Martin FPJ, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100153; Martinon F, 2006, NATURE, V440, P237, DOI 10.1038/nature04516; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McFall-Ngai M, 2007, NATURE, V445, P153, DOI 10.1038/445153a; MCFALLNGAI MJ, 1991, SCIENCE, V254, P1491, DOI 10.1126/science.1962208; Medzhitov R, 2002, SCIENCE, V296, P298, DOI 10.1126/science.1068883; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Meyer-Hoffert U, 2008, GUT, V57, P764, DOI 10.1136/gut.2007.141481; MILLER TL, 1985, ARCH MICROBIOL, V141, P116, DOI 10.1007/BF00423270; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659; Montalto M, 2004, DIGESTION, V69, P225, DOI 10.1159/000079152; Mukherjee S, 2008, CELL MOL LIFE SCI, V65, P3019, DOI 10.1007/s00018-008-8182-3; Mulder IE, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-79; NASH J, 1951, ANN MATH, V54, P286, DOI 10.2307/1969529; Neutra MR, 1998, AM J PHYSIOL, V274, P785; Niedergang F, 2005, TRENDS MICROBIOL, V13, P485, DOI 10.1016/j.tim.2005.08.001; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Nishiguchi MK, 1998, APPL ENVIRON MICROB, V64, P3209; Nuding S, 2009, MICROBES INFECT, V11, P384, DOI 10.1016/j.micinf.2009.01.001; O'Hara AM, 2006, EMBO REP, V7, P688, DOI 10.1038/sj.embor.7400731; Ogura Y, 2003, GUT, V52, P1591, DOI 10.1136/gut.52.11.1591; Oh PL, 2010, ISME J, V4, P377, DOI 10.1038/ismej.2009.123; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Palm NW, 2009, IMMUNOL REV, V227, P221, DOI 10.1111/j.1600-065X.2008.00731.x; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Petersen A, 2009, BMC MICROBIOL, V9, DOI 10.1186/1471-2180-9-245; Porcelli SA, 1999, ANNU REV IMMUNOL, V17, P297, DOI 10.1146/annurev.immunol.17.1.297; Pretzer G, 2005, J BACTERIOL, V187, P6128, DOI 10.1128/JB.187.17.6128-6136.2005; Pryde SE, 2002, FEMS MICROBIOL LETT, V217, P133, DOI 10.1111/j.1574-6968.2002.tb11467.x; Qi H, 2006, SCIENCE, V312, P1672, DOI 10.1126/science.1125703; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Rammensee HG, 1999, IMMUNOGENETICS, V50, P213, DOI 10.1007/s002510050595; Rawls JF, 2006, CELL, V127, P423, DOI 10.1016/j.cell.2006.08.043; Reid DM, 2009, CURR OPIN IMMUNOL, V21, P30, DOI 10.1016/j.coi.2009.01.003; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rijkers GT, 2010, J NUTR, V140, p671S, DOI 10.3945/jn.109.113779; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; Rook GAW, 2007, T ROY SOC TROP MED H, V101, P1072, DOI 10.1016/i.trstmh.2007.05.014; Rook GAW, 2009, IMMUNOLOGY, V126, P3, DOI 10.1111/j.1365-2567.2008.03007.x; Roos S, 2002, MICROBIOL-SGM, V148, P433; Ruas-Madiedo P, 2008, APPL ENVIRON MICROB, V74, P1936, DOI 10.1128/AEM.02509-07; RUBIO S, 1995, J BIOL CHEM, V270, P12162; SALYERS AA, 1977, APPL ENVIRON MICROB, V34, P529; SALYERS AA, 1977, APPL ENVIRON MICROB, V33, P319; Samuel BS, 2008, P NATL ACAD SCI USA, V105, P16767, DOI 10.1073/pnas.0808567105; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Scheppach W, 2004, CURR OPIN CLIN NUTR, V7, P563, DOI 10.1097/00075197-200409000-00009; Schreiber O, 2010, MICROCIRCULATION MUC; Schwiertz A, 2010, OBESITY, V18, P190, DOI 10.1038/oby.2009.167; Sekirov I, 2008, INFECT IMMUN, V76, P4726, DOI 10.1128/IAI.00319-08; Seth A, 2008, AM J PHYSIOL-GASTR L, V294, pG1060, DOI 10.1152/ajpgi.00202.2007; Shapiro JA, 1998, ANNU REV MICROBIOL, V52, P81, DOI 10.1146/annurev.micro.52.1.81; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Sokol H, 2008, P NATL ACAD SCI USA, V105, P16731, DOI 10.1073/pnas.0804812105; Stappenbeck TS, 2002, P NATL ACAD SCI USA, V99, P15451, DOI 10.1073/pnas.202604299; Stecher B, 2008, TRENDS MICROBIOL, V16, P107, DOI 10.1016/j.tim.2007.12.008; Stewart PS, 2001, LANCET, V358, P135, DOI 10.1016/S0140-6736(01)05321-1; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strugala V, 2008, INT J CLIN PRACT, V62, P762, DOI 10.1111/j.1742-1241.2007.01665.x; Swidsinski A, 2002, GASTROENTEROLOGY, V122, P44, DOI 10.1053/gast.2002.30294; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takaoka A, 2007, NATURE, V448, P501, DOI 10.1038/nature06013; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 2008, CURR OPIN IMMUNOL, V20, P17, DOI 10.1016/j.coi.2008.01.002; Tap J, 2009, ENVIRON MICROBIOL, V11, P2574, DOI 10.1111/j.1462-2920.2009.01982.x; Ten Bruggencate SJM, 2003, J NUTR, V133, P2313; Tenovuo J, 2002, ORAL DIS, V8, P23, DOI 10.1034/j.1601-0825.2002.1o781.x; Ting JPY, 2008, IMMUNITY, V28, P285, DOI 10.1016/j.immuni.2008.02.005; Ting JPY, 2006, NAT REV IMMUNOL, V6, P183, DOI 10.1038/nri1788; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105; van Vliet MJ, 2009, CLIN INFECT DIS, V49, P262, DOI 10.1086/599346; Vasquez N, 2007, INFLAMM BOWEL DIS, V13, P684, DOI 10.1002/ibd.20084; Visick KL, 2000, J BACTERIOL, V182, P4578, DOI 10.1128/JB.182.16.4578-4586.2000; von Hertzen LC, 2000, ANN MED, V32, P397, DOI 10.3109/07853890008995946; Walker AW, 2005, APPL ENVIRON MICROB, V71, P3692, DOI 10.1128/AEM.71.7.3692-3700.2005; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578; Willing B, 2009, INFLAMM BOWEL DIS, V15, P653, DOI 10.1002/ibd.20783; Xu JL, 2001, FOOD CHEM TOXICOL, V39, P393, DOI 10.1016/S0278-6915(00)00150-2; Yarovinsky F, 2008, J IMMUNOL, V181, P8478; Ye ZM, 2008, CURR OPIN IMMUNOL, V20, P3, DOI 10.1016/j.coi.2008.01.003; Zaneveld J, 2008, CURR OPIN CHEM BIOL, V12, P109, DOI 10.1016/j.cbpa.2008.01.015; Zhang DK, 2004, SCIENCE, V303, P1522, DOI 10.1126/science.1094351; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zoetendal EG, 2002, APPL ENVIRON MICROB, V68, P3401, DOI 10.1128/AEM.68.7.3401-3407.2002; Zoetendal EG, 1998, APPL ENVIRON MICROB, V64, P3854; Zoetendal Erwin G., 2001, Microbial Ecology in Health and Disease, V13, P129, DOI 10.1080/089106001750462669	209	79	80	4	59	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0168-6445			FEMS MICROBIOL REV	Fems Microbiol. Rev.	JUL	2011	35	4					681	704		10.1111/j.1574-6976.2011.00270.x		24	Microbiology	Microbiology	773ND	WOS:000291313100005	21361997	
J	Samoli, E; Nastos, PT; Paliatsos, AG; Katsouyanni, K; Priftis, KN				Samoli, E.; Nastos, P. T.; Paliatsos, A. G.; Katsouyanni, K.; Priftis, K. N.			Acute effects of air pollution on pediatric asthma exacerbation: Evidence of association and effect modification	ENVIRONMENTAL RESEARCH			English	Article						Air pollution; Asthma; Children; Desert dust; Time-series	4 EUROPEAN CITIES; TIME-SERIES; EMERGENCY ADMISSIONS; CASE-CROSSOVER; CHILDREN; EXPOSURE; VISITS; HEALTH; MORTALITY; PROJECT	We investigated the short-term effects of particulate matter with aerodynamic diameter < 10 mu g/m(3) (PM10), sulfur dioxide (SO2), nitrogen dioxide (NO2) and ozone (O-3) on pediatric asthma emergency admissions in Athens, Greece over the period 2001-2004. We explored effect modification patterns by season, sex, age and by the presence of desert dust transported mainly from the Sahara area. We used daily time-series data provided by the children's hospitals and the fixed monitoring stations. The associations were investigated using Poisson regression models controlling for seasonality, weather, influenza episodes, day of the week and holiday effects. A 10 mu g/m(3) increase in PM10, was associated with a 2.54% increase (95% confidence interval (Cl): 0.06%, 5.08%) in the number of pediatric asthma hospital admissions, while the same increase in SO2 was associated with a 5.98% (95% Cl: 0.88%, 11.33%) increase. O-3 was associated with a statistically significant increase in asthma admissions among older children in the summer. Our findings provide limited evidence of an association between NO2 exposure and asthma exacerbation. Statistically significant PM10 effects were higher during winter and during desert dust days, while SO2 effects occurred mainly during spring. Our study confirms previously reported PM10 effects on emergency hospital admissions for pediatric asthma and further provides evidence of stronger effects during desert dust days. We additionally report severe effects of SO2, even at today's low concentration levels. (C) 2011 Elsevier Inc. All rights reserved.	[Samoli, E.; Katsouyanni, K.] Med Sch Univ Athens, Dept Hyg Epidemiol & Med Stat, Athens 11527, Greece; [Nastos, P. T.] Univ Athens, Dept Geol & Geoenvironm, Lab Climatol & Atmospher Environm, GR-10679 Athens, Greece; [Paliatsos, A. G.] Technol Educ Inst Piraeus, Gen Dept Math, Piraeus, Greece; [Priftis, K. N.] Penteli Childrens Hosp, Allergy Pneumonol Dept, Athens, Greece	Samoli, E (reprint author), Med Sch Univ Athens, Dept Hyg Epidemiol & Med Stat, 75 Mikras Asias St, Athens 11527, Greece.	esamoli@med.uoa.gr; nastos@geol.uoa.gr; agpal@in.teipir.gr; kkatsouy@med.uoa.gr; kpriftis@otenet.gr	Katsouyanni, Klea/D-4856-2014; Nastos, Panagiotis/E-7455-2015	Katsouyanni, Klea/0000-0002-0132-9575; Nastos, Panagiotis/0000-0001-9336-6586			Abe T, 2009, AM J EMERG MED, V27, P153, DOI 10.1016/j.ajem.2008.01.013; Aekplakorn Wichai, 2003, Southeast Asian Journal of Tropical Medicine and Public Health, V34, P906; Anderson H R, 2003, Eur Respir J Suppl, V40, p39s; Anderson H.R., 2004, MET TIM SER STUD PAN; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; BRUMBACK BA, 2000, J AM STAT ASSOC, V95, P16, DOI 10.2307/2669519; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Clougherty JE, 2010, ENVIRON HEALTH PERSP, V118, P167, DOI 10.1289/ehp.0900994; Dougherty RH, 2009, CLIN EXP ALLERGY, V39, P193, DOI 10.1111/j.1365-2222.2008.03157.x; Georgoulis LB, 2002, ATMOS ENVIRON, V36, P963, DOI 10.1016/S1352-2310(01)00473-3; Gotschi T, 2002, ENVIRON SCI TECHNOL, V36, P1191, DOI 10.1021/es010079n; Gouveia N, 2000, OCCUP ENVIRON MED, V57, P477, DOI 10.1136/oem.57.7.477; Griffin DW, 2007, CLIN MICROBIOL REV, V20, P459, DOI 10.1128/CMR.00039-06; Gyan K, 2005, INT J BIOMETEOROL, V49, P371, DOI 10.1007/s00484-005-0257-3; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Halonen JI, 2010, J EPIDEMIOL COMMUN H, V64, P814, DOI 10.1136/jech.2009.087106; HOEK G, 1993, ARCH ENVIRON HEALTH, V48, P328; Holgate ST, 1999, AIR POLLUTION HLTH; Kallos G., 1997, P INT S REG WEATH PR; Kaskaoutis DG, 2008, ATMOS ENVIRON, V42, P6884, DOI 10.1016/j.atmosenv.2008.05.017; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Katsouyanni K, 2009, RES REP HLTH EFF I, V142, P5; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Middleton N, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-39; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Priftis KN, 2007, ACTA PAEDIATR, V96, P924, DOI 10.1111/j.1651.2227.2007.00299.x; Priftis KN, 2007, RESP MED, V101, P98, DOI 10.1016/j.rmed.2006.04.008; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Samet JM, 2000, RES REP HLTH EFF I, V94, P71; Samoli E, 2008, ENVIRON HEALTH PERSP, V116, P1480, DOI 10.1289/ehp.11345; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Strickland M.J., 2010, AM J RESP CRIT  0408; Sunyer J, 1997, THORAX, V52, P760; Sunyer J, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.8.e2; Touloumi G, 2004, ENVIRONMETRICS, V15, P101, DOI 10.1002/env.623; WHO, 2006, AIR QUAL GUID GLOB U; Zanobetti A, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-58; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	42	79	84	2	23	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	APR	2011	111	3					418	424		10.1016/j.envres.2011.01.014		7	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	743OC	WOS:000289026700014	21296347	
J	Spira-Cohen, A; Chen, LC; Kendall, M; Lall, R; Thurston, GD				Spira-Cohen, Ariel; Chen, Lung Chi; Kendall, Michaela; Lall, Ramona; Thurston, George D.			Personal Exposures to Traffic-Related Air Pollution and Acute Respiratory Health among Bronx Schoolchildren with Asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						pollution; asthma; children's health; diesel; elemental carbon; personal monitoring traffic; PM2.5	EXHALED NITRIC-OXIDE; LUNG-FUNCTION; CHILDHOOD ASTHMA; SOUTH BRONX; CHILDREN; ASSOCIATION; PARTICULATE; SYMPTOMS; INFLAMMATION; COMMUNITIES	BACKGROUND: Previous studies have reported relationships between adverse respiratory health outcomes and residential proximity to traffic pollution, but have not shown this at a personal exposure level. OBJECTIVE: We compared, among inner-city children with asthma, the associations of adverse asthma outcome incidences with increased personal exposure to particulate matter mass <= 2.5 mu m in aerodynamic diameter (PM2.5) air pollution versus the diesel-related carbonaceous fraction of PM2.5. METHODS: Daily 24-hr personal samples of PM2.5, including the elemental carbon (EC) fraction, were collected for 40 fifth-grade children with asthma at four South Bronx schools (10 children per school) during approximately 1 month each. Spirometry and symptom scores were recorded several times daily during weekdays. RESULTS: We found elevated same-day relative risks of wheeze [1.45; 95% confidence interval (CI), 1.03-2.04)], shortness of breath (1.41; 95% CI, 1.01-1.99), and total symptoms (1.30; 95% CI, 1.04-1.62) with an increase in personal EC, but not with personal PM2.5 mass. We found increased risk of cough, wheeze, and total symptoms with increased 1-day lag and 2-day average personal and school-site EC. We found no significant associations with school-site PM2.5 mass or sulfur. The EC effect estimate was robust to addition of gaseous pollutants. CONCLUSION: Adverse health associations were strongest with personal measures of EC exposure, suggesting that the diesel "soot" fraction of PM2.5 is most responsible for pollution-related asthma exacerbations among children living near roadways. Studies that rely on exposure to PM mass may underestimate PM health impacts.	[Spira-Cohen, Ariel; Chen, Lung Chi; Lall, Ramona; Thurston, George D.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; [Kendall, Michaela] Univ Exeter, European Ctr Environm & Human Hlth, Peninsula Coll Med & Dent, Truro, Cornwall, England	Thurston, GD (reprint author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	george.thurston@nyu.edu	Cjem, Lung-Chi/H-5030-2012	Chen, Lung Chi/0000-0003-1154-2107	Health Effects Institute; New York University-National Institute of Environmental Health Sciences Center of Excellence [5P30ES000260]; U.S. Environmental Protection Agency (EPA) [R827351, X-982152]; Science to Achieve Results graduate fellowship program	This work is supported by the Health Effects Institute, by New York University-National Institute of Environmental Health Sciences Center of Excellence grant 5P30ES000260, and by the U.S. Environmental Protection Agency (EPA) under grant R827351 (agreement X-982152) and under the Science to Achieve Results graduate fellowship program.	ASHER MI, 1995, EUR RESPIR J, V8, P463; Bailey D., 2007, EVERYONES STAT SOFTW; Balmes JR, 2009, J ALLERGY CLIN IMMUN, V123, P626, DOI 10.1016/j.jaci.2008.10.062; Bosson J, 2008, EUR RESPIR J, V31, P1234, DOI 10.1183/09031936.00078407; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Buckeridge DL, 2002, ENVIRON HEALTH PERSP, V110, P293; Chang J, 2009, OCCUP ENVIRON MED, V66, P90, DOI 10.1136/oem.2008.039412; Claudio L, 2006, ANN EPIDEMIOL, V16, P332, DOI 10.1016/j.annepidem.2005.06.046; Dales R, 2008, ENVIRON HEALTH PERSP, V116, P1423, DOI 10.1289/ehp.10943; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P550, DOI 10.1289/ehp.10911; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC; Kan HD, 2007, THORAX, V62, P873, DOI 10.1136/thx.2006.073015; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kulkarni N, 2006, NEW ENGL J MED, V355, P21, DOI 10.1056/NEJMoa052972; Maciejczyk PB, 2004, ATMOS ENVIRON, V38, P5283, DOI 10.1016/j.atmosenv.2004.02.062; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; NAPHTALI SZ, 2007, USING GIS EXAMINE EN; Narvaez RF, 2008, ENVIRON SCI TECHNOL, V42, P7330, DOI 10.1021/es801273h; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; New York State Department of Health Center for Community Health, 2009, NEW YORK STAT ASTHM; *NY STAT DEP TRANS, 2010, TRAFF DAT VIEW; Patel MM, 2009, AM J RESP CRIT CARE, V180, P1107, DOI 10.1164/rccm.200901-0122OC; Pinhiero J., 2000, MIXED EFFECTS MODELS; Pourazar J, 2005, AM J PHYSIOL-LUNG C, V289, pL724, DOI 10.1152/ajplung.00055.2005; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Sawyer G, 1998, CLIN EXP ALLERGY, V28, P1565; Spira-Cohen A, 2010, J EXPO SCI ENV EPID, V20, P446, DOI 10.1038/jes.2009.34; Suglia SF, 2008, ENVIRON HEALTH PERSP, V116, P1333, DOI 10.1289/ehp.11223; Thurston GD, 2003, JAMA-J AM MED ASSOC, V290, P1915, DOI 10.1001/jama.290.14.1915; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Trenga CA, 2006, CHEST, V129, P1614, DOI 10.1378/chest.129.6.1614; *US EPA, 2004, EPA600P99002AF NAT C; US EPA, 2008, EPA600R08047F NAT CT; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001	47	79	79	7	48	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2011	119	4					559	565		10.1289/ehp.1002653		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	744BA	WOS:000289065900040	21216722	
J	Cecchi, L; D'Amato, G; Ayres, JG; Galan, C; Forastiere, F; Forsberg, B; Gerritsen, J; Nunes, C; Behrendt, H; Akdis, C; Dahl, R; Annesi-Maesano, I				Cecchi, L.; D'Amato, G.; Ayres, J. G.; Galan, C.; Forastiere, F.; Forsberg, B.; Gerritsen, J.; Nunes, C.; Behrendt, H.; Akdis, C.; Dahl, R.; Annesi-Maesano, I.			Projections of the effects of climate change on allergic asthma: the contribution of aerobiology	ALLERGY			English	Review						allergic diseases; climate change; environment; pollen; spores	RAGWEED AMBROSIA-ARTEMISIIFOLIA; ELEVATED ATMOSPHERIC CO2; THUNDERSTORM-ASSOCIATED ASTHMA; LONG-RANGE TRANSPORT; GRASS-POLLEN SEASONS; COMMON RAGWEED; BIRCH POLLEN; ENVIRONMENTAL-FACTORS; DIESEL EXHAUST; AIR-POLLUTION	Climate change is unequivocal and represents a possible threat for patients affected by allergic conditions. It has already had an impact on living organisms, including plants and fungi with current scenarios projecting further effects by the end of the century. Over the last three decades, studies have shown changes in production, dispersion and allergen content of pollen and spores, which may be region- and species-specific. In addition, these changes may have been influenced by urban air pollutants interacting directly with pollen. Data suggest an increasing effect of aeroallergens on allergic patients over this period, which may also imply a greater likelihood of the development of an allergic respiratory disease in sensitized subjects and exacerbation of symptomatic patients. There are a number of limitations that make predictions uncertain, and further and specifically designed studies are needed to clarify current effects and future scenarios. We recommend: More stress on pollen/spore exposure in the diagnosis and treatment guidelines of respiratory and allergic diseases; collection of aerobiological data in a structured way at the European level; creation, promotion and support of multidisciplinary research teams in this area; lobbying the European Union and other funders to finance this research.	[Cecchi, L.] Univ Florence, Interdept Ctr Bioclimatol, I-50144 Florence, Italy; [D'Amato, G.] High Special Hosp A Cardarelli, Div Resp & Allerg Dis, Dept Chest Dis, Naples, Italy; [Ayres, J. G.] Univ Birmingham, Inst Occupat & Environm Med, Birmingham, W Midlands, England; [Galan, C.] Univ Cordoba, Dept Plant Biol, E-14071 Cordoba, Spain; [Forastiere, F.] Rome E Hlth Author, Dept Epidemiol, Rome, Italy; [Forsberg, B.] Umea Univ, S-90187 Umea, Sweden; [Gerritsen, J.] Univ Groningen, Beatrix Childrens Hosp, Univ Med Ctr Groningen, NL-9700 AB Groningen, Netherlands; [Nunes, C.] Ctr Imunoalergol Algarve, Portimao, Portugal; [Behrendt, H.] KKG Umweltdermatol & Allergol GSF TUM, Munich, Germany; [Akdis, C.] Univ Zurich, Swiss Inst Allergy & Asthma Res, CH-8006 Zurich, Switzerland; [Dahl, R.] Aarhus Univ Hosp, Dept Resp Dis, DK-8000 Aarhus, Denmark; [Annesi-Maesano, I.] INSERM, EPAR, UMR S 707, Paris, France; [Annesi-Maesano, I.] UPMC Univ Paris 061, Paris, France	Cecchi, L (reprint author), Univ Florence, Interdept Ctr Bioclimatol, Piazzale Cascine 18, I-50144 Florence, Italy.	lorenzo.cecchi@unifi.it	Dahl, Ronahl/F-8170-2013; Annesi-Maesano, Isabella/D-9173-2016; Forastiere, Francesco/J-9067-2016	Forastiere, Francesco/0000-0002-9162-5684			Ahas R, 2002, INT J CLIMATOL, V22, P1727, DOI 10.1002/joc.818; Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; Asero R, 2002, ALLERGY, V57, P1063, DOI 10.1034/j.1398-9995.2002.23766.x; Ayres JG, 2009, EUR RESPIR J, V34, P295, DOI 10.1183/09031936.00003409; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Belmonte J, 2008, INT J BIOMETEOROL, V52, P675, DOI 10.1007/s00484-008-0160-9; Burr ML, 1999, CLIN EXP ALLERGY, V29, P735; Buters JTM, 2008, INT ARCH ALLERGY IMM, V145, P122, DOI 10.1159/000108137; CAROSSO A, 1986, ANN ALLERGY, V56, P300; Cecchi Lorenzo, 2006, Ann Allergy Asthma Immunol, V96, P86; Celenza A, 1996, BRIT MED J, V312, P604; Charpin D, 2005, ALLERGY, V60, P293, DOI 10.1111/j.1398-9995.2005.00731.x; Clot Bernard, 2003, Aerobiologia, V19, P227, DOI 10.1023/B:AERO.0000006572.53105.17; Corden JM, 2001, AEROBIOLOGIA, V17, P127, DOI 10.1023/A:1010876917512; Corden Julie M., 2003, Aerobiologia, V19, P191, DOI 10.1023/B:AERO.0000006529.51252.2f; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; Curtis PS, 1998, OECOLOGIA, V113, P299, DOI 10.1007/s004420050381; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2008, CLIN EXP ALLERGY, V38, P1264, DOI 10.1111/j.1365-2222.2008.03033.x; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; D'Amato G, 2007, ALLERGY, V62, P11, DOI 10.1111/j.1398-9995.2006.01271.x; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; DAMATO G, 2008, J ALLERGY CLIN IMMUN, V121, P2; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347; EMBERLIN J, 1993, CLIN EXP ALLERGY, V23, P911, DOI 10.1111/j.1365-2222.1993.tb00275.x; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Frei T, 2008, INT J BIOMETEOROL, V52, P667, DOI 10.1007/s00484-008-0159-2; Frenguelli G, 2002, Monaldi Arch Chest Dis, V57, P141; Galan C, 2005, INT J BIOMETEOROL, V49, P184, DOI 10.1007/s00484-004-0223-5; Garcia-Mozo H, 2006, ANN AGR ENV MED, V13, P209; Gazala E, 2006, PEDIATR PULM, V41, P1125, DOI 10.1002/ppul.20442; Gehring U, 2005, ALLERGY, V60, P1079, DOI 10.1111/j.1398-9995.2005.00872.x; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Griffin D. W., 2001, AEROBIOLOGIA, V17, P203, DOI DOI 10.1023/A:1011868218901; Grize L, 2006, ALLERGY, V61, P556, DOI 10.1111/j.1398-9995.2006.01030.x; Harley KG, 2009, THORAX, V64, P353, DOI 10.1136/thx.2007.090241; HJELMROOS M, 1995, INT ARCH ALLERGY IMM, V108, P368; Husar RB, 2001, J GEOPHYS RES-ATMOS, V106, P18317, DOI 10.1029/2000JD900788; Jablonski LM, 2002, NEW PHYTOL, V156, P9, DOI 10.1046/j.1469-8137.2002.00494.x; JAGER S, 1991, GRANA, V30, P309; Jato V, 2009, INT J BIOMETEOROL, V53, P333, DOI 10.1007/s00484-009-0220-9; Kihlstrom A, 2003, ALLERGY, V58, P871, DOI 10.1034/j.1398-9995.2003.00232.x; Kinney PL, 2008, AM J PREV MED, V35, P459, DOI 10.1016/j.amepre.2008.08.025; KISS L, 2007, J BIOGEOGR, V33, P2156; Klironomos JN, 2005, NATURE, V433, P621, DOI 10.1038/nature03268; Klironomos JN, 1997, CAN J BOT, V75, P1670; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Law M, 2005, BRIT MED J, V330, P1187, DOI 10.1136/bmj.38435.582975.AE; Levetin E, 2008, CURR ALLERGY ASTHM R, V8, P418, DOI 10.1007/s11882-008-0081-z; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; Menzel A, 1999, NATURE, V397, P659, DOI 10.1038/17709; Mimet A, 2009, INT J BIOMETEOROL, V53, P287, DOI 10.1007/s00484-009-0214-7; Minero FJG, 1998, ALLERGY, V53, P266, DOI 10.1111/j.1398-9995.1998.tb03886.x; Mohan JE, 2006, P NATL ACAD SCI USA, V103, P9086, DOI 10.1073/pnas.0602392103; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Namork E, 2006, TOXICOL LETT, V165, P71, DOI 10.1016/j.toxlet.2006.01.016; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; Olesen JE, 2002, EUR J AGRON, V16, P239, DOI 10.1016/S1161-0301(02)00004-7; PACKE GE, 1985, LANCET, V2, P199; Prospero JM, 2005, AEROBIOLOGIA, V21, P1, DOI 10.1007/s10453-004-5872-7; Rasmussen Alix, 2002, Aerobiologia, V18, P253, DOI 10.1023/A:1021321615254; RIDOLO E, 2006, INT ARCH ALLERGY IMM, V142, P151; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Schmier JK, 2009, ALLERGY ASTHMA PROC, V30, P229, DOI 10.2500/aap.2009.30.3229; Shea KM, 2008, J ALLERGY CLIN IMMUN, V122, P443, DOI 10.1016/j.jaci.2008.06.032; Sherry RA, 2007, P NATL ACAD SCI USA, V104, P198, DOI 10.1073/pnas.0605642104; Singer BD, 2005, FUNCT PLANT BIOL, V32, P667, DOI 10.1071/FP05039; Skjoth CA, 2007, CLIN EXP ALLERGY, V37, P1204, DOI 10.1111/j.1365-2222.2007.02771.x; Skjoth C, 2009, INT J BIOMETEOROL, V53, P75, DOI 10.1007/s00484-008-0192-1; Solomon S, 2007, CLIMATE CHANGE 2007: THE PHYSICAL SCIENCE BASIS, P19; Spieksma F. Th. M., 2003, Aerobiologia, V19, P171, DOI 10.1023/B:AERO.0000006528.37447.15; Stach A, 2007, J INVEST ALLERG CLIN, V17, P39; Suarez-Cervera M, 2008, ANN ALLERG ASTHMA IM, V101, P57, DOI 10.1016/S1081-1206(10)60836-8; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; Tedeschini E, 2006, GRANA, V45, P222, DOI 10.1080/00173130600726646; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; *US EPA, 2008, USEPA600R06164F; Van Vliet AJH, 2002, INT J CLIMATOL, V22, P1757, DOI 10.1002/joc.820; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Voltolini S., 2000, AEROBIOLOGIA, V16, P245, DOI 10.1023/A:1007639030473; von Hertzen L, 2005, ALLERGY, V60, P283, DOI 10.1111/j.1398-9995.2005.00769.x; Wardman A E Dennis, 2002, Can Respir J, V9, P267; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; *WHO, 2003, WHO M ROM; Wjst M, 2005, PLOS MED, V2, P977, DOI 10.1371/journal.pmed.0020294; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Ziska LH, 2007, GLOBAL CHANGE BIOL, V13, P266, DOI 10.1111/j.1365-2486.2006.01264.x; Ziska LH, 2009, ENVIRON HEALTH PERSP, V117, P155, DOI 10.1289/ehp.11501; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060	99	79	82	3	37	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538			ALLERGY	Allergy	SEP	2010	65	9					1073	1081		10.1111/j.1398-9995.2010.02423.x		9	Allergy; Immunology	Allergy; Immunology	635JI	WOS:000280651000001	20560904	
J	Vassallo, MF; Camargo, CA				Vassallo, Milo F.; Camargo, Carlos A., Jr.			Potential mechanisms for the hypothesized link between sunshine, vitamin D, and food allergy in children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food allergy; vitamin D; vitamin D deficiency; mucosal immunity; epithelial barrier; microbial ecology; infections; sensitization; atopy	REGULATORY T-CELLS; BODY-MASS INDEX; D DEFICIENCY; ATOPIC-DERMATITIS; 1,25-DIHYDROXYVITAMIN D-3; UNITED-STATES; ORAL TOLERANCE; IMMUNE-SYSTEM; US CHILDREN; D-RECEPTOR	Epidemiologic data suggest that the incidence of food allergy (FA) is increasing among children, yet a satisfactory model of its pathogenesis remains elusive. FA is the consequence of maladaptive immune responses to common and otherwise innocuous food antigens. Concurrent with the increase in FA is an epidemic of vitamin D deficiency (VDD) caused by several factors, especially decreased sunlight/UVB exposure. There is growing appreciation of the importance of the pleiotropic hormone vitamin D in the development of tolerance, immune system defenses, and epithelial barrier integrity. We propose a "multiplehit'' model in which VDD in a developmentally critical period increases susceptibility to colonization with abnormal intestinal microbial flora and gastrointestinal infections, contributing to abnormal intestinal barrier permeability and excess and inappropriate exposure of the immune system to dietary allergens. A compounding effect (and additional "hit'') of VDD is the promotion of a pro-sensitization immune imbalance that might compromise immunologic tolerance and contribute to FA. We propose that early correction of VDD might promote mucosal immunity, healthy microbial ecology, and allergen tolerance and thereby blunt the FA epidemic in children. (J Allergy Clin Immunol 2010;126:217-22.)	[Vassallo, Milo F.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; [Camargo, Carlos A., Jr.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Camargo, CA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Rheumatol Allergy & Immunol,Dept Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	ccamargo@partners.org			National Institutes of Health (Bethesda, Md) [T32 AI-060548]; Massachusetts General Hospital Center for D-receptor Activation Research (Boston, Mass); Food Allergy and Anaphylaxis Network (Fairfax, Va)	M. F. V. was supported by T32 AI-060548 from the National Institutes of Health (Bethesda, Md). C. A. C. was supported, in part, by the Massachusetts General Hospital Center for D-receptor Activation Research (Boston, Mass) and the Food Allergy and Anaphylaxis Network (Fairfax, Va).	Adorini L, 2003, J CELL BIOCHEM, V88, P227, DOI 10.1002/jcb.10340; Ali FN, 2009, PEDIATRICS, V123, P791, DOI 10.1542/peds.2008-0634; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Berin M. C., 2008, Journal of Allergy and Clinical Immunology, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Boguniewicz M, 2010, J ALLERGY CLIN IMMUN, V125, P4, DOI 10.1016/j.jaci.2009.11.027; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; Camargo CA, 2007, AM J CLIN NUTR, V85, P788; Cochrane S, 2009, ALLERGY, V64, P1246, DOI 10.1111/j.1398-9995.2009.02128.x; De Benedetto A, 2009, J INVEST DERMATOL, V129, P14, DOI 10.1038/jid.2008.259; Devereux G, 2007, AM J CLIN NUTR, V85, P853; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Flegal KM, 2005, JAMA-J AM MED ASSOC, V293, P1861, DOI 10.1001/jama.2009.2014; Frank DN, 2008, CURR OPIN GASTROEN, V24, P4; Gartner LM, 2003, PEDIATRICS, V111, P908, DOI 10.1542/peds.111.4.908; Ginde AA, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2009.11.036; Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Green T. D., 2007, Pediatrics, V120, P1304, DOI 10.1542/peds.2007-0350; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; GRUSKAY FL, 1955, PEDIATRICS, V16, P763; HARVEY L, 2010, J STEROID BIOCH MOL; Heaney RP, 2009, J AM COLL NUTR, V28, P252; Heine G, 2008, EUR J IMMUNOL, V38, P2210, DOI 10.1002/eji.200838216; Hewison M, 2010, MOL CELL ENDOCRINOL, V321, P103, DOI 10.1016/j.mce.2010.02.013; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Holick MF, 2009, ANN EPIDEMIOL, V19, P73, DOI 10.1016/j.annepidem.2007.12.001; Hollis BW, 2008, AM J CLIN NUTR, V88, p507S; Hollis BW, 2009, NAT REV ENDOCRINOL, V5, P534, DOI 10.1038/nrendo.2009.178; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Janzi M, 2009, CLIN IMMUNOL, V133, P78, DOI 10.1016/j.clim.2009.05.014; Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; Lack G, 2008, J ALLERGY CLIN IMMUN, V121, P1331, DOI 10.1016/j.jaci.2008.04.032; Lagishetty V, 2010, ENDOCRINOLOGY, V151, P2423, DOI 10.1210/en.2010-0089; Lagunova Z, 2009, ANTICANCER RES, V29, P3713; Mansbach JM, 2009, PEDIATRICS, V124, P1404, DOI 10.1542/peds.2008-2041; Maverakis E, 2010, J AUTOIMMUN, V34, pJ247, DOI 10.1016/j.jaut.2009.11.011; Mora JR, 2008, NAT REV IMMUNOL, V8, P685, DOI 10.1038/nri2378; Mullins RJ, 2009, ANN ALLERG ASTHMA IM, V103, P488, DOI 10.1016/S1081-1206(10)60265-7; Nwaru BI, 2010, PEDIATR ALLERGY IMMU, V21, P29, DOI 10.1111/j.1399-3038.2009.00949.x; Ogden CL, 2010, JAMA-J AM MED ASSOC, V303, P242, DOI 10.1001/jama.2009.2012; Rautava Samuli, 2007, Curr Gastroenterol Rep, V9, P385, DOI 10.1007/s11894-007-0047-7; Rochat MK, 2010, CLIN EXP ALLERGY, V40, P786, DOI 10.1111/j.1365-2222.2009.03428.x; Rudders SA, 2010, ANN ALLERG ASTHMA IM, V104, P413, DOI 10.1016/j.anai.2010.01.022; Salzman NH, 2010, NAT IMMUNOL, V11, P76, DOI 10.1038/ni.1825; Schauber J, 2007, J CLIN INVEST, V117, P803, DOI 10.1172/JCI30142; Sheehan WJ, 2009, J ALLERGY CLIN IMMUN, V124, P850, DOI 10.1016/j.jaci.2009.06.044; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.09.051, 10.1016/j.jaci.2008.12.1128]; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sidbury R, 2008, BRIT J DERMATOL, V159, P245, DOI 10.1111/j.1365-2133.2008.08601.x; Slack E, 2009, SCIENCE, V325, P617, DOI 10.1126/science.1172747; Sudo N, 1997, J IMMUNOL, V159, P1739; Szeles L, 2009, J IMMUNOL, V182, P2074, DOI 10.4049/jimmunol.0803345; Unger WWJ, 2009, EUR J IMMUNOL, V39, P3147, DOI 10.1002/eji.200839103; Vassallo MF, 2010, ANN ALLERG ASTHMA IM, V104, P307, DOI 10.1016/j.anai.2010.01.019; Visness CM, 2009, J ALLERGY CLIN IMMUN, V123, P1163, DOI 10.1016/j.jaci.2008.12.1126; von Essen MR, 2010, NAT IMMUNOL, V11, P344, DOI 10.1038/ni.1851; Wagner CL, 2008, PEDIATRICS, V122, P1142, DOI 10.1542/peds.2008-1862; Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225; Weisberg P, 2004, AM J CLIN NUTR, V80, p1697S; Wjst M, 2006, PEDIATR ALLERGY IMMU, V17, P477, DOI 10.1111/j.1399-3038.2006.00456.x; Wortsman J, 2000, AM J CLIN NUTR, V72, P690	67	79	81	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2					217	222		10.1016/j.jaci.2010.06.011		6	Allergy; Immunology	Allergy; Immunology	642IL	WOS:000281203800004	20624647	
J	James, LK; Durham, SR				James, L. K.; Durham, S. R.			Update on mechanisms of allergen injection immunotherapy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							GRASS-POLLEN IMMUNOTHERAPY; REGULATORY T-CELLS; MESSENGER-RNA EXPRESSION; PLACEBO-CONTROLLED TRIAL; AFFINITY IGE RECEPTOR; PLASMACYTOID DENDRITIC CELLS; RANDOMIZED CONTROLLED-TRIAL; PHASE SKIN REACTIONS; HOUSE-DUST MITE; SUBLINGUAL IMMUNOTHERAPY	The incidence of allergic diseases is increasing at an alarming rate, paricularly in countries with a western lifestyle. Currently in the UK, approximately one quarter of the population suffers from seasonal allergic rhinitis. Most patients can be treated with conventional pharmacotherapy on an 'as needed' symptomatic basis whereas allergen immunotherapy represents a useful treatment approach in carefully selected patients with severe, IgE-mediated disease. Allergen immunotherapy can deliver improvements in hayfever symptoms over and above that which can be achieved by pharmacotherapy. In addition, unlike pharmacotherapy, allergen immunotherapy provides long-term clinical benefits. These include long-term disease remission, prevention of new atopic sensitisations and a reduction in disease progression from rhinitis to asthma. This review provides a comprehensive update on the mechanisms of allergen injection immunotherapy, recent data on the mechanisms of sublingual allergen immunotherapy is also included.	[James, L. K.; Durham, S. R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Allergy & Clin Immunol Sect, London SW7 2AZ, England	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Fac Med, Allergy & Clin Immunol Sect, Sir Alexander Fleming Bldg, London SW7 2AZ, England.	s.durham@imperial.ac.uk	James, Louisa/C-9831-2010	James, Louisa/0000-0002-2252-4636			Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Annacker O, 2001, J IMMUNOL, V166, P3008; Arvidsson MB, 2004, ALLERGY, V59, P74, DOI 10.1046/j.1398-9995.2003.00334.x; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Baecher-Allan C, 2001, J IMMUNOL, V167, P1245; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bauchau V, 2005, ALLERGY, V60, P350, DOI 10.1111/j.1398-9995.2005.00751.x; Bauchau V, 2004, EUR RESPIR J, V24, P758, DOI 10.1183/09031936.04.00013904; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Bodtger U, 2005, INT ARCH ALLERGY IMM, V136, P340, DOI 10.1159/000084227; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; Calderon MA, 2007, ALLERGY, V62, P958, DOI 10.1111/j.1398-9995.2007.01416.x; Cameron L, 2003, J IMMUNOL, V171, P3816; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Ciprandi G, 2006, ALLERGY, V61, P511, DOI 10.1111/j.1398-9995.2006.01046.x; Ciprandi G, 2006, INT IMMUNOPHARMACOL, V6, P1370, DOI 10.1016/j.intimp.2006.03.007; COCKCROFT DW, 1983, LANCET, V2, P253; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; COOKSON WOCM, 1989, AM REV RESPIR DIS, V139, P458; Corry DB, 1999, NATURE, V402, P18, DOI 10.1038/35037014; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Daeron M, 1997, INT ARCH ALLERGY IMM, V113, P138; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Faith A, 2003, CLIN EXP ALLERGY, V33, P1209, DOI 10.1046/j.1365-2222.2003.01748.x; FLING JA, 1989, J ALLERGY CLIN IMMUN, V83, P101, DOI 10.1016/0091-6749(89)90483-1; FOLCKENS WJ, 1999, ALLERGY, V54, P1130; Francis James N, 2004, Curr Opin Allergy Clin Immunol, V4, P543, DOI 10.1097/00130832-200412000-00012; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GAGA M, 1991, J IMMUNOL, V147, P816; GARCIA BE, 1993, J INVEST ALLERG CLIN, V3, P26; Gehlhar K, 1999, CLIN EXP ALLERGY, V29, P497; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; Groux H, 1997, NATURE, V389, P737; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Holgate ST, 1999, NATURE, V402, pB2; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; IPSEN H, 1988, ALLERGY, V43, P370, DOI 10.1111/j.1398-9995.1988.tb00431.x; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354; Ito T, 2007, J EXP MED, V204, P105, DOI 10.1084/jem.20061660; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jonuleit H, 2001, J EXP MED, V193, P1285, DOI 10.1084/jem.193.11.1285; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Karamloo F, 2005, EUR J IMMUNOL, V35, P3268, DOI 10.1002/eji.200425522; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; Koya T, 2007, J ALLERGY CLIN IMMUN, V119, P1241, DOI 10.1016/j.jaci.2007.01.039; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.011.041; LAMBIN P, 1993, J IMMUNOL METHODS, V165, P99, DOI 10.1016/0022-1759(93)90111-J; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Macaubas C, 2006, J IMMUNOL, V176, P5069; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; MARUYAMA N, 1994, AM J RESP CRIT CARE, V150, P1086; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Meltzer Eli O, 2004, J Allergy Clin Immunol, V114, P155, DOI 10.1016/j.jaci.2004.09.029; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Ng WF, 2001, BLOOD, V98, P2736, DOI 10.1182/blood.V98.9.2736; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; NISH WA, 1994, J ALLERGY CLIN IMMUN, V93, P484, DOI 10.1016/0091-6749(94)90358-1; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Nouri-Aria KT, 2005, J ALLERGY CLIN IMMUN, V116, P73, DOI 10.1016/j.jaci.2005.03.011; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Nouri-Aria KT, 2001, J ALLERGY CLIN IMMUN, V108, P205, DOI 10.1067/mai.2001.117175; Novak N, 2006, IMMUNOL ALLERGY CLIN, V26, P307, DOI 10.1016/j.iac.2006.02.010; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Plewako H, 2006, INT ARCH ALLERGY IMM, V141, P346, DOI 10.1159/000095461; Plewako H, 2006, ANN ALLERG ASTHMA IM, V97, P464; Prussin Calman, 2003, Journal of Allergy and Clinical Immunology, V111, pS486; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Rossi RE, 2007, VACCINE, V25, P957, DOI 10.1016/j.vaccine.2006.08.040; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; Sampson AP, 2000, CLIN EXP ALLERGY, V30, P22; Satoguina JS, 2005, J IMMUNOL, V174, P4718; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHARENBERG AM, 1995, EMBO J, V14, P3385; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; Soussi-Gounni A, 2001, J ALLERGY CLIN IMMUN, V107, P575, DOI 10.1067/mai.2001.114238; Stephens LA, 2001, EUR J IMMUNOL, V31, P1247, DOI 10.1002/1521-4141(200104)31:4<1247::AID-IMMU1247>3.0.CO;2-M; Sundstedt A, 2003, J IMMUNOL, V170, P1240; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Till S, 1997, CLIN EXP IMMUNOL, V110, P114, DOI 10.1111/j.1365-2249.1997.494-ce1392.x; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; TSICOPOULOS A, 1994, J ALLERGY CLIN IMMUN, V94, P764, DOI 10.1016/0091-6749(94)90185-6; Turner H, 1999, NATURE, V402, P24, DOI 10.1038/35037021; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2004, CLIN EXP ALLERGY, V34, P420, DOI 10.1111/j.1365-2222.2004.01899.x; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Vervloet D, 2007, INT ARCH ALLERGY IMM, V142, P239, DOI 10.1159/000097026; Vieira PL, 2004, J IMMUNOL, V172, P5986; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; WARNER JO, 1978, LANCET, V2, P912; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wilccock LK, 2005, J ALLERGY CLIN IM S1, V115, pS265, DOI 10.1016/j.jaci.2004.12.1068; Wilcock LK, 2006, J ALLERGY CLIN IMMUN, V117, pS330, DOI 10.1016/j.jaci.2005.12.1300; Wilcock LK, 2006, IMMUNOL ALLERGY CLIN, V26, P333, DOI 10.1016/j.iac.2006.02.004; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2002, AM J RESP CRIT CARE, V165, P22; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Ying S, 2001, J ALLERGY CLIN IMMUN, V107, P686, DOI 10.1067/mai.2001.114339; Ying S, 1998, IMMUNOLOGY, V93, P281	167	79	80	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUL	2008	38	7					1074	1088		10.1111/j.1365-2222.2008.02976.x		15	Allergy; Immunology	Allergy; Immunology	325KA	WOS:000257586600003	18691292	
J	Nguyen, LP; Omoluabi, O; Parra, S; Frieske, JM; Clement, C; Ammar-Aouchiche, Z; Ho, SB; Ehre, C; Kesimer, M; Knoll, BJ; Tuvim, MJ; Dickey, BF; Bond, RA				Nguyen, Long P.; Omoluabi, Ozozoma; Parra, Sergio; Frieske, Joanna M.; Clement, Cecilia; Ammar-Aouchiche, Zoulikha; Ho, Samuel B.; Ehre, Camille; Kesimer, Mehmet; Knoll, Brian J.; Tuvim, Michael J.; Dickey, Burton F.; Bond, Richard A.			Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						beta-blockers; beta-adrenoceptor; asthma; mucin; airway inflammation	HEART-FAILURE; ADRENERGIC-BLOCKADE; AIRWAY MUCUS; GOBLET CELL; OVEREXPRESSION; ABNORMALITIES; EXPRESSION; BUCINDOLOL; SECRETION; MICE	Single-dose administration of beta-adrenoceptor agonists produces bronchodilation and inhibits airway hyperresponsiveness (AHR), and is the standard treatment for the acute relief of asthma. However, chronic repetitive administration of beta-adrenoceptor agonists may increase AHR, airway inflammation, and risk of death. Based upon the paradigm shift that occurred with the use of beta-blockers in congestive heart failure, we previously determined that chronic administration of beta-blockers decreased AHR in a murine model of asthma. To elucidate the mechanisms for the beneficial effects of beta-blockers, we examined the effects of chronic administration of several beta-adrenoceptor ligands in a murine model of allergic asthma. Administration of beta-blockers resulted in a reduction in total cell counts, eosinophils, and the cytokines IL-13, IL-10, IL-5, and TGF-beta 1 in bronchoalveolar lavage, and attenuated epithelial mucin content and morphologic changes. The differences in mucin content also occurred if the beta-blockers were administered only during the ovalbumin challenge phase, but administration of beta-blockers for 7 days was not as effective as administration for 28 days. These results indicate that in a murine model of asthma, chronic administration of beta-blockers reduces inflammation and mucous metaplasia, cardinal features of asthma that may contribute to airflow obstruction and AHR. Similar to heart failure, our results provide a second disease model in which beta-blockers producing an acutely detrimental effect may provide a therapeutically beneficial effect with chronic administration.	[Nguyen, Long P.; Knoll, Brian J.; Bond, Richard A.] Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, Houston, TX 77204 USA; [Omoluabi, Ozozoma] Univ Houston, Coll Pharm, Dept Biol & Biochem, Houston, TX 77204 USA; [Clement, Cecilia; Ammar-Aouchiche, Zoulikha; Tuvim, Michael J.; Dickey, Burton F.] Univ Texas Houston, MD Anderson Canc Ctr, Dept Pulm Med, Houston, TX 77030 USA; [Clement, Cecilia; Ammar-Aouchiche, Zoulikha; Tuvim, Michael J.; Dickey, Burton F.] Texas A&M Univ Syst Houston Hlth Sci Ctr, Inst Biosci & Technol, Houston, TX USA; [Ho, Samuel B.] Vet Affairs San Diego Healthcare Syst, Dept Med, San Diego, CA USA; [Ho, Samuel B.] Univ Calif San Diego, San Diego, CA 92103 USA; [Ehre, Camille; Kesimer, Mehmet] Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC USA	Bond, RA (reprint author), Univ Houston, Coll Pharm, Dept Pharmacol & Pharmaceut Sci, 4800 Calhoun, Houston, TX 77204 USA.	RABond@uh.edu		Parra, Sergio/0000-0002-3191-0475; Dickey, Burton/0000-0002-4780-1847	NHLBI NIH HHS [R01HL72984]		Agrawal A, 2007, J APPL PHYSIOL, V102, P399, DOI 10.1152/japplphysiol.00630.2006; *AM LUNG ASS EP ST, 2002, BEST PRACT PROGR SER; Anderson JL, 2003, J CARD FAIL, V9, P266, DOI 10.1054/jcaf.2003.42; Barnes PJ, 1998, PHARMACOL REV, V50, P515; BOND RA, 1995, NATURE, V374, P272, DOI 10.1038/374272a0; Bond RA, 2003, INT CONGR SER, V1249, P27, DOI 10.1016/S0531-5131(03)00614-9; Bond RA, 2002, NAT REV DRUG DISCOV, V1, P825, DOI 10.1038/nrd918; Bond RA, 2001, TRENDS PHARMACOL SCI, V22, P273, DOI 10.1016/S0165-6147(00)01711-9; BOND RA, IN PRESS PHARM THER; Boskabady M H, 2000, Respirology, V5, P111, DOI 10.1046/j.1440-1843.2000.00236.x; Callaerts-Vegh Z, 2004, P NATL ACAD SCI USA, V101, P4948, DOI 10.1073/pnas.0400452101; Evans CM, 2004, AM J RESP CELL MOL, V31, P382, DOI 10.1165/rcmb.0060OC; Evans KLJ, 2003, J APPL PHYSIOL, V94, P245, DOI 10.1152/japplphysiol.00593.2002; Fahy JV, 2002, CHEST, V122, p320S, DOI 10.1378/chest.122.6_suppl.320S; HALL SA, 1995, J AM COLL CARDIOL, V25, P1154, DOI 10.1016/0735-1097(94)00543-Y; HANANIA NA, IN PRESS PULM PHARM; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kuyper LM, 2003, AM J MED, V115, P6, DOI 10.1016/S0002-9343(03)00241-9; Lechat P, 1998, CIRCULATION, V98, P1184; LIN R, IN PRESS PULM PHARM; Maack C, 2000, BRIT J PHARMACOL, V130, P1131, DOI 10.1038/sj.bjp.0703400; McGraw DW, 2000, AM J PHYSIOL-LUNG C, V279, pL379; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Rogers DF, 2004, CURR OPIN PHARMACOL, V4, P241, DOI 10.1016/j.coph.2004.01.011; SHEKELS LL, 1995, BIOCHEM J, V311, P775; SINGH BN, 1976, CLIN PHARMACOL THER, V19, P493; Wang SZ, 2001, AM J PHYSIOL-LUNG C, V281, pL1303; Williams OW, 2006, AM J RESP CELL MOL, V34, P527, DOI 10.1165/rcmb.2005-0436SF; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134; Witchitz S, 2000, AM J CARDIOL, V85, P1467, DOI 10.1016/S0002-9149(00)00796-7; Young HWJ, 2007, AM J RESP CELL MOL, V37, P273, DOI 10.1165/rcmb.2005-04600C; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC	34	79	82	1	8	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAR	2008	38	3					256	262		10.1165/rcmb.2007-0279RC		7	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	266LA	WOS:000253435500003	18096872	
J	Mitchell, CS; Zhang, JFJ; Sigsgaard, T; Jantunen, M; Lioy, PJ; Samson, R; Karol, MH				Mitchell, Clifford S.; Zhang, Junfeng Jim; Sigsgaard, Torben; Jantunen, Matti; Lioy, Paul J.; Samson, Robert; Karol, Meryl H.			Current state of the science: Health effects and indoor environmental quality	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						allergens; chemistry; exposure; fungi; humans; indoor air pollution; intervention; review	VOLATILE ORGANIC-COMPOUNDS; ASSESSMENT METHODOLOGY PTEAM; AIRBORNE PARTICULATE MATTER; POLYMERASE-CHAIN-REACTION; HAZARDOUS AIR-POLLUTANTS; WATER-DAMAGED BUILDINGS; HEART-RATE-VARIABILITY; OF-THE-LITERATURE; STACHYBOTRYS-CHARTARUM; TIME-SERIES	Our understanding of the relationship between human health and the indoor environment continues to evolve. Previous research on health and indoor environments has tended to concentrate on discrete pollutant sources and exposures and on specific disease processes. Recently, efforts have been made to characterize more fully the complex interactions between the health of occupants and the interior spaces they inhabit. In this article we review recent advances in source characterization, exposure assessment, health effects associated with indoor exposures, and intervention research related to indoor environments. Advances in source characterization include a better understanding of how chemicals are transported and processed within spaces and the role that other factors such as lighting and building design may play in determining health. Efforts are under way to improve our ability to measure exposures, but this remains a challenge, particularly for biological agents. Researchers are also examining the effects of multiple exposures as well as the effects of exposures on vulnerable populations such as children and the elderly. In addition, a number of investigators are also studying the effects of modifying building design, materials, and operations on occupant health. Identification of research priorities should include input from building designers, operators, and the public health community.	Johns Hopkins Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA; Univ Med & Dent New Jersey, Sch Publ Hlth, Dept Environm & Occupat Hlth, Piscataway, NJ USA; Univ Aarhus, Dept Environm & Occupat Med, Aarhus, Denmark; Natl Publ Hlth Inst, Dept Environm Hlth, Kuopio, Finland; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Environm & Community Med, Piscataway, NJ 08854 USA; Centraalbur voor Schimmelcultures, Dept Serv & Appl Res, Utrecht, Netherlands; Univ Pittsburgh, Sch Publ Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15260 USA	Mitchell, CS (reprint author), Maryland Dept Hlth & Mental Hyg, 210 W Preston St,Rm 327, Baltimore, MD 21201 USA.	cmitchell@dhmh.state.md.us	Lioy, Paul/F-6148-2011; Mitchell, Clifford/K-3936-2015	Sigsgaard, Torben/0000-0002-2043-7571			Adgate JL, 2004, ENVIRON HEALTH PERSP, V112, P1386, DOI 10.1289/ehp.7107; Afshari A, 2005, INDOOR AIR, V15, P141, DOI 10.1111/j.1600-0668.2005.00332.x; Bell ML, 2004, ANNU REV PUBL HEALTH, V25, P247, DOI 10.1146/annurev.publhealth.25.102802.124329; BeruBe KA, 2004, SCI TOTAL ENVIRON, V324, P41, DOI 10.1016/j.scitotenv.2003.11.003; Bonnefoy XR, 2003, AM J PUBLIC HEALTH, V93, P1559, DOI 10.2105/AJPH.93.9.1559; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, INDOOR AIR, V14, P243, DOI 10.1111/j.1600-0668.2004.00240.x; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; CLAYTON CA, 1993, J EXPO ANAL ENV EPID, V3, P227; Cruz P, 2004, ADV APPL MICROBIOL, V55, P437, DOI 10.1016/S0065-2164(04)55018-9; Cummins SK, 2001, PEDIATR CLIN N AM, V48, P1241, DOI 10.1016/S0031-3955(05)70372-2; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; Dales R, 2004, J ASTHMA, V41, P259, DOI 10.1081/JAS-120026082; De Croon EM, 2005, ERGONOMICS, V48, P119, DOI 10.1080/00140130512331319409; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Douwes J, 2005, INDOOR AIR, V15, P160, DOI 10.1111/j.1600-0668.2005.00333.x; Dubowski Y, 2004, PHYS CHEM CHEM PHYS, V6, P3879, DOI 10.1039/b404127e; Erwin EA, 2005, INDOOR AIR, V15, P33, DOI 10.1111/j.1600-0668.2005.00355.x; Fan ZH, 2005, ATMOS ENVIRON, V39, P5171, DOI 10.1016/j.atmosenv.2005.05.018; Fan ZH, 2003, ENVIRON SCI TECHNOL, V37, P1811, DOI 10.1021/es026231i; Ferro AR, 2004, ENVIRON SCI TECHNOL, V38, P1759, DOI 10.1021/es0263893; Fiedler N, 2005, ENVIRON HEALTH PERSP, V113, P1542, DOI 10.1289/ehp.8132; Fischer G, 2003, ARCH MICROBIOL, V179, P75, DOI 10.1007/s00203-002-0495-2; Francis H, 2003, CLIN EXP ALLERGY, V33, P101, DOI 10.1046/j.1365-2222.2003.01570.x; Garbesi K, 1999, HEALTH PHYS, V77, P183, DOI 10.1097/00004032-199908000-00008; Georgopoulos PG, 2005, J EXPO ANAL ENV EPID, V15, P439, DOI 10.1038/sj.jea.7500422; GEVAO B, 2006, CHEMOSPHERE, P603; Gold DR, 1996, J AIR WASTE MANAGE, V46, P335, DOI 10.1080/10473289.1996.10467468; Gunschera J, 2004, ENVIRON SCI POLLUT R, V11, P147, DOI 10.1065/espr2004.02.186; Hanninen OO, 2005, INDOOR AIR, V15, P246, DOI 10.1111/j.1600-0668.2005.00365.x; Hanninen OO, 2004, ATMOS ENVIRON, V38, P6411, DOI 10.1016/j.atmosenv.2004.07.015; Hanninen OO, 2004, J EXPO ANAL ENV EPID, V14, P440, DOI 10.1038/sj.jea.7500342; Harkema JR, 2005, EXP TOXICOL PATHOL, V57, P129, DOI 10.1016/j.etp.2005.05.013; Instanes C, 2005, INDOOR AIR, V15, P356, DOI 10.1111/j.1600-0668.2005.00381.x; IOM (Institute of Medicine Committee on Damp Indoor Spaces and Health), 2004, DAMP IND SPAC HLTH; Jantunen MJ, 1998, J EXPO ANAL ENV EPID, V8, P495; Jarvis BB, 2003, PHYTOCHEMISTRY, V64, P53, DOI 10.1016/S0031-9422(03)00275-9; JONG S C, 1976, Mycotaxon, V3, P409; Karol MH, 2002, TOXICOLOGY, V181, P305, DOI 10.1016/S0300-483X(02)00298-6; Keswani J, 2005, J ENVIRON MONITOR, V7, P311, DOI 10.1039/b415498c; KILBURN S, 2003, COCHRANE DB SYST REV, P1, DOI UNSP CD002989; Koistinen KJ, 2004, SCAND J WORK ENV HEA, V30, P36; Koschel D, 2005, RESP MED, V99, P943, DOI 10.1016/j.rmed.2005.01.004; Krieger J, 2002, ENVIRON HEALTH PERSP, V110, P311; Kuhn DM, 2003, CLIN MICROBIOL REV, V16, P144, DOI 10.1128/CMR.16.1.144-172.2003; LARSEN ERJ, 1975, FIRE FLAMM FIRE RETA, V2, P5; Laumbach RJ, 2005, CURR OPIN ALLERGY CL, V5, P135, DOI 10.1097/01.all.0000162305.05105.d0; Li Y, 2005, INDOOR AIR, V15, P96, DOI 10.1111/j.1600-0668.2004.00318.x; Li Y, 2005, INDOOR AIR, V15, P83, DOI 10.1111/j.1600-0668.2004.00317.x; Lioy PJ, 2006, J EXPO SCI ENV EPID, V16, P207, DOI 10.1038/sj.jes.7500456; Magari SR, 2002, EPIDEMIOLOGY, V13, P305, DOI 10.1097/00001648-200205000-00011; Mar TF, 2005, EPIDEMIOLOGY, V16, P681, DOI 10.1097/01.ede.0000173037.83211.d6; Marklund A, 2003, CHEMOSPHERE, V53, P1137, DOI 10.1016/S0045-6535(03)00666-0; McConnell R, 2003, ANN ALLERG ASTHMA IM, V91, P546; McDevitt JJ, 2004, MYCOPATHOLOGIA, V158, P325, DOI 10.1007/s11046-004-2304-8; MCKONE TE, 1991, J AIR WASTE MANAGE, V41, P832; Meklin T, 2004, J ENVIRON MONITOR, V6, P615, DOI 10.1039/b400250d; Meng QY, 2005, J EXPO ANAL ENV EPID, V15, P17, DOI 10.1038/sj.jea.7500378; Menzies D, 2003, LANCET, V362, P1785, DOI 10.1016/S0140-6736(03)14897-0; Meyer HW, 2005, INDOOR AIR, V15, P73, DOI 10.1111/j.1600-0668.2005.00351.x; Molhave L, 2005, INDOOR AIR, V15, P383, DOI 10.1111/j.1600-0668.2005.00366.x; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Morris RD, 2001, ENVIRON HEALTH PERSP, V109, P495, DOI 10.2307/3454659; Morrison GC, 2002, ENVIRON SCI TECHNOL, V36, P2185, DOI 10.1021/es0113089; Nazaroff WW, 2004, J EXPO ANAL ENV EPID, V14, pS71, DOI 10.1038/sj.jea.7500361; Nazaroff WW, 2004, INDOOR AIR, V14, P175, DOI 10.1111/j.1600-0668.2004.00286.x; Nielsen KF, 2002, MYCOPATHOLOGIA, V154, P201, DOI 10.1023/A:1016383402963; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Ott W, 2000, J AIR WASTE MANAGE, V50, P1390; Ott WR, 1998, SCI AM, V278, P86; Pandian MD, 1998, J EXPO ANAL ENV EPID, V8, P577; Pauley SM, 2004, MED HYPOTHESES, V63, P588, DOI 10.1016/j.mehy.2004.03.020; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; REISS R, 1995, J AIR WASTE MANAGE, V45, P811; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; Sallis JF, 2006, FUTURE CHILD, V16, P89, DOI 10.1353/foc.2006.0009; Salthammer T, 2002, J PHOTOCH PHOTOBIO A, V152, P1, DOI 10.1016/S1010-6030(02)00212-5; Samet JM, 1998, ENV OCCUPATIONAL MED, P1523; Schmechel D, 2006, J IMMUNOL METHODS, V309, P150, DOI 10.1016/j.jim.2005.12.001; Sebastian A, 2005, INDOOR AIR, V15, P20, DOI 10.1111/j.1600-0668.2005.00341.x; Sexton K, 2005, ENVIRON HEALTH PERSP, V113, P342, DOI 10.1289/ehp.7412; Sexton K, 2004, ENVIRON SCI TECHNOL, V38, P423, DOI 10.1021/es030319u; Sexton K, 2000, J EXPO ANAL ENV EPID, V10, P682; Shoemaker RC, 2005, NEUROTOXICOL TERATOL, V27, P29, DOI 10.1016/j.ntt.2004.07.005; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665; Stevens RG, 2005, EPIDEMIOLOGY, V16, P254, DOI 10.1097/01.ede.0000152525.21924.54; Terr AI, 2004, J ALLERGY CLIN IMMUN, V113, P221, DOI 10.1016/j.jaci.2003.11.014; THATCHER TL, 1995, ATMOS ENVIRON, V29, P1487, DOI 10.1016/1352-2310(95)00016-R; THOMAS KW, 1993, J EXPO ANAL ENV EPID, V3, P203; Tobias KRC, 2004, INT ARCH ALLERGY IMM, V133, P365, DOI 10.1159/000077356; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; Vesper SJ, 2004, J OCCUP ENVIRON MED, V46, P596, DOI 10.1097/01.jom.0000128160.17144.6e; Viegi G, 2004, INT J TUBERC LUNG D, V8, P1401; Vineis P, 2005, CARCINOGENESIS, V26, P1846, DOI 10.1093/carcin/bgi216; Wainman T, 2001, Environ Sci Technol, V35, P2201; Wallace L, 1996, J AIR WASTE MANAGE, V46, P98; Wallace L, 1991, J Expo Anal Environ Epidemiol, V1, P157; Weich S, 2002, BRIT J PSYCHIAT, V180, P428, DOI 10.1192/bjp.180.5.428; Weisel CP, 2005, J EXPO ANAL ENV EPID, V15, P123, DOI 10.1038/sj.jea.7500379; Weschler CJ, 1996, ENVIRON SCI TECHNOL, V30, P3250, DOI 10.1021/es960032f; Weschler CJ, 2006, ENVIRON HEALTH PERSP, V114, P442, DOI 10.1289/ehp.8271; Weschler CJ, 2004, INDOOR AIR, V14, P184, DOI 10.1111/j.1600-0668.2004.00287.x; WESCHLER CJ, 1989, JAPCA J AIR WASTE MA, V39, P1562; WESCHLER CJ, 1992, ENVIRON SCI TECHNOL, V26, P179, DOI 10.1021/es00025a022; Xu X, 2005, J EXPO ANAL ENV EPID, V15, P6, DOI 10.1038/sj.jea.7500374; ZHANG JF, 1994, J EXPO ANAL ENV EPID, V4, P25	109	79	79	7	73	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2007	115	6					958	964		10.1289/ehp.8987		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	179HK	WOS:000247280200045	17589607	
J	Eross, E; Dodick, D; Eross, M				Eross, Eric; Dodick, David; Eross, Michael			The sinus, allergy and migraine study (SAMS)	HEADACHE			English	Article						allergy; cranial autonomic symptoms; headache; migraine; sinus	PREVALENCE; HEADACHE	Objective.-The objective of this study is to classify (according to the current International Headache Society's criteria [ICHD-II]) the headache types that those with self-diagnosed sinus headache experience and to determine barriers to correct diagnosis. Background.-The American Migraine Study II estimates that 28 million Americans suffer from migraine headache. The majority of these patients remain undiagnosed and many are erroneously diagnosed as having sinus headache. Despite this common diagnosis, the concept of sinus headache remains an enigma with a relative paucity of information in the literature. Methods.-Advertising in the greater Phoenix, U.S. metropolitan area was used to recruit 100 willing and consecutive subjects to participate in this descriptive clinical study (The Sinus, Allergy and Migraine Study [SAMS]). All patients who believed they suffered from sinus headache and were over 18 years of age were enrolled without exclusion. A detailed history and exam was performed in each patient, and patients were given headache diagnoses based on the current International Headache Society's (IHS) criteria. Results.-Of the 100 subjects with self-diagnosed headache, IHS diagnoses mistaken as sinus headache included migraine with or without aura (52%), chronic migraine associated with medication overuse versus probable medication overuse headache (11%), probable migraine (23%), cluster headache (1%), hemicrania continua (1%), headache secondary to rhinosinusitis (3%), and headaches nonclassifiable (9%). Weather changes (83%), seasonal variation (73%), exposure to allergens (62%), and changes in altitude (38%) were frequent migraine triggers. Seventy-six percent of migraine subjects reported pain in the distribution of the second division of the trigeminal nerve (either unilateral or bilateral), and 62% experienced bilateral forehead and maxillary pain with their headaches. The most common associated features included nasal congestion (56%), eyelid edema (37%), rhinorrhea (25%), conjunctival injection (22%), lacrimation (19%), and ptosis (3%). The headaches nonclassifiable were characterized by a bilateral maxillary pressure of mild to moderate intensity associated with at least one cranial autonomic symptom. Features suggestive of migraine were absent in all 9 of these nonclassifiable cases. Conclusions.-The majority of those with self-diagnosed sinus headache have migraine or probable migraine. In those patients with migraine, the most common reasons for misdiagnosis include headache triggers, pain location, and associated features ("guilt by provocation, location, and association") commonly attributed to sinus headache. The clinician must be aware of these unique presentations of migraine so that a correct diagnosis can be made and effective treatment instituted. A portion of patients with self-diagnosed sinus headache suffer from a headache type, which is unclassifiable by the current IHS criteria. These headaches are characterized by bilateral maxillary pressure, mild to moderate pain intensity, cranial autonomic symptoms, and the complete absence of migraine features.	Arizona Neurol Inst, Scottsdale Headache Ctr, Scottsdale, AZ 85255 USA; Eross Informat Serv, Suwanee, GA USA; Mayo Clin, Coll Med, Dept Neurol, Scottsdale, AZ USA	Eross, E (reprint author), Arizona Neurol Inst, Scottsdale Headache Ctr, Scottsdale, AZ 85255 USA.	ericeross@yahoo.com					*AAOHNS, 2004, STAT AM AC OT HEAD N; *ALL ASTHM FDN AM, 2004, STAT ALL ASTHM FDN A; Blumenthal HJ, 2001, HEADACHE, V41, P883, DOI 10.1046/j.1526-4610.2001.041009883.x; CADY RK, 2003, NASAL ENDOSCOPY MIGR; Goadsby PJ, 2002, NEW ENGL J MED, V346, P257; *INT CLASS HEAD DI, 2004, CEPHALALGIA, V24; Lanza DC, 1997, OTOLARYNG HEAD NECK, V117, pS1, DOI 10.1016/S0194-5998(97)70001-9; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; McAuliffe GW, 1943, RES PUBL ASSOC RES N, V23, P185; Menken M, 2000, ARCH NEUROL-CHICAGO, V57, P418, DOI 10.1001/archneur.57.3.418; REILLY JS, 1990, OTOLARYNG HEAD NECK, V103, P856; SALAM SD, 1994, J MED LIBAN, V42, P200; Schreiber CP, 2004, ARCH INTERN MED, V164, P1769, DOI 10.1001/archinte.164.16.1769; SCHREIBER CP, 2001, NEUROLOGY S, V3, pA311; SCHREIBER CP, 2001, CEPHALALGIA, V21, P298; Stammberger H, 1988, Ann Otol Rhinol Laryngol Suppl, V134, P3; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Tarabichi M, 2000, OTOLARYNG HEAD NECK, V122, P842, DOI 10.1016/S0194-5998(00)70011-8; Von Korff M, 1998, NEUROLOGY, V50, P1741	19	79	79	0	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0017-8748			HEADACHE	Headache	FEB	2007	47	2					213	224		10.1111/j.1526-4610.2006.00688.x		12	Clinical Neurology	Neurosciences & Neurology	134VP	WOS:000244112800007	17300361	
J	Jutel, M; Akdis, M; Blaser, K; Akdis, CA				Jutel, M; Akdis, M; Blaser, K; Akdis, CA			Mechanisms of allergen specific immunotherapy - T-cell tolerance and more	ALLERGY			English	Review						allergy; histamine; immunoglobulins; specific immunotherapy; T-regulatory cells; tolerance	GRASS-POLLEN IMMUNOTHERAPY; IMMUNOLOGICAL SELF-TOLERANCE; EOSINOPHIL CATIONIC PROTEIN; MESSENGER-RNA EXPRESSION; HOUSE-DUST MITES; HAY-FEVER; SUBLINGUAL IMMUNOTHERAPY; ASTHMATIC-CHILDREN; IN-VITRO; VENOM IMMUNOTHERAPY	Specific immune suppression and induction of tolerance are essential processes in the regulation and circumvention of immune defence. The balance between allergen-specific T-regulatory (Treg) cells and T helper 2 cells appears to be decisive in the development of allergic and healthy immune response against allergens. Treg cells consistently represent the dominant subset specific for common environmental allergens in healthy individuals. In contrast, there is a high frequency of allergen-specific T helper 2 cells in allergic individuals. A decrease in interleukin (IL)-4, IL-5 and IL-13 production by allergen-specific CD4(+) T cells due to the induction of peripheral T cell tolerance is the most essential step in allergen-specific immunotherapy (SIT). Suppressed proliferative and cytokine responses against the major allergens are induced by multiple suppressor factors, such as cytokines like IL-10 and transforming growth factor (TGF)-beta and cell surface molecules like cytotoxic T lymphocyte antigen-4, programmed death-1 and histamine receptor 2. There is considerable rationale for targeting T cells to increase efficacy of SIT. Such novel approaches include the use of modified allergens produced using recombinant DNA technology and adjuvants or additional drugs, which may increase the generation of allergen-specific peripheral tolerance. By the application of the recent knowledge in Treg cells and related mechanisms of peripheral tolerance, more rational and safer approaches are awaiting for the future of prevention and cure of allergic diseases.	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Wroclaw Med Univ, Dept Internal Med & Allergol, Wroclaw, Poland	Jutel, M (reprint author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.						Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, CURR OPIN IMMUNOL, V12, P641, DOI 10.1016/S0952-7915(00)00156-4; Akdis CA, 2004, ALLERGY, V59, P897, DOI 10.1111/j.1398-9995.2004.00587.x; Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Akdis CA, 1999, FASEB J, V13, P603; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akdis M, 1999, J IMMUNOL, V163, P466; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P961, DOI 10.1016/j.jaci.2005.09.004; Akdis M, 2005, J ALLERGY CLIN IMMUN, V116, P969; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Banerjee B, 2000, MOL IMMUNOL, V37, P789, DOI 10.1016/S0161-5890(00)00095-X; Barrat FJ, 2002, J EXP MED, V195, P603, DOI 10.1084/jem.20011629; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bonifazi F, 2005, ALLERGY, V60, P1459, DOI 10.1111/j.1398-9995.2005.00960.x; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P439, DOI 10.1016/0091-6749(88)90017-6; Bousquet J, 2005, ALLERGY, V60, P1, DOI 10.1111/j.1398-9995.2005.00700.x; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; Carter LL, 2002, EUR J IMMUNOL, V32, P634, DOI 10.1002/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9; CHEN WY, 1995, J ASTHMA, V32, P29, DOI 10.3109/02770909509089497; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Corry DB, 1999, CURR OPIN IMMUNOL, V11, P610, DOI 10.1016/S0952-7915(99)00025-4; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; DelValle J, 1997, AM J PHYSIOL-GASTR L, V273, pG987; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; El Biaze M, 2003, ALLERGY, V58, P844, DOI 10.1034/j.1398-9995.2003.00282.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Faith A, 1999, J IMMUNOL, V162, P1836; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GOLDEN DBK, 1982, J ALLERGY CLIN IMMUN, V69, P489, DOI 10.1016/0091-6749(82)90172-5; Grabie N, 1999, INT IMMUNOL, V11, P907, DOI 10.1093/intimm/11.6.907; Groux H, 1997, NATURE, V389, P737; Hakansson L, 1997, J ALLERGY CLIN IMMUN, V99, P551, DOI 10.1016/S0091-6749(97)70084-8; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hellings PW, 2002, EUR J IMMUNOL, V32, P585, DOI 10.1002/1521-4141(200202)32:2<585::AID-IMMU585>3.0.CO;2-U; Janssen EM, 2000, J IMMUNOL, V164, P580; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 2002, CURR OPIN IMMUNOL, V14, P735, DOI 10.1016/S0952-7915(02)00395-3; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Jutel M, 1995, J IMMUNOL, V154, P4178; JUTEL M, 1997, ALLERGY S37, V52, P88; Karamloo F, 2005, EUR J IMMUNOL, V35, P3268, DOI 10.1002/eji.200425522; Ke Y, 1996, J IMMUNOL, V156, P916; Koning H, 1997, CYTOKINE, V9, P427, DOI 10.1006/cyto.1996.0185; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.011.041; Kussebi F., 2003, Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, V2, P297, DOI 10.2174/1568014033483699; Lehmann J, 2002, P NATL ACAD SCI USA, V99, P13031, DOI 10.1073/pnas.192162899; Levings MK, 2001, J IMMUNOL, V166, P5530; Levings MK, 2001, J EXP MED, V193, P1295, DOI 10.1084/jem.193.11.1295; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LICHTENSTEIN LM, 1966, J CLIN INVEST, V45, P1126, DOI 10.1172/JCI105419; Marcotte GV, 1998, J ALLERGY CLIN IMMUN, V101, P506, DOI 10.1016/S0091-6749(98)70358-6; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Marcucci F, 2001, ALLERGY, V56, P231; Marshall JS, 1996, J CLIN INVEST, V97, P1122, DOI 10.1172/JCI118506; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; McHugh RS, 2002, IMMUNITY, V16, P311, DOI 10.1016/S1074-7613(02)00280-7; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOSMANN TR, 1996, IMMUNOL TODAY, V17, P142; MULLER U, 1989, ALLERGY, V44, P412, DOI 10.1111/j.1398-9995.1989.tb04172.x; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Nocentini G, 1997, P NATL ACAD SCI USA, V94, P6216, DOI 10.1073/pnas.94.12.6216; Noon L, 1911, LANCET, V1, P1572; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Ohkawara Y, 1996, J CLIN INVEST, V97, P1761, DOI 10.1172/JCI118603; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oral HB, 2006, EUR J IMMUNOL, V36, P380, DOI 10.1002/eji.200425523; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; POWRIE F, 1994, J EXP MED, V179, P589, DOI 10.1084/jem.179.2.589; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Rolinck-Werninghaus C, 2005, INT ARCH ALLERGY IMM, V136, P134, DOI 10.1159/000083320; Rolland J, 1998, CURR OPIN IMMUNOL, V10, P640, DOI 10.1016/S0952-7915(98)80082-4; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Rossi RE, 2004, INT ARCH ALLERGY IMM, V135, P44, DOI 10.1159/000080042; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Seo N, 1999, J IMMUNOL, V163, P242; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Shim YK, 2003, CLIN EXP ALLERGY, V33, P52; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; SIMON HU, 1995, IMMUNOL TODAY, V16, P53, DOI 10.1016/0167-5699(95)80086-7; SONODA E, 1989, J EXP MED, V170, P1415, DOI 10.1084/jem.170.4.1415; Steinbrink K, 1997, J IMMUNOL, V159, P4772; Strober S, 1996, IMMUNOL REV, V149, P217, DOI 10.1111/j.1600-065X.1996.tb00906.x; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; Trautmann A, 2000, J CLIN INVEST, V106, P25, DOI 10.1172/JCI9199; Trautmann A, 2001, J ALLERGY CLIN IMMUN, V108, P839; Trautmann A, 2002, J ALLERGY CLIN IMMUN, V109, P329, DOI 10.1067/mai.2002.121460; Trautmann A, 2001, TRENDS IMMUNOL, V22, P530, DOI 10.1016/S1471-4906(01)02004-X; Treter S, 2000, CELL IMMUNOL, V206, P116, DOI 10.1006/cimm.2000.1739; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Varga EM, 2000, J IMMUNOL, V165, P2877; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; von Garnier C, 2000, EUR J IMMUNOL, V30, P1638, DOI 10.1002/1521-4141(200006)30:6<1638::AID-IMMU1638>3.0.CO;2-R; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wachholz Petra A, 2004, Curr Opin Allergy Clin Immunol, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; WALKER C, 1991, J IMMUNOL, V146, P1829; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Weiner HL, 1997, ANNU REV MED, V48, P341; Weiner HL, 2001, IMMUNOL REV, V182, P207, DOI 10.1034/j.1600-065X.2001.1820117.x; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wilson DR, 2003, COCHRANE DB SYST REV, DOI [10.1016/S1081-1206(10)60004-X, DOI 10.1002/14651858.CD002893]; Wood KJ, 2003, NAT REV IMMUNOL, V3, P199, DOI 10.1038/nri1027; Woodfolk JA, 2000, J IMMUNOL, V165, P4379; Yssel H, 2000, INT ARCH ALLERGY IMM, V121, P10, DOI 10.1159/000024292	132	79	91	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JUL	2006	61	7					796	807		10.1111/j.1398-9995.2006.01175.x		12	Allergy; Immunology	Allergy; Immunology	053KW	WOS:000238305000002	16792576	
J	Peters-Golden, M; Gleason, MM; Togias, A				Peters-Golden, M; Gleason, MM; Togias, A			Cysteinyl leukotrienes: multi-functional mediators in allergic rhinitis	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review						allergic rhinitis; cysteinyl leukotrienes; CysLT(1) receptor; eosinophils; inflammation; leukotriene C4 synthase; 5-lipoxygenase	COLONY-STIMULATING FACTOR; HUMAN MAST-CELLS; PLACEBO-CONTROLLED TRIAL; VEIN ENDOTHELIAL-CELLS; HUMAN NASAL-MUCOSA; HEMATOPOIETIC PROGENITOR CELLS; ARACHIDONIC-ACID METABOLITES; PERIPHERAL-BLOOD LEUKOCYTES; GENE DISRUPTION REVEALS; C-4 SYNTHASE EXPRESSION	Cysteinyl leukotrienes (CysLTs) are a family of inflammatory lipid mediators synthesized from arachidonic acid by a variety of cells, including mast cells, eosinophils, basophils, and macrophages. This article reviews the data for the role of CysLTs as multi-functional mediators in allergic rhinitis (AR). We review the evidence that: (1) CysLTs are released from inflammatory cells that participate in AR, (2) receptors for CysLTs are located in nasal tissue, (3) CysLTs are increased in patients with AR and are released following allergen exposure, (4) administration of CysLTs reproduces the symptoms of AR, (5) CysLTs play roles in the maturation, as well as tissue recruitment, of inflammatory cells, and (6) a complex inter-regulation between CysLTs and a variety of other inflammatory mediators exists.	Div Clin Immunol & Allergy, Baltimore, MD 21224 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Merck & Co Inc, West Point, PA USA; Johns Hopkins Univ, Baltimore, MD USA	Togias, A (reprint author), Div Clin Immunol & Allergy, 5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	atogias@jhmi.edu					Akaiwa M, 2001, CYTOKINE, V13, P75, DOI 10.1006/cyto.2000.0814; Akdis CA, 2003, J ALLERGY CLIN IMMUN, V112, P15, DOI 10.1067/mai.2003.1585; Amrani Y, 2001, AM J RESP CRIT CARE, V164, P2098; Baatjes AJ, 2002, PHARMACOL THERAPEUT, V95, P63, DOI 10.1016/S0163-7258(02)00233-4; Bandeira-Melo C, 2002, J IMMUNOL, V168, P4756; Bandeira-Melo C, 2002, J ALLERGY CLIN IMMUN, V109, P975, DOI 10.1067/mai.2002.124269; BASCOM R, 1988, Journal of Allergy and Clinical Immunology, V81, P580, DOI 10.1016/0091-6749(88)90198-4; Bautz F, 2001, BLOOD, V97, P3433, DOI 10.1182/blood.V97.11.3433; Becler K, 2002, ALLERGY, V57, P1021, DOI 10.1034/j.1398-9995.2002.23620.x; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BISGAARD H, 1985, ALLERGY, V40, P417, DOI 10.1111/j.1398-9995.1985.tb02680.x; BISGAARD H, 1984, PROSTAGLANDINS, V27, P369, DOI 10.1016/0090-6980(84)90196-5; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; Bloemers SM, 1998, J BIOL CHEM, V273, P2249, DOI 10.1074/jbc.273.4.2249; BOEHMLER AM, 2002, BLOOD, V100; BORGEAT P, 1979, P NATL ACAD SCI USA, V76, P3213, DOI 10.1073/pnas.76.7.3213; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.90.015; BRACCIONI F, 2001, EUR RESP SOC ANN C 2, V18; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; Brock TG, 1996, J IMMUNOL, V156, P2522; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Busse WW, 2001, NEW ENGL J MED, V344, P350; Chibana K, 2003, J IMMUNOL, V170, P4290; CHIBANA K, 2004, AM J RESP CRIT CARE, V169, pA62; Cho SH, 2004, J IMMUNOL, V173, P624; CIFONE MG, 1995, EUR J IMMUNOL, V25, P1080, DOI 10.1002/eji.1830250433; CIPRANDI G, 2003, ALLERG IMMUNOL PARIS, V35, P295; Coffey MJ, 2002, BBA-MOL CELL BIOL L, V1584, P81, DOI 10.1016/S1388-1981(02)00286-X; Coffey MJ, 1999, BLOOD, V94, P3897; Corrigan C, 2005, J ALLERGY CLIN IMMUN, V115, P316, DOI 10.1016/j.jaci.2004.10.051; Cowburn AS, 1999, J IMMUNOL, V163, P456; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Cyr MM, 2001, CURR OPIN IMMUNOL, V13, P727, DOI 10.1016/S0952-7915(01)00286-2; Denburg JA, 2004, IMMUNOL ALLERGY CLIN, V24, P87, DOI 10.1016/S0889-8561(03)00106-1; DENBURG JA, 1987, INT ARCH ALLER A IMM, V82, P321; Denzlinger C, 1996, CRIT REV ONCOL HEMAT, V23, P167, DOI 10.1016/1040-8428(96)00205-3; DENZLINGER C, 1990, BLOOD, V76, P1765; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734; Drazen JM, 1999, NEW ENGL J MED, V340, P197; Eglite S, 2000, J IMMUNOL, V165, P2183; ELLIS JL, 1991, J PHYSIOL-LONDON, V436, P469; Espinosa K, 2003, J ALLERGY CLIN IMMUN, V111, P1032, DOI 10.1067/mai.2003.1451; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; Figueroa DJ, 2001, AM J RESP CRIT CARE, V163, P226; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; FORDHUTCHINSON AW, 1994, ANN NY ACAD SCI, V744, P78, DOI 10.1111/j.1749-6632.1994.tb52725.x; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Friedmann P. S., 2001, Clinical and Experimental Allergy Reviews, V1, P156, DOI 10.1046/j.1472-9725.2001.00030.x; Gauvreau GM, 2005, J ALLERGY CLIN IMMUN, V116, P285, DOI 10.1016/j.jaci.2005.05.021; Gilchrist M, 2004, BLOOD, V104, P462, DOI 10.1182/blood-2003-08-2990; GOLDYNE ME, 1984, J BIOL CHEM, V259, P8815; Gronert K, 2001, AM J PATHOL, V158, P3, DOI 10.1016/S0002-9440(10)63937-5; Grossman J., 1997, Journal of Allergy and Clinical Immunology, V99, pS443; Harizi H, 2002, J IMMUNOL, V168, P2255; HENDERSON WR, 1994, ANN INTERN MED, V121, P684; Higashi N, 2003, ALLERGY, V58, P476, DOI 10.1034/j.1398-9995.2003.00159.x; HODGES MK, 1988, AM REV RESPIR DIS, V138, P799; Hsieh FH, 2001, J EXP MED, V193, P123, DOI 10.1084/jem.193.1.123; Hsieh Jie-Cheng, 2004, Pediatric Asthma Allergy & Immunology, V17, P59, DOI 10.1089/088318704322994958; Hui YQ, 2004, CIRCULATION, V110, P3360, DOI 10.1161/01.CIR.0000147775.50954.AA; Ichiyama T, 2003, CLIN EXP ALLERGY, V33, P802, DOI 10.1046/j.1365-2222.2003.01673.x; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KANWAR S, 1995, CIRC RES, V77, P879; KAWANO T, 2003, J ALLERGY CLIN IMMUN, V112, P411; Kay AB, 1999, J ALLERGY CLIN IMMUN, V103, pS203; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; KOHI F, 1990, ANN ALLERGY, V65, P228; Kojima T, 1991, Nihon Jibiinkoka Gakkai Kaiho, V94, P587; KOJIMA T, 1991, J OTOLARYNGOL JPN, V94, P366; Konno A, 1996, ANN OTO RHINOL LARYN, V105, P648; KONNO A, 1997, J CLIN THER MED, V13, P1921; Kurowski M, 2004, ALLERGY, V59, P280, DOI 10.1046/j.1398-9995.2003.00416.x; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Larfars G, 1999, BLOOD, V93, P1399; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lie WJ, 2003, CLIN EXP ALLERGY, V33, P1125, DOI 10.1046/j.1365-2222.2003.01726.x; LIM MC, 1995, AM J RESP CRIT CARE, V151, P136; LINDGREN JA, 1993, J LIPID MEDIATOR, V6, P313; Lotzer K, 2003, ARTERIOSCL THROM VAS, V23, pE32, DOI 10.1161/01.ATV.0000082690.23131.CB; Lynch KR, 1999, NATURE, V399, P789; MACGLASHAN DW, 1983, FED PROC, V42, P2504; Machida I, 2004, J IMMUNOL, V172, P1833; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Maspero JF, 2000, J ALLERGY CLIN IMMUN, V105, pS25; McAlexander MA, 1998, J PHARMACOL EXP THER, V285, P602; MCCOMAS J, 2003, ANN ALLERG ASTHMA IM, V90, P131; MCKINNON KP, 1993, TOXICOL APPL PHARM, V118, P215, DOI 10.1006/taap.1993.1027; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; Meltzer E O, 1997, J Allergy Clin Immunol, V99, pS805; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Menard G, 2000, AM J RESP CELL MOL, V23, P572; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357; Mita H, 2001, CLIN EXP ALLERGY, V31, P1714, DOI 10.1046/j.1365-2222.2001.01184.x; Mohle R, 2001, ANN NY ACAD SCI, V938, P26; MURPHY RC, 1979, P NATL ACAD SCI USA, V76, P4275, DOI 10.1073/pnas.76.9.4275; Nagata M, 1998, AM J RESP CELL MOL, V19, P158; Nagata M, 2002, J ALLERGY CLIN IMMUN, V109, P676, DOI 10.1067/mai.2002.122841; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592; Nettis E, 2001, ARCH DERMATOL, V137, P99; Numata T, 1999, ANN OTO RHINOL LARYN, V108, P467; Ochensberger B, 1999, EUR J IMMUNOL, V29, P11, DOI 10.1002/(SICI)1521-4141(199901)29:01<11::AID-IMMU11>3.0.CO;2-B; Offer S, 2003, NITRIC OXIDE-BIOL CH, V9, P10, DOI 10.1016/S1389-8603(03)00047-8; Ohshima N, 2002, INT ARCH ALLERGY IMM, V129, P67, DOI 10.1159/000065175; OKUDA M, 1988, ANN ALLERGY, V60, P537; Okunishi K, 2004, J IMMUNOL, V173, P6393; OPHIR D, 1988, ARCH OTOLARYNGOL, V114, P522; OWEN WF, 1987, J IMMUNOL, V138, P532; Pacor ML, 2001, CLIN EXP ALLERGY, V31, P1607, DOI 10.1046/j.1365-2222.2001.01189.x; Panettieri RA, 1998, AM J RESP CELL MOL, V19, P453; Parameswaran K, 2004, J ALLERGY CLIN IMMUN, V114, P73, DOI 10.1016/j.jaci.2004.03.054; PASTORELLO EA, 1994, J ALLERGY CLIN IMMUN, V93, P85, DOI 10.1016/0091-6749(94)90236-4; PATRIGNANI P, 1993, PHARMACOL RES, V27, P281, DOI 10.1006/phrs.1993.1027; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; PETERS SP, 1985, AM REV RESPIR DIS, V132, P367; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; PIPKORN U, 1987, NEW ENGL J MED, V316, P1506, DOI 10.1056/NEJM198706113162403; PIPKORN U, 1988, INT ARCH ALLER A IMM, V87, P349; POULIOT M, 1994, J EXP MED, V179, P1225, DOI 10.1084/jem.179.4.1225; Pullerits T, 2001, ALLERGY, V56, P871, DOI 10.1034/j.1398-9995.2001.00916.x; Pynaert G, 1999, MOL MED, V5, P685; Rajah R, 1996, AM J PHYSIOL-LUNG C, V271, pL1014; RAMIS I, 1991, PROSTAGLANDINS, V42, P411, DOI 10.1016/0090-6980(91)90032-B; RASP G, 1994, CLIN EXP ALLERGY, V24, P1151; Riddick CA, 1999, J IMMUNOL, V162, P1101; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; RYOYAMA K, 1993, CANCER IMMUNOL IMMUN, V37, P385, DOI 10.1007/BF01526795; Saeki S, 2004, J ALLERGY CLIN IMMUN, V114, P538, DOI 10.1016/j.jaci.2004.05.053; Saito H, 2004, IMMUNOLOGY, V113, P246, DOI 10.1111/j.1365-2567.2004.01944.x; Saito K, 2004, ANN ALLERG ASTHMA IM, V93, P594; SANDRINI A, 2003, CHEST, V124, P1341; Sanico AM, 1998, CLIN EXP ALLERGY, V28, P92; Sanico AM, 1998, J APPL PHYSIOL, V84, P537; SCHLEIMER RP, 1986, AM REV RESPIR DIS, V133, P614; SCHLEIMER RP, 1985, INT ARCH ALLER A IMM, V77, P241; SCOGGAN KA, 1995, BLOOD, V86, P3507; SHAW RJ, 1985, ALLERGY, V40, P1, DOI 10.1111/j.1398-9995.1985.tb04147.x; SHAW RJ, 1985, NATURE, V316, P150, DOI 10.1038/316150a0; Shichijo M, 1998, CLIN EXP ALLERGY, V28, P1228; SHINDO K, 1995, BIOCHEM BIOPH RES CO, V214, P869, DOI 10.1006/bbrc.1995.2367; Shirasaki H, 2002, CLIN EXP ALLERGY, V32, P1007, DOI 10.1046/j.1365-2222.2002.01425.x; SILBERSTEIN DS, 1986, J IMMUNOL, V137, P3290; Sjostrom M, 2002, BBA-MOL CELL BIOL L, V1583, P53, DOI 10.1016/S1388-1981(02)00160-9; Sjostrom M, 2001, EUR J BIOCHEM, V268, P2578, DOI 10.1046/j.1432-1327.2001.02142.x; SKONER DP, 1990, ANN ALLERGY, V65, P206; Sousa A, 2002, NEW ENGL J MED, V347, P1524; SPADA CS, 1994, J LEUKOCYTE BIOL, V55, P183; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; SPADA CS, 1986, PROSTAGLANDINS, V31, P795, DOI 10.1016/0090-6980(86)90181-4; Spanbroek R, 2000, BLOOD, V96, P3857; Spinozzi F, 2004, CLIN EXP ALLERGY, V34, P1876, DOI 10.1111/j.1365-2222.2004.02119.x; STEINHILBER D, 1993, P NATL ACAD SCI USA, V90, P5984, DOI 10.1073/pnas.90.13.5984; Steinke JW, 2004, IMMUNOL ALLERGY CLIN, V24, P45, DOI 10.1016/S0889-8561(03)00108-5; Steinke JW, 2004, CURR ALLERGY ASTHM R, V4, P217, DOI 10.1007/s11882-004-0029-x; Steinke JW, 2004, AM J RESP CELL MOL, V30, P212, DOI 10.1165/rcmb.2003-00710C; Stelmach I, 2002, CLIN EXP ALLERGY, V32, P264, DOI 10.1046/j.1365-2222.2002.01286.x; Stelmach I, 2002, J ALLERGY CLIN IMMUN, V109, P257, DOI 10.1067/mai.2002.121456; STENKE L, 1993, BLOOD, V81, P352; STEVENSON DD, 1980, J ALLERGY CLIN IMMUN, V66, P82, DOI 10.1016/0091-6749(80)90143-8; Suzuki M, 2003, J ASTHMA, V40, P395, DOI 10.1081/JAS-120018709; TAKAFUJI S, 1992, EUR J IMMUNOL, V22, P969, DOI 10.1002/eji.1830220414; TAKAFUJI S, 1991, J IMMUNOL, V147, P3855; TAMURA N, 1988, J IMMUNOL, V141, P4291; TAYLOR GW, 1989, LANCET, V1, P584; TERADA N, 1989, J OTOLARYNGOL JPN, V92, P1337; Thivierge M, 2000, J IMMUNOL, V165, P5221; Thivierge M, 2001, J IMMUNOL, V167, P2855; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; TOGIAS AG, 1986, AM REV RESPIR DIS, V133, P1133; Togias Alkis, 2003, Journal of Allergy and Clinical Immunology, V112, pS60, DOI 10.1016/S0091-6749(03)01878-5; Togias Alkis G., 2000, Journal of Allergy and Clinical Immunology, V106, pS247; Tohda Y, 1999, CLIN EXP ALLERGY, V29, P1532; TOMARI S, 2003, J ENDOCRINOL, V178, P37; TUTLUOGLU B, 2000, WORLD C LUNG HLTH 10, V17; Ueda T, 2003, ANN OTO RHINOL LARYN, V112, P955; van Adelsberg J., 2003, Journal of Allergy and Clinical Immunology, V111, pS146, DOI 10.1016/S0091-6749(03)80467-0; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; Vargaftig BB, 2003, AM J RESP CELL MOL, V28, P410, DOI 10.1165/rcmb.2002-0032OC; de Graaf-int Veld C, 1996, CLIN EXP ALLERGY, V26, P903, DOI 10.1111/j.1365-2222.1996.tb00625.x8877155; Virchow JC, 2001, CLIN EXP ALLERGY, V31, P836, DOI 10.1046/j.1365-2222.2001.01051.x; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V82, P414, DOI 10.1016/0091-6749(88)90000-0; Volovitz B, 1999, J ALLERGY CLIN IMMUN, V104, P1162; WANG C, 1995, ARS COMBINATORIA, V40, P3; Wang D, 1998, ALLERGY, V53, P375, DOI 10.1111/j.1398-9995.1998.tb03908.x; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; WELLER PF, 1983, P NATL ACAD SCI-BIOL, V80, P7626, DOI 10.1073/pnas.80.24.7626; WILLIAMS JD, 1984, J IMMUNOL, V132, P3034; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P616, DOI 10.1046/j.1365-2222.2001.01088.x; WU XQ, 2005, J ALLERGY CLIN IMMUN, V115, pS56, DOI 10.1016/j.jaci.2004.12.239; YAMAMURA H, 1994, EUR J PHARMACOL, V257, P235, DOI 10.1016/0014-2999(94)90134-1	202	79	86	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2006	36	6					689	703		10.1111/j.1365-2222.2006.02498.x		15	Allergy; Immunology	Allergy; Immunology	048UX	WOS:000237973100002	16776669	
J	Bornehag, CG; Sundell, J; Hagerhed-Engman, L; Sigsgaard, T				Bornehag, CG; Sundell, J; Hagerhed-Engman, L; Sigsgaard, T			Association between ventilation rates in 390 Swedish homes and allergic symptoms in children	INDOOR AIR			English	Article						ventilation rate; homes; asthma; allergic symptoms; children	HOUSE-DUST MITE; ATOPIC-DERMATITIS; YOUNG-CHILDREN; ASTHMA; EXPOSURE; SENSITIZATION; SENSITIVITY; REDUCTION; HEALTH	The aim of the study was to test the hypothesis that a low-ventilation rate in homes is associated with an increased prevalence of asthma and allergic symptoms among children. A total of 198 cases (with at least two of three symptoms: wheezing, rhinitis, eczema) and 202 healthy controls, living in 390 homes, were examined by physicians. Ventilation rates were measured by a passive tracer gas method, and inspections were carried out in the homes. About 60% of the multi-family houses and about 80% of the single-family houses did not fulfill the minimum requirement regarding ventilation rate in the Swedish building code (0.5 air changes per hour, ach). Cases had significantly lower ventilation rates than controls and a dose-response relationship was indicated.	Karlstad Univ, SE-65188 Karlstad, Sweden; Swedish Natl Testing & Res Inst, Boras, Sweden; Tech Univ Denmark, DK-2800 Lyngby, Denmark; Univ Aarhus, Aarhus, Denmark	Bornehag, CG (reprint author), Karlstad Univ, SE-65188 Karlstad, Sweden.	carl-gustaf.bornehag@kau.se	Sundell, Jan/B-2857-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Sigsgaard, Torben/0000-0002-2043-7571			Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bornehag CG, 2004, INDOOR AIR, V14, P59, DOI 10.1111/j.1600-0668.2004.00274.x; BORNEHAG CG, 2004, INDOOR AIR; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; Emenius G., 1998, Clinical and Experimental Allergy, V28, P1389; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; Holm L, 1999, ALLERGY, V54, P708, DOI 10.1034/j.1398-9995.1999.00010.x; Nahm DH, 1998, ANN ALLERG ASTHMA IM, V80, P411; Nordtest, 1997, VENT LOC MEAN AG AIR; NORLEN U, 1995, P HLTHH BUILD 95 MIL, V1, P393; Oie L, 1998, INDOOR AIR, V8, P190, DOI 10.1111/j.1600-0668.1998.t01-1-00006.x; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Ricci G, 1999, BRIT J DERMATOL, V140, P651; Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x; Sporik R, 1999, THORAX, V54, P675; STYMNE H, 1994, BUILD ENVIRON, V29, P373, DOI 10.1016/0360-1323(94)90037-X; SUNDELL J, 1995, ALLERGY, V50, P106; SUNDELL J, 1994, INDOOR AIR S, V2, P94; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x; Warner A, 1999, ALLERGY, V54, P681, DOI 10.1034/j.1398-9995.1999.00850.x; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Weschler CJ, 2000, INDOOR AIR, V10, P92, DOI 10.1034/j.1600-0668.2000.010002092.x	23	79	82	2	22	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	AUG	2005	15	4					275	280		10.1111/j.1600-0668.2005.00372.x		6	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	939BZ	WOS:000230048500008	15982274	
J	Dakhama, A; Park, JW; Taube, C; Joetham, A; Balhorn, A; Miyahara, N; Takeda, K; Gelfand, EW				Dakhama, A; Park, JW; Taube, C; Joetham, A; Balhorn, A; Miyahara, N; Takeda, K; Gelfand, EW			The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production	JOURNAL OF IMMUNOLOGY			English	Article							CHILDHOOD ASTHMA; PULMONARY-FUNCTION; BALB/C MICE; BRONCHIOLITIS; INFANTS; IMMUNITY; ALLERGEN; DISEASE; RISK; SENSITIZATION	Respiratory syncytial virus (RSV) infection in early life is suspected to play a role in the development of postbronchiolitis wheezing and asthma. Reinfection is common at all ages, but factors that determine the development of altered airway function after reinfection are not well understood. This study was conducted in a mouse model to define the role of age in determining the consequences on airway function after reinfection. Mice were infected shortly after birth or at weaning and were reinfected 5 wk later, followed by assessment of airway function, airway inflammation, and lung histopathology. Infection of mice at weaning elicited a protective airway response upon reinfection. In this age group, reinfection resulted in increased airway inflammation, but without development of airway hyperresponsiveness (AHR) or eosinophilia and decreased IL-13 levels. By contrast, neonatal infection failed to protect the airways and resulted in enhanced AHR after reinfection. This secondary response was associated with the development of airway eosinophilia, increased IL-13 levels, and mucus hyperproduction. Both CD4- and CD8-positive T cells were a source of IL-13 in the lung, and inhibition of IL-13 abolished AHR and mucus production in these mice. Inoculation of UV-inactivated virus failed to elicit these divergent responses to reinfection, emphasizing the requirement for active lung infection during initial exposure. Thus, neonatal RSV infection predisposes to the development of airway eosinophilia and enhanced AHR via an IL-13-dependent mechanism during reinfection, whereas infection at a later age protects against the development of these altered airway responses after reinfection.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA	Dakhama, A (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA.	dakhamaa@njc.org			NHLBI NIH HHS [HL36577, HL60015]		Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263; Bont L, 2002, PEDIATR RES, V52, P363, DOI 10.1203/01.PDR.0000028458.76706.C7; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Dakhama A, 2002, AM J RESP CRIT CARE, V165, P1137, DOI 10.1164/rccm.2109058; Donaldson DD, 1998, J IMMUNOL, V161, P2317; ENGLUND JA, 1988, ANN INTERN MED, V109, P203; Gelfand EW, 2004, J IMMUNOL, V173, P1298; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; Hall C B, 1999, J Pediatr, V135, P2; HALL CB, 1976, NEW ENGL J MED, V294, P414, DOI 10.1056/NEJM197602192940803; HALL CB, 1991, J INFECT DIS, V163, P693; HALL WJ, 1978, ANN INTERN MED, V88, P203; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; Johnson TR, 1999, J VIROL, V73, P8485; KATTAN M, 1977, PEDIATRICS, V59, P683; KIMPEN JLL, 1993, CLIN EXP IMMUNOL, V91, P78; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Leader S, 2003, J PEDIATR-US, V143, pS127, DOI 10.1067/S0022-3476(03)00510-9; Legg JP, 2003, AM J RESP CRIT CARE, V168, P633, DOI 10.1164/rccm.200210-1148OC; Martinez FD, 2003, PEDIATR INFECT DIS J, V22, pS76, DOI 10.1097/00006454-200302001-00011; Miyahara N, 2004, J IMMUNOL, V172, P2549; Openshaw PJM, 2003, PEDIATR INFECT DIS J, V22, pS58, DOI 10.1097/00006454-200302001-00009; Park JW, 2003, J ALLERGY CLIN IMMUN, V112, P1078, DOI 10.1016/j.jaci.2003.08.046; PARROTT RH, 1973, AM J EPIDEMIOL, V98, P289; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594; Renzi PM, 1999, AM J RESP CRIT CARE, V159, P1417; Renzi PM, 1997, J PEDIATR-US, V130, P584, DOI 10.1016/S0022-3476(97)70243-9; Roman M, 1997, AM J RESP CRIT CARE, V156, P190; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Schwarze J, 2000, AM J RESP CRIT CARE, V162, P380; Shay DK, 2001, J INFECT DIS, V183, P16, DOI 10.1086/317655; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; SLY PD, 1989, PEDIATR PULM, V7, P153, DOI 10.1002/ppul.1950070307; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2002, J IMMUNOL, V169, P6482; Waris ME, 1996, J VIROL, V70, P2852; Welliver RC, 2003, J PEDIATR-US, V143, pS112, DOI 10.1067/S0022-3476(03)00508-0; Welliver RC, 2003, PEDIATR INFECT DIS J, V22, pS6, DOI 10.1097/00006454-200302001-00002; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004	41	79	84	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2005	175	3					1876	1883				8	Immunology	Immunology	989BN	WOS:000233648000062	16034131	
J	Prescott, SL; Tang, MLK				Prescott, SL; Tang, MLK			The Australasian Society of Clinical Immunology and Allergy position statement: summary of allergy prevention in children	MEDICAL JOURNAL OF AUSTRALIA			English	Editorial Material							HOUSE-DUST MITE; CHILDHOOD ASTHMA PREVENTION; PLACEBO-CONTROLLED TRIAL; FATTY-ACID MODIFICATION; FOLLOW-UP; LUNG-FUNCTION; SYMPTOMS; RISK; IMMUNOTHERAPY; SENSITIZATION	A family history of allergy and asthma identifies children at high risk of allergic disease. Dietary restrictions in pregnancy are not recommended. Avoiding inhalant allergens during pregnancy has not been shown to reduce allergic disease, and is not recommended. Breastfeeding should be recommended because of other beneficial effects, but if breast feeding is not possible, a hydrolysed formula is recommended (rather than conventional cow's milk formulas) in high-risk infants only. Maternal dietary restrictions during breastfeeding are not recommended. Soy formulas and other formulas (eg, goat's milk) are not recommended for reducing food allergy risk. Complementary foods (including normal cow's milk formulas) should be delayed until a child is aged at least 4-6 months, but a preventive effect from this measure has only been demonstrated in high-risk infants. There is no evidence that an elimination diet after age 4-6 months has a protective effect, although this needs additional investigation. Further research is needed to determine the relationship between house dust mite exposure at an early age and the development of sensitisation and disease; no recommendation can yet be made about avoidance measures for preventing allergic disease. No recommendations can be made about exposure to pets in early life and the development of allergic disease. If a family already has pets it is not necessary to remove them, unless the child develops evidence of pet allergy (as assessed by an allergy specialist). Women should be advised not to smoke while pregnant, and parents should be advised not to smoke. No recommendations can be made on the use of probiotic supplements (or other microbial agents) for preventing allergic disease at this time. Immunotherapy may be considered as a treatment option for children with allergic rhinitis, and may prevent the subsequent development of asthma.	Univ Western Australia, Sch Paediat & Child Hlth Res, Perth, WA 6001, Australia; Royal Childrens Hosp, Dept Immunol, Melbourne, Vic, Australia	Prescott, SL (reprint author), Univ Western Australia, Sch Paediat & Child Hlth Res, POB D184, Perth, WA 6001, Australia.	susanp@ichr.uwa.edu.au	Prescott, Susan/H-5665-2014				Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; BURR ML, 1993, ARCH DIS CHILD, V68, P724; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; Foucard T, 2000, ACTA PAEDIATR, V89, P71, DOI 10.1080/080352500750027439; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Gore C, 2004, ALLERGY, V59, P151, DOI 10.1046/j.1398-9995.2003.00358.x; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kjellman NLM, 1998, ALLERGY, V53, P67; Koopman LP, 2002, AM J RESP CRIT CARE, V166, P307, DOI 10.1164/rccm.2106026; Kramer MS, 2003, COCHRANE DB SYST REV; KRAMER MS, 2000, COCHRANE DB SYST REV, DOI UNSP CD000132; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Oddy WH, 1999, BRIT MED J, V319, P815; Osborn D. A., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003664; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Platts-Mills TA, 2000, J ALLERGY CLIN IMMUN, V105, P503; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1544, DOI 10.1046/j.1365-2222.2001.01163.x; RAM FS, 2002, COCHRANE DB SYST REV, DOI [ARTN CD003795, DOI 10.1002/14651858.CD003795]; Schoetzau A, 2002, PEDIATR ALLERGY IMMU, V13, P234, DOI 10.1034/j.1399-3038.2002.01050.x; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; ZEIGER R, 1995, J ALLERGY CLIN IMMUN, V96, P1179	26	79	84	0	4	AUSTRALASIAN MED PUBL CO LTD	SYDNEY	LEVEL 1, 76 BERRY ST, SYDNEY, NSW 2060, AUSTRALIA	0025-729X			MED J AUSTRALIA	Med. J. Aust.	MAY 2	2005	182	9					464	+				4	Medicine, General & Internal	General & Internal Medicine	933YA	WOS:000229667600010	15865590	
J	Lammintausta, K; Kortekangas-Savolainen, O				Lammintausta, K; Kortekangas-Savolainen, O			The usefulness of skin tests to prove drug hypersensitivity	BRITISH JOURNAL OF DERMATOLOGY			English	Article						drug hypersensitivity; patch test; skin test	GENERALIZED EXANTHEMATOUS PUSTULOSIS; TOPICAL PROVOCATION; CUTANEOUS REACTIONS; ADVERSE REACTIONS; DIAGNOSIS; CAPTOPRIL; EXPOSURE; ERUPTION; ALLERGY; IGE	Background Suspected drug hypersensitivity is common. Only a minority of cutaneous adverse drug reactions (CADRs) are allergic in origin and will reappear after the next exposure. Methods to confirm suspected CADRs are needed and skin testing could serve as one possibility. Objectives To analyse the usefulness of skin tests in revealing drug allergy. The relevance of skin test results was evaluated with drug provocation studies. Methods During 1989-2001, 947 patients with a history of suspected CADR were examined with skin tests including patch tests (PTs) (826 patients), skin prick tests (SPTs) (935 patients) and photopatch tests (12 patients). The occurrence of positive and negative test reactions to different drugs was correlated with clinical history. Drug provocation was carried out in 246 patients. Results Antimicrobial drugs were suspected and tested most often. A positive PT reaction to one or more drug was seen in 89 of 826 (10.8%), most often to beta-lactams, clindamycin and trimethoprim. A positive SPT reaction was seen in 10 of 935 (1.1%) patients. Challenge was carried out in 17 patients with positive skin test results. Thirteen of 16 (81.2%) PT positives developed exanthema, three remained negative and one SPT-positive patient developed urticaria. Among skin test negatives, 207 of 229 (90.4%) challenges were negative and 22 of 229 (9.6%) were positive, 12 with exanthema, three with fixed drug eruptions and seven with urticaria. Conclusions Skin testing, especially the PT, was a useful screening method to find a cause of CADR if the reaction was exanthema and if antimicrobial, cardiovascular or antiepileptic drugs were suspected. The SPT detected occasional positives with antimicrobials. In cases of fixed drug eruption, PTs performed at the earlier reaction site were useful. When skin tests are negative or dubious, oral challenge should be carried out to confirm the association.	Univ Turku, Cent Hosp, Dept Dermatol, FIN-20520 Turku, Finland	Lammintausta, K (reprint author), Univ Turku, Cent Hosp, Dept Dermatol, Pl 52, FIN-20520 Turku, Finland.	kaija.lammintausta@tyks.fi					Aberer W, 2003, ALLERGY, V58, P854, DOI 10.1034/j.1398-9995.2003.00279.x; ALANKO K, 1987, BRIT J DERMATOL, V116, P561, DOI 10.1111/j.1365-2133.1987.tb05879.x; Barbaud A, 2001, CONTACT DERMATITIS, V45, P321, DOI 10.1034/j.1600-0536.2001.450601.x; Barbaud A, 1998, BRIT J DERMATOL, V139, P49; Barbaud A, 2001, CONTACT DERMATITIS, V44, P373; Bedard K, 2000, BRIT J DERMATOL, V142, P253, DOI 10.1046/j.1365-2133.2000.03293.x; Bigby M, 2001, ARCH DERMATOL, V137, P765; Brockow K, 2002, ALLERGY, V57, P45; Cousin F, 2003, ANN DERMATOL VENER, V130, P321; Eaton L, 2002, BRIT MED J, V324, P8, DOI 10.1136/bmj.324.7328.8b; Friedmann PS, 2003, CLIN EXP ALLERGY, V33, P861, DOI 10.1046/j.1365-2222.2003.01718.x; Gaig P, 2001, J INVEST ALLERG CLIN, V11, P204; Galindo PA, 2002, J INVEST ALLERG CLIN, V12, P299; GHADIALLY R, 1988, J AM ACAD DERMATOL, V19, P428, DOI 10.1016/S0190-9622(88)70194-2; Gniazdowska B, 1999, CONTACT DERMATITIS, V40, P63, DOI 10.1111/j.1600-0536.1999.tb05992.x; Gruchalla RS, 2000, J ALLERGY CLIN IMMUN, V105, P637, DOI 10.1067/mai.2000.106156; Hari Y, 2001, CLIN EXP ALLERGY, V31, P1398, DOI 10.1046/j.1365-2222.2001.01164.x; Heikkila H, 1996, BRIT J DERMATOL, V134, P678, DOI 10.1111/j.1365-2133.1996.tb06969.x; Knowles S, 1998, J AM ACAD DERMATOL, V38, P201, DOI 10.1016/S0190-9622(98)70241-5; Lammintausta K, 2002, BRIT J DERMATOL, V146, P643, DOI 10.1046/j.1365-2133.2002.04665.x; Lee AY, 1998, CONTACT DERMATITIS, V38, P258, DOI 10.1111/j.1600-0536.1998.tb05739.x; Manfredi M, 2004, J ALLERGY CLIN IMMUN, V113, P155, DOI 10.1016/j.jaci.2003.09.035; Mashiah J, 2003, ARCH DERMATOL, V139, P1181, DOI 10.1001/archderm.139.9.1181; Naisbitt DJ, 2003, J ALLERGY CLIN IMMUN, V111, P1393, DOI 10.1067/mai.2003.1507; OSAWA J, 1990, Journal of Dermatology (Tokyo), V17, P235; Padial MA, 2004, BRIT J DERMATOL, V150, P139, DOI 10.1111/j.1365-2133.2004.05717.x; PASCUAL C, 1995, J ALLERGY CLIN IMMUN, V95, P668, DOI 10.1016/S0091-6749(95)70170-2; Pichler W, 2002, ALLERGY, V57, P884, DOI 10.1034/j.1398-9995.2002.02161.x; Pichler WJ, 2004, ALLERGY, V59, P809, DOI 10.1111/j.1398-9995.2004.00547.x; Rebollo S, 2001, CONTACT DERMATITIS, V45, P306, DOI 10.1034/j.1600-0536.2001.450516.x; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; Sandra A, 1998, CONTACT DERMATITIS, V39, P208, DOI 10.1111/j.1600-0536.1998.tb05907.x; Schnyder B, 1998, CLIN EXP ALLERGY, V28, P1412; Torres MJ, 2004, ALLERGY, V59, P219, DOI 10.1046/j.1398-9995.2003.00308.x; Watanabe K, 1996, INTERNAL MED, V35, P142, DOI 10.2169/internalmedicine.35.142; Watsky KL, 1999, ARCH DERMATOL, V135, P93, DOI 10.1001/archderm.135.1.93; Yesudian PD, 2001, CONTACT DERMATITIS, V45, P53, DOI 10.1034/j.1600-0536.2001.045001053.x	37	79	82	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	MAY	2005	152	5					968	974		10.1111/j.1365-2133.2005.06429.x		7	Dermatology	Dermatology	924XF	WOS:000229013600018	15888154	
J	Schram, D; Doekes, G; Boeve, M; Douwes, J; Riedler, J; Ublagger, E; von Mutius, E; Budde, J; Pershagen, G; Nyberg, F; Alm, J; Braun-Fahrlander, C; Waser, M; Brunekreef, B				Schram, D; Doekes, G; Boeve, M; Douwes, J; Riedler, J; Ublagger, E; von Mutius, E; Budde, J; Pershagen, G; Nyberg, F; Alm, J; Braun-Fahrlander, C; Waser, M; Brunekreef, B		PARSIFAL Study Grp	Bacterial and fungal components in house dust of farm children, Rudolf Steiner School children and reference children - the PARSIFAL Study	ALLERGY			English	Article						beta(1,3)-glucans; anthroposophy; children; endotoxin; farm; fungal extracellular polysaccharides; house dust; microbial exposure	ANTHROPOSOPHIC LIFE-STYLE; EXTRACELLULAR POLYSACCHARIDES; ALLERGIC DISEASES; CULTURABLE FUNGI; GERMAN HOMES; HAY-FEVER; ASTHMA; ENDOTOXIN; EXPOSURE; ENVIRONMENTS	Background: Growing up on a farm and an anthroposophic lifestyle are associated with a lower prevalence of allergic diseases in childhood. It has been suggested that the enhanced exposure to endotoxin is an important protective factor of farm environments. Little is known about exposure to other microbial components on farms and exposure in anthroposophic families. Objective: To assess the levels and determinants of bacterial endotoxin, mould beta(1,3)-glucans and fungal extracellular polysaccharides (EPS) in house dust of farm children, Steiner school children and reference children. Methods: Mattress and living room dust was collected in the homes of 229 farm children, 122 Steiner children and 60 and 67 of their respective reference children in five European countries. Stable dust was collected as well. All samples were analysed in one central laboratory. Determinants were assessed by questionnaire. Results: Levels of endotoxin, EPS and glucans per gram of house dust in farm homes were 1.2- to 3.2-fold higher than levels in reference homes. For Steiner children, 1.1- to 1.6-fold higher levels were observed compared with their reference children. These differences were consistently found across countries, although mean levels varied considerably. Differences between groups and between countries were also significant after adjustment for home and family characteristics. Conclusion: Farm children are not only consistently exposed to higher levels of endotoxin, but also to higher levels of mould components. Steiner school children may also be exposed to higher levels of microbial agents, but differences with reference children are much less pronounced than for farm children. Further analyses are, however, required to assess the association between exposure to these various microbial agents and allergic and airway diseases in the PARSIFAL population.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Childrens Hosp, Salzburg, Austria; Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Karolinska Inst, Inst Environm Med, Ctr Allergy Res, Div Environm Epidemiol, S-10401 Stockholm, Sweden; AstraZeneca R&D Molndal, Molndal, Sweden; Soder Hosp, Sachs Childrens Hosp, Stockholm, Sweden; Karolinska Inst, Div Clin Immunol, Stockholm, Sweden; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland	Schram, D (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.		Lauener, Roger/O-8612-2016; van Hage, Marianne/A-9678-2017	Lauener, Roger/0000-0002-8412-606X; van Hage, Marianne/0000-0003-3091-1596; Alm, Johan/0000-0002-9062-4479; Douwes, Jeroen/0000-0003-3599-4036; Pershagen, Goran/0000-0002-9701-1130; brunekreef, bert/0000-0001-9908-0060			ADACHI Y, 1994, BIOL PHARM BULL, V17, P1554; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Alm JS, 2002, PEDIATR ALLERGY IMMU, V13, P402, DOI 10.1034/j.1399-3038.2002.01062.x; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2002, ALLERGY, V57, P1094, DOI 10.1034/j.1398-9995.2002.23644.x; Chew GL, 2001, INDOOR AIR, V11, P171, DOI 10.1034/j.1600-0668.2001.011003171.x; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; GOTO H, 1994, AM J IND MED, V25, P81, DOI 10.1002/ajim.4700250121; Hinze S, 1997, INT ARCH ALLERGY IMM, V112, P231; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Omland O, 2002, ANN AGR ENV MED, V9, P119; Radon K, 2002, ANN AGR ENV MED, V9, P41; Radon K, 2000, ALLERGY, V55, P219, DOI 10.1034/j.1398-9995.2000.00461.x; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; SAKURAI T, 1994, BIOL PHARM BULL, V17, P617; Stone BA, 1992, CHEM BIOL 1 3 BETA G; SUZUKI T, 1992, J PHARMACOBIO-DYNAM, V15, P277; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; ZHANG K, 1994, J CELL BIOCHEM, V56, P225, DOI 10.1002/jcb.240560217	33	79	79	1	11	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	MAY	2005	60	5					611	618		10.1111/j.1398-9995.2005.00748.x		8	Allergy; Immunology	Allergy; Immunology	913US	WOS:000228179800007	15813805	
J	Ebeling, C; Forsythe, P; Ng, J; Gordon, JR; Hollenberg, M; Vliagoftis, H				Ebeling, C; Forsythe, P; Ng, J; Gordon, JR; Hollenberg, M; Vliagoftis, H			Proteinase-activated receptor 2 activation in the airways enhances antigen-mediated airway inflammation and airway hyperresponsiveness through different pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						proteinase-activated receptor 2; allergy; rodent; airway inflammation; eosinophils; IL-13	MICROVASCULAR ENDOTHELIAL-CELLS; EPITHELIAL-CELLS; MITE ALLERGENS; MAST-CELLS; ASTHMA; HYPERREACTIVITY; TRYPTASE; RELEASE; SENSITIZATION; INDUCTION	Background: Serine proteinases such as mast cell tryptase, trypsin-like enzymes, and certain allergens are important in the pathogenesis of asthma. These proteinases can activate the proteinase-activated receptor (PAR)-2, which has been shown to be upregulated in the airways of patients with asthma. Objective: The purpose of this study was to investigate PAR-2 activation in the airways during allergen challenge and its effects on the 2 principle features of asthma, airway inflammation and airway hyperresponsiveness (AHR). Methods: Proteinase-activated receptor 2 activating peptide SLIGRL-NH2 (PAR-2 activating peptide [ap]) or control peptide LSIGRL-NH2 (PAR-2 control peptide [cp]) was administered alone or in conjunction with ovalbumin intranasally to mice, and AHR and airway inflammation were evaluated. Results: PAR2ap did not induce AHR or airway inflammation in ovalbumin-sensitized mice that had not been challenged with ovalbumin. When administered with ovalbumin, PAR-2ap enhanced AHR and airway inflammation compared with ovalbumin administered alone or with PAR-2cp. The enhanced AHR persisted for 5 days, whereas the enhancement to airway inflammation dissipated. Mice administered PAR-2ap alone during the 5 days after the final antigen challenge demonstrated an additional enhancement to airway inflammation compared with the control animals. PAR-2ap administered with allergen increased TNF and IL-5 mRNA in lung tissue and IL-13 and TNF in bronchoalveolar lavage fluid. Conclusion: Exogenous PAR-2 activation in parallel with allergen challenge enhances allergen-mediated AHR and airway inflammation through distinct mechanisms. PAR-2 activation can also enhance established airway inflammation even when dissociated from exposure to allergen. Therefore, PAR-2 activation may play a pathogenic role in the development of AHR and airway inflammation.	Univ Alberta, Pulm Res Grp, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Saskatchewan, Immunol Res Grp, Saskatoon, SK, Canada; Univ Calgary, Dept Therapeut & Pharmacol, Calgary, AB, Canada	Vliagoftis, H (reprint author), Univ Alberta, Pulm Res Grp, Dept Med, 550 HMRC, Edmonton, AB T6G 2S2, Canada.	harissios.vliagoftis@ualberta.ca	Vliagoftis, Harissios/C-6480-2013; Gordon, John/D-7621-2013				Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Barrios VE, 2003, BIOCHEM PHARMACOL, V66, P519, DOI 10.1016/S0006-2952(03)00292-2; Berger P, 1999, CLIN EXP ALLERGY, V29, P804; Cenac N, 2002, AM J PATHOL, V161, P1903, DOI 10.1016/S0002-9440(10)64466-5; Chow JM, 2000, BRIT J PHARMACOL, V131, P1584, DOI 10.1038/sj.bjp.0703738; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Forsythe P, 2004, AM J RESP CRIT CARE, V169, P220, DOI 10.1164/rccm.200307-979OC; Gordon JR, 2000, CELL IMMUNOL, V205, P128, DOI 10.1006/cimm.2000.1714; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Haraldsen G, 1996, J IMMUNOL, V156, P2558; Hewitt CRA, 1998, ALLERGY, V53, P60; Kauffman HF, 2003, CURR ALLERGY ASTHM R, V3, P430, DOI 10.1007/s11882-003-0080-z; Klarenbach SW, 2003, CIRC RES, V92, P272, DOI 10.1161/01.RES.0000057386.15390.A3; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Lindner JR, 2000, J IMMUNOL, V165, P6504; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Miike S, 2001, J IMMUNOL, V167, P6615; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672; Schmidlin F, 2002, J IMMUNOL, V169, P5315; Schneider AM, 2001, CELL IMMUNOL, V212, P101, DOI 10.1006/cimm.2001.1854; SCHWARTZ LB, 1990, J ALLERGY CLIN IMMUN, V86, P594, DOI 10.1016/S0091-6749(05)80222-2; SEKIZAWA K, 1989, J CLIN INVEST, V83, P175, DOI 10.1172/JCI113855; Shen HD, 1999, INT ARCH ALLERGY IMM, V119, P259, DOI 10.1159/000024202; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Steinhoff M, 2000, NAT MED, V6, P151; Sun G, 2001, J IMMUNOL, V167, P1014; Vergnolle N, 1999, BRIT J PHARMACOL, V127, P1083, DOI 10.1038/sj.bjp.0702634; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Vliagoftis Harissios, 2000, Journal of Allergy and Clinical Immunology, V106, P537; Walter DM, 2001, J IMMUNOL, V167, P4668; Yang M, 2001, AM J RESP CELL MOL, V25, P522; Yawn BP, 1999, J ALLERGY CLIN IMMUN, V103, P54, DOI 10.1016/S0091-6749(99)70525-7	36	79	82	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					623	630		10.1016/j.jaci.2004.11.042		8	Allergy; Immunology	Allergy; Immunology	907AN	WOS:000227687000029	15753914	
J	Hubbell, BJ; Hallberg, A; McCubbin, DR; Post, E				Hubbell, BJ; Hallberg, A; McCubbin, DR; Post, E			Health-related benefits of attaining the 8-hr ozone standard	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; benefit analysis; health impact assessment; ozone; standards	MINNEAPOLIS ST-PAUL; AIR-POLLUTION; HOSPITAL ADMISSIONS; DAILY MORTALITY; EMERGENCY-DEPARTMENT; SCHOOL ABSENTEEISM; ASTHMA; VISITS; ASSOCIATIONS; PHILADELPHIA	During the 2000-2002 time period, between 36 and 56% of ozone monitors each year in the United States faded to meet the current ozone standard of 80 ppb for the fourth highest maximum 8-hr ozone concentration. We estimated the health benefits of attaining the ozone standard at these monitors using the U.S. Environmental Protection Agency's Environmental Benefits Mapping and Analysis Program. We used health impact functions based on published epidemiologic studies, and valuation functions derived from the economics literature. The estimated health benefits for 2000 and 2001 are similar in magnitude, whereas the results for 2002 are roughly twice that of each of the prior 2 years. The simple average of health impacts across the 3 years includes reductions of 800 premature deaths, 4,500 hospital and emergency department admissions, 900,000 school absences, and > 1 million minor restricted activity days. The simple average of benefits (including premature mortality) across the 3 years is $5.7 billion [90% confidence interval (0), 0.6-15-01 for the quadratic rollback simulation method and $4.9 billion (90% CI, 0.5-14.0) for the proportional rollback simulation method. Results are sensitive to the form of the standard and to assumptions about background ozone levels. If the form of the standard is based on the first highest maximum 8-hr concentration, impacts are increased by a factor of 2-3. Increasing the assumed hourly background from zero to 40 ppb reduced impacts by 30 and 60% for the proportional and quadratic attainment simulation methods, respectively.	US EPA, OAQPS, Innovat Strategies & Econ Grp, Res Triangle Pk, NC 27703 USA; ABT Associates Inc, Bethesda, MD USA	Hubbell, BJ (reprint author), US EPA, OAQPS, Innovat Strategies & Econ Grp, 4930 Old Page Rd, Res Triangle Pk, NC 27703 USA.	hubbell.bryan@epa.gov		Hubbell, Bryan/0000-0002-7963-3438			Adams PF, 1999, VITAL HLTH STAT, V10, P1; *AG HEALTHC RES QU, 2000, HCUPNET HEALTHCARE; Anderson HR, 2004, META ANAL TIME SERIE; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; BERGER MC, 1987, S EC J, V53, P977; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; *CDC, 2004, NATL HOSP AMB MED CA; *CDC, 2004, CDC WOND; *CDC, 2004, CTR DIS CONTR PREV; Chen L, 2000, INHAL TOXICOL, V12, P997; Chen LM, 2004, PROSTATE, V59, P1, DOI 10.1002/pros.10346; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; Dominici F., 2003, REVISED ANAL TIME SE, P9; FAIRELY D, 2003, MORTALITY AIR POLLUT, P97; FREEMAN A, 1993, MEASUREMENT ENV RES; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Gold C, 1997, LECT NOTES COMPUTER, V1340, P21; Hall JV, 2003, CONTEMP ECON POLICY, V21, P407, DOI 10.1093/cep/byp021; HARRINGTON W, 1987, J URBAN ECON, V22, P101, DOI 10.1016/0094-1190(87)90052-0; Ito K, 1996, J EXPO ANAL ENV EPID, V6, P79; Jaffe DH, 2003, ENVIRON RES, V91, P21, DOI 10.1016/S0013-9351(02)00004-X; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; KINNEY PL, 1995, INHAL TOXICOL, V7, P59, DOI 10.3109/08958379509014271; Levy JI, 2001, ENVIRON HEALTH PERSP, V109, P1215, DOI 10.1289/ehp.011091215; Moolgavkar SH, 2000, ENVIRON HEALTH PERSP, V108, P777; MOOLGAVKAR SH, 1995, EPIDEMIOLOGY, V6, P476, DOI 10.1097/00001648-199509000-00003; MOOLGAVKAR SH, 1995, INHAL TOXICOL, V7, P35, DOI 10.3109/08958379509014269; Moolgavkar SH, 1997, EPIDEMIOLOGY, V8, P364, DOI 10.1097/00001648-199707000-00003; NRC (National Research Council), 2002, EST PUBL HLTH BEN PR; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; SAMET JM, 1997, AIR POLL WEATH MORB; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; SCHWARTZ J, 1995, THORAX, V50, P531, DOI 10.1136/thx.50.5.531; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Stanford R, 1999, AM J RESP CRIT CARE, V160, P211; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Thurston GD, 2001, J EXPO ANAL ENV EPID, V11, P286, DOI 10.1038/sj.jea.7500169; TOLLEY GS, 1986, VALUING HLTH S RISKS; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177; *US BUR LAB STAT, 2004, CONS PRIC IND; U.S. Census Bureau, 2001, STAT ABSTR US; *US DEP ED, 1996, COND ED 1996; *US EPA, 1996, REV NATL AMB AIR QUA; *US EPA, 2004, EPA20R04007 WASH DC; *US EPA, 2003, 454K03001 WASH DC U; *US EPA, 1999, EPA410R99001 WASH DC; *US EPA, 2004, 45203001 EPA; *US EPA, 2004, TECHN TRANSF NETW AI; *US EPA, 1996, EPA600P93004CF US EP, V3; Vingarzan R, 2004, ATMOS ENVIRON, V38, P3431, DOI 10.1016/j.atmosenv.2004.03.030; WEISEL CP, 1995, ENVIRON HEALTH PERSP, V103, P97, DOI 10.2307/3432456; World Health Organization (WHO), 2003, EUR035042688; *WOOD POOL EC INC, 2001, POP SINGL YEAR AGE C	55	79	82	1	17	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2005	113	1					73	82				10	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	885ZQ	WOS:000226196300033	15626651	
J	Kapoor, S; Roberts, G; Bynoe, Y; Gaughan, M; Habibi, P; Lack, G				Kapoor, S; Roberts, G; Bynoe, Y; Gaughan, M; Habibi, P; Lack, G			Influence of a multidisciplinary paediatric allergy clinic on parental knowledge and rate of subsequent allergic reactions	ALLERGY			English	Article						children; education; food allergy; multidisciplinary clinic	FOOD ALLERGY; PEANUT ALLERGY; ANAPHYLACTIC REACTIONS; IGE CONCENTRATIONS; CHILDREN; MANAGEMENT; EPINEPHRINE; ADOLESCENTS; CHALLENGES; HISTORY	Background: Studies have demonstrated that families of children with food allergy have significant deficiencies in their knowledge of how to avoid allergen exposure and how to manage allergic reactions. This study aims to assess the impact of a multidisciplinary paediatric allergy clinic consultation on parental knowledge of food allergy and to determine the rate of subsequent allergic reactions. Methods: Sixty-two subjects (< 17 years) referred with food allergy were prospectively enrolled. Parental knowledge was assessed by questionnaire and EpiPen trainer. Families saw a paediatric allergist, clinical nurse specialist and dietician. Knowledge was reassessed after 3 months and rate of allergic reactions after 1 year. Results: After one visit to the paediatric allergy clinic, there was a significant improvement in parental knowledge of allergen avoidance (26.9%, P < 0.001), managing allergic reactions (185.4%, P < 0.0001) and EpiPen usage (83.3%, P < 0.001). Additionally, there was a significant reduction in allergic reactions (P < 0.001). Children with egg, milk or multiple food allergies were more likely to suffer subsequent reactions. Conclusions: A single visit to a multidisciplinary allergy clinic considerably improves families' abilities to manage allergic reactions to foods with an accompanying reduction in allergic reactions. Young children with egg, milk or multiple food allergies were at greatest risk of further reactions.	St Marys Hosp, London W2 1NY, England	Roberts, G (reprint author), St Marys Hosp, Ground Floor Salton House,Praed St, London W2 1NY, England.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Clark AT, 2003, ARCH DIS CHILD, V88, P79, DOI 10.1136/adc.88.1.79; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Gold MS, 2000, J ALLERGY CLIN IMMUN, V106, P171; Grouhi M, 1999, J ALLERGY CLIN IMMUN, V104, P190, DOI 10.1016/S0091-6749(99)70134-X; Hourihane JO, 1996, BRIT MED J, V313, P518; Huang SW, 1998, J ALLERGY CLIN IMMUN, V102, P525, DOI 10.1016/S0091-6749(98)70145-9; NICKLAS RA, 1998, J ALLERGY CLIN ALLER, V101, pS466; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Roberts G, 2000, CLIN EXP ALLERGY, V30, P1495, DOI 10.1046/j.1365-2222.2000.00960.x; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; SPORIK R, 1997, J ALLERGY CLIN IMMUN, V100, P444; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898	19	79	79	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	FEB	2004	59	2					185	191		10.1046/j.1398-9995.2003.00365.x		7	Allergy; Immunology	Allergy; Immunology	771WC	WOS:000188808200010	14763932	
J	Watanabe, J; Miyazaki, Y; Zimmerman, GA; Albertine, KH; McIntyre, TM				Watanabe, J; Miyazaki, Y; Zimmerman, GA; Albertine, KH; McIntyre, TM			Endotoxin contamination of ovalbumin suppresses murine immunologic responses and development of airway hyper-reactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ENDOTHELIAL-CELLS; TOLL-LIKE RECEPTOR-2; BACTERIAL LIPOPOLYSACCHARIDE; ESCHERICHIA-COLI; ALLERGIC-ASTHMA; KAPPA-B; MICE; HYPERRESPONSIVENESS; INFLAMMATION; EXPOSURE	The reversible airway hyper-reactivity (AHR) of asthma is modeled by sensitizing and challenging mice with aerosolized ovalbumin. However, the C57BL/6 murine strain does not display the large increase in circulating IgG and IgE antibodies found in human atopy and asthma. We found that commercial ovalbumin was contaminated with lipopolysaccharide (LPS) in amounts sufficient to fully activate endothelial cells in an in vitro assay of the first step of inflammation. Desensitization of TLR4 by LPS pretreatment suppressed the inflammatory effect of ovalbumin. The presence of LPS was occult, because it does not require serum presentation and, like the LPS of Salmonella minnesota, was not suppressed by polymyxin B. Purified ovalbumin did not activate endothelial cells in vitro; however, endotoxin-free ovalbumin was far more effective than commercial material in stimulating IgE production and respiratory dysfunction in a C57BL/6 murine model of AHR. Moreover, endotoxin-free ovalbumin induced lung inflammation with alveolar enlargement and destruction in a histologic pattern that differed from the changes caused by commercial, endotoxin-contaminated ovalbumin. Reconstitution of purified ovalbumin with S. minnesota LPS decreased lung inflammation, decreased changes in lung function, and suppressed anti-ovalbumin antibody production. We conclude endotoxin contaminates ovalbumin preparations and that endotoxin co-administration with the ovalbumin antigen creates a state of tolerance in a murine model of AHR. Co-exposure to endotoxin and antigen occurs in humans through organic dusts, so murine models of AHR may reflect the clinical situation, but models based on commercial ovalbumin do not accurately reflect the effect of protein antigen alone on animal physiology.	Univ Utah, Eccles Inst Human Genet 4130, Dept Pathol, Salt Lake City, UT 84112 USA; Univ Utah, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	McIntyre, TM (reprint author), Univ Utah, Eccles Inst Human Genet 4130, Dept Pathol, Salt Lake City, UT 84112 USA.				NHLBI NIH HHS [HL 44513, P50 HL 50153]		Albertine KH, 2002, AM J PHYSIOL-LUNG C, V283, pL219, DOI 10.1152/ajplung.00324.2001; AWADE AC, 1994, J CHROMATOGR A, V677, P279, DOI 10.1016/0021-9673(94)80156-8; Brass DM, 2003, AM J PHYSIOL-LUNG C, V285, pL755, DOI 10.1152/ajplung.00001.2003; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; CAVAILLON JM, 1986, MOL IMMUNOL, V23, P965, DOI 10.1016/0161-5890(86)90127-6; Drazen JM, 1999, CLIN EXP ALLERGY, V29, P37; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Faure E, 2001, J IMMUNOL, V166, P2018; FOTHERGI.LA, 1970, BIOCHEM J, V116, P555; Gleich GJ, 1997, P NATL ACAD SCI USA, V94, P2101, DOI 10.1073/pnas.94.6.2101; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; HEGG PO, 1979, BIOCHIM BIOPHYS ACTA, V579, P73, DOI 10.1016/0005-2795(79)90088-6; HUNT LW, 1994, AM J RESP CRIT CARE, V149, P1471; JOHNSON JR, 1992, INFECT IMMUN, V60, P578; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; [Anonymous], 1994, J ENDOTOXIN RES; McIntyre TM, 2003, CURR OPIN HEMATOL, V10, P150, DOI 10.1097/00062752-200303000-00009; Neilsen PO, 2001, J IMMUNOL, V167, P5231; Nightingale JA, 1998, THORAX, V53, P563; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Rylander R, 2002, J ENDOTOXIN RES, V8, P241, DOI 10.1179/096805102125000452; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Strohmeier GR, 2001, J IMMUNOL, V166, P2063; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394; Tapping RI, 2000, J IMMUNOL, V165, P5780; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VACHIER MC, 1995, J CHROMATOGR B, V664, P201, DOI 10.1016/0378-4347(94)00411-W; Vasquez Y R, 2000, Respir Res, V1, P82; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wilder JA, 1999, AM J RESP CELL MOL, V20, P1326; Wooten RM, 1996, J IMMUNOL, V157, P4584; Zimmerman GA, 1997, J CLIN INVEST, V100, pS3; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232	42	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42361	42368		10.1074/jbc.M307752200		8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	733FP	WOS:000185989500098	12909619	
J	Kucharewicz, I; Kowal, K; Buczko, W; Bodzenta-Lukaszyk, A				Kucharewicz, I; Kowal, K; Buczko, W; Bodzenta-Lukaszyk, A			The plasmin system in airway remodeling	THROMBOSIS RESEARCH			English	Review						plasmin system; asthma; airway remodeling	ACTIVATOR INHIBITOR TYPE-2; INDUCED PULMONARY-FIBROSIS; BRONCHOALVEOLAR LAVAGE FLUID; NECROSIS-FACTOR-ALPHA; HUMAN MAST-CELLS; HOUSE DUST MITE; HUMAN-MONOCYTES; UROKINASE RECEPTOR; 5-LIPOXYGENASE PATHWAY; NEUTROPHIL AGGREGATION	Recent studies suggest that the plasmin system plays an active role in tissue remodeling. Plasmin degrades the extracellular matrix (ECM), either directly removing glycoproteins from ECM or by activating matrix metalloproteinases (MMPs). PAI-1 blocking MMPs may prevent ECM degradation, but inhibiting fibrinolysis leads to fibrin accumulation and fibrosis. Components of the plasmin system including tissue plasminogen activator (t-PA), urokinase plasminogen activator (u-PA), and plasminogen activator inhibitors PAI-1 and PAI-2 are synthesised by airway cells, and inflammatory mediators affect their expression. The plasmin system, in turn, actively influences the production of inflammatory mediators,and growth factors, extending pathological structural changes in the airway. Modulation of the plasmin system might be a new pharmacological strategy that could inhibit the development of airway remodeling. (C) 2003 Elsevier Ltd. All rights reserved.	Med Univ Bialystok, Dept Allergol & Internal Dis, PL-15276 Bialystok, Poland; Med Acad Bialystok, Dept Pharmacodynam, PL-15230 Bialystok, Poland	Kucharewicz, I (reprint author), Med Univ Bialystok, Dept Allergol & Internal Dis, M Sklodowska Curie St 24A, PL-15276 Bialystok, Poland.	ikuchar@poczta.onet.pl; Krzysztof.9327125@pharmanet.com; pharmdyn@amab.edu.pl; alergol@amb.edu.pl					Amin K, 2000, AM J RESP CRIT CARE, V162, P2295; Bianchi E, 1996, J CLIN INVEST, V98, P1133, DOI 10.1172/JCI118896; Buckova D, 2002, ALLERGY, V57, P446; Busse W, 1999, AM J RESP CRIT CARE, V160, P1035; CASTELLOTE JC, 1990, THROMB HAEMOSTASIS, V63, P67; CHANG WC, 1993, AM J PHYSIOL, V264, pC271; CHAPMAN HA, 1982, CELL, V28, P653, DOI 10.1016/0092-8674(82)90220-3; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Cho SH, 2001, J ALLERGY CLIN IMMUN, V108, P212, DOI 10.1067/mai.2001.117260; Cho SH, 2000, J IMMUNOL, V165, P3154; CHU CT, 1993, J IMMUNOL, V150, P48; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Cunnane G, 2001, ARTHRITIS RHEUM, V44, P1744, DOI 10.1002/1529-0131(200108)44:8<1744::AID-ART309>3.0.CO;2-K; DAWSON SJ, 1993, J BIOL CHEM, V268, P10739; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; DICKINSON JL, 1995, J BIOL CHEM, V270, P27894; Eitzman DT, 1996, J CLIN INVEST, V97, P232, DOI 10.1172/JCI118396; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; FuchsBuder T, 1996, AM J RESP CRIT CARE, V153, P163; Gundersen D, 1997, J IMMUNOL, V158, P1051; GYETKO MR, 1993, J LEUKOCYTE BIOL, V53, P598; GYETKO MR, 1992, J LEUKOCYTE BIOL, V51, P256; HAMILTON JA, 1992, BLOOD, V80, P121; HAMILTON JA, 1993, BLOOD, V82, P3616; HART PH, 1989, J EXP MED, V169, P1509, DOI 10.1084/jem.169.4.1509; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; HUMMEL S, 1996, AM J RESP CRIT CARE, V153, pA315; Irvin CG, 1997, AM J PHYSIOL-LUNG C, V272, pL1053; Jacob MP, 2001, PATHOL BIOL, V49, P326, DOI 10.1016/S0369-8114(01)00151-1; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, pS28; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; JOHSON PRA, 2001, AM J RESP CRIT CARE, V163, pA270; Khalil N, 1996, AM J RESP CELL MOL, V14, P131; Khalil N, 1996, AM J RESP CELL MOL, V15, P252; Kowal-Bielecka O, 2003, ARTHRITIS RHEUM, V48, P1639, DOI 10.1002/art.11042; KRUITHOF EKO, 1986, J BIOL CHEM, V261, P1207; KRUITHOF EKO, 1988, ENZYME, V40, P113; KUMAR S, 1991, J BIOL CHEM, V266, P20960; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LEVI M, 1993, THROMB HAEMOSTASIS, V69, P141; Levi-Schaffer F, 1999, P NATL ACAD SCI USA, V96, P9660, DOI 10.1073/pnas.96.17.9660; Margaglione M, 1998, ARTERIOSCL THROM VAS, V18, P562; MARUO K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P62, DOI 10.1016/0304-4165(91)90040-N; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; Mautino G, 1997, AM J RESP CELL MOL, V17, P583; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; Montemurro P, 1999, BRIT J HAEMATOL, V107, P294, DOI 10.1046/j.1365-2141.1999.01698.x; NAGATA S, 1987, J ALLERGY CLIN IMMUN, V80, P24, DOI 10.1016/S0091-6749(87)80186-0; NYKJAER A, 1994, J IMMUNOL, V152, P505; Oh CK, 2002, BIOCHEM BIOPH RES CO, V294, P1155, DOI 10.1016/S0006-291X(02)00577-6; OKADA Y, 1995, LAB INVEST, V72, P311; Peters-Golden M, 2002, AM J RESP CRIT CARE, V165, P229; PORTNOY J, 1990, ANN ALLERGY, V65, P109; Rijneveld AW, 2002, J IMMUNOL, V168, P3507; Ritchie H, 1999, THROMB HAEMOSTASIS, V81, P96; RYAN TJ, 1992, J CELL PHYSIOL, V151, P255, DOI 10.1002/jcp.1041510206; SAKSELA O, 1985, J CELL PHYSIOL, V122, P125, DOI 10.1002/jcp.1041220119; SAMAD F, 1994, BBA-MOL CELL RES, V1221, P307, DOI 10.1016/0167-4889(94)90255-0; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469; Shetty S, 2001, J BIOL CHEM, V276, P24549, DOI 10.1074/jbc.M101605200; Shigeta O, 1997, CIRCULATION, V96, P569; Sillalber C, 1999, J IMMUNOL, V162, P1032; SIMPSON AJ, 1991, J CLIN PATHOL, V44, P139, DOI 10.1136/jcp.44.2.139; Sommerhoff CP, 2001, AM J RESP CRIT CARE, V164, pS52; STACK MS, 1994, J BIOL CHEM, V269, P9416; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEWART GA, 1989, LANCET, V2, P154; Swaisgood CM, 2000, AM J PATHOL, V157, P177, DOI 10.1016/S0002-9440(10)64529-4; Syrovets T, 2001, BLOOD, V97, P3941, DOI 10.1182/blood.V97.12.3941; Tanaka H, 2001, INFLAMM RES, V50, P616, DOI 10.1007/PL00000243; Tarlton JF, 2000, AM J PATHOL, V157, P1927, DOI 10.1016/S0002-9440(10)64831-6; Thomas VA, 1998, BIOCHEMISTRY-US, V37, P2291, DOI 10.1021/bi972119z; VANHINSBERGH VWM, 1988, HAEMOSTASIS, V18, P307; VASSALLI JD, 1991, J CLIN INVEST, V88, P1067, DOI 10.1172/JCI115405; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; Vos CMP, 2003, J NEUROIMMUNOL, V138, P106, DOI 10.1016/S0165-5728(03)00036-5; WALTZ DA, 1993, J CLIN INVEST, V91, P1541, DOI 10.1172/JCI116360; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; WEIDE I, 1994, BLOOD, V83, P1941; Wilborn J, 1996, J CLIN INVEST, V97, P1827, DOI 10.1172/JCI118612; Wojta J, 2002, BLOOD, V100, P517, DOI 10.1182/blood.V100.2.517; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yu H, 2002, BLOOD, V99, P2810, DOI 10.1182/blood.V99.8.2810; Zeldin DC, 2002, AM J RESP CRIT CARE, V165, P146; ZHANG K, 1995, AM J PATHOL, V147, P352	87	79	80	1	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0049-3848			THROMB RES	Thromb. Res.		2003	112	1-2					1	7		10.1016/j.thromres.2003.10.011		7	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	775KP	WOS:000189039700001	15013265	
J	Tomita, K; Caramori, G; Lim, S; Ito, K; Hanazawa, T; Oates, T; Chiselita, I; Jazrawi, E; Chung, KF; Barnes, PJ; Adcock, IM				Tomita, K; Caramori, G; Lim, S; Ito, K; Hanazawa, T; Oates, T; Chiselita, I; Jazrawi, E; Chung, KF; Barnes, PJ; Adcock, IM			Increased p21(CIP1/WAF1) and B cell lymphoma leukemia-x(L) expression and reduced apoptosis in alveolar macrophages from smokers	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						p21(CIP1/WAF1); monocytes/macrophages; apoptosis; cigarette smoke; epithelial cells	OXIDATIVE STRESS; CHEMOKINE RECEPTOR; CIGARETTE SMOKERS; G(1) ARREST; KAPPA-B; DEATH; DNA; P21; REPLICATION; PROTEIN	Alveolar macrophages (AMs) are the predominant defense cells in the airway, and their numbers are increased in smokers and subjects with chronic obstructive pulmonary disease. This increase may result from increased recruitment, increased proliferation, or reduced cell death. Apoptosis regulates inflammatory cell survival, and p21(CIP1/WAF1) is an important inhibitory regulator of cycle progression after oxidative stress. We have investigated whether chronic smoke exposure influences the expression and localization of cell cycle and apoptotic proteins in AM and bronchial epithelial cells in vivo. The increased numbers of AMs seen in smokers were only partially due to enhanced proliferation. p21(CIP1/WAF1) protein expression was increased in AMs and biopsies isolated from smokers and was found predominantly within the cytoplasm. In addition, B cell lymphoma leukemia (BCl)-x(L), an antiapoptotic regulator, was also highly expressed in macrophages from smokers compared with nonsmokers and subjects with asthma. Hydrogen peroxide, an oxidative stress, induced cytoplasmic expression of p21(CiP1/WAF1) and failed to induce apoptosis in an in vitro model. These results suggested that AM and bronchial epithelial cells from smokers, in contrast to those from normal subjects and subjects with asthma, have reduced cell death. Thus, oxidative stress induced by cigarette smoking may contribute to the chronicity of inflammation in the airway, through a reduction of apoptosis.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Adcock, IM (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Adcock, Ian/0000-0003-2101-8843; Chung, Kian Fan/0000-0001-7101-1426			Adcock IM, 1996, AM J RESP CRIT CARE, V154, P771; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BARBERS RG, 1991, AM REV RESPIR DIS, V143, P1092; Baumstark-Khan C, 2000, PHOTOCHEM PHOTOBIOL, V72, P477, DOI 10.1562/0031-8655(2000)072<0477:FAODUF>2.0.CO;2; BERMUDEZ E, 1994, ENVIRON HEALTH PERSP, V102, P870, DOI 10.2307/3432120; BITTERMAN PB, 1984, J CLIN INVEST, V74, P460, DOI 10.1172/JCI111443; Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798; BRODY AR, 1975, LAB INVEST, V32, P125; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen QM, 1998, BIOCHEM J, V332, P43; CORY S, 1995, ANNU REV IMMUNOL, V13, P513, DOI 10.1146/annurev.immunol.13.1.513; Delaunay A, 2000, EMBO J, V19, P5157, DOI 10.1093/emboj/19.19.5157; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Esposito F, 1997, EUR J BIOCHEM, V245, P730, DOI 10.1111/j.1432-1033.1997.00730.x; FANG W, 1995, J IMMUNOL, V155, P66; GODLESKI JJ, 1972, J EXP MED, V136, P630, DOI 10.1084/jem.136.3.630; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; Hart L, 2000, AM J RESP CRIT CARE, V161, P224; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K., 2001, FASEB Journal, V15, P1110; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; KARP JE, 1995, NAT MED, V1, P309, DOI 10.1038/nm0495-309; KORSMEYER SJ, 1995, BBA-MOL BASIS DIS, V1271, P63, DOI 10.1016/0925-4439(95)00011-R; Kurihara T, 1997, J EXP MED, V186, P1757, DOI 10.1084/jem.186.10.1757; Lee B, 1999, BLOOD, V93, P1145; Levkau B, 1998, MOL CELL, V1, P553, DOI 10.1016/S1097-2765(00)80055-6; Marques LJ, 1997, AM J RESP CRIT CARE, V156, P1700; MCCREA KA, 1994, AM J RESP CRIT CARE, V150, P696; Mehlen P, 1996, J BIOL CHEM, V271, P16510; Mitsui K, 1999, BIOCHEM BIOPH RES CO, V264, P457, DOI 10.1006/bbrc.1999.1516; Newton R, 1996, BIOCHEM BIOPH RES CO, V218, P518, DOI 10.1006/bbrc.1996.0093; Ohta T, 1998, RESP MED, V92, P922, DOI 10.1016/S0954-6111(98)90191-3; Okada S, 1998, J IMMUNOL, V160, P2590; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; STEINMAN RA, 1994, ONCOGENE, V9, P3389; THOMAS ED, 1976, SCIENCE, V192, P1016, DOI 10.1126/science.775638; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WALLACE WAH, 1992, THORAX, V47, P437, DOI 10.1136/thx.47.6.437; Xaus J, 1999, IMMUNITY, V11, P103, DOI 10.1016/S1074-7613(00)80085-0; Yang E, 1996, BLOOD, V88, P386; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.0.CO;2-Y	47	79	84	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2002	166	5					724	731		10.1164/rccm.2104010		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	588ZZ	WOS:000177734100020	12204872	
J	Levy, JI; Carrothers, TJ; Tuomisto, JT; Hammitt, JK; Evans, JS				Levy, JI; Carrothers, TJ; Tuomisto, JT; Hammitt, JK; Evans, JS			Assessing the public health benefits of reduced ozone concentrations	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						benefit-cost analysis; epidemiology; exposure assessment; monetary valuation; ozone; premature mortality	PARTICULATE AIR-POLLUTION; DAILY MORTALITY; PULMONARY-FUNCTION; AMBIENT OZONE; HOSPITAL ADMISSIONS; UNITED-STATES; LUNG-FUNCTION; BRONCHIOLAR EPITHELIUM; CARDIOVASCULAR-DISEASE; RESPIRATORY MORBIDITY	In this paper we examine scientific evidence and related uncertainties in two steps of benefit-cost analyses of ozone reduction: estimating the health improvements attributable to reductions in ozone and determining the appropriate monetary values of these improvements. Although substantial evidence exists on molecular and physiologic impacts, the evidence needed to establish concentration-response functions is somewhat limited. Furthermore, because exposure to ozone depends on factors such as air conditioning use, past epidemiologic studies may not be directly applicable in unstudied settings. To evaluate the evidence likely to contribute significantly to benefits, we focus on four health outcomes: premature mortality, chronic asthma, respiratory hospital admissions, and minor restricted activity days. We determine concentration-response functions for these health outcomes for a hypothetical case study in Houston, Texas, using probabilistic weighting reflecting our judgment of the strength of the evidence and the possibility of confounding. We make a similar presentation for valuation, where uncertainty is due primarily to the lack of willingness-to-pay data for the population affected by ozone. We estimate that the annual monetary value of health benefits from reducing ozone concentrations in Houston is approximately $10 per person per microgram per cubic meter (24-hr average) reduced (95% confidence: interval, $0.70-$40). The central estimate exceeds past estimates by approximately a factor of five, driven by the inclusion of mortality. We discuss the implications of our findings for future analyses and determine areas of research that might help reduce the uncertainties in benefit estimation.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr, Boston, MA 02215 USA; Harvard Univ, Ctr Risk Anal, Boston, MA 02215 USA; Pharsight Corp, Mt View, CA USA; Natl Publ Hlth Inst, Dept Environm Hlth, Kuopio, Finland; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02215 USA	Levy, JI (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr, POB 15677, Boston, MA 02215 USA.		Levy, Jonathan/A-9102-2008; Levy, Jon/B-4542-2011	Levy, Jon/0000-0002-1116-4006			Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; *ABT ASS, 1999, EPA420R99032 OFF AIR; *ADV COUNC CLEAN A, 1999, EPASABCOUNCILADV0000; ARTHUR WB, 1981, AM ECON REV, V71, P54; Avol EL, 1998, ENVIRON SCI TECHNOL, V32, P463, DOI 10.1021/es970351m; BEATY TH, 1985, J CHRON DIS, V38, P703, DOI 10.1016/0021-9681(85)90024-4; BENSON V, 1995, VITAL HLTH STAT, V10; Blumenschein K, 1998, ANN ALLERG ASTHMA IM, V80, P189; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, EPIDEMIOLOGY, V8, P162, DOI 10.1097/00001648-199703000-00007; BURTRAW D, 1997, 9731REV RES FUT; CHANG LY, 1992, TOXICOL APPL PHARM, V115, P241, DOI 10.1016/0041-008X(92)90329-Q; CHESTNUT LG, 1988, 2301088042 EPA OFF P; Cropper M.L., 1995, 1497 WORLD BANK; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; DOCKERY DW, 1992, ENVIRON RES, V59, P362, DOI 10.1016/S0013-9351(05)80042-8; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dudley SE, 1997, RISK ANAL, V17, P403, DOI 10.1111/j.1539-6924.1997.tb00880.x; Evans J, 1996, PARTICLES OUR AIR CO, P189; Fairley D, 1999, ENVIRON HEALTH PERSP, V107, P637, DOI 10.2307/3434455; FOLINSBEE LJ, 1988, JAPCA J AIR WASTE MA, V38, P28; Gwynn RC, 2000, ENVIRON HEALTH PERSP, V108, P125, DOI 10.2307/3454510; Hammitt JK, 2000, ENVIRON SCI TECHNOL, V34, P1396, DOI 10.1021/es990733n; HARKEMA JR, 1993, AM J PATHOL, V143, P857; HAZUCHA MJ, 1989, J APPL PHYSIOL, V67, P1535; HILL AB, 1965, P ROY SOC MED, V58, P295; Hoek G, 1997, ARCH ENVIRON HEALTH, V52, P455; Hole DJ, 1996, BRIT MED J, V313, P711; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158; Hoyert DL, 1999, NATL VITAL STAT REPO, V47; Ito K, 1996, J EXPO ANAL ENV EPID, V6, P79; Jamason PF, 1997, AM J RESP CRIT CARE, V156, P1781; Kalkstein LS, 1997, ENVIRON HEALTH PERSP, V105, P84, DOI 10.1289/ehp.9710584; KALKSTEIN LS, 1989, ANN ASSOC AM GEOGR, V79, P44, DOI 10.1111/j.1467-8306.1989.tb00249.x; KALKSTEIN LS, 1997, PUBLICATION CLIMATOL, V50; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; KINNEY PL, 1995, INHAL TOXICOL, V7, P59, DOI 10.3109/08958379509014271; Kinney PL, 1996, ENVIRON HEALTH PERSP, V104, P170, DOI 10.2307/3432785; Korrick SA, 1998, ENVIRON HEALTH PERSP, V106, P93, DOI 10.1289/ehp.9810693; KREWSKI D, 2000, PARTICLE EPIDEMIOL 2; Krupnick A., 2000, AGE HLTH WILLINGNESS; KRUPNICK AJ, 1990, J ENVIRON ECON MANAG, V18, P1, DOI 10.1016/0095-0696(90)90048-4; LANGE P, 1990, J CLIN EPIDEMIOL, V43, P867, DOI 10.1016/0895-4356(90)90070-6; LARSEN U, 1990, INT J BIOMETEOROL, V34, P136, DOI 10.1007/BF01048710; LAST JA, 1993, TOXICOLOGY, V84, P83, DOI 10.1016/0300-483X(93)90110-E; Levy JI, 2000, ENVIRON HEALTH PERSP, V108, P109, DOI 10.2307/3454508; LIPPMANN M, 2000, ASS PARTICULATE MATT; Liu LJS, 1997, ENVIRON HEALTH PERSP, V105, P58, DOI 10.1289/ehp.9710558; Lutter R, 1997, ENVIRON SCI TECHNOL, V31, pA142; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; MARIASSY AT, 1990, J APPL PHYSIOL, V68, P2504; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; Moolgavkar SH, 2000, ENVIRON HEALTH PERSP, V108, P777; MOOLGAVKAR SH, 1995, EPIDEMIOLOGY, V6, P476, DOI 10.1097/00001648-199509000-00003; Moolgavkar SH, 1996, EPIDEMIOLOGY, V7, P420, DOI 10.1097/00001648-199607000-00014; Mudway I. S., 2000, Molecular Aspects of Medicine, V21, P1, DOI 10.1016/S0098-2997(00)00003-0; Murphy S., 2000, NATL VITAL STAT REPO, V48; *NAT AC PREC ASS P, 1998, 1996 BIENN REP C INT; *NAT CLIM DAT CTR, 2000, ANN CLIM SUMM; NG YK, 1992, J ECON, V55, P1, DOI 10.1007/BF01236005; O'Conor RM, 1997, J HEALTH ECON, V16, P667, DOI 10.1016/S0167-6296(97)80198-1; OSTRO BD, 1989, ENVIRON RES, V50, P238, DOI 10.1016/S0013-9351(89)80004-0; OWINGS MF, 1999, VITAL HLTH STAT, V13; Paige R., 1999, AIR POLLUTION HLTH, P531, DOI 10.1016/B978-012352335-8/50099-5; Passannante AN, 1998, J APPL PHYSIOL, V85, P1863; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; PINKERTON KE, 1993, AM J PATHOL, V142, P947; Plopper C. G., 1991, TROPOSPHERIC OZONE E, P137; Pope CA, 1996, ENVIRON HEALTH PERSP, V104, P414, DOI 10.2307/3432686; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; POPE CA, 1995, INHAL TOXICOL, V7, P1, DOI 10.3109/08958379509014267; POWELL CV, 1994, PEDIAT PULMONOL, V18, P3; Revesz RL, 1999, COLUMBIA LAW REV, V99, P941, DOI 10.2307/1123481; Rosen S., 1988, J RISK UNCERTAINTY, V1, P285, DOI 10.1007/BF00056139; Rowe RD, 1986, EPA2300986018 OFF PO; ROWE RD, 1984, EVALUATION OZONE OXI; Ryan G, 1999, J EPIDEMIOL COMMUN H, V53, P230; Samet JM, 2000, NATL MORBIDITY MOR 2; SCHELEGLE ES, 1987, AM REV RESPIR DIS, V136, P1350; Schunemann HJ, 2000, CHEST, V118, P656, DOI 10.1378/chest.118.3.656; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; Schwartz J, 2000, AM J EPIDEMIOL, V151, P440; SCHWARTZ J, 1991, ENVIRON RES, V56, P204, DOI 10.1016/S0013-9351(05)80009-X; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; Fletcher T, 1997, HLTH CROSSROADS TRAN; SENEFF MG, 1995, JAMA-J AM MED ASSOC, V274, P1852, DOI 10.1001/jama.274.23.1852; SHEPARD DS, 1984, MANAGE SCI, V30, P423, DOI 10.1287/mnsc.30.4.423; Sherwin R. P., 1991, TROPOSPHERIC OZONE E, P178; SHUMWAY RH, 1988, ENVIRON RES, V45, P224, DOI 10.1016/S0013-9351(88)80049-5; SPEKTOR DM, 1988, AM REV RESPIR DIS, V138, P821; Thurston GD, 1996, J EXPO ANAL ENV EPID, V6, P3; Thurston GD, 2001, J EXPO ANAL ENV EPID, V11, P286, DOI 10.1038/sj.jea.7500169; Thurston GD, 1999, AIR POLLUTION HLTH, P485, DOI 10.1016/B978-012352335-8/50097-1; Tolley G., 1986, VALUATION REDUCTIONS; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177; TYLER WS, 1988, TOXICOLOGY, V50, P131, DOI 10.1016/0300-483X(88)90086-8; U.S. Environmental Protection Agency, 1997, FED REG, V62, P1; *US DEP COMM, 2000, AM HOUS SURV MSA FIL; U.S. Environmental Protection Agency, 1999, EPA410R99001 OFF AIR; *US EPA, 1996, EPA600P93004CF OFF R; *US EPA, 1996, EPA600R95148 OFF RES; *US EPA, 1997, REG IMP AN PART MATT; *US EPA, 1999, EPA420R99023 OFF AIR; Viscusi W. K., 1992, FATAL TRADEOFFS PUBL; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; YING RL, 1990, AM REV RESPIR DIS, V142, P817; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991; Zemp E, 1999, AM J RESP CRIT CARE, V159, P1257; ZHANG WW, 1994, CANCER GENE THER, V1, P4	113	79	81	3	19	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	DEC	2001	109	12					1215	1226		10.1289/ehp.011091215		12	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	526NL	WOS:000174136500029	11748028	
J	Milanese, M; Crimi, E; Scordamaglia, A; Riccio, A; Pellegrino, R; Canonica, GW; Brusasco, V				Milanese, M; Crimi, E; Scordamaglia, A; Riccio, A; Pellegrino, R; Canonica, GW; Brusasco, V			On the functional consequences of bronchial basement membrane thickening	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						airway responsiveness; remodeling; asthma; chronic obstructive pulmonary disease; rhinitis	SUBEPITHELIAL FIBROSIS; AIRWAY INFLAMMATION; INDUCED BRONCHOCONSTRICTION; ASTHMA; METHACHOLINE; DISEASE; HYPERRESPONSIVENESS; RESPONSIVENESS; MECHANISM; COLLAGEN	Reticular basement membrane (RBM) thickness and airway responses to inhaled methacholine (MCh) were studied in perennial allergic asthma (n = 11), perennial allergic rhinitis (n = 8), seasonal allergic rhinitis (n = 5), and chronic obstructive pulmonary disease (COPD, n = 9). RBM was significantly thicker in asthma (10.1 +/- 3.7 mum) and perennial rhinitis (11.2 +/- 4.2 mum) than in seasonal rhinitis (4.7 +/- 0.7 mum) and COPD (5.2 +/- 0.7 mum). The dose (geometric mean) of MCh causing a 20% decrease of 1-s forced expiratory volume (FEV1) was significantly higher in perennial rhinitis (1,073 mug) than in asthma (106 mug). In COPD, the slope of the linear regression of all values of forced vital capacity plotted against FEV1 during the challenge was higher, and the intercept less, than in other groups, suggesting enhanced airway closure. In asthma, RBM thickness was positively correlated (r = 0.77) with the dose (geometric mean) of MCh causing a 20% decrease of FEV1 and negatively correlated (r = -0.73) with the forced vital capacity vs. FEV1 slope. We conclude that 1) RBM thickening is not unique to bronchial asthma, and 2) when present, it may protect against airway narrowing and air trapping. These findings support the opinion that RBM thickening represents an additional load on airway smooth muscle.	Univ Genoa, Dipartimento Sci Motorie & Riabilitat & Med Inter, I-16132 Genoa, Italy; Azienda Osped S Croce & Carle, I-12100 Cuneo, Italy	Brusasco, V (reprint author), Univ Genoa, Dipartimento Sci Motorie & Riabilitat, Largo R Benzi 10, I-16132 Genoa, Italy.						American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; Carroll NG, 2000, AM J RESP CRIT CARE, V161, P244; Chakir J, 1996, LAB INVEST, V75, P735; Chetta A, 1996, AM J RESP CRIT CARE, V153, P910; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; Crimi E, 2001, J APPL PHYSIOL, V91, P1029; DAVIDSON PT, 1987, AM REV RESPIR DIS, V136, P255; Gibbons WJ, 1996, AM J RESP CRIT CARE, V153, P582; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; LAMBERT RK, 1991, J APPL PHYSIOL, V71, P666; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; MINK SN, 1983, J APPL PHYSIOL, V55, P897; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; Pellegrino R, 1996, J APPL PHYSIOL, V81, P964; Roche WR, 1998, AM J RESP CRIT CARE, V157, pS191; ROCHE WR, 1989, LANCET, V1, P520; Seow CY, 2000, J APPL PHYSIOL, V88, P527; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814	30	79	81	0	0	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	SEP	2001	91	3					1035	1040				6	Physiology; Sport Sciences	Physiology; Sport Sciences	464VQ	WOS:000170552800003	11509495	
J	Corsini, E; Galli, CL				Corsini, E; Galli, CL			Epidermal cytokines in experimental contact dermatitis	TOXICOLOGY			English	Article; Proceedings Paper	7th Summer School in Immunotoxicology	SEP 14-16, 1999	ARLES, FRANCE			contact dermatitis; skin irritation; contact allergy; cytokines	TUMOR-NECROSIS-FACTOR; ACTIVATED LANGERHANS CELLS; SKIN IMMUNE-SYSTEM; FACTOR-ALPHA; IN-VIVO; HUMAN KERATINOCYTES; DENDRITIC CELLS; GUINEA-PIG; TNF-ALPHA; SENSITIZATION	Topical exposure to a variety of xenobiotics may result in irritant as well as allergic contact dermatitis both in rodents and in humans. Despite their induction by different mechanisms, they cannot be differentiated by macroscopic appearance and, by histological examination they are both generally characterized by a perivascular mononuclear cell infiltrate and capillary hyperpermeability. Recently, cytokines, a family of inducible glycoproteins that play a pivotal role in immune and inflammatory reactions, have been identified as useful tools for differentiation of irritant and allergic contact dermatitis. In this article the role of cytokines in the development and differentiation of irritant and allergic contact dermatitis is discussed. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Univ Milan, Inst Pharmacol Sci, Ctr Cosmet Toxicol, Toxicol Lab, I-20133 Milan, Italy	Corsini, E (reprint author), Univ Milan, Inst Pharmacol Sci, Ctr Cosmet Toxicol, Toxicol Lab, Via Balzaretti 9, I-20133 Milan, Italy.		Corsini, Emanuela/B-5602-2011	Galli, Corrado Lodovico/0000-0003-0078-5488			AIBA S, 1990, J IMMUNOL, V145, P2791; BERARDESCA E, 1994, CONTACT DERMATITIS, V31, P281, DOI 10.1111/j.1600-0536.1994.tb02019.x; BOS JD, 1993, IMMUNOL TODAY, V14, P75, DOI 10.1016/0167-5699(93)90062-P; BUEHLER EV, 1965, ARCH DERMATOL, V91, P171; Corsini E, 1996, TOXICOL APPL PHARM, V138, P268, DOI 10.1006/taap.1996.0125; Corsini E, 1997, J INVEST DERMATOL, V108, P892, DOI 10.1111/1523-1747.ep12292696; CUMBERBATCH M, 1994, IMMUNOLOGY, V81, P395; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; ENK AH, 1993, J IMMUNOL, V150, P3698; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; GAD SC, 1986, TOXICOL APPL PHARM, V84, P93, DOI 10.1016/0041-008X(86)90419-9; Goodwin B F, 1985, Curr Probl Dermatol, V14, P201; GORDON JR, 1990, NATURE, V346, P274, DOI 10.1038/346274a0; GROVES RW, 1995, BRIT J DERMATOL, V132, P345, DOI 10.1111/j.1365-2133.1995.tb08666.x; HEUFLER C, 1988, J EXP MED, V167, P700, DOI 10.1084/jem.167.2.700; Holliday M R, 1997, Am J Contact Dermat, V8, P158, DOI 10.1016/S1046-199X(97)90097-X; Jakob T, 1998, J IMMUNOL, V160, P4067; KIMBER I, 1990, J APPL TOXICOL, V10, P173, DOI 10.1002/jat.2550100306; KIMBER I, 1996, TOXICOLOGY CONTACT H, P127; Klecak G, 1985, Curr Probl Dermatol, V14, P152; KLECAK G, 1977, J SOC COSMET CHEM, V28, P53; KOCK A, 1990, J EXP MED, V172, P1609, DOI 10.1084/jem.172.6.1609; KONDO S, 1994, LYMPHOKINE CYTOK RES, V13, P367; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; Kupper T. S., 1995, J INVEST DERMATOL, V105, p62S; LARRICK JW, 1989, J LEUKOCYTE BIOL, V45, P429; Luster ML, 1995, TOXICOL LETT, V82-3, P471, DOI 10.1016/0378-4274(95)03577-X; MacMillan F. S. K., 1975, ANIMAL MODELS DERMAT, P12; MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268; MAURER T, 1975, AGENTS ACTIONS, V5, P174, DOI 10.1007/BF02027360; Maurer T., 1996, TOXICOLOGY CONTACT H, P107; MCKENZIE RC, 1990, J INVEST DERMATOL, V95, P1055; MILLER K, 1984, INT ARCH ALLER A IMM, V75, P120; MIZUTANI H, 1991, J CLIN INVEST, V87, P1066, DOI 10.1172/JCI115067; [Anonymous], 1979, COSMET TOILETRIES; Muller G, 1996, Am J Contact Dermat, V7, P177, DOI 10.1016/S1046-199X(96)90009-3; Pape KA, 1997, J IMMUNOL, V159, P591; PIGUET PF, 1991, J EXP MED, V173, P673, DOI 10.1084/jem.173.3.673; POBER JS, 1990, PHYSIOL REV, V70, P427; ROUDABUSH RL, 1965, TOXICOL APPL PHARM, V7, P559, DOI 10.1016/0041-008X(65)90041-4; SHELLEY WB, 1976, NATURE, V261, P46, DOI 10.1038/261046a0; STREILEIN JW, 1989, J IMMUNOL, V143, P3925; TRINCHIERI G, 1993, IMMUNOL TODAY, V14, P335, DOI 10.1016/0167-5699(93)90230-I; WAHLBERG JE, 1996, TOXICOLOGY CONTACT H, P57; WHO, 1990, ENV HLTH CRIT, V116; Williams IR, 1996, LIFE SCI, V58, P1485, DOI 10.1016/0024-3205(96)00042-2; Yamazaki S, 1998, EXP DERMATOL, V7, P35, DOI 10.1111/j.1600-0625.1998.tb00300.x	47	79	83	0	9	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-483X			TOXICOLOGY	Toxicology	JAN 17	2000	142	3					203	211		10.1016/S0300-483X(99)00145-6		9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	275NN	WOS:000084826400006	10667891	
J	Schuijs, MJ; Willart, MA; Vergote, K; Gras, D; Deswarte, K; Ege, MJ; Madeira, FB; Beyaert, R; van Loo, G; Bracher, F; von Mutius, E; Chanez, P; Lambrecht, BN; Hammad, H				Schuijs, Martijn J.; Willart, Monique A.; Vergote, Karl; Gras, Delphine; Deswarte, Kim; Ege, Markus J.; Madeira, Filipe Branco; Beyaert, Rudi; van Loo, Geert; Bracher, Franz; von Mutius, Erika; Chanez, Pascal; Lambrecht, Bart N.; Hammad, Hamida			ALLERGY Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells	SCIENCE			English	Article							NF-KAPPA-B; CHILDHOOD ASTHMA; AIRWAY INFLAMMATION; MITE ALLERGEN; ENZYME A20; EXPOSURE; RESPONSES; CHILDREN; IMMUNITY; ENVIRONMENT	Growing up on a dairy farm protects children from allergy, hay fever, and asthma. A mechanism linking exposure to this endotoxin (bacterial lipopolysaccharide)-rich environment with protection has remained elusive. Here we show that chronic exposure to low-dose endotoxin or farm dust protects mice from developing house dust mite (HDM)-induced asthma. Endotoxin reduced epithelial cell cytokines that activate dendritic cells (DCs), thus suppressing type 2 immunity to HDMs. Loss of the ubiquitin-modifying enzyme A20 in lung epithelium abolished the protective effect. A single-nucleotide polymorphism in the gene encoding A20 was associated with allergy and asthma risk in children growing up on farms. Thus, the farming environment protects from allergy by modifying the communication between barrier epithelial cells and DCs through A20 induction.	[Schuijs, Martijn J.; Willart, Monique A.; Vergote, Karl; Deswarte, Kim; Madeira, Filipe Branco; Lambrecht, Bart N.; Hammad, Hamida] VIB Inflammat Res Ctr, Immunoregulat Lab, Ghent, Belgium; [Schuijs, Martijn J.; Willart, Monique A.; Vergote, Karl; Deswarte, Kim; Madeira, Filipe Branco; Lambrecht, Bart N.; Hammad, Hamida] Univ Ghent, Dept Internal Med, B-9000 Ghent, Belgium; [Gras, Delphine; Chanez, Pascal] Aix Marseille Univ, Assistance Publ Hop Marseille, Dept Resp Med, UMR INSERM U1067,CNRS 7333, Marseille, France; [Ege, Markus J.; von Mutius, Erika] Univ Munich, Dr von Hauner Childrens Hosp, D-81377 Munich, Germany; [Beyaert, Rudi; van Loo, Geert] VIB Inflammat Res Ctr, Unit Mol Signal Transduct, Ghent, Belgium; [Beyaert, Rudi; van Loo, Geert] Univ Ghent, Dept Biomed Mol Biol, B-9000 Ghent, Belgium; [Bracher, Franz] Univ Munich, Dept Pharm, Ctr Drug Res, D-81377 Munich, Germany; [Lambrecht, Bart N.] Erasmus MC, Dept Pulm Med, Rotterdam, Netherlands	Lambrecht, BN (reprint author), VIB Inflammat Res Ctr, Immunoregulat Lab, Ghent, Belgium.	bart.lambrecht@ugent.be; hamida.hammad@ugent.be	van Loo, Geert/C-1505-2009; Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014; Gras, Delphine/A-7062-2017	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834; 	European Union FP7 grant "MedALL" (Mechanisms in Development of Allergy); European Union Innovative Medicines Initiative grant "EUBIOPRED"; Flanders Organization for Scientific Research (FWO) program; European Research Council Consolidator grant; Ghent University Multidisciplinary Research Platform grant; ARARD; Fonds de Recherche en Sante Respiratoire; ANR "Mucocil"; European Union [GABRIEL: LSHB-CT-2006-018996, HERA: ERC2009-AdG_20090506_250268]; Gottfried-Wilhelm-Leibniz award from the German Research Council	The data reported in this manuscript are tabulated in the main paper and in the supplementary materials. M.J.E. and E.v.M have filed patent applications (EP000002361632B1, EP000001964570B1, and US020080305089A1) that relate to identifying microorganisms and derived substances in farm dust that induce protection from several inflammatory diseases. This research was supported by European Union FP7 grant "MedALL" (Mechanisms in Development of Allergy) and by a European Union Innovative Medicines Initiative grant "EUBIOPRED." H.H. and B.N.L. are recipients of several Flanders Organization for Scientific Research (FWO) program grants. B.N.L. is a recipient of a European Research Council Consolidator grant and a Ghent University Multidisciplinary Research Platform grant (Group-ID). D.G. and P.C. are supported by grants from ARARD, Fonds de Recherche en Sante Respiratoire, and ANR "Mucocil." Population analyses were supported by two European Union research grants (GABRIEL: LSHB-CT-2006-018996, HERA: ERC2009-AdG_20090506_250268). E.v.M is supported by a Gottfried-Wilhelm-Leibniz award from the German Research Council. M.J.E. and E.v.M. are members of the German Center for Lung Research (DZL).	Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chang YJ, 2011, J CLIN INVEST, V121, P57, DOI 10.1172/JCI44845; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; El Bakkouri K, 2005, J BIOL CHEM, V280, P17938, DOI 10.1074/jbc.M413588200; Hammad H, 2015, IMMUNITY, V43, P29, DOI 10.1016/j.immuni.2015.07.007; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Illi S, 2012, J ALLERGY CLIN IMMUN, V129, P1470, DOI 10.1016/j.jaci.2012.03.013; Kadota K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072551; Lambrecht BN, 2015, NAT IMMUNOL, V16, P45, DOI 10.1038/ni.3049; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Li XN, 2012, J ALLERGY CLIN IMMUN, V130, P861, DOI 10.1016/j.jaci.2012.04.041; Llop-Guevara A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088714; McAlees JW, 2015, MUCOSAL IMMUNOL, V8, P863, DOI 10.1038/mi.2014.117; Musone SL, 2008, NAT GENET, V40, P1062, DOI 10.1038/ng.202; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Pearce N, 2013, LANCET RESP MED, V1, P96, DOI 10.1016/S2213-2600(13)70023-7; Perl AKT, 2005, AM J RESP CELL MOL, V33, P455, DOI 10.1165/rcmb.2005-0180OC; Peters M, 2006, THORAX, V61, P134, DOI 10.1136/thx.2005.049403; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Vereecke L, 2010, J EXP MED, V207, P1513, DOI 10.1084/jem.20092474; Vereecke L, 2009, TRENDS IMMUNOL, V30, P383, DOI 10.1016/j.it.2009.05.007; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wang J, 2009, J IMMUNOL, V183, P1384, DOI 10.4049/jimmunol.0803987; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	33	78	80	13	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	SEP 4	2015	349	6252					1106	1110		10.1126/science.aac6623		5	Multidisciplinary Sciences	Science & Technology - Other Topics	CQ5FO	WOS:000360628900043	26339029	
J	Hoff, T; Weller, W; DePuccio, M				Hoff, Timothy; Weller, Wendy; DePuccio, Matthew			The Patient-Centered Medical Home: A Review of Recent Research	MEDICAL CARE RESEARCH AND REVIEW			English	Review						health care quality; literature review; patient-centered medical home; primary care; research design	PRIMARY-CARE; HEALTH-CARE; CHILDREN; ACCESS; ASTHMA; DELIVERY; SERVICES; SYSTEM; NEEDS; MODEL	The patient-centered medical home is an important innovation in health care delivery. There is a need to assess the scope and substance of published research on medical homes. This article reviews published evaluations of medical home care for the period 2007 to 2010. Chief findings from these evaluations as a whole include associations between the provision of medical home care and improved quality, in addition to decreased utilization associated with medical home care in high-cost areas such as emergency department use. However, fewer associations were found across evaluations between medical home care and enhanced patient or family experiences. The early medical home research appears to reflect both the wide variation in how medical homes are being designed and implemented in practice and in how researchers are choosing to evaluate patient-centered medical home design and implementation. While some aspects of medical home care show promise, continued evolution of medical home evaluative research is needed.	[Hoff, Timothy] SUNY Albany, Sch Publ Hlth, Rensselaer, NY 12144 USA	Hoff, T (reprint author), SUNY Albany, Sch Publ Hlth, GEC Bldg,1 Univ Pl, Rensselaer, NY 12144 USA.	thoff@albany.edu	Webster, Susan/C-7360-2015	Webster, Susan/0000-0002-0684-4226			ANDERSEN RM, 1995, J HEALTH SOC BEHAV, V36, P1, DOI 10.2307/2137284; Barr MS, 2008, JAMA-J AM MED ASSOC, V300, P834, DOI 10.1001/jama.300.7.834; Beal A, 2009, J GEN INTERN MED, V24, P514, DOI 10.1007/s11606-009-1119-1; Berenson RA, 2008, HEALTH AFFAIR, V27, P1219, DOI 10.1377/hlthaff.27.5.1219; Bitton A, 2010, J GEN INTERN MED, V25, P584, DOI 10.1007/s11606-010-1262-8; Carrier E, 2009, MED CARE, V47, P714, DOI 10.1097/MLR.0b013e3181a469b0; Coleman K., 2010, COMMONWEALTH FUND IS, V85, P1; Coleman K, 2010, ANN FAM MED, V8, P493, DOI 10.1370/afm.1190; Cooley WC, 2009, PEDIATRICS, V124, P358, DOI 10.1542/peds.2008-2600; Davis K, 2011, J GEN INTERN MED, V26, P1201, DOI 10.1007/s11606-011-1720-y; Diedhiou A, 2010, MED CARE RES REV, V67, P450, DOI 10.1177/1077558710367735; Domino ME, 2009, MED CARE, V47, P1113, DOI 10.1097/MLR.0b013e3181adcc65; Dorr DA, 2008, J AM GERIATR SOC, V56, P2195, DOI 10.1111/j.1532-5415.2008.02005.x; Ferrante JM, 2010, J AM BOARD FAM MED, V23, P736, DOI 10.3122/jabfm.2010.06.100085; Ferrante JM, 2010, ANN FAM MED, V8, P108, DOI 10.1370/afm.1080; Friedberg Mark W, 2009, Am J Manag Care, V15, pS291; Gilfillan RJ, 2010, AM J MANAG CARE, V16, P607; Hoff T, 2010, MED CARE RES REV, V67, P383, DOI 10.1177/1077558710368550; Homer CJ, 2008, PEDIATRICS, V122, pE922, DOI 10.1542/peds.2007-3762; Jaen Carlos Roberto, 2010, Ann Fam Med, V8 Suppl 1, pS57, DOI 10.1370/afm.1121; Klitzner TS, 2010, J PEDIATR-US, V156, P1006, DOI 10.1016/j.jpeds.2009.12.012; Leff B, 2009, AM J MANAG CARE, V15, P555; McGrath Robert J, 2009, Pediatrics, V124 Suppl 4, pS443, DOI 10.1542/peds.2009-1255Q; National Academy of State Health Policy, 2011, MED HOM STAT; National Committee for Quality Assurance, 2012, PCHM 2011 CONT SCOR; Patient-Centered Primary Care Collaborative, 2012, PIL DEM JOINT PRINC; Patient-Centered Primary Care Collaborative, 2012, PIL DEM; Rankin KM, 2009, AM J MED QUAL, V24, P302, DOI 10.1177/1062860609335759; Reid RJ, 2009, AM J MANAG CARE, V27, P362; Reid RJ, 2010, HEALTH AFFAIR, V29, P835, DOI 10.1377/hlthaff.2010.0158; Rittenhouse DR, 2009, NEW ENGL J MED, V361, P2301, DOI 10.1056/NEJMp0909327; Roby DH, 2010, MED CARE RES REV, V67, P412, DOI 10.1177/1077558710368682; Romaire MA, 2010, ACAD PEDIATR, V10, P338, DOI 10.1016/j.acap.2010.06.010; ROSENSTOCK IM, 1966, MILBANK FUND Q, V44, P94, DOI 10.2307/3348967; Rosenthal TC, 2008, J AM BOARD FAM MED, V21, P427, DOI 10.3122/jabfm.2008.05.070287; Scobie Andrea, 2009, Healthc Manage Forum, V22, P47; Sidorov JE, 2008, HEALTH AFFAIR, V27, P1231, DOI 10.1377/hlthaff.27.5.1231; Starfield B, 2004, PEDIATRICS, V113, P1493; Stevens GD, 2010, J ASTHMA, V47, P1001, DOI [10.1080/02770903.2010.514636, 10.3109/02770903.2010.514636]	39	78	78	3	41	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1077-5587			MED CARE RES REV	Med. Care Res. Rev.	DEC	2012	69	6					619	644		10.1177/1077558712447688		26	Health Care Sciences & Services; Health Policy & Services	Health Care Sciences & Services	032QI	WOS:000310733600001	22645100	
J	Palmer, TM; Sterne, JAC; Harbord, RM; Lawlor, DA; Sheehan, NA; Meng, S; Granell, R; Smith, GD; Didelez, V				Palmer, Tom M.; Sterne, Jonathan A. C.; Harbord, Roger M.; Lawlor, Debbie A.; Sheehan, Nuala A.; Meng, Sha; Granell, Raquel; Smith, George Davey; Didelez, Vanessa			Instrumental Variable Estimation of Causal Risk Ratios and Causal Odds Ratios in Mendelian Randomization Analyses	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						causal inference; causality; confounding factors (epidemiology); effect modifiers (epidemiology); generalized method of moments; instrumental variables; Mendelian randomization analysis; structural models	STRUCTURAL MEAN MODELS; GENERALIZED-METHOD; INFERENCE; TRIALS; IDENTIFICATION; NONCOMPLIANCE; EPIDEMIOLOGY; EQUATION; BIAS; ENDOGENEITY	In this paper, the authors describe different instrumental variable (IV) estimators of causal risk ratios and odds ratios with particular attention to methods that can handle continuously measured exposures. The authors present this discussion in the context of a Mendelian randomization analysis of the effect of body mass index (BMI; weight (kg)/height (m)(2)) on the risk of asthma at age 7 years (Avon Longitudinal Study of Parents and Children, 19911992). The authors show that the multiplicative structural mean model (MSMM) and the multiplicative generalized method of moments (MGMM) estimator produce identical estimates of the causal risk ratio. In the example, MSMM and MGMM estimates suggested an inverse relation between BMI and asthma but other IV estimates suggested a positive relation, although all estimates had wide confidence intervals. An interaction between the associations of BMI and fat mass and obesity-associated (FTO) genotype with asthma explained the different directions of the different estimates, and a simulation study supported the observation that MSMM/MGMM estimators are negatively correlated with the other estimators when such an interaction is present. The authors conclude that point estimates from various IV methods can differ in practical applications. Based on the theoretical properties of the estimators, structural mean models make weaker assumptions than other IV estimators and can therefore be expected to be consistent in a wider range of situations.	[Palmer, Tom M.; Lawlor, Debbie A.; Smith, George Davey] Univ Bristol, Sch Social & Community Med, MRC Ctr Causal Anal Translat Epidemiol, Bristol BS8 2BN, Avon, England; [Sheehan, Nuala A.; Meng, Sha] Univ Leicester, Coll Med, Dept Hlth Sci, Leicester, Leics, England; [Sheehan, Nuala A.; Meng, Sha] Univ Leicester, Dept Genet, Coll Med, Leicester LE1 7RH, Leics, England; [Didelez, Vanessa] Univ Bristol, Sch Math, Fac Sci, Bristol BS8 2BN, Avon, England	Palmer, TM (reprint author), Univ Bristol, Sch Social & Community Med, MRC Ctr Causal Anal Translat Epidemiol, Oakfield House, Bristol BS8 2BN, Avon, England.	tom.palmer@bristol.ac.uk	Harbord, Roger/A-8699-2008; Davey Smith, George/A-7407-2013	Harbord, Roger/0000-0002-2257-8271; Davey Smith, George/0000-0002-1407-8314; Monsalve, Beatriz Elena/0000-0002-5994-866X; Palmer, Tom/0000-0003-4655-4511; Lawlor, Debbie A/0000-0002-6793-2262	Medical Research Council (MRC) [G0601625]; MRC Centre for Causal Analyses in Translational Epidemiology [G0600705]; Wellcome Trust	This work was funded by the Medical Research Council (MRC) Collaborative Project (grant G0601625). Drs. Tom M. Palmer, Debbie A. Lawlor, and George Davey Smith are employed by the MRC Centre for Causal Analyses in Translational Epidemiology, which funds Dr. Palmer's salary (MRC grant G0600705). The MRC, the Wellcome Trust, and the University of Bristol provide core funding support for the Avon Longitudinal Study of Parents and Children (ALSPAC).	Abadie A, 2003, J ECONOMETRICS, V113, P231, DOI 10.1016/S0304-4076(02)00201-4; Angrist JD, 1996, J AM STAT ASSOC, V91, P444, DOI 10.2307/2291629; Angrist JD, 2001, J BUS ECON STAT, V19, P2, DOI 10.1198/07350010152472571; BASMANN RL, 1957, ECONOMETRICA, V25, P77, DOI 10.2307/1907743; BLUNDELL RW, 1989, REV ECON STUD, V56, P37, DOI 10.2307/2297748; BLUNDELL RW, 2003, ADV EC ECONOMETRICS, P312, DOI 10.1017/CCOL0521818737.010; Bowden J, 2011, STAT MED, V30, P678, DOI 10.1002/sim.4138; Cameron A.C., 2005, MICROECONOMETRICS ME; Clarke P, 2009, 09209 U BRIST CTR MA; Clarke PS, 2010, BIOSTATISTICS, V11, P756, DOI 10.1093/biostatistics/kxq024; Cowell R. G., 1999, PROBABILISTIC NETWOR; Dhrymes P., 1970, ECONOMETRICS STAT FD; Didelez V, 2007, STAT METHODS MED RES, V16, P309, DOI 10.1177/0962280206077743; Didelez V, 2010, STAT SCI, V25, P22, DOI 10.1214/09-STS316; FIELLER EC, 1954, J ROY STAT SOC B, V16, P175; Fischer-Lapp K, 1999, CONTROL CLIN TRIALS, V20, P531, DOI 10.1016/S0197-2456(99)00027-6; Foster EM, 1997, SOC SCI RES, V26, P487, DOI 10.1006/ssre.1997.0606; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; GAREN J, 1984, ECONOMETRICA, V52, P1199, DOI 10.2307/1910996; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Greene W., 2008, ECONOMETRIC ANAL; Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722; Han ZF, 2010, NATURE, V464, P1205, DOI 10.1038/nature08921; HANSEN LP, 1982, ECONOMETRICA, V50, P1029, DOI 10.2307/1912775; Hernan MA, 2006, EPIDEMIOLOGY, V17, P360, DOI 10.1097/01.ede.0000222409.00878.37; Johnston KM, 2008, STAT MED, V27, P1539, DOI 10.1002/sim.3036; Lawlor DA, 2008, STAT MED, V27, P1133, DOI 10.1002/sim.3034; MULLAHY J, 1997, REV ECON STAT, V79, P568; Nagelkerke N, 2000, STAT MED, V19, P1849, DOI 10.1002/1097-0258(20000730)19:14<1849::AID-SIM506>3.0.CO;2-1; NICHOLS A, 2006, 5 N AM STAT US GROUP; Nichols A, 2007, IVPOIS STATA MODULE; Palmer TM, 2008, INT J EPIDEMIOL, V37, P1161, DOI 10.1093/ije/dyn080; Pearl J, 1995, BIOMETRIKA, V82, P669, DOI 10.1093/biomet/82.4.669; Pearl J., 2000, CAUSALITY MODELS REA; Rassen JA, 2009, AM J EPIDEMIOL, V169, P273, DOI 10.1093/aje/kwn299; RIVERS D, 1988, J ECONOMETRICS, V39, P347, DOI 10.1016/0304-4076(88)90063-2; Robins J, 2004, BIOMETRIKA, V91, P763, DOI 10.1093/biomet/91.4.763; ROBINS JM, 1994, COMMUN STAT THEORY, V23, P2379, DOI 10.1080/03610929408831393; Robins JM, 1989, HLTH SERVICE RES MET, P113; Robins JM, 1997, LECT NOTES STAT, P69; Robins JM, 1999, STAT MODELS EPIDEMIO, P1; Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Smith GD, 2007, PLOS MED, V4, P1985, DOI 10.1371/journal.pmed.0040352; Smith GD, 2010, PERSPECT PSYCHOL SCI, V5, P527, DOI 10.1177/1745691610383505; SMITH RJ, 1986, ECONOMETRICA, V54, P679, DOI 10.2307/1911314; [Anonymous], 2010, STAT STAT SOFTW REL; Stock JH, 2002, J BUS ECON STAT, V20, P518, DOI 10.1198/073500102288618658; Terza JV, 2008, J HEALTH ECON, V27, P531, DOI 10.1016/j.jhealeco.2007.09.009; Theil H., 1953, REPEATED LEAST SQUAR; Thomas DC, 2004, INT J EPIDEMIOL, V33, P21, DOI 10.1093/ije/dyh048; Thomas DC, 2007, ANN EPIDEMIOL, V17, P511, DOI 10.1016/j.annepidem.2006.12.005; Thompson JR, 2003, 2003GE1 U LEIC DEP H; Vansteelandt S, 2003, J ROY STAT SOC B, V65, P817, DOI 10.1046/j.1369-7412.2003.00417.x; Wald A, 1940, ANN MATH STAT, V11, P284, DOI 10.1214/aoms/1177731868; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Windmeijer F., 2006, CWP2106 CTR MICR MET; Windmeijer F., 2002, CWP1402 CTR MICR MET; Windmeijer FAG, 1997, J APPL ECONOMET, V12, P281; Wooldridge JM, 1997, ECON LETT, V56, P129, DOI 10.1016/S0165-1765(97)81890-3; Wooldridge J.M., 1997, HDB APPL ECONOMETRIC; Wooldridge JM, 2002, ECONOMETRIC ANAL CRO	62	78	78	0	14	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUN 15	2011	173	12					1392	1403		10.1093/aje/kwr026		12	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	775UK	WOS:000291488700007	21555716	
J	Ober, C; Vercelli, D				Ober, Carole; Vercelli, Donata			Gene-environment interactions in human disease: nuisance or opportunity?	TRENDS IN GENETICS			English	Review							EARLY RESPIRATORY-INFECTIONS; GENOME-WIDE ASSOCIATION; QUANTITATIVE TRAIT LOCI; TOBACCO-SMOKE EXPOSURE; CHILDHOOD ASTHMA; AIR-POLLUTION; LUNG-FUNCTION; HAY-FEVER; OCCUPATIONAL ASTHMA; HYGIENE HYPOTHESIS	Many environmental risk factors for common, complex human diseases have been revealed by epidemiologic studies, but how genotypes at specific loci modulate individual responses to environmental risk factors is largely unknown. Gene-environment interactions will be missed in genome-wide association studies and could account for some of the 'missing heritability' for these diseases. In this review, we focus on asthma as a model disease for studying gene-environment interactions because of relatively large numbers of candidate gene-environment interactions with asthma risk in the literature. Identifying these interactions using genome-wide approaches poses formidable methodological problems, and elucidating molecular mechanisms for these interactions has been challenging. We suggest that studying gene-environment interactions in animal models, although more tractable, might not be sufficient to shed light on the genetic architecture of human diseases. Lastly, we propose avenues for future studies to find gene environment interactions.	[Ober, Carole] Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; [Vercelli, Donata] Univ Arizona, Arizona Program Biol Complex Dis, Arizona Resp Ctr, Tucson, AZ 85719 USA; [Vercelli, Donata] Univ Arizona, Dept Cell Biol, Inst BIO5, Tucson, AZ 85719 USA	Ober, C (reprint author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu; donata@arc.arizona.edu			National Institutes of Health [HL085197, HL70831, HL101651, HL100800, HL66391, AI076715]	This work was supported by National Institutes of Health grants HL085197, HL70831, HL101651 to C.O. and HL100800, HL66391, AI076715 to D.V. The authors acknowledge S.A. Willis-Owen and W. Valdar for first using the expression 'nuisance or opportunity' in the context of GEIs in their 2009 review and F.D. Martinez, J.E. Gem, R.J. Lemanske, E. von Mutius and M. Ege for helpful discussions. The authors apologize to those investigators whose work was not cited owing to space constraints.	ABDULRAZZAQ YM, 1994, ALLERGY, V49, P737, DOI 10.1111/j.1398-9995.1994.tb02096.x; Aschard H, 2009, GENES IMMUN, V10, P559, DOI 10.1038/gene.2009.46; Aslund C, 2011, BEHAV GENET, V41, P262, DOI 10.1007/s10519-010-9356-y; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bardana EJ, 2008, J ALLERGY CLIN IMMUN, V121, pS408, DOI 10.1016/j.jaci.2007.08.005; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Cameron L, 2006, J IMMUNOL, V177, P8633; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Choi JH, 2009, INT ARCH ALLERGY IMM, V150, P156, DOI 10.1159/000218118; Cole SW, 2010, P NATL ACAD SCI USA, V107, P5681, DOI 10.1073/pnas.0911515107; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Dizier MH, 2007, EUR J HUM GENET, V15, P810, DOI 10.1038/sj.ejhg.5201830; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Dykewicz MS, 2009, J ALLERGY CLIN IMMUN, V123, P519, DOI 10.1016/j.jaci.2009.01.061; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Garantziotis S, 2010, ANNU REV PUBL HEALTH, V31, P37, DOI 10.1146/annurev.publhealth.012809.103633; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gerke J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001144; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gern JE, 2002, AM J MED, V112, p19S; Gibson G, 2010, NAT GENET, V42, P558, DOI 10.1038/ng0710-558; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Gomez LM, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.042; Gonzalgo ML, 1997, MUTAT RES-REV MUTAT, V386, P107, DOI 10.1016/S1383-5742(96)00047-6; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Holberg CJ, 1998, AM J RESP CRIT CARE, V158, P162; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Hunninghake GM, 2008, AM J RESP CRIT CARE, V177, P830, DOI 10.1164/rccm.200711-1697OC; Islam T, 2007, THORAX, V62, P957, DOI 10.1136/thx.2007.078964; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnston S L, 1997, Pediatr Pulmonol Suppl, V16, P88; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Kim SH, 2008, PHARMACOGENOMICS, V9, P85, DOI 10.2217/14622416.9.1.85; Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y; Korstanje R, 2004, J LIPID RES, V45, P881, DOI 10.1194/jlr.M300460-JLR200; Kubzansky LD, 2006, THORAX, V61, P863, DOI 10.1136/thx.2005.050971; Lanktree MB, 2009, GENOME MED, V1, DOI 10.1186/gm28; LeVan TD, 2001, J IMMUNOL, V167, P5838; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Mackay TFC, 2010, PHILOS T R SOC B, V365, P1229, DOI 10.1098/rstb.2009.0315; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murcray CE, 2009, AM J EPIDEMIOL, V169, P219, DOI 10.1093/aje/kwn353; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Ober C, 2008, NAT REV GENET, V9, P911, DOI 10.1038/nrg2415; Ober C, 2006, CURR ALLERGY ASTHM R, V6, P241, DOI 10.1007/s11882-006-0041-4; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pacheco KA, 2010, J ALLERGY CLIN IMMUN, V126, P232, DOI 10.1016/j.jaci.2010.04.019; Panasevich S, 2010, CLIN EXP ALLERGY, V40, P458, DOI 10.1111/j.1365-2222.2010.03452.x; Park CC, 2008, NAT GENET, V40, P421, DOI 10.1038/ng.113; PATTEMORE PK, 1992, CLIN EXP ALLERGY, V22, P325, DOI 10.1111/j.1365-2222.1992.tb03094.x; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, pe101; PIVNIOUK V, 2010, J IMMUNOL, V184; Ponsonby AL, 1999, THORAX, V54, P664; Raby BA, 2007, HUM MOL GENET, V16, P243, DOI 10.1093/hmg/ddl447; Ramadas RA, 2007, EUR RESPIR J, V29, P502, DOI 10.1183/09031936.00029506; Reijmerink NE, 2009, ALLERGY, V64, P898, DOI 10.1111/j.1398-9995.2009.01939.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rogers AJ, 2009, CLIN EXP ALLERGY, V39, P1721, DOI 10.1111/j.1365-2222.2009.03372.x; Romanoski CE, 2010, AM J HUM GENET, V86, P399, DOI 10.1016/j.ajhg.2010.02.002; Sadeghnejad A, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-2; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schwartz J, 2004, PEDIATRICS, V113, P1037; Seibold MA, 2008, HUM MOL GENET, V17, P2681, DOI 10.1093/hmg/ddn168; Sheikh Aziz, 2004, Curr Opin Otolaryngol Head Neck Surg, V12, P232, DOI 10.1097/01.moo.0000122311.13359.30; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2010, EUR RESPIR J, V36, P57, DOI 10.1183/09031936.00154509; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; Taneda S, 2001, AM J PATHOL, V159, P2355, DOI 10.1016/S0002-9440(10)63085-4; Thomsen SF, 2010, J ALLERGY CLIN IMMUN, V126, P626, DOI 10.1016/j.jaci.2010.06.017; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Tsai CT, 2009, ATHEROSCLEROSIS, V203, P249, DOI 10.1016/j.atherosclerosis.2008.06.004; Ueno T, 2004, PHYSIOL GENOMICS, V17, P38, DOI 10.1152/physiolgenomics.00043.2003; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; Vercelli D, 2006, CURR OPIN IMMUNOL, V18, P733, DOI 10.1016/j.coi.2006.09.002; Vercelli D, 2010, CURR OPIN ALLERGY CL, V10, P145, DOI 10.1097/ACI.0b013e32833653d7; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; VONEHRENSTEIN US, 2000, CLIN EXP ALLERGY, V30, P187; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Weiss LA, 2006, NAT GENET, V38, P218, DOI 10.1038/ng1726; Wellcome Trust Case Control Consortium, 2007, NATURE, V447, P661, DOI DOI 10.1038/NATURE05911; Wenten M, 2009, AM J EPIDEMIOL, V170, P1494, DOI 10.1093/aje/kwp310; Willis-Owen SAG, 2009, J ALLERGY CLIN IMMUN, V123, P14, DOI 10.1016/j.jaci.2008.09.016; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Wu T, 2010, HUM GENET, V128, P401, DOI 10.1007/s00439-010-0863-y; Yang JA, 2010, NAT GENET, V42, P565, DOI 10.1038/ng.608; Zambelli-Weiner A, 2005, J ALLERGY CLIN IMMUN, V115, P1203, DOI 10.1016/j.jaci.2005.03.001	115	78	81	2	23	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0168-9525			TRENDS GENET	Trends Genet.	MAR	2011	27	3					107	115		10.1016/j.tig.2010.12.004		9	Genetics & Heredity	Genetics & Heredity	739BB	WOS:000288685900004	21216485	
J	Cheraghi, M; Salvi, S				Cheraghi, Maria; Salvi, Sundeep			Environmental tobacco smoke (ETS) and respiratory health in children	EUROPEAN JOURNAL OF PEDIATRICS			English	Review						Environmental tobacco smoke (ETS); Asthma; Respiratory tract infection; Children	INFANT-DEATH-SYNDROME; ACTIVE MATERNAL SMOKING; CHILDHOOD LUNG-FUNCTION; AGE 5 YEARS; PARENTAL SMOKING; PASSIVE SMOKING; RISK-FACTORS; 1ST YEAR; POSTNATAL EXPOSURE; FAMILY-HISTORY	Environmental tobacco smoke (ETS) is a major risk factor for poor lung health in children. Although parental smoking is the commonest source of ETS exposure to children, they are also exposed to ETS in schools, restaurants, public places and public transport vehicles. Apart from containing thousands of chemicals, the particle size in the ETS is much smaller than the main stream smoke, and therefore has a greater penetrability in the airways of children. Exposure to ETS has been shown to be associated with increased prevalence of upper respiratory tract infections, wheeze, asthma and lower respiratory tract infections. Even developing fetuses are exposed to ETS via the umbilical cord blood if the mother is exposed to tobacco smoke. The placenta also does not offer any barrier to the penetration of ETS into the fetus. The immune system in these babies is more deviated toward the allergic and asthmatic inflammatory phenotype and therefore makes them more prone to develop asthma later in life. An increased awareness of the harmful effects of ETS on children's health is warranted.	[Cheraghi, Maria; Salvi, Sundeep] Chest Res Fdn, Pune 411014, Maharashtra, India; [Cheraghi, Maria] Univ Pune, Sch Hlth Sci, Pune, Maharashtra, India	Cheraghi, M (reprint author), Chest Res Fdn, Pune 411014, Maharashtra, India.	mariac@crfindia.com					Adair-Bischoff CE, 1998, ARCH PEDIAT ADOL MED, V152, P127; Al Mamun A, 2006, TOB CONTROL, V15, P452, DOI 10.1136/tc.2006.016790; Babu K Suresh, 2003, Paediatr Respir Rev, V4, P40; Besaratinia A, 2008, LANCET ONCOL, V9, P657, DOI 10.1016/S1470-2045(08)70172-4; Blizzard L, 2003, AM J PUBLIC HEALTH, V93, P482, DOI 10.2105/AJPH.93.3.482; Boffetta P, 2000, ENVIRON HEALTH PERSP, V108, P73, DOI 10.2307/3454298; Brower V, 2006, J NATL CANCER I, V98, P667, DOI 10.1093/jnci/djj221; BROWN RW, 1995, PEDIATR PULM, V19, P23, DOI 10.1002/ppul.1950190105; Burr M L, 1999, Pediatr Pulmonol Suppl, V18, P3; Castellazzi AM, 1999, J ALLERGY CLIN IMMUN, V103, P172, DOI 10.1016/S0091-6749(99)70542-7; Chen Y, 1996, EPIDEMIOLOGY, V7, P536, DOI 10.1097/00001648-199609000-00015; Cnattingius S, 2004, NICOTINE TOB RES, V6, pS125, DOI 10.1080/14622200410001669187; Cook DG, 1998, THORAX, V53, P295; Cook DG, 1998, THORAX, V53, P884; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; DOLL R, 1994, BRIT MED J, V309, P901; ESKENAZI B, 1995, AM J EPIDEMIOL, V142, pS19; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P991; ESKENAZI B, 1995, AM J EPIDEMIOL, V142, pS10; EY JL, 1995, PEDIATRICS, V95, P670; Frazer-Abel AA, 2004, J PHARMACOL EXP THER, V311, P758, DOI 10.1124/jpet.104.070060; Fryer A A, 1999, IARC Sci Publ, P303; GERGEN PJ, 1998, PEDIATRICS, V101, P8; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Goksor E, 2007, ACTA PAEDIATR, V96, P1030, DOI 10.1111/j.1651-2227.2007.00296.x; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gurkan F, 2000, EUR J EPIDEMIOL, V16, P465, DOI 10.1023/A:1007658411953; HAGLUND B, 1995, AM J EPIDEMIOL, V142, P619; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Hayes JD, 2000, PHARMACOLOGY, V61, P154, DOI 10.1159/000028396; Hugg T., 2007, EUR J PUBLIC HEALTH, V18, P55; Iyengar GV, 2001, SCI TOTAL ENVIRON, V280, P221, DOI 10.1016/S0048-9697(01)00827-0; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Jaakkola JJK, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-48; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; JAAKKOLA MS, 2000, RESP EPIDEMIOLOGY EU, V15, P322; Jauniaux E, 1999, OBSTET GYNECOL, V93, P25, DOI 10.1016/S0029-7844(98)00318-4; Jedrychowski W, 1997, ENVIRON HEALTH PERSP, V105, P302, DOI 10.1289/ehp.97105302; Jindal SK, 2004, INDIAN J MED RES, V120, P443; JINOT J, 1994, J CLIN EPIDEMIOL, V47, P339, DOI 10.1016/0895-4356(94)90154-6; Johansson A, 2008, ACTA PAEDIATR, V97, P354, DOI 10.1111/j.1651-2227.2007.00619.x; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; KESKINOGLU P, 2007, J TROP PEDIATRICS, V53, P569; Keskinoglu P, 2007, EUR J PEDIATR, V166, P455, DOI 10.1007/s00431-006-0263-4; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P795, DOI 10.1001/jama.273.10.795; Knight JM, 1998, J ASTHMA, V35, P113, DOI 10.3109/02770909809055412; Kum-Nji P, 2006, PEDIATRICS, V117, P1745, DOI 10.1542/peds.2005-1886; Lacayo CI, 2001, CLIN PHARMACOL THER, V69, pP95; Lambers DS, 1996, SEMIN PERINATOL, V20, P115, DOI 10.1016/S0146-0005(96)80079-6; Lanari M, 2002, PEDIATR PULM, V33, P458, DOI 10.1002/ppul.10052; LANDRIGAN PJ, 1995, FUTURE CHILD, V5, P34, DOI 10.2307/1602356; Larsson ML, 2001, CHEST, V120, P711, DOI 10.1378/chest.120.3.711; Law BJ, 2002, RESP MED, V96, pS1, DOI 10.1053/rmed.2002.1294; Lee W, 2002, PEDIATRICS, V110, P445; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; LICHTENSTEIGER W, 1988, PROG BRAIN RES, V73, P137; Lindbohm ML, 2002, SCAND J WORK ENV HEA, V28, P84; Majeed R, 2008, JCPSP-J COLL PHYSICI, V18, P299, DOI 05.2008/JCPSP.299302; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; Manuel J S, 2000, Environ Health Perspect, V108, pA30, DOI 10.1289/ehp.108-a30a; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Message SD, 2002, BRIT MED BULL, V61, P29, DOI 10.1093/bmb/61.1.29; Mishra V, 2005, POPUL ENVIRON, V26, P375, DOI 10.1007/s1111-005-0005-y; MITCHELL EA, 1993, PEDIATRICS, V91, P893; Moore M L, 2000, J Perinatol, V20, P176, DOI 10.1038/sj.jp.7200336; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; Moya J, 2004, PEDIATRICS, V113, P996; Mucci LA, 2004, CANCER EPIDEM BIOMAR, V13, P1528; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; Nanavaty U, 2001, AM J MED SCI, V321, P11, DOI 10.1097/00000441-200101000-00003; Numabe Y, 1998, Ann Periodontol, V3, P102, DOI 10.1902/annals.1998.3.1.102; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885; *OFF ENV HLTH HAZ, 2005, HLTH EFF ASS ENV TOB; Pabst MJ, 1995, J PERIODONTOL, V66, P1047; Palmer CNA, 2006, PEDIATRICS, V118, P710, DOI 10.1542/peds.2005-3030; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; PETO R, 1994, MORTALITY SMOKING DE; Rice D, 2000, ENVIRON HEALTH PERSP, V108, P511, DOI 10.2307/3454543; Roth MD, 2004, J NEUROIMMUNOL, V147, P82, DOI 10.1016/j.jneuroim.2003.10.017; Rudell B, 1999, OCCUP ENVIRON MED, V56, P527; Rylander R, 2000, ARCH ENVIRON HEALTH, V55, P300; Sasco AJ, 1999, HUM EXP TOXICOL, V18, P192, DOI 10.1191/096032799678839905; Schwartz J, 2000, AM J RESP CRIT CARE, V161, P802; Seeman JI, 2008, FOOD CHEM TOXICOL, V46, P1863, DOI 10.1016/j.fct.2008.02.021; Seymour BWP, 1997, J IMMUNOL, V159, P6169; Sheikh S, 1999, CHEST, V116, P52, DOI 10.1378/chest.116.1.52; Shields PG, 2000, J CLIN ONCOL, V18, P2309; SHIONO PH, 1986, TERATOLOGY, V34, P65, DOI 10.1002/tera.1420340109; SPITZER WO, 1990, CLIN INVEST MED, V13, P17; STANWELLSMITH RE, 1994, EPIDEMIOL INFECT, V112, P315; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Stillman F, 2007, TOB CONTROL, V16, P229, DOI 10.1136/tc.2006.018333; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1997, THORAX, V52, P905; Suarez-Varela MMM, 1999, EUR J EPIDEMIOL, V15, P35; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; Tamburlini G, 2002, CHILDRENS HLTH ENV R; [US Department of Health and Human Services Centers for Disease Control and Prevention National Centre for Health Statistics], 2004, DHHS PUB; U.S. Environmental Protection Agency, 1992, EPA600690006F; Vahidnia F, 2008, SEIZURE-EUR J EPILEP, V17, P320, DOI 10.1016/j.seizure.2007.10.003; Vardavas CI, 2006, EUR J PEDIATR, V165, P891, DOI 10.1007/s00431-006-0196-y; Vork KL, 2007, ENVIRON HEALTH PERSP, V115, P1394, DOI 10.1289/ehp.10155; Warren Charles W., 2008, Morbidity and Mortality Weekly Report, V57, P1; Weiss ST, 1999, CLIN EXP ALLERGY, V29, P96, DOI 10.1046/j.1365-2222.1999.00017.x; WEITZMAN M, 1992, PEDIATRICS, V90, P342; Wisborg K, 2000, ARCH DIS CHILD, V83, P203, DOI 10.1136/adc.83.3.203; Wu FY, 2008, PAEDIATR PERINAT EP, V22, P296, DOI 10.1111/j.1365-3016.2008.00927.x; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; Zhang SB, 1996, INT J IMMUNOPHARMACO, V18, P467, DOI 10.1016/S0192-0561(96)00054-9; Zlotkowska R, 2005, EUR J EPIDEMIOL, V20, P719, DOI 10.1007/s10654-005-0033-z	118	78	78	2	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6199			EUR J PEDIATR	Eur. J. Pediatr.	AUG	2009	168	8					897	905		10.1007/s00431-009-0967-3		9	Pediatrics	Pediatrics	457IR	WOS:000266922200002	19301035	
J	Kirby, AC; Coles, MC; Kaye, PM				Kirby, Alun C.; Coles, Mark C.; Kaye, Paul M.			Alveolar Macrophages Transport Pathogens to Lung Draining Lymph Nodes	JOURNAL OF IMMUNOLOGY			English	Article							PULMONARY DENDRITIC CELLS; PNEUMOCOCCAL PNEUMONIA; IN-VIVO; B-CELLS; SUBCAPSULAR SINUS; SIGLEC-F; MOUSE; ANTIGEN; INFLAMMATION; INFECTION	The first step in inducing pulmonary adaptive immunity to allergens and airborne pathogens is Ag acquisition and transport to the lung draining lymph nodes (dLN). Dendritic cells (DC) sample the airways, and active transfer of Ag to the lung dLN is considered an exclusive property of migratory DC. However, alveolar macrophages (AM) are the first phagocytes to contact inhaled particulate matter. Although having well-defined immunoregulatory capabilities, AM are generally considered as restricted to the alveoli. We show that murine AM constitutively migrate from lung to dLN and that following exposure to Streptococcus pneumoniae, AM rapidly transport bacteria to this site. Thus AM, and not DC, appear responsible for the earliest delivery of these bacteria to secondary lymphoid tissue. The identification of this novel transport pathway has important consequences for our understanding of lung immunity and suggests more widespread roles for macrophages in the transport of Ags to lymphoid organs than previously appreciated. The Journal of Immunology, 2009, 183: 1983-1989.	[Kirby, Alun C.] Univ York, Hull York Med Sch, Ctr Immunol & Infect, York YO10 5YW, N Yorkshire, England; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England	Kirby, AC (reprint author), Univ York, Hull York Med Sch, Ctr Immunol & Infect, Wentworth Way, York YO10 5YW, N Yorkshire, England.	ak510@york.ac.uk		Kirby, Alun/0000-0001-5663-2961	Wellcome Trust; Medical Research Council	This study was funded by a Wellcome Trust grant to P.M.K. and A.C.K. and by grants from The Medical Research Council (to M.C.C. and P.M.K.).	Arredouani M, 2004, J EXP MED, V200, P267, DOI 10.1084/jem.20040731; Arredouani MS, 2005, J IMMUNOL, V175, P6058; Bellingan GJ, 1996, J IMMUNOL, V157, P2577; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Blumenthal RL, 2001, J ALLERGY CLIN IMMUN, V107, P258, DOI 10.1067/mai.2001.112845; Cao CZ, 2005, BLOOD, V106, P3234, DOI 10.1182/blood-2005-03-1288; Carrasco YR, 2007, IMMUNITY, V27, P160, DOI 10.1016/j.immuni.2007.06.007; CORRY D, 1984, AM J PATHOL, V115, P321; Dockrell DH, 2003, J IMMUNOL, V171, P5380; FELS AOS, 1986, J APPL PHYSIOL, V60, P353; Gays F, 2006, J IMMUNOL, V177, P5840; HARMSEN AG, 1985, SCIENCE, V230, P1277, DOI 10.1126/science.4071052; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; HULBERT WC, 1989, J ELECTRON MICR TECH, V11, P137, DOI 10.1002/jemt.1060110208; Jakubzick C, 2006, J IMMUNOL, V176, P3578; Junt T, 2007, NATURE, V450, P110, DOI 10.1038/nature06287; Kirby AC, 2006, J INFECT DIS, V193, P205, DOI 10.1086/498874; Knapp S, 2003, AM J RESP CRIT CARE, V167, P171, DOI 10.1164/rccm.200207-698OC; Legge KL, 2003, IMMUNITY, V18, P265, DOI 10.1016/S1074-7613(03)00023-2; Marriott HM, 2006, J IMMUNOL, V177, P6480; Marriott HM, 2004, FASEB J, V18, P1126, DOI 10.1096/fj.03-1450fje; McKimmie CS, 2009, BLOOD, V113, P4224, DOI 10.1182/blood-2008-08-174698; Phan TG, 2007, NAT IMMUNOL, V8, P992, DOI 10.1038/ni1494; ROSEN H, 1990, EUR J IMMUNOL, V20, P1251, DOI 10.1002/eji.1830200609; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Tateno H, 2007, MOL CELL BIOL, V27, P5699, DOI 10.1128/MCB.00383-07; THEPEN T, 1989, J EXP MED, V170, P499, DOI 10.1084/jem.170.2.499; THEPEN T, 1993, ADV EXP MED BIOL, V329, P305; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vermaelen K, 2004, CYTOM PART A, V61A, P170, DOI 10.1002/cyto.a.20064; Vermaelen KY, 2001, J EXP MED, V193, P51; Zhang JQQ, 2004, EUR J IMMUNOL, V34, P1175, DOI 10.1002/eji.200324723; Zhang M, 2007, BLOOD, V109, P4280, DOI 10.1182/blood-2006-08-039255	34	78	78	1	5	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2009	183	3					1983	1989		10.4049/jimmunol.0901089		7	Immunology	Immunology	477LB	WOS:000268519500057	19620319	
J	Gent, JF; Koutrakis, P; Belanger, K; Triche, E; Holford, TR; Bracken, MB; Leaderer, BP				Gent, Janneane F.; Koutrakis, Petros; Belanger, Kathleen; Triche, Elizabeth; Holford, Theodore R.; Bracken, Michael B.; Leaderer, Brian P.			Symptoms and Medication Use in Children with Asthma and Traffic-Related Sources of Fine Particle Pollution	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						childhood asthma; fine particle pollution; PM(2.5); respiratory morbidity; source apportionment; traffic pollution	AIRBORNE PARTICULATE MATTER; AIR-POLLUTION; RESPIRATORY SYMPTOMS; SOURCE-APPORTIONMENT; LUNG-FUNCTION; EMISSION FACTORS; 1ST YEAR; ASSOCIATION; PM2.5; MORTALITY	BACKGROUND: Exposure to ambient fine particles [particulate matter <= 2.5 mu m diameter (PM(2.5))] is a potential factor in the exacerbation of asthma. National air quality particle standards consider total mass, not composition or sources, and may not protect against health impacts related to specific components. OBJECTIVE: We examined associations between daily exposure to fine particle components and sources, and symptoms and medication use in children with asthma. METHODS: Children with asthma (n = 149) 4-12 years of age were enrolled in a year-long study. We analyzed particle samples for trace elements (X-ray fluorescence) and elemental carbon (light reflectance). Using factor analysis/source apportionment, we identified particle sources (e.g., motor vehicle emissions) and quantified daily contributions. Symptoms and medication use were recorded on study diaries. Repeated measures logistic regression models examined associations between health outcomes and particle exposures as elemental concentrations and source contributions. RESULTS: More than half of mean PM(2.5) was attributed to traffic-related sources motor vehicles (42%) and road dust (12%). Increased likelihood of symptoms and inhaler use was largest for 3-day averaged exposures to traffic-related sources or their elemental constituents and ranged from a 10% increased likelihood of wheeze for each 5-mu g/m(3) increase in particles from motor vehicles to a 28% increased likelihood of shortness of breath for increases in road dust. Neither the other sources identified nor PM(2.5) alone was associated with increased health outcome risks. CONCLUSIONS: Linking respiratory health effects to specific particle pollution composition or sources is critical to efforts to protect public health. We associated increased risk of symptoms and inhaler use in children with asthma with exposure to traffic-related fine particles.	[Gent, Janneane F.; Belanger, Kathleen; Triche, Elizabeth; Holford, Theodore R.; Bracken, Michael B.; Leaderer, Brian P.] Yale Univ, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; [Koutrakis, Petros] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Gent, JF (reprint author), Yale Univ, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, Dept Epidemiol & Publ Hlth, 1 Church St,6th Floor, New Haven, CT 06510 USA.	janneane.gent@yale.edu	Triche, Elizabeth/I-4986-2014		National Institutes of Health [ES011013, ES05410]	This study was funded by National Institutes of Health grants ES011013 and ES05410.	Andersen ZJ, 2007, J EXPO SCI ENV EPID, V17, P625, DOI 10.1038/sj.jes.7500546; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Brown SG, 2007, J AIR WASTE MANAGE, V57, P741, DOI 10.3155/1047-3289.57.6.741; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Chardon B, 2007, OCCUP ENVIRON MED, V64, P320, DOI 10.1136/oem.2005.026187; Chimonas MAR, 2007, ENVIRON RES, V103, P397, DOI 10.1016/j.envres.2006.08.013; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Franklin M, 2008, EPIDEMIOLOGY, V19, P680, DOI 10.1097/EDE.0b013e3181812bb7; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; GENT JF, 2008, AM J RESP CRIT CARE, V177, pA186; Grieshop AP, 2006, ATMOS ENVIRON, V40, pS287, DOI 10.1016/j.atmosenv.2006.03.064; Hertz-Picciotto I, 2007, ENVIRON HEALTH PERSP, V115, P1510, DOI 10.1289/ehp.9617; Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC; Hong YC, 2007, ENVIRON HEALTH PERSP, V115, P430, DOI 10.1289/ehp.9531; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Johnston FH, 2006, INT J ENVIRON HEAL R, V16, P391, DOI 10.1080/09603120601093642; Kavouras IG, 2001, J AIR WASTE MANAGE, V51, P451, DOI 10.1080/10473289.2001.10464273; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Lewis TC, 2005, ENVIRON HEALTH PERSP, V113, P1068, DOI 10.1289/ehp.7533; Mar TF, 2004, INHAL TOXICOL, V16, P809, DOI 10.1080/08958370490506646; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; Moreno T, 2007, ATMOS ENVIRON, V41, P913, DOI 10.1016/j.atmosenv.2006.09.019; Moshammer H, 2006, EUR RESPIR J, V27, P1138, DOI 10.1183/09031936.06.00089605; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Ning Z, 2008, ATMOS ENVIRON, V42, P3099, DOI 10.1016/j.atmosenv.2007.12.039; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; Penttinen P, 2006, INHAL TOXICOL, V18, P191, DOI 10.1080/08958370500434230; Pino P, 2004, EPIDEMIOLOGY, V15, P702, DOI 10.1097/01.ede.0000142153.28496.d0; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Ranzi A, 2004, EUR J EPIDEMIOL, V19, P567; Rodriguez C, 2007, INT J ENVIRON HEAL R, V17, P351, DOI 10.1080/09603120701628669; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; Sarnat JA, 2008, ENVIRON HEALTH PERSP, V116, P459, DOI 10.1289/ehp.10873; Sigler JM, 2003, ENVIRON SCI TECHNOL, V37, P4343, DOI 10.1021/es026401r; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346; Tainio M, 2005, RISK ANAL, V25, P151, DOI 10.1111/j.0272-4332.2005.00574.x; THURSTON GD, 1985, ATMOS ENVIRON, V19, P9, DOI 10.1016/0004-6981(85)90132-5; Trenga CA, 2006, CHEST, V129, P1614, DOI 10.1378/chest.129.6.1614; U.S. Bureau of the Census, 2000, US CENS 2000; *US DEP HHS, 2002, GLOB STRAT ASTHM MAN; U.S. Environmental Protection Agency (U.S. EPA), 2008, NAT EM INV NEI; *US EPA, 2009, NAT AMB AIR QUAL STA; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Watson JG, 2002, CHEMOSPHERE, V49, P1093, DOI 10.1016/S0045-6535(02)00243-6; Watson J.G., 1999, ELEMENTAL ANAL AIRBO, V1, P67	49	78	80	0	16	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2009	117	7					1168	1174		10.1289/ehp.0800335		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	465WV	WOS:000267621200039	19654929	
J	Fonseca, DE; Kline, JN				Fonseca, David E.; Kline, Joel N.			Use of CpG oligonucleotides in treatment of asthma and allergic disease	ADVANCED DRUG DELIVERY REVIEWS			English	Review						Asthma; Atopy; Inflammation; CpG oligonucleotides; Immunotherapy	DENDRITIC CELLS; MURINE MODEL; IMMUNOSTIMULATORY DNA; INDOLEAMINE 2,3-DIOXYGENASE; AIRWAY INFLAMMATION; CUTTING EDGE; OLIGODEOXYNUCLEOTIDES; MOTIFS; EXPRESSION; ANTIGEN	In the last several decades, there has been a marked increase in the prevalence of atopic disorders including asthma in "Western" societies; a relationship has been identified between lack of early-life exposure to microbes or microbial products and increased susceptibility to atopic disorders. The innate immune system is activated by early microbial exposures, many of which utilize one of the Toll-like receptors, and there has been significant interest in studying how ligation of TLRs may be therapeutically useful. CpG oligonucleotides (CpG-ODN, resembling bacterial DNA) engage TLR-9 on B-cells, dendritic cells and other cell types, resulting in a cascade that includes induction of Th1-type and T-regulatory-type immune responses. Preclinical models of asthma have demonstrated that CpG-ODN are potent inhibitors of atopic responses, suppressing Th2 cytokine and, reducing airway eosinophilia, systemic levels of IgE, and bronchial hyperreactivity-in short the critical attributes of the asthmatic phenotype. In models of chronic allergen exposure, CpG-ODN are also effective at preventing the development of airway remodeling. In established asthma, CpG-ODN can reverse manifestations of disease both when used alone or in combination with allergen immunotherapy. Early clinical trials have had mixed results, including a significant benefit when CpG-ODN were conjugated to ragweed allergen in an allergic rhinitis immunotherapy study, but only limited efficacy seen when administered prior to allergen challenge in asthmatics. Further study of CpG-ODNs for the treatment of asthma and other atopic disorders is warranted by existing data. Published by Elsevier B.V.	[Fonseca, David E.; Kline, Joel N.] Univ Iowa, Roy J & Lucille Carver Coll Med, Div Pulm Crit Care & Occupat Med, Iowa City, IA USA	Kline, JN (reprint author), C33GH UIHC, 200 Hawkins Dr, Iowa City, IA 52242 USA.	joel-kline@uiowa.edu					Chen L, 2006, J IMMUNOL, V177, P2373; Cho JY, 2004, AM J RESP CELL MOL, V30, P651, DOI 10.1165/rcmb.2003-0066OC; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Fanucchi MV, 2004, AM J RESP CRIT CARE, V170, P1153, DOI 10.1164/rccm.200404-533OC; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hayashi T, 2004, J CLIN INVEST, V114, P270, DOI 10.1172/JCI200421275; Heyman K, 2008, EARLY RELEASE SELECT; Hussain I, 2002, LARYNGOSCOPE, V112, P1819, DOI 10.1097/00005537-200210000-00021; Jain VV, 2002, J ALLERGY CLIN IMMUN, V110, P867, DOI 10.1067/mai.2002.129371; JAIN VV, 2003, AM J PHYSIOL-LUNG C, V285, P1137; Jarnicki AG, 2008, J IMMUNOL, V180, P3797; Kadowaki N, 2001, J IMMUNOL, V166, P2291; Kitagaki K, 2006, CLIN EXP IMMUNOL, V143, P249, DOI 10.1111/j.1365-2249.2005.03003.x; Kitagaki K, 2002, CLIN DIAGN LAB IMMUN, V9, P1260, DOI 10.1128/CDLI.9.6.1260-1269.2002; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2003, NAT MED, V9, P831, DOI 10.1038/nm0703-831; Krieg AM, 2007, IMMUNOL REV, V220, P251, DOI 10.1111/j.1600-065X.2007.00572.x; Liu NS, 2003, NAT IMMUNOL, V4, P687, DOI 10.1038/ni941; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Mellor AL, 2003, J IMMUNOL, V171, P1652; Moseman EA, 2004, J IMMUNOL, V173, P4433; Peng SL, 2002, P NATL ACAD SCI USA, V99, P5545, DOI 10.1073/pnas.082114899; REINERO CR, 2008, IMMUNOPATHOL, V121, P241; Rhee CS, 2004, IMMUNOLOGY, V113, P106, DOI 10.1111/j.1365-2567.2004.01930.x; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schwartz DA, 1997, J CLIN INVEST, V100, P68, DOI 10.1172/JCI119523; Shirota H, 2000, AM J RESP CELL MOL, V22, P176; Shirota H, 2000, J IMMUNOL, V164, P5575; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sur S, 1999, J IMMUNOL, V162, P6284; Suzuki M, 2007, OTOLARYNG HEAD NECK, V136, P246, DOI 10.1016/j.otohns.2006.09.009; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Wingender G, 2006, EUR J IMMUNOL, V36, P12, DOI 10.1002/eji.200535602	42	78	86	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-409X			ADV DRUG DELIVER REV	Adv. Drug Deliv. Rev.	MAR 28	2009	61	3					256	262		10.1016/j.addr.2008.12.007		7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	429DR	WOS:000264901500009	19167442	
J	Cox, L; Williams, B; Sicherer, S; Oppenheimer, J; Sher, L; Hamilton, R; Golden, D				Cox, Linda; Williams, Brock; Sicherer, Scott; Oppenheimer, John; Sher, Larry; Hamilton, Robert; Golden, David			Pearls and pitfalls of allergy diagnostic testing: report from the American College of Allergy, Asthma and Immunology/American Academy of Allergy, Asthma and Immunology Specific IgE Test Task Force	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							NUTRITION EXAMINATION SURVEY; INTRADERMAL SKIN-TESTS; INSECT STING ALLERGY; VENOM IMMUNOTHERAPY; PRACTICE PARAMETER; ADVERSE-REACTIONS; NATIONAL-HEALTH; PEANUT ALLERGY; LUNG-FUNCTION; FOOD ALLERGY	The intended purpose of this monograph is to provide a general overview of allergy diagnostics for health care professionals who care for patients with allergic disease. For a more comprehensive review of allergy diagnostic testing, readers can refer to the Allergy Diagnostic Practice Parameters. A key message is that a positive allergy test result (skin or blood) indicates only the presence of allergen specific IgE (called sensitization). It does not necessarily mean clinical allergy (ie, allergic symptoms with exposure). It is important for this reason that the allergy evaluation be based on the patient's history and directed by a health care professional with sufficient understanding of allergy diagnostic testing to use the information obtained from his/her evaluation of the patient to determine (1) what allergy diagnostic tests to order, (2) how to interpret the allergy diagnostic test results, and (3) how to use the information obtained from the allergy evaluation to develop an appropriate therapeutic treatment plan.	[Cox, Linda] Nova SE Univ, Coll Osteopath Med, Dept Med, Davie, FL USA; [Williams, Brock] Univ Missouri, Sch Med, Kansas City, MO 64108 USA; [Sicherer, Scott] Mt Sinai Sch Med, Jaffe Food Allergy Inst, Dept Pediat, New York, NY USA; [Oppenheimer, John] Univ Med & Dent New Jersey, New Jersey Med Sch, Clin Res Pulm & Allergy Associates, Springfield, NJ USA; [Sher, Larry] Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; [Hamilton, Robert] Johns Hopkins Univ, Sch Med, Div Clin Immunol & Allergy, Dept Pathol & Med, Baltimore, MD USA; [Golden, David] Johns Hopkins Univ, Dept Med, Baltimore, MD USA	Cox, L (reprint author), Nova SE Univ, Coll Osteopath Med, Dept Med, 5333 N Dixie Hwy,Suite 210, Ft Lauderdale, FL 33334 USA.	lindaswolfox@msn.com					Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Bernardo FP, 2004, COMP AID CH, V18, P151; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bernstein DI, 2003, J ALLERGY CLIN IMMUN, V111, P610, DOI 10.1067/mai.2003.164; Bernstein IL, 2008, ANN ALLERG ASTHMA IM, V100, pS1; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Carr WW, 2005, J ALLERGY CLIN IMMUN, V116, P341, DOI 10.1016/j.jaci.2005.03.035; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Custovic A, 2005, ALLERGY, V60, P10, DOI 10.1111/j.1398-9995.2005.00851.x; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Gendo K, 2004, ANN INTERN MED, V140, P278; Golden DBK, 2006, ANN ALLERG ASTHMA IM, V96, pS16; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Hamilton RG, 2004, J ALLERGY CLIN IMMUN, V114, P213, DOI 10.1016/j.jaci.2004.06.046; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Komata T, 2007, J ALLERGY CLIN IMMUN, V119, P1272, DOI 10.1016/j.jaci.2007.01.038; Koskela H, 2003, CHEST, V124, P383, DOI 10.1378/chest.124.1.383; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Leduc V, 2006, ALLERGY, V61, P349, DOI 10.1111/j.1398-9995.2006.01013.x; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V6, P60; Lowe LA, 2004, ARCH PEDIAT ADOL MED, V158, P996, DOI 10.1001/archpedi.158.10.996; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Nelson HS, 1998, J ALLERGY CLIN IMMUN, V101, P153; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; Nelson HS, 2004, J ALLERGY CLIN IMMUN, V113, P1218, DOI 10.1016/j.jaci.2004.01.566; NELSON HS, 1994, ALLERGY PROC, V15, P265, DOI 10.2500/108854194778816490; Oppenheimer J, 2006, ANN ALLERG ASTHMA IM, V96, pS6; OWNBY DR, 1982, J ALLERGY CLIN IMMUN, V69, P536, DOI 10.1016/0091-6749(82)90180-4; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P144, DOI 10.1016/j.jaci.2004.04.009; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 2001, GASTROENTEROLOGY, V120, P1026, DOI 10.1053/gast.2001.23031; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson HA, 2000, J PEDIATR GASTR NUTR, V30, pS87, DOI 10.1097/00005176-200001001-00013; Sharma HP, 2008, J ALLERGY CLIN IMMUN, V121, P933, DOI 10.1016/j.jaci.2008.01.023; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P1146, DOI 10.1016/j.jaci.2004.07.034; Simpson A, 2005, J ALLERGY CLIN IMMUN, V116, P744, DOI 10.1016/j.jaci.2005.06.032; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stapel SO, 2008, ALLERGY, V63, P793, DOI 10.1111/j.1398-9995.2008.01705.x; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TURKELTAUB PC, 1989, J ALLERGY CLIN IMMUN, V84, P886, DOI 10.1016/0091-6749(89)90384-9; Valyasevi MA, 2000, ANN ALLERG ASTHMA IM, V85, P363; Williams PB, 2000, J ALLERGY CLIN IMMUN, V105, P1221, DOI 10.1067/mai.2000.105219; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; Wood RA, 2007, ANN ALLERG ASTHMA IM, V99, P34; [Anonymous], 2006, ANN ALLERGY ASTHMA I, V96, pS1	49	78	86	0	8	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	DEC	2008	101	6					580	592				13	Allergy; Immunology	Allergy; Immunology	383CJ	WOS:000261651400003	19119701	
J	Mine, Y; Yang, M				Mine, Yoshinori; Yang, Marie			Recent advances in the understanding of egg allergens: Basic, industrial, and clinical perspectives	JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY			English	Review						egg allergy; ovalbumin; ovomucoid; lysozyme; food processing; allergen detection; immunotherapy; immune tolerance	OVOMUCOID 3RD DOMAIN; IMMUNOGLOBULIN-E PRODUCTION; ORAL TOLERANCE INDUCTION; AMINO-ACID-SEQUENCE; T-CELL EPITOPE; IMMUNOSTIMULATORY DNA-SEQUENCE; ANTILYSOZYME ANTIBODY HYHEL-63; LINKED-IMMUNOSORBENT-ASSAY; CHICKEN SERUM-ALBUMIN; TH2 IMMUNE-RESPONSES	The emergence of egg allergy. has had both industrial and clinical implications. In industrialized countries, egg allergy accounts for one of the most prevalent food hypersensitivities, especially in children. Atopic dermatitis represents the most common clinical manifestation in infancy; however, the range of clinical signs is broad and encompasses life-threatening anaphylaxis. The dominant egg allergens are proteins and are mainly present in the egg white, for example, ovalbumin, ovomucoid, ovotransferrin, and lysozyme. However, egg yolk also displays low-level allergenicity, for example, (x-livetin. Strict avoidance of the offending food remains the most common recommendation for egg-allergic individuals. Nevertheless, the omnipresence of egg-derived components in prepackaged or prepared foods makes it difficult. Therefore, more efficient preventive approaches are investigated to protect consumers from inadvertent exposure and ensuing adverse reactions. On the one hand, commercial kits have become readily available that allow for the detection of egg contaminants at trace levels. On the other hand, attempts to produce hypoallergenic egg-containing products through food-processing techniques have met with promising results, but the approach is limited due to its potentially undesirable effects on the unique functional and sensory attributes of egg proteins. Therefore, the development of preventive or curative strategies for egg allergy remains strongly warranted. Pilot studies have suggested that oral immunotherapy (IT) with raw or cooked preparations of egg may represent a safe alternative, immediately available to allergic subjects, but remains applicable to only nonanaphylactic patients. Due to the limitations of conventional IT, novel forms of immunotherapy are sought based on information obtained from the-molecular characterization of major egg allergens. In the past decade, promising approaches to the treatment and prevention of egg allergy have been explored and include, among others, the production of hypoallergenic recombinant egg proteins, the development of customized peptides, and bacterial-mediated immunotherapy. Nonspecific approaches have also been evaluated, and preliminary trials with the use of probiotic bacteria have yielded encouraging results. The current understanding of egg allergens offers novel approaches toward the making of food products safe for human consumption and the development of efficient immunotherapeutic strategies.	[Mine, Yoshinori; Yang, Marie] Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada	Mine, Y (reprint author), Univ Guelph, Dept Food Sci, Guelph, ON N1G 2W1, Canada.	ymine@uoguelph.ca					Aalberse RC, 2006, MOL NUTR FOOD RES, V50, P625, DOI 10.1002/mnfr.200500270; ADORINI L, 1988, P NATL ACAD SCI USA, V85, P5181, DOI 10.1073/pnas.85.14.5181; ADORINI L, 1988, J EXP MED, V168, P2091, DOI 10.1084/jem.168.6.2091; Agrawal DK, 2004, INT IMMUNOPHARMACOL, V4, P127, DOI 10.1016/j.intimp.2003.11.005; Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; Akdis M, 2007, J ALLERGY CLIN IMMUN, V119, P780, DOI 10.1016/j.jaci.2007.01.022; Alessandri C, 2005, ALLERGY, V60, P128, DOI 10.1111/j.1398-9995.2004.00449.x; Allen CW, 2007, J PAEDIATR CHILD H, V43, P214, DOI 10.1111/j.1440-1754.2007.00996.x; Ando T, 2007, J ALLERGY CLIN IMMUN, V120, P916, DOI 10.1016/j.jaci.2007.05.023; ANET J, 1985, INT ARCH ALLER A IMM, V77, P364; Anibarro B, 2007, J INVEST ALLERG CLIN, V17, P168; Anibarro B, 2000, J ALLERGY CLIN IMMUN, V105, P834, DOI 10.1067/mai.2000.104547; ANIBARRO B, 1993, J ALLERGY CLIN IMMUN, V92, P628, DOI 10.1016/0091-6749(93)90089-X; Ankier S I, 1969, Prog Drug Res, V13, P340; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; AWADE AC, 1994, J CHROMATOGR A, V677, P279, DOI 10.1016/0021-9673(94)80156-8; BABAKHIN AA, 1995, ALLERGY PROC, V16, P261, DOI 10.2500/108854195778702620; Bagnasco M, 2001, CLIN EXP ALLERGY, V31, P54, DOI 10.1046/j.1365-2222.2001.00999.x; Bando N, 2003, BIOSCI BIOTECH BIOCH, V67, P2176, DOI 10.1271/bbb.67.2176; Baral VR, 2005, POSTGRAD MED J, V81, P693, DOI 10.1136/pgmj.2004.030288; Ben Nasser I, 2003, INT IMMUNOPHARMACOL, V3, P1569, DOI 10.1016/S1567-5769(03)00164-4; Bentley G A, 1996, EXS, V75, P301; BERNHISELBROADBENT J, 1994, J ALLERGY CLIN IMMUN, V93, P1047, DOI 10.1016/S0091-6749(94)70054-0; BERNSTEIN DI, 1987, J ALLERGY CLIN IMMUN, V80, P791, DOI 10.1016/S0091-6749(87)80267-1; BERNSTEIN JA, 1993, CHEST, V103, P532, DOI 10.1378/chest.103.2.532; Besler M, 2001, J CHROMATOGR B, V756, P207, DOI 10.1016/S0378-4347(01)00110-4; Besler M, 1999, INT S FOOD ALLERGENS, V1, P1; Bielory L, 2004, ANN ALLERG ASTHMA IM, V93, pS45; BLEUMINK E, 1971, INT ARCH ALLER A IMM, V40, P72; Boeniger M F, 2001, Appl Occup Environ Hyg, V16, P660, DOI 10.1080/104732201750175861; Bohle B, 2004, MOL NUTR FOOD RES, V48, P424, DOI 10.1002/mnfr.200400003; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Breiteneder H, 2006, MOL NUTR FOOD RES, V50, P628, DOI 10.1002/mnfr.200500274; BRETON C, 1988, J FOOD SCI, V53, P226, DOI 10.1111/j.1365-2621.1988.tb10215.x; BROWN W, 1994, IMMUNOL INVEST, V23, P73, DOI 10.3109/08820139409087790; Buchanan AD, 2007, J ALLERGY CLIN IMMUN, V119, P199, DOI 10.1016/j.jaci.2006.09.016; BURKS AW, 2007, J ALLERGY CLIN IMMUN, P120; Burks W, 2001, Curr Opin Allergy Clin Immunol, V1, P243, DOI 10.1097/00130832-200106000-00008; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; Byun MW, 2000, J FOOD PROTECT, V63, P940; CAFFARELLI C, 1995, J ALLERGY CLIN IMMUN, V95, P1215, DOI 10.1016/S0091-6749(95)70078-1; CANT A, 1985, BRIT MED J, V291, P932; Castellani O, 2006, FOOD HYDROCOLLOID, V20, P35, DOI 10.1016/j.foodhyd.2005.02.010; Castellani O, 2005, FOOD HYDROCOLLOID, V19, P769, DOI 10.1016/j.foodhyd.2004.09.010; Cauerhff A, 2004, P NATL ACAD SCI USA, V101, P3539, DOI 10.1073/pnas.0400060101; Celik-Bilgili S, 2005, CLIN EXP ALLERGY, V35, P268, DOI 10.1111/j.1365-2222.2005.02150.x; Chang JY, 2002, FEBS LETT, V511, P73, DOI 10.1016/S0014-5793(01)03284-7; Choi I, 2004, FOOD SCI BIOTECHNOL, V13, P434; Choo MK, 2003, PLANTA MED, V69, P518, DOI 10.1055/s-2003-40653; CLARK RC, 1985, INT J BIOCHEM, V17, P983, DOI 10.1016/0020-711X(85)90243-5; Cooke SK, 1997, J IMMUNOL, V159, P2026; COOMBS RRA, 1984, ANN ALLERGY, V53, P592; Coon JT, 2002, DRUG SAFETY, V25, P323, DOI 10.2165/00002018-200225050-00003; CRESPO JF, 1995, PEDIATR ALLERGY IMMU, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; Damodaran S, 1996, J COLLOID INTERF SCI, V178, P426, DOI 10.1006/jcis.1996.0137; de Laureto PP, 2002, PROTEIN SCI, V11, P2932, DOI 10.1110/ps.0205802; DEBLAY F, 1994, ALLERGY PROC, V15, P77, DOI 10.2500/108854194778703017; DE BOISSIEU D, 2006, ALLERGY IMMUNOL PARI, V38, P113; DEMEULESTER C, 2007, DETECTING ALLERGENS, P219; Devenney I, 2006, ACTA PAEDIATR, V95, P1133, DOI 10.1080/08035250500516672; DIAZ TC, 1986, ALLERGOL IMMUNOPATH, V14, P9; DJURTOFT R, 1991, ADV EXP MED BIOL, V289, P281; Eggesbo M, 2001, ALLERGY, V56, P403, DOI 10.1034/j.1398-9995.2001.056005403.x; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; Eigenmann PA, 1996, PEDIATR ALLERGY IMMU, V7, P12, DOI 10.1111/j.1399-3038.1996.tb00100.x; Eigenmann PA, 2003, ALLERGY, V58, P1217, DOI 10.1046/j.1398-9995.2003.00303.x; Eigenmann Philippe A, 2003, Curr Opin Allergy Clin Immunol, V3, P199, DOI 10.1097/00130832-200306000-00008; ELSAYED S, 1988, SCAND J IMMUNOL, V27, P587, DOI 10.1111/j.1365-3083.1988.tb02386.x; ELSAYED S, 1986, INT ARCH ALLER A IMM, V79, P101; ELSAYED S, 1994, INT ARCH ALLERGY IMM, V104, P65; Escudero C, 2003, ALLERGY, V58, P616, DOI 10.1034/j.1398-9995.2003.00201.x; Faeste CK, 2007, J AOAC INT, V90, P427; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; Fanaro S, 2005, ACTA PAEDIATR, V94, P22, DOI 10.1080/08035320510043538; Ferreira F, 2004, ADV IMMUNOL, V84, P79, DOI 10.1016/S0065-2776(04)84003-3; Ferreira F, 1998, FASEB J, V12, P231; Finegold I, 2007, ALLERGY ASTHMA PROC, V28, P44, DOI 10.2500/aap.2007.28.2971; Flinterman AE, 2007, INT ARCH ALLERGY IMM, V143, P237, DOI 10.1159/000099467; FORD RPK, 1982, ARCH DIS CHILD, V57, P649; Fremont S, 1997, ALLERGY, V52, P224, DOI 10.1111/j.1398-9995.1997.tb00980.x; Fujitani Shinobu, 2007, Allergol Int, V56, P131, DOI 10.2332/allergolint.O-06-450; Furuhashi M, 1997, BIOL NEONATE, V72, P210; GAMMON G, 1991, J EXP MED, V173, P609, DOI 10.1084/jem.173.3.609; Giansanti F, 2002, BIOCHEM CELL BIOL, V80, P125, DOI 10.1139/o01-208; Goodyear-Smith F, 2005, HUM VACCINES, V1, P118, DOI 10.4161/hv.1.3.1888; GREENGARD O, 1964, BIOCHIM BIOPHYS ACTA, V90, P406, DOI 10.1016/0304-4165(64)90208-9; Gremmel S, 2007, WOODHEAD PUBL FOOD S, P178, DOI 10.1533/9781845692278.2.178; Grimshaw KEC, 2006, P NUTR SOC, V65, P412, DOI 10.1079/PNS2006516; Guerin-Dubiard Catherine, 2007, P223, DOI 10.1007/978-3-540-37885-3_26; Gustafsson D, 2003, PEDIATR ALLERGY IMMU, V14, P448, DOI 10.1046/j.0905-6157.2003.00093.x; Han DK, 2004, YONSEI MED J, V45, P803; HAYGLASS KT, 1990, CLIN EXP IMMUNOL, V82, P429; Hefle SL, 2001, J FOOD PROTECT, V64, P1812; Heine RG, 2006, CURR ALLERGY ASTHM R, V6, P145, DOI 10.1007/s11882-006-0053-0; Hemmi H, 2000, NATURE, V408, P740; Herweijer H, 2003, GENE THER, V10, P453, DOI 10.1038/sj.gt.3301983; Hildebrandt S, 2008, J AGR FOOD CHEM, V56, P1727, DOI 10.1021/jf0725981; Hirose J, 2004, BIOSCI BIOTECH BIOCH, V68, P2490, DOI 10.1271/bbb.68.2490; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOLEN E, 1990, INT ARCH ALLER A IMM, V91, P136; Holen E, 2001, CLIN EXP ALLERGY, V31, P952, DOI 10.1046/j.1365-2222.2001.01102.x; Holen E, 1996, CLIN EXP ALLERGY, V26, P1080, DOI 10.1046/j.1365-2222.1996.d01-412.x; HONMA K, 1994, INT ARCH ALLERGY IMM, V103, P28; Honma K, 1996, CLIN EXP IMMUNOL, V103, P446; HOTTESTMANN K, 2005, SAPONINS, P239; Hourihane JOB, 2001, ALLERGY, V56, P86; Hsu SC, 2007, J ALLERGY CLIN IMMUN, V119, P1522, DOI 10.1016/j.jaci.2007.01.034; Huibregtse IL, 2007, GASTROENTEROLOGY, V133, P517, DOI 10.1053/j.gastro.2007.04.073; Huntington JA, 2001, J CHROMATOGR B, V756, P189, DOI 10.1016/S0378-4347(01)00108-6; Ikeda RK, 2003, AM J RESP CELL MOL, V28, P655, DOI 10.1165/rcmb.4853; Imai Takanori, 2003, Arerugi, V52, P1006; JAMES JM, 1995, NEW ENGL J MED, V332, P1262, DOI 10.1056/NEJM199505113321904; James JM, 1998, J PEDIATR-US, V133, P624, DOI 10.1016/S0022-3476(98)70101-5; Janssen EM, 2000, J IMMUNOL, V165, P7207; Jarvinen K. M., 2007, Allergy, V62, P758; Jeong HJ, 2001, IMMUNOPHARM IMMUNOT, V23, P107, DOI 10.1081/IPH-100102572; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Jonsson H., 2001, BIACORE J, V2, P16; KAHLERT H, 1992, MOL IMMUNOL, V29, P1191, DOI 10.1016/0161-5890(92)90055-3; Katayama S, 2006, J AGR FOOD CHEM, V54, P3271, DOI 10.1021/jf060169h; KATO A, 2004, PROTEINS FOOD PROCES, P353; KATO I, 1987, BIOCHEMISTRY-US, V26, P193, DOI 10.1021/bi00375a027; Kato Y, 2001, J AGR FOOD CHEM, V49, P3661, DOI 10.1021/jf0102766; Katsuki T, 1996, INT ARCH ALLERGY IMM, V109, P344; Khan MAS, 2000, J AGR FOOD CHEM, V48, P1503; Kim H, 2005, FEMS IMMUNOL MED MIC, V45, P259, DOI 10.1016/j.femsim.2005.05.005; Kim MJ, 2002, J FOOD PROTECT, V65, P1192; Kim SH, 2001, VACCINE, V19, P4107, DOI 10.1016/S0264-410X(01)00175-X; Kimoto H, 2004, MICROBIOL IMMUNOL, V48, P75; Kjaer TMR, 2002, SCAND J IMMUNOL, V55, P359, DOI 10.1046/j.0300-9475.2002.01076.x; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Knight AK, 2006, J ALLERGY CLIN IMMUN, V117, P842, DOI 10.1016/j.jaci.2005.12.1304; Kondo H, 1999, J BIOL CHEM, V274, P27623, DOI 10.1074/jbc.274.39.27623; Kondo M, 2005, J INVEST ALLERG CLIN, V15, P107; Kovacs-Nolan J, 2005, J AGR FOOD CHEM, V53, P8421, DOI 10.1021/jf050964f; Kovacs-Nolan J, 2000, J AGR FOOD CHEM, V48, P6261, DOI 10.1021/jf000358e; Krska R., 2004, Proteins in food processing, P292, DOI 10.1533/9781855738379.2.292; LANGELAND T, 1983, ALLERGY, V38, P131, DOI 10.1111/j.1398-9995.1983.tb01597.x; LANGELAND T, 1982, ALLERGY, V37, P521, DOI 10.1111/j.1398-9995.1982.tb02335.x; LANGELAND T, 1982, ALLERGY, V37, P323, DOI 10.1111/j.1398-9995.1982.tb01918.x; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; LAUNDRY SJ, 2006, FOOD ALLERGY, P123; Leduc V, 1999, ALLERGY, V54, P464, DOI 10.1034/j.1398-9995.1999.00928.x; Lee JW, 2002, J FOOD PROTECT, V65, P1196; Lee JW, 2001, J FOOD PROTECT, V64, P272; Lee Y. H., 1992, J PEDIATR, V121, P47; Leser C, 2001, J INVEST ALLERG CLIN, V11, P89; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li YL, 2003, BIOCHEMISTRY-US, V42, P11, DOI 10.1021/bi020589+; Li YL, 2000, BIOCHEMISTRY-US, V39, P6296, DOI 10.1021/bi000054l; LI-CHAN E, 1989, Critical Reviews in Poultry Biology, V2, P21; Maecker HT, 2001, J IMMUNOL, V166, P959; MARCUCCI F, 2007, ALLERGY IMMUNOL PARI, V39, P101; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; Martinez-Azumendi O, 2001, ACTAS ESP PSIQUIATRI, V29, P95; Masuda T, 2005, PROTEIN EXPRES PURIF, V39, P35, DOI 10.1016/j.pep.2004.09.009; Masuda T, 2000, J AGR FOOD CHEM, V48, P2670, DOI 10.1021/jf990999d; Matsuda R, 2006, J AOAC INT, V89, P1600; MATSUDA T, 1985, BIOCHEM BIOPH RES CO, V129, P505, DOI 10.1016/0006-291X(85)90180-9; MATSUDA T, 1986, J BIOCHEM-TOKYO, V100, P985; MATSUDA T, 1983, J AGR FOOD CHEM, V31, P942, DOI 10.1021/jf00119a005; Matsuzaki T, 1998, J DAIRY SCI, V81, P48; MILLER H, 1950, J ALLERGY, V21, P522, DOI 10.1016/0021-8707(50)90103-1; Mine Y, 2003, PROTEIN ENG, V16, P747, DOI 10.1093/protein/gzg095; Mine Y, 2003, BIOCHEM BIOPH RES CO, V302, P133, DOI 10.1016/S0006-291X(03)00117-7; Mine Y, 2002, J AGR FOOD CHEM, V50, P2679, DOI 10.1021/jf0112264; Mine Y, 2007, BBA-PROTEINS PROTEOM, V1774, P200, DOI 10.1016/j.bbapap.2006.12.003; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; Mizumachi K, 2003, BIOSCI BIOTECH BIOCH, V67, P712; Mizutani K, 2004, BIOSCI BIOTECH BIOCH, V68, P376, DOI 10.1271/bbb.68.376; Mizutani K, 2001, J BIOL CHEM, V276, P35940, DOI 10.1074/jbc.M102590200; Mohammad A, 2006, J NUTR SCI VITAMINOL, V52, P113, DOI 10.3177/jnsv.52.113; Mohan S, 2003, BIOPHYS J, V85, P3221; Morisset M, 2003, CLIN EXP ALLERGY, V33, P1046, DOI 10.1046/j.1365-2222.2003.01734.x; Morisset M, 2007, ALLERG IMMUNOL PARIS, V39, P12; Moudgil KD, 1998, J IMMUNOL, V161, P6046; Moudgil KD, 1997, J IMMUNOL, V159, P2574; Nguyen MD, 2001, ALLERGY, V56, P127, DOI 10.1034/j.1398-9995.2001.00937.x; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Niggemann B, 2006, ALLERGY, V61, P808, DOI 10.1111/j.1398-9995.2006.01066.x; NISBET AD, 1981, EUR J BIOCHEM, V115, P335, DOI 10.1111/j.1432-1033.1981.tb05243.x; NORMAN PS, 1982, J ALLERGY CLIN IMMUN, V70, P248, DOI 10.1016/0091-6749(82)90061-6; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Ohno H, 2005, BIOL PHARM BULL, V28, P1462, DOI 10.1248/bpb.28.1462; Ohta A, 1997, J IMMUNOL METHODS, V209, P85, DOI 10.1016/S0022-1759(97)00152-X; Otani H, 1997, FOOD AGR IMMUNOL, V9, P193, DOI 10.1080/09540109709354950; PADLAN EA, 1989, P NATL ACAD SCI USA, V86, P5938, DOI 10.1073/pnas.86.15.5938; Palm M, 1999, ALLERGY, V54, P1116, DOI 10.1034/j.1398-9995.1999.00305.x; Palmer K, 2006, CURR OPIN ALLERGY CL, V6, P202, DOI 10.1097/01.all.0000225161.60274.31; PATRIARCA C, 1984, ALLERGOL IMMUNOPATH, V12, P275; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; Patriarca G, 1998, HEPATO-GASTROENTEROL, V45, P52; Patriarca G, 2007, DIGEST DIS SCI, V52, P1662, DOI 10.1007/s10620-006-9245-7; Pedrosa C, 2000, ARCH BIOCHEM BIOPHYS, V382, P203, DOI 10.1006/abbi.2000.2024; Peng HJ, 1998, SCAND J IMMUNOL, V48, P491; Petersen SB, 2004, J BIOTECHNOL, V114, P269, DOI 10.1016/j.jbiotec.2004.07.004; Piccirillo CA, 2003, CURR PHARM DESIGN, V9, P83, DOI 10.2174/1381612033392404; Piquer-Gibert M, 2007, ALLERGOL IMMUNOPATH, V35, P209, DOI 10.1157/13110316; Poms RE, 2004, FOOD ADDIT CONTAM, V21, P1, DOI 10.1080/02652030310001620423; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; PRESSI G, 1994, J SCI FOOD AGR, V64, P163, DOI 10.1002/jsfa.2740640205; Prioult G, 2005, IMMUNOL REV, V206, P204, DOI 10.1111/j.0105-2896.2005.00277.x; Quirce S, 1998, CLIN EXP ALLERGY, V28, P478, DOI 10.1046/j.1365-2222.1998.00253.x; Quirce S, 2001, ALLERGY, V56, P754, DOI 10.1034/j.1398-9995.2001.056008754.x; RAUCH P, 1990, J FOOD SCI, V55, P103, DOI 10.1111/j.1365-2621.1990.tb06027.x; Raz E, 1999, Int Rev Immunol, V18, P271, DOI 10.3109/08830189909043030; Razafindratsita A, 2007, J ALLERGY CLIN IMMUN, V120, P278, DOI 10.1016/j.jaci.2007.04.009; RENZ H, 1993, J IMMUNOL, V151, P7206; Ria F, 2004, J IMMUNOL, V172, P3447; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Roman BS, 2007, CLIN EXP ALLERGY, V37, P287, DOI 10.1111/j.1365-2222.2007.02654.x; Roy K, 1999, NAT MED, V5, P387; Rupa P, 2007, CLIN EXP ALLERGY, V37, P918, DOI 10.1111/j.1365-2222.2007.02720.x; Rupa P, 2006, CLIN EXP IMMUNOL, V145, P493, DOI 10.1111/j.1365-2249.2006.03163.x; Rupa P, 2006, ALLERGY, V61, P836, DOI 10.1111/j.1398-9995.2006.01143.x; Rupa P, 2006, BIOCHEM BIOPH RES CO, V342, P710, DOI 10.1016/j.bbrc.2006.01.174; Rupa P, 2003, BIOTECHNOL LETT, V25, P1917, DOI 10.1023/B:BILE.0000003987.60659.ea; Rupa P, 2003, BIOTECHNOL LETT, V25, P427, DOI 10.1023/A:1022489724910; Saito R, 2003, BIOSCI BIOTECH BIOCH, V67, P2483, DOI 10.1271/bbb.67.2483; SAJDOK J, 1990, J SCI FOOD AGR, V53, P253, DOI 10.1002/jsfa.2740530213; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 1997, J ROY SOC MED, V90, P2; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Satkauskas S, 2001, MOL THER, V4, P317, DOI 10.1006/mthe.2001.0465; Sato R, 2001, APPL BIOCHEM BIOTECH, V91-3, P109, DOI 10.1385/ABAB:91-93:1-9:109; SATO T, 1994, EUR J IMMUNOL, V24, P1512, DOI 10.1002/eji.1830240708; Satter MA, 2002, J NUTR SCI VITAMINOL, V48, P51; Savage JH, 2007, J ALLERGY CLIN IMMUN, V120, P1413, DOI 10.1016/j.jaci.2007.09.040; Schloss OM, 1912, AM J DIS CHILD, V3, P341; Seo JH, 2004, J FOOD PROTECT, V67, P1725; Seo JH, 2007, INT IMMUNOPHARMACOL, V7, P464, DOI 10.1016/j.intimp.2006.11.012; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHIMOJO N, 1994, INT ARCH ALLERGY IMM, V105, P155; SHIMONKEVITZ R, 1984, J IMMUNOL, V133, P2067; Shirota H, 2000, J IMMUNOL, V164, P5575; Shriver-Lake LC, 2004, J AOAC INT, V87, P1498; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; SIGURS N, 1992, PEDIATRICS, V89, P735; SMITH AB, 1990, CHEST, V98, P398, DOI 10.1378/chest.98.2.398; Smith-Gill S J, 1996, EXS, V75, P277; So T, 1997, J BIOL CHEM, V272, P32136, DOI 10.1074/jbc.272.51.32136; So T, 2001, IMMUNOLOGY, V104, P259, DOI 10.1046/j.1365-2567.2001.01314.x; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; STEVENS L, 1991, COMP BIOCHEM PHYS B, V100, P1, DOI 10.1016/0305-0491(91)90076-P; Stevens Lewis, 1996, Science Progress, V79, P65; Suzuki K, 2002, CLIN EXP ALLERGY, V32, P1223, DOI 10.1046/j.1365-2745.2002.01433.x; SZEPFALUSI Z, 1994, J ALLERGY CLIN IMMUN, V93, P932, DOI 10.1016/0091-6749(94)90388-3; Taams LS, 2006, IMMUNOLOGY, V118, P1, DOI 10.1111/j.1365-2567.2006.02348.x; TABORSKY G, 1967, J BIOL CHEM, V242, P1495; TABORSKY G, 1983, ADV INORG BIOCHEM, V5, P235; Takagi K, 2005, INT ARCH ALLERGY IMM, V136, P23, DOI 10.1159/000082581; Takagi K, 2003, BIOL PHARM BULL, V26, P969, DOI 10.1248/bpb.26.969; Takahashi K, 1999, J NUTR SCI VITAMINOL, V45, P491; Takahashi N, 2006, CLIN EXP IMMUNOL, V145, P130, DOI 10.1111/j.1365-2249.2006.03111.x; Takahashi N, 2006, FEMS IMMUNOL MED MIC, V46, P461, DOI 10.1111/j.1574-695X.2006.00064.x; Takahashi N, 2006, BIOSCI BIOTECH BIOCH, V70, P2013, DOI 10.1271/bbb.60260; Tanabe S, 2000, BIOSCI BIOTECH BIOCH, V64, P2005, DOI 10.1271/bbb.64.2005; Tariq SM, 2000, PEDIATR ALLERGY IMMU, V11, P162, DOI 10.1034/j.1399-3038.2000.00077.x; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Teshima R, 2006, ALLERGOL INT, V55, P43, DOI 10.2332/allergolint.55.43; Teuber SS, 2006, FOOD ALLERGY, P49; Thomas K, 2007, FOOD CHEM TOXICOL, V45, P1116, DOI 10.1016/j.fct.2006.12.016; Torii Akiko, 2007, Allergol Int, V56, P293, DOI 10.2332/allergolint.O-06-459; TURIN L, 1994, J SCI FOOD AGR, V64, P39, DOI 10.1002/jsfa.2740640107; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; VALENTI P, 1985, MYCOPATHOLOGIA, V89, P169, DOI 10.1007/BF00447027; van Hengel AJ, 2007, ANAL BIOANAL CHEM, V389, P111, DOI 10.1007/s00216-007-1353-5; van Wijk F, 2007, BIOMED PHARMACOTHER, V61, P8, DOI 10.1016/j.biopha.2006.11.003; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; VANTOORENENBERGEN AW, 1994, INT ARCH ALLERGY IMM, V104, P199; Verhagen J, 2006, IMMUNOL ALLERGY CLIN, V26, P207, DOI 10.1016/j.iac.2006.02.008; Verstege A, 2005, CLIN EXP ALLERGY, V35, P1220, DOI 10.1111/j.1365-2222.2005.02324.x; VIDARD L, 1992, J IMMUNOL, V149, P498; von Baehr V, 2005, J INVEST ALLERG CLIN, V15, P234; Wal JM, 2003, ALLERGY, V58, P727, DOI 10.1034/j.1398-9995.2003.00225.x; Walsh B J, 2005, Allergol Immunopathol (Madr), V33, P183, DOI 10.1157/13077741; WALSH BJ, 1987, INT ARCH ALLER A IMM, V84, P228; WALSH BJ, 1988, INT ARCH ALLER A IMM, V87, P81; Watanabe Y, 2005, J IMMUNOL METHODS, V300, P115, DOI 10.1016/j.jim.2005.02.014; Weber P, 1998, INT IMMUNOL, V10, P1753, DOI 10.1093/intimm/10.12.1753; Weiner HL, 2000, J CLIN INVEST, V106, P935, DOI 10.1172/JCI11348; WICHERS H, 2003, PLANT FOOD ALLERGENS, P196, DOI 10.1002/9780470995174.ch12; WILLIAMS J, 1982, TRENDS BIOCHEM SCI, V7, P394, DOI 10.1016/0968-0004(82)90183-9; WILLIAMS J, 1982, EUR J BIOCHEM, V122, P297, DOI 10.1111/j.1432-1033.1982.tb05880.x; Williams KM, 2004, J AOAC INT, V87, P1485; Wu XM, 1998, EUR J IMMUNOL, V28, P134, DOI 10.1002/(SICI)1521-4141(199801)28:01<134::AID-IMMU134>3.0.CO;2-3; Xystrakis E, 2007, CURR OPIN ALLERGY CL, V7, P535; Yamada K, 2000, ALLERGY, V55, P565, DOI 10.1034/j.1398-9995.2000.00430.x; Yamada T, 1993, Arerugi, V42, P136; YANG M, 2008, EGG BIOSCIENCE BIOTE, P239, DOI 10.1002/9780470181249.ch6; Yeung JM, 2000, J AOAC INT, V83, P139; Yman IM, 2006, J AOAC INT, V89, P856; YOSHITADA N, 1980, RAKANU KAGAKU SHOKUH, V29, pA85; Youn CJ, 2004, J IMMUNOL, V173, P7556; Zeiger RS, 2002, J ALLERGY CLIN IMMUN, V110, P834, DOI 10.1067/mai.2002.129372; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI 10.1067/mai.2003.1411; Zhang JW, 1998, BIOCHEM BIOPH RES CO, V253, P124, DOI 10.1006/bbrc.1998.9761; ZHANG JW, 1999, BIOCHEM BIOPH RES CO, P610; 2006, CLIN EXP ALLERGY, V36, P1334	303	78	90	4	52	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0021-8561	1520-5118		J AGR FOOD CHEM	J. Agric. Food Chem.	JUL 9	2008	56	13					4874	4900		10.1021/jf8001153		27	Agriculture, Multidisciplinary; Chemistry, Applied; Food Science & Technology	Agriculture; Chemistry; Food Science & Technology	321VU	WOS:000257335400002	18543935	
J	Johnson, LA; Prevo, R; Clasper, S; Jackson, DG				Johnson, Louise A.; Prevo, Remko; Clasper, Steven; Jackson, David G.			Inflammation-induced uptake and degradation of the lymphatic endothelial hyaluronan receptor LYVE-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; L-SELECTIN LIGAND; MAJOR E-SELECTIN; ENDOCYTOSIS HARE; DENDRITIC CELLS; BINDING PROTEINS; GENE-EXPRESSION; TNF-ALPHA; CD44; LYMPHANGIOGENESIS	The hyaluronan receptor LYVE-1 is selectively expressed in the endothelium of lymphatic capillaries, where it has been proposed to function in hyaluronan clearance and hyaluronan-mediated leukocyte adhesion. However, recent studies suggest that hyaluronan homeostasis is unperturbed in LYVE-1(-/-) mice and that lymphatic adhesion/transmigration may be largely mediated by ICAM-1 and VCAM-1 rather than LYVE-1. Here we have explored the possibility that LYVE-1 functions during inflammation and report that the receptor is down-regulated by pro-inflammatory cytokines. Using cultured primary lymphatic endothelial cells, we show that surface expression of LYVE-1 is rapidly and reversibly lost after exposure to tumor necrosis factor-alpha( TNF alpha) and TNF beta via internalization and degradation of the receptor in lysosomes, coupled with a shutdown in gene expression. Curiously, internalization does not result in significant uptake of hyaluronan, a process that is largely insensitive to the novel LYVE-1 adhesion blocking monoclonal antibody 3A, and proceeds almost equally in resting and inflammation-activated lymphatic endothelial cells. Finally, we show that TNF can induce down-modulation of LYVE-1 in ex vivo murine dermal tissue explants and present evidence that the process occurs in vivo, in the context of murine allergen-induced skin inflammation. These findings suggest that LYVE-1 can function independently of hyaluronan and have implications for the use of LYVE-1 as a histological marker for lymphangiogenesis in human pathology.	John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England	Jackson, DG (reprint author), John Radcliffe Hosp, Weatherall Inst Mol Med, MRC, Human Immunol Unit, Oxford OX3 9DS, England.	djackson@hammer.imm.ox.ac.uk			Medical Research Council [G0801186, MC_U137884182]		ANSTEE DJ, 1991, IMMUNOLOGY, V74, P197; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baluk P, 2005, J CLIN INVEST, V115, P247, DOI 10.1172/JCI200522037; Banerji S, 1999, J CELL BIOL, V144, P789, DOI 10.1083/jcb.144.4.789; Breiteneder-Geleff S, 1999, AM J PATHOL, V154, P385, DOI 10.1016/S0002-9440(10)65285-6; Burdick MM, 2006, J BIOL CHEM, V281, P13899, DOI 10.1074/jbc.M513617200; CUMBERBATCH M, 1995, IMMUNOLOGY, V84, P31; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Dimitroff CJ, 2001, J CELL BIOL, V153, P1277, DOI 10.1083/jcb.153.6.1277; FAULKNER CB, 1995, INFECT IMMUN, V63, P4084; FRASER JRE, 1988, BIOCHEM J, V256, P153; FRASER JRE, 1989, CIBA F SYMP, V143, P41; Gale NW, 2007, MOL CELL BIOL, V27, P595, DOI 10.1128/MCB.01503-06; Gale NW, 2002, DEV CELL, V3, P411, DOI 10.1016/S1534-5807(02)00217-4; Gee K, 2003, J BIOL CHEM, V278, P37275, DOI 10.1074/jbc.M302309200; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; HARDINGHAM TE, 1992, FASEB J, V6, P861; Harris EN, 2007, J BIOL CHEM, V282, P2785, DOI 10.1074/jbc.M607787200; HARRISONLAVOIE KJ, 1993, EMBO J, V12, P2847; Jackson DG, 2001, TRENDS IMMUNOL, V22, P317, DOI 10.1016/S1471-4906(01)01936-6; Jackson DG, 2003, TRENDS CARDIOVAS MED, V13, P1, DOI 10.1016/S1050-1738(02)00189-5; Jackson DG, 2004, APMIS, V112, P526, DOI 10.1111/j.1600-0463.2004.apm11207-0811.x; JACKSON DG, 2004, GLYCOFORUM; Jeltsch M, 1997, SCIENCE, V276, P1423, DOI 10.1126/science.276.5317.1423; Johnson LA, 2006, J EXP MED, V203, P2763, DOI 10.1084/jem.20051759; KNUDSON CB, 1993, FASEB J, V7, P1233; Kriehuber E, 2001, J EXP MED, V194, P797, DOI 10.1084/jem.194.6.797; Levesque MC, 1999, CELL IMMUNOL, V193, P209, DOI 10.1006/cimm.1999.1456; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; Meyer K, 1934, J BIOL CHEM, V107, P629; Millan J, 2006, NAT CELL BIOL, V8, P113, DOI 10.1038/ncb1356; Mishra JP, 2005, J BIOL CHEM, V280, P26825, DOI 10.1074/jbc.M500244200; Mummert DI, 2004, J INVEST DERMATOL, V122, P846, DOI 10.1046/j.0022-202X.2004.22127.x; Mummert ME, 2002, J IMMUNOL, V169, P4322; NIGHTINGALE T, 2005, HYALURONAN STRUCTURE, V2, P615; Nisato RE, 2004, AM J PATHOL, V165, P11, DOI 10.1016/S0002-9440(10)63271-3; Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Pepper MS, 2001, CLIN CANCER RES, V7, P462; Prevo R, 2004, J BIOL CHEM, V279, P52580, DOI 10.1074/jbc.M406897200; Prevo R, 2001, J BIOL CHEM, V276, P19420, DOI 10.1074/jbc.M011004200; Pullinger BD, 1937, J PATHOL BACTERIOL, V45, P157, DOI 10.1002/path.1700450115; Rubbia-Brandt L, 2004, CLIN CANCER RES, V10, P6919, DOI 10.1158/1078-0432.CCR-04-0397; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; STERN R, 2006, INT J CELL BIOL, V85, P699; Stessels F, 2004, BRIT J CANCER, V90, P1429, DOI 10.1038/sj.bjc.6601727; TAMMI R, 1991, J INVEST DERMATOL, V97, P126, DOI 10.1111/1523-1747.ep12478553; TAMMI R, 1994, PROG HISTOCHEM CYTOC, V29, P1; Tamura Y, 2003, J BIOL CHEM, V278, P12613, DOI 10.1074/jbc.M210211200; Termeer CC, 2000, J IMMUNOL, V165, P1863; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Van der Auwera I, 2004, CLIN CANCER RES, V10, P7965, DOI 10.1158/1078-0432.CCR-04-0063; Van Trappen PO, 2001, GYNECOL ONCOL, V82, P1, DOI 10.1006/gyno.2001.6292; VANDERAUWERA I, 2006, BE J CANC, P1; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; West D. C., 1989, CIBA F SYMP, V143, P201; Wigle JT, 1999, CELL, V98, P769, DOI 10.1016/S0092-8674(00)81511-1; Witte MH, 2006, CANCER METAST REV, V25, P159, DOI 10.1007/s10555-006-8496-2; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	59	78	81	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 16	2007	282	46							33671	10.1074/jbc.M702889200		10	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	229XP	WOS:000250840200048	17884820	
J	Ko, FWS; Tam, W; Wong, TW; Lai, CKW; Wong, GWK; Leung, TF; Ng, SSS; Hui, DSC				Ko, F. W. S.; Tam, W.; Wong, T. W.; Lai, C. K. W.; Wong, G. W. K.; Leung, T.-F.; Ng, S. S. S.; Hui, D. S. C.			Effects of air pollution on asthma hospitalization rates in different age groups in Hong Kong	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						age; air pollution; asthma; exacerbation; Hong Kong	EMERGENCY-DEPARTMENT VISITS; ACUTE RESPIRATORY SYNDROME; AMBIENT AIR; CARDIOVASCULAR-DISEASES; HEART-FAILURE; ADMISSIONS; CHILDREN; MORTALITY; CITIES; ASSOCIATIONS	Aims To assess the relationship between levels of ambient air pollutants and hospitalization rates for asthma in Hong Kong (HK). Methods This is a retrospective ecological study. Data of daily emergency hospital admissions to 15 major hospitals in HK for asthma and indices of air pollutants [sulphur dioxide (SO2), nitrogen dioxide (NO2), ozone (O-3), particulates with an aerodynamic diameter of < 10 mu m particulate matter (PM10) and 2.5 mu m (PM2.5)] and meteorological variables from January 2000 to December 2005 were obtained from several government departments. Analysis was performed by the generalized additive models with Poisson distribution. The effects of time trend, season, other cyclical factors, temperature and humidity were adjusted. Autocorrelation and overdispersion were corrected. Results Altogether, 69 716 admissions were assessed. Significant associations were found between hospital admissions for asthma and levels of NO2, O-3, PM10 and PM2.5. The relative risks (RR) for hospitalization for every 10 mu g/m(3) increase in NO2, O-3, PM10 and PM2.5 were 1.028, 1.034, 1.019 and 1.021, respectively, at a lag day that ranged from cumulative lag 0-4 to 0-5. In a multi-pollutant model, O-3 was significantly associated with increased admissions for asthma. The younger age group (0-14 years) tended to have a higher RR for each 10 mu g/m(3) increase in pollutants than those aged 15-65 years. The elderly (aged >= 65 years) had a shorter 'best' lag time to develop asthma exacerbation following exposure to pollutants than those aged < 65 years. Conclusion Adverse effects of ambient concentrations of air pollutants on hospitalization rates for asthma are evident. Measures to improve air quality in HK are urgently needed.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Nethersole Sch Nursing, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Community & Family Med, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Pediat, Hong Kong, Hong Kong, Peoples R China	Hui, DSC (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Med & Therapeut, 30-32 Ngan Shing St, Hong Kong, Hong Kong, Peoples R China.	dschui@cuhk.edu.hk	Tam, Wilson/E-9887-2010; Wong, Tze Wai/K-5344-2013; Wang, Linden/M-6617-2014; Hui, David/O-2754-2015; Ko, Fanny/B-8958-2016	Ko, Fanny/0000-0001-8454-0087; Tam, Wilson/0000-0003-0641-3060			Anderson HR, 1998, THORAX, V53, P842; Arena VC, 2006, J OCCUP ENVIRON MED, V48, P38, DOI 10.1097/01.jom.0000183096.20678.f1; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Boutin-Forzano S, 2004, RESPIRATION, V71, P134, DOI 10.1159/000076673; CHANG A, 2005, AIR QUALITY HONG KON; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Galan I, 2003, EUR RESPIR J, V22, P802, DOI 10.1183/09031936.03.00013003; Hastie T, 1995, Stat Methods Med Res, V4, P187, DOI 10.1177/096228029500400302; Hastie T., 1990, GENERALIZED ADDITIVE; *HTLH EFF I, 2004, HLTH EFF OUTD AIR PO; *HTLH EFF I, 2003, REV AN TIM SER STUD; Hui DSC, 2003, CHEST, V124, P12, DOI 10.1378/chest.124.1.12; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Katsouyanni K, 2002, EPIDEMIOLOGY, V13, P742, DOI 10.1097/01.EDE.0000032424.22670.3E; Ko FWS, 2006, RESP MED, V100, P1598, DOI 10.1016/j.rmed.2005.12.007; Lee N, 2003, NEW ENGL J MED, V348, P1986, DOI 10.1056/NEJMoa030685; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; National Research Council, 2004, RES PRIOR AIRB PART, VIV; *NMMAPSDATA R PACK, NAT MORT MORB AIR PO; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Petroeschevsky A, 2001, ARCH ENVIRON HEALTH, V56, P37; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Stieb David M, 2002, Environ Health, V1, P7, DOI 10.1186/1476-069X-1-7; Wellenius GA, 2006, AM J CARDIOL, V97, P404, DOI 10.1016/j.amjcard.2005.08.061; World Health Organization, 2006, WHOCDSNTDWHOPESGCDPP, P1; *WHO, 1977, WHO INT CLASS DIS 19; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P565, DOI 10.1046/j.1365-2222.2001.01063.x; Wong TW, 2002, OCCUP ENVIRON MED, V59, P30, DOI 10.1136/oem.59.1.30; Wong TW, 1999, OCCUP ENVIRON MED, V56, P679; Yap FHY, 2004, J MED VIROL, V73, P617, DOI 10.1002/jmv.20135; 2002, STUDY AIR QUALITY PE; HONG KONG SPECIAL AD; 2005, IMPROVING AIR QUALIT, P1	40	78	83	5	22	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2007	37	9					1312	1319		10.1111/j.1365-2222.2007.02791.x		8	Allergy; Immunology	Allergy; Immunology	207LR	WOS:000249253100008	17845411	
J	Roder, E; Berger, MY; Hop, WCJ; Bernsen, RMD; de Groot, H; van Wijk, RG				Roder, Esther; Berger, Marjolein Y.; Hop, Wim C. J.; Bernsen, Roos M. D.; de Groot, Hans; van Wijk, Roy Gerth			Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						immunotherapy; sublingual; grass pollen; allergic rhinitis; child; adolescent; primary care	SEASONAL ALLERGIC RHINOCONJUNCTIVITIS; PLACEBO-CONTROLLED EVALUATION; RANDOMIZED CONTROLLED-TRIAL; HOUSE-DUST MITE; QUALITY-OF-LIFE; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; PEDIATRIC-PATIENTS; CHILDREN; RHINITIS	Background: Sublingual immunotherapy (SLIT) is considered safer and more convenient than subcutaneous therapy and therefore has been proposed as especially suitable for children and in primary care. Most efficacy studies in children lack power to be conclusive, and all have been performed in referral centers. Objective: To investigate the efficacy of SLIT with grass pollen allergen in children and adolescents with rhinoconjunctivitis in a primary care setting. Methods: Youngsters aged 6-18 years with hay fever were enrolled from general practices and randomly assigned to receive placebo or grass pollen mix for 2 years. The primary outcome was the mean daily total symptom score (scale 0-15) comprising sneezing, itching nose, watery running nose, nasal blockage, and itching eyes during the months May-August of the second treatment year. Results: Out of 204 youngsters randomized, 168 entered the intention-to-treat analysis (91 verum, 77 placebo). The mean daily total symptom score did not differ between participants allocated to verum and those allocated to placebo (difference for verum minus placebo: -0.08, 95% CI, -0.66-0.50; P =.78). No differences were found for rescue medication-free days, disease-specific quality of life, and overall evaluation of the treatment effect. Local side effects were more frequent in the verum group (39% vs 17% of participants; P =.001). Conclusion: Sublingual immunotherapy with grass pollen in a primary care setting is not effective in children and adolescents. Clinical implications: Currently, SLIT cannot be recommended for general practitioners as a therapeutic modality in youngsters with grass pollen allergy.	Erasmus MC Univ, Med Ctr, Sect Allergol, Dept Internal Med, NL-3000 CA Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr, Dept Gen Practice, NL-3000 CA Rotterdam, Netherlands; Erasmus MC Univ, Med Ctr, Dept Epidemiol & Biostat, NL-3000 CA Rotterdam, Netherlands	van Wijk, RG (reprint author), Erasmus MC Univ, Med Ctr, Sect Allergol, Dept Internal Med, POB 2040, NL-3000 CA Rotterdam, Netherlands.	r.gerthvanwijk@erasmusmc.nl					Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bodtger U, 2003, CLIN EXP ALLERGY, V33, P496, DOI 10.1046/j.1365-2222.2003.01611.x; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 1998, ALLERGY S, V53, P44; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; Juniper EF, 1998, J ALLERGY CLIN IMMUN, V101, P163; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lamberts H, 1987, INT CLASSIFICATION P; Malling HJ, 1998, ALLERGY, V53, P461; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Van Hoecke H, 2006, ALLERGY, V61, P705, DOI 10.1111/j.1398-9995.2006.01057.x; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wilson DR, 2003, COCHRANE DB SYST REV, V2; Winther L, 2000, ALLERGY, V55, P818, DOI 10.1034/j.1398-9995.2000.00367.x; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	31	78	80	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2007	119	4					892	898		10.1016/j.jaci.2006.12.651		7	Allergy; Immunology	Allergy; Immunology	157OK	WOS:000245729500017	17321581	
J	Passos, GF; Fernandes, ES; da Cunha, FM; Ferreira, J; Pianowski, LF; Campos, MM; Calixto, JB				Passos, Giselle F.; Fernandes, Elizabeth S.; da Cunha, Fernanda M.; Ferreira, Juliano; Pianowski, Luiz F.; Campos, Maria M.; Calixto, Joao B.			Anti-inflammatory and anti-allergic properties of the essential oil and active compounds from Cordia verbenacea	JOURNAL OF ETHNOPHARMACOLOGY			English	Article						essential oil; Cordia verbenacea; inflammation; allergy; TNF alpha; active compounds	CARRAGEENAN-INDUCED INFLAMMATION; CRUDE LEAF EXTRACT; PHARMACOLOGICAL ASSAY; UP-REGULATION; PLANT-ORIGIN; NITRIC-OXIDE; RAT; EDEMA; MODULATION; CYCLOOXYGENASE-2	The anti-inflammatory and anti-allergic effects of the essential oil of Cordia verbenacea (Boraginaceae) and some of its active compounds were evaluated. Systemic treatment with the essential oil of Cordia verbenacea (300-600 mg/kg, p.o.) reduced carrageenan-induced rat paw oedema, myeloperoxidase activity and the mouse oedema elicited by carrageenan, bradykinin, substance P, histamine and platelet-activating factor. It also prevented carrageenan-evoked exudation and the neutrophil influx to the rat pleura and the neutrophil migration into carrageenan-stimulated mouse air pouches. Moreover, Cordia verbenacea oil inhibited the oedema caused by Apis mellifera venom or ovalbumin in sensitized rats and ovalbumin-evoked allergic pleurisy. The essential oil significantly decreased TNF alpha, without affecting IL-1 beta production, in carrageenan-injected rat paws. Neither the PGE(2) formation after intrapleural injection of carrageenan nor the COX-1 or COX-2 activities in vitro were affected by the essential oil. Of high interest, the paw edema induced by carrageenan in mice was markedly inhibited by both sesquiterpenic compounds obtained from the essential oil: alpha-humulene and trans-caryophyllene (50 mg/kg, p.o.). Collectively, the present results showed marked anti-inflammatory effects for the essential oil of Cordia verbenacea and some active compounds, probably by interfering with TNFa production. Cordia verbenacea essential oil or its constituents might represent new therapeutic options for the treatment of inflammatory diseases. (c) 2006 Elsevier Ireland Ltd. All rights reserved.	Univ Fed Santa Catarina, Ctr Biol Sci, Dept Pharmacol, BR-88049900 Florianopolis, SC, Brazil	Calixto, JB (reprint author), Univ Fed Santa Catarina, Ctr Biol Sci, Dept Pharmacol, BR-88049900 Florianopolis, SC, Brazil.	calixto@farmaco.ufsc.br	Fernandes, Elizabeth/J-9397-2012; Ferreira, Juliano/A-9803-2013; Campos, Maria Martha/J-8829-2015; Marques da Cunha, Fernanda/G-3575-2012	Ferreira, Juliano/0000-0002-9562-0602; Campos, Maria Martha/0000-0002-1153-3633; Marques da Cunha, Fernanda/0000-0002-1583-5380; Campos, Maria/0000-0001-7738-9892			BRADLEY PP, 1982, J INVEST DERMATOL, V78, P206, DOI 10.1111/1523-1747.ep12506462; Calixto JB, 2004, PLANTA MED, V70, P93, DOI 10.1055/s-2004-815483; Calixto JB, 2003, PLANTA MED, V69, P973, DOI 10.1055/s-2003-45141; Calixto MC, 2003, INFLAMM RES, V52, P132, DOI 10.1007/s000110300026; Campos MM, 2002, BRIT J PHARMACOL, V135, P1107, DOI 10.1038/sj.bjp.0704488; CORREA CR, 1993, BRIT J PHARMACOL, V110, P193; de Carvalho PM, 2004, J ETHNOPHARMACOL, V95, P297, DOI 10.1016/j.jep.2004.07.028; DeCampos ROP, 1996, EUR J PHARMACOL, V316, P277, DOI 10.1016/S0014-2999(96)00661-9; Di Rosa M, 1971, J Pharm Pharmacol, V23, P297; DIROSA M, 1971, J PATHOL, V104, P15, DOI 10.1002/path.1711040103; EDWARDS JCW, 1981, J PATHOL, V134, P147, DOI 10.1002/path.1711340205; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; Feldmann M, 2002, NAT REV IMMUNOL, V2, P364, DOI 10.1038/nri802; GILLIGAN JP, 1994, INFLAMMATION, V18, P285, DOI 10.1007/BF01534269; HWANG SB, 1986, EUR J PHARMACOL, V120, P33, DOI 10.1016/0014-2999(86)90636-9; Ianaro A, 2000, J PHARMACOL EXP THER, V292, P156; Jorge LIF, 1998, REV BRASILEIRA FARMA, V79, P69; MARTINS MA, 1993, J LEUKOCYTE BIOL, V53, P104; Murakami M, 2004, PROG LIPID RES, V43, P3, DOI 10.1016/S0163-7827(03)00037-7; Nantel F, 1999, BRIT J PHARMACOL, V128, P853, DOI 10.1038/sj.bjp.0702866; Passos GF, 2004, J IMMUNOL, V172, P1839; Pinheiro RM, 2002, INFLAMM RES, V51, P603, DOI 10.1007/PL00012435; Portanova JP, 1996, J EXP MED, V184, P883, DOI 10.1084/jem.184.3.883; Salvemini D, 1996, BRIT J PHARMACOL, V118, P829; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SERTIE J A A, 1988, Planta Medica, V54, P7, DOI 10.1055/s-2006-962318; SERTIE JAA, 1990, PLANTA MED, V56, P36, DOI 10.1055/s-2006-960879; Sertie JAA, 2005, PHYTOMEDICINE, V12, P338, DOI 10.1016/j.phymed.2003.09.013; SERTIE JAA, 1991, J ETHNOPHARMACOL, V31, P239, DOI 10.1016/0378-8741(91)90008-2; SIN YM, 1992, ANN RHEUM DIS, V51, P112, DOI 10.1136/ard.51.1.112; STOCHLA K, 1982, AGENTS ACTIONS, V12, P201, DOI 10.1007/BF01965145; Ticli FK, 2005, TOXICON, V46, P318, DOI 10.1016/j.toxicon.2005.04.023; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI13416; Tratsk KS, 1997, INFLAMM RES, V46, P509, DOI 10.1007/s000110050234; Van Assche G, 2000, EXPERT OPIN INV DRUG, V9, P103; VINEGAR R, 1973, P SOC EXP BIOL MED, V143, P711	36	78	86	0	15	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0378-8741			J ETHNOPHARMACOL	J. Ethnopharmacol.	MAR 21	2007	110	2					323	333		10.1016/j.jep.2006.09.032		11	Plant Sciences; Chemistry, Medicinal; Integrative & Complementary Medicine; Pharmacology & Pharmacy	Plant Sciences; Pharmacology & Pharmacy; Integrative & Complementary Medicine	154DL	WOS:000245486900013	17084568	
J	Pham-Thi, N; Scheinmann, P; Fadel, R; Combebias, A; Andre, C				Pham-Thi, Nhan; Scheinmann, Pierre; Fadel, Riad; Combebias, Anne; Andre, Claude		Study Grp	Assessment of sublingual immunotherapy efficacy in children with house dust mite-induced allergic asthma optimally controlled by pharmacologic treatment and mite-avoidance measures	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						asthma; corticosteroids; house dust mite; allergy; sublingual immunotherapy	RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; DERMATOPHAGOIDES-PTERONYSSINUS; SWALLOW IMMUNOTHERAPY; INHALED CORTICOSTEROIDS; CLINICAL-EFFICACY; FOLLOW-UP; RHINITIS; EXTRACT; SAFETY	Although several studies have demonstrated the efficacy of subcutaneous immunotherapy in allergic asthma, few have shown the same benefit using sublingual immunotherapy (SLIT) in asthmatic patients. This study was conducted to assess the efficacy of house dust mite (HDM) SLIT in addition to allergen avoidance and standard pharmacologic treatment. A double-blind, placebo-controlled trial was performed in 111 children (aged 5-15 yr) with HDM-induced mild-to-moderate asthma. After a 4-week baseline phase, patients were randomly assigned to receive SLIT with tablets of HDM extract (n = 55) or placebo (n = 56) for 18 months. Pharmacologic treatment was adjusted every 3 months following a step-down approach. Asthma symptom scores, reduction in use of inhaled corticosteroids and inhaled beta(2)-agonists, rhinitis symptoms, lung function tests, skin sensitivity to HDM, dust mite-specific immunoglobulin (Ig) E and IgG(4), and quality of life (QoL) were assessed during the study. After 18 months of treatment, diurnal and nocturnal asthma symptoms scores did not show significant differences between SLIT and placebo groups. Inhaled corticosteroids and inhaled beta(2)-agonists use was reduced in both groups without significant differences between groups. There were no significant differences in lung function (forced expiratory volume in 1 s and peak flow rate variations) between groups. Rhinitis symptom score decreased in both groups, with no difference between the two groups. The severity dimension of QoL was significantly improved in the SLIT group (age 6-12 yr). SLIT induced a significant reduction of skin sensitivity to HDM (p < 0.01) and a significant increase in HDM-specific IgE and IgG(4) antibodies (p < 0.001) in the SLIT group compared with the placebo group. SLIT was well tolerated with mild/moderate local adverse events. No severe systemic reactions were reported. This study indicates that, when mild-moderate asthmatic children are optimally controlled by pharmacologic treatment and HDM avoidance, SLIT does not provide additional benefit, despite a significant reduction in allergic response to HDM. Under such conditions, only a complete, but ethically unfeasible, discontinuation of inhaled corticosteroid would have demonstrated a possible benefit of SLIT.	Hop Necker Enfants Malad, Dept Paediat Pneumol & Allergy, Paris, France; Stallergenes SA, Sci & Med Dept, Antony, France	Andre, C (reprint author), Stallergenes SA, Dept Med, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.	candre@stallergenes.fr					Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Bacharier LB, 2002, J ALLERGY CLIN IMMUN, V109, P916, DOI 10.1067/mai.2002.124665; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CHRISTIE MJ, 1993, PSYCHOSOM MED, V55, P541; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Gruber W, 1999, CLIN EXP ALLERGY, V29, P176; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hawkins G, 2003, BRIT MED J, V326, P1115, DOI 10.1136/bmj.326.7399.1115; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; KHINCHI M, 2004, ALLERGY, V58, P45; LIND P, 1986, ALLERGY, V41, P442, DOI 10.1111/j.1398-9995.1986.tb00325.x; Luczynska C, 2003, CLIN EXP ALLERGY, V33, P1648, DOI 10.1111/j.1365-2222.2003.01729.x; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Marcucci F, 2005, PEDIATR ALLERGY IMMU, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; *NHLBI WHO, 1995, PUBL NHLBI WHO; Novembre E, 2004, J ALLERGY CLIN IMMUN, V114, P851, DOI 10.1016/j.jaci.2004.07.012; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; Platts-Mills TA, 1997, J ALLERGY CLIN IMM S, V100, P2; Plaut Marshall, 2004, Clin Allergy Immunol, V18, P681; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; WAALKENS HJ, 1993, AM REV RESPIR DIS, V148, P1252; WARNER JO, 1978, LANCET, V2, P912; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	44	78	81	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	FEB	2007	18	1					47	57		10.1111/j.1399-3038.2006.00475.x		11	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	134CO	WOS:000244060400008	17295799	
J	Akdis, M				Akdis, Muebeccel			Healthy immune response to allergens: T regulatory cells and more	CURRENT OPINION IN IMMUNOLOGY			English	Review							IN-VIVO; BEE VENOM; AUTOIMMUNE-DISEASES; ANTIBODY-RESPONSES; ATOPIC-DERMATITIS; DENDRITIC CELLS; IMMUNOTHERAPY; IL-10; EXPRESSION; TOLERANCE	The specific immune response to allergens is decisive in the development of clinically healthy or allergic states. In healthy individuals, the B-cell response varies between there being no response and the production of IgG(4)- or IgG(1)-dominating allergen-specific antibodies in the presence or absence of low amounts of IgE. If a detectable immune response is mounted, T regulatory type 1 (Tr1) cells specific for common environmental allergens consistently represent the dominant subset in healthy individuals. Exposure to high doses of allergens leads to a high concentration of specific IgG(4), detectable IgE and a TO type of immune response. Induction of IL-10- and TGF-beta-producing TO cells, IgG(4) isotype blocking antibodies, and suppressed mast cells, basophils and eosinophils represent major components of a relatively normalized immune response after allergen-specific immunotherapy (SIT).	Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Akdis, M (reprint author), Swiss Inst Allergy & Asthma Res, Obere Str 22, CH-7270 Davos, Switzerland.	akdism@siaf.unizh.ch					Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 2004, CURR OPIN IMMUNOL, V16, P717, DOI 10.1016/j.coi.2004.09.004; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 2000, FASEB J, V14, P1666; Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Akdis CA, 2001, TRENDS IMMUNOL, V22, P175, DOI 10.1016/S1471-4906(01)01862-2; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; BACCHETTA R, 1994, J EXP MED, V179, P493, DOI 10.1084/jem.179.2.493; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; BECKER JC, 1994, INT IMMUNOL, V6, P1605, DOI 10.1093/intimm/6.10.1605; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Bilo BM, 2005, ALLERGY, V60, P1339, DOI 10.1111/j.1398-9995.2005.00963.x; CARBALLIDO JM, 1993, J IMMUNOL, V150, P3582; Chatila TA, 2000, J CLIN INVEST, V106, P75; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cottrez F, 2000, J IMMUNOL, V165, P4848; Diebold RJ, 1995, P NATL ACAD SCI USA, V92, P12215, DOI 10.1073/pnas.92.26.12215; ENK AH, 1994, J EXP MED, V179, P1397, DOI 10.1084/jem.179.4.1397; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Groux H, 1997, NATURE, V389, P737; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Huber S, 2004, J IMMUNOL, V173, P6526; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Karagiannidis C, 2004, J ALLERGY CLIN IMMUN, V114, P1425, DOI 10.1016/j.jaci.2004.07.014; Karamloo F, 2005, EUR J IMMUNOL, V35, P3268, DOI 10.1002/eji.200425522; Klunker S, 2003, J IMMUNOL, V171, P1078; Kruszewski Jerzy, 1994, Archivum Immunologiae et Therapiae Experimentalis, V42, P259; Kunzmann S, 2003, FASEB J, V17, P1089, DOI 10.1096/fj.02-1008com; Kussebi F, 2005, J ALLERGY CLIN IMMUN, V115, P323, DOI 10.1016/j.jaci.2004.011.041; Larche M, 2005, NAT MED, V11, pS69, DOI 10.1038/nm1226; Levings MK, 2001, J IMMUNOL, V166, P5530; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Mamura M, 2004, BLOOD, V103, P4594, DOI 10.1182/blood-2003-08-2897; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; McCoy KD, 2006, IMMUNITY, V24, P329, DOI 10.1016/j.immuni.2006.01.013; MOSMANN TR, 1996, IMMUNOL TODAY, V17, P142; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muller U, 1993, ALLERGY          S14, V48, P36; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Osna N, 2001, INT IMMUNOPHARMACOL, V1, P85, DOI 10.1016/S0162-3109(00)00268-X; Pereira EAL, 2005, ALLERGY, V60, P401, DOI 10.1111/j.1398-9995.2005.00738.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; SAKAGUCHI S, 1995, J IMMUNOL, V155, P1151; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; TAYLOR A, 2006, IN PRESS FASEB J; VanRee R, 1997, CLIN EXP ALLERGY, V27, P68, DOI 10.1046/j.1365-2222.1997.d01-416.x; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Zinkernagel RM, 1997, IMMUNOL REV, V156, P199, DOI 10.1111/j.1600-065X.1997.tb00969.x	58	78	86	1	5	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2006	18	6					738	744		10.1016/j.coi.2006.06.003		7	Immunology	Immunology	105NL	WOS:000242036900016	17023149	
J	Kunzli, N; Avol, E; Wu, J; Gauderman, WJ; Rappaport, E; Millstein, J; Bennion, J; McConnell, R; Gilliland, FD; Berhane, K; Lurmann, F; Winer, A; Peters, JM				Kunzli, Nino; Avol, Ed; Wu, Jun; Gauderman, W. James; Rappaport, Ed; Millstein, Joshua; Bennion, Jonathan; McConnell, Rob; Gilliland, Frank D.; Berhane, Kiros; Lurmann, Fred; Winer, Arthur; Peters, John M.			Health effects of the 2003 Southern California wildfires on children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						air pollution; asthma; sore throat; wheezing	AMBIENT AIR-POLLUTION; RESPIRATORY HEALTH; PARTICULATE MATTER; FOREST-FIRES; EXPOSURE; QUALITY; VISITS; ASTHMA; SMOKE	Rationale: In late October 2003, Southern California wildfires burned more than 3,000 km(2). The wildfires produced heavy smoke that affected several communities participating in the University of Southern California Children's Health Study (CHS). Objectives: To study the acute effects of fire smoke on the health of CHS participants. Methods: A questionnaire was used to assess smoke exposure and occurrence of symptoms among CHS high-school students (n = 873; age, 17-18 yr) and elementary-school children (n = 5,551; age, 6-7 yr), in a total of 16 communities. Estimates of particulate matter (PM10) concentrations during the 5 d with the highest fire activity were used to characterize community smoke level. Main Results: All symptoms (nose, eyes, and throat irritations; cough; bronchitis; cold; wheezing; asthma attacks), medication usage, and physician visits were associated with individually reported exposure differences within communities. Risks increased monotonically with the number of reported smoky days. For most outcomes, reporting rates between communities were also associated with the fire-related PM10 levels. Associations tended to be strongest among those without asthma. Individuals with asthma were more likely to take preventive action, such as wearing masks or staying indoors during the fire. Conclusions: Exposure to wildfire smoke was associated with increased eye and respiratory symptoms, medication use, and physician visits.	Inst Municipal Invest Med, E-08003 Barcelona, Spain; ICREA, Barcelona, Spain; Univ So Calif, Los Angeles, CA USA	Kunzli, N (reprint author), Inst Municipal Invest Med, C Doct Aiguader 80, E-08003 Barcelona, Spain.	kuenzli@imim.es	Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	NIEHS NIH HHS [3P01ES011627-03S2, 5P01ES11627, 5P30 ES07048]		Boman C, 2006, EUR RESPIR J, V27, P446, DOI 10.1183/09031936.06.00000806; DUCLOS P, 1990, ARCH ENVIRON HEALTH, V45, P53; Emmanuel S C, 2000, Respirology, V5, P175, DOI 10.1046/j.1440-1843.2000.00247.x; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; Heinrich J, 2005, OCCUP ENVIRON MED, V62, P517, DOI 10.1136/oem.2004.016766; Henderson DE, 2005, J AIR WASTE MANAGE, V55, P1516, DOI 10.1080/10473289.2005.10464746; Jalaludin B, 2000, AUST NZ J PUBL HEAL, V24, P174, DOI 10.1111/j.1467-842X.2000.tb00138.x; JALALUDIN B, 2004, ENV HLTH, V4, P20; Jalaludin BB, 2004, ENVIRON RES, V95, P32, DOI 10.1016/S0013-9351(03)00038-0; Johnson J. M., 2005, MORB MORTAL WKLY R S, V54, P190; KUNZLI N, 2005, EUR RESPIR J, V26, pS385; Malilay J, 1999, HLTH GUIDELINES VEGE, P258; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Mott JA, 2002, WESTERN J MED, V176, P157, DOI 10.1136/ewjm.176.3.157; Oglesby L, 2000, AM J EPIDEMIOL, V152, P75, DOI 10.1093/aje/152.1.75; Ovadnevaite J, 2006, SCI TOTAL ENVIRON, V356, P11, DOI 10.1016/j.scitotenv.2005.04.013; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; PETERS JM, 1974, NEW ENGL J MED, V291, P1320, DOI 10.1056/NEJM197412192912502; Phuleria HC, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD004626; Sastry N, 2002, DEMOGRAPHY, V39, P1, DOI 10.1353/dem.2002.0009; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213; VanEeden SF, 1997, MICROCIRCULATION-LON, V4, P369, DOI 10.3109/10739689709146801; Viswanathan S, 2006, J AIR WASTE MANAGE, V56, P56; Wu J, 2006, ATMOS ENVIRON, V40, P3333, DOI 10.1016/j.atmosenv.2006.01.056; Zelikoff JT, 2002, J TOXICOL ENV HEAL B, V5, P269, DOI 10.1080/10937400290070062	25	78	79	1	23	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 1	2006	174	11					1221	1228		10.1164/rccm.200604-519OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	109BU	WOS:000242283700013	16946126	
J	von Mutius, E; Schmid, S				von Mutius, E; Schmid, S		PASTURE Study Grp	The PASTURE project: EU support for the improvement of knowledge about risk factors and preventive factors for atopy in Europe	ALLERGY			English	Article						allergy; asthma; atopic sensitization; farming; hygiene hypothesis; infectious disease; microbial stimuli; toll-like receptors	HOUSE-DUST ENDOTOXIN; RESPIRATORY-SYNCYTIAL-VIRUS; TOLL-LIKE RECEPTOR-2; ALLERGIC SENSITIZATION; FARMERS CHILDREN; EARLY-LIFE; HAY-FEVER; 1ST YEAR; SCHOOL-AGE; ASTHMA	Since January 2002, the European Commission is funding a large project, 'Protection against Allergy - Study in Rural Environments' (PASTURE; contract no. QLK4-2001-00250), under the Fifth Framework Program in the field of epidemiology of allergic diseases. The aim of this paper was to describe the background and design as well as the aims of the project. Asthma and allergic disorders are a major public health problem in many Western countries. The aetiology of asthma and allergic disease remains poorly understood despite considerable research. Epidemiology has the potential to add greatly to the understanding by elucidating the risk factors for asthma and allergic disease and thereby suggesting productive avenues for research into causation and prevention. Several risk factors for the development of asthma and atopic disease in children such as passive smoke exposure during pregnancy and infancy, low birth weight or high body mass index later in life have been described. Furthermore, there is consistent evidence that the prevalence of atopy increases with higher socio-economic status. Levels of air pollution such as ozone, NO2, SO2 and particles are likely to provoke acute exacerbations of pre-existent respiratory disease. Their role in the inception of asthma and allergies remains to be clarified. Allergen exposure has been linked to the development of atopic sensitization to that particular allergen in children as well as in adults with occupational exposures. Exposure to house dust mite or cat allergen is, however, unlikely to contribute to the development of childhood asthma. In turn, pet keeping in the first year of life, particularly, dog keeping, has been inversely related to the development of wheeze and atopic illnesses. Several prospective birth cohort studies found a decreased prevalence of atopic disease in children having daily contact to pets, in particular to cats and dogs, during early infancy (1, 2). The protective effect might be attributable to allergen or other exposures associated with pet ownership, but may also in part be because of the removal of pets in families with sensitized or symptomatic children or in families with a positive history for atopy at the time the child was born.	Univ Munich, Univ Childrens Hosp, PASTURE, D-80337 Munich, Germany	Schmid, S (reprint author), Univ Munich, Univ Childrens Hosp, PASTURE, Lindwurmstr 4, D-80337 Munich, Germany.						Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cardoso MRA, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-19; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, AM J IND MED, V46, P396, DOI 10.1002/ajim.20088; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; FERRIS BG, 1978, AM REV RESPIR DIS, V188, P1; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2000, J ALLERGY CLIN IMMUN, V106, P201; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Korppi M, 2004, PEDIATR PULM, V38, P155, DOI 10.1002/ppul.20058; Kruisselbrink A, 2001, CLIN EXP IMMUNOL, V126, P2, DOI 10.1046/j.1365-2249.2001.01642.x; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Noble V, 1997, ARCH DIS CHILD, V76, P315; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; Remes ST, 2005, CLIN EXP ALLERGY, V35, P160, DOI 10.1111/j.1365-2222.2005.02172.x; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Williams LK, 2004, J ALLERGY CLIN IMMUN, V113, P291, DOI 10.1016/j.jaci.2003.11.010	38	78	78	0	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	APR	2006	61	4					407	413		10.1111/j.1398-9995.2006.01009.x		7	Allergy; Immunology	Allergy; Immunology	016BC	WOS:000235594500003	16512801	
J	Sunyer, J; Torrent, M; Munoz-Ortiz, L; Ribas-Fito, N; Carrizo, D; Grimalt, J; Anto, JM; Cullinan, P				Sunyer, J; Torrent, M; Munoz-Ortiz, L; Ribas-Fito, N; Carrizo, D; Grimalt, J; Anto, JM; Cullinan, P			Prenatal dichlorodiphenyldichloroethylene (DDE) and asthma in children	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; atopy; children; DDE dichlorodiphenyldichloroethylene; organochlorines	ORGANOCHLORINE COMPOUNDS; IMMUNE-SYSTEM; CORD BLOOD; EXPOSURE; HEALTH; HEXACHLOROBENZENE; ASSOCIATIONS; SUPPRESSION; INFECTIONS; CHILDHOOD	Prevalence of asthma increases with increasing dichlorodiphenyldichloroethylene (DDE) levels. However, the effect of early-life exposure, the fundamental window of exposure, is unknown. We assessed the association between prenatal DDE and other organochlorine compounds, and atopy and asthma during infancy. All women presenting for antenatal care in Menorca (Spain) over 12 months starting in mid-1997 were invited to take part in a longitudinal study; 482 children were subsequently enrolled, and 468 (97.1%) provided complete outcome data up to the fourth year of study. Prenatal exposure of organochlorine compounds was measured in cord serum in 405 (83%) children. Asthma was defined on the basis of wheezing at 4 years of age, persistent wheezing, or doctor-diagnosed asthma. We measured specific immunoglobulin-E (IgE) against house dust mite, cat, and grass in sera extracted at 4 years of age. DDE (median=1.03 ng/mL) was detected in all children, as well as hexachlorobenzene (0.68 ng/mL) and polychlorobiphenyls (0.69 ng/mL). Wheezing at 4 years of age increased with DDE concentration, particularly at the highest quartile [9% in the lowest quartile (<0.57 ng/mL) vs. 19% in the highest quartile (1.90 ng/mL); relative risk=2.63 (95% confidence interval 1.19-4.69), adjusting for maternal asthma, breast-feeding, education, social class, or other organochlorines]. The association was not modified by IgE sensitization and occurred with the same strength among nonatopic subjects and among those with persistent wheezing or diagnosed asthma. DDE was not associated with atopy alone. Prenatal exposure to DDE residues may contribute to development of asthma.	Inst Municipal Invest Med, Unitat Recerca Resp & Ambiental, E-08003 Barcelona, Catalonia, Spain; Univ Pompeu Fabra, Barcelona, Spain; IB SALUT, Area Salud Menorca, Menorca, Spain; CSIC, Barcelona, Spain; Univ London Imperial Coll Sci Technol & Med, Dept Occupat & Environm Med, London, England	Sunyer, J (reprint author), Inst Municipal Invest Med, Environm Resp Res Unit, C Doctor Aiguader 80, E-08003 Barcelona, Catalonia, Spain.	jsunyer@imim.es	Grimalt, Joan/E-2073-2011; Carrizo Gallardo, Daniel Alejandro/E-2461-2012; Sunyer, J/G-6909-2014	Grimalt, Joan/0000-0002-7391-5768; Carrizo Gallardo, Daniel Alejandro/0000-0003-1568-4591; Sunyer, J/0000-0002-2602-4110			BANARJEE BD, 1987, B ENVIRON CONTAM TOX, V39, P827; BANARJEE BD, 1987, B ENVIRON CONTAM TOX, V39, P822; Barr RG, 2004, ARCH INTERN MED, V164, P379, DOI 10.1001/archinte.164.4.379; Beard J, 2003, ENVIRON HEALTH PERSP, V111, P724, DOI 10.1289/ehp.5885; Bilrha H, 2003, ENVIRON HEALTH PERSP, V111, P1952, DOI 10.1289/ehp.6433; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Chen A, 2003, EMERG INFECT DIS, V9, P960; Cooper GS, 2004, ENVIRON HEALTH PERSP, V112, P1080, DOI 10.1289/ehp.6892; Dallaire F, 2004, ENVIRON HEALTH PERSP, V112, P1359, DOI 10.1289/ehp.7255; Daniel V, 2002, ARCH ENVIRON HEALTH, V57, P541; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Gluckman PD, 2004, SCIENCE, V305, P1733, DOI 10.1126/science.1095292; Hoppin JA, 2002, AM J RESP CRIT CARE, V165, P683, DOI 10.1164/rccm.2106074; Jackola DR, 2003, INT ARCH ALLERGY IMM, V132, P364, DOI 10.1159/000074904; Karmaus W, 2003, PAEDIATR PERINAT EP, V17, P212, DOI 10.1046/j.1365-3016.2003.00488.x; Karmaus W, 2001, ARCH ENVIRON HEALTH, V56, P485; LAHVIS GP, 1995, ENVIRON HEALTH PERSP, V103, P62; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87; Luebke RW, 2001, TOXICOL SCI, V62, P71, DOI 10.1093/toxsci/62.1.71; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Michielsen CCPPC, 1999, ENVIRON HEALTH PERSP, V107, P783, DOI 10.2307/3434341; Nakai K, 2002, TOHOKU J EXP MED, V196, P89, DOI 10.1620/tjem.196.89; NAKANISHI Y, 1985, ENVIRON HEALTH PERSP, V59, P31, DOI 10.2307/3429870; Oddy Wendy H, 2003, J Hum Lact, V19, P250, DOI 10.1177/0890334403255516; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; REHANA T, 1992, B ENVIRON CONTAM TOX, V48, P535; Reichrtova E, 1999, ENVIRON HEALTH PERSP, V107, P895, DOI 10.2307/3454477; Rogan WJ, 2003, PEDIATRICS, V112, P247; Sala M, 2001, CHEMOSPHERE, V43, P895, DOI 10.1016/S0045-6535(00)00450-1; Salem ML, 2000, INT ARCH ALLERGY IMM, V121, P161, DOI 10.1159/000024312; SHAFER KS, 2002, J EPIDEMIOL COMMUNIT, V56, P813; Van den Heuvell RL, 2002, ENVIRON HEALTH PERSP, V110, P595; Vine MF, 2001, AM J EPIDEMIOL, V153, P53, DOI 10.1093/aje/153.1.53; WEISBAND SP, 1995, COMMUN ACM, V38, P40, DOI 10.1145/219663.219678; Weisglas-Kuperus N, 2000, ENVIRON HEALTH PERSP, V108, P1203, DOI 10.2307/3434834; Wendo C, 2004, LANCET, V363, P1376, DOI 10.1016/S0140-6736(04)16095-9	36	78	79	0	6	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	DEC	2005	113	12					1787	1790		10.1289/ehp.8127		4	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	989ZP	WOS:000233713200054	16330365	
J	Martinez, TM; Llapur, CJ; Williams, TH; Coates, C; Gunderman, R; Cohen, MD; Howenstine, MS; Saba, O; Coxson, HO; Tepper, RS				Martinez, TM; Llapur, CJ; Williams, TH; Coates, C; Gunderman, R; Cohen, MD; Howenstine, MS; Saba, O; Coxson, HO; Tepper, RS			High-resolution computed tomography imaging of airway disease in infants with cystic fibrosis	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway structure; high-resolution computed tomography; lung disease	THIN-SECTION CT; PULMONARY-FUNCTION; WALL THICKNESS; YOUNG-CHILDREN; LUNG-DISEASE; ACUTE EXACERBATION; SCORING SYSTEM; ASTHMA; INFLAMMATION; EMPHYSEMA	Rationale: The development of early lung disease in patients with cystic fibrosis (CF) remains poorly defined. Objective: Determine whether asymptomatic infants with CF have evidence for changes in airway structure when assessed by high-resolution computed tomography, and whether airway structure correlates with airway function in this age group. Methods: Thirteen infants with CF (8-33 mo) and 13 control infants (7-25 mo) were evaluated. Airway wall and lumen areas were measured from three 1-mm-thick cross-sectional images obtained from upper, middle, and lower lobes during a respiratory pause with the lungs inflated to an airway pressure of 20 cm H2O. Lung tissue density was measured from images obtained during a respiratory pause at FRC. Forced expiratory flows were measured by the rapid thoracic compression technique in 11 infants with CF. Results: Airway wall area increased more per unit increase in airway size, whereas airway lumen area increased less per unit increase in airway size in the CF than in the control group. Among infants with CF, a greater ratio of wall to lumen area correlated with lower airway function. In addition, lung density at relaxed (passive) FRC was lower for infants with Cl: than for control infants (0.38 vs. 0.43 g/ml; p < 0.02). Conclusions: Our results indicate that infants with CF have thickened airway walls, narrowed airway lumens, and air trapping, when assessed by high-resolution computed tomography, and measurements of airway structure correlated with airway function.	Indiana Univ, Med Ctr, Dept Pediat Pulmonol & Crit Care, Indianapolis, IN 46204 USA; Indiana Univ, Med Ctr, Dept Radiol, Indianapolis, IN 46204 USA; Univ Iowa, Dept Radiol, Iowa City, IA 52242 USA; Vancouver Gen Hosp, Dept Radiol, Vancouver, BC, Canada; Univ British Columbia, St Pauls Hosp, James Hogg ICAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada	Tepper, RS (reprint author), James Whitcomb Riley Hosp Children, Sect Pediat Pulmonol, Dept Pediat, 702 Barnhill Dr,Room 4270, Indianapolis, IN 46202 USA.	rtepper@iupui.edu	Coxson, Harvey/A-9861-2017	Coxson, Harvey/0000-0001-5750-9711			Armstrong DS, 1997, AM J RESP CRIT CARE, V156, P1197; Awadh N, 1998, THORAX, V53, P248; BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; BHALLA M, 1991, RADIOLOGY, V179, P783; Bonnel AS, 2004, PEDIATR PULM, V38, P396, DOI 10.1002/ppul.20091; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865; Brody AS, 2004, J PEDIATR-US, V145, P32, DOI 10.1016/j.jpeds.2004.02.038; Brody AS, 1999, PEDIATR RADIOL, V29, P731, DOI 10.1007/s002470050684; CHOW CW, 1982, EUR J PEDIATR, V139, P240, DOI 10.1007/BF00442171; Coxson HO, 1999, AM J RESP CRIT CARE, V159, P851; Coxson HO, 2004, AM J RESP CRIT CARE, V170, P748, DOI 10.1164/rccm.200405-651OC; COXSON HO, 1995, J APPL PHYSIOL, V79, P1525; de Jong PA, 2004, EUR RESPIR J, V24, P1071, DOI 10.1183/09031936.04.10099804; de Jong PA, 2004, RADIOLOGY, V231, P434, DOI 10.1148/radiol.2312021393; Demirkazik FB, 2001, EUR J RADIOL, V37, P54, DOI 10.1016/S0720-048X(00)00236-9; Goris ML, 2003, CHEST, V123, P1655, DOI 10.1378/chest.123.5.1655; Helbich TH, 1999, RADIOLOGY, V213, P537; HOGG JC, 1994, THORAX, V49, P473, DOI 10.1136/thx.49.5.473; Jones M, 2000, AM J RESP CRIT CARE, V161, P353; KHAN TZ, 1995, AM J RESP CRIT CARE, V151, P1075; King GG, 1999, AM J RESP CRIT CARE, V159, P992; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; LLAPUR CJ, 2005, P AM THORAC SOC, pA576; Long FR, 1999, RADIOLOGY, V212, P588; Long FR, 2004, J PEDIATR-US, V144, P154, DOI 10.1016/j.jpeds.2003.09.026; Maffessanti M, 1996, J THORAC IMAG, V11, P27, DOI 10.1097/00005382-199601110-00002; MARTINEZ T, 2003, AM J RESP CRIT CARE, V167, pA41; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; Nakano Y, 2005, AM J RESP CRIT CARE, V171, P142, DOI 10.1164/rccm.200407-874OC; NAKANO Y, 2002, CHEST S, V122, pS275; NATHANSON I, 1991, PEDIATR PULM, V11, P81, DOI 10.1002/ppul.1950110112; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557; Ranganathan SC, 2002, AM J RESP CRIT CARE, V166, P1350, DOI 10.1164/rccm.2202041; Ranganathan SC, 2001, LANCET, V358, P1964, DOI 10.1016/S0140-6736(01)06970-7; Robinson TE, 2001, J PEDIATR-US, V138, P553, DOI 10.1067/mpd.2001.111820; Robinson TE, 2003, AM J RESP CRIT CARE, V168, P588, DOI 10.1164/rccm.200209-1093OC; ROBINSON TE, IN PRESS CHEST; Rosenfeld M, 2001, PEDIATR PULM, V32, P356, DOI 10.1002/ppul.1144; Saba OI, 2003, J APPL PHYSIOL, V95, P1063, DOI 10.1152/japplphysiol.00962.2002; Santamaria F, 1998, PEDIATRICS, V101, P908, DOI 10.1542/peds.101.5.908; SANTIS G, 1991, CLIN RADIOL, V44, P20, DOI 10.1016/S0009-9260(05)80220-X; Shah RM, 1997, AM J ROENTGENOL, V169, P375; TEPPER RS, 1993, PEDIATR PULM, V16, P96, DOI 10.1002/ppul.1950160204; TEPPER RS, 1988, PEDIATR PULM, V5, P15, DOI 10.1002/ppul.1950050105; Tepper RS, 2004, AM J RESP CRIT CARE, V170, P505, DOI 10.1164/rccm.200401-1320C; TOMASHEFSKI JF, 1986, AM REV RESPIR DIS, V133, P535	47	78	79	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 1	2005	172	9					1133	1138		10.1164/rccm.200412-1665OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	979UV	WOS:000232971400012	16051903	
J	Tager, IB; Balmes, J; Lurmann, F; Ngo, L; Alcorn, S; Kunzli, N				Tager, IB; Balmes, J; Lurmann, F; Ngo, L; Alcorn, S; Kunzli, N			Chronic exposure to ambient ozone and lung function in young adults	EPIDEMIOLOGY			English	Article							AIR-POLLUTION; LONG-TERM; PULMONARY-FUNCTION; NITROGEN-DIOXIDE; CHILDREN; ASSOCIATION; ASTHMA; POLLUTANTS; CALIFORNIA; MORTALITY	Background: Tropospheric ozone (O-3) is an oxidant, outdoor air pollutant. Chronic exposure has been associated with decreased lung function in children and adolescents. This study investigated the effects of long-term exposure to O-3 on lung function in college freshmen. Methods: We recruited University of California, Berkeley students (n = 255) who were lifelong residents of the Los Angeles and San Francisco Bay areas and who never smoked. Lifetime exposures to O-3, small particulate matter (PM10), and nitrogen dioxide (NO2) were based on spatial interpolation of compliance monitor measurements to all residences at which students lived. Spirometry was performed between February and May, times when students would not have had recent exposure to increased levels of O-3. Results: Lifetime exposure to O-3 was associated with decreased levels of measures of small airways ( < 2 mm) function (FEF75 and FEF25-75). There was an interaction with the FEF25-75/FVC ratio, a measure of intrinsic airway size. Subjects with a large ratio were less likely to have decreases in FEF75 and FEF25-75 for a given estimated lifetime exposure to O-3. This association was not altered by history of chronic respiratory disease, allergy, second-hand exposure to environmental tobacco smoke, exposure to PM10 and NO2, or measurement errors in exposure assessment. Conclusions: A history of increased level of lifetime exposure to ambient O-3 is associated with decreased function of airways in which O-3 deposition in the lungs is the greatest. Adolescents with intrinsically smaller airways appear to be at greatest risk. Any environmental or genetic factors that lead to reduced airway size may lead to increased susceptibility to the adverse effects of ambient ozone.	Univ Calif Berkeley, Div Epidemiol, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif Berkeley, Div Environm Hlth Sci, Sch Publ Hlth, Berkeley, CA 94720 USA; Sonoma Technol Inc, Petaluma, CA USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA	Tager, IB (reprint author), Univ Calif Berkeley, Div Epidemiol, Sch Publ Hlth, 140 Warren Hall, Berkeley, CA 94720 USA.	ibt@berkeley.edu	Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	NIEHS NIH HHS [P30 ES07048]; PHS HHS [R01-60689]		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Anderson HR, 1997, EUR RESPIR J, V10, P1064, DOI 10.1183/09031936.97.10051064; Avissar NE, 2000, AM J RESP CRIT CARE, V162, P1342; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; Blomberg A, 1997, AM J RESP CRIT CARE, V156, P418; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; CHOW JC, 1993, AEROSOL SCI TECH, V18, P105, DOI 10.1080/02786829308959588; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; DeMeo DL, 2004, THORAX, V59, P396, DOI 10.1136/thx.2003.012856; DOLISLAGER LJ, 1998, AIR WASTE MANAGEMENT, P108; Frank R, 2001, AM J RESP CRIT CARE, V164, P1253; Frischer T, 1999, AM J RESP CRIT CARE, V160, P390; FUJINAKA LE, 1985, EXP LUNG RES, V8, P167, DOI 10.3109/01902148509057520; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Geyh AS, 2000, ENVIRON HEALTH PERSP, V108, P265, DOI 10.2307/3454444; Ghio AJ, 1997, INHAL TOXICOL, V9, P255; HIGGINS ITT, 1990, AM REV RESPIR DIS, V141, P1136; HYATT RE, 1983, J APPL PHYSIOL, V55, P1; Ihorst G, 2004, EUR RESPIR J, V23, P292, DOI 10.1183/09031936.04.00021704; Kinney P L, 1998, Res Rep Health Eff Inst, P79; KINNEY PL, 1989, AM REV RESPIR DIS, V139, P56; Kinney PL, 1996, AM J RESP CRIT CARE, V154, P1430; Kinney PL, 1996, ENVIRON HEALTH PERSP, V104, P170, DOI 10.2307/3432785; KINNEY PL, 1991, ENVIRON RES, V54, P99, DOI 10.1016/S0013-9351(05)80094-5; KINNEY PL, 1998, RES REP HLTH EFF I, P109; KINNEY PL, 1992, TROPOSPHERIC OZONE E, V2, P203; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; Kunzli N, 1996, J EXPO ANAL ENV EPID, V6, P289; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; LOHMAN TG, 1988, ANTHROPOMETIC STANDA; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; MCMURRY P., 2004, NARSTO PARTICULATE M; MEAD J, 1980, AM REV RESPIR DIS, V121, P339; MILLER FJ, 1985, TOXICOL APPL PHARM, V79, P11, DOI 10.1016/0041-008X(85)90364-3; Motallebi N, 2003, J AIR WASTE MANAGE, V53, P1517; Mudway I. S., 2000, Molecular Aspects of Medicine, V21, P1, DOI 10.1016/S0098-2997(00)00003-0; *NAT CANC I, 1999, 994645 NIH; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; PRYOR WA, 1995, FREE RADICAL BIO MED, V19, P935, DOI 10.1016/0891-5849(95)02033-7; Schelegle ES, 2003, TOXICOL APPL PHARM, V191, P74, DOI 10.1016/S0041-008X(03)00218-7; Solomon C, 2000, EUR RESPIR J, V15, P922, DOI 10.1034/j.1399-3003.2000.15e19.x; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; TAGER IB, 1986, AM REV RESPIR DIS, V134, P502; TAGER IB, 1998, 81 HLTH EFF I; TAGER IB, 1998, PILOT STUDY ASSESS R; TYLER WS, 1988, TOXICOLOGY, V50, P131, DOI 10.1016/0300-483X(88)90086-8; *US EPA, EPA GREEN BOOK 8 HOU; *US EPA, 1993, EPA600891049AF; WEINMANN GG, 1995, AM J RESP CRIT CARE, V152, P1175; WILEY JA, 1991, A733149 CAL AIR RES; WILEY JA, 1991, AL17733 CAL AIR RES	58	78	81	2	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	NOV	2005	16	6					751	759		10.1097/01.ede.0000183166.68809.b0		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	976CD	WOS:000232709500006	16222164	
J	Frank, LD; Engelke, P				Frank, LD; Engelke, P			Multiple impacts of the built environment on public health: Walkable places and the exposure to air pollution	INTERNATIONAL REGIONAL SCIENCE REVIEW			English	Article						physical activity; air quality; built environment; travel behavior	PHYSICAL-ACTIVITY; URBAN FORM; LAND-USE; MYOCARDIAL-INFARCTION; CHILDHOOD ASTHMA; TRANSPORTATION; QUALITY; MORTALITY; WALKING; ATLANTA	While considerable attention has been paid to the public-health-related impacts of air pollution, relatively little research has been done to understand how other aspects of the built environment impact health. Americans are increasingly sedentary; erstwhile the rate of increase in obesity is alarming. New research suggests that increased auto dependence, and limited opportunities to walk for utilitarian purposes, has contributed to this emerging obesity, epidemic. Within socio-demographic strata, land use patterns and transportation investments collectively shape the desire to walk, drive, or to travel via other means. Mixed use and more compact community designs show significant promise for the promotion of physical activity and the reduction of regional air pollution levels. Opportunities exist to increase physical activity and improve regional air quality through more compact development. However, increased compactness, or density, often exacerbates traffic congestion and can increase exposure of harmful emissions within central areas. Therefore, strategies to reduce localized air pollution in existing and developing centers are required to enable larger health benefits from smart growth to be realized.	Univ British Columbia, Sch Community & Reg Planning, Vancouver, BC V5Z 1M9, Canada; Georgetown Univ, Dept Hist, Washington, DC 20057 USA	Frank, LD (reprint author), Univ British Columbia, Sch Community & Reg Planning, Vancouver, BC V5Z 1M9, Canada.	ldfrank@interchange.ubc.ca; poe@georgetown.edu					Bachman W, 2000, TRANSPORT RES C-EMER, V8, P205, DOI 10.1016/S0968-090X(00)00005-X; BOARNET M, 1996, URBAN STUD, V35, P1155; Brabec E, 2002, J PLAN LIT, V16, P499, DOI 10.1177/088541202400903563; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; *CAMBR SYST, 1996, MAK LAND US TRANSP A; *CARB, 2002, MOB SOURC EM INV PRO; Center for Disease Control and Prevention, 2001, MMWR-MORBID MORTAL W, V50, P166; CERVERO R, 1988, TRANSPORT Q, V42, P429; CERVERO R, 1995, J AM PLANN ASSOC, V61, P210, DOI 10.1080/01944369508975634; *CGER, 1992, RETH OZ PROBL URB RE; Churchman A, 1999, J PLAN LIT, V13, P389, DOI DOI 10.1177/08854129922092478; Craig CL, 2002, AM J PREV MED, V23, P36, DOI 10.1016/S0749-3797(02)00472-5; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Ewing R, 2003, AM J HEALTH PROMOT, V18, P47; Ewing R., 2001, TRANSPORTATION RES P, V35, P823; Frank LD, 2004, AM J PREV MED, V27, P87, DOI 10.1016/j.amepre.2004.04.011; Frank LD, 2005, AM J PREV MED, V28, P117, DOI 10.1016/j.amepre.2004.11.001; Frank LD, 2004, AM J PREV MED, V27, P146, DOI 10.1016/j.amepre.2004.06.018; Frank LD, 1998, J URBAN PLAN D-ASCE, V124, P11, DOI 10.1061/(ASCE)0733-9488(1998)124:1(11); Frank LD, 2000, TRANSPORT RES D-TR E, V5, P173, DOI 10.1016/S1361-9209(99)00032-2; Frank LD, 2000, J PLAN EDUC RES, V20, P6, DOI 10.1177/073945600128992564; Frank LD, 2001, J PLAN LIT, V16, P202, DOI 10.1177/08854120122093339; Frank L.D., 2003, HLTH COMMUNITY DESIG; Frank L., 1994, TRANSPORT RES REC, V1466, P44; Friedman B., 1994, TRANSPORT RES REC, V1466, P63; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; FRUMKIN H, 2004, PUBLIC HLTH IMPACT S; Gaffield SJ, 2003, AM J PUBLIC HEALTH, V93, P1527, DOI 10.2105/AJPH.93.9.1527; Gehl J., 1996, LIFE BUILDINGS; Giles-Corti B, 2003, AM J PUBLIC HEALTH, V93, P1583, DOI 10.2105/AJPH.93.9.1583; GIULIANO G, 1989, ENVIRON PLANN A, V21, P145, DOI 10.1068/a210145; Giuliano G., 1995, ACCESS, V6, P3; GREENWALD MJ, 2001, DUANES CLIN OPHTHALM, V1, P1; GUERARD A, 1903, TENEMENT HOUSE PROBL, V1; Handy S, 2005, INT REGIONAL SCI REV, V28, P146, DOI 10.1177/0160017604273626; Handy S., 1992, BUILT ENV, V18, P253; Handy SL, 1996, J PLAN EDUC RES, V15, P183, DOI 10.1177/0739456X9601500303; Hess P. M., 1999, TRANSPORT RES REC, V1674, P9, DOI DOI 10.3141/1674-02; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Holtzclaw J., 1994, USING RESIDENTIAL PA; Hu FB, 1999, JAMA-J AM MED ASSOC, V282, P1433, DOI 10.1001/jama.282.15.1433; Jackson K. T., 1987, CRABGRASS FRONTIER S; Kain J. F., 1992, HOUS POLICY DEBATE, V3, P371, DOI [10.1080/10511482.1992.9521100, DOI 10.1080/10511482.1992.9521100]; KITAMURA R, 1994, UCDITSRR9428; Kleeman MJ, 2000, ENVIRON SCI TECHNOL, V34, P1132, DOI 10.1021/es981276y; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; Krizek K. J, 2000, TRANSPORT RES REC, V1722, P48, DOI 10.3141/1722-06; Kujala UM, 1998, JAMA-J AM MED ASSOC, V279, P440, DOI 10.1001/jama.279.6.440; Mokdad AH, 2003, JAMA-J AM MED ASSOC, V289, P76, DOI 10.1001/jama.289.1.76; Moudon A., 1991, PUBLIC STREETS PUBLI; Moudon A. V., 1997, TRANSPORT RES REC, V1578, P48, DOI DOI 10.3141/1578-07; Noland RB, 2001, TRANSPORT RES A-POL, V35, P47, DOI 10.1016/S0965-8564(99)00047-6; NYBERG BF, 2000, SCAND J WORK ENV S1, V26, P49; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters A, 2001, CIRCULATION, V103, P2810; POPE C, 2000, JAMA-J AM MED ASSOC, V2887, P1132; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pushkarev B., 1982, URBAN RAIL AM EXPLOR; RAPOPORT Amos, 1987, PUBLIC STREETS PUBLI; Ritz B, 2002, AM J EPIDEMIOL, V155, P17, DOI 10.1093/aje/155.1.17; Saelens BE, 2003, ANN BEHAV MED, V25, P80, DOI 10.1207/S15324796ABM2502_03; Sallis JF, 1998, AM J PREV MED, V15, P379, DOI 10.1016/S0749-3797(98)00076-2; SALLIS JF, IN PRESS TRANSPORT A; Schauer JJ, 1996, ATMOS ENVIRON, V30, P3837, DOI 10.1016/1352-2310(96)00085-4; Schimek P., 1996, TRANSPORT RES REC, V1552, P120, DOI [10.3141/1552-17, DOI 10.3141/1552-17]; Shephard RJ, 1997, BRIT J SPORT MED, V31, P277; Stokols D, 2003, AM J HEALTH PROMOT, V18, P4; STOKOLS D, 1992, AM PSYCHOL, V47, P6, DOI 10.1037/0003-066X.47.1.6; STURM R, IN PRESS AM J PREVEN; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; Tolbert PE, 2000, J EXPO ANAL ENV EPID, V10, P446, DOI 10.1038/sj.jea.7500106; Troped PJ, 2003, PREV MED, V37, P304, DOI 10.1016/S0091-7435(03)00137-3; U.S. Department of Health and Human Services, 2010, HLTH PEOPL; U.S. Department of Health and Human Services, 1996, PHYS ACT HLTH REP SU; US Department of Health and Human Services Public Health Service Centers for Disease Control and Prevention National Center for Chronic Disease Prevention and Health Promotion & Division of Nutrition and Physical Activity, 1999, PROM PHYS ACT GUID C; *US EPA, 1996, MOB FLEET AV LOW ALT; *US EPA, 2000, EPA452K00002 OFF QUA; *US EPA, 2002, 454K02001 OFF AIR QU; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021	81	78	78	6	43	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0160-0176			INT REGIONAL SCI REV	Int. Reg. Sci. Rev.	APR	2005	28	2					193	216		10.1177/0160017604273853		24	Environmental Studies; Planning & Development; Urban Studies	Environmental Sciences & Ecology; Public Administration; Urban Studies	910PW	WOS:000227945100005		
J	Portengen, L; Preller, L; Tielen, M; Doekes, G; Heederik, D				Portengen, L; Preller, L; Tielen, M; Doekes, G; Heederik, D			Endotoxin exposure and atopic sensitization in adult pig farmers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxins; hypersensitivity; IgE; allergens; adult; occupational exposure; epidemiology	RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; ALLERGIC SENSITIZATION; LUNG-FUNCTION; HOUSE-DUST; ASTHMA; CHILDREN; POPULATION; CHILDHOOD; ENVIRONMENT	Background: Recent studies have reported a low prevalence of atopic sensitization and respiratory allergy in children growing up on farms. Objectives: We sought to evaluate the dose-response relationship between endotoxin and atopic sensitization in adult farmers and to assess the effect on respiratory health outcomes. Methods: Data on endotoxin exposure and serum IgE levels were available for 162 pig farmers from a cross-sectional, case-control study, with case selection on the basis of respiratory symptoms. Exposure to endotoxin was modeled in detail, and respiratory health effects were assessed during a medical examination. Exploratory analysis was done by using nonparametric modeling and was followed by classical parametric regression. Results: IgE to one or more common allergens was detected in sera from 28 (17%) farmers. The average (geometric mean) total serum IgE levels was 37 lU/mL (geometric SD, 4 IU/mL). A strong inverse relationship was found between endotoxin and sensitization to common allergens for exposures of 75 ng/m(3) or less, with an odds ratio of 0.03 (95% CI, 0.0-0.34) for a 2-fold increase in endotoxin. For endotoxin exposure of greater than 75 ng/m(3), the association was weak (odds ratio, 1.2 [95% Cl, 0.38-3.6]). No association was found between endotoxin exposure and total serum IgE levels. Endotoxin was associated with increased airway hyperresponsiveness to histamine and lower lung function in sensitized farmers, without evidence of a nonlinear relationship. Conclusions: The prevalence of atopic sensitization in adult pig farmers is low. Endotoxin or related exposures might protect from sensitization, even in an adult working population exposed to high levels of endotoxin, but is a risk factor for increased airway hyperresponsiveness and low lung function.	Univ Utrecht, IRAS, NL-3508 TD Utrecht, Netherlands; Univ Utrecht, Dept Herd Hlth & Reprod, NL-3508 TD Utrecht, Netherlands; TNO Chem, Food & Chem Risk Anal, Zeist, Netherlands	Portengen, L (reprint author), Univ Utrecht, IRAS, POB 80176, NL-3508 TD Utrecht, Netherlands.	L.Portengen@iras.uu.nl					BIERSTEKER K, 1974, TIJDSCHR SOC GENEESK, V52, P158; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2003, CLIN EXP ALLERGY, V33, P409, DOI 10.1046/j.1365-2222.2003.01650.x; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; Cormier Y, 2000, EUR RESPIR J, V15, P560, DOI 10.1034/j.1399-3003.2000.15.22.x; Doekes G, 1996, OCCUP ENVIRON MED, V53, P63; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Hastie T., 1990, GENERALIZED ADDITIVE; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; HOLLANDER A, 1993, AM IND HYG ASSOC J, V54, P647, DOI 10.1202/0002-8894(1993)054<0647:IAEITA>2.0.CO;2; Houba R, 1998, AM J RESP CRIT CARE, V158, P1499; Johnson Christine Cole, 2002, Curr Opin Allergy Clin Immunol, V2, P133, DOI 10.1097/00130832-200204000-00009; Kauffmann F, 2002, CLIN EXP ALLERGY, V32, P379, DOI 10.1046/j.1365-2222.2002.01325.x; Kerkhof M, 1996, ALLERGY, V51, P770, DOI 10.1111/j.1398-9995.1996.tb04465.x; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Koppelman GH, 2003, CLIN EXP ALLERGY, V33, P170, DOI 10.1046/j.1365-2222.2003.01591.x; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; PRELLER L, 1995, ANN OCCUP HYG, V39, P545, DOI 10.1016/0003-4878(95)00024-9; Preller L, 1995, SCAND J WORK ENV HEA, V21, P504; PRELLER L, 1995, OCCUP ENVIRON MED, V52, P654; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; RIJCKEN B, 1987, AM REV RESPIR DIS, V136, P62; Roy SR, 2003, J ALLERGY CLIN IMMUN, V112, P571, DOI 10.1067/mai.2003.1711; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Simpson JCG, 1999, ANN OCCUP HYG, V43, P107, DOI 10.1016/S0003-4878(98)00083-0; Vogelzang PFJ, 1997, INT ARCH OCC ENV HEA, V70, P327, DOI 10.1007/s004200050226; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Wahba G., 1990, SPLINE MODELS OBSERV; Wouters IM, 2002, OCCUP ENVIRON MED, V59, P106, DOI 10.1136/oem.59.2.106; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261; Zock JP, 1998, OCCUP ENVIRON MED, V55, P823	41	78	81	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					797	802		10.1016/j.jaci.2004.11.046		6	Allergy; Immunology	Allergy; Immunology	916GM	WOS:000228373400020	15806001	
J	Currie, J				Currie, J			Health disparities and gaps in school readiness	FUTURE OF CHILDREN			English	Article							UNITED-STATES; COGNITIVE-DEVELOPMENT; MATERNAL DEPRESSION; POSTNATAL DEPRESSION; BEHAVIOR PROBLEMS; CHILDHOOD ASTHMA; IRON-DEFICIENCY; YOUNG-CHILDREN; PRIMARY-CARE; LEAD LEVELS	The author documents pervasive racial disparities in the health of American children and analyzes how and how much those disparities contribute to racial gaps in school readiness. She explores a broad sample of health problems common to U.S. children, such as attention deficit hyperactivity disorder, asthma, and lead poisoning, as well as maternal health problems and health-related behaviors that affect children's behavioral and cognitive readiness for school. If a health problem is to affect the readiness gap, it must affect many children, it must be linked to academic performance or behavior problems, and it must show a racial disparity either in its prevalence or in its effects. The author focuses not only on the black-white gap in health status but also on the poor-nonpoor gap because black children tend to be poorer than white children. The health conditions Currie considers seriously impair cognitive skills and behavior in individual children. But most explain little of the overall racial gap in school readiness. Still, the cumulative effect of health differentials summed over all conditions is significant. Curries rough calculation is that racial differences in health conditions and in maternal health and behaviors together may account for as much as a quarter of the racial gap in school readiness. Currie scrutinizes several policy steps to lessen racial and socioeconomic disparities in children's health and to begin to close the readiness gap. Increasing poor children's eligibility for Medicaid and state child health insurance is unlikely to be effective because most poor children are already eligible for public insurance. The problem is that many are not enrolled. Even increasing enrollment may not work: socioeconomic disparities in health persist in Canada and the United Kingdom despite universal public health insurance. The author finds more promise in strengthening early childhood programs with a built-in health component, like Head Start; family-based services and home visiting programs; and WIC, the federal nutrition program for women. infants, and small children. In all three, trained staff can help parents get ongoing care for their children.	Univ Calif Los Angeles, Los Angeles, CA 90024 USA	Currie, J (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA.						AIZER A, 2003, AM EC REV PAPERS PRO, P238; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Annett RD, 2000, J ALLERGY CLIN IMMUN, V105, P717, DOI 10.1067/mai.2000.105226; Beck CT, 1999, J ADV NURS, V29, P623, DOI 10.1046/j.1365-2648.1999.00943.x; BHATTACHARYA J, 2002, WORKING PAPER NATL B, V9003; Bitler MP, 2003, J HUM RESOUR, V38, P1139, DOI 10.2307/3558984; BLOOM B, 2003, VITAL HLTH STAT S 10, V216; Boudreaux ED, 2003, PEDIATRICS, V111, P615; BRUCE ML, 1991, ARCH GEN PSYCHIAT, V48, P470; BUSSING R, 1995, ARCH PEDIAT ADOL MED, V149, P565; BUTZ AM, 1995, CLIN PEDIATR, V34, P581, DOI 10.1177/000992289503401103; Calam R, 2003, J ALLERGY CLIN IMMUN, V112, P499, DOI 10.1067/mai.2003.1639; CANFIELD RL, 2003, NEUROPSYCHOL DEV C C, V9, P35; Case A, 2002, AM ECON REV, V92, P1308, DOI 10.1257/000282802762024520; COGILL SR, 1986, BRIT MED J, V292, P1165; CUFFE S, 2003, 50 ANN M AM AC CHILD; Currie J, 2001, J ECON PERSPECT, V15, P213, DOI 10.1257/jep.15.2.213; Currie J, 2002, J HEALTH ECON, V21, P313, DOI 10.1016/S0167-6296(01)00125-4; Currie J, 2003, AM ECON REV, V93, P1813, DOI 10.1257/000282803322655563; CURRIE J, 2004, WORKING PAPER NATL B; CURRIE J, 2003, WORKING PAPER NATL B; CURRIE J, 2004, CHILD MENTAL HLTH HU; CURRIE J, 2003, MEANS TRESTED TRANSF; Curtis LJ, 2001, HEALTH ECON, V10, P287, DOI 10.1002/hec.591; DIXON A, 2003, 11 LOND SCH EC; Drane DL, 2000, PAEDIATR PERINAT EP, V14, P349, DOI 10.1046/j.1365-3016.2000.00301.x; FELDMAN RG, 1992, J CHILD NEUROL, V7, P354; Forste R, 2001, PEDIATRICS, V108, P291, DOI 10.1542/peds.108.2.291; FOSBRUG L, 1984, 8413 AAI; FOWLER MG, 1992, PEDIATRICS, V90, P939; Grantham-McGregor S, 2001, J NUTR, V131, p649S; GUTSTADT LB, 1989, AM J DIS CHILD, V143, P471; Halterman JS, 2001, AMBUL PEDIATR, V1, P201, DOI 10.1367/1539-4409(2001)001<0201:SRAUCW>2.0.CO;2; Heneghan AM, 2000, PEDIATRICS, V106, P1367, DOI 10.1542/peds.106.6.1367; HOBFOLL SE, 1995, J CONSULT CLIN PSYCH, V63, P445, DOI 10.1037/0022-006X.63.3.445; Jain A, 2002, PEDIATRICS, V109, P1044, DOI 10.1542/peds.109.6.1044; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P797, DOI 10.1097/00004583-199907000-00008; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; KOCHANSKA G, 1987, J ABNORM CHILD PSYCH, V15, P441, DOI 10.1007/BF00916460; KOWALESKIJONES L, 2000, 120700 I RES POV; Kuhlthau K, 2004, PEDIATRICS, V113, pE249, DOI 10.1542/peds.113.3.e249; Kurstjens S, 2001, J CHILD PSYCHOL PSYC, V42, P623, DOI 10.1017/S0021963001007296; Lewis PA Miall RC, 2003, CURRENT OPINION NEUR, V13, P1; LI RW, 2003, PEDIATRICS S, V111; LIAW FR, 1994, J CLIN CHILD PSYCHOL, V23, P360, DOI 10.1207/s15374424jccp2304_2; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; LINDGREN S, 1992, NEW ENGL J MED, V327, P926, DOI 10.1056/NEJM199209243271305; Looker A. C., 2002, Morbidity and Mortality Weekly Report, V51, P897; Looker AC, 1997, JAMA-J AM MED ASSOC, V277, P973, DOI 10.1001/jama.277.12.973; Martins C, 2000, J CHILD PSYCHOL PSYC, V41, P737, DOI 10.1017/S0021963099005958; Melman ST, 1998, ENVIRON HEALTH PERSP, V106, P655, DOI 10.2307/3434093; Meyer Pamela A, 2003, MMWR Surveill Summ, V52, P1; Murray L, 1996, CHILD DEV, V67, P2512, DOI 10.2307/1131637; Needleman HL, 2002, NEUROTOXICOL TERATOL, V24, P711, DOI 10.1016/S0892-0362(02)00269-6; NEWACHECK PW, 1994, ARCH PEDIAT ADOL MED, V148, P1143; ODOWD, 2002, MED HLTH RHODE ISLAN, V85, P345; Olds DL, 1999, FUTURE CHILD, V9, P44, DOI 10.2307/1602721; Olfson M, 2003, AM J PSYCHIAT, V160, P1071, DOI 10.1176/appi.ajp.160.6.1071; ORTEGA AN, 2002, PEDIATRICS, V109; Petterson SM, 2001, CHILD DEV, V72, P1794, DOI 10.1111/1467-8624.00379; POCOCK SJ, 1994, BRIT MED J, V309, P1189; RAYMOND KB, 1997, EFFECT RACE GENDER I; Rollman BL, 2002, GEN HOSP PSYCHIAT, V24, P381, DOI 10.1016/S0163-8343(02)00219-0; Sharp D, 1995, J CHILD PSYCHOL PSYC, V36, P1315, DOI 10.1111/j.1469-7610.1995.tb01666.x; Sherry B, 2001, PEDIATRICS, V107, P677, DOI 10.1542/peds.107.4.677; SWANSON JM, 1991, J LEARN DISABIL, V24, P219; *US BUR CENS, PEOPL FAM REL CHILDR; *US CDC, 2003, CHILDR BLOOD LEAD LE; U.S. Department of Health and Human Services, 1999, MENT HLTH REP SURG G; Wasserman RC, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.3.e38; WOLF JW, 2003, AM J PUBLIC HLTH, V93; YIP R, 1987, JAMA-J AM MED ASSOC, V258, P1619, DOI 10.1001/jama.258.12.1619; Zahn-Waxler C., 1990, DEV PSYCHOPATHOL, V2, P271, DOI 10.1017/S0954579400000778; Zito JM, 1997, PSYCHOPHARMACOL BULL, V33, P143	75	78	79	0	11	WOODROW WILSON SCH PUBLIC & INT AFFARIS, PRINCETON UNIV & BROOKINS INST	WASHINGTON	BROOKINGS INSTITUTION, 1775 MASSACHUSETTS AVE, NW, WASHINGTON, DC 20036 USA	1054-8289			FUTURE CHILD	Future Child.	SPR	2005	15	1					117	138		10.1353/foc.2005.0002		22	Family Studies; Health Policy & Services; Social Sciences, Interdisciplinary	Family Studies; Health Care Sciences & Services; Social Sciences - Other Topics	985IH	WOS:000233370300008	16130544	
J	Sallusto, F; Mackay, CR				Sallusto, F; Mackay, CR			Chemoattractants and their receptors in homeostasis and inflammation	CURRENT OPINION IN IMMUNOLOGY			English	Review							LEUKOTRIENE B-4 RECEPTOR; NAIVE T-CELLS; PROTEIN-COUPLED RECEPTOR; ALLERGIC AIRWAY DISEASE; DENDRITIC CELLS; LYMPH-NODES; SPHINGOSINE 1-PHOSPHATE; CHEMOKINE RECEPTORS; CHEMOTACTIC RESPONSIVENESS; EOSINOPHIL RECRUITMENT	The study of leukocyte migration continues to provide new insights into the regulation of lymphocyte priming in secondary lymphoid organs and effector responses in inflamed tissues. Chemoattractant receptors have always been viewed as facilitators of cell movement into a tissue. This whole concept must now be revised with the discovery of sphingosine 1 phosphate receptors, which control cell exit from lymphoid tissues. The chemoattractants that regulate lymphoid tissue homing are usually different to those that regulate leukocyte recruitment to inflamed tissues. There is evidence, however, of inflammatory pathways of leukocyte recruitment in lymph nodes and, conversely of constitutive pathways in peripheral tissues. Finally, antagonists (or agonists) of chemoattractant receptors and their signalling pathways represent the most attractive strategy for the treatment of a wide range of inflammatory diseases, including allergy.	Inst Res Biomed, CH-650 Bellinzona, Switzerland; Garvan Inst Med Res, Darlinghurst, NSW 2010, Australia	Sallusto, F (reprint author), Inst Res Biomed, Via Vincenzo Vela 6, CH-650 Bellinzona, Switzerland.	federica.sallusto@irb.unisi.ch; c.mackay@garvan.org.au	Mackay, Charles/A-9673-2008	Mackay, Charles/0000-0002-6338-7340			Alcami A, 2003, NAT REV IMMUNOL, V3, P36, DOI 10.1038/nri980; ALLENDE ML, 2004, J BIOL CHEM; ANCUTA P, 2003, J EXP MED, V197, P1707; Biedermann T, 2002, EUR J IMMUNOL, V32, P3171, DOI 10.1002/1521-4141(200211)32:11<3171::AID-IMMU3171>3.0.CO;2-4; Brandes M, 2003, BLOOD, V102, P3693, DOI 10.1182/blood-2003-04-1016; Brinkmann V, 2002, J BIOL CHEM, V277, P21453, DOI 10.1074/jbc.C220176200; Cassese G, 2003, J IMMUNOL, V171, P1684; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chiba K, 1998, J IMMUNOL, V160, P5037; Chong BF, 2004, J IMMUNOL, V172, P1575; Chung CD, 2003, J IMMUNOL, V170, P581; Cinamon G, 2004, NAT IMMUNOL, V5, P713, DOI 10.1038/ni1083; Colantonio L, 2002, EUR J IMMUNOL, V32, P1264, DOI 10.1002/1521-4141(200205)32:5<1264::AID-IMMU1264>3.0.CO;2-S; Cyster JG, 2003, IMMUNOL REV, V195, P5, DOI 10.1034/j.1600-065X.2003.00075.x; Dieli F, 2003, J EXP MED, V198, P391, DOI 10.1084/jem.20030235; Dudda JC, 2004, J IMMUNOL, V172, P857; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Fulkerson PC, 2004, P NATL ACAD SCI USA, V101, P1987, DOI 10.1073/pnas.0308544100; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Goetzl EJ, 2004, J LEUKOCYTE BIOL, V76, P30, DOI 10.1189/jlb.1103567; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Goodarzi K, 2003, NAT IMMUNOL, V4, P965, DOI 10.1038/ni972; Goya I, 2003, J IMMUNOL, V170, P2138; Haribabu B, 2000, J EXP MED, V192, P433, DOI 10.1084/jem.192.3.433; Hauser AE, 2002, J IMMUNOL, V169, P1277; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Ho IC, 2002, CELL, V109, pS109, DOI 10.1016/S0092-8674(02)00705-5; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Huang WW, 1998, J EXP MED, V188, P1063, DOI 10.1084/jem.188.6.1063; Humbles AA, 2000, NATURE, V406, P998; Humbles AA, 2002, P NATL ACAD SCI USA, V99, P1479, DOI 10.1073/pnas.261462598; Johnston B, 2003, J IMMUNOL, V171, P2960; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Kim CH, 2003, J IMMUNOL, V171, P152; Kunkel EJ, 2003, NAT REV IMMUNOL, V3, P822, DOI 10.1038/nri1203; Laffargue M, 2002, IMMUNITY, V16, P441, DOI 10.1016/S1074-7613(02)00282-0; Lametschwandtner G, 2004, J ALLERGY CLIN IMMUN, V113, P987, DOI 10.1016/j.jaci.2004.02.004; Langenkamp A, 2003, EUR J IMMUNOL, V33, P474, DOI 10.1002/immu.200310023; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; Lippert E, 2003, J IMMUNOL, V171, P1542; Ma B, 2004, J IMMUNOL, V172, P1872; Ma W, 2002, J CLIN INVEST, V109, P621, DOI 10.1172/JCI200214097; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Mandala S, 2002, SCIENCE, V296, P346, DOI 10.1126/science.1070238; Martin-Fontecha A, 2003, J EXP MED, V198, P615, DOI 10.1084/jem.20030448; Matloubian M, 2004, NATURE, V427, P355, DOI 10.1038/nature02284; Messi M, 2003, NAT IMMUNOL, V4, P78, DOI 10.1038/ni872; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Nagata K, 2003, PROSTAG LEUKOTR ESS, V69, P169, DOI 10.1016/S0952-3278(03)00078-4; Ngo VN, 1998, J EXP MED, V188, P181, DOI 10.1084/jem.188.1.181; Ogilvie P, 2003, BLOOD, V102, P789, DOI 10.1182/blood-2002-09-2773; Ott VL, 2003, NAT IMMUNOL, V4, P974, DOI 10.1038/ni971; Palframan RT, 2001, J EXP MED, V194, P1361, DOI 10.1084/jem.194.9.1361; Perrier P, 2004, J IMMUNOL, V172, P7031; Reiss Y, 2001, J EXP MED, V194, P1541, DOI 10.1084/jem.194.10.1541; RIVINO L, 2004, IN PRESS J EXP MED; Rot A, 2004, ANNU REV IMMUNOL, V22, P891, DOI 10.1146/annurev.immunol.22.012703.104543; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 2004, ANNU REV IMMUNOL, V22, P745, DOI 10.1146/annurev.immunol.22.012703.104702; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sanna MG, 2004, J BIOL CHEM, V279, P13839, DOI 10.1074/jbc.M311743200; Sawicka E, 2003, J IMMUNOL, V171, P6206; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Schoenberger SP, 2003, NAT IMMUNOL, V4, P937, DOI 10.1038/ni1003-937; Scimone ML, 2004, J EXP MED, V199, P1113, DOI 10.1084/jem.20031645; Serra HM, 2004, INT ARCH ALLERGY IMM, V133, P64, DOI 10.1159/000076129; Sundrud MS, 2003, J IMMUNOL, V171, P3542; Tager AM, 2000, J EXP MED, V192, P439, DOI 10.1084/jem.192.3.439; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Takeshita K, 2004, INT IMMUNOL, V16, P947, DOI 10.1093/intimm/dxh096; Vitale M, 2004, EUR J IMMUNOL, V34, P1715, DOI 10.1002/eji.200425100; von Andrian UH, 2003, NEW ENGL J MED, V348, P68, DOI 10.1056/NEJMe020157; Ward SG, 2004, TRENDS IMMUNOL, V25, P67, DOI 10.1016/j.it.2003.12.003; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506; Yoneyama H, 2004, INT IMMUNOL, V16, P915, DOI 10.1093/intimm/dxh093; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983	78	78	81	0	5	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2004	16	6					724	731		10.1016/j.coi.2004.09.012		8	Immunology	Immunology	871AY	WOS:000225102800007	15511664	
J	Becker, A; Watson, W; Ferguson, A; Dimich-Ward, H; Chan-Yeung, M				Becker, A; Watson, W; Ferguson, A; Dimich-Ward, H; Chan-Yeung, M			The Canadian asthma primary prevention study: Outcomes at 2 years of age	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; risk factors; primary prevention; environmental tobacco smoke; daycare; breast-feeding; early life	CAT ALLERGEN LEVELS; CHILDHOOD ASTHMA; HOUSE-DUST; EARLY-LIFE; MITE ALLERGEN; BIRTH COHORT; RISK-FACTORS; P-I; AVOIDANCE; EXPOSURE	Background: Avoidance of individual risk factors have not been successful in preventing the development of asthma. Objective: We sought to determine the effectiveness of a multifaceted intervention program in primary prevention of asthma in high-risk infants. Methods: We identified 545 high-risk infants on the basis of an immediate family history of asthma. Families were randomized into intervention or control groups. Intervention measures included avoidance of house dust mite, pet allergen, and environmental tobacco smoke. Breast-feeding was encouraged with formula supplementation if necessary, and introduction of solid foods was delayed. Results: At 2 years of age, 19.5% of the children had asthma, and 14.7% had atopy (positive skin test response to one or more common allergens). Significantly fewer children had asthma in the intervention group compared with in the control group (16.3% vs 23.0%), with 60% less persistent asthma at 2 years. There was a 90% reduction for recurrent wheeze in the intervention group compared with that seen in the control group. Exposure to maternal environmental tobacco smoke during pregnancy or the first year was a risk factor for asthma at 2 years of age. A positive skin test response, particularly to food, at 12 months predicted asthma at 2 years. There was no significant difference for atopy between the intervention and control groups, but daycare reduced atopy at 2 years. Conclusion: This multifaceted intervention program during a window of opportunity in the first year of life was effective in preventing asthma in high-risk children at 2 years of age. Future studies with this cohort at school age are important.	Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, Winnipeg, MB R3E 0Z2, Canada; Univ British Columbia, Dept Pediat, Div Allergy, Vancouver, BC V5Z 1M9, Canada; Univ British Columbia, Dept Med, Div Resp, Occupat & Environm Lung Dis Unit, Vancouver, BC V5Z 1M9, Canada	Becker, A (reprint author), Univ Manitoba, Dept Pediat & Child Hlth, Allergy & Clin Immunol Sect, AE101-671 William Ave, Winnipeg, MB R3E 0Z2, Canada.						ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BJORKSTEN B, 1998, ALLERGY PRINCIPLES P, P816; CASTRORODRIGUES JA, 2000, AM J RESP CRIT CARE, V182, P1403; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chan-Yeung M, 2002, ANN ALLERG ASTHMA IM, V88, P52; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; CHANYEUNG M, 1995, AM J RESP CRIT CARE, V152, P1805; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Fahy JV, 2001, AM J RESP CRIT CARE, V163, P822; GERGEN PJ, 1992, ANN ALLERGY, V68, P507; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MANFREDA J, 1993, CHEST, V103, P151, DOI 10.1378/chest.103.1.151; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; Oddy WH, 1999, BRIT MED J, V319, P815; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Platts-Mills TA, 1997, J ALLERGY CLIN IMM S, V100, P2; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Strunk RC, 2002, PEDIATRICS, V109, P357; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; WEISS ST, 1983, AM REV RESPIR DIS, V128, P933; Wright AL, 2001, THORAX, V56, P192, DOI 10.1136/thorax.56.3.192; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	38	78	81	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2004	113	4					650	656		10.1016/j.jaci.2004.01.754		7	Allergy; Immunology	Allergy; Immunology	814DY	WOS:000220956600010	15100668	
J	Auinger, P; Lanphear, BP; Kalkwarf, HJ; Mansour, ME				Auinger, P; Lanphear, BP; Kalkwarf, HJ; Mansour, ME			Trends in otitis media among children in the United States	PEDIATRICS			English	Article; Proceedings Paper	39th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 01-04, 1999	SAN FRANCISCO, CALIFORNIA	Ambulatory Pediat Assoc		otitis media; early-onset otitis media; National Health and Nutrition Examination Survey; allergy; epidemiology; pediatric; children	PASSIVE SMOKE EXPOSURE; MIDDLE-EAR DISEASE; RISK-FACTORS; YOUNG-CHILDREN; LIFE; ASTHMA; PREVALENCE; INFECTIONS; OUTCOMES; VACCINE	Background. The prevalence of repeated otitis media ( OM) increased during the 1980s, but it is unknown if the increase has continued. Objectives. To determine trends in the prevalence of OM, early-onset OM, and repeated OM among US children from 1988 to 1994 and to identify factors that may explain any observed changes. Methods. The Third National Health and Nutrition Examination Survey was administered in 2 phases: phase I ( 1988 - 1991) and phase II ( 1991 - 1994), each comprising a national probability sample. OM ( ever having had OM), early-onset OM ( first episode at < 12 months of age), and repeated OM (&GE; 3 episodes) were assessed for 8261 children < 6 years of age. Results. After controlling for risk factors for OM, the prevalence of OM from phase I to phase II increased from 66.7% to 69.7% ( odds ratio [ OR] = 1.1; 95% confidence interval [ CI] = .99, 1.1), early-onset OM increased from 41.1% to 45.8% ( OR = 1.1; 95% CI = 1.03, 1.2), and repeated OM increased from 34.8% to 41.1% ( OR = 1.2; 95% CI = 1.1, 1.4). This observed increase corresponds to 561 000 and 720 000 more children having early-onset OM and repeated OM, respectively. Child care use, early breastfeeding termination, asthma, and access to health care did not significantly increase from phase I to phase II. The prevalence of early-onset OM and repeated OM was higher for affluent children, but the greatest increase in prevalence was among impoverished children. There was an increase in allergic conditions from phase I to phase II for poor children (22.6% to 30.2%). Conclusions. The prevalence of early-onset OM and repeated OM continued to increase among preschool children in the United States. Further research to investigate this increasing prevalence should explore changes in management practice and an increase in prevalence of allergic conditions among poor children.	Univ Rochester, Dept Pediat, Sch Med & Dent, Rochester, NY 14620 USA; Amer Acad Pediat Ctr Child Hlth Res, Rochester, NY USA; Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA	Auinger, P (reprint author), Univ Rochester, Dept Pediat, Sch Med & Dent, 1351 Mt Hope Ave,Ste 130, Rochester, NY 14620 USA.				BHP HRSA HHS [1T-32 PE-10027, 2T-32 PE-12002]		ALHO OP, 1990, AM J EPIDEMIOL, V132, P1164; Bauchner H, 1999, PEDIATRICS, V103, P395, DOI 10.1542/peds.103.2.395; Belshe RB, 2000, PEDIATR INFECT DIS J, V19, pS66, DOI 10.1097/00006454-200005001-00010; Belshe RB, 1998, NEW ENGL J MED, V338, P1405, DOI 10.1056/NEJM199805143382002; Bennett KE, 1999, ARCH DIS CHILD, V80, P28; BERMAN S, 1995, NEW ENGL J MED, V332, P1560, DOI 10.1056/NEJM199506083322307; Berman S, 1997, PEDIATRICS, V100, P585, DOI 10.1542/peds.100.4.585; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BONDY J, 2000, PEDIATRICS, V105; DALY KA, 1994, AM J EPIDEMIOL, V139, P1116; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; DUNCAN B, 1993, PEDIATRICS, V91, P867; Edwards DJ, 2002, ACAD EMERG MED, V9, P22, DOI 10.1111/j.1553-2712.2002.tb01162.x; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439; EVANS R, 1987, CHEST, V91, pS65; EY JL, 1995, PEDIATRICS, V95, P670; HARDY AM, 1993, AM J PUBLIC HEALTH, V83, P1321, DOI 10.2105/AJPH.83.9.1321; HARSTEN G, 1989, ACTA OTO-LARYNGOL, V107, P111, DOI 10.3109/00016488909127487; HUBBARD TW, 1985, NEW ENGL J MED, V312, P1529, DOI 10.1056/NEJM198506133122401; KITCHENS GG, 1995, LARYNGOSCOPE, V105, P1, DOI 10.1288/00005537-199505001-00001; Kvaerner KJ, 1997, ACTA OTO-LARYNGOL, V117, P578, DOI 10.3109/00016489709113441; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; LANPHEAR BP, 1997, PEDIATRICS, V99; LANPHEAR BP, 2001, PEDIATRICS, V107; LEVINE OS, 1999, PEDIATRICS, V103; Lieu JEC, 2002, ARCH PEDIAT ADOL MED, V156, P147; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MCCRAIG LF, 2002, JAMA-J AM MED ASSOC, V287, P3096; McCraig LG, 1995, JAMA-J AM MED ASSOC, V273, P214; National Center for Health Statistics, 1994, VITAL HLTH STAT, V1, P1; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Paradise JL, 1997, PEDIATRICS, V99, P318, DOI 10.1542/peds.99.3.318; PLESS CE, 1995, ARCH PEDIAT ADOL MED, V149, P553; SCHAPPERT SM, 1992, VITAL HLTH STATISTIC, V214, P1; Shah B. V., 1997, SUDAAN USERS MANUAL; STAHLBERG MR, 1986, PEDIATR INFECT DIS J, V5, P30; STATHIS SL, 1999, PEDIATRICS, V104; STSAUVER J, 2000, EMERG INFECT DIS, V6, P662; TAINIO VM, 1988, PEDIATR RES, V23, P509, DOI 10.1203/00006450-198805000-00015; TEELE DW, 1989, J INFECT DIS, V160, P83; TEELE DW, 1990, J INFECT DIS, V162, P685; WALTER SD, 1976, BIOMETRICS, V32, P829, DOI 10.2307/2529268; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	44	78	80	2	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	SEP	2003	112	3					514	520		10.1542/peds.112.3.514		7	Pediatrics	Pediatrics	716NL	WOS:000185035100020	12949276	
J	Cooper, S; Oborne, J; Newton, S; Harrison, V; Coon, JT; Lewis, S; Tattersfield, A				Cooper, S; Oborne, J; Newton, S; Harrison, V; Coon, JT; Lewis, S; Tattersfield, A			Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial	THORAX			English	Article							ALTERNATIVE MEDICINE; YOGA	Background: Patients with asthma are interested in the use of breathing exercises but their role is uncertain. The effects of the Buteyko breathing technique, a device which mimics pranayama (a yoga breathing technique), and a dummy pranayama device on bronchial responsiveness and symptoms were compared over 6 months in a parallel group study. Methods: Ninety patients with asthma taking an inhaled corticosteroid were randomised after a 2 week run in period to Eucapnic Buteyko breathing, use of a Pink City Lung Exerciser (PCLE) to mimic pranayama, or a PCLE placebo device. Subjects practised the techniques at home twice daily for 6 months followed by an optional steroid reduction phase. Primary outcome measures were symptom scores and change in the dose of methacholine provoking a 20% fall in FEV1 (PD20) during the first 6 months. Results: Sixty nine patients (78%) completed the study. There was no significant difference in PD20 between the three groups at 3 or 6 months. Symptoms remained relatively stable in the PCLE and placebo groups but were reduced in the Buteyko group. Median change in symptom scores at 6 months was 0 (interquartile range -1 to 1) in the placebo group, -1 (-2 to 0.75) in the PCLE group, and -3 (-4 to 0) in the Buteyko group (p=0.003 for difference between groups). Bronchodilator use was reduced in the Buteyko group by two puffs/day at 6 months; there was no change in the other two groups (p=0.005). No difference was seen between the groups in FEV1, exacerbations, or ability to reduce inhaled corticosteroids. Conclusion: The Buteyko breathing technique can improve symptoms and reduce bronchodilator use but does not appear to change bronchial responsiveness or lung function in patients with asthma. No benefit was shown for the Pink City Lung Exerciser.	City Hosp Nottingham, Div Resp Med, Nottingham NG5 1PB, England	Cooper, S (reprint author), City Hosp Nottingham, Div Resp Med, Clin Sci Bldg, Nottingham NG5 1PB, England.		Cooper, Sue/A-7471-2011	Cooper, Sue/0000-0002-1994-6395			Bowler SD, 1998, MED J AUSTRALIA, V169, P575; Egbagbe E, 1997, THORAX, V52, P239; Ernst E, 1998, J ASTHMA, V35, P667, DOI 10.3109/02770909809048969; Harrison TW, 1999, THORAX, V54, P98; Hensley MJ, 1998, MED J AUSTRALIA, V169, P573; *HL SEL COMM SCI T, 2000, 6 HL SEL COMM SCI TE; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832; Keeley D, 2001, BRIT MED J, V322, P1075, DOI 10.1136/bmj.322.7294.1075; Manocha R, 2002, THORAX, V57, P110, DOI 10.1136/thorax.57.2.110; McCarthy M, 2002, LANCET, V359, P1213, DOI 10.1016/S0140-6736(02)08253-3; Opat AJ, 2000, J ASTHMA, V37, P557, DOI 10.3109/02770900009090810; SINGH V, 1990, LANCET, V335, P1381, DOI 10.1016/0140-6736(90)91254-8; Stalmatski A., 1997, FREEDOM ASTHMA BUTEY; Thomas M, 2001, BRIT MED J, V322, P1098, DOI 10.1136/bmj.322.7294.1098; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	15	78	79	1	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	AUG	2003	58	8					674	679		10.1136/thorax.58.8.674		6	Respiratory System	Respiratory System	705YP	WOS:000184425100009	12885982	
J	Matricardi, PM; Bjorksten, B; Bonini, S; Bousquet, J; Djukanovic, R; Dreborg, S; Gereda, J; Malling, HJ; Popov, T; Raz, E; Renz, H; Wold, A				Matricardi, PM; Bjorksten, B; Bonini, S; Bousquet, J; Djukanovic, R; Dreborg, S; Gereda, J; Malling, HJ; Popov, T; Raz, E; Renz, H; Wold, A		EAACI Task Force 7	Microbial products in allergy prevention and therapy	ALLERGY			English	Article							MONOPHOSPHORYL-LIPID-A; IMMUNOSTIMULATORY DNA-SEQUENCES; KILLED MYCOBACTERIUM-VACCAE; GRAM-NEGATIVE BACTERIA; LACTIC-ACID BACTERIA; VAXOM OM-85 BV; INTESTINAL MICROFLORA; IN-VITRO; INFLAMMATORY RESPONSE; ENDOTOXIN EXPOSURE		IRCCS, Asthma & Allergy Res Unit, Osped Pediat Bambino Gesu, Res Inst, I-00165 Rome, Italy	Matricardi, PM (reprint author), IRCCS, Asthma & Allergy Res Unit, Osped Pediat Bambino Gesu, Res Inst, Piazza S Onofrio 4, I-00165 Rome, Italy.			Wold, Agnes/0000-0001-9196-5040; Bonini, Sergio/0000-0003-0079-3031			ADLERBERTH I, 1991, ACTA PAEDIATR SCAND, V80, P602, DOI 10.1111/j.1651-2227.1991.tb11917.x; Adlerberth I, 1999, DEV GASTROINTESTINAL, P279; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.20001.113081; Arunachalam K, 2000, EUR J CLIN NUTR, V54, P263, DOI 10.1038/sj.ejcn.1600938; Baldrick P, 2001, VACCINE, V20, P737, DOI 10.1016/S0264-410X(01)00413-3; Baldridge JR, 2000, VACCINE, V18, P2416, DOI 10.1016/S0264-410X(99)00572-1; Barton LL, 2001, PEDIATRICS, V107, P775, DOI 10.1542/peds.107.4.775; Bauer M, 1999, IMMUNOLOGY, V97, P699, DOI 10.1046/j.1365-2567.1999.00811.x; BENE MC, 1993, SCAND J IMMUNOL, V38, P496, DOI 10.1111/j.1365-3083.1993.tb02594.x; BENNET R, 1991, SCAND J INFECT DIS, V23, P63, DOI 10.3109/00365549109023376; BIRD AP, 1980, NUCLEIC ACIDS RES, V8, P1499, DOI 10.1093/nar/8.7.1499; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bohle B, 1999, EUR J IMMUNOL, V29, P2344, DOI 10.1002/(SICI)1521-4141(199907)29:07<2344::AID-IMMU2344>3.0.CO;2-R; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Broide D, 1998, J IMMUNOL, V161, P7054; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Creticos PS, 2001, J ALLERGY CLIN IMMUN, V107, pS216; Donnet-Hughes A, 1999, J DAIRY SCI, V82, P863; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FONTANA VJ, 1965, JAMA-J AM MED ASSOC, V193, P123; FRANKLAND AW, 1955, BRIT MED J, V2, P941; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HALPERN GM, 1990, INT J IMMUNOTHER, V7, P207; HATA D, 1988, PEDIATR INFECT DIS J, V7, P669, DOI 10.1097/00006454-198809000-00018; HELIN T, 2002, ALLERGY, V37, P243; HENRICSON BE, 1990, INFECT IMMUN, V58, P2429; Heppner DG, 1996, J INFECT DIS, V174, P361; Hessle C, 1999, CLIN EXP IMMUNOL, V116, P276; Hessle C, 2000, INFECT IMMUN, V68, P3581, DOI 10.1128/IAI.68.6.3581-3586.2000; HESSLE C, 2000, INFECT IMMUN, V68, P1; Holgate ST, 2000, BRIT MED J, V320, P231, DOI 10.1136/bmj.320.7229.231; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Horner AA, 2001, IMMUNOL REV, V179, P102, DOI 10.1034/j.1600-065X.2001.790111.x; Horner AA, 2000, J ALLERGY CLIN IMMUN, V106, P349, DOI 10.1067/mai.2000.107933; Horner Anthony A., 2001, Journal of Allergy and Clinical Immunology, V108, P417; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Keul R, 1996, THORAX, V51, P150, DOI 10.1136/thx.51.2.150; KOIVIKKO A, 1973, ACTA ALLERGOL, V28, P202, DOI 10.1111/j.1398-9995.1973.tb01326.x; Liu AH, 2001, ALLERGY ASTHMA PROC, V22, P337; Magone MT, 2000, EUR J IMMUNOL, V30, P1841, DOI 10.1002/1521-4141(200007)30:7<1841::AID-IMMU1841>3.0.CO;2-E; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; MALLING HJ, 1993, ALLERGY, V48, P9; Malling HJ, 2000, ALLERGY, V55, P214, DOI 10.1034/j.1398-9995.2000.00110.x; Maraveyas A, 1999, ANN ONCOL, V10, P817, DOI 10.1023/A:1008307821189; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 1997, ALLERGY, V52, P879, DOI 10.1111/j.1398-9995.1997.tb01246.x; MAUEL J, 1994, RESPIRATION, V61, P8; MUELLER HL, 1969, JAMA-J AM MED ASSOC, V26, P1379; MYERS KR, 1995, INFECT IMMUN, V63, P168; National Institutes of Health, 1995, NIH PUBL, V95-2754; Oehling A, 1997, J INVEST ALLERG CLIN, V7, P14; OEHLING A, 1980, ALLERGOL IMMUNOPATH, V8, P177; OEHLING A, 1979, ALLERGOL IMMUNOPATH, V7, P47; OHELING A, 1996, GENETICS QUALITY LIF, P119; Parronchi P, 1999, J IMMUNOL, V163, P5946; Pelto L, 1998, CLIN EXP ALLERGY, V28, P1474, DOI 10.1046/j.1365-2222.1998.00449.x; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Roman M, 1997, NAT MED, V3, P849, DOI 10.1038/nm0897-849; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Roth M, 2000, THORAX, V55, P678, DOI 10.1136/thorax.55.8.678; Salkowski CA, 1997, INFECT IMMUN, V65, P3239; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; SCHIFFRIN EJ, 1995, J DAIRY SCI, V78, P491; Schrezenmeir J., 2001, AM J CLIN NUTR, V73, P361; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Shirtcliffe PM, 2001, AM J RESP CRIT CARE, V163, P1410; Spiegelberg HL, 2002, CURR OPIN MOL THER, V4, P64; TAKAYAMA K, 1984, REV INFECT DIS, V6, P439; Thoelen S, 1998, VACCINE, V16, P708, DOI 10.1016/S0264-410X(97)00254-5; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; ULRICH JT, 1995, VACCINE DESIGN SUBUN; Verthelyi D, 2002, J IMMUNOL, V168, P1659; Wang CC, 1998, IMMUNOLOGY, V93, P307; Wheeler AW, 2001, INT ARCH ALLERGY IMM, V126, P135, DOI 10.1159/000049504; Wheeler JG, 1997, ANN ALLERG ASTHMA IM, V79, P229; Wheeler JG, 1997, AM J MED SCI, V313, P120, DOI 10.1097/00000441-199702000-00011; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; WYBRAN J, 1990, LUNG, V168, P720, DOI 10.1007/BF02718199; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	88	78	80	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JUN	2003	58	6					461	471		10.1034/j.1398-9995.2003.00175.x		11	Allergy; Immunology	Allergy; Immunology	681TK	WOS:000183051300001	12757444	
J	Rosenman, KD; Reilly, MJ; Schill, DP; Valiante, D; Flattery, J; Harrison, R; Reinisch, F; Pechter, E; Davis, L; Tumpowsky, CM; Filios, M				Rosenman, KD; Reilly, MJ; Schill, DP; Valiante, D; Flattery, J; Harrison, R; Reinisch, F; Pechter, E; Davis, L; Tumpowsky, CM; Filios, M			Cleaning products and work-related asthma	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							OCCUPATIONAL ASTHMA; SURVEILLANCE SYSTEM; EXPOSURE; CLEANERS	To describe the characteristics of individuals with work-related asthma associated with exposure to cleaning products, data from the California-, Massachusetts-, Michigan-, and New Jersey state-based surveillance systems of work-related asthma were used to identify cases of asthma associated with exposure to cleaning products at work. From 1993 to 1997, 236 (12 %) of the 1915 confirmed cases of work-related asthma identfied by the four states were associated with exposure to cleaning products. Eighty Percent of the reports were of new-onset asthma and 20% were work-aggravated asthma. Among the new-onset cases, 22 % were consistent with reactive airways dysfunction syndrome. Individuals identfied were generally women (75 %), white non-Hispanic (68 %), and 45 years or older (64 %). Their most likely exposure had been in medical settings (39 %), schools (13 %), or hotels (6 %), and they were most likely to work as janitor/cleaners (22 %), nurse/nurses' aides (20 %), or clerical staff (13 %). However, cases were reported with exposure to cleaning products across a wide range of job titles. Cleaning products contain a diverse group of chemicals that are used in a wide range of industries and occupations as well as in the home. Their potential to cause or aggravate asthma has recently been recognized. Further work to characterize the specific agents and the circumstances of their use associated with asthma is needed. Additional research to investigate the frequency of adverse respiratory effects among regular users, such as housekeeping staff, is also needed. In the interim, we recommend attention to adequate ventilation, improved warning labels and Material Safety Data Sheets, and workplace training and education.	Michigan State Univ, E Lansing, MI 48824 USA; New Jersey Dept Hlth & Senior Serv, Trenton, NJ USA; Calif Dept Hlth Serv, Oakland, CA USA; Massachusetts Dept Publ Hlth, Boston, MA USA; NIOSH, Morgantown, WV USA	Rosenman, KD (reprint author), Michigan State Univ, 117 W Fee Hall, E Lansing, MI 48824 USA.						Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; BARRON T, 1999, HOW SELECT USE SAFE; Bernstein IL, 1999, ASTHMA WORKPLACE; BERNSTEIN JA, 1994, J ALLERGY CLIN IMMUN, V94, P257, DOI 10.1016/0091-6749(94)90048-5; Buck RG, 2000, S AFR MED J, V90, P884; BURGE PS, 1994, THORAX, V49, P842, DOI 10.1136/thx.49.8.842; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; FLYVHOLM MA, 1993, BRIT J IND MED, V50, P1043; Henneberger P K, 1999, Int J Occup Environ Health, V5, P1; Henneberger PK, 2000, AM J IND MED, V38, P140; Hunting KL, 1995, APPL OCCUP ENV HYG, V10, P317; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kreiss K., 1982, ENVIRON INT, V8, P337, DOI 10.1016/0160-4120(82)90047-2; KUJALA VM, 1995, RESP MED, V89, P693, DOI 10.1016/0954-6111(95)90137-X; LAMB VA, 1983, VIRGINIA MMWR, V32, P378; Litovitz TL, 2001, AM J EMERG MED, V19, P337, DOI 10.1053/ajem.2001.25272; Litovitz TL, 2000, AM J EMERG MED, V18, P517, DOI 10.1053/ajem.2000.9261; Lynch RM, 2000, ENVIRON HEALTH PERSP, V108, P911, DOI 10.1289/ehp.00108911; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; Mapp CE, 2000, EUR RESPIR J, V16, P570, DOI 10.1034/j.1399-3003.2000.016003570.x; MATTE TD, 1990, CHEST, V98, pS173, DOI 10.1378/chest.98.5_Supplement.173S; NG TP, 1995, OCCUP MED-OXFORD, V45, P45, DOI 10.1093/occmed/45.1.45; *NIOSH, 2000, 2000105 US DEP HHS P; Purohit A, 2000, INT ARCH OCC ENV HEA, V73, P423, DOI 10.1007/s004200000162; REILLY MJ, 1995, ARCH ENVIRON HEALTH, V50, P26; Rosenman KD, 1997, J OCCUP ENVIRON MED, V39, P415, DOI 10.1097/00043764-199705000-00007; SAVONIUS B, 1994, ALLERGY, V49, P877, DOI 10.1111/j.1398-9995.1994.tb00791.x; SHELTON D, 1992, J ALLERGY CLIN IMMUN, V90, P274, DOI 10.1016/0091-6749(92)90085-G; *SWORD, 2001, OCC DIS INT NET CTR; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	32	78	78	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1076-2752			J OCCUP ENVIRON MED	J. Occup. Environ. Med.	MAY	2003	45	5					556	563		10.1097/01.jom.0000058347.05741.f9		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	679CH	WOS:000182903100016	12762081	
J	Leonardi, A; Jose, PJ; Zhan, H; Calder, VL				Leonardi, A; Jose, PJ; Zhan, H; Calder, VL			Tear and mucus eotaxin-l and eotaxin-2 in allergic keratoconjunctivitis	OPHTHALMOLOGY			English	Article							IL-4 INDUCES EOTAXIN; VERNAL KERATOCONJUNCTIVITIS; ATOPIC KERATOCONJUNCTIVITIS; CONJUNCTIVAL FIBROBLASTS; HUMAN EOSINOPHIL; MESSENGER-RNA; EYE DISEASE; TNF-ALPHA; IN-VITRO; EXPRESSION	Objective: Eotaxin-1 and eotaxin-2 are potent eosinophil chemotactic and activating peptides that may be implicated in the pathogenesis of the chronic allergic eye diseases vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). The purpose of this study was to measure these chemokines, in tear and mucus samples of active-disease patients and in vitro cultured conjunctival epithelial cells and fibroblasts. Design: Comparative, observational case series and in vitro study. Participants: Sixteen patients with clinically active and untreated VKC or AKC, six age-matched control patients, and five nonactive seasonal allergic conjunctivitis patients. Methods: Tears were collected from the active VKC and AKC patients, and from the normal patients. Mucus was collected from six of these VKC patients. Tears were also collected from an additional five allergic patients after obtaining a positive reaction to conjunctival allergen challenge. Conjunctival epithelial cell and conjunctival fibroblast cultures were exposed to interleukin (IL)-4, IL-13, and tumor necrosis factor-alpha (TNF-alpha), or to combinations of these cytokines. Main Outcome Measures: Levels of eotaxin-1 and eotaxin-2 in tears, mucus, and culture medium. Results: High levels of eotaxin-1 and eotaxin-2 were found in mucus of VKC patients, whereas only eotaxin-2 was found to have increased significantly in tears of VKC and AKC patients compared with those of normal patients. Mucus contained higher levels of chemokines than did tears. Both tear eotaxin-1 and eotaxin-2 were correlated significantly with the percent of eosinophils in tear fluid. Eotaxin-1 also was correlated significantly with the sum clinical score and corneal involvement in VKC patients. Conjunctival epithelial cells in culture did not produce eotaxin-1 or eotaxin-2, either at baseline or after cytokine exposure. Conjunctival fibroblasts produced eotaxin-1 only after exposure to IL-4, TNF-alpha, and the combination of IL-4 plus TNF-alpha or IL-13 plus TNF-alpha. Conclusions: Eotaxin-1 and eotaxin-2 are implicated in eosinophil recruitment and in the pathogenesis of VKC and AKC. Cytokine-stimulated conjunctival fibroblasts may be one source of eotaxin-1 in severely allergic tissues. (C) 2003 by the American Academy of Ophthalmology.	Univ Padua, Dept Ophthalmol, Padua, Italy; Univ London Imperial Coll Sci Technol & Med, London, England; UCL, Inst Ophthalmol, Dept Clin Ophthalmol, London, England	Leonardi, A (reprint author), Via Foscari 8, I-35127 Padua, Italy.	andrea-leonardi@umpd.it					ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84; Abu El-Asrar AM, 2000, BRIT J OPHTHALMOL, V84, P1360; BONINI S, 1988, J ALLERGY CLIN IMMUN, V82, P462, DOI 10.1016/0091-6749(88)90020-6; Calder VL, 1999, CLIN EXP ALLERGY, V29, P1214; Chung KF, 1999, BRIT J PHARMACOL, V127, P1145, DOI 10.1038/sj.bjp.0702660; Culley FJ, 2000, J IMMUNOL, V165, P6447; Daugherty BL, 1996, J EXP MED, V183, P2349, DOI 10.1084/jem.183.5.2349; Dulkys Y, 2001, J INVEST DERMATOL, V116, P498, DOI 10.1046/j.1523-1747.2001.01299.x; Evans CAW, 1998, INFECT IMMUN, V66, P4522; Forssmann U, 1997, J EXP MED, V185, P2171, DOI 10.1084/jem.185.12.2171; Fukagawa K, 1999, J ALLERGY CLIN IMMUN, V103, P1220, DOI 10.1016/S0091-6749(99)70206-X; Fukagawa K, 2000, INT ARCH ALLERGY IMM, V121, P144, DOI 10.1159/000024310; JOSE PJ, 1994, J EXP MED, V179, P881, DOI 10.1084/jem.179.3.881; Kumagai N, 2000, INVEST OPHTH VIS SCI, V41, P1448; Leonardi A, 1999, INVEST OPHTH VIS SCI, V40, P3036; Leonardi A, 1999, EXP EYE RES, V68, P739, DOI 10.1006/exer.1999.0658; Leonardi A, 2000, INVEST OPHTH VIS SCI, V41, P4175; Leonardi A, 2000, AM J OPHTHALMOL, V129, P151, DOI 10.1016/S0002-9394(99)00295-0; Leonardi A, 1998, EXP EYE RES, V67, P105, DOI 10.1006/exer.1998.0499; Metz DP, 1997, J ALLERGY CLIN IMMUN, V100, P817, DOI 10.1016/S0091-6749(97)70279-3; Mochizuki M, 1998, J IMMUNOL, V160, P60; Rothenberg ME, 1996, MOL MED, V2, P334; Solomon A, 2000, INVEST OPHTH VIS SCI, V41, P1038; Terada N, 2000, CLIN EXP ALLERGY, V30, P348; Teran LM, 1999, AM J RESP CELL MOL, V20, P777; TROCME SD, 1989, AM J OPHTHALMOL, V108, P57; Trocme SD, 1997, INVEST OPHTH VIS SCI, V38, P593; TROCME SD, 1994, SURV OPHTHALMOL, V39, P241, DOI 10.1016/0039-6257(94)90197-X; Uchio E, 2000, CLIN EXP ALLERGY, V30, P103; Ying S, 1999, J IMMUNOL, V163, P6321	30	78	83	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-6420			OPHTHALMOLOGY	Ophthalmology	MAR	2003	110	3					487	492		10.1016/S0161-6420(02)01767-0		6	Ophthalmology	Ophthalmology	649XK	WOS:000181233100016	12623809	
J	Horak, F; Stubner, UP; Zieglmayer, R; Harris, AG				Horak, F; Stubner, UP; Zieglmayer, R; Harris, AG			Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						desloratadine; antihistamine; nasal obstruction; seasonal allergic rhinitis; allergen exposure; rhinomanometry	MUCOSAL BLOOD-FLOW; RECEPTOR ANTAGONISTS; ATOPIC PATIENTS; EFFICACY; CETIRIZINE; CHALLENGE; SYMPTOMS; SAFETY; LORATADINE; MANAGEMENT	Background: Unlike many antihistamines, desloratadine can reduce nasal congestion in patients with seasonal allergic rhinitis (SAR). Objective: We compared the effects of 5 mg of desloratadine and placebo on nasal airflow and SAR symptoms, including nasal congestion, in response to grass pollen in an allergen-exposure unit. Methods: In a randomized, double-blind, placebo-controlled, crossover trial, 47 subjects with histories of SAR received desloratadine or placebo every morning for 7 days and, after a 10-day washout period, were crossed over to the other treatment arm for 7 days. Subjects underwent a 6-hour allergen exposure on day 7 of each treatment period. Nasal airflow and nasal secretion weights were measured before and every 30 minutes during allergen exposure; SAR symptoms (including nasal congestion) were scored before exposure and every 15 minutes thereafter. Results: Nasal obstruction, as measured by nasal airflow, was less severe with desloratadine than with placebo (P < .02). Individual and combined SAR symptom severity scores, including nasal congestion and sneezing, were significantly lower with desloratadine than with placebo (all P less than or equal to .003). Within 30 minutes of allergen exposure, less severely decreased nasal airflow (P < .02), less nasal secretions (P < .001), and less severe symptoms, including nasal congestion (P < .002), rhinorrhea, and sneezing, occurred with desloratadine compared with placebo, and this continued throughout (0-6 hours) allergen exposure. Desloratadine was well tolerated, with an adverse event profile similar to that of placebo. Conclusion: In subjects with allergen-induced SAR symptoms, desloratadine significantly reduced the severity of nasal obstruction and accompanying complaints of nasal congestion and other SAR symptoms compared with the effects of placebo.	Univ Vienna, AKH Vienna, ENT Clin, A-1090 Vienna, Austria; Schering Plough Corp, Kenilworth, NJ 07033 USA	Horak, F (reprint author), Univ Vienna, AKH Vienna, ENT Clin, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.			Harris, Alan/0000-0002-6618-2092			*AM AC ALL ASTHM I, 2001, ALL REP; ANDERSSON KE, 1984, ANN OTO RHINOL LARYN, V93, P179; Bachert C, 2001, ALLERGY, V56, P14, DOI 10.1034/j.1398-9995.2001.00102.x; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; BROIDE D, 1995, ALLERGY, V50, P31, DOI 10.1111/j.1398-9995.1995.tb04261.x; Day JH, 1997, ANN ALLERG ASTHMA IM, V79, P163; DOCKHORN RJ, 1987, ANN ALLERGY, V58, P407; Geha Raif S., 2001, Journal of Allergy and Clinical Immunology, V107, P751; Gentile DA, 2000, IMMUNOL ALLERGY CLIN, V20, P355, DOI 10.1016/S0889-8561(05)70152-1; HORAK F, 1993, ALLERGY, V48, P226, DOI 10.1111/j.1398-9995.1993.tb00720.x; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; Horak F, 1998, ALLERGY, V53, P849, DOI 10.1111/j.1398-9995.1998.tb03990.x; HORAK F, 1987, WIEN KLIN WOCHENSCHR, V99, P509; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kreutner William, 2000, Arzneimittel-Forschung, V50, P345; *MED EC COMP, 2000, 2000 PHYS DESK REF N; Meltzer EO, 1998, J ALLERGY CLIN IMMUN, V102, P39, DOI 10.1016/S0091-6749(98)70053-3; Meltzer EO, 2001, CLIN DRUG INVEST, V21, P25, DOI 10.2165/00044011-200121010-00004; PIPKORN U, 1982, ALLERGY, V37, P129, DOI 10.1111/j.1398-9995.1982.tb01886.x; Schmidt BMW, 1999, J CLIN PHARMACOL, V39, P1062, DOI 10.1177/00912709922011836; SMALL P, 1991, ANN ALLERGY, V67, P520; Wang DY, 1996, ACTA OTO-LARYNGOL, V116, P91, DOI 10.3109/00016489609137720; Weiner JM, 1998, BRIT MED J, V317, P1624; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x	24	78	81	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2002	109	6					956	961		10.1067/mai.2002.124657		6	Allergy; Immunology	Allergy; Immunology	566RU	WOS:000176442700010	12063524	
J	Wright, RJ; Steinbach, SF				Wright, RJ; Steinbach, SF			Violence: An unrecognized environmental exposure that may contribute to greater asthma morbidity in high risk inner-city populations	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; case series; innercity; stress; violence	POSTTRAUMATIC-STRESS-DISORDER; URBAN AFRICAN-AMERICAN; PSYCHOLOGICAL STRESS; IMMUNE INTERACTIONS; CHILDHOOD ASTHMA; LIFE EVENTS; CHILDREN; HEALTH; SMOKING; HOSPITALIZATION	In the United States, rising trends in asthma prevalence and severity, which disproportionately impact minorities and the urban poor, have not been fully explained by traditional physical environmental risk factors. Exigencies of inner-city living can increase psychosocial risk factors (e.g., stress) that confer increased asthma morbidity. In the United States, chronic exposure to violence is a unique stressor existing in many high-risk urban neighborhoods. In this paper, we describe a series of cases that exemplify a temporal association between exposure to violence and the precipitation of asthma exacerbations in four urban pediatric patients. In the first three cases, the nature of the exposure is characterized by the proximity to violence, which ranged from direct victimization (through either the threat of physical assault or actual assault) to learning of the death of a peer. The fourth case characterizes a scenario in which a child was exposed to severe parental conflict (i.e., domestic violence) in the hospital setting. Increasingly, studies have begun to explore the effect of living in a violent environment, with a chronic pervasive atmosphere of fear and the perceived or real threat of violence, on health outcomes in population-based studies. Violence exposure may contribute to environmental demands that tax both the individual and the communities in which they live to impact the inner-city asthma burden. At the individual level, intervention strategies aimed to reduce violence exposure, to reduce stress, or to counsel victims or witnesses to violence may be complementary to more traditional asthma treatment in these populations. Change in policies that address the social, economic, and political factors that contribute to crime and violence in urban America may have broader impact.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pulm & Crit Care, Boston, MA 02115 USA; Boston Med Ctr, Dept Pediat, Boston, MA USA	Wright, RJ (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL 07427]		Acierno R, 1996, BEHAV MODIF, V20, P363, DOI 10.1177/01454455960204001; ADLER NE, 1994, AM PSYCHOL, V49, P15, DOI 10.1037/0003-066X.49.1.15; ATTAR BK, 1994, J CLIN CHILD PSYCHOL, V23, P391, DOI 10.1207/s15374424jccp2304_5; Augustyn M., 1995, CONT PEDIAT, V12, P35; Barker R. G., 1978, HABITATS ENV HUMAN B; BAUM A, 1990, HEALTH PSYCHOL, V9, P653, DOI 10.1037//0278-6133.9.6.653; BECKHAM JC, 1995, J TRAUMA STRESS, V8, P461, DOI 10.1007/BF02102970; BOXER GH, 1988, CHILD ABUSE NEGLECT, V12, P491, DOI 10.1016/0145-2134(88)90066-X; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; BROSSCHOT JF, 1994, PSYCHOSOM MED, V56, P216; BUSSE WE, 1994, AM J RESP CRIT CARE, V151, P249; Busse WW, 1997, CIBA F SYMP, V206, P208; Camargo CA, 1999, AM J RESP CRIT CARE, V159, pA150; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cohen S, 1995, MEASURING STRESS GUI, P3; Dohrenwend BP, 1969, SOCIAL STATUS PSYCHO; Donovan CE, 1999, THORAX, V54, P938; Evans GW, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P365; FEIGELMAN W, 1989, J PSYCHOACTIVE DRUGS, V21, P299; FITZPATRICK KM, 1993, J AM ACAD CHILD PSY, V32, P424, DOI 10.1097/00004583-199303000-00026; FLEMING AW, 1992, ARCH SURG-CHICAGO, V127, P671; FONG RL, 1995, J NATL MED ASSOC, V87, P203; GELHORN E, 1965, PERSPECT BIOL MED, V8, P488; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Gortmaker SL, 1996, ARCH PEDIAT ADOL MED, V150, P356; GRAHAM NMH, 1986, AM J EPIDEMIOL, V124, P389; Groves B, 1994, Disch Plann Update, V14, P14; GUSTAFSSON PA, 1987, ARCH DIS CHILD, V62, P258; HERMAN AA, 1988, AM J PUBLIC HEALTH, V8, P767; Isaacs M., 1992, IMPACT COMMUNITY VIO; Kauffman KS, 1995, NURS RES, V44, P231; Kawachi I, 1999, SOC SCI MED, V48, P719, DOI 10.1016/S0277-9536(98)00400-6; Kawachi I, 1999, HEALTH SERV RES, V34, P215; KIECOLT-GLASER J K, 1987, Annals of Behavioral Medicine, V9, P16, DOI 10.1207/s15324796abm0902_3; KIECOLTGLASER JK, 1991, PSYCHONEUROIMMUNOLOG, V2, P849; KLEINSCHMIDT I, 1997, J EPIDEMIOL COMMUNIT, V87, P1113; KRAUSE N, 1991, J GERONTOL, V46, pS183; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; McEwen BS, 1997, BRAIN RES REV, V23, P79, DOI 10.1016/S0165-0173(96)00012-4; NADEL JA, 1984, ANNU REV MED, V35, P451, DOI 10.1146/annurev.med.35.1.451; OSOFSKY JD, 1993, PSYCHIATRY, V56, P36; Pike JL, 1997, PSYCHOSOM MED, V59, P447; RABKIN JG, 1976, SCIENCE, V194, P1013, DOI 10.1126/science.790570; Reijneveld SA, 1998, INT J EPIDEMIOL, V27, P33, DOI 10.1093/ije/27.1.33; ROBICSEK R, 1993, NC MED J, V54, P578; ROMANO PS, 1991, AM J PUBLIC HEALTH, V81, P1415, DOI 10.2105/AJPH.81.11.1415; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sampson R. J., 1992, FACTS FRAMEWORKS FOR, P63; Sheehan K, 1997, ARCH PEDIAT ADOL MED, V151, P502; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Sternberg EM, 1997, J CLIN INVEST, V100, P2641, DOI 10.1172/JCI119807; Stringham P, 1998, PEDIATR CLIN N AM, V45, P439, DOI 10.1016/S0031-3955(05)70018-3; STRUNK RC, 1985, JAMA-J AM MED ASSOC, V254, P1193; TAYLOR L, 1994, J DEV BEHAV PEDIATR, V15, P120; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; VINGERHOETS A J J M, 1985, International Journal of Psychosomatics, V32, P28; Wallace D, 1998, AM J PUBLIC HEALTH, V88, P1853, DOI 10.2105/AJPH.88.12.1853; Weiss KB, 1992, CHEST, V101, P362; Wright RJ, 1998, THORAX, V53, P1066; WRIGHT RJ, 1998, AM J RESP CRIT CARE, V157, pA41; WRIGHT RJ, 2000, ALLERGY, P203; WRIGHT RJ, 1997, AM J RESP CRIT CARE, V155, pA972; ZAPATA BC, 1992, AM J PUBLIC HEALTH, V82, P685, DOI 10.2105/AJPH.82.5.685	65	78	79	2	8	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2001	109	10					1085	1089		10.2307/3454965		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	487GF	WOS:000171864800031	11675274	
J	Huecas, S; Villalba, M; Rodriguez, R				Huecas, S; Villalba, M; Rodriguez, R			Ole e 9, a major olive pollen allergen is a 1,3-beta-glucanase - Isolation, characterization, amino acid sequence, and tissue specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOGENESIS-RELATED PROTEINS; DUST-MITE ALLERGEN; TREE POLLEN; EUROPEA POLLEN; E-I; BETA-1,3-GLUCANASE; TOBACCO; EXPRESSION; IDENTIFICATION; PURIFICATION	Olive pollen allergy is a clinical disorder affecting the human population of Mediterranean areas. A novel major allergen, Ole e 9, has been isolated from olive pollen by gel permeation, hydrophobic affinity, and reverse-phase high performance liquid chromatographies. It is involved in the allergic responses of 65% of patients suffering olive pollinosis. Ole e 9 (molecular mass of 46.4 kDa) displays 1,3-beta -endoglucanase activity (38.9 +/- 5.6 mg of glucose released/min x mu mol of protein at pH 4.5-6.0 using laminarin as substrate). It is the first 1,3-beta -glucanase, a member of the "pathogenesis-related" protein family, detected in pollen tissue. Seven tryptic peptides of the allergen were sequenced by Edman degradation and used for designing primers to clone the cDNA codifying the protein. Specific cDNA for Ole e 9 was synthesized from total RNA and amplified using the polymerase chain reaction. The allergen sequence showed an open reading frame of 460 amino acids comprising a putative signal peptide of 26 residues. It shows 39, 33, and 32% sequence identity including the catalytic residues when compared with 1,3-beta -glucanases from wheat, willow, and Arabidopsis thaliana, respectively. Northern blot analysis showed that Ole e 9 transcript is specifically expressed in the pollen tissue, and highly conserved counterparts were only detected in taxonomically related pollens.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain	Rodriguez, R (reprint author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, Avda Complutense S-N, E-28040 Madrid, Spain.		Huecas, Sonia/K-1754-2014; Villalba, Mayte/K-5365-2014; RODRIGUEZ, ROSALIA/K-4993-2014	Huecas, Sonia/0000-0002-6419-441X; RODRIGUEZ, ROSALIA/0000-0002-4280-3691			ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; Batanero E, 1997, FEBS LETT, V410, P293, DOI 10.1016/S0014-5793(97)00582-6; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; BLANCA M, 1983, CLIN ALLERGY, V13, P473, DOI 10.1111/j.1365-2222.1983.tb02624.x; Boluda L, 1998, J ALLERGY CLIN IMMUN, V101, P210; BOUSQUET J, 1984, CLIN ALLERGY, V14, P249, DOI 10.1111/j.1365-2222.1984.tb02204.x; Brehler R, 1997, ALLERGY, V52, P404, DOI 10.1111/j.1398-9995.1997.tb01019.x; BREITENEDER H, 1989, EMBO J, V8, P1935; BUCCIAGLIA PA, 1994, PLANT MOL BIOL, V24, P903, DOI 10.1007/BF00014444; CHEN L, 1993, J BIOL CHEM, V268, P13318; CHEN L, 1995, J BIOL CHEM, V270, P8093; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; CHYE ML, 1995, PLANT MOL BIOL, V29, P397, DOI 10.1007/BF00043663; CruzOrtega R, 1997, PLANT PHYSIOL, V114, P1453, DOI 10.1104/pp.114.4.1453; DELCAMPILLO E, 1992, PLANT PHYSIOL, V99, P1015, DOI 10.1104/pp.99.3.1015; Delp G, 1999, PLANT MOL BIOL, V39, P565, DOI 10.1023/A:1006194822666; DUDLER T, 1995, J IMMUNOL, V155, P2605; Futamura N, 2000, PLANT CELL PHYSIOL, V41, P16; Garnier J, 1996, METHOD ENZYMOL, V266, P540; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; Hoffmann-Sommergruber K, 2000, INT ARCH ALLERGY IMM, V122, P155, DOI 10.1159/000024392; HOJ PB, 1995, PLANT J, V7, P367, DOI 10.1046/j.1365-313X.1995.7030367.x; Huecas S, 1999, EUR J BIOCHEM, V261, P539, DOI 10.1046/j.1432-1327.1999.00307.x; Juers DH, 1999, PROTEIN SCI, V8, P122; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUZURICA P, 1988, MOL IMMUNOL, V25, P329, DOI 10.1016/0161-5890(88)90027-2; Ledesma A, 1998, ALLERGY, V53, P520, DOI 10.1111/j.1398-9995.1998.tb04090.x; Ledesma A, 2000, FEBS LETT, V466, P192, DOI 10.1016/S0014-5793(99)01790-1; Leubner-Metzger G, 1999, PATHOGENESIS-RELATED PROTEINS IN PLANTS, P49; LOTAN T, 1989, PLANT CELL, V1, P881; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Macchia L, 1991, ALLERGENIC POLLEN PO, P87; Meins F. Jr., 1992, Genes involved in plant defense., P245; MEMELINK J, 1990, PLANT MOL BIOL, V14, P119, DOI 10.1007/BF00018553; Nelson N, 1944, J BIOL CHEM, V153, P375; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; ORI N, 1990, EMBO J, V9, P3429; Peumans WJ, 2000, EUR J BIOCHEM, V267, P1188, DOI 10.1046/j.1432-1327.2000.01117.x; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Sessa G, 1995, PLANT MOL BIOL, V29, P969, DOI 10.1007/BF00014970; SHINSHI H, 1988, P NATL ACAD SCI USA, V85, P5541, DOI 10.1073/pnas.85.15.5541; SOMOGYI M, 1952, J BIOL CHEM, V195, P19; Stone BA, 1992, CHEM BIOL 1 3 BETA G; Subroto T, 1996, PHYTOCHEMISTRY, V43, P29, DOI 10.1016/0031-9422(96)00196-3; SUNDERASAN E, 1995, J RUBBER RES, V10, P82; TANIGUCHI Y, 1995, ALLERGY, V50, P90, DOI 10.1111/j.1398-9995.1995.tb02489.x; Tejera ML, 1999, J ALLERGY CLIN IMMUN, V104, P797; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; VANLOON LC, 1970, VIROLOGY, V40, P199, DOI 10.1016/0042-6822(70)90395-8; vanRee R, 1997, ALLERGY, V52, P795; VELA C, 1982, INT ARCH ALLER A IMM, V68, P289; VILLALBA M, 1994, J BIOL CHEM, V269, P15217; VILLALBA M, 1993, EUR J BIOCHEM, V216, P863, DOI 10.1111/j.1432-1033.1993.tb18208.x; VOGELILANGE R, 1994, PLANT J, V5, P273, DOI 10.1046/j.1365-313X.1994.05020273.x; WARD ER, 1991, PLANT PHYSIOL, V96, P390, DOI 10.1104/pp.96.2.390; WHEELER AW, 1992, CLIN EXP ALLERGY, V22, P1052, DOI 10.1111/j.1365-2222.1992.tb00129.x; WHEELER AW, 1990, MOL IMMUNOL, V27, P631, DOI 10.1016/0161-5890(90)90005-K; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379	68	78	79	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 27	2001	276	30					27959	27966		10.1074/jbc.M103041200		8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	456QH	WOS:000170093400030	11373288	
J	Piirila, P; Wikman, H; Luukkonen, R; Kaaria, K; Rosenberg, C; Nordman, H; Norppa, H; Vainio, H; Hirvonen, A				Piirila, P; Wikman, H; Luukkonen, R; Kaaria, K; Rosenberg, C; Nordman, H; Norppa, H; Vainio, H; Hirvonen, A			Glutathione S-transferase genotypes and allergic responses to diisocyanate exposure	PHARMACOGENETICS			English	Article						allergic responses; diisocyanates; individual susceptibility; GSTs; occupational asthma; specific IgE	OCCUPATIONAL ASTHMA; TOLUENE-DIISOCYANATE; METHYL ISOCYANATE; IGE ANTIBODIES; POLYMORPHISM; ASSOCIATION; SUSCEPTIBILITY; WORKERS; LOCUS; ALLELES	Diisocyanates are the most common low molecular weight chemicals to cause occupational asthma, However, only some 5-10% of exposed workers develop asthma, which suggests an underlying genetic susceptibility, Diisocyanates and their metabolites may be conjugated with glutathione by glutathione S-transferases (GSTs). We examined whether polymorphisms in the GSTM1, GSTM3, GSTP1 and GSTT1 genes modify allergic responses to diisocyanate exposure. The study population consisted of 182 diisocyanate exposed workers, 109 diagnosed with diisocyanate-induce asthma and 73 without asthma, Lack of the GSTM1 gene (null genotype) was associated with a 1.89-fold risk of diisocyanate-induced asthma [95% confidence interval (CI) 1.01-3.52]. Moreover, among the asthma patients, the GSTM1 null genotype was associated with lack of diisocyanate-specific immunoglobulin (Ig)E antibodies [odds ratio (OR) 0.18, 95% CI 0.05-0.61] and with late reaction in the specific bronchial provocation test (OR 2.82, 95% CI 1.15-6.88). Similarly, GSTM3 AA genotype was related to late reaction in the specific bronchial provocation test (OR 3.75, 95% CI 1.26-11.2), The GSTP1 Val/Val genotype, on the other hand, was related to high total IgE levels (OR 5.46, 95% CI 1.15-26.0). The most remarkable effect was seen for the combination of GSTM1 null anti. the GSTM3 AA genotype which was strongly associated with lack of diisocyanate-specific IgE antibodies (OR 0.09, 35% CI 0.01-0.73) and with late reaction in the bronchial provocation test (OR 11.0, 95% CI 2.19-55.3). The results suggest, for the first time, that the polymorphic GSTs, especially the mu class GSTs, play an important role in inception of ill effects related to occupational exposure to diisocyanates. Pharmacogenetics 11:437-445 (C) 2001 Lippincott Williams & Wilkins.	Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, FIN-00250 Helsinki, Finland; Finnish Inst Occupat Hlth, Dept Occupat Med, FIN-00250 Helsinki, Finland; Finnish Inst Occupat Hlth, Dept Epidemiol, FIN-00250 Helsinki, Finland; Int Agcy Res Canc, F-69372 Lyon, France; Univ Helsinki Hosp, Lab Clin Physiol, Helsinki, Finland	Hirvonen, A (reprint author), Finnish Inst Occupat Hlth, Dept Ind Hyg & Toxicol, Topeltuksenkatu 41 AA, FIN-00250 Helsinki, Finland.			Piirila, Paivi/0000-0002-2535-4409			BAILLIE TA, 1991, ACCOUNTS CHEM RES, V24, P264, DOI 10.1021/ar00009a003; Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P252; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BAUR X, 1994, INT ARCH OCC ENV HEA, V66, P141, DOI 10.1007/BF00380772; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; BUTCHER BT, 1980, J ALLERGY CLIN IMMUN, V66, P213, DOI 10.1016/0091-6749(80)90041-X; BUTCHER BT, 1977, AM REV RESPIR DIS, V116, P411; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Day BW, 1997, CHEM RES TOXICOL, V10, P424, DOI 10.1021/tx960201+; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; GARCIASAEZ I, 1994, J MOL BIOL, V237, P298, DOI 10.1006/jmbi.1994.1232; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hirvonen A, 1999, ENVIRON HEALTH PERSP, V107, P37, DOI 10.2307/3434470; Inskip A, 1995, BIOCHEM J, V312, P713; Kanerva L, 1991, EXOGENOUS DERMATOSES, P103; KESKINEN H, 1988, CLIN ALLERGY, V18, P597, DOI 10.1111/j.1365-2222.1988.tb02911.x; MAPP CE, 1988, EUR RESPIR J, V1, P273; Mattey DL, 1999, ANN RHEUM DIS, V58, P164, DOI 10.1136/ard.58.3.164; NEWMANTAYLOR AJ, 1981, OCCUPATIONAL LUNG DI, P143; Ollier W, 1996, ARTHRITIS RHEUM, V39, P1763, DOI 10.1002/art.1780391023; PEARSON PG, 1991, CHEM RES TOXICOL, V4, P436, DOI 10.1021/tx00022a007; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; Saarikoski ST, 1998, INT J CANCER, V77, P516, DOI 10.1002/(SICI)1097-0215(19980812)77:4<516::AID-IJC7>3.0.CO;2-X; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160; SLATTER JG, 1991, CHEM RES TOXICOL, V4, P157, DOI 10.1021/tx00020a006; Strange RC, 1999, METABOLIC POLYMORPHI, P231; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; WEISS ST, 1996, GENETICS ASTHMA, P401; Yengi L, 1996, CANCER RES, V56, P1974; ZIMNIAK P, 1994, EUR J BIOCHEM, V224, P893, DOI 10.1111/j.1432-1033.1994.00893.x	35	78	80	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0960-314X			PHARMACOGENETICS	Pharmacogenetics	JUL	2001	11	5					437	445		10.1097/00008571-200107000-00007		9	Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy	Biotechnology & Applied Microbiology; Genetics & Heredity; Pharmacology & Pharmacy	454QR	WOS:000169983700007	11470996	
J	Bush, RK; Portnoy, JM				Bush, RK; Portnoy, JM			The role and abatement of fungal allergens in allergic diseases	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						fungi; allergic disease; asthma; environment; exposure; abatement	NUTRITION EXAMINATION SURVEY; MAJOR ALTERNARIA ALLERGEN; SICK BUILDING SYNDROME; 2ND NATIONAL-HEALTH; SCHOOL-AGE-CHILDREN; DUST MITE; INDOOR AIR; RESIDENTIAL CHARACTERISTICS; ENVIRONMENTAL-FACTORS; RESPIRATORY SYMPTOMS	Sensitivity to a variety of fungi is known to be a factor in allergic rhinitis and asthma. In this review methods for measuring exposure to fungi in the indoor environment are evaluated. A variety of markers for the presence of fungi are also described in addition to their known relationship to either toxic or adverse immunologic effects. Key studies documenting the clinical effects of different types of fungi are also reviewed, as well as a description of abatement methods that either have been successful or need further investigation. Although many studies have shown an association between exposure to fungi and allergic disease, in many cases a direct cause-and-effect relationship has not been established. Improved knowledge of the epidemiology and mechanisms behind fungal-induced human disease will hopefully establish this causal link and suggest methods for reducing morbidity.	Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, Madison, WI 53705 USA; Childrens Mercy Hosp, Sect Allergy Immunol, Kansas City, MO 64108 USA	Bush, RK (reprint author), Univ Wisconsin, William S Middleton Mem Vet Adm Hosp, Dept Med, 2500 OVerlook Terrace, Madison, WI 53705 USA.						AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; Abe K, 1996, APPL ENVIRON MICROB, V62, P959; ADEN E, 1999, J ALLERGY CLIN IMMUN, V103, P128; Ahearn DG, 1997, CURR MICROBIOL, V35, P305, DOI 10.1007/s002849900259; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; Banerjee B, 1998, IMMUNOL ALLERGY CLIN, V18, P601, DOI 10.1016/S0889-8561(05)70024-2; Bardana EJ, 1997, ANN ALLERG ASTHMA IM, V79, P283; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; BARR M, 1999, CLIN EXP ALLERGY, V29, P1442; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114; BRUCE C, 1997, J ALLERGY CLIN IMMUN, V59, P449; BURGE HA, 1992, CLIN REV ALLERG, V10, P153; BURGE HA, 1976, J ALLERGY CLIN IMMUN, V58, P491, DOI 10.1016/0091-6749(76)90193-7; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; Bush RK, 1999, J ALLERGY CLIN IMMUN, V104, P665, DOI 10.1016/S0091-6749(99)70340-4; BUSH RK, 2001, ENV ASTHMA, P69; Chapman JA, 1999, ALLERGY ASTHMA PROC, V20, P289, DOI 10.2500/108854199778251889; CHAPMAN MD, 1984, J IMMUNOL, V133, P2488; Codina R, 1998, J ALLERGY CLIN IMMUN, V102, P318, DOI 10.1016/S0091-6749(98)70102-2; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; CROFT W, 1986, ATMOS ENVIRON, V20, P249; DAmato G, 1997, ALLERGY, V52, P711, DOI 10.1111/j.1398-9995.1997.tb01227.x; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Dharmage S, 1999, INDOOR AIR, V9, P188, DOI 10.1111/j.1600-0668.1999.t01-1-00005.x; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Dill I, 1996, PEDIATR ALLERGY IMMU, V7, P151, DOI 10.1111/j.1399-3038.1996.tb00123.x; Dillon HK, 1999, ENVIRON HEALTH PERSP, V107, P473; Dotterud LK, 1995, PEDIATR ALLERGY IMMU, V6, P181, DOI 10.1111/j.1399-3038.1995.tb00282.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; *EPA, 1999, 402F99005 EPA; Esch RE, 1997, METHODS, V13, P2, DOI 10.1006/meth.1997.0491; Fischer G, 1999, CHEMOSPHERE, V39, P795; FOX RW, 1994, J ALLERGY CLIN IMMUN, V94, P413, DOI 10.1016/0091-6749(94)90107-4; FRANKLAND AW, 1973, NATURE, V245, P336, DOI 10.1038/245336a0; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GARRISON RA, 1993, ANN ALLERGY, V71, P548; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gorny RL, 1999, ANN AGR ENV MED, V6, P105; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786; HOMER W, 1994, FUNGI IMMUNOL ALLERG, V3, P551; Homer W. E., 1995, CLIN MICROBIOL REV, V8, P161; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109; Kenny LC, 1999, ANN OCCUP HYG, V43, P393; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; Levetin E., 1995, Aerobiologia, V11, P27, DOI 10.1007/BF02136141; LEVETIN E, 1995, BIOAEROSOLS, P108; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; LOPEZ M, 1985, CLIN REV ALLERG, V3, P183, DOI 10.1007/BF02992982; MALONEY MJ, 1987, ANN ALLERGY, V59, P192; McGrath JJ, 1999, CURR MICROBIOL, V38, P33, DOI 10.1007/PL00006768; Miller JD, 1997, AM IND HYG ASSOC J, V58, P39; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PARIS S, 1991, J ALLERGY CLIN IMMUN, V88, P902, DOI 10.1016/0091-6749(91)90247-L; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; Pieckova E, 1999, ANN AGR ENV MED, V6, P1; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; Platts-Mills T A, 1986, Allerg Immunol (Paris), V18, P17; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1983, MONOGR ALLERGY, V18, P153; PLATTSMILLS TAE, 1990, TOXICOL IND HEALTH, V6, P197; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; PORTNOY J, 1990, ANN ALLERGY, V65, P109; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P773, DOI 10.1016/0091-6749(93)90197-N; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; PRAHL P, 1992, ALLERGY, V47, P362, DOI 10.1111/j.1398-9995.1992.tb02072.x; Rao CY, 1996, J AIR WASTE MANAGE, V46, P899; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P501; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SAMSON RA, 1992, J MED VET MYCOL, V30, P9; Shen HD, 1998, INT ARCH ALLERGY IMM, V116, P29, DOI 10.1159/000023921; Shen HD, 1997, CLIN EXP ALLERGY, V27, P682, DOI 10.1046/j.1365-2222.1997.d01-546.x; SMEDJE G, 1996, 7 INT C IND AIR QUAL, P611; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1976, J ALLERGY CLIN IMMUN, V57, P46, DOI 10.1016/0091-6749(76)90078-6; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P229; Solomon W, 1998, ALLERGY PRINCIPLES P, P367; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; VERHOEFF AP, 1990, ALLERGY, V45, P275, DOI 10.1111/j.1398-9995.1990.tb00496.x; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; Vijay HM, 1999, ALLERGENS ALLERGEN I, P133; YUNGINGER JW, 1976, J ALLERGY CLIN IMMUN, V57, P293, DOI 10.1016/0091-6749(76)90085-3	94	78	81	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S430	S440				11	Allergy; Immunology	Allergy; Immunology	418KR	WOS:000167891800005	11242604	
J	Grootendorst, DC; Dahlen, SE; Van den Bos, JW; Duiverman, EJ; Veselic-Charvat, M; Vrijlandt, EJLE; O'Sullivan, S; Kumlin, M; Sterk, PJ; Roldaan, AC				Grootendorst, DC; Dahlen, SE; Van den Bos, JW; Duiverman, EJ; Veselic-Charvat, M; Vrijlandt, EJLE; O'Sullivan, S; Kumlin, M; Sterk, PJ; Roldaan, AC			Benefits of high altitude allergen avoidance in atopic adolescents with moderate to severe asthma, over and above treatment with high dose inhaled steroids	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergen avoidance; house dust mite; severe asthma; induced sputum; high altitude; urine; EPX; LTE4; 9 alpha 11 beta-PGF(2)	BRONCHIAL HYPERRESPONSIVENESS; CLINICAL SEVERITY; DUST MITES; CHILDREN; INFLAMMATION; GLUCOCORTICOIDS; MANAGEMENT; EXCRETION; PROTEIN	Background Some patients with severe asthma cannot be controlled with high doses of inhaled steroids (ICS), which may be related to ongoing environmental allergen exposure. Objective We investigated whether 10 weeks of high altitude allergen avoidance leads to sustained benefits regarding clinical and inflammatory markers of disease control in adolescents with persistent asthma despite treatment with high dose ICS. Methods Eighteen atopic asthmatic adolescents (12-18 yr, 500-2000 mug ICS daily) with established house dust mite allergy, participated in a parallel-group study. Quality of life (PAQL), lung function, bronchial hyperresponsiveness (BHR) to adenosine and histamine, induced sputum and urine samples were collected repeatedly from 10 patients during a 10-week admission period to the Swiss Alps (alt. 1560 m) and at 6 weeks after return to sea level. Results were compared with those in eight patients, studied in their home environment at sea level for a similar time period. Throughout the study, asthma medication remained unchanged in both groups. Results During admission to high altitude, PAQL, lung function, BHR to adenosine and histamine, and urinary levels of eosinophil protein X (U-EPX), leukotriene E-4 (U-LTE4) and 9 alpha 11 beta prostaglandin F-2 (U-9 alpha 11 beta PGF(2)) improved significantly (P < 0.05), with a similar tendency for sputum eosinophils (P < 0.07). Furthermore, the changes in PAQL and BHR to adenosine and histamine were greater in the altitude than in the control group (P < 0.05). At 6 weeks after renewed allergen exposure at sea level, the improvements in PAQL (P < 0.05), BHR to adenosine (P < 0.07) and histamine (P < 0.05), as well as U-EPX (P < 0.05) and U-LTE4 (P < 0.05) were maintained. Conclusion A short period of high altitude allergen avoidance, on top of regular treatment with ICS and long-acting beta (2)-agonists, results in improvement of asthma, as assessed by clinical and inflammatory markers of disease severity. These findings indicate that short-term, rigorous allergen avoidance can improve the long-term control of severe asthma over and above what can be achieved even by high doses of inhaled steroids.	Leiden Univ, Med Ctr, Dept Pulmonol, Lung Funct Lab C2P, NL-2300 RC Leiden, Netherlands; Dutch Asthma Ctr, Davos, Switzerland; Karolinska Inst, Natl Inst Environm Med, Stockholm, Sweden; Juliana Childrens Hosp, The Hague, Netherlands; Leiden Univ, Med Ctr, Dept Pathol, Leiden, Netherlands; Med Spectrum Twente Hosp, Enschede, Netherlands; Leijenburg Hosp, Dept Pulmonol, The Hague, Netherlands	Grootendorst, DC (reprint author), Leiden Univ, Med Ctr, Dept Pulmonol, Lung Funct Lab C2P, POB 9600, NL-2300 RC Leiden, Netherlands.						Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Barnes PJ, 1996, RESP MED, V90, P379, DOI 10.1016/S0954-6111(96)90108-0; BONER AL, 1985, ANN ALLERGY, V54, P42; British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; Cockcroft DW, 1996, J ALLERGY CLIN IMMUN, V98, P1016, DOI 10.1016/S0091-6749(96)80185-0; Custovic A, 1998, THORAX, V53, P63; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Grootendorst DC, 1999, EUR RESPIR J, V13, P647, DOI 10.1183/09031936.99.13364799; GUYATT GH, 1989, J CLIN EPIDEMIOL, V42, P913, DOI 10.1016/0895-4356(89)90105-4; Holgate ST, 1997, LANCET, V350, P5; In 'T Veen J. C. C. M., 1996, European Respiratory Journal, V9, P2441, DOI 10.1183/09031936.96.09122441; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KUMLIN M, 1995, CLIN EXP ALLERGY, V25, P467, DOI 10.1111/j.1365-2222.1995.tb01079.x; Lugosi E, 1997, ALLERGY, V52, P584, DOI 10.1111/j.1398-9995.1997.tb02605.x; National Heart Lung and Blood Institute National Asthma Education Program, 1997, NIH PUBL; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442; Piacentini GL, 1996, J ALLERGY CLIN IMMUN, V97, P1079, DOI 10.1016/S0091-6749(96)70261-0; QUANJER PH, 1995, PEDIATR PULM, V19, P135, DOI 10.1002/ppul.1950190209; Quanjer PH, 1993, EUR RESPIR J, V6, P16; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; VALLETTA EA, 1995, ALLERGY, V50, P366, DOI 10.1111/j.1398-9995.1995.tb01162.x; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582; Verberne AAPH, 1997, AM J RESP CRIT CARE, V156, P688; VERVLOET D, 1982, J ALLERGY CLIN IMMUN, V69, P290, DOI 10.1016/S0091-6749(82)80006-7; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Wisniewski AF, 1997, THORAX, V52, P853	32	78	80	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2001	31	3					400	408		10.1046/j.1365-2222.2001.01022.x		9	Allergy; Immunology	Allergy; Immunology	417UB	WOS:000167851600010	11260151	
J	Diette, GB; Skinner, EA; Markson, LE; Algatt-Bergstrom, P; Nguyen, TTH; Clark, RD; Wu, AW				Diette, GB; Skinner, EA; Markson, LE; Algatt-Bergstrom, P; Nguyen, TTH; Clark, RD; Wu, AW			Consistency of care with national guidelines for children with asthma in managed care	JOURNAL OF PEDIATRICS			English	Article							BETA-AGONISTS; QUALITY; THERAPY	Objective: To evaluate the consistency of pediatric asthma care with the National Asthma Education and Prevention Program Guidelines. Design: Cross-sectional survey at 2 managed care organizations in the United States (winter 1997-1998). The participants were parents of children (n = 318) age 5 to 17 years with asthma. There were no interventions. The outcome measures were indicators of care in 4 domains: (1) periodic physiologic assessment, (2) proper use of medications, (3) patient education, and (4) control of factors contributing to asthma severity. Results: Of 533 eligible patients with asthma, 318 (60%) parents responded; 59% of children were male, 76% were white, and 60% were aged 5 to 10 years. Deficiencies in care were identified in all care domains including, for patients with moderate and severe persistent symptoms, only 55% used long-term control medication daily, 49% had written instructions for handling asthma attacks, 44% had instructions for adjustment of medication before exposures, 56% had undergone allergy testing, and 54% had undergone pulmonary function testing. Conclusions: There are significant opportunities to improve the quality of care for children with asthma enrolled in managed care. A comprehensive approach to improving care may be necessary to address multiple aspects of care where opportunities exist.	Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Gen Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; Merck & Co Inc, W Point, PA USA	Diette, GB (reprint author), Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, 1830 E Monument St,Room 301, Baltimore, MD 21205 USA.						Adams P., 1995, VITAL HLTH STAT, V10, P94; ALGATTBERGSTROM P, MINN J MANAGED CARE, V5, P192; Diette GB, 1999, ARCH INTERN MED, V159, P2697, DOI 10.1001/archinte.159.22.2697; Eggleston PA, 1998, PEDIATRICS, V101, P349, DOI 10.1542/peds.101.3.349; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Friday GA, 1997, ANN ALLERG ASTHMA IM, V78, P221; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; Homer CJ, 1996, PEDIATRICS, V98, P18; Legorreta AP, 1998, ARCH INTERN MED, V158, P457, DOI 10.1001/archinte.158.5.457; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; National Heart Lung and Blood Institute National Asthma Education Program, 1997, NIH PUBL; Nestor A, 1998, ANN ALLERG ASTHMA IM, V81, P327; Pearson MG, 1996, RESP MED, V90, P539, DOI 10.1016/S0954-6111(96)90146-8; SPEIZER FE, 1968, BRIT MED J, V1, P339; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; STARFIELD B, 1993, PEDIATRICS, V91, P435; STEINWACHS DM, 1996, OUTCOMES MANAGEMENT; WARE JE, 1997, DIS MAN C JUN 18 NEW; Wu AW, 1999, AM J RESP CRIT CARE, V159, pA911; 1995, 12 ANN M ASS HLTH SE, P136	20	78	79	1	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JAN	2001	138	1					59	64		10.1067/mpd.2001.109600		6	Pediatrics	Pediatrics	393PK	WOS:000166478700011	11148513	
J	Emanuel, IA; Shah, SB				Emanuel, IA; Shah, SB			Chronic rhinosinusitis: Allergy and sinus computed tomography relationships	OTOLARYNGOLOGY-HEAD AND NECK SURGERY			English	Article; Proceedings Paper	Annual Meeting of the American-Academy-of-Otolaryngology-Head-and-Neck-Surgery	SEP 26-29, 1999	NEW ORLEANS, LOUISIANA	Amer Acad Otolaryngol Head & Neck Surg			MANAGEMENT	The management of chronic or recurrent rhinosinusitis problems is multifaceted and should include consideration of contributory and potentially correctable medical and anatomic factors. To date, the relationship between allergy and rhinosinusitis has not been clearly defined. The purpose of this study is to improve understanding of the relative roles of perennial and seasonal allergens in the cause of chronic rhinosinusitis. A retrospective review of 200 consecutive patients was carried out on patients who had chronic rhinosinusitis refractory to medical therapy and who subsequently underwent functional endoscopic sinus surgery. All of these patients had allergy testing for common perennial and seasonal inhalant allergens before surgery. Each patient had sinus CT imaging before undergoing the surgery. The CT scans of each patient were staged according to a validated, standardized grading system by investigators blinded to allergic profile. Allergy testing indicated that 84% of all patients tested positive for allergies. Moreover, 60% of all patients had significant allergic sensitivity; 52% of all patients had multiple allergen sensitivities. Furthermore, there was a predominance of perennial allergens, especially house dust mite over seasonal allergens. The vast majority of our patients undergoing functional endoscopic sinus surgery had concomitant allergy. This study highlights the potential contribution of perennial allergies to the development of rhinosinusitis, Given this direction, future studies may reveal that in the care of patients with perennial allergic rhinitis, early intervention with identification of the offending allergen(s), and subsequent treatment through avoidance, pharmacotherapy, and/or immunotherapy may help in the prevention of recurrent and chronic rhinosinusitis.	Univ Calif San Francisco, San Francisco, CA 94143 USA	Emanuel, IA (reprint author), 490 Post St,1230, San Francisco, CA 94102 USA.						Benninger MS, 1997, OTOLARYNG HEAD NECK, V117, pS41, DOI 10.1016/S0194-5998(97)70006-8; BENNINGER MS, 1992, AM J RHINOL, V6, P37, DOI 10.2500/105065892781874829; CALHOUN K, 1992, OTOLARYNG HEAD NECK, V107, P850; GLICKLICH RE, 1994, AM J RHINOL, V2, P291; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, pS55, DOI 10.1097/00006454-198511001-00003; SLAVIN R, 1985, J ALLERGY CLIN IMMUN, V82, P950	6	78	84	2	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0194-5998			OTOLARYNG HEAD NECK	Otolaryngol. Head Neck Surg.	DEC	2000	123	6					687	691		10.1067/mhn.2000.110961		5	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	381PQ	WOS:000165772400004	11112958	
J	Tomaki, M; Zhao, LL; Lundahl, J; Sjostrand, M; Jordana, M; Linden, A; O'Byrne, P; Lotvall, J				Tomaki, M; Zhao, LL; Lundahl, J; Sjostrand, M; Jordana, M; Linden, A; O'Byrne, P; Lotvall, J			Eosinophilopoiesis in a murine model of allergic airway eosinophilia: Involvement of bone marrow IL-5 and IL-5 receptor alpha	JOURNAL OF IMMUNOLOGY			English	Article							MESSENGER-RNA; IN-VIVO; INTERLEUKIN-5 EXPRESSION; CIRCULATING EOSINOPHILS; PULMONARY INFLAMMATION; BRONCHIAL BIOPSIES; MILD ASTHMA; LUNG DAMAGE; MAST-CELLS; T-CELLS	The airway inflammation in asthma is dominated by eosinophils. The aim of this study was to elucidate the contribution of newly produced eosinophils in airway allergic inflammation and to determine mechanisms of any enhanced eosinophilopoiesis, OVA-sensitized BALB/c mice were repeatedly exposed to allergen via airway route. Newly produced cells were identified using a thymidine analog, 5-bromo-2'-deoxyuridine, which is incorporated into DNA during mitosis. Identification of IL-5-producing cells in the bone marrow was performed using FAGS. Bone marrow CD3(+) cells were enriched to evaluate IL-5-protein release in vitro. Anti-ILS-treatment (TRFK-5) was given either systemically or directly to the airways. IL-SR-bearing cells were localized by immunocytochemistry. Repeated airway allergen exposure caused prominent airway eosinophilia after three to five exposures, and increased the number of immature eosinophils in the bone marrow. Up to 78% of bronchoalveolar lavage (BAL) granulocytes were 5-bromo-2'-deoxyuridine positive. After three allergen exposures, both CD3+ and non-CD3 cells acquired from the bone marrow expressed and released IL-5-protein. Anti-IL-5 given i.p. inhibited both bone marrow and airway eosinophilia. Intranasal administration of anti-IL-5 also reduced BAL eosinophilia, partly via local effects in the airways. Bone marrow cells, but not BAL eosinophils, displayed stainable amounts of the IL-5R alpha-chain. We conclude that the bone marrow is activated by airway allergen exposure, and that newly produced eosinophils contribute to a substantial degree to the airway eosinophilia induced by allergen. Airway allergen exposure increases the number of cells expressing IL-5-protein in the bone marrow. The bone marrow, as well as the lung, are possible targets for anti-IL-5-treatment.	Gothenburg Univ, Inst Heart & Lung Dis, Dept Resp Med & Allergol, Lung Pharmacol Grp, S-41346 Gothenburg, Sweden; Karolinska Inst, Karolinska Hosp, Dept Clin Immunol, S-10401 Stockholm, Sweden; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada; McMaster Univ, Dept Med, Hamilton, ON, Canada	Lotvall, J (reprint author), Gothenburg Univ, Inst Heart & Lung Dis, Dept Resp Med & Allergol, Lung Pharmacol Grp, Guldhedsgatan 10A, S-41346 Gothenburg, Sweden.			O'Byrne, Paul/0000-0003-0979-281X			ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; BARRY SC, 1991, CYTOKINE, V3, P339, DOI 10.1016/1043-4666(91)90503-6; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; BICKNELL S, 1994, AM J RESP CELL MOL, V10, P16; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471; Cameron L, 2000, J IMMUNOL, V164, P1538; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GULBENKIAN AR, 1992, AM REV RESPIR DIS, V146, P263; HALLDEN G, 1989, J IMMUNOL METHODS, V124, P103, DOI 10.1016/0022-1759(89)90191-9; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Humbles AA, 1997, J EXP MED, V186, P601, DOI 10.1084/jem.186.4.601; INGLEY E, 1991, BLOOD, V78, P339; Inman MD, 1996, AM J RESP CELL MOL, V15, P305; KOSHINO T, 1993, CHEST, V103, P1931; KRISS JP, 1962, CANCER RES, V22, P254; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; KROEGEL C, 1994, EUR RESPIR J, V7, P519, DOI 10.1183/09031936.94.07030519; KUNG TT, 1994, J ALLERGY CLIN IMMUN, V94, P1217, DOI 10.1016/0091-6749(94)90335-2; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360; Lawrence E, 1996, AM J RESP CELL MOL, V14, P217; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Lee NA, 1997, J IMMUNOL, V158, P1332; Lotvall J, 1998, THORAX, V53, P419; MAUSER PJ, 1995, AM J RESP CRIT CARE, V152, P467; Minshall EM, 1998, AM J RESP CRIT CARE, V158, P951; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510; OWEN WF, 1987, J IMMUNOL, V138, P532; Palframan RT, 1998, J EXP MED, V188, P1621, DOI 10.1084/jem.188.9.1621; Palframan RT, 1998, BLOOD, V91, P2240; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; Shardonofsky FR, 1999, J ALLERGY CLIN IMMUN, V104, P215, DOI 10.1016/S0091-6749(99)70138-7; SHAW RJ, 1984, CLIN EXP IMMUNOL, V56, P716; Sulakvelidze I, 1998, EUR RESPIR J, V11, P821, DOI 10.1183/09031936.98.11040821; Terashima T, 1996, AM J PHYSIOL-LUNG C, V271, pL587; Tsuyuki S, 1995, J CLIN INVEST, V96, P2924, DOI 10.1172/JCI118364; VANOOSTERHOUT AJM, 1993, AM REV RESPIR DIS, V147, P548; Venge P, 1998, ASTHMA: BASIC MECHANISMS AND CLINICAL MANAGEMENT, 3RD EDITION, P141, DOI 10.1016/B978-012079027-2/50090-3; Wang J, 1998, J CLIN INVEST, V102, P1132, DOI 10.1172/JCI2686; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Wood LJ, 1998, AM J RESP CELL MOL, V18, P759; Wood Lorna J., 1998, American Journal of Respiratory and Critical Care Medicine, V157, P99; WOOLLEY MJ, 1994, AM J RESP CELL MOL, V11, P600; Yasruel Z, 1997, AM J RESP CRIT CARE, V155, P1413; Ying S, 1997, J IMMUNOL, V158, P3539; Zhao LL, 1998, J ALLERGY CLIN IMMUN, V101, pS34	57	78	85	1	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	OCT 1	2000	165	7					4040	4050				11	Immunology	Immunology	357AZ	WOS:000089477500064	11034415	
J	Been, JV; Nurmatov, UB; Cox, B; Nawrot, TS; van Schayck, CP; Sheikh, A				Been, Jasper V.; Nurmatov, Ulugbek B.; Cox, Bianca; Nawrot, Tim S.; van Schayck, Constant P.; Sheikh, Aziz			Effect of smoke-free legislation on perinatal and child health: a systematic review and meta-analysis	LANCET			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; PRETERM BIRTHS ANALYSIS; FREE AIR LAWS; SECONDHAND SMOKE; NONCOMMUNICABLE DISEASES; MATERNAL SMOKING; NONSMOKING YOUTH; PUBLIC PLACES; GLOBAL BURDEN; EXPOSURE	Background Smoke-free legislation has the potential to reduce the substantive disease burden associated with second-hand smoke exposure, particularly in children. We investigated the effect of smoke-free legislation on perinatal and child health. Methods We searched 14 online databases from January, 1975 to May, 2013, with no language restrictions, for published studies, and the WHO International Clinical Trials Registry Platform for unpublished studies. Citations and reference lists of articles of interest were screened and an international expert panel was contacted to identify additional studies. We included studies undertaken with designs approved by the Cochrane Effective Practice and Organisation of Care that reported associations between smoking bans in workplaces, public places, or both, and one or more predefined early-life health indicator. The primary outcomes were preterm birth, low birthweight, and hospital attendances for asthma. Effect estimates were pooled with random-effects meta-analysis. This study is registered with PROSPERO, number CRD42013003522. Findings We identified 11 eligible studies (published 2008-13), involving more than 2.5 million births and 247 168 asthma exacerbations. All studies used interrupted time-series designs. Five North American studies described local bans and six European studies described national bans. Risk of bias was high for one study, moderate for six studies, and low for four studies. Smoke-free legislation was associated with reductions in preterm birth (four studies, 1 366 862 individuals; -10.4% [95% CI -18.8 to -2.0]; p=0.016) and hospital attendances for asthma (three studies, 225 753 events: -10.1% [95% CI -15.2 to -5.0]; p=0.0001). No significant effect on low birthweight was identified (six studies, >1.9 million individuals: -1.7% [95% CI -5.1 to 1.6]; p=0.31). Interpretation Smoke-free legislation is associated with substantial reductions in preterm births and hospital attendance for asthma. Together with the health benefits in adults, this study provides strong support for WHO recommendations to create smoke-free environments.	[Been, Jasper V.; van Schayck, Constant P.; Sheikh, Aziz] Maastricht Univ, Sch Publ Hlth & Primary Care CAPHRI, NL-6202 AZ Maastricht, Netherlands; [Been, Jasper V.; Nurmatov, Ulugbek B.; van Schayck, Constant P.; Sheikh, Aziz] Univ Edinburgh, Allergy & Resp Res Grp, Ctr Populat Hlth Sci, Edinburgh, Midlothian, Scotland; [Been, Jasper V.] Maastricht Univ, Med Ctr, Dept Paediat, NL-6202 AZ Maastricht, Netherlands; [Cox, Bianca; Nawrot, Tim S.] Hasselt Univ, Ctr Environm Sci, Hasselt, Belgium; [Nawrot, Tim S.] Univ Louvain, Dept Publ Hlth, Louvain, Belgium; [Sheikh, Aziz] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA	Been, JV (reprint author), Maastricht Univ, Med Ctr, Dept Paediat, POB 5800, NL-6202 AZ Maastricht, Netherlands.	jasper.been@mumc.nl	Sheikh, Aziz /D-2818-2009; Cox, Bianca/A-9480-2015	Sheikh, Aziz /0000-0001-7022-3056; Cox, Bianca/0000-0001-9824-6276	Thrasher Fund; Lung Foundation Netherlands; International Paediatric Research Foundation; Maastricht University; Commonwealth Fund	Thrasher Fund, Lung Foundation Netherlands, International Paediatric Research Foundation, Maastricht University, Commonwealth Fund.	Akhtar PC, 2007, BRIT MED J, V335, P545, DOI 10.1136/bmj.39311.550197.AE; Amaral M, 2009, EFFECT LOCAL SMOKING; Anandan C, 2010, ALLERGY, V65, P152, DOI 10.1111/j.1398-9995.2009.02244.x; Barnoya J, 2013, NICOTINE TOB RES, V15, P789, DOI 10.1093/ntr/nts200; Bartholomew KS, 2011, NEW ENGL J MED; Been JV, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-002261; Best D, 2009, PEDIATRICS, V124, pE1017, DOI 10.1542/peds.2009-2120; Bharadwaj P., 2012, 7006 IZA; Biglan A, 2000, Prev Sci, V1, P31, DOI 10.1023/A:1010024016308; Blencowe H, 2012, LANCET, V379, P2162, DOI 10.1016/S0140-6736(12)60820-4; Bonita R, 2013, LANCET, V381, P575, DOI 10.1016/S0140-6736(12)61993-X; Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Callinan JE, 2010, COCHRANE DB SYST REV, V4; Chang HH, 2013, LANCET, V381, P223, DOI 10.1016/S0140-6736(12)61856-X; Cheng KW, 2011, AM J PREV MED, V41, P566, DOI 10.1016/j.amepre.2011.08.014; Cochrane Effective Practice and Organisation of Care Review Group, DAT COLL CHECKL; Cochrane Effective Practice and Organisation of Care Review Group, SUGG RISK BIAS CRIT; Cox B, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f441; Crump C, 2011, JAMA-J AM MED ASSOC, V306, P1233, DOI 10.1001/jama.2011.1331; Dove MS, 2011, PEDIATRICS, V127, P102, DOI 10.1542/peds.2010-1532; Dove MS, 2010, PEDIATRICS, V126, P80, DOI 10.1542/peds.2009-3462; El-Mohandes AAE, 2010, PEDIATRICS, V125, P721, DOI 10.1542/peds.2009-1809; Gaudreau K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056102; Glantz S, 2012, LANCET, V379, P1269, DOI 10.1016/S0140-6736(11)60615-6; Gluckman PD, 2008, NEW ENGL J MED, V359, P61, DOI 10.1056/NEJMra0708473; Grad R, 2012, J ALLERGY CLIN IMMUN, V130, P299, DOI 10.1016/j.jaci.2012.05.022; Hade E, 2011, ANAL IMPACT ASS BIRT; HARLAP S, 1974, LANCET, V1, P529; Higgins JG, 2001, COCHRANE HDB SYSTEMA; Ho SY, 2010, TOB CONTROL, V19, P129, DOI 10.1136/tc.2009.032003; Holliday JC, 2009, BMC PUBLIC HEALTH, V9, DOI 10.1186/1471-2458-9-430; Jarvis MJ, 2012, TOB CONTROL, V21, P18, DOI 10.1136/tc.2010.041608; Kabir Z, 2009, BJOG-INT J OBSTET GY, V116, P1782, DOI 10.1111/j.1471-0528.2009.02374.x; Kabir Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057441; Kabir Z, 2012, J WOMENS HEALTH, V21, P616, DOI 10.1089/jwh.2012.3695; Lechner Michael, 2011, Foundations and Trends in Econometrics, V4, P165, DOI 10.1561/0800000014; Lee JT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020933; Lee JT, 2013, TOB CONTROL, DOI [10.1136/tobaccocontrol-2012-050817, DOI 10.1136/TOBCOCONTROL-2012-050817]; Leonardi-Bee J, 2008, ARCH DIS CHILD-FETAL, V93, pF351, DOI 10.1136/adc.2007.133553; Levy D, 2013, NICOTINE TOB RES, V15, P1797, DOI 10.1093/ntr/ntt073; Levy DT, 2013, B WORLD HEALTH ORGAN, V91, P509, DOI 10.2471/BLT.12.113878; Lightwood JM, 2009, CIRCULATION, V120, P1373, DOI 10.1161/CIRCULATIONAHA.109.870691; Lovasi GS, 2010, AM J EPIDEMIOL, V171, P54, DOI 10.1093/aje/kwp358; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Mackay DF, 2010, HEART, V96, P1525, DOI 10.1136/hrt.2010.199026; Mackay D, 2010, NEW ENGL J MED, V363, P1139, DOI 10.1056/NEJMoa1002861; Mackay DF, 2012, PLOS MED, V9, DOI 10.1371/journal.pmed.1001175; Dietz Patricia M., 2011, 17160 NBER; Markowitz S, 2008, J HEALTH ECON, V27, P106, DOI 10.1016/j.jhealeco.2007.03.006; McCowan LME, 2009, BMJ-BRIT MED J, V338, P1081; Meyers DG, 2009, J AM COLL CARDIOL, V54, P1249, DOI 10.1016/j.jacc.2009.07.022; Millett C, 2013, PEDIATRICS, V131, pE495, DOI 10.1542/peds.2012-2592; Moore GF, 2012, J PUBLIC HEALTH-UK, V34, P599, DOI 10.1093/pubmed/fds025; Moore GF, 2011, NICOTINE TOB RES, V13, P903, DOI 10.1093/ntr/ntr093; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; Naiman A, 2010, CAN MED ASSOC J, V182, P761, DOI 10.1503/cmaj.091130; Oberg M, 2011, LANCET, V377, P139, DOI 10.1016/S0140-6736(10)61388-8; Olivo-Marston SE, 2009, CANCER EPIDEM BIOMAR, V18, P3375, DOI 10.1158/1055-9965.EPI-09-0986; Page RL, 2012, J WOMENS HEALTH, V21, P621, DOI 10.1089/jwh.2011.3305; Peelen MJ, 2013, REIMPACT STEPWISE IN; Rayens MK, 2008, J ALLERGY CLIN IMMUN, V122, P537, DOI 10.1016/j.jaci.2008.06.029; Royal College of Physicians, 2010, PASS SMOK CHILDR; Rucker G, 2008, BMC MED RES METHODOL, V8, DOI 10.1186/1471-2288-8-79; Salmasi G, 2010, ACTA OBSTET GYN SCAN, V89, P423, DOI 10.3109/00016340903505748; Scollo M, 2003, TOB CONTROL, V12, P13, DOI 10.1136/tc.12.1.13; Shetty KD, 2011, J POLICY ANAL MANAG, V30, P6, DOI 10.1002/pam.20548; Sims M, 2012, ADDICTION, V107, P2009, DOI 10.1111/j.1360-0443.2012.03924.x; State of California Air Resources Board, 2005, PROP ID ENV TOB SMOK; Sterne JA, 2007, SYSTEMATIC REV HLTH, P189; Tan CE, 2012, CIRCULATION, V126, P2177, DOI 10.1161/CIRCULATIONAHA.112.121301; Tinuoye O, 2013, NICOTINE TOB RES, V15, P1475, DOI 10.1093/ntr/ntt033; U.S. Department of Health and Human Services, 2006, HLTH CONS INV EXP TO; World Health Organization, 2012, GLOB PROGR REP IMPL; World Health Organization, 2011, SCAL ACT NONC DIS MU; World Health Organization, 2013, WHO REP GLOB TOB EP; World Health Organization, 2005, WHO FRAM CONV TOB CO	76	77	79	9	57	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 3	2014	383	9928					1549	1560		10.1016/S0140-6736(14)60082-9		12	Medicine, General & Internal	General & Internal Medicine	AG5YO	WOS:000335495400026	24680633	
J	Palmer, DJ; Metcalfe, J; Makrides, M; Gold, MS; Quinn, P; West, CE; Loh, R; Prescott, SL				Palmer, Debra J.; Metcalfe, Jessica; Makrides, Maria; Gold, Michael S.; Quinn, Patrick; West, Christina E.; Loh, Richard; Prescott, Susan L.			Early regular egg exposure in infants with eczema: A randomized controlled trial	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergy prevention; complementary feeding; eczema; egg; food allergy; oral tolerance; randomized controlled trial	ORAL IMMUNOTHERAPY; ALLERGIC DISEASES; ATOPIC-DERMATITIS; BIRTH COHORT; CHILDREN; FISH; SENSITIZATION; CHALLENGE; TOLERANCE; FORMULAS	Background: Observational studies suggest that early regular ingestion of allergenic foods might reduce the risk of food allergy. Objective: We sought to determine whether early regular oral egg exposure will reduce subsequent IgE-mediated egg allergy in infants with moderate-to-severe eczema. Methods: In a double-blind, randomized controlled trial infants were allocated to 1 teaspoon of pasteurized raw whole egg powder (n = 49) or rice powder (n = 37) daily from 4 to 8 months of age. Cooked egg was introduced to both groups after an observed feed at 8 months. The primary outcome was IgE-mediated egg allergy at 12 months, as defined based on the results of an observed pasteurized raw egg challenge and skin prick tests. Results: A high proportion (31% [15/49]) of infants randomized to receive egg had an allergic reaction to the egg powder and did not continue powder ingestion. At 4 months of age, before any known egg ingestion, 36% (24/67) of infants already had eggspecific IgE levels of greater than 0.35 kilounits of antibody (kUA)/L. At 12 months, a lower (but not significant) proportion of infants in the egg group (33%) were given a diagnosis of IgE-mediated egg allergy compared with the control group (51%; relative risk, 0.65; 95% CI, 0.38-1.11; P 5.11). Egg-specific IgG4 levels were significantly (P <.001) greater in the egg group at both 8 and 12 months. Conclusion: Induction of immune tolerance pathways and reduction in egg allergy incidence can be achieved by early regular oral egg exposure in infants with eczema. Caution needs to be taken when these high-risk infants are first exposed to egg because many have sensitization already by 4 months of age.	[Palmer, Debra J.; Metcalfe, Jessica; West, Christina E.; Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; [Palmer, Debra J.; Makrides, Maria] Womens & Childrens Hlth Res Inst, Adelaide, SA, Australia; [Makrides, Maria; Gold, Michael S.] Univ Adelaide, Sch Paediat & Reprod Hlth, Children Youth & Womens Hlth Serv, Adelaide, SA, Australia; [Quinn, Patrick] Children Youth & Womens Hlth Serv, Adelaide, SA, Australia; [West, Christina E.] Umea Univ, Dept Clin Sci, S-90187 Umea, Sweden; [Loh, Richard; Prescott, Susan L.] Princess Margaret Hosp, Dept Immunol, Perth, WA, Australia	Palmer, DJ (reprint author), Univ Western Australia M561, Sch Paediat & Child Hlth, 35 Stirling Highway, Crawley, WA 6009, Australia.	debbie.palmer@uwa.edu.au	Palmer, Debra /L-8554-2013; Makrides, Maria/B-6392-2014; Prescott, Susan/H-5665-2014	Makrides, Maria/0000-0003-3832-541X; 	Women's and Children's Hospital Foundation; Ilhan Food Allergy Foundation	Supported by a grant from the Women's and Children's Hospital Foundation and a grant from the Ilhan Food Allergy Foundation.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99; Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; Baker SS, 2000, PEDIATRICS, V106, P346; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Burks AW, 2012, NEW ENGL J MED, V367, P233, DOI 10.1056/NEJMoa1200435; Caubet JC, 2012, J ALLERGY CLIN IMMUN, V129, P739, DOI 10.1016/j.jaci.2011.11.053; Filipiak B, 2007, J PEDIATR-US, V151, P352, DOI 10.1016/j.jpeds.2007.05.01; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Hesselmar B, 2010, ACTA PAEDIATR, V99, P1861, DOI 10.1111/j.1651-2227.2010.01939.x; Hill DJ, 2008, CLIN EXP ALLERGY, V38, P161, DOI 10.1111/j.1365-2222.2007.02861.x; Host A, 2008, PEDIATR ALLERGY IMMU, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; Jurado-Palomo J, 2009, INT ARCH ALLERGY IMM, V151, P331; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kunz B, 1997, DERMATOLOGY, V195, P10; Martino DJ, 2011, ALLERGY, V67, P191; Monti G, 2002, CLIN EXP ALLERGY, V32, P1515, DOI 10.1046/j.1365-2745.2002.01454.x; Mullins RJ, 2007, MED J AUSTRALIA, V186, P618; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Smith KM, 2000, AM J RESP CRIT CARE, V162, pS175; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Virtanen SM, 2010, BRIT J NUTR, V103, P266, DOI 10.1017/S0007114509991541; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	25	77	78	0	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					387	+		10.1016/j.jaci.2013.05.002		7	Allergy; Immunology	Allergy; Immunology	194KL	WOS:000322631700016	23810152	
J	Foegeding, EA; Davis, JP				Foegeding, E. Allen; Davis, Jack P.			Food protein functionality: A comprehensive approach	FOOD HYDROCOLLOIDS			English	Article						Protein; Protein functionality; Foams; Gels; Emulsions; Bioactivity; Allergenicity	EGG-WHITE PROTEIN; BOVINE BETA-LACTOGLOBULIN; PEANUT ARACHIS-HYPOGAEA; IGE-BINDING EPITOPES; AIR-WATER-INTERFACE; COWS MILK ALLERGY; COLD-SET GELS; WHEY-PROTEIN; ALPHA-LACTALBUMIN; BIOACTIVE PEPTIDES	Food protein functionality has classically been viewed from the perspective of how single molecules or protein ingredients function in solutions and form simple colloidal structures. Based on this approach, tests on protein solutions are used to produce values for solubility, thermal stability, gelation, emulsifying, foaming, fat binding and water binding to name a few. While this approach is beneficial in understanding the properties of specific proteins and ingredients, it is somewhat restricted in predicting performance in real foods where the complexities of ingredients and processing operations have a significant affect on the colloidal structures and therefore overall properties of the final food product. In addition, focusing on proteins as just biopolymers used to create food structures ignores the biological functions of proteins in the diet. These can be beneficial, as in providing amino acids for protein synthesis or bioactive peptides, or these can be detrimental, as in causing a food allergic response. This review will focus on integrating the colloidal/polymer and biological aspects of protein functionality. This will be done using foams and gels to illustrate colloidal/polymer aspects and bioactive peptides and allergenicity to demonstrate biological function. (C) 2011 Elsevier Ltd. All rights reserved.	[Foegeding, E. Allen; Davis, Jack P.] N Carolina State Univ, Dept Food Bioprocess & Nutr Sci, Raleigh, NC 27695 USA; [Davis, Jack P.] ARS, USDA, Market Qual & Handling Res Unit, Raleigh, NC USA	Foegeding, EA (reprint author), N Carolina State Univ, Dept Food Bioprocess & Nutr Sci, 236 Schaub Hall,Campus Box 7624, Raleigh, NC 27695 USA.	allen_foegeding@ncsu.edu			North Carolina Agricultural Research Service; Dairy Management Inc.	"Paper No. FSR-10-36 of the Journal Series of the Department of Food, Bioprocessing and Nutrition Science, North Carolina State University, Raleigh, NC 27695-7624. Support from the North Carolina Agricultural Research Service and Dairy Management Inc. as administered by the Dairy Research Institute are gratefully acknowledged. The authors would like to thank Ms. Paige Luck for the technical assistance in preparing the manuscript. The use of trade names in this publication does not imply endorsement by the North Carolina Agricultural Research Service of the products named nor criticism of similar ones not mentioned.	AKO K, 2009, SOFT MATTER, V5, pE4041; Alargova RG, 2004, LANGMUIR, V20, P10371, DOI 10.1021/la048647a; Alexander PA, 2007, P NATL ACAD SCI USA, V104, P11963, DOI 10.1073/pnas.0700922104; Bannon GA, 2006, MOL NUTR FOOD RES, V50, P638, DOI 10.1002/mnfr.200500276; Barbut S, 1995, FOOD RES INT, V28, P437, DOI 10.1016/0963-9969(95)00034-8; Barbut S., 1996, METHODS TESTING PROT, P186; Baussay K, 2006, BIOMACROMOLECULES, V7, P304, DOI 10.1021/bm050662m; Baussay K, 2006, J COLLOID INTERF SCI, V304, P335, DOI 10.1016/j.jcis.2006.09.059; Belloque J, 1998, J AGR FOOD CHEM, V46, P1805, DOI 10.1021/jf9709313; Berry TK, 2009, J FOOD SCI, V74, pE269, DOI 10.1111/j.1750-3841.2009.01178.x; Bertrand ME, 2007, FOOD HYDROCOLLOID, V21, P159, DOI 10.1016/j.foodhyd.2006.03.005; Binks BP, 2002, CURR OPIN COLLOID IN, V7, P21, DOI 10.1016/S1359-0294(02)00008-0; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Bromley EHC, 2006, EUR PHYS J E, V21, P145, DOI 10.1140/epje/i2006-10055-7; Bu GH, 2009, J SCI FOOD AGR, V89, P2428, DOI 10.1002/jsfa.3741; Buchert J, 2010, ANNU REV FOOD SCI T, V1, P113, DOI 10.1146/annurev.food.080708.100841; Burks AW, 2008, LANCET, V371, P1538, DOI 10.1016/S0140-6736(08)60659-5; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Campbell GM, 1999, TRENDS FOOD SCI TECH, V10, P283, DOI 10.1016/S0924-2244(00)00008-X; Campbell L, 2003, NAHRUNG, V47, P369, DOI 10.1002/food.200390084; Chatchatee P, 2001, J ALLERGY CLIN IMMUN, V107, P379, DOI 10.1067/mai.2001.112372; CHERRY J, 1981, ACS S SERIES, V147; Chobert Jean-Marc, 2003, Adv Food Nutr Res, V47, P1, DOI 10.1016/S1043-4526(03)47001-0; CLARK A, 1987, ADV POLYM SCI, V83; CLARK AH, 1980, INT J PEPT PROT RES, V16, P339; CLARK AH, 1981, INT J PEPT PROT RES, V17, P380; CLARK AH, 1981, INT J PEPT PROT RES, V17, P353; Clark AH, 2001, FOOD HYDROCOLLOID, V15, P383, DOI 10.1016/S0268-005X(01)00042-X; COKE M, 1990, J COLLOID INTERF SCI, V138, P489, DOI 10.1016/0021-9797(90)90231-C; Cornec M, 1999, J COLLOID INTERF SCI, V214, P129, DOI 10.1006/jcis.1999.6230; Corzo-Martinez M, 2010, INT DAIRY J, V20, P742, DOI 10.1016/j.idairyj.2010.04.002; Cox AR, 2009, FOOD HYDROCOLLOID, V23, P366, DOI 10.1016/j.foodhyd.2008.03.001; Cudennec B, 2008, FOOD CHEM, V111, P970, DOI 10.1016/j.foodchem.2008.05.016; Damodaran S, 2005, J FOOD SCI, V70, pR54; Davis JP, 2004, J FOOD SCI, V69, pC404; de Arauz LJ, 2009, TRENDS FOOD SCI TECH, V20, P146, DOI 10.1016/j.tifs.2009.01.056; de Jong S, 2009, FOOD HYDROCOLLOID, V23, P755, DOI 10.1016/j.foodhyd.2008.03.017; de Lagemaat JV, 2007, FOOD RES INT, V40, P153, DOI 10.1016/j.foodres.2006.09.006; de Wit JN, 2009, TRENDS FOOD SCI TECH, V20, P27, DOI 10.1016/j.tifs.2008.09.012; de Wit JN, 1998, J DAIRY SCI, V81, P597; del Castillo MD, 2007, J CEREAL SCI, V45, P327, DOI 10.1016/j.jcs.2006.09.005; Denkov ND, 2004, LANGMUIR, V20, P9463, DOI 10.1021/la049646o; Dickinson E, 1999, COLLOID SURFACE B, V15, P161, DOI 10.1016/S0927-7765(99)00042-9; Dickinson E, 1998, TRENDS FOOD SCI TECH, V9, P347, DOI 10.1016/S0924-2244(98)00057-0; Dickinson E, 2003, FOOD HYDROCOLLOID, V17, P25, DOI 10.1016/S0268-005X(01)00120-5; Dickinson E, 1992, INTRO FOOD COLLOIDS; Donato L, 2011, FOOD HYDROCOLLOID, V25, P734, DOI 10.1016/j.foodhyd.2010.08.020; Du ZP, 2003, LANGMUIR, V19, P3106, DOI 10.1021/la034042n; Edwards PJB, 2002, INT DAIRY J, V12, P331, DOI 10.1016/S0958-6946(02)00029-8; Fitzsimons SM, 2008, FOOD HYDROCOLLOID, V22, P576, DOI 10.1016/j.foodhyd.2007.01.013; Foegeding EA, 2006, FOOD HYDROCOLLOID, V20, P284, DOI 10.1016/j.foodhyd.2005.03.014; Fu TT, 2002, J AGR FOOD CHEM, V50, P7154, DOI 10.1021/jf020599h; Galazka VB, 2000, CURR OPIN COLLOID IN, V5, P182, DOI 10.1016/S1359-0294(00)00055-8; Glaser LA, 2007, FOOD HYDROCOLLOID, V21, P495, DOI 10.1016/j.foodhyd.2006.05.008; Gomez-Ruiz JA, 2004, J AGR FOOD CHEM, V52, P6315, DOI 10.1021/jf049532f; Gonzalez-Perez S, 2007, J SCI FOOD AGR, V87, P2173, DOI 10.1002/jsfa.2971; Gruber P, 2005, J AGR FOOD CHEM, V53, P2289, DOI 10.1021/jf048398w; Guichard E, 2006, BIOTECHNOL ADV, V24, P226, DOI 10.1016/j.biotechadv.2005.11.003; Hall G. M., 1996, METHODS TESTING PROT; HAMADA JS, 1994, CRIT REV FOOD SCI, V34, P283; HEGG PO, 1982, J FOOD SCI, V47, P1241, DOI 10.1111/j.1365-2621.1982.tb07656.x; Hilgenfeldt S, 2001, PHYS REV LETT, V86, P4704, DOI 10.1103/PhysRevLett.86.4704; Horne DS, 1998, INT DAIRY J, V8, P73, DOI 10.1016/S0958-6946(98)00022-3; HUTCHINGS JB, 1988, J TEXTURE STUD, V19, P103, DOI 10.1111/j.1745-4603.1988.tb00928.x; Ivanciuc O, 2009, REGUL TOXICOL PHARM, V54, pS11, DOI 10.1016/j.yrtph.2008.11.007; Moreno FJ, 2007, BIOMED PHARMACOTHER, V61, P50, DOI 10.1016/j.biopha.2006.10.005; Kamau SM, 2010, COMPR REV FOOD SCI F, V9, P197; Kasapis S, 2008, CRIT REV FOOD SCI, V48, P341, DOI 10.1080/10408390701347769; Kato Y, 2001, J AGR FOOD CHEM, V49, P3661, DOI 10.1021/jf0102766; Kilara A, 2003, CRIT REV FOOD SCI, V43, P607, DOI 10.1080/10408690390251138; Kitts DD, 2003, CURR PHARM DESIGN, V9, P1309, DOI 10.2174/1381612033454883; Koehler SA, 2000, LANGMUIR, V16, P6327, DOI 10.1021/la9913147; Kopper RA, 2005, INT ARCH ALLERGY IMM, V136, P16, DOI 10.1159/000082580; Korhonen H, 2003, CURR PHARM DESIGN, V9, P1297, DOI 10.2174/1381612033454892; Krebs MRH, 2007, BIOPHYS J, V92, P1336, DOI 10.1529/biophysj.106.094342; Kristinsson HG, 2000, CRIT REV FOOD SCI, V40, P43, DOI 10.1080/10408690091189266; Kuhn Janina, 2008, J Agric Food Chem, V56, P10218, DOI 10.1021/jf801810b; Kuwata K, 2001, NAT STRUCT BIOL, V8, P151, DOI 10.1038/84145; Le Floch-Fouere C, 2009, FOOD HYDROCOLLOID, V23, P352, DOI 10.1016/j.foodhyd.2008.01.007; Le Floch-Fouere C, 2010, FOOD HYDROCOLLOID, V24, P275, DOI 10.1016/j.foodhyd.2009.10.006; LEDWARD D, 1993, TRENDS FOOD SCI TECH, V41, P402; Lemon-Mule H, 2008, J ALLERGY CLIN IMMUN, V122, P977, DOI 10.1016/j.jaci.2008.09.007; LI-CHAN E, 1989, Critical Reviews in Poultry Biology, V2, P21; Lopez-Fandino R, 2006, CRIT REV FOOD SCI, V46, P351, DOI 10.1080/10408690590957278; Mackie A, 2010, CURR OPIN COLLOID IN, V15, P102, DOI 10.1016/j.cocis.2009.11.005; Mackie AR, 1999, J COLLOID INTERF SCI, V210, P157, DOI 10.1006/jcis.1998.5941; Majumder K, 2010, FOOD RES INT, V43, P1371, DOI 10.1016/j.foodres.2010.04.027; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Maleki SJ, 2003, J ALLERGY CLIN IMMUN, V112, P190, DOI 10.1067/mai.2003.1551; Marinova KG, 2009, FOOD HYDROCOLLOID, V23, P1864, DOI 10.1016/j.foodhyd.2009.03.003; Martin AH, 2002, J COLLOID INTERF SCI, V254, P175, DOI 10.1006/jcis.2002.8592; Martinez ML, 2010, J SCI FOOD AGR, V90, P1959, DOI 10.1002/jsfa.4059; McClements DJ, 2002, CRIT REV FOOD SCI, V42, P417, DOI 10.1080/20024091054210; Megias C, 2004, J AGR FOOD CHEM, V52, P1928, DOI 10.1021/jf034707r; Mills ENC, 2008, CURR OPIN ALLERGY CL, V8, P249, DOI 10.1097/ACI.0b013e3282ffb123; MINE Y, 1995, TRENDS FOOD SCI TECH, V6, P225, DOI 10.1016/S0924-2244(00)89083-4; Mine Y, 2007, CURR PHARM DESIGN, V13, P875, DOI 10.2174/138161207780414278; Minkiewicz P, 2008, J AOAC INT, V91, P965; Minkiewicz P, 2008, FOOD TECHNOL BIOTECH, V46, P1; Mondoulet L, 2005, J AGR FOOD CHEM, V53, P4547, DOI 10.1021/jf050091p; Moreno FJ, 2005, J AGR FOOD CHEM, V53, P9810, DOI 10.1021/jf0515227; Moro A, 2011, FOOD HYDROCOLLOID, V25, P1009, DOI 10.1016/j.foodhyd.2010.09.021; Morris VJ, 2008, SOFT MATTER, V4, P943, DOI 10.1039/b718904d; Moure A, 2006, FOOD RES INT, V39, P945, DOI 10.1016/j.foodres.2006.07.002; Murray BS, 2007, CURR OPIN COLLOID IN, V12, P232, DOI 10.1016/j.cocis.2007.07.009; Murray BS, 2011, FOOD HYDROCOLLOID, V25, P627, DOI 10.1016/j.foodhyd.2010.07.025; Nakamura S, 2008, FOOD CHEM, V109, P538, DOI 10.1016/j.foodchem.2007.12.075; Nicolai T, 2007, CURR OPIN COLLOID IN, V12, P23, DOI 10.1016/j.cocis.2007.03.002; Nicorescu I, 2009, FOOD HYDROCOLLOID, V23, P1209, DOI 10.1016/j.foodhyd.2008.09.005; Nicorescu I, 2011, FOOD HYDROCOLLOID, V25, P797, DOI 10.1016/j.foodhyd.2010.09.020; Norton JE, 2010, SOFT MATTER, V6, P3735, DOI 10.1039/c001018a; Nowak-Wegrzyn A, 2008, J ALLERGY CLIN IMMUN, V122, P342, DOI 10.1016/j.jaci.2008.05.043; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P234, DOI 10.1097/ACI.0b013e32832b88e7; Oliver CM, 2006, CRIT REV FOOD SCI, V46, P337, DOI 10.1080/10408690590957250; PAULSSON M, 1992, J COLLOID INTERF SCI, V150, P394, DOI 10.1016/0021-9797(92)90209-5; Pernell CW, 2002, COLLOID SURFACE A, V204, P9, DOI 10.1016/S0927-7757(01)01061-5; Pernell CW, 2002, J FOOD SCI, V67, P2945, DOI 10.1111/j.1365-2621.2002.tb08843.x; Peter PN, 1930, IND ENG CHEM, V22, P1124, DOI 10.1021/ie50250a028; Picariello G, 2010, J CHROMATOGR B, V878, P295, DOI 10.1016/j.jchromb.2009.11.033; Pihlanto A, 2006, INT DAIRY J, V16, P1306, DOI 10.1016/j.idairyj.2006.06.005; Polovic ND, 2009, J SCI FOOD AGR, V89, P8, DOI 10.1002/jsfa.3404; Quist EE, 2009, LWT-FOOD SCI TECHNOL, V42, P694, DOI 10.1016/j.lwt.2008.10.008; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Rodriguez Patino Juan M, 2008, Adv Colloid Interface Sci, V140, P95, DOI 10.1016/j.cis.2007.12.007; Sakurai K, 2009, BBA-GEN SUBJECTS, V1790, P527, DOI 10.1016/j.bbagen.2009.04.003; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schmitt DA, 2010, J AGR FOOD CHEM, V58, P1138, DOI 10.1021/jf902694j; Semenova MG, 2002, CURR OPIN COLLOID IN, V7, P438, DOI 10.1016/S1359-0294(02)00079-1; Sicherer SH, 2007, J ALLERGY CLIN IMMUN, V120, P491, DOI 10.1016/j.jaci.2007.07.015; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, pS116, DOI 10.1016/j.jaci.2009.08.028; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; Stubenrauch C, 2003, J PHYS-CONDENS MAT, V15, pR1197, DOI 10.1088/0953-8984/15/27/201; Taheri-Kafrani A, 2009, J AGR FOOD CHEM, V57, P4974, DOI 10.1021/jf804038t; Tanabe S, 2000, BIOSCI BIOTECH BIOCH, V64, P2005, DOI 10.1271/bbb.64.2005; Tavel L, 2008, J AGR FOOD CHEM, V56, P10208, DOI 10.1021/jf801841u; Tchuenbou-Magaia FL, 2009, FOOD HYDROCOLLOID, V23, P1877, DOI 10.1016/j.foodhyd.2009.03.005; Thomas K, 2009, FOOD CHEM TOXICOL, V47, P1041, DOI 10.1016/j.fct.2009.02.001; Turgeon SL, 2003, CURR OPIN COLLOID IN, V8, P401, DOI 10.1016/S1359-0294(03)00093-1; Ubbink J, 2008, SOFT MATTER, V4, P1569, DOI 10.1039/b802183j; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; van den Berg L, 2008, FOOD HYDROCOLLOID, V22, P1404, DOI 10.1016/j.foodhyd.2007.08.006; van den Berg L, 2007, FOOD HYDROCOLLOID, V21, P420, DOI 10.1016/j.foodhyd.2006.05.002; van der Linden E, 2007, CURR OPIN COLLOID IN, V12, P158, DOI 10.1016/j.cocis.2007.07.010; van der Linden E, 2009, MODERN BIOPOLYMER SCIENCE: BRIDGING THE DIVIDE BETWEEN FUNDAMENTAL TREATISE AND INDUSTRIAL APPLICATION, P29; van der Sman RGM, 2009, SOFT MATTER, V5, P501, DOI 10.1039/b718952b; Vardhanabhuti B, 2001, FOOD HYDROCOLLOID, V15, P165, DOI 10.1016/S0268-005X(00)00062-X; Veraverbeke WS, 2002, CRIT REV FOOD SCI, V42, P179, DOI 10.1080/10408690290825510; Vercruysse L, 2005, J AGR FOOD CHEM, V53, P8106, DOI 10.1021/jf0508908; Wakabayashi H, 2006, INT DAIRY J, V16, P1241, DOI 10.1016/j.idairyj.2006.06.013; Walstra P., 2003, PHYS CHEM FOODS; Wang WY, 2005, COMPR REV FOOD SCI F, V4, P63, DOI 10.1111/j.1541-4337.2005.tb00075.x; Wierenga PA, 2009, COLLOID SURFACE A, V344, P72, DOI 10.1016/j.colsurfa.2009.02.012; Wilde P, 2004, ADV COLLOID INTERFAC, V108, P63, DOI 10.1016/j.cis.2003.10.011; Wilde PJ, 2000, CURR OPIN COLLOID IN, V5, P176, DOI 10.1016/S1359-0294(00)00056-X; Williams A, 1996, COLLOID SURFACE A, V114, P267, DOI 10.1016/0927-7757(96)03534-0; WRIGHT HT, 1991, CRIT REV BIOCHEM MOL, V26, P1, DOI 10.1080/10409230490440532; Yang X, 2010, FOOD HYDROCOLLOID, V24, P227, DOI 10.1016/j.foodhyd.2009.09.011; Zhu KX, 2006, PROCESS BIOCHEM, V41, P1296, DOI 10.1016/j.procbio.2005.12.029	160	77	83	19	163	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-005X			FOOD HYDROCOLLOID	Food Hydrocolloids	DEC	2011	25	8					1853	1864		10.1016/j.foodhyd.2011.05.008		12	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	803KN	WOS:000293580300008		
J	Ege, MJ; Strachan, DP; Cookson, WOCM; Moffatt, MF; Gut, I; Lathrop, M; Kabesch, M; Genuneit, J; Buchele, G; Sozanska, B; Boznanski, A; Cullinan, P; Horak, E; Bieli, C; Braun-Fahrlander, C; Heederik, D; von Mutius, E				Ege, Markus J.; Strachan, David P.; Cookson, William O. C. M.; Moffatt, Miriam F.; Gut, Ivo; Lathrop, Mark; Kabesch, Michael; Genuneit, Jon; Buechele, Gisela; Sozanska, Barbara; Boznanski, Andrzej; Cullinan, Paul; Horak, Elisabeth; Bieli, Christian; Braun-Fahrlaender, Charlotte; Heederik, Dick; von Mutius, Erika		GABRIELA Study Grp	Gene-environment interaction for childhood asthma and exposure to farming in Central Europe	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Childhood asthma; atopy; GWAS; gene-by-environment interaction; candidate genes	GENOMEWIDE ASSOCIATION; GLUTAMATE; DISEASES; CHILDREN	Background: Asthma is a disease in which both genetic and environmental factors play important roles. The farming environment has consistently been associated with protection from childhood asthma and atopy, and interactions have been reported with polymorphisms in innate immunity genes. Objective: To detect gene-environment interactions for asthma and atopy in the farming environment. Methods: We performed a genome-wide interaction analysis for asthma and atopy by using 500,000 genotyped single nucleotide polymorphisms (SNPs) and farm-related exposures in 1708 children from 4 rural regions of Central Europe. We also tested selectively for interactions between farm exposures and 7 SNPs that emerged as genome-wide significant in a large meta-analysis of childhood asthma and 5 SNPs that had been reported previously as interacting with farm exposures for asthma or atopy. Results: Neither the asthma-associated SNPs nor the SNPs previously published for interactions with asthma showed significant interactions. The genome-wide interaction study did not reveal any significant interactions with SNPs within genes in the range of interacting allele frequencies from 30% to 70%, for which our study was well powered. Among rarer SNPs, we identified 15 genes with strong interactions for asthma or atopy in relation to farming, contact with cows and straw, or consumption of raw farm milk. Conclusion: Common genetic polymorphisms are unlikely to moderate the protective influence of the farming environment on childhood asthma and atopy, but rarer variants, particularly of the glutamate receptor, metabotropic 1 gene, may do so. Given the limited statistical power of our study, these findings should be interpreted with caution before being replicated in independent farm populations. (J Allergy Clin Immunol 2011;127:138-44.)	[Ege, Markus J.; von Mutius, Erika] Univ Childrens Hosp Munich, Munich, Germany; [Strachan, David P.] Univ London, Div Community Hlth Sci, London, England; [Cookson, William O. C. M.; Moffatt, Miriam F.; Cullinan, Paul] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Gut, Ivo; Lathrop, Mark] Ctr Natl Genotypage, Inst Genom, Evry, France; [Lathrop, Mark] Fdn Jean Dausset CEPH, Paris, France; [Kabesch, Michael] Hannover Med Sch, Clin Pediat Pneumol & Neonatol, D-3000 Hannover, Germany; [Genuneit, Jon; Buechele, Gisela] Univ Ulm, Inst Epidemiol, Ulm, Germany; [Sozanska, Barbara; Boznanski, Andrzej] Wroclaw Med Univ, Dept Paediat Allergol & Cardiol 1, Wroclaw, Poland; [Horak, Elisabeth] Innsbruck Med Univ, Div Cardiol & Pulmonol, Dept Pediat & Adolescents, Innsbruck, Austria; [Bieli, Christian; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Bieli, Christian; Braun-Fahrlaender, Charlotte] Univ Basel, Basel, Switzerland; [Heederik, Dick] Univ Utrecht, Inst Risk Assessment Sci, Div Environm Epidemiol, Utrecht, Netherlands	Ege, MJ (reprint author), Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.uni-muenchen.de	Loss, Georg/F-1557-2013; Genuneit, Jon/I-9323-2012	Genuneit, Jon/0000-0001-5764-1528; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515	European Commission [018996, LSH-2004-1.2.5-1]; GABRIEL consortium; German Research Foundation (DFG); Behring-Rontgen Foundation; Wellcome Trust; Roxall; Glaxo Wellcome; Novartis; Sanofi-Aventis; MSD; Bundesministerium fur Bildung und Forschung; Airsonett; Kuhne Foundation; European Union	Supported by the European Commission as part of GABRIEL (a multidisciplinary study to identify the genetic and environmental causes of asthma in the European Community) contract number 018996 under the Integrated Program LSH-2004-1.2.5-1. M.J.E received the Stephan-Weiland Fellowship of the GABRIEL consortium.; M. J. Ege has received research support from the European Union, the German Research Foundation (DFG), and the Behring-Rontgen Foundation. I. Gut has received research support from the European Commission (through Project GABRIEL) and the Wellcome Trust. M. Kabesch has received remuneration in the form of grants, honoraria, or consulting fees from Roxall, Glaxo Wellcome, Novartis, Sanofi-Aventis, MSD, and Allergopharma and has received research support from the DFG, Bundesministerium fur Bildung und Forschung, and the European Union. D. Heederik has received research support from the European Union. E. von Mutius has consulted for Novartis, GlaxoSmithKline, Protectimmun, and UCB and has received research support from Airsonett AB. M. Depner has received research support from the European Commission. R. Lauener has received research support from the European Union and the Kuhne Foundation. J. Weber has received research support from the European Commission. The rest of the authors have declared that they have no conflict of interest.	Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Dudbridge F, 2008, GENET EPIDEMIOL, V32, P227, DOI 10.1002/gepi.20297; Eder W, 2006, ALLERGY, V61, P1117, DOI 10.1111/j.1398-9995.2006.01128.x; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Li Y, 2009, ANNU REV GENOM HUM G, V10, P387, DOI 10.1146/annurev.genom.9.081307.164242; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murcray CE, 2009, AM J EPIDEMIOL, V169, P219, DOI 10.1093/aje/kwn353; Pacheco R, 2004, J BIOL CHEM, V279, P33352, DOI 10.1074/jbc.M401761200; Pacheco R, 2007, J NEUROIMMUNOL, V185, P9, DOI 10.1016/j.jneuoim.2007.01.003; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P12; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001	15	77	78	2	36	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2011	127	1					138	U226		10.1016/j.jaci.2010.09.041		11	Allergy; Immunology	Allergy; Immunology	702SY	WOS:000285917300020	21211648	
J	Hochberg, NS; Hamer, DH				Hochberg, Natasha S.; Hamer, Davidson H.			Anisakidosis: Perils of the Deep	CLINICAL INFECTIOUS DISEASES			English	Article							MAJOR ALLERGEN; GASTRIC ANISAKIASIS; PARASITIC ZOONOSES; BOWEL OBSTRUCTION; EATING SUSHI; SIMPLEX; FISH; DIAGNOSIS; NEMATODA; IDENTIFICATION	Anisakidosis, human infection with nematodes of the family Anisakidae, is caused most commonly by Anisakis simplex and Pseudoterranova decipiens. Acquired by the consumption of raw or undercooked marine fish or squid, anisakidosis occurs where such dietary customs are practiced, including Japan, coastal regions of Europe, and the United States. Severe epigastric pain, resulting from larval invasion of the gastric mucosa, characterizes gastric anisakidosis; other syndromes are intestinal and ectopic. Allergic anisakidosis is a frequent cause of foodborne allergies in areas with heavy fish consumption or occupational exposure. Diagnosis and treatment of gastric disease is usually made by a compatible dietary history and visualization and removal of the larva(e) on endoscopy; serologic testing for anti-A. simplex immunoglobulin E can aid in the diagnosis of intestinal, ectopic and allergic disease. Intestinal and/or ectopic cases may require surgical removal; albendazole has been used occasionally. Preventive measures include adequately freezing or cooking fish.	[Hochberg, Natasha S.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02118 USA; [Hamer, Davidson H.] Boston Univ, Sch Publ Hlth, Dept Int Hlth, Boston, MA 02118 USA; [Hochberg, Natasha S.; Hamer, Davidson H.] Boston Univ, Sch Med, Infect Dis Sect, Dept Med, Boston, MA 02118 USA; [Hochberg, Natasha S.; Hamer, Davidson H.] Boston Med Ctr, Travel Clin, Boston, MA 02111 USA; [Hamer, Davidson H.] Tufts Univ, Friedman Sch Nutr Sci & Policy, Boston, MA 02111 USA	Hochberg, NS (reprint author), Boston Univ, Sch Publ Hlth, Dept Epidemiol, 715 Albany St,Talbot 420E, Boston, MA 02118 USA.	nhoch@bu.edu		Hochberg, Natasha/0000-0002-5449-9973; Hamer, Davidson/0000-0002-4700-1495			Abollo E, 2001, PARASITOL RES, V87, P492, DOI 10.1007/s004360100389; ADAMS AA, 1990, LANCET, V336, P1328, DOI 10.1016/0140-6736(90)93019-L; Adroher FJ, 1996, PARASITOL RES, V82, P319, DOI 10.1007/s004360050120; Akbar A, 2005, DIGEST LIVER DIS, V37, P7, DOI 10.1016/j.dld.2004.09.011; Anadon AM, 2009, CLIN EXP IMMUNOL, V156, P471, DOI 10.1111/j.1365-2249.2009.03919.x; Arilla MC, 2008, PARASITOLOGY, V135, P735, DOI 10.1017/S0031182008004332; Audicana MT, 2008, CLIN MICROBIOL REV, V21, P360, DOI 10.1128/CMR.00012-07; Audicana MT, 2002, TRENDS PARASITOL, V18, P20, DOI 10.1016/S1471-4922(01)02152-3; Caballero ML, 2002, ANN ALLERG ASTHMA IM, V89, P74; Cespedes M, 2000, ABDOM IMAGING, V25, P548, DOI 10.1007/s002610000089; Chai JY, 2005, INT J PARASITOL, V35, P1233, DOI 10.1016/j.ijpara.2005.07.013; Chen Q, 2008, PARASITOL RES, V104, P79, DOI 10.1007/s00436-008-1161-7; CHORDAUGER S, 1995, PARASITE, V2, P395; DEARDORFF TL, 1989, J WILDLIFE DIS, V25, P416; Eguia A, 2003, ORAL SURG ORAL MED O, V96, P437, DOI 10.1016/S1079-2104(03)00264-6; Foti C, 2002, ACTA DERM-VENEREOL, V82, P121, DOI 10.1080/00015550252948167; Gill CJ, 2005, CLIN INFECT DIS, V41, P1764, DOI 10.1086/498153; Gomez B, 1998, ALLERGY, V53, P1148, DOI 10.1111/j.1398-9995.1998.tb03834.x; Gorbach SL, 2004, INFECT DIS; Ishikura H., 1990, PROGR CLIN PARASITOL, V3, P43; Ito Y, 2007, ASIAN J SURG, V30, P67, DOI 10.1016/S1015-9584(09)60131-7; KAKIZOE S, 1995, AM J GASTROENTEROL, V90, P761; Kanematsu M, 1997, AM J ROENTGENOL, V168, P1114; Kanisawa Y, 2000, ENDOSCOPY, V32, pS55; KARL H, 1994, INT J FOOD SCI TECH, V29, P661; KLIKS MM, 1986, JAMA-J AM MED ASSOC, V255, P2605; Klimpel S, 2004, PARASITOL RES, V94, P1, DOI 10.1007/s00436-004-1154-0; Leuckart R., 1876, MENSCHLICHEN PARASIT; Lopez-Serrano MC, 2000, J GASTROEN HEPATOL, V15, P503, DOI 10.1046/j.1440-1746.2000.02153.x; Manfredi MT, 2000, PARASITOL RES, V86, P551, DOI 10.1007/s004360000202; McClelland G, 2002, PARASITOLOGY, V124, pS183, DOI 10.1017/S0031182002001658; Mercado R, 2001, MEM I OSWALDO CRUZ, V96, P653, DOI 10.1590/S0074-02762001000500010; MIYAZAKI I, 1991, ANISAKIASIS ILLUSTRA, P314; Moneo I, 2000, J ALLERGY CLIN IMMUN, V106, P177, DOI 10.1067/mai.2000.106732; Moore DAJ, 2002, LANCET, V360, P54, DOI 10.1016/S0140-6736(02)09333-9; Muguruma N, 1999, GASTROINTEST ENDOSC, V49, P653, DOI 10.1016/S0016-5107(99)70401-3; Muraoka A, 1996, DIGEST DIS SCI, V41, P2362, DOI 10.1007/BF02100128; Nawa Y, 2005, CLIN INFECT DIS, V41, P1297, DOI 10.1086/496920; Neto V. A., 2007, REV INST MED TROP SP, V49, P261; Pacios E, 2005, CLIN INFECT DIS, V41, P1825, DOI 10.1086/498309; Perteguer MJ, 2000, ANN TROP MED PARASIT, V94, P259, DOI 10.1080/00034980050006447; Purello-D'Ambrosio F, 2000, ANN ALLERG ASTHMA IM, V84, P439; Sasaki T, 2003, SURG TODAY, V33, P123, DOI 10.1007/s005950300027; Schuster R, 2003, AM SURGEON, V69, P350; SHIRAHAMA M, 1992, RADIOLOGY, V185, P789; SUDDUTH RH, 2000, ANISAKIDOSIS STRICKL; Takabe K, 1998, AM J GASTROENTEROL, V93, P1172; Takei H, 2007, ANN DIAGN PATHOL, V11, P350, DOI 10.1016/j.anndiagpath.2006.03.018; Thoreau Henry David, 1906, WRITINGS HD THOREAU; Umehara A, 2008, PARASITOL INT, V57, P49, DOI 10.1016/j.parint.2007.08.003; FDA US, 2001, FISH FISH PROD HAZ C; Van Thiel P. H., 1960, Tropical and Geographical Medicine, V2, P97; Van Thiel P.H., 1962, PARASITOLOGY, V52, P16; Ventura MT, 2008, J INVEST ALLERG CLIN, V18, P253; WITTNER M, 1989, NEW ENGL J MED, V320, P1124, DOI 10.1056/NEJM198904273201706; Yu Jae-Ran, 2001, Korean Journal of Parasitology, V39, P193	56	77	78	4	37	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	1058-4838			CLIN INFECT DIS	Clin. Infect. Dis.	OCT 1	2010	51	7					806	812		10.1086/656238		7	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	646YX	WOS:000281583000009	20804423	
J	Frew, AJ				Frew, Anthony J.			Allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Immunotherapy; immunomodulation; rhinitis; asthma; T cell; B cell; IgE; IgG; sublingual	GRASS-POLLEN IMMUNOTHERAPY; LONG-TERM PREVENTION; HOUSE-DUST MITE; T-CELL-CLONES; DOUBLE-BLIND; BIRCH POLLEN; SUBLINGUAL IMMUNOTHERAPY; RAGWEED IMMUNOTHERAPY; CLINICAL-EFFICACY; CONTROLLED TRIAL	Specific immunotherapy (SIT) involves the administration of allergen extracts to achieve clinical tolerance of those allergens that cause symptoms in patients with allergic conditions. Immunotherapy is effective in patients with mild forms of allergic disease and also in those who do not respond well to standard drug therapy. Most SIT is given by means of injection, but there is increasing interest in performing SIT through the sublingual route. SIT remains the treatment of choice for patients with systemic allergic reactions to wasp and bee stings and should be considered as an option in patients with allergic rhinitis, asthma, or both. SIT can modify the course of allergic disease by reducing the risk of new allergic sensitizations and inhibiting the development of clinical asthma in children treated for allergic rhinitis. The precise mechanisms responsible for the beneficial effects of SIT remain a matter of research and debate. An effect on regulatory T cells seems most probable and is associated with switching of allergen-specific B cells toward IgG4 production. Few direct comparisons of SIT and drug therapy have been made. Existing data suggest that the effects of SIT take longer to develop, but once established, SIT achieves long-lasting relief of allergic symptoms, whereas the benefits of drugs only last as long as they are continued. (J Allergy Clin Immunol 2010;125:S306-13.)	Brighton Gen Hosp, Dept Resp Med, Brighton & Sussex Med Sch, Brighton BN2 3EW, E Sussex, England	Frew, AJ (reprint author), Brighton Gen Hosp, Dept Resp Med, Brighton & Sussex Med Sch, Brighton BN2 3EW, E Sussex, England.	anthony.frew@bsuh.nhs.uk			Allergy Therapeutics, Ltd; ARTU biological NV	A. J. Frew is on the Advisory Board for Allergopharma and Stallergenes; gives lectures for MSD, Schering-Plough, and Novartis; gives lectures and is on the Advisory Board for ALK-Abello, UK; has received research support from Allergy Therapeutics, Ltd, and ARTU biological NV; has provided expert witness testimony on the topic of antihistamine patents; is on the Executive Committee for the European Academy of Allergy and Clinical Immunology; and is a Council Member for the British Society for Allergy and Clinical Immunology.	Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alvarez-Cuesta E, 2007, ALLERGY, V62, P810, DOI 10.1111/j.1398-9995.2007.01365.x; Bachert C, 2007, CLIN EXP ALLERGY, V37, P772, DOI 10.1111/j.1365-2222.2007.02706.x; Bellinghausen I, 2001, INT ARCH ALLERGY IMM, V126, P97, DOI 10.1159/000049499; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Committee on the safety of medicines, 1986, BRIT MED J, V293, P948, DOI 10.1136/bmj.293.6552.948; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; Creticos PS, 2002, J ALLERGY CLIN IMMUN, V109, P743; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Fasler S, 1998, J ALLERGY CLIN IMMUN, V101, P521, DOI 10.1016/S0091-6749(98)70406-3; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Freeman J, 1914, LANCET, V1, P1178; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Graft DF, 2006, MED CLIN N AM, V90, P211, DOI 10.1016/j.mcna.2005.08.006; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; HORAK F, 1985, ARCH OTORHINOLARYNGO, V242, P242; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; ILIOPOULOS O, 1991, J ALLERGY CLIN IMMUN, V87, P855, DOI 10.1016/0091-6749(91)90134-A; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; Jutel M, 2006, ALLERGY, V61, P796, DOI 10.1111/j.1398-9995.2006.01175.x; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kline JN, 1998, J IMMUNOL, V160, P2555; Lewith GT, 2002, BRIT MED J, V324, P520, DOI 10.1136/bmj.324.7336.520; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; MAURO M, 2007, ALLERG IMMUNOL PARIS, V39, P119; MCHUGH SM, 1995, CLIN EXP ALLERGY, V25, P828, DOI 10.1111/j.1365-2222.1995.tb00025.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P293, DOI 10.1016/S0091-6749(97)70240-9; Nasser SMS, 2001, EUR J IMMUNOL, V31, P3704, DOI 10.1002/1521-4141(200112)31:12<3704::AID-IMMU3704>3.0.CO;2-3; Niggemann B, 2006, ALLERGY, V61, P855, DOI 10.1111/j.1398-9995.2006.01068.x; OHEHIR RE, 1991, INT IMMUNOL, V3, P819, DOI 10.1093/intimm/3.8.819; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; REILLY DT, 1986, LANCET, V2, P881; Shaikh WA, 1997, CLIN EXP ALLERGY, V27, P1279; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sur S, 1999, J IMMUNOL, V162, P6284; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; White P, 1998, CLIN EXP ALLERGY, V28, P266; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	59	77	83	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S306	S313		10.1016/j.jaci.2009.10.064		8	Allergy; Immunology	Allergy; Immunology	629CC	WOS:000280170600028	20176266	
J	North, ML; Khanna, N; Marsden, PA; Grasemann, H; Scott, JA				North, Michelle L.; Khanna, Nivedita; Marsden, Philip A.; Grasemann, Hartmut; Scott, Jeremy A.			Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						S-(2-boronoethyl)-L-cysteine; agmatinase; nitric oxide	NITRIC-OXIDE SYNTHASE; ALVEOLAR MACROPHAGES; ALLERGIC-ASTHMA; CANDIDATE GENE; MURINE MODELS; EXHALED AIR; L-ARGININE; INFLAMMATION; MICE; INHIBITION	North ML, Khanna N, Marsden PA, Grasemann H, Scott JA. Functionally important role for arginase 1 in the airway hyperresponsiveness of asthma. Am J Physiol Lung Cell Mol Physiol 296: L911-L920, 2009. First published March 13, 2009; doi: 10.1152/ajplung.00025.2009.-L-Arginine metabolism by the arginase and nitric oxide (NO) synthase (NOS) families of enzymes is important in NO production, and imbalances between these pathways contribute to airway hyperresponsiveness (AHR) in asthma. To investigate the role of arginase isozymes (ARG1 and ARG2) in AHR, we determined the protein expression of ARG1, ARG2, the NOS isozymes, and other proteins involved in L-arginine metabolism in lung tissues from asthma patients and in acute (3-wk) and chronic (12-wk) murine models of ovalbumin-induced airway inflammation. Expression of ARG1 was increased in human asthma, whereas ARG2, NOS isoforms, and the other L-arginine-related proteins (i.e., cationic amino acid transporters 1 and 2, agmatinase, and ornithine decarboxylase) were unchanged. In the acute murine model of allergic airway inflammation, augmentation of ARG1 expression was similarly the most dramatic change in protein expression. However, ARG2, NOS1, NOS2, and agmatinase were also increased, whereas NOS3 expression was decreased. Arginase inhibition in vivo with nebulized S-(2-boronoethyl)-L-cysteine attenuated the methacholine responsiveness of the central airways in mice from the acute model. Further investigations in the chronic murine model revealed an expression profile that more closely paralleled the human asthma samples: only ARG1 expression was significantly increased. Interestingly, in the chronic mouse model, which generates a remodeling phenotype, arginase inhibition attenuated methacholine responsiveness of the central and peripheral airways. The similarity in arginase expression between human asthma and the chronic model and the attenuation of AHR after in vivo treatment with an arginase inhibitor suggest the potential for therapeutic modification of arginase activity in asthma.	[North, Michelle L.; Marsden, Philip A.; Grasemann, Hartmut; Scott, Jeremy A.] Univ Toronto, Hosp Sick Children, Inst Med Sci, Toronto, ON M5G 1X8, Canada; [Scott, Jeremy A.] Univ Toronto, Hosp Sick Children, Inst Occupat & Environm Hlth Program, Dalla Lana Sch Publ Hlth,Fac Med, Toronto, ON M5G 1X8, Canada; [North, Michelle L.; Khanna, Nivedita; Scott, Jeremy A.] Univ Toronto, Hosp Sick Children, Div Occupat & Resp Med, Dept Med, Toronto, ON M5G 1X8, Canada; [North, Michelle L.; Khanna, Nivedita; Scott, Jeremy A.] Univ Toronto, Hosp Sick Children, Div Occupat & Resp Med, Fac Med, Toronto, ON M5G 1X8, Canada; [Marsden, Philip A.] Univ Toronto, Hosp Sick Children, Div Nephrol, Fac Med, Toronto, ON M5G 1X8, Canada; [Marsden, Philip A.] Univ Toronto, Hosp Sick Children, Div Nephrol, Dept Med, Toronto, ON M5G 1X8, Canada; [Grasemann, Hartmut] Univ Toronto, Hosp Sick Children, Div Physiol & Expt Med, Toronto, ON M5G 1X8, Canada; [Grasemann, Hartmut] Univ Toronto, Hosp Sick Children, Div Resp Med, Toronto, ON M5G 1X8, Canada; [North, Michelle L.; Khanna, Nivedita; Marsden, Philip A.; Scott, Jeremy A.] St Michaels Hosp, Res Ctr, Gage Occupat & Environm Hlth Unit, Toronto, ON M5B 1W8, Canada; [North, Michelle L.; Khanna, Nivedita; Marsden, Philip A.; Scott, Jeremy A.] St Michaels Hosp, Res Ctr, Keenan Res Ctr, Li Ka Shing Knowledge Inst, Toronto, ON M5B 1W8, Canada	Scott, JA (reprint author), Univ Toronto, Rm 6275A,Med Sci Bldg,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	jeremy.scott@utoronto.ca	Scott, Jeremy/D-2965-2009; Marsden, Philip/B-1441-2012	Scott, Jeremy/0000-0002-7513-6768; 	Ontario Thoracic Society; GlaxoSmithKline; AllerGen NCE; National Sanitarium Association; St. Michael's Hospital Research Centre; Heart and Stroke Foundation of Canada [T-5834]; Dr. Goran Enhorning Award in Pulmonary Physiology	This study was supported by an Ontario Thoracic Society/GlaxoSmithKline Grant-in-Aid of Research, AllerGen NCE, the National Sanitarium Association, St. Michael's Hospital Research Centre, and Heart and Stroke Foundation of Canada Grant T-5834. M.L. North is an Ontario Graduate Scholar in Science and Technology and recipient of the Dr. Goran Enhorning Award in Pulmonary Physiology.	ALVING K, 1993, EUR RESPIR J, V6, P1368; Belik J, 2008, AM J PHYSIOL-LUNG C, V294, pL498, DOI 10.1152/ajplung.00242.2007; Bergeron C, 2007, J ALLERGY CLIN IMMUN, V119, P391, DOI 10.1016/j.jaci.2006.10.030; Bratt JM, 2009, TOXICOL APPL PHARM, V234, P273, DOI 10.1016/j.taap.2008.10.007; Ckless K, 2008, J IMMUNOL, V181, P4255; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Di Valentin E, 2009, AM J PHYSIOL-LUNG C, V296, pL185, DOI 10.1152/ajplung.90367.2008; Epstein MM, 2006, EXP TOXICOL PATHOL, V57, P41, DOI 10.1016/j.etp.2006.02.005; Grasemann H, 1999, CLIN EXP ALLERGY, V29, P39; Grasemann H, 2005, AM J RESP CRIT CARE, V172, P1523, DOI 10.1164/rccm.200502-253OC; Grasemann H, 2000, BIOCHEM BIOPH RES CO, V272, P391, DOI 10.1006/bbrc.2000.2794; Greene AL, 2005, TOXICOL SCI, V88, P420, DOI 10.1093/toxsci/kfi311; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hammermann R, 1999, AM J RESP CELL MOL, V21, P155; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; HECKER M, 1995, FEBS LETT, V359, P251, DOI 10.1016/0014-5793(95)00039-C; Hirota JA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-120; Iyer RK, 2002, MOL GENET METAB, V75, P209, DOI 10.1006/mgme.2001.3277; Kenyon NJ, 2008, TOXICOL APPL PHARM, V230, P269, DOI 10.1016/j.taap.2008.03.004; Kenyon NJ, 2005, INFLAMM RES, V54, P57, DOI 10.1007/s00011-004-1325-6; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Lara A, 2008, AM J RESP CRIT CARE, V178, P673, DOI 10.1164/rccm.200710-1542OC; Lee SK, 2003, ALLERGY ASTHMA PROC, V24, P275; Li HL, 2006, J ALLERGY CLIN IMMUN, V117, P119, DOI 10.1016/j.jaci.2005.09.026; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; Maarsingh H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-23; Maarsingh H, 2008, AM J RESP CRIT CARE, V178, P565, DOI 10.1164/rccm.200710-1588OC; Maarsingh H, 2008, EUR J PHARMACOL, V585, P375, DOI 10.1016/j.ejphar.2008.02.096; Meurs H, 2002, BRIT J PHARMACOL, V136, P391, DOI 10.1038/sj.bjp.0704725; Meurs H, 2000, BRIT J PHARMACOL, V130, P1793, DOI 10.1038/sj.bjp.0703488; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Satriano J, 2004, AMINO ACIDS, V26, P321, DOI 10.1007/s00726-004-0078-4; Scott JA, 2002, CRIT CARE MED, V30, P2143, DOI 10.1097/01.CCM.0000027863.16345.79; Shapiro SD, 2006, AM J RESP CRIT CARE, V174, P1171, DOI 10.1164/rccm.2609001; Takemoto K, 2007, AM J PHYSIOL-LUNG C, V293, pL1419, DOI 10.1152/ajplung.00418.2006; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Vercelli D, 2003, J CLIN INVEST, V111, P1815, DOI 10.1172/JCI200318908; Wechsler ME, 2000, AM J RESP CRIT CARE, V162, P2043; Wenzel S, 2006, AM J RESP CRIT CARE, V174, P1173, DOI 10.1164/rccm.2609002; Zimmermann N, 2006, EUR J PHARMACOL, V533, P253, DOI 10.1016/j.ejphar.2005.12.047; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	43	77	82	1	13	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	JUN	2009	296	6					L911	L920		10.1152/ajplung.00025.2009		10	Physiology; Respiratory System	Physiology; Respiratory System	450YQ	WOS:000266438300007	19286931	
J	Melen, E; Nyberg, F; Lindgren, CM; Berglind, N; Zucchelli, M; Nordling, E; Hallberg, J; Svartengren, M; Morgenstern, R; Kere, J; Bellander, T; Wickman, M; Pershagen, G				Melen, Erik; Nyberg, Fredrik; Lindgren, Cecilia M.; Berglind, Niklas; Zucchelli, Marco; Nordling, Emma; Hallberg, Jenny; Svartengren, Magnus; Morgenstern, Ralf; Kere, Juha; Bellander, Tom; Wickman, Magnus; Pershagen, Goeran			Interactions between glutathione S-transferase P1, tumor necrosis factor, and traffic-related air pollution for development of childhood allergic disease	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						ADRB2; air pollution; allergy; asthma; genetics; GSTP1; interaction; nitrogen oxides; polymorphism; TNF	ENVIRONMENTAL TOBACCO-SMOKE; LUNG-FUNCTION; OXIDATIVE STRESS; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY ILLNESS; GENE POLYMORPHISM; PASSIVE SMOKING; ASTHMA; M1; ASSOCIATION	BACKGROUND: Air pollutants may induce airway inflammation and sensitization due to generation of reactive oxygen species. The genetic background to these mechanisms could be important effect modifiers. OBJECTIVE: Our goal was to assess interactions between exposure to air pollution and single nucleotide polymorphisms (SNPs) in the beta 2-adrenergic receptor (ADRB2), glutathione S-transferase P1 (GSTP1), and tumor necrosis factor (TNF) genes for development of childhood allergic disease. METHODS: In a birth cohort originally of 4,089 children, we assessed air pollution from local traffic using nitrogen oxides (traffic NOx) as an indicator based on emission databases and dispersion modeling and estimated individual exposure through geocoding of home addresses. We measured peak expiratory flow rates and specific IgE for inhalant and food allergens at 4 years of age, and selected children with asthma symptoms up to 4 years of age (n = 542) and controls (n = 542) for genotyping. RESULTS: Interaction effects on allergic sensitization were indicated between several GSTP1 SNPs and traffic NO. exposure during the first year of life (P-nominal < 0.001-0.06). Children with Ile105Val/Val105Val genotypes were at increased risk of sensitization to any allergen when exposed to elevated levels of traffic NO, (for a difference between the 5th and 95th percentile of exposure: odds ratio = 2.4; 95% confidence interval, 1.0-5.3). In children with TNF-308 GA/AA genotypes, the GSTP1-NOx interaction effect was even more pronounced. We observed no conclusive interaction effects for ADRB2. CONCLUSION: The effect of air pollution from traffic on childhood allergy appears to be modified by GSTP1 and TNF variants, supporting a role of genes controlling the antioxidative system and inflammatory response in allergy.	[Melen, Erik; Nyberg, Fredrik; Berglind, Niklas; Morgenstern, Ralf; Bellander, Tom; Wickman, Magnus; Pershagen, Goeran] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, SE-17176 Stockholm, Sweden; [Nyberg, Fredrik] AstraZeneca R&D, Molndal, Sweden; [Lindgren, Cecilia M.; Zucchelli, Marco; Kere, Juha] Karolinska Inst, Dept Biosci Novum, Stockholm, Sweden; [Lindgren, Cecilia M.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Berglind, Niklas; Nordling, Emma; Svartengren, Magnus; Bellander, Tom] Stockholm Cty Council, Dept Environm & Occupat Hlth, Stockholm, Sweden; [Zucchelli, Marco] Karolinska Inst, BEA Bioinformat Core Facil Novum, Stockholm, Sweden; [Hallberg, Jenny; Svartengren, Magnus] Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; [Wickman, Magnus] Karolinska Inst, Sachs Childrens Hosp, Stockholm, Sweden	Melen, E (reprint author), Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, SE-17176 Stockholm, Sweden.	erik.melen@ki.se	Kere, Juha/A-9179-2008; Osborne, Nicholas/N-4915-2015	Kere, Juha/0000-0003-1974-0271; Osborne, Nicholas/0000-0002-6700-2284; Pershagen, Goran/0000-0002-9701-1130; Lindgren, Cecilia/0000-0002-4903-9374	Wellcome Trust [090532]		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Brasch-Andersen C, 2004, HUM MUTAT, V24, P208, DOI 10.1002/humu.20074; Carroll WD, 2005, CLIN EXP ALLERGY, V35, P1155, DOI 10.1111/j.1365-2222.2005.02313.x; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271; Forsberg L, 2001, ARCH BIOCHEM BIOPHYS, V389, P84, DOI 10.1006/abbi.2001.2295; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Gao J, 2006, THORAX, V61, P466, DOI 10.1136/thx.2005.051284; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P346, DOI 10.1164/rccm.2111048; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Grievink L, 2000, CLIN EXP ALLERGY, V30, P1344, DOI 10.1046/j.1365-2222.2000.00835.x; Hallberg J, 2006, ACTA PAEDIATR, V95, P1191, DOI 10.1080/08035250600584794; Hannelius U, 2005, J MED GENET, V42, DOI 10.1136/jmg.2005.032987; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Holgate ST, 1999, J ALLERGY CLIN IMMUN, V104, P1139; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Kabesch M, 2004, THORAX, V59, P569, DOI 10.1136/thx.2003.016667; Lannero E, 2008, THORAX, V63, P172, DOI 10.1136/thx.2007.079053; Lee YL, 2004, CLIN EXP ALLERGY, V34, P1707, DOI 10.1111/j.1365-2222.2004.02099.x; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; MacNee W, 2001, EUR J PHARMACOL, V429, P195, DOI 10.1016/S0014-2999(01)01320-6; McCunney RJ, 2005, J OCCUP ENVIRON MED, V47, P1285, DOI 10.1097/01.jom.0000188561.75578.bf; Melen E, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.023135; Melen E, 2005, AM J RESP CRIT CARE, V171, P1089, DOI 10.1164/rccm.200410-13170C; Melen E, 2004, CLIN EXP ALLERGY, V34, P839, DOI 10.1111/j.1365-2222.2004.01957.x; Nickel R, 2005, PEDIATR ALLERGY IMMU, V16, P539, DOI 10.1111/j.1399-3038.2005.00307.x; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; Ralat LA, 2006, BIOCHEMISTRY-US, V45, P360, DOI 10.1021/bi0520737; REINEMER P, 1991, EMBO J, V10, P1997; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Rosenlund M, 2006, EPIDEMIOLOGY, V17, P383, DOI 10.1097/01.ede.0000219722.25569.0f; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; Strange RC, 2001, MUTAT RES-FUND MOL M, V482, P21, DOI 10.1016/S0027-5107(01)00206-8; Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Wang ZX, 2001, AM J RESP CRIT CARE, V163, P1404; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Wenten M, 2005, AM J RESP CRIT CARE, V172, P1563, DOI 10.1164/rccm.200506-4900C; Wilson AG, 1997, P NATL ACAD SCI USA, V94, P3195, DOI 10.1073/pnas.94.7.3195; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Zhang G, 2007, EUR RESPIR J, V30, P48, DOI 10.1183/09031936.00123206	50	77	78	2	23	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2008	116	8					1077	1084		10.1289/ehp.11117		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	335DE	WOS:000258270200030	18709160	
J	Jakiela, B; Brockman-Schneider, R; Amineva, S; Lee, WM; Gern, JE				Jakiela, Bogdan; Brockman-Schneider, Rebecca; Amineva, Svetlana; Lee, Wai-Ming; Gern, James E.			Basal cells of differentiated bronchial epithelium are more susceptible to rhinovirus infection	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						airway epithelium; basal cells; rhinovirus; ICAM-1 expression	HUMAN AIRWAY EPITHELIUM; PROINFLAMMATORY CYTOKINES; ASTHMA EXACERBATIONS; TRACHEAL EPITHELIUM; BARRIER FUNCTION; TIGHT JUNCTIONS; LUNG; PERMEABILITY; MECHANISMS; SECRETION	We used an in vitro model of differentiated tracheolbronchial epithelium to analyze the susceptibility of different cell types to infection with rhinoviruses (RVs). Primary cells from control subjects were cultured in an air-liquid interface to form differentiated epithelia. Suprabasal and basal fractions were separated after trypsin digestion, and cell suspensions were infected with serotypes RV16 and RVIA. These cell fractions were analyzed for expression of viral capsid protein VP2 (flow cytometry), viral replication (real-time PCR), cytolkeratin-14, and intercellular adhesion molecule-1 (ICAM-1). Compared with suprabasal fraction, basal cells had increased percentages of cells staining positive for VP2 (RVIA: 37.8% versus 9.1%, P < 0.01; RV16: 12.0 versus 3.0%, P < 0.05). The average number of viral RNA copies per cell was also higher in basal cells (2.2- and 2.4-fold increase in RV1A- and RV16-infected cells, respectively) compared with suprabasal cells. Furthermore, ICAM-1 was expressed by 33.3% of basal cells, compared with 8.1% of suprabasal cells (P < 0.05). Finally, in culture models of epithelial injury (detached suprabasal cells or scratched surface), there was significantly greater replication of RVIA compared with intact cell layer. These findings demonstrate that basal cells are more susceptible to RV infection than suprabasal cells. For major group RV, this may be in part due to increased expression of ICAM-1; however, minor group RV also replicated more effectively in basal cells. These results suggest the possibility that epithelial cell differentiation is associated with the maturation of antiviral defense mechanisms.	[Jakiela, Bogdan] Jagiellonian Univ, Dept Med, PL-31066 Krakow, Poland; [Brockman-Schneider, Rebecca; Amineva, Svetlana; Lee, Wai-Ming; Gern, James E.] Univ Wisconsin, Madison, WI USA	Jakiela, B (reprint author), Jagiellonian Univ, Dept Med, Ul Skawinska 8, PL-31066 Krakow, Poland.	bogumil.j@poczta.fm			NHLBI NIH HHS [P01 HL70831-01]; NIAID NIH HHS [U19 AI070503]		Ahdieh M, 2001, AM J PHYSIOL-CELL PH, V281, pC2029; Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Boers JE, 1998, AM J RESP CRIT CARE, V157, P2000; Borthwick DW, 2001, AM J RESP CELL MOL, V24, P662; Bossios A, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-114; Bruewer M, 2003, J IMMUNOL, V171, P6164; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Coyne CB, 2002, MOL BIOL CELL, V13, P3218, DOI 10.1091/mbc.E02-03-0134; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159; Grassme H, 2005, J BIOL CHEM, V280, P26256, DOI 10.1074/jbc.M500835200; Gray TE, 1996, AM J RESP CELL MOL, V14, P104; Holgate S T, 2003, Eur Respir J Suppl, V44, p24s; Holgate Stephen T, 2004, Proc Am Thorac Soc, V1, P93, DOI 10.1513/pats.2306034; Hong KU, 2004, AM J PATHOL, V164, P577, DOI 10.1016/S0002-9440(10)63147-1; Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Konno S, 2002, AM J RESP CELL MOL, V26, P594; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; Nakajima M, 1998, PATHOL INT, V48, P944; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Puchelle Edith, 2006, Proc Am Thorac Soc, V3, P726, DOI 10.1513/pats.200605-126SF; Rawlins EL, 2006, DEVELOPMENT, V133, P2455, DOI 10.1242/dev.02407; Reed CE, 2004, J ALLERGY CLIN IMMUN, V114, P997, DOI 10.1016/j.jaci.2004.07.060; Rodriguez-Boulan E, 2005, NAT REV MOL CELL BIO, V6, P233, DOI 10.1038/nrm1593; Sachs LA, 2003, IN VITRO CELL DEV-AN, V39, P56; Savolainen Carita, 2003, Paediatr Respir Rev, V4, P91, DOI 10.1016/S1526-0542(03)00030-7; Schleimer Robert P, 2004, Proc Am Thorac Soc, V1, P222, DOI 10.1513/pats.200402-018MS; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220; Shahana S, 2005, RESP MED, V99, P429, DOI 10.1016/j.rmed.2004.08.013; Tai HY, 2006, ALLERGY, V61, P382, DOI 10.1111/j.1398-9995.2005.00958.x; Takizawa Hajime, 2005, Current Drug Targets - Inflammation and Allergy, V4, P305, DOI 10.2174/1568010054022123; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; Uchida DA, 1996, EXP LUNG RES, V22, P85, DOI 10.3109/01902149609074019; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wu R, 1997, EUR RESPIR J, V10, P2398, DOI 10.1183/09031936.97.10102398; Zabner J, 2003, J APPL PHYSIOL, V95, P394, DOI 10.1152/japplphysiol.01134.2002; Zabner J, 1996, J VIROL, V70, P6994; Zhu J, 1999, EUR RESPIR J, V13, P1318, DOI 10.1183/09031936.99.13613299	45	77	79	0	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAY	2008	38	5					517	523		10.1165/rcmb.2007-0050OC		7	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	298MV	WOS:000255692700004	18063839	
J	Kozyrskyj, AL; Mai, XM; McGrath, P; HayGlasss, KT; Becker, AB; MacNeil, B				Kozyrskyj, Anita L.; Mai, Xiao-Mei; McGrath, Patrick; HayGlasss, Kent T.; Becker, Allan B.; MacNeil, Brian			Continued exposure to maternal distress in early life is associated with an increased risk of childhood asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; child; depression; postpartum	POSTPARTUM PSYCHIATRIC-DISORDERS; PSYCHOLOGICAL STRESS; BIRTH-COHORT; DEPRESSION; CHILDREN; EXPRESSION; REACTIVITY; PREDICTOR; SYMPTOMS; CORTISOL	Rationale: Evidence is emerging that exposure to maternal distress in early life plays a causal role in the development of childhood asthma. Objectives: Because much of the data are from high-risk cohorts, we undertook a birth cohort study in a complete population of children to test this association. Methods: Using Manitoba, Canada's, health care and prescription databases, this longitudinal study assessed the association between maternal distress during the first year of life and onward, and asthma at age 7 in a 1995 birth cohort of 13,907 children. Measurements and Main Results: Maternal distress was defined on the basis of health care or prescription medication use for depression or anxiety. Asthma status was derived from health care and prescription records for asthma, using a definition validated by comparison to pediatric allergist diagnosis. Multiple logistic regression was used to determine the likelihood of asthma (odds ratio [OR], 95% confidence interval [95% CI]). Independent of wellknown asthma risk factors, our population-based study of a non-high-risk cohort demonstrated an increased risk of childhood asthma (OR, 1.25; 95% CI, 1.01-1.55) among children exposed to continued maternal distress from birth until age 7. Exposure to maternal depression and anxiety limited to the first year of life did not have a demonstrable association with subsequent asthma. Of interest, we observed that the risk of asthma associated with continued maternal distress was increased in children living in high- versus low-income households (OR, 1.44; 95% CI, 1.12-1.85). Conclusions: Maternal distress in early life plays a role in the development of childhood asthma, especially if it continues beyond the postpartum period.	[Kozyrskyj, Anita L.; Mai, Xiao-Mei] Univ Manitoba, Fac Pharm, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Univ Manitoba, Dept Community Hlth Sci, Manitoba Ctr Hlth Policy, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.; Becker, Allan B.] Univ Manitoba, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada; [McGrath, Patrick] Dalhousie Univ, Fac Sci, Dept Psychol, Halifax, NS, Canada; [HayGlasss, Kent T.] Univ Manitoba, Dept Immunol, Fac Med, Winnipeg, MB, Canada; [MacNeil, Brian] Univ Manitoba, Sch Med Rehabil, Winnipeg, MB, Canada	Kozyrskyj, AL (reprint author), 210 Pharm Bldg, Winnipeg, MB R3T 2N2, Canada.	kozyrsk@cc.umanitoba.ca	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; MacNeil, Brian/0000-0002-2897-8049; HayGlass, Kent /0000-0002-4621-7737; McGrath, Patrick/0000-0002-9568-2571			Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Ball TM, 2006, J ALLERGY CLIN IMMUN, V117, P306, DOI 10.1016/j.jaci.2005.11.009; Beck CT, 1995, NURS RES, V44, P298; BOYCE WT, 1995, PSYCHOSOM MED, V57, P411; Brockington I, 2004, LANCET, V363, P303, DOI 10.1016/S0140-6736(03)15390-1; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chida Y, 2007, AM J RESP CRIT CARE, V175, P316, DOI 10.1164/rccm.200607-898OC; Coates AO, 2004, J BEHAV HEALTH SER R, V31, P117; Collins KA, 2004, CLIN PSYCHOL REV, V24, P583, DOI 10.1016/j.cpr.2004.06.001; Diego MA, 2005, INFANT BEHAV DEV, V28, P155, DOI 10.1016/j.infbeh.2005.02.002; Essex MJ, 2002, BIOL PSYCHIAT, V52, P776, DOI 10.1016/S0006-3223(02)01553-6; Georgiopoulos AM, 1999, OBSTET GYNECOL, V93, P653, DOI 10.1016/S0029-7844(98)00543-2; Hipwell AE, 2000, DEV PSYCHOPATHOL, V12, P157, DOI 10.1017/S0954579400002030; Hornstein C, 2006, ARCH WOMEN MENT HLTH, V9, P279, DOI 10.1007/s00737-006-0148-6; Klinnert M. D., 2001, PEDIATRICS, V108, P69; Kozyrskyj AL, 2006, J ALLERGY CLIN IMMUN, V117, pS87, DOI 10.1016/j.jaci.2005.12.348; Kozyrskyj AL, 1998, ANN PHARMACOTHER, V32, P1152, DOI 10.1345/aph.18117; Kozyrskyj ALOJ., 1999, CRIT PUBLIC HLTH, V9, P197, DOI 10.1080/09581599908402932; KOZYRSKYJ AL, 2005, ALLERGY ASTHMA CLIN, V1, P108; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Mantymaa M, 2003, CHILD CARE HLTH DEV, V29, P181, DOI 10.1046/j.1365-2214.2003.00330.x; McLearn KT, 2006, ARCH PEDIAT ADOL MED, V160, P279, DOI 10.1001/archpedi.160.3.279; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Meaney MJ, 2001, ANNU REV NEUROSCI, V24, P1161, DOI 10.1146/annurev.neuro.24.1.1161; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Phipatanakul W, 2005, ALLERGY, V60, P697, DOI 10.1111/j.1398-9995.2005.00825.x; Robinson JR, 1997, MED CARE, V35, P932, DOI 10.1097/00005650-199709000-00006; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schor EL, 2003, PEDIATRICS, V111, P1541; Song D, 2004, WOMEN HEALTH, V39, P1, DOI 10.1300/J013v39n01_01; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358; YALLOP YP, 2006, ALLERGEN ANN TRAIN W	39	77	79	2	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 15	2008	177	2					142	147		10.1164/rccm.200703-381OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	251BJ	WOS:000252345300004	17932381	
J	Macia, I; Moya, J; Ramos, R; Morera, R; Escobar, I; Saumench, J; Perna, V; Rivas, F				Macia, Ivan; Moya, Juan; Ramos, Ricard; Morera, Ricard; Escobar, Ignacio; Saumench, Josep; Perna, Valerio; Rivas, Francisco			Spontaneous pneumomediastinum: 41 cases	EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY			English	Article						spontaneous pneumomediastinum; mediastinal emphysema; dyspnea; chest pain; subcutaneous emphysema	SPONTANEOUS MEDIASTINAL EMPHYSEMA; COMPUTED-TOMOGRAPHY; EXPERIENCE; MANAGEMENT; DIAGNOSIS	Objective: Spontaneous pneumomediastinum is characterized by the presence of interstitial air in the mediastinum without any apparent precipitating factor. The purpose of this study is to review and discuss our experience with this condition. Methods: A descriptive, retrospective study of 41 cases - 34 men (83%) and 7 women (17%) - treated at our hospital for spontaneous pneumomediastinum from January 1990 through June 2006. Results: The mean age of the patients was 21 years (range, 14-35 years). Notably, 22% of patients had a prior history of asthma. No precipitating factor was identified in 51% of cases while onset was associated with physical effort in 12%. Chest pain (85%) and dyspnea (49%) were the most common symptoms. Subcutaneous emphysema, which presented in 71% of patients, was the most common sign. Pneumomediastinum was diagnosed by plain chest radiography in all cases. In certain cases, a computed tomography scan of the chest, contrast-enhanced swallow, or bronchoscopy was performed. All patients were admitted to the hospital with good progress and no instances of morbidity or mortality. Treatment included analgesia, rest, and/or initial oxygen therapy. The mean length of hospital stay was 5 days (range, 1-9 days) with only one case of early recurrence, which was resolved satisfactorily. Conclusions: Spontaneous pneumomediastinum is a benign process primarily affecting young men. Despite its tow incidence, spontaneous pneumomediastinum should be considered in the differential diagnosis of acute chest pain because it requires a high index of suspicion. Patients with spontaneous preumomediastinum respond well to medical treatment, with no recurrence in the great majority of cases. (C) 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All. rights reserved.	Hosp Univ Bellvitge, Dept Thorac Surg, Hosp Llobregat, Barcelona 08907, Spain; Univ Barcelona, Hosp Llobreget, Dept Thorac Surg, Hosp Univ Bellvitge,Sch Med, Barcelona, Spain; Univ Barcelona, Hosp Llobreget, Unit Human Anat, Hosp Univ Bellvitge,Sch Med, Barcelona, Spain	Macia, I (reprint author), Hosp Univ Bellvitge, Dept Thorac Surg, Hosp Llobregat, Feixa Llarga S-N, Barcelona 08907, Spain.	ivanmacia@yahoo.com					ABOLNIK I, 1991, CHEST, V100, P93, DOI 10.1378/chest.100.1.93; Ba-Ssalamah A, 1999, EUR RADIOL, V9, P724, DOI 10.1007/s003300050742; Bejvan SM, 1996, AM J ROENTGENOL, V166, P1041; Campillo-Soto A, 2005, ARCH BRONCONEUMOL, V41, P528, DOI 10.1157/13078656; Freixinet J, 2005, RESP MED, V99, P1160, DOI 10.1016/j.rmed.2005.02.025; Gerazounis M, 2003, J THORAC CARDIOV SUR, V126, P774, DOI 10.1016/S0022-5223(03)00124-7; Hamman L, 1939, B JOHNS HOPKINS HOSP, V64, P1; Jane M, 2002, MED CLIN-BARCELONA, V118, P81; Jougon JB, 2003, ANN THORAC SURG, V75, P1711, DOI 10.1016/S0003-4975(03)00027-4; Kaneki T, 2000, RESPIRATION, V67, P408, DOI 10.1159/000029539; Koullias GJ, 2004, EUR J CARDIO-THORAC, V25, P852, DOI 10.1016/j.ejcts.2004.01.042; Macklin MT, 1944, MEDICINE, V23, P281; MAUNDER RJ, 1984, ARCH INTERN MED, V144, P1447, DOI 10.1001/archinte.144.7.1447; Newcomb AE, 2005, CHEST, V128, P3298, DOI 10.1378/chest.128.5.3298; Panacek EA, 1992, ANN EMERG MED, V21, P67; Patel A, 2000, CHEST, V117, P1809, DOI 10.1378/chest.117.6.1809; Sakai M, 2006, J COMPUT ASSIST TOMO, V30, P92, DOI 10.1097/01.rct.0000187416.07698.8d; Weissberg D, 2004, EUR J CARDIO-THORAC, V26, P885, DOI 10.1016/j.ejcts.2004.05.050	18	77	82	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1010-7940			EUR J CARDIO-THORAC	Eur. J. Cardio-Thorac. Surg.	JUN	2007	31	6					1110	1114		10.1016/j.ejcts.2007.03.008		5	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	179LE	WOS:000247290300027	17420139	
J	Yeatts, K; Svendsen, E; Creason, J; Alexis, N; Herbst, M; Scott, J; Kupper, L; Williams, R; Neas, L; Cascio, W; Devlin, RB; Peden, DB				Yeatts, Karin; Svendsen, Erik; Creason, John; Alexis, Neil; Herbst, Margaret; Scott, James; Kupper, Lawrence; Williams, Ronald; Neas, Lucas; Cascio, Wayne; Devlin, Robert B.; Peden, David B.			Coarse particulate matter (PM2.5-10) affects heart rate variability, blood lipids, and circulating eosinophils in adults with asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; coarse PM; heart rate variability; inflammatory markers; lipids; systemic inflammation	AMBIENT AIR-POLLUTION; CARDIAC AUTONOMIC CONTROL; PHAGOCYTES IN-VIVO; INFLAMMATORY RESPONSE; HEALTHY-VOLUNTEERS; ELDERLY SUBJECTS; ENDOTOXIN; EXPOSURE; DISEASE; ASSOCIATION	INTRODUCTION: We investigated whether markers of airway and systemic inflammation, as well as heart rate variability (HRV) in asthmatics, change in response to fluctuations in ambient particulate matter (PM) in the coarse [PM with aerodynamic diameter 2.5-10 mu M (PM2.5-10)] and fine (PM2.5) size range. METHODS: Twelve adult asthmatics, living within a 30-mile radius of an atmospheric monitoring site in Chapel Hill, North Carolina, were followed over a 12-week period. Daily PM2.5-10 and PM2.5 concentrations were measured separately for each 24-hr period. Each subject had nine clinic visits, at which spirometric measures and peripheral blood samples for analysis of lipids, inflammatory cells, and coagulation-associated proteins were obtained. We also assessed HRV [SDNN24HR (standard deviation of all normal-to-normal intervals in a 24-hr recording), ASDNN5 (mean of the standard deviation in A 5-min segments of a 24-hr recording)] with four consecutive 24-hr ambulatory electrocardiogram measurements. Linear mixed models with a spatial covariance matrix structure and a 1-day lag were used to assess potential associations between PM levels and cardio- pulmonary end points. RESULTS: For a 1-mu g/m(3) increase in coarse PM, SDNN24HR, and ASDNN5 decreased 3.36% (p 0.02), and 0.77%, (p = 0.05) respectively. With a 1-mu g/m(3) increase in coarse PM, circulating eosinophils increased 0.16% (p = 0.01), triglycerides increased 4.8% (p = 0.02), and very low-density lipoprotein increased 1.15% (p = 0.01). No significant associations were found with fine PM, and none with lung function. CONCLUSION: These data suggest that small temporal increases in ambient coarse PM are sufficient to affect important cardiopulmonary and lipid parameters in adults with asthma. Coarse PM may have underappreciated health effects in susceptible populations.	Univ N Carolina, Sch Med, CEMALB, Chapel Hill, NC 27599 USA; US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC USA; E Carolina Univ, Brody Sch Med, Div Cardiol, Greenville, NC USA	Yeatts, K (reprint author), Univ N Carolina, Sch Med, CEMALB, Campus Box 7310,HSD Facil,104 Mason Farm Rd, Chapel Hill, NC 27599 USA.	Karin_Yeatts@unc.edu	Neas, Lucas/J-9378-2012; Wang, Linden/M-6617-2014; Svendsen, Erik/J-2671-2015	Svendsen, Erik/0000-0003-3941-0907	NHLBI NIH HHS [R01 HL062624, R01HL62624]; NIEHS NIH HHS [P30ES10126, P30 ES010126]		Adachi Yushi, 2006, Masui, V55, P436; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2006, J ALLERGY CLIN IMMUN, V117, P1396, DOI 10.1016/j.jaci.2006.02.030; Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; ALEXIZ NE, JACI, V115, P345; Beckwith CI, 2002, BRILLS TIBET STU LIB, V2, P27; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; Chen FL, 2007, ATMOS ENVIRON, V41, P1200, DOI 10.1016/j.atmosenv.2006.09.049; Chen LC, 2005, INHAL TOXICOL, V17, P217, DOI 10.1080/08958370590912815; Chen Y, 2004, INHAL TOXICOL, V16, P21, DOI 10.1080/0895837049258129; Chuang KJ, 2005, ENVIRON HEALTH PERSP, V113, P1693, DOI 10.1289/ehp.8145; Godin PJ, 1996, CRIT CARE MED, V24, P1117, DOI 10.1097/00003246-199607000-00009; Gold DR, 2000, CIRCULATION, V101, P1267; GOLDSTEIN B, 1995, CRIT CARE MED, V23, P1694, DOI 10.1097/00003246-199510000-00014; Gong H, 2004, INHAL TOXICOL, V16, P335, DOI 10.1080/08958370490439470; Hardardottir I, 1995, BIOCHEM SOC T, V23, P1013; Holguin F, 2003, EPIDEMIOLOGY, V14, P521, DOI 10.1097/01.ede.0000081999.1500.ae; Hudgins LC, 2003, J LIPID RES, V44, P1489, DOI 10.1194/jlr.M200440-JLR200; Koutrakis P, 2005, RES REP HLTH EFF I, V131, P1; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Levels JHM, 2003, CRIT CARE MED, V31, P1647, DOI 10.1097/01.CCM.0000063260.07222.76; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; Liao DP, 2004, AM J EPIDEMIOL, V159, P768, DOI 10.1093/aje/kwh109; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; Mar TF, 2004, INHAL TOXICOL, V16, P809, DOI 10.1080/08958370490506646; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Mueller-Anneling L, 2004, ENVIRON HEALTH PERSP, V112, P583, DOI 10.1289/ehp.6552; *NHLBI, 2003, UPD SEL TOP 2002; O'Neill MS, 2005, CIRCULATION, V111, P2913, DOI 10.1161/CIRCULATIONAHA.104.517110; Pacheco KA, 2003, AM J RESP CRIT CARE, V167, P983, DOI 10.1164/rccm.2112062; Park SK, 2005, ENVIRON HEALTH PERSP, V113, P304, DOI 10.1289/ehp.7447; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Pekkanen J, 2002, CIRCULATION, V106, P933, DOI 10.1161/01.CIR.0000027561.41736.3C; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; Rabinovitch N, 2005, J ALLERGY CLIN IMMUN, V116, P1053, DOI 10.1016/j.jaci.2005.08.045; Riediker M, 2004, AM J RESP CRIT CARE, V169, P934, DOI 10.1164/rccm.200310-1463OC; Ruckerl R, 2006, AM J RESP CRIT CARE, V173, P432, DOI 10.1164/rccm.200507-1123OC; Sajadieh A, 2004, EUR HEART J, V25, P363, DOI 10.1016/j.ehj.2003.12.003; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Sullivan JH, 2005, THORAX, V60, P462, DOI 10.1136/thx.2004.027532; Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003; Suwa T, 2002, EXP LUNG RES, V28, P1, DOI 10.1080/019021402753355508; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; TIMONEN KL, 2006, J EXPO SCI ENV EPID, V16, P16332; Tomao E, 2002, ANN SAUDI MED, V22, P287; United States Environmental Protection Agency, 1990, NAT AMB AIR QUAL STA; Voss LJ, 2004, BIOL NEONATE, V86, P39, DOI 10.1159/000077452; Wheeler A, 2006, ENVIRON HEALTH PERSP, V114, P560, DOI 10.1289/ehp.8337; Williams R, 2003, ATMOS ENVIRON, V37, P5365, DOI 10.1016/j.atmosenv.2003.09.010; Williams R, 2003, ATMOS ENVIRON, V37, P5349, DOI 10.1016/j.atmosenv.2003.09.019; YUE W, 2006, INT J CARDIOL; Zeka A, 2005, OCCUP ENVIRON MED, V62, P718, DOI 10.1136/oem.2004.017012	60	77	78	0	17	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2007	115	5					709	714		10.1289/ehp.9499		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	163KZ	WOS:000246159900029	17520057	
J	Mutti, A; Corradi, M; Goldoni, M; Vettori, MV; Bernard, A; Apostoli, P				Mutti, A; Corradi, M; Goldoni, M; Vettori, MV; Bernard, A; Apostoli, P			Exhaled metallic elements and serum pneumoproteins in asymptomatic smokers and patients with COPD or asthma	CHEST			English	Article						COPD; exhaled breath condensate; metals; pneumoproteins; trace elements	CLARA CELL PROTEIN; BREATH CONDENSATE; OXIDATIVE STRESS; TRACE-ELEMENTS; PULMONARY-DISEASE; TOBACCO-SMOKE; CADMIUM; CC16; DETERMINANTS; EMPHYSEMA	Study objectives: The aim of this study was to characterize the elemental composition of exhaled breath condensate (EBC) in order to identify new biomarkers of exposure and susceptibility in COPD patients. Serum pneumoproteins were used as lung-specific biomarkers of effect. Design: EBC was obtained from 50 healthy subjects, 30 healthy smokers, 30 asthmatics, and 50 patients with stable COPD, and was collected by cooling exhaled air. Trace elements and toxic metals in the samples were measured by means of inductively coupled plasma-mass spectrometry and electrothermal atomic absorption spectroscopy. The serum pneumoproteins were immuno-assayed. Results: The EBC of COPD subjects had higher levels of such toxic elements as lead, cadmium, and aluminum, and lower levels of iron and copper, than that of the nonsmoking control subjects. There were no between-group differences in surfactant protein (SP)-A and SP-B levels. Clara-cell protein and SP-D levels were negatively and positively influenced, respectively, by tobacco smoke. Conclusions: Our results show that toxic metals and transition elements are detectable in the EBC of studied subjects. We propose new biomarkers of exposure as a means of assessing the target tissue dose of carcinogenic and pneumotoxic substances from tobacco smoke or polluted workplaces, and the use of the transition elements involved in redox systems of oxidative stress as disease biomarkers associated with effect or susceptibility. Together with biomarkers of effect, such as serum pneumoproteins, the elemental composition of EBC may be clinically useful in distinguishing similar diseases.	Univ Parma, Lab Ind Toxicol, Dept Clin Med Nephrol & Hlth Sci, I-43100 Parma, Italy; Univ Parma, Natl Inst Occupat Safety & Prevent, I-43100 Parma, Italy; Univ Parma, Res Ctr, I-43100 Parma, Italy; Catholic Univ Louvain, Toxicol Unit, Brussels, Belgium; Univ Brescia, Lab Ind Hyg, Dept Expt & Appl Med, Brescia, Italy	Mutti, A (reprint author), Univ Parma, Lab Ind Toxicol, Dept Clin Med Nephrol & Hlth Sci, Via Gramsci 14, I-43100 Parma, Italy.	antonio.mutti@unipr.it	goldoni, matteo/E-9153-2011; BERNARD, Alfred/A-6511-2010; Mutti, Antonio/C-1095-2011	goldoni, matteo/0000-0002-1342-3921; BERNARD, Alfred/0000-0003-3171-3743; Mutti, Antonio/0000-0003-2189-3808; corradi, massimo/0000-0002-2808-4184	NHLBI NIH HHS [R01 HL072323, R01 HL72323, R01 HL072323-04]		Apostoli P, 2002, J CHROMATOGR B, V778, P63, DOI 10.1016/S0378-4347(01)00442-X; Apostoli P, 1997, J TRACE ELEM MED BIO, V11, P182; Bachelet M, 2002, FREE RADICAL RES, V36, P99, DOI 10.1080/10715760290001218; Baldi S, 2001, AM J RESP CRIT CARE, V164, P585; BERNARD A, 1992, LANCET, V339, P1620, DOI 10.1016/0140-6736(92)91891-B; CHIBA M, 1992, B WORLD HEALTH ORGAN, V70, P269; Doyle IR, 1998, AM J RESP CRIT CARE, V158, P1528; Effros RM, 2005, J APPL PHYSIOL, V99, P1286, DOI 10.1152/japplphysiol.00362.2005; Goldoni M, 2004, ENVIRON HEALTH PERSP, V112, P1293, DOI 10.1289/ehp.7108; Goldoni Matteo, 2005, BMC Pulm Med, V5, P10, DOI 10.1186/1471-2466-5-10; Hendrick DJ, 2004, THORAX, V59, P184, DOI 10.1136/thx.2003.018432; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hermans C, 2003, BIOMARKERS, V8, P461, DOI 10.1080/13547500310001647021; Hermans C, 1998, CLIN CHIM ACTA, V272, P101, DOI 10.1016/S0009-8981(98)00006-0; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Jiang F, 2003, BRIT J PHARMACOL, V139, P1127, DOI 10.1038/sj.bjp.0705354; Karadag F, 2004, RESPIROLOGY, V9, P33, DOI 10.1111/j.1440-1843.2003.00534.x; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KONDO H, 1993, AM J PHYSIOL, V265, pE839; Kubala-Kukus A, 1999, NUCL INSTRUM METH B, V150, P193, DOI 10.1016/S0168-583X(98)01057-X; Leth-Larsen R, 2004, MOL HUM REPROD, V10, P149, DOI 10.1093/molehr/gah022; MacNee W, 2003, EUR RESPIR J, V21, P47; MAIER EA, 1985, CLIN CHEM, V31, P551; Mannino DM, 2004, THORAX, V59, P194, DOI 10.1136/thorax.2003.012054; Mutlu GM, 2001, AM J RESP CRIT CARE, V164, P731; Nagae H, 1997, CLIN CHIM ACTA, V266, P157, DOI 10.1016/S0009-8981(97)00124-1; National Heart Lung and Blood Institute of the National Institutes of Health (NIH) and Giovanni Lorenzini Medical Science Foundation, 2002, NIH PUBL; *NRC, 1987, ENV HLTH PERSPECT, V74, P1; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pellegrino R, 1997, EUR RESPIR J, V10, P468, DOI 10.1183/09031936.97.10020468; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; Rahman I, 2004, REDOX REP, V9, P125, DOI 10.1179/135100004225005219; ROMEO L, 1992, SCI TOTAL ENVIRON, V120, P103, DOI 10.1016/0048-9697(92)90221-D; Rustemeier K, 2002, FOOD CHEM TOXICOL, V40, P93, DOI 10.1016/S0278-6915(01)00085-0; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304; Tatrai E, 2001, J APPL TOXICOL, V21, P479, DOI 10.1002/jat.784	36	77	84	0	14	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2006	129	5					1288	1297		10.1378/chest.129.5.1288		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	043RE	WOS:000237618400026	16685021	
J	Alati, R; Al Mamun, A; O'Callaghan, M; Najman, JM; Williams, GM				Alati, R; Al Mamun, A; O'Callaghan, M; Najman, JM; Williams, GM			In utero and postnatal maternal smoking and asthma in adolescence	EPIDEMIOLOGY			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; CHILDHOOD LUNG-FUNCTION; EARLY-ONSET ASTHMA; PARENTAL SMOKING; PASSIVE SMOKING; RESPIRATORY SYMPTOMS; CHILDREN; EXPOSURE; PREGNANCY; HEALTH	Background: Asthma in early childhood has been associated with maternal smoking during pregnancy and parental smoking soon after birth. However, less is known about these exposures and the development of asthma symptoms in adolescence. Methods: Data were taken from the Mater University Study, of Pregnancy, a large birth cohort study of mothers and children enrolled in Brisbane, Australia, beginning in 1981. Smoking was assessed at 2 stages during pregnancy and at the 6-month and 5-year follow-up visits. Asthma was assessed from maternal reports that were provided when the child was age 14 years. We conducted multivariable multinomial logistic regression analyses to assess the effect of maternal smoking on asthma symptoms. Results: There was a strong sex interaction such that girls whose mothers had smoked heavily (20 or more cigarettes per day) in pregnancy and at the 6-month follow up had increased odds of experiencing asthma symptoms at age 14 (odds ratio = 1.96; 95% confidence interval = 1.25-3.08). The contribution of heavy smoking during pregnancy appeared to be stronger than heavy smoking after the birth. No similar associations were seen for boys. Conclusion: Female adolescents whose mothers smoked heavily during the fetal period and the early months of life have increased risk of asthma symptoms in adolescence. In utero exposure to heavy smoking was found to have a stronger effect than postnatal environmental tobacco exposure.	Univ Queensland, Sch Populat Hlth, Brisbane, Qld 4006, Australia; Mater Childrens Hosp, Brisbane, Qld, Australia; Univ Queensland, Sch Social Sci, St Lucia, Qld, Australia	Alati, R (reprint author), Univ Queensland, Sch Populat Hlth, 1st Floor,Publ Hlth Bldg, Brisbane, Qld 4006, Australia.	r.alati@sph.uq.edu.au	Najman, Jackob/B-1527-2008; O'Callaghan, Michael/F-4414-2010; Alati, Rosa/G-2523-2010; Alati, Rosa /A-2335-2014; Mamun, Abdullah/A-4673-2011	Alati, Rosa /0000-0002-9240-3450; 			Achenbach TM, 1991, MANUAL CHILD BEHAV C; Becklake MR, 1999, THORAX, V54, P1119; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Cook DG, 1999, THORAX, V54, P357; Coultas DB, 1998, THORAX, V53, P381; Dell S, 2001, ARCH PEDIAT ADOL MED, V155, P1261; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Hofhuis W, 2003, ARCH DIS CHILD, V88, P1086, DOI 10.1136/adc.88.12.1086; Hogan JW, 2004, STAT MED, V23, P1455, DOI 10.1002/sim.1728; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Janson C, 2001, LANCET, V358, P2103, DOI 10.1016/S0140-6736(01)07214-2; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; Peat J K, 2001, Paediatr Respir Rev, V2, P207, DOI 10.1053/prrv.2001.0142; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1998, THORAX, V53, P204; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977	26	77	79	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	MAR	2006	17	2					138	144		10.1097/01.ede.0000198148.02347.33		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	015OX	WOS:000235561800007	16477253	
J	Winther, L; Arnved, J; Malling, HJ; Nolte, H; Mosbech, H				Winther, L; Arnved, J; Malling, HJ; Nolte, H; Mosbech, H			Side-effects of allergen-specific immunotherapy. A prospective multi-centre study	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; clinical database; immunotherapy; rhinitis; side-effects	SYSTEMIC REACTIONS; EXTRACT; SAFETY; EFFICACY	Background and objective The safety of allergen-specific immunotherapy (SIT) is a parameter of great interest in the overall assessment of the treatment. A clinical database was developed in order to obtain early warnings of changes in the frequency and severity of side-effects and sufficient data for the evaluation of possible risk factors. Methods During a 3-year period, four allergy centres in Copenhagen, Denmark, included data from all patients initiating SIT to a common database. Information on initial allergic symptoms, allergens used for treatment, treatment regimens and systemic side-effects (SSEs) during the build-up phase was collected. Results A total of 1038 patients received treatment with 1709 allergens (timothy, birch, mugwort, house dust mite (HDM), cat, and wasp and bee venom), 23 047 injections in total. Most SIT patients completed the updosing phase without side-effects, but there was a significant difference between allergens: wasp (89%), birch (82%), HDM (81%), cat (74%) and grass (70%) (P=0.004). A total of 582 SSEs were registered in 341 patients. Most side-effects were mild grade 2 reactions (78%). A difference in severity between allergens was observed (P=0.02), with grass giving most problems. The type of allergen but not patient- or centre-related parameters seemed predictive of side-effects. Conclusions Allergen extracts differ in their tendency to produce side-effects. Multi-centre studies like the present one allow more patients to be evaluated, and thereby provide a more efficient surveillance of side-effects. Online Internet-based registration to a central national database of every allergen injection would be an even more powerful tool for evaluation of risk factors and surveillance of side-effects.	Copenhagen Univ Hosp, Rigshosp, Allergy Clin, DK-2100 Copenhagen O, Denmark; Chest & Allergy Clin, Copenhagen, Denmark; Copenhagen Univ Hosp, Dept Internal Med 1, Bispebjerg, Denmark; Copenhagen Univ Hosp, Dept Internal Med B, Frederiksberg, Denmark	Winther, L (reprint author), Copenhagen Univ Hosp, Rigshosp, Allergy Clin 4222, 9 Blegdamsvej, DK-2100 Copenhagen O, Denmark.	lone.winther@dadlnet.dk					BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Brockow K, 1997, J ALLERGY CLIN IMMUN, V100, P458; Gastaminza G, 2003, CLIN EXP ALLERGY, V33, P470, DOI 10.1046/j.1365-2222.2003.01644.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; MALLING HJ, 1993, ALLERGY, V48, P9; Mellerup MT, 2000, CLIN EXP ALLERGY, V30, P1423, DOI 10.1046/j.1365-2222.2000.00910.x; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; Nettis E, 2002, CLIN EXP ALLERGY, V32, P1745, DOI 10.1046/j.1365-2222.2002.01544.x; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Winther L, 2000, ALLERGY, V55, P827, DOI 10.1034/j.1398-9995.2000.00368.x	12	77	79	0	1	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2006	36	3					254	260		10.1111/j.1365-2222.2006.02340.		7	Allergy; Immunology	Allergy; Immunology	015YS	WOS:000235588200002	16499635	
J	Wohrl, S; Vigl, K; Zehetmayer, S; Hiller, R; Jarisch, R; Prinz, M; Stingl, G; Kopp, T				Wohrl, S; Vigl, K; Zehetmayer, S; Hiller, R; Jarisch, R; Prinz, M; Stingl, G; Kopp, T			The performance of a component-based allergen-microarray in clinical practice	ALLERGY			English	Article						allergen biochip; allergen microarray; allergy; bronchial asthma; component-resolved diagnosis; diagnosis; methodology; rhinoconjunctivitis	RECOMBINANT ALLERGENS; RESOLVED DIAGNOSIS; POLLEN ALLERGENS; IN-VITRO; MITE ALLERGENS; GRASS-POLLEN; IGE; SENSITIZATION; STANDARDIZATION; REACTIVITY	Background: Currently, the diagnosis of IgE-mediated allergy is based on allergen-specific history and diagnostic procedures using natural allergen extracts for in vivo and in vitro tests. Objective: The aim of the study was to comparatively analyse a new component-based allergen-microarray and the 'quasi-standard' ImmunoCAP((R)) for their clinical relevance in patients with allergic rhinoconjunctivitis to five aeroallergens [house dust mite (HDM), cat dander, birch, grass and mugwort pollen] in a prospective, double-centre study. Methods: We enrolled 120 subjects at the two study centres. Allergic patients were defined as having an allergen-specific history plus a concomitant positive skin-prick test (SPT) to natural allergen extracts and specific serum IgE was measured by both methods. Each allergen was analysed separately. Results: The microarray performed equally well in receiver-operating characteristic curve (ROC) analyses when compared with the CAP in cat (23 allergic vs 97 non-allergic, ROC area under the curve microarray 0.950 vs CAP 0.894, P = 0.211), birch (31/89, 0.908 vs 0.878, P = 0.483) and grass pollen (47/73, 0.923 vs 0.915, P = 0.770). It was slightly less sensitive in HDM-allergic subjects (26 allergic vs 94 non-allergic, ROC area microarray 0.808 vs CAP 0.911, P = 0.053) and displayed a reduced sensitivity in the mugwort pollen-allergic patients (17/103, 0.723 vs 0.879, P = 0.032). Conclusions: Component-based testing and the whole-allergen CAP are equally relevant in the diagnosis of grass-, birch- and cat-allergic patients. Although slightly less sensitive, the microarray is sufficient for the diagnosis of HDM-allergic patients, but needs alternative and/or additional components for detecting mugwort allergy.	Med Univ Vienna MUW, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria; Med Univ Vienna MUW, Core Unit Med Stat & Informat, Sect Med Stat, A-1090 Vienna, Austria; VBC GENOMICS, Vienna, Austria; FAZ Floridsdorf Allergy Ctr, Vienna, Austria; Med Univ Vienna MUW, Core Unit Med Stat & Informat, Sect Med Comp Vis, A-1090 Vienna, Austria	Wohrl, S (reprint author), Med Univ Vienna MUW, Dept Dermatol, Div Immunol Allergy & Infect Dis, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.		Wohrl, Stefan/B-6954-2013	Wohrl, Stefan/0000-0002-6324-0007			Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Corti V, 2005, PROTEOMICS, V5, P729, DOI 10.1002/pmic.200401038; Deinhofer K, 2004, METHODS, V32, P249, DOI 10.1016/j.ymeth.2003.08.018; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Dolen WK, 2003, ALLERGY, V58, P717, DOI 10.1034/j.1398-9995.2003.00281.x; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; HARWANEGG C, 2004, PROTEIN MICROARRAYS, pCH13; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Herz U, 2004, METHODS, V32, P271, DOI 10.1016/j.ymeth.2003.08.013; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; JAHNSCHMID B, 2003, CLIN EXP ALLERGY, V333, P1443; JARISCH R, 2000, WIENER GESUNDHEITSBE, P80; JensenJarolim E, 1997, ALLERGY, V52, P844, DOI 10.1111/j.1398-9995.1997.tb02156.x; Johansson SGO, 2004, EXPERT REV MOL DIAGN, V4, P273, DOI 10.1586/14737159.4.3.273; Kalogeromitros D, 2004, OCCUP ENVIRON MED, V61, P709, DOI 10.1136/oem.2003.012427; Kim TE, 2002, EXP MOL MED, V34, P152; Leonard R, 2005, J BIOL CHEM, V280, P7932, DOI 10.1074/jbc.M410407200; MALANDAIN H, 2003, IMMUNOANALYSE BIOL S, V18, P144, DOI 10.1016/S0923-2532(03)00047-4; Mari A, 2003, CLIN EXP ALLERGY, V33, P43, DOI 10.1046/j.1365-2222.2003.01569.x; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Osterballe M, 2005, ALLERGY, V60, P218, DOI 10.1111/j.1398-9995.2005.00674.x; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Prinz M, 2005, ST HEAL T, V116, P441; Puc M, 2003, ANN AGR ENV MED, V10, P143; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Sanz ML, 1996, J INVEST ALLERG CLIN, V6, P152; Shreffler WG, 2004, J ALLERGY CLIN IMMUN, V113, P776, DOI 10.1016/j.jaci.2003.12.588; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Tresch S, 2003, CLIN EXP ALLERGY, V33, P1153, DOI 10.1046/j.1365-2222.2003.01717.x; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Yman L, 2001, ALLERGY, V56, P70, DOI 10.1034/j.1398-9995.2001.00921.x	33	77	82	1	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	MAR	2006	61	5					633	639		10.1111/j.1398-9995.2006.01078.x		7	Allergy; Immunology	Allergy; Immunology	027CY	WOS:000236392500020	16629796	
J	Celli, BR; Halbert, RJ; Nordyke, RJ; Schau, B				Celli, BR; Halbert, RJ; Nordyke, RJ; Schau, B			Airway obstruction in never smokers: Results from the Third National Health and Nutrition Examination Survey	AMERICAN JOURNAL OF MEDICINE			English	Article						environmental exposure; obstructive lung diseases; prevalence; risk factors; socioeconomic factors; smoking	CHRONIC RESPIRATORY SYMPTOMS; PULMONARY-DISEASE; PASSIVE SMOKING; LUNG-FUNCTION; SOCIOECONOMIC-STATUS; GENERAL-POPULATION; FLOW OBSTRUCTION; RISK-FACTORS; NHANES-III; EXPOSURE	PURPOSE: Chronic obstructive pulmonary disease (COPD) is usually described as a disease of cigarette smoking. COPD is rarely considered in persons with no smoking history except in the context of another exposure. Accordingly, the disease has not been well characterized in these "never smokers." METHODS: We evaluated airway obstruction (defined as forced expiratory Volume in I second/forced vital capacity < 0.70) in US adults aged 30 to 80 years interviewed in the Third National Health and Nutrition Examination Survey with valid spirometry who had never smoked. Previously described risk factors were examined for their association with obstruction in bivariate and multivariate analyses. RESULTS: Never smokers represented 42% of the Third National Health and Nutrition Examination Survey Population aged 30 to 80 years, with obstruction prevalence of 91 per 1000. Never smokers accounted for 4.56 million cases of obstruction, or 23% of the total burden. Among these obstructed never smokers, 19% reported a prior diagnosis of asthma alone, and 12.5% reported COPD (alone or with asthma), leaving 68.5% with no prior respiratory diagnosis. After adjustment for other factors, hi, her rates of obstruction were significantly associated with increasing age, male sex. lower body mass index, and a history of allergies. CONCLUSIONS: Never smokers represent a significant proportion of airway obstruction in US adults. Only one fifth of obstruction in this group is explained by asthma. COPD may explain much of the remainder, although known risk factors were not explanatory in this dataset. Recommendations that lung health screening programs be limited to smokers should be reconsidered. (c) 2005 Elsevier Inc. All rights reserved.	Cerner Hlth Insights, Beverly Hills, CA 90212 USA; Tufts Univ, Sch Med, Caritas St Elizabeths Med Ctr, Boston, MA 02111 USA; Univ Calif Los Angeles, Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA 90024 USA; Boehringer Ingelheim Int GmbH, Ingelheim, Germany; Univ Calif Los Angeles, Sch Publ Hlth, Dept Hlth Serv, Los Angeles, CA 90024 USA	Halbert, RJ (reprint author), Cerner Hlth Insights, 9100 Wilshire Blvd,Suite 655E, Beverly Hills, CA 90212 USA.	rhalbert@cerner.com					Abramson M, 2002, RESPIROLOGY, V7, P325, DOI 10.1046/j.1440-1843.2002.00408.x; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; BAKKE PS, 1991, THORAX, V46, P863, DOI 10.1136/thx.46.12.863; BECKLAKE MR, 1985, CHEST, V88, P608, DOI 10.1378/chest.88.4.608; Berglund DJ, 1999, CHEST, V115, P49, DOI 10.1378/chest.115.1.49; Birring SS, 2002, AM J RESP CRIT CARE, V166, P1078, DOI 10.1164/rccm.200203-245OC; Calverley PMA, 2000, CHEST, V117, p365S, DOI 10.1378/chest.117.5_suppl_2.365S; Celli BR, 2004, NEW ENGL J MED, V350, P1005, DOI 10.1056/NEJMoa021322; CHEN B H, 1990, World Health Statistics Quarterly, V43, P127; Chen Y, 2000, J CLIN EPIDEMIOL, V53, P755, DOI 10.1016/S0895-4356(99)00211-5; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Coultas DB, 2003, CURR OPIN PULM MED, V9, P96, DOI 10.1097/00063198-200303000-00002; DAYAL HH, 1994, ENVIRON RES, V65, P161, DOI 10.1006/enrs.1994.1029; Dennis RJ, 1996, CHEST, V109, P115, DOI 10.1378/chest.109.1.115; Eisner MD, 2003, OCCUP ENVIRON MED, V60, P759, DOI 10.1136/oem.60.10.759; Eisner MD, 2002, ENVIRON HEALTH PERSP, V110, P765; GILLUM RF, 1990, J NATL MED ASSOC, V82, P417; Global Initiative for Asthma, GLOB STRAT ASTHM MAN; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN; GULSVIK A, 1979, SCAND J RESPIR DIS, V60, P286; Hardie JA, 2002, EUR RESPIR J, V20, P1117, DOI 10.1183/09031936.02.00023202; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233; HIGGINS MW, 1977, AM REV RESPIR DIS, V116, P403; Hnizdo E, 2002, AM J EPIDEMIOL, V156, P738, DOI 10.1093/aje/kwf105; Hurd SS, 2000, CHEST, V117, p336S, DOI 10.1378/chest.117.5_suppl_2.336S; Iqbal A, 2002, RESPIROLOGY, V7, P233, DOI 10.1046/j.1440-1843.2002.00399.x; JABINE TB, DATA EVALUATION METH, V2; Janson C, 2001, LANCET, V358, P2103, DOI 10.1016/S0140-6736(01)07214-2; KORN RJ, 1987, AM REV RESPIR DIS, V136, P298; Larsson ML, 2003, EUR RESPIR J, V21, P672, DOI 10.1183/09031936.03.00033702; Le Moual N, 2000, OCCUP ENVIRON MED, V57, P126, DOI 10.1136/oem.57.2.126; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Melbostad E, 1997, SCAND J WORK ENV HEA, V23, P271; Meyer PA, 2002, CHEST, V122, P2003, DOI 10.1378/chest.122.6.2003; National Center for Health Statistics, 1994, DHHS PUBL, V94-1104; *NAT HEART LUNG BL, MORB MORT 2004 CHART; OXMAN AD, 1993, AM REV RESPIR DIS, V148, P38; PEAT JK, 1990, THORAX, V45, P32, DOI 10.1136/thx.45.1.32; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; Prescott E, 1999, EUR RESPIR J, V13, P1109, DOI 10.1034/j.1399-3003.1999.13e28.x; *RES TRIANGL I, 2001, SUDAAN COMP PROGR; SAMET JM, 1988, AM REV RESPIR DIS, V137, P815; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SAS Institute Inc., 2000, SAS COMP PROGR VERS; Sethi JM, 2000, CLIN CHEST MED, V21, P67, DOI 10.1016/S0272-5231(05)70008-3; WHITTEMORE AS, 1995, AM J PUBLIC HEALTH, V85, P702, DOI 10.2105/AJPH.85.5.702; XU XP, 1995, AM J RESP CRIT CARE, V151, P41; Zuskin E, 1997, AM J IND MED, V31, P344, DOI 10.1002/(SICI)1097-0274(199703)31:3<344::AID-AJIM11>3.0.CO;2-0	49	77	77	0	0	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0002-9343			AM J MED	Am. J. Med.	DEC	2005	118	12					1364	1372		10.1016/j.amjmed.2005.06.041		9	Medicine, General & Internal	General & Internal Medicine	996ER	WOS:000234157700012	16378780	
J	Ewan, PW; Clark, AT				Ewan, PW; Clark, AT			Efficacy of a management plan based on severity assessment in longitudinal and case-controlled studies of 747 children with nut allergy: proposal for good practice	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						food; nut; allergy; Management plan; anaphylaxis	PEANUT ALLERGY; ANAPHYLACTIC REACTIONS; FOOD CHALLENGES; PREVALENCE; FEATURES; SCHOOLS	There are few data on the long-term management of children with peanut/nut allergy. Advice is variable and often inadequate; further reactions are common. There is no consensus on the criteria for prescription of rescue medication, particularly adrenaline. A longitudinal prospective and case-control study in a tertiary allergy clinic. Patients/parents/school staff of 747 children with confirmed peanut or tree nut allergy received detailed verbal and written advice on nut avoidance, training in recognition and (self-) treatment of reactions and a written treatment plan. The severity of nut allergy was graded (mild-severe) and emergency medication was allocated according to our criteria: all received oral antihistamines, injected adrenaline (EpiPen) was given to those with reactions with airway narrowing, milder reactions to low-dose exposure or concomitant asthma. At annual follow-up over 25 906 patient-months (median: 39 months) retraining was given and details of further reactions (frequency, severity and treatment) were obtained. Criteria for allocation of EpiPen were evaluated. The worst reaction pre-enrolment was mild in 64% and moderate/severe in 36% (airway narrowing). Of 615 subjects followed up, 21% had a further reaction (eightfold reduction in frequency), mostly mild. There was a 60-fold reduction in the frequency of severe reactions. Of those with a moderate-severe initial reaction, 99.5% had no or a less severe follow-up reaction. No child with a mild or severe index reaction had a severe follow-up reaction. Only 1/615 (0.2%) had a severe follow-up reaction and only 2/615 (0.3%) used adrenaline, both successfully and had it available according to our criteria. Of mild-moderate reactions, 77% required oral antihistamines alone and 15% no treatment. Children who had follow-up reactions had more frequent and severe reactions pre-enrolment. The management plan greatly reduced the frequency and severity of further reactions and was successful for all children. Our criteria for selective prescription of EpiPen in the context of this management plan were appropriate. This is the first study to provide evidence on which to inform practice.	Univ Cambridge, Sch Clin, Dept Allergy, Addenbrookes NHS Trust, Cambridge CB2 2QQ, England	Clark, AT (reprint author), Univ Cambridge, Sch Clin, Dept Allergy, Addenbrookes NHS Trust, Cambridge CB2 2QQ, England.	atclark@doctors.org.uk					Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; Clark AT, 2003, CLIN EXP ALLERGY, V33, P1041, DOI 10.1046/j.1365-2745.2003.01624.x; Ewan PW, 1996, BRIT MED J, V312, P1074; Ewan PW, 2001, LANCET, V357, P111, DOI 10.1016/S0140-6736(00)03543-1; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1996, BRIT MED J, V313, P518; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kapoor S, 2004, ALLERGY, V59, P185, DOI 10.1046/j.1398-9995.2003.00365.x; Moneret-Vautrin DA, 2001, ALLERGY, V56, P1071, DOI 10.1034/j.1398-9995.2001.00047.x; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sheikh A, 2000, BRIT MED J, V320, P1441, DOI 10.1136/bmj.320.7247.1441; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sporik R, 2000, CLIN EXP ALLERGY, V30, P1540, DOI 10.1046/j.1365-2222.2000.00928.x; Tariq SM, 1996, BRIT MED J, V313, P514; Vickers DW, 1997, CLIN EXP ALLERGY, V27, P898; Watura JC, 2002, ARCH DIS CHILD, V86, P240, DOI 10.1136/adc.86.4.240; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	20	77	77	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2005	35	6					751	756		10.1111/j.1365-2222.2005.02266.x		6	Allergy; Immunology	Allergy; Immunology	937WG	WOS:000229956100013	15969666	
J	Ramos-Barbon, D; Presley, JF; Hamid, QA; Fixman, ED; Martin, JG				Ramos-Barbon, D; Presley, JF; Hamid, QA; Fixman, ED; Martin, JG			Antigen-specific CD4(+) T cells drive airway in smooth muscle remodeling experimental asthma	JOURNAL OF CLINICAL INVESTIGATION			English	Article							BROWN-NORWAY RATS; REPEATED ALLERGEN EXPOSURE; DNA-SYNTHESIS; IN-VIVO; EXPRESSION; INFLAMMATION; LYMPHOCYTES; FAS; HYPERRESPONSIVENESS; TRANSDUCTION	Airway smooth muscle (ASM) growth contributes to the mechanism of airway hyperresponsiveness in asthma. Here we demonstrate that CD4(+) T cells, central to chronic airway inflammation, drive ASM remodeling in experimental asthma. Adoptive transfer of CD4(+) T cells from sensitized rats induced an increase in proliferation and inhibition of apoptosis of airway myocytes in naive recipients upon repeated antigen challenge, which resulted in an increase in ASM mass. Genetically modified CD4(+) T cells expressing enhanced GFP (EGFP) were localized by confocal microscopy in juxtaposition to ASM cells, which suggests that CD4(+) T cells may modulate ASM cell function through direct cell-cell interaction in vivo. Coculture of antigen-stimulated CD4(+) T cells with cell cycle-arrested ASM cells induced myocyte proliferation, dependent on T cell activation and direct T cell-myocyte contact. Reciprocally, direct cell contact prevented postactivation T cell apoptosis, which suggests receptor-mediated T cell-myocyte crosstalk. Overall, our data demonstrate that activated CD4(+) T cells drive ASM remodeling in experimental asthma and suggest that a direct cell-cell interaction participates in CD4(+) T cell regulation of myocyte turnover and induction of remodeling.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H2X 2P2, Canada	Fixman, ED (reprint author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.	elizabeth.fixman@mcgill.ca; james.martin@mcgill.ca	RAMOS-BARBON, DAVID/C-6624-2009	RAMOS-BARBON, DAVID/0000-0002-9615-6557			Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Costa GL, 2000, J IMMUNOL, V164, P3581; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; EVANS LH, 1990, J VIROL, V64, P6176; Galipeau J, 1999, CANCER RES, V59, P2384; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Geng YJ, 1997, ARTERIOSCL THROM VAS, V17, P2200; Hamann KJ, 1998, AM J RESP CELL MOL, V19, P537; Hamann KJ, 2000, AM J PHYSIOL-LUNG C, V278, pL618; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JAMES AL, 1988, AM REV RESPIR DIS, V138, P136; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Lazaar AL, 2001, J IMMUNOL, V166, P155; Lazaar AL, 1998, J IMMUNOL, V161, P3120; LAZAAR AL, 1994, J EXP MED, V180, P807, DOI 10.1084/jem.180.3.807; Lee JH, 2001, AM J RESP CELL MOL, V25, P474; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Panettieri Reynold A. Jr., 2002, Journal of Allergy and Clinical Immunology, V110, pS269, DOI 10.1067/mai.2002.129429; Panettieri Reynold Jr., 1998, American Journal of Physiology, V274, pL417; PATERSON DJ, 1987, MOL IMMUNOL, V24, P1281, DOI 10.1016/0161-5890(87)90122-2; Ridgway W, 1998, J IMMUNOL, V161, P714; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Salmon M, 1999, BRIT J PHARMACOL, V127, P1151, DOI 10.1038/sj.bjp.0702669; Salmon M, 2000, AM J RESP CELL MOL, V23, P618; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423; WANG CG, 1993, AM REV RESPIR DIS, V148, P413; Watanabe A, 1997, AM J RESP CELL MOL, V16, P69; WATANABE A, 1995, J CLIN INVEST, V96, P1303, DOI 10.1172/JCI118165; Weinberg AD, 1999, J IMMUNOL, V162, P1818; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849; Wise JT, 1999, J IMMUNOL, V162, P5592; Ying S, 1997, J IMMUNOL, V158, P3539; Zacour ME, 1996, AM J RESP CELL MOL, V15, P590; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	36	77	82	0	3	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	JUN	2005	115	6					1580	1589		10.1172/JCI19711		10	Medicine, Research & Experimental	Research & Experimental Medicine	932ZC	WOS:000229592300032	15902312	
J	Lucarelli, M; Gatti, AM; Savarino, G; Quattroni, P; Martinelli, L; Monari, E; Boraschi, D				Lucarelli, M; Gatti, AM; Savarino, G; Quattroni, P; Martinelli, L; Monari, E; Boraschi, D			Innate defence functions of macrophages can be biased by nano-sized ceramic and metallic particles	EUROPEAN CYTOKINE NETWORK			English	Article						nanoparticles; inflammation; macrophages; TLR receptors; cytokines; innate immunity	TOLL-LIKE RECEPTORS; SIGNALING PATHWAYS; HOST-DEFENSE; INFLAMMATION; ACTIVATION; SILICA; OLIGODEOXYNUCLEOTIDES; NANOPARTICLE; DISEASE; MICE	Nano-sized particles of ceramic and metallic materials are generated by high-tech industrial activities, and can be generated from worn-out replacement and prosthetic implants. The interaction with the human body of such nanoparticles has been investigated, with a particular emphasis on innate defence mechanisms. Human macrophages (PMA-differentiated myelomonocytic U-937 cells) were exposed in vitro to non-toxic concentrations of TiO2 SiO2 ZrO2 or Co nanoparticles, and their inflammatory response (expression of TLR receptors and co-receptors, and cytokine production) was examined. Expression of TLR receptors was generally unaffected by exposure to the different nanoparticles, except for some notable cases. Exposure to nanoparticles of ZrO2 (and to a lesser extent TiO2), upregulated expression of viral TLR receptors TLR3 and TLR7. Expression of TLR10 was also increased by TiO2 and ZrO2 nanoparticles. On the other hand, TLR9 expression was decreased by SiO2 nanoparticles, and expression of the co-receptor CD14 was inhibited by Co nanoparticles. Basal and LPS-induced production of cytokines 1L-1beta, TNF-alpha, and 1L-1Ra was examined in macrophages exposed to nanoparticles. SiO2 nanoparticles strongly biased naive macrophages towards inflammation (M1 polarisation), by selectively inducing production of inflammatory cytokines IL-1beta and TNF-alpha. SiO2 nanoparticles also significantly amplified the inflammatory phenotype of LPS-polarised M1 macrophages. Other ceramic nanoparticles had little influence on cytokine production, either in resting macrophages, or in LPS-activated cells. Generally, Co nanoparticles had an overall pro-inflammatory effect on naive macrophages, by reducing anti-inflammatory IL-1Ra and inducing inflammatory TNF-alpha. However, Co nanoparticles reduced production of IL-1beta and IL-1Ra, but not TNF-alpha, in LPS-polarised M1 macrophages. Thus, exposure to different nanoparticles can modulate, in different ways, the defence/inflammatory capacities of macrophages. A thorough analysis of these biasing effects may shed light on the mechanisms of pathogensis of several diseases based on dysregulation of the immune response (allergies, autoimmunity, tumours).	CNR, Inst Biomed Technol, Unit Immunobiol, I-56124 Pisa, Italy; Univ Modena, INFM, Lab Biomat, I-41100 Modena, Italy	Boraschi, D (reprint author), CNR, CNR, Inst Biomed Technol,Area Ric S Cataldo, Unit Immunobiol & Cell Differentiat,Lab Cytokines, Via G Moruzzi 1, I-56124 Pisa, Italy.	borasc@tin.it	Monari, Emanuela/K-7743-2016	Monari, Emanuela/0000-0003-0924-4928			Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Arend WR, 2002, CYTOKINE GROWTH F R, V13, P323, DOI 10.1016/S1359-6101(02)00020-5; Barton GM, 2002, CURR TOP MICROBIOL, V270, P81; Beutler B, 2002, CURR TOP MICROBIOL, V270, P109; Chen Yuxiang, 2003, Current Gene Therapy, V3, P273, DOI 10.2174/1566523034578339; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; Dinarello CA, 1999, METHODS, V19, P121, DOI 10.1006/meth.1999.0837; DRISCOLL KE, 1991, TOXICOL APPL PHARM, V111, P201, DOI 10.1016/0041-008X(91)90024-9; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; Florence AT, 2004, J DRUG TARGET, V12, P65, DOI 10.1080/10611860410001693706; Florence AT, 2001, ADV DRUG DELIVER REV, V50, pS69, DOI 10.1016/S0169-409X(01)00184-3; Gatti AM, 1996, J BIOMED MATER RES, V31, P475, DOI 10.1002/(SICI)1097-4636(199608)31:4<475::AID-JBM6>3.0.CO;2-I; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; HENCH LL, 1978, BIOMATERIALS INTERFA; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Ioannou XP, 2003, VACCINE, V21, P4368, DOI 10.1016/S0264-410X(03)00437-7; Ito T, 2002, HUM IMMUNOL, V63, P1120, DOI 10.1016/S0198-8859(02)00750-4; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; McCluskie MJ, 2001, CRIT REV IMMUNOL, V21, P103; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Mosser DM, 2003, J LEUKOCYTE BIOL, V73, P209, DOI 10.1189/jlb.0602325; O'Neill L, 2000, BIOCHEM SOC T, V28, P557; Okamoto Masato, 2003, Journal of Medical Investigation, V50, P9; Parks CG, 1999, ENVIRON HEALTH PERSP, V107, P793, DOI 10.2307/3434342; Perera PY, 1997, J IMMUNOL, V158, P4422; PETERS K, 2004, 7 WORLD BIOM C P, P1881; Srivastava KD, 2002, AM J RESP CRIT CARE, V165, P527, DOI 10.1164/rccm.2106009; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Zhang DD, 2002, EXP LUNG RES, V28, P641, DOI 10.1080/01902140290108337	31	77	78	0	12	JOHN LIBBEY EUROTEXT LTD	MONTROUGE	127 AVE DE LA REPUBLIQUE, 92120 MONTROUGE, FRANCE	1148-5493			EUR CYTOKINE NETW	Eur. Cytokine Netw.	OCT-DEC	2004	15	4					339	346				8	Biochemistry & Molecular Biology; Cell Biology; Immunology	Biochemistry & Molecular Biology; Cell Biology; Immunology	888KS	WOS:000226373400008	15627643	
J	Ward, DJ; Ayres, JG				Ward, DJ; Ayres, JG			Particulate air pollution and panel studies in children: a systematic review	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Review							PEAK EXPIRATORY FLOW; CHRONIC RESPIRATORY SYMPTOMS; TIME-SERIES ANALYSIS; ASTHMATIC-CHILDREN; METHODOLOGICAL ISSUES; FINE PARTICLES; PM10 POLLUTION; MEDICATION USE; LOS-ANGELES; MEXICO-CITY	Background: Panel studies have been used to investigate the short term effects of outdoor particulate air pollution across a wide range of environmental settings. Aims: To systematically review the results of such studies in children, estimate summary measures of effect, and investigate potential sources of heterogeneity. Methods: Studies were identified by searching electronic databases to June 2002, including those where outcomes and particulate level measurements were made at least daily for greater than or equal to 8 weeks, and analysed using an appropriate regression model. Study results were compared using forest plots, and fixed and random effects summary effect estimates obtained. Publication bias was considered using a funnel plot. Results: Twenty two studies were identified, all except two reporting PM10 (24 hour mean) >50 mug. m(-3). Reported effects of PM10 on PEF were widely spread and smaller than those for PM2.5 (fixed effects summary: -0.012 v -0.063 l. min(-1) per mug. m(-3) rise). A similar pattern was evident for symptoms. Random effects models produced larger estimates. Overall, in between-study comparisons, panels of children with diagnosed asthma or pre-existing respiratory symptoms appeared less affected by PM10 levels than those without, and effect estimates were larger where studies were conducted in higher ozone conditions. Larger PM10 effect estimates were obtained from studies using generalised estimating equations to model autocorrelation and where results were derived by pooling subject specific regression coefficients. A funnel plot of PM10 results for PEF was markedly asymmetrical. Conclusions: The majority of identified studies indicate an adverse effect of particulate air pollution that is greater for PM2.5 than PM10. However, results show considerable heterogeneity and there is evidence consistent with publication bias, so limited confidence may be placed on summary estimates of effect. The possibility of interaction between particle and ozone effects merits further investigation, as does variability due to analytical differences that alter the interpretation of final estimates.	Univ Aberdeen, Dept Environm & Occupat Med, Aberdeen AB25 2ZP, Scotland; S Worcestershire Primary Care Trust, Publ Hlth Network, Worcester WR4 9RW, England	Ayres, JG (reprint author), Univ Aberdeen, Dept Environm & Occupat Med, Foresterhill Rd, Aberdeen AB25 2ZP, Scotland.	j.g.ayres@abdn.ac.uk					Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BRUNEKREEF B, 1998, EUR RESPIR REV, V8, P131; Committee on the Medical Effects of Air Pollutants, 1995, NONB PART HLTH; Committee on the Medical Effects of Air Pollutants, 1998, QUANT EFF AIR POLL H; *COMM MED EFF AIR, 1995, PAN EV STUD ASTHM OU, pCH6; Deeks J, 2001, SYSTEMATIC REV HLTH, P285, DOI 10.1002/9780470693926.ch15; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Egger M, 2001, SYSTEMATIC REV HLTH, P211, DOI 10.1002/9780470693926.ch12; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Greenland S., 1998, MODERN EPIDEMIOLOGY, P643; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; HOEK G, 1994, ENVIRON RES, V64, P136, DOI 10.1006/enrs.1994.1012; Jalaludin B, 2000, AUST NZ J PUBL HEAL, V24, P174, DOI 10.1111/j.1467-842X.2000.tb00138.x; Jalaludin BB, 2000, INT J EPIDEMIOL, V29, P549, DOI 10.1093/ije/29.3.549; NAVIDI W, 1999, 86 HLTH EFF I; Neas LM, 1999, EPIDEMIOLOGY, V10, P550, DOI 10.1097/00001648-199909000-00015; Neas LM, 1996, AM J EPIDEMIOL, V143, P797; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111; *NHS CTR REV DISS, 1996, 4 CRD U YORK NHS CTR; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; Peters A, 1996, AM J EPIDEMIOL, V144, P570; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pope CA, 1996, AM J RESP CRIT CARE, V154, pS229; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; Roemer W, 1999, OCCUP ENVIRON MED, V56, P86; ROEMER W, 1993, AM REV RESPIR DIS, V147, P118; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; Roemer W, 2000, EUR RESPIR J, V15, P553, DOI 10.1034/j.1399-3003.2000.15.21.x; Roemer W, 1998, EUR RESPIR REV, V8, P125; ROEMER W, 1998, EUR RESPIR REV, V8, P4; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Scarlett JF, 1996, THORAX, V51, P1109, DOI 10.1136/thx.51.11.1109; Schwartz J, 1996, J EPIDEMIOL COMMUN H, V50, pS3, DOI 10.1136/jech.50.Suppl_1.S3; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; SCHWARTZ J, 1991, ENVIRON HEALTH PERSP, V90, P181, DOI 10.2307/3430866; Segala C, 1998, EUR RESPIR J, V11, P677; Sterne JAC, 2001, SYSTEMATIC REV HLTH, P189, DOI DOI 10.1002/9780470693926.CH11; SUTTON AJ, 1998, HLTH TECHNOLOGY ASS, V2; Tager IB, 2000, ENVIRON HEALTH PERSP, V108, P615, DOI 10.2307/3454397; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Vichit-Vadakan N, 2001, ENVIRON HEALTH PERSP, V109, P381, DOI 10.2307/3434785; Ward DJ, 2002, THORAX, V57, P489, DOI 10.1136/thorax.57.6.489; WHITTEMORE AS, 1980, AM J PUBLIC HEALTH, V70, P687, DOI 10.2105/AJPH.70.7.687	52	77	79	2	15	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	APR 1	2004	61	4							e13	10.1136/oem.2003.007088		12	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	804MK	WOS:000220302600021	15031404	
J	Nave, R; Bethke, TD; van Marle, SP; Zech, K				Nave, R; Bethke, TD; van Marle, SP; Zech, K			Pharmacokinetics of [C-14]ciclesonide after oral and intravenous administration to healthy subjects	CLINICAL PHARMACOKINETICS			English	Review							TOPICAL STEROID CICLESONIDE; INHALED GLUCOCORTICOIDS; AIRWAY RESPONSIVENESS; ASTHMA; BUDESONIDE; RISK; CORTICOSTEROIDS; INHALATION	Background: Ciclesonide is a novel inhaled corticosteroid developed for the treatment of asthma. Objective: To investigate the extent of oral absorption and bioavailability of ciclesonide referenced to an intravenous infusion. This information provides an estimate for the contribution of the swallowed fraction to systemic exposure to ciclesonide after oral inhalation. Methods: In a randomised crossover study, six healthy male subjects (age range 19-40 years) received single doses of 6.9mg (oral administration) and 0.64mg (intravenous administration) of [C-14]ciclesonide, separated by a washout period of at least 14 days. Total radioactivity was determined in whole blood, plasma, urine and faeces. Serum concentrations of ciclesonide and its major metabolite, the pharmacologically active desisobutyryl-ciclesonide (des-CIC), were determined in serum by high-performance liquid chromatography with tandem mass spectrometry detection. Results: After a 10-minute intravenous infusion, the mean half-life for total radioactivity was 45.2 hours. Elimination of des-CIC was fast with a mean elimination half-life of 3.5 hours. After oral administration, the mean half-life for total radioactivity was 27.5 hours. On the basis of a comparison of dose-normalised areas under the curve of total plasma radioactivity versus time, 24.5% of orally administered [C-14]ciclesonide was absorbed. The parent compound ciclesonide was not detected in any of the serum samples after oral administration; serum concentrations of des-CIC were mostly near or below the lower limit of quantification. Thus, systemic bioavailability for des-CIC is <1 % and the absolute bioavailability of ciclesonide is even less than this. [C-14]Ciclesonide showed no retention in red blood cells. The mean cumulative excretion of total radioactivity was almost complete by 120 hours after oral and intravenous administration. Faecal excretion was the predominant route of excretion for total radioactivity after both routes of administration. Single oral and intravenous administration of ciclesonide was well tolerated. Conclusions: Because of an almost complete first-pass metabolism, ciclesonide is undetectable in serum after oral administration. Thus, any ciclesonide swallowed after oral inhalation does not contribute to systemically available ciclesonide or to its active metabolite. Drug-related metabolites are excreted mainly via the faeces, and overall recovery of administered radioactivity is virtually complete after an extended sample collection period.	ALTANA Pharma AG, D-78467 Constance, Germany; Pharma BioRes Grp BV, Zuidlaren, Netherlands	Nave, R (reprint author), ALTANA Pharma AG, Byk Gulden Str 2, D-78467 Constance, Germany.	ruediger.nave@altanapharma.com					BARNES PJ, 1995, NEW ENGL J MED, V332, P868; Barnes PJ, 1993, AM REV RESPIR DIS, V148, P1; Beasley R., 2000, J ALLERGY CLIN IMMUN, V105, P466; BLAKE KV, 2001, PHARMACOTHERAPY, V21; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; FALCOZ C, 1996, BR J CLIN PHARM, V41, P459; HALL M, 2000, XENOBIOTIC METAB D S, V15, P12; Kanniess F, 2001, PULM PHARMACOL THER, V14, P141, DOI 10.1006/pupt.2001.0288; Kumana CR, 2001, J ASTHMA, V38, P161, DOI 10.1081/JAS-100000035; LEECH JA, 1993, AM REV RESPIR DIS, V148, P113; Minto C, 2000, BRIT J CLIN PHARMACO, V50, P116, DOI 10.1046/j.1365-2125.2000.00218.x; Rohatagi S, 2004, J CLIN PHARMACOL, V44, P37, DOI 10.1177/0091270003260334; Rohatagi S, 2003, J CLIN PHARMACOL, V43, P365, DOI 10.1177/0091270002250998; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; Schmidt BMW, 1999, J CLIN PHARMACOL, V39, P1062, DOI 10.1177/00912709922011836; Stirling RG, 2000, BRIT MED BULL, V56, P1037, DOI 10.1258/0007142001903526; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; Weinbrenner A, 2002, J CLIN ENDOCR METAB, V87, P2160, DOI 10.1210/jc.87.5.2160; Woolcock AJ, 2001, MED J AUSTRALIA, V175, P141; Yang K D, 2000, Chang Gung Med J, V23, P641	22	77	80	0	2	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0312-5963			CLIN PHARMACOKINET	Clin. Pharmacokinet.		2004	43	7					479	486		10.2165/00003088-200443070-00004		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	825VK	WOS:000221786400004	15139796	
J	Pietropaoli, AP; Frampton, MW; Hyde, RW; Morrow, PE; Oberdorster, G; Cox, C; Speers, DM; Frasier, LM; Chalupa, DC; Huang, LS; Utell, MJ				Pietropaoli, AP; Frampton, MW; Hyde, RW; Morrow, PE; Oberdorster, G; Cox, C; Speers, DM; Frasier, LM; Chalupa, DC; Huang, LS; Utell, MJ			Pulmonary function, diffusing capacity, and inflammation in healthy and asthmatic subjects exposed to ultrafine particles	INHALATION TOXICOLOGY			English	Article							PARTICULATE AIR-POLLUTION; AMBIENT FINE PARTICLES; EMERGENCY-ROOM VISITS; NASAL NITRIC-OXIDE; OXIDATIVE STRESS; ENVIRONMENTAL AEROSOLS; ADHESION MOLECULES; HUMAN VOLUNTEERS; DIESEL EXHAUST; TERM EXPOSURE	Particulate air pollution is associated with asthma exacerbations and increased morbidity and mortality from respiratory causes. Ultrafine particles (particles less than 0.1 mum in diameter) may contribute to these adverse effects because they have a higher predicted pulmonary deposition, greater potential to induce pulmonary inflammation, larger surface area, and enhanced oxidant capacity when compared with larger particles on a mass basis. We hypothesized that ultrafine particle exposure Would induce airway inflammation in susceptible humans. This hypothesis was tested in a series of randomized, double-blind studies by exposing healthy subjects and mild asthmatic subjects to carbon ultrafine particles versus filtered air. Both exposures were delivered via a mouthpiece system during rest and moderate exercise. Healthy subjects were exposed to particle concentrations of 10, 25, and 50 mug/m(3), while asthmatics were exposed to 10 mug/m(3). Lung function and airway inflammation were assessed by symptom scores, pulmonary function tests, and airway nitric oxide parameters. Airway inflammatory cells were measured via induced sputum analysis in several of the protocols. There were no differences in any of these measurements in normal or asthmatic subjects when exposed to ultrafine particles at concentrations of 10 or 25 mug/m(3). However, exposing 16 normal subjects to the higher concentration of 50 mug/m(3) caused a reduction in maximal midexpiratory flow rate (-4.34 +/- 1.78% [ultrafine particles] vs. +1.08 +/- 1.86% [air], p =.042) and carbon monoxide diffusing capacity (-1.76 +/- 0.66 ml/min/mm Hg [ultrafine particles] vs. -0.18 +/- 0.41 ml/min/mm Hg [air], p =.040) at 21 h after exposure. There were no consistent differences in symptoms, induced sputum, or exhaled nitric oxide parameters in any of these studies. These results suggest that exposure to carbon ultrafine particles results in mild small-airways dysfunction together with impaired alveolar gas exchange in normal subjects. These effects do not appear related to airway inflammation. Additional studies are required to confirm these findings in normal subjects, compare them with additional susceptible patient populations, and determine their pathophysiologic mechanisms.	Univ Rochester, Med Ctr, Sch Med & Dent, Dept Med,Pulm & Crit Care Med Unit, Rochester, NY 14642 USA; Univ Rochester, Sch Med & Dent, Dept Environm Med, Rochester, NY USA; NIH, Dept Biostat, Bethesda, MD 20892 USA; Univ Rochester, Sch Med & Dent, Dept Biostat, Rochester, NY USA	Pietropaoli, AP (reprint author), Univ Rochester, Med Ctr, Sch Med & Dent, Dept Med,Pulm & Crit Care Med Unit, 601 Elmwood Ave,Box 692, Rochester, NY 14642 USA.	Anthony_Pietropaoli@urmc.rochester.edu			NCRR NIH HHS [RR0044]; NIEHS NIH HHS [P30 ES01247, R01 ES11853]		Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Batalha JRF, 2002, ENVIRON HEALTH PERSP, V110, P1191; BRAND P, 1991, ATMOS ENVIRON A-GEN, V25, P581, DOI 10.1016/0960-1686(91)90055-C; BRAND P, 1992, ATMOS ENVIRON A-GEN, V26, P2451, DOI 10.1016/0960-1686(92)90375-U; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; CHALUPA DC, 2002, INIS MONOGRAPHS, P242; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Elder ACP, 2000, INHAL TOXICOL, V12, P85, DOI 10.1080/089583700196419; Ghio AJ, 1999, INHAL TOXICOL, V11, P37, DOI 10.1080/089583799197258; Ghio AJ, 2000, AM J RESP CRIT CARE, V162, P981; Girgis RE, 2002, AM J RESP CRIT CARE, V165, P1587, DOI 10.1164/rccm.2104003; Gong H, 2003, INHAL TOXICOL, V15, P305, DOI 10.1080/08958370390168300; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; Holz O, 1998, THORAX, V53, P83; Huang YCT, 2003, INHAL TOXICOL, V15, P327, DOI 10.1080/08958370390187435; Hyde RW, 1997, J APPL PHYSIOL, V82, P1290; ICRP, 1994, ANN ICRP, V24, P1, DOI DOI 10.1016/0146-6453(94)90004-3; Jones B, 1989, DESIGN ANAL CROSS OV; Jorres RA, 2000, EUR RESPIR J, V16, P555, DOI 10.1034/j.1399-3003.2000.016003555.x; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KITTELSON DB, 2001, 200112 MNDOT; Lee YC, 1997, J ASTHMA, V34, P405, DOI 10.3109/02770909709055382; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li N, 2000, J IMMUNOL, V165, P3393; Li XY, 1999, INHAL TOXICOL, V11, P709; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; MONTEFORT S, 1994, AM J RESP CRIT CARE, V149, P1149; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; MORRIS RJ, 1980, J BIOL CHEM, V255, P8050; National Research Council, 1998, RES PRIOR AIRB PART; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Nightingale JA, 1998, THORAX, V53, P87; National Institutes of Health, 1997, NIH PUBL; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Oberdorster G., 2000, 96 HLTH EFF I; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4; Perillo IB, 2001, J APPL PHYSIOL, V91, P1931; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Pietropaoli AP, 1999, J APPL PHYSIOL, V87, P1532; Pizzichini E, 1996, EUR RESPIR J, V9, P1174, DOI 10.1183/09031936.96.09061174; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; ROUGHTON FJW, 1957, J APPL PHYSIOL, V11, P290; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Searle S. R., 1992, VARIANCE COMPONENTS; Shin HW, 2002, AM J RESP CRIT CARE, V165, P349; Silkoff PE, 2000, AM J RESP CRIT CARE, V161, P1218; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; STEARNS RC, 1994, ICEM, V13, P763; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; TSOUKIAS NM, 1998, J APPL PHYSIOL, V85, P658; U. S. Environmental Protection Agency, 1996, AIR QUAL CRIT PART M; *US EPA, 1998, EX SUMM PART MATT RE; UTELL MJ, 1998, INHAL TOXICOL, V10, P625; WALLENSTEIN S, 1977, BIOMETRICS, V33, P261, DOI 10.2307/2529321; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032	57	77	82	3	12	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	0895-8378			INHAL TOXICOL	Inhal. Toxicol.		2004	16			1			59	72		10.1080/08958370490443079		14	Toxicology	Toxicology	837CQ	WOS:000222605700007	15204794	
J	Borish, L				Borish, L			Allergic rhinitis: Systemic inflammation and implications for management	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic rhinitis; asthma; chronic hyperplastic eosinophilic sinusitis; eosinophils; leukotrienes; cytokines; inflammation	PLACEBO-CONTROLLED TRIAL; CHRONIC HYPERPLASTIC SINUSITIS; ADHESION MOLECULE EXPRESSION; RECEPTOR-MEDIATED MECHANISM; CHRONIC MAXILLARY SINUSITIS; MESSENGER-RNA EXPRESSION; CHRONIC-FATIGUE-SYNDROME; LATE ASTHMATIC RESPONSE; BONE-MARROW; DOUBLE-BLIND	Allergic rhinitis triggers a systemic increase of inflammation. Within minutes of allergen exposure, immune cells release histamine, proteases, cysteinyl leukotrienes, prostaglandins, and cytokines. Some produce the early symptoms, while others augment the production, systemic circulation, and subsequent infiltration of the nasal mucosa with inflammatory cells that sustain the symptoms. Systemic circulation of inflammatory cells permits their infiltration into other tissues where chemoattractant and adhesion molecules already exist. Consequently, allergic rhinitis is linked to comorbid conditions: asthma, chronic hyperplastic eosinophilic sinusitis, nasal pollyposis, and serous otitis media. Effective therapy should be directed at underlying inflammation and its systemic manifestations. It should improve the rhinitis and the comorbid conditions. Antihistamines relieve early symptoms by blocking basophil- and mast cell-generated histamine, but they do not significantly influence the pro-inflammatory loop. They are often little better than placebo. Oral corticosteroids provide the systemic anti-inflammatory efficacy, but their toxicity precludes such an approach. Intranasal corticosteroids effectively target the local inflammatory processes of rhinitis, reducing local inflammatory cells within the nares, but they do not directly access tissues involved in the comorbid conditions. Leukotriene modifiers have both systemic anti-inflammatory effects and an acceptable safety profile.	Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA	Borish, L (reprint author), Univ Virginia, Hlth Syst, Asthma & Allerg Dis Ctr, Beirne Carter Ctr Immunol Res, MR-4 Bldg,Room 5041,Lane Rd, Charlottesville, VA 22908 USA.						Abdelaziz MM, 1998, J ALLERGY CLIN IMMUN, V101, P410; Adams PF, 1999, VITAL HLTH STAT, V10, P200; Adams RJ, 2002, J ALLERGY CLIN IMMUN, V109, P636, DOI 10.1067/mai.2002.123237; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Amin K, 1999, INFLAMM RES, V48, P626, DOI 10.1007/s000110050513; ARRIGHI HM, 1995, J ALLERGY CLIN IMMUN, V95, P192; Bachert C, 1997, J ALLERGY CLIN IMMUN, V99, P837, DOI 10.1016/S0091-6749(97)80019-X; Baraniuk JN, 1998, ANN ALLERG ASTHMA IM, V81, P359; Baraniuk JN, 1998, AM J RHINOL, V12, P435, DOI 10.2500/105065898780707964; BARDIN PG, 1990, J ALLERGY CLIN IMMUN, V86, P82, DOI 10.1016/S0091-6749(05)80126-5; Baroody FM, 1999, J APPL PHYSIOL, V86, P659; Baroody FM, 2000, J ALLERGY CLIN IMMUN, V105, pS70, DOI 10.1016/S0091-6749(00)90647-X; Baroody FM, 2002, J ALLERGY CLIN IMMUN, V109, pS84, DOI 10.1016/S0091-6749(02)81352-5; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406; Bensch GW, 2002, ANN ALLERG ASTHMA IM, V88, P457; Bernstein DI, 1997, ANN ALLERG ASTHMA IM, V79, P443; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bjornsdottir US, 1999, ALLERGY, V54, P55, DOI 10.1111/j.1398-9995.1999.tb04389.x; Borish L, 2002, J ALLERGY CLIN IMMUN, V109, P606, DOI 10.1067/mai.2002.123024; Borish L, 1998, J ALLERGY CLIN IMMUN, V102, P222, DOI 10.1016/S0091-6749(98)70090-9; BORTS MR, 1989, J ALLERGY CLIN IMMUN, V83, P302; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Boyce JA, 2003, J ALLERGY CLIN IMMUN, V111, P24, DOI 10.1067/mai.2003.60; Braccioni F, 2002, J ALLERGY CLIN IMMUN, V110, P96, DOI 10.1067/mai.2002.125000; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Caffarelli C, 1996, OTOLARYNG HEAD NECK, V115, P454, DOI 10.1016/S0194-5998(96)70083-9; Cameron L, 2000, J ALLERGY CLIN IMMUN, V106, P46; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; CONNELL JT, 1968, J ALLERGY, V41, P123, DOI 10.1016/0021-8707(68)90053-1; CORREN J, 1992, J ALLERGY CLIN IMMUN, V90, P250, DOI 10.1016/0091-6749(92)90079-H; CORREN J, 1992, J ALLERGY CLIN IMMUN, V89, P611, DOI 10.1016/0091-6749(92)90329-Z; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; Cuffel B, 1999, PSYCHOSOMATICS, V40, P491; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187; DEMOLY P, 1994, J ALLERGY CLIN IMMUN, V94, P95, DOI 10.1016/0091-6749(94)90076-0; Denburg Judah A., 2000, Journal of Allergy and Clinical Immunology, V106, pS242; DONNELLY AL, 1995, AM J RESP CRIT CARE, V151, P1734; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404; Emanuel IA, 2000, OTOLARYNG HEAD NECK, V123, P687, DOI 10.1067/mhn.2000.110961; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; FINOTTO S, 1994, J IMMUNOL, V153, P2278; Flood-Page PT, 2003, AM J RESP CRIT CARE, V167, P199, DOI 10.1164/rccm.200208-789OC; Fontanari P, 1996, J APPL PHYSIOL, V81, P1739; Foresi A, 1996, J ALLERGY CLIN IMMUN, V98, P274, DOI 10.1016/S0091-6749(96)70150-1; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gleeson K, 1997, CHEST, V111, P1266, DOI 10.1378/chest.111.5.1266; Golden S, 2000, ANN ALLERG ASTHMA IM, V85, P53; GRIFFIN MP, 1982, J ALLERGY CLIN IMMUN, V69, P354, DOI 10.1016/0091-6749(82)90145-2; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1998, CLIN EXP ALLERGY, V28, P1145; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Howarth PH, 1997, ALLERGY, V52, P12; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Kaliner MA, 1997, J ALLERGY CLIN IMMUN, V99, pS829, DOI 10.1016/S0091-6749(97)70041-1; Karaman O, 2001, Allergol Immunopathol (Madr), V29, P55; KEMP JP, 1985, ANN ALLERGY, V54, P502; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; KNAPP HR, 1990, NEW ENGL J MED, V323, P1745, DOI 10.1056/NEJM199012203232506; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LEDFORD DK, 1998, J RESP DIS, V19, P576; Lee E, 2000, AM J RESP CRIT CARE, V161, P1881; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; MA X, 2000, AM J RESP CRIT CARE, V161, pA325; Marshall PS, 2000, ANN ALLERG ASTHMA IM, V84, P403; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683; Murris-Espin M, 1998, ANN ALLERG ASTHMA IM, V80, P399; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Nielsen LP, 2001, DRUGS, V61, P1563, DOI 10.2165/00003495-200161110-00004; Nouri-Aria KT, 2000, CLIN EXP ALLERGY, V30, P1709, DOI 10.1046/j.1365-2222.2000.00998.x; Numata T, 1999, ANN OTO RHINOL LARYN, V108, P467; OKUDA M, 1988, ANN ALLERGY, V60, P537; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472; Parikh A, 2001, RHINOLOGY, V39, P75; Parnes S M, 2000, Ear Nose Throat J, V79, P18; Pedersen KE, 1997, J PHARMACOL EXP THER, V281, P655; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; Peters EJ, 2003, ANN ALLERG ASTHMA IM, V90, P316; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; RASP G, 1994, CLIN EXP ALLERGY, V24, P1151; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; Sarti W, 1995, Sao Paulo Med J, V113, P968; SEBALDT RJ, 1990, P NATL ACAD SCI USA, V87, P6974, DOI 10.1073/pnas.87.18.6974; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, P55; Smurthwaite L, 2001, EUR J IMMUNOL, V31, P3422, DOI 10.1002/1521-4141(200112)31:12<3422::AID-IMMU3422>3.0.CO;2-T; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; SPADA CS, 1986, PROSTAGLANDINS, V31, P795, DOI 10.1016/0090-6980(86)90181-4; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Thio BJ, 2000, THORAX, V55, P826, DOI 10.1136/thorax.55.10.826; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; Togias A, 2002, J ALLERGY CLIN IMMUN, V109, pS2362; TOGIAS AG, 1989, ANN ALLERGY, V63, P465; VARNEY VA, 1991, BRIT MED J, V302, P265; VIEGAS M, 1987, BRIT MED J, V294, P414; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; Weiner JM, 1998, BRIT MED J, V317, P1624; WELSH PW, 1987, MAYO CLIN PROC, V62, P125; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; Wood LJ, 1998, AM J RESP CELL MOL, V18, P759; Wood LJ, 2002, AM J RESP CRIT CARE, V166, P883, DOI 10.1164/rccm.2108015; Wood Lorna J., 1998, American Journal of Respiratory and Critical Care Medicine, V157, P99; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Young MC, 1998, ALLERGY ASTHMA PROC, V19, P211, DOI 10.2500/108854198778557890	131	77	86	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2003	112	6					1021	1031		10.1016/j.jaci.2003.90.015		11	Allergy; Immunology	Allergy; Immunology	752HC	WOS:000187154200001	14657851	
J	Martin, JG; Campbell, HR; Iijima, H; Gautrin, D; Malo, JL; Eidelman, DH; Hamid, Q; Maghni, K				Martin, JG; Campbell, HR; Iijima, H; Gautrin, D; Malo, JL; Eidelman, DH; Hamid, Q; Maghni, K			Chlorine-induced injury to the airways in mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						chlorine; inducible nitric oxide synthase; nitric oxide; oxidative injury	EXHALED NITRIC-OXIDE; ACUTE LUNG INJURY; LONGITUDINAL DISTRIBUTION; DYSFUNCTION SYNDROME; PROTEIN NITRATION; PERSISTENT ASTHMA; OZONE; EXPOSURE; INFLAMMATION; RATS	Exposure to chlorine gas (Cl-2) causes occupational asthma that we hypothesized occurs through the induction of airway inflammation and airway hyperresponsiveness by oxidative damage. Respiratory mechanics and airway responsiveness to methacholine were assessed in A/J mice 24 hours after a 5-minute exposure to 100, 200, 400, or 800 ppm Cl-2 and 2 and 7 days after inhalation of 400 ppm Cl-2. Airway responsiveness was higher 24 hours after 400 and 800 ppm Cl-2. Responsiveness after inhalation of 400 ppm Cl-2 returned to normal by 2 days but was again elevated at 7 days. Airway epithelial loss, patchy alveolar damage, proteinaceous exudates, and inflammatory cells within alveolar walls were observed in animals exposed to 800 ppm Cl-2. Macrophages, granulocytes, epithelial cells, and nitrate/nitrite levels increased in lung lavage fluid. Increased inducible nitric oxide synthase expression and oxidation of lung proteins were observed. Epithelial cells and alveolar macrophages from mice exposed to 800 ppm Cl-2 stained for 3-nitrotyrosine residues. Inhibition of inducible nitric oxide synthase with 1400W (1 mg/kg) abrogated the Cl-2-induced changes in responsiveness. We conclude that chlorine exposure causes functional and pathological changes in the airways associated with oxidative stress. Inducible nitric oxide synthase is involved in the induction of changes in responsiveness to methacholine.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada; Univ Montreal, Hop Sacre Coeur, Div Resp, Montreal, PQ, Canada	Martin, JG (reprint author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain, Montreal, PQ H2X 2P2, Canada.				NIOSH CDC HHS [1R01 OH 04058-01]		ADELSON L, 1971, AM J CLIN PATHOL, V56, P430; BARROW CS, 1977, ARCH ENVIRON HEALTH, V32, P68; Bates JHT, 1997, J APPL PHYSIOL, V82, P55; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; CANNON WC, 1983, AM IND HYG ASSOC J, V44, P923, DOI 10.1202/0002-8894(1983)044<0923:TFPCAI>2.3.CO;2; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; CHESTER EH, 1977, CHEST, V72, P247, DOI 10.1378/chest.72.2.247; Demnati R., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P15; Demnati R, 1998, EUR RESPIR J, V11, P922, DOI 10.1183/09031936.98.11040922; DRISCOLL KE, 1993, TOXICOL APPL PHARM, V119, P306, DOI 10.1006/taap.1993.1074; Duguet A, 2001, AM J RESP CRIT CARE, V164, P1119; Eiserich JP, 1996, J BIOL CHEM, V271, P19199; Garvey EP, 1997, J BIOL CHEM, V272, P4959; Gautrin D, 1999, AM J RESP CRIT CARE, V160, P1232; Greenfield RA, 2002, AM J MED SCI, V323, P350, DOI 10.1097/00000441-200206000-00007; Henneberger PK, 1996, AM J RESP CRIT CARE, V153, P225; Iijima H, 2001, AM J RESP CRIT CARE, V163, P1233; Inoue H, 2000, AM J RESP CRIT CARE, V161, P249; Jia YL, 1996, J APPL PHYSIOL, V80, P404; Kenyon NJ, 2002, AM J PHYSIOL-LUNG C, V282, pL540; Lemiere C, 1997, EUR RESPIR J, V10, P241, DOI 10.1183/09031936.97.10010241; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; LI ZY, 1992, AM J PHYSIOL, V263, pL723; McGrogan I, 1998, AM J PHYSIOL-LUNG C, V274, pL220; Menaouar A, 1997, EUR RESPIR J, V10, P1100, DOI 10.1183/09031936.97.10051100; Nightingale JA, 1999, THORAX, V54, P1061; Nodelman V, 1999, J APPL PHYSIOL, V86, P1984; Nodelman V, 1999, J APPL PHYSIOL, V87, P2073; Olin AC, 1999, EUR RESPIR J, V14, P828, DOI 10.1034/j.1399-3003.1999.14d18.x; Schonhofer B, 1996, RESPIRATION, V63, P155; SCHUESSLER TF, 1995, IEEE T BIO-MED ENG, V42, P860, DOI 10.1109/10.412653; SHACTER E, 1994, FREE RADICAL BIO MED, V17, P429, DOI 10.1016/0891-5849(94)90169-4; STEVENS WHM, 1996, AIRWAYS SMOOTH MUSCL, P95; Tsuji C, 2000, AM J PHYSIOL-LUNG C, V278, pL719; vanderVliet A, 1997, J BIOL CHEM, V272, P7617; Wechsler ME, 2000, AM J RESP CRIT CARE, V162, P2043	36	77	79	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 1	2003	168	5					568	574		10.1164/rccm.200201-021OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	716QC	WOS:000185039000012	12724121	
J	Remes, ST; Iivanainen, K; Koskela, H; Pekkanen, J				Remes, ST; Iivanainen, K; Koskela, H; Pekkanen, J			Which factors explain the lower prevalence of atopy amongst farmers' children?	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; children; epidemiology; farm; risk factors; skin prick test	FATTY-ACIDS; HAY-FEVER; ALLERGIC SENSITIZATION; BIRTH COHORT; ASTHMA; CHILDHOOD; ENDOTOXIN; EXPOSURE; ENVIRONMENT; COMMUNITY	Background: The inverse association between farming and atopy in children has been attributed to microbial exposure, especially through livestock. Very little is known about other potential explanatory factors. Objective: To explore potential differences in lifestyle and environmental factors between farmer and non-farmer families, and whether these factors could explain the association between farming and childhood atopy. Methods: A cross-sectional study, including 366 farmers' and 344 non-farmers' children in eastern Finland. Information regarding exposure and background characteristics was gathered by a written questionnaire. Atopy was defined as having one or more positive skin prick test reactions (> 3 mm) against the six common aeroallergens. Results: Regardless of the current farming type, atopy was less frequent among the farmers' children than the non-farmers' children (aOR 0.56, 95% CI 0.40-0.78). Remarkable differences were seen in many lifestyle factors (including diet) between the farmer and non-farmer families, but only a few of the explored factors were associated with atopy. The frequency of current livestock contacts seemed to have an inverse, dose-dependent association with atopy (aOR 0.46, 95% CI 0.22-0.97 for daily vs. no contact). Having lived on a dairy farm in infancy (aOR 0.51, 95% CI 0.28-0.93), or having had cats or dogs in infancy (aOR 0.60, 95% CI 0.42-0.85), decreased the risk of atopy at school age. The inverse association between farming and atopy was not explained by the sociodemographic factors, or by differences in conventional risk factors of atopy. Animal contacts explained partially, but not completely, the association. Conclusion Higher frequency of animal contacts is one factor, but probably not the only one, explaining the inverse association of farming and atopy in children. The importance of early life exposures may have recently been over-emphasized, and current exposures discounted, when studying the risk factors of childhood atopy.	Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio 70701, Finland; Kuopio Univ Hosp, Dept Pediat, SF-70210 Kuopio, Finland; Kuopio Univ Hosp, Dept Resp Med, SF-70210 Kuopio, Finland	Remes, ST (reprint author), Natl Publ Hlth Inst, Environm Epidemiol Unit, POB 95, Kuopio 70701, Finland.						Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Bischof W, 2000, P HLTH BUILDINGS, V1, P251; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fogarty A, 2000, LANCET, V356, P1573, DOI 10.1016/S0140-6736(00)03132-9; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Hosmer DW, 1989, APPL LOGISTIC REGRES; Kankaanpaa P, 1999, ANN MED, V31, P282, DOI 10.3109/07853899908995891; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; PASANEN AL, 1989, AM IND HYG ASSOC J, V50, P631, DOI 10.1202/0002-8894(1989)050<0631:FCFFWI>2.0.CO;2; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; [Anonymous], 2001, STAT STAT SOFTW REL; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Vartiainen E, 2000, INT J EPIDEMIOL, V29, P49, DOI 10.1093/ije/29.1.49; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Willet WC, 1998, MONOGRAPHS EPIDEMIOL, V30	29	77	77	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2003	33	4					427	434		10.1046/j.1365-2222.2003.01566.x		8	Allergy; Immunology	Allergy; Immunology	665BX	WOS:000182100700005	12680856	
J	Talbot-Smith, A; Fritschi, L; Divitini, ML; Mallon, DFJ; Knuiman, MW				Talbot-Smith, A; Fritschi, L; Divitini, ML; Mallon, DFJ; Knuiman, MW			Allergy, atopy, and cancer: A prospective study of the 1981 Busselton cohort	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						allergy and immunology; asthma; hypersensitivity; immediate; neoplasms; skin tests	COLORECTAL-CANCER; POPULATION; ASTHMA; RISK; PREVALENCE; MORTALITY; DISEASES	The associations among certain allergic disorders, atopy upon skin-prick testing, and specific cancers were evaluated in a prospective study. Information regarding history of asthma and hay fever was collected by questionnaire from 3,308 cancer-free participants in the 1981 Busselton Health Survey. A subset of 1,005 participants also underwent skin-prick testing. The cohort was followed for a new diagnosis of cancer or death until the end of 1999. Cox proportional hazards regression analysis was used to estimate adjusted hazard ratios (relative risks) for breast, prostate, colorectal, lung, and hematologic cancers and melanoma. Having a skin reaction to house dust mites nearly tripled the risk of prostate cancer (relative risk=2.90, 95% confidence interval: 1.26, 6.68). History of asthma and hay fever were associated with a trend toward a reduced risk of colorectal cancer and increased risk of leukemia, but these results were not statistically significant. Hay fever was associated with melanoma risk in men but not in women. No association was found between breast and lung cancers and allergic disorders or atopy.	Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia; Fremantle Hosp, Dept Immunol, Perth, WA, Australia; Princess Margaret Hosp, Dept Immunol, Perth, WA, Australia	Fritschi, L (reprint author), Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia.		Knuiman, Matthew/I-5549-2013; Fritschi, Lin /K-2096-2012	Fritschi, Lin /0000-0002-7692-3560			ALDERSON M, 1974, LANCET, V2, P1475; ALLEGRA J, 1976, CANCER RES, V36, P3225; *AUSTR BUR STAT, 1991, 43730 AUSTR BUR STAT; BERNARD SM, 1984, LEUKEMIA RES, V8, P681, DOI 10.1016/0145-2126(84)90016-X; BORISH L, 1998, ALLERGY PRINCIPLES P, P108; *BUSS POP MED RES, 2002, BUSS HLTH STUD; Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5; COCKCROFT DW, 1979, ANN ALLERGY, V43, P345; ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x; FISHERMAN E, 1960, J ALLERGY, V1, P74; FORD R, 1978, ANN ALLERGY, V49, P240; Gabriel R, 1972, Br J Clin Pract, V26, P202; GALLAGHER RP, 1983, BRIT J CANCER, V48, P853, DOI 10.1038/bjc.1983.277; HUGHES WF, 1979, ANN ALLERGY, V43, P163; JAMES A, 1992, AM REV RESPIR DIS, V146, P895; JOHNSON K, 1966, LANCET, V86, P5; KALLEN B, 1993, EUR RESPIR J, V6, P694; Kaplan DH, 1998, P NATL ACAD SCI USA, V95, P7556, DOI 10.1073/pnas.95.13.7556; Little J, 1999, EUR J CANCER PREV, V8, pS61; LOGAN J, 1953, N Z Med J, V52, P210; MACKAY WD, 1966, BRIT J CANCER, V20, P434, DOI 10.1038/bjc.1966.52; MCDUFFIE HH, 1991, CHEST, V99, P404, DOI 10.1378/chest.99.2.404; MCWORTER WP, 1988, CANCER, V62, P451; Mercader M, 2001, P NATL ACAD SCI USA, V98, P14565, DOI 10.1073/pnas.251140998; MILLS PK, 1992, AM J EPIDEMIOL, V136, P287; Naito Y, 1998, CANCER RES, V58, P3491; PENN I, 1984, TRANSPLANT P, V16, P492; PEPYS J, 1975, CLIN ASPECTS IMMUNOL, P75; RIDDELL SR, 1995, ANNU REV IMMUNOL, V13, P545; ROBINETTE CD, 1978, J CHRON DIS, V31, P619, DOI 10.1016/0021-9681(78)90022-X; ROZENCWAIG R, 1982, POSTGRAD MED, V72, P42; SEVERSON RK, 1989, J CLIN EPIDEMIOL, V42, P995, DOI 10.1016/0895-4356(89)90165-0; URE D M J, 1969, Scottish Medical Journal, V14, P51; VENA JE, 1985, AM J EPIDEMIOL, V122, P66; VESTERINEN E, 1993, INT J EPIDEMIOL, V22, P976, DOI 10.1093/ije/22.6.976; WOOLCOCK AJ, 1987, THORAX, V42, P361, DOI 10.1136/thx.42.5.361	36	77	79	1	1	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	APR 1	2003	157	7					606	612		10.1093/aje/kwg020		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	665QF	WOS:000182131600005	12672680	
J	Lanari, M; Giovannini, M; Giuffre, L; Marini, A; Rondini, G; Rossi, GA; Merolla, R; Zuccotti, GV; Salvioli, GP				Lanari, M; Giovannini, M; Giuffre, L; Marini, A; Rondini, G; Rossi, GA; Merolla, R; Zuccotti, GV; Salvioli, GP		Investigators RADAR Study Grp	Prevalence of respiratory syncytial virus infection in Italian infants hospitalized for acute lower respiratory tract infections, and association between respiratory syncytial virus infection risk factors and disease severity	PEDIATRIC PULMONOLOGY			English	Article						respiratory syncytial virus; bronchiolitis; epidemiology; wheezing; pneumonia; passive tobacco smoke; gestational age; birth order; birth weight	INVESTIGATORS COLLABORATIVE NETWORK; CANADIAN CHILDREN; VIRAL-INFECTION; BRONCHIOLITIS; REHOSPITALIZATION; MANAGEMENT; GESTATION; ILLNESSES; SMOKING; ALLERGY	This study was designed to collect data on the prevalence of respiratory syncytial virus (RSV) infection in Italy in infants hospitalized for lower respiratory tract infections, and to evaluate which of the recognized risk factors might be associated with disease severity. Thirty-two centers throughout Italy participated in the study, Over a 6-month period (November 1, 1999 to April 30, 2000), we evaluated all children < 2 years of age hospitalized for lower respiratory tract infections. All subjects were tested for RSV within 24 hr of hospitalization by using an immuno-enzymatic diagnostic test (Abbott Testpack, RSV). Logistic regression was used to identify the factors that might be associated with more severe disease or could increase the likelihood of RSV positivity in hospitalized infants. Out of a total of 1,232 children enrolled, 40.6% were found to be RSV-posftive (RSV+). The peak of the RSV epidemic occurred in February, while the lowest prevalence of RSV positivity was seen in November (P < 0.05). A high proportion of study subjects had low birth weight and low gestational age. The clinical diagnosis at hospitalization was bronchiolitis in 66.7%, pneumonia in 15.3%, and wheezy bronchitis in 18.1%. In the bronchiolitis group, a higher prevalence of RSV+ was found in patients with gestational age less than or equal to 33 weeks or 34-35 weeks, as compared to those with agestational age > 36 weeks (P < 0.04). No differences were found in the proportion of RSV+ patients in the three gestational age subgroups with pneumonia and wheezy bronchitis (P > 0.05, each comparison). Independent of the clinical diagnosis at admission, RSV infection was associated with more severe respiratory impairment. Environmental smoke exposure was higher in subjects with bronchiolitis than in those with wheezy bronchitis (P < 0.04), and RSV 4 was positively related with the birth order (P < 0.05). The presence of older siblings and birth order plays an important role in RSV infection. The collected data show that, in Italy, RSV is an important cause of lower respiratory tractinfection in infants. Gestational age, birth order, birth weight, and exposure to tobacco smoke affected the prevalence and severity of RSV-related lower respiratory tract disease. (C) Wiley-Liss, Inc.	Univ Bologna, Policlin S Orsola, Bologna, Italy; Univ Milan, Osped San Raffaele, I-20127 Milan, Italy; Univ Palermo, Ist Materno Infantile, Palermo, Italy; Univ Milan, Milan, Italy; Univ Pavia, Policlin San Matteo, I-27100 Pavia, Italy; IRCCS G Gaslini Genova, UO Pneumol, Genoa, Italy; Abbott SpA, Direzone Med, Dept Med, I-04010 Campoverde, LT, Italy	Merolla, R (reprint author), Abbott SpA, Direzone Med, Dept Med, Via Pontina Km 52, I-04010 Campoverde, LT, Italy.						Adler A, 2001, PEDIATR PULM, V32, P418, DOI 10.1002/ppul.1153; ANDERSON LJ, 1988, PEDIATRICS, V82, P300; Behrendt CE, 1998, EUR J PEDIATR, V157, P215, DOI 10.1007/s004310050798; Carbonell-Estrany X, 2000, PEDIATR INFECT DIS J, V19, P592, DOI 10.1097/00006454-200007000-00002; CUNNINGHAM CK, 1991, PEDIATRICS, V88, P527; De Boeck K, 1996, MONALDI ARCH CHEST D, V51, P210; DESIERRA TM, 1993, J PEDIATR-US, V122, P787, DOI 10.1016/S0022-3476(06)80027-2; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543; GLEZEN WP, 1981, J PEDIATR-US, V98, P708; GROOTHUIS JR, 1988, PEDIATRICS, V82, P199; HALL CB, 1979, NEW ENGL J MED, V300, P393, DOI 10.1056/NEJM197902223000803; HALL CB, 1990, J INFECT DIS, V162, P1283; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; HEILMAN CA, 1990, J INFECT DIS, V161, P402; HEMMING VG, 1985, J INFECT DIS, V152, P1083; HEMMING VG, 1988, PEDIAT INFECT DIS S, V7, P103; HOLBERG CJ, 1991, AM J EPIDEMIOL, V133, P1135; KIM HW, 1973, AM J EPIDEMIOL, V98, P216; Langley JM, 1997, PEDIATRICS, V100, P943, DOI 10.1542/peds.100.6.943; Langley JM, 1997, J PEDIATR-US, V131, P113, DOI 10.1016/S0022-3476(97)70133-1; Law B, 1998, Paediatr Child Health, V3, P402; LAW BJ, 1993, PEDIATR INFECT DIS J, V12, P659, DOI 10.1097/00006454-199308000-00007; MACDONALD NE, 1982, NEW ENGL J MED, V307, P397, DOI 10.1056/NEJM198208123070702; MCCONNOCHIE KM, 1989, PEDIATR PULM, V6, P138, DOI 10.1002/ppul.1950060303; Noble V, 1997, ARCH DIS CHILD, V76, P315; Null D, 1998, PEDIATRICS, V102, P531; NWANKWO MU, 1988, TROP GEOGR MED, V40, P309; OLGIVIE MM, 1981, J MED VIROL, V7, P263; PRINCE GA, 1985, J VIROL, V55, P517; Ruuskanen O, 1993, Curr Probl Pediatr, V23, P50, DOI 10.1016/0045-9380(93)90003-U; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Societa Italiana di Neonatologia, 2000, RIV ITAL PED, V26, P379; SUNG RYT, 1987, J INFECT DIS, V156, P527; TANTIVANICH S, 1984, Southeast Asian Journal of Tropical Medicine and Public Health, V15, P63; WANG EEL, 1995, J PEDIATR-US, V126, P212, DOI 10.1016/S0022-3476(95)70547-3; Wang SZ, 1998, CLIN EXP ALLERGY, V28, P927; WRIGHT AL, 1991, J PEDIATR-US, V118, P207, DOI 10.1016/S0022-3476(05)80484-6	38	77	85	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	JUN	2002	33	6					458	465		10.1002/ppul.10052		8	Pediatrics; Respiratory System	Pediatrics; Respiratory System	555MJ	WOS:000175797600009	12001280	
J	Behrendt, H; Beckert, WM				Behrendt, H; Beckert, WM			Localization, release and bioavailability of pollen allergens: the influence of environmental factors	CURRENT OPINION IN IMMUNOLOGY			English	Review							PHLEUM-PRATENSE POLLEN; GRASS-POLLEN; AIR-POLLUTION; MAJOR ALLERGENS; LOLIUM-PERENNE; ELECTRON-MICROSCOPY; WALL PROTEINS; ASTHMA; PARTICLES; AEROSOL	Allergens are integral constituents of plants or animals and their normal functions and localization are being characterized. To trigger responses in humans, allergens must become bioavailable and the role of air pollutants - for example diesel-exhaust particles - in this process is causing concern. Finally, the fact that some pollen releases eicosanoid-like proinflammatory mediators may have wide implications.	Neuherberg Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, D-80802 Munich, Germany; Res Ctr Borstel, D-23845 Borstel, Germany	Behrendt, H (reprint author), Neuherberg Tech Univ Munich, GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy, Biedersteiner Str 29, D-80802 Munich, Germany.						Aas K., 1997, EUROPEAN ALLERGY WHI; Anto JM, 1997, THORAX, V52, P669; BECKER WM, 1997, NEW TRENDS ALLERGY, V4, P339; Becker Wolf-Meinhard, 1996, P119; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Behrendt H, 1999, INT ARCH ALLERGY IMM, V118, P414, DOI 10.1159/000024151; Behrendt H, 1995, PROG ALLER CLIN IMM, V3, P83; Behrendt H, 1991, NEW TRENDS ALLERGY, P467; BEHRENDT H, 1999, UMWELT GESUNDHEIT RI; BERRENS L, 1994, CLIN EXP ALLERGY, V24, P606, DOI 10.1111/j.1365-2222.1994.tb00962.x; Bufe A, 1996, PLANTA, V199, P413; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; Grobe K, 1999, EUR J BIOCHEM, V263, P33, DOI 10.1046/j.1432-1327.1999.00462.x; Grote M, 1999, INT ARCH ALLERGY IMM, V118, P1, DOI 10.1159/000024024; GROTE M, 1994, J HISTOCHEM CYTOCHEM, V42, P427; Grote M, 2000, J ALLERGY CLIN IMMUN, V105, P1140, DOI 10.1067/mai.2000.107044; HOWLETT BJ, 1973, J CELL SCI, V13, P603; HOWLETT BJ, 1981, HISTOCHEM J, V13, P461, DOI 10.1007/BF01005062; KING TP, 1995, CLIN EXP ALLERGY, V25, P27; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; KNOX RB, 1970, J CELL SCI, V6, P1; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; KNOX RB, 1975, BIOL J LINN SOC S1, V7, P177; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; MARSH SGE, 1999, HLA FACTS BOOK, P61; Monn Christian, 1999, Reviews on Environmental Health, V14, P79; MUTIUS E, 1998, LANCET, V351, P862; Newson R, 1998, EUR RESPIR J, V11, P694; Rantio-Lehtimaki Auli, 1995, P387; Riediker M, 2000, CLIN EXP ALLERGY, V30, P867; Ring J, 1999, INT ARCH ALLERGY IMM, V118, P403, DOI 10.1159/000024148; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P7; RISSE U, 2000, J AEROSOL SCI     S1, V31, pS27; Schappi GF, 1996, INT ARCH ALLERGY IMM, V110, P364; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Schramm G, 1996, INT ARCH ALLERGY IMM, V110, P354; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; STAFF IA, 1990, HISTOCHEM J, V22, P276, DOI 10.1007/BF01387183; Stanley R. G., 1974, POLLEN BIOL BIOCH MA; Suck R, 2000, CLIN EXP ALLERGY, V30, P324, DOI 10.1046/j.1365-2222.2000.00843.x; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; TAYLOR PE, 1994, HISTOCHEM J, V26, P392, DOI 10.1007/BF00160051; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; Vrtala S, 1999, J IMMUNOL, V163, P5489; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P116	51	77	81	1	11	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2001	13	6					709	715		10.1016/S0952-7915(01)00283-7		7	Immunology	Immunology	486BB	WOS:000171797600013	11677094	
J	Wilson, DR; Irani, AM; Walker, SM; Jacobson, MR; Mackay, IS; Schwartz, LB; Durham, SR				Wilson, DR; Irani, AM; Walker, SM; Jacobson, MR; Mackay, IS; Schwartz, LB; Durham, SR			Grass pollen immunotherapy inhibits seasonal increases in basophils and eosinophils in the nasal epithelium	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic rhinitis; immunotherapy; immunohistochemistry; basophil; mast cell; eosinophil; neutrophil	NATURAL ALLERGEN EXPOSURE; HUMAN BLOOD BASOPHILS; MAST-CELLS; MESSENGER-RNA; INDUCED RHINITIS; HAY-FEVER; TOPICAL CORTICOSTEROIDS; METACHROMATIC CELLS; ANTIGEN CHALLENGE; T-LYMPHOCYTES	Background Symptoms of allergic rhinitis are accompanied by infiltration of the nasal mucosa with inflammatory cells, predominantly eosinophils and metachromatic cells (basophils and mast cells). Specific immunotherapy (IT) reduces mucosal eosinophilia and numbers of metachromatic cells in the epithelium. A specific marker distinguishing basophils from mast cells was recently developed. Objectives The basophil-specific manoclanal antibody 2D7 was used to determine the influence of subcutaneous IT on numbers of nasal mucosal basophils compared with the effects of IT on neutrophils, eosinophils and mast cells. Method During a randomized, placebo-controlled trial of grass pollen IT in 44 adults with severe summer hay fever, nasal biopsies were taken at baseline, out of the pollen season, and at the peak of the pollen season following 2 years treatment. Biopsies were processed for immunohistochemistry far basophils (2D7(+)), mast cells (AA1(+)), eosinophils (MBP+) and neutrophils (neutrophil elastase(+)). Results In placebo-treated (PL) patients there were significant seasonal increases in basophils (P<0.01), mast cells (P<0.05) and eosinophils (P=0.002) irt the nasal submucosa. In IT-treated patients significant increases in 2D7 cells (P<0.01) and eosinophils (P=0.01) but not AA1(+) cells (P=0.9) were observed. These differences were significant between groups for eosinophils (P<0.05). In the epithelium there were seasonal increases in AA1(+) cells and eosinophils in both groups (PL: P<0.01, IT: P<0.05 far both). The between-group difference was significant for eosinophils (P=0.05). Basophils were observed in the epithelium of six out of 17 in the placebo group and one out of 20 in the IT group (P=0.03). Neutrophil numbers remained constant in both epithelium and submucosa. Conclusion Successful grass pollen immunotherapy was associated with inhibition of seasonal increases in basophils and eosinophils, but not mast cells or neutrophils within the nasal epithelium. Immunotherapy may act, at least in part, by reducing seasonal recruitment of basophils and eosinophils into the epithelium.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England; Virginia Commonwealth Univ, Dept Pediat, Div Rheumatol Allergy & Immunol, Richmond, VA USA; Virginia Commonwealth Univ, Dept Internal Med, Richmond, VA USA	Durham, SR (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258			Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; BASCOM R, 1988, Journal of Allergy and Clinical Immunology, V81, P580, DOI 10.1016/0091-6749(88)90198-4; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Bochner BS, 1996, J IMMUNOL, V157, P844; BORRES MP, 1990, ALLERGY, V45, P98, DOI 10.1111/j.1398-9995.1990.tb00465.x; BRADDING P, 1993, J IMMUNOL, V151, P3853; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; ENERBACK L, 1986, INT ARCH ALLER A IMM, V80, P44; Erel F, 2000, J INVEST ALLERG CLIN, V10, P14; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1992, CLIN EXP ALLERGY, V22, P701, DOI 10.1111/j.1365-2222.1992.tb00194.x; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Gauvreau GM, 1999, AM J RESP CRIT CARE, V160, P640; Gauvreau GM, 2000, AM J RESP CRIT CARE, V161, P1473; HIRSCH SR, 1976, J ALLERGY CLIN IMMUN, V58, P676, DOI 10.1016/0091-6749(76)90179-2; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Irani AMA, 1998, J ALLERGY CLIN IMMUN, V101, P354; Jacobson MR, 1999, CLIN EXP ALLERGY, V29, P1347; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; KEPLEY CL, 1995, J IMMUNOL, V154, P6548; KleinJan A, 2000, J ALLERGY CLIN IMMUN, V106, P677, DOI 10.1067/mai.2000.109621; LIU C-M, 1988, Rhinology (Utrecht), V26, P167; LOZEWICZ S, 1990, J ALLERGY CLIN IMMUN, V85, P125, DOI 10.1016/0091-6749(90)90233-T; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; McEuen AR, 1999, LAB INVEST, V79, P27; NACLERIO RM, 1985, NEW ENGL J MED, V313, P65, DOI 10.1056/NEJM198507113130201; Ochensberger B, 1996, BLOOD, V88, P3028; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; RASP G, 1993, ALLERGY, V48, P72, DOI 10.1111/j.1398-9995.1993.tb00688.x; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9; Uguccioni M, 1997, J CLIN INVEST, V100, P1137, DOI 10.1172/JCI119624; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170; VIEGAS M, 1987, INT ARCH ALLER A IMM, V82, P275; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Winther L, 1999, ALLERGY, V54, P436, DOI 10.1034/j.1398-9995.1999.00910.x; WOODS JW, 1993, J EXP MED, V178, P1935, DOI 10.1084/jem.178.6.1935; YING S, 1994, IMMUNOLOGY, V82, P200	41	77	82	0	0	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2001	31	11					1705	1713		10.1046/j.1365-2222.2001.01231.x		9	Allergy; Immunology	Allergy; Immunology	496XF	WOS:000172423100010	11696046	
J	Allaouchiche, B; Debon, R; Goudable, J; Chassard, D; Duflo, F				Allaouchiche, B; Debon, R; Goudable, J; Chassard, D; Duflo, F			Oxidative stress status during exposure to propofol, sevoflurane and desflurane	ANESTHESIA AND ANALGESIA			English	Article							ALVEOLAR MACROPHAGES; PROINFLAMMATORY CYTOKINES; BRONCHOALVEOLAR LAVAGE; ANTIOXIDANT STATUS; EXPIRED BREATH; RAT; EXPRESSION; ANESTHESIA; ASTHMA	We evaluated the circulating and lung oxidative status during general anesthesia established with propofol, sevoflurane, or desflurane in mechanically ventilated swines. Blood samples and bronchoalveolar lavage fluid (BAL) specimens were respectively performed via an internal jugular vein catheter and a nonbronchoscopic BAL for baseline oxidative activity measurements: malondialdehyde (MDA), superoxide dismutase (SOD), and glutathione peroxidase (GPX). A 4-h general anesthesia was then performed in the three groups of 10 swine: the Propofol group received 8 mg(.)kg(-1.)h(-1) of IV propofol as the sole anesthetic; the Desflurane group received 1.0 minimum alveolar concentration of desflurane; and the Sevoflurane group received 1.0 minimum alveolar concentration of sevoflurane. We observed significantly larger levels of MDA in plasma and BAL during desflurane exposure than with the other anesthetics. We also observed smaller concentrations of circulating GPX and alveolar GPX We found a significant decrease for MDA measurements in the plasma and the pulmonary lavage during propofol anesthesia. We also found larger values of GPX measurements in the serum and the pulmonary lavage. No significant changes were observed when animals were exposed to sevoflurane. No significant changes were found for circulating concentrations of SOD during exposure to all anesthetics. In this mechanically ventilated swine model, desflurane seemed to induce a local and systemic oxidative stress, whereas propofol and sevoflurane were more likely to have antioxidant properties.	Hop Hotel Dieu, Dept Anesthesiol & Intens Care, F-69288 Lyon 02, France; Hop Edouard Herriot, Dept Biochem, Lyon, France	Allaouchiche, B (reprint author), Hop Hotel Dieu, Dept Anesthesiol & Intens Care, 1,Pl Hop, F-69288 Lyon 02, France.						BALDWIN SR, 1986, LANCET, V1, P11; Boya P, 1999, J HEPATOL, V31, P808, DOI 10.1016/S0168-8278(99)80281-5; De la Cruz JP, 1999, ANESTH ANALG, V89, P1050, DOI 10.1097/00000539-199910000-00043; De la Cruz JP, 1998, ANESTH ANALG, V87, P1141, DOI 10.1097/00000539-199811000-00031; DOHLMAN AW, 1993, AM REV RESPIR DIS, V148, P955; GOODE HF, 1995, CRIT CARE MED, V23, P646, DOI 10.1097/00003246-199504000-00011; HALL JC, 1991, CHEST, V99, P923, DOI 10.1378/chest.99.4.923; Kotani N, 1999, ANESTH ANALG, V89, P1250; KOTANI N, 1995, ANESTH ANALG, V81, P1255, DOI 10.1097/00000539-199512000-00023; Kotani N, 1999, ANESTHESIOLOGY, V91, P187, DOI 10.1097/00000542-199907000-00027; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x; McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5; MURPHY PG, 1992, BRIT J ANAESTH, V68, P613, DOI 10.1093/bja/68.6.613; MUSACCHIO E, 1991, PHARMACOL TOXICOL, V69, P75; PAGLIA DE, 1967, J LAB CLIN MED, V70, P158; RICHARD MJ, 1992, CLIN CHEM, V38, P704; ROUBY JJ, 1989, ANESTHESIOLOGY, V71, P679, DOI 10.1097/00000542-198911000-00010; THOMPSON PJ, 1993, AM REV RESPIR DIS, V147, P164; VANVYVE T, 1992, AM REV RESPIR DIS, V146, P116	19	77	96	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-2999			ANESTH ANALG	Anesth. Analg.	OCT	2001	93	4					981	985		10.1097/00000539-200110000-00036		5	Anesthesiology	Anesthesiology	476PL	WOS:000171237900033	11574369	
J	Kilpelainen, M; Terho, EO; Helenius, H; Koskenvuo, M				Kilpelainen, M; Terho, EO; Helenius, H; Koskenvuo, M			Home dampness, current allergic diseases, and respiratory infections among young adults	THORAX			English	Article						asthma; allergic rhinitis; atopic dermatitis; dampness	HOUSE-DUST MITE; HAY-FEVER; ASTHMA; CHILDREN; SENSITIZATION; CHILDHOOD; SYMPTOMS; HEALTH; MOLDS; INFLAMMATION	Background-The relation between home dampness and respiratory symptoms among adults is well confirmed, but data on specific allergic diseases and respiratory infections is more limited. Individual factors that may enhance susceptibility to the effects of home dampness are mainly unknown. Methods-The association between home dampness and current physician diagnosed asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, common colds, and bacterial respiratory infections was studied in a questionnaire survey of 10 667 Finnish first year university students aged 18-25 years. The dampness categories analysed were visible mould and visible mould or damp stains or water damage during the last year. In multivariate analyses adjustment was made for parental education, active and passive smoking, type and place of residence, pets, and wall to wall carpets. The interaction effect of atopic heredity and dampness was investigated. Results-Visible mould or damp stains or water damage was reported by 15.0% of the respondents. In multivariate models there was a positive association between home dampness and current asthma, allergic rhinitis, and atopic dermatitis, as well as common colds greater than or equal to4 times per year and other respiratory infections, but not between home dampness and allergic conjunctivitis. The strongest association was found between exposure to visible mould and asthma (OR 2.21, 95% CI 1.48 to 3.28) and common colds (OR 1.49, 95% CI 1.18 to 1.87). The risk of current asthma in damp homes was highest among subjects with atopic heredity. Conclusions-The risk of current asthma, allergic rhinitis, and atopic dermatitis was higher in damp homes. Of the respiratory infections, the risk of common colds was most clearly increased.	Univ Turku, Dept Pulm Dis & Clin Allergol, FIN-20520 Turku, Finland; Univ Turku, Dept Biostat, SF-20500 Turku, Finland; Univ Turku, Dept Publ Hlth, SF-20500 Turku, Finland	Kilpelainen, M (reprint author), Univ Turku, Cent Hosp, Dept Pulm Dis & Clin Allergol, Kiinamyllynkatu 4-8, FIN-20520 Turku, Finland.						Becher R, 1996, TOXICOL LETT, V86, P155, DOI 10.1016/0378-4274(96)03685-5; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; Charpin D, 1999, CLIN EXP ALLERGY, V29, P1474; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; KILPELAINEN M, 2001, IN PRESS ALLERGY; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; MARTIN CJ, 1987, BRIT MED J, V294, P1125; NEVALAINEN A, 1995, INDOOR AIR INTEGRATE, P485; Nicolai T, 1998, THORAX, V53, P1035; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Pirhonen I, 1996, EUR RESPIR J, V9, P2618, DOI 10.1183/09031936.96.09122618; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; PLATT SD, 1989, BRIT MED J, V298, P1673; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; SAS Institute, 1996, SAS STAT SOFTW CHANG; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SUSITAIVAL P, 1996, TUOHILAMPI QUESTIONN; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; Williamson IJ, 1997, THORAX, V52, P229	29	77	78	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2001	56	6					462	467		10.1136/thorax.56.6.462		6	Respiratory System	Respiratory System	438XL	WOS:000169079500010	11359962	
J	Vailes, L; Sridhara, S; Cromwell, O; Weber, B; Breitenbach, M; Chapman, M				Vailes, L; Sridhara, S; Cromwell, O; Weber, B; Breitenbach, M; Chapman, M			Quantitation of the major fungal allergens, Alt a 1 and Asp f 1, in commercial allergenic products	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Alternaria; Aspergillus; allergen exposure; recombinant allergens; fungi; asthma	SCHOOL-AGE-CHILDREN; ALTERNARIA-ALTERNATA; BRONCHIAL HYPERRESPONSIVENESS; ASPERGILLUS-FUMIGATUS; CHILDHOOD ASTHMA; A-I; SENSITIZATION; EXTRACTS; CLADOSPORIUM; ASSOCIATION	Background: Alternaria is one of the most important fungi associated with allergic disease, whereas Aspergillus fumigatus is involved in a broad spectrum of pulmonary diseases. Currently, fungal extracts used for diagnosis in the United States are unstandardized, and their allergenic content cannot be compared directly. Objective: The goal of this study was to compare the variability of major allergen levels among US allergenic products derived from fungi: specifically, Alt a 1 levels in Alternaria alternata extracts, and Asp f 1 levels in A fumigatus extracts. Methods: A novel a-site monoclonal antibody ELISA was used for measuring Alt a 1 using recombinant Alt a 1 as a standard. Asp fl was also measured by ELISA, Allergenic products produced by 8 US manufacturers over a 2-year period were compared, as were multiple lots produced by a single company, Results: Alt a 1 levels in Alternaria extracts from 8 companies produced in 1998 and 1999 ranged from less than 0.01 to 6.09 mug/mL (mean 1.4 +/- 1.6 mug/mL, n = 15), In general, Alt al levels were consistent within and between companies (1.4 +/- 1.1 mug/mL, n = 27), with 21 of 32 (66%) of all extracts tested containing 0.7 to 2 mug/mL Alt a 1, Aspergillus extracts showed much greater variability in Asp fl levels, with extracts from 8 companies containing from less than 0.1 to 64 mug/mL Asp fl (mean 16.3 +/- 23.9 mug/mL, n = 15), Overall variability was greater for Aspergillus products within and between manufacturers (22 +/- 22 mug/mL Asp f 1, a = 20), Conclusions: ELISA-based assays for specific allergens showed greater consistency among allergenic products derived from Alternaria than from Aspergillus, These assays should facilitate improved quality control and standardization of fungal allergen extracts and lead to the development of more consistent products for clinical use.	Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Joachim Ganzer KG, Allergopharma, Reinbek, Germany; Salzburg Univ, A-5020 Salzburg, Austria	Vailes, L (reprint author), Univ Virginia, Dept Med, Asthma & Allerg Dis Ctr, Box 801355, Charlottesville, VA 22908 USA.				NIAID NIH HHS [AI 32557, AI 34607]		[Anonymous], 1997, J ALLERGY CLIN IMMUN, V99, P583; ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; ADEN E, 1999, J ALLERGY CLIN IMMUN, V103, P128; AGARWAL MK, 1982, J ALLERGY CLIN IMMUN, V70, P432, DOI 10.1016/0091-6749(82)90005-7; ALDOORY Y, 1987, MOULD HLTH WHO IS RI; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb04298.x; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; CURRAN IHA, 1993, INT ARCH ALLERGY IMM, V102, P267; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HELM RM, 1988, J ALLERGY CLIN IMMUN, V81, P651, DOI 10.1016/0091-6749(88)91035-4; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786; KLEINETEBBE J, 1993, CLIN EXP ALLERGY, V23, P211, DOI 10.1111/j.1365-2222.1993.tb00884.x; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PARIS S, 1990, J ALLERGY CLIN IMMUN, V85, P941, DOI 10.1016/0091-6749(90)90081-E; PARIS S, 1990, INT ARCH ALLER A IMM, V92, P1; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; PLATTSMILLS TAE, 1993, AEROBIOLOGY INHALANT, P498; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P930, DOI 10.1016/0091-6749(93)90351-F; Portnoy J, 1998, ANN ALLERG ASTHMA IM, V81, P59; STERINGER I, 1987, INT ARCH ALLER A IMM, V84, P190; Tariq SM, 1996, CLIN EXP ALLERGY, V26, P794; VANDERHEIDE S, 1985, ALLERGY, V40, P592; VIJAY HM, 1993, J ALLERGY CLIN IMMUN, V91, P826, DOI 10.1016/0091-6749(93)90338-G; VIJAY HM, 1984, INT ARCH ALLER A IMM, V74, P256; WAHL R, 1989, ANN ALLERGY, V63, P527; YUNGINGER JW, 1980, J ALLERGY CLIN IMMUN, V66, P138, DOI 10.1016/0091-6749(80)90061-5; ZHANG L, 1995, INT ARCH ALLERGY IMM, V108, P254	35	77	79	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					641	646				6	Allergy; Immunology	Allergy; Immunology	423RG	WOS:000168190100015	11295652	
J	Piirila, PL; Nordman, H; Keskinen, HM; Luukkonen, R; Salo, SP; Tuomi, TO; Tuppurainen, M				Piirila, PL; Nordman, H; Keskinen, HM; Luukkonen, R; Salo, SP; Tuomi, TO; Tuppurainen, M			Long-term follow-up of hexamethylene diisocyanate-, biphenylmethane diisocyanate-, and toluene diisocyanate-induced asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							OCCUPATIONAL ASTHMA; NATURAL-HISTORY; ISOCYANATES; ANTIBODIES; WORKERS; IGE; REACTIVITY; DIAGNOSIS; CHALLENGE; EXPOSURE	In 1976-1992 245 new cases of asthma induced by diisocyanates were diagnosed, caused by hexamethylene diisocyanate (HDI) in 39%, diphenylmethane diisocyanate (MDI) in 39%, and toluene diisocyanate (TDI) in 17% of the cases. Our aim was to study the clinical outcome of diisocyanate-induced asthma, A questionnaire was sent to the 235 patients alive in 7995, and validated by reexamining clinically 91 of them. The study was carried out on average 10 (3-19) yr after the diagnosis. Of the patients 82% experienced symptoms of asthma, 34% used no medication, and 35% were on regular medication. The patients having displayed immunoglobulin E (IgE) antibodies to isocyanates used less medication (OR 0.273; Cl 0.098, 0.758) and had fewer symptoms of asthma (OR 0.329; Cl 0.124, 0.875) than the IgE-negative ones. They also had a significantly shorter duration of symptoms (p = 0.0025), latency period (p = 0.0249), and duration of exposure (p = 0.0008) than the IgE-negative patients. This did not, however, entirely explain the more favourable outcome of the IgE-positive patients. Patients with HDI-induced asthma used less medication (OR 0.412; Cl 0.229, 0.739) than patients with MDI- and TDI-induced asthma. The results confirm the generally rather poor medical outcome of diisocyanate-induced asthma; the persistence of symptoms and unspecific bronchial reactivity were pronounced in TDI-induced asthma. A more favourable outcome was associated with IgE mediation and HDI inducement.	Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Helsinki Univ Hosp, Helsinki, Finland	Piirila, PL (reprint author), Finnish Inst Occupat Hlth, Topeliuksenkatu 41 A A, FIN-00250 Helsinki, Finland.			Piirila, Paivi/0000-0002-2535-4409			AAS K, 1973, INT ARCH ALLER A IMM, V45, P57; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; BELIN L, 1981, European Journal of Respiratory Diseases Supplement, V62, P148; BERGLUND E, 1963, ACTA MED SCAND, V173, P185; BURGE PS, 1982, EUR J RESPIR DIS, V63, P47; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; DIEM JE, 1982, AM REV RESPIR DIS, V126, P420; FLETCHER C, 1977, BRIT MED J, V1, P1645; Kanerva L, 1991, EXOGENOUS DERMATOSES, P103; KAROL MH, 1981, J OCCUP ENVIRON MED, V23, P741, DOI 10.1097/00043764-198111000-00007; KESKINEN H, 1988, CLIN ALLERGY, V18, P597, DOI 10.1111/j.1365-2222.1988.tb02911.x; Keskinen H, 1996, CLIN PHYSIOL, V16, P633, DOI 10.1111/j.1475-097X.1996.tb00740.x; Laitinen L A, 1974, Scand J Respir Dis Suppl, V86, P1; LOZEWICZ S, 1987, BRIT J DIS CHEST, V81, P14, DOI 10.1016/0007-0971(87)90103-3; MAESTRELLI P, 1993, AM REV RESPIR DIS, V148, P407; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; MAPP CE, 1988, EUR RESPIR J, V1, P273; MAPP CE, 1988, AM REV RESPIR DIS, V137, P1326; NORDMAN H, 1985, J ALLERGY CLIN IMMUN, V75, P91, DOI 10.1016/0091-6749(85)90018-1; PAGGIARO PL, 1984, CLIN ALLERGY, V14, P463, DOI 10.1111/j.1365-2222.1984.tb02230.x; PAGGIARO PL, 1993, CHEST, V103, P1123, DOI 10.1378/chest.103.4.1123; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEZZINI A, 1984, CLIN ALLERGY, V14, P453, DOI 10.1111/j.1365-2222.1984.tb02229.x; PISATI G, 1993, BRIT J IND MED, V50, P60; Quanjer Ph., 1983, B EUR PHYSIOPATHOL S, V19; Raulf-Heimsoth N, 1998, AM J IND MED, V34, P137; ROSENBERG C, 1984, AM IND HYG ASSOC J, V45, P117, DOI 10.1202/0002-8894(1984)045<0117:AIIPSP>2.3.CO;2; ROSENBERG N, 1987, CLIN ALLERGY, V17, P55, DOI 10.1111/j.1365-2222.1987.tb02319.x; SOVIJARVI ARA, 1993, CHEST, V104, P164, DOI 10.1378/chest.104.1.164; STREICHER RP, 1994, ANALYST, V119, P89, DOI 10.1039/an9941900089; TARLO SM, 1997, OCCUP ENVIRON MED, V54, P576; TAYLOR AJN, 1981, OCCUPATIONAL LUNG DI, P143; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; Viljanen AA, 1982, SCAND J CLIN INVES S, V42, P1	35	77	77	0	4	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG	2000	162	2					516	522				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	345RP	WOS:000088829200031	10934080	
J	Pope, M; Johnston, KW				Pope, M; Johnston, KW			Anaphylaxis after thrombin injection of a femoral pseudoaneurysm: Recommendations for prevention	JOURNAL OF VASCULAR SURGERY			English	Article							TOPICAL THROMBIN; COAGULATION	After the injection treatment of a femoral pseudoaneurysm, an anaphylactic reaction occurred in a patient undergoing hemodialysis who previously had repeated exposure to thrombin. Before injecting bovine thrombin in patients with a history of prior exposure, we recommend that they undergo skin prick testing to detect possible allergy.	Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 2C4, Canada; Univ Toronto, Toronto, ON, Canada	Johnston, KW (reprint author), Toronto Gen Hosp, Dept Surg, Eaton 5-309,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.						Brophy DP, 2000, RADIOLOGY, V214, P278; CAMBRIA RA, 2000, VASCULAR SURG, P1493; COPE C, 1986, AM J ROENTGENOL, V147, P383; Dorion RP, 1998, ARCH PATHOL LAB MED, V122, P887; GILLIS M, 1999, COMPENDIUM PHARM SPE; Liau CS, 1997, J VASC SURG, V26, P18, DOI 10.1016/S0741-5214(97)70141-1; ORTEL TL, 1994, AM J HEMATOL, V45, P128, DOI 10.1002/ajh.2830450206; Plaut Marshall, 1993, P1399; TADOKORO K, 1991, J ALLERGY CLIN IMMUN, V88, P620, DOI 10.1016/0091-6749(91)90156-I; Taylor BS, 1999, J VASC SURG, V30, P1052, DOI 10.1016/S0741-5214(99)70043-1; Tidrick RT, 1943, SURGERY, V14, P191	11	77	80	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0741-5214			J VASC SURG	J. Vasc. Surg.	JUL	2000	32	1					190	191		10.1067/mva.2000.106498		2	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	334ED	WOS:000088172500034	10876222	
J	Lambert, AL; Dong, WM; Selgrade, MJK; Gilmour, MI				Lambert, AL; Dong, WM; Selgrade, MJK; Gilmour, MI			Enhanced allergic sensitization by residual oil fly ash particles is mediated by soluble metal constituents	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						particulate matter; metals; adjuvant; asthma; immediate bronchoconstriction; IL-5; IL-6; IL-10; IL-13; TNF-alpha; IgE; eosinophils	PARTICULATE AIR-POLLUTION; MESSENGER-RNA EXPRESSION; DIESEL EXHAUST PARTICLES; EMERGENCY ROOM VISITS; HOUSE-DUST MITE; CYTOKINE PRODUCTION; IN-VIVO; EPITHELIAL-CELLS; IGE PRODUCTION; LEUKOCYTE ADHESION	Epidemiological studies have demonstrated an association between elevated levels of particulate matter (PM) air pollutants and exacerbation of asthma symptoms. We have shown in a Brown Norway (BN) rat model of house dust mite (HDM) allergy that preexposure to residual oil By ash (ROFA) particles enhanced the sensitization phase such that the secondary immune response and associated lung injury were increased after allergen challenge. To determine whether the metals present in ROFA mediated this effect, BN rats were intratracheally instilled with either ROFA (1000 mu g) or acidified saline + NiSO4 (105.12 mu g), VSO4 (98.2 mu g), FeSO4 (58.49 mu g), or a mixture (Mix) of each metal. HDM-specific IgE was higher in the serum of the ROFA, Ni, V, and Mix groups than in the HDM group after challenge, and antigen-induced bronchoconstriction responses were increased in the Ni group. Lymphocyte proliferation to antigen was increased in the ROFA, Ni, and V groups compared to controls. Total protein and eosinophil peroxidase levels were elevated in the Fe group, and eosinophil numbers in the bronchoalveolar lavage fluid (BALF) were increased in the ROFA and Fe groups compared to HDM control. IL-5 and IL-13 mRNA expression was also increased in the lung tissue of all metal and ROFA-treated groups, while BALF IL-10 was elevated in the Fe and Mix groups, and IL-6 and TNF-alpha were elevated in the metal and ROFA-treated groups compared to controls. These results suggest that ROFA's metallic constituents mediate enhancement of sensitization to HDM and that pulmonary inflammation may play a role in this adjuvant effect. (C) 2000 Academic Press.	US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Chapel Hill, NC 27599 USA	Gilmour, MI (reprint author), US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA.						Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; BONFIELD TL, 1995, AM J RESP CELL MOL, V13, P257; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Casale TB, 1996, AM J RESP CELL MOL, V15, P35; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; Devalia JL, 1996, TOXICOL LETT, V86, P169, DOI 10.1016/0378-4274(96)03687-9; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dockery DW, 1996, AM J RESP CRIT CARE, V154, pS250; Dong WM, 1998, TOXICOL SCI, V44, P63, DOI 10.1093/toxsci/44.1.63; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; DUSSELDORP A, 1995, AM J RESP CRIT CARE, V152, P1932; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; GASCAN H, 1991, J EXP MED, V173, P747, DOI 10.1084/jem.173.3.747; Gavett SH, 1997, ENVIRON RES, V72, P162, DOI 10.1006/enrs.1997.3732; GOEBELER M, 1993, J INVEST DERMATOL, V100, P759, DOI 10.1111/1523-1747.ep12476328; HATCH GE, 1985, ENVIRON RES, V36, P67, DOI 10.1016/0013-9351(85)90008-8; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Humbert M, 1997, AM J RESP CRIT CARE, V156, P704; Ichinose T, 1998, TOXICOL SCI, V44, P70, DOI 10.1093/toxsci/44.1.70; KEHRL JH, 1987, J EXP MED, V166, P786, DOI 10.1084/jem.166.3.786; KLEIN LM, 1989, P NATL ACAD SCI USA, V86, P8972, DOI 10.1073/pnas.86.22.8972; Kodavanti UP, 1997, INHAL TOXICOL, V9, P679; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; LAKKIS FG, 1993, BIOCHEM BIOPH RES CO, V197, P612, DOI 10.1006/bbrc.1993.2523; Lambert AL, 1998, AM J RESP CRIT CARE, V157, P1991; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; LEVY BS, 1984, J OCCUP ENVIRON MED, V26, P567, DOI 10.1097/00043764-198408000-00009; Levy F, 1997, INT ARCH ALLERGY IMM, V112, P49; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; MOSER R, 1992, J IMMUNOL, V149, P1432; MOSMANN TR, 1994, ADV IMMUNOL, V56, P1, DOI 10.1016/S0065-2776(08)60449-6; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOTOLESE A, 1992, CONTACT DERMATITIS, V26, P274, DOI 10.1111/j.1600-0536.1992.tb00252.x; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NEMERY B, 1990, EUR RESPIR J, V3, P202; NOBLE A, 1993, IMMUNOLOGY, V80, P326; NOVEY HS, 1983, J ALLERGY CLIN IMMUN, V72, P407, DOI 10.1016/0091-6749(83)90507-9; NUDEL U, 1983, NUCLEIC ACIDS RES, V11, P1759, DOI 10.1093/nar/11.6.1759; Peden DB, 1997, ALLERGY, V52, P37; Peters A, 1997, EUR RESPIR J, V10, P872; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Pritchard RJ, 1996, INHAL TOXICOL, V8, P457, DOI 10.3109/08958379609005440; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113; Salvi S, 1999, AM J RESP CELL MOL, V20, P984; SCHROEDER WH, 1987, JAPCA J AIR WASTE MA, V37, P1267; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; VANLOVEREN H, 1999, TOXICOL SCI, V48, P5; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; WILLIAMS CMM, 1995, IMMUNOLOGY, V86, P244; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; YAMAGUCHI M, 1988, AM J PERINAT, V5, P5, DOI 10.1055/s-2007-999641; YOKOYAMA A, 1995, AM J RESP CRIT CARE, V151, P1354	63	77	80	1	3	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	MAY 15	2000	165	1					84	93		10.1006/taap.2000.8932		10	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	348RU	WOS:000089000900008	10814556	
J	Weinberg, EG				Weinberg, EG			Urbanization and childhood asthma: An African perspective	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Africa; urbanization; childhood asthma; prevalence; parasites	EXERCISE-INDUCED BRONCHOSPASM; KENYAN SCHOOL-CHILDREN; PREVALENCE; URBAN; SCHOOLCHILDREN; INFECTION; BIRTH; ATOPY	The increasing prevalence of childhood asthma in the developed world is a cause for concern. Much research is currently being conducted in an attempt to identify possible reasons for this occurrence. A so-called Western lifestyle has been the factor most commonly cited to explain this worrying increase in asthma prevalence. In essence, this implies a way of life where children are exposed from early infancy to a wide range of foods, infections, indoor and outdoor allergens, and irritants and to the effects of motor vehicle pollution, Until fairly recently, children in many African countries lived mainly in rural areas and were not exposed to the effects of a Western lifestyle, Early studies in a limited number of African countries showed a very low rural prevalence of childhood asthma, especially where children lived according to a traditional lifestyle, These same studies showed that asthma was not uncommon in urbanized African children. There has been an increasing tendency over the past 20 years for those in rural communities to move to the large urban centers. More recent childhood asthma prevalence studies, especially those from Kenya and Ghana, have confirmed the urban-rural differences but have shown a much narrower gap. In part this may be the result of exposure of rural children to agricultural pesticides and irritants as well as of an increasing tendency to adopt a more Westernized lifestyle such as the use of beds with mattresses, pillows, and blankets, These circumstances on the African continent provide a natural laboratory in the quest for factors that influence the development of asthma in susceptible children, Once more fully elucidated, it is possible that much valuable information will be available to combat the relentless increase in childhood asthma both here as well as in the developed world.	Univ Cape Town, Allergy & Asthma Clin, Red Cross Childrens Hosp & Inst Child Hlth, ZA-7700 Rondebosch, South Africa	Weinberg, EG (reprint author), Univ Cape Town, Allergy & Asthma Clin, Red Cross Childrens Hosp & Inst Child Hlth, ZA-7700 Rondebosch, South Africa.						Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; BUCHANAN DJ, 1974, POSTGRAD MED J, V50, P680; CARLSEN KH, 1994, EUR RESPIR REV, V4, P5; CARSWELL GF, 1976, LANCET, V2, P706; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Custovic A, 1999, CLIN EXP ALLERGY, V29, P144; DESOUZA M, 1994, E AFR MED J, V71, P473; EGBUONU L, 1982, PEDIATRICS, V69, P550; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; Farooqi IS, 1998, THORAX, V53, P927; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; LUYT DK, 1995, S AFR MED J, V85, P999; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; MOHAMED N, 1995, THORAX, V50, P74, DOI 10.1136/thx.50.1.74; Morley D., 1986, MY NAME IS TODAY; Ng'ang'a LW, 1998, THORAX, V53, P919; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; PULLAN CR, 1982, BRIT MED J, V284, P1665; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; Salvi SS, 1999, CLIN EXP ALLERGY, V29, P4; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Stein CE, 1997, THORAX, V52, P895; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; VANNIEKERK CH, 1979, S AFR MED J, V55, P756; VANNIEKERK CH, 1977, LANCET, V1, P96; YAMANEBERHAN H, 1997, LANCET, V350, P85; Yobo EODA, 1997, THORAX, V52, P161	32	77	82	0	9	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				224	231		10.1016/S0091-6749(00)90069-1		8	Allergy; Immunology	Allergy; Immunology	285RQ	WOS:000085402200004	10669840	
J	Allen, KJ; Koplin, JJ; Ponsonby, AL; Gurrin, LC; Wake, M; Vuillermin, P; Martin, P; Matheson, M; Lowe, A; Robinson, M; Tey, D; Osborne, NJ; Dang, T; Tan, HTT; Thiele, L; Anderson, D; Czech, H; Sanjeevan, J; Zurzolo, G; Dwyer, T; Tang, MLK; Hill, D; Dharmage, SC				Allen, Katrina J.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Gurrin, Lyle C.; Wake, Melissa; Vuillermin, Peter; Martin, Pamela; Matheson, Melanie; Lowe, Adrian; Robinson, Marnie; Tey, Dean; Osborne, Nicholas J.; Thanh Dang; Tan, Hern-Tze Tina; Thiele, Leone; Anderson, Deborah; Czech, Helen; Sanjeevan, Jeeva; Zurzolo, Giovanni; Dwyer, Terence; Tang, Mimi L. K.; Hill, David; Dharmage, Shyamali C.			Vitamin D insufficiency is associated with challenge-proven food allergy in infants	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Vitamin D; food allergy; peanut allergy; egg allergy; population; oral food challenge; eczema; epigenetic	REGULATORY T-CELLS; UNITED-STATES; BIRTH COHORT; POPULATION; PREVALENCE; CHILDREN; LATITUDE; RADIATION; EXPOSURE; SEASON	Background: Epidemiological evidence has shown that pediatric food allergy is more prevalent in regions further from the equator, suggesting that vitamin D insufficiency may play a role in this disease. Objective: To investigate the role of vitamin D status in infantile food allergy. Methods: A population sample of 5276 one-year-old infants underwent skin prick testing to peanut, egg, sesame, and cow's milk or shrimp. All those with a detectable wheal and a random sample of participants with negative skin prick test results attended a hospital-based food challenge clinic. Blood samples were available for 577 infants (344 with challenge-proven food allergy, 74 sensitized but tolerant to food challenge, 159 negative on skin prick test and food challenge). Serum 25-hydroxyvitamin D levels were measured by using liquid chromatography tandem mass spectrometry. Associations between serum 25-hydroxyvitamin D and food allergy were examined by using multiple logistic regression, adjusting for potential risk and confounding factors. Results: Infants of Australian-born parents, but not of parents born overseas, with vitamin D insufficiency (<= 50 nmol/L) were more likely to be peanut (adjusted odds ratio [aOR], 11.51; 95% CI, 2.01-65.79; P = .006) and/or egg (aOR, 3.79; 95% CI, 1.1912.08; P = .025) allergic than were those with adequate vitamin D levels independent of eczema status. Among those with Australian-born parents, infants with vitamin D insufficiency were more likely to have multiple food allergies (>= 2) rather than a single food allergy (aOR, 10.48; 95% CI, 1.60-68.61 vs aOR, 1.82; 95% CI, 0.38-8.77, respectively). Conclusions: These results provide the first direct evidence that vitamin D sufficiency may be an important protective factor for food allergy in the first year of life. (J Allergy Clin Immunol 2013; 131:1109-16.)	[Allen, Katrina J.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Gurrin, Lyle C.; Wake, Melissa; Vuillermin, Peter; Martin, Pamela; Lowe, Adrian; Osborne, Nicholas J.; Thanh Dang; Tan, Hern-Tze Tina; Thiele, Leone; Anderson, Deborah; Czech, Helen; Sanjeevan, Jeeva; Zurzolo, Giovanni; Dwyer, Terence; Tang, Mimi L. K.; Hill, David; Dharmage, Shyamali C.] Murdoch Childrens Res Inst, Parkville, Vic, Australia; [Allen, Katrina J.; Koplin, Jennifer J.; Ponsonby, Anne-Louise; Wake, Melissa; Osborne, Nicholas J.; Tang, Mimi L. K.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia; [Allen, Katrina J.; Robinson, Marnie; Tey, Dean; Tang, Mimi L. K.] Royal Childrens Hosp, Dept Allergy & Immunol, Parkville, Vic 3052, Australia; [Gurrin, Lyle C.; Matheson, Melanie; Lowe, Adrian; Osborne, Nicholas J.; Dharmage, Shyamali C.] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Parkville, Vic 3052, Australia; [Wake, Melissa] Royal Childrens Hosp, Ctr Community Child Hlth, Parkville, Vic 3052, Australia; [Vuillermin, Peter] Barwon Hlth, Child Hlth Res Unit, Geelong, Vic, Australia; [Vuillermin, Peter] Deakin Univ, Geelong, Vic 3217, Australia; [Osborne, Nicholas J.] Univ Exeter, Peninsula Coll Med & Dent, European Ctr Environm & Human Hlth, Exeter EX4 4QJ, Devon, England	Allen, KJ (reprint author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	katie.allen@rch.org.au	Wake, Melissa/J-1396-2012; Osborne, Nicholas/D-2086-2011; Matheson, Melanie/O-4721-2015; Osborne, Nicholas/N-4915-2015	Wake, Melissa/0000-0001-7501-9257; Zurzolo, Giovanni/0000-0003-0230-0691; Dharmage, Shyamali/0000-0001-6063-1937; Osborne, Nicholas/0000-0002-6700-2284; Matheson, Melanie/0000-0002-5822-3499; Osborne, Nicholas/0000-0002-6700-2284; Lowe, Adrian/0000-0002-4691-8162; Tan, Hern-Tze Tina/0000-0002-8289-7573	National Health and Medical Research Council of Australia; Ilhan Food Allergy Foundation; AnaphylaxiStop; Charles and Sylvia Viertel Medical Research Foundation; Victorian Government's Operational Infrastructure Support Program; National Health and Medical Research Council; European Regional Development Fund; European Social Fund Convergence Programme; Australian Egg Corporation	This study was supported by funding from the National Health and Medical Research Council of Australia, the Ilhan Food Allergy Foundation, AnaphylaxiStop, the Charles and Sylvia Viertel Medical Research Foundation, and the Victorian Government's Operational Infrastructure Support Program.; Disclosure of potential conflict of interest: K. J. Allen is a Viertel Senior Medical Research Fellow and has received payment for lectures from Abbott, Wyeth, and Nutricia. J. J. Koplin is partly supported by a postdoctoral fellowship from a National Health and Medical Research Council Capacity Building Grant in Population Health. A.-L. Ponsonby, L. C. Gurrin, M. Wake, M. Matheson, A. Lowe, and S. C. Dharmage are supported by the National Health and Medical Research Council. D. Tey has received payment for lectures from Merck Sharp & Dohme, Abbott Nutrition, and Alphapharm. P. Martin and T. Dang are Australian Postgraduate Award PhD scholars, and H.-T. Tina Tan is a Malaysian Government PhD scholar. N. J. Osborne is supported by the European Regional Development Fund and the European Social Fund Convergence Programme, has received grants and travel support from the National Health and Medical Research Council, and has received grants from the Australian Egg Corporation. M. Tang is on the advisory board for the Nestle Nutrition Institute and Nutricia and has received speakers fees from Nutricia, Nestle Nutrition Institute, and Wyeth. The rest of the authors declare that they have no relevant conflicts of interest.	Armas LAG, 2007, J AM ACAD DERMATOL, V57, P588, DOI 10.1016/j.jaad.2007.03.004; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Camargo CA, 2007, J ALLERGY CLIN IMMUN, V120, P131, DOI 10.1016/j.jaci.2007.03.049; De Filippo C, 2010, P NATL ACAD SCI USA, V107, P14691, DOI 10.1073/pnas.1005963107; Ho MHK, 2008, J ALLERGY CLIN IMMUN, V121, P731, DOI 10.1016/j.jaci.2007.11.024; Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553; Keet CA, 2012, ALLERGY, V67, P775, DOI 10.1111/j.1398-9995.2012.02823.x; Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Liew WK, 2009, J ALLERGY CLIN IMMUN, V123, P434, DOI 10.1016/j.jaci.2008.10.049; Little RJA, 2002, STAT ANAL MISSING DA; Liu X, 2011, ALLERGY, V66, P1442, DOI 10.1111/j.1398-9995.2011.02681.x; Lucas RM, 2011, NEUROLOGY, V76, P540, DOI 10.1212/WNL.0b013e31820af93d; Merewood A, 2012, J HUM LACT, V28, P159, DOI 10.1177/0890334411434802; Morley R, 2009, EUR J CLIN NUTR, V63, P802, DOI 10.1038/ejcn.2008.55; Mullins RJ, 2012, CURR ALLERGY ASTHM R, V12, P64, DOI 10.1007/s11882-011-0230-7; Mullins RJ, 2011, PEDIAT ALLERG IMM-UK, V22, P583, DOI 10.1111/j.1399-3038.2011.01151.x; Osborne NJ, 2010, CLIN EXP ALLERGY, V40, P1516, DOI 10.1111/j.1365-2222.2010.03562.x; Osborne NJ, 2012, J ALLERGY CLIN IMMUN, V129, P865, DOI 10.1016/j.jaci.2012.01.037; Osborne NJ, 2011, J ALLERGY CLIN IMMUN, V127, P668, DOI 10.1016/j.jaci.2011.01.039; Pink B., 2006, INTRO SOCIOECONOMIC; Saraiva GL, 2005, OSTEOPOROSIS INT, V16, P1649, DOI 10.1007/s00198-005-1895-3; Sharief S, 2011, J ALLERGY CLIN IMMUN, V127, P1195, DOI 10.1016/j.jaci.2011.01.017; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.09.051, 10.1016/j.jaci.2008.12.1128]; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Tan THT, 2012, CLIN EXP ALLERGY, V42, P20, DOI 10.1111/j.1365-2222.2011.03823.x; Thieden E, 2009, PHOTOCHEM PHOTOBIOL, V85, P1480, DOI 10.1111/j.1751-1097.2009.00612.x; Institute of Medicine (US) Committee to Review Dietary Reference Intakes for Vitamin D and Calcium, 2011, DIETARY REFERENCE IN; van der Mei IAF, 2007, ENVIRON HEALTH PERSP, V115, P1132; Vassallo MF, 2010, ALLERGY, V65, P1492, DOI 10.1111/j.1398-9995.2010.02384.x; Vassallo MF, 2010, J ALLERGY CLIN IMMUN, V126, P217, DOI 10.1016/j.jaci.2010.06.011; Vuillermin PJ, 2013, CLIN EXP ALLERGY; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	33	76	79	4	35	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2013	131	4					1109	+		10.1016/j.jaci.2013.01.017		14	Allergy; Immunology	Allergy; Immunology	120QT	WOS:000317187200021	23453797	
J	Ziegler, SF				Ziegler, Steven F.			Thymic stromal lymphopoietin and allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Thymic stromal lymphopoietin; asthma; allergy; atopic dermatitis; inflammation	OBSTRUCTIVE PULMONARY-DISEASE; NASAL EPITHELIAL-CELLS; RETINOID-X-RECEPTOR; IGM(+) B-CELLS; CD4(+) T-CELLS; ATOPIC-DERMATITIS; DENDRITIC CELLS; TSLP RECEPTOR; CUTTING EDGE; OX40 LIGAND	The importance of the epithelium in initiating and controlling immune responses is becoming more appreciated. For example, allergen contact first occurs at mucosal sites exposed to the external environment, such as the skin, airways, and gastrointestinal tract. This exposure leads to the production of a variety of cytokines and chemokines that are involved in driving allergic inflammatory responses. One such product is thymic stromal lymphopoietin (TSLP). Recent studies in both human subjects and murine models have implicated TSLP in the development and progression of allergic diseases. This review will highlight recent advances in the understanding of the role of TSLP in these inflammatory diseases. Importantly, these insights into TSLP's multifaceted role could potentially allow for novel therapeutic manipulations of these disorders. (J Allergy Clin Immunol 2012; 130:845-52.)	[Ziegler, Steven F.] Benaroya Res Inst, Program Immunol, Seattle, WA 98101 USA; [Ziegler, Steven F.] Univ Washington, Dept Immunol, Seattle, WA 98195 USA	Ziegler, SF (reprint author), Benaroya Res Inst, Program Immunol, 1201 9th Ave, Seattle, WA 98101 USA.	sziegler@benaroyaresearch.org			National Institutes of Health [AI068731, AR056113, AR055695, HL098067, HL102708, AR059058]; Asthma and Allergy Foundation of America; National Institutes of Health; American Academy of Allergy, Asthma Immunology	Support was provided by grants AI068731, AR056113, AR055695, HL098067, HL102708, and AR059058 from the National Institutes of Health and a grant from the Asthma and Allergy Foundation of America.; S.F. Ziegler has received research support from the National Institutes of Health; has received lecture fees from the American Academy of Allergy, Asthma & Immunology; and has received travel support from the Federation of Clinical Immunology Societies.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Arima K, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000567; Besin G, 2008, DIABETES, V57, P2107, DOI 10.2337/db08-0171; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blazquez AB, 2010, GASTROENTEROLOGY, V139, P1301, DOI 10.1053/j.gastro.2010.06.055; Bleck B, 2010, J IMMUNOL, V185, P6636, DOI 10.4049/jimmunol.1000719; Boehme SA, 2009, INT IMMUNOL, V21, P81, DOI 10.1093/intimm/dxn127; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Boita M, 2011, INT J IMMUNOPATH PH, V24, P761; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Bunyavanich Supinda, 2011, Clin Mol Allergy, V9, P1, DOI 10.1186/1476-7961-9-1; Chavanas S, 2000, NAT GENET, V25, P141; Corrigan CJ, 2009, ALLERGY, V64, P1014, DOI 10.1111/j.1398-9995.2009.01947.x; Demehri S, 2008, PLOS BIOL, V6, P992, DOI 10.1371/journal.pbio.0060123; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Duan W, 2010, J ALLERGY CLIN IMMUN, V126, P1284, DOI 10.1016/j.jaci.2010.09.021; Dumortier A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009258; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Han H, 2012, MUCOSAL IMMUNOL, V5, P468, DOI 10.1038/mi.2012.34; Harada M, 2011, AM J RESP CELL MOL, V44, P787, DOI 10.1165/rcmb.2009-0418OC; Harada M, 2009, AM J RESP CELL MOL, V40, P368, DOI 10.1165/rcmb.2008-0041OC; He R, 2008, P NATL ACAD SCI USA, V105, P11875, DOI 10.1073/pnas.0801532105; Headley MB, 2009, J IMMUNOL, V182, P1641; Hulse KE, 2010, J ALLERGY CLIN IMMUN, V125, P247, DOI 10.1016/j.jaci.2009.10.027; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Iliev ID, 2009, GUT, V58, P1481, DOI 10.1136/gut.2008.175166; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jessup HK, 2008, J IMMUNOL, V181, P4311; JUDGE MR, 1994, BRIT J DERMATOL, V131, P615, DOI 10.1111/j.1365-2133.1994.tb04971.x; Kamekura R., 2009, CELL TISSUE RES, V338, P282; Kimura S, 2011, ALLERGY ASTHMA IMMUN, V3, P186, DOI 10.4168/aair.2011.3.3.186; Kitajima M, 2011, EUR J IMMUNOL, V41, P1862, DOI 10.1002/eji.201041195; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; Lee HC, 2008, J IMMUNOL, V181, P5189; Lei LY, 2011, J IMMUNOL, V186, P2254, DOI 10.4049/jimmunol.1002503; Leonard WJ, 2002, NAT IMMUNOL, V3, P605, DOI 10.1038/ni0702-605; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Levin SD, 1999, J IMMUNOL, V162, P677; Li DQ, 2011, J ALLERGY CLIN IMMUN, V128, P1318, DOI 10.1016/j.jaci.2011.06.041; Li M, 2005, P NATL ACAD SCI USA, V102, P14795, DOI 10.1073/pnas.0507385102; Li M, 2006, P NATL ACAD SCI USA, V103, P11736, DOI 10.1073/pnas.0604575103; Liu T, 2011, AM J MED SCI, V341, P40, DOI 10.1097/MAJ.0b013e3181f20489; Matsuda A, 2010, INVEST OPHTH VIS SCI, V51, P151, DOI 10.1167/iovs.09-4183; Miyata M, 2008, EUR J IMMUNOL, V38, P1487, DOI 10.1002/eji.200737809; Miyata M, 2009, EUR J IMMUNOL, V39, P3078, DOI 10.1002/eji.200939302; Mou ZL, 2009, ACTA OTO-LARYNGOL, V129, P297, DOI 10.1080/00016480802225884; Nagata Y, 2007, INT ARCH ALLERGY IMM, V144, P305, DOI 10.1159/000106319; Nguyen Khoa D, 2010, Allergy Asthma Clin Immunol, V6, P4, DOI 10.1186/1710-1492-6-4; Oh MH, 2011, J IMMUNOL, V186, P7232, DOI 10.4049/jimmunol.1100504; Omori M, 2007, J IMMUNOL, V178, P1396; Pandey A, 2000, NAT IMMUNOL, V1, P59; Park LS, 2000, J EXP MED, V192, P659, DOI 10.1084/jem.192.5.659; Quentmeier H, 2001, LEUKEMIA, V15, P1286, DOI 10.1038/sj.leu.2402175; Ray RJ, 1996, EUR J IMMUNOL, V26, P10, DOI 10.1002/eji.1830260103; Reardon C, 2011, IMMUNITY, V35, P223, DOI 10.1016/j.immuni.2011.05.015; Reche PA, 2001, J IMMUNOL, V167, P336; Rochman I, 2007, J IMMUNOL, V178, P6720; Rochman Y, 2010, P NATL ACAD SCI USA, V107, P19455, DOI 10.1073/pnas.1008271107; Rothenberg ME, 2010, NAT GENET, V42, P289, DOI 10.1038/ng.547; Semlali A, 2010, J ALLERGY CLIN IMMUN, V125, P844, DOI 10.1016/j.jaci.2010.01.044; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Shamim Z, 2007, INT J IMMUNOGENET, V34, P149, DOI 10.1111/j.1744-313X.2007.00657.x; Sherrill JD, 2010, J ALLERGY CLIN IMMUN, V126, P160, DOI 10.1016/j.jaci.2010.04.037; Shi LY, 2008, CLIN IMMUNOL, V129, P202, DOI 10.1016/j.clim.2008.07.015; Shigeno T, 2009, IMMUNOLOGY, V128, pe849, DOI 10.1111/j.1365-2567.2009.03094.x; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, pe1; Shikotra A, 2012, J ALLERGY CLIN IMMUN, V129, P104, DOI 10.1016/j.jaci.2011.08.031; Sims JE, 2000, J EXP MED, V192, P671, DOI 10.1084/jem.192.5.671; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Tonozuka Y, 2001, CYTOGENET CELL GENET, V93, P23, DOI 10.1159/000056941; Torgerson DG, 2011, NAT GENET, V43, P887, DOI 10.1038/ng.888; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; Watanabe N, 2004, NAT IMMUNOL, V5, P426, DOI 10.1038/ni1048; Watanabe N, 2005, NATURE, V436, P1181, DOI 10.1038/nature03886; Wong CK, 2010, AM J RESP CELL MOL, V43, P305, DOI 10.1165/rcmb.2009-0168OC; Xu G, 2010, ALLERGY, V65, P581, DOI 10.1111/j.1398-9995.2009.02252.x; Ying S, 2005, J IMMUNOL, V174, P8183; Ying S, 2008, J IMMUNOL, V181, P2790; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503; Zhang F, 2011, CLIN EXP IMMUNOL, V164, P256, DOI 10.1111/j.1365-2249.2011.04328.x; Zhang KQ, 2007, AM J PHYSIOL-LUNG C, V293, pL375, DOI 10.1152/ajplung.00045.2007; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106; Zheng XF, 2010, INVEST OPHTH VIS SCI, V51, P3076, DOI 10.1167/iovs.09-4122; Zhou BH, 2008, J IMMUNOL, V181, P6557; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu DD, 2009, CHINESE MED J-PEKING, V122, P2303, DOI 10.3760/cma.j.issn.0366-6999.2009.19.021; Ziegler SF, 2010, NAT IMMUNOL, V11, P289, DOI 10.1038/ni.1852	92	76	78	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2012	130	4					845	852		10.1016/j.jaci.2012.07.010		8	Allergy; Immunology	Allergy; Immunology	017MT	WOS:000309594800002	22939755	
J	Brehm, JM; Acosta-Perez, E; Klei, L; Roeder, K; Barmada, M; Boutaoui, N; Forno, E; Kelly, R; Paul, K; Sylvia, J; Litonjua, AA; Cabana, M; Alvarez, M; Colon-Semidey, A; Canino, G; Celedon, JC				Brehm, John M.; Acosta-Perez, Edna; Klei, Lambertus; Roeder, Kathryn; Barmada, Michael; Boutaoui, Nadia; Forno, Erick; Kelly, Roxanne; Paul, Kathryn; Sylvia, Jody; Litonjua, Augusto A.; Cabana, Michael; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa; Celedon, Juan C.			Vitamin D Insufficiency and Severe Asthma Exacerbations in Puerto Rican Children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						vitamin D; asthma exacerbations; Puerto Ricans; childhood	GENETIC ANCESTRY; AFRICAN ANCESTRY; LUNG-FUNCTION; INDUCTION; EXPOSURE; POPULATIONS; PREDICTORS; ADMIXTURE; MARKERS; ADULTS	Rationale: Vitamin D insufficiency (a serum 25(OH)D <30 ng/ml) has been associated with severe asthma exacerbations, but this could be explained by underlying racial ancestry or disease severity. Little is known about vitamin D and asthma in Puerto Ricans. Objectives To examine whether vitamin D insufficiency is associated with severe asthma exacerbations in Puerto Rican children, independently of racial ancestry, atopy, and time outdoors. Methods: A cross-sectional study was conducted of 560 children ages 6-14 years with (n = 287) and without (n = 273) asthma in San Juan, Puerto Rico. We measured plasma vitamin D and estimated the percentage of African racial ancestry among participants using genome-wide genotypic data. We tested whether vitamin D insufficiency is associated with severe asthma exacerbations, lung function, or atopy (greater than or equal to one positive IgE to allergens) using logistic or linear regression. Multivariate models were adjusted for African ancestry, time outdoors, atopy, and other covariates. Measurements and Main Results Vitamin D insufficiency was common in children with (44%) and without (47%) asthma. In multivariate analyses, vitamin D insufficiency was associated with higher odds of greater than or equal to one severe asthma exacerbation in the prior year (odds ratio [OR], 2.6; 95% confidence interval [CI], 1.5-4.9; P = 0.001) and atopy, and a lower FEV1/FVC in cases. After stratification by atopy, the magnitude of the association between vitamin D insufficiency and severe exacerbations was greater in nonatopic (OR, 6.2; 95% CI, 2-21.6; P = 0.002) than in atopic (OR, 2; 95% CI, 1-4.1; P = 0.04) cases. Conclusions Vitamin D insufficiency is associated with severe asthma exacerbations in Puerto Rican children, independently of racial ancestry, atopy, or markers of disease severity or control.	[Brehm, John M.; Boutaoui, Nadia; Celedon, Juan C.] UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Dept Pediat, Pittsburgh, PA 15224 USA; [Klei, Lambertus] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Psychiat, Pittsburgh, PA USA; [Barmada, Michael] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Human Genet, Pittsburgh, PA 15261 USA; [Acosta-Perez, Edna; Alvarez, Maria; Colon-Semidey, Angel; Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA; [Roeder, Kathryn] Carnegie Mellon Univ, Dept Stat, Pittsburgh, PA 15213 USA; [Forno, Erick] Univ Miami, Dept Pediat, Div Pediat Pulmonol, Miami, FL 33152 USA; [Kelly, Roxanne; Paul, Kathryn; Sylvia, Jody; Litonjua, Augusto A.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Cabana, Michael] Univ Calif San Francisco, Dept Pediat, Div Gen Pediat, San Francisco, CA USA	Celedon, JC (reprint author), UPMC, Childrens Hosp Pittsburgh, Div Pediat Pulm Med Allergy & Immunol, Dept Pediat, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	juan.celedon@chp.edu		acosta, edna/0000-0001-7101-3157; Barmada, M Michael/0000-0002-3604-6460; Litonjua, Augusto/0000-0003-0422-5875; Forno, Erick/0000-0001-6497-9885	National Institutes of Health [R01HL079966, K12HD052892]; Children's Hospital of Pittsburgh of the UPMC Health System	Supported by grant R01HL079966 from the National Institutes of Health. J.M.B. receives support from NIH grant K12HD052892. This project was supported in part by Children's Hospital of Pittsburgh of the UPMC Health System.	Bird HR, 2006, J AM ACAD CHILD PSY, V45, P1032, DOI 10.1097/01.chi.0000227879.65651.cf; Brehm JM, 2012, J ALLERGY CLIN IMMUN, V129, P1484, DOI 10.1016/j.jaci.2012.03.035; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Dwyer T, 1996, MELANOMA RES, V6, P231, DOI 10.1097/00008390-199606000-00006; Forno E, 2009, CURR OPIN ALLERGY CL, V9, P154, DOI 10.1097/ACI.0b013e3283292207; Freeman NCG, 2003, J EXPO ANAL ENV EPID, V13, P169, DOI 10.1038/sj.jea.7500266; Gent JF, 2009, ENVIRON RES, V109, P768, DOI 10.1016/j.envres.2009.04.010; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, P1243, DOI 10.1016/j.jaci.2012.01.044; Hansdottir S, 2008, J IMMUNOL, V181, P7090; Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840; Kabagambe EK, 2001, AM J EPIDEMIOL, V154, P1126, DOI 10.1093/aje/154.12.1126; Kuczmarski RJ, 2000, ADV DATA, V314, P1; Kumar R, 2010, NEW ENGL J MED, V363, P321, DOI 10.1056/NEJMoa0907897; Li JZ, 2008, SCIENCE, V319, P1100, DOI 10.1126/science.1153717; Mansbach JM, 2009, PEDIATRICS, V124, P1404, DOI 10.1542/peds.2008-2041; Martin Joyce A., 2011, Morbidity and Mortality Weekly Report, V60, P78; Palacios C, 2012, ANN NUTR METAB, V60, P35, DOI 10.1159/000335282; Parra EJ, 2004, NAT GENET, V36, pS54, DOI 10.1038/ng1440; Paul G, 2012, AM J RESP CRIT CARE, V185, P124, DOI 10.1164/rccm.201108-1502CI; Perez-Perdomo R, 2003, J ASTHMA, V40, P465, DOI 10.1081/JAS-120018713; Ramsey CD, 2005, PEDIATR PULM, V39, P268, DOI 10.1002/ppul.20177; Reddel HK, 2009, AM J RESP CRIT CARE, V180, P59, DOI 10.1164/rccm.200801-060ST; Rojas W, 2010, AM J PHYS ANTHROPOL, V143, P13, DOI 10.1002/ajpa.21270; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sankararaman S, 2008, AM J HUM GENET, V82, P290, DOI [10.1016/j.ajhg.2007.09.022, 10.1016/i.ajhg.2007.09.022]; Searing DA, 2010, J ALLERGY CLIN IMMUN, V125, P995, DOI 10.1016/j.jaci.2010.03.008; Shriver MD, 2003, HUM GENET, V112, P387, DOI 10.1007/s00439-002-0896-y; Signorello LB, 2010, CANCER EPIDEM BIOMAR, V19, P2325, DOI 10.1158/1055-9965.EPI-10-0482; Tang H, 2007, AM J HUM GENET, V81, P626, DOI 10.1086/520769; Thorisson GA, 2005, GENOME RES, V15, P1592, DOI 10.1101/gr.4413105; Via M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016513; Vila D, 2010, J ASTHMA, V47, P1136, DOI 10.3109/02770903.2010.517338; Wang S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000037; Wittke A, 2007, ARCH BIOCHEM BIOPHYS, V460, P306, DOI 10.1016/j.abb.2006.12.011; Wu AC, 2011, CHEST, V140, P100, DOI 10.1378/chest.10-2794; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; [Anonymous], 2011, HOUSEHOLD INCOME STA	38	76	79	0	8	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2012	186	2					140	146		10.1164/rccm.201203-0431OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	974OH	WOS:000306445300009	22652028	
J	Wills-Karp, M; Rani, R; Dienger, K; Lewkowich, I; Fox, JG; Perkins, C; Lewis, L; Finkelman, FD; Smith, DE; Bryce, PJ; Kurt-Jones, EA; Wang, TC; Sivaprasad, U; Hershey, GK; Herbert, DR				Wills-Karp, Marsha; Rani, Reena; Dienger, Krista; Lewkowich, Ian; Fox, James G.; Perkins, Charles; Lewis, Lauren; Finkelman, Fred D.; Smith, Dirk E.; Bryce, Paul J.; Kurt-Jones, Evelyn A.; Wang, Timothy C.; Sivaprasad, Umasundari; Hershey, Gurjit K.; Herbert, De'Broski R.			Trefoil factor 2 rapidly induces interleukin 33 to promote type 2 immunity during allergic asthma and hookworm infection	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							IN-VIVO; AIRWAY HYPERREACTIVITY; DENDRITIC CELLS; ACUTE SCHISTOSOMIASIS; CYTOKINE PRODUCTION; HELMINTH INFECTION; ADAPTIVE IMMUNITY; EFFECTOR FUNCTION; EPITHELIAL-CELLS; T-CELLS	The molecular mechanisms that drive mucosal T helper type 2 (T(H)2) responses against parasitic helminths and allergens remain unclear. In this study, we demonstrate in mice that TFF2 (trefoil factor 2), an epithelial cell-derived repair molecule, is needed for the control of lung injury caused by the hookworm parasite Nippostrongylus brasiliensis and for type 2 immunity after infection. TFF2 is also necessary for the rapid production of IL-33, a T(H)2-promoting cytokine, by lung epithelia, alveolar macrophages, and inflammatory dendritic cells in infected mice. TFF2 also increases the severity of allergic lung disease caused by house dust mite antigens or IL-13. Moreover, TFF2 messenger RNA expression is significantly increased in nasal mucosal brushings during asthma exacerbations in children. These experiments extend the biological functions of TFF2 from tissue repair to the initiation and maintenance of mucosal T(H)2 responses.	[Wills-Karp, Marsha; Rani, Reena; Dienger, Krista; Lewkowich, Ian; Perkins, Charles; Lewis, Lauren; Finkelman, Fred D.; Herbert, De'Broski R.] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA; [Sivaprasad, Umasundari; Hershey, Gurjit K.] Cincinnati Childrens Hosp Med Ctr, Div Asthma Res, Cincinnati, OH 45229 USA; [Fox, James G.] MIT, Div Comparat Med, Cambridge, MA 02139 USA; [Finkelman, Fred D.] Univ Cincinnati, Coll Med, Div Rheumatol Allergy & Immunol, Cincinnati, OH 45267 USA; [Finkelman, Fred D.] Cincinnati Vet Affairs Med Ctr, Dept Med, Cincinnati, OH 45220 USA; [Smith, Dirk E.] Amgen Inc, Dept Inflammat Res, Seattle, WA 98119 USA; [Bryce, Paul J.] Northwestern Univ, Feinberg Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA; [Kurt-Jones, Evelyn A.] Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA; [Wang, Timothy C.] Columbia Univ, Med Ctr, Dept Med, New York, NY 10032 USA	Herbert, DR (reprint author), Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA.	debroski.herbert@cchmc.org	Herbert, De'Broski/J-7357-2012	Herbert, De'Broski/0000-0002-2449-5365	US Department of Veterans Affairs, T.C; National Institutes of Health (NIH) [5R01DK060758]; NIH [R01AI076456, RO1 HL67736, RO1 AI1183315, U19A170235, P50ES015903];  [U19AI70235];  [R01AI095289];  [R01GM083204]	D. Finkelman is supported by a merit award from the US Department of Veterans Affairs, T.C. Wang is supported by National Institutes of Health (NIH) grant 5R01DK060758, G. K. Hershey is supported by grant U19AI70235, P.J. Bryce is supported by NIH grant R01AI076456, M. Wills- Karp is supported by NIH grants RO1 HL67736, RO1 AI1183315, U19A170235, and P50ES015903, IPL is supported by a Parker B. Francis Award, and D.R. Herbert is supported by grants R01AI095289 and R01GM083204.	Agrawal Anurag, 2007, Recent Pat Inflamm Allergy Drug Discov, V1, P188, DOI 10.2174/187221307782418865; Ali S, 2007, P NATL ACAD SCI USA, V104, P18660, DOI 10.1073/pnas.0705939104; Allen CDC, 2004, NAT IMMUNOL, V5, P943, DOI 10.1038/ni1100; Artis D, 2008, MUCOSAL IMMUNOL, V1, P252, DOI 10.1038/mi.2008.21; Baena-Cagnani C E, 2001, Curr Allergy Asthma Rep, V1, P297, DOI 10.1007/s11882-001-0037-z; Barron L, 2011, AM J PHYSIOL-GASTR L, V300, pG723, DOI 10.1152/ajpgi.00414.2010; Braman SS, 2006, CHEST, V130, p4S, DOI 10.1378/chest.130.1_suppl.4S; Brancato SK, 2011, AM J PATHOL, V178, P19, DOI 10.1016/j.ajpath.2010.08.003; Brooker S, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000779; Brooker S, 2010, INT J PARASITOL, V40, P1137, DOI 10.1016/j.ijpara.2010.04.004; Carriere V, 2007, P NATL ACAD SCI USA, V104, P282, DOI 10.1073/pnas.0606854104; Chang YJ, 2011, NAT IMMUNOL, V12, P631, DOI 10.1038/ni.2045; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Dubeykovskaya Z, 2009, J BIOL CHEM, V284, P3650, DOI 10.1074/jbc.M804935200; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Farrell JJ, 2002, J CLIN INVEST, V109, P193, DOI 10.1172/JCI12529; FINKELMAN FD, 1993, J IMMUNOL, V151, P1235; Finkelman FD, 1999, INT IMMUNOL, V11, P1811, DOI 10.1093/intimm/11.11.1811; Finkelman FD, 2004, IMMUNOL REV, V201, P139, DOI 10.1111/j.0105-2896.2004.00192.x; Follettie MT, 2006, PHARMACOGENOMICS J, V6, P141, DOI 10.1038/sj.tpj.6500357; Fox JG, 2007, AM J PATHOL, V171, P1520, DOI 10.2353/ajpath.2007.070249; Gonzalo JA, 2000, J IMMUNOL, V165, P499; Grivel JC, 1999, NAT MED, V5, P344; Guajardo JR, 2005, J ALLERGY CLIN IMMUN, V115, P243, DOI 10.1016/j.jaci.2004.10.032; Guo LY, 2009, P NATL ACAD SCI USA, V106, P13463, DOI 10.1073/pnas.0906988106; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Herbert DR, 2008, J IMMUNOL, V181, P7214; Herbert DR, 2010, J IMMUNOL, V184, P6438, DOI 10.4049/jimmunol.0902009; Herbert DR, 2009, J EXP MED, V206, P2947, DOI 10.1084/jem.20091268; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; Humphreys NE, 2008, J IMMUNOL, V180, P2443; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jankovic D, 2000, J IMMUNOL, V164, P3047; Karp CL, 2010, J ALLERGY CLIN IMMUN, V125, P955, DOI 10.1016/j.jaci.2010.03.002; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P8170; Kurt-Jones EA, 2007, INFECT IMMUN, V75, P471, DOI 10.1128/IAI.02039-05; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Lukacs NW, 2002, AM J PATHOL, V160, P1353, DOI 10.1016/S0002-9440(10)62562-X; Marsland BJ, 2008, EUR J IMMUNOL, V38, P479, DOI 10.1002/eji.200737827; Meyer TS, 1998, EQUINE VET J, V30, P284; Mohrs M, 2001, IMMUNITY, V15, P303, DOI 10.1016/S1074-7613(01)00186-8; Nair MG, 2006, J IMMUNOL, V177, P1393; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nikolaidis NM, 2006, EXP LUNG RES, V32, P483, DOI 10.1080/01902140601059547; Nikolaidis NM, 2003, AM J RESP CELL MOL, V29, P458, DOI 10.1165/rcmb.2002-0309OC; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Ohno T, 2009, J IMMUNOL, V183, P7890, DOI 10.4049/jimmunol.0802449; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Paulsen FP, 2008, J BIOL CHEM, V283, P13418, DOI 10.1074/jbc.M800177200; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Podolsky DK, 1997, J GASTROENTEROL, V32, P122, DOI 10.1007/BF01213309; Poulsen SS, 2005, REGUL PEPTIDES, V126, P163, DOI 10.1016/j.regpep.2004.09.007; Prefontaine D, 2010, J ALLERGY CLIN IMMUN, V125, P752, DOI 10.1016/j.jaci.2009.12.935; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Rani R, 2011, EUR J IMMUNOL, V41, P2000, DOI 10.1002/eji.201041135; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Rankin AL, 2010, J IMMUNOL, V184, P1526, DOI 10.4049/jimmunol.0903306; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Seki N, 2004, J IMMUNOL, V172, P6158; Takeuchi O, 2002, CURR TOP MICROBIOL, V270, P155; Taupin D, 2003, NAT REV MOL CELL BIO, V4, P721, DOI 10.1038/nrm1203; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Thim L, 2002, EUR J CLIN INVEST, V32, P519, DOI 10.1046/j.1365-2362.2002.01014.x; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Trzpis M, 2007, AM J PATHOL, V171, P386, DOI 10.2353/ajpath.2007.070152; van Panhuys N, 2008, P NATL ACAD SCI USA, V105, P12423, DOI 10.1073/pnas.0806372105; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zaiss MM, 2011, J IMMUNOL, V186, P6097, DOI 10.4049/jimmunol.1003487; Zaph C, 2007, NATURE, V446, P552, DOI 10.1038/nature05590	81	76	79	1	7	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	MAR 12	2012	209	3					607	622		10.1084/jem.20110079		16	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	923RH	WOS:000302635900018	22329990	
J	Cassani, B; Villablanca, EJ; Quintana, FJ; Love, PE; Lacy-Hulbert, A; Blaner, WS; Sparwasser, T; Snapper, SB; Weiner, HL; Mora, JR				Cassani, Barbara; Villablanca, Eduardo J.; Quintana, Francisco J.; Love, Paul E.; Lacy-Hulbert, Adam; Blaner, William S.; Sparwasser, Tim; Snapper, Scott B.; Weiner, Howard L.; Mora, J. Rodrigo			Gut-Tropic T Cells That Express Integrin alpha 4 beta 7 and CCR9 Are Required for Induction of Oral Immune Tolerance in Mice	GASTROENTEROLOGY			English	Article						Immune Regulation; Autoimmunity; Allergy; Intestine; Peyer's Patch	PLASMACYTOID DENDRITIC CELLS; RETINOIC-ACID; SMALL-INTESTINE; SUPPRESSION; COLITIS; ABSENCE; IL-10; TH17; INFLAMMATION; LYMPHOCYTES	BACKGROUND & AIMS: Induction of oral immune tolerance (OT) blocks proinflammatory responses to orally administered antigens and might be used to treat autoimmune conditions. We investigated whether gut-tropic T cells that express the integrin alpha 4 beta 7 and the chemokine receptor CCR9 are required for OT. METHODS: Skin delayed-type hypersensitivity and experimental autoimmune encephalomyelitis were used to monitor OT in mice. To assess the role of receptors that mediate localization of lymphocytes to the gut (gut-homing receptors) in induction of OT, we studied CCR9(-/-) and beta 7(-/-) mice and also blocked the alpha 4 beta 7 ligand MAdCAM-1 in wild-type mice. We used DEREG and Scurfy mice to assess the role of Foxp3(+) regulatory T cells (Treg) and IL-10(-/-) and IL-10R beta(-/-) mice to examine the role of interleukin (IL)-10 in induction of OT. RESULTS: OT could not be induced in CCR9(-/-) or beta 7(-/-) mice, or when MAdCAM-1 was blocked in wild-type mice, indicating that gut-homing receptors are required for oral tolerization. Consistent with the role of all-trans retinoic acid in inducing gut-homing T cells, OT could not be induced in mice depleted of vitamin A. OT was rescued in CCR9(-/-) mice following adoptive transfer of wild-type T cells, but not CCR9(-/-) or beta 7(-/-) T cells. Gut-homing T cells are therefore necessary and sufficient to induce OT. Wild-type Treg and IL-10 were required to restore OT to CCR9-/- mice, indicating that homing and functional differentiation of IL-10-producing Treg in the gut is required for OT. Conversely, transfer of CCR9(-/-) or beta 7(-/-) T cells to wild-type mice partially inhibited OT. CONCLUSIONS: Expression of CCR9 and alpha 4 beta 7 on T cells and their subsequent localization to the gut is required for induction of OT in mice. Therapies designed to block gut-homing receptors might, under some conditions, interfere with normal tolerogenic mechanisms in the intestinal mucosa.	[Cassani, Barbara; Villablanca, Eduardo J.; Mora, J. Rodrigo] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; [Snapper, Scott B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Snapper, Scott B.] Childrens Hosp, Gastrointestinal Unit, Boston, MA 02115 USA; [Quintana, Francisco J.; Weiner, Howard L.] Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; [Love, Paul E.; Lacy-Hulbert, Adam] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA; [Blaner, William S.] Columbia Univ, Dept Med, New York, NY USA; [Sparwasser, Tim] Ctr Expt & Clin Infect Res, Inst Infect Immunol, Hannover, Germany	Mora, JR (reprint author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.	j_rodrigo_mora@hms.harvard.edu	Villablanca, Eduardo/E-1380-2016; Cassani, Barbara/K-3871-2016	Villablanca, Eduardo/0000-0001-9522-9729; Cassani, Barbara/0000-0002-4115-8109; Lacy-Hulbert, Adam/0000-0003-2162-0156	EMBO; Crohn's & Colitis Foundation of America; National Institutes of Health [R00 AI075285-02, AI435801, NS38037, P30 AR042689, DP2 2009A054301]; National Multiple Sclerosis Society [RG4111A1]; Boston Area Diabetes Endocrinology Research Center; Cancer Research Institute; Massachusetts Life Science Center	B.C. was supported by an EMBO postdoctoral fellowship. E.J.V. was supported by a postdoctoral fellowship from the Crohn's & Colitis Foundation of America. F.J.Q. was supported by grants from the National Institutes of Health (R00 AI075285-02), National Multiple Sclerosis Society (RG4111A1), and Boston Area Diabetes Endocrinology Research Center. H.L.W. was supported by National Institutes of Health grants AI435801 and NS38037. J.R.M. was supported by grants from the Crohn's & Colitis Foundation of America, Cancer Research Institute, Massachusetts Life Science Center, National Institutes of Health Pilot Feasibility Award P30 AR042689, and National Institutes of Health Director's New Innovator Award DP2 2009A054301.	Arnaboldi PM, 2009, MUCOSAL IMMUNOL, V2, P427, DOI 10.1038/mi.2009.93; BENSON MJ, 2007, J EXP MED, V204, P1775; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Cha HR, 2010, J IMMUNOL, V184, P6799, DOI 10.4049/jimmunol.0902944; Chaudhry A, 2011, IMMUNITY, V34, P566, DOI 10.1016/j.immuni.2011.03.018; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Cong Y, 2004, ANN NY ACAD SCI, V1029, P319, DOI 10.1196/annals.1309.037; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Dubois B, 2009, GASTROENTEROLOGY, V137, P1019, DOI 10.1053/j.gastro.2009.03.055; Eksteen B, 2008, INFLAMM BOWEL DIS, V14, P1298, DOI 10.1002/ibd.20453; Ericsson A, 2004, EUR J IMMUNOL, V34, P2720, DOI 10.1002/eji.200425125; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; FERGUSON A, 1983, ANN ALLERGY, V51, P246; Goubier A, 2008, IMMUNITY, V29, P464, DOI 10.1016/j.immuni.2008.06.017; Hadeiba H, 2008, NAT IMMUNOL, V9, P1253, DOI 10.1038/ni.1658; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hauet-Broere F, 2003, EUR J IMMUNOL, V33, P2801, DOI 10.1002/eji.200324115; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Klonowski KD, 2004, IMMUNITY, V20, P551, DOI 10.1016/S1074-7613(04)00103-7; Lahl K, 2007, J EXP MED, V204, P57, DOI 10.1084/jem.20061852; Liu B, 2011, GASTROENTEROLOGY, V141, P653, DOI 10.1053/j.gastro.2011.04.053; Mora JR, 2008, INFLAMM BOWEL DIS, V14, P275, DOI 10.1002/ibd.20280; Mora JR, 2006, SCIENCE, V314, P1157, DOI 10.1126/science.1132742; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Murai M, 2009, NAT IMMUNOL, V10, P1178, DOI 10.1038/ni.1791; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; O'Byrne SM, 2005, J BIOL CHEM, V280, P35647, DOI 10.1074/jbc.M507924200; Papadakis KA, 2003, J IMMUNOL, V171, P159; Peron JPS, 2010, J NEUROIMMUNOL, V227, P10, DOI 10.1016/j.jneuroim.2010.06.002; Rizzo LV, 1999, J IMMUNOL, V162, P2613; Spahn TW, 2002, EUR J IMMUNOL, V32, P1109, DOI 10.1002/1521-4141(200204)32:4<1109::AID-IMMU1109>3.3.CO;2-B; Stenstad H, 2007, P NATL ACAD SCI USA, V104, P10122, DOI 10.1073/pnas.0700269104; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Uehara S, 2002, J IMMUNOL, V168, P2811; Uhlig HH, 2006, J IMMUNOL, V177, P5852; Wakabayashi A, 2006, IMMUNOLOGY, V119, P167, DOI 10.1111/j.1365-2567.2006.02418.x; Weiner HL, 2011, IMMUNOL REV, V241, P241, DOI 10.1111/j.1600-065X.2011.01017.x; Wendland M, 2007, P NATL ACAD SCI USA, V104, P6347, DOI 10.1073/pnas.0609180104; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Youn BS, 2001, BLOOD, V98, P925, DOI 10.1182/blood.V98.4.925; Zhang XM, 2001, J IMMUNOL, V167, P4245	44	76	78	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085			GASTROENTEROLOGY	Gastroenterology	DEC	2011	141	6					2109	2118		10.1053/j.gastro.2011.09.015		10	Gastroenterology & Hepatology	Gastroenterology & Hepatology	852DQ	WOS:000297329000032	21925467	
J	Valenta, R; Linhart, B; Swoboda, I; Niederberger, V				Valenta, R.; Linhart, B.; Swoboda, I.; Niederberger, V.			Recombinant allergens for allergen-specific immunotherapy: 10 years anniversary of immunotherapy with recombinant allergens	ALLERGY			English	Review						allergy; clinical trial; immunotherapy; recombinant allergen	BIRCH-POLLEN ALLERGEN; BET V 1; DUST MITE ALLERGEN; 3-YEAR DOUBLE-BLIND; B-CELL EPITOPES; PHL P 1; IMMUNOGLOBULIN-E; IGE ANTIBODIES; SUBLINGUAL IMMUNOTHERAPY; DIAGNOSTIC GATEKEEPERS	P>The broad applicability of allergen-specific immunotherapy for the treatment and eventually prevention of IgE-mediated allergy is limited by the poor quality and allergenic activity of natural allergen extracts that are used for the production of current allergy vaccines. Today, the genetic code of the most important allergens has been deciphered; recombinant allergens equalling their natural counterparts have been produced for diagnosis and immunotherapy, and a large panel of genetically modified allergens with reduced allergenic activity has been characterized to improve safety of immunotherapy and explore allergen-specific prevention strategies. Successful immunotherapy studies have been performed with recombinant allergens and hypoallergenic allergen derivatives and will lead to the registration of the first recombinant allergen-based vaccines in the near future. There is no doubt that recombinant allergen-based vaccination strategies will be generally applicable to most allergen sources, including respiratory, food and venom allergens and allow to produce safe allergy vaccines for the treatment of the most common forms of IgE-mediated allergies.	[Valenta, R.; Swoboda, I.] Med Univ Vienna, Christian Doppler Lab Allergy Res, A-1090 Vienna, Austria; [Valenta, R.; Linhart, B.] Med Univ Vienna, Div Immunopathol, Ctr Pathophysiol Infectiol & Immunol, Dept Pathophysiol & Allergy Res, A-1090 Vienna, Austria; [Niederberger, V.] Med Univ Vienna, ENT Dept, A-1090 Vienna, Austria	Valenta, R (reprint author), Med Univ Vienna, Christian Doppler Lab Allergy Res, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at			Austrian Science Fund, SFB [F1815, F1818, P23350-B11]; Christian Doppler Research Association; Biomay, Vienna, Austria	This article is dedicated to my mentor Prof. Dietrich Kraft. The study was supported by the Austrian Science Fund, SFB grants F1815, F1818, grant P23350-B11, by the Christian Doppler Research Association and a research grant from Biomay, Vienna, Austria.	Ball T, 1999, FASEB J, V13, P1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; BALL T, 1994, J BIOL CHEM, V269, P28323; BIRKNER T, 1990, ALLERGY, V45, P418, DOI 10.1111/j.1398-9995.1990.tb01092.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935; Brunetto B, 2010, ALLERGY, V65, P184, DOI 10.1111/j.1398-9995.2009.02150.x; Campana R, 2011, MOL IMMUNOL, V48, P431, DOI 10.1016/j.molimm.2010.09.016; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Constantin C, 2009, ALLERGY, V64, P1030, DOI 10.1111/j.1398-9995.2009.01955.x; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Curin M, 2010, INT ARCH ALLERGY IMM, V154, P258; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Focke M, 2010, CLIN EXP ALLERGY, V40, P385, DOI 10.1111/j.1365-2222.2009.03443.x; Focke M, 2009, EUR J CLIN INVEST, V39, P429, DOI 10.1111/j.1365-2362.2009.02109.x; Gadermaier G, 2008, ALLERGY, V63, P1543, DOI 10.1111/j.1398-9995.2008.01780.x; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hochwallner H, 2010, CLIN EXP ALLERGY, V40, P1809, DOI 10.1111/j.1365-2222.2010.03602.x; IPSEN H, 1988, ALLERGY, V43, P370, DOI 10.1111/j.1398-9995.1988.tb00431.x; IPSEN H, 1982, Journal of Allergy and Clinical Immunology, V69, P127; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Klimek L, 2005, ALLERGY CLIN IMMUN S, P15; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Laffer S, 1996, J ALLERGY CLIN IMMUN, V98, P652, DOI 10.1016/S0091-6749(96)70099-4; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Larenas-Linnemann D, 2010, CURR OPIN INVEST DR, V11, P586; Lin J, 2009, J ALLERGY CLIN IMMUN, V124, P315, DOI 10.1016/j.jaci.2009.05.024; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Mothes-Luksch N, 2008, J IMMUNOL, V181, P4864; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; NIESPODZIANA K, 2011, J ALLERGY C IN PRESS; Noon L, 1911, LANCET, V1, P1572; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; PETERSEN BN, 1988, ALLERGY, V43, P353, DOI 10.1111/j.1398-9995.1988.tb00429.x; Prausnitz C, 1921, ZBL BAKT           1, V86, P160; Pree I, 2010, CLIN EXP ALLERGY, V40, P1346, DOI 10.1111/j.1365-2222.2010.03548.x; Pree I, 2007, J IMMUNOL, V179, P5309; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Rak S, 2009, 27 C EAACI 2009 WARS; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; Schmid-Grendelmeier P, 2010, HAUTARZT, V61, P946, DOI 10.1007/s00105-010-1967-y; SEHON AH, 1990, EPITOPES ATOPIC ALLE; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Stumvoll S, 2003, J ALLERGY CLIN IMMUN, V111, P974, DOI 10.1067/mai.2003.1376; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2010, ANNU REV IMMUNOL, V28, P211, DOI 10.1146/annurev-immunol-030409-101218; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V98, P913, DOI 10.1016/S0091-6749(96)80007-8; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; Westritschnig K, 2003, CLIN EXP ALLERGY, V33, P22, DOI 10.1046/j.1365-2222.2003.01540.x; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x; Winther L, 2009, J ALLERGY CLIN IMMUN, V123, pS215, DOI 10.1016/j.jaci.2008.12.822; Zeiler T, 1997, J ALLERGY CLIN IMMUN, V100, P721, DOI 10.1016/S0091-6749(97)70264-1; ZHANG L, 1992, IMMUNOLOGY, V76, P158; ZHANG L, 1993, J IMMUNOL, V151, P791	89	76	87	0	6	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	JUN	2011	66	6					775	783		10.1111/j.1398-9995.2011.02565.x		9	Allergy; Immunology	Allergy; Immunology	754ZP	WOS:000289896700008	21352238	
J	Salo, PM; Calatroni, A; Gergen, PJ; Hoppin, JA; Sever, ML; Jaramillo, R; Arbes, SJ; Zeldin, DC				Salo, Paeivi M.; Calatroni, Agustin; Gergen, Peter J.; Hoppin, Jane A.; Sever, Michelle L.; Jaramillo, Renee; Arbes, Samuel J., Jr.; Zeldin, Darryl C.			Allergy-related outcomes in relation to serum IgE: Results from the National Health and Nutrition Examination Survey 2005-2006	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; allergy; allergic sensitization; serum IgE	INHALANT ALLERGENS; NATURAL-HISTORY; UNITED-STATES; RISK-FACTORS; DUST-MITE; SKIN-TEST; US HOMES; RHINITIS; PREVALENCE; ASTHMA	Background: The National Health and Nutrition Examination Survey (NHANES) 2005-2006 was the first population-based study to investigate levels of serum total and allergen-specific IgE in the general US population. Objective: We estimated the prevalence of allergy-related outcomes and examined relationships between serum IgE levels and these outcomes in a representative sample of the US population. Methods: Data for this cross-sectional analysis were obtained from NHANES 2005-2006. Study subjects aged 6 years and older (n = 8086) had blood taken for measurement of total IgE and 19 specific IgE levels against common aeroallergens, including Alternaria alternata, Aspergillus fumigatus, Bermuda grass, birch, oak, ragweed, Russian thistle, rye grass, cat dander, cockroach, dog dander, dust mite (Dermatophagoides farinae and Dermatophagoides pteronyssinus), mouse and rat urine proteins, and selected foods (egg white, cow's milk, peanut, and shrimp). Serum samples were analyzed for total and allergen-specific IgE by using the Pharmacia CAP System. Information on allergy-related outcomes and demographics was collected by questionnaire. Results: In NHANES 2005-2006, 6.6% reported current hay fever, and 23.5% had current allergies. Allergy-related outcomes increased with increasing total IgE levels (adjusted odds ratios for a 10-fold increase in total IgE level of 1.86 [95% CI, 1.44-2.41] for hay fever and 1.64 [ 95% CI, 1.41-1.91] for allergies). Increased levels of plant-, pet-, and mold-specific IgE contributed independently to allergy-related symptoms. The greatest increase in odds was observed for hay fever and plant-specific IgE (adjusted odds ratio, 4.75; 95% CI, 3.83-5.88). Conclusion: In the US population self-reported allergy symptoms are most consistently associated with increased levels of plant-, pet-, and mold-specific IgE. (J Allergy Clin Immunol 2011;127:1226-35.)	[Salo, Paeivi M.; Hoppin, Jane A.; Sever, Michelle L.; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA; [Calatroni, Agustin; Arbes, Samuel J., Jr.] Rho Inc, Chapel Hill, NC USA; [Gergen, Peter J.] NIAID, NIH, Bethesda, MD 20892 USA; [Jaramillo, Renee] SRA Int Inc, Durham, NC USA	Zeldin, DC (reprint author), NIEHS, NIH, 111 TW Alexander Dr,Room A222, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Sever, Michelle/0000-0002-2435-1214	National Institutes of Health, National Institute of Environmental Health Sciences	Supported by the Intramural Research Program of the National Institutes of Health, National Institute of Environmental Health Sciences.	Ahlstedt Staffan, 2006, Prim Care Respir J, V15, P228, DOI 10.1016/j.pcrj.2006.05.004; Anto JM, 2010, ALLERGY, V65, P1021, DOI 10.1111/j.1398-9995.2009.02301.x; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Bellanti JA, 2000, ALLERGY ASTHMA PROC, V21, P367, DOI 10.2500/108854100778249088; BLOOM B, 2007, VITAL HLTH STAT 10, V234, P1; Bloom B, 2006, VITAL HLTH STAT 10, V231, P1; Burney P, 2010, ALLERGY, V65, P1182, DOI 10.1111/j.1398-9995.2010.02346.x; Bush RK, 2006, J ALLERGY CLIN IMMUN, V117, P326, DOI 10.1016/j.jaci.2005.12.001; Calabria CW, 2009, ALLERGY ASTHMA PROC, V30, P386, DOI 10.2500/aap.2009.30.3258; Calatroni A, 2009, J ALLERGY CLIN IMMUN, V123, pS193, DOI 10.1016/j.jaci.2008.12.732; Callahan KA, 2003, ANN ALLERG ASTHMA IM, V90, P302; Crown WH, 2003, VALUE HEALTH, V6, P448, DOI 10.1046/j.1524-4733.2003.64231.x; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53; Custovic A, 1998, THORAX, V53, P33; Ferreira F, 2004, ALLERGY, V59, P243, DOI 10.1046/j.1398-9995.2003.00407.x; Gergen PJ, 2009, J ALLERGY CLIN IMMUN, V124, P447, DOI 10.1016/j.jaci.2009.06.011; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; Greisner WA, 1998, ALLERGY ASTHMA PROC, V19, P271, DOI 10.2500/108854198778557728; Heinzerling LM, 2009, ALLERGY, V64, P1498, DOI 10.1111/j.1398-9995.2009.02093.x; Jarvis D, 2005, J ALLERGY CLIN IMMUN, V116, P675, DOI 10.1016/j.jaci.2005.05.009; LIU AH, 2010, J ALLERGY CLIN IMMUN, V126, pE13; Liu AH, 2010, J ALLERGY CLIN IMMUN, V126, P798, DOI 10.1016/j.jaci.2010.07.026; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Meltzer EO, 2009, J ALLERGY CLIN IMMUN, V124, pS43, DOI 10.1016/j.jaci.2009.05.013; *NAT CTR HLTH STAT, 2010, NCHS RES ETH REV BOA; National Center for Health Statistics, 2008, LAB PROC MAN NHANES; [Anonymous], 2005, PUBL DAT GEN REL FIL; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nathan RA, 2007, ALLERGY ASTHMA PROC, V28, P3, DOI 10.2500/aap.2007.28.2934; Nathan RA, 2008, ALLERGY ASTHMA PROC, V29, P600, DOI 10.2500/aap.2008.29.3179; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Phipatanakul W, 2005, IMMUNOL ALLERGY CLIN, V25, P263, DOI 10.1016/j.iac.2005.03.001; PHIPATANAKUL W, 2005, IMMUNOL ALLERGY CLIN, V25, pR6; Pleis J, 2007, VITAL HLTH STAT 10, V235, P1; Pleis JR, 2006, VITAL HLTH STAT, V232, P1; RADAUER C, 2008, J ALLERGY CLIN IMMUN, V121, pE7; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Ryan D, 2008, ALLERGY, V63, P981, DOI 10.1111/j.1398-9995.2008.01653.x; Salo PM, 2008, J ALLERGY CLIN IMMUN, V121, pS231, DOI 10.1016/j.jaci.2007.12.915; Scala E, 2010, CLIN EXP ALLERGY, V40, P911, DOI 10.1111/j.1365-2222.2010.03470.x; Settipane RA, 2003, ALLERGY ASTHMA PROC, V24, P147; Settipane RA, 2001, ALLERGY ASTHMA PROC, V22, P185; Sinclair D, 2004, J CLIN PATHOL, V57, P956, DOI 10.1136/jcp.2004.017681; Soeria-Atmadja D, 2007, J ALLERGY CLIN IMMUN, V120, P1433, DOI 10.1016/j.jaci.2007.07.021; Wallace DV, 2008, J ALLERGY CLIN IMMUN, V122, pS1, DOI 10.1016/j.jaci.2008.06.003; WITTIG HJ, 1980, J ALLERGY CLIN IMMUN, V66, P305, DOI 10.1016/0091-6749(80)90026-3	48	76	79	3	21	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1226	U527		10.1016/j.jaci.2010.12.1106		17	Allergy; Immunology	Allergy; Immunology	756NG	WOS:000290018600018	21320720	
J	Katz, Y; Goldberg, MR; Rajuan, N; Cohen, A; Leshno, M				Katz, Yitzhak; Goldberg, Michael R.; Rajuan, Nelly; Cohen, Adi; Leshno, Moshe			The prevalence and natural course of food protein-induced enterocolitis syndrome to cow's milk: A large-scale, prospective population-based study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Food protein-induced enterocolitis syndrome; oral challenge; soy allergy; skin prick test	CLINICAL-FEATURES; ALLERGY; CHALLENGE; SOY	Background: The prevalence and natural history for food protein-induced enterocolitis syndrome (FPIES) have not been determined. Objective: We sought to determine the prevalence, clinical manifestations, and rate of recovery for FPIES in a large-scale, population-based prospective study. Methods: In a prospective study the feeding history of 13,019 infants was obtained. Infants with probable adverse reactions to cow's milk protein (CMP) were clinically examined, skin prick tested, and challenged orally. Diagnostic criteria for CMP-induced FPIES included age less than 9 months, delayed recurrent vomiting (usually with nausea), and lethargy after exposure to CMP in the absence of other IgE-mediated symptoms, such as rash, urticaria, and respiratory symptoms. In addition, a positive challenge response to milk resulted in the above-mentioned gastrointestinal symptoms, removal of milk from the diet resulted in the resolution of those symptoms, or both. Results: Ninety-eight percent of the cohort participated in the study. The cumulative incidence for FPIES was 0.34% (44/13,019 patients). The most common symptoms were recurrent vomiting (100%), lethargy (77%) diarrhea (25%), pallor (14%), and bloody diarrhea (4.5%). All patients had FPIES within the first 6 months of life. By the age of 3 years, 90% of the patients had recovered. We did not detect any concomitant reaction to soy. Eight patients with FPIES had IgE-mediated cow's milk allergy (IgE-CMA). Conclusions: The prevalence of FPIES is significant, and its clinical presentation is distinct from that of IgE-CMA. Most patients with FPIES recover, although a proportion might convert to IgE-CMA. The likelihood for a cross-reactivity to soy in this population was less than previously estimated. (J Allergy Clin Immunol 2011;127:647-53.)	[Katz, Yitzhak; Goldberg, Michael R.; Cohen, Adi] Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel; [Katz, Yitzhak; Rajuan, Nelly] Tel Aviv Univ, Dept Pediat, IL-69978 Tel Aviv, Israel; [Leshno, Moshe] Tel Aviv Univ, Sackler Fac Med, Fac Management, IL-69978 Tel Aviv, Israel	Katz, Y (reprint author), Assaf Harofeh Med Ctr, Inst Allergy & Immunol, IL-70300 Zerifin, Israel.	ykatz49@gmail.com			Israel Dairy Foundation; Israel dairy board	Supported by the Israel Dairy Foundation.; Y. Katz receives research support from the Israel dairy board. The rest of the authors have declared that they have no conflict of interest.	Bruni F, 2008, Allergy, V63, P1645, DOI 10.1111/j.1398-9995.2008.01911.x; Elizur A, 2007, ANN ALLERG ASTHMA IM, V98, P540; GRYBOSKI JD, 1967, PEDIATRICS, V40, P354; Hwang JB, 2009, ARCH DIS CHILD, V94, P425, DOI 10.1136/adc.2008.143289; Katz Y, 2010, J ALLERGY CLIN IMMUN, V126, P77, DOI 10.1016/j.jaci.2010.04.020; Levy Y, 2003, PEDIATR ALLERGY IMMU, V14, P325, DOI 10.1034/j.1399-3038.2003.00039.x; Maloney J, 2007, PEDIATR ALLERGY IMMU, V18, P360, DOI 10.1111/j.1399-3038.2007.00561.x; MEHER S, 2009, PEDIATRICS, V123, pE459; Nowak-Wegrzyn A, 2003, PEDIATRICS, V111, P829, DOI 10.1542/peds.111.4.829; Nowak-Wegrzyn A, 2009, CURR OPIN ALLERGY CL, V9, P371, DOI 10.1097/ACI.0b013e32832d6315; POWELL GK, 1978, J PEDIATR-US, V93, P553, DOI 10.1016/S0022-3476(78)80887-7; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V115, P149, DOI 10.1016/j.jaci.2004.09.033; Sicherer SH, 1998, J PEDIATR-US, V133, P214, DOI 10.1016/S0022-3476(98)70222-7	14	76	88	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2011	127	3					647	U163		10.1016/j.jaci.2010.12.1105		10	Allergy; Immunology	Allergy; Immunology	730FG	WOS:000288018400014	21377033	
J	Risnes, KR; Belanger, K; Murk, W; Bracken, MB				Risnes, Kari R.; Belanger, Kathleen; Murk, William; Bracken, Michael B.			Antibiotic Exposure by 6 Months and Asthma and Allergy at 6 Years: Findings in a Cohort of 1,401 US Children	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						anti-bacterial agents; asthma; child; cohort studies; hypersensitivity	EARLY-CHILDHOOD; HYGIENE HYPOTHESIS; 1ST YEAR; MEDICATION USE; INCREASED RISK; BIRTH COHORT; SCHOOL-AGE; EARLY-LIFE; T-CELLS; INFECTIONS	Many studies have reported that antibiotic use may be associated with increased risk of childhood asthma. Respiratory tract infections in small children may be difficult to distinguish from early symptoms of asthma, and studies may have been confounded by "protopathic" bias, where antibiotics are used to treat early symptoms of asthma. These analyses of a cohort including 1,401 US children assess the association between antibiotic use within the first 6 months of life and asthma and allergy at 6 years of age between 2003 and 2007. Antibiotic exposure was associated with increased risk of asthma (adjusted odds ratio = 1.52, 95% confidence interval (CI): 1.07, 2.16). The odds ratio if asthma was first diagnosed after 3 years of age was 1.66 (95% CI: 0.99, 2.79) and, in children with no history of lower respiratory infection in the first year of life, the odds ratio was 1.66 (95% CI: 1.12, 3.46). The adverse effect of antibiotics was particularly strong in children with no family history of asthma (odds ratio = 1.89, 95% CI: 1.00, 3.58) (P(interaction) = 0.03). The odds ratio for a positive allergy blood or skin test was 1.59 (95% CI: 1.10, 2.28). The results show that early antibiotic use was associated with asthma and allergy at 6 years of age, and that protopathic bias was unlikely to account for the main findings.	[Risnes, Kari R.; Belanger, Kathleen; Murk, William; Bracken, Michael B.] Yale Univ, Sch Publ Hlth, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT 06510 USA; [Risnes, Kari R.; Belanger, Kathleen; Murk, William; Bracken, Michael B.] Yale Univ, Sch Med, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT 06510 USA; [Risnes, Kari R.] St Olavs Univ Hosp, Dept Pediat, Trondheim, Norway; [Risnes, Kari R.] Norwegian Univ Sci & Technol, Dept Publ Hlth, N-7034 Trondheim, Norway	Bracken, MB (reprint author), Yale Univ, Sch Publ Hlth, Ctr Perinatal Pediat & Environm Epidemiol, 1 Church St,6th Floor, New Haven, CT 06510 USA.	michael.bracken@yale.edu			National Institutes of Health [AI41040, DA05484]; Liaison Committee; Norwegian University of Science and Technology; Central Norway Regional Health Authority	This study was supported by grants AI41040 and DA05484 from the National Institutes of Health. K. R. R. was financially supported by a grant from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology.	Ahn KM, 2005, J ASTHMA, V42, P745, DOI 10.1080/02770900500308023; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P747; Akdis CA, 2009, J ALLERGY CLIN IMMUN, V123, P735, DOI 10.1016/j.jaci.2009.02.030; Belanger K, 2010, OBSTET GYNECOL, V115, P559, DOI 10.1097/AOG.0b013e3181d06945; Bjorksten B., 2009, NESTLE NUTR WORKSHOP, V64, P251; Bjorksten B, 2009, NESTLE NUTR WORKS SE, V64, P11, DOI 10.1159/000235780; Bracken MB, 2003, OBSTET GYNECOL, V102, P739, DOI 10.1016/S0029-7844(03)00621-5; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Hamilton RG, 2010, J ALLERGY CLIN IMMUN, V125, pS284, DOI 10.1016/j.jaci.2009.09.055; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233; Holt PG, 2010, CLIN EXP IMMUNOL, V160, P22, DOI 10.1111/j.1365-2249.2010.04129.x; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Kang EM, 2009, OBSTET GYNECOL, V114, P1295, DOI 10.1097/AOG.0b013e3181c225c0; Kjellman N I, 1991, Allerg Immunol (Paris), V23, P351; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Kusel MMH, 2008, CLIN EXP ALLERGY, V38, P1921, DOI 10.1111/j.1365-2222.2008.03138.x; Mai XM, 2010, CLIN EXP ALLERGY, V40, P1230, DOI 10.1111/j.1365-2222.2010.03532.x; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Martel MJ, 2009, AM J EPIDEMIOL, V169, P195, DOI 10.1093/aje/kwn309; Martinez FD, 1999, LANCET, V354, pS12; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Nicholas C, 2009, AM J EPIDEMIOL, V170, P388, DOI 10.1093/aje/kwp139; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Oien Torbjorn, 2008, Prim Care Respir J, V17, P164, DOI 10.3132/pcrj.2008.00023; Platts-Mills TAE, 2001, AM J RESP CRIT CARE, V164, P1107; Platts-Mills TA, 2001, AM J RESP CRIT CARE, V164, P1108; PLESS CE, 1995, ARCH PEDIAT ADOL MED, V149, P553; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott Susan L, 2003, Curr Opin Allergy Clin Immunol, V3, P125, DOI 10.1097/00130832-200304000-00006; Ribeiro-do-Couto LM, 2001, EUR J IMMUNOL, V31, P3394, DOI 10.1002/1521-4141(200111)31:11<3394::AID-IMMU3394>3.0.CO;2-B; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P978; Stevenson MD, 2007, J PEDIATR-US, V151, P187, DOI 10.1016/j.jpeds.2007.03.001; Stille CJ, 2004, PEDIATRICS, V114, P1206, DOI 10.1542/peds.2004-0311; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tamim H, 2007, PHARMACOEPIDEM DR S, V16, P250, DOI 10.1002/pds.1360; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; von Mutius E, 2001, AM J RESP CRIT CARE, V164, P1106; von Mutius E, 2001, AM J RESP CRIT CARE, V164, P1108; von Mutius E, 2007, IMMUNOBIOLOGY, V212, P433, DOI 10.1016/j.imbio.2007.03.002	47	76	86	0	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	FEB 1	2011	173	3					310	318		10.1093/aje/kwq400		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	709TC	WOS:000286463300007	21190986	
J	Radulovic, S; Calderon, MA; Wilson, D; Durham, S				Radulovic, Suzana; Calderon, Moises A.; Wilson, Duncan; Durham, Stephen			Sublingual immunotherapy for allergic rhinitis	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review						Administration, Sublingual; Allergens [administration & dosage]; Desensitization, Immunologic [methods]; Randomized Controlled Trials as Topic; Rhinitis, Allergic, Perennial [therapy]; Rhinitis, Allergic, Seasonal [therapy]; Humans	PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; RANDOMIZED CONTROLLED-TRIAL; GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; STANDARDIZED 5-GRASS-POLLEN EXTRACT; PARIETARIA-JUDAICA EXTRACT; SWALLOW IMMUNOTHERAPY; CLINICAL-EFFICACY; BIRCH POLLEN	Background This is an update of a Cochrane Review first published in The Cochrane Library in Issue 2, 2003. Allergic rhinitis is a common condition which can significantly impair quality of life. Immunotherapy by injection can significantly reduce symptoms and medication use but its use is limited by the possibility of severe systemic adverse reactions. Immunotherapy by the sublingual route is therefore of considerable interest. Objectives To evaluate the efficacy and safety of sublingual immunotherapy for allergic rhinitis in adults and children. Search strategy We searched the Cochrane ENT Group Trials Register; CENTRAL (2010, Issue 3); PubMed; EMBASE; CINAHL; Web of Science; BIOSIS Previews; Cambridge Scientific Abstracts; mRCT and additional sources for published and unpublished trials. The date of the most recent search was 14 August 2009. Selection criteria Randomised, double-blind, placebo-controlled trials of sublingual immunotherapy in adults or children. Primary outcome measures were symptom and medication scores. We also collected adverse event data. Data collection and analysis Two independent authors selected studies and assessed risk of bias. One author extracted data which was rechecked by two other authors. We used the standardised mean difference (SMD) with a random-effects model to combine data. Main results We included a total of 60 randomised controlled trials in the review. Forty-nine were suitable for pooling in meta-analyses (2333 SLIT, 2256 placebo participants). Overall, we found a significant reduction in symptoms (SMD-0.49; 95% confidence interval (CI) -0.64 to -0.34, P < 0.00001) andmedication requirements (SMD -0.32; 95% CI -0.43 to -0.21, P < 0.00001) in participants receiving sublingual immunotherapy compared to placebo. None of the trials included in this review reported severe systemic reactions or anaphylaxis, and none of the systemic reactions reported required the use of adrenaline. Authors' conclusions This updated review reinforces the conclusion of the original 2003 Cochrane Review that sublingual immunotherapy is effective for allergic rhinitis and has been proven to be a safe route of administration.	[Radulovic, Suzana] St Thomas Hosp, Paediat Allergy Res Dept, LEAP Study Team, London SE1 7EH, England; [Calderon, Moises A.; Durham, Stephen] Royal Brompton Hosp, Dept Allergy & Resp Med, London SW3 6LY, England; [Wilson, Duncan] Univ Hosp Birmingham NHS Trust, Selly Oak Hosp, Birmingham, W Midlands, England	Radulovic, S (reprint author), St Thomas Hosp, Paediat Allergy Res Dept, LEAP Study Team, Lambeth Palace Rd, London SE1 7EH, England.	radulovics@yahoo.com			ITN (Immune Tolerance Network); ALK Abello, Horsholm, Denmark	The lead review author, Dr Suzana Radulovic, has received financial support from the ITN (Immune Tolerance Network) as an employee of the Paediatric Allergy Research Department at King's College London, UK.; The Department of Upper Respiratory Medicine, National Heart & Lung Institute, London, UK, headed by Professor Durham, has received financial support from ALK Abello, Horsholm, Denmark - manufacturers of allergen extracts.	Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Antico A, 2006, ALLERGY, V61, P1236, DOI 10.1111/j.1398-9995.2006.01155.x; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; BLACK PN, 2002, 21 C EUR AC ALL CLIN; Blazowski L, 2008, ALLERGY, V63, P374, DOI 10.1111/j.1398-9995.2007.01563.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2008, ALLERGY, V63, pS8; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; BUFE A, 2001, 20 C EUR AC ALL CLIN; Bufe A, 2009, J ALLERGY CLIN IMMUN, V123, P167, DOI 10.1016/j.jaci.2008.10.044; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; Calderon M, 2010, ALLERGY, V65, P420, DOI 10.1111/j.1398-9995.2009.02292.x; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; CALDERON MA, 2005, J ALLERGY CLIN IMMUN, V115, pS65, DOI 10.1016/j.jaci.2004.12.275; Calderon MA, 2008, DRUG TODAY, V44, P31; Cao Lan-Fang, 2007, Zhonghua Er Ke Za Zhi, V45, P736; Casale TB, 2009, J ALLERGY CLIN IMMUN, V124, P665, DOI 10.1016/j.jaci.2009.07.054; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; CORTHAY P, 1996, ANN M SWISS SOC ALL; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; D'Ambrosio F P, 1996, Allergol Immunopathol (Madr), V24, P146; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; DAHL R, 2006, ANN M AAAACI; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; de Groot H, 2009, ALLERGY, V64, P963, DOI 10.1111/j.1398-9995.2009.01998.x; DEBLAY F, 2003, 22 C EUR AC ALL CLIN, P780; Di Rienzo V., 2006, Clinical and Experimental Allergy Reviews, V6, P67, DOI 10.1111/j.1472-9725.2006.00102.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; DONATO RM, 1997, INT J IMMUNOPATHOLOG, V10, P228; Drachenberg KJ, 2001, ALLERGOLOGIE, V24, P525; DUBAKIENE R, 2003, 22 C EUR AC ALL CLIN; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Durham SR, 2007, ALLERGY, V62, P954, DOI 10.1111/j.1398-9995.2007.01402.x; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Emminger W, 2008, J ALLERGY CLIN IMMUN, V121, pS75, DOI 10.1016/j.jaci.2007.12.297; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Feliziani V, 1993, Allergol Immunopathol (Madr), V21, P173; FRANCIS N, 2003, J ALLERGY CLIN IMMUN, V111, P1255; GAMMERI E, 2004, J ALLERGY CLIN IMMUN, V2, pS108; Gozalo F, 1997, Allergol Immunopathol (Madr), V25, P219; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Higgins J, 2008, COCHRANE HDB SYSTEMA; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ibanez MD, 2007, PEDIATR ALLERGY IMMU, V18, P516, DOI 10.1111/j.1399-3038.2007.00556.x; INAL A, 2009, ALLERGY, P461; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; KARAKOC GK, 2003, ALLERGY CLIN IMMU S1, V1; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; KLEINETEBBE J, 2005, J ALLERGY CLIN IM S1, V115, pS266, DOI 10.1016/j.jaci.2004.12.1074; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lombardi C, 2005, J ALLERGY CLIN IMMUN, V115, pS207, DOI 10.1016/j.jaci.2004.12.841; Malling HJ, 2006, J INVEST ALLERG CLIN, V16, P162; Malling HJ, 2005, J ALLERGY CLIN IMMUN, V115, pS161, DOI 10.1016/j.jaci.2004.12.656; Marcucci F, 2005, PEDIATR ALLERGY IMMU, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; MITSCH A, 1996, TW PADIATRIE, V9, P628; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Nieto A, 2009, J ALLERGY CLIN IMMUN, V124, P157, DOI 10.1016/j.jaci.2009.04.015; [Anonymous], 2008, REV MAN REVMAN 5 0; Okubo Kimihiro, 2008, Allergol Int, V57, P265, DOI 10.2332/allergolint.O-07-514; Ott H, 2009, ALLERGY, V64, P179, DOI 10.1111/j.1398-9995.2008.01875.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; PALMACARLOS AG, 2006, REV MAN REVMAN 5 0, V34, P194; Panzner P, 2008, RESP MED, V102, P1296, DOI 10.1016/j.rmed.2008.03.024; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2006, ALLERGY, V61, P849, DOI 10.1111/j.1395-9995.2006.01098.x; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; PETER R, 2009, ALLERGY, V90, P352; Pfaar O, 2008, ANN ALLERG ASTHMA IM, V100, P256; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; RADJENOVIC G, 2004, 5 EUR C OT HEAD NECK, V209, P151; Roder E, 2007, J ALLERGY CLIN IMMUN, V119, P892, DOI 10.1016/j.jaci.2006.12.651; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; Rossi RE, 2004, INT ARCH ALLERGY IMM, V135, P44, DOI 10.1159/000080042; RUSSELLO M, 2004, 23 C EUR AC ALL CLIN; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; Sabbah A, 1993, Allerg Immunol (Paris), V25, P241; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; SMITH HE, 2002, ALLERGY, V57; Tari M G, 1994, Allergol Immunopathol (Madr), V22, P209; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TONNEL A, 2002, ALLERGIE IMMUNOLGIE, V34, P60; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; TROISE C, 2009, ALLERGY, P465; Valovirta E, 2006, ALLERGY, V61, P1177, DOI 10.1111/j.1398-9995.2006.01190.x; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507; Vervloet D, 2007, INT ARCH ALLERGY IMM, V142, P239, DOI 10.1159/000097026; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wessner D. B., 2001, Allergy (Copenhagen), V56, P88; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wilson DR, 2003, COCHRANE DB SYST REV, DOI [10.1016/S1081-1206(10)60004-X, DOI 10.1002/14651858.CD002893]; WUTRICH B, 2001, 20 C EUR AC ALL CLIN; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305; 2005, TRIAL IMMUNOLOGICAL; 2002, PLACEBO CONTROLLED D	125	76	78	0	10	JOHN WILEY & SONS LTD	CHICHESTER	THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND	1469-493X			COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2010		12							CD002893	10.1002/14651858.CD002893.pub2		135	Medicine, General & Internal	General & Internal Medicine	692NI	WOS:000285159100021		
J	Daley, D; Lemire, M; Akhabir, L; Chan-Yeung, M; He, JQ; McDonald, T; Sandford, A; Stefanowicz, D; Tripp, B; Zamar, D; Bosse, Y; Ferretti, V; Montpetit, A; Tessier, MC; Becker, A; Kozyrskyj, AL; Beilby, J; McCaskie, PA; Musk, B; Warrington, N; James, A; Laprise, C; Palmer, LJ; Pare, PD; Hudson, TJ				Daley, Denise; Lemire, Mathieu; Akhabir, Loubna; Chan-Yeung, Moira; He, Jian Qing; McDonald, Treena; Sandford, Andrew; Stefanowicz, Dorota; Tripp, Ben; Zamar, David; Bosse, Yohan; Ferretti, Vincent; Montpetit, Alexandre; Tessier, Marie-Catherine; Becker, Allan; Kozyrskyj, Anita L.; Beilby, John; McCaskie, Pamela A.; Musk, Bill; Warrington, Nicole; James, Alan; Laprise, Catherine; Palmer, Lyle J.; Pare, Peter D.; Hudson, Thomas J.			Analyses of associations with asthma in four asthma population samples from Canada and Australia	HUMAN GENETICS			English	Article							TOBACCO-SMOKE EXPOSURE; ALLERGIC DISORDERS; PRIMARY PREVENTION; CHILDHOOD ASTHMA; GENETIC-VARIANTS; LUNG-FUNCTION; ORMDL3 EXPRESSION; EARLY-LIFE; HIGH-RISK; IN-UTERO	Asthma, atopy, and related phenotypes are heterogeneous complex traits, with both genetic and environmental risk factors. Extensive research has been conducted and over hundred genes have been associated with asthma and atopy phenotypes, but many of these findings have failed to replicate in subsequent studies. To separate true associations from false positives, candidate genes need to be examined in large well-characterized samples, using standardized designs (genotyping, phenotyping and analysis). In an attempt to replicate previous associations we amalgamated the power and resources of four studies and genotyped 5,565 individuals to conduct a genetic association study of 93 previously associated candidate genes for asthma and related phenotypes using the same set of 861 single-nucleotide polymorphisms (SNPs), a common genotyping platform, and relatively harmonized phenotypes. We tested for association between SNPs and the dichotomous outcomes of asthma, atopy, atopic asthma, and airway hyperresponsiveness using a general allelic likelihood ratio test. No SNP in any gene reached significance levels that survived correction for all tested SNPs, phenotypes, and genes. Even after relaxing the usual stringent multiple testing corrections by performing a gene-based analysis (one gene at a time as if no other genes were typed) and by stratifying SNPs based on their prior evidence of association, no genes gave strong evidence of replication. There was weak evidence to implicate the following: IL13, IFNGR2, EDN1, and VDR in asthma; IL18, TBXA2R, IFNGR2, and VDR in atopy; TLR9, TBXA2R, VDR, NOD2, and STAT6 in airway hyperresponsiveness; TLR10, IFNGR2, STAT6, VDR, and NPSR1 in atopic asthma. Additionally we found an excess of SNPs with small effect sizes (OR < 1.4). The low rate of replication may be due to small effect size, differences in phenotypic definition, differential environmental effects, and/or genetic heterogeneity. To aid in future replication studies of asthma genes a comprehensive database was compiled and is available to the scientific community at http://genapha.icapture.ubc.ca.	[Daley, Denise; Akhabir, Loubna; He, Jian Qing; McDonald, Treena; Sandford, Andrew; Stefanowicz, Dorota; Tripp, Ben; Zamar, David; Pare, Peter D.] Univ British Columbia, James Hogg iCAPTURE Ctr, Vancouver, BC V6Z 1Y6, Canada; [Lemire, Mathieu; Ferretti, Vincent; Montpetit, Alexandre; Tessier, Marie-Catherine; Hudson, Thomas J.] McGill Univ, Montreal, PQ, Canada; [Lemire, Mathieu; Ferretti, Vincent; Montpetit, Alexandre; Tessier, Marie-Catherine; Hudson, Thomas J.] Genome Quebec Innovat Ctr, Montreal, PQ, Canada; [Lemire, Mathieu; Ferretti, Vincent; Hudson, Thomas J.] Ontario Inst Canc Res, Toronto, ON, Canada; [Chan-Yeung, Moira] Univ British Columbia, Occupat & Environm Lung Dis Unit, Vancouver, BC V6Z 1Y6, Canada; [Bosse, Yohan] Univ Laval, Ctr Rech, Hop Laval, Inst Univ Cardiol & Pneumol, Quebec City, PQ, Canada; [Bosse, Yohan] Univ Laval, Hosp Res Ctr, CRCHUL, Quebec City, PQ, Canada; [Becker, Allan; Kozyrskyj, Anita L.] Univ Manitoba, Dept Pediat & Child Hlth, Fac Med, Winnipeg, MB R3T 2N2, Canada; [Kozyrskyj, Anita L.] Manitoba Ctr Hlth Policy, Fac Pharm, Winnipeg, MB, Canada; [Kozyrskyj, Anita L.] Manitoba Ctr Hlth Policy, Dept Community Hlth Sci, Winnipeg, MB, Canada; [Beilby, John; Musk, Bill; James, Alan] Sir Charles Gairdner Hosp, Perth, WA 6000, Australia; [McCaskie, Pamela A.; Warrington, Nicole; Palmer, Lyle J.] Univ Western Australia, Lab Genet Epidemiol, Western Australian Inst Med Res, UWA Ctr Med Res, Perth, WA 6009, Australia; [McCaskie, Pamela A.; Warrington, Nicole; Palmer, Lyle J.] Univ Western Australia, Sch Populat Hlth, Perth, WA 6009, Australia	Pare, PD (reprint author), Univ British Columbia, James Hogg iCAPTURE Ctr, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	ppare@mrl.ubc.ca	Pare, Peter/C-7425-2011; Bosse, Yohan/C-7617-2012; Palmer, Lyle/K-3196-2014; Warrington, Nicole/P-4868-2014	Palmer, Lyle/0000-0002-1628-3055; Warrington, Nicole/0000-0003-4195-775X; Hudson, Thomas/0000-0002-1376-4849	AllerGen; National Centre of Excellence Network (Canada); Institutes of Gender and Health; BC Lung Association; Genome Quebec; Respiratory Health Network of the Fonds de la Recherche en Sante du Quebec (FRSQ); Michael Smith Foundation; Jacob Churg Distinguished Research Award; Burroughs Wellcome Fund; CIHR; Healthway, Western Australia; National Health and Medical Research Council of Australia; Wind-Over-Water Foundation	We thank all subjects who donated time and samples for this project, and numerous health care workers who helped with recruitment and phenotyping. Dr Paul Begin and Charles Morin for their collaboration and ascertainment of the Saguenay-Lac-Saint-Jean panel participants. Dr Louis-Philippe Boulet and Michel Laviolette for ascertainment, of the Quebec City family trios. For the Canadian Asthma Primary Prevention Study cohort we acknowledge Drs Alexander Ferguson and Wade Watson who phenotyped participants, Ms Roxanne Rousseau and Ms Marilyn Lilley who ascertained subjects and Ms Anne DyBuncio for data management. We gratefully acknowledge the assistance of James Chomin with the TaqMan genotyping of the MTHFR gene, Muriel Grenon for the assistance in recruiting subjects in the Saguenay Lac-St. Jean and Julie Park with the literature search and compiling of Supplementary Table S1. This work was supported by AllerGen, a , the Canadian Institutes of Health Research (CIHR), the Institutes of Gender and Health, BC Lung Association, Genome Quebec, and the Respiratory Health Network of the Fonds de la Recherche en Sante du Quebec (FRSQ). P. D. P was the recipient of a Michael Smith Foundation Scholarship and the Jacob Churg Distinguished Research Award. T. J. H. received a Clinician-Scientist Award in Translational Research from the Burroughs Wellcome Fund and an Investigator Award from CIHR. The 1994 Busselton follow-up study was funded by Healthway, Western Australia. A. L. J. is a recipient of a National Health and Medical Research Council of Australia Practitioner Fellowship. L. J. P. is supported by the National Health and Medical Research Council of Australia and the Wind-Over-Water Foundation. Y. Bosse and D. Daley were recipients of CIHR fellowship awards, and A. Kozyrskyj is a recipient of a New Investigator Award from the Canadian Institutes of Health Research. DD is the recipient of a Michael Smith Foundation Career Scholar Award. C. Laprise, A. Sandford and D. Daley hold Canadian Research Chair appointments.	Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; Becker A, 2004, J ALLERGY CLIN IMMUN, V113, P650, DOI 10.1016/j.jaci.2004.01.754; Becker AB, 1999, ARCH PEDIAT ADOL MED, V153, P689; Begin P, 2007, AM J RESP CRIT CARE, V175, P1109, DOI 10.1164/rccm.200607-10120C; Blakey J, 2005, THORAX, V60, P274, DOI 10.1136/thx.2004.027227; Chan-Yeung M, 1999, J ALLERGY CLIN IMMUN, V104, P317, DOI 10.1016/S0091-6749(99)70373-8; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; Chanock SJ, 2007, NATURE, V447, P655, DOI 10.1038/447655a; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Dudbridge F, 2008, HUM HERED, V66, P87, DOI 10.1159/000119108; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Godfrey S, 2000, Paediatr Respir Rev, V1, P148, DOI 10.1053/prrv.2000.0042; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; He JQ, 2003, GENES IMMUN, V4, P385, DOI 10.1038/sj.gene.6363985; Hebenstreit D, 2006, CYTOKINE GROWTH F R, V17, P173, DOI 10.1016/j.cytogfr.2006.01.004; Hegele RG, 2001, J PEDIATR-US, V138, P831, DOI 10.1067/mpd.2001.114479; Hirota T, 2008, J ALLERGY CLIN IMMUN, V121, P769, DOI 10.1016/j.jaci.2007.09.038; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; James Alan L, 2005, Med J Aust, V183, pS17; Kaan A, 2000, ANN ALLERG ASTHMA IM, V84, P37, DOI 10.1016/S1081-1206(10)62738-X; Kim JH, 2008, CLIN EXP ALLERGY, V38, P51, DOI 10.1111/j.1365-2222.2007.02874.x; Kozyrskyj AL, 2008, AM J RESP CRIT CARE, V177, P142, DOI 10.1164/rccm.200703-381OC; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Laprise C, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-21; Li J, 2005, HEREDITY, V95, P221, DOI 10.1038/sj.hdy.6800717; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Lincoln MR, 2005, NAT GENET, V37, P1108, DOI 10.1038/ng1647; Madore AM, 2008, HUM GENET, V123, P93, DOI 10.1007/s00439-007-0444-x; Mai XM, 2007, ALLERGY, V62, P1295, DOI 10.1111/j.1398-9995.2007.01491.x; Maier LM, 2006, J ALLERGY CLIN IMMUN, V117, P1306, DOI 10.1016/j.jaci.2005.12.1354; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P26, DOI 10.1513/pats.200607-144JG; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nakahata N, 2008, PHARMACOL THERAPEUT, V118, P18, DOI 10.1016/j.pharmthera.2008.01.001; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Poon AH, 2005, GENES IMMUN, V6, P519, DOI 10.1038/sj.gene.6364238; Poon AH, 2004, AM J RESP CRIT CARE, V170, P967, DOI 10.1164/rccm.200403-412oc; Raby BA, 2004, AM J RESP CRIT CARE, V170, P1057, DOI 10.1164/rccm.200404-447OC; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; SHARP AJ, 2008, HUM MUTAT; Shen R, 2005, MUTAT RES-FUND MOL M, V573, P70, DOI 10.1016/j.mrfmmm.2004.07.022; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166	50	76	76	2	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6717			HUM GENET	Hum. Genet.	MAY	2009	125	4					445	459		10.1007/s00439-009-0643-8		15	Genetics & Heredity	Genetics & Heredity	435ZX	WOS:000265383500010	19247692	
J	Rodrigues, LC; Newcombe, PJ; Cunha, SS; Alcantara-Neves, NM; Genser, B; Cruz, AA; Simoes, SM; Fiaccone, R; Amorim, L; Cooper, PJ; Barreto, ML				Rodrigues, L. C.; Newcombe, P. J.; Cunha, S. S.; Alcantara-Neves, N. M.; Genser, B.; Cruz, A. A.; Simoes, S. M.; Fiaccone, R.; Amorim, L.; Cooper, P. J.; Barreto, M. L.		SCAALA	Early infection with Trichuris trichiura and allergen skin test reactivity in later childhood	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergen skin test reactivity; asthma; atopy; immune programming; intestinal helminths; rhinitis; Trichuris trichiura	SCHOOL-AGE-CHILDREN; GEOHELMINTH INFECTIONS; GABONESE SCHOOLCHILDREN; HELMINTHIC INFECTION; HYGIENE HYPOTHESIS; ATOPY; PARASITES; ASTHMA; PREVALENCE; EXPOSURE	Background Allergic diseases cause a large and increasing burden in developed countries and in urban centres in middle-income countries. The causes of this increase are unknown and, currently, there are no interventions to prevent the development of allergic diseases. The 'hygiene hypothesis' has tried to explain the increase through a reduction in the frequency of childhood infections causing a failure to program the immune system for adequate immune regulation. Intestinal helminth parasites are prevalent in childhood in developing countries and are associated with a lower prevalence of allergen skin test reactivity and asthma. Objectives To investigate whether children who had intestinal helminth infections during early childhood have a lower prevalence of allergen skin test reactivity later in childhood. Methods We re-visited a population of 1055 children from whom stool samples had been collected for detection of intestinal helminth infections for another study, and collected new stool samples and performed allergen skin prick testing. Information on potential confounding variables was collected. Results Children with heavy infections with Trichuris trichiura in early childhood had a significantly reduced prevalence of allergen skin test reactivity in later childhood, even in the absence of T. trichiura infection at the time of skin testing in later childhood. Conclusion Early heavy infections with T. trichiura may protect against the development of allergen skin test reactivity in later childhood. Novel treatments to program immune-regulation in early childhood in a way that mimics the effects of early infections with T. trichiura may offer new strategies for the prevention of allergic disease.	[Rodrigues, L. C.; Newcombe, P. J.] London Sch Hyg & Trop Med, London WC1E 7HT, England; [Cunha, S. S.; Genser, B.; Simoes, S. M.; Barreto, M. L.] Univ Fed Bahia, Inst Saude Colet, Salvador, BA, Brazil; [Alcantara-Neves, N. M.] Univ Fed Bahia, Inst Ciencias Saude, Salvador, BA, Brazil; [Cruz, A. A.] Univ Fed Bahia, ProAR Fac Med, Salvador, BA, Brazil; [Fiaccone, R.; Amorim, L.] Univ Fed Bahia, Dept Stat, Salvador, BA, Brazil; [Cooper, P. J.] Univ San Francisco Quito, Inst Microbiol, Quito, Ecuador; [Cooper, P. J.] St Georges Univ London, Ctr Infect, London, England	Rodrigues, LC (reprint author), London Sch Hyg & Trop Med, London WC1E 7HT, England.	laura.rodrigues@ishtm.ac.uk	Amorim, Leila/B-4508-2015; Cruz, Alvaro/I-1676-2012	Amorim, Leila/0000-0002-1112-2332; Cruz, Alvaro/0000-0002-7403-3871; Rodrigues, Laura Cunha/0000-0001-9008-660X; Barreto, Mauricio/0000-0002-0215-4930			Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Barreto Mauricio L, 2006, BMC Pulm Med, V6, P15, DOI 10.1186/1471-2466-6-15; Barreto ML, 2007, LANCET, V370, P1622, DOI 10.1016/S0140-6736(07)61638-9; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Calder PC, 2006, BRIT J NUTR, V96, P774, DOI 10.1079/BJN20061917; Cooper PJ, 2006, BRIT MED BULL, V79-80, P203, DOI 10.1093/bmb/ldl015; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2004, CLIN REV ALLERG IMMU, V26, P5, DOI 10.1385/CRIAI:26:1:5; de Silva NR, 2003, TRENDS PARASITOL, V19, P547, DOI 10.1016/j.pt.2003.10.002; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; HOFFMAN W. A., 1934, PUERTO RICO J PUBLIC, V9, P281; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; LYNCH NR, 1983, INT ARCH ALLER A IMM, V72, P369; Maizels RM, 2004, IMMUNOL REV, V201, P89, DOI 10.1111/j.0105-2896.2004.00191.x; Moncayo AL, 2006, INT J BIOCHEM CELL B, V38, P1031, DOI 10.1016/j.biocel.2005.11.003; Ownby Dennis R, 2003, Curr Opin Allergy Clin Immunol, V3, P517, DOI 10.1097/00130832-200312000-00015; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Quinnell RJ, 2001, T ROY SOC TROP MED H, V95, P139, DOI 10.1016/S0035-9203(01)90138-5; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romei I, 2005, CLIN REV ALLERG IMMU, V28, P59, DOI 10.1385/CRIAI:28:1:059; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Strina A, 2003, AM J EPIDEMIOL, V157, P1032, DOI 10.1093/aje/kwg075; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; [Anonymous], 1987, WHO TECHN REP SER, V749; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	35	76	82	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2008	38	11					1769	1777		10.1111/j.1365-2222.2008.03027.x		9	Allergy; Immunology	Allergy; Immunology	364KH	WOS:000260334100011	18547322	
J	Bousquet, J; van Cauwenberge, P; Khaled, NA; Bachert, C; Baena-Cagnani, CE; Bouchard, J; Bunnag, C; Canonica, GW; Carlsen, KH; Chen, YZ; Cruz, AA; Custovic, A; Demoly, P; Dubakiene, R; Durham, S; Fokkens, W; Howarth, P; Kemp, J; Kowalski, ML; Kvedariene, V; Lipworth, B; Lockey, R; Lund, V; Mavale-Manuel, S; Meltzer, EO; Mullol, J; Naclerio, R; Nekam, K; Ohta, K; Papadopoulos, N; Passalacqua, G; Pawankar, R; Popov, T; Potter, P; Price, D; Scadding, G; Simons, FER; Spicak, V; Valovirta, E; Wang, DY; Yawn, B; Yusuf, O				Bousquet, J.; van Cauwenberge, P.; Khaled, N. Ait; Bachert, C.; Baena-Cagnani, C. E.; Bouchard, J.; Bunnag, C.; Canonica, G. W.; Carlsen, K. -H.; Chen, Y. -Z.; Cruz, A. A.; Custovic, A.; Demoly, P.; Dubakiene, R.; Durham, S.; Fokkens, W.; Howarth, P.; Kemp, J.; Kowalski, M. L.; Kvedariene, V.; Lipworth, B.; Lockey, R.; Lund, V.; Mavale-Manuel, S.; Meltzer, E. O.; Mullol, J.; Naclerio, R.; Nekam, K.; Ohta, K.; Papadopoulos, N.; Passalacqua, G.; Pawankar, R.; Popov, T.; Potter, P.; Price, D.; Scadding, G.; Simons, F. E. R.; Spicak, V.; Valovirta, E.; Wang, D. -Y.; Yawn, B.; Yusuf, O.			Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA(2)LEN)	ALLERGY			English	Review						ARIA; asthma; GA(2)LEN; IgE; pharmacotherapy; rhinitis	AQUEOUS NASAL SPRAY; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; LORATADINE 10 MG; INTRANASAL FLUTICASONE PROPIONATE; ENVIRONMENTAL EXPOSURE UNIT; RANDOMIZED CONTROLLED-TRIAL; EBASTINE 20 MG; LEUKOTRIENE RECEPTOR ANTAGONISTS; ADRENAL AXIS FUNCTION	The pharmacologic treatment of allergic rhinitis proposed by ARIA is an evidence-based and step-wise approach based on the classification of the symptoms. The ARIA workshop, held in December 1999, published a report in 2001 and new information has subsequently been published. The initial ARIA document lacked some important information on several issues. This document updates the ARIA sections on the pharmacologic and anti-IgE treatments of allergic rhinitis. Literature published between January 2000 and December 2004 has been included. Only a few studies assessing nasal and non-nasal symptoms are presented as these will be discussed in a separate document.	Univ Hosp Montpellier, Montpellier, France; INSERM, U454, Montpellier, France; Univ Ghent, Ghent, Belgium; Union, Paris, France; Ghent Univ Hosp, B-9000 Ghent, Belgium; Univ Cordoba, E-14071 Cordoba, Spain; St Josephs Hosp, La Malbaie, PQ, Canada; Mahidol Univ, Dept Otolaryngol, Bangkok 10700, Thailand; Univ Genoa, Genoa, Italy; Univ Oslo, Voksentoppen BKL, N-0316 Oslo, Norway; Capital Inst Pediat, Beijing, Peoples R China; Univ Fed Bahia, Sch Med, BR-41170290 Salvador, BA, Brazil; Univ Manchester, Manchester, Lancs, England; Vilnius State Univ, Vilnius, Lithuania; Royal Brompton Hosp, London SW3 6LY, England; Univ London Imperial Coll Sci Technol & Med, London, England; Univ Amsterdam, NL-1012 WX Amsterdam, Netherlands; Univ Southampton, Southampton SO9 5NH, Hants, England; Univ Lodz, PL-90131 Lodz, Poland; Univ Dundee, Asthma & Allergy Res Grp, Dundee DD1 4HN, Scotland; Univ S Florida, Div Allergy & Immunol, Tampa, FL USA; UCL, Inst Laryngol & Otol, Ear Inst, London, England; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Hosp Clin Barcelona, Barcelona, Catalonia, Spain; Otolaryngol Univ Chicago, Chicago, IL USA; Hosp Hosp Brothers, Budapest, Hungary; Teikyo Univ, Sch Med, Dept Med, Tokyo 173, Japan; Univ Athens, GR-10679 Athens, Greece; Univ Genoa, Genoa, Italy; Nippon Med Sch, Dept Otolaryngol, Tokyo 113, Japan; Med Univ Sofia, Clin Ctr Allergol, Sofia, Bulgaria; Univ Cape Town, Lung Inst, Allergy Diagnost & Clin Res Unit, ZA-7925 Cape Town, South Africa; Univ Aberdeen, Aberdeen, Scotland; Royal Natl Throat Nose & Ear Hosp, London WC1X 8DA, England; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Czech Initiat Asthma, Prague, Czech Republic; Turku Allergy Ctr, Turku, Finland; Natl Univ Singapore, Singapore 117548, Singapore; Univ Minnesota, Minneapolis, MN 55455 USA; Allergy & Asthma Clin, Islamabad, Pakistan	Bousquet, J (reprint author), CHU Montpellier, Hop Arnaud Villeneuve, Clin Malad Resp, F-34295 Montpellier 5, France.		Kvedariene, Violeta /D-7730-2011; Papadopoulos, Nikolaos/L-8670-2013; Custovic, Adnan/A-2435-2012; Cruz, Alvaro/I-1676-2012	Papadopoulos, Nikolaos/0000-0002-4448-3468; Custovic, Adnan/0000-0001-5218-7071; Cruz, Alvaro/0000-0002-7403-3871; Papadopoulos, Nikolaos/0000-0002-2508-3872; Price, David/0000-0002-9728-9992; Popov, Todor/0000-0001-5052-5866			Abelson MB, 2003, CLIN THER, V25, P931, DOI 10.1016/S0149-2918(03)80115-7; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Allen DB, 2002, ALLERGY ASTHMA PROC, V23, P407; Bachert C, 2004, J ALLERGY CLIN IMMUN, V114, P838, DOI 10.1016/j.jaci.2004.05.070; Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; Banfield C, 2002, CLIN PHARMACOKINET, V41, P37, DOI 10.2165/00003088-200241001-00006; Banfield C, 2002, CLIN PHARMACOKINET, V41, P29, DOI 10.2165/00003088-200241001-00005; Beck LA, 2004, J ALLERGY CLIN IMMUN, V114, P527, DOI 10.1016/j.jaci.2004.06.032; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; Bender BG, 2001, J PEDIATR-US, V138, P656, DOI 10.1067/mpd.2001.112647; Bennett M L, 2001, Am J Contact Dermat, V12, P193, DOI 10.1053/ajcd.2001.28690; Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182; Berger WE, 2003, ANN ALLERG ASTHMA IM, V91, P205; Berger WE, 2002, ANN ALLERG ASTHMA IM, V89, P485; Bernstein DI, 2004, CLIN EXP ALLERGY, V34, P952, DOI 10.1111/j.1365-2222.2004.01952.x; Bez C, 2004, CLIN EXP ALLERGY, V34, P1079, DOI 10.1111/j.1365-2222.2004.01998.x; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2003, ALLERGY, V58, P192, DOI 10.1034/j.1398-9995.2003.00054.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bross-Soriano D, 2004, OTOLARYNG HEAD NECK, V130, P187, DOI 10.1016/j.otohns.2003.09.020; Bucher HC, 2003, ARCH INTERN MED, V163, P1793, DOI 10.1001/archinte.163.15.1793; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Chervinsky P, 2004, ANN ALLERG ASTHMA IM, V92, P367; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160; Ciprandi G, 2001, ANN ALLERG ASTHMA IM, V87, P222; Craig TJ, 2003, ALLERGY ASTHMA PROC, V24, P53; Daley-Yates PT, 2004, CLIN THER, V26, P1905, DOI 10.1016/j.clinthera.2004.11.017; Davis GA, 2004, PHARMACOTHERAPY, V24, P26, DOI 10.1592/phco.24.1.26.34810; Day JH, 2004, ALLERGY ASTHMA PROC, V25, P59; Day JH, 2004, INT J CLIN PRACT, V58, P109, DOI 10.1111/j.1368-5031.2004.0117.x; Deruaz Cedric, 2004, Journal of Allergy and Clinical Immunology, V113, P669, DOI 10.1016/j.jaci.2004.01.773; Di Lorenzo G, 2004, CLIN EXP ALLERGY, V34, P259, DOI 10.1111/j.1365-2222.2004.01877.x; Dolor RJ, 2001, JAMA-J AM MED ASSOC, V286, P3097, DOI 10.1001/jama.286.24.3097; Dykewicz MS, 2003, ANN ALLERG ASTHMA IM, V91, P44; Ellegard EK, 2001, CLIN OTOLARYNGOL, V26, P394, DOI 10.1046/j.1365-2273.2001.00491.x; Fink RS, 2002, J CLIN ENDOCR METAB, V87, P4541, DOI 10.1210/jc.2002-020287; Fokkens WJ, 2004, PEDIATR ALLERGY IMMU, V15, P261, DOI 10.1111/j.1399-3038.2004.00135.x; Fokkens WJ, 2002, ANN ALLERG ASTHMA IM, V89, P279; Frank Hampel Jr, 2002, J Clin Pharmacol, V42, P1097; Freche C, 2002, ANN ALLERG ASTHMA IM, V89, P304; Gandon JM, 2002, BRIT J CLIN PHARMACO, V54, P51, DOI 10.1046/j.1365-2125.2002.01611.x; Gawchik S, 2003, ANN ALLERG ASTHMA IM, V90, P416; Gillen MS, 2001, BRIT J CLIN PHARMACO, V52, P201, DOI 10.1046/j.0306-5251.2001.01345.x; Goldman DP, 2004, JAMA-J AM MED ASSOC, V291, P2344, DOI 10.1001/jama.291.19.2344; Guadano EM, 2004, ALLERGY, V59, P766, DOI 10.1111/j.1398-9995.2004.00576.x; Gupta S, 2001, CLIN THER, V23, P451, DOI 10.1016/S0149-2918(01)80049-7; Hampel F, 2004, J INVEST ALLERG CLIN, V14, P56; Hanf G, 2004, EUR RESPIR J, V23, P414, DOI 10.1183/09031936.04.00024504; Hill SL, 2003, OTOLARYNG HEAD NECK, V129, P199, DOI 10.1016/S0194-5998(03)00607-7; Hindmarch I, 2001, CURR MED RES OPIN, V17, P273; Hindmarch I, 2001, CURR MED RES OPIN, V17, P241, DOI 10.1185/0300799019117011; Horak F, 2004, ARZNEIMITTEL-FORSCH, V54, P666; Horak F, 2003, ALLERGY, V58, P481, DOI 10.1034/j.1398-9995.2003.00148.x; Horak F, 2002, J ALLERGY CLIN IMMUN, V109, P956, DOI 10.1067/mai.2002.124657; Horak F, 2001, INT ARCH ALLERGY IMM, V125, P73, DOI 10.1159/000053799; Isaksson M, 2002, J AM ACAD DERMATOL, V46, P880, DOI 10.1067/mjd.2002.120464; Jen A, 2000, J ALLERGY CLIN IMMUN, V105, P732, DOI 10.1067/mai.2000.105225; Keith P, 2000, CLIN EXP ALLERGY, V30, P1460, DOI 10.1046/j.1365-2222.2000.00932.x; Kiely JL, 2004, THORAX, V59, P50; Kim KT, 2004, ANN ALLERG ASTHMA IM, V93, P61; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Kurowski M, 2004, ALLERGY, V59, P280, DOI 10.1046/j.1398-9995.2003.00416.x; LaForce CF, 2004, ANN ALLERG ASTHMA IM, V93, P154; Lavigne F, 2002, LARYNGOSCOPE, V112, P858, DOI 10.1097/00005537-200205000-00015; Lee DKC, 2004, BRIT J CLIN PHARMACO, V57, P714, DOI 10.1111/j.1365-2125.2004.02072.x; Lee DKC, 2004, CLIN EXP ALLERGY, V34, P650, DOI 10.1111/j.1365-2222.2004.1904.x; Leurs R, 2002, CLIN EXP ALLERGY, V32, P489, DOI 10.1046/j.0954-7894.2002.01314.x; Leynadier F, 2001, Acta Otorhinolaryngol Belg, V55, P305; Lin H, 2004, J ALLERGY CLIN IMMUN, V113, P297, DOI 10.1016/j.jaci.2003.11.044; Lund VJ, 2004, RHINOLOGY, V42, P57; Mansfield LE, 2004, ANN ALLERG ASTHMA IM, V92, P240; MARINKER M, 1998, COMPLIANCE ACCORDANC; McFadden E A, 2000, Ear Nose Throat J, V79, P257; MCFADDEN EA, 2000, ENT-EAR NOSE THROAT, V79, P257; MCFADDEN EA, 2000, ENT-EAR NOSE THROAT, V79, P260; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V106, P630, DOI 10.1067/mai.2000.109056; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Meltzer EO, 2004, PEDIATR ALLERGY IMMU, V15, P253, DOI 10.1111/j.1399-3038.2004.00167.x; Murray JJ, 2002, ALLERGY ASTHMA PROC, V23, P391; Nayak A, 2003, ALLERGY ASTHMA PROC, V24, P323; Nayak AS, 2001, ALLERGY, V56, P1077, DOI 10.1034/j.1398-9995.2001.00082.x; NAYAK AS, 2000, COCHRANE DB SYST REV, V2, P417; Ng Kar Hui, 2004, Pediatrics, V113, pe116, DOI 10.1542/peds.113.2.e116; Nicholson AN, 2003, AVIAT SPACE ENVIR MD, V74, P809; Parikh A, 2001, RHINOLOGY, V39, P75; Passalacqua Giovanni, 2002, Clin Allergy Immunol, V17, P65; Penttila M, 2000, CLIN EXP ALLERGY, V30, P94; Perry TT, 2004, ANN ALLERG ASTHMA IM, V93, P431; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Plewako H, 2002, J ALLERGY CLIN IMMUN, V110, P68, DOI 10.1067/mai.2002.125488; Potter PC, 2003, ANN ALLERG ASTHMA IM, V91, P368; Potter PC, 2003, ANN ALLERG ASTHMA IM, V91, P177; Potter PC, 2003, ALLERGY, V58, P893, DOI 10.1034/j.1398-9995.2003.00171.x; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Pullerits T, 2002, J ALLERGY CLIN IMMUN, V109, P949, DOI 10.1067/mai.2002.124467; Ratner P, 2004, INT ARCH ALLERGY IMM, V133, P371, DOI 10.1159/000077357; Ratner PH, 2000, J ALLERGY CLIN IMMUN, V105, P1101, DOI 10.1067/mai.2000.105525; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Salmun LM, 2000, CLIN THER, V22, P613, DOI 10.1016/S0149-2918(00)80048-X; Salmun Luis M, 2002, BMC Fam Pract, V3, P14, DOI 10.1186/1471-2296-3-14; Schenkel EJ, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e22; Sheth KK, 2004, ALLERGY ASTHMA PROC, V25, P115; SIMONS FE, 2004, NEW ENGL J MED, V351, P2207; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P1244, DOI 10.1067/mai.2003.1496; Simons FER, 2003, J ALLERGY CLIN IMMUN, V111, P617, DOI 10.1067/mai.2003.168; Simons FER, 2001, ANN ALLERG ASTHMA IM, V86, P44; Skoner DP, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.2.e23; Stevenson J, 2002, PEDIATR RES, V52, DOI 10.1023/01.PDR.0000024060.49308.89; Stubner P, 2004, CURR MED RES OPIN, V20, P891, DOI 10.1185/030079904125003700; Suissa S, 2004, AM J RESP CRIT CARE, V169, P83, DOI 10.1164/rccm.200305-6400C; Sullivan PW, 2004, VALUE HEALTH, V7, P402, DOI 10.1111/j.1524-4733.2004.74003.x; Tagawa M, 2002, BRIT J CLIN PHARMACO, V53, P296, DOI 10.1046/j.0306-5251.2001.01183.x; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214; Van Cauwenberge P, 2000, CLIN EXP ALLERGY, V30, P891; Verster JC, 2003, PSYCHOPHARMACOLOGY, V169, P84, DOI 10.1007/s00213-003-1462-6; Verster JC, 2003, J ALLERGY CLIN IMMUN, V111, P623, DOI 10.1067/mai.2003.63; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; Vuurman EFPM, 2004, EUR J CLIN PHARMACOL, V60, P307, DOI 10.1007/s00228-004-0757-9; Wahn U, 2003, J ALLERGY CLIN IMMUN, V111, P763, DOI 10.1067/mai.2003.1384; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Webb DR, 2002, ANN ALLERG ASTHMA IM, V88, P385; Whitcup SM, 2004, CLIN THER, V26, P29, DOI 10.1016/S0149-2918(04)90003-3; Wilson A, 2000, CLIN EXP ALLERGY, V30, P833; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P126, DOI 10.1046/j.0022-0477.2001.01252.x; Wilson AM, 2002, CLIN EXP ALLERGY, V32, P1504, DOI 10.1046/j.1365-2745.2002.01509.x; Wilson AM, 2001, ANN ALLERG ASTHMA IM, V87, P344; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P61, DOI 10.1046/j.1365-2222.2001.00964.x; Yang YH, 2001, ASIAN PAC J ALLERGY, V19, P171; [Anonymous], 2004, ALLERGY, V59, P373	134	76	81	1	2	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	SEP	2006	61	9					1086	1096		10.1111/j.1398-9995.2006.01144.x		11	Allergy; Immunology	Allergy; Immunology	070IF	WOS:000239514400010	16918512	
J	Bove, PF; van der Vliet, A				Bove, Peter F.; van der Vliet, Albert			Nitric oxide and reactive nitrogen species in airway epithelial signaling and inflammation	FREE RADICAL BIOLOGY AND MEDICINE			English	Review						guanylyl cyclase; cGMP; S-nitrosylation; NF-kappa B; asthma	NF-KAPPA-B; SOLUBLE GUANYLYL CYCLASE; PROTEIN-TYROSINE NITRATION; CILIARY BEAT FREQUENCY; S-NITROSYLATION; CYSTIC-FIBROSIS; GENE-EXPRESSION; MATRIX METALLOPROTEINASES; CYCLOOXYGENASE-2 EXPRESSION; DIFFERENTIAL SENSITIVITY	Nitric oxide (NO center dot) is produced by many diverse cell types as a cellular or intracellular signaling molecule, by the activation of nitric oxide synthases (NOSs). All three known NOS isoforms are expressed within the respiratory tract and mediate various air-way functional properties such as airway smooth muscle tone, ciliary function, epithelial electrolyte transport, and innate host defense. The respiratory epithelium is a major source of NO center dot in which it regulates normal epithelial cell function and signaling as well as signaling pathways involved in airway inflammation. In addition to its normal physiological properties, increased airway NO center dot production in inflammatory respiratory tract diseases such as asthma may activate additional signaling mechanisms to regulate inflammatory-immune pathways, and epithelial barrier (dys)function or repair. The biological actions of NO center dot are controlled at various levels, including mechanisms that regulate NOS localization and activation, and variable oxidative metabolism of NO center dot resulting in generation of bioactive reactive nitrogen species (RNS). Moreover, in addition to altered production of NO center dot or RNS, the presence of various target enzymes and/or metabolic regulators of NO center dot/RNS can be dramatically altered during airway inflammatory conditions, and contribute to alterations in W-mediated signaling pathways in disease. This review summarizes current knowledge regarding NO center dot-mediated epithelial signaling, as well as disease-related changes in airway NOS biology and target enzymes that affect NO center dot/RNS signaling mechanisms. A detailed understanding of these various changes and their impact on NO center dot signaling pathways are needed to fully appreciate the contributions of NO center dot/RNS to airway inflammation and to develop suitable therapeutic approaches based on regulating NO center dot function. (c) 2006 Elsevier Inc. All rights reserved.	Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA	van der Vliet, A (reprint author), Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05405 USA.	Albert.van-der-Vliet@uvm.edu			NHLBI NIH HHS [HL074295, HL068865]		Adler KB, 2001, AM J RESP CELL MOL, V25, P397; Alderton WK, 2001, BIOCHEM J, V357, P593, DOI 10.1042/0264-6021:3570593; Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; Aulak KS, 2004, AM J PHYSIOL-HEART C, V286, pH30, DOI 10.1152/ajpheart.00743.2003; Baker PRS, 2005, J BIOL CHEM, V280, P42464, DOI 10.1074/jbc.M504212200; Ballou DP, 2002, P NATL ACAD SCI USA, V99, P12097, DOI 10.1073/pnas.192209799; Banerjee T, 2002, PROSTAG LEUKOTR ESS, V66, P485, DOI 10.1054/plef.387; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bellamy TC, 2002, P NATL ACAD SCI USA, V99, P507, DOI 10.1073/pnas.012368499; Bellamy TC, 2002, J BIOL CHEM, V277, P31801, DOI 10.1074/jbc.M205936200; BELVISI MG, 1992, EUR J PHARMACOL, V210, P221, DOI 10.1016/0014-2999(92)90676-U; Birnboim HC, 2003, J IMMUNOL, V171, P528; Bogdan C, 2001, TRENDS CELL BIOL, V11, P66, DOI 10.1016/S0962-8924(00)01900-0; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; Bove PF, 2005, FREE RADICAL BIO MED, V39, pS97; Broide DH, 2005, P NATL ACAD SCI USA, V102, P17723, DOI 10.1073/pnas.0509235102; Brune B, 2003, CELL DEATH DIFFER, V10, P864, DOI 10.1038/sj.cdd.4401261; Chan GC, 2005, J IMMUNOL, V175, P3846; Chang MS, 2004, MOL PHARMACOL, V66, P561; Connelly L, 2003, J BIOL CHEM, V278, P26480, DOI 10.1074/jbc.M302238200; Connelly L, 2001, J IMMUNOL, V166, P3873; Cooper CE, 2002, TRENDS BIOCHEM SCI, V27, P33, DOI 10.1016/S0968-0004(01)02035-7; Daniliuc S, 2003, J IMMUNOL, V171, P3225; Darling KEA, 2003, INFECT IMMUN, V71, P2341, DOI 10.1128/IAI.71.5.2341-2349.2003; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Dinakar C, 2004, CURR ALLERGY ASTHM R, V4, P454, DOI 10.1007/s11882-004-0011-7; Dweik RA, 2001, P NATL ACAD SCI USA, V98, P2622, DOI 10.1073/pnas.051629498; El-Gayar S, 2003, J IMMUNOL, V171, P4561; Eriksson U, 2005, J IMMUNOL, V175, P2715; Ermert M, 2002, LAB INVEST, V82, P425; Erwin PA, 2006, J BIOL CHEM, V281, P151, DOI 10.1074/jbc.M510421200; Fang KH, 2000, AM J PHYSIOL-LUNG C, V279, pL716; Forstermann U, 1998, FASEB J, V12, P773; Friebe A, 2003, CIRC RES, V93, P96, DOI 10.1161/01.RES.0000082524.34487.31; Fuhrmann M, 1999, AM J RESP CELL MOL, V20, P292; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; Gaston B, 1998, LANCET, V351, P1317, DOI 10.1016/S0140-6736(97)07485-0; GASTON B, 1993, P NATL ACAD SCI USA, V90, P10957, DOI 10.1073/pnas.90.23.10957; Gaston Benjamin M, 2003, Mol Interv, V3, P253, DOI 10.1124/mi.3.5.253; Gertsberg I, 2004, J GEN PHYSIOL, V124, P527, DOI 10.1085/jgp.200409153; Glynne PA, 2002, J BIOL CHEM, V277, P33132, DOI 10.1074/jbc.M205764200; Gookin JL, 2002, AM J PHYSIOL-GASTR L, V283, pG157, DOI 10.1152/ajpgi.00005.2001; Gosh S., 2006, J IMMUNOL, V176, P5587; Grasemann H, 2005, AM J RESP CRIT CARE, V172, P1523, DOI 10.1164/rccm.200502-253OC; Grasemann H, 1999, J PEDIATR-US, V135, P770, DOI 10.1016/S0022-3476(99)70101-0; Grasemann H, 2000, BIOCHEM BIOPH RES CO, V272, P391, DOI 10.1006/bbrc.2000.2794; Gu ZZ, 2002, SCIENCE, V297, P1186, DOI 10.1126/science.1073634; Guittet O, 1998, J BIOL CHEM, V273, P22136, DOI 10.1074/jbc.273.34.22136; GUO FH, 1995, P NATL ACAD SCI USA, V92, P7809, DOI 10.1073/pnas.92.17.7809; Guo FH, 2000, J IMMUNOL, V164, P5970; Haendeler J, 2002, NAT CELL BIOL, V4, P743, DOI 10.1038/ncb851; HAMAD AM, 2003, J PHYSL LUNG CELL MO, V285, pL973; Han XN, 2004, AM J PHYSIOL-LUNG C, V286, pL259, DOI 10.1152/ajplung.00187.2003; Hara MR, 2005, NAT CELL BIOL, V7, P665, DOI 10.1038/ncb1268; Hardiman KA, 2004, AM J RESP CELL MOL, V30, P720, DOI 10.1165/rcmb.2003-0325OC; He B, 2003, EUR J BIOCHEM, V270, P2174, DOI 10.1046/j.1432-1033.2003.03574.x; Helms MN, 2005, AM J PHYSIOL-CELL PH, V289, pC717, DOI 10.1152/ajpcell.00006.2005; Hemish J, 2003, J BIOL CHEM, V278, P42321, DOI 10.1074/jbc.M308192200; Heo J, 2005, J MOL BIOL, V346, P1423, DOI 10.1016/j.jmb.2004.12.050; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; Hjoberg J, 2004, J APPL PHYSIOL, V97, P249, DOI 10.1152/japplphysiol.01389.2003; Hogg N, 2002, ANNU REV PHARMACOL, V42, P585, DOI 10.1146/annurev.pharmtox.42.092501.104328; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; Iijima H, 2005, INT ARCH ALLERGY IMM, V138, P40, DOI 10.1159/000087356; Ischiropoulos H, 2003, BIOCHEM BIOPH RES CO, V305, P776, DOI 10.1016/S0006-291X(03)00814-3; Jaffrey SR, 2002, CHEM BIOL, V9, P1329, DOI 10.1016/S1074-5521(02)00293-4; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; Kalra D, 2000, CIRCULATION, V102, P1302; Katusic ZS, 2001, AM J PHYSIOL-HEART C, V281, pH981; Kilani MM, 2004, INFLAMMATION, V28, P245, DOI 10.1007/s10753-004-6047-y; Kim SF, 2005, SCIENCE, V310, P1966, DOI 10.1126/science.1119407; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; Kolodziejski PJ, 2004, P NATL ACAD SCI USA, V101, P18141, DOI 10.1073/pnas.0406711102; Kone B.C., 2003, AM J PHYSIOL-RENAL, V285, P178; Konig P, 2005, J HISTOCHEM CYTOCHEM, V53, P155, DOI 10.1369/jhc.4A6453.2005; Kraynack NC, 2002, AM J PHYSIOL-LUNG C, V283, pL604, DOI 10.1152/ajplung.00459.2001; Kroncke KD, 2001, FASEB J, V15, P2503, DOI 10.1096/fj.01-0240hyp; Kuncewicz T, 2003, MOL CELL PROTEOMICS, V2, P156, DOI 10.1074/mcp.M300003-MCP200; Kuncewicz T, 2001, AM J PHYSIOL-RENAL, V281, pF326; Lander HM, 1996, NATURE, V381, P380, DOI 10.1038/381380a0; Lane C, 2004, THORAX, V59, P757, DOI 10.1136/thx.2003.014894; Lawrence T, 2005, NATURE, V434, P1138, DOI 10.1038/nature03491; Lee J, 2003, P NATL ACAD SCI USA, V100, P4843, DOI 10.1073/pnas.0735876100; Li CQ, 2005, CANCER LETT, V226, P1, DOI 10.1016/j.canlet.2004.10.021; Li DC, 2000, AM J RESP CELL MOL, V23, P175; Liu LM, 2001, NATURE, V410, P490, DOI 10.1038/35068596; MacPherson JC, 2001, J IMMUNOL, V166, P5763; Marshall HE, 2002, J BIOL CHEM, V277, P34223, DOI 10.1074/jbc.M201638200; Matata BM, 2002, J BIOL CHEM, V277, P2330, DOI 10.1074/jbc.M106393200; Meurs H, 2003, TRENDS PHARMACOL SCI, V24, P450, DOI 10.1016/S0165-6147(03)00227-X; Minamoto K, 2002, J EXP MED, V196, P1321, DOI 10.1084/jem.20012135; Mitchell DA, 2005, NAT CHEM BIOL, V1, P154, DOI 10.1038/nchembio720; Moncada S, 2002, NAT REV MOL CELL BIO, V3, P214, DOI 10.1038/nrm762; Morris CR, 2004, AM J RESP CRIT CARE, V170, P148, DOI 10.1164/rccm.200309-1304OC; Norford D, 1998, EXP LUNG RES, V24, P355; Okamoto T, 2004, BIOL CHEM, V385, P997, DOI 10.1515/BC.2004.130; Okamoto T, 2002, AM J RESP CELL MOL, V27, P463, DOI 10.1165/rcmb-2002-0039OC; Okamoto T, 2004, AM J PHYSIOL-LUNG C, V286, pL198, DOI 10.1152/ajplung.00136.2003; Papapetropoulos A, 2006, AM J PHYSIOL-LUNG C, V290, pL179, DOI 10.1152/ajplung.00330.2005; Papapetropoulos A, 2005, MOL PHARMACOL, V68, P1133, DOI 10.1124/mol.105.012682; Park HS, 2000, P NATL ACAD SCI USA, V97, P14382, DOI 10.1073/pnas.97.26.14382; Park SW, 2005, ONCOGENE, V24, P6689, DOI 10.1038/sj.onc.1208816; Park SW, 2005, MOL CELL PROTEOMICS, V4, P300, DOI 10.1074/mcp.M400195-MCP200; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Pechkovsky DV, 2002, AM J PHYSIOL-LUNG C, V282, pL684, DOI 10.1152/ajplung.00320.2000; Pilz RB, 2003, CIRC RES, V93, P1034, DOI 10.1161/01.RES.0000103311.52853.48; Poynter ME, 2004, J IMMUNOL, V173, P7003; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Radi R, 2004, P NATL ACAD SCI USA, V101, P4003, DOI 10.1073/pnas.0307446101; Razavi HM, 2004, AM J RESP CRIT CARE, V170, P227, DOI 10.1164/rccm.200306-8460C; Reynaert NL, 2005, ANTIOXID REDOX SIGN, V7, P129, DOI 10.1089/ars.2005.7.129; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Richardson G, 2002, CLIN SCI, V102, P99, DOI 10.1042/CS20010207; Rose F, 2002, J IMMUNOL, V169, P1474; Sadikot RT, 2006, J IMMUNOL, V176, P4923; Saitoh F, 2004, J BIOL CHEM, V279, P29461, DOI 10.1074/jbc.M401471200; Sellak H, 2002, CIRC RES, V90, P405, DOI 10.1161/hh0402.105898; SHAUL PW, 1994, J CLIN INVEST, V94, P2231, DOI 10.1172/JCI117585; Snyder AH, 2002, AM J RESP CRIT CARE, V165, P922, DOI 10.1164/rccm.2105032; Sparkman L, 2004, AM J PHYSIOL-LUNG C, V287, pL764, DOI 10.1152/ajplung.00165.2004; Speyer CL, 2003, AM J PATHOL, V163, P2319, DOI 10.1016/S0002-9440(10)63588-2; Spiecker M, 1997, J BIOL CHEM, V272, P30969, DOI 10.1074/jbc.272.49.30969; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Steudel W, 2000, AM J RESP CRIT CARE, V162, P1262; Stick SA, 2003, AM J RESP CELL MOL, V28, P641, DOI 10.1165/rcmb.F271; Toward TJ, 2004, AM J RESP CRIT CARE, V169, P227, DOI 10.1164/rccm.200211-1372OC; Trujillo M, 1998, J BIOL CHEM, V273, P7828, DOI 10.1074/jbc.273.14.7828; Uetani K, 2001, AM J PHYSIOL-LUNG C, V280, pL1179; van der Vliet A, 2000, AM J PHYSIOL-LUNG C, V279, pL537; van der Vliet A, 1998, J BIOL CHEM, V273, P30255, DOI 10.1074/jbc.273.46.30255; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; Watkins DN, 1997, BRIT J PHARMACOL, V121, P1482; Wu GY, 1998, BIOCHEM J, V336, P1; Xu W, 1999, J MEMBRANE BIOL, V171, P117, DOI 10.1007/s002329900564; XU W, 2006, FREE RAD BIOL MED; Yamasaki K, 1998, J CLIN INVEST, V101, P967, DOI 10.1172/JCI2067; Yasukawa T, 2005, J BIOL CHEM, V280, P7511, DOI 10.1074/jbc.M411871200; Yu ZY, 2004, J BIOL CHEM, V279, P46954, DOI 10.1074/jbc.M407192200; Zandi E, 1999, MOL CELL BIOL, V19, P4547; Zeidler MR, 2004, CURR OPIN PULM MED, V10, P31, DOI 10.1097/00063198-200401000-00006; Zhang YH, 2005, FREE RADICAL BIO MED, V38, P831, DOI 10.1016/j.freeradbiomed.2004.12.016; Zhang ZL, 2000, J BIOL CHEM, V275, P15839, DOI 10.1074/jbc.M000604200; Zheng S, 2003, IMMUNITY, V18, P619, DOI 10.1016/S1074-7613(03)00114-6; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912	147	76	84	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0891-5849			FREE RADICAL BIO MED	Free Radic. Biol. Med.	AUG 15	2006	41	4					515	527		10.1016/j.freeradbiomed.2006.05.011		13	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	071NF	WOS:000239608200001	16863984	
J	Kim, JK; Oh, SM; Kwon, HS; Oh, YS; Lim, SS; Shin, HK				Kim, JK; Oh, SM; Kwon, HS; Oh, YS; Lim, SS; Shin, HK			Anti-inflammatory effect of roasted licorice extracts on lipopolysaccharide-induced inflammatory responses in murine macrophages	BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS			English	Article						licorice; inflammation; inducible nitric oxide synthase; prostaglandin E-2; nuclear factor-kappa B; pro-inflammatory cytokines	NF-KAPPA-B; IMMUNE-SYSTEM; ISOLIQUIRITIGENIN; EXPRESSION; COLITIS; CELLS; MICE; ACTIVATION; RESOLUTION; MEDIATORS	Licorice, the roots of Glycyrrhiza inflata, is used by practitioners of alternative medicine to treat individuals with gastric or duodenal ulcers, bronchitis, cough, arthritis, adrenal insufficiency, and allergies. We investigated the anti-inflammatory properties of 4 licorice extracts: extracts of roasted licorice obtained by ethanol (rLE) or water extraction (rLW) and extracts of raw licorice obtained by ethanol (LE) or water extraction (LW). rLE demonstrated strong anti-inflammatory activity through its ability to reduce nitric oxide and prostaglandin E-2 production in the LPS-stimulated mouse macrophage cell, RAW264.7. It also inhibited the production of pro-inflammatory cytokines and CD14 expression on the LPS-stimulated RAW264.7 cells. Further study indicated that LPS-induced degradation and phosphorylation of I kappa-B alpha, along with DNA-binding of NF-kappa B, was significantly inhibited by rLE exposure in RAW264.7 cells. In the murine model, we found that in vivo exposure to rLE-induced an increase in the survival rate, reduced plasma levels of TNF-alpha and IL-6, and increased IL-10 production in LPS-treated mice. Collectively, these data suggest that the use of rLE may be a useful therapeutic approach to various inflammatory diseases. (c) 2006 Elsevier Inc. All rights reserved.			kimjin@hallym.ac.kr					Abe M, 2003, J GASTROENTEROL, V38, P962, DOI 10.1007/s00535-003-1179-7; Akashi S, 2000, J IMMUNOL, V164, P3471; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Berg DJ, 2002, GASTROENTEROLOGY, V123, P1527, DOI 10.1053/gast; Bogdan C., 2001, NAT IMMUNOL, V2, P2907; CALLISTE CA, 2001, ANTICANCER RES, V6, P3949; Carbonell-Barrachina AA, 2003, J AGR FOOD CHEM, V51, P1749, DOI 10.1021/jf026057h; Cook-Mills JM, 2005, J LEUKOCYTE BIOL, V77, P487, DOI 10.1189/jlb.0904554; Dai Q, 2005, BIOCHEM BIOPH RES CO, V332, P37, DOI 10.1016/j.bbrc.2005.04.088; Fichtner-Feigl S, 2005, J CLIN INVEST, V115, P3057, DOI 10.1172/JCI24792; FINTELMANN V, 1991, PLANTA MED, V57, pS48, DOI 10.1055/s-2006-960229; Fukai T, 2003, FITOTERAPIA, V74, P624, DOI 10.1016/S0367-326X(03)00164-3; Gomez PF, 2005, J IMMUNOL, V175, P6924; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Haggag Eman G, 2003, J Herb Pharmacother, V3, P41; Harris SG, 2002, TRENDS IMMUNOL, V23, P144, DOI 10.1016/S1471-4906(01)02154-8; INOUE H, 1986, CHEM PHARM BULL, V34, P897; Iontcheva I, 2004, INFECT IMMUN, V72, P2312, DOI 10.1128/IAI.72.4.2312-2320.2004; Ishiguro Y, 1999, J GASTROENTEROL, V34, P66, DOI 10.1007/s005350050218; Kamei J, 2004, ANN ALLERG ASTHMA IM, V93, pS45; Kamimura M, 2005, CIRC RES, V97, P305, DOI 10.1161/01.RES.0000177893.24574.13; Kanazawa M, 2003, EUR UROL, V43, P580, DOI 10.1016/S0302-2838(03)00090-3; KAPLANSKI G, 2004, TRENDS IMMUNOL, V24, P25; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KKEGAWA H, 1992, CHEM PHARM BULL, V40, P1439; Klotz L, 2005, J IMMUNOL, V175, P4948; Kuwajima H, 1999, YAKUGAKU ZASSHI, V119, P945; Kwon KH, 2005, BIOCHEM BIOPH RES CO, V337, P647, DOI 10.1016/j.bbrc.2005.09.107; LASKIN DL, 1995, ANNU REV PHARMACOL, V35, P655, DOI 10.1146/annurev.pharmtox.35.1.655; Lawrence T, 2002, NAT REV IMMUNOL, V2, P787, DOI 10.1038/nri915; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li XX, 2002, EXP HEMATOL, V30, P285, DOI 10.1016/S0301-472X(02)00777-4; Ponchel F, 2002, BLOOD, V100, P4550, DOI 10.1182/blood-2002-03-0671; Rose JW, 2004, J NEUROIMMUNOL, V149, P40, DOI 10.1016/j.jneuroim.2003.12.021; Sakagami T, 1997, INFECT IMMUN, V65, P3310; SMITH WL, 1994, ANN NY ACAD SCI, V714, P136, DOI 10.1111/j.1749-6632.1994.tb12037.x; Sung MW, 2004, ELECTROPHORESIS, V25, P3434, DOI 10.1002/elps.200305988; TAWATA M, 1992, EUR J PHARMACOL, V212, P87, DOI 10.1016/0014-2999(92)90076-G; VANROSSUM TG, 1998, ALIMENT PHARM THERAP, V12, P99; Vernooy JHJ, 2002, AM J RESP CELL MOL, V26, P152; Walsh NC, 2005, IMMUNOL REV, V208, P228, DOI 10.1111/j.0105-2896.2005.00338.x; Wu GY, 1998, BIOCHEM J, V336, P1; Yamazaki S, 2002, CANCER LETT, V183, P23, DOI 10.1016/S0304-3835(02)00113-1; Yokota T, 1998, PIGM CELL RES, V11, P355, DOI 10.1111/j.1600-0749.1998.tb00494.x; YU SM, 1995, BRIT J PHARMACOL, V114, P1587; Zhou SF, 2004, LIFE SCI, V74, P935, DOI 10.1016/j.lfs.2003.09.035	47	76	88	5	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0006-291X			BIOCHEM BIOPH RES CO	Biochem. Biophys. Res. Commun.	JUL 7	2006	345	3					1215	1223		10.1016/j.bbrc.2006.05.035		9	Biochemistry & Molecular Biology; Biophysics	Biochemistry & Molecular Biology; Biophysics	054AA	WOS:000238346500044	16716255	
J	Cvetkovski, RS; Zachariae, R; Jensen, H; Olsen, J; Johansen, JD; Agner, T				Cvetkovski, RS; Zachariae, R; Jensen, H; Olsen, J; Johansen, JD; Agner, T			Quality of life and depression in a population of occupational hand eczema patients	CONTACT DERMATITIS			English	Article						health-related quality of life; occupational skin disease; psychosocial factors; socioeconomic status	CONTACT-DERMATITIS; SKIN-DISEASE; INDEX DLQI; OUTPATIENTS; SEVERITY; WORKERS; IMPACT	Occupational hand eczema (OHE) is the most frequently recognized occupational disease in Denmark, and despite governmental attempts to reduce exposure to harmful occupational allergens, the number of new cases has remained almost unchanged since the mid-1990s. Some studies have indicated that OHE has considerable impact on quality of life (QoL) and may lead to depression. The aims of the study were to determine risk factors for low QoL, the frequency and severity of depression among OHE patients and changes in QoL and depression after 12 months of follow up. The study population, 758 patients, comprised all new recognized cases from the Danish National Board of Industrial Injuries Registry between October 2001 and November 2002. All patients received a questionnaire to determine impairment of QoL and depressive symptoms. A similar follow-up questionnaire was posted after 1 year. The response rate was 82% at baseline and 91% at follow up. The mean Dermatology Life Quality Index total score was 5.5 for all patients and 7.8 for severe OHE cases. Severe OHE cases and lower socioeconomic status were independently associated with low QoL. The prevalence of moderate-to-severe depression was 9%. Only minor changes in QoL and depressive symptoms were found after 12 months of follow up.	Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Copenhagen, Denmark; Aarhus Univ Hosp, Psychooncol Res Univ, DK-8000 Aarhus, Denmark; Aarhus Univ, DK-8000 Aarhus, Denmark; Univ Copenhagen, Danish Epidemiol Sci Ctr, Copenhagen, Denmark; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA; Gentofte Univ Hosp, Natl Allergy Res Ctr, Copenhagen, Denmark	Cvetkovski, RS (reprint author), Haderslevgade 38 4th, DK-1671 Copenhagen V, Denmark.	risk@dadlnet.dk					Adisesh A, 2002, CONTACT DERMATITIS, V46, P273, DOI 10.1034/j.1600-0536.2002.460505.x; Agner T, 1999, Am J Contact Dermat, V10, P12, DOI 10.1016/S1046-199X(99)90088-X; Anderson R T, 2001, Curr Allergy Asthma Rep, V1, P309, DOI 10.1007/s11882-001-0041-3; Antezana M, 2003, IMMUNOL ALLERGY CLIN, V23, P269, DOI 10.1016/S0889-8561(03)00027-4; Barros Aluisio J D, 2003, BMC Med Res Methodol, V3, P21, DOI 10.1186/1471-2288-3-21; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561; Coenraads PJ, 2004, HAUTARZT, V55, P28, DOI 10.1007/s00105-003-0659-2; Coenraads PJ, 2005, BRIT J DERMATOL, V152, P296, DOI 10.1111/J.1365-2133.2004.06270.X; Cvetkovski RS, 2005, BRIT J DERMATOL, V152, P93, DOI 10.1111/J.1365-2133.2005.06415.X; Dickel H, 2002, CONTACT DERMATITIS, V46, P197, DOI 10.1034/j.1600-0536.2002.460403.x; EDMAN B, 1988, CONTACT DERMATITIS, V19, P43, DOI 10.1111/j.1600-0536.1988.tb02866.x; Finlay AY, 2005, BRIT J DERMATOL, V152, P861, DOI 10.1111/j.1365-2133.2005.06502.x; FINLAY AY, 1994, CLIN EXP DERMATOL, V19, P210, DOI 10.1111/j.1365-2230.1994.tb01167.x; Hachem JP, 2002, CONTACT DERMATITIS, V46, P220, DOI 10.1034/j.1600-0536.2002.460406.x; Hahn HB, 2001, J AM ACAD DERMATOL, V45, P44, DOI 10.1067/mjd.2001.110880; Holness DL, 2001, CONTACT DERMATITIS, V44, P80; HOLNESS DL, 1991, CONTACT DERMATITIS, V25, P296, DOI 10.1111/j.1600-0536.1991.tb01877.x; Hongbo Y, 2004, BRIT J DERMATOL, V151, P45; Hutchings CV, 2001, CONTACT DERMATITIS, V45, P17, DOI 10.1034/j.1600-0536.2001.045001017.x; JOWETT S, 1985, SOC SCI MED, V20, P425, DOI 10.1016/0277-9536(85)90021-8; Kadyk DL, 2003, J AM ACAD DERMATOL, V49, P1037, DOI 10.1016/S0190-9622(03)02112-1; MEDING B, 1990, CONTACT DERMATITIS, V23, P6, DOI 10.1111/j.1600-0536.1990.tb00076.x; MEDING B, 2005, BRIT J DERMATOL, V152, P9875; Meyer JD, 2000, OCCUP MED-OXFORD, V50, P265; NETHERCOTT JR, 1994, J AM ACAD DERMATOL, V30, P569; Niemeier V, 2002, BRIT J DERMATOL, V146, P1031, DOI 10.1046/j.1365-2133.2002.04716.x; Skoet R, 2004, CONTACT DERMATITIS, V51, P159, DOI 10.1111/j.0105-1873.2004.00423.x; Thomson KF, 2002, BRIT J DERMATOL, V146, P627, DOI 10.1046/j.1365-2133.2002.04692.x; Wallenhammar LM, 2004, J INVEST DERMATOL, V122, P1381, DOI 10.1111/j.0022-202X.2004.22604.x; Yun YH, 2005, ONCOLOGY-BASEL, V68, P107, DOI 10.1159/000085703; Zachariae R, 2000, ACTA DERM-VENEREOL, V80, P272; Zachariae R, 2004, ACTA DERM-VENEREOL, V84, P205, DOI 10.1080/00015550410023284	32	76	83	0	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	FEB	2006	54	2					106	111		10.1111/j.0105-1873.2006.00783.x		6	Allergy; Dermatology	Allergy; Dermatology	013OD	WOS:000235417700007	16487283	
J	Fiocchi, A; Pajno, G; La Grutta, S; Pezzuto, F; Incorvaia, C; Sensi, L; Marcucci, F; Frati, F				Fiocchi, A; Pajno, G; La Grutta, S; Pezzuto, F; Incorvaia, C; Sensi, L; Marcucci, F; Frati, F			Safety of sublingual-swallow immunotherapy in children aged 3 to 7 years	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							HOUSE-DUST-MITE; DOUBLE-BLIND; ALLERGEN IMMUNOTHERAPY; THERAPEUTIC VACCINES; ASTHMATIC-CHILDREN; SYSTEMIC REACTIONS; YOUNG-CHILDREN; POSITION PAPER; EFFICACY; RHINOCONJUNCTIVITIS	Background: The minimum age to start specific immunotherapy with inhalant allergens in children has not been clearly established, and position papers discourage its use in children younger than 5 years. Objective: To assess the safety of high-dose sublingual-swallow immunotherapy (SLIT) in a group of children younger than 5 years. Methods: Sixty-five children (51 boys and 14 girls; age range, 38-80 months; mean +/- SD age, 60 +/- 10 years; median age, 60 months) were included in this observational study. They were treated with SLIT with a build-up phase of 11 days, culminating in a top dose of 300 IR (index of reactivity) and a maintenance phase of 300 IR 3 times a week. The allergens used were house dust mites in 42 patients, grass pollen in 11 patients, olive pollen in 5 patients, Parietaria pollen in 4 patients, and cypress pollen in 3 patients. All adverse reactions and changes in the treatment schedule were compared in 2 subgroups: children 38 to 60 months old and children 61 to 80 months old. Results: The average cumulative dose of SLIT was 36,900 IR. Adverse reactions were observed in 11 children, none of them severe enough to require discontinuation of immunotherapy. Six reactions occurred in the 60 months or younger age group and 7 in the older than 60 months age group, with no differences between these 2 groups. Conclusion: High-dose immunotherapy in children younger than 5 years does not cause more adverse reactions than in children aged 5 to 7 years. There is no reason to forbear studies on safety and efficacy of these preparations in young children.	Fatebenefratelli Melloni Univ Hosp, Dept Child & Maternal Med, Milan, Italy; Univ Messina, Sch Med, Dept Pediat, Messina, Italy; ARNAS, Childrens Hosp, Allergy Unit, Palermo, Italy; ASL SA2, Allergy Unit, Salerno, Italy; ICP Hosp, Allergy Rheumatol Unit, Milan, Italy; Univ Perugia, Sch Med, Dept Gynaecol Obstet & Pediat Sci, I-06100 Perugia, Italy	Fiocchi, A (reprint author), Macedonio Melloni Pediat Hosp, Via Macedonio Melloni 52, I-20121 Milan, Italy.	allerg@tin.it		Fiocchi, Alessandro/0000-0002-2549-0523			AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Akcakaya N, 2000, ANN ALLERG ASTHMA IM, V85, P317; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; BUSINCO L, 1995, PEDIATR ALLERGY IMMU, V6, P44, DOI 10.1111/j.1399-3038.1995.tb00257.x; Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; DuBuske LM, 2001, ANN ALLERG ASTHMA IM, V87, P56; Fiocchi A, 2004, ANN ALLERG ASTHMA IM, V93, P328; Frati F, 2003, ALLERG IMMUNOL PARIS, V35, P56; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Host A, 2003, ALLERGY, V58, P559, DOI 10.1034/j.1398-9995.2003.00238.x; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Li JT, 2003, ANN ALLERG ASTHMA IM, V90, P1; MALLING HJ, 1993, ALLERGY, V48, P9; MARCUCCI F, 2001, ALLERGY, V55, P1091; Moher D, 2001, ANN INTERN MED, V134, P657; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; OWNBY DR, 1994, J ALLERGY CLIN IMMUN, V94, P662, DOI 10.1016/0091-6749(94)90171-6; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 2004, ANN ALLERG ASTHMA IM, V93, P3; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P1285, DOI 10.1111/j.1398-9995.2004.00627.x; TAVES DR, 1974, CLIN PHARMACOL THER, V15, P443; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; Wilson DR, 2003, COCHRANE DB SYST REV, V2	30	76	80	1	4	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	SEP	2005	95	3					254	258				5	Allergy; Immunology	Allergy; Immunology	966TN	WOS:000232044900010	16200816	
J	Satinover, SM; Reefer, AJ; Pomes, A; Chapman, MD; Platts-Mills, TAE; Woodfolk, JA				Satinover, SM; Reefer, AJ; Pomes, A; Chapman, MD; Platts-Mills, TAE; Woodfolk, JA			Specific IgE and IgG antibody-binding patterns to recombinant cockroach allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cockroach; asthma; allergens; troponryosin; IgE antibody; IgG antibody; multiplex	INNER-CITY CHILDREN; FLOW-CYTOMETRIC ASSAY; AMERICAN COCKROACH; HOUSE-DUST; DERMATOPHAGOIDES-PTERONYSSINUS; BLATTELLA-GERMANICA; MOLECULAR-CLONING; MAJOR ALLERGEN; RISK-FACTORS; ASTHMA	Background: The specificity of serum antibody responses to different cockroach allergens has not been studied. Objective: We sought to quantitate serum IgE and IgG antibodies to a panel of purified cockroach allergens among cockroach-sensitized subjects. Methods: IgE antibodies to recombinant cockroach allergens (rBla g 1, rBla g 2, rBla g 4, rBla g 5, and rPer a 7) were measured in sera containing IgE antibodies to Blattella germanica extract (n = 118) by using a streptavidin CAP assay and a multiplex flow cytometric assay. Specific IgG antibodies were determined by using radioimmuno-precipitation techniques. Results: Specific IgE antibodies measured by means of CAP assay and multiplex assay were strongly correlated (r = 0.8, P < .001). The sum of IgE antibodies (in international units per milliliter) against all 5 allergens equated to IgE antibodies to cockroach extract. Although the prevalence of IgE antibodies was highest for rBla g 2 (54.4%) and rBla g 5 (37.4%), patterns of IgE antibody binding were unique to each subject. Surprisingly, only 16% of cockroach-sensitized subjects with IgE antibodies to house dust mite exhibited IgE antibody binding to cockroach tropomyosin (rPer a 7). Specific IgE antibodies were associated with increased IgG antibody levels, although detection of IgG in the absence of IgE was not uncommon. Conclusion: The techniques described offer a new approach for defining the hierarchy of purified allergens. IgE antibodies directed against 5 allergens constitute the majority of the IgE antibody repertoire for cockroach. Such distinct, patterns of IgE-IgG responsiveness to different cockroach allergens highlight the complexity of B-cell responses to environmental allergens.	Univ Virginia, Asthma & Allerg Dis Ctr, Div Allergy, Charlottesville, VA 22908 USA	Woodfolk, JA (reprint author), Univ Virginia, Asthma & Allerg Dis Ctr, Div Allergy, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu		Pomes, Anna/0000-0002-8729-1829	NIAID NIH HHS [AI 20565]		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Arruda L K, 2001, Curr Allergy Asthma Rep, V1, P466, DOI 10.1007/s11882-001-0035-1; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409; de Jager W, 2003, CLIN DIAGN LAB IMMUN, V10, P133, DOI 10.1128/CDLI.10.1.133-139.2003; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; ERWIN EA, 2005, IN PRESS J ALLERGY C; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HULETT AC, 1979, ANN ALLERGY, V42, P160; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; Lal G, 2004, CLIN DIAGN LAB IMMUN, V11, P272, DOI 10.1128/CDLI.11.2.272-279.2004; Lee CS, 2004, CLIN EXP ALLERGY, V34, P354, DOI 10.1111/j.1365-2222.2004.01878.x; Matsui EC, 2003, J ALLERGY CLIN IMMUN, V112, P87, DOI 10.1067/mai.2003.1588; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; Pickering JW, 2002, CLIN DIAGN LAB IMMUN, V9, P872, DOI 10.1128/CDLI.9.4.872-876.2002; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Pomes A, 2002, EUR J BIOCHEM, V269, P3086, DOI 10.1046/j.1432-1033.2002.02990.x; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; vanWijnen JH, 1997, ALLERGY, V52, P460; Wu CH, 1997, MOL IMMUNOL, V34, P1, DOI 10.1016/S0161-5890(97)00009-6; Wu CH, 1996, J BIOL CHEM, V271, P17937; Wu CH, 2000, ALLERGY, V55, P1179, DOI 10.1034/j.1398-9995.2000.00604.x; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4	34	76	79	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					803	809		10.1016/j.jaci.2005.01.018		7	Allergy; Immunology	Allergy; Immunology	916GM	WOS:000228373400021	15806002	
J	Muller, UR; Haeberli, G				Muller, UR; Haeberli, G			Use of beta-blockers during immunotherapy for Hymenoptera venom allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anaphylaxis; beta-blockers; hymenoptera venom immunotherapy	FATAL ANAPHYLACTIC REACTIONS; ADRENERGIC-BLOCKADE; HEART-FAILURE; RISK; HISTAMINE; EFFICACY; THERAPY; SAFETY; DRUGS	Background: B-Blockers may aggravate anaphylactic reactions and interfere with treatment. There is therefore concern about their use in patients who have a history of anaphylaxis or are on allergen immunotherapy. Immunotherapy is the best available treatment for prevention of life-threatening anaphylaxis to Hymenoptera stings, which is often observed in elderly patients who have cardiovascular disease and therefore are on beta-blocker treatment. Objective: To analyze the risk of beta-blocker treatment during venom immunotherapy. Methods: We screened all 1682 patients with Hymenoptera venom allergy seen during a period of 34 months for immunotherapy, cardiovascular disease, and treatment with beta-blockers. Results: Of the 1389 patients in whom immunotherapy was recommended, 11.2% had cardiovascular disease, and 44 of these were on beta-blockers before immunotherapy. In 31 of those, the drug was replaced before starting treatment. In 3 with coronary heart disease and I with severe ventricular arrhythmia, the drug was continued throughout immunotherapy. In 9, it was reintroduced after reaching the maintenance dose. In an additional 12 patients, beta-blockers were newly started during immunotherapy. Of 25 patients on beta-blockers during immunotherapy, 3 (12%) developed allergic side effects, compared with 23 (16.7%) of 117 with cardiovascular disease but without beta-blockers. Systemic allergic symptoms after re-exposure by sting challenge or field sting were observed in 1 of 7 (14.3%) with and 4 of 29 (13.8%) without beta-blockade. No severe reactions to treatment or sting reexposure were observed in patients with beta-blockade. Conclusion: Combination of beta-blockers with venom immunotherapy may be indicated in heavily exposed patients with severe cardiovascular disease.	Spital Bern Ziegler, Dept Med, CH-3007 Bern, Switzerland	Muller, UR (reprint author), Spital Bern Ziegler, Dept Med, Morillonstr 75-91, CH-3007 Bern, Switzerland.	ulrich.mueller@spitalbern.ch					ASSEM ESK, 1971, BRIT J PHARMACOL, V42, P620; AWAI LE, 1984, ANN ALLERGY, V53, P48; BERKELMAN RL, 1986, ANN INTERN MED, V104, P134; Foody JM, 2002, JAMA-J AM MED ASSOC, V287, P883, DOI 10.1001/jama.287.7.883; Freemantle N, 1999, BRIT MED J, V318, P1730; Haeberli G, 2003, CLIN EXP ALLERGY, V33, P1216, DOI 10.1046/j.1365-2222.2003.01755.x; HANNAWAY PJ, 1983, NEW ENGL J MED, V308, P1536; HELBLING A, 2004, CLIN EXP ALLERGY, V34, P1; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; INGALL M, 1984, JAMA-J AM MED ASSOC, V251, P1432; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; KALINER M, 1972, J EXP MED, V136, P556, DOI 10.1084/jem.136.3.556; KAPLAN AP, 1989, J ALLERGY CLIN IMMUN, V84, P129, DOI 10.1016/0091-6749(89)90186-3; LANG DM, 1995, DRUG SAFETY, V12, P299; LAXENAIRE M C, 1984, Annales Francaises d'Anesthesie et de Reanimation, V3, P453, DOI 10.1016/S0750-7658(84)80146-X; Locke M, 1998, J INSECT PHYSIOL, V44, P1; MADOWITZ JS, 1979, JAMA-J AM MED ASSOC, V241, P2813, DOI 10.1001/jama.241.26.2813; MALLING HJ, 1993, ALLERGY, V48, P14; MATSUMURA Y, 1976, J ALLERGY CLIN IMMUN, V58, P387, DOI 10.1016/0091-6749(76)90119-6; Mosbech H, 2000, ALLERGY, V55, P1005, DOI 10.1034/j.1398-9995.2000.00587.x; Mueller H L, 1966, J Asthma Res, V3, P331, DOI 10.3109/02770906609106941; MULLER U, 1993, ALLERGY, V48, P37; MULLER U, 1992, J ALLERGY CLIN IMMUN, V89, P529, DOI 10.1016/0091-6749(92)90319-W; Muller U., 1990, INSECT STING ALLERGY; MULLER UR, 2003, ALLERGY S74, V58, P99; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; PARRISH HM, 1963, AM J MED SCI, V245, P129; Pumphrey RSH, 1996, CLIN EXP ALLERGY, V26, P1364, DOI 10.1046/j.1365-2222.1996.d01-297.x; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; SASVARY T, 1994, SCHWEIZ MED WSCHR, V124, P1887; *SCHW BUND STAT, 1998, SEKT GES TOD SCHWEIZ; Skrbic D, 1996, ALLERGOLOGIE, V19, P123; TenBrook JA, 2004, J ALLERGY CLIN IMMUN, V113, P977, DOI 10.1016/j.jaci.2004.02.043; THURNHEER U, 1983, ALLERGY, V38, P465, DOI 10.1111/j.1398-9995.1983.tb02355.x; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TOOGOOD JH, 1987, CAN MED ASSOC J, V136, P929	37	76	77	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2005	115	3					606	610		10.1016/j.jsci.2004.11.012		5	Allergy; Immunology	Allergy; Immunology	907AN	WOS:000227687000026	15753911	
J	Forsberg, B; Hansson, HC; Johansson, C; Areskoug, H; Persson, K; Jarvholm, B				Forsberg, B; Hansson, HC; Johansson, C; Areskoug, H; Persson, K; Jarvholm, B			Comparative health impact assessment of local and regional particulate air pollutants in Scandinavia	AMBIO			English	Article							DAILY MORTALITY; RESPIRATORY SYMPTOMS; BACKGROUND SITES; ASTHMA SYMPTOMS; WOOD COMBUSTION; BOUNDARY-LAYER; POLLUTION; PARTICLES; URBAN; ASSOCIATION	The ongoing program Clean Air for Europe (CAFE) is an initiative from the EU Commission to establish a coordinated effort to reach better air quality in the EU. The focus is on particulate matter as it has been shown to have large impact on human health. CAFE requested that WHO make a review of the latest findings on air pollutants and health to facilitate assessments of the different air pollutants and their health effects. The WHO review project on health aspects of air pollution in Europe confirmed that exposure to particulate matter (PM), despite the lower levels we face today, still poses a significant risk to human health. Using the recommended uniform risk coefficients for health impact assessment of PM, regardless of sources, premature mortality related to long-range transported anthropogenic particles has been estimated to be about 3500 deaths per year for the Swedish population, corresponding to a reduction in life expectancy of up to about seven months. The influence of local sources is more difficult to estimate due to large uncertainties when linking available risk coefficients to exposure data, but the estimates indicate about 1800 deaths brought forward each year with a life expectancy reduction of about 2-3 months. However, some sectors of the population are exposed to quite high locally induced concentrations and are likely to suffer excessive reductions in life expectancy. Since the literature increasingly supports assumptions that combustion related particles are associated with higher relative risks, further studies may shift the focus for abatement strategies. CAFE sets out to establish a general cost effective abatement strategy for atmospheric particles. Our results, based on studies of background exposure, show that long-range transported sulfate rich particles dominate the health effects of PM in Sweden. The same results would be found for the whole of Scandinavia and many countries influenced by transboundary air pollution. However, several health studies, including epidemiological studies with a finer spatial resolution, indicate that engine exhaust particles are more damaging to health than other particles. These contradictory findings must be understood and source specific risk estimates have to be established by expert bodies, otherwise it will not be possible to find the most cost effective abatement strategy for Europe. We are not happy with today's situation where every strategy to reduce PM concentrations is estimated to have the same impact per unit change in the mass concentration. Obviously there is a striking need to introduce more specific exposure variables and a higher geographical resolution in epidemiology as well as in health impact assessments.	Umea Univ, Dept Publ Hlth & Clin Med, SE-90187 Umea, Sweden; Stockholm Univ, Dept Appl Environm Sci, SE-10691 Stockholm, Sweden; IVL Swedish Environm Res Inst, Swedish Urban Air Qual Network, SE-40014 Gothenburg, Sweden	Forsberg, B (reprint author), Umea Univ, Dept Publ Hlth & Clin Med, SE-90187 Umea, Sweden.	bertil.forsberg@envmed.umu.se; hc@itm.su.se; christer.johansson@itm.su.se; hans.areskoug@itm.su.se; karin.persson@ivi.se; bengt.jarvholm@envmed.umu.se	Johansson, Christer/C-6451-2011	Johansson, Christer/0000-0002-8459-9852			ANDERSSON J, 2001, DP010515 CONCAWE, P1; ARESKOUG H, 2004, 145 ITM LUFTL STOCKH; ARESKOUG H, 2004, 110 ITM LUFTL STOCKH; Becker S, 2003, EXP LUNG RES, V29, P29, DOI 10.1080/01902140390116535; Boman BC, 2003, SCAND J WORK ENV HEA, V29, P251; Castillejos M, 2000, INHAL TOXICOL, V12, P61, DOI 10.1080/089583700196392; Cifuentes LA, 2000, J AIR WASTE MANAGE, V50, P1287; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DURING I, 2002, P 11 INT S TRANSP AI; FORSBERG B, 1993, EUR RESPIR J, V6, P1109; Garshick E, 2003, EPIDEMIOLOGY, V14, P728, DOI 10.1097/01.ede.0000082045.50073.66; Glasius M, 2001, J GEOPHYS RES-ATMOS, V106, P7415, DOI 10.1029/2000JD900676; Goldberg MS, 2001, ENVIRON RES, V86, P26, DOI 10.1006/enrs.2001.4243; Harrison RM, 2004, ATMOS ENVIRON, V38, P4531, DOI 10.1016/j.atmosenv.2004.05.022; Hedberg E, 2002, ATMOS ENVIRON, V36, P4823, DOI 10.1016/S1352-2310(02)00417-X; Hetland RB, 2000, J TOXICOL ENV HEAL A, V60, P47, DOI 10.1080/009841000156583; Hetland RB, 2004, TOXICOL IN VITRO, V18, P203, DOI 10.1016/S0887-2333(03)00142-5; Hoek G, 2000, J AIR WASTE MANAGE, V50, P1380, DOI 10.1080/10473289.2000.10464182; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Janssen NAH, 2002, ENVIRON HEALTH PERSP, V110, P43; JOHANSSON C, 1999, STOCKHOLM STUDY HLTH; JOHN A, 2004, EUR AER C BUD 06 10; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; KITTELSON D, 2000, 2000012212 SAE, P1; KuEnzli N., 2000, LANCET, P795; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; Maricq MM, 1999, ENVIRON SCI TECHNOL, V33, P2007, DOI 10.1021/es981005n; Nafstad P, 2004, ENVIRON HEALTH PERSP, V112, P610, DOI 10.1289/ehp.6684; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; OMSTEDT G, 2002, 103 SMHI; Ostro BD, 2000, J EXPO ANAL ENV EPID, V10, P412, DOI 10.1038/sj.jea.7500094; Pope AC, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI DOI 10.1001/JAMA.287.9.1132; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; QUEROL X, 2004, IN PRESS ATMOS ENV; Ristovski ZD, 1998, ENVIRON SCI TECHNOL, V32, P3845, DOI 10.1021/es980102d; Roemer WH, 2001, EPIDEMIOLOGY, V12, P649, DOI 10.1097/00001648-200111000-00012; Sakurai H, 2003, ATMOS ENVIRON, V37, P1199, DOI 10.1016/S1352-2310(02)01017-8; Schwartz J, 2002, ENVIRON HEALTH PERSP, V110, P1025; Schwarze PE, 2002, INT J HYG ENVIR HEAL, V204, P327, DOI 10.1078/1438-4639-00108; SJOBERG K, 2004, 1553 IVL B; Tunved P, 2003, ATMOS CHEM PHYS, V3, P2183; Van Dingenen R, 2004, ATMOS ENVIRON, V38, P2561, DOI 10.1016/j.atmosenv.2004.01.040; WESTERLUND KG, 2002, AIR POLLUTION 10; *WHO, 2004, EUR045046026 WHO BON; *WHO, 2003, EUR035042688 WHO BON; World Health Organization, 2000, EUR005020369 WHO REG	49	76	77	1	19	ROYAL SWEDISH ACAD SCIENCES	STOCKHOLM	PUBL DEPT BOX 50005, S-104 05 STOCKHOLM, SWEDEN	0044-7447			AMBIO	Ambio	FEB	2005	34	1					11	19		10.1639/0044-7447(2005)034[0011:CHIAOL]2.0.CO;2		9	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	894HU	WOS:000226782600002	15789513	
J	Holguin, F; Mannino, DM; Anto, J; Mott, J; Ford, ES; Teague, WG; Redd, SC; Romieu, I				Holguin, F; Mannino, DM; Anto, J; Mott, J; Ford, ES; Teague, WG; Redd, SC; Romieu, I			Country of birth as a risk factor for asthma among Mexican Americans	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; Mexican Americans; migration	BODY-MASS INDEX; NHANES-III; RESPIRATORY SYMPTOMS; SERUM IGE; US ADULTS; IMMIGRANTS; PREVALENCE; ALLERGY; HEALTH; AGE	In the United States, among Hispanics, Mexican Americans have the lowest rate of asthma. However, this population includes Mexican Americans born in the United States and in Mexico, and risk factors that might impact the prevalence of asthma differ between these groups. To determine the prevalence of and risk factors for asthma among U.S.- and Mexican-born Mexican Americans, we analyzed data from two U.S. surveys that included 4,574 persons who self-reported their ethnicity as Mexican American from the Third National Health and Nutrition Examination Survey (NHANES III) 1998-1994 and 12,980 persons who self-reported their ethnicity as Mexican American from National Health Interview Survey (NHIS) 1997-2001. U.S.-born Mexican Americans were more likely than Mexican-born Mexican Americans to report ever having asthma in both the NHANES III (7% [SE 0.5] vs. 3% [SE 0.3], p < 0.001) and NHIS surveys (8.1% [0.4] vs. 2.5% [0.2], p < 0.001). In a multivariate regression model controlling for multiple demographic variables and health care, the risk for asthma was higher among U.S.-born Mexicans in NHANES III (odds ratio 2.1, 95% confidence interval 1.4-3.3) and NHIS (odds ratio 2.7, 95% confidence interval 1.6-5.5). In conclusion, the prevalence of asthma was higher in U.S.-born than in Mexican-born Mexican Americans. This finding highlights the importance of environmental exposures in developing asthma in a migratory population.	Ctr Dis Control & Prevent, Atlanta, GA 30333 USA; Emory Univ, Sch Med, Dept Pediat, Atlanta, GA 30322 USA; Municipal Inst Med Res, Barcelona, Spain; Inst Nacl Salud Publ, Cuernavaca, Morelos, Mexico	Holguin, F (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,NE,Mailstop E-17, Atlanta, GA 30333 USA.	fch5@cdc.gov	Osborne, Nicholas/N-4915-2015; Anto, J/H-2676-2014	Osborne, Nicholas/0000-0002-6700-2284; Anto, J/0000-0002-4736-8529; Mannino, David/0000-0003-3646-7828			Arif AA, 2003, EUR RESPIR J, V21, P827, DOI 10.1183/09031936.03.00054103; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Ballin A, 1998, MED HYPOTHESES, V51, P281, DOI 10.1016/S0306-9877(98)90047-0; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BOTMAN S, DHHS PUBLICATION; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; *CONS NAC POBL, MIGR MEX EST UN, P20; Crespo CJ, 2001, AM J PUBLIC HEALTH, V91, P1254, DOI 10.2105/AJPH.91.8.1254; Dervaderics M, 2002, IMMUNOL INVEST, V31, P29, DOI 10.1081/IMM-120003220; Documet Patricia I, 2004, J Immigr Health, V6, P5, DOI 10.1023/B:JOIH.0000014638.87569.2e; English P., 1998, PAN AM J PUBLIC HLTH, V3, P392, DOI 10.1590/S1020-49891998000600005; Gibson PG, 2003, PEDIATR PULM, V36, P209, DOI 10.1002/ppul.10323; Hjern A, 1999, PEDIATR ALLERGY IMMU, V10, P101, DOI 10.1034/j.1399-3038.1999.00023.x; HOLGUIN F, 2004, AM J RESP CRIT CARE, V169, pA625; KALYONCU AF, 1992, ALLERGY, V47, P277, DOI 10.1111/j.1398-9995.1992.tb02053.x; Kuczmarski MF, 2001, J AM DIET ASSOC, V101, P28, DOI 10.1016/S0002-8223(01)00008-6; Kuczmarski RJ, 1997, OBES RES, V5, P542; LEUNG RC, 1994, MED J AUSTRALIA, V161, P418; Liu Andrew H., 2003, Journal of Allergy and Clinical Immunology, V111, pS785, DOI 10.1067/mai.2003.148; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; NAHMIAS J, 1993, ISRAEL J MED SCI, V29, P338; *NAT CTR ENV HLTH, BEH RISK FACT SURV S; *NAT HEART LUNG BL, 2004, ASTHM DAT SURV; Ormerod LP, 1999, RESP MED, V93, P16, DOI 10.1016/S0954-6111(99)90071-9; Powell CVE, 1999, ARCH DIS CHILD, V81, P159; Rosenberg R, 1999, Fam Med, V31, P276; Singh GK, 2002, HUM BIOL, V74, P83, DOI 10.1353/hub.2002.0011; Sundquist J, 1999, AM J PUBLIC HEALTH, V89, P723, DOI 10.2105/AJPH.89.5.723; Sundquist J, 2000, INT J EPIDEMIOL, V29, P470, DOI 10.1093/ije/29.3.470; Sunyer J, 2000, AM J RESP CRIT CARE, V162, P930; Tedeschi A, 2003, CLIN EXP ALLERGY, V33, P449, DOI 10.1046/j.1365-2222.2003.01628.x; Tobias A, 2001, EUR RESPIR J, V18, P459, DOI 10.1183/09031936.01.00026501; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; *US DHHS, 1994, NATL CTR HLTH STAT P; Ventura MT, 2004, ALLERGY, V59, P632, DOI 10.1111/j.1398-9995.2004.00448.x; Wernette D.R., 1992, EPA J, V18, P16; Wong GWK, 2004, CURR OPIN PULM MED, V10, P62, DOI 10.1097/00063198-200401000-00011; 2003, ATLAS SALUD	38	76	77	2	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 15	2005	171	2					103	108		10.1164/rccm.200402-143OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	886UO	WOS:000226258400004	15516539	
J	Moreno, C; Cuesta-Herranz, J; Fernandez-Tavora, L; Alvarez-Cuesta, E				Moreno, C; Cuesta-Herranz, J; Fernandez-Tavora, L; Alvarez-Cuesta, E			Immunotherapy safety: a prospective multi-centric monitoring study of biologically standardized therapeutic vaccines for allergic diseases	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; compliance; immunotherapy; mite; pollen; rhinitis; safety; side-effects	SYSTEMIC REACTIONS; ASTHMA; FATALITIES; EXTRACTS	Background The fear of side-effects has led to strict regulations preventing a more widespread use of specific immunotherapy (SIT) in some countries, in spite of the low risk of systemic reactions (SRs) reported in well-controlled studies. The goal of the study was to carry out a prospective and multi-centric trial to evaluate the safety, risk factors and compliance degree of commercially available SIT. Materials and methods The study was carried out in 14 allergy departments from Spain. Four-hundred and eighty-eight patients with rhinitis and/or asthma were submitted to treatment with biologically standardized allergen extracts commercially available. They were administered following the European Academy of Allergy and Clinical Immunology guidelines. Results Four hundred and twenty-three patients (86.7%) completed the treatment and remained under control at the end of the trial. Out of 17 526 administered doses, 17 368 doses (99.1%) were not associated with a reaction. Eighteen patients (3.7%) experienced 53 (0.3% of the doses) SRs. All immediate SRs were mild or moderate and responded well to ordinary treatment measures. There were no fatal reactions, anaphylactic shock or life-threatening reactions. A higher ratio of SRs was found among asthmatic and dust mite allergic patients, although multi-variable logistic analysis did not demonstrate any risk factor associated with SRs. There was also a subgroup of patients at risk for recurrent reactions, and therefore 40% of SRs had been avoided if the maximal number of SRs had been previously limited to only three SRs. Conclusions This multi-centric study showed that SIT was a safe treatment with a very good compliance. Future guidelines of SIT should limit the maximal number of SRs.	Fdn Jimenez Diaz, Dept Allergy, E-28040 Madrid, Spain; Hosp Reina Sofia, Dept Allergy, Cordoba, Spain; Hosp Virgen de la Cinta, Allergy Unit, Huelva, Spain; Hosp Ramon y Cajal, Dept Allergy, E-28034 Madrid, Spain	Cuesta-Herranz, J (reprint author), Fdn Jimenez Diaz, Dept Allergy, Avda Reyes Catolicos 2, E-28040 Madrid, Spain.	icuesta@fid.es					Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; BOUSQUET J, 1998, ALLERGY S1, V44, P2; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339; Dreborg S, 1993, ALLERGY          S14, V48, P48, DOI DOI 10.1111/J.1398-9995.1993.TB04698.X; DuBuske LM, 2001, ANN ALLERG ASTHMA IM, V87, P56; Finegold I, 2001, ANN ALLERG ASTHMA IM, V87, P33; Frew AJ, 1999, LUNG BIOL HEALTH DIS, V136, P199; HEJJAOUI A, 1992, J ALLERGY CLIN IMMUN, V89, P925, DOI 10.1016/0091-6749(92)90214-M; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; Hutchinson DR, 1997, TRIAL INVESTIGATORS; Lamson R., 1924, JAMA-J AM MED ASSOC, V82, P1090; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47; LOWER T, 1993, ANN ALLERGY, V70, P480; Malling HJ, 2000, DRUG SAFETY, V23, P323, DOI 10.2165/00002018-200023040-00005; MALLING HJ, 1993, ALLERGY          S14, V48, P1; *NHLBI, 1995, NHLBI PUBL; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Salkind AR, 2001, JAMA-J AM MED ASSOC, V285, P2498, DOI 10.1001/jama.285.19.2498; SETTIPANE GA, 1983, AM J MED, V74, P102, DOI 10.1016/0002-9343(83)90537-5; TABAR AI, 1993, ALLERGY, V48, P450, DOI 10.1111/j.1398-9995.1993.tb00743.x; Theodoropoulos DS, 2000, ALLERGY ASTHMA PROC, V21, P159, DOI 10.2500/108854100778149007; TINKELMAN D, 1995, ANN ALLERG ASTHMA IM, V74, P241	23	76	91	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2004	34	4					527	531		10.1111/j.1365-2222.2004.1819.x		5	Allergy; Immunology	Allergy; Immunology	812RQ	WOS:000220857000006	15080803	
J	Joachim, RA; Quarcoo, D; Arck, PC; Herz, U; Renz, H; Klapp, BF				Joachim, RA; Quarcoo, D; Arck, PC; Herz, U; Renz, H; Klapp, BF			Stress enhances airway reactivity and airway inflammation in an animal model of allergic bronchial asthma	PSYCHOSOMATIC MEDICINE			English	Article						sonic stress; allergic asthma; airway inflammation; airway hyperreactivity; mouse model	M-2 RECEPTOR DYSFUNCTION; PSYCHOSOCIAL STRESS; HUMAN EOSINOPHILS; PSYCHOLOGICAL STRESS; CYTOKINE PRODUCTION; TRIGGERED ABORTION; ATOPIC-DERMATITIS; BREAST-CANCER; GUINEA-PIGS; MICE	Objective: Despite the long-standing clinical assumption that stress and asthma morbidity are associated, convincing experimental evidence on mechanisms has been unavailable. A wide range of immunological, endocrinological, and neuronal pathways are known to mediate and modulate a systemic stress response. Interestingly, most of these mediators play a crucial role in initiating and perpetuating symptoms associated with bronchial asthma. To explore potential mechanisms linking stress to asthma exacerbation we developed an animal model that combines allergic airway inflammation and exposure to stress. Methods: CBA/J mice were sensitized by intraperitoneal injection of ovalbumin (OVA) and challenged with OVA aerosol via the airways. Additionally, some mice were stressed by exposure to an ultrasonic stressor. Airway hyperreactivity (AHR) was measured in vitro by electric field stimulation (EFS) of tracheal smooth muscle elements. Bronchoalveolar lavage fluid (BAL) was obtained and cell numbers determined. Cytokine levels of IL-4, IL-5, and IFN-gamma in BAL were determined by ELISA. Results: Our findings demonstrate that exogenously applied stress dramatically enhances airway reactivity in OVA-sensitized and challenged mice. Further, stress significantly increases allergen-induced airway inflammation identified by increased leukocyte (ie, eosinophil) numbers in bronchoalveolar lavage fluids. Conclusions: We found further evidence that stress can indeed exacerbate airway hyperreactivity and airway inflammation in an animal model of allergic bronchial asthma and now introduce a novel murine model to identify stress-triggered pathways, including mediators as neurohormones, neuropeptides, and markers of inflammation.	Humboldt Univ, Dept Internal Med, Berlin, Germany; Humboldt Univ, Dept Pediat, Berlin, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany	Joachim, RA (reprint author), Forschungszentrum, Biomed, Charite Campus Virchow,R 2-0594,Augustenburger Pl, D-13353 Berlin, Germany.		Arck, Petra/D-7094-2013	Quarcoo, David/0000-0001-6398-2118			Ackerman KD, 1998, PSYCHOSOM MED, V60, P484; ADER R, 1995, LANCET, V345, P99, DOI 10.1016/S0140-6736(95)90066-7; Andersen BL, 1998, J NATL CANCER I, V90, P30, DOI 10.1093/jnci/90.1.30; ARCK PC, 1995, AM J REPROD IMMUNOL, V33, P74; ARCK PC, 2001, FASEB J; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; BUCKLEY TL, 1994, AM J RESP CRIT CARE, V149, P400; BuskeKirschbaum A, 1997, PSYCHOSOM MED, V59, P419; Chrousos George P., 2000, Journal of Allergy and Clinical Immunology, V106, pS275; CLARK DA, 1993, AM J REPROD IMMUNOL, V29, P141; Costello RW, 1998, BRIT J PHARMACOL, V124, P267, DOI 10.1038/sj.bjp.0701822; Coyle AJ, 1996, J IMMUNOL, V156, P2680; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; Evans CM, 2001, AM J RESP CRIT CARE, V163, P1484; Evans CM, 2000, AM J PHYSIOL-LUNG C, V279, pL477; GREENE BR, 1994, BEHAV RES THER, V32, P217, DOI 10.1016/0005-7967(94)90114-7; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; HUANG SK, 1995, J IMMUNOL, V155, P2688; Iwakabe K, 1998, IMMUNOL LETT, V62, P39, DOI 10.1016/S0165-2478(98)00021-2; Jacoby DB, 2001, J ALLERGY CLIN IMMUN, V107, P211, DOI 10.1067/mai.2001.112940; Kang DH, 2000, ANN BEHAV MED, V22, P276, DOI 10.1007/BF02895663; Kang DH, 2001, RES NURS HEALTH, V24, P245, DOI 10.1002/nur.1027; Koning H, 1997, CYTOKINE, V9, P427, DOI 10.1006/cyto.1996.0185; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83; LARSEN GL, 1992, J CLIN INVEST, V89, P747, DOI 10.1172/JCI115651; Leonard C, 1997, AM J RESP CELL MOL, V17, P368; LEVENSTEIN S, 1994, AM J GASTROENTEROL, V89, P1219; LEVY SM, 1990, PSYCHOSOM MED, V52, P73; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/rccm.2109065; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Maes M, 1998, CYTOKINE, V10, P313, DOI 10.1006/cyto.1997.0290; MAKKER HK, 1993, J ALLERGY CLIN IMMUN, V92, P82, DOI 10.1016/0091-6749(93)90041-D; MATSUSE T, 1991, AM REV RESPIR DIS, V144, P368; MINETTE PAH, 1989, J APPL PHYSIOL, V67, P2461; OBYRNE PM, 1988, J ALLERGY CLIN IMMUN, V81, P119, DOI 10.1016/0091-6749(88)90230-8; OHASHI Y, 1992, AM REV RESPIR DIS, V145, P1469; Qiu BS, 1999, NAT MED, V5, P1178; Ritz T, 2000, PSYCHOSOM MED, V62, P401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Schmid-Ott G, 2001, J ALLERGY CLIN IMMUN, V107, P171, DOI 10.1067/mai.2001.111850; SCHWEIZER RC, 1994, BLOOD, V83, P3697; Undem BJ, 1999, INT ARCH ALLERGY IMM, V118, P150, DOI 10.1159/000024053; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WARRINGA RAJ, 1992, AM J RESP CELL MOL, V7, P631; YAMAGUCHI Y, 1988, J EXP MED, V167, P43, DOI 10.1084/jem.167.1.43	51	76	79	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0033-3174			PSYCHOSOM MED	Psychosom. Med.	SEP-OCT	2003	65	5					811	815		10.1097/01.PSY.0000088582.50468.A3		5	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	727QQ	WOS:000185670300014	14508025	
J	Bolte, G; Bischof, W; Borte, M; Lehmann, I; Wichmann, HE; Heinrich, J				Bolte, G; Bischof, W; Borte, M; Lehmann, I; Wichmann, HE; Heinrich, J			Early endotoxin exposure and atopy development in infants: results of a birth cohort study	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; asthma; hygiene hypothesis	HOUSE-DUST ENDOTOXIN; INFLAMMATORY RESPONSE; INHALED ENDOTOXIN; EARLY-LIFE; ASTHMA; CHILDREN; ALLERGY; SENSITIZATION; RISK; PETS	Background Exposure to endotoxin in childhood is currently discussed to protect from the development of allergic diseases. Objective To study the effect of early endotoxin exposure on incidence of atopic sensitization, atopic dermatitis and wheezing until the age of 2 years in infants with different risk status in terms of parental atopy. Methods Data of 1942 infants of an ongoing birth cohort study were analysed by logistic regression. Endotoxin was measured in settled dust of the mothers' mattresses at infants' age of 3 months. Data on allergic symptoms and physicians' diagnoses were gathered by questionnaire. Sensitization to common food and inhalant allergens was assessed by specific serum IgE. Results High endotoxin levels increased the risk of repeated wheeze [adjusted odds ratio (OR) for 4th exposure quartile ((Q4)) 1.52, 95% confidence interval (CI) 1.08-2.14], but were associated with neither sensitization to food allergens nor atopic dermatitis. Stratification by parental atopy showed that there was an association of endotoxin exposure with incidence of repeated wheeze as well as with sensitization to inhalant allergens (P for trend = 0.008 and 0.044, respectively) only in infants with parental atopy, with the highest risk in the 4th exposure quartile (repeated wheeze: ORQ4 1.77, 95% CI 1.14-2.73; sensitization to inhalant allergens: ORQ4 1.69, 95% CI 0.70-4.11). Conclusion Early endotoxin exposure in terms of mattress dust endotoxin levels seemed to increase the risk of atopic reactions to inhalant allergens at the age of 2 years, especially in infants at risk due to parental atopy. Our data disagree with an early protective effect of endotoxin on atopy development until the age of 2 years.	GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Univ Ulm, Dept Epidemiol, Ulm, Germany; Univ Jena, Dept Indoor Climatol, Erfurt, Germany; Univ Leipzig, Dept Pediat, Leipzig, Germany; Hall Ltd, UFZ Ctr Environm Res Leipzig, Dept Human Exposure Res & Epidemiol, D-7010 Leipzig, Germany	Heinrich, J (reprint author), GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	joachim.heinrich@gsf.de					Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Bolte G, 2002, J ALLERGY CLIN IMMUN, V110, P634, DOI 10.1067/mai.2002.128652; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Christiani DC, 2001, AM J RESP CRIT CARE, V163, P847; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Fahlbusch B, 1999, ALLERGY, V54, P1215, DOI 10.1034/j.1398-9995.1999.00196.x; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; GEHRING U, 2002, J ALLERGY CLIN IMMUN, V109, P648; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Holt PG, 2000, AM J RESP CRIT CARE, V162, pS91; Lehmann I, 2002, ALLERGY, V57, P129, DOI 10.1046/j.0105-4538.2002.00001.x; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Martinez FD, 2002, PEDIATRICS, V109, P362; Martinez FD, 1999, LANCET S2, V354, pSII12; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Nelde A, 2001, INT ARCH ALLERGY IMM, V124, P461, DOI 10.1159/000053781; Nightingale JA, 1998, THORAX, V53, P563; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Silva JRL, 2000, TOXICOLOGY, V152, P31; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426	36	76	76	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2003	33	6					770	776		10.1046/j.1365-2222.2003.01665.x		7	Allergy; Immunology	Allergy; Immunology	688QA	WOS:000183445800010	12801311	
J	Fireman, P				Fireman, P			Symposium: Understanding asthma pathophysiology	ALLERGY AND ASTHMA PROCEEDINGS			English	Article; Proceedings Paper	Eastern Allergy Conference	MAY, 2001	NAPLES, FLORIDA				AIRWAY SMOOTH-MUSCLE; INFLAMMATION; HYPERRESPONSIVENESS; ADULTS; LIFE	Asthma is best described as a chronic disease that involves inflammation of the pulmonary airways and bronchial hyperresponsiveness that results in the clinical expression of a lower airway obstruction that usually is reversible. Physiologically, bronchial hyperresponsiveness is documented by decreased bronchial airflow after bronchoprovocation with methacholine or histamine. Other triggers that provoke airway obstruction include cold air, exercise, viral upper respiratory infection, cigarette smoke, and respiratory allergens. Bronchial provocation with allergen induces a prompt early phase immunoglobulin E (IgE)-mediated decrease in bronchial airflow (forced expiratory volume in 1 second) followed in many patients by a late-phase IgE-mediated reaction with a decrease in bronchial airflow for 4-8 hours. The gross pathology of asthmatic airways displays lung hyperinflation, smooth muscle hypertrophy, lamina reticularis thickening, mucosal edema, epithelial cell sloughing, cilia cell disruption, and mucus gland hypersecretion. Microscopically, asthma is characterized by the presence of increased numbers of eosinophils, neutrophils, lymphocytes, and plasma cells in the bronchial tissues, bronchial secretions, and mucus. Initially, there is recruitment of leukocytes from the bloodstream to the airway by activated CD, T-lymphocytes. The activated T-lymphocytes also direct the release of inflammatory mediators from eosinophils, mast cells, and lymphocytes. In addition, the subclass 2 helper T-lymphocytes subset of activated T-lymphocytes produces interleukin (IL)-4, IL-5, and IL-13. IL-4 in conjunction with IL-13 signals the switch from IgM to IgE antibodies. The cross-linkage of two IgE molecules by allergen causes mast cells to degranulate, releasing histamine, leukotrienes, and other mediators that perpetuate the airway inflammation. IL-5 activates the recruitment and activation of eosinophils. The activated mast cells and eosinophils also generate their cytokines that help to perpetuate the inflammation. Regardless of the triggers of asthma, the repeated cycles of inflammation in the lungs with injury to the pulmonary tissues followed by repair may produce long-term structural changes ("remodeling") of the airways. This review will discuss in greater detail the relationships of inflammation and airway hyperresponsiveness to the pathophysiology of asthma.	Univ Pittsburgh, Sch Med, Dept Allergy & Immunol, Pittsburgh, PA 15213 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA	Fireman, P (reprint author), Univ Pittsburgh, Sch Med, Dept Allergy & Immunol, 3705 5th Ave, Pittsburgh, PA 15213 USA.						Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Brusasco V, 1998, THORAX, V53, P992; CADE JF, 1971, CLIN SCI, V40, P361; DAVIS RS, 1983, J ALLERGY CLIN IMMUN, V72, P393, DOI 10.1016/0091-6749(83)90505-5; Djukanovic R, 2002, J ALLERGY CLIN IMMUN, V109, pS539, DOI 10.1067/mai.2002.124568; DONCET C, 1998, J CLIN INVEST, V101, P2129; ELLIS JL, 1994, PULM PHARMACOL, V7, P205, DOI 10.1006/pulp.1994.1024; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P28; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Lacy P, 2000, CHEM IMMUNOL, V76, P134; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lemanske RF, 2002, J ALLERGY CLIN IMMUN, V109, pS521, DOI 10.1067/mai.2002.124564; LEVIN ER, 1995, NEW ENGL J MED, V333, P355; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCFADDEN ER, 1980, SEMIN RESPIR MED, V1, P287, DOI 10.1055/s-2007-1012133; *NAT HEART LUNG BL, 1991, 913042 NAT HEART LUN; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; PROBST SM, 2000, J IMMUNOL, V165, P2214; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; Solway J, 1997, AM J RESP CELL MOL, V17, P144; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435	25	76	81	2	17	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1088-5412			ALLERGY ASTHMA PROC	Allergy Asthma Proc.	MAR-APR	2003	24	2					79	83				5	Allergy	Allergy	675GQ	WOS:000182685900001	12776439	
J	Carney, AS; Powe, DG; Huskisson, RS; Jones, NS				Carney, AS; Powe, DG; Huskisson, RS; Jones, NS			Atypical nasal challenges in patients with idiopathic rhinitis: more evidence for the existence of allergy in the absence of atopy?	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; idiopathic rhinitis; non-allergic rhinitis; allergen challenge; rhinomanometry; vasomotor rhinitis	LOCAL IGE PRODUCTION; SYSTEMATIC EVALUATION; NONALLERGIC RHINITIS; PRELIMINARY CRITERIA; ACOUSTIC RHINOMETRY; CLINICAL-PARAMETERS; PERENNIAL RHINITIS; PROVOCATION TEST; SKIN-TESTS; AIR-FLOW	Background The pathophysiology of idiopathic rhinitis is unknown although evidence is accumulating to suggest that many patients may have a localized form of allergic rhinitis in the absence of other atopic symptoms and markers. This study compares detailed nasal challenge results obtained from patients with idiopathic rhinitis to those of atopic and normal controls. Methods Patients with idiopathic rhinitis (n = 23), perennial allergic rhinitis (n = 8) and normal controls (n = 8) underwent a normal saline challenge to exclude hyper-reactivity and then bilateral nasal allergen challenges. Nasal patency was assessed by anterior active rhinomanometry. Results All of the patients with atopic rhinitis demonstrated positive bilateral allergen challenges. All normal control subjects had bilateral negative challenges. Two patients in the idiopathic group tested positively to saline and were excluded from further study with 62% of the remainder testing positive to allergens. Of the idiopathic patients testing positive, 85% were sensitive to house dust mite. Conclusion A significant proportion of patients with idiopathic rhinitis have positive nasal challenges, the vast majority to house dust mite allergen. These findings add to the weight of evidence that suggests 'localized allergy' may exist in the absence of systemic atopic markers.	Queens Med Ctr, Dept Otolaryngol Head & Neck Surg, Nottingham NG7 2UH, England; Queens Med Ctr, Dept Clin Lab Sci, Nottingham NG7 2UH, England	Carney, AS (reprint author), Flinders Med Ctr, Dept Otolaryngol Head & Neck Surg, Adelaide, SA 5042, Australia.						ANDERSSON M, 1989, ACTA OTO-LARYNGOL, V107, P270, DOI 10.3109/00016488909127508; AUSTIN CE, 1994, BRIT J CLIN PHARMACO, V37, P33; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; BASCOM R, 1991, ENVIRON HEALTH PERSP, V95, P39, DOI 10.2307/3431104; Berger G, 1997, AM J RHINOL, V11, P63, DOI 10.2500/105065897781446775; BERKINSHAW ER, 1987, AM J ORTHOD DENTOFAC, V92, P329, DOI 10.1016/0889-5406(87)90334-9; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748; BRAUN J J, 1982, Rhinology (Utrecht), V20, P3; Carney AS, 2000, CLIN OTOLARYNGOL, V25, P499, DOI 10.1046/j.1365-2273.2000.00384.x; Carney AS, 1996, CLIN OTOLARYNGOL, V21, P198, DOI 10.1111/j.1365-2273.1996.tb01724.x; Carney AS, 2001, CLIN OTOLARYNGOL, V26, P298, DOI 10.1046/j.1365-2273.2001.00474.x; Ciprandi G, 1998, INT ARCH ALLERGY IMM, V115, P157, DOI 10.1159/000023896; Clement P A, 1984, Rhinology, V22, P151; Coca AF, 1923, J IMMUNOL, V8, P163; Cook JA, 1996, CLIN OTOLARYNGOL, V21, P226, DOI 10.1111/j.1365-2273.1996.tb01730.x; DURHAM S, 1999, RHINITIS MECH MANAGE, P147; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128; Durham SR, 2000, AM J RHINOL, V14, P305, DOI 10.2500/105065800781329492; ECCLES R, 1978, ACTA OTO-LARYNGOL, V86, P464, DOI 10.3109/00016487809107526; ECCLES R, 1987, CLIN OTOLARYNGOL, V12, P11, DOI 10.1111/j.1365-2273.1987.tb00157.x; ERIKSSON NE, 1977, INT ARCH ALLER A IMM, V53, P341; ERIKSSON NE, 1976, INT ARCH ALLER A IMM, V52, P335; Ferguson BJ, 2000, LARYNGOSCOPE, V110, P799, DOI 10.1097/00005537-200005000-00010; Fernandes FR, 1996, J INVEST ALLERG CLIN, V6, P184; Flanagan P, 1997, ACTA OTO-LARYNGOL, V117, P590, DOI 10.3109/00016489709113443; Haavisto L, 1998, AM J RHINOL, V12, P275, DOI 10.2500/105065898781390082; HUGGINS KG, 1975, LANCET, V2, P148; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KAY AB, 1998, ALLERGY ALLERGIC DIS, V1, P23; Leimgruber A, 2000, CLIN EXP ALLERGY, V30, P1342, DOI 10.1046/j.1365-2222.2000.00963.x; Menz G, 1998, ALLERGY, V53, P15; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1417, DOI 10.1046/j.1365-2222.2000.00913.x; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1314; Pirila T, 1997, ACTA OTO-LARYNGOL, V117, P596, DOI 10.3109/00016489709113444; Pirila T, 1998, CLIN EXP ALLERGY, V28, P468; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; QUINE SM, 1999, NASAL AIRFLOW CHRONI, P169; RIECHELMANN H, 1995, CURR OPIN OTOLARYNGO, V3, P207, DOI 10.1097/00020840-199506000-00010; Schubert MS, 2001, ANN ALLERG ASTHMA IM, V87, P181; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SCHULZ O, 1998, EUR J IMMUNOL, V25, P1391; THOMAS WR, 1993, CLIN EXP ALLERGY, V23, P350, DOI 10.1111/j.1365-2222.1993.tb00338.x; TOGIAS A, 1988, J ALLERGY CLIN IMMUN, V81, P782, DOI 10.1016/0091-6749(88)90932-3; VENGE P, 1994, ALLERGY, V49, P1, DOI 10.1111/j.1398-9995.1994.tb00765.x; VINER AS, 1976, CLIN ALLERGY, V6, P251, DOI 10.1111/j.1365-2222.1976.tb01904.x	45	76	79	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2002	32	10					1436	1440				5	Allergy; Immunology	Allergy; Immunology	601ZJ	WOS:000178479300009	12372122	
J	Eagan, TML; Eide, GE; Gulsvik, A; Bakke, PS				Eagan, TML; Eide, GE; Gulsvik, A; Bakke, PS			Nonresponse in a community cohort study - Predictors and consequences for exposure-disease associations	JOURNAL OF CLINICAL EPIDEMIOLOGY			English	Article						cohort study; questionnaire; response bias; odds ratio; asthma; respiratory symptoms; smoking	MAIL SURVEY RESPONSE; CARDIOVASCULAR-DISEASE; RESPIRATORY SYMPTOMS; QUESTIONNAIRE; SMOKING; HEALTH; BIAS; POPULATION; RESPONDENTS; SWEDEN	We have assessed predictors for response in a Norwegian community cohort study, with an 11-year follow-up. We also examined to what extent the association of gender, age, and smoking to the incidence of respiratory symptoms and asthma differed if the analyses were based on the 65% (n = 2,079) initial responders, or were based on the 89% (n = 2,819) who responded after three reminders. The associations between the six symptoms/asthma and the gender, age, and smoking groups amounted to 42 odds ratios. The adjusted odds ratio for responding at follow-up was 1.39 (95% CI: 1.01, 1.90) for those being middle aged at baseline compared to younger subjects. The adjusted odds ratios for responding at follow-up for those being students, unemployed, or retired at baseline were 0.50 (95% CI: 0.35, 0.73), 0.29 (95% CI: 0.16, 0.55), 0.21 (95% CI: 0.13, 0.36), respectively, compared to being employed. Of the 42 odds ratios mentioned above, 25 differed less than 10% when comparing the initial and all respondents. Twelve differed 10-20% and five differed 20-45%. The study indicates that to ensure a high participation rate in a follow-up study one should pay special attention to those being late responders, unemployed, retired, or students at baseline. No overt differences were observed in the gender, age, and, smoking associations to the respiratory disorders when the analyses were based on the initial compared to all respondents. (C) 2002 Elsevier Science Inc. All rights reserved.	Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway; Univ Bergen, Sect Med Stat, Bergen, Norway; Haukeland Univ Hosp, Clin Res Ctr, N-5021 Bergen, Norway	Eagan, TML (reprint author), Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway.		Eagan, Tomas/P-3554-2014	Eagan, Tomas/0000-0001-8725-9960			BAKKE P, 1990, J EPIDEMIOL COMMUN H, V44, P316, DOI 10.1136/jech.44.4.316; BARTON J, 1980, AM J PUBLIC HEALTH, V70, P823, DOI 10.2105/AJPH.70.8.823; BECK GJ, 1982, AM REV RESPIR DIS, V125, P375; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; BOSTROM G, 1993, SCAND J SOC MED, V21, P77; Cohen BB, 1987, VITAL HLTH STAT, V1, P1; CRIQUI MH, 1979, J CHRON DIS, V32, P633, DOI 10.1016/0021-9681(79)90093-6; CRIQUI MH, 1978, AM J EPIDEMIOL, V108, P367; Doll R, 1999, B WORLD HEALTH ORGAN, V77, P84; FORTHOFER RN, 1983, AM J EPIDEMIOL, V117, P507; FOSS OP, 1986, SCAND J CLIN LAB INV, V46, P245, DOI 10.3109/00365518609083666; GREENLAND S, 1977, AM J EPIDEMIOL, V106, P184; GULSVIK A, 1979, SCAND J RESPIR DIS, V60, P275; GULSVIK A, 1991, EUR RESPIR REV, V1, P436; Hill A, 1997, J PUBLIC HEALTH MED, V19, P203; JACOBSEN BK, 1988, SCAND J SOC MED, V16, P101; JANZON L, 1986, J EPIDEMIOL COMMUN H, V40, P174, DOI 10.1136/jech.40.2.174; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87; Lund E, 1998, SCAND J SOC MED, V26, P154, DOI 10.1177/14034948980260020401; MACERA CA, 1990, J CLIN EPIDEMIOL, V43, P1427, DOI 10.1016/0895-4356(90)90112-3; PIETILA AM, 1995, SCAND J SOC MED, V23, P129; Ronmark E, 1997, ALLERGY, V52, P1071, DOI 10.1111/j.1398-9995.1997.tb00178.x; Ronmark E, 1999, EUR J EPIDEMIOL, V15, P293, DOI 10.1023/A:1007582518922; SELTZER CC, 1974, AM J EPIDEMIOL, V100, P453; SHEIKH K, 1981, J EPIDEMIOL COMMUN H, V35, P293, DOI 10.1136/jech.35.4.293; SMITH C, 1990, Health Education Research, V5, P381, DOI 10.1093/her/5.3.381; SPRY VM, 1989, AM J EPIDEMIOL, V130, P166; van den Akker M, 1998, FAM PRACT, V15, P261, DOI 10.1093/fampra/15.3.261; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534; YAMMARINO FJ, 1991, PUBLIC OPIN QUART, V55, P613, DOI 10.1086/269284	30	76	78	1	9	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0895-4356			J CLIN EPIDEMIOL	J. Clin. Epidemiol.	AUG	2002	55	8					775	781	PII S0895-4356(02)00431-6	10.1016/S0895-4356(02)00431-6		7	Health Care Sciences & Services; Public, Environmental & Occupational Health	Health Care Sciences & Services; Public, Environmental & Occupational Health	594FD	WOS:000178037500006	12384191	
J	Krieger, J; Takaro, TK; Allen, C; Song, L; Weaver, M; Chai, S; Dickey, P				Krieger, J; Takaro, TK; Allen, C; Song, L; Weaver, M; Chai, S; Dickey, P			The Seattle-King County Healthy Homes Project: Implementation of a comprehensive approach to improving indoor environmental quality for low-income children with asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						asthma; children; community health workers; Healthy Homes; indoor environmental quality; inner city; interventions	HOUSE-DUST MITE; INNER-CITY CHILDREN; CHILDHOOD ASTHMA; RISK-FACTORS; URBAN CHILDREN; TOBACCO-SMOKE; MECHANICAL VENTILATION; SOCIOECONOMIC-FACTORS; ALLERGEN REDUCTION; PATIENT COMPLIANCE	Pediatric asthma is a growing public health issue, disproportionately affecting low-income people and people of color. Exposure to indoor asthma triggers plays an important role in the development and exacerbation of asthma. We describe the implementation of the Seattle-King County Healthy Homes Project, a randomized, controlled trial of an outreach/education intervention to improve asthma-related health status by reducing exposure to allergens and irritants in the home. We randomly assigned 274 low-income children with asthma ages 4-12 to either a high- or a low-intensity group. In the high-intensity group, community health workers called Community Home Environmental Specialists (CHES) conducted initial home environmental assessments, provided individualized action plans, and made additional visits over a 12-month period to provide education and social support, encouragement of participant actions, provision of materials to reduce exposures (including bedding encasements), assistance with roach and rodent eradication, and advocacy for improved housing conditions. Members of the low-intensity group received the initial assessment, home action plan, limited education during the assessment visit, and bedding encasements. We describe the recruitment and training of CHES and challenges they faced and explain the assessment and exposure reduction protocols addressing dust mites, mold, tobacco smoke, Pets, cockroaches, rodents, dust, moisture, and toxic or hazardous chemicals. We also discuss the gap between the practices recommended in the literature and what is feasible in the home. We accomplished home interventions and participants found the project very useful. The project was limited in resolving structural housing quality issues that contributed to exposure to indoor triggers.	Publ Hlth Seattle & King Cty, Seattle, WA 98104 USA; Univ Washington, Sch Publ Hlth & Community Med, Seattle, WA 98195 USA; Univ Washington, Sch Med, Seattle, WA USA; Seattle Partners Healthy Communities, Seattle, WA USA; Washington Tox Coalit, Seattle, WA USA	Krieger, J (reprint author), Publ Hlth Seattle & King Cty, 999 3rd Ave,Ste 1200, Seattle, WA 98104 USA.				NIEHS NIH HHS [5 R21 ES09095]; ODCDC CDC HHS [U48/CCU009654-07]		Adilah N, 1997, NEW ZEAL MED J, V110, P438; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; *AM LUNG ASS, 1997, RES AIR CLEAN DEV TY; Andriessen JW, 1998, CLIN EXP ALLERGY, V28, P1191; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P99, DOI 10.1067/mai.2001.112119; Avner DB, 1997, J ALLERGY CLIN IMMUN, V100, P307, DOI 10.1016/S0091-6749(97)70242-2; Bandura A., 1977, SOCIAL LEARNING THEO; BANDURA A, 1986, SOCIAL FDN THOUGHT A; Baranowski T., 1997, HLTH BEHAV HLTH ED T, P153; Benson V, 1998, VITAL HLTH STAT, V10, P1; Berkman LF, 2000, SOCIAL EPIDEMIOLOGY, P137; Bierman CW, 1996, IMMUNOL ALLERGY CLIN, V16, P753, DOI 10.1016/S0889-8561(05)70269-1; BOWER J, 2001, HLTH HOUSE BUY ONE B; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; BURGE HA, 1982, J ALLERGY CLIN IMMUN, V70, P101, DOI 10.1016/0091-6749(82)90236-6; Bush RK, 2001, J ALLERGY CLIN IMMUN, V107, pS430, DOI 10.1067/mai.2001.113669; CABERA P, 1995, J ALLERGY CLIN IMMUN, V95, P635; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Chapman MD, 2001, J ALLERGY CLIN IMMUN, V107, pS414, DOI 10.1067/mai.2001.113672; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Christiansen SC, 1996, J ALLERGY CLIN IMMUN, V98, P288, DOI 10.1016/S0091-6749(96)70152-5; CLARK NM, 1995, ACAD MED, V70, P957, DOI 10.1097/00001888-199511000-00008; COLLIER C, 2000, UNPUB; CRAIN EF, 1994, PEDIATRICS, V94, P356; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; *CRIS CLIN, 2001, TURN HLTH HUM SERV K; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; DAVIES DJA, 1990, SCI TOTAL ENVIRON, V90, P13, DOI 10.1016/0048-9697(90)90182-T; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334; DEBLAY F, 1992, J ALLERGY CLIN IMMUN, V90, P135; Dharmage S, 1999, INDOOR AIR, V9, P188, DOI 10.1111/j.1600-0668.1999.t01-1-00005.x; DICKEY P, 1998, MASTER HOME ENV TRAI; Eggleston PA, 1998, IMMUNOL ALLERGY CLIN, V18, P75, DOI 10.1016/S0889-8561(05)70348-9; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS422, DOI 10.1067/mai.2001.113671; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS403, DOI 10.1067/mai.2001.113673; Eggleston PA, 2000, CLIN REV ALLERG IMMU, V18, P311, DOI 10.1385/CRIAI:18:3:311; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Eisinger A, 2001, J URBAN HEALTH, V78, P519, DOI 10.1093/jurban/78.3.519; ETZEL R, 1996, ENVIRON HEALTH PER S, V103, P55; ETZEL RA, 1999, HDB PEDIAT ENV HLTH; EVANS D, 1993, THORAX, V48, P685, DOI 10.1136/thx.48.7.685; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GERGEN PJ, 1992, AM REV RESPIR DIS, V146, P823; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Grant E N, 1999, Curr Opin Pulm Med, V5, P27, DOI 10.1097/00063198-199901000-00005; GRAVES EJ, 1998, VITAL HLTH STAT, V13, P1; Haynes RB, 1979, COMPLIANCE HLTH CARE; Heaney C. A., 1997, HLTH BEHAV HLTH ED T, P179; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; HUSS K, 1994, ANN ALLERGY, V72, P173; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; ISRAEL BA, 1985, HEALTH EDUC QUART, V12, P65, DOI 10.1177/109019818501200106; JACK E, 1999, ASTHMA SPEAKERS KIT; Jackson EJ, 1997, HEALTH EDUC BEHAV, V24, P418, DOI 10.1177/109019819702400403; JACOBS DE, 1999, HLTH HOMES INITIATIV; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Kane MP, 1999, J ASTHMA, V36, P371, DOI 10.3109/02770909909068230; Kimpen JLL, 2000, AM J RESP CRIT CARE, V162, pS108; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; KLEINMAN A, 1978, ANN INTERN MED, V88, P251; Kone A, 2000, PUBLIC HEALTH REP, V115, P243, DOI 10.1093/phr/115.2.243; Krieger JW, 2000, J URBAN HEALTH, V77, P50, DOI 10.1007/BF02350962; KRIEGER JW, IN PRESS HLTH ED BEH; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LARSON TV, 1994, ANNU REV PUBL HEALTH, V15, P133; Leung R, 1997, ENVIRON HEALTH PERSP, V105, P1132; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615; Lioy PJ, 1998, J EXPO ANAL ENV EPID, V8, P17; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Love MB, 1997, HEALTH EDUC BEHAV, V24, P510, DOI 10.1177/109019819702400409; Macey GP, 2001, ENVIRON MANAGE, V27, P893; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MANSON A, 1988, MED CARE, V26, P1119, DOI 10.1097/00005650-198812000-00003; MARDER D, 1992, CHEST, V101, pS427; Mason K, 1999, J ALLERGY CLIN IMMUN, V104, P499, DOI 10.1016/S0091-6749(99)70400-8; Meichenbaum D., 1987, FACILITATING TREATME; Mielke HW, 1992, TRACE SUBSTANCES ENV, V25, P121; Miller J. D., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81180-8; MILTON DK, 1999, BIOAEROSOLS ASSESSME; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; MURRAY AB, 1983, PEDIATRICS, V71, P418; *NAT ASTHM ED PREV, 1997, 2 NAT HLTH LUNG BLOO; NELSON H, 1995, PROVOCATIVE TESTING, P754; Nguyen M. C., UNPUB; Northridge ME, 1997, AM J PUBLIC HEALTH, V87, P730, DOI 10.2105/AJPH.87.5.730; O'Connor G T, 1999, Environ Health Perspect, V107, P243; OSTRO BD, 1994, AM J RESP CRIT CARE, V149, P1400; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Perlin SA, 2001, J AIR WASTE MANAGE, V51, P406; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; POLAND ML, 1991, AM J PREV MED, V7, P204; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; Prochaska J.O., 1997, HLTH BEHAV HLTH ED T, P60; Prochaska J.O., 1994, CHANGING GOOD; *PUBL HLTH SEATTL, 2001, SEATTL HLTH HOM PROJ; REID BL, 1989, INSECTICIDE ACARACID, V14; ROBERTS JW, 2001, UNPUB; ROBERTS JW, 1991, P ANN M AIR WAST MAN, V15, P134; Roberts JW, 1992, J EXP ANAL ENV EPI S, V1, P127; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Scharli AF, 1998, PEDIATR SURG INT, V13, P1; SCHNEIDER D, 2000, CHILDRENS ENV HLTH R; Senturia YD, 1998, CONTROL CLIN TRIALS, V19, P544, DOI 10.1016/S0197-2456(98)00032-4; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; SOLET D, 2000, MMWR-MORBID MORTAL W, V49, P929; Sporik R, 1999, THORAX, V54, P675; Strachan D, 1996, TOXICOL LETT, V86, P199, DOI 10.1016/0378-4274(96)03691-0; Sullivan M, 2001, HEALTH EDUC BEHAV, V28, P130, DOI 10.1177/109019810102800202; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Tovey ER, 1997, J ALLERGY CLIN IMMUN, V100, P464; *US EPA, 1999, 60088049C US EPA; *US EPA, 1998, ASB YOUR HOM; van der Heide S, 1999, J ALLERGY CLIN IMMUN, V104, P447, DOI 10.1016/S0091-6749(99)70391-X; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Vaughan JW, 2000, CLIN REV ALLERG IMMU, V18, P325, DOI 10.1385/CRIAI:18:3:325; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; Wahlgren DR, 1997, CHEST, V111, P81, DOI 10.1378/chest.111.1.81; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Willey C, 1999, Curr Hypertens Rep, V1, P477, DOI 10.1007/s11906-996-0019-6; WILLIESJACOBO LJ, 1993, J ALLERGY CLIN IMMUN, V92, P630, DOI 10.1016/0091-6749(93)90090-3; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; WITMER A, 1995, AM J PUBLIC HEALTH, V85, P1055, DOI 10.2105/AJPH.85.8_Pt_1.1055; Wood RA, 1997, J ALLERGY CLIN IMMUN, V100, P290, DOI 10.1016/S0091-6749(97)70239-2; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115; WOOTON M, 2000, RESIDENTIAL HAZARDS; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704; 2001, HLTH HOMES HLTH KIDS	142	76	77	4	17	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2002	110			2			311	322				12	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	542WE	WOS:000175066600025	11929743	
J	Smedje, G; Norback, D				Smedje, G; Norback, D			Incidence of asthma diagnosis and self-reported allergy in relation to the school environment - a four-year follow-up study in schoolchildren	INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE			English	Article						cat allergen; dust; formaldehyde; moulds	RISK FACTOR; NORTHERN SWEDEN; NASAL PATENCY; CAT ALLERGEN; DOG CAN-F-1; CHILDREN; DUST; SENSITIZATION; CLASSROOMS; EXPOSURE	SETTING: In schools, the indoor air quality is often poor and there is growing concern about its impact on the pupils' health. OBJECTIVE: To study the incidence of asthma diagnosis and self-reported allergy in schoolchildren in relation to the school environment. DESIGN: Data on asthma and allergies were collected through a postal questionnaire answered in 1993 and 1997 by 1347 (78%) pupils (initially aged 7-13 years) in 39 randomly chosen schools. Indoor pollutants were measured in about 100 classrooms in 1993 and 1995. Relationships between indoor pollutants and incidence of asthma diagnosis and self-reported allergy were studied by multiple logistic regression, adjusting for age, sex, atopy and smoking. RESULTS: The incidence of asthma diagnosis was higher in pupils attending schools with more settled dust and more cat allergen (Fel d 1) in this dust. Incidence of self-reported furry pet allergy was higher in schools with more respirable particles. Among children without a history of atopy, a new asthma diagnosis was more common at higher concentrations of formaldehyde and total moulds in the classroom air. CONCLUSION: A school environment with more dust, cat allergen, formaldehyde and moulds may affect the incidence of asthma and sensitivity to furry pets in schoolchildren.	Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden	Smedje, G (reprint author), Univ Uppsala Hosp, Dept Occupat & Environm Med, S-75185 Uppsala, Sweden.						ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1046/j.1365-2222.1996.d01-278.x; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65; DODGE R, 1993, J ALLERGY CLIN IMMUN, V92, P744, DOI 10.1016/0091-6749(93)90018-B; Dotterud LK, 1995, J EUR ACAD DERMATOL, V5, P240, DOI 10.1111/j.1468-3083.1995.tb00112.x; DYBENDAL T, 1994, ALLERGY, V49, P210, DOI 10.1111/j.1398-9995.1994.tb02651.x; GEBSKI V, 1992, SPIDA USERS MANUAL; GRAVESEN S, 1986, ALLERGY, V41, P520, DOI 10.1111/j.1398-9995.1986.tb00337.x; Janssen NAH, 1999, OCCUP ENVIRON MED, V56, P482; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; LARSSON L, 1995, THORAX, V50, P260, DOI 10.1136/thx.50.3.260; Lee SC, 1999, INDOOR AIR, V9, P134, DOI 10.1111/j.1600-0668.1999.t01-2-00008.x; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Norback D, 2000, ALLERGY, V55, P163, DOI 10.1034/j.1398-9995.2000.00353.x; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; QUACKENBOSS JJ, 1989, ENVIRON INT, V15, P169, DOI 10.1016/0160-4120(89)90023-8; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; VANMOERBEKE D, 1997, BRAINE ALLEUD; Walinder R, 1999, SCAND J WORK ENV HEA, V25, P137; Wantke F, 1996, CLIN EXP ALLERGY, V26, P276	35	76	79	1	4	INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D)	PARIS	68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE	1027-3719			INT J TUBERC LUNG D	Int. J. Tuberc. Lung Dis.	NOV	2001	5	11					1059	1066				8	Infectious Diseases; Respiratory System	Infectious Diseases; Respiratory System	489WD	WOS:000172014700012	11716342	
J	Peat, JK; Toelle, BG; Marks, GB; Mellis, CM				Peat, JK; Toelle, BG; Marks, GB; Mellis, CM			Continuing the debate about measuring asthma in population studies	THORAX			English	Article						asthma; atopy; population studies	HOUSE-DUST MITE; NEW-SOUTH-WALES; ALLERGIC DISORDERS; CHILDHOOD ASTHMA; BRONCHIAL RESPONSIVENESS; CLIMATIC REGIONS; CHILDREN; PREVALENCE; ATOPY; SENSITIZATION	The reasons for measuring atopy and airway hyperresponsiveness (AHR) and the methods of validating measurements of asthma in population studies continue to be debated. The debate has centred around standards against which to validate asthma measurements but the absence of a "gold standard" makes the criterion validation of measurements difficult. Questionnaires will always be useful but cannot be validated against a doctor diagnosis because of self-selection and recall biases. In practice, measurements should be selected on the merits of what they measure rather than being regarded as validated or non-validated alternatives. The measurement of AHR is invaluable because it is reliable, not influenced by variations in symptom perception or diagnostic trends, and is closely related to the underlying mechanisms of asthma. The value of AHR lies in its high specificity (rate of true negatives) and low sensitivity (rate of false positives) against asthma symptoms which gives additional information about symptomatic subjects. Atopy is also a useful test and, in quantifying its association with asthma, we should not place any currency on ecological evidence. Atopy is a strong risk factor for asthma in the presence of regionally specific allergens and ecological analyses that ignore these effects are diversionary rather than productive. For preventing asthma, we need to identify the group at greatest risk of developing it, measure the risk factors with precision, and develop interventions that are effective in changing environmental exposures and homogenous outcomes. This is the only approach that has the potential to lead to significant public health benefits.	Childrens Hosp, Dept Pediat & Child Hlth, Clin Epidemiol Unit, Westmead, NSW 2145, Australia; Cooperat Res Ctr Asthma, Camperdown, NSW 2050, Australia; Inst Resp Med, Camperdown, NSW 2050, Australia	Peat, JK (reprint author), Childrens Hosp, Dept Pediat & Child Hlth, Clin Epidemiol Unit, Westmead, NSW 2145, Australia.		Toelle, Brett/B-1531-2008	Toelle, Brett/0000-0002-7375-0019			ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Asher MI, 1998, EUR RESPIR J, V12, P315; BEASLEY R, 1997, INT TRENDS ASTHMA MO, P140; BRITTON J, 1994, EUR RESPIR J, V7, P881; Burney P, 1996, EUR RESPIR J, V9, P687; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; Gislason D, 1999, ALLERGY, V54, P1160, DOI 10.1034/j.1398-9995.1999.00093.x; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Jogi R, 1998, CLIN EXP ALLERGY, V28, P1072; LUYT DK, 1993, BRIT MED J, V306, P1386; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pearce N, 2000, THORAX, V55, P352, DOI 10.1136/thorax.55.5.352; Pearce N, 1999, THORAX, V54, P268; PEAT JK, 1994, EUR RESPIR J, V7, P1805, DOI 10.1183/09031936.94.07101805; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Peat JK, 2000, J ALLERGY CLIN IMMUN, V106, pS144, DOI 10.1067/mai.2000.109420; PEAT JK, 1991, AM REV RESPIR DIS, V144, P338; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; RONA RJ, 1995, THORAX, V50, P992, DOI 10.1136/thx.50.9.992; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; TOELLE BG, 1992, AM REV RESPIR DIS, V146, P633; TOELLE BG, 2000, RESPIROLOGY, V5, pA6; VONMUTIUS E, 1992, BRIT MED J, V305, P1395	29	76	77	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY	2001	56	5					406	411		10.1136/thorax.56.5.406		6	Respiratory System	Respiratory System	427LN	WOS:000168405800016	11312411	
J	Katelaris, CH; Carrozzi, FM; Burke, TV; Byth, K				Katelaris, CH; Carrozzi, FM; Burke, TV; Byth, K			A springtime Olympics demands special consideration for allergic athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pollen counts; athletes; allergic rhinoconjunctivitis; olympics; paralympics; asthma	QUALITY-OF-LIFE; HAY-FEVER; QUESTIONNAIRE; ASTHMA	Background: The Sydney Olympic and Paralympic Games will be held in September-October 2000, which is early to midspring in the southern hemisphere. Pollen-sensitive athletes may encounter problems with allergic symptoms triggered by pollen exposure, thus compromising their ability to attain peak performance. Objective: We sought to monitor pollen levels at the major Olympic venues to provide information for allergic athletes and their team doctors in order to adequately prepare them for Olympic competition. Methods: We performed aerobiologic monitoring of the major Olympic venues to provide a profile of the most prevalent pollen species appearing during the spring. In the second part of this study, we surveyed a population of elite Australian athletes from Olympic sports to ascertain the prevalence of allergic rhinoconjunctivitis, to investigate the major allergens involved in sensitization, and to conduct a pilot study to assess the effect of allergic rhinoconjunctivitis on quality of life. Results: The pollen counts obtained at the 3 major sites were high over the period of Olympic competition. Tree pollens appeared from July, and grasses appeared from early September and peaked in the second week of October, the beginning of Paralympic competition. A relatively small number of pollen varieties comprise the majority of the total pollen count. Two hundred fourteen athletes (61% male; mean age, 21 +/- 16 years) representing 12 Olympic sports participated in the study. Fifty-six percent gave a symptom history consistent with allergic rhinoconjunctivitis, 41% had symptoms of allergic rhinoconjunctivitis and a positive test response to any one allergen, and 29% had seasonal allergic rhinoconjunctivitis (a positive history and at least one positive skin prick test response to a seasonal allergen). Athletes from aquatic sports were more likely to have symptoms than those from other sports, Symptom scores were higher and quality of life ratings were poorer in allergic compared with nonallergic athletes over the spring period, Conclusion: Olympic team managers and medical officers need to adequately prepare Olympic athletes for the possibility of exposure to high pollen levels in the weeks leading up to this most important sporting event. Symptoms of pollen sensitivity, such as rhinoconjunctivitis and exacerbation of asthma, could be devastating to athletes expecting peak performance, Potential Olympic athletes should be screened for the possibility of pollen allergy and have medical programs with permitted medication tailored to meet their needs. This may involve preventative therapy with meditation, such as intranasal corticosteroid sprays or immunotherapy programs, if symptoms are particularly severe. The newer nonsedating antihistamines are the treatment of choice fur acute intermittent symptoms, Appropriate management will ensure that the allergic athlete will safely perform to maximum ability with permitted medication during the Spring 2000 Olympic Games in Sydney.	Westmead Hosp, ICPMR, Dept Clin Immunol & Allergy, Sydney, NSW 2145, Australia; Westmead Hosp, Westmead Millennium Inst, Sydney, NSW 2145, Australia	Katelaris, CH (reprint author), Westmead Hosp, ICPMR, Dept Clin Immunol & Allergy, Sydney, NSW 2145, Australia.						BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; Carrozzi FM, 1998, ASIAN PAC J ALLERGY, V16, P149; CONNELL JT, 1969, J ALLERGY, V43, P33, DOI 10.1016/0021-8707(69)90018-5; DAVIES R R, 1973, Clinical Allergy, V3, P263, DOI 10.1111/j.1365-2222.1973.tb01332.x; FITCH KD, 1984, J ALLERGY CLIN IMMUN, V73, P722, DOI 10.1016/0091-6749(84)90314-2; HELBLING A, 1990, SCHWEIZ MED WSCHR, V120, P231; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; JUNIPER EF, 1994, J ALLERGY CLIN IMMUN, V93, P413, DOI 10.1016/0091-6749(94)90349-2; TAUDORF E, 1988, INT ARCH ALLER A IMM, V86, P225; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1994, ALLERGY S19, V49, P5	12	76	77	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					260	266				7	Allergy; Immunology	Allergy; Immunology	343NH	WOS:000088708100007	10932068	
J	Dambuza, IM; Brown, GD				Dambuza, Ivy M.; Brown, Gordon D.			C-type lectins in immunity: recent developments	CURRENT OPINION IN IMMUNOLOGY			English	Review							HOUSE-DUST MITE; DENDRITIC CELL-RECEPTOR; FUNGAL BETA-GLUCANS; CANDIDA-ALBICANS; HOST-DEFENSE; AIRWAY INFLAMMATION; ANTIFUNGAL IMMUNITY; INNATE IMMUNITY; DAMAGED CELLS; CORD FACTOR	C-type lectin receptors (CLRs) comprise a large superfamily of proteins, which recognise a diverse range of ligands, and are defined by the presence of at least one C-type lectin-like domain (CTLD). Of particular interest are the single extracellular CTLD-containing receptors of the 'Dectin-1' and 'Dectin-2' clusters, which associate with signalling adaptors or possess integral intracellular signalling domains. These CLRs have traditionally been associated with the recognition of fungi, but recent discoveries have revealed diverse and unexpected functions. In this review, we describe their newly identified roles in anti-microbial host defence, homeostasis, autoimmunity, allergy and their functions in the recognition and response to dead and cancerous cells.	[Dambuza, Ivy M.; Brown, Gordon D.] Univ Aberdeen, Inst Med Sci, Div Appl Med, Aberdeen Fungal Grp,Immun Infect & Inflammat Prog, Aberdeen AB25 2ZD, Scotland	Brown, GD (reprint author), Univ Aberdeen, Inst Med Sci, Div Appl Med, Aberdeen Fungal Grp,Immun Infect & Inflammat Prog, Aberdeen AB25 2ZD, Scotland.	gordon.brown@abdn.ac.uk			Wellcome Trust [102705]; Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology [97377]	We thank the Wellcome Trust (Grant No. 102705) and Wellcome Trust Strategic Award in Medical Mycology and Fungal Immunology (Grant No. 97377) for funding. We apologise to our many colleagues whose recent work we were unable to cite due to space constraints.	Acton SE, 2012, IMMUNITY, V37, P276, DOI 10.1016/j.immuni.2012.05.022; Ahrens S, 2012, IMMUNITY, V36, P635, DOI 10.1016/j.immuni.2012.03.008; Barrett NA, 2011, J EXP MED, V208, P593, DOI 10.1084/jem.20100793; Barrett NA, 2009, J IMMUNOL, V182, P1119; Behler F, 2012, J IMMUNOL, V189, P3121, DOI 10.4049/jimmunol.1201399; Benezech C, 2014, BLOOD, V123, P3200, DOI 10.1182/blood-2013-03-489286; Bertozzi CC, 2010, BLOOD, V116, P661, DOI 10.1182/blood-2010-02-270876; Bourgeois C, 2011, J IMMUNOL, V186, P3104, DOI 10.4049/jimmunol.1002599; Wevers Brigitte A, 2014, CELL HOST MICROBE, V15, P494; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4; Chiba S, 2014, ELIFE, V3, DOI 10.7554/eLife.04177; Clarke DL, 2014, MUCOSAL IMMUNOL, V7, P558, DOI 10.1038/mi.2013.74; del Fresno C, 2013, IMMUNITY, V38, P1176, DOI 10.1016/j.immuni.2013.05.010; de Rivero Vaccari JC, 2014, J NEUROTRAUMA; Dorhoi A, 2010, J EXP MED, V207, P777, DOI 10.1084/jem.20090067; Drickamer K, 2002, BIOCHEM SOC SYMP, P59; Drummond RA, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003417; Ferwerda B, 2009, NEW ENGL J MED, V361, P1760, DOI 10.1056/NEJMoa0901053; Glocker EO, 2009, NEW ENGL J MED, V361, P1727, DOI 10.1056/NEJMoa0810719; Goodridge HS, 2011, NATURE, V472, P471, DOI 10.1038/nature10071; Goodridge HS, 2009, J IMMUNOL, V182, P1146; Gringhuis SI, 2012, NAT IMMUNOL, V13, P246, DOI 10.1038/ni.2222; Hardison SE, 2012, NAT IMMUNOL, V13, P817, DOI 10.1038/ni.2369; Heitmann L, 2013, IMMUNOBIOLOGY, V218, P506, DOI 10.1016/j.imbio.2012.06.005; Hernandez-Santos N, 2012, CELL HOST MICROBE, V11, P425, DOI 10.1016/j.chom.2012.04.008; Herzog BH, 2013, NATURE, V502, P105, DOI 10.1038/nature12501; Hise AG, 2009, CELL HOST MICROBE, V5, P487, DOI 10.1016/j.chom.2009.05.002; Iborra S, 2012, J CLIN INVEST, V122, P1628, DOI 10.1172/JCI60660; Ifrim DC, 2014, INFECT IMMUN, V82, P1064, DOI 10.1128/IAI.01189-13; Ishikawa T, 2013, CELL HOST MICROBE, V13, P477, DOI 10.1016/j.chom.2013.03.008; Jia XM, 2014, J EXP MED, V211, P2307, DOI 10.1084/jem.20132349; Karsten CM, 2012, NAT MED, V18, P1401, DOI 10.1038/nm.2862; Karumuthil-Melethil S, 2014, J IMMUNOL, V193, P3308, DOI 10.4049/jimmunol.1400186; Kerrigan AM, 2011, TRENDS IMMUNOL, V32, P151, DOI 10.1016/j.it.2011.01.002; Kerscher B, 2013, INT IMMUNOL, V25, P271, DOI 10.1093/intimm/dxt006; Lee WB, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002614; Lilly LM, 2012, J IMMUNOL, V189, P3653, DOI 10.4049/jimmunol.1201797; Iliev ID, 2012, SCIENCE, V336, P1314; Lobato-Pascual A, 2013, EUR J IMMUNOL, V43, P3167, DOI 10.1002/eji.201343752; Ma J, 2014, J IMMUNOL, V192, P1356, DOI 10.4049/jimmunol.1302835; Marakalala MJ, 2010, CLIN DEV IMMUNOL, DOI 10.1155/2010/567571; Miyake Y, 2013, IMMUNITY, V38, P1050, DOI 10.1016/j.immuni.2013.03.010; Neumann K, 2014, IMMUNITY, V40, P389, DOI 10.1016/j.immuni.2013.12.015; Norimoto A, 2014, AM J RESP CELL MOL, V51, P201, DOI 10.1165/rcmb.2013-0522OC; Parsons MW, 2014, J IMMUNOL, V192, P1361, DOI 10.4049/jimmunol.1301809; Plato A, 2013, INT REV IMMUNOL, V32, P134, DOI 10.3109/08830185.2013.777065; Puel A, 2011, SCIENCE, V332, P65, DOI 10.1126/science.1200439; Quintin J, 2012, CELL HOST MICROBE, V12, P223, DOI 10.1016/j.chom.2012.06.006; Redelinghuys P, 2011, IMMUNOL LETT, V136, P1, DOI 10.1016/j.imlet.2010.10.005; Rochereau N, 2013, PLOS BIOL, V11, DOI 10.1371/journal.pbio.1001658; Roug AS, 2014, BRIT J HAEMATOL, V164, P212, DOI 10.1111/bjh.12614; Saeed S, 2014, SCIENCE, V345, P1578, DOI 10.1126/science.1251086; Sancho D, 2013, CURR OPIN IMMUNOL, V25, P46, DOI 10.1016/j.coi.2012.12.007; Sancho D, 2012, ANNU REV IMMUNOL, V30, P491, DOI 10.1146/annurev-immunol-031210-101352; Sancho D, 2009, NATURE, V458, P899, DOI 10.1038/nature07750; Schraml BU, 2013, CELL, V154, P843, DOI 10.1016/j.cell.2013.07.014; Settler S, 2012, SCI WORLD J, V2012; Shan MM, 2013, SCIENCE, V342, P447, DOI 10.1126/science.1237910; Shenderov K, 2013, J IMMUNOL, V190, P5722, DOI 10.4049/jimmunol.1203343; Smeekens SP, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2343; Strasser D, 2009, IMMUNITY, V36, P32; Suzuki Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03177; Taylor PR, 2014, NAT IMMUNOL, V15, P143, DOI 10.1038/ni.2797; Tjota MY, 2014, J ALLERGY CLIN IMMUN, V134, P706, DOI 10.1016/j.jaci.2014.06.013; Wuthrich M, 2012, ANNU REV IMMUNOL, V30, P115, DOI 10.1146/annurev-immunol-020711-074958; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651; Yonekawa A, 2014, IMMUNITY, V41, P402, DOI 10.1016/j.immuni.2014.08.005; Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20051758; Zelenay S, 2012, J CLIN INVEST, V122, P1615, DOI 10.1172/JCI60644; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x; Zhang JG, 2012, IMMUNITY, V36, P646, DOI 10.1016/j.immuni.2012.03.009; Zhu LL, 2013, IMMUNITY, V39, P324, DOI 10.1016/j.immuni.2013.05.017	73	75	79	7	37	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915	1879-0372		CURR OPIN IMMUNOL	Curr. Opin. Immunol.	FEB	2015	32						21	27		10.1016/j.coi.2014.12.002		7	Immunology	Immunology	CD0RJ	WOS:000350781300005	25553393	
J	Macy, E; Contreras, R				Macy, Eric; Contreras, Richard			Health care use and serious infection prevalence associated with penicillin "allergy" in hospitalized patients: A cohort study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Adverse drug reaction; antibiotics; Clostridium difficile; electronic medical record; hospital use; methicillin-resistant Staphylococcus aureus; multiple drug intolerance syndrome; penicillin allergy; prevalence; vancomycin-resistant Enterococcus species	GROUP-B STREPTOCOCCUS; CLOSTRIDIUM-DIFFICILE; ANTIMICROBIAL STEWARDSHIP; PREGNANT-WOMEN; VANCOMYCIN USE; HISTORY; MANAGEMENT; ANTIBIOTICS; COSTS	Background: Penicillin is the most common drug "allergy" noted at hospital admission, although it is often inaccurate. Objective: We sought to determine total hospital days, antibiotic exposures, and the prevalence rates of Clostridium difficile, methicillin-resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) in patients with and without penicillin "allergy" at hospital admission. Methods: We performed a retrospective, matched cohort study of subjects admitted to Kaiser Foundation hospitals in Southern California during 2010 through 2012. Results: It was possible to match 51,582 (99.6% of all possible cases) unique hospitalized subjects with penicillin "allergy" to 2 unique discharge diagnosis category-matched, sex-matched, age-matched, and date of admission-matched control subjects each. Cases with penicillin "allergy" averaged 0.59 (9.9%; 95% CI, 0.47-0.71) more total hospital days during 20.1 +/- 10.5 months of follow-up compared with control subjects. Cases were treated with significantly more fluoroquinolones, clindamycin, and vancomycin (P < .0001) for each antibiotic compared with control subjects. Cases had 23.4% (95% CI, 15.6% to 31.7%) more C difficile, 14.1% (95% CI, 7.1% to 21.6%) more MRSA, and 30.1% (95% CI, 12.5% to 50.4%) more VRE infections than expected compared with control subjects. Conclusions: A penicillin "allergy" history, although often inaccurate, is not a benign finding at hospital admission. Subjects with a penicillin "allergy" history spend significantly more time in the hospital. Subjects with a penicillin "allergy" history are exposed to significantly more antibiotics previously associated with C difficile and VRE. Drug "allergies" in general, but most those notably to penicillin, are associated with increased hospital use and increased C difficile, MRSA, and VRE prevalence.	[Macy, Eric] So Calif Permanente Med Grp, Dept Allergy, San Diego Med Ctr, San Diego, CA 92120 USA; [Contreras, Richard] Kaiser Permanente Hlth Care Program, Dept Res & Evaluat, Pasadena, CA USA	Macy, E (reprint author), Kaiser Permanente, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	eric.m.macy@kp.org			Kaiser Permanente Health Care Program; ALK-Abello	Supported by the Kaiser Permanente Health Care Program and ALK-Abello.	Arroliga ME, 2003, INFECT CONT HOSP EP, V24, P347, DOI 10.1086/502212; Arroliga ME, 2000, CHEST, V118, P1106, DOI 10.1378/chest.118.4.1106; Forrest DM, 2001, CLIN INFECT DIS, V32, P1685, DOI 10.1086/320752; Frigas E, 2008, MAYO CLIN PROC, V83, P651, DOI 10.4065/83.6.651; Gilbert DN, 2010, SANFORD GUIDE ANTIMI; Hensgens MPM, 2012, J ANTIMICROB CHEMOTH, V67, P742, DOI 10.1093/jac/dkr508; Hulscher MEJL, 2010, LANCET INFECT DIS, V10, P167, DOI 10.1016/S1473-3099(10)70027-X; Jump RLP, 2010, EMERG INFECT DIS, V16, P827, DOI 10.3201/eid1605.071606; Kuntz JL, 2012, INFECT CONT HOSP EP, V33, P1031, DOI 10.1086/667733; Li JTC, 2000, MAYO CLIN PROC, V75, P902; Macy E, 2011, CLIN EXP ALLERGY, V41, P1498, DOI 10.1111/j.1365-2222.2011.03837.x; Macy E, 2003, J ALLERGY CLIN IMMUN, V111, P1111, DOI 10.1067/mai.1385; Macy E, 2009, AM J MED, V122, P1; Macy E, 2013, CLIN REV ALLERGY IMM; Macy E, 2011, PERM J, V2, P31; Macy E, 2006, ANN ALLERG ASTHMA IM, V97, P164; Macy Eric, 2004, Perm J, V8, P20; Macy E, 2013, J ALLER CL IMM-PRACT, V1, P258, DOI 10.1016/j.jaip.2013.02.002; Macy E, 2012, ANN ALLERG ASTHMA IM, V108, P88, DOI 10.1016/j.anai.2011.11.006; Macy E, 2010, ANN ALLERG ASTHMA IM, V105, P136, DOI 10.1016/j.anai.2010.06.014; Macy Eric, 2009, Perm J, V13, P12; Nichols GA, 2011, DIABETES CARE, V34, P2374, DOI 10.2337/dc11-0475; Park M, 2006, ANN ALLERG ASTHMA IM, V97, P681; Philipson EH, 2007, J REPROD MED, V52, P480; Reddy V, 2013, J ALLERGY CLIN IMMUN, V131, pAB170; Rimawi RH, 2013, J HOSP MED, V8, P341, DOI 10.1002/jhm.2036; Ritzwoller DP, 2005, J NATL CANC I MONOGR, V35, P80; Solensky R, 2002, ARCH INTERN MED, V162, P822, DOI 10.1001/archinte.162.7.822; Solensky R, 2003, CLIN REV ALLERG IMMU, V24, P201, DOI 10.1385/CRIAI:24:3:201; Solensky R, 2010, ANN ALLERG ASTHMA IM, V105, P259, DOI 10.1016/j.anai.2010.08.002; Unger NR, 2013, PHARMACOTHERAPY, V33, P856, DOI 10.1002/phar.1288; Warrington RJ, 2000, ALLERGY ASTHMA PROC, V21, P297, DOI 10.2500/108854100778248269; Zeiger RS, 2008, J ALLERGY CLIN IMMUN, V121, p[855, e5]	33	75	78	0	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2014	133	3					790	796		10.1016/j.jaci.2013.09.021		7	Allergy; Immunology	Allergy; Immunology	AC3EK	WOS:000332397600022	24188976	
J	Reponen, T; Lockey, J; Bernstein, DI; Vesper, SJ; Levin, L; Hershey, GKK; Zheng, S; Ryan, P; Grinshpun, SA; Villareal, M; LeMasters, G				Reponen, Tiina; Lockey, James; Bernstein, David I.; Vesper, Stephen J.; Levin, Linda; Hershey, Gurjit K. Khurana; Zheng, Shu; Ryan, Patrick; Grinshpun, Sergey A.; Villareal, Manuel; LeMasters, Grace			Infant origins of childhood asthma associated with specific molds	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; molds; speciation; infants; Environmental Relative Moldiness Index	QUANTITATIVE PCR ANALYSIS; RELATIVE MOLDINESS INDEX; 1ST YEAR; ALTERNARIA-ALTERNATA; HOUSE-DUST; US HOMES; CHILDREN; COHORT; SYMPTOMS; EXPOSURE	Background: The specific cause or causes of asthma development must be identified to prevent this disease. Objective: Our hypothesis was that specific mold exposures are associated with childhood asthma development. Methods: Infants were identified from birth certificates. Dust samples were collected from 289 homes when the infants were 8 months of age. Samples were analyzed for concentrations of 36 molds that comprise the Environmental Relative Moldiness Index (ERMI) and endotoxin, house dust mite, cat, dog, and cockroach allergens. Children were evaluated at age 7 years for asthma based on reported symptoms and objective measures of lung function. Host, environmental exposure, and home characteristics evaluated included a history of parental asthma, race, sex, upper and lower respiratory tract symptoms, season of birth, family income, cigarette smoke exposure, air conditioning, use of a dehumidifier, presence of carpeting, age of home, and visible mold at age 1 year and child's positive skin prick test response to aeroallergens and molds at age 7 years. Results: Asthma was diagnosed in 24% of the children at age 7 years. A statistically significant increase in asthma risk at age 7 years was associated with high ERMI values in the child's home in infancy (adjusted relative risk for a 10-unit increase in ERMI value, 1.8; 95% CI, 1.5-2.2). The summation of levels of 3 mold species, Aspergillus ochraceus, Aspergillus unguis, and Penicillium variabile, was significantly associated with asthma (adjusted relative risk, 2.2; 95% CI, 1.8-2.7). Conclusion: In this birth cohort study exposure during infancy to 3 mold species common to water-damaged buildings was associated with childhood asthma at age 7 years. (J Allergy Clin Immunol 2012;130:639-44.)	[Reponen, Tiina; Lockey, James; Levin, Linda; Zheng, Shu; Ryan, Patrick; Grinshpun, Sergey A.; LeMasters, Grace] Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA; [Lockey, James; Bernstein, David I.; Villareal, Manuel] Univ Cincinnati, Dept Internal Med, Cincinnati, OH 45267 USA; [Vesper, Stephen J.] US EPA, Cincinnati, OH 45268 USA; [Hershey, Gurjit K. Khurana; Ryan, Patrick] Cincinnati Childrens Hosp, Ctr Med, Cincinnati, OH USA	Reponen, T (reprint author), Univ Cincinnati, Dept Environm Hlth, POB 670056, Cincinnati, OH 45267 USA.	Tiina.Reponen@uc.edu	Ryan, Patrick /L-7062-2015; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Khurana Hershey, Gurjit/0000-0001-6663-977X	US Department of Housing and Urban Development [OHLHH0226-10]; National Institute of Environmental Health Sciences (NIEHS) [RO1 ES11170]; US Environmental Protection Agency (EPA) through its Office of Research and Development; US Housing and Urban Development; Mycometrics; EMSL; TestAmerica; Forensics Analytical; Roche; Aemtek; Microbial Insight; National Institute of Environmental Health Sciences	Supported in part by US Department of Housing and Urban Development grant no. OHLHH0226-10 and National Institute of Environmental Health Sciences (NIEHS) grant no. RO1 ES11170 awarded to the University of Cincinnati. The US Environmental Protection Agency (EPA), through its Office of Research and Development, partially funded and collaborated in the research described here. It has been subjected to the Agency's peer review and has been approved as an EPA publication. Mention of trade names or commercial products does not constitute endorsement or recommendation by the EPA for use. Commercial use of the Environmental Relative Moldiness Index technology can provide royalties to the EPA.; T. Reponen has received research support from US Housing and Urban Development. J. Lockey and G. LeMasters are involved in the Diesel, Allergens and Gene Interaction and Child Atopy study. S. J. Vesper has received royalties from Mycometrics, EMSL, TestAmerica, Forensics Analytical, Roche, Aemtek, and Microbial Insight. P. Ryan has received research support from the National Institute of Environmental Health Sciences. The rest of the authors declare that they have no relevant conflicts of interest.	Agarwal R, 2011, MED MYCOL, V49, pS150, DOI 10.3109/13693786.2010.504752; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Bundy KW, 2009, ANN ALLERG ASTHMA IM, V103, P26, DOI 10.1016/S1081-1206(10)60139-1; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Cho SH, 2006, SCI TOTAL ENVIRON, V371, P31, DOI 10.1016/j.scitotenv.2006.09.001; Cohen J., 1988, STAT POWER ANAL BEHA; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Crawford C, 2009, AEROBIOLOGIA, V25, P147, DOI 10.1007/s10453-009-9120-z; Epstein TG, 2011, J PEDIATR-US, V158, P265, DOI 10.1016/j.jpeds.2010.07.026; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781; Haugland RA, 2004, SYST APPL MICROBIOL, V27, P198, DOI 10.1078/072320204322881826; Haugland RA, 2002, J MICROBIOL METH, V50, P319, DOI 10.1016/S0167-7012(02)00037-4; Heinrich J, 2011, INT J HYG ENVIR HEAL, V214, P3, DOI 10.1016/j.ijheh.2010.08.009; HOLM S, 1979, SCAND J STAT, V6, P65; Hyvarinen A, 2006, INDOOR AIR, V16, P20, DOI 10.1111/j.1600-0668.2005.00392.x; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; LeMasters GK, 2006, J PEDIATR-US, V149, P505, DOI 10.1016/j.jpeds.2006.06.035; Meklin T, 2004, J ENVIRON MONITOR, V6, P615, DOI 10.1039/b400250d; Mendell MJ, 2011, ENVIRON HEALTH PERSP, V119, P748, DOI 10.1289/ehp.1002410; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Institute of Medicine National Academies of Science, 2004, DAMP IND SPAC HLTH, P355; Reponen T, 2011, ANN ALLERG ASTHMA IM, V107, P120, DOI 10.1016/j.anai.2011.04.018; Reponen T, 2010, SCI TOTAL ENVIRON, V408, P5565, DOI 10.1016/j.scitotenv.2010.07.090; Rosenbaum PF, 2010, J EXPO SCI ENV EPID, V20, P503, DOI 10.1038/jes.2009.27; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; Salo PM, 2009, J ALLERGY CLIN IMMUN, V124, P185, DOI 10.1016/j.jaci.2009.05.012; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Schmechel D, 2008, J ALLERGY CLIN IMMUN, V121, P763, DOI 10.1016/j.jaci.2007.09.046; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; Vesper S, 2011, J ENV PUBLIC HLTH, V2011, DOI DOI 10.1155/2011/242457; Vesper S, 2008, SCI TOTAL ENVIRON, V394, P192, DOI 10.1016/j.scitotenv.2008.01.031; Vesper S, 2007, J ENVIRON MONITOR, V9, P826, DOI 10.1039/b704359g; Vesper S, 2007, J OCCUP ENVIRON MED, V49, P829, DOI 10.1097/JOM.0b013e3181255e98; Vesper S, 2011, CRIT REV MICROBIOL, V37, P15, DOI 10.3109/1040841X.2010.506177; Vesper S, 2009, J URBAN HEALTH, V86, P850, DOI 10.1007/s11524-009-9384-1; Vesper SJ, 2006, J OCCUP ENVIRON MED, V48, P852, DOI 10.1097/01.jom.0000224736.52780.2f; WANG XB, 1993, AM REV RESPIR DIS, V148, P1502; World Health Organiszation Europe, 2009, WHO GUID IND AIR QUA; Wickman M, 2003, PEDIATR ALLERGY IMMU, V14, P441, DOI 10.1046/j.0905-6157.2003.00079.x; Haugland R. A., 2002, Patent No. [6,387,652, 6387652]	44	75	75	1	32	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2012	130	3					639	+		10.1016/j.jaci.2012.05.030		11	Allergy; Immunology	Allergy; Immunology	001LZ	WOS:000308463500010	22789397	
J	Hackett, TL; Singhera, GK; Shaheen, F; Hayden, P; Jackson, GR; Hegele, RG; Van Eeden, S; Bai, TR; Dorscheid, DR; Knight, DA				Hackett, Tillie-Louise; Singhera, Gurpreet K.; Shaheen, Furquan; Hayden, Patrick; Jackson, George R.; Hegele, Richard G.; Van Eeden, Stephan; Bai, Tony R.; Dorscheid, Delbert R.; Knight, Darryl A.			Intrinsic Phenotypic Differences of Asthmatic Epithelium and Its Inflammatory Responses to Respiratory Syncytial Virus and Air Pollution	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						airway epithelium; asthma; inflammation and repair; RSV; particulate matter	EPIDERMAL-GROWTH-FACTOR; ACTIVATED PROTEIN-KINASES; FINE PARTICULATE MATTER; BRONCHIAL EPITHELIUM; CYTOKINE PRODUCTION; FACTOR RECEPTOR; ALVEOLAR MACROPHAGES; DYSREGULATED REPAIR; SIGNAL TRANSDUCER; MAPK ACTIVATION	A substantial proportion of healthcare cost associated with asthma is attributable to exacerbations of the disease. Within the airway, the epithelium forms the mucosal immune barrier, the first structural cell defense against common environmental insults such as respiratory syncytial virus (RSV) and particulate matter. We sought to characterize the phenotype of differentiated asthmatic-derived airway epithelial cultures and their intrinsic inflammatory responses to environmental challenges. Air-liquid interface (ALI) cultures were generated from asthmatic (n = 6) and nonasthmatic (n = 6) airway epithelial cells. Airway tissue and ALI cultures were analyzed by immunohistochemistry for cytokeratin-5, E-cadherin, Ki67, Muc5AC, NF-kappa B, the activation of p38, and apoptosis. ALI cultures were exposed to RSV (4 x 10(6) plaque forming unit/ml), particulate matter collected by Environmental Health Canada (EHC-93, 100 mu g/ml), or mechanically wounded for 24, 48, and 96 hours and basolateral supernatants analyzed for inflammatory cytokines, using Luminex and ELISA. The airway epithelium in airway sections of patients with asthma as well as in vitro ALI cultures demonstrated a less differentiated epithelium, characterized by elevated numbers of basal cells marked by the expression of cytokeratin-5, increased phosphorylation of p38 mitogen-activated protein kinase, and less adherens junction protein E-cadherin. Transepithelial resistance was not different between asthmatic and nonasthmatic cultures. In response to infection with RSV, exposure to EHC-93, or mechanical wounding, asthmatic ALI cultures released greater concentrations of IL-6, IL-8, and granulocyte macrophage colony-stimulating factor, compared with nonasthmatic cultures (P < 0.05). This parallel ex vivo and in vitro study of the asthmatic epithelium demonstrates an intrinsically altered phenotype and aberrant inflammatory response to common environmental challenges, compared with nonasthmatic epithelium.	[Hackett, Tillie-Louise; Singhera, Gurpreet K.; Shaheen, Furquan; Van Eeden, Stephan; Bai, Tony R.; Dorscheid, Delbert R.; Knight, Darryl A.] Univ British Columbia, James Hogg Res Ctr, St Pauls Hosp, Vancouver, BC V6Z 1Y6, Canada; [Hackett, Tillie-Louise; Knight, Darryl A.] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V6Z 1Y6, Canada; [Bai, Tony R.; Dorscheid, Delbert R.] Univ British Columbia, Div Resp, Vancouver, BC V6Z 1Y6, Canada; [Bai, Tony R.; Dorscheid, Delbert R.] Univ British Columbia, Div Crit Care Med, Dept Med, Vancouver, BC V6Z 1Y6, Canada; [Hayden, Patrick; Jackson, George R.] MatTek Corp, Ashland, MA USA; [Hegele, Richard G.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	Hackett, TL (reprint author), Univ British Columbia, James Hogg Res Ctr, St Pauls Hosp, 1081 Burrard St,Room 165, Vancouver, BC V6Z 1Y6, Canada.	Tillie.Hackett@hli.ubc.ca			Allergen-National Centre for Excellence/Canadian Institutes for Health Research [79632]; CIHR/Canadian Lung Association/GlaxoSmithKline; Michael Smith Foundation for Health Research	This work was supported by Allergen-National Centre for Excellence/Canadian Institutes for Health Research grant 79632. T.-L. H. is a recipient of a CIHR/Canadian Lung Association/GlaxoSmithKline, Integrated and Mentored Pulmonary and Cardiovascular Training strategic training, and a Michael Smith Foundation for Health Research postdoctoral fellowship. D. A. K. is a Canada Research Chair in Airway Disease and Michael Smith Foundation for Health Research Career Investigator. D. R. D. is a CIHR New Investigator and Michael Smith Foundation for Health Research Career Investigator. S. V. E. is a senior scholar with the Michael Smith Foundation for Health Research and a CIHR/GSK Professor in Chronic Obstructive Pulmonary Disease.	Akhtar US, 2010, INHAL TOXICOL, V22, P37, DOI 10.3109/08958378.2010.518377; Allahverdian S, 2008, AM J RESP CELL MOL, V38, P153, DOI 10.1165/rcmb.2007-0173OC; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; BECKER S, 1992, AM J RESP CELL MOL, V6, P369; Boland S, 2001, TOXICOL IN VITRO, V15, P379, DOI 10.1016/S0887-2333(01)00040-6; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Choi J, 2010, PEDIAT ALLERG IMM-UK, V21, P474, DOI 10.1111/j.1399-3038.2009.00908.x; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI 10.1139/y08-004; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; ELWOOD RK, 1983, AM REV RESPIR DIS, V128, P523; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Fischer B, 2000, CHEST, V117, p317S, DOI 10.1378/chest.117.5_suppl_1.317S; Frampton MW, 1999, AM J PHYSIOL-LUNG C, V277, pL960; Freishtat RJ, 2011, AM J RESP CELL MOL, V44, P863, DOI 10.1165/rcmb.2010-0029OC; Fujii T, 2002, AM J RESP CELL MOL, V27, P34; Fujii T, 2001, AM J RESP CELL MOL, V25, P265; Gern JE, 2004, PEDIATR INFECT DIS J, V23, pS78, DOI 10.1097/01.inf.0000108196.46134.a6; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598; Gualtieri M, 2009, TOXICOL LETT, V188, P52, DOI 10.1016/j.toxlet.2009.03.003; Hackett TL, 2008, STEM CELLS, V26, P2576, DOI 10.1634/stemcells.2008-0171; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Hamilton L M, 2001, Monaldi Arch Chest Dis, V56, P48; Hansdottir S, 2010, J IMMUNOL, V184, P965, DOI 10.4049/jimmunol.0902840; Heijink IH, 2010, EUR RESPIR J, V35, P894, DOI 10.1183/09031936.00065809; Heijink IH, 2007, J IMMUNOL, V178, P7678; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; Huang YCT, 2004, INHAL TOXICOL, V16, P863, DOI 10.1080/08958370490519480; ILOWITE JS, 1989, AM REV RESPIR DIS, V139, P1139; Jackson GR, 2010, AM J RESP CRIT CARE, V181; Janssen-Heininger Yvonne M W, 2009, Proc Am Thorac Soc, V6, P249, DOI 10.1513/pats.200806-054RM; Johnson JE, 2007, MODERN PATHOL, V20, P108, DOI 10.1038/modpathol.3800725; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kicic A, 2010, AM J RESP CRIT CARE, V181, P889, DOI 10.1164/rccm.200907-1071OC; Kim YM, 2005, AM J PHYSIOL-LUNG C, V288, pL432, DOI 10.1152/ajplung.00285.2004; Kujime K, 2000, J IMMUNOL, V164, P3222; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Liu WM, 2008, J ALLERGY CLIN IMMUN, V121, P893, DOI 10.1016/j.jaci.2008.02.004; Marchant D, 2010, J VIROL, V84, P11359, DOI 10.1128/JVI.00804-10; MATSUSE T, 1992, AM REV RESPIR DIS, V146, P177; Mellow TE, 2004, EXP LUNG RES, V30, P43, DOI 10.1080/01902140490252812; Mills PR, 1999, AM J RESP CRIT CARE, V160, pS38; Mullings RE, 2001, J ALLERGY CLIN IMMUN, V108, P832; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; NEILSON K A, 1990, Pediatric Pathology, V10, P491; Niessen CM, 2008, BBA-BIOMEMBRANES, V1778, P562, DOI 10.1016/j.bbamem.2007.12.015; Noah TL, 1996, AM J RESP CELL MOL, V14, P417; NOAH TL, 1993, AM J PHYSIOL, V265, pL472; Parker J, 2010, PEDIATR RES, V67, P17, DOI 10.1203/PDR.0b013e3181c0b200; Pazdrak K, 2002, AM J PHYSIOL-LUNG C, V283, pL364, DOI 10.1152/ajplung.00331.2001; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Pourazar J, 2004, RESP MED, V98, P821, DOI 10.1016/j.rmed.2004.02.025; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Qian XL, 2004, EMBO J, V23, P1739, DOI 10.1038/sj.emboj.7600136; Ramgolam K, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-10; Riediker M, 2001, ANN ALLERG ASTHMA IM, V87, P311; Ross AJ, 2007, AM J RESP CELL MOL, V37, P169, DOI 10.1165/rcmb.2006-0466OC; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Sampath D, 1999, J CLIN INVEST, V103, P1353, DOI 10.1172/JCI6130; Saunders V, 2010, ENVIRON HEALTH PERSP, V118, P640, DOI 10.1289/ehp.0901461; Shahana S, 2006, RESP MED, V100, P2018, DOI 10.1016/j.rmed.2006.02.012; Sheeran P, 1999, PEDIATR INFECT DIS J, V18, P115, DOI 10.1097/00006454-199902000-00007; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; Tan WC, 2005, CURR OPIN PULM MED, V11, P21; Trautmann A, 2005, INT ARCH ALLERGY IMM, V138, P142, DOI 10.1159/000088436; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; Wadsworth SJ, 2006, J CLIN IMMUNOL, V26, P376, DOI 10.1007/s10875-006-9029-z; Wang S, 2010, J IMMUNOTOXICOL, V7, P298, DOI 10.3109/1547691X.2010.509289; Wark P A, 2001, Monaldi Arch Chest Dis, V56, P429; Zhang LQ, 2002, J VIROL, V76, P5654, DOI 10.1128/JVI.76.11.5654.5666.2002; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC	80	75	78	3	16	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1044-1549	1535-4989		AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	NOV	2011	45	5					1090	1100		10.1165/rcmb.2011-0031OC		11	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	884CF	WOS:000299681800026	21642587	
J	Mackie, A; Macierzanka, A				Mackie, Alan; Macierzanka, Adam			Colloidal aspects of protein digestion	CURRENT OPINION IN COLLOID & INTERFACE SCIENCE			English	Review						Interface; Protein; Digestion; Biosurfactant; Enzyme; Emulsion	IN-VITRO DIGESTIBILITY; SIMULATED GASTROINTESTINAL PROTEOLYSIS; INTRAGASTRIC ACID STABILITY; AIR-WATER-INTERFACE; BETA-LACTOGLOBULIN; FOOD ALLERGENS; ENZYMATIC-HYDROLYSIS; PANCREATIC LIPASE; EMULSIFIER TYPE; BILE-ACIDS	The increase in food related health issues has sparked an interest in research on the digestion processes of the gastrointestinal tract. Because of the difficulty and expense of undertaking human trials or even animal experiments, much of the current research uses in vitro models that simulate various aspects of digestion. The results of this research indicate that the rate and extent of protein digestion is governed by accessibility of the cleavage sites to enzymes and local flexibility of the substrate molecule. However, results have also shown that digestion of an allergenic protein to small fragments does not necessarily mean that it will no longer be immunologically active. Other factors are also important. For example, adsorption to an interface increased rates of digestion as did the presence of bile acids. In fact, interaction with a range of physiological surfactants has been shown to be extremely important in protein digestion. When protein is adsorbed to an emulsified food it can be displaced by the surfactants in either the stomach or the small intestine. Lipid interaction with the protein in solution has been demonstrated to be important in effecting rates of proteolysis and phospholipids in particular have provided a protective effect for some milk proteins. Conversely the presence of specific proteins has been shown to affect rates of lipid digestion. The number of such colloidal interactions that we now know may play a role in protein digestion highlights the importance of this area to understanding how we can produce food that optimises nutrition for the consumer. (C) 2009 Elsevier Ltd. All rights reserved.	[Mackie, Alan; Macierzanka, Adam] Inst Food Res, Norwich NR4 7UA, Norfolk, England	Mackie, A (reprint author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.	alan.mackie@bbsrc.ac.uk	Mackie, Alan/B-3753-2015	Mackie, Alan/0000-0002-5681-0593	BBSRC	The authors would like to acknowledge funding of this work by the BBSRC through an Institute Strategic Programme grant.	Adachi A, 2009, CLIN EXP ALLERGY, V39, P167, DOI 10.1111/j.1365-2222.2008.03148.x; Adel-Patient K, 2008, REV FR ALLERGOL, V48, P335, DOI 10.1016/j.allerg.2008.03.002; Armand M, 1997, OCL-OL CORPS GRAS LI, V4, P178; Armand M, 2007, CURR OPIN CLIN NUTR, V10, P156, DOI 10.1097/MCO.0b013e3280177687; Bublin M, 2008, MOL NUTR FOOD RES, V52, P1130, DOI 10.1002/mnfr.200700167; Burke JE, 2009, CARDIOVASC DRUG THER, V23, P49, DOI 10.1007/s10557-008-6132-9; Chicon R, 2008, J DAIRY SCI, V91, P928, DOI 10.3168/jds.2007-0657; Chicon R, 2008, INT DAIRY J, V18, P367, DOI 10.1016/j.idairyj.2007.11.010; Dickinson E, 2006, COLLOID SURFACE A, V288, P3, DOI 10.1016/j.colsurfa.2006.01.012; Mandalari G., 2009, MOL NUTR FO IN PRESS, V54, P767, DOI DOI 10.1002/MNFR.200900142; Eiwegger T, 2006, CLIN EXP ALLERGY, V36, P1281, DOI 10.1111/j.1365-2222.2006.02565.x; Foltz M, 2008, J AGR FOOD CHEM, V56, P837, DOI 10.1021/jf072611h; Gass J, 2007, GASTROENTEROLOGY, V133, P16, DOI 10.1053/j.gastro.2007.04.008; Goetze O, 2007, AM J PHYSIOL-GASTR L, V292, pG11, DOI 10.1152/ajpgi.00498.2005; Gunning PA, 2004, BIOMACROMOLECULES, V5, P984, DOI 10.1021/bm0344957; Hofmann AF, 2008, CELL MOL LIFE SCI, V65, P2461, DOI 10.1007/s00018-008-7568-6; Hur SJ, 2009, FOOD CHEM, V114, P253, DOI 10.1016/j.foodchem.2008.09.069; Moreno FJ, 2007, BIOMED PHARMACOTHER, V61, P50, DOI 10.1016/j.biopha.2006.10.005; Jenkins JA, 2005, J ALLERGY CLIN IMMUN, V115, P163, DOI 10.1016/j.jaci.2004.10.026; Jenkins JA, 2007, J ALLERGY CLIN IMMUN, V120, P1399, DOI 10.1016/j.jaci.2007.08.019; Kneepkens CMF, 2009, EUR J PEDIATR, V168, P891, DOI 10.1007/s00431-009-0955-7; Lucas JSA, 2008, PEDIAT ALLERG IMM-UK, V19, P392, DOI 10.1111/j.1399-3038.2007.00678.x; Lundin L, 2008, NUTR DIET, V65, pS79, DOI 10.1111/j.1747-0080.2008.00266.x; Macierzanka A, 2009, SOFT MATTER, V5, P538, DOI 10.1039/b811233a; Maldonado-Valderrama J, 2009, EUR PHYS J E, V30, P165, DOI 10.1140/epje/i2008-10426-0; Maldonado-Valderrama J, 2008, LANGMUIR, V24, P6759, DOI 10.1021/la800551u; Mandalari G, 2009, MOL NUTR FOOD RES, V53, pS131, DOI 10.1002/mnfr.200800321; Marciani L, 2007, AM J PHYSIOL-GASTR L, V292, pG1607, DOI 10.1152/ajpgi.00452.2006; Marciani L, 2009, BRIT J NUTR, V101, P919, DOI 10.1017/S0007114508039986; Mariniello L, 2007, J AGR FOOD CHEM, V55, P4717, DOI 10.1021/jf0637269; Monaci L, 2006, EUR FOOD RES TECHNOL, V223, P149, DOI 10.1007/s00217-005-0178-8; Moreno FJ, 2005, J AGR FOOD CHEM, V53, P9810, DOI 10.1021/jf0515227; Mortensen LS, 2009, AM J CLIN NUTR, V90, P41, DOI 10.3945/ajcn.2008.27281; Mun S, 2007, FOOD RES INT, V40, P770, DOI 10.1016/j.foodres.2007.01.007; Norton I, 2007, OBES REV, V8, P83, DOI 10.1111/j.1467-789X.2007.00298.x; Peyron S, 2006, J AGR FOOD CHEM, V54, P5643, DOI 10.1021/jf053178j; Reis PM, 2008, FOOD BIOPHYS, V3, P370, DOI 10.1007/s11483-008-9091-6; Restani P, 2009, ANAL BIOANAL CHEM, V395, P47, DOI 10.1007/s00216-009-2909-3; Sandra S, 2008, J AGR FOOD CHEM, V56, P7488, DOI 10.1021/jf800741w; Sarkar A, 2010, FOOD HYDROCOLLOID, V24, P142, DOI 10.1016/j.foodhyd.2009.08.012; Sarkar A, 2009, FOOD HYDROCOLLOID, V23, P1563, DOI 10.1016/j.foodhyd.2008.10.014; SINN J, 2006, COCHRANE DB SYST REV; Sletten GBG, 2008, FOOD AGR IMMUNOL, V19, P213, DOI 10.1080/09540100802350963; Stanciuc N, 2008, REV ROUM CHIM, V53, P921; Ten Have GAM, 2007, INT J SPORT NUTR EXE, V17, pS23; Tsoukala A, 2006, COLLOID SURFACE B, V53, P203, DOI 10.1016/j.colsurfb.2006.08.019; Tuncturk Y, 2006, FOOD HYDROCOLLOID, V20, P475, DOI 10.1016/j.foodhyd.2005.04.003; Untersmayr E, 2006, PHARMACOL THERAPEUT, V112, P787, DOI 10.1016/j.pharmthera.2006.06.004; Veldhorst MAB, 2009, PHYSIOL BEHAV, V96, P675, DOI 10.1016/j.physbeh.2009.01.004; Waninge R, 2005, J AGR FOOD CHEM, V53, P716, DOI 10.1021/jf049267y; WEST CM, 2006, INT ARCH ALLERGY LMM, V141, P217; Zeece M, 2008, INNOV FOOD SCI EMERG, V9, P62, DOI 10.1016/j.ifset.2007.05.004; Zhang XQ, 2007, BIOCHEMISTRY-US, V46, P5252, DOI 10.1021/bi602483p; Zhang XQ, 2006, BIOCHEMISTRY-US, V45, P8444, DOI 10.1021/bi0602967	54	75	75	10	74	ELSEVIER SCIENCE LONDON	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	1359-0294			CURR OPIN COLLOID IN	Curr. Opin. Colloid Interface Sci.	APR	2010	15	1-2					102	108		10.1016/j.cocis.2009.11.005		7	Chemistry, Physical	Chemistry	567WF	WOS:000275477400016		
J	Shore, SA				Shore, Stephanie A.			Obesity, airway hyperresponsiveness, and inflammation	JOURNAL OF APPLIED PHYSIOLOGY			English	Review						mice; leptin; adiponectin; tumor necrosis factor-alpha; adipokines	BODY-MASS INDEX; ADIPOSE-TISSUE HYPOXIA; NECROSIS-FACTOR-ALPHA; DIET-INDUCED OBESITY; EXERCISE-INDUCED BRONCHOSPASM; INDUCED INSULIN-RESISTANCE; ACUTE OZONE EXPOSURE; MURINE ASTHMA MODEL; HIGH-FAT DIET; PULMONARY-FUNCTION	Shore SA. Obesity, airway hyperresponsiveness, and inflammation. J Appl Physiol 108: 735-743, 2010. First published October 29, 2009; doi: 10.1152/japplphysiol.00749.2009.-Epidemiological data indicate that obesity is a risk factor for asthma, but the mechanistic basis for this relationship is not established. Here we review data from human subjects and animal models investigating the relationship between obesity and airway hyperresponsiveness, a characteristic feature of asthma. We discuss obesity as a state of chronic systemic inflammation resulting from interactions between adipocytes and adipose tissue macrophages that are recruited to obese adipose tissue. Finally, we focus on the possibility that aspects of this inflammation, particularly obesity-related changes in TNF-alpha, leptin, and adiponectin, may contribute to airway hyperresponsiveness in obesity. Determining how obesity promotes asthma may uncover novel therapeutic strategies that are effective in the obese asthmatic subject.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA	Shore, SA (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, 665 Huntington Ave, Boston, MA 02115 USA.	sshore@hsph.harvard.edu			National Institute of Environmental Health Sciences [ES-013307, ES-000002]; National Heart, Lung, and Blood Institute [HL-084044]	This work was supported by National Institute of Environmental Health Sciences Grants ES-013307 and ES-000002 and National Heart, Lung, and Blood Institute Grant HL-084044.	Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Adya R, 2008, CARDIOVASC RES, V78, P356, DOI 10.1093/cvr/cvm111; Arkan MC, 2005, NAT MED, V11, P191, DOI 10.1068/nm1185; Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4; Beuther DA, 2007, AM J RESP CRIT CARE, V175, P661, DOI 10.1164/rccm.200611-1717OC; Bustos P, 2005, INT J OBESITY, V29, P804, DOI 10.1038/sj.ijo.0802958; Caldefie-Chezet F, 2001, J LEUKOCYTE BIOL, V69, P414; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835; Chambers EC, 2008, LUNG, V186, P13, DOI 10.1007/s00408-007-9043-9; Chapman DG, 2008, EUR RESPIR J, V32, P1563, DOI 10.1183/09031936.00114007; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI14120; De Rosa V, 2007, IMMUNITY, V26, P241, DOI 10.1016/j.immuni.2007.01.011; del Rio-Navarro B, 2000, Allergol Immunopathol (Madr), V28, P5; Ehling A, 2006, J IMMUNOL, V176, P4468; Fantuzzi G, 2005, J ALLERGY CLIN IMMUN, V115, P911, DOI 10.1016/j.jaci.2005.02.023; Fantuzzi G, 2008, J ALLERGY CLIN IMMUN, V121, P326, DOI 10.1016/j.jaci.2007.10.018; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gokbel H, 1999, J SPORT MED PHYS FIT, V39, P361; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; HAKALA K, 1995, INT J OBESITY, V19, P343; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; HEDENSTIERNA G, 1976, ACTA ANAESTH SCAND, V20, P334; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hosogai N, 2007, DIABETES, V56, P901, DOI 10.2337/db06-0911; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Hug C, 2004, P NATL ACAD SCI USA, V101, P10308, DOI 10.1073/pnas.0403382101; Jackson MB, 2006, CLIN SCI, V110, P143, DOI 10.1042/CS20050243; Jang An-Soo, 2006, The Korean Journal of Internal Medicine, V21, P10; Johnston RA, 2006, AM J PHYSIOL-REG I, V290, pR126, DOI 10.1152/ajpregu.00306.2005; Johnston RA, 2008, J APPL PHYSIOL, V104, P1727, DOI 10.1152/japplphysiol.00075.2008; Johnston RA, 2007, J APPL PHYSIOL, V102, P149, DOI 10.1152/japplphysiol.00300.2006; Kadowaki T, 2008, FEBS LETT, V582, P74, DOI 10.1016/j.febslet.2007.11.070; KAPLAN TA, 1993, CLIN PEDIATR, V32, P220, DOI 10.1177/000992289303200407; Kim J, 2006, CLIN EXP ALLERGY, V36, P122, DOI 10.1111/j.1365-2222.2005.02407.x; Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.025; Komakula S, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-32; Lazarus R, 1997, PEDIATR PULM, V24, P187; Li AM, 2003, ARCH DIS CHILD, V88, P361, DOI 10.1136/adc.88.4.361; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Loffreda S, 1998, FASEB J, V12, P57; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881; Ma Z, 2009, CLIN EXP ALLERGY, V39, P1136, DOI 10.1111/j.1365-2222.2009.03272.x; Maniscalco M, 2008, RESP MED, V102, P102, DOI 10.1016/j.rmed.2007.07.029; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; Medoff BD, 2009, AM J RESP CELL MOL, V41, P397, DOI 10.1165/rcmb.2008-0415OC; Miller M, 2009, J IMMUNOL, V182, P684; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; Nawrocki AR, 2004, CURR OPIN PHARMACOL, V4, P281, DOI 10.1016/j.coph.2004.03.003; Nguyen MTA, 2007, J BIOL CHEM, V282, P35279, DOI 10.1074/jbc.M706762200; Nicolacakis K, 2008, J APPL PHYSIOL, V105, P1533, DOI 10.1152/japplphysiol.01260.2007; Ouchi N, 2000, CIRCULATION, V102, P1296; Pacifico L, 2006, EUR J ENDOCRINOL, V154, P691, DOI 10.1530/eje.1.02138; Pajvani UB, 2004, J BIOL CHEM, V279, P12152, DOI 10.1074/jbc.M311113200; Papathanassoglou E, 2006, J IMMUNOL, V176, P7745; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Rausch ME, 2008, INT J OBESITY, V32, P451, DOI 10.1038/sj.ijo.0803744; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Salome CM, 2008, INT J OBESITY, V32, P502, DOI 10.1038/sj.ijo.0803752; Savov JD, 2003, AM J PHYSIOL-LUNG C, V285, pL940, DOI 10.1152/ajplung.00102.2003; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; Serra A, 2006, CLIN NUTR, V25, P400, DOI 10.1016/j.clnu.2005.11.014; Shi H, 2006, J CLIN INVEST, V116, P3015, DOI 10.1172/JCI28898; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Shore SA, 2008, J APPL PHYSIOL, V105, P1127, DOI 10.1152/japplphysiol.00117.2008; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Shore SA, 2007, CURR OPIN PULM MED, V13, P56, DOI 10.1097/MCP.0b013e3280110196; Shore SA, 2007, J APPL PHYSIOL, V102, P516, DOI 10.1152/japplphysiol.00847.2006; Silha JV, 2005, INT J OBESITY, V29, P1308, DOI 10.1038/sj.ijo.0802987; Sood A, 2006, J ASTHMA, V43, P447, DOI 10.1080/02770900600758309; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Strissel KJ, 2007, DIABETES, V56, P2910, DOI 10.2337/db07-0767; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Tantisira KG, 2001, THORAX, V56, P64; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76; Tsatsanis C, 2005, BIOCHEM BIOPH RES CO, V335, P1254, DOI 10.1016/j.bbrc.2005.07.197; Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280; Vincent HK, 2006, INT J OBESITY, V30, P400, DOI 10.1038/sj.ijo.0803177; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Williams AS, 2007, J APPL PHYSIOL, V103, P1189, DOI 10.1152/japplphysiol.00172.2007; Winkler T, 2007, J APPL PHYSIOL, V103, P655, DOI 10.1152/japplphysiol.00041.2007; Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 2003, NATURE, V423, P762, DOI 10.1038/nature01705; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yamauchi T, 2007, NAT MED, V13, P332, DOI 10.1038/nm1557; Ye J, 2009, INT J OBESITY, V33, P54, DOI 10.1038/ijo.2008.229; Ye JP, 2007, AM J PHYSIOL-ENDOC M, V293, pE1118, DOI 10.1152/ajpendo.00435.2007; Yokota T, 2000, BLOOD, V96, P1723; Zaldivar F, 2006, INT J OBESITY, V30, P906, DOI 10.1038/sj.ijo.0803227; Zeyda M, 2007, INT J OBESITY, V31, P1420, DOI 10.1038/sj.ijo.0803632	108	75	79	0	7	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	MAR	2010	108	3					735	743		10.1152/japplphysiol.00749.2009		9	Physiology; Sport Sciences	Physiology; Sport Sciences	570JK	WOS:000275670400039	19875711	
J	Allen, RW; Davies, H; Cohen, MA; Mallach, G; Kaufman, JD; Adar, SD				Allen, Ryan W.; Davies, Hugh; Cohen, Martin A.; Mallach, Gary; Kaufman, Joel D.; Adar, Sara D.			The spatial relationship between traffic-generated air pollution and noise in 2 US cities	ENVIRONMENTAL RESEARCH			English	Article						Air pollution; Noise; Traffic; Confounding; Cardiovascular	AMBIENT NITROGEN-DIOXIDE; MAJOR HIGHWAY; MYOCARDIAL-INFARCTION; ULTRAFINE PARTICLES; HEART-DISEASE; LOS-ANGELES; EXPOSURE; ASTHMA; MORTALITY; ASSOCIATION	Traffic-gene rated air pollution and noise have both been linked to cardiovascular morbidity. Since traffic is a shared source, there is potential for correlated exposures that may lead to confounding in epidemiologic studies. As part of the Multi-Ethnic Study of Atherosclerosis and Air Pollution (MESA Air), 2-week NO and NO(2) concentrations were measured at up to 105 locations, selected primarily to characterize gradients near major roads, in each of 9 US communities. We measured 5-min A-weighted equivalent continuous sound pressure levels (L(eq)) and ultrafine particle (UFP) counts at a subset of these NO/NO(2) monitoring locations in Chicago, IL (N = 69 in December 2006; N = 36 in April 2007) and Riverside County, CA (N = 46 in April 2007). L(eq) and UFP were measured during non-"rush hour" periods (10:00-16:00) to maximize comparability between measurements. We evaluated roadway proximity exposure surrogates in relation to the measured levels, estimated noise-air pollution correlation coefficients, and evaluated the impact of regional-scale pollution gradients, wind direction, and roadway proximity on the correlations. Five-minute L(eq) measurements in December 2006 and April 2007 were highly correlated (r = 0.84), and measurements made at different times of day were similar (coefficients of variation: 0.5-13%), indicating that 5-min measurements are representative of long-term L(eq), Binary and continuous roadway proximity metrics characterized L(eq) as well or better than NO or NO(2). We found strong regional-scale gradients in NO and NO(2), particularly in Chicago, but only weak regional-scale gradients in L(eq) and UFP. L(eq) was most consistently correlated with NO, but the correlations were moderate (0.20-0.60). After removing the influence of regional-scale gradients the correlations generally increased (L(eq)-NO: r = 0.49-0.62), and correlations downwind of major roads (L(eq)-NO: r = 0.53-0.74) were consistently higher than those upwind (0.35-0.65). There was not a consistent effect of roadway proximity on the correlations. In conclusion, roadway proximity variables are not unique exposure surrogates in studies of endpoints hypothesized to be related to both air pollution and noise. Moderate correlations between traffic-generated air pollution and noise suggest the possibility of confounding, which might be minimized by considering regional pollution gradients and/or prevailing wind direction(s) in epidemiologic studies. (C) 2009 Elsevier Inc. All rights reserved.	[Allen, Ryan W.; Mallach, Gary] Simon Fraser Univ, Fac Hlth Sci, Burnaby, BC V5A 1S6, Canada; [Davies, Hugh] Univ British Columbia, Sch Environm Hlth, Vancouver, BC V5Z 1M9, Canada; [Cohen, Martin A.; Kaufman, Joel D.] Univ Washington, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA; [Kaufman, Joel D.; Adar, Sara D.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	Allen, RW (reprint author), Simon Fraser Univ, Fac Hlth Sci, 8888 Univ Dr, Burnaby, BC V5A 1S6, Canada.	allenr@sfu.ca	Kaufman, Joel/B-5761-2008; Adar, Sara/L-2278-2016	Kaufman, Joel/0000-0003-4174-9037; Adar, Sara/0000-0001-8383-485X	Simon Fraser University President's Research; US Environmental Protection Agency [R831697]; National Institute of Environmental Health Sciences [K24ES013195]	Funding Sources: Funding for this work was provided by the Simon Fraser University President's Research Grant and the US Environmental Protection Agency (Grant R831697). Joel Kaufman was supported by the National Institute of Environmental Health Sciences through grant K24ES013195.	Adar SD, 2007, INHAL TOXICOL, V19, P135, DOI 10.1080/08958370701496012; Ainslie B, 2008, ATMOS ENVIRON, V42, P2394, DOI 10.1016/j.atmosenv.2007.12.021; Alberola J, 2005, APPL ACOUST, V66, P1180, DOI 10.1016/j.apacoust.2005.03.001; ALLEN R, 2009, EPIDEMIOLOG IN PRESS, DOI DOI 10.1097/EDE.0B013E31819644CC; Babisch W, 2002, NOISE HEALTH, V4, P1; Babisch WF, 2005, EPIDEMIOLOGY, V16, P33, DOI 10.1097/01.ede.0000147104.84424.24; Babisch Wolfgang, 2006, Noise Health, V8, P1; Beckerman B, 2008, ATMOS ENVIRON, V42, P275, DOI 10.1016/j.atmosenv.2007.09.042; Beelen R, 2009, OCCUP ENVIRON MED, V66, P243, DOI 10.1136/oem.2008.042358; Bluhm GL, 2007, OCCUP ENVIRON MED, V64, P122, DOI 10.1136/oem.2005.025866; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Calixto A, 2003, CITIES, V20, P23, DOI 10.1016/S0264-2751(02)00093-8; Chen E, 2008, ENVIRON HEALTH PERSP, V116, P970, DOI 10.1289/ehp.11076; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; DAVIES HW, 2009, OCCUPATIONA IN PRESS, DOI DOI 10.1136/OEM.2008.041764; de Kluizenaar Y, 2007, J OCCUP ENVIRON MED, V49, P484, DOI 10.1097/JOM.0013618058a9ff; Dominici F, 2008, EPIDEMIOLOGY, V19, P558, DOI 10.1097/EDE.0b013e31817307dc; Finkelstein MM, 2004, AM J EPIDEMIOL, V160, P173, DOI 10.1093/aje/kwh181; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gilbert NL, 2007, ATMOS ENVIRON, V41, P2670, DOI 10.1016/j.atmosenv.2006.12.007; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Gordian ME, 2006, J EXPO SCI ENV EPID, V16, P49, DOI 10.1038/sj.jea.7500436; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hoffmann B, 2007, CIRCULATION, V116, P489, DOI 10.1161/CIRCULATIONAHA.107.693622; Hoffmann B, 2006, EUR HEART J, V27, P2696, DOI 10.1093/eurheartj/ehl278; HOTHERSALL DC, 1987, J SOUND VIB, V115, P459, DOI 10.1016/0022-460X(87)90290-2; ISING H, 2004, NOISE HLTH, V6, P23; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Klaeboe R, 2000, ATMOS ENVIRON, V34, P4727; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; MacLehose RF, 2007, EPIDEMIOLOGY, V18, P199, DOI 10.1097/01.ede.0000256320.30737.c0; Maheswaran R, 2003, STROKE, V34, P2776, DOI 10.1161/01.STR.0000101750.77547.11; Maschke C, 2000, INT J HYG ENVIR HEAL, V203, P45, DOI 10.1078/S1438-4639(04)70007-3; Pleijel H, 2004, SCI TOTAL ENVIRON, V332, P261, DOI 10.1016/j.scitotenv.2004.03.020; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Schwela D, 2005, Noise Health, V7, P41; SELANDER J, 2009, EPIDEMIOLOG IN PRESS, DOI DOI 10.1097/EDE.0B013E31819463BD; Su JG, 2008, SCI TOTAL ENVIRON, V390, P520, DOI 10.1016/j.scitotenv.2007.10.032; Thomas DC, 2007, EPIDEMIOLOGY, V18, P186, DOI 10.1097/01.ede.0000254682.47697.70; Tobias A, 2001, EUR J EPIDEMIOL, V17, P765, DOI 10.1023/A:1015663013620; Tonne C, 2007, ENVIRON HEALTH PERSP, V115, P53, DOI 10.1289/ehp.9587; van Kempen EEMM, 2002, ENVIRON HEALTH PERSP, V110, P307; Zhu YF, 2006, ENVIRON SCI TECHNOL, V40, P2531, DOI 10.1021/es0516514; Zhu YF, 2006, AEROSOL SCI TECH, V40, P422, DOI 10.1080/02786820600643321; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032	46	75	75	1	35	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	APR	2009	109	3					334	342		10.1016/j.envres.2008.12.006		9	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	426JT	WOS:000264704800018	19193368	
J	Jyrkka, J; Enlund, H; Korhonen, MJ; Sulkava, R; Hartikainen, S				Jyrkka, Johanna; Enlund, Hannes; Korhonen, Maarit J.; Sulkava, Raimo; Hartikainen, Sirpa			Patterns of Drug Use and Factors Associated with Polypharmacy and Excessive Polypharmacy in Elderly Persons Results of the Kuopio 75+Study: A Cross-Sectional Analysis	DRUGS & AGING			English	Article							HEALTH-CARE UTILIZATION; MEDICATION USE; OLDER-PEOPLE; MANAGED CARE; RISK-FACTORS; PRESCRIPTION; EVENTS; HOME; POPULATION; PHYSICIANS	Background: Although the increasing use of drugs in elderly persons has raised many concerns in recent years, the process leading to polypharmacy (PP) and excessive polypharmacy (EPP) remains largely unknown. Objective: To describe the number and type of drugs used and to evaluate the role of different factors associated with PP (i.e. 6-9 drugs) and EPP (i.e. >= 10 drugs), with special reference to the number and type of medical diagnoses and symptoms, in a population of home-dwelling elderly persons aged >= 75 years. Methods: The study was a cross-sectional analysis of a population-based cohort in 1998. The population consisted of home-dwelling elderly persons aged >= 75 years in the city of Kuopio, Finland. The data for the analysis were obtained from the Kuopio 75+ Study, which drew a random sample of 700 elderly residents aged >= 75 years living in the city of Kuopio from the population register. Of these, 601 attended a structured clinical examination and an interview carried out by a geriatrician and a trained nurse in 1998. For this analysis, all home-dwelling elderly participants (n=523) were included. Study data were expressed as proportions and means with standard deviations. The factors associated with PP and EPP were examined by multinomial logistic regression. Results: The most commonly used drugs were cardiovascular drugs (97% in EPP, 94% in PP and 59% in non-PP group) and analgesics (89%, 76% and 54%), respectively. Use of psychotropics was markedly higher in the EPP group (77%) than in the PP (42%) and non-PP groups (20%). The mean number of drugs per diagnosis was 3.6 in the EPP group, 2.6 in the PP group and 1.6 in the non-PP group. Factors associated only with EPP were moderate self-reported health (odds ratio [OR] 2.05; 95% CI 1.08, 3.89), female gender (OR 2.43; 95% CI 1.27, 4.65) and age >= 85 years (OR 2.84; 95% CI 1.41, 5.72). Factors that were associated with both PP and EPP included poor self-reported health (PP: OR 2.15; 95% CI 1.01, 4.59 and EPP: OR 6.02; 95% CI 2.55, 14.20), diabetes mellitus (PP: OR 2.28; 95% CI 1.26, 4.15 and EPP: OR 2.07; 95% CI 1.03, 4.18), depression (PP: OR 2.13; 95% CI 1.16, 3.90 and EPP: OR 2.93; 95% CI 1.51, 5.66), pain (PP: OR 2.69; 95% CI 1.68, 4.30 and EPP: OR 2.74; 95% CI 1.56, 4.82), heart disease (PP: OR 2.51; 95% CI 1.54, 4.08 and EPP: OR 4.63; 95% CI 2.45, 8.74) and obstructive pulmonary disease (including asthma or chronic obstructive pulmonary disease) [PP: OR 2.79; 95% CI 1.24, 6.25 and EPP: OR 6.82; 95% CI 2.87, 16.20]. Conclusions: The study indicates that the factors associated with PP and EPP are not uniform. Age >= 85 years, female gender and moderate self-reported health were factors associated only with EPP, while poor self-reported health and several specific disease states were associated with both PP and EPP. The high number of drugs per diagnosis observed in this study calls for a thorough assessment of the need for and outcomes associated with use of these drugs.	[Jyrkka, Johanna; Korhonen, Maarit J.; Sulkava, Raimo] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland; [Jyrkka, Johanna] Univ Kuopio, Dept Social Pharm, FIN-70211 Kuopio, Finland; [Jyrkka, Johanna; Korhonen, Maarit J.; Hartikainen, Sirpa] Univ Kuopio, Kuopio Res Ctr Geriatr Care, FIN-70211 Kuopio, Finland; [Enlund, Hannes] Kuwait Univ, Dept Pharm Practice, Kuwait, Kuwait; [Hartikainen, Sirpa] Univ Kuopio, Fac Pharm, FIN-70211 Kuopio, Finland; [Hartikainen, Sirpa] Leppavirta Hlth Ctr, Leppavirta, Finland	Jyrkka, J (reprint author), Univ Kuopio, Sch Publ Hlth & Clin Nutr, POB 1627, FIN-70211 Kuopio, Finland.	johanna.jyrkka@uku.fi			Nordic Red Feather of the Lions; Kuopio University Pharmacy Fund; Social Insurance of Finland; Jenny and Antti Wihuri Foundation; Orion-Farmos Research Foundation	The authors have no conflicts of interest that are directly relevant to the content of this study.	Alarcon T, 1999, AGE AGEING, V28, P429, DOI 10.1093/ageing/28.5.429; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Aparasu Rajender R, 2005, Res Social Adm Pharm, V1, P446, DOI 10.1016/j.sapharm.2005.06.004; Astrand B, 2006, EUR J CLIN PHARMACOL, V62, P749, DOI 10.1007/s00228-006-0143-x; Barat I, 2000, EUR J CLIN PHARMACOL, V56, P501, DOI 10.1007/s002280000157; Barat I, 2001, BRIT J CLIN PHARMACO, V51, P615, DOI 10.1046/j.0306-5251.2001.01401.x; Bjerrum L, 1998, EUR J CLIN PHARMACOL, V54, P197, DOI 10.1007/s002280050445; Cannon Katrina T, 2006, Am J Geriatr Pharmacother, V4, P134, DOI 10.1016/j.amjopharm.2006.06.010; Chen YF, 2001, J CLIN PHARM THER, V26, P129, DOI 10.1046/j.1365-2710.2001.00333.x; Denneboom W, 2006, BRIT J GEN PRACT, V56, P504; Fialova D, 2005, JAMA-J AM MED ASSOC, V293, P1348, DOI 10.1001/jama.293.11.1348; Field TS, 2004, J AM GERIATR SOC, V52, P1349, DOI 10.1111/j.1532-5415.2004.52367.x; Fillit HM, 1999, AM J MANAG CARE, V5, P587; Frazier Susan C, 2005, J Gerontol Nurs, V31, P4; Fulton Maryann M, 2005, J Am Acad Nurse Pract, V17, P123, DOI 10.1111/j.1041-2972.2005.0020.x; Green Jacqueline L, 2007, Am J Geriatr Pharmacother, V5, P31, DOI 10.1016/j.amjopharm.2007.03.004; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; Haider SI, 2007, INT J CLIN PHARM TH, V45, P643; Haider SI, 2008, CLIN THER, V30, P419, DOI 10.1016/j.clinthera.2008.02.010; Hajjar Emily R, 2007, Am J Geriatr Pharmacother, V5, P345, DOI 10.1016/j.amjopharm.2007.12.002; Hajjar ER, 2005, J AM GERIATR SOC, V53, pS178, DOI 10.1111/j.1532-5415.2005.53523.x; Jensen E, 2008, AGING CLIN EXP RES, V20, P145; Jorgensen T, 2001, ANN PHARMACOTHER, V35, P1004, DOI 10.1345/aph.10351; Junius-Walker U, 2007, FAM PRACT, V24, P14, DOI 10.1093/fampra/cml067; JYLHA M, 1994, J CLIN EPIDEMIOL, V47, P69, DOI 10.1016/0895-4356(94)90035-3; Jyrkka J, 2006, EUR J CLIN PHARMACOL, V62, P151, DOI 10.1007/s00228-005-0079-6; Kennerfalk A, 2002, ANN PHARMACOTHER, V36, P797; KLAUKKA T, 1993, MED CARE, V31, P445, DOI 10.1097/00005650-199305000-00006; KLAUKKA T, 1990, PUBL SOC INS I M, V71; Kuijpers MAJ, 2008, BRIT J CLIN PHARMACO, V65, P130, DOI 10.1046/j.0306-5251.2007.02961.x; Kuzuya M, 2006, J AM GERIATR SOC, V54, P598, DOI 10.1111/j.1532-5415.2006.00659.x; Lernfelt B, 2003, EUR J CLIN PHARMACOL, V59, P637, DOI 10.1007/s00228-003-0647-6; Linjakumpu T, 2002, J CLIN EPIDEMIOL, V55, P809, DOI 10.1016/S0895-4356(02)00411-0; Linjakumpu T, 2002, INT J GERIATR PSYCH, V17, P874, DOI 10.1002/gps.712; Linton A, 2007, J MANAGE CARE PHARM, V13, P155; NOMESCO, 2004, MED CONS NORD COUNTR; Rajska-Neumann A, 2007, ARCH GERONTOL GERIAT, V44, P303, DOI 10.1016/j.archger.2007.01.040; Rosholm JU, 1997, EUR J CLIN PHARMACOL, V53, P179, DOI 10.1007/s002280050359; Ruiz B, 2008, EUR J CLIN PHARMACOL, V64, P715, DOI 10.1007/s00228-008-0473-y; Saltvedt I, 2005, EUR J CLIN PHARMACOL, V61, P921, DOI 10.1007/s00228-005-0046-2; Sorensen L, 2005, AGE AGEING, V34, P626, DOI 10.1093/ageing/afi202; Steinman MA, 2006, J AM GERIATR SOC, V54, P1516, DOI 10.1111/j.1532-5415.2006.00889.x; Thomas HF, 1999, EUR J CLIN PHARMACOL, V55, P411, DOI 10.1007/s002280050649; Veehof LJG, 2000, FAM PRACT, V17, P261, DOI 10.1093/fampra/17.3.261; Zarowitz BJ, 2005, PHARMACOTHERAPY, V25, P1636, DOI 10.1592/phco.2005.25.11.1636; Ziere G, 2006, BRIT J CLIN PHARMACO, V61, P218, DOI 10.1111/j.1365-2125.2005.02543.x	46	75	80	0	9	ADIS INT LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 1311, NEW ZEALAND	1170-229X			DRUG AGING	Drugs Aging		2009	26	6					493	503				11	Geriatrics & Gerontology; Pharmacology & Pharmacy	Geriatrics & Gerontology; Pharmacology & Pharmacy	478AP	WOS:000268560400006	19591524	
J	Reibman, J; Marmor, M; Filner, J; Fernandez-Beros, ME; Rogers, L; Perez-Perez, GI; Blaser, MJ				Reibman, Joan; Marmor, Michael; Filner, Joshua; Fernandez-Beros, Maria-Elena; Rogers, Linda; Perez-Perez, Guillermo I.; Blaser, Martin J.			Asthma Is Inversely Associated with Helicobacter pylori Status in an Urban Population	PLOS ONE			English	Article								Background: Microbial exposures have been suggested to confer protection from allergic disorders and reduced exposures to gastrointestinal microbiota have been proposed as an explanation for the increase in asthma prevalence. Since the general prevalence of Helicobacter pylori has been decreasing, we hypothesized that H. pylori serostatus would be inversely related to the presence of asthma. Methods: Adults were recruited to participate in the New York University (NYU)/Bellevue Asthma Registry in New York City. Adult asthma cases (N = 318) and controls (N = 208) were identified and serum IgG antibodies to H. pylori whole cell antigens or the immunodominant CagA antigen were measured. Results: As expected, the asthma cases and controls differed with respect to atopy and lung function. Seropositivity to H. pylori or CagA antigen was present in 47.1% of the total case and control study population. Asthma was inversely associated with CagA seropositivity (=OR = 0.57, 95% CI = 0.36-0.89). Median age of onset of asthma (doctor's diagnosis) was older ( 21 years) among individuals with CagA+ strains than among H. pylori-individuals (11 years) (p = 0.006). Conclusion: These data are consistent with the hypothesis that colonization with CagA+ H. pylori strains is inversely associated with asthma and is associated with an older age of asthma onset in an urban population. The data suggest H. pylori as a marker for protection.	[Marmor, Michael; Filner, Joshua; Fernandez-Beros, Maria-Elena; Rogers, Linda; Perez-Perez, Guillermo I.; Blaser, Martin J.] NYU, Sch Med, Dept Med, New York, NY 10003 USA; [Reibman, Joan; Marmor, Michael] NYU, Sch Med, Dept Environm Med, New York, NY USA	Reibman, J (reprint author), NYU, Sch Med, Dept Med, New York, NY 10003 USA.	reibmj01@gcrc.med.nyu.edu		Marmor, Michael/0000-0001-6605-2661; Reibman, Joan/0000-0001-7878-1511; Perez Perez, Guillermo /0000-0002-0131-5798	Colton Family Foundation; Diane Belfer Program in Human Microbial Ecology; Senior Scholar Award of the Ellison Medical Foundation;  [MO 1RR00096];  [ES 000260];  [RO1 GM63270]	MO 1RR00096, ES 000260 (JR, MM), RO1 GM63270 (MB), Colton Family Foundation, The Diane Belfer Program in Human Microbial Ecology, Senior Scholar Award of the Ellison Medical Foundation (MB). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Anderson HR, 2005, BRIT MED J, V330, P1037, DOI 10.1136/bmj.330.7499.1037; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; ATS statement, 1994, AM J RESP CRIT CARE, V152, P1107; BANATVALA N, 1993, J INFECT DIS, V168, P219; Bergman MP, 2004, J EXP MED, V200, P979, DOI 10.1084/jem.20041061; Beswick EJ, 2007, INFECT IMMUN, V75, P4334, DOI 10.1128/IAI.00553-07; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Blaser MJ, 2005, GASTROENTEROLOGY, V128, P1512, DOI 10.1053/j.gastro.2005.03.053; Blaser MJ, 2004, J CLIN INVEST, V113, P321, DOI 10.1172/JCI200420925; BLASER MJ, 1995, CANCER RES, V55, P2111; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; Cassino C, 2000, AM J RESP CRIT CARE, V162, P1423; Chen Y, 2008, J INFECT DIS, V198, P553, DOI 10.1086/590158; Chen Y, 2007, ARCH INTERN MED, V167, P821, DOI 10.1001/archinte.167.8.821; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; Enright PL, 1999, CHEST, V116, P603, DOI 10.1378/chest.116.3.603; Everhart JE, 2000, GASTROENTEROL CLIN N, V29, P559, DOI 10.1016/S0889-8553(05)70130-8; Everhart JE, 2002, CLIN DIAGN LAB IMMUN, V9, P412, DOI 10.1128/CDLI.9.2.412-416.2002; Everhart JE, 2000, J INFECT DIS, V181, P1359, DOI 10.1086/315384; Garantziotis S, 2008, ANNU REV MED, V59, P343, DOI 10.1146/annurev.med.59.061206.112455; Guiney DG, 2003, INFECT IMMUN, V71, P4163, DOI 10.1128/IAI.71.7.4163-4166.2003; Hafsi N, 2004, J IMMUNOL, V173, P1249; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Harding SM, 2005, IMMUNOL ALLERGY CLIN, V25, P131, DOI 10.1016/j.iac.2004.09.006; Harding SM, 1997, CHEST, V111, P1389, DOI 10.1378/chest.111.5.1389; Ishihara S, 2004, J IMMUNOL, V173, P1406; Kiljander TO, 2004, CHEST, V126, P1490, DOI 10.1378/chest.126.5.1490; Kosunen TU, 1997, EPIDEMIOL INFECT, V119, P29, DOI 10.1017/S0950268897007565; KUIPERS EJ, 1995, J NATL CANCER I, V87, P1777, DOI 10.1093/jnci/87.23.1777; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Lundgren A, 2005, INFECT IMMUN, V73, P523, DOI 10.1128/IAI.73.1.523-531.2005; MAI UEH, 1992, J EXP MED, V175, P517, DOI 10.1084/jem.175.2.517; Malaty HM, 2002, LANCET, V359, P931, DOI 10.1016/S0140-6736(02)08025-X; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 1997, BRIT MED J, V314, P999; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; O'Keeffe J, 2008, HELICOBACTER, V13, P1, DOI 10.1111/j.1523-5378.2008.00559.x; Odenbreit S, 2000, SCIENCE, V287, P1497, DOI 10.1126/science.287.5457.1497; Oderda G, 2007, J PEDIATR GASTR NUTR, V45, P301; Peek RM, 2002, NAT REV CANCER, V2, P28, DOI 10.1038/nrc703; Perez-Perez GI, 2002, GUT, V50, P295, DOI 10.1136/gut.50.3.295; RAITALA A, 2005, MOL IMMUNOL; Ramsey CD, 2005, CURR OPIN PULM MED, V11, P14, DOI 10.1097/01.mcp.0000145791.13714.ae; Romero-Gallo J, 2002, CLIN DIAGN LAB IMMUN, V9, P1313, DOI 10.1128/CDLI.9.6.1313-1317.2002; Rowland M, 2006, GASTROENTEROLOGY, V130, P65, DOI 10.1053/j.gastro.2005.11.004; Segal ED, 1999, P NATL ACAD SCI USA, V96, P14559, DOI 10.1073/pnas.96.25.14559; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Sorkness RL, 2008, J APPL PHYSIOL, V104, P394, DOI 10.1152/japplphysiol.00329.2007; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Thjodleifsson B, 2007, SCAND J INFECT DIS, V39, P683, DOI 10.1080/00365540701225736; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572	54	75	78	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	DEC 29	2008	3	12							e4060	10.1371/journal.pone.0004060		6	Multidisciplinary Sciences	Science & Technology - Other Topics	437DI	WOS:000265466000018	19112508	
J	Williams, MA; Rangasamy, T; Bauer, SM; Killedar, S; Karp, M; Kensler, TW; Yamamoto, M; Breysse, P; Biswal, S; Georas, SN				Williams, Marc A.; Rangasamy, Tirumalai; Bauer, Stephen M.; Killedar, Smruti; Karp, Matthew; Kensler, Thomas W.; Yamamoto, Masayuki; Breysse, Patrick; Biswal, Shyam; Georas, Steve N.			Disruption of the transcription factor Nrf2 promotes pro-oxidative dendritic cells that stimulate Th2-like immunoresponsiveness upon activation by ambient particulate matter	JOURNAL OF IMMUNOLOGY			English	Article							HEME OXYGENASE-1 EXPRESSION; EXHAUST PARTICLE CHEMICALS; AIRWAY INFLAMMATION; IN-VIVO; T-CELLS; ALLERGIC INFLAMMATION; COSTIMULATORY MOLECULES; ENHANCES SUSCEPTIBILITY; GLUTATHIONE DEPLETION; CYTOKINE PRODUCTION	Oxidative stress is important in dendritic cell (DC) activation. Environmental particulate matter (PM) directs pro-oxidant activities that may alter DC function. Nuclear erythroid 2 p45-related factor 2 (Nrf2) is a redox-sensitive transcription factor that regulates expression of antioxidant and detoxification genes. Oxidative stress and defective antioxidant responses may contribute to the exacerbations of asthma. We hypothesized that PM would impart differential responses by Nrf2 wild-type DCs as compared with Nrf2(-/-) DCs. We found that the deletion of Nrf2 affected important constitutive functions of both bone marrow-derived and highly purified myeloid lung DCs such as the secretion of inflammatory cytokines and their ability to take up exogenous Ag. Stimulation of Nrf2(-/-) DCs with PM augmented oxidative stress and cytokine production as compared with resting or Nrf2(+/+) DCs. This was associated with the enhanced induction of Nrf2-regulated antioxidant genes. In contrast to Nrf2(+/+) DCs, coincubation of Nrf2(-/-) DCs with PM and the antioxidant N-acetyl cysteine attenuated PM-induced up-regulation of CD80 and CD86. Our studies indicate a previously underappreciated role of Nrf2 in innate immunity and suggest that deficiency in Nrf2-dependent pathways may be involved in susceptibility to the adverse health effects of air pollution in part by promoting Th2 cytokine responses in the absence of functional Nrf2. Moreover, our studies have uncovered a hierarchal response to oxidative stress in terms of costimulatory molecule expression and cytokine secretion in DCs and suggest an important role of heightened oxidative stress in proallergic Th2-mediated immune responses orchestrated by DCs.	[Williams, Marc A.; Rangasamy, Tirumalai; Bauer, Stephen M.; Killedar, Smruti; Karp, Matthew; Georas, Steve N.] Univ Rochester, Sch Med, Div Pulm & Crit Care Med, Rochester, NY 14642 USA; [Williams, Marc A.; Georas, Steve N.] Univ Rochester, Sch Med, Dept Environm Med, Rochester, NY 14642 USA; [Kensler, Thomas W.; Breysse, Patrick; Biswal, Shyam] Johns Hopkins Univ, Sch Med, Dept Environm Hlth Sci, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD 21205 USA; [Biswal, Shyam] Johns Hopkins Univ, Sch Med, Div Pulm & Crit Care Med, Baltimore, MD 21205 USA; [Yamamoto, Masayuki] Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan	Williams, MA (reprint author), Univ Rochester, Sch Med, Div Pulm & Crit Care Med, 601 Elmwood Ave,Box 692, Rochester, NY 14642 USA.	marc_williams@urmc.rochester.edu; steve_georas@urmc.rochester.edu	Yamamoto, Masayuki/A-4873-2010; Kensler, Thomas/D-8686-2014	Kensler, Thomas/0000-0002-6676-261X	National Institute of Environmental Health Sciences (NIEHS); U.S. Environmental Protection Agency [PO1ES09606]; Department of Medicine, University of Rochester School of Medicine and Dentistry; National Institutes of Health (NIH) [R01 HL073952, HL071933, P50 HL084945, CA 94076]; NIH NIEHS [P30 ES03819, P30 ES001247]	This research was supported in pari by a New Investigator Project from the Center for Childhood Asthma in the Urban Environment (funded by National Institute of Environmental Health Sciences (NIEHS) and U.S. Environmental Protection Agency Grant PO1ES09606 to S.N.G. and M.A.W.) as well as by the Department of Medicine, University of Rochester School of Medicine and Dentistry (Rochester, NY). The research was also supported by National Institutes of Health (NIH) Research Grants R01 HL073952 and HL071933 (to S.N.G.), COPD SCCOR P50 HL084945 and CA 94076 (to T.W.K.) and by NIH NIEHS Pilot Project Grants P30 ES03819 and P30 ES001247 (to M.A.W.).	Alavi A, 2003, SCIENCE, V301, P94, DOI 10.1126/science.1082015; Alderman CJJ, 2002, FREE RADICAL BIO MED, V32, P377, DOI 10.1016/S0891-5849(01)00735-3; Angermayr B, 2006, J HEPATOL, V44, P1033, DOI 10.1016/j.jhep.2005.09.021; Berry M, 2007, CURR OPIN PHARMACOL, V7, P279, DOI 10.1016/j.coph.2006.03.001; Blank F, 2007, AM J RESP CELL MOL, V36, P669, DOI 10.1165/rcmb.2006-0234OC; Bleck B, 2006, J IMMUNOL, V176, P7431; Boraschi D, 2006, EUR CYTOKINE NETW, V17, P224; Bureau F, 2002, J ALLERGY CLIN IMMUN, V110, P443, DOI 10.1067/mai.2002.126781; Bussolati B, 2004, BLOOD, V103, P761, DOI 10.1182/blood-2003-06-1974; Chan RCF, 2006, J ALLERGY CLIN IMMUN, V118, P455, DOI 10.1016/j.jaci.2006.06.006; Chauveau C, 2005, BLOOD, V106, P1694, DOI 10.1182/blood-2005-02-0494; Cooper AM, 2007, TRENDS IMMUNOL, V28, P33, DOI 10.1016/j.it.2006.11.002; Cross MJ, 2003, TRENDS BIOCHEM SCI, V28, P488, DOI 10.1016/S0968-0004(03)00193-2; Dominici F, 2005, J TOXICOL ENV HEAL A, V68, P1071, DOI 10.1080/15287390590935932; Eisenbarth SC, 2003, CURR OPIN IMMUNOL, V15, P620, DOI 10.1016/j.coi.2003.09.003; Fernandez M, 2003, BRIT J PHARMACOL, V139, P634, DOI 10.1038/sj.bjp.0705272; Finkelman FD, 2004, J IMMUNOL, V172, P3808; Gilston V, 2001, FREE RADICAL RES, V35, P681, DOI 10.1080/10715760100301201; Hammad H, 2007, ADV IMMUNOL, V93, P265, DOI 10.1016/S0065-2776(06)93007-7; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; Kang HK, 2006, LEUKEMIA LYMPHOMA, V47, P2224, DOI 10.1080/10428190600732236; Kang MJ, 2007, J IMMUNOL, V178, P1948; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Kensler TW, 2007, ANNU REV PHARMACOL, V47, P89, DOI 10.1146/annurev.pharmtox.46.120604.141046; Kidd Parris, 2003, Altern Med Rev, V8, P223; Kim HJ, 2007, J ALLERGY CLIN IMMUN, V119, P1225, DOI 10.1016/j.jaci.2007.01.016; Kroczek R, 2005, J ALLERGY CLIN IMMUN, V116, P906, DOI 10.1016/j.jaci.2005.07.005; Kuppner MC, 2003, BLOOD, V102, P3668, DOI 10.1182/blood-2003-05-1408; Kweon MH, 2006, J BIOL CHEM, V281, P33761, DOI 10.1074/jbc.M604748200; Laden F, 2006, AM J RESP CRIT CARE, V173, P667, DOI 10.1164/rccm.200503-443OC; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; Li N, 2004, J IMMUNOL, V173, P3467; Li N, 2000, J IMMUNOL, V165, P3393; Lich JD, 2006, IMMUNITY, V24, P241, DOI 10.1016/j.immuni.2006.03.004; LOONEY RJ, 1994, J ALLERGY CLIN IMMUN, V93, P476, DOI 10.1016/0091-6749(94)90357-3; Matsue H, 2003, J IMMUNOL, V171, P3010; McKinley L, 2005, CYTOKINE, V32, P178, DOI 10.1016/j.cyto.2005.09.006; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Meylan E, 2006, NATURE, V442, P39, DOI 10.1038/nature04946; Meyts I, 2006, J IMMUNOL, V177, P6460; Mizuashi M, 2005, J INVEST DERMATOL, V124, P579, DOI 10.1111/j.0022-202X.2005.23624.x; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Murata Y, 2002, EUR J IMMUNOL, V32, P2866, DOI 10.1002/1521-4141(2002010)32:10<2866::AID-IMMU2866>3.0.CO;2-V; Nakae S, 2007, J ALLERGY CLIN IMMUN, V119, P680, DOI 10.1016/j.jaci.2006.11.701; O'Garra A, 2000, TRENDS CELL BIOL, V10, P542, DOI 10.1016/S0962-8924(00)01856-0; Ohtani T, 2005, J IMMUNOL, V174, P2412; Otterbein L E, 2000, Am J Physiol Lung Cell Mol Physiol, V279, pL1029; Oyama T, 1998, J IMMUNOL, V160, P1224; Propst SM, 2000, J IMMUNOL, V165, P2214; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Reddy NM, 2007, AM J RESP CELL MOL, V37, P3, DOI 10.1165/rcmb.2007-0004RC; Rutault K, 1999, FREE RADICAL BIO MED, V26, P232, DOI 10.1016/S0891-5849(98)00194-4; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Takahashi A, 2004, CANCER IMMUNOL IMMUN, V53, P543, DOI 10.1007/s00262-003-0466-8; Tang CB, 2001, J ALLERGY CLIN IMMUN, V107, P863, DOI 10.1067/mai.2001.114987; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1127/JCI25790; TRUSH MA, 1978, PHARMACOLOGY, V16, P314, DOI 10.1159/000136787; Tse HM, 2007, J IMMUNOL, V178, P908; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vargaftig BB, 2003, AM J PHYSIOL-LUNG C, V284, pL260, DOI 10.1152/ajplung.00226.2002; Verhasselt V, 1999, J IMMUNOL, V162, P2569; Vermaelen K, 2005, AM J RESP CRIT CARE, V172, P530, DOI 10.1164/rccm.200410.138450; Walters DM, 2002, AM J RESP CELL MOL, V27, P413, DOI 10.1165/rcmb.4844; Williams MA, 1998, J INFECT DIS, V177, P107, DOI 10.1086/513802; WILLIAMS MA, 1995, BRIT J HAEMATOL, V90, P31, DOI 10.1111/j.1365-2141.1995.tb03377.x; Williams MA, 2002, J HEMATOTH STEM CELL, V11, P829, DOI 10.1089/152581602760404630; Williams MA, 2007, J ALLERGY CLIN IMMUN, V119, P488, DOI 10.1064/j.jaci.2006.10.022; Yamashita K, 2006, FASEB J, V20, P776, DOI 10.1096/fj.05-4791fje; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974	75	75	79	1	9	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	OCT 1	2008	181	7					4545	4559				15	Immunology	Immunology	356CG	WOS:000259755700017	18802057	
J	Romieu, I; Barraza-Villarreal, A; Escamilla-Nunez, C; Almstrand, AC; Diaz-Sanchez, D; Sly, PD; Olin, AC				Romieu, Isabelle; Barraza-Villarreal, Albino; Escamilla-Nunez, Consuelo; Almstrand, Ann-Charlotte; Diaz-Sanchez, David; Sly, Peter D.; Olin, Anna-Carin			Exhaled breath malondialdehyde as a marker of effect of exposure to air pollution in children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; clinical immunology; environment; epidemiology; pediatrics	OXIDATIVE STRESS; MEXICO-CITY; DNA-DAMAGE; OZONE EXPOSURE; IN-VIVO; CONDENSATE; LUNG; ANTIOXIDANT; GLUTATHIONE; ALDEHYDES	Background: Assessment of the adverse effects of oxidative stress related to air pollution is limited by the lack of biological markers of dose to the lungs. Objective: We evaluated the use of exhaled breath condensate (EBC) malondialdehyde as a biomarker of exposure to traffic-related pollution in children with asthma as part of a panel study in Mexico City. Methods: Standard spirometry and collection of EBC and nasal lavage were performed. Environmental monitoring sites were located within 5 km of the children's homes and schools. Data were analyzed by using generalized estimating equations. Results: A total of 480 samples of malondialdehyde were obtained from 107 patients with asthma, with a median level of 18.7 (interquartile range [IQR], 12.4-28.7) nmol. Ambient particulates less than 2.5 mu g/m(3) and ozone levels on the day of sampling were significantly associated with higher malondialdehyde levels. A 14.2-mu g/m(3) (IQR) increase in 8-hour moving average particulates less than 2.5 mu g/m(3) in size was associated with a 1.12-nmol increase in malondialdehyde and 4 15.9-ppb (IQR) increase in 8-hour moving average ozone with a 1.16-nmol increase in malondialdehyde. Malondialdehyde levels were inversely associated with forced vital capacity and FEV(1) and positively associated with IL-8 levels in nasal lavage. Conclusion: Exhaled breath condensate malondialdehyde was related to both air pollution exposure and changes in lung function and inflammatory markers.	[Romieu, Isabelle; Barraza-Villarreal, Albino; Escamilla-Nunez, Consuelo] Inst Nacl Salud Publ, Cuernavaca 62508, Morelos, Mexico; [Almstrand, Ann-Charlotte; Olin, Anna-Carin] Sahlgrens Univ Hosp, Dept Occupat & Environm Med, S-41345 Gothenburg, Sweden; [Diaz-Sanchez, David] Univ Calif Los Angeles, Los Angeles, CA USA; [Sly, Peter D.] Curtin Univ Technol, WHO, Collaborating Ctr Res Child Environm Hlth, Perth, WA 6001, Australia; [Sly, Peter D.] Univ Western Australia, Ctr Child Hlth Res, Perth, WA 6009, Australia	Romieu, I (reprint author), Inst Nacl Salud Publ, 655 Avendia Univ,Col Santa Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.	iromieu@correo.insp.mx	Sly, Peter/F-1486-2010	Sly, Peter/0000-0001-6305-2201			ANEMIYA T, 1973, ECONOMETRICA, V41, P997; Arbak P, 2004, J OCCUP HEALTH, V46, P281, DOI 10.1539/joh.46.281; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Borm PJA, 2007, OCCUP ENVIRON MED, V64, P73, DOI 10.1136/oem.2006.029090; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; BROWN RK, 1994, PEDIATR RES, V36, P487, DOI 10.1203/00006450-199410000-00013; Corradi M, 2003, AM J RESP CRIT CARE, V167, P395, DOI 10.1164/rccm.200206-507OC; Frampton MW, 1999, AM J RESP CRIT CARE, V159, P1134; Goldoni M, 2004, ENVIRON HEALTH PERSP, V112, P1293, DOI 10.1289/ehp.7108; Halliwell B, 2000, AM J CLIN NUTR, V72, P1082; Isik B, 2005, INHAL TOXICOL, V17, P695, DOI 10.1080/08958370500189883; Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Kostikas K, 2002, AM J RESP CRIT CARE, V165, P1364, DOI 10.1164/rccm.200111-068OC; Larstad M, 2002, J CHROMATOGR B, V766, P107, DOI 10.1016/S0378-4347(01)00437-6; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; LIANG KY, 1986, BIOMETRIKA, V73, P132; Marnett LJ, 2002, TOXICOLOGY, V181, P219, DOI 10.1016/S0300-483X(02)00448-1; Orman A, 2005, TOXICOLOGY, V207, P15, DOI 10.1016/j.tox.2004.07.021; OSIAS PP, 2004, PEDIATR ALLERGY IMMU, V15, P4; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Perez-Padilla R, 2003, PEDIATR PULM, V35, P177, DOI 10.1002/ppul.10232; Profita M, 2006, J ALLERGY CLIN IMMUN, V118, P1068, DOI 10.1016/j.jaci.2006.07.028; RAMIREZAGUILAR M, 2004, PERSONAL EXPOSURE AS, P26; Risom L, 2005, MUTAT RES-FUND MOL M, V592, P119, DOI 10.1016/j.mrfmmm.2005.06.012; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Romieu I, 2004, THORAX, V59, P8; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Sorensen M, 2003, ENVIRON HEALTH PERSP, V111, P161, DOI 10.1289/ehp.5646; *STAT CORP, 1996, STAT SOFTW REL 5 0; Takizawa Hajime, 2004, Curr Opin Allergy Clin Immunol, V4, P355, DOI 10.1097/00130832-200410000-00005; *US DEP HHS NIH NH, 1998, NIH PUBL; Vega E, 2004, J AIR WASTE MANAGE, V54, P786; Zar JH, 1996, BIOSTATISTICAL ANAL	34	75	78	3	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2008	121	4					903	909		10.1016/j.jaci.2007.12.004		7	Allergy; Immunology	Allergy; Immunology	286YY	WOS:000254884000014	18234317	
J	Van Overtvelt, L; Wambre, E; Maillere, B; von Hofe, E; Louise, A; Balazuc, AM; Bohle, B; Ebo, D; Leboulaire, C; Garcia, G; Moingeon, P				Van Overtvelt, Laurence; Wambre, Erik; Maillere, Bernard; von Hofe, Eric; Louise, Anne; Balazuc, Anne Marie; Bohle, Barbara; Ebo, Didier; Leboulaire, Christophe; Garcia, Gilles; Moingeon, Philippe			Assessment of Bet v 1-specific CD4(+) T cell responses in allergic and nonallergic individuals using MHC class II peptide tetramers	JOURNAL OF IMMUNOLOGY			English	Article							BIRCH POLLEN ALLERGEN; BET-V-I; SUBLINGUAL IMMUNOTHERAPY; REGULATORY-CELLS; IMMUNE DEVIATION; DENDRITIC CELLS; GRASS-POLLEN; TGF-BETA; MECHANISMS; INDUCTION	In this study, we used HLA-DRB1*0101, DRB1*0401, and DRBI*1501 peptide tetramers combined with cytokine surface capture assays to characterize CD4(+) T cell responses against the immunodominant T cell epitope (peptide 141-155) from the major birch pollen allergen Bet v 1, in both healthy and allergic individuals. We could detect Bet v I-specific T cells in the PBMC of 20 birch pollen allergic patients, but also in 9 of 9 healthy individuals tested. Analysis at a single-cell level revealed that allergen-specific CD4(+) T cells from healthy individuals secrete IFN-gamma and IL-10 in response to the allergen, whereas cells from allergic patients are bona fide Th2 cells (producing mostly IL-5, some IL-10, but no IFN-gamma), as corroborated by patterns of cytokines produced by T cell clones. A fraction of Bet v 1-specific cells isolated from healthy, but not allergic, individuals also expresses CTLA-4, glucocorticoid-induced TNF receptor, and Foxp 3, indicating that they represent regulatory T cells. In this model of seasonal exposure to allergen, we also demonstrate the tremendous dynamics of T cell responses in both allergic and nonallergic individuals during the peak pollen season, with an expansion of Bet v 1-specific precursors from 10(-6) to 10(-3) among circulating CD4(+) T lymphocytes. Allergy vaccines should be designed to recapitulate such naturally protective Th1/regulatory T cell responses observed in healthy individuals.	[Van Overtvelt, Laurence; Wambre, Erik; Moingeon, Philippe] Stallergenes SA, Rech & Dev, F-92183 Antony, France; [Maillere, Bernard] Commissariat Energie Atom, Serv Ingn Mol Prot, Gif Sur Yvette, France; [Louise, Anne; Balazuc, Anne Marie] Inst Pasteur, Paris, France; [Leboulaire, Christophe] Beckman Coulter, Marseille, France; [Garcia, Gilles] Hop Antoine Beclere, Dept Pneumol, Clamart, France; [von Hofe, Eric] Antigen Express, Worcester, MA 01605 USA; [Bohle, Barbara] Med Univ Vienna, Dept Pathophysiol, Vienna, Austria; [Ebo, Didier] Univ Antwerp, Dept Immunol Allergy & Rheumatology, Antwerp, Belgium	Moingeon, P (reprint author), Stallergenes SA, Rech & Dev, 6 Rue Alexis Tocqueville, F-92183 Antony, France.	pmoingeon@stallergenes.fr	EBO, Didier/H-4894-2016	EBO, Didier/0000-0003-0672-7529			Ahern DJ, 2005, CURR OPIN ALLERGY CL, V5, P531, DOI 10.1097/01.all.0000191239.20632.ab; Akdis CA, 2006, CHEM IMMUNOL ALLERGY, V91, P195; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; AKKERDAAS JH, 1995, ALLERGY, V50, P215, DOI 10.1111/j.1398-9995.1995.tb01136.x; Bacchetta R, 2007, J ALLERGY CLIN IMMUN, V120, P227, DOI 10.1016/j.jaci.2007.06.023; Bakker AH, 2005, CURR OPIN IMMUNOL, V17, P428, DOI 10.1016/j.coi.2005.06.008; Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Bateman EAL, 2006, J ALLERGY CLIN IMMUN, V118, P1350, DOI 10.1016/j.jaci.2006.07.040; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bullens DMA, 2005, CLIN EXP ALLERGY, V35, P1535, DOI 10.1111/j.1365-2222.2005.02352.x; Campbell J. Darren, 2004, FASEB Journal, V18, P329; Castelli FA, 2002, J IMMUNOL, V169, P6928; Ciprandi G, 2005, ANN ALLERG ASTHMA IM, V95, P38; Ciprandi G, 2007, ALLERGY ASTHMA PROC, V28, P40, DOI 10.2500/aap.2007.28.2974; Cools N, 2007, J LEUKOCYTE BIOL, V82, P1365, DOI 10.1189/jlb.0307166; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Dormann D, 1997, INT ARCH ALLERGY IMM, V114, P272; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; EBNER C, 1995, INT ARCH ALLERGY IMM, V107, P183; El Biaze M, 2003, ALLERGY, V58, P844, DOI 10.1034/j.1398-9995.2003.00282.x; Fourneau JM, 2004, J IMMUNOL METHODS, V285, P253, DOI 10.1016/j.jim.2003.11.011; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Hakansson L, 1997, J ALLERGY CLIN IMMUN, V99, P551, DOI 10.1016/S0091-6749(97)70084-8; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V116, P213, DOI 10.1016/j.jaci.2005.04.019; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kallinteris NL, 2006, EXPERT OPIN BIOL TH, V6, P1311, DOI 10.1517/14712598.6.12.1311; Kinnunen T, 2007, J ALLERGY CLIN IMMUN, V119, P965, DOI 10.1016/j.jaci.2007.01.011; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Macaubas C, 2006, J IMMUNOL, V176, P5069; McMichael AJ, 1999, J CLIN INVEST, V104, P1669, DOI 10.1172/JCI8943; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Nocentini G, 2007, EUR J IMMUNOL, V37, P1165, DOI 10.1002/eji.200636933; Rimaniol AC, 2003, CLIN EXP IMMUNOL, V132, P76, DOI 10.1046/j.1365-2249.2003.02118.x; Romagnani S, 2006, ALLERGY, V61, P3, DOI 10.1111/j.1398-9995.2006.01005; Romagnani S, 2007, J ALLERGY CLIN IMMUN, V119, P1511, DOI 10.1016/j.jaci.2007.04.005; Sakaguchi S, 2007, SCIENCE, V317, P627, DOI 10.1126/science.1142331; Samoilova EB, 1998, INT IMMUNOL, V10, P491, DOI 10.1093/intimm/10.4.491; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Scott-Taylor TH, 2005, CLIN EXP ALLERGY, V35, P1473, DOI 10.1111/j.1365-2222.2005.02355.x; Scriba TJ, 2005, J IMMUNOL, V175, P6334; Stock P, 2006, CURR OPIN ALLERGY CL, V6, P12, DOI 10.1097/01.all.0000200502.69672.44; SWOBODA I, 1995, J BIOL CHEM, V270, P2607; Taylor A, 2006, IMMUNOLOGY, V117, P433, DOI 10.1111/j.1365-2567.2006.02321.x; Texier C, 2000, J IMMUNOL, V164, P3177; Till S, 1997, J ALLERGY CLIN IMMUN, V99, P563, DOI 10.1016/S0091-6749(97)70085-X; Umetsu DT, 2006, IMMUNOL REV, V212, P238, DOI 10.1111/j.0105-2896.2006.00413.x; van Oosterhout AJM, 2005, EUR RESPIR J, V26, P918, DOI 10.1183/09031936.05.00011205; Verhagen J, 2005, INT REV IMMUNOL, V24, P533, DOI 10.1080/08830180500371173; WALKER C, 1991, J IMMUNOL, V146, P1829; Wambre E, 2008, INT ARCH ALLERGY IMM, V146, P99, DOI 10.1159/000113513; Yamazaki S, 2007, BLOOD, V110, P4293, DOI 10.1182/blood-2007-05-088831; Yang JB, 2006, CLIN IMMUNOL, V120, P21, DOI 10.1016/j.clim.2006.03.008; Yi HF, 2006, CELL MOL IMMUNOL, V3, P189; ZETTERQUIST H, 1992, HUM IMMUNOL, V34, P64, DOI 10.1016/0198-8859(92)90086-3	57	75	75	1	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	APR 1	2008	180	7					4514	4522				9	Immunology	Immunology	324GT	WOS:000257506700022	18354173	
J	Zhao, ZH; Zhang, Z; Wang, ZH; Ferm, M; Liang, YL; Norback, D				Zhao, Zhuohui; Zhang, Zheng; Wang, Zhuanhua; Ferm, Martin; Liang, Yanling; Norback, Dan			Asthmatic symptoms among pupils in relation to winter indoor and outdoor air pollution in schools in Taiyuan, China	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; asthma; China; formaldehyde; indoor; nitrogen dioxide; ozone; outdoor; school; sulfur dioxide	SICK BUILDING SYNDROME; VOLATILE ORGANIC-COMPOUNDS; RESPIRATORY SYMPTOMS; ALLERGEN LEVELS; HONG-KONG; HEALTH; PREVALENCE; SMOKING; ENVIRONMENT; POLLUTANTS	BACKGROUND: There are few studies on associations between children's respiratory heath and air pollution in schools in China. The industrial development and increased traffic may affect the indoor exposure to air pollutants in school environment. Moreover, there is a need to study respiratory effects of environmental tobacco smoke (ETS) and emissions from new building materials in homes in China. OBJECTIVES: We studied the associations between pupils' asthmatic symptoms and indoor and Outdoor air pollution in schools, as well as selected home exposures, in a coal-burning city in north China. METHODS: A questionnaire survey was administered to pupils (11-15 years of age) in 10 schools in urban Taiyuan, collecting data on respiratory health and selected home environmental factors. Indoor and outdoor school air pollutants and climate factors were measured in winter. RESULTS: A total of 1,993 pupils (90.2%) participated; 1.8% had cumulative asthma, 8.4% wheezing, 29.8% had daytime attacks of breathlessness, The indoor average concentrations of sulfur dioxide, nitrogen dioxide, ozone, and formaldehyde by class were 264.8, 39.4, 10.1, and 2.3 mu g/m(3), respectively. Outdoor levels were two to three times higher. Controlling for possible confounders, either wheeze or daytime or nocturnal attacks of breathlessness were positively associated with SO2, NO2, or formaldehyde. In addition, ETS and new furniture at home were risk factors for wheeze, daytime breathlessness, and respiratory infections. CONCLUSIONS: Indoor chemical air pollutants of mainly outdoor origin could be risk factors for pupils' respiratory symptoms at school, and home exposure to ETS and chemical emissions from new furniture could affect pupils' respiratory health.	[Zhao, Zhuohui; Norback, Dan] Univ Uppsala Hosp, Dept Occupat & Environm Med, SE-75185 Uppsala, Sweden; [Zhao, Zhuohui; Norback, Dan] Uppsala Univ, SE-75185 Uppsala, Sweden; [Zhang, Zheng; Wang, Zhuanhua] Shanxi Univ, Inst Biotechnol, Taiyuan, Shanxi Province, Peoples R China; [Liang, Yanling] Inst High Sch Student Hlth Care, Taiyuan, Shanxi Province, Peoples R China	Zhao, ZH (reprint author), Univ Uppsala Hosp, Dept Occupat & Environm Med, SE-75185 Uppsala, Sweden.	zhuohui.zhao@medsci.uu.se		Norback, Dan/0000-0002-5174-6668			Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Aunan K, 2004, SCI TOTAL ENVIRON, V329, P3, DOI 10.1016/j.scitotenv.2004.03.008; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; 蔡丽, 2002, [卫生毒理学杂志, Journal of Health Toxicology], V16, P48; Chen BH, 2004, TOXICOLOGY, V198, P291, DOI 10.1016/j.tox.2004.02.005; CHEN Y, 1988, INT J EPIDEMIOL, V17, P348, DOI 10.1093/ije/17.2.348; Chen Yu-zhi, 2004, Zhonghua Jiehe He Huxi Zazhi, V27, P112; Cheng Yibin, 2002, Wei Sheng Yan Jiu, V31, P266; Cooley JD, 1998, OCCUP ENVIRON MED, V55, P579; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Garcia-Marcos L, 1999, PEDIATR ALLERGY IMMU, V10, P96, DOI 10.1034/j.1399-3038.1999.00024.x; GOLDSTEIN IF, 1986, ENVIRON RES, V40, P332, DOI 10.1016/S0013-9351(86)80108-6; HOLGUIN F, 2007, AM J RESP CRIT CARE, DOI DOI 10.1164/RCCM.200611-16160C; Hugg TT, 2008, EUR J PUBLIC HEALTH, V18, P55, DOI 10.1093/eurpub/ckm053; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Kim JL, 2007, INDOOR AIR, V17, P122, DOI 10.1111/j.1600-0668.2006.00460.x; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kim S, 2005, INDOOR AIR, V15, P317, DOI 10.1111/j.1600-0668.2005.00368.x; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Lee SC, 2000, CHEMOSPHERE, V41, P109, DOI 10.1016/S0045-6535(99)00396-3; Mendell MJ, 2005, INDOOR AIR, V15, P27, DOI 10.1111/j.1600-0668.2004.00320.x; Mestl HES, 2003, AIR QUALITY ESTIMATE; Mi YH, 2006, INDOOR AIR, V16, P454, DOI 10.1111/j.1600-0668.2006.00439.x; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; NORBACK D, 1990, BRIT J IND MED, V47, P733; Norback Dan, 1992, INDOOR AIR, V2, P58, DOI 10.1111/j.1600-0668.1992.07-21.x; Ooi PL, 1998, OCCUP ENVIRON MED, V55, P188; Qian Z, 2007, INDOOR AIR, V17, P135, DOI 10.1111/j.1600-0668.2006.00463.x; RASBABSH J, 2005, USERS GUIDE MLWIN VE; Schneider D, 2001, ARCH ENVIRON HEALTH, V56, P103; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Sundell J, 1996, SCAND J WORK ENV HEA, V22, P5; *TAIYUAN URB PLANN, 2007, URB TRAFF PLANN MAP; Tanaka K, 2007, ANN EPIDEMIOL, V17, P1004, DOI 10.1016/j.annepidem.2007.07-108; Venners SA, 2001, AM J RESP CRIT CARE, V164, P973; Watts J, 2006, LANCET, V368, P719, DOI 10.1016/S0140-6736(06)69267-2; World Health Organization (WHO), 1987, WHO REG PUBL EUR SER, V23; WHO, 2005, WHO AIR QUAL GUID GL; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Wilkins CK, 2001, ENVIRON HEALTH PERSP, V109, P937, DOI 10.2307/3454995; Yang GH, 1999, JAMA-J AM MED ASSOC, V282, P1247, DOI 10.1001/jama.282.13.1247; Zhang YH, 2006, ENVIRON HEALTH PERSP, V114, P1227, DOI 10.1289/ehp.9014; ZHAO R, 1991, Zhonghua Yufang Yixue Zazhi, V25, P149; Zhao ZH, 2006, INDOOR AIR, V16, P404, DOI 10.1111/j.1600-0668.2006.00433.x	48	75	79	3	45	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2008	116	1					90	97		10.1289/ehp.10576		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	248GZ	WOS:000252142100030	18197305	
J	Shore, SA				Shore, Stephanie A.			Obesity and asthma: lessons from animal models	JOURNAL OF APPLIED PHYSIOLOGY			English	Review						mice; leptin; adiponectin; tumor necrosis factor-alpha; interleukin-6; adipokines	BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; INTERLEUKIN-6 RECEPTOR GENE; INDUCED AIRWAY INFLAMMATION; INDUCED LUNG INFLAMMATION; APPARENTLY HEALTHY-MEN; EMERGENCY-ROOM VISITS; ACUTE-PHASE REACTANTS; ACUTE OZONE EXPOSURE; DIET-INDUCED OBESITY	Epidemiological data indicate that obesity is a risk factor for asthma. These data are supported by observations in several murine models of obesity. Ob/ob, db/db, and Cpe(fat) mice each exhibit innate airway hyperresponsiveness, a characteristic feature of asthma. These mice also respond more vigorously to common asthma triggers, including ozone. Here we discuss the implications of these data with respect to several mechanisms proposed to explain the relationship between obesity and asthma: 1) common etiologies; 2) comorbidities; 3) mechanical factors; and 4) adipokines. We focus on the role of adipokines, especially TNF-alpha, IL-6, leptin, and adiponectin. Understanding the mechanistic basis for the relationship between obesity and asthma may lead to novel therapeutic strategies for treatment of the obese asthmatic subject.	Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, Boston, MA 02115 USA	Shore, SA (reprint author), Harvard Univ, Sch Publ Hlth, Program Mol & Integrat Physiol Sci, 665 Huntington Ave, Boston, MA 02115 USA.	sshore@hsph.harvard.edu			NHLBI NIH HHS [HL-33009]; NIEHS NIH HHS [ES-00002, ES-013307]		Akerman MJH, 2004, J ASTHMA, V41, P521, DOI 10.1081/JAS-120037651; Al-Shawwa B, 2006, J ASTHMA, V43, P231, DOI 10.1080/02770900600567056; Bastard JP, 2006, EUR CYTOKINE NETW, V17, P4; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Beckett WS, 2001, AM J RESP CRIT CARE, V164, P2045; Bennett WD, 2006, P AM THORAC SOC, V3, pA550; Berg AH, 2005, CIRC RES, V96, P939, DOI 10.1161/01.RES.0000163635.62927.34; Bergen HT, 2002, AM J RESP CELL MOL, V27, P71; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V115, P1102, DOI 10.1016/j.jaci.2005.03.018; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Breslow MJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE443; Bryson JM, 1999, AM J PHYSIOL-ENDOC M, V276, pE358; Caldefie-Chezet F, 2001, J LEUKOCYTE BIOL, V69, P414; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Campfield LA, 1998, SCIENCE, V280, P1383, DOI 10.1126/science.280.5368.1383; Celedon JC, 2001, AM J RESP CRIT CARE, V164, P1835; Chae CU, 2001, HYPERTENSION, V38, P399; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chinn S, 2002, THORAX, V57, P1028, DOI 10.1136/thorax.57.12.1028; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537; COLEMAN DL, 1990, J HERED, V81, P424; Combs TP, 2001, J CLIN INVEST, V108, P1875, DOI 10.1172/JCI14120; Considine RV, 1997, INT J BIOCHEM CELL B, V29, P1255, DOI 10.1016/S1357-2725(97)00050-2; D'Angelo E, 2004, J APPL PHYSIOL, V97, P260, DOI 10.1152/japplphysiol.01175.2003; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Engeli S, 2003, DIABETES, V52, P942, DOI 10.2337/diabetes.52.4.942; Esteve E, 2006, CLIN ENDOCRINOL, V65, P88, DOI 10.1111/j.1365-2265.2006.02553.x; Fain JN, 2004, ENDOCRINOLOGY, V145, P2273, DOI 10.1210/en.2003-1336; Fauroux B, 2000, PEDIATR PULM, V30, P41; Field AE, 2001, ARCH INTERN MED, V161, P1581, DOI 10.1001/archinte.161.13.1581; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Fredberg JJ, 2000, J ALLERGY CLIN IMMUN, V106, P615, DOI 10.1067/mai.2000.109429; Fricker LD, 1996, J BIOL CHEM, V271, P30619; Fukuhara A, 2005, SCIENCE, V307, P426, DOI 10.1126/science.1097243; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; Grunfeld C, 1996, J CLIN INVEST, V97, P2152, DOI 10.1172/JCI118653; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Gump A, 2001, J APPL PHYSIOL, V90, P2306; Gunnbjomsdottir MI, 2004, EUR RESPIR J, V24, P116, DOI 10.1183/09031936.04.00042603; Hakala K, 2000, CHEST, V118, P1315, DOI 10.1378/chest.118.5.1315; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hoshino M, 2001, J ALLERGY CLIN IMMUN, V107, P1034, DOI 10.1067/mai.2001.115626; Hosoi T, 2002, BRAIN RES, V949, P139, DOI 10.1016/S0006-8993(02)02974-8; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Houstis N, 2006, NATURE, V440, P944, DOI 10.1038/nature04634; Huber SA, 1999, ARTERIOSCL THROM VAS, V19, P2364; Ikemoto S, 1996, METABOLISM, V45, P1539, DOI 10.1016/S0026-0495(96)90185-7; Ishii M, 2003, P NATL ACAD SCI USA, V100, P10540, DOI 10.1073/pnas.1334189100; Jackson MB, 2006, CLIN SCI, V110, P143, DOI 10.1042/CS20050243; Jenkins JB, 2006, PHYSIOL BEHAV, V87, P255, DOI 10.1016/j.physbeh.2005.10.010; Johnston CJ, 1999, EXP LUNG RES, V25, P81, DOI 10.1080/019021499270448; Johnston CJ, 2000, INHAL TOXICOL, V12, P205; Johnston RA, 2006, AM J PHYSIOL-REG I, V290, pR126, DOI 10.1152/ajpregu.00306.2005; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL390, DOI 10.1152/ajplung.00007.2004; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL61, DOI 10.1152/ajplung.00101.2004; Johnston RA, 2006, P AM THORAC SOC, V3, pA528; Johnston RA, 2007, J APPL PHYSIOL, V102, P149, DOI 10.1152/japplphysiol.00300.2006; Kim J, 2006, CLIN EXP ALLERGY, V36, P122, DOI 10.1111/j.1365-2222.2005.02407.x; KIRKHAM P, 2000, PHARMACOL THERAPEUT, V111, P476; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; KOMAKULA S, 2005, P AM THORAC SOC, V2, pA771; Lacourse KA, 1998, FEBS LETT, V436, P61, DOI 10.1016/S0014-5793(98)01099-0; Lang JE, 2006, P AM THORAC SOC, V3, pA821; Laposky AD, 2006, AM J PHYSIOL-REG I, V290, pR894, DOI 10.1152/ajpreju.00304.2005; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Leiter EH, 2006, ENDOCRINOLOGY, V147, P919, DOI 10.1210/en.2005-0839; Leiter EH, 2004, DIABETES, V53, pS4, DOI 10.2337/diabetes.53.2007.S4; Leiter EH, 1997, DIABETES REV, V5, P131; LI ZY, 1992, AM J PHYSIOL, V263, pL723; Libinaki R, 1999, IUBMB LIFE, V48, P109, DOI 10.1080/713803473; Lin Y, 2001, J BIOL CHEM, V276, P42077, DOI 10.1074/jbc.M107101200; Litonjua AA, 2002, THORAX, V57, P581, DOI 10.1136/thorax.57.7.581; Loffreda S, 1998, FASEB J, V12, P57; Lollmann B, 1997, BIOCHEM BIOPH RES CO, V238, P648, DOI 10.1006/bbrc.1997.7205; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; MAFFEI M, 1995, NAT MED, V1, P1155, DOI 10.1038/nm1195-1155; Martin-Romero C, 2000, CELL IMMUNOL, V199, P15, DOI 10.1006/cimm.1999.1594; MATTSON MP, 1992, EXP GERONTOL, V27, P29, DOI 10.1016/0531-5565(92)90027-W; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Mohamed-Ali V, 1999, AM J PHYSIOL-ENDOC M, V277, pE971; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NISHINA PM, 1994, METABOLISM, V43, P554, DOI 10.1016/0026-0495(94)90195-3; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; Noviski N, 1999, J APPL PHYSIOL, V86, P202; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; O'Donnell CP, 1999, AM J RESP CRIT CARE, V159, P1477; Opara EC, 1996, J NUTR, V126, P273; Ouchi N, 2000, CIRCULATION, V102, P1296; Pacifico L, 2006, EUR J ENDOCRINOL, V154, P691, DOI 10.1530/eje.1.02138; Pajvani UB, 2005, NAT MED, V11, P797, DOI 10.1038/nm1262; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pradhan AD, 2001, JAMA-J AM MED ASSOC, V286, P327, DOI 10.1001/jama.286.3.327; Reifsnyder PC, 2002, DIABETES, V51, P825, DOI 10.2337/diabetes.51.3.825; Ridker PM, 2000, CIRCULATION, V101, P1767; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; RIVERASANCHEZ YM, 2004, AM J RESP CRIT CARE, V169, pA762; Rose-John S, 2006, J LEUKOCYTE BIOL, V80, P227, DOI 10.1189/jlb.1105674; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Sahly I, 1998, HUM MOL GENET, V7, P1437, DOI 10.1093/hmg/7.9.1437; SAMPSON MG, 1983, J APPL PHYSIOL, V55, P1269; Scherer PE, 2006, DIABETES, V55, P1537, DOI 10.2337/db06-0263; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; Serra A, 2006, CLIN NUTR, V25, P400, DOI 10.1016/j.clnu.2005.11.014; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P925, DOI 10.1016/j.jaci.2005.01.064; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2000, J APPL PHYSIOL, V88, P2023; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Shore SA, 2006, CURR OPIN PHARMACOL, V6, P230, DOI 10.1016/j.coph.2006.01.004; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Silha JV, 2005, INT J OBESITY, V29, P1308, DOI 10.1038/sj.ijo.0802987; Simard B, 2004, OBES SURG, V14, P1381, DOI 10.1381/0960892042584021; Skilton MR, 2006, INT J OBESITY, V30, P1041, DOI 10.1038/sj.ijo.0803397; Sood A, 2006, THORAX, V61, P300, DOI 10.1136/thx.2004.031468; Spivak H, 2005, AM J SURG, V189, P27, DOI 10.1016/j.amjsurg.2004.06.038; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; SURWIT RS, 1995, METABOLISM, V44, P645, DOI 10.1016/0026-0495(95)90123-X; Takahashi K, 2003, J BIOL CHEM, V278, P46654, DOI 10.1074/jbc.M309895200; Tanaka H, 2003, P NATL ACAD SCI USA, V100, P6251, DOI 10.1073/pnas.0837789100; Tankersley C, 1996, J APPL PHYSIOL, V81, P716; Tankersley CG, 1998, J APPL PHYSIOL, V85, P2261; Tartaglia LA, 1997, J BIOL CHEM, V272, P6093; Teramoto S, 2003, CIRCULATION, V107, pE40, DOI 10.1161/01.CIR.0000053956.46188.5F; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; Tsuchiya T, 1999, EUR J PHARMACOL, V365, P273, DOI 10.1016/S0014-2999(98)00884-X; van der Veer E, 2005, CIRC RES, V97, P25, DOI 10.1161/01.RES.0000173298.38808.27; VanHeek M, 1997, J CLIN INVEST, V99, P385, DOI 10.1172/JCI119171; Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280; Vincent HK, 2006, INT J OBESITY, V30, P400, DOI 10.1038/sj.ijo.0803177; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; Weisberg SP, 2003, J CLIN INVEST, V112, P1796, DOI 10.1172/JCI200319246; Weiss ST, 2005, NAT IMMUNOL, V6, P537, DOI 10.1038/ni0605-537; Weiss ST, 2004, AM J RESP CRIT CARE, V169, P963, DOI 10.1164/rccm.200303-403WS; Weister MJ, 1987, Toxicol. Appl. Pharmacol, V89, P429; Wolford JK, 2003, MOL GENET METAB, V80, P338, DOI 10.1016/j.ymgme.2003.07.003; Wulster-Radcliffe MC, 2004, BIOCHEM BIOPH RES CO, V316, P924, DOI 10.1016/j.bbrc.2004.02.130; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; Yamauchi T, 2003, J BIOL CHEM, V278, P2461, DOI 10.1074/jbc.M209033200; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; YAP JCH, 1995, J APPL PHYSIOL, V79, P1199; Yeh YF, 2001, INT ARCH ALLERGY IMM, V125, P329, DOI 10.1159/000053834; Yokota T, 2000, BLOOD, V96, P1723; You TJ, 2004, J CLIN ENDOCR METAB, V89, P1739, DOI 10.1210/jc.2003-031310; Yu M, 2002, TOXICOL SCI, V68, P488, DOI 10.1093/toxsci/68.2.488; Zaldivar F, 2006, INT J OBESITY, V30, P906, DOI 10.1038/sj.ijo.0803227; ZHANG LY, 1995, EXP LUNG RES, V21, P503, DOI 10.3109/01902149509031755; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	157	75	81	0	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	FEB	2007	102	2					516	528		10.1152/japplphysiol.00847.2006		13	Physiology; Sport Sciences	Physiology; Sport Sciences	133SM	WOS:000244033500006	17053103	
J	You, DH; Becnel, D; Wang, K; Ripple, M; Daly, M; Cormier, SA				You, Dahui; Becnel, David; Wang, Kai; Ripple, Michael; Daly, Melissa; Cormier, Stephania A.			Exposure of neonates to Respiratory Syncytial Virus is critical in determining subsequent airway response in adults	RESPIRATORY RESEARCH			English	Article							BRONCHIOLITIS; INFECTION; INFANCY; DISEASE; ALLERGY; ASTHMA; AGE; HYPERRESPONSIVENESS; INFLAMMATION; ENHANCEMENT	Background: Respiratory syncytial virus (RSV) is the most common cause of acute bronchiolitis in infants and the elderly. Furthermore, epidemiological data suggest that RSV infection during infancy is a potent trigger of subsequent wheeze and asthma development. However, the mechanism by which RSV contributes to asthma is complex and remains largely unknown. A recent study indicates that the age of initial RSV infection is a key factor in determining airway response to RSV rechallenge. We hypothesized that severe RSV infection during neonatal development significantly alters lung structure and the pulmonary immune micro-environment; and thus, neonatal RSV infection is crucial in the development of or predisposition to allergic inflammatory diseases such as asthma. Methods: To investigate this hypothesis the present study was conducted in a neonatal mouse model of RSV-induced pulmonary inflammation and airway dysfunction. Seven-day-old mice were infected with RSV (2 x 10(5) TCID50/g body weight) and allowed to mature to adulthood. To determine if neonatal RSV infection predisposed adult animals to enhanced pathophysiological responses to allergens, these mice were then sensitized and challenged with ovalbumin. Various endpoints including lung function, histopathology, cytokine production, and cellularity in bronchoalveolar lavage were examined. Results: RSV infection in neonates alone led to inflammatory airway disease characterized by airway hyperreactivity, peribronchial and perivascular inflammation, and subepithelial fibrosis in adults. If early RSV infection was followed by allergen exposure, this pulmonary phenotype was exacerbated. The initial response to neonatal RSV infection resulted in increased TNF-alpha levels in bronchoalveolar lavage. Interestingly, increased levels of IL-13 and mucus hyperproduction were observed almost three months after the initial infection with RSV. Conclusion: Neonatal RSV exposure results in long term pulmonary inflammation and exacerbates allergic airways disease. The early increase in TNF-alpha in the bronchoalveolar lavage implicates this inflammatory cytokine in orchestrating these events. Finally, the data presented emphasize IL-13 and TNF-alpha as potential therapeutic targets for treating RSV induced-asthma.	Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA	Cormier, SA (reprint author), Louisiana State Univ, Dept Biol Sci, Baton Rouge, LA 70803 USA.	dyou1@lsu.edu; dbecne1@lsu.edu; kwang@lsu.edu; mrippl1@lsu.edu; mdaly2@lsu.edu; scormier@lsu.edu			NCRR NIH HHS [P20 RR020159, P20 RR020159-020003, P20 RR020159-037537, P20 RR020159-047695]		Becnel D, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-122; Bell S, 2000, LANCET, V355, P858, DOI 10.1016/S0140-6736(99)00442-0; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Dakhama A, 2005, J IMMUNOL, V175, P1876; Hussell T, 2001, EUR J IMMUNOL, V31, P2566, DOI 10.1002/1521-4141(200109)31:9<2566::AID-IMMU2566>3.0.CO;2-L; Kalina W V, 2004, Clin Dev Immunol, V11, P113, DOI 10.1080/10446670410001722131; KARBER G., 1931, ARCH EXP PATHOL PH, V162, P480, DOI 10.1007/BF01863914; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/01.inf.0000019891.59210.1c; Lovell DJ, 2000, NEW ENGL J MED, V342, P763, DOI 10.1056/NEJM200003163421103; MCCONNOCHIE KM, 1984, PEDIATRICS, V74, P1; MOK JYQ, 1984, ARCH DIS CHILD, V59, P306; MURRAY M, 1992, ARCH DIS CHILD, V67, P482; Noble V, 1997, ARCH DIS CHILD, V76, P315; Openshaw PJM, 2005, CLIN MICROBIOL REV, V18, P541, DOI 10.1128/CMR.18.3.541-555.2005; Peebles RS, 2000, J INFECT DIS, V182, P671; Peebles RS, 2001, J INFECT DIS, V184, P1374; Peschon JJ, 1998, J IMMUNOL, V160, P943; PULLAN CR, 1982, BRIT MED J, V284, P1665; Rutigliano JA, 2004, J IMMUNOL, V173, P3408; Schwarze J, 2004, AM J RESP CRIT CARE, V169, P801, DOI 10.1164/rccm.200308-1203OC; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; SIMS DG, 1978, BRIT MED J, V1, P11; SORKNESS R, 1991, J APPL PHYSIOL, V70, P375; Spearman C, 1908, BRIT J PSYCHOL, V2, P227; Taube C, 2002, J IMMUNOL, V169, P6482; Uhl EW, 1996, AM J RESP CRIT CARE, V154, P1834; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004	29	75	76	0	1	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1465-9921			RESP RES	Respir. Res.	AUG 7	2006	7								107	10.1186/1465-9921-7-107		10	Respiratory System	Respiratory System	083VF	WOS:000240485600001	16893457	
J	Cunha, BA				Cunha, BA			The atypical pneumonias: clinical diagnosis and importance	CLINICAL MICROBIOLOGY AND INFECTION			English	Review						atypical pneumonias; clinical diagnosis of legionnaire's disease; community-acquired pneumonia; doxycycline; legionnaire's disease; Mycoplasma pneumonia; Chlamydia pneumonia; quinolones; review; telithromycin; therapy of Legionella	COMMUNITY-ACQUIRED PNEUMONIA; RESPIRATORY-TRACT INFECTIONS; CHLAMYDIA-PNEUMONIAE; MYCOPLASMA-PNEUMONIAE; MULTIPLE-SCLEROSIS; EARLY-SWITCH; LEGIONELLA-PNEUMONIA; LEGIONNAIRES-DISEASE; AMBULATORY PATIENTS; THERAPY	The most common atypical pneumonias are caused by three zoonotic pathogens, Chlamydia psittaci (psittacosis), Francisella tularensis (tularemia), and Coxiella burnetii (Q fever), and three nonzoonotic pathogens, Chlamydia pneumoniae, Mycoplasma pneumoniae, and Legionella. These atypical agents, unlike the typical pathogens, often cause extrapulmonary manifestations. Atypical CAPs are systemic infectious diseases with a pulmonary component and may be differentiated clinically from typical CAPs by the pattern of extrapulmonary organ involvement which is characteristic for each atypical CAP. Zoonotic pneumonias may be eliminated from diagnostic consideration with a negative contact history. The commonest clinical problem is to differentiate legionnaire's disease from typical CAP as well as from C. pneumoniae or M. pneumonia infection. Legionella is the most important atypical pathogen in terms of severity. It may be clinically differentiated from typical CAP and other atypical pathogens by the use of a weighted point system of syndromic diagnosis based on the characteristic pattern of extrapulmonary features. Because legionnaire's disease often presents as severe CAP, a presumptive diagnosis of Legionella should prompt specific testing and empirical anti-Legionella therapy such as the Winthrop-University Hospital Infectious Disease Division's weighted point score system. Most atypical pathogens are difficult or dangerous to isolate and a definitive laboratory diagnosis is usually based on indirect, i.e., direct flourescent antibody (DFA), indirect flourescent antibody (IFA). Atypical CAP is virtually always monomicrobial; increased IFA IgG tests indicate past exposure and not concurrent infection. Anti-Legionella antibiotics include macrolides, doxycycline, rifampin, quinolones, and telithromycin. The drugs with the highest level of anti-Legionella activity are quinolones and telithromycin. Therapy is usually continued for 2 weeks if potent anti-Legionella drugs are used. In adults, M. pneumoniae and C. pneumoniae may exacerbate or cause asthma. The importance of the atypical pneumonias is not related to their frequency (similar to 15% of CAPs), but to difficulties in their diagnosis, and their nonresponsiveness to beta-lactam therapy. Because of the potential role of C. pneumoniae in coronary artery disease and multiple sclerosis (MS), and the role of M. pneumoniae and C. pneumoniae in causing or exacerbating asthma, atypical CAPs also have public health importance.	Winthrop Univ Hosp, Div Infect Dis, Mineola, NY 11501 USA; SUNY Stony Brook, Sch Med, Stony Brook, NY 11794 USA	Cunha, BA (reprint author), Winthrop Univ Hosp, Div Infect Dis, Mineola, NY 11501 USA.						ALMIRALL J, 1993, EUR RESPIR J, V6, P14; Alvarez-Elcoro S, 1999, MAYO CLIN PROC, V74, P613; Amsden GW, 2005, DRUGS, V65, P605, DOI 10.2165/00003495-200565050-00003; Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954; Beovic B, 2003, EUR J CLIN MICROBIOL, V22, P584, DOI 10.1007/s10096-003-0997-0; Blasi F, 2004, EUR RESPIR J, V24, P171, DOI 10.1183/09031936.04.00135703; Bochud PY, 2001, MEDICINE, V80, P75, DOI 10.1097/00005792-200103000-00001; Castro-Guardiola A, 2001, AM J MED, V111, P367, DOI 10.1016/S0002-9343(01)00868-3; COTTON LM, 1987, CLIN CHEST MED, V8, P441; Cunha B A, 1991, Semin Respir Infect, V6, P168; CUNHA BA, 1991, POSTGRAD MED, V90, P89; Cunha BA, 1997, ADV THER, V14, P172; Cunha BA, 2000, CLIN MICROBIOL INFEC, V6, P270, DOI 10.1046/j.1469-0691.2000.00058-2.x; Cunha BA, 2005, INFECT MED, V22, P53; Cunha BA, 2000, AM J MED, V108, P436, DOI 10.1016/S0002-9343(99)00318-6; Cunha BA, 2003, EUR J CLIN MICROBIOL, V22, P579, DOI 10.1007/s10096-003-0996-1; Cunha BA, 2003, J CLIN MICROBIOL, V41, P3456, DOI 10.1128/JCM.41.7.3456-3457.2003; Cunha BA, 2000, CLIN MICROBIOL INFEC, V6, P633, DOI 10.1046/j.1469-0691.2000.0194f.x; Cunha BA, 2001, MED CLIN N AM, V85, P43, DOI 10.1016/S0025-7125(05)70304-7; Cunha BA, 2001, CLIN MICROBIOL INFEC, V7, P581, DOI 10.1046/j.1198-743x.2001.00328.x; Cunha BA, 1999, ARCH INTERN MED, V159, P1006, DOI 10.1001/archinte.159.9.1006; CUNHA BA, 2004, EUR J CLIN MICROBIOL, V22, P579; CUNHA BA, 1997, J CRIT ILLNESS, V12, P711; CUNHA BA, 1996, CURRENT DIAGNOSIS, V9; CUNHA BA, 1979, POSTGRAD MED COM SEP, P63; Cunha BA, 1996, POSTGRAD MED, V99, P131; CUNHA BA, 1998, ANTIBIOTICS CLIN, V2, P117; CUNHA BA, 2001, AM J MED, V23, P78; CUNHA BA, 1998, SEMIN RESP INFECT, V13, P115; CUNHA BA, 1999, ANTIBIOTICS CLIN, V3, P21; CUNHA BA, 2003, ANTIBIOTIC ESSENTIAL, P45; Cunha BA, 2006, PNEUMONIA ESSENTIALS; CUNHA BA, 1998, CHEST, V112, P945; Daian CM, 2000, ALLERGY ASTHMA PROC, V21, P107, DOI 10.2500/108854100778250860; Ericson K, 2000, CIRCULATION, V101, P2568; Esposito S, 2001, Paediatr Drugs, V3, P159, DOI 10.2165/00128072-200103030-00001; Fainardi E, 2004, J NEUROL SCI, V217, P181, DOI 10.1016/j.jns.2003.09.012; Falguera M, 2001, ARCH INTERN MED, V161, P1866, DOI 10.1001/archinte.161.15.1866; FELDMAN C, 2001, MED CLIN N AM, V86, P1493; FERNANDEZSABE N, 2003, CLIN INECT DIS, V15, P483; File TM, 1998, INFECT DIS CLIN N AM, V12, P569, DOI 10.1016/S0891-5520(05)70199-9; GARNINGER W, 2004, CHEMOTHERAPY, V50, P16; GILL MV, 1997, SEMIN RESPIR INFECT, V3, P67; Gorbach SL, 2004, INFECT DIS; Gupta SK, 2001, CHEST, V120, P1064, DOI 10.1378/chest.120.4.1064; GUPTA SK, 2001, MED CLIN N AM, V85, P1441; GURMAN G, 1991, ISRAEL J MED SCI, V27, P408; Haim M, 2004, INT J CARDIOL, V93, P25, DOI 10.1016/S0167-5273(03)00114-1; Hammerschlag MR, 2001, J ANTIMICROB CHEMOTH, V48, P25; Hammerschlag MR, 2001, CURR OPIN INFECT DIS, V14, P181, DOI 10.1097/00001432-200104000-00012; Hao Q, 2002, MULT SCLER, V8, P436, DOI 10.1191/1352458502ms840oa; Hindiyeh M, 2000, Semin Respir Infect, V15, P101; Honeybourne D, 2001, INT J ANTIMICROB AG, V18, pS57; Honeybourne D, 1997, Curr Opin Pulm Med, V3, P170, DOI 10.1097/00063198-199703000-00014; JOHNSON DH, 1993, POSTGRAD MED, V93, P69; Jokinen C, 2001, CLIN INFECT DIS, V32, P1141, DOI 10.1086/319746; Karetzky M, 1993, PNEUMONIAS; Kim EA, 2002, RADIOGRAPHICS, V22, pS137; LEVISON ME, 1984, PNEUMONIAS; Lieberman D, 1996, INFECTION, V24, P109, DOI 10.1007/BF01713313; LYNCH DA, 1991, CLIN CHEST MED, V12, P203; MacDowell AL, 2005, IMMUNOL ALLERGY CLIN, V25, P45, DOI 10.1016/j.iac.2004.09.011; Mandell GL, 2005, MANDELL DOUGLAS BENN; Marrie T J, 1998, Semin Respir Infect, V13, P3; Marrie TJ, 2004, INFECT DIS CLIN N AM, V18, P829, DOI 10.1016/j.idc.2004.07.002; MARRIE TJ, 1994, CLIN INFECT DIS, V18, P501; MARRIE TJ, 1989, REV INFECT DIS, V11, P586; Marrie TJ, 1996, AM J MED, V101, P508, DOI 10.1016/S0002-9343(96)00255-0; Marrie TJ, 2000, CLIN INFECT DIS, V31, P1066, DOI 10.1086/318124; Marrie Thomas J., 2001, COMMUNITY ACQUIRED P; Martin R E, 1991, Infect Dis Clin North Am, V5, P585; Micillo E, 2000, ALLERGY, V55, P42; Mulazimoglu L, 2001, CHEST, V120, P1049, DOI 10.1378/chest.120.4.1049; Muller-Serieys C, 2001, ANTIMICROB AGENTS CH, V45, P3104, DOI 10.1128/AAC.45.11.3104-3108.2001; Munger KL, 2003, EPIDEMIOLOGY, V14, P141, DOI 10.1097/00001648-200303000-00006; MURRAY HW, 1980, MED CLIN N AM, V64, P507; Mylotte JM, 2002, CLIN INFECT DIS, V35, P1205, DOI 10.1086/344281; Nightingale CH, 2003, COMMUNITY ACQUIRED R; PENNINGTON JE, 1994, RESP INFECT; Plouffe JF, 2000, CLIN INFECT DIS   S2, V31, P35; PUCCI E, 2000, ANN NEUROL, V48, P390; QUINTILIANI R, 1994, INFECT DIS CLIN PRAC, V3, pS161, DOI 10.1097/00019048-199405001-00007; QUINTILIANI R, 2001, INFECTION, V29, pS16; Ramirez JA, 2001, PHARMACOTHERAPY, V21, p79S, DOI 10.1592/phco.21.10.79S.34530; Ramirez JA, 1999, ARCH INTERN MED, V159, P2449, DOI 10.1001/archinte.159.20.2449; Rhew DC, 2001, ARCH INTERN MED, V161, P722, DOI 10.1001/archinte.161.5.722; Sahn S A, 1988, Semin Respir Infect, V3, P322; SCHLICK W, 1993, J ANTIMICROB CHEMOTH, V31, P111; Schuler P, 1997, EUR RESPIR J, V10, P1130, DOI 10.1183/09031936.97.10051130; Segreti J, 2005, AM J MED, V118, P21, DOI 10.1016/j.amjmed.2005.05.010; Sessa R, 1999, AM HEART J, V137, P1116, DOI 10.1016/S0002-8703(99)70371-6; Smilack JD, 1999, MAYO CLIN PROC, V74, P727; Sopena N, 1998, CHEST, V113, P1195, DOI 10.1378/chest.113.5.1195; Stubbs R, 1989, J Tenn Med Assoc, V82, P189; SUBRAMANIAM S, 2005, J INFECT DIS, V192, P1219; Vergis EN, 2000, SEM RESP CRIT CARE M, V21, P295, DOI 10.1055/s-2000-9934; Weinberg A N, 1991, Infect Dis Clin North Am, V5, P649; WOODHEAD MA, 1987, BRIT J DIS CHEST, V81, P133, DOI 10.1016/0007-0971(87)90130-6; Yassin HM, 2001, EXPERT OPIN INV DRUG, V10, P353, DOI 10.1517/13543784.10.2.353; Zamorano J, 2003, INT J CARDIOL, V90, P297, DOI 10.1016/S0167-5273(02)00573-9	100	75	82	1	19	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1198-743X			CLIN MICROBIOL INFEC	Clin. Microbiol. Infect.	MAY	2006	12			3			12	24		10.1111/j.1469-0691.2006.01393.x		13	Infectious Diseases; Microbiology	Infectious Diseases; Microbiology	032VE	WOS:000236803100003	16669925	
J	Merchant, JA; Naleway, AL; Svendsen, ER; Kelly, KM; Burmeister, LF; Stromquist, AM; Taylor, CD; Thorne, PS; Reynolds, SJ; Sanderson, WT; Chrischilles, EA				Merchant, JA; Naleway, AL; Svendsen, ER; Kelly, KM; Burmeister, LF; Stromquist, AM; Taylor, CD; Thorne, PS; Reynolds, SJ; Sanderson, WT; Chrischilles, EA			Asthma and farm exposures in a cohort of rural Iowa children	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						agricultural occupational exposures; ammonia; animal feeding operations; asthma; asthma diagnosis and treatment; asthma health care policy; asthma school screening; asthma underdiagnosis; asthma undertreatment; children; chronic wheeze; cough with exercise; farming; genetic selection; hydrogen sulfide; hygiene hypothesis; odor; rural	ALLERGIC SENSITIZATION; EARLY-CHILDHOOD; EARLY-LIFE; HAY-FEVER; ENDOTOXIN; HEALTH; PREVALENCE; DISEASES; ATOPY; RISK	Epidemiologic studies of farm children are of international interest because farm children are less often atopic, have less allergic disease, and often have less asthma than do nonfarm children-findings consistent with the hygiene hypothesis. We studied a cohort of rural Iowa children to determine the association between farm.and other environmental risk factors with four asthma outcomes: doctor-diagnosed asthma, doctor-diagnosed asthma/medication for wheeze, current wheeze, and cough with exercise. Doctor-diagnosed asthma prevalence was 12%, but at least one of these four health outcomes was found in more than a third of the cohort. Multivariable models of the four health outcomes found independent associations between male sex (three asthma outcomes), age (three asthma outcomes), a personal history of allergies (four asthma outcomes), family history of allergic disease (two asthma outcomes), premature birth (one asthma outcome), early respiratory infection (three asthma outcomes), high-risk birth (two asthma outcomes), and farm exposure to raising swine and adding antibiotics to feed (two asthma outcomes). The high prevalence of rural childhood asthma and asthma symptoms underscores the need for asthma screening programs and improved asthma diagnosis and treatment. The high prevalence of asthma health outcomes among farm children living on farms that raise swine (44.1 %, p = 0.01) and raise swine and add antibiotics to feed (55.8%, p = 0.013), despite lower rates of atopy and personal histories of allergy, suggests the need for awareness and prevention measures and more population-based studies to further assess environmental and genetic determinants of asthma among farm children.	Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA 52242 USA; Kaiser Permanente NW, Ctr Hlth Res, Portland, OR USA; US EPA, Natl Hlth & Environm Effects Res Lab, Human Studies Div, Epidemiol & Biomarkers Branch, Res Triangle Pk, NC 27711 USA; Univ Iowa, Coll Publ Hlth, Dept Biostat, Iowa City, IA USA; Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA	Merchant, JA (reprint author), Univ Iowa, Coll Publ Hlth, Gen Hosp, E220H1, Iowa City, IA 52242 USA.	james-merchant@uiowa.edu	Kelly, Kevin/E-2716-2013; Svendsen, Erik/J-2671-2015	Kelly, Kevin/0000-0002-9177-1454; Svendsen, Erik/0000-0003-3941-0907; Naleway, Allison/0000-0001-5747-4643	ODCDC CDC HHS [5 R01/CCR714364, U07/CCU706145]		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Anto JM, 1998, CLIN EXP ALLERGY, V28, P13; Arbour NC, 2000, NAT GENET, V25, P187; Asher MI, 1998, EUR RESPIR J, V12, P315; Bauer EJ, 1999, J SCHOOL HEALTH, V69, P12; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Campagna D, 2004, J EXPO ANAL ENV EPID, V14, P180, DOI 10.1038/sj.jea.7500313; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; Contreras JP, 2003, J ALLERGY CLIN IMMUN, V112, P1072, DOI 10.1016/j.jaci.2003.08.036; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Douwes J, 2001, AM J IND MED, V39, P608, DOI 10.1002/ajim.1060; DOUWES J, 2003, AM C GOVNM IND HYG, P219; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Farooqi IS, 1998, THORAX, V53, P927; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Hamscher G, 2003, ENVIRON HEALTH PERSP, V111, P1590, DOI 10.1289/ehp.6288; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Merchant JA, 2002, J RURAL HEALTH, V18, P521, DOI 10.1111/j.1748-0361.2002.tb00919.x; MUST A, 1991, AM J CLIN NUTR, V53, P839; *NAT AC SCI, 2003, AIR EM AN FEED OP CU; Niven R, 2003, CLIN EXP ALLERGY, V33, P273, DOI 10.1046/j.1365-2745.2003.01618.x; Park Hyesook, 2003, Appl Occup Environ Hyg, V18, P418, DOI 10.1080/10473220301425; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Reynolds K D, 1997, J Cardiovasc Risk, V4, P1; Reynolds S. J., 1997, Journal of Agromedicine, V4, P37, DOI 10.1300/J096v04n01_06; Reynolds SJ, 1996, AM J IND MED, V29, P33, DOI 10.1002/(SICI)1097-0274(199601)29:1<33::AID-AJIM5>3.0.CO;2-#; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; SVEDSEN ER, 2003, AM J RESP CRIT CARE, V167, pA155; Thu K., 1997, Journal of Agricultural Safety and Health, V3, P13; VONEHRENSTEIN GS, 2000, CLIN EXP ALLERGY, V30, P187; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wing S, 2000, ENVIRON HEALTH PERSP, V108, P233, DOI 10.2307/3454439	43	75	80	0	13	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2005	113	3					350	356		10.1289/ehp.7240		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	903MM	WOS:000227430100047	15743727	
J	van der Woude, HJ; Zaagsma, J; Postma, DS; Winter, TH; van Hulst, M; Aalbers, R				van der Woude, HJ; Zaagsma, J; Postma, DS; Winter, TH; van Hulst, M; Aalbers, R			Detrimental effects of beta-blockers in COPD - A concern for nonselective beta-blockers	CHEST			English	Article						airway hyperresponsiveness; beta-blockers; COPD	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; LUNG-FUNCTION; SEVERE BRONCHOCONSTRICTION; OFFICIAL STATEMENT; CHRONIC-BRONCHITIS; METHACHOLINE; RESPONSIVENESS	Introduction: beta-Blockers are known to worsen FEV1 and airway hyperresponsiveness (AHR) in patients with asthma. Both characteristics determine the outcome of COPD, a disease with frequent cardiac comorbidity requiring beta-blocker treatment. Design: A double-blind, placebo-controlled, randomized, cross-over study. Setting: An ambulatory, hospital outpatient clinic of pulmonary diseases. Patients: Patients with mild-to-moderate irreversible COPD and AHR. Intervention: Fifteen patients received propranolol (80 mg), metoprolol (100 mg), celiprolol (200 mg), or placebo for 4 days, followed by a washout period >= 3 days. On day 4 of treatment, FEV1 and PC20 were assessed. Immediately hereafter, formoterol (12 mu g) was administered and FEV1 was measured for up to 30 min. Results: PC20 was significantly lower (p < 0.01) with propranolol and metoprolol treatment (geometric means, 2.06 mg/mL and 2.02 mg/mL, respectively) than with placebo (3.16 mg/mL) or celiprolol (3.41 mg/mL). FEV1 deteriorated only after propranolol treatment (2.08 +/- 0.31 L) [mean +/- SD] compared with placebo (2.24 +/- 0.37 L). The fast bronchodilating effect of formoterol was hampered by propranolol (mean increase in FEV1 at 3 min, 6.7 +/- 8.9%) but was unaffected by the other beta-blockers (16.9 +/- 9.8%, 22 +/- 11.6%, and 16.9 +/- 9.0% for placebo, metoprolol, and celiprolol, respectively). Conclusions: Pulmonary effects did not occur by celiprolol. Only propranolol reduced FEV1 and the bronchodilating effect of formoterol. Both metoprolol and propranolol increased AHR. Thus, different classes of beta-blockers have different pulmonary effects. The anticipated beneficial cardiovascular effects of a P-blocker must be weighted against the putative detrimental pulmonary effects, ie, effect on FEV1 AHR, and response to additional beta(2)-agonists.	Martini Hosp, Dept Pulm Dis, NL-9721 SW Groningen, Netherlands; Martini Hosp, Dept Clin Pharm & Toxicol, NL-9721 SW Groningen, Netherlands; Univ Ctr Pharm, Groningen, Netherlands; Univ Groningen Hosp, Dept Pulm Dis, Groningen, Netherlands	van der Woude, HJ (reprint author), Martini Hosp, Dept Pulm Dis, Van Ketwich Verschuurlaan 82, NL-9721 SW Groningen, Netherlands.	jvbhw@home.nl					Aalbers R, 2002, EUR RESPIR J, V19, P936, DOI 10.1183/09031936.02.00240902; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Calverley PMA, 2003, THORAX, V58, P659, DOI 10.1136/thorax.58.8.659; Cazzola M, 2002, CHEST, V121, P230, DOI 10.1378/chest.121.1.230; Cazzola M, 2001, PULM PHARMACOL THER, V14, P41, DOI 10.1006/pupt.2000.0267; CLAGUE HW, 1984, EUR J CLIN PHARMACOL, V27, P517, DOI 10.1007/BF00556885; [Anonymous], 1997, THORAX S5, V52, pS1; Dart RA, 2003, CHEST, V123, P222, DOI 10.1378/chest.123.1.222; Gross NJ, 2003, THORAX, V58, P647, DOI 10.1136/thorax.58.8.647; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267; Hospers JJ, 2000, LANCET, V356, P1313, DOI 10.1016/S0140-6736(00)02815-4; Kendall MJ, 1999, HEART, V82, P5; Kendall MJ, 1997, AM J CARDIOL, V80, p15J; MACDONALD AG, 1967, BRIT J ANAESTH, V39, P919, DOI 10.1093/bja/39.12.919; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; *NIH, 2001, PUBL; NORRIS RJ, 1988, AM J CARDIOL, V61, pC14, DOI 10.1016/0002-9149(88)90479-1; PERKS WH, 1978, BRIT J CLIN PHARMACO, V5, P101; Politiek MJ, 1999, EUR RESPIR J, V13, P988, DOI 10.1034/j.1399-3003.1999.13e10.x; POSTMA DS, 1986, AM REV RESPIR DIS, V134, P276; QUANJER PH, 1993, EUR RESPIR J, V6, P5; RAMSDALE EH, 1984, THORAX, V39, P912, DOI 10.1136/thx.39.12.912; RAMSDALE EH, 1985, THORAX, V40, P422, DOI 10.1136/thx.40.6.422; Salpeter SR, 2003, RESP MED, V97, P1094, DOI 10.1016/S0954-6111(03)00168-9; Salpeter SR, 2002, ANN INTERN MED, V137, P715; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; Tashkin DP, 1996, AM J RESP CRIT CARE, V153, P1802; van der Woude HJ, 2001, THORAX, V56, P529, DOI 10.1136/thorax.56.7.529; 2004, FARMOCOTHERAPEUTISCH	31	75	82	3	3	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAR	2005	127	3					818	824		10.1378/chest.127.3.818		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	908HG	WOS:000227777500024	15764762	
J	Erwin, EA; Wickens, K; Custis, NJ; Siebers, R; Woodfolk, J; Barry, D; Crane, J; Platts-Mills, TAE				Erwin, EA; Wickens, K; Custis, NJ; Siebers, R; Woodfolk, J; Barry, D; Crane, J; Platts-Mills, TAE			Cat and dust mite sensitivity and tolerance in relation to wheezing among children raised with high exposure to both allergens	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; cat; mite; tolerance; high exposure	MODIFIED TH2 RESPONSE; CHILDHOOD ASTHMA; ATOPIC-DERMATITIS; IMMUNE-RESPONSE; NEW-ZEALAND; SENSITIZATION; ANTIBODIES; DETERMINANTS; PREVALENCE; ENDOTOXIN	Background: Recent evidence has suggested that high exposure to cat allergens is associated with decreased prevalence of sensitization to cat and, in some studies, decreased asthma. Objective: Our objective was to study antibodies to cat and mite allergens and their relationship to wheezing in a country with high exposure to both allergens. Methods: Sera from 112 wheezing and 112 control children aged 10 to 11 years in a nested case-control study in New Zealand were assayed for specific IgE antibody, as well as IgG antibody and IgG4 antibody, to Der p 1 and Fel d 1. Results: IgE antibody to both mite (99/224) and cat (41/224) were strongly associated with wheezing (odds ratios, 5.2 and 6.5, respectively). Children who had ever lived with a cat were less likely to have IgE antibody to cat (20/141 vs 21/83, P <.04); however, cat ownership had no effect on IgE antibody to mite (67/141 vs 32/83, P =.23). Among sensitized children, cat ownership was associated with a lower prevalence of IgE antibody to cat (28% vs 66%, P <.001), and this analysis remained significant after exclusion of children whose families had chosen not to own a cat. Among sensitized subjects, the mean titer of IgE antibody to cat (1.7 IU/mL) was 10-fold lower than for mite (22.1 IU/mL). A cat in the home had no significant effect on endotoxin or mite allergen in house dust, whereas cat allergen was much higher (40.8 vs 3.3 mug/g). Conclusion: The response to these 2 allergens was distinct on the basis of the prevalence of sensitization, the titer of IgE antibody, and the effect of cat ownership. The results suggest that induction of tolerance to cat allergen is an allergen-specific phenomenon that cannot be attributed to endotoxin or family choice. The strength of the IgE antibody response to dust mite in humid climates could contribute to the increased prevalence and severity of asthma.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Wellington Sch Med & Hlth Sci, Wellington Asthma Res Grp, Wellington, New Zealand; Healthcare Hawkes Bay, Hastings, New Zealand	Platts-Mills, TAE (reprint author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu	Siebers, Robert/A-4102-2009	Siebers, Robert/0000-0002-6359-3144	NIAID NIH HHS [P01-AI-50989, AI-20565]		Asher MI, 1998, EUR RESPIR J, V12, P315; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; Carneiro R, 2004, J INVEST DERMATOL, V122, P927, DOI 10.1111/j.0022-202X.2004.22407.x; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kaiser L, 2003, J BIOL CHEM, V278, P37730, DOI 10.1074/jbc.M304740200; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Mandal AK, 2004, J EXP MED, V199, P1317, DOI 10.1084/jem.20031666; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; OWMBY DR, 2002, JAMA-J AM MED ASSOC, V288, P963; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2003, J ALLERGY CLIN IMMUN, V111, P123, DOI 10.1067/mai.2003.10; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Portengen L, 2004, CLIN EXP ALLERGY, V34, P1243, DOI 10.1111/j.1365-2222.2004.02025.x; Reefer AJ, 2004, J IMMUNOL, V172, P2763; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Sawyer G, 1998, J ALLERGY CLIN IMMUN, V102, P765, DOI 10.1016/S0091-6749(98)70016-8; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Shao L, 2001, SEMIN IMMUNOL, V13, P163, DOI 10.1006/smim.2000.0311; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wickens K, 1997, CLIN EXP ALLERGY, V27, P1077, DOI 10.1111/j.1365-2222.1997.tb01260.x; Woodfolk JA, 2002, INT ARCH ALLERGY IMM, V129, P277, DOI 10.1159/000067595	32	75	79	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2005	115	1					74	79		10.1016/j.jaci.2004.10.030		6	Allergy; Immunology	Allergy; Immunology	886XS	WOS:000226267000010	15637550	
J	Sherriff, A; Farrow, A; Golding, J; Henderson, J				Sherriff, A; Farrow, A; Golding, J; Henderson, J		ALSPAC Study Team	Frequent use of chemical household products is associated with persistent wheezing in pre-school age children	THORAX			English	Article							VOLATILE ORGANIC-COMPOUNDS; RESPIRATORY SYMPTOMS; CHANGING PREVALENCE; SCHOOL ENVIRONMENT; MATERNAL SMOKING; ASTHMA; RISK; SCHOOLCHILDREN; CLEANERS; INDOOR	Background: In the UK and other developed countries the prevalence of asthma symptoms has increased in recent years. This is likely to be the result of increased exposure to environmental factors. A study was undertaken to investigate the association between maternal use of chemical based products in the prenatal period and patterns of wheeze in early childhood. Methods: In the population based Avon Longitudinal Study of Parents and Children (ALSPAC), the frequency of use of 11 chemical based domestic products was determined from questionnaires completed by women during pregnancy and a total chemical burden (TCB) score was derived. Four mutually exclusive wheezing patterns were defined for the period from birth to 42 months based on parental questionnaire responses ( never wheezed, transient early wheeze, persistent wheeze, and late onset wheeze). Multinomial logistic regression models were used to assess the relationship between these wheezing outcomes and TCB exposure while accounting for numerous potential confounding variables. Complete data for analysis was available for 7019 of 13 971 (50%) children. Results: The mean (SD) TCB score was 9.4 (4.1), range 0 - 30. Increased use of domestic chemical based products was associated with persistent wheezing during early childhood ( adjusted odds ratio ( OR) per unit increase of TCB 1.06 (95% confidence interval (CI) 1.03 to 1.09)) but not with transient early wheeze or late onset wheeze. Children whose mothers had high TCB scores (>90th centile) were more than twice as likely to wheeze persistently throughout early childhood than children whose mothers had a low TCB score (<10th centile) ( adjusted OR 2.3 (95% CI 1.2 to 4.4)). Conclusion: These findings suggest that frequent use of chemical based products in the prenatal period is associated with persistent wheezing in young children. Follow up of this cohort is underway to determine whether TCB is associated with wheezing, asthma, and atopy at later stages in childhood.	Univ Bristol, Unit Paediat & Perinatal Epidemiol, Div Child Hlth, Bristol BS8 1BR, Avon, England; Brunel Univ, Dept Hlth & Social Care, Isleworth TW7 5DU, Middx, England	Sherriff, A (reprint author), Univ Bristol, Unit Paediat & Perinatal Epidemiol, Div Child Hlth, Bristol BS8 1BR, Avon, England.	Andrea.Sherriff@bris.ac.uk		Golding, Jean/0000-0003-2826-3307			ANDERSON HR, 1994, BRIT MED J, V308, P1600; Arif AA, 2002, OCCUP ENVIRON MED, V59, P505, DOI 10.1136/oem.59.8.505; Becher R, 1996, TOXICOL LETT, V86, P155, DOI 10.1016/0378-4274(96)03685-5; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Farrow A, 1997, ENVIRON TECHNOL, V18, P605, DOI 10.1080/09593331808616578; FARROW A, 2004, IN PRESS ARCH ENV HL; GERSTMAN BB, 1993, PEDIATRICS, V81, P1; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Institute of Medicine, 2000, CLEAR AIR ASTHM IND; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lemus R., 1998, Reviews on Environmental Health, V13, P91; Lewis S, 1996, THORAX, V51, P670, DOI 10.1136/thx.51.7.670; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; Millqvist E, 1999, ALLERGY, V54, P495, DOI 10.1034/j.1398-9995.1999.00031.x; Murphy JFA, 1998, IRISH MED J, V91, P76; Nielsen J, 1999, OCCUP MED-OXFORD, V49, P291, DOI 10.1093/occmed/49.5.291; NINAN TK, 1992, BRIT MED J, V304, P873; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; OMRAN M, 1996, BRIT MED J, V3, P12; PEAT JK, 1994, BRIT MED J, V308, P1591; Ross DJ, 1998, OCCUP MED-OXFORD, V48, P481, DOI 10.1093/occmed/48.8.481; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Venn AJ, 2003, THORAX, V58, P955, DOI 10.1136/thorax.58.11.955; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	33	75	76	1	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JAN	2005	60	1					45	49		10.1136/thx.2004.021154		5	Respiratory System	Respiratory System	882TB	WOS:000225960100012	15618582	
J	Harris, J; Mason, DE; Li, J; Burdick, KW; Backes, BJ; Chen, T; Shipway, A; Van Heeke, G; Gough, L; Ghaemmaghami, A; Shakib, F; Debaene, F; Winssinger, N				Harris, J; Mason, DE; Li, J; Burdick, KW; Backes, BJ; Chen, T; Shipway, A; Van Heeke, G; Gough, L; Ghaemmaghami, A; Shakib, F; Debaene, F; Winssinger, N			Activity profile of dust mite allergen extract using substrate libraries and functional proteomic microarrays	CHEMISTRY & BIOLOGY			English	Article							CYSTEINE PROTEASE ACTIVITY; DERMATOPHAGOIDES-PTERONYSSINUS; ENHANCES ALLERGENICITY; PROTEOLYTIC ACTIVITY; SERINE HYDROLASES; MASS-SPECTROMETRY; DER-P-1; SPECIFICITY; INHIBITOR; PROTEINASES	Enzymatic activity in the fecal droppings from the house dust mite has been postulated to contribute to the elicited allergic response. Screening dust mite extracts through 137,180 tetrapeptide fluorogenic substrates allowed for the characterization of proteolytic substrate specificity from the potential cysteine and serine proteases in the extract. The extract was further screened against a 4000 member peptide nucleic acid (PNA) encoded inhibitor library designed to target cysteine proteases using microarray detection. Affinity chromatography coupled with mass spectrometry identified Der p 1 as one of the proteases targeted by the PNA inhibitors in the dust mite lysate. A phenotypic readout of Der p 1 function in allergy progression was demonstrated by the inhibition of CD25 cleavage from T cells by dust mite extract that had been treated with the Der p I inhibitor identified from the PNA-encoded inhibitor library.	Scripps Res Inst, Dept Mol Biol, San Diego, CA 92121 USA; Genom Inst Novartis Res Fdn, Dept Chem, San Diego, CA 92121 USA; Novartis Inst Biomed Res, Horsham RH12 5AB, W Sussex, England; Univ Nottingham, Inst Infect Immun & Inflammat, Ctr Biomol Sci, Nottingham NG7 2RD, England; Univ Louis Pasteur Strasbourg 1, Inst Sci & Ingn Supramol, F-67000 Strasbourg, France	Winssinger, N (reprint author), Scripps Res Inst, Dept Mol Biol, 10550 N Torrey Pines Rd, San Diego, CA 92121 USA.	harris@scripps.edu; winssinger@isis-ulp.org	Winssinger, Nicolas/B-6710-2017	Winssinger, Nicolas/0000-0003-1636-7766; Fairclough, Lucy/0000-0003-4581-9741			Aebersold R, 2001, CHEM REV, V101, P269, DOI 10.1021/cr990076h; Andersen JS, 2000, FEBS LETT, V480, P25, DOI 10.1016/S0014-5793(00)01773-7; ARTHUR RP, 1955, J INVEST DERMATOL, V25, P341, DOI 10.1038/jid.1955.138; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Backes BJ, 2000, NAT BIOTECHNOL, V18, P187; BAGAROZZI DA, 1997, PHYTOCHEMISTRY, V47, P593; Baxter SM, 2004, MOL CELL PROTEOMICS, V3, P209, DOI 10.1074/mcp.M300082-MCP200; Debaene F, 2004, TETRAHEDRON, V60, P8677, DOI 10.1016/j.tet.2004.05.107; FURKA A, 1991, INT J PEPT PROT RES, V37, P487; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4<1211::AID-IMMU1211>3.0.CO;2-R; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Greenbaum DC, 2002, CHEM BIOL, V9, P1085, DOI 10.1016/S1074-5521(02)00238-7; Griffin TJ, 1998, ANAL BIOCHEM, V260, P56, DOI 10.1006/abio.1998.2686; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Harris JL, 2001, CHEM BIOL, V8, P1131, DOI 10.1016/S1074-5521(01)00080-1; HERBERT CA, 1993, BRIT J PHARMACOL, V110, P840; Jeffery DA, 2003, CURR OPIN BIOTECH, V14, P87, DOI 10.1016/S0958-1669(02)00010-1; Jessani N, 2004, CURR OPIN CHEM BIOL, V8, P54, DOI 10.1016/j.cbpa.2003.11.004; John RJ, 2000, CLIN EXP ALLERGY, V30, P784, DOI 10.1046/j.1365-2222.2000.00840.x; KAM CM, 1993, BIOCONJUGATE CHEM, V4, P560, DOI 10.1021/bc00024a021; Kawamoto S, 2002, J BIOSCI BIOENG, V94, P285, DOI 10.1263/jbb.94.285; Kozarich JW, 2003, CURR OPIN CHEM BIOL, V7, P78, DOI 10.1016/S1367-5931(02)00013-3; KRANTZ A, 1991, BIOCHEMISTRY-US, V30, P4678, DOI 10.1021/bi00233a007; Licklider LJ, 2002, ANAL CHEM, V74, P3076, DOI 10.1021/ac025529o; Liu YS, 1999, P NATL ACAD SCI USA, V96, P14694, DOI 10.1073/pnas.96.26.14694; Lockhart DJ, 2000, NATURE, V405, P827, DOI 10.1038/35015701; MacBeath G, 2000, SCIENCE, V289, P1760; Maly DJ, 2002, J ORG CHEM, V67, P910, DOI 10.1021/jo016140o; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; OMARI TI, 1992, CLIN EXP PHARMACOL P, V19, P785; PlattsMills TAE, 1997, NEW ENGL J MED, V336, P1382, DOI 10.1056/NEJM199705083361909; PLATTSMILLS TAE, 1983, CLIN EXP DERMATOL, V8, P233, DOI 10.1111/j.1365-2230.1983.tb01776.x; Ring PC, 2000, CLIN EXP ALLERGY, V30, P1085; Schulz O, 1999, CLIN EXP ALLERGY, V29, P439; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Schulz O, 1998, J CLIN PATHOL-MOL PA, V51, P222; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Thomberry N. A., 1997, J BIOL CHEM, V272, P17907; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Winssinger N, 2002, P NATL ACAD SCI USA, V99, P11139, DOI 10.1073/pnas.172286899; Winssinger N, 2001, ANGEW CHEM INT EDIT, V40, P3152, DOI 10.1002/1521-3773(20010903)40:17<3152::AID-ANIE3152>3.0.CO;2-P; Yang CY, 2000, BBA-GENE STRUCT EXPR, V1517, P153, DOI 10.1016/S0167-4781(00)00235-9	44	75	75	0	6	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	1074-5521			CHEM BIOL	Chem. Biol.	OCT	2004	11	10					1361	1372		10.1016/j.chembiol.2004.08.008		12	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	864YH	WOS:000224668700008	15489163	
J	Murr, LE; Bang, JJ; Esquivel, EV; Guerrero, PA; Lopez, A				Murr, LE; Bang, JJ; Esquivel, EV; Guerrero, PA; Lopez, A			Carbon nanotubes, nanocrystal forms, and complex nanoparticle aggregates in common fuel-gas combustion sources and the ambient air	JOURNAL OF NANOPARTICLE RESEARCH			English	Article						carbon nanotubes; aggregates; methane; propane; natural gas; transmission electron microscopy; health risks; home environment	ULTRAFINE PARTICLES; MORTALITY; CLIMATE; AEROSOL; HEALTH; SIZE	Aggregated multiwall carbon nanotubes (with diameters ranging from similar to3 to 30 nm) and related carbon nanocrystal forms ranging in size from 0.4 to 2 mum (average diameter) have been collected in the combustion streams for methane/ air, natural gas/air, and propane gas/air flames using a thermal precipitator. Individual particle aggregates were collected on carbon/formvar-coated 3 mm nickel grids and examined in a transmission electron microscope, utilizing bright-field imaging, selected-area electron diffraction analysis, and energy-dispersive X-ray spectrometry techniques. The natural gas and propane gas sources were domestic (kitchen) stoves, and similar particle aggregates collected in the outdoor air were correspondingly identified as carbon nanocrystal aggregates and sometimes more complex aggregates of silica nanocrystals intermixed with the carbon nanotubes and other carbon nanocrystals. Finally, and in light of the potential for methane-series gas burning as major sources of carbon nanocrystal aggregates in both the indoor and outdoor air, data for natural gas consumption and corresponding asthma deaths and incidence are examined with a degree of speculation regarding any significance in the correlations.	Univ Texas, Dept Met & Mat Engn, El Paso, TX 79968 USA	Murr, LE (reprint author), Univ Texas, Dept Met & Mat Engn, M-201,500 W Univ Ave, El Paso, TX 79968 USA.	fekberg@utep.edu		Murr, Lawrence/0000-0001-5942-8376			Bang JJ, 2003, J AIR WASTE MANAGE, V53, P227; Bang JJ, 2002, J MATER SCI LETT, V21, P361, DOI 10.1023/A:1014994815240; BANG JJ, 2004, IN PRESS J NANOSCI N; BANG JJ, 2002, 5428 JOM; Buseck PR, 1999, P NATL ACAD SCI USA, V96, P3372, DOI 10.1073/pnas.96.7.3372; Chameides WL, 2002, SCIENCE, V297, P2214, DOI 10.1126/science.1076866; Chianelli RR, 1998, J HAZARDOUS SUB RES, V1, P1; Dagani R, 2003, CHEM ENG NEWS, V81, P30, DOI 10.1021/cen-v081n017.p030; ESQUIVEL EV, 2004, IN PRESS MAT CHARACT; GLADNEY ES, 1976, ATMOS ENVIRON, V10, P1071, DOI 10.1016/0004-6981(76)90116-5; Harris P., 2003, CARBON NANOTUBES REL; HAYES BS, 1980, BER BUNSEN PHYS CHEM, V84, P499; IIJIMA S, 1991, NATURE, V354, P56, DOI 10.1038/354056a0; KATRINAK KA, 1993, ENVIRON SCI TECHNOL, V27, P539, DOI 10.1021/es00040a013; Lighty JS, 2000, J AIR WASTE MANAGE, V50, P1565; Molina MJ, 1996, ANNU REV PHYS CHEM, V47, P327, DOI 10.1146/annurev.physchem.47.1.327; Momarca S., 1997, SCI TOTAL ENVIRON, V205, P137; Murr LE, 2004, J MATER SCI, V39, P2199, DOI 10.1023/B:JMSC.0000017787.53545.b7; MURR LE, 2004, IN PRESS J MAT SCI L; Murr L.E., 1991, ELECT ION MICROSCOPY; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Schwartz J, 1999, ENVIRON HEALTH PERSP, V107, P339, DOI 10.2307/3434536; Smith BW, 2000, CHEM PHYS LETT, V321, P169, DOI 10.1016/S0009-2614(00)00307-9; UGARTE D, 1992, NATURE, V359, P707, DOI 10.1038/359707a0	25	75	75	2	21	KLUWER ACADEMIC PUBL	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	1388-0764			J NANOPART RES	J. Nanopart. Res.	JUN	2004	6	2-3					241	251		10.1023/B:NANO.0000034651.91325.40		11	Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials Science, Multidisciplinary	Chemistry; Science & Technology - Other Topics; Materials Science	837EF	WOS:000222610500011		
J	Ryan, CA; Gildea, LA; Hulette, BC; Dearman, RJ; Kimber, I; Gerberick, GF				Ryan, CA; Gildea, LA; Hulette, BC; Dearman, RJ; Kimber, I; Gerberick, GF			Gene expression changes in peripheral blood-derived dendritic cells following exposure to a contact allergen	TOXICOLOGY LETTERS			English	Article						contact allergy; dendritic cells; gene expression; in vitro method; dinitrobenzenesulfonic acid	EPIDERMAL LANGERHANS CELLS; LYMPHOCYTIC ACTIVATION MOLECULE; E-CADHERIN EXPRESSION; CLASS-II MOLECULES; COSTIMULATORY MOLECULES; HLA-DR; MATURATION; CYTOKINES; HAPTENS; SENSITIZERS	A critical step in the induction of allergic contact allergy is the activation and subsequent migration of Langerhans cells (LC), an important antigen presenting dendritic cell (DC) of the skin. As the Langerhans cells migrate, they undergo a maturation process. It has been proposed that contact allergen exposure can induce DC maturation. While changes in DC gene expression profiles induced by various maturation stimuli have been explored, there are no published reports describing genomic-scale analysis of the changes induced by chemical allergen exposure. Therefore, to explore the concept of chemical allergen-induced DC maturation and to identify genes that are regulated by exposure to allergens we examined, at the transcriptional level, the effects of exposure to a contact allergen on DC. Peripheral blood-derived DC were exposed for 24 h to either 1 mM or 5 mM dinitrobenzenesulfonic acid (DNBS). Changes in gene expression were analyzed using Affymetrix U95Av2 GeneChip(R). Comparison of mean signal values from replicate cultures revealed 173 genes that were significantly different (P less than or equal to 0.001) between 1 mM DNBS treated and untreated control DC and 1249 significant gene changes between 5 mM DNBS treated and control DC. Real-time reverse-transcriptase polymerase chain reaction (RT-PCR) was used to evaluate the observed transcript changes for selected genes in DC derived from a second donor. Comparison of the fold-changes in transcript levels between the two platforms and donors revealed a good correlation in both direction and magnitude. RT-PCR analysis was also used to assess the allergen specificity of a selected number of genes in DC derived from a third donor. Many of the gene expression changes were found to be induced only by exposure to the allergen, DNBS, and not by exposure to a structurally similar non-allergen, benzenesulfonic acid. A number of gene expression changes induced by allergen exposure were found to be consistent with what is known of the DC maturation process, and thus provide support for the theory of contact allergen-induced DC maturation. Additionally, it is hoped that some of the transcript changes identified through this approach will be shown to be suitable for use in the development of an in vitro predictive assay for contact sensitization. (C) 2004 Elsevier Ireland Ltd. All rights reserved.	Procter & Gamble Co, Cent Prod Safety Dept, Miami Valley Labs, Cincinnati, OH 45253 USA; Syngenta Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England	Ryan, CA (reprint author), Procter & Gamble Co, Cent Prod Safety Dept, Miami Valley Labs, POB 538707, Cincinnati, OH 45253 USA.	ryan.ca@pg.com; gildea.la@pg.com; hulette.bc@pg.com; rebecca.dearman@syngenta.com; ian.kimber@syngenta.com; gerberick.gf@pg.com					Aiba S, 2003, J INVEST DERMATOL, V120, P390, DOI 10.1046/j.1523-1747.2003.12065.x; AIBA S, 1990, J IMMUNOL, V145, P2791; Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Aiba S, 2000, IMMUNOLOGY, V101, P68, DOI 10.1046/j.1365-2567.2000.00087.x; ALLEN RS, 2003, SCIENCE, V301, P1925; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Becker D, 1997, J IMMUNOL METHODS, V203, P171, DOI 10.1016/S0022-1759(97)00024-0; BECKER D, 1992, J INVEST DERMATOL, V99, P545, DOI 10.1111/1523-1747.ep12667308; BECKER D, 1992, J INVEST DERMATOL, V98, P700, DOI 10.1111/1523-1747.ep12499912; Bleharski JR, 2001, J IMMUNOL, V167, P3174; Chen Z, 2002, BIOCHEM BIOPH RES CO, V290, P66, DOI 10.1006/bbrc.2001.6147; Coutant KD, 1999, TOXICOL SCI, V52, P189, DOI 10.1093/toxsci/52.2.189; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; Degwert J, 1997, TOXICOL IN VITRO, V11, P613, DOI 10.1016/S0887-2333(97)00053-2; Dietz AB, 2000, BIOCHEM BIOPH RES CO, V275, P731, DOI 10.1006/bbrc.2000.3372; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; GIROLOMONI G, 1990, J INVEST DERMATOL, V94, P753, DOI 10.1111/1523-1747.ep12874611; Higashi N, 2002, J BIOL CHEM, V277, P20686, DOI 10.1074/jbc.M202104200; Huang Q, 2001, SCIENCE, V294, P870, DOI 10.1126/science.294.5543.870; Hulette BC, 2002, TOXICOL APPL PHARM, V182, P226, DOI 10.1006/taap.2002.9447; Imai T, 1996, J BIOL CHEM, V271, P21514; KIMBER I, 1992, TOXICOL APPL PHARM, V117, P137, DOI 10.1016/0041-008X(92)90230-P; Kruse M, 2001, J IMMUNOL, V167, P1989; Kuhn U, 1998, J IMMUNOL, V160, P667; Le Naour F, 2001, J BIOL CHEM, V276, P17920, DOI 10.1074/jbc.M100156200; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Manome H, 1999, IMMUNOLOGY, V98, P481, DOI 10.1046/j.1365-2567.1999.00916.x; MAURER D, 1999, DENDRITIC CELLS, P111; McColl SR, 2002, IMMUNOL CELL BIOL, V80, P489, DOI 10.1046/j.1440-1711.2002.01113.x; Messmer D, 2003, INT IMMUNOL, V15, P491, DOI 10.1093/intimm/dxg052; Moschella F, 2001, BRIT J HAEMATOL, V114, P444, DOI 10.1046/j.1365-2141.2001.02953.x; Naciff JM, 2003, TOXICOL SCI, V72, P314, DOI 10.1093/toxsci/kfg037; Ozawa H, 1996, J INVEST DERMATOL, V106, P441, DOI 10.1111/1523-1747.ep12343589; Pichowski JS, 2001, J APPL TOXICOL, V21, P115, DOI 10.1002/jat.742; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Schwarzenberger K, 1996, J INVEST DERMATOL, V106, P553, DOI 10.1111/1523-1747.ep12344019; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Tuschl H, 2000, TOXICOL IN VITRO, V14, P541, DOI 10.1016/S0887-2333(00)00051-5; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Verrier AC, 1999, INT ARCH ALLERGY IMM, V120, P56, DOI 10.1159/000024220; Wang BH, 2002, J IMMUNOL, V168, P3303	43	75	81	1	2	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0378-4274			TOXICOL LETT	Toxicol. Lett.	MAY 2	2004	150	3					301	316		10.1016/j.toxlet.2004.02.002		16	Toxicology	Toxicology	822CY	WOS:000221513600007	15110082	
J	Waser, M; Schierl, R; Von mutius, E; Maisch, S; Carr, D; Riedler, J; Eder, W; Schreuer, M; Nowak, D; Braun-Fahrlander, C				Waser, M; Schierl, R; Von mutius, E; Maisch, S; Carr, D; Riedler, J; Eder, W; Schreuer, M; Nowak, D; Braun-Fahrlander, C		ALEX Study Team	Determinants of endotoxin levels in living environments of farmers' children and their peers from rural areas	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; children; exposure assessment; farm animals and pets; farming; house and stable dust; indoor endotoxin; living room floor; mattress	IN-HOUSE DUST; HAY-FEVER; ALLERGIC SENSITIZATION; EXPOSURE; ASTHMA; ATOPY; CONTAMINANTS; PROTECT; LIFE; HOME	Background Lower frequencies of asthma and hayfever have been observed in children with contact to livestock. At school age, the amount of endotoxin measured in the dust of children's mattresses is inversely related to the occurrence of atopic asthma, hayfever and atopic sensitization both in children from farming and non-farming households. Objective The aim of the present study was to investigate which home and lifestyle characteristics of farm and non-farm families contribute to endotoxin levels measured in different indoor home environments. Methods In the framework of the Allergy and Endotoxin (ALEX) Study, endotoxin was measured in dust samples from the living room floor and the child's mattress of 319 farmers' families and 493 non-farming families, and in settled dust from stables. Endotoxin content of all dust samples was determined by a kinetic Limulus assay (Limulus-Amebocyte-Lysate test). Information about the child's activities on farms, home characteristics and cleaning behaviours was obtained from parental questionnaires. Results Endotoxin levels in stables did not predict the amount of endotoxin measured in floors or mattresses. However, a dose-dependent association between the child's activity on the farm and indoor home endotoxin levels was observed, both in farm and non-farm children. In non-farm children pet keeping and the frequency of floor cleaning were additionally associated with endotoxin levels, whereas in farm children parental farm activities, study area, time since last cleaning, the mattress type as well as younger age of the children contributed to increased microbial exposure. Conclusion These results demonstrate that regular contact to farm animals increases indoor home endotoxin concentrations, both in farm and non-farm children, and might thus explain the protective effect of contact to livestock on atopic outcomes. To assess children's individual exposure to a microbial environment, measures of mattress dust exposure are needed as stable endotoxin concentrations were not associated with indoor home levels.	Univ Basel, Inst Social & Prevent Med, Environm & Hlth Dept, CH-4051 Basel, Switzerland; Univ Munich, Inst Occupat & Environm Med, D-80539 Munich, Germany; Univ Munich, Dr Von Hauner Childrens Hosp, D-80539 Munich, Germany; Childrens Hosp Salzburg, Dept Paediat Pulmonol & Allergol, Salzburg, Austria; Salzburg Univ, Dept Sociol, A-5020 Salzburg, Austria	Waser, M (reprint author), Univ Basel, Inst Social & Prevent Med, Environm & Hlth Dept, Steinengraben 49, CH-4051 Basel, Switzerland.	Marco.Waser@unibas.ch					ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1202/0002-8894(1987)048<0745:ASOTRB>2.0.CO;2; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; De Lucca SD, 2000, J ALLERGY CLIN IMMUN, V106, P874, DOI 10.1067/mai.2000.110804; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Nowak D, 1998, DEUT TIERARZTL WOCH, V105, P225; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Radon K, 2002, ANN AGR ENV MED, V9, P41; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; van Rozendaal BAWM, 1999, BBA-MOL BASIS DIS, V1454, P261, DOI 10.1016/S0925-4439(99)00042-3; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	25	75	77	0	6	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2004	34	3					389	397		10.1111/j.1365-2222.2004.01873.x		9	Allergy; Immunology	Allergy; Immunology	801LY	WOS:000220098600011	15005732	
J	Green, RS; Smorodinsky, S; Kim, JJ; McLaughlin, R; Ostro, B				Green, RS; Smorodinsky, S; Kim, JJ; McLaughlin, R; Ostro, B			Proximity of California public schools to busy roads	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; children's health; environmental justice; ethnicity; schools; socioeconomic status; traffic	TRAFFIC DENSITY; AIR-POLLUTION; LOS-ANGELES; ENVIRONMENTAL JUSTICE; ULTRAFINE PARTICLES; CHILDHOOD-CANCER; MAJOR HIGHWAY; CHILDREN; ASTHMA; HEALTH	Residential proximity to busy roads has been associated with adverse health Outcomes, and school location may also be an important determinant of children's exposure to traffic-related pollutants. The goal of this study was to examine the characteristics of public schools (grades K-12) in California (n = 7,460) by proximity to major roads. We determined maximum daily traffic counts for all roads within 150 m of the school using a statewide road network and a geographic information system. Statewide, 173 schools (2.3%) with a total enrollment of 150,323 students were located within 150 m of high-traffic roads (greater than or equal to 50,000 vehides/day); 536 schools (7.2%) were within 150 m of medium-traffic roads (25,000-49,999 vehicles/day). Traffic exposure was related to race/ethnicity. For example, the overall percentage of nonwhite students was 78% at the schools located near high-traffic roads versus 60% at the schools with very low exposure (no streets with counted traffic data within 150 m). As the traffic exposure of schools increased, the percentage of both non-Hispanic black and Hispanic students attending the schools increased substantially. Traffic exposure was also related to school-based and census-tract-based socioeconomic indicators, including English language learners. The median percentage of children enrolled in free or reduced-price meal programs increased from 40.7% in the group with very low exposure to 60.5% in the highest exposure group. In summary, a substantial number of children in California attend schools dose to major roads with very high traffic counts, and a disproportionate number of those students are economically disadvantaged and nonwhite.	Off Environm Hlth Hazard Assessment, Calif Environm Protect Agcy, Oakland, CA 94612 USA; Environm Hlth Invest Branch, Calif Dept Hlth Serv, Oakland, CA USA	Ostro, B (reprint author), Off Environm Hlth Hazard Assessment, Calif Environm Protect Agcy, 1515 Clay St,16th Fl, Oakland, CA 94612 USA.	bostro@oehha.ca.gov					Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; *CAL AIR RES BOARD, 2003, AIR CLEAN DEV HOM; *CALT DIV TRANSP S, 1997, HIGHW PERF MON SYST; *CDE, 2000, DEM DAT FIL; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; FUNIER RB, 2003, J EXPO ANAL ENV EPID, V13, P240; Hitchins J, 2000, ATMOS ENVIRON, V34, P51, DOI 10.1016/S1352-2310(99)00304-0; Langholz B, 2002, ANN EPIDEMIOL, V12, P482, DOI 10.1016/S1047-2797(01)00317-9; Maantay J, 2002, ENVIRON HEALTH PERSP, V110, P161; Morello-Frosch R, 2002, ANN AM ACAD POLIT SS, V584, P47, DOI 10.1177/000271602237427; Morello-Frosch R, 2002, ENVIRON HEALTH PERSP, V110, P149; Pearson RL, 2000, J AIR WASTE MANAGE, V50, P175; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Reynolds P, 2002, CANCER CAUSE CONTROL, V13, P665, DOI 10.1023/A:1019579430978; *SAN DIEG ASS GOV, 2001, LOC STREET DAIL VEH; SAVITZ DA, 1989, SCAND J WORK ENV HEA, V15, P360; Selvin S, 1996, STAT ANAL EPIDEMIOLO; *STAT CAL LEG COUN, 2003, OFF CAL LEG INF; *US CENS BUR, 2002, AM FACTF; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn A, 2000, OCCUP ENVIRON MED, V57, P152, DOI 10.1136/oem.57.3.152; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilhelm M, 2003, ENVIRON HEALTH PERSP, V111, P207, DOI 10.1289/ehp.5688; WJST M, 1993, BRIT MED J, V307, P596; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zhu YF, 2002, ATMOS ENVIRON, V36, P4323, DOI 10.1016/S1352-2310(02)00354-0	31	75	75	1	11	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2004	112	1					61	66		10.1289/ehp.6566		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	761NH	WOS:000187914500041	14698932	
J	Guerra, S; Lohman, IC; Halonen, M; Martinez, FD; Wright, AL				Guerra, S; Lohman, IC; Halonen, M; Martinez, FD; Wright, AL			Reduced interferon gamma production and soluble CD14 levels in early life predict recurrent wheezing by 1 year of age	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						wheezing; asthma; IFN gamma; CD14 antigen; LPS receptor	RESPIRATORY SYNCYTIAL VIRUS; HOUSE-DUST ENDOTOXIN; BLOOD MONONUCLEAR-CELLS; DAY-CARE ATTENDANCE; IFN-GAMMA; 1ST YEAR; PERIPHERAL-BLOOD; RISK FACTOR; ASTHMA; CHILDREN	It is unknown whether reduced production of IFNgamma in early life, before any lower respiratory tract illness, is a risk factor for recurrent wheezing in infancy. We followed 238 infants prospectively from birth to I year of age. At birth and at 3 months of age, IFNgamma production from polyclonally stimulated peripheral blood mononuclear cells and soluble CD14 (sCD14) levels in plasma were measured. The odds of developing recurrent wheezing (assessed by questionnaire) in the first year of life were up to 4.5 times higher for children in the lowest quartile of IFNgamma production at 3 months (p = 0.0005) and 3.2 times higher for children in the lowest quartile of sCD14 levels at birth (p = 0.004) as compared with children in the other 3 combined quartiles of IFNgamma and sCD14, respectively. Findings were confirmed in the multivariate analysis. IFNgamma production at 3 months and sCD14 levels at birth were correlated (r = 0.188, p = 0.031). Our findings from a longitudinal cohort suggest that impaired IFNgamma production at 3 months and reduced plasmasCD14 levels at birth significantly increase the risk of developing recurrent wheezing in the first year of life.	Univ Arizona, Arizona Resp Ctr, Coll Med, Tucson, AZ 85724 USA	Wright, AL (reprint author), Univ Arizona, Arizona Resp Ctr, Coll Med, 1501 N Campbell Ave,POB 245030, Tucson, AZ 85724 USA.				NHLBI NIH HHS [HL61892, HL67672]; NIAID NIH HHS [AI44697, AI42268]		Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown H, 1999, APPL MIXED MODELS ME; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Guerra S, 2002, ALLERGY, V57, P41; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866; Halonen M, 1997, CLIN EXP ALLERGY, V27, P1234; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Koning H, 1997, CYTOKINE, V9, P416, DOI 10.1006/cyto.1996.0184; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; LANDMANN R, 1995, J INFECT DIS, V171, P639; Leech SC, 2000, ALLERGY, V55, P74, DOI 10.1034/j.1398-9995.2000.00222.x; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Lien E, 1998, BLOOD, V92, P2084; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Marbury MC, 1997, AM J RESP CRIT CARE, V155, P156; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258; Martinez FD, 1999, LANCET S2, V354, pSII12; Nockher WA, 1999, J NEUROIMMUNOL, V101, P161, DOI 10.1016/S0165-5728(99)00141-1; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roman M, 1997, AM J RESP CRIT CARE, V156, P190; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; van Schaik SM, 2000, J MED VIROL, V62, P257, DOI 10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M; van Schaik SM, 1999, J ALLERGY CLIN IMMUN, V103, P630, DOI 10.1016/S0091-6749(99)70235-6; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232	37	75	79	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 1	2004	169	1					70	76		10.1164/rccm.200304-499OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	757PK	WOS:000187570500016	14525803	
S	Walton, SF; Holt, DC; Currie, BJ; Kemp, DJ		Baker, JR; Muller, R; Rollinson, D		Walton, SF; Holt, DC; Currie, BJ; Kemp, DJ			Scabies: New future for a neglected disease	ADVANCES IN PARASITOLOGY, VOL 57	Advances in Parasitology		English	Review							HOUSE-DUST MITE; CROTAMITON 10-PERCENT CREAM; MITOCHONDRIAL-DNA SEQUENCES; CRUSTED NORWEGIAN SCABIES; IMMUNOSORBENT-ASSAY ELISA; TREATMENT AVAILABLE SOON; CDNA EXPRESSION LIBRARY; GROUP-III ALLERGEN; TEA-TREE OIL; SARCOPTES-SCABIEI	Scabies is a disease of global proportions in both human and animal populations, resulting from infestation of the skin with the "itch" mite Sarcoptes scabiei. Despite the availability of effective chemotherapy the intensely itching lesions engender significant morbidity primarily due to secondary sepsis and post-infective complications. Some patients experience an extreme form of the disease, crusted scabies, in which many hundreds of mites may infest the skin causing severe crusting and hyperkeratosis. Overcrowded living conditions and poverty have been identified as significant confounding factors in transmission of the mite in humans. Control is hindered by difficulties with diagnosis, the cost of treatment, evidence for emerging resistance and lack of effective vaccines. Historically research on scabies has been extremely limited because of the difficulty in obtaining sufficient quantities of the organism. Recent molecular approaches have enabled considerable advances in the study of population genetics and transmission dynamics of S. scabiei. However, the most exciting and promising development is the potential exploitation of newly available data from S. scabiei cDNA libraries and EST projects. Ultimately this knowledge may aid early identification of disease, novel forms of chemotherapy, vaccine development and new treatment possibilities for this important but neglected parasite.	Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0811, Australia; Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Australian Ctr Int & Trop Hlth & Nutr, Brisbane, Qld 4029, Australia; Univ Queensland, Brisbane, Qld 4029, Australia; Flinders Univ No Terr Clin Sch, Royal Darwin Hosp, Darwin, NT 0810, Australia	Walton, SF (reprint author), Charles Darwin Univ, Menzies Sch Hlth Res, Darwin, NT 0811, Australia.	Shelley.Walton@menzies.edu.au	Holt, Deborah/A-8002-2012; Walton, Shelley/A-9767-2012	Walton, Shelley/0000-0002-5857-6913			Adedayo O, 2003, POSTGRAD MED J, V79, P341, DOI 10.1136/pmj.79.932.341; AKI T, 1994, INT ARCH ALLERGY IMM, V103, P349; Al-Rawashdeh OF, 2000, J ZOO WILDLIFE MED, V31, P335; ALEXANDER JO, 1984, ARTHROPODS HUMAN SKI, P227; ANDERSON TJC, 1995, PARASITOLOGY, V110, P221; ANDERSON TJC, 1993, PARASITOLOGY, V107, P319; ANDO T, 1993, CLIN EXP ALLERGY, V23, P777, DOI 10.1111/j.1365-2222.1993.tb00366.x; ANDREWS JRH, 1991, MODERN ACAROLOGY, V1, P281; Arlian LG, 2004, J MED ENTOMOL, V41, P74, DOI 10.1603/0022-2585-41.1.74; Arlian LG, 1996, VET PARASITOL, V62, P133, DOI 10.1016/0304-4017(95)00854-3; ARLIAN LG, 1995, AM J TROP MED HYG, V52, P539; ARLIAN LG, 1994, EXP PARASITOL, V78, P51, DOI 10.1006/expr.1994.1005; ARLIAN LG, 1994, EXP PARASITOL, V78, P37, DOI 10.1006/expr.1994.1004; ARLIAN LG, 1991, J INVEST DERMATOL, V96, P349, DOI 10.1111/1523-1747.ep12465257; ARLIAN LG, 1984, J AM ACAD DERMATOL, V10, P979, DOI 10.1016/S0190-9622(84)80318-7; ARLIAN LG, 1988, J AM ACAD DERMATOL, V19, P806, DOI 10.1016/S0190-9622(88)70237-6; ARLIAN LG, 1988, J PARASITOL, V74, P427, DOI 10.2307/3282050; ARLIAN LG, 1988, J MED ENTOMOL, V25, P240; ARLIAN LG, 1984, J AM ACAD DERMATOL, V11, P210, DOI 10.1016/S0190-9622(84)70151-4; Arlian LG, 1996, J PARASITOL, V82, P66, DOI 10.2307/3284117; ARLIAN LG, 1989, ANNU REV ENTOMOL, V34, P139; ARLIAN LG, 1988, J MED ENTOMOL, V25, P52; ARLIAN LG, 1984, J AM ACAD DERMATOL, V11, P594, DOI 10.1016/S0190-9622(84)70212-X; AVISE J, 1994, MOL MARKERS NATURAL, P324; BACKHOUSE T. C., 1929, TRANS R SOC TROP MED & HYG, V23, P173, DOI 10.1016/S0035-9203(29)90549-6; Bailey A M, 2000, Australas J Dermatol, V41, P250, DOI 10.1046/j.1440-0960.2000.00447.x; Barkwell R, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63020-6; Bates P, 2003, VET REC, V152, P112; BECK AL, 1965, ARCH DERMATOL, V91, P54; Berrilli F, 2002, PARASITOL RES, V88, P772, DOI 10.1007/s00436-002-0655-y; Blackhall WJ, 1998, MOL BIOCHEM PARASIT, V95, P193, DOI 10.1016/S0166-6851(98)00087-5; Bornstein S, 1996, VET DERMATOL, V7, P21, DOI 10.1111/j.1365-3164.1996.tb00222.x; Bornstein S, 1997, VET REC, V141, P8; BORNSTEIN S, 1994, VET DERMATOL, V12, P107; Bremner PR, 1998, AM J RESP CRIT CARE, V158, P1724; Brites C, 2002, AIDS, V16, P1292, DOI 10.1097/00002030-200206140-00015; BRODELL RT, 1991, AM FAM PHYSICIAN, V44, P505; BROOK I, 1995, J CLIN MICROBIOL, V33, P2139; Budhiraja SS, 1999, J MANIP PHYSIOL THER, V22, P447, DOI 10.1016/S0161-4754(99)70033-3; BURGESS I, 1994, ADV PARASIT, V33, P235, DOI 10.1016/S0065-308X(08)60414-5; BUSH GL, 1975, ANNU REV ECOL SYST, V6, P339, DOI 10.1146/annurev.es.06.110175.002011; Buss DS, 2002, MED VET ENTOMOL, V16, P218, DOI 10.1046/j.1365-2915.2002.00365.x; CABRERA R, 1993, SEMIN DERMATOL, V12, P15; CAMPBELL WC, 1991, ANNU REV MICROBIOL, V45, P445; Carapetis JR, 1996, LANCET, V347, P1271, DOI 10.1016/S0140-6736(96)90797-7; Carapetis JR, 1997, PEDIATR INFECT DIS J, V16, P494, DOI 10.1097/00006454-199705000-00008; Cargill CF, 1997, VET PARASITOL, V70, P191, DOI 10.1016/S0304-4017(96)01137-5; CARSLAW RW, 1975, BRIT MED J, V2, P617; CARSON CF, 1995, J APPL BACTERIOL, V78, P264, DOI 10.1111/j.1365-2672.1995.tb05025.x; Cass A, 2001, MED J AUSTRALIA, V175, P24; CHAKRABARTI A, 1981, ANN TROP MED PARASIT, V75, P353; CHARLESWORTH EN, 1974, ARCH DERMATOL, V110, P572, DOI 10.1001/archderm.110.4.572; Chosidow O, 2000, LANCET, V355, P819, DOI 10.1016/S0140-6736(99)09458-1; CHOSIDOW O, 20 WORLD C DERM; CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364; CHUA KY, 1990, INT ARCH ALLER A IMM, V91, P118; COMMENS CA, 1994, MED J AUSTRALIA, V160, P317; COSKEY RJ, 1979, ARCH DERMATOL, V115, P109; Cox SD, 2001, J APPL MICROBIOL, V91, P492, DOI 10.1046/j.1365-2672.2001.01406.x; CROOM HB, 1991, J ARACHNOL, V19, P210; Currie B, 1997, LANCET, V350, P1551, DOI 10.1016/S0140-6736(05)63983-9; Currie B J, 2000, Australas J Dermatol, V41, P139, DOI 10.1046/j.1440-0960.2000.00417.x; CURRIE BJ, 1995, MED J AUSTRALIA, V163, P559; CURRIE BJ, 1994, MED J AUSTRALIA, V161, P636; Currie BJ, 2002, J PAEDIATR CHILD H, V38, P223, DOI 10.1046/j.1440-1754.2002.00850.x; CURRIE BJ, CLIN INFECT DIS; DAVIES JE, 1983, ARCH DERMATOL, V119, P142, DOI 10.1001/archderm.119.2.142; Davies PR, 1996, VET PARASITOL, V62, P143, DOI 10.1016/0304-4017(95)00853-5; DAVIS DP, 1990, J MED ENTOMOL, V27, P727; del Giudice Pascal, 2003, J Drugs Dermatol, V2, P13; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; DUNNE CL, 1991, T ROY SOC TROP MED H, V85, P550, DOI 10.1016/0035-9203(91)90255-W; EASON RJ, 1985, PAPUA NEW GUINEA MED, V28, P247; Editorial, 1976, LANCET, V1, P894; Elbers ARW, 2000, VET QUART, V22, P145; ELGART ML, 1990, DERMATOL CLIN, V8, P253; ELGART ML, 1972, SOUTH MED J, V3, P375; Epton MJ, 1999, INT ARCH ALLERGY IMM, V120, P185, DOI 10.1159/000024266; ESTES SA, 1983, J AM ACAD DERMATOL, V9, P397, DOI 10.1016/S0190-9622(83)70148-9; ESTES SA, 1993, SEMIN DERMATOL, V12, P26; ESTES SA, 1993, SEMIN DERMATOL, V12, P34; FAIN A, 1978, INT J DERMATOL, V17, P20, DOI 10.1111/j.1365-4362.1978.tb06040.x; FALK ES, 1980, BRIT J DERMATOL, V103, P367, DOI 10.1111/j.1365-2133.1980.tb07258.x; FALK ES, 1981, ALLERGY, V36, P233, DOI 10.1111/j.1398-9995.1981.tb01568.x; FALK ES, 1981, BRIT J DERMATOL, V104, P317, DOI 10.1111/j.1365-2133.1981.tb00955.x; FALK ES, 1980, BRIT J DERMATOL, V103, P283, DOI 10.1111/j.1365-2133.1980.tb07245.x; Fischer K, 2003, BIOTECHNIQUES, V34, P250; Fischer K, 2003, AM J TROP MED HYG, V68, P61; FOOTE SJ, 1990, NATURE, V345, P255, DOI 10.1038/345255a0; FRASER J, 1994, MED J AUSTRALIA, V160, P806; Fthenakis GC, 2001, VET PARASITOL, V95, P63, DOI 10.1016/S0304-4017(00)00417-9; Fujikawa A, 1996, MOL IMMUNOL, V33, P311, DOI 10.1016/0161-5890(95)00127-1; FUNAKI B, 1987, INT J DERMATOL, V26, P590, DOI 10.1111/j.1365-4362.1987.tb02312.x; Funk DJ, 1999, MOL BIOL EVOL, V16, P67; GEORGHIOU GP, 1990, ACS SYM SER, V421, P18; GILLESPIE RG, 1994, P NATL ACAD SCI USA, V91, P2290, DOI 10.1073/pnas.91.6.2290; GLAZIOU P, 1993, TROP MED PARASITOL, V44, P331; GLOVER R, 1987, J AM ACAD DERMATOL, V16, P396, DOI 10.1016/S0190-9622(87)80145-7; GOGNA NK, 1985, MED J AUSTRALIA, V142, P140; GREEN MS, 1989, EPIDEMIOL REV, V11, P126; GREENE WK, 1991, J IMMUNOL, V147, P3768; Guerrero FD, 2002, J MED ENTOMOL, V39, P770, DOI 10.1603/0022-2585-39.5.770; Harumal P, 2003, AM J TROP MED HYG, V68, P54; HENDERSON CA, 1992, TROP DOCT, V22, P165; HERNANDEZPEREZ E, 1983, J AM ACAD DERMATOL, V8, P1121; Hersch C, 1967, S Afr Med J, V41, P29; HILLIS D, 1996, MOL SYSTEMATICS, P521; HOEFLING KK, 1980, J AM ACAD DERMATOL, V3, P237; Hollanders W, 1997, VET PARASITOL, V69, P117, DOI 10.1016/S0304-4017(96)01117-X; HOLNESS DL, 1992, ARCH DERMATOL, V128, P1257, DOI 10.1001/archderm.128.9.1257; Holt DC, 2003, J INVEST DERMATOL, V121, P1419, DOI 10.1046/j.1523-1747.2003.12621.x; HOLT DC, IN PRESS J INVESTIGA; Hopkins RM, 1997, J PARASITOL, V83, P44, DOI 10.2307/3284315; Hoy WE, 1996, MED J AUSTRALIA, V165, P126; Huffam S E, 1998, Int J Infect Dis, V2, P152, DOI 10.1016/S1201-9712(98)90118-7; Jacobson M, 1999, VET PARASITOL, V81, P249, DOI 10.1016/S0304-4017(98)00247-7; Jensen JCE, 2002, ACTA VET SCAND, V43, P75, DOI 10.1186/1751-0147-43-75; Kane NS, 2000, P NATL ACAD SCI USA, V97, P13949, DOI 10.1073/pnas.240464697; Kar S. K., 1994, National Medical Journal of India, V7, P15; KEMP DJ, 1983, P NATL ACAD SCI-BIOL, V80, P3787, DOI 10.1073/pnas.80.12.3787; Kenyon F, 2003, PARASITOLOGY, V126, P451, DOI 10.1017/S0031182003003044; KETTLE DS, 1984, MED ENTOMOL, P356; KIDANE GZ, 1989, J BIOL CHEM, V264, P4244; KOCHER TD, 1989, P NATL ACAD SCI USA, V86, P6196, DOI 10.1073/pnas.86.16.6196; KOLAR KA, 1991, AM FAM PHYSICIAN, V44, P1317; LAWRENCE GW, 1994, MED J AUSTRALIA, V161, P232; Le Jambre LF, 2000, INT J PARASITOL, V30, P105, DOI 10.1016/S0020-7519(99)00172-1; Lee AJ, 1999, VET PARASITOL, V83, P241, DOI 10.1016/S0304-4017(99)00061-8; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; LINES DR, 1977, AUST NZ J MED, V7, P143, DOI 10.1111/j.1445-5994.1977.tb04681.x; Lizotte-Waniewski M, 2000, INFECT IMMUN, V68, P3491, DOI 10.1128/IAI.68.6.3491-3501.2000; Ljunggren EL, 2003, PARASITOLOGY, V127, P139, DOI 10.1017/S003118200300338X; Loukas A, 2001, CLIN MICROBIOL REV, V14, P689, DOI 10.1128/CMR.14.4.689-703.2001; Lower KS, 2001, VET DERMATOL, V12, P315, DOI 10.1046/j.0959-4493.2001.00265.x; LYMBERY AJ, 1990, PARASITOLOGY, V101, P283; MACDONALD RAS, 1922, LANCET          0415, P738; Mantle David, 2001, Adverse Drug Reactions and Toxicological Reviews, V20, P89; Martin RW, 1998, AUST VET J, V76, P411, DOI 10.1111/j.1751-0813.1998.tb12391.x; Mattsson JG, 2001, PARASITOLOGY, V122, P555, DOI 10.1017/S0031182001007648; MEINKING TL, 1995, NEW ENGL J MED, V333, P26, DOI 10.1056/NEJM199507063330105; Melby PC, 2000, INFECT IMMUN, V68, P5595, DOI 10.1128/IAI.68.10.5595-5602.2000; Mellanby K, 1941, Br Med J, V2, P405; MELLANBY K, 1942, BRIT MED J, P4252; Mellanby Kenneth, 1944, PARASITOLOGY, V35, P197; Mercier P, 2002, VET PARASITOL, V110, P25, DOI 10.1016/S0304-4017(02)00311-4; MOBERG SAW, 1984, J AM ACAD DERMATOL, V11, P242, DOI 10.1016/S0190-9622(84)70157-5; MOLLISON LC, 1993, LANCET, V341, P1281, DOI 10.1016/0140-6736(93)91186-P; MONTESU MA, 1991, AM J DERMATOPATH, V13, P425; MORGAN MS, 1994, FOLIA PARASIT, V41, P223; Morgan MS, 1997, AM J TROP MED HYG, V57, P190; Morner T., 1992, Revue Scientifique et Technique Office International des Epizooties, V11, P1115; MORSY T A, 1990, Journal of the Egyptian Society of Parasitology, V20, P565; MUMCUOGLU Y, 1979, RECENT ADV ACAROL, V2, P205; MUNOZ E, 1992, MED J AUSTRALIA, V156, P529; NAIR BKH, 1977, INDIAN J MED RES, V65, P513; NARAHASHI T, 1989, INSECTICIDE ACTION, P55; Narahashi T, 2000, J PHARMACOL EXP THER, V294, P1; NAVAJAS M, 1994, EXP APPL ACAROL, V18, P351, DOI 10.1007/BF00116316; NORINS AL, 1969, AM J DIS CHILD, V117, P239; Normaznah Y., 1996, Southeast Asian Journal of Tropical Medicine and Public Health, V27, P53; Oladimeji FA, 2000, J ETHNOPHARMACOL, V72, P305, DOI 10.1016/S0378-8741(00)00229-4; ORKIN M, 1971, J AMER MED ASSOC, V217, P593, DOI 10.1001/jama.217.5.593; ORKIN M, 1993, SEMIN DERMATOL, V12, P22; ORKIN M, 1975, JAMA-J AM MED ASSOC, V233, P882, DOI 10.1001/jama.233.8.882; PALLER AS, 1993, SEMIN DERMATOL, V12, P3; PATTERSON WD, 1973, BRIT MED J, V4, P211; PEAT JK, 1992, BRIT MED J, V305, P1326; PENCE DB, 1983, J PARASITOL, V69, P1100, DOI 10.2307/3280873; Pence DB, 2002, REV SCI TECH OIE, V21, P385; POONKING T, 1973, LANCET, V1, P475; Prens E, 1996, AM J PATHOL, V148, P1493; Prichard RK, 2001, TRENDS PARASITOL, V17, P445, DOI 10.1016/S1471-4922(01)01983-3; RAMAN A, 1995, LETT APPL MICROBIOL, V21, P242, DOI 10.1111/j.1472-765X.1995.tb01051.x; RAND KN, 1989, P NATL ACAD SCI USA, V86, P9657, DOI 10.1073/pnas.86.24.9657; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; Rehbein S, 2003, VET PARASITOL, V114, P267, DOI 10.1016/S0304-4017(03)00140-7; Richard KR, 1996, P NATL ACAD SCI USA, V93, P8792, DOI 10.1073/pnas.93.16.8792; ROTH WI, 1991, J AM ACAD DERMATOL, V24, P502, DOI 10.1016/S0190-9622(08)80078-3; Rubin GM, 2000, SCIENCE, V287, P2204, DOI 10.1126/science.287.5461.2204; RUIZMALDONADO R, 1977, ARCH DERMATOL, V113, P1733; Sachdev T R, 1982, J Indian Assoc Commun Dis, V5, P88; Salomone N, 1996, EXP APPL ACAROL, V20, P607, DOI 10.1007/BF00053324; Sangster NC, 1999, PARASITOL TODAY, V15, P141, DOI 10.1016/S0169-4758(99)01413-1; Santoro Anthony F, 2003, J Drugs Dermatol, V2, P397; Schmeller W, 2001, BRIT J DERMATOL, V144, P118, DOI 10.1046/j.1365-2133.2001.03962.x; SCHULTZ MW, 1990, ARCH DERMATOL, V126, P167, DOI 10.1001/archderm.126.2.167; Schwartzman R.M., 1983, P90; SCOTT DW, 1987, VET CLIN N AM-SMALL, V17, P117; Scott JP, 1999, INT J PARASITOL, V29, P437, DOI 10.1016/S0020-7519(98)00227-6; SEDDON HR, 1968, DIS DOMESTIC ANIMA 3, V3, P98; SHELLEY WB, 1988, J AM ACAD DERMATOL, V19, P673, DOI 10.1016/S0190-9622(88)70221-2; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; SHRANK AB, 1967, BMJ-BRIT MED J, V1, P669; Simon C., 1991, NATO ASI Series Series H Cell Biology, V57, P33; SIMPSON AJG, 1986, MOL BIOCHEM PARASIT, V18, P25, DOI 10.1016/0166-6851(86)90047-2; Skerratt LF, 1998, AUST VET J, V76, P408, DOI 10.1111/j.1751-0813.1998.tb12389.x; Skerratt LF, 2002, PARASITOL RES, V88, P376, DOI 10.1007/s00436-001-0556-5; Smith WA, 1996, CLIN EXP ALLERGY, V26, P571, DOI 10.1046/j.1365-2222.1996.d01-339.x; SMITH WA, 1994, CLIN EXP ALLERGY, V24, P220, DOI 10.1111/j.1365-2222.1994.tb00223.x; Smits JM, 2001, TIJDSCHR DIERGENEESK, V126, P2; STEVENSON WJ, 1988, SYNOPSIS ZOONOSES AU, P154; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STROMBERG PC, 1986, AM J VET RES, V47, P1551; Sun G, 2001, J IMMUNOL, V167, P1014; SVARTMAN M, 1972, LANCET, V1, P249; TANNENBAUM MH, 1965, JAMA-J AM MED ASSOC, V193, P141; TAPLIN D, 1983, J AM ACAD DERMATOL, V9, P546, DOI 10.1016/S0190-9622(83)70167-2; TAPLIN D, 1983, J AM ACAD DERMATOL, V9, P550, DOI 10.1016/S0190-9622(83)70168-4; TAPLIN D, 1991, LANCET, V337, P1016; TAPLIN D, 1990, ARCH DERMATOL, V126, P213, DOI 10.1001/archderm.126.2.213; TAPLIN D, 1990, PEDIATR DERMATOL, V7, P67, DOI 10.1111/j.1525-1470.1990.tb01078.x; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; THOMPSON RCA, 1996, PARASITOLOGY, V112, P1; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; UNNASCH TR, 1988, J CLIN INVEST, V82, P262, DOI 10.1172/JCI113581; van der Heijden HMJF, 2000, VET PARASITOL, V89, P95, DOI 10.1016/S0304-4017(00)00197-7; Veale AJ, 1996, MED J AUSTRALIA, V165, P192; Walton SF, 1999, AM J TROP MED HYG, V61, P542; Walton SF, 1997, MOL BIOCHEM PARASIT, V85, P187, DOI 10.1016/S0166-6851(96)02825-3; Walton SF, 1999, CLIN INFECT DIS, V29, P1226, DOI 10.1086/313466; WALTON SF, 2000, T ROY SOC TROP MED H, V94, P1; WALTON SF, IN PRESS ARCH DERMAT; WALTON SF, IN PRESS INT J PARAS; White AV, 2001, MED J AUSTRALIA, V174, P492; Witkowski JA, 2002, CLIN DERMATOL, V20, P87, DOI 10.1016/S0738-081X(01)00238-3; Wong LCF, 2001, MED J AUSTRALIA, V175, P367; Wong Li-Chuen, 2002, Australas J Dermatol, V43, P274, DOI 10.1046/j.1440-0960.2002.00626.x; Xu M, 1998, MOL BIOCHEM PARASIT, V91, P327, DOI 10.1016/S0166-6851(97)00215-6; Yang Y, 1996, J INVEST DERMATOL, V107, P367; Zahler M, 1999, INT J PARASITOL, V29, P759, DOI 10.1016/S0020-7519(99)00034-X	231	75	80	0	7	ACADEMIC PRESS LTD-ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL ROAD, LONDON NW1 7DX, ENGLAND	0065-308X		0-12-031757-5	ADV PARASIT	Adv.Parasitol.		2004	57						309	376		10.1016/S0065-308X(04)57005-7		68	Parasitology	Parasitology	BBC85	WOS:000224891700005	15504541	
J	Vermaelen, K; Pauwels, R				Vermaelen, K; Pauwels, R			Accelerated airway dendritic cell maturation, trafficking, and elimination in a mouse model of asthma	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							NECROSIS-FACTOR-ALPHA; CD4(+) T-CELLS; INHALED ANTIGEN; CLASS-II; IN-VIVO; ICOS; INFLAMMATION; RESPONSES; MICE; APOPTOSIS	Pulmonary dendritic cells (DC) can induce both tolerogenic as well as inflammatory immune responses in the lung. Conversely, little is known about the impact of ongoing airway inflammation on pulmonary DC biology. In noninflammatory conditions, expression of T cell costimulatory molecules on mouse airway DCs is low and only upregulated after homing into draining thoracic lymph nodes. In this study, we reveal that ongoing allergic airway inflammation induces a premature upregulation of the T cell costimulatory molecules CD40, B7-2 and intercellular adhesion molecule 1 on DCs still present in the airways. In contrast, high surface expression of inducible costimulator ligand, involved in respiratory tolerance induction is restricted to DCs from noninflamed lungs. In addition, during inflammation the migratory flux of allergen-transporting airway DCs toward draining thoracic nodes increases both in amplitude as well as in speed. Remarkably, migratory DCs from inflamed airways are short-lived in the draining lymph nodes, a finding that is temporally associated with a marked loss of the antiapoptotic protein Bcl-2 in these cells. This study demonstrates the profound effects of ongoing allergen-driven airway inflammation on the dynamics of pulmonary DC physiology, a knowledge that could be exploited in the development of novel DC-based immunotherapies.	State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Vermaelen, K (reprint author), State Univ Ghent Hosp, Dept Resp Dis, 7K12ie,De Pintelaan 185, B-9000 Ghent, Belgium.						Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; AKHARI O, 2001, NAT IMMUNOL, V2, P725; Bjorck P, 1997, INT IMMUNOL, V9, P365, DOI 10.1093/intimm/9.3.365; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254; Cochand L, 1999, AM J RESP CELL MOL, V21, P547; Coyle AJ, 2000, IMMUNITY, V13, P95, DOI 10.1016/S1074-7613(00)00011-X; Cumberbatch M, 1999, ARCH DERMATOL RES, V291, P453, DOI 10.1007/s004030050437; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326; Gonzalo JA, 2001, NAT IMMUNOL, V2, P597, DOI 10.1038/89739; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Ingulli E, 1997, J EXP MED, V185, P2133, DOI 10.1084/jem.185.12.2133; Iwai H, 2002, J IMMUNOL, V169, P4332; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kellermann SA, 1999, J IMMUNOL, V162, P3859; Krupa WM, 2002, AM J PATHOL, V161, P1815, DOI 10.1016/S0002-9440(10)64458-6; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Langenkamp A, 2002, EUR J IMMUNOL, V32, P2046, DOI 10.1002/1521-4141(200207)32:7<2046::AID-IMMU2046>3.0.CO;2-M; MACPHERSON GG, 1995, J IMMUNOL, V154, P1317; Matsue H, 1999, J IMMUNOL, V162, P5287; McLellan A, 2000, EUR J IMMUNOL, V30, P2612, DOI 10.1002/1521-4141(200009)30:9<2612::AID-IMMU2612>3.0.CO;2-G; Nopora A, 2002, J IMMUNOL, V169, P3006; PUGH CW, 1983, J EXP MED, V157, P1758, DOI 10.1084/jem.157.6.1758; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Vermaelen KY, 2001, J EXP MED, V193, P51; Yoshinaga SK, 2000, INT IMMUNOL, V12, P1439, DOI 10.1093/intimm/12.10.1439; Yoshinaga SK, 1999, NATURE, V402, P827, DOI 10.1038/45582	30	75	78	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	SEP	2003	29	3	1				405	409		10.1165/rcmb.2003-0008OC		5	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	717NE	WOS:000185095400016	12702544	
J	Lee, YL; Shaw, CK; Su, HJ; Lai, JS; Ko, YC; Huang, SL; Sung, FC; Guo, YL				Lee, YL; Shaw, CK; Su, HJ; Lai, JS; Ko, YC; Huang, SL; Sung, FC; Guo, YL			Climate, traffic-related air pollutants and allergic rhinitis prevalence in middle-school children in Taiwan	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; allergic rhinitis; children; climate; factor analysis	RESPIRATORY HEALTH; SUBTROPICAL CLIMATE; NITROGEN-DIOXIDE; HAY-FEVER; ASTHMA; SYMPTOMS; EPIDEMIOLOGY; ATOPY; POLLUTION; EXPOSURE	The prevalence of allergic rhinitis, a common respiratory disorder, may be rapidly increasing. Epidemiological studies, however, indicate little about its association with climatic factors and air pollution. The relationship between traffic-related air pollutants and allergic rhinitis in middle-school students was therefore investigated. In a nationwide survey of middle-school students in Taiwan conducted in 1995/1996, the lifetime prevalence of physician-diagnosed allergic rhinitis and typical symptoms of allergic rhinitis were compared with air-monitoring station data on temperature, relative humidity, sulphur dioxide (SO2), nitrogen oxides (NOx), ozone (03), carbon monoxide (CO) and particulate matter with a 50% cut-off aerodynamic diameter of 10 PM (PM10). A total of 331,686 nonsmoking children attended schools located within 2 km of 55 stations. Mean (range) annual exposures were: CO 853 (381-1,610) parts per billion (ppb), NOx 35.1 (10.2-72.4) ppb, SO2 7.57 (0.88-21.2) ppb, PM10 69.2 (40.1-116.2) mug.m(-3), O-3 21.3 (12.4-34.1) ppb, temperature 22.9 (19.6-25.1)degreesC, and relative humidity 76.2 (64.8-86.2)%. The prevalence of physician-diagnosed allergic rhinitis was 28.6 and 19.5% in males and females, respectively, with prevalence of questionnaire-determined allergic rhinitis 42.4 and 34.0%. After adjustment for age, parental education and history of atopic eczema, physician-diagnosed allergic rhinitis was found to be associated with higher nonsummer (September-May) warmth and traffic-related air pollutants, including CO, NOx and O-3. Questionnaire-determined allergic rhinitis correlated only with traffic-related air pollutants. Nonsummer warmth and traffic-related air pollution, probably mediated through exposure to common allergens such as dust mites, are possible risk factors for allergic rhinitis in middle-school-aged children.	Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, Tainan 704, Taiwan; Natl Cheng Kung Univ, Dept Internal Med, Tainan 704, Taiwan; Natl Cheng Kung Univ, Inst Basic Med Sci, Tainan 704, Taiwan; Tzu Chi Univ, Dept Publ Hlth, Hualien, Taiwan; China Med Coll, Dept Occupat Safety & Hlth, Taichung, Taiwan; Kaohsiung Med Univ, Dept Publ Hlth, Kaohsiung, Taiwan; Natl Yang Ming Univ, Inst Environm Hlth Sci, Taipei 112, Taiwan; Natl Taiwan Univ, Inst Environm Hlth, Taipei 10764, Taiwan	Guo, YL (reprint author), Natl Cheng Kung Univ, Dept Environm & Occupat Hlth, 138 Sheng Li Rd, Tainan 704, Taiwan.		Ko, Ying-Chin/C-2084-2009	GUO, Yue Leon/0000-0002-8530-4809; Su, Huey-Jen/0000-0003-3589-9987; LEE, YUNG-LING/0000-0002-2234-9479			41st World Medical Assembly, 1990, B PAN AM HLTH ORG, V24, P606; Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; Arlian LG, 1996, J MED ENTOMOL, V33, P257; Basagana X, 2001, AM J RESP CRIT CARE, V164, P1133; Bass DJ, 2000, ANN ALLERG ASTHMA IM, V85, P374; Brisman J, 2000, OCCUP ENVIRON MED, V57, P335, DOI 10.1136/oem.57.5.335; Butland BK, 1997, BRIT MED J, V315, P717; Chen PC, 1998, ENVIRON HEALTH PERSP, V106, P331, DOI 10.1289/ehp.98106331; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; de Marco R, 2002, CLIN EXP ALLERGY, V32, P1405, DOI 10.1046/j.1365-2745.2002.01466.x; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; Estela LBL, 1998, INT J BIOMETEOROL, V42, P77; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Hales S, 1998, ENVIRON HEALTH PERSP, V106, P607, DOI 10.1289/ehp.98106607; Hjern A, 2001, CLIN EXP ALLERGY, V31, P908, DOI 10.1046/j.1365-2222.2001.01096.x; KAISER HF, 1958, PSYCHOMETRIKA, V23, P187, DOI 10.1007/BF02289233; KLEINMAN L, 1995, J GEOPHYS RES-ATMOS, V100, P7263, DOI 10.1029/95JD00215; Ko Ying-Chin, 1996, Kaohsiung Journal of Medical Sciences, V12, P657; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Li CS, 1996, ARCH ENVIRON HEALTH, V51, P42; Li LF, 1999, J FORMOS MED ASSOC, V98, P486; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Magnus P, 1997, BRIT MED J, V314, P1795; Mygind N, 1996, PEDIATR ALLERGY IMMU, V7, P57, DOI 10.1111/j.1399-3038.1996.tb00397.x; Nathan R. A., 1997, J ALLERGY CLIN IMMUN, V99, pS808; NG TP, 1994, INT J EPIDEMIOL, V23, P553, DOI 10.1093/ije/23.3.553; Nicolai T, 1997, Arch Toxicol Suppl, V19, P201; Omran M, 1996, BRIT MED J, V312, P34; PICCOLO MC, 1988, ANN ALLERGY, V60, P107; Samir M, 1997, ARCH OTOLARYNGOL, V123, P746; Saraclar Y, 1997, J ASTHMA, V34, P23, DOI 10.3109/02770909709071200; SETTIPANE GA, 1977, J ALLERGY CLIN IMMUN, V59, P17, DOI 10.1016/0091-6749(77)90171-3; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; STRACHAN DP, 1989, BRIT MED J, V299, P1259; SULLIVAN SD, 1993, ALLERGY, V48, P146, DOI 10.1111/j.1398-9995.1993.tb04719.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; WANG JH, 1995, J ALLERGY CLIN IMMUN, V96, P669, DOI 10.1016/S0091-6749(95)70266-0; WANG JH, 1995, INT ARCH ALLERGY IMM, V107, P103; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; WJST M, 1993, BRIT MED J, V307, P596; WRIGHT AL, 1994, PEDIATRICS, V94, P895; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yang CY, 1997, ENVIRON RES, V75, P49, DOI 10.1006/enrs.1997.3774	47	75	81	0	19	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUN	2003	21	6					964	970		10.1183/09031936.03.00094602		7	Respiratory System	Respiratory System	685CH	WOS:000183242900010	12797489	
J	Ravindra, K; Mor, S; Kaushik, CP				Ravindra, K; Mor, S; Kaushik, CP			Short-term variation in air quality associated with firework events: A case study	JOURNAL OF ENVIRONMENTAL MONITORING			English	Article							SULFUR-DIOXIDE; AMBIENT AIR; HOSPITAL ADMISSIONS; DAILY MORTALITY; LUNG-FUNCTION; POLLUTION; EXPOSURE; CHILDREN; BIRMINGHAM; ASTHMA	The effect of fireworks on air quality as assessed from the ambient concentrations of various air pollutants (SO2, NO2, PM10 and TSP) during Diwali festival in Hisar city (India). in November 1999, The extensive use of fireworks as found to be related to short-term variation in air quality. During the festival the concentration of SO2 was observed to be increased similar to 10-fold at few sites. whereas the concentrations of NO2, PM10 and TSP increased 2-3 times. compared to the data collected on a typical winter day in December 1999. The maximum NO2 concentration was observed a day after the festival. The diurnal pattern of the above pollutants showed a slight increase in the night. The levels of these Pollutants observed during Diwali were found to be moderately high, which can be associated with. serious health impacts.	Guru Jambheshwar Univ, Dept Environm Sci & Engn, Hisar 125001, Haryana, India	Ravindra, K (reprint author), Univ Antwerp, Dept Chem, Micro & Trace Anal Ctr, Univ Pl 1, B-2610 Antwerp, Belgium.						Ackermann-Liebrich U., 1999, AIR POLLUTION HLTH, P559; *AM THOR SOC COMM, 1996, AM J RESP CRIT CARE, V131, P133; Attri AK, 2001, NATURE, V411, P1015, DOI 10.1038/35082634; Babu SS, 2001, CURR SCI INDIA, V81, P1208; BACH W, 1975, INT J ENVIRON STUD, V7, P183, DOI 10.1080/00207237508709692; Bakke B, 2001, SCAND J WORK ENV HEA, V27, P250; BALMES JR, 1987, AM REV RESPIR DIS, V136, P1117; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Bates DV, 1995, SCAND J WORK ENV HEA, V21, P405; Bates DV, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_2.S3; Becker JM, 2000, ANN ALLERG ASTHMA IM, V85, P512; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; Bull MJ, 2001, PEDIATRICS, V108, P190; Carranza JE, 2001, SPECTROCHIM ACTA B, V56, P851, DOI 10.1016/S0584-8547(01)00183-5; *CENTR POLL CONTR, 2000, NAT AMB QUAL STAT IN; CHAUHAN AJ, 1998, REV ENV HLTH, V13, P91; Clark H, 1997, ATMOS ENVIRON, V31, P2893, DOI 10.1016/S1352-2310(97)88278-7; DOCKERY DW, 1992, ENVIRON RES, V59, P362, DOI 10.1016/S0013-9351(05)80042-8; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dyke P, 1997, CHEMOSPHERE, V34, P1191, DOI 10.1016/S0045-6535(97)00418-9; Fischer P, 2001, EPIDEMIOLOGY, V12, pS98; Fleischer O, 1999, CHEMOSPHERE, V39, P925, DOI 10.1016/S0045-6535(99)00019-3; Gong H, 1995, TOXICOL IND HEALTH, V11, P467; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; HOLMES HH, 1983, ENCY AM, V11, P263; Lodge Jr J. P., 1989, METHODS AIR SAMPLING, P403; Michie CA, 2000, PEDIATR RES, V47, p479A; PONKA A, 1994, ENVIRON RES, V65, P207, DOI 10.1006/enrs.1994.1032; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; Ravindra K, 2001, REV ENV HLTH, V16, P169; RAVINDRA K, 1999, THESIS GJ U HISAR; Schindler C, 1998, EPIDEMIOLOGY, V9, P405, DOI 10.1097/00001648-199807000-00010; SCHWARTZ J, 1993, AM J EPIDEMIOL, V137, P1136; Schwela D, 2000, Rev Environ Health, V15, P13; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SUKUMAR A, 1992, SCI TOTAL ENVIRON, V114, P161, DOI 10.1016/0048-9697(92)90422-O; TAKIGUCHI SA, 2000, CRIT CARE MED, V28, P527; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; *WHO, 1999, WHO REG PUBL EUR SER, V23; World Health Organization (WHO), 1987, WHO REG PUBL EUR SER, V23; WHO, 2000, GUID AIR QUAL; World Health Organization, 1997, ENV HLTH CRIT, V188	42	75	82	0	19	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1464-0325			J ENVIRON MONITOR	J. Environ. Monit.	APR	2003	5	2					260	264		10.1039/b211943a		5	Chemistry, Analytical; Environmental Sciences	Chemistry; Environmental Sciences & Ecology	670DT	WOS:000182392700020	12729265	
J	Yoshida, Y; Sakaguchi, H; Ito, Y; Okuda, M; Suzuki, H				Yoshida, Y; Sakaguchi, H; Ito, Y; Okuda, M; Suzuki, H			Evaluation of the skin sensitization potential of chemicals using expression of co-stimulatory molecules, CD54 and CD86, on the naive THP-1 cell line	TOXICOLOGY IN VITRO			English	Article						CD54; CD86; THP-1 cell line; in vitro sensitization test	EPIDERMAL LANGERHANS CELLS; VITRO PRIMARY SENSITIZATION; HUMAN DENDRITIC CELLS; IN-VITRO; T-CELLS; CONTACT SENSITIVITY; MESSENGER-RNA; HAPTENS; PHENOTYPE; INDUCTION	It has been known that dendritic cells (DCs) including Langerhans cells (LCs) play a critical role in the skin sensitization process. Many attempts have been made to develop in vitro sensitization tests that employ DCs derived from peripheral blood mononuclear cells (PBMC-DC) or CD34 + hematopoietic progenitor cells (CD34 + HPC) purified from cord blood or bone marrow. However, the use of the DCs in in vitro methods has been difficult due to the nature of these cells such as low levels in the source and/or donor-to-donor variability. In our studies, we employed the human monocytic leukemia cell line, THP-1, in order to avoid some of these difficulties. At the start, we examined whether treatment of the cells with various cytokines could produce DCs from THP-1. Treatment of THP-1 cells with cytokines such as GM-CSF, IL-4, TNF-alpha, and/or PMA did induce some phenotypic changes in THP-1 cells that were characteristic of DCs. Subsequently, responses to a known sensitizer, dinitrochlorobenzene (DNCB), and a non-sensitizer, dimethyl sulfoxide (DMSO) or sodium lauryl sulfate (SLS), on the expression of co-stimulatory molecules, CD54 and CD86, were examined between the naive cells and the cytokine-treated cells. Interestingly, the naive THP-1 cells responded only to DNCB and the response to the sensitizer was more distinct than cytokine-treated THP-1 cells. Similar phenomena were also observed in the human myeloid leukemia cell line, KG-l. Furthermore, with treatment of DNCB, naive THP-1 cells showed augmented expression of HLA, CD80 and secretion of IL-1beta. The response of THP-1 cells to a sensitizer was similar to that of LCs/DCs. Upon demonstrating the differentiation of monocyte cells in our system, we then evaluated a series of chemicals, including known sensitizers and non-sensitizers, for their potential to augment CD54 and CD86 expression on naive THP-1 cells. Indeed, known sensitizers such as PPD and 2-MBT significantly augmented CD54 and CD86 expression in a dose-dependent manner while non-sensitizers, such as SLS and methyl salicylate (MS), did not. To note, the metal allergens such as (NH4)(2)[PtCl4], NiSO4 and CoSO4 augmented significantly only CD54 expression. Taking advantage of a cultured cell line, measurement of the co-stimulatory molecules, CD54 and CD86, on naive THP-1 cells following chemical exposure shows promise for the development of a simple, short-term in vitro sensitization test. (C) 2003 Elsevier Science Ltd. All rights reserved.	Kao Corp, Safety & Microbial Control Res Ctr, Tochigi 3213497, Japan	Yoshida, Y (reprint author), Kao Corp, Safety & Microbial Control Res Ctr, 2606 Akabane Ichikai Machi Haga Gun, Tochigi 3213497, Japan.						AIBA S, 1990, J IMMUNOL, V145, P2791; Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Aiba S, 2000, IMMUNOLOGY, V101, P68, DOI 10.1046/j.1365-2567.2000.00087.x; Ashikaga T, 2002, TOXICOL IN VITRO, V16, P711, DOI 10.1016/S0887-2333(02)00060-7; CAUX C, 1992, NATURE, V360, P258, DOI 10.1038/360258a0; Chapuis F, 1997, EUR J IMMUNOL, V27, P431, DOI 10.1002/eji.1830270213; Coutant KD, 1999, TOXICOL SCI, V52, P189, DOI 10.1093/toxsci/52.2.189; De Smedt ACA, 2001, TOXICOL IN VITRO, V15, P319, DOI 10.1016/S0887-2333(01)00029-7; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Guironnet G, 2000, TOXICOL IN VITRO, V14, P517, DOI 10.1016/S0887-2333(00)00043-6; Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201; Krasteva M, 1996, CLIN EXP ALLERGY, V26, P563, DOI 10.1046/j.1365-2222.1996.d01-342.x; Mossmann T, 1983, J IMMUNOL METHODS, V6, P55; MOULON C, 1993, IMMUNOLOGY, V80, P373; Ozawa H, 1996, J INVEST DERMATOL, V106, P441, DOI 10.1111/1523-1747.ep12343589; Pichowski JS, 2000, TOXICOL IN VITRO, V14, P351, DOI 10.1016/S0887-2333(00)00030-8; REID CDL, 1990, BLOOD, V76, P1139; Reutter K, 1997, TOXICOL IN VITRO, V11, P619, DOI 10.1016/S0887-2333(97)00048-9; ROMANI N, 1989, J INVEST DERMATOL, V93, P600, DOI 10.1111/1523-1747.ep12319727; Rougier N, 2000, TOXICOLOGY, V145, P73, DOI 10.1016/S0300-483X(99)00222-X; SALLUSTRO F, 1994, J EXP MED, V161, P526; St Louis DC, 1999, J IMMUNOL, V162, P3237; Tuschl H, 2000, TOXICOL IN VITRO, V14, P541, DOI 10.1016/S0887-2333(00)00051-5; Tuschl H, 2001, TOXICOL IN VITRO, V15, P327, DOI 10.1016/S0887-2333(01)00030-3	24	75	77	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-2333			TOXICOL IN VITRO	Toxicol. Vitro	APR	2003	17	2					221	228		10.1016/S0887-2333(03)00006-7		8	Toxicology	Toxicology	665YY	WOS:000182149900012	12650676	
J	Bottcher, MF; Bjorksten, B; Gustafson, S; Voor, T; Jenmalm, MC				Bottcher, MF; Bjorksten, B; Gustafson, S; Voor, T; Jenmalm, MC			Endotoxin levels in Estonian and Swedish house dust and atopy in infancy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; childhood; endotoxin	HAY-FEVER; BACTERIAL LIPOPOLYSACCHARIDE; ALLERGIC SENSITIZATION; RESPIRATORY SYMPTOMS; CELL-DEVELOPMENT; ASTHMA; EXPOSURE; PREVALENCE; CHILDREN; ECZEMA	Background Immune responses, including those to allergens, may be T helper (Th)2 skewed in newborns. In order to redress the fetal Th1/Th2 imbalance, Th1-stimulating factors, such as bacterial endotoxin, may be required. The increasing prevalence and severity of atopic diseases in industrialized countries, which are in marked contrast with the low prevalence of allergy among children in the formerly socialist countries of Europe, have been suggested to be caused by a reduced microbial stimulation. Aim To relate the endotoxin levels in house dust from two countries with a low (Estonia) and a high (Sweden) prevalence of allergy to the development of atopic disease and sensitization in the children during the first 2 years of life. Methods The study included 108 children from Tartu, Estonia and 111 children from Linkoping, Sweden. Skin prick tests were performed at 3, 6, 12 and 24 months of age, and questionnaires were distributed to the families. At 24 months, a paediatrician examined the children. Dust samples were collected from mattresses and carpets and the endotoxin concentration was determined by a chromogenic Limulus assay. Results The endotoxin levels were higher in Estonian than in Swedish house dust (median levels 29 (range 0.25-280) and 14 (range 0.25-99) EU/mg dust, respectively, P < 0.001). Furthermore, the levels were inversely related to the development of atopic disease and sensitization in the Swedish, but not in the Estonian, children. Conclusions The low prevalence of atopic disease in Estonia may, at least in part, be related to the high endotoxin levels in this country. The findings support that high levels of endotoxin, or other bacterial products with Th1-stimulating properties, might protect children from developing atopic disease.	Linkoping Univ, Dept Mol & Clin Med, Div Paediat, S-58183 Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Clin Res Ctr, S-58183 Linkoping, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Tartu Univ Clin, Childrens Clin, Tartu, Estonia	Bottcher, MF (reprint author), Linkoping Univ Hosp, Div Paediat, S-58185 Linkoping, Sweden.		Jenmalm, Maria/C-9679-2009	Jenmalm, Maria/0000-0002-2117-5366			ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Adkins P, 2001, J IMMUNOL, V166, P918; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; BRABACK L, 1995, ARCH DIS CHILD, V72, P487; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Butland BK, 1997, BRIT MED J, V315, P717; Corinti S, 2001, J IMMUNOL, V166, P4312; Eldridge MW, 2000, J ALLERGY CLIN IMMUN, V105, P475, DOI 10.1067/mai.2000.104552; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Johnson CC, 2000, J ALLERGY CLIN IMMUN, V105, pS80, DOI 10.1016/S0091-6749(00)90673-0; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Koulis A, 2000, CLIN EXP ALLERGY, V30, P747; MANETTI R, 1993, J EXP MED, V177, P1199, DOI 10.1084/jem.177.4.1199; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Riikjarv MA, 2000, EUR RESPIR J, V16, P86, DOI 10.1034/j.1399-3003.2000.16a15.x; Rogge L, 1998, J IMMUNOL, V161, P6567; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; Yang LP, 1995, EUR J IMMUNOL, V25, P3517, DOI 10.1002/eji.1830251247	32	75	76	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2003	33	3					295	300		10.1046/j.1365-2222.2003.01562.x		6	Allergy; Immunology	Allergy; Immunology	651QA	WOS:000181330600006	12614441	
J	Hovell, MF; Meltzer, SB; Wahlgren, DR; Matt, GE; Hofstetter, R; Jones, JA; Meltzer, EO; Bernert, JT; Pirkle, JL				Hovell, MF; Meltzer, SB; Wahlgren, DR; Matt, GE; Hofstetter, R; Jones, JA; Meltzer, EO; Bernert, JT; Pirkle, JL			Asthma management and environmental tobacco smoke exposure reduction in Latino children: A controlled trial	PEDIATRICS			English	Article						environmental tobacco smoke; passive smoking; coaching; Latino; women; children; asthma; cotinine	PASSIVE SMOKING; SOCIOECONOMIC-FACTORS; YOUNG-CHILDREN; RELIABILITY; COTININE; INCOME; CALIFORNIA; VALIDITY; HEALTH; HOSPITALIZATION	Objectives. This study tested the efficacy of coaching to reduce environmental tobacco smoke (ETS) exposure among asthmatic Latino children. Design. After asthma management education, families were randomly assigned to no additional service (control condition) or to coaching for ETS exposure reduction (experimental condition). Setting. The study was conducted in San Diego, California. Participants. Two hundred four Latino children (ages 3-17 years) with asthma participated. Intervention. Approximately 1.5 hours of asthma management education was provided; experimental families also obtained 7 coaching sessions (similar to45 minutes each) to reduce ETS exposure. Outcome Measures. Reported ETS exposure and children's urine cotinine were measured. Results. Parents in the coached condition reported their children exposed to significantly fewer cigarettes than parents of control children by 4 months (postcoaching). Reported prevalence of exposed children decreased to 52% for the coached families, but only to 69% for controls. By month 4, mean cotinine levels decreased among coached and increased among control children. Cotinine prevalence decreased from 54% to 40% among coached families, while it increased from 43% to 49% among controls. However, cotinine levels decreased among controls to the same level achieved by coached families by the 13-month follow-up. Conclusions. Asthma management education plus coaching can reduce ETS exposure more than expected from education alone, and decreases in the coached condition may be sustained for about a year. The delayed decrease in cotinine among controls is discussed.	San Diego State Univ, Grad Sch Publ Hlth, Ctr Behav Epidemiol & Community Hlth, San Diego, CA 92182 USA; San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA; San Diego State Univ, Dept Polit Sci, San Diego, CA 92182 USA; Allergy & Asthma Med Grp & Res Ctr, San Diego, CA USA; Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA	Hovell, MF (reprint author), C-BEACH,9245 Sky Pk Ct,Suite 230, San Diego, CA 92123 USA.				NHLBI NIH HHS [HL52835, R01 HL052835]		ADAMS EK, COSTS ENV TOBACCO SM; ANDERSEN RM, 1986, PUBLIC HEALTH REP, V101, P238; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188; BERMAN BA, IN PRESS ADDICT BEHA; Bernert JT, 1997, CLIN CHEM, V43, P2281; Brown E. R., 1999, NONCITIZEN CHILDRENS; California Department of Health Services, 2000, CAL TOB CONTR UPD; California Environmental Protection Agency, 1997, HLTH EFF EXP ENV TOB; Carey KB, 1997, PSYCHOL ADDICT BEHAV, V11, P26, DOI 10.1037/0893-164X.11.1.26; CHARLTON A, 1994, J FAM PRACTICE, V38, P267; Christiansen SC, 1996, J ASTHMA, V33, P17, DOI 10.3109/02770909609077759; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; COOK DG, 1994, BRIT MED J, V308, P384; Diggle P., 1995, ANAL LONGITUDINAL DA; EMERSON JA, 1995, J CLIN EPIDEMIOL, V48, P1251, DOI 10.1016/0895-4356(95)00021-U; Emmons KM, 2001, PEDIATRICS, V108, P18, DOI 10.1542/peds.108.1.18; English P., 1998, PAN AM J PUBLIC HLTH, V3, P392, DOI 10.1590/S1020-49891998000600005; *EUR ENV AG, 2002, 29 EUR ENV AG OFF OF; Fals-Stewart W, 2000, J CONSULT CLIN PSYCH, V68, P134, DOI 10.1037/0022-006X.68.1.134; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; FLEGAL C, 1999, CONFRONTING ATHMA CA; FLORO JN, 2000, W PSYCH ASS 80 ANN C; GERGEN PJ, 1998, PEDIATRICS, V101; GREENBERG RA, 1994, J BEHAV MED, V17, P273, DOI 10.1007/BF01857953; HAMMOND SK, 1987, ENVIRON SCI TECHNOL, V21, P494, DOI 10.1021/es00159a012; Hovell MF, 2000, BRIT MED J, V321, P337, DOI 10.1136/bmj.321.7257.337; HOVELL MF, 1994, CHEST, V106, P440, DOI 10.1378/chest.106.2.440; Hovell MF, 2000, TOB CONTROL, V9, P40; Hovell MF, 2000, TOB CONTROL, V9, P22; HOVELL MF, 2001, ENV TOBACCO SMOKE; JARVIS MJ, 1985, BRIT MED J, V291, P927; JARVIS MJ, 1999, CHILDRENS EXPOSURE P; Jones JA, 2001, PATIENT EDUC COUNS, V42, P67, DOI 10.1016/S0738-3991(00)00102-6; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P795, DOI 10.1001/jama.273.10.795; KREMASTINOU J, 1994, SCAND J INFECT DIS, V26, P719, DOI 10.3109/00365549409008641; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LEADERER BP, 1991, ENVIRON SCI TECHNOL, V25, P770, DOI 10.1021/es00016a023; LEVAN R, 1999, DISPARITY JOB BASED; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Matt GE, 1999, TOB CONTROL, V8, P282; Matt GE, 2000, HEALTH PSYCHOL, V19, P232, DOI 10.1037//0278-6133.19.3.232; Mattaini M. A., 1996, FINDING SOLUTIONS SO; MURRAY DM, 1987, ADDICT BEHAV, V12, P7, DOI 10.1016/0306-4603(87)90003-7; *NAT COAL HISP HLT, 1996, OTOLARYNGOL HEAD NEC, V114, P256; National Health and Medical Research Council, 1997, HLTH EFF PASS SMOK; National Institutes of Health, 1995, NIH PUBL, V95-2754; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; SCHAUFFLER H, 1999, STATE HLTH INSURANCE; Schmier JK, 1998, J ASTHMA, V35, P585, DOI 10.3109/02770909809048961; SOBELL MB, 1986, ADDICT BEHAV, V11, P149, DOI 10.1016/0306-4603(86)90040-7; SOLIS JM, 1990, AM J PUBLIC HEALTH, V80, P11, DOI 10.2105/AJPH.80.Suppl.11; *STAT CA DEP FIN, 1998, COUNT POP PROJ AG SE; Stata Statistical Software, 2000, STAT STAT SOFTW REL; Traynor MP, 1996, J HEALTH POLIT POLIC, V21, P543, DOI 10.1215/03616878-21-3-543; *US CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1038; US Census Bureau, CENS 2000 DAT STAT C; *US DHHS, 2000, STRAT RES PLAN RED U; *US DHHS, 1993, NIH PUBL; U.S. Environmental Protection Agency, 1992, EPA PUBL; Wahlgren DR, 1997, CHEST, V111, P81, DOI 10.1378/chest.111.1.81; Weinhardt LS, 1998, ANN BEHAV MED, V20, P25, DOI 10.1007/BF02893805; World Health Organization, 2000, WHO REG PUBL EUR SER, V91; World Health Organization, 1999, INT CONS ENV TOB SMO; Wilson SR, 2001, CHEST, V120, P1709, DOI 10.1378/chest.120.5.1709; WOOD PR, 1993, PEDIATRICS, V91, P62; 1999, PHYS SMOK FREE CAN O	68	75	77	1	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	NOV	2002	110	5					946	956		10.1542/peds.110.5.946		11	Pediatrics	Pediatrics	610QK	WOS:000178971800030	12415035	
J	Bernstein, DI; Cartier, A; Cote, J; Malo, JL; Boulet, LP; Wanner, M; Milot, J; L'Archeveque, J; Trudeau, C; Lummus, Z				Bernstein, DI; Cartier, A; Cote, J; Malo, JL; Boulet, LP; Wanner, M; Milot, J; L'Archeveque, J; Trudeau, C; Lummus, Z			Diisocyanate antigen-stimulated monocyte chemoattractant protein-1 synthesis has greater test efficiency than specific antibodies for identification of diisocyanate asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						occupational asthma; diisocyanate; MCP-1; antibody	HISTAMINE-RELEASING FACTORS; INDUCED OCCUPATIONAL ASTHMA; HUMAN SERUM-ALBUMIN; HEXAMETHYLENE DIISOCYANATE; DIPHENYLMETHANE DIISOCYANATE; IMMUNE-RESPONSES; EXPOSURE; ISOCYANATES; WORKERS; REACTIVITY	We previously reported that diisocyanate-human serum albumin (DIISO-HSA) stimulated production of monocyte chemoattractant protein-1 (MCP-1) by peripheral blood mononuclear cells is significantly associated with a clinical diagnosis of diisocyanate asthma (DA). Others have reported that antibodies for DIISO-HSA are specific but insensitive markers of DA. This study was performed to evaluate test characteristics of the in vitro MCP-1 assay compared with DIISO-HSA-specific immunoglobulin (Ig) G and IgE in identifying workers with DA. MCPA was quantitated in peripheral blood mononuclear cell supernatants 48 hours after incubation with DIISO-HSA antigens. Assay results were compared with outcomes of specific inhalation challenge (SIC) testing. Nineteen of 54 (35%) workers assayed for antibodies and MCPA stimulation had SIC-confirmed DA. Mean MCP-1 produced by SIC-positive workers was greater than SIC-negative workers (p less than or equal to 0.001). Diagnostic sensitivity, specificity, and test efficiency for specific IgG were 47%, 74%, and 65%, respectively, and for specific IgE were 21%, 89%, and 65%, respectively. Sensitivity, specificity, and test efficiency of the MCPA test were 79%, 91%, and 87%, respectively. This study indicates that the MCP-1 stimulation assay has greater sensitivity and specificity than the specific antibody assays in correctly identifying DA.	Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA; Hop Sacre Coeur, Lab Pneumol Res, Montreal, PQ H4J 1C5, Canada; Univ Laval, Hop Laval, Inst Cardiol & Pneumol, St Foy, PQ G1K 7P4, Canada	Bernstein, DI (reprint author), Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.				NIOSH CDC HHS [R01 OH 03519-01]		Aul DJ, 1999, J ALLERGY CLIN IMMUN, V103, P749, DOI 10.1016/S0091-6749(99)70415-X; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; Baur X, 1996, AM J IND MED, V29, P467, DOI 10.1002/(SICI)1097-0274(199605)29:5<467::AID-AJIM5>3.0.CO;2-J; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; BERNSTEIN DI, 1998, ALLERGY PRINCIPLES P, P963; BERNSTEIN IL, 1982, J ALLERGY CLIN IMMUN, V70, P24, DOI 10.1016/0091-6749(82)90197-X; BUTCHER BT, 1983, CLIN ALLERGY, V13, P31, DOI 10.1111/j.1365-2222.1983.tb02563.x; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHASE MW, 1982, ANN NY ACAD SCI, V392, P228, DOI 10.1111/j.1749-6632.1982.tb36110.x; GALLAGHER JS, 1981, J OCCUP ENVIRON MED, V23, P610, DOI 10.1097/00043764-198109000-00009; GRAMMER LC, 1990, J ALLERGY CLIN IMMUN, V86, P94, DOI 10.1016/S0091-6749(05)80128-9; HERD ZL, 1994, AM J RESP CRIT CARE, V150, P988; Hornbeck P, 1991, CURRENT PROTOCOLS IM; Kraw M, 1999, AM J IND MED, V35, P87, DOI 10.1002/(SICI)1097-0274(199901)35:1<87::AID-AJIM12>3.0.CO;2-X; Lange RW, 1999, CHEM RES TOXICOL, V12, P931, DOI 10.1021/tx990045h; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; Lummus ZL, 1996, TOXICOLOGY, V111, P191, DOI 10.1016/0300-483X(96)03376-8; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; MEREDITH SK, 1989, BR J IND MED, V48, P292; OBRIEN IM, 1979, CLIN ALLERGY, V9, P7, DOI 10.1111/j.1365-2222.1979.tb01517.x; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847; Redlich CA, 1997, SCAND J WORK ENV HEA, V23, P227; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; RYAN G, 1981, J ALLERGY CLIN IMMUN, V67, P156, DOI 10.1016/0091-6749(81)90012-9; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; Tee RD, 1998, J ALLERGY CLIN IMMUN, V101, P709; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330	30	75	76	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 15	2002	166	4					445	450		10.1164/rccm.2109018		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	584BE	WOS:000177446700006	12186818	
J	Rasmussen, F; Taylor, DR; Flanneryb, EM; Cowan, JO; Greene, JM; Herbison, GP; Sears, MR				Rasmussen, F; Taylor, DR; Flanneryb, EM; Cowan, JO; Greene, JM; Herbison, GP; Sears, MR			Risk factors for hospital admission for asthma from childhood to young adulthood: A longitudinal population study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; hospital admission; risk factors; allergy; longitudinal population study; epidemiology	HOUSE-DUST MITE; BRONCHIAL HYPERRESPONSIVENESS; INDOOR ALLERGENS; ECONOMIC BURDEN; SCHOOL ABSENCE; CHILDREN; EMERGENCY; SENSITIZATION; PREVALENCE; EXPOSURE	Background: Predictors of hospital admissions for asthma in children and young adults in a general population are not well defined, because most studies have used selected subpopulations. Objective: The purpose of this investigation was to determine risk factors for single and multiple hospital admissions for asthma. Methods: The members of a population-based, unselected birth cohort of 1037 New Zealanders answered questionnaires and underwent lung function, airway responsiveness, and allergy testing on 7 occasions to the age of 26 years. Results: Among the 766 study members (74% of the cohort) who reported wheezing symptoms ever by the age of 26 years, 136 hospitalizations were reported by 62 individuals (8.3% of those at risk, 6.2% of the total cohort). Only 55 of these 136 admissions involved children less than 9 years of age; admissions continued to occur between the ages of 9 and 18 years (40 admissions) and at >18 years (41 admissions). Those admitted were predominantly male, had earlier ages of onset of symptoms, were more atopic, and had more airway hyperresponsiveness to methacholine than those not admitted. Frequent symptoms and low lung function were evident among the 45 study members with single admissions and even more evident among the 17 study members with multiple (2-10) admissions. Conclusions: A surprisingly large fraction of this unselected population experienced hospitalization for asthma during the 26-year follow-up, many being admitted in later childhood, adolescence, and early adulthood. Clinical characteristics and markers of severity, including frequent respiratory symptoms, airway hyperresponsiveness, atopy, and low lung function, identify those at high risk for hospitalization for asthma, particularly with respect to multiple admissions.	St Josephs Healthcare, Firestone Inst Respiratory Hlth, Hamilton, ON L8N 4A6, Canada; Univ Otago, Dunedin Sch Med, Dept Prevent & Social Med, Dunedin, New Zealand; Univ Otago, Dunedin Sch Med, Dept Med, Dunedin, New Zealand; McMaster Univ, Hamilton, ON, Canada	Sears, MR (reprint author), St Josephs Healthcare, Firestone Inst Respiratory Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.						ANDERSON HR, 1989, THORAX, V44, P614, DOI 10.1136/thx.44.8.614; ANDERSON HR, 1983, ARCH DIS CHILD, V58, P777; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Blais L, 1998, THORAX, V53, P1025; CAMPBELL DA, 1995, THORAX, V50, P254, DOI 10.1136/thx.50.3.254; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Clough JB, 1998, CLIN EXP ALLERGY, V28, P22; DALES RE, 1995, THORAX, V50, P520, DOI 10.1136/thx.50.5.520; EISNER MD, 2000, RESPIR RES, V2, P53; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; JENKINS MA, 1994, BRIT MED J, V309, P90; LI D, 1995, AM J RESP CRIT CARE, V151, P647; Lozano P, 1999, J ALLERGY CLIN IMMUN, V104, P957; MILES J, 1995, CLIN EXP ALLERGY, V25, P1074; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; OSWALD H, 1994, BRIT MED J, V309, P95; PATTEMORE PK, 1990, AM REV RESPIR DIS, V142, P549; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; Rabbat A, 1996, INTENS CARE MED, V22, P530; Ray NF, 1998, CHEST, V113, P1277, DOI 10.1378/chest.113.5.1277; Sarpong SB, 1997, ANN ALLERG ASTHMA IM, V79, P455; Schaubel D, 1996, J ASTHMA, V33, P97, DOI 10.3109/02770909609054537; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P941, DOI 10.1111/j.1365-2222.1993.tb00279.x; SEARS MR, 1986, THORAX, V41, P283, DOI 10.1136/thx.41.4.283; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Singh AK, 1999, ARCH INTERN MED, V159, P1237, DOI 10.1001/archinte.159.11.1237; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Spee-van der Wekke J, 1998, J EPIDEMIOL COMMUN H, V52, P359; SPITZER WO, 1992, NEW ENGL J MED, V326, P501, DOI 10.1056/NEJM199202203260801; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; SPRINGETT VH, 1969, BMJ-BRIT MED J, V1, P402; *STAT CAN CAN I HL, 82570XIE STAT CAN CA; *US DEP HHS, 1991, 9150212 PHS US DEP H; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	37	75	79	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					220	227	UNSP 1/81/125295	10.1067/mai.2002.125295		8	Allergy; Immunology	Allergy; Immunology	585DY	WOS:000177509800005	12170261	
J	Bengtsson, AA; Rylander, L; Hagmar, L; Nived, O; Sturfelt, G				Bengtsson, AA; Rylander, L; Hagmar, L; Nived, O; Sturfelt, G			Risk factors for developing systemic lupus erythematosus: a case-control study in southern Sweden	RHEUMATOLOGY			English	Article						SLE; risk factors; smoking; alcohol; drug allergy; hypertension; family history	ORAL-CONTRACEPTIVES; DEFINED POPULATION; DISEASE; HISTORY; THERAPY; STRESS	Objective. To explore the risk factors that have been suggested to be associated with the development of SLE. Methods. A case-control study was performed and a questionnaire was developed to obtain the data. Consecutive female incident cases diagnosed between 1981 and 1999 in a defined,geographical area in southern Sweden were included. Controls, matched for calendar year of birth, were selected randomly from the same area. In total, 85 cases and 205 controls agreed to participate. The questionnaire included questions about formal education, body weight and height, medical history, family history of autoimmune diseases, exposure to ultraviolet radiation, animals, hair-colouring dyes, alfalfa (lucerne) sprouts, smoking and alcohol habits, history of physical traumata, blood transfusion, silicone breast implants, exogenous oestrogens, other medication, and significant negative life events. Results. Using a multivariate model, a history of hypertension [odds ratio (OR)=3.7, 95% confidence interval (CI) 1.4-9.8], drug allergy (OR=3.6, 95% CI 1.4-9.5), a type I/II sun-reactive Skin type (OR=2.3, 95% CI 1.1-4.8) and a family history of SLE (OR=6.8, 95% CI 1.4-32) were all significantly associated with an increased risk of developing SLE, whereas consumption of alcohol was inversely associated with the risk of SLE (use of alcohol very seldom, OR=1.0; 1-150 g/month, OR=0.4, 95% CI 0.2-1.0; > 150 g/month, OR=0.2, 95% CI 0.1-0.5). A suggested association with increased SLE risk was seen for smoking (OR=1.8, 95% CI 0.9-3.6) and blood transfusions (OR=23, 95% CI 0.9-5.8). Neither exposure to exogenous oestrogen nor exposure to hair-colouring dyes was associated with SLE. Conclusions. Risk factors of both exogenous and endogenous origin were identified in this population-based series of SLE patients.	Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden; Univ Lund Hosp, Dept Occupat & Environm Med, S-22185 Lund, Sweden	Bengtsson, AA (reprint author), Univ Lund Hosp, Dept Rheumatol, S-22185 Lund, Sweden.						ADAMS LE, 1991, DRUG SAFETY, V6, P431; Cooper GS, 1998, ARTHRITIS RHEUM, V41, P1714, DOI 10.1002/1529-0131(199810)41:10<1714::AID-ART3>3.0.CO;2-U; FITZPATRICK TB, 1988, ARCH DERMATOL, V124, P869, DOI 10.1001/archderm.124.6.869; FRENITITULAER LWJ, 1989, AM J EPIDEMIOL, V130, P404; FRITZLER MJ, 1994, LUPUS, V3, P455, DOI 10.1177/096120339400300605; GEIRSSON AJ, 1987, ANN RHEUM DIS, V46, P727, DOI 10.1136/ard.46.10.727; GINSBURG KS, 1992, ARTHRITIS RHEUM, V35, P776, DOI 10.1002/art.1780350711; GRIMES DA, 1985, AM J OBSTET GYNECOL, V153, P179; Hardy CJ, 1999, LUPUS, V8, P541, DOI 10.1191/096120399678840800; Hardy CJ, 1998, ANN RHEUM DIS, V57, P451, DOI 10.1136/ard.57.8.451; Hosmer DW, 1989, APPL LOGISTIC REGRES; JONES DRE, 1992, LANCET, V339, P1378, DOI 10.1016/0140-6736(92)91197-G; JONSSON H, 1990, BRIT J RHEUMATOL, V29, P185; JONSSON H, 1989, MEDICINE, V68, P141; MALINOW MR, 1981, LANCET, V1, P615; Manzi S, 2000, RHEUMATOLOGY, V39, P353, DOI 10.1093/rheumatology/39.4.353; MCALINDON T, 2000, ARTHRITIS RHEUM, V43, P237; MCALINDON T, 1997, ARTHRITIS RHEUM, V40, P162; Meier CR, 1998, J RHEUMATOL, V25, P1515; NAGATA C, 1995, INT J DERMATOL, V34, P333, DOI 10.1111/j.1365-4362.1995.tb03614.x; NIVED O, 1992, J INTERN MED, V232, P461; Panush RS, 2000, J RHEUMATOL, V27, P287; PETRI M, 1992, ARTHRITIS RHEUM, V35, P625, DOI 10.1002/art.1780350605; REIDENBERG MM, 1993, ARTHRITIS RHEUM, V36, P971, DOI 10.1002/art.1780360714; REIDENBERG MM, 1983, AM J MED, V75, P365, DOI 10.1016/0002-9343(83)91219-6; REIDENBERG MM, 1983, AM J MED, V75, P1037, DOI 10.1016/0002-9343(83)90885-9; SanchezGuerrero J, 1997, ARTHRITIS RHEUM, V40, P804, DOI 10.1002/art.1780400505; SANCHEZGUERRERO J, 1995, ANN INTERN MED, V122, P430; SanchezGuerrero J, 1996, ARTHRITIS RHEUM, V39, P657, DOI 10.1002/art.1780390418; SCHWARTZ RS, 1975, NEW ENGL J MED, V293, P132; Sontheimer RD, 1996, PHOTOCHEM PHOTOBIOL, V63, P583, DOI 10.1111/j.1751-1097.1996.tb05660.x; STROM BL, 1994, AM J EPIDEMIOL, V140, P632; STURFELT G, 1985, CLIN EXP RHEUMATOL, V3, P303; THERNLUND GM, 1995, DIABETES CARE, V18, P1323, DOI 10.2337/diacare.18.10.1323; WALLACE DJ, 1994, BAILLIERE CLIN RHEUM, V8, P149, DOI 10.1016/S0950-3579(05)80229-8; WINSA B, 1991, LANCET, V338, P1475, DOI 10.1016/0140-6736(91)92298-G	36	75	81	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324			RHEUMATOLOGY	RHEUMATOLOGY	MAY	2002	41	5					563	571		10.1093/rheumatology/41.5.563		9	Rheumatology	Rheumatology	555QQ	WOS:000175805100015	12011382	
J	Kosunen, TU; Hook-Nikanne, J; Salomaa, A; Sarna, S; Aromaa, A; Haahtela, T				Kosunen, TU; Hook-Nikanne, J; Salomaa, A; Sarna, S; Aromaa, A; Haahtela, T			Increase of allergen-specific immunoglobulin E antibodies from 1973 to 1994 in a Finnish population and a possible relationship to Helicobacter pylori infections	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article; Proceedings Paper	12th International Workshop on Gastroduodenal Pathology and Helicobacter Pylori	SEP, 1999	HELSINKI, FINLAND			allergy; allergen-specific IgE; atopy; Helicobacter pylori antibodies; prevalence rates	ADULT-POPULATION; ATOPY; IGE; PREVALENCE; CHILDREN; ASTHMA; VACCINATION; ADOLESCENTS; EXPOSURE; COHORT	Background The prevalence of atopic diseases - hayfever, asthma and eczema - has increased over the past decades. The increase may be associated with decreased rates of infections such as measles., hepatitis A, tuberculosis, toxoplasmosis, and, as recently suggested, Helicobacter pylori gastritis. Objective Since the increase of atopy has been mainly based on clinical studies. we wanted to study the prevalence of allergen-specific Immunoglobulin (Ig)E antibodies in two cross-sectional, adult population-based serum samples two decades apart. Since the sera had been tested for H. pylori antibodies, we also had a chance to look for a possible relationship between these two findings. Methods We determined the prevalence rate of allergen-specific serum IgE antibodies against birch and timothy pollen, and cat and dog epithelium allergens by the radioallergosorbent test in a 15-54-years-old Finnish population using 326 sera collected in 1973 and 319 sera collected in 1994 from randomly selected subjects. Results From 1973 to 1994 allergen-specific IgE prevalence rates and IgE antibody levels rose. In 1994, the prevalence rate of positive findings in 15-24-year-old population had increased from I I to 38% (3.5-fold increase, P=0.0001, OR 5.12, Cl 95% 2.32-11.3). In older 10-year age groups similar trends did not reach significance, but the overall change was significant with all three cut-off levels of allergen-specific IgE analysed. The percentage of IgE-positive persons rose mainly in the subgroup with no H. pylori antibodies. In 1994 21% of the H. pylori-negative subjects had IgE antibodies compared with 5% of the H. pylori-positive subjects (in 1973 11% in both subgroups). Conclusions IgE-based evidence for an increase in IgE-mediated allergy was uncovered. The increase occurred mainly in the subgroup with no antibodies to H. pylori, which support the hypothesis that H, pylori could be one of the microbes counteracting atopy.	Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Div Allergy, Helsinki, Finland; Vammala Hlth Ctr, Vammala, Finland; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Social Insurance Inst, Helsinki, Finland; Natl Publ Hlth Inst, Helsinki, Finland	Kosunen, TU (reprint author), Univ Helsinki, Dept Bacteriol & Immunol, Haartman Inst, POB 21, FIN-00014 Helsinki, Finland.			Sarna, Seppo/0000-0003-3458-1627			Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; *CENTR STAT OFF FI, 1975, STAT YB FINL 1974; *CENTR STAT OFF FI, 1995, STAT YB FINL 1994; *CYT SOFTW CORP, 1998, STATX 4 STAT SOFTW; Gassner M, 1992, Schweiz Rundsch Med Prax, V81, P426; HAAHTELA T, 1990, BRIT MED J, V301, P266; HAAHTELA T, 1980, ALLERGY, V35, P425, DOI 10.1111/j.1398-9995.1980.tb01789.x; Henderson CE, 1998, J IMMUNOL METHODS, V213, P99, DOI 10.1016/S0022-1759(98)00014-3; Henderson J, 1999, BRIT MED J, V318, P1173; Howarth PH, 1998, CLIN EXP ALLERGY, V28, P2; Kosunen TU, 1997, EPIDEMIOL INFECT, V119, P29, DOI 10.1017/S0950268897007565; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1997, BRIT MED J, V314, P999; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; Paganelli R, 1998, ALLERGY, V53, P763; POHJANPELTO P, 1984, SCAND J INFECT DIS, V16, P229, DOI 10.3109/00365548409070394; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rehnberg-Laiho L, 1998, PEDIATR INFECT DIS J, V17, P796, DOI 10.1097/00006454-199809000-00009; Shaheen S, 1997, BRIT MED J, V314, P987; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Talley Nicholas J., 1993, P63; von Hertzen L, 1999, J ALLERGY CLIN IMMUN, V104, P1211	27	75	78	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2002	32	3					373	378		10.1046/j.1365-2222.2002.01330.x		6	Allergy; Immunology	Allergy; Immunology	541QB	WOS:000174994300010	11940066	
J	Lack, G				Lack, G			Pediatric allergic rhinitis and comorbid disorders	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; asthma; cough variant rhinitis; postnasal drip; sinusitis	INTERCELLULAR-ADHESION MOLECULE-1; EUSTACHIAN-TUBE OBSTRUCTION; NASAL EPITHELIAL-CELLS; OTITIS-MEDIA; POLLEN EXPOSURE; DOSE-RESPONSE; ASTHMA; CHILDREN; CHALLENGE; HISTAMINE	Allergic rhinitis (AR) is rarely found in isolation and needs to be considered in the context of systemic allergic disease associated with numerous comorbid disorders, including asthma, chronic middle ear effusions, sinusitis, lymphoid hypertrophy with obstructive sleep apnea, disordered sleep, and consequent behavioral and educational effects. The coexistence of AR and asthma is complex. First, the diagnosis of asthma may be confounded by symptoms of cough caused by rhinitis and postnasal drip. This may lead to either inaccurate diagnosis of asthma or inappropriate assessment of asthma severity with over treatment of the patient. The term "cough variant rhinitis" is therefore proposed to describe rhinitis that manifests itself primarily as cough that results from postnasal drip. AR, however, also has a causal role in asthma; it appears both to be responsible for exacerbating asthma and to have a role in its pathogenesis. Postnasal drip with nasopharyngeal inflammation leads to a number of other conditions. Thus sinusitis is a frequent extension of rhinitis and is one of the most frequently missed diagnoses In children. Allergen exposure in the nasopharynx with release of histamine and other mediators can cause Eustachian tube obstruction possibly leading to middle car effusions. Chronic allergic inflammation of the upper airway causes lymphoid hypertrophy with prominence of adenoidal and tonsillar tissue. This may be associated with poor appetite, poor growth, and obstructive sleep apnea. AR is therefore part of a spectrum of allergic disorders that can profoundly affect the well being and quality of life of a child. Prospective cohort studies are required to assess the disease burden caused by AR in childhood and to further assess the potential educational impairment that may result. Because AR is part of a systemic disease process, its management requires a coordinated approach rather than a fragmented, organ-based approach.	St Marys Hosp, Dept Pediat Allergy & Immunol, London W2 1NY, England	Lack, G (reprint author), St Marys Hosp, Dept Pediat Allergy & Immunol, Praed St, London W2 1NY, England.						BAKER BM, 1982, ANN OTO RHINOL LARYN, V91, P277; Baram Y, 1998, NEURAL PROCESS LETT, V8, P1, DOI 10.1023/A:1009611427303; BAROODY FM, 1995, ARCH OTOLARYNGOL, V121, P1396; Bernstein JM, 1996, OTOLARYNG HEAD NECK, V114, P562, DOI 10.1016/S0194-5998(96)70247-4; BLUESTONE CD, 1983, J ALLERGY CLIN IMMUN, V72, P242, DOI 10.1016/0091-6749(83)90027-1; CAUWENBERGE PV, 1997, EUR RESPIR REV, V7, P286; CIPRANDI G, 1994, AM J RESP CRIT CARE, V150, P1653; Ciprandi G, 1995, J ALLERGY CLIN IMMUN, V96, P971, DOI 10.1016/S0091-6749(95)70235-0; CIPRANDI G, 1994, J ALLERGY CLIN IMMUN, V94, P738, DOI 10.1016/0091-6749(94)90182-1; COREY JP, 1994, AM J OTOLARYNG, V15, P138, DOI 10.1016/0196-0709(94)90063-9; Craig TJ, 1998, J ALLERGY CLIN IMMUN, V101, P633; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; Faniran AO, 1998, ARCH DIS CHILD, V79, P411; FRIEDMAN RA, 1983, J ALLERGY CLIN IMMUN, V71, P442, DOI 10.1016/0091-6749(83)90459-1; GAMBLE J E, 1992, Ear Nose and Throat Journal, V71, P397; HANNAWAY PJ, 1982, JAMA-J AM MED ASSOC, V247, P206, DOI 10.1001/jama.247.2.206; IRVIN CG, 1992, J ALLERGY CLIN IMMUN, V90, P521, DOI 10.1016/0091-6749(92)90179-6; KATO M, 1995, CLIN EXP ALLERGY, V25, P744, DOI 10.1111/j.1365-2222.1995.tb00012.x; KAUFMAN J, 1969, AM REV RESPIR DIS, V100, P626; KNIGHT LC, 1992, CLIN OTOLARYNGOL, V17, P308, DOI 10.1111/j.1365-2273.1992.tb01002.x; Koskela H, 1995, EUR RESPIR J, V8, P2088, DOI 10.1183/09031936.95.08122088; Matsuzaki Z, 1996, IMMUNOLOGY, V88, P565, DOI 10.1046/j.1365-2567.1996.d01-687.x; McColley SA, 1997, CHEST, V111, P170, DOI 10.1378/chest.111.1.170; MIGLETS A, 1973, LARYNGOSCOPE, V83, P1355, DOI 10.1288/00005537-197309000-00001; Mogi G, 1992, Acta Otolaryngol Suppl, V493, P155; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393; MULLARKEY MF, 1980, J ALLERGY CLIN IMMUN, V65, P122, DOI 10.1016/0091-6749(80)90196-7; OSUR SL, 1989, ALLERGY PROC, V10, P133, DOI 10.2500/108854189778961071; RACHELEFSKY GS, 1978, J ALLERGY CLIN IMMUN, V61, P310, DOI 10.1016/0091-6749(78)90052-0; SETTIPANE RJ, 1994, ALLERGY PROC, V15, P21, DOI 10.2500/108854194778816634; SHAPIRO GG, 1985, PEDIATR INFECT DIS J, V4, P55; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; SKONER DP, 1986, ARCH OTOLARYNGOL, V112, P840; SKONER DP, 1987, J ALLERGY CLIN IMMUN, V79, P27, DOI 10.1016/S0091-6749(87)80012-X; SKONER DP, 1991, ANN ALLERGY, V67, P619; VUURMAN EFPM, 1993, ANN ALLERGY, V71, P121; WATSON WTA, 1993, J ALLERGY CLIN IMMUN, V91, P97, DOI 10.1016/0091-6749(93)90301-U; WRIGHT AL, 1994, PEDIATRICS, V94, P895; Yumoto E, 1991, Nihon Jibiinkoka Gakkai Kaiho, V94, P534	39	75	78	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2001	108	1		S			S9	S15		10.1067/mai.2001.115562		7	Allergy; Immunology	Allergy; Immunology	459BU	WOS:000170230600003	11449201	
J	Mari, A				Mari, A			Multiple pollen sensitization: A molecular approach to the diagnosis	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						asthma; IgE; pollens; recombinant allergens; skin tests	REACTIVE CARBOHYDRATE DETERMINANTS; IN-VITRO DIAGNOSTICS; BIRCH POLLEN; BRONCHIAL HYPERRESPONSIVENESS; ALLERGIC DISEASES; MAJOR ALLERGEN; IGE-BINDING; TREE POLLEN; IDENTIFICATION; IMMUNOTHERAPY	Background: Sensitization to multiple pollen species is a frequent diagnostic event. Several allergenic molecules with a high level of homology have been identified in divergent pollen families and named panallergens. Methods: We sought to define the criteria to evaluate the prevalence of the multiple pollen sensitization, to identify specific markers of this condition, and to correlate them with the underlying allergic disease. Patients presenting an allergic respiratory disease underwent skin testing with 23 pollens. Patients fulfilling predefined selection criteria were grouped and classified as having multiple pollen sensitization. Patients in each subgroup were tested for IgE to rBet v 2, rJun o 2, rBet v 1, rPhl p 5 and bromelain. Demographical, allergological and clinical data were recorded in the subgroup of patients with multiple pollen sensitization. Results: Seventeen percent of the pollen-sensitized patients formed the multiple pollen-sensitized subgroup. These subjects were positive for most of the pollen species tested regardless of known exposure to them. None of the subjects sensitized to less than six pollen species were positive to panallergens, whereas 55% of the sera of the multiple pollen-sensitized group were positive to rBet v 2, and 15% to rJun o 2. IgE to rBet v 1 and rPhl p 5 were found positive in all the subgroups. Age, gender, bronchial asthma, oral allergy syndrome, skin test reactivity and previous specific immunotherapy differed significantly when these two subsets were considered. Conclusions: Allergy diagnosis based on allergenic molecules is crucial in the patient with multiple pollen sensitization. This condition appears to be determined by the sensitization to defined allergenic components (panallergens) rather than by pollen of multiple species as such. Detection of IgE to nonpanallergenic molecules allows to identify more relevant allergenic sources. Clinical aspects of the underlying allergic disease (e.g. asthma and oral allergy syndrome) seem to be differently related to IgE reactivity to panallergens. Ccpyright (C) 2001 S. Karger AG, Basel	Natl Hlth Serv, Allergy Unit, Rome, Italy	Mari, A (reprint author), Via Malipiero 28, I-04100 Latina, Italy.						Aalberse RC, 1997, CLIN REV ALLERG IMMU, V15, P375, DOI 10.1007/BF02737733; BARLETTA B, 2000, J ALLERGY CLIN IMMUN, V105, pS36; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; BRITTON WJ, 1986, INT J EPIDEMIOL, V15, P202, DOI 10.1093/ije/15.2.202; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; DAmato G, 1991, ALLERGENIC POLLEN PO; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249; Fritsch R, 1997, CLIN REV ALLERG IMMU, V15, P397, DOI 10.1007/BF02737735; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Liebers V, 1996, CLIN EXP ALLERGY, V26, P494, DOI 10.1046/j.1365-2222.1996.d01-343.x; Malling HJ, 1993, ALLERGY          S14, V48, P55; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mari A, 1996, J ALLERGY CLIN IMMUN, V98, P21, DOI 10.1016/S0091-6749(96)70222-1; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; *NIH NAT HEAT LUNG, 1995, 953659 NIH NHLBIWHO; PASTORELLO EA, 1997, FOOD ALLERGY ADVERSE, P137; PEAT JK, 1992, EUR RESPIR J, V5, P921; Pignatti S., 1982, FLORA ITALIA; Schafer T, 1997, ALLERGY, V52, P14; Solomon W, 1998, ALLERGY PRINCIPLES P, P367; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Tutin T. G., 1980, FLORA EUROPEA; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; van Ree R, 1999, CLIN EXP ALLERGY, V29, P848, DOI 10.1046/j.1365-2222.1999.00521.x; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; vanRee R, 1996, ALLERGY, V51, P108; Varela S, 1997, J ALLERGY CLIN IMMUN, V100, P748, DOI 10.1016/S0091-6749(97)70268-9	37	75	77	0	0	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	MAY	2001	125	1					57	65		10.1159/000053797		9	Allergy; Immunology	Allergy; Immunology	437CQ	WOS:000168973000008	11385289	
J	Bayram, H; Sapsford, RJ; Abdelaziz, MM; Khair, OA				Bayram, H; Sapsford, RJ; Abdelaziz, MM; Khair, OA			Effect of ozone and nitrogen dioxide on the release of proinflammatory mediators from bronchial epithelial cells of nonatopic nonasthmatic subjects and atopic asthmatic patients in vitro	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic asthma; ozone; nitrogen dioxide; bronchial epithelial cells; cytokines; soluble intercellular adhesion molecule 1	INFLAMMATORY MEDIATORS; INHALED ALLERGEN; AIR-POLLUTION; IN-VITRO; RESPONSES; CYTOKINES	Background: Although studies have suggested that ozone (O-3) and nitrogen dioxide (NO2) may play a role in the pathogenesis of asthma, the underlying mechanisms are not clear. Objective: We aimed to investigate the effects of O-3 and NO2 on the release of IL-8, GM-CSF, RANTES, and soluble intercellular adhesion molecule 1 (sICAM-1) from human bronchial epithelial cells (HBF,Cs) of nonatopic nonasthmatic subjects (nonasthmatic subjects) and atopic subjects with mild asthma (asthmatic subjects) in vitro. Methods: We cultured HBECs from bronchial biopsy specimens of nonasthmatic and asthmatic subjects; exposed these for 6 hours to air, 10 to 100 ppb O-3, or 100 to 400 ppb NO2; and analyzed the release of IL-8, GM-CSF, RANTES, and sICAM-1 after 24 hours' incubation. Results: There was no significant difference between the constitutive release of IL-8, GM-CSF; and sICAM-1 from HBECs of asthmatic and nonasthmatic subjects, RANTES was detected only in HBECs derived from asthmatic subjects. Exposure of HBECs of asthmatic subjects to both 50 to 100 ppb O-3 and 200 to 400 ppb NO2 significantly increased the release of IL-8, GM-CSF, RANTES, and sICAM-1 from these cells after 24 hours of incubation. However, 50 to 100 ppb O-3 and 200 to 400 ppb NO2 led to a significant increase in release of only IL-8 and sICAM-1 from HBECs of nonasthmatic subjects after 24 hours' incubation. A comparison between the pollutant-induced release of mediators demonstrated that 100 ppb O-3. induced release of GM-CSF and sICAM-1 was significantly greater in HBECs of asthmatic subjects (medians, 0.59 and 27.4 pg/mug cellular protein, respectively) than in HBECs of nonasthmatic subjects (medians, 0.27 and 14.4 pg/mug cellular protein, respectively; P<.02). Conclusion: These results suggest that O-3 and NO2 may modulate airway diseases, such as asthma, by increasing the release of inflammatory mediators from bronchial epithelial cells and that the cells of asthmatic subjects may be more susceptible to the adverse effects of these pollutants.	Univ Dicle, Sch Med, Dept Resp Med, TR-21280 Diyarbakir, Turkey; St Bartholomews & Royal London Sch Med & Dent, Acad Resp Med Dept, London, England; Royal Liverpool Univ Hosp, Dept Resp Med, Liverpool, Merseyside, England; City Hosp NHS Trust, Birmingham, W Midlands, England	Bayram, H (reprint author), Univ Dicle, Sch Med, Dept Resp Med, TR-21280 Diyarbakir, Turkey.						Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Balmes J. R., 1997, RES REP HLTH EFF I, V78, P1; Bayram H, 1998, J ALLERGY CLIN IMMUN, V102, P771, DOI 10.1016/S0091-6749(98)70017-X; Bayram H, 1999, J ALLERGY CLIN IMMUN, V104, P93, DOI 10.1016/S0091-6749(99)70119-3; Bloemen PGM, 1997, CLIN EXP ALLERGY, V27, P128; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P719, DOI 10.1016/S0091-6749(96)80146-1; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Calderon MA, 1997, J ALLERGY CLIN IMMUN, V99, P65, DOI 10.1016/S0091-6749(97)81046-9; DEVALIA JL, 1993, AM J RESP CELL MOL, V9, P271; DEVALIA JL, 1990, RESP MED, V84, P303, DOI 10.1016/S0954-6111(08)80058-3; DEVALIA JL, 1994, LANCET, V344, P1668, DOI 10.1016/S0140-6736(94)90458-8; DEVLIN RB, 1994, AM J PHYSIOL, V266, pL612; Devlin RB, 1999, INHAL TOXICOL, V11, P89, DOI 10.1080/089583799197195; DEVLIN RB, 1991, AM J RESP CELL MOL, V4, P72; Gormand F, 1995, PULM PHARMACOL, V8, P107, DOI 10.1006/pulp.1995.1013; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; JORRES R, 1995, EUR RESPIR J, V8, P416, DOI 10.1183/09031936.95.08030416; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Rusznak C, 1996, EUR RESPIR J, V9, P2296; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TAKAHASHI N, 1994, AM J RESP CRIT CARE, V150, P704; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Wang JH, 1997, EUR RESPIR J, V10, P834	28	75	79	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					287	294		10.1067/mai.2001.111141		8	Allergy; Immunology	Allergy; Immunology	403YV	WOS:000167071400015	11174195	
J	Wisnewski, AV; Srivastava, R; Herick, C; Xu, L; Lemus, R; Cain, H; Magoski, NM; Karol, MH; Bottomly, K; Redlich, CA				Wisnewski, AV; Srivastava, R; Herick, C; Xu, L; Lemus, R; Cain, H; Magoski, NM; Karol, MH; Bottomly, K; Redlich, CA			Identification of human lung and skin proteins conjugated with hexamethylene diisocyanate in vitro and in vivo	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							GLUCOSE-REGULATED PROTEIN; OCCUPATIONAL ASTHMA; GUINEA-PIGS; ISOCYANATE; EXPOSURE; ADDUCTS; IGE; ASSOCIATION; EXPRESSION; ANTIBODIES	Diiisocyanates are asthma-causing chemicals used in the commercial production of polyurethane. We have previously shown that human lung epithelial cell proteins can become conjugated with hexamethylene diisocyanate (HDI) and may be biologically important in diisocyanate-induced asthma. The objective of this study was to identify specific human lung and skin proteins that become conjugated with diisocyanate after in vitro and in vivo exposure. Following in vitro exposure of human airway epithelial cells (A549), keratin 18, the 78-kD glucose-regulated protein, trans-1,2-dihyrobenzene-1,2-diol dehydrogenase, and actin were identified as prominent diisocyanate-conjugated proteins through use of a combination of immunocytochemical and mass spectrometric techniques. Following in vivo inhalation of an HDI aerosol, keratin 18 was also identified as the predominant diisocyanate-conjugated protein in human endobronchial biopsy samples, whereas albumin was the predominant diisocyanate-conjugated protein in bronchoalveolar lavage fluid. Keratin was also identified as a predominant diisocyanate-conjugated protein in human skin biopsy samples after epicutaneous exposure to liquid-phase HDI, although the major skin diisocyanate-conjugated protein (56-kD) differed from the predominant lung diisocyanate-conjugated keratin (47-kD). The data from this study identify keratin and other proteins as potential "carriers" for diisocyanates in vivo, and suggest that HDI conjugation of these proteins may play a role in the pathogenesis of diisocyanate-induced asthma.	Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA	Wisnewski, AV (reprint author), Yale Univ, Sch Med, Dept Internal Med, 333 Cedar St,LCI-105, New Haven, CT 06520 USA.				NHLBI NIH HHS [K08HL03129, P01HL56389, R01 HL062622, R01 HL062622-01, R01 HL062622-02, R01HL62622]		AVERY SB, 1969, CLIN EXP IMMUNOL, V4, P585; BAUR X, 1983, J ALLERGY CLIN IMMUN, V71, P197, DOI 10.1016/0091-6749(83)90100-8; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; BERTORELLI G, 1998, CLIN EXP ALLERGY, V28, P527; BUTCHER BT, 1982, J ALLERGY CLIN IMMUN, V69, pS123; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; Cullinan P, 1998, CLIN EXP ALLERGY, V28, P668; Day BW, 1997, CHEM RES TOXICOL, V10, P424, DOI 10.1021/tx960201+; ELLGARD L, 1999, SCIENCE, V286, P1805; HENDERSHOT LM, 1988, MOL CELL BIOL, V8, P4250; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; JIN RZ, 1993, CHEM RES TOXICOL, V6, P906, DOI 10.1021/tx00036a023; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611; KENNEDY AL, 1993, FUND APPL TOXICOL, V20, P57, DOI 10.1006/faat.1993.1007; Lange RM, 1999, TOXICOL SCI, V50, P64, DOI 10.1093/toxsci/50.1.64; Liao JA, 1997, FEBS LETT, V417, P316, DOI 10.1016/S0014-5793(97)01315-X; Magin TM, 1998, J CELL BIOL, V140, P1441, DOI 10.1083/jcb.140.6.1441; Malo JL, 1999, AM J RESP CRIT CARE, V159, P1879; MOLOWA DT, 1986, J BIOL CHEM, V261, P2624; MYER HE, 1993, AM IND HYG ASSOC J, V54, P663, DOI 10.1202/0002-8894(1993)054<0663:ASOAHH>2.0.CO;2; Rao KS, 1996, CELL BIOL INT, V20, P261; RATTRAY NJ, 1994, TOXICOLOGY, V88, P15, DOI 10.1016/0300-483X(94)90108-2; Redlich CA, 1997, SCAND J WORK ENV HEA, V23, P227; SEPAI O, 1995, CARCINOGENESIS, V16, P2583, DOI 10.1093/carcin/16.10.2583; Shiraishi H, 1998, BIOCHEM J, V334, P399; Shiraishi H, 1999, ADV EXP MED BIOL, V463, P539; TYNER AL, 1985, P NATL ACAD SCI USA, V82, P4683, DOI 10.1073/pnas.82.14.4683; Ulrich H., 1996, CHEM TECHNOLOGY ISOC; WASS U, 1989, J ALLERGY CLIN IMMUN, V83, P126, DOI 10.1016/0091-6749(89)90487-9; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5	30	75	77	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC	2000	162	6					2330	2336				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	381ZV	WOS:000165794700061	11112159	
J	Pinkerton, KE; Green, FHY; Saiki, C; Vallyathan, V; Plopper, CG; Gopal, V; Hung, D; Bahne, EB; Lin, SS; Menache, MG; Schenker, MB				Pinkerton, KE; Green, FHY; Saiki, C; Vallyathan, V; Plopper, CG; Gopal, V; Hung, D; Bahne, EB; Lin, SS; Menache, MG; Schenker, MB			Distribution of particulate matter and tissue remodeling in the human lung	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; California; fibrosis; lung pathology; PM2.5; PM10; particulate matter; pigmentation	SAN-JOAQUIN VALLEY; SMALL AIRWAYS; CIGARETTE-SMOKING; DISEASES; PNEUMOCONIOSIS; POPULATION; PARENCHYMA; PARTICLES; EXPOSURE	We examined the relationship between intrapulmonary particle distribution of carbonaceous and mineral dusts and remodeling of the airways along anatomically distinct airway paths in the lungs of Hispanic males from the central valley of California. Lung autopsy specimens from the Fresno County Coroner's Office were prepared by intratracheal instillation of 2% glutaraldehyde at 30 cm H2O pressure. Two distinct airway paths into the apico-posterior and apico-anterior portions of the left upper lung lobe were followed. Tissue samples for histologic analysis were generally taken from the intrapulmonary second, fourth, sixth, and ninth airway generations. Parenchymal tissues beyond the 12th airway generation of each airway path were also analyzed. There was little evidence of visible particle accumulation in the larger conducting airways (generations 2-6), except in bronchial-associated lymphoid tissues and within peribronchial connective tissue. In contrast, terminal and respiratory bronchioles arising from each pathway revealed varying degrees of wall thickening and remodeling. Walls with marked thickening contained moderate to heavy amounts of carbonaceous and mineral dusts. Wall thickening was associated with increases in collagen and interstitial inflammatory cells, including dust-laden macrophages. These changes were significantly greater in first-generation respiratory bronchioles compared to second- and third-generation respiratory bronchioles. These findings suggest that accumulation of carbonaceous and mineral dust in the lungs is significantly affected by lung anatomy with the greatest retention in centers of lung acini. Furthermore, there is significant remodeling of this transitional zone in humans exposed to ambient particulate matter.	Univ Calif Davis, Dept Anat Physiol & Cell Biol, Sch Vet Med, Davis, CA 95616 USA; Univ Calif Davis, Dept Epidemiol & Prevent Med, Sch Med, Davis, CA 95616 USA; Univ Calgary, Dept Pathol & Lab Med, Fac Med, Calgary, AB T2N 1N4, Canada; NIOSH, Morgantown, WV USA; Fresno Med Coroners Off, Fresno, CA USA; Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA	Pinkerton, KE (reprint author), Univ Calif Davis, Dept Anat Physiol & Cell Biol, Sch Vet Med, 1321 Haring Hall, Davis, CA 95616 USA.				NCRR NIH HHS [RR00169]; NIEHS NIH HHS [ES05707]		ADESINA AM, 1991, AM REV RESPIR DIS, V143, P144; ALEXIS A, 1999, 1999 CALIFORNIA ALMA, P271; CHOW JC, 1992, ATMOS ENVIRON A-GEN, V26, P3335, DOI 10.1016/0960-1686(92)90350-T; CHOW JC, 1993, AEROSOL SCI TECH, V18, P105, DOI 10.1080/02786829308959588; Churg A, 1997, AM J RESP CRIT CARE, V155, P2109; CHURG A, 1990, EXP LUNG RES, V16, P159, DOI 10.3109/01902149009108838; CHURG A, 1992, SEMIN RESPIR MED, V13, P140, DOI 10.1055/s-2007-1006266; Churg A, 1999, J ENV MED, V1, P39, DOI 10.1002/(SICI)1099-1301(199901/03)1:1<39::AID-JEM6>3.3.CO;2-X; COSIO MG, 1980, AM REV RESPIR DIS, V122, P265; CRAIGHEAD JE, 1982, ARCH PATHOL LAB MED, V106, P544; CRAIGHEAD JE, 1988, ARCH PATHOL LAB MED, V112, P673; Darquenne C, 1996, J APPL PHYSIOL, V80, P1401; FEDERSPIEL WJ, 1988, J APPL PHYSIOL, V64, P2614; Fisher LD, 1993, BIOSTATISTICS METHOD, P256; Green FHY, 1998, PATHOLOGY OCCUPATION, P403; GREEN FHY, 1998, PATHOLOGY OCCUPATION, P209; HAHN FF, 1997, TOXICOLOGY RESP SYST, V3, P187; HARKEMA JR, 1993, AM J PATHOL, V143, P857; KLEINERMAN J, 1979, ARCH PATHOL LAB MED, V103, P375; LIPPMANN M, 1980, BRIT J IND MED, V37, P337; NEIUWENHUIJSEN MJ, 1998, AM J IND HYG ASS, V58, P34; NEIUWENHUIJSEN MJ, 1998, AM J IND HYG ASS J, V59, P9; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; Oberdorster G., 1988, J AEROSOL MED, V1, P289, DOI DOI 10.1089/JAM.1988.1.289; Plopper C, 1990, MODELS LUNG DISEASE, P537; Plopper Chalres G., 1994, P15; SHERWIN RP, 1979, LAB INVEST, V40, P576; Thun MJ, 1997, J NATL CANCER I, V89, P1580, DOI 10.1093/jnci/89.21.1580; THURLBECK WM, 1974, AM REV RESPIR DIS, V109, P239; TSUDA A, 1995, J APPL PHYSIOL, V79, P1055; TSUDA S, 1984, FUND APPL TOXICOL, V4, P378, DOI 10.1016/0272-0590(84)90195-7; WRIGHT JL, 1992, AM REV RESPIR DIS, V146, P240	32	75	81	2	7	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	NOV	2000	108	11					1063	1069		10.1289/ehp.001081063		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	373XP	WOS:000165315600028	11102298	
J	van Zijverden, M; van der Pijl, A; Bol, M; van Pinxteren, FA; de Haar, C; Penninks, AH; van Loveren, H; Pieters, R				van Zijverden, M; van der Pijl, A; Bol, M; van Pinxteren, FA; de Haar, C; Penninks, AH; van Loveren, H; Pieters, R			Diesel exhaust, carbon black, and silica particles display distinct Th1/Th2 modulating activity	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						particulate air pollution; immunotoxicology; Th1/Th2; popliteal lymph node; diesel exhaust particles; carbon black; silica	SYSTEMIC IGE PRODUCTION; ADJUVANT ACTIVITY; AIR-POLLUTION; ANTIBODY-PRODUCTION; FINE PARTICLES; IN-VITRO; ASTHMA; MICE; PREVALENCE; CHILDREN	Certain particulate air pollutants may play an important role in the increasing prevalence of respiratory allergy by stimulating T helper 2 cell (Th2)-mediated immune responses to common antigens. The study described here examined different particles, diesel exhaust particles (DEP), carbon black particles (CBP), and silica particles (SIP) for their immunomodulating capacity in both primary and secondary immune responses in female BALB/C mice. The primary response was studied after subcutaneous injection of 1 mg of particle together with 10 mug of reporter antigen TNP-OVA (2,4,6-trinitrophenyl coupled to ovalbumin) into the hind paw. Interferon-gamma (IFN-gamma) and interleukin 4 (IL-4) production was assessed in the popliteal lymph node (PLN) at Day 2 and Day 5 after injection by flow cytometry and ELISA. The number of IL-4-containing CD4(+) T cells increased between Day 2 and Day 5 in DEP- and CBP-exposed mice, in contrast to SIP-treated animals. IL-4 production by cultured PLN cells was also significantly increased for DEP- and CBP-treated animals. The secondary response was studied in different organs after an intranasal challenge with TNP-OVA (50 mug), which was given 4 weeks after the initial subcutaneous injection. Five days after challenge the number of antibody-forming cells (AFCs) was assessed in peribronchial lymph nodes (PBLN), spleen, bone marrow, and PLN, and antibody levels were determined in weekly obtained blood samples. It appeared that all particles acted as adjuvant, but the different particles stimulated distinct types of immune responses to TNP-OVA. DEP-treated animals show high IgG1 and IgE levels in serum and high IgG1 and IgE-forming AFC numbers in PBLN, bone marrow, and spleen. CBP-treated animals show even higher IgG1 and IgE levels and AFC numbers, and in addition display IgG2a production. SIP-injected animals display predominantly IgG2a responses. It is concluded that DEP are able to skew the immune response toward the T helper 2 (Th2) side, whereas SIP stimulate a Th1 response and CBP have a mixed activity, stimulating both Th1 and Th2 responses in this model, (C) 2000 Academic Press.	Univ Utrecht, RITOX Immunotoxicol, NL-3508 TD Utrecht, Netherlands; TNO, Nutr & Food Res Inst, Utrecht, Netherlands; RIVM, Natl Inst Publ Hlth & Environm, Utrecht, Netherlands	van Zijverden, M (reprint author), Univ Utrecht, RITOX Immunotoxicol, POB 80176, NL-3508 TD Utrecht, Netherlands.						Albers R, 1997, TOXICOL APPL PHARM, V143, P102, DOI 10.1006/taap.1996.8078; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BERUBE KA, 1997, EUR MICR ANAL, V49, P9; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Churg A, 1997, AM J RESP CRIT CARE, V155, P2109; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Davis GS, 1999, AM J RESP CELL MOL, V20, P813; Devalia JL, 1996, TOXICOL LETT, V86, P169, DOI 10.1016/0378-4274(96)03687-9; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Duhme H, 1996, EPIDEMIOLOGY, V7, P578, DOI 10.1097/00001648-199611000-00003; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; Frew AJ, 1997, CLIN EXP ALLERGY, V27, P237; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; *ISAAC, 1998, LANCET, V351, P1325; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Jacobs J, 1997, ENVIRON HEALTH PERSP, V105, P980; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; MANCINO D, 1983, INT ARCH ALLER A IMM, V71, P279; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; Murphy SA, 1998, LIFE SCI, V62, P1789, DOI 10.1016/S0024-3205(98)00141-6; Nilsen A, 1997, TOXICOLOGY, V124, P225, DOI 10.1016/S0300-483X(97)00150-9; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; OPENSHAW P, 1995, J EXP MED, V182, P1357, DOI 10.1084/jem.182.5.1357; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Schafer T, 1997, ALLERGY, V52, P14; Schielen P, 1995, J IMMUNOL METHODS, V188, P33, DOI 10.1016/0022-1759(95)00199-9; Steerenberg PA, 1999, INHAL TOXICOL, V11, P1109; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; Yang HM, 1997, EXP LUNG RES, V23, P269, DOI 10.3109/01902149709087372; Yuen IS, 1996, AM J RESP CELL MOL, V15, P268	46	75	78	1	7	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	OCT 15	2000	168	2					131	139		10.1006/taap.2000.9013		9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	371YQ	WOS:000165207200006	11032768	
J	Martin, JG; Duguet, A; Eidelman, DH				Martin, JG; Duguet, A; Eidelman, DH			The contribution of airway smooth muscle to airway narrowing and airway hyperresponsiveness in disease	EUROPEAN RESPIRATORY JOURNAL			English	Article						airways responsiveness; airway smooth muscle; asthma; mechanics; modelling	BROWN-NORWAY RATS; ANTIGEN CHALLENGE; GUINEA-PIGS; ASTHMA; BRONCHOCONSTRICTION; MECHANICS; MODEL; ORIENTATION; PRESSURE; EXPOSURE	Airway hyperresponsiveness (AHR), the exaggerated response to constrictor agonists in asthmatic subjects, is incompletely understood. Changes in either the quantity or properties of airway smooth muscle (ASM) are possible explanations for AHR. Morphometric analyses demonstrate structural changes in asthmatic airways, including subepithelial fibrosis, gland hyperplasia/hypertrophy, neovascularization and an increase in ASM mass. Mathematical modelling of airway narrowing suggests that, of all the changes in structure, the increase in ASM mass is the most probable cause of AHR. An increase in ASM mass in the large airways is more closely associated with a greater likelihood of dying from asthma than increases in ASM mass in other locations within the airway tree. ASM contraction is opposed by the elastic recoil of the lungs and airways, which appears to limit the degree of bronchoconstriction in vivo. The cyclical nature of tidal breathing applies stresses to the airway wall that enhance the bronchodilating influence of the lung tissues on the contracting ASR;I, in all probability by disrupting cross-bridges. However, the increase in ASM mass in asthma may overcome the limitation resulting from the impedances to ASM shortening imposed by the lung parenchyma and airway wall tissues. Additionally, ASM with the capacity to shorten rapidly may achieve shorter lengths and cause a greater degree of bronchoconstriction when stimulated to contract than slower ASM. Changes in ASM properties are induced by the process of sensitization and allergen-exposure such as enhancement of phospholipase C activity and inositol phosphate turnover, and increases in myosin Light chain kinase activity, Whether changes in ASM mass or biochemical/biomechanical properties form the basis for asthma remains to be determined.	McGill Univ, Meakins Christie Labs, Dept Med, Montreal, PQ H2X 2P2, Canada	Martin, JG (reprint author), McGill Univ, Meakins Christie Labs, Dept Med, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.						An SS, 1999, AM J PHYSIOL-LUNG C, V277, pL968; ANTONISSEN LA, 1979, J APPL PHYSIOL, V46, P681; BATES JHT, 1990, J APPL PHYSIOL, V69, P995; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Brown RH, 1997, J APPL PHYSIOL, V83, P366; BROWN RH, 1995, J APPL PHYSIOL, V79, P1242; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Chung KF, 2000, EUR RESPIR J, V15, P961, DOI 10.1034/j.1399-3003.2000.15e26.x; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; Fredberg JJ, 1997, AM J RESP CRIT CARE, V156, P1752; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959; Gillis HL, 1999, J APPL PHYSIOL, V86, P2001; GUNST SJ, 1988, J APPL PHYSIOL, V64, P2522; Hai CM., 1988, AM J PHYSIOL, V254, P99; HAKONARSON H, 1995, AM J PHYSIOL-LUNG C, V269, pL645; Halayko AJ, 1999, AM J PHYSIOL-LUNG C, V276, pL197; James A, 2000, EUR RESPIR J, V15, P782, DOI 10.1034/j.1399-3003.2000.15d25.x; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JIANG H, 1992, J APPL PHYSIOL, V72, P39; JIANG H, 1992, AM J RESP CELL MOL, V7, P567; John M, 1997, J IMMUNOL, V158, P1841; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Lei M, 1997, J APPL PHYSIOL, V82, P70; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; MACKLEM PT, 1987, CHEST, V91, pS189, DOI 10.1378/chest.91.6.189S; Mehta D, 1996, AM J PHYSIOL-CELL PH, V270, pC243; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; MORENO RH, 1993, J APPL PHYSIOL, V75, P738; PADRID P, 1995, AM J RESP CRIT CARE, V151, P184; SALARI H, 1992, J ALLERGY CLIN IMMUN, V90, P918, DOI 10.1016/0091-6749(92)90464-D; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423; SASAKI H, 1978, J APPL PHYSIOL, V45, P858; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; Solway J, 1997, AM J RESP CELL MOL, V17, P144; Tao FC, 1999, AM J RESP CRIT CARE, V160, P446; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749; Thorpe CW, 1997, J APPL PHYSIOL, V82, P1616; WANG CG, 1993, AM REV RESPIR DIS, V148, P413; WANG ZL, 1995, AM J RESP CRIT CARE, V152, P2097; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814; YAGER D, 1991, AM REV RESPIR DIS, V143, pS52; YOO J, 1994, AM J PHYSIOL-CELL PH, V267, pC1657	44	75	83	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	AUG	2000	16	2					349	354		10.1034/j.1399-3003.2000.16b25.x		6	Respiratory System	Respiratory System	346EF	WOS:000088857300025	10968513	
J	Cade, A; Brownlee, KG; Conway, SP; Haigh, D; Short, A; Brown, J; Dassu, D; Mason, SA; Phillips, A; Eglin, R; Graham, M; Chetcuti, A; Chatrath, M; Hudson, N; Thomas, A; Chetcuti, PAJ				Cade, A; Brownlee, KG; Conway, SP; Haigh, D; Short, A; Brown, J; Dassu, D; Mason, SA; Phillips, A; Eglin, R; Graham, M; Chetcuti, A; Chatrath, M; Hudson, N; Thomas, A; Chetcuti, PAJ			Randomised placebo controlled trial of nebulised corticosteroids in acute respiratory syncytial viral bronchiolitis	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article						acute viral bronchiolitis; respiratory syncytial virus; inhaled corticosteroids	VIRUS BRONCHIOLITIS; LUNG-FUNCTION; BUDESONIDE; CHILDREN; INFANTS; ASTHMA; DEXAMETHASONE; INFECTION; AGE	Objective--To evaluate short and long term effects of giving nebulised budesonide early in respiratory syncytial viral (RSV) bronchiolitis. Design--A multicentre randomised double blind placebo controlled trial. Subjects--Infants admitted to hospital with their first episode of RSV positive bronchiolitis. Intervention-Randomised to receive either 1 mg of nebulised budesonide (Bud) or placebo (Pla) twice daily from admission until 2 weeks after discharge. Follow up was for 12 months. Main outcome measures--Duration of hospital admission, time taken to become symptom free, re-admission rates, general practitioner consultation rates, and use of antiwheeze medication during follow up. Results--161 infants were studied. Both arms were similar with respect to initial clinical severity, age, sex, socioeconomic class, and tobacco exposure, Median time from first nebulisation to discharge: Bud and Pla, 2 days. Median number of days for 50% of infants to be symptom free for 48 hours: Bud, 10 days; Ma, 12 days. Respiratory re-admission rates in the 12 month follow up: Bud, 16%; Pla, 18%; median difference (95% confidence interval (Cl)), -2 (-14 to 10). Median respiratory related general practitioner attendances: Bud, 4.0; Pla, 4.5; median difference (95% CI), -1 (-2 to 0). Percentage of infants recieving at least one prescription for antiwheeze medication during follow up, corticosteroids: Bud, 50%; Pla, 60%; difference (95% CI), -10 (-26 to 6);bronchodilators: Bud, 60%; Pla, 67%; difference (95% CI), -7 (-22 to 8). Conclusions--There are no short or long term clinical benefits from the administration of nebulised corticosteroids in the acute phase of RSV bronchiolitis.	Gen Infirm, Dept Paediat & Child Hlth, Leeds, W Yorkshire, England; St James Univ Hosp, Leeds LS9 7TF, W Yorkshire, England; Seacroft Hosp, Leeds LS14 6UH, W Yorkshire, England; St Lukes Hosp, Bradford BD5 0NA, W Yorkshire, England; Huddersfield Royal Infirm, Huddersfield HO3 3AE, W Yorkshire, England; No & Yorkshire Clin Trials & Res Unit, Leeds LS16 6QB, W Yorkshire, England	Cade, A (reprint author), Gen Infirm, Dept Paediat & Child Hlth, Clarendor Wing,Belmont Grove, Leeds, W Yorkshire, England.						CARLSEN K, 1988, ARCH DIS CHILD, V63, P1428; CARLSEN KCL, 1992, ARCH DIS CHILD, V67, P1077; DABBOUS IA, 1966, PEDIATRICS, V37, P477; DAUGBJERG P, 1993, ACTA PAEDIATR, V82, P547, DOI 10.1111/j.1651-2227.1993.tb12750.x; EVERARD ML, 1994, ARCH DIS CHILD, V71, P428; Gardner M. J., 1989, STAT CONFIDENCE; GOODWIN A, 1995, BR J CLIN RES, V6, P113; Klassen TP, 1997, J PEDIATR-US, V130, P191, DOI 10.1016/S0022-3476(97)70342-1; KUIKKA L, 1994, ACTA PAEDIATR, V83, P744, DOI 10.1111/j.1651-2227.1994.tb13131.x; LEER JA, 1969, AM J DIS CHILD, V117, P495; MARTINEZ FD, 1991, AM REV RESPIR DIS, V143, P312; MCKENZIE S, 1992, FORFAR ARNEILS TXB P, P638; MURRAY M, 1992, ARCH DIS CHILD, V67, P482; NAHATA MC, 1994, J CLIN PHARM THER, V19, P117, DOI 10.1111/j.1365-2710.1994.tb01122.x; Parmar MKB, 1995, SURVIVAL ANAL PRACTI; PULLAN CR, 1982, BRIT MED J, V284, P1665; Reijonen T, 1996, ARCH PEDIAT ADOL MED, V150, P512; Richter H, 1998, J PEDIATR-US, V132, P849, DOI 10.1016/S0022-3476(98)70316-6; ROONEY JC, 1971, J PEDIATR-US, V79, P744, DOI 10.1016/S0022-3476(71)80385-2; Roosevelt G, 1996, LANCET, V348, P292, DOI 10.1016/S0140-6736(96)02285-4; SAMMARTINO L, 1995, J PAEDIATR CHILD H, V31, P61; SIGURS N, 1995, PEDIATRICS, V95, P500; SIMS DG, 1978, BRIT MED J, V1, P11; SPRINGER C, 1990, PEDIATR PULM, V9, P181, DOI 10.1002/ppul.1950090311; STOKES GM, 1981, J PEDIATR-US, V98, P871, DOI 10.1016/S0022-3476(81)80577-X; van Woensel JBM, 1997, THORAX, V52, P634; Wong J., 1997, European Respiratory Journal Supplement, V10, p430S; YOUNG S, 1995, ARCH DIS CHILD, V72, P16	28	75	87	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	FEB	2000	82	2					126	130		10.1136/adc.82.2.126		5	Pediatrics	Pediatrics	281HH	WOS:000085152500009	10648365	
J	Goleva, E; Jackson, LP; Harris, JK; Robertson, CE; Sutherland, ER; Hall, CF; Good, JT; Gelfand, EW; Martin, RJ; Leung, DYM				Goleva, Elena; Jackson, Leisa P.; Harris, J. Kirk; Robertson, Charles E.; Sutherland, E. Rand; Hall, Clifton F.; Good, James T., Jr.; Gelfand, Erwin W.; Martin, Richard J.; Leung, Donald Y. M.			The Effects of Airway Microbiome on Corticosteroid Responsiveness in Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						microbiome; asthma; corticosteroids	STEROID-RESISTANT ASTHMA; GLUCOCORTICOID-INSENSITIVE ASTHMA; PROTEIN-KINASE PHOSPHATASE-1; FIBEROPTIC BRONCHOSCOPY; COMMENSAL BACTERIA; RECEPTOR-BETA; LIPID-A; DISEASE; LIPOPOLYSACCHARIDES; MACROPHAGES	Rationale: The role of airway microbiome in corticosteroid response in asthma is unknown. Objectives: To examine airway microbiome composition in patients with corticosteroid-resistant (CR) asthma and compare it with patients with corticosteroid-sensitive (CS) asthma and normal control subjects and explore whether bacteria in the airways of subjects with asthma may direct alterations in cellular responses to corticosteroids. Methods: 16S rRNA gene sequencing was performed on bronchoalveolar lavage(BAL) samples of 39 subjects with asthma and 12 healthy control subjects. In subjects with asthma, corticosteroid responsiveness was characterized, BAL macrophages were stimulated with pathogenic versus commensal microorganisms, and analyzed by real-time polymerase chain reaction for the expression of corticosteroid-regulated genes and cellular p38 mitogen-activated protein kinase (MAPK) activation. Measurements and Main Results: Of the 39 subjects with asthma, 29 were CR and 10 were CS. BAL microbiome from subjects with CR and CS asthma did not differ in richness, evenness, diversity, and community composition at the phylum level, but did differ at the genus level, with distinct genus expansions in 14 subjects with CR asthma. Preincubation of asthmatic airway macrophages with Haemophilus parainfluenzae, a uniquely expanded potential pathogen found only in CR asthma airways, resulted in p38 MAPK activation, increased IL-8 (P < 0.01), mitogen-activated kinase phosphatase 1 mRNA (P < 0.01) expression, and inhibition of corticosteroid responses (P < 0.05). This was not observed after exposure to commensal bacterium Prevotella melaninogenica. Inhibition of transforming growth factor-beta-associated kinase-1 (TAK1), upstream activator of MAPK, but not p38 MAPK restored cellular sensitivity to corticosteroids. [GRAPHICS] Conclusions: A subset of subjects with CR asthma demonstrates airway expansion of specific gram-negative bacteria, which trigger TAK1/MAPK activation and induce corticosteroid resistance. TAK1 inhibition restored cellular sensitivity to corticosteroids.	[Goleva, Elena; Jackson, Leisa P.; Hall, Clifton F.; Gelfand, Erwin W.; Leung, Donald Y. M.] Natl Jewish Hlth, Dept Pediat, Denver, CO 80206 USA; [Sutherland, E. Rand; Good, James T., Jr.; Martin, Richard J.] Natl Jewish Hlth, Dept Med, Denver, CO 80206 USA; [Harris, J. Kirk; Gelfand, Erwin W.; Leung, Donald Y. M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA; [Robertson, Charles E.] Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA	Leung, DYM (reprint author), Natl Jewish Hlth, 1400 Jackson St,K926I, Denver, CO 80206 USA.	leungd@njhealth.org		ROBERTSON, CHARLES/0000-0002-4136-4121	NIAID; NHLBI of the National Institutes of Health [AI070140, 2R56AI070140, HL37260]; Edelstein Family Foundation	Supported by NIAID and NHLBI of the National Institutes of Health under Award Numbers AI070140, 2R56AI070140, and HL37260. The authors acknowledge The Edelstein Family Foundation for their generous support of this work.	Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316; Asai Y, 2007, J IMMUNOL, V179, P7674; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Busse WW, 2005, AM J RESP CRIT CARE, V172, P807, DOI 10.1164/rccm.200407-966WS; Chen PL, 2002, J IMMUNOL, V169, P6408; Chen WM, 2012, INT J SYST EVOL MICR, V62, P698, DOI 10.1099/ijs.0.030635-0; Drazen JM, 2012, J ALLERGY CLIN IMMUN, V129, P1200, DOI 10.1016/j.jaci.2012.03.026; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Erridge C, 2002, MICROBES INFECT, V4, P837, DOI 10.1016/S1286-4579(02)01604-0; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; [Anonymous], 2012, GLOB STRAT ASTHM MAN; Goleva E, 2012, J ALLERGY CLIN IMMUN, V129, pAB128; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Goleva E, 2008, J ALLERGY CLIN IMMUN, V122, P550, DOI 10.1016/j.jaci.2008.07.007; Goleva E, 2007, J ALLERGY CLIN IMMUN, V120, P1065, DOI 10.1016/j.jaci.2007.07.042; Goleva E, 2013, J ALLERGY CLIN IMMUN, V131, pAB138; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600; Hashimoto M, 2003, FEBS LETT, V543, P98, DOI 10.1016/S0014-5793(03)00414-9; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Ivanov II, 2011, CURR OPIN MICROBIOL, V14, P106, DOI 10.1016/j.mib.2010.12.003; Komaniecka I, 2010, MICROBIOL IMMUNOL, V54, P717, DOI 10.1111/j.1348-0421.2010.00269.x; Komaniecka I, 2010, CHEM-EUR J, V16, P2922, DOI 10.1002/chem.200902390; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Lai YP, 2009, NAT MED, V15, P1377, DOI 10.1038/nm.2062; Larsen JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031976; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Leung DYM, 2003, J ALLERGY CLIN IMMUN, V111, P3, DOI 10.1067/mai.2003.97; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Liu YS, 2007, NAT REV IMMUNOL, V7, P202, DOI 10.1038/nri2035; Lodowska J, 2007, POSTEPY HIG MED DOSW, V61, P106; Lu HS, 2011, INT J SYST EVOL MICR, V61, P404, DOI 10.1099/ijs.0.020206-0; Malmstrom K, 1999, ANN INTERN MED, V130, P487; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Minnicozzi M, 2011, IMMUNOL REV, V242, P106, DOI 10.1111/j.1600-065X.2011.01025.x; Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073; National Asthma Education and Prevention Program (National Heart Lung and Blood Institute) Third Expert Panel on the Management of Asthma. National Center for Biotechnology Information (US), 2007, NIH PUBLICATION, V07-4051; Netea MG, 2002, TRENDS IMMUNOL, V23, P135, DOI 10.1016/S1471-4906(01)02169-X; Park JH, 2004, APPL ENVIRON MICROB, V70, P262, DOI 10.1128/aEM.70.1.262-267.2004; Pragman AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047305; Reynolds SJ, 2005, J ENVIRON MONITOR, V7, P1371, DOI 10.1039/b509256f; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; SOKOLOWSKI JW, 1987, AM REV RESPIR DIS, V136, P1066; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2010, AM J RESP CRIT CARE, V181, P699, DOI 10.1164/rccm.200911-1710OC; Sze MA, 2012, AM J RESP CRIT CARE, V185, P1073, DOI 10.1164/rccm.201111-2075OC; Walsh GM, 2003, J ENDOCRINOL, V178, P37, DOI 10.1677/joe.0.1780037; Wieland CW, 2005, J IMMUNOL, V175, P6042; Yang M, 2012, J LEUKOCYTE BIOL, V91, P557, DOI 10.1189/jlb.0711357; Zhang Y, 2012, J ALLERGY CLIN IMMUN, V129, pAB146; Zhang Y, 2009, J BIOL CHEM, V284, P24542, DOI 10.1074/jbc.M109.021469; [Anonymous], 1985, AM REV RESP DIS, V132, P180	54	74	78	1	38	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2013	188	10					1193	1201		10.1164/rccm.201304-0775OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	251WO	WOS:000326963600011	24024497	
J	Ziello, C; Sparks, TH; Estrella, N; Belmonte, J; Bergmann, KC; Bucher, E; Brighetti, MA; Damialis, A; Detandt, M; Galan, C; Gehrig, R; Grewling, L; Bustillo, AMG; Hallsdottir, M; Kockhans-Bieda, MC; De Linares, C; Myszkowska, D; Paldy, A; Sanchez, A; Smith, M; Thibaudon, M; Travaglini, A; Uruska, A; Valencia-Barrera, RM; Vokou, D; Wachter, R; de Weger, LA; Menzel, A				Ziello, Chiara; Sparks, Tim H.; Estrella, Nicole; Belmonte, Jordina; Bergmann, Karl C.; Bucher, Edith; Brighetti, Maria Antonia; Damialis, Athanasios; Detandt, Monique; Galan, Carmen; Gehrig, Regula; Grewling, Lukasz; Gutierrez Bustillo, Adela M.; Hallsdottir, Margret; Kockhans-Bieda, Marie-Claire; De Linares, Concepcion; Myszkowska, Dorota; Paldy, Anna; Sanchez, Adriana; Smith, Matthew; Thibaudon, Michel; Travaglini, Alessandro; Uruska, Agnieszka; Valencia-Barrera, Rosa M.; Vokou, Despoina; Wachter, Reinhard; de Weger, Letty A.; Menzel, Annette			Changes to Airborne Pollen Counts across Europe	PLOS ONE			English	Article							AMBROSIA-ARTEMISIIFOLIA L.; CLIMATE-CHANGE; PUBLIC-HEALTH; ALLERGENIC POLLEN; ATMOSPHERIC CO2; COMMON RAGWEED; AEROALLERGENS; URBANIZATION; IMPACTS; SEASONS	A progressive global increase in the burden of allergic diseases has affected the industrialized world over the last half century and has been reported in the literature. The clinical evidence reveals a general increase in both incidence and prevalence of respiratory diseases, such as allergic rhinitis (common hay fever) and asthma. Such phenomena may be related not only to air pollution and changes in lifestyle, but also to an actual increase in airborne quantities of allergenic pollen. Experimental enhancements of carbon dioxide (CO2) have demonstrated changes in pollen amount and allergenicity, but this has rarely been shown in the wider environment. The present analysis of a continental-scale pollen data set reveals an increasing trend in the yearly amount of airborne pollen for many taxa in Europe, which is more pronounced in urban than semi-rural/rural areas. Climate change may contribute to these changes, however increased temperatures do not appear to be a major influencing factor. Instead, we suggest the anthropogenic rise of atmospheric CO2 levels may be influential.	[Ziello, Chiara; Sparks, Tim H.; Estrella, Nicole; Sanchez, Adriana; Menzel, Annette] Tech Univ Munich, Chair Ecoclimatol, Freising Weihenstephan, Germany; [Sparks, Tim H.; Estrella, Nicole; Menzel, Annette] Tech Univ Munich, Inst Adv Study, D-8046 Garching, Germany; [Sparks, Tim H.] Poznan Univ Life Sci, Inst Zool, Poznan, Poland; [Belmonte, Jordina; De Linares, Concepcion] Univ Autonoma Barcelona, Bot Unit, Bellaterra, Spain; [Belmonte, Jordina; De Linares, Concepcion] Univ Autonoma Barcelona, Inst Environm Sci & Technol ICTA, Bellaterra, Spain; [Bergmann, Karl C.] Charite, Allergie Ctr Charite, D-13353 Berlin, Germany; [Bucher, Edith] Agenzia Prov Ambiente, Biol Lab, Laives, BZ, Italy; [Brighetti, Maria Antonia; Travaglini, Alessandro] Univ Roma Tor Vergata, Dipartimento Biol, I-00173 Rome, Italy; [Damialis, Athanasios; Vokou, Despoina] Aristotle Univ Thessaloniki, Sch Biol, Dept Ecol, GR-54006 Thessaloniki, Greece; [Detandt, Monique] Sci Inst Publ Hlth, Sect Mycol & Aerobiol, Brussels, Belgium; [Galan, Carmen] Univ Cordoba, Dept Bot Ecol & Plant Physiol, Cordoba, Spain; [Gehrig, Regula] Fed Off Meteorol & Climatol MeteoSwiss, Zurich, Switzerland; [Grewling, Lukasz] Adam Mickiewicz Univ, Lab Aeropalynol, Poznan, Poland; [Gutierrez Bustillo, Adela M.] Univ Complutense Madrid, Dept Plant Biol 2, Madrid, Spain; [Hallsdottir, Margret] Iceland Inst Nat Hist, Gardabaer, Iceland; [Kockhans-Bieda, Marie-Claire] Ctr Hosp Luxembourg, Stn Aerobiol, Luxembourg, Luxembourg; [Myszkowska, Dorota] Jagiellonian Univ, Coll Med, Dept Clin & Environm Allergol, Krakow, Poland; [Paldy, Anna] Natl Inst Environm Hlth, Dept Biol, Budapest, Hungary; [Smith, Matthew] Univ Worcester, Natl Pollen & Aerobiol Res Unit, Worcester, England; [Thibaudon, Michel] Reseau Natl Surveillance Aerobiol, Brussieu, France; [Uruska, Agnieszka] Univ Gdansk, Lab Palaeoecol & Archaeobot, PL-80952 Gdansk, Poland; [Valencia-Barrera, Rosa M.] Univ Leon, Dept Biodivers & Environm Management, E-24071 Leon, Spain; [Wachter, Reinhard] Polleninformat Dienst Deutschland PID, Ganderkesee, Germany; [de Weger, Letty A.] Leiden Univ, Med Ctr, Dept Pulmonol, Leiden, Netherlands	Ziello, C (reprint author), Tech Univ Munich, Chair Ecoclimatol, Freising Weihenstephan, Germany.	ziello@wzw.tum.de	Damialis, Athanasios/C-6109-2013; Gutierrez-Bustillo, Adela Montserrat/L-7250-2014; Smith, Matt/C-3911-2014; De Linares, Concepcion/F-9313-2016; Menzel, Annette/B-1105-2013	Damialis, Athanasios/0000-0001-6400-384X; Gutierrez-Bustillo, Adela Montserrat/0000-0002-6782-0527; Smith, Matt/0000-0002-4170-2960; De Linares, Concepcion/0000-0002-2047-3337; Menzel, Annette/0000-0002-7175-2512; Belmonte, Jordina/0000-0002-6419-9595; Valencia-Barrera, Rosa M/0000-0002-6014-9961; Damialis, Athanasios/0000-0003-2917-5667; Sparks, Tim/0000-0003-4382-7051	Technische Universitat Munchen - Institute for AdvancedStudy; German Excellence Initiative; Bavarian State Ministry of the Environment and Public Health [U119]	This study is supported by the Technische Universitat Munchen - Institute for AdvancedStudy, funded by the German Excellence Initiative. The Ph.D. project of the first author is supported by Grant U119 from Bavarian State Ministry of the Environment and Public Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bartra J, 2007, J INVEST ALLERG CLIN, V17, P3; Beggs PJ, 2005, ENVIRON HEALTH PERSP, V113, P915, DOI 10.1289/ehp.7724; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; Chuine I, 1999, PLANT CELL ENVIRON, V22, P1, DOI 10.1046/j.1365-3040.1999.00395.x; Clot Bernard, 2003, Aerobiologia, V19, P227, DOI 10.1023/B:AERO.0000006572.53105.17; D'Amato G, 2008, CLIN EXP ALLERGY, V38, P1264, DOI 10.1111/j.1365-2222.2008.03033.x; D'Amato G, 2007, ALLERGY, V62, P976, DOI 10.1111/j.1398-9995.2007.01393.x; Dahl A., 1996, AEROBIOLOGIA, V12, P97, DOI DOI 10.1007/BF02248133; Damialis A, 2007, ATMOS ENVIRON, V41, P7011, DOI 10.1016/j.atmosenv.2007.05.009; Darbah JNT, 2008, ENVIRON POLLUT, V155, P446, DOI 10.1016/j.envpol.2008.01.033; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; EMBERLIN J, 1994, ALLERGY, V49, P15, DOI 10.1111/j.1398-9995.1994.tb04233.x; Emberlin J, 2007, INT J BIOMETEOROL, V51, P181, DOI 10.1007/s00484-006-0059-2; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Garcia-Mozo H, 2010, AEROBIOLOGIA, V26, P157, DOI 10.1007/s10453-009-9153-3; Gregg JW, 2003, NATURE, V424, P183, DOI 10.1038/nature01728; Haylock MR, 2008, J GEOPHYS RES-ATMOS, V113, DOI 10.1029/2008JD010201; Huynen M., 2003, WHO M; Jato V, 2006, AEROBIOLOGIA, V22, P13, DOI 10.1007/s10453-005-9011-x; Luedeling E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020155; Menzel A, 2006, GLOBAL CHANGE BIOL, V12, P1969, DOI 10.1111/j.1365-2486.2006.01193.x; Parry Martin, 2007, CLIMATE CHANGE 2007, P7; PETRI J.L., 2004, ACTA HORTIC, V662, P53; R Development Core Team, 2010, R LANG ENV STAT COMP; Reid CE, 2009, ECOHEALTH, V6, P458, DOI 10.1007/s10393-009-0261-x; Rogers CA, 2006, ENVIRON HEALTH PERSP, V114, P865, DOI 10.1289/ehp.8549; Rosenzweig C., 2007, CLIMATE CHANGE 2007, P79; Singer BD, 2005, FUNCT PLANT BIOL, V32, P667, DOI 10.1071/FP05039; Smith M, 2009, AEROBIOLOGIA, V25, P321, DOI 10.1007/s10453-009-9136-4; Spieksma F. Th. M., 2003, Aerobiologia, V19, P171, DOI 10.1023/B:AERO.0000006528.37447.15; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Ziska LH, 2008, MITIG ADAPT STRAT GL, V13, P607, DOI 10.1007/s11027-007-9134-1; Ziska LH, 2009, ENVIRON HEALTH PERSP, V117, P155, DOI 10.1289/ehp.11501; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	34	74	76	3	57	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 13	2012	7	4							e34076	10.1371/journal.pone.0034076		8	Multidisciplinary Sciences	Science & Technology - Other Topics	959UT	WOS:000305341600023	22514618	
J	Hinz, D; Bauer, M; Roder, S; Olek, S; Huehn, J; Sack, U; Borte, M; Simon, JC; Lehmann, I; Herberth, G				Hinz, D.; Bauer, M.; Roeder, S.; Olek, S.; Huehn, J.; Sack, U.; Borte, M.; Simon, J. C.; Lehmann, I.; Herberth, G.		LINA Study Grp	Cord blood Tregs with stable FOXP3 expression are influenced by prenatal environment and associated with atopic dermatitis at the age of one year	ALLERGY			English	Article						birth cohort; cord blood; environmental exposure; FOXP3; regulatory T cells	REGULATORY T-CELLS; IMMUNE-RESPONSES; PERIPHERAL-BLOOD; MATERNAL SMOKING; DNA METHYLATION; LINEAGE; INDUCTION; PREGNANCY; CHILDREN; DISEASE	Background: Regulatory T cells (Tregs) with stable FOXP3 expression are characterized by a specific demethylated region in the FOXP3 gene (Treg-specific demethylated region, TSDR). The aim of this study was to analyse the influence of prenatal factors on cord blood Treg numbers, as detected by changes in the TSDR demethylation, and the subsequent risk for allergic diseases. Methods: Analyses were performed within the LINA study in blood samples from pregnant women (34th gestational week) and in cord blood (n = 346 mother-child pairs). Treg numbers were detected via DNA demethylation in the FOXP3 TSDR. At age 1, total and specific IgE was measured in children's blood. In addition, maternal cytokine production (Th1/ Th2/ Th17) was analysed. Exposure and disease outcomes were assessed by questionnaires. Results: Boys had lower Treg numbers compared with girls (P < 0.001). Parental atopy history, particularly maternal hay fever and paternal asthma were related to lower Treg numbers in cord blood (adj. MR = 0.81, 95% CI = 0.68-0.97; adj. MR = 0.60, 95% CI = 0.45-0.81). Maternal cytokines (IL-13, IL-17E and IFN-gamma) and maternal smoking/ exposure to tobacco smoke during pregnancy were also associated with decreased cord blood Treg numbers (adj. MR = 0.89, 95% CI = 0.97-1.00). Children with lower Treg numbers at birth had a higher risk to develop atopic dermatitis (adj. OR = 1.55, 95% CI = 1.00-2.41) and sensitization to food allergens (adj. OR = 1.55, 95% CI = 1.06-2.25) during the first year of life. Conclusions: These results indicate that both genetic and environmental factors presumably influence the development of foetal Tregs. Low cord blood Treg numbers may predict early atopic dermatitis.	[Hinz, D.; Bauer, M.; Lehmann, I.; Herberth, G.] UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, D-04318 Leipzig, Germany; [Hinz, D.] Univ Klinikum, Klin Dermatol Venerol & Allergol, Leipzig, Germany; [Roeder, S.] UFZ Helmholtz Ctr Environm Res, Core Facil Studies, D-04318 Leipzig, Germany; [Olek, S.] Epiontis GmbH, Berlin, Germany; [Huehn, J.] Helmholtz Ctr Infect Res, Dept Expt Immunol, Braunschweig, Germany; [Sack, U.] Univ Leipzig, Inst Clin Immunol, Leipzig, Germany; [Borte, M.] Univ Leipzig, Acad Teaching Hosp, Municipal Hosp St Georg, Childrens Hosp, Leipzig, Germany	Lehmann, I (reprint author), UFZ Helmholtz Ctr Environm Res, Dept Environm Immunol, Permoserstr 15, D-04318 Leipzig, Germany.	irina.lehmann@ufz.de	Sack, Ulrich/J-6301-2015	Sack, Ulrich/0000-0002-7813-0492	Helmholtz Interdisciplinary Graduate School for Environmental Research (HIGRADE); German Research Foundation [KFO250]	We cordially thank the participants of the LINA study as well as Beate Fink and Anne Hain for their excellent technical assistance. The authors are grateful to Neil Jones and Sonja Nakasian for the careful revision of the manuscript. This work was partially supported by the Helmholtz Impulse and Networking Fund through Helmholtz Interdisciplinary Graduate School for Environmental Research (HIGRADE) and by the German Research Foundation (KFO250).	Baecher-Allan C, 2001, J IMMUNOL, V167, P1245; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Chen W, 2008, ALLERGY, V63, P1418, DOI 10.1111/j.1398-9995.2008.01880.x; Fontenot JD, 2005, IMMUNITY, V22, P329, DOI 10.1016/j.immuni.2005.01.016; Haddeland U, 2005, PEDIATR ALLERGY IMMU, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; Herberth G, 2011, ALLERGY, V66, P1065, DOI 10.1111/j.1398-9995.2011.02587.x; Hinz D, 2010, CLIN EXP ALLERGY, V40, P419, DOI 10.1111/j.1365-2222.2009.03434.x; Huehn J, 2009, NAT REV IMMUNOL, V9, P83, DOI 10.1038/nri2474; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Kopp MV, 2001, CLIN EXP ALLERGY, V31, P1536, DOI 10.1046/j.1365-2222.2001.01198.x; LIAPPIS N, 1992, MONATSSCHR KINDERH, V140, P300; Liu J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013267; Martino D, 2011, CHEST, V139, P640, DOI 10.1378/chest.10-1800; Noakes PS, 2006, EUR RESPIR J, V28, P721, DOI 10.1183/09031936.06.00050206; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Osman M, 2003, ARCH DIS CHILD, V88, P587, DOI 10.1136/adc.88.7.587; Palomares O, 2010, EUR J IMMUNOL, V40, P1232, DOI 10.1002/eji.200940045; Perneger TV, 1998, BRIT MED J, V316, P1236; Pillai V, 2007, CLIN IMMUNOL, V123, P18, DOI 10.1016/j.clim.2006.10.014; Prescott SL, 2007, EARLY HUM DEV, V83, pS41, DOI 10.1016/S0378-3782(07)70035-X; Reece P, 2011, J ALLERGY CLIN IMMUN, V127, P447, DOI 10.1016/j.jaci.2010.11.006; Rindsjo E, 2010, ALLERGY, V65, P822, DOI 10.1111/j.1398-9995.2009.02266.x; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Toker A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001783; Uekert SJ, 2006, J ALLERGY CLIN IMMUN, V118, P1375, DOI 10.1016/j.jaci.2006.09.008; Walker MR, 2003, J CLIN INVEST, V112, P1437, DOI 10.1172/JCI200319441; Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435; Wei J, 2007, P NATL ACAD SCI USA, V104, P18169, DOI 10.1073/pnas.0703642104; Wieczorek G, 2009, CANCER RES, V69, P599, DOI 10.1158/0008-5472.CAN-08-2361	33	74	78	2	15	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	MAR	2012	67	3					380	389		10.1111/j.1398-9995.2011.02767.x		10	Allergy; Immunology	Allergy; Immunology	894RX	WOS:000300445500012	22187950	
J	Kirkham, PA; Caramori, G; Casolari, P; Papi, AA; Edwards, M; Shamji, B; Triantaphyllopoulos, K; Hussain, F; Pinart, M; Khan, Y; Heinemann, L; Stevens, L; Yeadon, M; Barnes, PJ; Chung, KF; Adcock, IM				Kirkham, Paul A.; Caramori, Gaetano; Casolari, Paolo; Papi, Alberto A.; Edwards, Matt; Shamji, Betty; Triantaphyllopoulos, Kostas; Hussain, Farhana; Pinart, Mariona; Khan, Younis; Heinemann, Lucy; Stevens, Laurie; Yeadon, Mike; Barnes, Peter J.; Chung, Kian F.; Adcock, Ian M.			Oxidative Stress-induced Antibodies to Carbonyl-modified Protein Correlate with Severity of Chronic Obstructive Pulmonary Disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						COPD; autoimmunity; oxidative stress; carbonyl	LIPID-PEROXIDATION PRODUCTS; CIGARETTE-SMOKE; INDUCED EMPHYSEMA; T-CELLS; COPD; AUTOANTIBODIES; AUTOIMMUNITY; MICE; AUTOANTIGENS; INFLAMMATION	Rationale: There is increasing evidence for the presence of autoantibodies in chronic obstructive pulmonary disease (COPD). Chronic oxidative stress is an essential component in COPD pathogenesis and can lead to increased levels of highly reactive carbonyls in the lung, which could result in the formation of highly immunogenic carbonyl adducts on "self" proteins. Objectives: To determine the presence of autoantibodies to carbonyl-modified protein in patients with COPD and in a murine model of chronic ozone exposure. To assess the extent of activated immune responses toward carbonyl-modified proteins. Methods: Blood and peripheral lung were taken from patients with COPD, age-matched smokers, and nonsmokers with normal lung function, as well as patients with severe persistent asthma. Mice were exposed to ambient air or ozone for 6 weeks. Antibody titers were measured by ELISA, activated compliment deposition by immunohistochemistry, and cellular activation by ELISA and fluorescence-activated cell sorter. Measurements and Main Results: Antibody titer against carbonyl-modified self-protein was significantly increased in patients with Global Initiative for Chronic Obstructive Lung Disease stage III COPD compared with control subjects. Antibody levels inversely correlated with disease severity and showed a prevalence toward an IgG1 isotype. Deposition of activated complement in the vessels of COPD lung as well as autoantibodies against endothelial cells were also observed. Ozone-exposed mice similarly exhibited increased antibody titers to carbonyl-modified protein, as well as activated antigen-presenting cells in lung tissue and splenocytes sensitized to activation by carbonyl-modified protein. Conclusions: Carbonyl-modified proteins, arising as a result of oxidative stress, promote antibody production, providing a link by which oxidative stress could drive an autoimmune response in COPD.	[Kirkham, Paul A.; Triantaphyllopoulos, Kostas; Hussain, Farhana; Pinart, Mariona; Khan, Younis; Heinemann, Lucy; Stevens, Laurie; Yeadon, Mike; Barnes, Peter J.; Chung, Kian F.; Adcock, Ian M.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LY, England; [Kirkham, Paul A.; Edwards, Matt; Shamji, Betty] Novartis Inst Biomed Res, Horsham, W Sussex, England; [Caramori, Gaetano; Casolari, Paolo; Papi, Alberto A.] Univ Ferrara, Sect Resp Dis, I-44100 Ferrara, Italy; [Caramori, Gaetano; Casolari, Paolo; Papi, Alberto A.] Univ Ferrara, CEMICEF, I-44100 Ferrara, Italy; [Barnes, Peter J.; Chung, Kian F.; Adcock, Ian M.] Royal Brompton Resp Biomed Res Unit, London, England	Kirkham, PA (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	p.kirkham@imperial.ac.uk	Triantaphyllopoulos, Kostas/F-5182-2013; Pinart, Mariona/L-1931-2015	Pinart, Mariona/0000-0002-8223-1325; Adcock, Ian/0000-0003-2101-8843; Chung, Kian Fan/0000-0001-7101-1426; PAPI, ALBERTO/0000-0002-6924-4500	Royal Society; Associazione per la Ricerca e la Cura dell'Asma (ARCA, Padova, Italy); Wellcome Trust; Novartis Institutes for Biomedical Research; Novartis Institutes for Biomedical Research for research consumables; Consorzio Ferrara Ricerche; Novartis; Medical Research Council (MRC); British Lung Foundation; Engineering and Physical Sciences Research Council; Pfizer, UK; Chiesi Farmaceutici; Novartis, UK; Merck Sharp & Dohme (MSD), Italy; AZ; GSK; MSD; Boehringer Ingelheim (BI); Pfizer; Nycomed; Teva Pharmaceuticals; Chiesi; Daiichi-Sankyo; Cempra; Kyorin; Asthma UK	Supported by The Royal Society, Associazione per la Ricerca e la Cura dell'Asma (ARCA, Padova, Italy), The Wellcome Trust, and the Novartis Institutes for Biomedical Research. P.A.K. was a Royal Society Industry Fellow, and received additional support from the Novartis Institutes for Biomedical Research for research consumables. This work was also partly supported by Wellcome Trust grants to I.M.A. and K.F.C. G.C. was provided with support from Associazione per la Ricerca e la Cura dell'Asma (ARCA, Padova, Italy) and Consorzio Ferrara Ricerche.; P.A.K. received institutional grant support from the Royal Society, Novartis, the Medical Research Council (MRC), the British Lung Foundation, and the Engineering and Physical Sciences Research Council. He is employed by and owns stocks in Novartis. G.C. received institutional grant support from Pfizer, UK; Chiesi Farmaceutici; and Novartis, UK; and he received lecture fees from Merck Sharp & Dohme (MSD), Italy. P.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.A.P. is a Board member of Chiesi Farmaceutici, AstraZeneca (AZ), GlaxoSmithKline (GSK), Mundipharma, Novartis, Teva Pharmaceuticals, ProtAffin Biotechnologie, and Nycomed. He was a consultant for Chiesi Farmaceutici, GSK, Sunovion, and Zambon. He received institutional grant support from Chiesi Farmaceutici, AZ, GSK, MSD, Novartis, Boehringer Ingelheim (BI), and Pfizer. He received lecture fees from AZ, Chiesi Farmaceutici, GSK, BI, MSD, Novartis, Pfizer, and Nycomed. M.E. and B.S. are employed by the Novartis Institute for Biomedical Research. K.T. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. F.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Y.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.H. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. L.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.Y. is employed by Pfizer. P.J.B. is a Board member of AZ, BI, Chiesi, Teva Pharmaceuticals, and Novartis. He received lecture fees from AZ, BI, Teva Pharmaceuticals, and Chiesi, and he was an expert witness for BI and Teva Pharmaceuticals. He received grant support from GSK, AZ, Novartis, Daiichi-Sankyo, and Cempra. K.F.C. is on the Advisory Board of GSK, Novartis, and Merck. He received lecture fees from Novartis and GSK. He received travel accommodations from BI and Novartis. I.M.A. was a consultant for GSK, Chiesi, Novartis, Pfizer, and Merck. He was on the Advisory Board for Chiesi and GSK. He received lecture fees from Kyorin, AZ, and GSK and received grant support from Pfizer, GSK, AZ, Novartis, the MRC, and Asthma UK.	Akagawa M, 2006, P NATL ACAD SCI USA, V103, P6160, DOI 10.1073/pnas.0600865103; Allison MED, 2000, EUR J IMMUNOL, V30, P2881, DOI 10.1002/1521-4141(200010)30:10<2881::AID-IMMU2881>3.0.CO;2-9; Barreiro E, 2005, AM J RESP CRIT CARE, V171, P1116, DOI 10.1164/rccm.200407-887OC; Brandsma CA, 2011, EUR RESPIR J, V37, P1289, DOI 10.1183/09031936.00116710; Brusselle GG, 2009, EUR RESPIR J, V34, P219, DOI 10.1183/09031936.00150208; BURROWS B, 1977, AM REV RESPIR DIS, V115, P195; Cosio MG, 2009, NEW ENGL J MED, V360, P2445, DOI 10.1056/NEJMra0804752; Cottin V, 2009, EUR RESPIR J, V33, P219, DOI 10.1183/09031936.00140208; Dalle-Donne I, 2003, CLIN CHIM ACTA, V329, P23, DOI 10.1016/S0009-8981(03)00003-2; Dalle-Donne I, 2003, TRENDS MOL MED, V9, P169, DOI 10.1016/S1471-4914(03)00031-5; Dalle-Donne I, 2006, J CELL MOL MED, V10, P389, DOI 10.1111/j.1582-4934.2006.tb00407.x; Eggleton P, 2008, RHEUMATOLOGY, V47, P567, DOI 10.1093/rheumatology/ken014; ESTERBAUER H, 1991, FREE RADICAL BIO MED, V11, P81, DOI 10.1016/0891-5849(91)90192-6; Feghali-Bostwick CA, 2008, AM J RESP CRIT CARE, V177, P156, DOI 10.1164/rccm.200701-014OC; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2009, GLOB STRAT DIAGN MAN; Greene CM, 2010, AM J RESP CRIT CARE, V181, P31, DOI 10.1164/rccm.200904-0545OC; Hackett TL, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-180; Hall SR, 2001, IMMUNOLOGY, V104, P50, DOI 10.1046/j.1365-2567.2001.01290.x; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Karayama M, 2010, CHEST, V138, P1303, DOI 10.1378/chest.10-0863; Kirkham P, 2006, PHARMACOL THERAPEUT, V111, P476, DOI 10.1016/j.pharmthera.2005.10.025; Kirkham PA, 2004, BIOCHEM BIOPH RES CO, V318, P32, DOI 10.1016/j.bbrc.2004.04.003; Kirkham PA, 2003, FREE RADICAL BIO MED, V35, P697, DOI 10.1016/S0891-5849(03)00390-3; Kosmas EN, 1997, CHEST, V112, P341, DOI 10.1378/chest.112.2.341; Kurien BT, 2008, AUTOIMMUN REV, V7, P567, DOI 10.1016/j.autrev.2008.04.019; Lee SH, 2007, NAT MED, V13, P567, DOI 10.1038/nm1583; Leidinger P, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-20; Marc MM, 2010, SCAND J IMMUNOL, V71, P386, DOI 10.1111/j.1365-3083.2010.02385.x; Marwick JA, 2009, AM J RESP CRIT CARE, V179, P542, DOI 10.1164/rccm.200810-1570OC; Meja KK, 2008, AM J RESP CELL MOL, V39, P312, DOI 10.1165/rcmb.2008-0012OC; MILLER RD, 1980, J LAB CLIN MED, V95, P266; Moghaddam A, 2006, NAT MED, V12, P905, DOI 10.1038/nm1456; Nunez B, 2011, AM J RESP CRIT CARE, V183, P1025, DOI 10.1164/rccm.201001-0029OC; Rahman I, 2002, AM J RESP CRIT CARE, V166, P490, DOI 10.1164/rccm.2110101; Sheikh Z, 2007, AUTOIMMUNITY, V40, P512, DOI 10.1080/08916930701574331; Taraseviciene-Stewart L, 2005, AM J RESP CRIT CARE, V171, P734, DOI 10.1164/rccm.200409-127SOC; Torres-Ramos Yessica D, 2009, Open Respir Med J, V3, P61, DOI 10.2174/1874306400903010061; Triantaphyllopoulos K, 2011, AM J PHYSIOL-LUNG C, V300, pL691, DOI 10.1152/ajplung.00252.2010; van der Strate BWA, 2006, AM J RESP CRIT CARE, V173, P751, DOI 10.1164/rccm.200504-594OC; WAALKENS HJ, 1993, EUR RESPIR J, V6, P645; Wang GD, 2008, FREE RADICAL BIO MED, V44, P1475, DOI 10.1016/j.freeradbiomed.2008.01.012; Wood AM, 2011, EUR RESPIR J, V37, P32, DOI 10.1183/09031936.00033710; Yahya MD, 1996, J AUTOIMMUN, V9, P3, DOI 10.1006/jaut.1996.0002	43	74	79	1	13	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2011	184	7					796	802		10.1164/rccm.201010-1605OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	827DM	WOS:000295407300012	21965015	
J	Rappold, AG; Stone, SL; Cascio, WE; Neas, LM; Kilaru, VJ; Carraway, MS; Szykman, JJ; Ising, A; Cleve, WE; Meredith, JT; Vaughan-Batten, H; Deyneka, L; Devlin, RB				Rappold, Ana G.; Stone, Susan L.; Cascio, Wayne E.; Neas, Lucas M.; Kilaru, Vasu J.; Carraway, Martha Sue; Szykman, James J.; Ising, Amy; Cleve, William E.; Meredith, John T.; Vaughan-Batten, Heather; Deyneka, Lana; Devlin, Robert B.			Peat Bog Wildfire Smoke Exposure in Rural North Carolina Is Associated with Cardiopulmonary Emergency Department Visits Assessed through Syndromic Surveillance	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						cardiopulmonary health effects; satellite data; syndromic surveillance; wildfire smoke exposure	PARTICULATE AIR-POLLUTION; SOUTHERN CALIFORNIA WILDFIRES; CONGESTIVE-HEART-FAILURE; FOREST-FIRES; HOSPITAL ADMISSIONS; UNITED-STATES; ROOM VISITS; URBAN AREA; QUALITY; MORTALITY	BACKGROUND: In June 2008, burning peat deposits produced haze and air pollution far in excess of National Ambient Air Quality Standards, encroaching on rural communities of eastern North Carolina. Although the association of mortality and morbidity with exposure to urban air pollution is well established, the health effects associated with exposure to wildfire emissions are less well understood. OBJECTIVE: We investigated the effects of exposure on cardiorespiratory outcomes in the population affected by the fire. METHODS: We performed a population-based study using emergency department (ED) visits reported through the syndromic surveillance program NC DETECT (North Carolina Disease Event Tracking and Epidemiologic Collection Tool). We used aerosol optical depth measured by a satellite to determine a high-exposure window and distinguish counties most impacted by the dense smoke plume from surrounding referent counties. Poisson log-linear regression with a 5-day distributed lag was used to estimate changes in the cumulative relative risk (RR). RESULTS: In the exposed counties, significant increases in cumulative RR for asthma [1.65 (95% confidence interval, 1.25-2.1)], chronic obstructive pulmonary disease [1.73 (1.06-2.83)], and pneumonia and acute bronchitis [1.59 (1.07-2.34)] were observed. ED visits associated with cardiopulmonary symptoms [1.23 (1.06-1.43)] and heart failure [1.37 (1.01-1.85)] were also significantly increased. CONCLUSIONS: Satellite data and syndromic surveillance were combined to assess the health impacts of wildfire smoke in rural counties with sparse air-quality monitoring. This is the first study to demonstrate both respiratory and cardiac effects after brief exposure to peat wildfire smoke.	[Rappold, Ana G.; Stone, Susan L.; Cascio, Wayne E.; Neas, Lucas M.; Carraway, Martha Sue; Devlin, Robert B.] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; [Kilaru, Vasu J.] US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA; [Szykman, James J.] US EPA, Environm Sci Div, Natl Exposure Res Lab, NASA Langley Res Ctr, Hampton, VA USA; [Ising, Amy] Univ N Carolina, Sch Med, Dept Emergency Med, Chapel Hill, NC USA; [Cleve, William E.] Pitt Cty Mem Hosp, Greenville, NC USA; [Meredith, John T.] E Carolina Univ, Brody Sch Med, Dept Cardiovasc Sci, Greenville, NC USA; [Meredith, John T.] E Carolina Heart Inst, Greenville, NC USA; [Vaughan-Batten, Heather; Deyneka, Lana] N Carolina Dept Hlth & Human Serv, N Carolina Div Publ Hlth, Raleigh, NC USA; [Rappold, Ana G.; Stone, Susan L.; Cascio, Wayne E.; Neas, Lucas M.; Carraway, Martha Sue; Devlin, Robert B.] US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA	Rappold, AG (reprint author), US EPA, Environm Publ Hlth Div, Natl Hlth & Environm Effects Res Lab, MD 58B,109 TW Alexander Dr, Res Triangle Pk, NC 27711 USA.	rappold.ana@epa.gov	Neas, Lucas/J-9378-2012; Xiongfei, Zhao/G-7690-2015		U.S. Environmental Protection Agency (EPA)	This work was supported by internal funding by the U.S. Environmental Protection Agency (EPA).	Al-Saadi J, 2005, B AM METEOROL SOC, V86, P1249, DOI 10.1175/BAMS-86-9-1249; Braga ALF, 2001, J OCCUP ENVIRON MED, V43, P927; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Buehler JW, 2008, ADV DIS SURVEILL, V6, P1; Delfino RJ, 2009, OCCUP ENVIRON MED, V66, P189, DOI 10.1136/oem.2008.041376; Dominici F, 2007, AM J EPIDEMIOL, V166, P880, DOI 10.1093/aje/kwm222; DUCLOS P, 1990, ARCH ENVIRON HEALTH, V45, P53; Engel-Cox JA, 2004, ATMOS ENVIRON, V38, P2495, DOI 10.1016/j.atmosenv.2004.01.039; Johnson J. M., 2005, MORB MORTAL WKLY R S, V54, P190; Kunii O, 2002, ARCH ENVIRON HEALTH, V57, P16; Kunzli N, 2006, AM J RESP CRIT CARE, V174, P1221, DOI 10.1164/rccm.200604-519OC; Moore D, 2006, CAN J PUBLIC HEALTH, V97, P105; Mott JA, 2005, INT J HYG ENVIR HEAL, V208, P75, DOI 10.1016/j.ijheh.2005.01.018; Muraleedharan TR, 2000, ATMOS ENVIRON, V34, P3033, DOI 10.1016/S1352-2310(99)00512-9; North Carolina State Center for Health Statistics, 2009, 2009 BRFSS TOP E N C; Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875; National Interagency Fire Center, 2009, QUADR FIR REV 2009 F; O'Neill MS, 2007, OCCUP ENVIRON MED, V64, P373, DOI 10.1136/oem.2006.030023; O'Neill MS, 2005, CIRCULATION, V111, P2913, DOI 10.1161/CIRCULATIONAHA.104.517110; Page SE, 2002, NATURE, V420, P61, DOI 10.1038/nature01131; Peng D., 2008, STAT METHODS ENV EPI; Pope CA, 2008, AM J CARDIOL, V102, P1230, DOI 10.1016/j.amjcard.2008.06.044; Reilly M, 2010, RUSSIAN FIRES HEAT W; Sanhueza PA, 2009, J AIR WASTE MANAGE, V59, P1481, DOI 10.3155/1047-3289.59.12.1481; Sastry N, 2002, DEMOGRAPHY, V39, P1, DOI 10.1353/dem.2002.0009; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; See SW, 2007, ENVIRON SCI TECHNOL, V41, P3488, DOI 10.1021/es061943k; Soja AJ, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004570; Sorensen B., 1999, MMWR-MORBID MORTAL W, V48, P78; UNITED STATES CENSUS BUREAU, 2010, STAT COUNT QUICKFACT; U.S. EPA, 2009, EPA600R08139F; U.S. EPA (U.S. Environmental Protection Agency), 2009, EPA456F409002; U.S. Public Health Service and Health Care Financing Administration, 1980, 801260 DHHS PHS US P; Vedal S, 2006, ENVIRON RES, V102, P29, DOI 10.1016/j.envres.2006.03.008; Wang J, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL018174; Wellenius GA, 2006, AM J CARDIOL, V97, P404, DOI 10.1016/j.amjcard.2005.08.061; Wellenius GA, 2005, AM J EPIDEMIOL, V161, P1030, DOI 10.1093/aje/kwi135; Westerling AL, 2006, SCIENCE, V313, P940, DOI 10.1126/science.1128834; Williams S., 2010, SMOG FIRES CHOKES MO	39	74	74	4	45	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765	1552-9924		ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2011	119	10					1415	1420		10.1289/ehp.1003206		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	827CA	WOS:000295402400026	21705297	
J	Chung, KF; Caramori, G; Adcock, IM				Chung, Kian Fan; Caramori, Gaetano; Adcock, Ian M.			Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future	EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY			English	Review						Asthma; Chronic obstructive pulmonary disease; Corticosteroids; Beta-adrenergic agonists; Inflammation	OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; HISTONE DEACETYLASE ACTIVITY; MILD PERSISTENT ASTHMA; BONE-MINERAL DENSITY; LONG-TERM TREATMENT; AIR-FLOW OBSTRUCTION; NITRIC-OXIDE LEVELS; LOW-DOSE BUDESONIDE; REGULATORY T-CELLS	Inhaled corticosteroid (ICS) therapy in combination with long-acting beta-adrenergic agonists represents the most important treatment for chronic airways diseases such as asthma and chronic obstructive pulmonary disease (COPD). ICS therapy forms the basis for treatment of asthma of all severities, improving asthma control, lung function and preventing exacerbations of disease. Use of ICS has also been established in the treatment of COPD, particularly symptomatic patients, who experience useful gains in quality of life, likely from an improvement in symptoms such as breathlessness and in reduction in exacerbations, and an attenuation of the yearly rate of deterioration in lung function. The addition of long-acting beta-agonist (LABA) therapy with ICS increases the efficacy of ICS effects in moderate-to-severe asthma. Thus, a 800 mu g daily dose of the ICS budesonide reduced severe exacerbation rates by 49% compared to a low dose of 200 mu g daily, and addition of the LABA formoterol to budesonide (800 mu g) led to a 63% reduction. In COPD, the effects of ICS are less prominent but there are beneficial effects on the decline in FEV(1) and the rate of exacerbations. A reduction in the rate of decline in FEV(1) of 16 ml/year with a 25% reduction in exacerbation rate has been reported with the salmeterol and fluticasone combination. A non-significant 17.5% reduction in all-cause mortality rate with ICS and LABA is reported. Chronic inflammation is a feature of both asthma and COPD, although there are site and characteristic differences. ICS targets this inflammation although this effect of ICS is less effective in patients with severe asthma and with COPD; however, addition of LABA may potentiate the anti-inflammatory effects of ICS. An important consideration is the presence of corticosteroid insensitivity in these patients. Currently available ICS have variably potent binding activities to specific glucocorticoid receptors, leading to inhibition of gene expression by either binding to DNA and inducing anti-inflammatory genes or by repressing the induction of pro-inflammatory mediators. Local side effects of ICS include oral candidiasis, hoarseness and dysphonia, while systemic side effects, such as easy bruising and reduction in growth velocity or bone mineral densitometry, are usually restricted to doses above maximally recommended doses. Use of LABA alone in patients with asthma increases the risk of asthma-related events including deaths, but this is less observed with the combination of ICS and LABA. Therefore, use of LABA alone is not recommended for asthma therapy. Future progress in ICS development will be characterised by the introduction of ICS with greater efficacy with a limited side-effect profile, and by longer-acting ICS that can be used in combination with once-daily LABAs. Other agents that could improve the efficacy of corticosteroids or reverse corticosteroid insensitivity may be added to ICS. ICS in combination with LABAs will continue to remain the main focus of treatment of airways diseases.	[Chung, Kian Fan; Caramori, Gaetano; Adcock, Ian M.] Univ London Imperial Coll Sci Technol & Med, Airway Dis Sect, Natl Heart & Lung Inst, London SW3 6LY, England; [Caramori, Gaetano] Univ Ferrara, Dept Asthma & COPD, I-44100 Ferrara, Italy	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Airway Dis Sect, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	f.chung@imperial.ac.uk		Chung, Kian Fan/0000-0001-7101-1426			Adams NP, 2006, RESP MED, V100, P1297, DOI 10.1016/j.rmed.2006.04.015; Adams NP, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003534.pub3; Adcock IM, 2008, LANCET, V372, P1073, DOI 10.1016/S0140-6736(08)61449-X; Adcock IM, 2008, CHEST, V134, P394, DOI 10.1378/chest.08-0440; Adcock Ian M., 2002, Journal of Allergy and Clinical Immunology, V110, pS261, DOI 10.1067/mai.2002.129705; ADELROTH E, 1990, AM REV RESPIR DIS, V142, P91; Ahmad T, 2008, CURR OPIN INVEST DR, V9, P470; Altose MD, 2000, NEW ENGL J MED, V343, P1902; Barnes NC, 2006, AM J RESP CRIT CARE, V173, P736, DOI 10.1164/rccm.200508-1321OC; BARNES PJ, 1995, NEW ENGL J MED, V332, P868; Barnes PJ, 2004, LANCET, V363, P731, DOI 10.1016/S0140-6736(04)15650-X; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; BARNES PJ, 1990, AM REV RESPIR DIS, V141, pS70; Bateman ED, 2006, J ALLERGY CLIN IMMUN, V117, P563, DOI 10.1016/j.jaci.2005.11.036; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Baumgartner RA, 2003, EUR RESPIR J, V21, P123, DOI 10.1183/09031936.03.00028803; BEL EH, 1991, AM REV RESPIR DIS, V143, P109; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Bhavsar P, 2008, THORAX, V63, P784, DOI 10.1136/thx.2007.090027; Biggadike Keith, 2004, Proc Am Thorac Soc, V1, P352, DOI 10.1513/pats.200409-048TA; Boorsma M, 2008, COPD, V5, P97, DOI 10.1080/15412550801941000; BORISH L, 1992, J IMMUNOL, V149, P3078; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Bousquet J, 2007, RESP MED, V101, P2437, DOI 10.1016/j.rmed.2007.07.014; Brieva JL, 2000, AM J RESP CRIT CARE, V161, P293; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PMA, 2007, AM J RESP CRIT CARE, V176, P154, DOI 10.1164/rccm.200610-1563OC; Calverley PMA, 2007, NEW ENGL J MED, V356, P775, DOI 10.1056/NEJMoa063070; Calverley PMA, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-73; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; Chung KF, 2008, EUR RESPIR J, V31, P1334, DOI 10.1183/09031936.00018908; Chung K Fan, 2004, Treat Respir Med, V3, P279, DOI 10.2165/00151829-200403050-00002; Chung KF, 1999, THORAX, V54, P825; CHUNG KF, 1986, THORAX, V41, P657, DOI 10.1136/thx.41.9.657; Chung KF, 2008, AIRWAY SMOOTH MUSCLE IN ASTHMA AND COPD: BIOLOGY AND PHARMACOLOGY, P277, DOI 10.1002/9780470754221.ch14; Clark AR, 2008, J BIOL CHEM, V283, P25765, DOI 10.1074/jbc.R700053200; Clark DJ, 1996, THORAX, V51, P262, DOI 10.1136/thx.51.3.262; Cohen L, 2007, AM J RESP CRIT CARE, V176, P138, DOI 10.1164/rccm.200607-1062OC; Cosio BG, 2004, J EXP MED, V200, P689, DOI 10.1084/jem.20040416; COX G, 1995, J IMMUNOL, V154, P4719; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Culpitt SV, 1999, AM J RESP CRIT CARE, V160, P1635; Culpitt SV, 2003, AM J RESP CRIT CARE, V167, P24, DOI 10.1164/rccm.200204-298OC; Cumming RG, 1997, NEW ENGL J MED, V337, P8, DOI 10.1056/NEJM199707033370102; DE BK, 2008, EUR J PHARMACOL, V583, P290; Derendorf H, 2007, J CLIN PHARMACOL, V47, P782, DOI 10.1177/0091270007299763; Di Franco A, 2006, PULM PHARMACOL THER, V19, P353, DOI 10.1016/j.pupt.2005.09.003; DJUKANOVIC R, 1992, AM REV RESPIR DIS, V145, P669; Donnelly R, 1997, AM J RESP CRIT CARE, V156, P1746; Duong M, 2007, J ALLERGY CLIN IMMUN, V119, P322, DOI 10.1016/j.jaci.2006.10.018; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953; Edmonds ML, 2003, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD002308, DOI 10.1002/14651858.CD002308]; Elmstahl S, 2003, J ALLERGY CLIN IMMUN, V111, P91, DOI 10.1067/mai.2003.4; Etminan M, 2008, DRUG SAFETY, V31, P409, DOI 10.2165/00002018-200831050-00005; Farrow SN, 2008, CURR OPIN PHARMACOL, V8, P275, DOI 10.1016/j.coph.2008.02.001; FitzGerald JM, 2005, CLIN THER, V27, P393, DOI 10.1016/j.clinthera.2005.03.006; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Foresi A, 2000, CHEST, V117, P440, DOI 10.1378/chest.117.2.440; Gan Wen Qi, 2005, BMC Pulm Med, V5, P3, DOI 10.1186/1471-2466-5-3; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; GIBSON PG, 1992, CLIN EXP ALLERGY, V22, P525, DOI 10.1111/j.1365-2222.1992.tb00161.x; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32; Gizycki MJ, 2002, THORAX, V57, P799, DOI 10.1136/thorax.57.9.799; Goleva E, 2006, AM J RESP CRIT CARE, V173, P607, DOI 10.1164/rccm.200507-1046OC; Greenstone IR, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005533; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAAHTELA T, 1991, NEW ENGL J MED, V325, P388, DOI 10.1056/NEJM199108083250603; Hanania NA, 2003, CHEST, V124, P834, DOI 10.1378/chest.124.3.834; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Harrison TW, 2003, THORAX, V58, P258, DOI 10.1136/thorax.58.3.258; Harrison TW, 2001, THORAX, V56, P186, DOI 10.1136/thorax.56.3.186; Harrison TW, 2001, BIODRUGS, V15, P405, DOI 10.2165/00063030-200115060-00006; Hattotuwa KL, 2002, AM J RESP CRIT CARE, V165, P1592, DOI 10.1164/rccm.2105025; Hawrylowicz CM, 2005, J EXP MED, V202, P1459, DOI 10.1084/jem.20052211; Hew M, 2006, AM J RESP CRIT CARE, V174, P134, DOI 10.1164/rccm.200512-1930OC; Highland KB, 2003, ANN INTERN MED, V138, P969; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Horvath G, 2006, EUR RESPIR J, V27, P172, DOI 10.1183/09031936.06.00048605; Huchon G, 2009, RESP MED, V103, P41, DOI 10.1016/j.rmed.2008.09.002; in't Veen JCCM, 1999, AM J RESP CRIT CARE, V160, P93; Irusen E, 2002, J ALLERGY CLIN IMMUN, V109, P649, DOI 10.1067/mai.2002.122465; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Israel E, 2002, J ALLERGY CLIN IMMUN, V110, P847, DOI 10.1067/mai.2002.129413; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K, 2006, J EXP MED, V203, P7, DOI 10.1084/jem.20050466; Ito K, 2005, NEW ENGL J MED, V352, P1967, DOI 10.1056/NEJMoa041892; Ito K, 2002, P NATL ACAD SCI USA, V99, P8921, DOI 10.1073/pnas.132556899; Ito K, 2007, J PHARMACOL EXP THER, V321, P1, DOI 10.1124/jpet.106.111674; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; John M, 1998, AM J RESP CRIT CARE, V157, P256; Johnson M, 1996, J ALLERGY CLIN IMMUN, V97, P169, DOI 10.1016/S0091-6749(96)80217-X; Jones PW, 2003, EUR RESPIR J, V21, P68, DOI 10.1183/09031936.03.00013303; Jones PW, 1991, EUR RESPIR REV, V1, P445; JUNIPER EF, 1990, AM REV RESPIR DIS, V142, P832; JUNIPER EF, 1991, J ALLERGY CLIN IMMUN, V87, P483, DOI 10.1016/0091-6749(91)90006-A; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Kelly HW, 2008, PEDIATRICS, V122, pE53, DOI 10.1542/peds.2007-3381; Kent LM, 2009, J PHARMACOL EXP THER, V328, P458, DOI 10.1124/jpet.108.142950; Kharitonov SA, 1996, EUR RESPIR J, V9, P196, DOI 10.1183/09031936.96.09020196; Koopmans JG, 2006, THORAX, V61, P306, DOI 10.1136/thx.2005.051292; Koopmans JG, 2005, J ALLERGY CLIN IMMUN, V116, P1007, DOI 10.1016/j.jaci.2005.08.016; Kramer JM, 2009, NEW ENGL J MED, V360, P1592, DOI 10.1056/NEJMp0810561; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lane SJ, 1998, J CLIN INVEST, V102, P2156, DOI 10.1172/JCI2680; LAURSEN LC, 1988, ALLERGY, V43, P284, DOI 10.1111/j.1398-9995.1988.tb00901.x; Lazarus SC, 2007, AM J RESP CRIT CARE, V175, P783, DOI 10.1164/rccm.200511-17460C; Lee TA, 2004, AM J MED, V117, P618, DOI 10.1016/j.amjmed.2004.05.021; LEUNG DYM, 1995, J EXP MED, V181, P33, DOI 10.1084/jem.181.1.33; Levy ML, 1996, THORAX, V51, P1087, DOI 10.1136/thx.51.11.1087; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Loke TK, 2006, J ALLERGY CLIN IMMUN, V118, P368, DOI 10.1016/j.jaci.2006.04.055; Lotvall J, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-110; Mahler DA, 2002, AM J RESP CRIT CARE, V166, P1084, DOI 10.1164/rccm.2112055; Majori M, 1997, J ALLERGY CLIN IMMUN, V100, P379, DOI 10.1016/S0091-6749(97)70252-5; Maltais F, 2002, AM J RESP CRIT CARE, V165, P698, DOI 10.1164/rccm.2109093; Man S F Paul, 2005, Proc Am Thorac Soc, V2, P78, DOI 10.1513/pats.200406-034MS; Marban C, 2007, EMBO J, V26, P412, DOI 10.1038/sj.emboj.7601516; Martin RJ, 2007, J ALLERGY CLIN IMMUN, V119, P73, DOI 10.1016/j.jaci.2006.10.035; Marwick JA, 2008, P AM THORAC SOC, V5, pA333; Meyer S, 2004, CRIT REV BIOCHEM MOL, V39, P197, DOI 10.1080/10409230490513991; Miner JN, 2007, P NATL ACAD SCI USA, V104, P19244, DOI 10.1073/pnas.0705517104; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Nelson HS, 2006, CHEST, V129, P15, DOI 10.1378/chest.129.1.15; Nevin BJ, 2004, PULM PHARMACOL THER, V17, P219, DOI 10.1016/j.pupt.2004.04.002; Nie M, 2005, J IMMUNOL, V175, P478; Norman AW, 2004, NAT REV DRUG DISCOV, V3, P27, DOI 10.1038/nrd1283; O'Brien A, 2001, AM J RESP CRIT CARE, V164, P365; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Ogawa S, 2005, CELL, V122, P707, DOI 10.1016/j.cell.2005.06.029; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864; Orsida BE, 1999, THORAX, V54, P289; Overbeck SE, 2005, CHEST, V128, P1121, DOI 10.1378/chest.128.3.1121; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Papi A, 2007, EUR RESPIR J, V29, P682, DOI 10.1183/09031936.00095906; Papi A, 2007, NEW ENGL J MED, V356, P2040, DOI 10.1056/NEJMoa063861; Paul-Clark MJ, 2003, J IMMUNOL, V171, P3245; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Pauwels R. A., 2001, AM J RESP CRIT CARE, V163, P1256; Pedersen S, 2006, DRUG SAFETY, V29, P599, DOI 10.2165/00002018-200629070-00005; PETERS SP, 1986, RESPIRATION, V50, P116; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Reddel HK, 2006, EUR RESPIR J, V28, P182, DOI 10.1183/09031936.06.00105305; Renda T, 2008, EUR RESPIR J, V31, P62, DOI 10.1183/09031936.00036707; Rice-McDonald G, 2005, INTERN MED J, V35, P693, DOI 10.1111/j.1445-5994.2005.00972.x; Robinson DS, 2003, EUR RESPIR J, V22, P478, DOI 10.1183/09031936.03.00017003; Rodrigo G, 1998, AM J RESP CRIT CARE, V157, P698; Rodrigo GJ, 2000, CHEST, V118, P1547, DOI 10.1378/chest.118.6.1547; Roth M, 2002, LANCET, V360, P1293, DOI 10.1016/S0140-6736(02)11319-5; Rothschild Bruce M, 2008, Evid Based Med, V13, P76, DOI 10.1136/ebm.13.3.76; Saetta M, 2001, AM J RESP CRIT CARE, V163, P1304; SALMERON S, 1989, AM REV RESPIR DIS, V140, P167; Schacke H, 2004, P NATL ACAD SCI USA, V101, P227, DOI 10.1073/pnas.0300372101; Schacke H, 2002, PHARMACOL THERAPEUT, V96, P23, DOI 10.1016/S0163-7258(02)00297-8; Schaecke H, 2007, MOL CELL ENDOCRINOL, V275, P109, DOI 10.1016/j.mce.2007.05.014; SCHLEIMER RP, 1989, J PHARMACOL EXP THER, V250, P598; SCHLEIMER RP, 1993, EUR J CLIN PHARMACOL, V45, pS3, DOI 10.1007/BF01844196; SCHLEIMER RP, 1994, J ALLERGY CLIN IMMUN, V94, P1202, DOI 10.1016/0091-6749(94)90333-6; Sin DD, 2006, EUR J PHARMACOL, V533, P28, DOI 10.1016/j.ejphar.2005.12.049; Sin DD, 2003, JAMA-J AM MED ASSOC, V290, P2301, DOI 10.1001/jama.290.17.2301; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; Sin DD, 2001, AM J RESP CRIT CARE, V164, P580; Sin DD, 2008, AM J RESP CRIT CARE, V177, P1207, DOI 10.1164/rccm.200709-1356OC; Sin DD, 2007, CAN J PHYSIOL PHARM, V85, P141, DOI 10.1139/Y06-093; So AYL, 2007, PLOS GENET, V3, P927, DOI 10.1371/journal.pgen.0030094; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Soriano JB, 2002, EUR RESPIR J, V20, P819, DOI 10.1183/09031936.02.00301302; Soriano Joan B, 2003, Am J Respir Med, V2, P67; Sousa AR, 1997, THORAX, V52, P407; Suissa S, 2004, EUR RESPIR J, V23, P391, DOI 10.1183/09031936.04.00062504; Suissa S, 2004, AM J RESP CRIT CARE, V169, P83, DOI 10.1164/rccm.200305-6400C; Sutherland ER, 2003, ANN INTERN MED, V139, P864; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szulakowski P, 2006, AM J RESP CRIT CARE, V174, P41, DOI 10.1164/rccm.200505-725OC; Tarsin WY, 2006, INT J PHARM, V316, P131, DOI 10.1016/j.ijpharm.2006.02.040; Tattersfield AE, 2001, THORAX, V56, P272, DOI 10.1136/thorax.56.4.272; Todd GRG, 2003, ARCH DIS CHILD, V88, P554, DOI 10.1136/adc.88.6.554; Todd GRG, 2002, ARCH DIS CHILD, V87, P457, DOI 10.1136/adc.87.6.457; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; Usmani OS, 2005, AM J RESP CRIT CARE, V172, P704, DOI 10.1164/rccm.200408-1041OC; Valotis A, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-54; Van den Berge M, 2001, AM J RESP CRIT CARE, V164, P1127; van der Valk P, 2002, AM J RESP CRIT CARE, V166, P1358, DOI 10.1164/rccm.200206-512OC; van Rensen ELJ, 1999, THORAX, V54, P403; van Staa TP, 2001, J BONE MINER RES, V16, P581, DOI 10.1359/jbmr.2001.16.3.581; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; VATHENEN AS, 1991, AM REV RESPIR DIS, V143, P1317; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Webster JC, 2001, P NATL ACAD SCI USA, V98, P6865, DOI 10.1073/pnas.121455098; Weigel NL, 2007, MOL ENDOCRINOL, V21, P2311, DOI 10.1210/me.2007-0101; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86; Wilt TJ, 2007, ANN INTERN MED, V147, P639; Winkler Julia, 2004, Proc Am Thorac Soc, V1, P356, DOI 10.1513/pats.200403-025MS; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3; Woolcock A, 1996, AM J RESP CRIT CARE, V153, P1481; Wouters EFM, 2005, THORAX, V60, P480, DOI 10.1136/thx.2004.034280; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759; Zetterstrom O, 2001, EUR RESPIR J, V18, P262, DOI 10.1183/09031936.01.00065801	215	74	76	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0031-6970			EUR J CLIN PHARMACOL	Eur. J. Clin. Pharmacol.	SEP	2009	65	9					853	871		10.1007/s00228-009-0682-z		19	Pharmacology & Pharmacy	Pharmacology & Pharmacy	486ID	WOS:000269188700001	19557399	
J	Mylonas, KJ; Nair, MG; Prieto-Lafuente, L; Paape, D; Allen, JE				Mylonas, Katie J.; Nair, Meera G.; Prieto-Lafuente, Lidia; Paape, Daniel; Allen, Judith E.			Alternatively Activated Macrophages Elicited by Helminth Infection Can Be Reprogrammed to Enable Microbial Killing	JOURNAL OF IMMUNOLOGY			English	Article							ANTIGEN-PRESENTING CELLS; CD4(+) T-CELLS; TUMOR-INFILTRATING MACROPHAGES; LEISHMANIA-MEXICANA INFECTION; OXIDE-SYNTHESIZING PATHWAY; SYNTHASE ARGINASE BALANCE; SELECTIVE UP-REGULATION; IN-VIVO; PERITONEAL-MACROPHAGES; MURINE MACROPHAGES	The prime function of classically activated macrophages (activated by Th1-type signals, such as IFN-gamma) is microbial destruction. Alternatively activated macrophages (activated by Th2 cytokines, such as IL-4 and IL-13) play important roles in allergy and responses to helminth infection. We utilize a murine model of filarial infection, in which adult nematodes are surgically implanted into the peritoneal cavity of mice, as an in vivo source of alternatively activated macrophages. At 3 wk postinfection, the peritoneal exudate cell population is dominated by macrophages, termed nematode-elicited macrophages (NeM phi), that display IL-4-dependent features such as the expression of arginase 1, RELM-alpha (resistin-like molecule alpha), and Ym1. Since increasing evidence suggests that macrophages show functional adaptivity, the response of NeM phi to proinflammatory Th1-activating signals was investigated to determine whether a switch between alternative and classical activation could occur in macrophages differentiated in an in vivo infection setting. Despite the long-term exposure to Th2 cytokines and antiinflammatory signals in vivo, we found that NeM phi were not terminally differentiated but could develop a more classically activated phenotype in response to LPS and IFN-gamma. This was reflected by a switch in the enzymatic pathway for arginine metabolism from arginase to inducible NO synthase and the reduced expression of RELM-alpha and Ym1. Furthermore, this enabled NeM phi to become antimicrobial, as LPS/IFN-gamma-treated NeM phi produced NO that mediated killing of Leishmania mexicana. However, the adaptation to antimicrobial function did not extend to key regulatory pathways, such as IL-12 production, which remained unaltered. The Journal of Immunology, 2009, 182: 3084-3094.	[Mylonas, Katie J.; Nair, Meera G.; Prieto-Lafuente, Lidia; Paape, Daniel; Allen, Judith E.] Univ Edinburgh, Inst Immunol & Infect Res, Edinburgh EH9 3JT, Midlothian, Scotland	Allen, JE (reprint author), Univ Edinburgh, Inst Immunol & Infect Res, W Mains Rd, Edinburgh EH9 3JT, Midlothian, Scotland.	j.allen@ed.ac.uk	Allen, Judith/C-9198-2011; Paape, Daniel/G-1665-2015	Allen, Judith/0000-0002-3829-066X; Paape, Daniel/0000-0003-4355-8058	Wellcome Trust and the Medical Research Council, United Kingdom	This work was supported by the Wellcome Trust and the Medical Research Council, United Kingdom.	ALBINA JE, 1991, J SURG RES, V50, P403, DOI 10.1016/0022-4804(91)90210-D; ALBINA JE, 1991, J IMMUNOL, V147, P144; ALBINA JE, 1990, J IMMUNOL, V144, P3877; Alexander J, 1999, J CELL SCI, V112, P2993; Allen JE, 1996, INT IMMUNOL, V8, P143, DOI 10.1093/intimm/8.1.143; AUTHIER H, 2007, INT J PARASITOL, V38, P341; Authier Helene, 2008, Mol Immunol, V45, P235, DOI 10.1016/j.molimm.2007.04.007; BOGDAN C, 1991, EUR J IMMUNOL, V21, P327, DOI 10.1002/eji.1830210213; Brys L, 2005, J IMMUNOL, V174, P6095; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Dransfield Ian, 1996, P149; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Eming SA, 2007, J INVEST DERMATOL, V127, P514, DOI 10.1038/sj.jid.5700701; Erwig LP, 1998, J IMMUNOL, V161, P1983; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Gratchev A, 2006, IMMUNOBIOLOGY, V211, P473, DOI 10.1016/j.imbio.2006.05.017; Guiducci C, 2005, CANCER RES, V65, P3437; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hassan MF, 2006, AM J PATHOL, V169, P943, DOI 10.2353/ajpath.2006.051319; Herbert DR, 2004, IMMUNITY, V20, P623, DOI 10.1016/S1074-7613(04)00107-4; Hesse M, 2004, J IMMUNOL, V172, P3157; Hesse M, 2001, J IMMUNOL, V167, P6533; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; HSIEH CS, 1992, P NATL ACAD SCI USA, V89, P6065, DOI 10.1073/pnas.89.13.6065; Iniesta V, 2002, PARASITE IMMUNOL, V24, P113, DOI 10.1046/j.1365-3024.2002.00444.x; Joyce DA, 1996, CYTOKINE, V8, P49, DOI 10.1006/cyto.1996.0007; Katakura T, 2004, J IMMUNOL, V172, P1407; Kropf P, 2005, FASEB J, V19, P1000, DOI 10.1096/fj.04-3416fje; Lang R, 2002, J IMMUNOL, V169, P2253; LEIJH PCJ, 1984, INFECT IMMUN, V46, P448; Lin HH, 2005, J EXP MED, V201, P1615, DOI 10.1084/jem.20042307; Loke P, 2000, EUR J IMMUNOL, V30, P2669, DOI 10.1002/1521-4141(200009)30:9<2669::AID-IMMU2669>3.0.CO;2-1; Loke P, 2000, EUR J IMMUNOL, V30, P1127, DOI 10.1002/(SICI)1521-4141(200004)30:4<1127::AID-IMMU1127>3.0.CO;2-#; Loke P, 2003, P NATL ACAD SCI USA, V100, P5336, DOI 10.1073/pnas.0931259100; Loke P, 2007, J IMMUNOL, V179, P3926; Loke P'ng, 2002, BMC Immunol, V3, P7, DOI 10.1186/1471-2172-3-7; Major J, 2002, J IMMUNOL, V168, P2456; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Messerschmidt J. W., 1995, MASCULINITIES, V3, P1; MILLS CD, 1991, J IMMUNOL, V146, P2719; Misslitz A, 2000, MOL BIOCHEM PARASIT, V107, P251, DOI 10.1016/S0166-6851(00)00195-X; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; Munder M, 1998, J IMMUNOL, V160, P5347; Munder M, 2006, BLOOD, V108, P1627, DOI 10.1182/blood-2006-11-010389; Nair MG, 2005, INFECT IMMUN, V73, P385, DOI 10.1128/IAI.73.1.385-394.2005; Nair MG, 2003, IMMUNOL LETT, V85, P173, DOI 10.1016/S0165-2478(02)00225-0; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; Osborne J, 1999, INFECT IMMUN, V67, P1599; PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229, DOI 10.1073/pnas.86.7.2229; Porcheray F, 2005, CLIN EXP IMMUNOL, V142, P481, DOI 10.1111/j.1365-2249.2005.02934.x; PROUDFOOT L, 1995, EUR J IMMUNOL, V25, P745, DOI 10.1002/eji.1830250318; Reyes JL, 2007, PARASITE IMMUNOL, V29, P609, DOI 10.1111/j.1365-3024.2007.00973.x; Rodriguez-Sosa M, 2006, CELL IMMUNOL, V242, P61, DOI 10.1016/j.cellimm.2006.09.006; SATOSKAR A, 1995, INFECT IMMUN, V63, P4894; Satoskar A, 1997, J IMMUNOL, V159, P5005; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Sica A, 2007, J CLIN INVEST, V117, P1155, DOI 10.1172/JCI31422; Smith P, 2004, J IMMUNOL, V173, P1240; Sorensen M, 2003, FEBS LETT, V552, P110, DOI 10.1016/S0014-5793(03)00856-1; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stout RD, 2005, J IMMUNOL, V175, P342; Stout RD, 2004, J LEUKOCYTE BIOL, V76, P509, DOI 10.1189/jlb.0504272; Stout Robert D., 1997, Frontiers in Bioscience (online), V2, pD197; Taylor MD, 2006, J IMMUNOL, V176, P6918; Taylor MD, 2005, J IMMUNOL, V174, P4924; Terrazas LI, 2005, INT J PARASITOL, V35, P1349, DOI 10.1016/j.ijpara.2005.06.003; Watkins SK, 2007, J IMMUNOL, V178, P1357; Wen HT, 2008, BLOOD, V111, P1797, DOI 10.1182/blood-2007-08-106443; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Yu K., 1999, Tubercle and Lung Disease, V79, P191, DOI 10.1054/tuld.1998.0203; Zhang X, 2006, J IMMUNOL, V177, P1282	72	74	74	0	9	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	MAR 1	2009	182	5					3084	3094		10.4049/jimmunol.0803463		11	Immunology	Immunology	411MG	WOS:000263653100060	19234205	
J	Caceres, M; Ali, SZ; Braud, R; Weiman, D; Garrett, HE				Caceres, Manuel; Ali, Syed Z.; Braud, Rebecca; Weiman, Darryl; Garrett, H. Edward, Jr.			Spontaneous pneumomediastinum: A comparative study and review of the literature	ANNALS OF THORACIC SURGERY			English	Review							ADULT PATIENTS; EXPERIENCE	Background. Spontaneous pneumomediastinum (SPM) is an unusual occurrence with few cases reported. It is seen after intrathoracic pressure changes leading to alveolar rupture and dissection of air along the tracheobronchial tree. This study was undertaken to provide a thorough clinical and radiologic analysis of this patient population. Methods. A retrospective comparative analysis was performed on patients with SPM over 12 years. Patient demographics, clinical presentation, and radiographic and diagnostic studies were recorded. A clinical and radiologic comparison was performed with secondary pneumomediastinum. Results. Seventy-four patients were identified with a diagnosis of pneumomediastinum. A total of 28 patients with SPM were identified. The major initial complaints were chest pain (54%), shortness of breath (39%), and subcutaneous emphysema (32%). The main triggering events were emesis (36%) and asthma flare-ups (21%). No apparent triggering event was noted in 21% of patients. Chest radiograph was diagnostic in 69%; computed tomography was required in 31%. Esophagram, esophagoscopy, and bronchoscopy were performed on an individual basis and were invariably negative. When compared with secondary pneumomediastinum, SPM is more likely to be discovered by chest radiography, has a lower incidence of pneumothorax and pleural effusion, requires a shorter hospital stay, and has no associated mortality. Conclusions. Spontaneous pneumomediastinum is a benign condition that often presents with chest pain or dyspnea. It can develop without a triggering event and with no findings on chest radiography. Treatment is expectant and recurrence is low. Secondary causes must be ruled out to avoid an unfavorable outcome.	Appalachian Regional Healthcare, Dept Cardiothorac Surg, Hazard, KY USA; Univ Tennessee HSC, Dept Cardiothorac Surg, Memphis, TN USA; Louisiana State Univ, Baton Rouge, LA 70803 USA; Baptist Mem Hosp, Dept Cardiothorac Surg, Memphis, TN 38146 USA	Garrett, HE (reprint author), 6029 Walnut Grove Rd,Suite 401, Memphis, TN 38120 USA.	egarrettmd@cvsclinic.com					ABOLNIK I, 1991, CHEST, V100, P93, DOI 10.1378/chest.100.1.93; Campillo-Soto A, 2005, ARCH BRONCONEUMOL, V41, P528, DOI 10.1157/13078656; Gerazounis M, 2003, J THORAC CARDIOV SUR, V126, P774, DOI 10.1016/S0022-5223(03)00124-7; HALPERIN AK, 1985, N C MED J, V46, P21; Ito S, 1989, Kokyu To Junkan, V37, P1359; Jougon JB, 2003, ANN THORAC SURG, V75, P1711, DOI 10.1016/S0003-4975(03)00027-4; Kaneki T, 2000, RESPIRATION, V67, P408, DOI 10.1159/000029539; Koullias GJ, 2004, EUR J CARDIO-THORAC, V25, P852, DOI 10.1016/j.ejcts.2004.01.042; Macia I, 2007, EUR J CARDIO-THORAC, V31, P1110, DOI 10.1016/j.ejcts.2007.03.008; MECKLIN CC, 1979, ARCH INTERN MED, V64, P913; Mihos P, 2004, ANN THORAC SURG, V78, P983, DOI 10.1016/.j.athorascur.2004.03.017; Miura Hiroyuki, 2003, Ann Thorac Cardiovasc Surg, V9, P188; Mondello B, 2007, LUNG, V185, P9, DOI 10.1007/s00408-006-0002-7; Nemet D, 2004, EUR J EMERG MED, V11, P105, DOI 10.1097/01.mej.0000114644.63700.7d; Newcomb AE, 2005, CHEST, V128, P3298, DOI 10.1378/chest.128.5.3298; PANACEK EA, 1992, ANN EMERG MED, V21, P1222, DOI 10.1016/S0196-0644(05)81750-0; Praski Arkadiusz, 2007, Ginekol Pol, V78, P329; Shindo Y, 1995, J EXP CLIN MED, V20, P1; Weissberg D, 2004, EUR J CARDIO-THORAC, V26, P885, DOI 10.1016/j.ejcts.2004.05.050; YELLIN A, 1983, THORAX, V38, P383, DOI 10.1136/thx.38.5.383	20	74	79	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0003-4975			ANN THORAC SURG	Ann. Thorac. Surg.	SEP	2008	86	3					962	966		10.1016/j.athoracsur.2008.04.067		5	Cardiac & Cardiovascular Systems; Respiratory System; Surgery	Cardiovascular System & Cardiology; Respiratory System; Surgery	340AT	WOS:000258619100037	18721592	
J	Noss, I; Wouters, IM; Visser, M; Heederik, DJJ; Thorne, PS; Brunekreef, B; Doekes, G				Noss, Ilka; Wouters, Inge M.; Visser, Maaike; Heederik, Dick J. J.; Thorne, Peter S.; Brunekreef, Bert; Doekes, Gert			Evaluation of a low-cost electrostatic dust fall collector for indoor air endotoxin exposure assessment	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							HOUSE-DUST; AIRBORNE ENDOTOXIN; SAMPLING METHODS; ALLERGEN; MITE; CAT; COMPONENTS; CHILDREN; HOMES	Exposure to endotoxin in home environments has become a key issue in asthma and allergy research. Most studies have analyzed floor or mattress dust endotoxin, but its validity as a proxy for airborne exposure is unknown, while active airborne dust sampling is not feasible in large-scale population studies because of logistic and financial limitations. We therefore developed and evaluated a simple passive airborne dust collection method for airborne endotoxin exposure assessment. We explored an electrostatic dust fall collector (EDC), consisting of a 42- by 29.6-cm-sized folder with four electrostatic cloths exposed to the air. The EDC was tested during two 14-day periods in seven nonfarm and nine farm homes and in farm stables. In parallel, active airborne dust sampling was performed with Harvard impactors and floor dust collected by vacuuming, using nylon sampling socks. The endotoxin levels could be measured in all EDC cloth extracts. The levels (in EU/m(2)) between EDCs used simultaneously or in different sampling periods in the same home correlated strongly (r > 0.8). EDC endotoxin also correlated moderately to strongly (r = 0.6 to 0.8) with the endotoxin measured by active airborne dust sampling and living room floor dust sampling and-in farm homes-with the endotoxin captured by the EDC in stables. In contrast, endotoxin levels measured by floor dust sampling showed only a poor correlation with the levels measured by active airborne dust sampling. We therefore conclude that measuring endotoxin levels with the EDC is a valid measure of average airborne endotoxin exposure, while reproducibility over time is at least equivalent to that of reservoir dust analyses.	[Noss, Ilka; Wouters, Inge M.; Visser, Maaike; Heederik, Dick J. J.; Brunekreef, Bert; Doekes, Gert] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Thorne, Peter S.] Univ Iowa, Environm Hlth Sci Res Ctr, Iowa City, IA USA	Noss, I (reprint author), POB 80178, NL-3508 TD Utrecht, Netherlands.	i.noss@uu.nl		brunekreef, bert/0000-0001-9908-0060	European Commission [018996]; NIH [P30 ES05605]	This work was supported by the European Commission as part of GABRIEL, contract number 018996 under the Integrated Program LSH-2004-1.2.5-1. This work was also supported by the EU FP6-funded network of excellence GA<SUP>2</SUP>LEN. Peter S. Thorne was supported by NIH P30 ES05605.; We thank the participants of this validation study for their cooperation and James A. Deddens, University of Cincinnati, for his help with the statistical analysis.	Antens CJM, 2006, CLIN EXP ALLERGY, V36, P1525, DOI 10.1111/j.1365-2222.2006.02603.x; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; Fahlbusch B, 2003, ALLERGY, V58, P150, DOI 10.1034/j.1398-9995.2003.00036.x; Heinrich J, 2003, J EXPO ANAL ENV EPID, V13, P152, DOI 10.1038/sj.jea.7500267; Hyvarinen A, 2006, INDOOR AIR, V16, P20, DOI 10.1111/j.1600-0668.2005.00392.x; Janssen NAH, 1998, J EXPO ANAL ENV EPID, V8, P37; Karlsson AS, 2002, CLIN EXP ALLERGY, V32, P1776, DOI 10.1046/j.1365-2222.2002.01553.x; Karlsson AS, 2002, ALLERGY, V57, P164, DOI 10.1034/j.1398-9995.2002.1s3297.x; Krop EJM, 2007, OCCUP ENVIRON MED, V64, P267, DOI 10.1136/oem.2006.028845; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Platts-Mills JA, 2005, J ALLERGY CLIN IMMUN, V116, P384, DOI 10.1016/j.jaci.2005.05.012; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Renstrom A, 2002, J ENVIRON MONITOR, V4, P619, DOI 10.1039/b202756a; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Schram-Bijkerk D, 2006, INDOOR AIR, V16, P414, DOI 10.1111/j.1600-0668.2006.00435.x; Sotiriou M, 2008, ENVIRON MONIT ASSESS, V137, P351, DOI 10.1007/s10661-007-9770-7; Thorne PS, 2005, ANN OCCUP HYG, V49, P401, DOI 10.1093/annhyg/mei002; THORNE PS, 2007, AM J RESP CRIT CARE, V175, pA538; Tovey ER, 2003, ALLERGY, V58, P790, DOI 10.1034/j.1398-9995.2003.00228.x; Vissers M, 2001, CLIN EXP ALLERGY, V31, P1577, DOI 10.1046/j.1365-2222.2001.01204.x; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; Wurtz H, 2005, INDOOR AIR, V15, P33, DOI 10.1111/j.1600-0668.2005.00342.x	24	74	74	2	15	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240			APPL ENVIRON MICROB	Appl. Environ. Microbiol.	SEP	2008	74	18					5621	5627		10.1128/AEM.00619-08		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	345SR	WOS:000259017400004	18676704	
J	Andersen, ZJ; Wahlin, P; Raaschou-Nielsen, O; Ketzel, M; Scheike, T; Loft, S				Andersen, Z. J.; Wahlin, P.; Raaschou-Nielsen, O.; Ketzel, M.; Scheike, T.; Loft, S.			Size distribution and total number concentration of ultrafine and accumulation mode particles and hospital admissions in children and the elderly in Copenhagen, Denmark	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							PARTICULATE AIR-POLLUTION; CORONARY-HEART-DISEASE; 5 EUROPEAN CITIES; MYOCARDIAL-INFARCTION; EXPOSURE ASSESSMENT; URBAN AIR; FINE; AMBIENT; HEALTH; INDOOR	Objectives: To study the association between short-term exposure to ultrafine particles and morbidity in Copenhagen, Denmark. Methods: We studied the association between urban background levels of the total number concentration of particles (NCtot, 6-700 nm in diameter) measured at a single site (15 May 2001 to 31 December 2004) and hospital admissions due to cardiovascular (CVD) and respiratory disease (RD) in the elderly (age >= 65 years), and due to asthma in children (age 5-18 years). We examined these associations in the presence of PM10, PM2.5 (particulate matter < 10 and 2.5 mu m in diameter, respectively) and ambient gasses. We utilised data on size distribution to calculate NCtot for four modes with median diameters 12, 23, 57 and 212 nm, and NC100 (number concentration of particles < 100 nm in diameter) and examined their associations with health outcomes. We used a time series Poisson generalised additive model adjusted for overdispersion, season, day of the week, public holidays, school holidays, influenza, pollen and meteorology, with up to 5 days' lagged exposure. Results and conclusions: The adverse health effects of particulate matter on CVD and RD hospital admissions in the elderly were mainly mediated by PM10 and accumulation mode particles with lack of effects for NC100. For paediatric asthma, accumulation mode particles, NC100 and nitrogen oxides (mainly from traffic related sources) were relevant, whereas PM10 appeared to have little effect. Our results suggest that particle volume/mass from long-range transported air pollution is relevant for CVD and RD admissions in the elderly, and possibly particle numbers from traffic sources for paediatric asthma.	[Andersen, Z. J.; Scheike, T.] Univ Copenhagen, Inst Publ Hlth, Dept Biostat, DK-1014 Copenhagen K, Denmark; [Andersen, Z. J.; Loft, S.] Univ Copenhagen, Dept Environm & Occupat Hlth, Copenhagen, Denmark; [Wahlin, P.; Ketzel, M.] Aarhus Univ, Natl Environm Res Inst, Dept Atmospher Environm, Aarhus, Denmark; [Raaschou-Nielsen, O.] Inst Canc Epidemiol, Danish Canc Soc, Copenhagen, Denmark	Andersen, ZJ (reprint author), Univ Copenhagen, Inst Publ Hlth, Dept Biostat, 5 Entr,POB 2099, DK-1014 Copenhagen K, Denmark.	zorana@cancer.dk	Andersen, Zorana /P-4983-2014; Ketzel, Matthias/K-4246-2015	Andersen, Zorana /0000-0003-4138-9828; Ketzel, Matthias/0000-0001-9519-1935; Scheike, Thomas/0000-0002-2148-4740; Loft, Steffen/0000-0001-9552-8518			Aalto P, 2005, J AIR WASTE MANAGE, V55, P1064; Andersen ZJ, 2007, J EXPO SCI ENV EPID, V17, P625, DOI 10.1038/sj.jes.7500546; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Buzorius G, 1999, ATMOS ENVIRON, V33, P553, DOI 10.1016/S1352-2310(98)00287-8; Chalupa DC, 2004, ENVIRON HEALTH PERSP, V112, P879, DOI 10.1289/ehp.6851; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370390205065; de Hartog JJ, 2003, AM J EPIDEMIOL, V157, P613, DOI 10.1093/aje/kwg021; Delfino RJ, 2005, ENVIRON HEALTH PERSP, V113, P934, DOI 10.1289/ehp.7938; Donaldson K, 2001, OCCUP ENVIRON MED, V58, P211, DOI 10.1136/oem.58.3.211; Donaldson Ken, 2003, Ann Ist Super Sanita, V39, P405; Forastiere F, 2005, AM J RESP CRIT CARE, V172, P1549, DOI 10.1164/rccm.200412-1726OC; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Hastie T, 1990, GEN ADDITIVE MODELS; Hussein T, 2005, ATMOS ENVIRON, V39, P3697, DOI 10.1016/j.atmosenv.2005.03.011; Ibald-Mulli A, 2004, ENVIRON HEALTH PERSP, V112, P369, DOI 10.1289/ehp.6523; Ketzel M, 2003, ATMOS ENVIRON, V37, P2735, DOI 10.1016/S1352-2310(03)00245-0; Lanki T, 2006, OCCUP ENVIRON MED, V63, P844, DOI 10.1136/oem.2005.023911; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Palmgren F, 2003, PHYS CHEM EARTH, V28, P327, DOI 10.1016/S1474-7065(03)00053-6; Pekkanen J, 2004, SCAND J WORK ENV HEA, V30, P9; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Pekkanen J, 2002, CIRCULATION, V106, P933, DOI 10.1161/01.CIR.0000027561.41736.3C; PEKKANEN J, 2000, ULTRA EXPOSURE RISK; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; R Development Core Team, 2006, R LANG ENV STAT COMP; Ruuskanen J, 2001, ATMOS ENVIRON, V35, P3729, DOI 10.1016/S1352-2310(00)00373-3; Schlesinger RB, 2006, INHAL TOXICOL, V18, P95, DOI 10.1080/08958370500306016; Schneider T, 2004, ATMOS ENVIRON, V38, P6349, DOI 10.1016/j.atmosenv.2004.08.002; Schwartz J, 2004, PEDIATRICS, V113, P1037; Sioutas C, 2005, ENVIRON HEALTH PERSP, V113, P947, DOI 10.1289/ehp.7939; Stolzel M., 2007, Journal of Exposure Science and Environmental Epidemiology, V17, P458, DOI 10.1038/sj.jes.7500538; Timonen KL, 2006, J EXPO SCI ENV EPID, V16, P332, DOI 10.1038/sj.jea.7500460; Timonen KL, 2004, OCCUP ENVIRON MED, V61, P908, DOI 10.1136/oem.2004.012849; Vinzents PS, 2005, ENVIRON HEALTH PERSP, V113, P1485, DOI 10.1289/ehp.7562; von Klot S, 2005, CIRCULATION, V112, P3073, DOI 10.1161/CIRCULATIONAHA.105.548743; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; WAHLIN P, 2004, NAT ENV SCI, V172, P142; WHO, 2000, EUR SER, V91; World Health Organization, 1992, INT STAT CLASS DIS R; Tuch T, 2000, RES REP HLTH EFF I, V98, P5	44	74	78	3	23	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	JUL	2008	65	7					458	466		10.1136/oem.2007.033290		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	315OU	WOS:000256890100005	17989204	
J	Yang, IA; Fong, KM; Zimmerman, PV; Holgate, ST; Holloway, JW				Yang, I. A.; Fong, K. M.; Zimmerman, P. V.; Holgate, S. T.; Holloway, J. W.			Genetic susceptibility to the respiratory effects of air pollution	THORAX			English	Review							BRONCHIAL EPITHELIAL-CELLS; DIESEL EXHAUST PARTICLES; ACUTE LUNG INJURY; OBSTRUCTIVE PULMONARY-DISEASE; BRONCHOALVEOLAR LAVAGE FLUID; REPEATED OZONE EXPOSURES; S-TRANSFERASE M1; OXIDATIVE STRESS; NITROGEN-DIOXIDE; PARTICULATE AIR	There is large variation between individuals in their response to air pollutants. This review summarises the existing evidence that genetic factors influence the mechanisms of lung injury caused by air pollutants. Genetic association studies have compared the adverse effects of air pollutants between subjects with specific genotypes in biologically relevant genes. In human studies of ozone exposure, polymorphisms in oxidative stress genes (NQO1, GSTM1, GSTP1) modify respiratory symptoms, lung function, biomarkers and risk of asthma. Inflammatory gene polymorphisms (TNF) influence the lung function response to ozone, and the effect of different levels of ozone on the development of asthma. Polymorphisms in oxidative stress genes (GSTM1, GSTP1) alter the response to combined exposure to ragweed pollen and diesel exhaust particles. Importantly, polymorphisms in an oxidative stress gene (GSTM1) have predicted patients with asthma who benefit from antioxidant supplementation in Mexico City, which has chronically high ozone exposure. Genetic linkage studies of families have not been feasible for studying the effects of air pollution in humans, but some progress has been made with pedigrees of specially bred mice, in identifying chromosomal regions linked to effects of ozone or particles. A high priority now, in addition to avoiding exposure in the most susceptible people, is to clearly identify the most effective and safe chemopreventive agents for individuals who are genetically susceptible to the adverse effects of air pollution (eg, antioxidants to be taken during high ozone levels).	[Yang, I. A.; Fong, K. M.; Zimmerman, P. V.] Prince Charles Hosp, Dept Thorac Med, Brisbane, Qld 4032, Australia; [Yang, I. A.; Fong, K. M.; Zimmerman, P. V.] Univ Queensland, Prince Charles Hosp, Sch Med, Brisbane, Qld, Australia; [Holgate, S. T.; Holloway, J. W.] Univ Southampton, Inflammat & Repair Div, Southampton, Hants, England; [Holloway, J. W.] Univ Southampton, Sch Med, Div Human Genet, Southampton, Hants, England	Yang, IA (reprint author), Prince Charles Hosp, Dept Thorac Med, Rode Rd, Brisbane, Qld 4032, Australia.	Ian_Yang@health.qld.gov.au	Yang, Ian/B-9609-2008; Holloway, John/B-5424-2009; Zimmerman, Paul/A-1631-2011; Fong, Kwun/G-6369-2010	Yang, Ian/0000-0001-8338-1993; Holloway, John/0000-0001-9998-0464; 	Medical Research Council [, G0800766]		Annesi-Maesano I, 2003, Eur Respir J Suppl, V40, p57s; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Avissar NE, 2000, AM J RESP CRIT CARE, V162, P1342; Backus-Hazzard Gillian S, 2004, Curr Opin Allergy Clin Immunol, V4, P349, DOI 10.1097/00130832-200410000-00004; Bayley JP, 2004, GENES IMMUN, V5, P315, DOI 10.1038/sj.gene.6364055; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Bayram H, 2001, J ALLERGY CLIN IMMUN, V107, P287, DOI 10.1067/mai.2001.111141; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Bell ML, 2004, JAMA-J AM MED ASSOC, V292, P2372, DOI 10.1001/jama.292.19.2372; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Campbell H., 2002, Pharmacogenomics Journal, V2, P349; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Carroll WD, 2005, PEDIATR ALLERGY IMMU, V16, P32, DOI 10.1111/j.1399-3038.2005.00249.x; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537; Christiani DC, 2001, J OCCUP ENVIRON MED, V43, P526, DOI 10.1097/00043764-200106000-00003; Churg A, 2003, FREE RADICAL BIO MED, V34, P1230, DOI 10.1016/S0891-5849(03)00175-8; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; Corradi M, 2002, TOXICOL LETT, V134, P219, DOI 10.1016/S0378-4274(02)00169-8; D'Amato G, 2002, EUR RESP MON, V21, P30; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; DEVLIN RB, 1994, AM J PHYSIOL, V266, pL612; Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3; Filleul L, 2006, ENVIRON HEALTH PERSP, V114, P1344, DOI 10.1289/ehp.8328; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Gilmour PS, 2003, AM J PHYSIOL-LUNG C, V284, pL533, DOI 10.1152/ajplung.00277.2002; Gryparis A, 2004, AM J RESP CRIT CARE, V170, P1080, DOI 10.1164/rccm.200403-333OC; Guttmacher AE, 2002, NEW ENGL J MED, V347, P1512, DOI 10.1056/NEJMra012240; Hall IP, 2006, LANCET, V368, P771, DOI 10.1016/S0140-6736(06)69287-8; Hall IP, 2005, THORAX, V60, P357, DOI 10.1136/thx.2005.040790; Healy DG, 2006, LANCET NEUROL, V5, P701, DOI 10.1016/S1474-4422(06)70524-5; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Holz O, 1999, AM J RESP CRIT CARE, V159, P776; Holz O, 2002, CLIN EXP ALLERGY, V32, P681, DOI 10.1046/j.1365-2222.2002.01358.x; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Jorres RA, 2000, AM J RESP CRIT CARE, V161, P1855; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Kinnula VL, 2005, THORAX, V60, P693, DOI 10.1136/thx.2004.037473; Kleeberger S R, 2003, Eur Respir J Suppl, V40, p52s; Kleeberger SR, 2005, EXP TOXICOL PATHOL, V57, P147, DOI 10.1016/j.etp.2005.05.017; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620; Kleeberger SR, 1997, INHAL TOXICOL, V9, P601; Kleeberger SR, 2001, AM J PHYSIOL-LUNG C, V280, pL326; Krishna MT, 1998, EUR RESPIR J, V11, P1294, DOI 10.1183/09031936.98.11061294; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Laden F, 2006, AM J RESP CRIT CARE, V173, P667, DOI 10.1164/rccm.200503-443OC; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Larsen JE, 2006, CARCINOGENESIS, V27, P525, DOI 10.1093/carcin/bgi227; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Li N, 2002, J IMMUNOL, V169, P4531; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; MacNee W, 2003, Eur Respir J Suppl, V40, p47s; Mattick JS, 2003, MED J AUSTRALIA, V179, P212; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; MCDONNELL WF, 1985, AM REV RESPIR DIS, V131, P36; Medina-Ramon M, 2006, AM J EPIDEMIOL, V163, P579, DOI 10.1093/aje/kwj078; Mudway IS, 1999, OCCUP ENVIRON MED, V56, P473; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Ohtsuka Y, 2000, AM J RESP CELL MOL, V22, P574; Otto-Knapp R, 2003, INFLAMM RES, V52, P51, DOI 10.1007/s000110300000; Pourazar J, 2004, RESP MED, V98, P821, DOI 10.1016/j.rmed.2004.02.025; Prows DR, 1999, AM J PHYSIOL-LUNG C, V277, pL372; Prows DR, 2003, CHEMOSPHERE, V51, P1139, DOI 10.1016/S0045-6535(02)00710-5; Prows DR, 1997, NAT GENET, V17, P471, DOI 10.1038/ng1297-471; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Rusznak C, 1996, EUR RESPIR J, V9, P2298, DOI 10.1183/09031936.96.09112298; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samet JM, 2001, AM J RESP CRIT CARE, V164, P819; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Shore SA, 2001, AM J RESP CRIT CARE, V164, P602; Stenfors N, 2002, RESP MED, V96, P352, DOI 10.1053/rmed.2001.1265; Subramanian G, 2001, JAMA-J AM MED ASSOC, V286, P2296, DOI 10.1001/jama.286.18.2296; Sunyer J, 2002, THORAX, V57, P687, DOI 10.1136/thorax.57.8.687; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Takizawa H, 2000, CLIN EXP IMMUNOL, V120, P356, DOI 10.1046/j.1365-2249.2000.01213.x; Teare MD, 2005, LANCET, V366, P1036; Todd JA, 2006, NAT GENET, V38, P731, DOI 10.1038/ng0706-731; Trenga CA, 2006, CHEST, V129, P1614, DOI 10.1378/chest.129.6.1614; Uysal N, 2003, CURR OPIN PULM MED, V9, P144, DOI 10.1097/00063198-200303000-00009; Viegi G, 2006, RESPIROLOGY, V11, P523, DOI 10.1111/j.1400-1843.2006.00886.x; Winterton DL, 2001, ANN ALLERG ASTHMA IM, V86, P232; Yang IA, 2005, AM J RESP CRIT CARE, V171, P171, DOI 10.1164/rccm.200402-194OC; Yang IA, 2004, CLIN EXP ALLERGY, V34, P163, DOI 10.1111/j.1365-2222.2004.01893.x; Zeka A, 2004, ENVIRON HEALTH PERSP, V112, P1686, DOI 10.1289/ehp.7286	100	74	76	1	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2008	63	6					555	563		10.1136/thx.2007.079426		9	Respiratory System	Respiratory System	307AJ	WOS:000256289600017	18511640	
J	Alm, B; Erdes, L; Mollborg, P; Pettersson, R; Norvenius, SG; Aberg, N; Wennergren, G				Alm, Bernt; Erdes, Laslo; Moellborg, Per; Pettersson, Rolf; Norvenius, S. Gunnar; Aberg, Nils; Wennergren, Goeran			Neonatal antibiotic treatment is a risk factor for early wheezing	PEDIATRICS			English	Article						antibiotics; cohort studies; infant; wheezing	TOBACCO-SMOKE EXPOSURE; EARLY-CHILDHOOD; 1ST YEAR; BIRTH COHORT; ALLERGIC DISEASE; ASTHMA; LIFE; INFANCY; AGE; INFECTIONS	OBJECTIVE. The use of antibiotics in infancy and subsequent changes in the intestinal bacterial flora have been discussed as risk factors for the development of asthma. However, it has been difficult to exclude the possibility that antibiotics have been given in early episodes of wheezing. As a result, there has been a risk of reverse causation. To minimize the risk of reverse causation, we have focused on the effect of antibiotics that are already administered on the neonatal ward. METHODS. In a cohort study of infants born in western Sweden in 2003, we studied the development of wheezing. The families of the infants were randomly selected and sent a questionnaire at child ages 6 and 12 months. The response rate was 68.5% to the 6-month questionnaire and 68.9% to the 12-month questionnaire. RESULTS. At 12 months, 20.2% of infants had had 1 or more episodes of wheezing, and 5.3% had had 3 or more episodes. Inhaled corticosteroids had been taken by 4.1% of the infants. Independent risk factors for wheezing disorder treated with inhaled corticosteroids were neonatal antibiotic treatment, male gender, gestational age of <37 weeks, having a mother with asthma, having a sibling with asthma or eczema, and breastfeeding for <5 months. CONCLUSIONS. Treatment with antibiotics in the neonatal period was an independent risk factor for wheezing that was treated with inhaled corticosteroids at 12 months of age. These results indirectly support the hypothesis that an alteration in the intestinal flora can increase the risk of subsequent wheezing.	[Alm, Bernt; Norvenius, S. Gunnar; Aberg, Nils; Wennergren, Goeran] Univ Gothenburg, Dept Pediat, Gothenburg, Sweden; [Erdes, Laslo] Pediat Outpatient Clin, Skene, Sweden; [Moellborg, Per] Uddevalla Cent Hosp, Cent Infant Welf Bur, Uddevalla, Sweden; [Pettersson, Rolf] Skaraborg Hosp, Dept Pediat, Skovde, Sweden	Alm, B (reprint author), Univ Gothenburg, Queen Silvia Childrens Hosp, Dept Pediat, SE-41685 Gothenburg, Sweden.	bernt.alm@medfak.gu.se		Alm, Bernt/0000-0002-3557-2995			Alm B, 2006, ARCH DIS CHILD, V91, P915, DOI 10.1136/adc.2005.088328; Altman M, 2006, ACTA PAEDIATR, V95, P1228, DOI 10.1080/08035250600589058; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; NORTH K, 1999, PEDIATRICS, V103; Norusis M.J., 2005, SPSS 13 0 GUIDE DATA; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; PERSSON B, 2005, NATL HEALTHCARE QUAL; RYLANDER E, 1993, EUR J EPIDEMIOL, V9, P517; Stone KN, 2000, EARLY HUM DEV, V60, P137; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Thomas M, 2006, PEDIATR ALLERGY IMMU, V17, P184, DOI 10.1111/j.1399-3038.2006.00389.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wjst M, 2001, EUR J MED RES, V6, P263; WRIGHT AL, 1989, AM J EPIDEMIOL, V129, P1232; 2002, INFORM SWEDISH MED P, V13, P4	28	74	81	0	7	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2008	121	4					697	702		10.1542/peds.2007-1232		6	Pediatrics	Pediatrics	282OJ	WOS:000254576800006	18381533	
J	Andersen, ZJ; Wahlin, P; Raaschou-Nielsen, O; Scheike, T; Loft, S				Andersen, Zorana J.; Wahlin, Peter; Raaschou-Nielsen, Ole; Scheike, Thomas; Loft, Steffen			Ambient particle source apportionment and daily hospital admissions among children and elderly in Copenhagen	JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY			English	Article						pM(10); source apportionment; hospital admissions; cardiovascular; respiratory; asthma	PM SOURCE APPORTIONMENT; PARTICULATE AIR-POLLUTION; DAILY MORTALITY; FINE PARTICLES; RESPIRATORY-DISEASES; CHILDHOOD ASTHMA; EUROPEAN CITIES; RECEPTOR MODEL; HEALTH; ASSOCIATIONS	An association between particulate air pollution and morbidity and mortality is well established. However, little is known about which sources of particulate matter contribute most to the adverse health effects. Identification of responsible sources would merit more effficient control. For a 6-year period ( 01 January 1999 to 31 December 2004), we examined associations between urban background PM10 in the presence of gaseous pollutants ( CO, NO2) and hospital admissions due to cardiovascular and respiratory disease in the elderly (age >= 65), and asthma in children (age 5-18) in Copenhagen, Denmark. We further studied associations between fractions of PM10 assigned to six sources (biomass, secondary, oil, crustal, sea salt, and vehicle) and admissions during a 11/2 -year campaign. We used Poisson generalized additive time-series model adjusted for season, day of the week, public holidays, influenza epidemics, grass pollen, school holidays, and meteorology, with up to 5 days lagged air pollution exposure. We found positive associations between PM10 and the three health outcomes, with strongest associations for asthma. The PM10 effect remained robustin the presence of CO and NO2. We found different PM10 sources to be variably associated with different outcomes: crustal and secondary sources showed strongest associations with cardiovascular, biomass with respiratory, and vehicle with asthma admissions. These novel results may merit future research of potential mechanism, whereas at present, no single PM10 source can be attributed to all morbidity.	Univ Copenhagen, Inst Publ Hlth, Dept Biostat, Copenhagen 1014, Denmark; Univ Copenhagen, Dept Environm & Occupat Hlth, Copenhagen 1014, Denmark; Natl Environm Res Inst, Dept Atmospher Environm, Roskilde, Denmark; Inst Canc Epidemiol, Danish Canc Soc, Copenhagen, Denmark	Andersen, ZJ (reprint author), Univ Copenhagen, Inst Publ Hlth, Dept Biostat, Oster Farimagsgade 5 entr,B PO Box 2099, Copenhagen 1014, Denmark.	zojo@biostat.ku.dk	Andersen, Zorana /P-4983-2014	Andersen, Zorana /0000-0003-4138-9828; Scheike, Thomas/0000-0002-2148-4740; Loft, Steffen/0000-0001-9552-8518			AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson HR, 2005, EPIDEMIOLOGY, V16, P155, DOI 10.1097/01.ede.0000152528.22746.0f; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; BOMAN BC, 2003, SCAND J WORK ENV HEA, V29, P309; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Englert N, 2004, TOXICOL LETT, V149, P235, DOI 10.1016/j.toxlet.2003.12.035; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Hastie T., 1990, GENERALIZED ADDITIVE; *HEI, 2003, REV AN TIM SER STUD; Hopke PK, 2006, J EXPO SCI ENV EPID, V16, P275, DOI 10.1038/sj.jea.7500458; Ito K, 2006, J EXPO SCI ENV EPID, V16, P300, DOI 10.1038/sj.jea.7500464; Janssen NAH, 2002, ENVIRON HEALTH PERSP, V110, P43; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Lanki T, 2006, ENVIRON HEALTH PERSP, V114, P655, DOI 10.1289/ehp.8578; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; Lippmann M, 2005, ENVIRON HEALTH PERSP, V113, P1575, DOI 10.1289/ehp.8091; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; Mar TF, 2006, J EXPO SCI ENV EPID, V16, P311, DOI 10.1038/sj.jea.7500465; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; ORZOCCOLEVI M, 2006, EUR RESPIR J, V27, P446; OZKAYNAK H, 1987, RISK ANAL, V7, P449, DOI 10.1111/j.1539-6924.1987.tb00482.x; PAATERO P, 1994, ENVIRONMETRICS, V5, P111, DOI 10.1002/env.3170050203; Penttinen P, 2006, INHAL TOXICOL, V18, P191, DOI 10.1080/08958370500434230; R Development Core Team, 2006, R LANG ENV STAT COMP; SAMET JM, 2000, HLTH EFFECTS I RES 2, V94, P5; Schwartz J, 2004, PEDIATRICS, V113, P1037; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Sverdrup H.U., 1942, OCEANS; Wahlin P, 2006, ATMOS ENVIRON, V40, P2151, DOI 10.1016/j.atmosenv.2005.11.049; Wahlin P, 2003, ATMOS ENVIRON, V37, P4861, DOI 10.1016/j.atmosenv.2003.08.032; WATSON JG, 1984, ATMOS ENVIRON, V18, P1347, DOI 10.1016/0004-6981(84)90043-X; World Health Organization, 2005, EFF AIR POLL CHILDR; *WHO, 2004, MET AN TIM SER STUD	43	74	76	2	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1559-0631			J EXPO SCI ENV EPID	J. Expo. Sci. Environ. Epidemiol.	NOV	2007	17	7					625	636		10.1038/sj.jes.7500546		12	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	231RJ	WOS:000250966400004	17495872	
J	Johnston, RA; Zhu, M; Rivera-Sanchez, YM; Lu, FL; Theman, TA; Flynt, L; Shore, SA				Johnston, Richard A.; Zhu, Ming; Rivera-Sanchez, Yadira M.; Lu, Frank L.; Theman, Todd A.; Flynt, Lesley; Shore, Stephanie A.			Allergic airway responses in obese mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway responsiveness; eosinophil; immunoglobulin E; interleukin-13; pulmonary resistance	BODY-MASS INDEX; NECROSIS-FACTOR-ALPHA; ACUTE OZONE EXPOSURE; C-REACTIVE PROTEIN; RESPIRATORY SYMPTOMS; PULMONARY RESPONSES; INSULIN-RESISTANCE; WEIGHT-REDUCTION; ASTHMA; INFLAMMATION	Rationale: Epidemiologic data indicate an increased incidence of asthma in the obese. Objectives: To determine whether obese mice exhibit augmented pulmonary responses after allergen sensitization and challenge. Methods: Lean, wild-type (C57BL/6), obese ob/ob, and obese db/db mice were sensitized to ovalbumin (OVA), and then challenged with aerosolized OVA or phosphate-buffered saline (PBS). Changes in total pulmonary resistance (RL) induced by intravenous methacholine were measured by forced oscillation. Blood was collected, bronchoalveolar lavage (BAL) was performed, and lungs were harvested for measurement of cytokine expression by real-time reverse transcription-polymerase chain reaction. Measurements and Main Results: OVA challenge increased baseline R-L in ob/ob, but not wild-type, mice, and airway responsiveness was greater in ob/ob than wild-type mice, regardless of the challenge. Compared with PBS, OVA challenge caused an increase in the number of BAL fluid (BALF) cells, an increase in lung Th2 cytokine expression, and an increase in serum IgE. Significantly fewer BALF cells were recovered from OVA-challenged ob/ob versus wild-type mice, whereas serum IgE levels were elevated significantly more in ob/ob versus wild-type mice. BALIF and lung Th2 cytokine expression was not different in ob/ob versus wild-type mice. Airway responsiveness was greater in db/db versus wild-type mice, regardless of the challenge, and OVA caused airway hyperresponsiveness in db/db but not wild-type mice, despite reduced BALF cells in OVA-challenged db/db versus wild-type mice. Conclusions: These results demonstrate that obesity enhances OVA-induced changes in pulmonary resistance and serum IgE and that these changes are not the result of increased Th2 type airway inflammation.	Univ Texas, Med Branch, Dept Internal Med, Div Allergy Pulm Immunol Crit Care & Sleep, Galveston, TX 77555 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA 02115 USA; Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan; Natl Taiwan Univ Hosp, Dept Pediat, Taipei 100, Taiwan	Johnston, RA (reprint author), Univ Texas, Med Branch, Dept Internal Med, Div Allergy Pulm Immunol Crit Care & Sleep, 301 Univ Blvd,Room 8-104A,Med Res Bldg, Galveston, TX 77555 USA.	rajohnst@utmb.edu	Lu, Frank/G-6196-2012	Lu, Frank/0000-0002-5225-7751	NHLBI NIH HHS [HL-33009]; NIEHS NIH HHS [ES-013307, ES-00002]		Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Amrani Y, 1998, THORAX, V53, P713; Back M, 2007, CIRC RES, V100, P946, DOI 10.1161/01.RES.0000264498.60702.0d; Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Bellmeyer A, 2007, AM J RESP CRIT CARE, V175, P587, DOI 10.1164/rccm.200603-312OC; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150; Bruun JM, 2003, EUR J ENDOCRINOL, V148, P535, DOI 10.1530/eje.0.1480535; Bullo M, 2002, EUR J ENDOCRINOL, V146, P325, DOI 10.1530/eje.0.1460325; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Eum SY, 2003, J ALLERGY CLIN IMMUN, V111, P1049, DOI 10.1067/mai.2003.1416; Fauroux B, 2000, PEDIATR PULM, V30, P41; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gidding SS, 2004, J PEDIATR-US, V144, P766, DOI 10.1016/j.jpeds.2004.03.043; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamada K, 2003, J IMMUNOL, V170, P1683; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327; Hancox RJ, 2005, AM J RESP CRIT CARE, V171, P440, DOI 10.1164/rccm.200405-623OC; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Hotamisligil GS, 1997, DIABETES, V46, P451, DOI 10.2337/diabetes.46.3.451; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Jarvis D, 2002, CLIN EXP ALLERGY, V32, P831, DOI 10.1046/j.1365-2222.2002.01380.x; Johnston RA, 2006, AM J PHYSIOL-REG I, V290, pR126, DOI 10.1152/ajpregu.00306.2005; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL390, DOI 10.1152/ajplung.00007.2004; Johnston RA, 2007, J APPL PHYSIOL, V102, P149, DOI 10.1152/japplphysiol.00300.2006; Kaminuma O, 1997, INT ARCH ALLERGY IMM, V114, P10; Lang JE, 2007, AM J RESP CRIT CARE, V175, pA912; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; Mannino DM, 2006, INT J OBESITY, V30, P6, DOI 10.1038/sj.ijo.0803145; Mishra V, 2004, INT J OBESITY, V28, P1048, DOI 10.1038/sj.ijo.0802700; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Nieman DC, 1999, J AM DIET ASSOC, V99, P294, DOI 10.1016/S0002-8223(99)00077-2; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; RIVERASANCHEZ YM, 2004, AM J RESP CRIT CARE, V169, pA762; Ronmark E, 2005, EUR RESPIR J, V25, P282, DOI 10.1183/09031936.05.00054304; Schachter LM, 2003, THORAX, V58, P1031, DOI 10.1136/thorax.58.12.1031; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Shore SA, 2002, ASTHMA COPD BASIC ME, P79, DOI 10.1016/B978-012079028-9/50083-1; Shore SA, 2006, J ALLERGY CLIN IMMUN, V118, P389, DOI 10.1016/j.jaci.2006.04.021; Shore SA, 2007, J APPL PHYSIOL, V102, P516, DOI 10.1152/japplphysiol.00847.2006; Spivak H, 2005, AM J SURG, V189, P27, DOI 10.1016/j.amjsurg.2004.06.038; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tantisira KG, 2003, THORAX, V58, P1036, DOI 10.1136/thorax.58.12.1036; Teramoto S, 2003, CIRCULATION, V107, pE40, DOI 10.1161/01.CIR.0000053956.46188.5F; Thomson CC, 2003, CHEST, V124, P795, DOI 10.1378/chest.124.3.795; Turner DJ, 1996, AM J RESP CRIT CARE, V153, P545; Vasudevan AR, 2006, J CLIN ENDOCR METAB, V91, P256, DOI 10.1210/jc.2005-1280; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; Wickens K, 2005, THORAX, V60, P7, DOI 10.1136/thx.2002.001529; Wills-Karp M, 2004, SCIENCE, V305, P1726, DOI 10.1126/science.1104134; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; ZHU M, 2007, AM J RESP CRIT CARE, V175, pA912; Zhu Z, 2004, SCIENCE, V304, P1678, DOI 10.1126/science.1095336	65	74	76	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2007	176	7					650	658		10.1164/rccm.200702-323OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	215SP	WOS:000249829600006	17641156	
J	Stranger, M; Potgieter-Vermaak, SS; Van Grieken, R				Stranger, M.; Potgieter-Vermaak, S. S.; Van Grieken, R.			Comparative overview of indoor air quality in Antwerp, Belgium	ENVIRONMENT INTERNATIONAL			English	Article						indoor air quality; PM1; PM2.5; PM10; gaseous pollutants	SUSPENDED PARTICLE EXPOSURES; ENVIRONMENTAL TOBACCO-SMOKE; PEAK EXPIRATORY FLOW; LONG-TERM EXPOSURE; HONG-KONG; PARTICULATE MATTER; RESPIRATORY SYMPTOMS; NITROGEN-DIOXIDE; INDOOR/OUTDOOR RELATIONSHIPS; ELEMENTAL COMPOSITION	This comprehensive study, a first in Belgium, aimed at characterizing the residential and school indoor air quality of subgroups that took part in the European Community Respiratory Health Survey and the International Study of Asthma and Allergy in Childhood [Masoli M, Fabian D, Holt S, Beasley R. Global Burden of Asthma, Medical Research Institute of New Zealand, University of Southampton; 2004.] questionnaire-based asthma and related illnesses studies. The principal aim was to perform a base-line study to assess the indoor air quality in Antwerp in terms of various gaseous and particulate pollutants. Secondly, it aimed to establish correlations between these pollutants investigated, the pollutant levels in the indoor and outdoor micro-environments, findings of the previous questionnaire-based studies and an epidemiological study which ran in conjunction with this study. Lastly, these results were compared and evaluated with current indoor and ambient guidelines in various countries This paper presents selected results on PM1, PM2.5 and PM 10 mass concentrations and elemental C estimates as black smoke, as well as gaseous NO, SO2, O-3 and BTEX concentrations of 18 residences and 27 schools. These are related to current guidelines of Flanders, Germany, Norway, China and Canada and evaluated with reference to selected similar studies. It was found that indoor sources such as tobacco smoking and carpets, the latter causing re-suspension of dust, are responsible for elevated indoor respirable particulate matter and place school children and residents at risk. Both PM2.5 and PM10 equalled or exceeded the current guidelines adopted by Flanders, noting that 12-h and 24-h PM2.5 were compared with an annual limit value. Indoor and ambient NO2 concentrations in the school campaign were higher than the annual EU ambient norm. The other studied pollutant levels were below the current guidelines. (c) 2007 Elsevier Ltd. All rights reserved.	Univ Witwatersrand, Sch Chem, Inst Mol Sci, ZA-2050 Wits, South Africa; Univ Antwerp, Dept Chem, B-2610 Antwerp, Belgium; Univ Coll Antwerp, Higher Inst Prod Dev Design Sci, B-2000 Antwerp, Belgium	Potgieter-Vermaak, SS (reprint author), Univ Witwatersrand, Sch Chem, Inst Mol Sci, Private Bag X3, ZA-2050 Wits, South Africa.	sanjap@chem.wits.ac.za					Asher MI, 1998, EUR RESPIR J, V12, P315; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; BRUNEKREEF B, 2005, HLTH EFF I, P127; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; CARRER P, 2002, THADE PROJECT HLTH A; Chao CY, 2002, ATMOS ENVIRON, V36, P265, DOI 10.1016/S1352-2310(01)00411-3; Farhat SCL, 2005, BRAZ J MED BIOL RES, V38, P227, DOI 10.1590/S0100-879X2005000200011; Franchi M, 2006, ALLERGY, V61, P864, DOI 10.1111/j.1398-9995.2006.01106.x; FRANCHI M, 2006, THADE REPORT; Gallelli G, 2002, SCI TOTAL ENVIRON, V287, P31, DOI 10.1016/S0048-9697(01)00990-1; GODISH T, 1990, AIR QUALITY; Goldberg MS, 2001, ENVIRON RES, V86, P26, DOI 10.1006/enrs.2001.4243; Grontoft T, 2004, ATMOS ENVIRON, V38, P533, DOI 10.1016/j.atmosenv.2003.10.010; Haller L, 1999, J AIR WASTE MANAGE, V49, P161, DOI 10.1080/10473289.1999.10463788; Hiltermann TJN, 1998, EUR RESPIR J, V11, P686; Ho KF, 2004, ATMOS ENVIRON, V38, P6327, DOI 10.1016/j.atmosenv.2004.08.007; Hoek G, 1998, EUR RESPIR J, V11, P1307, DOI 10.1183/09031936.98.11061307; Jones NC, 2000, ATMOS ENVIRON, V34, P2603, DOI 10.1016/S1352-2310(99)00489-6; KUOSA A, 2001, ATMOS ENVIRON, V35, P3405; Lai HK, 2004, ATMOS ENVIRON, V38, P6399, DOI 10.1016/j.atmosenv.2004.07.013; Lee K, 2002, ENVIRON HEALTH PERSP, V110, P145; Lee SC, 2000, CHEMOSPHERE, V41, P109, DOI 10.1016/S0045-6535(99)00396-3; Lee SC, 1997, ENVIRON INT, V23, P791, DOI 10.1016/S0160-4120(97)00091-3; Liu YS, 2004, ENVIRON INT, V30, P189, DOI 10.1016/S0160-4120(03)00173-9; Masoli M., 2004, GLOBAL BURDEN ASTHMA; Monn C, 1998, SCI TOTAL ENVIRON, V215, P243, DOI 10.1016/S0048-9697(98)00124-7; Monn C, 1997, SCI TOTAL ENVIRON, V208, P15, DOI 10.1016/S0048-9697(97)00271-4; Monn C, 2001, ATMOS ENVIRON, V35, P1, DOI 10.1016/S1352-2310(00)00330-7; Peacock JL, 2003, OCCUP ENVIRON MED, V60, P82, DOI 10.1136/oem.60.2.82; Peters A, 1996, AM J EPIDEMIOL, V144, P570; Phillips K, 1999, ATMOS ENVIRON, V33, P1889, DOI 10.1016/S1352-2310(98)00205-2; Phillips K, 2001, ENVIRON INT, V27, P69, DOI 10.1016/S0160-4120(01)00057-5; Phillips K, 1998, ENVIRON INT, V24, P851, DOI 10.1016/S0160-4120(98)00072-5; Pikhart H, 2001, INT ARCH OCC ENV HEA, V74, P574; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Ramadour M, 2000, ALLERGY, V55, P1163, DOI 10.1034/j.1398-9995.2000.00637.x; Roemer W, 1998, EUR RESPIR J, V12, P1354, DOI 10.1183/09031936.98.12061354; Roemer W, 2000, EUR RESPIR J, V15, P553, DOI 10.1034/j.1399-3003.2000.15.21.x; Sawant AA, 2004, ATMOS ENVIRON, V38, P6269, DOI 10.1016/j.atmosenv.2004.08.043; Schneider P, 2001, SCI TOTAL ENVIRON, V267, P41, DOI 10.1016/S0048-9697(00)00766-X; Schwartz J, 2001, ENVIRON HEALTH PERSP, V109, P1001, DOI 10.2307/3454953; STRANGER M, IN PRESS ATM ENV; Wickman M, 2003, ALLERGY, V58, P570, DOI 10.1034/j.1398-9995.2003.00179.x; Wieringa MH, 2001, EUR RESPIR J, V17, P422, DOI 10.1183/09031936.01.17304220; Wieringa MH, 1998, INT J EPIDEMIOL, V27, P630, DOI 10.1093/ije/27.4.630; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460	47	74	79	10	35	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0160-4120			ENVIRON INT	Environ. Int.	AUG	2007	33	6					789	797		10.1016/j.envint.2007.02.014		9	Environmental Sciences	Environmental Sciences & Ecology	193KU	WOS:000248273700010	17399789	
J	Almqvist, C; Garden, F; Xuan, W; Mihrshahi, S; Leeder, SR; Oddy, W; Webb, K; Marks, GB				Almqvist, Catarina; Garden, Frances; Xuan, Wei; Mihrshahi, Seema; Leeder, Steve R.; Oddy, Wendy; Webb, Karen; Marks, Guy B.		CAPS Team	Omega-3 and omega-6 fatty acid exposure from early life does not affect atopy and asthma at age 5 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; allergy and immunology; birth cohort; child; eczema; omega-3 fatty acids; omega-6 fatty acids; primary prevention	CHILDHOOD ASTHMA; CHILDREN; DIETARY; ADULTS; RISK; PREVENTION; TRIAL; FISH	Background: The Childhood Asthma Prevention Study was a randomized controlled trial conducted in children with a family history of asthma in whom omega-3 fatty acid supplementation and restriction of dietary omega-6 fatty acids did not prevent asthma, eczema, or atopy at age 5 years. Objective: We sought to examine the relation of all measures of omega-3 and omega-6 polyunsaturated fatty acids with outcomes at age 5 years in the whole birth cohort, regardless of randomization group. Methods: Plasma fatty acids were measured at 18 months, 3 years, and 5 years. Compliance with the fatty acid supplements was estimated every 6 months. Dietary intake was assessed at 18 months by means of weighed-food record and at 3 years by means of food-frequency questionnaire. At age 5 years, 516 children were examined for wheeze and eczema (questionnaire) and atopy (skin prick tests, n = 488). Multiple logistic regression was used to evaluate associations between exposures and outcomes. Results: Plasma levels of omega-3 or omega-6 fatty acids were not associated with wheeze, eczema, or atopy at age 5 years (P = .11-.96). Overall, fatty acid exposure, measured as plasma levels, dietary intake, and compliance with supplements, was not associated with any respiratory or allergic outcomes (P =.35-.59). Conclusion: This observational analysis of the cohort, using the full range of observed variation in omega-3 and omega-6 fatty acid exposure, supports the negative findings of the randomized controlled trial. Clinical implications: Modification of dietary polyunsaturated fatty acids in early childhood is not helpful in preventing atopy and asthma.	Woolcock Inst Med Res, Sydney, NSW, Australia; Univ Sydney, Fac Med, Sydney, NSW 2006, Australia; Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Stockholm, Sweden; New S Wales Dept Hlth, Sydney, NSW, Australia; Childrens Hosp Westmead, Sydney, NSW, Australia; Curtin Univ Technol, Telethon Inst Child Hlth Res, Perth, WA 6001, Australia	Almqvist, C (reprint author), Woolcock Inst Med Res, PO Box M77,Missenden Rd, Camperdown, NSW 2050, Australia.	calmqvist@woolcock.org.au	Mihrshahi, Seema/A-9877-2009	Mihrshahi, Seema/0000-0001-6567-9884			ARM J P, 1988, Thorax, V43, P84, DOI 10.1136/thx.43.2.84; Bolte G, 2006, CLIN EXP ALLERGY, V36, P293, DOI 10.1111/j.1365-2222.2006.02441.x; Broadfield EC, 2004, CLIN EXP ALLERGY, V34, P1232, DOI 10.1111/j.1365-2222.2004.02032.x; Department of Health and Ageing National Health and Medical Research Council Ministry of Health, 2006, NUTR REF VAL AUSTR N; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; KIRSCH CM, 1988, CLIN ALLERGY, V18, P177, DOI 10.1111/j.1365-2222.1988.tb02857.x; Mann N. J., 2003, Nutrition & Dietetics, V60, P42; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; PEAT JK, 1992, EUR RESPIR J, V5, P921; Trak-Fellermeier MA, 2004, EUR RESPIR J, V23, P575, DOI 10.1183/09031936.04.00074404; WEBB K, 2005, NUTR DIETETICS, V62, P189; Woods RK, 2004, THORAX, V59, P105, DOI 10.1136/thorax.2003.009498; Woods RK, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858	17	74	76	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1438	1444		10.1016/j.jaci.2007.01.046		7	Allergy; Immunology	Allergy; Immunology	178PO	WOS:000247232800020	17379291	
J	Heederik, D; Sigsgaard, T; Thorne, PS; Kline, JN; Avery, R; Bonlokke, JH; Chrischilles, EA; Dosman, JA; Duchaine, C; Kirkhorn, SR; Kulhankova, K; Merchant, JA				Heederik, Dick; Sigsgaard, Torben; Thorne, Peter S.; Kline, Joel N.; Avery, Rachel; Bonlokke, Jakob H.; Chrischilles, Elizabeth A.; Dosman, James A.; Duchaine, Caroline; Kirkhorn, Steven R.; Kulhankova, Katarina; Merchant, James A.			Health effects of airborne exposures from concentrated animal feeding operations	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air quality; asthma; biological agents; endotoxin; inflammation; odor; poultry; swine	SWINE CONFINEMENT BUILDINGS; IN-HOUSE DUST; ENDOTOXIN EXPOSURE; LUNG-FUNCTION; OCCUPATIONAL ASTHMA; RESPIRATORY HEALTH; HAY-FEVER; ENVIRONMENTAL ENDOTOXIN; ALLERGIC SENSITIZATION; FARMERS CHILDREN	Toxic gases, vapors, and particles are emitted from concentrated animal feeding operations (CAFOs) into the general environment. These include ammonia, hydrogen sulfide, carbon dioxide, malodorous vapors, and particles contaminated with a wide range of microorganisms. Little is known about the health risks of exposure to these agents for people living in the surrounding areas. Malodor is one of the predominant concerns, and there is evidence that psychophysiologic changes may occur as a result of exposure to malodorous compounds. There is a paucity of data regarding community adverse health effects related to low-level gas and particulate emissions. Most information comes from studies among workers in CAFO installations. Research over the last decades has shown that microbial exposures, especially endotoxin exposure, are related to deleterious respiratory health effects, of which cross-shift lung function decline and accelerated decline over time are the most pronounced effects. Studies in naive subjects and workers have shown respiratory inflammatory responses related to the microbial load. This working group, which was part of the Conference on Environmental Health Impacts of Concentrated Animal Feeding Operations: Anticipating Hazards-Searching for Solutions, concluded that there is a great need to evaluate health effects from exposures to the toxic gases, vapors, and particles emitted into the general environment by CAFOs. Research should focus not only on nuisance and odors but also on potential health effects from microbial exposures, concentrating on susceptible subgroups, especially asthmatic children and the elderly, since these exposures have been shown to be related to respiratory health effects among workers in CAFOs.	Univ Iowa, Coll Publ Hlth, Iowa City, IA 52242 USA; Univ Utrecht, Utrecht, Netherlands; Univ Aarhus, DK-8000 Aarhus C, Denmark; Univ N Carolina, Chapel Hill, NC USA; Univ Saskatchewan, Saskatoon, SK, Canada; Univ Laval, Quebec City, PQ, Canada; Natl Farm Med Ctr, Marshfield, WI USA	Thorne, PS (reprint author), Univ Iowa, Coll Publ Hlth, 100 Oakdale Campus,176 IREH, Iowa City, IA 52242 USA.	peter-thorne@uiowa.edu		Sigsgaard, Torben/0000-0002-2043-7571; Bonlokke, Jakob/0000-0002-8247-6576	NIEHS NIH HHS [P30 ES005605, P30 ES05605-14S]		ATTWOOD P, 1987, AM IND HYG ASSOC J, V48, P745, DOI 10.1202/0002-8894(1987)048<0745:ASOTRB>2.0.CO;2; Avery RC, 2004, ARCH ENVIRON HEALTH, V59, P101, DOI 10.3200/AEOH.59.2.101-108; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BROUWER R, 1990, AM J IND MED, V17, P96; CORMIER Y, 1991, SCAND J WORK ENV HEA, V17, P269; CROOK B, 1991, AM IND HYG ASSOC J, V52, P271, DOI 10.1202/0002-8894(1991)052<0271:ADAMAA>2.0.CO;2; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; DONHAM KJ, 1984, ARCH ENVIRON HEALTH, V39, P96; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; Douwes J, 1997, INT J OCCUP ENV HEAL, V3, pS26; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gioannini TL, 2003, J ENDOTOXIN RES, V9, P401, DOI 10.1179/096805103225002773; HARRIES MG, 1982, BRIT MED J, V284, P867; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; KATILA ML, 1981, BRIT J IND MED, V38, P334; KEIKHAEFER MS, 1995, ANN AGR ENV MED, V2, P37; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; KIMPBELLDUNN M, 1999, AM J IND MED, V35, P51; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kline JN, 1998, J IMMUNOL, V160, P2555; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kruger T, 2004, CYTOKINE, V25, P73, DOI 10.1016/j.cyto.2003.10.001; Kullman GJ, 1998, AM IND HYG ASSOC J, V59, P403, DOI 10.1202/0002-8894(1998)059<0403:ODEFWI>2.0.CO;2; Liu AH, 2000, CLIN EXP ALLERGY, V30, P1535, DOI 10.1046/j.1365-2222.2000.01012.x; Martinez FD, 1999, LANCET S2, V354, pSII12; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262; MERCHANT JA, 2005, ENV HLTH PERSPECT, V113, P3350; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; NEIJARI C, 1996, RESP MED, V90, P401; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; RADON K, 2005, BIOMETRICS EPID 0915; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; RYLANDER R, 1989, SCAND J WORK ENV HEA, V15, P309; Rylander R, 1997, INT J OCCUP ENV HEAL, V3, pS32; SANDSTROM T, 1992, EUR RESPIR J, V5, P992; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; TOREN K, 1991, BRIT J IND MED, V48, P323; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Von Essen S, 2003, J Agric Saf Health, V9, P185; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zhiping Wang, 1996, American Journal of Respiratory and Critical Care Medicine, V154, P1261	60	74	75	8	49	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	FEB	2007	115	2					298	302		10.1289/ehp.8835		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	132ML	WOS:000243946800043	17384782	
J	Fleming, LE; Kirkpatrick, B; Backer, LC; Beam, JA; Wanner, A; Reich, A; Zaias, J; Cheng, YS; Pierce, R; Naar, J; Abraham, WM; Baden, DG				Fleming, Lora E.; Kirkpatrick, Barbara; Backer, Lorraine C.; Beam, Judy A.; Wanner, Adam; Reich, Andrew; Zaias, Julia; Cheng, Yung Sung; Pierce, Richard; Naar, Jerome; Abraham, William M.; Baden, Daniel G.			Aerosolized red-tide toxins (brevetoxins) and asthma	CHEST			English	Article						asthma; brevetoxins; harmful algal blooms; Karenia brevis; red tides; sensitive populations; spirometry	AIR-POLLUTION; MARINE AEROSOL; HUMAN EXPOSURE; FLORIDA; POPULATION; SHELLFISH; EVENTS; BREVIS; HEALTH	Background: With the increasing incidence of asthma, there is increasing concern over environmental exposures that may trigger asthma exacerbations. Blooms of the marine microalgae, Karenia brevis, cause red titles (or harmful algal blooms) annually throughout the Gulf of Mexico. K brevis produces higlily potent natural polyether toxins, called brevetoxins, which are sodium channel blockers, and possibly histamine activators. In experimental animals, brevetoxins cause significant bronchoconstriction. In humans, a significant increase in self-reported respiratory symptoms has been described after recreational and occupational exposures to Florida red-tide aerosols, particularly among individuals with asthma. Methods: Before and after 1 h spent on beaches with and without an active K brevis red-tide exposure, 97 persons 12 years of age with physician-diagnosed asthma were evaluated by questionnaire and spirometry. Concomitant environmental monitoring, water and air sampling, and personal monitoring for brevetoxins were performed. Results: Participants were significantly more likely to report respiratory symptoms after K brevis red-tide aerosol exposure than before exposure. Participants demonstrated small, but statistically significant, decreases in FEV1, midexpiratory phase of forced expiratory, flow, and peak expiratory flow after exposure, particularly among those participants regularly using asthma medications. No significant differences were detected when there was no Florida red tide (ie, during nonexposure periods). Conclusions: This study demonstrated objectively measurable adverse changes in lung function from exposure to aerosolized Florida red-tide toxins in asthmatic subjects, particularly among those requiring regular therapy with asthma medications. Future studies will assess these susceptible subpopulations in more deptb,as well as the possible long-term effects of these toxins.	Univ Miami, Dept Epidemiol & Publ Hlth, Sch Med, Miami, FL 33136 USA; Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Univ Miami, Natl Inst Environm Hlth Sci Marine, Miami, FL 33149 USA; Univ Miami, Freshwater Biomed Sci Ctr, Miami, FL 33149 USA; Mote Marine Lab, Sarasota, FL USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA; Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Cincinnati, Cincinnati, OH USA; Florida Dept Hlth, Tallahassee, FL USA; Lovelace Resp Res Inst, Albuquerque, NM USA; Univ N Carolina, Marine Sci Res Ctr, Wilmington, NC 28401 USA	Fleming, LE (reprint author), Univ Miami, Dept Epidemiol & Publ Hlth, Sch Med, 1801 NW 9th Ave,Highland Profess Bldg,Suite 200,R, Miami, FL 33136 USA.	lfleming@med.miami.edu			NIEHS NIH HHS [P01 ES010594, P01 ES 10594, P01 ES010594-06A1]		Abraham WM, 2005, AM J RESP CRIT CARE, V171, P26, DOI 10.1164/rccm.200406-735OC; ABRAHAM WM, 2005, ENV HLTH PERSPECT, V112, P632; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; ASAI S, 1982, J ALLERGY CLIN IMMUN, V69, P418, DOI 10.1016/0091-6749(82)90116-6; Backer LC, 2005, ENVIRON HEALTH PERSP, V113, P644, DOI 10.1289/ehp.7502; Backer LC, 2003, HARMFUL ALGAE, V2, P19, DOI 10.1016/S1568-9883(03)00005-2; Baden D., 1995, HDB CLIN NEUROLOGY 2, P141; Baden Daniel G., 1993, P49; BENSON JM, 2005, ENV HLTH PERSPECT, V112, P626; Bourdelais AJ, 2004, CELL MOL NEUROBIOL, V24, P553, DOI 10.1023/B:CEMN.0000023629.81595.09; Chan-Yeung M, 2000, INT J TUBERC LUNG D, V4, P633; Cheng YS, 2005, ENVIRON SCI TECHNOL, V39, P3443, DOI 10.1021/es048680j; Cheng YS, 2005, HARMFUL ALGAE, V4, P87, DOI 10.1016/j.hal.2003.12.002; CHENG YS, 2005, ENV HLTH PERSPECT, V13, P638; Desqueyroux H, 2002, ENVIRON RES, V89, P29, DOI 10.1006/enrs.2002.4357; Eisen EA, 1997, AM J IND MED, V31, P671; Fleming LE, 2005, ENVIRON HEALTH PERSP, V113, P650, DOI 10.1289/ehp.7500; Fleming LE, 2005, ENVIRON HEALTH PERSP, V113, P618, DOI 10.1289/ehp.7501; Fleming L. E., 2001, SEAFOOD ENV TOXINS, P287; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Kirkpatrick B, 2004, HARMFUL ALGAE, V3, P99, DOI 10.1016/j.hal.2003.08.005; Henry M., 2001, HARMFUL ALGAL BLOOMS, P447; Kirkpatrick B, 2006, HARMFUL ALGAE, V5, P526, DOI 10.1016/j.hal.2005.09.004; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES, P388; Koh YI, 2002, RESPIRATION, V69, P38, DOI 10.1159/000049368; Milton B, 2004, CHILD CARE HLTH DEV, V30, P711, DOI 10.1111/j.1365-2214.2004.00486.x; MORRIS PD, 1991, AM J PUBLIC HEALTH, V81, P471, DOI 10.2105/AJPH.81.4.471; Music S I, 1973, JFMA, V60, P27; Naar J, 2002, ENVIRON HEALTH PERSP, V110, P179; *NIOSH, 1997, NIOSH SPIR TRAIN GUI; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Pierce RH, 2005, HARMFUL ALGAE, V4, P965, DOI 10.1016/j.hal.2004.11.004; Pierce RH, 2003, B ENVIRON CONTAM TOX, V70, P161, DOI 10.1007/s00128-002-0170-y; Pierce RH, 2001, ENVIRON TOXICOL CHEM, V20, P107, DOI 10.1897/1551-5028(2001)020<0107:ITFHAT>2.0.CO;2; Poli MA, 2000, TOXICON, V38, P981, DOI 10.1016/S0041-0101(99)00191-9; Steidinger K.A., 1984, P201; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; WOODCOCK AH, 1948, J MAR RES, V7, P56	38	74	75	5	22	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JAN	2007	131	1					187	194		10.1378/chest.06-1830		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	126XF	WOS:000243548100029	17218574	
J	Campo, P; Kalra, HK; Levin, L; Reponen, T; Olds, R; Lummus, ZL; Cho, SH; Hershey, GKK; Lockey, J; Villareal, M; Stanforth, S; LeMasters, G; Bernstein, DI				Campo, Paloma; Kalra, Harpinder K.; Levin, Linda; Reponen, Tiina; Olds, Rolanda; Lummus, Zana L.; Cho, Seung-Hyun; Hershey, Gurjit K. Khurana; Lockey, James; Villareal, Manuel; Stanforth, Sherry; LeMasters, Grace; Bernstein, David I.			Influence of dog ownership and high endotoxin on wheezing and atopy during infancy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; birth cohort; wheeze; house dust; pet ownership	HOUSE-DUST ENDOTOXIN; HAY-FEVER; ALLERGIC SENSITIZATION; WRITTEN QUESTIONNAIRE; DECREASED PREVALENCE; ASTHMATIC-CHILDREN; RESPIRATORY HEALTH; CHILDHOOD ISAAC; TOBACCO-SMOKE; BIRTH COHORT	Background: Increased exposure to microbial products early in life may protect from development of atopic disorders in childhood. Few studies have examined the relationship of endotoxin exposure and pet ownership on atopy and wheezing during infancy. Objective: Evaluate relationships among high endotoxin exposure, pet ownership, atopy, and wheezing in high-risk infants. Methods: Infants (n = 532; mean age, 12.5 +/- 0.8 months) with at least 1 parent with confirmed atopy were recruited. A complete medical history and skin prick testing to foods and aeroallergens were performed at age 1 year. House dust samples were analyzed for endotoxin. Results: Prevalences of wheezing were not independently associated with dog or cat ownership or endotoxin levels. Percutaneous reactivity to at least 1 allergen was observed in 28.6% of infants. Univariate analyses showed significant associations of any wheezing, recurrent wheezing, and recurrent wheezing with an event with daycare attendance, number of siblings, respiratory infections, maternal smoking, and history of parental asthma. Logistic regression adjusting for the latter variables showed that recurrent wheezing (odds ratio, 0.4; 95% CI, 0.1-0.9) as well as 2 other wheeze outcomes were significantly reduced in homes with high endotoxin exposure in the presence of 2 or more dogs. Conclusion: Pet ownership or endotoxin did not independently modify aeroallergen sensitization or wheezing during infancy. However, high endotoxin exposure in the presence of multiple dogs was associated with reduced wheezing in infants. Clinical implications: A home environment with many dogs and high levels of endotoxin may be conducive to reduced wheezing in infancy.	Univ Cincinnati, Dept Internal Med, Div Immunol, Cincinnati, OH 45267 USA; Univ Cincinnati, Dept Environm Hlth, Cincinnati, OH 45267 USA	Bernstein, DI (reprint author), Univ Cincinnati, Dept Internal Med, Div Immunol, POB 670563, Cincinnati, OH 45267 USA.	bernstdd@ucmail.uc.edu		Khurana Hershey, Gurjit/0000-0001-6663-977X	NIEHS NIH HHS [1-R01-ES11170-04, R01 ES011170, R01 ES011170-04]		Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P707, DOI 10.1016/S0091-6749(99)70349-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; CHO SH, 2006, IN PRESS ANN ALLERGY; D'Amato G, 2002, Monaldi Arch Chest Dis, V57, P161; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Farooqi IS, 1998, THORAX, V53, P927; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Helsel DR, 2005, ENVIRON SCI TECHNOL, V39, p419A, DOI 10.1021/es053368a; Holt PG, 1997, THORAX, V52, P1; Hopkin JM, 1999, CLIN EXP ALLERGY, V29, P733; *INS CORP, 2000, S PLUS UN; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; LEMASTERS GK, 2003, AM J RESP CRIT CARE, V167, pA335; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Milton DK, 1997, AM IND HYG ASSOC J, V58, P861; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; Omran M, 1996, BRIT MED J, V312, P34; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Platts-Mills TAE, 2001, MEDIAT INFLAMM, V10, P288; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SHAW RA, 1992, CLIN EXP ALLERGY, V22, P561, DOI 10.1111/j.1365-2222.1992.tb00166.x; SMITH J M, 1971, Clinical Allergy, V1, P57, DOI 10.1111/j.1365-2222.1971.tb02447.x; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; Sole D, 1998, J INVEST ALLERG CLIN, V8, P376; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; VANASPEREN PP, 1984, J ALLERGY CLIN IMMUN, V73, P381, DOI 10.1016/0091-6749(84)90412-3; VANTO T, 1983, ACTA PAEDIATR SCAND, V72, P571, DOI 10.1111/j.1651-2227.1983.tb09773.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E., 2002, J ALLERGY CLIN IMMUN, V109, P525, DOI 10.1067/mai.2002.124565; Waser M, 2005, ALLERGY, V60, P177, DOI 10.1111/j.1398-9995.2004.00645.x; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	50	74	75	1	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1271	1278		10.1016/j.jaci.2006.08.008		8	Allergy; Immunology	Allergy; Immunology	117NP	WOS:000242880300010	17157656	
J	Turner, MC; Chen, Y; Krewski, D; Ghadirian, P				Turner, MC; Chen, Y; Krewski, D; Ghadirian, P			An overview of the association between allergy and cancer	INTERNATIONAL JOURNAL OF CANCER			English	Review							NON-HODGKINS-LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; FRANCISCO BAY AREA; CHRONIC ANTIGENIC-STIMULATION; CHRONIC LYMPHOCYTIC-LEUKEMIA; POPULATION-BASED COHORT; PREVIOUS LUNG-DISEASE; KILLER-CELL-ACTIVITY; PRIOR MEDICATION USE; ADULT BRAIN-TUMOR	Numerous epidemiological studies have evaluated some aspect of the association between a history of allergy and cancer occurrence. In this article, an overview of the epidemiological evidence is presented with a discussion of a number of methodological issues important in this area of study. Literature searches were conducted using the MEDLINE database from 1966 through to August 2005 to identify articles that explored a personal history of allergic disorders as a risk factor for cancer. Although it is difficult to draw conclusions between allergy and cancer at many sites because of insufficient evidence or a lack of consistency both within and among studies completed to date, strong inverse associations have been reported for pancreatic cancer and glioma, whereas lung cancer was positively associated with asthma. Additional studies are needed to confirm these finding and to address the limitations of previous studies, including the validity and reliability of exposure measures and control for confounding. Further, large prospective studies using cancer incidence would be particularly useful, including studies using biological markers of allergic status to reduce potential misclassification and to confirm the results of previous studies based on self-report. There is also a need for further basic research to clarify a potential mechanism, should an association exist. (c) 2006 Wiley-Liss, Inc.	Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Epidemiol & Community Med, Ottawa, ON K1N 6N5, Canada; Univ Montreal, Ctr Rech, CHUM, Unite Rech Epidemiol, Montreal, PQ H3C 3J7, Canada	Turner, MC (reprint author), Univ Ottawa, Inst Populat Hlth, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada.	mturner@uottawa.ca					Adami H. O., 2002, TXB CANC EPIDEMIOLOG; ALDERSON M, 1974, LANCET, V2, P1475; ALLEGRA J, 1976, CANCER RES, V36, P3225; ALLIONE A, 1994, CANCER RES, V54, P6022; American Cancer Society, CANC FACTS FIG 2004; AMLOT PL, 1978, BRIT MED J, V1, P327; Annesi-Maesano I, 2002, ALLERGY, V57, P107, DOI 10.1034/j.1398-9995.2002.1o3170.x; Balmaceda D, 2002, RESPIRATION, V69, P165, DOI 10.1159/000056320; Ben-Noun L, 1999, J INT MED RES, V27, P15; Bergmann RL, 2000, CLIN EXP ALLERGY, V30, P1740, DOI 10.1046/j.1365-2222.2000.00927.x; BERNSTEIN L, 1992, CANCER RES, V52, pS5510; Biesalski HK, 1997, EUR J CANCER PREV, V6, P316, DOI 10.1097/00008469-199708000-00002; BOFFETTA P, 1989, INT J CANCER, V43, P554, DOI 10.1002/ijc.2910430404; Boffetta P, 2002, EUR RESPIR J, V19, P127, DOI 10.1183/09031936.02.00245802; Bosetti C, 2004, EUR J CANCER PREV, V13, P173, DOI 10.1097/cej.0000130016.85687.cf; Boura P, 2001, HEPATO-GASTROENTEROL, V48, P1040; BOURGUET CC, 1993, CANCER, V72, P2148, DOI 10.1002/1097-0142(19931001)72:7<2148::AID-CNCR2820720714>3.0.CO;2-Q; Boyd C, 1999, J CLIN ONCOL, V17, P2244; Brenner AV, 2001, INT J EPIDEMIOL, V30, P118, DOI 10.1093/ije/30.1.118; Brenner AV, 2002, INT J CANCER, V99, P252, DOI 10.1002/ijc.10320; Briggs NC, 2002, CANCER EPIDEM BIOMAR, V11, P401; BROWN LM, 1987, J EPIDEMIOL COMMUN H, V41, P349, DOI 10.1136/jech.41.4.349; Callen JP, 2000, J AM ACAD DERMATOL, V43, P207, DOI 10.1067/mjd.2000.105502; *CAN CANC SOC, GEN CANC STAT; Chang ET, 2004, CANCER EPIDEM BIOMAR, V13, P1236; Chen YJ, 1999, NEOPLASMA, V46, P304; CLARK CJ, 1978, BRIT MED J, V1, P48; Clark NM, 2002, J CLIN EPIDEMIOL, V55, P870, DOI 10.1016/S0895-4356(02)00451-1; COCKCROFT DW, 1979, ANN ALLERGY, V43, P345; COGAN E, 1994, NEW ENGL J MED, V330, P535, DOI 10.1056/NEJM199402243300804; Cooper GS, 1996, CANCER EPIDEM BIOMAR, V5, P867; CUZICK J, 1988, BRIT J CANCER, V57, P516, DOI 10.1038/bjc.1988.118; Dai Q, 1997, EUR J CANCER PREV, V6, P152; DAI Q, 1995, INT J CANCER, V63, P337, DOI 10.1002/ijc.2910630305; Demissie K, 1998, ANN EPIDEMIOL, V8, P201; Dhand R, 1981, Indian J Chest Dis Allied Sci, V23, P47; DIPAOLO F, 1993, AM FAM PHYSICIAN, V48, P785; DOODY MM, 1992, CANCER CAUSE CONTROL, V3, P449, DOI 10.1007/BF00051358; EHLRICH P, 1909, NED TIJDSCHR GENEES, V1, P273; Elmer KB, 1999, AM FAM PHYSICIAN, V59, P2809; ERIKSSON M, 1993, EUR J CANCER, V29A, P259, DOI 10.1016/0959-8049(93)90188-L; ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x; Fabbro-Peray P, 2001, CANCER CAUSE CONTROL, V12, P201, DOI 10.1023/A:1011274922701; FARROW DC, 1990, INT J CANCER, V45, P816, DOI 10.1002/ijc.2910450504; Fidias P, 1996, CANCER, V77, P2332, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2332::AID-CNCR23>3.0.CO;2-X; FISHERMAN EW, 1960, J ALLERGY, V31, P74, DOI 10.1016/0021-8707(60)90026-5; Fishwick D, 1997, NEW ZEAL MED J, V110, P305; Friedman GD, 1998, PHARMACOEPIDEM DR S, V7, P99, DOI 10.1002/(SICI)1099-1557(199803/04)7:2<99::AID-PDS320>3.0.CO;2-0; Gabriel R, 1972, Br J Clin Pract, V26, P202; GALLAGHER RP, 1983, BRIT J CANCER, V48, P853, DOI 10.1038/bjc.1983.277; Gandini S, 2005, CANCER EPIDEM BIOMAR, V14, P1908, DOI 10.1158/1055-9965.EPI-05-0119; Gergen PJ, 2000, CLIN EXP ALLERGY, V30, P1717, DOI 10.1046/j.1365-2222.2000.00971.x; Ghadirian P, 1998, CANCER DETECT PREV, V22, P396, DOI 10.1046/j.1525-1500.1998.00058.x; Ghadirian P, 1998, CANCER DETECT PREV, V22, P485, DOI 10.1046/j.1525-1500.1998.00070.x; GIBSON R, 1976, J NATL CANCER I, V56, P891; Gould HJ, 1999, EUR J IMMUNOL, V29, P3527, DOI 10.1002/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5; GRAMENZI A, 1991, BRIT J CANCER, V63, P769, DOI 10.1038/bjc.1991.172; Grulich AE, 2005, J NATL CANCER I, V97, P587, DOI 10.1093/jnci/dji098; HALLGREN R, 1981, J ALLERGY CLIN IMMUN, V67, P398, DOI 10.1016/0091-6749(81)90086-5; Hallquist A, 1994, Eur J Cancer Prev, V3, P481, DOI 10.1097/00008469-199411000-00005; Heath JA, 2001, J PAEDIATR CHILD H, V37, P397, DOI 10.1046/j.1440-1754.2001.00665.x; Hedderson MM, 2003, CANCER CAUSE CONTROL, V14, P619, DOI 10.1023/A:1025686913626; Hellstrand K, 2000, CANCER INVEST, V18, P347, DOI 10.3109/07357900009012178; HENDERSON BE, 1979, INT J CANCER, V23, P598, DOI 10.1002/ijc.2910230503; HERRINTON LJ, 1993, CANCER CAUSE CONTROL, V4, P83, DOI 10.1007/BF00053148; Holly EA, 2003, AM J EPIDEMIOL, V158, P432, DOI 10.1093/aje/kwg174; Holly EA, 1997, J ACQ IMMUN DEF SYND, V15, P211; Holly EA, 1999, AM J EPIDEMIOL, V150, P375; HUGHES WF, 1979, ANN ALLERGY, V43, P163; Imai K, 2000, LANCET, V356, P1795, DOI 10.1016/S0140-6736(00)03231-1; ISAACS D, 1977, BRIT MED J, V2, P1332; JAIN M, 1991, INT J CANCER, V47, P384, DOI 10.1002/ijc.2910470313; JARVIS D, 1995, CLIN EXP ALLERGY, V25, P1083; Jenkins MA, 1996, INT J EPIDEMIOL, V25, P609, DOI 10.1093/ije/25.3.609; Johnson CC, 2002, EPIDEMIOL REV, V24, P154, DOI 10.1093/epirev/mxf013; JOHNSON KJ, 1979, ANN ALLERGY, V43, P375; Joseph CLM, 1996, J PEDIATR-US, V129, P735, DOI 10.1016/S0022-3476(96)70158-0; KALLEN B, 1993, EUR RESPIR J, V6, P694; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2005, AM J EPIDEMIOL, V162, P133, DOI 10.1093/aje/kwi170; Kelly JP, 1999, AM J EPIDEMIOL, V150, P861; KEOPSELL TD, 1987, AM J EPIDEMIOL, V126, P1051; Kershaw MH, 1998, ONCOL RES, V10, P133; Kilpelainen M, 2001, ALLERGY, V56, P377, DOI 10.1034/j.1398-9995.2001.056005377.x; Kim WJ, 2000, J UROLOGY, V164, P209, DOI 10.1016/S0022-5347(05)67496-4; KINLEN LJ, 1982, CANC EPIDEMIOLOGY PR, P94; Knopf PM, 2000, ALLERGY ASTHMA PROC, V21, P215, DOI 10.2500/108854100778248836; Knuiman MW, 1999, ANN EPIDEMIOL, V9, P297, DOI 10.1016/S1047-2797(98)00066-0; Krejsek J, 1998, ALLERGY, V53, P73, DOI 10.1111/j.1398-9995.1998.tb03776.x; KRIPKE ML, 1988, J NATL CANCER I, V80, P722, DOI 10.1093/jnci/80.10.722; KUMMET TD, 1983, LANCET, V2, P231; KUNE GA, 1988, CANCER RES, V48, P4399; Kusaka Y, 1997, INT ARCH ALLERGY IMM, V112, P331; Lange P, 1996, LANCET, V347, P1285; LERCHEN ML, 1986, AM J EPIDEMIOL, V123, P481; Levin J, 1999, CUTIS, V64, P113; LEWIS DR, 1994, CANCER CAUSE CONTROL, V5, P529, DOI 10.1007/BF01831381; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615; LINET MS, 1986, J NATL CANCER I, V77, P371; LINET MS, 1989, J CLIN EPIDEMIOL, V42, P1207, DOI 10.1016/0895-4356(89)90119-4; LINET MS, 1987, CANCER RES, V47, P2978; LINET MS, 1985, LEUKEMIAS EPIDEMIOLO, P223; Lipscomb M F, 1999, Curr Opin Pulm Med, V5, P10, DOI 10.1097/00063198-199901000-00003; Lipworth L, 2001, INT J EPIDEMIOL, V30, P303, DOI 10.1093/ije/30.2.303; MACKAY WD, 1966, BRIT J CANCER, V20, P434, DOI 10.1038/bjc.1966.52; Mackillop WJ, 2000, CANCER, V89, P901, DOI 10.1002/1097-0142(20000815)89:4<901::AID-CNCR25>3.0.CO;2-I; Maddox L, 2002, ANNU REV MED, V53, P477, DOI 10.1146/annurev.med.53.082901.103921; Margolis D, 2001, ARCH DERMATOL, V137, P778; Markiewicz MA, 1999, CRIT REV ONCOGENESIS, V10, P247; MARKOWE HLJ, 1987, BRIT MED J, V295, P949; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; MCCORMICK DP, 1971, CANCER-AM CANCER SOC, V27, P93, DOI 10.1002/1097-0142(197101)27:1<93::AID-CNCR2820270114>3.0.CO;2-0; McCullough ML, 2004, ONCOGENE, V23, P6349, DOI 10.1038/sj.onc.1207716; MCDUFFIE HH, 1991, CHEST, V99, P404, DOI 10.1378/chest.99.2.404; MCDUFFIE HH, 1988, CHEST, V93, P241, DOI 10.1378/chest.93.2.241; McDuffie HH, 2001, CANCER EPIDEM BIOMAR, V10, P1155; McGill KA, 1998, PEDIATRICS, V102, P77, DOI 10.1542/peds.102.1.77; Mckinney P A, 1990, Leuk Lymphoma, V2, P67, DOI 10.3109/10428199009042516; MCWHORTER WP, 1988, CANCER, V62, P451, DOI 10.1002/1097-0142(19880715)62:2<451::AID-CNCR2820620234>3.0.CO;2-D; MEERS PD, 1973, LANCET, V1, P884; MILLER CT, 1978, J CHRON DIS, V31, P51, DOI 10.1016/0021-9681(78)90080-2; MILLS PK, 1988, CANCER, V61, P2578, DOI 10.1002/1097-0142(19880615)61:12<2578::AID-CNCR2820611232>3.0.CO;2-0; MILLS PK, 1992, AM J EPIDEMIOL, V136, P287; Mocellin S, 2001, J IMMUNOTHER, V24, P392, DOI 10.1097/00002371-200109000-00002; Montgomery SM, 2002, BRIT J CANCER, V87, P989, DOI 10.1038/sj.bjc.6600585; MOUSSA MAA, 1985, METHOD INFORM MED, V24, P35; MULROW CD, 1987, ANN INTERN MED, V106, P485; NADALIN V, 2003, INT J CANCER, V10, P566; Negri E, 1999, EUR J CANCER, V35, P1838, DOI 10.1016/S0959-8049(99)00209-9; Negri E, 2002, CANCER CAUSE CONTROL, V13, P365, DOI 10.1023/A:1015263718760; NEWELL GR, 1973, JNCI-J NATL CANCER I, V51, P1437; NINAN TK, 1993, THORAX, V48, P1218, DOI 10.1136/thx.48.12.1218; NISHI M, 1989, J EPIDEMIOL COMMUN H, V43, P352, DOI 10.1136/jech.43.4.352; NISHIMURA T, 1999, J EXP MED, V190, P627; Ohgaki H, 2005, ACTA NEUROPATHOL, V109, P93, DOI 10.1007/s00401-005-0991-y; Ohrui T, 2002, J AM GERIATR SOC, V50, P202, DOI 10.1046/j.1532-5415.2002.50034.x; OXMAN AD, 1994, BMJ-BRIT MED J, V309, P648; PARRISH RW, 1983, POSTGRAD MED J, V59, P775; PAVLAKOU G, 1994, EUR RESPIR J, V18, P7; PEARCE NE, 1986, BRIT J CANCER, V54, P493, DOI 10.1038/bjc.1986.202; PEARCE NE, 1987, INT J CANCER, V39, P155, DOI 10.1002/ijc.2910390206; PERICLE F, 1994, J IMMUNOL, V153, P5659; Petridou E, 1997, BRIT J CANCER, V76, P1241, DOI 10.1038/bjc.1997.541; PETROIANU A, 1995, J INT MED RES, V23, P358; PLESS CE, 1995, ARCH PEDIAT ADOL MED, V149, P553; POLEDNAK AP, 1975, LANCET, V2, P1147; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Reali E, 2001, CANCER RES, V61, P5517; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; REYNOLDS P, 1987, AM J EPIDEMIOL, V125, P539; ROBINETTE CD, 1978, J CHRON DIS, V31, P619, DOI 10.1016/0021-9681(78)90022-X; RYAN P, 1992, INT J CANCER, V51, P20, DOI 10.1002/ijc.2910510105; Saleh M, 1999, J NATL CANCER I, V91, P438, DOI 10.1093/jnci/91.5.438; Samoszuk M, 1997, HISTOL HISTOPATHOL, V12, P807; Santillan AA, 2003, CANCER CAUSE CONTROL, V14, P327, DOI 10.1023/A:1023982402137; Schlehofer B, 1999, INT J CANCER, V82, P155, DOI 10.1002/(SICI)1097-0215(19990719)82:2<155::AID-IJC1>3.0.CO;2-P; Schuz J, 2003, INT J CANCER, V105, P255, DOI 10.1002/ijc.11054; Schwartzbaum J, 2003, INT J CANCER, V106, P423, DOI 10.1002/ijc.11230; SEVERSON RK, 1989, J CLIN EPIDEMIOL, V42, P995, DOI 10.1016/0895-4356(89)90165-0; SHERRILL DL, 1994, J ALLERGY CLIN IMMUN, V94, P954, DOI 10.1016/0091-6749(94)90113-9; Siemiatycki J, 2003, J TOXICOL ENV HEAL A, V66, P1591, DOI 10.1080/15287390390211522; Siemiatycki J., 1991, RISK FACTORS CANC WO; Silverman DT, 1999, BRIT J CANCER, V80, P1830, DOI 10.1038/sj.bjc.6690607; Soderberg KC, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-51; Spector L, 2004, EUR J CANCER, V40, P579, DOI 10.1016/j.ejca.2003.08.024; STANCIU L, 1990, ANN BIOL CLIN-PARIS, V48, P623; STEINECK G, 1995, ACTA ONCOL, V34, P741; STRANNEGAARD IL, 1980, ACTA DERM-VENER    S, V92, P48; SWERDLOW AJ, 1987, BRIT J CANCER, V55, P97, DOI 10.1038/bjc.1987.20; Talbot-Smith A, 2003, AM J EPIDEMIOL, V157, P606, DOI 10.1093/aje/kwg020; Tammemagi CM, 2003, INT J CANCER, V103, P792, DOI 10.1002/ijc.10882; Tavani A, 2000, EUR J CANCER PREV, V9, P59, DOI 10.1097/00008469-200002000-00008; TEPPER RI, 1989, CELL, V57, P503, DOI 10.1016/0092-8674(89)90925-2; TERR AI, 1991, BASIC CLIN IMMUNOL, P380; AW Thomson., 1998, CYTOKINE HDB; TIMONEN T, 1985, CLIN EXP IMMUNOL, V59, P85; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Turner MC, 2005, AM J EPIDEMIOL, V162, P212, DOI 10.1093/aje/kwi193; van der Spuy J, 2001, PROTEIN EXPRES PURIF, V21, P462, DOI 10.1006/prep.2001.1399; Varner AE, 2002, CHEST, V121, P1308, DOI 10.1378/chest.121.4.1308; Vaughan TL, 1998, CANCER EPIDEM BIOMAR, V7, P749; Vellutini M, 1997, EUR J EPIDEMIOL, V13, P931, DOI 10.1023/A:1007472407010; VENA JE, 1985, AM J EPIDEMIOL, V122, P66; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534; VESTERINEN E, 1993, ACTA ONCOL, V32, P517; VESTERINEN E, 1993, INT J EPIDEMIOL, V22, P976, DOI 10.1093/ije/22.6.976; Vineis P, 2000, J EPIDEMIOL COMMUN H, V54, P431, DOI 10.1136/jech.54.6.431; Volkers N, 1999, J NATL CANCER I, V91, P1916, DOI 10.1093/jnci/91.22.1916; WEED DL, 1994, J NATL CANCER I, V86, P1813; Wen WQ, 2000, CANCER CAUSE CONTROL, V11, P303, DOI 10.1023/A:1008958724739; Westergaard T, 1997, INT J CANCER, V72, P977; Westergaard T, 1997, J NATL CANCER I, V89, P939, DOI 10.1093/jnci/89.13.939; Wiemels JL, 2004, CANCER RES, V64, P8468, DOI 10.1158/0008-5472.CAN-04-1706; Wiemels JL, 2002, INT J CANCER, V98, P609, DOI 10.1002/ijc.10239; WILLIAMS AR, 1989, CANCER RES, V49, P4038; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; Williams HC, 1996, BRIT J DERMATOL, V135, P12; WOOLF SH, 1991, AM J PREV MED, V7, P53; WU AH, 1995, AM J EPIDEMIOL, V141, P1023; Yancik R, 1998, CANCER, V82, P2123, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2123::AID-CNCR6>3.3.CO;2-N; Yancik R, 2001, JAMA-J AM MED ASSOC, V285, P885, DOI 10.1001/jama.285.7.885; Ye W, 2001, BRIT J CANCER, V85, P1317, DOI 10.1054/bjoc.2001.2094; Zacharia B, 2003, MED HYPOTHESES, V60, P1, DOI 10.1016/S0306-9877(02)00217-7; ZHENG W, 1993, CANCER CAUSE CONTROL, V4, P361, DOI 10.1007/BF00051339	205	74	75	1	4	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	0020-7136			INT J CANCER	Int. J. Cancer	JUN 15	2006	118	12					3124	3132		10.1002/ijc.21752		9	Oncology	Oncology	039UA	WOS:000237331600028	16395696	
J	Bryce, PJ; Mathias, CB; Harrison, KL; Watanabe, T; Geha, RS; Oettgen, HC				Bryce, PJ; Mathias, CB; Harrison, KL; Watanabe, T; Geha, RS; Oettgen, HC			The H1 histamine receptor regulates allergic lung responses	JOURNAL OF CLINICAL INVESTIGATION			English	Article							INDUCED AIRWAY INFLAMMATION; T-CELL; INTERFERON-GAMMA; BRONCHIAL HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; EOSINOPHIL CHEMOTAXIS; CYTOKINE PRODUCTION; ANTIGEN RECEPTOR; EPITHELIAL-CELLS; DENDRITIC CELLS	Histamine, signaling via the type 1 receptor (H1R), has been shown to suppress Th2 cytokine production by in vitro cultured T cells. We examined the role of H1R in allergic inflammation in vivo using a murine asthma model. Allergen-stimulated splenic T cells from sensitized H1R(-/-) mice exhibited enhanced Th2 cytokine production. Despite this Th2 bias, allergen-challenged H1R(-/-) mice exhibited diminished lung Th2 cytokine mRNA levels, airway inflammation, goblet cell metaplasia, and airway hyperresponsiveness (AHR). Restoration of pulmonary Th2 cytokines in H1R(-/-) mice by intranasal IL-4 or IL-13 restored inflammatory lung responses and AHR Further investigation revealed that histamine acts as a T cell chemotactic factor and defective T cell trafficking was responsible for the absence of lung inflammation. Cultured T cells migrated in response to histamine in vitro, but this was ablated by blockade of H1R but not H2R In vivo, allergen-specific WT but not H1R(-/-) CD4(+) T cells were recruited to the lungs of naive recipients following inhaled allergen challenge. H1R(-/-) cells failed to confer airway inflammation or AHR observed after transfer of WT T cells. Our data establish a role for histamine and H1R in promoting the migration of Th2 cells into sites of allergen exposure.	Northwestern Univ, Feinburg Sch Med, Chicago, IL 60611 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Immunol, Boston, MA 02115 USA; RIKEN, Inst Phys & Chem Res, Res Ctr Allergy & Immunol, Yokohama, Japan	Bryce, PJ (reprint author), Northwestern Univ, Feinburg Sch Med, McGaw M315,240 E Huron St, Chicago, IL 60611 USA.	p-bryce@northwestern.edu		Mathias, Clinton/0000-0002-0223-4842	NIAID NIH HHS [5R01AI054471, R01 AI047417, R01 AI054471]; NIAMS NIH HHS [R01 AR047417]		Banu Y, 1999, J EXP MED, V189, P673, DOI 10.1084/jem.189.4.673; Blaeser F, 2003, J EXP MED, V198, P1189, DOI 10.1084/jem.20030471; Blumchen K, 2004, CLIN EXP ALLERGY, V34, P1124, DOI 10.1111/j.1365-2222.2004.01974.x; BROIDE DH, 1991, J ALLERGY CLIN IMMUN, V88, P637, DOI 10.1016/0091-6749(91)90158-K; Bryce PJ, 2003, J ALLERGY CLIN IMMUN, V112, P149, DOI 10.1067/mai.2003.1616; CARLSSON R, 1985, CELL IMMUNOL, V96, P104, DOI 10.1016/0008-8749(85)90343-0; Caron G, 2001, J IMMUNOL, V167, P3682; CASALE TB, 1987, J CLIN INVEST, V79, P1197, DOI 10.1172/JCI112937; CENTER DM, 1983, J IMMUNOL, V131, P1854; CIPRANDI G, 1995, J ALLERGY CLIN IMMUN, V95, P612, DOI 10.1016/S0091-6749(95)70324-1; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; Couillin I, 2004, J IMMUNOL, V173, P3281; Dy M, 2004, CYTOKINE GROWTH F R, V15, P393, DOI 10.1016/j.cytogfr.2004.06.003; Elliott KA, 2001, INT IMMUNOPHARMACOL, V1, P1923, DOI 10.1016/S1567-5769(01)00117-5; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Gantner F, 2002, J PHARMACOL EXP THER, V303, P300, DOI 10.1124/jpet.102.036939; Gelfand EW, 2002, J ALLERGY CLIN IMMUN, V110, P85, DOI 10.1067/mai.2002.124770; Hirata N, 1999, J ALLERGY CLIN IMMUN, V103, P944, DOI 10.1016/S0091-6749(99)70443-4; Hofstra CL, 2003, J PHARMACOL EXP THER, V305, P1212, DOI 10.1124/jpet.102.046581; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; Inoue I, 1996, P NATL ACAD SCI USA, V93, P13316, DOI 10.1073/pnas.93.23.13316; Jinquan Tan, 1995, Journal of Allergy and Clinical Immunology, V95, P979, DOI 10.1016/S0091-6749(95)70098-6; Jutel M, 2001, NATURE, V413, P420, DOI 10.1038/35096564; Kayasuga R, 2002, INT IMMUNOPHARMACOL, V2, P745, DOI 10.1016/S1567-5769(02)00010-3; Koarai A, 2003, AM J RESP CRIT CARE, V167, P758, DOI 10.1164/rccm.200206-619OC; Kozma GT, 2003, INT IMMUNOL, V15, P963, DOI 10.1093/intimm/dxg095; Krouwels FH, 1998, AM J RESP CELL MOL, V18, P721; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lagier B, 1997, CLIN EXP IMMUNOL, V108, P545, DOI 10.1046/j.1365-2249.1997.3791276.x; Lee JS, 1997, J FOOD DRUG ANAL, V5, P185; Ling P, 2004, BRIT J PHARMACOL, V142, P161, DOI 10.1038/sj.bjp.0705729; Ma RLZ, 2002, SCIENCE, V297, P620, DOI 10.1126/science.1072810; MARRACK P, 1983, J EXP MED, V158, P1077, DOI 10.1084/jem.158.4.1077; Matsubara M, 2005, BIOCHEM PHARMACOL, V69, P433, DOI 10.1016/j.bcp.2004.10.006; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Nakane H, 2004, INFLAMM RES, V53, P324, DOI 10.1007/s00011-004-1264-2; Nori M, 2003, CLIN EXP ALLERGY, V33, P1544, DOI 10.1046/j.1365-2222.2003.01701.x; OKADA C, 1994, INT ARCH ALLERGY IMM, V103, P384; Papi A, 2001, J ALLERGY CLIN IMMUN, V108, P221, DOI 10.1067/mai.2001.116861; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; SCHMIDT J, 1994, AGENTS ACTIONS, V42, P81, DOI 10.1007/BF01983469; Schroeder JT, 2001, CLIN EXP ALLERGY, V31, P1369, DOI 10.1046/j.1365-2222.2001.01130.x; Seto Y, 2003, J IMMUNOL, V170, P1077; Sirois J, 2000, J IMMUNOL, V164, P2964; Smits Agnis, 1999, Agricultural and Forest Entomology, V1, P19, DOI 10.1046/j.1461-9563.1999.00004.x; Takahashi H, 2003, CLIN EXP IMMUNOL, V133, P22, DOI 10.1046/j.1365-2249.2003.02182.x; Tamaoki J, 1997, J ALLERGY CLIN IMMUN, V99, P233, DOI 10.1016/S0091-6749(97)70102-7; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Togias Alkis, 2003, Journal of Allergy and Clinical Immunology, V112, pS60, DOI 10.1016/S0091-6749(03)01878-5; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; WHITE MV, 1990, J ALLERGY CLIN IMMUN, V86, P599, DOI 10.1016/S0091-6749(05)80223-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang M, 2001, AM J RESP CELL MOL, V25, P522	57	74	79	0	3	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	JUN	2006	116	6					1624	1632		10.1172/JCI26150		9	Medicine, Research & Experimental	Research & Experimental Medicine	048XL	WOS:000237979700024	16680192	
J	Kim, JL; Elfman, L; Mi, Y; Johansson, M; Smedje, G; Norback, D				Kim, JL; Elfman, L; Mi, Y; Johansson, M; Smedje, G; Norback, D			Current asthma and respiratory symptoms among pupils in relation to dietary factors and allergens in the school environment	INDOOR AIR			English	Article						asthma; cat allergen (Fel d 1); dietary factors; dog allergen (Can f 1); horse allergen (Equ cx); school environment	CHILDHOOD ASTHMA; CAT ALLERGEN; SWEDISH SCHOOLCHILDREN; ATOPIC SENSITIZATION; FISH CONSUMPTION; HEALTH-SURVEY; YOUNG-ADULTS; RISK-FACTORS; AIR-QUALITY; NEW-ZEALAND	The aim was to study asthma and allergy in relation to diet and the school environment. Pupils (5-14 years) in eight schools received a questionnaire, 1014 participated (68%). Settled dust was collected on ALK-filters and analyzed for allergens from cat (Fel d 1), dog (Can f 1), horse (Equ cx), house dust mites (Der p 1, Der f 1), and cockroach (Bla g 1) by ELISA. In total, 6.8% reported cat allergy, 4.8% dog allergy, 7.7% doctor's diagnosed asthma and 5.9% current asthma, and 7.8% reported wheeze. Current asthma was less common among those consuming more fresh milk (P < 0.05) and fish (P < 0.01). Poly-unsaturated fatty acids was associated with more wheeze (P < 0.05), olive oil was associated with less doctors' diagnosed asthma (P < 0.05). Totally, 74% of the classrooms had mean CO2 < 1000 ppm. The median concentration per gram dust was 860 ng/g Fel d 1, 750 ng/g Can f 1 and 954 U/g Equ cx. Horse allergen was associated with more wheeze (P < 0.05), daytime breathlessness (P < 0.05), current asthma (P < 0.05) and atopic sensitization (P < 0.05). Dog allergen was associated with wheeze (P < 0.05) and daytime breathlessness (P < 0.05). The associations between allergens and respiratory symptoms were more pronounced among those consuming margarine, not consuming butter, and with a low intake of milk. In conclusion, cat, dog and horse allergens in schools could be a risk factor for asthma and atopic sensitization, and dietary factors may interact with the allergen exposure.	Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden; Univ Hosp, SE-75185 Uppsala, Sweden	Kim, JL (reprint author), Uppsala Univ, Dept Med Sci, SE-75185 Uppsala, Sweden.	jeong-lim.kim@medsci.uu.se		Norback, Dan/0000-0002-5174-6668			ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; *AFS, 1993, VENT AIR QUAL, P5; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Amr S, 2003, ANN ALLERG ASTHMA IM, V90, P34; ANDERSSON K, 1981, SCAND J WORK ENV HEA, V7, P282; ANUNDI H, 1992, P 41 NORD M WORK ENV; Apter AJ, 2003, J ALLERGY CLIN IMMUN, V111, P938, DOI 10.1067/mai.2003.1417; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bolte G, 2001, AM J RESP CRIT CARE, V163, P277; BRABACK L, 1994, CLIN EXP ALLERGY, V24, P826, DOI 10.1111/j.1365-2222.1994.tb01805.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; Denny SI, 2003, CURR ALLERGY ASTHM R, V3, P130, DOI 10.1007/s11882-003-0025-6; Dotterud LK, 1995, J EUR ACAD DERMATOL, V5, P240, DOI 10.1111/j.1468-3083.1995.tb00112.x; Elfman L., 2000, P HLTH BUILDINGS, V1, P341; Emenius G, 2001, ALLERGY, V56, P771, DOI 10.1034/j.1398-9995.2001.056008771.x; FARCHI S, 2003, EUR RESPIR J, V22, P719; Fluge O, 1998, EUR RESPIR J, V12, P336, DOI 10.1183/09031936.98.12020336; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Fox A, 2003, J ENVIRON MONITOR, V5, P246, DOI 10.1039/b212341j; GEBSKI V, 1992, SPIDA USERS MANUAL V; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; Helm Ricki M, 2004, Curr Opin Allergy Clin Immunol, V4, P125, DOI 10.1097/00130832-200404000-00010; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Karlsson AS, 2002, ALLERGY, V57, P164, DOI 10.1034/j.1398-9995.2002.1s3297.x; Kiviranta H, 2003, CHEMOSPHERE, V50, P1201, DOI 10.1016/S0045-6535(02)00481-2; LARSSON L, 1995, THORAX, V50, P260, DOI 10.1136/thx.50.3.260; Lee SC, 2000, CHEMOSPHERE, V41, P109, DOI 10.1016/S0045-6535(99)00396-3; Meyer HW, 2004, INDOOR AIR, V14, P65, DOI 10.1046/j.1600-0668.2003.00213.x; MI YH, 2002, P 9 INT C IND AIR QU, V2, P449; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; PEAT JK, 1992, EUR RESPIR J, V5, P921; Perzanowski MS, 1999, J ALLERGY CLIN IMMUN, V103, P1018, DOI 10.1016/S0091-6749(99)70173-9; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; Ritz BR, 2002, ALLERGY, V57, P357, DOI 10.1034/j.1398-9995.2002.1s3404.x; Romieu I, 2001, EPIDEMIOL REV, V23, P268; RONNMARK E, 1998, RESP MED, V92, P316; Ruotsalainen R., 1995, P INDOOR AIR QUALITY, P489; Schneider D, 2001, ARCH ENVIRON HEALTH, V56, P103; SIMOPOULOS AP, 2002, J AM COLL NUTR, V6, P495; Simpson Angela, 2003, Curr Opin Allergy Clin Immunol, V3, P7, DOI 10.1097/00130832-200302000-00002; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2000, ARCH ENVIRON HEALTH, V55, P18; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; Soutar A, 1997, THORAX, V52, P166; Strachan DP, 1996, BRIT MED J, V312, P1195; Takemura Y, 2002, PREV MED, V34, P221, DOI 10.1006/pmed.2001.0978; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33; VONMUTIUS E, 2000, J ALLERGY CLIN IMMUN, V105, P1; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Woods RK, 2003, AM J CLIN NUTR, V78, P414	61	74	76	1	2	BLACKWELL MUNKSGAARD	FREDERIKSBERG C	1 ROSENORNS ALLE, DK-1970 FREDERIKSBERG C, DENMARK	0905-6947			INDOOR AIR	Indoor Air	JUN	2005	15	3					170	182		10.1111/j.1600-0668.2005.00334.x		13	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	921GF	WOS:000228751500004	15865617	
J	Hollingsworth, JW; Chen, BJ; Brass, DM; Berman, K; Gunn, MD; Cook, DN; Schwartz, DA				Hollingsworth, JW; Chen, BJ; Brass, DM; Berman, K; Gunn, MD; Cook, DN; Schwartz, DA			The critical role of hematopoietic cells in lipopolysaccharide-induced airway inflammation	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						innate immunity; lipopolysaccharide; macrophage; neutrophil; toll-like receptor	TOLL-LIKE RECEPTOR-4; ACUTE LUNG INJURY; NEUTROPHIL RECRUITMENT; BRONCHIAL REACTIVITY; ENDOTOXIN EXPOSURE; INHALED ENDOTOXIN; EPITHELIAL-CELLS; MICE; ASTHMA; TLR4	Rapid and selective recruitment of neutrophils into the airspace in response to LPS facilitates the clearance of bacterial pathogens. However, neutrophil infiltration can also participate in the development and progression of environmental airway disease. Previous data have revealed that Toll-like receptor 4 (tlr4) is required for neutrophil recruitment to the lung after either inhaled or systemically administrated LPS from Escherichia coli. Although many cell types express tlr4, endothelial cell expression of tlr4 is specifically required to sequester neutrophils in the lung in response to systemic endotoxin. To identify the cell types requiring trl4 expression for neutrophil recruitment after inhaled LPS, we generated chimeric mice separately expressing tlr4 on either hematopoietic cells or on structural lung cells. Neutrophil recruitment into the airspace was completely restored in tlr4-deficient mice receiving wild-type bone marrow. By contrast, wild-type animals receiving tlr4-deficient marrow had dramatically reduced neutrophil recruitment. Moreover, adoptive transfer of wild-type alveolar macrophages also restored the ability of tlr4-deficient recipient mice to recruit neutrophils to the lung. These data demonstrate the critical role of hematopoietic cells and alveolar macrophages in initiating LPS-induced neutrophil recruitment from the vascular space to the airspace.	Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Cellular Therapy, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA; Vet Adm Med Ctr, Durham, NC USA	Hollingsworth, JW (reprint author), Duke Univ, Med Ctr, Div Pulm Allergy & Crit Care Med, Box 3221, Durham, NC 27710 USA.	holli017@mc.duke.edu		Gunn, Michael/0000-0003-4602-0667	NHLBI NIH HHS [HL74538]; NIAID NIH HHS [AI-51445]; NIEHS NIH HHS [ES7031, ES011961, ES07498, ES11375, ES12496, ES12717]		Alves-Rosa F, 2003, BRIT J HAEMATOL, V121, P130, DOI 10.1046/j.1365-2141.2003.04259.x; Andonegui G, 2003, J CLIN INVEST, V111, P1011, DOI 10.1172/JCI200316510; Arbour NC, 2000, NAT GENET, V25, P187; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904; BERG JT, 1993, J APPL PHYSIOL, V74, P2812; Brass DM, 2003, AM J PHYSIOL-LUNG C, V285, pL755, DOI 10.1152/ajplung.00001.2003; Deetz DC, 1997, AM J RESP CRIT CARE, V155, P254; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98; Foster WM, 2000, J APPL PHYSIOL, V89, P1804; Fournier P, 2002, CANCER RES, V62, P6538; Gibbs DF, 1999, AM J RESP CELL MOL, V20, P1145; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Heikkila P, 2003, J SURG RES, V111, P45, DOI 10.1016/S0022-4804(03)00000-0; Heikkila P, 2002, ANTI-CANCER DRUG, V13, P245, DOI 10.1097/00001813-200203000-00006; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; Hoshino K, 1999, J IMMUNOL, V162, P3749; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kline JN, 2000, J APPL PHYSIOL, V89, P1172; Koay MA, 2002, AM J RESP CELL MOL, V26, P572; Lee W L, 2001, Curr Opin Crit Care, V7, P1, DOI 10.1097/00075198-200102000-00001; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Malcolm KC, 2003, AM J PHYSIOL-LUNG C, V284, pL663, DOI 10.1152/ajplung.00094.2002; Maus UA, 2003, J IMMUNOL, V170, P3273; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Miyamoto M, 2003, J IMMUNOL, V170, P4665; MOTUSKY H, 1995, INTUITIVE BIOSTATIST; Poltorak A, 1998, BLOOD CELL MOL DIS, V24, P340, DOI 10.1006/bcmd.1998.0201; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quinton LJ, 2004, AM J PHYSIOL-LUNG C, V286, pL465, DOI 10.1152/ajplung.00153.2003; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Savov JD, 2002, AM J PHYSIOL-LUNG C, V283, pL952, DOI 10.1152/ajplung.00420.2001; Schilling JD, 2003, P NATL ACAD SCI USA, V100, P4203, DOI 10.1073/pnas.0736473100; Schwartz DA, 1994, AM J PHYSIOL, V267, P609; Schwarze J., 1996, Journal of Allergy and Clinical Immunology, V97, P293, DOI 10.1016/S0091-6749(96)80662-2; SHA Q, 2004, AM J RESP CELL MOL B, V10, P10; Skerrett SJ, 2004, AM J PHYSIOL-LUNG C, V287, pL143, DOI 10.1152/ajplung.00030.2004; Slegers TPAM, 2003, GRAEF ARCH CLIN EXP, V241, P432, DOI 10.1007/s00417-003-0665-1; SUR S, 1993, AM REV RESPIR DIS, V148, P713; Taube C, 2003, CHEST, V123, p410S, DOI 10.1378/chest.123.3_suppl.410S; Weighardt H, 2004, EUR J IMMUNOL, V34, P558, DOI 10.1002/eji.200324714; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Wohlford-Lenane CL, 1999, AM J PHYSIOL-LUNG C, V276, pL736; Zarember KA, 2002, J IMMUNOL, V168, P554	50	74	74	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 15	2005	171	8					806	813		10.1164/rccm.200407.953OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	916VP	WOS:000228414800003	15618460	
S	Kleeberger, SR; Peden, D				Kleeberger, SR; Peden, D			Gene-environment interactions in asthma and other respiratory diseases	ANNUAL REVIEW OF MEDICINE	Annual Review of Medicine		English	Review; Book Chapter						pollutant; allergen; polymorphism; linkage analysis	OBSTRUCTIVE PULMONARY-DISEASE; NECROSIS-FACTOR-ALPHA; S-TRANSFERASE M1; CHRONIC BERYLLIUM DISEASE; DIESEL EXHAUST PARTICLES; CLASS-II ALLELES; CHILDHOOD LUNG-FUNCTION; HOUSE-DUST ENDOTOXIN; LINKAGE ANALYSIS; AIR-POLLUTION	It is generally agreed that many lung diseases such as asthma and chronic obstructive pulmonary disease (COPD) have polygenic inheritance, and that the association of a specific genotype or genotypes with the disease is likely to vary between populations. Furthermore, it is recognized that the etiology of many lung diseases involves a complex interplay between genetic background and exposure to multiple environmental stimuli, and understanding the mechanisms through which genes and environment interact represents a major challenge for pulmonary researchers. We discuss experimental approaches and challenges that must be overcome to identify disease genes for asthma, COPD and chronic bronchitis, and occupational lung diseases. In particular, common polymorphisms in CD14, glutathione S-transferase, and tumor necrosis factor alpha have been found to be important in gene-environment interaction and asthma pathogenesis. An understanding of gene-environment interactions in complex lung diseases is essential to the development of new strategies for lung disease prevention and treatment.	Natl Inst Environm Hlth Sci, Lab Resp Biol, Environm Genet Grp, NIH, Res Triangle Pk, NC 27709 USA; Ctr Environm Med Asthma & Lung Biol, Div Immunol & Infect Dis, Dept Pediat, Chapel Hill, NC 27599 USA	Kleeberger, SR (reprint author), Natl Inst Environm Hlth Sci, Lab Resp Biol, Environm Genet Grp, NIH, Res Triangle Pk, NC 27709 USA.	kleeber1@niehs.nih.gov			NHLBI NIH HHS [HL6262404, R01-HL66559]		Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363; Barnes PJ, 2002, NAT REV DRUG DISCOV, V1, P437, DOI 10.1038/nrd820; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Bastain TM, 2003, CLIN IMMUNOL, V109, P130, DOI 10.1016/S1521-6616(03)00168-2; Bergamaschi E, 2001, AM J RESP CRIT CARE, V163, P1426; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; Borm P J, 2001, Eur Respir J Suppl, V32, p127s; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cho HY, 2004, FASEB J, V18, P1258; Cho HY, 2002, AM J RESP CELL MOL, V26, P175; Cho HY, 2002, AM J RESP CELL MOL, V26, P42; Chrysofakis G, 2004, CHEST, V125, P71, DOI 10.1378/chest.125.1.71; Corbett EL, 2002, AM J RESP CRIT CARE, V165, P690, DOI 10.1164/rccm.2010050; David GL, 2003, AM J RESP CRIT CARE, V168, P1199, DOI 10.1164/rccm.200305-684OC; Di Somma C, 2003, HUM IMMUNOL, V64, P359, DOI 10.1016/S0198-8859(02)00819-4; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Djukanovic R, 1997, AM J RESP CRIT CARE, V155, P826; Dowson LJ, 2001, AM J RESP CRIT CARE, V164, P1805; Fagerstrom K, 2002, Monaldi Arch Chest Dis, V57, P281; Finkelman FD, 2004, J IMMUNOL, V172, P3808; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P710, DOI 10.1164/rccm.2112065; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P346, DOI 10.1164/rccm.2111048; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Gong MN, 2004, CHEST, V125, P203, DOI 10.1378/chest.125.1.203; Grandjean P., 1991, ECOGENETICS GENETIC; Hirano K, 2001, EUR RESPIR J, V18, P748, DOI 10.1183/09031936.01.00102101; Ho LI, 2001, CHEST, V120, P1493, DOI 10.1378/chest.120.5.1493; Home C, 2000, EUR RESPIR J, V15, P911; Huang SL, 1997, AM J RESP CRIT CARE, V156, P1436; Hull J, 1998, THORAX, V53, P1018; Ishii T, 2001, EUR RESPIR J, V18, P753, DOI 10.1183/09031936.01.00094401; Ishii T, 2000, EUR J CLIN INVEST, V30, P543; Jagirdar J, 1996, AM J RESP CRIT CARE, V154, P1076; JAKAB GJ, 1995, ENVIRON HEALTH PERSP, V103, P77, DOI 10.2307/3432454; Kanazawa H, 2000, AM J RESP CRIT CARE, V162, P1235; KHOURY MJ, 1990, EPIDEMIOL REV, V12, P41; KHOURY MJ, 1988, AM J HUM GENET, V42, P89; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lombardi G, 2001, J IMMUNOL, V166, P3549; Maier LA, 1999, AM J RESP CRIT CARE, V159, P1342; Maliarik MJ, 2000, AM J RESP CELL MOL, V22, P672; Mannino DM., 2002, CHEST, V121, p121S, DOI DOI 10.1159/000087670; Mapp CE, 1997, AM J RESP CRIT CARE, V156, pS139; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Marshall RP, 2002, AM J RESP CRIT CARE, V166, P646, DOI 10.1164/rccm.2108086; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McCanlies EC, 2003, AM J EPIDEMIOL, V157, P388, DOI 10.1093/aje/kwg001; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Moss M, 2000, CRIT CARE MED, V28, P2187; Mozzato-Chamay N, 2001, GENES IMMUN, V2, P153, DOI 10.1038/sj.gene.6363753; Nadif R, 2003, J MED GENET, V40, P96, DOI 10.1136/jmg.40.2.96; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2000, CLIN CHEST MED, V21, P245, DOI 10.1016/S0272-5231(05)70264-1; Ohtsuka Y, 2000, AM J RESP CELL MOL, V22, P574; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Peden DB, 2002, TOXICOLOGY, V181, P323, DOI 10.1016/S0300-483X(02)00301-3; Peden DB, 2003, MIDDLETONS ALLERGY P, P515; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; PLATTSMILLS TAE, 1990, ALLERGY PROC, V11, P269, DOI 10.2500/108854190778879729; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Postma DS, 1999, CLIN EXP ALLERGY, V29, P2; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; RICHELDI L, 1993, SCIENCE, V262, P242, DOI 10.1126/science.8105536; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Romieu I, 2004, THORAX, V59, P8; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROSENSTREICH DL, 1997, NEW ENGL J MED, V336, P1382; Rumold R, 2001, J IMMUNOL, V167, P4765; Saetta M, 2003, SARCOIDOSIS VASC DIF, V20, P28; Sakao S, 2001, AM J RESP CRIT CARE, V163, P420; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749; Sandford AJ, 2001, AM J RESP CRIT CARE, V163, P469; Schurmann M, 2001, AM J RESP CRIT CARE, V164, P840; SCHWARTZ J, 1994, ENVIRON RES, V64, P26, DOI 10.1006/enrs.1994.1004; Sengler Claudia, 2002, Respir Res, V3, P7, DOI 10.1186/rr179; Silverman EK, 2002, AM J HUM GENET, V70, P1229, DOI 10.1086/340316; Silverman EK, 2002, HUM MOL GENET, V11, P623, DOI 10.1093/hmg/11.6.623; Tang GJ, 2000, CRIT CARE MED, V28, P2733, DOI 10.1097/00003246-200008000-00008; Teramoto S, 2001, CHEST, V119, P315, DOI 10.1378/chest.119.1.315; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; Ueki A, 2001, IMMUNOBIOLOGY, V204, P458, DOI 10.1078/0171-2985-00055; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Vercelli D, 2002, J ALLERGY CLIN IMMUN, V109, P14, DOI 10.1067/mai.2002.121015; WEINMANN GG, 1995, AM J RESP CRIT CARE, V151, P33; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; Yucesoy B, 2001, TOXICOL APPL PHARM, V172, P75, DOI 10.1006/taap.2001.9124; Zhai RH, 1998, AM J IND MED, V34, P318, DOI 10.1002/(SICI)1097-0274(199810)34:4<318::AID-AJIM4>3.0.CO;2-O; Zhou W, 2002, CANCER RES, V62, P1377; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655; ZIEGLERHEITBROCK HWL, 1993, IMMUNOL TODAY, V14, P121, DOI 10.1016/0167-5699(93)90212-4	107	74	79	1	5	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0066-4219		978-0-8243-0556-7	ANNU REV MED	Annu. Rev. Med.		2005	56						383	400		10.1146/annurev/med.56.062904.144908		18	Medicine, General & Internal	General & Internal Medicine	904ND	WOS:000227504100021	15660518	
J	Hong, SJ; Lee, MS; Sohn, MH; Shim, JY; Han, YS; Park, KS; Ahn, YM; Son, BK; Lee, HB				Hong, SJ; Lee, MS; Sohn, MH; Shim, JY; Han, YS; Park, KS; Ahn, YM; Son, BK; Lee, HB		Korean ISAAC Study Grp	Self-reported prevalence and risk factors of asthma among Korean adolescents: 5-year follow-up study, 1995-2000	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						adolescent; asthma; middle-school children; prevalence; risk factor	BODY-MASS INDEX; CHILDHOOD ASTHMA; CHILDREN; SYMPTOMS; TRENDS; ISAAC; HOSPITALIZATION; QUESTIONNAIRE; ASSOCIATION; SMOKING	Objectives The International Study of Asthma and Allergies in Childhood (ISAAC) questionnaires have shown that the prevalence of childhood asthma is increasing worldwide. Although Asian countries used to have lower prevalence rates of allergic disease than Western countries, this prevalence is increasing in several Asian countries. To determine whether the prevalence of childhood asthma is changing in Korean adolescents, we compared findings from nationwide cross-sectional surveys in 1995 and 2000 on populations of middle-school children using the Korean version of the ISAAC questionnaire. Methods We developed Korean versions of the ISAAC written (WQ) and video (AVQ) questionnaires for allergic diseases. In 1995, the enrolled population consisted of 15 481 children, ages 12-15, and encompassing all three grades in middle school, selected from 34 schools across the nation; the response rate was 97.3%. In 2000, 15 894 children were selected from 31 of the same schools, and the response rate was 96.4%. The SAS system version 8.0 was utilized for all statistical analyses. Results The WQ showed that the lifetime and 12-month prevalence of wheeze did not change from 1995 to 2000. While the 12-month prevalence rates of sleep disturbed by wheezing and night cough increased, the rates of severe attack of wheezing and exercise-induced wheeze did not change, over this period of time. The lifetime prevalence of asthma diagnosis, however, increased significantly, from 2.7% in 1995 to 5.3% in 2000, as did the 12-month prevalence of asthma treatment, from 1.0% in 1995 to 1.9% in 2000. The AVQ also showed increases in the lifetime and 12-month prevalence rates of wheeze at rest, exercise-induced wheeze, nocturnal wheeze, nocturnal cough, and severe wheeze over this period of time. These were especially because of significant increases in the Provincial cities of Korea. Interestingly, the 12-month prevalence of wheeze was consistently high in Cheju with low air pollution indices, whereas this rate was low in Ulsan and Ansan with very high air pollution indices. Risk factor analysis showed that body mass index (BMI), passive smoking, and living with a dog or cat, but not air pollution, were associated with higher risk of wheeze. Conclusions In the 5-year period from 1995 to 2000, the prevalence of asthma symptoms has increased in Korean adolescents, much of it because of increases in Provincial Centers. BMI, passive smoking, and living with a dog or cat are important risk factors. Environmental factors other than air pollution may be associated with increases in asthma, especially in Provincial Centers.	Univ Ulsan, Dept Pediat, Ulsan 680749, South Korea; Univ Ulsan, Dept Prevent Med, Ulsan 680749, South Korea; Yonsei Univ, Dept Pediat, Seoul 120749, South Korea; Sungkyunkwan Univ, Dept Pediat, Seoul, South Korea; Chungbuk Univ, Dept Pediat, Cheongju, South Korea; Presbyterian Med Ctr, Dept Pediat, Philadelphia, PA USA; Kangnam Gen Hosp, Dept Pediat, Seoul, South Korea; Inha Univ, Dept Pediat, Inchon, South Korea; Hanyang Univ, Dept Pediat, Seoul, South Korea; Korean Acad Pediat Allergy & Resp Dis, Seoul, South Korea	Lee, HB (reprint author), Hanyang Univ, Dept Pediat, Coll Med, 17 Haengdang Dong, Seoul 133792, South Korea.	hablee@hanyang.ac.kr					AKINBAMI LJ, 2002, PEDIATRICS, V100, P315; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Beasley R., 2000, J ALLERGY CLIN IMMUN, V105, P466; Crane J., 1996, European Respiratory Journal Supplement, V9, p230S; CRATER DD, 2001, PEDIATRICS, V108, P1; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Evans R, 1987, CHEST S, V91, P65; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Guerra S, 2002, CHEST, V122, P1256, DOI 10.1378/chest.122.4.1256; HALFON N, 1986, AM J PUBLIC HEALTH, V76, P1308, DOI 10.2105/AJPH.76.11.1308; Hong SJ, 2003, J KOREAN MED SCI, V18, P48; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Jarvis D, 2000, ASTHMA RHINITIS, P17; Kim YY, 1997, CLIN EXP ALLERGY, V27, P761, DOI 10.1046/j.1365-2222.1997.710839.x; LEE HR, 1983, KOREAN MED J, V26, P254; Lee SI, 2001, J KOREAN MED SCI, V16, P155; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; MORKJAROENPONG V, 2002, J ALLERGY CLIN IMMUN, V100, P147; Pearce N, 2000, THORAX, V55, P352, DOI 10.1136/thorax.55.5.352; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Senthilselvan A, 1998, CHEST, V114, P388, DOI 10.1378/chest.114.2.388; Shin TS, 1990, KOREAN J ALLERGY, V10, P201; SLY RM, 1984, ANN ALLERGY, V53, P20; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079; von Kries R, 1999, BRIT MED J, V319, P147; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WOOLCOCK AJ, 1991, EUR RESPIR REV, V1, P243	33	74	76	0	0	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2004	34	10					1556	1562		10.1111/j.1365-2222.2004.02084.x		7	Allergy; Immunology	Allergy; Immunology	861RB	WOS:000224434800008	15479270	
J	Heine, G; Schnuch, A; Uter, W; Worm, M				Heine, G; Schnuch, A; Uter, W; Worm, M			Frequency of contact allergy in German children and adolescents patch tested between 1995 and 2002: results from the Information Network of Departments of Dermatology and the German Contact Dermatitis Research Group	CONTACT DERMATITIS			English	Article						allergic contact dermatitis; children; clinical epidemiology; contact allergy; patch testing	SENSITIZATION; THIMEROSAL; IVDK; EPIDEMIOLOGY; ADULTS; DKG; SEX; AGE	Allergic contact dermatitis (ACD) affects approximately 7% of the general population. To evaluate the frequency of ACD in children, we analysed patch test results collected by the Information Network of Departments of Dermatology between 1995 and 2002. Data of 285 children (6-12 year) and 2175 adolescent patients (13-18 year) were analysed to determine the frequency of sensitization to the 30 most common contact allergens, adjusting for age and sex. As control group, we defined adult patients (60-66 year, n = 7904). The top allergens in children were thimerosal, gentamicin sulphate, nickel-II-sulphate, ammoniated mercury, cobalt-II-chloride, fragrance mix, bufexamac, Compositae mix, propylene glycol and turpentine. The overall proportion of sensitized patients according to the patch test results was 52.6% in the children group compared to 49.7% in the adolescent group. These findings were similar in the adult group at 52.2%. The detailed analysis regarding sex, occupation, atopy, site of eczema and age showed distinct patterns in each group indicating age-specific exposures. Atopy-related diseases were more common in children compared to adults. On the basis of the data of this study, the relationship between atopy and the risk of development of ACD, at least in children, needs further investigation.	Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, D-10117 Berlin, Germany; Univ Gottingen, Informat Network, Dept Dermatol, D-3400 Gottingen, Germany; Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Erlangen, Germany	Worm, M (reprint author), Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Campus Charite Mitte,Schumannstr 20-21, D-10117 Berlin, Germany.	margitta.worm@charite.de	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Uter, Wolfgang/0000-0002-4498-3710			ABERER W, 1991, CONTACT DERMATITIS, V24, P6, DOI 10.1111/j.1600-0536.1991.tb01621.x; Akhavan A, 2003, CLIN DERMATOL, V21, P158, DOI 10.1016/S0738-081X(02)00372-3; Brasch J, 1997, CONTACT DERMATITIS, V37, P286, DOI 10.1111/j.1600-0536.1997.tb02466.x; Brasch J, 1998, HAUTARZT, V49, P184, DOI 10.1007/s001050050725; Brehler R, 1995, DTSCH DERMATOLOGE, V43, P688; Bruckner A L, 2002, Skin Therapy Lett, V7, P3; Kay AB, 2001, NEW ENGL J MED, V344, P30; KWANGSUKSTITH C, 1995, CONTACT DERMATITIS, V33, P289, DOI 10.1111/j.1600-0536.1995.tb02041.x; LOCHNER J, 2001, DERMATOL BERUF UMWEL, V49, P228; MAZIAK M, 2003, ALLERGY, V58, P572; Niggemann B, 2003, ALLERGY, V58, P707, DOI 10.1034/j.1398-9995.2003.00219.x; Patrizi A, 1999, CONTACT DERMATITIS, V40, P94, DOI 10.1111/j.1600-0536.1999.tb05998.x; Schafer T, 2001, ALLERGY, V56, P1192, DOI 10.1034/j.1398-9995.2001.00086.x; Schnuch A, 1997, CONTACT DERMATITIS, V37, P200, DOI 10.1111/j.1600-0536.1997.tb02435.x; Schnuch A, 2002, CONTACT DERMATITIS, V47, P32, DOI 10.1034/j.1600-0536.2002.470107.x; Schnuch A, 2001, HAUTARZT, V52, P864, DOI 10.1007/s001050170048; Schnuch A, 2003, CONTACT DERMATITIS, V49, P107, DOI 10.1111/j.0105-1873.2003.0128f.x; Die Schnuch A., 1994, MANUALE ALLERGOLOGIC, V16.2, P1; Schnuch A, 1997, DIAGNOSTISCHE VERFAH, P99; SCHULZ KH, 1990, MANUALE ALLERGOLOGIC, V4, P2; Shah M, 1997, J AM ACAD DERMATOL, V37, P964, DOI 10.1016/S0190-9622(97)70073-2; Spiewak R, 2002, ALLERGOLOGIE, V25, P374; Suneja T, 2001, J AM ACAD DERMATOL, V45, P23, DOI 10.1067/mjd.2001.113473; Vender R B, 2002, Skin Therapy Lett, V7, P4; Wesley NO, 2003, FOOD CHEM TOXICOL, V41, P857, DOI 10.1016/S0278-6915(03)00036-X; Weston William L., 1997, Current Opinion in Pediatrics, V9, P372, DOI 10.1097/00008480-199708000-00012; Weston WL, 2000, PEDIATR CLIN N AM, V47, P897, DOI 10.1016/S0031-3955(05)70247-9; Westphal GA, 2003, CONTACT DERMATITIS, V48, P93, DOI 10.1034/j.1600-0536.2003.480208.x; Wohrl S, 2003, PEDIATR DERMATOL, V20, P119, DOI 10.1046/j.1525-1470.2003.20204.x	29	74	75	1	2	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	SEP	2004	51	3					111	117		10.1111/j.0105-1873.2004.00411.x		7	Allergy; Dermatology	Allergy; Dermatology	861QZ	WOS:000224434600002	15479199	
J	Adhikari, A; Sen, MM; Gupta-Bhattacharya, S; Chanda, S				Adhikari, A; Sen, MM; Gupta-Bhattacharya, S; Chanda, S			Air-borne viable, non-viable, and allergenic fungi in a rural agricultural area of India: a 2-year study at five outdoor sampling stations	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						airborne fungi; bioaerosol; allergy; rural area; aerobiology; air microbiology	DIFFERENT SITES; AIRBORNE; SPORES; SYMPTOMS; ASTHMA; MICROORGANISMS; ENVIRONMENTS; ENUMERATION; DUSTS	The information on airborne allergenic fungal flora in rural agricultural areas is largely lacking. Adequate information is not available to the bioaerosol researchers regarding the choice of single versus multiple sampling stations for the monitoring of both viable and non-viable airborne fungi. There is no long-term study estimating the ratios of viable and non-viable fungi in the air and earlier studies did not focus on the fractions of airborne allergenic fungi with respect to the total airborne fungal load. To fill these knowledge gaps, volumetric paired assessments of airborne viable and non-viable fungi were performed in five outdoor sampling stations during two consecutive years in a rural agricultural area of India. Samples were collected at 10-day intervals by the Burkard Personal Slide Sampler and the Andersen Two-Stage Viable Sampler. The data on the concentrations of total and individual fungal types from five stations and 2 different years were analyzed and compared by statistical methods. The allergenicity of the prevalent airborne viable fungi was estimated by the skin-prick tests of > 100 rural allergy patients using the antigenic fungal extracts from isolates collected with the Andersen sampler. The ranges of total fungal spore concentration were 82-2365 spores per cubic meter of air (spores/m(3)) in the first sampling year and 156-2022 spores/m(3) in the second sampling year. The concentration ranges of viable fungi were 72-1796 colony-forming units per cubic meter of air (CFU/m(3)) in the first sampling year and 155-1256 CFU/m(3) in the second sampling year. No statistically significant difference was observed between the total spore data of the 2 years, however, the data between five stations showed a significant difference (P<0.0001). No statistically significant difference existed between stations and years with respect to the concentration of viable fungi. When the data of individual allergenic fungal concentrations were compared between stations and years, no statistically significant difference was observed in all cases except for Aspergillus japonicus and Rhizopus nigricans, which showed significant difference in case of stations and years, respectively. The ratios between the total fungal spores collected by the Burkard sampler and the viable fungi collected by the Andersen sampler from all sampling stations ranged between 0.29 and 7.61. The antigenic extracts of eight prevalent viable airborne fungi (A. flavus, A. japonicus, A. fumigatus, Alternaria alternata, Cladosporium cladosporioides, Curvularia pallescens, Fusarium roseum, and R. nigricans) demonstrated > 60% positive reactions in the skin prick test. These selected allergenic fungi collectively represented 31.7-63.2% of the total airborne viable fungi in different stations. The study concluded that: (i) a rich fungal airspora existed in the rural study area, (ii) to achieve representative information on the total airborne fungal spores of an area, the monitoring in multiple sampling stations is preferable over a single sampling station; for viable fungi, however, one station can be considered, (iii) the percentage of airborne fungal viability is higher in rural agricultural areas, and (iv) approximately 52% of the viable airborne fungi in the rural study area were allergenic. (C) 2003 Elsevier B.V. All rights reserved.	Univ S Florida, Dept Internal Med, Div Allergy & Immunol, Joy McCann Culverhouse Airway Dis Ctr, Tampa, FL 33612 USA; Ctr Study Man & Environm, Kolkata 700091, W Bengal, India; Bose Inst, Dept Bot, Div Palynol & Environm Biol, Kolkata 700009, W Bengal, India	Adhikari, A (reprint author), Univ Cincinnati, Ctr Hlth Related Aerosol Studies, Dept Environm Hlth, 3223 Eden Ave,POB 67056, Cincinnati, OH 45267 USA.	adhikaa@email.uc.edu					ABDELHAFEZ SII, 1990, J BASIC MICROB, V30, P467, DOI 10.1002/jobm.3620300702; Aizenberg V, 2000, AIHAJ, V61, P855, DOI 10.1202/0002-8894(2000)061<0855:POAOCB>2.0.CO;2; Al-Suwaine A. S., 1999, AEROBIOLOGIA, V15, P121, DOI 10.1023/A:1007595400116; ANDERSEN AA, 1958, J BACTERIOL, V76, P471; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; BROWN HM, 1978, CLIN ALLERGY, V8, P599, DOI 10.1111/j.1365-2222.1978.tb01514.x; Chakraborty P, 2001, ANN AGR ENV MED, V8, P123; Chakraborty S., 2000, AEROBIOLOGIA, V16, P211, DOI 10.1023/A:1007644300296; Crook B, 1997, J AEROSOL SCI, V28, P417, DOI 10.1016/S0021-8502(96)00444-2; Cvetnic Z, 1997, ATMOS ENVIRON, V31, P491, DOI 10.1016/S1352-2310(96)00158-6; DiGiorgio C, 1996, ATMOS ENVIRON, V30, P155, DOI 10.1016/1352-2310(95)00143-M; EDUARD W, 1990, AM IND HYG ASSOC J, V51, P427; Emberim J., 1995, AEROBIOLOGIA, V11, P253, DOI 10.1007/bf02447205; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; GUPTA SK, 1993, ASIAN PAC J ALLERGY, V11, P19; HAMILTON ED, 1957, ACTA ALLERGOL, V13, P143; Hamilton RG, 1997, METHODS, V13, P53, DOI 10.1006/meth.1997.0495; Henriquez V. I., 2001, AEROBIOLOGIA, V17, P137, DOI 10.1023/A:1010833101583; Herrero B., 1996, AEROBIOLOGIA, V12, P27, DOI 10.1007/BF02248120; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; Kakde U.B., 2001, AEROBIOLOGIA, V17, P177, DOI DOI 10.1023/A:1010849522964; KARLSSON K, 1989, SCAND J WORK ENV HEA, V15, P353; Khandelwal A., 2001, AEROBIOLOGIA, V17, P77, DOI 10.1023/A:1007614903730; KRAMER CL, 1984, COMP AIRSPORA CONCEN, V23, P117; Lacey J., 1995, P407; LACEY ME, 1962, J GEN MICROBIOL, V29, P485; Latge J. P., 1991, The fungal spore and disease initiation in plants and animals., P379; LONG DL, 1972, J ALLERGY CLIN IMMUN, V49, P255, DOI 10.1016/0091-6749(72)90093-0; Macher J.M., 1997, APPL OCCUP ENV HYG, V12, P730, DOI 10.1080/1047322X.1997.10387755; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; Mitakakis TZ, 2001, GRANA, V40, P230, DOI 10.1080/001731301317223268; Mitakakis TZ, 2001, AEROBIOLOGIA, V17, P171, DOI [10.1023/A:1011028412526, DOI 10.1023/A:1011028412526]; Nayak B. K., 1998, AEROBIOLOGIA, V14, P59, DOI 10.1007/BF02694596; PALMAS F, 1990, GRANA, V29, P87; Rosas I, 1997, AEROBIOLOGIA, V13, P23, DOI 10.1007/BF02694787; Spiewak R, 2001, ANN AGR ENV MED, V8, P255; STRACHAN DP, 1988, BRIT MED J, V297, P1223; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P709; Terr AI, 1994, BASIC CLIN IMMUNOL, P314; VITTAL BPR, 1988, INDIA ANN ALLERGY, V60, P99; Waisel Y., 1997, AEROBIOLOGIA, V13, P281, DOI 10.1007/BF02694496; Wathes C. M., 1995, P547	44	74	84	3	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697	1879-1026		SCI TOTAL ENVIRON	Sci. Total Environ.	JUN 29	2004	326	1-3					123	141		10.1016/j.scitotenv.2003.12.007		19	Environmental Sciences	Environmental Sciences & Ecology	824YL	WOS:000221723000010	15142771	
J	Taube, C; Wei, XD; Swasey, CH; Joetham, A; Zarini, S; Lively, T; Takeda, K; Loader, J; Miyahara, N; Kodama, T; Shultz, LD; Donaldson, DD; Hamelmann, EH; Dakhama, A; Gelfand, EW				Taube, C; Wei, XD; Swasey, CH; Joetham, A; Zarini, S; Lively, T; Takeda, K; Loader, J; Miyahara, N; Kodama, T; Shultz, LD; Donaldson, DD; Hamelmann, EH; Dakhama, A; Gelfand, EW			Mast cells, Fc epsilon RI, and IL-13 are required for development of airway hyperresponsiveness after aerosolized allergen exposure in the absence of adjuvant	JOURNAL OF IMMUNOLOGY			English	Article							N-TERMINAL KINASE; C-KIT LIGAND; DEFICIENT MICE; PULMONARY EOSINOPHILIA; BRONCHIAL RESPONSIVENESS; CYTOKINE PRODUCTION; PHASE-SEPARATION; IGE PRODUCTION; TRITON X-114; ASTHMA MODEL	In certain models of allergic airway disease, mast cells facilitate the development of inflammation and airway hyper-responsiveness (AHR). To define the role of the high affinity IgE receptor (Fcis an element ofRI) in the development of AHR, mice with a disruption of the a subunit of the high affinity IgE receptor (Fcis an element ofRI(-/-)) were exposed on 10 consecutive days to nebulized OVA. Forty-eight hours after the last nebulization, airway responsiveness was monitored by the contractile response of tracheal smooth muscle to electrical field. stimulation (EFS). After the 10-day OVA challenge protocol, wild-type mice demonstrated increased responsiveness to EFS, whereas similarly challenged Fcis an element ofRI(-/-) mice showed a low response to EFS, similar to nonexposed animals. Further, allergen-challenged Fcis an element ofRI(-/-) mice showed less airway inflammation, goblet cell hyperplasia, and lower levels of IL-13 in lung homogenates compared with the controls. IL-13-deficient mice failed to develop an increased response to EFS or goblet cell hyperplasia after the 10-day OVA challenge. We transferred bone marrow-derived mast cells from wild-type mice to Fcis an element ofRI(-/-) mice 1 day before initiating the challenge protocol. After the 10-day OVA challenge, recipient Fcis an element ofRI(-/-) mice demonstrated EFS-induced responses similar to those of challenged wild-type mice. Transferred mast cells could be detected in tracheal preparations. These results show that Fcis an element ofRI is important for the development of AHR after an aerosolized allergen sensitization protocol and that this effect is mediated through Fcis an element ofRI on mast cells and production of IL-13 in the lung.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Wyeth Inst, Cambridge, MA 02140 USA; Jackson Lab, Bar Harbor, ME 04609 USA	Gelfand, EW (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [HL36577, HL61005]; NIAID NIH HHS [AI42246, AI30389]		AIDA Y, 1990, J IMMUNOL METHODS, V132, P191, DOI 10.1016/0022-1759(90)90029-U; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOULET LP, 1983, J ALLERGY CLIN IMMUN, V71, P399, DOI 10.1016/0091-6749(83)90069-6; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Dombrowicz D, 1997, J CLIN INVEST, V99, P915, DOI 10.1172/JCI119256; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; Donaldson DD, 1998, J IMMUNOL, V161, P2317; DVORAK AM, 1994, AM J PATHOL, V144, P160; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; GRUNSTEIN M, 2002, AM J PHYSIOL, V281, pL520; Haczku A, 2000, AM J RESP CRIT CARE, V161, P952; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Hoshino T, 1999, J Immunol, V162, P51; Ishizuka T, 1999, J IMMUNOL, V162, P2087; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kobayashi T, 2000, J IMMUNOL, V164, P3855; Kraneveld AD, 2002, J IMMUNOL, V169, P2044; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; LARSEN GL, 1992, J CLIN INVEST, V89, P747, DOI 10.1172/JCI115651; Larsen GL, 1994, AM J PHYSIOL, V266, P263; Marietta EV, 1996, EUR J IMMUNOL, V26, P49, DOI 10.1002/eji.1830260108; Masuda A, 2002, J IMMUNOL, V169, P3801; Mayr SI, 2002, J IMMUNOL, V169, P2061; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033; Nagai H, 1996, CLIN EXP ALLERGY, V26, P642, DOI 10.1111/j.1365-2222.1996.tb00590.x; NAKANO T, 1985, J EXP MED, V162, P1025, DOI 10.1084/jem.162.3.1025; NOGAMI M, 1990, AM REV RESPIR DIS, V141, P1289; Ogawa K, 1999, INT ARCH ALLERGY IMM, V120, P15, DOI 10.1159/000053586; OTSU K, 1987, J EXP MED, V165, P615, DOI 10.1084/jem.165.3.615; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; QURESHI R, 1988, J IMMUNOL, V141, P2090; RENZ H, 1994, J IMMUNOL, V152, P351; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; ROTTEM M, 1993, J IMMUNOL, V151, P4950; Schaefer BC, 2001, CELL IMMUNOL, V214, P110, DOI 10.1006/cimm.2001.1895; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stassen M, 2001, J IMMUNOL, V166, P4391; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2002, J IMMUNOL, V169, P6482; Tomkinson A, 2001, J IMMUNOL, V166, P5792; Walter DM, 2001, J IMMUNOL, V167, P4668; WERSHIL BK, 1987, J IMMUNOL, V139, P2605; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	61	74	76	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	MAY 15	2004	172	10					6398	6406				9	Immunology	Immunology	818XD	WOS:000221276900076	15128831	
J	Prescott, SL; Calder, PC				Prescott, SL; Calder, PC			N-3 polyunsaturated fatty acids and allergic disease	CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE			English	Review						n-3 polyunsaturated fatty acids; fish oil; docosahexaenoic acid; arachidonic acid; allergic disease; atopy; eicosapentaenoic acid; asthma	TUMOR-NECROSIS-FACTOR; HOUSE-DUST MITE; TYPE-2 CYTOKINE PRODUCTION; FISH-OIL SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; T-HELPER TYPE-1; BRONCHIAL-ASTHMA; DIETARY SUPPLEMENTATION; ATOPIC-DERMATITIS; CHILDHOOD ASTHMA	Purpose of review With escalating rates of allergic disease, it is vital to explore novel causal pathways. This review examines the evidence for a potential role of changing dietary intake of omega-3 polyunsaturated fatty acids in the development, treatment and prevention of allergic diseases. Recent findings Although it is difficult to determine the contribution of altered (decreased) dietary intake of omega-3 polyunsaturated fatty acids to the recent rise in the incidence of allergic disease, there is growing evidence that these nutrients have antiinflammatory properties and may modulate immune responses. These fatty acids have few side effects, and may be of some benefit in established allergic diseases (such as asthma and atopic dermatitis), although these effects are not strong. Because of this limited efficacy in established disease, the focus has shifted to the potential benefits of these immune modulators in earlier life for disease prevention. Two recent preliminary reports in infants suggest that dietary omega-3 polyunsaturated fatty acid supplements in pregnancy or in the early postnatal period could have immunomodulatory properties and associated clinical effects, although more studies are now needed. Novel synthetic polyunsaturated fatty acids with more potent and selective antiinflammatory effects may also provide safe therapeutic and preventive strategies in the future. Summary Dietary factors are important but still under-explored candidates in the search for environmental strategies to reduce the enormous impact of allergic diseases in modernized societies. There is an ongoing need for further research into the role of omega-3 polyunsaturated fatty acids in allergic disease, particularly in early life before atopy is established.	Univ Western Australia, Sch Paediat & Child Hlth, Perth, WA 6009, Australia; Univ Southampton, Inst Human Nutr, Southampton, Hants, England	Prescott, SL (reprint author), Princess Margaret Hosp, Sch Pediat & Child Hlth, POB D184, Perth, WA 6001, Australia.	susanp@ichr.uwa.edu.au	Calder, Philip/E-9739-2013; Prescott, Susan/H-5665-2014	Calder, Philip/0000-0002-6038-710X; 			ARM J P, 1988, Thorax, V43, P84, DOI 10.1136/thx.43.2.84; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; BERTHJONES J, 1993, LANCET, V341, P1557, DOI 10.1016/0140-6736(93)90697-F; BETZ M, 1991, J IMMUNOL, V146, P108; BJORNEBOE A, 1987, BRIT J DERMATOL, V117, P463, DOI 10.1111/j.1365-2133.1987.tb04926.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Broughton KS, 1997, AM J CLIN NUTR, V65, P1011; Calder PC, 2003, LIPIDS, V38, P343, DOI 10.1007/s11745-003-1068-y; Calder PC, 2002, BRIT J NUTR, V87, pS31, DOI [10.1079/BJN2001455, 10.1079/BJN2001482]; Calder PC, 2001, LIPIDS, V36, P1007, DOI 10.1007/s11745-001-0812-7; Caughey GE, 1996, AM J CLIN NUTR, V63, P116; Costabile M, 2001, J IMMUNOL, V167, P3980; Curtis CL, 2002, ARTHRITIS RHEUM, V46, P1544, DOI 10.1002/art.10305; Curtis CL, 2000, J BIOL CHEM, V275, P721, DOI 10.1074/jbc.275.2.721; DRY J, 1991, INT ARCH ALLER A IMM, V95, P156; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; DUNSTAN J, IN PRESS EUR J CLIN; DUNSTAN J, IN PRESS CLIN IMMUNO; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; ENDRES S, 1989, NEW ENGL J MED, V320, P265, DOI 10.1056/NEJM198902023200501; Foitzik T, 2002, JPEN-PARENTER ENTER, V26, P351, DOI 10.1177/0148607102026006351; Gewirtz AT, 2002, ADV EXP MED BIOL, V507, P229; GIBNEY MJ, 1993, EUR J CLIN NUTR, V47, P255; Gorelova Zh. Yu., 1999, Voprosy Pitaniya, V68, P31; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Harizi H, 2003, J IMMUNOL, V170, P139; Hashimoto N, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P634; HILKENS CMU, 1995, EUR J IMMUNOL, V25, P59, DOI 10.1002/eji.1830250112; Hodge L, 1996, MED J AUSTRALIA, V164, P137; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; Hughes DA, 1996, BIOCHEM SOC T, V24, pS389; Hughes DA, 1997, CLIN EXP IMMUNOL, V110, P516, DOI 10.1046/j.1365-2249.1997.4351455.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kalinski P, 1997, J IMMUNOL, V159, P28; Kankaanpaa P, 1999, ANN MED, V31, P282, DOI 10.3109/07853899908995891; KATAMURA K, 1995, INT ARCH ALLERGY IMM, V106, P101; Kimura M, 2002, INT ARCH ALLERGY IMM, V127, P191, DOI 10.1159/000053863; KIRSCH CM, 1988, ARCH INTERN MED, V148, P1023; LEE TH, 1985, NEW ENGL J MED, V312, P1217, DOI 10.1056/NEJM198505093121903; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Lewis S, 1998, LANCET, V351, P1220, DOI 10.1016/S0140-6736(98)22017-4; Machura E, 1996, Pediatr Pol, V71, P97; Masuev KA, 1997, TERAPEVT ARKH, V69, P31; Masuev KA, 1997, TERAPEVT ARKH, V69, P33; Mayser P, 2002, JPEN-PARENTER ENTER, V26, P151, DOI 10.1177/0148607102026003151; MCDONALD CF, 1990, EFFECT FISH OIL DERI; MEYDANI SN, 1991, J NUTR, V121, P547; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Miles EA, 2003, CLIN EXP ALLERGY, V33, P624, DOI 10.1046/j.1365-2222.2003.01637.x; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; Ng TW, 2002, ALLERGY, V57, P207, DOI 10.1034/j.1398-9995.2002.1o3369.x; Obata T, 1999, CLIN EXP ALLERGY, V29, P1129; Okamoto M, 2000, INTERNAL MED, V39, P107, DOI 10.2169/internalmedicine.39.107; Petursdottir DH, 2002, J NUTR, V132, P3740; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott Susan L, 2003, Curr Opin Allergy Clin Immunol, V3, P125, DOI 10.1097/00130832-200304000-00006; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; ROPER RL, 1995, J IMMUNOL, V154, P162; Sakakibara H, 1995, Nihon Kyobu Shikkan Gakkai Zasshi, V33, P395; Sanderson P, 1997, J LEUKOCYTE BIOL, V62, P771; Simopoulos AP, 1999, AM J CLIN NUTR, V70, p560S; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; SPERLING RI, 1993, J CLIN INVEST, V91, P651, DOI 10.1172/JCI116245; STENIUSAARNIALA B, 1989, ANN ALLERGY, V62, P534; Surette ME, 2003, CLIN THER, V25, P972, DOI 10.1016/S0149-2918(03)80117-0; Takemura Y, 2002, PREV MED, V34, P221, DOI 10.1006/pmed.2001.0978; THIEN FCK, 1993, AM REV RESPIR DIS, V147, P1138; Vachier I, 2002, BIOCHEM BIOPH RES CO, V290, P219, DOI 10.1006/bbrc.2001.6155; Villani F, 1998, RESPIRATION, V65, P265, DOI 10.1159/000029274; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; WOODS RK, 2003, DIETARY MARINE FATTY; ZEIGER R, 1995, J ALLERGY CLIN IMMUN, V96, P1179	76	74	78	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1363-1950			CURR OPIN CLIN NUTR	Curr. Opin. Clin. Nutr. Metab. Care	MAR	2004	7	2					123	129		10.1097/00075197-200403000-00004		7	Endocrinology & Metabolism; Nutrition & Dietetics	Endocrinology & Metabolism; Nutrition & Dietetics	804MT	WOS:000220303500003	15075701	
J	Lee, SL; Wong, W; Lau, YL				Lee, SL; Wong, W; Lau, YL			Increasing prevalence of allergic rhinitis but not asthma among children in Hong Kong from 1995 to 2001 (Phase 3 International Study of Asthma and Allergies in Childhood)	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						trend prevalence; asthma; allergic rhinitis; eczema; children; Hong Kong	ATOPIC ECZEMA; WORLDWIDE VARIATIONS; CRITICAL-APPRAISAL; SCHOOL-CHILDREN; BIRTH COHORT; RISK-FACTORS; SYMPTOMS; SENSITIZATION; ISAAC; RHINOCONJUNCTIVITIS	There is a worldwide belief that the prevalence of asthma and other allergic diseases is increasing but the measures used in many studies are susceptible to systematic errors. We examined the trend of asthma, allergic rhinitis and eczema prevalence in school children aged 6-7 years in Hong Kong from 1995 to 2001 using standardized ISAAC methodology. There were 4448 and 3618 children participating in 2001 and 1995, respectively. The prevalence of life-time rhinitis (42.4% vs. 38.9%, p < 0.01), current rhinitis (37.4% vs. 35.1%, p < 0.03), current rhinoconjunctivitis (17.2 vs. 13.6 %, p < 0.01) and life-time eczema (30.7% vs. 28.1%, p = 0.01) increased significantly. There was no significant change in prevalence of life-time asthma, life-time wheeze and current wheeze albeit a significant increase in severe asthma symptoms. We investigated a number of potential risk factors including sex, family history of atopy, sibship size, birth weight, respiratory tract infections, pet ownership and exposure to tobacco smoke. However, the increases in prevalence of rhinitis and eczema could not be entirely explained by the change of prevalence of these risk factors. The odds ratio OR for the study period remained significantly associated with current rhinitis (OR 1.31, 95% confidence intervals CI 1.17-1.46), current rhinoconjunctivitis (OR 1.63, 95% Cl 1.41-1.87) and life-time eczema (OR 1.30, 95% CI 1.16-1.45) after adjustment for these confounding variables using logistic regression model. Further study is warranted to elucidate the factors contributing to the observable change in the prevalence of rhinitis in our population.	Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China	Lau, YL (reprint author), Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Hong Kong, Peoples R China.	lauylung@hkucc.hku.hk	Lau, Yu Lung/C-4322-2009				Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Chan HH, 2001, CLIN EXP ALLERGY, V31, P903, DOI 10.1046/j.1365-2222.2001.01089.x; Corne JM, 2001, AM J RESP CRIT CARE, V163, P1101; del Giudice MM, 2002, ALLERGY, V57, P169, DOI 10.1034/j.1398-9995.2002.1s3252.x; *ENV PROT DEP HONG, AIR QUAL HONG KONG 2; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261; Lau YL, 1998, J PAEDIATR CHILD H, V34, P47, DOI 10.1046/j.1440-1754.1998.00217.x; Magnus P, 1997, BRIT MED J, V314, P1795; Mitchell EA, 2001, EUR J EPIDEMIOL, V17, P667, DOI 10.1023/A:1015500508261; PEAT JK, 1994, BRIT MED J, V308, P1591; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; Schafer T, 1999, J ALLERGY CLIN IMMUN, V104, P1280, DOI 10.1016/S0091-6749(99)70025-4; Soto-Quiros ME, 2002, PEDIATR ALLERGY IMMU, V13, P342, DOI 10.1034/j.1399-3038.2002.02035.x; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; Ulrik CS, 2000, ALLERGY, V55, P1019, DOI 10.1034/j.1398-9995.2000.00630.x; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Wieringa MH, 2001, CLIN EXP ALLERGY, V31, P1553, DOI 10.1046/j.1365-2222.2001.01188.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Zhao TB, 2000, J PAEDIATR CHILD H, V36, P128, DOI 10.1046/j.1440-1754.2000.00457.x	24	74	83	0	0	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	FEB	2004	15	1					72	78		10.1046/j.0905-6157.2003.00109.x		7	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	803ST	WOS:000220251500010	14998385	
J	Delfino, RJ; Gong, H; Linn, WS; Hu, Y; Pellizzari, ED				Delfino, RJ; Gong, H; Linn, WS; Hu, Y; Pellizzari, ED			Respiratory symptoms and peak expiratory flow in children with asthma in relation to volatile organic compounds in exhaled breath and ambient air	JOURNAL OF EXPOSURE ANALYSIS AND ENVIRONMENTAL EPIDEMIOLOGY			English	Article						epidemiology; panel study; exposure biomarkers; hazardous air pollutants; air pollution	ANTIINFLAMMATORY MEDICATION USE; POLLUTANTS; POLLUTION; EXPOSURE; SEVERITY; INDOOR; MODELS; EXACERBATIONS; ASSOCIATIONS; FORMALDEHYDE	Indoor volatile organic compounds (VOCs) have been associated with asthma, but there is little epidemiologic work on ambient exposures, and no data on relationships between respiratory health and exhaled breath VOCs, which is a biomarker of VOC exposure. We recruited 26 Hispanic children with mild asthma in a Los Angeles community with high VOC levels near major freeways and trucking routes. Two dropped out, three had invalid peak expiratory flow (PEF) or breath VOC data, leaving 21. Children filled out symptom diaries and performed PEF maneuvers daily, November 1999 January 2000. We aimed to collect breath VOC samples on asthma episode and baseline symptom-free days, but six subjects only gave samples on symptom-free days. We analyzed 106 breath samples by GC-MS. Eight VOCs were quanti. able in >75% of breath samples (benzene, methylene chloride, styrene, tetrachloroethylene, toluene, m,p-xylene, o-xylene, and p-dichlorobenzene). Generalized estimating equation and mixed linear regression models for VOC exposure-response relationships controlled for temperature and respiratory infections. We found marginally positive associations between bothersome or more severe asthma symptoms and same day breath concentrations of benzene [odds ratio ( OR) 2.03, 95% confidence interval (CI) 0.80, 5.11] but not other breath VOCs. Ambient petroleum-related VOCs measured on the same person-days as breath VOCs showed notably stronger associations with symptoms, including toluene, m,p-xylene, o-xylene, and benzene (OR 5.93, 95% CI 1.64, 21.4). On breath sample days, symptoms were also associated with 1-h ambient NO2, OR 8.13 (1.52, 43.4), and SO2, OR 2.36 (1.16, 4.81). Consistent inverse relationships were found between evening PEF and the same ambient VOCs, NO2, and SO2. There were no associations with O-3. Given the high traffic density of the region, stronger associations for ambient than for breath VOCs suggest that ambient VOC measurements were better markers for daily exposure to combustion-related compounds thought to be causally related to acute asthma. Alternatively, the low sample size of symptom responses (5-21 responses per 108 breath samples) may have led to the nonsignificant results for breath VOCs.	Univ Calif Irvine, Coll Med, Dept Med, Div Epidemiol, Irvine, CA 92697 USA; Univ So Calif, Keck Sch Med, Dept Prevent Med, Downey, CA 90242 USA; Los Amigos Res & Educ Inst, Environm Hlth Serv, Downey, CA 90242 USA; Res Triangle Inst, Analyt & Chem Sci & Exposure Anal Res Program, Res Triangle Pk, NC 27709 USA	Delfino, RJ (reprint author), Univ Calif Irvine, Coll Med, Dept Med, Div Epidemiol, 224 Irvine Hall, Irvine, CA 92697 USA.				NIEHS NIH HHS [1P01 ES09581-01]		American Thoracic Society Workshop, 1999, AM J RESP CRIT CARE, V160, P1778; Bernstein IL, 1999, ASTHMA WORKPLACE; Buchdahl R, 2000, OCCUP ENVIRON MED, V57, P86, DOI 10.1136/oem.57.2.86; ChanYeung M, 1996, AM J RESP CRIT CARE, V154, P889; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; ENRIGHT PL, 1995, CHEST, V107, P657, DOI 10.1378/chest.107.3.657; GORDON SM, 1992, J EXPO ANAL ENV EP S, V1, P41; Hagen JA, 2000, EPIDEMIOLOGY, V11, P136, DOI 10.1097/00001648-200003000-00009; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; JENNRICH RI, 1986, BIOMETRICS, V42, P805, DOI 10.2307/2530695; KOREN HS, 1992, ARCH ENVIRON HEALTH, V47, P39; LEIKAUF GD, 1995, ENVIRON HEALTH PERSP, V103, P253, DOI 10.2307/3432382; Levine M, 2001, PHARMACOTHERAPY, V21, P405, DOI 10.1592/phco.21.5.405.34503; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LINDSTROM MJ, 1988, J AM STAT ASSOC, V83, P1014; Littell R., 1996, SAS SYSTEM MIXED MOD; MAGGI CA, 1995, PHYSIOL REV, V75, P277; MEGGS WJ, 1993, ENVIRON HEALTH PERSP, V101, P234, DOI 10.2307/3431548; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; *NAT HEART LUNG BL, 1997, PUBL NHLBI; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; PELLIZZARI ED, 1992, J EXPO ANAL ENV EPID, V2, P341; RAYMER JH, 1990, J ANAL TOXICOL, V14, P337; [Anonymous], 2000, MULT AIR TOX EXP STU; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; SAS Institute, 2000, SAS ONL VERS 8; Thompson AJ, 2001, ARCH ENVIRON HEALTH, V56, P234; WALLACE L, 1993, J EXPO ANAL ENV EPID, V3, P75; Wallace L, 1991, J Expo Anal Environ Epidemiol, V1, P157; Wallace L, 1996, ENVIRON HEALTH PERSP, V104, P861, DOI 10.2307/3433003; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115	40	74	77	4	30	NATURE PUBLISHING GROUP	NEW YORK	345 PARK AVE SOUTH, NEW YORK, NY 10010-1707 USA	1053-4245			J EXPO ANAL ENV EPID	J. Expo. Anal. Environ. Epidemiol.	SEP	2003	13	5					348	363		10.1038/sj.jea.7500287		16	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	721UD	WOS:000185335400003	12973363	
J	Leung, TF; Tang, NLS; Sung, YM; Li, AM; Wong, GWK; Chan, IHS; Lam, CWK				Leung, TF; Tang, NLS; Sung, YM; Li, AM; Wong, GWK; Chan, IHS; Lam, CWK			The C-159T polymorphism in the CD14 promoter is associated with serum total IgE concentration in atopic Chinese children	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						atopy; CD14; Chinese; immunoglobulin E	IMMUNOGLOBULIN-E; ASTHMA; GENE; ENDOTOXIN; CHILDHOOD; EXPOSURE; LINKAGE; MARKERS; SUSCEPTIBILITY; PREVALENCE	Activation of macrophages through CD14 by microbes is crucial in inducing immunity by type 1 T helper cells. A C-to-T polymorphism at position -159 of CD14 was associated with serum total IgE level in Caucasians but not in Japanese subjects. The objective of this study is to determine whether this polymorphic marker is associated with atopy and asthma phenotypes in Chinese children. Restriction fragment length polymorphism was used to characterize CD14/-159 genotypes. Microparticle immunoassay was used to measure serum total IgE level; fluorescent enzyme immunoassay was performed to measure serum concentrations of specific IgE to aeroallergens; and enzyme-linked immunosorbent assay was used to measure serum levels of soluble CD14 (sCD14). Lung function in asthmatics was assessed by spirometry. Two hundred and fifty-eight patients and 92 control children were recruited. Their mean serum total IgE concentrations were 331 and 74 kIU/l, respectively (p < 0.0001). Atopy, defined as the presence of at least one allergen-specific IgE in serum, was found in 220 (85%) patients and in 41 (45%) controls (p < 0.0001). Serum sCD14 levels were significantly associated with CD14/-159 genotypes (p = 0.004). Atopic subjects with CC genotype in CD14/-159 had the highest serum total IgE levels compared with CT and TT genotypes, with the respective mean values being 661, 427 and 380 kIU/l (p = 0.015). Similarly, a higher proportion of subjects with CC genotype had increased serum total IgE concentration (p = 0.039). This polymorphic marker was not associated with asthma or aeroallergen sensitization in our cohort. Our results suggest that the C-159T of CD14 was associated with serum total IgE concentration in atopic Chinese children.	Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, Shatin, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Prince Wales Hosp, Dept Chem Pathol, Shatin, Hong Kong, Peoples R China	Leung, TF (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Dept Paediat, 6-F Clin Sci Bldg, Shatin, Hong Kong, Peoples R China.			Tang, Nelson/0000-0002-3607-5819			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; Gao PS, 1999, CLIN GENET, V56, P164; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GOYERT SM, 1988, SCIENCE, V239, P497, DOI 10.1126/science.2448876; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; LAM KK, 1983, BRIT J DIS CHEST, V77, P390, DOI 10.1016/S0007-0971(83)80076-X; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; SENGLER C, 2002, J ALLERGY CLIN IMMUN, V109, pA670; Shek LPC, 2001, ALLERGY, V56, P749, DOI 10.1034/j.1398-9995.2001.056008749.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; Vercelli D, 2002, J ALLERGY CLIN IMMUN, V109, P14, DOI 10.1067/mai.2002.121015; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P1225, DOI 10.1046/j.1365-2222.2001.01140.x; ZAMBELLIWEINER A, 2002, J ALLERGY CLIN IMMUN, V109, P672	30	74	74	0	3	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	AUG	2003	14	4					255	260		10.1034/j.1399-3038.2003.00048.x		6	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	711HB	WOS:000184732600003	12911501	
J	Beard, J; Sladden, T; Morgan, G; Berry, G; Brooks, L; McMichael, A				Beard, J; Sladden, T; Morgan, G; Berry, G; Brooks, L; McMichael, A			Health impacts of pesticide exposure in a cohort of outdoor workers	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; cohort study; DDT; diabetes; leukemia; neoplasms; pancreatic cancer; pesticides	PANCREATIC-CANCER; ORGANOCHLORINE COMPOUNDS; DIABETES-MELLITUS; RISK-FACTORS; MORTALITY; SERUM; LEUKEMIA; MEN; DDT	We compared mortality of 1,999 outdoor staff working as part of an insecticide application program during 1935-1996 with that of 1,984 outdoor workers not occupationally exposed to insecticides, and with the Australian population. Surviving subjects also completed a morbidity questionnaire. Mortality was significantly higher in both exposed and control subjects compared with the Australian population. The major cause was mortality from smoking-related diseases. Mortality was also significantly increased in exposed subjects for a number of conditions that do not appear to be the result of smoking patterns. Compared with the general Australian population, mortality over the total study period was increased for asthma [standardized mortality ratio (SMR) = 3.45; 95% confidence interval (CI), 1.39-7.10] and for diabetes (SMR = 3.57; 95% CI, 1.16-8.32 for subjects working < 5 years). Mortality from pancreatic cancer was more frequent in subjects exposed to 1,1,1-trichloro-2,2-bis (p-chlorophenyl) ethane (SMR = 5.27; 95% CI, 1.09-15.40 for subjects working < 3 years). Compared with the control population, mortality from leukemia was increased in subjects working with more modern chemicals (standardized incidence ratio = 20.90; 95% CI, 1.54-284.41 for myeloid leukemia in the highest exposure group). There was also an increase in self-reported chronic illness and asthma, and lower neuropsychologic functioning scores among surviving exposed subjects when compared with controls. Diabetes was reported more commonly by subjects reporting occupational use of herbicides. These findings lend weight to other studies suggesting an association between adverse health effects and exposure to pesticides.	Univ Sydney, No Rivers Univ Dept Rural Hlth, Lismore, NSW 2480, Australia; So Cross Univ, So Cross Inst Hlth Res, Lismore, NSW, Australia; Univ Sydney, Sch Biostat, Lismore, NSW 2480, Australia; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 2601, Australia	Beard, J (reprint author), Univ Sydney, No Rivers Univ Dept Rural Hlth, POB 498, Lismore, NSW 2480, Australia.		Beard, John/K-9621-2014	Beard, John/0000-0002-8557-0242			ALBERGHINI V, 1991, Medicina del Lavoro, V82, P18; Au WW, 1999, ENVIRON HEALTH PERSP, V107, P501; AXELSON O, 1988, AM J IND MED, V13, P105, DOI 10.1002/ajim.4700130107; BLAIR A, 1988, AM J IND MED, V13, P3; Blondell J M, 1990, Med Lav, V81, P524; Breslow N. E., 1987, IARC SCI PUBL, V82; BROWN LM, 1990, CANCER RES, V50, P6585; Calle EE, 1998, CANCER CAUSE CONTROL, V9, P403, DOI 10.1023/A:1008819701485; Cameron G R, 1945, Br Med J, V1, P865; Cantor KP, 1999, AM J IND MED, V36, P239, DOI 10.1002/(SICI)1097-0274(199908)36:2<239::AID-AJIM3>3.3.CO;2-M; Checkoway H, 1989, RES METHODS OCCUPATI, V13; GARABRANT DH, 1992, J NATL CANCER I, V84, P764, DOI 10.1093/jnci/84.10.764; HANSEN ES, 1992, AM J IND MED, V21, P651, DOI 10.1002/ajim.4700210505; HAYES WJ, 1956, JAMA-J AM MED ASSOC, V162, P890; Henriksen GL, 1997, EPIDEMIOLOGY, V8, P252, DOI 10.1097/00001648-199705000-00005; Hoppin JA, 2000, CANCER EPIDEM BIOMAR, V9, P199; International Agency for Research on Cancer (IARC) Pentachlorophenol, 1991, IARC MON EV CARC RIS, V53; Kristensen P, 1996, SCAND J WORK ENV HEA, V22, P14; Krzystyniak K, 1995, ENVIRON HEALTH PERSP, V103, P17, DOI 10.2307/3432719; LAWS ER, 1967, ARCH ENVIRON HEALTH, V15, P766; MORGAN DP, 1980, ARCH ENVIRON CON TOX, V9, P349; MUSSALORAUHAMAA H, 1991, SCI TOTAL ENVIRON, V103, P159, DOI 10.1016/0048-9697(91)90142-2; PEARCE N, 1987, AM J EPIDEMIOL, V125, P1085; PEARCE N, 1990, AM J IND MED, V18, P133, DOI 10.1002/ajim.4700180206; Porta M, 1999, LANCET, V354, P2125, DOI 10.1016/S0140-6736(99)04232-4; RAMADA F, 1987, ECOTOXICOLOGY; RATCLIFFE DA, 1970, J APPL ECOL, V7, P67, DOI 10.2307/2401613; Shobha T R, 2000, J Assoc Physicians India, V48, P1197; Takahashi H, 2000, J TOXICOL-CLIN TOXIC, V38, P153, DOI 10.1081/CLT-100100931; THOMAS TL, 1985, INT J EPIDEMIOL, V14, P432, DOI 10.1093/ije/14.3.432; VENZON DJ, 1988, APPL STAT-J ROY ST C, V37, P87, DOI 10.2307/2347496; VIEL JF, 1993, SOC SCI MED, V37, P771, DOI 10.1016/0277-9536(93)90371-A; WONG O, 1984, BRIT J IND MED, V41, P15	33	74	78	1	13	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2003	111	5					724	730		10.1289/ehp.5885		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	677CB	WOS:000182788400030	12727601	
J	Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Burge, HA; Friedman, W; Zeldin, DC				Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Burge, HA; Friedman, W; Zeldin, DC			House dust mite allergen in US beds: Results from the first National Survey of Lead and Allergens in Housing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	97th International Conference of the American-Thoracic-Society	MAY 18-23, 2001	SAN FRANCISCO, CALIFORNIA	Amer Thorac Soc		house dust mite allergen; indoor allergens; surveys; epidemiology	REDUCING RELATIVE-HUMIDITY; DER-P-I; INDOOR ALLERGENS; RISK FACTOR; AVOIDANCE MEASURES; SEASONAL-VARIATION; ASTHMATIC-PATIENTS; CHILDHOOD ASTHMA; GRASS-POLLEN; EXPOSURE	Background: Although exposure to house dust mite allergen is a major risk factor for allergic sensitization and asthma, nationwide estimates of dust mite allergen levels in US homes have not been reported. Objective: The purpose of this study was to estimate the prevalence of dust mite allergen in beds of US homes and to identify predictors of dust mite allergen concentration. Methods: Data were obtained from the first National Survey of Lead and Allergens in Housing, a cross-sectional survey of 831 permanently occupied noninstitutional housing units that permitted resident children. Dust mite allergen concentration (Der f 1 plus Der p 1) was determined from a dust sample collected from a bed. The percentages of homes with concentrations at or greater than detection, 2.0 mug/g bed dust, and 10.0 mug/g bed dust were estimated. Independent predictors of allergen concentration were assessed with multivariable linear regression. Results: The percentages of US homes with dust mite allergen concentrations at or greater than detection, 2.0 mug/g, and 10.0 mug/g were 84.2% (SE, 1.73), 46.2% (SE, 2.0), and 24.2% (SE, 2.1), respectively. Independent predictors of higher levels were older homes, non-West census regions, single-family homes, no resident children, lower household income, heating sources other than forced air, musty or mildew odor, and higher bedroom humidity. Conclusion: Most US homes have detectable levels of dust mite allergen in a bed. Levels previously associated with allergic sensitization and asthma are common in US bedrooms. Predictors can be used to identify conditions under which homes are more likely to have increased dust mite allergen levels.	NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA; Analyt Sci, Durham, NC USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; US Dept Housing & Urban Dev, Off Healthy Homes & Lead Hazard Control, Washington, DC USA	Zeldin, DC (reprint author), NIEHS, Div Intramural Res, NIH, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.						Adilah N, 1997, NEW ZEAL MED J, V110, P438; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P99, DOI 10.1067/mai.2001.112119; Bellanti JA, 2000, ANN ALLERG ASTHMA IM, V84, P249, DOI 10.1016/S1081-1206(10)62762-7; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; CHAPMAN MD, 1987, J ALLERGY CLIN IMMUN, V80, P184, DOI 10.1016/0091-6749(87)90128-X; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P461; DUSBABEK F, 1975, Folia Parasitologica (Ceske Budejovice), V22, P219; FELDMANMUHSAM B, 1985, J MED ENTOMOL, V22, P663; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; FRIEDMAN FM, 1992, ALLERGY PROC, V13, P259, DOI 10.2500/108854192778817095; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; HART BJ, 1990, CLIN EXP ALLERGY, V20, P203, DOI 10.1111/j.1365-2222.1990.tb02669.x; Hill DJ, 1997, J ALLERGY CLIN IMMUN, V99, P323, DOI 10.1016/S0091-6749(97)70049-6; Hirsch T, 1998, ENVIRON HEALTH PERSP, V106, P659; Korsgaard J, 1998, ALLERGY, V53, P77; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Mihrshahi S, 2002, ALLERGY, V57, P137, DOI 10.1034/j.1398-9995.2002.5720999.x; Nahm DH, 1998, ANN ALLERG ASTHMA IM, V80, P411; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; Pitten FA, 2000, HAUTARZT, V51, P655, DOI 10.1007/s001050051190; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Pope A. M., 1993, INDOOR ALLERGENS ASS; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; *US EPA, 1996, PUBL US EPA; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VANDERHEIDE S, 1994, J ALLERGY CLIN IMMUN, V93, P470, DOI 10.1016/0091-6749(94)90356-5; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527; Vojta PJ, 2001, ENVIRON HEALTH PERSP, V109, P815, DOI 10.2307/3454824; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x	49	74	78	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					408	414		10.1067/mai.2003.16		7	Allergy; Immunology	Allergy; Immunology	644WF	WOS:000180942700028	12589364	
J	Hillert, L; Berglind, N; Arnetz, BB; Bellander, T				Hillert, L; Berglind, N; Arnetz, BB; Bellander, T			Prevalence of self-reported hypersensitivity to electric or magnetic fields in a population-based questionnaire survey	SCANDINAVIAN JOURNAL OF WORK ENVIRONMENT & HEALTH			English	Article						allergy; cross-sectional; hypersensitivity to electricity; symptoms	CHEMICAL ODOR INTOLERANCE; VISUAL-DISPLAY UNITS; SENSITIVITY; SYMPTOMS; INDIVIDUALS	Objectives The prevalence of medically unexplained symptoms attributed to exposure to electromagnetic fields is still largely unknown. Previous studies have investigated reported hypersensitivity to electricity in selected groups recruited from workplaces or outpatient clinics. The aim of this study was to estimate the prevalence of self-reported hypersensitivity to electric or magnetic fields in the general population and to describe characteristics of the group reporting such hypersensitivity with regard to demographics, other complaints, hypersensitivities, and traditional allergies. Methods A cross-sectional questionnaire survey was conducted in 1997 among 15 000 men and women between 19 and 80 years of age in Stockholm County. The response rate was 73%. Results One and a half percent of the respondents reported hypersensitivity to electric or magnetic fields. Prevalence was highest among women and in the 60- to 69-year age group. The hypersensitive group reported all symptoms, allergies, and other types of hypersensitivities included in the survey (as well as being disturbed by various factors in the: home) to a significantly greater extent than the rest of the respondents. No specific symptom profile set off the hypersensitive group from the rest of the respondents. Conclusions The results should be interpreted with caution. But they suggest that there is widespread concern among the general population about risks to health posed by electric and magnetic fields. More research is warranted to explore ill health among people reporting hypersensitivity to electric or magnetic fields.	Norrbacka Karolinska Hosp, Dept Environm Hlth, SE-17176 Stockholm, Sweden; Karolinska Inst, Dept Publ Hlth Sci, Div Occupat Med, S-10521 Stockholm, Sweden; Uppsala Univ, Dept Publ Hlth & Caring Sci, Sect Social Med, Uppsala, Sweden; Karolinska Inst, Inst Environm Med, Div Environm Epidemiol, S-10401 Stockholm, Sweden	Hillert, L (reprint author), Norrbacka Karolinska Hosp, Dept Environm Hlth, SE-17176 Stockholm, Sweden.						Arnetz BB, 1999, SCAND J WORK ENV HEA, V25, P569; Baldwin CM, 1999, TOXICOL IND HEALTH, V15, P403, DOI 10.1177/074823379901500314; Bell IR, 1997, ARCH ENVIRON HEALTH, V52, P6; BERG M, 1992, J OCCUP ENVIRON MED, V34, P698; BERGDAHL J, 1995, ACTA ODONTOL SCAND, V53, P304, DOI 10.3109/00016359509005992; BERGDAHL J, 1994, SCAND J DENT RES, V102, P41; Bergqvist U, 1997, ARBETE HALSA, P19; Davidoff AL, 1996, ARCH ENVIRON HEALTH, V51, P201; Feighery C, 1999, BRIT MED J, V319, P236; Fiedler N, 1997, ENVIRON HEALTH PERSP, V105, P409; FRANSSON K, 1996, ELOVERKANSLIGHET BLA; Furhoff AK, 1998, SCAND J PRIM HEALTH, V16, P247, DOI 10.1080/028134398750003043; Hillert L, 1999, J PSYCHOSOM RES, V47, P429, DOI 10.1016/S0022-3999(99)00048-3; Hillert L, 1997, J PSYCHOSOM RES, V42, P427, DOI 10.1016/S0022-3999(96)00374-1; Kreutzer R, 1999, AM J EPIDEMIOL, V150, P1; Langworth S, 1997, SCAND J WORK ENV HEA, V23, P65; MAYOU R, 1993, PSYCHOTHER PSYCHOSOM, V59, P69; PORTIER CJ, 1998, NIH PUBLICATIONS; Sandstrom M, 1997, J OCCUP ENVIRON MED, V39, P15, DOI 10.1097/00043764-199701000-00006; WANG T, 1994, COST 244 M EL HYP GR, P123; *WHO, 1983, WHO EURO REP STUD, P78	21	74	86	0	9	SCAND J WORK ENV HEALTH	HELSINKI	TOPELIUKSENKATU 41A, SF-00250 HELSINKI, FINLAND	0355-3140			SCAND J WORK ENV HEA	Scand. J. Work Environ. Health	FEB	2002	28	1					33	41				9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	524GU	WOS:000174005500006	11871850	
J	Redlich, CA; Karol, MH				Redlich, CA; Karol, MH			Diisocyanate asthma: clinical aspects and immunopathogenesis	INTERNATIONAL IMMUNOPHARMACOLOGY			English	Review						diisocyanate; asthma; adduct; airway hyperreactivity; immunopathogenesis; thiol reactions; occupational	INDUCED OCCUPATIONAL ASTHMA; ISOCYANATE-INDUCED ASTHMA; NONSPECIFIC BRONCHIAL HYPERRESPONSIVENESS; DYSFUNCTION SYNDROME RADS; PEAK EXPIRATORY FLOW; HUMAN SERUM-ALBUMIN; HLA CLASS-II; TOLUENE-DIISOCYANATE; HEXAMETHYLENE-DIISOCYANATE; GUINEA-PIGS	Diisocyanates, highly reactive chemicals used in the production of polyurethanes, are currently the most frequently reported cause of chemically induced occupational asthma and their use continues to rise. The prevalence of diisocyanate asthma among exposed workers is estimated to range from 5% to 15%. Routes of exposure include the respiratory tract and skin. Workplace exposures are difficult to quantify and control, and there is no simple diagnostic test for the disease. This review considers recent concepts in exposure, clinical aspects and pathogenesis of the disease. The pathogenesis of diisocyanate asthma remains unclear, with evidence supporting both immunological and noninummological mechanisms. Knowledge of the chemical reactivity of diisocyanates, the target biomolecules, and the cellular sites of reaction are fundamental to understanding diisocyanate toxicity and disease. Recent findings of chemical interactions with biological nucleophiles will be described. The importance of diisocyanate-adducted biomolecules will be emphasized and their potential contributions: to pathogenesis discussed. It is anticipated that greater understanding of the immunopathogenesis of diisocyanate asthma, including the initial cell/diisocyanate reactions, should lead to clinically useful markers of exposure and early disease. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA 15261 USA; Yale Univ, Occupat & Environm Med Program, New Haven, CT USA	Karol, MH (reprint author), Univ Pittsburgh, Dept Environm & Occupat Hlth, 130 DeSoto St, Pittsburgh, PA 15261 USA.				NCEH CDC HHS [NIEHS 05651, NIEHS K24]		Balboni A, 1996, EUR RESPIR J, V9, P207, DOI 10.1183/09031936.96.09020207; BANKS DE, 1990, CHEST, V97, P121, DOI 10.1378/chest.97.1.121; BAUR X, 1995, J ALLERGY CLIN IMMUN, V95, P1004, DOI 10.1016/S0091-6749(95)70101-X; Baur X, 1996, LUNG, V174, P23; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; Bernstein DI, 1999, AM J IND MED, V36, P459, DOI 10.1002/(SICI)1097-0274(199910)36:4<459::AID-AJIM7>3.0.CO;2-W; Bernstein JA, 1996, TOXICOLOGY, V111, P181, DOI 10.1016/0300-483X(96)03375-6; Bernstein JA, 1997, J ALLERGY CLIN IMMUN, V99, P245, DOI 10.1016/S0091-6749(97)70104-0; BIGNON JS, 1994, AM J RESP CRIT CARE, V149, P71; Bright P, 1996, THORAX, V51, P857, DOI 10.1136/thx.51.8.857; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BROWN WE, 1982, TOXICOL APPL PHARM, V63, P45, DOI 10.1016/0041-008X(82)90025-4; Carlton G N, 2000, Appl Occup Environ Hyg, V15, P705; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; CLARKE CW, 1981, AUST NZ J MED, V11, P290; Cullinan P, 1998, CLIN EXP ALLERGY, V28, P668; Day W. R., 1924, OXFORD FORESTRY MEMO, V3, P1; England E, 2000, Appl Occup Environ Hyg, V15, P472; Fabbri L M, 1991, Clin Exp Allergy, V21 Suppl 1, P42, DOI 10.1111/j.1365-2222.1991.tb01705.x; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36; FINOTTO S, 1991, BRIT J IND MED, V48, P116; Friedman-Jimenez G, 2000, AM J IND MED, V37, P121, DOI 10.1002/(SICI)1097-0274(200001)37:1<121::AID-AJIM10>3.0.CO;2-S; Grammer LC, 1998, ALLERGY ASTHMA PROC, V19, P301, DOI 10.2500/108854198778557755; JIN RZ, 1993, CHEM RES TOXICOL, V6, P906, DOI 10.1021/tx00036a023; Karol M H, 1987, Bull Eur Physiopathol Respir, V23, P571; KAROL MH, 1994, AM J RESP CRIT CARE, V149, P611; KAROL MH, 1981, TOXICOL APPL PHARM, V58, P221, DOI 10.1016/0041-008X(81)90426-9; Karol MH, 1997, INHAL TOXICOL, V9, P63; KAROL MH, 2001, IN PRESS ANN ALLERGY, V87; KENNEDY AL, 1989, TOXICOL APPL PHARM, V100, P280, DOI 10.1016/0041-008X(89)90314-1; KENNEDY AL, 1993, FUND APPL TOXICOL, V20, P57, DOI 10.1006/faat.1993.1007; Kimber I, 1996, TOXICOL LETT, V86, P89, DOI 10.1016/0378-4274(96)03678-8; Kopferschmitt-Kubler MC, 1998, RESP MED, V92, P1093, DOI 10.1016/S0954-6111(98)90400-0; Lange RM, 1999, TOXICOL SCI, V50, P64, DOI 10.1093/toxsci/50.1.64; Lange RW, 1999, CHEM RES TOXICOL, V12, P931, DOI 10.1021/tx990045h; Lantz RC, 2001, TOXICOL SCI, V60, P348, DOI 10.1093/toxsci/60.2.348; Lemiere C, 1996, AM J RESP CRIT CARE, V154, P329; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; LEMUS R, 2001, IN PRESS ENV HLTH PE, V109; Leroyer C, 1998, AM J RESP CRIT CARE, V158, P827; Leroyer C, 1998, THORAX, V53, P152; Liu RM, 2001, AM J RESP CELL MOL, V24, P499; Lummus ZL, 1998, J ALLERGY CLIN IMMUN, V102, P265, DOI 10.1016/S0091-6749(98)70095-8; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376; Maitre A, 1996, INT ARCH OCC ENV HEA, V69, P65; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; Mapp C, 1999, ANN ALLERG ASTHMA IM, V83, P645, DOI 10.1016/S1081-1206(10)62888-8; Mapp CE, 2000, CLIN EXP ALLERGY, V30, P651; MAPP CE, 1986, EUR J RESPIR DIS, V68, P89; MAPP CE, 1994, EUR RESPIR J, V7, P544, DOI 10.1183/09031936.94.07030544; Meredith SK, 2000, OCCUP ENVIRON MED, V57, P830, DOI 10.1136/oem.57.12.830; Monso E, 2000, EUR RESPIR J, V16, P729, DOI 10.1034/j.1399-3003.2000.16d27.x; MOSCATO G, 1995, J ALLERGY CLIN IMMUN, V96, P295; NIOSH, 1996, PREV ASTHM DEATH DII, P96; Ott MG, 2000, OCCUP ENVIRON MED, V57, P43, DOI 10.1136/oem.57.1.43; Park Hae-Sim, 1998, Journal of Korean Medical Science, V13, P21; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847; Park HS, 1997, CLIN EXP ALLERGY, V27, P1145; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; Pauluhn J, 2000, TOXICOL SCI, V56, P105, DOI 10.1093/toxsci/56.1.105; Perfetti L, 1998, CHEST, V114, P398, DOI 10.1378/chest.114.2.398; PERRIN B, 1991, J ALLERGY CLIN IMMUN, V87, P630, DOI 10.1016/0091-6749(91)90381-W; PERRIN B, 1992, EUR RESPIR J, V5, P40; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Piirila P, 2001, PHARMACOGENETICS, V11, P437, DOI 10.1097/00008571-200107000-00007; Piirila PL, 2000, AM J RESP CRIT CARE, V162, P516; Redlich CA, 1996, CHEST, V109, pS6, DOI 10.1378/chest.109.3_Supplement.6S; Redlich CA, 1997, SCAND J WORK ENV HEA, V23, P227; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; Redlich CA, 1999, SEM RESP CRIT CARE M, V20, P591, DOI 10.1055/s-2007-1009478; Rihs HP, 1997, AM J IND MED, V32, P522, DOI 10.1002/(SICI)1097-0274(199711)32:5<522::AID-AJIM13>3.3.CO;2-T; Tarlo SM, 1997, OCCUP ENVIRON MED, V54, P756; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.0.CO;2-2; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; VANDENPLAS O, 1993, AM REV RESPIR DIS, V147, P338; VANDENPLAS O, 1993, J ALLERGY CLIN IMMUN, V91, P850, DOI 10.1016/0091-6749(93)90342-D; VANDENPLAS O, 1993, BRIT J IND MED, V50, P213; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; WISNEWSKI AV, 2000, AM J RESP CRIT CARE, V162, P1	83	74	76	1	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1567-5769			INT IMMUNOPHARMACOL	Int. Immunopharmacol.	FEB	2002	2	2-3					213	224		10.1016/S1567-5769(01)00174-6		12	Immunology; Pharmacology & Pharmacy	Immunology; Pharmacology & Pharmacy	513DA	WOS:000173361600007	11811926	
J	Gautrin, D; Ghezzo, H; Infante-Rivard, C; Malo, JL				Gautrin, D; Ghezzo, H; Infante-Rivard, C; Malo, JL			Natural history of sensitization, symptoms and occupational diseases in apprentices exposed to laboratory animals	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; immunological sensitization; occupational asthma	DETERMINANTS; METHACHOLINE; ASTHMA; AGENTS; VOLUME; ATOPY; TESTS	The natural history of the development of sensitization and disease due to high-molecular-weight allergens is not well characterized. This study describes the timecourse of the incidence of work-related symptoms, skin reactivity and occupational rhinoconjunctivitis (RC) and asthma (OA); and assesses the predictive value of skin testing and RC symptoms in apprentices exposed to laboratory animals, in a 3-4-yr programme. Four-hundred and seventeen apprentices at five institutions were assessed prospectively with questionnaire, skin-testing with animal-derived allergens, spirometry and airway responsiveness (n = 373). Depending on the school, students were seen 8 (n = 136), 20 (n = 345), 32 (n = 355) and 44 (n = 98) months after starting the programme. At all visits, the incidence was greater for work-related RC symptoms followed in order by skin reactivity, occupational RC, and, almost equally, OA and work-related respiratory symptoms. The incidence-density figures were comparable for each followup period and for most indices up to 32 months after entry into the study and then tended to decrease. The positive predictive values (PPVs) of skin reactivity to work-related allergens for the development of work-related RC and respiratory symptoms were 30% and 9.0%, respectively, while the PPVs of work-related RC for the development of OA was 11.4%. Sensitization, symptoms and diseases occur maximally in the first 2-3 yrs after starting exposure to laboratory animals. Skin reactivity to work-related allergens and rhinoconjuctivitis symptoms have low positive predictive values.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; McGill Univ, Joint Dept Epidemiol & Biostat & Occupat Hlth, Montreal, PQ H3A 2T5, Canada	Gautrin, D (reprint author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin Blvd W, Montreal, PQ H4J 1C5, Canada.						American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; DEHAUT P, 1983, THORAX, V38, P516, DOI 10.1136/thx.38.7.516; Gautrin D, 2000, AM J RESP CRIT CARE, V162, P1222; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899; GORDON S, 1999, ASTHMA WORKPLACE, P399; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1983, AM REV RESPIR DIS, V128, P8; MALO JL, 1993, LUNG BIOL HLTH DIS, V68, P117; MALO JL, 1999, EUR RESP MON, V11, P106; Monso E, 2000, AM J RESP CRIT CARE, V161, P1508; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Troyanov S, 2000, EUR RESPIR J, V16, P9, DOI 10.1034/j.1399-3003.2000.16a03.x	16	74	76	0	0	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146, WEST ST, STE 2.4 HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAY	2001	17	5					904	908		10.1183/09031936.01.17509040		5	Respiratory System	Respiratory System	458RU	WOS:000170209000012	11488324	
J	Hajat, S; Haines, A; Atkinson, RW; Bremner, SA; Anderson, HR; Emberlin, J				Hajat, S; Haines, A; Atkinson, RW; Bremner, SA; Anderson, HR; Emberlin, J			Association between air pollution and daily consultations with general practitioners for allergic rhinitis in London, United Kingdom	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						air pollutants; air pollution; family practice; ozone; primary health care; rhinitis; sulfur dioxide	TIME-SERIES; HAY-FEVER; PREVALENCE; DISORDERS; COMPUTER; ASTHMA	Few published studies have looked at the health effects of air pollution in the primary care setting, and most have concentrated on lower rather than upper respiratory diseases, The authors investigated the association of daily consultations with general practitioners for allergic rhinitis with air pollution in London, United Kingdom. Generalized additive models were used to regress time series of daily numbers of patients consulting for allergic rhinitis against 1992-1994 measures of air pollution, after control for possible confounders and adjustment for overdispersion and serial correlation. In children, a 10th-90th percentile increase in sulfur dioxide (SO(3)) levels 4 days prior to consultation (13-31 mug/m(3)) was associated with a 24.5% increase in consultations (95% confidence interval: 14.6, 35.2; p < 0.00001); a 10th-90th percentile increase in averaged ozone (O(3)) concentrations on the day of consultation and the preceding 3 days (6-29 parts per billion) was associated with a 37.6% rise (95% confidence interval: 23,3, 53.5; p < 0,00001). For adults, smaller effect sizes were observed for SO(3) and O(3). The association with SO(3) remained highly significant in the presence of other pollutants. This study suggests that air pollution worsens allergic rhinitis symptoms, leading to substantial increases in consultations. SO(3) and O(3) seem particularly responsible, and both seem to contribute independently.	Univ Coll Worcester, Natl Pollen Res Unit, Worcester, MA USA; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England; UCL Royal Free & Univ Coll, Sch Med, Dept Primary Care & Populat Sci, London, England	Hajat, S (reprint author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England.	Shakoor.Hajat@lshtm.ac.uk	Bremner, Stephen/R-4038-2016; CPRD, CPRD/B-9594-2017	Bremner, Stephen/0000-0003-0790-7070; 			BASCOM R, 1990, AM REV RESPIR DIS, V142, P594; BOWER JS, 1995, AEARAMP200150011 NAT; BUCK SF, 1960, J ROY STAT SOC B, V22, P302; CHELL M, 1993, LONDON ENERGY STUDY; De Swert LFA, 1999, EUR J PEDIATR, V158, P89, DOI 10.1007/s004310051024; FINN R, 1992, LANCET, V340, P1453; Hajat S, 1999, THORAX, V54, P597; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; *MATHS INC, 1997, S PLUS VERS 4; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NAZARETH I, 1993, BRIT MED J, V307, P32; ROSS AM, 1994, BRIT MED J, V308, P897; Ross AM, 1996, BRIT J GEN PRACT, V46, P451; Shusterman DJ, 1998, J ALLERGY CLIN IMMUN, V101, P732, DOI 10.1016/S0091-6749(98)70302-1; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; ZEGER SL, 1988, BIOMETRIKA, V75, P621	19	74	79	3	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	APR 1	2001	153	7					704	714		10.1093/aje/153.7.704		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	419CD	WOS:000167931000013	11282799	
J	Lanphear, BP; Aligne, CA; Auinger, P; Weitzman, M; Byrd, RS				Lanphear, BP; Aligne, CA; Auinger, P; Weitzman, M; Byrd, RS			Residential exposures associated with asthma in US children	PEDIATRICS			English	Article						NHANES; children; pediatric; prevention; epidemiology; allergic rhinitis; medical costs; day care; housing; pets and environment	CHILDHOOD ASTHMA; PARENTAL SMOKING; RISK-FACTORS; RESPIRATORY SYMPTOMS; INDOOR ALLERGENS; SENSITIZATION; HEALTH; PREVALENCE; MORBIDITY; TOBACCO	Objective. Residential exposures are recognized risk factors for childhood asthma, but the relative contribution of specific risk factors and the overall contribution of housing to asthma in US children is unknown. The objective of this study was to identify risk factors and estimate the population attributable risk of residential exposures for doctor-diagnosed asthma for US children. Methods. A cross-sectional survey was conducted from 1988 to 1994. Survey participants were 8257 children who were <6 years old and who participated in the Third National Health and Nutrition Examination Survey, a survey of the health and nutritional status of children and adults in the United States. The main outcome measure was doctor-diagnosed asthma, as reported by the parent. Results. Six percent of children had doctor-diagnosed asthma. The prevalence of asthma was higher among boys (6.7%) than girls (5.1%) and was higher among black children (8.9%) than white children (5.2%). Risk factors for doctor-diagnosed asthma included a family history of atopy (odds ratio [OR]: 2.2; 95% confidence interval [CI]: 1.5, 3.1), child's history of allergy to a pet (OR: 24.2; 95% CI: 8.4, 69.5), exposure to environmental tobacco smoke (OR: 1.8; 95% CI: 1.2-2.6), use of a gas stove or oven for heat (OR: 1.8; 95% CI: 1.02-3.2), and presence of a dog in the household (OR: 1.6; 95% CI: 1.1, 2.3). The population attributable risk of <greater than or equal to>1 residential exposure for doctor-diagnosed asthma in US children <6 years old was 39.2%, or an estimated 533 000 excess cases, whereas having a family history of atopy accounted for 300 000. The attributable cost of asthma as a result of residential exposures for children <6 years old was $402 million (95% CI: $296-$507 million) annually. Conclusions. The elimination of identified residential risk factors, if causally associated with asthma, would result in a 39% decline in doctor-diagnosed asthma among US children <6 years old.	Childrens Hosp, Med Ctr, Cincinnati, OH 45229 USA; Univ Rochester, Sch Med, Dept Pediat, Rochester, NY 14642 USA; Amer Acad Pediat Ctr Child Hlth Res, Rochester, NY USA; Univ Calif Davis, Dept Pediat, Sacramento, CA 95817 USA	Lanphear, BP (reprint author), Childrens Hosp, Med Ctr, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	BHP HRSA HHS [1T-32 PE-10027, 2T-32 PE-12002]		Aligne CA, 1997, ARCH PEDIAT ADOL MED, V151, P648; Burr ML, 1999, THORAX, V54, P27; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1221; Centers for Disease C Prevention, 1996, MMWR-MORBID MORTAL W, V45, P350; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; COUGHLIN SS, 1994, EPIDEMIOL REV, V16, P51; CRONER S, 1992, ALLERGY, V47, P150, DOI 10.1111/j.1398-9995.1992.tb00956.x; DUFF AL, 1993, PEDIATRICS, V92, P535; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GERGEN PJ, 1998, PEDIATRICS, V101; HALFON N, 1993, PEDIATRICS, V91, P56; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Lanphear BP, 1998, SCIENCE, V281, P1617, DOI 10.1126/science.281.5383.1617; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Pirkle JL, 1998, ENVIRON HEALTH PERSP, V106, P745, DOI 10.1289/ehp.98106745; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; Pollock D A, 1988, MMWR CDC Surveill Summ, V37, P13; Pope A. M., 1993, INDOOR ALLERGENS ASS; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Samet JM., 1987, CHEST, V91, P74; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STODDARD JJ, 1995, AM J EPIDEMIOL, V141, P96; TAYLOR WR, 1992, PEDIATRICS, V90, P657; U.S. Bureau of the Census, 1999, STAT ABSTR US; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Weiss KB, 1992, CHEST, V101, P362; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; YOUNG S, 1991, NEW ENGL J MED, V324, P168; YUNINGER JW, 1992, AM REV RESPIR DIS, V146, P888; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	41	74	74	2	6	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2001	107	3					505	511		10.1542/peds.107.3.505		7	Pediatrics	Pediatrics	406KW	WOS:000167216200024	11230590	
J	Hannuksela, ML; Ellahham, S				Hannuksela, ML; Ellahham, S			Benefits and risks of sauna bathing	AMERICAN JOURNAL OF MEDICINE			English	Review							HIGH AMBIENT-TEMPERATURE; SUDDEN CORONARY DEATH; PLASMA-RENIN ACTIVITY; FINNISH SAUNA; HEAT EXPOSURE; THERMAL-STRESS; HYPERTENSIVE PATIENTS; BETA-ENDORPHIN; TRIPLOCHITON SCLEROXYLON; MATERNAL HYPERTHERMIA	Although sauna bathing causes various acute, transient cardiovascular and hormonal changes, it is well tolerated by most healthy adults and children. Sauna bathing does not influence fertility and is safe during the uncomplicated pregnancies of healthy women. Some studies have suggested that long-term sauna bathing may help lower blood pressure in patients with hypertension and improve the left ventricular ejection fraction in patients with chronic congestive heart failure, but additional data are needed to confirm these findings. The transient improvements in pulmonary function that occur in the sauna may provide some relief to patients with asthma and chronic bronchitis. Sauna bathing may also alleviate pain and improve joint mobility in patients with rheumatic disease. Although sauna bathing does not cause drying of the skin-and may even benefit patients with psoriasis-sweating may increase itching in patients with atopic dermatitis. Contraindications to sauna bathing include unstable angina pectoris, recent myocardial infarction, and severe aortic stenosis. Sauna bathing is safe, however, for most people with coronary heart disease with stable angina pectoris or old myocardial infarction. Very few acute myocardial infarctions and sudden deaths occur in saunas, but alcohol consumption during sauna bathing increases the risk of hypotension, arrhythmia, and sudden death, and should be avoided. (C) 2001 by Excerpta Medica, Inc.	Univ Oulu, Dept Internal Med, FIN-90220 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90220 Oulu, Finland; Washington Hosp Ctr, Div Cardiol, Washington, DC 20010 USA	Hannuksela, ML (reprint author), Univ Oulu, Dept Internal Med, Kajaanintie 50, FIN-90220 Oulu, Finland.						AHONEN E, 1988, ANN CLIN RES, V20, P257; BARKVE TF, 1986, AM HEART J, V112, P537, DOI 10.1016/0002-8703(86)90518-1; BROWNWOODMAN PDC, 1984, ARCH ANDROLOGY, V12, P9; BUSSIEN JP, 1986, ACTA ENDOCRINOL-COP, V112, P166; COX NJM, 1989, ARCH PHYS MED REHAB, V70, P911; DAVIES H, 1975, AM J PHYS MED REHAB, V54, P178; Einenkel D, 1977, Z Arztl Fortbild (Jena), V71, P1069; EISALO A, 1988, ANN CLIN RES, V20, P267; EISALO A, 1956, ANN MED EXP BIOL S4, V34; ERNST E, 1990, ANN MED, V22, P225, DOI 10.3109/07853899009148930; Estlander T, 1999, CONTACT DERMATITIS, V41, P164, DOI 10.1111/j.1600-0536.1999.tb06112.x; Giannetti N, 1999, AM J MED, V107, P228, DOI 10.1016/S0002-9343(99)00220-X; HAKULINEN T, 1987, SCAND J SOC MED, V15, P3; HANNUKSELA M, 1988, ANN CLIN RES, V20, P276; Hasan J, 1966, Am J Phys Med, V45, P296; Hasan J, 1967, Am J Phys Med, V46, P1226; HELAMAA E, 1988, ANN CLIN RES, V20, P224; HOFFMANN A, 1983, SCHWEIZ MED WSCHR, V113, P1054; HUSSI E, 1977, ANN CLIN RES, V9, P301; IISALO E, 1969, Annals of Clinical Research, V1, P251; ISOMAKI H, 1988, ANN CLIN RES, V20, P271; JENSSEN TG, 1988, ACTA PHYSIOL SCAND, V132, P519, DOI 10.1111/j.1748-1716.1988.tb08359.x; JEZOVA D, 1985, HORM METAB RES, V17, P693, DOI 10.1055/s-2007-1013648; JEZOVA D, 1994, ACTA PHYSIOL SCAND, V150, P293, DOI 10.1111/j.1748-1716.1994.tb09689.x; Joffe M, 1996, LANCET, V347, P1519, DOI 10.1016/S0140-6736(96)90673-X; JOKINEN E, 1988, ANN CLIN RES, V20, P283; JOKINEN E, 1991, ACTA PAEDIATR SCAND, V80, P370, DOI 10.1111/j.1651-2227.1991.tb11864.x; JOKINEN E, 1991, ACTA PHYSIOL SCAND, V142, P437, DOI 10.1111/j.1748-1716.1991.tb09178.x; JOKINEN E, 1989, THESIS U TURKU FINLA; Kanerva L, 1998, CONTACT DERMATITIS, V38, P170, DOI 10.1111/j.1600-0536.1998.tb05691.x; KARJANOJA M, 1997, SAUNA MADE FINLAND; KAUPPINEN K, 1986, ANN CLIN RES, V18, P173; Kauppinen K, 1997, ANN NY ACAD SCI, V813, P654, DOI 10.1111/j.1749-6632.1997.tb51764.x; Kauppinen K, 1989, Arctic Med Res, V48, P131; Kauppinen K, 1989, Arctic Med Res, V48, P75; Kauppinen K, 1989, Arctic Med Res, V48, P55; Kauppinen K, 1989, Arctic Med Res, V48, P64; KAUPPINEN K, 1989, THESIS TAMPERE FINLA; KENTALA E, 1976, ANN CLIN RES, V8, P408; KISS D, 1994, RESPIRATION, V61, P86; KOIVISTO VA, 1980, BRIT MED J, V280, P1411; KOIVISTO VA, 1983, ACTA DIABETOL LAT, V20, P175; KORTELAINEN ML, 1991, AM J FOREN MED PATH, V12, P115, DOI 10.1097/00000433-199106000-00006; KOSKINEN P, 1987, BRIT HEART J, V57, P468; KOSUNEN KJ, 1976, J APPL PHYSIOL, V41, P323; KUKKONENHARJULA K, 1988, ANN CLIN RES, V20, P262; KUKKONENHARJULA K, 1994, EUR J APPL PHYSIOL O, V69, P10, DOI 10.1007/BF00867920; KUKKONENHARJULA K, 1989, EUR J APPL PHYSIOL O, V58, P543, DOI 10.1007/BF02330710; LAATIKAINEN T, 1988, EUR J APPL PHYSIOL O, V57, P98, DOI 10.1007/BF00691246; LAHTI A, 1980, CONTACT DERMATITIS, V6, P464, DOI 10.1111/j.1600-0536.1980.tb05567.x; LAITINEN LA, 1988, ANN CLIN RES, V20, P244; LAMMINTAUSTA R, 1976, ANN CLIN RES, V8, P266; LEPPALUOTO J, 1986, ACTA PHYSIOL SCAND, V128, P467, DOI 10.1111/j.1748-1716.1986.tb08000.x; LEPPALUOTO J, 1988, ANN CLIN RES, V20, P240; LEPPALUOTO J, 1991, J APPL PHYSIOL, V71, P716; LEPPALUOTO J, 1987, J CLIN ENDOCR METAB, V65, P1035; LEPPALUOTO J, 1986, ACTA PHYSIOL SCAND, V128, P77, DOI 10.1111/j.1748-1716.1986.tb07952.x; Leppo JA, 1999, AM J MED, V107, P290; Luurila O J, 1978, Adv Cardiol, V25, P73; Luurila O J, 1980, Acta Med Scand Suppl, V641, P1; LUURILA OJ, 1992, J INTERN MED, V231, P319; LUURILA OJ, 1989, AM J CARDIOL, V64, P97, DOI 10.1016/0002-9149(89)90662-0; MARKKOLA L, 1989, EUR J PEDIATR, V149, P221, DOI 10.1007/BF01958288; MILLER P, 1978, LANCET, V1, P519; MILUNSKY A, 1992, JAMA-J AM MED ASSOC, V268, P882, DOI 10.1001/jama.268.7.882; NURMIKKO T, 1992, PAIN, V49, P43, DOI 10.1016/0304-3959(92)90186-F; NURMIKKO T, 1991, THESIS U TAMPERE FIN; Penttila A, 1985, Beitr Gerichtl Med, V43, P223; PERASALO J, 1988, ANN CLIN RES, V20, P220; PIRHONEN JP, 1994, AM J PERINAT, V11, P313, DOI 10.1055/s-2007-994542; PROCOPE BJ, 1965, INT J FERTIL, V10, P333; Puranen M, 1996, SCAND J INFECT DIS, V28, P243, DOI 10.3109/00365549609027165; REIJULA K, 1994, THORAX, V49, P622, DOI 10.1136/thx.49.6.622; ROINE R, 1992, J INTERN MED, V231, P333; ROMO M, 1976, LANCET, V2, P809; Saikhun J, 1998, INT J ANDROL, V21, P358; SALMINEN K, 1974, ZBL BAKT MIK HYG B, V158, P552; SAXEN L, 1982, TERATOLOGY, V25, P309, DOI 10.1002/tera.1420250307; SCHNIZER W, 1992, PHYS REHAB KUR MED, V2, P88, DOI 10.1055/s-2008-1062110; SCHOOLFIELD GC, 1992, KALEVALA EPIC FINNIS; SHOENFELD Y, 1976, ARCH PHYS MED REHAB, V57, P126; SIEWERT C, 1994, Z KARDIOL, V83, P652; SIRVIO J, 1987, Revue Roumaine de Medecine Endocrinologie, V25, P21; SOHAR E, 1976, ISRAEL J MED SCI, V12, P1275; STEIN G, 1973, Z PHYSIOTHER, V25, P327; STRBAK V, 1987, METABOLISM, V36, P426; SUDAKOV KV, 1988, PAVLOVIAN J BIOL SCI, V23, P89; SUHONEN O, 1983, ACTA MED SCAND, V214, P207; SUHONEN O, 1987, ACTA MED SCAND, V221, P335; SUOMINEN J, 1993, BRIT MED J, V306, P1579; TAGGART P, 1972, BMJ-BRIT MED J, V3, P71; TEI C, 1995, CIRCULATION, V91, P2582; Tei C, 1996, J Cardiol, V27, P29; TENKANEN L, 1993, CANCER CAUSE CONTROL, V4, P133, DOI 10.1007/BF00053154; TIKKANEN J, 1991, EUR J EPIDEMIOL, V7, P628; TUOMISTO J, 1976, ACTA ENDOCRINOL-COP, V83, P522; UHARI M, 1979, BRIT MED J, V1, P1216; Vaananen A, 1988, Duodecim, V104, P636; VAHAESKELI K, 1988, ANN CLIN RES, V20, P279; VAHAESKELI K, 1991, AM J PERINAT, V8, P385, DOI 10.1055/s-2007-999422; VAHAESKELI K, 1991, EUR J OBSTET GYN R B, V39, P169, DOI 10.1016/0028-2243(91)90053-N; VAHAESKELI K, 1992, EUR J OBSTET GYN R B, V43, P97, DOI 10.1016/0028-2243(92)90065-7; Vaha-Eskeli K., 1990, EUR J OBSTET GYN R B, V38, P9; VAHAESKELI K, 1991, THESIS U TURKU FINLA; VAHAESKELI KK, 1992, AM J OBSTET GYNECOL, V167, P785; VAHAESKELI KK, 1991, ANN MED, V23, P121, DOI 10.3109/07853899109148035; VALTAKARI P, 1988, ANN CLIN RES, V20, P230; VANAKOSKI J, 1995, EUR J CLIN PHARMACOL, V48, P133; Vanakoski J, 1996, EUR J CLIN PHARMACOL, V51, P335, DOI 10.1007/s002280050208; Vanakoski J, 1996, PHARMACOL TOXICOL, V78, P94; Vanakoski J, 1997, INT J CLIN PHARM TH, V35, P204; Vanakoski J, 1996, CLIN PHARMACOL THER, V60, P308, DOI 10.1016/S0009-9236(96)90057-0; VANAKOSKI J, 1993, EUR J CLIN PHARMACOL, V45, P377; Vanakoski J, 1998, CLIN PHARMACOKINET, V34, P311, DOI 10.2165/00003088-199834040-00004; VANAKOSKI J, 1996, THESIS U HELSINKI FI; VANHENGSTUM M, 1991, THORAX, V46, P732, DOI 10.1136/thx.46.10.732; VESCOVI PP, 1993, BIOMED PHARMACOTHER, V47, P301, DOI 10.1016/0753-3322(93)90078-Y; VESCOVI PP, 1992, STRESS MEDICINE, V8, P187, DOI 10.1002/smi.2460080310; VESCOVI PP, 1990, NEUROENDOCRINOL LETT, V12, P143; Vescovi PP, 1997, ALCOHOL CLIN EXP RES, V21, P1195, DOI 10.1097/00000374-199710000-00006; Vierula M, 1996, INT J ANDROL, V19, P11, DOI 10.1111/j.1365-2605.1996.tb00427.x; VUORI I, 1988, ANN CLIN RES, V20, P249; VUORI I, 1987, ANN CLIN RES, V19, P156; VUORI I, 1978, CARDIOLOGY, V63, P287, DOI 10.1159/000169908; Winterfeld H J, 1992, Schweiz Rundsch Med Prax, V81, P1016; Winterfeld H J, 1993, Z Gesamte Inn Med, V48, P247; WINTERFELD HJ, 1988, Z KARDIOL, V77, P190; YLIKAHRI R, 1988, ANN CLIN RES, V20, P287	128	74	82	5	24	EXCERPTA MEDICA INC	NEW YORK	650 AVENUE OF THE AMERICAS, NEW YORK, NY 10011 USA	0002-9343			AM J MED	Am. J. Med.	FEB 1	2001	110	2					118	126		10.1016/S0002-9343(00)00671-9		9	Medicine, General & Internal	General & Internal Medicine	398NA	WOS:000166761500007	11165553	
J	Olin, AC; Aldenbratt, A; Ekman, A; Ljungkvist, G; Jungersten, L; Alving, K; Toren, K				Olin, AC; Aldenbratt, A; Ekman, A; Ljungkvist, G; Jungersten, L; Alving, K; Toren, K			Increased nitric oxide in exhaled air after intake of a nitrate-rich meal	RESPIRATORY MEDICINE			English	Article						nitric oxide; nasal nitric oxide; nitrate; nitrite; L-arginine; breath analysis	L-ARGININE; HUMAN-SALIVA; ASTHMA; NASAL; GENERATION; RHINITIS; MASS	Exhaled and nasal NO (ENO, NNO) have been suggested as markers for inflammation in lower and upper respiratory tract respectively. It is still unknown how a number of factors, apart from airway inflammation, can influence NO levels. The aim of this study was to determine the effect of a nitrate-rich meal on ENO and NNO. Sixteen healthy subjects were observed during 1 week on normal diet before a nitrate-restricted diet was introduced in the next. On day 3 of the second week they were made to ingest a nitrate rich meal. ENO, NNO, plasma nitrate and plasma L-arginine were followed before the meal and afterwards for 3 h. ENO and NNO as well as plasma nitrate and plasma L-arginine were significantly elevated after the nitrate-rich meal. The median maximal increase of ENO and NNO was 47% and 13% respectively. We found a moderate but significant correlation between the rise in plasma nitrate and ENO (r(s)=0.57, P=0.027) but none between plasma nitrate and NNO (r(s)=-0.02, P=0.95). As nitrate in the diet seems to substantially influence the levels of ENO it is important either to restrictor register the intake of nitrate-rich food prior to measuring ENO.	Sahlgrenska Univ Hosp, Dept Occupat & Environm Med, S-41266 Gothenburg, Sweden; Sahlgrenska Univ Hosp, Dept Clin Physiol, Gothenburg, Sweden; Karolinska Inst, Dept Physiol & Pharmacol, Stockholm, Sweden; Sahlgrenska Univ Hosp, Sect Resp Med & Allergol, Gothenburg, Sweden	Olin, AC (reprint author), Sahlgrenska Univ Hosp, Dept Occupat & Environm Med, St Sigfridsgatan 85 B, S-41266 Gothenburg, Sweden.			Alving, Kjell/0000-0003-0784-0443			Altman DG, 1991, PRACTICAL STAT MED R; ALVING K, 1993, EUR RESPIR J, V6, P1368; BERGLUND E, 1963, ACTA MED SCAND, V173, P185; BOER P, 1984, AM J PHYSIOL, V247, pF632; Byrnes CA, 1997, EUR RESPIR J, V10, P1021, DOI 10.1183/09031936.97.10051021; de Gouw HWFM, 1999, THORAX, V54, P1033; DUNCAN C, 1995, NAT MED, V1, P546, DOI 10.1038/nm0695-546; EISENBRAND G, 1980, ONCOLOGY, V37, P227; GRANLI T, 1989, FOOD CHEM TOXICOL, V27, P675, DOI 10.1016/0278-6915(89)90122-1; Jungersten L, 1996, CLIN PHYSIOL, V16, P369, DOI 10.1111/j.1475-097X.1996.tb00726.x; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, CLIN SCI, V88, P135; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1997, J ALLERGY CLIN IMMUN, V99, P58; LUNDBERG JON, 1994, GUT, V35, P1543, DOI 10.1136/gut.35.11.1543; Lundberg JON, 1996, EUR RESPIR J, V9, P1344, DOI 10.1183/09031936.96.09071344; LUNDBERG JON, 1995, NAT MED, V1, P370, DOI 10.1038/nm0495-370; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Massaro AF, 1999, AM J RESP CRIT CARE, V159, pA860; MATRICARDI PM, 1990, CLIN EXP ALLERGY, V20, P151, DOI 10.1111/j.1365-2222.1990.tb02660.x; Nagase S, 1997, BIOCHEM BIOPH RES CO, V233, P150, DOI 10.1006/bbrc.1997.6428; OLIN AC, 1998, EUR RESPIR J, V12, pS249; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; SPACKMAN DH, 1958, ANAL CHEM, V30, P1190, DOI 10.1021/ac60139a006; TANNENBAUM SR, 1976, FOOD COSMET TOXICOL, V14, P549, DOI 10.1016/S0015-6264(76)80006-5; ten Hacken NHT, 1998, AM J RESP CRIT CARE, V158, P902; TESCH JW, 1976, J CHROMATOGR, V126, P743, DOI 10.1016/S0021-9673(01)84117-0; WENNMALM A, 1993, CIRC RES, V73, P1121; Zetterquist W, 1999, EUR RESPIR J, V13, P327, DOI 10.1034/j.1399-3003.1999.13b18.x	30	74	77	0	3	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0954-6111			RESP MED	Respir. Med.	FEB	2001	95	2					153	158		10.1053/rmed.2000.1010		6	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	401BH	WOS:000166906700008	11217912	
J	Rylander, R; Lin, RH				Rylander, R; Lin, RH			(1 -> 3)-beta-D-glucan - relationship to indoor air-related symptoms, allergy and asthma	TOXICOLOGY			English	Article; Proceedings Paper	Symposium on Indoor Environmental Factors Enhancing Allergic Immune Response: Focus on Endotoxin and Particles	JUN 26, 1999	OSLO, NORWAY	EUROTOX, Immunotoxicol & Chem Allergy Special Sect		moulds; airways inflammation; respiratory symptoms; (1 -> 3)-beta-D-glucan	AIRWAYS INFLAMMATION; ENDOTOXIN; GLUCAN; (1->3)-BETA-D-GLUCAN; INTERLEUKIN-1; INHALATION; AIRBORNE; ATOPY	(1 --> 3)-beta -D-glucan is a polyglucose structure in the cell wall of moulds, some bacteria and plants. Due to its unique (1 --> 3)-beta linkage it binds to specific receptors on phagocytosing cells and induces changes in their metabolism. Under realistic environmental concentrations, available data suggest that these changes express themselves as alterations of the defense mechanisms to other agents. Inhalation of (I --> 3)-beta -D-glucan in humans causes symptoms from the upper respiratory tract and induction of cytokines in blood monocytes. (1 --> 3)-beta -D-glucan can be used as a marker of mould biomass in field studies. Relationships between the amount of (1 --> 3)-beta -D-glucan and the extent of symptoms as well as lung function changes and inflammatory markers have been described. In view of the mechanisms involved in the normal development of the immune system, children seem to be a particular group at risk due to (I --> 3)-beta -D-glucan exposure. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Univ Gothenburg, Dept Environm Med, S-40530 Gothenburg, Sweden; Natl Taiwan Univ, Coll Med, Grad Inst Immunol, Taipei, Taiwan	Rylander, R (reprint author), Univ Gothenburg, Dept Environm Med, Box 414, S-40530 Gothenburg, Sweden.	ragnar.rylander@envmed.gu.se					ABEL G, 1992, INT J IMMUNOPHARMACO, V14, P1363, DOI 10.1016/0192-0561(92)90007-8; ADACHI Y, 1999, PHARM PHARM LETT, V1, P17; ADACHI Y, 1999, CARBOHYD RES, V316, P225; BEIJER L, 1998, P 22 COTT OTH ORG DU, P251; COOK JA, 1980, CIRC SHOCK, V7, P225; DEROCHEMONTEIXGALVE B, 1991, INFECT IMMUN, V59, P3646; DOUEWES J, 1997, MEDIAT INFLAMM, V6, P257; DOUWES J, 2000, UNPUB GLUCAN ENDOTOX; FOGEL DB, 1994, IEEE T NEURAL NETWOR, V1, P3; FOGELMARK B, 1992, AGENTS ACTIONS, V35, P50, DOI 10.1007/BF01990951; Fogelmark B, 1997, INDOOR BUILT ENVIRON, V6, P291, DOI 10.1177/1420326X9700600506; FOGELMARK B, 2000, UNPUB AGENTS ACTIONS; GRAVESEN S, 1994, MICROFUNGI MUNKSGAAR, P53; Holt PG, 1999, ENVIRON HEALTH PERSP, V107, P485; Ohno N, 1999, CARBOHYD RES, V316, P161, DOI 10.1016/S0008-6215(99)00049-X; RYLANDER R, 1989, INT CONGR SER, V860, P219; Rylander R, 1997, ARCH ENVIRON HEALTH, V52, P281; Rylander R, 1998, MEDIAT INFLAMM, V7, P105; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P501; RYLANDER R, 1996, INDOOR BUILT ENVIRON, V5, P106, DOI 10.1177/1420326X9600500206; RYLANDER R, 1995, 16 EUR C ALL CLIN IM, P409; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; SHERWOOD ER, 1987, INT J IMMUNOPHARMACO, V9, P261, DOI 10.1016/0192-0561(87)90049-X; STONE BA, 1998, CHEM BIOL 1 ARROW 3, P1; TAMURA H, 1994, CLIN CHIM ACTA, V226, P109, DOI 10.1016/0009-8981(94)90110-4; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Wan GH, 1999, EUR J IMMUNOL, V29, P2491, DOI 10.1002/(SICI)1521-4141(199908)29:08<2491::AID-IMMU2491>3.3.CO;2-I	29	74	75	0	1	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-483X			TOXICOLOGY	Toxicology	NOV 2	2000	152	1-3					47	52		10.1016/S0300-483X(00)00291-2		6	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	379EC	WOS:000165627100007	11090939	
J	Coreno, A; Skowronski, M; Kotaru, C; McFadden, ER				Coreno, A; Skowronski, M; Kotaru, C; McFadden, ER			Comparative effects of long-acting beta(2)-agonists, leukotriene receptor antagonists, and a 5-lipoxygenase inhibitor on exercise-induced asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						exercise-induced asthma; beta(2)-agonist; leukotriene receptor antagonist; 5-lipoxygenase inhibitor	INDUCED BRONCHOCONSTRICTION; INDUCED BRONCHOSPASM; REFRACTORY PERIOD; MONTELUKAST; SALMETEROL; CHILDREN; ZAFIRLUKAST; PROTECTION; DURATION	Background: Exercise-induced asthma (EIA) is a common problem that can be controlled with long-acting beta-agonists and leukotriene-modifying compounds. There is, however, limited information on the comparative effectiveness of the two classes of drugs, as well as the relative potencies of the antileukotriene agents. Objective: The purpose of the present study was to provide data on the above issues. Methods: We performed a random-order, blinded, double-dummy, placebo-controlled trial in 10 patients with EIA. Each subject received standard single doses of salmeterol, montelukast, zafirlukast, zileuton, and placebo on separate days. The participants performed 4 minutes of cycle ergometry while breathing frigid air 1, 4, 8, and 12 hours after administration of the test agents. The primary endpoint was the extent of the decrement in the FEV1 10 minutes after exertion. Results: With placebo, symptomatic airway narrowing developed at all times (mean +/- SE decrease in FEV1 ranged between 21% +/- 5% and 26% +/- 5%). Salmeterol acted quickly and significantly blunted the obstructive response for 12 hours (Delta FEV1 first hour: 8% +/- 3%; Delta FEV1 twelfth hour: 8% +/- 3%; P < .0001 vs placebo and P = .72 vs time). The leukotriene-modifying agents produced effects within 1 hour of ingestion. Like salmeterol, montelukast and zafirlukast also offered long-lasting protection, and there were no significant differences between them (montelukast Delta FEV1 twelfth hour: 9% +/- 4%; zafirlukast Delta FEV1 twelfth hour: 11% +/- 2%; P = .75) or the beta(2)-agonist (montelukast vs salmeterol: P = .72; zafirlukast vs salmeterol: P = .48). Zileuton provided equivalent prophylaxis for the first 4 hours (Delta FEV1 fourth hour: 11% +/- 2%); however, by 8 hours, it was less efficacious than all of the other active compounds, and by 12 hours it did not differ from placebo (Delta FEV1 twelfth hour: 19% +/- 4%; P = .33). Conclusions: Single doses of the currently available leukotriene receptor antagonists provide prompt effective and persistent defense against EIA that equals that seen with a long-acting beta(2)-agonist. The synthesis inhibitor zileuton affords a comparable magnitude of prophylaxis but has a considerably shorter duration of action.	Univ Hosp Cleveland, Div Pulm & Crit Care Med, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Airway Dis Ctr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA	McFadden, ER (reprint author), Univ Hosp Cleveland, Div Pulm & Crit Care Med, 11100 Euclid Ave, Cleveland, OH 44106 USA.				NCRR NIH HHS [MO 1 RR 00080]; NHLBI NIH HHS [HL-33791, HL-07288]		Adelroth E, 1997, J ALLERGY CLIN IMMUN, V99, P210, DOI 10.1016/S0091-6749(97)70098-8; Bronsky EA, 1997, CLIN PHARMACOL THER, V62, P556, DOI 10.1016/S0009-9236(97)90051-5; Calhoun WJ, 1998, AM J RESP CRIT CARE, V157, pS238; DEAL EC, 1979, J APPL PHYSIOL, V46, P467; Edelman JM, 2000, ANN INTERN MED, V132, P97; EDMUNDS AT, 1978, AM REV RESPIR DIS, V117, P247; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746; GILBERT IA, 1988, J APPL PHYSIOL, V64, P2167; KEMP JP, 1994, AM J RESP CRIT CARE, V150, P1612; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; Meltzer SS, 1996, AM J RESP CRIT CARE, V153, P931; Nelson JA, 1998, NEW ENGL J MED, V339, P141, DOI 10.1056/NEJM199807163390301; PATESSIO A, 1991, EUR RESPIR J, V4, P296; Pearlman DS, 1999, J PEDIATR-US, V134, P273, DOI 10.1016/S0022-3476(99)70449-X; Reiss TF, 1997, THORAX, V52, P1030; ROSSING TH, 1982, J APPL PHYSIOL, V52, P1119; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882; STEARNS DR, 1981, J APPL PHYSIOL, V50, P503; Villaran C, 1999, J ALLERGY CLIN IMMUN, V104, P547, DOI 10.1016/S0091-6749(99)70322-2; Zar JH, 1984, BIOSTATISTICAL ANAL	23	74	74	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					500	506				7	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900013	10984370	
J	Schuller, HM; Jull, BA; Sheppard, BJ; Plummer, HK				Schuller, HM; Jull, BA; Sheppard, BJ; Plummer, HK			Interaction of tobacco-specific toxicants with the neuronal or, nicotinic acetylcholine receptor and its associated mitogenic signal transduction pathway: potential role in lung carcinogenesis and pediatric lung disorders	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article; Proceedings Paper	Congress on Neuronal Nicotinic Receptors - From Structure to Therapeutics	OCT 01-04, 1999	VENICE, ITALY	Dept Pharmacol, Univ Milan, CNR Ctr Molec & Cellular Pharmacol, European Comm & Munichs VerUm Fdn		alpha 7 nicotinic receptor; nicotine; nicotine-derived nitrosamine; small cell lung carcinoma; pulmonary neuroendocrine cell; mitogenic signal transduction	INFANT-DEATH-SYNDROME; PULMONARY NEUROENDOCRINE CELLS; GASTRIN-RELEASING PEPTIDE; MATERNAL SMOKING; FUNCTIONAL EXPRESSION; CARCINOMA CELLS; ENDOCRINE-CELLS; CALCIUM-CHANNEL; CARBON-DIOXIDE; RISK-FACTORS	Pulmonary neuroendocrine cells function as hypoxia-sensitive chemoreceptors, and they release peptides and biogenic amines that are important mediators of pulmonary neonatal adaptation. Some of these products additionally act as autocrine growth factors. Increased numbers of pulmonary neuroendocrine cells have been observed in several smoking-associated pediatric lung disorders such as bronchopulmonary dysplasia, cystic fibrosis, sudden infant death syndrome, and asthma. Disturbed pulmonary neuroendocrine function has been implicated in the etiology of this disease complex. One of the most common smoking-associated lung cancer types, small cell lung carcinoma, expresses phenotypic and functional features of pulmonary neuroendocrine cells. We, as well as others, have shown that the release of the autocrine growth factors 5-hydroxytryptamine (5-HT, serotonin) and mammalian bombesisn/gastrin releasing peptide (MB/GRP) by cell lines derived from human small cell lung carcinoma or fetal hamster pulmonary neuroendocrine cells are regulated by a neuronal nicotinic acetylcholine receptor comprised of alpha(7) subunits. In radio-receptor assays, nicotine and the nicotine-derived carcinogenic nitrosamines N'-nictrosonornicotine (NNN) and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) bound with high affinity to this receptor with affinitites NNK > nicotine > NNN. Binding of nicotine or NNK to the alpha(7) receptor resulted in calcium influx and overexpression and activation of the serine-threonine protein kinase Raf-1. In turn, this event lead to overexpression and activation of the mitogen activated (MAP) kinases extracellular signal regulated kinase 1 (ERK1) and extracellular signal regulated kinase 2 (ERK2) and stimulation of DNA synthesis accompanied by an increase in cell numbers in fetal pulmonary neuroendocrine cells and small cell carcinoma cells. Exposure of fetal pulmonary neuroendocrine cells for 6 days to NNK caused a prominant up-regulation of Raf-1. Our findings suggest that chronic exposure to nicotine and NNK in pregnant women who smoke may up-regulate the alpha(7) nicotinic receptor as well as components of its associated mitogenic signal transduction pathway, thus increasing the susceptibilities of the infants for the development of pediatric lung disorders. Similarly, up-regulation of one or several components of this nicotinic receptor pathway in smokers may be an important factor for the development of small cell lung carcinoma. (C) 2000 Elsevier Science B.V. All rights reserved.	Univ Tennessee, Coll Vet Med, Carcinogenesis & Dev Therapeut Program, Knoxville, TN 37909 USA	Schuller, HM (reprint author), Univ Tennessee, Coll Vet Med, Carcinogenesis & Dev Therapeut Program, 2407 River Dr, Knoxville, TN 37909 USA.				NCI NIH HHS [CA51211]		AGUAYO SM, 1993, ANAT REC, V236, P122, DOI 10.1002/ar.1092360116; BARRY ELR, 1995, J NEUROSCI, V15, P274; BECKER KL, 1984, ENDOCRINE LUNG HLTH, P2; BELINSKY SA, 1988, CANCER RES, V49, P5303; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Breese CR, 1997, J PHARMACOL EXP THER, V282, P7; BUNN PA, 1992, CANCER RES, V52, P24; Cattaneo MG, 1997, BIOCHEM J, V328, P499; CATTANEO MG, 1993, CANCER RES, V53, P5566; CODIGNOLA A, 1993, J BIOL CHEM, V268, P26240; CODIGNOLA A, 1994, FEBS LETT, V342, P286, DOI 10.1016/0014-5793(94)80518-0; COOK RM, 1993, CURR PROB CANCER, V17, P71; Cutz E, 1996, PEDIATRICS, V98, P668; CUTZ E, 1988, ANN NY ACAD SCI, V533, P461, DOI 10.1111/j.1749-6632.1988.tb37281.x; CUTZ E, 1997, CELLULAR MOL BIOL AI; CUTZ E, 1985, PEDIATR PULM, V1, P21; Farrell RE, 1997, IMMUNOL INVEST, V26, P3, DOI 10.3109/08820139709048910; FARRELL RE, 1993, RNA METHODOLOGIES LA; FINNEGAN MCM, 1993, LEUKEMIA LYMPHOMA, V10, P387, DOI 10.3109/10428199309148565; FISCHER S, 1990, CARCINOGENESIS, V11, P723, DOI 10.1093/carcin/11.5.723; GAZDAR AF, 1984, ENDOCRINE LUNG HLTH, P501; Grando SA, 1996, J INVEST DERMATOL, V107, P412, DOI 10.1111/1523-1747.ep12363399; HECHT SS, 1993, CARCINOGENESIS, V14, P229, DOI 10.1093/carcin/14.2.229; HECHT SS, 1988, CARCINOGENESIS, V9, P875, DOI 10.1093/carcin/9.6.875; HECHT SS, 1993, ENVIRON HEALTH PERSP, V99, P57, DOI 10.2307/3431458; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEYSLEY LE, 1998, SERIES LUNG BIOL HLT, V122, P371; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; HULME EC, 1990, RECEPTOR BIOCH PRACT, P303; Innis M. A., 1990, PCR PROTOCOLS GUIDE; JOHNSON DE, 1982, PEDIATR RES, V16, P446, DOI 10.1203/00006450-198206000-00009; JOHNSON DE, 1988, AM REV RESPIR DIS, V137, P123; Johnson DE, 1989, AM REV RESPIR DIS, V143, P815; Knight JM, 1998, J ASTHMA, V35, P113, DOI 10.3109/02770909809055412; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LAI SL, 1995, ANTICANCER RES, V15, P225; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LAUWERYNS JM, 1977, CELL TISSUE RES, V182, P425; Lechin F, 1996, ANN ALLERG ASTHMA IM, V77, P245; LINDSTROM J, 1995, ADV PHAR SC, P45; LINNOILA RI, 1993, ANAT REC, V236, P231, DOI 10.1002/ar.1092360128; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MALLOY MH, 1992, AM J PUBLIC HEALTH, V82, P1380, DOI 10.2105/AJPH.82.10.1380; MCPHERSON GA, 1985, J PHARMACOL METHOD, V14, P213, DOI 10.1016/0160-5402(85)90034-8; Merryman JI, 1997, CHEST, V112, P779, DOI 10.1378/chest.112.3.779; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; NOVAK EJ, 1994, CYTOMETRY, V17, P135, DOI 10.1002/cyto.990170205; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; OSANN KE, 1991, CANCER RES, V51, P4893; PARK PG, 1995, CANCER RES, V55, P3504; Peng X, 1997, MOL PHARMACOL, V51, P776; PLUMMER HK, 1999, IN PRESS EXP LUNG RE; ROZENGURT E, 1990, PHILOS T ROY SOC B, V327, P209, DOI 10.1098/rstb.1990.0055; Schellscheidt J, 1997, ACTA PAEDIATR, V86, P857; SCHOENDORF KC, 1992, PEDIATRICS, V90, P905; SCHULLER HM, 1989, BIOCHEM PHARMACOL, V38, P3439, DOI 10.1016/0006-2952(89)90112-3; SCHULLER HM, 1989, TOXICOL IN VITRO, V3, P37, DOI 10.1016/0887-2333(89)90022-2; SCHULLER HM, 1994, NEUROTOXICOLOGY, V15, P877; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; SEGUELA P, 1993, J NEUROSCI, V13, P596; Sekhon HS, 1999, J CLIN INVEST, V103, P637, DOI 10.1172/JCI5232; SEUWEN K, 1988, NATURE, V335, P254, DOI 10.1038/335254a0; SHER E, 1990, CANCER RES, V50, P3892; STANISLAWSKI EC, 1981, ARCH INVEST MED, V12, P559; SUNDAY ME, 1988, LAB INVEST, V59, P5; TABBASIAN AR, 1989, AM REV RESP, V40, P436; WAGNER SN, 1993, VIRCHOWS ARCH B, V63, P325, DOI 10.1007/BF02899279; WEISS W, 1991, CHRONIC OBSTRUCTIVE, P344; WILLEY JC, 1984, EXP CELL RES, V153, P245, DOI 10.1016/0014-4827(84)90466-X; WILLIAMS ME, 1992, SCIENCE, V257, P389, DOI 10.1126/science.1321501; WILLIAMS ME, 1992, NEURON, V8, P71, DOI 10.1016/0896-6273(92)90109-Q; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0	73	74	78	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999			EUR J PHARMACOL	Eur. J. Pharmacol.	MAR 30	2000	393	1-3			SI		265	277		10.1016/S0014-2999(00)00094-7		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	306GQ	WOS:000086589300033	10771023	
J	Kiel, MA; Roder, E; van Wijk, RG; Al, MJ; Hop, WCJ; Rutten-van Molken, MPMH				Kiel, Menno A.; Roder, Esther; van Wijk, Roy Gerth; Al, Maiwenn J.; Hop, Wim C. J.; Rutten-van Molken, Maureen P. M. H.			Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; specific allergen immunotherapy; subcutaneous; sublingual; subcutaneous allergen immunotherapy; sublingual allergen immunotherapy; persistence; compliance; adherence; cost	TERM CLINICAL-EFFICACY; QUANTITATIVE ASSESSMENT; SLIT FORMULATION; EASY PROJECT; RHINITIS; ADHERENCE; ASTHMA; MEDICATION; CHILDREN; IMPACT	Background: Subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) are safe and effective treatments of allergic rhinitis, but high levels of compliance and persistence are crucial to achieving the desired clinical effects. Objective: Our objective was to assess levels and predictors of compliance and persistence among grass pollen, tree pollen, and house dust mite immunotherapy users in real life and to estimate the costs of premature discontinuation. Methods: We performed a retrospective analysis of a community pharmacy database from The Netherlands containing data from 6486 patients starting immunotherapy for 1 or more of the allergens of interest between 1994 and 2009. Two thousand seven hundred ninety-six patients received SCIT, and 3690 received SLIT. Time to treatment discontinuation was analyzed and included Cox proportional hazard models with time-dependent covariates, where appropriate. Results: Overall, only 18% of users reached the minimally required duration of treatment of 3 years (SCIT, 23%; SLIT, 7%). Median durations for SCIT and SLIT users were 1.7 and 0.6 years, respectively (P < .001). Other independent predictors of premature discontinuation were prescriber, with patients of general practitioners demonstrating longer persistence than those of allergologists and other medical specialists; single-allergen immunotherapy, lower socioeconomic status; and younger age. Of the persistent patients, 56% were never late in picking up their medication from the pharmacy. Direct medication costs per nonpersistent patient discontinuing in the third year of treatment were (sic)3800, an amount that was largely misspent. Conclusion: Real-life persistence is better in SCIT users than in SLIT users, although it is low overall. There is an urgent need for further identification of potential barriers and measures that will enhance persistence and compliance.	[Kiel, Menno A.; Al, Maiwenn J.; Rutten-van Molken, Maureen P. M. H.] Erasmus Univ, Inst Med Technol Assessment, Dept Hlth Econ iMTA, NL-3000 DR Rotterdam, Netherlands; [Kiel, Menno A.; Roder, Esther; van Wijk, Roy Gerth] Erasmus MC Univ Med Ctr, Dept Internal Med, Sect Allergol, Rotterdam, Netherlands; [Hop, Wim C. J.] Erasmus MC Univ Med Ctr, Dept Biostat, Rotterdam, Netherlands	Kiel, MA (reprint author), Inst Med Technol Assessment iMTA, Dept Hlth Econ, Rm W-J5-69,50 Burg Oudlaan,POB 1738, NL-3000 DR Rotterdam, Netherlands.	kiel@bmg.eur.nl	Al, Maiwenn/E-3272-2014; Rutten-van Molken, Maureen/G-8481-2014	Al, Maiwenn/0000-0001-9763-0436; Rutten-van Molken, Maureen/0000-0001-8706-3159	ZonMw (NWO); ALK-Abello; GlaxoSmithKline; HAL; Meda Pharma; Novartis; Phadia; Stallergenes; Allergopharma	E. Roder has received research support from ZonMw (NWO), and her thesis was financially supported by ALK-Abello, GlaxoSmithKline, HAL, Meda Pharma, Novartis, Phadia, and Stallergenes. R. Gerth van Wijk has received consultancy fees from Allergopharma, has received research support from ZonMw (NWO), and has participated in European Academy of Allergology and Clinical Immunology immunotherapy task forces. The rest of the authors declare they have no relevant conflicts of interest.	Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Brozek JL, 2010, J ALLERGY CLIN IMMUN, V126, P466, DOI 10.1016/j.jaci.2010.06.047; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Calderon MA, 2010, EVID BASED CHILD HLT, V5, P1279; COHN JR, 1993, J ALLERGY CLIN IMMUN, V91, P734, DOI 10.1016/0091-6749(93)90192-I; de Bot Cindy M A, 2012, Pediatr Allergy Immunol, V23, P150, DOI 10.1111/j.1399-3038.2011.01219.x; Donahue JG, 1999, ANN ALLERG ASTHMA IM, V82, P339; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Hakkaart-van Roijen L, 2010, HANDLEIDING KOSTENON; Hankin CS, 2008, J ALLERGY CLIN IMMUN, V121, P227, DOI 10.1016/j.jaci.2007.10.026; Herings RMC, 2012, PHARMACOEPIDEM DR S, P270; Incorvaia Cristoforo, 2008, Patient Prefer Adherence, V2, P247; Lombardi C, 2004, J ALLERGY CLIN IMMUN, V113, P1219, DOI 10.1016/j/jaci.2004.03.013; Osterberg L, 2005, NEW ENGL J MED, V353, P487, DOI 10.1056/NEJMra050100; Passalacqua G, 2007, PEDIATR ALLERGY IMMU, V18, P58, DOI 10.1111/j.1399-3038.2006.00471.x; Passlacqua G, 2006, J ALLERGY CLIN IMMUN, V117, P946, DOI 10.1016/j.jaci.2005.12.1312; Peterson AM, 2007, VALUE HEALTH, V10, P3, DOI 10.1111/j.1524-4733.2006.00139.x; PHARMO, PHARMO I HOM COMM PH; Radulovic S, 2010, COCHRANE DB SYST REV, V12, DOI DOI 10.1002/14651858.CD002893.PUB2; Sachs A, 2009, NHG STANDAARDEN HUIS, P980, DOI 10.1007/978-90-313-6614-9_61; Sociaal & Cultureel Planbureau (SCP), RANG NAAR SOC STAT P, P20133; Senna G, 2009, CURR OPIN ALLERGY CL, V9, P544, DOI 10.1097/ACI.0b013e328332b8df; Sieber J, 2011, CURR MED RES OPIN, V27, P855, DOI 10.1185/03007995.2011.559538; TINKELMAN D, 1995, ANN ALLERG ASTHMA IM, V74, P241; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Vita D, 2010, ALLERGY, V65, P668, DOI 10.1111/j.1398-9995.2009.02223.x	27	73	76	3	12	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2013	132	2					353	+		10.1016/j.jaci.2013.03.013		10	Allergy; Immunology	Allergy; Immunology	194KL	WOS:000322631700012	23651609	
J	Oliphant, CJ; Barlow, JL; McKenzie, ANJ				Oliphant, Chris J.; Barlow, Jillian L.; McKenzie, Andrew N. J.			Insights into the initiation of type 2 immune responses	IMMUNOLOGY			English	Review						allergens; interleukin-25; interleukin-33; innate lymphoid cells; nuocytes; T helper type 2 cells; thymic stromal lymphopoietin; type 2 responses	THYMIC STROMAL LYMPHOPOIETIN; INFLAMMATORY DENDRITIC CELLS; DUST-MITE ALLERGEN; CD4(+) T-CELLS; CYTOKINE-DEPENDENT IMMUNITY; HUMAN EPITHELIAL-CELLS; IN-VITRO DEVELOPMENT; NALP3 INFLAMMASOME; ADAPTIVE IMMUNITY; IL-4 PRODUCTION	Type 2 immune responses, characterized by the differentiation of CD4(+) T helper type 2 (Th2) cells and the production of the type 2 cytokines interleukin-4 (IL-4), IL-5, IL-9 and IL-13, are associated with parasitic helminth infections and inflammatory conditions such as asthma and allergies. Until recently the initiating factors associated with type 2 responses had been poorly understood. This review addresses the recent advances in identifying the diverse range of antigens/allergens associated with type 2 responses and the function, expression and sources of type-2-initiating cytokines (thymic stromal lymphopoietin, IL-25 and IL-33). We also discuss the latest findings regarding innate lymphoid cells, such as nuocytes, as early sources of type 2 cytokines and their importance in protective immunity to helminth infections. These developments represent major breakthroughs in our understanding of type 2 immunity, and highlight the increased complexity existing between the innate and adaptive arms of these responses. These additional steps in the type 2 immune pathway also offer potential targets for therapeutic intervention.	[Oliphant, Chris J.; Barlow, Jillian L.; McKenzie, Andrew N. J.] MRC, Mol Biol Lab, Cambridge CB2 2QH, England	Oliphant, CJ (reprint author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	oliphant@mrc-lmb.cam.ac.uk			American Asthma Foundation; Centocor	We thank Dr J. Walker for critical reading of and helpful suggestions to the manuscript. ANM and CJO are supported by the American Asthma Foundation, and ANM and JLB are supported by Centocor funding.	Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Al-Shami A, 2004, J EXP MED, V200, P159, DOI 10.1084/jem.20031975; Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Angkasekwinai P, 2010, NAT IMMUNOL, V11, P250, DOI 10.1038/ni.1846; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Cayrol C, 2009, P NATL ACAD SCI USA, V106, P9021, DOI 10.1073/pnas.0812690106; Chambers L, 1998, BIOCHEM BIOPH RES CO, V253, P837, DOI 10.1006/bbrc.1998.9862; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Dolgachev V, 2009, J IMMUNOL, V183, P5705, DOI 10.4049/jimmunol.0901666; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Everts B, 2009, J EXP MED, V206, P1673, DOI 10.1084/jem.20082460; Fallon PG, 2006, J EXP MED, V203, P1105, DOI 10.1084/jem.20051615; Finkelman FD, 2000, J IMMUNOL, V164, P2303; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Franchi L, 2008, EUR J IMMUNOL, V38, P2085, DOI 10.1002/eji.200838549; FRIEND SL, 1994, EXP HEMATOL, V22, P321; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Hong J, 2011, J BIOL CHEM, V286, P20078, DOI 10.1074/jbc.M111.219089; Hornung V, 2008, NAT IMMUNOL, V9, P847, DOI 10.1038/ni.1631; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Humphreys NE, 2008, J IMMUNOL, V180, P2443; Isaksen DE, 1999, J IMMUNOL, V163, P5971; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jankovic D, 2000, J IMMUNOL, V164, P3047; Jung JS, 2009, CHEST, V135, P1173, DOI 10.1378/chest.08-1595; Kool M, 2008, J IMMUNOL, V181, P3755; Kool M, 2008, J EXP MED, V205, P869, DOI 10.1084/jem.20071087; Kouzaki H, 2009, J IMMUNOL, V183, P1427, DOI 10.4049/jimmunol.0900904; Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575; LEGROS G, 1990, J EXP MED, V172, P921, DOI 10.1084/jem.172.3.921; Li HF, 2008, J IMMUNOL, V181, P17; Li HF, 2007, J IMMUNOL, V178, P5271; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Massacand JC, 2009, P NATL ACAD SCI USA, V106, P13968, DOI 10.1073/pnas.0906367106; McKerrow JH, 2006, ANNU REV PATHOL-MECH, V1, P497, DOI 10.1146/annurev.pathol.1.110304.100151; Min B, 2004, J EXP MED, V200, P507, DOI 10.1084/jem.20040590; Mitre E, 2004, J IMMUNOL, V172, P2439; Moro K, 2010, NATURE, V463, P540, DOI 10.1038/nature08636; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Oboki K, 2010, P NATL ACAD SCI USA, V107, P18581, DOI 10.1073/pnas.1003059107; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Okano M, 2001, J IMMUNOL, V167, P442; Owyang AM, 2006, J EXP MED, V203, P843, DOI 10.1084/jem.20051496; Park GM, 2000, CLIN EXP ALLERGY, V30, P1293, DOI 10.1046/j.1365-2222.2000.00883.x; Pecaric-Petkovic T, 2009, BLOOD, V113, P1526, DOI 10.1182/blood-2008-05-157818; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; PFEIFFER C, 1995, J EXP MED, V181, P1569, DOI 10.1084/jem.181.4.1569; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Rickel EA, 2008, J IMMUNOL, V181, P4299; Saenz SA, 2010, NATURE, V464, P1362, DOI 10.1038/nature08901; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schramm G, 2007, J IMMUNOL, V178, P6023; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Steinfelder S, 2009, J EXP MED, V206, P1681, DOI 10.1084/jem.20082462; Sullivan BM, 2011, NAT IMMUNOL, V12, P527, DOI 10.1038/ni.2036; Suzukawa M, 2008, J IMMUNOL, V181, P5981; SWAIN SL, 1990, J IMMUNOL, V145, P3796; Talabot-Ayer D, 2009, J BIOL CHEM, V284, P19420, DOI 10.1074/jbc.M901744200; Tanaka S, 2011, NAT IMMUNOL, V12, P77, DOI 10.1038/ni.1966; Tao X, 1997, J IMMUNOL, V158, P4237; Taylor BC, 2009, J EXP MED, V206, P655, DOI 10.1084/jem.20081499; Terrier B, 2010, BLOOD, V116, P4523, DOI 10.1182/blood-2010-02-267542; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Wada T, 2010, J CLIN INVEST, V120, P2867, DOI 10.1172/JCI42680; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhang F, 2011, CLIN EXP IMMUNOL, V164, P256, DOI 10.1111/j.1365-2249.2011.04328.x; Zhao AP, 2010, J IMMUNOL, V185, P6921, DOI 10.4049/jimmunol.1000450; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	81	73	78	0	18	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0019-2805			IMMUNOLOGY	Immunology	DEC	2011	134	4					378	385		10.1111/j.1365-2567.2011.03499.x		8	Immunology	Immunology	853XS	WOS:000297459600003	22044021	
J	Kearley, J; Erjefalt, JS; Andersson, C; Benjamin, E; Jones, CP; Robichaud, A; Pegorier, S; Brewah, Y; Burwell, TJ; Bjermer, L; Kiener, PA; Kolbec, R; Lloyd, CM; Coyle, AJ; Humbles, AA				Kearley, Jennifer; Erjefalt, Jonas S.; Andersson, Cecilia; Benjamin, Ebony; Jones, Carla P.; Robichaud, Annette; Pegorier, Sophie; Brewah, Yambasu; Burwell, Timothy J.; Bjermer, Leif; Kiener, Peter A.; Kolbec, Roland; Lloyd, Clare M.; Coyle, Anthony J.; Humbles, Alison A.			IL-9 Governs Allergen-induced Mast Cell Numbers in the Lung and Chronic Remodeling of the Airways	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						IL-9; mast cells; asthma; airway remodeling; AHR	FIBROBLAST-GROWTH-FACTOR; TRANSGENIC MICE; PULMONARY INFLAMMATION; SMOOTH-MUSCLE; INTERLEUKIN 9; MILD ASTHMA; TGF-BETA; HYPERRESPONSIVENESS; CHALLENGE; EXPRESSION	Rationale: IL-9 is a pleiotropic cytokine that has multiple effects on structural as well as numerous hematopoietic cells, which are central to the pathogenesis of asthma. Objectives: The contribution of IL-9 to asthma pathogenesis has thus far been unclear, due to conflicting reports in the literature. These earlier studies focused on the role of IL-9 in acute inflammatory models; here we have investigated the effects of IL-9 blockade during chronic allergic inflammation. Methods: Mice were exposed to either prolonged ovalbumin or house dust mite allergen challenge to induce chronic inflammation and airway remodeling. Measurements and Main Results: We found that IL-9 governs allergen-induced mast cell (MC) numbers in the lung and has pronounced effects on chronic allergic inflammation. Anti-IL-9 antibody-treated mice were protected from airway remodeling with a concomitant reduction in mature MC numbers and activation, in addition to decreased expression of the profibrotic mediators transforming growth factor-beta 1, vascular endothelial growth factor, and fibroblast growth factor-2 in the lung. Airway remodeling was associated with impaired lung function in the peripheral airways and this was reversed by IL-9 neutralization. In human asthmatic lung tissue, we identified MCs as the main IL-9 receptor expressing population and found them to be sources of vascular endothelial growth factor and fibroblast growth factor-2. Conclusions: Our data suggest an important role for an IL-9-MC axis in the pathology associated with chronic asthma and demonstrate that an impact on this axis could lead to a reduction in chronic inflammation and improved lung function in patients with asthma.	[Kearley, Jennifer; Benjamin, Ebony; Brewah, Yambasu; Burwell, Timothy J.; Kiener, Peter A.; Kolbec, Roland; Coyle, Anthony J.; Humbles, Alison A.] MedImmune LLC, Dept Resp Inflammat & Autoimmun, Gaithersburg, MD 20878 USA; [Erjefalt, Jonas S.; Andersson, Cecilia; Bjermer, Leif] Lund Univ, Dept Expt Med Sci, Unit Airway Inflammat, Lund, Sweden; [Jones, Carla P.; Pegorier, Sophie; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, Natl Heart & Lung Inst, Fac Med, London, England; [Robichaud, Annette] Sci Resp Equipment Inc, Montreal, PQ, Canada	Humbles, AA (reprint author), MedImmune LLC, Dept Resp Inflammat & Autoimmun, 1 MedImmune Way, Gaithersburg, MD 20878 USA.	humblesa@medimmune.com		Lloyd, Clare/0000-0001-8977-6726	MedImmune	Funded by MedImmune.	Abonia JP, 2006, BLOOD, V108, P1588, DOI 10.1182/blood-2005-12-012781; Bates JHT, 2006, J APPL PHYSIOL, V100, P500, DOI 10.1152/japplphysiol.01013.2005; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown JM, 2007, AM J RESP CELL MOL, V36, P43, DOI 10.1165/rcmb.2006-0197OC; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Cheng G, 2002, AM J RESP CRIT CARE, V166, P409, DOI 10.1164/rccm.2105079; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Curran AK, 2008, J ASTHMA, V45, P377, DOI 10.1080/02770900801971784; Evans MJ, 2002, LAB INVEST, V82, P1747, DOI 10.1097/01.LAB.0000043911.94235.F3; Fattouh R, 2008, AM J RESP CRIT CARE, V177, P593, DOI 10.1164/rccm.200706-958OC; Godfraind C, 1998, J IMMUNOL, V160, P3989; Holgate ST, 2008, CLIN EXP ALLERGY, V38, P872, DOI 10.1111/j.1365-2222.2008.02971.x; HULNTNER L, 1990, EUR J IMMUNOL, V20, P1413; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; HUMBLES AA, 2007, AM J RESP CRIT CARE, V175, pA798; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; Johnson JR, 2004, AM J RESP CRIT CARE, V169, P378, DOI 10.1164/rccm.200308-1094OC; Jones TG, 2009, J IMMUNOL, V183, P5251, DOI 10.4049/jimmunol.0901471; Kariyawasam HH, 2007, AM J RESP CRIT CARE, V175, P896, DOI 10.1164/rccm.200609-1260OC; Kearley J, 2009, AM J RESP CRIT CARE, V179; Khan WI, 2003, INFECT IMMUN, V71, P2430, DOI 10.1128/IAI.71.5.2430-2438.2003; KLEEBERGER SR, 1993, AM REV RESPIR DIS, V148, P1284; Kung TT, 2001, AM J RESP CELL MOL, V25, P600; Laprise C, 1999, EUR RESPIR J, V14, P63, DOI 10.1034/j.1399-3003.1999.14a12.x; Le AV, 2007, J IMMUNOL, V178, P7310; Lee CG, 2004, NAT MED, V10, P1095, DOI 10.1038/nm1105; LOUAHED J, 1995, J IMMUNOL, V154, P5061; Lu LF, 2006, NATURE, V442, P997, DOI 10.1038/nature05010; Matsuzawa S, 2003, J IMMUNOL, V170, P3461; McLane MP, 1998, AM J RESP CELL MOL, V19, P713; McMillan S, 2002, J EXP MED, V195, P51, DOI 10.1084/jem.20011732; McMillan SJ, 2005, J IMMUNOL, V174, P5774; Mcmillan SJ, 2004, CLIN EXP ALLERGY, V34, P497, DOI 10.1111/j.1365-2222.2004.01895.x; Nicolaides NC, 1997, P NATL ACAD SCI USA, V94, P13175, DOI 10.1073/pnas.94.24.13175; OBRIENLADNER AR, 1993, AGENTS ACTIONS, V39, P20, DOI 10.1007/BF01975709; PESCI A, 1993, CHEST, V103, P989, DOI 10.1378/chest.103.4.989; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Qu ZH, 1998, J HISTOCHEM CYTOCHEM, V46, P1119; Redington AE, 2001, J ALLERGY CLIN IMMUN, V107, P384, DOI 10.1067/mai.2001.112268; RENAULD JC, 1995, J LEUKOCYTE BIOL, V57, P353; Shute JK, 2004, THORAX, V59, P557, DOI 10.1136/thx.2002.002626; Southam DS, 2007, J ALLERGY CLIN IMMUN, V119, P848, DOI 10.1016/j.jaci.2006.12.623; Takai S, 2003, J PHARMACOL EXP THER, V305, P17, DOI 10.1124/jpet.102.045179; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tesseur I, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-15; Townsend MJ, 2000, IMMUNITY, V13, P573, DOI 10.1016/S1074-7613(00)00056-X; van den Brle S, 2007, AM J RESP CELL MOL, V37, P202, DOI 10.1165/rcmb.2006-0397OC; Wiener Z, 2004, CYTOKINE, V26, P122, DOI 10.1016/j.cyto.2004.01.006; Woodman L, 2008, J IMMUNOL, V181, P5001; Yu M, 2006, J CLIN INVEST, V116, P1633, DOI 10.1172/JCI25702; Zanini A, 2007, J ALLERGY CLIN IMMUN, V120, P329, DOI 10.1016/j.jaci.2007.04.021	53	73	78	0	7	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2011	183	7					865	875		10.1164/rccm.200909-1462OC		11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	747KN	WOS:000289318800012	20971830	
J	Muller, T; Robaye, B; Vieira, RP; Ferrari, D; Grimm, M; Jakob, T; Martin, SF; Di Virgilio, F; Boeynaems, JM; Virchow, JC; Idzko, M				Mueller, T.; Robaye, B.; Vieira, R. P.; Ferrari, D.; Grimm, M.; Jakob, T.; Martin, S. F.; Di Virgilio, F.; Boeynaems, J. -M.; Virchow, J. C.; Idzko, M.			The purinergic receptor P2Y(2) receptor mediates chemotaxis of dendritic cells and eosinophils in allergic lung inflammation	ALLERGY			English	Article						asthma; ATP; chemotaxis; dendritic cells; eosinophils	OXYGEN RADICAL PRODUCTION; PHARMACOLOGICAL CHARACTERIZATION; NUCLEOTIDE RECEPTORS; INTERNATIONAL UNION; TISSUE DISTRIBUTION; CAPACITY; RELEASE; ASTHMA; IDENTIFICATION; EXPRESSION	Background: Extracellular ATP contributes to the pathogenesis of asthma via signalling at purinergic receptors. However, the precise purinergic receptors subtypes mediating the pro-asthmatic effects of ATP have not been identified, yet. Methods: In vivo studies were performed using the OVA-alum model. Functional expression of the P2Y(2) purinergic receptor subtype on human monocyte-derived dendritic cells and eosinophils was investigated using real-time PCR, migration assays, and production of reactive oxygen species. Results: Compared to wild-type animals P2Y(2)-/- mice showed reduced allergic airway inflammation which can be explained by defective migration of blood myeloid DCs towards ATP in vitro and in vivo, whereas the influence of ATP on maturation and cytokine production was not changed. Additionally, ATP failed to induce migration of bone marrow-derived eosinophils from P2Y(2)R-deficient animals. The relevance of our findings for humans was confirmed in functional studies with human monocyte-derived DCs and eosinophils. Interestingly, stimulation of human DCs derived from allergic individuals with house dust mite allergen induced functional up-regulation of the P2Y(2)R subtype. Furthermore, eosinophils isolated from asthmatic individuals expressed higher levels of P2Y(2)R compared to healthy controls. This was of functional relevance as these eosinophils were more sensitive to ATP-induced migration and production of reactive oxygen metabolites. Conclusions: In summary, P2Y(2)R appears to be involved in asthmatic airway inflammation by mediating ATP-triggered migration of mDCs and eosinophils, as well as reactive oxygen species production. Together our data suggest that targeting P2Y(2)R might be a therapeutic option for the treatment of asthma.	[Mueller, T.; Vieira, R. P.; Grimm, M.; Idzko, M.] Univ Med Ctr Freiburg, Dept Pneumol, D-79106 Freiburg, Germany; [Robaye, B.; Boeynaems, J. -M.] Univ Libre Bruxelles, IRIBHM, Brussels, Belgium; [Robaye, B.; Boeynaems, J. -M.] Univ Libre Bruxelles, Erasme Hosp, Brussels, Belgium; [Ferrari, D.; Di Virgilio, F.] Univ Ferrara, Dept Gen Pathol, I-44100 Ferrara, Italy; [Jakob, T.; Martin, S. F.] Univ Med Ctr Freiburg, Allergy Res Grp, D-79106 Freiburg, Germany; [Virchow, J. C.] Univ Med Ctr Rostock, Dept Pneumol, Rostock, Germany	Muller, T (reprint author), Univ Med Ctr Freiburg, Dept Pneumol, Killianstr 5, D-79106 Freiburg, Germany.	marco.idzko@uniklinink-freiburg.de	Vieira, Rodolfo/E-9315-2011; Jakob, Thilo/J-1621-2012; Ferrari, Davide/F-5644-2015	Vieira, Rodolfo/0000-0001-6379-1143; Ferrari, Davide/0000-0002-5727-9204	German Research Foundation (DFG [7/4-1]	This work was supported by a grant to M.I. from the German Research Foundation (DFG, ID 7/4-1).	Abbracchio MP, 2006, PHARMACOL REV, V58, P281, DOI 10.1124/pr.58.3.3; Chen Y, 2006, SCIENCE, V314, P1792, DOI 10.1126/science.1132559; Communi D, 1996, BIOCHEM BIOPH RES CO, V222, P303, DOI 10.1006/bbrc.1996.0739; Communi D, 1996, EUR J PHARMACOL, V317, P383, DOI 10.1016/S0014-2999(96)00740-6; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dichmann S, 2000, BLOOD, V95, P973; Dyer KD, 2008, J IMMUNOL, V181, P4004; Ferrari D, 2000, FEBS LETT, V486, P217, DOI 10.1016/S0014-5793(00)02306-1; Ferrari D, 2000, FASEB J, V14, P2466, DOI 10.1096/fj.00-0031com; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; Idzko M, 2002, BLOOD, V100, P925, DOI 10.1182/blood.V100.3.925; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Idzko M, 2006, J CLIN INVEST, V116, P2935, DOI 10.1172/JCI28295; Inoue Y, 2008, SHOCK, V30, P173, DOI 10.1097/SHK.0b013e318160dad4; Janssens R, 1996, BIOCHEM BIOPH RES CO, V221, P588, DOI 10.1006/bbrc.1996.0640; KAY AB, 1992, AM REV RESPIR DIS, V145, pS22; Khakh BS, 2001, PHARMACOL REV, V53, P107; la Sala A, 2002, BLOOD, V99, P1715, DOI 10.1182/blood.V99.5.1715; la Sala A, 2001, J IMMUNOL, V166, P1611; Lambrecht BN, 2005, ALLERGY, V60, P271, DOI 10.1111/j.1398-9995.2005.00708.x; Marteau F, 2003, MOL PHARMACOL, V64, P104, DOI 10.1124/mol.64.1.104; Matos JE, 2005, J PHYSIOL-LONDON, V564, P269, DOI 10.1113/jphysiol.2004.080002; Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113; Ralevic V, 1997, BRIT J PHARMACOL, V121, P1121, DOI 10.1038/sj.bjp.0701262; van der Weyden L, 2000, MOL CELL BIOCHEM, V213, P75, DOI 10.1023/A:1007168215748; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	27	73	75	1	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	DEC	2010	65	12					1545	1553		10.1111/j.1398-9995.2010.02426.x		9	Allergy; Immunology	Allergy; Immunology	673UG	WOS:000283688400006	20880147	
J	Pare, G; Moqadem, K; Pineau, G; St-Hilaire, C				Pare, Guy; Moqadem, Khalil; Pineau, Gilles; St-Hilaire, Carole			Clinical Effects of Home Telemonitoring in the Context of Diabetes, Asthma, Heart Failure and Hypertension: A Systematic Review	JOURNAL OF MEDICAL INTERNET RESEARCH			English	Review						Home telemonitoring; information technology; chronic illnesses; clinical effects	RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE CONTROL; URBAN AFRICAN-AMERICANS; MONITORING-SYSTEM; GLYCEMIC CONTROL; FOLLOW-UP; HIGH-RISK; MANAGEMENT; TELEMEDICINE; CARE	Background: Home telemonitoring figures among the various solutions that could help attenuate some of the problems associated with aging populations, rates of chronic illness, and shortages of health professionals. Objective: The primary aim of this study was to further our understanding of the clinical effects associated with home telemonitoring programs in the context of chronic diseases. Methods: We conducted a systematic review which covered studies published between January 1966 and December 2008. MEDLINE, The Cochrane Library, and the INAHTA (International Network of Agencies for Health Technology Assessment) database were consulted. Our inclusion criteria consisted of: (I) English language publications in peer-reviewed journals or conference proceedings and (2) studies involving patients with diabetes, asthma, heart failure, or hypertension, and presenting results on the clinical effects of home telemonitoring. Results: In all, 62 empirical studies were analyzed. The results from studies involving patients with diabetes indicated a trend toward patients with home telemonitoring achieving better glycemic control. In most trials in which patients with asthma were enrolled, results showed significant improvements in patients' peak expiratory flows, significant reductions in the symptoms associated with this illness, and improvements in perceived quality of life. Virtually all studies involving patients with hypertension demonstrated the ability of home telemonitoring to reduce systolic and/or diastolic blood pressure. Lastly, due to the equivocal nature of current findings of home telemonitoring involving patients with heart failure, larger trials are still needed to confirm the clinical effects of this technology for these patients. Conclusions: Although home telemonitoring appears to be a promising approach to patient management, designers of future studies should consider ways to make this technology more effective as well as controlling possible mediating variables.	[Pare, Guy] HEC Montreal, Montreal, PQ H3T 2A7, Canada; [Moqadem, Khalil; Pineau, Gilles; St-Hilaire, Carole] Agence Evaluat Technol & Modes Intervent Sante, Quebec Dept Hlth, Montreal, PQ, Canada	Pare, G (reprint author), HEC Montreal, 3000 Cote Ste Catherine Rd, Montreal, PQ H3T 2A7, Canada.	guy.pare@hec.ca			AETMIS; Canada Research Chairs Program	The authors would like to thank the Editor, Gunther Eysenbach, and the three anonymous reviewers for their helpful comments and suggestions on an earlier version of this manuscript. Further, the AETMIS and the Canada Research Chairs Program are gratefully acknowledged for providing financial support for this research.	AHRING KK, 1992, DIABETES CARE, V15, P971, DOI 10.2337/diacare.15.8.971; Antonicelli R, 2008, J TELEMED TELECARE, V14, P300, DOI 10.1258/jtt.2008.071213; Artinian NT, 2007, NURS RES, V56, P312, DOI 10.1097/01.NNR.0000289501.45284.6e; Artinian NT, 2001, HEART LUNG, V30, P191, DOI 10.1067/mhl.2001.112684; Barnason S, 2003, HEART LUNG, V32, P147, DOI 10.1016/S0147-9563(03)00036-0; Bellazzi R, 2002, COMPUT METH PROG BIO, V69, P147, DOI 10.1016/S0169-2607(02)00038-X; Bellazzi Riccardo, 2003, Diabetes Technol Ther, V5, P621, DOI 10.1089/152091503322250640; Benatar D, 2003, ARCH INTERN MED, V163, P347, DOI 10.1001/archinte.163.3.347; Bergenstal Richard M, 2005, Diabetes Technol Ther, V7, P241, DOI 10.1089/dia.2005.7.241; Biermann E, 2002, COMPUT METH PROG BIO, V69, P137, DOI 10.1016/S0169-2607(02)00037-8; BILLIARD A, 1991, DIABETES CARE, V14, P130, DOI 10.2337/diacare.14.2.130; Bondmass M, 2000, TELEMED J, V6, P15, DOI 10.1089/107830200311815; BONDMASS M, 1999, INTERNET J ADV NURSI, V3; Bruderman I, 1997, Telemed J, V3, P127, DOI 10.1089/tmj.1.1997.3.127; Bujnowska-Fedak MM, 2006, J TELEMED TELECARE, V12, P8, DOI 10.1258/135763306777978551; *CAN HOM CAR ASS, 2008, INT INF COMM TECHN H; Chan DS, 2007, PEDIATRICS, V119, P569, DOI 10.1542/peds.2006-1884; Chan DS, 2003, AM J HEALTH-SYST PH, V60, P1976; Chase HP, 2003, DIABETES CARE, V26, P1475, DOI 10.2337/diacare.26.5.1475; Chumbler NR, 2005, J TELEMED TELECARE, V11, P150, DOI 10.1258/1357633053688723; Cleland JGF, 2005, J AM COLL CARDIOL, V45, P1654, DOI 10.1016/j.jacc.2005.01.050; DALTON KJ, 1987, INT J BIOMED COMPUT, V21, P175, DOI 10.1016/0020-7101(87)90085-7; Dansky Kathryn H, 2008, Clin Nurs Res, V17, P182, DOI 10.1177/1054773808320837; Dar O, 2009, EUR J HEART FAIL, V11, P319, DOI 10.1093/eurjhf/hfn050; de Lusignan S, 2001, EUR J HEART FAIL, V3, P723, DOI 10.1016/S1388-9842(01)00190-8; de Lusignan S, 1999, ST HEAL T, V64, P126; DelliFraine JL, 2008, J TELEMED TELECARE, V14, P62, DOI 10.1258/jtt.2007.070709; Friedman RH, 1996, AM J HYPERTENS, V9, P285, DOI 10.1016/0895-7061(95)00353-3; Goldberg LR, 2003, AM HEART J, V146, P705, DOI 10.1016/S0002-8703(03)00393-4; Gomez EJ, 2002, COMPUT METH PROG BIO, V69, P163, DOI 10.1016/S0169-2607(02)00039-1; Guendelman S, 2002, ARCH PEDIAT ADOL MED, V156, P114; Health Council of Canada, 2007, POP PATT CHRON HLTH; Hopp FP, 2007, IMPLEMENT SCI, V2, DOI 10.1186/1748-5908-2-14; Jaana M, 2007, DIS MANAG HEALTH OUT, V15, P19, DOI 10.2165/00115677-200715010-00004; Jaana M, 2009, AM J MANAG CARE, V15, P313; Jan RL, 2007, TELEMED J E-HEALTH, V13, P257, DOI 10.1089/tmj.2006.0053; JOVELL AJ, 1995, MED CLIN-BARCELONA, V105, P740; Kwon HS, 2004, DIABETES CARE, V27, P478, DOI 10.2337/diacare.27.2.478; Ladyzynski P, 2007, J TELEMED TELECARE, V13, P44, DOI 10.1258/135763307779701167; Lavery LA, 2004, DIABETES CARE, V27, P2642, DOI 10.2337/diacare.27.11.2642; Liesenfeld B, 2000, Diabetes Technol Ther, V2, P561, DOI 10.1089/15209150050501970; Logan AG, 2007, AM J HYPERTENS, V20, P942, DOI 10.1016/j.amjhyper.2007.03.020; Madsen LB, 2008, BLOOD PRESSURE, V17, P227, DOI 10.1080/08037050802433701; MARRERO DG, 1995, DIABETES EDUCATOR, V21, P313, DOI 10.1177/014572179502100409; Meneghini LF, 1998, DIABETES CARE, V21, P591, DOI 10.2337/diacare.21.4.591; Mengden T, 2004, BLOOD PRESS MONIT, V9, P321, DOI 10.1097/00126097-200412000-00010; Moher D, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000097; Montori VM, 2004, DIABETES CARE, V27, P1088, DOI 10.2337/diacare.27.5.1088; Mortara A, 2009, EUR J HEART FAIL, V11, P312, DOI 10.1093/eurjhf/hfp022; Moyer-Knox D, 2004, J CARD FAIL, V10, P219, DOI 10.1016/j.cardfail.2003.09.009; Naef R W 3rd, 1998, J Perinatol, V18, P226; Nakamoto Hidetomo, 2004, Adv Perit Dial, V20, P105; *OECD, 2007, DIR EMPL LAB SOC AFF; Ostojic V, 2005, TELEMED J E-HEALTH, V11, P28, DOI 10.1089/tmj.2005.11.28; Parati G, 2009, J HYPERTENS, V27, P198, DOI 10.1097/HJH.0b013e3283163caf; Pare G, 2007, J AM MED INFORM ASSN, V14, P269, DOI 10.1197/jamia.M2270; Piette JD, 2000, AM J MED, V108, P20, DOI 10.1016/S0002-9343(99)00298-3; Polisena J, 2009, DIABETES OBES METAB, V11, P913, DOI 10.1111/j.1463-1326.2009.01057.x; Port K, 2005, J TELEMED TELECARE, V11, P34, DOI 10.1258/1357633054461705; Port K, 2003, J TELEMED TELECARE, V9, pS65, DOI 10.1258/135763303322196394; Rasmussen LM, 2005, J ALLERGY CLIN IMMUN, V115, P1137, DOI 10.1016/j.jaci.2005.03.030; Rickerby J, 2003, J HUM HYPERTENS, V17, P495, DOI 10.1038/sj.jhh.1001582; Rogers MAM, 2001, ANN INTERN MED, V134, P1024; Roine R, 2001, CAN MED ASSOC J, V165, P765; Roth A, 2004, INT J CARDIOL, V97, P49, DOI 10.1016/j.ijcard.2003.07.030; Scalvini S, 2005, J TELEMED TELECARE, V11, P18, DOI 10.1258/1357633054461750; Scherr D, 2006, J TELEMED TELECARE, V12, P255, DOI 10.1258/135763306777889046; Schofield RS, 2005, TELEMED J E-HEALTH, V11, P20, DOI 10.1089/tmj.2005.11.20; Schwarz Karen A, 2008, Prog Cardiovasc Nurs, V23, P18, DOI 10.1111/j.1751-7117.2008.tb00527.x; Shea S, 2006, J AM MED INFORM ASSN, V13, P40, DOI 10.1197/jamia.M1917; SHULTZ EK, 1992, ANN NY ACAD SCI, V670, P141, DOI 10.1111/j.1749-6632.1992.tb26084.x; Smith Sheree M, 2009, Prim Care Respir J, V18, P159, DOI 10.4104/pcrj.2009.00038; Soran OZ, 2008, J CARD FAIL, V14, P711, DOI 10.1016/j.cardfail.2008.06.448; Stone RA, 2010, DIABETES CARE, V33, P478, DOI 10.2337/dc09-1012; Trappenburg JCA, 2008, TELEMED J E-HEALTH, V14, P138, DOI 10.1089/tmj.2007.0037; TREMBLAY M, 2008, ANAL IMPACTS MONDIAL; Tsang MW, 2001, J TELEMED TELECARE, V7, P47, DOI 10.1258/1357633011936138; *UN EC SOC AFF, 2007, WORLD POP PROSP 2006; Vahatalo M., 2004, PRACT DIABETES INT, V21, P192, DOI [DOI 10.1002/PDI.642], DOI 10.1002/PDI.642]; Welch G, 2003, DIABETES, V52, pA100; WHO, 2006, GLOB SHORT HLTH WORK; *WHO DEP CHRON DIS, 2005, PREV CHRON DIS VIT I; Willems DCM, 2008, J EVAL CLIN PRACT, V14, P600, DOI 10.1111/j.1365-2753.2007.00936.x; Wojcicki J M, 2001, Diabetes Technol Ther, V3, P581, DOI 10.1089/15209150152811207; Woodend AK, 2008, HEART LUNG, V37, P36, DOI [10.1016/j.hrtlng.2007.04.004, 10.1016/j.hrtlng,2007.04.004]; Woodend A. K., 2002, J CARD FAIL S1, V8, P98	86	73	74	1	24	JMIR PUBLICATIONS, INC	TORONTO	59 WINNERS CIRCLE, TORONTO, ON M4L 3Y7, CANADA	1438-8871			J MED INTERNET RES	J. Med. Internet Res.	APR-JUN	2010	12	2							e21	10.2196/jmir.1357		15	Health Care Sciences & Services; Medical Informatics	Health Care Sciences & Services; Medical Informatics	611YK	WOS:000278860800012	20554500	
J	Delfino, RJ; Staimer, N; Tjoa, T; Gillen, D; Kleinman, MT; Sioutas, C; Cooper, D				Delfino, Ralph J.; Staimer, Norbert; Tjoa, Thomas; Gillen, Dan; Kleinman, Michael T.; Sioutas, Constantinos; Cooper, Dan			Personal and ambient air pollution exposures and lung function decrements in children with asthma	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; epidemiology; forced expiratory flow rates; longitudinal data analysis; nitrogen dioxide; panel study; particulate air pollution	ANTIINFLAMMATORY MEDICATION USE; NITROGEN-DIOXIDE EXPOSURE; PEAK EXPIRATORY FLOW; PARTICULATE AIR; ULTRAFINE PARTICLES; POLLUTANTS; SYMPTOMS; HEALTH; ASSOCIATION; MASS	BACKGROUND: Epidemiologic studies have shown associations between asthma outcomes and outdoor air pollutants such as nitrogen dioxide and particulate matter mass < 2.5 mu m in diameter (PM2.5). Independent effects of specific pollutants have been difficult to detect because most studies have relied on highly correlated central-site measurements. OBJECTIVES: This study was designed to evaluate the relationship of daily changes in percent-predicted forced expiratory volume in 1 see (FEV1) with personal and ambient air pollutant exposures. METHODS: For 10 days each, we followed 53 subjects with asthma who were 9-18 years of age and living in the Los Angeles, California, air basin. Subjects self-administered home spirometry in the morning, afternoon, and evening. We measured personal hourly PM2.5 mass, 24-hr PM2.5 elemental and organic carbon (EC-OC), and 24-hr NO2, and the same 24-hr average outdoor central-site (ambient) exposures. We analyzed data with transitional mixed models controlling for personal temperature and humidity, and as-needed beta(2)-agonist inhaler use. RESULTS: FEV1 decrements were significantly associated with increasing hourly peak and daily average personal PM2.5, but not ambient PM2.5. Personal NO2 was also inversely associated with FEV1. Ambient NO2 was more weakly associated. We found stronger associations among 37 subjects not taking controller bronchodilators as follows: Personal EC-OC was inversely associated with morning FEV1; for an interquartile increase of 71 mu g/m(3) 1-hr maximum personal PM2.5, overall percent-predicted FEV1 decreased by 1.32% [95% confidence interval (CI), -2.00 to -0.65%]; and for an interquartile increase of 16.8 ppb 2-day average personal NO2, overall percent-predicted FLV1 decreased by 2.45% (95% CI, -3.57 to -1.33%). Associations of both personal PM2.5 and NO2 with FEV1 remained when co-regressed, and both confounded ambient NO2. CONCLUSIONS: Independent pollutant associations with lung function might be missed using ambient data alone. Different sets of causal components are suggested by independence of FEV1 associations with personal PM2.5 mass from associations with personal NO2.	[Delfino, Ralph J.; Staimer, Norbert; Tjoa, Thomas] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92617 USA; [Gillen, Dan] Univ Calif Irvine, Sch Informat & Comp Sci, Dept Stat, Irvine, CA 92617 USA; [Kleinman, Michael T.] Univ Calif Irvine, Sch Med, Dept Community & Environm Med, Irvine, CA 92617 USA; [Cooper, Dan] Univ Calif Irvine, Sch Med, Dept Pediat, Irvine, CA 92617 USA; [Sioutas, Constantinos] Univ So Calif, Sch Engn, Dept Civil & Environm Engn, Los Angeles, CA USA	Delfino, RJ (reprint author), Univ Calif Irvine, Sch Med, Dept Epidemiol, 100 Theory,Suite 100, Irvine, CA 92617 USA.	rdelfino@uci.edu	Wang, Linden/M-6617-2014		NCRR NIH HHS [M01 RR000827, MO1-RR00827]; NICHD NIH HHS [HD048721, P01 HD048721]; NIEHS NIH HHS [ES11615, R01 ES011615]		Aekplakorn W, 2003, INT J EPIDEMIOL, V32, P854, DOI 10.1093/ije/dyg237; Becklake MR, 1999, THORAX, V54, P1119; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Biswas S, 2007, ATMOS ENVIRON, V41, P3479, DOI 10.1016/j.atmosenv.2006.11.059; Chakrabarti B, 2004, ATMOS ENVIRON, V38, P3329, DOI 10.1016/j.atmosenv.2004.03.007; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Cyrys J, 2003, J EXPO ANAL ENV EPID, V13, P134, DOI 10.1038/sj.jea.7500262; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Diggle P, 2002, ANAL LONGITUDINAL DA; Fujita EM, 2007, J AIR WASTE MANAGE, V57, P721, DOI 10.3155/1047-3289.57.6.721; Fung K, 2002, J AIR WASTE MANAGE, V52, P1333; Giannini D, 1997, J ASTHMA, V34, P105, DOI 10.3109/02770909709075654; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; Kraft M, 2005, INT J HYG ENVIR HEAL, V208, P305, DOI 10.1016/j.ijheh.2005.04.002; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Lewis TC, 2005, ENVIRON HEALTH PERSP, V113, P1068, DOI 10.1289/ehp.7533; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; *NAT I OCC SAF HLT, 1994, DHHS PUBL NAT I OCC; Persinger RL, 2002, MOL CELL BIOCHEM, V234, P71, DOI 10.1023/A:1015973530559; Rabinovitch N, 2006, AM J RESP CRIT CARE, V173, P1098, DOI 10.1164/rccm.200509-1393OC; Rabinovitch N, 2004, J ALLERGY CLIN IMMUN, V114, P1131, DOI 10.1016/j.jaci.2004.08.026; *RAND CAL, 2007, RAND CAL POP DENS ST; Sarnat JA, 2005, EPIDEMIOLOGY, V16, P385, DOI 10.1097/01.ede.0000155505.04775.33; Sarnat JA, 2007, CURR OPIN PULM MED, V13, P63, DOI 10.1097/MCP.0b013e3280117d25; Schauer JJ, 2000, ENVIRON SCI TECHNOL, V34, P1821, DOI 10.1021/es981312t; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Seaton A, 2003, THORAX, V58, P1012, DOI 10.1136/thorax.58.12.1012; Sheppard L, 2005, J EXPO ANAL ENV EPID, V15, P366, DOI 10.1038/sj.jea.7500413; Sioutas C, 2005, ENVIRON HEALTH PERSP, V113, P947, DOI 10.1289/ehp.7939; SPENGLER J, 1994, J AIR WASTE MANAGE, V44, P39; Staimer N, 2005, ANAL BIOANAL CHEM, V383, P955, DOI 10.1007/s00216-005-0086-6; Thiadens HA, 1999, THORAX, V54, P1055; Thompson R, 2006, PEDIATR PULM, V41, P819, DOI 10.1002/ppul.20449; Trasande L, 2005, J ALLERGY CLIN IMMUN, V115, P689, DOI 10.1016/j.jaci.2005.01.056; Trenga CA, 2006, CHEST, V129, P1614, DOI 10.1378/chest.129.6.1614; U.S. EPA (U.S. Environmental Protection Agency), 2008, NAT AMB AIR QUAL STA; Molenberghs G, 2001, LINEAR MIXED MODELS; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088	46	73	77	3	24	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2008	116	4					550	558				9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	282KL	WOS:000254566500041	18414642	
J	Kovesi, T; Kulka, R; Dales, R				Kovesi, Thomas; Kulka, Ryan; Dales, Robert			Exhaled nitric oxide concentration is affected by age, height, and race in healthy 9-to 12-year-old children	CHEST			English	Article						Asian continental ancestry group; asthma; breath tests; child; continental population groups; growth; nitric oxide; reference values	BODY-MASS INDEX; CHINESE CHILDREN; REFERENCE VALUES; SCHOOL-AGE; ASTHMA; AIR; SCHOOLCHILDREN; ADOLESCENTS; MARKER	Background: The fractional concentration of exhaled nitric oxide (FENO) is a useful indicator of airway inflammation in children and adults with asthma. Methods: We determined the range of FENO concentrations and the factors affecting it in a large sample of healthy school children attending grades 4 through 6, in Windsor, ON, Canada. Results: FENO was measured in 657 children between 9.1 and 12.9 years of age. The range of FENO concentrations in healthy school children was 12.7 parts per billion (ppb) [95% confidence interval (0), 11.8 to 13.7 ppb] in whites and 22.8 ppb [95% CI, 17.9 to 27.7 ppb] in Asian-Canadian children (p < 0.001). FENO values also appeared to be higher in African-Canadian children than in whites, although the CI was wide because of the small number of African-Canadian children sampled. FENO rose slightly but significantly with age (p = 0.007) and with height (p = 0.023). Body mass index and gender did not significantly alter the measured FENO. FVC had a nonsignificant effect on FENO. Participation in physical activity during the same day had a borderline-significant effect on measured FENO, but a reported history of a respiratory tract infection in the preceding 2 weeks did not. Conclusions: FENO concentrations in healthy school-aged children appeared to be affected by race, and, to a lesser extent, by age and height. These factors should be taken into consideration when interpreting clinical results.	[Kovesi, Thomas] Childrens Hosp Eastern Ontario, Dept Pediat, Ottawa, ON K1H 8L1, Canada; [Kulka, Ryan] Hlth Canada, Air Hlth Effects Div, Ottawa, ON, Canada; [Dales, Robert] Hlth Canada, Biostat & Epidemiol Div, Ottawa, ON, Canada	Kovesi, T (reprint author), Childrens Hosp Eastern Ontario, Dept Pediat, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	kovesi@cheo.on.ca		Kovesi, Thomas/0000-0002-0521-8936			American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Baraldi E, 2005, AM J RESP CRIT CARE, V171, P68, DOI 10.1164/rccm.200403-298Oc; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; DALES RE, 2007, WINDSOR CHILDRENS CH; de Winter-de Groot KM, 2005, J ALLERGY CLIN IMMUN, V115, P419, DOI 10.1016/j.jaci.2004.11.025; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Franklin P, 2000, AM J RESP CRIT CARE, V161, P1757; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69; Gabriele C, 2005, PEDIATR ALLERGY IMMU, V16, P243, DOI 10.1111/j.1399-3038.2005.00255.x; Ip MSM, 2000, AM J RESP CRIT CARE, V162, P424; Kazaks A, 2005, J ALLERGY CLIN IMMUN, V116, P929, DOI 10.1016/j.jaci.2005.06.005; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903; Leung TF, 2005, CLIN EXP ALLERGY, V35, P1288, DOI 10.1111/j.1365-2222.2005.02342.x; MALMBERG LP, 2006, PEDIAT PULMONOL, V41, P435; Mieskonen ST, 2002, PEDIATR PULM, V33, P347, DOI 10.1002/ppul.10084; MOSTELLER RD, 1987, NEW ENGL J MED, V317, P1098; Olin AC, 2006, CHEST, V130, P1319, DOI 10.1378/chest.130.5.1319; Olivieri M, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-94; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; POLGAR C, 1971, STANDARD VALUES PULM, P87; Rolla G, 2004, CHEST, V126, P1546, DOI 10.1378/chest.126.5.1546; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; Santamaria F, 2005, J ALLERGY CLIN IMMUN, V116, P1163, DOI 10.1016/j.jaci.2005.07.018; Sartori C, 1999, AM J RESP CRIT CARE, V160, P879; Verges S, 2006, J SPORT SCI, V24, P1157, DOI 10.1080/02640410500457364; Wong GWK, 2005, CLIN EXP ALLERGY, V35, P889, DOI 10.1111/j.1365-2222.2005.02263.x	30	73	83	2	11	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JAN	2008	133	1					169	175		10.1378/chest.07-1177		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	251PL	WOS:000252385600029	17925422	
J	Villeneuve, PJ; Chen, L; Rowe, BH; Coates, F				Villeneuve, Paul J.; Chen, Li; Rowe, Brian H.; Coates, Frances			Outdoor air pollution and emergency department visits for asthma among children and adults: A case-crossover study in northern Alberta, Canada	ENVIRONMENTAL HEALTH			English	Article							SOUTHERN CALIFORNIA CHILDREN; RESPIRATORY HOSPITAL ADMISSIONS; LUNG-FUNCTION GROWTH; CHILDHOOD ASTHMA; ROOM VISITS; NITROGEN-DIOXIDE; TIME-SERIES; SAINT-JOHN; ASSOCIATION; OZONE	Background: Recent studies have observed positive associations between outdoor air pollution and emergency department (ED) visits for asthma. However, few have examined the possible confounding influence of aeroallergens, or reported findings among very young children. Methods: A time stratified case-crossover design was used to examine 57,912 ED asthma visits among individuals two years of age and older in the census metropolitan area of Edmonton, Canada between April 1, 1992 and March 31, 2002. Daily air pollution levels for the entire region were estimated from three fixed-site monitoring stations. Similarly, daily levels of aeroallergens were estimated using rotational impaction sampling methods for the period between 1996 and 2002. Odds ratios and their corresponding 95% confidence intervals were estimated using conditional logistic regression with adjustment for temperature, relative humidity and seasonal epidemics of viral related respiratory disease. Results: Positive associations for asthma visits with outdoor air pollution levels were observed between April and September, but were absent during the remainder of the year. Effects were strongest among young children. Namely, an increase in the interquartile range of the 5-day average for NO(2) and CO levels between April and September was associated with a 50% and 48% increase, respectively, in the number of ED visits among children 2-4 years of age (p < 0.05). Strong associations were also observed with these pollutants among those 75 years of age and older. Ozone and particulate matter were also associated with asthma visits. Air pollution risk estimates were largely unchanged after adjustment for aeroallergen levels. Conclusion: Our findings, taken together, suggest that exposure to ambient levels of air pollution is an important determinant of ED visits for asthma, particularly among young children and the elderly.	[Villeneuve, Paul J.; Chen, Li] Hlth Canada, Biostat & Epidemiol Div, Ottawa, ON, Canada; [Rowe, Brian H.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; [Coates, Frances] Aerobiol Res Labs, Ottawa, ON, Canada	Villeneuve, PJ (reprint author), Hlth Canada, Biostat & Epidemiol Div, Ottawa, ON, Canada.	Paul_Villeneuve@hc-sc.gc.ca; Li_Chen@hc-sc.gc.ca; brian.rowe@ualberta.ca; aerobio@aerobiology.ca					Anderson HR, 1998, THORAX, V53, P842; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Boutin-Forzano S, 2004, RESPIRATION, V71, P134, DOI 10.1159/000076673; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; *CAC, 2005 CAC EM CAN; CASTELLSAGUE J, 1995, THORAX, V50, P1051, DOI 10.1136/thx.50.10.1051; Chauhan AJ, 2003, BRIT MED BULL, V68, P95, DOI 10.1093/bmb/ldg022; Chen KS, 2004, J AIR WASTE MANAGE, V54, P36; Chen L, 2001, Rev Environ Health, V16, P133; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; EDER BK, 1994, J APPL METEOROL, V33, P1182, DOI 10.1175/1520-0450(1994)033<1182:AACSDT>2.0.CO;2; Erbas B, 2005, INT J ENVIRON HEAL R, V15, P11, DOI 10.1080/09603120400018717; Farhat SCL, 2005, BRAZ J MED BIOL RES, V38, P227, DOI 10.1590/S0100-879X2005000200011; Frenz D, 1997, AEROBIOLOGIA, V13, P205, DOI 10.1007/BF02694509; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; Galan I, 2003, EUR RESPIR J, V22, P802, DOI 10.1183/09031936.03.00013003; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059; GRISCOM NT, 1978, RADIOL CLIN N AM, V16, P367; GUAY M, 2007, UNPUB CORRELATIONAL; Hinwood AL, 2006, INT J ENVIRON HEAL R, V16, P27, DOI 10.1080/09603120500397680; Janes H, 2005, EPIDEMIOLOGY, V16, P717, DOI 10.1097/01.edu.0000181315.18836.9d; KESTEN S, 1993, CHEST, V104, P254, DOI 10.1378/chest.104.1.254; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; Linaker CH, 2000, THORAX, V55, P930, DOI 10.1136/thorax.55.11.930; Linn W S, 1999, Curr Opin Pulm Med, V5, P21, DOI 10.1097/00063198-199901000-00004; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144; Mathieu-Nolf M, 2002, J TOXICOL-CLIN TOXIC, V40, P483; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Medina S, 1997, ENVIRON RES, V75, P73, DOI 10.1006/enrs.1997.3773; Oyana TJ, 2004, J ENVIRON HEALTH, V66, P25; Oyana Tonny J, 2005, Int J Health Geogr, V4, P14, DOI 10.1186/1476-072X-4-14; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Sandstrom T, 2003, Eur Respir J Suppl, V40, p92s; SAS&REG; Institute Inc, 2004, SAS VERS 8; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Schwartz J, 2000, ENVIRON HEALTH PERSP, V108, P563, DOI 10.2307/3454620; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Sears MR, 1996, CAN RESP J, V3, P261; Shannon MW, 2004, PEDIATRICS, V114, P1699, DOI 10.1542/peds.2004-2166; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313; Stieb DM, 2000, J EXPO ANAL ENV EPID, V10, P461, DOI 10.1038/sj.jea.7500112; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Sun HL, 2006, AM J EMERG MED, V24, P709, DOI 10.1016/j.ajem.2006.03.006; Sunyer J, 1997, THORAX, V52, P760; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541; Thompson AJ, 2001, ARCH ENVIRON HEALTH, V56, P234; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; Tsai SS, 2006, INHAL TOXICOL, V18, P549, DOI 10.1080/0895837006866176; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; YANG Q, 2003, INHAL TOXICOL, V57, P1297; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	70	73	80	0	10	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1476-069X			ENVIRON HEALTH-GLOB	Environ. Health	DEC 24	2007	6								40	10.1186/1476-069X-6-40		15	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	272MP	WOS:000253863800001	18157917	
J	Weckmann, M; Collison, A; Simpson, JL; Kopp, MV; Wark, PAB; Smyth, MJ; Yagita, H; Matthaei, KI; Hansbro, N; Whitehead, B; Gibson, PG; Foster, PS; Mattes, J				Weckmann, Markus; Collison, Adam; Simpson, Jodie L.; Kopp, Matthias V.; Wark, Peter A. B.; Smyth, Mark J.; Yagita, Hideo; Matthaei, Klaus I.; Hansbro, Nicole; Whitehead, Bruce; Gibson, Peter G.; Foster, Paul S.; Mattes, Joerg			Critical link between TRAIL and CCL20 for the activation of T(H)2 cells and the expression of allergic airway disease	NATURE MEDICINE			English	Article							APOPTOSIS-INDUCING LIGAND; DENDRITIC CELLS; IN-VIVO; EXPERIMENTAL ASTHMA; TUMOR-METASTASIS; INHALED ANTIGEN; ATOPIC ASTHMA; HYPERREACTIVITY; INFLAMMATION; IL-13	The role of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in immune responses mediated by T-helper 2 (T(H)2) lymphocytes is unknown. Here we characterize the development of allergic airway disease in TRAIL-deficient (Tnfsf10(-/-)) mice and in mice exposed to short interfering RNA targeting TRAIL. We show that TRAIL is abundantly expressed in the airway epithelium of allergic mice and that inhibition of signaling impairs production of the chemokine CCL20 and homing of myeloid dendritic cells and T cells expressing CCR6 and CD4 to the airways. Attenuated homing limits TH2 cytokine release, inflammation, airway hyperreactivity and expression of the transcriptional activator STAT6. Activation of STAT6 by interleukin-13 restores airway hyperreactivity in Tnfsf10(-/-) mice. Recombinant TRAIL induces pathognomic features of asthma and stimulates the production of CCL20 in primary human bronchial epithelium cells. TRAIL is also increased in sputum of asthmatics. The function of TRAIL in the airway epithelium identifies this molecule as a target for the treatment of asthma.	Univ Freiburg, Dept Paediat & Adolescent Med, D-79106 Freiburg, Germany; Univ Newcastle, Fac Hlth, Sch Biomed Sci, CARD, Newcastle, NSW 2301, Australia; Hunter Med Res Inst, Newcastle, NSW 2301, Australia; Hunter Med Res Inst, Dept Resp & Sleep Med, Newcastle, NSW 2305, Australia; Peter MacCallum Canc Ctr, Canc Immunol Program, Melbourne, Vic 3002, Australia; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Canberra, ACT 2601, Australia; John Hunter Childrens Hosp, Dept Paediat, Newcastle, NSW 2305, Australia	Mattes, J (reprint author), Univ Freiburg, Dept Paediat & Adolescent Med, D-79106 Freiburg, Germany.	joerg.mattes@newcastle.edu.au	Klaus, Matthaei/D-8691-2011; Foster, Paul/G-5057-2013; Smyth, Mark/H-8709-2014	Smyth, Mark/0000-0001-7098-7240; Wark, Peter/0000-0001-5676-6126			Aggarwal Bharat B., 2002, Current Drug Targets - Inflammation and Allergy, V1, P327, DOI 10.2174/1568010023344571; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Begue B, 2006, GASTROENTEROLOGY, V130, P1962, DOI 10.1053/j.gastro.2006.03.022; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; Bousquet J, 2005, B WORLD HEALTH ORGAN, V83, P548; Busse WW, 1998, J ALLERGY CLIN IMMUN, V102, pS17, DOI 10.1016/S0091-6749(98)70002-8; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Daigle I, 2001, SWISS MED WKLY, V131, P231; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kayagaki N, 1999, J IMMUNOL, V163, P1906; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lamhamedi-Cherradi SE, 2003, NAT IMMUNOL, V4, P255, DOI 10.1038/ni894; Le Borgne M, 2006, IMMUNITY, V24, P191, DOI 10.1016/j.immuni.2006.01.005; Lewkowich IP, 2005, J EXP MED, V202, P1549, DOI 10.1084/jem.20051506; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Lundy SK, 2005, J IMMUNOL, V174, P2054; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2001, J IMMUNOL, V167, P1683; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Robertson NM, 2002, J IMMUNOL, V169, P5986; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Smyth MJ, 2001, J EXP MED, V193, P661, DOI 10.1084/jem.193.6.661; Takeda K, 2002, J EXP MED, V195, P161, DOI 10.1084/jem.20011171; Takeda K, 2001, NAT MED, V7, P94, DOI 10.1038/83416; Taube C, 2002, J IMMUNOL, V169, P6482; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC; van Rift LS, 2004, J ALLERGY CLIN IMMUN, V114, P166, DOI 10.1016/j.jaci.2004.03.044; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202; Walczak H, 1999, NAT MED, V5, P157; Walter DM, 2001, J IMMUNOL, V167, P4668; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yuan BB, 2004, NUCLEIC ACIDS RES, V32, pW130, DOI 10.1093/nar/gkh366; Zhang XR, 2003, CELL DEATH DIFFER, V10, P203, DOI 10.1038/sj.cdd.4401138; Zhang YY, 2004, J NATL CANCER I, V96, P201, DOI 10.1093/jnci/djh024; [Anonymous], 1987, AM REV RESP DIS, V136, P225	50	73	77	0	4	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	NOV	2007	13	11					1308	1315		10.1038/nm1660		8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	228NP	WOS:000250736900023	17934471	
J	Buckley, DA				Buckley, D. A.			Fragrance ingredient labelling in products on sale in the UK	BRITISH JOURNAL OF DERMATOLOGY			English	Article						allergic contact dermatitis; consumer products; fragrance; labelling; limonene; linalool	PATCH-TEST POPULATION; ALLERGY; PERFUMES; CHLOROATRANOL; SENSITIZATION; LINALOOL; LYRAL(R); MIX	Background The seventh amendment of the European Union (EU) Cosmetics Directive (March 2005) and the Detergents Regulations of the EU (October 2005) are now legal requirements in Europe. Cosmetic products and detergents must be labelled for 26 individual named fragrances, when present at concentrations of > 10 parts per million (p.p.m.) in leave-on products and > 100 p.p.m. in rinse-off products. Objectives To make an assessment of the exposure pattern to fragrance of the U.K. consumer and to determine the frequency with which the constituent fragrances of fragrance mix I (FM I) and fragrance mix II (FM II) are included in products currently sold in the U.K. Methods A study of perfumed cosmetic and household products available on the shelves of U.K. retailers was carried out in January 2006. Products were included if 'parfum' or 'aroma' was listed among the ingredients. Three hundred products were surveyed and any of the 26 listed fragrances named on the label were recorded. Results The top six most frequently labelled fragrances were linalool (190; 63%), limonene (189; 63%), citronellol (145; 48%), geraniol (126; 42%), butyl phenyl methyl propional (Lilial((TM))) (126; 42%) and hexyl cinnamal (125; (42%). One of these, geraniol, is present in FM I and two others, citronellol and hexyl cinnamal, in FM II, thus tested as part of the British Standard patch test series. The frequencies of other constituents of FM I were as follows: eugenol, 80 (27%); hydroxycitronellal, 52 (17%); isoeugenol, 27 (9%); cinnamic alcohol, 25 (8%); amyl cinnamal, 22 (7%); cinnamal, 17 (6%); Evernia prunastri (oak moss absolute), 13 (4%). The other constituents of FM II occurred as follows: coumarin, 90 (30%); hydroxyisohexyl-3-cyclohexene carboxaldehyde (Lyral((TM))), 88 (29%); citral, 74 (25%); farnesol, 23 (8%). Linalool (n = 46; 66%) was the most frequently found fragrance in 70 personal care products (soap, shampoo, shower gel). Linalool (n = 47; 80%) and limonene (n = 45; 76%) were the most frequent in 59 products for men (e.g. aftershave). Limonene (n = 29; 51%) predominated in 57 household products (washing-up liquid, detergent). Limonene (n = 43; 98%) and linalool (n = 42; 95%) were the most frequent fragrances in 44 perfumes for women. Alpha-isomethyl ionone (n = 28; 72%) was the most frequent in 39 cosmetics (foundation, lipstick, etc). Citronellol predominated (n = 15; 88%) in 17 deodorants and limonene (n = 9; 64%) was the commonest in 14 dental products (toothpaste and mouthwash). Thirty-four products (11%) contained none of the listed fragrances but were labelled as containing 'parfum' or 'aroma'. Conclusions There is ongoing consumer exposure to the most frequent sensitizers in FM I: E. prunastri, isoeugenol and the cinnamon fragrances cinnamal and cinnamic alcohol. Hydroxyisohexyl-3-cyclohexene carboxaldehyde (Lyral((TM))) is present at significant concentrations in almost one-third of products. Linalool and limonene, fragrance terpenes which are significant allergens in their oxidized state, are the most frequent fragrances encountered by individuals living in the U.K. The current exposure pattern of the U.K. consumer suggests that we should add oxidized limonene and oxidized linalool to the test series for patients suspected to have fragrance allergy.	Great Western Hosp, Dept Dermatol, Swindon SN3 6BB, Wilts, England	Buckley, DA (reprint author), Great Western Hosp, Dept Dermatol, Marlborough Rd, Swindon SN3 6BB, Wilts, England.	dbuckley@doctors.org.uk					Basketter DA, 2002, CONTACT DERMATITIS, V47, P161, DOI 10.1034/j.1600-0536.2002.470307.x; Baxter KF, 2003, CONTACT DERMATITIS, V48, P117, DOI 10.1034/j.1600-0536.2003.480212_4.x; Buckley DA, 2006, BRIT J DERMATOL, V154, P885, DOI 10.1111/j.1365-2133.2006.07170.x; Buckley DA, 2000, BRIT J DERMATOL, V142, P279, DOI 10.1046/j.1365-2133.2000.03298.x; Frosch PJ, 2005, CONTACT DERMATITIS, V52, P216, DOI 10.1111/j.0105-1873.2005.00563.x; Frosch PJ, 2005, CONTACT DERMATITIS, V52, P207, DOI 10.1111/j.0105-1873.2005.00565.x; Frosch PJ, 1999, BRIT J DERMATOL, V141, P1076, DOI 10.1046/j.1365-2133.1999.03208.x; Giusti F, 2001, CONTACT DERMATITIS, V44, P37; Heydorn S, 2003, CONTACT DERMATITIS, V48, P317, DOI 10.1034/j.1600-0536.2003.00133.x; Johansen JD, 2003, CONTACT DERMATITIS, V49, P180, DOI 10.1111/j.0105-1873.2003.0214.x; Johansen J. P., 2006, CONTACT DERMATITIS, P507, DOI 10.1007/3-540-31301-X_31; Larsen W, 1996, Am J Contact Dermat, V7, P77, DOI 10.1016/S1046-199X(96)90078-0; Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x; Matura M, 2002, J AM ACAD DERMATOL, V47, P709, DOI 10.1067/mjd.2002.124817; Murphy LA, 2003, CONTACT DERMATITIS, V49, P52; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Rastogi SC, 2004, CONTACT DERMATITIS, V50, P367, DOI 10.1111/j.0105-1873.2004.00379.x; Rastogi SC, 2003, CONTACT DERMATITIS, V48, P130, DOI 10.1034/j.1600-0536.2003.00035.x; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; Schnuch A, 2004, CONTACT DERMATITIS, V50, P65, DOI 10.1111/j.0105-1873.2004.00302.x; Skold M, 2002, CONTACT DERMATITIS, V46, P267, DOI 10.1034/j.1600-0536.2002.460504.x; WHITE JML, 2007, IN PRESS BR J DERMAT	23	73	74	1	16	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	AUG	2007	157	2					295	300		10.1111/j.1365-2133.2007.08018.x		6	Dermatology	Dermatology	196WJ	WOS:000248513200011	17573873	
J	Cao, DS; Bromberg, PA; Samet, JM				Cao, Dongsun; Bromberg, Philip A.; Samet, James M.			COX-2 expression induced by diesel particles involves chromatin modification and degradation of HDAC1	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						diesel exhaust particles; COX-2; HDAC; airway epithelial cells	BRONCHIAL EPITHELIAL-CELLS; CYCLOOXYGENASE-2 PROMOTER ACTIVATION; ENDOPEROXIDE SYNTHASE-2 GENE; EXHAUST PARTICLES; HISTONE DEACETYLASE-1; REGULATING CYCLOOXYGENASE-2; TRANSCRIPTIONAL ACTIVATION; INFLAMMATORY MEDIATORS; OXIDATIVE STRESS; RESPONSE ELEMENT	Cyclooxygenase-2 (COX-2) plays an important role in the inflammatory response induced by physiologic and stress stimuli. Exposure to diesel exhaust particulate matter (DEP) has been shown to induce pulmonary inflammation and exacerbate asthma and chronic obstructive pulmonary disease. DEP is a potent inducer of inflammatory reponses in human airway epithelial cells. The mechanism through which DEP inhalation induces inflammatory mediator expression is not understood. In this report, we demonstrate that DEP can induce the expression of COX-2 gene in a human bronchial epithelial cell line (BEAS-2B) at both transcriptional and protein levels. The induction of COX-2 gene expression involves chromatin modification, in particular acetylation and deacetylation of histones. We show that exposure to DEP increases the acetylation of histone H4 associated with the COX-2 promoter and causes degradation of histone deacetylase 1 (HDAC1). Further, we establish that HDAC1 plays a pivotal role in mediating the transcriptional activation of the COX-2 gene in BEAS-2B cells exposed to DEP, supported by evidence that the down-regulation of HDAC1 using siRNA leads to activation of COX-2 gene expression, whereas overexpression of HDAC1 results in its repression. Finally, DEP exposure induced recruitment of histone acetyltransferase (HAT) p300 to the promoter of the COX-2 gene, suggesting that acetylation is also important in regulating its expression in response to DEP exposure. These results show for the first time acetylation via selective degradation of HDAC1, and that recruitment of HAT plays an important role in DEP-induced expression of the COX-2 gene.	Natl Hlth & Environm Effects Res Lab, Human Studies Div, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Res Triangle Pk, NC USA	Samet, JM (reprint author), Natl Hlth & Environm Effects Res Lab, Human Studies Div, Res Triangle Pk, NC 27711 USA.	samet.james@epa.gov					APPLEBY SB, 1994, BIOCHEM J, V302, P723; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Barnes PJ, 2005, EUR RESPIR J, V25, P552, DOI 10.1183/09031936.05.00117504; BARRY CC, 1994, ENVIRONMENT, V36, P5; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bonner JC, 2002, AM J PATHOL, V161, P459, DOI 10.1016/S0002-9440(10)64202-2; Cao DS, 2005, MOL CELL BIOL, V25, P364, DOI 10.1128/MCB.25.1.364-376.2004; Colombo R, 2002, EMBO REP, V3, P1062, DOI 10.1093/embo-reports/kvf213; Dangond F, 1998, BIOCHEM BIOPH RES CO, V247, P833, DOI 10.1006/bbrc.1998.8891; David G, 2002, J BIOL CHEM, V277, P23658, DOI 10.1074/jbc.M203690200; Deng WG, 2004, BLOOD, V103, P2135, DOI 10.1182/blood-2003-09-3131; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; Diaz-Sanchez D, 2000, CLIN IMMUNOL, V97, P140, DOI 10.1006/clim.2000.4921; Fasanaro P, 2006, FASEB J, V20, P1242, DOI 10.1096/fj.05-4695fje; Fischle W, 1999, J BIOL CHEM, V274, P11713, DOI 10.1074/jbc.274.17.11713; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hofer TPJ, 2004, J LEUKOCYTE BIOL, V75, P856, DOI 10.1189/jlb.0803387; INOUE H, 1995, J BIOL CHEM, V270, P24965; INOUE H, 1994, FEBS LETT, V350, P51, DOI 10.1016/0014-5793(94)00731-4; Inoue K, 2004, J APPL TOXICOL, V24, P415, DOI 10.1002/jat.984; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; Ito K, 2002, AM J RESP CRIT CARE, V166, P392, DOI 10.1164/rccm.2110060; Jones PL, 2003, CURR TOP MICROBIOL, V274, P237; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Karagiannis TC, 2006, ONCOGENE, V25, P3885, DOI 10.1038/sj.onc.1209417; Karagiannis TC, 2006, CELL CYCLE, V5, P288, DOI 10.4161/cc.5.3.2421; Kawasaki S, 2001, AM J RESP CELL MOL, V24, P419; Lander HM, 1997, FASEB J, V11, P118; Li XF, 2004, J BIOL CHEM, V279, P34201, DOI 10.1074/jbc.M405179200; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mosley AL, 2003, J BIOL CHEM, V278, P19660, DOI 10.1074/jbc.M212375200; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; SAMET JM, 1998, AM J PHYSIOL, V275, P551; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Shringarpure R, 2003, J BIOL CHEM, V278, P311, DOI 10.1074/jbc.M206279200; Smith WL, 1996, J BIOL CHEM, V271, P33157; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Takizawa H, 1999, J IMMUNOL, V162, P4705; Tsatsanis C, 2006, INT J BIOCHEM CELL B, V38, P1654, DOI 10.1016/j.biocel.2006.03.021; Vanden Berghe W, 1999, J BIOL CHEM, V274, P32091, DOI 10.1074/jbc.274.45.32091; Yang WM, 1996, P NATL ACAD SCI USA, V93, P12845, DOI 10.1073/pnas.93.23.12845; Zhou Q, 2000, J BIOL CHEM, V275, P35256, DOI 10.1074/jbc.M003106200	50	73	78	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	AUG	2007	37	2					232	239		10.1165/rcmb.2006-0449OC		8	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	196RF	WOS:000248499000013	17395887	
J	Vesper, S; McKinstry, C; Haugland, R; Wymer, L; Bradham, K; Ashley, P; Cox, D; Dewalt, G; Friedman, W				Vesper, Stephen; McKinstry, Craig; Haugland, Richard; Wymer, Larry; Bradham, Karen; Ashley, Peter; Cox, David; Dewalt, Gray; Friedman, Warren			Development of an environmental relative moldiness index for US homes	JOURNAL OF OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							QUANTITATIVE PCR ANALYSIS; AIRBORNE FUNGI; OUTDOOR AIR; ASTHMA; PROPAGULES; BUILDINGS; DUSTBORNE; CHILDREN; WATER; DUST	Objective: The objective of this study, was to establish a national relative moldiness index for homes in the United States. Methods: As part of the Housing and Urban Development's American Healthy Homes Survey, dust samples were collected by vacuuming 2 m(2) in the bedrooms plus 2 m(2) in the living rooms from a nationally, representative 1096 homes in the United States using the Mitest sampler. Five milligrams of sieved (300 mu m pore, nylon mesh) dust was analyzed by mold-specific quantitative polymerase chain reaction for the 36 indicator species in 1096 samples. Results: On the basis of this standardized national sampling and analysis, an "Environmental Relative Moldiness Index" was created with values ranging from about -10 to 20 or above (lowest to highest). vi Conclusions: The Environmental Relative Moldiness Index scale may be useful for home mold-burden estimates in epidemiological studies.	US EPA, Natl Exposure Res Lab, Cincinnati, OH 45268 USA; Pacific NW Natl Lab, Richland, WA 99352 USA; US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA; Dept Housing & Urban Dev, Washington, DC USA; Quan Tech, Arlington, VA USA	Vesper, S (reprint author), US EPA, Natl Exposure Res Lab, 26 W ML King Dr, Cincinnati, OH 45268 USA.	vesper.stephen@epa.gov					Brinkman NE, 2003, APPL ENVIRON MICROB, V69, P1775, DOI 10.1128/AEM.69.3.1775-1782.2003; Chao HJ, 2002, MYCOPATHOLOGIA, V154, P93, DOI 10.1023/A:1015592224368; Chew GL, 2003, ALLERGY, V58, P13, DOI 10.1034/j.1398-9995.2003.00013.x; Collett D., 2003, MODELING SURVIVAL DA; GODISH T, 2006, INDOOR ENV QUALITY P; Haugland RA, 2004, SYST APPL MICROBIOL, V27, P198, DOI 10.1078/072320204322881826; Haugland RA, 2002, J MICROBIOL METH, V50, P319, DOI 10.1016/S0167-7012(02)00037-4; HAUGLAND RA, 2005, BIOAEROSOLS FUNGI BA, P327; Helsel D, 2005, NONDETECTS DATA ANAL; Kercsmar CM, 2006, ENVIRON HEALTH PERSP, V114, P1574, DOI 10.1289/ehp.8742; Meklin T, 2004, J ENVIRON MONITOR, V6, P615, DOI 10.1039/b400250d; Melkin T., 2007, SCI TOTAL ENVIRON, V382, P130; O'Connor GT, 2004, J ALLERGY CLIN IMMUN, V114, P599, DOI 10.1016/j.jaci.2004.05.064; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; Spicer R, 2005, J OCCUP ENVIRON HYG, V2, P257, DOI 10.1080/15459620590946401; VERHOEFF AP, 1992, ALLERGY, V47, P83; Vesper SJ, 2004, J OCCUP ENVIRON MED, V46, P596, DOI 10.1097/01.jom.0000128160.17144.6e; Vesper SJ, 2007, J EXPO SCI ENV EPID, V17, P88, DOI 10.1038/sj.jes.7500528; Vesper SJ, 2006, J OCCUP ENVIRON MED, V48, P852, DOI 10.1097/01.jom.0000224736.52780.2f	19	73	73	2	18	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1076-2752	1536-5948		J OCCUP ENVIRON MED	J. Occup. Environ. Med.	AUG	2007	49	8					829	833		10.1097/JOM.0b013e3181255e98		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	200OF	WOS:000248772000002	17693779	
J	Hunninghake, GM; Soto-Quiros, ME; Avila, L; Ly, NP; Liang, C; Sylvia, JS; Klanderman, BJ; Silverman, EK; Celedon, JC				Hunninghake, Gary M.; Soto-Quiros, Manuel E.; Avila, Lydiana; Ly, Ngoc P.; Liang, Catherine; Sylvia, Jody S.; Klanderman, Barbara J.; Silverman, Edwin K.; Celedon, Juan C.			Sensitization to Ascaris lumbricoides and severity of childhood asthma in Costa Rica	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Ascaris; helminth; atopy; exacerbation; severity; asthma; Costa Rica	IMMUNOGLOBULIN-E; GEOHELMINTH INFECTIONS; ALLERGIC SENSITIZATION; ANTHELMINTIC TREATMENT; IGE ANTIBODIES; RURAL AREA; CHILDREN; ATOPY; REACTIVITY; PARASITES	Background: Little is known about sensitization (defined as a positive IgE) to helminths and disease severity in patients with asthma. Objectives: To examine the relationship between sensitization (defined as a positive IgE) to Ascaris lumbricoides and measures of asthma morbidity and severity in a Costa Rican population with low prevalence of parasitic infection but high prevalence of parasitic exposure. Methods: Cross-sectional study of 439 children (ages 6 to 14 years) with asthma. Linear regression and logistic regression were used for the multivariate statistical analysis. Results: After adjustment for parental education and other covariates, sensitization to Ascaris lumbricoides was associated with having at least 1 positive skin test to allergens (odds ratio, 5.15; 95% CI, 2.36-11.21; P < .001), increased total serum IgE and eosinophils in peripheral blood, reductions in FEV1 and FEV1/forced vital capacity, increased airway responsiveness and bronchodilator responsiveness, and hospitalizations for asthma in the previous year (odds ratio, 3.08; 95% Cl, 1.23-7.68; P = .02). Conclusion: Sensitization to Ascaris lumbricoides is associated with increased severity and morbidity of asthma among children in Costa Rica. This association is likely mediated by an increased degree of atopy among children with asthma who are sensitized to Asearis. Clinical implications: In areas with a low prevalence of helminthiasis such as Costa Rica, Ascaris sensitization may be an important marker of severe atopy and disease morbidity in children with asthma.	Channing Labs, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Pulm & Crit Care Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Hosp Nacl Ninos Dr Carlos Saenz Herrera, Div Pediat Pulmonol, San Jose, Costa Rica; Massachusetts Gen Hosp, Pediat Pulm Div, Boston, MA 02114 USA	Celedon, JC (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.	juan.celedon@channing.harvard.edu			NHLBI NIH HHS [F32 HL083634, F32 HL083634-01, HL04370, HL66289]		Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bernardini R, 2005, INT J IMMUNOPATH PH, V18, P671; BLUMENTHAL MN, 1995, CLIN EXP ALLERGY, V25, P29, DOI 10.1111/j.1365-2222.1995.tb00416.x; [Anonymous], 1995, NORM AT INT SAL PRIM, P13; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Carroll WD, 2006, ARCH DIS CHILD, V91, P405, DOI 10.1136/adc.2005.088278; CHAN MS, 1994, PARASITOLOGY, V109, P373; CHATHAM M, 1982, AM REV RESPIR DIS, V126, P235; COOPER E, 1999, TROPICAL INFECT DIS; Cooper PJ, 2004, PARASITE IMMUNOL, V26, P455, DOI 10.1111/j.0141-9838.2004.00728.x; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2004, J INFECT DIS, V190, P1338, DOI 10.1086/423944; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2004, CLIN REV ALLERG IMMU, V26, P5, DOI 10.1385/CRIAI:26:1:5; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Escamilla MA, 1996, AM J MED GENET, V67, P244, DOI 10.1002/(SICI)1096-8628(19960531)67:3<244::AID-AJMG2>3.0.CO;2-N; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; GYORKOS TW, 1989, AM J EPIDEMIOL, V130, P976; Karadag B, 2006, ALLERGY, V61, P996, DOI 10.1111/j.1398-9995.2006.01107.x; Khuroo MS, 1996, GASTROENTEROL CLIN N, V25, P553, DOI 10.1016/S0889-8553(05)70263-6; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; *MIN SAL, 1997, ENC NAC NUTR 1996; MORALES MT, 1997, ACTA PEDIAT COSTARRI, V11, P106; MORRIS AJ, 1992, J CLIN MICROBIOL, V30, P3213; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P640, DOI 10.1111/j.1365-2222.2006.02479.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Ramsay CE, 1999, HUM GENET, V104, P269, DOI 10.1007/s004390050947; REVOLTELLA R, 1980, INT ARCH ALLER A IMM, V62, P23; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Siroux V, 2003, CLIN EXP ALLERGY, V33, P746, DOI 10.1046/j.1365-2222.2003.01674.x; Soto-Quiros ME, 1998, ALLERGY, V53, P499, DOI 10.1111/j.1398-9995.1998.tb04087.x; TURNER KJ, 1980, AUST J EXP BIOL MED, V58, P249, DOI 10.1038/icb.1980.25; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107	41	73	74	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2007	119	3					654	661		10.1016/j.jaci.2006.12.609		8	Allergy; Immunology	Allergy; Immunology	146HL	WOS:000244925000019	17336615	
J	Perros, F; Dorfmuller, P; Souza, R; Durand-Gasselin, I; Mussot, S; Mazmanian, M; Herve, P; Emilie, D; Simonneau, G; Humbert, M				Perros, F.; Dorfmuller, P.; Souza, R.; Durand-Gasselin, I.; Mussot, S.; Mazmanian, M.; Herve, P.; Emilie, D.; Simonneau, G.; Humbert, M.			Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension	EUROPEAN RESPIRATORY JOURNAL			English	Article						dendritic cells; immunopathology; inflammation; monocrotaline; pulmonary arterial hypertension	ARTERIAL-HYPERTENSION; IMATINIB MESYLATE; PERIPHERAL-BLOOD; TUMOR; PRECURSORS; ANTIBODIES; DISEASES; ASTHMA	In the present study, the hypothesis that dendritic cells (DCs), key players in immunity and tolerance, might be involved in the immunopathology of idiopathic pulmonary arterial hypertension (IPAH) was tested. The phenotype and localisation of DCs were characterised by immunohistochemistry and double-labelling immunofluorescence in lung samples from controls, human IPAH patients and an experimental pulmonary hypertension model (monocrotaline-exposed rats). As compared with controls, morphometric analysis demonstrated increased numbers of dendritic cell-specific intercellular adhesion molecule-grabbing nonintegrin (DC-SIGN)-positive cells in muscular pulmonary arteries in IPAH and OX-62-positive DCs in monocrotaline-induced pulmonary hypertension. In human samples, the mean +/- SEM number of DC-SIGN-positive cells(.)artery(-1) of 100-300 mu m diameter was 1.4 +/- 0.4 in controls versus 26.4 +/- 2.7 in IPAH. In rats, the number of OX-62-positive cells(.)artery(-1) of 50-150 mu m diameter was 0.5 +/- 0.2 in controls, and 0.7 +/- 0.5, 3.1 +/- 0.5 and 8.4 +/- 0.6 at day 7, 14 and 28 after monocrotaline exposure, respectively. Human complex lesions of muscular pulmonary arteries showed transmural DC infiltration. Phenotyping revealed an immature DC profile in human and experimental pulmonary hypertension. The results support the concept that immature dendritic cells accumulate in remodelled pulmonary vessels and hence could be involved in the immunopathology of pulmonary hypertension.	Univ Paris 11, UPRES EA2705, Serv Pneumol,Assistance Publ Hop Paris, Ctr Natl Reference Hypertens Arterielle Pulm, Paris, France; INSERM, U764, Inst Federat Rech 13, Clamart, France; Univ Paris Sud, Ctr Chirurg Marie Lannelongue, Chirurg Expt Lab, UPRES EA2705, Le Plessis Robinson, France	Humbert, M (reprint author), Hop Antoine Beclere, Serv Pneumol & Reanimat Resp, 157 Rue Porte de Trivaux, F-92140 Clamart, France.	marc.humbert@abc.aphp.fr	Souza, Rogerio/I-3584-2013	Souza, Rogerio/0000-0003-2789-9143; Dorfmuller, Peter/0000-0003-2499-6829			Appel S, 2005, STEM CELLS, V23, P1082, DOI 10.1634/stemcells.2005-0069; Appel S, 2004, BLOOD, V103, P538, DOI 10.1182/blood-2003-03-0975; Ardavin Carlos, 2004, Immunity, V20, P17, DOI 10.1016/S1074-7613(03)00352-2; Balabanian K, 2002, AM J RESP CRIT CARE, V165, P1419, DOI 10.1164/rccm.2106007; Bowers R, 2004, AM J RESP CRIT CARE, V169, P764, DOI 10.1164/rccm.200301-147OC; BRENAN M, 1992, J EXP MED, V175, P1457, DOI 10.1084/jem.175.6.1457; Cambi A, 2005, CELL MICROBIOL, V7, P481, DOI 10.1111/j.1462-5822.2005.00506.x; Cochand L, 1999, AM J RESP CELL MOL, V21, P547; Conejo-Garcia JR, 2004, NAT MED, V10, P950, DOI 10.1038/nm1097; D'hulst AI, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-147; Demedts IK, 2005, AM J RESP CELL MOL, V32, P177, DOI 10.1165/rcmb.2004-0279OC; Dorfmuller P, 2003, EUR RESPIR J, V22, P358, DOI 10.1183/09031936.03.00038903; Dorfmuller P, 2002, AM J RESP CRIT CARE, V165, P534, DOI 10.1164/rccm.2012112; Frid MG, 2006, AM J PATHOL, V168, P659, DOI 10.2353/ajpath.2006.050599; Gabrilovich D, 1998, BLOOD, V92, P4150; Ghofrani HA, 2005, NEW ENGL J MED, V353, P1412, DOI 10.1056/NEJMc051946; HUMBERT M, 1995, AM J RESP CRIT CARE, V151, P1628; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Millonig G, 2001, ARTERIOSCL THROM VAS, V21, P503; Mohty M, 2004, BLOOD, V103, P4666, DOI 10.1182/blood-2003-09-3220; Montani D, 2005, EUR RESPIR J, V26, P969, DOI 10.1183/09031936.05.00133904; Morelli AE, 2000, CURR OPIN NEPHROL HY, V9, P607, DOI 10.1097/00041552-200011000-00004; Mouthon L, 2005, EUR RESPIR J, V26, P986, DOI 10.1183/09031936.05.00112105; Nicolls MR, 2005, EUR RESPIR J, V26, P1110, DOI 10.1183/09031936.05.00045705; Ota M, 2004, THORAX, V59, P408, DOI 10.1136/thx.2003.006049; Palucka AK, 2005, P NATL ACAD SCI USA, V102, P3372, DOI 10.1073/pnas.0408506102; Patterson KC, 2006, ANN INTERN MED, V145, P152; Pietra GG, 2004, J AM COLL CARDIOL, V43, p25S, DOI 10.1016/j.jacc.2004.02.033; Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005; Reddy A, 1997, BLOOD, V90, P3640; Sanchez O, 2006, CHEST, V130, P182, DOI 10.1378/chest.130.1.182; Schermuly RT, 2005, J CLIN INVEST, V115, P2811, DOI 10.1172/JCI24838; Smyth MJ, 2006, NEW ENGL J MED, V354, P2282, DOI 10.1056/NEJMcibr061878; Soilleux EJ, 2002, J LEUKOCYTE BIOL, V71, P445; Souza R, 2006, THORAX, V61, P736, DOI 10.1136/thx.2006.064097; Taieb J, 2006, NAT MED, V12, P214, DOI 10.1038/nm1356; Tamby MC, 2006, EUR RESPIR J, V28, P799, DOI 10.1183/09031936.06.00152705; Tamby MC, 2005, THORAX, V60, P765, DOI 10.1136/thx.2004.029082; Todate A, 2000, AM J RESP CRIT CARE, V162, P148; Trinite B, 2005, J IMMUNOL, V175, P2408; Van Rijt LS, 2005, CLIN EXP ALLERGY, V35, P1125, DOI 10.1111/j.1365-2222.2005.02321.x	41	73	76	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2007	29	3					462	468		10.1183/09031936.00094706		7	Respiratory System	Respiratory System	146XH	WOS:000244967500008	17107989	
J	Bai, N; Khazaei, M; van Eeden, SF; Laher, I				Bai, Ni; Khazaei, Majid; van Eeden, Stephan F.; Laher, Ismail			The pharmacology of particulate matter air pollution-induced cardiovascular dysfunction	PHARMACOLOGY & THERAPEUTICS			English	Review						particulate matter air pollution; inflammation; cardiovascular effect; reactive oxygen species; endothelial dysfunction	C-REACTIVE PROTEIN; DIESEL EXHAUST PARTICLES; HEART-RATE-VARIABILITY; CORONARY-ARTERY-DISEASE; ULTRAFINE CARBON-BLACK; BRONCHIAL EPITHELIAL-CELLS; HUMAN ALVEOLAR MACROPHAGES; HUMAN ENDOTHELIAL-CELLS; SMOOTH-MUSCLE-CELLS; SOUTH-POLAR-PLATEAU	Since the London fog of 1952, in which more than 4000 people were killed in 4 days, the combined efforts of scientists from several disciplines, including those from the environmental health, clinical and biomedical disciplines, have raised serious concerns about the impact of air pollutants on human health. These environmental pollutants are rapidly being recognized as important and independent risk factors for several diseases such as asthma, chronic obstructive pulmonary disease, lung cancer, atherosclerosis, ischemic heart disease and stroke. Although the relative effects of particulate matter air pollution (aerodynamic diameter < 10 mu m, or PM10) are greater for respiratory than for cardiovascular deaths, the number of deaths attributable to PM10 is much larger for cardiovascular than for respiratory reasons due to the higher prevalence of cardiovascular disease in the general population. This review summarizes current understanding of the mechanisms underlying the associations between PM10 exposure and cardiovascular morbidity and mortality. (c) 2006 Elsevier Inc. All rights reserved.	Univ British Columbia, Dept Pharmacol & Therapeut, Fac Med, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V5Z 1M9, Canada	Laher, I (reprint author), Univ British Columbia, Dept Pharmacol & Therapeut, Fac Med, 2176 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	ilaher@interchange.ubc.ca	Khazaei, Majid/E-7533-2012; Laher, Ismail/L-3947-2013	Laher, Ismail/0000-0002-3917-4417			Albert CM, 2002, CIRCULATION, V105, P2595, DOI 10.1161/01.CIR.0000017493.03108.1C; Bagate K, 2004, INHAL TOXICOL, V16, P431, DOI 10.1080/08958370490439588; Bai YS, 2001, FREE RADICAL BIO MED, V30, P555, DOI 10.1016/S0891-5849(00)00499-8; BALLOU SP, 1992, CYTOKINE, V4, P361, DOI 10.1016/1043-4666(92)90079-7; Barna BP, 1996, J LEUKOCYTE BIOL, V59, P397; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066; Batalha JRF, 2002, ENVIRON HEALTH PERSP, V110, P1191; BATH PMW, 1991, ARTERIOSCLER THROMB, V11, P254; Bayram H, 1998, AM J RESP CELL MOL, V18, P441; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; BERK BC, 1990, AM J CARDIOL, V65, P168, DOI 10.1016/0002-9149(90)90079-G; Bermudez EA, 2002, ARTERIOSCL THROM VAS, V22, P1668, DOI 10.1161/01.ATV.0000029781.31325.66; Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC; Bouthillier L, 1998, AM J PATHOL, V153, P1873, DOI 10.1016/S0002-9440(10)65701-X; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; Brown DM, 2004, AM J PHYSIOL-LUNG C, V286, pL344, DOI 10.1152/ajplung.00139.2003; Brown DM, 2000, OCCUP ENVIRON MED, V57, P685, DOI 10.1136/oem.57.10.685; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Calderon-Garciduenas L, 2002, TOXICOL PATHOL, V30, P373, DOI 10.1080/01926230252929954; Carr MJ, 2001, ENVIRON HEALTH PERSP, V109, P567, DOI 10.2307/3454671; Carter AM, 1997, CIRCULATION, V96, P1424; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; CERMAK J, 1993, BLOOD, V82, P513; Cheng TJ, 2003, ENVIRON HEALTH PERSP, V111, P147; Cheng YW, 1999, J TOXICOL ENV HEAL A, V57, P75, DOI 10.1080/009841099157791; Conway DSG, 2004, J AM COLL CARDIOL, V43, P2075, DOI 10.1016/j.jacc.2003.11.062; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; Creason J, 2001, J EXPO ANAL ENV EPID, V11, P116, DOI 10.1038/sj.jea.7500154; CUSHING SD, 1990, P NATL ACAD SCI USA, V87, P5134, DOI 10.1073/pnas.87.13.5134; Cuzzocrea S, 2004, FASEB J, V18, P94, DOI 10.1096/fj.03-0428com; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dolmetsch RE, 1998, NATURE, V392, P933; Dominici F, 2003, AM J EPIDEMIOL, V157, P1055, DOI 10.1093/aje/kwg087; Donaldson K, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454663; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; FOWLER MB, 1986, CIRCULATION, V74, P1290; Fujii T, 2002, AM J RESP CELL MOL, V27, P34; Fujii T, 2001, AM J RESP CELL MOL, V25, P265; FURUYAMA A, 2005, ARCH TOXICOL, V23, P1; GALVEDEROCHEMONTEIX B, 1993, J LEUKOCYTE BIOL, V53, P439; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; Ghio AJ, 2003, INHAL TOXICOL, V15, P1465, DOI 10.1080/08958370390249111; Ghio AJ, 2000, AM J RESP CRIT CARE, V162, P981; Gibbons GH, 1997, AM J CARDIOL, V79, P3, DOI 10.1016/S0002-9149(97)00122-7; Gilmour PS, 2005, OCCUP ENVIRON MED, V62, P164, DOI 10.1136/oem.2004.014951; Gilmour PS, 1996, OCCUP ENVIRON MED, V53, P817; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598; Gimbrone MA, 1999, THROMB HAEMOSTASIS, V82, P722; Godleski J. J., 2000, RES REP HLTH EFF I, V91, P5; Gold DR, 2000, CIRCULATION, V101, P1267; Goldberg MS, 2001, ENVIRON HEALTH PERSP, V109, P487, DOI 10.2307/3454658; Gong H, 2004, INHAL TOXICOL, V16, P335, DOI 10.1080/08958370490439470; Gordon T., 2000, RES REP HLTH EFF I, V93, P5; Goto Y, 2004, AM J RESP CRIT CARE, V170, P891, DOI 10.1164/rccm.200402-235OC; Goto Y, 2004, AM J PHYSIOL-LUNG C, V287, pL79, DOI 10.1152/ajplung.00425.2003; GUENTER CA, 1970, ARCH INTERN MED, V125, P630, DOI 10.1001/archinte.125.4.630; Gumbleton M, 2001, ADV DRUG DELIVER REV, V49, P281, DOI 10.1016/S0169-409X(01)00142-9; Hadnagy W, 1996, TOXICOL LETT, V88, P147, DOI 10.1016/0378-4274(96)03730-7; Hasdai D, 1997, CIRCULATION, V96, P3390; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hoek G, 2001, EPIDEMIOLOGY, V12, P355, DOI 10.1097/00001648-200105000-00017; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hunter AL, 2005, VASC PHARMACOL, V43, P213, DOI 10.1016/j.vph.2005.07.005; IBALDMULLI A, 2001, AM J PUBLIC HEALTH, V91, P51; Ihling C, 1996, J PATHOL, V179, P303, DOI 10.1002/(SICI)1096-9896(199607)179:3<303::AID-PATH585>3.0.CO;2-9; IKEDA M, 1995, JPN J PHARMACOL, V68, P183, DOI 10.1254/jjp.68.183; Ishii H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-87; Ishii H, 2004, AM J PHYSIOL-LUNG C, V287, pL176, DOI 10.1152/ajplung.00290.2003; Ito T, 2000, ENVIRON TOXICOL PHAR, V9, P1, DOI 10.1016/S1382-6689(00)00053-3; Jimenez LA, 2000, TOXICOL APPL PHARM, V166, P101, DOI 10.1006/taap.2000.8957; Jimenez LA, 2002, AM J PHYSIOL-LUNG C, V282, pL237; Kadiiska MB, 1997, CHEM RES TOXICOL, V10, P1104, DOI 10.1021/tx970049r; Katsouyanni K, 2001, EPIDEMIOLOGY, V12, P521, DOI 10.1097/00001648-200109000-00011; Kennedy T, 1998, AM J RESP CELL MOL, V19, P366; Khandoga A, 2004, CIRCULATION, V109, P1320, DOI 10.1161/01.CIR.0000118524.62298.E8; KLEIGER RE, 1987, AM J CARDIOL, V59, P256, DOI 10.1016/0002-9149(87)90795-8; Kodavanti UP, 2002, J TOXICOL ENV HEAL A, V65, P1545, DOI 10.1080/00984100290071667; Kreuter J, 2001, ADV DRUG DELIVER REV, V47, P65, DOI 10.1016/S0169-409X(00)00122-8; KUBES P, 1991, P NATL ACAD SCI USA, V88, P4651, DOI 10.1073/pnas.88.11.4651; KUMAGAI Y, 1995, FREE RADICAL BIO MED, V18, P365, DOI 10.1016/0891-5849(94)00125-4; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Le Tertre A, 2002, J EPIDEMIOL COMMUN H, V56, P773, DOI 10.1136/jech.56.10.773; LEE E, 1995, ARTERIOSCL THROM VAS, V15, P2284; Lee JT, 2000, ENVIRON RES, V84, P247, DOI 10.1006/enrs.2000.4096; Lefkowitz RJ, 2000, CIRCULATION, V101, P1634; Lefkowitz RJ, 2001, JAMA-J AM MED ASSOC, V285, P581, DOI 10.1001/jama.285.5.581; LERMAN A, 1991, NEW ENGL J MED, V325, P997, DOI 10.1056/NEJM199110033251404; LI H, 1993, ARTERIOSCLER THROMB, V13, P197; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; LI XY, 1994, AM J RESP CRIT CARE, V149, P1518; Li XY, 1999, INHAL TOXICOL, V11, P709; Liao DP, 1999, ENVIRON HEALTH PERSP, V107, P521, DOI 10.2307/3434393; Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; Linn WS, 2000, ENVIRON HEALTH PERSP, V108, P427, DOI 10.2307/3454383; Liu XL, 2005, INHAL TOXICOL, V17, P467, DOI 10.1080/08958370590964467; Liu YP, 2006, AM J PHYSIOL-REG I, V290, pR57, DOI 10.1152/ajpregu.00424.2005; LOGAN W P D, 1953, Lancet, V1, P336; LUDMER PL, 1986, NEW ENGL J MED, V315, P1046, DOI 10.1056/NEJM198610233151702; Maheswaran R, 2005, EUR HEART J, V26, P2543, DOI 10.1093/eurheartj/ehi457; Maheswaran R, 2005, STROKE, V36, P239, DOI 10.1161/01.STR.0000151363.71221.12; Mathew V, 1996, MAYO CLIN PROC, V71, P769; Mazzera DM, 2001, CHEMOSPHERE, V45, P347, DOI 10.1016/S0045-6535(00)00591-9; MCMURRAY JJ, 1992, CIRCULATION, V85, P1374; Mills PR, 1999, AM J RESP CRIT CARE, V160, pS38; Morris RD, 1998, ENVIRON HEALTH PERSP, V106, P649; MUCHMORE HG, 1970, ARCH INTERN MED, V125, P646, DOI 10.1001/archinte.125.4.646; Mukae H, 2000, AM J PHYSIOL-LUNG C, V279, pL924; Mukae H, 2001, AM J RESP CRIT CARE, V163, P201; Muto E, 1996, LIFE SCI, V59, P1563, DOI 10.1016/0024-3205(96)00487-0; Nadziejko Chrinstine, 2002, Cardiovasc Toxicol, V2, P245, DOI 10.1385/CT:2:4:245; Nakagomi A, 2000, CIRCULATION, V101, P1785; Nemery B, 2001, LANCET, V357, P704, DOI 10.1016/S0140-6736(00)04135-0; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Nemmar A, 2003, TOXICOL APPL PHARM, V186, P38, DOI 10.1016/S0041-008X(02)00024-8; Nemmar A, 2002, AM J RESP CRIT CARE, V166, P998, DOI 10.1164/rccm.200110-026OC; Nemmar A, 2001, AM J RESP CRIT CARE, V164, P1665; Nemmar A, 1999, TOXICOL APPL PHARM, V160, P250, DOI 10.1006/taap.1999.8762; Nurkiewicz TR, 2004, ENVIRON HEALTH PERSP, V112, P1299, DOI 10.1289/ehp.7001; O'Neill MS, 2005, CIRCULATION, V111, P2913, DOI 10.1161/CIRCULATIONAHA.104.517110; Oberdorster G, 2002, J TOXICOL ENV HEAL A, V65, P1531, DOI 10.1080/00984100290071658; Oberdorster G, 1996, CHEST, V109, P68; Ogita H, 2004, ENDOTHELIUM-J ENDOTH, V11, P123, DOI 10.1080/10623320490482664; Papapetropoulos A, 1996, CIRC RES, V79, P512; Pasceri V, 2000, CIRCULATION, V102, P2165; Peters A, 1999, AM J EPIDEMIOL, V150, P1094; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Ponka A, 1998, ARCH ENVIRON HEALTH, V53, P281; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pope CA, 1999, AM J RESP CRIT CARE, V159, P365; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; RADOMSKI MW, 1990, P NATL ACAD SCI USA, V87, P5193, DOI 10.1073/pnas.87.13.5193; Rahman I, 1998, THORAX, V53, P601; RAJAVASHISTH TB, 1990, NATURE, V344, P254, DOI 10.1038/344254a0; Ramage L, 2004, INHAL TOXICOL, V16, P447, DOI 10.1080/08958370490439614; Ramage L, 2004, INHAL TOXICOL, V16, P607, DOI 10.1080/089573704904644599; RAY SG, 1992, BRIT HEART J, V67, P383; Ridker PM, 1998, CIRCULATION, V98, P731; Riediker M, 2004, AM J RESP CRIT CARE, V169, P934, DOI 10.1164/rccm.200310-1463OC; Robbie L, 2001, ANN NY ACAD SCI, V947, P167; Ross R, 1999, NEW ENGL J MED, V340, P115; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Sakai M, 2004, J APPL PHYSIOL, V97, P1774, DOI 10.1152/japplphysiol.00024.2004; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; SEAGRAVE J, 2004, INHAL TOXICOL, V1, P93; Seaton A, 1999, THORAX, V54, P1027; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SIMEONOVA PP, 1995, AM J RESP CELL MOL, V12, P676; StillerWinkler R, 1996, J CLIN EPIDEMIOL, V49, P527, DOI 10.1016/0895-4356(95)00579-X; Stone V, 2000, EUR RESPIR J, V15, P297, DOI 10.1034/j.1399-3003.2000.15b13.x; Stone V, 2000, AM J RESP CRIT CARE, V162, pS44; Sullivan GW, 2000, J LEUKOCYTE BIOL, V67, P591; Sullivan J, 2005, EPIDEMIOLOGY, V16, P41, DOI 10.1097/01.ede.0000147116.34813.56; Sullivan JH, 2005, THORAX, V60, P462, DOI 10.1136/thx.2004.027532; Suwa T, 2002, J AM COLL CARDIOL, V39, P935, DOI 10.1016/S0735-1097(02)01715-1; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213; Terada N, 1999, CLIN EXP ALLERGY, V29, P52; Terashima T, 1997, AM J RESP CRIT CARE, V155, P1441; Terashima T, 1998, BLOOD, V92, P1062; Thomson E, 2005, TOXICOL SCI, V88, P103, DOI 10.1093/toxsci/kfi272; Thomson E, 2004, BBA-MOL BASIS DIS, V1689, P75, DOI 10.1016/j.bbadis.2004.02.001; TSUJI H, 1994, CIRCULATION, V90, P878; Ulrich MMW, 2002, J TOXICOL ENV HEAL A, V65, P1571, DOI 10.1080/00984100290071676; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; van Eeden SF, 1999, CHEST, V116, p43S, DOI 10.1378/chest.116.suppl_1.43S; VANEEDEN SF, 2004, AM J RESPIR CELL MOL, V169, pA885; VANEEDEN SF, 2005, AM J RESPIR CELL MOL, V2, pA162; Verma S, 2002, CIRCULATION, V106, P913, DOI 10.1161/01.CIR.0000029802.88087.5E; Vincent R, 2001, RES REP HLTH EFF I, V104, P5; Watkinson WP, 2001, ENVIRON HEALTH PERSP, V109, P539, DOI 10.2307/3454666; WHITE CR, 1994, P NATL ACAD SCI USA, V91, P1044, DOI 10.1073/pnas.91.3.1044; WILCOX JN, 1989, P NATL ACAD SCI USA, V86, P2839, DOI 10.1073/pnas.86.8.2839; Willerson JT, 2002, PROG CARDIOVASC DIS, V44, P469, DOI 10.1053/pcad.2002.123782; Yarnell J, 2005, EUR HEART J, V26, P332, DOI 10.1093/eurhreartj/ehi052; Yeh ETH, 2001, CIRCULATION, V104, P974; Yin XJ, 2004, TOXICOL SCI, V82, P143, DOI 10.1093/toxsci/kfh255; Yokota S, 2005, INHAL TOXICOL, V17, P671, DOI 10.1080/08958370500189628; Yokota S, 2004, INHAL TOXICOL, V16, P319, DOI 10.1080/08958370490428454; Zanobetti A, 2004, CIRCULATION, V110, P2184, DOI 10.1161/01.CIR.0000143831.33243.D8; Zanobetti A, 2001, AM J RESP CRIT CARE, V164, P831; Zanobetti A, 2005, ENVIRON HEALTH PERSP, V113, P978, DOI 10.1289/ehp.7550; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961; Zhang Q, 2004, AM J PHYSIOL-LUNG C, V286, pL427, DOI 10.1152/ajplung.00221.2003; Zouridakis E, 2004, CIRCULATION, V110, P1747, DOI 10.1161/01.CIR.0000142664.18739.92	193	73	78	3	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0163-7258			PHARMACOL THERAPEUT	Pharmacol. Ther.	JAN	2007	113	1					16	29		10.1016/j.pharmthera.2006.06.005		14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	129FE	WOS:000243713100002	16920197	
J	Matsubara, S; Li, GM; Takeda, K; Loader, JE; Pine, P; Masuda, ES; Miyahara, N; Miyahara, S; Lucas, JJ; Dakhama, A; Gelfand, EW				Matsubara, S; Li, GM; Takeda, K; Loader, JE; Pine, P; Masuda, ES; Miyahara, N; Miyahara, S; Lucas, JJ; Dakhama, A; Gelfand, EW			Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						airway hyperresponsiveness; eosinophils; goblet cell metaplasia; mast cells; spleen tyrosine kinase	AFFINITY IGE RECEPTOR; FC-EPSILON-RI; CD8(+) T-CELLS; PASSIVE TRANSFER; TERMINAL KINASE; ALLERGIC-ASTHMA; SMOOTH-MUSCLE; INFLAMMATION; SYK; PROTEIN	Rationale: Spleen tyrosine kinase (Syk) is important for Fc and B-cell receptor-mediated signaling. Objective: To determine the activity of a specific Syk inhibitor (11406) on mast cell activation in vitro and on the development of allergen-induced airway hyperresponsiveness (AHR) and inflammation in vivo. Methods: AHR and inflammation were induced after 10 d of allergen (ovalbumin [OVA]) exposure exclusively via the airways and in the absence of adjuvant. This approach was previously established to be IgE, Fc epsilon RI, and mast cell dependent. Alternatively, mice were passively sensitized with OVA-specific IgE, followed by limited airway challenge. In vitro, the inhibitor was added to cultures of IgE-sensitized bone marrow-derived mast cells (BMMCs) before crosslinking with allergen. Results: The inhibitor prevented OVA-induced degranulation of passively IgE-sensitized murine IBMMCs and inhibited the production of interieukin (IL)-13, tumor necrosis factor a, IL-2, and IL-6 in these sensitized BMMCs. When administered in vivo, R406 inhibited AHR, which developed in BALB/c mice exposed to aerosolized 1% OVA for 10 consecutive d (20 min/d), as well as pulmonary eosinophilia and goblet cell metaplasia. A similar inhibition of AHR was demonstrated in mice passively sensitized with OVA-specific IgE and exposed to limited airway challenge. Conclusion: This study delineates a functional role for Syk in the development of mast cell- and IgE-mediated AHR and airway inflammation, and these results indicate that inhibition of Syk may be a target in the treatment of allergic asthma.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, Denver, CO 80206 USA; Rigel Pharmaceut Inc, San Francisco, CA USA	Gelfand, EW (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Cell Biol, 1400 Jackson St, Denver, CO 80206 USA.	gelfande@njc.org			NHLBI NIH HHS [HL-36577, HL-42246, HL-61005, P01 HL036577, P01 HL036577-21A15977]		Bang LM, 2004, BIODRUGS, V18, P415, DOI 10.2165/00063030-200418060-00007; BENHAMOU M, 1993, J BIOL CHEM, V268, P23318; Blank U, 2004, TRENDS IMMUNOL, V25, P266, DOI 10.1016/j.it.2004.03.005; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Busse WW, 2001, NEW ENGL J MED, V344, P350; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Costello PS, 1996, ONCOGENE, V13, P2595; DARBY C, 1994, J IMMUNOL, V152, P5429; Garrington TP, 2000, EMBO J, V19, P5387, DOI 10.1093/emboj/19.20.5387; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; Gurish MF, 2001, J EXP MED, V194, pF1, DOI 10.1084/jem.194.1.F1; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; Ishizuka T, 1999, J IMMUNOL, V162, P2087; Ishizuka T, 1997, P NATL ACAD SCI USA, V94, P6358, DOI 10.1073/pnas.94.12.6358; Ishizuka T, 1996, J BIOL CHEM, V271, P12762; Kim Y, 2001, J IMMUNOL, V166, P5183; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404; LARSEN GL, 1992, J CLIN INVEST, V89, P747, DOI 10.1172/JCI115651; Larsen GL, 1994, AM J PHYSIOL, V266, P263; Luskova P, 2004, CURR PHARM DESIGN, V10, P1727, DOI 10.2174/1381612043384538; Luster AD, 2004, NAT REV IMMUNOL, V4, P711, DOI 10.1038/nri1438; Macedo-Soares MF, 2004, J ALLERGY CLIN IMMUN, V114, P97, DOI 10.1016/j.jaci.2004.03.033; MATSUBARA S, 2005, P AM THORAC SOC, V2, pA754; Mayr SI, 2002, J IMMUNOL, V169, P2061; Miyahara N, 2005, J IMMUNOL, V174, P4979; Miyahara N, 2004, NAT MED, V10, P865, DOI 10.1038/nm1081; Mocsai A, 2002, IMMUNITY, V16, P547, DOI 10.1016/S1074-7613(02)00303-5; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Robinson DS, 2004, J ALLERGY CLIN IMMUN, V114, P58, DOI 10.1016/j.jaci.2004.03.034; Sedlik C, 2003, J IMMUNOL, V170, P846; Seow CJ, 2002, EUR J PHARMACOL, V443, P189, DOI 10.1016/S0014-2999(02)01534-0; Siraganian R.P., 1999, SIGNAL TRANSDUCTION, P115; Stenton GR, 2002, J IMMUNOL, V169, P1028; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Taube C, 2004, J IMMUNOL, V172, P6398; Tomkinson A, 2001, J IMMUNOL, V166, P5792; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wong BR, 2004, EXPERT OPIN INV DRUG, V13, P743, DOI 10.1517/13543784.13.7.743; Yamamoto N, 2003, J PHARMACOL EXP THER, V306, P1174, DOI 10.1124/jpet.103.052316; Yang GY, 2004, CYTOKINE, V28, P224, DOI 10.1016/j.cyto.2004.08.007; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71	45	73	77	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN 1	2006	173	1					56	63		10.1164/rccm.200503-361OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	001GA	WOS:000234520400010	16192454	
J	Kattan, M; Stearns, SC; Crain, EF; Stout, JW; Gergen, PJ; Evans, R; Visness, CM; Gruchalla, RS; Morgan, WJ; O'Connor, GT; Mastin, JP; Mitchell, HE				Kattan, M; Stearns, SC; Crain, EF; Stout, JW; Gergen, PJ; Evans, R; Visness, CM; Gruchalla, RS; Morgan, WJ; O'Connor, GT; Mastin, JP; Mitchell, HE			Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; inner city; cost-effectiveness; asthma intervention; allergen mitigation	UNITED-STATES; ILLNESS; TRENDS	Background: Exposure to indoor allergens contributes to increased asthma morbidity. The Inner-City Asthma Study, a randomized trial involving home environmental allergen and irritant remediation among children aged 6 through 11 years with moderate-to-severe asthma, successfully reduced asthma symptoms. A cost-effectiveness analysis can help stakeholders to evaluate the potential costs and benefits of adopting such a program. Objective: We sought to assess the cost-effectiveness of the environmental intervention of the Inner-City Asthma Study. Methods: Incremental cost-effectiveness ratios for a 2-year study period were calculated. Health outcome was measured as symptom-free days. Resource use measures included ambulatory visits, hospitalizations, and pharmaceutical use. CIs were obtained by using bootstrapping. Results: The intervention, which cost $1469 per family, led to statistically significant reductions in symptom days, unscheduled clinic visits, and use of beta-agonist inhalers. Over the year of the intervention and a year of follow-up, the intervention cost was $27.57 per additional symptom-free day (95% CI, $7.46-$67.42). Subgroup analysis showed that targeting the intervention to selected high-risk subgroups did not reduce the incremental cost-effectiveness ratio. Conclusions: A targeted home-based environmental intervention improved health and reduced service use in inner-city children with moderate-to-severe asthma. The intervention is cost-effective when the aim is to reduce asthma symptom days and the associated costs.	Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; Univ N Carolina, Dept Hlth Policy & Adm, Chapel Hill, NC USA; Albert Einstein Coll Med, Jacobi Med Ctr, Dept Pediat Emergency Med, Bronx, NY 10467 USA; Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; NIAID, Asthma Allergy Inflammat Branch, Div Allergy Immunol Transplantat, NIH, Bethesda, MD 20892 USA; Northwestern Univ, Sch Med, Dept Pediat, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Rho Inc, Chapel Hill, NC USA; Univ Texas, SW Med Ctr Dallas, Dept Med, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75235 USA; Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ USA; Boston Univ, Sch Med, Boston, MA 02215 USA; Natl Inst Environm Hlth Sci, Res Triangle Pk, NC USA	Kattan, M (reprint author), Mt Sinai Sch Med, Dept Pediat, Box 1202B,1 Gustave L Levy Pl, New York, NY 10029 USA.	meyer.kattan@mssm.edu		O'Connor, George/0000-0002-6476-3926	NIAID NIH HHS [AI-39900, AI-39761, AI-39769, AI-39776, AI-39785, AI-39789, AI-39901, AI-39902]		Chaudhary MA, 1996, STAT MED, V15, P1447; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Krahn MD, 1996, CAN MED ASSOC J, V154, P821; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; Paltiel AD, 2001, J ALLERGY CLIN IMMUN, V108, P39; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; STEIN REK, 1987, LANCET, V2, P1506; Sullivan SD, 2003, J ALLERGY CLIN IMMUN, V112, P1229, DOI 10.1016/j.jaci.2003.09.025; Sullivan SD, 2002, J ALLERGY CLIN IMMUN, V110, P576, DOI 10.1067/mai.2002.128009; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304	14	73	76	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2005	116	5					1058	1063		10.1016/j.jaci.2005.07.032		6	Allergy; Immunology	Allergy; Immunology	017IG	WOS:000235686700017	16275376	
J	Tauchi, M; Hida, A; Negishi, T; Katsuoka, F; Noda, S; Mimura, J; Hosoya, T; Yanaka, A; Aburatani, H; Fujii-Kuriyama, Y; Motohashi, H; Yamamoto, M				Tauchi, M; Hida, A; Negishi, T; Katsuoka, F; Noda, S; Mimura, J; Hosoya, T; Yanaka, A; Aburatani, H; Fujii-Kuriyama, Y; Motohashi, H; Yamamoto, M			Constitutive expression of aryl hydrocarbon receptor in keratinocytes causes inflammatory skin lesions	MOLECULAR AND CELLULAR BIOLOGY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; DIESEL EXHAUST PARTICLES; CONTACT HYPERSENSITIVITY; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; POLYAROMATIC HYDROCARBONS; ATOPIC-DERMATITIS; DIOXIN RECEPTOR; TRANSGENIC MICE; IGE; INDUCTION	Occupational and environmental exposure to polycyclic aromatic hydrocarbons (PAHs) has been suggested to provoke inflammatory and/or allergic disorders, including asthma, rhinitis, and dermatitis. The molecular mechanisms of this PAH-mediated inflammation remain to be clarified. Previous studies implied the involvement of PAHs as irritants and allergens, with the reactive oxygen species generated from the oxygenated PAHs believed to be an exacerbating factor. It is also possible that PAHs contribute to the pathogenesis through activation of aryl-hydrocarbon receptor (AhR)-mediated transcription, since PAHs are potent inducers of the AhR. To address this point, we generated transgenic mouse lines expressing the constitutive active form of the AhR in keratinocytes. In these lines of mice, the AhR activity was constitutively enhanced in the absence of ligands, so that any other direct effects of PAHs and their metabolites could be ignored. At birth, these transgenic mice were normal, but severe skin lesions with itching developed postnatally. The skin lesions were accompanied by inflammation and immunological imbalance and resembled typical atopic dermatitis. We demonstrate that constitutive activation of the AhR pathway causes inflammatory skin lesions and suggests a new mechanism for the exacerbation of inflammatory diseases after exposure to occupational and environmental xenobiotics.	Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 3058577, Japan; Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki 3058577, Japan; Mochida Pharmaceut Co Ltd, Pharmaceut Res Ctr, Jimba, Gotemba 4128524, Japan; Japan Sci & Technol Corp, ERATO, Environm Response Project, Tsukuba, Ibaraki 3058577, Japan; Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo 1538904, Japan; Japan Sci & Technol Corp, SORST, Kawaguchi 3320012, Japan	Motohashi, H (reprint author), Univ Tsukuba, Ctr TARA, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058577, Japan.	hozumim@tara.tsukuba.ac.jp	Mimura, Junsei/E-7893-2013				ANDERSON C, 1995, J IMMUNOL, V155, P3530; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152906299; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P153, DOI 10.1097/01.all.0000162308.89857.6c; Bonvallot V, 2001, AM J RESP CELL MOL, V25, P515; Casale GP, 2000, MOL CARCINOGEN, V27, P125, DOI 10.1002/(SICI)1098-2744(200002)27:2<125::AID-MC8>3.0.CO;2-0; COENRAADS PJ, 1994, DERMATOL CLIN, V12, P569; DAVILA DR, 1995, J TOXICOL ENV HEALTH, V45, P101; DiazSanchez D, 1997, ALLERGY, V52, P52; Frazer IH, 1998, EUR J IMMUNOL, V28, P2791, DOI 10.1002/(SICI)1521-4141(199809)28:09<2791::AID-IMMU2791>3.0.CO;2-B; Fujimaki H, 2002, TOXICOL SCI, V66, P117, DOI 10.1093/toxsci/66.1.117; GUO LF, 1993, EMBO J, V12, P973; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; KARRAS JG, 1995, TOXICOL LETT, V75, P225, DOI 10.1016/0378-4274(94)03185-A; Kepley CL, 2003, CLIN IMMUNOL, V107, P10, DOI 10.1016/S1521-6616(03)00004-4; KLEMME JC, 1987, CANCER RES, V47, P6074; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Leung D, 1999, J ALLERGY CLIN IMMUN, V104, P99; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Mastrangelo G, 2003, INT J IMMUNOPATH PH, V16, P145; Matikainen T, 2001, NAT GENET, V28, P355, DOI 10.1038/ng575; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; Nakayama T, 2001, INT IMMUNOL, V13, P95, DOI 10.1093/intimm/13.1.95; Nickoloff BJ, 1999, J CLIN INVEST, V104, P1161, DOI 10.1172/JCI8633; NOHARA XK, 2005, J IMMUNOL, V174, P2770; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Pei XH, 2002, CYTOKINE, V19, P236, DOI 10.1006/cyto.2002.1967; Pereira LV, 2000, GENE, V255, P363, DOI 10.1016/S0378-1119(00)00313-9; Rydzynski K, 2004, TOXICOLOGY, V198, P75, DOI 10.1016/j.tox.2004.01.020; Saxon A, 2000, IMMUNOPHARMACOLOGY, V48, P325, DOI 10.1016/S0162-3109(00)00234-4; Sjogren M, 1996, MUTAT RES-FUND MOL M, V358, P97, DOI 10.1016/0027-5107(96)00175-3; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Tohyama M, 2001, J DERMATOL SCI, V27, P130, DOI 10.1016/S0923-1811(01)00127-X; Walker DB, 2004, TOXICOLOGY, V197, P57, DOI 10.1016/j.tox.2003.12.012; Wu MT, 2003, J OCCUP ENVIRON MED, V45, P1034, DOI 10.1097/01.jom.0000088876.25970.96; Yamamoto O, 2003, J DERMATOL SCI, V32, P85, DOI 10.1016/S0923-1811(03)00097-5	38	73	76	1	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0270-7306			MOL CELL BIOL	Mol. Cell. Biol.	NOV	2005	25	21					9360	9368		10.1128/MCB.25.21.9360-9368.2005		9	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	976SW	WOS:000232754600018	16227587	
J	Jarvis, D; Luczynska, C; Chinn, S; Potts, J; Sunyer, J; Janson, C; Svanes, C; Kunzli, N; Leynaert, B; Heinrich, J; Kerkhof, M; Ackermann-Liebrich, U; Anto, MM; Cerveri, I; de Marco, R; Gislason, T; Neukirch, F; Vermeire, P; Wjst, M; Burney, P				Jarvis, D; Luczynska, C; Chinn, S; Potts, J; Sunyer, J; Janson, C; Svanes, C; Kunzli, N; Leynaert, B; Heinrich, J; Kerkhof, M; Ackermann-Liebrich, U; Anto, MM; Cerveri, I; de Marco, R; Gislason, T; Neukirch, F; Vermeire, P; Wjst, M; Burney, P			Change in prevalence of IgE sensitization and mean total IgE with age and cohort	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						ECRHS; atopy; total IgE; cohort	RESPIRATORY-HEALTH-SURVEY; SKIN-TEST REACTIVITY; 8 YEARS APART; HAY-FEVER; SERUM IGE; IMMUNOGLOBULIN-E; INCREASING PREVALENCE; COPENHAGEN ALLERGY; ASTHMA; ATOPY	Background: Cross-sectional studies show that the prevalence of IgE sensitization is lower in older age groups than younger age groups. This could reflect either a decrease in sensitization with aging or a higher prevalence of sensitization in more recent birth cohorts. Objective: To assess change in IgE sensitization and mean total IgE in young adults as they age. Methods: Serum specific IgE to common allergens and total IgE were measured on 2 occasions about 9 years apart in 6371 young adults living in 28 centers, mainly in Western Europe, who took part in the European Community Respiratory Health Survey II. Outcomes were analyzed by using generalized estimating equations, and adjustments were made for differences between laboratory measures on the 2 occasions. Results: Overall, there was no net change in the prevalence of sensitization to at least 1 of house dust mite, grass, or cat (net change per 10 years of follow-up, -0.1%; 95% CI, -1.7% to 1.5%), although there was a fall in mean total IgE (ratio of geometric mean total IgE, 0.86; 95% CI, 0.79 to 0.93). There was evidence that sensitization to at least 1 allergen was higher in more recent cohorts, and this was largely explained by a higher prevalence of sensitization to grass. Conclusion: The disease burden associated with IgE sensitization in adults, and particularly with IgE sensitization to grass, is likely to continue to increase for some time despite current evidence that the increase in allergy seen in children may have ceased.	Univ London Kings Coll, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Pompeu Fabra, Inst Municipal Invest Med, Barcelona, Spain; Univ Uppsala, S-75105 Uppsala, Sweden; Haukeland Hosp, Dept Med, Dept Thorac Med, Bergen, Norway; Univ So Calif, Keck Sch Med, Div Environm Hlth, Dept Prevent Med, Los Angeles, CA 90089 USA; Inst Natl Sante & Rech Med Epidemiol, Paris, France; GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Univ Groningen, Dept Hlth Sci, Groningen, Netherlands; Univ Basel, Int Social & Prevent Med, CH-4003 Basel, Switzerland; Univ Pavia, Ist Ricovero & Curea Carattere Sci San Matteo, Div Resp Dis, Pavia, Italy; Univ Verona, Div Epidemiol & Stat, Dept Med & Publ Hlth, I-37100 Verona, Italy; Univ Hosp, Dept Allergy Resp Med & Sleep, Reykjavik, Iceland; Univ Antwerp, Antwerp, Belgium	Jarvis, D (reprint author), Univ London Kings Coll, Dept Publ Hlth Sci, 42 Weston St, London SE1 3QD, England.	deborah.jarvis@kcl.ac.uk	de Marco, Roberto/A-5470-2008; Kerkhof, Marjan/A-8846-2008; SESM, SESM/C-1440-2008; Jarvis, Deborah/E-6494-2011; Kunzli, Nino/F-7195-2014; Sunyer, J/G-6909-2014	Kunzli, Nino/0000-0001-8360-080X; Sunyer, J/0000-0002-2602-4110	NCRR NIH HHS [2 S07 RR05521-28]		Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P919, DOI 10.1016/0091-6749(87)90241-7; BARBEE RA, 1987, J ALLERGY CLIN IMMUN, V79, P16, DOI 10.1016/S0091-6749(87)80010-6; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Broadfield E, 2002, J ALLERGY CLIN IMMUN, V109, P969, DOI 10.1067/mai.2002.124772; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURROWS B, 1981, AM REV RESPIR DIS, V124, P523; CRIQUI MH, 1990, ANN ALLERGY, V64, P308; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Gassner-Bachmann M, 2000, DEUT MED WOCHENSCHR, V125, P924, DOI 10.1055/s-2000-6778; GERRARD JW, 1980, ANN ALLERGY, V44, P261; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; Linneberg A, 2002, CLIN EXP ALLERGY, V32, P1702, DOI 10.1046/j.1365-2222.2002.01537.x; Linneberg A, 2000, ALLERGY, V55, P767, DOI 10.1034/j.1398-9995.2000.00672.x; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; ORYSZCZYN M, 1990, ANN ALLERGY, V67, P355; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; Ronchetti R, 2003, CLIN EXP ALLERGY, V33, P1232, DOI 10.1046/j.1365-2222.2003.01746.x; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; StataCorp, 2003, STAT STAT SOFTW REL; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, BRIT MED J, V308, P692	31	73	73	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					675	682		10.1016/j.jaci.2005.05.009		8	Allergy; Immunology	Allergy; Immunology	017IE	WOS:000235686500032	16159642	
J	Johnson, CC; Ownby, DR; Alford, SH; Havstad, SL; Williams, LK; Zoratti, EM; Peterson, EL; Joseph, CLM				Johnson, CC; Ownby, DR; Alford, SH; Havstad, SL; Williams, LK; Zoratti, EM; Peterson, EL; Joseph, CLM			Antibiotic exposure in early infancy and risk for childhood atopy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergy; antibiotics; atopy; children; IgE; skin testing	PRACTICE RESEARCH DATABASE; ALLERGIC DISEASE; INFECTIOUS-DISEASES; BIRTH COHORT; SERUM IGE; 1ST YEAR; ASTHMA; LIFE; AGE; CHILDREN	Background: The increase in pediatric allergy and asthma parallels the increase in use of antibiotics. Antibiotics disturb the flora of the gastrointestinal tract, possibly perturbing the developing immune system. Objective: We evaluated whether antibiotic use during early infancy increased the risk for atopy. Methods: Antibiotic prescriptions documented in medical records were collected from a birth cohort born from 1987 through 1989 (n=725). At 6 to 7 years of age, 448 were followed by means of examination, including skin prick tests and serum IgE measurements to common allergens. Results: Adjusted odds ratios (aORs) and 95% CIs were calculated comparing children with any versus those with no antibiotic use in the first 6 months and the outcomes of atopy (any positive skin test response), seroatopy (any positive specific IgE test result), either atopy or seroatopy, and both atopy and seroatopy. Atopy increased with antibiotic use approaching statistical significance (aOR, 1.48, 95% Cl, 0.94-2.34; P =.09)., however, the risk was concentrated among children with less than 2 pets in the home (aOR, 1.73; 95% Cl, 1.07-2.80; P=.024) and children breast-fed for 4 or more months (aOR, 3.02; 95% CI, 1.27-7.17; P=.013). The aORs were generally in the same direction for seroatopy and the combined categories. Conclusion: Antibiotic use in early life appears to contribute to increased risk for atopy in certain subgroups of children.	Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; Henry Ford Hlth Syst, Ctr Hlth Serv Res, Detroit, MI USA; Henry Ford Hlth Syst, Div Gen Med, Dept Internal Med, Detroit, MI USA; Henry Ford Hlth Syst, Sect Allergy & Immunol, Div Pulm Crit Care Allergy Immunol & Sleep Med, Detroit, MI USA; Wayne State Univ, Environm Hlth Sci Ctr Mol & Cellular Toxicol Huma, Detroit, MI 48202 USA; Med Coll Georgia, Sect Allergy Immunol, Augusta, GA USA	Johnson, CC (reprint author), Henry Ford Hlth Syst, Dept Biostat & Res Epidemiol, 1 Ford Pl,5C, Detroit, MI 48202 USA.	cjohnso1@hfhs.org		Johnson, Christine Cole/0000-0002-6864-6604	NHLBI NIH HHS [HL 67427]; NIAID NIH HHS [AI 50681, AI 24156]; NIEHS NIH HHS [P03 ES 06639]		Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Bremner SA, 2003, CLIN EXP ALLERGY, V33, P1518, DOI 10.1046/j.1365-2222.2003.01794.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cullinan P, 2004, THORAX, V59, P11; Dowell SF, 1998, PEDIATRICS, V101, P163; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Farooqi IS, 1998, THORAX, V53, P927; Finkelstein JA, 2003, PEDIATRICS, V112, P620, DOI 10.1542/peds.112.3.620; Foliaki S, 2004, INT J EPIDEMIOL, V33, P558, DOI 10.1093/ije/dyh031; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Levy J, 2000, AM J GASTROENTEROL, V95, pS8, DOI 10.1016/S0002-9270(99)00808-4; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Noverr MC, 2004, INFECT IMMUN, V72, P4996, DOI 10.1128/IAI.72.9.4996-5003.2004; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Strachan DP, 2000, THORAX S1, V55, pS2; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Williams LK, 2004, J ALLERGY CLIN IMMUN, V113, P291, DOI 10.1016/j.jaci.2003.11.010; Wjst M, 2001, EUR J MED RES, V6, P263; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3	27	73	75	1	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1218	1224		10.1016/j.jaci.2005.04.020		7	Allergy; Immunology	Allergy; Immunology	935WZ	WOS:000229815400017	15940137	
J	Cristaudo, A; Sera, F; Severino, V; De Rocco, M; Di Lella, E; Picardo, M				Cristaudo, A; Sera, F; Severino, V; De Rocco, M; Di Lella, E; Picardo, M			Occupational hypersensitivity to metal salts, including platinum, in the secondary industry	ALLERGY			English	Article						hypersensitivity; iridium; occupational; palladium; platinum group elements; platinum salts; rhodium; skin test	REFINERY WORKERS; MEDICAL SURVEILLANCE; PROSPECTIVE COHORT; ALLERGY; EXPOSURE; ASTHMA	Background: Exposure to platinum group elements (PGEs) - platinum (Pt), palladium (Pd), rhodium (Rh) and iridium (Ir) - may cause acute toxicity or hypersensitivity with respiratory symptoms, urticaria and (less frequently) contact dermatitis. Our aim was to determine the prevalence and the clinical characteristics of hypersensitivity to platinum salts and to other elements of the platinum group. Methods: A total of 153 subjects working in a catalyst manufacturing and recycling factory were examined. The examination consisted of a work exposure and medical questionnaire, physical examination, skin prick test for PGEs and other common aeroallergens, and patch tests for PGEs. Skin prick tests and patch tests were performed with H-2[PtCl6], K-2[PtCl4], Na-2[PtCl6], IrCl3, RhCl3, PdCl2, aqueous solutions at different concentrations. Results: Positive prick test reactions to Pt-salts at various concentrations were found in 22 (14.4%) of 153 workers; eight had simultaneous reactions to all Pt-salts tested; seven had positive responses to H-2[PtCl6] only; four had simultaneous positive reactions to both H-2[PtCl6] and K-2[PtCl4]; three had positive reactions to H-2[PtCl6] and Na-2[PtCl6]. Three of 22 had positive reactions to H-2[PtCl6] and IrCl3 solutions, two of these had positive reactions to H-2[PtCl6], IrCl3 and RhCl3 solutions. Positive patch test reactions to platinum salts at day 2 were seen in two of 153 subjects. Conclusions: The results of this study demonstrate that Pt-salts are important allergens in the catalyst industry and that the clinical manifestations involve both the respiratory system and the skin. Hexachloroplatinic acid should be considered the most important salt to use for skin prick tests.	Ist S Maria & S Gallicano, Serv Allergol, IRCCS, I-0144 Rome, Italy; IRCCS, IDI, Lab Epidemiol, Rome, Italy	Cristaudo, A (reprint author), Ist S Maria & S Gallicano, Serv Allergol, IRCCS, Via Elio Chianesi 53, I-0144 Rome, Italy.		Sera, Francesco/C-8176-2011; Picardo, Mauro/A-6978-2011; Cristaudo, Antonio/K-5944-2016	Picardo, Mauro/0000-0003-4899-6639; Cristaudo, Antonio/0000-0002-0737-983X			BAKER DB, 1990, AM J IND MED, V18, P653, DOI 10.1002/ajim.4700180604; BOLMAUDORFF U, 1992, INT ARCH OCC ENV HEA, V64, P257, DOI 10.1007/BF00378283; BURROWS D, 1999, OCCUPATIONAL SKIN DI; CALVERLEY AE, 1995, OCCUP ENVIRON MED, V52, P661; Cotton F. A., 1988, ADV INORGANIC CHEM; GUY HR, 1999, METALS SKIN TOPIC EF; HUGHES EG, 1980, J SOC OCCUP MED, V30, P27; *INT PROGR CHEM SA, 1991, ENV HLTH CRIT PLAT, P125; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; LOEBENSTEIN JR, 1988, US BUREAU MINES MINE, V1, P689; MERGET R, 1991, BRIT J IND MED, V48, P830; Merget R, 2000, J ALLERGY CLIN IMMUN, V105, P364, DOI 10.1016/S0091-6749(00)90089-7; Merget R, 2001, SCI TOTAL ENVIRON, V270, P165, DOI 10.1016/S0048-9697(00)00788-9; Merget R, 2001, J ALLERGY CLIN IMMUN, V107, P707; Niezborala M, 1996, OCCUP ENVIRON MED, V53, P252; Quirce S, 1998, ALLERGY, V53, P633, DOI 10.1111/j.1398-9995.1998.tb03949.x; Santucci B, 2000, CONTACT DERMATITIS, V43, P333, DOI 10.1034/j.1600-0536.2000.043006333.x; Schuppe HC, 1997, INT ARCH ALLERGY IMM, V112, P125; SPSS Inc, 2001, SPSS WIND REL 11 0 1; WEDEPOHL KH, 1995, GEOCHIM COSMOCHIM AC, V59, P1217	20	73	75	0	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	FEB	2005	60	2					159	164		10.1111/j.1398-9995.2004.00521.x		6	Allergy; Immunology	Allergy; Immunology	887VF	WOS:000226332900005	15647035	
J	Nygaard, UC; Samuelsen, M; Aase, A; Lovik, M				Nygaard, UC; Samuelsen, M; Aase, A; Lovik, M			The capacity of particles to increase allergic sensitization is predicted by particle number and surface area, not by particle mass	TOXICOLOGICAL SCIENCES			English	Article						PM; particle size; adjuvant effect; allergy; mice; IgE	DIESEL EXHAUST PARTICLES; CARBON-BLACK; PARTICULATE MATTER; AIR-POLLUTION; ULTRAFINE PARTICLES; URBAN AIR; RESPIRATORY HEALTH; ADJUVANT ACTIVITY; OXIDATIVE STRESS; IMMUNE-RESPONSES	Particle exposure has traditionally been monitored as mass concentration of PM10 (particles with an aerodynamic diameter less than 10 mum), more recently also as PM2.5. The mass concentration is strongly influenced by the large particles. Therefore, particle mass is a poor measure for characterizing the amount of the small, possibly more biologically potent particles. We used polystyrene particles (PSP) ranging in diameter from 0.0588 to 11.14 mum, carbon black (CB), and diesel exhaust particles (DEP), to study the adjuvant effect of particles on the immune response to the allergen ovalbumin (OVA) after sc injection into the footpad of BALB/cA mice. At a given mass dose, the small particles (0.0588 and 0.202 mum PSP, CB, and DEP) increased the allergen-specific IgE serum levels to a substantially higher degree than the larger particles (1.053, 4.64, and 11.14 mum PSP). Further, in the draining lymph node during the primary response, the fine particles (0.202 mum) with OVA increased cell numbers, expression of surface markers (CD19, MHC class II, CD86, and CD23) and ex vivo production of IL-4 and IL-10, whereas the largest (11.14 mum) particles did not. Linear regression analyses indicated that the IgE response was not predicted by particle mass (R-2 = 0.06), but was predicted by the total particle surface area (R-2 = 0.64), number of particles (R-2 = 0.62), and particle diameter (R-2 = 0.58). In conclusion, we found that fine particles exerted stronger adjuvant effects on allergic responses than larger particles at equal mass doses. Consequently, the dose described as total particle surface area or particle number predicts the adjuvant effect of particles better than the currently used particle mass.	Norwegian Inst Publ Hlth, Div Environm Med, NO-0403 Oslo, Norway; Norwegian Inst Publ Hlth, Div Infect Dis Control, NO-0403 Oslo, Norway	Nygaard, UC (reprint author), Norwegian Inst Publ Hlth, Div Environm Med, POB 4404 Nydalen, NO-0403 Oslo, Norway.	unni.cecilie.nygaard@fhi.no					Al-Humadi NH, 2002, EXP LUNG RES, V28, P333, DOI 10.1080/01902140290091976; Becker S, 2003, EXP LUNG RES, V29, P29, DOI 10.1080/01902140390116535; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Churg A, 1997, AM J RESP CRIT CARE, V155, P2109; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370390205065; Donaldson K, 2003, FREE RADICAL BIO MED, V34, P1369, DOI 10.1016/S0891-5849(03)00150-3; Donaldson K, 2000, PHILOS T ROY SOC A, V358, P2741; Dreher KL, 2000, INHAL TOXICOL, V12, P45, DOI 10.1080/08958378.2000.11463230; Gilmour PS, 2004, TOXICOL APPL PHARM, V195, P35, DOI 10.1016/j.taap.2003.10.003; Granum B, 2002, TOXICOL SCI, V65, P7, DOI 10.1093/toxsci/65.1.7; Granum B, 2001, TOXICOLOGY, V156, P149, DOI 10.1016/S0300-483X(00)00375-9; Granum B, 2000, INHAL TOXICOL, V12, P365, DOI 10.1080/08958378.2000.11463247; Harrison RM, 2000, PHILOS T ROY SOC A, V358, P2567; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Junker M, 2000, ATMOS ENVIRON, V34, P3171, DOI 10.1016/S1352-2310(99)00372-6; Lambert AL, 2000, TOXICOL APPL PHARM, V165, P84, DOI 10.1006/taap.2000.8932; Lighty JS, 2000, J AIR WASTE MANAGE, V50, P1565; Lison D, 1997, ARCH TOXICOL, V71, P725, DOI 10.1007/s002040050453; LOVDAL T, 2003, TOXICOL SCI S, V72, P593; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Maynard AD, 2002, ATMOS ENVIRON, V36, P5561, DOI 10.1016/S1352-2310(02)00743-4; Moshammer H, 2003, ATMOS ENVIRON, V37, P1737, DOI 10.1016/S1352-2310(03)00073-6; Murphy SAM, 1999, OCCUP ENVIRON MED, V56, P813; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; NYGAARD UC, IN PRESS TOXICOLOGY; OBERDORSTER G, 1994, ENVIRON HEALTH PERSP, V102, P173, DOI 10.2307/3432080; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Ormstad H, 1998, TOXICOLOGY, V129, P227, DOI 10.1016/S0300-483X(98)00079-1; Osornio-Vargas AR, 2003, ENVIRON HEALTH PERSP, V111, P1289, DOI 10.1289/ehp.5913; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Schins RPF, 2004, TOXICOL APPL PHARM, V195, P1, DOI 10.1016/j.taap.2003.10.002; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Siegel PD, 2004, J TOXICOL ENV HEAL A, V67, P221, DOI 10.1080/15287390490266891; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; TILNEY NL, 1971, J ANAT, V109, P369; TOEWS GB, 1997, PULMONARY DEFENCES, P197; Tran CL, 2000, INHAL TOXICOL, V12, P1113, DOI 10.1080/08958370050166796; Tuschl H, 2002, TOXICOLOGY, V172, P35, DOI 10.1016/S0300-483X(01)00583-2; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; VANZIJVERDEN M, 2002, TOXICOL APPL PHARM, V178, P144; Veronesi B, 2002, INHAL TOXICOL, V14, P159, DOI 10.1080/089583701753403971; Zanobetti A, 2003, ENVIRON HEALTH PERSP, V111, P1188, DOI 10.1289/ehp.5712	44	73	76	3	15	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080			TOXICOL SCI	Toxicol. Sci.	DEC	2004	82	2					515	524		10.1093/toxsci/kfh287		10	Toxicology	Toxicology	873AY	WOS:000225252300019	15456925	
J	Lee, YL; Lin, YC; Lee, YC; Wang, JY; Hsiue, TR; Guo, YL				Lee, YL; Lin, YC; Lee, YC; Wang, JY; Hsiue, TR; Guo, YL			Glutathione S-transferase P1 gene polymorphism and air pollution as interactive risk factors for childhood asthma	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						air pollution; asthma; children; gene-environmental interaction; GSTP1 polymorphism	GENOME-WIDE SEARCH; BRONCHIAL HYPERRESPONSIVENESS; RESPIRATORY SYMPTOMS; ENVIRONMENTAL EXPOSURES; SUSCEPTIBILITY LOCI; PULMONARY-FUNCTION; IMMUNOGLOBULIN-E; SCHOOL-CHILDREN; GSTP1 LOCUS; ATOPY	Background Polymorphisms at the glutathione S-transferase (GST) P1 locus were associated with asthma-related phenotypes and bronchial hyper-responsiveness. Objective This study investigated whether GSTP1 genotypes and outdoor air pollution were interactive risk factors on childhood asthma. Methods Four hundred and thirty-six subjects were recruited for oral mucosa samplings from 2853 fourth- to ninth-grade schoolchildren from three districts with different air pollution levels in southern Taiwan. PCR-based assays were performed by oral mucosa DNA to determine GSTP1 genotypes. We also conducted a nested case-control study comprising 61 asthmatic children and 95 controls confirmed by International Study of Asthma and Allergies in Childhood questionnaire results and methacholine challenge test. Multiple logistic regression was used to adjust for potential confounding factors. Results All participants were homozygous at the Ala-114 locus. Although only a marginally significant association existed between the frequency of homozygosity at the Ile-105 locus and asthma when air pollution was not considered, we found a significant gene-environmental interaction between GSTP1-105 alleles and air pollution after adjusting for confounders (P=0.035). Specifically, we found that compared with participants carrying any Val-105 allele in low air pollution, those who are Ile-105 homozygotes in high air pollution district had a significantly increased risk of asthma (adjusted odds ratio (AOR)=5.52, 95% confidence interval (CI)=1.64-21.25). Compared with participants carrying any Val-105 allele, in high air pollution district, children with Ile-105 homozygotes had a significantly increased risk of asthma (AOR=3.79, 95% CI=1.01-17.08), but those who carried two Ile-105 alleles in low or moderate air pollution districts did not show similar tendencies. The risk of asthma also revealed a clear dose-response relationship with outdoor air pollution in children with Ile-105 homozygotes. Conclusion Our result suggests a gene-environmental interaction between GSTP1-105 genotypes and outdoor air pollution on childhood asthma.	Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 704, Taiwan; Natl Cheng Kung Univ, Coll Med, Inst Basic Med Sci, Tainan 704, Taiwan; Natl Cheng Kung Univ Hosp, Dept Internal Med, Tainan 70428, Taiwan; Kaohsiung Med Univ, Coll Dent Med, Kaohsiung, Taiwan; Natl Cheng Kung Univ Hosp, Dept Pediat, Tainan 70428, Taiwan	Guo, YL (reprint author), Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, 138 Sheng Li Rd, Tainan 704, Taiwan.	leonguo@mail.ncku.edu.tw		Lin, Ying-Chu/0000-0002-2499-8632; GUO, Yue Leon/0000-0002-8530-4809; LEE, YUNG-LING/0000-0002-2234-9479			41st World Medical Assembly, 1990, B PAN AM HLTH ORG, V24, P606; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; ATS statement, 1979, AM REV RESPIR DIS, V119, P831; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bleecker ER, 1997, AM J RESP CRIT CARE, V156, pS113; BOARD PG, 1989, ANN HUM GENET, V53, P205, DOI 10.1111/j.1469-1809.1989.tb01786.x; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; CONSTANTIN D, 1994, ENVIRON HEALTH PERSP, V102, P161, DOI 10.2307/3431947; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Doull IJM, 1996, AM J RESP CRIT CARE, V153, P1280; Fryer AA, 2000, AM J RESP CRIT CARE, V161, P1437; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; Fusco D, 2001, EUR RESPIR J, V17, P1143, DOI 10.1183/09031936.01.00005501; GILL P, 1985, NATURE, V318, P577, DOI 10.1038/318577a0; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; GREENE LS, 1995, J AM COLL NUTR, V14, P317; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Hu X, 1997, BIOCHEM BIOPH RES CO, V238, P397, DOI 10.1006/bbrc.1997.7311; Ishibe N, 1998, CANCER RES, V58, P667; Kauffmann F, 1999, CLIN EXP ALLERGY, V29, P17; Lee YL, 2003, PEDIATRICS, V112, pE389, DOI 10.1542/peds.112.5.e389; Lin YC, 2004, CLIN EXP ALLERGY, V34, P548, DOI 10.1111/j.1365-2222.2004.1928.x; Lin YC, 2002, CHEST, V121, P347, DOI 10.1378/chest.121.2.347; Marsh DG, 1997, NAT GENET, V15, P389; Martinez J, 1996, ARCH BIOCHEM BIOPHYS, V336, P191, DOI 10.1006/abbi.1996.0549; Pikhart H, 2001, INT ARCH OCC ENV HEA, V74, P574; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346; Sotir M, 2003, ENVIRON HEALTH PERSP, V111, P657, DOI 10.1289/ehp.5824; Soutar A, 1997, THORAX, V52, P166; SPARROW D, 1987, AM REV RESPIR DIS, V135, P1255; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Strange RC, 1999, METABOLIC POLYMORPHI, P231; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798	40	73	76	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2004	34	11					1707	1713		10.1111/j.1365-2222.2004.02099.x		7	Allergy; Immunology	Allergy; Immunology	870TF	WOS:000225080300009	15544594	
J	Strid, J; Thomson, M; Hourihane, J; Kimber, I; Strobel, S				Strid, J; Thomson, M; Hourihane, J; Kimber, I; Strobel, S			A novel model of sensitization and oral tolerance to peanut protein	IMMUNOLOGY			English	Article						sensitization; oral tolerance; peanut; allergy	IMMUNE-RESPONSES; T-CELLS; ATOPIC-DERMATITIS; SUPPRESSION; ALLERGEN; PREVALENCE; ANTIGENS; IDENTIFICATION; INDUCTION; OVALBUMIN	The prevalence of food allergic diseases is rising and poses an increasing clinical problem. Peanut allergy affects around 1% of the population and is a common food allergy associated with severe clinical manifestations. The exact route of primary sensitization is unknown although the gastrointestinal immune system is likely to play an important role. Exposure of the gastrointestinal tract to soluble antigens normally leads to a state of antigen-specific systemic hyporesponsiveness (oral tolerance). A deviation from this process is thought to be responsible for food-allergic diseases. In this study, we have developed a murine model to investigate immunoregulatory processes after ingestion of peanut protein and compared this to a model of oral tolerance to chicken egg ovalbumin (OVA). We demonstrate that oral tolerance induction is highly dose dependent and differs for the allergenic proteins peanut and OVA. Tolerance to peanut requires a significantly higher oral dose than tolerance to OVA. Low doses of peanut are more likely to induce oral sensitization and increased production of interleukin-4 and specific immunoglobulin E upon challenge. When tolerance is induced both T helper 1 and 2 responses are suppressed. These results show that oral tolerance to peanut can be induced experimentally but that peanut proteins have a potent sensitizing effect. This model can now be used to define regulatory mechanisms following oral exposure to allergenic proteins on local, mucosal and systemic immunity and to investigate the immunomodulating effects of non-oral routes of allergen exposure on the development of allergic sensitization to peanut and other food allergens.	UCL, Inst Child Hlth, Immunobiol Unit, London WC1N 1EH, England; Southampton Univ Hosp NHS Trust, Wellcome Trust Clin Res Facil, Southampton, Hants, England; Syngenta, Cent Toxicol Lab, Macclesfield, Cheshire, England; Peninsula Postgrad Hlth Inst, Plymouth, Devon, England	Strid, J (reprint author), UCL, Inst Child Hlth, Immunobiol Unit, 30 Guilford St, London WC1N 1EH, England.	j.strid@ich.ucl.ac.uk	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Strid, Jessica/0000-0003-3690-2201			Afuwape AO, 2004, CLIN EXP IMMUNOL, V136, P40, DOI 10.1111/j.1365-2249.2004.02400.x; Armitage P., 1971, STAT METHODS MED RES; AROEIRA LS, 1995, SCAND J IMMUNOL, V41, P319, DOI 10.1111/j.1365-3083.1995.tb03573.x; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; BURKS AW, 1991, J ALLERGY CLIN IMMUN, V88, P172, DOI 10.1016/0091-6749(91)90325-I; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; FREED DLJ, 2002, FOOD ALLERGY INTOLER, P837; GARSIDE P, 1995, J IMMUNOL, V154, P5649; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; Kolopp-Sarda MN, 2001, CLIN EXP ALLERGY, V31, P47, DOI 10.1046/j.1365-2222.2001.733/ca1804.x; Koppelman SJ, 2001, ALLERGY, V56, P132, DOI 10.1034/j.1398-9995.2001.056002132.x; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; MacDonald TT, 1998, CURR OPIN IMMUNOL, V10, P620, DOI 10.1016/S0952-7915(98)80079-4; Mayer L, 2000, CLIN IMMUNOL, V94, P1, DOI 10.1006/clim.1999.4791; MELAMED D, 1994, EUR J IMMUNOL, V24, P1974, DOI 10.1002/eji.1830240906; MILLER SD, 1979, J IMMUNOL, V123, P2344; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Powrie F, 1996, J EXP MED, V183, P2669, DOI 10.1084/jem.183.6.2669; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Smith KM, 2000, AM J RESP CRIT CARE, V162, pS175; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5	28	73	75	0	0	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0019-2805			IMMUNOLOGY	Immunology	NOV	2004	113	3					293	303		10.1111/j.1365-2567.2004.01989.x		11	Immunology	Immunology	864LC	WOS:000224634000002	15500615	
J	Beyer, M; Bartz, H; Horner, K; Doths, S; Koerner-Rettberg, C; Schwarze, J				Beyer, M; Bartz, H; Horner, K; Doths, S; Koerner-Rettberg, C; Schwarze, J			Sustained increases in numbers of pulmonary dendritic cells after respiratory syncytial virus infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						respiratory syncytial virus; antigen-presenting cells; dendritic cells; CD11c antigen; airway inflammation; mice; virus-induced asthma	COLONY-STIMULATING FACTOR; ANTIGEN-PRESENTING CELLS; T-CELLS; AIRWAY SENSITIZATION; ALLERGIC SENSITIZATION; IMMUNE-RESPONSE; MICE; MACROPHAGE; HYPERRESPONSIVENESS; EXPRESSION	Background: Respiratory syncytial virus (RSV) bronchiolitis in infants can lead to wheezing and early allergic sensitization. In mice, RSV infection enhances allergic airway inflammation and airway hyperresponsiveness. Dendritic cells are critical in inducing T-cell responses to both viruses and allergens and could be pivotal in regulating interactions between these. Objective: This study addresses the effects of RSV infection on phenotype and function of pulmonary dendritic cells. Methods: BALB/c mice were infected with RSV, and expression of CD11c, MHC II, and CD86 on lung and spleen cells was monitored by flow cytometry for 21 days after infection. CD11c(+) cells were isolated to assess their phagocytic capacity and their ability to induce proliferation in allogenic T cells. Results: Numbers of pulmonary CD11c(+) MHC IIhi cells increased 13-fold starting from day 6 after RSV infection. This was associated with increased CD86 expression, reduced phagocytosis, and increased allogenic T-cell stimulatory capacity in CD11c(+) cells. These changes in the lung outlasted acute infection and were not observed in spleens. Conclusion: RSV infection results in sustained increases in numbers of mature dendritic cells in the lung. These might well contribute to the development of intense airway inflammation and airway hyperresponsiveness after RSV infection and to enhancement of subsequent responses to allergen exposure.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Med, London W2 1PG, England; Ruhr Univ Bochum, St Josef Hosp, Klin Kinder & Jugendmed, D-4630 Bochum, Germany	Schwarze, J (reprint author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, Dept Resp Med, Norfolk Pl, London W2 1PG, England.		Schwarze, Jurgen/F-7396-2011	Schwarze, Jurgen/0000-0002-6899-748X			ANDERSON JJ, 1990, J GEN VIROL, V71, P1561, DOI 10.1099/0022-1317-71-7-1561; Brimnes MK, 2003, J EXP MED, V198, P133, DOI 10.1084/jem.20030266; Bukreyev A, 2001, J VIROL, V75, P12128, DOI 10.1128/JVI.75.24.12128-12140.2001; CHRISTENSEN PJ, 1995, AM J RESP CELL MOL, V13, P426; Cochand L, 1999, AM J RESP CELL MOL, V21, P547; Constant SL, 2002, J CLIN INVEST, V110, P1441, DOI 10.1172/JC1200216109; Foster S, 2003, IMMUNOLOGY, V108, P109, DOI 10.1046/j.1365-2567.2003.01539.x; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326; GRAHAM BS, 1991, J CLIN INVEST, V88, P1026, DOI 10.1172/JCI115362; HOLT PG, 1988, J EXP MED, V167, P262, DOI 10.1084/jem.167.2.262; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; KEIZER GD, 1987, J IMMUNOL, V138, P3130; Lin YL, 2003, EUR J IMMUNOL, V33, P2736, DOI 10.1002/eji.200324087; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Masten BJ, 1999, J IMMUNOL, V162, P1310; Masten BJ, 1997, AM J RESP CELL MOL, V16, P335; Matsuse H, 2000, J IMMUNOL, V164, P6583; McWilliam AS, 1996, J EXP MED, V184, P2429, DOI 10.1084/jem.184.6.2429; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1046/j.1365-2222.1996.d01-337.x; NOAH TL, 1993, AM J PHYSIOL, V265, P472; OPENSHAW PJ, 1995, AM J RESP CRIT CARE, V152, P59; Ruedl C, 1996, EUR J IMMUNOL, V26, P1801, DOI 10.1002/eji.1830260821; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Schwarze J, 1999, J IMMUNOL, V163, P5729; Schwarze J, 1999, J IMMUNOL, V162, P4207; Schwarze J, 1997, J CLIN INVEST, V100, P226, DOI 10.1172/JCI119516; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Smyth RL, 1999, LANCET, V354, P1997, DOI 10.1016/S0140-6736(05)76769-6; Spender LC, 1998, J GEN VIROL, V79, P1751; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Vremec D, 2000, J IMMUNOL, V164, P2978; Vremec D, 1997, J IMMUNOL, V159, P565; Ward C, 2001, J HEART LUNG TRANSPL, V20, P1064, DOI 10.1016/S1053-2498(01)00319-9; Yamamoto N, 2000, EUR J IMMUNOL, V30, P316, DOI 10.1002/1521-4141(200001)30:1<316::AID-IMMU316>3.0.CO;2-0; Yamamoto N, 2001, J VIROL, V75, P499, DOI 10.1128/JVI.75.1.499-505.2001	37	73	80	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2004	113	1					127	133		10.1016/j.jaci.2004.10.057		7	Allergy; Immunology	Allergy; Immunology	760MP	WOS:000187837900017	14713917	
J	Simonte, SJ; Ma, SH; Mofidi, S; Sicherer, SH				Simonte, SJ; Ma, SH; Mofidi, S; Sicherer, SH			Relevance of casual contact with peanut butter in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; inhalation; skin contact	TREE-NUT-ALLERGY; NATURAL-HISTORY; FOOD ALLERGIES; IGE; IMMUNOTHERAPY; REGISTRY; TESTS	Background: Casual skin contact or inhalation of peanut butter fumes is reported and feared to cause allergic reactions in highly sensitive children with peanut allergy but has not been systematically studied. Objective: We sought to determine the clinical relevance of exposure to peanut butter by means of inhalation and skin contact in children with peanut allergy. Methods: Children with significant peanut allergy (recent peanut-specific IgE antibody concentration >50 kIU/L or evidence of peanut-specific IgE antibody and one of the following: clinical anaphylaxis, a reported inhalation-contact reaction, or positive double-blind, placebo-controlled oral challenge result to peanut) underwent double-blind, placebo-controlled, randomized exposures to peanut butter by means of contact with intact skin (0.2 mL pressed flat for 1 minute) and inhalation (surface area of 6.3 square inches 12 inches from the face for 10 minutes). Placebo challenges were performed by using soy butter mixed with histamine (contact), and scent was masked with soy butter, tuna, and mint (inhalation). Results: Thirty children underwent the challenges (median age, 7.7 years; median peanut IgE level, >100 kIU/L; 13 with prior history of contact and 11 with inhalation reactions). None experienced a systemic or respiratory reaction. Erythema (3 subjects), pruritus without erythema (5 subjects), and wheat-and-flare reactions (2 subjects) developed only at the site of skin contact with peanut butter. From this number of participants, it can be stated with 96% confidence that at least 90% of highly sensitive children with peanut allergy would not experience a systemic-respiratory reaction from casual exposure to peanut butter. Conclusions: Casual exposure to peanut butter is unlikely to elicit significant allergic reactions. The results cannot be generalized to larger exposures or to contact with peanut in other forms (flour and roasted peanuts).	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Elliot & Roslyn Jaffe Food Allergy Inst, New York, NY USA	Sicherer, SH (reprint author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [K23 AI01709]		Baker SS, 2000, PEDIATRICS, V106, P346; CARLSTON JA, 1988, ANN ALLERGY, V61, P80; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; Devenney I, 2000, Ann Allergy Asthma Immunol, V85, P457; Hallett R, 2002, NEW ENGL J MED, V346, P1833, DOI 10.1056/NEJM200206063462320; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; Jones R. T., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81179-1; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Polasani R, 1997, ANN ALLERG ASTHMA IM, V78, P35; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SICHERER SH, 1999, J ALLERGY CLIN IMMUN, V103, P186; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Tan BM, 2001, ANN ALLERG ASTHMA IM, V86, P583; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P915, DOI 10.1067/mai.2002.129235	21	73	74	0	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2003	112	1					180	182		10.1067/mai.2003.1486		3	Allergy; Immunology	Allergy; Immunology	698QQ	WOS:000184010600027	12847496	
J	Dunphy, JL; Barcham, GJ; Bischof, RJ; Young, AR; Nash, A; Meeusen, ENT				Dunphy, JL; Barcham, GJ; Bischof, RJ; Young, AR; Nash, A; Meeusen, ENT			Isolation and characterization of a novel eosinophil-specific galectin released into the lungs in response to allergen challenge	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; THYMIC EPITHELIAL-CELLS; RECOMBINANT GALECTIN-1; EXTRACELLULAR-MATRIX; MOLECULAR-CLONING; ENDOGENOUS LECTIN; GENE-EXPRESSION; IN-VIVO; APOPTOSIS; BINDING	A novel galectin cDNA (galectin-14) was cloned from ovine eosinophil-rich leukocytes by low stringency reverse transcriptase-PCR and cDNA library screening. Data base searches indicate that this gene encodes a novel prototype galectin that contains one putative carbohydrate recognition domain and exhibits most identity to galectin-9/ecalectin, a potent eosinophil chemoattractant. The sugar binding properties of the recombinant molecule were confirmed by a hemagglutination assay and lactose inhibition. The mRNA and protein of galectin-14 are expressed at high levels in eosinophil-rich cell populations. Flow cytometry and cytospot staining demonstrate that the protein localizes to the cytoplasmic, but not the granular, compartment of eosinophils. In contrast, galectin-14 mRNA and protein were not detected in neutrophils, macrophages, or lymphocytes. Western blot analysis of bronchoalveolar lavage fluid indicates that galectin-14 is released from eosinophils into the lumen of the lungs after challenge with house dust mite allergen. The restricted expression of this novel galectin to eosinophils and its release into the lumen of the lung in a sheep asthma model indicates that it may play an important role in eosinophil function and allergic inflammation.	Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia; AMRAD Operat Pty Ltd, Burnley, Vic 3121, Australia	Meeusen, ENT (reprint author), Univ Melbourne, Sch Vet Sci, Ctr Anim Biotechnol, Parkville, Vic 3010, Australia.						ACKERMAN SJ, 1993, J IMMUNOL, V150, P456; Ahmed H, 1996, J BIOCHEM-TOKYO, V120, P1007; Akahani S, 1997, CANCER RES, V57, P5272; Bairoch A, 1997, NUCLEIC ACIDS RES, V25, P217, DOI 10.1093/nar/25.1.217; BAUM LG, 1995, J EXP MED, V181, P877, DOI 10.1084/jem.181.3.877; BISCHOF RJ, 2002, CLIN EXP ALLERGY, V32, P1; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chung CD, 2000, J IMMUNOL, V165, P3722; COOPER DNW, 1990, J CELL BIOL, V110, P1681, DOI 10.1083/jcb.110.5.1681; Cortegano I, 1998, J IMMUNOL, V161, P385; Dabbagh K, 1999, J IMMUNOL, V162, P6233; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; Dunphy J, 2001, VET IMMUNOL IMMUNOP, V82, P153, DOI 10.1016/S0165-2427(01)00356-7; Dunphy JL, 2000, J BIOL CHEM, V275, P32106, DOI 10.1074/jbc.M003739200; Greenhalgh CJ, 1996, IMMUNOL CELL BIOL, V74, P497, DOI 10.1038/icb.1996.82; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Hadari YR, 2000, J CELL SCI, V113, P2385; HIRABAYASHI J, 1994, GLYCOCONJUGATE J, V11, P437, DOI 10.1007/BF00731280; Hirashima M, 2000, INT ARCH ALLERGY IMM, V122, P6, DOI 10.1159/000053623; KANE JF, 1995, CURR OPIN BIOTECH, V6, P494, DOI 10.1016/0958-1669(95)80082-4; Kasai K, 1996, J BIOCHEM-TOKYO, V119, P1; Kay AB, 1997, INT ARCH ALLERGY IMM, V113, P196; Kuwabara I, 1996, J IMMUNOL, V156, P3939; LealPinto E, 1997, J BIOL CHEM, V272, P617; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Matsumoto R, 1998, J BIOL CHEM, V273, P16976, DOI 10.1074/jbc.273.27.16976; Matsushita N, 2000, J BIOL CHEM, V275, P8355, DOI 10.1074/jbc.275.12.8355; MCDOWELL GH, 1969, RES VET SCI, V10, P13; Meeusen ENT, 2000, PARASITOL TODAY, V16, P95, DOI 10.1016/S0169-4758(99)01607-5; Mehul B, 1997, J CELL SCI, V110, P1169; NOWAK TP, 1976, BIOCHEM BIOPH RES CO, V68, P650, DOI 10.1016/0006-291X(76)91195-5; Pace KE, 2000, J IMMUNOL, V165, P2331; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Rabinovich GA, 1999, IMMUNOLOGY, V97, P100; Sano H, 2000, J IMMUNOL, V165, P2156; Tureci O, 1997, J BIOL CHEM, V272, P6416; Vasta GR, 1999, DEV COMP IMMUNOL, V23, P401, DOI 10.1016/S0145-305X(99)00020-8; Vespa GNR, 1999, J IMMUNOL, V162, P799; Wada J, 1997, J BIOL CHEM, V272, P6078; YAMAOKA A, 1995, J IMMUNOL, V154, P3479; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; Yang RY, 1998, BIOCHEMISTRY-US, V37, P4086, DOI 10.1021/bi971409c; YOSHII T, 2001, J BIOL CHEM, V277, P6852	46	73	73	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14916	14924		10.1074/jbc.M200214200		9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	545EH	WOS:000175203000073	11839756	
J	Keeler, GJ; Dvonch, JT; Yip, FY; Parker, EA; Israel, BA; Marsik, FJ; Morishita, M; Barres, JA; Robins, TG; Brakefield-Caldwell, W; Sam, M				Keeler, GJ; Dvonch, JT; Yip, FY; Parker, EA; Israel, BA; Marsik, FJ; Morishita, M; Barres, JA; Robins, TG; Brakefield-Caldwell, W; Sam, M			Assessment of personal and community-level exposures to particulate matter among children with asthma in Detroit, Michigan, as part of Community Action Against Asthma (CAAA)	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						ambient PM; childhood asthma; community-based participatory research; particulate matter; personal exposure; urban air quality	EMERGENCY ROOM VISITS; DUST MITE ALLERGENS; AIR-POLLUTION; HOSPITAL ADMISSIONS; CHILDHOOD ASTHMA; RESPIRATORY-DISEASE; MATERNAL SMOKING; SULFUR-DIOXIDE; PUBLIC-HEALTH; MORBIDITY	We report on the research conducted by the Community Action Against Asthma (CAAA) in Detroit, Michigan, to evaluate personal and community-level exposures to particulate matter (PM) among children with asthma living in an urban environment. CAAA is a community-based participatory research collaboration among academia, health agencies, and community-based organizations. CAAA investigates the effects of environmental exposures on the residents of Detroit through a participatory process that engages participants from the affected communities in all aspects of the design and conduct of the research; disseminates the results to all parties involved; and uses the research results to design, in collaboration with all partners, interventions to reduce the identified environmental exposures. The CAAA PM exposure assessment includes four seasonal measurement campaigns each year that are conducted for a 2-week duration each season. In each seasonal measurement period, daily ambient measurements of PM2.5 and PM10 (particulate matter with a mass median aerodynamic diameter less than 2.5 mum and 10 mum, respectively) are collected at two elementary schools in the eastside and southwest communities of Detroit. Concurrently, indoor measurements Of PM2.5 and PM10 are made at the schools as well as inside the homes of a subset of 20 children with asthma. Daily personal exposure measurements of PM10 are also collected for these 20 children with asthma. Results from the first Five seasonal assessment periods reveal that mean personal PM10 (68.4 +/- 39.2 mug/m(3)) and indoor home PM10 (52.2 +/- 30.6 mug/m(3)) exposures are significantly greater (p < 0.05) than the outdoor PM10 concentrations (25.8 +/- 11.8 mug/m(3)). The same was also found for PM2.5 (indoor PM2.5 = 34.4 21.7 mug/m(3); outdoor PM2.5 = 15.6 +/- 8.2 mug/m(3)). In addition, significant differences (p < 0.05) in community-level exposure to both PM10 and PM2.5 are observed between the two Detroit communities (southwest PM10 = 28.9 +/- 14.4 mug/m(3), PM2.5 = 17.0 +/- 9.3 mug/m(3), eastside PM10 = 23.8 +/- 12.1 mug/m(3), PM2.5 = 15.5 +/- 9.0 mug/m(3)). The increased levels in the southwest Detroit community are likely due to the proximity to heavy industrial pollutant point sources and interstate motorways. Trace element characterization of filter samples collected over the 2-year period will allow a more complete assessment of the PM components. When combined with other project measures, including concurrent seasonal twice-daily peak expiratory flow and forced expiratory volume at 1 sec and daily asthma symptom and medication dairies for 300 children with asthma living in the two Detroit communities, these data will allow not only investigations into the sources of PM in the Detroit airshed with regard to PM exposure assessment but also the role of air pollutants in exacerbation of childhood asthma.	Univ Michigan, Air Qual Lab, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA; Community Act Asthma, Detroit, MI USA; Detroit Hlth Dept, Div Environm Hlth, Detroit, MI USA	Keeler, GJ (reprint author), Univ Michigan, Air Qual Lab, Dept Environm Hlth Sci, 109 S Observ St, Ann Arbor, MI 48109 USA.		Dvonch, Joseph/K-3632-2013		NIEHS NIH HHS [1-P01-ES09589-01]		ABBEY DE, 1993, ARCH ENVIRON HEALTH, V48, P33; *AM LUNG ASS, 1998, TRENDS ASTHM MORB MO; *AM LUNG ASS, 1998, MIN AIR POLL FACT SH; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Barber K, 1996, ANN ALLERG ASTHMA IM, V76, P427; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P243, DOI 10.2307/3432380; BEGGS PJ, 1995, ARCH ENVIRON HEALTH, V50, P87; Brauer M, 2000, J EXPO ANAL ENV EPID, V10, P478, DOI 10.1038/sj.jea.7500136; Bryant B. I., 1992, RACE INCIDENCE ENV H; BULLARD RD, 1983, SOCIOL INQ, V53, P273, DOI 10.1111/j.1475-682X.1983.tb00037.x; Bullard R. D., 1994, UNEQUAL PROTECTION E; CASSINELLI ME, 1998, DHHS NIOSH PUBL; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; *COMM ENV JUST, 1999, ENV JUST EX SUMM; Commission for Racial Justice United Church of Christ, 1987, TOX WAST RAC US NAT; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; CUIJPERS CEJ, 1995, ENVIRON RES, V68, P11, DOI 10.1006/enrs.1995.1003; DOCKERY DW, 1994, ANNU REV PUBL HEALTH, V15, P107, DOI 10.1146/annurev.pu.15.050194.000543; Dvonch JT, 1998, SCI TOTAL ENVIRON, V213, P95, DOI 10.1016/S0048-9697(98)00144-2; DVONCH JT, 2000, J AEROSOL SCI     S1, V31, pS190; Eatough DJ, 2001, AEROSOL SCI TECH, V34, P1; Eggleston PA, 1998, IMMUNOL ALLERGY CLIN, V18, P75, DOI 10.1016/S0889-8561(05)70348-9; FORASTIERE F, 1992, INT J EPIDEMIOL, V21, P67; GERGEN PJ, 1988, PEDIATRICS, V8, P1; GILDEMEISTER AG, 2001, THESIS U MICHIIGAN A; GOREN AI, 1995, ARCH ENVIRON HEALTH, V50, P112; Grant EN, 1999, J ALLERGY CLIN IMMUN, V104, pS1, DOI 10.1016/S0091-6749(99)70268-X; HOUSE JS, 1997, UNDERSTANDING REDUCI; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; Huntzicker J. J., 1982, PARTICULATE CARBON A, P79; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; Israel B A, 2001, J Public Health Manag Pract, V7, P1; Israel BA, 1998, ANNU REV PUBL HEALTH, V19, P173, DOI 10.1146/annurev.publhealth.19.1.173; Janssen NAH, 1997, OCCUP ENVIRON MED, V54, P888; Joseph CLM, 1996, J PEDIATR-US, V129, P735, DOI 10.1016/S0022-3476(96)70158-0; KESTEN S, 1995, ANN ALLERG ASTHMA IM, V74, P269; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; KRIEGER N, 1994, SOC SCI MED, V39, P887, DOI 10.1016/0277-9536(94)90202-X; KRIEGER N, 1993, AM J PREV MED, V9, P82; Leaderer BP, 1997, J PHARM PHARMACOL, V49, P39; LONG SE, 1992, METHODS DETERMINATIO; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MCCONNEL R, 1999, ENV HLTH PERSPECT, V9, P757; *MICH DEP COMM HLT, 1997, HLTH STAT REP; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; NAES LN, 1991, AM J EPIDEMIOL, V134, P204; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21; NEWMANTAYLOR A, 1995, LANCET, V345, P296; OGSTON SA, 1985, BRIT MED J, V290, P957; OSTRO BD, 1994, AM J RESP CRIT CARE, V149, P1400; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1995, ALLERGY, V50, P5, DOI 10.1111/j.1398-9995.1995.tb02729.x; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262; POPE CA, 1991, AM REV RESPIR DIS, V144, P668; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHWARTZ J, 1993, ENVIRON RES, V62, P7, DOI 10.1006/enrs.1993.1083; SCHWARTZ J, 1995, THORAX, V50, P531, DOI 10.1136/thx.50.5.531; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Silvestri M, 1996, ANN ALLERG ASTHMA IM, V76, P239; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; [Anonymous], 1998, FIN GUID INC ENV JUS; *US EPA, 1996, EPA600P95001AF001CF; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wernette D.R., 1992, EPA J, V18, P16; Wheeler AJ, 2000, ENVIRON MONIT ASSESS, V65, P69, DOI 10.1023/A:1006447807980; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WILLIAMS DR, 1995, ANNU REV SOCIOL, V21, P349, DOI 10.1146/annurev.so.21.080195.002025	77	73	74	5	29	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2002	110			2			173	181				9	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	542WE	WOS:000175066600008	11929726	
J	Michalec, L; Choudhury, BK; Postlethwait, E; Wild, JS; Alam, R; Lett-Brown, M; Sur, S				Michalec, L; Choudhury, BK; Postlethwait, E; Wild, JS; Alam, R; Lett-Brown, M; Sur, S			CCL7 and CXCL10 orchestrate oxidative stress-induced neutrophilic lung inflammation	JOURNAL OF IMMUNOLOGY			English	Article							OZONE-INDUCED INFLAMMATION; OBSTRUCTIVE PULMONARY-DISEASE; AIR-POLLUTION; ASTHMATIC SUBJECTS; CHEMOATTRACTANT CINC; GENE-EXPRESSION; INDUCED SPUTUM; IFN-GAMMA; CHEMOKINES; HYPERRESPONSIVENESS	Oxidative stress from ozone (03) exposure augments airway neutrophil recruitment and chemokine production. We and others have shown that severe and sudden asthma is associated with airway neutrophilia, and that 03 oxidative stress is likely to augment neutrophilic airway inflammation in severe asthma. However, very little is known about chemokines that orchestrate oxidative stress-induced neutrophilic airway inflammation in vivo. To identify these chemokines, three groups of BALB/c mice were exposed to sham air, 0.2 ppm O-3, or 0.8 ppm O-3 for 6 h. Compared with sham air, 0.8 ppm O-3, but not 0.2 ppm O-3, induced pronounced neutrophilic airway inflammation that peaked at 18 h postexposure. The 0.8 ppm 03 up-regulated lung mRNA of CXCL1,2,3 (mouse growth-related oncogene-a and macrophage-inflammatory protein-2), CXCL10 (IFN-gamma-inducible protein-10), CCL3 (macrophage-inflammatory protein-1alpha), CCL7 (monocyte chemoattractant protein-3), and CCL11 (eotaxin) at 0 h postexposure, and expression of CXCL10, CCL3, and CCL7 mRNA was sustained 18 h postexposure. 03 increased lung protein levels of CXCL10, CCL7, and CCR3 (CCL7R). The airway epithelium was identified as a source of CCL7. The role of up-regulated chemokines was determined by administering control IgG or IgG Abs against six murine chemokines before 03 exposure. As expected, anti-mouse growth-related oncogene-a inhibited neutrophil recruitment. Surprisingly, Abs to CCL7 and CXCL10 also decreased neutrophil recruitment by 63 and 72%, respectively. These findings indicate that CCL7 and CXCL10, two chemokines not previously reported to orchestrate neutrophilic inflammation, play a critical role in mediating oxidative stress-induced neutrophilic airway inflammation. These observations may have relevance in induction of neutrophilia in severe asthma.	NIH, Asthma & Allerg Dis Res Ctr, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Internal Med, Div Allergy & Immunol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA	Sur, S (reprint author), NIH, Asthma & Allerg Dis Res Ctr, Galveston, TX 77555 USA.						Anderson HR, 1998, THORAX, V53, P842; Bless NM, 2000, J IMMUNOL, V164, P2650; Bonecchi R, 1999, J IMMUNOL, V162, P474; Chang MMJ, 1998, AM J PHYSIOL-LUNG C, V275, pL524; DRISCOLL KE, 1987, J TOXICOL ENV HEALTH, V21, P27; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98; Foster WM, 2000, J APPL PHYSIOL, V89, P1804; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Haddad EB, 1996, FEBS LETT, V379, P265, DOI 10.1016/0014-5793(95)01524-8; Haraguchi M, 1999, AM J RESP CRIT CARE, V159, P1005; Hiltermann TJN, 1998, FREE RADICAL BIO MED, V24, P952, DOI 10.1016/S0891-5849(97)00381-X; Horvath I, 1998, THORAX, V53, P668; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Johnston CJ, 1999, EXP LUNG RES, V25, P81, DOI 10.1080/019021499270448; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; KLEEBERGER SR, 1993, AM J PHYSIOL, V264, pL15; KLEEBERGER SR, 1990, AM J PHYSIOL, V258, pL313; KLEEBERGER SR, 1993, AM J PHYSIOL, V264, pL21; Koto H, 1997, AM J RESP CRIT CARE, V156, P234; Michelson PH, 1999, OTOLARYNG HEAD NECK, V120, P225, DOI 10.1016/S0194-5998(99)70411-0; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; Nightingale JA, 1999, THORAX, V54, P1061; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Peden DB, 1997, J ALLERGY CLIN IMMUN, V100, P802, DOI 10.1016/S0091-6749(97)70277-X; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Stafford S, 1997, J IMMUNOL, V158, P4953; Struyf S, 2001, BLOOD, V97, P2197, DOI 10.1182/blood.V97.8.2197; SUR S, 1993, AM REV RESPIR DIS, V148, P713; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Vagaggini B, 1999, EUR RESPIR J, V13, P274, DOI 10.1034/j.1399-3003.1999.13b09.x; Ward SG, 1998, IMMUNITY, V9, P1, DOI 10.1016/S1074-7613(00)80583-X; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; Zhao QY, 1998, AM J PHYSIOL-LUNG C, V274, pL39	37	73	76	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JAN 15	2002	168	2					846	852				7	Immunology	Immunology	510DP	WOS:000173193700038	11777981	
J	Vandenplas, O; Jamart, J; Delwiche, JP; Evrard, G; Larbanois, A				Vandenplas, O; Jamart, J; Delwiche, JP; Evrard, G; Larbanois, A			Occupational asthma caused by natural rubber latex: Outcome according to cessation or reduction of exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; disability; latex; occupational lung disease	HEALTH-CARE WORKERS; BRONCHIAL HYPERRESPONSIVENESS; TOLUENE DIISOCYANATE; GLOVES; DISABILITY; WORKPLACE; IMPACT; CEDAR	Background: The long-term effects of reducing exposure to latex in subjects with latex-induced asthma remain unknown. Objective: The purpose of this study was to compare the health and socioeconomic outcomes of subjects with latex-induced asthma before and after reduction or cessation of exposure to latex. Methods: Thirty-six subjects with latex-induced asthma as ascertained by specific inhalation challenges were investigated after a median follow-up of 56 months (range, 12 to 92 months). Initial and follow-up visits included use of a detailed questionnaire and measurement of the concentration of histamine causing a 20% fall in FEV1 (PC20). At follow-up, information on employment, financial status, and quality of life was collected. Results: At follow-up, 16 subjects were no longer exposed to latex, whereas 20 subjects had reduced exposure. In the subjects who avoided exposure, asthma severity decreased from a median score of 8.5 to 3.5 (P = .001) and the median histamine PC20 value increased from 0.4 mg/mL to 2.3 mg/mL (P = .002). In the subjects who reduced their exposure, asthma-severity score improved from 6.5 to 2.5 (P < .001) and PC20 values rose from 0.5 mg/mL to 2.4 mg/mL (P < .001). Cessation of exposure to latex was associated with asthma-related work disability (69%) and loss of income (62%) more frequently than was reduction of exposure (35% and 30%, respectively). Conclusion: Reduction of exposure to latex should be considered a reasonably safe alternative that is associated with fewer socioeconomic consequences than removal from exposure.	Univ Catholique Louvain, Clin Univ Mont Godinne, Serv Pneumol, B-5530 Yvoir, Belgium; Univ Catholique Louvain, Clin Univ Mont Godinne, Ctr Biostat & Documentat Med, B-5530 Yvoir, Belgium; Fons Malad Profess, Brussels, Belgium	Vandenplas, O (reprint author), Univ Catholique Louvain, Clin Univ Mont Godinne, Serv Pneumol, B-5530 Yvoir, Belgium.						Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; CHANYEUNG M, 1995, CHEST, V108, P1084, DOI 10.1378/chest.108.4.1084; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; COTE J, 1990, AM REV RESPIR DIS, V141, P373; European Community for Coal and Steel, 1983, B EUR PHYSIOPATHO S5, V19, P45; GRAMMER LC, 1993, AM REV RESPIR DIS, V148, P54; Hamilton RG, 2000, J ALLERGY CLIN IMMUN, V105, P839, DOI 10.1067/mai.2000.105224; Heilman DK, 1996, J ALLERGY CLIN IMMUN, V98, P325, DOI 10.1016/S0091-6749(96)70157-4; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832; Laoprasert N, 1998, J ALLERGY CLIN IMMUN, V102, P998, DOI 10.1016/S0091-6749(98)70338-0; Lin FJ, 1996, OCCUP ENVIRON MED, V53, P753; Merget R, 1999, INT ARCH OCC ENV HEA, V72, P33, DOI 10.1007/s004200050331; PAGGIARO PL, 1993, CHEST, V103, P1123, DOI 10.1378/chest.103.4.1123; PISATI G, 1993, BRIT J IND MED, V50, P60; Poley GE, 2000, J ALLERGY CLIN IMMUN, V105, P1054, DOI 10.1067/mai.2000.106925; Ross DJ, 1999, CLIN EXP ALLERGY, V29, P750; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Vandenplas O, 1996, THORAX, V51, P472, DOI 10.1136/thx.51.5.472; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P887; Vandenplas O, 1999, ASTHMA WORKPLACE, P425	26	73	76	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2002	109	1					125	130		10.1067/mai.2002.120760		6	Allergy; Immunology	Allergy; Immunology	519RM	WOS:000173739300021	11799378	
J	Gwynn, RC; Thurston, GD				Gwynn, RC; Thurston, GD			The burden of air pollution: Impacts among racial minorities	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article; Proceedings Paper	Workshop on Inhaled Environmental/Occupational Irritants and Allergens - Mechanisms of Cardiovascular and Systemic Responses	MAR 31-APR 02, 2000	SCOTTSDALE, ARIZONA	Amer Thorac Soc		acidic aerosols; air pollution; epidemiology; ethnicity; ozone; particulate matter; poverty; race; respiratory hospital admissions; socioeconomic status; sulfate; time-series techniques	CHILDHOOD ASTHMA; NEW-YORK; SOCIOECONOMIC-FACTORS; HEALTH; RACE; HOSPITALIZATION; PREVALENCE; MORTALITY; POVERTY; MATTER	Various epidemiologic investigations have shown that ambient air pollution levels are associated with acute increases in hospital admissions and mortality in the United States and abroad. The objectives of this investigation were a) to determine if racial minorities are more adversely affected by ambient air pollution than their white counterparts and b) to assess the contribution of socioeconomic status to any observed racial differences in pollution effect. Time-series regression methods were conducted to investigate these hypotheses for daily respiratory hospital admissions in New York City, New York. Pollutants considered included mean daily levels of particulate matter with a mass median aerodynamic diameter less than 10 mum (PM10), ozone (O-3), strong aerosol acidity (H+), and sulfates (SO42). The relative risk for respiratory hospital admission was calculated for each pollutant for a maximum minus mean increment in mean daily pollutant concentration. The greatest difference between the white and nonwhite subgroups was observed for O-3, where the white relative risk (RR) was 1.032 [95% confidence interval (Cl): 0.977-1.089] and the nonwhite RR was 1.122 (95% Cl: 1.074-1.172). Although not statistically different from each other, the various pollutants' RR estimates for the Hispanic nonwhite category in New York City were generally larger in magnitude than those for the non-Hispanic white group. When these analyses incorporated differences in the underlying respiratory hospitalization rates across races (that for nonwhites, was roughly twice that for whites), the disparities in attributable risks from pollution (in terms of excess admissions per day per million persons) were even larger for nonwhites versus whites. However, when insurance status was used as an indicator of socioeconomic/health coverage status, higher RRs were indicated for the poor/working poor (i.e., those on Medicaid and the uninsured) than for those who were economically better off (i.e., the privately insured), even among non-Hispanic whites. Thus, although potential racial differences in pollution exposures could not be explored as a factor, within-race analyses suggested that most of the apparent differences in air pollutant effects found across races were explained by socioeconomic and/or health care disparities.	NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; Ctr Dis Control & Prevent, Atlanta, GA USA	Thurston, GD (reprint author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.				NIEHS NIH HHS [ES00260, ES05711, R01 ES04612]		BOWMAN JE, 1990, GENETIC VARIATION DI; BROWN P, 1995, ENVIRON RES, V69, P15, DOI 10.1006/enrs.1995.1021; *CDCP, 1995, JAMA-J AM MED ASSOC, V273, P451; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; Gwynn RC, 2000, ENVIRON HEALTH PERSP, V108, P125, DOI 10.2307/3454510; Hajat S, 1999, THORAX, V54, P597; HALFON N, 1993, PEDIATRICS, V91, P56; Ito K, 1996, J EXPO ANAL ENV EPID, V6, P79; KING M, 1998, MOBILIZING REGION WE, P2; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; MAK H, 1982, J ALLERGY CLIN IMMUN, V70, P367, DOI 10.1016/0091-6749(82)90026-4; Medina S, 1997, ENVIRON RES, V75, P73, DOI 10.1006/enrs.1997.3773; Nauenberg E, 1999, PUBLIC HEALTH REP, V114, P135; Olden K, 1996, OTOLARYNG HEAD NECK, V114, P255, DOI 10.1016/S0194-5998(96)70178-X; SEXTON K, 1993, TOXICOL IND HEALTH, V9, P843; SHUMWAY RH, 1983, STAT ANAL DAILY LOND, P53; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P415; *US EPA, AER INF RETR SYST; *US HLTH CAR FIN A, 1989, INT CLASS DIS; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WHITE R, 1995, JAMA-J AM MED ASSOC, V273, P1484; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Zanobetti A, 2000, J OCCUP ENVIRON MED, V42, P469, DOI 10.1097/00043764-200005000-00002	24	73	75	4	20	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2001	109			4			501	506		10.2307/3454660		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	467KG	WOS:000170700500005	11544154	
J	Bredehorst, R; David, K				Bredehorst, R; David, K			What establishes a protein as an allergen?	JOURNAL OF CHROMATOGRAPHY B			English	Review						food allergy; proteins	HOUSE-DUST MITE; IGE-BINDING EPITOPES; BOVINE BETA-LACTOGLOBULIN; LIPID TRANSFER PROTEIN; BIRCH POLLEN PROFILIN; T-CELL EPITOPES; DER-P-I; MAJOR ALLERGEN; CROSS-REACTIVITY; X-RAY	There is little known about the factors that determine the allergenicity of food proteins. Apparently, the ability of a food protein to induce an allergic response requires its presence in substantial amounts in the food supply, its durability during food processing, and its resistance to digestion in the gastrointestinal tract. In addition to the mode and degree of exposure, structural characteristics appear to play an important, role for the capacity of a protein to modulate the immune response towards allergic reactions. Until now, however, there has been no indication for common structural characteristics of linear T cell or linear IgE (B cell) epitopes and the knowledge of structural characteristics of conformational IgE binding sites is very limited. Experimental data point only to certain surface areas of allergenic proteins which are important for IgE binding. Therefore, it is not possible to suggest any structural motif or conformational sequence pattern common to all allergenic proteins. Furthermore, glycosylation appears not to be a common critical determinant of allergenicity since food allergens comprise both glycoproteins and nonglycosylated proteins. Based on the few published three-dimensional structures of allergenic proteins including food proteins, one unifying feature of allergens appears to be their spherical shape. The three-dimensional structures of many more allergens have to be determined, however, to allow for a better understanding of the molecular basis of allergenicity. Most recently, new ideas have been introduced as to why certain biochemical or biologic functions such as enzymatic activities may predispose a protein to become an allergen. Proteolytically active allergens have been demonstrated to irritate the human mucosal surface, to enhance their own transmucosal uptake, and to augment IgE production. Therefore, the functional activity of some allergens may play a role among other factors in the process of sensitization and allergic responses. (C) 2001 Elsevier Science B.V. All rights reserved.	Univ Hamburg, Inst Biochem & Food Chem, D-20146 Hamburg, Germany	Bredehorst, R (reprint author), Univ Hamburg, Inst Biochem & Food Chem, Martin Luther King Pl 6, D-20146 Hamburg, Germany.						AAS K, 1978, ALLERGY, V33, P3, DOI 10.1111/j.1398-9995.1978.tb01501.x; Aas K, 1975, Dev Biol Stand, V29, P90; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; BAER A, 1976, J DAIRY RES, V43, P419, DOI 10.1017/S0022029900016009; BALL G, 1994, CLIN EXP ALLERGY, V24, P758, DOI 10.1111/j.1365-2222.1994.tb00987.x; BANTANERO E, 1999, J ALLERGY CLIN IMMUN, V103, P147; BARTON KA, 1982, J BIOL CHEM, V257, P6089; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BOCSKEI Z, 1992, NATURE, V360, P186, DOI 10.1038/360186a0; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; Brownlow S, 1997, STRUCTURE, V5, P481, DOI 10.1016/S0969-2126(97)00205-0; Bufe A, 1998, INT ARCH ALLERGY IMM, V117, P215, DOI 10.1159/000024013; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; Burks W, 1998, ALLERGY, V53, P725; BUUS S, 1987, IMMUNOL REV, V98, P115, DOI 10.1111/j.1600-065X.1987.tb00522.x; CALKHOVEN PG, 1987, ALLERGY, V42, P382, DOI 10.1111/j.1398-9995.1987.tb02225.x; Davis PJ, 1998, ALLERGY, V53, P102; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; DREBORG S, 1983, ALLERGY, V38, P162; EBNER C, 1991, J ALLERGY CLIN IMMUN, V88, P588, DOI 10.1016/0091-6749(91)90152-E; EIGENMANN PA, 1996, PAEDIAT ALLERGY IMMU, V135, P935; ELSAYED S, 1993, STRUCTURE ANTIGENS, V2, P293; ERIKSSON NE, 1982, ALLERGY, V37, P437, DOI 10.1111/j.1398-9995.1982.tb02323.x; Fedorov AA, 1997, INT ARCH ALLERGY IMM, V113, P109; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; GarciaCasado G, 1996, GLYCOBIOLOGY, V6, P471, DOI 10.1093/glycob/6.4.471; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; HERIAN AM, 1990, INT ARCH ALLER A IMM, V92, P193; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HIGGINS JA, 1994, J ALLERGY CLIN IMMUN, V93, P891, DOI 10.1016/0091-6749(94)90383-2; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; Honma K, 1996, CLIN EXP IMMUNOL, V103, P446; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; ISHIZAKA K, 1985, J IMMUNOL, V135, P1; JANKIEWICZ A, 1998, ALLERGO J, V7, P87; KAHLERT H, 1992, MOL IMMUNOL, V29, P1191, DOI 10.1016/0161-5890(92)90055-3; Liebers V, 1996, CLIN EXP ALLERGY, V26, P494, DOI 10.1046/j.1365-2222.1996.d01-343.x; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nishiyama C, 1995, MOL IMMUNOL, V32, P1021, DOI 10.1016/0161-5890(95)00091-7; OBRIEN RM, 1994, J ALLERGY CLIN IMMUN, V93, P628, DOI 10.1016/S0091-6749(94)70074-5; OHEHIR RE, 1991, ANNU REV IMMUNOL, V9, P67; Pastorello EA, 2000, J ALLERGY CLIN IMMUN, V105, P371, DOI 10.1016/S0091-6749(00)90090-3; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; RIHS HP, 1994, INT ARCH ALLERGY IMM, V105, P190; Romagnani S, 1997, IMMUNOL TODAY, V18, P263, DOI 10.1016/S0167-5699(97)80019-9; Rouvinen J, 1999, J BIOL CHEM, V274, P2337, DOI 10.1074/jbc.274.4.2337; Schenk S, 1995, J ALLERGY CLIN IMMUN, V96, P986, DOI 10.1016/S0091-6749(95)70237-7; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SHANTI KN, 1993, J IMMUNOL, V151, P5354; STAIGER CJ, 1993, PLANT J, V4, P631, DOI 10.1046/j.1365-313X.1993.04040631.x; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; STASWICK PE, 1981, J BIOL CHEM, V256, P8752; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; Szepfalusi Z, 1998, J ALLERGY CLIN IMMUN, V101, P514, DOI 10.1016/S0091-6749(98)70359-8; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thorn KS, 1997, STRUCTURE, V5, P19, DOI 10.1016/S0969-2126(97)00163-9; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; Valenta R, 1996, IMMUNOL CELL BIOL, V74, P187, DOI 10.1038/icb.1996.26; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; VANEKKREBITZ M, 1995, BIOCHEM BIOPH RES CO, V214, P538, DOI 10.1006/bbrc.1995.2320; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VIDALI L, 1995, PLANT PHYSIOL, V108, P115, DOI 10.1104/pp.108.1.115; Vieths Stefan, 1996, P130; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Williams SC, 1998, J IMMUNOL METHODS, V213, P1, DOI 10.1016/S0022-1759(98)00022-2; Wilson IBH, 1998, GLYCOBIOLOGY, V8, P651, DOI 10.1093/glycob/8.7.651; WUTTRICH B, 1990, ALLERGY, V45, P566; YSSEL H, 1992, J IMMUNOL, V148, P738; Zeiler T, 1997, J ALLERGY CLIN IMMUN, V100, P721, DOI 10.1016/S0091-6749(97)70264-1	82	73	78	1	12	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-4347			J CHROMATOGR B	J. Chromatogr. B	MAY 25	2001	756	1-2					33	40		10.1016/S0378-4347(01)00069-X		8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	435PG	WOS:000168889400005	11419725	
J	D'Urzo, AD; De Salvo, MC; Ramirez-Rivera, A; Almeida, J; Sichletidis, L; Rapatz, G; Kottakis, J				D'Urzo, AD; De Salvo, MC; Ramirez-Rivera, A; Almeida, J; Sichletidis, L; Rapatz, G; Kottakis, J		FOR-INT-03 Study Grp	In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium - A 3-week, randomized, double-blind, within-patient, multicenter study	CHEST			English	Article						beta(2)-agonist; COPD; formoterol; ipratropium; salbutamol	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW LIMITATION; SEVERE ASTHMA; STABLE COPD; SALMETEROL; BROMIDE; MANAGEMENT; DURATION; AGONIST; THERAPY	Study objectives: To compare the efficacy of adding formoterol or salbutamol to regular ipratropium bromide treatment in COPD patients whose conditions were suboptimally controlled with ipratropium bromide alone. Design: A randomized, double-blind, double-dummy, two-period, crossover clinical trial. Setting: Twenty-four clinics and university medical centers in nine countries. Patients: One hundred seventy-two patients with baseline FEV1, less than or equal to 65% predicted, with FEV, reversibility to salbutamol not exceeding the normal variability of the measurement, and symptomatic despite regular treatment with ipratropium bromide. Interventions: Each patient received two treatments in random order: either inhaled formoterol dry powder, 12 mug bid, in addition to ipratropium bromide, 40 mug qid for 3 weeks, followed by salbutamol, 200 mug qid, in addition to ipratropium, 40 mug qid for 3 weeks, or vice versa. Measurements and results: Efficacy end points included morning premedication peak expiratory now (PEF) during the last week of treatment (primary end point), the area under the curve (AUC) for FEV, measured for 6 h after morning dose on the last day of treatment, and symptom scores (from daily diary recordings). Morning PEF and the AUC for FEV,were significantly better for formoterol/ipratropium than for salbutamol/ipratropium (p = 0.0003 and p < 0.0001, respectively). The formoterol/ipratropium combination also induced a greater improvement in mean total symptom scores (p = 0.0042), The safety profile of the two treatments was comparable. Conclusions: In COPD patients requiring combination bronchodilator treatment, the addition of formoterol to regular ipratropium treatment is more effective than the addition of salbutamol.	Novartis Pharmaceut, Novartis HRC, Horsham RH12 5AB, W Sussex, England; Primary Care Asthma Clin, Toronto, ON, Canada; Hosp Gen Agudis E Tornu, Buenos Aires, DF, Argentina; Hosp Enfermedades Cardiovasc & Torax, IMSS, Monterrey, Mexico; Hosp Sao Joaa, Serv Pneumol, Porto, Portugal; Univ Thessaloniki, Papanicolaou Hosp, Pneumol Clin, GR-54006 Salonika, Greece	Kottakis, J (reprint author), Novartis Pharmaceut, Novartis HRC, Wimblehurst Rd, Horsham RH12 5AB, W Sussex, England.						ABINSHEGANADEN J, 1996, SINGAPORE MED J, V37, P252; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P77; ANDERSON GP, 1993, LIFE SCI, V52, P2145, DOI 10.1016/0024-3205(93)90729-M; BAI TR, 1992, AM J RESP CELL MOL, V6, P647; BONE R, 1994, CHEST, V105, P1411; Bouros D, 1999, EUR RESPIR J, V14, P627, DOI 10.1034/j.1399-3003.1999.14c24.x; British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; BROWN IG, 1984, THORAX, V39, P272, DOI 10.1136/thx.39.4.272; BUCKNER CK, 1981, J CLIN INVEST, V67, P376, DOI 10.1172/JCI110045; BUSSE WW, 1977, AM REV RESPIR DIS, V115, P783; Calverley P, 2000, THORAX, V55, P78, DOI 10.1136/thorax.55.1.78; CASALI L, 1979, INT J CLIN PHARM TH, V7, P277; CAZZOLA M, 1994, PULM PHARMACOL, V7, P103, DOI 10.1006/pulp.1994.1012; Dahl R, 2000, AM J RESP CRIT CARE, V161, pA489; FRIEDMAN M, 1995, CHEST, V107, pS194, DOI 10.1378/chest.107.5_Supplement.194S; GOLDIE RG, 1986, BRIT J CLIN PHARMACO, V22, P669; GRASSI V, 1986, RESPIRATION, V50, P226; GROSS NJ, 1984, NEW ENGL J MED, V311, P421, DOI 10.1056/NEJM198408163110701; Grove A, 1996, THORAX, V51, P689, DOI 10.1136/thx.51.7.689; IKEDA A, 1995, CHEST, V107, P401, DOI 10.1378/chest.107.2.401; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; LIGHTBODY IM, 1978, BRIT J DIS CHEST, V72, P181, DOI 10.1016/0007-0971(78)90039-6; ODONNELL DE, 1993, AM REV RESPIR DIS, V148, P1351; Pauwels Romain A., 2000, Chest, V117, p20S, DOI 10.1378/chest.117.2_suppl.20S; REBUCK AS, 1971, AM J MED, V51, P788, DOI 10.1016/0002-9343(71)90307-X; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; RENNARD SI, 1995, CHEST S, V107, P1715; SENIOR RM, 1998, AM J RESP CRIT CARE, V157, P139; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Sichletidis L, 1999, INT J CLIN PRACT, V53, P185; van Noord JA, 2000, EUR RESPIR J, V15, P878, DOI 10.1034/j.1399-3003.2000.15e11.x; vanNoord JA, 1996, EUR RESPIR J, V9, P1684, DOI 10.1183/09031936.96.09081684; Wilson JD, 1996, EUR RESPIR REV, V6, P286; 1998, FED REG, V63, P179	34	73	74	1	2	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2001	119	5					1347	1356		10.1378/chest.119.5.1347		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	432TH	WOS:000168711400011	11348938	
J	Caffarelli, C; Sensi, LG; Marcucci, F; Cavagni, G				Caffarelli, C; Sensi, LG; Marcucci, F; Cavagni, G			Preseasonal local allergoid immunotherapy to grass pollen in children: a double-blind, placebo-controlled, randomized trial	ALLERGY			English	Article						asthma; children; grass pollen; local immunotherapy; rhinitis	EOSINOPHIL CATIONIC PROTEIN; HOUSE DUST MITE; SUBLINGUAL IMMUNOTHERAPY; MONOCLONAL-ANTIBODIES; STANDARDIZED GRASS; HAY-FEVER; RHINITIS; ASTHMA; EFFICACY; EXTRACT	Background: We assessed the efficacy of preseasonal local allergoid immunotherapy in a group of children with asthma and/or rhinitis and/or rhinoconjunctivitis due to grass pollen. Methods: We randomly assigned 24 children allergic to grass pollen to receive local allergoid immunotherapy for 3 months before the pollen season and 24 such patients to receive identically appearing placebo. The immunotherapy consisted of tablets of monomeric allergoid grass pollen allergens held in the mouth until they dissolved and then swallowed. The study was double-blind. Symptoms and medications were scored on diary cards during the pollen season. Nasal eosinophil cationic protein levels were measured by the monoclonal antibodies EG1 and EG2 outside the pollen season and at low and at high pollen concentration during the pollen season. Results: The active-treatment group had a statistically significant reduction of total symptoms (P < 0.05), especially bronchial symptoms (P < 0.05), in comparison with the placebo group. Immunotherapy was well tolerated and compliance was good. Nasal levels of EG2 and EG1 increased significantly during the pollen season, but there was no difference between groups. EG2/EGI increased significantly only in the placebo group during natural allergen exposure (P < 0.01). Conclusions: Our results suggest that this immunotherapy is effective for the treatment of asthma due to grass pollen in children.	Univ Parma, Dept Pediat, I-43100 Parma, Italy; Dept Pediat, Perugia, Italy; Pediat Dept Modena Sud, Sassuolo, Italy	Caffarelli, C (reprint author), Pediat Clin, Via Gramsci 14, I-43100 Parma, Italy.						Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; *EEC, 1991, III359391EN EEC; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Giannarini L, 1998, CLIN EXP ALLERGY, V28, P404; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; Holt PG, 1998, LANCET, V351, P613, DOI 10.1016/S0140-6736(05)78425-7; HOLT PG, 1994, LANCET, V344, P456, DOI 10.1016/S0140-6736(94)91776-0; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; Klimek L, 1999, J ALLERGY CLIN IMMUN, V103, P47, DOI 10.1016/S0091-6749(99)70524-5; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MALLING HJ, 1993, ALLERGY, V48, P9; Mistrello G, 1996, ALLERGY, V51, P8, DOI 10.1111/j.1398-9995.1996.tb04543.x; MOQBEL R, 1992, CLIN EXP ALLERGY, V22, P265, DOI 10.1111/j.1365-2222.1992.tb03082.x; Nakajima H, 1999, J LEUKOCYTE BIOL, V66, P447; NOVEMBRE E, 1991, RIV ITAL PED, V17, P75; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SCADDING GK, 1986, CLIN ALLERGY, V16, P483, DOI 10.1111/j.1365-2222.1986.tb01983.x; Sensi LG, 1997, CLIN EXP ALLERGY, V27, P270; SVENSSON C, 1990, J ALLERGY CLIN IMMUN, V85, P828, DOI 10.1016/0091-6749(90)90064-B; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VANNIEKERK CH, 1987, CLIN ALLERGY, V17, P507; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; YMAN L, 1975, DEV BIOL STAND, V1, P51; 1998, ALLERGY S44, V53, P1	31	73	74	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	DEC	2000	55	12					1142	1147		10.1034/j.1398-9995.2000.00655.x		6	Allergy; Immunology	Allergy; Immunology	375QH	WOS:000165412400005	11117271	
J	Leynadier, F; Herman, D; Vervloet, D; Andre, C				Leynadier, F; Herman, D; Vervloet, D; Andre, C			Specific immunotherapy with a standardized latex extract versus placebo in allergic healthcare workers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						latex; urticaria; rhinoconjunctivitis; asthma; anaphylactic shock; specific immunotherapy	NATURAL-RUBBER LATEX; CROSS-REACTIVITY; SYSTEMIC REACTIONS; HYPERSENSITIVITY; ANTIBODIES; CHILDREN; ANTIGENS; ASTHMA; BANANA	Background: The prevalence of allergy to natural rubber latex proteins has increased over recent years among healthcare professionals but also in children undergoing multiple operations. Exposure to the antigen mainly occurs through the respiratory mucosa and the percutaneous route. Clinical manifestations range from urticaria to angioedema, rhinoconjunctivitis, bronchial asthma, or anaphylactic shock. Preventive measures have been proposed to reduce the risk of sensitization by using only powder-free or synthetic gloves and latex-free material in operating units, but this is not always possible. Objective: The aim of this study was to investigate the efficacy and safety of specific immunotherapy in sensitized workers. Methods: Seventeen patients with latex skin allergy and rhinitis (9 of whom also had asthma) were included in this randomized, double-blind, placebo-controlled trial (9 in the active group and 8 in the placebo group) for 1 year. Treatment started with a 2-day course of rush immunotherapy in hospital. Treatment efficacy was assessed after 6 and 12 months by means of symptom and medication scores recorded on diary cards. Conjunctival provocation tests were also performed. Results: Patients in the active treatment group had a significantly tower total rhinitis score after 6 (P < .04) and 12 months (P < .05), conjunctivitis score after 6 months (P < .02), and cutaneous score after 12 months (P < .03) than in the placebo group, Asthma symptoms after 6 or 12 months of treatment were not significantly different between the two groups after adjustment for baseline values. The global medication score was markedly decreased in the latex-treated group. A significant difference in conjunctival reactivity was observed in favor of the active group: the number of patients for whom the threshold dose was increased after 12 months of treatment was significantly greater in the active group than in the placebo group (P < .02). Most injections were well tolerated, but several adverse effects, including hypotension, urticaria, wheezing, and pharyngeal edema, were observed. Conclusion: The clinical benefits observed during the present study included a significant improvement of rhinitis, conjunctivitis, and cutaneous symptoms. Immunotherapy also decreased allergen-specific conjunctival reactivity. Latex-specific immunotherapy may allow sensitized personnel to remain at work, but further trials need to be conducted in a larger number of patients.	Stallergenes SA, Sci & Med Dept, F-92183 Antony, France; Hop Rothschild, F-75571 Paris, France; Hop Bichat, Serv Med Interne, Ctr Allergie, F-75877 Paris, France; Hop St Marguerite, Dept Malad Resp, Marseille, France	Andre, C (reprint author), Stallergenes SA, Sci & Med Dept, 6 Rue Alexis de Tocqueville, F-92183 Antony, France.						AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; ABELSON MB, 1990, ARCH OPHTHALMOL-CHIC, V108, P84; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; BAUR X, 1993, LANCET, V342, P1148, DOI 10.1016/0140-6736(93)92127-F; BLANCO C, 1994, ANN ALLERGY, V73, P309; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; Cantani A, 1999, J INVEST ALLERG CLIN, V9, P14; FRANKLAND AW, 1995, CLIN EXP ALLERGY, V25, P199, DOI 10.1111/j.1365-2222.1995.tb01028.x; Gritter M, 1997, Lippincotts Prim Care Pract, V1, P142; KWITTKEN PL, 1995, PEDIATRICS, V95, P693; LEVY DA, 1992, ALLERGY, V47, P579, DOI 10.1111/j.1398-9995.1992.tb02378.x; MAKINENKILJUNEN S, 1994, J ALLERGY CLIN IMMUN, V93, P990, DOI 10.1016/S0091-6749(94)70046-X; Malling HJ, 1998, ALLERGY, V53, P461; MATHEW SN, 1993, ANN ALLERGY, V70, P483; MRAIHI L, 1991, J ALLERGY CLIN IMMUN, V87, P129, DOI 10.1016/0091-6749(91)90224-C; Nel A, 1998, ANN ALLERG ASTHMA IM, V81, P388, DOI 10.1016/S1081-1206(10)63135-3; PEREIRA C, 1999, ALLERGY, V54, P287; SLATER JE, 1992, J ALLERGY CLIN IMMUN, V89, P673, DOI 10.1016/0091-6749(92)90373-A; SPANER D, 1989, J ALLERGY CLIN IMMUN, V83, P1135, DOI 10.1016/0091-6749(89)90457-0; TURJANMAA K, 1995, IMMUNOL ALLERGY CLIN, V15, P71; Turjanmaa K, 1997, ALLERGY, V52, P41, DOI 10.1111/j.1398-9995.1997.tb02544.x; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5	22	73	76	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					585	590				6	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900025	10984382	
J	Bisgaard, H; Nielsen, KG				Bisgaard, H; Nielsen, KG			Bronchoprotection with a leukotriene receptor antagonist in asthmatic preschool children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							EXERCISE-INDUCED BRONCHOCONSTRICTION; COLD DRY AIR; CONTROLLED TRIAL; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; FLUTICASONE PROPIONATE; NEBULIZED BUDESONIDE; 14-YEAR-OLD CHILDREN; MONTELUKAST; CHALLENGE	We hypothesized that a leukotriene receptor antagonist (LTRA) could provide bronchoprotection against the cold, dry air-induced response in asthmatic preschool children. In a randomized, double-blind, placebo-controlled crossover study, we examined the effect of the specific LTRA montelukast at 5 mg/d for 2 d on the bronchoconstriction induced by hyperventilation of cold, dry air in 13 asthmatic children 3 to 5 yr old. The bronchoconstriction was measured as the specific airway resistance (sRaw) in a whole-body plethysmograph before and 4 min after challenge with cold, dry air. The repeatability of the bronchoprotection was examined by repeating the placebo-controlled study in six of the 13 children. sRaw increased by an average of 46% (95% confidence interval [CI]: 30 to 63%) after placebo treatment and 17% (95% CI: 3 to 31%) after montelukast (p < 0.01). Eight of the children were receiving regular treatment with budesonide delivered by an inhaler with a spacer in a mean daily dose of 350 mu g, but the bronchoprotection provided by montelukast was independent of concurrent steroid treatment. There was no convincing evidence of failure to respond, and the protective effect of montelukast was consistent upon repeated testing (p = 0.02). We conclude that the LTRA montelukast provided clinically significant bronchoprotection against the effect of hyperventilation of cold dry air in asthmatic children 3 to 5 yr old. The bronchoprotection appeared to be homogeneous among the children, and seemed independent of steroid treatment. This suggests that LTRAs may be of therapeutic use in limiting clinical symptoms of asthma in young children.	Univ Copenhagen Hosp, Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark	Bisgaard, H (reprint author), Univ Copenhagen Hosp, Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark.		Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592			ARGYROS GJ, 1993, AM REV RESPIR DIS, V147, P1419; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; CONNETT GJ, 1993, ARCH DIS CHILD, V69, P351; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953; Fischer AR, 1997, THORAX, V52, P1074; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356; ISRAEL E, 1990, NEW ENGL J MED, V323, P1740, DOI 10.1056/NEJM199012203232505; KANENGISER S, 1994, PEDIATR PULM, V18, P144, DOI 10.1002/ppul.1950180305; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; KLUB G, 1996, EUR RESPIR J, V10, P1599; Klug B, 1998, PEDIATR PULM, V25, P322, DOI 10.1002/(SICI)1099-0496(199805)25:5<322::AID-PPUL6>3.0.CO;2-K; Klug B, 1999, EUR RESPIR J, V14, P1185, DOI 10.1183/09031936.99.14511859; Klug B, 1996, PEDIATR PULM, V21, P290; Knorr B, 1998, JAMA-J AM MED ASSOC, V279, P1181, DOI 10.1001/jama.279.15.1181; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lofdahl CG, 1999, BRIT MED J, V319, P87; Malmstrom K, 1999, ANN INTERN MED, V130, P487; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCFADDEN ER, 1987, CHEST, V91, pS151, DOI 10.1378/chest.91.6.151S; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1997, THORAX, V52, P45; SLY PD, 1990, J ASTHMA, V27, P137, DOI 10.3109/02770909009073314; Warner JO, 1998, PEDIATR PULM, V25, P1; ZACH M, 1995, PEDIATR PULM, V19, P323, DOI 10.1002/ppul.1950190602; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016	31	73	78	0	6	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL	2000	162	1					187	190				4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	333JH	WOS:000088126800031	10903240	
J	Rowe, J; Macaubas, C; Monger, TM; Holt, BJ; Harvey, J; Poolman, JT; Sly, PD; Holt, PG				Rowe, J; Macaubas, C; Monger, TM; Holt, BJ; Harvey, J; Poolman, JT; Sly, PD; Holt, PG			Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized	INFECTION AND IMMUNITY			English	Article							CELL-MEDIATED-IMMUNITY; BORDETELLA-PERTUSSIS; WHOLE-CELL; EARLY-CHILDHOOD; T-CELLS; ENVIRONMENTAL ALLERGENS; NEONATAL TOLERANCE; HOUSEHOLD EXPOSURE; INHALANT ALLERGEN; CONTROLLED TRIAL	Immune responses to exogenous antigens in infant experimental animals display various degrees of Th2 polarization. Preliminary evidence from small human studies suggest a similar age-dependent response pattern to vaccines, but detailed investigations on vaccine immunity during infancy have not yet been undertaken. We report below the results of a comprehensive prospective study on responses to the tetanus component of the diphtheria, tetanus, acellular pertussis (DTaP) vaccine in a cohort of 55 healthy children, employing peripheral blood mononuclear cells (PBMC) collected at the 2-, 4-, and 6-month vaccinations and at 12 months. Antigen-specific production of interleukin-4 (IL-4), IL-5, IL-6, IL-9, IL-10, IL-13, and gamma interferon (IFN-gamma) was determined at each sample point, in parallel with polyclonal (phytohemagglutinin PHA-induced) cytokine responses. Our results indicate early and persistent Th2 responses to the vaccine, in contrast to a more delayed and transient pattern of IFN-gamma production, This initial disparity between the Th1 and Th2 components of the vaccine response was mirrored by patterns of polyclonally induced cytokine production, suggesting that the delayed maturation of the Th1 component of the vaccine response during infancy is secondary to developmental processes occurring within the overall Th cell system.	TVW Telethon Inst Child Hlth Res, Div Cell Biol, W Perth, WA 6872, Australia; Univ Western Australia, Dept Microbiol, Perth, WA 6009, Australia; Univ Western Australia, Dept Paediat, Perth, WA 6009, Australia; SmithKline Beecham Pharmaceut, Rixensart, Belgium	Holt, PG (reprint author), TVW Telethon Inst Child Hlth Res, Div Cell Biol, POB 855, W Perth, WA 6872, Australia.		Sly, Peter/F-1486-2010; Holt, Patrick/H-1548-2011	Sly, Peter/0000-0001-6305-2201; Holt, Patrick/0000-0003-1193-0935			*AD HOC STUD GROUP, 1988, LANCET, V31, P955; Ausiello CM, 1999, INFECT IMMUN, V67, P4064; Ausiello CM, 1997, INFECT IMMUN, V65, P2168; Barrios C, 1996, EUR J IMMUNOL, V26, P2666, DOI 10.1002/eji.1830261118; Barrios C, 1996, EUR J IMMUNOL, V26, P1489, DOI 10.1002/eji.1830260713; Chen NX, 1995, TRANSPLANTATION, V60, P1187; CHEN NX, 1995, TRANSPLANTATION, V59, P933, DOI 10.1097/00007890-199504150-00002; Cherry JD, 1998, VACCINE, V16, P1901, DOI 10.1016/S0264-410X(98)00226-6; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; ELGHAZALI GEB, 1993, EUR J IMMUNOL, V23, P2740, DOI 10.1002/eji.1830231103; Greco D, 1996, NEW ENGL J MED, V334, P341, DOI 10.1056/NEJM199602083340601; Gustafsson L, 1996, NEW ENGL J MED, V334, P349, DOI 10.1056/NEJM199602083340602; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Mahon BP, 1996, INFECT IMMUN, V64, P5295; Marchant A, 1999, J IMMUNOL, V163, P2249; MILLS KHG, 1993, INFECT IMMUN, V61, P399; Prescott SL, 1998, J IMMUNOL, V160, P4730; PRESCOTT SL, 1999, LANCET, V353, P96; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Ryan M, 1998, IMMUNOLOGY, V93, P1; Schmitt HJ, 1996, JAMA-J AM MED ASSOC, V275, P37, DOI 10.1001/jama.275.1.37; Singh RR, 1996, J EXP MED, V183, P1613, DOI 10.1084/jem.183.4.1613; Storsaeter J, 1998, VACCINE, V16, P1907, DOI 10.1016/S0264-410X(98)00227-8; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261; Zepp F, 1996, INFECT IMMUN, V64, P4078	28	73	74	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567			INFECT IMMUN	Infect. Immun.	JUL	2000	68	7					3873	3877		10.1128/IAI.68.7.3873-3877.2000		5	Immunology; Infectious Diseases	Immunology; Infectious Diseases	326AT	WOS:000087710200012	10858197	
J	Peden, DB				Peden, DB			Development of atopy and asthma: Candidate environmental influences and important periods of exposure	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; atopy; immunoglobulin E (IgE); immunoglobulin G (IgG); T-helper cell type 1 (Th1); T-helper cell type 2 (Th2)	INTERFERON-GAMMA PRODUCTION; SERUM IGE LEVELS; DIESEL-EXHAUST; IN-VIVO; ALLERGIC SENSITIZATION; ADJUVANT ACTIVITY; IMMUNE-RESPONSES; RISK FACTOR; MICE; ASSOCIATION	Atopy is a major risk factor for the development of asthma. immune processes that lead to the development of antigen-specific IgE are essential to the development of atopy. This review examines the immune processes that are candidate targets for modulation by environmental agents; environmental and lifestyle factors that have been suggested as modulators of the development of atopy; and the impact of known environmental agents on atopic processes in the airway. The most important periods of immune development with regard to expression of atopy are likely during gestation and early childhood. A better understanding of which environmental agents are important, as well as the period of life during which these agents may exert an important effect, is essential to devising rational environmental avoidance strategies for at-risk populations.	Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC 27599 USA	Peden, DB (reprint author), Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.						American Academy of Pediatrics Committee on Environmental Health, 1997, PEDIATRICS, V9, P639; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; BARNES KC, 1999, ASTHMA CAUSES MECH E, P197; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BJORKSTEN B, 1998, ALLERGY PRINCIPLES P, V1, P28; BLUMENTAHAL MN, 1998, ALL PRINC PRACT, V1, P28; BORISH L, 1998, ALLERGY PRINCIPLES P, V1, P108; Braun KM, 1998, TOXICOL APPL PHARM, V149, P136, DOI 10.1006/taap.1997.8346; Burr M L, 1999, Pediatr Pulmonol Suppl, V18, P3; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; *COMM HLTH EFF IND, 1993, IND ALL ASS CONTR AD, P131; de Longueville M, 1997, PEDIATR ALLERGY IMMU, V8, P177; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DUFF AL, 1992, PEDIATR CLIN N AM, V47, P431; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351; Edenharter G, 1998, CLIN EXP ALLERGY, V28, P671; EDFORSLUBS ML, 1971, ACTA ALLERGOL, V26, P249, DOI 10.1111/j.1398-9995.1971.tb01300.x; ERB KJ, 1998, J EXP MED, V187, P551; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; HALONEN M, 1992, AM REV RESPIR DIS, V146, P866; Holberg CJ, 1998, AM J RESP CRIT CARE, V158, P162; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Holt PG, 1999, CLIN EXP ALLERGY, V29, P8, DOI 10.1046/j.1365-2222.1999.00003.x-i2; Howarth PH, 1998, CLIN EXP ALLERGY, V28, P1; Huston DP, 1997, JAMA-J AM MED ASSOC, V278, P1804, DOI 10.1001/jama.278.22.1804; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Lemanske RF, 1997, JAMA-J AM MED ASSOC, V278, P1855, DOI 10.1001/jama.278.22.1855; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1991, NEW ENGL J MED, V301, P1551; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1997, J CLIN INVEST, V100, P3184, DOI 10.1172/JCI119874; Martinez FD, 1998, J ALLERGY CLIN IMMUN, V102, P915, DOI 10.1016/S0091-6749(98)70328-8; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V77, P616, DOI 10.1016/0091-6749(86)90355-6; *NHLBI, 1997, NISH PUBL; Peden DB, 1997, ALLERGY, V52, P37; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; PEDEN DB, 1999, AIR POLLUTION HLTH, P865, DOI 10.1016/B978-012352335-8/50112-5; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1999, ASTHMA CAUSES MECH E, P1; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 1998, J IMMUNOL, V160, P4730; PRESCOTT SL, 1999, LANCET, V353, P96; Puck JM, 1997, JAMA-J AM MED ASSOC, V278, P1835; SHEARER WT, 1998, ALLERGY PRINCIPLES P, V1, P1; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; TAKAFUJI S, 1989, CIBA F SYMP, V147, P188; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; TAKAFUJI S, 1989, INT ARCH ALLER A IMM, V90, P1; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Wang CC, 1998, IMMUNOLOGY, V93, P307; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WILLSKARP M, 1998, ASTHMA CAUSES MECH E, P87	59	73	75	1	2	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2000	108			3			475	482		10.2307/3454539		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	326RK	WOS:000087748400018	10852847	
J	Eldridge, MW; Peden, DB				Eldridge, MW; Peden, DB			Allergen provocation augments endotoxin-induced nasal inflammation in subjects with atopic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; dust mite; antigen; asthma; eosinophils; neutrophils; allergy	AIR-POLLUTION; OZONE; MORTALITY; CHALLENGE; RESPONSES; EXPOSURE; WORKERS; HEALTH	Background: Recent epidemiologic and in vivo studies have suggested that inhaled endotoxin plays an important role in asthma pathogenesis. Objective: The present study examines the effect of nasal allergen provocation on subsequent endotoxin challenge in subjects with atopic asthma. Methods: By using a split-nose randomized crossover design, individual nares of 12 asthmatic subjects underwent challenge and lavage as follows, Immediately after a baseline nasal lavage, one nares received normal saline, and the other received dust mite antigen, Four hours later both nares were exposed to either saline or endotoxin. Dust mite antigen (Dermatophagoides farinae) and endotoxin (Escherichia roll 026:B6) doses were 100 AU and 1000 ng, respectively. Postchallenge lavages were done at 8 and 24 hours after the initial challenge. The subjects then returned a minimum of 3 weeks later for crossover to the study arm. Nasal lavage fluid was analyzed for total and differential cell counts, IL-8, IL-6, intercellular adhesion molecule 1, GM-CSF, eosinophil cationic protein, myeloperoxidase, and soluble CD14. Results: A significant increase in the total inflammatory cell count was seen at 8 hours for the dust mite/endotoxin exposure compared with the saline/saline and saline/endotoxin exposures. Differential cell counts revealed a similar neutrophilic and eosinophilic inflammation for the dust mite/endotoxin exposure at 8 hours. Conclusions: These data demonstrate an interaction between allergen and endotoxin exposure in asthmatic subjects, suggesting that a prior allergen challenge significantly augments the endotoxin-induced inflammation. Moreover, these data provide further evidence that concomitant exposure to allergen and endotoxin may he an important factor in asthma pathogenesis.	Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pediat, Div Pulm Med & Allergy, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Gen Clin Res Ctr, Chapel Hill, NC 27599 USA; Natl Inst Environm Hlth Sci, Chapel Hill, NC USA	Eldridge, MW (reprint author), Univ N Carolina, Sch Med, Ctr Environm Med & Lung Biol, 104 Mason Farm Rd,CB 7310, Chapel Hill, NC 27599 USA.				NHLBI NIH HHS [1RO1HL62624-01]; NIEHS NIH HHS [N01-ES-35356]		ATS, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BASHA MA, 1994, CHEST, V106, P1757, DOI 10.1378/chest.106.6.1757; COCKCROFT DW, 1987, ANN ALLERGY, V59, P89; Cook DG, 1997, THORAX, V52, P1081; DONHAM K, 1989, BRIT J IND MED, V46, P31; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; HALLSWORTH M, 1994, EUR RESPIR J, V44, P1096; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; McFadden ER, 1997, ANN INTERN MED, V127, P142; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Michelson PH, 1999, OTOLARYNG HEAD NECK, V120, P225, DOI 10.1016/S0194-5998(99)70411-0; Peden DB, 1996, REGUL TOXICOL PHARM, V24, pS76, DOI 10.1006/rtph.1996.0081; Peden DB, 1997, ALLERGY, V52, P37; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; Peden DB, 1996, OTOLARYNG HEAD NECK, V114, P242, DOI 10.1016/S0194-5998(96)70175-4; Peden DB, 1997, ALLERGY S38, V52, P57; RYLANDER R, 1985, AM REV RESPIR DIS, V131, P209; Saitou M, 1997, Fukushima J Med Sci, V43, P75; SALOMONSSON P, 1992, AM REV RESPIR DIS, V146, P1535; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Sunyer J., 1997, European Respiratory Journal, V10, P2490, DOI 10.1183/09031936.97.10112490; Virchow JC, 1998, EUR RESPIR J, V11, P317, DOI 10.1183/09031936.98.11020317; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683	27	73	75	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2000	105	3					475	481		10.1067/mai.2000.104552		7	Allergy; Immunology	Allergy; Immunology	347UC	WOS:000088946700012	10719296	
J	Braun, JM; Sathyanarayana, S; Hauser, R				Braun, Joseph M.; Sathyanarayana, Sheela; Hauser, Russ			Phthalate exposure and children's health	CURRENT OPINION IN PEDIATRICS			English	Review						children; endocrine disruption; epidemiology; phthalates	IN-UTERO EXPOSURE; BODY TOPICAL APPLICATION; PERSONAL CARE PRODUCTS; SCHOOL-AGE-CHILDREN; NEW-YORK-CITY; URINARY CONCENTRATIONS; PRENATAL EXPOSURE; BISPHENOL-A; DIETHYLHEXYL PHTHALATE; DI(2-ETHYLHEXYL)PHTHALATE DEHP	Purpose of review Phthalates are multifunctional chemicals used in personal care products, medications, and plastics. We reviewed the epidemiological literature examining the relationship between early life phthalate exposure and pediatric health outcomes. Recent findings Five studies from Asia, Europe, and the United States suggest that childhood exposure to di-2-ethylhexyl phthalate (DEHP) and butylbenzyl phthalate (BBzP) may increase the risk of allergic diseases including asthma and eczema. Six studies from four different prospective cohorts report that gestational BBzP, DEHP, di-butyl phthalate (DBP), and di-ethyl phthalate (DEP) exposures are associated with alterations in infant/toddler physical development as well as parent-reported externalizing, internalizing, and autistic-like child behavior. However, there are inconsistencies related to the specific phthalates and behavioral domains. Two small studies report shorter anogenital distance among male infants with higher gestational phthalate exposure. Summary Several epidemiological studies suggest fetal and childhood exposure to some phthalates may perturb normal development, with several studies consistently reporting increased risk of allergic diseases with DEHP and BBzP exposure. Although anticipatory guidance is not evidence-based at this time, providers can counsel concerned patients to reduce phthalate exposures in order to protect the developing fetus and child from potential adverse health outcomes.	[Braun, Joseph M.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA; [Sathyanarayana, Sheela] Univ Washington, Dept Pediat, Seattle Childrens Res Inst, Seattle, WA 98195 USA; [Hauser, Russ] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Fertil Ctr, Dept Obstet & Gynecol,Div Reprod Endocrinol & Inf, Boston, MA USA; [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Braun, JM (reprint author), Brown Univ, Dept Epidemiol, Box G-S121-2, Providence, RI 02912 USA.	joseph_braun_1@brown.edu	Braun, Joseph/H-8649-2014		NIEHS [K99 ES020346, R01 ES021357, R01 ES009718]	J.M.B. was supported by NIEHS grants K99 ES020346 and R01 ES021357. R. H. is supported by NIEHS grant R01 ES009718.	Adibi JJ, 2009, AM J EPIDEMIOL, V169, P1015, DOI 10.1093/aje/kwp001; AUTIAN J, 1973, Environmental Health Perspectives, V4, P3, DOI 10.2307/3428178; Becker K, 2009, INT J HYG ENVIR HEAL, V212, P685, DOI 10.1016/j.ijheh.2009.08.002; Benayoun L, 2001, AM J RESP CRIT CARE, V164, P1487; Boas M, 2010, ENVIRON HEALTH PERSP, V118, P1458, DOI 10.1289/ehp.0901331; Borch J, 2006, TOXICOLOGY, V223, P144, DOI 10.1016/j.tox.2006.03.015; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Braun JM, 2012, ENVIRON HEALTH PERSP, V120, P739, DOI 10.1289/ehp.1104139; Buckley JP, 2012, J EXPO SCI ENV EPID, V22, P468, DOI 10.1038/jes.2012.33; Carlstedt F, 2013, INDOOR AIR, V23, P32, DOI 10.1111/j.1600-0668.2012.00788.x; Cho SC, 2010, ENVIRON HEALTH PERSP, V118, P1027, DOI 10.1289/ehp.0901376; Duty SM, 2005, ENVIRON HEALTH PERSP, V113, P1530, DOI 10.1289/ehp.8083; Engel SM, 2010, ENVIRON HEALTH PERSP, V118, P565, DOI 10.1289/ehp.0901470; Engel SM, 2009, NEUROTOXICOLOGY, V30, P522, DOI 10.1016/j.neuro.2009.04.001; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Frederiksen H, 2012, INT J ANDROL, V35, P216, DOI 10.1111/j.1365-2605.2012.01260.x; Green R, 2005, ENVIRON HEALTH PERSP, V113, P1222, DOI 10.1289/chp.7932; Hannas BR, 2011, TOXICOL SCI, V123, P206, DOI 10.1093/toxsci/kfr146; Hatch EE, 2008, ENVIRON HEALTH-GLOB, V7, DOI 10.1186/1476-069X-7-27; Hauser R, 2005, Occup Environ Med, V62, P806, DOI 10.1136/oem.2004.017590; Hauser R, 2004, ENVIRON HEALTH PERSP, V112, P1734, DOI 10.1289/ehp.7212; Hauser R, 2004, ENVIRON HEALTH PERSP, V112, P751, DOI 10.1289/ehp.6804; Hernandez-Diaz S, 2009, ENVIRON HEALTH PERSP, V117, P185, DOI 10.1289/ehp.11766; Howdeshell KL, 2007, TOXICOL SCI, V99, P190, DOI 10.1093/toxsci/kfm069; Hsu NY, 2012, INDOOR AIR, V22, P186, DOI 10.1111/j.1600-0668.2011.00753.x; Huang PC, 2009, ENVIRON INT, V35, P14, DOI 10.1016/j.envint.2008.05.012; Hubinger JC, 2010, J COSMET SCI, V61, P457; Hurst CH, 2003, TOXICOL SCI, V74, P297, DOI 10.1093/toxsci/kfg145; Janjua NR, 2008, INT J ANDROL, V31, P118, DOI 10.1111/j.1365-2605.2007.00841.x; Janjua NR, 2007, ENVIRON SCI TECHNOL, V41, P5564, DOI 10.1021/es0628755; Just AC, 2012, AM J RESP CRIT CARE, V186, P830, DOI 10.1164/rccm.201203-0398OC; Just AC, 2012, ENVIRON HEALTH PERSP, V120, P1475, DOI 10.1289/ehp.1104544; Just AC, 2010, J EXPO SCI ENV EPID, V20, P625, DOI 10.1038/jes.2010.13; Kelley KE, 2012, ENVIRON HEALTH PERSP, V120, P379, DOI 10.1289/ehp.1103998; Kim BN, 2009, BIOL PSYCHIAT, V66, P958, DOI 10.1016/j.biopsych.2009.07.034; Kim Y, 2011, ENVIRON HEALTH PERSP, V119, P1495, DOI 10.1289/ehp.1003178; Koch HM, 2006, INT J ANDROL, V29, P155, DOI 10.1111/j.1365-2605.2005.00607.x; Koch HM, 2005, ARCH TOXICOL, V79, P689, DOI 10.1007/s00204-005-0004-x; Koch HM, 2007, INT J HYG ENVIR HEAL, V210, P9, DOI 10.1016/j.ijheh.2006.11.008; Kolarik B, 2008, ENVIRON HEALTH PERSP, V116, P98, DOI 10.1289/ehp.10498; Koniecki D, 2011, ENVIRON RES, V111, P329, DOI 10.1016/j.envres.2011.01.013; Koo HJ, 2004, J TOXICOL ENV HEAL A, V67, P1901, DOI 10.1080/15287390490513300; Latini G, 2003, ENVIRON HEALTH PERSP, V111, P1783, DOI 10.1289/ehp.6202; Loff S, 2008, J PEDIATR GASTR NUTR, V47, P81, DOI 10.1097/MPG.0b013e318164d933; Lovekamp-Swan T, 2003, MOL CELL ENDOCRINOL, V201, P133, DOI 10.1016/S0303-7207(02)00423-9; MacLeod DJ, 2010, INT J ANDROL, V33, P279, DOI 10.1111/j.1365-2605.2009.01005.x; Main KM, 2006, ENVIRON HEALTH PERSP, V114, P270, DOI 10.1289/ehp.8075; Meeker JD, 2009, ENVIRON HEALTH PERSP, V117, P1587, DOI 10.1289/ehp.0800522; Miodovnik A, 2011, NEUROTOXICOLOGY, V32, P261, DOI 10.1016/j.neuro.2010.12.009; Needham LL, 2005, NEUROTOXICOLOGY, V26, P547, DOI 10.1016/j.neuro.2004.09.006; Philippat C, 2012, ENVIRON HEALTH PERSP, V120, P464, DOI 10.1289/ehp.1103634; Romero-Franco M, 2011, ENVIRON INT, V37, P867, DOI 10.1016/j.envint.2011.02.014; Rudel RA, 2011, ENVIRON HEALTH PERSP, V119, P914, DOI 10.1289/ehp.1003170; Sathyanarayana Sheela, 2008, Curr Probl Pediatr Adolesc Health Care, V38, P34, DOI 10.1016/j.cppeds.2007.11.001; Sathyanarayana S, 2008, PEDIATRICS, V121, pE260, DOI 10.1542/peds.2006-3766; Silva MJ, 2004, ENVIRON HEALTH PERSP, V112, P331, DOI 10.1289/ehp.6723; Simmchen J, 2012, TRANSFUS MED REV, V26, P27, DOI 10.1016/j.tmrv.2011.06.001; Suzuki Y, 2012, INT J ANDROL, V35, P236, DOI 10.1111/j.1365-2605.2011.01190.x; Swan SH, 2010, INT J ANDROL, V33, P259, DOI 10.1111/j.1365-2605.2009.01019.x; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; Teitelbaum SL, 2012, ENVIRON RES, V112, P186, DOI 10.1016/j.envres.2011.12.006; Testa C, 2012, ASN NEURO, V4, P223, DOI 10.1042/AN20120015; Vandentorren S, 2011, ENVIRON RES, V111, P761, DOI 10.1016/j.envres.2011.05.018; Weuve J, 2006, ENVIRON HEALTH PERSP, V114, P1424, DOI 10.1289/ehp.8926; Whyatt RM, 2012, ENVIRON HEALTH PERSP, V120, P290, DOI 10.1289/ehp.1103705; Whyatt RM, 2009, PEDIATRICS, V124, pE1213, DOI 10.1542/peds.2009-0325; Wolff MS, 2008, ENVIRON HEALTH PERSP, V116, P1092, DOI 10.1289/ehp.11007; Wolff MS, 2010, ENVIRON HEALTH PERSP, V118, P1039, DOI 10.1289/ehp.0901690; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Yolton K, 2011, NEUROTOXICOL TERATOL, V33, P558, DOI 10.1016/j.ntt.2011.08.003; Zhang YH, 2009, J PEDIATR-US, V155, P500, DOI 10.1016/j.jpeds.2009.04.007; [Anonymous], 2002, FDA PUBLIC HLTH NOTI; [Anonymous], 2011, RESOURCES HLTH PROFE	75	72	75	3	113	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1040-8703			CURR OPIN PEDIATR	CURR. OPIN. PEDIATR.	APR	2013	25	2					247	254		10.1097/MOP.0b013e32835e1eb6		8	Pediatrics	Pediatrics	105YV	WOS:000316109500015	23429708	
J	Donovan, GH; Butry, DT; Michael, YL; Prestemon, JP; Liebhold, AM; Gatziolis, D; Mao, MY				Donovan, Geoffrey H.; Butry, David T.; Michael, Yvonne L.; Prestemon, Jeffrey P.; Liebhold, Andrew M.; Gatziolis, Demetrios; Mao, Megan Y.			The Relationship Between Trees and Human Health Evidence from the Spread of the Emerald Ash Borer	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							PHYSICAL-ACTIVITY; STREET TREES; GREEN SPACE; ASTHMA; INEQUALITIES; MORTALITY; EXPOSURE; DISEASE; FOREST; AREAS	Background: Several recent studies have identified a relationship between the natural environment and improved health outcomes. However, for practical reasons, most have been observational, cross-sectional studies. Purpose: A natural experiment, which provides stronger evidence of causality, was used to test whether a major change to the natural environment-the loss of 100 million trees to the emerald ash borer, an invasive forest pest-has influenced mortality related to cardiovascular and lower-respiratory diseases. Methods: Two fixed-effects regression models were used to estimate the relationship between emerald ash borer presence and county-level mortality from 1990 to 2007 in 15 U. S. states, while controlling for a wide range of demographic covariates. Data were collected from 1990 to 2007, and the analyses were conducted in 2011 and 2012. Results: There was an increase in mortality related to cardiovascular and lower-respiratory-tract illness in counties infested with the emerald ash borer. The magnitude of this effect was greater as infestation progressed and in counties with above-average median household income. Across the 15 states in the study area, the borer was associated with an additional 6113 deaths related to illness of the lower respiratory system, and 15,080 cardiovascular-related deaths. Conclusions: Results suggest that loss of trees to the emerald ash borer increased mortality related to cardiovascular and lower-respiratory-tract illness. This finding adds to the growing evidence that the natural environment provides major public health benefits. (Am J Prev Med 2013; 44(2): 139-145) Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine	[Donovan, Geoffrey H.; Gatziolis, Demetrios; Mao, Megan Y.] US Forest Serv, USDA, PNW Res Stn, Portland, OR 97205 USA; [Butry, David T.] NIST, Gaithersburg, MD 20899 USA; [Michael, Yvonne L.] Drexel Univ, Dept Epidemiol & Biostat, Philadelphia, PA 19104 USA; [Prestemon, Jeffrey P.] US Forest Serv, USDA, So Res Stn, Res Triangle Pk, NC USA; [Liebhold, Andrew M.] US Forest Serv, No Res Stn, USDA, Morgantown, WV USA	Donovan, GH (reprint author), US Forest Serv, USDA, PNW Res Stn, 620 SW Main,Suite 400, Portland, OR 97205 USA.	gdonovan@fs.fed.us	Liebhold, Andrew/C-1423-2008	Liebhold, Andrew/0000-0001-7427-6534			ANGRIST JD, 1995, J AM STAT ASSOC, V90, P431, DOI 10.2307/2291054; Baum CF, 2001, STATA J, V1, P101; CDC, 2009, LEAD CAUS DEATH; Dadvand P., 2012, ENVIRON INT, V44, P3; Donovan GH, 2011, HEALTH PLACE, V17, P390, DOI 10.1016/j.healthplace.2010.11.004; Donovan GH, 2010, LANDSCAPE URBAN PLAN, V94, P77, DOI 10.1016/j.landurbplan.2009.07.019; Donovan GH, 2009, ENERG BUILDINGS, V41, P662, DOI 10.1016/j.enbuild.2009.01.002; Everson-Rose SA, 2005, ANNU REV PUBL HEALTH, V26, P469, DOI 10.1146/annurev.publhealth.26.021304.144542; Feng J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033385; Frumkin Howard, 2001, American Journal of Preventive Medicine, V20, P234, DOI 10.1016/S0749-3797(00)00317-2; Fry J. A., 2011, PE&RS, Photogrammetric Engineering & Remote Sensing, V77, P858; Glymour MM, 2006, METHODS SOCIAL EPIDE, P429; Greene W., 2000, ECONOMETRIC ANAL; Kaczynski AT, 2007, LEISURE SCI, V29, P315, DOI 10.1080/01490400701394865; Krieger N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/aje/kwf068; Lee ACK, 2011, J PUBLIC HEALTH-UK, V33, P212, DOI 10.1093/pubmed/fdq068; Lovasi GS, 2008, J EPIDEMIOL COMMUN H, V62, P647, DOI 10.1136/jech.2007.071894; Lucas SR, 2005, J ALLERGY CLIN IMMUN, V115, P928, DOI 10.1016/j.jaci.2005.01.033; Maas J, 2006, J EPIDEMIOL COMMUN H, V60, P587, DOI 10.1136/jech.2005.043125; Maas J, 2009, J EPIDEMIOL COMMUN H, V63, P967, DOI 10.1136/jech.2008.079038; Mitchell R, 2008, LANCET, V372, P1655, DOI 10.1016/S0140-6736(08)61689-X; National Heart Lung and Blood Institute, 2007, MORB MORT 2007 CHART; NCHS, 2010, COMPR MORT FIL 1999; NCHS, 2007, COMPR MORT FIL 1989; Nowak David J., 2006, Urban Forestry & Urban Greening, V4, P115, DOI 10.1016/j.ufug.2006.01.007; Oguma Y, 2004, AM J PREV MED, V26, P407, DOI 10.1016/j.ampere.2004.02.007; Park BJ, 2008, SCAND J FOREST RES, V23, P278, DOI 10.1080/02827580802055978; Poland TM, 2006, J FOREST, V104, P118; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Rothman KJ, 2008, MODERN EPIDEMIOLOGY; Stock JH, 2008, ECONOMETRICA, V76, P155, DOI 10.1111/j.0012-9682.2008.00821.x; Takona T, 2002, J EPIDEMIOL COMMUNIT, V56, P913; Troy A, 2008, LANDSCAPE URBAN PLAN, V87, P233, DOI 10.1016/j.landurbplan.2008.06.005; Tzoulas K, 2007, LANDSCAPE URBAN PLAN, V81, P167, DOI 10.1016/j.landurbplan.2007.02.001; ULRICH RS, 1984, SCIENCE, V224, P420, DOI 10.1126/science.6143402; van den Berg AE, 2010, SOC SCI MED, V70, P1203, DOI 10.1016/j.socscimed.2010.01.002; Wright RJ, 1998, THORAX, V53, P1066	37	72	81	14	130	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797			AM J PREV MED	Am. J. Prev. Med.	FEB	2013	44	2					139	145		10.1016/j.amepre.2012.09.066		7	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	077ZJ	WOS:000314067600009	23332329	
J	Huffman, JA; Prenni, AJ; DeMott, PJ; Pohlker, C; Mason, RH; Robinson, NH; Frohlich-Nowoisky, J; Tobo, Y; Despres, VR; Garcia, E; Gochis, DJ; Harris, E; Mueller-Germann, I; Ruzene, C; Schmer, B; Sinha, B; Day, DA; Andreae, MO; Jimenez, JL; Gallagher, M; Kreidenweis, SM; Bertram, AK; Poschl, U				Huffman, J. A.; Prenni, A. J.; DeMott, P. J.; Poehlker, C.; Mason, R. H.; Robinson, N. H.; Froehlich-Nowoisky, J.; Tobo, Y.; Despres, V. R.; Garcia, E.; Gochis, D. J.; Harris, E.; Mueller-Germann, I.; Ruzene, C.; Schmer, B.; Sinha, B.; Day, D. A.; Andreae, M. O.; Jimenez, J. L.; Gallagher, M.; Kreidenweis, S. M.; Bertram, A. K.; Poeschl, U.			High concentrations of biological aerosol particles and ice nuclei during and after rain	ATMOSPHERIC CHEMISTRY AND PHYSICS			English	Article							NUCLEATION-ACTIVE BACTERIA; MINERAL DUST PARTICLES; FUNGAL SPORES; PSEUDOMONAS-SYRINGAE; ATMOSPHERIC AEROSOLS; THUNDERSTORM ASTHMA; SIZE DISTRIBUTIONS; AIRBORNE BACTERIA; SPLASH DISPERSAL; UV-APS	Bioaerosols are relevant for public health and may play an important role in the climate system, but their atmospheric abundance, properties, and sources are not well understood. Here we show that the concentration of airborne biological particles in a North American forest ecosystem increases significantly during rain and that bioparticles are closely correlated with atmospheric ice nuclei (IN). The greatest increase of bioparticles and IN occurred in the size range of 2-6 mu m, which is characteristic for bacterial aggregates and fungal spores. By DNA analysis we found high diversities of airborne bacteria and fungi, including groups containing human and plant pathogens (mildew, smut and rust fungi, molds, Enterobacteriaceae, Pseudomonadaceae). In addition to detecting known bacterial and fungal IN (Pseudomonas sp., Fusarium sporotrichioides), we discovered two species of IN-active fungi that were not previously known as biological ice nucleators (Isaria farinosa and Acremonium implicatum). Our findings suggest that atmospheric bioaerosols, IN, and rainfall are more tightly coupled than previously assumed.	[Huffman, J. A.] Univ Denver, Dept Chem & Biochem, Denver, CO 80208 USA; [Huffman, J. A.; Poehlker, C.; Froehlich-Nowoisky, J.; Harris, E.; Mueller-Germann, I.; Ruzene, C.; Schmer, B.; Sinha, B.; Andreae, M. O.; Poeschl, U.] Max Planck Inst Chem, D-55020 Mainz, Germany; [Prenni, A. J.; DeMott, P. J.; Tobo, Y.; Garcia, E.; Kreidenweis, S. M.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; [Mason, R. H.; Bertram, A. K.] Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada; [Robinson, N. H.; Gallagher, M.] Univ Manchester, Ctr Atmospher Sci, Manchester M13 9PL, Lancs, England; [Despres, V. R.] Johannes Gutenberg Univ Mainz, Inst Gen Bot, D-55099 Mainz, Germany; [Gochis, D. J.] Natl Ctr Atmospher Res, Boulder, CO 80307 USA; [Sinha, B.] IISER Mohali, Dept Earth & Environm Sci, Sect 81, Sas Nagar 140306, India; [Day, D. A.; Jimenez, J. L.] Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA; [Day, D. A.; Jimenez, J. L.] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Huffman, JA (reprint author), Univ Denver, Dept Chem & Biochem, 2190 E Illif Ave, Denver, CO 80208 USA.	alex.huffman@du.edu; anthony.prenni@colostate.edu; bertram@chem.ubc.ca; u.poschl@mpic.de	; Tobo, Yutaka/D-9158-2013; Huffman, J. Alex/A-7449-2010; Andreae, Meinrat/B-1068-2008; Robinson, Niall/I-8063-2013; Jimenez, Jose/A-5294-2008; Sinha, Baerbel/H-1250-2012; Poschl, Ulrich/A-6263-2010; Robinson, Niall/B-7865-2013; Froehlich, Janine/D-6227-2015; Mason, Ryan/K-1450-2015; Pohlker, Christopher/S-5207-2016; Kreidenweis, Sonia/E-5993-2011	Gallagher, Martin/0000-0002-4968-6088; Harris, Eliza/0000-0002-7102-8305; Tobo, Yutaka/0000-0003-0951-3315; Huffman, J. Alex/0000-0002-5363-9516; Andreae, Meinrat/0000-0003-1968-7925; Jimenez, Jose/0000-0001-6203-1847; Sinha, Baerbel/0000-0001-8614-7473; Poschl, Ulrich/0000-0003-1412-3557; Froehlich, Janine/0000-0002-1278-0054; Mason, Ryan/0000-0003-2942-3608; Kreidenweis, Sonia/0000-0002-2561-2914	ETBC (Emerging Topics in Biogeochemical Cycles); University of Colorado; Colorado State University; Penn State University [NSF ATM-0919189]; University of Denver; Max Planck Society; Max Planck Graduate Center; Johannes Gutenberg University Mainz; Geocycles Cluster Mainz (LEC Rheinland-Pfalz); German Research Foundation [DFG PO1013/5-1, FOR 1525 INUIT]; National Sciences and Engineering Research Council of Canada; Japanese Society for the Promotion of Science (JSPS); NSF [ATM-0919042, AGS-1036028]; U.S. DOE (BER, ASR program) [DE-SC0006035]	The BEACHON-RoMBAS campaign was partially supported by an ETBC (Emerging Topics in Biogeochemical Cycles) grant to the National Center for Atmospheric Research (NCAR), the University of Colorado, Colorado State University, and Penn State University (NSF ATM-0919189). J. A. Huffman acknowledges internal faculty funding from the University of Denver. The Mainz team acknowledges financial support from the Max Planck Society (MPG), the Max Planck Graduate Center with the Johannes Gutenberg University Mainz (MPGC), the Geocycles Cluster Mainz (LEC Rheinland-Pfalz), and the German Research Foundation (DFG PO1013/5-1, FOR 1525 INUIT). R. H. Mason and A. K. Bertram acknowledge financial support from the the National Sciences and Engineering Research Council of Canada. Y. Tobo acknowledges the Japanese Society for the Promotion of Science (JSPS) Postdoctoral Fellowships for Research Abroad. CFDC measurements and analysis were funded by NSF (ATM-0919042, AGS-1036028). J. L. Jimenez and D. A. Day acknowledge U.S. DOE (BER, ASR program) DE-SC0006035. N. H. Robinson and M. Gallagher thank Defence Science and Technology Laboratory (DSTL) for loan of WIBS-4 instrument. The authors wish to thank: the USFS, NCAR, R. Oakes, A. Guenther, and J. Smith for providing logistical support and access to the Manitou Experimental Forest field site; A. Turnipseed for providing meteorological data; A. Sun for help with ice nucleation microscopy measurements; W. Elbert for useful discussions; J. D. Forster, T. C. J. Hill, S. Lelieveld, T. Pooya, and M. G. Grant for technical assistance in bioaerosol analysis.	Allitt U, 2000, AEROBIOLOGIA, V16, P397, DOI 10.1023/A:1026503500730; Augustin S., 2012, ATMOS CHEM PHYS DISC, V12, P32911, DOI [10.5194/acpd-12-32911-2012, DOI 10.5194/ACPD-12-32911-2012]; BIGG EK, 1964, J ATMOS SCI, V21, P396, DOI 10.1175/1520-0469(1964)021<0396:TROLMO>2.0.CO;2; Boyer DG, 2008, AGR FOREST METEOROL, V148, P1395, DOI 10.1016/j.agrformet.2008.04.001; Bozlee BJ, 2005, SPECTROCHIM ACTA A, V61, P2342, DOI 10.1016/j.saa.2005.02.033; Bridge P, 2001, PLANT SOIL, V232, P147, DOI 10.1023/A:1010346305799; Burrows SM, 2009, ATMOS CHEM PHYS, V9, P9281; BUTTERWORTH J, 1991, J APPL BACTERIOL, V71, P484, DOI 10.1111/j.1365-2672.1991.tb03822.x; Celenza A, 1996, BRIT MED J, V312, P604; Christner BC, 2008, SCIENCE, V319, P1214, DOI 10.1126/science.1149757; Connolly PJ, 2009, ATMOS CHEM PHYS, V9, P2805, DOI 10.5194/acp-9-2805-2009; CONSTANTINIDOU HA, 1990, PHYTOPATHOLOGY, V80, P934, DOI 10.1094/Phyto-80-934; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; DeMott PJ, 2010, P NATL ACAD SCI USA, V107, P11217, DOI 10.1073/pnas.0910818107; DeMott PJ, 2011, B AM METEOROL SOC, V92, P1623, DOI 10.1175/BAMS-D-10-3119.1; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Despres VR, 2007, BIOGEOSCIENCES, V4, P1127; Despres VR, 2012, TELLUS B, V64, DOI 10.3402/tellusb.v64i0.15598; Diehl K, 2001, ATMOS RES, V58, P75, DOI 10.1016/S0169-8095(01)00091-6; DiGangi JP, 2011, ATMOS CHEM PHYS, V11, P10565, DOI 10.5194/acp-11-10565-2011; Dymarska M, 2006, J GEOPHYS RES-ATMOS, V111, DOI 10.1029/2005JD006627; Edgar RC, 2004, BMC BIOINFORMATICS, V5, P1, DOI 10.1186/1471-2105-5-113; Elbert W, 2007, ATMOS CHEM PHYS, V7, P4569; Elbert W, 2012, NAT GEOSCI, V5, P459, DOI 10.1038/ngeo1486; Faulwetter RC, 1917, J AGRIC RES, V10, P639; Felsenstein J., 2004, PHYLIP PHYLOGENY INF; Fierer N, 2008, APPL ENVIRON MICROB, V74, P200, DOI 10.1128/AEM.01467-07; FITT BDL, 1989, ANNU REV PHYTOPATHOL, V27, P241, DOI 10.1146/annurev.py.27.090189.001325; Foot Virginia E, 2008, Proceedings of the SPIE - The International Society for Optical Engineering, V7116, DOI 10.1117/12.800226; Frohlich-Nowoisky J, 2012, BIOGEOSCIENCES, V9, P1125, DOI 10.5194/bg-9-1125-2012; Frohlich-Nowoisky J, 2009, P NATL ACAD SCI USA, V106, P12814, DOI 10.1073/pnas.0811003106; Gabey AM, 2010, ATMOS CHEM PHYS, V10, P4453, DOI 10.5194/acp-10-4453-2010; Garcia E, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2012JD018343; HALLETT J, 1974, NATURE, V249, P26, DOI 10.1038/249026a0; HIRST J. M., 1953, TRANS BRIT MYCOL SOC, V36, P375; Hirst J. M., 1963, J GEN MICROBIOL, V33, P334; Hoose C, 2012, ATMOS CHEM PHYS, V12, P9817, DOI 10.5194/acp-12-9817-2012; Hoose C, 2010, ENVIRON RES LETT, V5, DOI 10.1088/1748-9326/5/2/024009; Huber L., 1998, EPIDEMIOLOGY PLANT D, P348; Huber T, 2004, BIOINFORMATICS, V20, P2317, DOI 10.1093/bioinformatics/bth226; Huffman JA, 2012, ATMOS CHEM PHYS, V12, P11997, DOI 10.5194/acp-12-11997-2012; Huffman JA, 2010, ATMOS CHEM PHYS, V10, P3215; Iannone R, 2011, ATMOS CHEM PHYS, V11, P1191, DOI 10.5194/acp-11-1191-2011; Kaye PH, 2005, OPT EXPRESS, V13, P3583, DOI 10.1364/OPEX.13.003583; Korolev A, 2007, J ATMOS SCI, V64, P3372, DOI 10.1175/JAS4035.1; LEACH CM, 1976, MYCOLOGIA, V68, P63, DOI 10.2307/3758898; Levin EJT, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2011JD016854; LIGHTHART B, 1995, APPL ENVIRON MICROB, V61, P1492; Lighthart B., 2000, AEROBIOLOGIA, V16, P7, DOI DOI 10.1023/A:1007694618888; LINDEMANN J, 1982, APPL ENVIRON MICROB, V44, P1059; Madden LV, 1997, CAN J PLANT PATHOL, V19, P225; MADELIN TM, 1994, J AEROSOL SCI, V25, P1405, DOI 10.1016/0021-8502(94)90216-X; MAENHAUT W, 1993, NUCL INSTRUM METH B, V75, P249, DOI 10.1016/0168-583X(93)95653-M; MAKI LR, 1974, APPL MICROBIOL, V28, P456; MARPLE VA, 1991, AEROSOL SCI TECH, V14, P434, DOI 10.1080/02786829108959504; Miguel AG, 2006, AEROSOL SCI TECH, V40, P690, DOI 10.1080/02786820600798869; Mohler O, 2007, BIOGEOSCIENCES, V4, P1059; Mohler O, 2006, ATMOS CHEM PHYS, V6, P3007; Morris CE, 2013, ATMOS CHEM PHYS, V13, P4223, DOI 10.5194/acp-13-4223-2013; Morris CE, 2004, J PHYS IV, V121, P87, DOI 10.1051/jp4:2004121004; Morris CE, 2008, ISME J, V2, P321, DOI 10.1038/ismej.2007.113; Nikolcheva Liliya G., 2004, Mycological Progress, V3, P41, DOI 10.1007/s11557-006-0075-y; PACKE GE, 1985, LANCET, V2, P199; Paul PA, 2004, PHYTOPATHOLOGY, V94, P1342, DOI 10.1094/PHYTO.2004.94.12.1342; Pohlker C, 2012, ATMOS MEAS TECH, V5, P37, DOI 10.5194/amt-5-37-2012; Pohlker C, 2012, SCIENCE, V337, P1075, DOI 10.1126/science.1223264; Poschl U, 2010, SCIENCE, V329, P1513, DOI 10.1126/science.1191056; Pohlker C., 2013, ATMOS MEAS TECH DISC, V6, P5693, DOI DOI 10.5194/AMTD-6-5693-2013; Poschl U, 2005, ANGEW CHEM INT EDIT, V44, P7520, DOI 10.1002/anie.200501122; Pratt KA, 2009, NAT GEOSCI, V2, P397, DOI 10.1038/NGEO521; Prenni AJ, 2013, GEOPHYS RES LETT, V40, P227, DOI 10.1029/2012GL053953; Prenni AJ, 2009, NAT GEOSCI, V2, P401, DOI 10.1038/NGEO517; Pummer BG, 2012, ATMOS CHEM PHYS, V12, P2541, DOI 10.5194/acp-12-2541-2012; Richard C, 1996, PHYTOPROTECTION, V77, P83; Robinson NH, 2013, ATMOS MEAS TECH, V6, P337, DOI 10.5194/amt-6-337-2013; Rogers DC, 2001, J ATMOS OCEAN TECH, V18, P725, DOI 10.1175/1520-0426(2001)018<0725:ACFDCF>2.0.CO;2; Sands D.C., 1982, J HUNGARIAN METEOROL, V86, P148; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Schumacher C. J., 2013, ATMOS CHEM PHYS DISC, V13, P17123, DOI [10.5194/acpd-13-17123-2013, DOI 10.5194/ACPD-13-17123-2013]; Sesartic A, 2013, ENVIRON RES LETT, V8, DOI 10.1088/1748-9326/8/1/014029; Sinha BW, 2008, ATMOS CHEM PHYS, V8, P7217; STALEY JT, 1985, ANNU REV MICROBIOL, V39, P321, DOI 10.1146/annurev.mi.39.100185.001541; Sullivan RC, 2010, ATMOS CHEM PHYS, V10, P11471, DOI 10.5194/acp-10-11471-2010; Taylor PE, 2004, CURR ALLERGY ASTHM R, V4, P409, DOI 10.1007/s11882-004-0092-3; Taylor PE, 2004, CLIN EXP ALLERGY, V34, P1591, DOI 10.1111/j.1365-2222.2004.02078.x; Tobo Y., 2013, J GEOPHYS R IN PRESS; VALI G, 1971, J ATMOS SCI, V28, P402, DOI 10.1175/1520-0469(1971)028<0402:QEOERA>2.0.CO;2; WEISBURG WG, 1991, J BACTERIOL, V173, P697; White TJ, 1990, PCR PROTOCOLS GUIDE, P315, DOI DOI 10.1139/B07-071	89	72	73	13	128	COPERNICUS GESELLSCHAFT MBH	GOTTINGEN	BAHNHOFSALLEE 1E, GOTTINGEN, 37081, GERMANY	1680-7316			ATMOS CHEM PHYS	Atmos. Chem. Phys.		2013	13	13					6151	6164		10.5194/acp-13-6151-2013		14	Meteorology & Atmospheric Sciences	Meteorology & Atmospheric Sciences	182TL	WOS:000321767200003		
J	Bacharier, LB; Cohen, R; Schweiger, T; Yin-DeClue, H; Christie, C; Zheng, J; Schechtman, KB; Strunk, RC; Castro, M				Bacharier, Leonard B.; Cohen, Rebecca; Schweiger, Toni; Yin-DeClue, Huiquing; Christie, Chandrika; Zheng, Jie; Schechtman, Kenneth B.; Strunk, Robert C.; Castro, Mario			Determinants of asthma after severe respiratory syncytial virus bronchiolitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Bronchiolitis; respiratory syncytial virus; asthma; prospective cohort; CCL5	LONGITUDINAL BIRTH-COHORT; DAY-CARE ATTENDANCE; EARLY-CHILDHOOD; EARLY-LIFE; RSV BRONCHIOLITIS; ALLERGIC SENSITIZATION; PARENTAL HISTORY; DIAGNOSED ASTHMA; YOUNG-CHILDREN; 1ST YEAR	Background: The development of asthma after respiratory syncytial virus (RSV) bronchiolitis has been demonstrated in case-control studies, although the determinants of post-RSV asthma remain undefined. Objectives: We sought to evaluate the potential determinants of physician-diagnosed asthma after severe RSV bronchiolitis during infancy. Methods: We enrolled 206 children during an initial episode of severe RSV bronchiolitis at 12 months of age or less in a prospective cohort study and followed these children for up to 6 years. In a subset of 81 children, we analyzed CCL5 (RANTES) mRNA expression in upper airway epithelial cells. Results: Forty-eight percent of children had physician-diagnosed asthma before the seventh birthday. Independent determinants significantly associated with increased risk for physician-diagnosed asthma by the seventh birthday included maternal asthma (odds ratio [OR], 5.2; 95% CI, 1.7-15.9; P = .004), exposure to high levels of dog allergen (OR, 3.2; 95% CI, 1.3-7.7; P = .012), aeroallergen sensitivity at age 3 years (OR, 10.7; 95% CI, 2.1-55.0; P = .005), recurrent wheezing during the first 3 years of life (OR, 7.3; 95% CI, 1.2-43.3; P = .028), and CCL5 expression in nasal epithelia during acute RSV infection (OR, 3.8; 95% CI, 1.2-2.4; P < .001). White children (OR, 0.19; 95% CI, 0.04-0.93; P = .041) and children attending day care (OR, 0.18; 95% CI, 0.04-0.84; P = .029) had a decreased risk of physician-diagnosed asthma. Conclusions: Approximately 50% of children who experience severe RSV bronchiolitis have a subsequent asthma diagnosis. The presence of increased CCL5 levels in nasal epithelia at the time of bronchiolitis or the development of allergic sensitization by age 3 years are associated with increased likelihood of subsequent asthma. (J Allergy Clin Immunol 2012;130:91-100.)	[Cohen, Rebecca; Schweiger, Toni; Yin-DeClue, Huiquing; Christie, Chandrika; Castro, Mario] Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, St Louis, MO 63110 USA; [Bacharier, Leonard B.; Strunk, Robert C.] Washington Univ, Sch Med, Dept Pediat, Div Pediat Allergy Immunol & Pulm Med, St Louis, MO 63110 USA; [Zheng, Jie; Schechtman, Kenneth B.] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63110 USA; [Zheng, Jie; Schechtman, Kenneth B.] St Louis Childrens Hosp, St Louis, MO 63178 USA	Castro, M (reprint author), Washington Univ, Sch Med, Dept Internal Med, Div Pulm & Crit Care Med, Campus Box 8052,660 S Euclid, St Louis, MO 63110 USA.	castrom@wustl.edu		ZHENG, JIE/0000-0003-4958-2091	National Institutes of Health [HL 61895]; Asthmatx; Amgen; Ception/Cephalon; Genentech; MedImmune; Merck; National Institutes of Health; Novartis; GlaxoSmithKline	Supported by National Institutes of Health grant HL 61895.; Disclosure of potential conflict of interest: L. B. Bacharier is on the advisory board for AstraZeneca, has received honoraria from GlaxoSmithKline, and is on the advisory board and has received honoraria from Merck. M. Castro is a consultant and speaker for Asthmatx; is on the advisory board and is a speaker for Genentech; is a speaker for AstraZeneca, Merck, and GlaxoSmithKline; has received research support from Asthmatx, Amgen, Ception/Cephalon, Genentech, MedImmune, Merck, the National Institutes of Health, Novartis, and GlaxoSmithKline; and has received royalties from Elsevier. The rest of the authors declare that they have no relevant conflicts of interest.	Akinbami LJ, 2005, PEDIATRICS, V115, P1254, DOI 10.1542/peds.2004-0897; ALAM R, 1993, J IMMUNOL, V150, P3442; Alford SH, 2004, J ALLERGY CLIN IMMUN, V114, P1046, DOI 10.1016/j.jaci.2004.08.036; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804; Bjerg A, 2007, PEDIATRICS, V120, P741, DOI 10.1542/peds.2006-3742; Bradley JP, 2005, PEDIATRICS, V115, pE7, DOI 10.1542/peds.2004-0059; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Castro M, 2008, J ALLERGY CLIN IMMUN, V122, P726, DOI 10.1016/j.jaci.2008.07.010; Caudri D, 2009, AM J RESP CRIT CARE, V180, P491, DOI 10.1164/rccm.200903-0327OC; Celedon JC, 2002, ARCH PEDIAT ADOL MED, V156, P241; Dik N, 2004, CHEST, V126, P1147, DOI 10.1378/chest.126.4.1147; Finkelstein JA, 2000, PEDIATRICS, V106, P886; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543; Goetghebuer T, 2004, PEDIATR PULM, V38, P321, DOI 10.1002/ppul.20069; Goetghebuer T, 2004, CLIN EXP ALLERGY, V34, P801, DOI 10.1111/j.1365-2222.2004.01947.x; Henderson J, 2005, PEDIATR ALLERGY IMMU, V16, P386, DOI 10.1111/j.1399-3038.2005.00298.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Humbert M, 1997, AM J RESP CELL MOL, V16, P1; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Janssen R, 2007, J INFECT DIS, V196, P826, DOI 10.1086/520886; Jedrychowski W, 2008, INT J OCCUP MED ENV, V21, P111, DOI 10.2478/v10001-008-0013-0; Juntti H, 2003, ALLERGY, V58, P878, DOI 10.1034/j.1398-9995.2003.00233.x; Koga S, 1999, TRANSPLANTATION, V67, P854, DOI 10.1097/00007890-199903270-00012; Koponen P, 2012, EUR RESPIR J, V39, P76, DOI 10.1183/09031936.00040211; KORPPI M, 1994, ARCH PEDIAT ADOL MED, V148, P1079; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Leader S, 2002, PEDIATR INFECT DIS J, V21, P629, DOI 10.1097/01.inf.0000019891.59210.1c; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; MCCONNOCHIE KM, 1985, J PEDIATR-US, V107, P54, DOI 10.1016/S0022-3476(85)80614-4; McDaniel M, 2006, PEDIATRICS, V117, pE868, DOI 10.1542/peds.2005-1721; Miller JE, 2001, AM J EPIDEMIOL, V154, P245, DOI 10.1093/aje/154.3.245; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; Schauer U, 2002, EUR RESPIR J, V20, P1277, DOI 10.1183/09031936.02.00019902; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; SIGURS N, 1995, PEDIATRICS, V95, P500; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2; Sigurs N, 2000, AM J RESP CRIT CARE, V161, P1501; Sigurs N, 2010, THORAX, V65, P1045, DOI 10.1136/thx.2009.121582; Simon PA, 2003, J ASTHMA, V40, P535, DOI 10.1081/JAS-120018788; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Thomsen SF, 2009, AM J RESP CRIT CARE, V179, P1091, DOI 10.1164/rccm.200809-1471OC; Turner S, 2011, AM J RESP CRIT CARE, V184, P407, DOI 10.1164/rccm.201012-2075OC; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Wegienka G, 2011, CLIN EXP ALLERGY, V41, P979, DOI 10.1111/j.1365-2222.2011.03747.x; Werk LN, 2000, PEDIATRICS, V105, P585, DOI 10.1542/peds.105.3.585; Yoo KH, 2007, J ALLERGY CLIN IMMUN, V120, P1468, DOI 10.1016/j.jaci.2007.09.008	52	72	77	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2012	130	1					91	+		10.1016/j.jaci.2012.02.010		13	Allergy; Immunology	Allergy; Immunology	977GN	WOS:000306644800012	22444510	
J	Dimitroulopoulou, C				Dimitroulopoulou, C.			Ventilation in European dwellings: A review	BUILDING AND ENVIRONMENT			English	Review						Ventilation; Rates; Regulations; Health	VOLATILE ORGANIC-COMPOUNDS; INDOOR AIR-QUALITY; HOUSE-DUST; BUILDING CHARACTERISTICS; MECHANICAL VENTILATION; ALLERGIC SENSITIZATION; CATALAN DWELLINGS; YOUNG-CHILDREN; MITE ALLERGEN; LONG-TERM	Adequate ventilation is essential for the health and comfort of building occupants. This review examines, first of all, why residential ventilation is an issue of concern in Europe and how is related to the human health. A review of the current status of residential ventilation standards and regulations in Europe is also provided, as a reference. Finally, a review of measurements of ventilation rates in European dwellings is provided, where the compatibility with the European standards/regulations is examined. The review shows that ventilation is increasingly becoming recognised as an important component of a healthy dwelling. Ventilation requirements receive major attention in building regulations, across Europe. However, ventilation measurements across Europe show that ventilation is in practice often poor, resulting in reduced ventilation rates (lower than 0.5 h(-1), which is currently a standard in many European countries), increased concentrations of indoor pollutants and hence exposure to health risk. Surveys showed that although occupants generally think that ventilation is important, their understanding of the ventilation systems in their own houses is low, resulting to under-ventilated homes. (C) 2011 Elsevier Ltd. All rights reserved.	[Dimitroulopoulou, C.] Univ W Macedonia, Dept Mech Engn, Sialvera, Kozani, Greece; [Dimitroulopoulou, C.] Univ W Macedonia, Dept Mech Engn, Bakola, Kozani, Greece	Dimitroulopoulou, C (reprint author), Univ W Macedonia, Dept Mech Engn, Sialvera, Kozani, Greece.	sanidimi@gmail.com			European Union	This work was carried out as part of the EPHECT project. EPHECT is a European collaborative action, which has received funding from the European Union, in the framework of the Health Programme. The author would like to thank Prof. Peder Wolkoff, NCRWE, Denmark, for his constructive comments and for providing material for this review and Prof. Eduardo de Oliveira Fernandes, IDMEC-FEUP, Portugal, for his valuable comments.	Aaron SD, 2008, CAN MED ASSOC J, V179, P1121, DOI 10.1503/cmaj.081332; Aizlewood C, 2006, INDOOR BUILT ENVIRON, V15, P393, DOI 10.1177/1420326X06069578; Akimenko W, 1984, IND AIR 84 STOCKH, P6; Andersen CE, 1997, INDOOR AIR, V7, P278, DOI 10.1111/j.1600-0668.1997.00007.x; Andriessen JW, 1998, CLIN EXP ALLERGY, V28, P1191; Boxem G, 2008, IND AIR 2008 17 22 A; Beko G, 2010, BUILD ENVIRON, V45, P2289, DOI 10.1016/j.buildenv.2010.04.014; Beko G, 2011, BUILD ENVIRON, V46, P2230, DOI 10.1016/j.buildenv.2011.05.002; Bergsoe NC, 1991, 213 SBI NAT I BUILD; BIA, 2001, 32001 BIA HVBG; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bornehag CG, 2005, INDOOR AIR, V15, P275, DOI 10.1111/j.1600-0668.2005.00372.x; Bornehag CG, 2004, INDOOR AIR, V14, P59, DOI 10.1111/j.1600-0668.2004.00274.x; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; BRE, 1985, 297 BRE; BRE, 1989, 162 BRE; CEN-European Committee for Standardization, 2010, EUR COMM STAND; Charvat P, 2008, 63 AIVC INT EN AG; Coelho C, 2005, INDOOR AIR, V15, P267, DOI 10.1111/j.1600-0668.2005.00371.x; Concannon P., 2002, 57 AIVC; Crump D, 2009, INDOOR AIR QUALITY H; Dales R, 2004, J ASTHMA, V41, P259, DOI 10.1081/JAS-120026082; De Brouwere K, 2009, Q INTAIR MODELLERING; de Gids WF, 2004, ONDERZOEK NAAR VENTI; Deroubaix P, 2009, AIR, V30; Dimitroulopoulou C., 2005, VENTILATION AIR TIGH; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Emenius C, 1998, CLIN EXP ALLERGY, V28, P1389; Emenius G, 2004, ACTA PAEDIATR, V93, P899, DOI 10.1080/08035250410025582; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; Engvall K, 2005, INDOOR AIR, V15, P120, DOI 10.1111/j.1600-0668.2004.00325.x; Feist W, 2005, ENERG BUILDINGS, V37, P1186, DOI 10.1016/j.enbuild.2005.06.020; Feist W, 2000, RECOMMENDATION INSID; Feist W., 2007, PASSIVE HOUSE PLANNI; Feist W., 2001, 36 CEPHEUS; Fernandes EO, 2011, COMMUNICATION; Grimsrud D, 2000, P HLTH BUILDINGS, P9; Hagerhed-Engman L, 2009, INDOOR AIR, V19, P184, DOI 10.1111/j.1600-0668.2008.00573.x; Hanninen OO, 2004, ATMOS ENVIRON, V38, P6411, DOI 10.1016/j.atmosenv.2004.07.015; Hasselaar E, 2002, VENTILATIE PRAKTIJK; Heinrich J, 2011, INT J HYG ENVIR HEAL, V214, P3, DOI 10.1016/j.ijheh.2010.08.009; Henderson M, 2007, APPROACHING NET ZERO; Heseltine E., 2009, WHO GUIDELINES INDOO; Hodgson M, 2002, ENVIRON HEALTH PERSP, V110, P663; Holm L, 1999, ALLERGY, V54, P708, DOI 10.1034/j.1398-9995.1999.00010.x; Holme J, 2010, INDOOR AIR, V20, P329, DOI 10.1111/j.1600-0668.2010.00658.x; Jaakkola JJK, 2008, ENVIRON HEALTH PERSP, V116, P845, DOI 10.1289/ehp.10846; Jacob B, 2002, ENVIRON HEALTH PERSP, V110, P647; Johnson L, 2009, ALLERGY ASTHMA PROC, V30, P377, DOI 10.2500/aap.2009.30.3257; Kirchner S, 2006, NATL SURVEY INDOOR A; Krooss J, 1997, GEFAHRST REINHALT L, V57, P357; Kurnitski J, 2007, P 2 EUR BLOW DOOR S, P152; Kurnitski J, 2008, TRENDS DRIVERS FINNI; Kvisgaard B, 1990, AIR CHANGE RATE AIRT; Liddament M. W, 2001, 53 AIVC; LIDDAMENT M. W., 1996, GUIDE ENERGY EFFICIE; Limb MJ, 1995, ANNOTATED BIBLIOGRAP; Lucas JP, 2009, DESESB2009037 CSTB; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; MAILAHN W, 1989, ENVIRON INT, V15, P537, DOI 10.1016/0160-4120(89)90073-1; McWilliams J, 2007, ANNOTATED BIBLIO, V13; Missia DA, 2010, ATMOS ENVIRON, V44, P4388, DOI 10.1016/j.atmosenv.2010.07.049; Montoya MI, 2011, BUILD ENVIRON, V46, P2003, DOI 10.1016/j.buildenv.2011.04.009; Montoya MI, 2010, BUILD ENVIRON, V45, P1458, DOI 10.1016/j.buildenv.2009.12.009; Nielsen GD, 2007, INDOOR AIR, V17, P236, DOI 10.1111/j.1600-0668.2006.00468.x; Oie L, 1998, INDOOR AIR, V8, P190, DOI 10.1111/j.1600-0668.1998.t01-1-00006.x; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Parfitt Y, 1985, 17 AIC; Pinto M, 2006, AIVC 27 C 2006 EPIC2, V3, P761; Ruotsalainen R., 1992, INDOOR AIR, V2, P137, DOI 10.1111/j.1600-0668.1992.02-23.x; Ruotsalainen R, 1991, INDOOR AIR, V4, P428; Santamouris M, 2007, INT J VENT, V5, P367; Schild PG, 2007, 07 AIR INF VENT CTR; SEIFERT B, 1989, ENVIRON INT, V15, P397, DOI 10.1016/0160-4120(89)90054-8; Seifert B, 2000, P HLTH BUILD 2000 SL, V4, P3; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; Seppanen OA, 2004, INDOOR AIR, V14, P102, DOI 10.1111/j.1600-0668.2004.00279.x; Sfakianaki A, 2008, BUILD ENVIRON, P398; Spertini F, 2010, ALLERGY, V65, P623, DOI 10.1111/j.1398-9995.2009.02230.x; STYMNE H, 1994, BUILD ENVIRON, V29, P373, DOI 10.1016/0360-1323(94)90037-X; SUNDELL J, 1995, ALLERGY, V50, P106; Sundell J, 1994, INDOOR AIR S2, P94; Ucci M.RidleyI, 2004, 2 WHO INT HOUS HLTH; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.0.CO;2-2; van der Wal J.F., 1991, INDOOR AIR, V1, P621; Visser CA, 2010, PEDIAT PULMONOL, V45, P156; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x; Warner A, 1999, ALLERGY, V54, P681, DOI 10.1034/j.1398-9995.1999.00850.x; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; World Health Organization, 1989, 111 WHO; Wichmann J, 2010, ATMOS ENVIRON, V44, P4536, DOI 10.1016/j.atmosenv.2010.08.023; Wolkoff P, 2008, ENVIRON INT, V34, P1204, DOI 10.1016/j.envint.2008.04.005; Wright GR, 2009, ALLERGY, P1671; Yoshino H, 2004, AIVC 25 C VENT RETR, P227; Yu C, 2002, 208098 BRE; Zuraimi M.S., 2011, PEDIAT ALLERGY IMMUN, V22, P112	96	72	73	5	65	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0360-1323			BUILD ENVIRON	Build. Environ.	JAN	2012	47						109	125		10.1016/j.buildenv.2011.07.016		17	Construction & Building Technology; Engineering, Environmental; Engineering, Civil	Construction & Building Technology; Engineering	830MW	WOS:000295662100014		
J	Kuhlthau, KA; Bloom, S; Van Cleave, J; Knapp, AA; Romm, D; Klatka, K; Homer, CJ; Newacheck, PW; Perrin, JM				Kuhlthau, Karen A.; Bloom, Sheila; Van Cleave, Jeanne; Knapp, Alixandra A.; Romm, Diane; Klatka, Kirsten; Homer, Charles J.; Newacheck, Paul W.; Perrin, James M.			Evidence for Family-Centered Care for Children With Special Health Care Needs: A Systematic Review	ACADEMIC PEDIATRICS			English	Review						children with special health care needs; family-centered care	MEDICAL HOME; NATIONAL-SURVEY; MENTAL-HEALTH; ASTHMA; SERVICES; OUTCOMES; SATISFACTION; PHYSICIANS; INSURANCE; EDUCATION	OBJECTIVE: Family-centered care (FCC) has received widespread endorsement for use in care in the United States. In this study, we conducted a systematic review of evidence for FCC focusing specifically on family-provider partnership as the activity that constitutes FCC. METHODS: We found and reviewed articles from the medical, nursing, psychology, and sociology literature spanning 1986 to 2010. We also reviewed articles obtained through related references and through recommendations from key informants. Four sets of terms were used to search, including FCC, child/adolescent, children with special health care needs (CSHCN, defined broadly or by condition), and a relevant outcome. RESULTS: Twenty-four studies met the review criteria. Eight were cross-sectional studies from the National Survey of Children With Special Health Care Needs, and 7 were reports of randomized, controlled trials. Of the 24 articles reviewed, 13 examined populations of CSHCN or similar populations, 6 examined children with asthma, and the remaining studied children with other specific conditions. We found positive associations of FCC with improvements in efficient use of services, health status, satisfaction, access to care, communication, systems of care, family functioning, and family impact/cost. There was little available evidence, however, for some outcomes, including cost and transition. CONCLUSIONS: The available evidence suggests that FCC is associated with improved outcomes for CSHCN. With positive findings for most of the studies reviewed here and the compelling arguments for FCC, we recommend the use of this approach by individuals and organizations.	[Kuhlthau, Karen A.; Bloom, Sheila; Van Cleave, Jeanne; Knapp, Alixandra A.; Romm, Diane; Klatka, Kirsten; Perrin, James M.] MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, Boston, MA 02114 USA; [Kuhlthau, Karen A.; Van Cleave, Jeanne; Perrin, James M.] Harvard Univ, Sch Med, Boston, MA USA; [Homer, Charles J.] Natl Initiat Child Healthcare Qual, Boston, MA USA; [Newacheck, Paul W.] Univ Calif San Francisco, Inst Hlth Policy Studies, San Francisco, CA 94143 USA; [Newacheck, Paul W.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	Kuhlthau, KA (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Policy, 50 Staniford St,Ste 901, Boston, MA 02114 USA.	kkuhlthau@partners.org			Maternal and Child Health Bureau [5 U53MC04473-03-00]	We thank our funders at the Maternal and Child Health Bureau, cooperative agreement 5 U53MC04473-03-00, members of our advisory group, and Jill Hurson.	Baruffi G, 2005, MATERN CHILD HLTH J, V9, pS99, DOI 10.1007/s10995-005-3861-2; Blumberg Stephen J, 2009, Pediatrics, V124 Suppl 4, pS361, DOI 10.1542/peds.2009-1255F; Clark NM, 2000, EUR RESPIR J, V16, P15, DOI 10.1034/j.1399-3003.2000.16a04.x; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Committee on Hospital Care American Academy of Pediatrics, 2013, PEDIATRICS 1, V112, P691; Coulter A, 2007, BRIT MED J, V335, P24, DOI 10.1136/bmj.39246.581169.80; Denboba D, 2006, PEDIATRICS, V118, P1607, DOI 10.1542/peds.2006-0383; Downs SH, 1998, J EPIDEMIOL COMMUN H, V52, P377; *FAM CTR CAR, FAM CTR CAR SELF ASS; Farmer JE, 2005, PEDIATRICS, V116, P649, DOI 10.1542/peds.2004-0647; Frost M, 2010, J PEDIATR NURS, V25, P144, DOI 10.1016/j.pedn.2009.09.001; Gavin LA, 1999, J PEDIATR PSYCHOL, V24, P355, DOI 10.1093/jpepsy/24.4.355; Guendelman S, 2002, ARCH PEDIAT ADOL MED, V156, P114; Hoagwood KE, 2005, J CHILD PSYCHOL PSYC, V46, P690, DOI 10.1111/j.1469-7610.2005.01451.x; *I FAM CTR CAR, ADV PRACT PAT FAM CT; JESSOP DJ, 1994, PEDIATRICS, V93, P602; Mangione-Smith R, 2005, AMBUL PEDIATR, V5, P75, DOI 10.1367/A04-106R.1; McPherson M, 1998, PEDIATRICS, V102, P137, DOI 10.1542/peds.102.1.137; *NAT CTR CULT COMP, 2007, GUID ADV FAM CTR CUL; Ngui EM, 2006, PEDIATRICS, V117, P1184, DOI 10.1542/peds.2005-1088; Nilsen E S, 2006, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD004563.PUB2; Owens Julie Sarno, 2005, J Atten Disord, V9, P261, DOI 10.1177/1087054705279299; Palfrey JS, 2004, PEDIATRICS, V113, P1507; Perrin JM, 2007, ARCH PEDIAT ADOL MED, V161, P933, DOI 10.1001/archpedi.161.10.933; Seal P., 2005, PEDIATRICS, V115, P1607; Sia CJ, 2002, PEDIATRICS, V110, P184; Smaldone A, 2005, MATERN CHILD HLTH J, V9, pS75, DOI 10.1007/s10995-005-3859-9; STEIN REK, 1991, PEDIATRICS, V88, P490; Stille C, 2010, ACAD PEDIATR, V10, P211, DOI 10.1016/j.acap.2010.05.002; van Dyck PC, 2002, AMBUL PEDIATR, V2, P29, DOI 10.1367/1539-4409(2002)002<0029:TNSOCW>2.0.CO;2; Van Riper M, 1999, RES NURS HEALTH, V22, P357, DOI 10.1002/(SICI)1098-240X(199910)22:5<357::AID-NUR2>3.0.CO;2-Q; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57; Wang G, 2007, MATERN CHILD HLTH J, V11, P559, DOI 10.1007/s10995-007-0200-9; Weiland Jeanne, 2003, J Pediatr Health Care, V17, P284, DOI 10.1016/S0891-5245(03)00109-3; Wissow LS, 1998, MED CARE, V36, P1439, DOI 10.1097/00005650-199810000-00002; Wolraich Mark L, 2005, J Atten Disord, V9, P354, DOI 10.1177/1087054705278834; Young MC, 2005, MATERN CHILD HLTH J, V9, pS49, DOI 10.1007/s10995-005-4748-y; ADV PRACTICE PATIENT; ACHIEVING MEASURING	39	72	73	5	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1876-2859			ACAD PEDIATR	Acad. Pediatr.	MAR-APR	2011	11	2					136	143				8	Pediatrics	Pediatrics	736WO	WOS:000288525900012	21396616	
J	Wilson, KM; Klein, JD; Blumkin, AK; Gottlieb, M; Winickoff, JP				Wilson, Karen M.; Klein, Jonathan D.; Blumkin, Aaron K.; Gottlieb, Mark; Winickoff, Jonathan P.			Tobacco-Smoke Exposure in Children Who Live in Multiunit Housing	PEDIATRICS			English	Article						secondhand smoke; passive smoking; environmental tobacco smoke; multiunit housing; apartment	SECONDHAND SMOKE; THIRDHAND-SMOKE; UNITED-STATES; US CHILDREN; NICOTINE; ASSOCIATION; ASTHMA; HOME; ADOLESCENTS; DUST	OBJECTIVE: There is no safe level of secondhand tobacco-smoke exposure, and no previous studies have explored multiunit housing as a potential contributor to secondhand tobacco-smoke exposure in children. We hypothesized that children who live in apartments have higher cotinine levels than those who live in detached homes, when controlling for demographics. METHODS: We analyzed data from the 2001-2006 National Health and Nutrition Examination Survey. The housing types we included in our study were detached houses (including mobile homes), attached houses, and apartments. Our study subjects were children between the ages of 6 and 18 years. Cotinine levels were used to assess secondhand tobacco-smoke exposure, and those living with someone who smoked inside the home were excluded. chi(2) tests, t tests, and Tobit regression models were used in Stata. Sample weights accounted for the complex survey design. RESULTS: Of 5002 children in our study, 73% were exposed to secondhand tobacco smoke. Children living in apartments had an increase in cotinine of 45% over those living in detached houses. This increase was 212% (P < .01) for white residents and 46% (P < .03) for black residents, but there was no significant increase for those of other races/ethnicities. At every cutoff level of cotinine, children in apartments had higher rates of exposure. The exposure effect of housing type was most pronounced at lower levels of cotinine. CONCLUSIONS: Most children without known secondhand tobacco-smoke exposure inside the home still showed evidence of tobacco-smoke exposure. Children in apartments had higher mean cotinine levels than children in detached houses. Potential causes for this result could be seepage through walls or shared ventilation systems. Smoking bans in multiunit housing may reduce children's exposure to tobacco smoke. Pediatrics 2011;127:85-92	[Wilson, Karen M.; Klein, Jonathan D.; Blumkin, Aaron K.] Univ Rochester, Dept Pediat, Rochester, NY 14642 USA; [Wilson, Karen M.; Klein, Jonathan D.; Gottlieb, Mark; Winickoff, Jonathan P.] Amer Acad Pediat, Julius B Richmond Ctr Excellence, Elk Grove Village, IL USA; [Gottlieb, Mark] Northeastern Univ, Publ Hlth Advocacy Inst, Sch Law, Boston, MA 02115 USA; [Winickoff, Jonathan P.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp Children, Boston, MA 02115 USA	Wilson, KM (reprint author), Univ Rochester, Dept Pediat, 601 Elmwood Ave,Box 777, Rochester, NY 14642 USA.	karen_wilson@urmc.rochester.edu		Gottlieb, Mark/0000-0001-8679-307X	Julius B. Richmond Center of Excellence of the American Academy of Pediatrics through Flight Attendant Medical Research Institute; Julius B. Richmond Center of Excellence, American Academy of Pediatrics; Flight Attendant Medical Research Institute; Legacy Foundation	This study was funded by the Julius B. Richmond Center of Excellence of the American Academy of Pediatrics through a grant from the Flight Attendant Medical Research Institute. Drs Wilson, Klein, Winickoff, and Gottlieb receive support from the Julius B. Richmond Center of Excellence, American Academy of Pediatrics; the Flight Attendant Medical Research Institute; and from the Legacy Foundation. All of the authors contributed substantially to this work and approved of the final draft as submitted. Mr Blumkin is the programmer/analyst for the study and had full access to all the data provided by the NHANES; and Dr Wilson is the lead author of the study. They both take full responsibility for the accuracy of the data analysis.	Baker RJ, 2006, ENVIRON HEALTH PERSP, V114, P1126, DOI 10.1289/ehp.8501; BATES N, 2007, SEGMENTING POPULATIO; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188; Benowitz NL, 2002, NICOTINE TOB RES, V4, P149, DOI DOI 10.1080/14622200210123581; Braun JM, 2008, ENVIRON HEALTH PERSP, V116, P956, DOI 10.1289/ehp.11177; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; The Center for Social Gerontology, SMOK FREE ENV LAW PR; Ellis JA, 2009, NICOTINE TOB RES, V11, P362, DOI 10.1093/ntr/ntp021; Farber HJ, 2008, CHEST, V133, P1367, DOI 10.1378/chest.07-2369; Flouris AD, 2009, AM J RESP CRIT CARE, V179, P1029, DOI 10.1164/rccm.200812-1920OC; HUGHES CJ, SOME SMOKERS EVEN HO; Kallio K, 2007, CIRCULATION, V115, P3205, DOI 10.1161/CIRCULATIONAHA.106.674804; Kaufmann R. B., 2010, Morbidity and Mortality Weekly Report, V59, P1141; Klepeis NE, 2007, J AIR WASTE MANAGE, V57, P522, DOI 10.3155/1047-3289.57.5.522; Kline RL, 2000, TOB CONTROL, V9, P201, DOI 10.1136/tc.9.2.201; Kraev TA, 2009, TOB CONTROL, V18, P438, DOI 10.1136/tc.2009.029728; Matt GE, 2004, TOB CONTROL, V13, P29, DOI 10.1136/tc.2003.003889; Matt GE, 2008, NICOTINE TOB RES, V10, P1467, DOI 10.1080/14622200802279898; Menzies D, 2006, JAMA-J AM MED ASSOC, V296, P1742, DOI 10.1001/jama.296.14.1742; Moritsugu KP, 2007, AM J PREV MED, V32, P542, DOI 10.1016/j.amepre.2007.02.026; Prandota Joseph, 2004, Am J Ther, V11, P517, DOI 10.1097/01.mjt.0000140648.30948.bd; Siegmund B, 1999, J AGR FOOD CHEM, V47, P3113, DOI 10.1021/jf990089w; Singer BC, 2002, ENVIRON SCI TECHNOL, V36, P846, DOI 10.1021/es011058w; Sleiman M, 2010, P NATL ACAD SCI USA, V107, P6576, DOI 10.1073/pnas.0912820107; Spengler JD, 1999, ENVIRON HEALTH PERSP, V107, P313, DOI 10.2307/3434423; *STAT CORP, 2007, STAT STAT SOFTW COMP; Teach SJ, 2006, PEDIATRICS, V117, pS78, DOI 10.1542/peds.2005-2000E; Thorne S. L., 2008, Morbidity and Mortality Weekly Report, V57, P1221; TOBIN J, 1958, ECONOMETRICA, V26, P24, DOI 10.2307/1907382; US Department of Health and Human Services, SURG GEN CALL ACT PR; *US DEP HOUS URB D, PIH200921 US DEP HOU; Van Loy MD, 2001, ENVIRON SCI TECHNOL, V35, P560, DOI 10.1021/es001372a; Weitzman M, 2005, CIRCULATION, V112, P862, DOI 10.1161/CIRCULATIONAHA.104.520650; WHITAKER D, KING COUNTY HLTH BOA; Whitehead T, 2009, AM J EPIDEMIOL, V169, P1113, DOI 10.1093/aje/kwp021; Winickoff JP, 2010, NEW ENGL J MED, V362, P2319, DOI 10.1056/NEJMhle1000941; Winickoff JP, 2009, PEDIATRICS, V123, pE74, DOI 10.1542/peds.2008-2184; YATES D, BELMONT BE 1 US CITY; Yolton K, 2005, ENVIRON HEALTH PERSP, V113, P98	39	72	75	2	24	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JAN	2011	127	1					85	92		10.1542/peds.2010-2046		8	Pediatrics	Pediatrics	700YT	WOS:000285782200049	21149434	
J	Uller, L; Leino, M; Bedke, N; Sammut, D; Green, B; Lau, L; Howarth, PH; Holgate, ST; Davies, DE				Uller, Lena; Leino, Marina; Bedke, Nicole; Sammut, David; Green, Ben; Lau, Laurie; Howarth, Peter H.; Holgate, Stephen T.; Davies, Donna E.			Double-stranded RNA induces disproportionate expression of thymic stromal lymphopoietin versus interferon-beta in bronchial epithelial cells from donors with asthma	THORAX			English	Article							MEDIATED ALLERGIC INFLAMMATION; TOLL-LIKE RECEPTOR-3; RHINOVIRUS INFECTION; VIRAL-INFECTIONS; PROTEIN-KINASE; IN-VITRO; EXACERBATIONS; CHEMOKINES; DISEASE; PHENOTYPE	Background Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that strongly activates dendritic cells and can initiate allergic inflammation. Since exposure to rhinovirus or double-stranded (ds) RNA (a surrogate of viral infection) induces TSLP expression in bronchial epithelial cells (BECs), this cytokine may link innate antiviral responses and the type 2 adaptive immune response. Objective As BECs from donors with asthma have a deficient interferon (IFN) response to rhinovirus infection, a study was undertaken to test the hypothesis that their antiviral response shows a bias towards TSLP production. Methods Primary BECs were grown from subjects with asthma and healthy volunteers. After exposure to dsRNA, interleukin (IL)-8, IFN beta and TSLP mRNA and protein expression were measured by RT-qPCR and ELISA, respectively. Results dsRNA dose-dependently increased IL-8 expression in BECs with no significant difference between the groups. However, BECs from subjects with asthma expressed less IFN beta and more TSLP mRNA and protein in response to dsRNA than BECs from those without asthma (median (IQR) 57 (38-82) pg/ml vs 106 (57-214) pg/ml for IFN beta (p<0.05) and 114 (86-143) pg/ml vs 65 (32-119) pg/ml for TSLP (p<0.05) in response to 10 mu g/ml dsRNA for 24 h). Induction of TSLP mRNA by dsRNA was blocked by Toll-like receptor 3 or protein kinase inhibitors or by preventing de novo protein synthesis, but not by neutralisation of type I IFN receptors. Conclusion BECs from subjects with asthma are biased towards higher TSLP and lower IFN beta production in response to dsRNA, suggesting that viral infection in asthma may lead to an altered mediator profile that biases towards a Th2 immune response.	[Uller, Lena; Leino, Marina; Bedke, Nicole; Sammut, David; Green, Ben; Lau, Laurie; Howarth, Peter H.; Holgate, Stephen T.; Davies, Donna E.] Univ Southampton, Sch Med, Div Infect Inflammat & Repair, Brooke Labs, Southampton, Hants, England	Uller, L (reprint author), Southampton Gen Hosp, Sir Henry Wellcome Labs, Brooke Labs, Mailpoint 810,Level F,South Block, Southampton SO16 6YD, Hants, England.	lena.uller@med.lu.se	Davies, Donna/H-2993-2012		Medical Research Council (MRC) UK; Swedish Medical Research Council; Swedish Heart-Lung Foundation; VINNOVA	Medical Research Council (MRC) UK, Swedish Medical Research Council, Swedish Heart-Lung Foundation and VINNOVA.	Allakhverdi Z, 2007, J EXP MED, V204, P253, DOI 10.1084/jem.20062211; Bengtson SH, 2007, INT IMMUNOPHARMACOL, V7, P1880, DOI 10.1016/j.intimp.2007.07.002; Bochkov YA, 2010, MUCOSAL IMMUNOL, V3, P69, DOI 10.1038/mi.2009.109; Chu JJH, 2003, J GEN VIROL, V84, P3305, DOI 10.1099/vir.0.19447-0; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; de Bouteiller O, 2005, J BIOL CHEM, V280, P38133, DOI 10.1074/jbc.M507163200; Garcia MA, 2007, BIOCHIMIE, V89, P799, DOI 10.1016/j.biochi.2007.03.001; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159; Gern JE, 2003, AM J RESP CELL MOL, V28, P731, DOI 10.1165/rcmb.2002-0055OC; Heinecke L, 2008, J ALLERGY CLIN IMMUN, V121, P1155, DOI 10.1016/j.jaci.2008.02.009; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holgate ST, 2007, TRENDS IMMUNOL, V28, P248, DOI 10.1016/j.it.2007.04.007; Jammi NV, 2003, BIOCHEM BIOPH RES CO, V308, P50, DOI 10.1016/S0006-291X(03)01318-4; Jartti T, 2008, EUR RESPIR J, V32, P314, DOI 10.1183/09031936.00161907; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kato A, 2007, J IMMUNOL, V179, P1080; Konno S, 2002, AM J RESP CELL MOL, V26, P594; Lee HC, 2007, P NATL ACAD SCI USA, V104, P914, DOI 10.1073/pnas.0607305104; Liu YJ, 2006, J EXP MED, V203, P269, DOI 10.1084/jem.20051745; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Longhi MP, 2009, J EXP MED, V206, P1589, DOI 10.1084/jem.20090247; Lopez-Souza N, 2009, J ALLERGY CLIN IMMUN, V123, P1384, DOI 10.1016/j.jaci.2009.03.010; Lordan JL, 2002, J IMMUNOL, V169, P407; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Rate A, 2009, J IMMUNOL, V182, P72; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Tanaka J, 2009, CLIN EXP ALLERGY, V39, P89, DOI 10.1111/j.1365-2222.2008.03151.x; Wang J, 2008, CELL MOL IMMUNOL, V5, P99; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wark PAB, 2007, J ALLERGY CLIN IMMUN, V120, P586, DOI 10.1016/j.jaci.2007.04.046; Wark PAB, 2009, RESPIROLOGY, V14, P180, DOI 10.1111/j.1440-1843.2009.01480.x; Ying S, 2005, J IMMUNOL, V174, P8183; Ying S, 2008, J IMMUNOL, V181, P2790	35	72	72	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUL	2010	65	7					626	632		10.1136/thx.2009.125930		7	Respiratory System	Respiratory System	624GY	WOS:000279806400014	20627922	
J	Midoro-Horiuti, T; Tiwari, R; Watson, CS; Goldblum, RM				Midoro-Horiuti, Terumi; Tiwari, Ruby; Watson, Cheryl S.; Goldblum, Randall M.			Maternal Bisphenol A Exposure Promotes the Development of Experimental Asthma in Mouse Pups	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						airway hyperresponsiveness; asthma; bisphenol A; environmental estrogen; eosinophilia; experimental asthma; IgE; maternal exposure; perinatal sensitization	TANDEM MASS-SPECTROMETRY; SOLID-PHASE EXTRACTION; T-CELL RESPONSES; BREAST-MILK; EARLY-LIFE; ENDOCRINE DISRUPTORS; IMMUNE-SYSTEM; CORD-BLOOD; ER-ALPHA; MICE	BACKGROUND: We recently reported that various environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators in vitro. OBJECTIVES: We hypothesized that environmental estrogens Would enhance allergic sensitization as well as bronchial inflammation and responsiveness. To test this hypothesis, we exposed fetal and neonatal mice to the common environmental estrogen bisphenol A (BPA) via maternal loading and assessed the pups' response to allergic sensitization and bronchial challenge. METHODS: Female BALB/c mice received 10 mu g/mL BPA in their drinking water from I week before impregnation to the end of the study. Neonatal mice were given a single 5 mu g intraperitoneal dose of ovalbumin (OVA) with aluminum hydroxide on postnatal day 4 and 3% OVA by nebulization for 10 ruin on days 13, 14, and 15. Forty-eight hours after the last nebulization, we assessed serum IgE antibodies to OVA by enzyme-linked immunosorbent assay (ELISA) and airway inflammation and hyperresponsiveness by enumerating eosinophils in bronchoalveolar lavage fluid, whole-body barometric plethysmography, and a forced oscillation technique. RESULTS: Neonates from BPA-exposed mothers responded to this "suboptimal" sensitization with higher serum IgE anti-OVA concentrations compared with those from unexposed mothers (p < 0.05), and eosinophilic inflammation in their airways was significantly greater. Airway responsiveness of the OVA-sensitized neonates from BPA-treated mothers was enhanced compared with those from unexposed mothers (P < 0.05). CONCLUSIONS: Perinatal exposure to BPA enhances allergic sensitization and bronchial inflammation and responsiveness in a Susceptible animal model of asthma.	[Midoro-Horiuti, Terumi; Tiwari, Ruby; Goldblum, Randall M.] Univ Texas Med Branch, Child Hlth Res Ctr, Dept Pediat, Galveston, TX 77555 USA; [Midoro-Horiuti, Terumi; Watson, Cheryl S.; Goldblum, Randall M.] Univ Texas Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA	Midoro-Horiuti, T (reprint author), Univ Texas Med Branch, Child Hlth Res Ctr, Childrens Hosp, Room 2-300,301 Univ Blvd, Galveston, TX 77555 USA.	tmidoro@utmb.edu			National Institute of Environmental Health Sciences [R21 ES016428]; National Institute of Allergy and Infectious Diseases [K08 AI1055792, R01 AI1052428]	This project was supported by grain R21 ES016428 from the National Institute of Environmental Health Sciences (T.M.H.) and by grants K08 AI1055792 (T. M. H.) and R01 AI1052428 (R.M.G.) front the National Institute of Allergy and Infectious Diseases.	Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Allam JP, 2005, ALLERGY, V60, P743, DOI 10.1111/j.1398-9995.2005.00815.x; ANDERSON SC, 2003, ANDERSON ATLAS HEMAT, P57; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Castro SM, 2006, AM J RESP CRIT CARE, V174, P1361, DOI 10.1164/rccm.200603-319OC; Curran EM, 2004, CLIN EXP IMMUNOL, V135, P219, DOI 10.1111/j.1365-2249.2004.02368.x; DEWAILLY E, 1993, ENVIRON HEALTH PERSP, V101, P618, DOI 10.2307/3431646; Dirtu AC, 2008, ANAL BIOANAL CHEM, V391, P1175, DOI 10.1007/s00216-007-1807-9; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Fernandez MF, 2007, REPROD TOXICOL, V24, P259, DOI 10.1016/j.reprotox.2007.06.007; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Iwata M, 2004, IMMUNOL LETT, V94, P135, DOI 10.1016/j.imlet.2004.04.013; Johnson CC, 1996, CLIN EXP ALLERGY, V26, P624, DOI 10.1111/j.1365-2222.1996.tb00588.x; Kabuto H, 2004, LIFE SCI, V74, P2931, DOI 10.1016/j.lfs.2003.07.060; Kim YH, 2003, BIOCHEM BIOPH RES CO, V312, P441, DOI 10.1016/j.bbrc.2003.10.135; King CL, 1998, J IMMUNOL, V160, P3578; Kuroda N, 2003, J PHARMACEUT BIOMED, V30, P1743, DOI 10.1016/S0731-7085(02)00516-2; Lambert KC, 2005, J IMMUNOL, V175, P5716; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Leme AS, 2006, J IMMUNOL, V176, P762; McCoy L, 2005, J ASTHMA, V42, P757, DOI 10.1080/02770900500308189; Nakano N, 2009, J ALLERGY CLIN IMMUN, V123, P74, DOI 10.1016/j.jaci.2008.10.040; Narita S, 2007, ENVIRON HEALTH PERSP, V115, P48, DOI 10.1289/ehp.9378; Ohshima Y, 2007, PEDIATR RES, V62, P60, DOI 10.1203/PDR.0b013e3180674dae; Padmanabhan V, 2008, J PERINATOL, V28, P258, DOI 10.1038/sj.jp.7211913; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Sayed BA, 2007, IMMUNOL REV, V217, P53, DOI 10.1111/j.1600-065X.2007.00524.x; Schonfelder G, 2002, ENVIRON HEALTH PERSP, V110, pA703; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Siegrist CA, 2001, VACCINE, V19, P3331, DOI 10.1016/S0264-410X(01)00028-7; Solomon GM, 2002, ENVIRON HEALTH PERSP, V110, pA339; Sudowe S, 1997, IMMUNOLOGY, V91, P464, DOI 10.1046/j.1365-2567.1997.00268.x; Sun Y, 2004, BIOMED CHROMATOGR, V18, P501, DOI 10.1002/bmc.345; Tsukioka T, 2003, ANAL SCI, V19, P151, DOI 10.2116/analsci.19.151; Volkel W, 2005, DRUG METAB DISPOS, V33, P1748, DOI 10.1124/dmd.105.005454; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079; Wang SL, 2004, CHEMOSPHERE, V54, P1459, DOI 10.1016/j.chemosphere.2003.08.012; Watson CS, 2001, INT IMMUNOPHARMACOL, V1, P1049, DOI 10.1016/S1567-5769(01)00036-4; Yang LS, 2006, MOL IMMUNOL, V43, P357, DOI 10.1016/j.molimm.2005.02.012; Ye XY, 2005, ANAL BIOANAL CHEM, V383, P638, DOI 10.1007/s00216-005-0019-4; Zaitsu M, 2007, MOL IMMUNOL, V44, P1987	44	72	77	0	9	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	FEB	2010	118	2					273	277		10.1289/ehp.0901259		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	555BQ	WOS:000274482400030	20123615	
J	Boulet, LP				Boulet, L-P.			Influence of comorbid conditions on asthma	EUROPEAN RESPIRATORY JOURNAL			English	Review						Asthma comorbidities; gastro-oesophageal reflux disease; glottic dysfunction; obesity; obstructive sleep apnoea; rhinitis/sinusitis	QUALITY-OF-LIFE; OBSTRUCTIVE PULMONARY-DISEASE; ALLERGIC RHINITIS; AIRWAY INFLAMMATION; SLEEP-APNEA; FOLLOW-UP; ATOPIC-DERMATITIS; INCIDENT ASTHMA; LUNG-FUNCTION; GASTROESOPHAGEAL-REFLUX	Various conditions such as rhinosinusitis, gastro-oesophageal reflux disease, psychological disturbances, chronic Infections and obstructive sleep apnoea are often observed In asthmatic patients and may affect asthma control and outcomes. These comorbidities may change the asthma phenotype, be part of the same pathophysiological process, act as confounding factors In the diagnosis or assessment of control of asthma, and/or result from specific environmental exposures. The Influences of these conditions on asthma are variable and for many of them still uncertain; nevertheless, they may alter asthma responses to current therapy. A systematic evaluation and an appropriate treatment of asthma-associated comorbid conditions should be part of asthma management, particularly for severe disease. With regard to clinical research, associated conditions may Influence the results of trials and should be taken Into account in the subjects' Inclusion criteria and analysis of data.	Univ Laval, Inst Univ Cardiol & Pneumol, Ste Foy, PQ G1V 4G5, Canada	Boulet, LP (reprint author), Univ Laval, Inst Univ Cardiol & Pneumol, 2725 Chemin, Ste Foy, PQ G1V 4G5, Canada.	lpboulet@med.ulaval.ca	panduru, mihaela/H-2411-2011				Aaron SD, 2004, CHEST, V125, P2046, DOI 10.1378/chest.125.6.2046; Abramson M, 2002, RESPIROLOGY, V7, P325, DOI 10.1046/j.1440-1843.2002.00408.x; Ahmad T, 2008, CURR OPIN INVEST DR, V9, P470; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Baiardini I, 2008, ALLERGY, V63, P660, DOI 10.1111/j.1398-9995.2008.01649.x; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bilodeau L, 2007, AM J RESP CRIT CARE, V175, pA198; Boulet LP, 2007, CAN RESPIR J, V14, P217; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Boulet Louis-Philippe, 2006, Can Respir J, V13 Suppl A, P5; Boulet Louis-Philippe, 2007, Can Respir J, V14, P201; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2003, CURR OPIN PULM MED, V9, P46, DOI 10.1097/00063198-200301000-00008; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Brenner BE, 2005, THORAX, V60, P806, DOI 10.1136/thx.2004.033928; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; BRESLAU N, 1993, ARCH GEN PSYCHIAT, V50, P31; Ceylan E, 2007, RESPIROLOGY, V12, P272, DOI 10.1111/j.1440-1843.2006.00964.x; Chanez P, 2007, J ALLERGY CLIN IMMUN, V119, P1337, DOI 10.1016/j.jaci.2006.11.702; Chapman KR, 2008, EUR RESPIR J, V31, P320, DOI 10.1183/09031936.00039707; Chaudhuri R, 2006, AM J RESP CRIT CARE, V174, P127, DOI 10.1164/rccm.200510-1589OC; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; Coughlan JL, 2001, THORAX, V56, P198, DOI 10.1136/thorax.56.3.198; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; DAHLEM NW, 1977, J ALLERGY CLIN IMMUN, V60, P295, DOI 10.1016/0091-6749(77)90108-7; Denning DW, 2006, EUR RESPIR J, V27, P615, DOI 10.1183/09031936.06.00074705; Devouassoux G, 2007, J ALLERGY CLIN IMMUN, V119, P597, DOI 10.1016/j.jaci.2006.11.638; Dixon AE, 2008, LUNG, V186, P361, DOI 10.1007/s00408-008-9119-1; Dixon AE, 2006, CHEST, V130, P429, DOI 10.1378/chest.130.2.429; ELHAI H, 1999, ANN ALLERG ASTHMA IM, V82, P574; Eneli IU, 2008, THORAX, V63, P671, DOI 10.1136/thx.2007.086470; Feldman JM, 2005, PSYCHOSOM MED, V67, P989, DOI 10.1097/01.psy.0000188556.97979.13; Field SK, 1999, CHEST, V116, P766, DOI 10.1378/chest.116.3.766; FitzGerald JM, 2006, THORAX, V61, P992, DOI 10.1136/thx.2005.045195; Forbes L, 2007, THORAX, V62, P855, DOI 10.1136/thx.2006.058362; Galli E, 2007, ALLERGY ASTHMA PROC, V28, P540, DOI 10.2500/aap2007.28.3048; Gaugris S, 2006, J ASTHMA, V43, P1, DOI 10.1080/027700500446823; Coughlan J. L., 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001496; Global Strategy for Asthma Management and Prevention, 2006, GLOB STRAT ASTHM MAN; Greisner WA, 2000, ALLERGY ASTHMA PROC, V21, P371, DOI 10.2500/108854100778249123; Guerra S, 2002, J ALLERGY CLIN IMMUN, V109, P419, DOI 10.1067/mai.2002.121701; Guerra S, 2005, CURR OPIN PULM MED, V11, P7; Harding S M, 2001, Minerva Gastroenterol Dietol, V47, P75; Hasler G, 2005, AM J RESP CRIT CARE, V171, P1224, DOI 10.1164/rccm.200412-1669OC; Havemann BD, 2007, GUT, V56, P1654, DOI 10.1136/gut.2007.122465; Heaney LG, 2005, RESP MED, V99, P1152, DOI 10.1016/j.rmed.2005.02.013; Holgate ST, 2006, J ALLERGY CLIN IMMUN, V117, P496, DOI 10.1016/j.jaci.2006.01.039; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Humbert M, 2007, ALLERGY, V62, P95, DOI 10.1111/j.1398-9995.2006.01308.x; Humbert M, 2009, ALLERGY, V64, P81, DOI 10.1111/j.1398-9995.2008.01846.x; Husein OF, 2008, LARYNGOSCOPE, V118, P740, DOI 10.1097/MLG.0b013e31815ed13a; Ibrahim WH, 2007, POSTGRAD MED J, V83, P164, DOI 10.1136/pgmj.2006.052522; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; JUNIPER EF, 1989, AM REV RESPIR DIS, V140, P924; Kasasbeh A, 2007, SLEEP MED REV, V11, P47, DOI 10.1016/j.smrv.2006.05.001; Katon W, 2007, J ADOLESCENT HEALTH, V41, P455, DOI 10.1016/j.jadohealth.2007.05.023; Kuehn BM, 2008, JAMA-J AM MED ASSOC, V299, P158, DOI 10.1001/jama.2007.54-a; Lafond C, 2007, EUR RESPIR J, V29, P307, DOI 10.1183/09031936.00059706; Lamblin C, 2001, AM J RESP CRIT CARE, V163, P1226; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154; Lavoie KL, 2006, CHEST, V130, P1039, DOI 10.1378/chest.130.4.1039; Lehrer P, 2002, J CONSULT CLIN PSYCH, V70, P691, DOI 10.1037//0022-006X.70.3.691; Lehrer PM, 2008, J ANXIETY DISORD, V22, P671, DOI 10.1016/j.janxdis.2007.07.001; Lessard A, 2008, CHEST, V134, P317, DOI 10.1378/chest.07-2959; Littner MR, 2005, CHEST, V128, P1128, DOI 10.1378/chest.128.3.1128; Livingston E, 2005, DRUGS, V65, P1521, DOI 10.2165/00003495-200565110-00005; Mallia P, 2006, CHEST, V130, P1203, DOI 10.1378/chest.130.4.1203; Maniscalco M, 2008, RESP MED, V102, P102, DOI 10.1016/j.rmed.2007.07.029; Miles JF, 1997, CLIN EXP ALLERGY, V27, P1151; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Mosen DM, 2008, J ALLERGY CLIN IMMUN, V122, P507, DOI 10.1016/j.jaci.2008.06.024; NEWMAN KB, 1995, AM J RESP CRIT CARE, V152, P1382; Nolte Hendrik, 2006, Respir Med, V100, P354, DOI 10.1016/j.rmed.2005.05.012; Nouwen A, 1999, BEHAV MODIF, V23, P217, DOI 10.1177/0145445599232002; Nowobilski R, 2007, J ASTHMA, V44, P203, DOI 10.1080/02770900701209772; OTTO BAP, 2008, HEAD NECK SURG, V16, P270; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Peters S, 2007, J ASTHMA, V44, P149, DOI 10.1080/02770900600925478; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Philip G, 2004, CURR MED RES OPIN, V20, P1549, DOI 10.1185/030079904X3348; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2008, J ALLERGY CLIN IMMUN, V121, P1428, DOI 10.1016/j.jaci.2008.02.041; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Price D, 2005, CLIN EXP ALLERGY, V35, P282, DOI 10.1111/j.1365-2222.2005.02182.x; Price DB, 2006, ALLERGY, V61, P737, DOI 10.1111/j.1398-9995.2006.01007.x; Rey E, 2007, BRIT MED J, V334, P582, DOI 10.1136/bmj.39112.717674.BE; Rimington LD, 2001, THORAX, V56, P266, DOI 10.1136/thorax.56.4.266; RoweJones JM, 1997, ALLERGY, V52, P20; Saint-Pierre P, 2006, ALLERGY, V61, P79, DOI 10.1111/j.1398-9995.2005.00953.x; Schatz M, 1999, J ALLERGY CLIN IMMUN, V103, pS330, DOI 10.1016/S0091-6749(99)70258-7; Schatz M, 2008, ANN ALLERG ASTHMA IM, V101, P240, DOI 10.1016/S1081-1206(10)60488-7; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Shore SA, 2007, CURR OPIN PULM MED, V13, P56, DOI 10.1097/MCP.0b013e3280110196; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; St-Laurent J, 2008, CLIN EXP ALLERGY, V38, P1582, DOI 10.1111/j.1365-2222.2008.03032.x; Sutherland ER, 2008, AM J RESP CRIT CARE, V178, P682, DOI 10.1164/rccm.200801-076OC; Sutherland ER, 2007, CHEST, V132, P1962, DOI 10.1378/chest.06-2415; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; ten Brinke A, 2005, EUR RESPIR J, V26, P812, DOI 10.1183/09031936.05.00037905; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; ten Brinke A, 2001, J PSYCHOSOM RES, V50, P7, DOI 10.1016/S0022-3999(00)00203-8; Thomson Neil C, 2006, Treat Respir Med, V5, P467, DOI 10.2165/00151829-200605060-00010; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Togias A, 1999, ALLERGY, V54, P94, DOI 10.1111/j.1398-9995.1999.tb04410.x; Togias Alkis G., 2000, Journal of Allergy and Clinical Immunology, V106, pS247; Tonnel AB, 2008, PRESSE MED, V37, P161, DOI 10.1016/j.lpm.2007.07.013; Tsicopoulos A, 2004, J ALLERGY CLIN IMMUN, V113, P462, DOI 10.1016/j.jaci.2003.12.009; Wainwright NWJ, 2007, ALLERGY, V62, P554, DOI 10.1111/j.1398-9995.2006.01316.x; Warner JO, 2001, J ALLERGY CLIN IMMUN, V108, P929, DOI 10.1067/mai.2001.120015; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Yigla M, 2003, J ASTHMA, V40, P865, DOI 10.1081/JAS-120023577; Yorke J, 2007, PEDIATR PULM, V42, P114, DOI 10.1002/ppul.20464; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; Zamarron C, 2008, EUR J INTERN MED, V19, P390, DOI 10.1016/j.ejim.2007.12.006; [Anonymous], 2000, WHO TECH REP SER, V894, P1	121	72	75	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	APR	2009	33	4					897	906		10.1183/09031936.00121308		10	Respiratory System	Respiratory System	427MC	WOS:000264782400027	19336592	
J	Cooper, PJ; Rodrigues, LC; Cruz, AA; Barreto, ML				Cooper, P. J.; Rodrigues, L. C.; Cruz, A. A.; Barreto, M. L.			Asthma in Latin America: a public health challenge and research opportunity	ALLERGY			English	Review						asthma; allergy; Latin America; urbanization	SCHISTOSOMA-MANSONI INFECTION; BODY-MASS INDEX; CHILDHOOD ASTHMA; RISK-FACTORS; SCHOOL-CHILDREN; ALLERGIC SENSITIZATION; ASCARIS-LUMBRICOIDES; COSTA-RICA; RURAL AREA; BRONCHIAL RESPONSIVENESS	Asthma has emerged as an important public health problem in many Latin American countries over the past decade. In Brazil and Costa Rica, the prevalence of asthma and associated morbidity is as great or greater as reported in traditional high prevalence countries such as the US, but remains neglected as a public health priority. Asthma in Latin America is associated particularly with underprivileged populations living in cities but remains relatively rare in many rural populations. The causes of asthma in Latin America are likely to be associated with urbanization, migration, and the adoption of a modern 'Westernized' lifestyle and environmental changes that follow these processes that include changes in diet, physical activity, hygiene, and exposures to allergens, irritants, and outdoor and indoor pollutants. Because of the enormous social, genetic, and environmental contrasts within and between Latin American countries, and the large differences in prevalence associated with these differences, the investigation of asthma in Latin America provides important research opportunities to identify the social and biological mechanisms that underlie asthma development. Asthma in Latin America poses enormous challenges for health policy makers, health services, and researchers to respond to and alleviate the growing burden of asthma disability, particularly among marginalized urban populations.	[Cooper, P. J.] Ctr Invest FEPIS, Quininde, Ecuador; [Cooper, P. J.] Univ San Francico Quito, Inst Microbiol, Quito, Ecuador; [Rodrigues, L. C.] London Sch Hyg & Trop Med, London WC1, England; [Cooper, P. J.] Univ London St Georges Hosp, Ctr Infect, London, England; [Cruz, A. A.] WHO, CH-1211 Geneva, Switzerland; [Barreto, M. L.] Univ Fed Bahia, Inst Saude Colet, BR-41170290 Salvador, BA, Brazil	Cooper, PJ (reprint author), Casilla 17-14-39, Carcelen, Quito, Ecuador.		Cruz, Alvaro/I-1676-2012	Cruz, Alvaro/0000-0002-7403-3871; Barreto, Mauricio/0000-0002-0215-4930	Wellcome Trust [074679/Z/04/Z]; The Wellcome Trust Latin American Centres of Excellence Programme [072405/Z/03/Z]	PJC is supported by Wellcome Trust, Grant No. 074679/Z/04/Z. MLB, PJC, AAC, and LCR are involved in the SCAALA-Social Change Allergy and Asthma in Latin America-programme that is funded by The Wellcome Trust Latin American Centres of Excellence Programme, Grant No. 072405/Z/03/Z.	ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Addo-Yobo EOD, 2007, PLOS MED, V4, P355, DOI 10.1371/journal.pmed.0040070; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Almqvist C, 2005, CLIN EXP ALLERGY, V35, P612, DOI 10.1111/j.1365-2222.2005.02243.x; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Asher MI, 1998, EUR RESPIR J, V12, P315; BACKER V, 1992, ANN ALLERGY, V69, P116; Barreto Mauricio L, 2006, BMC Pulm Med, V6, P15, DOI 10.1186/1471-2466-6-15; Beasley C.R.W., 1998, FATAL ASTHMA, P13; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bell ML, 2006, ENVIRON RES, V100, P431, DOI 10.1016/j.envres.2005.08.002; Benicio MHD, 2004, B WORLD HEALTH ORGAN, V82, P516; Bergmann RL, 2000, CLIN EXP ALLERGY, V30, P1740, DOI 10.1046/j.1365-2222.2000.00927.x; Bermudez Odilia I., 2003, Cad. Saúde Pública, V19, pS87, DOI 10.1590/S0102-311X2003000700010; BRABACK L, 2005, EUR RESPIR J, V26, P1; Braun-Fahrlander C, 2003, CLIN EXP ALLERGY, V33, P409, DOI 10.1046/j.1365-2222.2003.01650.x; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; Bustos P, 2005, INT J OBESITY, V29, P804, DOI 10.1038/sj.ijo.0802958; CARRASCO E, 1987, CHEST, V91, pS93, DOI 10.1378/chest.91.6.93S; CASTILLEJOS M, 1992, AM REV RESPIR DIS, V145, P276; Centers for Disease Control and Prevention, 2004, MMWR-MORBID MORTAL W, V53, P145; *CDCP, 2007, MMWR-MORBID MORTAL W, V567, P497; Celedon JC, 2001, CHEST, V120, P785, DOI 10.1378/chest.120.3.785; Chatkin G, 2007, J ASTHMA, V44, P133, DOI 10.1080/02770900601182483; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; Choudhry S, 2006, HUM GENET, V118, P652, DOI 10.1007/s00439-005-0071-3; Choudhry Shweta, 2007, Proc Am Thorac Soc, V4, P226, DOI 10.1513/pats.200701-029AW; CLIFFORD RD, 1989, ARCH DIS CHILD, V64, P1133; CLIFFORD RD, 1987, ARCH DIS CHILD, V62, P66; Cooper PJ, 2008, CLIN EXP ALLERGY, V38, P551, DOI 10.1111/j.1365-2222.2008.02934.x; Cooper Philip J, 2006, BMC Pulm Med, V6, P24, DOI 10.1186/1471-2466-6-24; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2004, CLIN EXP ALLERGY, V34, P845, DOI 10.1111/j.1365-2222.2004.01958.x; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; COOPER PJ, 2006, BR MED B, V80, P203; Court CS, 2002, THORAX, V57, P951, DOI 10.1136/thorax.57.11.951; Cunha SS, 2007, REV PANAM SALUD PUBL, V22, P438; Cunha S. S., 2007, BMC PUBLIC HEALTH, V7, P205; Del-Rio-Navarro BE, 2003, J INVEST ALLERG CLIN, V13, P118; Dennis R, 2004, ANN ALLERG ASTHMA IM, V93, P568; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Eldeirawi K, 2005, J ALLERGY CLIN IMMUN, V116, P42, DOI 10.1016/j.jaci.2005.03.041; Farhat SCL, 2005, BRAZ J MED BIOL RES, V38, P227, DOI 10.1590/S0100-879X2005000200011; FERNANDEZCALDAS E, 1993, J INVEST ALLERG CLIN, V3, P245; Ferreira MU, 2007, J TROP PEDIATRICS, V53, P119, DOI 10.1093/tropej/fml083; Filozof C, 2001, Obes Rev, V2, P99, DOI 10.1046/j.1467-789x.2001.00029.x; Fischer Gilberto Bueno, 2005, Paediatr Respir Rev, V6, P8, DOI 10.1016/j.prrv.2004.11.002; Franco R, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-82; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Gold DR, 2005, J ALLERGY CLIN IMMUN, V116, P38, DOI 10.1016/j.jaci.2005.04.033; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; Hagel I, 2007, ACTA TROP, V103, P231, DOI 10.1016/j.actatropica.2007.06.010; HIJJAR MA, 1988, B CAMPANHA NACL TUBE, V2, P53; Holguin F, 2005, AM J RESP CRIT CARE, V171, P103, DOI 10.1164/rccm.200402-143OC; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Kalyoncu AF, 2002, EUR RESPIR J, V19, P980, DOI 10.1183/09031936.02.00305302; Kurukulaaratchy RJ, 2005, ALLERGY, V60, P1280, DOI 10.1111/j.1398-9995.2005.00890.x; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; Mallol J, 2005, Allergol Immunopathol (Madr), V33, P257, DOI 10.1157/13080928; Mallol J, 2004, Allergol Immunopathol (Madr), V32, P100; Mallol J, 2000, PEDIATR PULM, V30, P439, DOI 10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E; MALLOL J, 2008, THORAX, V643, P167; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Neffen H, 2005, REV PANAM SALUD PUBL, V17, P191; NEFFEN HE, 2007, CURR ALLERGY CLIN IM, V20, P8; Nicolaou N, 2005, ALLERGY, V60, P1357, DOI 10.1111/j.1398-9995.2005.00961.x; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Pearce N, 1999, THORAX, V54, P268; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Penny ME, 2001, THORAX, V56, P607, DOI 10.1136/thorax.56.8.607; Pereira MU, 2007, EUR RESPIR J, V29, P1154, DOI 10.1183/09031936.00127606; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; PLATTSMILLS TAE, 2005, ALLERGY, V60, pS25; Ponte Eduardo, 2007, J. bras. pneumol., V33, P15, DOI 10.1590/S1806-37132007000100006; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Rona RJ, 1999, J EPIDEMIOL COMMUN H, V53, P15; Salari K, 2005, GENET EPIDEMIOL, V29, P76, DOI 10.1002/gepi.20079; SALARI K, 2007, PAEDIATR PERINAT EP, V21, pS15; Salvi SS, 2001, AM J RESP CRIT CARE, V164, P1343; Santillan AA, 2003, INT J OBESITY, V27, P1430, DOI 10.1038/sj.ijo.0802395; Schaub B, 2005, CURR OPIN ALLERGY CL, V5, P185, DOI 10.1097/01.all.0000162313.64308.b5; Schei MA, 2004, J EXPO ANAL ENV EPID, V14, pS110, DOI 10.1038/sj.jea.7500365; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Silva JM, 2005, PEDIATR ALLERGY IMMU, V16, P393, DOI 10.1111/j.1399-3038.2005.00308.x; Solé Dirceu, 2006, J. Pediatr. (Rio J.), V82, P341, DOI 10.1590/S0021-75572006000600006; Solem K, 2006, IEEE T BIO-MED ENG, V53, P13, DOI 10.1109/TBME.2005.859780; Soto-Quiros ME, 2002, PEDIATR PULM, V33, P237, DOI 10.1002/ppul.10070; SOTOQUIROS M, 1994, CLIN EXP ALLERGY, V24, P1130; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; STRACHAN DP, 1998, THORAX, V53, P214; Takeuchi H, 2008, CLIN EXP ALLERGY, V38, P276, DOI 10.1111/j.1365-2222.2007.02890.x; *UN FUND POP ACT, POP ISS MIGR URB; Viinanen A, 2007, ALLERGY, V62, P272, DOI 10.1111/j.1398-9995.2006.01279.x; Viinanen A, 2005, ALLERGY, V60, P1370, DOI 10.1111/j.1398-9995.2005.00877.x; Villarreal AB, 2003, J ASTHMA, V40, P413, DOI 10.1081/JAS-120018711; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; *WHO, 2007, GEN M REP SEOUL REP; World Health Organization, 2007, GLOB SURV PREV CONTR; WITT C, 1986, J ALLERGY CLIN IMMUN, V77, P698, DOI 10.1016/0091-6749(86)90413-6; Wright RJ, 2008, AM J RESP CRIT CARE, V177, P129, DOI 10.1164/rccm.200710-1526ED; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	114	72	78	0	6	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	JAN	2009	64	1					5	17		10.1111/j.1398-9995.2008.01902.x		13	Allergy; Immunology	Allergy; Immunology	387TL	WOS:000261974400002	19076533	
J	Johnston, RA; Theman, TA; Lu, FL; Terry, RD; Williams, ES; Shore, SA				Johnston, Richard A.; Theman, Todd A.; Lu, Frank L.; Terry, Raya D.; Williams, Erin S.; Shore, Stephanie A.			Diet-induced obesity causes innate airway hyperresponsiveness to methacholine and enhances ozone-induced pulmonary inflammation	JOURNAL OF APPLIED PHYSIOLOGY			English	Article						bronchoalveolar lavage fluid; chemokine; leptin; lung elastance; resistance	HIGH-FAT DIET; NECROSIS-FACTOR-ALPHA; INDUCED LUNG INFLAMMATION; BODY-MASS INDEX; INSULIN-RESISTANCE; TISSUE MECHANICS; DEFICIENT MICE; C57BL/6J MICE; ASTHMA; RESPONSES	We previously reported that genetically obese mice exhibit innate airway hyperresponsiveness (AHR) and enhanced ozone (O-3)-induced pulmonary inflammation. Such genetic deficiencies in mice are rare in humans, and they may not be representative of human obesity. Thus the purpose of this study was to determine the pulmonary phenotype of mice with diet-induced obesity (DIO), which more closely mimics the cause of human obesity. Therefore, wild-type C57BL/6 mice were reared from the time of weaning until at least 30 wk of age on diets in which either 10 or 60% of the calories are derived from fat in the form of lard. Body mass was similar to 40% greater in mice fed 60 vs. 10% fat diets. Baseline airway responsiveness to intravenous methacholine, measured by forced oscillation, was greater in mice fed 60 vs. 10% fat diets. We also examined lung permeability and inflammation after exposure to room air or O-3 (2 parts/million for 3 h), an asthma trigger. Four hours after the exposure ended, O-3-induced increases in bronchoalveolar lavage fluid protein, interleukin-6, KC, macrophage inflammatory protein-2, interferon-gamma-inducible protein-10, and eotaxin were greater in mice fed 60 vs. 10% fat diets. Innate AHR and augmented responses to O-3 were not observed in mice raised from weaning until 20-22 wk of age on a 60% fat diet. These results indicate that mice with DIO exhibit innate AHR and enhanced O3-induced pulmonary inflammation, similar to genetically obese mice. However, mice with DIO must remain obese for an extended period of time before this pulmonary phenotype is observed.	[Johnston, Richard A.; Theman, Todd A.; Lu, Frank L.; Terry, Raya D.; Williams, Erin S.; Shore, Stephanie A.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA 02115 USA; [Lu, Frank L.] Natl Taiwan Univ, Dept Pediat, Natl Taiwan Univ Hosp, Taipei 10764, Taiwan; [Lu, Frank L.] Natl Taiwan Univ, Dept Pediat, Natl Taiwan Univ Hosp, Coll Med, Taipei 10764, Taiwan	Johnston, RA (reprint author), Univ Texas Med Branch, Dept Internal Med, Div Allergy Pulm Immunol Crit Care & Sleep, Rm 8-104A,Med Res Bldg,301 Univ Blvd, Galveston, TX 77555 USA.	rajohnst@utmb.edu	Lu, Frank/G-6196-2012	Lu, Frank/0000-0002-5225-7751	NHLBI NIH HHS [HL-084044, R01 HL084044]; NIEHS NIH HHS [ES-013307, ES00002, R01 ES013307]		Bastard JP, 2002, J CLIN ENDOCR METAB, V87, P2084, DOI 10.1210/jc.87.5.2084; Bhalla DK, 1999, J TOXICOL ENV HEAL B, V2, P31, DOI 10.1080/109374099281232; Bhalla DK, 1999, J TOXICOL ENV HEAL A, V57, P329, DOI 10.1080/009841099157647; Black BL, 1998, METABOLISM, V47, P1354, DOI 10.1016/S0026-0495(98)90304-3; Breslow MJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE443; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Castro-Rodriguez Jose A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1344; Chen MS, 2001, ASIA PAC J OPER RES, V18, P131; CHEN XL, 1995, AM J RESP CELL MOL, V12, P396; Cho HY, 2001, AM J PHYSIOL-LUNG C, V280, pL537; DING DJ, 1987, J APPL PHYSIOL, V62, P1324; Farooqi IS, 2006, PROG BRAIN RES, V153, P119, DOI 10.1016/S0079-6123(06)53006-7; Fauroux B, 2000, PEDIATR PULM, V30, P41; Ford ES, 2005, J ALLERGY CLIN IMMUN, V115, P897, DOI 10.1016/j.jaci.2004.11.050; Formiguera X, 2004, BEST PRACT RES CL GA, V18, P1125, DOI 10.1016/j.bpg.2004.06.030; Gainsford T, 1996, P NATL ACAD SCI USA, V93, P14564, DOI 10.1073/pnas.93.25.14564; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P406, DOI 10.1093/aje/kwg175; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; Hjoberg J, 2004, J APPL PHYSIOL, V97, P249, DOI 10.1152/japplphysiol.01389.2003; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; Ikemoto S, 1996, METABOLISM, V45, P1539, DOI 10.1016/S0026-0495(96)90185-7; Ito M, 2007, HEPATOL RES, V37, P50, DOI 10.1111/j.1872-034X.2007.00008.x; Jang AS, 2005, RESPIRATION, V72, P79, DOI 10.1159/000083405; Johnston RA, 2006, AM J PHYSIOL-REG I, V290, pR126, DOI 10.1152/ajpregu.00306.2005; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL390, DOI 10.1152/ajplung.00007.2004; Johnston RA, 2005, AM J PHYSIOL-LUNG C, V288, pL61, DOI 10.1152/ajplung.00101.2004; JOHNSTON RA, 2007, AM J RESP CRIT CARE, V175, pA963; Johnston RA, 2007, AM J RESP CRIT CARE, V176, P650, DOI 10.1164/rccm.200702-323OC; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332; Lang JE, 2007, AM J RESP CRIT CARE, V175, pA912; Leibel RL, 1997, J BIOL CHEM, V272, P31937, DOI 10.1074/jbc.272.51.31937; Libinaki R, 1999, IUBMB LIFE, V48, P109, DOI 10.1080/713803473; Lin S, 2000, INT J OBESITY, V24, P639, DOI 10.1038/sj.ijo.0801209; Loffreda S, 1998, FASEB J, V12, P57; Lu FL, 2006, AM J PHYSIOL-LUNG C, V290, pL856, DOI 10.1152/ajplung.00386.2005; MANISCALCO M, 2007, WEIGHT LOSS ASTHMA C, V102, P102; Michalec L, 2002, J IMMUNOL, V168, P846; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; O'Brien PE, 2002, OBES SURG, V12, P652, DOI 10.1381/096089202321019639; Opara EC, 1996, J NUTR, V126, P273; Park JW, 2004, AM J RESP CELL MOL, V30, P830, DOI 10.1165/rcmb.2003.0373OC; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pillow JJ, 2001, J APPL PHYSIOL, V91, P2730; Pryor WA, 1995, TOXICOL LETT, V82-3, P287, DOI 10.1016/0378-4274(95)03563-X; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; SAMPSON MG, 1983, J APPL PHYSIOL, V55, P1269; Santos-Alvarez J, 1999, CELL IMMUNOL, V194, P6, DOI 10.1006/cimm.1999.1490; Savov JD, 2004, AM J RESP CELL MOL, V31, P69, DOI 10.1165/rcmb.2003-0001OC; Schreyer SA, 1998, J CLIN INVEST, V102, P402, DOI 10.1172/JCI2849; Shore SA, 2003, J APPL PHYSIOL, V95, P938, DOI 10.1152/japplphysiol.00336.2003; Shore SA, 2006, PHARMACOL THERAPEUT, V110, P83, DOI 10.1016/j.pharmthera.2005.10.002; Shore SA, 2005, J ALLERGY CLIN IMMUN, V115, P103, DOI 10.1016/j.jaci.2004.10.007; Spivak H, 2005, AM J SURG, V189, P27, DOI 10.1016/j.amjsurg.2004.06.038; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; SURWIT RS, 1988, DIABETES, V37, P1163, DOI 10.2337/diabetes.37.9.1163; Surwit RS, 1998, P NATL ACAD SCI USA, V95, P4061, DOI 10.1073/pnas.95.7.4061; TANKERSLEY CG, 1994, TOXICOL LETT, V72, P279, DOI 10.1016/0378-4274(94)90039-6; Teramoto S, 2003, CIRCULATION, V107, pE40, DOI 10.1161/01.CIR.0000053956.46188.5F; THOMAS PS, 1995, AM J RESP CRIT CARE, V152, P76; TILG H, 1994, BLOOD, V83, P113; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; *US EPA, 1986, AIR QUAL CRIT OZ OTH, V4; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Vozarova B, 2001, OBES RES, V9, P414, DOI 10.1038/oby.2001.54; WIESTER MJ, 1987, TOXICOL APPL PHARM, V89, P429, DOI 10.1016/0041-008X(87)90162-1; Xu HY, 2003, J CLIN INVEST, V112, P1821, DOI 10.1172/JCI200319451; YAP JCH, 1995, J APPL PHYSIOL, V79, P1199; ZERAH F, 1993, CHEST, V103, P1470, DOI 10.1378/chest.103.5.1470; Zhao QY, 1998, AM J PHYSIOL-LUNG C, V274, pL39	72	72	74	0	6	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	8750-7587			J APPL PHYSIOL	J. Appl. Physiol.	JUN	2008	104	6					1727	1735		10.1152/japplphysiol.00075.2008		9	Physiology; Sport Sciences	Physiology; Sport Sciences	309BI	WOS:000256434700025	18323466	
J	Kapoor, R; Menon, C; Hoffstad, O; Bilker, W; Leclerc, P; Margolis, DJ				Kapoor, Roger; Menon, Chandrakala; Hoffstad, Ole; Bilker, Warren; Leclerc, Patricia; Margolis, David J.			The prevalence of atopic triad in children with physician-confirmed atopic dermatitis	JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY			English	Article							FOLLOW-UP; ASTHMA; CHILDHOOD; PREDISPOSE; MUTATIONS; ALLERGIES; EXPOSURE; CRITERIA; ECZEMA; ISAAC	Background: Atopic dermatitis (AD) is often associated with comorbidities such as allergic rhinitis and asthma. Objective: We sought to describe the frequency of these comorbidities in children with AD Methods: We conducted a cross-sectional study of the first 2270 children with physician-confirmed AD enrolled in a large postmarketing cohort. All were queried for information on comorbidities using a questionnaire from the International Study of Asthma and Allergies in Childhood. Results: In all, 71.3% reported at least one additional form of atopy (symptoms of asthma or allergic rhinitis). A total of 33.3% reported only symptoms of asthma or allergic rhinitis whereas 38.0% reported I symptoms of asthma and allergic rhinitis. By age 3 years, nearly 66% reported at least one additional form of atopy. A statistically significant trend toward poorer disease control was observed for those with additional atopic illnesses (P <.001). Limitations: This is a cross-sectional study Conclusion: Individuals with AD exhibit a predisposition to additional atopic illnesses by age 3 years and in turn the presence of these illnesses correlates with poor disease control.	[Menon, Chandrakala; Hoffstad, Ole; Bilker, Warren; Margolis, David J.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Bilker, Warren] Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; [Margolis, David J.] Univ Penn, Sch Med, Dept Dermatol, Philadelphia, PA 19104 USA; [Leclerc, Patricia] Novartis Pharmaceut Corp, E Hanover, NJ USA; [Kapoor, Roger] George Washington Univ, Sch Med, Washington, DC USA	Margolis, DJ (reprint author), Univ Penn, Sch Med, Dept Biostat & Epidemiol, 815 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA.	margo@med.mail.upenn.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Abramovits W, 2005, J AM ACAD DERMATOL, V53, pS86, DOI 10.1016/j.jaad.2005.04.034; Akdis CA, 2006, ALLERGY, V61, P969, DOI 10.1111/j.1398-9995.2006.01153.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BUFFUM WP, 1966, AM J DIS CHILD, V112, P214; Callen J, 2007, BRIT J DERMATOL, V156, P203, DOI 10.1111/j.1365-2133.2006.07538x; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Diepgen TL, 1996, J CLIN EPIDEMIOL, V49, P1031, DOI 10.1016/0895-4356(96)00119-9; Ellwood P, 2005, INT J TUBERC LUNG D, V9, P10; Fiset PO, 2006, J ALLERGY CLIN IMMUN, V118, P287, DOI 10.1016/j.jaci.2006.03.046; Gustafsson D, 2000, ALLERGY, V55, P240, DOI 10.1034/j.1398-9995.2000.00391.x; Hanifin JM, 2004, J AM ACAD DERMATOL, V50, P391, DOI 10.1016/j.jaad.2003.08.003; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Leung Donald Y M, 2003, J Allergy Clin Immunol, V112, pS117, DOI 10.1016/j.jaci.2003.09.034; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Nomura Ichiro, 2003, Journal of Allergy and Clinical Immunology, V112, P1195, DOI 10.1016/j.jaci.2003.08.049; Purvis DJ, 2005, BRIT J DERMATOL, V152, P742, DOI 10.1111/j.1365-2133.2005.06540.x; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Tay YK, 1999, INT J DERMATOL, V38, P689, DOI 10.1046/j.1365-4362.1999.00667.x; Voigt LF, 2003, AM J EPIDEMIOL, V157, P66, DOI 10.1093/aje/kwf185; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x	29	72	76	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0190-9622			J AM ACAD DERMATOL	J. Am. Acad. Dermatol.	JAN	2008	58	1					68	73		10.1016/j.jaad.2007.06.041		6	Dermatology	Dermatology	250GG	WOS:000252287400009	17692428	
J	Leggat, PA; Kedjarune, U; Smith, DR				Leggat, Peter A.; Kedjarune, Ureporn; Smith, Derek R.			Occupational health problems in modern dentistry: A review	INDUSTRIAL HEALTH			English	Review						dentistry; infectious diseases; dermatitis; musculoskeletal pain	GENERAL DENTAL PRACTITIONERS; MUSCULOSKELETAL DISORDERS; SOUTHERN THAILAND; BACTERIAL AEROSOLS; HAND DERMATITIS; LATEX; PERSONNEL; PREVALENCE; ALLERGY; INFECTION	Despite numerous technical advances in recent years, many occupational health problems still persist in modern dentistry. These include percutaneous exposure incidents (PEI); exposure to infectious diseases (including bioaerosols), radiation, dental materials, and noise; musculoskeletal disorders; dermatitis and respiratory disorders; eye injuries; and psychological problems. PEI remain a particular concern, as there is an almost constant risk of exposure to serious infectious agents. Strategies to minimise PEI and their consequences should continue to be employed, including sound infection control practices, continuing education and hepatitis B immunisation. As part of any infection control protocols, dentists should continue to utilise personal protective measures and appropriate sterilisation or other high-level disinfection techniques. Aside from biological hazards, dentists continue to suffer a high prevalence of musculoskeletal disorders (MSD), especially of the back, neck and shoulders. To fully understand the nature of these problems, further studies are needed to identify causative factors and other correlates of MSD. Continuing education and investigation of appropriate interventions to help reduce the prevalence of MSD and contact dermatitis are also needed. For these reasons, it is therefore important that dentists remain constantly informed regarding up-to-date measures on how to deal with newer technologies and dental materials.	James Cook Univ N Queensland, Anton Breinl Ctr Publ Hlth & Trop Med, Townsville, Qld 4811, Australia; Prince Songkla Univ, Fac Dent, Dept Oral Biol & Occlus, Hat Yai 90112, Songkla, Thailand; NIOSH, Int Ctr Res Promot & Informat, Tama Ku, Kawasaki, Kanagawa 2148585, Japan	Leggat, PA (reprint author), James Cook Univ N Queensland, Anton Breinl Ctr Publ Hlth & Trop Med, Townsville, Qld 4811, Australia.		Smith, Derek/F-4844-2010	Smith, Derek/0000-0002-8202-2523			Akesson I, 1997, INT ARCH OCC ENV HEA, V69, P461, DOI 10.1007/s004200050175; AKESSON I, 1995, OCCUP ENVIRON MED, V52, P116; Akesson I, 1999, INT ARCH OCC ENV HEA, V72, P395, DOI 10.1007/s004200050391; Al Wazzan K A, 2001, J Contemp Dent Pract, V2, P17; ALWAZZAN KA, 2001, INT DENT J, V51, P88; *AM DENT ASS, 2007, AMA STAT DENT AM; *AM DENT ASS, 1995, DENT MAN HIV INF PAT; Bassett S, 1983, J Can Dent Assoc, V49, P251; Bennett AM, 2000, BRIT DENT J, V189, P664, DOI 10.1038/sj.bdj.4800859a; BERRY EA, 1986, J AM DENT ASSOC, V112, P70; BILLER F E, 1946, Oral Hyg, V36, P1194; BORGANELLI GN, 1993, J DENT RES, V72, P1275, DOI 10.1177/00220345930720090301; BURKE FJT, 1995, CONTACT DERMATITIS, V32, P35, DOI 10.1111/j.1600-0536.1995.tb00838.x; Burke FJT, 1997, BRIT DENT J, V182, P250; Chadwick RG, 2007, BRIT DENT J, V203, DOI 10.1038/bdj.2007.580; CHADWICK RG, 2007, BR DENT J, V203, P198; Charbonneau A, 1999, AIDS CARE, V11, P61, DOI 10.1080/09540129948207; Checchi L, 2005, J AM DENT ASSOC, V136, P877; Chiodo G T, 1997, Gen Dent, V45, P532; Chiodo G.T., 1997, GEN DENT, V45, P536; Chiodo G.T., 1997, GEN DENT, V45, P538; Chowanadisai S, 2000, INT DENT J, V50, P36; Cleveland JL, 1997, INFECT CONT HOSP EP, V18, P717; Council on dental materials instruments and equipments; Council on dental practice and Council on dental therapeutics, 1998, J AM DENT ASSOC, V116, P241; de Wet E, 1997, J Dent Assoc S Afr, V52, P15; DEVERALL A, 1969, Journal of the Dental Association of South Africa, V24, P368; DEVRIES B, 1994, MED J AUSTRALIA, V160, P398; *FED DENT INT, 1997, POL STAT WHO CONS ST; Finsen L, 1998, APPL ERGON, V29, P119, DOI 10.1016/S0003-6870(97)00017-3; FREESE AS, 1985, TIC, V44, P1; Giannandrea P F, 1996, MSDA J, V39, P73; Gijbels F, 2006, CLIN ORAL INVEST, V10, P8, DOI 10.1007/s00784-005-0003-6; Gordon BL, 2001, J DENT, V29, P509, DOI 10.1016/S0300-5712(01)00043-4; GRENIER D, 1995, APPL ENVIRON MICROB, V61, P3165; Hamann CP, 1998, J AM DENT ASSOC, V129, P43; Harrel SK, 2004, J AM DENT ASSOC, V135, P429; Hill JG, 1998, J AM DENT ASSOC, V129, P212; *HOSP INF CONTR GR, 1995, J MED ASS THAI S2, V78, pS125; Jaakkola MS, 2007, ALLERGY, V62, P648, DOI 10.1111/j.1398-9995.2007.01379.x; JACOBSEN N, 1991, COMMUNITY DENT ORAL, V19, P155, DOI 10.1111/j.1600-0528.1991.tb00132.x; JACOBSEN N, 1995, COMMUNITY DENT ORAL, V23, P177, DOI 10.1111/j.1600-0528.1995.tb00225.x; JAINKITTIVONG A, 1998, ORAL SURG ORAL MED O, V85, P339; KANERVA L, 1994, DERMATOL CLIN, V12, P517; Katelaris CH, 1996, MED J AUSTRALIA, V164, P711; Leggat PA, 2006, AUST DENT J, V51, P324, DOI 10.1111/j.1834-7819.2006.tb00451.x; Leggat PA, 2006, AUST DENT J, V51, P158, DOI 10.1111/j.1834-7819.2006.tb00420.x; Leggat PA, 2006, INT DENT J, V56, P154; Leggat PA, 2004, IND HEALTH, V42, P207, DOI 10.2486/indhealth.42.207; Leggat PA, 2003, INT DENT J, V53, P126; Leggat PA, 2001, INT DENT J, V51, P348; Leggat PA, 2001, INT DENT J, V51, P39; Leggat PA, 2001, INT DENT J, V51, P11; Leggat PA, 2001, J OCCUP HLTH STAFF A, V17, P279; LEHTO TU, 1991, COMMUNITY DENT ORAL, V19, P38, DOI 10.1111/j.1600-0528.1991.tb00103.x; Logan H L, 1997, J Am Coll Dent, V64, P39; Mandel I D, 1993, J Am Dent Assoc, V124, P40; Marshall ED, 1997, AUST DENT J, V42, P240, DOI 10.1111/j.1834-7819.1997.tb00128.x; MARTIN MD, 1995, J AM DENT ASSOC, V126, P1502; McCarthy GM, 1997, INFECT CONT HOSP EP, V18, P699; McDonald RI, 1997, AUST DENT J, V42, P109, DOI 10.1111/j.1834-7819.1997.tb00105.x; MESSITE J, 1984, OCCUPATIONAL HAZARDS, P1; MILERAD E, 1990, SCAND J WORK ENV HEA, V16, P129; Murray CA, 2001, BRIT DENT J, V190, P377, DOI 10.1038/sj.bdj.4800978a; Murray Peter E, 2007, Med Oral Patol Oral Cir Bucal, V12, pE258; Nermin Yamalik, 2006, Int Dent J, V56, P359; Ohlson CG, 2002, SWED DENT J, V26, P141; Piirila P, 2002, INT ARCH OCC ENV HEA, V75, P209, DOI 10.1007/s00420-001-0302-4; PORTER K, 1990, J DENT, V18, P258, DOI 10.1016/0300-5712(90)90025-A; Puriene Alina, 2007, Stomatologija, V9, P10; *QUEESL, INF CONTR GUID; RamosGomez F, 1997, J AM DENT ASSOC, V128, P1253; Rankin J A, 1990, J Dent Pract Adm, V7, P2; RANKIN KV, 1993, J AM DENT ASSOC, V124, P67; Ratzon N. Z., 2000, WORK, V15, P153; Rice V.J., 1996, INT J OCCUP SAF ERGO, V2, P218; SANCHEZ E, 1995, J AM DENT ASSOC, V126, P259; Scott A, 2003, BRIT DENT J, V195, P686, DOI 10.1038/sj.bdj.4810821; SCULLY C, 1990, OCCUPATIONAL HAZARDS, P142; SCULLY C, 1990, OCCUPATIONAL HAZARDS, P55; SCULLY C, 1990, OCCUPATIONAL HAZARDS, P1; SCULLY C, 1990, OCCUPATIONAL HAZARDS, P22; SERB P, 1994, AUST DENT J, V39, P67; Setcos JC, 1998, INT J PROSTHODONT, V11, P150; Shugars D, 1987, Gen Dent, V35, P272; Shugars D A, 1990, J Dent Educ, V54, P661; Sinclair Neil A., 2004, New Zealand Dental Journal, V100, P38; SMIT HA, 1992, CONTACT DERMATITIS, V26, P11, DOI 10.1111/j.1600-0536.1992.tb00861.x; Smith DR, 2006, INT DENT J, V56, P283; Smith N J, 1987, Int Dent J, V37, P43; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; *THAI MIN PUBL HLT, 1998, ANN REP AIDS STAT SO; Thomson WM, 1997, COMMUNITY DENT ORAL, V25, P391, DOI 10.1111/j.1600-0528.1997.tb01728.x; Treasure P, 1994, Int Dent J, V44, P342; VERRUSIO AC, 1989, J AM DENT ASSOC, V118, P553; WALL TP, 1984, J AM DENT ASSOC, V108, P81; Wallenhammar LM, 2000, CONTACT DERMATITIS, V43, P192, DOI 10.1034/j.1600-0536.2000.043004192.x; Walsh L J, 1995, Quintessence Int, V26, P203; Wells A, 1999, J Dent Educ, V63, P805; Yengopal V, 2001, SADJ, V56, P580; Zakrzewska JM, 2001, BRIT DENT J, V190, P88, DOI 10.1038/sj.bdj.4800891a	100	72	80	8	43	NATL INST OCCUPATIONAL SAFETY & HEALTH, JAPAN	KAWASAKI KANAGAWA	21-1 NAGAO 6-CHOME TAMA-KU, KAWASAKI KANAGAWA, 214, JAPAN	0019-8366			IND HEALTH	Ind. Health	OCT	2007	45	5					611	621		10.2486/indhealth.45.611		11	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	227HB	WOS:000250646700003	18057804	
J	Hagvall, L; Backtorp, C; Svensson, S; Nyman, G; Borje, A; Karlberg, AT				Hagvall, Lina; Backtorp, Carina; Svensson, Sophie; Nyman, Gunnar; Borje, Anna; Karlberg, Ann-Therese			Fragrance compound geraniol forms contact allergens on air exposure. Identification and quantification of oxidation products and effect on skin sensitization	CHEMICAL RESEARCH IN TOXICOLOGY			English	Article							OXIDIZED D-LIMONENE; LYMPH-NODE ASSAY; DERMATITIS; HYDROPEROXIDES; ALDEHYDES; CAPACITY; LINALOOL; POTENCY; COMMON	Fragrances are common causes of contact allergy. Geraniol (trans-3,7-dimethyl-2,6-octadiene-1-ol) is an important fragrance terpene. It is considered a weak contact allergen and is used for fragrance allergy screening among consecutive dermatitis patients. Analogous to other monoterpenes studied, such as limonene and linalool, geraniol has the potential to autoxidize on air exposure and form highly allergenic compounds. The aim of the present study was to investigate and propose a mechanism for the autoxidation of geraniol at room temperature. To investigate whether allergenic compounds are formed, the sensitizing potency of geraniol itself, air-exposed geraniol, and its oxidation products was determined using the local lymph node assay in mice. The results obtained show that the allylic alcohol geraniol follows an oxidation pattern different from those of linalool and limonene, which autoxidize forming hydroperoxides as the only primary oxidation products. The autoxidation of geraniol follows two paths, originating from allylic hydrogen abstraction near the two double bonds. From geraniol, hydrogen peroxide is primarily formed together with aldehydes geranial and neral from a hydroxyhydroperoxide. In addition, small amounts of a hydroperoxide are formed, analogous to the formation of the major linalool hydroperoxide. The autoxidation of geraniol greatly influenced the sensitizing effect of geraniol. The oxidized samples had moderate sensitizing capacity, quite different from that of pure geraniol. The hydroperoxide formed is believed to be the major contributor to allergenic activity, together with the aldehydes geranial and neral. On the basis of the present study and previous experience, we recommend that the possibility of autoxidation and the subsequent formation of contact allergenic oxidation products are considered in risk assessments performed on fragrance terpenes.	Univ Gothenburg, Dept Chem Dermatochem & Skin Allergy, SE-41296 Gothenburg, Sweden; Univ Gothenburg, Dept Chem, SE-41296 Gothenburg, Sweden; Sahlgrens Acad, SE-40530 Gothenburg, Sweden; Univ Hosp, SE-40530 Gothenburg, Sweden	Karlberg, AT (reprint author), Univ Gothenburg, Dept Chem Dermatochem & Skin Allergy, SE-41296 Gothenburg, Sweden.	karlberg@chem.gu.se	Nyman, Gunnar/B-1705-2009; Borje, Anna/A-7581-2010; Karlberg, Ann-Therese/A-7706-2010				Basketter DA, 2001, CONTACT DERMATITIS, V45, P89, DOI 10.1034/j.1600-0536.2001.045002089.x; Basketter DA, 1999, J APPL TOXICOL, V19, P261, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<261::AID-JAT572>3.0.CO;2-5; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; Bergh M, 1999, J PHARM SCI, V88, P483, DOI 10.1021/js980210y; Bergstrom MA, 2006, CHEM RES TOXICOL, V19, P760, DOI 10.1021/tx060006n; Bezard M, 1997, CHEM RES TOXICOL, V10, P987, DOI 10.1021/tx970014r; BOLLAND JL, 1949, Q REV CHEM SOC, V3, P1, DOI 10.1039/qr9490300001; DeGroot AC, 1997, CONTACT DERMATITIS, V36, P57; DEROCH IS, 1968, BELG CHEM IND, V33, P994; Frisch MJ, 2004, GAUSSIAN 03; FROSCH PJ, 1995, CONTACT DERMATITIS, V33, P333, DOI 10.1111/j.1600-0536.1995.tb02048.x; Guengerich FP, 2001, CHEM RES TOXICOL, V14, P611, DOI 10.1021/tx0002583; Heinmoller P, 1998, ANAL CHEM, V70, P1437, DOI 10.1021/ac970867o; Jensen F., 1999, INTRO COMPUTATIONAL; KARLBERG AT, 1994, ARCH DERMATOL RES, V286, P97, DOI 10.1007/BF00370734; KARLBERG AT, 1992, CONTACT DERMATITIS, V26, P332, DOI 10.1111/j.1600-0536.1992.tb00129.x; Karlberg AT, 1997, CONTACT DERMATITIS, V36, P201, DOI 10.1111/j.1600-0536.1997.tb00270.x; Kimber I, 2003, FOOD CHEM TOXICOL, V41, P1799, DOI 10.1016/S0278-6915(03)00223-0; Kimber I, 1995, TOXICOLOGY, V103, P63, DOI 10.1016/0300-483X(95)03114-U; Knapp H, 1998, J AGR FOOD CHEM, V46, P1966, DOI 10.1021/jf970987x; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Liang CP, 2004, MOL NUTR FOOD RES, V48, P308, DOI 10.1002/mnfr.200400027; MAIR RD, 1964, ANAL CHEM, V36, P194, DOI 10.1021/ac60207a061; Matura M, 2005, CONTACT DERMATITIS, V52, P320, DOI 10.1111/j.0105-1873.2005.00605.x; Matura M, 2002, J AM ACAD DERMATOL, V47, P709, DOI 10.1067/mjd.2002.124817; Mutterer V, 2000, CHEM RES TOXICOL, V13, P1028, DOI 10.1021/tx9901433; Parejo I, 2000, J PHARMACOL TOXICOL, V43, P183, DOI 10.1016/S1056-8719(00)00085-X; PARLANT C, 1964, B SOC CHIM FR, P3161; Patlewicz G, 2001, CONTACT DERMATITIS, V44, P331, DOI 10.1034/j.1600-0536.2001.044006331.x; Patlewicz GY, 2002, CONTACT DERMATITIS, V47, P219, DOI 10.1034/j.1600-0536.2002.470406.x; PATLEWICZ GY, 2004, CONTACT DERMATITIS, V50, P891; Pedersen LK, 2004, CONTACT DERMATITIS, V50, P265, DOI 10.1111/j.0105-1873.2004.00342.x; Rastogi SC, 1996, CONTACT DERMATITIS, V34, P423, DOI 10.1111/j.1600-0536.1996.tb02246.x; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; SANTUCCI B, 1987, CONTACT DERMATITIS, V16, P93, DOI 10.1111/j.1600-0536.1987.tb01386.x; Schnuch A, 2004, CONTACT DERMATITIS, V50, P65, DOI 10.1111/j.0105-1873.2004.00302.x; Skold M, 2004, CHEM RES TOXICOL, V17, P1697, DOI 10.1021/tx049831z; Skold M, 2002, CONTACT DERMATITIS, V46, P267, DOI 10.1034/j.1600-0536.2002.460504.x; Svensson S, 2004, J CHROMATOGR B, V809, P199, DOI 10.1016/j.jchromb.2004.06.027	40	72	72	3	19	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0893-228X	1520-5010		CHEM RES TOXICOL	Chem. Res. Toxicol.	MAY	2007	20	5					807	814		10.1021/tx700017v		8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology	Pharmacology & Pharmacy; Chemistry; Toxicology	169GT	WOS:000246581400012	17428070	
J	D'Amato, G; Liccardi, G; Frenguelli, G				D'Amato, G.; Liccardi, G.; Frenguelli, G.			Thunderstorm-asthma and pollen allergy	ALLERGY			English	Review						allergic asthma; bronchial asthma; bronchial hyperreactivity; climate changes; environment and allergy; pollen allergy; pollinosis; respiratory allergy; thunderstorm-asthma	GRASS-POLLEN; ENVIRONMENTAL-FACTORS; AIR-POLLUTION; HAY-FEVER; EPIDEMICS; RISK; SENSITIZATION; COMMUNITY; ORBICULES; OUTBREAK	Thunderstorms have been linked to asthma epidemics, especially during the pollen seasons, and there are descriptions of asthma outbreaks associated with thunderstorms, which occurred in several cities, prevalently in Europe (Birmingham and London in the UK and Napoli in Italy) and Australia (Melbourne and Wagga Wagga). Pollen grains can be carried by thunderstorm at ground level, where pollen rupture would be increased with release of allergenic biological aerosols of paucimicronic size, derived from the cytoplasm and which can penetrate deep into lower airways. In other words, there is evidence that under wet conditions or during thunderstorms, pollen grains may, after rupture by osmotic shock, release into the atmosphere part of their content, including respirable, allergen-carrying cytoplasmic starch granules (0.5-2.5 mu m) or other paucimicronic components that can reach lower airways inducing asthma reactions in pollinosis patients. The thunderstorm-asthma outbreaks are characterized, at the beginning of thunderstorms by a rapid increase of visits for asthma in general practitioner or hospital emergency departments. Subjects without asthma symptoms, but affected by seasonal rhinitis can experience an asthma attack. No unusual levels of air pollution were noted at the time of the epidemics, but there was a strong association with high atmospheric concentrations of pollen grains such as grasses or other allergenic plant species. However, subjects affected by pollen allergy should be informed about a possible risk of asthma attack at the beginning of a thunderstorm during pollen season.	High Special Hosp A Cardarelli, Dept Resp Dis, Div Pneumol & Allergol, I-80121 Naples, Italy; Univ Perugia, Dept Plant Biol, I-06100 Perugia, Italy	D'Amato, G (reprint author), High Special Hosp A Cardarelli, Dept Resp Dis, Div Pneumol & Allergol, Via Rione Sirignano 10, I-80121 Naples, Italy.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; FRENGUELLI, Giuseppe/0000-0002-6282-2814			Anto JM, 1997, THORAX, V52, P669; ANTO JM, 2002, MONOGRAPH EUROPEAN R, P108; ANTO JM, 1999, DIFFICULT ASTHMA, P333; Bauman A, 1996, BRIT MED J, V312, P590; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Celenza A, 1996, BRIT MED J, V312, P604; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 2005, CLIN EXP ALLERGY, V35, P1113, DOI 10.1111/j.1365-2222.2005.02328.x; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; D'Amato G, 2001, ALLERGY, V56, P1109, DOI 10.1034/j.1398-9995.2001.00317.x; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; D'Amato G, 2005, BMJ; Davidson AC, 1996, BRIT MED J, V312, P601; ElGhazaly G, 1995, GRANA, V34, P300; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; MURRAY V, 1994, BRIT MED J, V309, P131; Newson R, 1998, EUR RESPIR J, V11, P694; Newson R, 1997, THORAX, V52, P669; PACKE GE, 1985, LANCET, V2, P199; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Schappi GF, 1999, ALLERGY, V54, P478, DOI 10.1034/j.1398-9995.1999.00838.x; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Taylor PE, 2004, CLIN EXP ALLERGY, V34, P1591, DOI 10.1111/j.1365-2222.2004.02078.x; Taylor PE, 2002, J ALLERGY CLIN IMMUN, V109, P51, DOI 10.1067/mai.2002.120759; Thommen AA, 1930, NY STATE J MED, P437; Traidl-Hoffmann C, 2003, INT ARCH ALLERGY IMM, V131, P1, DOI 10.1159/000070428; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; Vinckier S, 2001, ALLERGY, V56, P1129, DOI 10.1034/j.1398-9995.2001.00172.x; Wallis D. N., 1995, European Respiratory Journal, V8, p500S; Wardman A E Dennis, 2002, Can Respir J, V9, P267	35	72	73	4	18	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JAN	2007	62	1					11	16		10.1111/j.1398-9995.2006.01271.x		6	Allergy; Immunology	Allergy; Immunology	113YQ	WOS:000242634300003	17156336	
J	Kikuchi, Y; Takai, T; Kuhara, T; Ota, M; Kato, T; Hatanaka, H; Ichikawa, S; Tokura, T; Akiba, H; Mitsuishi, K; Ikeda, S; Okumura, K; Ogawa, H				Kikuchi, Yuko; Takai, Toshiro; Kuhara, Takatoshi; Ota, Mikiko; Kato, Takeshi; Hatanaka, Hideki; Ichikawa, Saori; Tokura, Tomoko; Akiba, Hisaya; Mitsuishi, Kouichi; Ikeda, Shigaku; Okumura, Ko; Ogawa, Hideoki			Crucial commitment of proteolytic activity of a purified recombinant major house dust mite allergen der p1 to sensitization toward IgE and IgG responses	JOURNAL OF IMMUNOLOGY			English	Article							CYSTEINE PROTEASE ACTIVITY; DER-F-I; DERMATOPHAGOIDES-PTERONYSSINUS; CRYSTAL-STRUCTURE; SEQUENCE POLYMORPHISMS; ENHANCES ALLERGENICITY; POTENTIAL ALLERGENS; ANTIBODY-RESPONSE; HEAT DENATURATION; GROUP-1 ALLERGEN	The major proteolytic allergen derived from the house dust mite Dermatophagoides pteronyssinus, Der Ill, is one of the most clinically relevant allergens worldwide. In the present study, we evaluate the contribution of the proteolytic activity and structure of a highly purified rDer p 1 to immune responses. Mice were i.p. immunized with three forms of rDer p I adsorbed to Alum: one enzymatically active, one treated with an irreversible cysteine protease-specific inhibitor, E-64, and one heat denatured. Immunization with E-64-treated or heat-denatured rDer p I elicited much less production of serum total IgE and not only rDer p 1-specific IgE but also IgGs compared with immunization with active rDer p 1. Assays for Ab-binding and its inhibition and structural analyses indicated that E-64-treated rDer p I retained its global structure and conformational B cell epitopes. A proliferative response and production of IL-5 by spleen cells restimulated with rDer p I were observed on immunization with the active rDer p 1 but not E-64-treated rDer p 1. The cells from mice immunized with heat-denatured rDer p I exhibited the highest levels of proliferation and production of IL-5 and IFN-gamma. The results indicate that the proteolytic activity of the highly purified rDer p I crucially commits to the sensitization process, including both IgE and IgG responses. Additionally, we demonstrated immunogenic differences by functional or structural manipulations of the rDer p 1. The findings have implications for sensitization to this relevant allergen in humans and for the design of modified allergen-vaccines for future allergen-specific immunotherapy.	Juntendo Univ, Sch Med, Atopy Res Ctr, Bunkyo Ku, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Dermatol, Tokyo 1138421, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan; Univ Tokyo, Fac Pharmaceut Sci, Dept Hyg Chem, Chiba, Japan; Kyushu Univ, Grad Sch Syst Life Sci, Fukuoka 812, Japan; Japan Womens Univ, Fac Sci, Dept Mat & Biol Sci, Tokyo 112, Japan	Takai, T (reprint author), Juntendo Univ, Sch Med, Atopy Res Ctr, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	t-takai@med.juntendo.ac.jp	Takai, Toshiro/K-5690-2013				ANDO T, 1991, INT ARCH ALLER A IMM, V96, P199; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; Chambers L, 1998, BIOCHEM BIOPH RES CO, V253, P837, DOI 10.1006/bbrc.1998.9862; CHAPMAN MD, 1983, J ALLERGY CLIN IMMUN, V72, P27, DOI 10.1016/0091-6749(83)90048-9; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; CHUA KY, 1993, INT ARCH ALLERGY IMM, V101, P364; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Collins SP, 1996, CLIN EXP ALLERGY, V26, P36, DOI 10.1111/j.1365-2222.1996.tb00054.x; Comoy EE, 1998, J IMMUNOL, V160, P2456; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; Epton MJ, 2002, CLIN EXP ALLERGY, V32, P1341, DOI 10.1046/j.1365-2222.2002.01473.x; Fujishima A, 1997, FEBS LETT, V407, P47, DOI 10.1016/S0014-5793(97)00216-0; Furuya M, 2005, CANCER RES, V65, P2617, DOI 10.1158/0008-5472.CAN-04-3123; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P728, DOI 10.1046/j.1365-2222.2002.01374.x; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4<1211::AID-IMMU1211>3.0.CO;2-R; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Grunstein MM, 2005, J ALLERGY CLIN IMMUN, V116, P94, DOI 10.1016/j.jaci.2005.03.046; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; HEYMANN PW, 1986, J IMMUNOL, V137, P2841; Holt PG, 2005, NAT IMMUNOL, V6, P957, DOI 10.1038/ni1005-957; Ichikawa S, 1998, J BIOL CHEM, V273, P356, DOI 10.1074/jbc.273.1.356; Ichikawa S, 2005, J BIOCHEM, V137, P255, DOI 10.1093/jb/mvi039; INO Y, 1989, INT ARCH ALLER A IMM, V89, P321; Johansen P, 2005, EUR J IMMUNOL, V35, P3591, DOI 10.1002/eji.200535076; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; KAMATA I, 1995, CLIN EXP IMMUNOL, V102, P71; Kato T, 2005, J ALLERGY CLIN IMMUN, V116, P169, DOI 10.1016/j.jaci.2005.03.044; King C, 1998, J IMMUNOL, V161, P3645; Korematsu S, 2000, J IMMUNOL, V165, P2895; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; LOMBARDERO M, 1990, J IMMUNOL, V144, P1353; Machado DC, 1996, EUR J IMMUNOL, V26, P2972, DOI 10.1002/eji.1830261224; Magi M, 2004, J ALLERGY CLIN IMMUN, V114, P545, DOI 10.1016/j.jaci.2004.04.014; Meno K, 2005, J IMMUNOL, V175, P3835; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; MIYAMOTO T, 1968, J ALLERGY, V42, P14, DOI 10.1016/0021-8707(68)90128-7; Moriguchi K, 2005, PLANT CELL, V17, P389, DOI 10.1105/tpc.104.028456; Nakazawa T, 2005, FEBS LETT, V579, P1988, DOI 10.1016/j.febslet.2005.01.088; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Pollock KGJ, 2003, J IMMUNOL, V170, P1746; Sakata Y, 2004, J BIOL CHEM, V279, P5081, DOI 10.1074/jbc.M311585200; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; STEWART GA, 1991, INT ARCH ALLER A IMM, V95, P248; Takahashi K, 2000, INT ARCH ALLERGY IMM, V122, P108, DOI 10.1159/000024366; Takai T, 2000, FEBS LETT, V484, P102, DOI 10.1016/S0014-5793(00)02096-2; Takai T, 2006, INT ARCH ALLERGY IMM, V139, P181, DOI 10.1159/000091163; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P194, DOI 10.1159/000086331; Takai T, 2005, J ALLERGY CLIN IMMUN, V115, P555, DOI 10.1016/j.jaci.2004.11.024; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; Takai T, 2002, FEBS LETT, V531, P265, DOI 10.1016/S0014-5793(02)03534-2; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P388, DOI 10.1007/s11882-005-0012-1; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V81, P884, DOI 10.1016/0091-6749(88)90946-3; VARUGHESE KI, 1992, BIOCHEMISTRY-US, V31, P5172, DOI 10.1021/bi00137a012; VARUGHESE KI, 1989, BIOCHEMISTRY-US, V28, P1330, DOI 10.1021/bi00429a058; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214; YASUEDA H, 1989, INT ARCH ALLER A IMM, V88, P402; Yasuhara T, 2001, BIOSCI BIOTECH BIOCH, V65, P563, DOI 10.1271/bbb.65.563; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x; Zhao BG, 1997, NAT STRUCT BIOL, V4, P109, DOI 10.1038/nsb0297-109	73	72	77	0	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2006	177	3					1609	1617				9	Immunology	Immunology	065DT	WOS:000239140300035	16849469	
J	Lusuardi, M; De Benedetto, F; Paggiaro, P; Sanguinetti, CM; Brazzola, G; Ferri, P; Donner, CF				Lusuardi, M; De Benedetto, F; Paggiaro, P; Sanguinetti, CM; Brazzola, G; Ferri, P; Donner, CF			A randomized controlled trial on office spirometry in asthma and COPD in standard general practice - Data from spirometry in asthma and COPD: a comparative evaluation Italian study	CHEST			English	Article						asthma; COPD; general practice; office spirometry	OBSTRUCTIVE PULMONARY-DISEASE; PRIMARY-CARE; PERSISTENT COUGH; POPULATION; PROGRAM	Study objectives: To evaluate whether office spirometry by general practitioners (GPs) is feasible and may improve the diagnosis of asthma and COPD. Methods: A prospective, randomized, comparative trial was planned involving 57 Italian pulmonology centers and 570 GPs who had to enroll consecutive subjects aged IS to 65 years with symptoms of asthma or COPD without a previous diagnosis. Patients were randomized 1:1 into two groups with an interactive voice responding system: conventional evaluation alone vs conventional evaluation and spirometry. Office spirometry was performed by GPs who were trained by reference specialists using a portable electronic spirometer (Spirobank Office; MIR; Home, Italy). Diagnosis was confirmed by the reference specialist center in blind fashion. Results: Seventy-four GPs complied to the trial. Of :333 patients enrolled, 136 nonrandom violators completed the protocol. Per-protocol analysis showed a concordant diagnosis between GPs and specialists in 78.6% of cases in the conventional evaluation-plus-spirometry group vs 69.2% in the conventional evaluation group (p = 0.35). In the intention-to-treat analysis, the respective percentages of concordant diagnosis were 57.9 and 56.7 (p = 0.87). Conclusions: Office spirometry by GPs is feasible, but frequent protocol violation and inadequate sample size did not allow us to prove a significant advantage of office spirometry in improving the diagnosis of asthma and COPD in standard general practice as organized at present in Italy, thus reinforcing the need for close cooperation between GPs and specialists in respiratory medicine.	AUSL Reggio Emilia, S Sebastiano Hosp, Cardiopulm Rehabil, I-42015 Correggio, RE, Italy; San Camillo Hosp, Dept Resp Med, Chieti, Italy; Univ Pisa, Cardiothorac Dept, I-56100 Pisa, Italy; S Filippo Neri Hosp, Dept Resp Med, Rome, Italy; SIMESA, Astra Zeneca Grp, Milan, Italy; IRCCS, Salvatore Maugeri Fdn, Div Pulm Dis, Veruno, Italy	Lusuardi, M (reprint author), AUSL Reggio Emilia, S Sebastiano Hosp, Cardiopulm Rehabil, Via Mandriolo 11, I-42015 Correggio, RE, Italy.	lusuardimi@ausl.re.it	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Bolton CE, 2005, RESP MED, V99, P493, DOI 10.1016/j.rmed.2004.09.015; Buffels J, 2004, CHEST, V125, P1394, DOI 10.1378/chest.125.4.1394; Chan B, 1997, CAN MED ASSOC J, V156, P169; Dowson L J, 1999, Monaldi Arch Chest Dis, V54, P186; Eaton T, 1999, CHEST, V116, P416, DOI 10.1378/chest.116.2.416; Ferguson GT, 2000, CHEST, V117, P1146, DOI 10.1378/chest.117.4.1146; Griffiths C, 1999, RESP MED, V93, P903, DOI 10.1016/S0954-6111(99)90057-4; Hankinson JL, 1999, CHEST, V116, P276, DOI 10.1378/chest.116.2.276; NIH National Institutes of Health, 2006, NIH PUBL, V07-4518; Pinnock H, 1999, ASTHMA GEN PRACT, V7, P23; Schermer T, 2003, EUR RESPIR J, V22, P725, DOI 10.1183/0903196.03.00075203; Schermer TR, 2003, THORAX, V58, P861, DOI 10.1136/thorax.58.10.861; Takahashi TU, 2003, RESPIROLOGY, V8, P504, DOI 10.1046/j.1440-1843.2003.00501.x; Thiadens HA, 1999, THORAX, V54, P1055; Thiadens HA, 1998, BRIT MED J, V316, P1286; van den Boom G, 1998, AM J RESP CRIT CARE, V158, P1730; Voelkel NF, 2000, CHEST, V117, p372S, DOI 10.1378/chest.117.5_suppl_2.372S; Vrijhoef HJM, 2003, J CLIN NURS, V12, P366; 2001, AM J RESPIR CRIT CAR, V163, P1256	19	72	72	2	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	APR	2006	129	4					844	852		10.1378/chest.129.4.844		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	034CB	WOS:000236901000007	16608929	
J	Magnusson, LL; Olesen, AB; Wennborg, H; Olsen, J				Magnusson, LL; Olesen, AB; Wennborg, H; Olsen, J			Wheezing, asthma, hayfever, and atopic eczema in childhood following exposure to tobacco smoke in fetal life	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopic diseases; prenatal; smoke exposure; tobacco; wheezing	CORD-SERUM IGE; PERINATAL RISK-FACTORS; MATERNAL SMOKING; PARENTAL SMOKING; LUNG-FUNCTION; ALLERGIC SENSITIZATION; BRONCHIAL HYPERRESPONSIVENESS; REPRODUCTIVE HEALTH; RESPIRATORY ILLNESS; FAMILY-HISTORY	Prenatal maternal smoking has been associated with adverse respiratory effects in childhood such as lung deficits and wheezing, but results concerning asthma, hayfever, and atopic eczema are inconsistent. In the present study, we investigate the effects of maternal smoking in pregnancy on asthma, hayfever, atopic eczema, and wheezing in the offspring up to the age of 14-18. The study was based on a cohort of mothers enrolled during midwife visits around the 36th week of gestation in Odense and Aalborg, Denmark, 1984-1987. Singleton, live born children (n=11 144) were followed-up in 2002 to obtain a childhood history of atopic diseases, by means of questionnaires to the parents. Multivariate logistic regression analyses for medical diagnoses of asthma, hayfever, atopic eczema, and symptoms of wheezing before the age of 3, were carried out on 7844 children. After adjustment for confounders, late prenatal smoke exposure was associated with wheezing, with an odds ratio (OR) of 1.2, and a 95% confidence interval (CI) of 1.1-1.5. Furthermore, slightly reduced estimates for hayfever (OR 0.8, CI 0.7-1.0) and atopic eczema (OR 0.8, CI 0.7-0.9) were obtained for children exposed in late pregnancy compared with non-exposed. Late gestational smoke exposure was associated with wheezing but not with asthma, while null or even protective estimates were indicated for hayfever and atopic eczema. However, lack of control options for hereditary factors may have affected the results.	Karolinska Inst, Dept Biosci, Novum, S-14157 Huddinge, Sweden; Aarhus Univ Hosp, Danish Epidemiol Sci Ctr, DK-8000 Aarhus, Denmark; Aarhus Univ Hosp, Dept Dermatol, DK-8000 Aarhus, Denmark; Univ Calif Los Angeles, Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA	Magnusson, LL (reprint author), Karolinska Inst, Dept Biosci, Novum, S-14157 Huddinge, Sweden.	linda.magnusson@biosci.ki.se	Magnusson Hanson, Linda/D-2435-2017	Magnusson Hanson, Linda/0000-0002-2908-1903			*ARB, 1979, DANKS FAG KOD; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Atici A, 1995, PEDIATR ALLERGY IMMU, V6, P213, DOI 10.1111/j.1399-3038.1995.tb00288.x; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; BERGMANN RL, 1995, ALLERGY, V50, P65, DOI 10.1111/j.1398-9995.1995.tb02484.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; [California Environmental Protection Agency (Cal EPA) Office of Environmental Health Hazard Assessment], 1997, HLTH EFF EXP ENV TOB; CUNNINGHAM J, 1995, AM J RESP CRIT CARE, V152, P565; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Dempsey DA, 2001, DRUG SAFETY, V24, P277, DOI 10.2165/00002018-200124040-00005; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Frey U, 2004, AM J RESP CRIT CARE, V170, P260, DOI 10.1164/rccm.200307-1002OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gupta R, 2004, CLIN EXP ALLERGY, V34, P520, DOI 10.1111/j.1365-2222.2004.1935.x; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; Hjern A, 2001, CLIN EXP ALLERGY, V31, P908, DOI 10.1046/j.1365-2222.2001.01096.x; Hu FB, 1997, ANN ALLERG ASTHMA IM, V79, P80; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; Kerkhof M, 2003, CLIN EXP ALLERGY, V33, P1336, DOI 10.1046/j.1365-2222.2003.01751.x; Kramer U, 2004, BRIT J DERMATOL, V150, P111, DOI 10.1111/j.1365-2133.2004.05710.x; Kulig M, 1998, CLIN EXP ALLERGY, V28, P1397, DOI 10.1046/j.1365-2222.1998.00439.x; Kuyucu S, 2004, PEDIATR ALLERGY IMMU, V15, P62, DOI 10.1046/j.0905-6157.2003.00115.x; Landau L I, 2001, Paediatr Respir Rev, V2, P202, DOI 10.1053/prrv.2001.0141; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Lewis SA, 1998, RESP MED, V92, P1237, DOI 10.1016/S0954-6111(98)90427-9; Lindbohm ML, 2002, SCAND J WORK ENV HEA, V28, P84; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; MARTINEZ FD, 1988, NEW ENGL J MED, V319, P1112, DOI 10.1056/NEJM198810273191702; Melen E, 2004, CLIN EXP ALLERGY, V34, P839, DOI 10.1111/j.1365-2222.2004.01957.x; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; Murray CS, 2004, PEDIATR PULM, V37, P492, DOI 10.1002/ppul.20019; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; O'Connell EJ, 2004, ALLERGY, V59, P7, DOI 10.1111/j.1398-9995.2004.00563.x; Olesen AB, 1997, BRIT MED J, V314, P1003; Olesen AB, 2001, ACTA DERM-VENEREOL, V81, P277, DOI 10.1080/00015550152572921; OLSEN J, 1993, SCAND J SOC MED, V21, P90; Olsen J, 2000, EPIDEMIOL REV, V22, P76; OLSEN J, 1989, SCAND J SOC MED, V17, P277; ORYSZCZYN MP, 1991, J ALLERGY CLIN IMMUN, V87, P1169, DOI 10.1016/0091-6749(91)92163-U; OWNBY DR, 1991, J ALLERGY CLIN IMMUN, V88, P555, DOI 10.1016/0091-6749(91)90148-H; RONA RJ, 1993, BRIT MED J, V306, P817; Schafer T, 1997, J AM ACAD DERMATOL, V36, P550, DOI 10.1016/S0190-9622(97)70242-1; Schultz Larsen F, 1992, Acta Derm Venereol Suppl (Stockh), V176, P7; Sekhon HS, 2004, EUR RESPIR J, V23, P906, DOI 10.1183/09031936.04.00069604; Sekhon HS, 2001, AM J RESP CRIT CARE, V164, P989; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; StataCorp, 2003, STAT STAT SOFTW REL; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Stocks J, 2003, RESPIROLOGY, V8, P266, DOI 10.1046/j.1440-1843.2003.00478.x; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1998, THORAX, V53, P204; Tariq SM, 2000, POSTGRAD MED J, V76, P694, DOI 10.1136/pmj.76.901.694; TAYLOR B, 1984, LANCET, V2, P1255; Upton MN, 2000, BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; Vonk JM, 2004, J ALLERGY CLIN IMMUN, V114, P270, DOI 10.1016/j.jaci.2004.03.051; WILLIAMS HC, 1996, SO D I DEFINE ATOPIC; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240	66	72	76	0	4	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	DEC	2005	35	12					1550	1556				7	Allergy; Immunology	Allergy; Immunology	990XT	WOS:000233777400006	16393320	
J	Kang, CM; Jang, AS; Ahn, MH; Shin, LA; Kim, JH; Choi, YS; Rhim, TY; Park, CS				Kang, CM; Jang, AS; Ahn, MH; Shin, LA; Kim, JH; Choi, YS; Rhim, TY; Park, CS			Interleukin-25 and interieukin-13 production by alveolar macrophages in response to particles	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						cytokines; inflammation; lung; macrophages	PARTICULATE AIR-POLLUTION; IN-VIVO; DIESEL EXHAUST; CHEMOKINE EXPRESSION; CYTOKINE PRODUCTION; PULMONARY-FUNCTION; TITANIUM-DIOXIDE; CELL-FUNCTION; RAT LUNG; MATTER	Particle inhalation-induced lung inflammation acts as an adjuvant to allergens or respiratory viral infection in a process that is mediated by macrophages and epitheliums. The production of interleukin (IL)-4 and IL-13 by activated T cells is involved in the augmentation of Th2-type immune responses to particles, and IL-25 induces the synthesis of 11-4 and IL-13. However, whether IL-13 and IL-25 are directly regulated by particle instillation in the lung has not been studied. The aim of this study was to reveal particle induction of IL-13 and IL-25 in the lung. TiO2 instillation potently induced the mRNA expression for IL-25 and IL-13 in lung tissue extracts 24 h after treatment, as compared with the sham group. Immunostaining for IL-25 and IL-13 showed strong positivity for macrophages in the inflammatory lung lesions of TiO2-treated rats. The alveolar macrophages expressed IL-25 and IL-13 24h after in vitro stimulation with TiO2 particles in dose- and time-dependent manners, with maximal induction at 24 and 48 h after stimulation, respectively. The sequence of the rat IL-25 gene is 95% homologous with the mouse IL-25 gene. These findings indicate that alveolar macrophages play an important role in particle-induced lung inflammation via direct induction of IL-13 and IL-25 production.	Soonchunhyang Univ Hosp, Dept Internal Med, Div Allergy & Resp Dis, Gyeonggido 420767, South Korea; Soonchunhyang Univ Hosp, Genome Res Ctr Allergy & Resp Dis, Puchon, South Korea; Soonchunhyang Univ Hosp, Div Allergy & Resp Dis, Puchon, South Korea	Park, CS (reprint author), Soonchunhyang Univ Hosp, Dept Internal Med, Div Allergy & Resp Dis, 1174 Jung Dong, Gyeonggido 420767, South Korea.	mdcspark@unitel.co.kr					Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; BRODY AR, 1992, J LEUKOCYTE BIOL, V51, P640; BURD PR, 1995, J EXP MED, V181, P1373, DOI 10.1084/jem.181.4.1373; Churg A, 1999, AM J PHYSIOL-LUNG C, V277, pL975; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Driscoll KE, 1995, TOXICOL LETT, V82-3, P483, DOI 10.1016/0378-4274(95)03578-8; Fahy O, 2002, J IMMUNOL, V168, P5912; Fernvik E, 2002, J TOXICOL ENV HEAL A, V65, P1025, DOI 10.1080/00984100290071108; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Fujii T, 2001, AM J RESP CELL MOL, V25, P265; GARABRANT DH, 1987, SCAND J WORK ENV HEA, V13, P47; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamilton RF, 2004, EXP LUNG RES, V30, P147, DOI 10.1080/01902140490266439; Hoshino T, 1999, J Immunol, V162, P51; Hurst SD, 2002, J IMMUNOL, V169, P443; Ikeda K, 2003, BLOOD, V101, P3594, DOI 10.1182/blood-2002-09-2817; Lanone S, 2002, J CLIN INVEST, V110, P463, DOI 10.1172/JCI200214136; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Lentsch AB, 1999, J IMMUNOL, V162, P1071; Li HM, 1996, J IMMUNOL, V156, P4833; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Lindroos PM, 1997, AM J RESP CELL MOL, V16, P283; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Pagan I, 2003, J TOXICOL ENV HEAL A, V66, P1087, DOI 10.1080/15287390390213908; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565; POPE CA, 1993, AM REV RESPIR DIS, V147, P1336; ROBERTS JR, 2003, J TOXICOL ENV HEAL A, V67, P251; Ruth JH, 2000, CYTOKINE, V12, P432, DOI 10.1006/cyto.1999.0595; Sahoo SK, 2002, J CONTROL RELEASE, V82, P105, DOI 10.1016/S0168-3659(02)00127-X; Salvi S, 1999, CLIN EXP ALLERGY, V29, P1187; Schafer T, 1997, ALLERGY, V52, P14; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SOZZANI P, 1995, J BIOL CHEM, V270, P5084; TEMPLETON DM, 1994, HDB METALS CLIN ANAL, P627; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; Ward PA, 2002, MOL CELL BIOCHEM, V234, P225, DOI 10.1023/A:1015944709177; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Zelikoff JT, 2003, INHAL TOXICOL, V15, P131, DOI 10.1080/08958370390168201	44	72	78	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	SEP	2005	33	3					290	296		10.1165/rcmb.2005-0003OC		7	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	961VI	WOS:000231689500011	15961726	
J	Sepp, E; Julge, K; Mikelsaar, M; Bjorksten, B				Sepp, E; Julge, K; Mikelsaar, M; Bjorksten, B			Intestinal microbiota and immunoglobulin E responses in 5-year-old Estonian children	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; bacteroides; bifidobacteria; children; clostridia; gut microbiota; IgE	ATOPIC DISEASES; ALLERGY; MICROFLORA; CHILDHOOD; INFANTS; EXPOSURE; BIFIDOBACTERIA; SENSITIZATION; PREVALENCE; ANTIBODIES	Background Over the last few decades, several studies from different parts of the world have indicated an increasing prevalence of allergic diseases. This has been related to environmental factors, like changes of microbial pressure. Our previous studies have demonstrated differences in the intestinal microbiota between allergic and non-allergic children. Aim To test the hypothesis that the intestinal microbiota and IgE response are related, both in allergic and non-allergic 5-year-old Estonian children. Methods The study group comprised 19 allergic and 19 non-allergic 5-year-old children, selected from a larger group who had been followed from birth. The diagnosis of allergy was based on clinical examination of the children and on data obtained from the questionnaires. The faecal microbiota were quantified by seeding serial dilutions on nine different media for incubation in different environment. The composition of the gut microbiota was expressed both as absolute counts of the various species and their relative share among the total counts of identified microbiota. Results Bifidobacteria were less commonly detected in children with allergic diseases than in healthy children and clostridia comprised a higher proportion among their gut microbes. Children with specific IgE antibodies to defined allergens had higher counts of clostridia and the counts of clostridia correlated with the level of serum IgE, but only so in allergic children. In non-allergic children, the serum IgE levels showed a positive correlation with the counts of bacteroides. Conclusion The development of allergic diseases seems to be associated with the composition of the gut microbial ecosystem. High counts of potential pathogens, such as clostridia, are associated with clinical manifestations of allergy and IgE antibody formation.	Univ Tartu, Dept Microbiol, EE-50411 Tartu, Estonia; Tartu Univ Clin, Childrens Clin, Tartu, Estonia; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden	Sepp, E (reprint author), Univ Tartu, Dept Microbiol, Ravila St 19, EE-50411 Tartu, Estonia.	epp.sepp@ut.ee	Sepp, Epp/H-6798-2015				APPELT DM, 1993, J STRUCT BIOL, V111, P85, DOI 10.1006/jsbi.1993.1039; Balows A, 1991, MANUAL CLIN MICROBIO; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Brandtzaeg P, 2002, ANN NY ACAD SCI, V964, P13; BRANDTZAEG P, 1989, GASTROENTEROLOGY, V97, P1562; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Butel MJ, 1998, J MED MICROBIOL, V47, P391; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HALLER D, 2003, J BIOL CHEM, V26, P23851; Hentges DJ, 1989, ANAEROBIC INFECT HUM, P37; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; JANSSENS S, 2003, CLIN MICR REV, P637; Julge K, 2001, CLIN EXP ALLERGY, V31, P1854, DOI 10.1046/j.1365-2222.2001.01235.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Karlsson H, 2002, INFECT IMMUN, V70, P6688, DOI 10.1128/IAI.70.12.6688-6696.2002; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kimura K, 1997, APPL ENVIRON MICROB, V63, P3394; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Macfarlane G T, 1997, Scand J Gastroenterol Suppl, V222, P3, DOI 10.1080/00365521.1997.11720708; Mackie R I, 1999, Am J Clin Nutr, V69, p1035S; MARLER LM, 1992, J CLIN MICROBIOL, V30, P514; Matsuki T, 1999, APPL ENVIRON MICROB, V65, P4506; Matsumoto Mitsuharu, 2004, Microbial Ecology in Health and Disease, V16, P13, DOI 10.1080/08910600310026167; Mayer L, 2003, PEDIATRICS, V111, P1595; Mikelsaar M, 1993, LACTIC ACID BACTERIA, P237; NORHAGEN G, 1990, Microbial Ecology in Health and Disease, V3, P269; Norin Elisabeth, 2004, Microbial Ecology in Health and Disease, V16, P8, DOI 10.1080/08910600410026364; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; ROLFE RD, 1990, OLD HERBORN U SEMINA, P48; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Strannegard O, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.056002091.x; VANDERWAAIJ D, 1983, INFECTION S2, V11, P90; VOLLAARD EJ, 1994, ANTIMICROB AGENTS CH, V38, P409; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; WATANABE S, 2001, J ALLERGY CLIN IMMUN, V111, P587; Wold AE, 1998, ALLERGY, V53, P20; YASUI H, 1995, J INFECT DIS, V172, P403	42	72	80	0	3	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2005	35	9					1141	1146		10.1111/j.1365-2222.2005.02315.x		6	Allergy; Immunology	Allergy; Immunology	964SX	WOS:000231901900004	16164439	
J	Choudhry, S; Avila, PC; Nazario, S; Ung, N; Kho, J; Rodriguez-Santana, JR; Casal, J; Tsai, HJ; Torres, A; Ziv, E; Toscano, M; Sylvia, JS; Alioto, M; Salazar, M; Gomez, I; Fagan, JK; Salas, J; Lilly, C; Matallana, H; Castro, RA; Selman, M; Weiss, ST; Ford, JG; Drazen, JM; Rodriguez-Cintron, W; Chapela, R; Silverman, EK; Burchard, EG				Choudhry, S; Avila, PC; Nazario, S; Ung, N; Kho, J; Rodriguez-Santana, JR; Casal, J; Tsai, HJ; Torres, A; Ziv, E; Toscano, M; Sylvia, JS; Alioto, M; Salazar, M; Gomez, I; Fagan, JK; Salas, J; Lilly, C; Matallana, H; Castro, RA; Selman, M; Weiss, ST; Ford, JG; Drazen, JM; Rodriguez-Cintron, W; Chapela, R; Silverman, EK; Burchard, EG		Genet Asthma Latino Amer Study	CD14 tobacco gene-environment interaction modifies asthma severity and Immunoglobulin E levels in Latinos with asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma genetics; CD14; gene-environment interaction; IgE; Latinos; tobacco	MENTHOL CIGARETTE USE; PUERTO-RICAN; PROMOTER POLYMORPHISMS; CHILDHOOD ASTHMA; ATOPIC DISEASES; PASSIVE SMOKING; SOLUBLE CD14; CHILDREN; IGE; ASSOCIATION	Background: A recent family-based genomewide screen revealed linkage between the 5q31 region and the diagnosis of asthma, but only in those exposed to environmental tobacco smoke (ETS). Among the candidate genes in this region is CD14. Methods: To determine whether polymorphisms in the CD14 gene are related to this gene-by-environment interaction in Latinos, we used both family-based and cross-sectional cohort analysis to test for interactions between CD14 genotypes/haplotypes, exposure to ETS, and asthma-related phenotypes in 659 Mexican and Puerto Rican families. Results: We identified 21 single nucleotide polymorphisms (SNPs) in the CD14 gene by sequencing 72 Puerto Ricans, Mexicans, and African Americans with asthma. Three SNPs, -810, -159, and +1437, were further genotyped in families with asthma. Among all subjects with asthma exposed to ETS, without regard to ethnicity, CD14 +1437 genotypes were associated with asthma severity. SNP +1437 GG or GC genotypes were significantly associated with lower baseline FEV1, using both family-based (p = 0.0009) and cross-sectional cohort (p 0.03) analyses. Subjects with asthma with the GG or GC genotypes who were exposed to ETS had mean baseline FEV1 (% predicted) values 8.6% lower than subjects not exposed to ETS (p = 0.03). As previously observed in whites, we found an interaction between plasma IgE levels, SNP -159 genotypes, and ETS exposure (p = 0.0002). The lowest IgE levels were in those subjects with the TT genotype and who were exposed to ETS regardless of ethnicity. Conclusions: Our data suggest a gene-by-environment interaction between CD14 genotypes and ETS, which affects pulmonary function and IgE levels among Latinos with asthma.	Univ Calif San Francisco, San Francisco Gen Hosp, Lung Biol Ctr, San Francisco, CA 94110 USA; Univ Puerto Rico, Sch Med, San Juan Vet Affairs Med Ctr, San Juan, PR 00936 USA; Pediat Pulm Program San Juan, San Juan, PR USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harlem Hosp Med Ctr, Harlem Lung Ctr, New York, NY USA; Columbia Univ, New York, NY USA; Inst Nacl Enfermedades Resp, Mexico City, DF, Mexico	Burchard, EG (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Lung Biol Ctr, Bldg 30,5th Floor,Room 3501H,1001 Potrero Ave, San Francisco, CA 94110 USA.	esteban.burchard@ucsf.edu	Tsai, Hui-Ju /E-3937-2010; Ziv, Elad/L-5396-2014				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Buckova D, 2003, ALLERGY, V58, P1023, DOI 10.1034/j.1398-9995.2003.00271.x; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1239OC; Burchard EG, 2003, NEW ENGL J MED, V348, P1170, DOI 10.1056/NEJMsb025007; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Chen XN, 1999, GENOME RES, V9, P492; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; ENRIGHT PL, 1991, AM REV RESPIR DIS, V143, P1215; Enright PL, 1994, AM J RESP CRIT CAR S, V149, P9; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gardiner PS, 2004, NICOTINE TOB RES, V6, pS55, DOI 10.1080/1462220310001649478; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Giovino GA, 2004, NICOTINE TOB RES, V6, pS67, DOI 10.1080/14622203710001649696; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hasday JD, 1999, CHEST, V115, P829, DOI 10.1378/chest.115.3.829; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; Hoffjan S, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-14; Hoffjan S, 2002, CURR OPIN IMMUNOL, V14, P709, DOI 10.1016/S0952-7915(02)00393-X; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504; Horvath S, 2001, EUR J HUM GENET, V9, P301, DOI 10.1038/sj.ejhg.5200625; Kabesch M, 2004, ALLERGY, V59, P520, DOI 10.1111/j.1398-9995.2004.00439.x; Kimata H, 2003, EUR J CLIN INVEST, V33, P1024, DOI 10.1046/j.1365-2362.2003.01250.x; Kitch BT, 2004, CHEST, V126, P1875, DOI 10.1378/chest.126.6.1875; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Laird NM, 2000, GENET EPIDEMIOL, V19, P36; Larsson L, 2004, INDOOR AIR, V14, P421, DOI 10.1111/j.1600-0668.2004.00290.x; Leung TF, 2003, PEDIATR ALLERGY IMMU, V14, P255, DOI 10.1034/j.1399-3038.2003.00048.x; LeVan TD, 2005, AM J RESP CRIT CARE, V171, P773, DOI 10.1164/rccm.200404-530OC; Mackay J, 2002, TOBACCO ATLAS; O'Connell JR, 1998, AM J HUM GENET, V63, P259, DOI 10.1086/301904; O'Donnell AR, 2004, AM J RESP CRIT CARE, V169, P615, DOI 10.1164/rccm.200302-278OC; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ott J, 1999, ANAL HUMAN GENETIC L; Paull K, 2005, PEDIATR PULM, V39, P311, DOI 10.1002/ppul.20161; Perez-Stable EJ, 2001, AM J PUBLIC HEALTH, V91, P1424, DOI 10.2105/AJPH.91.9.1424; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; Sopori M, 2002, NAT REV IMMUNOL, V2, P372, DOI 10.1038/nri803; SPIELMAN RS, 1993, AM J HUM GENET, V52, P506; Strachan DP, 1998, THORAX, V53, P204; TAGER IB, 1989, CHEST, V96, P1161, DOI 10.1378/chest.96.5.1161; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Wells AJ, 1998, AM J PUBLIC HEALTH, V88, P1503, DOI 10.2105/AJPH.88.10.1503; Ziv E, 2003, PHARMACOGENOMICS, V4, P431, DOI 10.1517/phgs.4.4.431.22758; [Anonymous], 1999, NAT GENET, V22, P1	51	72	74	1	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2005	172	2					173	182		10.1164/rccm.200409-1232OC		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	943QG	WOS:000230368400005	15879416	
J	Wang, JL; Visness, CM; Sampson, HA				Wang, JL; Visness, CM; Sampson, HA			Food allergen sensitization in inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; food allergy; sensitization; IgE; inner-city children	MANIFESTATIONS	Background: Asthma continues to be an increasing cause of morbidity in the pediatric population, and studies have shown an association between food sensitivity and asthma. Objective: We investigated the degree of food allergen sensitization in inner-city patients with asthma. Methods: Five hundred four random serum samples from the National Cooperative Inner City Asthma Study were evaluated for specific IgE (UniCap) to 6 common food allergens (egg, milk, soy, peanut, wheat, and fish). Statistical analyses were performed to determine food sensitization prevalence and its association with asthma morbidity. Results: Forty-five percent of patients had evidence of sensitization (food-specific IgE &GE; 0.35 kU/L) to at least 1 food. Nineteen percent had IgE levels at &GE; 50% positive predictive value for clinical reactivity to at least 1 food, with 4% of patients having levels &GT; 95% positive predictive value for food allergy. Children sensitized to foods had higher rates of asthma hospitalization (P &LT; .01) and required more steroid medications (P = .025). Sensitization to foods also correlated with sensitization to more indoor and outdoor aeroallergens (P &LT; .001). Conclusion: Food allergen sensitization is highly prevalent in the inner-city population with asthma, and it is associated with increased asthma healthcare and medication use. Therefore, food allergen sensitivity may be a marker for increased asthma severity.	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, New York, NY 10029 USA; Rho Fed Syst Div Inc, Chapel Hill, NC USA	Sampson, HA (reprint author), Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.	hugh.sampson@mssm.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [AI030779, AI-30752, AI-30756, AI-30772, AI-30773-01, AI-30777, AI-30780, N01-AI-15105, U0I AI-30751]		BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Bock SA, 1992, PEDIATR ALLERGY IMMU, V3, P188, DOI 10.1111/j.1399-3038.1992.tb00048.x; DEY AN, 2004, VITAL HLTH STAT, V10, P3; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HILL DJ, 1986, J PEDIATR-US, V109, P270, DOI 10.1016/S0022-3476(86)80384-5; JAMES JM, 1994, AM J RESP CRIT CARE, V149, P59; James JM, 2003, PEDIATRICS, V111, P1625; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Mitchell H, 1997, PEDIATR PULM, V24, P237; NOVEMBRE E, 1988, J ALLERGY CLIN IMMUN, V81, P1059, DOI 10.1016/0091-6749(88)90181-9; OEHLING A, 1980, ALLERGOL IMMUNOPATH, V8, P7; ONORATO J, 1986, J ALLERGY CLIN IMMUN, V78, P1139, DOI 10.1016/0091-6749(86)90263-0; Roberts G, 2003, J ALLERGY CLIN IMMUN, V112, P168, DOI 10.1067/mai.2003.1569; Roberts Graham, 2003, Paediatr Respir Rev, V4, P205, DOI 10.1016/S1526-0542(03)00058-7; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603	18	72	74	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					1076	1080		10.1016/j.jaci.2005.02.014		5	Allergy; Immunology	Allergy; Immunology	925LR	WOS:000229055100027	15867869	
J	Matsui, EC; Simons, E; Rand, C; Butz, A; Buckley, TJ; Breysse, P; Eggleston, PA				Matsui, EC; Simons, E; Rand, C; Butz, A; Buckley, TJ; Breysse, P; Eggleston, PA			Airborne mouse allergen in the homes of inner-city children with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mouse allergen; inner-city asthma; particulate matter; Mus m 1	SKIN-TEST SENSITIVITY; EXPOSURE; SENSITIZATION; PREVALENCE; CATS	Background: Airborne mouse allergen has not previously been measured in inner-city homes, and its relationship to settled dust mouse allergen levels is unknown. Objective: To quantify airborne and settled dust Mus m 1 levels in homes of inner-city patients with asthma and to identify risk factors for mouse allergen exposure. Methods: One hundred inner-city school-age children with asthma in Baltimore underwent skin testing to a panel of aeroallergens, and their homes were inspected by a trained technician. Air and settled dust were sampled in the child's bedroom. Mus m 1, particulate matter smaller than 10 microns (PM10), and particulate matter smaller than 2.5 microns were quantified in air samples, and Mus m 1 was quantified in settled dust samples. Results: Mus m 1 was detected in settled dust samples from 100% of bedrooms. Airborne mouse allergen was detected in 48 of 57 (84%) bedrooms, and the median airborne mouse allergen concentration was 0.03 ng/m(3). The median PM10 concentration was 48 mug/m(3). Airborne and settled dust mouse allergen levels were moderately correlated (r = .52; P < .0001), and airborne Mus m 1 and PM10 levels were weakly correlated (r =.29; P = .03). Having cracks or holes in doors or walls, evidence of food remains in the kitchen, and mouse infestation were all independently associated with having detectable airborne mouse allergen. Conclusion: Airborne mouse allergen concentrations in many inner-city homes may be similar to those found in animal facilities, where levels are sufficiently high to elicit symptoms in sensitized individuals. Exposed food remains, cracks and holes in doors or walls, and evidence of mouse infestation appear to be risk factors for having detectable airborne Mus m 1.	Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA	Matsui, EC (reprint author), Johns Hopkins Univ Hosp, Dept Pediat, 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	ematsui@jhmi.edu			NHLBI NIH HHS [HL058942]; NIEHS NIH HHS [ES09606]		Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Korpi A, 2004, J ALLERGY CLIN IMMUN, V113, P677, DOI 10.1016/j.jaci.2003.11.039; Lewis RD, 1998, AM IND HYG ASSOC J, V59, P606, DOI 10.1202/0002-8894(1998)059<0606:FATROD>2.0.CO;2; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361; Matsui EC, 2004, ANN ALLERG ASTHMA IM, V93, P171; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Mitchell H, 1997, PEDIATR PULM, V24, P237; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; Swartz LJ, 2004, ENVIRON RES, V95, P156, DOI 10.1016/j.envres.2003.08.003; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60	16	72	72	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2005	115	2					358	363		10.1016/j.jaci.2004.11.007		6	Allergy; Immunology	Allergy; Immunology	897YU	WOS:000227043600024	15696095	
J	Fulkerson, PC; Zimmermann, N; Hassman, LM; Finkelman, FD; Rothenberg, ME				Fulkerson, PC; Zimmermann, N; Hassman, LM; Finkelman, FD; Rothenberg, ME			Pulmonary chemokine expression is coordinately regulated by STAT1, STAT6, and IFN-gamma	JOURNAL OF IMMUNOLOGY			English	Article							SOCS-1 GENE-EXPRESSION; AIRWAY INFLAMMATION; T-CELLS; EOSINOPHILIC INFLAMMATION; EXPERIMENTAL ASTHMA; EOTAXIN EXPRESSION; EPITHELIAL-CELLS; MUCUS PRODUCTION; TNF-ALPHA; TH2 CELLS	The expression of distinct chemokines within the asthmatic lung suggests that specific regulatory mechanisms may mediate various stages of asthmatic disease. Global transcript expression profiling was used to define the spectrum and kinetics of chemokine involvement in an experimental murine model of asthma. Seventeen chemokines were induced in the lungs of allergen-inoculated mice, as compared with saline-treated mice. Two (CXCL13 and CCL9) of the 17 identified chemokines have not previously been associated with allergic airway disease. Seven (7 of 17; CCL2, CCL7, CCL9, CCL11, CXCL1, CXCL5, CXCL10) of the allergen-induced chemokines were induced early after allergen challenge and remained induced throughout the experimental period. Three chemokines (CXCL2, CCL3, and CCL17) were induced only during the early phase of the inflammatory response after the initial allergen challenge, while seven chemokines (CCL6, CCL8, CCL12, CCL22, CXCL9, CXCL12, and CXCL13) were increased only after a second allergen exposure. Unexpectedly, expression of only three chemokines, CCL11, CCL17, and CCL22, was STAT6 dependent, and many of the identified chemokines were overexpressed in STAT6-deficient mice, providing an explanation for the enhanced neutrophilic inflammation seen in these mice. Notably, IFN-gamma and STAT1 were shown to contribute to the induction of two STAT6-independent chemokines, CXCL9 and CXCL10. Taken together, these results show that only a select panel of chemokines (those targeting Th2 cells and eosinophils) is positively regulated by STAT6; instead, many of the allergen-induced chemokines are negatively regulated by STAT6. Collectively, we demonstrate that allergen-induced inflammation involves coordinate regulation by STAT1, STAT6, and IFN-gamma.	Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Ctr Med,Div Allergy & Immunol, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Mol Genet, Cincinnati, OH 45257 USA; Univ Cincinnati, Coll Med, Dept Biochem & Mol Biol, Cincinnati, OH 45257 USA; Univ Cincinnati, Coll Med, Dept Internal Med, Div Immunol, Cincinnati, OH 45257 USA	Rothenberg, ME (reprint author), Univ Cincinnati, Coll Med, Cincinnati Childrens Hosp, Ctr Med,Div Allergy & Immunol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	Marc.Rothenberg@cchmc.org					Akimoto T, 1998, J EXP MED, V187, P1537, DOI 10.1084/jem.187.9.1537; Alexander WS, 2002, NAT REV IMMUNOL, V2, P410, DOI 10.1038/nri818; Atasoy U, 2003, J IMMUNOL, V171, P4369; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Dickensheets HL, 1999, P NATL ACAD SCI USA, V96, P10800, DOI 10.1073/pnas.96.19.10800; Eddleston J, 2002, J IMMUNOL, V169, P6445; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Fujisawa T, 2000, J ALLERGY CLIN IMMUN, V106, P507; Fulkerson PC, 2004, P NATL ACAD SCI USA, V101, P1987, DOI 10.1073/pnas.0308544100; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gonzalo JA, 2000, J IMMUNOL, V165, P499; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hebenstreit D, 2003, J IMMUNOL, V171, P5901; Huang TJ, 2001, J IMMUNOL, V166, P207; Kampen GT, 2000, BLOOD, V95, P1911; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Lee NA, 2001, J ALLERGY CLIN IMMUN, V107, P945, DOI 10.1067/mai.2001.116002; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Li L, 1998, J IMMUNOL, V161, P3128; Lukacs N W, 1999, Chem Immunol, V72, P102, DOI 10.1159/000058729; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; Luster AD, 1998, NEW ENGL J MED, V338, P436; Mahalingam S, 2001, J BIOL CHEM, V276, P7568, DOI 10.1074/jbc.M005773200; Matsukura S, 2001, AM J RESP CELL MOL, V24, P755; Medoff BD, 2002, J IMMUNOL, V168, P5278; Mishra A, 2001, J CLIN INVEST, V107, P83, DOI 10.1172/JCI10224; Nagase H, 2000, J IMMUNOL, V164, P5935; Ohmori Y, 1997, J IMMUNOL, V159, P5474; Ohmori Y, 1998, J BIOL CHEM, V273, P29202, DOI 10.1074/jbc.273.44.29202; Ono SJ, 2003, J ALLERGY CLIN IMMUN, V111, P1185, DOI 10.1067/mai.2003.1594; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Pope SM, 2001, J ALLERGY CLIN IMMUN, V108, P594; Ramana CV, 2002, TRENDS IMMUNOL, V23, P96, DOI 10.1016/S1471-4906(01)02118-4; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; ROBINSON DS, 1993, SPRINGER SEMIN IMMUN, V15, P17; Saetta M, 1999, AM J RESP CRIT CARE, V160, pS17; Sato T, 2004, BIOCHEM BIOPH RES CO, V314, P468, DOI 10.1016/j.bbrc.2003.12.124; SEMINARIO MC, 1994, CURR OPIN IMMUNOL, V6, P860, DOI 10.1016/0952-7915(94)90005-1; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283; Venkataraman C, 1999, J IMMUNOL, V162, P4053; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Witherden IR, 2004, AM J RESP CELL MOL, V30, P500, DOI 10.1165/rcmb.4890; Wurtz O, 2004, INT IMMUNOL, V16, P501, DOI 10.1093/intimm/dxh050; Yu CR, 2004, J IMMUNOL, V173, P737; Zhu Z, 2002, J IMMUNOL, V168, P2953; Zimmermann N, 2000, J IMMUNOL, V165, P5839; Zimmermann N, 2003, J CLIN INVEST, V111, P1863, DOI 10.1172/JCI200317912; Zimmermann N, 2004, J IMMUNOL, V172, P1815; Zimmermann N, 2003, J ALLERGY CLIN IMMUN, V111, P227, DOI 10.1067/mai.2003.139	54	72	75	0	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	DEC 15	2004	173	12					7565	7574				10	Immunology	Immunology	878RT	WOS:000225665100056	15585884	
J	Moorcroft, AJ; Dodd, ME; Morris, J; Webb, AK				Moorcroft, AJ; Dodd, ME; Morris, J; Webb, AK			Individualised unsupervised exercise training in adults with cystic fibrosis: a 1 year randomised controlled trial	THORAX			English	Article							PULMONARY-FUNCTION; LUNG-FUNCTION; CHILDREN; PROGRAM; TOLERANCE; CAPACITY; ASTHMA	Background: Short term studies of exercise training have shown benefits in cystic fibrosis. Transferring exercise programmes to the community and sustaining them long term is a challenge for the patient. The effectiveness of an individualised unsupervised home based exercise programme was examined in adults with cystic fibrosis over a 1 year period. Methods: Subjects were randomised to undertake three sessions per week of upper and lower body exercise based on individualised preferences (n = 30) or to a control group ( n = 18). They were evaluated at baseline and at 12 months. The primary outcome measure was improved fitness as assessed by change in blood lactate concentration at the end of an identical constant work rate for both arm and leg ergometric testing. Secondary outcome measurements were heart rate and pulmonary function. Results: For leg exercise, significant differences were seen at 12 months between the active and control groups in the mean (SE) change in blood lactate levels (-0.38 (0.23) mmol/l v 0.45 (0.25) mmol/l, p<0.05) and heart rate (-4.8 (2.5) bpm v 3.4 (2.5) bpm, p<0.05), confirming a training effect. For arm ergometry there was no change in lactate levels at 12 months but there was a significant difference in forced vital capacity (46 (72) ml v -167 (68) ml, p<0.05). Conclusions: A training effect, as measured by a reduction in lactate levels and heart rate, can be achieved with unsupervised individualised home exercise in adults with cystic fibrosis. A benefit to pulmonary function was observed and together these findings suggest that exercise programmes should be encouraged as an important component of care in cystic fibrosis.	Univ S Manchester Hosp NHS Trust, Manchester Adult CF Ctr, Wythenshawe Hosp, Manchester M23 9LT, Lancs, England; Royal Shrewsbury Hosp, Shrewsbury SY3 8XQ, Salop, England; Wythenshawe Hosp, Manchester M23 9LT, Lancs, England	Webb, AK (reprint author), Univ S Manchester Hosp NHS Trust, Manchester Adult CF Ctr, Wythenshawe Hosp, Manchester M23 9LT, Lancs, England.	the5webbs@hotmail.com					Abbott J, 1996, THORAX, V51, P1233, DOI 10.1136/thx.51.12.1233; ABBOTT J, 1994, THORAX, V49, P115, DOI 10.1136/thx.49.2.115; ANDREASSON B, 1987, ACTA PAEDIATR SCAND, V76, P70, DOI 10.1111/j.1651-2227.1987.tb10417.x; BLOMQUIST M, 1986, ARCH DIS CHILD, V61, P362; BORG GAV, 1982, MED SCI SPORT EXER, V14, P377, DOI 10.1249/00005768-198205000-00012; CASSABURI R, 1991, AM REV RESPIR DIS, V143, P9; CERNY FJ, 1984, AM J DIS CHILD, V138, P261; CERNY FJ, 1982, AM REV RESPIR DIS, V126, P217; COATES AL, 1980, ACTA PAEDIATR SCAND, V69, P353, DOI 10.1111/j.1651-2227.1980.tb07092.x; COREY M, 1976, AM REV RESPIR DIS, V114, P1085; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; DEJONG W, 1994, CHEST, V105, P463, DOI 10.1378/chest.105.2.463; EDLUND LD, 1986, AM J DIS CHILD, V140, P80; FRANKLIN BA, 1985, SPORTS MED, V2, P100; GODFREY S, 1971, ARCH DIS CHILD, V46, P144; Gulmans VAM, 1999, PEDIATR PULM, V28, P39, DOI 10.1002/(SICI)1099-0496(199907)28:1<39::AID-PPUL7>3.0.CO;2-8; Heijerman H G, 1992, Int J Rehabil Res, V15, P252, DOI 10.1097/00004356-199209000-00011; HOLZER FJ, 1984, AUST PAEDIATR J, V20, P297; Jones NL, 1988, CLIN EXERCISE TESTIN; KEREM E, 1992, NEW ENGL J MED, V326, P1187, DOI 10.1056/NEJM199204303261804; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; LANDS LC, 1992, CLIN SCI, V83, P391; LEWIN LO, 1990, J CLIN EPIDEMIOL, V43, P125; Mahadeva R, 1998, BRIT MED J, V316, P1771; MARCOTTE JE, 1986, PEDIATR PULM, V2, P274, DOI 10.1002/ppul.1950020505; Milla CE, 1998, CHEST, V113, P1230, DOI 10.1378/chest.113.5.1230; NIXON PA, 1992, NEW ENGL J MED, V327, P1785, DOI 10.1056/NEJM199212173272504; ONEILL PA, 1987, BRIT J DIS CHEST, V81, P62, DOI 10.1016/0007-0971(87)90109-4; ORENSTEIN DM, 1981, CHEST, V80, P392, DOI 10.1378/chest.80.4.392; PENKETH ARL, 1987, THORAX, V42, P526, DOI 10.1136/thx.42.7.526; SALH W, 1989, THORAX, V44, P1006, DOI 10.1136/thx.44.12.1006; SCHNEIDERMANWALKER, 2000, J PEDIATR, V136, P304; STRAUSS GD, 1987, CHEST, V92, P273, DOI 10.1378/chest.92.2.273; ZACH MS, 1981, LANCET, V2, P1201	34	72	72	1	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	DEC	2004	59	12					1074	1080		10.1136/thx.2003.015313		7	Respiratory System	Respiratory System	874NV	WOS:000225358000016	15563708	
J	Newson, RB; Shaheen, SO; Henderson, AJ; Emmett, PM; Sherriff, A; Calder, PC				Newson, RB; Shaheen, SO; Henderson, AJ; Emmett, PM; Sherriff, A; Calder, PC		ALSPAC Study Team	Umbilical cord and maternal blood red cell fatty acids and early childhood wheezing and eczema	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						n-3/n-6 Fatty acids; wheezing; eczema; birth cohort; prenatal	AIRWAY RESPONSES; ATOPIC DISEASE; BIRTH-WEIGHT; CHILDREN; PROSTAGLANDIN-E2; ALLERGY; LYMPHOCYTES; PREGNANCY; GAMMA; RISK	Background: Few studies have explored whether fetal exposure to n-6 and n-3 fatty acids influences the inception of atopic disease. Objective: To assess prenatal fatty acid exposures as predictors of early childhood wheezing and eczema. Methods: In the Avon Longitudinal Study of Parents and Children, late pregnancy maternal blood samples and umbilical cord blood samples were assayed for n-6 and n-3 fatty acids (percentage of total red cell phospholipid), and mothers were asked about wheezing and eczema in their children. We measured associations of 11 n-6 and n-3 fatty acid exposures with wheezing at 30 to 42 months, with wheezing patterns defined by presence (+) or absence (-) of wheezing during 2 periods, 0 to 6 months and 30 to 42 months (transient infant, +/-; later-onset, -/+; persistent, +/+; n = 1191 and n = 2764 for cord and maternal analyses, respectively), and with eczema at 18 to 30 months (n = 1238 and n = 2945 for cord and maternal analyses, respectively). Results: In cord blood red cells, the ratio of arachidonic:eicosapentaenoic acid was positively associated with eczema (adjusted odds ratio [OR] per doubling, 1.14; 95% CI, 1.00-1.31; P = .044), the ratio of linoleic acid: a-linolenic acid was positively associated with later-onset wheeze (OR, 1.30; CI, 1.04-1.61; P = .019), and the ratio of a-linolenic acid:n-3 products was negatively associated with later-onset wheeze (OR, 0.86; CI, 0.75-0.99; P = .040). However, these associations were no longer significant after adjusting for multiple comparisons. Conclusions: It seems unlikely that fetal exposure to n-6 and n-3 fatty acids is an important determinant of early childhood wheezing and atopic disease.	Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, London SE1 3QD, England; Univ Bristol, Inst Child Hlth, Unit Paediat & Perinatal Epidemiol, Bristol, Avon, England; Univ Southampton, Inst Human Nutr, Southampton, Hants, England	Shaheen, SO (reprint author), Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Sci, Capital House,42 Weston St, London SE1 3QD, England.	seif.shaheen@kcl.ac.uk	Calder, Philip/E-9739-2013	Calder, Philip/0000-0002-6038-710X; Henderson, Alexander John/0000-0001-9650-231X; Emmett, Pauline/0000-0003-1076-4779			Benbernou N, 1997, IMMUNOLOGY, V91, P361, DOI 10.1046/j.1365-2567.1997.00260.x; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BETZ M, 1991, J IMMUNOL, V146, P108; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Calder PC, 2000, PEDIATR ALLERGY IMMU, V11, P29, DOI 10.1034/j.1399-3038.2000.00508.x; Duchen K, 2000, PEDIATR ALLERGY IMMU, V11, P29, DOI 10.1034/j.1399-3038.2000.00052.x; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Elias SL, 2001, AM J CLIN NUTR, V73, P807; GALLI E, 1994, BRIT J DERMATOL, V130, P752, DOI 10.1111/j.1365-2133.1994.tb03413.x; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; HORROBIN DF, 2000, AM J CLIN NUTR S, V71, pS72; MANKU MS, 1982, PROSTA LEUKOTR MED, V9, P615, DOI 10.1016/0262-1746(82)90019-1; Martin JG, 2002, J IMMUNOL, V169, P3963; MATLOFF SM, 1983, J ALLERGY CLIN IMMUN, V72, P359, DOI 10.1016/0091-6749(83)90500-6; PAVORD ID, 1995, LANCET, V345, P436, DOI 10.1016/S0140-6736(95)90409-3; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Rump P, 2001, AM J CLIN NUTR, V73, P797; Sherriff A, 2001, INT J EPIDEMIOL, V30, P1473, DOI 10.1093/ije/30.6.1473; SNIJDEWINT FGM, 1993, J IMMUNOL, V150, P5321; [Anonymous], 2001, STAT STAT SOFTW REL; University of Bristol, AV LONG STUD PAR CHI; Wijendran V, 1999, AM J CLIN NUTR, V70, P53; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WRIGHT S, 1990, OMEGA 6 ESSENTIAL FA, P55; Yu G, 1998, PEDIATR ALLERGY IMMU, V9, P133, DOI 10.1111/j.1399-3038.1998.tb00359.x; Yu G, 1998, EUR J PEDIATR, V157, P298, DOI 10.1007/s004310050815; Yu G, 1996, ACTA PAEDIATR, V85, P679, DOI 10.1111/j.1651-2227.1996.tb14124.x	29	72	73	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					531	537		10.1016/j.jaci.2004.05.010		7	Allergy; Immunology	Allergy; Immunology	853AX	WOS:000223799600010	15356553	
J	Wong, GWK; Ko, FWS; Hui, DSC; Fok, TF; Carr, D; von Mutius, E; Zhong, NS; Chen, YZ; Lai, CKW				Wong, GWK; Ko, FWS; Hui, DSC; Fok, TF; Carr, D; von Mutius, E; Zhong, NS; Chen, YZ; Lai, CKW			Factors associated with difference in prevalence of asthma in children from three cities in China: multicentre epidemiological survey	BRITISH MEDICAL JOURNAL			English	Article							RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; HOME-ENVIRONMENT; LUNG-FUNCTION; YOUNG-ADULTS; SCHOOLCHILDREN; POPULATION; RISK	Objective To determine the factors associated with difference in prevalence of asthma in children in different regions of China. Design Multicentre epidemiological survey. Setting Three cities in china. Participants 10 902 schoolchildren aged 10 years. Main outcome measures Asthma and atopic symptoms, atopic sensitisation, and early and current exposure to environmental factors. Results Children from Hong Kong had a significantly higher prevalence of wheeze in the past year than those from Guangzhou and Beijing (odds ratio 1.64, 95% confidence interval 1.35 to 1.99). Factors during the first year of life and currently that were significantly associated with wheeze were cooking with gas (odds ratio 2.04, 1.34 to 3.13), foam pillows (2.58, 1.66 to 3.99), and damp housing (1.89,1.26 to 2.83). Factors protecting against wheeze were cotton quilts and the consumption of fruit and raw vegetables. Conclusion Environmental factors and diet may explain the differences in prevalence of asthma between children living in different regions of China.	Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China; Chinese Univ Hong Kong, Dept Med & Therapeut, Hong Kong, Hong Kong, Peoples R China; Univ Childrens Hosp, Munich, Germany; Guangzhou Inst Resp Dis, Guangzhou, Peoples R China; Capital Inst Paediat, Clin & Educ Ctr Asthma, Beijing, Peoples R China	Wong, GWK (reprint author), Chinese Univ Hong Kong, Dept Paediat, Hong Kong, Hong Kong, Peoples R China.	wingkunvong@cuhk.edu.hk	Hui, David/O-2754-2015; Ko, Fanny/B-8958-2016	Ko, Fanny/0000-0001-8454-0087			ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; Burr ML, 1999, THORAX, V54, P27; BURR ML, 1989, ARCH DIS CHILD, V64, P1118; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Goren AI, 1997, EUR RESPIR J, V10, P2279, DOI 10.1183/09031936.97.10102279; Greenland S., 1998, MODERN EPIDEMIOLOGY; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; The International Study of Asthma and Allergies in Childhood (ISAAC) Steering Committee, 1998, LANCET, V351, P1125; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Leung R, 1997, EUR RESPIR J, V10, P354, DOI 10.1183/09031936.97.10020354; Pearce N, 1999, THORAX, V54, P268; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1544, DOI 10.1046/j.1365-2222.2001.01163.x; Shaheen SO, 2001, AM J RESP CRIT CARE, V164, P1823; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319; Strachan D, 1997, BRIT MED J, V314, P518; STRACHAN DP, 1995, BRIT MED J, V311, P1053; Williamson IJ, 1997, THORAX, V52, P229; Wong GWK, 2002, EUR RESPIR J, V19, P288, DOI 10.1183/09031936.02.002319.02; Wong GWK, 2001, CLIN EXP ALLERGY, V31, P1225, DOI 10.1046/j.1365-2222.2001.01140.x; Woods RK, 2003, AM J CLIN NUTR, V78, P414	23	72	74	0	8	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	AUG 28	2004	329	7464					486	488B		10.1136/bmj.329.7464.486		5	Medicine, General & Internal	General & Internal Medicine	851KS	WOS:000223684600014	15331473	
J	Polk, S; Sunyer, J; Munoz-Ortiz, L; Barnes, M; Torrent, M; Figueroa, C; Harris, J; Vall, O; Anto, JM; Cullinan, P				Polk, S; Sunyer, J; Munoz-Ortiz, L; Barnes, M; Torrent, M; Figueroa, C; Harris, J; Vall, O; Anto, JM; Cullinan, P			A prospective study of Fel d1 and Der p1 exposure in infancy land childhood wheezing	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						allergens cohort; infants; wheezing	HOUSE-DUST MITE; ENVIRONMENTAL RISK-FACTORS; ALLERGEN EXPOSURE; CAT ALLERGEN; ASTHMA; CHILDREN; SENSITIZATION; LIFE; SYMPTOMS; FEL-D-1	The impact of domestic exposure to cat allergen (Fel d1) and house dust mite (Der p1) on wheezing from birth to the age of 4 years was investigated in a multicenter prospective birth cohort; 1,611 mothers were recruited before delivery in Ashford, England, and Barcelona and Menorca, Spain. Exposures were gathered via dust sample collection at children's home in their first year of life. Families provided complete outcome data (wheezing status in all 4 years) for 1,289 children. Domestic allergen levels varied substantially between centers. Six hundred three (47%) children never wheezed during their first 4 years of life. Der p1 did not correlate with any type of wheezing outcome. Fel d1 significantly increased the risk of wheezing in 3- and 4-year-olds in comparison to 1-year-olds. Distinct risk profiles were found for wheezing at different ages. Multivariate analysis revealed an interaction between Fel d1 and maternal asthma among children who wheeze in Year 4 (relative risk = 2.77; 95% confidence interval = 1.19-6.46). Our data support the idea that several patterns of wheezing with different risk profiles exist among young children. The effect of Fel d1 exposure varied according to age and maternal asthma.	Inst Municipal Invest Med, Environm Resp Res Unit, E-08003 Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Hosp del Mar, Serv Pediat, Barcelona, Spain; IB SALUT, Area Salud Menorca, Menorca, Spain; Univ London Imperial Coll Sci Technol & Med, Dept Occupat & Environm Med, London SW7 2AZ, England	Sunyer, J (reprint author), Inst Municipal Invest Med, Environm Resp Res Unit, C Doctor Aiguader 80, E-08003 Barcelona, Spain.	jsunyer@imim.es	vall, oriol/G-2980-2010; Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110			Atkinson W, 1999, EUR RESPIR J, V13, P583, DOI 10.1183/09031936.99.13358599; Basagana X, 2002, PEDIATR ALLERGY IMMU, V13, P412, DOI 10.1034/j.1399-3038.2002.02081.x; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; Carter PM, 2003, ANN ALLERG ASTHMA IM, V90, P41; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Diggle P. J., 1994, OXFORD STAT SCI SERI, V13; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Halonen M, 1999, AM J RESP CRIT CARE, V160, P564; Heinrich J, 2003, J EXPO ANAL ENV EPID, V13, P152, DOI 10.1038/sj.jea.7500267; Heissenhuber A, 2003, ALLERGY, V58, P154, DOI 10.1034/j.1398-9995.2003.00037.x; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786; HOLT PG, 1999, NATURE, V402, pR12; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; Martin YC, 1998, PERSPECT DRUG DISCOV, V12, P3, DOI 10.1023/A:1017037831628; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; PERZANOWSKI MS, 1999, J ALLERGY CLIN IMMUN, V103, P1002; Pichini S, 2000, ENVIRON HEALTH PERSP, V108, P1079, DOI 10.1289/ehp.001081079; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; RITZ BR, 2001, ALELRGY, V57, P357; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; Sandford AJ, 2000, AM J RESP CRIT CARE, V161, pS202; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sunyer J, 2001, CLIN EXP ALLERGY, V31, P1352, DOI 10.1046/j.1365-2222.2001.01187.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033	34	72	74	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2004	170	3					273	278		10.1164/rccm.200310-1348OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	841DX	WOS:000222910600018	15117746	
J	Tiemessen, MM; Van Leperen-Van Dijk, AG; Bruijnzeel-Koomen, CAFM; Garssen, J; Knol, EF; Van Hoffen, E				Tiemessen, MM; Van Leperen-Van Dijk, AG; Bruijnzeel-Koomen, CAFM; Garssen, J; Knol, EF; Van Hoffen, E			Cow's milk-specific T-cell reactivity of children with and without persistent cow's milk allergy: Key role for IL-10	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						antigen-specific T cells; cow's milk; food allergy; tolerance; IL-10	HOUSE-DUST MITE; ATOPIC-DERMATITIS; LYMPHOCYTE-RESPONSES; PERIPHERAL-BLOOD; DIETARY ANTIGEN; FOOD ALLERGY; INTERLEUKIN-10; EXPRESSION; TOLERANCE; ASTHMA	Background: The role of antigen-specific T cells in the mechanism of food allergy or maintenance of tolerance toward an innocuous antigen, such as cow's milk, is not yet fully understood. Objective: The cow's milk-specific T-cell response of donors with various allergic backgrounds was investigated. Methods: Cow's milk-specific T-cell clones (TCCs) were generated from the blood of children with persistent cow's milk allergy (CMA) and the blood of cow's milk-tolerant allergic and nonallergic control subjects. The TCCs were characterized by their antigen-specific proliferation, cytokine production, and activation status. Results: Cow's milk-specific TCCs of children with persistent CMA were T(H)2 skewed, and the production of IL-4 and IL-13 was significantly correlated with the expression of the activation marker CD25. TCCs of the allergic control subjects were characterized by a high production of IL-10, which was positively correlated with the production of IL-4 and IFN-gamma and with the expression of CD25. TCCs derived from nonallergic control subjects had an attenuated response toward cow's milk in that they did not produce high levels of cytokines nor did they express high levels of surface markers. As in the allergic control subjects, in the nonallergic control subjects IL-10 production was positively correlated with the expression of CD25. Conclusion: The activation status of T cells derived from persistent donors with CMA was associated with the production of IL-4 and IL-13, whereas activated TCCs of cow's milk-tolerant control subjects were characterized by the production of IL-10 and, to a lesser extent, IFN-gamma. These findings suggest that activated CD4(+) T cells (characterized by a high CD25 expression) might contribute to the tolerogenic immune response toward an antigen, such as cow's milk, through the production of IL-10.	Univ Utrecht, Med Ctr, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Numico Res, Wageningen, Netherlands	Tiemessen, MM (reprint author), Univ Utrecht, Med Ctr, Dept Dermatol Allergol, G02-124,POB 85-500, NL-3508 GA Utrecht, Netherlands.	e.vanhoffen@azu.nl	garssen, johan/I-7159-2016				Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Bashir MEH, 2002, J IMMUNOL, V169, P3284; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; deJong EC, 1996, J ALLERGY CLIN IMMUN, V98, P73, DOI 10.1016/S0091-6749(96)70228-2; GURKA G, 1989, J ALLERGY CLIN IMMUN, V83, P945, DOI 10.1016/0091-6749(89)90110-3; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HIGGINS JA, 1995, IMMUNOLOGY, V84, P91; Jarvinen KM, 2002, J ALLERGY CLIN IMMUN, V110, P293, DOI 10.1067/mai.2002.126080; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Katsuki T, 1996, INT ARCH ALLERGY IMM, V109, P344; Kitani A, 2003, J EXP MED, V198, P1179, DOI 10.1084/jem.20030917; Lagging E, 1998, IMMUNOL LETT, V60, P45, DOI 10.1016/S0165-2478(97)00130-2; Nagata S, 2000, J IMMUNOL, V165, P5315; Neumann C, 1996, J MOL MED-JMM, V74, P401, DOI 10.1007/BF00210634; Ng TW, 2002, ALLERGY, V57, P207, DOI 10.1034/j.1398-9995.2002.1o3369.x; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Perez-Machado MA, 2003, EUR J IMMUNOL, V33, P2307, DOI 10.1002/eji.200323308; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2003, CLIN EXP ALLERGY, V33, P725, DOI 10.1046/j.1365-2222.2003.01655.x; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Schade RR, 2002, J ALLERGY CLIN IMMUN, V109, P357, DOI 10.1067/mai.2002.121457; Sicherer SH, 1999, CLIN EXP ALLERGY, V29, P507; Smart V, 2003, J IMMUNOL, V171, P2116; Torres MJ, 2003, BLOOD CELL MOL DIS, V30, P124, DOI 10.1016/S1079-9796(03)00004-4; Turcanu V, 2003, J CLIN INVEST, V111, P1065, DOI 10.1172/JCI200316142; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Vila L, 2001, CLIN EXP ALLERGY, V31, P1599, DOI 10.1046/j.1365-2222.2001.01218.x; Werfel T, 1996, CLIN EXP ALLERGY, V26, P1380, DOI 10.1046/j.1365-2222.1996.d01-294.x; YSSEL H, 1984, J IMMUNOL METHODS, V72, P219, DOI 10.1016/0022-1759(84)90450-2; Zemann Barbara, 2003, J Allergy Clin Immunol, V111, P1069	30	72	74	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2004	113	5					932	939		10.1016/j.jaci.2003.12.016		8	Allergy; Immunology	Allergy; Immunology	818UC	WOS:000221269000017	15131577	
J	Clifton, VL; Murphy, VE				Clifton, VL; Murphy, VE			Maternal asthma as a model for examining fetal sex-specific effects on maternal physiology and placental mechanisms that regulate human fetal growth	PLACENTA			English	Article; Proceedings Paper	9th Annual Meeting of the International-Federation-of-Placenta-Associations	SEP 24-28, 2003	Mainz, GERMANY	Int Federat Placenta Assoc			11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-2; GLUCOCORTICOID EXPOSURE; ALVEOLAR MACROPHAGES; INTRAUTERINE GROWTH; BLOOD MONOCYTES; HUMAN-PREGNANCY; ATOPIC DISEASE; MESSENGER-RNA; IMMUNE-SYSTEM; T-CELLS	Studying the effect of maternal asthma during pregnancy on placental function and fetal development has highlighted that there is a strong interaction between mother, placenta and fetus and these interactions appear to be sex-specific. This work has found that the female fetus alters maternal asthma during pregnancy by upregulating maternal inflammatory pathways. When asthma-associated inflammatory pathways are not treated with inhaled steroids during pregnancy, the female fetus has reduced growth and adrenal function due to alterations in placental glucocorticold metabolism. When the mother uses inhaled steroid for the treatment of her asthma during pregnancy, female fetal growth and placental function are comparable to the control population. The growth of the male fetus appears to be unaffected by asthma or inhaled steroid use. These findings indicate there may be different mechanisms regulating placental glucocorticoid and immune mechanisms depending on fetal sex in both asthmatic and non-asthmatic pregnancies. (C) 2004 IFPA and Elsevier Ltd. All rights reserved.	John Hunter Hosp, Hunter Med Res Inst, Mothers & Babies Res Ctr, Dept Endocrinol, Newcastle, NSW 2310, Australia	Clifton, VL (reprint author), John Hunter Hosp, Hunter Med Res Inst, Mothers & Babies Res Ctr, Dept Endocrinol, Locked Bag 1,HRMC, Newcastle, NSW 2310, Australia.	vclifton@mail.newcastle.edu.au	Clifton, Vicki/A-1445-2012	Clifton, Vicki/0000-0002-4892-6748			ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; Andres R L, 2000, Semin Neonatol, V5, P231, DOI 10.1053/siny.2000.0025; Beecroft N, 1998, BRIT MED J, V317, P856; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; Benediktsson R, 1997, CLIN ENDOCRINOL, V46, P161, DOI 10.1046/j.1365-2265.1997.1230939.x; BURTON PJ, 1994, J ENDOCRINOL, V143, P505, DOI 10.1677/joe.0.1430505; Clifton VL, 2001, AM J RESP CRIT CARE, V164, P546; Condon J, 1997, MOL CELL ENDOCRINOL, V127, P121, DOI 10.1016/S0303-7207(97)04000-8; Da Silva JAP, 1999, ANN NY ACAD SCI, V876, P102; Da Silva JA, 1999, ANN NY ACAD SCI, V876, P117; DAYNES RA, 1989, EUR J IMMUNOL, V19, P2319, DOI 10.1002/eji.1830191221; Dayyani F, 2003, J LEUKOCYTE BIOL, V74, P33, DOI 10.1189/jlb.1202612; Dean F, 1999, BRAIN RES, V846, P253, DOI 10.1016/S0006-8993(99)02064-8; DeKruyff R, 1998, J IMMUNOL, V160, P2231; Dodds L, 1999, BRIT MED J, V318, P1011; DOUCETTE JT, 1993, EPIDEMIOLOGY, V4, P143, DOI 10.1097/00001648-199303000-00010; FITZSIMONS R, 1986, J ALLERGY CLIN IMMUN, V78, P349, DOI 10.1016/S0091-6749(86)80088-4; Fonager K, 1998, AM J GASTROENTEROL, V93, P2426, DOI 10.1016/S0002-9270(98)00579-6; French NP, 1999, AM J OBSTET GYNECOL, V180, P114, DOI 10.1016/S0002-9378(99)70160-2; Gosset P, 2001, J ALLERGY CLIN IMMUN, V107, P114, DOI 10.1067/mai.2001.111126; Hennebold JD, 1997, INT IMMUNOL, V9, P105, DOI 10.1093/intimm/9.1.105; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Johnson CC, 1996, CLIN EXP ALLERGY, V26, P624, DOI 10.1111/j.1365-2222.1996.tb00588.x; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; Kovar J, 2001, PEDIATR PULM, V32, P8, DOI 10.1002/ppul.1082; KUEHR J, 1993, CLIN EXP ALLERGY, V23, P600, DOI 10.1111/j.1365-2222.1993.tb00900.x; Lim S, 2000, ALLERGY, V55, P489; LOUIS R, 1994, CHEST, V106, P1094, DOI 10.1378/chest.106.4.1094; Magee MH, 2001, J CLIN PHARMACOL, V41, P1180, DOI 10.1177/00912700122012733; Mathy NL, 2000, IMMUNOLOGY, V100, P63, DOI 10.1046/j.1365-2567.2000.00997.x; Mazzarella G, 2000, ALLERGY, V55, P36, DOI 10.1034/j.1398-9995.2000.00505.x; McKay LI, 1999, ENDOCR REV, V20, P435, DOI 10.1210/er.20.4.435; Murphy VE, 2003, AM J RESP CRIT CARE, V168, P1317, DOI 10.1164/rccm.200303-374OC; Murphy VE, 2002, J CLIN ENDOCR METAB, V87, P1660, DOI 10.1210/jc.87.4.1660; PAPAGEORGIOU AN, 1981, PEDIATRICS, V67, P614; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Quinlivan JA, 2002, J PERINAT MED, V30, P209, DOI 10.1515/JPM.2002.029; Ramirez F, 1998, Dev Immunol, V6, P233, DOI 10.1155/1998/73401; Raven PW, 1996, ENDOCR RES, V22, P751; REINISCH JM, 1978, SCIENCE, V202, P436, DOI 10.1126/science.705336; Rivera DL, 1998, FASEB J, V12, P189; Schatz M, 1999, J ALLERGY CLIN IMMUN, V103, pS330, DOI 10.1016/S0091-6749(99)70258-7; SCHATZ M, 1990, CHEST, V98, P389, DOI 10.1378/chest.98.2.389; Shams M, 1998, HUM REPROD, V13, P799, DOI 10.1093/humrep/13.4.799; SIITERI PK, 1966, J CLIN ENDOCR METAB, V26, P751; SIMMONS D, 1994, BIOL NEONATE, V65, P287; Smith JT, 2000, ENDOCRINOLOGY, V141, P2422, DOI 10.1210/en.141.7.2422; Tang CB, 1998, AM J RESP CRIT CARE, V157, P1120; Tang CB, 1998, J ALLERGY CLIN IMMUN, V102, P368, DOI 10.1016/S0091-6749(98)70122-8; Terpigorev SA, 2003, B EXP BIOL MED+, V135, P582, DOI 10.1023/A:1025489604819; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Welberg LAM, 2000, EUR J NEUROSCI, V12, P1047, DOI 10.1046/j.1460-9568.2000.00958.x; Wendel PJ, 1996, AM J OBSTET GYNECOL, V175, P150, DOI 10.1016/S0002-9378(96)70265-X; Zhu YK, 2001, J ALLERGY CLIN IMMUN, V108, P989, DOI 10.1067/mai.2001.120193	55	72	73	0	6	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0143-4004			PLACENTA	Placenta	APR	2004	25			A			S45	S52		10.1016/j.placenta.2004.01.004		8	Developmental Biology; Obstetrics & Gynecology; Reproductive Biology	Developmental Biology; Obstetrics & Gynecology; Reproductive Biology	824NN	WOS:000221693400007	15033307	
J	Topilski, I; Flaishon, L; Naveh, Y; Harmelin, A; Levo, Y; Shachar, I				Topilski, I; Flaishon, L; Naveh, Y; Harmelin, A; Levo, Y; Shachar, I			The anti-inflammatory effects of 1,25-dihydroxyvitamin D3 on Th2 cells in vivo are due in part to the control of integrin-mediated T lymphocyte homing	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						CD4 T cells; Th2 cells; vitamin D; asthma; cytoskeleton rearrangement; migration	HIGH ENDOTHELIAL VENULES; DENDRITIC CELLS; IFN-GAMMA; RECEPTOR EXPRESSION; IMMUNE-RESPONSE; B-CELLS; D-3; ACTIVATION; MICE; INHIBITION	The fat soluble vitamin D3 metabolite 1,25-dihydroxyvitamin D3 [1,25(OH)(2)D-3], and its nuclear receptor play an important role in regulating immune responses. While 1,25(OH)(2)D-3 is known to inhibit transcription of cytokine genes that are required for Th1 differentiation or are products of differentiated Th1 cells, its role in regulating differentiation of Th2 cells is less clear. In this study, we show that 1,25(OH)(2)D-3 has anti-inflammatory effects in an in vivo Th2-dependent asthma model. In addition, we demonstrate that 1,25(OH)(2)D-3 down-regulates the cytoskeleton rearrangement required for promoting integrin-mediated adhesion of naive and effector CD4(+) T cells. Finally, 1,25(OH)(2)D-3 inhibits chemokine-induced migration of naive cells and their homing to the lymph nodes. Thus, in addition to its regulation of cytokine transcription, 1,25(OH)(2)D-3 regulates migration of cells and thus controls the skewing of various Th subsets in the secondary lymphoid organs and inhibits Th function at sites of inflammation.	Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; Sourasky Med Ctr, Tel Aviv, Israel; Weizmann Inst Sci, Expt Anim Ctr, IL-76100 Rehovot, Israel	Shachar, I (reprint author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	Idit.Shachar@weizmann.ac.il					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; BHALLA AK, 1984, J IMMUNOL, V133, P1748; Boonstra A, 2001, J IMMUNOL, V167, P4974; BUTCHER EC, 1980, EUR J IMMUNOL, V10, P556, DOI 10.1002/eji.1830100713; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Cantorna MT, 1996, P NATL ACAD SCI USA, V93, P7861, DOI 10.1073/pnas.93.15.7861; Cantorna MT, 1998, J NUTR, V128, P68; Cantorna MT, 1998, J IMMUNOL, V160, P5314; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; D'Ambrosio D, 1998, J CLIN INVEST, V101, P252, DOI 10.1172/JCI1050; Flaishon L, 2000, J EXP MED, V192, P1381, DOI 10.1084/jem.192.9.1381; Flaishon L, 2002, J IMMUNOL, V168, P3707; Flaishon L, 2001, J BIOL CHEM, V276, P46701, DOI 10.1074/jbc.M103484200; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Franitza S, 2002, EUR J IMMUNOL, V32, P193, DOI 10.1002/1521-4141(200201)32:1<193::AID-IMMU193>3.0.CO;2-H; GOWANS JL, 1964, PROC R SOC SER B-BIO, V159, P257, DOI 10.1098/rspb.1964.0001; Griffin MD, 2001, P NATL ACAD SCI USA, V98, P6800, DOI 10.1073/pnas.121172198; HUANG SK, 1995, J IMMUNOL, V155, P2688; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; LEMIRE JM, 1992, AUTOIMMUNITY, V12, P143, DOI 10.3109/08916939209150321; LEMIRE JM, 1995, J NUTR, V125, pS1704; LEMIRE JM, 1991, J CLIN INVEST, V87, P1103, DOI 10.1172/JCI115072; Lemon BD, 1997, MOL CELL BIOL, V17, P1923; Lemon BD, 1996, MOL CELL BIOL, V16, P1006; LOWE K E, 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P65; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; O'Kelly J, 2002, J CLIN INVEST, V109, P1091, DOI 10.1172/JCI200212392; Penna G, 2000, J IMMUNOL, V164, P2405; Piemonti L, 2000, J IMMUNOL, V164, P4443; Potsch C, 1999, EUR J IMMUNOL, V29, P3562, DOI 10.1002/(SICI)1521-4141(199911)29:11<3562::AID-IMMU3562>3.0.CO;2-R; PROVVEDINI DM, 1983, SCIENCE, V221, P1181, DOI 10.1126/science.6310748; Randolph DA, 1999, SCIENCE, V286, P2159, DOI 10.1126/science.286.5447.2159; REICHEL H, 1987, J CLIN ENDOCR METAB, V64, P1; RIGBY WFC, 1984, J CLIN INVEST, V74, P1451, DOI 10.1172/JCI111557; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; SHACHAR I, 1995, IMMUNITY, V3, P373, DOI 10.1016/1074-7613(95)90121-3; SHIMIZU Y, 1992, IMMUNOL TODAY, V13, P106, DOI 10.1016/0167-5699(92)90151-V; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Staeva-Vieira TP, 2002, J IMMUNOL, V168, P1181; Stein JV, 2000, J EXP MED, V191, P61, DOI 10.1084/jem.191.1.61; Topilski I, 2002, J IMMUNOL, V168, P1610; TSOUKAS CD, 1984, SCIENCE, V224, P1438, DOI 10.1126/science.6427926; Veldman CM, 2000, ARCH BIOCHEM BIOPHYS, V374, P334, DOI 10.1006/abbi.1999.1605; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; Xie HJ, 1999, J EXP MED, V189, P1765, DOI 10.1084/jem.189.11.1765; YU XP, 1991, J BIOL CHEM, V266, P7588	52	72	82	0	1	WILEY-V C H VERLAG GMBH	WEINHEIM	PO BOX 10 11 61, D-69451 WEINHEIM, GERMANY	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	APR	2004	34	4					1068	1076		10.1002/eji.200324532		9	Immunology	Immunology	812JA	WOS:000220834600017	15048717	
J	Jaakkola, JJK; Piipari, R; Jaakkola, MS				Jaakkola, JJK; Piipari, R; Jaakkola, MS			Occupation and asthma: A population-based incident case-control study	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						asthma; case-control studies; occupational diseases; occupations	MALODOROUS SULFUR-COMPOUNDS; KARELIA AIR-POLLUTION; ADULT-ONSET ASTHMA; RESPIRATORY SYMPTOMS; GENERAL-POPULATION; EXPOSURE; COMMUNITY; SAMPLE; RISK	The authors assessed the relations between occupation and risk of developing asthma in adulthood in a 1997-2000 population-based incident case-control study of 521 cases and 932 controls in south Finland. The occupations were classified according to potential exposure to asthma-causing inhalants. Asthma risk was increased consistently for both men and women in the chemical (adjusted odds ratio (OR) = 5.69, 95% confidence interval (CI): 1.08, 29.8), rubber and plastic (OR = 2.61, 95% CI: 0.92, 7.42), and wood and paper (OR = 1.72, 95% CI: 0.71, 4.17) industries. Risk in relation to occupation was increased only for men-for bakers and food processors (OR = 8.62, 95% CI: 0.86, 86.5), textile workers (OR = 4.70, 95% CI: 0.29, 77.1), electrical and electronic production workers (OR 2.83, 95% CI: 0.82, 6.93), laboratory technicians (OR = 1.66, 95% CI: 0.17, 16.6), and storage workers (OR 1.57, 95% CI: 0.40, 6.19). Of the predominantly men's occupations, metal (OR = 4.52, 95% CI: 2.35, 8.70) and forestry (OR = 6.00, 95% CI: 0.96, 37.5) work were the strongest determinants of asthma. For women, asthma risk increased for waiters (OR = 3.03, 95% CI: 1.10, 8.31), cleaners (OR = 1.42, 95% CI: 0.81, 2.48), and dental workers (OR = 4.74, 95% CI: 0.48, 46.5). Results suggest an increased asthma risk both in traditional industries and forestry and in several nonindustrial occupations.	Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, Helsinki, Finland; Finnish Inst Occupat Hlth, Helsinki, Finland	Jaakkola, JJK (reprint author), Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England.		Jaakkola, Jouni/G-4314-2012				BAKKE P, 1991, EUR RESPIR J, V4, P273; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; *COMM NAT ASTHM PR, 1994, MIN SOC AFF HLTH PUB, V16; Cullinan P, 1997, CLIN EXP ALLERGY, V27, P41, DOI 10.1111/j.1365-2222.1997.tb01825.x; delaHoz RE, 1997, AM J IND MED, V31, P195, DOI 10.1002/(SICI)1097-0274(199702)31:2<195::AID-AJIM9>3.0.CO;2-Z; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; Forastiere F, 1998, AM J RESP CRIT CARE, V157, P1864; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755; Jaakkola JJK, 2002, J ALLERGY CLIN IMMUN, V109, P784, DOI 10.1067/mai.2002.123870; JAAKKOLA JJK, 1990, AM REV RESPIR DIS, V142, P1344; Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543; JAAKKOLA MS, 2002, SCAND J WORK ENV S2, V28, P54; JAAKKOLA MS, 2001, EUR RESPIR J, V14, pP1906; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Kogevinas M, 1996, AM J RESP CRIT CARE, V154, P137; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Monso E, 1998, ARCH ENVIRON HEALTH, V53, P93; NG TP, 1994, AM J IND MED, V25, P709, DOI 10.1002/ajim.4700250510; ParttiPellinen K, 1996, ARCH ENVIRON HEALTH, V51, P315; VIEGI G, 1991, AM REV RESPIR DIS, V143, P510; XU XP, 1993, CHEST, V104, P1364, DOI 10.1378/chest.104.5.1364	28	72	73	0	3	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	NOV 15	2003	158	10					981	987		10.1093/aje/kwg238		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	742XV	WOS:000186544200009	14607806	
J	Medina-Ramon, M; Zock, JP; Kogevinas, M; Sunyer, J; Anto, JM				Medina-Ramon, M; Zock, JP; Kogevinas, M; Sunyer, J; Anto, JM			Asthma symptoms in women employed in domestic cleaning: a community based study	THORAX			English	Article							OCCUPATIONAL ASTHMA; EXPOSURE; RISK; WORK; CLEANERS	Background: Epidemiological studies have shown an association between cleaning work and asthma, but the risk factors are uncertain. The aim of this study was to assess the risk of asthma in women employed in domestic cleaning. Methods: A cross sectional study was conducted in 4521 women aged 30 to 65 years. Information on respiratory symptoms and cleaning work history was obtained using a postal questionnaire with telephone follow up. Asthma was defined as reported symptoms in the last year or current use of drugs to treat asthma. Odds ratios (OR) with 95% confidence intervals (CI) for asthma in different cleaning groups were estimated using adjusted unconditional logistic regression models. Results: 593 women (13%) were currently employed in domestic cleaning work. Asthma was more prevalent in this group than in women who had never worked in cleaning (OR 1.46 (95% CI, 1.10 to 1.92)). Former domestic cleaning work was reported by 1170 women (26%), and was strongly associated with asthma (OR 2.09 (1.70 to 2.57)). Current and former non-domestic cleaning work was not significantly associated with asthma. Consistent results were obtained for other respiratory symptoms. Twenty five per cent of the asthma cases in the study population were attributable to domestic cleaning work. Conclusions: Employment in domestic cleaning may induce or aggravate asthma. This study suggests that domestic cleaning work has an important public health impact, probably involving not only professional cleaners but also people undertaking cleaning tasks at home.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Pompeu Fabra Univ, Dept Expt & Hlth Sci, Barcelona, Spain	Anto, JM (reprint author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Dr Aiguader 80, E-08003 Barcelona, Spain.		Kogevinas, Manolis/C-3918-2017; Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110			BERNSTEIN JA, 1994, J ALLERGY CLIN IMMUN, V94, P257, DOI 10.1016/0091-6749(94)90048-5; Blanc PD, 1999, AM J MED, V107, P580, DOI 10.1016/S0002-9343(99)00307-1; BURGE PS, 1994, THORAX, V49, P842, DOI 10.1136/thx.49.8.842; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Chan-Yeung M., 1999, ASTHMA WORKPLACE, P129; Checkoway H., 1989, RES METHODS OCCUPATI, P72; Fishwick D, 1997, AM J RESP CRIT CARE, V156, P1440; Forastiere F, 1998, AM J RESP CRIT CARE, V157, P1864; Galobardes B, 1998, J CLIN EPIDEMIOL, V51, P875, DOI 10.1016/S0895-4356(98)00063-8; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Karjalainen A, 2002, EUR RESPIR J, V19, P90, DOI 10.1183/09031936.02.00201002; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; MEREDITH S, 1993, J EPIDEMIOL COMMUN H, V47, P459, DOI 10.1136/jech.47.6.459; PEPYS J, 1999, ASTHMA WORKPLACE, P5; Quirce S, 2000, J ASTHMA, V37, P267, DOI 10.3109/02770900009055449; REILLY MJ, 1995, ARCH ENVIRON HEALTH, V50, P26; Reinisch F, 2001, AM J IND MED, V39, P72; Symanski E, 1998, OCCUP ENVIRON MED, V55, P300; Venables KM, 1997, LANCET, V349, P1465, DOI 10.1016/S0140-6736(96)07219-4; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	23	72	72	0	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	NOV 1	2003	58	11					950	954		10.1136/thorax.58.11.950		5	Respiratory System	Respiratory System	737PU	WOS:000186241600011	14586047	
J	Cookson, W				Cookson, W			Genetics and genomics of asthma and allergic diseases	IMMUNOLOGICAL REVIEWS			English	Review							FC-EPSILON-RI; CHRONIC LYMPHOCYTIC-LEUKEMIA; INFLAMMATORY BOWEL-DISEASE; IMMUNOGLOBULIN-E RESPONSES; CALCIUM-BINDING PROTEIN; MAJOR SUSCEPTIBILITY LOCUS; ATOPIC-DERMATITIS; WIDE SEARCH; BETA-SUBUNIT; RHEUMATOID-ARTHRITIS	Asthma and eczema (atopic dermatitis) are characterized by a number of unexplained phenomena: the familial aggregation of disease, the initiation of disease by apparently trivial exposure to allergens, the preferential transmission of disease from affected mothers and the large increase in prevalence of disease in Westernized societies in the last century. A number of genes and chromosomal regions have been identified that consistently show linkage to asthma and its related phenotypes. Known loci modify the strength of the atopic response, nonspecific inflammation, the ability to respond to particular allergens and nonspecific airway reactivity. Eczema has been shown to be due to a different set of genetic loci that are shared with other skin diseases such as psoriasis and leprosy. Genetic and genomic studies both provide evidence that epithelial surfaces are active in the induction of allergic disease.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	Cookson, W (reprint author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.						AguiarPasseti T, 1997, J LEUKOCYTE BIOL, V62, P852; Akolkar PN, 1997, AM J GASTROENTEROL, V92, P2241; Albuquerque RV, 1998, CLIN EXP ALLERGY, V28, P578; Anderson GG, 2002, EUR J HUM GENET, V10, P266, DOI 10.1038/sj/ejhg/5200801; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Becker KG, 1998, P NATL ACAD SCI USA, V95, P9979, DOI 10.1073/pnas.95.17.9979; Belcher CE, 2000, P NATL ACAD SCI USA, V97, P13847, DOI 10.1073/pnas.230262797; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Benson M, 2002, CLIN EXP ALLERGY, V32, P301, DOI 10.1046/j.1365-2222.2002.01300.x; Beyer KWU, 1998, J ALLERGY CLIN IMMUN, V101, P152; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; BOS J, 2000, IMMUNOLOGY ATOPIC DE; Bradley M, 2002, HUM MOL GENET, V11, P1539, DOI 10.1093/hmg/11.13.1539; BRANDRUP F, 1978, ARCH DERMATOL, V114, P874, DOI 10.1001/archderm.114.6.874; BRANDTZAEG P, 1995, ADV EXP MED BIOL, V371, P201; BRUN JG, 1994, SCAND J IMMUNOL, V40, P675, DOI 10.1111/j.1365-3083.1994.tb03523.x; BUFE A, 1995, FEBS LETT, V363, P6, DOI 10.1016/0014-5793(95)00259-C; Burden AD, 1998, J INVEST DERMATOL, V110, P958, DOI 10.1046/j.1523-1747.1998.00213.x; Cabral A, 2001, J BIOL CHEM, V276, P19231, DOI 10.1074/jbc.M100336200; Camp RDR, 1998, TXB DERMATOLOGY, P1589; Capon F, 1999, J INVEST DERMATOL, V112, P32, DOI 10.1046/j.1523-1747.1999.00471.x; Chagani T, 1999, AM J RESP CRIT CARE, V160, P278; Chavanas S, 2000, AM J HUM GENET, V66, P914, DOI 10.1086/302824; Chavanas S, 2000, NAT GENET, V25, P141; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; Coca AF, 1923, J IMMUNOL, V8, P163; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; COOKSON WOCM, 1988, LANCET, V1, P86; COOKSON WOCM, 1992, LANCET, V340, P381, DOI 10.1016/0140-6736(92)91468-N; COOKSON WOCM, 1989, LANCET, V1, P1292; Cookson WOCM, 2001, NAT GENET, V27, P372, DOI 10.1038/86867; Cornish CJ, 1996, J CELL PHYSIOL, V166, P427, DOI 10.1002/(SICI)1097-4652(199602)166:2<427::AID-JCP21>3.0.CO;2-6; COX H, 1999, CLIN GENETIC ASPECTS; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; De Heller-Milev M, 2000, BRIT J DERMATOL, V143, P733, DOI 10.1046/j.1365-2133.2000.03768.x; Dekker JW, 1997, CLIN EXP ALLERGY, V27, P574, DOI 10.1046/j.1365-2222.1997.540848.x; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812; Djian P, 2000, J CELL BIOL, V151, P381, DOI 10.1083/jcb.151.2.381; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Donnadieu E, 2000, J IMMUNOL, V165, P3917; Duerr RH, 1998, AM J HUM GENET, V63, P95, DOI 10.1086/301929; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351; EIBERG H, 1985, CYTOGENET CELL GENET, V40, P622; Enlund F, 1999, EUR J HUM GENET, V7, P783, DOI 10.1038/sj.ejhg.5200365; Eue I, 2000, INT IMMUNOL, V12, P1593, DOI 10.1093/intimm/12.11.1593; FARBER EM, 1974, ARCH DERMATOL, V109, P207, DOI 10.1001/archderm.109.2.207; Freedberg IM, 2001, J INVEST DERMATOL, V116, P633, DOI 10.1046/j.1523-1747.2001.01327.x; Gaffney PM, 2000, AM J HUM GENET, V66, P547, DOI 10.1086/302767; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Haagerup A, 2002, ALLERGY, V57, P680, DOI 10.1034/j.1398-9995.2002.23523.x; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; HALL JG, 1990, ARCH DIS CHILD, V65, P1013; Hardas BD, 1996, J INVEST DERMATOL, V106, P753, DOI 10.1111/1523-1747.ep12345807; Hardwick LJ, 1997, J RHEUMATOL, V24, P197; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HILL MR, 1995, BRIT MED J, V311, P776; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Hofmann MA, 1999, CELL, V97, P889, DOI 10.1016/S0092-8674(00)80801-6; Holberg CJ, 1996, AM J RESP CRIT CARE, V154, P144; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Holt PG, 1990, PEDIATR ALLERGY IMMU, V1, P3, DOI 10.1111/j.1399-3038.1990.tb00002.x; Holt P.G., 1999, NATURE, V402, P12, DOI 10.1038/35037009; Howard TD, 2001, AM J RESP CELL MOL, V25, P377; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; JARRETT E, 1979, NATURE, V280, P145, DOI 10.1038/280145a0; JARRETT EEE, 1983, IMMUNOLOGY, V48, P49; Jawaheer D, 2001, AM J HUM GENET, V68, P927, DOI 10.1086/319518; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Jinquan Tan, 1996, Journal of Investigative Dermatology, V107, P5, DOI 10.1111/1523-1747.ep12294284; JUHLIN L, 1969, ARCH DERMATOL, V100, P12, DOI 10.1001/archderm.100.1.12; Kalachikov S, 1997, GENOMICS, V42, P369, DOI 10.1006/geno.1997.4747; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; KAUFMAN HS, 1970, LANCET, V2, P1061; Koch PJ, 2000, J CELL BIOL, V151, P389, DOI 10.1083/jcb.151.2.389; Komada T, 1996, BIOCHEM BIOPH RES CO, V220, P871, DOI 10.1006/bbrc.1996.0496; Komatsu N, 2002, J INVEST DERMATOL, V118, P436, DOI 10.1046/j.0022-202x.2001.01663.x; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Koumantaki Y, 1997, J RHEUMATOL, V24, P1522; Kraan TCTMV, 1999, GENES IMMUN, V1, P61; Kuokkanen S, 1997, AM J HUM GENET, V61, P1379, DOI 10.1086/301637; KUPERMAN DA, 2002, NAT MED, V8, P225; LACKMANN M, 1993, J IMMUNOL, V150, P2981; LACOUR M, 1994, DERMATOLOGY, V188, P255; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Laval SH, 2001, AM J HUM GENET, V68, P918, DOI 10.1086/319509; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; LEE SC, 1993, J INVEST DERMATOL, V100, P65, DOI 10.1111/1523-1747.ep12354504; Lee YA, 2000, NAT GENET, V26, P470, DOI 10.1038/82625; Lemke H, 2002, ADV IMMUNOL, V80, P203, DOI 10.1016/S0065-2776(02)80016-5; Lemke H, 1999, SCAND J IMMUNOL, V50, P348, DOI 10.1046/j.1365-3083.1999.00620.x; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Lohman FP, 1997, EXP CELL RES, V231, P141, DOI 10.1006/excr.1996.3458; LUDVIKSSON BR, 1992, J PEDIATR-US, V121, P23, DOI 10.1016/S0022-3476(05)82535-1; Mabuchi H, 2001, CANCER RES, V61, P2870; Magert HJ, 1999, J BIOL CHEM, V274, P21499, DOI 10.1074/jbc.274.31.21499; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637; MARKOVA NG, 1993, MOL CELL BIOL, V13, P613; MARSH DG, 1981, NEW ENGL J MED, V305, P1551, DOI 10.1056/NEJM198112243052603; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; Millichip MI, 1998, BIOCHEM BIOPH RES CO, V245, P594, DOI 10.1006/bbrc.1998.8485; Mischke D, 1996, J INVEST DERMATOL, V106, P989, DOI 10.1111/1523-1747.ep12338501; Moffatt M. F., 1994, Lancet (North American Edition), V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Moffatt MF, 1997, IMMUNOGENETICS, V46, P226, DOI 10.1007/s002510050266; Moffatt MF, 2001, EUR J HUM GENET, V9, P341, DOI 10.1038/sj.ejhg.5200636; Moffatt MF, 1998, CLIN EXP ALLERGY S1, V28, P65; Morishita Y, 1999, CLIN EXP ALLERGY, V29, P1110; Mostoslavsky R, 2001, NATURE, V414, P221, DOI 10.1038/35102606; NAGATA S, 1987, J ALLERGY CLIN IMMUN, V80, P24, DOI 10.1016/S0091-6749(87)80186-0; Nakagawa Y, 1998, AM J HUM GENET, V63, P547, DOI 10.1086/301974; Noguchi E, 2002, AM J RESP CRIT CARE, V166, P43, DOI 10.1164/rccm.2110052; Noguchi E, 2001, HUM IMMUNOL, V62, P1251, DOI 10.1016/S0198-8859(01)00338-X; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; ONO Y, 1974, NATURE, V250, P593, DOI 10.1038/250593a0; OSCIER DG, 1994, BLOOD REV, V8, P88, DOI 10.1016/S0268-960X(05)80013-X; Palmer LJ, 2000, AM J RESP CRIT CARE, V161, P1836; Passey RJ, 1999, J LEUKOCYTE BIOL, V66, P549; Ramoz N, 1999, J INVEST DERMATOL, V112, P259, DOI 10.1046/j.1523-1747.1999.00536.x; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Ring PC, 2000, CLIN EXP ALLERGY, V30, P1085; Rioux JD, 1998, AM J HUM GENET, V63, P1086, DOI 10.1086/302053; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; Sartono E, 1996, EUR J IMMUNOL, V26, P501, DOI 10.1002/eji.1830260233; Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199; Sawcer S, 1996, NAT GENET, V13, P464, DOI 10.1038/ng0896-464; Schultz Larsen F, 1993, J Am Acad Dermatol, V28, P719; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; Song PI, 2002, J INVEST DERMATOL, V119, P424, DOI 10.1046/j.1523-1747.2002.01847.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STEINBAKK M, 1990, LANCET, V336, P763, DOI 10.1016/0140-6736(90)93237-J; STEINERT PM, 1995, J BIOL CHEM, V270, P17702; STERN CMM, 1976, IMMUNOLOGY, V30, P443; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; TOMFOHRDE J, 1994, SCIENCE, V264, P1141, DOI 10.1126/science.8178173; Tomic-Canic M, 1998, J DERMATOL SCI, V17, P167, DOI 10.1016/S0923-1811(98)00016-4; Tosh K, 2002, J INFECT DIS, V186, P1190, DOI 10.1086/343806; Trembath RC, 1997, HUM MOL GENET, V6, P813, DOI 10.1093/hmg/6.5.813; Turner H, 1999, NATURE, V402, P24, DOI 10.1038/35037021; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Vorechovsky I, 1999, AM J HUM GENET, V64, P1096, DOI 10.1086/302326; Wa TCLK, 1999, CLIN EXP ALLERGY, V29, P1204; WACHTER AM, 1992, ANN ALLERGY, V69, P407; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304; Watson PH, 1998, INT J BIOCHEM CELL B, V30, P567, DOI 10.1016/S1357-2725(97)00066-6; Weskamp G, 1996, J CELL BIOL, V132, P717, DOI 10.1083/jcb.132.4.717; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wiltshire S, 1998, HUM MOL GENET, V7, P27, DOI 10.1093/hmg/7.1.27; Winchester EC, 2000, HUM GENET, V107, P591, DOI 10.1007/s004390000410; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Witte JS, 2002, EUR J HUM GENET, V10, P82, DOI 10.1038/sj/ejhg/5200746; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; YOUNG RP, 1995, AM J RESP CRIT CARE, V151, P219; YOUNG RP, 1994, CLIN EXP ALLERGY, V24, P431, DOI 10.1111/j.1365-2222.1994.tb00931.x; YUI S, 1995, J LEUKOCYTE BIOL, V58, P307	178	72	79	0	2	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-2896			IMMUNOL REV	Immunol. Rev.	DEC	2002	190	1					195	206		10.1034/j.1600-065X.2002.19015.x		12	Immunology	Immunology	627QU	WOS:000179946400015	12493016	
J	Douwes, J; Pearce, N				Douwes, J; Pearce, N			Asthma and the westernization 'package'	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Review							EARLY BCG VACCINATION; MODIFIED TH2 RESPONSE; HUMAN IMMUNE-SYSTEM; IN-HOUSE DUST; HAY-FEVER; INTESTINAL MICROFLORA; ATOPIC DISEASE; YOUNG-ADULTS; ENVIRONMENTAL ALLERGENS; INFECTIOUS-DISEASES		Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Univ Utrecht, IRAS, Div Environm & Occupat Hlth, NL-3508 TC Utrecht, Netherlands	Douwes, J (reprint author), Massey Univ, Ctr Publ Hlth Res, Wellington Campus,Private Box 756, Wellington, New Zealand.			Douwes, Jeroen/0000-0003-3599-4036			Aaby P, 2000, CLIN EXP ALLERGY, V30, P644, DOI 10.1046/j.1365-2222.2000.00803.x; Alm JS, 1998, ALLERGY, V53, P537, DOI 10.1111/j.1398-9995.1998.tb04093.x; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Crater DD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e97; Custovic A., 1998, EUR RESPIR REV, V8, P155; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; Gruber C, 2001, PEDIATRICS, V107, pE36, DOI 10.1542/peds.107.3.e36; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; HEINRICH J, IN PRESS EUR RESP J; HERTZ U, 2000, AM J RESP CRIT CARE, V162, pS62; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hessle C, 1999, CLIN EXP IMMUNOL, V116, P276; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JOHANSSON ML, 1993, APPL ENVIRON MICROB, V59, P15; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Kuehni CE, 2001, LANCET, V357, P1821, DOI 10.1016/S0140-6736(00)04958-8; Leadbitter P, 1999, THORAX, V54, P905; Liu AH, 2000, CLIN EXP ALLERGY, V30, P1535, DOI 10.1046/j.1365-2222.2000.01012.x; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1997, BRIT MED J, V314, P999; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; O'Donnell RA, 2002, THORAX, V57, P566, DOI 10.1136/thorax.57.7.566; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Pearce N, 1999, THORAX, V54, P268; PEARCE N, 2002, OXFORD TXB PUBLIC HL, V3, P1255; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Pekkanen J, 2001, CLIN EXP ALLERGY, V31, P95, DOI 10.1046/j.1365-2222.2001.00930.x; Pekkanen J, 1999, EUR RESPIR J, V14, P951, DOI 10.1034/j.1399-3003.1999.14d37.x; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Prescott SL, 2000, ALLERGY, V55, P470; Prescott SL, 1998, J IMMUNOL, V160, P4730; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Russell G, 1997, BRIT MED J, V315, P1014; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Shaheen SO, 1996, BRIT MED J, V313, P969; Shaheen SO, 1999, THORAX, V54, P396; Shida K, 1998, INT ARCH ALLERGY IMM, V115, P278, DOI 10.1159/000069458; Shida K, 2002, CLIN EXP ALLERGY, V32, P563, DOI 10.1046/j.0954-7894.2002.01354.x; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; Svanes C, 1998, EUR RESPIR J, V12, P1366, DOI 10.1183/09031936.98.12061366; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Szepfalusi Z, 2000, PEDIATR RES, V48, P404; Szepfalusi Z, 2000, J ALLERGY CLIN IMMUN, V106, P530; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Upton MN, 2000, BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Warner I, 1998, J NURS ADMIN, V28, P3; Warner JA, 1996, PEDIATR ALLERGY IMMU, V7, P98, DOI 10.1111/j.1399-3038.1996.tb00406.x; Weiss KB, 1992, CHEST, V101, P362; Yuan W, 2002, INT J EPIDEMIOL, V31, P1240, DOI 10.1093/ije/31.6.1240	88	72	74	2	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	2002	31	6					1098	1102		10.1093/ije/31.6.1098		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	650TJ	WOS:000181279100003	12540698	
J	de Marco, R; Poli, A; Ferrari, M; Accordini, S; Giammanco, G; Bugiani, M; Villani, S; Ponzio, M; Bono, R; Carrozzi, L; Cavallini, R; Cazzoletti, L; Dallari, R; Ginesu, F; Lauriola, P; Mandrioli, P; Perfetti, L; Pignato, S; Pirina, P; Struzzo, P				de Marco, R; Poli, A; Ferrari, M; Accordini, S; Giammanco, G; Bugiani, M; Villani, S; Ponzio, M; Bono, R; Carrozzi, L; Cavallini, R; Cazzoletti, L; Dallari, R; Ginesu, F; Lauriola, P; Mandrioli, P; Perfetti, L; Pignato, S; Pirina, P; Struzzo, P		ISAYA Study Grp	The impact of climate and traffic-related NO2 on the prevalence of asthma and allergic rhinitis in Italy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic rhinitis; asthma; climate; outdoor NO2 pollution; traffic-related pollution	RESPIRATORY HEALTH SURVEY; DIESEL EXHAUST PARTICLES; LONG-TERM EXPOSURE; AIR-POLLUTION; CHILDHOOD ASTHMA; LUNG-FUNCTION; INDOOR ALLERGENS; NEW-ZEALAND; SYMPTOMS; POLLUTANTS	Background Environmental factors are likely to be involved in explaining the wide geographical variation in asthma and atopic diseases that has been documented in many recent epidemiological studies. Aim To evaluate to what extent climate and outdoor NO2 pollution can explain the geographical variation in the prevalence of asthma and allergic rhinitis, and to estimate the relative risk for exposure to different levels of these two factors. Methods The impact of climate and long-term exposure to nitrogen dioxide (NO2) pollution on asthma and allergic rhinitis was assessed in a cross-sectional study, carried out during 1998 to 2000 on young adults aged 20 to 44 years (n = 18 873), living in 13 areas from two different Italian climatic regions (subcontinental and Mediterranean). Results Mediterranean areas had a significantly higher prevalence of asthma-like symptoms (P < 0.001), higher annual mean temperature (16.2 degreesC vs. 12.9 degreesC), lower temperature range (16.0 Cdegrees vs. 22.1 Cdegrees) and lower NO2 levels (31.46 mug/m(3) vs. 57.99 mug/m(3)) than subcontinental ones. Mediterranean climate was associated with an increased risk of wheeze (OR = 1.23; 95% CI 1.13 to 1.35), tightness in the chest (OR = 1.21; 95% CI 1.11 to 1.33), shortness of breath (OR = 1.21; 95% CI 1.08 to 1.36) and asthma attacks (OR = 1.19; 95% CI 1.07 to 1.31). After adjusting for climate, an increase of 18.3 mug/m(3) in NO2 levels moderately increased the risk of asthma attacks (OR = 1.13; 95% CI 0.98 to 1.32), tightness in the chest (OR = 1.11; 95% CI 0.98 to 1.26) and wheeze (OR = 1.11; 95% CI 0.96 to 1.28). When the levels of outdoor NO2 exposure rose, the prevalence of allergic rhinitis increased significantly in the Mediterranean region (OR = 1.38; 95% CI 1.12 to 1.69), but not in the subcontinental one (OR = 1.03; 95% CI 0.83 to 1.28). Conclusion Our results show that the prevalence of asthma increases when annual mean temperature increases and temperature range decreases. Furthermore, climate interacts with NO2 outdoor exposure, increasing the risk for allergic rhinitis in people exposed to high stable temperatures. A long-term role for the effect of traffic pollution on asthma is also suggested.	Univ Verona, Inst Biol 2, Dipartimento Med & Sanit Pubbl, Sez Epidemiol & Stat Med,Unit Epidemiol & Med Sta, I-37134 Verona, Italy; Univ Verona, Unit Hyg & Prevent Environm & Occupat Med, I-37134 Verona, Italy; Univ Verona, Dept Biomed & Surg Sci, Sect Internal Med, I-37134 Verona, Italy; Univ Catania, Inst Hyg & Prevent Med, Catania, Italy; Natl Hlth Serv, CPA ASL Unit Resp Med 4, Turin, Italy; Univ Pavia, Fac Med, Dept Appl Hlth Sci, I-27100 Pavia, Italy; Univ Turin, Dept Microbiol & Publ Hlth, Turin, Italy; Univ Pisa, CNR, Inst Clin Physiol, Cardiopulm Dept, I-56100 Pisa, Italy; Hosp Pisa, Pisa, Italy; AUSL Modena, Natl Hlth Serv, Hosp Sassuolo, Unit Pulmonol, Modena, Italy; Univ Sassari, Inst Resp Dis, I-07100 Sassari, Italy; ARPA Emilia Romogna Agenzia Reg Prevent & Ambient, Environm Epidemiol Unit, Modena, Italy; CNR, Inst Atmospher & Ocean Sci, Bologna, Italy; Ctr Pavia, Salvatore Maugeri Fdn, Allergy & Clin Immunol Unit, Pavia, Italy; Municipal Udine, Udine, Italy	de Marco, R (reprint author), Univ Verona, Inst Biol 2, Dipartimento Med & Sanit Pubbl, Sez Epidemiol & Stat Med,Unit Epidemiol & Med Sta, Strada le Grazie 8, I-37134 Verona, Italy.		de Marco, Roberto/A-5470-2008; SESM, SESM/C-1440-2008; bucca, caterina/C-9886-2009; Bono, Roberto/J-8954-2012; Struzzo, Pierluigi/I-7502-2012; Osborne, Nicholas/N-4915-2015	bucca, caterina/0000-0002-9941-9236; Struzzo, Pierluigi/0000-0003-0570-3103; Osborne, Nicholas/0000-0002-6700-2284; Bono, Roberto/0000-0002-2471-6594			Accorsi CA, 1990, AEROBIOLOGIA, V6, P9; AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; Alvarez MJ, 1997, J INVEST ALLERG CLIN, V7, P572; Bernard SM, 2001, ENVIRON HEALTH PERSP, V109, P199, DOI 10.2307/3435010; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; Cross S, 1997, Community Nurse, V3, P25; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; de Marco R, 1999, EUR RESPIR J, V14, P1044, DOI 10.1183/09031936.99.14510449; DEMARCO R, 1995, ALLERGY, V50, P755; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Estela LBL, 1998, INT J BIOMETEOROL, V42, P77; *EUR COMM RESP HLT, 1994, MED HLTH; Dunn G., 1991, APPL MULTIVARIATE DA; Fleiss J. L., 1981, STAT METHODS RATES P; Gluck U, 2000, ORL J OTO-RHINO-LARY, V62, P68, DOI 10.1159/000027720; Goldstein H., 1995, MULTILEVEL STAT MODE; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; Hales S, 1998, ENVIRON HEALTH PERSP, V106, P607, DOI 10.1289/ehp.98106607; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Hosmer DW, 1989, APPL LOGISTIC REGRES; *I NAZ STAT, 1998, ANN STAT MET; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Kunzli N, 1997, ENVIRON RES, V72, P8, DOI 10.1006/enrs.1996.3687; LAOR A, 1993, BRIT MED J, V307, P841; Lim T O, 1991, Med J Malaysia, V46, P230; Millqvist E, 2000, CLIN PHYSIOL, V20, P212; NISHINO N, 1996, EPIDEMIOLOGY, V7, pS31; PEARCE N, 1993, EUR RESPIR J, V6, P1455; PEAT JK, 1993, CLIN EXP ALLERGY, V23, P812, DOI 10.1111/j.1365-2222.1993.tb00258.x; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; PIAZZA A, 1988, ANN HUM GENET, V52, P203, DOI 10.1111/j.1469-1809.1988.tb01098.x; PICCOLO MC, 1988, ANN ALLERGY, V60, P107; Rasbash J, 2000, USERS GUIDE MLWIN VE; SCHWARTZ J, 1989, ENVIRON RES, V50, P309, DOI 10.1016/S0013-9351(89)80012-X; Steerenberg PA, 1999, INHAL TOXICOL, V11, P1109; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541; Thurston GD, 1999, AIR POLLUTION HLTH, P485, DOI 10.1016/B978-012352335-8/50097-1; Verlato G, 2002, ARCH ENVIRON HEALTH, V57, P48; WANG JH, 1995, J ALLERGY CLIN IMMUN, V96, P669, DOI 10.1016/S0091-6749(95)70266-0; Warner AM, 1996, PEDIATR ALLERGY IMMU, V7, P61, DOI 10.1111/j.1399-3038.1996.tb00108.x	49	72	72	0	12	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2002	32	10					1405	1412		10.1046/j.1365-2745.2002.01466.x		8	Allergy; Immunology	Allergy; Immunology	601ZJ	WOS:000178479300004	12372117	
J	Lewis, SA; Weiss, ST; Platts-Mills, TAE; Burge, H; Gold, DR				Lewis, SA; Weiss, ST; Platts-Mills, TAE; Burge, H; Gold, DR			The role of indoor allergen sensitization and exposure in causing morbidity in women with asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						home allergens; cockroach; cat; sensitization; asthma morbidity	INNER-CITY CHILDREN; RISK-FACTORS; COCKROACH ALLERGEN; DETERMINANTS; EOSINOPHILIA; PREDICTORS; AVOIDANCE; ANTIGEN; HOMES; AREA	Longitudinal evidence that indoor allergen exposure causes morbidity in sensitized individuals with asthma is scarce. We evaluated the association of allergen sensitization and home exposure to short and long-term morbidity in 140 women with asthma and to asthma prevalence in 458 women from metropolitan Boston. Cockroach (Blattella germanica), dust mite (Dermatophagoides farinae), and cat (Felis domesticus) allergens in home dust samples, and specific immunoglobulln E antibodies were measured at outset, and doctor-diagnosed asthma and markers of asthma morbidity were ascertained by questionnaire during a 4-year follow-up. Cat- and cockroach-sensitive (immunoglobulin E immunocap [Cap] class greater than or equal to 1) women with asthma reported greater morbidity in the past year at the start, and during follow-up, if high levels of the relevant allergen were found. Women with asthma sensitized to cat allergen and with concentrations at 8 mug/g or greater were more likely to have used steroid (adjusted odds ratio [95% confidence interval] 2.7 [1.2-6.2]) and wheezed without a cold (odds ratio 6.8 [3.314.0]) during follow-up. Those sensitized and exposed to cockroach (Bla g I or 2 greater than or equal to 2 U/g) were at least three times more likely to have used steroid and to have attended a hospital emergency room; the size of the effect upon steroid use was maintained, but the precision was reduced and the 95% confidence interval included one (p = 0.07), with adjustment for race and poverty. We conclude that cockroach and cat allergens may contribute to asthma morbidity in sensitized women.	Univ Nottingham, Div Med Res, City Hosp, Nottingham NG5 1PB, England; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Univ Virginia, Dept Med, Div Asthma Allergy & Immunol, Charlottesville, VA USA; Harvard Univ, Sch Publ Hlth, Sch Med, Boston, MA 02115 USA	Lewis, SA (reprint author), Univ Nottingham, Div Med Res, City Hosp, Clin Sci Bldg,Hucknall Rd, Nottingham NG5 1PB, England.				NCEH CDC HHS [R01 A1/EHS35786]; PHS HHS [A120565]		Arshad SH, 1998, AM J RESP CRIT CARE, V157, P1900; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; COCKCROFT DW, 1979, AM REV RESPIR DIS, V120, P1053; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; MORRISON SJ, 1981, PRACTITIONER, V225, P1663; O'Connor G T, 1999, Environ Health Perspect, V107, P243; PERONI DG, 1994, AM J RESP CRIT CARE, V149, P1442; PLATTSMILLS TAE, 1982, LANCET, V2, P675; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Shaver JR, 1997, AM J RESP CRIT CARE, V155, P442; Sicherer SH, 1997, J ALLERGY CLIN IMMUN, V99, P798, DOI 10.1016/S0091-6749(97)80014-0; SIMON HU, 1994, PEDIATR PULM, V17, P304, DOI 10.1002/ppul.1950170507; SUONIEMI I, 1981, ALLERGY, V36, P263, DOI 10.1111/j.1398-9995.1981.tb01573.x; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	23	72	74	1	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2002	165	7					961	966		10.1164/rccm.2103044		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	536ZA	WOS:000174730700016	11934722	
J	Anees, W; Huggins, V; Pavord, ID; Robertson, AS; Burge, PS				Anees, W; Huggins, V; Pavord, ID; Robertson, AS; Burge, PS			Occupational asthma due to low molecular weight agents: eosinophilic and non-eosinophilic variants	THORAX			English	Article							EXHALED NITRIC-OXIDE; RED CEDAR ASTHMA; INDUCED SPUTUM; AIRWAY INFLAMMATION; BRONCHIAL RESPONSIVENESS; FLOW-RATE; DIAGNOSIS; SEVERITY; COUNTS	Background: Despite having a work related deterioration in peak expiratory flow (PEF), many workers with occupational asthma show a low degree of within day diurnal variability atypical of non-occupational asthma. It was hypothesised that these workers would have a neutrophilic rather than an eosinophilic airway inflammatory response. Methods: Thirty eight consecutive workers with occupational asthma induced by low molecular weight agents underwent sputum induction and assessment of airway physiology while still exposed at work. Results: Only 14 (36.8%) of the 38 workers had sputum eosinophilia (>2.2%). Both eosinophilic and non-eosinophilic groups had sputum neutrophilia (mean (SD) 59.5 (19.6)% and 55.1 (18.8)%, respectively). The diurnal variation and magnitude of fall in PEF during work periods was not significantly different between workers with and without sputum eosinophilia. Those with eosinophilia had a lower forced expiratory volume in 1 second (FEV1; 61.4% v 83% predicted, mean difference 21.6, 95% confidence interval (CI) 9.2 to 34.1 p=0.001) and greater methacholine reactivity (geometric mean PD20 253 mug v 1401 mug, p=0.007), hey also had greater bronchodilator reversibility (397 ml v 161 ml, mean difference 236, 95% Cl of difference 84 to 389, p=0.003) which was unrelated to differences in baseline FEV1. The presence of sputum eosinophilia did not relate to the causative agent, duration of exposure, atopy, or lack of treatment. Conclusions: Asthma caused by low molecular weight agents can be separated into eosinophilic and non-eosinophilic pathophysiological variants with the latter predominating. Both groups had evidence of sputum neutrophilia. Sputum eosinophilia was associated with more severe disease and greater bronchodilator reversibility but no difference in PEF response to work exposure.	Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Birmingham B9 5SS, W Midlands, England; Glenfield Gen Hosp, Dept Resp Med, Leicester LE3 9QP, Leics, England	Anees, W (reprint author), Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Birmingham B9 5SS, W Midlands, England.						AMIN K, 2001, AM J RESP CRIT CARE, V62, P2295; Belda J, 2000, AM J RESP CRIT CARE, V161, P475; Burge PS, 1999, OCCUP ENVIRON MED, V56, P758; BURGE PS, 1979, THORAX, V34, P317, DOI 10.1136/thx.34.3.317; Chan-Yeung M, 1999, AM J RESP CRIT CARE, V159, P1434; COTE J, 1990, J ALLERGY CLIN IMMUN, V85, P592, DOI 10.1016/0091-6749(90)90098-O; Di Franco A, 1998, RESP MED, V92, P550; Fahy JV, 1998, EUR RESPIR J, V11, P1240, DOI 10.1183/09031936.98.11061240; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; JONES P, 1992, AM REV RESPIR DIS, V145, P132; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; MILLER MR, 1992, THORAX, V47, P904, DOI 10.1136/thx.47.11.904; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; Park HS, 1998, CLIN EXP ALLERGY, V28, P724; Pavord ID, 1997, THORAX, V52, P498; PERRIN B, 1992, EUR RESPIR J, V5, P40; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172; Vyas A, 2000, OCCUP ENVIRON MED, V57, P752, DOI 10.1136/oem.57.11.752; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	24	72	77	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2002	57	3					231	236		10.1136/thorax.57.3.231		6	Respiratory System	Respiratory System	529TM	WOS:000174314700008	11867827	
J	Warman, KL; Silver, EJ; Stein, REK				Warman, KL; Silver, EJ; Stein, REK			Asthma symptoms, morbidity, and antiinflammatory use in inner-city children	PEDIATRICS			English	Article; Proceedings Paper	38th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 01-08, 1998	NEW ORLEANS, LOUISIANA	Ambulatory Pediat Assoc		inner-city children; asthma severity; persistent asthma; guidelines; morbidity; antiinflammatory therapy; inhaled steroids; symptom days	AIRWAY INFLAMMATION; PULMONARY-FUNCTION; LUNG-FUNCTION; SEVERITY	Background. Asthma is a major cause of morbidity that disproportionately affects inner-city children. For children with persistent asthma, defined as having asthma symptoms 3 or more days per week or 3 or more nights per month, national guidelines recommend the use of daily antiinflammatory agents. Despite these recommendations, antiinflammatory agents remain underused, particularly in inner-city children with high asthma morbidity. Objectives. The objectives of our study were to determine: 1) whether persistent asthma symptoms in inner-city children are related to acute care utilization and to the frequency of acute exacerbations; 2) whether children with persistent asthma are receiving recommended daily antiinflammatory agents; and 3) whether antiinflammatory medication use relates to sociodemographic factors, caretaker self-efficacy, the frequency of primary care visits, and/or measures of quality asthma care. Design and Methods. A 64-item telephone survey was administered between July 1996 and June 1997 to 219 parental caretakers of 2- to 12-year-old children who had been hospitalized with asthma at an inner-city medical center between January 1995 and February 1996. Persistent asthma symptoms were assessed by inquiring about the frequency of daily and nocturnal asthma symptoms over the last 4 weeks. Children's asthma severity was classified by applying the 1997 National Asthma Education and Prevention Program (NAEPP) Asthma Guidelines' severity classification scheme based on the frequency of asthma symptoms. Asthma morbidity was defined as the frequency of acute asthma exacerbations, emergency department visits and hospitalizations. Daily antiinflammatory medication use was compared by sociodemographic factors, caretaker self-efficacy, frequency of primary care visits, and measures of quality asthma home management. Results. In this sample, quantifying persistent asthma symptoms and applying the NAEPP symptom criteria identified 17% of the children with mild intermittent asthma, 27% with mild persistent asthma and 56% with moderate to severe persistent asthma. There were no differences in the age of the children in the 3 groups (mean age: 6 years). Asthma morbidity, as measured by the number of asthma exacerbations in the last 6 months, was significantly higher in the children with moderate to severe persistent asthma compared with children with mild intermittent asthma (9.8 vs 3.5) or mild persistent asthma (9.8 vs 4.5). In addition, there were significantly more emergency department visits in the moderate to severe group than in the mild persistent (3.05 vs 1.69) or mild intermittent group (3.05 vs 1.76). Lastly, as asthma symptom frequency increased, there were trends toward more hospitalizations and more days hospitalized. Overall, 35% of the 219 families reported giving daily antiinflammatory medications to their child (mostly cromolyn sodium). Of the 181 children (83%) who met NA-EPP symptom criteria for persistent asthma, only 39% were receiving daily antiinflammatory treatment. Of the children with symptoms of moderate to severe asthma, only 15% were receiving inhaled steroids in contrast to the guidelines' recommendations. Use of antiinflammatory agents was not related to caretaker sociodemographic factors or self-efficacy scores. Measures of quality asthma home management, which included use of mattress covers, written plans, and peak flow meters, correlated positively with use of antiinflammatory agents. Children whose families reported using daily antiinflammatory medications had more primary care visits in the last 6 months than those children not receiving antiinflammatory medications. Conclusion. Questioning parents about the frequency of their child's asthma symptoms is an important, inexpensive, and readily accessible bedside and office tool that may aid in the detection of persistent symptoms and help direct therapy. Our study suggests that classifying asthma severity by quantifying persistent asthma symptoms, as defined in the NAEPP Guidelines, is a clinically useful tool that relates to asthma morbidity. In our sample of previously hospitalized children with asthma, 83% met 1997 NAEPP symptom criteria for persistent asthma, and yet only 35% were receiving daily antiinflammatory agents. Use of antiinflammatory agents correlated positively with other indicators of quality asthma home management. Additional work is necessary to increase appropriate use of antiinflammatory agents in this population, and in particular, to increase inhaled steroid use for children with moderate or severe symptoms.	Albert Einstein Coll Med, Dept Pediat, Bronx, NY 10467 USA	Warman, KL (reprint author), Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, 1621 Eastchester Rd, Bronx, NY 10461 USA.						AAS K, 1981, ALLERGY, V36, P3, DOI 10.1111/j.1398-9995.1981.tb01818.x; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Berg A O, 1992, J Am Board Fam Pract, V5, P629; BUSSE WW, 1993, AM REV RESPIR DIS, V147, pS20; Clark NM, 1998, PEDIATRICS, V101, P831, DOI 10.1542/peds.101.5.831; Colice GL, 1999, AM J RESP CRIT CARE, V160, P1962; CRAIN EF, 1994, PEDIATRICS, V94, P356; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; Droste JHJ, 1999, PEDIATR PULM, V27, P260, DOI 10.1002/(SICI)1099-0496(199904)27:4<260::AID-PPUL6>3.0.CO;2-6; Goodman DC, 1999, PEDIATRICS, V104, P187, DOI 10.1542/peds.104.2.187; ILFELD FW, 1978, ARCH GEN PSYCHIAT, V35, P716; LAITINEN LA, 1992, J ALLERGY CLIN IMMUN, V90, P32, DOI 10.1016/S0091-6749(06)80008-4; Lang DM, 1997, ARCH INTERN MED, V157, P1193, DOI 10.1001/archinte.157.11.1193; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; *NAEPP WHO, 1995, NIH PUBL; *NAT ASTHM ED PREV, 1997, NIH PUBL, V2; ROCHE WR, 1991, CLIN EXP ALLERGY, V21, P545, DOI 10.1111/j.1365-2222.1991.tb00845.x; SVENDSEN UG, 1987, J ALLERGY CLIN IMMUN, V80, P68; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547; WARMAN KL, 1999, 39 ANN M AMB PED ASS	20	72	73	0	22	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2001	108	2					277	282		10.1542/peds.108.2.277		6	Pediatrics	Pediatrics	458TZ	WOS:000170211800028	11483788	
J	Gutgesell, C; Heise, S; Seubert, S; Seubert, A; Domhof, S; Brunner, E; Neumann, C				Gutgesell, C; Heise, S; Seubert, S; Seubert, A; Domhof, S; Brunner, E; Neumann, C			Double-blind placebo-controlled house dust mite control measures in adult patients with atopic dermatitis	BRITISH JOURNAL OF DERMATOLOGY			English	Article						acaricides; atopic dermatitis; clinical trial; house dust mite; mattress encasing	PATCH TEST; ALLERGEN AVOIDANCE; CONTROLLED TRIAL; EXPOSURE; ASTHMA; ECZEMA	Background Avoidance of allergens has been shown to be of benefit in patients with atopic asthma sensitized to indoor allergens. In atopic dermatitis, there is so far little information about the effect of house dust mite elimination strategies. Objectives We therefore performed a randomized controlled study of house dust mite control in patients with this disease. Methods Twenty adult patients with moderate to severe atopic dermatitis were included. Inclusion criteria were a positive RAST to house dust mite antigen (CAP class > 3) and a concentration of > 2 mug g(-1) of the house dust mite antigen Der p1 in the patient's mattress dust. Patients were randomized to either the active treatment group (allergen-impermeable mattress encasing, acaricide spray containing tannic acid and benzylbenzoate) or a control group (allergen-permeable encasing, spray containing water and traces of ethanol). Severity of disease was estimated every 2 months by an established score (SCORAD), and eosinophil cationic protein (ECP) in the serum was determined by enzyme-linked immunosorbent assay. Furthermore, the use of topical steroids was quantified. Patients assessed daytime pruritus and pruritus-induced sleeplessness weekly on a visual analogue scale. The study lasted 1 year. Results At the end of the study, the active treatment group showed a statistically significant reduction in Der p1 exposure as compared with the control group. However, when comparing the change from the start to the end of the study, there was no statistically significant difference between active treatment and control groups as measured by the SCORAD score and by ECP levels in the serum. Some patients in the active treatment group reported less pruritus-induced sleeplessness, but there was no statistically significant difference between the two treatment groups. Conclusions For adult patients with atopic dermatitis it was shown that 1 year of house dust mite avoidance reduced the allergen exposure, but an improvement of overall disease activity was not demonstrated.	Univ Gottingen, Dept Dermatol, D-37075 Gottingen, Germany; Univ Gottingen, Dept Med Stat, D-37075 Gottingen, Germany	Gutgesell, C (reprint author), Univ Gottingen, Dept Dermatol, Von Siebold Str 3, D-37075 Gottingen, Germany.						Brunner E, 2000, BIOMETRICAL J, V42, P663, DOI 10.1002/1521-4036(200010)42:6<663::AID-BIMJ663>3.0.CO;2-7; BRUNNER E, 1999, NICHTPARAMETRISCHE A; Cameron MM, 1997, BRIT J DERMATOL, V137, P1; COLLOFF MJ, 1989, BRIT J DERMATOL, V121, P199, DOI 10.1111/j.1365-2133.1989.tb01799.x; Ebata T, 1999, BRIT J DERMATOL, V141, P82; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Gutgesell C, 1999, CLIN EXP ALLERGY, V29, P920, DOI 10.1046/j.1365-2222.1999.00553.x; HENDERSON AJW, 1990, ALLERGY, V45, P445, DOI 10.1111/j.1398-9995.1990.tb01095.x; Marks GB, 1998, ALLERGY, V53, P108; MITCHELL EB, 1982, LANCET, V1, P127; Pichler CE, 1999, ALLERGOLOGIE, V22, P171; Ricci G, 2000, BRIT J DERMATOL, V143, P379, DOI 10.1046/j.1365-2133.2000.03666.x; Ring J, 1997, INT ARCH ALLERGY IMM, V113, P379; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SANDA T, 1992, J ALLERGY CLIN IMMUN, V89, P653, DOI 10.1016/0091-6749(92)90370-H; STALDER JF, 1993, DERMATOLOGY, V186, P23; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8	18	72	74	0	2	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	JUL	2001	145	1					70	74		10.1046/j.1365-2133.2001.04283.x		5	Dermatology	Dermatology	452UX	WOS:000169879000011	11453909	
J	Li, XM; Kleiner, G; Huang, CK; Lee, SY; Schofield, B; Soter, NA; Sampson, HA				Li, XM; Kleiner, G; Huang, CK; Lee, SY; Schofield, B; Soter, NA; Sampson, HA			Murine model of atopic dermatitis associated with food hypersensitivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopic dermatitis; eczema; food hypersensitivity; murine model; T(H)2-like cytokines; IgE-mediated hypersensitivity	POLYMERASE CHAIN-REACTION; ALOPECIA-AREATA; T-CELLS; INTESTINAL PERMEABILITY; ALLERGIC DERMATITIS; IGE HYPERPRODUCTION; AEROSOLIZED ANTIGEN; MESSENGER-RNA; C3H/HEJ MICE; NC/NGA MICE	Background: Atopic dermatitis (AD) is an eczematous skin eruption that generally begins in early infancy and affects up to 126 of the population. The cause of this disorder is not fully understood, although it is frequently the first sign of atopic disease and is characterized by an elevated serum IgE level, eosinophilia, and histologic tissue changes characterized early by spongiosis and a CD4(+) T(H)2 cellular infiltrate. Hypersensitivity to foods has been implicated as one causative factor in up to 40% of children with moderate-to-severe AD. Objective: The purpose of this study was to establish a murine model of food-induced AD. Methods: Female C3H/HeJ mice were sensitized orally to cow's milk or peanut with a cholera toxin adjuvant and then subjected to low-grade allergen exposure. Histologic examination of skin lesions, allergen-specific serum Ig levels, and allergen-induced T-cell proliferation and cytokine production were examined. Results: An eczematous eruption developed in approximately one third of mice after low-grade exposure to milk or peanut proteins. Peripheral blood eosinophilia and elevated serum IgE levels were noted. Histologic examination of the Lesional skin revealed spongiosis and a cellular infiltrate consisting of CD4(+) lymphocytes, eosinophils, and mast cells, IL-5 and IL-13 mRNA expression was elevated only in the skin of mice with the eczematous eruption. Treatment of the eruption with topical corticosteroids led to decreased pruritus and resolution of the cutaneous eruption. Conclusion: This eczematous eruption resembles AD in human subjects and should provide a useful model for studying immunopathogenic mechanisms of food hypersensitivity in AD.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; NYU, Sch Med, Ronald O Perelman Dept Dermatol, New York, NY USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD USA	Sampson, HA (reprint author), CUNY Mt Sinai Sch Med, Dept Pediat, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [AI43668, AI24439, AI44236]; NIEHS NIH HHS [ES 03819]		ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; ALBANI S, 1989, ANN ALLERGY, V63, P489; BILLINGHAM RE, 1953, NATURE, V172, P603, DOI 10.1038/172603a0; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; BUTLER JM, 1983, J AM ACAD DERMATOL, V8, P33, DOI 10.1016/S0190-9622(83)70004-6; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; ELIAS J, 1986, J ALLERGY CLIN IMMUN, V78, P914, DOI 10.1016/0091-6749(86)90240-X; FLICK J A, 1988, Pediatric Research, V23, p303A; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; GEAVES MW, 2000, J ALLERGY CLIN IMMUN, V105, P664; GEBA GP, 1997, ALLERGY ALLERGIC DIS, P1056; GUNDEL RH, 1997, ALLERGY ALLERGIC DIS, P1037; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 1993, ALLERGY PRINCIPLES P, P1581; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; HILL DJ, 1989, J PEDIATR-US, V114, P761, DOI 10.1016/S0022-3476(89)80133-7; HOFFMANN R, 1994, J INVEST DERMATOL, V103, P530, DOI 10.1111/1523-1747.ep12395722; Hsu CH, 1996, CLIN EXP ALLERGY, V26, P1329, DOI 10.1111/j.1365-2222.1996.tb00530.x; JACKSON PG, 1981, LANCET, V1, P1285; JONES SM, 1996, ATOPIC DERMATITIS PA, P41; Krzesicki RF, 1997, AM J RESP CELL MOL, V16, P693; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 1999, J IMMUNOL, V162, P3045; Madani S, 2000, J AM ACAD DERMATOL, V42, P549, DOI 10.1016/S0190-9622(00)90164-6; Matsuda H, 1997, INT IMMUNOL, V9, P461, DOI 10.1093/intimm/9.3.461; MIHM MC, 1976, J INVEST DERMATOL, V67, P305, DOI 10.1111/1523-1747.ep12514346; Morita E, 1999, J DERMATOL SCI, V19, P37, DOI 10.1016/S0923-1811(98)00047-4; MUDDE GC, 1995, IMMUNOL TODAY, V16, P380, DOI 10.1016/0167-5699(95)80005-0; Noh GW, 1998, ALLERGY, V53, P1202, DOI 10.1111/j.1398-9995.1998.tb03842.x; Nomura I, 1999, J ALLERGY CLIN IMMUN, V104, P441, DOI 10.1016/S0091-6749(99)70390-8; PIKE MG, 1986, J INVEST DERMATOL, V86, P101, DOI 10.1111/1523-1747.ep12284035; Roosje PJ, 1998, VET PATHOL, V35, P268; SAGER N, 1992, J ALLERGY CLIN IMMUN, V89, P801, DOI 10.1016/0091-6749(92)90434-4; SALOGA J, 1993, J CLIN INVEST, V91, P133, DOI 10.1172/JCI116162; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; Sampson HA, 1999, IMMUNOL ALLERGY CLIN, V19, P495, DOI 10.1016/S0889-8561(05)70104-1; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SICHERER SH, 1999, J ALLERGY CLIN IMM S, V104, P717; Simpson AECM, 1997, INFLAMM RES, V46, P65, DOI 10.1007/s000110050078; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; SUNDBERG JP, 1994, J INVEST DERMATOL, V102, P847, DOI 10.1111/1523-1747.ep12382416; Suto H, 1999, INT ARCH ALLERGY IMM, V120, P70, DOI 10.1159/000053599; Tobin DJ, 1997, J INVEST DERMATOL, V109, P329, DOI 10.1111/1523-1747.ep12335848; UDALL JN, 1981, PEDIATR RES, V15, P241, DOI 10.1203/00006450-198103000-00008; UNO H, 1980, J INVEST DERMATOL, V75, P52, DOI 10.1111/1523-1747.ep12521130; WALKER C, 1993, CLIN EXP ALLERGY, V23, P145, DOI 10.1111/j.1365-2222.1993.tb00310.x; Wang LF, 1996, J IMMUNOL, V156, P4079; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258	53	72	72	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2001	107	4					693	702		10.1067/mai.2001.114110		10	Allergy; Immunology	Allergy; Immunology	423RG	WOS:000168190100023	11295660	
J	Thorn, J; Brisman, J; Toren, K				Thorn, J; Brisman, J; Toren, K			Adult-onset asthma is associated with self-reported mold or environmental tobacco smoke exposures in the home	ALLERGY			English	Article						asthma; epidemiology; home environment; questionnaire	RISK-FACTORS; OCCUPATIONAL EXPOSURES; RESPIRATORY SYMPTOMS; CHILDHOOD ASTHMA; BRONCHIAL HYPERREACTIVITY; HEALTH; DAMPNESS; CHILDREN; POPULATION	Background: In recent years, we have gained better knowledge about the influence of indoor environments on respiratory symptoms and asthma. The purpose of this study was to examine certain exposures in the home environment and the risk of adult-onset asthma. Methods: A nested case-referent study of adult-onset asthma was performed in a random population sample (n = 15 813), aged 20-50 years. Cases for the study included subjects reporting "physician-diagnosed" asthma (n = 174). The referents (n = 870) were randomly selected from the whole population sample. The case-referent sample was investigated with a comprehensive mailed questionnaire about exposures in the home environment, asthma, respiratory symptoms, smoking habits, and atopy. Odds ratios (OR) with 95% confidence intervals (CI) were calculated while controlling for age, sex, smoking, and atopy. Results: Increased adjusted OR for asthma were associated with exposure to molds (OR 2.2, 95% CI 1.4-3.5), environmental tobacco smoke (OR 2.4, 95% CI 1.4-4.1), and the presence of a wood stove (OR 1.7, 95% CI 1.2-2.5). Conclusions: This population-based case-referent study indicates that self-reported domestic exposures to molds or environmental tobacco smoke can be associated with adult-onset asthma.	Univ Gothenburg, Dept Environm Med, S-40530 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Occupat & Environm Med, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Resp Med & Allergol, S-41345 Gothenburg, Sweden	Thorn, J (reprint author), Univ Gothenburg, Dept Environm Med, Box 414, S-40530 Gothenburg, Sweden.			Brisman, Jonas/0000-0003-2333-3273			ANDRAE S, 1988, ARCH DIS CHILD, V63, P473; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; Dales RE, 1999, ENVIRON HEALTH PERSP, V107, P481; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; FAGBULE D, 1994, ANN TROP PAEDIATR, V14, P15; Flodin U, 1996, SCAND J WORK ENV HEA, V22, P451; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Fritschi L, 1996, AM J EPIDEMIOL, V144, P521; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; LINDFORS A, 1995, ARCH DIS CHILD, V73, P408; MARTIN CJ, 1987, BRIT MED J, V294, P1125; Nicolai T, 1998, THORAX, V53, P1035; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; TESCHKE K, 1994, AM J IND MED, V26, P327, DOI 10.1002/ajim.4700260306; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Toren K, 1999, INT J TUBERC LUNG D, V3, P192; Toren K, 1999, SCAND J WORK ENV HEA, V25, P430; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; Williamson IJ, 1997, THORAX, V52, P229	27	72	73	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	APR	2001	56	4					287	292		10.1034/j.1398-9995.2001.00805.x		6	Allergy; Immunology	Allergy; Immunology	415DR	WOS:000167706000004	11284794	
J	Mitakakis, TZ; Barnes, C; Tovey, ER				Mitakakis, TZ; Barnes, C; Tovey, ER			Spore germination increases allergen release from Alternaria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Editorial Material						allergen; Alt a 1; Alternaria; germination; Halogen; immunoassay	ASPERGILLUS-FUMIGATUS	Allergen released from individual spores of the fungus Alternaria has not been investigated. Germination of spores has been suggested to increase allergen release. This study examined allergen released from individual spores and the effect of germination on allergen availability. Allergen release was determined with the Halogen (Inhalix, Sydney, Australia) immunoassay, by use of serum IgE from Alternaria-sensitized subjects and 3 Alt a 1-specific antibodies. Not all spores released allergen. Germination of the spores significantly increased the proportion that released allergen (P < .0001 for all antibodies). Alt a 1 may be a minor contributor to the total allergen released from spores except when spores have germinated. How these results reflect the allergen content of spores in the air that we breathe requires investigation.	Univ Sydney, Sch Biol Sci, Inst Resp Med, Allergen Unit, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Inst Resp Med, Sydney, NSW, Australia; Childrens Mercy Hosp, Kansas City, MO 64108 USA	Mitakakis, TZ (reprint author), Univ Sydney, Sch Biol Sci, Inst Resp Med, Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan/G-8604-2017	Tovey, Euan/0000-0002-1802-7266			DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; MORRISON VA, 1993, CLIN INFECT DIS, V16, P265; PORTNOY J, 1993, J ALLERGY CLIN IMMUN, V91, P930, DOI 10.1016/0091-6749(93)90351-F; Razmovski V, 2000, J ALLERGY CLIN IMMUN, V105, P725, DOI 10.1067/mai.2000.105222; REIJULA KE, 1991, J ALLERGY CLIN IMMUN, V87, P683, DOI 10.1016/0091-6749(91)90389-6; SALVAGGIO JE, 1994, J ALLERGY CLIN IMMUN, V94, P304, DOI 10.1016/0091-6749(94)90090-6; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; VIJAY HM, 1993, J ALLERGY CLIN IMMUN, V91, P826, DOI 10.1016/0091-6749(93)90338-G	9	72	72	1	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2001	107	2					388	390		10.1067/mai.2001.112602		3	Allergy; Immunology	Allergy; Immunology	403YV	WOS:000167071400030	11174210	
J	Schelegle, ES; Gershwin, LJ; Miller, LA; Fanucchi, MV; Van Winkle, LS; Gerriets, JP; Walby, WF; Omlor, AM; Buckpitt, AR; Tarkington, BK; Wong, VJ; Joad, JP; Pinkerton, KB; Wu, R; Evans, MJ; Hyde, DM; Plopper, CG				Schelegle, ES; Gershwin, LJ; Miller, LA; Fanucchi, MV; Van Winkle, LS; Gerriets, JP; Walby, WF; Omlor, AM; Buckpitt, AR; Tarkington, BK; Wong, VJ; Joad, JP; Pinkerton, KB; Wu, R; Evans, MJ; Hyde, DM; Plopper, CG			Allergic asthma induced in rhesus monkeys by house dust mite (Dermatophagoides farinae)	AMERICAN JOURNAL OF PATHOLOGY			English	Article							LYMPHOCYTE-T ACTIVATION; ANTIGEN CHALLENGE; MEDIATOR RELEASE; MACACA-MULATTA; AIRWAY; HISTAMINE; PROSTAGLANDINS; PRIMATES; DISEASE; CELLS	To establish whether allergic asthma could be induced experimentally in a nonhuman primate using a common human allergen, three female rhesus mon keys (Macaca mulatta) were sensitized with house dust mite (Dermatophagoides farinae) allergen (HDMA) by subcutaneous injection, followed by four intranasal sensitizations, and exposure to allergen aerosol 3 hours per day, 3 days per week for up to 13 weeks. Before aerosol challenge, all three monkeys skin-tested positive for HDMA, During aerosol challenge with HDMA, sensitized monkeys exhibited cough and rapid shallow breathing and increased airway resistance,which was reversed by albuterol aerosol treatment. Compared to nonsensitized monkeys, there was a fourfold reduction in the dose of histamine aerosol necessary to produce a 150% increase in airway resistance in sensitized monkeys, After aerosol challenge, serum levels of histamine were elevated in sensitized monkeys, Sensitized monkeys exhibited increased levels of HDMA-specific IgE in serum, numbers of eosinophils and exfoliated cells within lavage, and elevated CD25 expression on circulating CD4(+) lymphocytes, Intrapulmonary bronchi of sensitized monkeys had focal mucus tell hyperplasia, interstitial infiltrates of eosinophils, and thickening of the basement membrane zone, We conclude that a model of allergic asthma can be induced in rhesus monkeys using a protocol consisting of subcutaneous injection, intranasal instillation, and aerosol challenge with HDMA.	Univ Calif Davis, Sch Vet Med, Dept Anat Physiol & Cell Biol, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Dept Mol Biosci, Davis, CA 95616 USA; Univ Calif Davis, Sch Vet Med, Calif Reg Primate Res Ctr, Exposure Facil, Davis, CA 95616 USA; Univ Calif Davis, Sch Med, Dept Pediat, Davis, CA 95616 USA	Univ Calif Davis, Sch Vet Med, Dept Anat Physiol & Cell Biol, 1 Shields Ave, Davis, CA 95616 USA.	esschelegle@ucdavis.edu			NCI NIH HHS [P01 CA095616]; NCRR NIH HHS [P51 RR000169, RR00169]; NIEHS NIH HHS [ES 05707, F32 ES005707, P01 ES000628, P01 ES0628, P30 ES005707]		BLEECKER ER, 1986, AM J MED, V81, P93, DOI 10.1016/0002-9343(86)90470-5; CARTIER A, 1982, J ALLERGY CLIN IMMUN, V70, P170, DOI 10.1016/0091-6749(82)90038-0; COCKCROFT DW, 1987, ANN ALLERGY, V59, P405; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; CORRIGAN CJ, 1988, LANCET, V1, P1129; Csendes T., 1988, Acta Cybernetica, V8, P361; DUBOIS AB, 1956, J APPL PHYSIOL, V8, P587; DVORAK AM, 1983, AM REV RESPIR DIS, V128, P49; GERSHWIN LJ, 1985, J IMMUNOL METHODS, V76, P39, DOI 10.1016/0022-1759(85)90479-X; GUNDEL RH, 1991, AM REV RESPIR DIS, V144, P76; HINNERS RG, 1968, ARCH ENVIRON HEALTH, V16, P194; LIU MC, 1990, AM REV RESPIR DIS, V142, P126; Madwed JB, 1997, J APPL PHYSIOL, V83, P1690; MCFADDEN ER, 1968, NEW ENGL J MED, V278, P1027, DOI 10.1056/NEJM196805092781901; Mercer T. T., 1970, J AEROSOL SCI, V1, P9, DOI 10.1016/0021-8502(70)90024-8; MIADONNA A, 1990, J ALLERGY CLIN IMMUN, V85, P906, DOI 10.1016/0091-6749(90)90076-G; Miller LA, 1998, AM J RESP CELL MOL, V19, P892; *NIH, 1997, GUID DIAGN MAN ASTHM, P1; OZOLS J, 1990, METHOD ENZYMOL, V182, P587; Ozwara H, 1997, J MED PRIMATOL, V26, P164; PARE PD, 1976, J APPL PHYSIOL, V41, P668; PESLIN R, 1985, J APPL PHYSIOL, V59, P492; PLOPPER CG, 1986, ANAT EMBRYOL, V174, P167, DOI 10.1007/BF00824332; PLOPPER CG, 1986, AM J ANAT, V175, P59, DOI 10.1002/aja.1001750107; PLOPPER CG, 1992, CHEST, V101, P2; Plopper C, 1990, MODELS LUNG DISEASE, P537; REIMANN KA, 1994, CYTOMETRY, V17, P102, DOI 10.1002/cyto.990170113; SHORE PA, 1959, J PHARMACOL EXP THER, V127, P182; STGEORGE JA, 1986, ANAT REC, V216, P60, DOI 10.1002/ar.1092160111; TEAGUE SV, 1978, HEALTH PHYS, V35, P392; WELLS E, 1986, J IMMUNOL, V137, P3933; Yasue M, 1998, INT ARCH ALLERGY IMM, V115, P303, DOI 10.1159/000069461	32	72	76	1	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	JAN	2001	158	1					333	341		10.1016/S0002-9440(10)63973-9		9	Pathology	Pathology	390XV	WOS:000166325800038	11141508	
J	Meding, B				Meding, B			Differences between the sexes with regard to work-related skin disease	CONTACT DERMATITIS			English	Review						females; differences between the sexes; hand eczema; high-risk occupation; males; occupational skin disease; prevalence; prevention; risk factor; wet work	HAND DERMATITIS; ALLERGENIC ACTIVITY; ECZEMA; HAIRDRESSERS; SURFACTANTS; OCCUPATION; POPULATION; OXIDATION; BAKERS; ATOPY	Work-related skin disease is common and usually presents as hand eczema. From the Occupational Injury Information System in Sweden, as well as from registers of industrial injuries in other countries, it is evident that females report skin disease more often than males. Epidemiological studies of hand eczema also show that women are more often affected than men, in particular young women. The most common type of hand eczema is irritant contact dermatitis, which is often caused by wet work. Many female-dominated occupations involve extensive wet work, e.g., hairdressing, catering, cleaning and health-care work. These occupations are also high-risk occupations for hand eczema. Experimental studies of skin irritation have not confirmed differences between the sexes; thus, the higher prevalence of irritant contact dermatitis among females is most likely due to exposure, occupational and non-occupational. Nickel allergy is the most common contact allergy, which is most frequent in young females, and in 30-40% results over time in hand eczema. Hand eczema has an impact on quality of life and females seem to report a higher degree of discomfort than males. To achieve the optimal effect of preventive efforts regarding occupational skin disease, the focus for prevention should aim at reducing wet exposure.	Natl Inst Working Life, S-11279 Stockholm, Sweden; Karolinska Inst, Dept Med Occupat & Environm Dermatol, Stockholm, Sweden	Meding, B (reprint author), Natl Inst Working Life, S-11279 Stockholm, Sweden.						Agner T, 1992, Acta Derm Venereol Suppl (Stockh), V173, P1; Agrup G, 1969, ACTA DERM VENERE S61, V49, P1; Bergh M, 1998, J PHARM SCI, V87, P276, DOI 10.1021/js9704036; Bergh M, 1997, CONTACT DERMATITIS, V37, P9, DOI 10.1111/j.1600-0536.1997.tb00368.x; Bergh M, 1998, CONTACT DERMATITIS, V39, P14, DOI 10.1111/j.1600-0536.1998.tb05805.x; Brisman J, 1998, OCCUP ENVIRON MED, V55, P750; CHERRY NM, 1994, DHHS NIOSH PUBLICATI, P608; Conde-Salazar L, 1995, AM J CONTACT DERMATI, V6, P19, DOI 10.1016/1046-199X(95)90064-0; De Groot A.C., 1994, PATCH TESTING TEST C; DIEPGEN T, 1991, Z HAUTKRANKHEITEN, V66, P935; FROSCH PJ, 1993, CONTACT DERMATITIS, V28, P180, DOI 10.1111/j.1600-0536.1993.tb03383.x; Halkier-Sorensen L, 1996, Contact Dermatitis, V35, P1; HANSEN KS, 1983, CONTACT DERMATITIS, V9, P343, DOI 10.1111/j.1600-0536.1983.tb04426.x; HEDLIN M, 1994, 10 NAT BOARD OCC SAF; LAMMINTAUSTA K, 1993, ACTA DERM-VENEREOL, V73, P119; LAMMINTAUSTA K, 1981, CONTACT DERMATITIS, V7, P301, DOI 10.1111/j.1600-0536.1981.tb04085.x; LARSSONSTYMNE B, 1985, CONTACT DERMATITIS, V13, P289, DOI 10.1111/j.1600-0536.1985.tb02580.x; Lidegaard O, 1997, CNS DRUGS, V7, P1; Liden C, 1996, BRIT J DERMATOL, V134, P193; MARKLUND S, 1997, RISK FRISK FAKTORER, V6, P118; Meding B, 1990, Acta Derm Venereol Suppl (Stockh), V153, P1; MEDING B, 1994, 43 NORD ARB LOEN NOR, P81; MellstrOm GA, 1994, PROTECTIVE GLOVES OC, P39; Menne T, 1979, Derm Beruf Umwelt, V27, P129; Menne T., 1989, NICKEL SKIN IMMUNOLO, P109; *NAT BOARD OCC SAF, 1995, ARB ARB 1993; Nielsen J, 1996, CONTACT DERMATITIS, V34, P284; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; NILSSON E, 1985, CONTACT DERMATITIS, V13, P216, DOI 10.1111/j.1600-0536.1985.tb02553.x; ROSDAHL I, 1996, 1 U LINK LEAD EQ ORG, P61; RYSTEDT I, 1985, ACTA DERM-VENEREOL, V65, P305; Schultz Larsen F, 1993, J Am Acad Dermatol, V28, P719; SMIT HA, 1993, INT J EPIDEMIOL, V22, P288, DOI 10.1093/ije/22.2.288; STINGENI L, 1995, CONTACT DERMATITIS, V33, P172, DOI 10.1111/j.1600-0536.1995.tb00540.x; TACKE J, 1995, CONTACT DERMATITIS, V33, P112, DOI 10.1111/j.1600-0536.1995.tb00511.x; *TRGS, 1996, 531 TRGS; Turjanmaa K, 1996, ALLERGY, V51, P593, DOI 10.1111/j.1398-9995.1996.tb04678.x; *US DEP HHS, 1997, DHHS PUBLICATION P 3, P48; VANDERWALLE HB, 1994, CONTACT DERMATITIS, V30, P217	39	72	76	1	8	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	AUG	2000	43	2					65	71		10.1034/j.1600-0536.2000.043002065.x		7	Allergy; Dermatology	Allergy; Dermatology	339JB	WOS:000088473000001	10945743	
J	Omenaas, E; Jentoft, HF; Vollmer, WM; Buist, AS; Gulsvik, A				Omenaas, E; Jentoft, HF; Vollmer, WM; Buist, AS; Gulsvik, A			Absence of relationship between tuberculin reactivity and atopy in BCG vaccinated young adults	THORAX			English	Article						atopy; asthma; tuberculosis; immunisation; BCG vaccination	INFECTION; RESPONSES; DISORDER; CHILDREN	Background-An inverse association between tuberculin responses and atopy has been observed in Japanese children, indicating that BCG immunisation, subclinical exposure to Mycobacterium tuberculosis without clinical disease, or host characteristics may influence the T helper (Th) lymphocyte balance with decreased atopy as a result. This study was undertaken to determine whether tuberculin reactivity is inversely related to atopy in young adults vaccinated with BCG at the age of 14. Methods-Men and women aged 20-44 years were tested using the adrenaline-Pirquet test with Norwegian produced synthetic medium tuberculin (n = 891). In addition, their serum total and specific IgE antibodies against mite, cat, timothy grass, mould and birch were measured. Results-Of the 574 subjects with complete examinations, 64% had a positive adrenaline-Pirquet tuberculin test (greater than or equal to 4 mm) and 27% exhibited IgE antibodies (greater than or equal to 0.35 kU/l) to one or more of the five specific allergens. The geometric mean of total serum IgE in the population was 30.2 kU/l. Tuberculin reactivity and log IgE were not correlated (r = 0.043, p 0.30). The mean tuberculin reactivity was 4.6 mm, 4.9 mm, and 5.0 mm in the lower, middle and upper tertile of IgE distribution (< 14 kU/l, 14-61 kU/l, > 61 kU/l). The prevalence of atopy, as assessed by either the presence of any of the five specific IgE antibodies or by each specific IgE antibody separately, did not differ between subjects with a positive and those with a negative tuberculin test. These results persisted after adjustment for age, sex, and smoking status in multivariate logistic regression analyses. Conclusions-In this young adult population, BCG vaccinated at the age of 14, no significant relationship between a positive tuberculin reaction and atopy was observed. If a true relationship had been found, our study suggests that it may be limited to populations immunised in early childhood when a substantial modulation of the immune system can occur.	Univ Bergen, Dept Thorac Med, N-5020 Bergen, Norway; Kaiser Permanente Ctr Hlth Res, Oakland, CA 94612 USA; Oregon Hlth Sci Univ, Portland, OR 97201 USA	Omenaas, E (reprint author), Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway.						Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; BJARTVEIT K, 1996, CONTROL TUBERCULOSIS; BJERKEDAL T, 1967, AM J EPIDEMIOL, V85, P157; BJORLO R, 1985, PREPARATION SYNTHETI; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; COOKSON OCM, 1997, SCIENCE, V275, P41; DIXON JD, 1990, BMDP STAT SOFTWARE; EILERTSEN E, 1964, ACTA TUB PNEUM S S60, V34, P84; Farooqi IS, 1998, THORAX, V53, P927; HANSEN OG, 1937, ACTA TUBERC SCAND, V6, P130; JENTOFT H, 1999, INT J TUBERC LUNG D, V4, P326; Jentoft H. F., 1996, European Respiratory Journal Supplement, V9, p203S; Martinati LC, 1997, ALLERGY, V52, P1036; OMENAAS E, 1994, CLIN EXP ALLERGY, V24, P530, DOI 10.1111/j.1365-2222.1994.tb00950.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Silverman M, 1997, LANCET, V350, P380, DOI 10.1016/S0140-6736(05)64130-X; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; von Pirquet C., 1907, BERL KLIN WSCHR, V48, P699; WAALER H, 1975, B INT UNION TUBERC, V1, P5	22	72	73	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2000	55	6					454	458		10.1136/thorax.55.6.454		5	Respiratory System	Respiratory System	319WP	WOS:000087367100005	10817791	
J	Lams, BEA; Sousa, AR; Rees, PJ; Lee, TH				Lams, BEA; Sousa, AR; Rees, PJ; Lee, TH			Subepithelial immunopathology of the large airways in smokers with and without chronic obstructive pulmonary disease	EUROPEAN RESPIRATORY JOURNAL			English	Article						airway; chronic obstructive pulmonary disease; eosinophils; inflammation; lymphocytes; neutrophils	AIR-FLOW OBSTRUCTION; CHRONIC-BRONCHITIS; BRONCHOALVEOLAR LAVAGE; PERIPHERAL AIRWAYS; CELL-POPULATIONS; INDUCED SPUTUM; T-LYMPHOCYTES; INFLAMMATION; ASTHMA; BIOPSIES	Previous work has shown an increase in CD8+ T-cells, neutrophils and eosinophils in small airway subepithelium in smokers, The authors have now investigated whether similar changes occur in the large airways. Immunohistochemistry on frozen sections of bronchial biopsies were obtained at bronchoscopy in 11 nonsmokers, eight asymptomatic smokers and 11 smokers with chronic bronchitis and chronic obstructive pulmonary disease (COPD). There was an increase in the number of CD8+ cells infiltrating the bronchial subepithelium in the COPD group compared to the asymptomatic smokers (305 (109-400) versus 92 (41-550) cells.mm(-2), p=0.030). There was a negative correlation between the number of CD8+ cells and the forced expiratory volume in one second (FEV1) %predicted (p=0.005, r=-0.62), and a positive correlation between the number of CD8+ cells and the number of pack years smoked (p=0.017, r=0.42). There was a negative correlation between the activated/total eosinophils ratio and the FEV1 % pred (p=0.017, r=-0.51). There was a negative correlation between pack years smoked and the number of neutrophils (p=0.022, r=-0.36). Smokers who develop chronic obstructive pulmonary disease have increased numbers of CD8+ T-cells in large airways when compared to asymptomatic smokers. Airway obstruction was associated with an increase in the proportion of eosinophils that were activated.	Guys Kings Coll & St Thomas Hosp, Sch Med & Dent, Dept Resp Med & Allergy, London, England	Lee, TH (reprint author), Guys Hosp, Dept Allergy & Resp Med, 5th Floor,Thomas Guy House, London SE1 9RT, England.						AMADORI A, 1995, NAT MED, V1, P1279, DOI 10.1038/nm1295-1279; BOSKEN CH, 1992, AM REV RESPIR DIS, V145, P911; BOUSQUET J, 1991, INT ARCH ALLER A IMM, V94, P227; *BTS, 1997, THORAX S5, V52, P1; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; COSTABEL U, 1992, RESPIRATION, V59, P17; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DiStefano A, 1996, AM J RESP CRIT CARE, V153, P629; DOLL R, 1976, BRIT MED J, V2, P1525; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666; FLETCHER C, 1977, BRIT MED J, V1, P1645; FOURNIER M, 1989, AM REV RESPIR DIS, V140, P737; GESSER B, 1995, BIOCHEM BIOPH RES CO, V210, P660, DOI 10.1006/bbrc.1995.1711; Keatings VM, 1997, THORAX, V52, P372; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lams BEA, 1998, AM J RESP CRIT CARE, V158, P1518; LUSUARDI M, 1994, THORAX, V49, P1211, DOI 10.1136/thx.49.12.1211; MARTIN TR, 1985, AM REV RESPIR DIS, V132, P254; Mueller R, 1996, RESP MED, V90, P79, DOI 10.1016/S0954-6111(96)90202-4; Nasser SMS, 1996, AM J RESP CRIT CARE, V153, P90; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; Pesci A, 1998, RESP MED, V92, P863, DOI 10.1016/S0954-6111(98)90389-4; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527	28	72	74	0	0	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2000	15	3					512	516		10.1034/j.1399-3003.2000.15.14.x		5	Respiratory System	Respiratory System	295JG	WOS:000085962500014	10759445	
J	Hammad, H; Lambrecht, BN				Hammad, H.; Lambrecht, B. N.			Dendritic cells and airway epithelial cells at the interface between innate and adaptive immune responses	ALLERGY			English	Review						allergens; asthma; dendritic cells; epithelium	HOUSE-DUST MITE; THYMIC STROMAL LYMPHOPOIETIN; REGULATORY T-CELLS; HELPER TYPE-2 RESPONSE; BRONCHIAL LYMPH-NODE; IN-VIVO; ALLERGIC INFLAMMATION; INHALED ANTIGEN; RESPIRATORY-TRACT; TH2 RESPONSES	P>Because they can recognize and sample inhaled allergens, dendritic cells (DC) have been shown to be responsible for the initiation and maintenance of adaptive Th2 responses in asthma. It is increasingly clear that DC functions are strongly influenced by a crosstalk with neighboring cells like epithelial cells. Whereas the epithelium was initially considered only as a barrier, it is now seen as a central player in controlling the function of lung DCs through release of innate cytokines-promoting Th2 responses. Clinically relevant allergens, as well as known environmental and genetic risk factors for allergy and asthma, often interfere directly or indirectly with the innate immune functions of airway epithelial cells and DC. A better understanding of these interactions might lead to a better prevention and ultimately to new treatments for asthma.	[Hammad, H.] Univ Ghent, Dynam Imaging Unit, Immunoregulat Lab, B-9000 Ghent, Belgium	Hammad, H (reprint author), Univ Ghent, Dynam Imaging Unit, Immunoregulat Lab, Blok B Ground Floor,Pintelaan 185, B-9000 Ghent, Belgium.	hamida.hammad@ugent.be	Hammad, Hamida/J-9391-2015; Lambrecht, Bart/K-2484-2014	Hammad, Hamida/0000-0003-3762-8603; Lambrecht, Bart/0000-0003-4376-6834			Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Al-Ramli W, 2009, J ALLERGY CLIN IMMUN, V123, P1185, DOI 10.1016/j.jaci.2009.02.024; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Angkasekwinai P, 2007, J EXP MED, V204, P1509, DOI 10.1084/jem.20061675; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Ballantyne SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1324, DOI 10.1016/j.jaci.2007.07.051; Barrett NA, 2009, J IMMUNOL, V182, P1119; Beaty SR, 2007, J IMMUNOL, V178, P1882; BENSASSON SZ, 1990, P NATL ACAD SCI USA, V87, P1421, DOI 10.1073/pnas.87.4.1421; Bogiatzi SI, 2007, J IMMUNOL, V178, P3373; Bratke K, 2007, THORAX, V62, P168, DOI 10.1136/thx.2006.067793; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; Claudio E, 2009, J IMMUNOL, V182, P1617; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; del Rio ML, 2007, J IMMUNOL, V178, P6861; Demedts IK, 2006, AM J RESP CELL MOL, V35, P387, DOI 10.1165/rcmb.2005-0382OC; Di Stefano A, 2002, EUR RESPIR J, V20, P556, DOI 10.1183/09031936.02.00272002; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; GeurtsvanKessel C H, 2008, Mucosal Immunol, V1, P442, DOI 10.1038/mi.2008.39; GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Hammad H, 2003, EUR CYTOKINE NETW, V14, P219; Hammad H, 2003, J IMMUNOL, V171, P3936; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Headley MB, 2009, J IMMUNOL, V182, P1641; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; Hintzen G, 2006, J IMMUNOL, V177, P7346; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Hurst SD, 2002, J IMMUNOL, V169, P443; Idzko M, 2007, NAT MED, V13, P913, DOI 10.1038/nm1617; Idzko M, 2007, J CLIN INVEST, V117, P464, DOI 10.1172/JCI28949; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jahnsen FL, 2006, J IMMUNOL, V177, P5861; Jakubzick C, 2008, J IMMUNOL, V180, P3019; Jakubzick C, 2008, J EXP MED, V205, P2839, DOI 10.1084/jem.20081430; Kearley J, 2009, AM J RESP CRIT CARE, V179, P772, DOI 10.1164/rccm.200805-666OC; Kim MR, 2002, BLOOD, V100, P2330, DOI 10.1182/blood-2002-01-0012; Kohl J, 2006, J CLIN INVEST, V116, P783, DOI 10.1172/JCI26582; Kondo Y, 2008, INT IMMUNOL, V20, P791, DOI 10.1093/intimm/dxn037; Kool M, 2009, J IMMUNOL, V183, P1074, DOI 10.4049/jimmunol.0900471; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 1999, EUR J IMMUNOL, V29, P3815, DOI 10.1002/(SICI)1521-4141(199912)29:12<3815::AID-IMMU3815>3.0.CO;2-#; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Louahed J, 2000, AM J RESP CELL MOL, V22, P649; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1647; Medoff BD, 2009, J IMMUNOL, V182, P623; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Miyata M, 2009, EUR J IMMUNOL, V39, P3078, DOI 10.1002/eji.200939302; Moro K., 2009, NATURE, V463, P540, DOI DOI 10.1038/NATURE08636; Moussion C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003331; Nathan AT, 2009, J ALLERGY CLIN IMMUN, V123, P612, DOI 10.1016/j.jaci.2008.12.006; Neill DR, 2010, NATURE, V464, P1367, DOI 10.1038/nature08900; Nolte MA, 2007, J EXP MED, V204, P1487, DOI 10.1084/jem.20070325; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Price AE, 2010, P NATL ACAD SCI USA, V107, P11489, DOI 10.1073/pnas.1003988107; Provoost S, 2009, ALLERGY, V64, P1539, DOI 10.1111/j.1398-9995.2009.02056.x; Raymond M, 2009, J ALLERGY CLIN IMMUN, V124, P1333, DOI 10.1016/j.jaci.2009.07.021; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Robays LJ, 2007, J IMMUNOL, V178, P5305; Ryanna K, 2009, ALLERGY, V64, P335, DOI 10.1111/j.1398-9995.2009.01972.x; SAENZ SA, 2009, NATURE, V464, P1362; Saenz SA, 2008, IMMUNOL REV, V226, P172, DOI 10.1111/j.1600-065X.2008.00713.x; Saenz SA, 2010, TRENDS IMMUNOL, V31, P407, DOI 10.1016/j.it.2010.09.001; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Schnyder-Candrian S, 2006, J EXP MED, V203, P2715, DOI 10.1084/jem.20061401; Seshasayee D, 2007, J CLIN INVEST, V117, P3868, DOI 10.1172/JCI33559; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Soumelis V, 2004, SPRINGER SEMIN IMMUN, V25, P325, DOI 10.1007/s00281-003-0152-0; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Sun YC, 2005, CHINESE MED J-PEKING, V118, P953; Sung SSJ, 2006, J IMMUNOL, V176, P2161; Swaidani S, 2009, J IMMUNOL, V182, P1631; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2002, BLOOD, V100, P3663, DOI 10.1182/blood-2002-03-0673; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Veldhoen M, 2008, NAT IMMUNOL, V9, P1341, DOI 10.1038/ni.1659; Veres TZ, 2009, AM J PATHOL, V174, P808, DOI 10.2353/ajpath.2009.080800; Vermaelen K, 2004, CYTOM PART A, V61A, P170, DOI 10.1002/cyto.a.20064; Vermaelen KY, 2003, J IMMUNOL, V171, P1016; Vermaelen KY, 2001, J EXP MED, V193, P51; von Garnier C, 2005, J IMMUNOL, V175, P1609; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhou BH, 2005, NAT IMMUNOL, V6, P1047, DOI 10.1038/ni1247; Zhou WS, 2007, J LEUKOCYTE BIOL, V81, P809, DOI 10.1189/jlb.0606375	115	71	74	2	18	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	MAY	2011	66	5					579	587		10.1111/j.1398-9995.2010.02528.x		9	Allergy; Immunology	Allergy; Immunology	746NU	WOS:000289254800001	21251015	
J	Ronmark, EP; Ekerljung, L; Lotvall, J; Toren, K; Ronmark, E; Lundback, B				Ronmark, Erik P.; Ekerljung, Linda; Lotvall, Jan; Toren, Kjell; Ronmark, Eva; Lundback, Bo			Large scale questionnaire survey on respiratory health in Sweden: Effects of late- and non-response	RESPIRATORY MEDICINE			English	Article						Asthma; Allergy; Questionnaire; Non-response; Epidemiology	POSTAL SURVEY; RISK-FACTORS; YOUNG-ADULTS; SYMPTOMS; ASTHMA; PREVALENCE; POPULATION; EXPOSURE; DISEASE; COHORT	Background: Participation rates in epidemiologic studies conducted with postal questionnaires have steadily declined since 1970s. This can lead to an increased risk for selection bias. The aim of this study was to examine cause and effect of non-response in a large cross sectional study assessing respiratory health in western Sweden. Methods: The study sample was 29,218. The response rate to the initial postal. questionnaire was 33%. The response rates to subsequent postal reminders were 15%, 7% and 7% of eligible participants totalling a participation of 62%. Of those who did not respond to the postal survey, a random sample of 400 subjects were identified and contacted for interview by telephone. Results: Non-responders did not differ significantly in prevalence of airway diseases or symptoms when compared with responders. Mate sex, young age and smokers were underestimated among non-responders. No clear trends in prevalence of respiratory symptoms and report of asthma were found with delayed response to the postal. survey. The proportion of smokers and men increased with increasing number of reminders. Letters reminding subjects about the study did increase the participation rate but did not alter the risk estimates. Conclusion: We conclude that with a response rate of 62%, our estimate of disease and symptom prevalence was not biased in this Swedish population. However, smoking was underestimated. No general. trend for late-responders was seen and therefore we conclude that extrapolation of results to non-responders is not possible in our study. Causes of non-response were mainly due to circumstantial factors. (C) 2009 Elsevier Ltd. All rights reserved.	[Ronmark, Erik P.] Univ Gothenburg, VBG Grp, Ctr Asthma & Allergy Res, Dept Internal Med,Sahlgrenska Acad,LFG Lab, SE-41346 Gothenburg, Sweden; [Toren, Kjell] Univ Gothenburg, VBG Grp, Ctr Asthma & Allergy Res, Dept Environm & Occupat Med,Sahlgrenska Acad, SE-41346 Gothenburg, Sweden; [Ronmark, Eva; Lundback, Bo] Sunderby Cent Hosp Norrbotten, Dept Med, OLIN Studies, Lulea, Sweden; [Ronmark, Eva] Umea Univ, Dept Publ Hlth & Clin Med, Div Environm & Occupat Med, Umea, Sweden	Ronmark, EP (reprint author), Univ Gothenburg, VBG Grp, Ctr Asthma & Allergy Res, Dept Internal Med,Sahlgrenska Acad,LFG Lab, Guldhedsgatan 10A, SE-41346 Gothenburg, Sweden.	erik.ronmark@gu.se		Lotvall, Jan/0000-0001-9195-9249	Herman Krefting Foundation; Swedish Heart Lung Foundation	The Herman Krefting Foundation for Asthma and Allergy Research is greatly acknowledged for funding the study. Additional funding was provided by the Swedish Heart Lung Foundation and the health authorities of the Vastra Gotaland Region. The authors thank the assistants Eva-Marie Romell and Madeleine Ahrnens, Gothenburg, for help with collecting the data and associate professor Matthew Perzanowski, Columbia University, New York, for valuable comments and language revision of the paper.	BAKKE P, 1990, J EPIDEMIOL COMMUN H, V44, P316, DOI 10.1136/jech.44.4.316; Bostrom M, 2008, SCAND J WORK ENV HEA, V34, P120; Brogger J, 2003, AM J EPIDEMIOL, V157, P558, DOI 10.1093/aje/kwg003; Brogger J, 2002, AM J EPIDEMIOL, V155, P572, DOI 10.1093/aje/155.6.572; DEHEER W, 1999, J OFFIC STAT, P13; DEMARCO R, 1994, EUR RESPIR J, V7, P2139, DOI 10.1183/09031936.94.07122139; DRANE JW, 1991, AM J EPIDEMIOL, V134, P908; Drivsholm T, 2006, SCAND J PUBLIC HEALT, V34, P623, DOI 10.1016/14034940600607616; Eagan TML, 2002, J CLIN EPIDEMIOL, V55, P775, DOI 10.1016/S0895-4356(02)00431-6; Ekerljung L, 2008, RESP MED, V102, P1730, DOI 10.1016/j.rmed.2008.07.011; GULSVIK A, 1979, SCAND J RESPIR DIS, V60, P275; Hartge P, 1999, EPIDEMIOLOGY, V10, P105; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Kotaniemi JT, 2001, EUR J EPIDEMIOL, V17, P809, DOI 10.1023/A:1015615130459; Lindstrom M, 2001, CHEST, V119, P852, DOI 10.1378/chest.119.3.852; Lund E, 1998, SCAND J SOC MED, V26, P154, DOI 10.1177/14034948980260020401; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; Monso E, 1998, ARCH ENVIRON HEALTH, V53, P93; OFTSTAD JAG, 1987, INFORM APPROVAL BIOM; Pallasaho P, 1999, RESP MED, V93, P798, DOI 10.1016/S0954-6111(99)90265-2; Pallasaho P, 2004, INT J TUBERC LUNG D, V8, P1292; Pealer LN, 2001, HEALTH EDUC BEHAV, V28, P547, DOI 10.1177/109019810102800503; Raat H, 2007, PEDIATR PULM, V42, P357, DOI 10.1002/ppul.20576; Radon K, 2002, EPIDEMIOLOGY, V13, P748, DOI 10.1097/00001648-200211000-00029; Ronmark E, 1999, EUR J EPIDEMIOL, V15, P293, DOI 10.1023/A:1007582518922; SAMET JM, 1987, CHEST, V91, pS74, DOI 10.1378/chest.91.6.74S; Statistics Sweden, 2014, 114 STAT SWED; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Weisel CP, 2008, ANN ALLERG ASTHMA IM, V100, P112, DOI 10.1016/S1081-1206(10)60419-X	29	71	71	0	5	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111			RESP MED	Respir. Med.	DEC	2009	103	12					1807	1815		10.1016/j.rmed.2009.07.014		9	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	526FK	WOS:000272272900005	19695859	
J	Schuttelaar, MLA; Kerkhof, M; Jonkman, MF; Koppelman, GH; Brunekreef, B; de Jongste, JC; Wijga, A; McLean, WHI; Postma, DS				Schuttelaar, M. L. A.; Kerkhof, M.; Jonkman, M. F.; Koppelman, G. H.; Brunekreef, B.; de Jongste, J. C.; Wijga, A.; McLean, W. H. I.; Postma, D. S.			Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure	ALLERGY			English	Article						asthma; atopy; children; eczema; filaggrin	ATOPIC-DERMATITIS; ICHTHYOSIS VULGARIS; RARE MUTATIONS; PREDISPOSE; GENE; POPULATION; EXPRESSION; VALIDATION; PREVALENT; CHILDREN	Background: Filaggrin gene (FLG) mutations contribute to the development of eczema and asthma, but their contribution to sensitization and hay fever remains unclear. Methods: FLG mutations R501X, 2282del4 and R2447X were genotyped in the Prevention and Incidence of Asthma and Mite Allergy birth cohort (n = 934) to evaluate longitudinally, for up to 8 years, their association with eczema, sensitization, asthma, hay fever and their interaction with cat exposure. Results: The combined FLG mutations were significantly associated with eczema at all ages when occurring in the first year of life (OR = 2.0; 95% CI: 1.4-2.8). Combined FLG mutations were associated with both atopic and nonatopic eczema, as well as asthma (OR = 3.7; 95% CI: 1.8-7.5). When the FLG 2282del4 mutation was analysed separately, it was significantly associated with the development of eczema during the first year, having eczema up to 8 years and sensitization at the age of 8 years, which was enhanced by early-life cat exposure (ORs being 8.2; 95% CI: 2.6-25.9, 6.0; 95% CI: 3.2-11.3 and 5.4; 95% CI: 1.2-23.6 respectively). FLG 2282del4 was significantly associated with hay fever from the age 5 years onwards (OR = 3.9; 95% CI: 1.5-10.5). Conclusions: FLG mutations are associated both with atopic and nonatopic eczema starting in the first year of life. FLG mutations combined with eczema in the first year of life are associated with a later development of asthma and hay fever, a clear example of the atopic march. We confirm that cat exposure enhances the effect of a FLG mutation on the development of eczema and sensitization.	[Schuttelaar, M. L. A.; Jonkman, M. F.] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, NL-9700 RB Groningen, Netherlands; [Kerkhof, M.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9700 RB Groningen, Netherlands; [Koppelman, G. H.] Univ Groningen, Univ Med Ctr Groningen, Dept Pediat Pulmonol & Pediat Allergol, NL-9700 RB Groningen, Netherlands; [Brunekreef, B.] Univ Med Ctr Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, B.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [de Jongste, J. C.] Erasmus Univ, Sophia Childrens Hosp, Dept Pediat, Med Ctr, Rotterdam, Netherlands; [Wijga, A.] Natl Inst Publ Hlth & Environm, RIVM, NL-3720 BA Bilthoven, Netherlands; [McLean, W. H. I.] Univ Dundee, Epithelial Genet Grp, Human Genet Unit, Div Pathol & Neurosci, Dundee, Scotland; [Postma, D. S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulmonol, NL-9700 RB Groningen, Netherlands	Schuttelaar, MLA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, POB 30-001, NL-9700 RB Groningen, Netherlands.		McLean, William/C-6352-2009	McLean, William Henry Irwin/0000-0001-5539-5757; brunekreef, bert/0000-0001-9908-0060	Netherlands Asthma Foundation; Ministry of the Environment, ZorgOnderzoek Nederland; National Institute of Public Health and the Environment; J.P. Nater Fund	The PIAMA study was supported by the Netherlands Asthma Foundation, the Ministry of the Environment, ZorgOnderzoek Nederland and the National Institute of Public Health and the Environment. M.L.A. Schuttelaar was supported by the J.P. Nater Fund. We thank all the members of the PIAMA study group as well as the children and their parents for their participation in our study.	ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barker JNWN, 2007, J INVEST DERMATOL, V127, P564, DOI 10.1038/sj.jid.5700587; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; BRUNEKREEF B, 2002, PEDIATR ALLERGY IMMU, V13, pS55; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Curtiss FR, 2007, J MANAGE CARE PHARM, V13, P810; De Benedetto A, 2008, J INVEST DERMATOL, V128, P1594, DOI 10.1038/sj.jid.5701208; HALKEN S, 2004, PEDIATR ALLERGY IMMU, V15, pS4; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Koppelman GH, 2006, CURR ALLERGY ASTHM R, V6, P103, DOI 10.1007/s11882-006-0047-y; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Morar N, 2007, J INVEST DERMATOL, V127, P1667, DOI 10.1038/sj.jid.5700739; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Ruether A, 2006, BRIT J DERMATOL, V155, P1093, DOI 10.1111/j.1365-2133.2006.07500.x; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2006, J INVEST DERMATOL, V126, P1770, DOI 10.1038/sj.jid.5700459; Seguchi T, 1996, ARCH DERMATOL RES, V288, P442, DOI 10.1007/BF02505232; Singer J. D., 2003, APPL LONGITUDINAL DA; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2007, J INVEST DERMATOL, V127, P724, DOI 10.1038/sj.jid.5700630; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams H, 2006, J ALLERGY CLIN IMMUN, V118, P209, DOI 10.1016/j.jaci.2006.04.043; Ying S, 2006, J ALLERGY CLIN IMMUN, V118, P1386, DOI 10.1016/j.jaci.2006.08.030	27	71	74	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	DEC	2009	64	12					1758	1765		10.1111/j.1398-9995.2009.02080.x		8	Allergy; Immunology	Allergy; Immunology	516CT	WOS:000271520000008	19839980	
J	Taubel, M; Rintala, H; Pitkaranta, M; Paulin, L; Laitinen, S; Pekkanen, J; Hyvarinen, A; Nevalainen, A				Taubel, Martin; Rintala, Helena; Pitkaranta, Miia; Paulin, Lars; Laitinen, Sirpa; Pekkanen, Juha; Hyvarinen, Anne; Nevalainen, Aino			The occupant as a source of house dust bacteria	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Microbial markers; mattress dust; floor dust; indoor; microbial exposure; bacteria; sequencing; endotoxin; LPS; muramic acid	ENDOTOXIN EXPOSURE; SCHOOL-CHILDREN; FARM CHILDREN; BIRTH COHORT; DIVERSITY; CULTURE; RISK; DETERMINANTS; ENVIRONMENT; COMPONENTS	Background: Markers for microbial groups are commonly measured in house dust samples to assess indoor exposure to microbes in studies on asthma and allergy. However, little is known about the sources of different microbes. A better understanding of the nature and origin of microbes present in the immediate environment of human beings is crucial if one wants to elucidate protective as well as adverse effects on human health. Objective: To determine the extent to which the bacterial composition of mattress and floor dust reflects the presence of the human body in relation to other environmental sources. Methods: House dust and skin surface swab samples of occupants in 4 homes were collected and analyzed for their bacterial content, using a culture-independent methodology. Bacterial sequences analyzed from the different house dusts and skin surface swabs represented random samples of bacteria present in a given sample. Highly similar sequences were grouped to assess biodiversity and to draw conclusions about the sources of bacteria. Results: The bacterial flora in the house dust samples was found to be highly diverse and dominated by gram-positive bacteria. To a considerable extent, the presence of different bacterial groups was attributed to human sources. In the individuals' mattress dust samples, 69% to 88% of the bacterial sequences analyzed were associated with human origins. The respective percentages for the individual floor dusts ranged from 45% to 55%. Conclusion: Our study indicates that human-derived bacteria account for a large part of the mainly gram-positive bacterial content in house dust. (J Allergy Clin Immunol 2009;124:834-40.)	[Taubel, Martin; Rintala, Helena; Pekkanen, Juha; Hyvarinen, Anne; Nevalainen, Aino] Natl Inst Hlth & Welf, Dept Environm Hlth, FIN-70701 Kuopio, Finland; [Pitkaranta, Miia; Paulin, Lars] Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; [Laitinen, Sirpa] Finnish Inst Occupat Hlth, Kuopio, Finland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	Taubel, M (reprint author), Natl Inst Hlth & Welf, Dept Environm Hlth, POB 95, FIN-70701 Kuopio, Finland.	martin.taubel@thl.fi			Academy of Finland [106103, 111177]	Supported by the Academy of Finland with grant nos. 106103 and 111177.	Abraham JH, 2005, ENVIRON HEALTH PERSP, V113, P1516, DOI 10.1289/ehp.7632; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andersson AM, 1999, J APPL MICROBIOL, V86, P622, DOI 10.1046/j.1365-2672.1999.00706.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Bouillard L, 2005, ANN AGR ENV MED, V12, P187; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Dekio I, 2005, J MED MICROBIOL, V54, P1231, DOI 10.1099/jmm.0.46075-0; EVANS CA, 1976, J CLIN MICROBIOL, V3, P576; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Giovannangelo M, 2007, INDOOR AIR, V17, P70, DOI 10.1111/j.1600-0668.2006.00461.x; Horak B, 1996, ANN ALLERG ASTHMA IM, V76, P41; Hyvarinen A, 2006, INDOOR AIR, V16, P20, DOI 10.1111/j.1600-0668.2005.00392.x; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Lappalainen MHJ, 2008, CLIN EXP ALLERGY, V38, P1483, DOI 10.1111/j.1365-2222.2008.03054.x; Lee L, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-27; Pakarinen J, 2008, ENVIRON MICROBIOL, V10, P3317, DOI 10.1111/j.1462-2920.2008.01723.x; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2004, APPL ENVIRON MICROB, V70, P262, DOI 10.1128/aEM.70.1.262-267.2004; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Rintala H, 2008, BMC MICROBIOL, V8, DOI 10.1186/1471-2180-8-56; Saraf A, 1997, APPL ENVIRON MICROB, V63, P2554; Schloss PD, 2006, APPL ENVIRON MICROB, V72, P6773, DOI 10.1128/AEM.00474-06; Schloss PD, 2005, APPL ENVIRON MICROB, V71, P1501, DOI 10.1128/AEM.71.3.1501-1506.2005; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; von Wintzingerode F, 1997, FEMS MICROBIOL REV, V21, P213; Waser M, 2004, CLIN EXP ALLERGY, V34, P389, DOI 10.1111/j.1365-2222.2004.01873.x; Zhao ZH, 2008, PEDIAT ALLERG IMM-UK, V19, P455, DOI 10.1111/j.1399-3038.2007.00664.x	31	71	72	2	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					834	840		10.1016/j.jaci.2009.07.045		7	Allergy; Immunology	Allergy; Immunology	506UV	WOS:000270802800031	19767077	
J	Inomata, N				Inomata, Naoko			Wheat allergy	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen; exercise-induced anaphylaxis; food-dependent; gliadin; IgE; wheat allergy	EXERCISE-INDUCED ANAPHYLAXIS; CONTROLLED FOOD CHALLENGE; OMEGA-5 GLIADIN; IGE-ANTIBODIES; ATOPIC-DERMATITIS; MAJOR ALLERGEN; 4-YEAR-OLD CHILDREN; PROTEOMIC ANALYSIS; CEREAL-GRAINS; DOUBLE-BLIND	Purpose of review This review describes the diverse clinical manifestations of IgE-mediated allergy to ingested wheat and summarizes recent advances in characterization of clinically significant allergens and diagnostic workup. Recent findings Recent population-based studies have shown the prevalence of wheat allergy and sensitization more precisely than past studies among small populations and in hospital settings. Intensive research has demonstrated the diverse profile of both water/salt-soluble and insoluble allergens involved in clinical types of wheat allergies determined depending on the patient age, the sensitization route, and the protein state during the exposure. Consequently, some new allergens, including nonspecific lipid transfer protein (Tri a 14), have been identified. For diagnosis, the role of water/salt-insoluble gliadins, particularly omega-5 gliadin, a major allergen of wheat-dependent, exercise-induced anaphylaxis, was assessed as compared with the results of oral challenges. The mechanisms of eliciting anaphylactic symptoms by exercise in wheat-de pendent, exercise-induced anaphylaxis were speculated upon; one is the allergenicity strengthened by activated tissue transglutaminase and another is the increased absorption of allergens through the gastrointestinal tract. Summary Findings of the recent studies show potential for more precise diagnosis in each clinical type of wheat allergies.	Yokohama City Univ Med, Dept Dermatol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Inomata, N (reprint author), Yokohama City Univ Med, Dept Dermatol, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	ninomata@med.yokohama-cu.ac.jp					Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99; Akagawa M, 2007, J AGR FOOD CHEM, V55, P6863, DOI 10.1021/jf070843a; Battais F, 2005, ALLERGY, V60, P815, DOI 10.1111/j.1398-9995.2005.00795.x; Benhamou AH, 2007, ALLERGY, V62, P1471, DOI 10.1111/j.1398-9995.2007.01484.x; Beyer K, 2008, J ALLERGY CLIN IMMUN, V122, P419, DOI 10.1016/j.jaci.2008.06.006; Bodinier M, 2008, INT ARCH ALLERGY IMM, V146, P307, DOI 10.1159/000121465; Chiang WC, 2007, CLIN EXP ALLERGY, V37, P1055, DOI 10.1111/j.1365-2222.2007.02752.x; Crespo JF, 2003, ALLERGY, V58, P98, DOI 10.1034/j.1398-9995.2003.02170.x; Du Toit G, 2007, PEDIATR ALLERGY IMMU, V18, P455, DOI 10.1111/j.1399-3038.2007.00599.x; Harada S, 2001, BRIT J DERMATOL, V145, P336, DOI 10.1046/j.1365-2133.2001.04329.x; Imamura T, 2008, PEDIATR ALLERGY IMMU, V19, P270, DOI 10.1111/j.1399-3038.2007.00621.x; Ito K, 2008, ALLERGY, V63, P1536, DOI 10.1111/j.1398-9995.2008.01753.x; Jacquenet S, 2008, INT ARCH ALLERGY IMM, V149, P74; James JM, 1997, J ALLERGY CLIN IMMUN, V99, P239, DOI 10.1016/S0091-6749(97)70103-9; Johansson S. G., 2003, J ALLERGY CLIN IMMUN, V113, P832; JONES SM, 1995, J ALLERGY CLIN IMMUN, V96, P341, DOI 10.1016/S0091-6749(95)70053-6; Keet CA, 2007, IMMUNOL ALLERGY CLIN, V27, P193, DOI 10.1016/j.iac.2007.03.005; Kozai H, 2006, IMMUNOL LETT, V102, P83, DOI 10.1016/j.imlet.2005.07.007; Lack G, 2008, NEW ENGL J MED, V359, P1252, DOI 10.1056/NEJMcp0800871; Lauriere M, 2007, ALLERGY, V62, P890, DOI 10.1111/j.1398-9995.2007.01456.x; Lauriere M, 2006, CONTACT DERMATITIS, V54, P283, DOI 10.1111/j.0105-1873.2006.00830.x; Majamaa H, 1999, ALLERGY, V54, P851, DOI 10.1034/j.1398-9995.1999.00081.x; Matricardi PM, 2008, CLIN EXP ALLERGY, V38, P493, DOI 10.1111/j.1365-2222.2007.02912.x; Matsuo H, 2008, ALLERGY, V63, P233, DOI 10.1111/j.1398-9995.2007.01504.x; Matsuo H, 2005, J IMMUNOL, V175, P8116; Matsuo H, 2005, CLIN EXP ALLERGY, V35, P461, DOI 10.1111/j.1365-2222.2005.02213.x; Matsuo H, 2004, J BIOL CHEM, V279, P12135, DOI 10.1074/jbc.M311340200; Matsuo H, 2009, J DERMATOL SCI, V53, P241, DOI 10.1016/j.jdermsci.2008.09.004; Mills ENC, 2008, CURR OPIN ALLERGY CL, V8, P249, DOI 10.1097/ACI.0b013e3282ffb123; Morita E, 2003, J DERMATOL SCI, V33, P99, DOI 10.1016/S0923-1811(03)00156-7; Morita E, 2007, J DERMATOL SCI, V47, P109, DOI 10.1016/j.jdermsci.2007.03.004; Ostblom E, 2008, CLIN EXP ALLERGY, V38, P1325, DOI 10.1111/j.1365-2222.2008.03010.x; Ostblom E, 2008, ALLERGY, V63, P418, DOI 10.1111/j.1398-9995.2007.01575.x; Ostblom E, 2008, ACTA PAEDIATR, V97, P85, DOI 10.1111/j.1651-2227.2007.00556.x; Palacin A, 2007, J ALLERGY CLIN IMMUN, V120, P1132, DOI 10.1016/j.jaci.2007.07.008; Palosuo K, 1999, J ALLERGY CLIN IMMUN, V103, P912, DOI 10.1016/S0091-6749(99)70438-0; Palosuo K, 2003, J ALLERGY CLIN IMMUN, V111, P1386, DOI 10.1067/mai.2003.1498; Palosuo Kati, 2003, Curr Opin Allergy Clin Immunol, V3, P205, DOI 10.1097/00130832-200306000-00009; Pastorello EA, 2007, INT ARCH ALLERGY IMM, V144, P10, DOI 10.1159/000102609; Perez-Pimiento AJ, 2007, J INVEST ALLERG CLIN, V17, P202; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Ramesh S, 2008, CLIN REV ALLERG IMMU, V34, P217, DOI 10.1007/s12016-007-8034-1; Salvatori N, 2008, CLIN EXP ALLERGY, V38, P1349, DOI 10.1111/j.1365-2222.2008.03023.x; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; Simonato B, 2001, CLIN EXP ALLERGY, V31, P1771, DOI 10.1046/j.1365-2222.2001.01200.x; Snegaroff J, 2007, J AGR FOOD CHEM, V55, P9837, DOI 10.1021/jf071432x; Sotkovsky P, 2008, PROTEOMICS, V8, P1677, DOI 10.1002/pmic.200700347; Tatham AS, 2008, CLIN EXP ALLERGY, V38, P1712, DOI 10.1111/j.1365-2222.2008.03101.x; Tsai HJ, 2009, CLIN EXP ALLERGY, V39, P101, DOI 10.1111/j.1365-2222.2008.03111.x; Varjonen E, 2000, ALLERGY, V55, P386, DOI 10.1034/j.1398-9995.2000.00451.x; VARJONEN E, 1994, CLIN EXP ALLERGY, V24, P481, DOI 10.1111/j.1365-2222.1994.tb00938.x; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Weichel M, 2006, ALLERGY, V61, P128, DOI 10.1111/j.1398-9995.2006.00999.x; Zuidmeer L, 2008, J ALLERGY CLIN IMMUN, V121, P1210, DOI 10.1016/j.jaci.2008.02.019	57	71	76	1	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1528-4050			CURR OPIN ALLERGY CL	Curr. Opin. Allergy Clin. Immunol.	JUN	2009	9	3					238	243		10.1097/ACI.0b013e32832aa5bc		6	Allergy; Immunology	Allergy; Immunology	452YU	WOS:000266577900010	19318930	
J	Marenholz, I; Kerscher, T; Bauerfeind, A; Esparza-Gordillo, J; Nickel, R; Keil, T; Lau, S; Rohde, K; Wahn, U; Lee, YA				Marenholz, Ingo; Kerscher, Tamara; Bauerfeind, Anja; Esparza-Gordillo, Jorge; Nickel, Renate; Keil, Thomas; Lau, Susanne; Rohde, Klaus; Wahn, Ulrich; Lee, Young-Ae			An interaction between filaggrin mutations and early food sensitization improves the prediction of childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Genetic prediction; interaction; asthma; eczema; food sensitization; filaggrin; mutations; subphenotype; prevention; pulmonary function	1ST 6 YEARS; ATOPIC-DERMATITIS; ALLERGIC RHINITIS; NATURAL COURSE; DUST-MITE; FOLLOW-UP; RISK; LIFE; DISEASE; COHORT	Background: Asthma prediction in early infancy is essential for the development of new preventive strategies. Loss-of-function mutations in the filaggrin gene (FLG) were identified as risk factors for eczema and associated asthma. Objective: We evaluated the utility of the FLG mutations for the prediction of asthma. Methods: Eight hundred seventy-one individuals of the prospective German Multicenter Allergy Study cohort were genotyped for 3 FLG mutations. Information on asthma, eczema, and food sensitization was available from birth to 13 years of age. Pulmonary function was measured from 7 to 13 years of age. The predictive value of the FLG mutations and of atopic phenotypes in infancy was assessed for asthma. Results: In infants with eczema and sensitization to food allergens, the FLG mutations predicted childhood asthma with a positive predictive value of 100% (95% CI, 65.5% to 100%). This subgroup was characterized by a significant decrease in pulmonary function until puberty and represented 8.1% of all asthmatic children and 19.1% of patients with asthma after infantile eczema. We found a strong synergistic interaction between the FLG-null alleles and early food sensitization in the disease transition from eczema to asthma (relative excess risk due to interaction, 2.64; 95% CI, 1.70-3.98; P = .00040). Conclusion: FLG mutations and food sensitization represent 2 distinct mechanisms interacting in the pathogenesis of asthma. In infants with eczema and food sensitization, genotyping of the FLG mutations allows the prediction of asthma before the onset of symptoms. Our findings might facilitate the development of early subgroup-specific interventions to prevent the progression from eczema to asthma. (J Allergy Clin Immunol 2009;123:911-6.)	[Keil, Thomas; Lee, Young-Ae] Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany; [Marenholz, Ingo; Kerscher, Tamara; Bauerfeind, Anja; Esparza-Gordillo, Jorge; Rohde, Klaus; Lee, Young-Ae] Max Delbruck Ctr Mol Med, Berlin, Germany	Lee, YA (reprint author), Charite Univ Med Berlin, Inst Social Med Epidemiol & Hlth Econ, D-13353 Berlin, Germany.	yolee@mdc-berlin.de	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	German Ministry for Education and Research through the Clinical Research Group for Allergy; German National Genome Research Network; European Union; Global Allergy and Asthma European Network	Supported by grants from the German Ministry for Education and Research through the Clinical Research Group for Allergy and the German National Genome Research Network, the European Union through a Marie-Curie fellowship to J.E.-G., and the Global Allergy and Asthma European Network.	Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Assmann SF, 1996, EPIDEMIOLOGY, V7, P286, DOI 10.1097/00001648-199605000-00012; Berg AO, 2005, ANN INTERN MED, V143, P355; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bossuyt PM, 2003, ANN INTERN MED, V138, pW1, DOI DOI 10.7326/0003-4819-138-1-200301070-00010; Bottema RWB, 2008, EUR RESPIR J, V32, P593, DOI 10.1183/09031936.00162407; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; Danov Z, 2007, CURR OPIN ALLERGY CL, V7, P174, DOI 10.1097/ACI.0b013e32801d216a; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Grody WW, 2003, ANNU REV MED, V54, P473, DOI 10.1146/annurev.med.54.101601.152127; Guerra S, 2008, ANNU REV MED, V59, P327, DOI 10.1146/annurev.med.59.060406.213232; Halonen M, 2006, ALLERGY ASTHMA PROC, V27, P328, DOI 10.2500/aap.2006.27.2888; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; Lal S, 2007, EUR J GASTROEN HEPAT, V19, P321, DOI 10.1097/MEG.0b013e328013e9a8; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lowe AJ, 2007, CLIN EXP ALLERGY, V37, P1624, DOI 10.1111/j.1365-2222.2007.02822.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Nickel R, 2002, CLIN EXP ALLERGY, V32, P1274, DOI 10.1046/j.1365-2745.2002.01482.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Stein Renato T, 2004, Paediatr Respir Rev, V5, P155, DOI 10.1016/j.prrv.2004.01.007; Thompson D, 2004, J MAMMARY GLAND BIOL, V9, P221, DOI 10.1023/B:JOMG.0000048770.90334.3b; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Wahn U, 2001, J ALLERGY CLIN IMMUN, V107, P567, DOI 10.1067/mai.2001.112943	37	71	73	2	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2009	123	4					911	916		10.1016/j.jaci.2009.01.051		6	Allergy; Immunology	Allergy; Immunology	431JW	WOS:000265058600020	19348926	
J	Alm, B; Aberg, N; Erdes, L; Mollborg, P; Pettersson, R; Norvenius, SG; Goksor, E; Wennergren, G				Alm, B.; Aberg, N.; Erdes, L.; Mollborg, P.; Pettersson, R.; Norvenius, S. G.; Goksor, E.; Wennergren, G.			Early introduction of fish decreases the risk of eczema in infants	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							ATOPIC-DERMATITIS; BIRTH COHORT; 1ST YEAR; INTESTINAL MICROFLORA; ALLERGY DEVELOPMENT; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; LIFE; SENSITIZATION; ASSOCIATION	Background: Atopic eczema in infants has increased in western societies. Environmental factors and the introduction of food may affect the risk of eczema. Aims: To investigate the prevalence of eczema among infants in western Sweden, describe patterns of food introduction and assess risk factors for eczema at 1 year of age. Methods: Data were obtained from a prospective, longitudinal cohort study of infants born in western Sweden in 2003; 8176 families were randomly selected and, 6 months after the infant's birth, were invited to participate and received questionnaires. A second questionnaire was sent out when the infants were 12 months old. Both questionnaires were completed and medical birth register data were obtained for 4921 infants (60.2% of the selected population). Results: At 1 year of age, 20.9% of the infants had previous or current eczema. Median age at onset was 4 months. In multivariable analysis, familial occurrence of eczema, especially in siblings (OR 1.87; 95% confidence interval (CI) 1.50 to 2.33) or the mother (OR 1.54; 95% CI 1.30 to 1.84), remained an independent risk factor. Introducing fish before 9 months of age (OR 0.76; 95% CI 0.62 to 0.94) and having a bird in the home (OR 0.35; 95% CI 0.17 to 0.75) were beneficial. Conclusions: One in five infants suffer from eczema during the first year of life. Familial eczema increased the risk, while early fish introduction and bird keeping decreased it. Breast feeding and time of milk and egg introduction did not affect the risk.	[Alm, B.; Aberg, N.; Norvenius, S. G.; Goksor, E.; Wennergren, G.] Univ Gothenburg, Dept Paediat, Queen Silvia Childrens Hosp, SE-41685 Gothenburg, Sweden; [Mollborg, P.] Uddevalla Cent Hosp, Cent Infant Welf Unit, Uddevalla, Sweden; [Erdes, L.] Skene Hosp, Paediat Outpatient Clin, Skene, Sweden; [Pettersson, R.] Skaraborg Hosp, Dept Paediat, Skovde, Sweden	Alm, B (reprint author), Univ Gothenburg, Dept Paediat, Queen Silvia Childrens Hosp, SE-41685 Gothenburg, Sweden.	bernt.alm@medfak.gu.se		Alm, Bernt/0000-0002-3557-2995	Sahlgrenska Academy at the University of Gothenburg; Research Foundation of the Swedish Asthma and Allergy Association; Swedish Foundation for Health Care Sciences and Allergy Research; Health & Medical Care Committee of the Region Vastra Gotaland	The study was supported by the Sahlgrenska Academy at the University of Gothenburg, the Research Foundation of the Swedish Asthma and Allergy Association, the Swedish Foundation for Health Care Sciences and Allergy Research, and the Health & Medical Care Committee of the Region Vastra Gotaland.	ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Alm B, 2006, ARCH DIS CHILD, V91, P915, DOI 10.1136/adc.2005.088328; Alm B, 2008, PEDIATRICS, V121, P697, DOI 10.1542/peds.2007-1232; Alm JS, 2002, PEDIATR ALLERGY IMMU, V13, P402, DOI 10.1034/j.1399-3038.2002.01062.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Cochran WG, 1977, SAMPLING TECHNIQUES; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; Hagendorens MM, 2005, CLIN EXP ALLERGY, V35, P733, DOI 10.1111/j.1365-2222.2005.02254.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; HOLT PG, 1996, EUR RESPIR REV, V6, P128; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kull I, 2005, J ALLERGY CLIN IMMUN, V116, P657, DOI 10.1016/j.jaci.2005.04.028; Laubereau B, 2004, J PEDIATR-US, V144, P602, DOI 10.1016/j.jpeds.2003.12.029; Linneberg A, 2006, J ALLERGY CLIN IMMUN, V117, P184, DOI 10.1016/j.jaci.2005.09.042; Ludvigsson JF, 2005, PEDIATR ALLERGY IMMU, V16, P201, DOI 10.1111/j.1399-3038.2005.00257.x; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Nafstad P, 2002, CLIN EXP ALLERGY, V32, P1150, DOI 10.1046/j.1365-2745.2002.01415.x; NORUSIS MJ, 2005, SPSS 13 0 GUID DAT A; Oien T, 2008, ALLERGY, V63, P53; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pesonen M, 2006, CLIN EXP ALLERGY, V36, P1011, DOI 10.1111/j.1365-2222.2006.02526.x; Ponsonby AL, 2002, J CLIN EPIDEMIOL, V55, P556, DOI 10.1016/S0895-4356(01)00519-4; Snijders BEP, 2007, PEDIATRICS, V119, pE137, DOI 10.1542/peds.2006-0772; *SOC, 2004, SMOK HAB PREGN WOM P; Strachan D, 1997, BRIT MED J, V314, P518; Sugiyama M, 2007, PEDIATRICS, V119, pE716, DOI 10.1542/peds.2006-0893; *SWED SOC PAED ALL, 2006, PREV INF MOJL MINSK; Thomsen SF, 2007, ALLERGY ASTHMA PROC, V28, P535, DOI 10.2500/aap2007.28.3041; Wadonda-Kabondo N, 2004, ARCH DIS CHILD, V89, P917, DOI 10.1136/adc.2003.034033; Wickman M, 2003, ALLERGY, V58, P742, DOI 10.1034/j.1398-9995.2003.00078.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1	40	71	72	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	JAN	2009	94	1					11	15		10.1136/adc.2008.140418		5	Pediatrics	Pediatrics	387CP	WOS:000261929600004	18818269	
J	Bhalla, DK; Hirata, F; Rishi, AK; Gairola, CG				Bhalla, Deepak K.; Hirata, Fusao; Rishi, Arun K.; Gairola, C. Gary			Cigarette Smoke, Inflammation, and Lung Injury: A Mechanistic Perspective	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS			English	Review							NECROSIS-FACTOR-ALPHA; ENVIRONMENTAL TOBACCO-SMOKE; NF-KAPPA-B; INDUCED PULMONARY INFLAMMATION; BRONCHIAL EPITHELIAL-CELLS; CONNECTIVE-TISSUE BREAKDOWN; GROWTH-FACTOR-BETA; INTERCELLULAR-ADHESION MOLECULE-1; BRONCHOALVEOLAR LAVAGE FLUID; INHIBITS CYTOKINE PRODUCTION	Inflammation is a common feature in the pathogenesis of cigarette smoke-associated diseases. The recruitment of inflammatory cells into the lung following cigarette smoke exposure presents a risk of tissue damage through the release of toxic mediators, including proteolytic enzymes and reactive oxygen species. This review represents a toxicological approach to investigation of cigarette smoke-induced lung injury, with a focus on laboratory studies and an emphasis on inflammatory mechanisms. The studies discussed in this review analyze the role of inflammation and inflammatory mediators in the development of injury. In cases where information relating to cigarette smoke is limited, examples are taken from other models of lung injury applicable to cigarette smoke. The primary aim of the review is to summarize published work so as to permit (1) an evaluation of chronic lung injury and inflammatory responses in animal models, (2) a discussion of inflammatory mediators in the development of chronic injury, and (3) identification of immunological mechanisms of injury. These studies discuss the currently understood roles of cytokines, cell adhesion molecules, and oxidative stress in inflammatory reactions and lung injury. A role for lipocortin 1 (annexin 1), a naturally occurring defense factor against inflammation, is discussed because of the possibility that impaired synthesis and degradation of lipocortin 1 will influence immune responses in animals exposed to cigarette smoke either by augmenting T helper cell Th1 response or by shifting Th1 to Th2 response. While Th1 augmentation will increase the risk for development of emphysema, Th1 to Th2 shift will favor development of asthma.	[Bhalla, Deepak K.; Hirata, Fusao] Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, Detroit, MI 48202 USA; [Rishi, Arun K.] Wayne State Univ, Dept Internal Med, Detroit, MI 48202 USA; [Rishi, Arun K.] Wayne State Univ, Karmanos Canc Inst, Detroit, MI 48202 USA; [Gairola, C. Gary] Univ Kentucky, Grad Ctr Toxicol, Lexington, KY USA	Bhalla, DK (reprint author), Wayne State Univ, Dept Pharmaceut Sci, Eugene Applebaum Coll Pharm & Hlth Sci, 259 Mack Ave, Detroit, MI 48202 USA.	ad6268@wayne.edu			Susan G. Komen Breast Cancer Foundation; V. A. Merit Award	Partly supported by a grant from the Susan G. Komen Breast Cancer Foundation (F. Hirata) and a V. A. Merit Award (A.K.Rishi).	Alati R, 2006, EPIDEMIOLOGY, V17, P138, DOI 10.1097/01.ede.0000198148.02347.33; ALBELDA SM, 1991, AM J RESP CELL MOL, V4, P195; Alberg AJ, 2003, CHEST S1, V123, P21; ANDERSON R, 1991, AM REV RESPIR DIS, V144, P570; Anto RJ, 2002, CARCINOGENESIS, V23, P1511, DOI 10.1093/carcin/23.9.1511; Bhalla DK, 1997, INHAL TOXICOL, V9, P829; Bhalla DK, 1999, J TOXICOL ENV HEAL B, V2, P31, DOI 10.1080/109374099281232; Bhalla DK, 2002, TOXICOL SCI, V69, P400, DOI 10.1093/toxsci/69.2.400; Bhalla DK, 1996, J CELL PHYSIOL, V169, P429, DOI 10.1002/(SICI)1097-4652(199612)169:3<429::AID-JCP3>3.0.CO;2-Q; Bhalla DK, 2000, J TOXICOL ENV HEAL A, V59, P211, DOI 10.1080/009841000156899; BITTLEMAN DB, 1995, AM J RESP CELL MOL, V13, P323; Borland R, 2006, TOB CONTROL, V15, P34, DOI 10.1136/tc.2004.008748; BOUCHER RC, 1980, LAB INVEST, V43, P94; Bracke KR, 2007, CLIN EXP ALLERGY, V37, P1467, DOI 10.1111/j.1365-2222.2007.02808.x; Bracke KR, 2006, J IMMUNOL, V177, P4350; BURNS AR, 1994, J IMMUNOL, V153, P3177; BYRON KA, 1994, CLIN EXP IMMUNOL, V95, P954; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Carnevali S, 1998, AM J PHYSIOL-LUNG C, V274, pL591; Castro P, 2004, EUR J PHARMACOL, V498, P279, DOI 10.1016/j.ejphar.2004.07.047; Chen FE, 1999, ONCOGENE, V18, P6845, DOI 10.1038/sj.onc.1203224; CHOW CK, 1993, ANN NY ACAD SCI, V686, P289, DOI 10.1111/j.1749-6632.1993.tb39189.x; Churg A, 2004, AM J RESP CRIT CARE, V170, P492, DOI 10.1164/rccm.200404-5110C; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; Churg A, 2002, AM J RESP CRIT CARE, V166, P849, DOI 10.1164/rccm.200202-097OC; Churg A, 2002, AM J RESP CELL MOL, V27, P368, DOI 10.1165/rcmb.4791; Churg A, 2008, AM J PHYSIOL-LUNG C, V294, pL612, DOI 10.1152/ajplung.00390.2007; Coggins CRE, 2007, INT J TOXICOL, V26, P331, DOI 10.1080/1091581070140190; Cohen MD, 2001, TOXICOL APPL PHARM, V171, P71, DOI 10.1006/taap.2000.9106; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; COZEN W, 2002, J CLIN IMMUNOL, V6, P617; D'hulst AI, 2005, EUR RESPIR J, V26, P204, DOI 10.1183/09031936.05.00095204; Danahay H, 2002, AM J PHYSIOL-LUNG C, V282, pL226; De Sario Manuela, 2005, Epidemiol Prev, V29, P52; DEAN DC, 1989, AM J RESP CELL MOL, V1, P5; [Anonymous], 2004, HLTH CONS SMOK REP S; *DEP HLTH HUM SERV, 1964, 1103 PHS DEP HLTH HU; DEVESA SS, 1987, J NATL CANCER I, V79, P701; Dezateux C, 1999, AM J RESP CRIT CARE, V159, P403; Dhala Atiya, 2006, Clin Occup Environ Med, V5, P139; Dhami R, 2000, AM J RESP CELL MOL, V22, P244; DiFranza JR, 2004, PEDIATRICS, V113, P1007; DUBAR V, 1993, EXP LUNG RES, V19, P345, DOI 10.3109/01902149309064351; [Anonymous], 2004, CHEST; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Esamai FO, 1998, E AFR MED J, V75, P47; EY JL, 1995, PEDIATRICS, V95, P670; Ferreira AM, 2005, CYTOKINE, V30, P64, DOI 10.1016/j.cyto.2004.12.00; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; Frode TS, 2001, CYTOKINE, V13, P162, DOI 10.1006/cyto.2000.0816; Fuke S, 2004, AM J RESP CELL MOL, V31, P405, DOI 10.1165/rcmb.2004.0131OC; Gabrielson E, 2006, RESPIROLOGY, V11, P533, DOI 10.1111/j.1400-1843.2006.00909.x; GAIROLA CG, 1986, TOXICOL APPL PHARM, V84, P567, DOI 10.1016/0041-008X(86)90262-0; GIDDING SS, 1994, CIRCULATION, V90, P2581; Gold R, 1999, ACTA NEUROPATHOL, V98, P583; Goulding NJ, 1998, INFLAMM RES, V47, pS158; Green PG, 1998, J NEUROPHYSIOL, V80, P3120; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Hasnis E, 2007, J PHYSIOL PHARMACOL, V58, P275; HAUX F, 1998, AM J RESP CELL MOL B, V18, P51; He J, 1999, NEW ENGL J MED, V340, P920, DOI 10.1056/NEJM199903253401204; Hellermann GR, 2002, RESPIR RES, V3, DOI 10.1186/rr172; Hellings PW, 2003, AM J RESP CELL MOL, V28, P42, DOI 10.1165/rcmb.4832; Hirata F, 1989, ANTIINFLAMMATORY STE, P67; HIRATA F, 1984, ADV INFLAMMAT RES, V7, P71; Hirata F., 1998, ENCY IMMUNOLOGY, P111; HIRATA F, 1983, J IMMUNOL, V130, P1903; Hoffmann D, 1997, J TOXICOL ENV HEALTH, V50, P307, DOI 10.1080/009841097160393; HOLT PG, 1987, THORAX, V42, P241, DOI 10.1136/thx.42.4.241; Hoo AF, 1998, AM J RESP CRIT CARE, V158, P700; Howard DJ, 1998, CANCER EPIDEM BIOMAR, V7, P141; Husgafvel-Pursiainen K, 2004, MUTAT RES-REV MUTAT, V567, P427, DOI 10.1016/j,mrrev.2004.06.004; HYNES RO, 1990, FIBRONECTINS, P1; IARC, 2004, IARC MON EV CARC RIS, V83, P59; ISHIZAKA K, 1987, INT ARCH ALLER A IMM, V82, P383; ISHIZAKA K, 1989, INT ARCH ALLER A IMM, V88, P8; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; JOHNSON JD, 1990, CRIT REV TOXICOL, V20, P369, DOI 10.3109/10408449009089870; JONES JG, 1980, LANCET, V1, P66; KOHN AD, 1996, J BIOL CHEM, V271, P2190; Kolls JK, 2003, AM J RESP CELL MOL, V28, P9, DOI 10.1165/rcmb.2002-0255PS; Kooi EMW, 2004, PEDIATR PULM, V38, P419, DOI 10.1002/ppul.20093; Krzysiek R, 2000, BLOOD, V96, P2338; Kulik G, 1997, MOL CELL BIOL, V17, P1595; Kuper H, 2002, J INTERN MED, V252, P206, DOI 10.1046/j.1365-2796.2002.01022.x; Kuschner WG, 1996, EUR RESPIR J, V9, P1989, DOI 10.1183/09031936.96.09101989; LAFLEUR M, 1987, J BIOL CHEM, V262, P2111; Lancaster LH, 2001, INFLAMMATION, V25, P25, DOI 10.1023/A:1007071527408; Landau LI, 2008, PAEDIATR RESPIR REV, V9, P39, DOI 10.1016/j.prrv.2007.11.002; LANNERO E, 2006, RESP RES, V5, P3; Lappalainen U, 2005, AM J RESP CELL MOL, V32, P311, DOI 10.1165/rcmb.2004.0309OC; LEFF JA, 1993, AM J PHYSIOL, V265, pL501; LEHR HA, 1993, ANN NY ACAD SCI, V686, P112, DOI 10.1111/j.1749-6632.1993.tb39163.x; LEHR HA, 1994, P NATL ACAD SCI USA, V91, P7688, DOI 10.1073/pnas.91.16.7688; LIMPER AH, 1992, CHEST, V101, P1663, DOI 10.1378/chest.101.6.1663; Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1; Liu JY, 2001, AM J RESP CELL MOL, V25, P3; LOFT S, 1992, CARCINOGENESIS, V13, P2241, DOI 10.1093/carcin/13.12.2241; LOGHMANI F, 2008, INFLAMMATION, V26, P73; Lucey EC, 2002, LAB INVEST, V82, P79; LUDWIG PW, 1985, AM REV RESPIR DIS, V131, P828; Mack M, 2001, J IMMUNOL, V166, P4697; MACNEE W, 1989, NEW ENGL J MED, V321, P924, DOI 10.1056/NEJM198910053211402; MacNee W, 2007, CLIN CHEST MED, V28, P479, DOI 10.1016/j.ccm.2007.06.008; Maes T, 2006, INT ARCH ALLERGY IMM, V141, P354, DOI 10.1159/000095462; MAJORI M, 1999, J ALLERGY CLIN IMMUN, V103, P451; MALEFYT RD, 1991, J EXP MED, V174, P1209; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; Marx J, 2004, SCIENCE, V306, P966, DOI 10.1126/science.306.5698.966; MCKEOWNLONGO PJ, 1987, REV INFECT DIS, V9, pS322; Mercer-Jones MA, 1999, J LEUKOCYTE BIOL, V65, P249; Miller LM, 2002, EXP LUNG RES, V28, P435, DOI 10.1080/01902140290096728; Milner AD, 1999, ARCH DIS CHILD, V80, pF8; Mio T, 1997, AM J RESP CRIT CARE, V155, P1770; Morrison D, 1999, AM J RESP CRIT CARE, V159, P473; MORROW JD, 1995, NEW ENGL J MED, V332, P1198, DOI 10.1056/NEJM199505043321804; Moshammer H, 2006, AM J RESP CRIT CARE, V173, P1255, DOI 10.1164/rccm.200510-1552OC; MOSHER DF, 1987, FIBRONECTIN, P48; Mulligan MS, 1997, J IMMUNOL, V159, P3483; MULLIGAN MS, 1993, J IMMUNOL, V150, P2407; Murin S, 1997, CLIN REV ALLERG IMMU, V15, P307, DOI 10.1007/BF02737703; NAKAMURA Y, 1995, AM J RESP CRIT CARE, V151, P1497; Newman SP, 1997, ADV EXP MED BIOL, V407, P249; Nouri-Shirazi M, 2007, IMMUNOL LETT, V109, P155, DOI 10.1016/j.imlet.2007.02.005; Nuhoglu C, 2003, PEDIATR INT, V45, P426, DOI 10.1046/j.1442-200X.2003.01753.x; NUHOGLU C, 2004, CELL SIGNAL, V16, P1201; Nureki S, 2005, CLIN IMMUNOL, V116, P83, DOI 10.1016/j.clim.2005.03.001; Ouyang Y, 2000, J ALLERGY CLIN IMMUN, V106, P280; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; PATEL JA, 1995, AM J RESP CELL MOL, V13, P602; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; Pearson AC, 1997, J TOXICOL ENV HEALTH, V50, P143, DOI 10.1080/009841097160546; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Piedboeuf B, 1996, AM J RESP CELL MOL, V15, P71; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; PRYOR WA, 1983, ENVIRON HEALTH PERSP, V47, P345, DOI 10.2307/3429523; Rahman I, 2002, BIOCHEM PHARMACOL, V64, P935, DOI 10.1016/S0006-2952(02)01153-X; Rahman I, 2002, MOL CELL BIOCHEM, V234, P239, DOI 10.1023/A:1015905010086; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; Raychaudhuri B, 2000, CYTOKINE, V12, P1348, DOI 10.1006/cyto.2000.0721; Reardon JZ, 2007, CLIN CHEST MED, V28, P559, DOI 10.1016/j.ccm.2007.06.006; Reinhart PG, 1999, TOXICOL LETT, V110, P35, DOI 10.1016/S0378-4274(99)00136-8; RENNARD SI, 1981, J CLIN INVEST, V69, P113; Rennard Stephen I, 2006, Proc Am Thorac Soc, V3, P703, DOI 10.1513/pats.200605-121SF; Rhee Hae Jin, 2000, European Journal of Biochemistry, V267, P3220, DOI 10.1046/j.1432-1327.2000.01345.x; Roth M, 2008, INT J TUBERC LUNG D, V12, P375; Rouse RL, 2007, ENVIRON HEALTH PERSP, V115, P1757, DOI 10.1289/ehp.10358; RUOSLAHTI E, 1988, ANNU REV BIOCHEM, V57, P375; Rushton Lesley, 2004, Reviews on Environmental Health, V19, P291; Rusznak C, 2000, AM J RESP CELL MOL, V23, P530; Ryder MI, 2002, ORAL MICROBIOL IMMUN, V17, P331, DOI 10.1034/j.1399-302X.2002.170601.x; Schick S, 2006, TOB CONTROL, V15, P424, DOI 10.1136/tc.2006.016162; Schierhorn K, 1999, AM J RESP CELL MOL, V20, P1013; Sears MR, 2000, CLIN CHEST MED, V21, P315, DOI 10.1016/S0272-5231(05)70269-0; Shanley TP, 2000, CYTOKINE, V12, P1054, DOI 10.1006/cyto.1999.0655; Shields PG, 2002, ONCOGENE, V21, P6870, DOI 10.1038/sj.onc.1205832; Sime PJ, 1998, AM J PATHOL, V153, P825, DOI 10.1016/S0002-9440(10)65624-6; SMART SJ, 1994, J IMMUNOL, V152, P4087; Smith CJ, 2000, TOXICOL SCI, V54, P462, DOI 10.1093/toxsci/54.2.462; Smith RE, 1996, AM J RESP CELL MOL, V15, P693; Solito E, 1998, CYTOKINE, V10, P514, DOI 10.1006/cyto.1997.0325; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stick S, 2006, CURR OPIN ALLERGY CL, V6, P312, DOI 10.1097/01.all.0000244789.10863.c4; Stocks J, 2003, RESPIROLOGY, V8, P266, DOI 10.1046/j.1440-1843.2003.00478.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Stone PCW, 2002, BIOCHEM BIOPH RES CO, V295, P1150, DOI 10.1016/S0006-291X(02)00800-8; Stringer B, 1998, J TOXICOL ENV HEAL A, V55, P31; Subauste MC, 2001, INFLAMMATION, V25, P373, DOI 10.1023/A:1012850630351; Sugawara T, 2001, CYTOKINE, V15, P328, DOI 10.1006/cyto.2001.0946; Sullivan DE, 2005, AM J RESP CELL MOL, V32, P342, DOI 10.1165/rcmb.2004-0288OC; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; Tager IB, 2008, PAEDIATR RESPIR REV, V9, P29, DOI 10.1016/j.prrv.2007.11.006; Takubo Y, 2002, AM J RESP CRIT CARE, V166, P1596, DOI 10.1164/rccm.2202001; Terashima T, 1999, AM J RESP CELL MOL, V20, P171; Terashima T, 1997, AM J RESP CRIT CARE, V155, P1021; Thatcher TH, 2007, AM J PATHOL, V170, P855, DOI 10.2353/ajpath.2007.060391; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214; Tsao FHC, 1998, AM J RESP CELL MOL, V18, P120; UEDE T, 1983, J IMMUNOL, V130, P878; van den Berg R, 2001, ENVIRON TOXICOL PHAR, V9, P147, DOI 10.1016/S1382-6689(00)00070-3; van der Vaart H, 2004, THORAX, V59, P713, DOI 10.1136/thx.2003.012468; Van Miert E, 2005, TOXICOL LETT, V159, P115, DOI 10.1016/j.toxlet.2005.05.007; Vassallo R, 2005, J IMMUNOL, V175, P2684; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; Vishwanatha JK, 1998, CLIN CANCER RES, V4, P2559; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Wang HJ, 2003, AM J PHYSIOL-LUNG C, V284, pL205, DOI 10.1152/ajplung.00042.2002; Wang Lei, 2008, Birth Defects Research, V84, P54, DOI 10.1002/bdrc.20114; Warren C.W., 2006, TOBACCO CONTROL S2, V15, pii4; Warshamana GS, 2001, EXP MOL PATHOL, V71, P13, DOI 10.1006/exmp.2001.2376; Weber C, 1996, CIRCULATION, V93, P1488; World Health Organization, 2004, IARC MON, V83; [Anonymous], 1997, TOB HLTH GLOB STAT R; Witschi H, 2007, INT J TOXICOL, V26, P339, DOI 10.1080/10915810701490380; Wouters Emiel F M, 2005, Proc Am Thorac Soc, V2, P26, DOI 10.1513/pats.200408-039MS; Wright JL, 2004, AM J RESP CELL MOL, V31, P501, DOI 10.1165/rcmb.2004-0051OC; Yamashiro S, 2000, BLOOD, V96, P3958; Yang SR, 2008, AM J RESP CELL MOL, V38, P689, DOI 10.1165/rcmb.2007-0379OC; Yang SR, 2006, AM J PHYSIOL-LUNG C, V291, pL46, DOI 10.1152/ajplung.00241.2005; Yu M, 2002, TOXICOL SCI, V65, P99, DOI 10.1093/toxsci/65.1.99; Zhu Z, 2002, J IMMUNOL, V168, P2953; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; ZUANYAMORIM C, 1995, J CLIN INVEST, V95, P2644, DOI 10.1172/JCI117966	207	71	74	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1093-7404	1521-6950		J TOXICOL ENV HEAL B	J. Toxicol. Env. Health-Pt b-Crit. Rev.		2009	12	1					45	64	PII 907306217	10.1080/10937400802545094		20	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	389ZF	WOS:000262133400003	19117209	
J	Sackesen, C; Ercan, H; Dizdar, E; Soyer, O; Gumus, P; Tosun, BN; Buyuktuncer, Z; Karabulut, E; Besler, T; Kalayci, O				Sackesen, Cansin; Ercan, Hulya; Dizdar, Evrim; Soyer, Ozge; Gumus, Pinar; Tosun, Berat Nursal; Bueyuektuncer, Zebra; Karabulut, Erdem; Besler, Tanju; Kalayci, Omer			A comprehensive evaluation of the enzymatic and nonenzymatic antioxidant systems in childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						amino acid; antioxidant; ascorbic acid; asthma; glutathione; glutathione peroxidase; lycopene; malondialdehyde; oxidative stress; superoxide dismutase; alpha-tocopherol; beta-carotene	EXTRACELLULAR-SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; AMINO-ACIDS; PROTEIN OXIDATION; CYSTEINE KINETICS; PLASMA LYCOPENE; FREE-RADICALS; GLUTATHIONE; CHILDREN; SERUM	Background: Even though there is ample evidence on the oxidative stress in asthma, there is limited information on the antioxidant defense systems. Objectives: To conduct a comprehensive evaluation of various components of both enzymatic and nonenzymatic antioxidants in a large group of children with asthma. Methods: A total of 164 children with mild asthma and 173 healthy children were included in the study. Levels of the enzymes glutathione peroxidase and superoxide dismutase were measured by using ELISA, whereas reduced glutathione, ascorbic acid, alpha-tocopherol, lycopene, beta-carotene, amino acids participating in glutathione synthesis, and amino acids susceptible to oxidation were measured by HPLC. All comparisons were adjusted for atopy, body mass index, smoke exposure, and pet ownership. Results: Levels of the enzymes glutathione peroxidase and superoxide dismutase and of the nonenzymatic components of the antioxidant system including reduced glutathione, ascorbic acid, alpha-tocopherol, lycopene, and beta-carotene were significantly lower in children with asthma compared with healthy controls (P <.001 for each). Of the amino acids contributing to glutathione synthesis, glycine and glutamine were significantly lower in children with asthma (P <.001). The majority of the amino acid susceptible to oxidative stress displayed lower levels in children with asthma (P <.05). Conclusion: Childhood asthma is associated with significant decreases in various components of both enzymatic and nonenzymatic antioxidant defenses.	[Karabulut, Erdem] Hacettepe Univ, Sch Med, Dept Biostat, TR-06100 Ankara, Turkey; [Sackesen, Cansin; Ercan, Hulya; Dizdar, Evrim; Soyer, Ozge; Gumus, Pinar; Kalayci, Omer] Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey; [Tosun, Berat Nursal; Bueyuektuncer, Zebra; Besler, Tanju] Hacettepe Univ, Sch Hlth Technol, Dept Nutr & Dietet, TR-06100 Ankara, Turkey	Sackesen, C (reprint author), Hacettepe Univ, Sch Med, Pediat Allergy & Asthma Unit, TR-06100 Ankara, Turkey.	csackesen@yahoo.com	Karabulut, Erdem/E-9242-2013; BESLER, HALIT TANJU/I-9965-2013	BESLER, HALIT TANJU/0000-0002-6523-7995			Andreadis AA, 2003, FREE RADICAL BIO MED, V35, P213, DOI 10.1016/S0891-5849(03)00278-8; ARNAUD J, 1991, J CHROMATOGR-BIOMED, V572, P103, DOI 10.1016/0378-4347(91)80476-S; Atmaca G, 2004, YONSEI MED J, V45, P776; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Besler HT, 2003, NUTR NEUROSCI, V6, P189, DOI 10.1080/1028415031000115945; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152; CEBALLOSPICOT I, 1992, CLIN CHEM, V38, P66; COMMITTEE IS, 1998, PHASE 2 MODULES INT, P11; Deneke S.M., 1989, AM J PHYSIOL, V257, P163; Ercan H, 2006, J ALLERGY CLIN IMMUN, V118, P1097, DOI 10.1016/j.jaci.2006.08.012; Fang YZ, 2002, NUTRITION, V18, P872, DOI 10.1016/S0899-9007(02)00916-4; Fogarty A, 2004, EUR RESPIR J, V23, P565, DOI 10.1183/09031936.04.00090404; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; Ford ES, 2004, J ASTHMA, V41, P179, DOI 10.1081/JAS-120026075; Fukagawa NK, 1996, AM J PHYSIOL-ENDOC M, V270, pE209; HALLIWELL B, 1988, HUM TOXICOL, V7, P7; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Heber D, 2002, EXP BIOL MED, V227, P920; HIRAMATSU T, 1994, AM J CLIN NUTR, V60, P525; JONES DP, 2000, DETOXIFICATION PROTE; Kalayci O, 2006, ALLERGY, V61, P97, DOI 10.1111/j.1398-9995.2006.00979.x; Kim YG, 2003, LIFE SCI, V72, P1171, DOI 10.1016/S0024-3205(02)02366-4; KINNULA VL, 1995, LAB INVEST, V73, P3; Levine RL, 2001, EXP GERONTOL, V36, P1495, DOI 10.1016/S0531-5565(01)00135-8; Maier CM, 2002, NEUROSCIENTIST, V8, P323; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misso NLA, 2005, EUR RESPIR J, V26, P257, DOI 10.1183/09031936.05.00006705; Mizuno Y, 2006, PEDIATR INT, V48, P261, DOI 10.1111/j.1442-200X.2006.02200.x; Nadeem A, 2003, J ALLERGY CLIN IMMUN, V111, P72, DOI 10.1067/mai.2003.17; OBLED C, 2004, SULFUR CONTAINING AM; OWEN S, 1991, NEW ENGL J MED, V325, P586; Park EM, 1998, FREE RADICAL BIO MED, V25, P79, DOI 10.1016/S0891-5849(98)00041-0; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; Rahman I, 1999, AM J PHYSIOL, V277, P1067; Riccioni G, 2007, J ASTHMA, V44, P429, DOI 10.1080/02770900701421880; Riccioni G, 2006, ALLERGY, V61, P1371, DOI 10.1111/j.1398-9995.2006.01100.x; Rubin RN, 2004, AM J RESP CRIT CARE, V169, P393, DOI 10.1164/rccm.200301-055OC; Sackesen C, 2005, ALLERGY, V60, P1485, DOI 10.1111/j.1398-9995.2005.00874.x; Saraclar Y, 2003, ANN ALLERG ASTHMA IM, V91, P477; Stadtman ER, 2006, FREE RADICAL RES, V40, P1250, DOI 10.1080/10715760600918142; Stadtman ER, 2003, AMINO ACIDS, V25, P207, DOI 10.1007/s00726-003-0011-2; STIPANUK MH, 1992, J NUTR, V122, P420; van der Vliet A, 1999, AM J PHYSIOL-LUNG C, V276, pL289; Wood LG, 2005, J AM COLL NUTR, V24, P448; Yilmaz T, 2004, OTOLARYNG HEAD NECK, V131, P797, DOI 10.1016/j.otohns.2004.07.001; Yilmaz T, 2004, INT J PEDIATR OTORHI, V68, P1053, DOI 10.1016/j.ijporl.2004.04.003	50	71	72	0	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					78	85		10.1016/j.jaci.2008.03.035		8	Allergy; Immunology	Allergy; Immunology	325RD	WOS:000257605100013	18485467	
J	Bell, ML; Levy, JK; Lin, Z				Bell, M. L.; Levy, J. K.; Lin, Z.			The effect of sandstorms and air pollution on cause-specific hospital admissions in Taipei, Taiwan	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							DUST STORM EVENTS; DAILY STROKE ADMISSIONS; LONG-RANGE TRANSPORT; DAILY MORTALITY; CARDIOVASCULAR-DISEASE; AMBIENT AIR; PARTICLES; QUALITY; PARTICULATE; KAOHSIUNG	Objective: Relatively little research exists focusing on the impact of air pollution on hospital admissions in Asia compared to the extensive work conducted in the USA and Europe. The issue is of particular importance because of the frequency, intensity and health effects of Asian sandstorms. This work investigates the relation between cause-specific hospital admissions and sandstorms and air pollution in Taipei, Taiwan's capital. Methods: Time-series analyses of asthma, pneumonia, ischaemic heart disease and cerebrovascular disease hospital admissions were performed for Taipei. An eight-year time period (1995-2002) was considered for various indicators of sandstorms and the pollutants NO2, CO, ozone, SO2, PM10, and PM2.5. Pollution effects based on single-day lags of 0, 1, 2 and 3 days were explored, along with the average of the same day and previous three days (L03). Results: The risk of ischaemic heart disease admissions was associated with several sandstorm metrics, including indicators of high PM10 levels in the Taipei area, indicators of high PM10 at a monitor designed to measure background pollution, the PM coarse fraction, and the ratio of PM10 to PM2.5. However, the lag structure of effect was not consistent across sandstorm indicators. Hospital admissions for this disease were 16-21% higher on sandstorm days compared to other days. This cause was also associated with transportation-related pollutants, NO2, CO and PM2.5. Asthma admissions rose 4.48% (95% CI 0.71% to 8.38%) per 28 mu g/m(3) increase in L03 PM10 levels and 7.60% (95% CI 2.87% to 12.54%) per 10 ppb increase in L03 ozone. Cerebrovascular disease admissions were associated with PM10 and CO, both at lag 3 days. SO2 exhibited no relation with admissions. Conclusions: Risk of hospital admissions in Taipei may be increased by air pollution and sandstorms. Additional research is needed to clarify the lag structure and magnitude of such effects.	[Bell, M. L.] Yale Univ, Sch Forestry & Environm Studies, New Haven, CT 06511 USA; [Levy, J. K.] Western Washington Univ, Dept Environm Studies, Bellingham, WA 98225 USA; [Lin, Z.] Chinese Acad Sci, Inst Atmospher Phys, Beijing, Peoples R China	Bell, ML (reprint author), Yale Univ, Sch Forestry & Environm Studies, 205 Prospect St, New Haven, CT 06511 USA.	michelle.bell@yale.edu					BELL ML, 2005, ENVIRON SCI POLICY, V85, P525; Bennett CM, 2006, SCI TOTAL ENVIRON, V366, P918, DOI 10.1016/j.scitotenv.2005.12.025; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Chan CC, 2006, EUR HEART J, V27, P1238, DOI 10.1093/eurheartj/ehi835; Chang CC, 2006, J TOXICOL ENV HEAL A, V69, P229, DOI 10.1080/15287390500227415; Chang CC, 2005, ENVIRON RES, V98, P114, DOI 10.1016/j.envres.2004.07.005; Chang G.Q, 2003, CHINESE J SCH DOCTOR, V17, P295; Chang SC, 2007, ENVIRON MONIT ASSESS, V127, P87, DOI 10.1007/s10661-006-9262-1; Chen CH, 2006, J ASTHMA, V43, P287, DOI 10.1080/02770900600622935; Chen YS, 2005, J TOXICOL ENV HEAL A, V68, P1457, DOI 10.1080/15287390590967388; Chen YS, 2004, ENVIRON RES, V95, P151, DOI 10.1016/j.envres.2003.08.008; Cheng MT, 2005, CHEMOSPHERE, V61, P1439, DOI 10.1016/j.chemosphere.2005.04.120; Cheng TM, 2003, HEALTH AFFAIR, V22, P61, DOI 10.1377/hlthaff.22.3.61; Chou CCK, 2004, TERR ATMOS OCEAN SCI, V15, P881; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Dong J W, 1996, Zhonghua Liu Xing Bing Xue Za Zhi, V17, P13; Fang GC, 2002, SCI TOTAL ENVIRON, V287, P141, DOI 10.1016/S0048-9697(01)00996-2; KALKSTEIN LS, 1986, B AM METEOROL SOC, V67, P842, DOI 10.1175/1520-0477(1986)067<0842:AEOSDI>2.0.CO;2; Kan HD, 2007, ENVIRON INT, V33, P376, DOI 10.1016/j.envint.2006.12.001; Kuo HW, 2002, ARCH ENVIRON HEALTH, V57, P194; Kwon HJ, 2002, ENVIRON RES, V90, P1, DOI 10.1006/enrs.2002.4377; Lee HC, 2004, TERR ATMOS OCEAN SCI, V15, P1035; Lin CY, 2005, ATMOS ENVIRON, V39, P6066, DOI 10.1016/j.atmosenv.2005.06.046; Park JW, 2005, RESPIROLOGY, V10, P470, DOI 10.1111/j.1440-1843.2005.00728.x; *TEPA, 2006, ENV PROT DAT TAIW; Tsai SS, 2006, INHAL TOXICOL, V18, P549, DOI 10.1080/0895837006866176; Tsai SS, 2003, STROKE, V34, P2612, DOI 10.1161/01.STR.0000095564.33543.64; Tzeng GH, 2002, J ENVIRON MANAGE, V65, P109, DOI 10.1006/jema.2001.0527; USEPA, 2004, AIR QUAL CRIT PART M; WHO, 2005, WHO AIR QUAL GUID GL; XIAO HP, 1990, CHINESE J PUBLIC HLT, V66, P195; Xie SD, 2005, SCI TOTAL ENVIRON, V345, P153, DOI 10.1016/j.scitotenv.2004.10.013; XU XP, 1995, ARCH ENVIRON HEALTH, V50, P214; XU XP, 1995, ENVIRON HEALTH PERSP, V103, P286; Yang CY, 2005, ENVIRON RES, V99, P79, DOI 10.1016/j.envres.2004.12.009; Yang CY, 2005, INHAL TOXICOL, V17, P817, DOI 10.1080/08958370500241254; Yang CY, 2004, J TOXICOL ENV HEAL A, V67, P483, DOI 10.1080/15287390490276502; Zhang RJ, 2003, POWDER TECHNOL, V137, P77, DOI 10.1016/j.powtec.2003.08.056; Zhou Y. R., 1997, J MOD PREV MED, V24, P43	40	71	77	3	20	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	FEB	2008	65	2					104	111		10.1136/oem.2006.031500		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	254QF	WOS:000252601700005	17626134	
J	Pijnenburg, MWH; De Jongste, JC				Pijnenburg, M. W. H.; De Jongste, J. C.			Exhaled nitric oxide in childhood asthma: a review	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							PRIMARY CILIARY DYSKINESIA; BRONCHIOLITIS OBLITERANS SYNDROME; EXPERIMENTAL RHINOVIRUS INFECTION; RESPIRATORY SYNCYTIAL VIRUS; AIRWAY EPITHELIAL-CELLS; GRASS-POLLEN EXPOSURE; SCHOOL-AGE-CHILDREN; CYSTIC-FIBROSIS; LUNG-FUNCTION; HEALTHY-CHILDREN	As an 'inflammometer', the fraction of nitric oxide in exhaled air (FENO) is increasingly used in the management of paediatric asthma. FENO provides us with valuable, additional information regarding the nature of underlying airway inflammation, and complements lung function testing and measurement of airway hyper-reactivity. This review focuses on clinical applications of FENO in paediatric asthma. First, FENO provides us with a practical tool to aid in the diagnosis of asthma and distinguish patients who will benefit from inhaled corticosteroids from those who will not. Second, FENO is helpful in predicting exacerbations, and predicting successful steroid reduction or withdrawal. In atopic asthmatic children FENO is beneficial in adjusting steroid doses, discerning those patients who require additional therapy from those whose medication dose could feasibly be reduced. In pre-school children FENO may be of help in the differential diagnosis of respiratory symptoms, and may potentially allow for better targeting and monitoring of anti-inflammatory treatment.	[Pijnenburg, M. W. H.; De Jongste, J. C.] Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Paediat Paediat Resp Med, NL-3000 CB Rotterdam, Netherlands	Pijnenburg, MWH (reprint author), Erasmus Univ, Med Ctr, Sophia Childrens Hosp, Dept Paediat Paediat Resp Med, NL-3000 CB Rotterdam, Netherlands.	m.pijnenburg@erasmusmc.nl					ALVING K, 1993, EUR RESPIR J, V6, P1368; Arnal JF, 1999, EUR RESPIR J, V13, P307, DOI 10.1034/j.1399-3003.1999.13b15.x; Artlich A, 1996, EUR J PEDIATR, V155, P698; Artlich A, 2001, BIOL NEONATE, V79, P21, DOI 10.1159/000047061; Artlich A, 1999, EUR RESPIR J, V13, P1396, DOI 10.1183/09031936.99.13614029; ASANO K, 1994, P NATL ACAD SCI USA, V91, P10089, DOI 10.1073/pnas.91.21.10089; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST.PUBMED:15817806; Avital A, 2003, PEDIATR PULM, V36, P433, DOI 10.1002/ppul.10377; Avital A, 2001, PEDIATR PULM, V32, P308, DOI 10.1002/ppul.1124; Baraldi E, 2004, EUR RESPIR J, V24, P881, DOI 10.1183/09031936.04.0000504; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P1284; Baraldi E, 2005, AM J RESP CRIT CARE, V171, P68, DOI 10.1164/rccm.200403-298Oc; Baraldi E, 1999, AM J RESP CRIT CARE, V159, P262; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Baraldi E, 1997, J PEDIATR-US, V131, P381, DOI 10.1016/S0022-3476(97)80062-5; Baraldi E, 1998, PEDIATR PULM, V26, P30, DOI 10.1002/(SICI)1099-0496(199807)26:1<30::AID-PPUL6>3.0.CO;2-M; Baraldi E, 2000, AM J RESP CRIT CARE, V162, P1828; BARNES PJ, 1993, THORAX, V48, P1034, DOI 10.1136/thx.48.10.1034; Barreto M, 2001, PEDIATR ALLERGY IMMU, V12, P247, DOI 10.1034/j.1399-3038.2001.00041.x; Baur X, 2005, EUR RESPIR J, V25, P309, DOI 10.1183/09031936.05.00021504; Beck-Ripp J, 2002, EUR RESPIR J, V19, P1015, DOI 10.1183/09031936.02.01582001; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P1227; Boehmer ALM, 2006, CURR OPIN PULM MED, V12, P34, DOI 10.1097/01.mcp.0000199810.42011.8e; Brett SJ, 1998, AM J RESP CRIT CARE, V157, P993; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Bruce C, 2002, THORAX, V57, P361, DOI 10.1136/thorax.57.4.361; Brugiere O, 2005, EUR RESPIR J, V25, P813, DOI 10.1183/09091936.05.00057004; Brussee JE, 2005, EUR RESPIR J, V25, P455, DOI 10.1183/09031936.05.00079604; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Buchvald F, 2003, CLIN EXP ALLERGY, V33, P1735, DOI 10.1111/j.1365-2222.2003.01822.x; Buchvald F, 2003, ANN ALLERG ASTHMA IM, V91, P309; Buchvald F, 2001, AM J RESP CRIT CARE, V163, P699; Byrnes CA, 1997, PEDIATR PULM, V24, P312; Canady RG, 1999, AM J RESP CRIT CARE, V159, P311; Cardinale F, 2005, PEDIATR ALLERGY IMMU, V16, P236, DOI 10.1111/j.1399-3038.2005.00265.x; Colon-Semidey AJ, 2000, PEDIATR PULM, V30, P385, DOI 10.1002/1099-0496(200011)30:5<385::AID-PPUL4>3.0.CO;2-#; Corbelli R, 2004, CHEST, V126, P1054, DOI 10.1378/chest.126.4.1054; CREMONA G, 1995, EUR RESPIR J, V8, P1883, DOI 10.1183/09031936.95.08111883; Daniel PF, 2005, PEDIATR ALLERGY IMMU, V16, P248, DOI 10.1111/j.1399-3038.2005.00209.x; de Gouw HWFM, 1998, EUR RESPIR J, V11, P126, DOI 10.1183/09031936.98.11010126; de Kluijver J, 2002, AM J RESP CRIT CARE, V166, P294, DOI 10.1164/rccm.2112097; del Giudice MM, 2004, J ASTHMA, V41, P759, DOI 10.1081/JAS-200027862; Delgado-Corcoran Claudia, 2004, Pediatr Crit Care Med, V5, P48, DOI 10.1097/01.CCM.0000105310.00799.51; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Downey D, 2000, J PATHOL, V190, P115, DOI 10.1002/(SICI)1096-9896(200002)190:2<115::AID-PATH491>3.0.CO;2-V; Dundas I, 2006, CURR OPIN PULM MED, V12, P28, DOI 10.1097/01.mcp.0000199809.42011.58; Fisher AJ, 1998, THORAX, V53, P454; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032; Franklin PJ, 2006, EUR RESPIR J, V28, P730, DOI 10.1183/09031936.06.00007206; Franklin PJ, 2006, EUR RESPIR J, V27, P350, DOI 10.1183/09031936.06.00071005; Franklin PJ, 2004, EUR RESPIR J, V23, P369, DOI 10.1183/09031936.04.00084604; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69; Franklin PJ, 2003, THORAX, V58, P1048, DOI 10.1136/thorax.58.12.1048; Fritsch M, 2006, PEDIATR PULM, V41, P855, DOI 10.1002/ppul.20455; Fuglsang G, 1998, PEDIATR PULM, V25, P314, DOI 10.1002/(SICI)1099-0496(199805)25:5<314::AID-PPUL5>3.0.CO;2-I; Gabbay E, 2000, AM J RESP CRIT CARE, V162, P2182; Gabriele C, 2005, PEDIATR ALLERGY IMMU, V16, P243, DOI 10.1111/j.1399-3038.2005.00255.x; Gabriele C, 2006, PEDIATR RES, V60, P461, DOI 10.1203/01.pdr.0000238242.39881.64; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; Gentile DA, 2002, ACTA OTO-LARYNGOL, V122, P61, DOI 10.1080/00016480252775751; Gibson PG, 2000, EUR RESPIR J, V16, P1008; Grasemann H, 2005, AM J RESP CRIT CARE, V172, P1523, DOI 10.1164/rccm.200502-253OC; Grasemann H, 1997, PEDIATR PULM, V24, P173, DOI 10.1002/(SICI)1099-0496(199709)24:3<173::AID-PPUL2>3.0.CO;2-O; Grasemann H, 1998, ARCH DIS CHILD, V78, P49; Grasemann H, 2006, RESP RES, V7, P1, DOI 10.1186/1465-9921-7-87; Gratziou C, 2001, CLIN EXP ALLERGY, V31, P409, DOI 10.1046/j.1365-2222.2001.01001.x; Hamad AM, 2003, AM J PHYSIOL-LUNG C, V285, pL973, DOI 10.1152/ajplung.00033.2003; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Henriksen AH, 1999, EUR RESPIR J, V13, P301, DOI 10.1034/j.1399-3003.1999.13b14.x; Ho LP, 1998, THORAX, V53, P680; Ho LP, 1998, EUR RESPIR J, V12, P1290, DOI 10.1183/09031936.98.12061290; Horvath I, 2003, THORAX, V58, P68, DOI 10.1136/thorax.58.1.68; Hunt J, 2000, J PEDIATR-US, V137, P14, DOI 10.1067/mpd.2000.107526; JAIN B, 1993, BIOCHEM BIOPH RES CO, V191, P83, DOI 10.1006/bbrc.1993.1187; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 1998, THORAX, V53, P91; Jobsis Q, 1999, EUR RESPIR J, V13, P1406; Jobsis Q, 2001, THORAX, V56, P285, DOI 10.1136/thorax.56.4.285; Jobsis Q, 2001, EUR RESPIR J, V17, P898, DOI 10.1183/09031936.01.17508980; Jouaville LF, 2003, CLIN EXP ALLERGY, V33, P1506, DOI 10.1046/j.1365-2222.2003.01800.x; Kao YJ, 2001, AM J RESP CRIT CARE, V163, P532; Karadag B, 1999, EUR RESPIR J, V13, P1402, DOI 10.1183/09031936.99.13614069; Katsara M, 2006, RESP MED, V100, P1512, DOI 10.1016/j.rmed.2006.01.012; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1889; Kissoon N, 1999, PEDIATR PULM, V28, P282, DOI 10.1002/(SICI)1099-0496(199910)28:4<282::AID-PPUL8>3.3.CO;2-U; Kissoon N, 2002, PEDIATR PULM, V34, P203, DOI 10.1002/ppul.10154; Kroesbergen A, 1999, EUR RESPIR J, V14, P871, DOI 10.1034/j.1399-3003.1999.14d24.x; Latzin P, 2002, PEDIATR ALLERGY IMMU, V13, P37; Latzin P, 2006, AM J RESP CRIT CARE, V174, P1292, DOI 10.1164/rccm.200606-782OC; Leung TF, 2005, THORAX, V60, P822, DOI 10.1136/thx.2004.039321; Lex C, 2006, AM J RESP CRIT CARE, V174, P1286, DOI 10.1164/rccm.200603-352OC; Lim S, 1999, AM J RESP CRIT CARE, V159, P22; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; Loveless MO, 1997, THORAX, V52, P185; Lundberg JON, 1996, ARCH DIS CHILD, V75, P323; LUNDBERG JON, 1994, EUR RESPIR J, V7, P1501, DOI 10.1183/09031936.94.07081501; LUNDBERG JON, 1994, ACTA PHYSIOL SCAND, V152, P431, DOI 10.1111/j.1748-1716.1994.tb09826.x; Malmberg LP, 2006, PEDIATR PULM, V41, P635, DOI 10.1002/ppul.20417; Malmberg LP, 2003, THORAX, V58, P494, DOI 10.1136/thorax.58.6.494; Maniscalco M, 2002, ARCH ENVIRON HEALTH, V57, P437; Maniscalco M, 2002, AM J RESP CRIT CARE, V165, P1188; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mattes J, 2002, PEDIATR RES, V51, P190, DOI 10.1203/00006450-200202000-00011; Mattes J, 1999, EUR RESPIR J, V13, P1391, DOI 10.1183/09031936.99.13613969; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Meyts I, 2003, EUR J PEDIATR, V162, P506, DOI 10.1007/s00431-003-1215-x; Mieskonen ST, 2002, PEDIATR PULM, V33, P347, DOI 10.1002/ppul.10084; Moeller A, 2006, THORAX, V61, P514, DOI 10.1136/thx.2005.054643; Moeller A, 2004, PEDIATR PULM, V38, P250, DOI 10.1002/ppul.20055; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Moodley YP, 1999, EUR RESPIR J, V14, P822, DOI 10.1034/j.1399-3003.1999.14d17.x; Morris SM, 1994, AM J PHYSIOL, V266, P829; Murphy AW, 1998, CHEST, V114, P452, DOI 10.1378/chest.114.2.452; Narang I, 2002, THORAX, V57, P586, DOI 10.1136/thorax.57.7.586; Nelson BV, 1997, J PEDIATR-US, V130, P423, DOI 10.1016/S0022-3476(97)70204-X; *NIH NAT HEART LUN, 2002, NIH PUBLICATION; Nordvall SL, 2005, ALLERGY, V60, P469, DOI 10.1111/j.1398-9995.2005.00735.x; Ojoo JC, 2005, THORAX, V60, P22, DOI 10.1136/thx.2003.017327; Olin AC, 2001, RESP MED, V95, P153, DOI 10.1053/rmed.2000.1010; Overbeck SE, 2005, CHEST, V128, P1121, DOI 10.1378/chest.128.3.1121; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Payne DNR, 2001, AM J RESP CRIT CARE, V164, P1376; Pedroletti C, 2003, PEDIATR RES, V54, P496, DOI 10.1203/01.PDR.0000081761.33822.36; PERSSON MG, 1994, EUR J PHARM-ENVIRON, V270, P273, DOI 10.1016/0926-6917(94)90001-9; Piacentini GL, 2000, PEDIATR PULM, V29, P430, DOI 10.1002/(SICI)1099-0496(200006)29:6<430::AID-PPUL3>3.0.CO;2-0; Piacentini GL, 1998, AM J RESP CRIT CARE, V158, P1299; Piacentini GL, 2002, THORAX, V57, P771, DOI 10.1136/thorax.57.9.771; Piacentini GL, 1999, EUR RESPIR J, V13, P1386, DOI 10.1183/09031936.99.13613919; Piacentini GL, 2000, EUR RESPIR J, V15, P839, DOI 10.1034/j.1399-3003.2000.15e05.x; Pijnenburg MW, 2006, PEDIATR ALLERGY IMMU, V17, P189, DOI 10.1111/j.1399-3038.2006.00394.x; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; Pijnenburg MW, 2005, AM J RESP CRIT CARE, V172, P831, DOI 10.1164/rccm.200503-458OC; Pijnenburg MWH, 2002, EUR RESPIR J, V20, P919, DOI 10.1183/09031936.02.01282002; Prasad A, 2006, RESP MED, V100, P167, DOI 10.1016/j.rmed.2005.03.039; Ratjen F, 2000, PEDIATR ALLERGY IMMU, V11, P230, DOI 10.1034/j.1399-3038.2000.00093.x; Ricciardolo FLM, 2003, THORAX, V58, P175, DOI 10.1136/thorax.58.2.175; Ricciardolo FLM, 2004, PHYSIOL REV, V84, P731, DOI 10.1152/physrev.00034.2003; Riley MS, 1997, CHEST, V111, P44, DOI 10.1378/chest.111.1.44; Roberts G, 2004, THORAX, V59, P752, DOI 10.1136/thx.2003.008722; ROIHA H, 2006, EUR RESPIR J, V29, P251, DOI 10.1183/09031936.00016106; Rolla G, 1998, ANN INTERN MED, V129, P375; Rolla G, 2000, J RHEUMATOL, V27, P1693; Rosias PPR, 2004, PEDIATR PULM, V38, P107, DOI 10.1002/ppul.20056; Saito J, 2004, J ALLERGY CLIN IMMUN, V114, P512, DOI 10.1016/j.jaci.2004.05.033; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Sanders SP, 2001, J ALLERGY CLIN IMMUN, V107, P235, DOI 10.1067/mai.2001.112028; Silkoff PE, 1999, AM J RESP CRIT CARE, V159, P940; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Silkoff PE, 1997, AM J RESP CRIT CARE, V155, P260; Silvestri M, 1999, EUR RESPIR J, V13, P321, DOI 10.1034/j.1399-3003.1999.13b17.x; Silvestri M, 2001, THORAX, V56, P857, DOI 10.1136/thorax.56.11.857; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sorkness CA, 2007, J ALLERGY CLIN IMMUN, V119, P64, DOI 10.1016/j.jaci.2006.09.042; Spallarossa D, 2001, J ASTHMA, V38, P545; Spergel JM, 2005, J ASTHMA, V42, P879, DOI 10.1080/02770900500371344; Steerenberg PA, 2003, THORAX, V58, P242, DOI 10.1136/thorax.58.3.242; Stirling RG, 1998, THORAX, V53, P1030; Storme L, 1998, ARCH PEDIATRIE, V5, P389, DOI 10.1016/S0929-693X(98)80025-0; Straub DA, 2005, CHEST, V127, P509, DOI 10.1378/chest.127.2.509; Straub DA, 2005, EUR RESPIR J, V25, P289, DOI 10.1183/09031936.05.00031904; Strunk RC, 2003, J ALLERGY CLIN IMMUN, V112, P883, DOI 10.1067/mai.2003.1795; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; Taylor DR, 2006, THORAX, V61, P817, DOI 10.1136/thx.2005.056093; Taylor ES, 2004, AM J RESP CRIT CARE, V169, P1019, DOI 10.1164/rccm.200310-1473OC; ten Hacken NHT, 1998, AM J RESP CRIT CARE, V158, P902; Terada A, 2001, AM J RESP CRIT CARE, V164, P1879; Thomas PS, 2005, J ASTHMA, V42, P291, DOI 10.1081/JAS-200057908; Tsai YG, 2001, J PEDIATR-US, V139, P433, DOI 10.1067/mpd.2001.116295; Tsang KW, 2002, CHEST, V121, P88, DOI 10.1378/chest.121.1.88; Uetani K, 2000, J IMMUNOL, V165, P988; Vahlkvist S, 2006, J ALLERGY CLIN IMMUN, V117, P1272, DOI 10.1016/j.jaci.2006.03.018; van Amsterdam JGC, 2003, CLIN EXP ALLERGY, V33, P187, DOI 10.1046/j.1365-2222.2003.01597.x; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953; van Rensen ELJ, 1999, THORAX, V54, P403; Verleden GM, 2004, TRANSPLANTATION, V78, P730, DOI 10.1097/01.tp.0000131814.44106.c0; Warke TJ, 2004, J ASTHMA, V41, P751, DOI 10.1081/JAS-200027838; Warke TJ, 2003, ARCH ENVIRON HEALTH, V58, P613, DOI 10.3200/AEOH.58.10.613-616; WARKE TJ, 2003, THORAX, V58, P281; Wildhaber JH, 1999, AM J RESP CRIT CARE, V159, P74; WILSON N, 1995, ARCH DIS CHILD, V72, P317; Wilson NM, 2000, THORAX, V55, P768, DOI 10.1136/thorax.55.9.768; Wong GWK, 2005, CLIN EXP ALLERGY, V35, P889, DOI 10.1111/j.1365-2222.2005.02263.x; Xue C, 1996, J HISTOCHEM CYTOCHEM, V44, P463; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; Yates DH, 1997, EUR RESPIR J, V10, P1483, DOI 10.1183/09031936.97.10071483; Yates DH, 1996, EUR RESPIR J, V9, P1130, DOI 10.1183/09031936.96.09061130; Yates DH, 2001, AM J RESP CRIT CARE, V164, P1043; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; Zeiger RS, 2006, J ALLERGY CLIN IMMUN, V117, P45, DOI 10.1016/j.jaci.2005.10.012	198	71	76	1	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2008	38	2					246	259		10.1111/j.1365-2222.2007.02897.x		14	Allergy; Immunology	Allergy; Immunology	253CB	WOS:000252495200003	18076708	
J	Hernandez-Diaz, S; Van Marter, LJ; Werler, MM; Louik, C; Mitchell, AA				Hernandez-Diaz, Sonia; Van Marter, Linda J.; Werler, Martha M.; Louik, Carol; Mitchell, Allen A.			Risk factors for persistent pulmonary hypertension of the newborn	PEDIATRICS			English	Article						pulmonary hypertension; newborn; PPHN; epidemiology; race; BMI; Cesarean section	EXTRACORPOREAL MEMBRANE-OXYGENATION; NEONATAL RESPIRATORY MORBIDITY; ELECTIVE CESAREAN-SECTION; BIRTH-DEFECTS; NITRIC-OXIDE; DELIVERY; LABOR; PREGNANCY; TERM; EXPOSURE	Objective. Persistent pulmonary hypertension of the newborn, a clinical syndrome that results from the failure of the normal fetal-to-neonatal circulatory transition, is associated with substantial infant mortality and morbidity. We performed a case-control study to determine possible antenatal and perinatal predictors of persistent pulmonary hypertension of the newborn. Methods. Between 1998 and 2003, the Slone Epidemiology Center enrolled 377 mothers of infants with persistent pulmonary hypertension of the newborn and 836 mothers of matched control subjects. Within 6 months of delivery, study nurses interviewed participants regarding demographic, medical, and obstetric characteristics. Results. Factors that were independently associated with an elevated risk for persistent pulmonary hypertension of the newborn were infant male gender and black or Asian maternal race compared with white race. High prepregnancy BMI (> 27 vs < 20) was also associated with persistent pulmonary hypertension of the newborn, as were diabetes and asthma. Compared with infants who were delivered vaginally, the risk for persistent pulmonary hypertension of the newborn was higher for those who were born by cesarean section. Compared with infants who were born within 37 to 41 gestational weeks, the risk was higher for those who were born between 34 and 37 completed weeks and for those born beyond 41 weeks. Compared with infants within the 10th and 90th percentiles of birth weight for gestational age distribution, the risk was higher for infants above the 90th percentile. Conclusions. Our findings suggest an increased risk for persistent pulmonary hypertension of the newborn associated with cesarean delivery; late preterm or postterm birth; being large for gestational age; and maternal black or Asian race, overweight, diabetes, and asthma. It remains unclear whether some of these factors are direct causes of persistent pulmonary hypertension of the newborn or simply share common causes with it; however, clinicians should be alert to the increased need for monitoring and intervention among pregnancies with these risk factors.	Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Newborn Med, Boston, MA 02115 USA	Mitchell, AA (reprint author), Boston Univ, Slone Epidemiol Ctr, 1010 Commonwealth Ave, Boston, MA 02215 USA.	amitchell@slone.bu.edu		Louik, Carol/0000-0001-5429-5084; Werler, Martha/0000-0003-3392-6814; Mitchell, Allen/0000-0003-0950-6799	NHLBI NIH HHS [HL50763]		Abman S H, 1999, Pediatr Pulmonol Suppl, V18, P201; Anderson JL, 2005, EPIDEMIOLOGY, V16, P87, DOI 10.1097/01.ede.0000147122.97061.bb; Bearer C, 1997, ENVIRON HEALTH PERSP, V105, P202; BROWN MJ, 1983, J PHYSIOL-LONDON, V344, P137; Clark Reese H, 2003, J Perinatol, V23, P300, DOI 10.1038/sj.jp.7210908; Clark RH, 2000, NEW ENGL J MED, V342, P469, DOI 10.1056/NEJM200002173420704; Dakshinamurti S, 2005, PEDIATR PULM, V39, P492, DOI 10.1002/ppul.20201; Farrow KN, 2005, SEMIN PERINATOL, V29, P8, DOI 10.1053/j.sempert.2005.02.003; Fricker J, 1996, LANCET, V347, P1397, DOI 10.1016/S0140-6736(96)91029-6; GERSONY WM, 1969, CIRCULATION S3, V39, P87; GLASS P, 1995, J PEDIATR-US, V127, P447, DOI 10.1016/S0022-3476(95)70082-X; GOLDBERG SJ, 1971, PEDIATRICS, V48, P528; HAGEMAN JR, 1984, AM J DIS CHILD, V138, P592; HALES KA, 1993, INT J GYNECOL OBSTET, V43, P35, DOI 10.1016/0020-7292(93)90271-W; HERITAGE CK, 1985, AM J OBSTET GYNECOL, V152, P627; Hernan MA, 2002, AM J EPIDEMIOL, V155, P176, DOI 10.1093/aje/155.2.176; Hook B, 1997, PEDIATRICS, V100, P348, DOI 10.1542/peds.100.3.348; Jaillard S, 2003, J PERINAT MED, V31, P538, DOI 10.1515/JPM.2003.084; KESZLER M, 1992, PEDIATRICS, V89, P670; Levine EM, 2001, OBSTET GYNECOL, V97, P439, DOI 10.1016/S0029-7844(00)01150-9; McMahon MJ, 1996, NEW ENGL J MED, V335, P689, DOI 10.1056/NEJM199609053351001; MITCHELL AA, 1981, JAMA-J AM MED ASSOC, V245, P2311; MITCHELL AA, 1986, AM J EPIDEMIOL, V123, P670; MORRISON JJ, 1995, BRIT J OBSTET GYNAEC, V102, P101, DOI 10.1111/j.1471-0528.1995.tb09060.x; REECE EA, 1987, OBSTET GYNECOL, V70, P696; Ros HS, 1998, AM J EPIDEMIOL, V147, P1062; Sorof JM, 2003, PEDIATRICS, V111, P61, DOI 10.1542/peds.111.1.61; van den Berg A, 2001, EUR J OBSTET GYN R B, V98, P9, DOI 10.1016/S0301-2115(01)00292-5; VanMarter LJ, 1996, PEDIATRICS, V97, P658; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Walsh-Sukys MC, 2000, PEDIATRICS, V105, P14, DOI 10.1542/peds.105.1.14; WALSHSUKYS MC, 1993, CLIN PERINATOL, V20, P127; WHITE E, 1985, AM J EPIDEMIOL, V121, P651	33	71	76	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	AUG	2007	120	2					E272	E282		10.1542/peds.2006-3037		11	Pediatrics	Pediatrics	196SY	WOS:000248503500049	17671038	
J	Bourdin, A; Neveu, D; Vachier, I; Paganin, F; Godard, P; Chanez, P				Bourdin, Arnaud; Neveu, Dorine; Vachier, Isabelle; Paganin, Fabrice; Godard, Philippe; Chanez, Pascal			Specificity of basement membrane thickening in severe asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; COPD; remodeling; basement membrane; ROC	AIR-FLOW OBSTRUCTION; SUBEPITHELIAL FIBROSIS; COLLAGEN DEPOSITION; BRONCHIAL-ASTHMA; WALL THICKNESS; LUNG-FUNCTION; EXPRESSION; MATRIX-METALLOPROTEINASE-9; INFLAMMATION; TRANSITION	Background: Reticular basement membrane (RBM) thickness is considered a hallmark for airway remodeling in airway diseases such as asthma. It is still unclear whether this measurement could be associated with disease severity or apply to chronic obstructive pulmonary disease (COPD). A wide range of results, at baseline or after therapeutic intervention, have been reported using different measurement methods. Objective: To determine whether increased RBM thickness could be associated specifically with severe asthma and in COPD in large samples. Methods: We blindly measured RBM thickness in endobronchial biopsies from 50 patients with severe asthma (mean age, 53 years; FEV1 66% predicted, inhaled steroids >= 1500 mu g and 20 mg daily dose of oral corticosteroids, lifelong nonsmokers), 50 untreated patients with mild asthma mean age, 33 years; FEV, 93%pred, lifelong nonsmokers), 50 patients with COPD (mean age, 57 years; FEV1 53%pred, all current smokers), and 18 control subjects using 2 different validated quantitative and computer-assisted methods (repeated multiple point-to-point vs area by length ratio). Results: Reticular basement membrane thickness was higher in severe asthma compared with mild asthma and COPD (P =.0053). On the basis of receiver operating characteristic curves, RBM thickness was effective in differentiating severe asthma from other groups (sensitivity and specificity, 98% and 95%, respectively, above a threshold of 5 mu m vs control, 70% and 75% at 7 mu m vs mild, 83% and 68% at 6 mu m vs COPD). Conclusion: Increased RBM thickness was specifically associated with severe asthma, whereas surprisingly, COPD and mild asthma had similar remodeling features. Clinical implications: Reticular basement membrane thickness can be considered a hallmark of severe asthma.	CHU Montpellier, Hop Arnaud De Villeneuve, Serv Malad Resp, Montpellier, France; CHU Montpellier, Hop Arnaud De Villeneuve, Dept Med Informat, Montpellier, France	Chanez, P (reprint author), Hop Arnaud De Villeneuve, F-34295 Montpellier 5, France.	chanez@montp.inserm.fr		Vachier, Isabelle/0000-0003-2730-5165			American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Bel EH, 2004, CURR OPIN PULM MED, V10, P44, DOI 10.1097/00063198-200401000-00008; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; BLAND JM, 1986, LANCET, V1, P307; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207.710OC; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; Corsico A, 2003, J APPL PHYSIOL, V95, P441, DOI 10.1152/japplphysiol.01018.2002; Deykin A, 2002, AM J RESP CRIT CARE, V165, P1597, DOI 10.1164/rccm.2201081; Elston WJ, 2004, EUR RESPIR J, V24, P375, DOI 10.1183/09031936.04.00063003; Fabbri LM, 2003, AM J RESP CRIT CARE, V167, P418, DOI 10.1164/rccm.200203-183OC; Ferrando RE, 2003, J ALLERGY CLIN IMMUN, V112, P1243, DOI 10.1016/j.jaci.2003.09.038; Fouty B, 2006, EUR RESPIR J, V27, P1160, DOI 10.1183/09031936.06.00078605; HANLEY JA, 1982, RADIOLOGY, V143, P29; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; Jeffery P, 2003, AM J RESP CRIT CARE, V168, pS1, DOI 10.1164/rccm.200202-150WS; Jeffery Peter K, 2004, Proc Am Thorac Soc, V1, P176, DOI 10.1513/pats.200402-009MS; KIDA K, 1983, AM REV RESPIR DIS, V128, P125; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Milanese M, 2001, J APPL PHYSIOL, V91, P1035; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; *NIH, 2001, NHLBI WHO WORKSH BET; *NIH, 2002, NHLBI WHO WORKSH BET; ROCHE WR, 1989, LANCET, V1, P520; Saglani S, 2006, EUR RESPIR J, V28, P505, DOI 10.1183/09031936.06.00056405; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Sullivan P, 1998, EUR RESPIR J, V12, P811, DOI 10.1183/09031936.98.12040811; Ward C, 2005, J HEART LUNG TRANSPL, V24, P533, DOI 10.1016/j.healun.2004.02.018; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	33	71	76	0	0	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2007	119	6					1367	1374		10.1016/j.jaci.2007.01.055		8	Allergy; Immunology	Allergy; Immunology	178PO	WOS:000247232800011	17481707	
J	Locke, NR; Royce, SG; Wainewright, JS; Samuel, CS; Tang, ML				Locke, Natasha R.; Royce, Simon G.; Wainewright, Jacquetta S.; Samuel, Chrishan S.; Tang, Mimi L.			Comparison of airway remodeling in acute, subacute, and chronic models of allergic airways disease	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						asthma; fibrosis; inflammation; mice	MURINE MODEL; MOUSE MODEL; EXPERIMENTAL ASTHMA; CHILDHOOD ASTHMA; BRONCHIAL-ASTHMA; ATOPIC ASTHMA; ANIMAL-MODELS; INFLAMMATION; FIBROSIS; EXPRESSION	The relationship between airway inflammation and structural changes of airway remodeling, and their relative effects on airway function, are poorly understood. Remodeling is thought to result from chronic repetitive injury to the airway wall caused by airway inflammation; however, the mechanisms regulating remodeling changes have not been clearly defined. We examined the sequence of events in remodeling using three commonly used mouse models of allergic airways disease in which mice are exposed to nebulized ovalbumin for four consecutive days (acute), seven consecutive days (subacute), or three times a week for 6 wk (chronic). Surprisingly, we found that a very short period of exposure to ovalbumin was sufficient to elicit early changes of remodeling. Goblet cell hyperplasia and epithelial thickening were evident after just 4 d. In chronically challenged mice, these changes persisted and, in addition, subepithelial Collagen deposition was significantly increased. This Collagen deposition was associated with a failure to upregulate matrix metalloproteinase (MIMP)-2, in conjunction with increased transforming growth factor-beta and MMP-9 expression. The relationship between inflammation, remodeling changes, and airway hyperresponsiveness (AHR) were examined. The acute and subacute models exhibited marked airway inflammation, whereas the chronic model had very modest inflammation. Conversely, airway fibrosis was only evident in the chronic model. AHR was present in all three models; however, it was significantly higher in the chronic model compared with the acute (P < 0.05) and subacute (P < 0.05) models. These data demonstrate that both airway inflammation and airway fibrosis may contribute to AHR, with airway fibrosis leading to the greatest increases in AHR.	Royal Childrens Hosp, Dept Allergy & Immunol, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Univ Melbourne, Howard Florey Inst Expt Physiol & Med, Parkville, Vic 3052, Australia	Tang, ML (reprint author), Royal Childrens Hosp, Dept Allergy & Immunol, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	mimi.tang@rch.org.au					Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chiappara G, 2001, Curr Opin Allergy Clin Immunol, V1, P85, DOI 10.1097/00130832-200102000-00015; Cockcroft DW, 2006, J ALLERGY CLIN IMMUN, V118, P551, DOI 10.1016/j.jaci.2006.07.012; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; Foster PS, 2000, LAB INVEST, V80, P655; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLOP PM, 1975, PHYSIOL REV, V55, P418; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Kenyon NJ, 2003, TOXICOL APPL PHARM, V186, P90, DOI 10.1016/S0041-008X(02)00025-X; Keramidaris E, 2001, J ALLERGY CLIN IMMUN, V107, P734, DOI 10.1067/mai.2001.114050; Kumar RK, 2002, LAB INVEST, V82, P495; Kumar RK, 2001, IMMUNOL CELL BIOL, V79, P141, DOI 10.1046/j.1440-1711.2001.00981.x; Lee CG, 2004, J EXP MED, V200, P377, DOI 10.1084/jem.20040104; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; Leung SY, 2004, CLIN EXP ALLERGY, V34, P213, DOI 10.1111/j.1365-2222.2004.01870.x; MAKINO S, 1995, ALLERGY PROC, V16, P13, DOI 10.2500/108854195778690110; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; MORENO RH, 1986, AM REV RESPIR DIS, V133, P1171; Nagao K, 2003, AM J RESP CELL MOL, V29, P314, DOI 10.1165/rcmb.2003-0035OC; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; Pohunek P, 1997, EUR RESPIR J, V10, P160; Ramos-Barbon D, 2004, CLIN REV ALLERG IMMU, V27, P3, DOI 10.1385/CRIAI:27:1:003; Rankin JA, 1996, P NATL ACAD SCI USA, V93, P7821, DOI 10.1073/pnas.93.15.7821; Richter A, 2001, AM J RESP CELL MOL, V25, P385; ROCHE WR, 1989, LANCET, V1, P520; Sakai K, 2001, INT ARCH ALLERGY IMM, V126, P126, DOI 10.1159/000049503; SAMUEL CS, 1996, ENDOCRINOLOGY, V137, P3384; Scherf W, 2005, EUR J IMMUNOL, V35, P198, DOI 10.1002/eji.200425209; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Shirakawa I, 2000, Immunol Today, V21, P60; Takeda S, 2001, J NON-CRYST SOLIDS, V281, P1, DOI 10.1016/S0022-3093(00)00422-1; Temelkovski J, 1998, THORAX, V53, P849; VANESSENZANDVLIET EE, 1994, EUR RESPIR J, V7, P63, DOI 10.1183/09031936.94.07010063; Vercelli D, 2003, CURR OPIN IMMUNOL, V15, P609, DOI 10.1016/j.coi.2003.09.005; Wegmann M, 2005, E SCHERING RES FDN W, V50, P69; WIGGS BR, 1990, J APPL PHYSIOL, V69, P849; Wiggs BR, 1992, AM REV RESPIR DIS, V145, P1249; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	47	71	82	0	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAY	2007	36	5					625	632		10.1165/rcmb.2006-0083OC		8	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	162BW	WOS:000246062500014	17237192	
J	Leggat, PA; Smith, DR; Kedjarune, U				Leggat, Peter A.; Smith, Derek R.; Kedjarune, Ureporn			Surgical applications of cyanoacrylate adhesives: A review of toxicity	ANZ JOURNAL OF SURGERY			English	Review						cyanoacrylate; medical; occupational allergy; occupational asthma; occupational skin disease; surgery; toxic effect	CELL-CULTURE METHOD; TISSUE ADHESIVE; ISOBUTYL CYANOACRYLATE; CAROTID-ARTERY; CYTO-TOXICITY; SURGERY; GLUE; 2-CYANOACRYLATE; CYTOTOXICITY; MANAGEMENT	Cyanoacrylate (CA) and its homologues have a variety of medical and commercial applications as biological adhesives and sealants. Homologues of CA are being widely promoted in surgery as a tissue adhesive to replace traditional suturing techniques. Potential benefits of using CA adhesives include better cosmetic results, more rapid wound closure, and perhaps most significantly, the potential for significant reductions in percutaneous injuries from suture needles, which would in turn also reduce the risk of transmission of infectious diseases. Nevertheless, certain concerns have been raised regarding the potential toxicity of CA within patients, as well as among health professionals who are occupationally exposed when using CA compounds. Reported toxicity of CA in the workplace may result in dermatological, allergic and respiratory conditions. To help reduce the occupational burden, therefore, medical staff using CA adhesives should avoid direct contact with the compound and use appropriate personal protective measures at all times. Maintaining higher levels of humidity, optimizing room ventilation and using special air conditioning filters in surgical suites and operating theatres may also be useful in minimizing the exposure to volatile CA adhesives.	James Cook Univ N Queensland, Anton Breinl Ctr Publ Hlth & Trop Med, Townsville, Qld 4811, Australia; NIOSH, Int Ctr Res Promot & Informat, Kawasaki, Kanagawa, Japan; Prince Songkla Univ, Fac Dent, Dept Oral Biol & Occlus, Hat Yai, Thailand	Leggat, PA (reprint author), James Cook Univ N Queensland, Anton Breinl Ctr Publ Hlth & Trop Med, Townsville, Qld 4811, Australia.	peter.leggat@jcu.edu.au	Smith, Derek/F-4844-2010	Smith, Derek/0000-0002-8202-2523			Agarwal A, 1998, BRIT J NEUROSURG, V12, P213, DOI 10.1080/02688699845014; ANDERSEN M, 1982, MUTAT RES, V102, P373, DOI 10.1016/0165-1218(82)90100-8; APPLEBAUM JS, 1993, ANN EMERG MED, V22, P1190, DOI 10.1016/S0196-0644(05)80988-6; BELSITO DV, 1987, CONTACT DERMATITIS, V17, P234, DOI 10.1111/j.1600-0536.1987.tb02719.x; BENSON AL, 1975, AM IND HYG ASSOC J, V36, P741, DOI 10.1080/0002889758507333; CARY R, 2001, METHYL CYANOACRYLATE; Causton B. E., 1992, MAT SCI TECHNOLOGY C, V14, P291; CIAPETTI G, 1994, BIOMATERIALS, V15, P92, DOI 10.1016/0142-9612(94)90256-9; CIAPETTI G, 1994, BIOMATERIALS, V15, P63, DOI 10.1016/0142-9612(94)90199-6; Conde-Salazar L, 1998, Am J Contact Dermat, V9, P188, DOI 10.1016/S1046-199X(98)90024-0; Coover Jr HW, 1959, SOC PLAST ENG J, V15, P413; Coulthard P, 2002, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004287; DEBLANCO LP, 1994, ENDOD DENT TRAUMATOL, V10, P15; ERICA L, 1997, CURR OPIN PEDIATR, V9, P459; Esposito C, 2004, SURG ENDOSC, V18, P290, DOI 10.1007/s00464-003-9032-x; Goodman M, 2000, J TOXICOL ENV HEAL A, V59, P135, DOI 10.1080/009841000156943; Guin JD, 1998, INT J DERMATOL, V37, P31, DOI 10.1046/j.1365-4362.1998.00252.x; HANFT JR, 1991, J AM PODIAT MED ASSN, V81, P653; Horsley WS, 1997, ANN THORAC SURG, V63, P1492, DOI 10.1016/S0003-4975(97)00115-X; Juan GM, 1999, NEUROL MED-CHIR, V39, P908, DOI 10.2176/nmc.39.908; JUAN GM, 1999, NEUROL MED CHIR TOKY, V39, P912; Kanerva L, 1997, CONTACT DERMATITIS, V37, P255, DOI 10.1111/j.1600-0536.1997.tb02460.x; Kaplan M, 2005, HEART SURG FORUM, V8, pE169, DOI 10.1532/HSF98.20041126; Kawamura S, 1998, NEUROL MED-CHIR, V38, P12, DOI 10.2176/nmc.38.12; KAWAMURA S, 1998, NEUROL MED CHIR TOKY, V38, P18; KILPIKARI J, 1986, Journal of Biomedical Materials Research, V20, P1095, DOI 10.1002/jbm.820200803; KIM JC, 1995, J CATARACT REFR SURG, V21, P320; KUBIAK C, 1989, BIOMATERIALS, V10, P553, DOI 10.1016/0142-9612(89)90062-8; LEAHEY AB, 1993, OPHTHALMOLOGY, V100, P173; Leggat PA, 2004, IND HEALTH, V42, P207, DOI 10.2486/indhealth.42.207; LEGGAT PA, 1999, J OCCUP HLTH SAFETY, V15, P373; LENAERTS V, 1984, BIOMATERIALS, V5, P65, DOI 10.1016/0142-9612(84)90002-4; LOWENFELS AB, 1989, ARCH SURG-CHICAGO, V124, P1284; Makary MA, 2006, WORLD J SURG, V30, P1224, DOI 10.1007/s00268-005-0605-9; MATTHEWS SCW, 1993, BRIT J BIOMED SCI, V50, P17; Maw JL, 2000, AM J OTOL, V21, P301, DOI 10.1016/S0196-0709(00)80035-6; Maw JL, 2000, AM J OTOL, V21, P310, DOI 10.1016/S0196-0709(00)80037-X; Montanaro L, 2001, BIOMATERIALS, V22, P59, DOI 10.1016/S0142-9612(00)00163-0; MULLER RH, 1990, BIOMATERIALS, V11, P590, DOI 10.1016/0142-9612(90)90084-4; Oowaki H, 2000, BIOMATERIALS, V21, P1039, DOI 10.1016/S0142-9612(99)00278-1; PAPATHEOFANIS FJ, 1989, J BIOMED MATER RES, V23, P661, DOI 10.1002/jbm.820230609; Pineros-Fernandez A, 2005, ANN PLAS SURG, V55, P188, DOI 10.1097/01.sap.0000164386.72523.3c; Quinn James, 1997, JAMA (Journal of the American Medical Association), V277, P1527, DOI 10.1001/jama.277.19.1527; Quirce S, 2001, ALLERGY, V56, P446, DOI 10.1034/j.1398-9995.2001.056005446.x; RIETVELD EC, 1987, MUTAT RES, V188, P97, DOI 10.1016/0165-1218(87)90097-8; ROBICSEK F, 1994, J CARDIAC SURG, V9, P353, DOI 10.1111/j.1540-8191.1994.tb00855.x; *ROYAL AUSTR COLL, 1998, POL INF CONTR SURG; Seewald S, 2003, ENDOSCOPY, V35, P136, DOI 10.1055/s-2003-37020; THAKEB F, 1995, ENDOSCOPY, V27, P358, DOI 10.1055/s-2007-1005714; Thumwanit V, 1999, AUST DENT J, V44, P248, DOI 10.1111/j.1834-7819.1999.tb00228.x; TORIUMI DM, 1994, OTOLARYNG CLIN N AM, V27, P203; TORIUMI DM, 1991, LARYNGOSCOPE, V101, P339; TSENG YC, 1990, J BIOMED MATER RES, V24, P1355, DOI 10.1002/jbm.820241007; Vote BJT, 2000, CLIN EXP OPHTHALMOL, V28, P437, DOI 10.1046/j.1442-9071.2000.00351.x; WESSELS IF, 1989, OPHTHALMIC SURG LAS, V20, P211; Yasuda H, 2005, NEUROPATHOLOGY, V25, P66, DOI 10.1111/j.1440-1789.2004.00590.x	56	71	75	2	30	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	APR	2007	77	4					209	213		10.1111/j.1445-2197.2007.04020.x		5	Surgery	Surgery	144KA	WOS:000244793700004	17388821	
J	Ueda, T; Niimi, A; Matsumoto, H; Takemura, M; Hirai, T; Yamaguchi, M; Matsuoka, H; Jinnai, M; Muro, S; Chin, K; Mishima, M				Ueda, Tetsuya; Niimi, Akio; Matsumoto, Hisako; Takemura, Masaya; Hirai, Toyohiro; Yamaguchi, Masafumi; Matsuoka, Hirofumi; Jinnai, Makiko; Muro, Shigeo; Chin, Kazuo; Mishima, Michiaki			Role of small airways in asthma: Investigation using high-resolution computed tomography	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; small airways; high-resolution computed tomography; lung density; airway responsiveness; airway inflammation; airway remodeling; air trapping	OBSTRUCTIVE PULMONARY-DISEASE; LOW-ATTENUATION AREAS; CT LUNG DENSITOMETRY; WALL THICKNESS; SPUTUM INDUCTION; FATAL ASTHMA; DISTAL LUNG; INFLAMMATION; EMPHYSEMA; HYDROFLUOROALKANE	Background: Small airways may have an important role in asthma but are more difficult to assess pathologically than central airways. Computed tomographic indices of lung density are assumed to reflect air trapping and may be a useful noninvasive measure of small airways disease, but their pathophysiological relevance remains undetermined. Objective: To evaluate lung density on high-resolution computed tomography and examine its correlations with clinical and physiologic variables in 29 patients with stable asthma. Methods: Both lungs were scanned at full-inspiratory and fullexpiratory phases to quantify percentage of lung field occupied by low attenuation area (LAA%; < -960 Hounsfield units) and mean lung density. Asthma severity, pulmonary function, methacholine airway sensitivity and reactivity, and sputum eosinophil counts were evaluated. Results: The mean lung density increased and LAA% decreased in all patients at expiratory phase compared with inspiratory phase. The inspiratory density indices and expiratory mean lung density correlated only with FEV1/forced vital capacity (FVC). Expiratory LAA% correlated more strongly than other variables with FEV1/FVC and with indices of peripheral airflow obstruction. Expiratory/inspiratory ratios of LAA% and mean lung density correlated, the former more strongly, with disease severity, residual volume/total lung capacity, and airway sensitivity, as well as with indices of global (FEV1 and FEV1/FVC) and peripheral airflow obstruction. Conclusion: Expiratory/inspiratory high-resolution computed tomography is useful for assessing small airways disease in asthma. Small airways involvement is associated with airflow obstruction, airway hypersensitivity, and more severe disease. Clinical implications: Small airways are an important therapeutic target in asthma.	Kyoto Univ, Dept Resp Med, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; Kyoto Univ, Dept Phys Thearpy Resp Med, Kyoto, Japan	Niimi, A (reprint author), Kyoto Univ, Dept Resp Med, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan.	niimi@kuhp.kyoto-u.ac.jp		Matsuoka, Hirofumi/0000-0001-5219-7501			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Balzar S, 2005, AM J RESP CRIT CARE, V171, P431, DOI 10.1164/rccm.200407-949OC; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Beigelman-Aubry C, 2002, RADIOLOGY, V223, P181, DOI 10.1148/radiol.2231010779; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V116, P983, DOI 10.1016/j.jaci.2005.07.029; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; Eda S, 1997, AM J RESP CRIT CARE, V155, P1290; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53; GELB AF, 1973, NEW ENGL J MED, V288, P395, DOI 10.1056/NEJM197302222880805; Gershman NH, 1999, J ALLERGY CLIN IMMUN, V104, P322, DOI 10.1016/S0091-6749(99)70374-X; Gevenois PA, 1996, AM J ROENTGENOL, V167, P1169; Goldin JG, 1999, J ALLERGY CLIN IMMUN, V104, pS258; Goldin JG, 1998, RADIOLOGY, V208, P321; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Guckel C, 1999, J APPL PHYSIOL, V86, P701; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; Hansell DM, 2001, EUR RESPIR J, V17, P1294, DOI 10.1183/09031936.01.00206101; Hauber HP, 2003, J ALLERGY CLIN IMMUN, V112, P58, DOI 10.1067/mai.2003.1612; in 't Veen Johannes C. C. M., 2000, American Journal of Respiratory and Critical Care Medicine, V161, P1902; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Ketai L, 2005, J ASTHMA, V42, P667, DOI 10.1080/02770900500264978; King GG, 1999, AM J RESP CRIT CARE, V159, P992; Kraft M, 1999, AM J RESP CRIT CARE, V159, P228; Kraft M, 1999, EUR RESPIR J, V14, P1403, DOI 10.1183/09031936.99.14614039; Kubo K, 1998, AM J RESP CRIT CARE, V158, P979; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Matsumoto H, 2005, THORAX, V60, P277, DOI 10.1136/thx.2004.028936; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; MCFADDEN ER, 1972, AM J MED, V52, P725, DOI 10.1016/0002-9343(72)90078-2; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Mishima M, 1999, J COMPUT ASSIST TOMO, V23, P380, DOI 10.1097/00004728-199905000-00011; Mishima M, 1999, P NATL ACAD SCI USA, V96, P8829, DOI 10.1073/pnas.96.16.8829; Mitsunobu F, 2003, AM J RESP CRIT CARE, V167, P411, DOI 10.1164/rccm.2112070; Mitsunobu F, 2001, J ASTHMA, V38, P413; Mitsunobu F, 2001, THORAX, V56, P851, DOI 10.1136/thorax.56.11.851; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Niimi A, 2004, CLIN REV ALLERG IMMU, V27, P45, DOI 10.1385/CRIAI:27:1:045; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211.1268OC; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; SAKAI N, 1994, CHEST, V106, P1319, DOI 10.1378/chest.106.5.1319; Sutherland ER, 2004, J ALLERGY CLIN IMMUN, V113, P1046, DOI 10.1016/j.jaci.2004.03.016; Takemura M, 2004, CHEST, V125, P1352, DOI 10.1378/chest.125.4.1352; TAKISHIMA T, 1981, CHEST, V80, P600, DOI 10.1378/chest.80.5.600; Zeidler MR, 2006, EUR RESPIR J, V27, P307, DOI 10.1183/09031936.06.00005605; 2004, GLOBAL STRATEGY ASTH	52	71	75	0	2	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2006	118	5					1019	1025		10.1016/j.jaci.2006.07.032		7	Allergy; Immunology	Allergy; Immunology	137GY	WOS:000244282300004	17088124	
J	Lue, KH; Lin, YH; Sun, HL; Lu, KH; Hsieh, JC; Chou, MC				Lue, Ko-Huang; Lin, Yung-Hsiang; Sun, Hai-Lun; Lu, Ko-Hsiu; Hsieh, Jie-Cheng; Chou, Ming-Chih			Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article						sublingual immunotherapy; house dust mite; asthma; IgG4	HOUSE-DUST MITE; ALLERGEN-SPECIFIC IMMUNOTHERAPY; CONTROLLED-TRIAL; ANTIBODY-LEVELS; EFFICACY; RHINITIS; EXTRACT; SAFETY; SLIT; IGG	Immunotherapy through oral routes is thought to be a valuable therapeutic option for asthma. The clinical and immunologic effects of sublingual immunotherapy (SLIT) in children with asthma caused by mites were evaluated in a double-blind, placebo-controlled study for 6 months. Patients (aged 6-12 yr) with mild-to-moderate asthma, with single sensitization to mite allergen, received either SLIT or placebo with a standardized Dermatophagoides pteronyssinus (D.p.)/D. farinae (D.f.) 50/50 extract. The cumulative dose was around 41824 IR, equivalent to 1.7 mg of D.p. and 3.0 mg of D.f. allergen. Symptom and medication scores were assessed throughout the study. Serum total immunoglobulin (Ig)E, eosinophil count, eosinophil cationic protein, specific IgE, specific IgG4, and skin sensitivity were evaluated before starting the treatment and after the treatment period. Twenty patients completed the study. At the beginning of the treatment, no differences were observed between the groups for symptom and medication scores, skin sensitivity, or immunologic parameters. After 6 months of treatment, there was a significant difference in nighttime asthma symptom scores and specific IgG4 (p < 0.05) in the SLIT group compared with the placebo group. Daytime symptom and medication scores, total IgE, eosinophil count, forced expiratory volume in 1 s, and mean evening peak expiratory flow rate reached significant differences in the SLIT group during the treatment period (p < 0.05). No severe adverse effects were reported. Our results revealed that treatment for 6 months with SLIT is clinically effective in decreasing asthmatic symptoms and medication use in children with mild-to-moderate asthma because of mite sensitivity. The clinical usefulness of this form of immunotherapy and the mechanism underlying its immunologic effects deserve further studies.	Chung Shan Med Univ Hosp, Dept Pediat, Taichung 402, Taiwan; Chung Shan Med Univ, Inst Med, Taichung, Taiwan	Lue, KH (reprint author), Chung Shan Med Univ Hosp, Dept Pediat, 110,Sect 1,Chien Kuo N Rd, Taichung 402, Taiwan.	cshy095@csh.org.tw					Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bodtger U, 2003, ALLERGY, V58, P1180, DOI 10.1046/j.1398-9995.2003.00323.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; DJURUP R, 1985, ALLERGY, V40, P469, DOI 10.1111/j.1398-9995.1985.tb00253.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; LIN KL, 1991, ANN ALLERGY, V67, P63; Lu FM, 1998, ANN ALLERG ASTHMA IM, V80, P419; Madonini E, 2000, INT J IMMUNOPATH PH, V13, P77; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Marcucci F, 2003, ALLERGY, V58, P657, DOI 10.1034/j.1398-9995.2003.00193.x; Marcucci F, 2001, ALLERGY, V56, P1091, DOI 10.1034/j.1398-9995.2001.00226.x; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno Giovanni B, 2003, Paediatr Drugs, V5, P777, DOI 10.2165/00148581-200305110-00006; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25	23	71	77	0	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.	SEP	2006	17	6					408	415		10.1111/j.1399-3038.2006.00443.x		8	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	076FG	WOS:000239941800003	16925685	
J	Beisswenger, C; Kandler, K; Hess, C; Garn, H; Felgentreff, K; Wegmann, M; Renz, H; Vogelmeier, C; Bals, R				Beisswenger, Christoph; Kandler, Kerstin; Hess, Christian; Garn, Holger; Felgentreff, Kerstin; Wegmann, Michael; Renz, Harald; Vogelmeier, Claus; Bals, Robert			Allergic airway inflammation inhibits pulmonary antibacterial host defense	JOURNAL OF IMMUNOLOGY			English	Article							INNATE IMMUNE-RESPONSE; ANTIMICROBIAL PEPTIDES; ATOPIC-DERMATITIS; LUNG INFLAMMATION; RISK-FACTORS; ASTHMA; PNEUMONIA; POLARIZATION; PATHOGENESIS; EPITHELIUM	The innate immune system of the lung is a multicomponent host defense system and in addition has an instructing role in regulating the quality and quantity of the adaptive immune response. When the interaction between innate and adaptive immunity is disturbed, pathological conditions such as asthma can develop. It was the aim of the study to investigate the effect of the allergic inflammation of the lung on the innate host defense during bacterial infection. Human bronchial epithelial cells were preinculvated with Th2 cytokines and infected with Pseudomonas aeruginosa. The effect of the Th2 cytokines on the mRNA levels of antimicrobial peptides and the antimicrobial activity of HBEC was determined. To investigate the influence of an allergic inflammation on pulmonary host defense in vivo, mice sensitized and challenged with OVA were infected with P. aeruginosa, and the number of viable bacteria in the lungs was determined together with markers of inflammation like cytokines and antimicrobial peptides. Exposure of airway epithelial cells to Th2 cytokines resulted in a significantly decreased antimicrobial activity of the cells and in suppressed mRNA levels of the antimicrobial peptide human beta-defensin 2. Furthermore, mice with allergic airway inflammation had significantly more viable bacteria in their lungs after infection. This was consistent with reduced levels of proinflammatory cytokines and of the antimicrobial peptide cathelin-related antimicrobial peptide. These results show that an allergic airway inflammation suppresses the innate antimicrobial host defense. The adaptive immune system modulates the functions of the pulmonary innate immune system.	Univ Marburg, Dept Internal Med, Div Pulm Dis, D-3550 Marburg, Germany; Univ Marburg, Dept Clin Chem & Mol Diagnost, D-3550 Marburg, Germany	Bals, R (reprint author), Hosp Univ Marburg, Dept Internal Med, Div Pulmonol, Baldingerstr 1, D-35043 Marburg, Germany.	bals@mailer.uni-marburg.de					Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; Bals Robert, 2004, J Cyst Fibros, V3 Suppl 2, P49, DOI 10.1016/j.jcf.2004.05.010; Beisswenger Christoph, 2005, V86, P55; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; Eisenbarth SC, 2004, CURR OPIN PEDIATR, V16, P659, DOI 10.1097/01.mop.0000145920.00101.e4; Jackson ML, 2004, CLIN INFECT DIS, V39, P1642, DOI 10.1086/425615; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Knight DA, 2003, RESPIROLOGY, V8, P432, DOI 10.1046/j.1440-1843.2003.00493.x; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lee SW, 2002, J KOREAN MED SCI, V17, P7; Lemanske RF, 2003, CHEST, V123, p385S, DOI 10.1378/chest.123.3_suppl.385S-a; Mahalanabis D, 2002, EPIDEMIOL INFECT, V129, P65, DOI 10.1017/S0950268802006817; Neurath MF, 2002, NAT MED, V8, P567, DOI 10.1038/nm0602-567; Nomura I, 2003, J IMMUNOL, V171, P3262; Ohmori Y, 2000, J BIOL CHEM, V275, P38095, DOI 10.1074/jbc.M006227200; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Rodriguez D, 2003, J IMMUNOL, V171, P1001; Selsted ME, 2005, NAT IMMUNOL, V6, P551, DOI 10.1038/ni1206; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Sur S, 1999, J IMMUNOL, V162, P6284; Zanetti M, 2005, CURR ISSUES MOL BIOL, V7, P179; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	24	71	74	0	1	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2006	177	3					1833	1837				5	Immunology	Immunology	065DT	WOS:000239140300060	16849494	
J	Chan, RCF; Wang, MY; Li, N; Yanagawa, Y; Onoe, K; Lee, JJ; Nel, AE				Chan, Ray Chun-Fai; Wang, Meiying; Li, Ning; Yanagawa, Yoshiki; Onoe, Kazunori; Lee, James J.; Nel, Andre E.			Pro-oxidative diesel exhaust particle chemicals inhibit LPS-induced dendritic cell responses involved in T-helper differentiation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						dendritic cells; T(H)1/T(H)2 cells; LPS; cell differentiation	NF-KAPPA-B; ANTIGEN-PRESENTING CELLS; AIRWAY INFLAMMATION; EPITHELIAL-CELLS; DEPOSITION PATTERNS; HEME OXYGENASE-1; INHALED ANTIGEN; TH2 RESPONSES; MURINE MODEL; ACTIVATION	Background: Epidemiologic studies show that exposure to ambient particulate matter leads to asthma exacerbation. Diesel exhaust particles (DEPs), a model pollutant, act as an adjuvant for allergic sensitization. Increasing evidence shows that this effect could be mediated by an effect on dendritic cells (DCs). Objective: Our aim was to elucidate the mechanism by which pro-oxidative DEP chemicals change DC function so that these antigen-presenting cells strengthen the immune response to an experimental allergen. Methods: We exposed murine bone marrow-derived DCs and a homogeneous myeloid DC line, BC1, to DEPs and organic extracts made from these particles to determine how the induction of oxidative stress affects cellular maturation, cytokine production, and activation of antigen-specific T cells. Results: DEP extracts induced oxidative stress in DCs. This change in redox equilibrium interfered in the ability of Toll-like receptor agonists to induce the expression of maturation receptors (eg, CD86, CD54, and I-A(d)) and IL-12 production. This perturbation of DC function was accompanied by decreased IFN-gamma and increased IL-10 induction in antigen-specific T cells. The molecular basis for the perturbation of DC function is the activation of a nuclear factor-erythroid 2 (NF-E2)-related factor 2-mediated signaling pathway that suppresses IL-12 production. NF-E2-related factor 2 deficiency abrogates the perturbation of DC function by DEPs. Conclusion: These data provide the first report that prooxidative DEP chemicals can interfere in T(H)1-promoting response pathways in a homogeneous DC population and provide a novel explanation for the adjuvant effect of DEPs on allergic inflammation.	Univ Calif Los Angeles, Div Clin Immunol & Allergy, Dept Med, Los Angeles, CA 90095 USA; Hokkaido Univ, Div Immunobiol, Inst Med Genet, Sapporo, Hokkaido, Japan; Mayo Clin, Div Pulm Med, Scottsdale, AZ USA	Nel, AE (reprint author), Univ Calif Los Angeles, Div Clin Immunol & Allergy, Dept Med, Los Angeles, CA 90095 USA.	anel@mednet.ucla.edu	Nel, Andre/J-2808-2012		NIAID NIH HHS [U19 AI 070453]; NIEHS NIH HHS [R01 ES 12053, R01 ES 013432, R01 ES 10553]		Akdis M, 2006, CHEM IMMUNOL ALLERGY, V91, P159; Amsen D, 2004, CELL, V117, P515, DOI 10.1016/S0092-8674(04)00451-9; An HZ, 2002, IMMUNOLOGY, V106, P38, DOI 10.1046/j.1365-2567.2002.01401.x; Balashazy I, 2000, HEALTH PHYS, V78, P147; Banning A, 2005, ANTIOXID REDOX SIGN, V7, P889, DOI 10.1089/ars.2005.7.889; Bengtsson A, 2001, CLIN EXP IMMUNOL, V123, P350, DOI 10.1046/j.1365-2249.2001.01453.x; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chan RCF, 2004, BRIT J CANCER, V90, P1636, DOI 10.1038/sj.bjc.6601706; Chapman TJ, 2005, VIROLOGY, V340, P296, DOI 10.1016/j.virol.2005.06.023; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Devouassoux G, 2002, J ALLERGY CLIN IMMUN, V109, P847, DOI 10.1067/mai.2002.122843; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Finkelman FD, 2004, J IMMUNOL, V172, P3808; Gao XQ, 2004, P NATL ACAD SCI USA, V101, P10446, DOI 10.1073/pnas.0403886101; Geiser M, 2005, ENVIRON HEALTH PERSP, V113, P1555, DOI 10.1289/ehp.8006; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1067/mai.2003.1780; Hiura TS, 1999, J IMMUNOL, V163, P5582; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; HOSKEN NA, 1995, J EXP MED, V182, P1579, DOI 10.1084/jem.182.5.1579; Justice JP, 2001, AM J PHYSIOL-LUNG C, V280, pL363; Kantengwa S, 2003, AM J RESP CRIT CARE, V167, P431, DOI 10.1164/rccm.200205-425OC; Kaye SR, 2000, J AEROSOL SCI, V31, P849, DOI 10.1016/S0021-8502(99)00565-0; Khoshnan A, 1999, J IMMUNOL, V163, P5444; Kobayashi M, 2005, ANTIOXID REDOX SIGN, V7, P385, DOI 10.1089/ars.2005.7.385; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2005, ALLERGY, V60, P271, DOI 10.1111/j.1398-9995.2005.00708.x; Laouini D, 2003, J CLIN INVEST, V112, P1058, DOI 10.1172/JCI200318246; Li N, 2004, J IMMUNOL, V173, P3467; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2002, J IMMUNOL, V169, P4531; Miyabara Y, 1998, J ALLERGY CLIN IMMUN, V102, P805, DOI 10.1016/S0091-6749(98)70021-1; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ohtani T, 2005, J IMMUNOL, V174, P2412; Peterson JD, 1998, P NATL ACAD SCI USA, V95, P3071, DOI 10.1073/pnas.95.6.3071; Phalen RF, 2006, TOXICOL SCI, V92, P126, DOI 10.1093/toxsci/kfj182; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Soares MP, 2004, J IMMUNOL, V172, P3553; Stancovski I, 1997, CELL, V91, P299, DOI 10.1016/S0092-8674(00)80413-4; Takeda K, 2004, SEMIN IMMUNOL, V16, P3, DOI 10.1016/j.smim.2003.10.003; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Winzler C, 1997, J EXP MED, V185, P317, DOI 10.1084/jem.185.2.317; Xiao GG, 2003, J BIOL CHEM, V278, P50781, DOI 10.1074/jbc.M306423200; Yanagawa Y, 2002, J LEUKOCYTE BIOL, V71, P125	45	71	72	1	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					455	465		10.1016/j.jaci.2006.06.006		11	Allergy; Immunology	Allergy; Immunology	075IH	WOS:000239877700023	16890772	
J	Sahsuvaroglu, T; Arain, A; Kanaroglou, P; Finkelstein, N; Newbold, B; Jerrett, M; Beckerman, B; Brook, J; Finkelstein, M; Gilbert, NL				Sahsuvaroglu, Talar; Arain, Altaf; Kanaroglou, Pavlos; Finkelstein, Norm; Newbold, Bruce; Jerrett, Michael; Beckerman, Bernardo; Brook, Jeffrey; Finkelstein, Murray; Gilbert, Nicolas L.			A land use regression model for predicting ambient concentrations of nitrogen dioxide in Hamilton, Ontario, Canada	JOURNAL OF THE AIR & WASTE MANAGEMENT ASSOCIATION			English	Article							PARTICULATE AIR-POLLUTION; EXPOSURE ASSESSMENT; PERSONAL EXPOSURE; ENVIRONMENTAL JUSTICE; SPATIAL VARIABILITY; CHILDHOOD ASTHMA; MAJOR HIGHWAY; URBAN AREA; CHILDREN; MORTALITY	This paper reports on the development of a land use regression (LUR) model for predicting the intraurban variation of traffic-related air pollution in Hamilton, Ontario, Canada, an industrial city at the western end of Lake Ontario. Although land use regression has been increasingly used to characterize exposure gradients within cities, research to date has yet to test whether this method can produce reliable estimates in an industrialized location. Ambient concentrations of nitrogen dioxide (NO,) were measured for a 2-week period in October 2002 at > 100 locations across the city and subsequently at 30 of these locations in May 2004 to assess seasonal effects. Predictor variables were derived for land use types, transportation, demography, and, physical geography using geographic information systems. The LUR model explained 76% of the variation in NO2. Traffic density, proximity to a highway, and industrial land use were all positively correlated with NO, concentrations, whereas open land use and distance from the lake were negatively correlated with NO2. Locations downwind of a major highway resulted in higher NO2 levels. Cross-validation of the results confirmed model stability Over different seasons. Our findings demonstrate that land use regression can effectively predict NO, variation at the intraurban scale in an industrial setting. Models predicting exposure within smaller areas may lead to improved detection of health effects in epidemiologic studies.	McMaster Univ, Sch Geog & Earth Sci, Div Biostat, Dept Prevent Med, Hamilton, ON L8S 4K1, Canada; Univ So Calif, Dept Prevent Med, Div Biostat, Los Angeles, CA 90089 USA; Environm Canada, Meteorol Serv Canada, Toronto, ON M3H 5T4, Canada; Mt Sinai Hosp, Family Med Ctr, Toronto, ON M5G 1X5, Canada; Hlth Canada, Air Hlth Effects Div, Ottawa, ON K1A 0L2, Canada	Sahsuvaroglu, T (reprint author), McMaster Univ, Sch Geog & Earth Sci, Div Biostat, Dept Prevent Med, 1280 Main St W, Hamilton, ON L8S 4K1, Canada.	sahsuvt@mcmaster.ca		Gilbert, Nicolas/0000-0001-6985-8046; Arain, M. Altaf/0000-0002-1433-5173	NIEHS NIH HHS [5P01 ES011627, 5P30 ES07048]		Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; Buzzelli M, 2003, ANN ASSOC AM GEOGR, V93, P557, DOI 10.1111/1467-8306.9303003; CHOW GC, 1960, ECONOMETRICA, V28, P591, DOI 10.2307/1910133; Cyrys J, 2005, ENVIRON HEALTH PERSP, V113, P987, DOI 10.1289/ehp.7662; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; FERGUSON E, 2004, INT J HEALTH GEOGR, V3, P24, DOI 10.1186/1476-072X-3-24; Finkelstein MM, 2003, CAN MED ASSOC J, V169, P397; Finkelstein MM, 2004, AM J EPIDEMIOL, V160, P173, DOI 10.1093/aje/kwh181; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gauvin S, 2001, ARCH ENVIRON HEALTH, V56, P336; GETIS A, 1995, US CANADA LAND PEOPL; Gilbert NL, 2003, SCI TOTAL ENVIRON, V312, P43, DOI 10.1016/S0048-9697(03)00228-6; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059; Griffith D.A., 1987, SPATIAL AUTOCORRELAT; Harrison RM, 2002, OCCUP ENVIRON MED, V59, P671, DOI 10.1136/oem.59.10.671; HEWITT CN, 1991, ATMOS ENVIRON B-URB, V25, P429; *HLTH CAN, REG REL HLTH AIR QUA; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; HUBBE J, 1997, J APPL METEOROL, V66, P1221; Isaaks EH, 1989, INTRO APPL GEOSTATIS; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Jerrett M, 2001, ENVIRON PLANN A, V33, P955, DOI 10.1068/a33137; JERRETT M, 2006, IN PRESS J TOXICOL E; Kanaroglou PS, 2005, ATMOS ENVIRON, V39, P2399, DOI 10.1016/j.atmosenv.2004.06.049; KANAROGLU P, 2003, P TRANSP AIR POLL C; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lebret E, 2000, ATMOS ENVIRON, V34, P177, DOI 10.1016/S1352-2310(99)00292-7; Linaker CH, 2000, OCCUP ENVIRON MED, V57, P472, DOI 10.1136/oem.57.7.472; Lynn P. P., 1975, Computer Applications, V2; Mage D, 1999, J AIR WASTE MANAGE, V49, P1280; Melnick A.L., 2002, INTRO GEOGRAPHIC INF; Monn C, 2001, ATMOS ENVIRON, V35, P1, DOI 10.1016/S1352-2310(00)00330-7; Mukala K, 2000, ARCH ENVIRON HEALTH, V55, P431; Mukerjee S, 2004, J AIR WASTE MANAGE, V54, P307; Nafstad P, 2004, ENVIRON HEALTH PERSP, V112, P610, DOI 10.1289/ehp.6684; Nerriere E, 2005, ENVIRON RES, V97, P32, DOI 10.1016/j.envres.2004.07.009; Odland J, 1988, SPATIAL AUTOCORRELAT; Palin LA, 2001, OCCUP ENVIRON MED, V58, P682, DOI 10.1136/oem.58.10.682; Rijnders E, 2001, ENVIRON HEALTH PERSP, V109, P411, DOI 10.2307/3434789; ROSS Z, 2005, J EXP ANAL ENV EPIDE, V15, P1; Sahsuvaroglu T., 2003, PUBLIC HLTH ASSESSME; Schwartz J, 1996, J EPIDEMIOL COMMUN H, V50, pS3, DOI 10.1136/jech.50.Suppl_1.S3; Statistics Canada, POP DWELL COUNTS CAN; THOMAS D, 1993, ANNU REV PUBL HEALTH, V14, P69; Van Atten Chris, 2005, Reviews on Environmental Health, V20, P195; Zhu YF, 2002, ATMOS ENVIRON, V36, P4323, DOI 10.1016/S1352-2310(02)00354-0	51	71	73	5	28	AIR & WASTE MANAGEMENT ASSOC	PITTSBURGH	ONE GATEWAY CENTER, THIRD FL, PITTSBURGH, PA 15222 USA	1047-3289			J AIR WASTE MANAGE	J. Air Waste Manage. Assoc.	AUG	2006	56	8					1059	1069				11	Engineering, Environmental; Environmental Sciences; Meteorology & Atmospheric Sciences	Engineering; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	070WJ	WOS:000239556300001	16933638	
J	Brightling, CE				Brightling, CE			Chronic cough due to nonasthmatic eosinophilic bronchitis - ACCP evidence-based clinical practice guidelines	CHEST			English	Article						airway smooth muscle; asthma; cough; eosinophilic bronchitis; eosinophils; mast cells	CHRONIC NONPRODUCTIVE COUGH; AIR-FLOW OBSTRUCTION; INDUCED SPUTUM; VARIANT ASTHMA; ATOPIC COUGH; INFLAMMATION; FREQUENCY; SPECTRUM; THERAPY; DISEASE	Objectives: Nonasthmatic eosinophilic bronchitis is a newly recognized cause of chronic cough. Our objective was to review the pathogenesis, natural history, diagnosis, and treatment of this condition. Methods: The current literature was reviewed using an Ovid MEDLINE and PubMed literature review for all studies published in the English language from 1963 to December 2004 using the medical subject heading term "eosinophilic bronchitis." Results: Nonasthmatic eosinophilic bronchitis is a common cause of chronic cough. it is characterized by the presence of eosinophilic airway inflammation, similar to that seen in asthma. However, in contrast to asthma, nonasthmatic eosinophilic bronchitis is not associated with variable airflow limitation or airway hyperresponsiveness. The differences in functional association are related to differences in the localization of mast cells within the airway wall, with airway smooth muscle infiltration occurring in patients with asthma, and epithelial infiltration in patients with nonasthmatic eosinophilic bronchitis. Diagnosis is made by the confirmation of eosinophilic airway inflammation usually with induced sputum analysis after the exclusion of other causes for chronic cough on clinical, radiologic, and lung function assessment. The cough usually responds well to treatment with inhaled corticosteroids. The dose and duration of treatment differ between patients. The condition can be transient, episodic, or persistent unless treated, and occasionally patients may require long-term prednisone treatment. Conclusions: Further study of this condition may improve our understanding of airway inflammation and airway responsiveness, leading to novel targets for therapeutic agents for the treatment of both asthma and nonasthmatic eosinophilic bronchitis.	Univ Hosp Leicester NHS Trust, Glenfield Gen Hosp, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	Brightling, CE (reprint author), Univ Hosp Leicester NHS Trust, Glenfield Gen Hosp, Inst Lung Hlth, Groby Rd, Leicester LE3 9QP, Leics, England.	ceb17@le.ac.uk					Ayik SO, 2003, RESP MED, V97, P695, DOI 10.1053/rmed.2003.1503; Belda J, 2000, AM J RESP CRIT CARE, V161, P475; Berlyne GS, 2000, J ALLERGY CLIN IMMUN, V106, P638, DOI 10.1067/mai.2000.109622; Berry MA, 2005, CLIN EXP ALLERGY, V35, P598, DOI 10.1111/j.1365-2222.2005.02222.x; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 1999, EUR RESPIR J, V14, P1228, DOI 10.1183/09031936.99.14512289; Brightling CE, 2000, EUR RESPIR J, V15, P682, DOI 10.1034/j.1399-3003.2000.15d10.x; Brightling CE, 2003, THORAX, V58, P528, DOI 10.1136/thorax.58.6.528; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406; Brightling CE, 2000, CLIN EXP ALLERGY, V30, P4; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brightling Christopher E., 2000, American Journal of Respiratory and Critical Care Medicine, V162, P878; Carney IK, 1997, AM J RESP CRIT CARE, V156, P211; Efthimiadis A, 2002, EUR RESPIR J, V37, p19s; Fujimura M, 2003, CLIN EXP ALLERGY, V33, P588, DOI 10.1046/j.1365-2222.2003.01658.x; Fujimura M, 2003, THORAX, V58, P14, DOI 10.1136/thorax.58.1.14; Fujimura M, 2000, CLIN EXP ALLERGY, V30, P41; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V101, P320; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; Hancox RJ, 2001, LANCET, V358, P1104, DOI 10.1016/S0140-6736(01)06224-9; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640; IRWIN RS, 1981, AM REV RESPIR DIS, V123, P413; Keatings VM, 1997, THORAX, V52, P372; Lemiere C, 1997, J ALLERGY CLIN IMMUN, V100, P852, DOI 10.1016/S0091-6749(97)70286-0; McGarvey LPA, 1998, THORAX, V53, P738; Paggiaro PL, 2002, EUR RESPIR J, V37, P3; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pavord ID, 1997, THORAX, V52, P498; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511; Pizzichini M M, 1999, Can Respir J, V6, P323	31	71	78	1	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JAN	2006	129	1		S			116S	121S		10.1378/chest.129.1_suppl.116S		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	009BT	WOS:000235086800015	16428700	
J	van Neerven, RJ; Knoll, EF; Ejrnaes, A; Wurtzen, PA				van Neerven, R. J.; Knoll, E. F.; Ejrnaes, A.; Wurtzen, P. A.			IgE-mediated allergen presentation and blocking antibodies: Regulation of T-Cell activation in allergy	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Review						allergen presentation; blocking antibodies; IgE immunotherapy	FC-EPSILON-RI; GRASS-POLLEN IMMUNOTHERAPY; LOW-AFFINITY RECEPTOR; EPIDERMAL LANGERHANS CELLS; BASOPHIL HISTAMINE-RELEASE; LATE ASTHMATIC RESPONSE; ANTIGEN-SPECIFIC IGE; HAY-FEVER PATIENTS; IN-VIVO; SERUM-IGE	it is well established that both the production of IgE by B lymphocytes and the maturation and recruitment of eosinophils in late-phase reactions are dependent on the activation of allergen-specific type-2 T-helper cells. What is less well known is the fact that efficient activation of allergen-specific T cells upon low-dose exposure to allergens is critically dependent on IgE-mediated or -facilitated allergen presentation. In fact, changes in the level of IgE-mediated allergen presentation may account for many of the immunological effects described for specific immunotherapy or anti-IgE treatment. This review aims to summarize the current knowledge, and will discuss the clinical relevance of blocking IgG antibodies induced by specific immunotherapy and anti-IgE monoclonal antibodies that both interfere with IgE-mediated allergen presentation. Copyright (c) 2006 S. Karger AG, Basel.	Univ Utrecht, Med Ctr, Dept Dermatol & Allergol, NL-3584 CX Utrecht, Netherlands; Bioceros BV, Utrecht, Netherlands; ALK Abello AS, Dept Biol Allergy Res, Horsholm, Denmark	van Neerven, RJ (reprint author), Univ Utrecht, Med Ctr, Dept Dermatol & Allergol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	jneerven@umcutrecht.nl					ADKINSON NF, 1979, J IMMUNOL, V122, P965; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis CA, 1999, FASEB J, V13, P603; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; Barata LT, 1998, J ALLERGY CLIN IMMUN, V101, P222; BEHRENS BL, 1984, AM REV RESPIR DIS, V130, P1134; BERNSTEIN IL, 1979, INT ARCH ALLER A IMM, V58, P30; BIEBER T, 1992, J EXP MED, V175, P1285, DOI 10.1084/jem.175.5.1285; Bolhaar STHP, 2004, CLIN EXP ALLERGY, V34, P761, DOI [10.1111/j.1365-2222.2004.1939.x, 10.1111/j.1365-2222.2004.01939.x]; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V79, P947, DOI 10.1016/0091-6749(87)90245-4; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BUJANOWSKIWEBER J, 1989, IMMUNOLOGY, V66, P505; Carballido JM, 1997, EUR J IMMUNOL, V27, P515, DOI 10.1002/eji.1830270224; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; CONNELL JT, 1970, J ALLERGY, V45, P115; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; DELARA JMT, 1994, ANN NY ACAD SCI, V725, P50; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Des RA, 1997, J ALLERGY CLIN IMMUN, V99, P450; DEUSCHL H, 1977, CLIN ALLERGY, V7, P315, DOI 10.1111/j.1365-2222.1977.tb01459.x; DEVEY ME, 1976, CLIN ALLERGY, V6, P227, DOI 10.1111/j.1365-2222.1976.tb01901.x; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Durham SR, 1998, J ALLERGY CLIN IMMUN, V102, P157, DOI 10.1016/S0091-6749(98)70079-X; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Ejrnaes AM, 2004, MOL IMMUNOL, V41, P471, DOI 10.1016/j.molimm.2004.04.018; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FREW AJ, 1988, J IMMUNOL, V141, P4158; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; Getahun A, 2005, J IMMUNOL, V175, P1473; GLEICH G J, 1975, Clinical Allergy, V5, P79, DOI 10.1111/j.1365-2222.1975.tb01838.x; GOLDEN DBK, 1992, J ALLERGY CLIN IMMUN, V90, P386, DOI 10.1016/S0091-6749(05)80019-3; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; Hamelmann E, 1997, AM J RESP CELL MOL, V16, P674; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Harris N, 1997, J EXP MED, V185, P177, DOI 10.1084/jem.185.1.177; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hauber HP, 2004, INT ARCH ALLERGY IMM, V134, P79, DOI 10.1159/000078384; HEYMAN B, 1993, EUR J IMMUNOL, V23, P1739, DOI 10.1002/eji.1830230754; Holgate S, 2005, J ALLERGY CLIN IMMUN, V115, P459, DOI 10.1016/j.jaci.2004.11.053; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; JAROLIM E, 1990, J ALLERGY CLIN IMMUN, V85, P996, DOI 10.1016/0091-6749(90)90043-4; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; JUTEL M, 1995, J IMMUNOL, V154, P4187; Kay AB, 2001, NEW ENGL J MED, V344, P30; Kay AB, 2001, NEW ENGL J MED, V344, P109; Keatings VM, 1997, J ALLERGY CLIN IMMUN, V99, P693, DOI 10.1016/S0091-6749(97)70032-0; KEHRY MR, 1989, P NATL ACAD SCI USA, V86, P7556, DOI 10.1073/pnas.86.19.7556; Kepley CL, 2000, J ALLERGY CLIN IMMUN, V106, P337, DOI 10.1067/mai.2000.107931; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; Langeveld-Wildschut EG, 2000, J ALLERGY CLIN IMMUN, V105, P1008, DOI 10.1067/mai.2000.106544; Lantz CS, 1997, J IMMUNOL, V158, P2517; LARSEN JN, 2000, ALLERGY S, V55, P177; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Lessof M H, 1977, Monogr Allergy, V12, P253; LESSOF MH, 1978, JOHNS HOPKINS MED J, V142, P1; Leung Donald Y. M., 2003, Journal of Allergy and Clinical Immunology, V111, pS805, DOI 10.1067/mai.2003.155; LICHTENSTEIN LM, 1968, J IMMUNOL, V101, P317; Loveless MH, 1940, J IMMUNOL, V38, P25; MacGlashan D, 1998, BLOOD, V91, P1633; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; MAURER D, 1995, J IMMUNOL, V154, P6285; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Maurer D, 1998, J IMMUNOL, V161, P2731; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; MULLER UR, 1986, J ALLERGY CLIN IMMUN, V78, P115, DOI 10.1016/0091-6749(86)90123-5; Noon L, 1911, LANCET, V1, P1572; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Novak N, 2001, CURR OPIN IMMUNOL, V13, P721, DOI 10.1016/S0952-7915(01)00285-0; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Oshiba A, 1997, J IMMUNOL, V159, P4056; OTSUKA H, 1991, CLIN EXP ALLERGY, V21, P115, DOI 10.1111/j.1365-2222.1991.tb00812.x; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PIRRON U, 1990, EUR J IMMUNOL, V20, P1547, DOI 10.1002/eji.1830200721; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1976, J CLIN INVEST, V57, P1041, DOI 10.1172/JCI108346; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 2004, J CLIN INVEST, V114, P1389, DOI 10.1172/JCI200423595; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Saini SS, 1999, J IMMUNOL, V162, P5624; SANTAMARIA LF, 1993, HUM IMMUNOL, V37, P23, DOI 10.1016/0198-8859(93)90139-R; Schwarze J, 1998, AM J RESP CRIT CARE, V158, P519; SECRIST H, 1993, J EXP MED, V178, P2123, DOI 10.1084/jem.178.6.2123; Sehra S, 2003, J IMMUNOL, V171, P2080; SQUIRE CM, 1994, J IMMUNOL, V152, P4388; Svenson M, 2003, MOL IMMUNOL, V39, P603, DOI 10.1016/S0161-5890(02)00198-0; TAKIGAWA M, 1991, CLIN EXP IMMUNOL, V84, P275; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tkaczyk C, 1998, IMMUNOLOGY, V94, P318, DOI 10.1046/j.1365-2567.1998.00525.x; Tsuyuki S, 1997, J EXP MED, V185, P1671, DOI 10.1084/jem.185.9.1671; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1111/j.1365-2222.1996.tb00591.x; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; van Neerven RJJ, 2004, CLIN EXP ALLERGY, V34, P420, DOI 10.1111/j.1365-2222.2004.01899.x; van Neerven RJJ, 2001, INT ARCH ALLERGY IMM, V124, P400, DOI 10.1159/000053770; VANDERGIESSEN M, 1976, INT ARCH ALLER A IMM, V50, P625; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; VANDERHEIJDEN FL, 1991, J INVEST DERMATOL, V97, P389, DOI 10.1111/1523-1747.ep12480966; VANDERZWAN JC, 1983, BRIT MED J, V287, P1329; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Wilson DR, 2001, J ALLERGY CLIN IMMUN, V107, P971, DOI 10.1067/mai.2001.115483; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; YOKOTA A, 1992, P NATL ACAD SCI USA, V89, P5030, DOI 10.1073/pnas.89.11.5030	124	71	72	1	4	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.		2006	141	2					119	129		10.1159/000094714		11	Allergy; Immunology	Allergy; Immunology	086NC	WOS:000240679300004	16864979	
J	Brasel, TL; Martin, JM; Carriker, CG; Wilson, SC; Straus, DC				Brasel, TL; Martin, JM; Carriker, CG; Wilson, SC; Straus, DC			Detection of airborne Stachybotrys chartarum macrocyclic trichothecene mycotoxins in the indoor environment	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							SICK BUILDING SYNDROME; PULMONARY HEMOSIDEROSIS; SATRATOXIN-G; CONTAMINATION; EXPOSURE; FUNGI; MICE; ATRA; ANGUIDINE; SAMPLERS	The existence of airborne mycotoxins in mold-contaminated buildings has long been hypothesized to be a potential occupant health risk. However, little work has been done to demonstrate the presence of these compounds in such environments. The presence of airborne macrocyclic trichothecene mycotoxins in indoor environments with known Stachybotrys chartarum contamination was therefore investigated. In seven buildings, air was collected using a high-volume liquid impaction bioaerosol sampler (SpinCon PAS 450-10) under static or disturbed conditions. An additional building was sampled using an Andersen GPS-1 PUF sampler modified to separate and collect particulates smaller than conidia. Four control buildings (i.e., no detectable S. chartarum growth or history of water damage) and outdoor air were also tested. Samples were analyzed using a macrocyclic trichothecene-specific enzyme-linked immunosorbent assay (ELISA). ELISA specificity was tested using phosphate-buffered saline extracts of the fungal genera Aspergillus, Chaetomium, Cladosporium, Fusarium, Memnoniella, Penicillium, Rhizopus, and Trichoderma, five Stachybotrys strains, and the indoor air allergens Can f 1, Der p 1, and Fel d 1. For test buildings, the results showed that detectable toxin concentrations increased with the sampling time and short periods of air disturbance. Trichothecene values ranged from < 10 to > 1,300 pg/m(3) of sampled air. The control environments demonstrated statistically significantly (P < 0.001) lower levels of airborne trichothecenes. ELISA specificity experiments demonstrated a high specificity for the trichothecene-producing strain of S. chartarum. Our data indicate that airborne macrocyclic trichothecenes can exist in Stachybotrys-contaminated buildings, and this should be taken into consideration in future indoor air quality investigations.	Texas Tech Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, Lubbock, TX 79430 USA	Straus, DC (reprint author), Texas Tech Univ, Hlth Sci Ctr, Dept Microbiol & Immunol, 3601 4th St, Lubbock, TX 79430 USA.	david.straus@ttuhsc.edu					Andersson MA, 1997, APPL ENVIRON MICROB, V63, P387; Barnes C, 2002, ANN ALLERG ASTHMA IM, V89, P29; Barnes C, 2000, ANN ALLERG ASTHMA IM, V84, P47, DOI 10.1016/S1081-1206(10)62740-8; BRASEL TL, 2004, APPL ENVIRON MICROB, V71, P114; Cage BR, 1996, ANN ALLERG ASTHMA IM, V77, P401; Chao H. J., 2001, MYCOPATHOLOGIA, V154, P93; Chung YJ, 2003, TOXICOL MECH METHOD, V13, P247, DOI [10.1080/713857196, 10.1080/15376520390223543]; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; de Hoog G. S., 2000, ATLAS CLIN FUNGI; Dharmage S, 2002, CLIN EXP ALLERGY, V32, P714, DOI 10.1046/j.1365-2222.2002.01371.x; Elidemir O, 1999, PEDIATRICS, V104, P964, DOI 10.1542/peds.104.4.964; Erwin EA, 2003, IMMUNOL ALLERGY CLIN, V23, P469, DOI 10.1016/S0889-8561(03)00004-3; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; Feinberg B, 1989, TRICHOTHECENE MYCOTO, VI, P27; GOODWIN W, 1978, CANCER, V42, P23, DOI 10.1002/1097-0142(197807)42:1<23::AID-CNCR2820420104>3.0.CO;2-I; Gorny RL, 2002, APPL ENVIRON MICROB, V68, P3522, DOI 10.1128/AEM.68.7.3522-3531.2002; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505; Gregory L, 2004, TOXICOL PATHOL, V32, P26, DOI 10.1080/01926230490360790; HARRISON J, 1992, RESP MED, V86, P225, DOI 10.1016/S0954-6111(06)80060-0; Higgins JA, 2003, APPL ENVIRON MICROB, V69, P593, DOI 10.1128/AEM.69.1.593-599.2003; Hinkley SF, 2000, METH MOL B, V157, P173, DOI 10.1385/1-59259-064-0:173; Hinkley SF, 2000, PHYTOCHEMISTRY, V55, P663, DOI 10.1016/S0031-9422(00)00231-4; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; Hossain MA, 2004, J ALLERGY CLIN IMMUN, V113, P200, DOI 10.1016/j.jaci.2003.12.018; Jarvis BB, 1998, APPL ENVIRON MICROB, V64, P3620; Jaward FM, 2004, ENVIRON SCI TECHNOL, V38, P34, DOI 10.1021/es034705n; Johanning E, 1996, INT ARCH OCC ENV HEA, V68, P207; LEHRER SB, 1983, CLIN CHEST MED, V4, P23; MARITTA S, 2002, ENV HLTH PERSPECT, V110, P543; Martin JW, 2002, ANAL CHEM, V74, P584, DOI 10.1021/ac015630d; Mason CD, 2001, TOXICOL APPL PHARM, V172, P21, DOI 10.1006/taap.2001.9127; MURPHY WK, 1978, CANCER TREAT REP, V62, P1497; PASANEN AL, 1993, ATMOS ENVIRON A-GEN, V27, P9, DOI 10.1016/0960-1686(93)90065-7; Pessi AM, 2002, APPL ENVIRON MICROB, V68, P963, DOI 10.1128/AEM.68.2.963-967.2002; Portnoy J, 2000, ANN ALLERG ASTHMA IM, V84, P19, DOI 10.1016/S1081-1206(10)62735-4; Rand T. G., 2002, Mycopathologia, V156, P119, DOI 10.1023/A:1022920205355; RAO CY, 2000, INDOOR AIR QUALITY H; Revankar SG, 2003, AM J MED SCI, V325, P262; Scheel CM, 2001, ARCH ENVIRON HEALTH, V56, P413; SCHICK MR, 1987, J IMMUNOL, V138, P3419; Shoeib M, 2002, ENVIRON SCI TECHNOL, V36, P4142, DOI 10.1021/es020635t; SMORAGIEWICZ W, 1993, INT ARCH OCC ENV HEA, V65, P113, DOI 10.1007/BF00405729; SORENSON WG, 1987, APPL ENVIRON MICROB, V53, P1370; Germaine G., 1996, IDENTIFYING FILAMENT; Sutton D. A., 1998, GUIDE CLIN SIGNIFICA; Tuomi T, 1998, ANALYST, V123, P1835, DOI 10.1039/a803813i; Wannemacher R, 1997, TXB MILITARY MED 1, P655; Wilkins CK, 1998, PHARMACOL TOXICOL, V83, P112; Wilson SC, 2004, J OCCUP ENVIRON HYG, V1, P442, DOI 10.1080/15459620490462823	50	71	72	1	18	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240			APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2005	71	11					7376	7388		10.1128/AEM.71.11.7376-7388.2005		13	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	983IN	WOS:000233225000111	16269780	
J	Fang, ZG; Ouyang, ZY; Hu, LF; Wang, XK; Zheng, H; Lin, XQ				Fang, ZG; Ouyang, ZY; Hu, LF; Wang, XK; Zheng, H; Lin, XQ			Culturable airborne fungi in outdoor environments in Beijing, China	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						culturable airborne fungi; bioaerosol; aerobiology; size distribution pattern	CONTROL CHILDREN; INDOOR AIR; BIOAEROSOLS; RESIDENCES; BUILDINGS; ALLERGENS; MICROBES; STATIONS; ASTHMA	Airborne fungi are being proposed as a cause of adverse health effects. They may adversely affect human health through allergy, infection, and toxicity. Moreover, they have a great influence on urban air quality in Beijing. In this study, a systematical survey on the culturable airborne fungi was carried out for I year in Beijing urban area. Fungal samples were collected for 3 min, three times each day, and continued for three consecutive days of each month with FA-1 sampler from three sampling sites. Results showed that the culturable fungal concentrations ranged from 24 CFU (Colony forming units) /m(3) to 13960 CFU/m(3), and the mean and median was 1165 CFU/m(3) and 710 CFU/m(3), respectively. Fungal concentrations in the greener area around the Research Center for Eco-Environmental Sciences (RCEES) and Beijing Botanical Garden (BBG) were significantly higher than in the densely urban and highly trafficked area of Xizhimen (XZM) (***P < 0.001), but no significant difference was found between RCEES and BBG (P > 0.05). The variation of fungal concentrations in different seasons was significant in RCEES and BBG, where the concentrations were higher in Summer and Autumn, and lower in Spring and Winter. However, there were no significant differences in fungal concentrations between the Spring and the Winter for three sampling sites (P > 0.05). Fourteen genera, including 40 species of culturable fungi, were identified in this study. Penicillium, with the most abundant species, which comprised more than 50% of the total isolated fungal species. Cladosporium were the most dominant fungal group, and contributed to more than one third of the total fungal concentration, followed by non-sporing isolates, Alternaria, Pencillium and Asperigillus. The concentration percentage of Cladosporium was significantly higher in RCEES than in XZM (*P < 0.05), and the concentration percentages of Penicillium (**P < 0.01) and Aspergillus (*P < 0.05) were higher in XZM than in RCEES and in BBG. For other groups' concentration percentages, no significant differences were observed among the sampling sites.	Chinese Acad Sci, Key Lab Syst Ecol, Res Ctr Ecoenvironm Sci, Beijing 100085, Peoples R China; Hunan Agr Univ, Coll Biosafety Sci & Technol, Changsha 410128, Peoples R China	Ouyang, ZY (reprint author), Chinese Acad Sci, Key Lab Syst Ecol, Res Ctr Ecoenvironm Sci, POB 2871, Beijing 100085, Peoples R China.	zyouyang@mail.rcees.ac.cn					Adhikari A, 2004, SCI TOTAL ENVIRON, V326, P123, DOI 10.1016/j.scitotenv.2003.12.007; Al-Suwaine A. S., 1999, AEROBIOLOGIA, V15, P121, DOI 10.1023/A:1007595400116; BANERJEE UC, 1987, GRANA, V26, P103; Bush R., 2001, J ALLERGY CLIN IMMUN, V107, P430, DOI 10.1067/mai.2001.113669; Cvetnic Z, 1997, ATMOS ENVIRON, V31, P491, DOI 10.1016/S1352-2310(96)00158-6; FU CL, 2000, MICROBIOLOGY, V27, P266; Giorgio C.D., 1996, ATMOS ENVIRON, V30, P155; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hameed AAA, 2001, J ENVIRON MONITOR, V3, P206, DOI 10.1039/b007159p; Hargreaves M, 2003, SCI TOTAL ENVIRON, V312, P89, DOI 10.1016/S0048-9697(03)00169-4; HARRISON J, 1992, RESP MED, V86, P225, DOI 10.1016/S0954-6111(06)80060-0; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; HU QX, 1990, CHINA ENV SCI, V10, P99; Huang CY, 2002, ATMOS ENVIRON, V36, P4385, DOI 10.1016/S1352-2310(02)00322-9; Ju T.Z., 2003, IND SAF ENV PROT, V29, P17; Kuder E. M, 2003, INT BIODETERIOR, V52, P203; LEACH CM, 1975, PHYTOPATHOLOGY, V65, P1303; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; LI DW, 1994, GRANA, V33, P166; LV AH, 1996, ARIS ENV MONIT, V10, P174; LYON FL, 1984, GRANA, V23, P177; Meklin T, 2002, ATMOS ENVIRON, V36, P6031, DOI 10.1016/S1352-2310(02)00769-0; MORRING KL, 1983, AM IND HYG ASSOC J, V44, P662, DOI 10.1202/0002-8894(1983)044<0662:SFAFAS>2.3.CO;2; Pandit T, 1995, AEROBIOLOGIA, V11, P177, DOI 10.1007/BF02450036; Picco AM, 2000, INT BIODETER BIODEGR, V45, P43, DOI 10.1016/S0964-8305(00)00047-0; RAHKONEN P, 1990, AEROSOL SCI TECH, V13, P505, DOI 10.1080/02786829008959465; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; REPONEN T, CHARACTERISTICS EXPO; Reponen T., 1992, J AEROSOL SCI     S1, V23, P663, DOI 10.1016/0021-8502(92)90499-L; Rosas I, 1997, AEROBIOLOGIA, V13, P23, DOI 10.1007/BF02694787; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; Singh A, 1995, AEROBIOLOGIA, V11, P231, DOI 10.1007/BF02447203; Singh A.B., 1990, IND J AEROBIOL, V3, P32; Su JH, 1992, APPL ENVIRON MICROB, V58, P181; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; Waisel Y., 1997, AEROBIOLOGIA, V13, P281, DOI 10.1007/BF02694496; Wu CH, 1982, HUANJING KEXUE XUEBA, V2, P255; ZHAI JH, 2000, CHINA PUBLIC HLTH, V16; ZHANG ZL, 1987, CHINA ENV SCI, V7, P43	41	71	78	7	24	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697			SCI TOTAL ENVIRON	Sci. Total Environ.	NOV 1	2005	350	1-3					47	58		10.1016/j.scitotenv.2005.01.032		12	Environmental Sciences	Environmental Sciences & Ecology	983IQ	WOS:000233225300005	16227072	
J	Arruda, LK; Sole, D; Baena-Cagnani, CE; Naspitz, CK				Arruda, LK; Sole, D; Baena-Cagnani, CE; Naspitz, CK			Risk factors for asthma and atopy	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergen sensitization; asthma; gene-environment interactions; respiratory viral infections; risk factors for asthma	CHILDHOOD ASTHMA; SEX-DIFFERENCES; BRONCHIAL HYPERRESPONSIVENESS; ALLERGIC RHINITIS; INDOOR ALLERGENS; VIRAL-INFECTIONS; MATERNAL SMOKING; IMMUNOGLOBULIN-E; BIRTH COHORT; BREAST-MILK	Purpose of review The aim of this article is to provide information on risk factors associated with the development of atopy and asthma in childhood. Recent findings Several gene polymorphisms have been associated with susceptibility to asthma and allergy; complex gene-environmental interactions, however, appear to play a key role in the development of the disease. Early life sensitization to aeroallergens, presence of atopic dermatitis or allergic rhinitis, maternal smoking during pregnancy and children's environmental exposure to tobacco smoke, lower respiratory tract infections with respiratory syncytial virus and potentially with other viruses including rhinovirus and metapneumovirus, exposure to air pollutants, several perinatal factors other than maternal smoking, are among factors associated with an increased risk for development of chronic asthma. Summary The prevalence of asthma and allergic diseases is increasing progressively. Those who are involved in the care of young children should be prepared to recognize risk factors for development of these diseases and to appreciate the role of gene-environment interactions. Preventive measures established at an early age may modify the natural history of asthma and other allergic diseases.	Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Internal Med, Div Clin Immunol, Sao Paulo, Brazil; Univ Fed Sao Paulo, Div Pediat Allergy Immunol & Rheumatol, Paulista Sch Med, Sao Paulo, Brazil; Catholic Univ Cordoba, Cordoba, Argentina	Arruda, LK (reprint author), USP, Fac Med Ribeirao Preto, Dept Clin Med, Av Bandeirantes 3900, BR-14049900 Ribeirao Preto, Brazil.	karla@fmrp.usp.br	Arruda, L. Karla /D-5845-2013; Sole, Dirceu/D-7789-2013	Arruda, L. Karla /0000-0002-7505-210X; 			Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Blumenthal JB, 2002, MED CLIN N AM, V86, P937, DOI 10.1016/S0025-7125(02)00028-7; Bottcher MF, 2003, PEDIATR ALLERGY IMMU, V14, P35, DOI 10.1034/j.1399-3038.2003.02120.x; Boulay Marie-Eve, 2003, Curr Opin Allergy Clin Immunol, V3, P51, DOI 10.1097/00130832-200302000-00009; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Bousquet J, 2003, ALLERGY, V58, P691, DOI 10.1034/j.1398-9995.2003.00105.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Braunstahl GJ, 2003, CURR OPIN PULM MED, V9, P46, DOI 10.1097/00063198-200301000-00008; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; COPENHAVER CC, 2004, AM J RESP CRIT CARE, V1170, P175; de Marco R, 2004, J ALLERGY CLIN IMMUN, V113, P845, DOI 10.1016/j.jaci.2004.01.780; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Martin Fernandez-Mayoralas D, 2004, AN PEDIATR, V60, P236; Ferriani V. P. L., 2004, Journal of Allergy and Clinical Immunology, V113, pS97, DOI 10.1016/j.jaci.2003.12.338; Frye C, 2003, ALLERGY, V58, P229, DOI 10.1034/j.1398-9995.2003.00077.x; Fuhlbrigge Anne L, 2003, Curr Opin Allergy Clin Immunol, V3, P29, DOI 10.1097/00130832-200302000-00005; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Graham LeRoy M, 2004, Paediatr Respir Rev, V5 Suppl A, pS59, DOI 10.1016/S1526-0542(04)90012-7; Guilbert TW, 2004, J ALLERGY CLIN IMMUN, V114, P1282, DOI 10.1016/j.jaci.2004.09.020; Guler N, 2004, J ALLERGY CLIN IMMUN, V114, P254, DOI 10.1016/j.jaci.2004.03.053; Halapi E, 2004, CURR OPIN PULM MED, V10, P22, DOI 10.1097/00063198-200401000-00005; Hanson LA, 2003, ANN ALLERG ASTHMA IM, V90, P59; Hershey GKK, 2004, J ALLERGY CLIN IMMUN, V113, P392, DOI 10.1016/j.jaci.2004.01.564; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Holt Patrick G, 2004, Paediatr Respir Rev, V5 Suppl A, pS27, DOI 10.1016/S1526-0542(04)90006-1; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; JOHANSSON SGO, 2004, WORLD ALLERGY ORG PR, P211; Koh Young Yull, 2003, Curr Opin Allergy Clin Immunol, V3, P159, DOI 10.1097/00130832-200306000-00002; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kurukulaaratchy RJ, 2004, PEDIATRICS, V113, P345, DOI 10.1542/peds.113.2.345; Kuyucu S, 2004, PEDIATR ALLERGY IMMU, V15, P62, DOI 10.1046/j.0905-6157.2003.00115.x; LEE YL, 2003, PEDIATRICS X, V112, pE289; Lemanske RF, 2004, J ALLERGY CLIN IMMUN, V114, P1023, DOI 10.1016/j.jaci.2004.08.031; Liu CA, 2003, J ALLERGY CLIN IMMUN, V112, P899, DOI 10.1067/mai.2003.1812; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-15830C; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Manolio TA, 2003, HUM GENET, V113, P437, DOI 10.1007/s00439-003-1005-6; MARTINEZ FD, 2001, TXB PEDIAT ASTHMA IN, P67; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; McNamara PS, 2004, LANCET, V363, P1031, DOI 10.1016/S0140-6736(04)15838-8; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murphy VE, 2003, AM J RESP CRIT CARE, V168, P1317, DOI 10.1164/rccm.200303-374OC; Nafstad P, 2000, J ALLERGY CLIN IMMUN, V106, P867, DOI 10.1067/mai.2000.110558; Nicolai T, 2003, PEDIATR ALLERGY IMMU, V14, P280, DOI 10.1034/j.1399-3038.2003.00047.x; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Oddy WH, 2004, J ASTHMA, V41, P605, DOI 10.1081/JAS-200026402; Osman M, 2003, ARCH DIS CHILD, V88, P587, DOI 10.1136/adc.88.7.587; PausJenssen ES, 2003, ANN ALLERG ASTHMA IM, V91, P34; Peroni DG, 2003, CLIN EXP ALLERGY, V33, P1349, DOI 10.1046/j.1365-2222.2003.01766.x; Platts-Mills TA, 2000, J ALLERGY CLIN IMMUN, V105, P503; Romagnani S, 2004, J ALLERGY CLIN IMMUN, V113, P395, DOI 10.1016/j.jaci.2003.11.025; Rullo VEV, 2002, J ALLERGY CLIN IMMUN, V110, P582, DOI 10.1067/mai.2002.127511; SAMET JM, 2001, TXB PEDIAT ASTHMA IN, P35; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Simpson Angela, 2004, Curr Opin Allergy Clin Immunol, V4, P45, DOI 10.1097/00130832-200402000-00010; Smit Joost J, 2004, Curr Opin Allergy Clin Immunol, V4, P57, DOI 10.1097/00130832-200402000-00012; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; Stoney RM, 2004, CLIN EXP ALLERGY, V34, P194, DOI 10.1111/j.1365-2222.2004.01852.x; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Tobias KRC, 2004, INT ARCH ALLERGY IMM, V133, P365, DOI 10.1159/000077356; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2003, CURR OPIN IMMUNOL, V15, P609, DOI 10.1016/j.coi.2003.09.005; von Mutius E, 2004, J ALLERGY CLIN IMMUN, V113, P373, DOI 10.1016/j.jaci.2003.12.040; Vonk JM, 2004, J ALLERGY CLIN IMMUN, V114, P270, DOI 10.1016/j.jaci.2004.03.051; Warner JO, 2004, ARCH DIS CHILD, V89, P97, DOI 10.1136/adc.2003.013029; Wijga A, 2003, PEDIATR ALLERGY IMMU, V14, P156, DOI 10.1034/j.1399-3038.2003.00022.x; Williams JV, 2004, NEW ENGL J MED, V350, P443, DOI 10.1056/NEJMoa025472; Wjst M, 1997, PEDIATR ALLERGY IMMU, V8, P200, DOI 10.1111/j.1399-3038.1997.tb00161.x; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Xu BZ, 2000, THORAX, V55, P691, DOI 10.1136/thorax.55.8.691; Yoshinaka T, 2002, GENE, V282, P227, DOI 10.1016/S0378-1119(01)00818-6; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166	81	71	75	5	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA	1528-4050			CURR OPIN ALLERGY CL	Curr. Opin. Allergy Clin. Immunol.	APR	2005	5	2					153	159		10.1097/01.all.0000162308.89857.6c		7	Allergy; Immunology	Allergy; Immunology	970GJ	WOS:000232293000008	15764906	
J	Reibman, J; Lin, S; Hwang, SAA; Gulati, M; Bowers, JA; Rogers, L; Berger, KI; Hoerning, A; Gomez, M; Fitzgerald, EF				Reibman, J; Lin, S; Hwang, SAA; Gulati, M; Bowers, JA; Rogers, L; Berger, KI; Hoerning, A; Gomez, M; Fitzgerald, EF			The World Trade Center residents' respiratory health study: New-onset respiratory symptoms and pulmonary function	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; environmental; disasters; environmental hazards; reactive airways dysfunction; World Trade Center	AIRWAYS DYSFUNCTION SYNDROME; FINE PARTICULATE MATTER; PERSISTENT ASTHMA; LOWER MANHATTAN; SYNDROME RADS; QUESTIONNAIRE; FIREFIGHTERS; SEPTEMBER-11; GUIDELINES; VALIDITY	The destruction of the World Trade Center (WTC) on 11 September 2001 in New York City resulted in the massive release of pulverized dust and combustion products. The dust and smoke settled in the surrounding area, which encompassed a large residential community. We hypothesized that previously normal residents in the community surrounding the former WTC would have an increased incidence of persistent respiratory symptoms and abnormalities in screening spirometry. A hybrid cross-sectional and retrospective cohort study using a symptom-based questionnaire and onsite screening spirometry in residents in an exposed area and in a control area was performed 12 +/- 4 months after the collapse. Surveys were analyzed from 2,812 residents. New-onset respiratory symptoms were described by 55.8% of residents in the exposed area, compared with 20.1% in the control area after the event. Persistent new-onset symptoms were identified in 26.4 versus 7.5% of residents in the exposed area versus control area, respectively. No differences in screening spirometry between the groups were detected. A small pilot study suggested the possibility of an increase in bronchial hyperresponsiveness in exposed participants with persistent symptoms. The data demonstrate an increased rate of new-onset and persistent respiratory health effects in residents near the former WTC compared with a control population.	NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; New York State Dept Hlth, Albany, NY USA	Reibman, J (reprint author), NYU, Sch Med, Dept Med, Div Pulm & Crit Care Med, 550 1st Ave,Room NB7N24, New York, NY 10016 USA.	reibmj01@gcrc.med.nyu.edu	Fitzgerald, Edward/F-4087-2010	Lin, Shao/0000-0002-5535-7504	NCRR NIH HHS [M01RR00096]; NIEHS NIH HHS [P30 ES00260]; ODCDC CDC HHS [U1Q/CCU221059]		ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Banauch GI, 2003, AM J RESP CRIT CARE, V168, P54, DOI 10.1164/rccm.200211-1329OC; Bardana EJ, 1999, ANN ALLERG ASTHMA IM, V83, P583, DOI 10.1016/S1081-1206(10)62876-1; BROOKS S, 1998, ENV OCCUPATIONAL MED, P481; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Demeter SL, 2001, SCI TOTAL ENVIRON, V270, P49, DOI 10.1016/S0048-9697(00)00786-5; Fagan J, 2003, PSYCHOSOM MED, V65, P993, DOI 10.1097/01.PSY.0000097334.48556.5F; Fagan J, 2002, MMWR-MORBID MORTAL W, V51, P781; Feldman DM, 2004, CHEST, V125, P1256, DOI 10.1378/chest.125.4.1256; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P981, DOI 10.1289/ehp.5931; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; KIPEN HM, 1994, J OCCUP ENVIRON MED, V36, P1133, DOI 10.1097/00043764-199410000-00017; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; McGee JK, 2003, ENVIRON HEALTH PERSP, V111, P972, DOI 10.1289/ehp.5930; *NAT HEART LUNG BL, 2002, NIH PUBL, V2; Offenberg JH, 2003, ENVIRON SCI TECHNOL, V37, P502, DOI 10.1021/es025730g; Payne JP, 2004, J OCCUP ENVIRON MED, V46, P420, DOI 10.1097/01.jom.0000126021.25149.64; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; Ravault C, 2001, INT J TUBERC LUNG D, V5, P191; Service RF, 2003, SCIENCE, V301, P1649, DOI 10.1126/science.301.5640.1649; Stellman J.M., 1998, ENCY OCCUPATIONAL HL; *US CENS BUR, 2000, CENS 2000 RESP RAT D	28	71	73	3	4	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2005	113	4					406	411				6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	913NO	WOS:000228158900038	15811830	
J	Tan, WC				Tan, WC			Viruses in asthma exacerbations	CURRENT OPINION IN PULMONARY MEDICINE			English	Article						exacerbations of asthma; viruses; epidemiology	RHINOVIRUS RESPIRATORY-INFECTIONS; EPITHELIAL-CELLS; INFLUENZA VACCINATION; TRACT INFECTION; INDUCED SPUTUM; ATOPIC ASTHMA; RISK-FACTORS; CHILDREN; LUNG; EXPRESSION	Purpose of review Respiratory viruses are well recognized as major triggers of acute exacerbations of asthma in children and adults, resulting in frequent outpatients visits and hospitalizations, Clinical and epidemiologic evidence supports this association. The application of molecular diagnostic methods has improved understanding of viral epidemiology and the pathophysiological mechanisms involved in viral induced acute asthma. This article reviews publications since October 2002 for an update of the role of viruses in exacerbations of asthma. Recent findings Respiratory viruses are present in most patients hospitalized for life-threatening asthma and acute nonlife-threatening asthma. Rhinovirus is the most common, but coinfection with other viruses may be important. Patients with asthma are not more susceptible to upper respiratory tract rhinovirus infections than healthy people but suffer from more severe consequences of the lower respiratory tract infection. Recent epidemiologic studies suggest that viruses provoke asthma attacks by additive or synergistic interactions with allergen exposure or with air pollution. An impaired antiviral immunity to rhinovirus may lead to impaired viral clearance and hence prolonged symptoms. Respiratory viral infections cause asthmatic exacerbations by triggering recruitment of T(H)2-type cells into the lungs, There is no specific antiviral strategy for prevention of respiratory-triggered asthma exacerbations, although clinical trials of potential antiviral agents are ongoing. Indirect prevention strategies focus on the reduction of overall airway inflammation to reduce the severity of the host response to respiratory viral infections. Summary Respiratory viral infections are a major cause of morbidity and mortality in asthma. There is a lack of specific antiviral strategies in the prevention or reduction of viral-triggered asthma exacerbations. Recent advances in understanding of the epidemiology and immunopathogenesis of respiratory viral infection in asthma provide opportunities or identification of specific targets for antiviral agents and strategies for management and prevention.	Natl Univ Singapore Hosp, Dept Med, Singapore 119074, Singapore	Tan, WC (reprint author), Natl Univ Singapore Hosp, Dept Med, Lower Kent Ridge Rd, Singapore 119074, Singapore.	mdctanwc@nus.edu.sg					ABRAMSON MJ, 1995, MED J AUSTRALIA, V163, P542; Akazawa Shiho, 2004, Nihon Kokyuki Gakkai Zasshi, V42, P353; Anzueto A, 2003, CHEST, V123, P1664, DOI 10.1378/chest.123.5.1664; Avila PC, 2000, J ALLERGY CLIN IMMUN, V105, P923, DOI 10.1067/mai.2000.106214; BIANCO A, 2002, MONALDI ARCH CHEST D, V7, P188; Bisgaard H, 2003, AM J RESP CRIT CARE, V167, P379, DOI 10.1164/rccm.200207-747OC; Bossios A, 2004, INT ARCH ALLERGY IMM, V134, P223, DOI 10.1159/000078769; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; Bueving HJ, 2004, AM J RESP CRIT CARE, V169, P488, DOI 10.1164/rccm.200309-1251OC; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Cates CJ, 2003, COCHRANE LIB; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; de Kluijver J, 2003, CLIN EXP ALLERGY, V33, P1415, DOI 10.1046/j.1365-2222.2003.01770.x; de Kluijver Josephine, 2003, American Journal of Respiratory and Critical Care Medicine, V168, P1174, DOI 10.1164/rccm.200212-1520OC; DOULL IJ, 2003, J PEDIAT S, V142, pS24; Doull IJM, 2003, J PEDIATR-US, V142, pS21, DOI 10.1067/mpd.2003.22; Duits LA, 2003, FEMS IMMUNOL MED MIC, V38, P59, DOI 10.1016/S0928-8244(03)00106-8; EMPEY DW, 1976, AM REV RESPIR DIS, V113, P131; Ferreira A, 2002, RESPIRATION, V69, P136, DOI 10.1159/000056316; Gern JE, 2003, J PEDIATR-US, V142, pS9, DOI 10.1067/mpd.2003.20; Gern JE, 2002, AM J MED, V112, p19S; Greenberg SB, 2003, ARCH INTERN MED, V163, P278, DOI 10.1001/archinte.163.3.278; Grunberg K, 1999, AM J RESP CRIT CARE, V160, P1375; Grunberg K, 2000, CLIN EXP ALLERGY, V30, P1015; Ieki K, 2004, CLIN EXP ALLERGY, V34, P745, DOI 10.1111/j.1365-2222.2004.01941.x; JOHNSTON SL, 1993, THORAX, V48, P1055; Johnston SL, 2003, AM J RESP CRIT CARE, V168, P1145, DOI 10.1164/rccm.2309004; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Kramarz P, 2000, VACCINE, V18, P2288, DOI 10.1016/S0264-410X(99)00551-4; Lemanske RF, 2003, CHEST, V123, p385S, DOI 10.1378/chest.123.3_suppl.385S-a; Lemanske RF, 2003, J PEDIATR-US, V142, pS3, DOI 10.1067/mpd.2003.19; LEMANSKE RF, 2003, J PEDIAT S, V142, pS7; Lemanske Robert F. Jr., 2003, Journal of Allergy and Clinical Immunology, V111, pS502; Macek V, 1999, Can Respir J, V6, P37; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; *NHLBI WHO, 2003, NHLBI WHO WORKSH REP; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Osur SL, 2002, ANN ALLERG ASTHMA IM, V89, P553; Papadopoulos NG, 2002, THORAX, V57, P328, DOI 10.1136/thorax.57.4.328; Papadopoulos Nikolaos G, 2003, Curr Opin Allergy Clin Immunol, V3, P39, DOI 10.1097/00130832-200302000-00007; Papi A, 2001, J ALLERGY CLIN IMMUN, V108, P221, DOI 10.1067/mai.2001.116861; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Rawlinson WD, 2003, J INFECT DIS, V187, P1314, DOI 10.1086/368411; Sanders SP, 2004, J ALLERGY CLIN IMMUN, V113, P697, DOI 10.1016/j.jaci.2004.01.755; Schwarze J, 2004, THORAX, V59, P517, DOI 10.1136/thx.2003.017343; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Simpson JL, 2003, J CLIN VIROL, V26, P339, DOI 10.1016/S1386-6532(02)00084-7; Sotir M, 2003, ENVIRON HEALTH PERSP, V111, P657, DOI 10.1289/ehp.5824; Stephens R, 2002, J IMMUNOL, V169, P5458; STOKES GM, 1981, J PEDIATR-US, V98, P871, DOI 10.1016/S0022-3476(81)80577-X; Tan WC, 2003, AM J MED, V115, P272, DOI 10.1016/S0002-9343(03)00353-X; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; Thumerelle C, 2003, PEDIATR PULM, V35, P75, DOI 10.1002/ppul.10191; Watson MW, 2003, RESPIROLOGY, V8, P234, DOI 10.1046/j.1440-1843.2003.00462.x; Weinberger M, 2003, J PEDIATR-US, V142, pS34, DOI 10.1067/mpd.2003.24; Wilson Nicola M, 2003, Paediatr Respir Rev, V4, P184, DOI 10.1016/S1526-0542(03)00052-6; Xiang XY, 2002, J VIROL METHODS, V101, P127, DOI 10.1016/S0166-0934(01)00431-1; Yamaya M, 2003, VIRAL IMMUNOL, V16, P99, DOI 10.1089/088282403322017857; Zambrano JC, 2003, J ALLERGY CLIN IMMUN, V111, P1008, DOI 10.1067/mai.2003.1396	62	71	77	1	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1070-5287			CURR OPIN PULM MED	Curr. Opin. Pulm. Med.	JAN	2005	11	1					21	26				6	Respiratory System	Respiratory System	882AL	WOS:000225910700004	15591884	
J	Spahn, JD; Cherniack, R; Paull, K; Gelfand, EW				Spahn, JD; Cherniack, R; Paull, K; Gelfand, EW			Is forced expiratory volume in one second the best measure of severity in childhood asthma?	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Editorial Material							AIR-FLOW OBSTRUCTION; TO-MODERATE ASTHMA; LUNG-FUNCTION; INHALED CORTICOSTEROIDS; MANAGEMENT PROGRAM; CHILDREN; RESPONSIVENESS; BECLOMETHASONE; POPULATION; PLACEBO		Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Div Clin Pharmacol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Div Pulm Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Med & Allergy Clin Immunol, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80206 USA	Spahn, JD (reprint author), Univ Colorado, Hlth Sci Ctr, Natl Jewish Med & Res Ctr, 1400 Jackson St, Denver, CO 80206 USA.	spahnj@njc.org					Bacharier LB, 2002, J ALLERGY CLIN IMMUN, V109, pS266, DOI 10.1016/S0091-6749(02)81946-7; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Galant SP, 1996, ANN ALLERG ASTHMA IM, V77, P112; Jenkins HA, 2003, CHEST, V124, P1318, DOI 10.1378/chest.124.4.1318; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Malmstrom K, 1999, ANN INTERN MED, V130, P487; MAROTTA A, 2003, J ALLERGY CLIN IMMUN, V112, P17; National Asthma Education and Prevention Program, 2002, NIH PUBL; [Anonymous], 2002, NIH PUBL, V01-4913; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Sharek PJ, 2002, PEDIATRICS, V110, P797, DOI 10.1542/peds.110.4.797; Simons FER, 1997, NEW ENGL J MED, V337, P1659, DOI 10.1056/NEJM199712043372304; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P410, DOI 10.1067/mai.2002.122635; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; VANESSENZANDVLIET EE, 1992, AM REV RESPIR DIS, V146, P547; Weiss ST, 2000, AM J RESP CRIT CARE, V162, P50; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4	21	71	74	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 1	2004	169	7					784	786		10.1164/rccm.200309-1234OE		3	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	807IB	WOS:000220494100006	14754761	
J	Eisenbarth, SC; Piggott, DA; Bottomly, K				Eisenbarth, SC; Piggott, DA; Bottomly, K			The master regulators of allergic inflammation: dendritic cells in Th2 sensitization	CURRENT OPINION IN IMMUNOLOGY			English	Review							T-HELPER-CELL; EOSINOPHILIC AIRWAY INFLAMMATION; TOLL-LIKE RECEPTORS; IN-VIVO; INHALED ANTIGEN; CUTTING EDGE; IMMUNE-RESPONSES; MURINE MODEL; TYPE-2 TH2; DIFFERENTIATION	The development of Th2 responses to inhaled proteins represents a malfunction of the adaptive immune system in that protein antigens are not microbial in nature and should not elicit an adaptive immune reaction. This derailing of the immune system may result from false alarms generated by the innate immune system, resulting in unexpected dendritic cell (DC) maturation after exposure to allergens. Conditions in the local microenvironment during DC maturation may also result in the preferential induction of Th2 responses. Recent progress has been made in our understanding of the role of DCs in both Th2 sensitization to aeroallergens and the regulation of Th2 and Th1 immunity.	Yale Univ, Dept Immunobiol, New Haven, CT 06510 USA	Eisenbarth, SC (reprint author), Yale Univ, Dept Immunobiol, 300 Cedar St, New Haven, CT 06510 USA.						Akira S, 2003, IMMUNOL LETT, V85, P85, DOI 10.1016/S0165-2478(02)00228-6; Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Belladonna ML, 2002, J IMMUNOL, V168, P5448; Boonstra A, 2003, J EXP MED, V197, P101, DOI 10.1084/jem.20021908; Bozza S, 2002, J IMMUNOL, V168, P1362; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; d'Ostiani CF, 2000, J EXP MED, V191, P1661, DOI 10.1084/jem.191.10.1661; DABBAGH K, 2002, J IMMUNOL, V168, P4525; de Jong EC, 2002, J IMMUNOL, V168, P1704; De Smedt T, 2002, J IMMUNOL, V168, P661; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Dodge IL, 2003, J IMMUNOL, V170, P4457; Drouin SM, 2002, J IMMUNOL, V169, P5926; Edwards AD, 2002, J IMMUNOL, V169, P3652; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Graffi SJ, 2002, CLIN IMMUNOL, V103, P176, DOI 10.1006/clim.2002.5190; Greenwald RJ, 2002, J IMMUNOL, V168, P991; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Gutzmer R, 2002, J ALLERGY CLIN IMMUN, V109, P524, DOI 10.1067/mai.2002.121944; Hammad H, 2002, J IMMUNOL, V169, P1524; HOSHINO A, 2003, EUR J IMMUNOL, V33, P661; Hurst SD, 2002, J IMMUNOL, V169, P443; Idzko M, 2002, J ALLERGY CLIN IMMUN, V109, P839, DOI 10.1067/mai.2002.124044; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Jember AGH, 2001, J EXP MED, V193, P387, DOI 10.1084/jem.193.3.387; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; KeaneMyers A, 1997, J IMMUNOL, V158, P2042; Lambrecht B N, 2001, Curr Opin Allergy Clin Immunol, V1, P51, DOI 10.1097/00130832-200102000-00010; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; MacDonald AS, 2002, J IMMUNOL, V168, P4643; MacDonald AS, 2002, J IMMUNOL, V168, P537; Manickasingham SR, 2003, EUR J IMMUNOL, V33, P101, DOI 10.1002/immu.200390001; Masten BJ, 1999, J IMMUNOL, V162, P1310; Medzhitov R, 2000, NEW ENGL J MED, V343, P338; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pflanz S, 2002, IMMUNITY, V16, P779, DOI 10.1016/S1074-7613(02)00324-2; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Reider N, 2002, J ALLERGY CLIN IMMUN, V109, P89, DOI 10.1067/mai.2002.120556; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; Shortman K, 2002, NAT REV IMMUNOL, V2, P151, DOI 10.1038/nri746; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Takeda A, 2003, J IMMUNOL, V170, P4886; Tanaka H, 2000, J EXP MED, V192, P405, DOI 10.1084/jem.192.3.405; Trinchieri G, 2003, NAT REV IMMUNOL, V3, P133, DOI 10.1038/nri1001; Vieira PL, 2000, J IMMUNOL, V164, P4507; Whelan M, 2000, J IMMUNOL, V164, P6453; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275	55	71	75	0	0	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2003	15	6					620	626		10.1016/j.coi.2003.09.003		7	Immunology	Immunology	748LB	WOS:000186862400005	14630194	
J	Al-Ghamdi, SM; Akbar, HO; Qari, YA; Fathaldin, OA; Al-Rashed, RS				Al-Ghamdi, SM; Akbar, HO; Qari, YA; Fathaldin, OA; Al-Rashed, RS			Pattern of admission to hospitals during muslim pilgrimage (Hajj)	SAUDI MEDICAL JOURNAL			English	Article							SAUDI-ARABIA; MENINGOCOCCAL DISEASE; AL-MUNAWARAH; HEATSTROKE; MANAGEMENT; OUTBREAK; MAKKAH	Objectives: The pattern of medical conditions necessitating admission differs according to the weather condition in that particular year. Previous studies had been conducted during the hot weather, none over the last 10 years, were carried out during, the milder weather we are experiencing. The aim of this study is to establish the pattern of admission during this mild weather and to elucidate the possible risk factors. Methods: A prospective study was performed in 4 hospitals in 2 different locations in Al-Mashaer, Kingdom of Saudi Arabia. Data were collected during one working shift in 2 hospitals in Arafat on the 9th of Dhul Hijjah 1422, corresponding to 21st of February 2002, and another working shift in 2 hospitals in Mina on the 10th of Dhul Hijjah 1422, corresponding to 22nd of February 2002. Results: A cohort of 76 patients from Arafat hospitals and 84 patients from Mina' hospitals were included (total 160 patients). Males constituted 62% and females 38% with the median age of 60 +/- 15years. The respiratory system was the most commonly affected (57%), followed by cardiovascular system (19.4%), and gastrointestinal tract (GIT) in 6.3% of cases. There were only 3 cases of heat-related admissions with only one confirmed case of heat stroke. Similarly, only one case of meningitis was confirmed in this cohort. Pneumonia was encountered in 63 cases (39.4%) and exacerbation of asthma and chronic obstructive pulmonary diseases (COPD) in 23 cases (14.4%). Pre-existing co-morbid medical conditions had included bronchial asthma and COPD (22.5%), hypertension (17.5%), and Diabetes mellitus (15%). Short-term follow up (24-48 hours) identified 2 deaths (1.3%), 94 patients (59%) were transferred to other secondary or tertiary care facilities and 64 (40%) were discharged home. Conclusion: Hospital admission during Hajj is related to old age and occurs in patients with associated co-morbid conditions. During this mild weather lower respiratory tract infections and exacerbation of bronchial asthma and COPD are the most commonly encountered diseases during Hajj.	King Abdulaziz Univ Hosp, Dept Med, Fac Med, Jeddah 80215, Saudi Arabia; King Saud Univ, Fac Med, Dept Med, Riyadh, Saudi Arabia	Al-Ghamdi, SM (reprint author), King Abdulaziz Univ Hosp, Dept Med, Fac Med, POB 80215, Jeddah 80215, Saudi Arabia.						Aguilera JF, 2002, EMERG INFECT DIS, V8, P761; ALASKA A, 1987, ANN SAUDI MED, V7, P135; ALASKA AK, 1987, LANCET, V1, P381; ALHARTHI SS, 1986, SAUDI MED J, V7, P369; El Bushra HE, 2000, EPIDEMIOL INFECT, V125, P555, DOI 10.1017/S0950268800004805; ELHASSAN OM, 1990, SAUDI MED J, V11, P290; GHAZNAWI HI, 1987, ANN SAUDI MED, V7, P323; GHAZNAWI HI, 1988, SAUDI MED J, V9, P274; KHOGALI M, 1983, INT J EPIDEMIOL, V12, P267, DOI 10.1093/ije/12.3.267; Memish ZA, 2002, SAUDI MED J, V23, P259; Memish ZA, 2002, CLIN INFECT DIS, V34, P84, DOI 10.1086/323403; MOORE PS, 1988, JAMA-J AM MED ASSOC, V260, P2686, DOI 10.1001/jama.260.18.2686; Rahman MM, 1999, ANN PLAS SURG, V43, P154; YAQUB BA, 1986, Q J MED, V59, P523; Yousuf M, 1995, ANN SAUDI MED, V15, P619	15	71	74	0	0	SAUDI MED J	RIYADH	ARMED FORCES HOSPITAL, PO BOX 7897,, RIYADH 11159, SAUDI ARABIA	0379-5284			SAUDI MED J	Saudi Med. J.	OCT	2003	24	10					1073	1076				4	Medicine, General & Internal	General & Internal Medicine	745BC	WOS:000186666500008	14578971	
J	Etzel, RA				Etzel, RA			How environmental exposures influence the development and exacerbation of asthma	PEDIATRICS			English	Article						asthma; indoor air pollution; outdoor air pollution	HOUSE-DUST MITE; OUTDOOR AIR-POLLUTION; EMERGENCY ROOM VISITS; CHILDHOOD ASTHMA; PASSIVE SMOKING; PULMONARY-FUNCTION; EPIDEMIC ASTHMA; RESPIRATORY HEALTH; NORMAL-CHILDREN; ORLEANS ASTHMA	Environmental exposures may increase a child's risk of developing asthma and also may increase the risk of asthma exacerbations. This article reviews several environmental exposures and suggests whether they contribute to asthma prevalence, asthma exacerbations, or both. Outdoor air exposures and violence are not likely to cause the increase in asthma prevalence. Exposure to outdoor air pollutants primarily leads to increased exacerbations, sometimes manifested as asthma clusters. Clinicians should be alert for space-time clusters of asthma exacerbations in the community, because these clusters may suggest a modifiable point-source exposure. Indoor air exposures are more strongly linked to the increase in asthma prevalence. Exposure to dust mites and tobacco smoke are risk factors for the development of asthma and may also exacerbate existing asthma. Effective measures to prevent exposures to these pollutants are available. With proper management, the amount of environmental exposures can be decreased. Whether decreasing these exposures will result in decreases in asthma prevalence and exacerbations is not yet documented.	George Washington Univ, Dept Environm & Occupat Hlth, Sch Publ Hlth & Hlth Serv, Washington, DC USA	Etzel, RA (reprint author), 4320 Diplomacy Dr,Ste 2630, Anchorage, AK 99508 USA.						American Academy of Pediatrics, 1986, PEDIATRICS, V77, P755; ANTO JM, 1993, NEW ENGL J MED, V329, P1760, DOI 10.1056/NEJM199312093292402; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; AVOL EL, 1987, JAPCA J AIR WASTE MA, V37, P158; AVOL EL, 1985, AM REV RESPIR DIS, V132, P619; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432345; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BOOTH S, 1965, ARCH ENVIRON HEALTH, V10, P152; Brown CM, 1997, PUBLIC HEALTH REP, V112, P198; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; BURCHFIEL CM, 1986, AM REV RESPIR DIS, V133, P966; BURGE HA, 1989, IMMUNOL ALLERGY CLIN, V9, P307; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; CARROLL RE, 1968, AM J PUBLIC HEALTH N, V58, P1677, DOI 10.2105/AJPH.58.9.1677; *CDCP, 1990, MMWR-MORBID MORTAL W, V39, P493; Centers for Disease Control and Prevention, 1998, CDC SURVEILL SUMM, V47, P1; Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P1; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Churches T, 1991, NSW PUBLIC HLTH B, V2, P72, DOI DOI 10.1071/NB91035; CULLINAN P, 1994, BRIT MED J, V308, P1585; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; DASSEN W, 1986, JAPCA J AIR WASTE MA, V36, P1223; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; DUCLOS P, 1990, ARCH ENVIRON HEALTH, V45, P53; Duffy DL, 1998, AM J RESP CRIT CARE, V157, P840; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; EHRLICH R, 1992, AM REV RESPIR DIS, V145, P594; ETZEL RA, 1995, ENVIRON HEALTH PERSP, V103, P55, DOI 10.2307/3432346; ETZEL RA, 1999, HDB PEDIAT ENV HLTH; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; EVANS R, 1987, CHEST, V91, pS65; Figley KD, 1928, J AMER MED ASSOC, V90, P79; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GOLDFARB AA, 1968, ANN ALLERGY, V26, P321; GOLDSTEIN IF, 1980, INT J BIOMETEOROL, V24, P329, DOI 10.1007/BF02250575; GOLDSTEIN IF, 1984, ENVIRON RES, V33, P201, DOI 10.1016/0013-9351(84)90017-3; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Gotzsche PC, 2001, COCHRANE DATABASE SY, V2; HENDRICK DJ, 1989, THORAX, V44, P609, DOI 10.1136/thx.44.8.609; HJELMROOS M, 1993, GRANA, V32, P40; HOLBERG CJ, 1993, PEDIATRICS, V91, P885; Holgate ST, 1999, NATURE, V402, pB2; Holt PG, 1999, NATURE, V402, pB12; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; Institute of Medicine Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; INGRAM JM, 1993, IMMUNOL ALLERGY CLIN, V13, P785; Jones AP, 2000, J ASTHMA, V37, P103, DOI 10.3109/02770900009055434; KOENIG JQ, 1983, AM REV RESPIR DIS, V128, P221; KOENIG JQ, 1989, ENVIRON HEALTH PERSP, V79, P173, DOI 10.2307/3430546; KOENIG JQ, 1990, AM REV RESPIR DIS, V141, P377; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LEWIS R, 1962, PUBLIC HEALTH REP, V77, P947, DOI 10.2307/4591673; LITONJUA A, 1998, AM J RESP CRIT CARE, V157, pA643; MARTIN CJ, 1987, BRIT MED J, V294, P1125; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MATTHEWS TJ, 2001, NATL VITAL STAT REP, V49, P1; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; MCDONNELL WF, 1985, AM REV RESPIR DIS, V132, P875; MURRAY AB, 1993, J ALLERGY CLIN IMMUN, V91, P102, DOI 10.1016/0091-6749(93)90302-V; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; MURRAY AB, 1983, PEDIATRICS, V71, P418; MURRAY AB, 1989, PEDIATRICS, V84, P451; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; National Heart Lung and Blood Institute, 1997, NIH PUBLICATION, V97-4053; OCONNOR GT, 1987, AM REV RESPIR DIS, V135, P800; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; OLDIGS M, 1991, PEDIATR PULM, V10, P123, DOI 10.1002/ppul.1950100215; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; PLATT SD, 1989, BRIT MED J, V298, P1673; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; PLATTSMILLS TAE, 1993, AM REV RESPIR DIS, V148, P553; Pope A. M., 1993, INDOOR ALLERGENS ASS; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; RAIZENNE ME, 1989, ENVIRON HEALTH PERSP, V79, P179, DOI 10.2307/3430547; REIGART JR, 1993, PEDIATRICS, V91, P1210; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RYLANDER E, 1995, EPIDEMIOLOGY, V6, P289, DOI 10.1097/00001648-199505000-00017; SALVAGGI.J, 1970, J ALLERGY, V45, P257, DOI 10.1016/0021-8707(70)90032-8; SALVAGGIO JE, 1967, J ALLERGY, V39, P227, DOI 10.1016/0021-8707(67)90015-9; SAMET J, 1990, AM REV RESPIR DIS, V142, P915; SCHWAB M, 1992, ENVIRON INT, V18, P173, DOI 10.1016/0160-4120(92)90005-O; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; SLY RM, 1988, J ALLERGY CLIN IMMUN, V82, P705, DOI 10.1016/0091-6749(88)90069-3; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, J EPIDEMIOL COMMUN H, V43, P7, DOI 10.1136/jech.43.1.7; STRACHAN DP, 1986, FAM PRACT, V3, P137, DOI 10.1093/fampra/3.3.137; STRACHAN DP, 1988, BRIT MED J, V297, P1223; SUNYER J, 1989, LANCET, V1, P179; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Teague WG, 2001, PEDIATR CLIN N AM, V48, P1167, DOI 10.1016/S0031-3955(05)70367-9; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; Vojta PJ, 2001, ENVIRON HEALTH PERSP, V109, P815, DOI 10.2307/3454824; Vollmer WM, 1998, AM J RESP CRIT CARE, V157, P1079; Wanner HU, 1993, BIOL PARTICLES INDOO; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WEILL H, 1964, JAMA-J AM MED ASSOC, V190, P811; WEILL HANS, 1965, J AIR POLLUT CONTR ASS, V15, P467; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; White MC, 1997, AM J EPIDEMIOL, V145, P432; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965	121	71	71	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2003	112	1		S			233	239				7	Pediatrics	Pediatrics	698KQ	WOS:000183999100004	12837915	
J	Andre, C; Perrin-Fayolle, M; Grosclaude, M; Couturier, P; Basset, D; Cornillon, J; Piperno, D; Girodet, B; Sanchez, R; Vallon, C; Bellier, P; Nasr, M				Andre, C; Perrin-Fayolle, M; Grosclaude, M; Couturier, P; Basset, D; Cornillon, J; Piperno, D; Girodet, B; Sanchez, R; Vallon, C; Bellier, P; Nasr, M			A double-blind placebo-controlled evaluation of sublingual immunotherapy with a standardized ragweed extract in patients with seasonal rhinitis - Evidence for a dose-response relationship	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						sublingual-swallow immunotherapy; ragweed; seasonal rhinitis	HOUSE-DUST MITE; ALLERGIC RHINOCONJUNCTIVITIS; SWALLOW IMMUNOTHERAPY; CLINICAL EFFICACY; CONTROLLED TRIAL; POLLEN EXTRACT; CHILDREN; ASTHMA; SENSITIZATIONS	Background: There is a growing consensus on the benefits of sublingual-swallow immunotherapy in the treatment of allergic diseases. Methods: This randomized, double-blind placebo-controlled study was undertaken to assess the efficacy and safety of sublingual immunotherapy with standardized ragweed pollen extract tablets, in patients with an allergic rhinitis. A total of 110 outpatients were randomized (immunotherapy [I]: 55; placebo [P]: 55), of whom 99 were analyzable for efficacy (I: 48; P: 51) and 106 analyzable for safety (I: 53; P: 53). After a 28-day progression phase, the patients received a maintenance treatment during 6.5 months. Efficacy variables included a global assessment of efficacy (patient/investigator), symptoms and medication scores as well as the frequency of asthma attacks. Results: In the active treatment group, 43 patients completed the study, versus 49 on placebo. During the whole period of pollination, the difference favoring immunotherapy was highly significant for the global assessment by the patient (p = 0.004) and by the investigator (p = 0.005). Adverse reactions were reported more often in the active treatment but mild or moderate, and they abated after dose adjustment. A subgroup analysis of those patients receiving the highest dose of immunotherapy (3 tablets 3 times a week) showed a highly significant response for rhinitis and conjunctivitis total scores by comparison to lower dosages. Conclusion: This study confirms the efficacy and safety of sublingual immunotherapy and strongly suggests a dose-response relationship. Copyright (C) 2003 S. Karger AG, Basel	Stallergenes SA, Dept Sci & Med, F-92183 Antony, France; Ctr Hosp Lyon Sud, Dept Pneumol & Immunol Clin, Lyon, France; Clin Rhone Moyen, Grp Allergol & Immunol, Lyon, France; Grp Lyonnais Allergol, Lyon, France; PAROT, Ctr Med, Lyon, France	Andre, C (reprint author), Stallergenes SA, Dept Sci & Med, 6 Rue Alexis Tocqueville, F-92183 Antony, France.						Bousquet J, 1998, ALLERGY S, V53, P44; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; GOLDEN DBK, 1981, J ALLERGY CLIN IMMUN, V67, P370, DOI 10.1016/0091-6749(81)90082-8; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; KHINCHI MS, 2000, ALLERGY S, V55, P24; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Malling HJ, 1998, ALLERGY, V53, P461; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Noirey N, 2000, J ALLERGY CLIN IMMUN, V105, P1194, DOI 10.1067/mai.2000.106545; Noon L, 1911, LANCET, V1, P1572; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x	19	71	74	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	JUN	2003	131	2					111	118		10.1159/000070926		8	Allergy; Immunology	Allergy; Immunology	696PG	WOS:000183894800006	12811019	
J	Chu, HW; Honour, JM; Rawlinson, CA; Harbeck, RJ; Martin, RJ				Chu, HW; Honour, JM; Rawlinson, CA; Harbeck, RJ; Martin, RJ			Effects of respiratory Mycoplasma pneumoniae infection on allerizen-induced bronchial hyperresponsiveness and lung inflammation in mice	INFECTION AND IMMUNITY			English	Article							HOUSE-DUST ENDOTOXIN; CHLAMYDIA-PNEUMONIAE; IMMUNE-RESPONSE; CHRONIC ASTHMA; MURINE MODEL; DISEASE; ADULTS; SENSITIZATION; CHILDREN; EXPOSURE	Airway mycoplasma infection may be associated with asthma pathophysiology. However, the direct effects of mycoplasma infection on asthma remain unknown. Using a murine allergic-asthma model, we evaluated the effects of different timing of airway Mycoplasma pneumoniae infection on bronchial hyperresponsiveness (BHR), lung inflammation, and the protein levels of Th1 (gamma interferon [IFN-gamma]) and Th2 (interleukin 4 [IL-4]) cytokines in bronchoalveolar lavage fluid. When mycoplasma infection occurred 3 days before allergen (ovalbumin) sensitization and challenge, the infection reduced the BHR and inflammatory-cell influx into the lung. This was accompanied by a significant induction of Th1 responses (increased IFN-gamma and decreased IL-4 production). Conversely, when mycoplasma infection occurred 2 days after allergen sensitization and challenge, the infection initially caused a temporary reduction of BHR and then increased BHR, lung inflammation, and IL-4 levels. Our data suggest that mycoplasma infection could modulate both physiological and immunological responses in the murine asthma model. Our animal models may also provide a new means to understand the role of infection in asthma pathogenesis and give evidence for the asthma hygiene hypothesis.	Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA	Martin, RJ (reprint author), Natl Jewish Med & Res Ctr, Dept Med, 1400 Jackson St,Room B116, Denver, CO 80206 USA.						Busse WW, 2001, NEW ENGL J MED, V344, P350; Chan ED, 1999, CHEST, V115, P1188, DOI 10.1378/chest.115.4.1188; CIMOLAI N, 1992, MICROBIOL IMMUNOL, V36, P465; Cook PJ, 1998, THORAX, V53, P254; Dorigo-Zetsma JW, 2001, J CLIN MICROBIOL, V39, P1184, DOI 10.1128/JCM.39.3.1184-1186.2001; Esposito S, 2000, EUR RESPIR J, V16, P1142, DOI 10.1034/j.1399-3003.2000.16f21.x; Fayon M, 1999, ACTA PAEDIATR, V88, P1216, DOI 10.1080/080352599750030310; Ford JG, 2001, J IMMUNOL, V167, P1769; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GIL JC, 1993, ANN ALLERGY, V70, P23; Hardy RD, 2002, INFECT IMMUN, V70, P649, DOI 10.1128/IAI.70.2.649-654.2002; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Koh YI, 2001, J CLIN IMMUNOL, V21, P51, DOI 10.1023/A:1006745116360; Kraft M, 1998, AM J RESP CRIT CARE, V158, P998; Kraft M, 2002, CHEST, V121, P1782, DOI 10.1378/chest.121.6.1782; Kraft M, 2000, CLIN CHEST MED, V21, P301, DOI 10.1016/S0272-5231(05)70268-9; Martin RJ, 2001, AM J RESP CELL MOL, V24, P577; Martin RJ, 2001, J ALLERGY CLIN IMMUN, V107, P595; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Snedecor G. W., 1989, STAT METHODS, P177; Stampfli MR, 1998, CLIN EXP ALLERGY, V28, P1581; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394; Walzl G, 2000, J EXP MED, V192, P1317, DOI 10.1084/jem.192.9.1317; Yamamoto N, 2001, J VIROL, V75, P499, DOI 10.1128/JVI.75.1.499-505.2001; YANO T, 1994, AM J RESP CRIT CARE, V149, P1348	26	71	78	0	5	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0019-9567			INFECT IMMUN	Infect. Immun.	MAR	2003	71	3					1520	1526		10.1128/IAI.71.3.1520-1526.2003		7	Immunology; Infectious Diseases	Immunology; Infectious Diseases	650NU	WOS:000181270900059	12595471	
J	Schuller, HM; Plummer, HK; Jull, BA				Schuller, HM; Plummer, HK; Jull, BA			Receptor-mediated effects of nicotine and its nitrosated derivative NNK on pulmonary neuroendocrine cells	ANATOMICAL RECORD PART A-DISCOVERIES IN MOLECULAR CELLULAR AND EVOLUTIONARY BIOLOGY			English	Article; Proceedings Paper	Experimental Biology 2002 Meeting	APR 20-24, 2002	NEW ORLEANS, LOUISIANA			PNEC; SCLC; alpha(7)nAChR; asthma; nicotine; NNK	TOBACCO-SPECIFIC CARCINOGEN; LUNG-CANCER; N-NITROSAMINES; NEUROEPITHELIAL BODIES; ACETYLCHOLINE-RECEPTOR; AIRWAY CHEMORECEPTORS; DNA METHYLATION; POINT MUTATIONS; CARBON-DIOXIDE; NEVER-SMOKERS	Pulmonary neuroendocrine cells (PNECs) have been implicated in the development of small cell lung carcinoma (SCLC) and pediatric asthma, and smoking is a risk factor for both diseases. We as well as others have shown that the alpha(7) nicotinic acetylcholine receptor (alpha(7) nAChR) regulates the release of 5-hydroxytryptamine (5-HT, serotonin) in PNECs and SCLC. Serotonin is an autocrine growth factor for PNECs and SCLC and acts as bronchoconstrictor. We found that nicotine and its nitrosated carcinogenic derivative 4.(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) bind to the alpha(7) nAChR in SCLC and PNECs, resulting in the influx of Ca2+, release of 5-HT, and activation of a mitogenic pathway mediated by protein kinase C (PKC), Raf-1, mitogen activated protein kinase (MAPK) and c-myc. Exposure to 10% CO2 acted synergistically. Unstimulated SCLC cells from smokers demonstrated high base levels of 5-HT release and of individual downstream signaling components in comparison to PNECs. Subchronic exposure of PNECs to NNK up-regulated the alpha(7) nAChR and its associated serotonergic mitogenic pathway in PNECs, an effect that may contribute to the development of SCLC in smokers and pediatric asthma in children of mothers who smoke. (C) 2003 Wiley-Liss, Inc.	Univ Tennessee, Coll Vet Med, Dept Pathol, Expt Oncol Lab, Knoxville, TN 37996 USA	Schuller, HM (reprint author), Univ Tennessee, Coll Vet Med, Dept Pathol, Expt Oncol Lab, 2407 River Dr, Knoxville, TN 37996 USA.						AGUAYO SM, 1993, ANAT REC, V236, P122, DOI 10.1002/ar.1092360116; Alshehri M, 1997, CHEST, V112, P553, DOI 10.1378/chest.112.2.553; American Cancer Society, 2002, CANC FACTS FIG; [Anonymous], 2002, ASTHM CHILDR FACT SH, V1, P1; BELINSKY SA, 1990, MUTAT RES, V233, P105, DOI 10.1016/0027-5107(90)90155-W; BELINSKY SA, 1990, CANCER RES, V50, P3772; Bratel T, 2000, RESP MED, V94, P1221, DOI 10.1053/rmed.2000.0953; Brown MJ, 1997, AM J ROENTGENOL, V168, P1561; Brunnemann KD, 1996, CRIT REV TOXICOL, V26, P121, DOI 10.3109/10408449609017926; Lodrup Carlsen K., 2001, CURR OPIN ALLERGY CL, V1, P139; CATTANEO MG, 1993, CANCER RES, V53, P5566; Cazzola M, 2000, TRENDS PHARMACOL SCI, V21, P13, DOI 10.1016/S0165-6147(99)01408-X; CODIGNOLA A, 1994, FEBS LETT, V342, P286, DOI 10.1016/0014-5793(94)80518-0; Cutz E, 1985, Pediatr Pulmonol, V1, pS21; Cutz E, 1999, RESP PHYSIOL, V115, P201, DOI 10.1016/S0034-5687(99)00018-3; Fraig M, 2002, AM J SURG PATHOL, V26, P647, DOI 10.1097/00000478-200205000-00011; GOPALAKRISHNAN M, 1995, EUR J PHARM-MOLEC PH, V290, P237, DOI 10.1016/0922-4106(95)00083-6; Gotti C, 1997, PROG NEUROBIOL, V53, P199, DOI 10.1016/S0301-0082(97)00034-8; Hecht SS, 1998, CHEM RES TOXICOL, V11, P559, DOI 10.1021/tx980005y; HECHT SS, 1986, CANCER RES, V46, P498; Hecht SS, 1996, CRIT REV TOXICOL, V26, P163, DOI 10.3109/10408449609017929; HOFFMANN D, 1981, CANCER RES, V41, P2386; Hoffmann D, 1996, CRIT REV TOXICOL, V26, P199, DOI 10.3109/10408449609017931; HOFFMANN D, 1991, CRIT REV TOXICOL, V21, P305, DOI 10.3109/10408449109017917; Joad JP, 2000, CLIN CHEST MED, V21, P37, DOI 10.1016/S0272-5231(05)70006-X; JOHNSON DE, 1982, PEDIATR RES, V16, P446, DOI 10.1203/00006450-198206000-00009; JOHNSON DE, 1989, AM REV RESPIR DIS, V140, P1807; Jull BA, 2001, J CANCER RES CLIN, V127, P707; Kelly A, 2001, J WOMEN HEALTH GEN-B, V10, P515, DOI 10.1089/15246090152543085; Knight JM, 1998, J ASTHMA, V35, P113, DOI 10.3109/02770909809055412; KRYSTAL G, 1988, MOL CELL BIOL, V8, P3373; Lackmann GM, 1999, J NATL CANCER I, V91, P459, DOI 10.1093/jnci/91.5.459; Lechin F, 1996, ANN ALLERG ASTHMA IM, V77, P245; Lee PN, 2001, INHAL TOXICOL, V13, P951, DOI 10.1080/089583701753210353; Merryman JI, 1997, CHEST, V112, P779, DOI 10.1378/chest.112.3.779; MILLER MS, 1994, INT J ONCOL, V4, P5; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; MUSCAT JE, 1995, CANCER LETT, V88, P1, DOI 10.1016/0304-3835(94)03608-L; OREFFO VIC, 1993, CARCINOGENESIS, V14, P451, DOI 10.1093/carcin/14.3.451; OSANN KE, 1991, CANCER RES, V51, P4893; Plummer HK, 2000, EXP LUNG RES, V26, P121; Schuller HM, 1999, CANCER RES, V59, P4510; SCHULLER HM, 1990, CANCER RES, V50, P1960; Schuller HM, 2000, EUR J PHARMACOL, V393, P265, DOI 10.1016/S0014-2999(00)00094-7; SCHULLER HM, 1994, NEUROTOXICOLOGY, V15, P877; Schuller HM, 1998, BIOCHEM PHARMACOL, V55, P1377, DOI 10.1016/S0006-2952(97)00651-5; Sekhon HS, 1999, J CLIN INVEST, V103, P637, DOI 10.1172/JCI5232; Sheppard BJ, 2000, INT J ONCOL, V16, P513; Sher E, 1998, ANN NY ACAD SCI, V841, P606, DOI 10.1111/j.1749-6632.1998.tb10993.x; Ulrik Charlotte Suppli, 2002, Ugeskr Laeger, V164, P891; WAGNER SN, 1993, VIRCHOWS ARCH B, V63, P325, DOI 10.1007/BF02899279; WONG AJ, 1986, SCIENCE, V233, P461, DOI 10.1126/science.3014659; Youngson C, 1997, MICROSC RES TECHNIQ, V37, P101, DOI 10.1002/(SICI)1097-0029(19970401)37:1<101::AID-JEMT10>3.3.CO;2-S; YOUNGSON C, 1994, ADV EXP MED BIOL, V360, P179; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; ZHENG TZ, 1994, CANCER, V74, P1556, DOI 10.1002/1097-0142(19940901)74:5<1556::AID-CNCR2820740511>3.0.CO;2-0	56	71	72	0	0	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0003-276X			ANAT REC PART A	Anat. Rec. Part A	JAN	2003	270A	1					51	58		10.1002/ar.a.10019		8	Anatomy & Morphology	Anatomy & Morphology	670ML	WOS:000182412500007	12494489	
J	Iwasaki, M; Nagata, K; Takano, S; Takahashi, K; Ishii, N; Ikezawa, Z				Iwasaki, M; Nagata, K; Takano, S; Takahashi, K; Ishii, N; Ikezawa, Z			Association of a new-type prostaglandin D2 receptor CRTH2 with circulating T helper 2 cells in patients with atopic dermatitis	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article						cell surface receptors; chemotaxis; flow cytometry; human; T lymphocyte subsets	LYMPHOCYTE-ASSOCIATED ANTIGEN; CHEMOKINE RECEPTORS; TH2 CELLS; IN-SITU; SELECTIVE EXPRESSION; CYTOKINE PATTERN; T-HELPER-2 CELLS; SURFACE-MOLECULE; HOMING RECEPTOR; HUMAN CD4(+)	Prostaglandin D-2 is known to be the major prostanoid produced by allergen-activated mast cells, but its role in the formation of allergic diseases is not well established because of complexity of its receptor system and lack of appropriate inhibitors. We have recently identified a new-type prostaglandin D2 receptor, named CRTH2. Studies with normal subjects have shown that CRTH2 appears to be selectively expressed by T helper 2 cells but not T helper 1 cells among circulating CD4(+) lymphocytes. The exact correlation between CRTH2 and T helper 2 cells in various disease settings and the impact of CRTH2-mediated prostaglandin D-2 activities on various T helper 2 responses in vivo still remain to be elucidated, however. In this study, we investigated the correlation between CRTH2 and T helper 2 cells among circulating CD4+ lymphocytes in normal adults and patients with atopic dermatitis, a T-helper-2-involving disease. The results showed that virtually all CRTH2(+)CD4(+) lymphocytes had a pure T helper 2 phenotype and formed not all but a large proportion of circulating T helper 2 cells for both normal and atopic dermatitis subjects. In chemotaxis assays, peripheral blood CRTH2(+)CD4(+) lymphocytes were significantly attracted by prostaglandin D2 as well as by a typical T-helper-2-attracting chemokine, thymus and activation regulated chemokine, whereas they showed little chemotactic migration toward typical T-helper-1-attracting chemokines, macrophage inflammatory protein 1beta and interferon-gamma inducible protein 10. Furthermore, in atopic dermatitis patients, a preferential increase of CRTH2(+) cells was noted within the disease-related cutaneous lymphocyte-associated antigen-positive, but not the cutaneous lymphocyte-associated antigen-negative, CD4(+) lymphocyte compartment. Our results suggest the involvement of the prostaglandin D-2/CRTH2 system in both normal and pathogenic T helper 2 responses.	BML, R&D Ctr, Kawagoe, Saitama 3501101, Japan; Toho Univ, Sch Med, Dept Biol Mol, Tokyo, Japan; Yokohama City Univ, Sch Med, Dept Dermatol, Kanagawa, Japan; Natl Inst Infect Dis, Leprosy Res Ctr, Dept Bioregulat, Tokyo, Japan	Nagata, K (reprint author), BML, R&D Ctr, 1361-1 Matoba, Kawagoe, Saitama 3501101, Japan.						Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238; Akdis M, 1997, J IMMUNOL, V159, P4611; Akdis M, 2000, EUR J IMMUNOL, V30, P3533, DOI 10.1002/1521-4141(2000012)30:12<3533::AID-IMMU3533>3.0.CO;2-5; Angeli V, 2001, J EXP MED, V193, P1135, DOI 10.1084/jem.193.10.1135; Annunziato F, 2001, J ALLERGY CLIN IMMUN, V108, P815; Austrup F, 1997, NATURE, V385, P81, DOI 10.1038/385081a0; Balashov KE, 1999, P NATL ACAD SCI USA, V96, P6873, DOI 10.1073/pnas.96.12.6873; BARR RM, 1988, BRIT J PHARMACOL, V94, P773; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BOIE Y, 1995, J BIOL CHEM, V270, P18910; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; CHARLESWORTH EN, 1993, CLIN EXP ALLERGY, V23, P391, DOI 10.1111/j.1365-2222.1993.tb00344.x; Cosmi L, 2000, EUR J IMMUNOL, V30, P2972, DOI 10.1002/1521-4141(200010)30:10<2972::AID-IMMU2972>3.0.CO;2-#; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; FLOWER RJ, 1976, BRIT J PHARMACOL, V56, P229; GILES H, 1988, PROSTAGLANDINS, V35, P277, DOI 10.1016/0090-6980(88)90093-7; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hamid Q, 1996, J ALLERGY CLIN IMMUN, V98, P225, DOI 10.1016/S0091-6749(96)70246-4; HAMID Q, 1994, J CLIN INVEST, V94, P870, DOI 10.1172/JCI117408; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Imai T, 1999, INT IMMUNOL, V11, P81, DOI 10.1093/intimm/11.1.81; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI13543; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; MOSMANN TR, 1989, ANNU REV IMMUNOL, V7, P145, DOI 10.1146/annurev.immunol.7.1.145; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nagata K, 1999, J IMMUNOL, V162, P1278; Nakazawa M, 1997, J ALLERGY CLIN IMMUN, V99, P673, DOI 10.1016/S0091-6749(97)70030-7; Narumiya S, 1999, PHYSIOL REV, V79, P1193; PIENKOWSKI MM, 1988, J ALLERGY CLIN IMMUN, V82, P95, DOI 10.1016/0091-6749(88)90057-7; Qin SX, 1998, J CLIN INVEST, V101, P746, DOI 10.1172/JCI1422; Rajka G, 1989, Acta Derm Venereol Suppl (Stockh), V144, P13; REINHOLD U, 1991, CLIN EXP IMMUNOL, V86, P444; Rogge L, 2000, NAT GENET, V25, P96, DOI 10.1038/75671; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; RUZICKA T, 1986, J INVEST DERMATOL, V86, P105, DOI 10.1111/1523-1747.ep12284061; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Santamaria Babi L F, 1995, J Exp Med, V181, P1935, DOI 10.1084/jem.181.5.1935; Syrbe U, 1999, SPRINGER SEMIN IMMUN, V21, P263, DOI 10.1007/BF00812257; Teraki Y, 2000, BRIT J DERMATOL, V143, P373, DOI 10.1046/j.1365-2133.2000.03665.x; Teraki Y, 1997, J IMMUNOL, V159, P6018; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; Tsuda H, 2001, CLIN EXP IMMUNOL, V123, P105, DOI 10.1046/j.1365-2249.2001.01422.x; Vestergaard C, 2000, J INVEST DERMATOL, V115, P640, DOI 10.1046/j.1523-1747.2000.00115.x; Yawalkar N, 1999, J INVEST DERMATOL, V113, P43, DOI 10.1046/j.1523-1747.1999.00619.x	56	71	72	1	1	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0022-202X			J INVEST DERMATOL	J. Invest. Dermatol.	SEP	2002	119	3					609	616		10.1046/j.1523-1747.2002.01862.x		8	Dermatology	Dermatology	592RV	WOS:000177951400010	12230502	
J	Herrick, CA; Xu, L; Wisnewski, AV; Das, J; Redlich, CA; Bottomly, K				Herrick, CA; Xu, L; Wisnewski, AV; Das, J; Redlich, CA; Bottomly, K			A novel mouse model of diisocyanate-induced asthma showing allergic-type inflammation in the lung after inhaled antigen challenge	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; diisocyanate; skin; airway; lung; eosinophils; T(H)2; IL-4; IL-13; IFN-gamma	HUMAN SERUM-ALBUMIN; TOLUENE DIISOCYANATE; OCCUPATIONAL ASTHMA; NONATOPIC ASTHMA; BRONCHIAL-MUCOSA; INTERFERON-GAMMA; EXPOSURE; WORKERS; IL-4; ISOCYANATES	Background: Exposure to diisocyanates, a group of highly reactive, low-molecular-weight compounds, is a major cause of occupational asthma. In contrast to mouse models of atopic asthma, previous mouse models of diisocyanate-induced asthma have failed to show lung inflammation with characteristics of human disease. Objective: Our goal was to establish a novel mouse model of diisocyanate-induced asthma in which lung inflammation reminiscent of that seen in human asthma is generated after inhaled antigen challenge. Methods: BALB/c mice were epicutaneously sensitized to hexamethylene diisocyanate (HDI) and then challenged with an HDI-protein conjugate administered by means of an intranasal droplet. Results: HDI sensitization resulted in development of contact hypersensitivity and HDI-specific antibody production. Most importantly, however, vigorous inflammatory responses with characteristics of human asthma were generated in the lung after inhaled HDI challenge. Challenge of sensitized, but not unsensitized, mice resulted in airway eosinophilia, mucus hypersecretion, and production of T(H)1-type (IFN-gamma) and T(H)2 type (IL-4, IL-5, and IL-13) cytokines by lung inflammatory cells. Despite the mixed T(H)1/T(H)2 response induced by HDI sensitization, use of cytokine-dericient mice revealed that airway eosinophilia was mediated by T(H)2 cytokines and not by IFN-gamma. Conclusion: We report a novel mouse model of diisocyanate-induced asthma that, in contrast to previous models, demonstrates antigen-induced lung inflammation with characteristics of human disease. This model will allow investigation of the immunopathogenesis of diisocyanate-induced asthma and should provide insight into this common form of occupational disease.	Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Herrick, CA (reprint author), Yale Univ, Sch Med, Dept Dermatol, 333 Cedar St,POB 208059, New Haven, CT 06520 USA.				NHLBI NIH HHS [R01-HL65209, R01 HL062622, P50-HL56389, R01 HL062622-01, R01-HL62622, R01 HL062622-02]; NIEHS NIH HHS [K24-ES00355]		Amin K, 2000, AM J RESP CRIT CARE, V162, P2295; BAUR X, 1984, J ALLERGY CLIN IMMUN, V73, P610, DOI 10.1016/0091-6749(84)90520-7; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P821, DOI 10.1016/0091-6749(92)90437-7; BENTLEY AM, 1994, J INVEST ALLERG CLIN, V4, P222; Bernstein JA, 1996, TOXICOLOGY, V111, P181, DOI 10.1016/0300-483X(96)03375-6; Busse WW, 2001, NEW ENGL J MED, V344, P350; CARTIER A, 1989, J ALLERGY CLIN IMMUN, V84, P507, DOI 10.1016/0091-6749(89)90364-3; CHANYEUNG M, 1995, NEW ENGL J MED, V333, P107, DOI 10.1056/NEJM199507133330207; Cohn L, 2001, J IMMUNOL, V166, P2760; Ebino K, 1999, INHAL TOXICOL, V11, P171, DOI 10.1080/089583799197131; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36; Herrick CA, 2000, J CLIN INVEST, V105, P765, DOI 10.1172/JCI8624; Hnizdo E, 2001, CLIN EXP ALLERGY, V31, P32, DOI 10.1046/j.1365-2222.2001.00981.x; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Lee Millina, 1998, Journal of Korean Medical Science, V13, P459; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669; Lushniak BD, 1998, AM J IND MED, V33, P471, DOI 10.1002/(SICI)1097-0274(199805)33:5<471::AID-AJIM6>3.0.CO;2-V; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P1292; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376; Maestrelli P, 1997, CLIN EXP ALLERGY, V27, P47, DOI 10.1111/j.1365-2222.1997.tb01826.x; Matheson JM, 2001, CLIN EXP ALLERGY, V31, P1067, DOI 10.1046/j.1365-2222.2001.01125.x; PAGGIARO PL, 1994, EUR RESPIR J, V7, P761, DOI 10.1183/09031936.94.07040761; Park HS, 1999, J ALLERGY CLIN IMMUN, V104, P847; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; RATTRAY NJ, 1994, TOXICOLOGY, V88, P15, DOI 10.1016/0300-483X(94)90108-2; Scheerens H, 1999, AM J RESP CRIT CARE, V159, P1074; Scheerens H, 1996, AM J RESP CRIT CARE, V154, P858; TSE KS, 1985, ALLERGY, V40, P314, DOI 10.1111/j.1398-9995.1985.tb00242.x; Vandebriel RJ, 2000, TOXICOL APPL PHARM, V162, P77, DOI 10.1006/taap.1999.8841; VANDENPLAS O, 1993, BRIT J IND MED, V50, P213; Wisnewski AV, 1999, AM J RESP CRIT CARE, V159, pA234	31	71	71	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					873	878		10.1067/mai.2002.123533		6	Allergy; Immunology	Allergy; Immunology	553QW	WOS:000175687800020	11994714	
J	Vally, H; Thompson, PJ				Vally, H; Thompson, PJ			Role of sulfite additives in wine induced asthma: Single dose and cumulative dose studies	THORAX			English	Article						asthma; wine; sulfite additives	METABISULFITE-INDUCED BRONCHOCONSTRICTION; SODIUM METABISULFITE; CHALLENGE; RESPONSES	Background-Wine appears to be a significant trigger for asthma. Although sulfite additives have been implicated as a major cause of wine induced asthma, direct evidence is limited. Two studies were undertaken to assess sulfite reactivity in wine sensitive asthmatics. The first study assessed sensitivity to sulfites in wine using a single dose sulfited wine challenge protocol followed by a double blind, placebo controlled challenge. In the second study a cumulative dose sulfited wine challenge protocol was employe to establish if wine sensitive asthmatics as a group have an increased sensitivity to sulfites. Methods-In study 1, 24 asthmatic patients with a strong history of wine induced asthma were screened. Subjects showing positive responses to single blind high sulfite (300 ppm) wine challenge were rechallenged on separate days in a double blind, placebo controlled fashion with wines of varying sulfite levels to characterise their responses to these drinks. In study 2, wine sensitive asthmatic patients (n=12) and control asthmatics (n=6) were challenged cumulatively with wine containing increasing concentrations of sulfite in order to characterise further their sensitivity to sulfites in wine. Results-Four of the 24 self-reporting wine sensitive asthmatic patients were found to respond to sulfite additives in wine when challenged in a single dose fashion (study 1). In the double blind dose-response study all four had a significant fall in forced expiratory volume in one second (FEV) (> 15% from baseline) following exposure to wine containing 300 ppm sulfite, but did not respond to wines containing 20, 75 or 150 ppm sulfite. Responses were maximal at 5 minutes (mean (SD) maximal decline in FEV, 28.7 (13)%) and took 15-60 minutes to return to baseline levels. In the cumulative dose-response study (study 2) no significant difference was observed in any of the lung function parameters measured (FEV,, peak expiratory flow (PEF), mid phase forced expiratory flow (FEF25-75)) between wine sensitive and normal asthmatic subjects. Conclusions-Only a small number of wine sensitive asthmatic patients responded to a single dose challenge with sulfited wine under laboratory conditions. This may suggest that the role of sulfites and/or wine in triggering asthmatic responses has been overestimated. Alternatively, cofactors or other components in wine may play an important role in wine induced asthma. Cumulative sulfite dose challenges did not detect an increased sensitivity to sulfite in wine sensitive asthmatics and an alternative approach to identifying sulfite/wine sensitive asthma may be required.	Univ Western Australia, Dept Med, Perth, WA 6009, Australia; Asthma & Allergy Res Inst Inc, Perth, WA, Australia	Vally, H (reprint author), Sir Charles Gairdner Hosp, Asthma & Allergy Res Inst Inc, Ground Floor,E Block, Nedlands, WA 6009, Australia.						BAKER GJ, 1982, AUST NZ J MED, V12, P213; DAHL R, 1986, J ALLERGY CLIN IMMUN, V78, P1126, DOI 10.1016/0091-6749(86)90261-7; DELOHERY J, 1984, AM REV RESPIR DIS, V130, P1027; DIXON C M S, 1988, American Review of Respiratory Disease, V137, P238; GERSHWIN ME, 1985, J ALLERGY CLIN IMMUN, V75, P411, DOI 10.1016/0091-6749(85)90080-6; HALPERN GM, 1985, ANN ALLERGY, V55, P686; Lazarus SC, 1997, AM J RESP CRIT CARE, V156, P1725; MANSOUR E, 1992, J APPL PHYSIOL, V72, P1831; NICHOL GM, 1989, THORAX, V44, P1009, DOI 10.1136/thx.44.12.1009; NICHOL GM, 1990, AM REV RESPIR DIS, V142, P576; OCONNOR BJ, 1994, THORAX, V49, P307, DOI 10.1136/thx.49.4.307; PAVORD ID, 1994, EUR RESPIR J, V7, P50, DOI 10.1183/09031936.94.07010050; RANKINE B, 1962, AUST WINE BREW SPIRI, V80, P14; SAKAMOTO T, 1994, AM J RESP CRIT CARE, V149, P387; SEALE JP, 1988, ANN ALLERGY, V61, P209; SUN J, 1995, THORAX, V50, P875, DOI 10.1136/thx.50.8.875; Vally H, 2000, J ALLERGY CLIN IMMUN, V105, P462, DOI 10.1067/mai.2000.104548; Vally H, 1999, J ALLERGY CLIN IMMUN, V103, P41, DOI 10.1016/S0091-6749(99)70523-3; *W AUSTR FOOD MON, 1992, SULF DIOX FOODS; WALL PJ, 1998, USAGE SULFUR DIOXIDE; Wang M, 1996, THORAX, V51, P799, DOI 10.1136/thx.51.8.799; WRIGHT W, 1990, AM REV RESPIR DIS, V141, P1400	22	71	74	1	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	OCT	2001	56	10					763	769		10.1136/thorax.56.10.763		7	Respiratory System	Respiratory System	477NB	WOS:000171289100006	11562514	
J	Annesi-Maesano, I; Moreau, D; Strachan, D				Annesi-Maesano, I; Moreau, D; Strachan, D			In utero and perinatal complications preceding asthma	ALLERGY			English	Article						asthma; birth weight; family history; in utero; in utero exposure to smoking; labor; malpresentation of fetus; passive smoking; perinatal; pregnancy; risk factors; threatened labor	CHILDHOOD ASTHMA; RISK FACTOR; RESPIRATORY-DISEASE; BRONCHIAL-ASTHMA; PREGNANCY; BIRTH; EPIDEMIOLOGY; PREMATURITY; MORBIDITY; EXPOSURE	Background: It has been suggested that pregnancy and early life may influence the development of asthma in the offspring, but published studies have not carefully controlled for potential biases. Methods: In a large British birth cohort of 4065 natural children of 2583 mothers, we investigated whether in utero and perinatal influences contribute to the development and the severity of asthma in childhood, allowing for possible confounders of the relationship, and considering the nonindependence of familial data. Results: Child asthma (10.1%) was more frequently reported by mothers when there had been health complications during pregnancy (prevalence = 14.3%; adjusted odds ratio [ORadj] = 2.01; 95% confidence interval, 1.52-2.67), labor, or delivery (19.3%, ORadj = 1.35, 1.01-1.81); child illness or health complications during the first week of life (22.6%, ORadj = 1.35, 1.01-1.82); and birth weight of < 2.5 kg (7.0%, ORadj = 1.57, 1.10-2.25). Specific causes of health complications during pregnancy which significantly related to asthma were early or threatened labor (ICD: 644) (4.8%, ORadj = 1.58, 1.03-2.40) and the malposition or malpresentation of the fetus (ICD: 652) (1.6%, ORadj = 3.63, 1.47-8.91). Conclusions: The results provide further evidence that in utero and perinatal factors may increase the risk of developing asthma.	INSERM, U472, Dept Toxicol & Environm Epidemiol, Epidemiol & Biostat Unit, F-94807 Villejuif, France; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	Annesi-Maesano, I (reprint author), INSERM, U472, Dept Toxicol & Environm Epidemiol, Epidemiol & Biostat Unit, 16 Ave PV Couturier, F-94807 Villejuif, France.		Annesi-Maesano, Isabella/D-9173-2016				ANNESI I, 1994, REV MAL RESPIR, V11, P325; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; BAHNA SL, 1972, ACTA ALLERGOL, V27, P397, DOI 10.1111/j.1398-9995.1972.tb01439.x; BERTRAND JM, 1985, NEW ENGL J MED, V312, P742, DOI 10.1056/NEJM198503213121202; DOUCETTE JT, 1993, EPIDEMIOLOGY, V4, P143, DOI 10.1097/00001648-199303000-00010; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; GLUCK JC, 1976, ANN ALLERGY, V37, P164; GORDON M, 1970, AM J OBSTET GYNECOL, V106, P421; HALKEN S, 1995, ALLERGY, V50, P97; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233; INFANTERIVARD C, 1995, EPIDEMIOLOGY, V6, P178, DOI 10.1097/00001648-199503000-00016; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; Landau LI, 1996, PEDIATR PULM, V22, P314, DOI 10.1002/(SICI)1099-0496(199611)22:5<314::AID-PPUL4>3.0.CO;2-K; Langley-Evans S, 1997, CLIN EXP ALLERGY, V27, P1377, DOI 10.1046/j.1365-2222.1997.1690965.x; LAO TT, 1990, EUR J OBSTET GYN R B, V35, P1983; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Oryszczyn MP, 1999, CLIN EXP ALLERGY, V29, P334; ORYSZCZYN MP, 1991, J ALLERGY CLIN IMMUN, V87, P1169, DOI 10.1016/0091-6749(91)92163-U; SALK L, 1974, AM J DIS CHILD, V127, P30; Schatz M, 1997, CLIN PERINATOL, V24, P407; SCHATZ M, 1995, AM J RESP CRIT CARE, V151, P1170; SCHATZ M, 1993, ALLERGY PRINCIPLES P, P1301; Schaubel D, 1996, J ASTHMA, V33, P255, DOI 10.3109/02770909609055366; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; Stein RT, 1997, THORAX, V52, P946; Strachan DP, 1996, BRIT MED J, V312, P1195; STRACHAN DP, 1994, CLIN EXP ALLERGY, V24, P603, DOI 10.1111/j.1365-2222.1994.tb00961.x; Svanes C, 1998, EUR RESPIR J, V12, P1366, DOI 10.1183/09031936.98.12061366; SYUTKINA EV, 1995, CLIN DRUG INVEST, V9, P354, DOI 10.2165/00044011-199509060-00006; VanReempts PJ, 1996, AM J PERINAT, V13, P277, DOI 10.1055/s-2007-994342; VONMUTIUS E, 1993, J PEDIATR-US, V123, P223, DOI 10.1016/S0022-3476(05)81692-0	33	71	71	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JUN	2001	56	6					491	497		10.1034/j.1398-9995.2001.056006491.x		7	Allergy; Immunology	Allergy; Immunology	443HR	WOS:000169336200005	11421892	
J	Wilson, DR; Nouri-Aria, KT; Walker, SM; Pajno, GB; O'Brien, F; Jacobson, MR; Mackay, IS; Durham, SR				Wilson, DR; Nouri-Aria, KT; Walker, SM; Pajno, GB; O'Brien, F; Jacobson, MR; Mackay, IS; Durham, SR			Grass pollen immunotherapy: Symptomatic improvement correlates with reductions in eosinophils and IL-5 mRNA expression in the nasal mucosa during the pollen season	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; eosinophils; IL-5; immunotherapy	RECOMBINANT HUMAN INTERLEUKIN-5; NATURAL ALLERGEN EXPOSURE; COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; MAST-CELLS; TISSUE EOSINOPHILIA; INDUCED RHINITIS; HAY-FEVER; ASTHMA; INFLAMMATION	Background: Tissue eosinophilia and infiltration by T(H)2-type T tells are characteristic features of allergic rhinitis both after allergen challenge and during natural allergen exposure. Specific immunotherapy inhibits allergen-induced nasal eosinophilia. Objectives: We sought to assess, in the context of a randomized trial, the relationships between symptomatic improvement after immunotherapy and eosinophil numbers and IL-5 expression in the nasal mucosa during the pollen season. Methods: Nasal biopsy specimens were taken from 37 adults with severe summer hay fever at baseline (out of season) and at peak season after 2 years of treatment with a depot grass pollen extract or placebo. Biopsy specimens were processed for immunohistochemistry by using mAbs against eosinophils (EG2), T cells (CD3), and IL-2 receptor-positive cells (CD25), as well as for in situ hybridization by using a sulfur 35-labeled antisense riboprobe directed against IL-5. Results: Immunotherapy significantly reduced symptoms (49%, P = .01) and medication requirements (80%, P = .007) compared with placebo. There was a 400% increase (P = .004) in eosinophils during the pollen season in placebo-treated patients, which was inhibited in the immunotherapy group (20% increase, P = .04 between groups). Seasonal increases were also observed for CD25(+) cells (P = .002), CD3(+) cells (P = .02), and IL-5 mRNA-expressing cells (P = .03) in the placebo group but not in the immunotherapy group. A significant correlation was observed between eosinophils and IL-5 expression (r = 0.5, P < .05). Both eosinophils (r = 0.6, P < .02) and IL-5 (r = 0.6, P < .02) correlated with symptoms after immunotherapy. Conclusion: Improvement in symptoms after grass pollen immunotherapy may result, at least in part, from inhibition of IL-5-dependent tissue eosinophilia during the pollen season. Conclusion: Improvement in symptoms after grass pollen immunotherapy may result, at least in part, from inhibition of IL-5-dependent tissue eosinophilia during the pollen season.	Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Upper Resp Med, London SW3 6LY, England	Durham, SR (reprint author), Natl Heart & Lung Inst, Imperial Coll, Sch Med, Dept Upper Resp Med, Dovehouse St, London SW3 6LY, England.		Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258; Jacobson, Mikila/0000-0002-2921-6169			Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; Cameron L, 2000, J IMMUNOL, V164, P1538; COLLINS PD, 1995, J EXP MED, V182, P1169, DOI 10.1084/jem.182.4.1169; DJURUP R, 1984, ALLERGY, V39, P472; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Fujisawa T, 1997, INT ARCH ALLERGY IMM, V114, P81; FURIN MJ, 1991, J ALLERGY CLIN IMMUN, V88, P27, DOI 10.1016/0091-6749(91)90297-2; HAMID Q, 1991, J CLIN INVEST, V87, P1541, DOI 10.1172/JCI115166; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Ishihara K, 2000, INT ARCH ALLERGY IMM, V122, P36, DOI 10.1159/000053630; Kaminuma O, 1997, INT ARCH ALLERGY IMM, V114, P10; Kita H, 2000, J ALLERGY CLIN IMMUN, V106, P521, DOI 10.1067/mai.2000.108430; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LOPEZ AF, 1988, J EXP MED, V167, P219, DOI 10.1084/jem.167.1.219; Masuyama K, 1998, J ALLERGY CLIN IMMUN, V102, P610, DOI 10.1016/S0091-6749(98)70277-5; MOQBEL R, 1995, J IMMUNOL, V155, P4939; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Mould AW, 1997, J CLIN INVEST, V99, P1064, DOI 10.1172/JCI119234; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; Robinson DS, 1999, AM J RESP CELL MOL, V20, P9; Roboz G J, 1999, Curr Opin Hematol, V6, P164, DOI 10.1097/00062752-199905000-00007; Romagnani S, 1998, ALLERGY, V53, P12; ROTHENBERG ME, 1989, J IMMUNOL, V143, P2311; TERADA N, 1992, J ALLERGY CLIN IMMUN, V90, P160, DOI 10.1016/0091-6749(92)90067-C; VALENT P, 1994, J ALLERGY CLIN IMMUN, V94, P1177, DOI 10.1016/0091-6749(94)90329-8; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170; VARNEY VA, 1991, BRIT MED J, V302, P265; Walker C, 1998, J IMMUNOL, V161, P1962; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WALSH GM, 1990, IMMUNOLOGY, V71, P258; WANG JM, 1989, EUR J IMMUNOL, V19, P701, DOI 10.1002/eji.1830190420; YING S, 1993, AM J RESP CELL MOL, V9, P356	41	71	74	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2001	107	6					971	976		10.1067/mai.2001.115483		6	Allergy; Immunology	Allergy; Immunology	445JR	WOS:000169454800006	11398073	
J	Arlian, LG; Neal, JS; Morgan, MS; Vyszenski-Moher, DL; Rapp, CM; Alexander, AK				Arlian, LG; Neal, JS; Morgan, MS; Vyszenski-Moher, DL; Rapp, CM; Alexander, AK			Reducing relative humidity is a practical way to control dust mites and their allergens in homes in temperate climates	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; relative humidity; dehumidification; allergen; Der p 1; Der f 1; dermatophagoides species	DERMATOPHAGOIDES-FARINAE ACARI; MECHANICAL VENTILATION; WATER-BALANCE; HOUSE; PYROGLYPHIDAE; AIR; PTERONYSSINUS; REDUCTION; PREVALENCE; EFFICACY	Background: Maintaining a relative humidity [RH) of less than 50% is one recommendation fur reducing numbers of house dust mites and their allergens in homes, Objective: The purpose of this study was to determine whether, in a humid temperate climate, indoor RH could be sufficiently lowered to control dust mites and their allergens. Methods: During a period spanning 2 humid summers (May 1998 to October 1999), dust mite and allergen densities were determined in 3 groups of homes. One group (low RH group, n = 23) maintained an RN of less than 51%, Most of these homes used a high-efficiency dehumidifier and air conditioning. A second group of homes (group A) used air conditioning only (n = 19) or air conditioning and dehumidification (n = 5) but did not maintain an RH of less than 51%, A third group of homes (group C, n = 24) controlled climate by opening windows and had an RH of greater than 51%. Normal housecleaning was maintained in all homes during the study, Results: The low RH group homes started in June with a mean +/- SE of 401 +/- 124 live mites and 17 +/- 3 mug of total Der 1 allergen per gram of dust. After 17 months of maintaining an RH of less than 51%, these declined significantly to 8 +/- 3 live mites per gram LP =.004) and 4 +/- 1 mug of Der 1 per gram of dust (P <.001). In contrast, group A and C homes exhibited seasonal peaks of 500 to 1000 mites and 40 to 70 <mu>g of Der 1 per gram of dust At all time points after the baseline sample, the low RH group homes had significantly less (P <.001) allergen than the group A and C homes, After 17 months, allergen levels were more than 10 Limes lo,Per in low Rfi homes compared with humid homes, Conclusion: This study showed that it is practical to maintain an indoor RH of less than 51% during the humid summer season in a temperate climate, and this resulted in significant reductions in mite and allergen levels.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA	Arlian, LG (reprint author), Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.						ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1981, PHYSIOL ZOOL, V54, P393; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437; Arlian LG, 1999, J MED ENTOMOL, V36, P457; Arlian LG, 1998, J MED ENTOMOL, V35, P962; BRANDT RL, 1976, J MED ENTOMOL, V13, P327; Bronswijk JE, 1971, J ALLERGY, V47, P31; CABRERA P, 1995, J ALLERGY CLIN IMMUN, V95, P635, DOI 10.1016/S0091-6749(95)70328-4; Crane J, 1998, ALLERGY, V53, P755; CUSTOVIC A, 1995, CLIN EXP ALLERGY, V25, P312, DOI 10.1111/j.1365-2222.1995.tb01048.x; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; CUSTOVIC A, 1995, J ALLERGY CLIN IMMUN, V96, P134, DOI 10.1016/S0091-6749(95)70044-7; De Boer R, 1998, J MED ENTOMOL, V35, P905; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; deBoer R, 1997, ALLERGY, V52, P299; ELLINGSON AR, 1995, ANN ALLERGY, V55, P680; Fletcher AM, 1996, CLIN EXP ALLERGY, V26, P1051, DOI 10.1111/j.1365-2222.1996.tb00643.x; Glass EV, 1998, EXP APPL ACAROL, V22, P31, DOI 10.1023/A:1006081323887; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HARVING H, 1991, ALLERGY, V46, P33, DOI 10.1111/j.1398-9995.1991.tb00647.x; KORSGAARD J, 1991, DUST MITE ALLERGENS, P87; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; Niven RM, 1999, J ALLERGY CLIN IMMUN, V103, P756, DOI 10.1016/S0091-6749(99)70416-1; PLATTSMILLS TAE, 1986, J ALLERGY CLIN IMMUN, V77, P850, DOI 10.1016/0091-6749(86)90383-0; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0	32	71	75	1	16	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					99	104		10.1067/mai.2001.112119		6	Allergy; Immunology	Allergy; Immunology	394PW	WOS:000166533300018	11149998	
J	Diaz-Sanchez, D; Jyrala, M; Ng, D; Nel, A; Saxon, A				Diaz-Sanchez, D; Jyrala, M; Ng, D; Nel, A; Saxon, A			In vivo nasal challenge with diesel exhaust particles enhances expression of the CC chemokines rantes, MIP-1 alpha, and MCP-3 in humans	CLINICAL IMMUNOLOGY			English	Article						diesel; pollution; chemokines; allergy; inflammation	IN-VIVO; MESSENGER-RNA; ALLERGIC INFLAMMATION; CYTOKINE PRODUCTION; MONONUCLEAR-CELLS; RAGWEED ALLERGEN; IGE PRODUCTION; RESPONSES; EOTAXIN; EOSINOPHILS	Diesel exhaust particles (DEP) enhance allergic inflammation by increasing in vivo IgE and cytokine production in the human upper respiratory mucosa. CC chemokines have been shown to play an important role in inflammation. We examined whether DEP could alter the production of CC chemokines by cells residing in the human nasal mucosa. At both 6 and 24 h following intranasal DEP challenge, the levels of nasal RANTES, MIP-1 alpha, and MCP-3 were significantly elevated compared to baseline. In contrast, DEP did not enhance levels of Eotaxin at any time, demonstrating that the action of DEP was not simply a global effect on all CC chemokines. Challenge with saline resulted in no significant change in expression of any chemokine at any time. Challenge with DEP also resulted in an increase in total cell counts in nasal lavage fluids. Increases in lymphocyte, monocyte/macrophage, and neutrophil cells were observed but there was no change in eosinophil cell numbers. In contrast, there was a significant enhancement of ECP protein levels in washes performed 6 to 24 h after DEP challenge. Elevated specific nasal chemokine expression following exposure to DEP likely participates in the inflammation, cellular infiltration, and increase in IgE observed in the absence of allergen. (C) 2000 Academic Press.	Univ Calif Los Angeles, Sch Med, Dept Med,Hart & Louise Lyon Lab, Div Clin Immunol Allergy, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Jonsson Comprehens Canc Ctr Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Inst Mol Biol, Los Angeles, CA 90095 USA	Diaz-Sanchez, D (reprint author), Univ Calif Los Angeles, Sch Med, Dept Med,Hart & Louise Lyon Lab, Div Clin Immunol Allergy, Los Angeles, CA 90095 USA.		Nel, Andre/J-2808-2012		NIAID NIH HHS [AI-34567]		Alam R, 1997, J ALLERGY CLIN IMMUN, V99, P273, DOI 10.1016/S0091-6749(97)70042-3; ALAM R, 1992, J EXP MED, V176, P781, DOI 10.1084/jem.176.3.781; Bartels J, 1996, BIOCHEM BIOPH RES CO, V225, P1045, DOI 10.1006/bbrc.1996.1292; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804; BUSSE WW, 1993, AM REV RESPIR DIS, V147, pS20; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Fahy O, 1999, J ALLERGY CLIN IMMUN, V103, P1115, DOI 10.1016/S0091-6749(99)70187-9; Gilmour MI, 1995, TOXICOLOGY, V105, P335, DOI 10.1016/0300-483X(95)03230-D; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Homey B, 1999, CURR OPIN IMMUNOL, V11, P626, DOI 10.1016/S0952-7915(99)00028-X; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Kimata H, 1996, J EXP MED, V183, P2397, DOI 10.1084/jem.183.5.2397; Kita H, 1996, J EXP MED, V183, P2421, DOI 10.1084/jem.183.6.2421; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Lilly CM, 1997, J CLIN INVEST, V99, P1767, DOI 10.1172/JCI119341; MURANAKA M, 1986, J ALLERGY CLIN IMMUN, V79, P639; OPDENAKKER G, 1994, GENOMICS, V21, P403, DOI 10.1006/geno.1994.1283; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617; Pasmans SGMA, 1996, J ALLERGY CLIN IMMUN, V98, P962, DOI 10.1016/S0091-6749(96)80013-3; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; RUSZNAK C, 1994, ALLERGY, V49, P21, DOI 10.1111/j.1398-9995.1994.tb04234.x; Schroder JM, 1996, J LEUKOCYTE BIOL, V59, P1; SIM TC, 1995, AM J RESP CRIT CARE, V152, P927; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6	29	71	73	1	2	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1521-6616			CLIN IMMUNOL	Clin. Immunol.	NOV	2000	97	2					140	145		10.1006/clim.2000.4921		6	Immunology	Immunology	375BX	WOS:000165380600008	11027454	
J	Nafstad, P; Magnus, P; Jaakkola, JJK				Nafstad, P; Magnus, P; Jaakkola, JJK			Risk of childhood asthma and allergic rhinitis in relation to pregnancy complications	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						pregnancy complications; prenatal conditions; asthma; allergic rhinitis; childhood	ATOPIC DISEASE; MATERNAL SMOKING; EARLY-LIFE; INFECTIONS; CHILDREN; ILLNESS; COHORT	Background: Events occurring during Fetal life may affect the development of the immune and respiratory systems and increase the risk of asthma and allergic diseases. Objectives: We sought to elaborate the relations between the occurrence of pregnancy complications and other pregnancy-related conditions and the risk of bronchial obstruction during the first 2 years of life and the occurrence of asthma and allergic rhinitis by the age of 4 years. Pregnancy complications were considered both as predictors of the health outcomes and as possible effects caused by other prenatal factors. Methods: A population-based, l-year, cohort study was carried out involving 2531 children horn in Oslo, Norway. We collected information on maternally related (hyperemesis, hypertension, and preeclampsia) and uterus-related complications in pregnancy (antepartum hemorrhage, preterm contractions, insufficient placenta, and restricted growth of the uterus) and the child's health and environmental exposures at birth and at 6, 12, 18, and 24 months and 4 years of age. The outcomes of interest were bronchial obstruction during the first 2 years and asthma and allergic rhinitis at the age of 4 years. Results: In a logistic regression analysis adjusting for potential confounders, uterus-related, but not other pregnancy-related, complications increased the risk of bronchial obstruction (odds ratio [OR], 2.1; 95% confidence interval [CI], 1,3-3.4), asthma (OR, 3.0; 95% CI, 1.8-5.4), and allergic rhinitis (OR, 2.9; 95% CI, 1.6-5.2). These relations were similar in children of atopic and nonatopic parents. Conclusions: Uterus-related complications in pregnancy increase the risk of having asthma and allergic rhinitis in childhood.	Natl Inst Publ Hlth, Dept Populat Hlth Sci, Epidemiol Sect, N-0403 Oslo, Norway; Nord Sch Publ Hlth, Gothenburg, Sweden	Nafstad, P (reprint author), Natl Inst Publ Hlth, Dept Populat Hlth Sci, Epidemiol Sect, POB 4404, N-0403 Oslo, Norway.		Jaakkola, Jouni/G-4314-2012				ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; BJORKSTEN B, 1994, ALLERGY, V49, P400, DOI 10.1111/j.1398-9995.1994.tb00831.x; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; *ISAAC STEER COMM, 1998, PHASE 2 MODULES INT; *ISAAC STEER COMM, 1993, ISAAC INT STUD ASTHM; Leadbitter P, 1999, THORAX, V54, P905; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; Martinez FD, 1997, CIBA F SYMP, V206, P233; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Nafstad P, 1996, EUR RESPIR J, V9, P2623, DOI 10.1183/09031936.96.09122623; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; NILSSON L, 1997, PEDIATR ALLERGY IMMU, V3, P134; Pekkanen J, 1999, ACTA PAEDIATR, V88, P710; Ponsonby AL, 1999, THORAX, V54, P664; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strachan DP, 1996, BRIT MED J, V312, P1195; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Tomeo CA, 1999, EPIDEMIOLOGY, V10, P774, DOI 10.1097/00001648-199911000-00022; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Xu B, 1999, ALLERGY, V54, P829, DOI 10.1034/j.1398-9995.1999.00117.x; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723	27	71	72	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					867	873		10.1067/mai.2000.110558		7	Allergy; Immunology	Allergy; Immunology	417ZK	WOS:000167865200010	11080708	
J	Smith, CK; Moore, CA; Elahi, EN; Smart, ATS; Hotchkiss, SAM				Smith, CK; Moore, CA; Elahi, EN; Smart, ATS; Hotchkiss, SAM			Human skin absorption and metabolism of the contact allergens, cinnamic aldehyde, and cinnamic alcohol	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						cinnamic aldehyde; alcohol; acid; human; skin; metabolism; absorption; pyrazole; dehydrogenase; enzyme	GLUTATHIONE S-TRANSFERASES; DEHYDROGENASE GENE FAMILY; EUROPEAN STANDARD SERIES; PERCUTANEOUS-ABSORPTION; RAT SKIN; FRAGRANCE MATERIALS; BENZYL ACETATE; SENSITIZATION; DERMATITIS; CINNAMALDEHYDE	trans-Cinnamaldehyde and trans-cinnamic alcohol have been commonly reported to cause allergic contact dermatitis (ACD) in humans. Cinnamaldehyde is a more potent skin sensitizer than cinnamic alcohol. It has been hypothesized that cinnamic alcohol is a "prohapten" that requires metabolic activation, presumably by oxidoreductase enzymes such as alcohol dehydrogenase (ADH) or cytochrome P450 2E1 (CYP2E1), to the protein-reactive cinnamaldehyde (a hapten). In this study, the in vitro percutaneous absorption and metabolism of cinnamaldehyde and cinnamic alcohol (78 mu mol dose) has been examined using freshly excised, metabolically viable, full-thickness breast and abdomen skin from six female donors. Penetration rates and total cumulative recoveries of cinnamic compounds that were present in receptor fluid, extracted from within the skin, evaporated from the skin surface, or remained unabsorbed on the skin surface after 24 h were quantified by reversed-phase high-performance liquid chromatography. Biotransformation of cinnamaldehyde to both cinnamic alcohol and cinnamic acid was observed. Topically applied cinnamic alcohol was converted to cinnamaldehyde (found on the skin surface only) and cinnamic acid. To establish whether these biotransformations were enzymatic, experiments were performed in the absence and presence of varying concentrations (80-320 mu mol) of the ADH/CYP2E1 inhibitors pyrazole: or 4-methylpyrazole. The observation that pyrazole significantly reduced (p < 0.05) the total penetration of cinnamic metabolites into receptor fluid, following either cinnamaldehyde or cinnamic alcohol treatment, but did not significantly affect parent chemical penetration, suggests that we are measuring cutaneous metabolic products of ADH activity. The skin absorption and metabolism of cinnamaldehyde and cinnamic alcohol will play an important role in the manifestation of ACD following topical exposure to these compounds. (C) 2000 Academic Press.	Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Sect Mol Toxicol, London SW7 2AZ, England	Smith, CK (reprint author), Univ London Imperial Coll Sci Technol & Med, Sch Med, Div Biomed Sci, Sect Mol Toxicol, Sir Alexander Fleming Bldg, London SW7 2AZ, England.						Albert M R, 1998, Am J Contact Dermat, V9, P207, DOI 10.1016/S1046-199X(98)90030-6; ASHCROFT JA, 1997, HUM EXP TOXICOL, V17, P400; Bangha E, 1996, DERMATOLOGY, V193, P17; Barry B. W., 1983, DERMATOLOGICAL FORMU; Basketter DA, 1996, CONTACT DERMATITIS, V35, P146, DOI 10.1111/j.1600-0536.1996.tb02332.x; BASKETTER DA, 1992, ACTA DERM-VENEREOL, V72, P264; BeckleyKartey SAJ, 1997, TOXICOL APPL PHARM, V145, P34, DOI 10.1006/taap.1997.8154; BLACKER KL, 1991, J INVEST DERMATOL, V97, P442, DOI 10.1111/1523-1747.ep12481276; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; BRONAUGH RL, 1985, J PHARM SCI, V74, P64, DOI 10.1002/jps.2600740117; CALNAN CD, 1980, CONTACT DERMATITIS, V6, P500, DOI 10.1111/j.1600-0536.1980.tb05581.x; Cheung C, 1999, BIOCHEM BIOPH RES CO, V261, P100, DOI 10.1006/bbrc.1999.0943; CHEUNG C, 2000, UNPUB INTERSPECIES V; DANNEMAN PJ, 1983, FOOD CHEM TOXICOL, V21, P721, DOI 10.1016/0278-6915(83)90203-X; DICKER E, 1991, ALCOHOL CLIN EXP RES, V15, P1072, DOI 10.1111/j.1530-0277.1991.tb05214.x; DRAKE TE, 1976, ARCH DERMATOL, V112, P202, DOI 10.1001/archderm.112.2.202; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; DUPUIS G, 1982, ALLERGIC CONTACT DER; Hewitt PG, 2000, DRUG METAB DISPOS, V28, P748; Hirai A, 1997, J INVEST DERMATOL, V109, P314, DOI 10.1111/1523-1747.ep12335833; HOTCHKISS SA, 1990, FOOD CHEM TOXICOL, V28, P443, DOI 10.1016/0278-6915(90)90091-Z; HOTCHKISS SAM, 1992, FOOD CHEM TOXICOL, V30, P145, DOI 10.1016/0278-6915(92)90150-J; JIMBO Y, 1983, Journal of Dermatology (Tokyo), V10, P229; Johansen JD, 1996, CONTACT DERMATITIS, V34, P106, DOI 10.1111/j.1600-0536.1996.tb02139.x; Johansen JD, 1996, CONTACT DERMATITIS, V34, P165, DOI 10.1111/j.1600-0536.1996.tb02167.x; JULIA P, 1987, EUR J BIOCHEM, V162, P179, DOI 10.1111/j.1432-1033.1987.tb10559.x; Katsarou A, 1999, ANN ALLERG ASTHMA IM, V82, P449, DOI 10.1016/S1081-1206(10)62720-2; Landsteiner K, 1936, J EXP MED, V64, P625, DOI 10.1084/jem.64.4.625; LARSEN WG, 1985, J AM ACAD DERMATOL, V12, P1, DOI 10.1016/S0190-9622(85)70001-1; LETIZIA CS, 1999, SAFETY EVALUATION CI; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LOFTSSON T, 1981, ARCH PHARM CHEMI SCI, V10, P17; MAJETI VA, 1977, CONTACT DERMATITIS, V3, P16, DOI 10.1111/j.1600-0536.1977.tb03581.x; MALTEN KE, 1984, CONTACT DERMATITIS, V11, P1, DOI 10.1111/j.1600-0536.1984.tb00162.x; MANZUR F, 1995, CONTACT DERMATITIS, V32, P55, DOI 10.1111/j.1600-0536.1995.tb00850.x; Marks JG, 1998, J AM ACAD DERMATOL, V38, P911, DOI 10.1016/S0190-9622(98)70587-0; MILLARD LG, 1973, BRIT MED J, V1, P676; PIETRUSZKO R, 1975, BIOCHEM PHARMACOL, V24, P1603, DOI 10.1016/0006-2952(75)90087-8; SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702; Schorr W F, 1975, Contact Dermatitis, V1, P108, DOI 10.1111/j.1600-0536.1975.tb05335.x; Sertoli A, 1999, Am J Contact Dermat, V10, P18, DOI 10.1016/S1046-199X(99)90089-1; Sharma VK, 1998, CONTACT DERMATITIS, V38, P127, DOI 10.1111/j.1600-0536.1998.tb05677.x; SINGHAL SS, 1993, BIOCHIM BIOPHYS ACTA, V1163, P266, DOI 10.1016/0167-4838(93)90161-J; SINGHAL SS, 1992, BIOCHIM BIOPHYS ACTA, V1171, P19, DOI 10.1016/0167-4781(92)90135-M; SMITH CK, 2000, UNPUB HIGH PERFORMAN; STELTENKAMP RJ, 1980, FOOD COSMET TOXICOL, V18, P419, DOI 10.1016/0015-6264(80)90200-X; SUMMER KH, 1980, MUTAT RES, V77, P91, DOI 10.1016/0165-1218(80)90124-X; Svensson S, 1996, FEBS LETT, V394, P217, DOI 10.1016/0014-5793(96)00954-4; WEIBEL H, 1989, CONTACT DERMATITIS, V20, P167, DOI 10.1111/j.1600-0536.1989.tb04651.x; WEIBEL H, 1989, ACTA DERM-VENEREOL, V69, P302; WEIBEL H, 1989, CONTACT DERMATITIS, V20, P161, DOI 10.1111/j.1600-0536.1989.tb04650.x; Yoshida A, 1998, EUR J BIOCHEM, V251, P549, DOI 10.1046/j.1432-1327.1998.2510549.x	52	71	74	4	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	NOV 1	2000	168	3					189	199		10.1006/taap.2000.9025		11	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	400WB	WOS:000166893700003	11042091	
J	Szepfalusi, Z; Pichler, J; Elsasser, S; van Duren, K; Ebner, C; Bernaschek, G; Urbanek, R				Szepfalusi, Z; Pichler, J; Elsasser, S; van Duren, K; Ebner, C; Bernaschek, G; Urbanek, R			Transplacental priming of the human immune system with environmental allergens can occur early in gestation	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cord blood cells; allergen; T-cell proliferation; diaplacentral transfer; sensitization	CELL PROLIFERATIVE RESPONSES; BLOOD MONONUCLEAR-CELLS; RESPIRATORY-TRACT; DENDRITIC CELLS; BIRCH-POLLEN; T-CELLS; ANTIGENS; MEMORY; IMMUNIZATION; TOLERANCE	Background: Allergen-specific T cells play an important role in the allergic immune response to various environmental allergens. In vitro studies have shown that T-cell responses to these allergens do occur prenatally. Some allergens (milk proteins) appear to lead more often to fetal T-cell priming than others (house dust mite allergen, ovalbumin, and birch and grass pollen allergens). Objective: We sought to determine the window of opportunity for prenatal T-cell priming with inhalant and nutritive allergens. Methods: The T-cell reactivity of cord blood cells derived through cordocentesis from unborn (n = 62) and term babies (n = 114) in response to inhalant allergens (birch pollen major allergen, recombinant Bet v 1, and timothy grass major allergen, recombinant Phl p 1) was investigated. Results: The results demonstrate that allergen-specific T-cell reactivity is as common in preterm as in term infants (Bet v 1, 8% and 5%, respectively; Phl p 1, 20% and 25%, respectively). Conclusions: Our data support the hypothesis that differential handling of the allergenic proteins by the feto-placental barrier and possibly by antigen-presenting cells may directly modulate the ensuing T-cell immune response.	Univ Vienna, AKH, Dept Pediat, A-1090 Vienna, Austria; Univ Vienna, Inst Gen & Expt Pathol, A-1090 Vienna, Austria; Univ Vienna, Dept Gynecol & Obstet, A-1090 Vienna, Austria	Szepfalusi, Z (reprint author), Univ Vienna, AKH, Dept Pediat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.						AASE JM, 1972, NEW ENGL J MED, V286, P1379, DOI 10.1056/NEJM197206292862603; BACH JF, 1978, DEFINITION IMMUNOLOG; BAKER CJ, 1988, NEW ENGL J MED, V319, P1180, DOI 10.1056/NEJM198811033191802; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; FERREIRA FD, 1993, J BIOL CHEM, V268, P19574; HAHNZORIC M, 1992, PEDIATR RES, V32, P150, DOI 10.1203/00006450-199208000-00005; Hara T, 1996, P NATL ACAD SCI USA, V93, P5136, DOI 10.1073/pnas.93.10.5136; Holt PG, 1990, PEDIATR ALLERGY IMMU, V1, P3, DOI 10.1111/j.1399-3038.1990.tb00002.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; KONDO N, 1992, ARCH DIS CHILD, V67, P1003; Kopp MV, 2000, PEDIATR ALLERGY IMMU, V11, P4, DOI 10.1034/j.1399-3038.2000.00053.x; Malhotra I, 1997, J CLIN INVEST, V99, P1759, DOI 10.1172/JCI119340; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1046/j.1365-2222.1996.d01-383.x; NELSON DJ, 1995, J IMMUNOL, V155, P3517; NELSON DJ, 1994, J EXP MED, V179, P203, DOI 10.1084/jem.179.1.203; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358; PICINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75; Prescott SL, 1998, J IMMUNOL, V160, P4730; RAWLE FC, 1984, J IMMUNOL, V133, P195; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Singh RR, 1996, J EXP MED, V183, P1613, DOI 10.1084/jem.183.4.1613; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; Szepfalusi Z, 1998, J ALLERGY CLIN IMMUN, V101, P514, DOI 10.1016/S0091-6749(98)70359-8; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Van Duren-Schmidt K, 1997, PEDIATR RES, V41, P1; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261	30	71	74	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2000	106	3					530	536				7	Allergy; Immunology	Allergy; Immunology	356YN	WOS:000089471900017	10984374	
J	Cho, YS; Choi, MG; Jeong, JJ; Chung, WC; Lee, IS; Kim, SW; Han, SW; Choi, KY; Chung, IS				Cho, YS; Choi, MG; Jeong, JJ; Chung, WC; Lee, IS; Kim, SW; Han, SW; Choi, KY; Chung, IS			Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Asan-si, Korea	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Article							HELICOBACTER-PYLORI INFECTION; GASTRIC-ACID-SECRETION; DUODENAL-ULCER; DISEASE; SYMPTOMS; ESOPHAGITIS; QUESTIONNAIRE; VALIDATION; CHINESE	BACKGROUND AND AIMS: This study estimated the prevalence and clinical spectrum of gastroesophageal reflux disease (GERD) in Asan-si, Korea, as the prevalence is believed to be lower than in Western countries. METHODS: A cross-sectional survey, using a reliable and valid questionnaire, was performed on randomly selected 2,240 Asan-si residents aged between 18 and 69 yr. All respondents were interviewed at their homes or offices by a team of interviewers. RESULTS: Of the 1,902 eligible subjects, 1,417 (78.4%: male 762; female 655) were surveyed. The prevalence of heartburn occurring at least once a month, at least once a week, and at least twice a week was 4.71% (95% confidence interval (CI), 3.6-5.8), 2.0% (95% CI, 1.2-2.7), and 1.3% (95% CI, 0.7-1.9), respectively. The corresponding figures for acid regurgitation were 4.4% (95% CI, 3.3-5.5) and 2.0% (95% CI, 1.3-2.8), respectively. The prevalence of GERD, defined as heartburn and/or acid regurgitation experienced at least weekly, was 3.5% (95% CI, 2.6-4.5). No significant difference was detected between sexes. The prevalence of heartburn was associated with increasing age (p < 0.001). Nineteen percent of our population reported at least one of the atypical symptoms, for instance, chest pain, dysphagia, globus sensation, asthma, bronchitis, pneumonia, or hoarseness. The frequency of frequent GERD among subjects reporting any of the atypical symptoms was 12.6%, which was higher than that of the subjects without atypical symptoms. Patients with typical reflux symptoms were more common among those with atypical symptoms, compared to those without such symptoms (p < 0.001). Using a logistic regression model after adjusting for age and sex, typical reflux symptoms were associated with chest pain (odds ratio (OR), 9.3; 95% CI, 5.9-14.7), dysphagia (OR, 6.4; 95% CI, 2.8-14.7), globus sensation (OR, 3.9; 95% CI, 1.5-9.7), hoarseness (OR, 4.3; 95% CI, 1.4-13.1), asthma (OR, 2.6; 95% CI, 1.4-4.8), and bronchitis (OR, 1.2; 95% CI, 0.6-2.3). CONCLUSION: The prevalence of GERD was 3.5% in this Korean population. Heartburn and acid regurgitation were significantly associated with chest pain, dysphagia, globus sensation, hoarseness, and asthma.	Catholic Univ Korea, Coll Med, Dept Internal Med, Div Gastroenterol, Seoul, South Korea	Choi, MG (reprint author), Kangnam St Marys Hosp, Dept Internal Med, Div Gastroenterol, 505 Banpo Dong, Seoul 137040, South Korea.		Choi, Myung-Gyu/D-6079-2014	Choi, Myung-Gyu/0000-0003-4083-5187			Chang CS, 1997, AM J GASTROENTEROL, V92, P668; Choi H, 1999, KOREAN J GASTROENTER, V33, P741; Choo KY, 2000, KOREAN J GASTROINTES, V6, P31; Dent J, 1999, GUT, V44, pS1; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; El-Serag HB, 1998, GUT, V43, P327; FELDMAN M, 1988, GASTROENTEROLOGY, V95, P630; Gislason T, 2002, CHEST, V121, P158, DOI 10.1378/chest.121.1.158; Goh KL, 2000, J GASTROEN HEPATOL, V15, P230, DOI 10.1046/j.1440-1746.2000.02148.x; Ho KY, 1998, AM J GASTROENTEROL, V93, P1816; Hu WHC, 1997, GASTROENTEROLOGY, V112, pA153; Jeon SG, 2000, KOREAN J INTERN MED, V58, P145; JOCHEM VJ, 1992, GASTROENTEROLOGY, V102, P1400; Kinoshita Y, 1997, GUT, V41, P452; KLAUSER AG, 1990, LANCET, V335, P205, DOI 10.1016/0140-6736(90)90287-F; Labenz J, 1997, GASTROENTEROLOGY, V112, P1442, DOI 10.1016/S0016-5085(97)70024-6; Lagergren J, 2000, GUT, V47, P26, DOI 10.1136/gut.47.1.26; LAM SK, 1980, GUT, V21, P324, DOI 10.1136/gut.21.4.324; Lee JI, 2003, J GASTROENTEROL, V38, P23, DOI 10.1007/s005350300002; Lee SJ, 2001, J GASTROEN HEPATOL, V16, P373, DOI 10.1046/j.1440-1746.2001.02464.x; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; LOCKE GR, 1994, MAYO CLIN PROC, V69, P539; Locke GR, 1999, AM J MED, V106, P642, DOI 10.1016/S0002-9343(99)00121-7; Lundell LR, 1999, GUT, V45, P172; Manterola C, 2002, J CLIN EPIDEMIOL, V55, P1041, DOI 10.1016/S0895-4356(02)00454-7; Moayyedi P, 2001, GASTROENTEROLOGY, V121, P1120, DOI 10.1053/gast.2001.29332; NEBEL OT, 1972, GASTROENTEROLOGY, V63, P778; Nebel OT, 1976, DIGEST DIS SCI, V21, P953; Park Hyo Jin, 1996, Yonsei Medical Journal, V37, P278; PARSONNET J, 1995, ALIMENT PHARM THERAP, V9, P45; Spechler SJ, 2002, ALIMENT PHARM THERAP, V16, P1795, DOI 10.1046/j.0269-2813.2002.01351.x; Wilson LJ, 1999, AM J GASTROENTEROL, V94, P2840, DOI 10.1016/S0002-9270(99)00482-7	32	105	110	1	1	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0002-9270			AM J GASTROENTEROL	Am. J. Gastroenterol.	APR	2005	100	4					747	753		10.1111/j.1572-0241.2005.41245.x		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	907LU	WOS:000227720400005	15784014	
J	Ariga, M; Neitzert, B; Nakae, S; Mottin, G; Bertrand, C; Pruniaux, MP; Jin, SLC; Conti, M				Ariga, M; Neitzert, B; Nakae, S; Mottin, G; Bertrand, C; Pruniaux, MP; Jin, SLC; Conti, M			Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation	JOURNAL OF IMMUNOLOGY			English	Article							CYCLIC ADENOSINE-MONOPHOSPHATE; NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE-A; T-CELL-ACTIVATION; LEUKOCYTE ADHESION; INTRACELLULAR CAMP; PDE4 INHIBITORS; BETA-ARRESTINS; TNF-ALPHA; AMP	Neutrophils have been implicated in the pathogenesis of many inflammatory lung diseases, including chronic obstructive pulmonary disease and asthma. With this study, we investigated how disruption of cAMP signaling impacts the function of neutrophil recruitment to the lung. Four genes code for type 4 phosphodiesterases (PDE4s), enzymes critical for regulation of cAMP levels and cell signaling. Ablation of two of these genes, PDE4B and PDE4D, but not PDE4A, has profound effects on neutrophil function. In a paradigm of mouse lung injury induced by endotoxin inhalation, the number of neutrophils recovered in the bronchoalveolar lavage was markedly decreased in PDE4D(-/-) and PDE4B(-/-) mice 4 and 24 h after exposure to LPS. Acute PDE4 inhibition with rolipram had additional inhibitory effects on nentrophil migration in PDE4B(-/-) and, to a lesser extent, PDE4D(-/-) mice. This decreased neutrophil recruitment occurred without major changes in chemokine accumulation in bronchoalveolar lavage, suggesting a dysfunction intrinsic to neutrophils. This hypothesis was confirmed by investigating the expression of adhesion molecules on the surface of neutrophils and chemotaxis in vitro. CD18 expression was decreased after ablation of both PDE4B and PDE4D, whereas CD11 expression was not significantly affected. Chemotaxis in response to KC and macrophage inflammatory protein-2 was markedly reduced in PDE4B(-/-) and PDE4D(-/-) neutrophils. The effect of PDE4 ablation on chemotaxis was comparable, but not additive, to the effects of acute PDE4 inhibition with rolipram. These data demonstrate that PDE4B and PDE4D play complementary, but not redundant, roles in the control of neutrophil function.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA; Pfizer Global Res & Dev, Fresnes, France	Conti, M (reprint author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, 300 Pasteur Dr, Stanford, CA 94305 USA.	marco.conti@stanford.edu			NCI NIH HHS [9R01CA72074-18]; NHLBI NIH HHS [1P01HL67674-02, HL67674]; NIAID NIH HHS [2R37AI23990-16, R01AI50209]		ACKERMAN V, 1994, CHEST, V105, P687, DOI 10.1378/chest.105.3.687; Au BT, 1998, BRIT J PHARMACOL, V123, P1260, DOI 10.1038/sj.bjp.0701723; Baillie GS, 2003, P NATL ACAD SCI USA, V100, P940, DOI 10.1073/pnas.262787199; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Barnette MS, 1996, BIOCHEM PHARMACOL, V51, P949; Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420; BESSLER H, 1986, J LEUKOCYTE BIOL, V40, P747; Campbell JJ, 1997, EUR J IMMUNOL, V27, P2571, DOI 10.1002/eji.1830271016; Conti M, 1999, Prog Nucleic Acid Res Mol Biol, V63, P1; Corbel M, 2002, J PHARMACOL EXP THER, V301, P258, DOI 10.1124/jpet.301.1.258; Dasi FJ, 2000, INFLAMM RES, V49, P600, DOI 10.1007/s000110050637; de Moraes VLG, 1998, BRIT J PHARMACOL, V123, P631; DERIAN CK, 1995, J IMMUNOL, V154, P308; DEVI S, 1995, J IMMUNOL, V154, P5376; DUBRAVEC DB, 1990, P NATL ACAD SCI USA, V87, P6758, DOI 10.1073/pnas.87.17.6758; ENGELS P, 1994, FEBS LETT, V350, P291, DOI 10.1016/0014-5793(94)00788-8; Fine JS, 2001, INFLAMMATION, V25, P61, DOI 10.1023/A:1007152903135; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; FREVERT CW, 1995, J IMMUNOL, V154, P335; Gantner F, 1997, J ALLERGY CLIN IMMUN, V100, P527; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; Glavas NA, 2001, P NATL ACAD SCI USA, V98, P6319, DOI 10.1073/pnas.101131098; Haddad E, 2001, BRIT J PHARMACOL, V132, P1715, DOI 10.1038/sj.bjp.0704022; Haddad JJ, 2002, J PHARMACOL EXP THER, V300, P559, DOI 10.1124/jpet.300.2.559; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; HARVATH L, 1991, J IMMUNOL, V146, P224; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; HOWELL RE, 1990, LIFE SCI, V46, P563, DOI 10.1016/0024-3205(90)90123-9; Jin SLC, 1999, P NATL ACAD SCI USA, V96, P11998, DOI 10.1073/pnas.96.21.11998; Jin SLC, 2002, P NATL ACAD SCI USA, V99, P7628, DOI 10.1073/pnas.122041599; Jones SL, 2002, J LEUKOCYTE BIOL, V71, P1042; KAMMER GM, 1988, IMMUNOL TODAY, V9, P222, DOI 10.1016/0167-5699(88)91220-0; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Luttrell LM, 2002, J CELL SCI, V115, P455; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; NIELSON CP, 1990, J ALLERGY CLIN IMMUN, V86, P801, DOI 10.1016/S0091-6749(05)80186-1; PARHAMI F, 1993, J CLIN INVEST, V92, P471, DOI 10.1172/JCI116590; Perry SJ, 2002, SCIENCE, V298, P834, DOI 10.1126/science.1074683; Profita M, 2003, THORAX, V58, P573, DOI 10.1136/thorax.58.7.573; RIVKIN I, 1976, INT ARCH ALLER A IMM, V50, P95; Robinson CH, 2002, RADIOACTIV ENVIRONM, V2, P1; Seldon PM, 2001, BRIT J PHARMACOL, V134, P58, DOI 10.1038/sj.bjp.0704238; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; Souness JE, 2000, IMMUNOPHARMACOLOGY, V47, P127, DOI 10.1016/S0162-3109(00)00185-5; TANNENBAUM CS, 1989, J IMMUNOL, V142, P1274; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Tasken KA, 2001, J BIOL CHEM, V276, P21999, DOI 10.1074/jbc.C000911200; Teixeira MM, 1997, TRENDS PHARMACOL SCI, V18, P164, DOI 10.1016/S0165-6147(97)01049-3; TENOR H, 1995, J INVEST DERMATOL, V105, P70, DOI 10.1111/1523-1747.ep12313330; THOMPSON WJ, 1971, BIOCHEMISTRY-US, V10, P311; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351; TORPHY TJ, 1994, TRENDS PHARMACOL SCI, V15, P370, DOI 10.1016/0165-6147(94)90157-0; Trifilieff A, 2002, J PHARMACOL EXP THER, V301, P241, DOI 10.1124/jpet.301.1.241; VanUffelen BE, 1998, BIOCHEM PHARMACOL, V56, P1061, DOI 10.1016/S0006-2952(98)00147-6; Wang SH, 1999, SCI TECHNOL WELD JOI, V4, P170, DOI 10.1179/136217199101537716	58	105	112	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	DEC 15	2004	173	12					7531	7538				8	Immunology	Immunology	878RT	WOS:000225665100052	15585880	
J	Hollingsworth, JW; Cook, DN; Brass, DM; Walker, JKL; Morgan, DL; Foster, WM; Schwartz, DA				Hollingsworth, JW; Cook, DN; Brass, DM; Walker, JKL; Morgan, DL; Foster, WM; Schwartz, DA			The role of toll-like receptor 4 in environmental airway injury in mice	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						toll-like receptor; innate immunity; endotoxin; ozone; residual oil fly ash	OIL FLY-ASH; INDUCED LUNG INFLAMMATION; 18-20 H POSTEXPOSURE; GRAIN DUST; ALVEOLAR MACROPHAGES; POLLUTION PARTICLES; CYTOKINE PRODUCTION; EPITHELIAL-CELLS; OZONE EXPOSURE; CUTTING EDGE	Inhalation of toxins commonly found in air pollution contributes to the development and progression of asthma and environmental airway injury. In this study, we investigated the requirement of toll-like receptor 4 (TLR4) in mice for pulmonary responses to three environmental toxins: aerosolized lipopolysaccharide, particulate matter (residual oil fly ash), and ozone. The physiologic and biologic responses to these toxins were evaluated by the extent of airway responsiveness, neutrophil recruitment to the lower respiratory tract, changes in inflammatory cytokines, and the concentration of protein in the lavage fluid. Genetically engineered, TLR4-deficient mice (C57BL/6(TLR4-/-)) were unresponsive to inhaled lipopolysaccharide, except for minimal increases in some inflammatory cytokines. In contrast, C57BL/6(TLR4-/-) mice did not differ from wild-type mice in their airway response to instilled residual oil fly ash or acute ozone exposure; however, we found that, despite a robust inflammatory response, C57BL/6(TLR4-/-) mice are protected against the development of airway hyperresponsiveness after subchronic ozone exposure. These data demonstrate in the mouse that the requirement of TLR4 for pulmonary inflammation depends on the nature of the toxin and appears specific to toxin and exposure conditions.	Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC 27710 USA; NIEHS, Res Triangle Pk, NC 27709 USA	Hollingsworth, JW (reprint author), Duke Univ, Med Ctr, Div Pulm & Crit Care Med, Durham, NC 27710 USA.	holli017@mc.duke.edu			NHLBI NIH HHS [HL074518, HL07538, HL62641, HL66604, HL66611]; NIEHS NIH HHS [ES012496, ES00703, ES012717, ES07498, ES11375, ES7031]		Arbour NC, 2000, NAT GENET, V25, P187; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; Brass DM, 2003, AM J PHYSIOL-LUNG C, V285, pL755, DOI 10.1152/ajplung.00001.2003; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; COOK DN, IN PRESS GENETICS; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; Devlin RB, 1994, AM J PHYSIOL, V266, P612; Dockery D.W., 1993, NEW ENGL J MED, V329, P1754; Dong WM, 1996, EXP LUNG RES, V22, P577, DOI 10.3109/01902149609046043; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; Foster WM, 1996, J APPL PHYSIOL, V81, P1143; Foster WM, 2000, J APPL PHYSIOL, V89, P1804; Gavett SH, 1999, AM J RESP CRIT CARE, V160, P1897; Gavett SH, 1997, ENVIRON RES, V72, P162, DOI 10.1006/enrs.1997.3732; Ghio AJ, 2002, ENVIRON HEALTH PERSP, V110, P89; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704; HAGLIND P, 1987, J OCCUP ENVIRON MED, V29, P904; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hirschfeld M, 2000, J IMMUNOL, V165, P618; Hoebe K, 2003, NATURE, V424, P743, DOI 10.1038/nature01889; HOLLINGSWORTH JW, 2002, AM J RESP CELL MOL B, V165, pA417; Hoshino K, 1999, J IMMUNOL, V162, P3749; Jagielo PJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1052; Jagielo PJ, 1996, CHEST, V110, P263, DOI 10.1378/chest.110.1.263; KEHRL HR, 1987, AM REV RESPIR DIS, V135, P1124; Kleeberger SR, 1997, NAT GENET, V17, P475, DOI 10.1038/ng1297-475; Kleeberger SR, 2000, AM J RESP CELL MOL, V22, P620; Kleeberger SR, 2001, AM J PHYSIOL-LUNG C, V280, pL326; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kodavanti UP, 1997, AM J PHYSIOL-LUNG C, V272, pL521; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MOTUSKY H, 1995, INTUITIVE BIOSTATIST; O'Grady NP, 2001, AM J RESP CRIT CARE, V163, P1591; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SCHWARTZ DA, 1994, AM J PHYSIOL-LUNG C, V267, pL609; Schwartz DA, 1996, CHEST, V109, pS57, DOI 10.1378/chest.109.3_Supplement.57S; Schwarze J., 1996, Journal of Allergy and Clinical Immunology, V97, P293, DOI 10.1016/S0091-6749(96)80662-2; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; Visscher PM, 1999, GENET RES, V74, P81, DOI 10.1017/S0016672399003857; WEINMANN GG, 1995, AM J RESP CRIT CARE, V151, P33; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Yazawa N, 2003, BLOOD, V102, P1374, DOI 10.1182/blood-2002-11-3573	51	105	107	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2004	170	2					126	132		10.1164/rccm.200311-1499OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	837NU	WOS:000222643000007	15020293	
J	Powe, DG; Jagger, C; Kleinjan, A; Carney, AS; Jenkins, D; Jones, NS				Powe, DG; Jagger, C; Kleinjan, A; Carney, AS; Jenkins, D; Jones, NS			'Entopy': localized mucosal allergic disease in the absence of systemic responses for atopy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; idiopathic; IgE; inflammation; mast cells; nasal mucosa; rhinitis	IDIOPATHIC RHINITIS; NASAL-MUCOSA; SERUM IGE; B-CELLS; SKIN; PROVOCATION; EXPRESSION; ANTIBODIES	Background The Th2 immune response in the nasal mucosa of subjects with allergic rhinitis is mediated by allergen-specific IgE. Moreover, these subjects show positive responses for markers of systemic atopy, including allergen-specific skin sensitivity and raised serum IgE titres. In contrast, idiopathic rhinitis (IR) subjects with similar histological nasal mucosal features differ in being defined as non-allergic because they have negative atopic responses. Objective We hypothesized that it is possible to have an allergic Th2 disease pathway localized in the nasal mucosa of 'non-allergic' rhinitis subjects despite an absence of atopic responses. Methods The presence of house dust mite and grass pollen-specific IgE antibodies was investigated in non-atopic ( n=10) and atopic ( n=11) subjects with persistent rhinitis and compared to normal ( n=12) control subjects. Biotin-labelled allergen was used to localize specific allergen-binding antibodies in situ in sections of nasal mucosa. Results Grass pollen allergen binding was detected in the nasal mucosa of 3/10 non-atopic IR subjects but, in contrast, dust mite-specific antibodies were not detected. Specific antibodies were present in a total of 8/11 mucosal samples from the allergic group, but none was detected in normal control tissues. Conclusion These findings support the concept of localized nasal allergy in 'non-atopic' rhinitis subjects. We propose the term 'entopy' to define this phenomenon and believe that this concept has a wider implication for localized allergic responses in other mucosal sites.	Erasmus Univ, Dept Clin Lab Sci, Rotterdam, Netherlands; Erasmus Univ, Dept Otorhinolaryngol, Rotterdam, Netherlands; Flinders Med Ctr, Dept Otolaryngol, Bedford Pk, SA 5042, Australia; Med & Surg Sci Univ Hosp, Queens Med Ctr, Nottingham, England	Powe, DG (reprint author), Univ Nottingham Hosp, Queens Med Ctr, Dept Clin Lab Sci, Div Pathol, Nottingham NG7 2UH, England.						ARSHAD SH, 2001, PEDIATRICS, V108, pU82; BLOM HM, 1995, EUR ARCH OTO-RHINO-L, V1, pS33; BOBROW MN, 1989, J IMMUNOL METHODS, V125, P279, DOI 10.1016/0022-1759(89)90104-X; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; CALDERON MA, 1994, J ALLERGY CLIN IMMUN, V93, P635, DOI 10.1016/S0091-6749(94)70075-3; Carney AS, 2002, CLIN EXP ALLERGY, V32, P1436, DOI 10.1046/j.1365-2745.2002.01465.x; Carney AS, 1996, CLIN OTOLARYNGOL, V21, P198, DOI 10.1111/j.1365-2273.1996.tb01724.x; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Fahlbusch B, 2001, ALLERGY, V56, P1081, DOI 10.1034/j.1398-9995.2001.00106.x; FROESE A, 1980, J IMMUNOL, V139, P600; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; HUGGINS KG, 1975, LANCET, V2, P148; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KAUR B, 1998, INT STUDY ASTHMA ALL; KleinJan A, 2000, EUR RESPIR J, V15, P491, DOI 10.1034/j.1399-3003.2000.15.11.x; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; LEECH S, 2001, BRIT SOC ALL CLIN IM; LUND VJ, 1994, ALLERGY S, V91, P1; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; Ng MLS, 2000, CLIN EXP ALLERGY, V30, P1417, DOI 10.1046/j.1365-2222.2000.00913.x; ORYSZCZYN MP, 1995, AM J RESP CRIT CARE, V151, P663; Panzani RC, 2001, ALLERGY, V56, P1, DOI 10.1111/j.1398-9995.2001.tb04419.x; Powe DG, 2001, CLIN EXP ALLERGY, V31, P864, DOI 10.1046/j.1365-2222.2001.01106.x; POWE DG, 2001, J ALLERGY CLIN IMMUN, V107, P784; Salzano FA, 1997, ALLERGY, V52, P32; SIBBALD B, 1991, THORAX, V46, P895, DOI 10.1136/thx.46.12.895; Simola M, 1999, ANN ALLERG ASTHMA IM, V82, P152, DOI 10.1016/S1081-1206(10)62589-6; SOLLEY GO, 1976, J CLIN INVEST, V58, P408, DOI 10.1172/JCI108485; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170; WANG AC, 1970, P NATL ACAD SCI USA, V66, P337, DOI 10.1073/pnas.66.2.337	33	105	113	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2003	33	10					1374	1379		10.1046/j.1365-2222.2003.01737.x		6	Allergy; Immunology	Allergy; Immunology	727KN	WOS:000185657300009	14519143	
J	Werner, M; Topp, R; Wimmer, K; Richter, K; Bischof, W; Wjst, M; Heinrich, J				Werner, M; Topp, R; Wimmer, K; Richter, K; Bischof, W; Wjst, M; Heinrich, J			TLR4 gene variants modify endotoxin effects on asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; TLR4; gene polymorphism; asthma; ECRHS	HOUSE-DUST ENDOTOXIN; TOLL-LIKE RECEPTOR-4; INNATE IMMUNITY; INHALED LIPOPOLYSACCHARIDE; RESPIRATORY SYMPTOMS; EUROPEAN-COMMUNITY; EXPOSURE; CHILDREN; CD14; HYPERRESPONSIVENESS	Background: Environmental exposure to endotoxin might have a crucial role in immune maturation and development of asthma. Objective: The aim of this study was to investigate whether the effect of endotoxin concentration in settled house dust on asthma is modified by the presence of variation in the TLR4 gene. Methods: We performed a cross-sectional study within the German follow-up of the European Community Respiratory Health Survey. Multivariate logistic regression analysis and nonparametric effect estimates (S-Plus) were applied to examine the association between endotoxin exposure and diagnosed asthma, related clinical symptoms, and bronchial hyperreactivity (BHR) stratified for noncarriers and carriers of G299/1399 polymorphism in the TLR4 gene. Results: In the noncarrier group (n = 279), the prevalence of asthma was significantly increased with elevated endotoxin levels in house dust with adjusted odds ratio 6.24 (95% CI, 1.33-29.17) in the second tertile, and 4.54 (95% CI, 0.94-21.96) in the third tertile compared with the lowest endotoxin fertile. The carriers of the polymorphisms (n = 55) showed a nonsignificant trend to have a lower risk of asthma (crude odds ratio, 0.67; 95% CI, 0.06-8.06 for the second tertile and 1.33; 95% CI, 0.17-10.58 for the third tertile). We found a similar association for wheeze and endotoxin exposure that was also attenuated in subjects with G299/1399 polymorphisms. Conclusions: The G299/1399 polymorphisms were associated with a modified response to endotoxin, but the functional relationship still needs clarification.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Neuherberg, Germany; Grosshansdorf Hosp, Pulm Res Inst, Ctr Pneumol & Thorac Surg, Grosshansdorf, Germany; Univ Jena, Inst Occupat Social & Environm Med, Erfurt, Germany	Heinrich, J (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Arbour NC, 2000, NAT GENET, V25, P187; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Chinn S, 2002, THORAX, V57, P393, DOI 10.1136/thorax.57.5.393; Dabbagh K, 2002, J IMMUNOL, V168, P4524; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Douwes J, 1997, INT J OCCUP ENV HL S, V3, pS26; Dubin W, 1996, AM J PHYSIOL-LUNG C, V270, pL736; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Heinrich J, 2002, EUR RESPIR J, V20, P617, DOI 10.1183/09031936.02.02322001; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kopp EB, 1999, CURR OPIN IMMUNOL, V11, P13, DOI 10.1016/S0952-7915(99)80003-X; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Martinez FD, 1999, LANCET S2, V354, pSII12; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; Medzhitov R, 1997, NATURE, V388, P394; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; O'Neill LAJ, 2002, TRENDS IMMUNOL, V23, P296, DOI 10.1016/S1471-4906(02)02222-6; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; QUANJER PH, 1993, EUR RESPIR J, V6, P5; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; SANDSTROM T, 1992, EUR RESPIR J, V5, P992	37	105	113	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					323	330		10.1067/mai.2003.1648		8	Allergy; Immunology	Allergy; Immunology	709WY	WOS:000184650600016	12897738	
J	Guendelman, S; Meade, K; Benson, M; Chen, YQ; Samuels, S				Guendelman, S; Meade, K; Benson, M; Chen, YQ; Samuels, S			Improving asthma outcomes and self-management behaviors of inner-city children - A Randomized trial of the health buddy interactive device and an asthma diary	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							QUALITY-OF-LIFE; INTERVENTION; EDUCATION; EMERGENCY; COMPUTER; PROGRAM; IMPACT; CARE; FLOW	Background: Asthma is an important cause of morbidity, absence from school, and use of health services among children. Computer-based educational programs can be designed to enhance children's self-management skills and to reduce adverse outcomes. Objective: To assess the effectiveness of an interactive device programmed for the management of pediatric asthma. Design: A randomized controlled trial (66 participants were in the intervention group and 68 were in the control group). Setting: Interventions conducted at home and in an outpatient hospital clinic. Participants: Inner-city children aged 8 to 16 years diagnosed as having asthma by a physician. Intervention: An asthma self-management and education program, the Health Buddy, designed to enable children to assess and monitor their asthma symptoms and quality of life and to transmit this information to health care providers (physicians, nurses, or other case managers) through a secure Web site. Control group participants used an asthma diary. Main Outcome Measures: Any limitation in activity was the primary outcome. Secondary outcomes included perceived asthma symptoms, absence from school, any peak flow reading in the yellow or red zone, and use of health services. Results: After adjusting for covariates, the odds of having any limitation in activity during the 90-day trial were significantly (P = .03) lower for children randomized to the Health Buddy. The intervention group also was significantly (P = .01) less likely to report peak flow readings in the yellow or red zone or to make urgent calls to the hospital (P = .05). Self-care behaviors, which were important correlates of asthma outcomes, also improved far more for the intervention group. Conclusion: Compared with the asthma diary, monitoring asthma symptoms and functional status with the Health Buddy increases self-management skills and improves asthma outcomes.	Univ Calif Berkeley, Div Hlth Sci Policy & Management, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Calif Berkeley, Maternal & Child Hlth Program, Sch Publ Hlth, Berkeley, CA 94720 USA; Univ Calif Berkeley, Sch Publ Hlth, Div Biostat, Berkeley, CA 94720 USA; Childrens Hosp Oakland, Ambulatory Serv, Oakland, CA USA	Guendelman, S (reprint author), Univ Calif Berkeley, Div Hlth Sci Policy & Management, Sch Publ Hlth, 404 Earl Warren Hall,7360, Berkeley, CA 94720 USA.		eshaghian, azam/Q-8826-2016	eshaghian, azam/0000-0001-7918-2895			Bandura A., 1977, SOCIAL LEARNING THEO; BILLINGS J, 1996, HLTH AFF, V15, P245; Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1; Centers for Disease C Prevention, 1996, MMWR-MORBID MORTAL W, V45, P350; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; Gustafson DH, 1999, AM J PREV MED, V16, P1, DOI 10.1016/S0749-3797(98)00108-1; Homer C, 2000, PEDIATRICS, V106, P210; HOWLAND J, 1988, CHEST, V94, P964, DOI 10.1378/chest.94.5.964; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Lieu TA, 1997, PEDIATRICS, V100, P334, DOI 10.1542/peds.100.3.334; Mansour ME, 2000, PEDIATRICS, V106, P512, DOI 10.1542/peds.106.3.512; MELTZER AA, 1989, CHEST, V96, P329, DOI 10.1378/chest.96.2.329; Mitchell H, 1997, PEDIATR PULM, V24, P237; Murphy S J, 1996, Pediatr Rev, V17, P227, DOI 10.1542/pir.17-7-227; MURRAY AB, 1983, PEDIATRICS, V71, P418; National Asthma Education and Prevention Program, 1997, 2 US DEP HLTH HUM SE; National Asthma Education Program, 1991, GUID DIAGN MAN ASTHM; Redline S, 1996, PEDIATR PULM, V21, P203; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; RUBIN DH, 1986, PEDIATRICS, V77, P1; SHIELDS MC, 1990, AM J PUBLIC HEALTH, V80, P36; Vollmer WM, 1999, AM J RESP CRIT CARE, V160, P1647; WICKMAN M, 1994, ALLERGY, V49, P114, DOI 10.1111/j.1398-9995.1994.tb00810.x; WIGAL J K, 1990, Pediatric Asthma Allergy and Immunology, V4, P17, DOI 10.1089/pai.1990.4.17; ZEGER SL, 1988, BIOMETRICS, V44, P1049, DOI 10.2307/2531734	25	105	113	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	FEB	2002	156	2					114	120				7	Pediatrics	Pediatrics	518WN	WOS:000173691000004	11814370	
J	Furlong, TJ; DeSimone, J; Sicherer, SH				Furlong, TJ; DeSimone, J; Sicherer, SH			Peanut and tree nut allergic reactions in restaurants and other food establishments	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut; tree nut; allergy; restaurant		Background: The clinical features of food-allergic reactions in restaurants and other food establishments have not been studied. Of the registrants in the United States Peanut and Tree Nut Allergy Registry (PAR), 13.7% have reported reactions associated with such establishments. Objective: The purpose of this study was to determine the features of allergic reactions to peanut and tree nut in restaurant foods and foods purchased at other private establishments (eg, ice cream shops and bakeries). Methods: Telephone interviews were conducted through use of a structured questionnaire. Subjects/parental surrogates were randomly selected from among the 706 PAR registrants who reported a reaction in a restaurant or other food establishment. Results: Details were obtained for 156 episodes (29 first-time reactions) from 129 subjects/parental surrogates. Most reactions were caused by peanut (67%) or tree nut (24%); for some reactions (9%), the cause was a combination of peanut and another nut or was unknown. Symptoms began at a median of 5 minutes after exposure and were severe in 27% of reactions. Overall, 86% of reactions were treated (antihistamines, 86%; epinephrine, 40%). Establishments commonly cited were Asian food restaurants (19%), ice cream shops (14%), and bakeries/doughnut shops (13%). Among meal courses, desserts were a common cause (43%). Of 106 registrants with previously diagnosed allergy who ordered food specifically for ingestion by the allergic individual, only 45% gave prior notification about the allergy to the establishment. For 83 (78%) of these 106 reactions, someone in the establishment knew that the food contained peanut or tree nut as an ingredient; in 50% of these incidents, the food item was "hidden" (in sauces, dressings, egg rolls, etc), visual identification being prevented. In 23 (22%) of the 106 cases, exposures were reported from contamination caused primarily by shared cooking/serving supplies. In the remaining 21 subjects with previously diagnosed allergy, reactions resulted from ingestion of food not intended for them, ingestion of food selected from buffet/food bars, or skin contact/inhalation (residual food on tables, 2; peanut shells covering floors, 2; being within 2 feet of the cooking of the food, 1). Conclusions: Restaurants and other food establishments pose a number of dangers for peanut- and tree nut-allergic individuals, particularly with respect to cross-contamination and unexpected ingredients in desserts and Asian food. Failure to establish a clear line of communication between patron and establishment is a frequent cause of errors.	Mt Sinai Sch Med, Dept Pediat, Div Allergy & Immunol, Jaffe Food Allergy Inst, New York, NY USA; Food Allergy & Anaphylaxis Network, Fairfax, VA USA	Sicherer, SH (reprint author), Mt Sinai Hosp, Div Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [K23 AI01709-01]; NICHD NIH HHS [HD28822-08]		Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Hourihane JO, 1998, BRIT MED J, V316, P1271; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SICHERER SH, 1999, J ALLERGY CLIN IMMUN, V103, P186; Sicherer S.H., 1998, PEDIATRICS, V102, P6; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	10	105	107	0	13	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					867	870				4	Allergy; Immunology	Allergy; Immunology	498RG	WOS:000172523800032	11692117	
J	Bahceciler, NN; Isik, U; Barlan, IB; Basaran, MM				Bahceciler, NN; Isik, U; Barlan, IB; Basaran, MM			Efficacy of sublingual immunotherapy in children with asthma and rhinitis: A double-blind, placebo-controlled study	PEDIATRIC PULMONOLOGY			English	Article						sublingual immunotherapy; asthma; rhinitis; house dust mite; children	HOUSE-DUST-MITE; DERMATOPHAGOIDES-PTERONYSSINUS; POLLEN EXTRACT; TRIAL; SLIT	To evaluate the efficacy of specific sublingual immunotherapy (SLIT), we enrolled 15 children with asthma and rhinitis (7 girls, 8 boys, mean +/- SD age of 11.7 +/- 3.3) allergic to house dust mite (HDM) into a double-blind, placebo-controlled study. After a run-in period, patients were randomized to receive either placebo (n = 7) or SLIT (n = 8) with a standardized Dermatophagoides pteronyssinus (D. pteronyssinus) + Dermatophagoides farinea (D. farinea) 50/50 extract. They received increasing doses up to 100 index units of reactivity (IR) every day for 4 weeks, then 100 IR/day for another 4 weeks, followed by maintenance therapy consisting of 20 drops 2 times a week for 4 months. Efficacy was assessed at the end of 6 months of therapy according to symptom and medication scores, serum total IgE levels, results of lung function tests, methacholine provocation tests, and skin prick tests. Daily means for the asthma score and use of inhaled beta-2-mimetics decreased significantly in the SLIT group (P = 0.05, P = 0.028, respectively), whereas no such difference was observed in the placebo group. At the end of follow-up, mean daily doses of intranasal steroids needed for control of rhinitis symptoms decreased significantly in the SLIT group (P = 0.04). Baseline skin sensitivity to D. pteronyssinus and D. farinea was not significantly different between in the two groups, whereas end-point wheal diameter obtained with D.pteronyssinus extract was significantly less in the SLIT vs. the placebo group (p = 0.026). At the end of 6 months, peak expiratory flow (PEF) values in the placebo group was significantly lower than in the SLIT group (P = 0.049). Throughout the treatment period, the SLIT group was found to have less asthma exacerbations than the placebo group (p = 0.007). The provocation concentration causing a 20% drop in forced expired volume in 1 sec did not change throughout the treatment period in either groups. None of the patients reported local or systemic side effects from SLIT. Results of this study suggests that SLIT may be a useful alternative or additional therapy in the treatment of children with asthma/rhinitis due to HDM. (C) 2001 Wiley-Liss, Inc.	Marmara Univ Hosp, Dept Pediat, Div Allergy & Immunol, Istanbul, Turkey	Bahceciler, NN (reprint author), Vefa Bey Sok 2-B Yesil Apt D 39, TR-80680 Istanbul, Turkey.						BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Committee on the safety of medicines, 1986, BRIT MED J, V293, P948, DOI 10.1136/bmj.293.6552.948; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; HEDLIN G, 1990, CLIN EXP ALLERGY, V20, P491, DOI 10.1111/j.1365-2222.1990.tb03141.x; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; MACHIELS JJ, 1990, J CLIN INVEST, V85, P1024, DOI 10.1172/JCI114532; *NAT HEART LUNG BL, 1992, PUBL NAT HEART LUNG; Polgar P, 1971, PULMONARY TESTING CH, P100; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SHEFFER AL, 1992, CLIN EXP ALLERGY   S, P22; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VANWILSEM EJG, 1994, IMMUNOLOGY, V83, P128; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WARNER JO, 1978, LANCET, V2, P912	21	105	111	1	11	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	JUL	2001	32	1					49	55		10.1002/ppul.1088		7	Pediatrics; Respiratory System	Pediatrics; Respiratory System	448LW	WOS:000169629200008	11416876	
J	Chapman, JT; Otterbein, LE; Elias, JA; Choi, AMK				Chapman, JT; Otterbein, LE; Elias, JA; Choi, AMK			Carbon monoxide attenuates aero allergen-induced inflammation in mice	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						heme oxygenase; asthma; eosinophils; ovalbumin; cytokines	HYPEROXIC LUNG INJURY; CYTOKINE MESSENGER-RNA; MURINE MODEL; AIRWAY HYPERRESPONSIVENESS; BRONCHOALVEOLAR LAVAGE; BRONCHIAL HYPERRESPONSIVENESS; EOSINOPHILIC INFLAMMATION; PULMONARY INFLAMMATION; HEME OXYGENASE-1; OXIDATIVE STRESS	Carbon monoxide (CO) generated by catalysis of heme by heme oxygenase is increased in the exhaled air of asthmatic patients. Based on recent studies demonstrating that asthma is an inflammatory disease associated with increased oxidants and that CO confers cytoprotection in oxidant-induced lung injury and inflammation, we sought to better understand the functional role of CO in asthma by using an aeroallergen model. Mice were sensitized to ovalbumin, challenged with aerosolized ovalbumin, and maintained in either CO (250 parts/million) or room air for 48 h. The differential effects of CO on bronchoalveolar lavage (BAL) fluid cell types were observed, with a marked attenuation of BAL fluid eosinophils in the CO-treated animals at 24 and 48 h. A marked reduction of the proinflammatory cytokine interleukin-5 was observed in the CO-treated mice, with no significant changes for other proinflammatory cytokines. These differential Effects of CO were also observed with leukotrienes (LTs) and prostaglandins in that CO significantly decreased BAL fluid PGE(2), and LTB4 but exerted negligible effect on thromboxane B-2 or LTC4/D-4/E-4. Our data suggest a putative immunoregulatory role for CO in aeroallergen-induced inflammation in mice.	Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Yale Univ, Sch Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Connecticutt Vet Affairs Healthcare Syst, W Haven, CT 06516 USA; Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Cleveland, OH 44195 USA	Choi, AMK (reprint author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, MUH 628 NW, Pittsburgh, PA 15213 USA.				NHLBI NIH HHS [HL-55330, HL-60234]; NIAID NIH HHS [AI-42365]		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; BRUSSELLE G, 1995, AM J RESP CELL MOL, V12, P254; Cieslewicz G, 1999, J CLIN INVEST, V104, P301, DOI 10.1172/JCI7010; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Cohn L, 1998, J IMMUNOL, V161, P3813; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1997, J EXP MED, V185, P1715; COTT GR, 1986, AM J PHYSIOL, V250, pC222; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; Coyle AJ, 1998, EUR J IMMUNOL, V28, P2640, DOI 10.1002/(SICI)1521-4141(199809)28:09<2640::AID-IMMU2640>3.0.CO;2-X; DECHATELET LR, 1977, BLOOD, V50, P525; Eum SY, 1995, P NATL ACAD SCI USA, V92, P12290, DOI 10.1073/pnas.92.26.12290; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Garlisi CG, 1997, AM J RESP CELL MOL, V17, P642; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gauvreau GM, 1999, AM J RESP CRIT CARE, V159, P31; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; GLEICH GJ, 1989, INT ARCH ALLER A IMM, V88, P59; Hajat S, 1999, THORAX, V54, P597; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; HOLM BA, 1988, J APPL PHYSIOL, V65, P2672; HOLM BA, 1985, J APPL PHYSIOL, V59, P1402; Horvath I, 1998, THORAX, V53, P668; Huang J, 1998, ARCH TOXICOL, V72, P141, DOI 10.1007/s002040050480; HUANG SK, 1995, J IMMUNOL, V155, P2688; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; JACKSON RM, 1985, CHEST, V88, P900, DOI 10.1378/chest.88.6.900; Jagels MA, 1999, AM J RESP CELL MOL, V21, P418; Jenkinson S G, 1993, New Horiz, V1, P504; Jia YX, 1999, INT ARCH ALLERGY IMM, V120, P141, DOI 10.1159/000024232; JONES RA, 1971, TOXICOL APPL PHARM, V19, P46, DOI 10.1016/0041-008X(71)90188-8; KANTEN WE, 1983, AM J PHYSIOL, V244, pH320; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83; Lefort J, 1996, J ALLERGY CLIN IMMUN, V97, P788, DOI 10.1016/S0091-6749(96)80157-6; LENFANT C, 1990, CHEST, V98, P226, DOI 10.1378/chest.98.1.226; MASON RJ, 1982, P NATL ACAD SCI-BIOL, V79, P6033, DOI 10.1073/pnas.79.19.6033; MATALON S, 1994, J APPL PHYSIOL, V76, P989; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; MATALON S, 1988, EXP LUNG RES, V14, P1021, DOI 10.3109/01902148809064190; MINOO P, 1992, AM J PHYSIOL, V263, pL291; MINOO P, 1991, AM J PHYSIOL, V261, pL386; MURALI PS, 1992, INFECT IMMUN, V60, P1952; Ndisang JF, 1999, IMMUNOPHARMACOLOGY, V43, P65, DOI 10.1016/S0162-3109(99)00045-4; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422; PALMER RMJ, 1980, PROSTAGLANDINS, V20, P411, DOI 10.1016/S0090-6980(80)80058-X; Paredi P, 1999, EUR RESPIR J, V13, P48, DOI 10.1183/09031936.99.13104899; Peacock CD, 1999, J ALLERGY CLIN IMMUN, V104, P153, DOI 10.1016/S0091-6749(99)70127-2; PETAJAN JH, 1976, ARCH NEUROL-CHICAGO, V33, P152; Ponath PD, 1996, J CLIN INVEST, V97, P604, DOI 10.1172/JCI118456; Rahman I, 1996, AM J RESP CRIT CARE, V154, P1055; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; ROONEY SA, 1994, FASEB J, V8, P957; Schwarze J, 1999, J IMMUNOL, V162, P2997; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STUPFEL M, 1970, ANN NY ACAD SCI, V174, P342, DOI 10.1111/j.1749-6632.1970.tb49799.x; Tohda Y, 1999, METHOD FIND EXP CLIN, V21, P541, DOI 10.1358/mf.1999.21.8.794836; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Wagener FADTG, 1999, J PHARMACOL EXP THER, V291, P416; WARDLAW AJ, 1989, J ALLERGY CLIN IMMUN, V84, P19, DOI 10.1016/0091-6749(89)90173-5; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; Whitsett JA, 1998, BBA-MOL BASIS DIS, V1408, P303, DOI 10.1016/S0925-4439(98)00076-3; WIKENHEISER KA, 1992, AM J PHYSIOL, V262, pL32; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	69	105	106	0	7	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	JUL	2001	281	1					L209	L216				8	Physiology; Respiratory System	Physiology; Respiratory System	447AR	WOS:000169546800027	11404264	
J	Kurup, VP; Banerjee, B; Hemmann, S; Greenberger, PA; Blaser, K; Crameri, R				Kurup, VP; Banerjee, B; Hemmann, S; Greenberger, PA; Blaser, K; Crameri, R			Selected recombinant Aspergillus fumigatus allergens bind specifically to IgE in ABPA	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic asthma; allergic bronchopulmonary aspergillosis; ELISA; recombinant Aspergillus allergens; specific IgE	SKIN-TEST REACTIVITY; BRONCHOPULMONARY ASPERGILLOSIS; MAJOR ALLERGEN; CYSTIC-FIBROSIS; EXPRESSION; CLONING; SYSTEM; I/A; PURIFICATION; DIAGNOSIS	Background Allergic bronchopulmonary aspergillosis (ABPA) is a hypersensitivity lung disease resulting from exposure to Aspergillus fumigatus allergens. Patients with ABPA show elevated Aspergillus-specific serum IgE, a major criterion used in the diagnosis of the disease. Crude culture filtrate and mycelial antigens have been used widely to demonstrate IgE antibody to Aspergillus in the sera of patients. While these antigens have been useful in the diagnosis of ABPA, occasionally they present inconsistency in their reactivity and lack of specificity. Although in recent years, a number of purified A. fumigatus allergens have been produced by molecular cloning, no attempt was made to evaluate them systematically. Objective To evaluate the recombinant proteins from A. fumigatus for their IgE antibody binding, we studied sera from ABPA patients and controls by antigen specific enzyme linked immunosorbent assay (ELISA). Methods Recombinant Aspergillus allergens Asp f 1, f 2, f 3, f 4, and f 6 were studied for their specific binding to IgE in the sera of ABPA patients, A. fumigatus skin prick test positive asthmatics, and normal controls from the USA and Switzerland. The sera were blinded and studied by ELISA in two different laboratories. Results All the recombinant allergens showed IgE antibody binding with sera from patients with ABPA, whereas only fewer asthmatics and normal sera showed significant binding. The three selected recombinant allergens together reacted with all the ABPA patients studied. Conclusions The results demonstrate that Asp f 2, f 4, and f 6 can be used in the serodiagnosis of ABPA, while IgE antibody binding to Asp f 1 and f 3 was not specific.	Vet Affairs Med Ctr, Res Serv 151I, Milwaukee, WI 53295 USA; Med Coll Wisconsin, Dept Med, Div Allergy Immunol, Milwaukee, WI 53226 USA; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Northwestern Univ, Sch Med, Div Allergy Immunol, Chicago, IL 60611 USA	Kurup, VP (reprint author), Vet Affairs Med Ctr, Res Serv 151I, 5000 W Natl Ave, Milwaukee, WI 53295 USA.				NIAID NIH HHS [AI42349]		ARRUDA LK, 1992, J IMMUNOL, V149, P3354; Banerjee B, 1998, INFECT IMMUN, V66, P5175; Banerjee B, 1996, J LAB CLIN MED, V127, P253, DOI 10.1016/S0022-2143(96)90093-1; Banerjee B, 1997, J ALLERGY CLIN IMMUN, V99, P821, DOI 10.1016/S0091-6749(97)80017-6; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1996, INT ARCH ALLERGY IMM, V110, P41; Crameri R, 1996, CLIN EXP ALLERGY, V26, P1411, DOI 10.1046/j.1365-2222.1996.d01-296.x; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; GREENBERGER PA, 1988, ALLERGY PRINCIPLE PR, P1219; Hemmann S, 1998, EUR J IMMUNOL, V28, P1155, DOI 10.1002/(SICI)1521-4141(199804)28:04<1155::AID-IMMU1155>3.3.CO;2-Y; Hemmann S, 1997, AM J RESP CRIT CARE, V156, P1956; Hemmann S, 1998, CLIN EXP ALLERGY, V28, P860; HOCHULI E, 1988, BIO-TECHNOL, V6, P1321, DOI 10.1038/nbt1188-1321; KUMAR A, 1993, J ALLERGY CLIN IMMUN, V91, P1024, DOI 10.1016/0091-6749(93)90215-2; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439; KURUP VP, 1994, J LAB CLIN MED, V123, P749; KURUP VP, 1998, ALLERGIC BRONCHOPULM, P13; MOSER M, 1992, J IMMUNOL, V149, P454; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Nikolaizik WH, 1996, INT ARCH ALLERGY IMM, V111, P403; PATTERSON R, 1982, ANN INTERN MED, V96, P286; ROSENBERG M, 1977, ANN INTERN MED, V86, P405; SLAVIN RG, 1993, J LAB CLIN MED, V121, P380	25	105	118	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUL	2000	30	7					988	993				6	Allergy; Immunology	Allergy; Immunology	334CP	WOS:000088167800012	10848921	
J	Lee, SH; Heng, D; Ng, WK; Chan, HK; Tan, RBH				Lee, Sie Huey; Heng, Desmond; Ng, Wai Kiong; Chan, Hak-Kim; Tan, Reginald B. H.			Nano spray drying: A novel method for preparing protein nanoparticles for protein therapy	INTERNATIONAL JOURNAL OF PHARMACEUTICS			English	Article						Nano spray dryer; Protein therapy; Nanoparticles; Bovine serum albumin; Spray drying	FORMULATION APPROACH; AEROSOL PERFORMANCE; DRUG-DELIVERY; POWDERS; PARTICLES; STABILITY; TAGUCHI; CRYSTALLIZATION; MICROPARTICLES; OPTIMIZATION	There has been an increasing interest in the development of protein nanotherapeutics for diseases such as cancer, diabetes and asthma. Spray drying with prior micro mixing is commonly used to obtain these powders. However, the separation and collection of protein nanoparticles with conventional spray dryer setups has been known to be extremely challenging due to its typical low collection efficiency for fine particles less than 2 mu m. To date, there has been no feasible approach to produce these protein nanoparticles in a single step and with high yield (>70%). In this study, we explored the feasibility of the novel Nano Spray Dryer B-90 (equipped with a vibrating mesh spray technology and an electrostatic particle collector) for the production of bovine serum albumin (BSA) nanoparticles. A statistical experimental design method (Taguchi method based on three levels, five variables L-18 orthogonal array robust design) was implemented to study the effect of and optimize the experimental conditions of: (1) spray mesh size, (2) BSA solution concentration, (3) surfactant concentration, (4) drying air flow rate and (5) inlet temperature on: (1) size and (2) morphology (axial ratio). Particle size and morphology were predominantly influenced by the spray mesh size and surfactant concentration, respectively. The drying air flow rate and inlet temperature had minimal impact. Optimized production of smooth spherical nanoparticles (median size: 460 +/- 10 nm, axial ratio: 1.03 +/- 0.00, span 1.03 +/- 0.03, yield: 72 +/- 4%) was achieved using the 4 mu m spray mesh at BSA concentration of 0.1% (w/v), surfactant concentration of 0.05% (w/v), drying flow rate of 150 L/min and inlet temperature of 120 degrees C. The Nano Spray Dryer B-90 thus offers a new, simple and alternative approach for the production of protein nanoparticles suited for a variety of drug delivery applications. (C) 2010 Elsevier B.V. All rights reserved.	[Lee, Sie Huey; Heng, Desmond; Ng, Wai Kiong; Tan, Reginald B. H.] ASTAR, Inst Chem & Engn Sci, Singapore 627833, Singapore; [Chan, Hak-Kim] Univ Sydney, Fac Pharm, Adv Drug Delivery Grp, Sydney, NSW 2006, Australia; [Tan, Reginald B. H.] Natl Univ Singapore, Dept Chem & Biomol Engn, Singapore 117576, Singapore	Heng, D (reprint author), ASTAR, Inst Chem & Engn Sci, 1 Pesek Rd, Singapore 627833, Singapore.	desmond_heng@ices.a-star.edu.sg; reginald_tan@ices.a-star.edu.sg			Science and Engineering Research Council of A*STAR (Agency for Science, Technology and Research), Singapore [ICES/09-122A02]	This work was supported by the Science and Engineering Research Council of A*STAR (Agency for Science, Technology and Research), Singapore (grant no. ICES/09-122A02). We are grateful to Miss Tan Li Teng, Mr. Ng Jun Wei and Miss Shirley Yap for their assistance in the experiments. We also thank Dr. Cordin Arpagaus (BUCHI Labortechnik AG) for the fruitful discussion and Dr. Philip Kwok (The University of Sydney) for the helpful advice.	Adi S, 2008, EUR J PHARM SCI, V35, P12, DOI 10.1016/j.ejps.2008.05.009; Adler M, 2000, PHARMACEUT RES, V17, P863, DOI 10.1023/A:1007568511399; BROADHEAD J, 1992, DRUG DEV IND PHARM, V18, P1169, DOI 10.3109/03639049209046327; BUCHI Labortechnik AG, 2009, SWITZ BROCH NAN DRYE; Cal K, 2010, J PHARM SCI-US, V99, P575, DOI 10.1002/jps.21886; Chan HK, 1997, PHARMACEUT RES, V14, P431, DOI 10.1023/A:1012035113276; Chew NYK, 2005, PHARM RES, V22, P148, DOI 10.1007/s11095-004-9020-4; Chiou H, 2008, J AEROSOL SCI, V39, P500, DOI 10.1016/j.jaerosci.2008.02.002; Cleland JL, 2001, CURR OPIN BIOTECH, V12, P212, DOI 10.1016/S0958-1669(00)00202-0; Coppi G, 2002, INT J PHARM, V242, P263, DOI 10.1016/S0378-5173(02)00171-0; Costantino HR, 1998, J PHARM SCI, V87, P1406, DOI 10.1021/js9800679; Crowder TM, 2002, PHARMACEUT RES, V19, P239, DOI 10.1023/A:1014426530935; DIEMUNSCH AM, 1993, DRUG DEV IND PHARM, V19, P1461, DOI 10.3109/03639049309047185; Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103; GHADIRI MR, 1994, NATURE, V369, P301, DOI 10.1038/369301a0; Heng D, 2009, J NANOPART RES, V12, P1743; Heng D, 2008, PHARM RES-DORDR, V25, P1696, DOI 10.1007/s11095-008-9560-0; Jia L, 2005, CURR NANOSCI, V1, P237, DOI 10.2174/157341305774642939; Kaerger JS, 2004, PHARM RES, V21, P372, DOI 10.1023/B:PHAM.0000016252.97296.f1; Kaye RS, 2009, J CONTROL RELEASE, V135, P127, DOI 10.1016/j.jconrel.2008.11.009; Kerwin BA, 1998, J PHARM SCI, V87, P1062, DOI 10.1021/js980140v; Kim KD, 2007, COLLOID SURFACE A, V311, P170, DOI 10.1016/j.colsurfa.2007.06.017; Koster VS, 1996, INT J PHARM, V134, P235, DOI 10.1016/0378-5173(95)04409-4; Langrish TAG, 2006, DRY TECHNOL, V24, P1619, DOI 10.1080/07373930601031133; Larry R.B., 2005, EXPERT OPINION DRUG, V2, P29; Lee SH, 2007, BIOMATERIALS, V28, P2041, DOI 10.1016/j.biomaterials.2007.01.003; Maa Y F, 1997, Pharm Dev Technol, V2, P213, DOI 10.3109/10837459709031441; Masters K., 1976, SPRAY DRYING; Merisko-Liversidge E, 2004, PHARM RES, V21, P1545, DOI 10.1023/B:PHAM.0000041446.14569.e2; Merisko-Liversidge E, 2003, EUR J PHARM SCI, V18, P113, DOI 10.1016/S0928-0987(02)00251-8; Mosen K, 2004, PHARM DEV TECHNOL, V9, P409, DOI 10.1081/PDT-200035795; Muller R.H., 2006, NANOPARTICULATES DRU, P308; Noyes A., 1897, J AM CHEM SOC, V19, P930, DOI DOI 10.1021/JA02086A003; Palmieri GF, 1997, DRUG DEV IND PHARM, V23, P1069, DOI 10.3109/03639049709150495; Peace GS, 1993, TAGUCHI METHODS HAND; Rasband W. S., 1997, IMAGE; Salama RO, 2009, J PHARM SCI-US, V98, P2709, DOI 10.1002/jps.21653; Schmidt K., 2010, PHARM DEV TECHNOL, P1, DOI DOI 10.3109/10837450.2010.485320; Shaji J, 2008, INDIAN J PHARM SCI, V70, P269, DOI 10.4103/0250-474X.42967; Shoyele SA, 2006, ADV DRUG DELIVER REV, V58, P1009, DOI 10.1016/j.addr.2006.07.010; Souto E. B., 2008, International Journal of Cosmetic Science, V30, P157, DOI 10.1111/j.1468-2494.2008.00433.x; Taguchi G., 1986, INTRO QUALITY ENG DE; Wang W, 2008, INT J PHARM, V347, P31, DOI 10.1016/j.ijpharm.2007.06.042; Yang K, 2007, J BIOMECH, V40, P3251, DOI 10.1016/j.jbiomech.2006.12.016	44	104	109	6	72	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0378-5173			INT J PHARMACEUT	Int. J. Pharm.	JAN 17	2011	403	1-2					192	200		10.1016/j.ijpharm.2010.10.012		9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	711AG	WOS:000286557500024	20951781	
J	Corren, J; Casale, TB; Lanier, B; Buhl, R; Holgate, S; Jimenez, P				Corren, J.; Casale, T. B.; Lanier, B.; Buhl, R.; Holgate, S.; Jimenez, P.			Safety and tolerability of omalizumab	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						anti-IgE; omalizumab; safety; tolerability	SEVERE ALLERGIC-ASTHMA; ANTI-IGE ANTIBODY; ANTIIMMUNOGLOBULIN-E THERAPY; CHURG-STRAUSS-SYNDROME; SEVERE PERSISTENT ASTHMA; LONG-TERM CONTROL; QUALITY-OF-LIFE; MONOCLONAL-ANTIBODY; CANCER INCIDENCE; CROHNS-DISEASE	Omalizumab (Xolair((R))) is a recombinant humanized monoclonal anti-IgE antibody with proven efficacy in patients with moderate-to-severe and severe persistent allergic (IgE-mediated) asthma. To review clinical study data to assess the safety profile of omalizumab. We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post-marketing safety data. Analysis focuses on the risk of immune-system effects, hypersensitivity reactions, malignant neoplasia, parasitic infections and thrombocytopenia. Omalizumab exhibited a good safety and tolerability profile that was maintained up to 4 years in one study. The incidence of anaphylaxis was 0.14% in omalizumab-treated patients and 0.07% in control patients. No omalizumab-treated patient developed measurable anti-omalizumab antibodies. Post-marketing, based on estimated exposure of 57 300 patients (June 2003-December 2006), the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients. Current clinical trial data do not support an increased risk of malignant neoplasia or thrombocytopenia with omalizumab. Data indicate that the proven efficacy of add-on omalizumab in patients with moderate-to-severe or severe allergic asthma is accompanied by a favourable safety and tolerability profile.	[Casale, T. B.] Allergy Res Fdn, Los Angeles, CA 90025 USA; [Lanier, B.] Lanier Educ & Res Network, Ft Worth, TX USA; [Buhl, R.] Mainz Univ Hosp, Dept Pulm, Mainz, Germany; [Jimenez, P.] Novartis Pharmaceut, E Hanover, NJ USA; [Holgate, S.] Southampton Gen Hosp, Southampton SO9 4XY, Hants, England	Corren, J (reprint author), Allergy Res Fdn, 11620 Wilshire Blvd,Suite 200, Los Angeles, CA 90025 USA.	jcorren@ucla.edu	Casale, Thomas/K-4334-2013	Casale, Thomas/0000-0002-3149-7377	Novartis and Genentech	P. J. is an employee of Novartis Pharmaceuticals.	Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; ADKINSON NF, 2003, MIDDLETONS ALLERGY P, V2; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Bargagli E, 2008, INT ARCH ALLERGY IMM, V145, P268, DOI 10.1159/000109296; Bousquet J, 2005, ALLERGY, V60, P302, DOI 10.1111/j.1398-9995.2004.00770.x; Bousquet J, 2003, ALLERGY S, V58, pA4; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; CALIFF RM, 1994, NEW ENGL J MED, V330, P956; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Chervinsky P, 2003, ANN ALLERG ASTHMA IM, V91, P160; Choy EHS, 1998, BRIT J RHEUMATOL, V37, P484; Chung K, 2007, ALLERGY, V62, P210; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; Cruz AA, 2007, CLIN EXP ALLERGY, V37, P197, DOI 10.1111/j.1365-2222.2007.02650.x; D'Cruz DP, 1999, BRIT MED J, V318, P475; Dery JP, 2004, AM J CARDIOL, V93, P979, DOI 10.1016/j.amjcard.2003.12.051; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; ENBREL R, 2006, FULL PRESCRIBING INF; ERIKSSON NE, 1995, ALLERGY, V50, P718, DOI 10.1111/j.1398-9995.1995.tb01212.x; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; Fleiss J. L., 1981, STAT METHODS RATES P; *GEN INC, 2009, ALTO STUD SYN FIN RE; *GEN INC, 2007, OM XOL R FULL PRESCR; Giavina-Bianchi P, 2008, INT ARCH ALLERGY IMM, V146, P176, DOI 10.1159/000113524; GONZALEZPEREZ A, 2007, EUR RESP J S51, V30, pS625; Hanauer SB, 2002, LANCET, V359, P1541, DOI 10.1016/S0140-6736(02)08512-4; Hebert J, 2006, J ALLERGY CLIN IMMUN, V117, pS9, DOI 10.1016/j.jaci.2005.12.038; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Hommes DW, 2003, NETH J MED, V61, P100; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; JARRETT EEE, 1982, PROG ALLERGY, V31, P178; KALLEN B, 1993, EUR RESPIR J, V6, P694; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lanier BQ, 2003, ANN ALLERG ASTHMA IM, V91, P154; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; MCWHORTER WP, 1988, CANCER, V62, P451, DOI 10.1002/1097-0142(19880715)62:2<451::AID-CNCR2820620234>3.0.CO;2-D; Milgrom H, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e36; Miller MK, 2006, J ALLERGY CLIN IMMUN, V117, pS12, DOI 10.1016/j.jaci.2005.12.049; MILLS PK, 1992, AM J EPIDEMIOL, V136, P287; PRESTA LG, 1993, J IMMUNOL, V151, P2623; REYNOLDS P, 1987, AM J EPIDEMIOL, V125, P539; Ries LAG, 2002, SEER CANC STAT REV, P1973; Ruppert AA, 2008, J ALLERGY CLIN IMMUN, V121, P253, DOI 10.1016/j.jaci.2007.10.040; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; VESTERINEN E, 1993, INT J EPIDEMIOL, V22, P976, DOI 10.1093/ije/22.6.976; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Webb LM, 2006, ANN ALLERG ASTHMA IM, V97, P39; Winchester DE, 2006, NEW ENGL J MED, V355, P1281	51	104	107	0	11	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2009	39	6					788	797		10.1111/j.1365-2222.2009.03214.x		10	Allergy; Immunology	Allergy; Immunology	444XW	WOS:000266015200004	19302249	
J	Jartti, T; Lee, WM; Pappas, T; Evans, M; Lemanske, RF; Gern, JE				Jartti, T.; Lee, W-M.; Pappas, T.; Evans, M.; Lemanske, R. F., Jr.; Gern, J. E.			Serial viral infections in infants with recurrent respiratory illnesses	EUROPEAN RESPIRATORY JOURNAL			English	Article						infant; respiratory virus; rhinovirus; virus persistence; virus strain; wheezing	RHINOVIRUS INFECTION; ACUTE BRONCHIOLITIS; CHILDHOOD ASTHMA; CHILDREN; LIFE; ASSOCIATION; PERSISTENCE; 1ST-YEAR; SYMPTOMS; VIRUSES	To better understand the viral aetiology of recurrent and prolonged illnesses, nasal secretions were prospectively collected from 285 infants at increased risk of developing asthma. Of these, 27 infants had recurrent (at least five) moderate-to-severe respiratory illnesses (MSIs). The viral aetiology of the 150 MSIs and 86 scheduled visits was analysed by molecular diagnostics. The demographic and clinical data were compared with infants who had 0-4 MSIs. Frequently ill infants had higher exposure to other children and more wheezing illnesses than less symptomatic children. Viruses were detected in 136 (91 %) out of 150 MSIs, 14 (67%) out of 21 mild illnesses and 29 (45%) out of 65 asymptomatic visits. Human rhinovirus was the most common aetiological agent (61, 43 and 35% in MSIs, mild illnesses and asymptomatic visits, respectively). Mixed viral infections were generally associated with more severe illnesses (27, 0 and 5%, respectively). Among the 27 frequently ill infants, only eight (5.3%) out of 150 MSIs were prolonged (>= 2 weeks duration). Considering all samples, detection of the same virus strain >= 2 weeks apart was unusual (5.3% of all 244 positive findings). Human rhinovirus infections occur early, pervasively and repetitively in these high-risk infants. Infants with prolonged or recurrent respiratory illnesses most often have a series of infections rather than persistent infection with one virus strain.	[Jartti, T.; Lee, W-M.; Pappas, T.; Gern, J. E.] Univ Wisconsin, Dept Paediat, Madison, WI USA; [Evans, M.] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; [Lemanske, R. F., Jr.] Univ Wisconsin, Dept Med, Madison, WI USA	Jartti, T (reprint author), Turku Univ Hosp, Dept Paediat, POB 52, FIN-20520 Turku, Finland.	tuomas.jartti@tyks.fi			NCRR NIH HHS [1UL1RR025011, UL1 RR025011, UL1 RR025011-01]; NHLBI NIH HHS [P01 HL070831, P01 HL070831-01, P01 HL70831, R01 HL061879, R01 HL061879-02, R01 HL61879]		Allander T, 2007, CLIN INFECT DIS, V44, P904, DOI 10.1086/512196; Brooks GD, 2003, AM J RESP CRIT CARE, V168, P1091, DOI 10.1164/rccm.200306-737OC; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gern JE, 2005, J ALLERGY CLIN IMMUN, V115, P668, DOI 10.1016/j.jaci.2005.01.057; HAMPARIAN VV, 1987, VIROLOGY, V159, P191; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; Hogg JC, 2001, AM J RESP CRIT CARE, V164, pS71; Jacques J, 2006, J CLIN VIROL, V35, P463, DOI 10.1016/j.jcv.2005.11.009; Jartti T, 2004, J MED VIROL, V72, P695, DOI 10.1002/jmv.20027; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111; Kaiser L, 2006, AM J RESP CRIT CARE, V174, P1392, DOI 10.1164/rccm.200604-489OC; Kling S, 2005, CLIN EXP ALLERGY, V35, P672, DOI 10.1111/j.1365-2222.2005.02244.x; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lee WM, 2007, J CLIN MICROBIOL, V45, P2626, DOI 10.1128/JCM.02501-06; Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Malmstrom K, 2006, J ALLERGY CLIN IMMUN, V118, P591, DOI 10.1016/j.jaci.2006.04.032; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1067/mai.2003.1716; Nokso-Koivisto J, 2002, CLIN INFECT DIS, V35, P540; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-1188C; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Smyth RL, 2006, LANCET, V368, P312, DOI 10.1016/S0140-6736(06)69077-6; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588	30	104	106	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	AUG	2008	32	2					314	320		10.1183/09031936.00161907		7	Respiratory System	Respiratory System	337DZ	WOS:000258417000011	18448489	
J	Waser, M; Michels, KB; Bieli, C; Floistrup, H; Pershagen, G; von Mutius, E; Ege, M; Riedler, J; Schram-Bijkerk, D; Brunekreef, B; van Hage, M; Lauener, R; Braun-Fahrlander, C				Waser, M.; Michels, K. B.; Bieli, C.; Floistrup, H.; Pershagen, G.; von Mutius, E.; Ege, M.; Riedler, J.; Schram-Bijkerk, D.; Brunekreef, B.; van Hage, M.; Lauener, R.; Braun-Fahrlaender, C.		PARSIFAL Study Grp	Inverse association of farm milk consumption with asthma and allergy in rural and suburban populations across Europe	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; anthroposophy; asthma; children; diet; farming; gastrointestinal microflora; self-production; sensitization	ANTHROPOSOPHIC LIFE-STYLE; HAY-FEVER; FUNGAL MICROBIOTA; LOW-PREVALENCE; BIRTH COHORT; CHILDREN; ATOPY; CHILDHOOD; DISEASES; RISK	Background Dietary interventions as a means for atopy prevention attract great interest. Some studies in rural environments claimed an inverse association between consumption of farm-produced dairy products and the prevalence of allergic diseases, but current evidence is controversial. Objective To investigate whether consumption of farm-produced products is associated with a lower prevalence of asthma and allergy when compared with shop-purchased products. Methods Cross sectional multi-centre study (PARSIFAL) including 14 893 children aged 5-13 years from five European countries (2823 from farm families and 4606 attending Steiner Schools as well as 5440 farm reference and 2024 Steiner reference children). A detailed questionnaire including a dietary component was completed and allergen-specific IgE was measured in serum. Results Farm milk consumption ever in life showed a statistically significant inverse association with asthma: covariate adjusted odds ratio (aOR) 0.74 [95% confidence interval (CI) 0.61-0.88], rhinoconjunctivitis: aOR 0.56 (0.43-0.73) and sensitization to pollen and the food mix fx5 (cut-off level of >= 3.5 kU/L): aOR 0.67 (0.47-0.96) and aOR 0.42 (0.19-0.92), respectively, and sensitization to horse dander: aOR 0.50 (95% CI 0.28-0.87). The associations were observed in all four subpopulations and independent of farm-related co-exposures. Other farm-produced products were not independently related to any allergy-related health outcome. Conclusion Our results indicate that consumption of farm milk may offer protection against asthma and allergy. A deepened understanding of the relevant protective components of farm milk and a better insight into the biological mechanisms underlying this association are warranted as a basis for the development of a safe product for prevention.	Univ Basel, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; Brigham & Womens Hosp, Obstet & Gynecol Epidemiol Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Univ Munich, Dr Hauner Childrens Hosp, D-80539 Munich, Germany; Childrens Hosp, Schwarzach, Austria; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; Univ Utrecht, Julius Ctr Hlth Sci & Primary Care, Med Ctr, Utrecht, Netherlands; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Univ Hosp, Stockholm, Sweden; Univ Zurich, Childrens Hosp, Zurich, Switzerland	Waser, M (reprint author), Univ Basel, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.	Marco.Waser@unibas.ch	Lauener, Roger/O-8612-2016; van Hage, Marianne/A-9678-2017	Lauener, Roger/0000-0002-8412-606X; van Hage, Marianne/0000-0003-3091-1596; Pershagen, Goran/0000-0002-9701-1130; brunekreef, bert/0000-0001-9908-0060; Douwes, Jeroen/0000-0003-3599-4036; Ege, Markus/0000-0001-6643-3923			Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Allerberger Franz, 2003, International Journal of Infectious Diseases, V7, P42, DOI 10.1016/S1201-9712(03)90041-5; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bolte G, 2001, AM J RESP CRIT CARE, V163, P277; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1118; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Gassner-Bachmann M, 2000, DEUT MED WOCHENSCHR, V125, P924, DOI 10.1055/s-2000-6778; Hauswirth CB, 2004, CIRCULATION, V109, P103, DOI 10.1161/01.CIR.0000105989.74749.DD; HEBEISEN DF, 1993, INT J VITAM NUTR RES, V63, P229; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Isolauri E, 2000, HOSP MED, V61, P6; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McKeever TM, 2004, AM J RESP CRIT CARE, V170, P725, DOI 10.1164/rccm.200405-611PP; Noverr MC, 2005, INFECT IMMUN, V73, P30, DOI 10.1128/IAI.73.1.30-38.2005; Noverr MC, 2004, INFECT IMMUN, V72, P4996, DOI 10.1128/IAI.72.9.4996-5003.2004; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SHARP SJ, 1998, STATA TECHNICAL B, P16; Ublagger E, 2005, CLIN EXP ALLERGY, V35, P1033, DOI 10.1111/j.1365-2222.2005.02308.x; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Woods RK, 2003, AM J CLIN NUTR, V78, P414	36	104	105	3	24	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2007	37	5					661	670		10.1111/j.1365-2222.2006.02640.x		10	Allergy; Immunology	Allergy; Immunology	160KP	WOS:000245939700005	17456213	
J	Miller, GE; Chen, E				Miller, GE; Chen, E			Life stress and diminished expression of genes encoding glucocorticoid receptor and beta(2)-adrenergic receptor in children with asthma	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article							CYTOKINE PROFILES; CHILDHOOD ASTHMA; MESSENGER-RNA; BIRTH-COHORT; GENERATION; INFLAMMATION; DEPRESSION; RESISTANCE; CHALLENGE; EXPOSURE	Despite evidence that stressful experience can exacerbate the symptoms of asthma, little is known about the biological mechanisms through which this occurs. This study examined whether life stress reduces expression of the genes coding for the glucocorticoid receptor and the beta(2)-adrenergic receptor. A total of 77 children were enrolled in the study (59% male; mean age, 13.5 years). Thirty-nine of them were physician-diagnosed with asthma, and 38 were healthy. After an in-depth interview regarding stressful experiences, leukocytes were collected through antecubital venipuncture, and real-time RT-PCR was used to quantify mRNA. Chronic stress was associated with reduced expression of mRNA for the beta(2)-adrenergic receptor among children with asthma. In the sample of healthy children, however, the direction of this effect was reversed. The occurrence of a major life event in the 6 months before the study was not sufficient to influence patterns of gene expression. When such events occurred in the context of a chronic stressor, however, their association with patterns of gene expression was accentuated. Children with asthma who simultaneously experienced acute and chronic stress exhibited a 5.5-fold reduction in glucocorticoid receptor mRNA and a 9.5-fold reduction in beta(2)-adrenergic receptor mRNA relative to children with asthma without comparable stressor exposure. These findings suggest that stressful experience diminishes expression of the glucocorticoid and beta(2)-adrenergic receptor genes in children with asthma. To the extent that it diminishes sensitivity to the antiinflammatory properties of glucocorticoids or the bronchodilatory properties of beta-agonists, this process could explain the increased asthma morbidity associated with stress.	Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	Miller, GE (reprint author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	gemiller@psych.ubc.ca; echen@psych.ubc.ca					ADRIAN C, 1993, J CONSULT CLIN PSYCH, V61, P354, DOI 10.1037/0022-006X.61.2.354; Aiken L. S., 1991, MULTIPLE REGRESSION; BAI TR, 1993, AM J RESP CELL MOL, V8, P325; BLALOCK JE, 1994, IMMUNOL TODAY, V15, P504, DOI 10.1016/0167-5699(94)90205-4; Bloomberg GR, 2005, IMMUNOL ALLERGY CLIN, V25, P83, DOI 10.1016/j.iac.2004.09.001; Busse WW, 2001, NEW ENGL J MED, V344, P350; BUSSE WW, 1995, AM J RESP CRIT CARE, V151, P249; Cherniack R, 1999, CONTROL CLIN TRIALS, V20, P91; COHEN S, 2001, ASTHMA RESP INFECT, P193; Gagliardo R, 2000, AM J RESP CRIT CARE, V162, P7; Gao HP, 2001, CHINESE MED J-PEKING, V114, P1317; HAMMEN C, 1991, J ABNORM PSYCHOL, V100, P555, DOI 10.1037/0021-843X.100.4.555; HAMMEN C, 1988, BRIT J CLIN PSYCHOL, V27, P37; Heijink IH, 2004, CLIN EXP ALLERGY, V34, P1356, DOI 10.1111/j.1365-2222.2004.02037.x; Johnson Malcolm, 2002, Journal of Allergy and Clinical Immunology, V110, pS282, DOI 10.1067/mai.2002.129430; Kang DH, 1997, J INTERF CYTOK RES, V17, P481, DOI 10.1089/jir.1997.17.481; KLINNERT MD, 1994, PSYCHIATRY, V57, P51; Klinnert M. D., 2001, PEDIATRICS, V108, P69; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/rccm.2109065; McEwen BS, 1998, NEW ENGL J MED, V338, P171; Meduri GU, 2004, ANN NY ACAD SCI, V1024, P24, DOI 10.1196/annals.1321.004; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Mills PJ, 2004, AM J GERIAT PSYCHIAT, V12, P281, DOI 10.1176/appi.ajgp.12.3.281; Mrazek DA, 1999, PEDIATR PULM, V27, P85, DOI 10.1002/(SICI)1099-0496(199902)27:2<85::AID-PPUL4>3.0.CO;2-B; NEWNHAM DM, 1993, EUR J CLIN PHARMACOL, V45, P535, DOI 10.1007/BF00315310; Rudolph KD, 1999, CHILD DEV, V70, P660, DOI 10.1111/1467-8624.00048; Sandberg S, 2004, THORAX, V59, P1046, DOI 10.1136/thx.2004.024604; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; Vachier I, 1996, CLIN EXP IMMUNOL, V103, P311, DOI 10.1046/j.1365-2249.1996.d01-628.x; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358	34	104	107	4	12	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 4	2006	103	14					5496	5501		10.1073/pnas.0506312103		6	Multidisciplinary Sciences	Science & Technology - Other Topics	030LP	WOS:000236636400047	16567656	
J	Martinez, FD				Martinez, FD			Safety of long-acting beta agonists - An urgent need to clear the air	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							BRONCHODILATOR TREATMENT; ASTHMA; SALMETEROL		Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ 85721 USA	Martinez, FD (reprint author), Univ Arizona, Coll Med, Arizona Resp Ctr, Tucson, AZ 85721 USA.						Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; CASTLE W, 1993, BRIT MED J, V306, P1034; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3	4	104	106	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 22	2005	353	25					2637	2639		10.1056/NEJMp058299		3	Medicine, General & Internal	General & Internal Medicine	995IQ	WOS:000234094400003	16371628	
J	Hausermann, P; Harr, T; Bircher, AJ				Hausermann, P; Harr, T; Bircher, AJ			Baboon syndrome resulting from systemic drugs: is there strife between SDRIFE and allergic contact dermatitis syndrome?	CONTACT DERMATITIS			English	Article						allergic contact dermatitis syndrome; baboon syndrome; systemic contact dermatitis	ERUPTION; PSEUDOEPHEDRINE; EXANTHEM; HYPERSENSITIVITY; ETHYLENEDIAMINE; AMINOPHYLLINE; MANIFESTATION; AMOXICILLIN; CINCHOCAINE; MERCURY	The term 'baboon syndrome' (BS) was introduced 20 years ago to classify patients in whom a specific skin eruption resembling the red gluteal area of baboons occurred after systemic exposure to contact allergens. Thereafter, similar eruptions have been reported after systemic exposure to beta-lactam antibiotics and other drugs. In addition to the presentation of 2 of our own cases, we have reviewed and characterized the main clinical and histological aspects of published reports of drug-related baboon syndrome (DRBS) and compared the primary clinical signs from such cases to those found in other distinct drug eruptions. Of approximately 100 published baboon syndrome cases, 50 were identified as drug-induced. Of these, 8 were representatives of systemically induced contact dermatitis (SCD), and 42 were examples of drug eruptions elicited by systemic administration of either oral or intravenous drugs. The main clinical findings included a sharply defined symmetrical erythema of the gluteal area and in the flexural or intertriginous folds without any systemic symptoms and signs. 14 of 42 cases were elicited by amoxicillin, 30 of the 42 patients were male, and latency periods were between a few hours and a few days after exposure. DRBS is a rare, prognostically benign and often underdiagnosed drug eruption with distinct clinical features. The term baboon syndrome, however, does not reflect the complete range of symptoms and signs and is ethically and culturally problematic. Moreover, baboon syndrome is historically often equated with a mercury-induced exanthem in patients with previous contact sensitization. Symmetrical drug-related intertriginous and flexural exanthema, or SDRIFE, specifically refers to the distinctive clinical pattern of this drug eruption, and the following diagnostic criteria are proposed: 1) exposure to a systemically administered drug either at the first or repeated dose (excluding contact allergens); 2) sharply demarcated erythema of the gluteal/perianal area and/or V-shaped erythema of the inguinal/perigenital area; 3) involvement of at least one other intertriginous/flexural localization; 4) symmetry of affected areas; and 5) absence of systemic symptoms and signs.	Univ Basel Hosp, Dept Dermatol, Allergy Unit, CH-4031 Basel, Switzerland	Bircher, AJ (reprint author), Univ Basel Hosp, Dept Dermatol, Allergy Unit, Petersgraben 4, CH-4031 Basel, Switzerland.	andreas.bircher@unibas.ch					Amichai B, 2002, CLIN EXP DERMATOL, V27, P523; ANDERSEN KE, 1984, CONTACT DERMATITIS, V10, P97, DOI 10.1111/j.1600-0536.1984.tb00343.x; Barbaud A, 1999, DERMATOLOGY, V199, P258, DOI 10.1159/000018259; Bocquet H, 1996, SEMIN CUTAN MED SURG, V15, P250, DOI 10.1016/S1085-5629(96)80038-1; Britschgi M, 2001, J CLIN INVEST, V107, P1433, DOI 10.1172/JCI12118; Chowdhury MMU, 1999, CLIN EXP DERMATOL, V24, P336; DEGROOT AC, 1991, CONTACT DERMATITIS, V24, P201; DUVE S, 1994, ACTA DERM-VENEREOL, V74, P480; Erdmann SM, 2001, CONTACT DERMATITIS, V44, P260; Gallo R, 2002, CONTACT DERMATITIS, V46, P110, DOI 10.1034/j.1600-0536.2002.460211.x; Garcia-Bravo B, 2000, CONTACT DERMATITIS, V43, P359; Goossens C, 1997, DERMATOLOGY, V194, P421; Gordon Ellen, 2002, J Drugs Dermatol, V1, P66; Guin JD, 1999, CONTACT DERMATITIS, V40, P170, DOI 10.1111/j.1600-0536.1999.tb06026.x; HAPPLE R, 1994, HAUTARZT, V45, P1, DOI 10.1007/PL00013249; Helmbold P, 1998, DERMATOLOGY, V197, P402, DOI 10.1159/000018047; HERFS H, 1993, HAUTARZT, V44, P466; Isaksson M, 2003, ACTA DERM-VENEREOL, V83, P69, DOI 10.1080/00015550310002837; Kick G, 2000, CONTACT DERMATITIS, V43, P366; Kohler LD, 1996, INT J DERMATOL, V35, P502, DOI 10.1111/j.1365-4362.1996.tb01667.x; LACHAPELLE JM, 2003, PATCH TESTING PRICK, V189, P7; LECHNER T, 1987, MYCOSES, V30, P143; Lerch M, 2004, CONTACT DERMATITIS, V50, P349, DOI 10.1111/j.0105-1873.2004.00366.x; LOZE I, 2001, NOUV DERMATOL, V20, P624; Marques C, 1995, CONTACT DERMATITIS, V33, P443, DOI 10.1111/j.1600-0536.1995.tb02095.x; MENNE T, 1984, HAUTARZT, V35, P319; Menne T, 1994, AM J CONTACT DERMATI, V5, P1; MONTAG G, 1996, AKTUEL DERMATOL, V22, P311; NAKAYAMA H, 1983, CONTACT DERMATITIS, V9, P411, DOI 10.1111/j.1600-0536.1983.tb04439.x; Panhans-Gross A, 1999, CONTACT DERMATITIS, V41, P352, DOI 10.1111/j.1600-0536.1999.tb06195.x; Pfeiff B, 1991, DTSCH DERMATOLOGE, V39, P559; Proske S., 2003, DMW Deutsche Medizinische Wochenschrift, V128, P545, DOI 10.1055/s-2003-37850; RASMUSSEN LP, 1995, UGESKRIFT LAEGER, V147, P1341; RATNER JH, 1974, ARCH DERMATOL, V110, P921, DOI 10.1001/archderm.110.6.921; ROUJEAU JC, 1991, ARCH DERMATOL, V127, P8; Sanchez TS, 2000, CONTACT DERMATITIS, V42, P312; Sanchez-Morillas L, 2003, CONTACT DERMATITIS, V48, P234, DOI 10.1034/j.1600-0536.2003.00088.x; SCHULTZ ES, 1996, DERMATOSEN, V44, P266; SHELLEY WB, 1987, J AM ACAD DERMATOL, V17, P403, DOI 10.1016/S0190-9622(87)70220-5; STRUB C, 2002, SCHWEIZ RUNDSCH MED, V91, P232; STUBB S, 1989, BRIT J DERMATOL, V120, P583, DOI 10.1111/j.1365-2133.1989.tb01337.x; Wakelin SH, 1999, CLIN EXP DERMATOL, V24, P71; Weiss JM, 2001, HAUTARZT, V52, P1104, DOI 10.1007/s001050170022; WOLF R, 1992, ACTA DERM-VENEREOL, V72, P441; WOLF R, 1993, INT J DERMATOL, V32, P515, DOI 10.1111/j.1365-4362.1993.tb02837.x; WOLF R, 1995, INT J DERMATOL, V34, P341, DOI 10.1111/j.1365-4362.1995.tb03616.x; Wolf Ronni, 2003, Dermatol Online J, V9, P2	47	104	108	0	1	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	NOV	2004	51	5-6					297	310		10.1111/j.0105-1873.2004.00445.x		14	Allergy; Dermatology	Allergy; Dermatology	878ER	WOS:000225629900014	15606657	
J	Bottcher, MF; Hmani-Aifa, M; Lindstrom, A; Jenmalm, MC; Mai, XM; Nilsson, L; Zdolsek, HA; Bjorksten, B; Soderkvist, P; Vaarala, O				Bottcher, MF; Hmani-Aifa, M; Lindstrom, A; Jenmalm, MC; Mai, XM; Nilsson, L; Zdolsek, HA; Bjorksten, B; Soderkvist, P; Vaarala, O			A TLR4 polymorphism is associated with asthma and reduced lipopolysaccharide-induced interleukin-12(p70) responses in Swedish children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; TLR4; lipopolysaccharide; IL-12; IL-10	TOLL-LIKE RECEPTOR-4; T-CELL; ENDOTOXIN EXPOSURE; INTERFERON-GAMMA; ALLERGIC DISEASE; IGE PRODUCTION; HOUSE-DUST; CD14 GENE; ATOPY; CHALLENGE	Background: Bacterial signals play an important role in the maturation of the immune system. Polymorphisms in genes coding for receptors to bacterial components can alter the immune responsiveness of the host to microbial agents and may indicate the development of aberrant immune responses that are associated with immune-mediated diseases such as atopic diseases. Objective: The study's objective was to investigate the relationship between TLR4 and CD14 gene polymorphisms, the LPS responsiveness of PBMCs, and the presence of asthma and allergic rhinoconjunctivitis in children. Methods: The TLR4 (Asp299Gly) and CD14/-159 polymorphisms were determined in 115 Swedish children aged 8 and 14 years. LPS-induced IL-12(p70), IL-10, and IFN-gamma responses of PBMCs from 69 of the children were analyzed by means of ELISA. The levels of soluble CD14 in serum samples were analyzed by means of ELISA, and the total IgE levels were analyzed by means of UniCAP Total IgE (Pharmacia Diagnostics, Uppsala, Sweden). Results: Decreased LPS-induced IL-12(p70) and IL-10 responses were associated with the TLR4 (Asp299Gly) polymorphism and independently with asthma, especially atopic asthma. The TLR4 (Asp299Gly) polymorphism was associated with a 4-fold higher prevalence of asthma in school-aged children (adjusted odds ratio 4.5, 95% CI 1.1-17.4) but not to allergic rhinoconjunctivitis. Conclusion: A TLR4 polymorphism modifies innate immune responses in children and may be an important determinant for the development of asthma. This may influence the outcome of intervention studies that use microbial stimuli as immune modulators.	Linkoping Univ, Dept Mol & Clin Med, Div Pediat, Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Clin Res Ctr, Linkoping, Sweden; Linkoping Univ, Fac Hlth Sci, Dept Biomed & Surg, Div Cell Biol, Linkoping, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Stockholm, Sweden; Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland	Bottcher, MF (reprint author), Linkoping Univ Hosp, Div Paediat, KFC, S-58185 Linkoping, Sweden.	MalFa@imk.liu.se	Jenmalm, Maria/C-9679-2009	Jenmalm, Maria/0000-0002-2117-5366			Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Akdis CA, 1999, FASEB J, V13, P603; Arbour NC, 2000, NAT GENET, V25, P187; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P1690, DOI 10.1046/j.1365-2222.2002.01463.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; Cleveland MG, 1996, INFECT IMMUN, V64, P1906; Corinti S, 2001, J IMMUNOL, V166, P4312; Egan RW, 1996, ALLERGY, V51, P71, DOI 10.1111/j.1398-9995.1996.tb04561.x; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gross E, 1999, HUM GENET, V105, P72, DOI 10.1007/s004390051066; Hattevig G, 1993, Pediatr Allergy Immunol, V4, P182, DOI 10.1111/j.1399-3038.1993.tb00089.x; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Lorenz E, 2001, AM J PHYSIOL-LUNG C, V281, pL1106; MACATONIA SE, 1995, J IMMUNOL, V154, P5071; Mai XM, 2002, PEDIATR ALLERGY IMMU, V13, P361, DOI 10.1034/j.1399-3038.2002.01011.x; MANETTI R, 1994, J EXP MED, V179, P1273, DOI 10.1084/jem.179.4.1273; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; PUNNONEN J, 1993, J IMMUNOL, V151, P1280; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Sudo N, 1997, J IMMUNOL, V159, P1739; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5	32	104	110	0	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2004	114	3					561	567		10.1016/j.jaci.2004.04.050		7	Allergy; Immunology	Allergy; Immunology	853AX	WOS:000223799600014	15356557	
J	Benn, CS; Melbye, M; Wohlfahrt, J; Bjorksten, B; Aaby, P				Benn, CS; Melbye, M; Wohlfahrt, J; Bjorksten, B; Aaby, P			Cohort study of sibling effect, infectious diseases, and risk of atopic dermatitis during first 18 months of life	BRITISH MEDICAL JOURNAL			English	Article							FAMILY-SIZE; HAY-FEVER; RESPIRATORY-INFECTIONS; BIRTH COHORT; CHILDREN; ASTHMA; PREVALENCE; ALLERGY; DETERMINANTS; ANTIBODIES	Objectives To determine whether early infectious diseases could explain the association between number of siblings and other markers of microbial exposure and the development of atopic dermatitis before the age of 18 months. Design Cohort study. Information on atopic dermatitis, infectious diseases occurring before 6 months of age, number of siblings, early day care, pet keeping, farm residence, and background factors was collected in telephone interviews. Setting Danish national birth cohort. Participants 24341 mother-child pairs. Main outcome measures Incidence rate ratios of atopic dermatitis. Results 13070 children (54%) had at least one clinically apparent infectious disease before 6 months of age. At age 18 months, 2638 (10.8%) of the children had had atopic dermatitis. The risk of atopic dermatitis increased with each infectious disease before 6 months of age (incidence rate ratio 1.08,95% confidence interval 1.04 to 1.13). The risk of atopic dermatitis decreased with each additional exposure to three or more siblings, day care, pet ownership, and farm residence (0.86, 0.81 to 0.93). Conclusions Early infections do not seem to protect against allergic diseases. The protective effect of number of siblings, day care, pet ownership, and farm residence remained after adjustment for clinically apparent infectious diseases, suggesting that the effect is established independently early in life.	Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark; Projecto Saude Bandim, Bissau, Guinea Bissau; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Stockholm, Sweden	Benn, CS (reprint author), Statens Serum Inst, Danish Epidemiol Sci Ctr, Dept Epidemiol Res, Copenhagen, Denmark.	C.Benn.cb@ssi.dk					Benn CS, 2003, ACTA DERM-VENEREOL, V83, P347; Bjorksten B, 1999, J ALLERGY CLIN IMMUN, V104, P1119; Bodner C, 1998, THORAX, V53, P28; Bohme M, 2002, ACTA DERM-VENEREOL, V82, P98, DOI 10.1080/00015550252948112; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Linneberg A, 2003, J ALLERGY CLIN IMMUN, V111, P847, DOI 10.1067/mai.2003.1335; Matricardi P M, 2001, Curr Opin Allergy Clin Immunol, V1, P413, DOI 10.1097/01.all.0000011054.18314.67; Matricardi PM, 1997, BRIT MED J, V314, P999; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Ponsonby AL, 1999, THORAX, V54, P664; RYSTEDT I, 1986, BRIT J DERMATOL, V114, P575, DOI 10.1111/j.1365-2133.1986.tb04064.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Strannegard O, 2001, ALLERGY, V56, P91, DOI 10.1034/j.1398-9995.2001.056002091.x; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009	23	104	104	1	3	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	MAY 22	2004	328	7450					1223	1226		10.1136/bmj.38069.512245.FE		6	Medicine, General & Internal	General & Internal Medicine	824HL	WOS:000221677200015	15121716	
J	Salam, MT; Li, YF; Langholz, B; Gilliland, FD				Salam, MT; Li, YF; Langholz, B; Gilliland, FD			Early-life environmental risk factors for asthma: Findings from the children's health study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; breast-feeding; cockroach; day care; farm environment; herbicide; pesticide; sibship size; wood smoke	SOUTHERN CALIFORNIA COMMUNITIES; INNER-CITY CHILDREN; DAY-CARE ATTENDANCE; PULMONARY-FUNCTION; CHILDHOOD ASTHMA; 1ST YEAR; COCKROACH ALLERGEN; DIFFERING LEVELS; EARLY EXPOSURE; AIR-POLLUTION	Early-life experiences and environmental exposures have. been associated with childhood asthma. To investigate further whether the timing of such experiences and exposures is associated with the occurrence of asthma by 5 years of age, we conducted a prevalence case-control study nested within the Children's Health Study, a population-based study of > 4,000 school-aged children in 12 southern California communities. Cases were defined as physician-diagnosed asthma by age 5, and controls were asthma-free at study entry, frequency- matched on age, sex, and community of residence and countermatched on in utero exposure to maternal smoking. Telephone interviews were conducted with mothers to collect additional exposure and asthma histories. Conditional logistic regression models were fitted to estimate odds ratios (ORs) and 95% confidence intervals (CIs). Asthma diagnosis before 5 years of age was associated with exposures in the first year of life to wood or oil smoke, soot, or exhaust (OR = 1.74; 95% CI, 1.02-2.96), cockroaches (OR = 2.03; 95% CI, 1.03-4.02), herbicides (OR = 4.58; 95% CI, 1.36-15.43), pesticides (OR = 2.39; 95% CI, 1.17-4.89), and farm crops, farm dust, or farm animals (OR = 1.88; 95% CI, 1.07-3.28). The ORs for herbicide, pesticide, farm animal, and crops were largest among children with early-onset persistent asthma. The risk of asthma decreased with an increasing number of siblings (P-trend 0.01). Day care attendance within the first 4 months of life was positively associated with early-onset transient wheezing (OR = 2.42; 95% CI, 1.28-4.59). In conclusion, environmental exposures during the first year of life are associated with childhood asthma risk.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.	gillilan@use.edu	LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [1R01HL61768]; NIEHS NIH HHS [5P30 ES07048, 1P01 ES09581]		Alp H, 2001, ANN ALLERG ASTHMA IM, V86, P51; Antony AB, 2002, J ALLERGY CLIN IMMUN, V110, P589, DOI 10.1067/mai.2002.127798; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Bener A, 1999, Allerg Immunol (Paris), V31, P52; Bener A, 2002, Allerg Immunol (Paris), V34, P281; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Castro-Rodriguez JA, 1999, AM J RESP CRIT CARE, V159, P1891; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Chen Ping, 2002, Zhonghua Jiehe He Huxi Zazhi, V25, P603; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Ernst P, 2002, AM J RESP CRIT CARE, V165, P563, DOI 10.1164/rccm.2201002; Faustman EM, 2000, ENVIRON HEALTH PERSP, V108, P13, DOI 10.2307/3454629; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hoppin JA, 2002, AM J RESP CRIT CARE, V165, P683, DOI 10.1164/rccm.2106074; Infante-Rivard C, 2001, AM J EPIDEMIOL, V153, P653, DOI 10.1093/aje/153.7.653; Johnson CC, 2002, EPIDEMIOL REV, V24, P154, DOI 10.1093/epirev/mxf013; Karmaus W, 2001, ARCH ENVIRON HEALTH, V56, P485; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Landrigan PJ, 1999, ENVIRON HEALTH PERSP, V107, P431; Langholz B., 2001, BIOSTATISTICS, V2, P63, DOI 10.1093/biostatistics/2.1.63; LARSON TV, 1994, ANNU REV PUBL HEALTH, V15, P133; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; McConnell R, 2002, EPIDEMIOLOGY, V13, P288, DOI 10.1097/00001648-200205000-00009; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; Nafstad P, 1999, PEDIATRICS, V103, P753, DOI 10.1542/peds.103.4.753; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Ronmark E, 2002, RESP MED, V96, P1006, DOI 10.1053/rmed.2002.1391; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; Strachan DP, 2000, THORAX S1, V55, pS2; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009; Zheng TZ, 2002, AM J EPIDEMIOL, V156, P977, DOI 10.1093/aje/kwf127	45	104	106	0	10	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2004	112	6					760	765		10.1289/ehp.6662		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	822DD	WOS:000221514400044	15121522	
J	Ebo, DG; Hagendorens, MM; Bridts, CH; Schuerwegh, AJ; De Clerck, LS; Stevens, WJ				Ebo, DG; Hagendorens, MM; Bridts, CH; Schuerwegh, AJ; De Clerck, LS; Stevens, WJ			In vitro allergy diagnosis: should we follow the flow?	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							BASOPHIL HISTAMINE-RELEASE; GRASS-POLLEN ALLERGENS; RUBBER LATEX ALLERGY; HUMAN MAST-CELLS; HYMENOPTERA-VENOM; RECOMBINANT ALLERGENS; CD63 EXPRESSION; ACTIVATION TEST; IGE ANTIBODIES; CDNA CLONING	During the last 5 years, an increasing number of studies have demonstrated that flow cytometric quantification of in vitro basophil activation can be a quite performant and reliable tool to measure IgE-dependent allergen-specific responses in allergic patients. So far, most assays have used CD63 as a basophil activation marker and native allergen extracts for stimulation. However, other basophil markers and recombinant allergens have recently been introduced. The technique has been applied for the diagnosis of allergy to pollen, house dust mite, food, natural rubber latex, hymenoptera venom and drugs. In addition, the technique has proven to be useful in non-IgE-mediated reactions such as hypersensitivity to drugs as well as detection of auto-antibodies in chronic urticaria. This review will focus on some specific issues: (1) principles of flow cytometric analysis of in vitro-activated basophils, (2) general technical aspects of the technique (including passive sensitization), (3) clinical applications and (4) recommendations for further development and evaluation of the technique.	Univ Antwerp, Dept Immunol Allergol Rheumatol, B-2020 Antwerp, Belgium	Stevens, WJ (reprint author), Immunol Lab, Univ Pl 1, B-2610 Antwerp, Belgium.	Immuno@uia.ua.ac.be	BRIDTS, Chris/M-7933-2016; EBO, Didier/H-4894-2016	BRIDTS, Chris/0000-0002-3324-7320; EBO, Didier/0000-0003-0672-7529			Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; ABRAHAMSEN O, 2001, CLIN EXP ALLERGY, P368; Abuaf N, 1999, J ALLERGY CLIN IMMUN, V104, P411, DOI 10.1016/S0091-6749(99)70386-6; Andersson K, 2003, INT ARCH ALLERGY IMM, V130, P87, DOI 10.1159/000069013; Asero R, 1999, ALLERGY, V54, P87, DOI 10.1034/j.1398-9995.1999.00922.x; Binder M, 2002, INT ARCH ALLERGY IMM, V129, P160, DOI 10.1159/000065875; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; Bochner BS, 1997, METHODS, V13, P61, DOI 10.1006/meth.1997.0497; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P292; Boumiza R, 2003, CLIN EXP ALLERGY, V33, P259, DOI 10.1046/j.1365-2222.2003.01594.x; BUCKLEY MF, 1990, J BIOL CHEM, V265, P17506; Budde IK, 2001, INT ARCH ALLERGY IMM, V126, P277; Buhring HJ, 2001, BLOOD, V97, P3303, DOI 10.1182/blood.V97.10.3303; Buhring HJ, 1999, BLOOD, V94, P2343; Chapman MD, 1997, ALLERGY, V52, P374, DOI 10.1111/j.1398-9995.1997.tb01014.x; Cozon G, 1999, Allergol Immunopathol (Madr), V27, P182; Crockard AD, 2001, CLIN EXP ALLERGY, V31, P345, DOI 10.1046/j.1365-2222.2001.01043.x; de Weck AL, 2003, CLIN EXP ALLERGY, V33, P849; Decco ML, 1999, ANN ALLERG ASTHMA IM, V82, P29, DOI 10.1016/S1081-1206(10)62656-7; DEISSLER H, 1995, J BIOL CHEM, V270, P9849; Deissler H, 1999, FASEB J, V13, P657; Demoly P, 2003, ALLERGY, V58, P553, DOI 10.1034/j.1398-9995.2003.00253.x; DeWeck AL, 1997, ALLERGOLOGIE, V20, P487; De Weck AL, 2002, ACI INT, V14, P204, DOI 10.1027/0838-1925.14.5.204; De Weck A., 1993, ALLERGY CLIN IMMUNOL, V5, P9; Ebo D. G., 2003, Journal of Allergy and Clinical Immunology, V111, pS254, DOI 10.1016/S0091-6749(03)80908-9; Ebo DG, 2000, ALLERGY, V55, P1098, DOI 10.1034/j.1398-9995.2000.00825.x; Ebo DG, 1997, J ALLERGY CLIN IMMUN, V100, P618, DOI 10.1016/S0091-6749(97)70165-9; Ebo DG, 2003, CLIN EXP ALLERGY, V33, P849, DOI 10.1046/j.1365-2222.2003.00691.x; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Ebo DG, 2001, ANN ALLERG ASTHMA IM, V87, P243; Erdmann SM, 2003, CLIN EXP ALLERGY, V33, P607, DOI 10.1046/j.1365-2222.2003.01660.x; FORTSON JS, 1986, J AM ACAD DERMATOL, V15, P1137, DOI 10.1016/S0190-9622(86)70282-X; FUREDER W, 1994, ALLERGY, V49, P861, DOI 10.1111/j.1398-9995.1994.tb00788.x; Gamboa PM, 2003, ALLERGY, V58, P312, DOI 10.1034/j.1398-9995.2003.00096.x; Ghannadan M, 2002, INT ARCH ALLERGY IMM, V127, P299, DOI 10.1159/000057747; Gregoire C, 2001, CLIN REV ALLERG IMMU, V21, P215; Greiner M, 2000, PREV VET MED, V45, P23, DOI 10.1016/S0167-5877(00)00115-X; Hamilton RG, 1998, J ALLERGY CLIN IMMUN, V102, P482, DOI 10.1016/S0091-6749(98)70139-3; HAMILTON RG, 2003, J ALLERGY CLIN IMMUN, pS687; HARLE DG, 1985, J IMMUNOL METHODS, V78, P293, DOI 10.1016/0022-1759(85)90087-0; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Hauswirth AW, 2002, J ALLERGY CLIN IMMUN, V110, P102, DOI 10.1067/mai.2002.125257; Kahlert H, 2003, CLIN EXP ALLERGY, V33, P1266, DOI 10.1046/j.1365-2222.2003.01756.x; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Knol E F, 1996, Eur Respir J Suppl, V22, p126s; KURIMOTO Y, 1991, EUR J IMMUNOL, V21, P361, DOI 10.1002/eji.1830210217; Kurup VP, 2003, CURR ALLERGY ASTHM R, V3, P416, DOI 10.1007/s11882-003-0078-6; Lambert C, 2003, CYTOM PART B-CLIN CY, V52B, P13, DOI 10.1002/cyto.b.10012; Lie WJ, 2000, CLIN EXP ALLERGY, V30, P882; Lie WJH, 1998, J ALLERGY CLIN IMMUN, V101, P683; Lockey RF, 1995, ALLERGY PROC, V16, P293, DOI 10.2500/108854195778667800; Lorenz AR, 2001, J CHROMATOGR B, V756, P255, DOI 10.1016/S0378-4347(01)00086-X; Majlesi Y, 2003, J LEUKOCYTE BIOL, V73, P107, DOI 10.1189/jlb.0202075; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; METZELAAR MJ, 1991, J BIOL CHEM, V266, P3239; Miadonna A, 1996, ALLERGY, V51, P525; Moneret-Vautrin DA, 1999, ANN ALLERG ASTHMA IM, V82, P33, DOI 10.1016/S1081-1206(10)62657-9; MONERETVAUTRIN DA, 2003, ALLERG IMMUNOL PARIS, V35, P113; Muller UR, 2002, ALLERGY, V57, P570, DOI 10.1034/j.1398-9995.2002.02157.x; MURATA J, 1994, J BIOL CHEM, V269, P30479; NIEUWENHUIS HK, 1987, BLOOD, V70, P838; NOLTE H, 1993, ALLERGY PROC, V14, P251, DOI 10.2500/108854193778812017; NURNBERG W, 1995, ACTA DERM-VENEREOL, V75, P54; ORTOLANI C, 1989, J ALLERGY CLIN IMMUN, V83, P683, DOI 10.1016/0091-6749(89)90083-3; Pajno GB, 2000, ALLERGY, V55, P199, DOI 10.1034/j.1398-9995.2000.00494.x; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; Pauli G, 2000, INT ARCH ALLERGY IMM, V123, P183, DOI 10.1159/000024443; Platz IJ, 2001, INT ARCH ALLERGY IMM, V126, P335, DOI 10.1159/000049531; PLEBANI M, 1996, ALLERGY, P407; Rueff F, 1996, ALLERGY, V51, P216, DOI 10.1111/j.1398-9995.1996.tb04596.x; Sainte-Laudy J, 2000, CLIN EXP ALLERGY, V30, P1166; Sainte-Laudy J, 1998, INFLAMM RES, V47, P401, DOI 10.1007/s000110050351; Sanz ML, 2002, J INVEST ALLERG CLIN, V12, P143; Sanz ML, 2003, INT ARCH ALLERGY IMM, V130, P33, DOI 10.1159/000068367; Sanz ML, 2002, CLIN EXP ALLERGY, V32, P277, DOI 10.1046/j.1365-2222.2002.01305.x; Sanz ML, 2001, CLIN EXP ALLERGY, V31, P1007, DOI 10.1046/j.1365-2222.2001.01122.x; SANZ ML, 1995, ALLERGY CLIN IMMUNOL, V7, P56; Saporta M, 2001, ALLERGY, V56, P442, DOI 10.1034/j.1398-9995.2001.056005442.x; Schafer T, 1996, ALLERGY, V51, P372; SCHLEIMER RP, 1989, J IMMUNOL, V143, P1310; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Skamstrup HK, 2001, ALLERGY, V56, P109; Sperr WR, 1997, INT ARCH ALLERGY IMM, V114, P68; Stevens WJ, 1998, CLIN EXP ALLERGY, V28, P249; SUGIYAMA H, 1993, ANN ALLERGY, V71, P391; Sussman GL, 2002, J ALLERGY CLIN IMMUN, V110, pS33, DOI 10.1067/mai.2002.124969; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; Valent F, 2001, IMMUNOL REV, V179, P74; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; VARRO R, 2000, CYTOMETRY, V10, pS116; Vieths S, 2001, ALLERGY, V56, P78, DOI 10.1034/j.1398-9995.2001.00923.x; Wedi B, 2000, J ALLERGY CLIN IMMUN, V105, P552, DOI 10.1067/mai.2000.104939; Yoshimura C, 2002, J ALLERGY CLIN IMMUN, V109, P817, DOI 10.1067/mai.2002.123532; YOUNG E, 1994, LANCET, V343, P1127, DOI 10.1016/S0140-6736(94)90234-8; Zuberbier T, 2000, ALLERGY, V55, P951, DOI 10.1034/j.1398-9995.2000.00445.x	98	104	108	3	12	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2004	34	3					332	339		10.1111/j.1365-2222.2004.01891.x		8	Allergy; Immunology	Allergy; Immunology	801LY	WOS:000220098600003	15005724	
J	Downs, SH; Marks, GB; Mitakakis, TZ; Leuppi, JD; Car, NG; Peat, JK				Downs, SH; Marks, GB; Mitakakis, TZ; Leuppi, JD; Car, NG; Peat, JK			Having lived on a farm and protection against allergic diseases in Australia	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; farming; children; allergic diseases	HAY-FEVER; ASTHMA; CHILDHOOD; CHILDREN; SENSITIZATION; EXPOSURE; PREVALENCE; HISTORY	Background Farmers' children in northern Europe have a lower prevalence of atopy, hay fever and asthma than other children. Farms in Australia differ in scale and operation from those in Europe and the prevalence of allergic diseases in children is higher. Objective To investigate whether having lived on a farm as a child in Australia is associated with a lower risk of allergic diseases. Methods Cross-sectional study of children (n = 1500) aged 7-12 years from two rural towns: Wagga Wagga in a mixed farming region, and Moree in a crop farming region. Parents answered a questionnaire and children had a skin prick test for atopy. Results Twenty percent of children had lived on a farm for at least 1 year. The effect of having lived on a farm differed between the towns (P < 0.001). It was associated with a lower risk of atopy in Wagga (adjusted odds ratio (aOR) 0.47, 95% confidence interval (CI) 0.32-0.72) but not in Moree (aOR 0.97, 95% CI 0.62-1.53). Children from Wagga were more likely to have lived on a livestock farm than children from Moree (26.1% vs. 9.1%, 95% CI for the difference 8.9-25.4). Conclusion Having lived on a farm in Australia can confer protection against atopy in children. Further studies are needed to identify possible protective mechanisms associated with farm animals or to establish whether the protective effect is explained by other related exposures.	Univ Sydney, Inst Resp Med, Sydney, NSW 2006, Australia; New Childrens Hosp, Westmead, NSW, Australia; Charles Sturt Univ, Sch Biomed Sci, Bathurst, NSW 2795, Australia	Downs, SH (reprint author), Inst Resp Med, POB M77,Missenden Rd PO, Camperdown, NSW 2050, Australia.		Downs, Sara/D-8478-2011	Downs, Sara/0000-0003-1044-3182			ABDELHAFEZ SII, 1990, J BASIC MICROB, V30, P467, DOI 10.1002/jobm.3620300702; American Thoracic Society, 1998, AM J RESP CRIT CARE, V158, pS1; *AUSTR BUR STAT, 1998, 71131 AUSTR BUR STAT; Beard M, 1996, APPL OCCUP ENV HYG, V11, P1409; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; *DEP TECHN SERV, 1998, WAGG WAGG DRAFT NAT; *GWYD CATCHM TASKF, 1997, GWYD COMM CATCHM PLA; HENSLEY MJ, 1988, THORAX, V43, P103, DOI 10.1136/thx.43.2.103; Holt PG, 1997, THORAX, V52, P1; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; JAMES AL, 1990, BRIT J IND MED, V47, P466; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kimbell-Dunn M, 1999, AM J IND MED, V35, P51, DOI 10.1002/(SICI)1097-0274(199901)35:1<51::AID-AJIM7>3.0.CO;2-F; Knoblauch A, 1996, OCCUP ENVIRON MED, V53, P577; LEON DA, 1993, LANCET, V342, P479, DOI 10.1016/0140-6736(93)91599-H; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; MacDonald IAR, 1996, EPIDEMIOL INFECT, V116, P279; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; PEAT JK, 1992, CHEST, V102, P153, DOI 10.1378/chest.102.1.153; Pepys J., 1975, BRIT J HOSP MED, V14, P412; Poppe C, 1998, CAN VET J, V39, P559; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; SALOME CM, 1987, CLIN ALLERGY, V17, P271, DOI 10.1111/j.1365-2222.1987.tb02015.x; *SCHWEIZ BAUERNV, 1998, STAT ERH SCHATZ LAND; SREERAMULU T, 1970, Journal of Palynology, V6, P31; Trevena WB, 1996, LANCET, V347, P60, DOI 10.1016/S0140-6736(96)91593-7; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; 1993, 71201 AUSTR BUR STAT	30	104	107	0	6	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2001	31	4					570	575		10.1046/j.1365-2222.2001.01070.x		6	Allergy; Immunology	Allergy; Immunology	431YN	WOS:000168659500010	11359424	
J	Blyth, DI; Wharton, TF; Pedrick, MS; Savage, TJ; Sanjar, S				Blyth, DI; Wharton, TF; Pedrick, MS; Savage, TJ; Sanjar, S			Airway subepithelial fibrosis in a murine model of atopic asthma - Suppression by dexamethasone or anti-interleukin-5 antibody	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							BRONCHIAL-ASTHMA; BASEMENT-MEMBRANE; CELL HYPERPLASIA; INFLAMMATION; EXPRESSION; COLLAGEN; WALL; HYPERREACTIVITY; RESPONSIVENESS; METHACHOLINE	Fibrosis in the reticular layer beneath the epithelial basement membrane Is a feature of airway remodeling in human asthma, We previously reported the presence of subepithelial fibrosis (SEF) in a disease model of atopic asthma in which mice were sensitized and intratracheally challenged with ovalbumin (OVA) (Blyth and colleagues, Am. J. Respir. Cell Mol. Biol, 1996;14:425-438), Here, we describe further studies to quantify the degree of SEF after its induction by repeated exposure of the airways to allergen. The amount of subepithelial reticulin in the airways of animals challenged three times with 80 mu g OVA was typically increased 1.4-fold. The increased amount of reticulin showed no reduction after a 50-d period after the third allergen challenge. A reduction in SEF was achieved by daily treatment with dexamethasone (DEX) for 8 d during the allergen challenge period, or by treatment with anti-interleukin-5 antibody (TRFK5) at the time of allergen challenge, Postchallenge treatment with DEX for 15 d resulted in significant resolution of previously established SEF, Severe nonallergic inflammation during repeated exposure of airways to lipopolysaccharide did not induce SEF. The results indicate that development of SEF is associated with eosinophil infiltration into airways, and may occur only when the inflammatory stimulus is allergic in nature.	Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Resp Dis Unit, Stevenage SG1 2NY, Herts, England; Glaxo Wellcome Res & Dev Ltd, Mol Pathol Unit, Stevenage SG1 2NY, Herts, England	Blyth, DI (reprint author), Glaxo Wellcome Res & Dev Ltd, Med Res Ctr, Resp Dis Unit, Gunnels Wood Rd, Stevenage SG1 2NY, Herts, England.						Awadh N, 1998, THORAX, V53, P248; BEASLEY R, 1993, J ALLERGY CLIN IMMUN, V92, P148, DOI 10.1016/0091-6749(93)90097-Y; Blyth D. I., 1998, Journal of Pharmacy and Pharmacology, V50, P70; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Chakir J, 1996, LAB INVEST, V75, P735; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Garlisi CG, 1999, AM J RESP CELL MOL, V20, P248; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; Gordon H, 1936, AM J PATHOL, V12, P545; Hoshino M, 1998, THORAX, V53, P21; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; HOWARD CV, 1998, UNBIASED STEREOLOGY, P198; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JEFFERY PK, 1992, RESPIRATION, V59, P13; LAURENT GJ, 1991, CHEST, V99, pS67, DOI 10.1378/chest.99.3_Supplement.67S; LEE JV, 1985, SOC APPLIED BACTERIO, V21, P13; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864; Orsida BE, 1999, THORAX, V54, P289; Pohunek P., 1997, European Respiratory Journal Supplement, V10, p160S; ROCHE WR, 1989, LANCET, V1, P520; ROGERS DF, 1992, BRIT MED BULL, V48, P120; SAETTA M, 1995, AM J RESP CRIT CARE, V151, P489; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temelkovski J, 1998, THORAX, V53, P849; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; UNSWORTH DJ, 1982, BRIT J EXP PATHOL, V63, P154; Warner JO, 1998, CLIN EXP ALLERGY, V28, P71; Warner JO, 1998, PEDIATR ALLERGY IMMU, V9, P53, DOI 10.1111/j.1399-3038.1998.tb00302.x; WEIBEL ER, 1966, J CELL BIOL, V30, P23, DOI 10.1083/jcb.30.1.23; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814; Wilson JW, 1997, CLIN EXP ALLERGY, V27, P363; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	42	104	108	0	5	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	AUG	2000	23	2					241	246				6	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	344FW	WOS:000088749400019	10919992	
J	Kubo, A; Nagao, K; Amagai, M				Kubo, Akiharu; Nagao, Keisuke; Amagai, Masayuki			Epidermal barrier dysfunction and cutaneous sensitization in atopic diseases	JOURNAL OF CLINICAL INVESTIGATION			English	Review							THYMIC STROMAL LYMPHOPOIETIN; EPITHELIAL TIGHT JUNCTIONS; PROTEASE BLEOMYCIN HYDROLASE; DOWN-REGULATES FILAGGRIN; OF-FUNCTION MUTATIONS; STRATUM-CORNEUM; LANGERHANS CELLS; DENDRITIC CELLS; NETHERTON-SYNDROME; SKIN-BARRIER	Classic atopic dermatitis is complicated by asthma, allergic rhinitis, and food allergies, cumulatively referred to as atopic diseases. Recent discoveries of mutations in the filaggrin gene as predisposing factors for atopic diseases have refocused investigators' attention on epidermal barrier dysfunction as a causative mechanism. The skin's barrier function has three elements: the stratum corneum (air-liquid barrier), tight junctions (liquid-liquid barrier), and the Langerhans cell network (immunological barrier). Clarification of the molecular events underpinning epidermal barrier function and dysfunction should lead to a better understanding of the pathophysiological mechanisms of atopic diseases.	[Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Tokyo 1608582, Japan; [Kubo, Akiharu] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo 1608582, Japan	Amagai, M (reprint author), Keio Univ, Sch Med, Dept Dermatol, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.	amagai@a7.keio.jp	Nagao, Keisuke/J-5116-2013; Amagai, Masayuki/K-5325-2013; Kubo, Akiharu/I-2711-2014	Nagao, Keisuke/0000-0002-7005-3138; Amagai, Masayuki/0000-0003-3314-7052; Kubo, Akiharu/0000-0003-0902-3586	Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Health, Labour, and Welfare of Japan	This work was supported by Grants-in-Aid for Scientific Research and the "Promotion of Environmental Improvement for Independence of Young Researchers" program funding from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and by Health Labour Sciences Research Grants for Research on Allergic Diseases and Immunology from the Ministry of Health, Labour, and Welfare of Japan.	Aberg KM, 2008, J INVEST DERMATOL, V128, P917, DOI 10.1038/sj.jid.5701099; Akiyama M, 2010, BRIT J DERMATOL, V162, P472, DOI 10.1111/j.1365-2133.2009.09582.x; Van Itallie CM, 2009, CSH PERSPECT BIOL, V1, DOI DOI 10.1101/cshperspect.a002584; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Basu K, 2008, ALLERGY, V63, P1211, DOI 10.1111/j.1398-9995.2008.01660.x; Beck Lisa A., 2000, Journal of Allergy and Clinical Immunology, V106, pS258; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Blank F, 2007, AM J RESP CELL MOL, V36, P669, DOI 10.1165/rcmb.2006-0234OC; Bonnart C, 2010, J CLIN INVEST, V120, P871, DOI 10.1172/JCI41440; Braff MH, 2005, J INVEST DERMATOL, V124, P394, DOI 10.1111/j.0022-202X.2004.23443.x; Brandner JM, 2002, EUR J CELL BIOL, V81, P253, DOI 10.1078/0171-9335-00244; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Chavanas S, 2000, NAT GENET, V25, P141; Chieppa M, 2006, J EXP MED, V203, P2841, DOI 10.1084/jem.20061884; CHRISTOPHERS E, 1971, J INVEST DERMATOL, V56, P165, DOI 10.1111/1523-1747.ep12260765; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cork MJ, 2009, J INVEST DERMATOL, V129, P1892, DOI 10.1038/jid.2009.133; Dai XJ, 2011, J ALLERGY CLIN IMMUN, V127, P806, DOI 10.1016/j.jaci.2010.12.006; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; De Benedetto A, 2008, J INVEST DERMATOL, V128, P1594, DOI 10.1038/sj.jid.5701208; De Benedetto A, 2011, J ALLERGY CLIN IMMUN, V127, P773, DOI 10.1016/j.jaci.2010.10.018; Denecker G, 2007, NAT CELL BIOL, V9, P666, DOI 10.1038/ncb1597; Deraison C, 2007, MOL BIOL CELL, V18, P3607, DOI 10.1091/mbc.E07-02-0124; Descargues P, 2005, NAT GENET, V37, P56, DOI 10.1038/ng1493; Descargues P, 2006, J INVEST DERMATOL, V126, P1622, DOI 10.1038/sj.jid.5700284; Ebner S, 2007, J ALLERGY CLIN IMMUN, V119, P982, DOI 10.1016/j.jaci.2007.01.003; Elentner A, 2009, J CELL MOL MED, V13, P2658, DOI 10.1111/j.1582-4934.2009.00797.x; Elias P M, 1998, J Investig Dermatol Symp Proc, V3, P87; ENK AH, 1993, J IMMUNOL, V150, P3698; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; FARQUHAR MG, 1965, J CELL BIOL, V26, P263, DOI 10.1083/jcb.26.1.263; Fartasch M, 1999, ARCH DERMATOL, V135, P823, DOI 10.1001/archderm.135.7.823; Feldmeyer L, 2006, HUM MUTAT, V27, P408, DOI 10.1002/humu.20333; FRENK E, 1972, ARCH DERMATOL FORSCH, V245, P42, DOI 10.1007/BF00596151; Furuse M, 2006, TRENDS CELL BIOL, V16, P181, DOI 10.1016/j.tcb.2006.02.006; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Gutowska-Owsiak D, 2011, BRIT J DERMATOL, V165, P492, DOI 10.1111/j.1365-2133.2011.10400.x; Hackett TL, 2007, CURR OPIN ALLERGY CL, V7, P63, DOI 10.1097/ACI.0b013e328013d61b; Hadj-Rabia S, 2004, GASTROENTEROLOGY, V127, P1386, DOI 10.1053/j.gast.2004.07.022; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; HASHIMOTO K, 1971, J INVEST DERMATOL, V57, P17, DOI 10.1111/1523-1747.ep12292052; Hoste E, 2011, J INVEST DERMATOL, V131, P2233, DOI 10.1038/jid.2011.153; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Hvid M, 2011, EXP DERMATOL, V20, P633, DOI 10.1111/j.1600-0625.2011.01280.x; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Ichiyasu H, 2004, AM J RESP CELL MOL, V30, P761, DOI 10.1165/rcmb.2003-0370OC; Ishida-Yamamoto A, 2004, J INVEST DERMATOL, V122, P1137, DOI 10.1111/j.0022-202X.2004.22515.x; Kamata Y, 2011, J BIOL CHEM, V286, P8204, DOI 10.1074/jbc.M110.169292; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Kaplan DH, 2010, TRENDS IMMUNOL, V31, P446, DOI 10.1016/j.it.2010.08.006; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kato T, 2009, ALLERGY, V64, P1366, DOI 10.1111/j.1398-9995.2009.02023.x; Kim BE, 2011, J INVEST DERMATOL, V131, P1272, DOI 10.1038/jid.2011.24; Kodama M, 2010, INT ARCH ALLERGY IMM, V152, P67, DOI 10.1159/000312128; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Kuroda S, 2010, J DERMATOL SCI, V59, P107, DOI 10.1016/j.jdermsci.2010.06.001; LANDMANN L, 1981, CELL TISSUE RES, V215, P369; Lesiak A, 2011, EXP DERMATOL, V20, P491, DOI 10.1111/j.1600-0625.2010.01243.x; LESSARD RJ, 1968, J INVEST DERMATOL, V50, P171; MACKENZIE IC, 1975, J INVEST DERMATOL, V65, P45, DOI 10.1111/1523-1747.ep12598037; MACKENZIE IC, 1970, NATURE, V226, P653, DOI 10.1038/226653a0; Matsui T, 2011, EMBO MOL MED, V3, P320, DOI 10.1002/emmm.201100140; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; MITTAL AK, 1979, CELL TISSUE RES, V202, P213; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Montagna W, 1974, STRUCTURE FUNCTION S; Morita K, 2002, J INVEST DERMATOL, V118, P1073, DOI 10.1046/j.1523-1747.2002.01774.x; Muller FB, 2002, BRIT J DERMATOL, V146, P495, DOI 10.1046/j.1365-2133.2002.04625.x; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Niess JH, 2005, SCIENCE, V307, P254, DOI 10.1126/science.1102901; Nishibu A, 2007, J DERMATOL SCI, V45, P23, DOI 10.1016/j.jdermsci.2006.10.003; Nishijima T, 1997, J INVEST DERMATOL, V109, P175, DOI 10.1111/1523-1747.ep12319282; Nishio Y, 2003, GENES IMMUN, V4, P515, DOI 10.1038/sj.gene.6363889; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Ogasawara N, 2011, ACTA OTO-LARYNGOL, V131, P116, DOI 10.3109/00016489.2010.520022; Oji V, 2010, AM J HUM GENET, V87, P274, DOI 10.1016/j.ajhg.2010.07.005; Oren A, 2003, EXP MOL PATHOL, V74, P180, DOI 10.1016/S0014-4800(02)00023-0; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Ovaere P, 2009, TRENDS BIOCHEM SCI, V34, P453, DOI 10.1016/j.tibs.2009.08.001; Ozcan E, 2008, J ALLERGY CLIN IMMUN, V122, P1054, DOI 10.1016/j.jaci.2008.10.023; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pearton DJ, 2002, J INVEST DERMATOL, V119, P661, DOI 10.1046/j.1523-1747.2002.01831.x; Poninska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016933; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Rawlings AV, 2005, J INVEST DERMATOL, V124, P1099, DOI 10.1111/j.1523-1747.2005.23726.x; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; Schroder JM, 2006, CELL MOL LIFE SCI, V63, P469, DOI 10.1007/s00018-005-5364-0; Schulzke JD, 2009, ANN NY ACAD SCI, V1165, P294, DOI 10.1111/j.1749-6632.2009.04062.x; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Schwartz DR, 1999, P NATL ACAD SCI USA, V96, P4680, DOI 10.1073/pnas.96.8.4680; SCOTT IR, 1986, DEV BIOL, V115, P84, DOI 10.1016/0012-1606(86)90230-7; Simon M, 2001, J BIOL CHEM, V276, P20292, DOI 10.1074/jbc.M100201200; Simpson EL, 2010, J AM ACAD DERMATOL, V63, P587, DOI 10.1016/j.jaad.2009.11.011; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Spergel JM, 2010, ANN ALLERG ASTHMA IM, V105, P99, DOI 10.1016/j.anai.2009.10.002; Stefansson K, 2008, J INVEST DERMATOL, V128, P18, DOI 10.1038/sj.jid.5700965; STREILEIN JW, 1982, J EXP MED, V155, P863, DOI 10.1084/jem.155.3.863; Sundberg JP., 1984, HDB MOUSE MUTATIONS, V2, P269; Takano K, 2005, J HISTOCHEM CYTOCHEM, V53, P611, DOI 10.1369/4A6539.2005; Thyssen JP, 2010, BRIT J DERMATOL, V162, P1278, DOI 10.1111/j.1365-2133.2010.09708.x; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Tsukita S, 2002, CURR OPIN CELL BIOL, V14, P531, DOI 10.1016/S0955-0674(02)00362-9; Tsukita S, 2008, ONCOGENE, V27, P6930, DOI 10.1038/onc.2008.344; Turksen K, 2002, DEVELOPMENT, V129, P1775; Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653; Uitto J, 2010, J INVEST DERMATOL, V130, P1778, DOI 10.1038/jid.2010.90; Vasilopoulos Y, 2007, ALLERGY, V62, P514, DOI 10.1111/j.1398-9995.2007.01350.x; Vasilopoulos Y, 2004, J INVEST DERMATOL, V123, P62, DOI 10.1111/j.0022-202X.2004.22708.x; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WOOD LC, 1992, J CLIN INVEST, V90, P482, DOI 10.1172/JCI115884; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Yang T, 2004, GENE DEV, V18, P2354, DOI 10.1101/gad.1232104	126	103	113	0	25	AMER SOC CLINICAL INVESTIGATION INC	ANN ARBOR	35 RESEARCH DR, STE 300, ANN ARBOR, MI 48103 USA	0021-9738			J CLIN INVEST	J. Clin. Invest.	FEB	2012	122	2					440	447		10.1172/JCI57416		8	Medicine, Research & Experimental	Research & Experimental Medicine	885GF	WOS:000299765800005	22293182	
J	Martino, D; Prescott, S				Martino, David; Prescott, Susan			Epigenetics and Prenatal Influences on Asthma and Allergic Airways Disease	CHEST			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; TOBACCO-SMOKE EXPOSURE; REGULATORY T-CELLS; IFN-GAMMA PROMOTER; MATERNAL SMOKING; CHILDHOOD ASTHMA; SUBSEQUENT DEVELOPMENT; DEVELOPMENTAL ORIGINS; POSTNATAL-DEVELOPMENT; CYTOKINE RESPONSES	Uterine life is arguably the most critical time in developmental programming, when environmental exposures may have the greatest potential to influence evolving fetal structure and function. There has been substantial progress in understanding the epigenetic mechanisms through which environmental exposures can permanently alter the expression of fetal genes and contribute to the increasing propensity for many complex diseases. These concepts of "developmental origins" of disease are being applied across virtually all fields of medicine, and emerging epigenetic paradigms are the likely mechanism behind the environment-driven epidemic of asthma and allergic disease. Here, we examine the epigenetic regulation of immune development and the early immune profiles that contribute to allergic risk. In particular we review new evidence that key environmental exposures, such as microbial exposure, dietary changes, tobacco smoke, and pollutants, can induce epigenetic changes in gene expression and alter disease risk. Although most of these factors have already been clearly implicated in epidemiologic studies of asthma and allergic disease, new studies investigating the mechanisms of these effects may provide new avenues for using these pathways for disease prevention. CHEST 2011; 139(3):640-647	[Martino, David; Prescott, Susan] Univ Western Australia, Sch Paediat & Child Hlth Res, Perth, WA 6840, Australia	Prescott, S (reprint author), Univ Western Australia, Princess Margaret Hosp Children, Sch Paediat & Child Hlth Res, GPO Box D 184, Perth, WA 6840, Australia.	sprescott@meddent.uwa.edu.au	Prescott, Susan/H-5665-2014	Martino, David/0000-0001-6823-4696	National Health and Medical Research Fellowship	Dr Prescott is funded by a National Health and Medical Research Fellowship.	Baccarelli A, 2009, CURR OPIN PEDIATR, V21, P243, DOI 10.1097/MOP.0b013e32832925cc; Barnes PJ, 2006, CHEST, V129, P151, DOI 10.1378/chest.129.1.151; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737S94; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bobetsis YA, 2007, J DENT RES, V86, P169; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Breckler LA, 2008, ALLERGY, V63, P1473, DOI 10.1111/j.1398-9995.2008.01718.x; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; DANIEL V, 1995, ARCH ENVIRON HEALTH, V50, P287; Daniel V, 2001, ENVIRON HEALTH PERSP, V109, P173, DOI 10.2307/3434772; Devereux G, 2007, AM J CLIN NUTR, V85, P853; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Fields PE, 2002, J IMMUNOL, V169, P647; Gheorghe CP, 2010, INT J DEV BIOL, V54, P507, DOI 10.1387/ijdb.082770cg; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Higashimoto Y, 2002, AM J RESP CRIT CARE, V166, P200, DOI 10.1164/rccm.2111032; Hogg JC, 2001, AM J RESP CRIT CARE, V164, pS71; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holt PG, 2000, AM J RESP CRIT CARE, V161, pS172; Husemoen LLN, 2006, INT J EPIDEMIOL, V35, P954, DOI 10.1093/ije/dyl094; Hylkema Machteld N, 2009, Proc Am Thorac Soc, V6, P660, DOI 10.1513/pats.200907-065DP; Kim KY, 2010, ENVIRON HEALTH PERSP, V118, P370, DOI 10.1289/ehp.0901131; Klunker S, 2009, J EXP MED, V206, P2701, DOI 10.1084/jem.20090596; Kumar RK, 2009, DIS MODEL MECH, V2, P549, DOI 10.1242/dmm.001719; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Martino DJ, 2010, ALLERGY, V65, P7, DOI 10.1111/j.1398-9995.2009.02186.x; Maslowski KM, 2009, NATURE, V461, P1282, DOI 10.1038/nature08530; Matsui EC, 2009, J ALLERGY CLIN IMMUN, V123, P1253, DOI 10.1016/j.jaci.2009.03.007; Mattick JS, 2007, J EXP BIOL, V210, P1526, DOI 10.1242/jeb.005017; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Mikovits JA, 1998, MOL CELL BIOL, V18, P5166; Miller RL, 2008, J CLIN INVEST, V118, P3265, DOI 10.1172/JCI37171; Noakes PS, 2007, THORAX, V62, P714, DOI 10.1136/thx.2006.061630; Noakes PS, 2006, CHEMOSPHERE, V63, P1304, DOI 10.1016/j.chemosphere.2005.09.008; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Ohshima Y, 2002, PEDIATR RES, V51, P195, DOI 10.1203/00006450-200202000-00012; Osei-Kumah A, 2006, PLACENTA, V27, P847, DOI 10.1016/j.placenta.2005.08.007; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Prescott SL, 2010, CLIN EXP IMMUNOL, V159, P65, DOI 10.1111/j.1365-2249.2009.04042.x; Prescott SL, 2000, ALLERGY, V55, P470; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; Rahman I, 2006, EUR RESPIR J, V28, P219, DOI 10.1183/09031936.06.00053805; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Schaub Bianca, 2009, J Allergy Clin Immunol, V123, P774, DOI 10.1016/j.jaci.2009.01.056; Schumacher A, 2009, J IMMUNOL, V182, P5488, DOI 10.4049/jimmunol.0803177; Scott NM, 2009, J IMMUNOL, V182, P1411; Shaheen SO, 2009, AM J RESP CRIT CARE, V180, P690, DOI 10.1164/rccm.200906-0893ED; Siegle JS, 2010, RESP RES, V11, DOI 10.1186/1465-9921-11-14; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; STRACHAN DP, 1989, BRIT MED J, V299, P1259; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TULIE M, 2010, J ALLERGY C IN PRESS; Ulrey CL, 2005, HUM MOL GENET, V14, pR139, DOI 10.1093/hmg/ddi100; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; White GP, 2002, J IMMUNOL, V168, P2820; Whitrow MJ, 2009, AM J EPIDEMIOL, V170, P1486, DOI 10.1093/aje/kwp315; Yerkovich ST, 2007, PEDIATR RES, V62, P547; Zaghouani H, 2009, TRENDS IMMUNOL, V30, P585, DOI 10.1016/j.it.2009.09.002	67	103	106	2	18	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAR	2011	139	3					640	647		10.1378/chest.10-1800		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	731ZS	WOS:000288150500026	21362650	
J	Jurewicz, J; Hanke, W				Jurewicz, Joanna; Hanke, Wojciech			EXPOSURE TO PHTHALATES: REPRODUCTIVE OUTCOME AND CHILDREN HEALTH. A REVIEW OF EPIDEMIOLOGICAL STUDIES	INTERNATIONAL JOURNAL OF OCCUPATIONAL MEDICINE AND ENVIRONMENTAL HEALTH			English	Review						Exposure to phthalates; Children health; Reproductive outcome	IN-UTERO EXPOSURE; SCHOOL-AGE-CHILDREN; N-BUTYL PHTHALATE; ANOGENITAL DISTANCE; SEMEN QUALITY; DI(2-ETHYLHEXYL) PHTHALATE; URINARY CONCENTRATIONS; ENDOCRINE DISRUPTORS; BIS(2-ETHYLHEXYL) PHTHALATE; ENVIRONMENTAL CHEMICALS	Phthalates are a family of industrial chemicals that have been used for a variety of purposes. As the potential consequences of human exposure to phthalates have raised concerns in the general population, they have been studied in susceptible subjects such as pregnant women, infants and children. This article aims at evaluating the impact of exposure to phthalates on reproductive outcomes and children health by reviewing most recent published literature. Epidemiological studies focusing on exposure to phthalates and pregnancy outcome, genital development, semen quality, precocious puberty, thyroid function, respiratory symptoms and neurodevelopment in children for the last ten years were identified by a search of the PubMed, Medline, Ebsco, Agricola and Toxnet literature bases. The results from the presented studies suggest that there are strong and rather consistent indications that phthalates increase the risk of allergy and asthma and have an adverse impact on children's neurodevelopment reflected by quality of alertness among girls, decreased (less masculine) composite score in boys and attention deficit hyperactivity disorder. Results of few studies demonstrate negative associations between phthalate levels commonly experienced by the public and impaired sperm quality (concentration, morphology, motility). Phthalates negatively impact also on gestational age and head circumference; however, the results of the studies were not consistent. In all the reviewed studies, exposure to phthalates adversely affected the level of reproductive hormones (luteinizing hormone, free testosterone, sex hormone-binding globulin), anogenital distance and thyroid function. The urinary levels of phthalates were significantly higher in the pubertal gynecomastia group, in serum in girls with premature thelarche and in girls with precocious puberty. Epidemiological studies, in spite of their limitations, suggest that phthalates may affect reproductive outcome and children health. Considering the suggested health effects, more epidemiologic data is urgently needed and, in the meantime, precautionary policies must be implemented.	[Jurewicz, Joanna; Hanke, Wojciech] Nofer Inst Occupat Med, Dept Environm Epidemiol, PL-91348 Lodz, Poland	Jurewicz, J (reprint author), Nofer Inst Occupat Med, Dept Environm Epidemiol, Sw Teresy 8, PL-91348 Lodz, Poland.	joannaj@imp.lodz.pl	Jurewicz, Joanna/F-7598-2010; Hanke, Wojciech/F-7604-2010	Hanke, Wojciech/0000-0001-7162-2569	Norwegian Financial Mechanism within the Polish-Norwegian Research Fund, Norway [PNRF-218-AI-1/07]	This study was performed under the project "Prenatal and postnatal exposure to tobacco smoke, PAHs and heavy metals and the risk of respiratory diseases, allergy and poor mental and physical development" supported by the grant PNRF-218-AI-1/07 from Norway through the Norwegian Financial Mechanism within the Polish-Norwegian Research Fund.	Ablake M, 2004, INT J ANDROL, V27, P274, DOI 10.1111/j.1365-2605.2004.00482.x; Andrade AJM, 2006, TOXICOLOGY, V227, P185, DOI 10.1016/j.tox.2006.07.022; Api AM, 2001, FOOD CHEM TOXICOL, V39, P97, DOI 10.1016/S0278-6915(00)00124-1; Arcadi FA, 1998, FOOD CHEM TOXICOL, V36, P963, DOI 10.1016/S0278-6915(98)00065-9; Boas M, 2006, EUR J ENDOCRINOL, V154, P599, DOI 10.1530/eje.1.02128; Borch J, 2006, TOXICOL LETT, V163, P183, DOI 10.1016/j.toxlet.2005.10.020; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Brasche S, 2005, INT J HYG ENVIR HEAL, V208, P247, DOI 10.1016/j.ijheh.2005.03.003; Brown JS, 2009, SCHIZOPHRENIA BULL, V35, P256, DOI 10.1093/schbul/sbm147; BUSTAMENTEMONTE.LP, 2008, EPIDEMIOLOGY, V19, P270; Calafat AM, 2006, TOXICOLOGY, V217, P22, DOI 10.1016/j.tox.2005.08.013; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Cho SC, 2010, ENVIRON HEALTH PERSP, V118, P1027, DOI 10.1289/ehp.0901376; Colon I, 2000, ENVIRON HEALTH PERSP, V108, P895, DOI 10.2307/3434999; Dallaire F, 2003, ENVIRON HEALTH PERSP, V111, P1660, DOI 10.1289/ehp.6269; DIRVEN HAAM, 1993, INT ARCH OCC ENV HEA, V64, P549, DOI 10.1007/BF00517699; Durmaz E, 2010, PEDIATRICS, V125, P122; Duty SM, 2003, ENVIRON HEALTH PERSP, V111, P1164, DOI 10.1289/ehp.5756; Duty SM, 2005, HUM REPROD, V20, P604, DOI 10.1093/humrep/deh656; Duty SM, 2003, EPIDEMIOLOGY, V14, P269, DOI 10.1097/00001648-200305000-00005; Engel SM, 2010, ENVIRON HEALTH PERSP, V118, P565, DOI 10.1289/ehp.0901470; Engel SM, 2009, NEUROTOXICOLOGY, V30, P522, DOI 10.1016/j.neuro.2009.04.001; Engman LH, 2007, SCAND J PUBLIC HEALT, V35, P125, DOI 10.1080/14034940600975658; FABER KA, 1992, BIOL REPROD, V46, P101, DOI 10.1095/biolreprod46.1.101; FOSTER PM, 2001, HUM REPROD UPDATE, P231; Foster PMD, 2006, INT J ANDROL, V29, P140, DOI 10.1111/j.1365-2605.2005.00563.x; Gallavan RH, 1999, REPROD TOXICOL, V13, P383, DOI 10.1016/S0890-6238(99)00036-2; Ge RS, 2007, REPROD TOXICOL, V23, P366, DOI 10.1016/j.reprotox.2006.12.006; Gladen BC, 1999, REPROD TOXICOL, V13, P41, DOI 10.1016/S0890-6238(98)00054-9; Gray LE, 2000, TOXICOL SCI, V58, P350, DOI 10.1093/toxsci/58.2.350; Hauser R, 2007, HUM REPROD, V22, P688, DOI 10.1093/humrep/del428; Hauser R, 2004, ENVIRON HEALTH PERSP, V112, P1734, DOI 10.1289/ehp.7212; Hauser R, 2006, EPIDEMIOLOGY, V17, P682, DOI 10.1097/01.ede.0000235996.89953.d7; Howdeshell KL, 2008, TOXICOL SCI, V105, P153, DOI 10.1093/toxsci/kfn077; Huang PC, 2007, HUM REPROD, V22, P2715, DOI 10.1093/humrep/dem205; Huang PC, 2009, ENVIRON INT, V35, P14, DOI 10.1016/j.envint.2008.05.012; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P560, DOI 10.2105/AJPH.94.4.560; James DK, 2005, HIGH RISK PREGNANCY; Jonsson AG, 2005, EPIDEMIOLOGY, V16, P487; Kamrin MA, 2009, J TOXICOL ENV HEAL B, V12, P157, DOI 10.1080/10937400902729226; Kavlock R, 2002, REPROD TOXICOL, V16, P721, DOI 10.1016/S0890-6238(02)00031-X; Kavlock RJ, 1996, ENVIRON HEALTH PERSP, V104, P715, DOI 10.2307/3432708; Key T J, 2001, Lancet Oncol, V2, P133, DOI 10.1016/S1470-2045(00)00254-0; Kim BN, 2009, BIOL PSYCHIAT, V66, P958, DOI 10.1016/j.biopsych.2009.07.034; Koch HM, 2004, ARCH TOXICOL, V78, P123, DOI 10.1007/00204-003-0522-3; Kolarik B, 2008, ENVIRON HEALTH PERSP, V116, P98, DOI 10.1289/ehp.10498; Larsson M, 2010, INDOOR AIR, V20, P494, DOI 10.1111/j.1600-0668.2010.00671.x; Latini G, 2004, REPROD TOXICOL, V19, P27, DOI 10.1016/j.reprotox.2004.05.011; Latini G, 2003, ENVIRON HEALTH PERSP, V111, P1783, DOI 10.1289/ehp.6202; LEWIS M, 1992, PEDIATRICS, V89, P1010; LIWNICZ BH, 1989, CLIN CHEM THEORY ANA, P607; Lomenick JP, 2010, J PEDIATR-US, V156, P221, DOI 10.1016/j.jpeds.2009.09.047; Longnecker MP, 2007, AM J EPIDEMIOL, V165, P1015, DOI 10.1093/aje/kwk109; Lopez-Carrillo L, 2010, ENVIRON HEALTH PERSP, V118, P539, DOI 10.1289/ehp.0901091; LOTTRUP AM, 2006, INT J ANDROL, V29, P172; Masuo Y, 2004, REGUL PEPTIDES, V123, P225, DOI 10.1016/j.regpep.2004.05.010; Meeker JD, 2007, ENVIRON HEALTH PERSP, V115, P1029, DOI 10.1289/ehp.9852; Mein KM, 2006, ENV HLTH PERSPECT, V114, P270; MOORE KL, 1998, DEVELOPING HUMAN CLI, P157; Moore RW, 2001, ENVIRON HEALTH PERSP, V109, P229, DOI 10.2307/3434690; *NAT RES COUNC COM, 2008, PHTH CUM RISK ASS TA; NYDICK M, 1961, JAMA-J AM MED ASSOC, V178, P449; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; PALANZA P, 1995, PHYSIOL BEHAV, V58, P827, DOI 10.1016/0031-9384(95)00107-T; Pant N, 2008, TOXICOL APPL PHARM, V231, P112, DOI 10.1016/j.taap.2008.04.001; Partsch CJ, 2001, HUM REPROD UPDATE, V7, P292, DOI 10.1093/humupd/7.3.292; Qiao Lili, 2007, Wei Sheng Yan Jiu, V36, P93; Rudel RA, 2003, ENVIRON SCI TECHNOL, V37, P4543, DOI 10.1021/es0264596; Sathyanarayana S, 2008, PEDIATRICS, V121, pE260, DOI 10.1542/peds.2006-3766; Selgrade MK, 2006, ENVIRON HEALTH PERSP, V114, P615, DOI 10.1289/ehp.8376; SHAPE RM, 1995, ENV HLTH PERSPECT, V103, P1136; Sharpe RM, 2001, TOXICOL LETT, V120, P221, DOI 10.1016/S0378-4274(01)00298-3; Shea KM, 2003, PEDIATRICS, V111, P1467, DOI 10.1542/peds.111.6.1467; Silva MJ, 2004, B ENVIRON CONTAM TOX, V72, P1226, DOI 10.1007/s00128-004-0374-4; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Swan S. H., 2009, INT J ANDROL, V32, P1; Swan SH, 2008, ENVIRON RES, V108, P177, DOI 10.1016/j.envres.2008.08.007; Tabacova S, 1997, ARCH ENVIRON HEALTH, V52, P341; Tanaka T, 2005, FOOD CHEM TOXICOL, V43, P581, DOI 10.1016/j.fct.2005.01.001; TANDON R, 1991, Indian Journal of Experimental Biology, V29, P1044; Teitelbaum SL, 2008, ENVIRON RES, V106, P257, DOI 10.1016/j.envres.2007.09.010; Wang SL, 2005, ENVIRON HEALTH PERSP, V113, P1645, DOI 10.1289/ehp.7994; Welsh M, 2008, J CLIN INVEST, V118, P1479, DOI 10.1172/JCI34241; Wirth JJ, 2008, SYST BIOL REPROD MEC, V54, P143, DOI 10.1080/19396360802055921; Wolff MS, 2008, ENVIRON HEALTH PERSP, V116, P1092, DOI 10.1289/ehp.11007; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Zhang YH, 2006, BIOMED ENVIRON SCI, V19, P205	90	103	105	10	70	VERSITA	WARSAW	SOLIPSKA 14A-1, 02-482 WARSAW, POLAND	1232-1087			INT J OCCUP MED ENV	Int. J. Occup. Med. Environ. Health		2011	24	2					115	141		10.2478/s13382-011-0022-2		27	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	808LN	WOS:000293979300001	21594692	
J	Lopata, AL; O'Hehir, RE; Lehrer, SB				Lopata, A. L.; O'Hehir, R. E.; Lehrer, S. B.			Shellfish allergy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							HOUSE-DUST-MITE; MAJOR SHRIMP ALLERGEN; INVERTEBRATE PAN-ALLERGEN; CROSS-REACTIVE ALLERGEN; CALCIUM-BINDING PROTEIN; FISH PROCESSING WORKERS; PEN A-1 TROPOMYOSIN; SEAFOOD ALLERGY; FOOD ALLERGY; ANISAKIS-SIMPLEX	Seafood plays an important role in human nutrition and health. The growing international trade in seafood species and products has added to the popularity and frequency of consumption of a variety of seafood products across many countries. This increased production and consumption of seafood has been accompanied by more frequent reports of adverse health problems among consumers as well as processors of seafood. Adverse reactions to seafood are often generated by contaminants but can also be mediated by the immune system and cause allergies. These reactions can result from exposure to the seafood itself or various non-seafood components in the product. Non-immunological reactions to seafood can be triggered by contaminants such as parasites, bacteria, viruses, marine toxins and biogenic amines. Ingredients added during processing and canning of seafood can also cause adverse reactions. Importantly all these substances are able to trigger symptoms which are similar to true allergic reactions, which are mediated by antibodies produced by the immune system against specific allergens. Allergic reactions to 'shellfish', which comprises the groups of crustaceans and molluscs, can generate clinical symptoms ranging from mild urticaria and oral allergy syndrome to life-threatening anaphylactic reactions. The prevalence of crustacean allergy seems to vary largely between geographical locations, most probably as a result of the availability of seafood. The major shellfish allergen is tropomyosin, although other allergens may play an important part in allergenicity such as arginine kinase and myosin light chain. Current observations regard tropomyosin to be the major allergen responsible for molecular and clinical cross-reactivity between crustaceans and molluscs, but also to other inhaled invertebrates such as house dust mites and insects. Future research on the molecular structure of tropomyosins with a focus on the immunological and particularly clinical cross-reactivity will improve diagnosis and management of this potentially life-threatening allergy and is essential for future immunotherapy.	[Lopata, A. L.] RMIT Univ, Allergy Res Grp, Melbourne, Vic 3083, Australia; [O'Hehir, R. E.] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [O'Hehir, R. E.] Monash Univ, Melbourne, Vic 3004, Australia; [Lehrer, S. B.] Tulane Univ, Dept Med, Sect Allergy Rheumatol & Clin Immunol, New Orleans, LA 70118 USA	Lopata, AL (reprint author), RMIT Univ, Allergy Res Grp, Bundoora W Campus, Melbourne, Vic 3083, Australia.	andreas.lopata@rmit.edu.au	Lopata, Andreas/C-3831-2012; O'Hehir, Robyn/H-3627-2011; Osborne, Nicholas/N-4915-2015	Lopata, Andreas/0000-0002-2940-9235; O'Hehir, Robyn/0000-0002-3489-7595; Osborne, Nicholas/0000-0002-6700-2284			Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Arlian LG, 2003, ALLERGY, V58, P1299, DOI 10.1046/j.1398-9995.2003.00344.x; Asero R, 2005, INT ARCH ALLERGY IMM, V137, P62, DOI 10.1159/000085105; Asturias JA, 2000, MOL BIOCHEM PARASIT, V108, P263, DOI 10.1016/S0166-6851(00)00218-8; Audicana MT, 2008, CLIN MICROBIOL REV, V21, P360, DOI 10.1128/CMR.00012-07; Auerswald L, 2006, FOOD CHEM, V98, P231, DOI 10.1016/j.foodchem.2005.05.071; *AUSTR BUR AGR RES, 2006, AUSTR FISH STAT 2006; Ayuso R, 2002, INT ARCH ALLERGY IMM, V127, P27, DOI 10.1159/000048166; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Ayuso R, 2002, J ALLERGY CLIN IMMUN, V109, pS94, DOI 10.1016/S0091-6749(02)81383-5; Ayuso R, 2008, J ALLERGY CLIN IMMUN, V122, P795, DOI 10.1016/j.jaci.2008.07.023; Ayuso R, 2009, J ALLERGY CLIN IMMUN, V124, P114, DOI 10.1016/j.jaci.2009.04.016; BANZET ML, 1992, REV FR ALLERGOL, V32, P198, DOI 10.1016/S0335-7457(05)80359-4; Barraclough RM, 2006, OCCUP MED-OXFORD, V56, P63, DOI 10.1093/occmed/kqi175; BERNSTEIN M, 1982, J ALLERGY CLIN IMMUN, V70, P205, DOI 10.1016/0091-6749(82)90043-4; Binder M, 2001, J IMMUNOL, V167, P5470; Blotzer IC, 2004, ALLERGOLOGIE, V27, P191; Chiang WC, 2007, CLIN EXP ALLERGY, V37, P1055, DOI 10.1111/j.1365-2222.2007.02752.x; CRESPO JF, 1995, PEDIATR ALLERGY IMMU, V6, P39, DOI 10.1111/j.1399-3038.1995.tb00256.x; CRESPO JF, 1995, ALLERGY, V50, P918, DOI 10.1111/j.1398-9995.1995.tb02499.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; DAUL CB, 1988, J ALLERGY CLIN IMMUN, V81, P1180, DOI 10.1016/0091-6749(88)90888-3; DESJARDINS A, 1995, J ALLERGY CLIN IMMUN, V96, P608, DOI 10.1016/S0091-6749(95)70259-8; DOHI M, 1991, J ALLERGY CLIN IMMUN, V87, P34, DOI 10.1016/0091-6749(91)90210-F; Fernandes J, 2003, CLIN EXP ALLERGY, V33, P956, DOI 10.1046/j.1365-2222.2003.01722.x; Garcia-Orozco KD, 2007, INT ARCH ALLERGY IMM, V144, P23, DOI 10.1159/000102610; Gill BV, 2009, J ALLERGY CLIN IMMUN, V124, P1055, DOI 10.1016/j.jaci.2009.06.030; Goetz DW, 2000, ANN ALLERG ASTHMA IM, V85, P461; Goh DLM, 1999, ALLERGY, V54, P84, DOI 10.1034/j.1398-9995.1999.00925.x; Guarneri F, 2007, INT J DERMATOL, V46, P146; HEFLE SL, 1995, J ALLERGY CLIN IMMUN, V95, P332; Hill DJ, 1999, ANN MED, V31, P272, DOI 10.3109/07853899908995890; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; HOFFMAN DR, 1981, ANN ALLERGY, V47, P17; Howse D, 2006, ENVIRON RES, V101, P163, DOI 10.1016/j.envres.2005.06.008; Ishikawa M, 1998, FISHERIES SCI, V64, P854; Jeebhay MF, 2007, INT ARCH ALLERGY IMM, V144, P143, DOI 10.1159/000103226; Jeebhay MF, 2005, ANN OCCUP HYG, V49, P423, DOI [10.1093/annhyg/meh113, 10.1093/annhyg/mch113]; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; Jeebhay MF, 2008, AM J IND MED, V51, P899, DOI 10.1002/ajim.20635; Jenkins JA, 2007, J ALLERGY CLIN IMMUN, V120, P1399, DOI 10.1016/j.jaci.2007.08.019; Jeong KY, 2006, PROTEIN PEPTIDE LETT, V13, P835; Johansson E, 2001, ALLERGY, V56, P660, DOI 10.1034/j.1398-9995.2001.00798.x; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; Lehrer SB, 2003, MAR BIOTECHNOL, V5, P339, DOI 10.1007/s10126-002-0082-1; LEHRER SB, 1988, J ALLERGY CLIN IMMUN, V81, P189, DOI 10.1016/0091-6749(88)90319-3; LEHRER SB, 1987, SOUTHERN MED J, V80, P2; Lehrer SB, 1998, REV FR ALLERGOL, V38, P846, DOI 10.1016/S0335-7457(98)80154-8; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Lopata AL, 1997, J ALLERGY CLIN IMMUN, V100, P642, DOI 10.1016/S0091-6749(97)70168-4; Lopata AL, 2005, ALLERGY, V60, P200, DOI 10.1111/j.1398-9995.2005.00661.x; Lopata A. L., 2000, ALLERGY CLIN IMMUNOL, V12, P271, DOI 10.1027/0838-1925.12.6.271; Lopata AL, 2009, CURR OPIN ALLERGY CL, V9, P270, DOI 10.1097/ACI.0b013e32832b3e6f; Martins L, 1999, J ALLERGY CLIN IMMUN, V103, pS104; MAULITZ RM, 1979, J ALLERGY CLIN IMMUN, V63, P433, DOI 10.1016/0091-6749(79)90218-5; McCann D, 2007, LANCET, V370, P1560, DOI 10.1016/S0140-6736(07)61306-3; Miyake T, 1988, Arerugi, V37, P53; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; Motoyama K, 2006, FOOD CHEM TOXICOL, V44, P1997, DOI 10.1016/j.fct.2006.06.018; Motoyama K, 2007, J AGR FOOD CHEM, V55, P985, DOI 10.1021/jf062798x; Nieuwenhuizen N, 2006, J ALLERGY CLIN IMMUN, V117, P1098, DOI 10.1016/j.jaci.2005.12.1357; [Anonymous], 2007, SEAF CONS INCR 2006; ONEIL CE, 1995, FOOD TECHNOL-CHICAGO, V49, P103; Pajno GB, 2002, J ALLERGY CLIN IMMUN, V109, P627, DOI 10.1067/mai.2002.122844; Peroni DG, 2000, PEDIATR ALLERGY IMMU, V11, P260, DOI 10.1034/j.1399-3038.2000.00001.x; Petrus M, 1997, ARCH PEDIATRIE, V4, P767, DOI 10.1016/S0929-693X(97)83419-7; Petrus M, 1999, ARCH PEDIATRIE, V6, P1075, DOI 10.1016/S0929-693X(00)86982-1; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Reese G, 2002, J ALLERGY CLIN IMMUN, V109, pS307, DOI 10.1016/S0091-6749(02)82078-4; Roberts G, 2002, ALLERGY, V57, P713, DOI 10.1034/j.1398-9995.2002.03366.x; Rolland JM, 2009, PHARMACOL THERAPEUT, V121, P273, DOI 10.1016/j.pharmthera.2008.11.007; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Scholl I, 2004, INT ARCH ALLERGY IMM, V135, P247, DOI 10.1159/000081950; Shiomi K, 2008, INT ARCH ALLERGY IMM, V146, P91, DOI 10.1159/000113512; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2003, PEDIATRICS, V111, P1591; Taylor AV, 2000, J ALLERGY CLIN IMMUN, V105, P166, DOI 10.1016/S0091-6749(00)90192-1; Taylor S. L., 2008, Food allergy: adverse reactions to foods and food additives, P353, DOI 10.1002/9781444300062.ch29; Taylor SL, 2008, ADV FOOD NUTR RES, V54, P139, DOI 10.1016/S1043-4526(07)00004-6; vanRee R, 1996, ALLERGY, V51, P387; vanRee R, 1996, ALLERGY, V51, P108; Vierk KA, 2007, J ALLERGY CLIN IMMUN, V119, P1504, DOI 10.1016/j.jaci.2007.03.011; Villacis J, 2006, CLIN EXP ALLERGY, V36, P1457, DOI 10.1111/j.1365-2222.2006.02590.x; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56; Wu AY, 2004, ALLERGY ASTHMA PROC, V25, P237; Yu CJ, 2003, J IMMUNOL, V170, P445; Zhang Y, 2006, J DERMATOL, V33, P174, DOI 10.1111/j.1346-8138.2006.00040.x; Zinn C, 1997, S AFR MED J, V87, P146	89	103	110	5	45	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2010	40	6					850	858		10.1111/j.1365-2222.2010.03513.x		9	Allergy; Immunology	Allergy; Immunology	592TE	WOS:000277402400005	20412131	
J	Nagel, G; Weinmayr, G; Kleiner, A; Garcia-Marcos, L; Strachan, DP				Nagel, Gabriele; Weinmayr, Gudrun; Kleiner, Andrea; Garcia-Marcos, Luis; Strachan, David P.		ISAAC Phase Two Study Grp	Effect of diet on asthma and allergic sensitisation in the International Study on Allergies and Asthma in Childhood (ISAAC) Phase Two	THORAX			English	Article							MEDITERRANEAN DIET; FATTY-ACIDS; VITAMIN-C; ANTIOXIDANT VITAMIN; SYMPTOM PREVALENCE; PULMONARY-FUNCTION; SCHOOL-CHILDREN; LUNG-FUNCTION; SERUM LEVELS; RISK-FACTOR	Background The increasing prevalence of asthma and allergy might be related to diet, particularly in Western countries. A study was undertaken to assess the association between dietary factors, asthma and allergy in a large international study including objective measurements of atopy. Methods Between 1995 and 2005, cross-sectional studies were performed in 29 centres in 20 countries. Parental questionnaires were used to collect information on allergic diseases and exposure factors and data from 50 004 randomly selected schoolchildren (8-12 years, 29 579 with skin prick testing) were analysed. Random effect models for meta-analysis were applied to calculate combined ORs. Results Fruit intake was associated with a low prevalence of current wheeze in affluent (OR(adj) 0.86, 95% CI 0.73 to 1.02) and non-affluent countries (OR(adj) 0.71, 95% CI 0.57 to 0.88). Consumption of fish in affluent countries (OR(adj) 0.85, 95% CI 0.74 to 0.97) and of cooked green vegetables in non-affluent countries (OR(adj) 0.78, 95% CI 0.65 to 0.95) was associated with a lower prevalence of current wheeze. Overall, more frequent consumption of fruit, vegetables and fish was associated with a lower lifetime prevalence of asthma, whereas high burger consumption was associated with higher lifetime asthma prevalence. None of the food items was associated with allergic sensitisation. Except for fruit juice and fruit consumption, no associations were found with atopic wheeze. Food selection according to the 'Mediterranean diet' was associated with a lower prevalence of current wheeze and asthma ever (p(trend)=0.03). Conclusion Diet is associated with wheeze and asthma but not with allergic sensitisation in children. These results provide further evidence that adherence to the 'Mediterranean diet' may provide some protection against wheeze and asthma in childhood.	[Nagel, Gabriele; Weinmayr, Gudrun; Kleiner, Andrea] Univ Ulm, Inst Epidemiol, D-89081 Ulm, Germany; [Garcia-Marcos, Luis] Univ Murcia, Arrixaca Univ Childrens Hosp, Pediat Resp Units, Murcia, Spain; [Garcia-Marcos, Luis] Univ Murcia, Arrixaca Univ Childrens Hosp, Allergy Unit, Murcia, Spain; [Garcia-Marcos, Luis] CIBER Epidemiol & Publ Hlth CIBERSP, Murcia, Spain; [Strachan, David P.] Univ London, St Georges Hosp, Div Community Hlth Sci, London, England	Nagel, G (reprint author), Univ Ulm, Inst Epidemiol, Helmholtzstr 22, D-89081 Ulm, Germany.	gabriele.nagel@uni-ulm.de	Nagel, Gabriele/C-3635-2012; Hatziagorou, Elpis/D-3247-2012; MARTINEZ-GIMENO, ANTONIO/A-9416-2010; Ellwood, Philippa/G-7555-2015; De sario, Manuela/K-1932-2016; Forastiere, Francesco/J-9067-2016; Jones, Marcus/A-3580-2011	Nagel, Gabriele/0000-0001-6185-8535; MARTINEZ-GIMENO, ANTONIO/0000-0003-4051-1860; Ellwood, Philippa/0000-0002-1994-4023; De sario, Manuela/0000-0002-1117-2735; Forastiere, Francesco/0000-0002-9162-5684; Jones, Marcus/0000-0002-8263-1265; Pearce, Neil/0000-0002-9938-7852; brunekreef, bert/0000-0001-9908-0060; Beasley, Richard/0000-0003-0337-406X	European Commission [QLK4-CT-1999-01288]	The coordination and central laboratory analyses of the European centres were funded by the Fifth Framework Programme of the European Commission (QLK4-CT-1999-01288). The agencies funding the field work are listed elsewhere.<SUP>15</SUP>	Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Bolte G, 2006, CLIN EXP ALLERGY, V36, P293, DOI 10.1111/j.1365-2222.2006.02441.x; Buchele G, 2007, PEDIATR PULM, V42, P131, DOI 10.1002/ppul.20485; BYERS T, 1993, EPIDEMIOLOGY, V4, P350, DOI 10.1097/00001648-199307000-00011; Castro-Rodriguez JA, 2008, J PEDIATR, V152, P823, DOI 10.1016/j.jpeds.2008.01.003; Chatzi L, 2007, THORAX, V62, P677, DOI 10.1136/thx.2006.069419; Chatzi L, 2007, PEDIATR ALLERGY IMMU, V18, P480, DOI 10.1111/j.1399-3038.2007.00596.x; de Batlle J, 2008, ALLERGY, V63, P1310, DOI 10.1111/j.1398-9995.2008.01722.x; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Fogarty A, 2000, CLIN EXP ALLERGY, V30, P615, DOI 10.1046/j.1365-2222.2000.00766.x; Forastiere F, 2000, THORAX, V55, P283, DOI 10.1136/thorax.55.4.283; Garcia-Marcos L, 2007, THORAX, V62, P503, DOI 10.1136/thx.2006.060020; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Kankaanpaa P, 1999, ANN MED, V31, P282, DOI 10.3109/07853899908995891; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nagel G, 2005, EUR J CLIN NUTR, V59, P8, DOI 10.1038/sj.ejcn.1602025; Nja F, 2005, ACTA PAEDIATR, V94, P147, DOI 10.1080/08035250410023638; Normand SLT, 1999, STAT MED, V18, P321, DOI 10.1002/(SICI)1097-0258(19990215)18:3<321::AID-SIM28>3.0.CO;2-P; Richardson DB, 2007, EPIDEMIOLOGY, V18, P441, DOI 10.1097/EDE.0b013e318060d25c; Schunemann HJ, 2001, AM J RESP CRIT CARE, V163, P1246; Tabak C, 2006, THORAX, V61, P1048, DOI 10.1136/thx.2005.043034; Tabak C, 1999, THORAX, V54, P1021; Trichopoulou A, 2005, BRIT MED J, V330, P991, DOI [10.1136/bmj.38415.644155.8F, 10.1136/bmj.384156441558F]; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Weiland SK, 1999, LANCET, V353, P2040, DOI 10.1016/S0140-6736(99)01609-8; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wickens K, 2005, ALLERGY, V60, P1537, DOI 10.1111/j.1398-9995.2005.00945.x; Woods RK, 2003, AM J CLIN NUTR, V78, P414	36	103	106	1	25	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2010	65	6					516	522		10.1136/thx.2009.128256		7	Respiratory System	Respiratory System	605NJ	WOS:000278354000013	20522849	
S	Valenta, R; Ferreira, F; Focke-Tejkl, M; Linhart, B; Niederberger, V; Swoboda, I; Vrtala, S		Paul, WE; Littman, DR; Yokoyama, WM		Valenta, Rudolf; Ferreira, Fatima; Focke-Tejkl, Margarete; Linhart, Birgit; Niederberger, Verena; Swoboda, Ines; Vrtala, Susanne			From Allergen Genes to Allergy Vaccines	ANNUAL REVIEW OF IMMUNOLOGY, VOL 28	Annual Review of Immunology		English	Review; Book Chapter						allergy; recombinant allergen; specific immunotherapy; IgE; T cell; peptide; diagnosis	BIRCH-POLLEN ALLERGEN; HOUSE-DUST MITE; BET V 1; T-CELL EPITOPE; LATE ASTHMATIC REACTIONS; SHORT RAGWEED ALLERGEN; FC-EPSILON-RI; PHL P 5; OVERLAPPING SYNTHETIC PEPTIDES; RANDOMIZED CONTROLLED-TRIAL	IgE-mediated allergy is a hypersensitivity disease affecting more than 25% of the population. The structures of the most common allergens have been revealed through molecular cloning technology in the past two decades. On the basis of this knowledge of the sequences and three-dimensional structures of culprit allergens, investigators can now analyze the immune recognition of allergens and the mechanisms of allergic inflammation in allergic patients. Allergy vaccines have been constructed that are able to selectively target the aberrant immune responses in allergic patients via different pathways of the immune system. Here we review various types of allergy vaccines that have been developed based on allergen structures, results from their clinical application in allergic patients, and future strategies for allergen-specific immunotherapy and allergy prophylaxis.	[Valenta, Rudolf; Focke-Tejkl, Margarete; Swoboda, Ines] Med Univ Vienna, Christian Doppler Lab Allergy Res, A-1090 Vienna, Austria; [Valenta, Rudolf; Focke-Tejkl, Margarete; Linhart, Birgit; Swoboda, Ines; Vrtala, Susanne] Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, A-1090 Vienna, Austria; [Niederberger, Verena] Med Univ Vienna, Dept Otorhinolaryngol, A-1090 Vienna, Austria; [Ferreira, Fatima] Salzburg Univ, Christian Doppler Lab Allergy Diag & Therapy, A-5020 Salzburg, Austria	Valenta, R (reprint author), Med Univ Vienna, Christian Doppler Lab Allergy Res, A-1090 Vienna, Austria.	rudolf.valenta@meduniwien.ac.at	Ferreira, Fatima/E-4889-2011	Ferreira, Fatima/0000-0003-0989-2335	Austrian Science Fund FWF [F 4613]		Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Alderuccio F, 2003, TRENDS IMMUNOL, V24, P176, DOI 10.1016/S1471-4906(03)00066-8; Alexander C, 2005, ALLERGY, V60, P1269, DOI 10.1111/j.1398-9995.2005.00885.x; Alexander C, 2005, CLIN EXP ALLERGY, V35, P52, DOI 10.1111/j.1365-2222.2005.02143.x; Ali FR, 2004, AM J RESP CRIT CARE, V169, P20, DOI 10.1164/rccm.200305-690OC; Andreasson U, 2006, J MOL BIOL, V362, P212, DOI 10.1016/j.jmb.2006.06.062; ARNON R, 1992, FASEB J, V6, P3265; Asai K, 2001, IMMUNITY, V14, P791, DOI 10.1016/S1074-7613(01)00157-1; Astori M, 2000, J IMMUNOL, V165, P3497; Ball T, 1999, FASEB J, V13, P1277; BALL T, 1994, J BIOL CHEM, V269, P28323; Baranyi U, 2008, J IMMUNOL, V180, P8168; Bauer R, 2006, J ALLERGY CLIN IMMUN, V118, P269, DOI 10.1016/j.jaci.2006.03.033; Bellinghausen I, 2005, IMMUNOLOGY, V116, P103, DOI 10.1111/j.1365-2567.2005.02205.x; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Berrens L, 1971, Monogr Allergy, V7, P1; Bischoff SC, 2007, NAT REV IMMUNOL, V7, P93, DOI 10.1038/nri2018; Bohle B, 1998, J IMMUNOL, V160, P2022; Bohle B, 2004, J IMMUNOL, V172, P6642; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BRACY JL, 1998, SCIENCE, V281, P845; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; BROWN MA, 1987, CELL, V50, P809, DOI 10.1016/0092-8674(87)90339-4; Campana R, 2008, J ALLERGY CLIN IMMUN, V121, P528, DOI 10.1016/j.jaci.2007.09.014; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Chapman MD, 2008, J ALLERGY CLIN IMMUN, V122, P882, DOI 10.1016/j.jaci.2008.07.030; CHAPMAN MD, 1980, J IMMUNOL, V125, P587; Christensen LH, 2008, J ALLERGY CLIN IMMUN, V122, P298, DOI 10.1016/j.jaci.2008.05.026; Chu RS, 1997, J EXP MED, V186, P1623, DOI 10.1084/jem.186.10.1623; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Coker HA, 2005, J ALLERGY CLIN IMMUN, V116, P445, DOI 10.1016/j.jaci.2005.04.032; Cooke RA, 1935, J EXP MED, V62, P733, DOI 10.1084/jem.62.6.733; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAVID MF, 1977, J ALLERGY CLIN IMMUN, V60, P180, DOI 10.1016/0091-6749(77)90122-1; Davies JM, 2004, CLIN EXP ALLERGY, V34, P429, DOI 10.1111/j.1365-2222.2004.01900.x; Denepoux S, 2000, FEBS LETT, V465, P39, DOI 10.1016/S0014-5793(99)01703-2; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; EBNER C, 1993, J IMMUNOL, V150, P1047; EBNER C, 1995, J IMMUNOL, V154, P1932; EBNER C, 1993, EUR J IMMUNOL, V23, P1523, DOI 10.1002/eji.1830230719; Edlmayr J, 2009, J IMMUNOL, V182, P6298, DOI 10.4049/jimmunol.0713622; Eibensteiner P, 2000, IMMUNOLOGY, V101, P112, DOI 10.1046/j.1365-2567.2000.00078.x; Ejrnaes AM, 2006, CLIN EXP ALLERGY, V36, P273, DOI 10.1111/j.1365-2222.2006.02442.x; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; Faith A, 1999, J IMMUNOL, V162, P1836; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Fellrath JM, 2003, J ALLERGY CLIN IMMUN, V111, P854, DOI 10.1067/mai.2003.1337; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira Fatima, 2006, Inflammation & Allergy Drug Targets, V5, P5, DOI 10.2174/187152806775269295; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Flicker S, 2006, J ALLERGY CLIN IMMUN, V117, P1336, DOI 10.1016/j.jaci.2006.02.012; Flicker S, 2000, J IMMUNOL, V165, P3849; Focke M, 2008, CLIN EXP ALLERGY, V38, P1400, DOI 10.1111/j.1365-2222.2008.03031.x; Focke M, 2004, CLIN EXP ALLERGY, V34, P1525, DOI 10.1111/j.1365-2222.2004.02081.x; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; FOCKE M, 2009, CLIN EXP AL IN PRESS; Gafvelin G, 2007, J BIOL CHEM, V282, P3778, DOI 10.1074/jbc.M607938200; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Ganglberger E, 2001, FASEB J, V15, P2524, DOI 10.1096/fj.00-0888fje; Gieras A, 2007, J ALLERGY CLIN IMMUN, V119, P384, DOI 10.1016/j.jaci.2006.09.034; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; GREENE WK, 1991, J IMMUNOL, V147, P3768; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Harwanegg C, 2003, CLIN EXP ALLERGY, V33, P7, DOI 10.1046/j.1365-2222.2003.01550.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P394, DOI 10.1067/mai.2001.117460; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hochreiter R, 2003, EUR J IMMUNOL, V33, P1667, DOI 10.1002/eji.200323377; HoffmannSommergruber K, 1996, CLIN EXP ALLERGY, V26, P79, DOI 10.1111/j.1365-2222.1996.tb00059.x; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; Horst A, 2002, CLIN EXP IMMUNOL, V130, P370, DOI 10.1046/j.1365-2249.2002.02025.x; HOST A, 1995, EUR J CLIN NUTR, V49, pS13; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; HUANG SK, 1995, J IMMUNOL, V154, P6157; HUANG SK, 1991, EUR J IMMUNOL, V21, P1469, DOI 10.1002/eji.1830210621; Hufnagl K, 2005, J ALLERGY CLIN IMMUN, V116, P370, DOI 10.1016/j.jaci.2005.04.002; Huibregtse IL, 2007, GASTROENTEROLOGY, V133, P517, DOI 10.1053/j.gastro.2007.04.073; Hulse KE, 2008, J ALLERGY CLIN IMMUN, V121, P756, DOI 10.1016/j.jaci.2007.10.016; ISHIZAKA K, 1966, J IMMUNOL, V97, P75; Jahn-Schmid B, 2005, J ALLERGY CLIN IMMUN, V115, P399, DOI 10.1016/j.jaci.2004.10.010; Jarnicki AG, 2001, INT IMMUNOL, V13, P1223, DOI 10.1093/intimm/13.10.1223; JOHNSON P, 1965, NATURE, V206, P935, DOI 10.1038/206935b0; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kahlert H, 2008, INT ARCH ALLERGY IMM, V145, P193, DOI 10.1159/000109288; Kalesnikoff J, 2001, IMMUNITY, V14, P801, DOI 10.1016/S1074-7613(01)00159-5; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Katoh N, 2000, J CLIN INVEST, V105, P183, DOI 10.1172/JCI6895; Kay A. B., 2008, ALLERGY ALLERGIC DIS; King TP, 2001, J IMMUNOL, V166, P6057; Klimek L, 2005, ALLERGY CLIN IMMUN S, P15; Korematsu S, 2000, J IMMUNOL, V165, P2895; Kulig M, 1999, J ALLERGY CLIN IMMUN, V103, P1173, DOI 10.1016/S0091-6749(99)70195-8; Kundig TM, 2006, J ALLERGY CLIN IMMUN, V117, P1470, DOI 10.1016/j.jaci.2006.01.040; LAMB JR, 1983, J EXP MED, V157, P1434, DOI 10.1084/jem.157.5.1434; Larche M, 2007, J ALLERGY CLIN IMMUN, V119, P906, DOI 10.1016/j.jaci.2007.02.015; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; LEE WY, 1977, NATURE, V267, P618, DOI 10.1038/267618a0; Lim A, 2007, J ALLERGY CLIN IMMUN, V120, P696, DOI 10.1016/j.jaci.2007.05.035; Linhart B, 2005, CURR OPIN IMMUNOL, V17, P646, DOI 10.1016/j.coi.2005.09.010; Linhart B, 2005, J ALLERGY CLIN IMMUN, V115, P1010, DOI 10.1016/j.jaci.2004.12.1142; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; Linhart B, 2008, BIOL CHEM, V389, P925, DOI 10.1515/BC.2008.105; Linhart B, 2007, J IMMUNOL, V178, P3924; Loveless MH, 1940, J IMMUNOL, V38, P25; Maggi L, 2007, J ALLERGY CLIN IMMUN, V120, P429, DOI 10.1016/j.jaci.2007.05.002; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; MALLEY A, 1970, J ALLERGY, V45, P14, DOI 10.1016/0021-8707(70)90013-4; MALLEY A, 1964, J IMMUNOL, V93, P420; Marazuela EG, 2008, MOL IMMUNOL, V45, P438, DOI 10.1016/j.molimm.2007.05.030; Mari A, 2008, ALLERGY, V63, P891, DOI 10.1111/j.1398-9995.2008.01703.x; Mari A, 2005, INT ARCH ALLERGY IMM, V138, P88, DOI 10.1159/000087848; Martinez-Gomez JM, 2009, ALLERGY, V64, P172, DOI 10.1111/j.1398-9995.2008.01812.x; Maurer D, 1996, J IMMUNOL, V157, P607; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Mothes-Luksch N, 2008, J IMMUNOL, V181, P4864; MUDDE GC, 1990, IMMUNOLOGY, V69, P335; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Naclerio RM, 1997, J ALLERGY CLIN IMMUN, V100, P505; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 2007, INT ARCH ALLERGY IMM, V142, P133, DOI 10.1159/000096439; Niemi M, 2007, STRUCTURE, V15, P1413, DOI 10.1016/j.str.2007.09.012; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; OHEHIR RE, 1988, IMMUNOLOGY, V64, P627; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Padavattan S, 2009, J IMMUNOL, V182, P2141, DOI 10.4049/jimmunol.0803018; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Pauli G, 2008, J ALLERGY CLIN IMMUN, V122, P951, DOI 10.1016/j.jaci.2008.09.017; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Pree I, 2007, J IMMUNOL, V179, P5309; Purohit A, 2008, CLIN EXP ALLERGY, V38, P1514, DOI 10.1111/j.1365-2222.2008.03042.x; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; Rak S, 2009, 27 C EAACI 2009 WARS; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Reisinger J, 2005, J ALLERGY CLIN IMMUN, V116, P347, DOI 10.1016/j.jaci.2005.04.003; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; Roy K, 1999, NAT MED, V5, P387; Sallusto F, 1996, J ALLERGY CLIN IMMUN, V97, P627, DOI 10.1016/S0091-6749(96)70308-1; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; Saxon Andrew, 2004, Curr Opin Allergy Clin Immunol, V4, P563, DOI 10.1097/00130832-200412000-00015; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SEHON AH, 1990, EPITOPES ATOPIC ALLE; SEIBERLER S, 1994, EMBO J, V13, P3481; Sellge G, 2005, CLIN EXP ALLERGY, V35, P774, DOI 10.1111/j.1365-2222.2005.02248.x; Shreffler WG, 2006, J IMMUNOL, V177, P3677; Shreffler WG, 2009, J ALLERGY CLIN IMMUN, V123, P43, DOI [10.1016/j.jaci.2008.09.051, 10.1016/j.jaci.2008.12.1128]; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; SISKIND GW, 1966, J EXP MED, V123, P673, DOI 10.1084/jem.123.4.673; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P469, DOI 10.1016/S0091-6749(98)70137-X; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; SNAPPER CM, 1987, SCIENCE, V236, P944, DOI 10.1126/science.3107127; SNOW RE, 1995, J IMMUNOL, V154, P5576; Sone T, 1998, J IMMUNOL, V161, P448; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Steinberger P, 1996, J BIOL CHEM, V271, P10967; Steptoe RJ, 2003, J CLIN INVEST, V111, P1357, DOI 10.1172/JCI200315995; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Suphioglu C, 2001, FEBS LETT, V502, P46, DOI 10.1016/S0014-5793(01)02661-8; Takagi H, 2008, VACCINE, V26, P6027, DOI 10.1016/j.vaccine.2008.09.019; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Tarzi M, 2006, CLIN EXP ALLERGY, V36, P465, DOI 10.1111/j.1365-2222.2006.02469.x; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Toda M, 2000, IMMUNOLOGY, V99, P179, DOI 10.1046/j.1365-2567.2000.00935.x; Tordesillas L, 2009, MOL IMMUNOL, V46, P722, DOI 10.1016/j.molimm.2008.10.018; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; ULMER JB, 1993, SCIENCE, V259, P1745, DOI 10.1126/science.8456302; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 2004, ADV IMMUNOL, V82, P105, DOI 10.1016/S0065-2776(04)82003-0; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; Valenta R, 1998, INT ARCH ALLERGY IMM, V117, P160, DOI 10.1159/000024005; VALENTA R, 2008, ALLERGY ALLERGIC DIS, P898; Valenta R, 2007, J ALLERGY CLIN IMMUN, V119, P826, DOI 10.1016/j.jaci.2007.01.025; Valenta R, 2009, TRENDS IMMUNOL, V30, P109, DOI 10.1016/j.it.2008.12.004; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; Van Overtvelt L, 2008, J IMMUNOL, V180, P4514; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; VANDERHEIJDEN FL, 1993, J IMMUNOL, V150, P3643; VANDERSTOEP N, 1993, J EXP MED, V177, P99, DOI 10.1084/jem.177.1.99; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANNEERVEN RJJ, 1994, J IMMUNOL, V152, P4203; VANNEERVEN RJJ, 1994, IMMUNOLOGY, V82, P351; vanNeerven RJJ, 1996, IMMUNOL TODAY, V17, P526, DOI 10.1016/0167-5699(96)10058-X; VANNEERVEN RJJ, 1993, J IMMUNOL, V151, P2326; vanReijsen FC, 1997, J INVEST DERMATOL, V108, P530, DOI 10.1111/1523-1747.ep12291799; VANTHOF W, 1991, MOL IMMUNOL, V28, P1225; Verhoef A, 2005, PLOS MED, V2, P253, DOI 10.1371/journal.pmed.0020078; Visco V, 1996, J IMMUNOL, V157, P956; Vrtala S, 2000, J IMMUNOL, V165, P6653; Vrtala S, 1996, J ALLERGY CLIN IMMUN, V98, P913, DOI 10.1016/S0091-6749(96)80007-8; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2004, METHODS, V32, P313, DOI 10.1016/j.ymeth.2003.08.016; Wachholz Petra A, 2004, Curr Opin Allergy Clin Immunol, V4, P313, DOI 10.1097/01.all.0000136753.35948.c0; Wallner BP, 1996, CLIN IMMUNOL IMMUNOP, V80, P105, DOI 10.1006/clin.1996.0102; Wallner M, 2007, J ALLERGY CLIN IMMUN, V120, P374, DOI 10.1016/j.jaci.2007.05.021; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Weghofer M, 2008, EUR J CLIN INVEST, V38, P959, DOI 10.1111/j.1365-2362.2008.02048.x; Weiss R, 2006, INT ARCH ALLERGY IMM, V139, P332, DOI 10.1159/000091946; Weiss R, 2002, VACCINE, V20, P3148, DOI 10.1016/S0264-410X(02)00250-5; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Westritschnig K, 2008, EUR J CLIN INVEST, V38, P260, DOI 10.1111/j.1365-2362.2008.01938.x; Westritschnig K, 2004, J IMMUNOL, V172, P5684; Westritschnig K, 2007, J IMMUNOL, V179, P7624; Wiedermann U, 1999, J ALLERGY CLIN IMMUN, V103, P1202, DOI 10.1016/S0091-6749(99)70200-9; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; WIERENGA EA, 1990, EUR J IMMUNOL, V20, P1519, DOI 10.1002/eji.1830200717; Winkler B, 2006, ALLERGY, V61, P173, DOI 10.1111/j.1398-9995.2006.01014.x; Wurtzen PA, 1999, J ALLERGY CLIN IMMUN, V104, P115, DOI 10.1016/S0091-6749(99)70122-3; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; YSSEL H, 1992, J IMMUNOL, V148, P738; Zeiler T, 1997, J ALLERGY CLIN IMMUN, V100, P721, DOI 10.1016/S0091-6749(97)70264-1; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI 10.1067/mai.2003.1411; ZHANG L, 1992, IMMUNOLOGY, V76, P158; ZHANG L, 1993, J IMMUNOL, V151, P791; Zhu DC, 2005, NAT MED, V11, P446, DOI 10.1038/nm1219	241	103	106	0	9	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	0732-0582		978-0-8243-3028-6	ANNU REV IMMUNOL	Annu. Rev. Immunol.		2010	28						211	241		10.1146/annurev-immunol-030409-101218		31	Immunology	Immunology	BOR04	WOS:000277363600009	20192803	
J	Lopez-Souza, N; Favoreto, S; Wong, H; Ward, T; Yagi, S; Schnurr, D; Finkbeiner, WE; Dolganov, GM; Widdicombe, JH; Boushey, HA; Avila, PC				Lopez-Souza, Nilceia; Favoreto, Silvio; Wong, Hofer; Ward, Theresa; Yagi, Shigeo; Schnurr, David; Finkbeiner, Walter E.; Dolganov, Gregory M.; Widdicombe, Jonathan H.; Boushey, Homer A.; Avila, Pedro C.			In vitro susceptibility to rhinovirus infection is greater for bronchial than for nasal airway epithelial cells in human subjects	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Human rhinovirus; nasal and bronchial airway epithelial cells; air-liquid interface	HUMAN TRACHEAL EPITHELIUM; BIOELECTRIC PROPERTIES; SITU HYBRIDIZATION; CULTURES; ASTHMA; EXACERBATIONS; EXPRESSION; DIFFERENTIATION; REPLICATION; DISEASE	Background: Human rhinoviruses (HRVs) characteristically cause upper respiratory tract infection, but they also infect the lower airways, causing acute bronchitis and exacerbating asthma. Objective: Our purpose was to study ex vivo the differences in the response to HRV infection of nasal and bronchial epithelial cultures from the same healthy and asthmatic individuals using conditions favoring development of fully differentiated, pseudostratified mucociliary epithelium. Methods: Cells from the inferior turbinates and bronchial tree of 5 healthy and 6 asthmatic individuals were cultured at an air-liquid interface. Cultures were infected with HRV-16, and after 48 hours, the degree of infection was measured. Results: Baseline median transepithelial resistance was lower in human bronchial epithelial (HBE) cell cultures than in human nasal epithelial (HNE) cell cultures (195 Omega.cm(2) [95% CI, 164-252] vs 366 Omega.cm(2) [95% CI, 234-408], respectively; P < .01). Virus replicated more easily in HBE cells than in HNE cells based on virus shedding in apical wash (log tissue culture infective dose of 50%/0.1 mL = 2.0 [95% CI, 1.0-2.5] vs 0.5 [95% CI, 0.5-1.5], P < .01) and on a 20- to 30-fold greater viral load and number of infected cells in HBE cell cultures than in FINE cell cultures. The increases in expression of RANTES and double-stranded RNA-dependent protein kinase were greater in HBE cell cultures than in HNE cell cultures, as were the concentrations of IL-8, IL-1 alpha, RANTES, and IP-10 in basolateral medium. However, no significant differences between asthmatic and healthy subjects (including IFN-beta 1 expression) were found. Conclusions: Differentiated nasal epithelial cells might have mechanisms of increased resistance to rhinovirus infection compared with bronchial epithelial cells. We could not confirm previous reports of increased susceptibility to HRV infection in epithelial cells from asthmatic subjects. (J Allergy Clin Immunol 2009;123:1384-90.)	[Favoreto, Silvio; Avila, Pedro C.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA; [Lopez-Souza, Nilceia; Wong, Hofer; Ward, Theresa; Boushey, Homer A.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Finkbeiner, Walter E.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA USA; [Boushey, Homer A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Yagi, Shigeo; Schnurr, David] Calif Dept Publ Hlth, Viral & Rickettsial Dis Lab, Richmond, CA USA; [Dolganov, Gregory M.] Stanford Med Sch, Div Infect Dis & Geog Med, Stanford, CA USA; [Widdicombe, Jonathan H.] Univ Calif Davis, Dept Physiol & Membrane Biol, Davis, CA 95616 USA	Avila, PC (reprint author), Northwestern Univ, Feinberg Sch Med, Dept Med, 676 N St Clair St,Rm 14-018, Chicago, IL 60611 USA.	pa@northwestern.edu			National Institutes of Health [P01A1050496]; Northwestern University; Cystic Fibrosis Foundation; Cystic Fibrosis Research, Inc; GlaxoSmithKline; Genentech	W. E. Finkbeiner has received research support from the Cystic Fibrosis Foundation and the National Institutes of Health. G. M. Dolganov has provided legal consultation or expert witness testimony on the topic of gene expression assays. J. H. Widdicombe has received research support from Cystic Fibrosis Research, Inc. H. A. Boushey has received research support from GlaxoSmithKline and honoraria from Genentech and Novartis and has served as a member and chair of the Health Effect's Institute's review committee. P.C. Avila has received research support from Genentech. The rest of the authors have declared that they have no conflict of interest.	ARRUDA E, 1995, J INFECT DIS, V171, P1329; BALLARD ST, 1992, J APPL PHYSIOL, V73, P2021; BARDIN PG, 1994, AM J RESP CELL MOL, V10, P207; Bianco A, 1998, EUR RESPIR J, V12, P619, DOI 10.1183/09031936.98.12030619; BOUCHER RC, 1981, J APPL PHYSIOL, V51, P706; Chen Y, 2006, AM J RESP CELL MOL, V34, P192, DOI 10.1165/rcmb.2004-0417OC; Come JM, 2002, LANCET, V359, P831; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Dolganov GM, 2001, GENOME RES, V11, P1473, DOI 10.1101/gr.191301; Fleming HE, 1999, AM J RESP CRIT CARE, V160, P100; Gern J. E., 1997, AM J RESP CRIT CARE, V155, P1159; Hunt SL, 1999, GENE DEV, V13, P437, DOI 10.1101/gad.13.4.437; HUNTER CA, 1995, IMMUNOLOGY, V84, P16; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jakiela B, 2008, AM J RESP CELL MOL, V38, P517, DOI 10.1165/rcmb.2007-0050OC; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; LENNETTE DA, 1995, DIAGNOSTIC PROCEDURE; Lopez-Souza N, 2004, AM J PHYSIOL-LUNG C, V286, pL373, DOI 10.1152/ajplung.00300.2003; Lopez-Souza N, 2003, IN VITRO CELL DEV-AN, V39, P266; Message SD, 2004, J LEUKOCYTE BIOL, V75, P5, DOI 10.1189/jlb.0703315; Mosser AG, 2005, AM J RESP CRIT CARE, V171, P645, DOI 10.1164/rccm.200407-970OC; Mosser AG, 2002, J INFECT DIS, V185, P734, DOI 10.1086/339339; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Papadopoulos N G, 2000, Can Respir J, V7, P409; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Proud D, 2004, J IMMUNOL, V172, P4637; Schroth MK, 1999, AM J RESP CELL MOL, V20, P1220; Seemungal TAR, 2000, EUR RESPIR J, V16, P677, DOI 10.1034/j.1399-3003.2000.16d19.x; SMYTH AR, 1995, ARCH DIS CHILD, V73, P117; Terajima M, 1997, AM J PHYSIOL-LUNG C, V273, pL749; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Widdicombe JH, 2003, IN VITRO CELL DEV-AN, V39, P51; WINTHER B, 1986, JAMA-J AM MED ASSOC, V256, P1763, DOI 10.1001/jama.256.13.1763; WINTHER B, 1990, AM REV RESPIR DIS, V141, P839; YAMAYA M, 1992, AM J PHYSIOL, V262, pL713; Yoon JH, 2002, DIFFERENTIATION, V70, P77, DOI 10.1046/j.1432-0436.2002.700202.x; [Anonymous], 1991, J ALLERGY CLIN IMMUN, V88, P425	37	103	103	0	10	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2009	123	6					1384	1390		10.1016/j.jaci.2009.03.010		7	Allergy; Immunology	Allergy; Immunology	455WO	WOS:000266799100033	19428098	
J	Burgel, PR; Nadel, JA				Burgel, P-R.; Nadel, J. A.			Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases	EUROPEAN RESPIRATORY JOURNAL			English	Review						asthma; chronic obstructive pulmonary disease; cystic fibrosis; interleukin-8; mucins; neutrophils	OBSTRUCTIVE PULMONARY-DISEASE; NECROSIS-FACTOR-ALPHA; MUCIN GENE-EXPRESSION; PROTEIN-COUPLED RECEPTORS; GOBLET CELL HYPERPLASIA; RESPIRATORY EPITHELIAL-CELLS; ACTIVATING-FACTOR RECEPTOR; GRAM-NEGATIVE BACTERIA; C-ERBB RECEPTORS; NF-KAPPA-B	Inhaled air is contaminated with pathogens and particulates that may deposit in the airways and damage the host. In response to these invaders, the airway epithelium has developed innate immune responses that provide a defence against the invaders and protect the airway structure and function. Thus, the epithelium of conducting airways becomes the "battleground" between the invaders and the host. Recent evidence suggests that airway epithelial surface signalling through the epidermal growth factor receptor (EGFR) is a convergent pathway producing innate immune responses to a variety of infectious and noninfectious noxious stimuli. In the present review, the EGFR signalling pathways leading to airway mucin production, neutrophil recruitment (via interleukin-8 production) and airway epithelial repair were examined. The importance of these findings in human airway diseases was also investigated. The current authors suggest that the exaggerated innate immune responses found in chronic inflammatory airway diseases (e.g. chronic obstructive pulmonary disease, cystic fibrosis and severe asthma) contribute to the pathogenesis or the aggravation of these diseases. Potential therapies include inhibition of the various elements of the described epidermal growth factor receptor cascade. In considering each therapeutic intervention, the potential benefits must be considered in relation to potential deleterious effects.	[Nadel, J. A.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Nadel, J. A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; [Nadel, J. A.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; [Burgel, P-R.] Univ Paris 05, Hop Cochin, AP HP, UPRES EA 2511, Paris, France; [Burgel, P-R.] Univ Paris 05, Hop Cochin, AP HP, Serv Pneumol, Paris, France	Nadel, JA (reprint author), Univ Calif San Francisco, Cardiovasc Res Inst, Box 0130, San Francisco, CA 94143 USA.	jay.nadel@ucsf.edu					Agusti C, 1998, AM J RESP CRIT CARE, V158, P1253; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Amishima M, 1998, AM J RESP CRIT CARE, V157, P1907; Andrianifahanana M, 2006, BBA-REV CANCER, V1765, P189, DOI 10.1016/j.bbcan.2006.01.002; Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Babior B M, 1995, Curr Opin Hematol, V2, P55; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; Bals R, 2004, EUR RESPIR J, V23, P327, DOI 10.1183/09031936.03.00098803; BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650; Barker AF, 2002, NEW ENGL J MED, V346, P1383, DOI 10.1056/NEJMra012519; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Barnes PJ, 2005, EUR RESPIR J, V25, P1084, DOI 10.1183/09031936.05.00139104; Berry MA, 2006, NEW ENGL J MED, V354, P697, DOI 10.1056/NEJMoa050580; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Borchers MT, 1998, AM J PHYSIOL-LUNG C, V274, pL573; Boxall C, 2006, EUR RESPIR J, V27, P208, DOI 10.1183/09031936.06.00130004; Burgel PR, 2007, THORAX, V62, P153, DOI 10.1136/thx.2006.062190; Burgel PR, 2004, THORAX, V59, P992, DOI 10.1136/thx.2003.018879; Burgel PR, 2001, J IMMUNOL, V167, P5948; Calafat J, 1997, BLOOD, V90, P1255; Caramori G, 2004, HISTOPATHOLOGY, V45, P477, DOI 10.1111/j.1365-2559.2004.01952.x; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIES J, 1995, INFECT IMMUN, V63, P2485; Davies JR, 1999, BIOCHEM J, V344, P321, DOI 10.1042/0264-6021:3440321; de Boer WI, 2006, AM J CLIN PATHOL, V125, P184, DOI 10.1039/W1AXKGT7UA37X257; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Desseyn JL, 1997, J BIOL CHEM, V272, P16873, DOI 10.1074/jbc.272.27.16873; DiMango E, 1998, J CLIN INVEST, V101, P2598, DOI 10.1172/JCI2865; Dohrman A, 1998, BBA-MOL BASIS DIS, V1406, P251, DOI 10.1016/S0925-4439(98)00010-6; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; DUSSER DJ, 1989, J CLIN INVEST, V84, P900, DOI 10.1172/JCI114251; Erjefalt JS, 1997, CLIN EXP ALLERGY, V27, P1458, DOI 10.1046/j.1365-2222.1997.1200932.x; Fan YX, 2004, J BIOL CHEM, V279, P38143, DOI 10.1074/jbc.M405760200; Fillon S, 2006, J IMMUNOL, V177, P6182; Frey MR, 2004, J BIOL CHEM, V279, P44513, DOI 10.1074/jbc.M406253200; Geiser T, 2004, AM J PHYSIOL-LUNG C, V287, pL448, DOI 10.1152/ajplung.00177.2003; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; GIBSON RL, 2003, AM J RESP CRIT CARE, V168, P901; Gomez MI, 2007, EMBO J, V26, P701, DOI 10.1038/sj.emboj.7601554; Gon Y, 2004, AM J RESP CELL MOL, V31, P330, DOI 10.1165/rcmb.2003-04380C; Greene CM, 2005, J IMMUNOL, V174, P1638; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Groneberg DA, 2002, HISTOPATHOLOGY, V40, P367, DOI 10.1046/j.1365-2559.2002.01378.x; Groskreutz DJ, 2006, J IMMUNOL, V176, P1733; Guillot L, 2004, J BIOL CHEM, V279, P2712, DOI 10.1074/jbc.M305790200; GUM JR, 1994, J BIOL CHEM, V269, P2440; GUPTA R, 1992, J BIOL CHEM, V267, P3160; Guzman K, 1996, AM J PHYSIOL-LUNG C, V271, pL1023; Hamilton LM, 2003, CLIN EXP ALLERGY, V33, P233, DOI 10.1046/j.1365-2222.2003.01593.x; Hardie WD, 1999, PEDIATR DEVEL PATHOL, V2, P415, DOI 10.1007/s100249900144; HARKEMA JR, 1993, TOXICOL LETT, V68, P251, DOI 10.1016/0378-4274(93)90136-L; Hauber HP, 2004, EUR RESPIR J, V23, P846, DOI 10.1183/09031936.04.00096504; Hays SR, 2006, AM J RESP CRIT CARE, V174, P1018, DOI 10.1164/rccm.200603-310OC; HEBDA PA, 1988, J INVEST DERMATOL, V91, P440, DOI 10.1111/1523-1747.ep12476480; Hogg JC, 2007, AM J RESP CRIT CARE, V176, P454, DOI 10.1164/rccm.200612-1772OC; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hovenberg HW, 1996, BIOCHEM J, V318, P319; Innes AL, 2006, CHEST, V130, P1102, DOI 10.1378/chest.130.4.1102; INOUE H, 1994, AM J RESP CELL MOL, V11, P651; JANY B, 1991, BIOCHEM BIOPH RES CO, V181, P1, DOI 10.1016/S0006-291X(05)81373-7; JORENS PG, 1992, T ASSOC AM PHYSICIAN, V105, P190; Kaneko T, 1996, AM J RESP CRIT CARE, V153, P136; KHERADMAND F, 1994, AM J PHYSIOL-LUNG C, V267, pL728; KINNULA VL, 1992, AM J PHYSIOL, V262, pL708; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Koff JL, 2006, J IMMUNOL, V177, P8693; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; Kohri K, 2002, EUR RESPIR J, V20, P1263, DOI 10.1183/09031936.02.00001402; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Kuwahara I, 2006, AM J PHYSIOL-LUNG C, V291, pL407, DOI 10.1152/ajplung.00471.2005; Kuyper LM, 2003, AM J MED, V115, P6, DOI 10.1016/S0002-9343(03)00241-9; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394; Laroux FS, 2005, J IMMUNOL, V175, P5596; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Lou YP, 1998, AM J RESP CRIT CARE, V157, P1927; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Marguet C, 1999, AM J RESP CRIT CARE, V159, P1533; Martin Thomas R, 2005, Proc Am Thorac Soc, V2, P403, DOI 10.1513/pats.200508-090JS; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515; MASSION PP, 1994, J CLIN INVEST, V93, P26, DOI 10.1172/JCI116954; MASSION PP, 1995, AM J PHYSIOL-LUNG C, V268, pL85; MATTHAY MA, 1993, J CELL SCI, V106, P869; McNamara N, 2001, GLYCOCONJUGATE J, V18, P715, DOI 10.1023/A:1020875423678; Meezaman D, 1994, J Biol Chem, V269, P12932; MERCER RR, 1994, AM J RESP CELL MOL, V10, P613; Muir A, 2004, AM J RESP CELL MOL, V30, P777, DOI 10.1165/rcmb.2003-0329OC; Muller T, 2005, AM J RESP CELL MOL, V33, P601, DOI 10.1165/rcmb.2005-0181OC; NADEL JA, 1991, ANN NY ACAD SCI, V624, P286, DOI 10.1111/j.1749-6632.1991.tb17027.x; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; Nakanaga T, 2007, AM J PHYSIOL-LUNG C, V292, pL1289, DOI 10.1152/ajplung.00356.2006; O'Donnell RA, 2004, THORAX, V59, P1032, DOI 10.1136/thx.2004.028043; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Okumura S, 2005, J ALLERGY CLIN IMMUN, V115, P272, DOI 10.1016/j.jaci.2004.10.004; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Polosa R, 1999, AM J RESP CELL MOL, V20, P914; Prenzel N, 1999, NATURE, V402, P884; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Rahman I, 2006, EUR J PHARMACOL, V533, P222, DOI 10.1016/j.ejphar.2005.12.087; RAPPOLEE DA, 1988, SCIENCE, V241, P708, DOI 10.1126/science.3041594; Ricciardolo FLM, 2003, CLIN EXP ALLERGY, V33, P905, DOI 10.1046/j.1365-2222.2003.01686.x; RICHMANEISENSTAT JBY, 1993, AM J PHYSIOL, V264, pL413; Richter A, 2002, AM J RESP CELL MOL, V27, P85; Rogan MP, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-29; Rogers DF, 2006, ANN MED, V38, P116, DOI 10.1080/07853890600585795; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; ROSE MC, 1987, PEDIATR RES, V22, P545, DOI 10.1203/00006450-198711000-00015; Rosell A, 2005, ARCH INTERN MED, V165, P891, DOI 10.1001/archinte.165.8.891; Rowe SM, 2005, NEW ENGL J MED, V352, P1992, DOI 10.1056/NEJMra043184; Saetta M, 2000, AM J RESP CRIT CARE, V161, P1016; Schafer R, 2003, AM J PHYSIOL-LUNG C, V285, pL376, DOI 10.1152/ajplung.00447.2002; Scharfman A, 1996, AM J RESP CRIT CARE, V154, pS163; Schlondorff J, 1999, J CELL SCI, V112, P3603; SCHULTZ G, 1991, J CELL BIOCHEM, V45, P346, DOI 10.1002/jcb.240450407; SCHULTZ GS, 1987, SCIENCE, V235, P350, DOI 10.1126/science.3492044; Sethi S, 2002, NEW ENGL J MED, V347, P465, DOI 10.1056/NEJMoa012561; Shao MXG, 2005, J IMMUNOL, V175, P4009; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shao MXG, 2004, AM J PHYSIOL-LUNG C, V287, pL420, DOI 10.1152/ajplung.00019.2004; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; Soong G, 2004, J CLIN INVEST, V113, P1482, DOI 10.1172/JCI200420773; Subauste MC, 2001, INT IMMUNOPHARMACOL, V1, P1229, DOI 10.1016/S1567-5769(01)00063-7; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; Takeyama K, 2000, J IMMUNOL, V164, P1546; Takeyama K, 1998, AM J PHYSIOL-LUNG C, V275, pL294; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; THOMPSON JS, 1989, CELL TISSUE KINET, V22, P303, DOI 10.1111/j.1365-2184.1989.tb00215.x; Thornton David J, 2004, Proc Am Thorac Soc, V1, P54, DOI 10.1513/pats.2306016; Tournier JM, 2006, AM J PATHOL, V168, P55, DOI 10.2353/ajpath.2006.050333; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; Venkatakrishnan G, 2000, J BIOL CHEM, V275, P6868, DOI 10.1074/jbc.275.10.6868; VERDUGO P, 1990, ANNU REV PHYSIOL, V52, P157, DOI 10.1146/annurev.ph.52.030190.001105; Voynow JA, 2005, AM J RESP CRIT CARE, V172, P1013, DOI 10.1164/rccm.200410-1398OC; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wang HJ, 2001, AM J RESP CELL MOL, V25, P772; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737; WIDDICOMBE JG, 1995, EUR RESPIR J, V8, P1193, DOI 10.1183/09031936.95.08071193; Williams OW, 2006, AM J RESP CELL MOL, V34, P527, DOI 10.1165/rcmb.2005-0436SF; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729; WONG DTW, 1990, J EXP MED, V172, P673, DOI 10.1084/jem.172.3.673; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI200213870; Zaas AK, 2005, TRENDS CARDIOVAS MED, V15, P195, DOI 10.1016/j.tcm.2005.07.001; ZAHM JM, 1991, AM J RESP CELL MOL, V5, P242; Zuhdi A.M., 2000, AM J RESP CELL MOL B, V22, P253	166	103	105	0	5	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2008	32	4					1068	1081		10.1183/09031936.00172007		14	Respiratory System	Respiratory System	358VB	WOS:000259944500032	18827153	
J	Van Ree, R; Chapman, MD; Ferreira, F; Vieths, S; Bryan, D; Cromwell, O; Villalba, M; Durham, SR; Becker, WM; Aalbers, M; Andre, C; Barber, D; Bahima, AC; Custovic, A; Didierlaurent, A; Dolman, C; Dorpema, JW; Di Felice, G; Eberhardt, F; Fernandez Caldas, E; Fernandez Rivas, M; Fiebig, H; Focke, M; Fotisch, K; Gadermaier, G; Das, RG; Gonzalez Mancebo, E; Himly, M; Kinaciyan, T; Knulst, AC; Kroon, AM; Lepp, U; Marco, FM; Mari, A; Moingeon, P; Monsalve, R; Neubauer, A; Notten, S; Heer, PO; Pauli, G; Pini, C; Purohit, A; Quiralte, J; Rak, S; Raulf-Heimsoth, M; SanMiguel Moncin, MM; Simpson, B; Tsay, A; Vailes, L; Wallner, M; Weber, B				Van Ree, R.; Chapman, M. D.; Ferreira, F.; Vieths, S.; Bryan, D.; Cromwell, O.; Villalba, M.; Durham, S. R.; Becker, W. M.; Aalbers, M.; Andre, C.; Barber, D.; Bahima, A. Cistero; Custovic, A.; Didierlaurent, A.; Dolman, C.; Dorpema, J. W.; Di Felice, G.; Eberhardt, F.; Fernandez Caldas, E.; Fernandez Rivas, M.; Fiebig, H.; Focke, M.; Foetisch, K.; Gadermaier, G.; Das, R. G.; Gonzalez Mancebo, E.; Himly, M.; Kinaciyan, T.; Knulst, A. C.; Kroon, A. M.; Lepp, U.; Marco, F. M.; Mari, A.; Moingeon, P.; Monsalve, R.; Neubauer, A.; Notten, S.; Heer, P. Ooievaarde; Pauli, G.; Pini, C.; Purohit, A.; Quiralte, J.; Rak, S.; Raulf-Heimsoth, M.; SanMiguel Moncin, M. M.; Simpson, B.; Tsay, A.; Vailes, L.; Wallner, M.; Weber, B.			The CREATE Project: development of certified reference materials for allergenic products and validation of methods for their quantification	ALLERGY			English	Article							1ST INTERNATIONAL STANDARD; SMALL-ANGLE SCATTERING; DUST MITE ALLERGEN; DERMATOPHAGOIDES-PTERONYSSINUS; IMMUNOLOGICAL RESPONSE; RECOMBINANT ALLERGENS; CIRCULAR-DICHROISM; MASS-SPECTROMETRY; INDOOR ALLERGENS; COMPUTER-PROGRAM	Allergen extracts have been used for diagnosis and treatment of allergy for around 100 years. During the second half of 20th century, the notion increasingly gained foothold that accurate standardization of such extracts is of great importance for improvement of their quality. As a consequence, manufacturers have implemented extensive protocols for standardization and quality control. These protocols have overall IgE-binding potencies as their focus. Unfortunately, each company is using their own in-house reference materials and their own unique units to express potencies. This does not facilitate comparison of different products. During the last decades, most major allergens of relevant allergen sources have been identified and it has been established that effective immunotherapy requires certain minimum quantities of these allergens to be present in the administered maintenance dose. Therefore, the idea developed to introduce major allergens measurements into standardization protocols. Such protocols based on mass units of major allergen, quantify the active ingredients of the treatment and will at the same time allow comparison of competitor products. In 2001, an EU funded project, the CREATE project, was started to support introduction of major allergen based standardization. The aim of the project was to evaluate the use of recombinant allergens as reference materials and of ELISA assays for major allergen measurements. This paper gives an overview of the achievements of the CREATE project.	Acad Med Ctr, Amsterdam, Netherlands; [Chapman, M. D.; Tsay, A.; Vailes, L.] Indoor Biotechnol, Charlottesville, VA USA; [Ferreira, F.; Gadermaier, G.; Himly, M.; Wallner, M.] Salzburg Univ, A-5020 Salzburg, Austria; [Vieths, S.; Foetisch, K.] Paul Ehrlich Inst, D-6070 Langen, Germany; [Bryan, D.; Dolman, C.; Das, R. G.] NIBSC, Potters Bar, Herts, England; [Cromwell, O.; Fiebig, H.; Weber, B.] Allergopharma, Reinbek, Germany; [Villalba, M.] Univ Complutense, E-28040 Madrid, Spain; [Durham, S. R.] Univ London Imperial Coll Sci & Technol, London, England; [Becker, W. M.; Lepp, U.] Res Ctr, Borstel, Germany; [Aalbers, M.; Notten, S.; Heer, P. Ooievaarde] Sanquin, Amsterdam, Netherlands; [Andre, C.; Didierlaurent, A.; Moingeon, P.] Stallergenes SA, Antony, France; [Barber, D.; Monsalve, R.] ALK Abello, Madrid, Spain; [Bahima, A. Cistero; SanMiguel Moncin, M. M.] Univ Inst Dexeus, Barcelona, Spain; [Custovic, A.; Simpson, B.] Univ Manchester, Manchester, Lancs, England; [Dorpema, J. W.] HAL Allergy BV, Haarlem, Netherlands; [Di Felice, G.; Pini, C.] Ist Super Sanita, I-00161 Rome, Italy; [Fernandez Caldas, E.] CBF Leti SA, Madrid, Spain; [Fernandez Rivas, M.] Hosp Clin San Carlos, Madrid, Spain; [Focke, M.; Kinaciyan, T.] Med Univ Vienna, Vienna, Austria; [Gonzalez Mancebo, E.] Hosp Ramon & Cajal, E-28034 Madrid, Spain; [Knulst, A. C.] Univ Med Ctr Utrecht, Utrecht, Netherlands; [Kroon, A. M.] European Allergen Manufacturers Grp, Haarlem, Netherlands; [Marco, F. M.] ASAC Pharmaceut Int SA, Alicante, Spain; [Mari, A.] IRCCS, IDI, CACeS, Rome, Italy; [Neubauer, A.] Biomay AG, Vienna, Austria; [Pauli, G.; Purohit, A.] Univ Hosp, Strasbourg, France; [Quiralte, J.] Complejo Hosp Jaen, Jaen, Spain; [Rak, S.] Sahlgrens Univ Hosp, Gothenburg, Sweden; [Raulf-Heimsoth, M.] Ruhr Univ Bochum, BGFA, D-4630 Bochum, Germany	Van Ree, R (reprint author), Acad Med Ctr, Amsterdam, Netherlands.		Dolman, Carl/E-2485-2013; Villalba, Mayte/K-5365-2014; MARCO, FRANCISCO/L-8723-2014; Ferreira, Fatima/E-4889-2011; Himly, Martin/D-1568-2015; DI FELICE, GABRIELLA/B-9985-2016; IBIS, ALERGICAS/C-1733-2016; Custovic, Adnan/A-2435-2012; Wallner, Michael/L-5437-2015; Gadermaier, Gabriele/L-5997-2015	Dolman, Carl/0000-0002-7774-6375; MARCO, FRANCISCO/0000-0001-5113-3637; Ferreira, Fatima/0000-0003-0989-2335; Himly, Martin/0000-0001-5416-085X; DI FELICE, GABRIELLA/0000-0001-7387-9683; Custovic, Adnan/0000-0001-5218-7071; Wallner, Michael/0000-0001-6568-7892; Gadermaier, Gabriele/0000-0002-4886-417X			AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; ARNTZEN FC, 1989, J ALLERGY CLIN IMMUN, V83, P66, DOI 10.1016/0091-6749(89)90479-X; BAER H, 1986, J ALLERGY CLIN IMMUN, V78, P624, DOI 10.1016/0091-6749(86)90080-1; Batard T, 2005, INT ARCH ALLERGY IMM, V136, P239, DOI 10.1159/000083950; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409; Chirino AJ, 2004, NAT BIOTECHNOL, V22, P1383, DOI 10.1038/nbt1030; DAS REG, 1982, COMPUT PROG BIOMED, V15, P13, DOI 10.1016/0010-468X(82)90052-6; FERREIRA F, 2006, ARB P EHRLICH I BUND, V95, P75; FORD A, 1985, J ALLERGY CLIN IMMUN, V75, P676, DOI 10.1016/0091-6749(85)90093-4; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58; GAINES RE, 1985, COMPUT METH PROG BIO, V21, P25, DOI 10.1016/0169-2607(85)90059-8; GJESING B, 1985, J ALLERGY CLIN IMMUN, V75, P258, DOI 10.1016/0091-6749(85)90055-7; GLATTER O, 1977, J APPL CRYSTALLOGR, V10, P415, DOI 10.1107/S0021889877013879; Hakkaart GAJ, 1998, CLIN EXP ALLERGY, V28, P169; HELM RM, 1984, J ALLERGY CLIN IMMUN, V73, P790, DOI 10.1016/0091-6749(84)90449-4; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; KIRKWOOD TBL, 1984, J BIOL STAND, V12, P207, DOI 10.1016/S0092-1157(84)80055-4; Kleine Budde I, 2001, Int Arch Allergy Immunol, V126, P277, DOI 10.1159/000049524; LARSEN JN, 1988, J ALLERGY CLIN IMMUN, V82, P318, DOI 10.1016/0091-6749(88)90002-4; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Lill J, 2003, MASS SPECTROM REV, V22, P182, DOI 10.1002/mas.10048; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 2007, J ALLERGY CLIN IMMUN, V119, P769, DOI 10.1016/j.jaci.2007.01.036; NORMAN PS, 1986, J ALLERGY CLIN IMMUN, V77, P405, DOI 10.1016/0091-6749(86)90173-9; NORMAN PS, 1994, ARB PEI GSH, V87, P59; Pilz I, 1979, Methods Enzymol, V61, P148; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; PLATTSMILLS TAE, 1991, J ALLERGY CLIN IMMUN, V87, P621, DOI 10.1016/0091-6749(91)90379-3; PLATTSMILLS TAE, 1985, CLIN REV ALLERG, V3, P271, DOI 10.1007/BF02992996; *POS STAT, 2007, J ALLERGY CLIN IMMUN, V99, P583; Reinders J, 2004, PROTEOMICS, V4, P3686, DOI 10.1002/pmic.200400869; SCHEINER O, 1994, ARB PEI GSH, V87, P221; Smith AM, 2001, INT ARCH ALLERGY IMM, V124, P61, DOI 10.1159/000053669; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Tyler MI, 2000, METH MOL B, V159, P1; Valenta R, 2004, METHODS, V32, P207, DOI 10.1016/j.ymeth.2003.08.001; van Ree R, 2007, J ALLERGY CLIN IMMUN, V119, P270, DOI 10.1016/j.jaci.2006.10.033; van Ree Ronald, 2004, Allergy, V59, P571; vanRee R, 1997, ALLERGY, V52, P795; van Ree R, 1999, ARB P EHRLICH I BUND, V93, P87; Verdino P, 2004, METHODS, V32, P241, DOI 10.1016/j.vmeth.2003.08.017	44	103	105	1	17	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	MAR	2008	63	3					310	326		10.1111/j.1398-9995.2007.01612.x		17	Allergy; Immunology	Allergy; Immunology	259GQ	WOS:000252928200009	18269676	
J	Hertz-Picciotto, I; Park, HY; Dostal, M; Kocan, A; Trnovec, T; Sram, R				Hertz-Picciotto, Irva; Park, Hye-Youn; Dostal, Miroslav; Kocan, Anton; Trnovec, Tomas; Sram, Radim			Prenatal exposures to persistent and non-persistent organic compounds and effects on immune system development	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY			English	Article; Proceedings Paper	International Conference on Foetal Programming and Development Toxicity	MAY 20-24, 2007	Torshavn, DENMARK				ENVIRONMENTAL TOBACCO-SMOKE; INTERFERON-GAMMA PRODUCTION; IN-VITRO EXPOSURE; POLYCHLORINATED-BIPHENYLS; CRITICAL WINDOWS; CORD-BLOOD; CHILDRENS HEALTH; ULTRAFINE PARTICLES; AUTOIMMUNE-DISEASE; CONGENITAL-RUBELLA	Immune system development, particularly in the prenatal period, has far-reaching consequences for health during early childhood, as well as throughout life. Environmental disturbance of the complex balances of Th1 and Th2 response mechanisms can alter that normal development. Dysregulation of this process or an aberrant trajectory or timing of events can result in atopy, asthma, a compromised ability to ward off infection, or other auto-immune disease. A wide range of chemical, physical and biological agents appear to be capable of disrupting immune development. This MiniReview briefly reviews developmental milestones of the immune system in the prenatal period and early life, and then presents examples of environmentally induced alterations in immune markers. The first example involves a birth cohort study linked to an extensive programme of air pollution monitoring; the analysis shows prenatal ambient polycyclic aromatic hydrocarbons (PAH) and fine particle (PM2.5) exposures to be associated with altered lymphocyte immunophenotypic distributions in cord blood and possible changes in cord serum immunoglobulin E levels. The second example is a study of prenatal-polychlorinated biphenyl (PCB) exposures and the foetal development of the thymus, the organ responsible for lymphocyte maturation. Mothers with higher serum concentrations of PCBs gave birth to neonates having smaller indices of thymus size. Finally, this report underscores the tight connection between development of the immune system and that of the central nervous system, and the plausibility that disruption of critical events in immune development may play a role in neurobehavioural disorders.	Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Park, Hye-Youn] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA; [Dostal, Miroslav; Sram, Radim] Acad Sci Czech Republic, Inst Expt Med, Prague, Czech Republic; [Kocan, Anton; Trnovec, Tomas] Slovak Med Univ, Bratislava, Slovakia	Hertz-Picciotto, I (reprint author), Univ Calif Davis, Dept Publ Hlth Sci, TB 168, Davis, CA 95616 USA.	ihp@ucdavis.edu	Dostal, Miroslav/H-2832-2014; Sram, Radim/H-2455-2014	Sram, Radim/0000-0003-4256-3816	NCI NIH HHS [R01-CA96525]; NIEHS NIH HHS [1P01-ES11269]		ALLEN JR, 1976, TOXICOLOGY, V6, P331, DOI 10.1016/0300-483X(76)90037-8; Ashwood P, 2004, AUTOIMMUN REV, V3, P557, DOI 10.1016/j.autrev.2004.07.036; Ashwood P, 2008, J AUTISM DEV DISORD, V38, P169, DOI 10.1007/s10803-006-0353-1; Becker KG, 2007, MED HYPOTHESES, V69, P731, DOI 10.1016/j.mehy.2007.02.019; BERGMANN RL, 1995, ALLERGY, V50, P65, DOI 10.1111/j.1398-9995.1995.tb02484.x; Betancur C, 2002, MOL PSYCHIATR, V7, P67, DOI 10.1038/sj/mp/4000923; Boulanger LM, 2004, NAT REV NEUROSCI, V5, P521, DOI 10.1038/nrn1428; BRAUNSCHWEIG D, 2007, AUTISM MATERNALLY DE; Brown AS, 2004, ARCH GEN PSYCHIAT, V61, P774, DOI 10.1001/archpsyc.61.8.774; Brown-Connolly NE, 2002, J TELEMED TELECARE, V8, P7, DOI 10.1258/135763302320301812; Bunn TL, 2001, TOXICOL SCI, V64, P57; CHESS S, 1978, J PEDIATR-US, V93, P699, DOI 10.1016/S0022-3476(78)80921-4; CHESS S, 1971, J AUTISM CHILD SCHIZ, V1, P33, DOI 10.1007/BF01537741; Cook Edwin H. Jr., 1996, Current Opinion in Pediatrics, V8, P348, DOI 10.1097/00008480-199608000-00008; Courage CM, 2002, CHILDRENS HLTH ENV R, P142; Cozen W, 2004, J CLIN IMMUNOL, V24, P617, DOI 10.1007/s10875-004-6247-0; Dallaire F, 2006, ENVIRON HEALTH PERSP, V114, P1301, DOI 10.1289/ehp.8683; DEYKIN EY, 1979, AM J EPIDEMIOL, V109, P628; Dietert RR, 2007, CURR MED CHEM, V14, P1075, DOI 10.2174/092986707780362899; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; DiFranza JR, 2004, PEDIATRICS, V113, P1007; ENSTROM A, 2007, IN PRESS AM J BIOCH; Galloway TS, 2002, ENVIRON SCI TECHNOL, V36, P2219, DOI 10.1021/es010300w; Gern JE, 2006, J ALLERGY CLIN IMMUN, V117, P72, DOI 10.1016/j.jaci.2005.10.002; Gimpl G, 2001, PHYSIOL REV, V81, P629; Heilmann C, 2006, PLOS MED, V3, P1352, DOI 10.1371/journal.pmed.0030311; HERR CE, IN PRESS OCCUP ENV M; Hertz-Picciotto I, 2005, ENVIRON HEALTH PERSP, V113, P1391, DOI 10.1289/ehp.7610; Hertz-Picciotto I, 2002, EPIDEMIOLOGY, V13, P172, DOI 10.1097/00001648-200203000-00012; Hertz-Pieciotto I, 2003, FRESEN ENVIRON BULL, V12, P208; Holladay SD, 1999, ENVIRON HEALTH PERSP, V107, P687, DOI 10.2307/3434328; Huh GS, 2000, SCIENCE, V290, P2155, DOI 10.1126/science.290.5499.2155; Jalava PI, 2007, INHAL TOXICOL, V19, P213, DOI 10.1080/08958370601067863; Jedrychowski W, 2005, EUR J EPIDEMIOL, V20, P775, DOI 10.1007/s10654-005-1048-1; Jones CA, 2000, ALLERGY, V55, P2, DOI 10.1034/j.1398-9995.2000.00109.x; Keller JM, 2006, ENVIRON HEALTH PERSP, V114, P70, DOI 10.1289/ehp.8143; Keller JM, 2004, ENVIRON HEALTH PERSP, V112, P1074, DOI 10.1289/ehp.6923; King CL, 1998, J IMMUNOL, V160, P3578; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Landreth KS, 2002, HUM EXP TOXICOL, V21, P493, DOI 10.1191/0960327102ht287oa; Levin M, 2004, J TOXICOL ENV HEAL A, V67, P1517, DOI 10.1080/15287390490486761; Ling ZD, 1998, EXP NEUROL, V149, P411, DOI 10.1006/exnr.1998.6715; Loomis D, 1997, OCCUP ENVIRON MED, V54, P720; Luebke RW, 2006, J TOXICOL ENV HEAL B, V9, P1, DOI 10.1080/15287390500194326; Lundborg M, 2007, ENVIRON RES, V104, P250, DOI 10.1016/j.envres.2007.01.002; Marx CE, 2001, BIOL PSYCHIAT, V50, P743, DOI 10.1016/S0006-3223(01)01209-4; Massague J, 2000, GENE DEV, V14, P627; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Meyer U, 2006, J NEUROSCI, V26, P4752, DOI 10.1523/JNEUROSCI.0099-06.2006; Miller LS, 2007, SEMIN IMMUNOPATHOL, V29, P15, DOI 10.1007/s00281-007-0061-8; Molloy CA, 2006, J NEUROIMMUNOL, V172, P198, DOI 10.1016/j.jneuroim.2005.11.007; NAKANISHI Y, 1985, ENVIRON HEALTH PERSP, V59, P31, DOI 10.2307/3429870; Ng SP, 2006, TOXICOL SCI, V89, P135, DOI 10.1093/toxsci/kfj006; Oddy WH, 2003, J ALLERGY CLIN IMMUN, V112, P723, DOI 10.1067/mai.2003.1747; Palfi M, 1998, AM J REPROD IMMUNOL, V39, P24; Park HY, 2008, ENVIRON HEALTH PERSP, V116, P104, DOI 10.1289/ehp.9769; Pinto JP, 1998, ENVIRON SCI TECHNOL, V32, P843, DOI 10.1021/es970174p; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 1998, J IMMUNOL, V160, P4730; Ramadas RA, 2007, EUR RESPIR J, V29, P502, DOI 10.1183/09031936.00029506; Revello MG, 2004, J CLIN VIROL, V29, P71, DOI 10.1016/j.jev.2003.09.012; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Schmitt KRL, 2007, NEUROSCI RES, V59, P68, DOI 10.1016/j.neures.2007.05.011; Shi LM, 2003, J NEUROSCI, V23, P297; SMIALOWICZ RJ, 1989, TOXICOLOGY, V56, P197, DOI 10.1016/0300-483X(89)90133-9; SONNEBORN D, IN PRESS PAEDIAT PER; SVENSSON BG, 1994, INT ARCH OCC ENV HEA, V65, P351, DOI 10.1007/BF00383243; Sweeten TL, 2003, PEDIATRICS, V112, pE420, DOI 10.1542/peds.112.5.e420; Torres AR, 2006, HUM IMMUNOL, V67, P346, DOI 10.1016/j.humimm.2006.01.001; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401; Tryphonas Helen, 2001, P193; Vos J G, 1972, Sci Total Environ, V1, P289, DOI 10.1016/0048-9697(72)90024-1; VOS JG, 1971, TOXICOL APPL PHARM, V19, P617, DOI 10.1016/0041-008X(71)90294-8; Wang L, 2007, J ALLERGY CLIN IMMUN, V120, P445, DOI 10.1016/j.jaci.2007.03.028; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Weisglas-Kuperus N, 2000, ENVIRON HEALTH PERSP, V108, P1203, DOI 10.2307/3434834; Weisglas-Kuperus N, 2004, TOXICOL LETT, V149, P281, DOI 10.1016/j.toxlet.2003.12.039; West LJ, 2002, HUM EXP TOXICOL, V21, P499, DOI 10.1191/0960327102ht288oa; Yeatts K, 2006, ENVIRON HEALTH PERSP, V114, P634, DOI 10.1289/ehp.8381; Zimmerman AW, 2007, BRAIN BEHAV IMMUN, V21, P351, DOI 10.1016/j.bbi.2006.08.005; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	83	103	106	2	31	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1742-7835			BASIC CLIN PHARMACOL	Basic Clin. Pharmacol. Toxicol.	FEB	2008	102	2					146	154		10.1111/j.1742-7843.2007.00190.x		9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	254LU	WOS:000252588900013	18226068	
J	Noakes, PS; Hale, J; Thomas, R; Lane, C; Devadason, SG; Prescott, SL				Noakes, P. S.; Hale, J.; Thomas, R.; Lane, C.; Devadason, S. G.; Prescott, S. L.			Maternal smoking is associated with impaired neonatal toll-like-receptor-mediated immune responses	EUROPEAN RESPIRATORY JOURNAL			English	Article						cord blood; cotinine; cytokines; innate immunity; smoking; toll-like receptors	ENVIRONMENTAL TOBACCO-SMOKE; BRONCHIAL EPITHELIAL-CELLS; RESPIRATORY-INFECTIONS; INHALANT ALLERGEN; DENDRITIC CELLS; EARLY-CHILDHOOD; LIPOPOLYSACCHARIDE; EXPOSURE; EXPRESSION; RESPONSIVENESS	Infants of smokers have much higher rates of respiratory infection, asthma and airway disease. The current study assessed the effects of maternal smoking in pregnancy on neonatal toll-like-receptor (TLR)-mediated immune responses as a possible contributing factor to the elevated rates of respiratory illness. In a prospective birth cohort, the cord blood immune responses of neonates of smoking and nonsmoking mothers were compared. Maternal and cord serum cotinine were measured to confirm the level of cigarette smoke exposure. Neonatal cytokine responses were assessed to optimal doses of TILR2, TLR3, TLR4 and TLR9 ligands. Cotinine levels confirmed maternal reporting of cigarette smoking in pregnancy, with significantly higher cotinine levels in maternal and cord blood compared with the nonsmoking group. Infants of smoking mothers showed significantly attenuated innate TLR-mediated responses compared with infants of nonsmokers. The current findings indicate that in addition to effects on developing airways, maternal smoking also has significant immunological effects in pregnancy, which could contribute to the well recognised, subsequent increased risk of respiratory infections and asthma. These effects appear to be mediated through effects on toll-like receptor-mediated innate response pathways, which also promote regulatory pathways in the inhibition of allergic immune responses in the postnatal period, suggesting that other environmental interactions are highly relevant to the "hygiene hypothesis".	Univ Western Australia, Sch Paediat & Child Hlth Res, Perth, WA 6009, Australia	Prescott, SL (reprint author), Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth Res, POB D184, Perth, WA 6001, Australia.	susanp@ichr.uwa.edu.au	Prescott, Susan/H-5665-2014				Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Ceppa F, 2000, J CHROMATOGR B, V746, P115, DOI 10.1016/S0378-4347(00)00306-6; Chan-Yeung M, 2003, RESPIROLOGY, V8, P131, DOI 10.1046/j.1440-1843.2003.00453.x; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; DiFranza JR, 2004, PEDIATRICS, V113, P1007; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Jedrychowski W, 1997, ENVIRON HEALTH PERSP, V105, P302, DOI 10.1289/ehp.97105302; Kim E, 2005, IMMUNOL LETT, V99, P24, DOI 10.1016/j.imlet.2004.11.025; Kim I, 2005, J CHROMATOGR B, V814, P233, DOI 10.1016/j.jchromb.2004.10.034; Laan M, 2004, J IMMUNOL, V173, P4164; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MAGNUSSON CGM, 1986, J ALLERGY CLIN IMMUN, V78, P898, DOI 10.1016/0091-6749(86)90237-X; Martinez F D, 1999, Lancet, V354 Suppl 2, pSII12, DOI 10.1016/S0140-6736(99)90437-3; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; Monteil MA, 2004, REV PANAM SALUD PUBL, V16, P193, DOI 10.1590/S1020-49892004000900006; Nafstad P, 2005, PEDIATRICS, V116, pE255, DOI 10.1542/peds.2004-2785; Nareika A, 2005, AM J PHYSIOL-ENDOC M, V289, pE534, DOI 10.1152/ajpendo.00462.2004; Noakes PS, 2003, ALLERGY, V58, P1053, DOI 10.1034/j.1398-9995.2003.00290.x; Nouri-Shirazi M, 2003, IMMUNOLOGY, V109, P365, DOI 10.1046/j.1365-2567.2003.01655.x; Pasare C, 2003, CURR OPIN IMMUNOL, V15, P677, DOI 10.1016/j.coi.2003.09.002; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P358, DOI 10.1111/j.1365-2222.2005.02187.x; Prescott SL, 2003, CLIN EXP ALLERGY, V33, P566, DOI 10.1046/j.1365-2222.2003.01659.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Sousa CRE, 1999, CURR OPIN IMMUNOL, V11, P392; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Upham JW, 2004, J ALLERGY CLIN IMMUN, V114, P1202, DOI 10.1016/j.jaci.2004.06.051; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; Valacchi G, 2005, ANTIOXID REDOX SIGN, V7, P25, DOI 10.1089/ars.2005.7.25; WEISS ST, 1985, AM REV RESPIR DIS, V131, P573; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Zhou LM, 2003, AM J RESP CELL MOL, V28, P762, DOI 10.1165/rcmb.2002-0261OC	35	103	105	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	OCT	2006	28	4					721	729		10.1183/09031936.06.00050206		9	Respiratory System	Respiratory System	095YU	WOS:000241345000010	16870663	
J	Alexis, NE; Lay, JC; Zeman, K; Bennett, WE; Peden, DB; Soukup, JM; Devlin, RB; Becker, S				Alexis, NE; Lay, JC; Zeman, K; Bennett, WE; Peden, DB; Soukup, JM; Devlin, RB; Becker, S			Biological material on inhaled coarse fraction particulate matter activates airway phagocytes in vivo in healthy volunteers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						PM(2.5-1)0; airway macrophages; TNF-alpha; mCD14; eotaxin	ALVEOLAR MACROPHAGE RESPONSES; DIESEL EXHAUST PARTICLES; POLLUTION PARTICLES; INSOLUBLE COMPONENTS; ATOPIC ASTHMATICS; ENDOTOXIN; EXPOSURE; INFLAMMATION; DEPOSITION; ULTRAFINE	Background: In vitro, endotoxin on coarse fraction particulate matter (PM2.5-10) accounts for the majority of the ability of PM2.5-10 to induce cytokine responses from alveolar macrophages. Objective: We examined in vivo whether inhaled PM2.5-10 from local ambient air induce inflammatory and immune responses in the airways of healthy human beings and whether biologic material on PM2.5-10 accounts for these effects. Methods: On 3 separate visits, 9 healthy subjects inhaled nebulized saline (0.9%, control), PM2.5-10 collected from local ambient air that was heated to inactivate biological material (PM2.5-10-), or nonheated PM (PM2.5-10+)- PM2.5-10 deposition (similar to 0.65 mg/subject) targeted the bronchial airways (confirmed by using radiolabeled aerosol), and induced sputum was obtained 2 to 3 hours postinhalation for analysis of cellular and biochemical markers of inflammation and innate immune function. Results: Inhaled PM2.5-10+ induced elevated inflammation (% PMNs, macrophage mRNA TNF-alpha), increased eotaxin, upregulated immune surface phenotypes on macrophages (mCD14, CD11b, HLA-DR), and increased phagocytosis (monocytes) versus saline (P < .05). Biological inactivation of PM2.5-10 (PM2.5-10-) had no effect on neutrophilia but significantly (P < .05) attenuated mRNA TNF-alpha, eotaxin levels, cell surface marker responses, and phagocytosis. Conclusion: Biological components of PM2.5-10 are not necessary to induce neutrophil responses but are essential in mediating macrophage responses. The ability Of PM2.5-10 to activate monocytic cells and potentially skew the airways toward an allergic phenotype by enhancing eotaxin levels may enhance responses to allergens or bacteria in individuals with allergy. Clinical implications: PM2.5-10 might enhance the response of individuals with allergy to airborne bacteria.	Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA	Alexis, NE (reprint author), Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA.	Neil_Alexis@med.unc.edu	Lay, John/A-6380-2012		NHLBI NIH HHS [R01 HL066559, R01 HL 66559, R01 HL062624, R01 HL062624-06, R01 HL066559-04, R01HL-62624]		Albert I, 2005, INT J FOOD MICROBIOL, V100, P197, DOI 10.1016/j.ijfoodmicro.2004.10.016; Alexis N, 2000, CLIN IMMUNOL, V97, P21, DOI 10.1006/clim.2000.4911; Alexis N, 2002, CLIN IMMUNOL, V104, P217, DOI 10.1006/clim.2002.5236; Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Alexis NE, 2001, AM J RESP CRIT CARE, V164, P1964; Becker S, 2005, ENVIRON HEALTH PERSP, V113, P1032, DOI 10.1289/ehp.7996; Becker S, 2003, J TOXICOL ENV HEAL A, V66, P847, DOI 10.1080/15287390390156227; Becker S, 2003, EXP LUNG RES, V29, P29, DOI 10.1080/01902140390116535; Becker S, 2002, AM J RESP CELL MOL, V27, P611, DOI 10.1165/rcmb.4868; Becker Susanne, 2005, Toxicol Appl Pharmacol, V207, P269, DOI 10.1016/j.taap.2005.01.023; Bennett WD, 2002, J AEROSOL MED, V15, P179, DOI 10.1089/089426802320282301; Boehlecke B, 2003, J ALLERGY CLIN IMMUN, V112, P1241, DOI 10.1016/j.jaci.2003.08.052; BOVALLIUS A, 1978, APPL ENVIRON MICROB, V35, P1231; Conroy DM, 1997, MEM I OSWALDO CRUZ, V92, P183, DOI 10.1590/S0074-02761997000800024; Daniels AU, 2000, J BIOMED MATER RES, V49, P469, DOI 10.1002/(SICI)1097-4636(20000315)49:4<469::AID-JBM5>3.0.CO;2-A; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Eldridge MW, 2000, J TOXICOL ENV HEAL A, V61, P27, DOI 10.1080/00984100050116762; HEYDER J, 1986, J AEROSOL SCI, V17, P811, DOI 10.1016/0021-8502(86)90035-2; Ichinose T, 1998, TOXICOL SCI, V44, P70, DOI 10.1093/toxsci/44.1.70; ILOWITE JS, 1989, ARCH ENVIRON HEALTH, V44, P267; Imrich A, 2000, TOXICOL APPL PHARM, V167, P140, DOI 10.1006/taap.2000.9002; Kim CS, 1996, J APPL PHYSIOL, V81, P2203; Kitchens RL, 2000, CHEM IMMUNOL, V74, P61; Landmann R, 2000, MICROBES INFECT, V2, P295, DOI 10.1016/S1286-4579(00)00298-7; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 1998, AIR POLLUTION HLTH, P673; Roos-Engstrand E, 2005, EUR RESPIR J, V25, P797, DOI 10.1183/09031936.05.0007804; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096	32	103	105	1	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2006	117	6					1396	1403		10.1016/j.jaci.2006.02.030		8	Allergy; Immunology	Allergy; Immunology	053UX	WOS:000238332300029	16751003	
J	Eggleston, PA; Butz, A; Rand, C; Curtin-Brosnan, J; Kanchanaraksa, S; Swartz, L; Breysse, P; Buckley, T; Diette, G; Merriman, B; Krishnan, JA				Eggleston, PA; Butz, A; Rand, C; Curtin-Brosnan, J; Kanchanaraksa, S; Swartz, L; Breysse, P; Buckley, T; Diette, G; Merriman, B; Krishnan, JA			Home environmental intervention in inner-city asthma: a randomized controlled clinical trial	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							COCKROACH ALLERGEN; AIR-POLLUTION; CHILDREN; EXPOSURE; PARTICLES; MORBIDITY; ABATEMENT; SMOKING; FILTER	Background: Airborne pollutants and indoor allergens increase asthma morbidity in inner-city children; therefore, reducing exposure, if feasible, should improve asthma morbidity. Objective: To conduct a randomized controlled trial of methods to reduce environmental pollutant and allergen exposure in the homes of asthmatic children living in the inner city. Methods: After the completion of questionnaires, spirometry and allergen skin tests, home inspection, and measurement of home air pollutant and allergen levels, 100 asthmatic children aged 6 to 12 years were randomized to the treatment group (home-based education, cockroach and rodent extermination, mattress and pillow encasings, and high-efficiency particulate air cleaner) or to the control group (treated at the end of the I-year trial). Outcomes were evaluated by home evaluations at 6 and 12 months, clinic evaluation at 12 months, and multiple telephone interviews. Results: In the treatment group, 84% received cockroach extermination and 75% used the air cleaner. Levels of particulate matter 10 Am or smaller declined by LIP to 39% in the treatment group but increased in the control group (P < .001). Cockroach allergen levels decreased by 51% in the treatment group. Daytime symptoms increased in the control group and decreased in the treatment group (P = .04). Other measures of morbidity, such as spirometry findings, nighttime symptoms, and emergency department use, were not significantly changed. Conclusions: A tailored, multifaceted environmental treatment reduced airborne particulate matter and indoor allergen levels in inner-city homes, which, in turn, had a modest effect on morbidity.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Sch Med, Dept Internal Med, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Environm Hlth Sci, Baltimore, MD 21218 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21218 USA	Eggleston, PA (reprint author), Johns Hopkins Univ Hosp, Dept Pediat, 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	pegglest@jhmi.edu			NHLBI NIH HHS [HL058942]; NIEHS NIH HHS [ES09606]		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V112, P339, DOI 10.1067/mai.2003.1597; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; *CHILDH ASTHM MAN, 2000, NEW ENGLAND J MED, V0343; Custovic A, 1998, THORAX, V53, P63; DiazSanchez D, 1996, J ALLERGY CLIN IMMUN, V98, P114, DOI 10.1016/S0091-6749(96)70233-6; Evans R, 1999, J PEDIATR-US, V135, P332, DOI 10.1016/S0022-3476(99)70130-7; Francis H, 2003, CLIN EXP ALLERGY, V33, P101, DOI 10.1046/j.1365-2222.2003.01570.x; Gavett SH, 1999, AM J RESP CRIT CARE, V160, P1897; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; KOUTRAKIS P, 1993, ANAL CHEM, V65, P209, DOI 10.1021/ac00051a004; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mitchell H, 1997, PEDIATR PULM, V24, P237; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; PALMES ED, 1976, AM IND HYG ASSOC J, V37, P570, DOI 10.1080/0002889768507522; Peden DB, 1998, J ALLERGY CLIN IMMUN, V102, P32, DOI 10.1016/S0091-6749(98)70052-1; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Radloff L.S., 1997, APPL PSYCH MEAS, V3, P385; REISMAN RE, 1990, J ALLERGY CLIN IMMUN, V85, P1050, DOI 10.1016/0091-6749(90)90050-E; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; Strachan DP, 1998, THORAX, V53, P204; Swartz LJ, 2004, ENVIRON RES, V95, P156, DOI 10.1016/j.envres.2003.08.003; *US DEP HHS, 2003, US HHS POV GUID; *US EPA, 1997, FED REGISTER, V62, P130; VANDERHEIDE S, 1997, J ALLERGY CLIN IMMNO, V132, P1217; Wallace L, 1996, J AIR WASTE MANAGE, V46, P98; Wallace LA, 2003, ENVIRON HEALTH PERSP, V111, P1265, DOI 10.1289/ehp.6135; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60; Wood RA, 1998, AM J RESP CRIT CARE, V158, P115	35	103	106	1	17	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	DEC	2005	95	6					518	524				7	Allergy; Immunology	Allergy; Immunology	996KV	WOS:000234173700007	16400889	
J	Medina-Ramon, M; Zock, JP; Kogevinas, M; Sunyer, J; Torralba, Y; Borrell, A; Burgos, F; Anto, JM				Medina-Ramon, M; Zock, JP; Kogevinas, M; Sunyer, J; Torralba, Y; Borrell, A; Burgos, F; Anto, JM			Asthma, chronic bronchitis, and exposure to irritant agents in occupational domestic cleaning: a nested case-control study	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							RESPIRATORY-HEALTH-SURVEY; AIRWAYS DYSFUNCTION SYNDROME; WORK-RELATED ASTHMA; PERSISTENT ASTHMA; SYMPTOMS; PRODUCTS; GAS; RESPONSIVENESS; EXPERIENCE; DISEASE	Background: Women employed in domestic cleaning are at increased risk for symptoms of obstructive lung disease, but the agents responsible are unknown. Aims: To investigate common tasks and products in occupational domestic cleaning in relation to respiratory morbidity. Methods: Case-control study in domestic cleaning women nested within a large population based survey of women aged 30-65 years; 160 domestic cleaning women with asthma symptoms, chronic bronchitis symptoms, or both and 386 without a history of respiratory symptoms were identified. Detailed exposures were evaluated for 40 cases who reported still having symptoms at the recruitment interview, and 155 controls who reported not having symptoms. All tasks performed and products used when cleaning houses were determined in a face-to-face interview. Lung function, methacholine challenge, and serum IgE testing were performed. Personal exposure measurements of airborne chlorine and ammonia were performed in a subsample. Associations between asthma, chronic bronchitis, and cleaning exposures were evaluated using multiple logistic regression analysis. Results: Airborne chlorine (median level 0-0.4 ppm) and ammonia (0.6-6.4 ppm) were detectable during occupational domestic cleaning activities. Cases used bleach more frequently than controls; adjusted odds ratio (OR) for intermediate exposure was 3.3 (95% CI 0.9 to 11) and for high exposure 4.9 (1.5 to 15). Other independent associations included accidental inhalation of vapours and gases from cleaning agents and washing dishes. These associations were more pronounced for cases with asthma symptoms than for those with symptoms of chronic bronchitis, but were not related to sensitisation to common allergens. Conclusions: Asthma symptoms in domestic cleaning women are associated with exposure to bleach and possibly other irritant agents. The public health impact of the use of irritant cleaning products could be widespread since the use of these products is common both in the workplace and at home.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Univ Barcelona, Hosp Clin, Dept Med, Serv Pneumol & Allergia Resp, Barcelona, Spain	Anto, JM (reprint author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Dr Aiguader 80, E-08003 Barcelona, Spain.	jmanto@imim.es	Burgos, Felip/E-5734-2015; Kogevinas, Manolis/C-3918-2017; Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	Burgos, Felip/0000-0002-4938-4581; Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110			Alberts WM, 1996, CHEST, V109, P1618, DOI 10.1378/chest.109.6.1618; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Arif AA, 2003, AM J IND MED, V44, P368, DOI 10.1002/ajim.10291; Balmes JR, 2002, CLIN CHEST MED, V23, P727, DOI 10.1016/S0272-5231(02)00031-X; Becklake M, 1999, ASTHMA WORKPLACE, P27; Brooks SM, 1998, CHEST, V113, P42, DOI 10.1378/chest.113.1.42; BROOKS SM, 1985, CHEST, V88, P376, DOI 10.1378/chest.88.3.376; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; CHANYEUNG M, 1994, AM J RESP CRIT CARE, V149, P1676; Chinn S, 2004, THORAX, V59, P646, DOI 10.1136/thx.2004.021642; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; [Anonymous], 1997, THORAX S5, V52, pS1; DAS R, 1993, TOXICOL IND HEALTH, V9, P439; GAULTRIN D, 1999, ASTHMA WORKPLACE, P565; HATTIS RP, 1991, JAMA-J AM MED ASSOC, V266, P2529; Hendrick DJ, 1996, THORAX, V51, P947, DOI 10.1136/thx.51.9.947; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Karjalainen A, 2001, AM J RESP CRIT CARE, V164, P565; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; KIPEN HM, 1994, J OCCUP ENVIRON MED, V36, P1133, DOI 10.1097/00043764-199410000-00017; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Kruger D, 1997, RISK ASSESSMENT PREV; Medina-Ramon M, 2003, THORAX, V58, P950, DOI 10.1136/thorax.58.11.950; NG TP, 1994, AM J IND MED, V25, P709, DOI 10.1002/ajim.4700250510; *NIOSH, 2001, NIOSH PUBL; Pascuzzi TA, 1998, MIL MED, V163, P102; Quirce S, 2000, J ASTHMA, V37, P267, DOI 10.3109/02770900009055449; RACIOPPI F, 1994, FOOD CHEM TOXICOL, V32, P845, DOI 10.1016/0278-6915(94)90162-7; REILLY MJ, 1995, ARCH ENVIRON HEALTH, V50, P26; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; Rosenman KD, 2003, J OCCUP ENVIRON MED, V45, P556, DOI 10.1097/01.jom.0000058347.05741.f9; Strachan DP, 1996, BRIT MED J, V312, P1195; Sunyer J, 1996, AM J RESP CRIT CARE, V153, P1273; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; Zock JP, 2002, EUR RESPIR J, V20, P679, DOI 10.1183/09031936.02.00279702; Zock JP, 2001, SCAND J WORK ENV HEA, V27, P76	36	103	105	0	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	SEP	2005	62	9					598	606		10.1136/oem.2004.017640		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	956JO	WOS:000231296200004	16109815	
J	Bornehag, CG; Sundell, J; Hagerhed-Engman, L; Sigsggard, T; Janson, S; Aberg, N				Bornehag, CG; Sundell, J; Hagerhed-Engman, L; Sigsggard, T; Janson, S; Aberg, N		DBH Study Grp	'Dampness' at home and its association with airway, nose, and skin symptoms among 10,851 preschool children in Sweden: a cross-sectional study	INDOOR AIR			English	Article; Proceedings Paper	9th International Conference on Indoor Air Quality and Climate (Indoor Air 2002)	2002	Monterey, CA	Swedish Assoc Asthma & Allergy		dampness; asthma; rhinitis; eczema; children	CHILDHOOD ASTHMA; BRONCHIAL OBSTRUCTION; SUBTROPICAL AREA; YOUNG-CHILDREN; HEALTH; PREVALENCE; BUILDINGS; EXPOSURE; BAMSE	There is convincing epidemiological evidence that 'dampness' in buildings is associated with respiratory effects. In order to identify health-relevant exposures in buildings with 'dampness', the study 'Dampness in Buildings and Health' (DBH) was initiated. In the first step of the study, cross-sectional data on home characteristics including 'dampness' problems, and symptoms in airway, nose, and skin among 10,851 children (1-6 years), were collected by means of a questionnaire to the parents. The prevalence of wheezing during the last 12 months was 18.9% and doctor-diagnosed asthma 5.4%. Rhinitis during the last 12 months was reported for 11.1% of the children and eczema during the last 12 months 18.7%. Gender, allergic symptoms among parents, and age of the child were associated with symptoms. Water leakage was reported in 17.8% of the buildings, condensation on windows in 14.3%, and detached flooring materials in 8.3%. Visible mould or damp spots were reported in only 1.5% of the buildings. The four 'dampness' indices were associated to higher prevalence of symptoms in both crude and adjusted analysis. Furthermore, it was found that the combination of water leakage in the home and PVC as flooring material in the child's or parent's bedroom was associated to higher prevalence of symptoms among children. However, the interpretation of this finding is unclear. The combination of water leakage and PVC may be a proxy, for example, reconstruction because of water damages.	Karlstad Univ, S-65188 Karlstad, Sweden; Swedish Natl & Testing Res Inst, Boras, Sweden; Tech Univ Denmark, Int Ctr Indoor Environm & Energy, DK-2800 Lyngby, Denmark; Aarhus Univ, Inst Environm & Occupat Med, Aarhus, Denmark; Sahlgrenska Univ Hosp, Gothenburg, Sweden	Bornehag, CG (reprint author), Karlstad Univ, S-65188 Karlstad, Sweden.	carl-gustaf.bornehag@kau.se	Sundell, Jan/B-2857-2012				Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, INDOOR AIR, V14, P243, DOI 10.1111/j.1600-0668.2004.00240.x; Emenius G, 2004, ACTA PAEDIATR, V93, P899, DOI 10.1080/08035250410025582; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; Haverinen U, 2001, INDOOR AIR, V11, P192, DOI 10.1034/j.1600-0668.2001.011003192.x; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; Nicolai T, 1998, THORAX, V53, P1035; PEARCE N, 1993, EUR RESPIR J, V6, P1455; Yang CY, 1998, CHEST, V114, P393, DOI 10.1378/chest.114.2.393; Yang CY, 1998, PEDIATR PULM, V26, P120, DOI 10.1002/(SICI)1099-0496(199808)26:2<120::AID-PPUL8>3.0.CO;2-Q	13	103	114	2	20	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	AUG	2005	15			10			48	55		10.1111/j.1600-0668.2005.00306.x		8	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	930BJ	WOS:000229390500007	15926944	
J	Skoet, R; Olsen, J; Mathiesen, B; Iversen, L; Johansen, JD; Agner, T				Skoet, R; Olsen, J; Mathiesen, B; Iversen, L; Johansen, JD; Agner, T			A survey of occupational hand eczema in Denmark	CONTACT DERMATITIS			English	Article						allergic contact dermatitis; atopic dermatitis; contact urticaria; irritant contact dermatitis; occupational hand eczema; prevention; socio-economic impact	SKIN-DISEASE; CONTACT-DERMATITIS; RISK-FACTORS; ALLERGY; POPULATION; PROGNOSIS; WORKERS; NICKEL; DERMATOSES; PREVALENCE	Occupational hand eczema (OHE) is the most frequently recognized work-related disease in Denmark and the annual cost to society is high. Understanding of the epidemiology of OHE is essential to be able to give appropriate recommendations for its prevention. The study comprised 758 persons, 490 females and 268 males with recognized OHE in the period October 2001 to November 2002. Data were obtained prospectively from the National Board of Industrial Industry Registry and from a self-administered questionnaire (response rate, 82%). The most frequently recognized diagnosis was irritant contact dermatitis (ICD), mainly caused by wet occupations. The proportion of occupational ICD was equal for males and females, 59.7% and 63.1%, respectively. The estimated rates of OHE were high for bakers, hairdressers and dental surgery assistants, and a high proportion of apprentices were found among hairdressers. The prevalence of atopic dermatitis was low (16.4%) compared to previous studies among hand eczema patients. The prevalence of occupational allergic contact dermatitis in the study population was substantially higher among males than females, and the most frequent causes among males were allergy to chromium (leather exposure), rubber additives (gloves) and nickel due to exposure from work tools and metalworking industry.	Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Copenhagen, Denmark; Danish Epidemiol Sci Ctr, Copenhagen, Denmark; Danish Epidemiol Sci Ctr, Aarhus, Denmark; Natl Board Ind Injuries, Copenhagen, Denmark; Ribe Cty, Ribe, Denmark; Univ Copenhagen, Gentofte Hosp, Natl Allergy Res Ctr, Copenhagen, Denmark	Skoet, R (reprint author), Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Niels Andersensvej 65, DK-2900 Hellerup, Denmark.	risk@dadlnet.dk					Adisesh A, 2002, CONTACT DERMATITIS, V46, P273, DOI 10.1034/j.1600-0536.2002.460505.x; Agner T, 2002, CONTACT DERMATITIS, V47, P253, DOI 10.1034/j.1600-0536.2002.470501.x; AVNSTORP C, 1992, ACTA DERM-VENER    S, P179; Bock M, 2003, BRIT J DERMATOL, V149, P1165, DOI 10.1111/j.1365-2133.2003.05748.x; Bryld LE, 2003, BRIT J DERMATOL, V149, P1214, DOI 10.1111/j.1365-2133.2003.05678.x; COENRAADS PJ, 1984, CLIN EXP DERMATOL, V9, P149, DOI 10.1111/j.1365-2230.1984.tb00776.x; *DAN WORK ENV SERV, 1983, 661 DAN WORK ENV SER; Dickel H, 2003, J INVEST DERMATOL, V121, P37, DOI 10.1046/j.1523-1747.2003.12323.x; Dickel H, 2002, CONTACT DERMATITIS, V46, P197, DOI 10.1034/j.1600-0536.2002.460403.x; Dickel H, 2002, INT ARCH OCC ENV HEA, V75, P423, DOI 10.1007/s00420-002-0328-2; Diepgen TL, 1999, INT ARCH OCC ENV HEA, V72, P496, DOI 10.1007/s004200050407; Douglas E, 1999, OCCUP MED-OXFORD, V49, P85, DOI 10.1093/occmed/49.2.85; Halkier-Sorensen L, 1996, Contact Dermatitis, V35, P1; Kalimo K, 1997, CONTACT DERMATITIS, V37, P121, DOI 10.1111/j.1600-0536.1997.tb00316.x; Liden C, 1998, CONTACT DERMATITIS, V39, P127, DOI 10.1111/j.1600-0536.1998.tb05861.x; Liden C., 2001, TXB CONTACT DERMATIT, P933; Meding B, 2000, CONTACT DERMATITIS, V43, P65, DOI 10.1034/j.1600-0536.2000.043002065.x; MEDING B, 1990, CONTACT DERMATITIS, V22, P13, DOI 10.1111/j.1600-0536.1990.tb01499.x; NETHERCOTT JR, 1994, J AM ACAD DERMATOL, V30, P569; Nielsen NH, 2002, CONTACT DERMATITIS, V47, P71, DOI 10.1034/j.1600-0536.2002.470203.x; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Papa G, 2000, INT J IMMUNOPATH PH, V13, P43; ROSEN RH, 1993, CONTACT DERMATITIS, V29, P88, DOI 10.1111/j.1600-0536.1993.tb03489.x; TAYLOR JS, 1988, ARCH DERMATOL, V124, P1557, DOI 10.1001/archderm.124.10.1557; Uter W, 1998, INT ARCH OCC ENV HEA, V71, P487, DOI 10.1007/s004200050310; Uter W, 2003, CONTACT DERMATITIS, V48, P33, DOI 10.1034/j.1600-0536.46.s4.29_102.x; VANDERWALLE HB, 1994, CONTACT DERMATITIS, V30, P265; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Zachariae COC, 1996, CONTACT DERMATITIS, V35, P83, DOI 10.1111/j.1600-0536.1996.tb02295.x; 1995, PRACTICAL GUIDE THEI	30	103	109	2	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	OCT	2004	51	4					159	166		10.1111/j.0105-1873.2004.00423.x		8	Allergy; Dermatology	Allergy; Dermatology	864PJ	WOS:000224645100001	15500664	
J	Rundell, KW; Anderson, SD; Spiering, BA; Judelson, DA				Rundell, KW; Anderson, SD; Spiering, BA; Judelson, DA			Field exercise vs laboratory eucapnic voluntary hyperventilation to identify airway hyperresponsiveness in elite cold weather athletes	CHEST			English	Article						airway hyperresponsiveness; dry air; exercise; exercise-induced bronchoconstriction; eucapnic volontary hyperpnea	WORKING PARTY STANDARDIZATION; EUROPEAN RESPIRATORY SOCIETY; THERMALLY-INDUCED ASTHMA; REFRACTORY PERIOD; BRONCHIAL RESPONSIVENESS; INDUCED BRONCHOSPASM; OFFICIAL STATEMENT; HYPERTONIC SALINE; CHALLENGE; CHILDREN	Study objective: For the 2002 Winter Olympic Games, athletes were required to submit objective evidence of asthma or exercise-induced bronchoconstriction (EIB) for approval to inhale a beta(2)-agonist. Eucapnic voluntary hyperventilation (EVH) was recommended as a laboratory challenge that would identify airway hyperresponsiveness (AHR) consistent with EIB. The objective was to compare the change in FEV1 provoked by EVH with that provoked by exercise in cold weather athletes. Design: Spirometry was measured before and for 15 min after challenges. The two challenges were performed in random order at least 24 h apart. Setting: EVH was performed in the laboratory at 19degreesC, and exercise took place in the field in the cold (2degreesC, 45% relative humidity). Participants: Thirty-eight athletes (25 female subjects; median age, 16 years). Interventions: For the EVH, athletes inhaled dry air containing 5% carbon dioxide for 6 min at a target ventilation equivalent to 30 times baseline FEV1. Exercise was performed by cross-country skiing, ice skating, or running for 6 to 8 min. Measurements and results: AHR consistent with EIB was defined as greater than or equal to10% fall in FEV1 from baseline after challenge. Eleven athletes were exercise positive (EX+) [FEV1 fall, 20.5 +/- 7.3%], and 17 athletes were EVH positive (FEV1 fall, 14.5 +/- 4.5%) [mean +/- SD]. Of 19 subjects with AHR, 58% were identified by exercise and 89% were identified by EVH. EVH identified 9 of 11 subjects who were EX+ and a further 8 subjects with potential for EIB. The average ventilation during EVH was 28 times FEV1. Conclusion: Performing EVH for 6 min in the laboratory had a greater chance of identifying AHR in these athletes compared with 6 to 8 min of field exercise in the cold. The EVH test will be useful to evaluate elite summer sports athletes whose widely different forms of exercise provide an "equipment" challenge to any laboratory.	Marywood Univ, Human Performance Lab, Scranton, PA 18509 USA; US Olymp Comm, Lake Placid, NY USA; Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia	Rundell, KW (reprint author), Marywood Univ, Human Performance Lab, 2300 Adams Ave, Scranton, PA 18509 USA.	rundell@marywood.edu		Anderson, Sandra/0000-0002-6308-8770			Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; Anderson SD, 2001, MED SCI SPORT EXER, V33, P893, DOI 10.1097/00005768-200106000-00007; Anderson SD, 2001, BRIT J SPORT MED, V35, P344, DOI 10.1136/bjsm.35.5.344; Anderson SD, 1997, ALLERGIC RESP DIS SP, P87; Anderson SD, 1999, EXERCISE INDUCED AST, P77; Anderson S, 2003, J ALLERGY CLIN IMMUN, V111, P44; ARGYROS GJ, 1995, CHEST, V108, P419, DOI 10.1378/chest.108.2.419; Argyros GJ, 1996, CHEST, V109, P1520, DOI 10.1378/chest.109.6.1520; BACKER V, 1991, J ALLERGY CLIN IMMUN, V88, P68, DOI 10.1016/0091-6749(91)90302-5; BARYISHAY E, 1983, AM REV RESPIR DIS, V127, P572; Brannan JD, 1998, AM J RESP CRIT CARE, V158, P1120; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; CUSTOVIC A, 1994, CHEST, V105, P1127, DOI 10.1378/chest.105.4.1127; Folgering H, 1997, EUR RESP MON, V6, P51; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; HABY MM, 1995, EUR RESPIR J, V8, P729; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; HURWITZ KM, 1995, CHEST, V108, P1240, DOI 10.1378/chest.108.5.1240; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; McFadden ER, 1999, AM J RESP CRIT CARE, V160, P221; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; OBYRNE PM, 1982, AM REV RESPIR DIS, V125, P281; QUANJER PH, 1993, EUR RESPIR J, V6, P5; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; ROSENTHAL RR, 1990, AM REV RESPIR DIS, V141, P368; Rundell KW, 2000, MED SCI SPORT EXER, V32, P309, DOI 10.1097/00005768-200002000-00010; Rundell KW, 2003, MED SCI SPORT EXER, V35, P18, DOI 10.1249/01.MSS.0000043285.21875.E4; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; SILVERMAN M, 1972, ARCH DIS CHILD, V47, P882; SMITH CM, 1990, EUR RESPIR J, V3, P144; Spiering B. A., 2002, Medicine & Science in Sports & Exercise, V34, pS52, DOI 10.1097/00005768-200205001-00288; STERK PJ, 1993, EUR RESPIR J, V6, P53, DOI 10.1183/09041950.053s1693; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; Weiler JM, 2000, J ALLERGY CLIN IMMUN, V106, P267, DOI 10.1067/mai.2000.108605; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003	36	103	104	0	6	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAR	2004	125	3					909	915		10.1378/chest.125.3.909		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	802GS	WOS:000220152600019	15006949	
J	Gelfand, EW				Gelfand, Erwin W.			Inflammatory mediators in allergic rhinitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic rhinitis; inflammation; inflammatory mediators; asthma; chronotherapy; chronobiology; unified airway	ANTIGEN CHALLENGE; NASAL SECRETIONS; MAST-CELLS; ASTHMA; EXPOSURE; EXPRESSION; EOSINOPHILS; IMMUNOLOGY; HISTAMINE; AIRWAYS	Allergic rhinitis (AR) is part of a systemic disease complex. There is a close relationship between AR and asthma, which has led to the "one airway, one disease" concept. Both conditions share common immunopathology and pathophysiology. In patients with AR, allergen-triggered early and late responses are mediated by a series of inflammatory cells. Within minutes of contact with allergen, IgE-sensitized mast cells degranulate, releasing both preformed and newly synthesized mediators. Immunologic processes in both nasal and bronchial tissue involve T(H)2 lymphocytes and eosinophils. Eosinophils are the predominant cell in the chronic inflammatory process characteristic of the late-phase allergic response. Eosinophils release an array of proinflammatory mediators, including cysteinyl leukotrienes, cationic proteins, eosinophil peroxidase, and major basic protein, and might serve as a major source of IL-3, IL-5, GM-CSF, and IL-13. Neuropeptides also appear to contribute to the pathophysiology of AR symptoms. Both AR and asthma exhibit marked day-night variation in symptom severity. Acknowledging both the chronobiology of AR and circadian rhythm-dependent attributes of antiallergy medications might enhance the beneficial effects of allergy therapies. (J Allergy Clin Immunol 2004; 114: S135-8.)		Gelfand, EW (reprint author), Care of Sweetman L, Amer Acad Allergy Asthma & Immunol, 611 E Wells St, Milwaukee, WI 53202 USA.						ADAMS PF, 1999, CURRENT ESTIMATES NA, P1; BASCOM R, 1988, AM REV RESPIR DIS, V138, P406; BINDER E, 1982, ALLERGY, V37, P389, DOI 10.1111/j.1398-9995.1982.tb02317.x; BISGAARD H, 1986, CLIN ALLERGY, V16, P289, DOI 10.1111/j.1365-2222.1986.tb01960.x; Bjornsdottir US, 1999, ALLERGY, V54, P55, DOI 10.1111/j.1398-9995.1999.tb04389.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Busse WW, 2001, NEW ENGL J MED, V344, P350; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Fregonese L, 2002, CLIN EXP ALLERGY, V32, P745, DOI 10.1046/j.1365-2222.2002.01384.x; Gelfaned EW, 2002, AM J MED, V113, p2S; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; Howarth PH, 1997, ALLERGY, V52, P12; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; Kay AB, 2001, NEW ENGL J MED, V344, P30; Larsen WJ, 2001, HUMAN EMBRYOLOGY, p[351, 465]; LEDFORD DK, 1998, J RESP DIS, V19, P576; MA X, 2000, AM J CRIT CARE MED, V161, P325; MARTIN RJ, 1993, NOCTURNAL ASTHMA MEC; MIADONNA A, 1987, AM REV RESPIR DIS, V136, P357; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; OKUDA M, 1988, ANN ALLERGY, V60, P537; PIPKORN U, 1988, J ALLERGY CLIN IMMUN, V82, P1046, DOI 10.1016/0091-6749(88)90143-1; REINBERG A, 1988, J ALLERGY CLIN IMMUN, V81, P51, DOI 10.1016/0091-6749(88)90220-5; Reinberg A, 1989, CHRONOPHARMACOLOGY C, P115; REINBERG A, 1985, ANN REV CHRONOPHARMA, V3, P441; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; SMOLENSKY MH, 1995, J ALLERGY CLIN IMMUN, V95, P1087; Spada CS, 1997, ADV EXP MED BIOL, V400, P699; Togias A, 2003, J ALLERGY CLIN IMMUN, V111, P1171, DOI 10.1067/mai.2003.1592; Togias A, 2000, J ALLERGY CLIN IMMUN, V105, pS599, DOI 10.1067/mai.2000.106885; Trousseau A, 1865, CLIN MED HOTEL DIEU, V2, P373; VIEGAS M, 1987, BRIT MED J, V294, P414; WANG DY, 1995, INT ARCH ALLERGY IMM, V106, P278; WANG DY, 1994, ACTA OTO-LARYNGOL, V114, P552, DOI 10.3109/00016489409126103; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; WRIGHT AL, 1994, PEDIATRICS, V94, P895	39	103	108	1	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.		2004	114	5		S			S135	S138		10.1016/j.jaci.2004.08.043		4	Allergy; Immunology	Allergy; Immunology	V17HV	WOS:000207929200002	15536444	
J	Silverman, RA; Boudreaux, ED; Woodruff, PG; Clark, S; Camargo, CA				Silverman, RA; Boudreaux, ED; Woodruff, PG; Clark, S; Camargo, CA		Multicenter Airway Res Collaborati	Cigarette smoking among asthmatic adults presenting to 64 emergency departments	CHEST			English	Article						acute disease; asthma; emergency medicine; smoking	LUNG-FUNCTION; ALLERGIC RHINITIS; PASSIVE SMOKING; BRONCHIAL HYPERRESPONSIVENESS; PULMONARY-FUNCTION; MATERNAL SMOKING; CHILDREN; SYMPTOMS; PREVALENCE; EXPOSURE	Study objectives: The emergency department (ED) is an important focal point for asthmatic individuals with uncontrolled illness. Anecdotally, many adults presenting to the ED with acute asthma are active cigarette smokers. The present study determined the prevalence of cigarette smoking among adults presenting to the ED with acute asthma and identified the factors associated with current smoking status. Design: A prospective cohort study conducted as part of the Multicenter Airway Research Collaboration. Patients: A structured interview was performed in 1,847 patients, ages 18 to 54 years, who presented to the ED with acute asthma. Setting: Sixty-four EDs in 21 US states and 4 Canadian provinces. Results: Thirty-five percent of the enrolled asthmatic patients were current smokers with a median of 10 pack-years (interduartile range, 4 to 20 pack-years), while 23% were former smokers, and 42% were never-smokers. Current smokers comprised 33% of asthmatic patients aged 18 to 29 years, 40% for ages 30 to 39 years, and 33% for ages 40 to 54 (p < 0.001). In a multivariate analysis, the factors independently associated with current smoking status (p < 0.05) were as follows: age 30 to 39 years; white race/ethnicity; non-high school graduate; lower household income; lack of private insurance; no recent inhaled steroid usage; and no history of systemic steroid usage. Although 50% of current smokers admitted that smoking worsens their asthma symptoms, only 4% stated that smoking was responsible for their current exacerbation. Conclusions: Although cigarette smoke is generally recognized as a respiratory irritant, cigarette smoking is common among adults presenting to the ED with acute asthma. The ED visit may provide an opportunity for patients to be targeted for smoking cessation efforts.	Long Isl Jewish Med Ctr, Dept Emergency Med, New Hyde Pk, NY 11040 USA; Earl K Long Med Ctr, Dept Emergency Med, Baton Rouge, LA USA; Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA USA; Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA USA	Silverman, RA (reprint author), Long Isl Jewish Med Ctr, Dept Emergency Med, 270-05 76th Ave, New Hyde Pk, NY 11040 USA.			Boudreaux, Edwin/0000-0002-3223-6371	NHLBI NIH HHS [HL-03533, HL-63253]		ABULHOSN RS, 1987, AM REV RESPIR DIS, V135, P567; ANDERSON DO, 1962, NEW ENGL J MED, V267, P787, DOI 10.1056/NEJM196210182671601; ASHLEY F, 1975, ANN INTERN MED, V82, P739; Barkley R., 1997, ADHD REPORT, V5, P1; BECK GJ, 1981, AM REV RESPIR DIS, V123, P149; Belousova EG, 1997, CHEST, V112, P1539, DOI 10.1378/chest.112.6.1539; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BURCHFIEL CM, 1995, AM J RESP CRIT CARE, V151, P1778; BURROWS B, 1977, AM REV RESPIR DIS, V115, P195; [Anonymous], 1997, SOURC ZIP COD DEM; Cassino C, 1999, AM J RESP CRIT CARE, V159, P1773; Centers for Disease C Prevention, 1996, MMWR-MORBID MORTAL W, V45, P962; Centers for Disease Control and Prevention, 1998, BEH RISK FACT SURV S; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Eisner MD, 2000, AM J PUBLIC HEALTH, V90, P1307, DOI 10.2105/AJPH.90.8.1307; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; Giovino Gary A., 1994, Morbidity and Mortality Weekly Report, V43, P1; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; *HLTH CAN, 1996, FED CENS DAT STAT CA; LARSSON L, 1995, THORAX, V50, P260, DOI 10.1136/thx.50.3.260; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; LOWENSTEIN SR, 1995, ACAD EMERG MED, V2, P165, DOI 10.1111/j.1553-2712.1995.tb03189.x; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; McCammond JP, 2000, INT J ALGEBR COMPUT, V10, P1, DOI 10.1142/S0218196700000029; MCCREA KA, 1994, AM J RESP CRIT CARE, V150, P696; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721; *METR INS CO, 1992, STAT B METR INS CO, V73, P12; MURRAY AB, 1986, J ALLERGY CLIN IMMUN, V77, P575, DOI 10.1016/0091-6749(86)90348-9; Oryszczyn MP, 2000, AM J RESP CRIT CARE, V161, P1241; PETERS JM, 1967, AM REV RESPIR DIS, V95, P774; Plaschke P, 1999, J ALLERGY CLIN IMMUN, V104, P58, DOI 10.1016/S0091-6749(99)70114-4; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; PROCHASKA JO, 1994, HEALTH PSYCHOL, V13, P39, DOI 10.1037/0278-6133.13.1.39; Rasmussen F, 2000, CHEST, V117, P1330, DOI 10.1378/chest.117.5.1330; Richman PB, 1999, ACAD EMERG MED, V6, P807, DOI 10.1111/j.1553-2712.1999.tb01211.x; SANDVIK L, 1995, BRIT MED J, V311, P715; SEELEY JE, 1971, SCIENCE, V172, P41; SHEPHARD RJ, 1979, ENVIRON RES, V20, P392, DOI 10.1016/0013-9351(79)90015-X; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P372, DOI 10.2105/AJPH.90.3.372; Siroux V, 2000, EUR RESPIR J, V15, P470, DOI 10.1034/j.1399-3003.2000.15.08.x; SOYSETH V, 1995, CHEST, V107, P389, DOI 10.1378/chest.107.2.389; STANKUS RP, 1988, J ALLERGY CLIN IMMUN, V82, P331, DOI 10.1016/0091-6749(88)90003-6; Strachan DP, 1996, BRIT MED J, V312, P1195; Sunyer J., 1997, European Respiratory Journal, V10, P2490, DOI 10.1183/09031936.97.10112490; TAGER IB, 1976, AM REV RESPIR DIS, V113, P619; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; U. S. Department of Health and Human Services, 1984, HLTH CONS SMOK CHRON; VESTERINEN E, 1988, THORAX, V43, P534, DOI 10.1136/thx.43.7.534; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; Wei HG, 2000, ACAD EMERG MED, V7, P710, DOI 10.1111/j.1553-2712.2000.tb02052.x; Weiss KB, 1992, CHEST, V101, P362; WEITZMAN M, 1990, PEDIATRICS, V85, P505; XU X, 1994, EUR RESPIR J, V7, P477, DOI 10.1183/09031936.94.07030477; MULTICENTER AIRWAY R	59	103	111	2	3	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2003	123	5					1472	1479		10.1378/chest.123.5.1472		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	676VJ	WOS:000182773000027	12740263	
J	Jaakkola, MS; Nordman, H; Piipari, R; Uitti, J; Laitinen, J; Karjalainen, A; Hahtola, P; Jaakkola, JJK				Jaakkola, MS; Nordman, H; Piipari, R; Uitti, J; Laitinen, J; Karjalainen, A; Hahtola, P; Jaakkola, JJK			Indoor dampness and molds and development of adult-onset asthma: A population-based incident case-control study	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; case-control study; molds; occupational exposure; population-based	DAY-CARE-CENTERS; RESPIRATORY SYMPTOMS; HOME DAMPNESS; HEALTH; CHILDREN; EXPOSURE; INFLAMMATION; ASSOCIATIONS; BUILDINGS; DISEASE	Previous cross-sectional and prevalent case-control studies have suggested increased risk of asthma in adults related to dampness problems and molds in homes. We conducted a population-based incident case-control study to assess the effects of indoor dampness problems and molds at work and at home on development of asthma in adults. We recruited systematically all new cases of asthma during a 2.5-year study period (1997-2000) and randomly selected controls from a source population consisting of adults 21-63 years old living in the Pirkanmaa Hospital district, South Finland. The clinically diagnosed case series consisted of 521 adults with newly diagnosed asthma and the control series of 932 controls, after we excluded 76 (7.5%) controls with a history of asthma. In logistic regression analysis adjusting for confounders, the risk of asthma was related to the presence of visible mold and/or mold odor in the workplace (odds ratio, 1.54; 95% confidence interval, 1.01-2.32) but not to water damage or damp stains alone. We estimated the fraction of asthma attributable to workplace mold exposure to be 35.1% (95% confidence interval, 1.0-56.9%) among the exposed. Present results provide new evidence of the relation between workplace exposure to indoor molds and adult-onset asthma.	Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland; Finnish Inst Occupat Hlth, Tampere, Finland; Tampere Univ Hosp, Dept Clin Physiol, Tampere, Finland; Tampere Univ Hosp, Dept Pulm Med, Tampere, Finland; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, Helsinki, Finland; Nordic Sch Publ Hlth, Environm Hlth Program, Gothenburg, Sweden	Jaakkola, JJK (reprint author), Finnish Inst Occupat Hlth, FIN-00250 Helsinki, Finland.		Jaakkola, Jouni/G-4314-2012				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Bornehag CG, 2001, INDOOR AIR, V11, P72; BRUNEKREEF B, 1992, ALLERGY, V47, P498, DOI 10.1111/j.1398-9995.1992.tb00672.x; BRUNEKREEF B, 1992, SCI TOTAL ENVIRON, V127, P79, DOI 10.1016/0048-9697(92)90471-4; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; *COMM NATL ASTHM P, 1994, 16 MIN SOC AFF HLTH; DALES RE, 1991, AM REV RESPIR DIS, V143, P505; DALES RE, 1991, AM J EPIDEMIOL, V134, P196; Greenland S., 1998, MODERN EPIDEMIOLOGY, P295; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; HYNDMAN SJ, 1990, SOC SCI MED, V30, P131, DOI 10.1016/0277-9536(90)90336-Q; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223; Johanning E, 1999, ENVIRON HEALTH PERSP, V107, P489; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P68; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325; Nafstad P, 1998, AM J RESP CRIT CARE, V157, P410; [Anonymous], 1998, INDOOR AIR S; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; PLATT SD, 1989, BRIT MED J, V298, P1673; RUOTSALAINEN R, 1995, INT ARCH OCC ENV HEA, V66, P369, DOI 10.1007/BF00383142; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; Thorn J, 1998, AM J RESP CRIT CARE, V157, P1798; Thorn J, 2001, ALLERGY, V56, P287, DOI 10.1034/j.1398-9995.2001.00805.x; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P58; Williamson IJ, 1997, THORAX, V52, P229	32	103	104	1	4	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAY	2002	110	5					543	547				5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	552NL	WOS:000175626400033	12003761	
J	Otterbein, LE				Otterbein, LE			Carbon monoxide: Innovative anti-inflammatory properties of an age-old gas molecule	ANTIOXIDANTS & REDOX SIGNALING			English	Review							TUMOR-NECROSIS-FACTOR; HEME OXYGENASE-1 SUPPRESSES; OXIDATIVE STRESS; LUNG INJURY; EXHALED AIR; PROVIDES PROTECTION; PHYSIOLOGICAL IMPORTANCE; IMMUNOLOGICAL RESPONSE; ACTIVATED MACROPHAGES; FACTOR BIOSYNTHESIS	Observations of the effects of carbon monoxide (CO) on mammalian systems have been known for thousands of years. To be sure, CO is deadly under certain conditions and concentrations, but perhaps as the data presented here will make clear, it also possesses other diverse functional and immunomodulatory properties. This review, together with the other reviews in this issue, will detail that over the past three decades, fundamental functional role(s) for this gas molecule are beginning to emerge. This review outlines that at low concentrations, exogenously administered CO is a molecule involved in the regulation of the inflammatory response in a variety of disease models. CO has been shown to modulate such cellular functions as cytokine production, cell proliferation and apoptosis, protecting the lungs and hearts of rodents from such stressors as endotoxin, ischemia/reperfusion injury, cardiac xenograft rejection, and asthma. Although the mechanism by which this simple diatomic gas provides this protection remains obscure, the conclusions are the same: CO at low concentrations, concentrations that are well below those that would otherwise create toxic effects, is proving beneficial in models of acute injury. CO, akin to nitric oxide, is proving to be an extraordinary signaling molecule generated by the cell that is vital in the regulation of cellular homeostasis.	Univ Pittsburgh, Montefiore Univ Hosp, Sch Med, Div Pulm & Crit Care Med, Pittsburgh, PA 15213 USA	Univ Pittsburgh, Montefiore Univ Hosp, Sch Med, Div Pulm & Crit Care Med, 3459 5th Ave,Room 628 NW, Pittsburgh, PA 15213 USA.	lotterbein@usa.net					Antuni JD, 2000, THORAX, V55, P138, DOI 10.1136/thorax.55.2.138; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; BENIGNUS VA, 1996, CARBON MONOXIDE, P211; BERNARD C, 1858, CR HEBD ACAD SCI, V48, P393; Bernard C., 1857, LECONS EFFECTS SUBST; BEUTLER B, 1986, SCIENCE, V232, P977, DOI 10.1126/science.3754653; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Chapman JT, 2001, AM J PHYSIOL-LUNG C, V281, pL209; CHOI AMK, 1995, AM J RESP CELL MOL, V13, P74; Christian JL, 1999, BIOESSAYS, V21, P382, DOI 10.1002/(SICI)1521-1878(199905)21:5<382::AID-BIES5>3.0.CO;2-V; CLERCH LB, 1993, J CLIN INVEST, V91, P499, DOI 10.1172/JCI116228; COBURN RF, 1967, J CLIN INVEST, V46, P346, DOI 10.1172/JCI105536; COBURN RF, 1979, PREV MED, V8, P310, DOI 10.1016/0091-7435(79)90008-2; De Saint-Martin L., 1898, CR HEBD ACAD SCI, V126, P1036; Downard PJ, 1997, J SURG RES, V71, P7, DOI 10.1006/jsre.1997.5135; Drabkin D. L., 1943, AM J MED SCI, V205, P755; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; Foey AD, 1998, J IMMUNOL, V160, P920; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Gains SP, 1999, J VASC RES, V36, P114, DOI 10.1159/000025633; GEPPERT TD, 1994, MOL MED, V1, P93; GOLDBAUM LR, 1977, AVIAT SPACE ENVIR MD, V48, P969; Grehant N., 1894, GAS SANG; Hack CE, 1997, ADV IMMUNOL, V66, P101, DOI 10.1016/S0065-2776(08)60597-0; Haldane JBS, 1927, BIOCHEM J, V21, P1068; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; HAN JH, 1991, BIOCHIM BIOPHYS ACTA, V1090, P22, DOI 10.1016/0167-4781(91)90032-H; Hartsfield CL, 1997, AM J PHYSIOL-LUNG C, V273, pL980; Hasko G, 1998, EUR J IMMUNOL, V28, P468, DOI 10.1002/(SICI)1521-4141(199802)28:02<468::AID-IMMU468>3.0.CO;2-Z; Hayashi S, 1999, CIRC RES, V85, P663; Henningsson R, 1999, DIABETES, V48, P66, DOI 10.2337/diabetes.48.1.66; Hill CS, 1996, CELL SIGNAL, V8, P533, DOI 10.1016/S0898-6568(96)00122-2; HOROWITZ AL, 1987, RADIOLOGY, V162, P787; Horvath I, 1999, CLIN EXP ALLERGY, V29, P1276; Horvath I, 1998, THORAX, V53, P867; Hsu MF, 1997, FREE RADICAL BIO MED, V23, P1035, DOI 10.1016/S0891-5849(97)00132-9; Johnson RA, 1999, BRAZ J MED BIOL RES, V32, P1; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182; KHARITONOV VG, 1995, P NATL ACAD SCI USA, V92, P2568, DOI 10.1073/pnas.92.7.2568; Lapresle J, 1967, Prog Brain Res, V24, P31; Lin Y, 1997, J IMMUNOL, V158, P5658; Lin Y, 1997, TRANSPLANTATION, V64, P1677, DOI 10.1097/00007890-199712270-00008; LLESUY SF, 1994, BBA-MOL CELL RES, V1223, P9, DOI 10.1016/0167-4889(94)90067-1; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; Mantell LL, 1997, CELL DEATH DIFFER, V4, P600, DOI 10.1038/sj.cdd.4400278; Marilena G, 1997, BIOCHEM MOL MED, V61, P136, DOI 10.1006/bmme.1997.2610; Mirabella C, 1999, INT ARCH ALLERGY IMM, V118, P259, DOI 10.1159/000024092; Mirabella C, 1999, INFLAMM RES, V48, pS11; Monma M, 1999, CLIN EXP ALLERGY, V29, P1537; Morita T, 1997, J BIOL CHEM, V272, P32804, DOI 10.1074/jbc.272.52.32804; Motterlini R, 1998, CIRC RES, V83, P568; NABESHIMA T, 1991, J PHARMACOL EXP THER, V256, P378; Ndisang JF, 1999, IMMUNOPHARMACOLOGY, V43, P65, DOI 10.1016/S0162-3109(99)00045-4; Nemeth ZH, 1997, SHOCK, V7, P371; Nicloux M, 1929, CR SOC BIOL, V101, P189; Nicloux M., 1898, CR HEBD ACAD SCI, V126, P1526; OTTERBEIN L, 1995, AM J RESP CELL MOL, V13, P595; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Otterbein LE, 1999, AM J PHYSIOL-LUNG C, V276, pL688; Otterbein LE, 2000, NAT MED, V6, P422; Otterbein LE, 1998, AM J PHYSIOL-LUNG C, V275, pL14; Pannen BHJ, 1998, J CLIN INVEST, V102, P1220, DOI 10.1172/JCI3428; Paredi P, 1999, THORAX, V54, P917; Paredi P, 1999, CHEST, V116, P1007, DOI 10.1378/chest.116.4.1007; Penny D. G., 1996, CARBON MONOXIDE, P1; Read RC, 1998, J ANTIMICROB CHEMOTH, V41, P65, DOI 10.1093/jac/41.suppl_1.65; Sammut IA, 1998, BRIT J PHARMACOL, V125, P1437, DOI 10.1038/sj.bjp.0702212; Sanghera JS, 1996, J IMMUNOL, V156, P4457; Sato K, 2001, J IMMUNOL, V166, P4185; Scharte M, 2000, BIOCHEM BIOPH RES CO, V267, P423, DOI 10.1006/bbrc.1999.1936; Shinoda Y, 1998, HEPATOLOGY, V28, P286, DOI 10.1002/hep.510280202; Siow RCM, 1999, CARDIOVASC RES, V41, P385, DOI 10.1016/S0008-6363(98)00278-8; SJORSTRAND T., 1949, SCANDINAVIAN JOUR CLIN AND LAB INVEST, V1, P201; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; STEINBERG KP, 1994, AM J RESP CRIT CARE, V150, P113; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; STUPFEL M, 1970, ANN NY ACAD SCI, V174, P342, DOI 10.1111/j.1749-6632.1970.tb49799.x; Szabo C, 1997, SHOCK, V7, P304, DOI 10.1097/00024382-199704000-00011; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; THOM SR, 1990, J APPL PHYSIOL, V68, P997; Uasuf CG, 1999, J PEDIATR-US, V135, P569, DOI 10.1016/S0022-3476(99)70054-5; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; Visser JA, 1998, MOL CELL ENDOCRINOL, V146, P7, DOI 10.1016/S0303-7207(98)00198-1; WILLS GD, 1987, WEED TECHNOL, V1, P2; Yachie A, 1999, J CLIN INVEST, V103, P129, DOI 10.1172/JCI4165; Yamara M, 1999, EUR RESPIR J, V13, P757, DOI 10.1034/j.1399-3003.1999.13d10.x; Yamaya M, 1998, AM J RESP CRIT CARE, V158, P311; Zhuo Min, 1999, Learning and Memory (Cold Spring Harbor), V6, P63	89	103	107	2	8	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1523-0864	1557-7716		ANTIOXID REDOX SIGN	Antioxid. Redox Signal.	APR	2002	4	2					309	319		10.1089/152308602753666361		11	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	547HN	WOS:000175327100010	12006182	
J	Luque, I; Leyva, L; Torres, MJ; Rosal, M; Mayorga, C; Segura, JM; Blanca, M; Juarez, C				Luque, I; Leyva, L; Torres, MJ; Rosal, M; Mayorga, C; Segura, JM; Blanca, M; Juarez, C			In vitro T-cell responses to beta-lactam drugs in immediate and nonimmediate allergic reactions	ALLERGY			English	Article						drug allergy; beta-lactams; lymphocyte transformation test; skin tests; T cells	LYMPHOCYTE-TRANSFORMATION TEST; PENICILLIN ALLERGY; CROSS-REACTIVITY; GOOD TOLERANCE; CUTANEOUS REACTIONS; IGE ANTIBODIES; MODIFIED SELF; ANTIBIOTICS; HYPERSENSITIVITY; AMOXICILLIN	Background: beta -Lactam drugs may induce both cellular and humoral allergic reactions, and there is evidence that T cells play an important role in the pathogenesis of these reactions. The aim of this work was to assess the sensitivity and specificity of the lymphocyte transformation test (LTT) as an in vitro diagnostic tool, in patients with either an immediate or a nonimmediate reaction to penicillin G and/or amoxicillin. Methods: Fifty patients with a well-documented history of allergic reactions to beta -lactams (31 immediate and 19 nonimmediate) were studied by means of skin tests (prick and intradermal), radioallergosorbent test (RAST), and, when necessary, controlled administration of the drug. Twenty-eight healthy subjects with good tolerance to penicillins served as controls. LTT was performed in all subjects. Results: Skin tests were positive in 77.4% of the patients with immediate reactions and in 36.8% of those with nonimmediate reactions. The overall sensitivity of LTT in the allergic patients was 62%, but, when analyzed separately, sensitivity was 64.5% for the immediate group and 57.9% for the nonimmediate group. The LTT specificity was 92.8%. Conclusions: The LTT should be considered a useful in vitro diagnostic tool to identify subjects allergic to penicillins, especially patients with nonimmediate reactions where the LTT has a better diagnostic value than skin tests. Interestingly, positive T-cell proliferative responses can be observed 10 or more years after the occurrence of the reaction without further exposure to the drug.	Carlos Haya Hosp, Res Unit Allerg Dis, Malaga, Spain; Univ Hosp La Paz, Allergy Serv, Madrid, Spain; Carlos Haya Hosp, Dept Internal Med, Malaga, Spain	Leyva, L (reprint author), Hosp Civil, Res Unit Allerg Dis, Pab 5 Sotano,Plaza Hosp Civil S-N, Malaga 29009, Spain.		Luque, Inmaculada/K-9464-2014	Luque, Inmaculada/0000-0003-1838-2636			ASSEM E S K, 1975, Clinical Allergy, V5, P43, DOI 10.1111/j.1365-2222.1975.tb01835.x; BARNA BP, 1980, AM J CLIN PATHOL, V73, P172; BELL SJD, 1989, ALLERGY, V44, P199, DOI 10.1111/j.1398-9995.1989.tb02262.x; BLANCA M, 1989, J ALLERGY CLIN IMMUN, V83, P381, DOI 10.1016/0091-6749(89)90122-X; BLANCA M, 1994, CLIN EXP ALLERGY, V24, P407, DOI 10.1111/j.1365-2222.1994.tb00928.x; BLANCA M, 1990, CLIN EXP ALLERGY, V20, P475, DOI 10.1111/j.1365-2222.1990.tb03139.x; BLANCA M, 1995, ALLERGY, V50, P777; BLANCA M, 1991, ALLERGY, V46, P632, DOI 10.1111/j.1398-9995.1991.tb00635.x; BLANCA M, 1988, ALLERGY, V43, P508, DOI 10.1111/j.1398-9995.1988.tb01628.x; BRANDER C, 1995, J IMMUNOL, V155, P2670; Brugnolo F, 1999, J IMMUNOL, V163, P1053; Cederbrant K, 1998, ALLERGY, V53, P1155, DOI 10.1111/j.1398-9995.1998.tb03835.x; Cederbrant K, 1997, INT ARCH ALLERGY IMM, V112, P212; DEHAAN P, 1986, ALLERGY, V41, P75; DEWDNEY JM, 1977, ANTIGENS, V5, P73; De Weck A. L., 1983, ALLERGIC REACTIONS D; Dutton RW, 1998, ANNU REV IMMUNOL, V16, P201, DOI 10.1146/annurev.immunol.16.1.201; Gonzalez FJ, 1997, INT ARCH ALLERGY IMM, V113, P345; HERTL M, 1993, J INVEST DERMATOL, V101, P794, DOI 10.1111/1523-1747.ep12371697; HERTL M, 1995, BRIT J DERMATOL, V132, P215; HERTL M, 1993, BRIT J DERMATOL, V128, P619, DOI 10.1111/j.1365-2133.1993.tb00255.x; HERTL M, 1992, DERMATOS BER UMWELT, V40, P102; HOMBURGER HA, 1993, ALLERGY PRINCIPLES P, P554; KOPONEN M, 1986, J ALLERGY CLIN IMMUN, V78, P645, DOI 10.1016/0091-6749(86)90083-7; Leyva L, 2000, J ALLERGY CLIN IMMUN, V105, P157, DOI 10.1016/S0091-6749(00)90191-X; MARIA VAJ, 1994, J HEPATOL, V21, P151, DOI 10.1016/S0168-8278(05)80388-5; MARIA VAJ, 1997, GUT, V41, P573; MauriHellweg D, 1996, J IMMUNOL, V157, P1071; MORENO F, 1995, INT ARCH ALLERGY IMM, V108, P74; MOSS RB, 1984, J PEDIATR, V104, P2456; NORMAN PS, 1983, ALLERGY PRINCIPLES P, P297; Nyfeler B, 1997, CLIN EXP ALLERGY, V27, P175; Padovan E, 1997, EUR J IMMUNOL, V27, P1303, DOI 10.1002/eji.1830270602; Padovan E., 1998, Clinical and Experimental Allergy, V28, P33; Padovan E, 1996, EUR J IMMUNOL, V26, P42, DOI 10.1002/eji.1830260107; RICCIARDI BR, 1983, PHARMACOL BIOCHEM BE, V18, P61, DOI 10.1016/0091-3057(83)90148-X; Romano A, 1999, J ALLERGY CLIN IMMUN, V103, P1186, DOI 10.1016/S0091-6749(99)70197-1; Romano A, 1997, ALLERGY, V52, P89, DOI 10.1111/j.1398-9995.1997.tb02550.x; SHAPIRO S, 1969, LANCET, V2, P969; SILVIUDAN F, 1993, J ALLERGY CLIN IMMUN, V91, P694, DOI 10.1016/0091-6749(93)90188-L; STEJSKAL VDM, 1986, J ALLERGY CLIN IMMUN, V77, P411, DOI 10.1016/0091-6749(86)90175-2; STEJSKAL VDM, 1994, TOXICOL IN VITRO, V8, P991, DOI 10.1016/0887-2333(94)90233-X; TERRADOS S, 1995, ALLERGY, V50, P563, DOI 10.1111/j.1398-9995.1995.tb01200.x; VEGA JM, 1994, ALLERGY, V49, P317, DOI 10.1111/j.1398-9995.1994.tb02275.x; VEGA JM, 1991, ALLERGY, V46, P154, DOI 10.1111/j.1398-9995.1991.tb00560.x; VICKERS MR, 1974, IMMUNOLOGY, V26, P425; Von Greyerz S., 1998, Clinical and Experimental Allergy, V28, P7; WARRINGTON RJ, 1993, J ALLERGY CLIN IMMUN, V92, P626, DOI 10.1016/0091-6749(93)90088-W; WARRINGTON RJ, 1979, CAN MED ASSOC J, V120, P1089	49	103	108	2	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JUL	2001	56	7					611	618		10.1034/j.1398-9995.2001.000115.x		8	Allergy; Immunology	Allergy; Immunology	445UG	WOS:000169476500004	11421918	
J	Siegel, JP				Siegel, JP			The mammalian safety of Bacillus thuringiensis-based insecticides	JOURNAL OF INVERTEBRATE PATHOLOGY			English	Review						Bacillus thuringiensis; mammalian safety; infection of animals and man; Bacillus cereus enterotoxins; persistence of spores; clearance of spores	CEREUS; STRAINS; MICE; ENTEROTOXIN; ISRAELENSIS; PESTICIDES; RESPONSES; INFECTION; TOXICITY	United States Environmental Protection Agency between the years 1961 and 1995 registered 177 products containing viable Bacillus thuringiensis (Bt), Numerous laboratory studies have demonstrated that Bt and Bt products are noninfectious and are toxic to mammals only at a dose greater than or equal to 10(8) colony forming units (cfu) per mouse (a human equivalent based on the weight of >10(11) cfu), In contrast, as few as three vegetative cells of Bacillus anthracis can kill mice (a human equivalent of >10(3) cfu), There are only two literature reports of Bt infection in man between the year 1997 and the present, and all infected individuals had experienced either extensive burns or a blast injury, which predisposed them to infection. Two epidemiology studies conducted during large-scale aerial Bt serovar kurstaki spray campaigns reported no increased incidence of illness, Some recent papers have expressed concern about the production of Bacillus cereus enterotoxins by Bt isolates, Laboratory studies found no evidence of illness in rats and sheep fed Bt products, nor have epidemiology studies found increased incidence of diarrhea during Bt aerial spray campaigns, Increases in human antibody levels following exposure to Bt products have been reported but there was no increased incidence in asthma or other illness, Based on laboratory studies and field experience, Bt insecticides have an excellent safety record.	ARS, USDA, Hort Crops Res Ctr, Fresno, CA 93727 USA	Siegel, JP (reprint author), ARS, USDA, Hort Crops Res Ctr, 2021 S Peach Ave, Fresno, CA 93727 USA.						ABDELHAMEED A, 1994, WORLD J MICROB BIOT, V10, P406, DOI 10.1007/BF00144461; ADLERSBERG L, 1969, J RETICULOENDOTH SOC, V6, P536; BAUMANN L, 1984, J INVERTEBR PATHOL, V44, P329, DOI 10.1016/0022-2011(84)90031-4; Bernstein IL, 1999, ENVIRON HEALTH PERSP, V107, P575, DOI 10.2307/3434400; Bishop AH, 1999, WORLD J MICROB BIOT, V15, P375, DOI 10.1023/A:1008983818692; Burges HD, 1981, MICROBIAL CONTROL PE, P738; CARLSON CR, 1994, APPL ENVIRON MICROB, V60, P1719; DAMGAARD PH, 1995, FEMS IMMUNOL MED MIC, V12, P245, DOI 10.1111/j.1574-695X.1995.tb00199.x; Damgaard PH, 1997, FEMS IMMUNOL MED MIC, V18, P47, DOI 10.1016/S0928-8244(97)00021-7; DROBNIEWSKI FA, 1993, CLIN MICROBIOL REV, V6, P324; ELLIOTT LJ, 1988, APPL OCCUP ENV HYG, V3, P119; Fares Nagui H., 1998, Natural Toxins, V6, P219, DOI 10.1002/(SICI)1522-7189(199811/12)6:6<219::AID-NT30>3.0.CO;2-K; FISHER R, 1959, AGR FOOD CHEM, V7, P686; Gaviria A, 2000, FEMS MICROBIOL LETT, V190, P151, DOI 10.1016/S0378-1097(00)00317-7; GORDON RE, 1977, US DHEW PUBL; GREEN M, 1990, AM J PUBLIC HEALTH, V80, P848, DOI 10.2105/AJPH.80.7.848; HADLEY WM, 1987, FUND APPL TOXICOL, V8, P236, DOI 10.1016/0272-0590(87)90122-9; HART K, 2000, PESTIC TOXIC CHEM NE, V28, P13; Helgason E, 2000, J CLIN MICROBIOL, V38, P1615; Hernandez E, 1999, FEMS IMMUNOL MED MIC, V24, P43, DOI 10.1016/S0928-8244(99)00005-X; Hernandez E, 1998, J CLIN MICROBIOL, V36, P2138; IGNOFFO CM, 1973, ANN NY ACAD SCI, V217, P141, DOI 10.1111/j.1749-6632.1973.tb32756.x; JACKSON SG, 1995, LETT APPL MICROBIOL, V21, P103, DOI 10.1111/j.1472-765X.1995.tb01017.x; KRAMER JM, 1988, FOODBORNE BACTERIAL, P22; Laferriere M, 1987, IMMUNOLOGIC STUDY CO; LAMANNA C, 1963, J BACTERIOL, V85, P532; MCCLINTOCK JT, 1995, PESTIC SCI, V45, P95, DOI 10.1002/ps.2780450202; MIKESELL P, 1985, MICROBIOLOGY, P52; Noble M. A., 1992, MICROBIOLOGICAL EPID; PETRAS SF, 1985, APPL ENVIRON MICROB, V50, P1496; Ripabelli G, 2000, LETT APPL MICROBIOL, V30, P358, DOI 10.1046/j.1472-765X.2000.00729.x; SALMITOU S, 2000, MICROBIOL, V146, P2825; SAMPLES JR, 1983, J INFECT DIS, V148, P614; Siegel J. P., 1990, Bacterial control of mosquitoes & black flies: biochemistry, genetics & applications of Bacillus thuringiensis israelensis and Bacillus sphaericus., P202; Siegel Joel P., 1997, P325, DOI 10.1016/B978-012432555-5/50017-8; SIEGEL JP, 1987, J ECON ENTOMOL, V80, P717; SIEGEL JP, 1990, J ECON ENTOMOL, V83, P347; Sneath P. H., 1986, BERGEYS MANUAL SYSTE, V2, P1104; SPIRA WM, 1972, APPL MICROBIOL, V24, P341; Tsai San-Fu, 1997, Journal of the Chinese Society of Veterinary Science, V23, P515; Vazquez-Padron RI, 1999, LIFE SCI, V64, P1897, DOI 10.1016/S0024-3205(99)00136-8; Warren R. E., 1984, Lancet, P678	42	103	118	1	21	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-2011			J INVERTEBR PATHOL	J. Invertebr. Pathol.	JAN	2001	77	1					13	21		10.1006/jipa.2000.5000		9	Zoology	Zoology	402RH	WOS:000167001600002	11161988	
J	Holloway, JA; Warner, JO; Vance, GHS; Diaper, ND; Warner, JA; Jones, CA				Holloway, JA; Warner, JO; Vance, GHS; Diaper, ND; Warner, JA; Jones, CA			Detection of house-dust-mite allergen in amniotic fluid and umbilical-cord blood	LANCET			English	Article							FETAL	Mononuclear cells In umbilical-cord blood display allergen-specific reactivity, but how allergen exposure occurs In utero is unknown. We Investigated the presence of a common inhalant allergen (Der p 1), to which mothers are exposed throughout pregnancy, by ELISA in matched maternal blood and amniotic fluid samples at 16-17 weeks of gestation, and in matched maternal and umbilical-cord blood at term (greater than or equal to 37 weeks of gestation). Der p 1 was detectable In 24 of 43 amniotic fluid samples where It was also present In maternal blood, and in 15 of 24 cord-plasma samples at significantly higher concentrations than in the maternal plasma (p=0.022). The detection of Der p 1 In the amniotic fluid and the fetal circulation provides direct evidence of transamniotic and transplacental allergen exposure.	Univ Southampton, Allergy & Inflammat Sci Div, Southampton, Hants, England	Warner, JO (reprint author), Southampton Gen Hosp, Child Hlth Mailpoint 803,Level G Ctr Block, Southampton SO16 6YD, Hants, England.		Holloway, Judith/A-1757-2010	Holloway, Judith/0000-0002-2268-3071	NHLBI NIH HHS [HL-61858]		DAHL GMK, 1984, COMP BIOCHEM PHYS A, V77, P199, DOI 10.1016/0300-9629(84)90046-X; Jenmalm MC, 2000, CLIN EXP ALLERGY, V30, P34, DOI 10.1046/j.1365-2222.2000.00771.x; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536; Szepfalusi Z, 2000, PEDIATR RES, V48, P404	5	103	106	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	DEC 2	2000	356	9245					1900	1902		10.1016/S0140-6736(00)03265-7		3	Medicine, General & Internal	General & Internal Medicine	379WD	WOS:000165665400017	11130390	
J	Ewart, SL; Kuperman, D; Schadt, E; Tankersley, C; Grupe, A; Shubitowski, DM; Peltz, G; Wills-Karp, M				Ewart, SL; Kuperman, D; Schadt, E; Tankersley, C; Grupe, A; Shubitowski, DM; Peltz, G; Wills-Karp, M			Quantitative trait loci controlling allergen-induced airway hyperresponsiveness in inbred mice	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							GENOME-WIDE SEARCH; TRANSCRIPTION FACTOR GATA-3; BRONCHIAL HYPERREACTIVITY; UNDERLYING ASTHMA; LINKAGE ANALYSIS; MURINE MODEL; MOUSE MODEL; T-CELLS; EXPRESSION; INFLAMMATION	Identification of the genetic loci underlying asthma in humans has been hampered by variability in clinical phenotype, uncontrolled environmental influences, and genetic heterogeneity. To circumvent these complications, the genetic regulation of asthma-associated phenotypes was studied in a murine model. We characterized the strain distribution patterns for the asthma-related phenotypes airway hyperresponsiveness (AHR), lung eosinophils, and ovalbumin (OVA)-specific serum immunoglobulin (Ig) E induced by allergen exposure protocols in A/J, AKR/J, BALB/cJ, C3H/HeJ, and C57BL/6J inbred strains and in (C3H/HeJ x A/J)F1 mice. Expression of AHR differed between strains and was sometimes discordant with lung eosinophils or serum IgE. Furthermore, we identified two distinct quantitative trait loci (QTL) for susceptibility to allergen-induced AHR, Abhr1 (allergen-induced bronchial hyperresponsiveness) (lod = 4.2) and Abhr2 (lod = 3.7), on chromosome 2 in backcross progeny from A/J and C3H/HeJ mice. In addition, a QTL on chromosome 7 was suggestive of linkage to this trait. These QTL differ from those we have previously found to control noninflammatory AHR in the same crosses. Elucidation of the genes underlying these QTL will facilitate the identification of biochemical pathways regulating AHR in animal models of asthma and may provide insights into the pathogenesis of human disease.	Michigan State Univ, Dept Large Anim Clin Sci, E Lansing, MI 48824 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Baltimore, MD 21205 USA; Univ Calif Los Angeles, Dept Biomath, Los Angeles, CA 90024 USA; Rosette Inpharmat, Dept Bioinformat, Kirkland, WA USA; Roche BioSci, Palo Alto, CA USA	Wills-Karp, M (reprint author), Childrens Hosp, Med Ctr, 3333 Brunet Ave, Cincinnati, OH 45229 USA.				NCRR NIH HHS [RR00097]; NHLBI NIH HHS [R01-HL58527]; NIEHS NIH HHS [ES-03819]		BASTEN CA, 1994, QTL CARTOGRAPHER RES; Basten C.J., 1997, QTL CARTOGRAPHER REF; Basten C. J., 1994, 5 WORLD C GEN APPL L, P65; CHURCHILL GA, 1994, GENETICS, V138, P963; COOKSON WOCM, 1989, LANCET, V1, P1292; Corry DB, 1996, J EXP MED, V183, P109, DOI 10.1084/jem.183.1.109; Corry DB, 1997, J EXP MED, V185, P1715; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Doerge RW, 1996, GENETICS, V142, P285; DRAGANI TA, 1995, MAMM GENOME, V6, P778, DOI 10.1007/BF00539002; Ewart SL, 1996, AM J RESP CELL MOL, V14, P627; Ewart SL, 1996, AM J RESP CELL MOL, V14, P487; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; GERGEN PJ, 1990, JAMA-J AM MED ASSOC, V264, P1688, DOI 10.1001/jama.264.13.1688; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HYNE V, 1995, THEOR APPL GENET, V91, P471, DOI 10.1007/BF00222975; Keane-Myers A, 1998, J IMMUNOL, V161, P919; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LEVITT RC, 1988, FASEB J, V2, P2605; Lincoln S, 1993, CONSTRUCTING GENETIC; Liu BH, 1998, STAT GENOMICS LINKAG; LONGO G, 1987, AM J DIS CHILD, V141, P331; Lynch M., 1998, GENETICS ANAL QUANTI; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Newhouse M T, 1989, Agents Actions Suppl, V28, P17; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; Sambrook J., 1989, MOL CLONING LAB MANU; Whittaker JC, 1996, HEREDITY, V77, P23, DOI 10.1038/hdy.1996.104; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zhang YM, 1999, HUM MOL GENET, V8, P601, DOI 10.1093/hmg/8.4.601; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	42	103	103	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	OCT	2000	23	4					537	545				9	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	364JB	WOS:000089888300017	11017920	
J	Burge, HA; Rogers, CA				Burge, HA; Rogers, CA			Outdoor allergens	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; exposure; fungal spores; outdoor allergens; pollen; predictive models	RAGWEED-POLLEN DETERMINANTS; EMERGENCY ROOM VISITS; AIR-POLLUTION; SOYBEAN-DUST; GRASS-POLLEN; ATMOSPHERIC AEROSOL; EPIDEMIC ASTHMA; EXPOSURE; PARTICLES; SYMPTOMS	Outdoor allergens are an important part of the exposures that lead to allergic disease. Understanding the role of outdoor allergens requires a knowledge of the nature of outdoor allergen-bearing particles, the distributions of their source, and the nature of the aerosols (particle types, sizes, dynamics of concentrations). Primary sources for outdoor allergens include vascular plants (pollen, fern spores, soy dust), and fungi (spores. hyphae). Nonvascular plants, algae, and arthropods contribute small numbers of allergen-bearing particles. Particles are released from sources into the air by wind, rain, mechanical disturbance, or active discharge mechanisms. Once airborne, they follow the physical laws that apply to all airborne particles. Although some outdoor allergens penetrate indoor spaces, exposure occurs mostly outdoors. Even short-term peak outdoor exposures can be important in eliciting acute symptoms. Monitoring of airborne biological particles is usually by particle impaction and microscopic examination. Centrally located monitoring stations give regional-scale measurements for aeroallergen levels. Evidence for the role of outdoor allergens in allergic rhinitis is strong and is rapidly increasing for a role in asthma. Pollen and fungal spore exposures have both been implicated in acute exacerbations of asthma, and sensitivity to some fungal spores predicts the existence of asthma. Synergism and/or antagonism probably occurs with other outdoor air particles and gases. Control involves avoidance of exposure (staying indoors, preventing entry of outdoor aerosols) as well as immunotherapy. which is effective for pollen but of limited effect for spores. Outdoor allergens have been the subject of only limited studies with respect to the epidemiology of asthma. Much remains to be studied with respect to prevalence patterns, exposure acid disease relationships, and control.	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Burge, HA (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.		Rogers, Christine/A-2189-2008	Rogers, Christine/0000-0003-0887-9606			ACEVES M, 1991, J ALLERGY CLIN IMMUN, V88, P124, DOI 10.1016/0091-6749(91)90309-C; AGARWAL MK, 1983, J ALLERGY CLIN IMMUN, V72, P40, DOI 10.1016/0091-6749(83)90050-7; AGARWAL MK, 1984, J ALLERGY CLIN IMMUN, V74, P687, DOI 10.1016/0091-6749(84)90231-8; Anto JM, 1999, THORAX, V54, P670; ARIZMENDI CM, 1993, INT J BIOMETEOROL, V37, P139, DOI 10.1007/BF01212623; Arx J. A., 1970, GENERA FUNGI SPORULA; AYLOR DE, 1975, PLANT PHYSIOL, V56, P97, DOI 10.1104/pp.56.1.97; Ballester F, 1999, AM J EPIDEMIOL, V149, P315; Barnett H. L., 1987, ILLUSTRATED GENERA I; BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BURGE H, 1990, MICROBIAL ECOLOGY LE, P222; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; Carmichael J. W., 1980, GENERA HYPHOMYCETES; Chamberlain A., 1981, PLANTS THEIR ATMOSPH, P147; CODINA R, 2000, J ALLERGY CLIN IMMUN, V105, P572; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P566, DOI 10.1111/j.1365-2222.1994.tb00954.x; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; DHILLON M, 1991, ANN ALLERGY, V66, P385; EGGLESTON P, 1998, J ALLERGY CLIN IMMUN, V4, P563; EPSTEIN E, 1993, SCIENCE AND ENGINEERING OF COMPOSTING : DESIGN, ENVIRONMENTAL, MICROBIOLOGICAL AND UTILIZATION ASPECTS, P319; Erdtman G, 1966, POLLEN MORPHOLOGY PL; Falleroni AE, 1996, ANN ALLERG ASTHMA IM, V77, P298; FISCHBACH FA, 1986, GRANA, V25, P221; FORSBERG B, 1993, EUR RESPIR J, V6, P1109; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P437, DOI 10.1016/0091-6749(94)90352-2; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; Gregory PH, 1961, MICROBIOLOGY ATMOSPH; GROTE M, 1986, HISTOCHEM J, V18, P24, DOI 10.1007/BF01676194; HABENICHT HA, 1984, J ALLERGY CLIN IMMUN, V74, P64, DOI 10.1016/0091-6749(84)90088-5; HIRST JM, 1963, J GEN MICROBIOL, V33, P335; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; HOWLETT B, 1984, ENCY PLANT PHYSL, V17, P655; HOWLETT BJ, 1981, BIOCHEM J, V197, P695; HOWLETT BJ, 1979, CURR ADV PLANT SCI, V35, P1; HOWLETT R, 1975, P R SOC LONDON, V188, P166; JOHNSEN CR, 1992, ALLERGY, V47, P510, DOI 10.1111/j.1398-9995.1992.tb00674.x; Kendrick B, 1992, 5 KINGDOM; KESTEN S, 1995, ANN ALLERG ASTHMA IM, V74, P269; KING TP, 1962, BIOCHEMISTRY-US, V1, P709, DOI 10.1021/bi00910a027; KING TP, 1979, J ALLERGY CLIN IMMUN, V64, P159, DOI 10.1016/0091-6749(79)90090-3; KNOX R, 1997, CLIN EXP ALLERGY, V273, P246; Lebowitz M. D., 1982, ENVIRON INT, V8, P375, DOI 10.1016/0160-4120(82)90053-8; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; LEVETIN E, 1989, ANN ALLERGY, V62, P306; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; MARZIN C, 1993, REV MAL RESPIR, V10, P229; MAUNSELL K, 1971, ACTA ALLERGOL, V25, P329; MICHEL FB, 1977, AM REV RESPIR DIS, V115, P609; MOLLER C, 1986, CLIN ALLERGY, V16, P135, DOI 10.1111/j.1365-2222.1986.tb00757.x; MOSEHOLM L, 1987, Pollen et Spores, V29, P305; MYGIND N, 1983, ALLERGY PRINCIPLES P, P1101; Neas LM, 1996, AM J EPIDEMIOL, V143, P797; NEWILL CA, 1995, J ALLERGY CLIN IMMUN, V95, P707, DOI 10.1016/S0091-6749(95)70176-1; NORRISHILL J, 1995, GRANA, V34, P182; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PALMGREN U, 1986, J APPL BACTERIOL, V61, P401, DOI 10.1111/j.1365-2672.1986.tb04303.x; POLLART S, 1989, J ALLERGY CLIN IMMUN, V833, P875; POLLART S, 1988, J ALLERGY CLIN IMMUN, V88, P224; Pont F, 1997, Arch Bronconeumol, V33, P453; Poulos LM, 1999, CLIN EXP ALLERGY, V29, P1232, DOI 10.1046/j.1365-2222.1999.00613.x; RAYNOR GS, 1969, ARCH ENVIRON HEALTH, V19, P92; RODRIGO MJ, 1990, J ALLERGY CLIN IMMUN, V85, P778, DOI 10.1016/0091-6749(90)90198-D; RUFFIN J, 1986, CYTOBIOS, V46, P119; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SEXTON K, 1983, ENVIRON RES, V32, P151, DOI 10.1016/0013-9351(83)90202-5; SMID T, 1992, AM IND HYG ASSOC J, V53, P362, DOI 10.1202/0002-8894(1992)053<0362:ETDEAF>2.0.CO;2; SOLOMON AM, 1980, J ARID ENVIRON, V3, P169; SOLOMON WR, 1980, J ALLERGY CLIN IMMUN, V65, P305, DOI 10.1016/0091-6749(80)90160-8; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SOLOMON WR, 1980, INT J BIOMETEOROL, V24, P107, DOI 10.1007/BF02253798; SPENGLER JD, 1983, SCIENCE, V221, P9, DOI 10.1126/science.6857273; Stark PC, 1997, AEROBIOLOGIA, V13, P177, DOI 10.1007/BF02694505; STARR JR, 1966, Q J ROY METEOR SOC, V92, P490, DOI 10.1002/qj.49709239405; STEPHEN E, 1990, INT J BIOMETEOROL, V34, P87, DOI 10.1007/BF01093452; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; Suphioglu C, 1998, INT ARCH ALLERGY IMM, V116, P253, DOI 10.1159/000023953; WAYNE PW, UNPUB; WEEKE B, 1974, ACTA ALLERGOL, V29, P409; Wodehouse R. P., 1959, POLLEN GRAINS; ZEJDA JE, 1993, TUBERCLE LUNG DIS, V74, P74, DOI 10.1016/0962-8479(93)90031-R; 1999, POLLEN SPORE REPORT	85	103	111	1	19	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2000	108			4			653	659		10.2307/3454401		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	350VH	WOS:000089121500008	10931783	
J	Farsalinos, KE; Romagna, G; Tsiapras, D; Kyrzopoulos, S; Voudris, V				Farsalinos, Konstantinos E.; Romagna, Giorgio; Tsiapras, Dimitris; Kyrzopoulos, Stamatis; Voudris, Vassilis			Characteristics, Perceived Side Effects and Benefits of Electronic Cigarette Use: A Worldwide Survey of More than 19,000 Consumers	INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH			English	Article						lectronic cigarette; smoking; tobacco; nicotine; harm reduction; public health	NICOTINE DELIVERY; SMOKING-CESSATION; INTERNET SURVEY; VAPOR EXTRACT; SAFETY	Background: Electronic cigarette (EC) use has grown exponentially over the past few years. The purpose of this survey was to assess the characteristics and experiences of a large sample of EC users and examine the differences between those who partially and completely substituted smoking with EC use. Methods: A questionnaire was prepared, translated into 10 different languages and uploaded in an online survey tool. EC users were asked to participate irrespective of their current smoking status. Participants were divided according to their smoking status at the time of participation in two subgroups: former smokers and current smokers. Results: In total, 19,414 participants were included in the analysis, with 88 of them (0.5%) reported not being smokers at the time of EC use initiation. Complete substitution of smoking was reported by 81.0% of participants (former smokers) while current smokers had reduced smoking consumption from 20 to 4 cigarettes per day. They were using ECs for a median of 10 months. They initiated EC use with a median of 18 mg/mL nicotine-concentration liquids; 21.5% used higher than 20 mg/mL. Only 3.5% of participants were using 0-nicotine liquids at the time of the survey. Former smokers were highly dependent (Fagerstrom Test for Cigarette Dependence = 7) and were heavier smokers (21 cigarettes per day when smoking) compared to current smokers. The most important reasons for initiating EC use for both subgroups was to reduce the harm associated with smoking and to reduce exposure of family members to second-hand smoking. Most considered ECs as less harmful than tobacco cigarettes, while 11.0% considered them absolutely harmless. Side effects were reported by more than half of the participants (59.8%), with the most common being sore/dry mouth and throat; side effects were mild and in most cases were subsequently resolved (partially or completely). Participants experienced significant benefits in physical status and improvements in pre-existing disease conditions (including respiratory disease such as asthma and chronic obstructive lung disease). Being former smoker was independently associated with positive effects in health and improvements in disease conditions. Conclusions: The results of this worldwide survey of dedicated users indicate that ECs are mostly used to avoid the harm associated with smoking. They can be effective even in highly-dependent smokers and are used as long-term substitutes for smoking. High levels of nicotine are used at initiation; subsequently, users try to reduce nicotine consumption, with only a small minority using non-nicotine liquids. Side effects are minor and health benefits are substantial, especially for those who completely substitute smoking with EC use. Further population and interventional studies are warranted.	[Farsalinos, Konstantinos E.; Tsiapras, Dimitris; Kyrzopoulos, Stamatis; Voudris, Vassilis] Onassis Cardiac Surg Ctr, Kallithea 17674, Greece; [Romagna, Giorgio] ABICH Srl, Biol & Chem Toxicol Res Inst, I-28924 Verbania, VB, Italy	Farsalinos, KE (reprint author), Onassis Cardiac Surg Ctr, Sygrou 356, Kallithea 17674, Greece.	kfarsalinos@gmail.com; giorgio.romagna@gmail.com; dtsiapras@hotmail.com; stkyrz@gmail.com; vvoudris@otenet.gr		Farsalinos, Konstantinos/0000-0001-6839-4710	funding campaign of E-Cigarette Research Advocates Group	The study was funded by a funding campaign of E-Cigarette Research Advocates Group, the owners of the website www.ecigarette-research.com. This is a non-profit group of electronic cigarette users with no relation to the electronic cigarette or other industry. The website does not promote or present any electronic cigarette product and do not accept any advertisements. The sole purpose of the group is to inform about research conducted on electronic cigarettes. Konstantinos E. Farsalinos has been allowed to present studies and post comments concerning electronic cigarette research on this website, without providing or receiving any form of payment. The study was investigator-initiated and investigator-driven. The sponsor had no involvement in the study design, data collection, analysis and interpretation, writing or approving the manuscript and decision to submit the manuscript for publication.	Bullen C, 2013, LANCET, V382, P1629, DOI 10.1016/S0140-6736(13)61842-5; Caponnetto P, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066317; Dawkins L, 2014, PSYCHOPHARMACOLOGY, V231, P401, DOI 10.1007/s00213-013-3249-8; Dawkins L, 2013, ADDICTION, V108, P1115, DOI 10.1111/add.12150; Etter JF, 2014, ADDICTION, V109, P825, DOI 10.1111/add.12475; Etter JF, 2014, ADDICT BEHAV, V39, P491, DOI 10.1016/j.addbeh.2013.10.028; Etter JF, 2011, ADDICTION, V106, P2017, DOI 10.1111/j.1360-0443.2011.03505.x; Fagerstrom K, 2012, NICOTINE TOB RES, V14, P75, DOI 10.1093/ntr/ntr137; Farsalinos KE, 2014, INT J DRUG POLICY, V25, P340, DOI 10.1016/j.drugpo.2014.03.003; Farsalinos KE, 2014, SCI REP-UK, V4, DOI 10.1038/srep04133; Farsalinos KE, 2013, INT J ENV RES PUB HE, V10, P7272, DOI 10.3390/ijerph10127272; Farsalinos KE, 2013, INT J ENV RES PUB HE, V10, P5146, DOI 10.3390/ijerph10105146; Farsalinos Konstantinos E, 2013, Subst Abuse, V7, P139, DOI 10.4137/SART.S12756; Goniewicz ML, 2013, DRUG ALCOHOL REV, V32, P133, DOI 10.1111/j.1465-3362.2012.00512.x; Goniewicz ML, 2014, TOB CONTROL, V23, P133, DOI 10.1136/tobaccocontrol-2012-050859; Mayer B, 2014, ARCH TOXICOL, V88, P5, DOI 10.1007/s00204-013-1127-0; Moore D, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b1024; Nides MA, 2014, AM J HEALTH BEHAV, V38, P265, DOI 10.5993/AJHB.38.2.12; Popova L, 2013, AM J PUBLIC HEALTH, V103, P923, DOI 10.2105/AJPH.2012.301070; Rigotti NA, 2010, CIRCULATION, V121, P221, DOI 10.1161/CIRCULATIONAHA.109.869008; Rodu Brad, 2006, Harm Reduct J, V3, P37, DOI 10.1186/1477-7517-3-37; Romagna G, 2013, INHAL TOXICOL, V25, P354, DOI 10.3109/08958378.2013.793439; Vansickel AR, 2010, CANCER EPIDEM BIOMAR, V19, P1945, DOI 10.1158/1055-9965.EPI-10-0288; Vickerman KA, 2013, NICOTINE TOB RES, V15, P1787, DOI 10.1093/ntr/ntt061; Williams M, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0057987, DOI 10.1371/JOURNAL.PONE.0057987]	25	102	102	6	37	MDPI AG	BASEL	POSTFACH, CH-4005 BASEL, SWITZERLAND	1660-4601			INT J ENV RES PUB HE	Int. J. Environ. Res. Public Health	APR	2014	11	4					4356	4373		10.3390/ijerph110404356		18	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	AG9TM	WOS:000335762700044	24758891	
J	Kessler, R; Partridge, MR; Miravitlles, M; Cazzola, M; Vogelmeier, C; Leynaud, D; Ostinelli, J				Kessler, R.; Partridge, M. R.; Miravitlles, M.; Cazzola, M.; Vogelmeier, C.; Leynaud, D.; Ostinelli, J.			Symptom variability in patients with severe COPD: a pan-European cross-sectional study	EUROPEAN RESPIRATORY JOURNAL			English	Article						Breathlessness; chronic obstructive pulmonary disease; symptoms; symptom variability; treatment	OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; AIR-FLOW OBSTRUCTION; CIRCADIAN VARIATION; EXACERBATIONS; ASTHMA; VALIDATION; TIOTROPIUM; IMPACT	In between exacerbations, chronic obstructive pulmonary disease (COPD) is usually regarded as a stable condition, but there is increasing recognition of variability in this state. This cross-sectional study assessed patients' perception of symptom variability. Participants were outpatients >45 yrs old with COPD, current or ex-smokers, forced expiratory volume in 1 s (FEV1) <50% predicted, FEV1/forced vital capacity <0.7 and no exacerbation leading to therapeutic intervention in the previous 3 months. Patients' perceptions of COPD symptoms and their impact on daily life activities were recorded. Alterations in therapy use in response to COPD worsening were also recorded. COPD symptoms were experienced by 2,258 (92.5%) out of 2,441 patients during the 7 days before interview. Breathlessness was the most common symptom (72.5%). Daily and/or weekly symptom variability was reported by 62.7% of symptomatic patients; the morning was the worst time of day. Factors associated with perception of variability of breathlessness included younger age, symptom severity and recruitment to the study by general practitioners. The perception of variability was significantly different between European countries or regions. Patient-perceived COPD symptoms vary over the day and the week, and impact on daily activities; morning being the worst time of day. The majority of patients appear not to adjust treatment when symptoms worsen.	[Kessler, R.] Nouvel Hop Civil, Dept Pneumol, F-67000 Strasbourg, France; [Leynaud, D.; Ostinelli, J.] AstraZeneca, Dept Med, Rueil Malmaison, France; [Partridge, M. R.] Univ London Imperial Coll Sci Technol & Med, NHLI Div, Charing Cross Hosp, London, England; [Miravitlles, M.] Hosp Clin Barcelona, CIBERES, IDIBAPS, Fundacio Clin, Barcelona, Spain; [Cazzola, M.] Univ Roma Tor Vergata, Dept Internal Med, Rome, Italy; [Cazzola, M.] San Raffaele Pisana Hosp, Pulm Rehabil Grp, Rome, Italy; [Vogelmeier, C.] Univ Marburg, Div Resp Dis, Marburg, Germany	Kessler, R (reprint author), Nouvel Hop Civil, Dept Pneumol, 1 Pl Hop, F-67000 Strasbourg, France.	Romain.Kessler@chru-strasbourg.fr	Cazzola, Mario/G-9397-2012	Miravitlles, Marc/0000-0002-9850-9520	AstraZeneca	This study was funded by AstraZeneca.	Barnett M, 2005, J CLIN NURS, V14, P805, DOI 10.1111/j.1365-2702.2005.01125.x; Barr R Graham, 2005, Am J Med, V118, P1415; Calverley PMA, 2003, THORAX, V58, P855, DOI 10.1136/thorax.58.10.855; Cazzola M, 2008, EUR RESPIR J, V31, P416, DOI 10.1183/09031936.00099306; CLARK T J H, 1987, Chest, V91, p137S, DOI 10.1378/chest.91.6.137S; Engstrom CP, 2001, EUR RESPIR J, V18, P69, DOI 10.1183/09031936.01.00044901; Esteban C, 2010, EUR RESPIR J, V36, P292, DOI 10.1183/09031936.00021409; Ferrer M, 1997, ANN INTERN MED, V127, P1072; Gibson PG, 2009, THORAX, V64, P728, DOI 10.1136/thx.2008.108027; Gilbert C, 2007, AM J RESP CRIT CARE, V175, pA15; Haughney J, 2005, EUR RESPIR J, V26, P623, DOI 10.1183/09031936.05.00142704; HETZEL MR, 1980, THORAX, V35, P732, DOI 10.1136/thx.35.10.732; Jones PW, 2009, EUR RESPIR J, V34, P648, DOI 10.1183/09031936.00102509; JONES PW, 1991, THORAX, V46, P676, DOI 10.1136/thx.46.9.676; Katula Jeffrey A, 2004, Health Qual Life Outcomes, V2, P18, DOI 10.1186/1477-7525-2-18; Kessler R, 2006, CHEST, V130, P133, DOI 10.1378/chest.130.1.133; LEWINSOHN HC, 1960, BRIT MED J, V1, P462; Miravitlles M, 2004, THORAX, V59, P387, DOI 10.1136/thx.2003.008730; Miravitlles M, 2007, RESP MED, V101, P453, DOI 10.1016/j.rmed.2006.07.010; Ng TP, 2007, ARCH INTERN MED, V167, P60, DOI 10.1001/archinte.167.1.60; Partridge MR, 2010, EUR RESPIR J, V36, P96, DOI 10.1183/09031936.00123709; Partridge Martyn R, 2009, Ther Adv Respir Dis, V3, P1, DOI 10.1177/1753465809344870; Partridge MR, 2009, CURR MED RES OPIN, V25, P2043, DOI 10.1185/03007990903103006; POSTMA DS, 1985, CHEST, V87, P653, DOI 10.1378/chest.87.5.653; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rutten-van Molken MPMH, 2006, CHEST, V130, P1117; Soriano JB, 2003, CHEST, V124, P474, DOI 10.1378/chest.124.2.474; TURNERWARWICK M, 1988, AM J MED, V85, P6, DOI 10.1016/0002-9343(88)90231-8; van Noord JA, 2006, CHEST, V129, P509, DOI 10.1378/chest.129.3.509; WILLAMS SJ, 1993, CHRONIC RESP ILLNESS	30	102	108	0	4	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936	1399-3003		EUR RESPIR J	Eur. Resp. J.	FEB	2011	37	2					264	272		10.1183/09031936.00051110		9	Respiratory System	Respiratory System	713IF	WOS:000286730400009	21115606	
J	Delfino, RJ; Brummel, S; Wu, J; Stern, H; Ostro, B; Lipsett, M; Winer, A; Street, DH; Zhang, L; Tjoa, T; Gillen, DL				Delfino, R. J.; Brummel, S.; Wu, J.; Stern, H.; Ostro, B.; Lipsett, M.; Winer, A.; Street, D. H.; Zhang, L.; Tjoa, T.; Gillen, D. L.			The relationship of respiratory and cardiovascular hospital admissions to the southern California wildfires of 2003	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							AIR-POLLUTION; FOREST-FIRES; PARTICULATE MATTER; LONGITUDINAL DATA; ACUTE ASTHMA; EXPOSURE; SMOKE; MORTALITY; QUALITY; CONSEQUENCES	Objective: There is limited information on the public health impact of wildfires. The relationship of cardiorespiratory hospital admissions (n=40 856) to wildfire-related particulate matter (PM(2.5)) during catastrophic wildfires in southern California in October 2003 was evaluated. Methods: Zip code level PM(2.5) concentrations were estimated using spatial interpolations from measured PM(2.5), light extinction, meteorological conditions, and smoke information from MODIS satellite images at 250 m resolution. Generalised estimating equations for Poisson data were used to assess the relationship between daily admissions and PM(2.5), adjusted for weather, fungal spores (associated with asthma), weekend, zip code-level population and sociodemographics. Results: Associations of 2-day average PM(2.5) with respiratory admissions were stronger during than before or after the fires. Average increases of 70 mu g/m(3) PM(2.5) during heavy smoke conditions compared with PM(2.5) in the pre-wildfire period were associated with 34% increases in asthma admissions. The strongest wildfire-related PM(2.5) associations were for people ages 65 99 years (10.1% increase per 10 mu g/m(3) PM(2.5), 95% CI 3.0% to 17.8%) and ages 0-4 years (8.3%, 95% CI 2.2% to 14.9%) followed by ages 20-64 years (4.1%, 95% CI 20.5% to 9.0%). There were no PM(2.5)-asthma associations in children ages 5-18 years, although their admission rates significantly increased after the fires. Per 10 mg/m3 wildfire-related PM(2.5), acute bronchitis admissions across all ages increased by 9.6% (95% CI 1.8% to 17.9%), chronic obstructive pulmonary disease admissions for ages 20-64 years by 6.9% (95% CI 0.9% to 13.1%), and pneumonia admissions for ages 5-18 years by 6.4% (95% CI 21.0% to 14.2%). Acute bronchitis and pneumonia admissions also increased after the fires. There was limited evidence of a small impact of wildfire-related PM(2.5) on cardiovascular admissions. Conclusions: Wildfire-related PM(2.5) led to increased respiratory hospital admissions, especially asthma, suggesting that better preventive measures are required to reduce morbidity among vulnerable populations.	[Delfino, R. J.; Wu, J.; Tjoa, T.] Univ Calif Irvine, Sch Med, Dept Epidemiol, Irvine, CA 92617 USA; [Brummel, S.; Stern, H.; Gillen, D. L.] Univ Calif Irvine, Sch Informat & Comp Sci, Dept Stat, Irvine, CA 92617 USA; [Wu, J.] Univ Calif Irvine, Program Publ Hlth, Irvine, CA 92617 USA; [Ostro, B.] Calif Off Environm Hlth Hazard Assessment, Air Pollut Epidemiol Sect, Oakland, CA USA; [Lipsett, M.; Zhang, L.] Calif Dept Hlth Serv, Environm Hlth Investigat Branch, Exposure Assessment Sect, Oakland, CA USA; [Winer, A.] Univ Calif Los Angeles, Sch Publ Hlth, Dept Environm Hlth Sci, Los Angeles, CA 90024 USA; [Street, D. H.] Independent Consultant, Salem, OR USA	Delfino, RJ (reprint author), Univ Calif Irvine, Sch Med, Dept Epidemiol, 100 Theory Dr,Suite 100, Irvine, CA 92617 USA.	rdelfino@uci.edu			South Coast Air Quality Management District [04182]; National Institutes of Health, National Institute of Environmental Health Sciences [ES-11615]	This study was funded by the South Coast Air Quality Management District contract no. 04182, and the National Institutes of Health, National Institute of Environmental Health Sciences grant no. ES-11615.	Barregard L, 2008, OCCUP ENVIRON MED, V65, P319, DOI 10.1136/oem.2006.032458; Becklake MR, 1999, THORAX, V54, P1119; Bell ML, 2001, ENVIRON HEALTH PERSP, V109, P389, DOI 10.2307/3434786; CDC, 1999, MMWR-MORBID MORTAL W, V48, P78; Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P898, DOI 10.1289/ehp.11189; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; DUCLOS P, 1990, ARCH ENVIRON HEALTH, V45, P53; Emmanuel S C, 2000, Respirology, V5, P175, DOI 10.1046/j.1440-1843.2000.00247.x; Frankenberg E, 2005, DEMOGRAPHY, V42, P109, DOI 10.1353/dem.2005.0004; Goodman PG, 2004, ENVIRON HEALTH PERSP, V112, P179, DOI 10.1289/ehp.6451; Henderson DE, 2005, J AIR WASTE MANAGE, V55, P1516, DOI 10.1080/10473289.2005.10464746; Huber P. J., 1967, P 5 BERK S MATH STAT, V1, P221, DOI DOI 10.3238/ARZTEBL.2011.0523A; Jalava PI, 2006, TOXICOL APPL PHARM, V215, P341, DOI 10.1016/j.taap.2006.03.007; Janson S, 1998, J ASTHMA, V35, P427, DOI 10.3109/02770909809048951; Johnson J. M., 2005, MORB MORTAL WKLY R S, V54, P190; Kunii O, 2002, ARCH ENVIRON HEALTH, V57, P16; Kunzli N, 2006, AM J RESP CRIT CARE, V174, P1221, DOI 10.1164/rccm.200604-519OC; Moore D, 2006, CAN J PUBLIC HEALTH, V97, P105; Mott JA, 2005, INT J HYG ENVIR HEAL, V208, P75, DOI 10.1016/j.ijheh.2005.01.018; Mott JA, 2002, WESTERN J MED, V176, P157, DOI 10.1136/ewjm.176.3.157; Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875; PEPE MS, 1994, COMMUN STAT SIMULAT, V23, P939, DOI 10.1080/03610919408813210; Phuleria HC, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD004626; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Rodrigo GJ, 2004, CHEST, V125, P1081, DOI 10.1378/chest.125.3.1081; Sastry N, 2002, DEMOGRAPHY, V39, P1, DOI 10.1353/dem.2002.0009; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Smith MA, 1996, INT J EPIDEMIOL, V25, P1227, DOI 10.1093/ije/25.6.1227; *STAT CA, 2006, CAL COUNT POP EST CO; Sutherland ER, 2005, J ALLERGY CLIN IMMUN, V115, P420, DOI 10.1016/j.jaci.2004.11.030; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; Vedal S, 2006, ENVIRON RES, V102, P29, DOI 10.1016/j.envres.2006.03.008; Viswanathan S, 2006, J AIR WASTE MANAGE, V56, P56; Weber RW, 2003, IMMUNOL ALLERGY CLIN, V23, P411, DOI 10.1016/S0889-8561(03)00062-6; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; Westerling AL, 2006, SCIENCE, V313, P940, DOI 10.1126/science.1128834; WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; Wu J, 2006, ATMOS ENVIRON, V40, P3333, DOI 10.1016/j.atmosenv.2006.01.056; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	40	102	102	3	39	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	MAR	2009	66	3					189	197		10.1136/oem.2008.041376		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	410DM	WOS:000263557000009	19017694	
J	Bridevaux, PO; Gerbase, MW; Probst-Hensch, NM; Schindler, C; Gaspoz, JM; Rochat, T				Bridevaux, P-O; Gerbase, M. W.; Probst-Hensch, N. M.; Schindler, C.; Gaspoz, J-M; Rochat, T.			Long-term decline in lung function, utilisation of care and quality of life in modified GOLD stage 1 COPD	THORAX			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; SF-36 HEALTH SURVEY; NUTRITION-EXAMINATION-SURVEY; NATIONAL-HEALTH; AIR-POLLUTION; UNITED-STATES; RISK-FACTORS; FOLLOW-UP; PREVALENCE; POPULATION	Background: Little is known about the long-term outcomes of individuals with mild chronic obstructive pulmonary disease ( COPD) as defined by the Global Initiative for Chronic Obstructive Lung Disease ( GOLD). Methods: A population cohort of 6671 randomly selected adults without asthma was stratified into categories of modified GOLD-defined COPD (prebronchodilator spirometry). Further stratification was based on the presence or absence of respiratory symptoms. After 11 years, associations between baseline categories of COPD and decline in forced expiratory volume in 1 s (FEV(1)), respiratory care utilisation and quality of life as measured by the SF-36 questionnaire were examined after controlling for age, sex, smoking and educational status. Results: At baseline, modified GOLD criteria were met by 610 (9.1%) participants, 519 (85.1%) of whom had stage 1 COPD. At follow-up, individuals with symptomatic stage 1 COPD (n=224) had a faster decline in FEV1 (-9 ml/year (95% CI -13 to -5)), increased respiratory care utilisation (OR 1.6 (95% CI 1.0 to 2.6)) and a lower quality of life than asymptomatic subjects with normal lung function (n=3627, reference group). In contrast, individuals with asymptomatic stage 1 COPD (n=295) had no significant differences in FEV1 decline (-3 ml/year (95% CI -7 to +1)), respiratory care utilisation (OR 1.05 (95% CI 0.63 to 1.73)) or quality of life scores compared with the reference group. Conclusions: In population-based studies, respiratory symptoms are of major importance for predicting long-term clinical outcomes in subjects with COPD with mild obstruction. Population studies based on spirometry only may misestimate the prevalence of clinically relevant COPD.	[Bridevaux, P-O; Gerbase, M. W.; Rochat, T.] Hop Cantonal Geneva, Div Pulm Med, CH-1211 Geneva, Switzerland; [Gaspoz, J-M] Univ Geneva, Univ Hosp Geneva, Div Community Med & Primary Care, CH-1211 Geneva 4, Switzerland; [Probst-Hensch, N. M.] Univ Zurich, Inst Social & Prevent Med, Mol Epidemiol Canc Registry, CH-8006 Zurich, Switzerland; [Probst-Hensch, N. M.] Univ Zurich, Inst Surg Pathol, Mol Epidemiol Canc Registry, CH-8006 Zurich, Switzerland; [Schindler, C.] Univ Basel, Inst Social & Prevent Med, Basel, Switzerland	Bridevaux, PO (reprint author), Hop Cantonal Geneva, Div Pulm Med, 24 Rue Micheli du Crest, CH-1211 Geneva, Switzerland.	Pierre-Olivier.Bridevaux@hcuge.ch	Schindler, Christian/D-3472-2015		Swiss National Science Foundation [4026-28099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, 32-4253.94]	The Swiss National Science Foundation ( grants no 4026-28099, 3347CO-108796, 3247BO-104283, 3247BO-104288, 3247BO-104284, 32-65896.01, 32-59302.99, 32-52720.97, 32-4253.94), the Federal Office for Forest, Environment and Landscape, the Federal Office of Public Health, the Federal Office of Roads and Transport, the canton's government of Aargau, Basel-Stadt, Basel-Land, Geneva, Luzern, Ticino, Zurich, the Swiss Lung League, the canton's Lung League of Basel Stadt/Basel Landschaft, Geneva, Ticino and Zurich.	Ackermann-Liebrich U, 2005, SOZ PRAVENTIV MED, V50, P245, DOI 10.1007/s00038-005-4075-5; Antonelli-Incalzi R, 2003, EUR RESPIR J, V22, P444, DOI 10.1183/09031936.03.00101203; Apolone G, 1998, J CLIN EPIDEMIOL, V51, P1025, DOI 10.1016/S0895-4356(98)00094-8; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Garrido PC, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-31; de Marco R, 2007, AM J RESP CRIT CARE, V175, P32, DOI 10.1164/rccm.200603-381OC; Ekberg-Aronsson M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-98; Fan Vincent S, 2007, COPD, V4, P29, DOI 10.1080/15412550601169430; Fan VS, 2002, CHEST, V122, P429, DOI 10.1378/chest.122.2.429; Fletcher C, 1976, NATURAL HIST CHRONIC; [Anonymous], 2006, GLOB STRAT DIAGN MAN; Halbert RJ, 2006, EUR RESPIR J, V28, P523, DOI 10.1183/09031936.06.00124605; James AL, 2007, EUR RESPIR J, V30, P134, DOI 10.1183/09031936.00146905; Johannessen A, 2005, THORAX, V60, P842, DOI 10.1136/thx.2005.043943; Kim SJ, 2006, INT J TUBERC LUNG D, V10, P1393; Kunzli N, 2005, SWISS MED WKLY, V135, P503; LANGE P, 1989, J INTERN MED, V226, P25; Leplege A, 1998, J CLIN EPIDEMIOL, V51, P1013, DOI 10.1016/S0895-4356(98)00093-6; Lindberg A, 2005, CHEST, V127, P1544, DOI 10.1378/chest.127.5.1544; Mannino DM, 2007, THORAX, V62, P237, DOI 10.1136/thx.2006.068379; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Mannino DM, 2006, THORAX, V61, P472, DOI 10.1136/thx.2005.052449; Mannino DM, 2006, AM J RESP CRIT CARE, V173, P985, DOI 10.1164/rccm.200508-1344OC; Mannino DM, 2006, RESP MED, V100, P115, DOI 10.1016/j.rmed.2005.03.035; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; Mapel DW, 2000, ARCH INTERN MED, V160, P2653, DOI 10.1001/archinte.160.17.2653; Martin BW, 1997, SOZ PRAVENTIV MED, V42, P67, DOI 10.1007/BF01318136; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; Pena VS, 2000, CHEST, V118, P981, DOI 10.1378/chest.118.4.981; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Schilling J, 2001, SOZ PRAVENTIV MED, V46, P195, DOI 10.1007/BF01324256; Shirtcliffe P, 2007, EUR RESPIR J, V30, P232, DOI 10.1183/09031936.00157906; Viegi G, 2000, CHEST, V117, p339S; Wareing PW, 2001, INT J FOOD SCI TECH, V36, P1, DOI 10.1046/j.1365-2621.2001.00419.x	35	102	105	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	SEP	2008	63	9					768	774		10.1136/thx.2007.093724		7	Respiratory System	Respiratory System	341PF	WOS:000258725700005	18505800	
J	Mudarri, D; Fisk, WJ				Mudarri, D.; Fisk, W. J.			Public health and economic impact of dampness and mold	INDOOR AIR			English	Article						public; health; economic; impact; dampness; mold	BUILDING-RELATED SYMPTOMS; ADOLESCENT SCHOOL-CHILDREN; RESPIRATORY SYMPTOMS; OFFICE WORKERS; RISK-FACTORS; FLOOR DUST; AIRWAY INFLAMMATION; ASTHMA PREVALENCE; SYSTEMIC SYMPTOMS; EXPOSURE	The public health risk and economic impact of dampness and mold exposures was assessed using current asthma as a health endpoint. Individual risk of current asthma from exposure to dampness and mold in homes from W.J. Fisk, Q. Lei-Gomez & M.J. Mendell [(2007) Indoor Air 17, 226-235], and asthma risks calculated from additional studies that reported the prevalence of dampness and mold in homes were used to estimate the proportion of US current asthma cases that are attributable to dampness and mold exposure at 21% (95% confidence internal 12-29%). An examination of the literature covering dampness and mold in schools, offices, and institutional buildings, which is summarized in the Appendix, suggests that risks from exposure in these buildings are similar to risks from exposures in homes. Of the 21.8 million people reported to have asthma in the USA, approximately 4.6 (2.7-6.3) million cases are estimated to be attributable to dampness and mold exposure in the home. Estimates of the national cost of asthma from two prior studies were updated to 2004 and used to estimate the economic impact of dampness and mold exposures. By applying the attributable fraction to the updated national annual cost of asthma, the national annual cost of asthma that is attributable to dampness and mold exposure in the home is estimated to be $3.5 billion ($2.1-4.8 billion). Analysis indicates that exposure to dampness and mold in buildings poses significant public health and economic risks in the USA. These findings are compatible with public policies and programs that help control moisture and mold in buildings.	Lawrence Berkeley Natl Lab, Indoor Environm Dept, Berkeley, CA 94720 USA; US EPA, Indoor Environm Div, Off Radiat & Indoor Air, Washington, DC 20460 USA	Fisk, WJ (reprint author), Lawrence Berkeley Natl Lab, Indoor Environm Dept, 1 Cyclotron Rd,90R3058, Berkeley, CA 94720 USA.	wjfisk@lbl.gov					Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, INDOOR AIR, V14, P243, DOI 10.1111/j.1600-0668.2004.00240.x; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; *CDC, 2006, ENV HAZ HLTH EFF AST; *CDC, 2006, NCHS NHIS DATA ASTHM; *CDC, 2006, NAT CTR HLTH STAT HL; Chao HJ, 2003, ENVIRON HEALTH PERSP, V111, P1242, DOI 10.1289/ehp.5697; CHIAVERINI LC, 2003, HLTH NUMBERS, V5; Cox-Ganser JM, 2005, ENVIRON HEALTH PERSP, V113, P485, DOI 10.1289/ehp.7559; Dangman Kenneth H, 2005, Conn Med, V69, P9; Ebbehoj NE, 2005, INDOOR AIR, V15, P7, DOI 10.1111/j.1600-0668.2005.00352.x; FISK WJ, 2007, IN PRESS INDOOR AIR; Freeman NCG, 2003, J EXPO ANAL ENV EPID, V13, P169, DOI 10.1038/sj.jea.7500266; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; *IOM, 2004, BOARD HLTH PROM DIS; Lander F, 2001, INFLAMM RES, V50, P227, DOI 10.1007/s000110050748; LEVIN H, 2005, 58694 LBNL; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Meklin T, 2002, INDOOR AIR, V12, P175, DOI 10.1034/j.1600-0668.2002.00169.x; Mendell MJ, 2003, AM J IND MED, V43, P630, DOI 10.1002/ajim.10211; Menzies D, 2003, LANCET, V362, P1785, DOI 10.1016/S0140-6736(03)14897-0; Menzies D, 1998, J ALLERGY CLIN IMMUN, V101, P38, DOI 10.1016/S0091-6749(98)70191-5; Meyer HW, 2005, INDOOR AIR, V15, P17, DOI 10.1111/j.1600-0668.2005.00356.x; Meyer HW, 2004, INDOOR AIR, V14, P65, DOI 10.1046/j.1600-0668.2003.00213.x; Park JH, 2006, INDOOR AIR, V16, P192, DOI 10.1111/j.1600-0668.2005.00415.x; Park JH, 2004, INDOOR AIR, V14, P425, DOI 10.1111/j.1600-0668.2004.00291.x; PRAHL RJ, 2002, MOLD 1 BILLION CHALL; Purokivi MK, 2001, EUR RESPIR J, V18, P951, DOI 10.1183/09031936.01.00201201; Rudblad S, 2001, AM J RHINOL, V15, P135, DOI 10.2500/105065801781543727; RUOTSALAINEN R, 1995, INT ARCH OCC ENV HEA, V66, P369, DOI 10.1007/BF00383142; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; Savilahti R, 2001, ALLERGY, V56, P175, DOI 10.1034/j.1398-9995.2001.056002175.x; Savilahti R, 2000, ARCH ENVIRON HEALTH, V55, P405; Seppanen O, 2002, INDOOR AIR, V12, P98, DOI 10.1034/j.1600-0668.2002.01111.x; Slezak JA, 1998, J ASTHMA, V35, P203, DOI 10.3109/02770909809068208; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; SPENGLER J, 1994, INDOOR AIR, V4, P72, DOI 10.1111/j.1600-0668.1994.t01-2-00002.x; Stark PC, 2003, AM J RESP CRIT CARE, V168, P232, DOI 10.1164/rccm.200207-730OC; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; Taskinen T, 1999, ACTA PAEDIATR, V88, P1373, DOI 10.1080/080352599750030112; U.S. Census Bureau, 2006, STAT ABSTR US; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P58; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262	46	102	105	4	29	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	JUN	2007	17	3					226	235		10.1111/j.1600-0668.2007.00474.x		10	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	183VM	WOS:000247600500006	17542835	
J	Roth, U; von Roepenack-Lahaye, E; Clemens, S				Roth, Udo; von Roepenack-Lahaye, Edda; Clemens, Stephan			Proteome changes in Arabidopsis thaliana roots upon exposure to Cd2+	JOURNAL OF EXPERIMENTAL BOTANY			English	Article						cadmium; heavy metal accumulation; heavy metal tolerance; MALDI-TOF-MS; phytochelatins; proteomics	GLUTATHIONE S-TRANSFERASES; POLYACRYLAMIDE-GELS; MEMBRANE PROTEOME; CADMIUM RESPONSE; PLANT-RESPONSES; FISSION YEAST; PROTEINS; STRESS; METALS; ACCUMULATION	Cadmium is a major environmental pollutant that enters human food via accumulation in crop plants. Responses of plants to cadmium exposure-which directly influence accumulation rates-are not well understood. In general, little is known about stress-elicited changes in plants at the proteome level. Alterations in the root proteome of hydroponically grown Arabidopsis thaliana plants treated with 10 mu M Cd2+ for 24 h are reported here. These conditions trigger the synthesis of phytochelatins (PCs), glutathione-derived metal-binding peptides, shown here as PC2 accumulation. Two-dimensional gel electrophoresis using different pH gradients in the first dimension detected on average similar to 1100 spots per gel type. Forty-one spots indicated significant changes in protein abundance upon Cd2+ treatment. Seventeen proteins found in 25 spots were identified by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Selected results were independently confirmed by western analysis and selective enrichment of a protein family (glutathione S-transferases) through affinity chromatography. Most of the identified proteins belong to four different classes: metabolic enzymes such as ATP sulphurylase, glycine hydroxymethyltransferase, and trehalose-6-phosphate phosphatase; glutathione S-transferases; latex allergen-like proteins; and unknown proteins. These results represent a basis for reverse genetics studies to better understand plant responses to toxic metal exposure and to the generation of internal sinks for reduced sulphur.	Leibniz Inst Plant Biochem, Halle, Germany	Clemens, S (reprint author), Leibniz Inst Plant Biochem, Halle, Germany.	sclemens@ipb-halle.de	Clemens, Stephan/A-5107-2009	Clemens, Stephan/0000-0003-0570-1060			Amme S, 2006, J EXP BOT, V57, P1537, DOI 10.1093/jxb/erj129; Baginsky S, 2006, J EXP BOT, V57, P1485, DOI 10.1093/jxb/erj130; Barbey R, 2005, EMBO J, V24, P521, DOI 10.1038/sj.emboj.7600556; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; Carter C, 2004, PLANT CELL, V16, P3285, DOI 10.1105/tpc.104.027078; Castro AJ, 2005, J EXP BOT, V56, P2783, DOI 10.1093/jxb/eri271; Chen DR, 2003, MOL BIOL CELL, V14, P214, DOI 10.1091/mbc.E02-08-0499; Clemens S, 1998, P NATL ACAD SCI USA, V95, P12043, DOI 10.1073/pnas.95.20.12043; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett C, 2002, ANNU REV PLANT BIOL, V53, P159, DOI 10.1146/annurev.arplant.53.100301.135154; Connolly EL, 2002, PLANT CELL, V14, P1347, DOI 10.1105/tpc.001263; DEKNECHT JA, 1995, PLANT SCI, V106, P9, DOI 10.1016/0168-9452(95)04066-4; Dixon DP, 2002, GENOME BIOL, V3; Edwards R, 2000, TRENDS PLANT SCI, V5, P193, DOI 10.1016/S1360-1385(00)01601-0; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Fauchon M, 2002, MOL CELL, V9, P713, DOI 10.1016/S1097-2765(02)00500-2; Friso G, 2004, PLANT CELL, V16, P478, DOI 10.1105/tpc.017814; Garg AK, 2002, P NATL ACAD SCI USA, V99, P15898, DOI 10.1073/pnas.252637799; Gorg A, 2000, ELECTROPHORESIS, V21, P1037, DOI 10.1002/(SICI)1522-2683(20000401)21:6<1037::AID-ELPS1037>3.0.CO;2-V; GRUBBS FE, 1969, TECHNOMETRICS, V11, P1, DOI 10.2307/1266761; Harrison C, 2005, EMBO J, V24, P599, DOI 10.1038/sj.emboj.7600536; Heiss S, 1999, PLANT MOL BIOL, V39, P847, DOI 10.1023/A:1006169717355; Jarup L, 2003, BRIT MED BULL, V68, P167, DOI 10.1093/bmb/ldg032; Jones AME, 2004, PHYTOCHEMISTRY, V65, P1805, DOI 10.1016/j.phytochem.2004.04.005; Kaul S, 2000, NATURE, V408, P796; Kovalchuk I, 2005, MUTAT RES-FUND MOL M, V570, P149, DOI 10.1016/j.mrfmmm.2004.10.004; Lane TW, 2005, NATURE, V435, P42, DOI 10.1038/435042a; Markovic-Housley Z, 2003, J MOL BIOL, V325, P123, DOI 10.1016/S0022-2836(02)01197-X; Marmagne A, 2004, MOL CELL PROTEOMICS, V3, P675, DOI 10.1074/mcp.M400001-MCP200; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; NRIAGU JO, 1988, NATURE, V333, P134, DOI 10.1038/333134a0; Peck SC, 2001, PLANT CELL, V13, P1467, DOI 10.1105/tpc.13.6.1467; Peck SC, 2005, PLANT PHYSIOL, V138, P591, DOI 10.1104/pp.105.060285; Pinot F, 2000, Rev Environ Health, V15, P299; Saito K, 2004, PLANT PHYSIOL, V136, P2443, DOI 10.1104/pp.10.1104.046755; Sappl PG, 2004, PLANT MOL BIOL, V54, P205, DOI 10.1023/B:PLAN.0000028786.57439.b3; Sarry JE, 2006, PROTEOMICS, V6, P2180, DOI 10.1002/pmic.200500543; Sharma SS, 2006, J EXP BOT, V57, P711, DOI 10.1093/jxb/erj073; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Smith AP, 2004, J BIOL CHEM, V279, P26098, DOI 10.1074/jbc.M402807200; Smith AP, 2003, PLANT J, V36, P433, DOI 10.1046/j.1365-313X.2003.01890.x; Suzuki N, 2001, PLANT CELL ENVIRON, V24, P1177, DOI 10.1046/j.1365-3040.2001.00773.x; Utriainen M, 1998, PLANT CELL ENVIRON, V21, P821, DOI 10.1046/j.1365-3040.1998.00326.x; Vatamaniuk OK, 2004, J BIOL CHEM, V279, P22449, DOI 10.1074/jbc.M313142200; Vido K, 2001, J BIOL CHEM, V276, P8469, DOI 10.1074/jbc.M008708200; von Roepenack-Lahaye E, 2004, PLANT PHYSIOL, V134, P548, DOI 10.1104/pp.103.032714; WAGNER GJ, 1993, ADV AGRON, V51, P173, DOI 10.1016/S0065-2113(08)60593-3; Weber M, 2006, PLANT CELL ENVIRON, V29, P950, DOI 10.1111/j.1365-3040.2005.01479.x; Xiang CB, 1998, PLANT CELL, V10, P1539, DOI 10.1105/tpc.10.9.1539; Zimmermann P, 2004, PLANT PHYSIOL, V136, P2621, DOI 10.1104/pp.104.046367	50	102	112	2	30	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0022-0957			J EXP BOT	J. Exp. Bot.	DEC	2006	57	15					4003	4013		10.1093/jxb/erl170		11	Plant Sciences	Plant Sciences	115DX	WOS:000242716100004	17075075	
J	Derendorf, H; Nave, R; Drollmann, A; Cerasoli, F; Wurst, W				Derendorf, H.; Nave, R.; Drollmann, A.; Cerasoli, F.; Wurst, W.			Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma	EUROPEAN RESPIRATORY JOURNAL			English	Review						ciclesonide; clinical relevance; cortisol; lipid conjugation; on-site activation; side-effects	METERED-DOSE INHALER; ADRENAL AXIS FUNCTION; HIGH LUNG DEPOSITION; DRY POWDER INHALER; MOMETASONE FUROATE; FLUTICASONE PROPIONATE; PERSISTENT ASTHMA; BECLOMETHASONE DIPROPIONATE; INTRANASAL CORTICOSTEROIDS; OROPHARYNGEAL DEPOSITION	The pharmacokinetic and pharmacodynamic effects of inhaled corticosterolds (ICS) have shaped the efficacy and safety of these agents in the treatment of asthma. Important pharmacokinetic and pharmacodynamic characteristics that can enhance the efficacy of ICS include small particle size, high glucocorticoid-receptor-binding affinity, long pulmonary residence time and lipid conjugation. These characteristics can increase or prolong the anti-inflammatory effects of an ICS. Important pharmacokinetic characteristics that can enhance the safety of ICS include on-site activation in the lung, low oropharyngeal exposure, negligible oral bioavailability, high protein-binding and rapid systemic clearance. The degree of oropharyngeal exposure is relevant to local side-effects, such as oropharyngeal candidiasis, dysphonia and coughing. Pharmacokinetic properties that influence the degree of systemic exposure are relevant to the pharmacodynamic effect of ICS-induced hypothalamic-pituitary-adrenal axis suppression and cortisol suppression, an indicator of potential long-term systemic side-effects, such as reduced growth velocity and bone density, fractures, and skin bruising and thinning. Therefore, significant differences in the pharmacokinetic and pharmacodynamic characteristics of the currently available inhaled corticosteroids warrant careful consideration when used in clinical practice as they may result in differences in efficacy and local and systemic safety profiles.	Univ Florida, Dept Pharmaceut, Coll Pharm 100494, Gainesville, FL 32610 USA; ALTANA Pharm, Constance, Germany; ALTANA Pharm, Florham Pk, NJ USA	Derendorf, H (reprint author), Univ Florida, Dept Pharmaceut, Coll Pharm 100494, Gainesville, FL 32610 USA.	hartmut@cop.ufl.edu	Derendorf, Hartmut/B-4628-2012	Derendorf, Hartmut/0000-0003-4016-1370			Affrime MB, 2000, J CLIN PHARMACOL, V40, P1227; Agertoft L, 1999, J AEROSOL MED, V12, P161, DOI 10.1089/jam.1999.12.161; Balter MS, 2001, CHEST, V120, P1829, DOI 10.1378/chest.120.6.1829; Banov CH, 2004, J ASTHMA, V41, P5, DOI 10.1081/JAS-120026092; Barnes PJ, 2003, ANN INTERN MED, V139, P359; BARNES PJ, 1990, AM REV RESPIR DIS S, V141, P70; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177; Berger WE, 2005, DRUGS, V65, P1973, DOI 10.2165/00003495-200565140-00005; Borgstrom L, 1999, J ALLERGY CLIN IMMUN, V104, pS246; BORGSTROM L, 1994, EUR RESPIR J, V7, P69, DOI 10.1183/09031936.94.07010069; Boulet LP, 2006, RESP MED, V100, P785, DOI 10.1016/j.rmed.2005.11.030; Boulet LP, 1998, CHEST, V113, P587, DOI 10.1378/chest.113.3.587; Bousquet J, 2000, EUR RESPIR J, V16, P808, DOI 10.1183/09031936.00.16580800; BUHL R, 2005, PULM PHARM THER; COLICE GL, 2005, INHALED CORTICOSTERO; Crim C, 2001, CLIN THER, V23, P1339, DOI 10.1016/S0149-2918(01)80113-2; D'Urzo A, 2005, CURR MED RES OPIN, V21, P1281, DOI 10.1185/030079905X56402; Daley-Yates PT, 2004, CLIN THER, V26, P1905, DOI 10.1016/j.clinthera.2004.11.017; Daley-Yates PT, 2001, BRIT J CLIN PHARMACO, V51, P400, DOI 10.1046/j.0306-5251.2001.01374.x; Derendorf H, 1997, RESP MED, V91, P22, DOI 10.1016/S0954-6111(97)90102-5; DERENDORF H, 1995, J CLIN PHARMACOL, V35, P302; Derendorf H, 2001, EUR RESPIR J, V17, P157, DOI 10.1183/09031936.01.17101570; DERENDORF H, 2002, INHALED STEROIDS AST, P3; DERENDORF H, 1998, J ALLERGY CLIN IMMUN, V101, P440; Derom E, 2005, PULM PHARMACOL THER, V18, P328, DOI 10.1016/j.pupt.2005.01.004; Dickens GR, 2000, ANN ALLERG ASTHMA IM, V84, P528; Dietzel K, 2001, NEW DRUGS ASTHMA ALL, P91; Edsbacker S, 2002, ANN ALLERG ASTHMA IM, V88, P609; Fardon TC, 2004, AM J RESP CRIT CARE, V170, P960, DOI 10.1164/rccm.200404-500oc; Fuller R., 1995, J AEROSOL MED S2, V8, P11, DOI 10.1089/jam.1995.8.Suppl_2.S-11; Georgitis JW, 1999, CHEST, V115, P210, DOI 10.1378/chest.115.1.210; HANANIA NA, 1995, AM J MED, V98, P196, DOI 10.1016/S0002-9343(99)80404-5; Hansel TT, 2006, CLIN THER, V28, P906, DOI 10.1016/j.clinthera.2006.06.014; Hubbard WC, 2003, ANAL BIOCHEM, V322, P243, DOI 10.1016/j.ab.2003.08.006; KALINER M, 2003, WORLD ALL ORG C 18 I, P33; Kelly H W, 1999, Respir Care Clin N Am, V5, P537; Kelly HW, 2003, J ALLERGY CLIN IMMUN, V112, P469, DOI 10.1067/mai.2003.1718; Kennedy MJ, 2002, ANN ALLERG ASTHMA IM, V88, P523; Leach CL, 2006, J AEROSOL MED, V19, P117, DOI 10.1089/jam.2006.19.117; Leach CL, 2002, CHEST, V122, P510, DOI 10.1378/chest.122.2.510; Leach CL, 1998, EUR RESPIR J, V12, P1346, DOI 10.1183/09031936.98.12061346; Lipworth BJ, 2000, DRUG SAFETY, V23, P11, DOI 10.2165/00002018-200023010-00002; Lipworth BJ, 2001, CHEST, V120, P1034, DOI 10.1378/chest.120.3.1034; Lipworth BJ, 1997, THORAX, V52, P476; Martin RJ, 2002, AM J RESP CRIT CARE, V165, P1377, DOI 10.1164/rccm.2105013; Meibohm B, 1997, J CLIN PHARMACOL, V37, P1000; Meibohm B, 1997, J CLIN PHARMACOL, V37, P704; Miller-Larsson A, 2000, AM J RESP CRIT CARE, V162, P1455; Miller-Larsson A, 1998, DRUG METAB DISPOS, V26, P623; MILLERLARSSON A, 2003, AM J RESP CRIT CA S7, V167, pA773; Mutch E, 2003, EUR RESP J S45, V22, pS267; Nave R, 2005, PULM PHARMACOL THER, V18, P390, DOI 10.1016/j.pupt.2005.02.012; Nave R, 2005, EUR J CLIN PHARMACOL, V61, P203, DOI 10.1007/s00228-005-0910-0; Nave R, 2004, CLIN PHARMACOKINET, V43, P479, DOI 10.2165/00003088-200443070-00004; NAVE R, 2003, EUR RESPIR J, V22, pS33; Nave R, 2004, AM J RESP CRIT CARE, V169, pA91; Newman S, 2006, RESP MED, V100, P375, DOI 10.1016/j.rmed.2005.09.027; O'Connor BJ, 2002, ALLERGY, V57, P341; OCONNOR BJ, 2002, EUR RESP J S38, V20, pS406; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Pedersen S, 2006, PEDIATR PULM, V41, P954, DOI 10.1002/ppul.20474; Pedersen S, 1997, ALLERGY, V52, P1; Pelaia G, 2003, LIFE SCI, V72, P1549, DOI 10.1016/S0024-3205(02)02446-3; Pickering H, 2000, CLIN THER, V22, P1483, DOI 10.1016/S0149-2918(00)83046-5; Postma DS, 2001, EUR RESPIR J, V17, P1083, DOI 10.1183/09031936.01.00099701; Pritchard JN, 2001, J AEROSOL MED, V14, pS19; Richter K, 2005, J CLIN PHARMACOL, V45, P146, DOI 10.1177/0091270004271094; Rohatagi S., 2003, Journal of Allergy and Clinical Immunology, V111, pS218, DOI 10.1016/S0091-6749(03)80757-1; Rohatagi S, 2003, J CLIN PHARMACOL, V43, P365, DOI 10.1177/0091270002250998; Rohatagi Shashank, 2005, Am J Ther, V12, P201; RYRFELDT A, 1982, EUR J RESPIR DIS, V63, P86; Selroos O, 2004, J ASTHMA, V41, P771, DOI 10.1081/JAS-200038344; Sharpe M, 2001, DRUGS, V61, P1325, DOI 10.2165/00003495-200161090-00011; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Szefler S, 2005, CHEST, V128, P1104, DOI 10.1378/chest.128.3.1104; THORSSON L, 1994, EUR RESPIR J, V7, P1839, DOI 10.1183/09031936.94.07101839; Todd GRG, 2002, EUR RESPIR J, V19, P1207, DOI 10.1183/09031936.02.00274402; TOOGOOD JH, 1980, J ALLERGY CLIN IMMUN, V65, P145, DOI 10.1016/0091-6749(80)90200-6; Tunek A, 1997, DRUG METAB DISPOS, V25, P1311; UKENA D, 2006, IN PRESS PULM PHARM; Umland SP, 2002, PULM PHARMACOL THER, V15, P35, DOI 10.1006/pupt.2001.0312; Valotis A, 2004, J PHARM SCI-US, V93, P1337, DOI 10.1002/jps.20049; Vanden Burgt J A, 2000, J Allergy Clin Immunol, V106, P1209; Wardlaw A, 2004, ANN ALLERG ASTHMA IM, V93, P49; Weinbrenner A, 2002, J CLIN ENDOCR METAB, V87, P2160, DOI 10.1210/jc.87.5.2160; WILLIAMSON IJ, 1995, EUR RESPIR J, V8, P590; Yudt MR, 2002, MOL ENDOCRINOL, V16, P1719, DOI 10.1210/me.2002-0106; Zeidler Michelle, 2004, Treat Respir Med, V3, P35, DOI 10.2165/00151829-200403010-00005	88	102	115	1	12	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	NOV	2006	28	5					1042	1050		10.1183/09031936.00074905		9	Respiratory System	Respiratory System	104XP	WOS:000241994200026	17074919	
J	Brasche, S; Bischof, W				Brasche, S; Bischof, W			Daily time spent indoors in German homes - Baseline data for the assessment of indoor exposure of German occupants	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Article						time patterns; time spent at home; German homes; exposure estimation	ACTIVITY-PATTERNS	Comprehensive time-activity studies, for use as a basis for estimates of personal exposure, are not readily available in Germany. This analysis of time spent indoors at home is based on data from "Dampness and mould in homes" (2000/ 2001) - a study of about 12,000 persons living in 5530 randomly selected apartments and houses in Germany. The results show the mean times per day people in Germany spend in their homes, classified by gender, age group, building location, city size, region, building type, owner-occupier status, number of people at home, smoking and ventilation habits, moisture emission and ill health factors such as asthma, allergy and number of acute respiratory infections per year. The overall mean time spent at home, 15.7 h per, is in accordance with results from US-American (15.6 h/day) and Canadian (15.8h/day) human activity surveys carried out in the nineties, as well as being consistent with the German Environmental Survey (1990/92) and a small German study in 1987. (c) 2005 Elsevier GmbH. All rights reserved.	Univ Jena, Inst Occupat Social & Environm Med, Dept Indoor Climatol, D-07740 Jena, Germany	Brasche, S (reprint author), Univ Jena, Inst Occupat Social & Environm Med, Dept Indoor Climatol, Bachstr 18, D-07740 Jena, Germany.	sabine.brasche@med.uni-jena.de					BRASCHE S, 2003, BUNDESGESUNDHIETSBL, V8, P683; Chapin F. S., 1974, HUMAN ACTIVITY PATTE; Dorre WH, 1997, J EXPO ANAL ENV EPID, V7, P471; EHLING M, 2003, BLEIBT ZEIT ZEITVERW; HARTMANN T, 2001, THESIS TU DRESDEN I; Krause C., 1998, UMWELTMED FORSCH PRA, V4, P249; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; SCHMIDTHOPFNER SH, 1995, STANDARDS EXPOSITION, P41; Szalai A, 1972, USE TIME DAILY ACTIV	9	102	105	4	30	URBAN & FISCHER VERLAG	JENA	BRANCH OFFICE JENA, P O BOX 100537, D-07705 JENA, GERMANY	1438-4639			INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.		2005	208	4					247	253		10.1016/j.ijheh.2005.03.003		7	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	952OT	WOS:000231016100003	16078638	
J	Basagana, X; Sunyer, J; Kogevinas, M; Zock, JP; Duran-Tauleria, E; Jarvis, D; Burney, P; Anto, JM				Basagana, X; Sunyer, J; Kogevinas, M; Zock, JP; Duran-Tauleria, E; Jarvis, D; Burney, P; Anto, JM		European Community Respiratory Hlt	Socioeconomic status and asthma prevalence in young adults - The European Community Respiratory Health Survey	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						adult; asthma; education; prevalence; social class	DIAGNOSED ASTHMA; ADMISSION RATES; AIR-POLLUTION; RISK-FACTORS; SOCIAL-CLASS; SYMPTOMS; EPIDEMIOLOGY; CHILDREN; AREA; DEPRIVATION	The authors assessed the association between asthma prevalence and socioeconomic status at both the individual and center levels simultaneously .by using data from 32 centers in 15 countries. Included were 10,971 subjects aged 20-44 years selected from the general population and interviewed in 1991-1992. Socioeconomic status at both the individual and aggregated levels was measured on the basis of occupation and educational level. Associations were assessed by using multilevel models adjusted for age, sex, body mass index, parental asthma, childhood respiratory infections, presence of immunoglobulin E to common allergens, rhinitis, smoking, and occupational exposure to irritants. Asthma prevalence was higher in lower socioeconomic groups, whether defined by educational level (odds ratio for finishing full-time studies-<16 vs. >19 years = 1.28, 95% confidence interval: 1.00, 1.64) or social class (odds ratio for semiskilled and unskilled manual workers vs. professional/managerial = 1.51, 95% confidence interval: 1.20, 1.90), regardless of atopic status. The relation was consistent between centers. Irrespective of individual socioeconomic status, subjects living in areas in which educational levels were lower had a higher risk of asthma (p < 0.05). This center-level association partially explained geographic differences in asthma prevalence, but considerable heterogeneity still remained. The authors concluded that community influences of living in a low-educational area are associated with asthma, independently of subjects' own educational level and social class.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Univ Pompeu Fabra, Dept Expt & Hlth Sci, Barcelona, Spain; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England	Sunyer, J (reprint author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, Doctor Aiguader 80, E-08003 Barcelona, Spain.	jsunyer@imim.es	Jarvis, Deborah/E-6494-2011; Basagana, Xavier/C-3901-2017; Kogevinas, Manolis/C-3918-2017; Anto, J/H-2676-2014; Sunyer, J/G-6909-2014	Basagana, Xavier/0000-0002-8457-1489; Anto, J/0000-0002-4736-8529; Sunyer, J/0000-0002-2602-4110			Bozicevic I, 2000, COLLEGIUM ANTROPOL, V24, P325; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Chan-Yeung M., 1999, ASTHMA WORKPLACE, P129; Chatkin JM, 1999, CHEST, V116, P1780, DOI 10.1378/chest.116.6.1780; Chen JT, 2002, ENVIRON HEALTH PERSP, V110, P211; CLARK NM, 1990, PATIENT EDUC COUNS, V15, P191, DOI 10.1016/0738-3991(90)90062-P; CONNOLLY CK, 1989, POSTGRAD MED J, V65, P282; Court CS, 2002, THORAX, V57, P951, DOI 10.1136/thorax.57.11.951; *CTR MULT MOD, 2001, MLWIN VERS 1 1 MULT; Diez-Roux AV, 2000, ANNU REV PUBL HEALTH, V21, P171, DOI 10.1146/annurev.publhealth.21.1.171; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Duran-Tauleria E, 1999, THORAX, V54, P476; ERNST P, 1995, AM J RESP CRIT CARE, V152, P570; Erzen D, 1997, AM J RESP CRIT CARE, V155, P1060; Goldstein H., 1995, MULTILEVEL STAT MODE; Hedeker D, 1996, COMPUT METH PROG BIO, V49, P157, DOI 10.1016/0169-2607(96)01720-8; HOX JJ, 1995, APPL MULTILEVELS ANA; ISOAHO R, 1994, J CLIN EPIDEMIOL, V47, P1109, DOI 10.1016/0895-4356(94)90097-3; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Kogevinas M, 1998, EUR RESPIR J, V11, P1363, DOI 10.1183/09031936.98.11061363; Kreft Ita G. G., 1996, MULTILEVEL TECHNIQUE; Lang DM, 1997, ARCH INTERN MED, V157, P1193, DOI 10.1001/archinte.157.11.1193; Larsen K, 2000, BIOMETRICS, V56, P909, DOI 10.1111/j.0006-341X.2000.00909.x; LEWIS S, 1995, EUR RESPIR J, V8, P349, DOI 10.1183/09031936.95.08030349; Lewis SA, 2001, J ALLERGY CLIN IMMUN, V107, P615; LIBERATOS P, 1988, EPIDEMIOL REV, V10, P87; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; LITTLEJOHNS P, 1993, RESP MED, V87, P139, DOI 10.1016/0954-6111(93)90142-M; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McDonnell WF, 1999, ENVIRON RES, V80, P110, DOI 10.1006/enrs.1998.3894; MCWHORTER WP, 1989, AM REV RESPIR DIS, V139, P721; Molarius A, 1998, QUALITY ASSESSMENT D; Montnemery P, 2001, RESP MED, V95, P744, DOI 10.1053/rmed.2001.1129; Pallasaho P, 1999, RESP MED, V93, P798, DOI 10.1016/S0954-6111(99)90265-2; Pearce N, 1998, ASTHMA EPIDEMIOLOGY; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Rona RJ, 2000, THORAX, V55, P239, DOI 10.1136/thorax.55.3.239; Rose D., 1997, CONSTRUCTING CLASSES; Salmond C, 1999, J EPIDEMIOL COMMUN H, V53, P476; Snijders T. A. B., 1999, MULTILEVEL ANAL INTR; Sunyer J, 1998, AM J RESP CRIT CARE, V157, P512; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; Verlato G, 2002, ARCH ENVIRON HEALTH, V57, P48; WALTERS S, 1995, THORAX, V50, P948, DOI 10.1136/thx.50.9.948; Watson JP, 1996, EUR RESPIR J, V9, P2087, DOI 10.1183/09031936.96.09102087; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; Wieringa MH, 1997, EUR RESPIR J, V10, P1460, DOI 10.1183/09031936.97.10071460; Wright RJ, 2003, NEIGHBORHOODS HLTH, P233; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383	52	102	105	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUL 15	2004	160	2					178	188		10.1093/aje/kwh186		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	836LG	WOS:000222556600012	15234940	
J	Bjorksten, B				Bjorksten, B			Effects of intestinal microflora and the environment on the development of asthma and allergy	SPRINGER SEMINARS IN IMMUNOPATHOLOGY			English	Article						intestinal microflora; environment; asthma and allergy	PLACEBO-CONTROLLED TRIAL; NEONATAL GUT FLORA; ATOPIC DISEASE; PARENTAL SMOKING; EARLY-CHILDHOOD; INFECTIOUS-DISEASES; BCG VACCINATION; EARLY EXPOSURE; HOUSE-DUST; SCHOOL-AGE	The aim of previous research into the causes of allergic diseases, including asthma was mostly to identify potential risk factors in the environment. No major risk factors have been identified, however. Over the past 10 years, focus has, therefore, more been directed towards protective factors that could enhance the development of tolerance to allergens which were previously encountered early in life, but are now lost in modern affluent societies. In particular, the role of childhood infections has been discussed, but so far these studies have not been conclusive. Recent epidemiological studies and experimental research suggest that the microbial environment and exposure to microbial products in infancy modifies immune responses and enhances the development of tolerance to ubiquitous allergens. The intestinal microflora may play a particular role in this respect, as it is the major external driving force in the maturation of the immune system after birth, and animal experiments have shown it to be a prerequisite for normal development of oral tolerance. Recent studies have shown differences in the composition of the microflora between healthy and allergic infants in countries with a high and low prevalence of allergies and between healthy and allergic infants within such countries. These differences are apparent within the first week of life and thus precede clinical symptoms. The use of live microorganisms that might be beneficial to health has a long tradition and the safety is well documented. Very recently, several prospective intervention studies, modifying the gut flora from birth have yielded encouraging results and may suggest a new mode of primary prevention of allergy in the future.	Karolinska Inst, Ctr Allergy Res, S-17177 Stockholm, Sweden; Karolinska Inst, Dept Environm Med, S-17177 Stockholm, Sweden	Bjorksten, B (reprint author), Karolinska Inst, Ctr Allergy Res, S-17177 Stockholm, Sweden.	bengt.bjorksten@cfa.ki.se					Adlerberth I, 1998, EPIDEMIOL INFECT, V121, P587, DOI 10.1017/S0950268898001484; Alm JS, 1997, LANCET, V350, P400, DOI 10.1016/S0140-6736(97)02207-1; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Azizi B. H. O., 1995, Southeast Asian Journal of Tropical Medicine and Public Health, V26, P280; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P72, DOI 10.1067/mai.2002.125833; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; BJORKSTEN B, 1983, IMMUNOL TODAY, V4, P215, DOI 10.1016/0167-5699(83)90029-4; Borriello SP, 2003, CLIN INFECT DIS, V36, P775, DOI 10.1086/368080; Bottcher MF, 2003, CLIN EXP ALLERGY, V33, P295, DOI 10.1046/j.1365-2222.2003.01562.x; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; BRANDTZAEG P, 1996, RECENT DEV INFANT NU, P349; BULLEN CL, 1977, J MED MICROBIOL, V10, P403; BURR ML, 1993, ARCH DIS CHILD, V68, P724; Cook DG, 1997, THORAX, V52, P1081; D'Souza AL, 2002, BRIT MED J, V324, P1361, DOI 10.1136/bmj.324.7350.1361; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; GERRARD JW, 1976, ANN ALLERGY, V37, P91; Golding J, 1997, EARLY HUM DEV, V49, pS83, DOI 10.1016/S0378-3782(97)00055-8; Golding J, 1997, EARLY HUM DEV, V49, pS121, DOI 10.1016/S0378-3782(97)00058-3; Gruber C, 2001, PEDIATR ALLERGY IMMU, V12, P296, DOI 10.1034/j.1399-3038.2001.1r046.x; Halmerbauer G, 2002, PEDIATR ALLERGY IMMU, V13, P47, DOI 10.1034/j.1399-3038.13.s.15.11.x; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Holzapfel WH, 1998, INT J FOOD MICROBIOL, V41, P85, DOI 10.1016/S0168-1605(98)00044-0; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Huang JS, 2002, DIGEST DIS SCI, V47, P2625, DOI 10.1023/A:1020501202369; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Julge K, 2001, CLIN EXP ALLERGY, V31, P1854, DOI 10.1046/j.1365-2222.2001.01235.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; KANDLER O, 1984, P 40 GEN M SOC INS M; Kirjavainen PV, 2002, GUT, V51, P51, DOI 10.1136/gut.51.1.51; Kirjavainen PV, 2003, J PEDIATR GASTR NUTR, V36, P223, DOI 10.1097/00005176-200302000-00012; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2003, ALLERGY, V58, P461, DOI 10.1034/j.1398-9995.2003.00175.x; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; MEVISSENVERHAGE EAE, 1985, EUR J CLIN MICROBIOL, V4, P14, DOI 10.1007/BF02148653; MEVISSENVERHAGE EAE, 1985, EUR J CLIN MICROBIOL, V4, P273, DOI 10.1007/BF02013651; Mikelsaar Marika, 2002, Microbial Ecology in Health and Disease, V14, P75, DOI 10.1080/08910600260081711; Nafstad P, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.3.e38; Nagler-Anderson C, 2001, NAT REV IMMUNOL, V1, P59, DOI 10.1038/35095573; Nagler-Anderson Cathryn, 2001, Trends in Immunology, V22, P120, DOI 10.1016/S1471-4906(00)01830-5; Neish AS, 2002, MICROBES INFECT, V4, P309, DOI 10.1016/S1286-4579(02)01543-5; Nilssen L, 1997, PEDIATR ALLERGY IMMU, V8, P134, DOI 10.1111/j.1399-3038.1997.tb00166.x; Ouwehand AC, 2001, J ALLERGY CLIN IMMUN, V108, P144, DOI 10.1067/mai.2001.115754; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat J, 1998, EUR RESPIR J, V12, p28S; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Sepp Epp, 2000, Microbial Ecology in Health and Disease, V12, P22, DOI 10.1080/089106000435554; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sigurs N, 2002, RESPIR RES, V3, DOI 10.1186/rr186; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1997, THORAX, V52, P905; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1998, THORAX, V53, P204; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; Strachan DP, 2000, THORAX S1, V55, pS2; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Van Niel CW, 2002, PEDIATRICS, V109, P678, DOI 10.1542/peds.109.4.678; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	77	102	106	2	25	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0344-4325			SPRINGER SEMIN IMMUN	Springer Semin. Immunopathol.	FEB	2004	25	3-4					257	270		10.1007/s00281-003-0142-2		14	Immunology; Pathology	Immunology; Pathology	801IP	WOS:000220089900003	15007630	
J	Hashimoto, M; Kisseleva, L; Sawa, S; Furukawa, T; Komatsu, S; Koshiba, T				Hashimoto, M; Kisseleva, L; Sawa, S; Furukawa, T; Komatsu, S; Koshiba, T			A novel rice PR10 protein, RSOsPR10, specifically induced in roots by biotic and abiotic stresses, possibly via the jasmonic acid signaling pathway	PLANT AND CELL PHYSIOLOGY			English	Article						fungal infection; jasmonic acid; Oryza sativa; pathogenesis-related (PR) protein; root specific; stress response	PATHOGENESIS-RELATED PROTEINS; BIRCH POLLEN ALLERGEN; PISUM-SATIVUM L; DISEASE RESISTANCE; ABSCISIC-ACID; RIBONUCLEASE-ACTIVITY; SEQUENCE SIMILARITY; TRANSGENIC TOBACCO; GENE-EXPRESSION; CDNA CLONING	Plant roots have important roles not only in absorption of water and nutrients, but also in stress tolerance such as desiccation, salt, and low temperature. We have investigated stress-response proteins from rice roots using 2-dimensional polyacrylamide-gel electrophoresis and found a rice protein, RO-292, which was induced specifically in roots when 2-week-old rice seedlings were subjected to salt and drought stress. The full-length RO-292 cDNA was cloned, and was determined to encode a protein of 160 amino acid residues (16.9 kDa, pI 4.74). The deduced amino acid sequence showed high similarity to known rice PR10 proteins, OSPR10a/PBZ1 and OsPR10b. RO-292 mRNA accumulated rapidly upon drought, NaCl, jasmonic acid and probenazole, but not by exposure to low temperature or by abscisic acid and salicylic acid. The RO-292 gene was also up-regulated by infection with rice blast fungus. Interestingly, induction was observed almost exclusively in roots, thus we named the gene RSOsPR10 (root specific rice PR10). The present results indicate that RSOsPR10 is a novel rice PR10 protein, which is rapidly induced in roots by salt, drought stresses and blast fungus infection possibly through activation of the jasmonic acid signaling pathway, but not the abscisic acid and salicylic acid signaling pathway.	Tokyo Metropolitan Univ, Dept Biol Sci, Hachioji, Tokyo 1920397, Japan; Moscow MV Lomonosov State Univ, Ctr Biotechnol, Moscow 119992, Russia; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Metropolitan Coll, Akishima, Tokyo 1968540, Japan; Natl Inst Agrobiol Sci, Dept Mol Genet, Tsukuba, Ibaraki 3058602, Japan	Koshiba, T (reprint author), Tokyo Metropolitan Univ, Dept Biol Sci, Minami Osawa, Hachioji, Tokyo 1920397, Japan.	koshiba-tomokazu@c.metro-u.ac.jp					Agrawal Ganesh Kumar, 2002, Proteomics, V2, P947, DOI 10.1002/1615-9861(200208)2:8<947::AID-PROT947>3.0.CO;2-J; Agrawal GK, 2002, PLANT PHYSIOL BIOCH, V40, P1061, DOI 10.1016/S0981-9428(02)01471-7; ALEXANDER D, 1993, P NATL ACAD SCI USA, V90, P7327, DOI 10.1073/pnas.90.15.7327; Bantignies B, 2000, PLANT MOL BIOL, V42, P871, DOI 10.1023/A:1006475303115; BARRATT DHP, 1991, PLANTA, V184, P14, DOI 10.1007/BF00208230; BREITENEDER H, 1995, EUR J BIOCHEM, V233, P484, DOI 10.1111/j.1432-1033.1995.484_2.x; BREITENEDER H, 1989, EMBO J, V8, P1935; Bufe A, 1996, PLANTA, V199, P413; Carpin S, 1998, PLANT MOL BIOL, V36, P791, DOI 10.1023/A:1005951208815; CLAES B, 1990, PLANT CELL, V2, P19, DOI 10.1105/tpc.2.1.19; CROWELL DN, 1992, PLANT MOL BIOL, V18, P459, DOI 10.1007/BF00040662; Ekramoddoullah AKM, 2000, PHYSIOL PLANTARUM, V110, P240, DOI 10.1034/j.1399-3054.2000.110214.x; FRISTENSKY B, 1988, PLANT MOL BIOL, V11, P713, DOI 10.1007/BF00017470; Fujimoto Y, 1998, EUR J BIOCHEM, V258, P794, DOI 10.1046/j.1432-1327.1998.2580794.x; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Gonneau M, 2001, PLANT MOL BIOL, V46, P539, DOI 10.1023/A:1010693213437; HoffmannSommergruber K, 1997, GENE, V197, P91, DOI 10.1016/S0378-1119(97)00246-1; Huang JC, 1997, PLANT MOL BIOL, V34, P681, DOI 10.1023/A:1005824306560; ITURRIAGA EA, 1994, PLANT MOL BIOL, V24, P235, DOI 10.1007/BF00040591; Jwa NS, 2001, BIOCHEM BIOPH RES CO, V286, P973, DOI 10.1006/bbrc.2001.5507; Lee MW, 2001, MOL PLANT MICROBE IN, V14, P527, DOI 10.1094/MPMI.2001.14.4.527; LINTHORST HJM, 1991, CRIT REV PLANT SCI, V10, P123, DOI 10.1080/07352689109382309; Lo SCC, 1999, MOL PLANT MICROBE IN, V12, P479, DOI 10.1094/MPMI.1999.12.6.479; MATTON DP, 1989, MOL PLANT MICROBE IN, V2, P325, DOI 10.1094/MPMI-2-325; McGee J. David, 2001, Molecular Plant-Microbe Interactions, V14, P877, DOI 10.1094/MPMI.2001.14.7.877; Midoh N, 1996, PLANT CELL PHYSIOL, V37, P9; MOISEYEV GP, 1994, PLANTA, V193, P470; Moons A, 1997, PLANT CELL, V9, P2243; MYLONA P, 1994, PLANT MOL BIOL, V26, P39, DOI 10.1007/BF00039518; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Poupard P, 2003, PHYSIOL MOL PLANT P, V62, P3, DOI 10.1016/S0885-5765(03)00008-0; Rakwal R, 1999, ELECTROPHORESIS, V20, P3472, DOI 10.1002/(SICI)1522-2683(19991101)20:17<3472::AID-ELPS3472>3.3.CO;2-S; Rakwal R, 2003, PLANT PHYSIOL BIOCH, V41, P453, DOI 10.1016/S0981-9428(03)00053-6; Rakwal R, 2001, PLANT SCI, V161, P469, DOI 10.1016/S0168-9452(01)00433-2; Reymond P, 1998, CURR OPIN PLANT BIOL, V1, P404, DOI 10.1016/S1369-5266(98)80264-1; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; SELABUURLAGE MB, 1993, PLANT PHYSIOL, V101, P857; SIKORSKI MM, 1996, PLANT PHYSIOL, V110, P335; SOMSSICH IE, 1986, P NATL ACAD SCI USA, V83, P2427, DOI 10.1073/pnas.83.8.2427; Swoboda I, 1996, PHYSIOL PLANTARUM, V96, P433; Tanaka N, 2003, MOL PLANT MICROBE IN, V16, P422, DOI 10.1094/MPMI.2003.16.5.422; Truesdell GM, 1997, PLANT MOL BIOL, V33, P737, DOI 10.1023/A:1005728420374; Turner JG, 2002, PLANT CELL, V14, pS153, DOI 10.1105/tpc.000679; Van Loon LC, 1999, PHYSIOL MOL PLANT P, V55, P85, DOI 10.1006/pmpp.1999.0213; Walter MH, 1996, EUR J BIOCHEM, V239, P281, DOI 10.1111/j.1432-1033.1996.0281u.x; WALTER MH, 1990, MOL GEN GENET, V222, P353, DOI 10.1007/BF00633840; WARNER SAJ, 1992, PLANT MOL BIOL, V19, P555, DOI 10.1007/BF00026782; WARNER SAJ, 1993, PLANT J, V3, P191, DOI 10.1046/j.1365-313X.1993.t01-11-00999.x; WOLOSHUK CP, 1991, PLANT CELL, V3, P619, DOI 10.1105/tpc.3.6.619; Xiong LZ, 2003, PLANT CELL, V15, P745, DOI 10.1105/tpc.008714; ZEEVAART JAD, 1988, ANNU REV PLANT PHYS, V39, P439, DOI 10.1146/annurev.arplant.39.1.439	51	102	117	1	20	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0032-0781			PLANT CELL PHYSIOL	Plant Cell Physiol.		2004	45	5					550	559		10.1093/pcp/pch063		10	Plant Sciences; Cell Biology	Plant Sciences; Cell Biology	825LY	WOS:000221761200007	15169937	
J	Valenta, R; Kraft, D				Valenta, R; Kraft, D			From allergen structure to new forms of allergen-specific immunotherapy	CURRENT OPINION IN IMMUNOLOGY			English	Review							BIRCH POLLEN ALLERGEN; DUST MITE ALLERGEN; T-CELL EPITOPE; CROSS-REACTIVE ALLERGEN; SKIN PRICK TEST; BET-V-I; ENGINEERED HYPOALLERGENIC DERIVATIVES; ASPERGILLUS-FUMIGATUS ALLERGENS; QUANTITATIVE IGE INHIBITION; SITE-DIRECTED MUTAGENESIS	During the past decade, genetic information for most of the common allergens has been obtained. Using these genetic blueprints it has become possible to reconstruct, by recombinant DNA technology, almost complete repertoires of the relevant allergens and their epitopes. Recombinant allergens with the allergenic features of naturally occurring allergens have promoted allergy research and form the basis of new multiallergen tests for refined allergy diagnosis. Allergen derivatives with reduced allergenic activity have also been produced by recombinant DNA technology to increase safety and specificity of allergen-specific immunotherapy. These derivatives can be engineered to contain relevant T cell epitopes and to maintain those sequence motifs which are required for inducing protective antibody responses and therefore hold great promise for improving allergen-specific immunotherapy.	Univ Vienna, Sch Med, Dept Pathophysiol, A-1090 Vienna, Austria	Valenta, R (reprint author), Univ Vienna, Sch Med, Dept Pathophysiol, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	Rudolf.Valenta@akh-wien.ac.at					Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; Arquint O, 1999, J ALLERGY CLIN IMMUN, V104, P1239; Ball T, 1999, FASEB J, V13, P1277; Ball T, 1999, EUR J IMMUNOL, V29, P2026, DOI 10.1002/(SICI)1521-4141(199906)29:06<2026::AID-IMMU2026>3.0.CO;2-2; BALL T, 1994, J BIOL CHEM, V269, P28323; Ballmer-Weber BK, 2002, J ALLERGY CLIN IMMUN, V110, P167, DOI 10.1067/mai.2002.125601; Beezhold DH, 2001, J ALLERGY CLIN IMMUN, V107, P1069, DOI 10.1067/mai.2001.115482; Bhalla PL, 1999, P NATL ACAD SCI USA, V96, P11676, DOI 10.1073/pnas.96.20.11676; Binder M, 2001, J IMMUNOL, V167, P5470; Bonura A, 2001, INT ARCH ALLERGY IMM, V126, P32, DOI 10.1159/000049492; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; BREITENEDER H, 1993, EUR J BIOCHEM, V212, P355, DOI 10.1111/j.1432-1033.1993.tb17669.x; BREITENEDER H, 1989, EMBO J, V8, P1935; BRINER TJ, 1993, P NATL ACAD SCI USA, V90, P7608, DOI 10.1073/pnas.90.16.7608; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Crameri R, 1998, INT IMMUNOL, V10, P1211, DOI 10.1093/intimm/10.8.1211; Crameri R, 1998, INT ARCH ALLERGY IMM, V115, P99, DOI 10.1159/000023889; EBNER C, 1993, J IMMUNOL, V150, P1047; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; FANG KSY, 1988, P NATL ACAD SCI USA, V85, P895, DOI 10.1073/pnas.85.3.895; Fedorov AA, 1997, STRUCTURE, V5, P33, DOI 10.1016/S0969-2126(97)00164-0; Ferreira F, 1998, FASEB J, V12, P231; Ferreira F, 2002, INT ARCH ALLERGY IMM, V128, P171, DOI 10.1159/000064249; Ferreira F, 1996, J EXP MED, V183, P599, DOI 10.1084/jem.183.2.599; Ferreira FD, 1996, J ALLERGY CLIN IMMUN, V97, P95, DOI 10.1016/S0091-6749(96)70287-7; Flicker S, 2000, J IMMUNOL, V165, P3849; Fluckiger S, 2002, EUR J IMMUNOL, V32, P10, DOI 10.1002/1521-4141(200201)32:1<10::AID-IMMU10>3.0.CO;2-I; Focke M, 2001, FASEB J, V15, P2042, DOI 10.1096/fj.01-0016fje; Gajhede M, 1996, NAT STRUCT BIOL, V3, P1040, DOI 10.1038/nsb1296-1040; Ganglberger E, 2000, FASEB J, V14, P2177, DOI 10.1096/fj.99-1000com; Ganglberger E, 2001, FASEB J, V15, P2524, DOI 10.1096/fj.00-0888fje; Ganglberger E, 2001, INT ARCH ALLERGY IMM, V125, P216, DOI 10.1159/000053819; GRONLUND H, 2002, IN PRESS IMMUNOLOGY; Hartl A, 1999, J ALLERGY CLIN IMMUN, V103, P107, DOI 10.1016/S0091-6749(99)70533-6; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Haselden BM, 2000, INT ARCH ALLERGY IMM, V122, P229, DOI 10.1159/000024403; HAUSWIRTH AW, 2002, J ALLERGY CLIN IMMUN, V110, P78; Hayek B, 1998, J IMMUNOL, V161, P7031; Heiss S, 1999, J INVEST DERMATOL, V113, P830, DOI 10.1046/j.1523-1747.1999.00796.x; Hemmann S, 1999, J ALLERGY CLIN IMMUN, V104, P601, DOI 10.1016/S0091-6749(99)70330-1; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hoffmann-Sommergruber K, 1999, J ALLERGY CLIN IMMUN, V104, P478, DOI 10.1016/S0091-6749(99)70397-0; HOYNE GF, 1993, J EXP MED, V178, P1783, DOI 10.1084/jem.178.5.1783; Hsu CH, 1996, INT IMMUNOL, V8, P1405, DOI 10.1093/intimm/8.9.1405; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; Kauppinen J, 1999, CLIN EXP ALLERGY, V29, P989; Kazemi-Shirazi L, 2000, J ALLERGY CLIN IMMUN, V105, P116, DOI 10.1016/S0091-6749(00)90186-6; Kazemi-Shirazi L, 2002, INT ARCH ALLERGY IMM, V127, P259, DOI 10.1159/000057742; Kihlstrom A, 2002, J ALLERGY CLIN IMMUN, V110, P78, DOI 10.1067/mai.2002.125829; King TP, 2001, J IMMUNOL, V166, P6057; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; Korematsu S, 2000, J IMMUNOL, V165, P2895; Kronqvist M, 2000, CLIN EXP ALLERGY, V30, P670, DOI 10.1046/j.1365-2222.2000.00822.x; Kronqvist M, 2001, INT ARCH ALLERGY IMM, V126, P41, DOI 10.1159/000049493; Kusunoki T, 2000, ANN ALLERG ASTHMA IM, V84, P366, DOI 10.1016/S1081-1206(10)62788-3; Linhart B, 2002, FASEB J, V16, P1301, DOI 10.1096/fj.01-1012fje; MAGLIO O, 2002, IN PRESS PROTEIN ENG; Menz G, 1996, CLIN EXP ALLERGY, V26, P50, DOI 10.1111/j.1365-2222.1996.tb00056.x; Mirza O, 2000, J IMMUNOL, V165, P331; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Moverare R, 2002, INT ARCH ALLERGY IMM, V128, P325, DOI 10.1159/000063855; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Muller U, 1997, CLIN EXP ALLERGY, V27, P915; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Niederberger V, 2002, EUR J IMMUNOL, V32, P576, DOI 10.1002/1521-4141(200202)32:2<576::AID-IMMU576>3.0.CO;2-U; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 1999, FASEB J, V13, P843; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Noguchi E, 1996, INT ARCH ALLERGY IMM, V110, P380; Nopp A, 2000, J ALLERGY CLIN IMMUN, V106, P101, DOI 10.1067/mai.2000.106924; Okada T, 1998, FEBS LETT, V434, P255, DOI 10.1016/S0014-5793(98)00992-2; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Olsson S, 1998, MOL IMMUNOL, V35, P1017, DOI 10.1016/S0161-5890(98)00101-1; Pandjaitan B, 2000, J ALLERGY CLIN IMMUN, V105, P279, DOI 10.1016/S0091-6749(00)90077-0; Pauli G, 2000, CLIN EXP ALLERGY, V30, P1076; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Pauli G, 2000, INT ARCH ALLERGY IMM, V123, P183, DOI 10.1159/000024443; Peng ZK, 2001, INT IMMUNOL, V13, P3, DOI 10.1093/intimm/13.1.3; Rabjohn P, 2002, INT ARCH ALLERGY IMM, V128, P15, DOI 10.1159/000057999; Raz E, 1996, P NATL ACAD SCI USA, V93, P5141, DOI 10.1073/pnas.93.10.5141; Rodriguez R, 2001, INT ARCH ALLERGY IMM, V125, P185, DOI 10.1159/000053815; ROGERS BL, 1993, MOL IMMUNOL, V30, P559, DOI 10.1016/0161-5890(93)90030-F; ROGERS BL, 1991, J IMMUNOL, V147, P2547; Rossi RE, 2001, ALLERGY, V56, P1180, DOI 10.1034/j.1398-9995.2001.00258.x; Ruoppi P, 2001, CLIN EXP ALLERGY, V31, P915, DOI 10.1046/j.1365-2222.2001.01086.x; Scheurer S, 2001, J ALLERGY CLIN IMMUN, V107, P724, DOI 10.1067/mai.2001.113864; Schmid-Grendelmeier P, 2001, INT ARCH ALLERGY IMM, V125, P96, DOI 10.1159/000053803; Schramm G, 1999, J IMMUNOL, V162, P2406; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Singh MB, 1999, INT ARCH ALLERGY IMM, V119, P75, DOI 10.1159/000024181; Slater JE, 1998, J ALLERGY CLIN IMMUN, V102, P469, DOI 10.1016/S0091-6749(98)70137-X; Smith AM, 1996, MOL IMMUNOL, V33, P399, DOI 10.1016/0161-5890(95)00150-6; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Suck R, 2002, ALLERGY, V57, P821, DOI 10.1034/j.1398-9995.2002.23705.x; Swoboda I, 2002, EUR J IMMUNOL, V32, P270, DOI 10.1002/1521-4141(200201)32:1<270::AID-IMMU270>3.0.CO;2-X; Swoboda I, 2002, J IMMUNOL, V168, P4576; Tada Y, 1996, FEBS LETT, V391, P341, DOI 10.1016/0014-5793(96)00773-9; Takai T, 1997, NAT BIOTECHNOL, V15, P754, DOI 10.1038/nbt0897-754; Tang B, 2000, BIOCHEM BIOPH RES CO, V270, P1128, DOI 10.1006/bbrc.2000.2546; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Tinghino R, 2002, J ALLERGY CLIN IMMUN, V109, P314, DOI 10.1067/mai.2002.121528; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; Vailes LD, 2001, CLIN EXP ALLERGY, V31, P1891, DOI 10.1046/j.1365-2222.2001.00745.x; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V88, P889, DOI 10.1016/0091-6749(91)90245-J; VALENTA R, 1993, J ALLERGY CLIN IMMUN, V91, P88, DOI 10.1016/0091-6749(93)90300-5; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1995, CURR OPIN IMMUNOL, V7, P751, DOI 10.1016/0952-7915(95)80043-3; VALENTA R, 1992, INT ARCH ALLERGY IMM, V97, P287; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Hage-Hamsten M, 1999, J ALLERGY CLIN IMMUN, V104, P969; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223; Van Uden J, 1999, J ALLERGY CLIN IMMUN, V104, P902; VANHAGEHAMSTEN M, 2002, IN PRESS CLIN EXP AL; VERDINO P, 2002, EMBO J, V21, P1; Vrtala S, 2000, J IMMUNOL, V165, P6653; Vrtala S, 1998, J IMMUNOL, V160, P6137; Vrtala S, 1997, J CLIN INVEST, V99, P1673, DOI 10.1172/JCI119330; Vrtala S, 2001, FASEB J, V15, P2045, DOI 10.1096/fj.00-0767fje; VRTALA S, 1995, INT ARCH ALLERGY IMM, V107, P290; Vrtala S, 1999, J IMMUNOL, V163, P5489; Wagner B, 2001, J ALLERGY CLIN IMMUN, V108, P621; Wagner S, 2001, INT ARCH ALLERGY IMM, V125, P120, DOI 10.1159/000053805; Wagner S, 2000, EUR J BIOCHEM, V267, P7006, DOI 10.1046/j.1432-1327.2000.01801.x; WESTRITSCHNIG K, 2002, IN PRESS CLIN EXP AL; Wiedermann U, 2001, INT ARCH ALLERGY IMM, V126, P68, DOI 10.1159/000049496; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342; YSSEL H, 1992, J IMMUNOL, V148, P738; Zeiler T, 1997, J ALLERGY CLIN IMMUN, V100, P721, DOI 10.1016/S0091-6749(97)70264-1; ZHANG L, 1992, IMMUNOLOGY, V76, P158; ZHANG L, 1993, J IMMUNOL, V151, P791	138	102	106	0	5	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915	1879-0372		CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2002	14	6					718	727		10.1016/S0952-7915(02)00402-8		10	Immunology	Immunology	607VZ	WOS:000178812600007	12413521	
J	Portengen, L; Sigsgaard, T; Omland, O; Hjort, C; Heederik, D; Doekes, G				Portengen, L; Sigsgaard, T; Omland, O; Hjort, C; Heederik, D; Doekes, G			Low prevalence of atopy in young Danish farmers and farming students born and raised on a farm	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; Denmark; farm childhood; farming; IgE; skin prick tests; young farmers	HAY-FEVER; ALLERGIC SENSITIZATION; RESPIRATORY SYMPTOMS; STORAGE MITES; ASTHMA; EXPOSURE; CHILDREN; DUST; RISK; POPULATION	Background Recent studies have shown that in several countries atopic sensitization to common allergens (common atopy) and atopic symptoms are markedly less prevalent in children living on a farm, compared with non-farm children living in the same rural areas. Living conditions on farms may, however, vary largely between different countries. It is also not yet known whether the 'protective' effect of a farm environment can also be found in adults. Materials and methods Common atopy and respiratory health were assessed by skin prick tests (SPT), questionnaire and measurement of bronchial hyper-responsiveness (BHR) in the Sund Stald (SUS) study, a cohort study on respiratory health in Danish farming students and conscripts from the same rural areas as controls. Results of SPT were confirmed by IgE serology in all SPT+ subjects and a subset of SPT- subjects. Prevalences of common atopy, respiratory symptoms and bronchial hyper- responsiveness were compared for farmers and controls, and for those who had or had not lived on a farm in early childhood. Results In multiple logistic regression analyses adjusting for ever smoking and a familial history of allergy, both being a farmer (ORs 0.62-0.75) and having had a farm childhood (ORs 0.55-0.75) appeared to contribute independently to a lower risk of sensitization to common allergens as assessed by SPT and IgE serology. A farm childhood was also inversely associated with high total IgE (OR 0.68), presence of respiratory symptoms (ORs 0.69-0.79) and BHR (OR 0.61) in these analyses. Direction and strength of the association between being a farmer and respiratory symptoms or BHR varied widely (ORs 0.69-1.28). Conclusions The 'anti-atopy' protective effect of a farm childhood could be confirmed in Danish farming students: prevalences of positive SPT, specific and total IgE, allergic symptoms and BHR were lower in those being born or raised on a farm. Past exposure to the farm environment in early childhood may therefore also contribute to a lower risk of atopic sensitization and disease at a later age.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Univ Aarhus, Dept Environm & Occupat Med, DK-8000 Aarhus C, Denmark	Doekes, G (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.						Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; CROOK B, 1991, AM IND HYG ASSOC J, V52, P271, DOI 10.1202/0002-8894(1991)052<0271:ADAMAA>2.0.CO;2; Doekes G, 1996, OCCUP ENVIRON MED, V53, P63; DONHAM KJ, 1986, AM J IND MED, V10, P294, DOI 10.1002/ajim.4700100318; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; IVERSEN M, 1988, THORAX, V43, P872, DOI 10.1136/thx.43.11.872; IVERSEN M, 1990, ALLERGY, V45, P347, DOI 10.1111/j.1398-9995.1990.tb00510.x; IVERSEN M, 1990, CLIN EXP ALLERGY, V20, P211, DOI 10.1111/j.1365-2222.1990.tb02670.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; MATSON SC, 1983, J ALLERGY CLIN IMMUN, V72, P299, DOI 10.1016/0091-6749(83)90035-0; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; Radon K, 2000, ALLERGY, V55, P219, DOI 10.1034/j.1398-9995.2000.00461.x; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; Sigsgaard T., 1997, J AGROMED, V4, P63, DOI 10.1300/J096v04n01_09; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4	28	102	103	1	8	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2002	32	2					247	253		10.1046/j.1365-2222.2002.01310.x		7	Allergy; Immunology	Allergy; Immunology	537PM	WOS:000174767800017	11929489	
J	Weber, RW				Weber, RW			Cross-reactivity of plant and animal allergens	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY			English	Review							BIRCH-POLLEN ALLERGEN; SHORT RAGWEED POLLEN; TIMOTHY GRASS-POLLEN; GROUP-I ALLERGENS; T-CELL EPITOPES; COMPLEMENTARY-DNA CLONING; MAJOR APPLE ALLERGEN; DUST-MITE ALLERGENS; AMINO-ACID-SEQUENCE; SHARE IGE EPITOPES		Austin Allergy Associates, Austin, TX 78749 USA	Weber, RW (reprint author), Austin Allergy Associates, 6600 S Mopac Expressway,Suite 2180, Austin, TX 78749 USA.						Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; ARLIAN LG, 1991, EXP APPL ACAROL, V10, P167, DOI 10.1007/BF01198649; Arlian LG, 1999, ANN ALLERG ASTHMA IM, V83, P529, DOI 10.1016/S1081-1206(10)62864-5; Arlian LG, 2000, ANN ALLERG ASTHMA IM, V85, P161; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1051, DOI 10.1016/0091-6749(93)90219-6; ARMSTRONG C, 1924, US PUBLIC HLTH REP, V39, P2422; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; Asturias JA, 1999, J IMMUNOL, V162, P4342; Asturias JA, 1997, CLIN EXP ALLERGY, V27, P1307, DOI 10.1046/j.1365-2222.1997.1470952.x; Asturias JA, 1998, MOL IMMUNOL, V35, P469, DOI 10.1016/S0161-5890(98)00036-4; BALDO BA, 1982, INT ARCH ALLER A IMM, V68, P295; BALDO BA, 1988, INT ARCH ALLER A IMM, V86, P201; BALDO BA, 1992, MOL IMMUNOL, V29, P1209, DOI 10.1016/0161-5890(92)90057-5; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Batanero E, 1996, J ALLERGY CLIN IMMUN, V97, P1264, DOI 10.1016/S0091-6749(96)70194-X; Batanero E, 1996, EUR J BIOCHEM, V241, P772, DOI 10.1111/j.1432-1033.1996.00772.x; Bauer L, 1996, CLIN EXP ALLERGY, V26, P1161, DOI 10.1111/j.1365-2222.1996.tb00503.x; BAUR X, 1986, SCIENCE, V233, P351, DOI 10.1126/science.2425431; BECKER CG, 1981, BLOOD, V58, P861; BENGTSSON A, 1985, INT ARCH ALLER A IMM, V78, P139; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNTON HS, 1924, JAMA-J AM MED ASSOC, V82, P1434; Black JH, 1929, J ALLERGY, V1, P71, DOI 10.1016/S0021-8707(29)90084-8; BOND JF, 1991, J IMMUNOL, V146, P3380; BONIL.O, 1961, J ALLERGY, V32, P246, DOI 10.1016/0021-8707(61)90055-7; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUTIN Y, 1988, CLIN ALLERGY, V18, P287, DOI 10.1111/j.1365-2222.1988.tb02871.x; BRANDYS J, 1993, PLANTA MED, V59, P221, DOI 10.1055/s-2006-959656; Breitenbach M, 1997, INT ARCH ALLERGY IMM, V113, P114; Brown A, 1927, J IMMUNOL, V13, P73; BURGE HA, 1985, CLIN REV ALLERG, V3, P319, DOI 10.1007/BF02992998; Caballero T, 1997, CLIN EXP ALLERGY, V27, P1203; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; Caraballo L, 1998, INT ARCH ALLERGY IMM, V117, P38, DOI 10.1159/000023988; CHAPMAN MD, 1987, J IMMUNOL, V139, P1479; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; Chow LP, 2000, BIOCHEM BIOPH RES CO, V269, P14, DOI 10.1006/bbrc.2000.2253; CLEGG MT, 1993, P NATL ACAD SCI USA, V90, P363, DOI 10.1073/pnas.90.2.363; Coca AF, 1925, J IMMUNOL, V10, P445; Cooke RA, 1916, J IMMUNOL, V1, P201; COOKE ROBERT A., 1935, JOUR ALLERGY, V6, P311, DOI 10.1016/S0021-8707(35)90086-7; CORNFORD CA, 1990, INT ARCH ALLER A IMM, V93, P41; COULTER KM, 1987, MOL IMMUNOL, V24, P1207, DOI 10.1016/0161-5890(87)90167-2; Crespo JF, 1998, J ALLERGY CLIN IMMUN, V101, pS238; CRESPO JF, 1995, ALLERGY, V50, P918, DOI 10.1111/j.1398-9995.1995.tb02499.x; CROMWELL H. W., 1933, JOUR ALLERGY, V4, P347, DOI 10.1016/S0021-8707(33)90023-4; CROSBY B L, 1990, Journal of Allergy and Clinical Immunology, V85, P176; De Vouge MW, 1998, INT ARCH ALLERGY IMM, V116, P261, DOI 10.1159/000023954; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; DEGROOT H, 1990, J ALLERGY CLIN IMMUN, V86, P107; DELAHOZ F, 1990, MOL IMMUNOL, V27, P651, DOI 10.1016/0161-5890(90)90008-N; DEZUBIRIA A, 1990, J ALLERGY CLIN IMMUN, V86, P26; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; DIRKSEN A, 1980, ALLERGY, V35, P611, DOI 10.1111/j.1398-9995.1980.tb01812.x; DONOVAN GR, 1993, BIOCHIM BIOPHYS ACTA, V1171, P272, DOI 10.1016/0167-4781(93)90065-L; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; Engel E, 1997, J BIOL CHEM, V272, P28630, DOI 10.1074/jbc.272.45.28630; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; ERIKSSON NE, 1978, ALLERGY, V33, P299, DOI 10.1111/j.1398-9995.1978.tb01555.x; ESCH RE, 1987, J ALLERGY CLIN IMMUN, V79, P489, DOI 10.1016/0091-6749(87)90367-8; FAHLBUSCH B, 1993, CLIN EXP ALLERGY, V23, P51, DOI 10.1111/j.1365-2222.1993.tb02484.x; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; FARNHAM JE, 1982, N ENGL SOC ALLERGY P, V3, P320; FEHLNER PF, 1991, J IMMUNOL, V146, P2664; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; Ferrandiz R, 1998, INT ARCH ALLERGY IMM, V116, P206, DOI 10.1159/000023946; Focke M, 1998, INT ARCH ALLERGY IMM, V117, P105, DOI 10.1159/000023996; FORD AW, 1992, CLIN EXP ALLERGY, V22, P793, DOI 10.1111/j.1365-2222.1992.tb02820.x; Freeman J, 1911, LANCET, V2, P814; Fritsch R, 1998, J ALLERGY CLIN IMMUN, V102, P679, DOI 10.1016/S0091-6749(98)70287-8; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; Garcia-Robaina JC, 1998, J INVEST ALLERG CLIN, V8, P285; GERACI D, 1985, INT ARCH ALLER A IMM, V78, P421; GHOSH B, 1994, J IMMUNOL, V152, P2882; GLEICH GJ, 1980, J ALLERGY CLIN IMMUN, V65, P110, DOI 10.1016/0091-6749(80)90194-3; GONZALEZ RM, 1987, ANN ALLERGY, V59, P149; GREENE WK, 1990, INT ARCH ALLER A IMM, V92, P30; GRIFFITH GW, 1971, CAN J BIOCHEM, V49, P396; Grobe K, 1999, EUR J BIOCHEM, V263, P33, DOI 10.1046/j.1432-1327.1999.00462.x; GRUBB GLENN D., 1938, JOUR ALLERGY, V9, P211, DOI 10.1016/S0021-8707(38)90213-8; Guilloux L, 1998, ALLERGY, V53, P151, DOI 10.1111/j.1398-9995.1998.tb03863.x; Gupta N, 1996, J ALLERGY CLIN IMMUN, V98, P903, DOI 10.1016/S0091-6749(96)80006-6; Hales BJ, 2000, CLIN EXP ALLERGY, V30, P927, DOI 10.1046/j.1365-2222.2000.00900.x; HALMEPURO L, 1984, INT ARCH ALLER A IMM, V74, P235; HARRIS DJ, 1992, J ALLERGY CLIN IMMUN, V89, P318; Hayek B, 1998, J IMMUNOL, V161, P7031; Heiss S, 1996, J ALLERGY CLIN IMMUN, V98, P938, DOI 10.1016/S0091-6749(96)80010-8; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196; HIRSCHWEHR R, 1992, J ALLERGY CLIN IMMUN, V90, P927, DOI 10.1016/0091-6749(92)90465-E; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1985, J ALLERGY CLIN IMMUN, V75, P611, DOI 10.1016/0091-6749(85)90038-7; HOFFMAN DR, 1990, J ALLERGY CLIN IMMUN, V85, P988, DOI 10.1016/0091-6749(90)90042-3; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; Hoffmann-Sommergruber K, 1999, CLIN EXP ALLERGY, V29, P840, DOI 10.1046/j.1365-2222.1999.00529.x; HOLGATE ST, 1988, CLIN ALLERGY, V18, P549, DOI 10.1111/j.1365-2222.1988.tb02906.x; HUANG X, 1995, ALLERGY, V50, P648, DOI 10.1111/j.1398-9995.1995.tb02581.x; IPSEN H, 1991, MOL IMMUNOL, V28, P1279, DOI 10.1016/0161-5890(91)90015-C; JensenJarolim E, 1997, CLIN EXP ALLERGY, V27, P1299, DOI 10.1046/j.1365-2222.1997.1580956.x; Judd W.S., 1999, PLANT SYSTEMATICS PH; KAGAYA K, 1989, J IMMUNOL, V143, P3353; KALVERAM KJ, 1978, INT ARCH ALLER A IMM, V57, P549; Karamloo F, 1999, J ALLERGY CLIN IMMUN, V104, P991, DOI 10.1016/S0091-6749(99)70080-1; KATELARIS C, 1982, ALLERGY, V37, P21, DOI 10.1111/j.1398-9995.1982.tb04113.x; Katial RK, 1997, ANN ALLERG ASTHMA IM, V79, P340; KERNERMAN SM, 1992, ANN ALLERGY, V69, P493; KIM SJ, 1979, AM REV RESPIR DIS, V120, P1297; KIMURA T, 1969, JPN J ALLERGY, V69, P1005; KING TP, 1985, J ALLERGY CLIN IMMUN, V75, P621, DOI 10.1016/0091-6749(85)90040-5; King TP, 1998, J ALLERGY CLIN IMMUN, V101, P397; KING TP, 1967, ANN ALLERGY, V25, P541; KING TP, 1980, ALLERGY, V35, P187, DOI 10.1111/j.1398-9995.1980.tb01738.x; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; King TP, 1997, J ALLERGY CLIN IMMUN, V99, P630, DOI 10.1016/S0091-6749(97)70025-3; KOIVIKKO A, 1988, ALLERGY, V43, P192; Konieczny A, 1997, IMMUNOLOGY, V92, P577, DOI 10.1046/j.1365-2567.1997.00386.x; KRILIS S, 1983, J ALLERGY CLIN IMMUN, V71, P261, DOI 10.1016/0091-6749(83)90079-9; KUO MC, 1993, MOL IMMUNOL, V30, P1077; KURATA JH, 1977, ANN ALLERGY, V38, P384; KURUP VP, 1988, INT ARCH ALLER A IMM, V86, P400; KWAASI AAA, 1994, INT ARCH ALLERGY IMM, V104, P281; LAFFER S, 1994, J ALLERGY CLIN IMMUN, V94, P689, DOI 10.1016/0091-6749(94)90176-7; Lamson RW, 1931, P SOC EXP BIOL MED, V28, P0502; Le Mao J, 1998, J ALLERGY CLIN IMMUN, V102, P631, DOI 10.1016/S0091-6749(98)70280-5; LEAVENGOOD DC, 1985, J ALLERGY CLIN IMMUN, V76, P789, DOI 10.1016/0091-6749(85)90749-3; LEE YS, 1979, AM J BOT, V66, P245, DOI 10.2307/2442600; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; LEITERMANN K, 1984, J ALLERGY CLIN IMMUN, V74, P147, DOI 10.1016/0091-6749(84)90278-1; LEMAO J, 1992, MOL IMMUNOL, V29, P205; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LIND P, 1987, SCAND J IMMUNOL, V25, P1, DOI 10.1111/j.1365-3083.1987.tb01040.x; Lovborg U, 1999, CLIN EXP ALLERGY, V29, P973; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; LOWENSTEIN H, 1983, J IMMUNOL, V130, P727; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; Lowenstein H, 1978, Prog Allergy, V25, P1, DOI 10.1159/000314432; MARSH DG, 1966, INT ARCH ALLER A IMM, V29, P521; MARTIN BG, 1985, ANN ALLERGY, V54, P99; Martinez A, 1997, Allergol Immunopathol (Madr), V25, P118; MARTINOROZCO E, 1994, INT ARCH ALLERGY IMM, V104, P160; MATTHEWS PA, 1988, MOL IMMUNOL, V25, P63, DOI 10.1016/0161-5890(88)90091-0; MATTHIESEN F, 1991, J ALLERGY CLIN IMMUN, V88, P763, DOI 10.1016/0091-6749(91)90184-P; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; Midoro-Horiuti T, 1999, J ALLERGY CLIN IMMUN, V104, P613, DOI 10.1016/S0091-6749(99)70332-5; MOORE MARJORIE B., 1931, JOUR ALLERGY, V2, P85, DOI 10.1016/S0021-8707(31)90023-3; Morgan MS, 1996, ANN ALLERG ASTHMA IM, V77, P386; MUGGELBERG ML, 1988, J ALLERGY CLIN IMMUN, V81, P266, DOI 10.1016/0091-6749(88)90626-4; Muller WD, 1996, INT ARCH ALLERGY IMM, V109, P352; NEMERGUT RA, 1977, ANN ALLERGY, V38, P219; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V101, P258; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Niederberger V, 1999, FASEB J, V13, P843; NILSEN BM, 1991, J BIOL CHEM, V266, P2660; OBISPO TM, 1993, CLIN EXP ALLERGY, V23, P311, DOI 10.1111/j.1365-2222.1993.tb00328.x; ONEIL CE, 1988, INT ARCH ALLER A IMM, V85, P161; Ortiz JCG, 1996, J INVEST ALLERG CLIN, V6, P378; Pandjaitan B, 2000, J ALLERGY CLIN IMMUN, V105, P279, DOI 10.1016/S0091-6749(00)90077-0; Park JW, 1999, ANN ALLERG ASTHMA IM, V83, P533, DOI 10.1016/S1081-1206(10)62865-7; Pastorello EA, 1999, J ALLERGY CLIN IMMUN, V103, P520, DOI 10.1016/S0091-6749(99)70480-X; PAULL BR, 1979, J ALLERGY CLIN IMMUN, V64, P539, DOI 10.1016/0091-6749(79)90065-4; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; PERRICK D, 1991, J ALLERGY CLIN IMMUN, V87, P98, DOI 10.1016/0091-6749(91)90218-D; PETERSEN A, 1993, J ALLERGY CLIN IMMUN, V92, P789, DOI 10.1016/0091-6749(93)90055-K; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; PRINCE HOMER E., 1939, JOUR ALLERGY, V10, P537, DOI 10.1016/S0021-8707(39)90248-0; Puerta Llerena L, 1991, J Allergy Clin Immunol, V88, P943; Rackemann FM, 1936, J ALLERGY, V7, P319, DOI 10.1016/S0021-8707(36)90316-7; RAFNAR T, 1991, J BIOL CHEM, V266, P1229; Rappaport BZ, 1929, P SOC EXP BIOL MED, V26, P771; Rautiainen J, 1998, J ALLERGY CLIN IMMUN, V101, P349; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240; Reider N, 2000, CLIN EXP ALLERGY, V30, P1436, DOI 10.1046/j.1365-2222.2000.00902.x; Reindl J, 2000, J ALLERGY CLIN IMMUN, V106, P379, DOI 10.1067/mai.2000.107602; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V70, P281, DOI 10.1016/0091-6749(82)90064-1; ROEBBER M, 1982, J IMMUNOL, V129, P120; ROEBBER M, 1983, J IMMUNOL, V131, P706; Scheurer S, 1999, MOL IMMUNOL, V36, P155, DOI 10.1016/S0161-5890(99)00033-4; Schmechel D, 1999, J ALLERGY CLIN IMMUN, V103, pS188; Schreiber MC, 1997, GENE, V191, P135, DOI 10.1016/S0378-1119(97)00010-3; Schwietz LA, 2000, ANN ALLERG ASTHMA IM, V84, P87, DOI 10.1016/S1081-1206(10)62746-9; SEGAL AT, 1970, J ALLERGY, V45, P44; SEIBERLER S, 1994, EMBO J, V13, P3481; SELLERS ED, 1931, J ALLERGY, V3, P166; SERAFINI UMBERTO, 1957, ACTA ALLERGOL, V11, P3, DOI 10.1111/j.1398-9995.1957.tb03005.x; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; Shen HD, 1999, CLIN EXP ALLERGY, V29, P642; SHEN HD, 1988, INT ARCH ALLER A IMM, V85, P167; SHEN HD, 1992, CLIN EXP ALLERGY, V22, P485, DOI 10.1111/j.1365-2222.1992.tb00151.x; Shen HD, 2000, J ALLERGY CLIN IMMUN, V105, P827, DOI 10.1067/mai.2000.105220; Shen HD, 1996, CLIN EXP ALLERGY, V26, P444, DOI 10.1111/j.1365-2222.1996.tb00561.x; SMITH PM, 1994, MOL IMMUNOL, V31, P491, DOI 10.1016/0161-5890(94)90068-X; Smith PM, 1997, INT ARCH ALLERGY IMM, V114, P265; SOLOMON WR, 1969, J ALLERGY, V44, P25, DOI 10.1016/0021-8707(69)90045-8; SOLOMON WR, 1981, J ALLERGY CLIN IMMUN, V48, pS56; Son DY, 1999, EUR J NUTR, V38, P201, DOI 10.1007/s003940050063; SPAIN WC, 1930, J ALLERGY, V1, P209, DOI 10.1016/S0021-8707(30)90250-X; Spitzauer S, 1997, CLIN EXP ALLERGY, V27, P196; Spitzauer S, 1997, J ALLERGY CLIN IMMUN, V99, P100, DOI 10.1016/S0091-6749(97)81050-0; SPITZAUER S, 1994, J ALLERGY CLIN IMMUN, V93, P614, DOI 10.1016/S0091-6749(94)70073-7; SRIRAMARAO P, 1993, INT ARCH ALLERGY IMM, V100, P79; Stapel SO, 1998, ALLERGY, V53, P769; STOTT DI, 1989, J IMMUNOL METHODS, V119, P153, DOI 10.1016/0022-1759(89)90394-3; Street MD, 1996, BBA-GENE STRUCT EXPR, V1305, P87, DOI 10.1016/0167-4781(95)00197-2; STULL ARTHUR, 1932, JOUR ALLERGY, V3, P120, DOI 10.1016/S0021-8707(32)90371-2; STULL ARTHUR, 1932, JOUR ALLERGY, V3, P352, DOI 10.1016/S0021-8707(32)90231-7; SUZUKI S, 1975, INT ARCH ALLER A IMM, V48, P800; Tangen O, 1975, Dev Biol Stand, V29, P175; TARLO SM, 1979, J ALLERGY CLIN IMMUN, V64, P43, DOI 10.1016/0091-6749(79)90082-4; TARLO SM, 1979, J ALLERGY CLIN IMMUN, V64, P49; TEE RD, 1987, J ALLERGY CLIN IMMUN, V79, P627, DOI 10.1016/S0091-6749(87)80159-8; Tinghino R, 1998, J ALLERGY CLIN IMMUN, V101, P772, DOI 10.1016/S0091-6749(98)70306-9; Tsai LC, 1998, J ALLERGY CLIN IMMUN, V102, P295, DOI 10.1016/S0091-6749(98)70099-5; TUFT L, 1937, J ALLERGY, V8, P464, DOI 10.1016/S0021-8707(37)90402-7; UNDERDOWN BJ, 1969, BIOCHEMISTRY-US, V8, P980, DOI 10.1021/bi00831a031; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALENTA R, 1991, J ALLERGY CLIN IMMUN, V87, P677, DOI 10.1016/0091-6749(91)90388-5; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332; VALLIER P, 1988, CLIN ALLERGY, V18, P491, DOI 10.1111/j.1365-2222.1988.tb02899.x; Vallverdu A, 1998, J ALLERGY CLIN IMMUN, V101, P363; VANDALEN G, 1981, ANN ALLERGY, V46, P276; VANREE R, 1994, ALLERGY, V49, P254; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P726, DOI 10.1016/S0091-6749(95)70178-8; VANREE R, 1992, INT ARCH ALLERGY IMM, V98, P97; VANREE R, 1995, J ALLERGY CLIN IMMUN, V95, P970, DOI 10.1016/S0091-6749(95)70097-8; VIANDER M, 1983, INT ARCH ALLER A IMM, V71, P252; Wahl R, 1996, J ALLERGY CLIN IMMUN, V98, P99, DOI 10.1016/S0091-6749(96)70231-2; WATSON SH, 1922, JAMA-J AM MED ASSOC, V78, P719; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WEBER RW, 1981, ANN ALLERGY, V46, P208; WEBER RW, 1984, ANN ALLERGY, V52, P226; WEBER RW, 1986, ANN ALLERGY, V56, P527; WEBER RW, 1978, J ALLERGY CLIN IMMUN, V61, P172, DOI 10.1016/0091-6749(78)90385-8; WEBER RW, 1987, ANN ALLERGY, V58, P287; WEBER RW, 1983, ANN ALLERGY, V50, P363; WEDNER HJ, 1987, INT ARCH ALLER A IMM, V84, P116; Welch J, 2000, CLIN EXP ALLERGY, V30, P370, DOI 10.1046/j.1365-2222.2000.00763.x; WICHER K, 1980, J ALLERGY CLIN IMMUN, V66, P244, DOI 10.1016/0091-6749(80)90047-0; WODEHOUSE ROGER P., 1957, ANN ALLERGY, V15, P527; Wu CH, 1998, J ALLERGY CLIN IMMUN, V101, P832, DOI 10.1016/S0091-6749(98)70312-4; WURTZEN PA, 1995, ALLERGY, V50, P489, DOI 10.1111/j.1398-9995.1995.tb01184.x; YASUEDA H, 1983, J ALLERGY CLIN IMMUN, V71, P77, DOI 10.1016/0091-6749(83)90550-X; YOO TJ, 1975, ANN ALLERGY, V34, P87; Yun YY, 1999, J ALLERGY CLIN IMMUN, V104, P879; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; Zeiler T, 1999, J IMMUNOL, V162, P1415; ZETTERST.O, 1972, ACTA ALLERGOL, V27, P15, DOI 10.1111/j.1398-9995.1972.tb01638.x; ZHU XJ, 1995, J IMMUNOL, V155, P5064	253	102	77	1	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1080-0549			CLIN REV ALLERG IMMU	Clin. Rev. Allergy Immunol.	OCT	2001	21	2-3					153	202		10.1385/CRIAI:21:2-3:153		50	Allergy; Immunology	Allergy; Immunology	485LC	WOS:000171755000005	11725603	
J	D'Amato, G; Liccardi, G; D'Amato, M; Cazzola, M				D'Amato, G; Liccardi, G; D'Amato, M; Cazzola, M			The role of outdoor air pollution and climatic changes on the rising trends in respiratory allergy	RESPIRATORY MEDICINE			English	Article						air pollution; bronchial asthma; airway hyper-responsiveness; hay fever; pollinosis; respiratory allergy; urban pollution	DIESEL EXHAUST PARTICLES; POLLEN-RELATED ALLERGY; GRASS-POLLEN; ASTHMATIC-CHILDREN; PARTICULATE MATTER; OZONE EXPOSURE; HEALTH; INFLAMMATION; MORTALITY; AIRWAYS	Evidence suggests that allergic respiratory diseases such as hay fever and bronchial asthma have become more common world-wide in the last two decades, and the reasons for this increase are still largely unknown. A major responsible factor could be outdoor air pollution, derived from cars and other vehicles. Studies have demonstrated that urbanization and high levels of vehicle emissions and westernized lifestyle is correlated with the increasing frequency of pollen-induced respiratory allergy. People who live in urban areas tend to be more affected by pollen-induced respiratory allergy than those from of rural areas. Pollen allergy has been one of the most frequent models used to study the interrelationship between air pollution and respiratory allergic diseases. Pollen grains or plant-derived paucimicronic components carry allergens that can produce allergic symptoms. They may also interact with air pollution (particulate matter; ozone) in producing these effects. There is evidence that air pollutants may promote airway sensitization by modulating the allergenicity of airborne allergens. Furthermore, airway mucosal damage and impaired mucociliary clearance induced by air pollution may facilitate the access Of inhaled allergens to the cells of the immune system. In addition, vegetation reacts with air pollution and environmental conditions and influence the plant allergenicity. Several factors influence this interaction, including type of air pollutants, plant species, nutrient balance: climatic factors, degree of airway sensitization and hyperresponsiveness of exposed subjects.	Azienda Osped Alta Specialita A Cardarelli, Div Pneumol & Allergol, I-80121 Naples, Italy	D'Amato, G (reprint author), Azienda Osped Alta Specialita A Cardarelli, Div Pneumol & Allergol, Via Rione Sirignano,10, I-80121 Naples, Italy.		Cazzola, Mario/G-9397-2012; D'Amato, Maria/H-3074-2012	D'Amato, Maria/0000-0002-5906-5701			Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; *AM THOR SOC, 1996, AM J RESP CRIT CARE, V153, P3; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Boezen HM, 1999, LANCET, V353, P874, DOI 10.1016/S0140-6736(98)06311-9; BOUSQUET J, 1993, CLIN EXP ALLERGY, V23, P484; Burney P, 1999, LANCET, V353, P859, DOI 10.1016/S0140-6736(99)00002-1; Burney P, 1996, EUR RESPIR J, V9, P687; BUSSE WW, 1972, J ALLERGY CLIN IMMUN, V50, P289, DOI 10.1016/0091-6749(72)90027-9; Celenza A, 1996, BRIT MED J, V312, P604; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; COSTA DL, 1998, AM J RESP CRIT CARE, V157, pA880; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; D'Amato G, 1998, PULM PHARMACOL THER, V11, P369, DOI 10.1006/pupt.1999.0159; D'Amato G, 2000, CLIN EXP ALLERGY, V30, P628; DAMATO G, 1991, ANN ALLERGY, V67, P421; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P210, DOI 10.1111/j.1365-2222.1994.tb00222.x; DAmato G, 1991, ALLERGENIC POLLEN PO, P113; DAMATO G, 2001, NAPLES ITALY, P91; Devalia JL, 1998, ALLERGY, V53, P335, DOI 10.1111/j.1398-9995.1998.tb03903.x; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Donaldson K, 1997, ENVIRON HEALTH PERSP, V105, P1285, DOI 10.2307/3433548; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; Emberlin J, 1997, GRANA, V36, P29; EMBERLIN J, 1993, CLIN EXP ALLERGY, V23, P911, DOI 10.1111/j.1365-2222.1993.tb00275.x; Emberlin J., 1998, EUR RESPIR REV, V53, P164; *EUR COMM, 1996, J EPIDEMIOL COMM S1, V50, pS2; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; GHIO AJ, 1993, AM J RESP CELL MOL, V8, P403; Gielen MH, 1997, AM J RESP CRIT CARE, V155, P2105; GRAHAM DE, 1990, AM REV RESPIR DIS, V142, P152; HJELMEROOS M, 1994, P 5 INT C AER BANGL; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; Kehrl HR, 1999, J ALLERGY CLIN IMMUN, V104, P1198; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; KOREN HS, 1989, AM REV RESPIR DIS, V139, P407; Lebowitz MD, 1996, EUR RESPIR J, V9, P1029, DOI 10.1183/09031936.96.09051029; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Roemer W, 2000, EUR RESPIR J, V15, P553, DOI 10.1034/j.1399-3003.2000.15.21.x; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; SCHENKER M, 1993, NEW ENGL J MED, V329, P1807, DOI 10.1056/NEJM199312093292410; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SELTZER J, 1986, J APPL PHYSIOL, V60, P1321; Smith KR, 1997, CHEM RES TOXICOL, V10, P828, DOI 10.1021/tx960164m; SOLOMON WR, 1983, J ALLERGY CLIN IMMUN, V72, P443, DOI 10.1016/0091-6749(83)90579-1; SPIEKSMA FTM, 1995, CLIN EXP ALLERGY, V25, P234, DOI 10.1111/j.1365-2222.1995.tb01034.x; TAKAFUJI S, 1987, J ALLERGY CLIN IMMUN, V79, P639, DOI 10.1016/S0091-6749(87)80161-6; THURSTON GD, 1997, AM J RESP CRIT CARE, V155, pA426; *UN ENV PROGR WHO, 1994, ENVIRONMENT, V36, P5; Viegi G, 1998, INT J TUBERC LUNG D, V2, P947	55	102	103	2	11	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0954-6111			RESP MED	Respir. Med.	JUL	2001	95	7					606	611		10.1053/rmed.2001.1112		6	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	448YE	WOS:000169656900011	11453319	
J	Belamarich, PF; Luder, E; Kattan, M; Mitchell, H; Islam, S; Lynn, H; Crain, EF				Belamarich, PF; Luder, E; Kattan, M; Mitchell, H; Islam, S; Lynn, H; Crain, EF			Do obese inner-city children with asthma have more symptoms than nonobese children with asthma?	PEDIATRICS			English	Article; Proceedings Paper	37th Annual Meeting of the Ambulatory-Pediatric-Association	MAY 02-06, 1997	WASHINGTON, D.C.	Ambulatory Pediat Assoc		asthma; obesity; children; peak expiratory flow; inner-city	BODY-MASS INDEX; UNITED-STATES; ADOLESCENTS; OVERWEIGHT; ASSOCIATION; SAMPLE; GROWTH; BLACK	Objective. To test whether obesity is associated with decreased peak expiratory flow rates (PEFR), increased asthma symptoms, and increased health service use. Design/Methods. Secondary analysis of data from a cross-sectional convenience sample. Setting. Emergency departments (EDs) and primary care clinics in 8 inner-city areas in 7 cities. Participants. One thousand three hundred twenty-two children aged 4 to 9 years with asthma. Measures. Obesity was defined as a body mass index (BMI, weight/height(2)) >95th percentile. Nonobese children were those with a BMI between the 5th and 95th percentile. Underweight children with a BMI <5th percentile were eliminated from the study. Demographic and anthropometric data were obtained during a baseline interview with the primary caretaker and the child. Symptoms, health service use data and measurements of PEFR were obtained by parental report during the baseline interview and at 3-month intervals by telephone interview over the following 9-month period. Results. Obese (n = 249) and nonobese (n = 1073) children did not differ in terms of age, gender, family income, passive smoke exposure, caretaker's mental health, and skin test reactivity to indoor allergens. Obese children were more often Latino (28% vs 17%) and, in the 3 months before the baseline interview, were more likely to have used oral steroids (30% vs 24%). There were no differences between groups in terms of baseline PEFR scores. During the 9 months after baseline assessment, the obese group had a higher mean number of days of wheeze per 2-week period (4.0 vs 3.4), and a greater proportion of obese individuals had unscheduled ED visits (39% vs 31%). There were no differences between the groups in terms of frequency of hospitalization, or in nocturnal awakening. Conclusions. In our sample of inner-city children with asthma, obese children used more medicine, wheezed more, and a greater proportion had unscheduled ED visits than the nonobese children.	Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, Div Gen Pediat, Bronx, NY USA; Mt Sinai Sch Med, Dept Pediat, New York, NY USA; Rho Inc, Chapel Hill, NC USA; Michigan State Univ, Flint, MI USA; Albert Einstein Coll Med, Jacobi Med Ctr, Dept Pediat, Bronx, NY 10467 USA	Belamarich, PF (reprint author), Pediat Acad Associates, 1621 Eastchester Rd, Bronx, NY 10461 USA.		Islam, Shaheen/E-3288-2011		NIAID NIH HHS [AI-30752, AI-30756, UO1 AI-30751]		Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Dietz WH, 1998, J PEDIATR-US, V132, P191; Dixon JB, 1999, OBES SURG, V9, P385, DOI 10.1381/096089299765552981; Eid N, 2000, PEDIATRICS, V105, P354, DOI 10.1542/peds.105.2.354; FUNG KP, 1990, ARCH DIS CHILD, V65, P512; Gennuso J, 1998, ARCH PEDIAT ADOL MED, V152, P1197; GORTMAKER SL, 1987, AM J DIS CHILD, V141, P535; HSU KHK, 1979, J PEDIATR-US, V95, P192; INSELMAN LS, 1993, PEDIATR PULM, V16, P130, DOI 10.1002/ppul.1950160209; KAPLAN TA, 1993, CLIN PEDIATR, V32, P220, DOI 10.1177/000992289303200407; Lazarus R, 1997, PEDIATR PULM, V24, P187; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; McCowan C, 1998, BRIT MED J, V316, P668; Mitchell H, 1997, PEDIATR PULM, V24, P237; Najjar MF, 1987, VITAL HLTH STATISTIC, P238; Pietrobelli A, 1998, J PEDIATR-US, V132, P204, DOI 10.1016/S0022-3476(98)70433-0; RAY CS, 1983, AM REV RESPIR DIS, V128, P501; ROCHE AF, 1981, AM J CLIN NUTR, V34, P2831; Rosner B, 1998, J PEDIATR-US, V132, P211, DOI 10.1016/S0022-3476(98)70434-2; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SHOHAT M, 1987, ARCH DIS CHILD, V62, P63; TROIANO RP, 1995, ARCH PEDIAT ADOL MED, V149, P1085; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; 1992, MMWR MORB MORTAL WKL, V41, P733	24	102	108	1	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	DEC	2000	106	6					1436	1441		10.1542/peds.106.6.1436		6	Pediatrics	Pediatrics	383ZP	WOS:000165914800034	11099600	
J	Nielsen, KG; Bisgaard, H				Nielsen, KG; Bisgaard, H			The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2-to 5-year-old asthmatic children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							YOUNG-CHILDREN; DRY AIR; BRONCHIAL RESPONSIVENESS; INHALATION SUSPENSION; NEBULIZED BUDESONIDE; PERSISTENT ASTHMA; CHALLENGE; HISTAMINE; INFANTS; HYPERVENTILATION	We hypothesized that measurement of lung function (LF) and bronchial hyperresponsiveness (BHR) could serve as supplemental tools in evaluating the efficacy of treatment with inhaled corticosteroids in asthmatic children aged 2 to 5 yr. We studied 38 children (mean age: 53 mo; range: 35 to 71 mo) with moderately severe asthma in a single-center, randomized, double-blind, parallel-group, placebo-controlled study involving 8 wk of treatment. Budesonide (BUD) 400 mu g twice daily was administered via a pressurized metered-dose inhaler and metal spacer device. Symptom scores (SSc) and use of short-acting beta(2)-agonist were monitored with diary cards. LF in awake children was measured as the specific airway resistance (sRaw), using whole-body plethysmography; as resistance by the interrupter technique (Rint); and as resistance and reactance at 5 Hz (Rrs5, Xrs5) by the impulse oscillation technique. Cold air challenge (CACh) and methacholine challenge (MCh) were used to assess BHR. Children in the BUD group experienced significantly fewer night- and daytime symptoms (p < 0.05) and more symptom-free days (p < 0.05), but not nights (p = 0.07), than children in the placebo group. Daytime (p < 0.05) but not nighttime (p = 0.09) use of rescue medication and asthma exacerbation rates (3.7 versus 9.3 exacerbations/yr) (p = 0.006) were both in favor of BUD. LF measured with the Rint technique, Rrs5, and Xrs5 were significantly improved by BUD. BHR as measured by CACh improved significantly with BUD, whereas no improvement was found on MCh. In conclusion, inhaled BUD at a total dose of 800 mu g daily significantly Improved SSc, asthma exacerbation rates, lung function, and BHR as assessed by CACh in asthmatic children aged 2 to 5 yr.	Univ Copenhagen Hosp, Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark	Bisgaard, H (reprint author), Univ Copenhagen Hosp, Rigshosp, Dept Pediat, DK-2100 Copenhagen, Denmark.		Kronow, Joern/B-1054-2011	Bisgaard, Hans/0000-0003-4131-7592			Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; BISGAARD H, 1990, LANCET, V336, P649, DOI 10.1016/0140-6736(90)92147-A; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126; Bisgaard H, 2000, AM J RESP CRIT CARE, V162, P187; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Claussen M, 1993, Pneumologie, V47, P209; CONNETT GJ, 1993, ARCH DIS CHILD, V69, P351; DEAL EC, 1980, AM REV RESPIR DIS, V121, P621; DEBENEDICTIS FM, 1995, PEDIATR PULM, V19, P326, DOI 10.1002/ppul.1950190603; deBlic J, 1996, J ALLERGY CLIN IMMUN, V98, P14, DOI 10.1016/S0091-6749(96)70221-X; Fischer AR, 1997, THORAX, V52, P1074; ILANGOVAN P, 1993, ARCH DIS CHILD, V68, P356; KANENGISER S, 1994, PEDIATR PULM, V18, P144, DOI 10.1002/ppul.1950180305; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; Klug B, 1997, PEDIATR PULM, V23, P278, DOI 10.1002/(SICI)1099-0496(199704)23:4<278::AID-PPUL5>3.0.CO;2-I; Klug B, 1998, PEDIATR PULM, V25, P322, DOI 10.1002/(SICI)1099-0496(199805)25:5<322::AID-PPUL6>3.0.CO;2-K; Klug B, 1999, EUR RESPIR J, V14, P1185, DOI 10.1183/09031936.99.14511859; Klug B, 1996, PEDIATR PULM, V21, P290; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MCLAUGHLIN FJ, 1983, PEDIATRICS, V72, P503; MODL M, 1995, EUR RESPIR J, V8, P1742, DOI 10.1183/09031936.95.08101742; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; REISMAN J, 1987, PEDIATR PULM, V3, P251, DOI 10.1002/ppul.1950030410; SLY PD, 1990, J ASTHMA, V27, P137, DOI 10.3109/02770909009073314; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; STICK SM, 1995, ARCH DIS CHILD, V73, P327; TAL A, 1984, J PEDIATR-US, V104, P516, DOI 10.1016/S0022-3476(84)80539-9; VATHENEN AS, 1991, THORAX, V46, P811, DOI 10.1136/thx.46.11.811; Warner JO, 1998, PEDIATR PULM, V25, P1; ZACH M, 1995, PEDIATR PULM, V19, P323, DOI 10.1002/ppul.1950190602; ZACH M, 1984, PEDIATR RES, V18, P469, DOI 10.1203/00006450-198405000-00016; ZACH MS, 1987, J ALLERGY CLIN IMMUN, V80, P9, DOI 10.1016/S0091-6749(87)80184-7	33	102	104	0	8	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT	2000	162	4					1500	1506				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	364RD	WOS:000089905900052	11029368	
J	Kelly, D; Coutts, AGP				Kelly, D; Coutts, AGP			Early nutrition and the development of immune function in the neonate	PROCEEDINGS OF THE NUTRITION SOCIETY			English	Article; Proceedings Paper	Summer Meeting of the Nutrition-Society	JUN 29-JUL 02, 1999	UNIV GLASGOW, GLASGOW, SCOTLAND	Nutr Soc	UNIV GLASGOW	intestine; immunity; neonate; colostrum	INTESTINAL EPITHELIAL-CELLS; FIMBRIATED ESCHERICHIA-COLI; BLOOD GROUP ANTIGENS; HUMAN-MILK; T-CELLS; IMMUNOHISTOCHEMICAL ANALYSIS; MUCOSAL SURFACES; SUCKLING PIGS; EXPRESSION; COLOSTRUM	The present review will concentrate on the development of the gut-associated lymphoid tissue and the role of early nutrition in promoting immune function. The intestine is the largest immune organ in the body, and as such is the location for the majority of lymphocytes and other immune effector cells. The intestine is exposed to vast quantities of dietary and microbial antigens, and is the most common portal of entry for pathogens, some of which are potentially lethal. The development of normal immune function of the intestine is therefore vital for survival, and is dependent on appropriate antigen exposure and processing, and also an intact intestinal barrier. In early life innate mechanisms of defence are probably more important than active or adaptive mechanisms in responding to an infectious challenge, since the healthy neonate is immunologically naive (has not seen antigen) and has not acquired immunological memory. During this period maternal colostrum and milk can significantly augment resistance to enteric infections. The mechanisms of enhancing disease resistance are thought to be passive, involving a direct supply of anti-microbial factors, and active, by promoting the development of specific immune function. A tolerance response to dietary and non-invasive antigens is generally induced in the gut. However, it must also be able to mount an adequate immune response to ensure clearance of foreign antigens. It is now recognized that regulation of tolerance and active immune responses is critical to health, and failure to regulate these responses can lead to recurrent infections, inflammatory diseases and allergies. The education of the immune system in early life is thought to be critical in minimizing the occurrence of these immune-based disorders. During this phase of development maternal milk provides signals to the immune system that generate appropriate response and memory. One factor that has been proposed to contribute to the increase in the incidence of immune-based disorders, e.g. atopic diseases in Western countries, is thought to be the increased prevalence of formula-feeding.	Rowett Res Inst, Dept Intestinal Cell Biol & Immunol, Aberdeen AB21 9SB, Scotland	Kelly, D (reprint author), Rowett Res Inst, Dept Intestinal Cell Biol & Immunol, Greenburgn Rd, Aberdeen AB21 9SB, Scotland.	dk@rri.sari.ac.uk					Bertotto A, 1996, ARCH DIS CHILD, V74, pF135, DOI 10.1136/fn.74.2.F135; BERTOTTO A, 1990, EUR J IMMUNOL, V20, P1877, DOI 10.1002/eji.1830200838; Bessler H, 1996, BIOL NEONATE, V69, P376; BONA C, 1997, IMMUNOLOGIST, V5, P5; Brandtzaeg P, 1998, NUTR REV, V56, pS5; BRANDTZAEG P, 1996, RECENT DEV INFANT NU, P349; Brightbill HD, 1999, SCIENCE, V285, P732, DOI 10.1126/science.285.5428.732; BURRIN DG, 1992, J NUTR, V122, P1205; Campbell NA, 1999, J BIOL CHEM, V274, P26259, DOI 10.1074/jbc.274.37.26259; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; Delespesse G, 1998, VACCINE, V16, P1415, DOI 10.1016/S0264-410X(98)00101-7; Dyrynda E, 1998, BIOCHEMIST       FEB, P6; Fairhurst RM, 1998, IMMUNOL TODAY, V19, P257, DOI 10.1016/S0167-5699(97)01235-8; GAROFALO R, 1995, PEDIATR RES, V37, P444, DOI 10.1203/00006450-199504000-00010; Golding J, 1997, EARLY HUM DEV, V49, pS83, DOI 10.1016/S0378-3782(97)00055-8; Goldman AS, 1997, CURR TOP MICROBIOL, V222, P205; Hansen S, 1998, IMMUNOBIOLOGY, V199, P165; Hawkes JS, 1999, PEDIATR RES, V45, P648, DOI 10.1203/00006450-199905010-00006; Helgeland L, 1996, IMMUNOLOGY, V89, P494, DOI 10.1046/j.1365-2567.1996.d01-783.x; Hodgins DC, 1999, J VIROL, V73, P186; Husband AJ, 1996, BRAIN BEHAV IMMUN, V10, P188, DOI 10.1006/brbi.1996.0018; Insoft RM, 1996, PEDIATR CLIN N AM, V43, P551, DOI 10.1016/S0031-3955(05)70420-X; Jeyasingham MD, 1999, VET MICROBIOL, V68, P219, DOI 10.1016/S0378-1135(99)00052-8; Jullien D, 1997, J CLIN INVEST, V99, P2071, DOI 10.1172/JCI119378; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KELLY D, 1991, GUT, V32, P386, DOI 10.1136/gut.32.4.386; KELLY D, 1991, HISTOCHEM J, V23, P55, DOI 10.1007/BF01886508; KELLY D, 1993, BIOL NEONATE, V64, P235; KING TP, 1991, HISTOCHEM J, V23, P43, DOI 10.1007/BF01886507; Kolb H, 1999, IMMUNOL TODAY, V20, P108, DOI 10.1016/S0167-5699(98)01425-X; Kovarik J, 1998, IMMUNOL TODAY, V19, P150, DOI 10.1016/S0167-5699(97)01230-9; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853; Kunz C, 1999, CLIN PERINATOL, V26, P307; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; MattsbyBaltzer I, 1996, PEDIATR RES, V40, P257, DOI 10.1203/00006450-199608000-00011; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Newburg DS, 1999, CURR MED CHEM, V6, P117; Newburg DS, 1998, LANCET, V351, P1160, DOI 10.1016/S0140-6736(97)10322-1; Pabst HF, 1997, ACTA PAEDIATR, V86, P1291, DOI 10.1111/j.1651-2227.1997.tb14900.x; Pickering LK, 1998, PEDIATRICS, V101, P242, DOI 10.1542/peds.101.2.242; Rennels MB, 1996, J INFECT DIS, V174, pS107; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Schroten H, 1998, INFECT IMMUN, V66, P3971; SEIGNOLE D, 1991, J GEN MICROBIOL, V137, P1591; Siegrist CA, 1998, VACCINE, V16, P1473, DOI 10.1016/S0264-410X(98)00111-X; Silva AM, 1999, J APPL MICROBIOL, V86, P331, DOI 10.1046/j.1365-2672.1999.00674.x; Strobel S, 1998, IMMUNOL TODAY, V19, P173, DOI 10.1016/S0167-5699(97)01239-5; TAATJES DJ, 1990, EUR J CELL BIOL, V53, P255; Teraguchi S, 1996, INFECT IMMUN, V64, P1075; TOMASI TB, 1983, REV INFECT DIS, V5, pS784; Vesikari T, 1996, J INFECT DIS, V174, pS81; Wang T, 1996, BIOL NEONATE, V70, P339; Wilson M, 1998, INFECT IMMUN, V66, P2401; Wold AE, 1998, ACTA PAEDIATR, V87, P19, DOI 10.1080/08035259850157804; Xanthou M, 1997, ACTA PAEDIATR, V86, P1288, DOI 10.1111/j.1651-2227.1997.tb14899.x; Zanetti M, 1992, Int Rev Immunol, V8, P209, DOI 10.3109/08830189209055574	58	102	106	1	11	C A B INTERNATIONAL	WALLINGFORD	C/O PUBLISHING DIVISION, WALLINGFORD OX10 8DE, OXON, ENGLAND	0029-6651			P NUTR SOC	Proc. Nutr. Soc.	MAY	2000	59	2					177	185		10.1017/S0029665100000197		9	Nutrition & Dietetics	Nutrition & Dietetics	340VU	WOS:000088556800001	10946785	
J	Little, SA; Chalmers, GW; MacLeod, KJ; McSharry, C; Thomson, NC				Little, SA; Chalmers, GW; MacLeod, KJ; McSharry, C; Thomson, NC			Non-invasive markers of airway inflammation as predictors of oral steroid responsiveness in asthma	THORAX			English	Article						airway inflammation; nitric oxide; induced sputum eosinophilia; asthma; corticosteroids	NITRIC-OXIDE; EXHALED AIR; SPUTUM	Background-Sputum eosinophil counts and exhaled nitric oxide (NO) levels are increased in asthma and both measurements fall in response to corticosteroids. Methods-Exhaled NO levels and sputum eosinophil counts were assessed as noninvasive markers of the response to an oral steroid in 37 patients (19 women) with stable chronic asthma (mean (SD) age 48.6 (12.2) years, asthma duration 25.9 (17.3) years, and baseline forced expiratory volume in one second (FEV1) 76.3 (21.9)% predicted). Spirometric tests, with reversibility to a beta agonist (2.5 mg nebulised salbutamol), and induced sputum (using nebulised 3% saline) were performed at recruitment and following treatment with 30 mg prednisolone/day for 14 days. Results-Baseline NO levels correlated with the percentage improvement in FEV, from baseline to the post-steroid, postbronchodilator value (r(s) = 0.47, p = 0.003), with an NO level of >10 ppb at baseline having a positive predictive value of 83% for an improvement in FEV, of greater than or equal to 15% (sensitivity 59%, specificity 90%). Sputum eosinophilia (greater than or equal to 4%) had a positive predictive value of 68% (sensitivity 54%, specificity 76%) for an increase in FEV1 of greater than or equal to 15%. A combination of sputum eosinophilia and increased NO levels resulted in a positive predictive value of 72% and a negative predictive value of 79% (sensitivity 76%, specificity 75%). Conclusion-Exhaled NO levels and sputum eosinophilia may be useful in predicting the response to a trial of oral steroid in asthma.	Univ Glasgow, Western Infirm, Dept Resp Med, Glasgow G11 6NT, Lanark, Scotland; Univ Glasgow, Western Infirm, Dept Immunol, Glasgow G11 6NT, Lanark, Scotland	Little, SA (reprint author), Univ Glasgow, Western Infirm, Dept Resp Med, Glasgow G11 6NT, Lanark, Scotland.			Thomson, Neil/0000-0003-1632-6630			Fabbri LM, 1998, AM J RESP CRIT CARE, V157, pS195; HARGREAVE FE, 1981, J ALLERGY CLIN IMMUN, V68, P347, DOI 10.1016/0091-6749(81)90132-9; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; TURNER MO, 1995, THORAX, V50, P1057, DOI 10.1136/thx.50.10.1057; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403	10	102	107	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2000	55	3					232	234		10.1136/thorax.55.3.232		3	Respiratory System	Respiratory System	289JE	WOS:000085616400011	10679543	
J	Locke, GR; Zinsmeister, AR; Talley, NJ; Fett, SL; Melton, LJ				Locke, GR; Zinsmeister, AR; Talley, NJ; Fett, SL; Melton, LJ			Risk factors for irritable bowel syndrome: Role of analgesics and food sensitivities	AMERICAN JOURNAL OF GASTROENTEROLOGY			English	Article							FUNCTIONAL GASTROINTESTINAL DISORDERS; EPIDEMIOLOGY; POPULATION; PREVALENCE; SYMPTOMS; DYSPEPSIA; HISTORY	OBJECTIVE: Symptoms of irritable bowel syndrome (IBS) are reported by 10% of the general population; however, evaluation of traditional risk factors has not provided any insight into the pathogenesis of this condition. The objective of this study was to identify additional risk factors for irritable bowel syndrome. METHODS: A valid self-report questionnaire that records the gastrointestinal (GI) symptoms required for a diagnosis of IBS, self-reported measures of potential risk factors, and a psychosomatic symptom checklist was mailed to an age- and gender-stratified random sample of Olmsted County, Minnesota residents aged 30-64 yr. A logistic regression model that adjusted for age, gender, and psychosomatic symptom score was used to identify factors significantly associated with IBS. RESULTS: A total of 643 (72%) of 892 eligible subjects returned the survey. IBS symptoms were reported by 12% of the respondents. IBS was significantly associated with use of analgesics (acetaminophen, aspirin, or nonaspirin nonsteroidal antiinflammatory drugs) for reasons other than IBS, reporting a food allergy or sensitivity, and ratings of somatic symptoms. No association was detected for age, gender, body mass index, smoking history, alcohol use, educational level, exposure to pets in the household, or water supply. Among subjects reporting the use of just one type of analgesic, IBS was associated with acetaminophen but not aspirin or nonaspirin nonsteroidal antiinflammatory drugs used alone. The odds of having IBS were higher among subjects reporting more reasons for taking analgesics and intolerance to a higher number of foods. CONCLUSIONS: IBS is significantly associated with analgesic use. However, this is confounded by other somatic pain complaints. IBS symptoms are associated with the reporting of many food allergies or sensitivities. The role of food-induced symptoms in IBS requires further investigation.	Mayo Clin & Mayo Fdn, Div Gastroenterol & Internal Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Hlth Sci Res, Rochester, MN 55905 USA	Locke, GR (reprint author), Mayo Clin & Mayo Fdn, Div Gastroenterol & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.		Talley, nicholas/D-5399-2013	Talley, nicholas/0000-0003-2537-3092	NIA NIH HHS [AG09440]; NIAMS NIH HHS [AR30582]		AGREUS L, 1995, GASTROENTEROLOGY, V109, P671, DOI 10.1016/0016-5085(95)90373-9; AGREUS L, 1994, SCAND J GASTROENTERO, V29, P102, DOI 10.3109/00365529409090447; ATTANASIO V, 1984, J BEHAV MED, V7, P247, DOI 10.1007/BF00845390; DROSSMAN DA, 1993, DIGEST DIS SCI, V38, P1569, DOI 10.1007/BF01303162; Drossman DA, 1997, GASTROENTEROLOGY, V112, P2120, DOI 10.1053/gast.1997.v112.agast972120; KAY L, 1994, J INTERN MED, V236, P23; KURLAND LT, 1981, SCI AM, V245, P54; Locke GR, 1997, GASTROENTEROLOGY, V112, P1448, DOI 10.1016/S0016-5085(97)70025-8; Locke GR, 1996, GASTROENTEROL CLIN N, V25, P1, DOI 10.1016/S0889-8553(05)70362-9; LONGSTRETH GF, 1993, DIGEST DIS SCI, V38, P1581, DOI 10.1007/BF01303163; Melton LJ, 1996, MAYO CLIN PROC, V71, P266; Niec AM, 1998, AM J GASTROENTEROL, V93, P2184; TALLEY NJ, 1995, AM J EPIDEMIOL, V142, P76; TALLEY NJ, 1992, AM J EPIDEMIOL, V136, P165; TALLEY NJ, 1991, EUR J GASTROEN HEPAT, V3, P71; TALLEY NJ, 1994, GASTROENTEROLOGY, V107, P1040; TALLEY NJ, 1989, ANN INTERN MED, V111, P671; TALLEY NJ, 1993, GASTROENTEROLOGY, V105, P781; TALLEY NJ, 1991, GASTROENTEROLOGY, V101, P927; Thompson WG, 1989, GASTROENTEROL INT, P92	20	102	104	0	5	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0002-9270			AM J GASTROENTEROL	Am. J. Gastroenterol.	JAN	2000	95	1					157	165				9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	273CY	WOS:000084690800028	10638576	
J	Kanatani, KT; Ito, I; Al-Delaimy, WK; Adachi, Y; Mathews, WC; Ramsdell, JW				Kanatani, Kumiko T.; Ito, Isao; Al-Delaimy, Wael K.; Adachi, Yuichi; Mathews, William C.; Ramsdell, Joe W.		Toyama Asian Desert Dust Asthma St	Desert Dust Exposure Is Associated with Increased Risk of Asthma Hospitalization in Children	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						Asian dust; Kosa; mineral dust; African dust; quartz	ASIAN SAND DUST; BIDIRECTIONAL CASE-CROSSOVER; OPTICAL-PARTICLE COUNTER; PEAK EXPIRATORY FLOW; RESPIRATORY SYMPTOMS; PARTICULATE MATTER; LIDAR MEASUREMENTS; HUMAN HEALTH; TRADE WINDS; AEROSOL	Rationale: Desert dust particles, including quartz, which causes inflammatory responses in the airway in animal studies, are transported to widespread regions around the globe. Epidemiologically, areas impacted by desert dust storms, such as communities in the Middle East and the Caribbean, seem to have higher incidences of asthma than might be expected. Objectives: We investigated the magnitude of association between airborne mineral dust concentration and hospitalization of children for asthma exacerbation by using Light Detection And Ranging (LIDAR) with a polarization analyzer for an exposure measurement, which can distinguish mineral dust particles from other particles. Methods: A case-crossover design was used. The exposure measurement was LIDAR's nonspherical extinction coefficient. The outcome measurement was hospitalization of children aged 1 to 15 years for asthma exacerbation in eight principal hospitals in Toyama, a local area in japan bordering the Japan Sea, during February to April, 2005 to 2009. Measurements and Main Results: During the study period, there were 620 admissions for asthma exacerbation, and 6 days with a heavy dust event (daily mineral dust concentration > 0.1 mg/m(3)). Conditional logistic regression showed a statistically significant association between asthma hospitalization and a heavy dust event. The crude odds ratio (OR) of the heavy dust event for hospitalization on the day was 1.88 (95% confidence interval [Cl], 1.04-3.41; P = 0.037), and the OR of heavy dust event during the previous week was 1.83 (95% Cl, 1.31-2.56; P = 0.00043). The OR adjusted by other air pollutant levels, pollen, and meteorological factors was 1.71 (95% Cl, 1.18-2.48; P = 0.0050). Conclusions: Heavy dust events are associated with an increased risk of hospitalizations for asthma.	[Kanatani, Kumiko T.] Kyoto Univ, Grad Sch Med, Sakyo Ku, Kyoto 6068507, Japan; [Ito, Isao] Kyoto Univ, Dept Resp Med, Kyoto 6068507, Japan; [Kanatani, Kumiko T.] Univ Calif San Diego, Clin Res Course, San Diego, CA 92103 USA; [Al-Delaimy, Wael K.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA; [Mathews, William C.] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; [Adachi, Yuichi] Toyama Univ, Dept Pediat, Fac Med, Toyama 930, Japan	Kanatani, KT (reprint author), Kyoto Univ, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.	kumiko.kanatani@ax7.ecs.kyoto-u.ac.jp	Kanatani, Kumiko/C-8276-2011; MORENO-GRAU, STELLA/E-6540-2012; Mathews, William/E-4451-2010	Mathews, William/0000-0002-2352-0725	National Institutes of Health	K.T.K. was a full-time employee for 1 year and a part-time employee for 2 years of Bayer Yakuhin, Ltd and received up to $1,000 from Taiho Seiyaku for a lecture at a seminar. I.I. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.K.A-D. received 85,001 S10,000 for serving as an expert witness for the Hansen Food Company. Y.A. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. W.C.M. received more than $100,001 from the National Institutes of Health in sponsored grants. J.W.R. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.	Adachi Mitsuru, 2008, Arerugi, V57, P107; Al Frayh AR, 2001, ANN ALLERG ASTHMA IM, V86, P292; ALKASSIMI FA, 1991, THORAX, V46, P861, DOI 10.1136/thx.46.11.861-d; Bener A, 1996, HUM BIOL, V68, P405; BROWELL EV, 1990, GEOPHYS RES LETT, V17, P385, DOI 10.1029/GL017i004p00385; Chohnabayashi Naohiko, 2010, Arerugi, V59, P123; Choi DS, 1997, J MICROBIOL, V35, P1; Choi JC, 2001, J GEOPHYS RES-ATMOS, V106, P18067, DOI 10.1029/2001JD900090; Derbyshire E, 2007, AMBIO, V36, P73, DOI 10.1579/0044-7447(2007)36[73:NMDAHH]2.0.CO;2; Eagan TML, 2002, AM J RESP CRIT CARE, V166, P933, DOI 10.1164/rccm.200203-238OC; Eisenbarth SC, 2008, NATURE, V453, P1122, DOI 10.1038/nature06939; Griffin DW, 2007, CLIN MICROBIOL REV, V20, P459, DOI 10.1128/CMR.00039-06; Gyan K, 2005, INT J BIOMETEOROL, V49, P371, DOI 10.1007/s00484-005-0257-3; Hiyoshi K, 2005, ENVIRON RES, V99, P361, DOI 10.1016/j.envres.2005.03.008; Hong CS, 2004, ENVIRON MONIT ASSESS, V92, P43, DOI 10.1023/B:EMAS.0000014508.76989.a5; Hong YC, 2010, SCI TOTAL ENVIRON, V408, P754, DOI 10.1016/j.scitotenv.2009.11.015; Howitt M. E., 2000, POSTGRAD DOCTOR CARI, V16, P86; Ichinose T, 2008, ARCH ENVIRON CON TOX, V55, P348, DOI 10.1007/s00244-007-9128-8; Ichinose T, 2008, INHAL TOXICOL, V20, P685, DOI 10.1080/08958370801935133 ; Ichinose T, 2006, J TOXICOL ENV HEAL A, V69, P1571, DOI 10.1080/15287390500470833; Iwasaka Y, 2004, ENVIRON MONIT ASSESS, V92, P5, DOI 10.1023/B:EMAS.0000014505.43198.48; KRUEGER D, 1995, J ATMOSPHERIC OCEANI, V10, P533; Lin M, 2003, J EPIDEMIOL COMMUN H, V57, P50, DOI 10.1136/jech.57.1.50; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; MANCINO D, 1984, INT ARCH ALLER A IMM, V73, P10; Marenco F, 1997, APPL OPTICS, V36, P6875, DOI 10.1364/AO.36.006875; Matthias V, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2004JD004638; Murayama T, 1999, J GEOPHYS RES-ATMOS, V104, P31781, DOI 10.1029/1999JD900503; Murphy SA, 1998, LIFE SCI, V62, P1789, DOI 10.1016/S0024-3205(98)00141-6; Park JW, 2005, RESPIROLOGY, V10, P470, DOI 10.1111/j.1440-1843.2005.00728.x; PROSPERO JM, 1986, NATURE, V320, P735, DOI 10.1038/320735a0; Prospero JM, 2008, INT J BIOMETEOROL, V52, P823, DOI 10.1007/s00484-008-0176-1; Rutherford S, 1999, INT J BIOMETEOROL, V42, P217, DOI 10.1007/s004840050108; Shimizu A, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2002JD003253; Sugimoto N, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016349; Sugimoto N, 2008, P SPIE, V7153; Sugimoto N, 2006, APPL OPTICS, V45, P7468, DOI 10.1364/AO.45.007468; TAKAMURA T, 1994, APPL OPTICS, V33, P7132, DOI 10.1364/AO.33.007132; Tecer LH, 2008, J TOXICOL ENV HEAL A, V71, P512, DOI 10.1080/15287390801907459; TEGEN I, 1995, J GEOPHYS RES-ATMOS, V100, P18707, DOI 10.1029/95JD02051; Uno I, 2009, NAT GEOSCI, V2, P557, DOI 10.1038/NGEO583; Valiante DJ, 2004, AM J PUBLIC HEALTH, V94, P876, DOI 10.2105/AJPH.94.5.876; Willart MAM, 2009, CLIN EXP ALLERGY, V39, P12, DOI 10.1111/j.1365-2222.2008.03118.x; Yang CY, 2005, INHAL TOXICOL, V17, P817, DOI 10.1080/08958370500241254; Yoo Y, 2008, J KOREAN MED SCI, V23, P66, DOI 10.3346/jkms.2008.23.1.66; 2006, J GEOPHYS RES, V111	46	101	104	1	13	AMER THORACIC SOC	NEW YORK	25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA	1073-449X	1535-4970		AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2010	182	12					1475	1481		10.1164/rccm.201002-0296OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	697RU	WOS:000285534600006	20656941	
J	Thomas, WR; Hales, BJ; Smith, WA				Thomas, Wayne R.; Hales, Belinda J.; Smith, Wendy-Anne			House dust mite allergens in asthma and allergy	TRENDS IN MOLECULAR MEDICINE			English	Review							BLOMIA-TROPICALIS ALLERGENS; IGE CROSS-REACTIVITY; DERMATOPHAGOIDES-PTERONYSSINUS; MAJOR ALLERGEN; CYSTEINE PROTEASES; STRUCTURAL BIOLOGY; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; P 2; RECOMBINANT	IgE antibodies in house dust mite (HDM) allergy follow a predictable pattern. Half are directed against two dominant allergens and the remainder largely against four midpotency allergens. This hierarchical pattern is not changed by the titre of the IgE response or severity of disease. The structures of these allergens are known and they can be produced as authentic recombinant allergens. There is also evidence that the allergenicity is augmented by the biological activity of the key allergens, validating them as targets for vaccination. Collectively, these developments should facilitate the development of new diagnostics, improve immunotherapy and allow vaccination with defined reagents. Highly purified recombinant polypeptides representing the important mite allergens are now available so that informative and reproducible experiments can be performed with mite allergens in place of poorly defined and variable extracts.	[Thomas, Wayne R.; Hales, Belinda J.; Smith, Wendy-Anne] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Subiaco, WA 6008, Australia	Thomas, WR (reprint author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, 100 Roberts Rd, Subiaco, WA 6008, Australia.	wayne@ichr.uwa.edu.au	Hales, Belinda/C-3858-2013	Hales, Belinda/0000-0003-2193-3996	National Health and Medical Research Council	The authors are supported by the National Health and Medical Research Council.	Arlian Larry G, 2002, Curr Allergy Asthma Rep, V2, P401, DOI 10.1007/s11882-002-0074-2; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Batard T, 2006, INT ARCH ALLERGY IMM, V140, P295, DOI 10.1159/000093707; Chan SL, 2008, J IMMUNOL, V181, P2586; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Cheong N, 2003, ALLERGY, V58, P912, DOI 10.1034/j.1398-9995.2003.00215.x; Cheong N, 2009, INT ARCH ALLERGY IMM, V149, P25, DOI 10.1159/000176303; Chevigne A, 2007, J MOL BIOL, V374, P170, DOI 10.1016/j.jmb.2007.08.025; Chiou YL, 2009, J CELL PHYSIOL, V220, P311, DOI 10.1002/jcp.21764; Chruszcz M, 2009, J MOL BIOL, V386, P520, DOI 10.1016/j.jmb.2008.12.049; Chua KY, 2007, PROTEIN PEPTIDE LETT, V14, P325; de Halleux S, 2006, J ALLERGY CLIN IMMUN, V117, P571, DOI 10.1016/j.jaci.2005.11.032; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.0000/S0022-2836(02)00027-X; Erban T, 2009, ARCH INSECT BIOCHEM, V71, P139, DOI 10.1002/arch.20312; Fernandez-Caldas E, 2004, ALLERGY, V59, P1161, DOI 10.1111/j.1398-9995.2004.00727.x; Gao YF, 2007, J ALLERGY CLIN IMMUN, V120, P105, DOI 10.1016/j.jaci.2007.02.032; Hales BJ, 2007, CLIN EXP ALLERGY, V37, P1357, DOI 10.1111/j.1365-2222.2007.02786.x; Hales BJ, 2009, CLIN EXP ALLERGY, V39, P1170, DOI 10.1111/j.1365-2222.2009.03252.x; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hales BJ, 2002, CLIN EXP ALLERGY, V32, P1461, DOI 10.1046/j.1365-2745.2002.01500.x; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Ichikawa S, 2009, GENES CELLS, V14, P1055, DOI 10.1111/j.1365-2443.2009.01334.x; Johannessen BR, 2005, FEBS LETT, V579, P1208, DOI 10.1016/j.febslet.2004.11.115; Kandane-Rathnayake RK, 2009, THORAX, V64, P1025, DOI 10.1136/thx.2009.118430; Kikuchi Y, 2006, J IMMUNOL, V177, P1609; Larenas-Linnemann D, 2008, ANN ALLERG ASTHMA IM, V100, P137, DOI 10.1016/S1081-1206(10)60422-X; Maneachotesuwan K, 2009, J ALLERGY CLIN IMMUN, V123, P239, DOI 10.1016/j.jaci.2008.10.018; McCall C, 2001, VET IMMUNOL IMMUNOP, V78, P231, DOI 10.1016/S0165-2427(00)00258-0; McGlade JP, 2007, J IMMUNOL, V178, P2794; Meno K, 2005, J IMMUNOL, V175, P3835; Mills KL, 2002, J ALLERGY CLIN IMMUN, V109, pS180, DOI 10.1016/S0091-6749(02)81668-2; Mora C, 2003, CLIN EXP ALLERGY, V33, P28, DOI 10.1046/j.1365-2222.2003.01480.x; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; Mueller GA, 2010, J ALLERGY CLIN IMMUN, V125, P909, DOI 10.1016/j.jaci.2009.12.016; Naik MT, 2008, STRUCTURE, V16, P125, DOI 10.1016/j.str.2007.10.022; Park GM, 2000, CLIN EXP ALLERGY, V30, P1293, DOI 10.1046/j.1365-2222.2000.00883.x; Park JW, 2002, CLIN EXP ALLERGY, V32, P1042, DOI 10.1046/j.1365-2222.2002.01421.x; Piboonpocanun S, 2006, CLIN EXP ALLERGY, V36, P510, DOI 10.1111/j.1365-2222.2006.02464.x; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Roeber D, 2003, ACTA CRYSTALLOGR D, V59, P1046, DOI 10.1107/S0907444903004438; Shen HD, 1996, CLIN EXP ALLERGY, V26, P308; Smith WA, 2001, J ALLERGY CLIN IMMUN, V107, P985, DOI 10.1067/mai.2001.114652; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; STEWART GA, 1991, INT ARCH ALLER A IMM, V95, P248; Sutherland TE, 2009, CLIN EXP ALLERGY, V39, P943, DOI 10.1111/j.1365-2222.2009.03243.x; Takahashi K, 2000, INT ARCH ALLERGY IMM, V122, P108, DOI 10.1159/000024366; Takai T, 2006, INT ARCH ALLERGY IMM, V139, P181, DOI 10.1159/000091163; Thanyaratsrisakul S., 2010, INT ARCH ALLERGY IMM, V151, P190; Thomas WR, 2007, PROTEIN PEPTIDE LETT, V14, P943, DOI 10.2174/092986607782541169; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P388, DOI 10.1007/s11882-005-0012-1; Thomas WR, 2005, CURR ALLERGY ASTHM R, V5, P197, DOI 10.1007/s11882-005-0038-4; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tsai JJ, 1998, INT ARCH ALLERGY IMM, V115, P144, DOI 10.1159/000023894; van Ree R, 2002, CLIN EXP ALLERGY, V32, P975; Wang LH, 2009, INT ARCH ALLERGY IMM, V148, P199, DOI 10.1159/000161580; Weber E, 2003, J ALLERGY CLIN IMMUN, V112, P79, DOI 10.1067/mai.2003.1602; Weghofer M, 2008, EUR J CLIN INVEST, V38, P959, DOI 10.1111/j.1365-2362.2008.02048.x; Weghofer M, 2008, ALLERGY, V63, P758, DOI 10.1111/j.1398-9995.2008.01647.x; Weghofer M, 2005, CLIN EXP ALLERGY, V35, P1384, DOI 10.1111/j.1365-2222.2005.02345.x; Weghofer M, 2008, INT ARCH ALLERGY IMM, V147, P101, DOI 10.1159/000135696; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Yasuhara T, 2001, CLIN EXP ALLERGY, V31, P116, DOI 10.1046/j.1365-2222.2001.00945.x; Yi Fong Cheng, 2006, Inflammation & Allergy Drug Targets, V5, P261; Zakzuk J, 2009, CLIN EXP ALLERGY, V39, P608, DOI 10.1111/j.1365-2222.2008.03193.x; Zhang J, 2007, ALLERGY, V62, P1302, DOI 10.1111/j.1397-9995.2007.01492.x; Zhang J, 2009, ALLERGY, V64, P469, DOI 10.1111/j.1398-9995.2008.01852.x	68	101	107	3	16	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1471-4914			TRENDS MOL MED	Trends Mol. Med	JUL	2010	16	7					321	328		10.1016/j.molmed.2010.04.008		8	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	632YY	WOS:000280467200004	20605742	
J	Halonen, JI; Lanki, T; Yli-Tuomi, T; Tiittanen, P; Kulmala, M; Pekkanen, J				Halonen, Jaana I.; Lanki, Timo; Yli-Tuomi, Tarja; Tiittanen, Pekka; Kulmala, Markku; Pekkanen, Juha			Particulate Air Pollution and Acute Cardiorespiratory Hospital Admissions and Mortality Among the Elderly	EPIDEMIOLOGY			English	Article							EMERGENCY-DEPARTMENT VISITS; SOURCE APPORTIONMENT; ULTRAFINE PARTICLES; EUROPEAN CITIES; FINE PARTICLES; AMBIENT PM2.5; URBAN AIR; ASSOCIATIONS; HEALTH; HELSINKI	Background: It is known that particulate air pollution affects cardiorespiratory health; however, it is unclear which particle size fractions and sources of particles are responsible for the health effects. Methods: Daily levels of nucleation (<0.03 mu m), Aitken (0.03-0.1 mu m), accumulation (0.1-0.29 mu m), and coarse mode (2.5-10 mu m) particles, particles with diameter <2.5 mu m (PM(2.5)), and gaseous pollutants were measured at central outdoor measurement sites in Helsinki, Finland between 1998 and 2004. We determined the associations of particles with daily cardiorespiratory mortality and acute hospital admissions among the elderly (>= 65 years). For the analyses we used Poisson generalized additive models and for the source apportionment of PM(2.5) we used the EPA positive matrix factorization method. Results: There was a suggestion of an association of hospital admissions for arrhythmia with Aitken mode particles and PM,., from traffic. Otherwise few associations were observed between various sizes and types of particles and either cardiovascular admissions or mortality. In contrast, most particle fractions had positive associations with admissions for pneumonia and asthma-chronic obstructive pulmonary disease (COPD). The strongest and most consistent associations were found for accumulation mode particles (3.1%; 95% confidence interval = 0.43-5.8 for pneumonia over the 5-day mean, and 3.8%; 1.3-6.3 for asthma-COPD at lag 0, for an interquartile increase in particles). We also found a positive association of respiratory mortality mainly with accumulation mode particles (5.1%; 1.2-9.0 at lag 0). Conclusions: All particle fractions including Aitken, accumulation, and coarse mode had especially adverse respiratory health effects among the elderly. Overall associations were stronger for respiratory than for cardiovascular outcomes.	[Halonen, Jaana I.; Lanki, Timo; Yli-Tuomi, Tarja; Tiittanen, Pekka; Pekkanen, Juha] Natl Publ Hlth Inst KTL, Environm Epidemiol Unit, FIN-70701 Kuopio, Finland; [Kulmala, Markku] Univ Helsinki, Dept Phys Sci, Helsinki, Finland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	Halonen, JI (reprint author), Natl Publ Hlth Inst KTL, Environm Epidemiol Unit, POB 95, FIN-70701 Kuopio, Finland.	jaana.halonen@ktl.fi	Kulmala, Markku/I-7671-2016	Kulmala, Markku/0000-0003-3464-7825; Yli-Tuomi, Tarja/0000-0001-9332-2241	Centre of Excellence Programme 2002-2007 of the Academy of Finland [53307]; TEKES [40715/01]; Ministry of Education (Graduate School in Environment Health SYTYKE)	Supported by the Centre of Excellence Programme 2002-2007 of the Academy of Finland (Contract 53307), the National Technology Fund (TEKES, Contract 40715/01), and the Ministry of Education (Graduate School in Environment Health SYTYKE).	AGA E, 2003, EUROPEAN RESP J S, V40, P28; Analitis A, 2006, EPIDEMIOLOGY, V17, P230, DOI 10.1097/01.ede.0000199439.57655.6b; ANDERSEN ZJ, 2007, OCCUP ENV MED; Andersen ZJ, 2007, J EXPO SCI ENV EPID, V17, P625, DOI 10.1038/sj.jes.7500546; Brunekreef B, 2005, EUR RESPIR J, V26, P309, DOI 10.1183/09031936.05.00001805; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; Buzorius G, 1999, ATMOS ENVIRON, V33, P553, DOI 10.1016/S1352-2310(98)00287-8; Chen Y, 2004, INHAL TOXICOL, V16, P21, DOI 10.1080/0895837049258129; Delfino RJ, 2005, ENVIRON HEALTH PERSP, V113, P934, DOI 10.1289/ehp.7938; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Franklin M, 2007, J EXPO SCI ENV EPID, V17, P279, DOI 10.1038/sj.jes.7500530; Gleason PP, 1999, ARCH INTERN MED, V159, P2562, DOI 10.1001/archinte.159.21.2562; Goldberg MS, 2001, ENVIRON RES, V86, P26, DOI 10.1006/enrs.2001.4243; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Hoek G, 2000, J AIR WASTE MANAGE, V50, P1380, DOI 10.1080/10473289.2000.10464182; Hoek G, 2008, ATMOS ENVIRON, V42, P156, DOI 10.1016/j.atmosenv.2007.09.026; Hussein T, 2004, ATMOS CHEM PHYS, V4, P391; JANSSEN NA, 2005, OCCUP ENVIRON MED, V12, P868; Kettunen J, 2007, STROKE, V38, P918, DOI 10.1161/01.STR.0000257999.49706.3b; Kim Sunghye, 2006, COPD, V3, P75, DOI 10.1080/15412550600651271; Koponen IK, 2001, ATMOS ENVIRON, V35, P1465; Kulmala M, 2004, J AEROSOL SCI, V35, P143, DOI 10.1016/j.jaerosci.2003.10.003; Kulmala Markku, 2000, Boreal Environment Research, V5, P315; Lanki T, 2006, OCCUP ENVIRON MED, V63, P844, DOI 10.1136/oem.2005.023911; Lanki T, 2006, ENVIRON HEALTH PERSP, V114, P655, DOI 10.1289/ehp.8578; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; Paatero P, 1997, CHEMOMETR INTELL LAB, V37, P23, DOI 10.1016/S0169-7439(96)00044-5; Peel JL, 2007, AM J EPIDEMIOL, V165, P625, DOI 10.1093/aje/kwk051; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Pekkanen J, 2004, SCAND J WORK ENV HEA, V30, P9; Penttinen P, 2006, INHAL TOXICOL, V18, P191, DOI 10.1080/08958370500434230; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; R_Development_Core_Team, 2005, R LANG ENV STAT COMP; Rich DQ, 2005, AM J EPIDEMIOL, V161, P1123, DOI 10.1093/aje/kwi143; Salomaa V., 2003, European Heart Journal, V24, P311, DOI 10.1016/S0195-668X(02)00421-9; Sarnat J. A., 2008, ENV HLTH PERSPECT, V116, P459; Schwarze PE, 2006, HUM EXP TOXICOL, V25, P559, DOI 10.1177/096032706072520; Vallius M, 2005, SCI TOTAL ENVIRON, V337, P147, DOI 10.1016/j.scitotenv.2004.06.018; Vallius M, 2003, ATMOS ENVIRON, V37, P615, DOI 10.1016/S1352-2310(02)00925-1; WHO, 2007, WHO WORKSH BONN GERM; Wood SN, 2000, J ROY STAT SOC B, V62, P413, DOI 10.1111/1467-9868.00240; Zanobetti A, 2006, J EPIDEMIOL COMMUN H, V60, P890, DOI 10.1136/jech.2005.039834	42	101	107	5	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	JAN	2009	20	1					143	153		10.1097/EDE.0b013e31818c7237		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	387DB	WOS:000261930800023	19234403	
J	Farfel, M; DiGrande, L; Brackbill, R; Prann, A; Cone, J; Friedman, S; Walker, DJ; Pezeshki, G; Thomas, P; Galea, S; Williamson, D; Frieden, TR; Thorpe, L				Farfel, Mark; DiGrande, Laura; Brackbill, Robert; Prann, Angela; Cone, James; Friedman, Stephen; Walker, Deborah J.; Pezeshki, Grant; Thomas, Pauline; Galea, Sandro; Williamson, David; Frieden, Thomas R.; Thorpe, Lorna			An Overview of 9/11 Experiences and Respiratory and Mental Health Conditions among World Trade Center Health Registry Enrollees	JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE			English	Article						World Trade Center; Asthma; Respiratory symptoms; Posttraumatic stress disorder; Serious psychological distress; Population estimates of WTC disaster health outcomes; World Trade Center Health Registry (WTCHR); Environmental exposures; New York City; Children; Terrorism; WTC attacks; Epidemiology; Mental health	POSTTRAUMATIC-STRESS-DISORDER; NEW-YORK-CITY; SEPTEMBER-11 TERRORIST ATTACKS; NATIONAL COMORBIDITY SURVEY; CENTER DISASTER SITE; ST-HELENS ERUPTIONS; PTSD CHECKLIST; PULMONARY-FUNCTION; CIVILIAN VERSION; POLICE OFFICERS	To date, health effects of exposure to the September 11, 2001 disaster in New York City have been studied in specific groups, but no studies have estimated its impact across the different exposed populations. This report provides an overview of the World Trade Center Health Registry (WTCHR) enrollees, their exposures, and their respiratory and mental health outcomes 2-3 years post-9/11. Results are extrapolated to the estimated universe of people eligible to enroll in the WTCHR to determine magnitude of impact. Building occupants, persons on the street or in transit in lower Manhattan on 9/11, local residents, rescue and recovery workers/volunteers, and area school children and staff were interviewed and enrolled in the WTCHR between September 2003 and November 2004. A total of 71,437 people enrolled in the WTCHR, for 17.4% coverage of the estimated eligible exposed population (nearly 410,000); 30% were recruited from lists, and 70% were self-identified. Many reported being in the dust cloud from the collapsing WTC Towers (51%), witnessing traumatic events (70%), or sustaining an injury (13%). After 9/11, 67% of adult enrollees reported new or worsening respiratory symptoms, 3% reported newly diagnosed asthma, 16% screened positive for probable posttraumatic stress disorder (PTSD), and 8% for serious psychological distress (SPD). Newly diagnosed asthma was most common among rescue and recovery workers who worked on the debris pile (4.1%). PTSD was higher among those who reported Hispanic ethnicity (30%), household income <$25,000 (31%), or being injured (35%). Using previously published estimates of the total number of exposed people per WTCHR eligibility criteria, we estimate between 3,800 and 12,600 adults experienced newly diagnosed asthma and 34,600-70,200 adults experienced PTSD following the attacks, suggesting extensive adverse health impacts beyond the immediate deaths and injuries from the acute event.	[Farfel, Mark; DiGrande, Laura; Prann, Angela; Cone, James; Friedman, Stephen; Walker, Deborah J.; Pezeshki, Grant; Frieden, Thomas R.; Thorpe, Lorna] New York City Dept Hlth & Mental Hyg, New York, NY USA; [Brackbill, Robert; Williamson, David] Agcy Tox Subst & Dis Registry, Atlanta, GA USA; [Thomas, Pauline] Univ Med & Dent New Jersey, New Jersey Med Sch, Newark, NJ 07103 USA; [Galea, Sandro] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA	Farfel, M (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY USA.	mfarfel@health.nyc.gov			CDC's National Center for Environmental Health [U50/ATU272750]	This research was supported by Cooperative Agreement Number U50/ATU272750 from the Agency for Toxic Substances and Disease Registry with additional funding from the CDC's National Center for Environmental Health. The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the ATSDR. The manuscript underwent ATSDR external peer review.	Adams RE, 2006, SOC SCI MED, V62, P176, DOI 10.1016/j.socscimed.2005.05.008; Andrykowski MA, 1998, J CONSULT CLIN PSYCH, V66, P586, DOI 10.1037//0022-006X.66.3.586; Banauch GI, 2006, AM J RESP CRIT CARE, V174, P312, DOI 10.1164/rccm.200511-1736OC; BAXTER PJ, 1983, ARCH ENVIRON HEALTH, V38, P138; BEDON D, 1988, STAT GEOGRAPHY; BERNSTEIN RS, 1986, AM J PUBLIC HEALTH, V76, P25, DOI 10.2105/AJPH.76.Suppl.25; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Brackbill Robert M., 2006, Morbidity and Mortality Weekly Report, V55, P1; Breslau N, 1997, ARCH GEN PSYCHIAT, V54, P1044; BROOKS N, 1992, J TRAUMA STRESS, V5, P527, DOI 10.1002/jts.2490050403; *CDCP, 2004, PHYS HLTH STAT WORLD; Chow Stirling, 2005, EUL DIAGR WORKSH PAR; CONE JE, 1994, CHEST, V106, P500, DOI 10.1378/chest.106.2.500; Cowan DN, 2002, MIL MED, V167, P777; DiGrande L, 2008, J TRAUMA STRESS, V21, P264, DOI 10.1002/jts.20345; Dobie DJ, 2002, GEN HOSP PSYCHIAT, V24, P367, DOI 10.1016/S0163-8343(02)00207-4; DOOLEY E, 1995, BRIT J PSYCHIAT, V167, P233, DOI 10.1192/bjp.167.2.233; FAIRBROTHER G, 2005, CENTURY FDN REPORT; Feldman DM, 2004, CHEST, V125, P1256, DOI 10.1378/chest.125.4.1256; Galea S, 2002, NEW ENGL J MED, V346, P982, DOI 10.1056/NEJMsa013404; Galea S, 2003, AM J EPIDEMIOL, V158, P514, DOI 10.1093/aje/kwg187; Gavett SH, 2003, ENVIRON HEALTH PERSP, V111, P981, DOI 10.1289/ehp.5931; GREEN BL, 1992, J NERV MENT DIS, V180, P760, DOI 10.1097/00005053-199212000-00004; Havenaar JM, 1997, AM J PSYCHIAT, V154, P1605; Herbert R, 2006, ENVIRON HEALTH PERSP, V114, P1853, DOI 10.1289/ehp.9592; Herbstman JB, 2005, ENVIRON RES, V99, P85, DOI 10.1016/j.envres.2004.08.010; Hoven CW, 2005, ARCH GEN PSYCHIAT, V62, P545, DOI 10.1001/archpsyc.62.5.545; KERN DG, 1991, AM REV RESPIR DIS, V144, P1058; Kessler RC, 2003, ARCH GEN PSYCHIAT, V60, P184, DOI 10.1001/archpsyc.60.2.184; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P617, DOI 10.1001/archpsyc.62.6.617; Marmar C, 1990, TRAUMA VIETNAM WAR G; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lang AJ, 2003, J TRAUMA STRESS, V16, P257, DOI 10.1023/A:1023796007788; Levin S, 2002, AM J IND MED, V42, P545, DOI 10.1002/ajim.10154; Lin S, 2005, AM J EPIDEMIOL, V162, P499, DOI 10.1093/aje/kwi233; Lin S, 2007, J ASTHMA, V44, P325, DOI 10.1080/02770900701344181; Lioy PJ, 2006, ENVIRON SCI TECHNOL, V40, P6876, DOI 10.1021/es062980e; Lioy PJ, 2002, ENVIRON HEALTH PERSP, V110, P703; Mitchell A., 2005, ESRI GUIDE GIS ANAL, V2; Murphy J, 2007, STAT MED, V26, P1688, DOI 10.1002/sim.2806; Nelson DE, 2001, SOZ PRAVENTIV MED, V46, pS3; Neria Y, 2006, GEN HOSP PSYCHIAT, V28, P213, DOI 10.1016/j.genhosppsych.2006.02.002; Norris FH, 2002, PSYCHIATRY, V65, P240, DOI 10.1521/psyc.65.3.240.20169; North CS, 1999, JAMA-J AM MED ASSOC, V282, P755, DOI 10.1001/jama.282.8.755; North CS, 2002, JAMA-J AM MED ASSOC, V288, P633, DOI 10.1001/jama.288.5.633; *NYCDOHMH, 2003, NYC COMM HLTH SURV; *NYCDOHMH, 2004, NYC COMM HLTH SURV; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; PALINKAS LA, 1993, AM J PSYCHIAT, V150, P1517; PENK WE, 1989, J CLIN PSYCHOL, V45, P729, DOI 10.1002/1097-4679(198909)45:5<729::AID-JCLP2270450507>3.0.CO;2-H; Perrin MA, 2007, AM J PSYCHIAT, V164, P1385, DOI 10.1176/appi.apj.2007.06101645; Pole N, 2001, J NERV MENT DIS, V189, P442, DOI 10.1097/00005053-200107000-00005; Prezant DJ, 2002, NEW ENGL J MED, V347, P806, DOI 10.1056/NEJMoa021300; PROMISLOFF RA, 1990, CHEST, V98, P928, DOI 10.1378/chest.98.4.928; Reibman J, 2005, ENVIRON HEALTH PERSP, V113, P406; Rose D, 2006, AM J PUBLIC HEALTH, V96, P880, DOI 10.2105/AJPH.2004.050039; Rudd RA, 2007, J ASTHMA, V44, P65, DOI 10.1080/02770900601125896; Ruggiero KJ, 2003, J TRAUMA STRESS, V16, P495, DOI 10.1023/A:1025714729117; Salzman SH, 2004, J OCCUP ENVIRON MED, V46, P113, DOI 10.1097/01.jom.0000111612.68916.d0; Sama Susan R, 2003, Environ Health, V2, P10, DOI 10.1186/1476-069X-2-10; *SAS, 2005, STAT AN SYST VERS 9; Schlenger WE, 2002, JAMA-J AM MED ASSOC, V288, P581, DOI 10.1001/jama.288.5.581; Schuster MA, 2001, NEW ENGL J MED, V345, P1507, DOI 10.1056/NEJM200111153452024; Selley C, 1997, BRIT J PSYCHIAT, V171, P478, DOI 10.1192/bjp.171.5.478; Silver RC, 2002, JAMA-J AM MED ASSOC, V288, P1235, DOI 10.1001/jama.288.10.1235; Skloot G, 2004, CHEST, V125, P1248, DOI 10.1378/chest.125.4.1248; Smith D W, 1999, J Okla State Med Assoc, V92, P193; Smith MY, 1999, J TRAUMA STRESS, V12, P485, DOI 10.1023/A:1024719104351; Thomas PA, 2008, ENVIRON HEALTH PERSP, V116, P1383, DOI 10.1289/ehp.11205; Tomita Katsuyuki, 2005, J Med Invest, V52, P80, DOI 10.2152/jmi.52.80; Trout D, 2002, J OCCUP ENVIRON MED, V44, P601, DOI 10.1097/01.jom.0000023384.41727.fc; Viswanathan S, 2006, J AIR WASTE MANAGE, V56, P56; Weathers FW, 1996, MEASUREMENT STRESS T; Wheeler K, 2007, ENVIRON HEALTH PERSP, V115, P1584, DOI 10.1289/ehp.10248; Yehuda R, 2005, NEUROPSYCHOPHARMACOL, V30, P1773, DOI 10.1038/sj.npp.1300817;	77	101	101	3	14	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1099-3460			J URBAN HEALTH	J. Urban Health	NOV	2008	85	6					880	909		10.1007/s11524-008-9317-4		30	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	376JU	WOS:000261180700009	18785012	
J	Friedman, DS; Hahn, SR; Gelb, L; Tan, J; Shah, SN; Kim, EE; Zimmerman, TJ; Quigley, HA				Friedman, David S.; Hahn, Steven R.; Gelb, Laurie; Tan, Jason; Shah, Sonali N.; Kim, Elizabeth E.; Zimmerman, Thom J.; Quigley, Harry A.			Doctor-patient communication, health-related beliefs, and adherence in glaucoma	OPHTHALMOLOGY			English	Article							BEHAVIORAL SKILLS MODEL; MANAGED CARE POPULATION; PHARMACY CLAIMS DATA; OPEN-ANGLE GLAUCOMA; QUALITY-OF-LIFE; ANTIRETROVIRAL THERAPY; FUTURE-DIRECTIONS; ASTHMA-TREATMENT; CHRONIC DISEASE; EMPIRICAL-TEST	Objective: To use multiple data sources to determine drivers of patient adherence to topical ocular hypotensive therapy. Design: Retrospective database and chart reviews in combination with prospective patient surveys. Diverse medical environments where insured patients in the research database seek care. Participants: Three hundred patients with a new claim diagnosis for open-angle glaucoma who initially were prescribed one of three prostaglandins and 103 physicians participating in the same medical plans. Methods: A structured interview addressing self-reported adherence, experiences with medication, communication with the physician, and health-related beliefs associated with adherence behavior was administered to surveyed patients. Phone interviews were conducted with participating ophthalmologists. Main Outcome Measure: Of adherence, medication possession ratio. Results: Eight variables were associated independently with a lower medication possession ratio: (1) hearing all of what you know about glaucoma from your doctor (compared with some or nothing); (2) not believing that reduced vision is a risk of not taking medication as recommended; (3) having a problem paying for medications; (4) difficulty while traveling or away from home; (5) not acknowledging stinging and burning; (6) being nonwhite; (7) receiving samples; and (8) not receiving a phone call visit reminder. The multivariate model explained 21% of the variance. Conclusions: These findings indicate that doctor-patient communications and health-related beliefs of patients contribute to patient adherence. Patient learning styles that are associated with less concern about the future effects of glaucoma and the risks of not taking medications are associated with lower adherence. Specifically, knowledge about potential vision loss from glaucoma is a critical element that tends to be missed by more passive doctor-dependent patients who tend to be poorly adherent. These findings suggest that educational efforts in the office may improve patient adherence to medical therapies.	[Friedman, David S.; Quigley, Harry A.] Wilmer Eye Inst, Baltimore, MD 21287 USA; [Friedman, David S.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; [Hahn, Steven R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA; [Hahn, Steven R.] Albert Einstein Coll Med, Dept Psychiat, Bronx, NY 10467 USA; [Hahn, Steven R.] Medintel On Call, Pleasantville, NY USA; [Tan, Jason] HealthCore Inc, Wilmington, DE USA; [Shah, Sonali N.; Kim, Elizabeth E.] Pfizer Inc, New York, NY USA; [Zimmerman, Thom J.] Univ Louisville, Sch Med, Dept Ophthalmol & Visual Sci, Louisville, KY 40292 USA	Friedman, DS (reprint author), Johns Hopkins Univ Hosp, 600 N Wolfe St,Wilmer 120, Baltimore, MD 21287 USA.	David.Friedman@jhu.edu					Amico KR, 2005, AIDS CARE, V17, P661, DOI 10.1080/09540120500038058; Back AL, 2005, CA-CANCER J CLIN, V55, P164; Bender BG, 2002, J ALLERGY CLIN IMMUN, V109, pS554, DOI 10.1067/mai.2002.124570; BLOCH S, 1977, BRIT J OPHTHALMOL, V61, P531, DOI 10.1136/bjo.61.8.531; BOUR T, 1993, J FR OPHTALMOL, V16, P380; Boyle D, 2005, ACAD MED, V80, P29, DOI 10.1097/00001888-200501000-00008; Brawley LR, 2000, CONTROL CLIN TRIALS, V21, p156S, DOI 10.1016/S0197-2456(00)00073-8; Bultman DC, 2000, PATIENT EDUC COUNS, V40, P173, DOI 10.1016/S0738-3991(99)00083-X; Burnier M, 2001, J HYPERTENS, V19, P335, DOI 10.1097/00004872-200102000-00022; Chapman KR, 2000, RESP MED, V94, P2, DOI 10.1053/rmed.1999.0667; Clowes JA, 2004, J CLIN ENDOCR METAB, V89, P1117, DOI 10.1210/jc.2003-030501; Curtin R B, 1999, ANNA J, V26, P307; Dasgupta S, 2002, AM J MANAG CARE, V8, pS255; Delgado PL, 2000, J CLIN PSYCHIAT, V61, P6; DiMatteo MR, 2002, MED CARE, V40, P794, DOI 10.1097/01.MLR.0000024612.61915.2D; DiMatteo MR, 2006, MED CARE, V44, P297, DOI 10.1097/01.mlr.0000214527.98190.2a; DiMatteo MR, 2004, PATIENT EDUC COUNS, V55, P339, DOI 10.1016/j.pec.2003.04.003; DiMatteo MR, 2004, MED CARE, V42, P200, DOI 10.1097/01.mlr.0000114908.90348.f9; DiMatteo MR, 2003, PATIENT EDUC COUNS, V50, P23, DOI 10.1016/S0738-3991(03)00075-2; DIMATTEO MR, 1995, FORMULARY, V30, P596; DiMatteo MR, 1995, FORMULARY, V30, P605; DiMatteo MR., 1995, FORMULARY, V30, P601; Doran E, 2004, AUST NZ J PUBL HEAL, V28, P62, DOI 10.1111/j.1467-842X.2004.tb00634.x; Drieschner KH, 2004, CLIN PSYCHOL REV, V23, P1115, DOI 10.1016/j.cpr.2003.09.003; Ellis S, 2000, CONTROL CLIN TRIALS, V21, p218S, DOI 10.1016/S0197-2456(00)00082-9; Evans WG, 2006, CANCER J, V12, P417, DOI 10.1097/00130404-200609000-00010; Fiscella RG, 2003, AM J OPHTHALMOL, V136, P18, DOI 10.1016/S0002-9394(03)00102-8; Friedman DS, 2007, INVEST OPHTH VIS SCI, V48, P5052, DOI 10.1167/iovs.07-0290; Godin G, 2005, AIDS CARE, V17, P493, DOI 10.1080/09540120412331291715; Goldring AB, 2002, HEALTH PSYCHOL, V21, P219, DOI 10.1037//0278-6133.21.3.219; Golin Carol, 2002, Journal of General Internal Medicine, V17, P857; HALL JA, 1988, MED CARE, V26, P657, DOI 10.1097/00005650-198807000-00002; Haynes RB, 2002, JAMA-J AM MED ASSOC, V288, P2880, DOI 10.1001/jama.288.22.2880; Haynes RB, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000011; Haynes R. B., 2005, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD000011.PUB2; HAYS RD, 1994, J BEHAV MED, V17, P347, DOI 10.1007/BF01858007; Hess LM, 2006, ANN PHARMACOTHER, V40, P1280, DOI 10.1345/aph.1H018; Horne R, 2006, CHEST, V130, p65S, DOI 10.1378/chest.130.1_suppl.65S; JAVITT JC, 1991, NEW ENGL J MED, V325, P1418, DOI 10.1056/NEJM199111143252005; Johnson Mary Jayne, 2002, Res Theory Nurs Pract, V16, P179, DOI 10.1891/088971802780956570; KASS MA, 1986, AM J OPHTHALMOL, V101, P515; Kennedy J, 2004, CLIN THER, V26, P607, DOI 10.1016/S0149-2918(04)90063-X; KLINGLE RS, 1995, COMMUN RES, V22, P148, DOI 10.1177/009365095022002002; Knight KM, 2006, BRIT J HEALTH PSYCH, V11, P319, DOI 10.1348/135910705X52516; Konstas AGP, 2000, EYE, V14, P752; Krueger KP, 2005, ADV THER, V22, P313, DOI 10.1007/BF02850081; Kyngas H, 2001, SEIZURE-EUR J EPILEP, V10, P549, DOI 10.1053/seiz.2001.0557; Littenberg B, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-198; Loghmain-Adham M, 2003, AM J MANAG CARE, V9, P155; Loh A, 2007, PATIENT EDUC COUNS, V65, P69, DOI 10.1016/j.pec.2006.05.007; MACKEAN JM, 1983, BRIT J OPHTHALMOL, V67, P46, DOI 10.1136/bjo.67.1.46; Martin LR, 2001, BEHAV MED, V27, P111; MAZZE RS, 1984, AM J MED, V77, P211, DOI 10.1016/0002-9343(84)90693-4; McDonald HP, 2002, JAMA-J AM MED ASSOC, V288, P2868, DOI 10.1001/jama.288.22.2868; Mishra P, 2006, PATIENT EDUC COUNS, V63, P29, DOI 10.1016/j.pec.2005.08.006; Nischal K C, 2005, Indian J Dermatol Venereol Leprol, V71, P316; Nordqvist O, 2006, PATIENT EDUC COUNS, V62, P21, DOI 10.1016/j.pec.2005.09.014; Nordstrom BL, 2005, AM J OPHTHALMOL, V140, P598, DOI 10.1016/j.ajo.2005.04.051; Olthoff CMG, 2005, OPHTHALMOLOGY, V112, P953, DOI 10.1016/j.ophtha.2004.12.035; PATEL SC, 1995, OPHTHALMIC SURG LAS, V26, P233; Reardon G, 2004, AM J OPHTHALMOL, V137, pS3, DOI 10.1016/j.ajo.2003.10.035; Rose M, 2002, DIABETES CARE, V25, P35, DOI 10.2337/diacare.25.1.35; Roter DL, 1998, MED CARE, V36, P1138, DOI 10.1097/00005650-199808000-00004; SABATE E, 2003, ADHERENCE LONG TERM, P7; Schafheutle EI, 2002, HEALTH SOC CARE COMM, V10, P187, DOI 10.1046/j.1365-2524.2002.00356.x; Schuster P, 2005, COMPLEXITY, V11, P12, DOI 10.1002/cplx.20101; Schwartz Gail F, 2005, Curr Opin Ophthalmol, V16, P114, DOI 10.1097/01.icu.0000156139.05323.26; Sharkey JR, 2005, J AM GERIATR SOC, V53, P666, DOI 10.1111/j.1532-5415.2005.53217.x; Shaya FT, 2002, AM J MANAG CARE, V8, pS271; Sikka Rishi, 2005, Am J Manag Care, V11, P449; Simmons MS, 2000, CHEST, V118, P290, DOI 10.1378/chest.118.2.290; Smith JD, 2005, J MIDWIFERY WOM HEAL, V50, P380, DOI 10.1016/j.jmwh.2005.01.011; SOMMER A, 1991, NEW ENGL J MED, V325, P1412, DOI 10.1056/NEJM199111143252004; SPAETH GL, 1970, INVEST OPHTH VISUAL, V9, P73; Spooner JJ, 2002, AM J MANAG CARE, V8, pS262; Starace F, 2006, HEALTH PSYCHOL, V25, P153, DOI 10.1037/0278-6133.25.2.153; Stewart M, 2000, J FAM PRACTICE, V49, P796; Stewart M, 1999, Cancer Prev Control, V3, P25; Strauss K, 2006, J GEN INTERN MED, V21, P378, DOI 10.1111/j.1525-1497.2006.00386.x; van Veen L, 2006, FLUID MECH APPL, V79, P93; Wilkinson J, 1997, Br J Nurs, V6, P879	81	101	103	3	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0161-6420			OPHTHALMOLOGY	Ophthalmology	AUG	2008	115	8					1320	1327		10.1016/j.ophtha.2007.11.023		8	Ophthalmology	Ophthalmology	334QW	WOS:000258237300010	18321582	
J	Skold, M; Borje, A; Harambasic, E; Karlberg, AT				Skold, M; Borje, A; Harambasic, E; Karlberg, AT			Contact allergens formed on air exposure of linalool. Identification and quantification of primary and secondary oxidation products and the effect on skin sensitization	CHEMICAL RESEARCH IN TOXICOLOGY			English	Article							LYMPH-NODE ASSAY; 15-HYDROPEROXYABIETIC ACID; D-LIMONENE; HYDROPEROXIDE; AUTOXIDATION; REARRANGEMENT; MONOTERPENES; MECHANISM; ALDEHYDES; RESPONSES	Linalool (3,7-dimethyl-1,6-octadien-3-ol) is an important fragrance chemical, frequently used in scented products because of its fresh, flowery odor. Linalool is an unsaturated hydrocarbon and is therefore susceptible to oxidation in the presence of air. The primary oxidation products, that is, hydroperoxides, formed in the autoxidation process, are reactive compounds that can be suspected to act as sensitizers. In the present investigation, we studied the autoxidation of linalool with emphasis on the formation of hydroperoxides. The oxidation products were isolated using flash chromatography and preparative HPLC and were identified with NMR and GC/ MS, using synthesized reference compounds. Two hydroperoxides and several different secondary oxidation products were identified, among which some contain structural features that make them potential allergens. The amounts of linalool and the major oxidation products were quantified over time, using GC and an HPLC-method, suitable for the analysis of thermolabile primary oxidation products. The hydroperoxide 7-hydroperoxy-3,7-dimethylocta-1,5-diene-3-ol was found to be present in 15% in an oxidized sample. The local lymph node assay (LLNA) was used to investigate the sensitizing potential of pure linalool, two samples of air-exposed linalool, and oxidation products of linalool (an alpha,beta-unsaturated aldehyde, a mixture of two hydroperoxides, and an alcohol). Pure linalool showed no sensitizing potential. The air-exposed samples of linalool produced clearly positive responses, and the hydroperoxides were the strongest allergens of the tested oxidation products. The study demonstrates the importance of autoxidation on the sensitizing potential of linalool. We also conclude that the sensitizing potential differs with the composition of the oxidation mixture and thus with the air exposure time.	Univ Gothenburg, Dept Chem Dermatochem & Skin Allergy, SE-41296 Gothenburg, Sweden; Natl Inst Working Life, SE-11391 Stockholm, Sweden	Karlberg, AT (reprint author), Univ Gothenburg, Dept Chem Dermatochem & Skin Allergy, SE-41296 Gothenburg, Sweden.	karlberg@chem.gu.se	Borje, Anna/A-7581-2010; Karlberg, Ann-Therese/A-7706-2010	Skold, Maria/0000-0002-4231-8864			BACKSTROM P, 1982, ACTA CHEM SCAND B, V36, P31, DOI 10.3891/acta.chem.scand.36b-0031; Basketter DA, 2002, CONTACT DERMATITIS, V47, P161, DOI 10.1034/j.1600-0536.2002.470307.x; Basketter DA, 2001, CONTACT DERMATITIS, V45, P89, DOI 10.1034/j.1600-0536.2001.045002089.x; Basketter DA, 1999, J APPL TOXICOL, V19, P261, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<261::AID-JAT572>3.0.CO;2-5; Basketter DA, 1998, FOOD CHEM TOXICOL, V36, P327, DOI 10.1016/S0278-6915(97)00158-0; Beckwith A. L. J., 1989, J CHEM SOC P2, V7, P815; Bezard M, 1997, CHEM RES TOXICOL, V10, P987, DOI 10.1021/tx970014r; BLAKEWAY JM, 1987, INT J COSMETIC SCI, V9, P203, DOI 10.1111/j.1467-2494.1987.tb00475.x; Bodin A, 2003, CHEM RES TOXICOL, V16, P575, DOI 10.1021/tx025609n; CASABIANCA H, 1998, J HIGH RES CHROMATOG, V21, P107, DOI 10.1002/(SICI)1521-4168(19980201)21:2<107::AID-JHRC107>3.0.CO;2-A; Choi S, 2001, J ORG CHEM, V66, P8192, DOI 10.1021/jo016013s; DEGROOT AC, 1994, UNWANTED EFFECTS COS, P579; Fenn R. S., 1989, PERFUMER FLAVORIST, V14, P1; FRIMER AA, 1979, CHEM REV, V79, P359, DOI 10.1021/cr60321a001; FRINGUELLI F, 1992, J ORG CHEM, V57, P1198, DOI 10.1021/jo00030a029; Fujii T., 1972, YUKUGAKU, V21, P904; Gallarate M, 2000, J COSMET SCI, V51, P209; GUITTET E, 1981, SYNTHETIC COMMUN, V11, P723, DOI 10.1080/00397918108063649; KARLBERG AT, 1994, ARCH DERMATOL RES, V286, P97, DOI 10.1007/BF00370734; KARLBERG AT, 1988, J PHARM PHARMACOL, V40, P42; KARLBERG AT, 1992, CONTACT DERMATITIS, V26, P332, DOI 10.1111/j.1600-0536.1992.tb00129.x; Khomenko TM, 2002, RUSS J ORG CHEM+, V38, P498, DOI 10.1023/A:1016538920756; Kimber I, 1995, TOXICOLOGY, V103, P63, DOI 10.1016/0300-483X(95)03114-U; KITAHARA T, 1980, AGR BIOL CHEM TOKYO, V44, P897; Liu ZS, 1999, J CHEM RES, P324, DOI 10.1039/a809950b; Lowe JR, 1997, J AM CHEM SOC, V119, P11534, DOI 10.1021/ja9723038; MATURA M, 2003, J EUR ACAD DERMATOL, V17, P125; [Anonymous], 1979, COSMET TOILETRIES; Mutterer V, 2000, CHEM RES TOXICOL, V13, P1028, DOI 10.1021/tx9901433; Oladimeji F. A., 2001, PHARM PHARM LETT, V2, P64; Patlewicz G, 2001, CONTACT DERMATITIS, V44, P331, DOI 10.1034/j.1600-0536.2001.044006331.x; Patlewicz GY, 2002, CONTACT DERMATITIS, V47, P219, DOI 10.1034/j.1600-0536.2002.470406.x; Pokorny J, 1998, DEV FOOD SCI, V40, P667; PORTER NA, 1994, J AM CHEM SOC, V116, P6697, DOI 10.1021/ja00094a027; Pratt DA, 2003, ORG LETT, V5, P387, DOI 10.1021/ol027094x; Pudil F, 1998, DEV FOOD SCI, V40, P707; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; *RIFM, 1986, 5664 RIFM; SCHENCK GO, 1965, LIEBIGS ANN CHEM, V687, P26; Skold M, 2002, CONTACT DERMATITIS, V46, P267, DOI 10.1034/j.1600-0536.2002.460504.x	41	101	102	3	15	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0893-228X			CHEM RES TOXICOL	Chem. Res. Toxicol.	DEC	2004	17	12					1697	1705		10.1021/tx049831z		9	Chemistry, Medicinal; Chemistry, Multidisciplinary; Toxicology	Pharmacology & Pharmacy; Chemistry; Toxicology	881XK	WOS:000225902600019	15606147	
J	Neidell, MJ				Neidell, MJ			Air pollution, health, and socio-economic status: the effect of outdoor air quality on childhood asthma	JOURNAL OF HEALTH ECONOMICS			English	Article						pollution; health; asthma; socio-economic status; avoidance behavior; zip code fixed effect	ACUTE RESPIRATORY ILLNESS; EMERGENCY-ROOM VISITS; CHILDREN; DISEASE; CITIES; IMPACT	This paper estimates the effect of air pollution on child hospitalizations for asthma using naturally occurring seasonal variations in pollution within zip codes. Of the pollutants considered, carbon monoxide (CO) has a significant effect on asthma for children ages 1-18: if 1998 pollution levels were at their 1992 levels, there would be a 5-14% increase in asthma admissions. Also, households respond to information about pollution with avoidance behavior, suggesting it is important to account for these endogenous responses when measuring the effect of pollution on health. Finally, the effect of pollution is greater for children of lower socio-economic status (SES), indicating that pollution is one potential mechanism by which SES affects health. (C) 2004 Elsevier B.V. All rights reserved.	Univ Chicago, CISES, Chicago, IL 60637 USA	Neidell, MJ (reprint author), Univ Chicago, CISES, 5734 S Ellis Ave, Chicago, IL 60637 USA.	mneidell@uchicago.edu					*AIR RES BOARD, 1990, AIR RES BOARD SETS N; Alberini A, 1998, J URBAN ECON, V44, P68, DOI 10.1006/juec.1997.2057; *AM AC PED, 2000, GUID CHILDS ALL ASTH; Bjorksten B, 1999, ALLERGY, V54, P17, DOI 10.1111/j.1398-9995.1999.tb04383.x; Bresnahan BW, 1997, LAND ECON, V73, P340, DOI 10.2307/3147172; Case A, 2002, AM ECON REV, V92, P1308, DOI 10.1257/000282802762024520; CHAY K, 2003, IN PRESS Q J EC; Chay K., 2000, DOES AIR QUALITY MAT; *COMM MED EFF AIR, 2000, ASTHM OUTD AIR POLL; Currie J, 1999, AM ECON REV, V89, P245, DOI 10.1257/aer.89.2.245; Desqueyroux H, 1999, REV EPIDEMIOL SANTE, V47, P361; Duhme Heinrich, 1998, Toxicology Letters (Shannon), V102-103, P307, DOI 10.1016/S0378-4274(98)00322-1; Eggleston PA, 1999, ENVIRON HEALTH PERSP, V107, P439; Ernster VL, 1996, ANNU REV PUBL HEALTH, V17, P97; Fauroux B, 2000, PEDIATR PULM, V30, P41; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Gouveia N, 2000, OCCUP ENVIRON MED, V57, P477, DOI 10.1136/oem.57.7.477; Greenstone M, 2002, J POLIT ECON, V110, P1175, DOI 10.1086/342808; HARRINGTON W, 1987, J URBAN ECON, V22, P101, DOI 10.1016/0094-1190(87)90052-0; KRUPNICK A, 1990, J ENVIRON ECON MANAG, V17, P1; LETOURNEAU M, 1992, PEDIAT EMERGENCY MED; *MAN RISK MED INS, AIM FACT BOOK 1998; *NAT I ENV HLTH ST, 2000, ASTHM ALL PREV; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; NYSTAD W, 2000, INT J SPORTS MED, V21, P98, DOI 10.1055/s-2000-8498; NYSTROM M, 2001, CALIFORNIA AIR QUALI; PORTNEY PR, 1990, REG SCI URBAN ECON, V20, P407, DOI 10.1016/0166-0462(90)90019-Y; PORTNEY PR, 1986, J URBAN ECON, V20, P21, DOI 10.1016/0094-1190(86)90013-6; RANSOM MR, 1995, CONTEMP ECON POLICY, V13, P86; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SHONKOFF J, 1990, HDB EARLY CHILDHOOD; SPEIZER F, 2001, HIGH EFF I ANN C AIR; *US EPA, 2003, CRIT POLL; *US EPA, 1999, CONC STRAT AMB AIR M; US EPA, 2000, 600P99001F US EPA; *US EPA, 1999, 454R99010 US EPA; Vacek L, 1999, ALLERGY ASTHMA PROC, V20, P87, DOI 10.2500/108854199778612536; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4; von Mutius E, 2000, REV FR ALLERGOL, V40, P689, DOI 10.1016/S0335-7457(00)80073-8; Wilson R., 1996, PARTICLES OUR AIR CO; ZECKHAUSER R, 1976, 41D KENN SCH	42	101	106	2	22	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-6296			J HEALTH ECON	J. Health Econ.	NOV	2004	23	6					1209	1236		10.1016/j.jhealeco.2004.05.002		28	Economics; Health Care Sciences & Services; Health Policy & Services	Business & Economics; Health Care Sciences & Services	877WZ	WOS:000225607100007	15556243	
J	Martin, AJ; Pratt, N; Kennedy, JD; Ryan, P; Ruffin, RE; Miles, H; Marley, J				Martin, AJ; Pratt, N; Kennedy, JD; Ryan, P; Ruffin, RE; Miles, H; Marley, J			Natural history and familial relationships of infant spilling to 9 years of age	PEDIATRICS			English	Article						children; gastroesophageal reflux; natural history	PEDIATRIC GASTROESOPHAGEAL REFLUX; BARRETTS-ESOPHAGUS; CHILDREN; PREVALENCE; SYMPTOMS; ADENOCARCINOMA; DISEASE; ASTHMA; QUESTIONNAIRE; CHILDHOOD	Objectives. To determine the natural history of infant spilling (regurgitation/vomiting) during the first 2 years of life and to determine the relationship between infant spilling and gastroesophageal reflux (GER) symptoms at 9 years of age. Methods. A prospective birth cohort was followed with daily symptom diaries during the first 2 years of life and reviewed at 9 years of age (range: 8-11 years). The prevalence of infant spilling during the first 2 years of life, the prevalence of GER symptoms between 8 and 11 years of age (mean age: 9.7 years), relative risk of infant spilling predisposing to GER symptoms at 9 years of age, and prevalence of maternal GER symptoms and relationship with infant spilling and GER at 9 years of age were measured. Results. A total of 693 children who represented 83% of an original sample of 836 children and were followed for 2 years from birth with daily symptom diaries were contacted at 9 (8-11) years of age. Spilling of most feeds each day was common in infancy and reached a peak prevalence of 41% between 3 and 4 months of age and thereafter declined to <5% between 13 and 14 months of age. Infants with spilling on 90 days or more during the first 2 years of life (classified as frequent spilling) were more likely to have GER symptoms at 9 years of age. Children with frequent infant spilling, compared with those with no spilling, had a relative risk of 2.3 (95% confidence interval [CI]: 1.3-4.0) of 1 or more GER symptoms at 9 years of age, 4.6 (95% CI: 1.5-13.8) for heartburn, 2.7 (95% CI: 1.4-5.5) for vomiting, and 4.7 (95% CI: 1.6-14.0) for acid regurgitation. Gender, breastfeeding, and environmental tobacco smoke exposure were not significant factors related to infant spilling. Prepregnancy smoking and smoking in the same room as the child at the 9-month and 18-month follow-ups had a significant effect on GER symptoms at 9 years of age. Infant spilling and GER at 9 years of age were significantly related to maternal GER symptoms but not to paternal GER symptoms. Conclusions. Spilling in infancy is very common, but the majority of children settle by 13 to 14 months of age. However, those with frequent spilling (> 90 days) are more likely to have GER symptoms at 9 years of age. In addition, a maternal history of GER was significantly related both to infant spilling and to GER at 9 years, suggesting that a genetic component may be involved. Physicians should consider studying children with a history of frequent infant spilling to determine whether this group is at increased risk for GER disease.	Womens & Childrens Hosp, Dept Pulm Med, Adelaide, SA 5006, Australia; Univ Adelaide, Dept Publ Hlth, Adelaide, SA, Australia; Univ Adelaide, Dept Med, Adelaide, SA 5001, Australia; Univ Adelaide, Dept Gen Practice, Adelaide, SA, Australia	Martin, AJ (reprint author), Womens & Childrens Hosp, Dept Pulm Med, Kermode St, Adelaide, SA 5006, Australia.		Marley, John/F-1239-2010; Pratt, Nicole/A-1348-2011				ABRAMSON M, 1992, AUST NZ J MED, V22, P358, DOI 10.1111/j.1445-5994.1992.tb02148.x; Alaswad B, 1996, J Okla State Med Assoc, V89, P233; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; *AUSTR I HLTH WELF, 1994, AUSTR HLTH 1994; BUTS JP, 1986, EUR J PEDIATR, V145, P396, DOI 10.1007/BF00439246; CARRE IJ, 1959, ARCH DIS CHILD, V34, P344; CRABB DW, 1985, ANN INTERN MED, V103, P52; DOUGLAS RM, 1994, INT J EPIDEMIOL, V23, P818, DOI 10.1093/ije/23.4.818; ENG C, 1993, CANCER EPIDEM BIOMAR, V2, P397; Hart JJ, 1996, AM FAM PHYSICIAN, V54, P2463; HEACOCK HJ, 1992, J PEDIATR GASTR NUTR, V14, P41, DOI 10.1097/00005176-199201000-00009; Hu FZ, 2000, JAMA-J AM MED ASSOC, V284, P325, DOI 10.1001/jama.284.3.325; JOCHEM VJ, 1992, GASTROENTEROLOGY, V102, P1400; LOCKE GR, 1994, MAYO CLIN PROC, V69, P539; Locke GR, 1999, AM J MED, V106, P642, DOI 10.1016/S0002-9343(99)00121-7; MCGREADY SJ, 1999, GASTROESOPHAGEAL REF, P237; Nelson SP, 2000, ARCH PEDIAT ADOL MED, V154, P150; Nelson SP, 1997, ARCH PEDIAT ADOL MED, V151, P569; NELSON SP, 1998, PEDIATRICS, V102; Omari TI, 1998, J PEDIATR-US, V133, P650, DOI 10.1016/S0022-3476(98)70106-4; ORENSTEIN S, 1999, GASTROESOPHAGEAL REF, P269; Orenstein S R, 1999, Pediatr Rev, V20, P24, DOI 10.1542/pir.20-1-24; ORENSTEIN SR, 1988, J PEDIATR-US, V112, P847, DOI 10.1016/S0022-3476(88)80204-X; Orenstein SR, 1996, CLIN PEDIATR, V35, P607, DOI 10.1177/000992289603501201; PEETERS S, 1991, J PEDIATR GASTR NUTR, V13, P314, DOI 10.1097/00005176-199110000-00015; Ramos A G, 1994, Pediatr Rev, V15, P24, DOI 10.1542/pir.15-1-24; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; Romero Y, 1997, GASTROENTEROLOGY, V113, P1449, DOI 10.1053/gast.1997.v113.pm9352846; Sacco O, 2000, PEDIATR PULM, V30, P313, DOI 10.1002/1099-0496(200010)30:4<313::AID-PPUL7>3.0.CO;2-H; SHABIB SM, 1995, J PEDIATR-US, V127, P435, DOI 10.1016/S0022-3476(95)70078-1; SHEPHERD RW, 1987, CLIN PEDIATR, V26, P55, DOI 10.1177/000992288702600201; STANCIU C, 1972, BRIT MED J, V3, P793; Tolaymat N, 1998, W V Med J, V94, P22; TREEM WR, 1991, CLIN PEDIATR, V30, P435, DOI 10.1177/000992289103000705; VANDENPLAS Y, 1993, EUR J PEDIATR, V152, P704, DOI 10.1007/BF01953980; WEINTRAUB M, 1989, HOSP FORMUL, V24, P7	36	101	102	0	4	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2002	109	6					1061	1067		10.1542/peds.109.6.1061		7	Pediatrics	Pediatrics	557KE	WOS:000175907100024	12042543	
J	Cavezzi, A; Frullini, A; Ricci, S; Tessari, L				Cavezzi, A; Frullini, A; Ricci, S; Tessari, L			Treatment of varicose veins by foam sclerotherapy: Two clinical series	PHLEBOLOGY			English	Article						sclerosing foam; sclerotherapy; ultrasound imaging; varicose veins	ULTRASOUND-GUIDED SCLEROTHERAPY; SCLEROSING FOAM; DETERMINANTS	Objective: To assess the efficacy and safety of sclerotherapy of varicose veins (VV) with sclerosing foam (SF) made using Tessari's method (three-way tap and two plastic syringes). Design: Two multi-centre prospective clinical series were documented (CS1 and CS2). In CS1, which ran from March to December 2000, 177 patients (39 men, 138 women), mean age 56 years, were treated in three centres for VV related to incompetence of saphenous veins, recurrence, perforators or collaterals. Conventional or duplex-guided sclerotherapy was performed using SF made of purified sodium tetradecyl sulphate (PSTS) 0.2-3% (Fibro-vein, STD Pharmaceuticals, UK) and air. An average of 1.6 (SD 0.8) sessions per patient were performed and 2.9 (SD 1.0) ml of SF (i.e. 0.6 ml of PSTS) per session was employed. An elastic stocking providing 20-30 or 30-40 mmHg compression was worn by patients following treatment. All the patients were reviewed (clinical examination and colour duplex ultrasonography) at 1 month. Sixty-six patients had a further follow-up 45-370 days after treatment. The 17 patients in CS2, a multi-centre study, were treated in March and April 2001. An independent observer assessed patients with major VV (CEAP and VV type distribution similar to CS1) before and after the treatment, and also observed the treatment, which was carried out using the technique employed in CS1. Results: In CS1 at 1 month follow-up there was: (A) obliteration of the vessel or antegrade flow in 161 (91%) patients, (13) minimal retrograde flow in the treated vein without visible VV, in 15 (8.4%) cases and (C) persistence of vessel patency with retrograde flow and visible VV (failure) in 1 (0.6%) case. At 45-370 days (mean 138 days) follow-up results were: type A in 44 (67%) cases, type B in 17 (26%) cases and type C in 5 (8%) cases. The main complications were extension of sclerothrombus from superficial to deep veins (n = 2), allergy (n = 1), malaise (n = 1) and scotoma (n = 1). In CS2 at 30 days follow-up 100% of the treated venous segments had a type A outcome after an average of 1.4 sessions. No relevant complication occurred in this series. Conclusions: Sclerotherapy of major VV by means of SF prepared by Tessari's method is a safe and effective form of treatment. Low doses and a low concentration of drug may be successfully employed. Further studies are needed to establish the long-term results and overall safety of this form of foam sclerotherapy.		Cavezzi, A (reprint author), Via Miramare 7, I-63039 San Benedetto Tronto, AP, Italy.						BACCAGLINI U, 1996, PHLEBOLOGIE, V3, P309; Bhowmick A, 2001, PHLEBOLOGY, V16, P41; BRIZZIO E, 1986, 9 WORLD C PHLEB KYOT, P25; Cabrera J, 2000, PHLEBOLOGY, V15, P19, DOI 10.1007/s005230070032; Cavendish R, 1999, HIST TODAY, V49, P50; CAVEZZI A, 2000, MINERVA CARDIOANG S1, V48, P248; CAVEZZI A, 2000, AUST NZ J PHLEBOL, V4, P100; DISTEFANO R, 1999, VASOMED S, V1, P7; Frullini A, 2000, DERMATOL SURG, V26, P705, DOI 10.1046/j.1524-4725.2000.00071.x; Frullini A., 2000, Phlebologie, V53, P431; Frullini A, 2002, DERMATOL SURG, V28, P11, DOI 10.1046/j.1524-4725.2002.01182.x; Frullini A, 2000, ACTA PHLEBOLOGICA, V1, P43; Gachet G., 2001, PHLEBOLOGIE, V54, P63; Mingo Garcia J, 1999, REV ESP MED CIR COSM, V7, P29; Cabrera Garrido JR, 1997, PHLEBOLOGIE, V50, P181; Henriet J. P., 1997, Phlebologie, V50, P355; Kanter A, 1996, DERMATOL SURG, V22, P648; Kanter A, 1998, DERMATOL SURG, V24, P131; Kanter A, 1998, DERMATOL SURG, V24, P136; Monfreux A., 1997, Phlebologie, V50, P351; ORBACH E J, 1950, J Int Coll Surg, V13, P765; SADOUN S, 1998, 13 WORLD C PHLEB; SCHADECK M, 1985, COMM 19 C PATH VASC; Tessari L, 2001, DERMATOL SURG, V27, P58, DOI 10.1111/j.1524-4725.2001.00192.x; Tessari L, 2000, PHLEBOLOGIE, V53, P129; VARCOE P, 2000, AUST NZ J PHLEBOL, V4, P117	26	101	110	0	2	SPRINGER-VERLAG LONDON LTD	GODALMING	SWEETAPPLE HOUSE CATTESHALL ROAD, GODALMING GU7 3DJ, SURREY, ENGLAND	0268-3555			PHLEBOLOGY	Phlebology		2002	17	1					13	18		10.1007/BF02667958		6	Surgery; Peripheral Vascular Disease	Surgery; Cardiovascular System & Cardiology	614CU	WOS:000179171400004		
J	Jeffery, PK				Jeffery, PK			Comparison of the structural and inflammatory features of COPD and asthma	CHEST			English	Article; Proceedings Paper	Thomas L Petty 42nd Annual Aspen Lung conference - Mechanisms of COPD	JUN 02-05, 1999	ASPEN, COLORADO	Glaxo Wellcome Inc		airway asthma; biopsy; chronic bronchitis; COPD; emphysema; inflammation	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; CHRONIC MUCUS HYPERSECRETION; ACTIVATED LYMPHOCYTES-T; CHRONIC-BRONCHITIS; PERIPHERAL AIRWAYS; CIGARETTE SMOKERS; ATOPIC ASTHMA; EOSINOPHILIC BRONCHITIS; EMPHYSEMATOUS LUNGS	At least three conditions contribute to COPD, (1) Chronic bronchitis (mucous hypersecretion) is an inflammatory condition in which CD8+ T-lymphocytes, neutrophils, and CD68+ monocytes/macrophages predominate. The condition is defined clinically by the presence of chronic cough and recurrent increases in bronchial secretions sufficient to cause expectoration, There is enlargement of mucus-secreting glands and goblet cell hyperplasia, which can occur in the absence of airflow limitation. (2) Adult chronic bronchiolitis (small or peripheral airways disease) is an inflammatory condition of small bronchi and bronchioli in which there are predominantly CD8+ and pigmented macrophages, The functional defect is difficult to detect clinically but may be recognized by sophisticated tests of small airway function. There is mucous metaplasia, enlargement of the mass of bronchiolar smooth muscle, and loss of alveolar attachments. (3) Emphysema is an inflammatory condition of the alveoli in which T-lymphocytes, neutrophils, and pigmented alveolar macrophages are involved, associated with the release of excessive amounts of elastases. It is defined anatomically by permanent, destructive enlargement of airspaces distal to terminal bronchioli without obvious fibrosis. In contrast, asthma is a clinical syndrome characterized by allergic inflammation of bronchi and bronchioli in which CD4+ (helper) T-lymphocytes and eosinophils predominate. There is increased production and release of interleukin (IL)-4 and IL-5, which is referred to as a The-type response. There is usually increased tracheobronchial responsiveness to a variety of stimuli, and the condition is usually manifest as variable airflow obstruction. While differences between COPD and asthma have been highlighted, new data are emerging that indicate there may also be similarities.	Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Sch Med, Lung Pathol Unit, London SW3 6NP, England	Jeffery, PK (reprint author), Univ London Imperial Coll Sci Technol & Med, Royal Brompton Hosp, Sch Med, Lung Pathol Unit, Sydney St, London SW3 6NP, England.						AILSBY RL, 1973, J PATHOL, V109, P75, DOI 10.1002/path.1711090108; AMADORI A, 1995, NAT MED, V1, P1279, DOI 10.1038/nm1295-1279; ANDERSON AE, 1962, AM J MED, V32, P218, DOI 10.1016/0002-9343(62)90291-7; AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; BIGNON J, 1969, AM REV RESPIR DIS, V99, P669; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Cantin A, 1985, Eur J Respir Dis Suppl, V139, P7; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; CHANG SC, 1957, CANCER, V10, P1246, DOI 10.1002/1097-0142(195711/12)10:6<1246::AID-CNCR2820100623>3.0.CO;2-Z; COSIO MG, 1980, AM REV RESPIR DIS, V122, P265; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; EBERT RV, 1981, BRIT J DIS CHEST, V75, P277, DOI 10.1016/0007-0971(81)90006-1; EBERT RV, 1975, AM REV RESPIR DIS, V111, P4; Elliott WM, 1999, AM J RESP CRIT CARE, V159, pA810; FINKELSTEIN R, 1995, AM J RESP CRIT CARE, V152, P1666; FLETCHER CM, 1984, SMOKING LUNG, V17, P397; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; GIBSON PG, 1989, LANCET, V1, P1346; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; GILLOOLY M, 1993, THORAX, V48, P491, DOI 10.1136/thx.48.5.491; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; GLYNN A. A., 1960, THORAX, V15, P142, DOI 10.1136/thx.15.2.142; GODFREY RWA, 1995, EUR RESPIR J, V8, P922; HALE KA, 1984, AM REV RESPIR DIS, V130, P716; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; HOPKIN JM, 1981, BRIT MED J, V283, P1209; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; JEFFERY PK, 1975, J ANAT, V120, P295; JEFFERY PK, 1994, AIRWAYS AND VASCULAR REMODELLING IN ASTHMA AND CARDIOVASCULAR DISEASE, P3; JEFFERY PK, 1990, METABOLIC MOL BASIS, P466; JEFFERY PK, 1995, ASTHMA RHINITIS, P80; JEFFERY PK, 1997, ALLERGY ALLERGIC DIS, P1412; KIMBEL P, 1985, CHRONIC OBSTRUCTIVE, V28, P105; Klienerman J, 1974, TXB PULMONARY DIS, P571; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505; KRAMPS JA, 1984, AM REV RESPIR DIS, V129, P959; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; LAMB D, 1993, THORAX, V48, P1012, DOI 10.1136/thx.48.10.1012; Lams BEA, 1998, AM J RESP CRIT CARE, V158, P1518; LANG MR, 1994, THORAX, V49, P319, DOI 10.1136/thx.49.4.319; LINHARTOVA A, 1977, THORAX, V32, P50; MACKLEM PT, 1970, RESP PHYSIOL, V8, P191, DOI 10.1016/0034-5687(70)90015-0; MACNEE W, 1993, THORAX, V48, P79, DOI 10.1136/thx.48.1.79; MISOKOVITCH G, 1974, ACTA MORPHOL ACAD SC, V22, P91; MITCHELL RS, 1976, AM REV RESPIR DIS, V114, P137; MULLEN JBM, 1985, BRIT MED J, V291, P1235; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; O'Shaughnessy T. C., 1996, European Respiratory Journal Supplement, V9, p14S; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; O'Shaughnessy TC, 1996, AM J RESP CRIT CARE, V153, pA879; PETO R, 1983, AM REV RESPIR DIS, V128, P491; PRESCOTT E, 1995, EUR RESPIR J, V8, P1333, DOI 10.1183/09031936.95.08081333; REID LM, 1954, LANCET, V1, P275; REYNOLDS HY, 1987, AM REV RESPIR DIS, V135, P250; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1046/j.1365-2222.1996.d01-386.x; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633; SAETTA M, 1985, AM REV RESPIR DIS, V132, P894; Shapiro SD, 1995, P ASSOC AM PHYSICIAN, V107, P346; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; SNIDER GL, 1986, AM REV RESPIR DIS, V133, P942; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527; THURLBECK WM, 1985, CHRONIC OBSTRUCTIVE, P129; VERBEKEN EK, 1992, J APPL PHYSIOL, V72, P2343; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530; VIGNOLA AM, 1993, AM REV RESPIR DIS, V148, P689; WANNER A, 1977, AM REV RESPIR DIS, V116, P73; WRIGHT JL, 1988, LUNG, V166, P277, DOI 10.1007/BF02714058; WRIGHT RR, 1965, MED THORAC, V22, P210; Zhu J, 1999, AM J RESP CRIT CARE, V159, pA450	84	101	103	1	4	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	MAY	2000	117	5		1			251S	260S		10.1378/chest.117.5_suppl_1.251S		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	316PY	WOS:000087178200022	10843939	
J	Wan, H; Winton, HL; Soeller, C; Gruenert, DC; Thompson, PJ; Cannell, MB; Stewart, GA; Garrod, DR; Robinson, C				Wan, H; Winton, HL; Soeller, C; Gruenert, DC; Thompson, PJ; Cannell, MB; Stewart, GA; Garrod, DR; Robinson, C			Quantitative structural and biochemical analyses of tight junction dynamics following exposure of epithelial cells to house dust mite allergen Der p 1	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						house dust mite; allergen; Der p 1; tight junction; epithelium; asthma; cysteine peptidase	DERMATOPHAGOIDES-PTERONYSSINUS; MEMBRANE-PROTEIN; OCCLUDIN; PERMEABILITY; SEQUENCE; DER-P-1; FIBROBLASTS; DISRUPTION; COMPONENT; CLAUDIN-1	Background House dust mite allergen Der p 1 is a cysteine peptidase. Previously, we have suggested that the proteolytic activity of this allergen may contribute to asthma by damaging the barrier formed by the airways epithelium. Objective The present study applied novel techniques to compare changes in permeability with quantitative events in tight junctions (TJs) and desmosomes (DMs) of epithelial cells exposed to Der p 1. Methods Confluent monolayers of Madin-Darby canine kidney (MDCK) and 16HBE14o-human bronchial epithelial cells were used as experimental models. Permeability was estimated from mannitol clearance. Digital imaging with quantification of TJs and DMs was achieved by fluorescent antibody staining and 2-photon molecular excitation microscopy (2PMEM). Biochemical changes in TJs were studied by immunoblotting, radiolabelling and immunoprecipitation. Results Der p 1 caused a time-dependent breakage of TJs and reduction in their content of the protein ZO-1. Reduction in ZO-1 immunofluorescence at TJs occurred with a small increase in the amount of diffuse, cytoplasmic immunoreactive ZO-1 staining. Morpho-logical changes in TJs occurred in synchrony with increases in epithelial permeability. DM puncta increased both in size and intensity of staining. Immunoblotting demonstrated that the disruption of TJ morphology was associated with cleavage of ZO-1 and occludin. Cells recovered from allergen exposure by de novo synthesis of occludin. Conclusion Der p 1 could contribute to sensitization and allergic responses by degrading the function of the airway epithelial barrier.	St George Hosp, Sch Med, Dept Pharmacol & Clin Pharmacol, London SW17 0RE, England; Univ Calif San Francisco, Dept Lab Med, Inst Cardiovasc Res, Gene Therapy Core Ctr, San Francisco, CA 94143 USA; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Med, Nedlands, WA 6009, Australia; Univ Western Australia, Queen Elizabeth II Med Ctr, Dept Microbiol, Nedlands, WA 6009, Australia; Univ Manchester, Sch Biol Sci, Manchester, Lancs, England	Robinson, C (reprint author), St George Hosp, Sch Med, Dept Pharmacol & Clin Pharmacol, Cranmer Terrace, London SW17 0RE, England.		Soeller, Christian/G-5525-2011	Robinson, Clive/0000-0001-6253-7864			ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; Anderson JM, 1995, AM J PHYSIOL, V32, P467; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BACALLAO R, 1994, J CELL SCI, V107, P3301; Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1006/abio.1976.9999; Chambers Louise, 1997, Biochemical Society Transactions, V25, p85S; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Denker BM, 1998, AM J PHYSIOL-RENAL, V274, pF1; FARQUHAR MG, 1963, J CELL BIOL, V17, P375, DOI 10.1083/jcb.17.2.375; Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539; FURUSE M, 1994, J CELL BIOL, V127, P1617, DOI 10.1083/jcb.127.6.1617; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GONZALEZMARISCAL L, 1985, J MEMBRANE BIOL, V86, P113, DOI 10.1007/BF01870778; HERBERT CA, 1990, LANCET, V336, P1132, DOI 10.1016/0140-6736(90)92611-K; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; Hewitt CRA, 1997, CLIN EXP ALLERGY, V27, P201, DOI 10.1111/j.1365-2222.1997.tb00694.x; King C, 1998, J IMMUNOL, V161, P3645; McCarthy KM, 1996, J CELL SCI, V109, P2287; MORITA S, 1999, P NATL ACAD SCI USA, V96, P511; Muresan Z, 1998, MOL BIOL CELL, V9, p83A; PARRISH EP, 1987, J PATHOL, V153, P265, DOI 10.1002/path.1711530311; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; ROBINSON C, 1995, IMMUNOPHARMACOLOGY R, P187, DOI 10.1016/B978-012352325-9/50012-5; Schneeberger EE, 1992, AM J PHYSIOL, V262, P647; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Soeller C, 1996, PFLUG ARCH EUR J PHY, V432, P555, DOI 10.1007/s004240050169; STEWART GA, 1991, INT ARCH ALLER A IMM, V95, P248; STEWART GA, 1992, EXP APPL ACAROL, V16, P165, DOI 10.1007/BF01201499; VanItallie CM, 1997, J CELL SCI, V110, P1113; VESTWEBER D, 1985, EMBO J, V4, P3393; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; WAN H, 1998, MICROSC MICROANAL, V4, P416; Winton HL, 1998, CLIN EXP ALLERGY, V28, P1273; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905; Wong V, 1997, AM J PHYSIOL-CELL PH, V273, pC1859	38	101	106	1	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2000	30	5					685	698				14	Allergy; Immunology	Allergy; Immunology	314CU	WOS:000087037700013	10792361	
J	Kitch, BT; Chew, G; Burge, HA; Muilenberg, ML; Weiss, ST; Platts-Mills, TAE; O'Connor, G; Gold, DR				Kitch, BT; Chew, G; Burge, HA; Muilenberg, ML; Weiss, ST; Platts-Mills, TAE; O'Connor, G; Gold, DR			Socioeconomic predictors of high allergen levels in homes in the greater Boston area	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; cat; cockroach; dog; dust mite; indoor allergens; inner city	INNER-CITY CHILDREN; HOUSE DUST MITES; RISK-FACTORS; AFFINITY PURIFICATION; COCKROACH ALLERGEN; INDOOR ALLERGENS; ASTHMA MORTALITY; UNITED-STATES; P-I; EXPOSURE	In the United States, childhood asthma morbidity and prevalence rates are the highest in less affluent urban minority communities. More than 80% of childhood asthmatics are allergic to one or more inhalant allergens. We evaluated whether socioeconomic status was associated with a differential in the levels and types of indoor home allergens. Dust samples for an ELISA allergen assay were collected from the homes of 499 families as part of a metropolitan Boston, Massachusetts, longitudinal birth cohort study of home allergens and asthma in children with a parental history of asthma or allergy. The proportion of homes with maximum home allergen levels in the highest category was 42% for dust mite allergen (greater than or equal to 10 mu g/g Der p 1 or Der f 1), 13% for cockroach allergen (greater than or equal to 2 U/g Bla g 1 or Bla g 2), 26% for cat allergen (greater than or equal to 8 mu g/g Fel d 1), and 20% for dog allergen (greater than or equal to 10 mu g/g Can f 1). Homes in the high-poverty area (> 20% of the population below the poverty level) were more likely to have high cockroach allergen levels than homes in the low-poverty area [51 vs. 3%; OR, 33; 95% confidence interval (CI), 12-90], but less likely co have high levels of dust mite allergen (16 vs. 53%; OR, 0.2; CI, 0.1-0.4). Lower family income, less maternal education, and race/ethnicity (black or Hispanic vs. white) were also associated with a lower risk of high dust mite levels and a greater risk of high cockroach allergen levels. Within a single U.S. metropolitan area we found marked between-community differences in the types of allergens present in the home, bur not necessarily in the overall burden of allergen exposure.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; Harvard Univ, Beth Israel Hosp, Sch Med, Div Pulm, Boston, MA 02215 USA; Univ Virginia, Med Ctr, Dept Med, Div Allergy & Immunol, Charlottesville, VA USA; Boston Univ, Sch Med, Dept Med, Ctr Pulm, Boston, MA 02118 USA; Harvard Univ, Sch Med, Boston, MA USA	Kitch, BT (reprint author), Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.			O'Connor, George/0000-0002-6476-3926	NHLBI NIH HHS [HL07427]; NIAID NIH HHS [R01 AI/EHS-35789]		ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; BRANDT RL, 1976, J MED ENTOMOL, V13, P327; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHANYEUNG M, 1995, CLIN EXP ALLERGY, V25, P240, DOI 10.1111/j.1365-2222.1995.tb01035.x; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; DEGROOT H, 1991, J ALLERGY CLIN IMMUN, V87, P1056, DOI 10.1016/0091-6749(91)92150-Y; EVANS R, 1992, CHEST, V101, pS368; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GERGEN PJ, 1988, PEDIATRICS, V81, P1; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; GOTTLIEB DJ, 1995, CHEST, V108, P28, DOI 10.1378/chest.108.1.28; HARVING H, 1993, ALLERGY, V48, P106, DOI 10.1111/j.1398-9995.1993.tb00694.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; KOEHLER PG, 1987, J ECON ENTOMOL, V80, P446; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; MARDER D, 1992, CHEST, V101, pS426, DOI 10.1378/chest.101.6_Supplement.426S; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Warner AM, 1996, PEDIATR ALLERGY IMMU, V7, P61, DOI 10.1111/j.1399-3038.1996.tb00108.x; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	30	101	104	0	1	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2000	108	4					301	307		10.2307/3454347		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	306KT	WOS:000086596400025	10753087	
J	Mansbach, JM; Piedra, PA; Teach, SJ; Sullivan, AF; Forgey, T; Clark, S; Espinola, JA; Camargo, CA				Mansbach, Jonathan M.; Piedra, Pedro A.; Teach, Stephen J.; Sullivan, Ashley F.; Forgey, Tate; Clark, Sunday; Espinola, Janice A.; Camargo, Carlos A., Jr.		MARC-30 Investigators	Prospective Multicenter Study of Viral Etiology and Hospital Length of Stay in Children With Severe Bronchiolitis	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							RESPIRATORY SYNCYTIAL VIRUS; REAL-TIME PCR; RHINOVIRUS INFECTION; HUMAN METAPNEUMOVIRUS; ASTHMA DEVELOPMENT; CLINICAL SYMPTOMS; DISEASE SEVERITY; RISK-FACTORS; INFANTS; EXPRESSION	Objective: To determine whether hospital length of stay (LOS) for acute bronchiolitis is influenced by the infecting pathogen. Design: A prospective observational cohort study was performed during 3 consecutive years. Setting: Sixteen US hospitals participated in the study. Participants: Children younger than 2 years hospitalized with bronchiolitis were included. Main Exposure: The results of nasopharyngeal aspirate polymerase chain reaction pathogen testing served as the main exposure. Main Outcome Measure: Hospital LOS was determined. Results: Of 2207 participants, 72.0% had respiratory syncytial virus (RSV) and 25.6% had human rhinovirus (HRV); the incidence of each of the other viruses and bacteria was 7.8% or less. Multiple pathogen infections were present in 29.8% of the children. There were 1866 children (84.5%) with RSV and/or HRV. Among these 1866 children, the median age was 4 months and 59.5% were male. The median LOS was 2 days (interquartile range, 1-4 days). Compared with children who had only RSV, an LOS of 3 or more days was less likely among children with HRV alone (adjusted odds ratio [AOR], 0.36; 95% CI, 0.20-0.63; P < .001) and those with HRV plus non-RSV pathogens (AOR, 0.39; 95% CI, 0.23-0.66; P < .001) but more likely among children with RSV plus HRV(AOR, 1.33; 95% CI, 1.02-1.73; P =. 04), controlling for 15 demographic and clinical factors. Conclusions: In this multicenter study of children hospitalized with bronchiolitis, RSV was the most common virus detected, but HRV was detected in one-quarter of the children. Since 1 in 3 children had multiple virus infections and HRV was associated with LOS, these data challenge the effectiveness of current RSV-based cohorting practices, the sporadic testing for HRV in bronchiolitis research, and current thinking that the infectious etiology of severe bronchiolitis does not affect short-term outcomes.	[Mansbach, Jonathan M.] Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med, Boston, MA 02115 USA; [Sullivan, Ashley F.; Forgey, Tate; Espinola, Janice A.; Camargo, Carlos A., Jr.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02115 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA; [Piedra, Pedro A.] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA; [Teach, Stephen J.] Childrens Natl Med Ctr, Dept Pediat, Washington, DC 20010 USA; [Clark, Sunday] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA	Mansbach, JM (reprint author), Harvard Univ, Sch Med, Childrens Hosp Boston, Dept Med, 300 Longwood Ave,Main Clin Bldg 9 S,Ste 9157, Boston, MA 02115 USA.	jonathan.mansbach@childrens.harvard.edu			National Institutes of Health [U01 AI-67693, K23 AI-77801, UL1 RR-031988]	This study was supported by grants U01 AI-67693, K23 AI-77801, and UL1 RR-031988 from the National Institutes of Health.	Aberle JH, 1999, AM J RESP CRIT CARE, V160, P1263; Aberle JH, 2005, PEDIATR INFECT DIS J, V24, P605, DOI 10.1097/01.inf.0000168741.59747.2d; Arnold R, 2005, J IMMUNOL, V174, P7359; Beckham JD, 2005, J INFECTION, V50, P322, DOI 10.1016/j.jinf.2004.07.011; Bont L, 2001, J INFECT DIS, V184, P355, DOI 10.1086/322035; Bush A, 2007, BRIT MED J, V335, P1037, DOI 10.1136/bmj.39374.600081.AD; Calvo C, 2010, ACTA PAEDIATR, V99, P883, DOI 10.1111/j.1651-2227.2010.01714.x; Canducci F, 2008, J MED VIROL, V80, P716, DOI 10.1002/jmv.21108; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Carroll KN, 2007, PEDIATRICS, V119, P1104, DOI 10.1542/peds.2006-2837; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Doan Q, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006452.pub2; Drews AL, 1997, CLIN INFECT DIS, V25, P1421, DOI 10.1086/516137; Fry AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017780; Gerna G, 2009, J MED VIROL, V81, P1498, DOI 10.1002/jmv.21548; Greensill J, 2003, EMERG INFECT DIS, V9, P372; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Harris JAS, 2007, PEDIATRICS, V120, P890, DOI 10.1542/peds.2007-1305; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; Jansen RR, 2011, J CLIN MICROBIOL, V49, P2631, DOI 10.1128/JCM.02094-10; Jartti T, 2011, PEDIAT ALLERG IMM-UK, V22, P350, DOI 10.1111/j.1399-3038.2011.01170.x; Jartti T, 2009, PEDIATR INFECT DIS J, V28, P311, DOI 10.1097/INF.0b013e31818ee0c1; Knorr L, 2006, BMC INFECT DIS, V6, DOI 10.1186/1471-2334-6-62; Kotaniemi-Syrjanen A, 2003, J ALLERGY CLIN IMMUN, V111, P66, DOI 10.1067/mai.2003.33; Kusel MMH, 2007, J ALLERGY CLIN IMMUN, V119, P1105, DOI 10.1016/j.jaci.2006.12.669; Kuzik BA, 2007, J PEDIATR-US, V151, P266, DOI 10.1016/j.jpeds.2007.04.010; Lehtinen P, 2007, J ALLERGY CLIN IMMUN, V119, P570, DOI 10.1016/j.jaci.2006.11.003; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Lieberthal AS, 2006, PEDIATRICS, V118, P1774, DOI 10.1542/peds.2006-2223; Mansbach JM, 2008, ACAD EMERG MED, V15, P111, DOI 10.1111/j.1553-2712.2007.00034.x; Marguet C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004596; Miron Dan, 2010, Pediatr Infect Dis J, V29, pe7, DOI 10.1097/INF.0b013e3181c2a212; Papadopoulos NG, 2002, AM J RESP CRIT CARE, V165, P1285, DOI 10.1164/rccm.200112-1188C; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Regamey N, 2008, PEDIATR INFECT DIS J, V27, P100, DOI 10.1097/INF.0b013e31815922c8; Semple MG, 2005, J INFECT DIS, V191, P382, DOI 10.1086/426457; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; Simoes EAF, 2003, J PEDIATR-US, V143, pS118, DOI 10.1067/S0022-3476(03)00511-0; Stempel HE, 2009, ACTA PAEDIATR, V98, P123, DOI 10.1111/j.1651-2227.2008.01023.x; Thomas NJ, 2010, PEDIATR CRIT CARE ME, V11, P12, DOI 10.1097/PCC.0b013e3181b0653d; Wainwright C, 2003, NEW ENGL J MED, V349, P27, DOI 10.1056/NEJMoa022226; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Winchell JM, 2008, J CLIN MICROBIOL, V46, P3116, DOI 10.1128/JCM.00440-08; Winther B, 2006, J MED VIROL, V78, P644, DOI 10.1002/jmv.20588; Wright PF, 2007, J CLIN MICROBIOL, V45, P2126, DOI 10.1128/JCM.02553-06	45	100	108	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	AUG	2012	166	8					700	706		10.1001/archpediatrics.2011.1669		7	Pediatrics	Pediatrics	984KU	WOS:000307189300003	22473882	
J	Holt, PG; Sly, PD				Holt, Patrick G.; Sly, Peter D.			Viral infections and atopy in asthma pathogenesis: new rationales for asthma prevention and treatment	NATURE MEDICINE			English	Review							FC-EPSILON-RI; RESPIRATORY SYNCYTIAL VIRUS; PLASMACYTOID DENDRITIC CELLS; HOUSE-DUST-MITE; INNATE IMMUNE-RESPONSE; MEMORY T-CELLS; LUNG-FUNCTION; BONE-MARROW; CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION	Prospective birth cohort studies tracking asthma initiation and consolidation in community cohorts have identified viral infections occurring against a background of allergic sensitization to aeroallergens as a uniquely potent risk factor for the expression of acute severe asthma-like symptoms and for the ensuing development of asthma that can persist through childhood and into adulthood. A combination of recent experimental and human studies have suggested that underlying this bipartite process are a series of interactions between antiviral and atopic inflammatory pathways that are mediated by local activation of myeloid cell populations in the airway mucosa and the parallel programming and recruitment of their replacements from bone marrow. Targeting key components of these pathways at the appropriate stages of asthma provides new opportunities for the treatment of established asthma but, more crucially, for primary and secondary prevention of asthma during childhood.	[Holt, Patrick G.] Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; [Sly, Peter D.] Univ Queensland, Queensland Childrens Med Res Inst, Brisbane, Qld, Australia	Holt, PG (reprint author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia.	patrick@ichr.uwa.edu.au	Sly, Peter/F-1486-2010	Sly, Peter/0000-0001-6305-2201			Al-Garawi A, 2012, J IMMUNOL, V188, P832, DOI 10.4049/jimmunol.1102349; ALBLAS ABV, 1981, J EXP MED, V154, P235; Beyer M, 2004, J ALLERGY CLIN IMMUN, V113, P127, DOI 10.1016/j.jaci.2004.10.057; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bochkov YA, 2011, NAT MED, V17, P627, DOI 10.1038/nm.2358; Bosco A, 2010, MUCOSAL IMMUNOL, V3, P399, DOI 10.1038/mi.2010.13; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Busse WW, 2011, NEW ENGL J MED, V364, P1005, DOI 10.1056/NEJMoa1009705; Busse WW, 2001, NEW ENGL J MED, V344, P350; BUSSE WW, 1989, CLIN EXP ALLERGY, V19, P1, DOI 10.1111/j.1365-2222.1989.tb02336.x; Cavanagh LL, 2005, NAT IMMUNOL, V6, P1029, DOI 10.1038/ni1249; Cheung DS, 2010, J IMMUNOL, V185, P4983, DOI 10.4049/jimmunol.1002456; Choy DF, 2011, J IMMUNOL, V186, P1861, DOI 10.4049/jimmunol.1002568; Collet JP, 1997, AM J RESP CRIT CARE, V156, P1719; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Vrese M, 2006, VACCINE, V24, P6670, DOI 10.1016/j.vaccine.2006.05.048; Demehri S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000067; Di Rosa F, 2005, TRENDS IMMUNOL, V26, P360, DOI 10.1016/j.it.2005.04.011; Durham SR, 2008, CURR OPIN ALLERGY CL, V8, P577, DOI 10.1097/ACI.0b013e3283196764; Gao LL, 2010, VACCINE, V28, P4445, DOI 10.1016/j.vaccine.2010.03.062; Gauvreau Gail M, 2005, Expert Rev Clin Immunol, V1, P87, DOI 10.1586/1744666X.1.1.87; Gill MA, 2005, J INFECT DIS, V191, P1105, DOI 10.1086/428589; Gill MA, 2010, J IMMUNOL, V184, P5999, DOI 10.4049/jimmunol.0901194; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grayson MH, 2007, J EXP MED, V204, P2759, DOI 10.1084/jem.20070360; Hales BJ, 2008, THORAX, V63, P221, DOI 10.1136/thx.2006.069492; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hales BJ, 2012, THORAX, V67, P321, DOI 10.1136/thoraxjnl-2011-200650; Hermesh T, 2010, CELL HOST MICROBE, V7, P343, DOI 10.1016/j.chom.2010.04.006; HIBBERT ME, 1990, PEDIATR PULM, V8, P172, DOI 10.1002/ppul.1950080308; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holgate Stephen T, 2008, Allergol Int, V57, P1, DOI 10.2332/allergolint.R-07-154; Hollams EM, 2010, EUR RESPIR J, V36, P509, DOI 10.1183/09031936.00184109; Hollams EM, 2009, J ALLERGY CLIN IMMUN, V124, P463, DOI 10.1016/j.jaci.2009.06.019; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Holt PG, 2010, J ALLERGY CLIN IMMUN, V125, P653, DOI 10.1016/j.jaci.2009.12.018; HOPPER JL, 1991, J APPL PHYSIOL, V70, P770; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jackson DJ, 2010, J ALLERGY CLIN IMMUN, V125, pAB116; Jackson DJ, 2012, AM J RESP CRIT CARE, V185, P281, DOI 10.1164/rccm.201104-0660OC; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Johnston Sebastian L, 2007, Proc Am Thorac Soc, V4, P267, DOI 10.1513/pats.200701-030AW; Ker J, 2009, ANN ALLERG ASTHMA IM, V103, P282, DOI 10.1016/S1081-1206(10)60526-1; Kim EY, 2008, NAT MED, V14, P633, DOI 10.1038/nm1770; Klemets P, 2010, THORAX, V65, P698, DOI 10.1136/thx.2009.132670; Koraka P, 2003, J MED VIROL, V70, P91, DOI 10.1002/jmv.10358; Kraft S, 2007, NAT REV IMMUNOL, V7, P365, DOI 10.1038/nri2072; Larsen G L, 1999, J Pediatr, V135, P21; Lloyd CM, 2010, NAT MED, V16, P273, DOI 10.1038/nm0310-273; Martinez Fernando D, 2005, Proc Am Thorac Soc, V2, P157, DOI 10.1513/pats.200504-044AW; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; Maurer D, 1996, J IMMUNOL, V157, P607; McWilliam AS, 1997, J VIROL, V71, P226; Miller EK, 2012, AM J RESP CRIT CARE, V185, P508, DOI 10.1164/rccm.201108-1462OC; Moore WC, 2010, AM J RESP CRIT CARE, V181, P315, DOI 10.1164/rccm.200906-0896OC; Navarro S, 2011, MUCOSAL IMMUNOL, V4, P53, DOI 10.1038/mi.2010.51; NELSON DJ, 1995, AM J RESP CRIT CARE, V151, P475; Novak N, 2003, J CLIN INVEST, V111, P1047, DOI 10.1172/JCI200315932; Novak N, 2003, J ALLERGY CLIN IMMUN, V111, P38, DOI 10.1067/mai.2003.2; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Oddy WH, 2002, EUR RESPIR J, V19, P899, DOI 10.1183/09031936.02.00103602; Olenec JP, 2010, J ALLERGY CLIN IMMUN, V125, P1001, DOI 10.1016/j.jaci.2010.01.059; Pechkovsky DV, 2010, CLIN IMMUNOL, V137, P89, DOI 10.1016/j.clim.2010.06.017; Rakes Gary P., 1999, American Journal of Respiratory and Critical Care Medicine, V159, P785; Razi CH, 2010, J ALLERGY CLIN IMMUN, V126, P763, DOI 10.1016/j.jaci.2010.07.038; Robays LJ, 2007, J IMMUNOL, V178, P5305; Schaad UB, 2002, CHEST, V122, P2042, DOI 10.1378/chest.122.6.2042; Semper AE, 2003, J ALLERGY CLIN IMMUN, V112, P411, DOI 10.1067/mai.2003.1626; Shaaban R, 2008, LANCET, V372, P1049, DOI 10.1016/S0140-6736(08)61446-4; Sherrill DL, 2005, RESP MED, V99, P1377, DOI 10.1016/j.rmed.2005.03.025; Sihra BS, 1997, J ALLERGY CLIN IMMUN, V99, P699, DOI 10.1016/S0091-6749(97)70033-2; Simoes EAF, 2007, J PEDIATR-US, V151, P34, DOI 10.1016/j.jpeds.2007.02.032; Siracusa MC, 2011, NATURE, V477, P229, DOI 10.1038/nature10329; Sly PD, 2008, ANN NY ACAD SCI, V1140, P163, DOI 10.1196/annals.1454.017; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Smit JJ, 2006, J EXP MED, V203, P1153, DOI 10.1084/jem.20052359; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Soto-Martinez Manuel, 2010, Chron Respir Dis, V7, P173, DOI 10.1177/1479972309345929; Stein RT, 2010, THORAX, V65, P1033, DOI 10.1136/thx.2009.133967; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Strickland DH, 2011, MUCOSAL IMMUNOL, V4, P43, DOI 10.1038/mi.2010.43; Subrata LS, 2009, J IMMUNOL, V183, P2793, DOI 10.4049/jimmunol.0900695; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; Tandon MK, 2010, CHEST, V137, P805, DOI 10.1378/chest.09-1382; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weber KSC, 2001, EUR J IMMUNOL, V31, P2458, DOI 10.1002/1521-4141(200108)31:8<2458::AID-IMMU2458>3.0.CO;2-L; Wenzel S, 2007, LANCET, V370, P1422, DOI 10.1016/S0140-6736(07)61600-6; Wood LJ, 2002, AM J RESP CRIT CARE, V166, P883, DOI 10.1164/rccm.2108015; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Zhang Z, 2009, P NATL ACAD SCI USA, V106, P1536, DOI 10.1073/pnas.0812668106	94	100	102	1	23	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2012	18	5					726	735		10.1038/nm.2768		10	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	938WE	WOS:000303763500040	22561836	
J	Kelly, FJ; Fussell, JC				Kelly, F. J.; Fussell, J. C.			Air pollution and airway disease	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; GLUTATHIONE-S-TRANSFERASE; DIESEL EXHAUST PARTICLES; LONG-TERM EXPOSURE; POLYCYCLIC AROMATIC-HYDROCARBONS; RESPIRATORY SYNCYTIAL VIRUS; CASE-CROSSOVER ANALYSIS; EMERGENCY-ROOM VISITS; TUMOR-NECROSIS-FACTOR; LUNG-FUNCTION	Epidemiological and toxicological research continues to support a link between urban air pollution and an increased incidence and/or severity of airway disease. Detrimental effects of ozone (O(3)), nitrogen dioxide (NO(2)) and particulate matter (PM), as well as traffic-related pollution as a whole, on respiratory symptoms and function are well documented. Not only do we have strong epidemiological evidence of a relationship between air pollution and exacerbation of asthma and respiratory morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD), but recent studies, particularly in urban areas, have suggested a role for pollutants in the development of both asthma and COPD. Similarly, while prevalence and severity of atopic conditions appear to be more common in urban compared with rural communities, evidence is emerging that traffic-related pollutants may contribute to the development of allergy. Furthermore, numerous epidemiological and experimental studies suggest an association between exposure to NO(2), O(3), PM and combustion products of biomass fuels and an increased susceptibility to and morbidity from respiratory infection. Given the considerable contribution that traffic emissions make to urban air pollution researchers have sought to characterize the relative toxicity of traffic-related PM pollutants. Recent advances in mechanisms implicated in the association of air pollutants and airway disease include epigenetic alteration of genes by combustion-related pollutants and how polymorphisms in genes involved in antioxidant pathways and airway inflammation can modify responses to air pollution exposures. Other interesting epidemiological observations related to increased host susceptibility include a possible link between chronic PM exposure during childhood and vulnerability to COPD in adulthood, and that infants subjected to higher prenatal levels of air pollution may be at greater risk of developing respiratory conditions. While the characterization of pollutant components and sources promise to guide pollution control strategies, the identification of susceptible subpopulations will be necessary if targeted therapy/prevention of pollution-induced respiratory diseases is to be developed.	[Kelly, F. J.; Fussell, J. C.] Kings Coll London, MRC HPA Ctr Environm & Hlth, London SE1 9NH, England	Kelly, FJ (reprint author), Kings Coll London, MRC HPA Ctr Environm & Hlth, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	frank.kelly@kcl.ac.uk	Kelly, Frank/C-6125-2009	Kelly, Frank/0000-0003-2558-8392			AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; Akhtar T, 2007, CHEST, V132, P1472, DOI 10.1378/chest.06-2529; Al-Shirawi N, 2006, ANN THORAC MED, V1, P41, DOI DOI 10.4103/1817-1737.25870; Andersen ZJ, 2008, OCCUP ENVIRON MED, V65, P458, DOI 10.1136/oem.2007.033290; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Auten RL, 2009, AM J RESP CRIT CARE, V180, P1218, DOI 10.1164/rccm.200901-0116OC; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Bayer-Oglesby L, 2005, ENVIRON HEALTH PERSP, V113, P1632, DOI 10.1289/ehp.8159; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Behndig AF, 2009, INHAL TOXICOL, V21, P250, DOI 10.1080/08958370802474736 ; BEHRENDT H, 1992, INT ARCH ALLERGY IMM, V99, P425; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Bell ML, 2009, AM J RESP CRIT CARE, V179, P1115, DOI 10.1164/rccm.200808-1240OC; BHALLA DK, 1987, J TOXICOL ENV HEALTH, V21, P73; Bhatta N, 2008, Kathmandu Univ Med J (KUMJ), V6, P195; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brown JS, 2002, AM J RESP CRIT CARE, V166, P1240, DOI 10.1164/rccm.00205-399OC; Brown JS, 2001, J AEROSOL MED, V14, P443, DOI 10.1089/08942680152744659; Cao DS, 2007, AM J RESP CELL MOL, V37, P232, DOI 10.1165/rcmb.2006-0449OC; Cardozo DM, 2008, J MED MICROBIOL, V57, P185, DOI 10.1099/jmm.0.47470-0; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Chehregani A, 2004, ECOTOX ENVIRON SAFE, V58, P267, DOI 10.1016/j.ecoenv.2003.12.004; Chen E, 2008, ENVIRON HEALTH PERSP, V116, P970, DOI 10.1289/ehp.11076; Cheng SL, 2004, EUR RESPIR J, V23, P818, DOI 10.1183/09031936.04.00104904; Ciencewicki J, 2007, INHAL TOXICOL, V19, P1135, DOI 10.1080/08958370701665434; Ciencewicki J, 2007, INHAL TOXICOL, V19, P1121, DOI 10.1080/08958370701665426; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Clougherty JE, 2009, ENVIRON HEALTH PERSP, V117, P1351, DOI 10.1289/ehp.0900612; D'Amato G, 2008, CLIN EXP ALLERGY, V38, P1264, DOI 10.1111/j.1365-2222.2008.03033.x; DEFRANCISCO A, 1993, INT J EPIDEMIOL, V22, P1174, DOI 10.1093/ije/22.6.1174; Dherani M, 2008, B WORLD HEALTH ORGAN, V86, P390, DOI 10.2471/BLT.07.044529; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fedulov AV, 2008, AM J RESP CELL MOL, V38, P57, DOI 10.1165/rcmb.2007-0124OC; Forastiere F, 2007, AM J IND MED, V50, P208, DOI 10.1002/ajim.20368; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gasser M, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-30; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Gehring U, 2010, AM J RESP CRIT CARE, V181, P596, DOI 10.1164/rccm.200906-0858OC; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; GERGEN PJ, 1987, J ALLERGY CLIN IMMUN, V80, P669, DOI 10.1016/0091-6749(87)90286-7; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Girod CE, 2005, CHEST, V128, P3055, DOI 10.1378/chest.128.4.3055; Gordian ME, 2006, J EXPO SCI ENV EPID, V16, P49, DOI 10.1038/sj.jea.7500436; Goss CH, 2004, AM J RESP CRIT CARE, V169, P816, DOI 10.1164/rccm.200306-779OC; Gotschi T, 2008, INT J EPIDEMIOL, V37, P1349, DOI 10.1093/ije/dyn136; Greenberg D, 2006, CLIN INFECT DIS, V42, P897, DOI 10.1086/500935; Grigg Jonathan, 2009, Proc Am Thorac Soc, V6, P564, DOI 10.1513/pats.200905-026RM; HAHON N, 1985, ENVIRON RES, V37, P44, DOI 10.1016/0013-9351(85)90048-9; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Hamada K, 2007, J TOXICOL ENV HEAL A, V70, P688, DOI 10.1080/15287390600974692; Harre ESM, 1997, THORAX, V52, P1040; Hertz-Picciotto I, 2005, ENVIRON HEALTH PERSP, V113, P1391, DOI 10.1289/ehp.7610; Hirshon JM, 2008, ENVIRON HEALTH PERSP, V116, P826, DOI 10.1289/ehp.10759; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; HORVATH SM, 1981, AM REV RESPIR DIS, V123, P496; Hwang BF, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-23; Jakab GJ., 1988, RES REP HLTH EFFECTS, V20, P1; Jaspers I, 2005, TOXICOL SCI, V85, P990, DOI 10.1093/toxsci/kfi141; Jedrychowski W, 2005, EUR J EPIDEMIOL, V20, P775, DOI 10.1007/s10654-005-1048-1; JOHNSON AWBR, 1992, ANN TROP PAEDIATR, V12, P421; Just J, 2002, EUR RESPIR J, V20, P899, DOI 10.1183/09031936.02.00236902; Kaan PM, 2003, AM J RESP CELL MOL, V28, P697, DOI 10.1165/rcmb.2002-0115OC; Kamdar O, 2008, FEBS LETT, V582, P3601, DOI 10.1016/j.febslet.2008.09.030; Kelly FJ, 1999, FOOD CHEM TOXICOL, V37, P963, DOI 10.1016/S0278-6915(99)00087-3; Kelly FJ, 2003, OCCUP ENVIRON MED, V60, P612, DOI 10.1136/oem.60.8.612; Kinney PL, 1996, ENVIRON HEALTH PERSP, V104, P170, DOI 10.2307/3432785; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Ko FWS, 2007, THORAX, V62, P780, DOI 10.1136/thx.2006.076166; KULLE TJ, 1985, AM REV RESPIR DIS, V132, P36; Lambert AL, 2003, TOXICOL SCI, V72, P331, DOI 10.1093/toxsci/kfg031; LANGLEY SC, 1993, PEDIATR RES, V33, P247, DOI 10.1203/00006450-199303000-00008; Leech Judith A, 2006, J Expo Sci Environ Epidemiol, V16, P238, DOI 10.1038/sj.jea.7500452; Li YF, 2006, AM J RESP CRIT CARE, V173, P970, DOI 10.1164/rccm.200508-1256OC; Lin L., 2010, ALLERGY ASTHMA CLIN, V6, P7; Lin M, 2005, PEDIATRICS, V116, pE235, DOI 10.1542/peds.2004-2012; Lin S, 2008, ENVIRON HEALTH PERSP, V116, P1725, DOI 10.1289/ehp.11184; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Liu SM, 2007, RESPIROLOGY, V12, P29, DOI 10.1111/j.1440-1843.2006.00958.x; MacNee W, 2000, CHEST, V117, p390S, DOI 10.1378/chest.117.5_suppl_2.390S; Mantecca P, 2009, TOXICOL LETT, V189, P206, DOI 10.1016/j.toxlet.2009.05.023; Mauad T, 2008, AM J RESP CRIT CARE, V178, P721, DOI 10.1164/rccm.200803-436OC; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; McConnell R, 2010, ENVIRON HEALTH PERSP, V118, P1021, DOI 10.1289/ehp.0901232; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; McDonnell WF, 1997, AM J RESP CRIT CARE, V156, P715; MCDONNELL WF, 1983, J APPL PHYSIOL, V54, P1345; McDonnell WF, 1999, EUR RESPIR J, V14, P845, DOI 10.1034/j.1399-3003.1999.14d21.x; MCELROY MC, 1992, BIOCHIM BIOPHYS ACTA, V1117, P153, DOI 10.1016/0304-4165(92)90073-4; Medina-Ramon M, 2006, AM J EPIDEMIOL, V163, P579, DOI 10.1093/aje/kwj078; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Meng YY, 2008, ANN EPIDEMIOL, V18, P343, DOI 10.1016/j.annepidem.2008.01.006; Meng YY, 2010, J EPIDEMIOL COMMUN H, V64, P142, DOI 10.1136/jech.2009.083576; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Mosges R, 2007, ALLERGY, V62, P969, DOI 10.1111/j.1398-9995.2007.01440.x; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Mortimer K, 2008, EPIDEMIOLOGY, V19, P550, DOI 10.1097/EDE.0b013e31816a9dcb; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; MTANGO FDE, 1992, TROP MED PARASITOL, V43, P229; Mudway IS, 2004, ARCH BIOCHEM BIOPHYS, V423, P200, DOI 10.1016/j.abb.2003.12.018; Mudway IS, 2004, AM J RESP CRIT CARE, V169, P1089, DOI 10.1164/rccm.200309-13251-1325PP; Naess O, 2007, AM J EPIDEMIOL, V165, P435, DOI 10.1093/aje/kwk016; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; ODempsey TJD, 1996, INT J EPIDEMIOL, V25, P885, DOI 10.1093/ije/25.4.885; Oftedal B, 2009, ENVIRON HEALTH PERSP, V117, P839, DOI 10.1289/ehp.11491; PANDE JN, 1998, RESP MED TROPICS, P259; Parker JD, 2009, ENVIRON HEALTH PERSP, V117, P140, DOI 10.1289/ehp.11497; Patel MM, 2009, AM J RESP CRIT CARE, V180, P1107, DOI 10.1164/rccm.200901-0122OC; Pauwels R, 2001, EUR RESPIR J, V18, P901, DOI 10.1183/09031936.01.0027401; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Penttinen P, 2006, INHAL TOXICOL, V18, P191, DOI 10.1080/08958370500434230; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Pierse N, 2006, THORAX, V61, P216, DOI 10.1136/thx.2004.036418; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; POPE CA, 1993, AM REV RESPIR DIS, V147, P1336; Qian ZM, 2004, ENVIRON INT, V30, P611, DOI 10.1016/j.envint.2003.11.003; Qu F, 2009, CHEM-BIOL INTERACT, V179, P219, DOI 10.1016/j.cbi.2008.10.059; RIELD M, 2005, J ALLERGY CLIN IMMUN, V115, P221; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2008, J ALLERGY CLIN IMMUN, V121, P903, DOI 10.1016/j.jaci.2007.12.004; Rosenlund M, 2009, THORAX, V64, P573, DOI 10.1136/thx.2007.094953; Salam MT, 2007, AM J RESP CRIT CARE, V176, P1192, DOI 10.1164/rccm.200704-561OC; Salam MT, 2007, THORAX, V62, P1050, DOI 10.1136/thx.2007.080127; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; Schindler C, 2009, AM J RESP CRIT CARE, V179, P579, DOI 10.1164/rccm.200803-388OC; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600; Shah SD, 2004, ENVIRON SCI TECHNOL, V38, P2544, DOI 10.1021/es0350583; Shima M, 2002, ARCH ENVIRON HEALTH, V57, P529; Sienra-Monge JJ, 2004, CLIN EXP IMMUNOL, V138, P317, DOI 10.1111/j.1365-2249.2004.02606.x; Sigaud S, 2007, TOXICOL APPL PHARM, V223, P1, DOI 10.1016/j.taap.2007.04.014; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V115, P337, DOI 10.1016/j.jaci.2004.11.035; Sint T, 2008, INHAL TOXICOL, V20, P25, DOI 10.1080/08958370701758759 ; Spannhake EW, 2002, ENVIRON HEALTH PERSP, V110, P665; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Sunyer J, 2000, AM J EPIDEMIOL, V151, P50; Sunyer J, 2001, INT J EPIDEMIOL, V30, P1138, DOI 10.1093/ije/30.5.1138; Svendsen ER, 2007, ANN ALLERG ASTHMA IM, V99, P244; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Vibhuti A, 2007, BIOCHEM BIOPH RES CO, V359, P136, DOI 10.1016/j.bbrc.2007.05.076; Watts J, 2006, LANCET, V368, P719, DOI 10.1016/S0140-6736(06)69267-2; WOLCOTT JA, 1982, APPL ENVIRON MICROB, V44, P723; Wong TW, 1999, OCCUP ENVIRON MED, V56, P679; Wu WD, 2008, TOXICOL APPL PHARM, V231, P260, DOI 10.1016/j.taap.2008.04.012; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yu Jui-Huan, 2005, Journal of Microbiology Immunology and Infection, V38, P123; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	160	100	103	3	68	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	AUG	2011	41	8					1059	1071		10.1111/j.1365-2222.2011.03776.x		13	Allergy; Immunology	Allergy; Immunology	791WS	WOS:000292700000004	21623970	
J	Maisonneuve, P; Lowenfels, AB				Maisonneuve, Patrick; Lowenfels, Albert B.			Epidemiology of Pancreatic Cancer: An Update	DIGESTIVE DISEASES			English	Article; Proceedings Paper	173rd Falk Symposium From Chronic Inflammation to Cancer	JUN 04-05, 2010	Brno, CZECH REPUBLIC			Pancreatic cancer; Epidemiology; Time trends; Etiology; Risk factors	BODY-MASS INDEX; ABO BLOOD-GROUP; OF-THE-LITERATURE; VITAMIN-D STATUS; PHYSICAL-ACTIVITY; COHORT-CONSORTIUM; POOLED-ANALYSIS; PERIODONTAL-DISEASE; DIABETES-MELLITUS; CIGARETTE-SMOKING	Pancreatic cancer, although infrequent, has a very poor prognosis, making it one of the 4 or 5 most common causes of cancer mortality in developed countries. Its incidence varies greatly across regions, which suggests that lifestyle factors such as diet, and environmental factors, such as vitamin D exposure, play a role. Because pancreatic cancer is strongly age-dependent, increasing population longevity and ageing will lead to an increase of the global burden of pancreatic cancer in the coming decades. Smoking is the most common known risk factor, causing 20-25% of all pancreatic tumors. Although a common cause of pancreatitis, heavy alcohol intake is associated only with a modest increased risk of pancreatic cancer. While viruses do not represent a major risk factor, people infected with Helicobacter pylori appeared to be at high risk of pancreatic cancer. Many factors associated with the metabolic syndrome, including overweight and obesity, impaired glucose tolerance, and long-standing diabetes also increase the risk disease, while atopic allergy and use of metformin as a treatment for diabetes have been associated with a reduced risk of pancreatic cancer. A family history of pancreatic cancer is associated with an increased risk of pancreatic cancer and it is estimated that 5-10% of patients with pancreatic cancer have an underlying germline disorder. Having a non-O blood group, another inherited characteristic, has also been steadily associated with an increased risk of pancreatic cancer. While many risk factors for pancreatic cancer are not modifiable, adopting a healthy lifestyle could substantially reduce pancreatic cancer risk. Copyright (C) 2010 S. Karger AG, Basel	[Maisonneuve, Patrick] European Inst Oncol, Div Epidemiol & Biostat, IT-20141 Milan, Italy; [Lowenfels, Albert B.] New York Med Coll, Dept Surg, Valhalla, NY 10595 USA	Maisonneuve, P (reprint author), European Inst Oncol, Div Epidemiol & Biostat, Via Ripamonti 435, IT-20141 Milan, Italy.	patrick.maisonneuve@ieo.it		Maisonneuve, Patrick/0000-0002-5309-4704	C.D. Smithers Foundation; Solvay Pharmaceuticals	A.B. Lowenfels was supported by grants from the C.D. Smithers Foundation and Solvay Pharmaceuticals. The authors declare that no conflict of interest exists in relation to the content of the article.	Amundadottir L, 2009, NAT GENET, V41, P986, DOI 10.1038/ng.429; ANNESE V, 1990, INT J PANCREATOL, V6, P81; Arslan AA, 2010, ARCH INTERN MED, V170, P791, DOI 10.1001/archinternmed.2010.63; Bae JM, 2009, PANCREAS, V38, P168, DOI 10.1097/MPA.0b013e318188c497; Bao Y, 2010, BRIT J CANCER, V102, P1422, DOI 10.1038/sj.bjc.6605658; Bao Y, 2008, CANCER EPIDEM BIOMAR, V17, P2671, DOI 10.1158/1055-9965.EPI-08-0488; Boffetta P, 2008, LANCET ONCOL, V9, P667, DOI 10.1016/S1470-2045(08)70173-6; Bonovas S, 2008, AM J GASTROENTEROL, V103, P2646, DOI 10.1111/j.1572-0241.2008.02051.x; Capurso G, 2007, ALIMENT PHARM THERAP, V26, P1089, DOI 10.1111/j.1365-2036.2007.03495.x; Chari ST, 2008, GASTROENTEROLOGY, V134, P95, DOI 10.1053/j.gastro.2007.10.040; Collins JJ, 2001, AM J IND MED, V39, P336, DOI 10.1002/1097-0274(200103)39:3<336::AID-AJIM1022>3.0.CO;2-K; Curado M.P., 2007, IARC SCI PUBLICATION, V160; de Gonzalez A. Berrington, 2003, British Journal of Cancer, V89, P519, DOI 10.1038/sj.bjc.6601140; Deutsch M, 1999, CLIN ONCOL-UK, V11, P280, DOI 10.1053/clon.1999.9065; Duell EJ, 2009, CANCER CAUSE CONTROL, V20, P1757, DOI 10.1007/s10552-009-9408-x; El-Serag HB, 2009, HEPATOLOGY, V49, P116, DOI 10.1002/hep.22606; EVERHART J, 1995, JAMA-J AM MED ASSOC, V273, P1605, DOI 10.1001/jama.273.20.1605; Ferlay J., 2010, GLOBOCAN 2008 CANC I; Ferlay J, 2010, INT J CANC; Fitzpatrick SG, 2010, J DENT, V38, P83, DOI 10.1016/j.jdent.2009.10.007; Fryzek JP, 2005, AM J EPIDEMIOL, V162, P222, DOI 10.1093/aje/kwi183; Gandini S, 2005, CANCER EPIDEM BIOMAR, V14, P1908, DOI 10.1158/1055-9965.EPI-05-0119; Gapstur SM, 2000, JAMA-J AM MED ASSOC, V283, P2552, DOI 10.1001/jama.283.19.2552; Genkinger JM, 2009, CANCER EPIDEM BIOMAR, V18, P765, DOI 10.1158/1055-9965.EPI-08-0880; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Giovannucci E, 2009, ANN EPIDEMIOL, V19, P84, DOI 10.1016/j.annepidem.2007.12.002; Gnagnarella P, 2008, AM J CLIN NUTR, V87, P1793; Gong ZH, 2009, CANCER CAUSE CONTROL, V20, P1317, DOI 10.1007/s10552-009-9352-9; Hart AR, 2008, CLIN GASTROENTEROL H, V6, P275, DOI 10.1016/j.cgh.2007.12.041; Hassan MM, 2008, J CLIN ONCOL, V26, P4557, DOI 10.1200/JCO.2008.17.3526; Hassan MM, 2007, AM J GASTROENTEROL, V102, P2696, DOI 10.1111/j.1572-0241.2007.01510.x; Huxley R, 2005, BRIT J CANCER, V92, P2076, DOI 10.1038/sj.bjc.6602619; Iodice S, 2008, J THROMB HAEMOST, V6, P781, DOI 10.1111/j.1538-7836.2008.02928.x; Iodice S, 2008, LANGENBECK ARCH SURG, V393, P535, DOI 10.1007/s00423-007-0266-2; Jee SH, 2005, JAMA-J AM MED ASSOC, V293, P194, DOI 10.1001/jama.293.2.194; Jiao L, 2009, AM J EPIDEMIOL, V169, P1043, DOI 10.1093/aje/kwp034; Jiao L, 2009, ARCH INTERN MED, V169, P764, DOI 10.1001/archinternmed.2009.46; Khasawneh J, 2009, P NATL ACAD SCI USA, V106, P3354, DOI 10.1073/pnas.0802864106; Kinoshita S, 2007, INT J HEALTH GEOGR, V6, DOI 10.1186/1476-072X-6-34; Landi S, 2009, MUTAT RES-REV MUTAT, V681, P299, DOI 10.1016/j.mrrev.2008.12.001; Larsson SC, 2006, J NATL CANCER I, V98, P407, DOI 10.1093/jnci/djj094; Larsson SC, 2007, INT J CANCER, V120, P1993, DOI 10.1002/ijc.22535; Larsson SC, 2006, CANCER EPIDEM BIOMAR, V15, P2561, DOI 10.1158/1055-9965.EPI-06-0574; Larsson SC, 2006, AM J CLIN NUTR, V84, P1171; Larsson SG, 2007, GASTROENTEROLOGY, V132, P113, DOI 10.1053/j.gastro.2006.10.017; Lee PN, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-36; Li DH, 2009, GASTROENTEROLOGY, V137, P482, DOI 10.1053/j.gastro.2009.04.013; Li DH, 2009, JAMA-J AM MED ASSOC, V301, P2553, DOI 10.1001/jama.2009.886; LOWENFELS AB, 1993, NEW ENGL J MED, V328, P1433, DOI 10.1056/NEJM199305203282001; Luo JH, 2007, CANCER CAUSE CONTROL, V18, P603, DOI 10.1007/s10552-007-9002-z; Lynch SM, 2009, AM J EPIDEMIOL, V170, P403, DOI 10.1093/aje/kwp134; MACMAHON B, 1981, NEW ENGL J MED, V304, P630, DOI 10.1056/NEJM198103123041102; Maisonneuve P, 2010, ANN EPIDEMIOL, V20, P92, DOI 10.1016/j.annepidem.2009.11.010; Maisonneuve P, 2009, J NATL CANCER I, V101, P1156, DOI 10.1093/jnci/djp198; Malka D, 2002, GUT, V51, P849, DOI 10.1136/gut.51.6.849; Meyer MS, 2008, CANCER CAUSE CONTROL, V19, P895, DOI 10.1007/s10552-008-9163-4; Mohr SB, 2010, PANCREAS, V39, P669, DOI 10.1097/MPA.0b013e3181ce654d; Mueller NT, 2010, CANCER EPIDEM BIOMAR, V19, P447, DOI 10.1158/1055-9965.EPI-09-0862; Muscat JE, 2005, CANCER-AM CANCER SOC, V103, P1420, DOI 10.1002/cncr.20953; Nothlings U, 2007, AM J EPIDEMIOL, V166, P924, DOI 10.1093/aje/kwm172; O'Rorke MA, 2010, INT J CANCER, V126, P2957, DOI 10.1002/ijc.24997; Ojajarvi A, 2007, SCAND J WORK ENV HEA, V33, P325; Patel AV, 2005, CANCER EPIDEM BIOMAR, V14, P459, DOI 10.1158/1055-9965.EPI-04-0583; Permuth-Wey J, 2009, FAM CANCER, V8, P109, DOI 10.1007/s10689-008-9214-8; Raimondi S, 2007, CANCER EPIDEM BIOMAR, V16, P1894, DOI 10.1158/1055-9965.EPI-07-0341; Raimondi S, 2010, BEST PRACT RES CL GA, V24, P349, DOI 10.1016/j.bpg.2010.02.007; Raimondi S, 2009, NAT REV GASTRO HEPAT, V6, P699, DOI 10.1038/nrgastro.2009.177; Reeves GK, 2007, BRIT MED J, V335, P1134, DOI 10.1136/bmj.39367.495995.AE; Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X; Risch HA, 2010, J NATL CANCER I, V102, P502, DOI 10.1093/jnci/djq007; Rohrmann S, 2009, CANCER CAUSE CONTROL, V20, P785, DOI 10.1007/s10552-008-9293-8; Schernhammer ES, 2005, CANCER EPIDEM BIOMAR, V14, P2098, DOI 10.1158/1055-9965.EPI-05-0059; Sherman PW, 2008, Q REV BIOL, V83, P339, DOI 10.1086/592850; Silverman DT, 2003, EPIDEMIOLOGY, V14, P45, DOI 10.1097/00001648-200301000-00013; Stattin P, 2007, DIABETES CARE, V30, P561, DOI 10.2337/dc06-0922; Stevens RJ, 2007, BRIT J CANCER, V96, P507, DOI 10.1038/sj.bjc.6603571; Stocks T, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000201; Stolzenberg-Solomon RZ, 2005, JAMA-J AM MED ASSOC, V294, P2872, DOI 10.1001/jama.294.22.2872; Stolzenberg-Solomon RZ, 2001, AM J EPIDEMIOL, V153, P680, DOI 10.1093/aje/153.7.680; Tramacere I, 2010, INT J CANCER, V126, P1474, DOI 10.1002/ijc.24936; Turner MC, 2006, INT J CANCER, V118, P3124, DOI 10.1002/ijc.21752; [Anonymous], WORLD POP PROSP 2008; VOGEL F, 1970, AM J HUM GENET, V22, P464; Vrieling A, 2010, INT J CANCER, V126, P2394, DOI 10.1002/ijc.24907; Vrieling A, 2009, INT J CANCER, V124, P1926, DOI 10.1002/ijc.24134; Wahi MM, 2009, ANN EPIDEMIOL, V19, P103, DOI 10.1016/j.annepidem.2008.11.003; World Health Organization, 2008, MORT DAT; Wolpin BM, 2010, CANCER RES, V70, P1015, DOI 10.1158/0008-5472.CAN-09-2993; Zheng W, 2009, NUTR CANCER, V61, P437, DOI 10.1080/01635580802710741	89	100	104	2	32	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0257-2753	1421-9875		DIGEST DIS	Dig. Dis.		2010	28	4-5					645	656		10.1159/000320068		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	684LK	WOS:000284551200015	21088417	
J	O'Hehir, RE; Gardner, LM; de Leon, MP; Hales, BJ; Biondo, M; Douglass, JA; Rolland, JM; Sandrini, A				O'Hehir, Robyn E.; Gardner, Leanne M.; de Leon, Maria P.; Hales, Belinda J.; Biondo, Mark; Douglass, Jo A.; Rolland, Jennifer M.; Sandrini, Alessandra			House Dust Mite Sublingual Immunotherapy The Role for Transforming Growth Factor-beta and Functional Regulatory T Cells	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						allergen immunotherapy; sublingual administration; regulatory T cells; transforming growth factor-beta; T lymphocytes	GRASS-POLLEN IMMUNOTHERAPY; STANDARDIZED 5-GRASS-POLLEN EXTRACT; SYSTEMIC IMMUNOLOGICAL CHANGES; RANDOMIZED CONTROLLED-TRIAL; SEASONAL ALLERGIC RHINITIS; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; TGF-BETA; IMMUNE-RESPONSES; CLINICAL-EFFICACY	Rationale: Sublingual allergen-specific immunotherapy is gaining popularity for treatment of allergic diseases, but underlying immunological mechanisms are unresolved. Objectives: To perform detailed immunological investigation of sublingual house dust mite (HDM) immunotherapy. Methods: A 12-month randomized double-blind placebo-controlled study of sublingual HDM immunotherapy in 30 HDM-allergic subjects was performed, with 1-year open extension in 9 patients on active treatment. HDM-stimulated blood mononuclear cells were analyzed for proliferation, cytokines, and regulatory T cells (Tregs) by flow cytometry and ELISA. Effects of blocking transforming growth factor (TGF)-beta and IL-10 on proliferation were determined. Treg suppressor function and allergen-specific antibody levels were measured. Clinical efficacy was assessed by symptom, medication, and juniper quality-of-life scores. Measurements and Main Results: Allergen-induced CD4(+) T-cell division and IL-5 production were significantly decreased after 6- and 12-months' active treatment but not placebo. sTGF-beta RII blocked immunotherapy-induced suppression of allergen-specific T-cell proliferation, maximal at 6 months. Decreased allergen-specific CD4(+) T-cell proliferation and increased IL-10 secretion and serum Der p 2-specific IgG(4) were maximal at 24 months' active treatment. Treg (CD4(+)CD25(+)CD127(lo)/Foxp3(+)) function was demonstrated by suppression of allergen-specific effector T-cell (CD4(+)CD25(-)CD127(hi)) proliferation and cytokine production. Clinical efficacy of immunotherapy was supported by significantly decreased rhinitis symptom score, total asthma score, and Juniper quality-of-life score. Conclusions: This study establishes the novel finding that TGF-beta mediates the immunological suppression seen early in clinically effective sublingual HDM immunotherapy in addition to an increase in Tregs with suppressor function. Clinical trial registered with www.clinicaltrials.gov (NCT00250263).	[O'Hehir, Robyn E.; Gardner, Leanne M.; de Leon, Maria P.; Biondo, Mark; Douglass, Jo A.; Sandrini, Alessandra] Alfred Hosp, Dept Allergy Immunol & Resp Med, Melbourne, Vic 3004, Australia; [O'Hehir, Robyn E.; Gardner, Leanne M.; de Leon, Maria P.; Biondo, Mark; Rolland, Jennifer M.; Sandrini, Alessandra] Monash Univ, Dept Immunol, Melbourne, Vic 3004, Australia; [Hales, Belinda J.] Telethon Inst Child Hlth Res, Perth, WA, Australia	O'Hehir, RE (reprint author), Alfred Hosp, Dept Allergy Immunol & Resp Med, Commercial Rd, Melbourne, Vic 3004, Australia.	robyn.ohehir@med.monash.edu.au	Rolland, Jennifer/E-7543-2011; O'Hehir, Robyn/H-3627-2011; Hales, Belinda/C-3858-2013	O'Hehir, Robyn/0000-0002-3489-7595; Hales, Belinda/0000-0003-2193-3996	National Health and Medical Research Council, Australia; Cooperative Research Centre for Asthma and Airways, Australia; Alfred Research Trusts	Supported by Program Grant funding from the National Health and Medical Research Council, Australia; the Cooperative Research Centre for Asthma and Airways, Australia; and the Alfred Research Trusts.	Aberer W, 2007, J INVEST ALLERG CLIN, V17, P131; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Altman DG, 2001, BRIT MED J, V323, P446; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; Calderon M, 2006, J INVEST ALLERG CLIN, V16, P338; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Dahl R, 2008, J ALLERGY CLIN IMMUN, V121, P512, DOI 10.1016/j.jaci.2007.10.039; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 2008, CURR OPIN ALLERGY CL, V8, P577, DOI 10.1097/ACI.0b013e3283196764; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRIEDMAN A, 1994, P NATL ACAD SCI USA, V91, P6688, DOI 10.1073/pnas.91.14.6688; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Gardner LM, 2004, INT ARCH ALLERGY IMM, V133, P1, DOI 10.1159/000075248; Hales BJ, 2006, J ALLERGY CLIN IMMUN, V118, P361, DOI 10.1016/j.jaci.2006.04.001; Hales BJ, 2004, INT ARCH ALLERGY IMM, V135, P101, DOI 10.1159/000080652; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; HOLGATE ST, 2008, CELLULAR MOL TARGETS, P142; Huber S, 2004, J IMMUNOL, V173, P6526; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2006, ALLERGY, V61, P796, DOI 10.1111/j.1398-9995.2006.01175.x; Kildsgaard J, 2007, ANN ALLERG ASTHMA IM, V98, P366; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; LI S, 2007, ALLERGY CLIN IMMUN S, V2; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Lue KH, 2006, PEDIATR ALLERGY IMMU, V17, P408, DOI 10.1111/j.1399-3038.2006.00443.x; Marcucci F, 2005, ALLERGY, V60, P952, DOI 10.1111/j.1398-9995.2005.00786.x; MILLER A, 1992, P NATL ACAD SCI USA, V89, P421, DOI 10.1073/pnas.89.1.421; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Niu CK, 2006, RESP MED, V100, P1374, DOI 10.1016/j.rmed.2005.11.016; Novak N, 2006, IMMUNOL ALLERGY CLIN, V26, P307, DOI 10.1016/j.iac.2006.02.010; O'Hehir RE, 2007, CURR MED CHEM, V14, P2235, DOI 10.2174/092986707781696609; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 2006, CURR OPIN ALLERGY CL, V6, P449, DOI 10.1097/01.all.0000246617.41871.40; Penagos M, 2008, CHEST, V133, P599, DOI 10.1378/chest.06-1425; Pilette C, 2007, J IMMUNOL, V178, P4658; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; QIN SX, 1993, SCIENCE, V259, P974, DOI 10.1126/science.8094901; Rolland JM, 2009, PHARMACOL THERAPEUT, V121, P273, DOI 10.1016/j.pharmthera.2008.11.007; Savage NDL, 2008, J IMMUNOL, V181, P2220; Savolainen J, 2006, ALLERGY, V61, P1184, DOI 10.1111/j.1398-9995.2006.01206.x; Scadding G, 2009, J ASTHMA, V46, P322, DOI 10.1080/02770900902785729; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Upton MN, 2000, BRIT MED J, V321, P88, DOI 10.1136/bmj.321.7253.88; van Neerven RJJ, 1999, J IMMUNOL, V163, P2944; Wachholz PA, 2003, CLIN EXP ALLERGY, V33, P1171, DOI 10.1046/j.1365-2222.2003.01765.x; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zheng SG, 2004, J IMMUNOL, V172, P5213	71	100	105	1	9	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2009	180	10					936	947		10.1164/rccm.200905-0686OC		12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	519VR	WOS:000271797600008	19696440	
J	Spitzer, C; Barnow, S; Volzke, H; John, U; Freyberger, HJ; Grabe, HJ				Spitzer, Carsten; Barnow, Sven; Voelzke, Henry; John, Ulrich; Freyberger, Harald J.; Grabe, Hans Joergen			Trauma, Posttraumatic Stress Disorder, and Physical Illness: Findings from the General Population	PSYCHOSOMATIC MEDICINE			English	Article						trauma; posttraumatic stress disorder (PTSD); physical health; cardiovascular and pulmonary disease; general population	ADVERSE CHILDHOOD EXPERIENCES; HEART-DISEASE; PRIMARY-CARE; MYOCARDIAL-INFARCTION; PSYCHIATRIC-DISORDERS; VIETNAM VETERANS; HEALTH; SYMPTOMS; EXPOSURE; COMMUNITY	Objective: To determine in a general population sample the differential impact on physical health of exposure to traumatic experiences and posttraumatic stress disorder (PTSD). Trauma exposure and PTSD have been associated with physical illness in specific populations, such as veterans. Methods: Medical histories including cardiovascular, endocrine, pulmonary, and other chronic diseases were obtained from 3171 adults living in the community. They were administered the PTSD module of the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM-IV), and were assigned to three groups: no trauma (n = 1440); trauma, but no PTSD (n = 1669) and trauma with subsequent PTSD (n = 62). Results: After adjustments for sociodemographic factors, smoking, body mass index, blood pressure, depression, and alcohol use disorders, subjects with trauma history had higher odds ratios (ORs) for angina pectoris and heart failure (OR = 1.2; 95% Confidence Interval [CI] 1.1-1.3), stroke (OR = 1.2; 95 CI = 1.0-1.5), bronchitis, asthma, renal disease, and polyarthritis (ORs between 1.1 and 1.3) compared with nontraumatized participants. The PTSD positive subsample had increased ORs for angina (OR = 2.4; 95% CI = 1.3-4.5), heart failure (OR = 3.4; 95% CI = 1.9-6.0), bronchitis, asthma, liver, and peripheral arterial disease (ORs, range = 2.5-3.1). Conclusions: Our findings suggest a strong association between PTSD and cardiovascular and pulmonary diseases. Particular diagnostic and treatment attention should be paid to physical illness in PTSD positive patients in primary care, medical, and mental health settings.	[Spitzer, Carsten] Univ Med Ctr Hamburg Eppendorf, Dept Psychosomat Med & Psychotherapy, D-20246 Hamburg, Germany; Schon Kliniken, Klinikum Eilbek, Hamburg, Germany; [Barnow, Sven] Univ Heidelberg, Inst Psychol, Heidelberg, Germany; [Voelzke, Henry] Ernst Moritz Arndt Univ Greifswald, Inst Community Med, Greifswald, Germany; [John, Ulrich] Ernst Moritz Arndt Univ Greifswald, Inst Epidemiol & Social Med, Greifswald, Germany; [Freyberger, Harald J.; Grabe, Hans Joergen] Ernst Moritz Arndt Univ Greifswald, Dept Psychiat & Psychotherapy, Greifswald, Germany	Spitzer, C (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Psychosomat Med & Psychotherapy, Martinistr 52, D-20246 Hamburg, Germany.	c.spitzer@uke.uni-hamburg.de		John, Ulrich/0000-0003-0587-5298	Federal Ministry of Education and Research [ZZ9603, 01ZZ0103, 01ZZ0403]; Ministry of Cultural Affairs as well as the Social Ministry, of the Federal State of Mecklenburg-West Pomerania	The work is part of the Community, Medicine Research net of the University of Greifswald, Germany, which is funded by, the Federal Ministry of Education and Research (Grants ZZ9603, 01ZZ0103, 01ZZ0403), the Ministry of Cultural Affairs as well as the Social Ministry, of the Federal State of Mecklenburg-West Pomerania. The Community Medicine Research encompasses several research projects, which are sharing data of the population-based Study of Health in Pomerania (SHIP) (http://ship.community-medicine.de).	Armenian HK, 1998, AM J EPIDEMIOL, V148, P1077; BARON RM, 1986, J PERS SOC PSYCHOL, V51, P1173, DOI 10.1037/0022-3514.51.6.1173; Boscarino JA, 1997, PSYCHOSOM MED, V59, P605; Boscarino JA, 2004, ANN NY ACAD SCI, V1032, P141, DOI 10.1196/annals.1314.011; Boscarino JA, 2008, PSYCHOSOM MED, V70, P668, DOI 10.1097/PSY.0b013e31817bccaf; Breslau N, 2002, CAN J PSYCHIAT, V47, P923; Bronner MB, 2009, J TRAUMA STRESS, V22, P74, DOI 10.1002/jts.20379; Cloitre M, 2001, WOMEN HEALTH, V34, P1, DOI 10.1300/J013v34n03_01; Dirkzwager AJE, 2007, PSYCHOSOM MED, V69, P435, DOI 10.1097/PSY.0b013e318052e20a; Dobie DJ, 2004, ARCH INTERN MED, V164, P394, DOI 10.1001/archinte.164.4.394; Dong M, 2003, ARCH INTERN MED, V163, P1949, DOI 10.1001/archinte.163.16.1949; Dong MX, 2004, CIRCULATION, V110, P1761, DOI 10.1161/01.CIR.0000143074.54995.7F; Elhai JD, 2005, J TRAUMA STRESS, V18, P541, DOI 10.1002/jts.20062; Engel CC, 2000, PSYCHOSOM MED, V62, P739; Fiellin DA, 2000, ARCH INTERN MED, V160, P1977, DOI 10.1001/archinte.160.13.1977; First MB, 1997, STRUCTURED CLIN INTE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Friedman Matthew J., 2004, TRAUMA HLTH PHYS HLT; Gander ML, 2006, EUR J CARDIOV PREV R, V13, P165, DOI 10.1097/01.hjr.0000214606.60995.46; Goodwin RD, 2004, PSYCHOL MED, V34, P509, DOI 10.1017/S003329170300134X; Green B. L., 2004, TRAUMA HLTH PHYS HLT; Hapke U, 2006, EUR ARCH PSY CLIN N, V256, P299, DOI 10.1007/s00406-006-0654-6; John U, 2001, SOZ PRAVENTIV MED, V46, P186, DOI 10.1007/BF01324255; KEHOE R, 1994, AM J EPIDEMIOL, V139, P813; Keil U., 1985, 2085 GSF; KESSLER RC, 1995, ARCH GEN PSYCHIAT, V52, P1048; Kubzansky LD, 2007, ARCH GEN PSYCHIAT, V64, P109, DOI 10.1001/archpsyc.64.1.109; Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878; McEwen BS, 1999, ANN NY ACAD SCI, V896, P30, DOI 10.1111/j.1749-6632.1999.tb08103.x; Norman SB, 2006, J TRAUMA STRESS, V19, P461, DOI 10.1002/jts.20129; O'Toole BI, 2008, J PSYCHOSOM RES, V64, P33, DOI 10.1016/j.jpsychores.2007.07.006; PERLOFF D, 1993, CIRCULATION, V88, P2460; Rohleder N, 2006, Minerva Endocrinol, V31, P273; Sareen J, 2007, PSYCHOSOM MED, V69, P242, DOI 10.1097/PSY.0b013e31803146d8; Schnurr PP, 1999, J NERV MENT DIS, V187, P353, DOI 10.1097/00005053-199906000-00004; Schnurr PP, 2000, HEALTH PSYCHOL, V19, P91, DOI 10.1037/0278-6133.19.1.91; Schnurr P. P., 2004, TRAUMA HLTH PHYS HLT; Shemesh E, 2004, PSYCHOSOM MED, V66, P521, DOI 10.1097/01.psy.0000126199.05189.86; Spiro Avron 3rd, 2006, J Ambul Care Manage, V29, P71; Spitzer C, 2008, J CLIN PSYCHIAT, V69, P693; Spitzer C, 2010, J PSYCHIATR RES, V44, P15, DOI 10.1016/j.jpsychires.2009.06.002; Stein MB, 2000, PSYCHOSOM MED, V62, P838; Weisberg RB, 2002, PSYCHIATR SERV, V53, P848, DOI 10.1176/appi.ps.53.7.848; Wittchen H, 1999, INT J METH PSYCH RES, V8, P59, DOI DOI 10.1002/MPR.57; Yehuda R, 2000, J CLIN PSYCHIAT, V61, P14	45	100	101	3	16	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0033-3174			PSYCHOSOM MED	Psychosom. Med.	NOV-DEC	2009	71	9					1012	1017		10.1097/PSY.0b013e3181bc76b5		6	Psychiatry; Psychology; Psychology, Multidisciplinary	Psychiatry; Psychology	522UP	WOS:000272024800016	19834051	
J	Eduard, W; Pearce, N; Douwes, J				Eduard, Wijnand; Pearce, Neil; Douwes, Jeroen			Chronic Bronchitis, COPD, and Lung Function in Farmers The Role of Biological Agents	CHEST			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; DOSE-RESPONSE RELATIONSHIPS; RESPIRATORY SYMPTOMS; ANIMAL FARMERS; EXPOSURE; ENDOTOXIN; WORKERS; ASTHMA; DUST; ENVIRONMENT	Background: Farmers have an increased risk of respiratory morbidity and mortality. The causal agents have not been fully established. Methods: In a cross-sectional study of 4,735 Norwegian farmers, we assessed respiratory symptoms and lung function. Atopy was assessed in a subsample (n = 1,213). Personal exposures to dust, fungal spores, actinomycete spores, endotoxins, bacteria, storage mites, (1 -> 3)-beta-D-glucans, fungal antigens, organic dust, inorganic dust, silica, ammonia, and hydrogen sulfide were measured for 127 randomly selected farms. Results: Compared to crop farmers, livestock farmers were more likely to have chronic bronchitis (odds ratio [OR], 1.9; 95% confidence interval [CI], 1.4 to 2.6) and COPD (OR, 1.4; 95% CI, 1.1 to 1.7). FEV(1) (-41 mL; 95% CI, -75 to -7) was significantly reduced, but FVC (-15 mL; 95% CI, -54 to 24) was not. Exposure to most agents were predictors of respiratory morbidity, except FVC. Ammonia, hydrogen sulfide, and inorganic dust were most strongly associated in multiple regression models adjusted for coexposures, but the effects of specific biological agents could not be assessed in multiple regression models because they were too highly correlated. Farmers with atopy had a significantly lower FEV(1) (OR, -87 mL; 95% CI, -170 to -7), but atopy was not directly associated with chronic bronchitis, COPD, and FVC. However, the effects of farming and specific exposures on COPI) were substantially greater in farmers with atopy. Conclusions: Livestock farmers have an increased risk of chronic bronchitis, COPD, and reduced FEV(1). Ammonia, hydrogen sulfide, inorganic dust, and organic dust may be causally involved, but a role for specific biological agents cannot be excluded. Farmers with atopy appear more susceptible to develop farming-related COPI). (CHEST 2009; 136:716-725)	[Eduard, Wijnand] Natl Inst Occupat Hlth, Oslo, Norway; [Pearce, Neil; Douwes, Jeroen] Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand	Eduard, W (reprint author), Natl Inst Occupat Hlth, POB 8149, NO-0033 Dep Oslo, Norway.	wijnand.eduard@stami.no		Pearce, Neil/0000-0002-9938-7852; Douwes, Jeroen/0000-0003-3599-4036	Agricultural Besearch Council of Norway; Agricultural Agreement Research Fund; Agricultural Investment Fund; Norske Meierier (Norwegian Dairies); Gjensidige (insurance company); Forenede (insurance company); Health Research Council (HRC) of New Zealand	Support/Funding: This project was financially supported by the Agricultural Besearch Council of Norway, the Agricultural Agreement Research Fund, the Agricultural Investment Fund, Norske Meierier (Norwegian Dairies), Gjensidige (insurance company), and Forenede (insurance company). Pharmacia Diagnostics supplied the reagents for the Phadebas Phadiatop and specific IgE tests, and Nycomed Pharma performed the RAST analyses. The Centre for Public Health Research is supported by a Programme Grant from the Health Research Council (HRC) of New Zealand.	American Thoracic Society, 1998, AM J RESP CRIT CARE, V158, pS1; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; *AM THOR SOC, 1962, AM REV RESPIR DIS, V85, P769; Baldacci S, 2001, EUR RESPIR J, V17, P773, DOI 10.1183/09031936.01.17407730; Brutsche MH, 2006, THORAX, V61, P671, DOI 10.1136/thx.2005.052241; CHECKOWAY H, 2004, RES METHODS OCCUPATI, P286; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; DONHAM KJ, 1995, AM J IND MED, V27, P405, DOI 10.1002/ajim.4700270309; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Eduard W, 2001, OCCUP ENVIRON MED, V58, P113, DOI 10.1136/oem.58.2.113; Eduard W., 2006, ARBETE HALSA, V21, P1; Eduard W, 1988, ANN OCCUP HYG, V32, P447; Global Initiative for Chronic Obstructive Lung Disease, 2007, GLOB STRAT DIAGN MAN; Heederik D, 1997, ANN AGR ENV MED, V4, P17; Heldal K, 1996, ANN OCCUP HYG, V40, P437, DOI 10.1016/0003-4878(95)00089-5; Kirychuk SP, 2006, J OCCUP ENVIRON MED, V48, P741, DOI 10.1097/01.jom.0000216215.39521.3c; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lamprecht B, 2007, AM J IND MED, V50, P421, DOI 10.1002/ajim.20470; Langhammer A, 2001, EUR RESPIR J, V18, P770, DOI 10.1183/09031936.01.00255301; Linaker C, 2002, OCCUP MED-OXFORD, V52, P451, DOI 10.1093/occmed/52.8.451; Medical Research Council, 1960, BRIT MED J, V2, P1665; MEHL R, 1998, ALLERGY S, V53, pS28; Melbostad E, 1997, SCAND J WORK ENV HEA, V23, P271; Melbostad E, 2000, SCAND J CLIN LAB INV, V60, P111, DOI 10.1080/00365510050184921; Monso E, 2004, AM J IND MED, V46, P357, DOI 10.1002/ajim.20077; Omland O, 2002, ANN AGR ENV MED, V9, P119; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Radon K, 2001, EUR RESPIR J, V17, P747, DOI 10.1183/09031936.01.17407470; Rushton Lesley, 2007, Reviews on Environmental Health, V22, P195; Skogstad A, 1999, J ENVIRON MONITOR, V1, P379, DOI 10.1039/a902941i; Steenland K, 2000, SCAND J WORK ENV HEA, V26, P37; THELIN A, 1984, EUR J RESPIR DIS, V65, P266; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Weiss ST, 2000, AM J RESP CRIT CARE, V162, pS134	37	100	102	0	8	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	SEP	2009	136	3					716	725		10.1378/chest.08-2192		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	493JT	WOS:000269733400013	19318669	
J	Mills, ENC; Mackie, AR; Burney, P; Beyer, K; Frewer, L; Madsen, C; Botjes, E; Crevel, RWR; van Ree, R				Mills, E. N. C.; Mackie, A. R.; Burney, P.; Beyer, K.; Frewer, L.; Madsen, C.; Botjes, E.; Crevel, R. W. R.; van Ree, R.			The prevalence, cost and basis of food allergy across Europe	ALLERGY			English	Review						allergy; diagnosis; foods prevalence; socioeconomic	MULTICENTER	The development of effective management strategies to optimize the quality of life for allergic patients is currently hampered by a lack of good quality information. Estimates of how many individuals suffer from food allergy and the major foods involved vary widely and inadequacies of in vitro diagnostics make food challenges the only reliable means of diagnosis in many instances. The EuroPrevall project brings together a multidisciplinary partnership to address these issues. Cohorts spanning the main climatic regions of Europe are being developed in infants through a birth cohort, community surveys in school-age children and adults and an outpatient clinic study. Confirmatory double-blind placebo-controlled food challenge diagnosis is being undertaken using foods as they are eaten with titrated doses to allow no-effect and lowest-observable effect levels for allergenic foods to be determined. The cohorts will also facilitate validation of novel in vitro diagnostics through the development of the EuroPrevall Serum Bank. Complementary studies in Ghana, western Siberia, India and China will allow LIS to gain insights into how different dietary patterns and exposure to microorganisms affect food allergies. New instruments to assess the socioeconomic impact of food allergy are being developed in the project and their application in the clinical cohorts will allow, for the first time, an assessment to be made of the burden this disease places on allergy sufferers and their communities.	Inst Food Res, Norwich NR4 7UA, Norfolk, England; Univ London Imperial Coll Sci Technol & Med, London, England; Humboldt Univ, Univ Childrens Hosp Charite, Dept Paediat Pneumol & Immunol, Berlin, Germany; Univ Wageningen & Res Ctr, Dept Mkt & Consumer Behav, Wageningen, Netherlands; Tech Univ Denmark, Natl Food Inst, Soborg, Denmark; European Federat Allergy & Airways Dis Patients A, Brussels, Belgium; SEAC, Unilever Colworth, Sharnbrook, Beds, England; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	Mills, ENC (reprint author), Inst Food Res, Norwich Res Pk, Norwich NR4 7UA, Norfolk, England.						ASERO R, 2006, MOL NUTR FOOD RES, V51, P135; Beyer K, 2005, CURR OPIN ALLERGY CL, V5, P261, DOI 10.1097/01.all.0000168792.27948.f9; Bindslev-Jensen C, 2002, ALLERGY, V57, P741, DOI 10.1034/j.1398-9995.2002.23797.x; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; Crevel RWR, 2007, FOOD CHEM TOXICOL, V45, P691, DOI 10.1016/j.fct.2006.09.005; de Blok BMJ, 2007, ALLERGY, V62, P733, DOI 10.1111/j.1398-9995.2006.01303.x; DunnGalvin A, 2006, ALLERGY, V61, P1336, DOI 10.1111/j.1398-9995.2006.01181.x; Eigenmann PA, 2002, ALLERGY, V57, P449, DOI 10.1034/j.1398-9995.2002.13494.x; Fernandez-Rivas M., 2004, PLANT FOOD ALLERGENS, P1; Hourihane JOB, 2001, ALLERGY, V56, P86; Knibb R.C., 2000, PSYCHOL HEALTH MED, V5, P419, DOI 10.1080/713690215; Miles S, 2005, ALLERGY, V60, P996, DOI 10.1111/j.1398-9995.2005.00868.x; Mills ENC, 2004, ALLERGY, V59, P1262, DOI 10.1111/j.1398-9995.2004.00720.x; Nickel R, 2002, PEDIATR ALLERGY IMMU, V13, P7, DOI 10.1034/j.1399-3038.13.s.15.4.x; Niggemann B, 2005, ALLERGY, V60, P865, DOI 10.1111/j.1398-9995.2005.00828.x; ONG LML, 1995, SOC SCI MED, V40, P903, DOI 10.1016/0277-9536(94)00155-M; Ortolani C, 1999, ALLERGY, V54, P27, DOI 10.1034/j.1398-9995.1999.00913.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Taylor SL, 2004, CLIN EXP ALLERGY, V34, P689, DOI 10.1111/j.1365-2222.2004.1886.x; Woods RK, 2001, EUR J CLIN NUTR, V55, P298, DOI 10.1038/sj.ejcn.1601159	20	100	106	0	13	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JUL	2007	62	7					717	722		10.1111/j.1398-9995.2007.01425.x		6	Allergy; Immunology	Allergy; Immunology	179VP	WOS:000247318500001	17573717	
J	Galassi, C; De Sario, M; Biggeri, A; Bisanti, L; Chellini, E; Ciccone, G; Petronio, MG; Piffer, S; Sestini, P; Rusconi, F; Viegi, G; Forastiere, F				Galassi, C; De Sario, M; Biggeri, A; Bisanti, L; Chellini, E; Ciccone, G; Petronio, MG; Piffer, S; Sestini, P; Rusconi, F; Viegi, G; Forastiere, F			Changes in prevalence of asthma and allergies among children and adolescents in Italy: 1994-2002	PEDIATRICS			English	Article						asthma; rhinitis; eczema; children; adolescents	INCREASING PREVALENCE; HAY-FEVER; SYMPTOMS; SCHOOLCHILDREN; RHINITIS; GERMANY; ECZEMA; TRENDS; ISAAC; SENSITIZATION	BACKGROUND. Several studies conducted during the 1990s indicated an increase in the prevalence of symptoms of asthma; more recent investigations suggest that the trend is stabilizing or may even be reversing. OBJECTIVE. We compared 2 cross-sectional surveys conducted in 1994 and 2002 in 8 areas in northern and central Italy, to evaluate prevalence changes for asthma, allergic rhinitis, and eczema. METHODS. The International Study of Asthma and Allergies in Childhood methods and questionnaires were used to investigate 6- to 7-year-old children (16 115 and 11 287 questionnaires completed by parents in 1994-1995 and 2002, respectively) and 13- to 14-year-old adolescents (19 723 and 10 267 questionnaires completed by adolescents in 1994-1995 and 2002, respectively). In each phase, the overall response rate was > 90%. Prevalence changes were calculated as the absolute difference between the prevalence recorded on the 2 occasions. RESULTS. The prevalence of wheeze (past 12 months) increased slightly among children (change: 0.8%; 95% confidence interval [CI]: 0.0% to 1.6%) and was rather stable among adolescents. Symptoms of allergic rhinitis (children: change: 5.2%; 95% CI: 4.0% to 6.4%; adolescents: change: 4.1%; 95% CI: 1.9% to 6.3%) and symptoms of atopic eczema ( children: change: 4.4%; 95% CI: 3.6% to 5.2%; adolescents: change: 2.1%; 95% CI: 1.2% to 3.0%) increased clearly in both age groups. There was some heterogeneity across the centers among adolescents, especially for allergic rhinitis, with larger increases seen in the 3 metropolitan areas. The changes observed paralleled profound family changes, ie, better parental education, higher rates of maternal employment, and lower rates of exposure to parental smoke. These factors, however, do not explain all of the observed changes in prevalence. CONCLUSIONS. The results indicate that the epidemiologic features of asthma and allergies in Italy are changing rapidly, although the causes are still uncertain.	Reg Hlth Agcy, Bologna, Italy; San Giovanni Battista Hosp, Ctr Canc Prevent, Canc Epidemiol Unit, Turin, Italy; Rome E Local Hlth Author, Dept Epidemiol, Rome, Italy; Univ Florence, Dept Stat, Florence, Italy; Local Hlth Author, Milan, Italy; Ctr Study & Prevent Canc, Florence, Italy; Empoli Local Hlth Author, Empoli, Italy; Provincial Hlth Author, Epidemiol Unit, Trento, Italy; Univ Siena, Inst Resp Dis, I-53100 Siena, Italy; Univ Milan, A Meyer Childrens Univ Hosp, Florence, Italy; CNR, Inst Clin Physiol, Pisa, Italy	Galassi, C (reprint author), AO San Giovanni Battista CPO Piemonte, Serv Epidemiol Tumori, Via Santena 7, I-10126 Turin, Italy.	claudia.galassi@cpo.it	Forastiere, Francesco/J-9067-2016; De sario, Manuela/K-1932-2016; Rusconi, Franca/K-2346-2016; Galassi, Claudia/K-3041-2016; Ciccone, Giovannino/K-3136-2016	Forastiere, Francesco/0000-0002-9162-5684; De sario, Manuela/0000-0002-1117-2735; Rusconi, Franca/0000-0002-9544-6472; Galassi, Claudia/0000-0003-1502-4390; Ciccone, Giovannino/0000-0001-7644-9574			Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; Anthracopoulos M, 2001, THORAX, V56, P569, DOI 10.1136/thorax.56.7.569; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Behrens T, 2004, PEDIATR ALLERGY IMMU, V15, P331, DOI 10.1111/j.1399-3038.2004.00157.x; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Chinn S, 2004, THORAX, V59, P646, DOI 10.1136/thx.2004.021642; Ciccone G, 1997, EUR RESPIR J, V10, P1780; Deeks J, 2001, SYSTEMATIC REV HLTH, P285, DOI 10.1002/9780470693926.ch15; Douwes J, 2002, INT J EPIDEMIOL, V31, P1098, DOI 10.1093/ije/31.6.1098; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Esamai F, 2002, East Afr Med J, V79, P514; Greenland S., 1998, MODERN EPIDEMIOLOGY, P643; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; International Study of Asthma and Allergy in Children (ISAAC), 2000, PHAS 3 MAN; *ISAAC, 1993, PHAS ON MAN; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261; Kwong GNM, 2001, THORAX, V56, P312, DOI 10.1136/thorax.56.4.312; Lee SL, 2004, PEDIATR ALLERGY IMMU, V15, P72, DOI 10.1046/j.0905-6157.2003.00109.x; Linneberg A, 2001, RESP MED, V95, P258, DOI 10.1053/rmed.2001.1031; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Renzoni E, 1999, EUR RESPIR J, V14, P597, DOI 10.1034/j.1399-3003.1999.14c19.x; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; Sunyer J, 2003, OCCUP ENVIRON MED, V60, DOI 10.1136/oem.60.8.e2; Toelle BG, 2004, BRIT MED J, V328, P386, DOI 10.1136/bmj.328.7436.386; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484	26	100	105	0	2	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JAN	2006	117	1					34	42		10.1542/peds.2004-2709		9	Pediatrics	Pediatrics	999QV	WOS:000234406100006	16396858	
J	Beggs, PJ; Bambrick, HJ				Beggs, PJ; Bambrick, HJ			Is the global rise of asthma an early impact of anthropogenic climate change?	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article							RAGWEED AMBROSIA-ARTEMISIIFOLIA; OUTDOOR AIR-POLLUTION; CHILDHOOD ASTHMA; ENVIRONMENTAL-FACTORS; PUBLIC-HEALTH; RESPIRATORY ALLERGY; COMMON RAGWEED; ATOPIC ECZEMA; PREVALENCE; POLLEN	The increase in asthma incidence, prevalence, and morbidity over recent decades presents a significant challenge to public health. Pollen is an important trigger of some types of asthma, and both pollen quantity and season depend on climatic and meteorologic variables. Over the same period as the global rise in asthma, there have been considerable increases in atmospheric carbon dioxide concentration and global average surface temperature. We hypothesize anthropogenic climate change as a plausible contributor to the rise in asthma. Greater concentrations of carbon dioxide and higher temperatures may increase pollen quantity and induce longer pollen seasons. Pollen allergenicity can also increase as a result of these changes in climate. Exposure in early life to a more allergenic environment may also provoke the development of other atopic conditions, such as eczema and allergic rhinitis. Although the etiology of asthma is complex, the recent global rise in asthma could be an early, health effect of anthropogenic climate change.	Macquarie Univ, Div Environm & Life Sci, Dept Phys Geog, Sydney, NSW 2109, Australia; Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia	Beggs, PJ (reprint author), Macquarie Univ, Div Environm & Life Sci, Dept Phys Geog, Sydney, NSW 2109, Australia.	paul.beggs@mq.edu.au					Ahlholm JU, 1998, CLIN EXP ALLERGY, V28, P1384; ALBRITTON L, 2001, SCI BASIS CONTRIBUTI, P21; Anderson HR, 2004, BRIT MED J, V328, P1052, DOI 10.1136/bmj.38057.583727.47; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Beggs PJ, 2004, CLIN EXP ALLERGY, V34, P1507, DOI 10.1111/j.1365-2222.2004.02061.x; BJORKSTEN F, 1981, ACTA MED SCAND, V209, P299; Burge HA, 2000, ENVIRON HEALTH PERSP, V108, P653, DOI 10.2307/3454401; Carlsen KCL, 2002, PEDIATR ALLERGY IMMU, V13, P29; Charpin D, 1999, CLIN EXP ALLERGY, V29, P1474; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Corden JM, 2001, AEROBIOLOGIA, V17, P127, DOI 10.1023/A:1010876917512; CURSON P, 1993, CLIMATIC CHANGE, V25, P405, DOI 10.1007/BF01098384; D'Amato G, 2001, RESP MED, V95, P606, DOI 10.1053/rmed.2001.1112; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Eder Waltraud, 2004, Curr Opin Allergy Clin Immunol, V4, P113, DOI 10.1097/00130832-200404000-00008; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Ellwood P, 2001, EUR RESPIR J, V17, P436, DOI 10.1183/09031936.01.17304360; Emberlin J, 2002, INT J BIOMETEOROL, V46, P159, DOI 10.1007/s00484-002-0139-x; Fitter AH, 2002, SCIENCE, V296, P1689, DOI 10.1126/science.1071617; Fleming DM, 2000, THORAX, V55, P657, DOI 10.1136/thorax.55.8.657; Foliaki S, 2004, INT J EPIDEMIOL, V33, P558, DOI 10.1093/ije/dyh031; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Grossman J, 1997, CHEST, V111, pS11, DOI 10.1378/chest.111.2_Supplement.11S; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; HJELMROOS M, 1995, INT ARCH ALLERGY IMM, V108, P368; HUYNEN M, 2003, HLTH GLOBAL ENV CH S, V1; IPCC-Intergovernmental Panel on Climate Change, 2001, CLIM CHANG 2001 IMP; Isolauri E, 2004, CLIN EXP ALLERGY, V34, P1007, DOI 10.1111/j.1365-2222.2004.01999.x; Kaiser HB, 2004, ALLERGY ASTHMA PROC, V25, P7; Kao CC, 2001, ASIAN PAC J ALLERGY, V19, P63; KEELING CD, 2003, ATMOSPHERIC CARBON D; Kerr RA, 2002, SCIENCE, V297, P497; LONGSTRETH J, 1991, ENVIRON HEALTH PERSP, V96, P139, DOI 10.2307/3431222; Menzel A, 1999, NATURE, V397, P659, DOI 10.1038/17709; Menzel A, 2000, INT J BIOMETEOROL, V44, P76, DOI 10.1007/s004840000054; Nolte H, 2001, ANN ALLERG ASTHMA IM, V87, P7; Patz JA, 2002, P NATL ACAD SCI USA, V99, P12506, DOI 10.1073/pnas.212467899; Pearce N, 2000, J Epidemiol Biostat, V5, P5; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Yool A., 2001, CLIMATE CHANGE 2001, P183; Rios JLM, 2004, ANN ALLERG ASTHMA IM, V92, P629; Robertson CF, 2004, MED J AUSTRALIA, V180, P273; Rodo X, 2002, P NATL ACAD SCI USA, V99, P12901, DOI 10.1073/pnas.182203999; Root TL, 2003, NATURE, V421, P57, DOI 10.1038/nature01333; Seaton A, 2000, PEDIATR ALLERGY IMMU, V11, P37, DOI 10.1034/j.1399-3038.2000.00509.x; SIGURS N, 1992, PEDIATRICS, V89, P735; SPIEKSMA FTM, 1995, GRANA, V34, P51; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; Strachan DP, 2000, THORAX S1, V55, pS2; Sunyer J, 1999, EUR RESPIR J, V14, P885, DOI 10.1034/j.1399-3003.1999.14d26.x; Ulrik CS, 2000, ANN ALLERG ASTHMA IM, V85, P293; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; von Mutius E, 1998, CLIN EXP ALLERGY, V28, P50; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Weinberg EG, 2000, J ALLERGY CLIN IMMUN, V105, P224, DOI 10.1016/S0091-6749(00)90069-1; World Health Organization, 2002, WORLD HLTH REP 2002; Wilkinson P., 2003, CLIMATE CHANGE HUMAN, P204; Woodward A, 2003, CLIMATE CHANGE HUMAN, P61; WULFF RD, 1985, OECOLOGIA, V66, P458, DOI 10.1007/BF00378315; Ziska LH, 2000, AUST J PLANT PHYSIOL, V27, P893, DOI 10.1071/PP00032; Ziska LH, 2003, J ALLERGY CLIN IMMUN, V111, P290, DOI 10.1067/mai.2003.53	66	100	101	1	15	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2005	113	8					915	919		10.1289/ehp.7724		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	951OV	WOS:000230941100025	16079058	
J	Galan, I; Tobias, A; Banegas, JR; Aranguez, E				Galan, I; Tobias, A; Banegas, JR; Aranguez, E			Short-term effects of air pollution on daily asthma emergency room admissions	EUROPEAN RESPIRATORY JOURNAL			English	Article						air pollution; asthma; emergency room admissions; pollen; time-series	HOSPITAL ADMISSIONS; ENVIRONMENTAL-FACTORS; CHILDHOOD ASTHMA; SULFUR-DIOXIDE; APHEA PROJECT; MEXICO-CITY; VISITS; ASSOCIATION; POLLUTANTS; MORTALITY	Many time-series studies have shown positive associations between air pollutants and asthma morbidity. However, few studies have included pollen as a potential confounder when examining this relationship. This study analysed the short-term association between air pollutants (sulphur dioxide (SO2), particles measured with a median aerodynamic diameter of <10 mum (PM10), nitrogen dioxide (NO2) and ozone (O-3)) and asthma emergency room admissions in Madrid, Spain, in 1995-1998, adjusting for four types of pollen with allergenic potential (Olea europaea, Plantago sp., Poaceae and Urticaceae). Data were analysed using autoregressive Poisson regression and generalised additive models (GAM). The strongest associations were observed at 1 day lag for O-3, and 3 days lag for the remaining pollutants. Using Poisson regression, a single-pollutant model showed that a 10-mug-m(-3) rise in pollutant level led to relative risks of: 1.039 for PM10; 1.029 for SO2; 1.033 for NO2; and 1.045 for O-3. Adjustment for the different types of pollen led to no substantial variation in these associations. In the multipollutant models for cold-season pollutants (including PM10, SO2 and the four types of pollen) and photochemical pollutants (including NO2, O-3 and the four types of pollen) the associations for PM10, NO2 and O-3 held, but no relationship with SO2 was evident. GAM analysis yielded the same results, both in terms of lags and of quantification of the effect for all pollutants. In conclusion, the usual air pollution levels in Madrid were associated with an increase in asthma emergency room admissions, and this association remained controlling for the presence of ambient pollen.	Univ Carlos III Madrid, Dept Stat & Econometr, E-28903 Getafe, Spain; Inst Publ Hlth, Dept Epidemiol, Madrid, Spain; Univ Autonoma Madrid, Dept Prevent Med & Publ Hlth, Madrid, Spain	Tobias, A (reprint author), Univ Carlos III Madrid, Dept Stat & Econometr, C Madrid 126, E-28903 Getafe, Spain.		Galan, Ignacio/P-6451-2015; Osborne, Nicholas/N-4915-2015	Galan, Ignacio/0000-0003-0624-9993; Osborne, Nicholas/0000-0002-6700-2284			AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Anderson HR, 1998, THORAX, V53, P842; Atkinson RW, 1999, EUR RESPIR J, V13, P257, DOI 10.1183/09031936.99.13225799; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Atkinson RW, 1999, ARCH ENVIRON HEALTH, V54, P398; Ballester Diez F, 1999, Rev Esp Salud Publica, V73, P165, DOI 10.1590/S1135-57271999000200006; BATES DV, 1990, ENVIRON RES, V51, P51, DOI 10.1016/S0013-9351(05)80182-3; Brunekreef B, 2000, LANCET, V355, P1517, DOI 10.1016/S0140-6736(00)02168-1; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Casillas AM, 1999, ANN ALLERG ASTHMA IM, V83, P624, DOI 10.1016/S1081-1206(10)62884-0; CASTELLSAGUE J, 1995, THORAX, V50, P1051, DOI 10.1136/thx.50.10.1051; Chen L, 2001, Rev Environ Health, V16, P133; CODY RP, 1992, ENVIRON RES, V58, P184, DOI 10.1016/S0013-9351(05)80214-2; DEVALIA JL, 1998, EUR RESPIR REV, V8, P175; *DIR GEN SAL PUBL, 2000, B EPIDEMIOLOGICO COM, V12, P33; Dominici F, 2002, AM J EPIDEMIOL, V156, P193, DOI 10.1093/aje/kwf062; Fauroux B, 2000, PEDIATR PULM, V30, P41; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; Hagen JA, 2000, EPIDEMIOLOGY, V11, P136, DOI 10.1097/00001648-200003000-00009; Hastie T, 1990, GEN ADDITIVE MODELS; Higgins BG, 2000, EUR RESPIR J, V16, P61, DOI 10.1034/j.1399-3003.2000.16a11.x; ISHIZAKI T, 1987, ANN ALLERGY, V58, P265; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Jonasson G, 2000, ALLERGY, V55, P232, DOI 10.1034/j.1398-9995.2000.00387.x; Katsouyanni K, 2002, EPIDEMIOLOGY, V13, P742, DOI 10.1097/01.EDE.0000032424.22670.3E; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; Linneberg A, 2001, RESP MED, V95, P258, DOI 10.1053/rmed.2001.1031; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; MAGNUSSEN H, 1998, EUR RESPIR REV, V8, P141; Polosa R, 1999, Can Respir J, V6, P436; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samoli E, 2001, ENVIRON HEALTH PERSP, V109, P349, DOI 10.2307/3454893; SANDSTROM T, 1998, EUR RESPIR REV, V8, P168; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ JB, 1996, PDA J PHARM SCI TECH, V50, P1; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; SUBIZA J, 1995, J ALLERGY CLIN IMMUN, V96, P15, DOI 10.1016/S0091-6749(95)70028-5; Sunyer J, 1997, THORAX, V52, P760; SUNYER J, 1998, EUR RESPIR REV, V8, P139; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Tenias JM, 1998, OCCUP ENVIRON MED, V55, P541; THIBAUT G, 1991, AUDIT DEVALUATION RE; Thompson AJ, 2001, ARCH ENVIRON HEALTH, V56, P234; Tunnicliffe WS, 2001, EUR RESPIR J, V17, P604, DOI 10.1183/09031936.01.17406040; WALTERS S, 1994, THORAX, V49, P133, DOI 10.1136/thx.49.2.133; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x; Yang W, 1997, INHAL TOXICOL, V9, P15, DOI 10.1080/089583797198385	52	100	102	2	9	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	NOV	2003	22	5					802	808		10.1183/09031936.03.00013003		7	Respiratory System	Respiratory System	739UE	WOS:000186364200017	14621088	
J	Linneberg, A; Ostergaard, C; Tvede, M; Andersen, LP; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T				Linneberg, A; Ostergaard, C; Tvede, M; Andersen, LP; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T			IgG antibodies against microorganisms and atopic disease in Danish adults: The Copenhagen Allergy Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergic rhinitis; atopy; Campylobacter jejuni; Clostridium difficile; Helicobacter pylori; hepatitis A virus; respiratory hypersensitivity; Toxoplasma gondii	HEPATITIS-A; INTESTINAL MICROFLORA; HELICOBACTER-PYLORI; HYGIENE HYPOTHESIS; HAY-FEVER; PREVALENCE; INFECTION; ASTHMA; POPULATION; INFANTS	Background: Seropositivity to food-borne and orofecal microorganisms (hepatitis A virus, Helicobacter pylori, and Toxoplasma gondii), which are considered to be markers of poor hygiene, has been reported to be associated with a lower prevalence of atopy. In contrast, colonization of the gut with Clostridium difficile, a potential intestinal bacterial pathogen, in early childhood may be associated with a higher prevalence of atopy. Objective: The objective of this study was to investigate the association between atopy and exposure to 2 groups of food-borne and orofecal microorganisms: (1) markers of a poor hygiene and (2) intestinal bacterial pathogens. Methods: A cross-sectional population-based study of 15- to 69-year-olds living in Copenhagen, Denmark, was carried out in 1990 to 1991. Atopy was defined as a positive test result for specific IgE to at least 1 of 6 inhalant allergens. Exposure to microorganisms was assessed as IgG seropositivity to microorganisms. Results: Seropositivity to 2 or 3 markers of poor hygiene (hepatitis A virus, H pylori, and T gondii) was associated with a lower prevalence of atopy (adjusted odds ratio, 0.5; 95% CI, 0.3 to 0.8). In contrast, seropositivity to 2 or 3 intestinal bacterial pathogens (C difficile, Campylobacter jejuni, and Yersinia enterocolitica) was associated with a higher prevalence of atopy (adjusted odds ratio, 1.7; 95% Cl, 1.2 to 2.6). Conclusion: Exposure to markers of poor hygiene was associated with a lower prevalence of atopy, whereas exposure to intestinal bacterial pathogens was associated with a higher prevalence of atopy. These findings raise the hypothesis that different groups of food-borne and orofecal microorganisms may have different effects on the risk of atopy.	Glostrup Univ Hosp, Ctr Prevent Med, DK-2600 Glostrup, Denmark; Statens Serum Inst, Dept Res & Dev, DK-2300 Copenhagen, Denmark; Natl Univ Hosp, Dept Clin Microbiol, Rigshosp, Copenhagen, Denmark; Gentofte Univ Hosp, Dept Dermatol, Copenhagen, Denmark; Frederiksberg Univ Hosp, Dept Internal Med B, DK-2000 Copenhagen, Denmark; Gentofte Univ Hosp, Dept Resp Med Y, Copenhagen, Denmark	Linneberg, A (reprint author), Glostrup Univ Hosp, Ctr Prevent Med, 57 Ndr Ringvej,Entrance 8,7th Floor, DK-2600 Glostrup, Denmark.			Jorgensen, Torben/0000-0001-9453-2830; Linneberg, Allan/0000-0002-0994-0184			ANDERSEN LP, 1991, P 5 INT WORKSH CAMP; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bodner C, 2000, THORAX, V55, P383, DOI 10.1136/thorax.55.5.383; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; BRIEM H, 1991, SCAND J INFECT DIS, V23, P135, DOI 10.3109/00365549109023390; CLAYTON D, 1993, STAT MODELS EPIDEMIO, P252; Crane J, 2002, ALLERGY, V57, P663, DOI 10.1034/j.1398-9995.2002.25004.x; FORSGREN M, 1991, LANCET, V337, P1413, DOI 10.1016/0140-6736(91)93095-Q; Gdalevich M, 1998, EPIDEMIOL INFECT, V121, P477, DOI 10.1017/S0950268898001198; JOHANSEN HK, 1995, CLIN DIAGN LAB IMMUN, V2, P149; Joussemet M, 1999, GASTROEN CLIN BIOL, V23, P447; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; Karmaus W, 2001, AM J EPIDEMIOL, V154, P909, DOI 10.1093/aje/154.10.909; Klingler PJ, 2000, DIGEST DIS, V18, P147, DOI 10.1159/000051388; Kosunen TU, 2002, CLIN EXP ALLERGY, V32, P373, DOI 10.1046/j.1365-2222.2002.01330.x; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1999, LANCET, V354, P430, DOI 10.1016/S0140-6736(05)75853-0; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; NIELSEN NH, 1993, ALLERGY, V48, P319, DOI 10.1111/j.1398-9995.1993.tb02400.x; NOGUCHI A, 1991, J INFECTION, V23, P255, DOI 10.1016/0163-4453(91)92828-S; PEREZTRALLERO E, 1994, SCAND J INFECT DIS, V26, P133, DOI 10.3109/00365549409011775; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, THORAX S1, V55, pS2; Strid MA, 2001, CLIN DIAGN LAB IMMUN, V8, P314, DOI 10.1128/CDLI.8.2.314-319.2001; WALKER J, 1992, EPIDEMIOL INFECT, V108, P99; Wold AE, 1998, ALLERGY, V53, P20	34	100	101	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2003	111	4					847	853		10.1067/mai.2003.1335		7	Allergy; Immunology	Allergy; Immunology	667WW	WOS:000182258500028	12704368	
J	Burke, W; Fesinmeyer, M; Reed, K; Hampson, L; Carlsten, C				Burke, W; Fesinmeyer, M; Reed, K; Hampson, L; Carlsten, C			Family history as a predictor of asthma risk	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							PRIMARY-SCHOOL CHILDREN; CHILDHOOD ASTHMA; ALLERGIC DISEASES; AIRWAY HYPERRESPONSIVENESS; BRONCHIAL-ASTHMA; PARENTAL SMOKING; YOUNG-CHILDREN; PREVALENCE; SYMPTOMS; ATOPY	Background: Asthma, one of the most important chronic diseases of children, disproportionately affects minority and low-income children. Many environmental risk factors for asthma have been identified, including animal, mite, and other allergens; cigarette smoke; and air pollutants. Genetics also play an important causative role, as indicated by familial aggregation and the identification of candidate genes and chromosomal regions linked to asthma risk. Using a positive family history of asthma to identify children at increased risk could provide a basis for targeted prevention efforts, aimed at reducing exposure to environmental risk factors. Methods: To assess the predictive value of family history as an indicator of risk for childhood asthma, we reviewed population-based studies that evaluated family history of asthma and atopic disease in children with asthma. Results: Our search identified 33 studies from all geographic regions of the world for review. The studies varied in definitions of positive family history and asthma phenotype and used study populations with asthma prevalence ranging from 2% to 26%. Nevertheless, family history of asthma in one or more first-degree relatives was consistently identified as a risk factor for asthma. In ten studies, sensitivity and predictive value of a positive family history of asthma could be calculated: sensitivity ranged from 4% to 43%, positive predictive value from 11% to 37%, and negative predictive value from 86% to 97%. Conclusion: Although a positive family history predicts an increased risk of asthma, it identifies a minority of children at risk. Positive family history may have utility in targeting some individual prevention efforts, but the low positive predictive value limits its value as a means to direct environmental remediation efforts.	Univ Washington, Dept Med Hist & Eth, Seattle, WA 98195 USA; Univ Washington, Inst Publ Hlth Genet, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Burke, W (reprint author), Univ Washington, Dept Med Hist & Eth, Box 357120,1959 NE Pacific, Seattle, WA 98195 USA.			Hampson, Lindsay/0000-0002-0740-7984	NIEHS NIH HHS [P3 ES 07033]; ODCDC CDC HHS [U36/CCU 300430-20]		ABDULRAZZAQ YM, 1994, ALLERGY, V49, P737, DOI 10.1111/j.1398-9995.1994.tb02096.x; Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; Abuekteish F, 1996, ANN TROP PAEDIATR, V16, P227; Agabiti N, 1999, EPIDEMIOLOGY, V10, P692, DOI 10.1097/00001648-199911000-00008; Akcakaya N, 2000, EUR J EPIDEMIOL, V16, P693, DOI 10.1023/A:1026593509093; ALFRAYH AR, 1990, J ROY SOC HEALTH, V110, P98, DOI 10.1177/146642409011000309; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beckett WS, 1996, AM J RESP CRIT CARE, V154, P894; Belousova EG, 1999, AUST NZ J MED, V29, P794, DOI 10.1111/j.1445-5994.1999.tb00782.x; Bener A., 1993, Indian Journal of Pediatrics, V60, P791, DOI 10.1007/BF02751050; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Centers for Disease Control and Prevention (CDC), 1996, JAMA-J AM MED ASSOC, V275, P1535; *CDCP, 2002, AIR POLL RESP HLTH A; Celedon JC, 2001, CHEST, V120, P785, DOI 10.1378/chest.120.3.785; Chhabra SK, 1998, J ASTHMA, V35, P291, DOI 10.3109/02770909809068220; Chhabra SK, 1999, ANN ALLERG ASTHMA IM, V83, P385, DOI 10.1016/S1081-1206(10)62835-9; Csonka P, 2000, PEDIATR ALLERGY IMMU, V11, P225, DOI 10.1034/j.1399-3038.2000.00088.x; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; FRISCHER T, 1993, EUR J PEDIATR, V152, P771, DOI 10.1007/BF01954000; Grant EN, 1999, ANN ALLERG ASTHMA IM, V83, P113, DOI 10.1016/S1081-1206(10)62621-X; Gray L, 2000, CLIN EXP ALLERGY, V30, P393; GUSTAFSSON D, 1992, ARCH DIS CHILD, V67, P1008; Heinzmann A, 2001, Curr Opin Allergy Clin Immunol, V1, P387, DOI 10.1097/00130832-200110000-00002; HENDERSON FW, 1995, AM J RESP CRIT CARE, V151, P1786; Host A, 2000, ALLERGY, V55, P600, DOI 10.1034/j.1398-9995.2000.00122.x; Jenkins M A, 1993, Paediatr Perinat Epidemiol, V7, P67, DOI 10.1111/j.1365-3016.1993.tb00602.x; Kalyoncu AF, 1999, PEDIATR ALLERGY IMMU, V10, P261; Karunasekera KAW, 2001, J TROP PEDIATRICS, V47, P142, DOI 10.1093/tropej/47.3.142; Kelly YJ, 1996, ARCH DIS CHILD, V75, P489; Lanphear BP, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.6.e98; Lara M, 2002, PEDIATRICS, V109, P919, DOI 10.1542/peds.109.5.919; LESON S, 1995, J ASTHMA, V32, P285, DOI 10.3109/02770909509044836; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; London SJ, 2001, EPIDEMIOLOGY, V12, P577, DOI 10.1097/00001648-200109000-00019; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; Maier WC, 1997, ENVIRON HEALTH PERSP, V105, P208, DOI 10.1289/ehp.97105208; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsuoka S, 1999, PEDIATR INT, V41, P46, DOI 10.1046/j.1442-200x.1999.01011.x; Mattes J, 1998, CLIN EXP ALLERGY, V28, P1480; Montefort S, 1998, CLIN EXP ALLERGY, V28, P1089; Ng'ang'a LW, 1998, THORAX, V53, P919; Nilsson L, 1999, ALLERGY, V54, P716, DOI 10.1034/j.1398-9995.1999.00896.x; Norrman E, 1998, ALLERGY, V53, P28, DOI 10.1111/j.1398-9995.1998.tb03770.x; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; Ones U, 1997, ALLERGY, V52, P570, DOI 10.1111/j.1398-9995.1997.tb02602.x; Patino CM, 2001, ALLERGY, V56, P279, DOI 10.1034/j.1398-9995.2001.00135.x; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ronchetti R, 2001, EUR RESPIR J, V17, P881, DOI 10.1183/09031936.01.17508810; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; ROUX P, 1993, S AFR MED J, V83, P177; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; Saraclar Y, 1998, RESP MED, V92, P203, DOI 10.1016/S0954-6111(98)90096-8; Sears MR, 1996, ARCH DIS CHILD, V75, P392; Selcuk ZT, 1997, CLIN EXP ALLERGY, V27, P262, DOI 10.1111/j.1365-2222.1997.tb00704.x; Shapiro GG, 2002, PEDIATR PULM, V33, P47, DOI 10.1002/ppul.10029; SHAW R, 1994, NEW ZEAL MED J, V107, P387; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83; Siersted HC, 1998, BRIT MED J, V316, P651; Takemura Y, 2001, AM J EPIDEMIOL, V154, P115, DOI 10.1093/aje/154.2.115; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV; Von Mutius E., 2000, ARCH DIS CHILD, V82, pii2; Wang TN, 2001, J ASTHMA, V38, P485; Wickens K, 2001, AUST NZ J PUBL HEAL, V25, P44, DOI 10.1111/j.1467-842X.2001.tb00549.x; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352; Wolf RL, 1999, CHEST, V116, p224S, DOI 10.1378/chest.116.suppl_2.224S	67	100	107	1	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797			AM J PREV MED	Am. J. Prev. Med.	FEB	2003	24	2					160	169		10.1016/S0749-3797(02)00589-5		10	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	643BV	WOS:000180842800007	12568822	
J	Paredi, P; Kharitonov, SA; Barnes, PJ				Paredi, P; Kharitonov, SA; Barnes, PJ			Analysis of expired air for oxidation products	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	17th Transatlantic Airway Conference on Oxidants and Antioxdants	2002	LUZERN, SWITZERLAND	Boehringer Ingelheim Co		oxidative stress; noninvasive assessment	EXHALED CARBON-MONOXIDE; OBSTRUCTIVE PULMONARY-DISEASE; SMOOTH-MUSCLE CELLS; MESSENGER-RNA EXPRESSION; NITRIC-OXIDE; CYSTIC-FIBROSIS; LIPID-PEROXIDATION; ASTHMATIC-PATIENTS; HEME OXYGENASE-1; BREATH CONDENSATE	Chronic inflammation is a critical feature of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. This inflammation is associated with the increased production of reactive oxygen species or oxidative stress in the lungs. Oxidative stress may have several adverse effects and may amplify the inflammatory process; however, monitoring oxidative stress is difficult and may not be reflected by changes in blood markers. We have therefore developed several noninvasive markers in the exhaled breath that may indicate oxidative stress in the lungs, and we studied these in relationship to the severity of chronic inflammatory lung diseases. We analyzed the exhaled breath for the content of nitric oxide as a marker of inflammation, carbon monoxide as a marker of oxidative stress, and ethane, which is one of the end products of lipid peroxidation. In addition, we measured the concentration of markers of oxidative stress such as isoprostanes in exhaled breath condensate. Our results confirm that there are increased inflammation, oxidative stress, and lipid peroxidation in lung disease, as shown by elevated levels of nitric oxide, carbon monoxide, and ethane, respectively. The finding of lower levels of these gases in patients on steroid treatment and of higher levels in those with more severe lung disease, as assessed by lung function tests and clinical symptoms, reinforces the hypothesis that the noninvasive measurement of exhaled gases maybe useful in monitoring the underlying pathologic pathways of lung disease. Longitudinal studies are required to assess the clinical usefulness of these measurements in the monitoring of chronic inflammatory lung disease.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.						ALVING K, 1993, EUR RESPIR J, V6, P1368; Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; Antuni JD, 2000, THORAX, V55, P138, DOI 10.1136/thorax.55.2.138; AULIK I. V., 1966, BYUL EKSP BIOL MED, V62, P115; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; Brown RK, 1996, EUR RESPIR J, V9, P334, DOI 10.1183/09031936.96.09020334; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689; CHIARA O, 1991, CRIT CARE MED, V19, P260, DOI 10.1097/00003246-199102000-00023; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9; Durante W, 1997, CIRC RES, V80, P557; Grasemann H, 1998, ARCH DIS CHILD, V78, P49; Habib MP, 1999, CHEST, V115, P684, DOI 10.1378/chest.115.3.684; Hanazawa T, 2000, AM J RESP CRIT CARE, V162, P1273; Hecht SS, 1997, P SOC EXP BIOL MED, V216, P181; Horvath I, 1998, THORAX, V53, P668; Inoue H, 1999, LUNG, V177, P53, DOI 10.1007/PL00007627; Jones KL, 1998, AM J PHYSIOL-LUNG C, V275, pL1120; Katsuyama K, 1999, ENDOCRINOLOGY, V140, P2183, DOI 10.1210/en.140.5.2183; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Kelley TJ, 1998, J CLIN INVEST, V102, P1200, DOI 10.1172/JCI2357; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; Kharitonov SA, 2001, AM J RESP CRIT CARE, V163, P1693; King RC, 1998, ANN THORAC SURG, V66, P1732, DOI 10.1016/S0003-4975(98)00991-6; KNEEPKENS CMF, 1994, FREE RADICAL BIO MED, V17, P127; KOUNO T, 1994, JPN J PHARMACOL, V64, P163, DOI 10.1254/jjp.64.163; Marumo T, 1998, HYPERTENSION, V32, P1083; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; Meagher LC, 1996, J IMMUNOL, V156, P4422; Montuschi P, 1999, AM J RESP CRIT CARE, V160, P216; NATHAN C, 1994, J BIOL CHEM, V269, P13725; Olivenstein R, 1999, J ALLERGY CLIN IMMUN, V103, P238, DOI 10.1016/S0091-6749(99)70497-5; Olopade CO, 1997, CHEST, V111, P862, DOI 10.1378/chest.111.4.862; ONORATO DJ, 1994, AM J RESP CRIT CARE, V149, P1132; Paredi P, 2000, AM J RESP CRIT CARE, V161, P1247; Paredi P, 2000, AM J RESP CRIT CARE, V162, P1450; Paredi P, 2000, AM J RESP CRIT CARE, V162, P369; Paredi P, 1999, CHEST, V115, P1352, DOI 10.1378/chest.115.5.1352; Paredi P, 1998, THORAX, V53, P775; Paredi P, 1999, EUR RESPIR J, V13, P48, DOI 10.1183/09031936.99.13104899; Paredi P, 2002, AM J RESP CRIT CARE, V165, P181; Paredi P, 1999, THORAX, V54, P917; PAREDI P, 2001, AM J RESP CRIT CARE, V165, P181; Piacentini GL, 2002, EUR RESPIR J, V20, P108, DOI 10.1183/09031936.02.00237702; Repine JE, 1997, AM J RESP CRIT CARE, V156, P341; Salvato G, 2001, THORAX, V56, P902, DOI 10.1136/thorax.56.12.902; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; WILMOTT RW, 1990, AM REV RESPIR DIS, V142, P365; Yamara M, 1999, EUR RESPIR J, V13, P757, DOI 10.1034/j.1399-3003.1999.13d10.x; ZARLING EJ, 1987, CLIN CHEM, V33, P140; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140	51	100	102	1	10	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2002	166	12		S			S31	S37		10.1164/rccm.2206012		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	625DT	WOS:000179802200007	12471086	
J	Hoffjan, S; Ober, C				Hoffjan, S; Ober, C			Present status on the genetic studies of asthma	CURRENT OPINION IN IMMUNOLOGY			English	Review							RECEPTOR-ALPHA-CHAIN; QUANTITATIVE-TRAIT LOCI; SERUM IGE LEVELS; GENOME-WIDE SEARCH; INTERLEUKIN-4 RECEPTOR; ATOPIC ASTHMA; IL-4 RECEPTOR; CODING REGION; AIRWAY HYPERRESPONSIVENESS; PROMOTER POLYMORPHISMS	Asthma, one of the most common chronic diseases, is a complex and heterogeneous disorder. The results of genome screens for asthma-related traits in 11 different populations identified at least 18 regions of the genome that probably house asthma/atopy genes. The most consistently replicated regions are on chromosomes 2% 5q, 6p, 12q and 13q. Positional cloning projects are ongoing in laboratories around the world to identify the asthma susceptibility loci in these regions. In addition, many candidate genes have been associated with asthma phenotypes, such as the genes in the IL-4/IL-13 pathway.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA	Hoffjan, S (reprint author), Univ Chicago, Dept Human Genet, 920 E 58th St, Chicago, IL 60637 USA.						Ahmed S, 2000, EXP CLIN IMMUNOGENET, V17, P18, DOI 10.1159/000019120; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barnes KC, 2000, ALLERGY, V55, P803, DOI 10.1034/j.1398-9995.2000.00123.x; Barnes KC, 1999, CLIN EXP ALLERGY, V29, P47; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Borish LC, 2001, J ALLERGY CLIN IMMUN, V107, P963, DOI 10.1067/mai.2001.115624; Burchard EG, 1999, AM J RESP CRIT CARE, V160, P919; Celedon JC, 2002, CLIN EXP ALLERGY, V32, P387, DOI 10.1046/j.1365-2222.2002.01348.x; COLLILA S, 2001, AM J HUM GENET S, V69, P213; Cookson W, 1999, NATURE, V402, pB5; Cookson WOC, 2002, CHEST, V121, p7S, DOI 10.1378/chest.121.3_suppl.7S-a; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118; Deichmann K, 1997, BIOCHEM BIOPH RES CO, V231, P696, DOI 10.1006/bbrc.1997.6115; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812; Dizier MH, 1999, GENET EPIDEMIOL, V16, P84, DOI 10.1002/(SICI)1098-2272(1999)16:1<84::AID-GEPI7>3.0.CO;2-D; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Elliott K, 2001, J ALLERGY CLIN IMMUN, V108, P285, DOI 10.1067/mai.2001.117180; Ewart SL, 2000, AM J RESP CELL MOL, V23, P537; Gao PS, 2000, J MED GENET, V37, P380; Graves PE, 2000, J ALLERGY CLIN IMMUN, V105, P506, DOI 10.1067/mai.2000.104940; Grimbacher B, 1998, NEW ENGL J MED, V338, P1073; Haagerup A, 2001, EUR J HUM GENET, V9, P945, DOI 10.1038/sj.ejhg.5200753; Haagerup A, 2001, ALLERGY, V56, P775, DOI 10.1034/j.1398-9995.2001.056008775.x; Hackstein H, 2001, IMMUNOGENETICS, V53, P264, DOI 10.1007/s002510100324; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; Hakonarson H, 2001, CURR OPIN PEDIATR, V13, P267, DOI 10.1097/00008480-200106000-00010; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hijazi Z, 2000, INT ARCH ALLERGY IMM, V122, P190, DOI 10.1159/000024396; Holberg CJ, 2001, J ALLERGY CLIN IMMUN, V108, P772, DOI 10.1067/mai.2001.119158; Horikawa Y, 2000, NAT GENET, V26, P163; Howard TD, 2001, AM J RESP CELL MOL, V25, P377; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Izuhara K, 2000, J ALLERGY CLIN IMMUN, V106, pS65; Jung T, 1999, EUR J IMMUNOL, V29, P864, DOI 10.1002/(SICI)1521-4141(199903)29:03<864::AID-IMMU864>3.0.CO;2-T; Koppelman GH, 2002, J ALLERGY CLIN IMMUN, V109, P498, DOI 10.1067/mai.2002.122235; Kraan TCTMV, 1999, GENES IMMUN, V1, P61; Kruse S, 1999, IMMUNOLOGY, V96, P365; Laitinen T, 2001, NAT GENET, V28, P87, DOI 10.1038/ng0501-87; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Leung TF, 2001, CLIN EXP ALLERGY, V31, P1515, DOI 10.1046/j.1365-2222.2001.01212.x; Liu X, 2000, J ALLERGY CLIN IMMUN, V106, P167; Loots GG, 2000, SCIENCE, V288, P136, DOI 10.1126/science.288.5463.136; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Mathias RA, 2001, GENET EPIDEMIOL, V20, P340, DOI 10.1002/gepi.5; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; Mitsuyasu H, 1999, J IMMUNOL, V162, P1227; MOFFAT MF, 2002, AM J RESP CRIT CARE, V165, pA808; Mohrs M, 2001, NAT IMMUNOL, V2, P842, DOI 10.1038/ni0901-842; Noguchi E, 2001, HUM IMMUNOL, V62, P1251, DOI 10.1016/S0198-8859(01)00338-X; Nolte H, 2001, ANN ALLERG ASTHMA IM, V87, P7; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Ober C, 2000, CLIN CHEST MED, V21, P245, DOI 10.1016/S0272-5231(05)70264-1; Oiso N, 2000, BRIT J DERMATOL, V142, P1003, DOI 10.1046/j.1365-2133.2000.03485.x; Patuzzo C, 2000, J MED GENET, V37, P382, DOI 10.1136/jmg.37.5.382; Punnonen J, 1997, J ALLERGY CLIN IMMUN, V100, P792, DOI 10.1016/S0091-6749(97)70276-8; ROSENWASSER LJ, 1995, CLIN EXP ALLERGY, V25, P74, DOI 10.1111/j.1365-2222.1995.tb00428.x; Sandford AJ, 2000, J ALLERGY CLIN IMMUN, V106, P135; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shirakawa T, 2000, IMMUNOL TODAY, V21, P60, DOI 10.1016/S0167-5699(99)01492-9; Suzuki I, 2000, CLIN EXP ALLERGY, V30, P1746, DOI 10.1046/j.1365-2222.2000.00983.x; Symula DJ, 1999, NAT GENET, V23, P241; Takabayashi A, 2000, EXP CLIN IMMUNOGENET, V17, P63, DOI 10.1159/000019125; Tamura K, 2001, CLIN EXP ALLERGY, V31, P1509, DOI 10.1046/j.1365-2222.2001.01191.x; Tanaka K, 2001, CLIN EXP ALLERGY, V31, P1522, DOI 10.1046/j.1365-2222.2001.01205.x; Tekkanat KK, 2001, J IMMUNOL, V166, P3542; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Walley AJ, 2001, GENOMICS, V72, P15, DOI 10.1006/geno.2000.6435; Wang HY, 1999, J IMMUNOL, V162, P4385; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wjst M, 1998, BIOINFORMATICS, V14, P827, DOI 10.1093/bioinformatics/14.9.827; Wu X, 2001, GENES IMMUN, V2, P128, DOI 10.1038/sj.gene.6363746; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Xu X, 2001, AM J HUM GENET, V69, P1271, DOI 10.1086/324650; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Yokouchi Y, 2002, GENES IMMUN, V3, P9, DOI 10.1038/sj/gene/6363815; Zhang YM, 1999, HUM MOL GENET, V8, P601, DOI 10.1093/hmg/8.4.601; Zhu SK, 2000, AM J RESP CRIT CARE, V161, P1655	83	100	104	1	1	CURRENT BIOLOGY LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0952-7915			CURR OPIN IMMUNOL	Curr. Opin. Immunol.	DEC	2002	14	6					709	717		10.1016/S0952-7915(02)00393-X		9	Immunology	Immunology	607VZ	WOS:000178812600006	12413520	
J	Comhair, SAA; Bhathena, PR; Farver, C; Thunnissen, FBJM; Erzurum, SC				Comhair, SAA; Bhathena, PR; Farver, C; Thunnissen, FBJM; Erzurum, SC			Extracellular glutathione peroxidase induction in asthmatic lungs: evidence for redox regulation of expression in human airway epithelial cells	FASEB JOURNAL			English	Article						reactive oxygen species; asthma; lung; nitrotyrosine	NITRIC-OXIDE SYNTHASE; PLASMA GLUTATHIONE; SUPEROXIDE-DISMUTASE; EXHALED AIR; GENE; ANTIOXIDANT; OXIDATION; PEROXYNITRITE; INFLAMMATION; SEQUENCE	A critical first-line antioxidant defense on the airway epithelial surface against reactive oxygen and nitrogen species (ROS and RNS) is extracellular glutathione peroxidase (eGPx). Little is known about the regulation of eGPx or its role in ROS-mediated lung diseases such as asthma. Here we show that eGPx is increased in the asthmatic airway in comparison to healthy controls. Higher levels of eGPx mRNA in asthmatic airway epithelium verified bronchial epithelial cells as the source for the increased eGPx, The eGPx mRNA in bronchial epithelial cells in vitro increased eightfold after exposure to ROS and glutathione, an essential cofactor for eGPx activity. Alterations in intracellular and extracellular oxidized and reduced glutathione were temporally associated with eGPx induction, further supporting redox mechanisms in gene expression, Overexpression of superoxide dismutase, but not catalase, inhibited induction and identified superoxide as a key intermediary. The eGPx mRNA half-life was not affected by ROS, suggesting a transcriptional mechanism for eGPx regulation. Fusion genes of deletion fragments of the eGPx gene 5' flanking region driving a reporter gene conclusively identified the ROS-responsive region, which contained the consensus DNA binding site for the redox-regulated transcription factor, activator protein 1.	Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Lerner Res Inst, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Lerner Res Inst, Cleveland, OH 44195 USA; Canisius Wilhelmina Hosp, Dept Pathol, NL-6500 GS Nijmegen, Netherlands	Erzurum, SC (reprint author), Cleveland Clin Fdn, Dept Pulm & Crit Care Med, Lerner Res Inst, 9500 Euclid Ave,A90, Cleveland, OH 44195 USA.				NHLBI NIH HHS [HL 60917]		ADAMS JD, 1983, J PHARMACOL EXP THER, V227, P749; Arteel GE, 1999, FEBS LETT, V445, P226, DOI 10.1016/S0014-5793(99)00073-3; ASAHI M, 1995, J BIOL CHEM, V270, P21035; Asahi M, 1997, J BIOL CHEM, V272, P19152, DOI 10.1074/jbc.272.31.19152; Avissar N, 1996, AM J PHYSIOL-LUNG C, V270, pL173; AVISSAR N, 1991, J NUTR, V121, P1243; AVISSAR N, 1994, AM J PHYSIOL, V266, pC367; CALHOUN WJ, 1992, AM REV RESPIR DIS, V145, P317; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152; Cheng WH, 1999, FASEB J, V13, P1467; CHU FF, 1992, BLOOD, V79, P3233; Comhair SAA, 1999, AM J RESP CRIT CARE, V159, P1824; Comhair SAA, 2000, LANCET, V355, P624, DOI 10.1016/S0140-6736(99)04736-4; COMHAIR SAA, 2000, RESP CELL MOL BIOL, V23, P350; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; Deneke S.M., 1989, AM J PHYSIOL, V257, P163; DeRaeve HR, 1997, AM J PHYSIOL-LUNG C, V272, pL148; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hou YC, 1996, BIOCHEM BIOPH RES CO, V228, P88, DOI 10.1006/bbrc.1996.1620; HOWIE AF, 1995, BIOCHEM J, V308, P713; Jobsis Q, 1997, EUR RESPIR J, V10, P519; Kaminsky DA, 1999, J ALLERGY CLIN IMMUN, V104, P747; KANAZAWA H, 1991, CHEST, V100, P1319, DOI 10.1378/chest.100.5.1319; KELLY FJ, 1999, LANCET, V354, P9177; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kingsley PD, 1998, MOL REPROD DEV, V49, P343, DOI 10.1002/(SICI)1098-2795(199804)49:4<343::AID-MRD1>3.0.CO;2-N; Klatt P, 1999, FASEB J, V13, P1481; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MARKLUND S, 1974, EUR J BIOCHEM, V47, P469, DOI 10.1111/j.1432-1033.1974.tb03714.x; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; Misso NLA, 2000, FREE RADICAL BIO MED, V28, P934, DOI 10.1016/S0891-5849(00)00177-5; *NAT ASTHM ED PREV, 1997, PUBL NAT ASTHM ED PR, V97, P7809; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286; Pinkus R, 1996, J BIOL CHEM, V271, P13422; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; Ren B, 1997, J MOL BIOL, V268, P869, DOI 10.1006/jmbi.1997.1005; Saleh D, 1998, FASEB J, V12, P929; Sen CK, 1996, FASEB J, V10, P709; SIEST J, 1997, J BIOL CHEM, V44; SMITH LJ, 1993, AM REV RESPIR DIS, V147, P1461; Smith L. J., 1996, FOLDING DESIGN, V1, pR95; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Tham DM, 1998, AM J PHYSIOL-GASTR L, V275, pG1463; THOMAS EL, 1988, J BIOL CHEM, V263, P2178; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; WINTERBOURN CC, 1989, BIOCHEM PHARMACOL, V38, P271, DOI 10.1016/0006-2952(89)90037-3; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S; YOSHIMURA S, 1994, GENE, V145, P293	51	100	103	1	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	JAN	2001	15	1					70	78		10.1096/fj.00-0085com		9	Biochemistry & Molecular Biology; Biology; Cell Biology	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	390TH	WOS:000166312400015	11149894	
J	Gagliardo, R; Chanez, P; Vignola, AM; Bousquet, J; Vachier, I; Godard, P; Bonsignore, G; Demoly, P; Mathieu, M				Gagliardo, R; Chanez, P; Vignola, AM; Bousquet, J; Vachier, I; Godard, P; Bonsignore, G; Demoly, P; Mathieu, M			Glucocorticoid receptor alpha and beta in glucocorticoid dependent asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							COLONY-STIMULATING FACTOR; NF-KAPPA-B; BRONCHIAL-MUCOSA; TRANSCRIPTION FACTORS; HUMAN NEUTROPHILS; MESSENGER-RNA; EXPRESSION; GENE; INFLAMMATION; ISOFORM	Patients with glucocorticoid (CC)-dependent asthma present an ongoing inflammation of the airways despite chronic long-term treatment with oral GC. Interleukin (IL)-8 and granulocyte/macrophage colony-stimulating factor (GM-CSF) have been implicated in airway inflammation in severe asthma and their synthesis is normally repressed by GC. To further characterize the inflammatory process in GC-dependent asthma, we measured the release of IL-8 and CM-CSF by peripheral blood mononuclear cells (PBMC) of eight normal subjects, six untreated controlled asthmatics, six untreated uncontrolled asthmatics, and nine CC-dependent asthmatics. We show that PBMC from CC-dependent asthmatics released high amounts of these cytokines despite chronic in vivo exposure to CC (p < 0.001 versus normal subjects). In contrast, when untreated uncontrolled asthmatics were given a short course of oral CC, IL-8 and CM-CSF production was inhibited (p = 0.0078). Release of IL-8 and GM-CSF by PBMC of CC-dependent asthmatics was reduced after in vitro GC treatment (p < 0.002). We investigated whether the incapacity of CC to inhibit production of these cytokines in vivo was the result of a dysregulation of the glucocorticoid receptor (GR) in CC-dependent asthma. GR alpha and GR beta are, respectively, the functional receptor and a putative dominant negative form of the receptor. Western blot and polymerase chain reaction (PCR) analyses indicated that GR alpha was expressed at similar level in all groups and was largely predominant over GR beta. Thus, persistent release of IL-8 and CM-CSF in CC-dependent asthma is not associated with low expression of GR alpha or overexpression of GR beta.	CHU Montpellier, INSERM U454, F-34095 Montpellier 5, France; CHU Montpellier, Serv Malad Resp, F-34095 Montpellier, France; CNRS, Ist Fisiopatol Resp, Palermo, Italy	Mathieu, M (reprint author), CHU Montpellier, INSERM U454, F-34095 Montpellier 5, France.						American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Andersson O, 1999, J ALLERGY CLIN IMMUN, V103, P595, DOI 10.1016/S0091-6749(99)70230-7; Bamberger CM, 1997, MOL CELL ENDOCRINOL, V136, P23, DOI 10.1016/S0303-7207(97)00209-8; BAMBERGER CM, 1995, J CLIN INVEST, V95, P2435, DOI 10.1172/JCI117943; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Brogan IJ, 1999, MOL CELL ENDOCRINOL, V157, P95, DOI 10.1016/S0303-7207(99)00156-2; CARMICHAEL J, 1981, BRIT MED J, V282, P1419; Castro M, 1996, MOL MED, V2, P597; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; CHANEZ P, 1996, AM J RESP CRIT CARE, V153, pA212; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COX G, 1995, J IMMUNOL, V154, P4719; de Lange P, 1999, MOL CELL ENDOCRINOL, V153, P163, DOI 10.1016/S0303-7207(99)00072-6; DYKEWICZ MS, 1986, ARCH INTERN MED, V146, P2369, DOI 10.1001/archinte.146.12.2369; Hamid QA, 1999, AM J RESP CRIT CARE, V159, P1600; Hancox RJ, 1999, THORAX, V54, P488; Hecht K, 1997, J BIOL CHEM, V272, P26659, DOI 10.1074/jbc.272.42.26659; HOLLENBERG SM, 1985, NATURE, V318, P635, DOI 10.1038/318635a0; Jatakanon A, 1999, AM J RESP CRIT CARE, V160, P1532; Leung DYM, 1997, J EXP MED, V186, P1567, DOI 10.1084/jem.186.9.1567; Mathieu M, 1999, GENE THER, V6, P245, DOI 10.1038/sj.gt.3300814; MUKAIDA N, 1994, J BIOL CHEM, V269, P13289; Oakley RH, 1996, J BIOL CHEM, V271, P9550; Pizzichini MMM, 1999, EUR RESPIR J, V13, P15, DOI 10.1183/09031936.99.13101599; SCHRECK R, 1990, MOL CELL BIOL, V10, P1281; SHER ER, 1994, J CLIN INVEST, V93, P33, DOI 10.1172/JCI116963; Shute JK, 1997, AM J RESP CRIT CARE, V155, P1877; TOBLER A, 1992, BLOOD, V79, P45; Vachier I, 1996, CLIN EXP IMMUNOL, V103, P311, DOI 10.1046/j.1365-2249.1996.d01-628.x; Vachier I, 1998, AM J RESP CRIT CARE, V158, P963; Vrugt B, 1999, EUR RESPIR J, V13, P1245, DOI 10.1183/09031936.99.13612539; WALLAERT B, 1995, J EXP MED, V182, P1897, DOI 10.1084/jem.182.6.1897; WALZ A, 1991, J LEUKOCYTE BIOL, V50, P279; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Wenzel SE, 1997, AM J RESP CRIT CARE, V156, P737	35	100	109	1	2	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL	2000	162	1					7	13				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	333JH	WOS:000088126800003	10903212	
J	Zhou, Y; Wu, Y; Yang, L; Fu, LX; He, KB; Wang, SX; Hao, JM; Chen, JC; Li, CY				Zhou, Yu; Wu, Ye; Yang, Liu; Fu, Lixin; He, Kebin; Wang, Shuxiao; Hao, Jiming; Chen, Jinchuan; Li, Chunyan			The impact of transportation control measures on emission reductions during the 2008 Olympic Games in Beijing, China	ATMOSPHERIC ENVIRONMENT			English	Article						Olympic Games; Transportation control measures; Emission inventory; Beijing	URBAN AIR-QUALITY; MOTOR-VEHICLE GROWTH; VEHICULAR EMISSIONS; CHILDHOOD ASTHMA; POLLUTION; AREA; ROAD; MODELS; BUSAN; KOREA	Traffic congestion and air pollution were two major challenges for the planners of the 2008 Olympic Games in Beijing. The Beijing municipal government implemented a package of temporary transportation control measures during the event. In this paper. we report the results of a recent research project that investigated the effects of these measures on urban motor vehicle emissions in Beijing. Bottom-up methodology has been used to develop grid-based emission inventories with micro-scale vehicle activities and speed-dependent emission factors. The urban traffic emissions of volatile organic compounds (VOC). carbon monoxide (CO), nitrogen oxides (NO(x)) and particulate matter with an aerodynamic diameter of 10 mu m or less (PM(10)) during the 2008 Olympics were reduced by 55.5%, 56.8%, 45.7% and 51.6%, respectively, as compared to the grid-based emission inventory before the Olympics. Emission intensity was derived from curbside air quality monitoring at the North 4th Ring Road site, located about 7 km from the National Stadium. Comparison between the emission intensity before and during the 2008 Olympics shows a reduction of 44.5% and 49.0% in daily CO and NO(x) emission from motor vehicles. The results suggest that reasonable traffic system improvement strategies along with vehicle technology improvements can contribute to controlling total motor vehicle emissions in Beijing after the Olympic Games. (C) 2009 Elsevier Ltd. All rights reserved.	[Zhou, Yu; Wu, Ye; Yang, Liu; Fu, Lixin; He, Kebin; Wang, Shuxiao; Hao, Jiming] Tsinghua Univ, Dept Environm Sci & Engn, Beijing 100084, Peoples R China; [Zhou, Yu; Wu, Ye; Yang, Liu; Fu, Lixin; He, Kebin; Wang, Shuxiao; Hao, Jiming] Tsinghua Univ, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100084, Peoples R China; [Chen, Jinchuan; Li, Chunyan] Beijing Transportat Res Ctr, Beijing 100055, Peoples R China	Hao, JM (reprint author), Tsinghua Univ, Dept Environm Sci & Engn, Beijing 100084, Peoples R China.	hjm-den@tsinghua.edu.cn	wang, shuxiao/H-5990-2011; Wu, Ye/O-9779-2015	wang, shuxiao/0000-0001-9727-1963; 	State Key Joint Laboratory of Environment Simulation and Pollution Control [08Y04ESPCT]; National Natural Science Foundation of China [50678092, 50908121]	This study is sponsored by the Special Fund of State Key Joint Laboratory of Environment Simulation and Pollution Control (08Y04ESPCT) and National Natural Science Foundation of China (Project No. 50678092 and Project No. 50908121). The authors thank Mr. Chuck Freed of US EPA and Mr. Jerry Davis of North Carolina State University for their helpful advice to improve this paper. The contents of this paper are solely the responsibility of the authors and do not necessarily represent official views of the sponsors.	BENSON PE, 1992, ATMOS ENVIRON B-URB, V26, P379, DOI 10.1016/0957-1272(92)90013-I; *BSB, 2008, BEIJ STAT YB 2008; Frantzeskakis JM, 2006, ITE J, V76, P26; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Fu L., 1999, CHINA ENV SCI, V19, P552; Fu L. X., 1997, ACTA SCI CIRCUMSTANT, V17, P474; Fu LX, 2001, J AIR WASTE MANAGE, V51, P658; Fu L., 2000, ENV SCI, V21, P68; Gramotnev G, 2003, ATMOS ENVIRON, V37, P465, DOI 10.1016/S1352-2310(02)00923-8; Hao JM, 2006, TRANSPORT RES A-POL, V40, P639, DOI 10.1016/j.tra.2005.11.005; Hao JM, 2005, J AIR WASTE MANAGE, V55, P1298; Hao JM, 2001, J ENVIRON SCI HEAL A, V36, P215, DOI 10.1081/ESE-100102619; Hao JM, 2000, ATMOS ENVIRON, V34, P453, DOI 10.1016/S1352-2310(99)00324-6; He KB, 2002, ANNU REV ENERG ENV, V27, P397, DOI 10.1146/annurev.energy.27.122001.083421; Hu J., 2004, ENV SCI, V25, P19; Hu J., 2006, J TSINGHUA U SCI TEC, V46, P350; Huo H, 2007, TRANSP RES RECORD, P69, DOI 10.3141/2038-09; Lee BK, 2005, ATMOS ENVIRON, V39, P2323, DOI 10.1016/j.atmosenv.2004.11.044; Lee JT, 2007, J AIR WASTE MANAGE, V57, P968; LI C, 2008, URBAN TRANSPORT CHIN, V6, P69; Oanh NTK, 2008, ATMOS RES, V89, P223, DOI 10.1016/j.atmosres.2008.02.005; Palmgren F, 1999, SCI TOTAL ENVIRON, V235, P101, DOI 10.1016/S0048-9697(99)00196-5; Streets DG, 2007, ATMOS ENVIRON, V41, P480, DOI 10.1016/j.atmosenv.2006.08.046; Tang J., 2000, ENV SCI, V21, P95; *TSINGH U, 2008, EXP EV AIR POLL CONT; Walsh MP, 2007, NAT RESOUR FORUM, V31, P21, DOI 10.1111/j.1477-8947.2007.00136.x; WANG HK, 2008, CHIN J ENVIRON SCI, V29, P2970; Wang HK, 2009, SCI TOTAL ENVIRON, V407, P1947, DOI 10.1016/j.scitotenv.2008.11.008; WANG S, 2008, J TRANSPORTATION SYS, V8, P121; Westerdahl D, 2009, ATMOS ENVIRON, V43, P697, DOI 10.1016/j.atmosenv.2008.09.042; Wu Y., 2002, ENV SCI, V23, P6; Yao ZL, 2007, J AIR WASTE MANAGE, V57, P1379, DOI 10.3155/1047-3289.57.11.1379; Zhou Y, 2007, J AIR WASTE MANAGE, V57, P1071, DOI 10.3155/1047-3289.57.9.1071	33	99	116	10	98	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	JAN	2010	44	3					285	293		10.1016/j.atmosenv.2009.10.040		9	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	553GE	WOS:000274353500001		
J	Nathan, AT; Peterson, EA; Chakir, J; Wills-Karp, M				Nathan, Amy T.; Peterson, Elizabeth A.; Chakir, Jamila; Wills-Karp, Marsha			Innate immune responses of airway epithelium to house dust mite are mediated through beta-glucan-dependent pathways	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; allergy; house dust mite; epithelium; dendritic cell; chemokine; pattern recognition; innate immunity	T-CELL RESPONSES; DERMATOPHAGOIDES-PTERONYSSINUS; DENDRITIC CELLS; RECEPTOR CCR6; ATOPIC ASTHMA; MOUSE LUNG; ALLERGEN; INFLAMMATION; ENDOTOXIN; CCL20	Background: House dust mite (HDM) induces allergic asthma in sensitized individuals, although the mechanisms by which HDM is sensed and recognized by the airway mucosa, leading to dendritic cell (DC) recruitment, activation, and subsequent T(H)2-mediated responses, are unknown. Objective: We sought to define the pathways by which HDM activates respiratory epithelium to induce allergic airway responses. Methods: Using a human airway epithelial cell line (16HBE14o-), we studied secretion of the DC chemokine CCL20 after exposure to HDM or other allergens, investigated components of the HDM responsible for the induction of chemokine release, and examined activation of signaling pathways. Central findings were also confirmed in primary human bronchial cells. Results: We demonstrate that exposure of airway epithelium to HDM results in specific and rapid secretion of CCL20, a chemokine attractant for immature DCs. The induction of CCL20 secretion is dose and time dependent and quite specific to HDM because other allergens, such as ragweed pollen and cockroach antigen, fail to significantly induce CCL20 secretion. Induction of CCL20 secretion is not protease or Toll-like receptor 2/4 dependent but, interestingly, relies on beta-glucan moieties within the HDM extract, as evidenced by the ability of other beta-glucans to competitively inhibit its secretion and by the fact that disruption of these structures by treatment of HDM with beta-glucanase significantly reduces subsequent chemokine secretion. Conclusion: Taken together, our results describe a novel mechanism for specific pattern recognition of HDM-derived beta-glucan moieties, which initiates allergic airway inflammation and, through recruitment of DCs, might link innate pattern recognition at the airway surface with adaptive immune responses. (J Allergy Clin Immunol 2009;123:612-8.)	[Nathan, Amy T.; Peterson, Elizabeth A.] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Neonatol, Cincinnati, OH 45229 USA; [Wills-Karp, Marsha] Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Immunobiol, Cincinnati, OH 45229 USA; [Chakir, Jamila] Laval Hosp, Res Ctr, Dept Med, Laval, PQ, Canada	Nathan, AT (reprint author), Cincinnati Childrens Hosp, Med Ctr, Dept Pediat, Div Neonatol, 3333 Burnet Ave,MLC 7038, Cincinnati, OH 45229 USA.	Amy.Nathan@cchmc.org			National Institutes of Health [P01 HL076383, R01 H667737]	M.W.-K. received grant support from the National Institutes of Health (P01 HL076383 and R01 H667737).	Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Chen JZ, 2007, MYCOL RES, V111, P635, DOI 10.1016/j.mycres.2007.02.011; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Finkelman FD, 2005, J IMMUNOL, V174, P4630; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; Goulet F, 1996, AM J RESP CELL MOL, V15, P312; Grunstein MM, 2005, J ALLERGY CLIN IMMUN, V116, P94, DOI 10.1016/j.jaci.2005.03.046; Hart DNJ, 1997, BLOOD, V90, P3245; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; Hodgson MJ, 2001, AM J IND MED, V39, P616, DOI 10.1002/ajim.1061; Holt PG, 2000, J AEROSOL MED, V13, P361, DOI 10.1089/jam.2000.13.361; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kondo S, 2004, INFLAMM RES, V53, P489, DOI 10.1007/s00011-004-1287-8; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Maruo K, 1997, J ALLERGY CLIN IMMUN, V100, P253, DOI 10.1016/S0091-6749(97)70233-1; OBRIEN RM, 1992, J ALLERGY CLIN IMMUN, V89, P1021, DOI 10.1016/0091-6749(92)90225-Q; OBRIEN RM, 1994, CLIN EXP ALLERGY, V24, P737, DOI 10.1111/j.1365-2222.1994.tb00984.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; Power CA, 1997, J EXP MED, V186, P825, DOI 10.1084/jem.186.6.825; RAWLE FC, 1984, J IMMUNOL, V133, P195; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sato T, 2006, J LEUKOCYTE BIOL, V80, P204, DOI 10.1189/jlb.0106069; Scapini P, 2002, EUR J IMMUNOL, V32, P3515, DOI 10.1002/1521-4141(200212)32:12<3515::AID-IMMU3515>3.0.CO;2-3; Schutyser E, 2003, CYTOKINE GROWTH F R, V14, P409, DOI 10.1016/S1359-6101(03)00049-2; Starner TD, 2003, AM J RESP CELL MOL, V29, P627, DOI 10.1165/rcmb.2002-0272OC; Sugita S, 2002, J IMMUNOL, V168, P5621; Tada R, 2006, BIOL PHARM BULL, V29, P240, DOI 10.1248/bpb.29.240; Thorley AJ, 2005, AM J RESP CELL MOL, V32, P262, DOI 10.1165/rcmb.2004-0196OC; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Van Asselt L, 1999, INDOOR BUILT ENVIRON, V8, P216, DOI 10.1159/000024644; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; Walters DM, 2001, AM J RESP CRIT CARE, V164, P1438; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wong CK, 2006, INT IMMUNOL, V18, P1327, DOI 10.1093/intimm/dxl065	41	99	100	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					612	618		10.1016/j.jaci.2008.12.006		7	Allergy; Immunology	Allergy; Immunology	426TQ	WOS:000264731200019	19178937	
J	Jeon, SK; Kim, HJ; Youm, JK; Ahn, SK; Choi, EH; Sohn, MH; Kim, KE; Hong, JH; Shin, DM; Lee, SH				Jeon, Se Kyoo; Kim, Hyun Jeong; Youm, Jong-Kyung; Ahn, Sung Ku; Choi, Eung Ho; Sohn, Myung Hyun; Kim, Kyu-Earn; Hong, Jeong Hee; Shin, Dong Min; Lee, Seung Hun			Mite and cockroach allergens activate protease-activated receptor 2 and delay epidermal permeability barrier recovery	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							HOUSE-DUST MITES; ATOPY PATCH TEST; EPITHELIAL-CELLS; STRATUM-CORNEUM; THROMBIN RECEPTOR; TIGHT JUNCTIONS; HAIRLESS MICE; DERMATITIS; SKIN; ASSOCIATION	Protease-activated receptor-2 (PAR-2) is known to be involved in epidermal permeability barrier function homeostasis. PAR-2 activation occurs after barrier disruption and further activation of PAR-2 by activating peptide significantly delays barrier recovery rate. Cockroach and house dust mite allergens, both known to be associated with the development of asthma, allergic rhinitis, and atopic dermatitis, have protease activity, which can activate PAR-2. In this study, we investigated the effects of both allergens on the epidermal barrier function as well as on the epidermal calcium gradient. Both allergens, when topically applied on the barrier-disrupted site, increased protease activities in the epidermis and delayed barrier recovery and lamellar body secretion in murine skin. The topical application of PAR-2-specific antagonist or protease inhibitors normalized the barrier recovery. Cockroach allergens induced intracellular calcium oscillations in cultured human keratinocytes through PAR-2-involved pathway, which was confirmed by desensitization protocol. Abnormal calcium ion distribution after barrier disruption was also observed in allergens-applied skin. These results suggest that allergens with protease activity can influence the epidermal permeability barrier homeostasis through PAR-2 activation and consequent modulation of the calcium ions in skin.	[Jeon, Se Kyoo; Youm, Jong-Kyung] Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 132720, South Korea; [Kim, Hyun Jeong; Lee, Seung Hun] Yonsei Univ, Coll Med, Dept Dermatol, Seoul 132720, South Korea; [Ahn, Sung Ku; Choi, Eung Ho] Yonsei Univ, Wonju Coll Med, Dept Dermatol, Wonju, South Korea; [Sohn, Myung Hyun; Kim, Kyu-Earn] Yonsei Univ, Coll Med, Dept Pediat, Seoul 132720, South Korea; [Hong, Jeong Hee; Shin, Dong Min] Yonsei Univ, Coll Dent, Oral Sci Res Ctr, Dept Oral Biochem,Brain Korea Project 21, Seoul 132720, South Korea	Lee, SH (reprint author), Yonsei Univ, Yongdong Severance Hosp, Coll Med, Dept Dermatol, 146-92 Dogok Dong, Seoul 132720, South Korea.	ydshderm@yumc.yonsei.ac.kr					Ahn SK, 2001, ARCH DERMATOL RES, V293, P308, DOI 10.1007/s004030100226; Ashida Y, 2001, J INVEST DERMATOL, V116, P261, DOI 10.1046/j.1523-1747.2001.01238.x; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Beltrani Vincent, 2002, Am J Contact Dermat, V13, P80, DOI 10.1053/ajcd.2002.32026; Beltrani VS, 2003, CLIN DERMATOL, V21, P177, DOI 10.1016/S0738-081X(02)00366-8; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; D'Andrea MR, 1998, J HISTOCHEM CYTOCHEM, V46, P157; Darsow U, 2004, ALLERGY, V59, P1318, DOI 10.1111/j.1398-9995.2004.00556.x; Denda M, 1997, J INVEST DERMATOL, V109, P84, DOI 10.1111/1523-1747.ep12276640; Denda M, 2004, J INVEST DERMATOL, V122, P140, DOI 10.1046/j.0022-202X.2003.22115.x; Egelrud T, 2005, BRIT J DERMATOL, V153, P1200, DOI 10.1111/j.1365-2133.2005.06834.x; Elias PM, 2005, J INVEST DERMATOL, V125, P183, DOI 10.1111/j.0022-202X.2005.23668.x; Folster-Holst R, 2005, BRIT J DERMATOL, V152, P1365, DOI 10.1111/j.1365-2133.2005.06602.x; Gfesser M, 1996, BRIT J DERMATOL, V135, P560, DOI 10.1111/j.1365-2133.1996.tb03831.x; Goon A, 2005, CLIN EXP DERMATOL, V30, P627, DOI 10.1111/j.1365-2230.2005.01916.x; Hachem JP, 2006, J INVEST DERMATOL, V126, P2074, DOI 10.1038/sj.jid.5700351; Hansson L, 2002, J INVEST DERMATOL, V118, P444, DOI 10.1046/j.0022-202x.2001.01684.x; Holzhausen M, 2005, MEM I OSWALDO CRUZ, V100, P177, DOI 10.1590/S0074-02762005000900030; Hong JH, 2004, J ALLERGY CLIN IMMUN, V113, P315, DOI 10.1016/j.jaci.2003.11.026; HOU SYE, 1991, J INVEST DERMATOL, V96, P215; Ingordo V, 2002, J EUR ACAD DERMATOL, V16, P450, DOI 10.1046/j.1468-3083.2002.00525.x; Jeong KY, 2004, CLIN DIAGN LAB IMMUN, V11, P680, DOI 10.1128/CDLI.11.4.680-685.2004; Kanke T, 2005, J PHARMACOL SCI, V97, P38, DOI 10.1254/jphs.FMJ04005X7; Kato A, 2003, BRIT J DERMATOL, V148, P665, DOI 10.1046/j.1365-2133.2003.05243.x; Kelso EB, 2006, J PHARMACOL EXP THER, V316, P1017, DOI 10.1124/jpet.105.093807; Komatsu N, 2005, BRIT J DERMATOL, V153, P274, DOI 10.1111/j.1365-2133.2005.06754.x; Kondo S, 2004, INFLAMM RES, V53, P489, DOI 10.1007/s00011-004-1287-8; Lee SH, 2006, YONSEI MED J, V47, P293; LEE SH, 1992, J CLIN INVEST, V89, P530, DOI 10.1172/JCI115617; Loffler H, 2003, ACTA DERM-VENEREOL, V83, P328, DOI 10.1080/00015550310006554; Nakamura T, 2006, J INVEST DERMATOL, V126, P2719, DOI 10.1038/sj.jid.5700584; Nystedt S, 1996, J BIOL CHEM, V271, P14910; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rattenholl A, 2003, DRUG DEVELOP RES, V59, P408, DOI 10.1002/ddr.10311; SANTULLI RJ, 1995, P NATL ACAD SCI USA, V92, P9151, DOI 10.1073/pnas.92.20.9151; Seiberg M, 2000, J INVEST DERMATOL, V115, P162, DOI 10.1046/j.1523-1747.2000.00035.x; Sharlow ER, 2000, J CELL SCI, V113, P3093; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Sun G, 2001, J IMMUNOL, V167, P1014; Vergnolle N, 2001, NAT MED, V7, P821, DOI 10.1038/89945; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004	43	99	104	0	3	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X			J INVEST DERMATOL	J. Invest. Dermatol.	AUG	2008	128	8					1930	1939		10.1038/jid.2008.13		10	Dermatology	Dermatology	331SA	WOS:000258031700011	18305573	
J	Barraza-Villarreal, A; Sunyer, J; Hernandez-Cadena, L; Escamilla-Nunez, MC; Sienra-Monge, JJ; Ramirez-Aguilar, M; Cortez-Lugo, M; Holguin, F; Diaz-Sanchez, D; Olin, AC; Romieu, I				Barraza-Villarreal, Albino; Sunyer, Jordi; Hernandez-Cadena, Leticia; Consuelo Escamilla-Nunez, Maria; Jose Sienra-Monge, Juan; Ramirez-Aguilar, Matiana; Cortez-Lugo, Marlene; Holguin, Fernando; Diaz-Sanchez, David; Olin, Anna Carin; Romieu, Isabelle			Air pollution, airway inflammation, and lung function in a cohort study of Mexico City schoolchildren	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; airway inflammation; asthma; epidemiology; lung function; schoolchildren	EXHALED NITRIC-OXIDE; DIESEL EXHAUST PARTICLES; PEAK EXPIRATORY FLOW; ASTHMATIC-CHILDREN; PARTICULATE MATTER; ANTIOXIDANT SUPPLEMENTATION; RESPIRATORY HEALTH; BREATH CONDENSATE; PULMONARY-FUNCTION; CHILDHOOD ASTHMA	BACKGROUND: The biological mechanisms involved in inflammatory response to air pollution are not dearly understood. OBJECTIVE: In this study we assessed the association of short-term air pollutant exposure with inflammatory markers and lung function. METHODS: We studied a cohort of 158 asthmatic and 50 nonasthmatic school-age children, followed an average of 22 weeks. We conducted spirometric tests, measurements of fractional exhaled nitric oxide (Fe(NO)), interleukin-8 (IL-8) in nasal lavage, and pH of exhaled breath condensate every 15 days during follow-up. Data were analyzed using linear mixed-effects models. RESULTS: An increase of 17.5 mu g/m(3) in the 8-hr moving average of PM(2.5) levels (interquartile range) was associated with a 1.08-ppb increase in Fe(NO) [95% confidence interval (CI), 1.01-1.16] and a 1.07-pg/mL increase in IL-8 (95% CI 0.98-1.19) in asthmatic children and a 1.16 pg/ml increase in IL-8 (95% CI, 1.00-1.36) in nonasthmatic children. The 5-day accumulated average of exposure to particulate matter < 2.5 pm in aerodynamic diamter (PM(2.5)) was significantly inversely associated with forced expiratory volume in 1 see (FEV(1)) (p = 0.048) and forced vital capacity (FVC) (p = 0.012) in asthmatic children and with FVC (p = 0.021) in nonasthmatic children. FeNO and FEV(1) were inversely associated (p = 0.005) in asthmatic children. CONCLUSIONS: Exposure to PM(2.5) resulted in acute airway inflammation and decrease in lung function in both asthmatic and nonasthmatic children.	[Barraza-Villarreal, Albino; Hernandez-Cadena, Leticia; Consuelo Escamilla-Nunez, Maria; Cortez-Lugo, Marlene; Romieu, Isabelle] Ist Nacl Salud Publ, Cuernavaca 62508, Morelos, Mexico; [Sunyer, Jordi] IMIM, Environm Epidemiol Res Ctr, CREAL, Barcelona, Spain; [Jose Sienra-Monge, Juan] Hosp Infantil Mexico Dr Federico Gomez, Mexico City, DF, Mexico; [Ramirez-Aguilar, Matiana] COFEPRIS, Mexico City, DF, Mexico; [Holguin, Fernando] Emory Univ, Sch Med, Dept Pulm Allergy & Crit Care, Atlanta, GA USA; [Diaz-Sanchez, David] US EPA, Human Studies Div, Chapel Hill, NC USA; [Olin, Anna Carin] Sahlgrens Univ Hosp, Dept Occupat & Environm Med, S-41345 Gothenburg, Sweden	Romieu, I (reprint author), Ist Nacl Salud Publ, 655 Ave Univ,Col Santa Maria Ahuacatitlan, Cuernavaca 62508, Morelos, Mexico.	iromieu@correo.insp.mx	Sunyer, J/G-6909-2014	Sunyer, J/0000-0002-2602-4110	NCATS NIH HHS [UL1 TR000454]		ATS statement, 1994, AM J RESP CRIT CARE, V152, P1107; Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218; Barnes PJ, 1998, MOL MED TODAY, V4, P452, DOI 10.1016/S1357-4310(98)01335-5; Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904; Brunetti L, 2006, PEDIATR ALLERGY IMMU, V17, P422, DOI 10.1111/j.1399-3038.2006.00426.x; Calderon-Garciduenas L, 2006, ENVIRON HEALTH PERSP, V114, P1432, DOI 10.1289/ehp.8377; CASTILLEJOS M, 1992, AM REV RESPIR DIS, V145, P276; CASTILLEJOS M, 1995, AM J RESP CRIT CARE, V152, P1501; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Diaz-Sanchez D, 2005, AM J PHYSIOL-LUNG C, V289, P722; Dinakar C, 2004, CURR ALLERGY ASTHM R, V4, P454, DOI 10.1007/s11882-004-0011-7; Fischer PH, 2002, INT ARCH OCC ENV HEA, V75, P348, DOI 10.1007/s00420-002-0320-x; GASTON B, 1994, AM J RESP CRIT CARE, V149, P538; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; *GINA, 2006, GLOB IN ASTHM GINA W; *GOB DISTR FED, 1999, VOL TRANS EST MAESTR; HAUSMAN JA, 1978, ECONOMETRICA, V46, P1251, DOI 10.2307/1913827; Holguin F, 2007, AM J RESP CRIT CARE, V176, P1236, DOI 10.1164/rccm.200611-1616OC; Horvath I, 2005, EUR RESPIR J, V26, P523, DOI 10.1183/09031936.05.00029705; Hunt J, 2002, J ALLERGY CLIN IMMUN, V110, P28, DOI 10.1067/mai.2002.124966; Hunt JF, 2000, AM J RESP CRIT CARE, V161, P694; Ichinose T, 1997, TOXICOLOGY, V122, P183, DOI 10.1016/S0300-483X(97)00096-6; Janssen NAH, 2001, ATMOS ENVIRON, V35, P3875, DOI 10.1016/S1352-2310(01)00144-3; Kodama Y, 2002, ENVIRON RES, V89, P236, DOI 10.1006/enrs.2002.4350; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; Koenig JQ, 2003, ENVIRON HEALTH PERSP, V111, P1625, DOI 10.1289/ehp.6160; Leonardi GS, 2000, INHAL TOXICOL, V12, P1; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Mar TF, 2005, ENVIRON HEALTH PERSP, V113, P1791, DOI 10.1289/ehp.7883; Moshammer H, 2006, EUR RESPIR J, V27, P1138, DOI 10.1183/09031936.06.00089605; Narayanan PK, 1999, RADIAT RES, V152, P57, DOI 10.2307/3580049; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Romieu I, 2008, EUR RESPIR J, V31, P179, DOI 10.1183/09031936.00128106; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Romieu I, 1998, AM J RESP CRIT CARE, V158, P226; Romieu I, 2004, THORAX, V59, P8; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu I, 2008, J ALLERGY CLIN IMMUN, V121, P903, DOI 10.1016/j.jaci.2007.12.004; Rosias PPR, 2004, PEDIATR PULM, V38, P107, DOI 10.1002/ppul.20056; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; Silkoff PE, 2000, J ALLERGY CLIN IMMUN, V105, P438, DOI 10.1067/mai.2000.104938; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Stamler JS, 2001, CELL, V106, P675, DOI 10.1016/S0092-8674(01)00495-0; Steerenberg PA, 1999, EUR RESPIR J, V13, P334, DOI 10.1034/j.1399-3003.1999.13b19.x; Steerenberg PA, 2001, ARCH ENVIRON HEALTH, V56, P167; Stenfors N, 2004, EUR RESPIR J, V23, P82, DOI 10.1183/09031936.03.00004603; Svendsen ER, 2007, ANN ALLERG ASTHMA IM, V99, P244; Takizawa Hajime, 2004, Curr Opin Allergy Clin Immunol, V4, P355, DOI 10.1097/00130832-200410000-00005; Van Amsterdam JGC, 2000, ARCH ENVIRON HEALTH, V55, P418; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; WATSON JG, 1999, ELEMENTAL ANAL AIRBO, P67; Wu H, 2007, J ALLERGY CLIN IMMUN, V120, P322, DOI 10.1016/j.jaci.2007.04.022; Yeatts K, 2007, ENVIRON HEALTH PERSP, V115, P709, DOI 10.1289/ehp.9499	56	99	100	8	40	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2008	116	6					832	838		10.1289/ehp.10926		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	306NC	WOS:000256254100039	18560490	
J	Fang, L; Adkins, B; Deyev, V; Podack, ER				Fang, Lei; Adkins, Becky; Deyev, Vadim; Podack, Eckhard R.			Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							DOMAIN-CONTAINING RECEPTOR; CD4(+) T-CELLS; NF-KAPPA-B; INDUCE AIRWAY HYPERREACTIVITY; DEATH-DOMAIN; NKT CELLS; SIGNAL-TRANSDUCTION; HUMAN EOSINOPHILS; CUTTING EDGE; MURINE MODEL	We identify the tumor necrosis factor receptor superfamily 25 (TNFRSF25)/TNFSF15 pair as critical trigger for allergic lung inflammation, which is a cardinal feature of asthma. TNFRSF25 (TNFR25) signals are required to exert T helper cell 2 (Th2) effector function in Th2-polarized CD4 cells and co-stimulate interleukin (IL)-13 production by glycosphingo-lipid-activated NKT cells. In vivo, antibody blockade of TNFSF15 (TL1A), which is the ligand for TNFR25, inhibits lung inflammation and production of Th2 cytokines such as IL-13, even when administered days after airway antigen exposure. Similarly, blockade of TNFR25 by a dominant-negative (DN) transgene, DN TNFR25, confers resistance to lung inflammation in mice. Allergic lung inflammation-resistant, NKT-deficient mice become susceptible upon adoptive transfer of wild-type NKT cells, but not after transfer of DN TNFR25 transgenic NKT cells. The TNFR25/TL1A pair appears to provide an early signal for Th2 cytokine production in the lung, and therefore may be a drug target in attempts to attenuate lung inflammation in asthmatics.	[Fang, Lei; Adkins, Becky; Deyev, Vadim; Podack, Eckhard R.] Univ Miami, Leonard Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA	Podack, ER (reprint author), Univ Miami, Leonard Miller Sch Med, Dept Microbiol & Immunol, Miami, FL 33136 USA.	epodack@miami.edu			NCI NIH HHS [CA 39201, R01 CA039201]; NIAID NIH HHS [AI 061807, R01 AI061807]		Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Au-Yeung BB, 2006, J IMMUNOL, V176, P3895; Bamias G, 2006, P NATL ACAD SCI USA, V103, P8441, DOI 10.1073/pnas.0510903103; Bamias G, 2003, J IMMUNOL, V171, P4868; BEAUVAIS F, 1995, J LEUKOCYTE BIOL, V57, P851; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; BOLDIN MP, 1995, J BIOL CHEM, V270, P7795; Chiba A, 2004, ARTHRITIS RHEUM, V50, P305, DOI 10.1002/art.11489; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; CHINNAIYAN AM, 1995, CELL, V81, P512; Cui JQ, 1997, SCIENCE, V278, P1623, DOI 10.1126/science.278.5343.1623; Fowell DJ, 1999, IMMUNITY, V11, P399, DOI 10.1016/S1074-7613(00)80115-6; Godfrey DI, 2004, J CLIN INVEST, V114, P1379, DOI 10.1172/JCI200423594; Harhaj EW, 2005, VIROLOGY, V333, P145, DOI 10.1016/j.virol.2004.12.008; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; Lisbonne M, 2003, J IMMUNOL, V171, P1637; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Meyer EH, 2006, P NATL ACAD SCI USA, V103, P2782, DOI 10.1073/pnas.0510282103; Meyer EH, 2007, J IMMUNOL, V179, P4661; Micheau O, 2003, CELL, V114, P181, DOI 10.1016/S0092-8674(03)00521-X; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Papadakis KA, 2004, J IMMUNOL, V172, P7002; Roh GS, 2005, INT IMMUNOPHARMACOL, V5, P427, DOI 10.1016/j.intimp.2004.09.036; Salek-Ardakani S, 2003, J EXP MED, V198, P315, DOI 10.1084/jem.20021937; Schneider T, 1997, AM J RESP CELL MOL, V17, P702; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Sen Yang, 2005, J Immunol, V175, P4914; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Terabe M, 2004, CANCER IMMUNOL IMMUN, V53, P79, DOI 10.1007/s00262-003-0445-0; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P775; Van Kaer L, 2004, IMMUNOL RES, V30, P139, DOI 10.1385/IR:30:2:139; Wang ECY, 2001, MOL CELL BIOL, V21, P3451, DOI 10.1128/MCB.21.10.3451-3461.2001; Wang ECY, 2001, IMMUNOGENETICS, V53, P59, DOI 10.1007/s002510000290; Warzocha K, 1998, BIOCHEM BIOPH RES CO, V242, P376, DOI 10.1006/bbrc.1997.7948; Wen L, 2003, J BIOL CHEM, V278, P39251, DOI 10.1074/jbc.M305833200; Wills-Karp M, 2004, CURR ALLERGY ASTHM R, V4, P123; YAMAGUCHI Y, 1991, BLOOD, V78, P2542; Yang CR, 2004, CANCER RES, V64, P1122, DOI 10.1158/0008-5472.CAN-03-0609; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	41	99	102	0	4	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	MAY 12	2008	205	5					1037	1048		10.1084/jem.20072528		12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	317EE	WOS:000257001800007	18411341	
S	Thai, P; Loukoianov, A; Wachi, S; Wu, R				Thai, Philip; Loukoianov, Artem; Wachi, Shinichiro; Wu, Reen			Regulation of airway mucin gene expression	ANNUAL REVIEW OF PHYSIOLOGY	Annual Review of Physiology		English	Review; Book Chapter						mucus; transcription; lung; epigenetics; differentiation	GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; BRONCHIAL EPITHELIAL-CELLS; OBSTRUCTIVE PULMONARY-DISEASE; HUMAN RESPIRATORY-TRACT; IN-VITRO; NEUTROPHIL ELASTASE; PSEUDOMONAS-AERUGINOSA; DNA METHYLATION	Mucins are important components that exert a variety of functions in cell-cell interaction, epidermal growth factor receptor signaling, and air-ways protection. In the conducting airways of the lungs, mucins are the major contributor to the viscoelastic property of mucous secretion, which is the major barrier to trapping inhaled microbial organism, particulates, and oxidative pollutants. The homeostasis of mucin production is an important feature in conducting air-ways for the maintenance of mucociliary function. Aberrant mucin secretion and accumulation in airway lumen are clinical hallmarks associated with various lung diseases, such as asthma, chronic obstructive pulmonary disease, cystic fibrosis, emphysema, and lung cancer. Among 20 known mucin genes identified, 11 of them have been verified at either the mRNA and/or protein level in airways. The regulation of mucin genes is complicated, as are the mediators and signaling pathways. This review summarizes the current view on the mediators, the signaling pathways, and the transcriptional units that are involved in the regulation of airway mucin gene expression. In addition, we also point out essential features of epigenetic mechanisms for the regulation of these genes.	[Thai, Philip] Univ Calif Davis, Ctr Comparat Resp Biol & Med, Div Pulm & Crit Care, Dept Internal Med, Davis, CA 95616 USA	Thai, P (reprint author), Univ Calif Davis, Ctr Comparat Resp Biol & Med, Div Pulm & Crit Care, Dept Internal Med, Davis, CA 95616 USA.	rwu@ucdavis.edu			NHLBI NIH HHS [R01 HL077315, R01 HL077902, T32 HL007013, T32 HL07013]		Aarbiou J, 2004, AM J RESP CELL MOL, V30, P193, DOI 10.1165/rcmb.2002-02670C; Allen A, 1998, INT J BIOCHEM CELL B, V30, P797, DOI 10.1016/S1357-2725(98)00028-4; AN G, 1994, AM J RESP CELL MOL, V10, P546; Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; Bergeron C, 2006, CHEST, V129, P1068, DOI 10.1378/chest.129.4.1068; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595; Bhattacharya SK, 1999, NATURE, V397, P579; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V276, pL549; Brar SS, 2002, AM J PHYSIOL-LUNG C, V282, pL782, DOI 10.1152/ajplung.00206.2001; Buisine MP, 1998, BIOCHEM J, V332, P729; Buisine MP, 1999, AM J RESP CELL MOL, V20, P209; Burgel PR, 2001, J IMMUNOL, V167, P5948; Caramori G, 2004, HISTOPATHOLOGY, V45, P477, DOI 10.1111/j.1365-2559.2004.01952.x; CARDOSO WV, 1995, AM J RESP CELL MOL, V12, P464; Carmody RJ, 2007, CELL MOL IMMUNOL, V4, P31; Casalino-Matsuda SM, 2006, AM J RESP CELL MOL, V34, P581, DOI 10.1165/rcmb.2005-0386OC; Chen R, 2004, BIOCHEM BIOPH RES CO, V324, P1087, DOI 10.1016/j.bbrc.2004.09.157; Chen Y, 2004, AM J RESP CELL MOL, V30, P155, DOI 10.1165/remb.2003-01030C; Chen Y, 2001, AM J RESP CELL MOL, V25, P542; Chen Y, 2001, AM J RESP CELL MOL, V25, P409; Chen Y, 2001, AM J RESP CRIT CARE, V164, P1059; Chen Y, 2003, J BIOL CHEM, V278, P17036, DOI 10.1074/jbc.M210429200; Chen YJ, 2006, AM J RESP CELL MOL, V34, P338, DOI 10.1165/rcmb.2005-0176OC; CHOW CK, 1993, ANN NY ACAD SCI, V686, P289, DOI 10.1111/j.1749-6632.1993.tb39189.x; Chung Kian F., 2005, Current Drug Targets - Inflammation and Allergy, V4, P619, DOI 10.2174/156801005774912806; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Copin MC, 2001, HUM PATHOL, V32, P274, DOI 10.1053/hupa.2001.22752; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Damera G, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-39; Damera G, 2006, BIOSCIENCE REP, V26, P55, DOI 10.1007/s10540-006-9000-5; Davies JR, 1999, BIOCHEM J, V344, P321, DOI 10.1042/0264-6021:3440321; Deshmukh HS, 2005, AM J RESP CRIT CARE, V171, P305, DOI 10.1164/rccm.200408-1003OC; Diamond G, 2000, IMMUNOL REV, V173, P27, DOI 10.1034/j.1600-065X.2000.917304.x; DOHRMAN A, 1994, EXP LUNG RES, V20, P367, DOI 10.3109/01902149409064393; Erjefalt JS, 1997, THORAX, V52, P1010; Escande F, 2001, BIOCHEM J, V358, P763, DOI 10.1042/0264-6021:3580763; Evans CM, 2004, AM J RESP CELL MOL, V31, P382, DOI 10.1165/rcmb.0060OC; Fischer BM, 2003, AM J PHYSIOL-LUNG C, V284, pL671, DOI 10.1152/ajplung.00220.2002; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447; Gan WQ, 2004, THORAX, V59, P574, DOI 10.1136/thx.2003.019588; Gensch E, 2004, J BIOL CHEM, V279, P39085, DOI 10.1074/jbc.M406866200; Gray T, 2004, MOL PHARMACOL, V66, P337, DOI 10.1124/mol.66.2.337; GRAY TE, 1996, J RESP CELL MOL BIOL, V14, P104; Griffin S, 2007, CELL MICROBIOL, V9, P670, DOI 10.1111/j.1462-5822.2006.00819.x; Groneberg DA, 2002, HISTOPATHOLOGY, V40, P367, DOI 10.1046/j.1365-2559.2002.01378.x; Guzman K, 1995, BIOCHEM BIOPH RES CO, V217, P412, DOI 10.1006/bbrc.1995.2792; Hamada T, 2005, CANCER LETT, V227, P175, DOI 10.1016/j.canlet.2004.11.058; Hanski C, 1997, LAB INVEST, V77, P685; Harper R, 2001, AM J RESP CELL MOL, V25, P178; Hendrich B, 2003, TRENDS GENET, V19, P269, DOI 10.1016/S0168-9525(03)00080-5; Herrmann A, 1999, J BIOL CHEM, V274, P15828, DOI 10.1074/jbc.274.22.15828; Hewson CA, 2004, J MOL BIOL, V344, P683, DOI 10.1016/j.jmb.2004.09.059; Ho JJL, 2003, INT J ONCOL, V22, P273; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hovenberg HW, 1996, BIOCHEM J, V318, P319; Hovenberg HW, 1996, GLYCOCONJUGATE J, V13, P839, DOI 10.1007/BF00702348; Inatomi T, 1997, BIOCHEM BIOPH RES CO, V236, P789, DOI 10.1006/bbrc.1997.7051; Inoue D, 2006, RESP PHYSIOL NEUROBI, V154, P484, DOI 10.1016/j.resp.2005.11.006; Iwashita J, 2003, IMMUNOL CELL BIOL, V81, P275, DOI 10.1046/j.1440-1711.2003.t01-1-01163.x; Jayawickreme SP, 1999, AM J PHYSIOL-LUNG C, V276, pL596; Jono H, 2002, J BIOL CHEM, V277, P45547, DOI 10.1074/jbc.M206883200; Kamio K, 2005, AM J RESP CRIT CARE, V171, P949, DOI 10.1164/rccm.200409-1168OC; Kao CY, 2005, J IMMUNOL, V175, P6676; Kim YD, 2002, J KOREAN MED SCI, V17, P765; Kim YD, 2000, BIOCHEM BIOPH RES CO, V274, P112, DOI 10.1006/bbrc.2000.3107; Kirkham S, 2002, BIOCHEM J, V361, P537, DOI 10.1042/0264-6021:3610537; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; Kohri K, 2002, EUR RESPIR J, V20, P1263, DOI 10.1183/09031936.02.00001402; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Koo JS, 2002, EXP LUNG RES, V28, P315, DOI 10.1080/01902140252964393; Koo JS, 1999, AM J RESP CELL MOL, V20, P43; Koo JS, 1999, BIOCHEM J, V338, P351, DOI 10.1042/0264-6021:3380351; Krunkosky TM, 2003, FREE RADICAL BIO MED, V35, P1158, DOI 10.1016/S0891-5849(03)00498-2; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Kuwahara I, 2005, AM J PHYSIOL-LUNG C, V289, pL355, DOI 10.1152/ajplung.00040.2005; Kuyper LM, 2003, AM J MED, V115, P6, DOI 10.1016/S0002-9343(03)00241-9; LANGE P, 1990, THORAX, V45, P579, DOI 10.1136/thx.45.8.579; Lappalainen U, 2005, AM J RESP CELL MOL, V32, P311, DOI 10.1165/rcmb.2004.0309OC; Lee HW, 2002, J BIOL CHEM, V277, P32624, DOI 10.1074/jbc.M200353200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; LEVINE SJ, 1995, AM J RESP CELL MOL, V12, P196; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li JD, 1997, P NATL ACAD SCI USA, V94, P967, DOI 10.1073/pnas.94.3.967; Li SM, 2006, AM J RESP CELL MOL, V35, P593, DOI 10.1165/rcmb.2006-01100C; Li SM, 2006, AM J RESP CELL MOL, V35, P95, DOI 10.1165/rcmb.2005-0305OC; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Lora JM, 2005, J BIOL CHEM, V280, P36510, DOI 10.1074/jbc.M507977200; Louahed J, 2000, AM J RESP CELL MOL, V22, P649; McMillan J, 2002, MIDDLE EAST POLICY, V9, P1, DOI 10.1111/1475-4967.00035; McNamara N, 2001, P NATL ACAD SCI USA, V98, P9086, DOI 10.1073/pnas.161290898; Mesquita P, 2003, CANCER LETT, V189, P129, DOI 10.1016/S0304-3835(02)00549-9; Mizoshita T, 2007, HISTOL HISTOPATHOL, V22, P251, DOI 10.14670/HH-22.251; Morcillo EJ, 2006, CURR OPIN PULM MED, V12, P1, DOI 10.1097/01.mcp.0000198064.27586.37; MURRAY JF, 2000, TEXT RESPIRATORY MED; Ng HH, 1999, NAT GENET, V23, P58; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Park KS, 2006, AM J RESP CELL MOL, V34, P151, DOI 10.1165/rcmb.2005-0332OC; Perez-Vilar J, 2007, AM J RESP CELL MOL, V36, P183, DOI 10.1165/rcmb.2006-0291TR; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P15386, DOI 10.1074/jbc.M010534200; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; Reader JR, 2003, AM J RESP CELL MOL, V28, P664, DOI 10.1165/rcmb.2002-0207OC; Reid CJ, 1997, AM J RESP CELL MOL, V17, P592; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Rose MC, 2000, J AEROSOL MED, V13, P245, DOI 10.1089/jam.2000.13.245; Rousseau K, 2004, GENOMICS, V83, P936, DOI 10.1016/j.ygeno.2003.11.003; Sha Q, 2004, AM J RESP CELL MOL, V31, P358, DOI 10.1165/rcmb.2003-03880C; Shankar V, 1997, AM J RESP CELL MOL, V16, P232; Shao MXG, 2005, J IMMUNOL, V175, P4009; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shao MXG, 2004, AM J PHYSIOL-LUNG C, V287, pL420, DOI 10.1152/ajplung.00019.2004; Sharma P, 1998, AM J RESP CELL MOL, V19, P30; Shimizu T, 2003, AM J RESP CRIT CARE, V168, P581, DOI 10.1164/rccm.200212-1437OC; Siedow A, 2002, TUMOR BIOL, V23, P54, DOI 10.1159/000048689; Singh PK, 2006, TRENDS CELL BIOL, V16, P467, DOI 10.1016/j.tcb.2006.07.006; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; Song ZP, 2005, PLANT SPEC BIOL, V20, P83; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; Thai P, 2005, AM J RESP CELL MOL, V33, P523, DOI 10.1165/rcmb.2004-0220RC; Thornton DJ, 1997, J BIOL CHEM, V272, P9561; Thornton DJ, 1996, BIOCHEM J, V316, P967; Thornton DJ, 2000, AM J PHYSIOL-LUNG C, V278, pL1118; Tyner JW, 2006, J CLIN INVEST, V116, P309, DOI 10.1172/JCI25167; VanWinkle LS, 1997, AM J PATHOL, V151, P443; Vermeer PD, 2003, AM J RESP CELL MOL, V28, P286, DOI 10.1165/rcmb.4887; VESTBO J, 1989, RESP MED, V83, P207, DOI 10.1016/S0954-6111(89)80033-2; von Mensdorff-Pouilly S, 2000, INT J BIOL MARKER, V15, P343; Voynow JA, 2004, AM J PHYSIOL-LUNG C, V287, pL1293, DOI 10.1152/ajplung.00140.2004; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Waggoner Darrel, 2007, Semin Pediatr Neurol, V14, P7, DOI 10.1016/j.spen.2006.11.004; Wan HJ, 2005, J BIOL CHEM, V280, P13809, DOI 10.1074/jbc.M414122200; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Yamada N, 2006, INT J CANCER, V119, P1850, DOI 10.1002/ijc.22047; Yoshisue H, 2004, BIOSCI BIOTECH BIOCH, V68, P2024, DOI 10.1271/bbb.68.2024; Young HWJ, 2007, AM J RESP CELL MOL, V37, P273, DOI 10.1165/rcmb.2005-04600C; Yuan-Chen WD, 2007, AM J PATHOL, V170, P20; Zhen GH, 2007, AM J RESP CELL MOL, V36, P244, DOI 10.1165/rcmb.2006-0180OC; Zheng S, 2007, FREE RADICAL BIO MED, V42, P1398, DOI 10.1016/j.freeradbiomed.2007.01.040; ZRIHANLICHT S, 1995, INT J CANCER, V62, P245, DOI 10.1002/ijc.2910620303; Zuhdi A.M., 2000, AM J RESP CELL MOL B, V22, P253	147	99	101	1	6	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0066-4278		978-0-8243-0370-9	ANNU REV PHYSIOL	Annu. Rev. Physiol.		2008	70						405	429		10.1146/annurev.physiol.70.113006.100441		25	Physiology	Physiology	281IF	WOS:000254489400018	17961085	
J	Wright, RJ; Subramanian, SV				Wright, Rosalind J.; Subramanian, S. V.			Advancing a multilevel framework for epidemiologic research on asthma disparities	CHEST			English	Article; Proceedings Paper	National Workshop to Reduce Asthma Disparities	JAN, 2005	Chicago, IL			air pollution; asthma disparities; environmental justice; housing; indoor allergens; stress; tobacco smoke; violence	INNER-CITY CHILDREN; DIESEL EXHAUST PARTICLES; AROMATIC-HYDROCARBON CONCENTRATIONS; AIR-POLLUTION; HAY-FEVER; CIGARETTE-SMOKING; RISK-FACTORS; ALLERGIC SENSITIZATION; ENVIRONMENTAL EXPOSURE; SOCIOECONOMIC-STATUS	Our understanding of asthma epidemiology is growing increasingly complex. Asthma outcomes are clearly socially patterned, with asthma ranking as a leading cause of health disparities among minority and low socioeconomic groups. Yet, the increasing prevalence and marked disparities in asthma remain largely. unexplained by known risk factors. In the United States, asthma disproportionately affects nonwhite children living in urban areas and children living in poverty. Low socioeconomic status (SES), ethnic minority group status, and residence in an inner-city environment are closely intertwined in the United States, making it a challenge to fully disentangle the independent effects of each of these characteristics on asthma morbidity. In addition, studies show geographic variation in asthma outcomes across large cities and neighborhoods within cities that cannot be explained by economic factors alone. Although more limited data are available, studies in rural areas also suggest the stratification of risk based on SES and the proportion of minorities. Among low-SES areas, those with predominantly minority, segregated populations seem especially burdened. Marginalized populations of lower socioeconomic position are disproportionately exposed to irritants (eg, tobacco smoke), pollutants (eg, diesel-related particles), and indoor allergens (eg, cockroach and mouse allergen). Moreover, these marginalized individuals may also live in communities that are increasingly socially toxic, which, in turn, may be related to the increased experience of psychosocial stress that may influence asthma morbidity. Epidemiologic trends suggest that asthma may provide an excellent paradigm for understanding the role of community-level contextual factors in disease. Specifically, a multilevel approach that includes an ecological perspective may help to explain heterogeneities in asthma expression across socioeconomic and geographic boundaries that, to date, remain largely unexplained. Traditionally, asthma epidemiology has focused on individual-level risk factors and family factors. Far less attention has been given to the broader social context in which individuals live. A multilevel approach that explicitly recognizes the embedding of asthma within its biological, psycho-socioeconomic, environmental, and community contexts, is likely to provide a better understanding of asthma disparities at different stages in the life course. Is it simply asthma disparities or is it social disparities in asthma?	Brigham & Womens Hosp, Harvard Med Sch, Dept Med, Channing Lab, Boston, MA 02115 USA; Harvard Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA USA	Wright, RJ (reprint author), Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	rosalind.wright@channing.harvard.edu					Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; American Lung Association, 2001, ENVIRON HEALTH PER S, V109, P357; ANDA RF, 1990, JAMA-J AM MED ASSOC, V264, P1541, DOI 10.1001/jama.264.12.1541; ATTAR BK, 1994, J CLIN CHILD PSYCHOL, V23, P391, DOI 10.1207/s15374424jccp2304_5; BACHEN EA, 1995, PSYCHOSOM MED, V57, P366; BAUER K, 2003, INT J APPL PHIL, V17, P2410; BECKHAM JC, 1995, J TRAUMA STRESS, V8, P461, DOI 10.1007/BF02102970; BOR W, 1993, SOC SCI MED, V9, P27; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braveman P, 2000, B WORLD HEALTH ORGAN, V78, P232; BURKART KM, 2005, ASTHMA PREVENTION, P377; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CASTRO FG, 1987, J HEALTH SOC BEHAV, V28, P273, DOI 10.2307/2136846; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; COHEN S, 1990, HEALTH PSYCHOL, V9, P466, DOI 10.1037/0278-6133.9.4.466; COHEN S, 1991, NEW ENGL J MED, V325, P606, DOI 10.1056/NEJM199108293250903; Cookson W, 1999, NATURE SB, V402, P5, DOI 10.1038/35037002; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; CRAIN EF, 1994, PEDIATRICS, V94, P356; Cunningham J, 1996, AM J PUBLIC HEALTH, V86, P1406, DOI 10.2105/AJPH.86.10.1406; CURRY SJ, 1993, AM J PREV MED, V9, P78; DEMPSTER AP, 1981, J AM STAT ASSOC, V76, P341, DOI 10.2307/2287835; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiezRoux AV, 1997, AM J EPIDEMIOL, V146, P48; Dunn JR, 2002, J EPIDEMIOL COMMUN H, V56, P671, DOI 10.1136/jech.56.9.671; Dunn JR, 1999, ANN NY ACAD SCI, V896, P399, DOI 10.1111/j.1749-6632.1999.tb08153.x; Dunn JR, 2000, SOC SCI MED, V51, P563, DOI 10.1016/S0277-9536(99)00496-7; Duster T, 2005, SCIENCE, V307, P1050, DOI 10.1126/science.1110303; Evans GW, 2004, AM J PUBLIC HEALTH, V94, P1942, DOI 10.2105/AJPH.94.11.1942; Evans GW, 2001, HANDBOOK OF HEALTH PSYCHOLOGY, P365; EVANS R, 1992, CHEST, V101, pS368; FEIGELMAN W, 1989, J PSYCHOACTIVE DRUGS, V21, P299; FINKELHOR D, 1995, AM J ORTHOPSYCHIAT, V65, P177, DOI 10.1037/h0079618; FISHER E, 2001, HLTH BEHAV HDB; Ganz ML, 2000, AM J PUBLIC HEALTH, V90, P367, DOI 10.2105/AJPH.90.3.367; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; GOLDIN C, 1998, 6439 MAT BUR EC RES; Goldstein H., 2003, MULTILEVEL STAT MODE; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; Haan M. N., 1989, PATHWAYS HLTH ROLE S, P76; Hertzman C, 1999, ANN NY ACAD SCI, V896, P85, DOI 10.1111/j.1749-6632.1999.tb08107.x; Hertzman C, 1996, SOC SCI MED, V43, P1083, DOI 10.1016/0277-9536(96)00028-7; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Ireson Carol L, 2005, J Ky Med Assoc, V103, P103; ISAAES M, 1992, VIOLENCE IMPACT COMM; JACKSON F L C, 1992, Ethnicity and Disease, V2, P120; JUN HJ, 2007, AM J PUBLIC HLTH; Karvonen S, 1996, SOC SCI MED, V43, P1467, DOI 10.1016/0277-9536(96)00044-5; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; Kawachi I, 1997, BRIT MED J, V314, P1037; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Kennedy BP, 1996, BRIT MED J, V312, P1004; Kennedy BP, 1998, SOC SCI MED, V47, P7, DOI 10.1016/S0277-9536(98)00097-5; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; KLEINSCHMIDT I, 1997, J EPIDEMIOL COMMUNIT, V87, P1113; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Levy JI, 2003, J EXPO ANAL ENV EPID, V13, P364, DOI 10.1038/sj.jea.7500289; Levy JI, 2002, J EXPO ANAL ENV EPID, V12, P104, DOI 10.1038/sj/jea/7500203; Longford N., 1993, RANDOM COEFFICIENT M; MARDER D, 1992, CHEST S, V10, pS79; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MARWICK C, 1995, JAMA-J AM MED ASSOC, V274, P1004, DOI 10.1001/jama.274.13.1004; McAlister-Groves B, 1993, JAMA-J AM MED ASSOC, V269, P262; McKinlay JB, 2000, AM J PUBLIC HEALTH, V90, P25, DOI 10.2105/AJPH.90.1.25; Meyerowitz BE, 1998, PSYCHOL BULL, V123, P47, DOI 10.1037//0033-2909.123.1.47; MILLER J, 2000, AM J PUBLIC HEALTH, V86, P1406; MITCHELL EA, 1989, INT J EPIDEMIOL, V18, P888, DOI 10.1093/ije/18.4.888; Murray CJL, 1999, B WORLD HEALTH ORGAN, V77, P537; Nelson DA, 1997, ANN ALLERG ASTHMA IM, V78, P21; Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Ohta K, 1999, J ALLERGY CLIN IMMUN, V104, P1024; Ormstad H, 1998, CLIN EXP ALLERGY, V28, P702; Ortiz L, 2004, J RURAL HEALTH, V20, P246, DOI 10.1111/j.1748-0361.2004.tb00035.x; OSOFSKY JD, 1993, PSYCHIATRY, V56, P36; Ossorio P, 2005, AM PSYCHOL, V60, P115, DOI 10.1037/0003-066X.60.1.115; Pandya RJ, 2002, ENVIRON HEALTH PERSP, V110, P103; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; PERRIN JM, 1989, NEW ENGL J MED, V320, P1183, DOI 10.1056/NEJM198905043201805; Phinney JS, 1996, AM PSYCHOL, V51, P918, DOI 10.1037/0003-066X.51.9.918; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; POTTER JD, 1992, JAMA-J AM MED ASSOC, V268, P1573; RAMANO PS, 1991, AM J PUBLIC HEALTH, V81, P1415; Ramsay DS, 1996, J PEDIATR PSYCHOL, V21, P833, DOI 10.1093/jpepsy/21.6.833; Raudenbush S., 2002, HIERARCHICAL LINEAR; REIHSAUS E, 1993, AM J RESP CELL MOL, V8, P334; Reijneveld SA, 1998, INT J EPIDEMIOL, V27, P33, DOI 10.1093/ije/27.1.33; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Sampson RJ, 1999, AM SOCIOL REV, V64, P633, DOI 10.2307/2657367; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sandel M, 2006, ARCH DIS CHILD, V91, P942, DOI 10.1136/adc.2006.098376; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHUBINER H, 1993, J ADOLESCENT HEALTH, V14, P214, DOI 10.1016/1054-139X(93)90008-D; Shaw M, 2004, ANNU REV PUBL HEALTH, V25, P397, DOI 10.1146/annurev.publhealth.25.101802.123036; SLY RM, 1988, ANN ALLERGY, V60, P433; SORENSEN A, 1998, THEORETICAL MECH EMP; STANKUS R P, 1988, Journal of Allergy and Clinical Immunology, V81, P563, DOI 10.1016/0091-6749(88)90195-9; STANKUS RP, 1990, J ALLERGY CLIN IMMUN, V86, P781, DOI 10.1016/S0091-6749(05)80183-6; Stevenson LA, 2001, J ALLERGY CLIN IMMUN, V108, P747, DOI 10.1067/mai.2001.119410; STOKOLS D, 1992, AM PSYCHOL, V47, P6, DOI 10.1037/0003-066X.47.1.6; STOREY E, 2003, SURVEY ASTHMA PREVAL, P10; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strunk Robert C., 2002, Journal of Allergy and Clinical Immunology, V109, P229, DOI 10.1067/mai.2002.120950; Subramanian SV, 2002, ANNU REV PUBL HEALTH, V23, P287, DOI 10.1146/annurev.publhealth.23.100901.140540; Subramanian SV, 2004, SOC SCI MED, V58, P1961, DOI 10.1016/S0277-9536(03)00415-5; SUBRAMANIAN SV, 2004, ENCY HLTH BEHAV; Subramanian S.V., 2003, MULTILEVEL METHODS P; Susser E, 2004, EPIDEMIOLOGY, V15, P519, DOI 10.1097/01.ede.0000135911.42282.b4; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; Thomson CC, 2002, ARCH PEDIAT ADOL MED, V156, P818; TWAROG FJ, 1977, J ALLERGY CLIN IMMUN, V59, P154, DOI 10.1016/0091-6749(77)90218-4; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; WAGENER DK, 1993, TOXICOL IND HEALTH, V9, P775; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787; WEISS KB, 1990, JAMA-J AM MED ASSOC, V264, P1683, DOI 10.1001/jama.264.13.1683; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; WILLIAMS DR, 1990, SOC PSYCHOL QUART, V53, P81, DOI 10.2307/2786672; WILSON JW, 1987, TRULY DISADVANCED IN; Wood Alastair J. J., 2002, Journal of Allergy and Clinical Immunology, V110, pS318, DOI 10.1067/mai.2002.129701; Woolcock M, 1998, THEOR SOC, V27, P151, DOI 10.1023/A:1006884930135; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Wright RJ, 2003, NEIGHBORHOODS HLTH, P233; Wright RJ, 2006, CLIN CHEST MED, V27, P413, DOI 10.1016/j.ccm.2006.04.003; WUTHRICH B, 1989, INT ARCH ALLER A IMM, V90, P3; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Yamashita N, 2001, J ALLERGY CLIN IMMUN, V107, P135, DOI 10.1067/mai.2001.111433; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; Zaas D, 2003, SEM RESP CRIT CARE M, V24, P185, DOI 10.1055/s-2003-39017	141	99	101	5	19	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2007	132	5		S			757S	769S		10.1378/chest.07-1904		13	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	235MV	WOS:000251239300003	17998340	
J	Hayashi, N; Tsukamoto, Y; Sallas, WM; Lowe, PJ				Hayashi, Naoto; Tsukamoto, Yuko; Sallas, William M.; Lowe, Philip J.			A mechanism-based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						atopic asthma; binding model monoclonal antibody; IgE; NONMEM	ANTI-IGE ANTIBODIES; MONOCLONAL-ANTIBODY; GAMMAE-ANTIBODIES; IMMUNOGLOBULIN-G; THERAPY; METABOLISM; DISEASE; MYELOMA; RABBITS	Aim Omalizumab, a humanized IgG monoclonal antibody that binds to human immunoglobulin E (IgE), interrupts the allergic cascade in asthmatic patients. The aim was to compare simultaneously drug exposure and IgE biomarker responses in Japanese and White patient populations. Methods An instantaneous equilibrium drug-ligand binding and turnover population model was built from 202 Japanese patients. A posterior predictive evaluation for the steady-state distributions of omalizumab and IgE was then carried out against 531 White patients. Results The mean parameters estimated from the Japanese patients were as follows: omalizumab clearance 7.32 +/- 0.153 ml h(-1), IgE clearance 71.0 +/- 4.68 ml h(-1) and the difference between that for omalizumab and the complex 5.86 +/- 0.920 ml h(-1), the volume of distribution for omalizumab and IgE 5900 +/- 107 ml, and that for the complex 3630 +/- 223 ml, the rate of IgE production 30.3 +/- 2.04 mu g h(-1). Half-lives of IgG (23 days) and IgE (2.4 days) were close to previous reports. The dissociation constant for binding, 1.07 nM, was similar to in vitro values. Clearance and volume of distribution for omalizumab varied with bodyweight, whereas the clearance and rate of production of IgE were predicted accurately by baseline IgE. Overall, these covariates explained much of the interindividual variability. Conclusions The predictiveness of the Japanese model was confirmed by Monte-Carlo simulations for a White population, also providing evidence that the pharmacokinetics of omalizumab and IgE were similar in these two populations. Furthermore, the model enabled the estimation of not only omalizumab disposition parameters, but also the binding with and the rate of production, distribution and elimination of its target, IgE.	Novartis Pharma AG, Modelling & Simulat, CH-4056 Basel, Switzerland; Novartis Pharma AG, Drug Metab & Pharmacokinet, Basel, Switzerland; Novartis Pharma KK, Drug Metab & Pharmacokinet, Tokyo, Japan; Nova Pharmaceut Corp, Modeling & Simulat, E Hanover, NJ USA	Lowe, PJ (reprint author), Novartis Pharma AG, Modelling & Simulat, Lichtstr 35, CH-4056 Basel, Switzerland.	phil.lowe@novartis.com		Lowe, Philip/0000-0003-4074-8227			Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; BILL A, 1977, ACTA PHYSIOL SCAND, V101, P28, DOI 10.1111/j.1748-1716.1977.tb05980.x; Boushey H. A., 1998, Research in Immunology, V149, P189, DOI 10.1016/S0923-2494(98)80024-2; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Charles P, 1999, J IMMUNOL, V163, P1521; Fick R B, 1999, Pediatr Pulmonol Suppl, V18, P115; Frazer JK, 1999, FUNDAMENTAL IMMUNOLO, P37; *GEN INC, 2003, XOL OM SUBC US PACK; HEDGER MP, 1994, J ANDROL, V15, P583; Heusser C, 1997, CURR OPIN IMMUNOL, V9, P805, DOI 10.1016/S0952-7915(97)80182-3; Holgate ST, 1998, ALLERGY, V53, P83; ISHIZAKA K, 1967, J IMMUNOL, V99, P1187; ISHIZAKA K, 1970, CLIN EXP IMMUNOL, V6, P25; Jardieu P, 1996, FROM GENETICS TO QUALITY OF LIFE, P193; Jardieu P, 1995, CURR OPIN IMMUNOL, V7, P779, DOI 10.1016/0952-7915(95)80047-6; Jardieu PM, 1999, INT ARCH ALLERGY IMM, V118, P112, DOI 10.1159/000024043; JOHANSSON SG, 1967, IMMUNOLOGY, V13, P381; Junghans RP, 1997, IMMUNOL RES, V16, P29, DOI 10.1007/BF02786322; JUWEID M, 1992, EUR J NUCL MED, V19, P159; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; Lobo ED, 2004, J PHARM SCI-US, V93, P2645, DOI 10.1002/jps.20178; Meno-Tetang GML, 2005, BASIC CLIN PHARMACOL, V96, P182, DOI 10.1111/j.1742-7843.2005.pto960307.x; Patalano F, 1999, ALLERGY, V54, P103; PRESTA LG, 1993, J IMMUNOL, V151, P2623; SABOURAUD AE, 1992, J PHARMACOL EXP THER, V260, P1214; SCHERRMANN JM, 1989, J TOXICOL-CLIN TOXIC, V27, P1; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Streeten D. H., 1998, J CHRONIC FATIGUE SY, V4, P3, DOI 10.1300/J092v04n01_02; Valentine JL, 1996, J PHARMACOL EXP THER, V278, P717; WALDMANN TA, 1969, PROG ALLERGY, V13, P1, DOI 10.1159/000287491; WALDMANN TA, 1976, J IMMUNOL, V117, P1139	31	99	101	1	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0306-5251			BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	MAY	2007	63	5					548	561		10.1111/j.1365-2125.2006.02803.x		14	Pharmacology & Pharmacy	Pharmacology & Pharmacy	158RO	WOS:000245811700006	17096680	
J	Python, F; Goebel, C; Aeby, P				Python, Francois; Goebel, Carsten; Aeby, Pierre			Assessment of the U937 cell line for the detection of contact allergens	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						CD86; IL-1 beta; IL-8; U937 cell line; In vitro sensitization test	LYMPH-NODE ASSAY; SURFACE-MARKER EXPRESSION; GENERATED DENDRITIC CELLS; IN-VITRO MODEL; COSTIMULATORY MOLECULES; SIGNALING PATHWAYS; CHEMICAL ALLERGEN; SKIN SENSITIZERS; MESSENGER-RNA; CYTOKINE	The human myeloid cell line U937 was evaluated as an in vitro test system to identify contact sensitizers in order to develop alternatives to animal tests for the cosmetic industry. Specific culture conditions (i.e., presence of interleukin-4, IL-4) were applied to obtain a dendritic cell-like phenotype. In the described test protocol, these cells were exposed to test chemicals and then analyzed by flow cytometry for CD86 expression and by quantitative real-time reverse transcriptase-polymerase chain reaction for IL-I beta and IL-8 gene expressions. Eight sensitizers, three non-sensitizers and five oxidative hair dye precursors were examined after 24-, 48- and 72-h exposure times. Test item-specific modulations of the chosen activation markers (CD86, IL-1 beta and IL-8) suggest that this U937 activation test could discriminate test items classified as contact sensitizers or non-sensitizers in the local lymph node assay in mice (LLNA). More specifically, a test item can be considered as a potential sensitizer when it significantly induced the upregulation of the expression of at least two markers. Using this approach, we could correctly evaluate the dendritic cell (DC) activation potential for 15 out of 16 tested chemicals. We conclude that the U937 activation test may represent an useful tool in a future in vitro test battery for predicting sensitizing properties of chemicals. (c) 2007 Elsevier Inc. All rights reserved.	Procter & Gamble Co, Wella Cosmital SA, Expt Prod Safety, Marly, Switzerland; Procter & Gamble Co, Wella Serv GmbH, Human Safety Assessment, Darmstadt, Germany	Python, F (reprint author), Rte Chesalles 21, CH-1723 Marly, Switzerland.	python.f@pg.com					Aeby P, 2004, J INVEST DERMATOL, V122, P1154, DOI 10.1111/j.0022-202X.2004.22402.x; Aiba S, 1997, EUR J IMMUNOL, V27, P3031, DOI 10.1002/eji.1830271141; Ashikaga T, 2002, TOXICOL IN VITRO, V16, P711, DOI 10.1016/S0887-2333(02)00060-7; Azam P, 2006, TOXICOL APPL PHARM, V212, P14, DOI 10.1016/j.taap.2005.06.018; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Basketter DA, 2002, FOOD CHEM TOXICOL, V40, P593, DOI 10.1016/S0278-6915(01)00130-2; BASKETTER DA, 1994, FOOD CHEM TOXICOL, V32, P543, DOI 10.1016/0278-6915(94)90112-0; Boisleve F, 2004, J INVEST DERMATOL, V123, P494, DOI 10.1111/j.0022-202X.2004.23229.x; Casati S, 2005, ATLA-ALTERN LAB ANIM, V33, P47; Coquette A, 2003, TOXICOL IN VITRO, V17, P311, DOI 10.1016/S0887-2333(03)00019-5; Coutant KD, 1999, TOXICOL SCI, V52, P189, DOI 10.1093/toxsci/52.2.189; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; Dearman RJ, 1999, J APPL TOXICOL, V19, P299, DOI 10.1002/(SICI)1099-1263(199909/10)19:5<299::AID-JAT591>3.0.CO;2-C; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Feghali Carol A., 1997, Frontiers in Bioscience (online), V2, pD12; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gerberick GF, 2004, CONTACT DERMATITIS, V50, P274, DOI 10.1111/j.0105-1873.2004.00290.x; Heydorn S, 2003, CONTACT DERMATITIS, V48, P317, DOI 10.1034/j.1600-0536.2003.00133.x; Hu ZB, 1996, LEUKEMIA, V10, P1025; Hulette BC, 2005, TOXICOL APPL PHARM, V209, P159, DOI 10.1016/j.taap.2005.03.019; Hulette BC, 2002, TOXICOL APPL PHARM, V182, P226, DOI 10.1006/taap.2002.9447; Hulette BC, 2001, ARCH DERMATOL RES, V293, P147, DOI 10.1007/s004030000201; Jugde F, 2005, TOXICOLOGY, V212, P227, DOI 10.1016/j.tox.2005.04.019; Kimber I, 2003, FOOD CHEM TOXICOL, V41, P1799, DOI 10.1016/S0278-6915(03)00223-0; Kimber I, 2002, CONTACT DERMATITIS, V47, P315, DOI 10.1034/j.1600-0536.2002.470601.x; Koss A, 1996, LEUKEMIA LYMPHOMA, V22, P163, DOI 10.3109/10428199609051744; LEPOITTEVIN JP, 1998, ALLERGIC CONTACT DER; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; Masterson AJ, 2002, BLOOD, V100, P701, DOI 10.1182/blood.V100.2.701; Nagorsen D, 2004, CYTOKINE, V25, P31, DOI 10.1016/j.cyto.2003.08.012; Pichowski JS, 2000, TOXICOL IN VITRO, V14, P351, DOI 10.1016/S0887-2333(00)00030-8; Reutter K, 1997, TOXICOL IN VITRO, V11, P619, DOI 10.1016/S0887-2333(97)00048-9; Rollins BJ, 1997, BLOOD, V90, P909; Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432; Ryan CA, 2005, TOXICOL SCI, V88, P4, DOI 10.1093/toxsci/kfi245; Ryan CA, 2004, TOXICOL LETT, V150, P301, DOI 10.1016/j.toxlet.2004.02.002; Ryan CA, 2002, FOOD CHEM TOXICOL, V40, P1719, DOI 10.1016/S0278-6915(02)00116-3; Sakaguchi H, 2006, TOXICOL IN VITRO, V20, P774, DOI 10.1016/j.tiv.2005.10.014; Sallusto F, 1999, EUR J IMMUNOL, V29, P1617, DOI 10.1002/(SICI)1521-4141(199905)29:05<1617::AID-IMMU1617>3.0.CO;2-3; Scapini P, 2000, IMMUNOL REV, V177, P195, DOI 10.1034/j.1600-065X.2000.17706.x; St Louis DC, 1999, J IMMUNOL, V162, P3237; Staquet MJ, 2004, TOXICOL IN VITRO, V18, P493, DOI 10.1016/j.tiv.2003.12.005; Straube F, 2005, ARCH TOXICOL, V79, P37, DOI 10.1007/s00204-004-0606-8; Toebak MJ, 2006, TOXICOL IN VITRO, V20, P117, DOI 10.1016/j.tiv.2005.06.039; Tuschl H, 2000, TOXICOL IN VITRO, V14, P541, DOI 10.1016/S0887-2333(00)00051-5; Tuschl H, 2001, TOXICOL IN VITRO, V15, P327, DOI 10.1016/S0887-2333(01)00030-3; VANDEBRIEL RJ, 2005, TOXICOL APPL PHARM, V207, pS142; Yoshida Y, 2003, TOXICOL IN VITRO, V17, P221, DOI 10.1016/S0887-2333(03)00006-7	48	99	103	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	APR 15	2007	220	2					113	124		10.1016/j.taap.2006.12.026		12	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	157GX	WOS:000245707900001	17306317	
J	Arshad, SH; Bateman, B; Sadeghnejad, A; Gant, C; Matthews, SM				Arshad, Syed Hasan; Bateman, Belinda; Sadeghnejad, Alireza; Gant, Carole; Matthews, Sharon M.			Prevention of allergic disease during childhood by allergen avoidance: The Isle of Wight prevention study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						atopy; allergy; asthma; rhinitis; atopic dermatitis; food allergy; prevention; diet; house dust mite; randomized controlled trial	HOUSE-DUST MITE; BIRTH-COHORT; ASTHMA; EXPOSURE; INFANCY; SENSITIZATION; RISK; AGE; OUTCOMES; ATOPY	Background: Early life allergen exposure may increase the risk of childhood allergy, but the protective effect of reduction in allergen exposure remains uncertain. Objective: To evaluate the effect of reduction in food and house dust mite (HDM) allergen exposure in infancy in preventing asthma and allergy. Methods: Infants, at higher risk because of family predisposition, were recruited prenatally and randomized to prophylactic (n = 58) and control (n = 62) groups. Prophylactic group infants were either breast-fed with mother on a low allergen diet or given an extensively hydrolyzed formula. Exposure to HDM was reduced by the use of an acaricide and mattress covers. The control group followed standard advice. Development of allergic diseases and sensitization to common allergens (atopy) was assessed blindly at ages 1, 2, 4, and 8 years in all 120 children. Results: Repeated measurement analysis, adjusted for all relevant confounding variables, confirmed a preventive effect on asthma: adjusted odds ratio (OR), 0.24; 95% CI, 0.09-0.66; P = .005; atopic dermatitis, OR, 0.23; Cl, 0.08-0.64; P = .005; rhinitis, OR, 0.42; CI, 0.19-0.92; P = .03; and atopy, OR, 0.13; Cl, 0.05-0.32; P < .001. The protective effect was primarily observed in the subgroup of children with persistent disease (symptoms at all visits) and in those with evidence of allergic sensitization. Conclusion: Allergic diseases can be reduced, for at least the first 8 years of life, by combined food and HDM allergen avoidance in infancy. Clinical implications: Strict food and HDM allergen avoidance should be considered for prevention of allergy in high-risk infants.	St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, Wales; Wake Forest Univ, Sch Med, Ctr Human Genom, Winston Salem, NC 27109 USA	Arshad, SH (reprint author), St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport PO30 5TG, Wight, Wales.	sha@soton.ac.uk	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Arshad SH, 2003, THORAX, V58, P489, DOI 10.1136/thorax.58.6.489; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braman SS, 2006, CHEST S1, V130, p4S, DOI DOI 10.1378/CHEST.130.1_; Chan-Yeung M, 2005, J ALLERGY CLIN IMMUN, V116, P49, DOI 10.1016/j.jaci.2005.03.029; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; DOLD S, 1992, ARCH DIS CHILD, V67, P1018; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; Hide D W, 1994, Pediatr Allergy Immunol, V5, P61, DOI 10.1111/j.1399-3038.1994.tb00351.x; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Host A, 1994, PEDIATR ALLERGY IMMU, V5, P5, DOI 10.1111/j.1399-3038.1994.tb00352.x; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; KRAMER MS, 2001, COCHRANE LIB, V1, DOI UNSP CD000133; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Oddy WH, 2002, J ALLERGY CLIN IMMUN, V110, P65, DOI 10.1067/mai.2002.125296; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Spergel Jonathan M., 2003, Journal of Allergy and Clinical Immunology, V112, pS118, DOI 10.1016/j.jaci.2003.09.033; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stokes ME, 2001, CATEGORICAL DATA ANA; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4	30	99	104	1	8	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2007	119	2					307	313		10.1016/j.jaci.2006.12.621		7	Allergy; Immunology	Allergy; Immunology	137YB	WOS:000244327900006	17291851	
J	Zambelli-Weiner, A; Ehrlich, E; Stockton, ML; Grant, AV; Zhang, S; Levett, PN; Beaty, TH; Barnes, KC				Zambelli-Weiner, A; Ehrlich, E; Stockton, ML; Grant, AV; Zhang, S; Levett, PN; Beaty, TH; Barnes, KC			Evaluation of the CD14/-260 polymorphism and house dust endotoxin exposure in the Barbados Asthma Genetics Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						CD14; endotoxin; LPS; asthma; allergy; atopy; asthma severity; IgE; genetics; gene-environment interaction	CIRCULATING SOLUBLE CD14; INFLAMMATORY RESPONSE; PULMONARY-FUNCTION; INNATE IMMUNITY; VITAL CAPACITY; NORMAL MEN; TESTS; ASSOCIATION; POPULATIONS; INHALATION	Background: Both a functional promoter polymorphism in the gene encoding CD14 (C-260T) and exposure to endotoxin are believed to play key roles in modulating the immune response and expression of atopic disease. Objective: We aimed to evaluate the role of the CD14 C-260T polymorphism in a population of African descent and to test for interaction between this genotype and house dust endotoxin (HDE) exposure on atopic phenotypes. Methods: Asthmatic probands and their families were recruited as part of the Barbados Asthma Genetics Study. The C-260T polymorphism and two additional CD14 promoter markers (G-1461T, C-1721T) were genotyped. Endotoxin was measured in house dust samples. Results: Using a Family-Based Association Test, the C-260T allele appeared to be protective against asthma (z = -2.444; P = .015) and asthma severity (z = -2.615; P = .009) under a recessive model. No significant associations were observed for the G-1461T and C-1721T markers both individually and in haplotypes. In a case-control analysis, the CD14 TT genotype was found to reduce risk of asthma compared with the CD 14 CC/CT genotypes (odds ratio [OR], 0.26; 95% CI, 0.14-0.49) and was associated with lower asthma severity scores (P < .002). The TT genotype might protect against asthma for individuals with low HDE (OR, 0.09; 95% CI, 0.03-0.24), but may be a risk factor for individuals with high HDE (OR, 11.66; 95% CI, 1.03-131.7), suggesting a gene-environment interaction. Conclusion: These data suggest that the CD14-260 polymorphism may play a role in controlling risk to atopic disease and underscore the importance of incorporating key environmental exposures into studies of genetic risk factors.	Johns Hopkins Sch Med, Dept Med, Div Clin Immunol & Allergy, Baltimore, MD USA; Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA; Univ W Indies, Fac Med, Sch Clin Med & Res, Bridgetown, Barbados	Barnes, KC (reprint author), Johns Hopkins Asthma & Allergy Ctr, 3A-62A,5501 Hopkins Bayview Circle, Baltimore, MD 21224 USA.	kbarnes@jhmi.edu			NIAID NIH HHS [AI 20059]; NIEHS NIH HHS [T32 ES 07141]		Akashi S, 2000, BIOCHEM BIOPH RES CO, V268, P172, DOI 10.1006/bbrc.2000.2089; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Barnes KC, 1999, J ALLERGY CLIN IMMUN, V104, P791; Barnes KC, 1997, J MED ENTOMOL, V34, P212; Cella M, 1997, CURR OPIN IMMUNOL, V9, P10, DOI 10.1016/S0952-7915(97)80153-7; Chun DTW, 2002, ANN AGR ENV MED, V9, P49; GAENSLER EA, 1951, AM REV TUBERC PULM, V64, P256; Gao PS, 1999, CLIN GENET, V56, P164; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; Heinzmann A, 2003, EUR J IMMUNOGENET, V30, P345, DOI 10.1046/j.1365-2370.2003.00414.x; HORVATH S, 2001, GENET EPIDEMIOL S, V21, P403; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; KORY RC, 1961, AM J MED, V30, P243, DOI 10.1016/0002-9343(61)90096-1; Lake SL, 2000, AM J HUM GENET, V67, P1515, DOI 10.1086/316895; LANDMANN R, 1995, J INFECT DIS, V171, P639; LEUALLEN EC, 1955, AM REV TUBERC PULM, V72, P783; LEWONTIN RC, 1988, GENETICS, V120, P849; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; Michel O, 2000, TOXICOLOGY, V152, P25, DOI 10.1016/S0300-483X(00)00288-2; MILLER WF, 1959, J APPL PHYSIOL, V14, P157; Nickel RG, 1999, HUM IMMUNOL, V60, P738, DOI 10.1016/S0198-8859(99)00039-7; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Peden DB, 1999, J ALLERGY CLIN IMMUN, V104, P388, DOI 10.1016/S0091-6749(99)70383-0; PEMBERTON J, 1956, J APPL PHYSIOL, V9, P291; Rabinowitz D, 2000, HUM HERED, V50, P211, DOI 10.1159/000022918; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; RIZZO MC, 1999, ACI INT, V11, P153; RYLANDER R, 1989, AM REV RESPIR DIS, V140, P981; Rylander R., 1997, INT J OCCUP ENV HL S, V3, P32; Sengler C, 2003, CLIN EXP ALLERGY, V33, P166, DOI 10.1046/j.1365-2222.2003.01549.x; StataCorp, 2003, STAT STAT SOFTW REL; Togias A, 1997, INT ARCH ALLERGY IMM, V113, P87; Vercelli D, 2001, J ENDOTOXIN RES, V7, P45, DOI 10.1179/096805101101532521; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Woo JG, 2003, J ALLERGY CLIN IMMUN, V112, P438, DOI 10.1067/mai.2003.1634; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107	39	99	101	1	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1203	1209		10.1016/j.jaci.2005.03.001		7	Allergy; Immunology	Allergy; Immunology	935WZ	WOS:000229815400015	15940135	
J	Gidaro, GB; Marcucci, F; Sensi, L; Incorvaia, C; Frati, F; Ciprandi, G				Gidaro, GB; Marcucci, F; Sensi, L; Incorvaia, C; Frati, F; Ciprandi, G			The safety of sublingual-swallow immunotherapy: an analysis of published studies	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						high allergen dose; low allergen dose; safety; sublingual immunotherapy	DOUBLE-BLIND PLACEBO; HOUSE-DUST-MITE; STANDARDIZED 5-GRASS-POLLEN EXTRACT; LOCAL ALLERGOID IMMUNOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; PARIETARIA-JUDAICA EXTRACT; GRASS-POLLEN; SEASONAL RHINOCONJUNCTIVITIS; PEDIATRIC-PATIENTS; CHILDREN	Background As the main target of sublingual immunotherapy (SLIT) is to reduce at most the occurrence of adverse events (AE), safety represents a critical issue. This aspect deserves particular mention when a higher dose of allergen extract than traditional subcutaneous immunotherapy (SCIT) is required to be effective: that may be up to 500 times that employed for SCIT. Objective All published controlled studies concerning SLIT-swallow were analysed to evaluate AE rates. Methods Studies were subdivided in two groups: (i) studies using low allergen dose (LAD), i.e. ranging from 1 to 50 times the dose commonly administered with SCIT, and (ii) studies with high allergen dose (HAD), i.e. ranging from 50 to 500 times the dose administered with SCIT. Results Twenty-five studies were altogether analysed: 13 studies belonged to the low-dose group, 12 belonged to the high-dose group. We considered all patients with at least one AE. Local reactions were significantly more frequent in the LAD group than in the HAD group (P < 0.0001), while there was no difference in the rate of systemic reactions. Severe systemic reactions were never reported. Conclusion This study represents the first analysis of the safety of SLIT concerning the allergen dose employed in the treatment. There is evidence that AE occurrence is substantially not dose-dependent. This fact highlights two main clinical aspects: the elevated tolerability of SLIT in general and the safety of HAD regimen.	Stallergenes, Dept Sci, Milan, Italy; Univ Perugia, Dept Obstet Gynaecol & Pediat, I-06100 Perugia, Italy; ICP Hosp, Allergy Rheumatol Unit, Milan, Italy; San Martino Hosp, Head Neck Dept, Genoa, Italy	Ciprandi, G (reprint author), AO Osped San Martino, Padigl Special Piano Terzo, Dipartimento Reg Testa Collo, Allergol UO ORL, Largo R Benzi 10, I-16132 Genoa, Italy.	gio.cip@libero.it					Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; Ariano R, 2001, Allergol Immunopathol (Madr), V29, P238; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BOUSQUET J, 2001, J ALLERGY CLIN IMMUN, V108, P315; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Hordijk G J, 1998, Allergol Immunopathol (Madr), V26, P234; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Lombardi C, 2001, ALLERGY, V56, P889; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Mortemousque B, 2003, CLIN EXP ALLERGY, V33, P464, DOI 10.1046/j.1365-2222.2003.01622.x; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P31, DOI 10.1097/00130832-200402000-00007; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; STEWART GE, 1992, J ALLERGY CLIN IMMUN, V90, P567, DOI 10.1016/0091-6749(92)90129-P; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tonnel AB, 2004, ALLERGY, V59, P491, DOI 10.1111/j.1398-9995.2004.00456.x; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Williams AP, 2004, CLIN EXP ALLERGY, V34, P513, DOI 10.1111/j.1365-2222.2004.1927.x; Wilson DR, 2003, COCHRANE DB SYST REV, DOI [10.1016/S1081-1206(10)60004-X, DOI 10.1002/14651858.CD002893]	45	99	117	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2005	35	5					565	571		10.1111/j.1365-2222.2005.02240.x		7	Allergy; Immunology	Allergy; Immunology	927ES	WOS:000229175800005	15898976	
J	Kandavelu, V; Kastien, H; Thampi, KR				Kandavelu, V; Kastien, H; Thampi, KR			Photocatalytic degradation of isothiazolin-3-ones in water and emulsion paints containing nanocrystalline TiO2 and ZnO catalysts	APPLIED CATALYSIS B-ENVIRONMENTAL			English	Article						titanium dioxide; zinc oxide; photodegradation; isothiazolin-3-ones; heterogeneous photocatalysis; allergens	MICROBICIDAL 3-ISOTHIAZOLONE COMPOUNDS; ELECTRODES; FILMS; PHOTODEGRADATION; DISPERSIONS; SUSPENSIONS; TEMPERATURE; IRRADIATION; ENVIRONMENT; POLLUTANTS	The photocatalytic degradation of isothiazolin-3-ones has been studied using the catalytically active TiO2 and ZnO and the inactive paint grade TiO2, under various illumination and chemical conditions. The reaction follows a pseudo-first-order kinetics. Three types of lamps have been used. The photocatalytic degradation is faster under UV lamp, when it is compared to reaction under suntest and fluorescent lamps. In the presence of oxygen and H2O2, the reaction proceeds faster than in air atmosphere. ZnO exhibits comparable activity with TiO2 and in some cases it was found to be even better than TiO2. The reaction was studied in aqueous suspensions as well as on gas-solid interfaces. The degradation of isothiazolin-3-ones in paint formulations was also studied. (C) 2003 Elsevier B.V. All rights reserved.	EPFL, LPI, CH-1015 Lausanne, Switzerland; Swisslack AG, CH-8304 Wallisellen, Switzerland	Thampi, KR (reprint author), EPFL, LPI, CH-1015 Lausanne, Switzerland.	ravindranathan.thampi@epfl.ch					ALSAYYED G, 1991, J PHOTOCH PHOTOBIO A, V58, P99, DOI 10.1016/1010-6030(91)87101-Z; Barbe CJ, 1997, J AM CERAM SOC, V80, P3157; CROW WD, 1967, AUST J CHEM, V20, P2729; CROW WD, 1969, AUST J CHEM, V22, P765; CROW WD, 1965, J ORG CHEM, V30, P2660, DOI 10.1021/jo01019a037; Dhananjeyan MR, 2000, CHEM COMMUN, P1443, DOI 10.1039/b003108i; Dhananjeyan MR, 2001, J PHYS CHEM B, V105, P12046, DOI 10.1021/jp011339q; Fujishima A., 1999, TIO2 PHOTOCATALYSIS; GOOSSENS A, 1997, CONTACT DERMATITIS, V39, P133; HARBOUR JR, 1979, J PHYS CHEM-US, V83, P652, DOI 10.1021/j100469a003; HOFFMANN MR, 1995, CHEM REV, V95, P69, DOI 10.1021/cr00033a004; Honda H, 1998, J ILLUM ENG SOC, V27, P42; Jerschow E, 2001, FOOD CHEM TOXICOL, V39, P1095, DOI 10.1016/S0278-6915(01)00059-X; KAMAT PV, 1993, CHEM REV, V93, P267, DOI 10.1021/cr00017a013; Kikuchi Y, 1997, J PHOTOCH PHOTOBIO A, V106, P51, DOI 10.1016/S1010-6030(97)00038-5; KORMANN C, 1988, ENVIRON SCI TECHNOL, V22, P798, DOI 10.1021/es00172a009; KRZEMINSKI SF, 1975, J AGR FOOD CHEM, V23, P1068, DOI 10.1021/jf60202a054; KRZEMINSKI SF, 1975, J AGR FOOD CHEM, V23, P1060, DOI 10.1021/jf60202a053; LI Y, 1996, STUD SURF SCI CATAL, V103, P391; LINDUIST I, 1963, INORGANIC ADDUCT MOL; Malato S, 2002, CATAL TODAY, V76, P209, DOI 10.1016/S0920-5861(02)00220-1; MARKHAM MC, 1965, J CATAL, V4, P229, DOI 10.1016/0021-9517(65)90013-8; Ollis D.F., 1993, PHOTOCATALYTIC PURIF; Rajesh B, 2002, FUEL, V81, P2177, DOI 10.1016/S0016-2361(02)00162-X; Rastogi SC, 2000, CONTACT DERMATITIS, V43, P339, DOI 10.1034/j.1600-0536.2000.043006339.x; Reinhardi E, 2001, CONTACT DERMATITIS, V45, P257, DOI 10.1034/j.1600-0536.2001.450501.x; RICHARD C, 1992, J PHOTOCH PHOTOBIO A, V66, P225, DOI 10.1016/1010-6030(92)85216-H; SAKAI H, 1995, CHEM LETT, P185, DOI 10.1246/cl.1995.185; Sunada K, 1998, ENVIRON SCI TECHNOL, V32, P726, DOI 10.1021/es970860o; THAMPI KR, 1983, J INDIAN CHEM SOC, V60, P1156; THAMPI KR, 1987, NATURE, V327, P506, DOI 10.1038/327506a0; THAMPI KR, 1983, ELECTROCHIM ACTA, V28, P1869; THAMPI KR, 1990, J CATAL, V126, P572; Toren K, 1997, AM J IND MED, V31, P551, DOI 10.1002/(SICI)1097-0274(199705)31:5<551::AID-AJIM8>3.0.CO;2-W; *US EPA, 1982, PEST ASS GUID SUBD N; WILLIAMS TM, 1999, 303 NACE; Yeber MC, 1999, CHEMOSPHERE, V39, P1679, DOI 10.1016/S0045-6535(99)00068-5; Zhang FL, 1998, APPL CATAL B-ENVIRON, V15, P147, DOI 10.1016/S0926-3373(97)00043-X	38	99	105	2	28	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0926-3373			APPL CATAL B-ENVIRON	Appl. Catal. B-Environ.	MAR 18	2004	48	2					101	111		10.1016/j.apcatb.2003.09.022		11	Chemistry, Physical; Engineering, Environmental; Engineering, Chemical	Chemistry; Engineering	803ZV	WOS:000220269900003		
J	Yang, IA; Barton, SJ; Rorke, S; Cakebread, JA; Keith, TP; Clough, JB; Holgate, ST; Holloway, JW				Yang, IA; Barton, SJ; Rorke, S; Cakebread, JA; Keith, TP; Clough, JB; Holgate, ST; Holloway, JW			Toll-like receptor 4 polymorphism and severity of atopy in asthmatics	GENES AND IMMUNITY			English	Article						asthma; atopy; Toll-like receptor 4; polymorphism (genetics)	TOLL-LIKE RECEPTOR-4; HOUSE-DUST ENDOTOXIN; MUTATIONS; EXPOSURE; GENE; SENSITIZATION; ASSOCIATION; CHILDREN; HYGIENE; RISK	Endotoxin exposure may have a protective effect against asthma and atopy. An Asp299Gly polymorphism in the Toll-like receptor 4 (TLR4) gene reduces responsiveness to endotoxin. This study determined the effect of TLR4 polymorphism on the risk and severity of asthma and atopy. In all, 336 UK Caucasian families with greater than or equal to2 affected sibs (physician's diagnosis of asthma and current medication use) and 179 Caucasians without asthma or a family history of asthma were genotyped using ARMS-PCR. No association of the TLR4 polymorphism was found with the risk of developing asthma, either in parent-affected sibling trios, or in case-control analyses (P>0.05). In the first affected asthmatic siblings, the atopy severity score (based on size and number of positive skin-prick tests and specific IgE) was higher in those with the Asp/Gly or Gly/Gly genotypes (mean 1.8, s.d. 1.1, n=39) compared to those with the Asp/Asp genotype (mean 1.2, s.d. 1.0, n=279) (P=0.003, t-test). No associations were found with total <LF>IgE, FEV1 % predicted, slope of FEV1 response to methacholine or asthma severity score (P>0.05). This study confirms the previously observed lack of association of TLR4 polymorphisms with asthma. In contrast, the findings suggest that genetically determined hyporesponsiveness to endotoxin may increase atopy severity.	Univ Southampton, Asthma Genet Lab, Div Human Genet, Southampton, Hants, England; Univ Southampton, Div Infection Inflammat & Repair, Southampton, Hants, England; Genome Therapeut Corp, Waltham, MA USA	Yang, IA (reprint author), Southampton Gen Hosp, Div Human Genet, Mailpoint 808,Tremona Rd, Southampton SO16 6YD, Hants, England.	I.Yang@soton.ac.uk	Yang, Ian/B-9609-2008; Holloway, John/B-5424-2009	Yang, Ian/0000-0001-8338-1993; Holloway, John/0000-0001-9998-0464; Barton, Sheila/0000-0003-4963-4242			Agnese DM, 2002, J INFECT DIS, V186, P1522, DOI 10.1086/344893; Arbour NC, 2000, NAT GENET, V25, P187; Beutler B, 2003, ANNU REV PHARMACOL, V43, P609, DOI 10.1146/annurev.pharmtox.43.100901.135729; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Holgate ST, 1999, NATURE, V402, P2, DOI 10.1038/35037000; HOLLOWAY JW, 2001, SEVERE ASTHMA PATHOG, P19; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Lorenz E, 2002, ARCH INTERN MED, V162, P1028, DOI 10.1001/archinte.162.9.1028; Pearce N, 1999, THORAX, V54, P268; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Sayers I, 2003, THORAX, V58, P417, DOI 10.1136/thorax.58.5.417; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; von Mutius E, 2002, J ALLERGY CLIN IMMUN, V109, pS525, DOI 10.1067/mai.2002.124565; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Ye S, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.17.e88	22	99	110	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-4879			GENES IMMUN	Genes Immun.	JAN	2004	5	1					41	45		10.1038/sj.gene.6364037		5	Genetics & Heredity; Immunology	Genetics & Heredity; Immunology	765VG	WOS:000188304600006	14735148	
J	Gilliland, FD; Berhane, KT; Li, YF; Gauderman, WJ; McConnell, R; Peters, J				Gilliland, FD; Berhane, KT; Li, YF; Gauderman, WJ; McConnell, R; Peters, J			Children's lung function and antioxidant vitamin, fruit, juice, and vegetable intake	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						antioxidants; ascorbic acid; child; diet; respiratory function tests; vitamin A; vitamin E	SOUTHERN CALIFORNIA COMMUNITIES; FOOD FREQUENCY QUESTIONNAIRE; PULMONARY-FUNCTION; GENERAL-POPULATION; AIR-POLLUTION; DIETARY ANTIOXIDANTS; DIFFERING LEVELS; ASTHMA; OBSTRUCTION; ASSOCIATION	The authors investigated the relation between children's pulmonary function and intake of fruits, vegetables, juices, and vitamins A, C, and E by examining cross-sectional data from 2,566 children in the Children's Health Study collected during 1997-1998. Low total vitamin C intake (less than or equal to10th percentile) was associated with deficits in forced vital capacity for both boys and girls and with deficits in flows that were larger in girls (forced expiratory volume in 1 second (FEV1), -3.3%, 95% confidence interval (CI): -6.0, -0.5; forced expiratory flow between 25% and 75% of forced vital capacity (FEF25-75), -5.5%, 95% CI: -10.5, -0.3) compared with boys (FEV1, -2.3%, 95% CI: -4.8, 0.3; FEF25-75, -2.4%, 95% CI: -7.4, 2.8). Low dietary vitamin E intake was associated with lower FEF25-75 (boys: FEF25-75 , -8.9%, 95% CI: -14.2, -3.3; girls: FEF25-75 , -2.5%, 95% CI: -8.3, 3.7). Deficits in FEF25-75 were associated with low dietary vitamin A intake in girls (FEF25-75, -7.9%, 95% CI: -12.7, -2.8) and with low total vitamin A intake in boys with asthma (FEF25-75, -15.6%, 95% CI: -27.6, -1.6). Low intakes of orange and other fruit juices, which were the largest source of vitamin C, were associated with deficits in forced vital capacity and FEV1 in boys. In summary, lung function levels were lower in children with inadequate dietary antioxidant vitamin intake.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.		LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [1 R01 HL61768]; NIEHS NIH HHS [1P01 ES09581, 5P30 ES07048]		Becker R. A., 1988, NEW S LANGUAGE; BRITTON JR, 1995, AM J RESP CRIT CARE, V151, P1383; Butland BK, 2000, THORAX, V55, P102, DOI 10.1136/thorax.55.2.102; Chen RL, 2001, AM J EPIDEMIOL, V153, P157, DOI 10.1093/aje/153.2.157; Cook DG, 1997, THORAX, V52, P628; Enright PL, 2000, CHEST, V118, P665, DOI 10.1378/chest.118.3.665; Fogarty A, 2000, Curr Opin Pulm Med, V6, P86, DOI 10.1097/00063198-200001000-00015; Gilliland FD, 1999, ENVIRON HEALTH PERSP, V107, P403; Gilliland FD, 2002, AM J EPIDEMIOL, V155, P125, DOI 10.1093/aje/155.2.125; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198; Grievink L, 1998, THORAX, V53, P166; HASTIE T, 1993, J ROY STAT SOC B MET, V55, P757; Hastie T, 1990, GEN ADDITIVE MODELS; Hu GZ, 2000, AM J EPIDEMIOL, V151, P975; Hu GZ, 1998, AM J EPIDEMIOL, V148, P594; Institute of Medicine, 2000, DIET REF INT VIT C V; *I MED, 2001, DIET REF INT VIT A V; Kassaye T, 2001, INT J EPIDEMIOL, V30, P457, DOI 10.1093/ije/30.3.457; Mathew R, 1991, Magnes Trace Elem, V10, P220; McKeever TM, 2002, AM J RESP CRIT CARE, V165, P1299, DOI 10.1164/rccm.2109030; Ness AR, 1996, EUR J CLIN NUTR, V50, P573; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Rockett HRH, 1997, PREV MED, V26, P808, DOI 10.1006/pmed.1997.0200; Rockett HRH, 1997, AM J CLIN NUTR, V65, P1116; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Romieu I, 2001, EPIDEMIOL REV, V23, P268; Schunemann HJ, 1997, AM J EPIDEMIOL, V146, P939; Schunemann HJ, 2001, EPIDEMIOL REV, V23, P248; Schunemann HJ, 2002, AM J EPIDEMIOL, V155, P463, DOI 10.1093/aje/155.5.463; Schunemann HJ, 2001, AM J RESP CRIT CARE, V163, P1246; Sempertegui F, 2001, INT J EPIDEMIOL, V30, P465, DOI 10.1093/ije/30.3.465; Soutar A, 1997, THORAX, V52, P166; Tabak C, 2001, CLIN EXP ALLERGY, V31, P747, DOI 10.1046/j.1365-2222.2001.01064.x; TROISI RJ, 1995, AM J RESP CRIT CARE, V151, P1401; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420; Weiss ST, 1997, CIBA F SYMP, V206, P244; WEISS ST, 1997, CIBA F SYMP, V206, P253; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51; Wypij D, 1996, AM J RESP CRIT CARE, V154, pS223; WYPIJ D, 1994, STAT SINICA, V3, P329	41	99	101	0	4	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	SEP 15	2003	158	6					576	584		10.1093/aje/kwg181		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	721HK	WOS:000185310800010	12965883	
J	Almqvist, C; Egmar, AC; Hedlin, G; Lundqvist, M; Nordvall, SL; Pershagen, G; Svartengren, M; van Hage-Hamsten, M; Wickman, M				Almqvist, C; Egmar, AC; Hedlin, G; Lundqvist, M; Nordvall, SL; Pershagen, G; Svartengren, M; van Hage-Hamsten, M; Wickman, M			Direct and indirect exposure to pets - risk of sensitization and asthma at 4 years in a birth cohort	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergens; allergy and immunology; animals; asthma; cats; child; dogs; domestic; endotoxins; prevention; primary	CAT ALLERGEN; CHILDREN; CHILDHOOD; OWNERSHIP; SCHOOL; HOMES; LIFE; SYMPTOMS; ENVIRONMENT; PREVALENCE	Introduction There are conflicting data on the association between early exposure to pets and allergic diseases. Bias related to retrospective information on pet ownership has been addressed as a reason for distorted study results. Objective To elucidate how early exposure to cat and dog relates to IgE-sensitization and asthma in children at 2 and 4 years of age, in a prospective birth-cohort study. Methods Four thousand and eighty-nine families with children born 1994-1996 in predefined areas of Stockholm answered questionnaires on environmental factors and symptoms of allergic disease at birth, one, two and four years of age. Dust samples collected from the mothers' beds at birth were analysed for Fel d 1 and Can f 1 in a subgroup of the cohort. Blood samples taken at four years from 2614 children were analysed for allergen-specific IgE to common airborne allergens. Risk associations were calculated with a multiple logistic regression model, with adjustment for potential confounders. Results A correlation was seen between allergen levels and reported exposure to cat and dog. Exposure to cat seemed to increase the risk of cat sensitization, OR (odds ratio) 1.44 (95% confidence interval 1.03-2.01), whereas dog exposure did not have any effect on dog sensitization, OR 1.16 (0.79-1.72). Dog ownership was related to a reduced risk of sensitization to other airborne allergens, OR 0.36 (0.15-0.83), and a similar tendency was seen for cat ownership OR 0.63 (0.37-1.07). Early dog ownership seemed to be associated with a lower risk of asthma, OR 0.50 (0.24-1.03), with no corresponding effect after cat ownership, OR 0.88 (0.56-1.38). Conclusion Early exposure to cat seems to increase the risk of sensitization to cat but not of asthma at 4 years of age. Dog ownership, on the other hand, appears to be associated with lowered risk of sensitization to airborne allergens and asthma. Both aetiological relationships and selection effects have to be considered in the interpretation of these findings.	Karolinska Hosp, S-17176 Stockholm, Sweden; Karolinska Inst, Astrid Lindgren Childrens Hosp, Dept Woman & Child Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Uppsala Univ, Inst Woman & Child Hlth, Uppsala, Sweden; Karolinska Inst, Dept Publ Hlth Sci, Stockholm, Sweden; Karolinska Hosp & Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Karolinska Inst, Inst Sodersjukhuset, Sachs Childrens Hosp, Stockholm, Sweden	Almqvist, C (reprint author), Karolinska Hosp, Norrbacka 3rd Floor, S-17176 Stockholm, Sweden.		van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596			Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694; Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Custovic A, 1998, THORAX, V53, P33; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Egmar AC, 1998, PEDIATR ALLERGY IMMU, V9, P31, DOI 10.1111/j.1399-3038.1998.tb00297.x; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Lannero E, 2002, PEDIATR ALLERGY IMMU, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MURRAY AB, 1983, J ALLERGY CLIN IMMUN, V72, P145, DOI 10.1016/0091-6749(83)90522-5; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Parvaneh S, 1999, ALLERGY, V54, P229, DOI 10.1034/j.1398-9995.1999.00855.x; Pearce N, 1999, THORAX, V54, P268; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2002, CLIN EXP ALLERGY, V32, P335, DOI 10.1046/j.1365-2222.2002.01352.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; *SOC IND, 1989, OCC POP HOUS CENS 19; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Svedmyr J, 1999, ACTA PAEDIATR, V88, P42; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wahn U, 1997, PEDIATR ALLERGY IMMU, V8, P16	33	99	99	2	8	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2003	33	9					1190	1197		10.1046/j.1365-2222.2003.01764.x		8	Allergy; Immunology	Allergy; Immunology	727UC	WOS:000185678400005	12956738	
J	Basketter, DA; Angelini, G; Ingber, A; Kern, PS; Menne, T				Basketter, DA; Angelini, G; Ingber, A; Kern, PS; Menne, T			Nickel, chromium and cobalt in consumer products: revisiting safe levels in the new millennium	CONTACT DERMATITIS			English	Review						nickel; chromate; cobalt; thresholds; consumer products; elicitation	ALLERGIC CONTACT-DERMATITIS; LYMPH-NODE ASSAY; RISK ASSESSMENT; HAND ECZEMA; EXPOSURE; SKIN; SENSITIZATION; THRESHOLDS; REACTIVITY; MODELS	The transition metals nickel (Ni), chromium (Cr) and cobalt (Co) are common causes of allergic contact dermatitis (ACD). Given the high frequency with which these allergens can be associated with hand eczema in those responsible for domestic work, it has been suggested that contamination of household consumer products with these metals may be of relevance to the causation/chronicity of hand dermatitis. Dose-response studies using 48 h occlusive patch test conditions in sensitized individuals show that greater than or equal to90% of sensitized patients fail to react below 1 p.p.m., even on irritated skin. Assessment under more realistic exposure conditions has shown that in the presence of irritants and/or following repeated exposures, such individuals rarely react to levels below 10 p.p.m. On the basis of this information, it was recommended a decade ago that household (and other consumer) products should not contain more than 5 p.p.m. of each of Ni, Cr or Co and that, for an even greater degree of protection, the ultimate target level should be 1 p.p.m. The data generated since the original recommendations were made serve to reinforce the validity of these recommendations. Indeed, it is our view that typically the level of each of these transition metals should not normally exceed 1 p.p.m. Then, where consumer products meet this guideline fully, modern quantitative risk assessment shows clearly that elicitation of ACD is highly improbable, and the chance of the induction of sensitization is even lower.	Unilever Colworth, SEAC, Sharnbrook MK44 1LQ, Beds, England; Univ Bari, Dept Internal Med Immunol & Infect Dis, Unit Dermatol, I-70121 Bari, Italy; Haddassah Hosp, Dept Dermatol, Jerusalem, Israel; Procter & Gamble Co, European Tech Ctr, Strombeek Bever, Belgium; Gentofte Univ Hosp, Dept Dermatol, Hellerup, Denmark	Basketter, DA (reprint author), Unilever Colworth, SEAC, Sharnbrook MK44 1LQ, Beds, England.						Agner T, 2002, CONTACT DERMATITIS, V47, P21, DOI 10.1034/j.1600-0536.2002.470105.x; ANGELINI G, 2002, CONTACT DERMATITIS, V46, P28; Banfield CC, 1998, CONTACT DERMATITIS, V38, P316, DOI 10.1111/j.1600-0536.1998.tb05765.x; Basketter D, 2001, CONTACT DERMATITIS, V44, P70, DOI 10.1034/j.1600-0536.2001.440202.x; BASKETTER DA, 1993, CONTACT DERMATITIS, V28, P15, DOI 10.1111/j.1600-0536.1993.tb03318.x; Basketter DA, 1997, FOOD CHEM TOXICOL, V35, P417, DOI 10.1016/S0278-6915(97)00129-4; Basketter DA, 2003, CLIN EXP DERMATOL, V28, P218, DOI 10.1046/j.1365-2230.2003.01247.x; Basketter DA, 2002, CONTACT DERMATITIS, V47, P1, DOI 10.1034/j.1600-0536.2002.470101.x; Basketter DA, 2001, CONTACT DERMATITIS, V45, P89, DOI 10.1034/j.1600-0536.2001.045002089.x; BASKETTER DA, 1993, HAND ECZEMA, P85; Robinson M., 1996, TOXICOLOGY CONTACT H, P152; Felter SP, 2002, CONTACT DERMATITIS, V47, P257, DOI 10.1034/j.1600-0536.2002.470502.x; FELTER SP, 2002, REGUL TOXICOL PHARM, V37, P1; FORTINA AB, 2002, CONTACT DERMATITIS, V46, P65; Francomano M, 2000, CONTACT DERMATITIS, V42, P169; GAIKEMA FJ, 2002, NDCCP00701; Gerberick G F, 2001, Am J Contact Dermat, V12, P156, DOI 10.1053/ajcd.2001.23926; Gerberick GF, 2001, CONTACT DERMATITIS, V45, P333, DOI 10.1034/j.1600-0536.2001.450603.x; Hansen MB, 2002, CONTACT DERMATITIS, V47, P127, DOI 10.1034/j.1600-0536.2002.470301.x; *IKW ZWEI, 1999, UNT BEW HAUTV MOD HA; Ingber A, 1998, CONTACT DERMATITIS, V38, P101, DOI 10.1111/j.1600-0536.1998.tb05660.x; *ISPESL, 2001, TREV C; Iyer VJ, 2002, CONTACT DERMATITIS, V47, P357, DOI 10.1034/j.1600-0536.2002.470608.x; Kimber I, 1995, TOXICOLOGY, V103, P63, DOI 10.1016/0300-483X(95)03114-U; Kimber I, 1999, FOOD CHEM TOXICOL, V37, P553, DOI 10.1016/S0278-6915(99)00048-4; Liden C., 2001, TXB CONTACT DERMATIT, P933; Meneghini C L, 1995, Curr Probl Dermatol, V23, P41; MENNE T, 1993, CONTACT DERMATITIS, V29, P180; Nava C, 1989, G Ital Med Lav, V11, P109; Nava C, 1993, G Ital Med Lav, V15, P83; NETHERCOTT J, 1994, OCCUP ENVIRON MED, V51, P371; Nielsen NH, 1999, BRIT J DERMATOL, V141, P676; Nielsen NH, 2000, CONTACT DERMATITIS, V43, P212, DOI 10.1034/j.1600-0536.2000.043004212.x; Robinson MK, 2000, CONTACT DERMATITIS, V42, P251, DOI 10.1034/j.1600-0536.2000.042005251.x; Sharma VK, 1998, CONTACT DERMATITIS, V38, P127, DOI 10.1111/j.1600-0536.1998.tb05677.x; VERMEIRE TG, 1993, SCI TOTAL ENVIRON, V136, P155, DOI 10.1016/0048-9697(93)90305-P; VILAPLANA J, 1987, CONTACT DERMATITIS, V16, P139, DOI 10.1111/j.1600-0536.1987.tb01407.x	37	99	100	0	5	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	JUL	2003	49	1					1	7		10.1111/j.0105-1873.2003.00149.x		7	Allergy; Dermatology	Allergy; Dermatology	748ZB	WOS:000186891900001	14641113	
J	Host, A; Andrae, S; Charkin, S; Diaz-Vazquez, C; Dreborg, S; Eigenmann, PA; Friedrichs, F; Grinsted, P; Lack, G; Meylan, G; Miglioranzi, P; Muraro, A; Nieto, A; Niggemann, B; Pascual, C; Pouech, MG; Rance, F; Rietschel, E; Wickman, M				Host, A; Andrae, S; Charkin, S; Diaz-Vazquez, C; Dreborg, S; Eigenmann, PA; Friedrichs, F; Grinsted, P; Lack, G; Meylan, G; Miglioranzi, P; Muraro, A; Nieto, A; Niggemann, B; Pascual, C; Pouech, MG; Rance, F; Rietschel, E; Wickman, M			Allergy testing in children: why, who, when and how?	ALLERGY			English	Editorial Material							HOUSE-DUST-MITE; LATE ASTHMATIC RESPONSES; BLIND CONTROLLED TRIAL; COMMON FOOD PROTEINS; SKIN PRICK TEST; ATOPIC-DERMATITIS; IGE CONCENTRATIONS; COWS MILK; IN-VITRO; BRONCHIAL HYPERREACTIVITY			Host, A (reprint author), Odense Univ Hosp, Dept Pediat, DK-5000 Odense C, Denmark.		Osborne, Nicholas/N-4915-2015; Eigenmann, Philippe/A-6569-2017	Osborne, Nicholas/0000-0002-6700-2284; Eigenmann, Philippe/0000-0003-1738-1826			Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; Abramson MJ, 2000, COCHRANE DB SYST REV; Ahlstedt S, 2002, CLIN EXP ALLERGY, V32, P11, DOI 10.1046/j.0022-0477.2001.01289.x; Annus T, 2001, CLIN EXP ALLERGY, V31, P1846, DOI 10.1046/j.1365-2222.2001.01238.x; *BAND LIB, BIAS DIAGN TEST LEV; Berger W E, 2001, Curr Allergy Asthma Rep, V1, P498, DOI 10.1007/s11882-001-0058-7; Board of Directors, 1993, J ALLERGY CLIN IMMUN, V92, P636; Bohme M, 2001, ACTA DERM-VENEREOL, V81, P193, DOI 10.1080/000155501750376294; BONER AL, 1985, ANN ALLERGY, V54, P42; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1046/j.1365-2222.1997.d01-418.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Brehler R, 2001, ARCH INTERN MED, V161, P1057, DOI 10.1001/archinte.161.8.1057; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; BURR MK, 1989, ARCH DIS CHILD, V64, P1454; BUSTOS GJ, 1995, CLIN EXP ALLERGY, V25, P568, DOI 10.1111/j.1365-2222.1995.tb01096.x; Carswell F, 1996, CLIN EXP ALLERGY, V26, P386, DOI 10.1111/j.1365-2222.1996.tb00554.x; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Crimi P, 2001, J INVEST ALLERG CLIN, V11, P103; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Dreborg S, 2001, PEDIATR ALLERGY IMMU, V12, P24, DOI 10.1034/j.1399-3038.2001.121406.x; DREBORG S, 1996, PEDIAT ALLERGY IMM S, P14; Dreborg S., 1989, ALLERGY S10, V44, P22; Dreborg S, 1985, ALLERGY S4, V40, P66; Dreborg SKG, 2001, IMMUNOL ALLERGY CLIN, V21, P329, DOI 10.1016/S0889-8561(05)70210-1; DURHAM SR, 1988, J ALLERGY CLIN IMMUN, V82, P764, DOI 10.1016/0091-6749(88)90077-2; EAACI, 1993, ALLERGY, V48, P48; Eccles M, 1998, BRIT MED J, V316, P1232; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Eigenmann PA, 2000, PEDIATR ALLERGY IMMU, V11, P95, DOI 10.1034/j.1399-3038.2000.00071.x; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eigenmann PA, 1998, PEDIATR ALLERGY IMMU, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Garcia-Ara C, 2001, J ALLERGY CLIN IMMUN, V107, P185, DOI 10.1067/mai.2001.111592; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; GOTZSCHE PC, 2002, COCHRANE DATABASE SY, V3, DOI ARTN CD001187; Grootendorst DC, 2001, CLIN EXP ALLERGY, V31, P400, DOI 10.1046/j.1365-2222.2001.01022.x; Haby MM, 2001, THORAX, V56, P589, DOI 10.1136/thorax.56.8.589; Halken S, 2003, J ALLERGY CLIN IMMUN, V111, P169, DOI 10.1067/mai.2003.5; Halken S, 2000, ALLERGY, V55, P793, DOI 10.1034/j.1398-9995.2000.00117.x; Harbour R, 2001, BRIT MED J, V323, P334, DOI 10.1136/bmj.323.7308.334; HARVING H, 1994, ALLERGY, V49, P866, DOI 10.1111/j.1398-9995.1994.tb00789.x; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; Holm L, 2001, ALLERGY, V56, P152, DOI 10.1034/j.1398-9995.2001.056002152.x; HOST A, 1990, ALLERGY, V45, P587, DOI 10.1111/j.1398-9995.1990.tb00944.x; Host A, 2000, ALLERGY, V55, P600, DOI 10.1034/j.1398-9995.2000.00122.x; IIKURA Y, 1992, ANN ALLERGY, V68, P233; Isolauri E, 1996, J ALLERGY CLIN IMMUN, V97, P9, DOI 10.1016/S0091-6749(96)70277-4; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Magnus P, 1997, BRIT MED J, V314, P1795; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; MARKS GB, 1995, CLIN EXP ALLERGY, V25, P114, DOI 10.1111/j.1365-2222.1995.tb01015.x; MARKS GB, 1995, J ALLERGY CLIN IMMUN, V96, P441, DOI 10.1016/S0091-6749(95)70285-7; MARKS GB, 1994, CLIN EXP ALLERGY, V24, P1078, DOI 10.1111/j.1365-2222.1994.tb02746.x; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MEDILLO G, 1991, ALLERGY, V46, P321; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; Muller UR, 1998, CLIN EXP ALLERGY, V28, P4; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Nickel R, 1997, J ALLERGY CLIN IMMUN, V99, P613, DOI 10.1016/S0091-6749(97)70021-6; Niggemann B, 1994, Pediatr Allergy Immunol, V5, P11, DOI 10.1111/j.1399-3038.1994.tb00212.x; Niggemann B, 2000, ALLERGY, V55, P281, DOI 10.1034/j.1398-9995.2000.00464.x; National Institutes of Health, 2002, GLOB STRAT ASTHM MAN; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; NOLTE H, 1987, ALLERGY, V42, P366, DOI 10.1111/j.1398-9995.1987.tb02223.x; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740; OSTERGAARD PA, 1990, ALLERGY, V45, P1; Oxford Centre for Evidence-Based Medicine, 2001, LEV EV GRAD REC; Pearce N, 1999, THORAX, V54, P268; Piacentini GL, 1998, CLIN EXP ALLERGY, V28, P561; PIACENTINI GL, 1993, J ALLERGY CLIN IMMUN, V92, P644, DOI 10.1016/0091-6749(93)90006-2; Piacentini GL, 1996, J ALLERGY CLIN IMMUN, V97, P1079, DOI 10.1016/S0091-6749(96)70261-0; Ponsonby AL, 2002, CHEST, V121, P135, DOI 10.1378/chest.121.1.135; Resano A, 1998, J INVEST ALLERG CLIN, V8, P271; Roehr CC, 2001, J ALLERGY CLIN IMMUN, V107, P548, DOI 10.1067/mai.2001.112849; Salkind AR, 2001, JAMA-J AM MED ASSOC, V285, P2498, DOI 10.1001/jama.285.19.2498; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sanz ML, 1996, J INVEST ALLERG CLIN, V6, P152; Sasai K, 1996, J PEDIATR-US, V128, P834, DOI 10.1016/S0022-3476(96)70337-2; Schultz Larsen F, 1996, J Am Acad Dermatol, V34, P760; Schultz Larsen F, 1993, J Am Acad Dermatol, V28, P719; SCHULTZ LF, 1996, PEDIAT ALLERGY IMMUN, V7, P51; SEARS MR, 1993, CLIN EXP ALLERGY, V23, P949, DOI 10.1111/j.1365-2222.1993.tb00280.x; Selner JC, 1999, ANN ALLERG ASTHMA IM, V82, P407, DOI 10.1016/S1081-1206(10)62714-7; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V104, pS114, DOI 10.1016/S0091-6749(99)70053-9; Silvestri M, 1996, ANN ALLERG ASTHMA IM, V76, P239; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Trindade JC, 1998, PEDIATR ALLERGY IMMU, V9, P23; vanderHeide S, 1997, EUR RESPIR J, V10, P1217, DOI 10.1183/09031936.97.10061217; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; Vanto T, 1999, ALLERGY, V54, P837, DOI 10.1034/j.1398-9995.1999.00134.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; Wahn U, 2000, ALLERGY, V55, P591, DOI 10.1034/j.1398-9995.2000.00111.x; Wahn U, 1998, PEDIATR ALLERGY IMMU, V9, P116; Warner JA, 2000, J ALLERGY CLIN IMMUN, V105, P75, DOI 10.1016/S0091-6749(00)90181-7; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x; WICKMAN M, 1994, ALLERGY, V49, P114, DOI 10.1111/j.1398-9995.1994.tb00810.x; Wolkerstorfer A, 2002, CLIN EXP ALLERGY, V32, P70, DOI 10.1046/j.0022-0477.2001.01265.x; Yman L, 2001, ALLERGY, V56, P70, DOI 10.1034/j.1398-9995.2001.00921.x; Yunginger JW, 2000, J ALLERGY CLIN IMMUN, V105, P1077, DOI 10.1067/mai.2000.107041; ZETTERSTROM O, 1981, ALLERGY, V36, P537, DOI 10.1111/j.1398-9995.1981.tb01871.x	114	99	110	0	6	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	JUL	2003	58	7					559	569		10.1034/j.1398-9995.2003.00238.x		11	Allergy; Immunology	Allergy; Immunology	693QZ	WOS:000183731000003	12823111	
J	Jain, VV; Kitagaki, K; Businga, T; Hussain, I; George, C; O'Shaughnessy, P; Kline, JN				Jain, VV; Kitagaki, K; Businga, T; Hussain, I; George, C; O'Shaughnessy, P; Kline, JN			CpG-oligodeoxynucleotides inhibit airway remodeling in a murine model of chronic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; murine; CpG oligodeoxynucleotides; airway remodeling; collagen; subepithelial fibrosis; transforming growth factor beta; regulatory T lymphocytes	SUBEPITHELIAL FIBROSIS; FLOW OBSTRUCTION; BRONCHIAL-ASTHMA; INFLAMMATION; RESPONSIVENESS; CELLS; METHACHOLINE; GENERATION; MODULATION; RESPONSES	Background: We have previously demonstrated that CpG oligodeoxymicleotides (CpG-ODNs) protect against eosinophilia and airway hyperresponsiveness in marine models of allergen-induced asthma. Acute inflammation is hypothesized to induce chronic airway responses, but no previous studies have evaluated the effects of CpG-ODNs on allergen-induced airway remodeling. Because remodeling is thought to be responsible for many of the long-term adverse effects on asthmatic patients, we evaluated whether CpG-ODNs might similarly prevent these changes using a murine model of recurrent allergen exposure. Objective: The purpose of this study was to evaluate the effect of CpG-ODNs on chronic inflammatory changes and airway remodeling by using a marine model of chronic allergen-induced asthma. Methods: C57BL/6 mice were sensitized to ovalbumin (OVA) and subsequently exposed to nebulized OVA by means of inhalation 3 times weekly for 6 weeks. Some mice received CpG-ODNs by means of intraperitoneal injection at the time of sensitization. At the end of the exposure period, mice were evaluated for the development of airway inflammation, airway hyperresponsiveness, and airway remodeling. Results: OVA-sensitized mice exposed to recurrent airway challenge with OVA have chronic inflammation, persistent airway hyperresponsiveness, and evidence of airway remodeling, including subepithelial collagen deposition and goblet cell hyperplasia-metaplasia. These changes are significantly reduced in mice treated with CpG-ODNs. Interestingly, mice treated with CpG-ODNs exhibit increased levels of bronchoalveolar lavage transforming growth factor P, suggesting that regulatory T cells might be responsible for some of these protective effects. Conclusion: CpG-ODNs are effective not only in preventing acute inflammation but also appear to reduce markers of airway remodeling that develop after chronic allergen exposure.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA; Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Med, Iowa City, IA USA	Kline, JN (reprint author), UIHC, 200 Newton Rd, Iowa City, IA 52242 USA.			Jain, Vipul/0000-0001-5575-7869	NHLBI NIH HHS [HL59324]; NIDDK NIH HHS [DK54759]; NIEHS NIH HHS [ES05605]		AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; BOLENDER RP, 1993, AM J PHYSIOL, V265, pL521; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Broide D, 1998, J IMMUNOL, V161, P7054; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; Haneda K, 1997, J IMMUNOL, V159, P4484; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152; Kline JN, 1999, J ALLERGY CLIN IMMUN, V104, P1258; Kline JN, 2002, AM J PHYSIOL-LUNG C, V283, pL170, DOI 10.1152/ajplung.00402.2001; Kline JN, 1998, J IMMUNOL, V160, P2555; Krieg Arthur M., 2002, Trends in Immunology, V23, P64, DOI 10.1016/S1471-4906(01)02150-0; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557; ROCHE WR, 1989, LANCET, V1, P520; Russ JC, 2001, PRACTICAL STEREOLOGY; Santeliz JV, 2002, J ALLERGY CLIN IMMUN, V109, P455, DOI 10.1067/mai.2002.122156; Serebrisky D, 2000, J IMMUNOL, V165, P5906; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Sur S, 1999, J IMMUNOL, V162, P6284; Temelkovski J, 1998, THORAX, V53, P849; Terui T, 2001, J IMMUNOL, V167, P3661; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806; Zhang XM, 2001, J IMMUNOL, V167, P4245; ZuanyAmorim C, 1996, J IMMUNOL, V157, P377	33	99	113	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2002	110	6					867	872		10.1067/mai.2002.129371		6	Allergy; Immunology	Allergy; Immunology	624TL	WOS:000179777400008	12464952	
J	Wickens, K; Lane, JM; Fitzharris, P; Siebers, R; Riley, G; Douwes, J; Smith, T; Crane, J				Wickens, K; Lane, JM; Fitzharris, P; Siebers, R; Riley, G; Douwes, J; Smith, T; Crane, J			Farm residence and exposures and the risk of allergic diseases in New Zealand children	ALLERGY			English	Article						animals; allergic rhinitis; asthma; eczema; endotoxin; Der p 1; farming; hayfever; probiotics; skin prick test; wheeze	HAY-FEVER; ASTHMA PREVALENCE; EARLY-CHILDHOOD; SENSITIZATION; ENDOTOXIN; ATOPY; ENVIRONMENT; COMMUNITY; URBAN; SIZE	Background: Studies in Europe have reported a reduced prevalence of allergy in farmers children. We aimed to determine if there is a similar reduction in allergy among New Zealand farm children. Methods: Two hundred and ninety-three children participated (60%) aged 7-10 years, from selected schools in small towns and the surrounding rural area. Skin prick tests (SPT) to eight common allergens were performed. Parents completed questionnaires about allergic and infectious diseases, place of residence, exposure to animals, and diet, and they provided dust from the livingroom floor. Endotoxin was measured using an Limulus amoebocyte lysate (LAL) assay and Der p 1 using enzyme-linked immunoassay ( ELISA). Results: Current farm abode was found to increase the risk of having symptoms associated with allergy, but not SPT positivity. Independent inverse associations were found for early-life exposures: at least weekly consumption of yoghurt with hayfever (odds ratio (OR) = 0.3, 95% confidence intervals (CI) 0.1-0.7) and allergic rhinitis (OR = 0.3, 95% CI 0.2-0.7); any unpasteurized milk consumption with atopic eczema/dermatitis syndrome (AEDS) (OR = 0.2, 95% CI 0.1-0.8); cats inside or outside with hayfever (OR = 0.4, 95% CI 0.1-1. 0) and AEDS (OR = 0.4, 95% CI 0.2-0.8); dogs inside or outside with asthma (OR = 0.4, 95% CI 0.2-0.8); and pigs with SPT positivity (OR = 0.2, 95% CI 0.1-0.9). Conclusions: Despite finding a protective effect of early-life animal exposures, we found a greater prevalence of allergic disease on farms.	Univ Otago, Wellington Asthma Res Grp, Wellington, New Zealand; Univ Utrecht, Div Environm & Occupat Hlth, IRAS, Utrecht, Netherlands	Wickens, K (reprint author), Wellington Sch Med, Wellington Asthma Res Grp, POB 7343, Wellington, New Zealand.		Siebers, Robert/A-4102-2009	Douwes, Jeroen/0000-0003-3599-4036; Siebers, Robert/0000-0002-6359-3144			ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Attena F, 1999, EUR J EPIDEMIOL, V15, P569, DOI 10.1023/A:1007564323390; Barnes M, 2001, CLIN EXP ALLERGY, V31, P1822, DOI 10.1046/j.1365-2222.2001.01240.x; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Blackley CH, 1873, EXPT RES CAUSES NATU; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Farooqi IS, 1998, THORAX, V53, P927; Gassner-Bachmann M, 2000, DEUT MED WOCHENSCHR, V125, P924, DOI 10.1055/s-2000-6778; Hasan MMS, 2000, J ASTHMA, V37, P353, DOI 10.3109/02770900009055459; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Matsuzaki T, 1998, J DAIRY SCI, V81, P48; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Min YG, 1997, CLIN OTOLARYNGOL, V22, P139, DOI 10.1046/j.1365-2273.1997.00879.x; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; PEAT JK, 1994, BRIT MED J, V308, P1591; PEAT JK, 1995, MED J AUSTRALIA, V163, P22; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rosenberg R, 1999, Fam Med, V31, P276; Selim SA, 1997, J AM VET MED ASSOC, V211, P1029; STRACHAN DP, 1989, BRIT MED J, V299, P1259; STRACHAN DP, 1995, CLIN EXP ALLERGY, V25, P296, DOI 10.1111/j.1365-2222.1995.tb01046.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Ukai K, 1998, Arerugi, V47, P420; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; vonMutius E, 1996, BRIT MED J, V312, P1448; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009; WOODS RK, 2000, AUSTR RESPIROL, V5, P257; WUTHRICH B, 1991, ALLERGY CLIN IMMUNOL, V3, P41; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49	44	99	100	1	10	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	DEC	2002	57	12					1171	1179		10.1034/j.1398-9995.2002.t01-1-23644.x		9	Allergy; Immunology	Allergy; Immunology	621VH	WOS:000179611400012	12464046	
J	Perera, FP; Illman, SM; Kinney, PL; Whyatt, RM; Kelvin, EA; Shepard, P; Evans, D; Fullilove, M; Ford, J; Miller, RL; Mayer, IH; Rauh, VA				Perera, FP; Illman, SM; Kinney, PL; Whyatt, RM; Kelvin, EA; Shepard, P; Evans, D; Fullilove, M; Ford, J; Miller, RL; Mayer, IH; Rauh, VA			The challenge of preventing environmentally related disease in young children: Community-based research in New York City	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; cancer; children; development; environmental health; prenatal; prevention; susceptibility	POLYCYCLIC AROMATIC-HYDROCARBONS; DIESEL EXHAUST PARTICLES; SERUM COTININE LEVELS; MOLECULAR EPIDEMIOLOGY; BIRTH-WEIGHT; CANCER PREVENTION; INDOOR ALLERGENS; PASSIVE SMOKING; TOBACCO-SMOKE; RISK-FACTORS	Rates of developmental and respiratory diseases are disproportionately high in underserved, minority populations such as those in New York City's Washington Heights, Harlem, and the South Bronx. Blacks and Latinos in these neighborhoods represent high risk groups for asthma, adverse birth outcomes, impaired development, and some types of cancer. The Columbia Center for Children's Environmental Health in Washington Heights uses molecular epidermiologic methods to study the health effects of urban indoor and outdoor air pollutants on children, prenatally and postnatally, in a cohort of over 500 African-American and Dominican (originally from the Dominican Republic) mothers and newborns. Extensive data are collected to determine exposures to particulate matter < 2.5 &mu;m in aerodynamic diameter (PM2.5), polycyclic aromatic hydrocarbons (PAHs), diesel exhaust particulate (DEP), nitrogen oxide, nonpersistent pesticides, home allergens (dust mite, mouse, cockroach), environmental tobacco smoke (ETS), and lead and other metals. Biomarkers, air sampling, and clinical assessments are used to study the effects of these exposures on children's increased risk for allergic sensitization, asthma and other respiratory disorders, impairment of neurocognitive and behavioral development, and potential cancer risk. The center conducts its research and community education in collaboration with 10 community-based health and environmental advocacy organizations. This unique academic-community partnership helps to guide the center's research so that it is most relevant to the context of the low-income, minority neighborhoods in which the cohort resides, and information is delivered back to these communities in meaningful ways. In turn, communities become better equipped to relay environmental health concerns to policy makers. In this paper we describe the center's research and its academic-community partnership and present some preliminary findings.	Columbia Univ, Joseph L Mailman Sch Publ Hlth, Columbia Ctr Childrens Environm Hlth, New York, NY 10032 USA; W Harlem Environm Act Inc, New York, NY USA	Perera, FP (reprint author), Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Environm Hlth Sci, 60 Haven Ave,B-116, New York, NY 10032 USA.				NCRR NIH HHS [RR 00645]; NIEHS NIH HHS [R01 ES 08977, P01 ES009600, P50 ES 09600, R01 ES 06722, R01 ES008977]		*AM CANC SOC, 1996, CANC FACTS FIG 1996; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; BINKOVA B, 1995, CARCINOGENESIS, V16, P1037, DOI 10.1093/carcin/16.5.1037; BUI QQ, 1986, TOXICOLOGY, V42, P195, DOI 10.1016/0300-483X(86)90009-0; Calabrese EJ, 1986, AGE SUSCEPTIBILITY T; Campbell CG, 1997, BRAIN RES BULL, V43, P179, DOI 10.1016/S0361-9230(96)00436-4; CASSEL J, 1976, AM J EPIDEMIOL, V104, P107; Centers for Disease Control and Prevention [CDC], 1998, MMWR-MORBID MORTAL W, V47, P1; Chanda SM, 1996, PHARMACOL BIOCHEM BE, V53, P771, DOI 10.1016/0091-3057(95)02105-1; CHEN LH, 1995, AM J EPIDEMIOL, V142, P158; Claudio L, 1999, J ASTHMA, V36, P343, DOI 10.3109/02770909909068227; *COMM STUD NEW YOR, INFOSHARE; CRAIN EF, 1994, PEDIATRICS, V94, P356; CRAWFORD MA, 1989, J INTERN MED, V225, P159; David RJ, 1997, NEW ENGL J MED, V337, P1209, DOI 10.1056/NEJM199710233371706; DAY NE, 1980, J NATL CANCER I, V64, P977; *DHHS, 1986, REP SECR TASK FORC B; Duran-Tauleria E, 1999, THORAX, V54, P476; ENGLISH PB, 1994, AM J PUBLIC HEALTH, V84, P1439, DOI 10.2105/AJPH.84.9.1439; Faustman EM, 2000, ENVIRON HEALTH PERSP, V108, P13, DOI 10.2307/3454629; FULLILOVE MT, 1991, B NEW YORK ACAD MED, V67, P571; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Goldstein I F, 1987, Experientia Suppl, V51, P133; *GREAT BOST PHYS S, 2000, HARMS WAY TOX THREAT; GREENE LS, 1995, J AM COLL NUTR, V14, P317; GROOPMAN JD, 1994, CANCER RES, V54, pS1907; HARRIS CC, 1991, CANCER RES, V51, pS5023; HATCH GE, 1995, AM J CLIN NUTR S, V61, pS325; HECHT SS, 1994, CANCER RES, V54, pS1912; HULKA BS, 1991, CANCER EPIDEM BIOMAR, V1, P13; HULKA BS, 1991, HLTH ENV DIGEST, V5, P1; Jacobson JL, 1996, NEW ENGL J MED, V335, P783, DOI 10.1056/NEJM199609123351104; Kinney PL, 2000, ENVIRON HEALTH PERSP, V108, P213, DOI 10.2307/3454436; KLIEGMAN RM, 1992, PEDIATRICS, V89, P710; Knight JM, 1996, CHEST, V109, P446, DOI 10.1378/chest.109.2.446; KRASNER M, 1994, NEW YORK CITY COMMUN; LAIB RJ, 1985, CARCINOGENESIS, V6, P65, DOI 10.1093/carcin/6.1.65; LU LJW, 1986, CANCER RES, V46, P3046; LU LJW, 1990, CARCINOGENESIS, V11, P1367, DOI 10.1093/carcin/11.8.1367; MAKRIDES M, 1995, LANCET, V345, P1463, DOI 10.1016/S0140-6736(95)91035-2; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; May M, 2000, ENV HLTH PERSPECT, V108, P262; MCCLELLAN RO, 1987, ANNU REV PHARMACOL, V27, P279; MEYER I, UNPUB; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995; MILLER RL, IN PRESS AM J RESP C; Mott L., 1994, HANDLE CARE CHILDREN; National Research Council, 1993, PEST DIETS INF CHILD; NEEDLEMAN HL, 1979, NEW ENGL J MED, V301, P163; NEUBERT D, 1988, ARCH TOXICOL, V35, P2943; *NEW YORK CIT HLTH, 1998, NEW YORK CIT HLTH DE; *NYPIRG, 1999, DIRT POW RIS NEW YOR; OMENN GS, 1991, MUTAT RES, V247, P283, DOI 10.1016/0027-5107(91)90023-H; Peat JK, 1987, CLIN ALLERGY, V17, P297; PEQUES M, COMMUNICATION; Perera FP, 2000, J NATL CANCER I, V92, P602, DOI 10.1093/jnci/92.8.602; Perera FP, 1998, AM J EPIDEMIOL, V147, P309; PERERA FP, 1982, J CHRON DIS, V35, P581, DOI 10.1016/0021-9681(82)90078-9; Perera FP, 1996, JNCI-J NATL CANCER I, V88, P496, DOI 10.1093/jnci/88.8.496; PERERA FP, 1987, J NATL CANCER I, V78, P887; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1994, ANN ALLERGY, V72, P381; Plopper CG, 2000, ENVIRON HEALTH PERSP, V108, pA252, DOI 10.1289/ehp.108-a252; Rauh VA, 2001, AM J PUBLIC HEALTH, V91, P1815, DOI 10.2105/AJPH.91.11.1815; SARPONG SB, 1996, J ALLERGY CLIN IMMUN, V97, P1394; Perera F, 1993, MOL EPIDEMIOLOGY PRI; SHIMIZU Y, 1991, J RADIAT RES, V32, P54, DOI 10.1269/jrr.32.SUPPLEMENT2_54; SPORIK R, 1991, ARCH DIS CHILD, V66, P1050; SPORIK R, 1990, NEW ENGL J MED, V323, P505; SRIVASTAVA VK, 1986, J TOXICOL ENV HEALTH, V18, P459; Susser M, 1996, AM J PUBLIC HEALTH, V86, P674, DOI 10.2105/AJPH.86.5.674; *TEX NAT RES CONS, 2002, NAT AMB AIR QUAL STA; *US DEP HHS, 1982, SUMM HIST FIG FED RE; U. S. Department of Health and Human Services, 1990, HLTH BEN SMOK CESS R; [U. S. Environmental Protection Agency National Ambient Air Quality Standards (NAAQS)], 2002, NAT AMB AIR QUAL STA; U.S. Environmental Protection Agency, 1996, ENV HLTH THREATS CHI; VERBECK D, 1997, KEEPING TRACK NEW YO; Voigt RG, 1996, PEDIATR RES, V39, P1915; WAGENKNECHT LE, 1992, AM J PUBLIC HEALTH, V82, P33, DOI 10.2105/AJPH.82.1.33; WAGENKNECHT LE, 1993, ENVIRON RES, V63, P39, DOI 10.1006/enrs.1993.1124; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; Weiss B, 2000, ENVIRON HEALTH PERSP, V108, P373; WHITMORE RW, 1994, ARCH ENVIRON CON TOX, V26, P47, DOI 10.1007/BF00212793; WHO, 1986, ENV HLTH CRIT, V59; WHYATT RM, 1995, ENVIRON HEALTH PERSP, V103, P105, DOI 10.2307/3432357; Whyatt RM, 2001, CANCER EPIDEM BIOMAR, V10, P581; Whyatt RM, 2001, ENVIRON HEALTH PERSP, V109, P417, DOI 10.2307/3454902; WHYATT RM, IN PRESS ENV HLTH PE; WISE PH, 1993, AM J PREV MED, V31, P7; ZAPATA BC, 1992, AM J PUBLIC HEALTH, V82, P685, DOI 10.2105/AJPH.82.5.685	91	99	100	3	14	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	FEB	2002	110	2					197	204				8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	526KR	WOS:000174130100031	11836150	
J	Ayuso, R; Lehrer, SB; Reese, G				Ayuso, R; Lehrer, SB; Reese, G			Identification of continuous, allergenic regions of the major shrimp allergen Pen a 1 (tropomyosin)	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						tropomyosin; Pen a 1; invertebrate allergens; IgE-binding sequences	IGE-BINDING EPITOPES; MUSCLE PROTEIN TROPOMYOSIN; CROSS-REACTIVE ALLERGEN; MOLECULAR CHARACTERIZATION; MUTATIONAL ANALYSIS; AMERICAN COCKROACH; NITROCELLULOSE; CLONING; MITE; IMMUNOTHERAPY	Background: Crustaceans and mollusks are a frequent cause of allergic reactions. The only major allergen identified in shrimp is the muscle protein tropomyosin; at least 80% of shrimp-allergic subjects react to tropomyosin. Furthermore, tropomyosin is an important allergen in other crustaceans such as lobsters, crabs and mollusks, as well as other arthropods such as house dust mites and cockroaches, and has been implied as the cause of clinical cross-sensitivity among invertebrates. In contrast, vertebrate tropomyosins are considered nonallergenic. Objective: The basis of the allergenicity of proteins has not yet been resolved. Thus, tropomyosin molecules provide an excellent opportunity to study the relationship between protein structure and allergenicity. The aim of the current study was to identify the IgE-binding regions of Pen a 1 and compare these regions with homologous sequences in other allergenic and nonallergenic tropomyosins. Methods: Forty-six overlapping peptides (length: 15 amino acids; offset: 6 amino acids) spanning the entire Pen a 1 molecule were synthesized and tested for IgE antibody reactivity with sera from 18 shrimp-allergic subjects to identify the IgE-binding regions of shrimp tropomyosin. Results: Based on the frequency and intensity of the IgE reactivities, five major IgE-binding regions were identified. All five major IgE-binding regions were 15-38 amino acids long. The major IgE-binding regions identified were: region 1: Pen a 1 (43-57); region 2: Pen a 1 (85-105); region 3: Pen a 1 (133148); region 4: Pen a 1 (187-202), and region 5: Pen a 1 (247-284). In addition, 22 peptides were categorized as minor IgE-binding regions, and 12 peptides did not bind any IgE antibodies. No substantial differences in amino acid group composition in the five IgE-binding regions compared to the whole molecule were detected. Sequence identities and similarities of the Pen a 1 IgE-binding regions with homologous regions of allergenic arthropod tropomyosins were as high as 100%, whereas identities and similarities with homologous vertebrate sequences ranged from 36 to 76% and 53 to 85%, respectively. Conclusion: Five major IgE-binding regions of the allergenic shrimp tropomyosin, Pen a 1, were identified which are positioned at regular intervals of approximately 42 amino acids (7 heptads), suggesting a relationship with the repetitive coiled-coil structure of the tropomyosin molecule. The high degree of similarity between Pen a 1 IgE-binding regions and homologous sequences in invertebrate tropomyosins and the lower percentage of similarity with homologous regions of vertebrate tropomyosins supports a structural basis for cross-reactivity of allergenic tropomyosins. Copyright (C) 2002 S. Karger AG, Basel.	Tulane Univ, Sch Med SL57, New Orleans, LA 70112 USA	Lehrer, SB (reprint author), Tulane Univ, Sch Med SL57, 1700 Perdido St, New Orleans, LA 70112 USA.						AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; Asturias JA, 1999, J IMMUNOL, V162, P4342; Ayuso R, 2000, ALLERGY, V55, P348, DOI 10.1034/j.1398-9995.2000.00285.x; BANZET ML, 1992, REV FR ALLERGOL, V32, P198, DOI 10.1016/S0335-7457(05)80359-4; Beezhold DH, 1999, J ALLERGY CLIN IMMUN, V103, P1166, DOI 10.1016/S0091-6749(99)70194-6; Burks AW, 1997, EUR J BIOCHEM, V245, P334, DOI 10.1111/j.1432-1033.1997.t01-1-00334.x; CARRILLO T, 1994, ANN ALLERGY, V73, P504; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; DEMEULEMESTER C, 1987, ELECTROPHORESIS, V8, P71, DOI 10.1002/elps.1150080113; *FOOD DRUG ADM, 1996, REP FDA AD HOC COMM; Ishikawa M, 1998, J FOOD SCI, V63, P44, DOI 10.1111/j.1365-2621.1998.tb15672.x; Ishikawa M, 1998, BIOSCI BIOTECH BIOCH, V62, P1337, DOI 10.1271/bbb.62.1337; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEARY JJ, 1983, P NATL ACAD SCI-BIOL, V80, P4045, DOI 10.1073/pnas.80.13.4045; LEHRER SB, 1987, J ALLERGY CLIN IMMUN, V80, P133, DOI 10.1016/0091-6749(87)90121-7; Leung PSC, 1998, J ALLERGY CLIN IMMUN, V102, P847, DOI 10.1016/S0091-6749(98)70027-2; Leung PSC, 1998, MOL MAR BIOL BIOTECH, V7, P12; Leung PSC, 1996, J ALLERGY CLIN IMMUN, V98, P954, DOI 10.1016/S0091-6749(96)80012-1; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Martinez A, 1997, Allergol Immunopathol (Madr), V25, P118; Miyazawa H, 1996, J ALLERGY CLIN IMMUN, V98, P948, DOI 10.1016/S0091-6749(96)80011-X; Muller U, 1998, J ALLERGY CLIN IMMUN, V101, P747, DOI 10.1016/S0091-6749(98)70402-6; Mykles DL, 1998, J MUSCLE RES CELL M, V19, P105, DOI 10.1023/A:1005352410725; Pascual CY, 1997, ALLERGY, V52, P514, DOI 10.1111/j.1398-9995.1997.tb02594.x; Pomes A, 1998, J BIOL CHEM, V273, P30801, DOI 10.1074/jbc.273.46.30801; Rabjohn P, 1999, J CLIN INVEST, V103, P535, DOI 10.1172/JCI5349; Reese G, 1997, INT ARCH ALLERGY IMM, V113, P240; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; Reese G, 1999, INT ARCH ALLERGY IMM, V118, P300, DOI 10.1159/000024108; Restani P, 1997, J AM COLL NUTR, V16, P383; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SMILLIE LB, 1979, TRENDS BIOCHEM SCI, V4, P151, DOI 10.1016/0968-0004(79)90003-3; Stanley JS, 1997, ARCH BIOCHEM BIOPHYS, V342, P244, DOI 10.1006/abbi.1997.9998; TAYLOR SL, 1988, MARINE TOXINS VENOMS, V3, P149; vanRee R, 1996, ALLERGY, V51, P108	38	99	116	2	12	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	JAN	2002	127	1					27	37		10.1159/000048166		11	Allergy; Immunology	Allergy; Immunology	530LJ	WOS:000174358900006	11893851	
J	Wong, CM; Atkinson, RW; Anderson, HR; Hedley, AJ; Ma, S; Chau, PYK; Lam, TH				Wong, CM; Atkinson, RW; Anderson, HR; Hedley, AJ; Ma, S; Chau, PYK; Lam, TH			A tale of two cities: Effects of air pollution on hospital admissions in Hong Kong and London compared	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; cardiac and respiratory hospital admissions; daily time-series; Hong Kong; London	SHORT-TERM ASSOCIATIONS; MORTALITY; DISEASES; PHILADELPHIA; ASTHMA	The causal interpretation of reported associations between daily air pollution and daily admissions requires consideration of residual confounding, correlation between pollutants, and effect modification. If results obtained in Hong Kong and London-which differ in climate, lifestyle, and many other respects-were similar, a causal association would be supported. We used identical statistical methods for the analysis in each city. Associations between daily admissions and pollutant levels were estimated using Poisson regression. Nonparametric smoothing methods were used to model seasonality and the nonlinear dependence of admissions on temperature, humidity, and influenza admissions. For respiratory, admissions (greater than or equal to 65 years of age), significant positive associations were observed with particulate matter < 10 mum in aerodynamic diameter (PM10), nitrogen dioxide, sulfur dioxide, and ozone in both cities. These associations tended to be stronger at shorter lags in Hong Kong and at longer lap in London. Associations were stronger in the cool season in Hong Kong and in the warm season in London, periods during which levels of humidity are at their lowest in each city. For cardiac admissions (all ages) in both cities, significant positive associations were observed for PM10, NO2, and SO2 with similar lag patterns. Associations tended to be stronger in the cool season. The associations with NO2 and SO2 were the most robust in two-pollutant models. Patterns of association for pollutants with ischemic heart disease were similar in the two cities. The associations between O-3 and cardiac admissions were negative in London but positive in Hong Kong. We conclude that air pollution has remarkably similar associations with daily cardiorespiratory admissions in both cities, in spite of considerable differences between cities in social, lifestyle, and environmental factors. The results strengthen the argument that air pollution causes detrimental short-term health effects.	Univ Hong Kong, Dept Community Med, Hong Kong, Hong Kong, Peoples R China; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	Hedley, AJ (reprint author), Univ Hong Kong, Dept Community Med, Patrick Manson Bldg S Wing,7 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.		Hedley, Anthony/C-4305-2009; Wong, Chit Ming/C-4438-2009; Lam, Tai Hing/C-4317-2009; Hedley, Anthony/A-9113-2013				Akaike H, 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_; Anderson HR, 1998, THORAX, V53, P842; Asher MI, 1998, EUR RESPIR J, V12, P315; Atkinson RW, 1999, ARCH ENVIRON HEALTH, V54, P398; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; Bremner SA, 1999, OCCUP ENVIRON MED, V56, P237; Buckingham C., 1997, LONDON ATMOSPHERIC E; *CENS STAT DEP, 1998, HONG KONG ANN DIG ST; *CENS STAT DEP, 1998, 20 CENS STAT DEP; Cleveland RC, 1990, J OFF STAT, V6, P3; deLeon AP, 1996, J EPIDEMIOL COMMUN H, V50, pS63; *DEP HLTH, 1998, STAT SMOK ENGL 1976; *DEP HLTH, 1998, DEP HLTH ANN REP 199; *ENV PROT DEP, 1997, AIR QUAL HONG KONG 1; *ENV PROT DEP, 1996, AIR QUAL HONG KONG 1; *ENV PROT DEP, 1998, AIR QUAL HONG KONG 1; Hastie T, 1990, GEN ADDITIVE MODELS; JANUS ED, 1996, HONG KONG CARDIOVASC; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; KATSOUYANNI K, COMMUNICATION; Kelsall JE, 1997, AM J EPIDEMIOL, V146, P750; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; Levy JI, 2000, ENVIRON HEALTH PERSP, V108, P109, DOI 10.2307/3454508; *OFF NAT STAT, 1996, MORT STAT ENGL WAL; *OFF NAT STAT, 1998, LIV BRIT RES 1996 GE; *OFF POP CENS SURV, 1992, SER DH5 OFF POP CENS, V19; *PLANN ENV LANDS B, CLEAN AIR HONG KONG; Pope III CAD, 1999, AIR POLLUTION HLTH, P673; Samet J, 1998, ENVIRON RES, V77, P9, DOI 10.1006/enrs.1997.3821; Samet J., 2000, 94 HLTH EFF I; SCHWARTZ JB, 1996, PDA J PHARM SCI TECH, V50, P1; Segi M., 1960, CANC MORTALITY SELEC; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; STEDMAN JR, 2000, ATMOS ENVIRON, V35, P297; Thurston GD, 1999, AIR POLLUTION HLTH, P485, DOI 10.1016/B978-012352335-8/50097-1; World Health Organization, 1975, MAN INT STAT CLASS D; Wong CA, 1999, J EPIDEMIOL COMMUN H, V53, P580; Wong CM, 2001, ENVIRON HEALTH PERSP, V109, P335, DOI 10.2307/3454891; Wong TW, 1999, OCCUP ENVIRON MED, V56, P679; Wu Chengping, COMMUNICATION	40	99	111	5	19	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2002	110	1					67	77				11	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	521WH	WOS:000173864000028	11781167	
J	Maestrelli, P; Saetta, M; Mapp, CE; Fabbri, LM				Maestrelli, P; Saetta, M; Mapp, CE; Fabbri, LM			Remodeling in response to infection and injury - Airway inflammation and hypersecretion of mucus in smoking subjects with chronic obstructive pulmonary disease	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	16th Annual Transatlantic Airway Conference (TAC)	JAN, 2001	SAN FRANCISCO, CALIFORNIA			histology; sputum cytology; glands; goblet cells; biopsies	NEUTROPHIL CHEMOTACTIC FACTOR; T-CELL CLONES; CHRONIC-BRONCHITIS; PERIPHERAL AIRWAYS; FLOW LIMITATION; INDUCED SPUTUM; LYMPHOCYTES-T; UP-REGULATION; SMOKERS; ASTHMA	Airway epithelium represents the first line of defense against toxic inhalants. In some subjects, cigarette smoking causes airway inflammation, hypersecretion of mucus, and poorly reversible airflow limitation through mechanisms that are still largely unknown. Likewise, it is unclear why only some smokers develop chronic obstructive pulmonary disease (COPD). Two cell types consistently result in relation to chronic airflow limitation in COPD: neutrophils and CD8(+) cells. Neutrophils are compartmentalized in the mucosal surface of the airways and air spaces, that is, the epithelium and lumen, whereas CD8(+) cells exhibit a more extensive distribution along the subepithelial zone of the airways and lung parenchyma, including alveolar walls and arteries. This pattern of inflammatory cell distribution is observed in mild or moderate COPD, and in patients who have developed COPD, it is not modified by smoking cessation. The number of neutrophils further increases in the submucosa of patients with severe COPD, suggesting a role for these cells in the progression of the disease. Hypersecretion of mucus is a major manifestation in COPD. Mucus is produced by bronchial glands and goblet cells lining the airway epithelium. Unlike mucous gland enlargement, greater mucosal inflammation is associated with sputum production. Whereas neutrophil infiltration of submucosal glands occurs only in smokers with COPD, goblet cell hyperplasia in peripheral airways occurs both in smokers with or without COPD, suggesting that the major determinant of goblet cell hyperplasia is cigarette smoke itself.	Univ Padua, Resp Pathophysiol Unit, Dept Environm Med & Publ Hlth, I-35136 Padua, Italy; Univ Ferrara, I-44100 Ferrara, Italy; Univ Modena & Reggio Emilia, Modena, Italy	Maestrelli, P (reprint author), Univ Padua, Resp Pathophysiol Unit, Dept Environm Med & Publ Hlth, Via Giustiniani 2, I-35136 Padua, Italy.		Fabbri, Leonardo/I-4055-2012	Fabbri, Leonardo/0000-0001-8894-1689			AMADORI A, 1995, NAT MED, V1, P1279, DOI 10.1038/nm1295-1279; Balzano G, 1999, AM J RESP CRIT CARE, V160, P1486; BARNES PJ, 1991, AM REV RESPIR DIS, V144, P1187; CANNON MJ, 1988, J EXP MED, V168, P1163, DOI 10.1084/jem.168.3.1163; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DELPRETE GF, 1993, EUR J IMMUNOL, V23, P1445, DOI 10.1002/eji.1830230707; Di Stefano A, 1998, AM J RESP CRIT CARE, V158, P1277; DISTEFANO A, 1994, AM J RESP CRIT CARE, V149, P803; DiStefano A, 1996, AM J RESP CRIT CARE, V153, P629; Gibson PG, 1998, CLIN EXP ALLERGY, V28, P1081; HALE KA, 1984, AM REV RESPIR DIS, V130, P718; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P449; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Lams BEA, 2000, EUR RESPIR J, V15, P512, DOI 10.1034/j.1399-3003.2000.15.14.x; Lucchini RE, 1997, AM J RESP CRIT CARE, V156, P1963; LUMSDEN AB, 1984, THORAX, V39, P844, DOI 10.1136/thx.39.11.844; Macklem PT, 1998, AM J RESP CRIT CARE, V157, pS181; MacNee W, 2000, CHEST, V117, p303S, DOI 10.1378/chest.117.5_suppl_1.303S-a; MAESTRELLI P, 1994, SCAND J WORK ENV HEA, V20, P376; MAESTRELLI P, 1988, IMMUNOLOGY, V64, P219; MAESTRELLI P, 1988, IMMUNOLOGY, V65, P605; Maestrelli P, 1996, AM J RESP CRIT CARE, V154, P1296; MAPP CE, 2000, AM J RESP CRIT CARE, V161, pA571; MULLEN JBM, 1985, BRIT MED J, V291, P1235; Nadel JA, 2000, CHEST, V117, p386S, DOI 10.1378/chest.117.5_suppl_2.386S; NAGAI A, 1985, AM REV RESPIR DIS, V132, P946; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; PETO R, 1983, AM REV RESPIR DIS, V128, P491; REID LM, 1954, LANCET, V1, P275; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; SAETTA M, 1994, AM J RESP CRIT CARE, V150, P1646; Saetta M, 1997, AM J RESP CRIT CARE, V156, P1633; Saetta M, 2000, AM J RESP CRIT CARE, V161, P1016; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134; Stanescu D, 1996, THORAX, V51, P267, DOI 10.1136/thx.51.3.267; Takanashi S, 1999, EUR RESPIR J, V14, P309, DOI 10.1034/j.1399-3003.1999.14b12.x; Takeyama K, 2000, J IMMUNOL, V164, P1546; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527; TURATO G, 1995, AM J RESP CRIT CARE, V152, P1262; Vestbo J, 1996, AM J RESP CRIT CARE, V153, P1530; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458; Zhu J, 2001, AM J RESP CRIT CARE, V164, P109	50	99	101	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2001	164	10		S			S76	S80				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	504AH	WOS:000172833700011	11734472	
J	Redington, AE; Meng, QH; Springall, DR; Evans, TJ; Creminon, C; Maclouf, J; Holgate, ST; Howarth, PH; Polak, JM				Redington, AE; Meng, QH; Springall, DR; Evans, TJ; Creminon, C; Maclouf, J; Holgate, ST; Howarth, PH; Polak, JM			Increased expression of inducible nitric oxide synthase and cyclo-oxygenase-2 in the airway epithelium of asthmatic subjects and regulation by corticosteroid treatment	THORAX			English	Article						asthma; corticosteroids; immunohistochemistry; in situ hybridisation; nitric oxide synthase; cyclo-oxygenase (COX)	HUMAN ENDOTHELIAL-CELLS; EXHALED AIR; HUMAN TISSUES; CYCLOOXYGENASE; CDNA; PROSTAGLANDIN-D2; LOCALIZATION; INHALATION; INDUCTION; CLONING	Background-Nitric oxide (NO) and prostanoids are mediators of vascular and bronchial tone that are postulated to be involved in asthma. increased levels of both are found in asthmatic subjects and are synthesised by enzymes that have cytokine inducible forms: inducible NO synthase (iNOS) and cyclo-oxygenase-2 (COX-2), respectively. We hypothesised that the in vivo expression of iNOS and COX-2 in the airways would be increased in asthma, and that these cytokine inducible enzymes may represent targets for regulation by corticosteroid treatment. Methods-Bronchial biopsy specimens were obtained from three groups of subjects: atopic asthmatics treated with p, agonists alone (n=7), atopic asthmatics additionally receiving regular treatment with corticosteroids (n=8), and nonasthmatic control subjects (n=10). Expression of iNOS and COX-2 mRNA and immunoreactive protein was studied using in situ hybridisation and quantitative immunohistochemistry. Results-Immunoreactivity and the hybridisation signal for iNOS and COX-2 were mainly localised in the airway epithelium. The proportion of epithelium immunostained was significantly greater in the non-steroid treated asthmatic subjects (iNOS 8.6 (1.8)%; COX-2 26.3 (4.6)%) than either the steroid treated asthmatics (iNOS 3.4 (1.0)%, p=0.009; COX-2 13.0 (0.6)%, p=0.0015) or the non-asthmatic controls (iNOS 4.2 (0.9)%, p=0.018; COX-2 11.6 (0.6)%, p=0.0003). Similarly, the hybridisation signal was stronger in the non-steroid treated group of asthmatic subjects than in the other two groups. Conclusions-These findings highlight the potential role of the airway epithelium both as a contributor to the inflammatory process in asthma and as a target for inhaled corticosteroid treatment in this disease.	Univ Southampton, Med Gen Hosp, Southampton SO16 6YD, Hants, England; Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Sch Med, Dept Histochem, London W12 0NN, England; Univ London Imperial Coll Sci Technol & Med, Sch Med, Dept Infect Dis, London SW7 2AZ, England; CEA Saclay, DRM, SPI, F-91191 Gif Sur Yvette, France; Hop Lariboisiere, INSERM U348, F-75475 Paris 10, France	Redington, AE (reprint author), Castle Hill Hosp, Acad Dept Med, Castle Rd, Cottingham HU16 5JQ, E Yorkshire, England.						ALVING K, 1993, BRIT J PHARMACOL, V110, P739; ALVING K, 1993, EUR RESPIR J, V6, P1368; ASANO K, 1996, AM J PHYSIOL, V271, P126; CAMPBELL AM, 1993, AM REV RESPIR DIS, V147, P529; CHURCHILL L, 1989, AM REV RESPIR DIS, V140, P449; COLEMAN RA, 1989, BRIT J PHARMACOL, V96, P688; Demoly P, 1997, AM J RESP CRIT CARE, V155, P670; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HABIB A, 1993, J BIOL CHEM, V268, P23448; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; HEISS LN, 1994, P NATL ACAD SCI USA, V91, P267, DOI 10.1073/pnas.91.1.267; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOGMAN M, 1993, AM REV RESPIR DIS, V148, P1474; Kacmarek RM, 1996, AM J RESP CRIT CARE, V153, P128; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; KOBZIK L, 1993, AM J RESP CELL MOL, V9, P371; LIU MC, 1990, AM REV RESPIR DIS, V142, P126; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MITCHELL JA, 1994, BRIT J PHARMACOL, V113, P1008; Ndukwu IM, 1997, AM J PHYSIOL-LUNG C, V273, pL626; Newton R., 1997, Life Sciences, V60, P67; OBANION MK, 1992, P NATL ACAD SCI USA, V89, P4888, DOI 10.1073/pnas.89.11.4888; ONEILL GP, 1993, FEBS LETT, V330, P156; Pang L, 1998, CLIN EXP ALLERGY, V28, P1050; PERSSON MG, 1994, LANCET, V343, P146, DOI 10.1016/S0140-6736(94)90935-0; Redington A. E., 1993, Regional Immunology, V5, P174; Redington AE, 1997, EUR RESPIR J, V10, P1026, DOI 10.1183/09031936.97.10051026; Redington AE, 1997, J ALLERGY CLIN IMMUN, V100, P544; Ricciardolo FLM, 1996, LANCET, V348, P374, DOI 10.1016/S0140-6736(96)04450-9; ROBBINS RA, 1994, BIOCHEM BIOPH RES CO, V203, P209, DOI 10.1006/bbrc.1994.2169; Saleh D, 1997, AM J RESP CRIT CARE, V155, P1763; SARIH M, 1993, BIOCHEM BIOPH RES CO, V191, P503, DOI 10.1006/bbrc.1993.1246; SHERMAN PA, 1993, BIOCHEMISTRY-US, V32, P11600, DOI 10.1021/bi00094a017; Sousa AR, 1997, THORAX, V52, P940; SPRINGALL DR, 1992, HISTOCHEMISTRY, V98, P259, DOI 10.1007/BF00271040; Taha R, 2000, AM J RESP CRIT CARE, V161, P636; Walenga RW, 1996, PROSTAGLANDINS, V52, P341, DOI 10.1016/S0090-6980(96)00101-3; Watkins DN, 1999, EUR RESPIR J, V13, P999, DOI 10.1034/j.1399-3003.1999.13e12.x; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	43	99	106	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY	2001	56	5					351	357		10.1136/thorax.56.5.351		7	Respiratory System	Respiratory System	427LN	WOS:000168405800007	11312402	
J	Jacobs, EA; Joffe, A; Knight, JR; Kulig, J; Rogers, PD				Jacobs, EA; Joffe, A; Knight, JR; Kulig, J; Rogers, PD		Comm Substance Abuse	Tobacco's toll: Implications for the pediatrician	PEDIATRICS			English	Article							CIGARETTE-SMOKING; ADOLESCENTS; PREVENTION; DEPRESSION; ALCOHOL; YOUTH; RISK	The disease of tobacco addiction, which is pervasive in the United States, begins in childhood and adolescence. Twenty-five percent of the population regularly uses tobacco, despite evidence that such use is the leading preventable cause of death in the United States. Tobacco use reportedly kills 2.5 times as many people each year as alcohol and drug abuse combined. According to 1998 data from the World Health Organization, there were 1.1 billion smokers worldwide and 10 000 tobacco-related deaths per day. Furthermore, in the United States, 43% of children aged 2 to 11 years are exposed to environmental tobacco smoke, which has been implicated in sudden infant death syndrome, low birth weight, asthma, middle ear disease, pneumonia, cough, and upper respiratory infection. Pediatricians play a crucial role in reducing both tobacco use (by children, adolescents, and their parents) and exposure to tobacco smoke and should rank this among their highest health prevention priorities.	Amer Acad Pediat, Comm Subst Abuse, Elk Grove Village, IL 60007 USA	Jacobs, EA (reprint author), Amer Acad Pediat, Comm Subst Abuse, Elk Grove Village, IL 60007 USA.						American Psychiatric Association, 1994, DIAGN STAT MAN MENT; AMMERMAN SD, 1998, CONT PEDIAT, V15, P64; Belcher HME, 1998, ARCH PEDIAT ADOL MED, V152, P952; Bobo JK, 1998, ADDICTION, V93, P877, DOI 10.1046/j.1360-0443.1998.9368779.x; Brown RA, 1996, J AM ACAD CHILD PSY, V35, P1602, DOI 10.1097/00004583-199612000-00011; Recommendations to prevent and control iron deficiency in the United States, 1998, MMWR-MORBID MORTAL W, V47, P1; Centers for Disease Control and Prevention, 1998, MMWR-MORBID MORTAL W, V47, P229; Centers for Disease Control and Prevention, 1994, MMWR-MORBID MORTAL W, V43, P1; Cronk CE, 1997, AM J PUBLIC HEALTH, V87, P760, DOI 10.2105/AJPH.87.5.760; ELDERS MJ, 1994, AM J PUBLIC HEALTH, V84, P543, DOI 10.2105/AJPH.84.4.543; EPPS RP, 1993, NIH PUBL; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; FIORE MC, 2000, AHRQ PUBL; GIOVINO GA, 1995, EPIDEMIOL REV, V17, P48; Gold DR, 1996, NEW ENGL J MED, V335, P931, DOI 10.1056/NEJM199609263351304; HEYMAN R, 1997, ADOLESCENT HLTH UPDA, V9, P1; Heyman RB, 1998, PEDIATRICS, V101, P125; Hughes JR, 1999, JAMA-J AM MED ASSOC, V281, P72, DOI 10.1001/jama.281.1.72; Jackson C, 1997, AM J PUBLIC HEALTH, V87, P359, DOI 10.2105/AJPH.87.3.359; Jessor R., 1978, LONGITUDINAL RES DRU, P41; JOHNSTON LD, 2000, NIH PUBL; KINNEY H, 1998, J NEUROPATHOL EXP NE, V57, P1018; Klein JD, 1995, PEDIATR ANN, V24, P646; LYNCH BS, 1994, GROWING UP TOBACCO F, P71; Lynch B. S., 1994, GROWING UP TOBACCO F, P29; MILLBERGER S, 1997, J AM ACAD CHILD ADOL, V36, P37; Moskowitz WB, 1999, ARCH PEDIAT ADOL MED, V153, P446; MYERS MG, 1994, PEDIATRICS, V93, P561; National Institute on Drug Abuse, 1998, NIH PUBL; Patton GC, 1998, AM J PUBLIC HEALTH, V88, P1518, DOI 10.2105/AJPH.88.10.1518; Pomerleau O F, 1995, J Subst Abuse, V7, P373, DOI 10.1016/0899-3289(95)90030-6; PROCHASKA JO, 1983, J CONSULT CLIN PSYCH, V51, P390, DOI 10.1037/0022-006X.51.3.390; Rubes J, 1998, FERTIL STERIL, V70, P715, DOI 10.1016/S0015-0282(98)00261-1; SANDLER DP, 1985, AM J PUBLIC HEALTH, V75, P487, DOI 10.2105/AJPH.75.5.487; Smith TA, 1996, PEDIATRICS, V98, P659; *TOB CONTR SEC CA, 1997, CIG US CAL 1990 1996; Tomar SL, 1998, AM J PUBLIC HEALTH, V88, P20, DOI 10.2105/AJPH.88.1.20; *US DEPT HHS, 1998, TOB US AM US RAC ETH	38	99	99	1	3	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	APR	2001	107	4					794	798				5	Pediatrics	Pediatrics	422KC	WOS:000168116200053		
J	Dales, RE; Cakmak, S; Burnett, RT; Judek, S; Coates, F; Brook, JR				Dales, RE; Cakmak, S; Burnett, RT; Judek, S; Coates, F; Brook, JR			Influence of ambient fungal spores on emergency visits for asthma to a regional children's hospital	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							AIR-POLLUTION; RESPIRATORY-DISEASES; CANADIAN CITIES; ROOM VISITS; PARTICULATE; ASSOCIATION; ALTERNARIA; POLLEN; OZONE	The impact of ambient aeroallergens on morbidity from childhood asthma is largely unknown. To address this issue, we studied the association between daily emergency department visits for asthma to a childrens' hospital, and daily concentrations of both pollen grains and fungal spores during a 5-yr period between 1993 and 1997. Air pollution and meteorological data accounted for in the analyses included ozone, nitrogen dioxide, sulfur dioxide, sulfates, temperature, barometric pressure, and relative humidity. The daily number of asthma visits ranged from 0 to 36 per day with an average of 7.5. Fungal spores, but not pollen grains, were associated with visits (p < 0.05). The percentage increase associated with each group, independent of the others, was 1.9% (SE 0.9) for deuteromycetes, 4.1% (1.6) for basidiomycetes, 2.8% (1.0) for ascomycetes, and 8.8% for these spores combined. In summary, fungal spores account for a significant proportion of the asthma exacerbations in children that prompt an emergency department visit.	Univ Ottawa, Ottawa, ON K1H 8L6, Canada; Ottawa Gen Hosp, Ottawa, ON K1H 8L6, Canada; Hlth Canada, Ottawa, ON K1A 0L2, Canada; Aerobiol Res Labs, Ottawa, ON, Canada; Environm Canada, Atomospher Environm Serv, Toronto, ON M3H 5T4, Canada	Dales, RE (reprint author), Univ Ottawa, Gen Campus,501 Smyth Rd, Ottawa, ON K1H 8L6, Canada.			Cakmak, Sabit/0000-0001-9921-2107			BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, ENVIRON RES, V72, P24, DOI 10.1006/enrs.1996.3685; Burnett RT, 1997, EPIDEMIOLOGY, V8, P162, DOI 10.1097/00001648-199703000-00007; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; CLEVELAND WS, 1988, J AM STAT ASSOC, V83, P596, DOI 10.2307/2289282; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; Epton MJ, 1997, THORAX, V52, P528; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hastie T, 1990, GEN ADDITIVE MODELS; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; LI DW, 1995, MYCOLOGIA, V87, P190, DOI 10.2307/3760904; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P819, DOI 10.1016/0091-6749(85)90755-9; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P246; Neas LM, 1996, AM J EPIDEMIOL, V143, P797; Perzanowski MS, 1998, J ALLERGY CLIN IMMUN, V101, P626; PLATTSMILLS T, 1999, ASTHMA LINK ENV IMMU; REED CE, 1985, J ALLERGY CLIN IMMUN, V76, P773, DOI 10.1016/0091-6749(85)90746-8; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; *STAT SCI INC, 1993, S PLUS US MAN; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4	25	99	102	1	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC	2000	162	6					2087	2090				4	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	381ZV	WOS:000165794700021	11112119	
J	Langdeau, JB; Turcotte, H; Bowie, DM; Jobin, J; Desgagne, P; Boulet, LP				Langdeau, JB; Turcotte, H; Bowie, DM; Jobin, J; Desgagne, P; Boulet, LP			Airway hyperresponsiveness in elite athletes	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							INDOOR SWIMMING POOLS; EXERCISE-INDUCED BRONCHOSPASM; CROSS-COUNTRY SKIERS; ICE HOCKEY PLAYERS; BRONCHIAL RESPONSIVENESS; HIGH PREVALENCE; FIGURE SKATERS; INDUCED ASTHMA; EXPOSURE; RISK	It has been suggested that high-level training could contribute to the development of airway hyperresponsiveness (AHR), but the comparative effects of different sports on airway function remains to be determined. We evaluated 150 nonsmoking volunteers 18 to 55 yr of age; 100 athletes divided into four subgroups of 25 subjects each according to the predominant estimated hydrocaloric characteristic of ambient air inhaled during training: dry air (DA), cold air (CA), humid air (HA) and a mixture of dry and humid air (MA), and 50 sedentary subjects. Each subject had a respiratory questionnaire, a methacholine challenge, allergy skin-prick tests, and heart rate variability recording for evaluation of parasympathetic tone. The athletes had a 49% prevalence of AHR (PC20 < 16 mg/ml), with a mean PC20 of 16.9 mg/ml, compared with 28% (PC20: 35.4) in sedentary subjects (p = 0.009). The prevalence (%) of AHR and mean PC,, (mg/ml) varied as followed in the four subgroups of athletes: DA: 32% and 30.9; CA: 52% and 15.8; HA: 76% and 7.3; and MA: 32% and 21.5 (p = 0.002). The estimated parasympathetic tone was higher in athletes (p < 0.001), but this parameter showed only a weak correlation with PC20 (r = -0.17, p = 0.04). This study has shown a significantly higher prevalence of AHR in athletes than in the control group because of the higher prevalence in the CA and HA groups. Parasympathetic activity may act as modulator of airway responsiveness, but the increased prevalence of AHR in our athlete population may be related to the type and possibly the content of inhaled air during training.	Univ Laval, Ctr Rech, Hop Laval, Inst Cardiol & Pneumol, St Foy, PQ G1V 4G5, Canada	Boulet, LP (reprint author), Univ Laval, Ctr Rech, Hop Laval, Inst Cardiol & Pneumol, 2725 Chemin St Foy, St Foy, PQ G1V 4G5, Canada.						Aggazzotti G, 1998, SCI TOTAL ENVIRON, V217, P155, DOI 10.1016/S0048-9697(98)00174-0; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BARNES PJ, 1982, CLIN SCI, V62, P349; BRUDNO DS, 1994, ANN ALLERGY, V73, P227; Camm AJ, 1996, CIRCULATION, V93, P1043; CAMUS G, 1994, INTENS CARE MED, V20, P602, DOI 10.1007/BF01705731; DEMEERSMAN RE, 1992, EUR J APPL PHYSIOL O, V64, P434; GOLDSMITH RL, 1992, J AM COLL CARDIOL, V20, P552; HEDBERG K, 1989, JAMA-J AM MED ASSOC, V262, P3014; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Helenius IJ, 1997, THORAX, V52, P157; HERY M, 1995, ANN OCCUP HYG, V39, P427, DOI 10.1016/0003-4878(95)00013-5; Juniper EF, 1991, HISTAMINE METHACHOLI; KALLENBACH JM, 1985, CHEST, V87, P644, DOI 10.1378/chest.87.5.644; LARSSON K, 1993, BRIT MED J, V307, P1326; Leuppi JD, 1998, EUR RESPIR J, V12, P13, DOI 10.1183/09031936.98.12010013; LEVESQUE B, 1994, ENVIRON HEALTH PERSP, V102, P1082, DOI 10.2307/3431996; MALO JL, 1983, AM REV RESPIR DIS, V128, P8; MANFREDA J, 1996, AM J RESP CRIT CARE, V153, pA432; Mannix ET, 1996, CHEST, V109, P312, DOI 10.1378/chest.109.2.312; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; NIEMAN DC, 1995, THORAX, V50, P1229, DOI 10.1136/thx.50.12.1229; Pennanen AS, 1997, J AIR WASTE MANAGE, V47, P1079, DOI 10.1080/10473289.1997.10464405; POMERANZ B, 1985, AM J PHYSIOL, V248, pH151; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; Pribyl CR, 1996, CLIN J SPORT MED, V6, P232, DOI 10.1097/00042752-199610000-00005; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; RUPP NT, 1993, ANN ALLERGY, V70, P339; Sandsund M, 1997, ANN NY ACAD SCI, V813, P751, DOI 10.1111/j.1749-6632.1997.tb51778.x; SHEPHARD RJ, 1994, SPORTS MED, V18, P340, DOI 10.2165/00007256-199418050-00006; Shi X, 1995, MED SCI SPORTS EXERC, V10, P1406; SMITH ML, 1989, MED SCI SPORTS EXERC, V21, P4; STAND V, 1997, AM J RESP CRIT CARE, V155, P881; Sue-Chu M, 1998, AM J RESP CRIT CARE, V158, P597; ZWICK H, 1990, LUNG, V168, P111	35	99	102	0	6	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAY	2000	161	5					1479	1484				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	312LU	WOS:000086945400016	10806142	
J	Christodoulopoulos, P; Cameron, L; Durham, S; Hamid, Q				Christodoulopoulos, P; Cameron, L; Durham, S; Hamid, Q			Molecular pathology of allergic disease - II: Upper airway disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic rhinitis; chronic sinusitis; inflammation; cytokines; chemokines	COLONY-STIMULATING FACTOR; MESSENGER-RNA EXPRESSION; MAJOR BASIC-PROTEIN; ENDOTHELIAL ADHESION MOLECULES; CHRONIC HYPERPLASTIC SINUSITIS; GRASS-POLLEN IMMUNOTHERAPY; NITRIC-OXIDE SYNTHASE; PHASE NASAL RESPONSES; NECROSIS-FACTOR-ALPHA; FC-EPSILON-RI	Allergic upper airway diseases such as allergic rhinitis and chronic sinusitis are an increasing problem. Although the pathogenesis remains elusive, an individual's genetic predisposition as well as exposure to the allergen are currently considered factors in their development. Clinical symptoms of sneezing, rhinorrhea, and congestion are primarily a consequence of granulocyte release of chemical mediators such as histamine, prostanoids, and leukotrienes as well as the infiltration of inflammatory cells, Observations subsequent to allergen provocation are comparable to natural exposure and as such much of our understanding of allergic responses is derived from this model, A prominence of CD4(+) T cells and eosinophils, synthesis and release of T(H)2 cytokines, and the coordinate expression of chemokines and adhesion molecules are all characteristic of the allergic response observed in rhinitis and sinusitis. Corticosteroids and immunotherapy target these inflammatory processes and have been observed to successfully reduce and shift the predominantly T(H)2 environment toward T(H)1 cytokine expression. As our understanding of the pathophysiologic features of allergic upper airway disease improves, as well as the relationship between their development and that of lower airway disease, new strategies of diagnosis and treatment will allow for more effective modulation of the allergic process and associated morbidity.	McGill Univ, Meakins Christie Labs, Montreal, PQ H2X 2P2, Canada; Royal Brompton Hosp, Natl Heart & Lung Inst, London SW3 6LY, England	Hamid, Q (reprint author), McGill Univ, Meakins Christie Labs, 3626 St Urbain St, Montreal, PQ H2X 2P2, Canada.						AlGhamdi K, 1997, J OTOLARYNGOL, V26, P160; Arnal JF, 1997, CLIN EXP ALLERGY, V27, P358; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BASCOM R, 1988, Journal of Allergy and Clinical Immunology, V81, P580, DOI 10.1016/0091-6749(88)90198-4; BEASLEY R, 1993, J ALLERGY CLIN IMMUN, V92, P148, DOI 10.1016/0091-6749(93)90097-Y; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; BOCHNER BS, 1994, J ALLERGY CLIN IMMUN, V94, P427, DOI 10.1016/0091-6749(94)90195-3; BOCHNER BS, 1995, J IMMUNOL, V154, P799; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BRADDING P, 1993, J IMMUNOL, V151, P3853; BRADDING P, 1992, J EXP MED, V176, P1381, DOI 10.1084/jem.176.5.1381; BROIDE DH, 1992, J CLIN INVEST, V90, P1414, DOI 10.1172/JCI116008; BUSATTIL A, 1977, J ANAT, V124, P445; Cameron LA, 1998, J ALLERGY CLIN IMMUN, V101, P330; Cendan E, 1994, Rev Prat, V44, P1825; Center DM, 1996, IMMUNOL TODAY, V17, P476, DOI 10.1016/0167-5699(96)10052-I; Chakir J, 1996, LAB INVEST, V75, P735; Christodoulopoulos P, 1999, J ALLERGY CLIN IMMUN, V103, P1036, DOI 10.1016/S0091-6749(99)70176-4; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; Cotran RS, 1989, ROBBINS PATHOLOGIC B, P39; CRETICOS PS, 1984, NEW ENGL J MED, V310, P1626, DOI 10.1056/NEJM198406213102502; CRUIKSHANK WW, 1994, P NATL ACAD SCI USA, V91, P5109, DOI 10.1073/pnas.91.11.5109; Davidsson Ake, 1994, Rhinology (Utrecht), V32, P184; DEL PG, 1988, J IMMUNOL, V140, P4193; DENBURG JA, 1985, BLOOD, V66, P312; Dewson G, 1999, AM J RESP CELL MOL, V20, P720; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOLOVICH J, 1990, RHINITIS ASTHMA, P233; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1992, J IMMUNOL, V148, P2390; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Eidelman DH, 1996, AM J RESP CELL MOL, V15, P582; ELOVIC A, 1994, J ALLERGY CLIN IMMUN, V93, P864, DOI 10.1016/0091-6749(94)90379-4; ERJEFALT I, 1991, CLIN EXP ALLERGY, V21, P217, DOI 10.1111/j.1365-2222.1991.tb00833.x; Ferguson E. A., 1997, Rhinology (Utrecht), V35, P120; Fischer A, 1996, AM J RESP CRIT CARE, V154, P209; FREW AJ, 1988, J IMMUNOL, V141, P4158; GAJEWSKI TF, 1988, J IMMUNOL, V140, P4245; GarciaZepeda EA, 1996, J IMMUNOL, V157, P5613; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; Ghaffar O, 1998, OTOLARYNG HEAD NECK, V118, P504, DOI 10.1016/S0194-5998(98)70209-8; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17; Ghaffar O, 1998, AM J RESP CELL MOL, V18, P706; GHAFFAR O, 1999, IN PRESS CLIN EXP AL; GIBSON PG, 1990, CLIN EXP ALLERGY, V20, P661, DOI 10.1111/j.1365-2222.1990.tb02705.x; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; GORDON JR, 1991, J EXP MED, V174, P103, DOI 10.1084/jem.174.1.103; GRIFFITHSJOHNSON DA, 1993, BIOCHEM BIOPH RES CO, V197, P1167, DOI 10.1006/bbrc.1993.2599; Guo FH, 1997, J CLIN INVEST, V100, P829, DOI 10.1172/JCI119598; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; Hamilos DL, 1996, AM J RESP CELL MOL, V15, P443; HAMILOS DL, 1995, J ALLERGY CLIN IMMUN, V96, P537, DOI 10.1016/S0091-6749(95)70298-9; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; HISAMATSU K, 1990, J ALLERGY CLIN IMMUN, V86, P52, DOI 10.1016/S0091-6749(05)80123-X; Holgate ST, 1996, J ALLERGY CLIN IMMUN, V98, P1, DOI 10.1016/S0091-6749(96)70220-8; HUGGINS KG, 1975, LANCET, V2, P148; Iciek LA, 1997, J IMMUNOL, V158, P4769; IGARASHI Y, 1992, FASEB J, V6, pA2005; IGARASHI Y, 1992, J ALLERGY CLIN IMMUN, P89; ILIOPOULOS O, 1990, J ALLERGY CLIN IMMUN, V86, P851, DOI 10.1016/S0091-6749(05)80146-0; ILIOPOULOS O, 1992, J IMMUNOL, V148, P2223; Jahnke V, 1978, Acta Otorhinolaryngol Belg, V32, P48; JAHNSEN FL, 1995, AM J RESP CELL MOL, V12, P624; JULIUSSON S, 1992, J ALLERGY CLIN IMMUN, V90, P898, DOI 10.1016/0091-6749(92)90462-B; KALINER MA, 1991, AM REV RESPIR DIS, V144, pS52; Kamil A, 1998, OTOLARYNG HEAD NECK, V118, P804, DOI 10.1016/S0194-5998(98)70273-6; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KERN EB, 1983, POSTGRAD MED, V74, P156; KITA H, 1991, J EXP MED, V174, P745, DOI 10.1084/jem.174.3.745; KLEMENTSSON H, 1991, CLIN EXP ALLERGY, V21, P705, DOI 10.1111/j.1365-2222.1991.tb03199.x; KNANI J, 1992, J ALLERGY CLIN IMMUN, V90, P880, DOI 10.1016/0091-6749(92)90460-J; Kondo H, 1999, LARYNGOSCOPE, V109, P91, DOI 10.1097/00005537-199901000-00018; Kuna P, 1998, AM J RESP CRIT CARE, V157, P873; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; Laberge S, 1997, J ALLERGY CLIN IMMUN, V100, P569; LEE BJ, 1994, J ALLERGY CLIN IMMUN, V94, P1006, DOI 10.1016/0091-6749(94)90119-8; Li L, 1999, J IMMUNOL, V162, P2477; LORENZ M, 1995, SCIENCE, V267, P1825, DOI 10.1126/science.7892607; LOZEWICZ S, 1992, J ALLERGY CLIN IMMUN, V89, P951, DOI 10.1016/0091-6749(92)90217-P; LUKACS NW, 1995, AM J RESP CELL MOL, V13, P1; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; MASUDA S, QUANTITATIVE HISTOCH; MASUYAMA K, 1994, IMMUNOLOGY, V82, P192; MAYER M, 1993, ANAESTHESIST, V42, P592; MCDONALD DM, 1996, NEUROGENIC INFLAMMAT, P575; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; MELTZER EO, 1995, ALLERGY, V50, P15, DOI 10.1111/j.1398-9995.1995.tb02736.x; Minshall E, 1998, OTOLARYNG HEAD NECK, V118, P648, DOI 10.1177/019459989811800514; MINSHALL E, 1999, J ALLERGY CLIN IMMUN, V103, pA222; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; Minshall EM, 1997, AM J RESP CELL MOL, V17, P683; MONTEFORT S, 1992, AM J RESP CELL MOL, V7, P393; MOQBEL R, 1994, J ALLERGY CLIN IMMUN, V94, P1183, DOI 10.1016/0091-6749(94)90330-1; MOY JN, 1990, J IMMUNOL, V145, P2626; Munoz-Bellido FJ, 1998, ALLERGY, V53, P420, DOI 10.1111/j.1398-9995.1998.tb03916.x; MYGIND N, 1993, ALLERGY, V48, P476, DOI 10.1111/j.1398-9995.1993.tb01103.x; MYGIND N, 1997, ALLERGY ALLERGIC DIS, P1300; Mygind N, 1982, NOSE UPPER AIRWAY PH, P71; NACLERIO RM, 1994, J ALLERGY CLIN IMMUN, V94, P1303, DOI 10.1016/0091-6749(94)90346-8; Naclerio RM, 1997, ALLERGY, V52, P7; NACLERIO RM, 1993, ANN ALLERGY, V71, P292; *NAT I ALL INF DIS, 1979, NIH PUBL; Oddera S, 1996, ALLERGY, V51, P100, DOI 10.1111/j.1398-9995.1996.tb04565.x; Ohashi Y, 1997, ANN OTO RHINOL LARYN, V106, P483; OHKAWARA Y, 1992, AM J RESP CELL MOL, V7, P385; OHNO I, 1995, AM J RESP CELL MOL, V13, P639; OHNO I, 1992, J CLIN INVEST, V89, P1662, DOI 10.1172/JCI115764; OKUDA M, 1983, ANN ALLERGY, V50, P116; OKUDA M, 1988, ANN ALLERGY, V60, P537; ORGEL HA, 1991, J ALLERGY CLIN IMMUN, V88, P257, DOI 10.1016/0091-6749(91)90336-M; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059; PELIKAN Z, 1978, ANN ALLERGY, V41, P37; PIPKORN U, 1983, ALLERGY, V38, P125, DOI 10.1111/j.1398-9995.1983.tb01596.x; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; PUNNONEN J, 1995, J IMMUNOL, V155, P4248; Rajakulasingam K, 1997, AM J RESP CRIT CARE, V155, P696; RAK S, 1994, CLIN EXP ALLERGY, V24, P930, DOI 10.1111/j.1365-2222.1994.tb02724.x; Robinson DS, 1999, INT ARCH ALLERGY IMM, V118, P98, DOI 10.1159/000024039; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Rochester CL, 1996, J IMMUNOL, V156, P4449; ROUSSET F, 1991, J ALLERGY CLIN IMMUN, V87, P58, DOI 10.1016/0091-6749(91)90213-8; Sanai A, 1999, ACTA OTO-LARYNGOL, V119, P473; SANICO AM, 1996, J ALLERGY CLIN IMMUN, V97, pA30; SCADDING GK, 1995, CLIN EXP ALLERGY, V25, P737, DOI 10.1111/j.1365-2222.1995.tb00011.x; SCHALL TJ, 1988, J IMMUNOL, V141, P1018; SCHLEIMER RP, 1992, J IMMUNOL, V148, P1086; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645; Sehmi R, 1997, J CLIN INVEST, V100, P2466, DOI 10.1172/JCI119789; SHALIT M, 1995, CELL IMMUNOL, V160, P50, DOI 10.1016/0008-8749(95)80008-7; SHIMODA K, 1996, NATURE, V380, P627; SOMASSE T, 1996, J EXP MED, V184, P473; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Sornasse T, 1996, J EXP MED, V184, P473, DOI 10.1084/jem.184.2.473; STELLATO C, 1995, J IMMUNOL, V155, P410; SVENSSON C, 1995, CLIN EXP ALLERGY, V25, P942, DOI 10.1111/j.1365-2222.1995.tb00396.x; Symon FA, 1999, EUR J IMMUNOL, V29, P1324, DOI 10.1002/(SICI)1521-4141(199904)29:04<1324::AID-IMMU1324>3.0.CO;2-2; SZABO SJ, 1995, IMMUNITY, V2, P665, DOI 10.1016/1074-7613(95)90011-X; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; TEDESCHI A, 1994, EUR RESPIR J, V7, P1445, DOI 10.1183/09031936.94.07081445; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; TERADA N, 1994, J ALLERGY CLIN IMMUN, V94, P629, DOI 10.1016/0091-6749(94)90140-6; THOMAS LL, 1989, IMMUNOLOGY, V66, P61; THORNHILL MH, 1991, J IMMUNOL, V146, P592; VARNEY VA, 1992, AM REV RESPIR DIS, V146, P170; VOLOVITZ B, 1988, J ALLERGY CLIN IMMUN, V82, P414, DOI 10.1016/0091-6749(88)90000-0; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Wardlaw AJ, 1996, ANN NY ACAD SCI, V796, P124, DOI 10.1111/j.1749-6632.1996.tb32574.x; WARREN WD, 1995, J IMMUNOL, V155, P5637; WHITE MV, 1992, J ALLERGY CLIN IMMUN, V90, P699, DOI 10.1016/0091-6749(92)90155-U; Wilson SJ, 1998, CLIN EXP ALLERGY, V28, P220; WILSON SJ, 1995, AM J RESP CRIT CARE, V151, pA563; Wright ED, 1998, J OTOLARYNGOL, V27, P281; Wright ED, 1999, CLIN EXP ALLERGY, V29, P1320; Wright ED, 1998, OTOLARYNG HEAD NECK, V118, P490, DOI 10.1177/019459989811800411; XU JC, 1994, IMMUNITY, V1, P423, DOI 10.1016/1074-7613(94)90073-6; YING S, 1994, IMMUNOLOGY, V82, P200; YING S, 1993, AM J RESP CELL MOL, V9, P356	164	99	100	0	0	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2000	105	2	1				211	223		10.1016/S0091-6749(00)90068-X		13	Allergy; Immunology	Allergy; Immunology	285RQ	WOS:000085402200003	10669839	
J	Cortessis, VK; Thomas, DC; Levine, AJ; Breton, CV; Mack, TM; Siegmund, KD; Haile, RW; Laird, PW				Cortessis, Victoria K.; Thomas, Duncan C.; Levine, A. Joan; Breton, Carrie V.; Mack, Thomas M.; Siegmund, Kimberly D.; Haile, Robert W.; Laird, Peter W.			Environmental epigenetics: prospects for studying epigenetic mediation of exposure-response relationships	HUMAN GENETICS			English	Review							MONOZYGOTIC TWINS DISCORDANT; DNA METHYLATION PATTERNS; DIETHYLSTILBESTROL IN-UTERO; DIETARY-PROTEIN RESTRICTION; EPIGENOME-WIDE ASSOCIATION; GENE-EXPRESSION PROFILES; SQUAMOUS-CELL CARCINOMA; COLORECTAL-CANCER RISK; CPG ISLAND METHYLATION; IFN-GAMMA PROMOTER	Changes in epigenetic marks such as DNA methylation and histone acetylation are associated with a broad range of disease traits, including cancer, asthma, metabolic disorders, and various reproductive conditions. It seems plausible that changes in epigenetic state may be induced by environmental exposures such as malnutrition, tobacco smoke, air pollutants, metals, organic chemicals, other sources of oxidative stress, and the microbiome, particularly if the exposure occurs during key periods of development. Thus, epigenetic changes could represent an important pathway by which environmental factors influence disease risks, both within individuals and across generations. We discuss some of the challenges in studying epigenetic mediation of pathogenesis and describe some unique opportunities for exploring these phenomena.	[Cortessis, Victoria K.; Thomas, Duncan C.; Levine, A. Joan; Mack, Thomas M.; Haile, Robert W.] Univ So Calif, Dept Prevent Med, Keck Sch Med, USC Norris Comprehens Canc Ctr, Los Angeles, CA 90089 USA; [Laird, Peter W.] Univ So Calif, Dept Surg, Keck Sch Med, USC Norris Comprehens Canc Ctr,Epigenome Ctr, Los Angeles, CA 90089 USA; [Laird, Peter W.] Univ So Calif, Dept Biochem & Mol Biol, Keck Sch Med, USC Norris Comprehens Canc Ctr,Epigenome Ctr, Los Angeles, CA 90089 USA	Thomas, DC (reprint author), Univ So Calif, Dept Prevent Med, Keck Sch Med, USC Norris Comprehens Canc Ctr, 2001 N Soto St,SSB 202F, Los Angeles, CA 90089 USA.	dthomas@usc.edu	Laird, Peter/G-8683-2012		NIH [R21 ES020794, P30 ES 07048, P30 CA014089]; Whittier Foundation	Supported in part by NIH grants R21 ES020794, P30 ES 07048, P30 CA014089 and a Whittier Foundation grant to the Norris Comprehensive Cancer Center.	Adli M, 2011, NAT PROTOC, V6, P1656, DOI 10.1038/nprot.2011.402; Ainsworth HE, 2011, GENET EPIDEMIOL, V35, P19, DOI 10.1002/gepi.20547; Akbarian S, 2010, CURR TOP BEHAV NEURO, V4, P611, DOI 10.1007/7854_2010_38; Andersen AN, 2008, LANCET, V372, P694, DOI 10.1016/S0140-6736(08)61042-9; Anway MD, 2008, PROSTATE, V68, P517, DOI 10.1002/pros.20724; Anway MD, 2005, SCIENCE, V308, P1466, DOI 10.1126/science.1108190; Apostolidou S, 2007, J MOL MED-JMM, V85, P379, DOI 10.1007/s00109-006-0131-8; Arita A, 2011, ENV HLTH PERSPECT, V120, P198; Aryee MJ, 2011, BIOSTATISTICS, V12, P197, DOI 10.1093/biostatistics/kxq055; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Badcock C, 2008, NATURE, V454, P1054, DOI 10.1038/4541054a; Baranzini SE, 2010, NATURE, V464, P1351, DOI 10.1038/nature08990; Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Bayarsaihan D, 2011, J DENT RES, V90, P9, DOI 10.1177/0022034510378683; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Begemann M, 2011, CLIN GENET, V80, P83, DOI 10.1111/j.1399-0004.2010.01514.x; Bell JT, 2012, PLOS GENET, V8, P189, DOI 10.1371/journal.pgen.1002629; Bell JT, 2012, INT J EPIDEMIOL, V41, P140, DOI 10.1093/ije/dyr179; Bell JT, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-1-r10; Bell O, 2011, NAT REV GENET, V12, P554, DOI 10.1038/nrg3017; Benchaib M, 2005, HUM REPROD, V20, P768, DOI 10.1093/humrep/deh684; Benchaib M, 2003, FERTIL STERIL, V80, P947, DOI 10.1016/S0015-0282(03)01151-8; Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969; Berman BP, 2011, NAT GENET IN PRESS, V43; Beyan H, 2010, DIABETES, V59, P1751, DOI 10.2337/db09-1433; Birney E, 2010, HUM MOL GENET, V19, pR204, DOI 10.1093/hmg/ddq404; Bjornsson HT, 2008, JAMA-J AM MED ASSOC, V299, P2877, DOI 10.1001/jama.299.24.2877; Bocklandt S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014821; Boggs BA, 2002, NAT GENET, V30, P73, DOI 10.1038/ng787; Boks MP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006767; Bollati V, 2010, HEREDITY, V105, P105, DOI 10.1038/hdy.2010.2; Bollati V, 2007, CANCER RES, V67, P876, DOI 10.1158/0008-5472.CAN-06-2995; Bollati V, 2010, ENVIRON HEALTH PERSP, V118, P763, DOI 10.1289/ehp.0901300; Breitling LP, 2012, EUR HEART J     0411; Breitling LP, 2011, AM J HUM GENET, V88, P450, DOI 10.1016/j.ajhg.2011.03.003; Breton CV, 2011, AM J RESP CRIT CARE, V184, P191, DOI 10.1164/rccm.201012-2029OC; Breton CV, 2011, EPIGENETICS-US, V6, P895, DOI 10.4161/epi.6.7.15768; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Brouwers MM, 2006, HUM REPROD, V21, P666, DOI 10.1093/humrep/dei398; Bruce KD, 2010, J NUTR, V140, P648, DOI 10.3945/jn.109.111179; Burdge GC, 2007, BRIT J NUTR, V97, P435, DOI 10.1017/S0007114507352392; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Campion J, 2009, OBES REV, V10, P383, DOI 10.1111/j.1467-789X.2009.00595.x; Cantone L, 2011, ENVIRON HEALTH PERSP, V119, P964, DOI 10.1289/ehp.1002955; Carrell DT, 2010, MOL HUM REPROD, V16, P37, DOI 10.1093/molehr/gap090; Chan TL, 2006, NAT GENET, V38, P1178, DOI 10.1038/ng1866; Chanda S, 2006, TOXICOL SCI, V89, P431, DOI 10.1093/toxsci/kfj030; Christensen Brock C., 2011, Frontiers in Genetics, V2, P84, DOI 10.3389/fgene.2011.00084; Ciappio ED, 2011, NUTR REV, V69, P561, DOI 10.1111/j.1753-4887.2011.00424.x; Clifford Harry, 2011, Frontiers in Genetics, V2, P88, DOI 10.3389/fgene.2011.00088; Cohn BA, 2011, REPROD TOXICOL, V31, P302, DOI 10.1016/j.reprotox.2010.10.004; Coolen MW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025590; Cortessis VK, 2011, FERTIL STERIL, V96, P1325, DOI 10.1016/j.fertnstert.2011.09.036; Cortessis VK, 2009, BIENNIAL REVIEW OF INFERTILITY, VOL 1, P239, DOI 10.1007/978-1-60327-392-3_16; Cropley JE, 2006, P NATL ACAD SCI USA, V103, P17308, DOI 10.1073/pnas.0607090103; Curtin K, 2011, PATHOLOG RES INT, DOI DOI 10.4061/2011/902674; D'Angelo DV, 2011, FERTIL STERIL, V96, pe2; Dempster EL, 2011, HUM MOL GENET, V20, P4786, DOI 10.1093/hmg/ddr416; DIECKMANN WJ, 1953, AM J OBSTET GYNECOL, V66, P1062; Diergaarde B, 2003, CANCER EPIDEM BIOMAR, V12, P1130; Diplas AI, 2009, EPIGENETICS, V4, P235; Dolinoy DC, 2008, ENVIRON MOL MUTAGEN, V49, P4, DOI 10.1002/em.20366; Dolinoy DC, 2007, P NATL ACAD SCI USA, V104, P13056, DOI 10.1073/pnas.0703739104; Dolinoy DC, 2007, REPROD TOXICOL, V23, P297, DOI 10.1016/j.reprotox.2006.08.012; Durham AL, 2011, BBA-GEN SUBJECTS, V1810, P1103, DOI 10.1016/j.bbagen.2011.03.006; Eaton AM, 2005, CANCER EPIDEM BIOMAR, V14, P2023, DOI 10.1158/1055-9965.EPI-05-0131; El Hajj N, 2011, SEX DEV, V5, P60, DOI 10.1159/000323806; El-Osta A, 2008, J EXP MED, V205, P2409, DOI 10.1084/jem.20081188; Elashoff RM, 2007, STAT MED, V26, P2813, DOI 10.1002/sim.2749; Enokida H, 2006, CANCER, V106, P79, DOI 10.1002/cncr.21577; Estecio MRH, 2010, GENOME RES, V20, P1369, DOI 10.1101/gr.107318.110; Faulk C, 2011, EPIGENETICS-US, V6, P791, DOI 10.4161/epi.6.7.16209; Feinberg AP, 2007, NATURE, V447, P433, DOI 10.1038/nature05919; Feltus FA, 2006, GENOMICS, V87, P572, DOI 10.1016/j.ygeno.2005.12.016; Feng SH, 2010, SCIENCE, V330, P622, DOI 10.1126/science.1190614; FERGUSON JH, 1953, AM J OBSTET GYNECOL, V65, P592; Ferguson-Smith AC, 2011, NAT REV GENET, V12, P565, DOI 10.1038/nrg3032; Fields PE, 2002, J IMMUNOL, V169, P647; Filipponi D, 2009, EPIGENETICS-US, V4, P27, DOI 10.4161/epi.4.1.7311; Fortier AL, 2008, HUM MOL GENET, V17, P1653, DOI 10.1093/hmg/ddn055; Fraga MF, 2005, P NATL ACAD SCI USA, V102, P10604, DOI 10.1073/pnas.0500398102; Furrow RE, 2011, GENETICS, V189, P1377, DOI 10.1534/genetics.111.131912; Galetzka D, 2012, EPIGENETICS-US, V7, P47, DOI 10.4161/epi.7.1.18814; Gao Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033503; Gertz J, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002228; Gervin K, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002454; Gervin K, 2011, GENOME RES, V21, P1813, DOI 10.1101/gr.119685.110; Gordon L, 2011, EPIGENETICS-US, V6, P579, DOI 10.4161/epi.6.5.15072; Greenland S, 2000, INT J EPIDEMIOL, V29, P722, DOI 10.1093/ije/29.4.722; Guo L, 2008, DEV BIOL, V320, P79, DOI 10.1016/j.ydbio.2008.04.025; Haas CS, 2006, ARTHRITIS RHEUM, V54, P2047, DOI 10.1002/art.21953; Harris RA, 2010, NAT BIOTECHNOL, V28, P1097, DOI 10.1038/nbt.1682; Harris RA, 2012, INFLAMM BOWEL DIS; Heijmans BT, 2008, P NATL ACAD SCI USA, V105, P17046, DOI 10.1073/pnas.0806560105; Heijmans BT, 2007, HUM MOL GENET, V16, P547, DOI 10.1093/hmg/ddm/010; HENDERSON BE, 1976, PEDIATRICS, V58, P505; Herceg Z, 2011, MUTAT RES-REV MUTAT, V727, P55, DOI 10.1016/j.mrrev.2011.04.001; Hitchins MP, 2011, CANCER CELL, V20, P200, DOI 10.1016/j.ccr.2011.07.003; Ho SM, 2010, J ALLERGY CLIN IMMUN, V126, P453, DOI 10.1016/j.jaci.2010.07.030; Houshdaran S, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001289; Huang HS, 2012, NATURE, V481, P185, DOI 10.1038/nature10726; Huang YP, 2011, INT J CANCER, V128, P2261, DOI 10.1002/ijc.25569; Hughes LAE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007951; Iacopetta B, 2007, CANCER SCI, V98, P1454, DOI 10.1111/j.1349-7006.2007.00548.x; Ideraabdullah FY, 2011, DEV BIOL, V355, P349, DOI 10.1016/j.ydbio.2011.04.036; Jaffe AE, 2012, INT J EPIDEMIOL, V41, P200, DOI 10.1093/ije/dyr238; Jaffe AE, 2012, BIOSTATISTICS, V13, P166, DOI 10.1093/biostatistics/kxr013; Jardim MJ, 2011, MUTAT RES-FUND MOL M, V717, P38, DOI 10.1016/j.mrfmmm.2011.03.014; Javierre BM, 2010, GENOME RES, V20, P170, DOI 10.1101/gr.100289.109; Jiang GF, 2008, TOXICOLOGY, V244, P49, DOI 10.1016/j.tox.2007.10.028; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kakiuchi C, 2008, AM J MED GENET B, V147B, P557, DOI 10.1002/ajmg.b.30643; Kalfa N, 2011, FERTIL STERIL, V95, P2574, DOI 10.1016/j.fertnstert.2011.02.047; Kaminsky Z, 2008, TWIN RES HUM GENET, V11, P1, DOI 10.1375/twin.11.1.1; Kanwal R, 2011, CLIN GENET, V81, P303; Kerkel K, 2008, NAT GENET, V40, P904, DOI 10.1038/ng.174; Keshet I, 2006, NAT GENET, V38, P149, DOI 10.1038/ng1719; Kim DH, 2001, CANCER RES, V61, P3419; Klip H, 2002, LANCET, V359, P1102, DOI 10.1016/S0140-6736(02)08152-7; Kobayashi H, 2007, HUM MOL GENET, V16, P2542, DOI 10.1093/hmg/ddm187; Koukoura O, 2011, PLACENTA, V32, P51, DOI 10.1016/j.placenta.2010.10.017; Koukoura O, 2011, INT J MOL MED, V28, P481, DOI 10.3892/ijmm.2011.754; Kristensen LS, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-453; Kuratomi G, 2008, MOL PSYCHIATR, V13, P429, DOI 10.1038/sj.mp.4002001; Kwon NH, 2008, J CLIN IMMUNOL, V28, P139, DOI 10.1007/s10875-007-9148-1; Laird PW, 2010, NAT REV GENET, V11, P191, DOI 10.1038/nrg2732; Langevin SM, 2012, EPIGENETICS-US, V7, P291, DOI 10.4161/epi.7.3.19134; Langevin SM, 2011, EPIGENETICS-US, V6, P908, DOI 10.4161/epi.6.7.16431; Lee H, 2012, INT J EPIDEMIOL, V41, P188, DOI 10.1093/ije/dyr237; Li L, 2011, REPROD TOXICOL, V32, P98, DOI 10.1016/j.reprotox.2011.05.016; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lienert F, 2011, NAT GENET, V43, P1091, DOI 10.1038/ng.946; Ligtenberg MJL, 2009, NAT GENET, V41, P112, DOI 10.1038/ng.283; Lillycrop KA, 2005, J NUTR, V135, P1382; Lillycrop KA, 2011, P NUTR SOC, V70, P64, DOI 10.1017/S0029665110004027; Lim U, 2012, CANC EPIGENETICS MET, V863; Limsui D, 2010, J NATL CANCER I, V102, P1012, DOI 10.1093/jnci/djq201; Liu XD, 2009, BIOCHEM BIOPH RES CO, V380, P177, DOI 10.1016/j.bbrc.2009.01.066; Lovat F, 2011, SEMIN ONCOL, V38, P724, DOI 10.1053/j.seminoncol.2011.08.006; Lumey LH, 2011, ANNU REV PUBL HEALTH, V32, P237, DOI 10.1146/annurev-publhealth-031210-101230; Lumey L H, 1992, Paediatr Perinat Epidemiol, V6, P240, DOI 10.1111/j.1365-3016.1992.tb00764.x; Majumdar S, 2010, ENVIRON TOXICOL, V25, P315, DOI 10.1002/tox.20497; Marques CJ, 2008, MOL HUM REPROD, V14, P67, DOI 10.1093/molehr/gam093; Marsit CJ, 2006, CARCINOGENESIS, V27, P112, DOI 10.1093/carcin/bgi172; Mastroeni D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006617; Matigian N, 2007, MOL PSYCHIATR, V12, P815, DOI 10.1038/sj.mp.4001998; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; McDaniell R, 2010, SCIENCE, V328, P235, DOI 10.1126/science.1184655; McDonald SD, 2010, EUR J OBSTET GYN R B, V148, P105, DOI 10.1016/j.ejogrb.2009.09.019; McDonald SD, 2009, EUR J OBSTET GYN R B, V146, P138, DOI 10.1016/j.ejogrb.2009.05.035; MCGRATH J, 1984, CELL, V37, P179, DOI 10.1016/0092-8674(84)90313-1; McMinn J, 2006, PLACENTA, V27, P540, DOI 10.1016/j.placenta.2005.07.004; Mill J, 2008, AM J HUM GENET, V82, P696, DOI 10.1016/j.ajhg.2008.01.008; Mitchell LE, 2005, AM J EPIDEMIOL, V162, P676, DOI 10.1093/aje/kwi249; Mitchell MM, 2011, EPIGENETICS-US, V6, P95, DOI 10.4161/epi.6.1.13405; Molitor J, 2003, AM J HUM GENET, V73, P1368, DOI 10.1086/380415; MOLLER H, 1995, INT J CANCER, V61, P761, DOI 10.1002/ijc.2910610604; Morgan HD, 1999, NAT GENET, V23, P314, DOI 10.1038/15490; Murphy SK, 2011, GENE, V494, P36, DOI DOI 10.1016/J.GENE.2011.11.062; Nadeau K, 2010, J ALLERGY CLIN IMMUN, V126, P845, DOI 10.1016/j.jaci.2010.08.008; Nagarajan Raman P, 2006, Epigenetics, V1, pe1; Nan HM, 2005, WORLD J GASTROENTERO, V11, P3834; Nana-Sinkam SP, 2009, AM J RESP CRIT CARE, V179, P4, DOI 10.1164/rccm.200807-1042PP; Nelissen ECM, 2011, HUM REPROD UPDATE, V17, P397, DOI 10.1093/humupd/dmq052; Nguyen A, 2010, FASEB J, V24, P3036, DOI [10.1096/fj.10-154484, 10.1096/fj.09-154484]; O'Hanlon TP, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3330; Oates NA, 2006, AM J HUM GENET, V79, P155, DOI 10.1086/505031; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ollikainen M, 2010, HUM MOL GENET, V19, P4176, DOI 10.1093/hmg/ddq336; Pacheco SE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020280; Palmer JR, 2005, EPIDEMIOLOGY, V16, P583, DOI 10.1097/01.ede.0000164789.59728.6d; Patel CJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010746; Pauley KM, 2008, ANN NY ACAD SCI, V1143, P226, DOI 10.1196/annals.1443.009; Pavanello S, 2009, INT J CANCER, V125, P1692, DOI 10.1002/ijc.24492; Pembrey ME, 2006, EUR J HUM GENET, V14, P159, DOI 10.1038/sj.ejhg.5204538; Perera F, 2011, REPROD TOXICOL, V31, P363, DOI 10.1016/j.reprotox.2010.12.055; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Pilsner JR, 2009, ENVIRON HEALTH PERSP, V117, P1466, DOI 10.1289/ehp.0800497; Pirola L, 2011, GENOME RES, V21, P1601, DOI 10.1101/gr.116095.110; Plagemann A, 2009, J PHYSIOL-LONDON, V587, P4963, DOI 10.1113/jphysiol.2009.176156; Pons JC, 2005, PRENATAL DIAG, V25, P418, DOI 10.1002/pd.1136; Pozharny Y, 2010, AM J OBSTET GYNECOL, V202, DOI 10.1016/j.ajog.2010.01.039; Ptashne M, 2007, CURR BIOL, V17, pR233, DOI 10.1016/j.cub.2007.02.030; Rakyan VK, 2011, NAT REV GENET, V12, P529, DOI 10.1038/nrg3000; Reddy MA, 2011, CARDIOVASC RES, V90, P421, DOI 10.1093/cvr/cvr024; Relton CL, 2012, INT J EPIDEMIOL, V41, P161, DOI 10.1093/ije/dyr233; Rosa A, 2008, AM J MED GENET B, V147B, P459, DOI 10.1002/ajmg.b.30616; Russo AL, 2005, CLIN CANCER RES, V11, P2466, DOI 10.1158/1078-0432.CCR-04-1962; Saffery R., 2011, INT J EPIDEMIOL, V41, P55; Salam MT, 2012, J ALLERGY CLIN IMMUN, V129, pe7; Samowitz WS, 2006, J NATL CANCER I, V98, P1731, DOI 10.1093/jnci/djj468; Sato A, 2007, HUM REPROD, V22, P26, DOI 10.1093/humrep/del316; Savage T, 2011, HUM REPROD, V26, P2392, DOI 10.1093/humrep/der212; Scesnaite A, 2012, MUTAGENESIS; Schalkwyk LC, 2010, AM J HUM GENET, V86, P196, DOI 10.1016/j.ajhg.2010.01.014; Schemhammer ES, 2008, CANCER EPIDEM BIOMAR, V17, P2895, DOI 10.1158/1055-9965.EPI-08-0638; Schlesinger Y, 2007, NAT GENET, V39, P232, DOI 10.1038/ng1950; Schneider E, 2010, NUCLEIC ACIDS RES, V38, P3880, DOI 10.1093/nar/gkq126; Schroeder DI, 2011, GENOME RES, V21, P1583, DOI 10.1101/gr.119131.110; Serman L, 2007, PLACENTA, V28, P803, DOI 10.1016/j.placenta.2007.04.001; Sharma S, 2010, CARCINOGENESIS, V31, P27, DOI 10.1093/carcin/bgp220; Sharp AJ, 2011, GENOME RES, V21, P1592, DOI 10.1101/gr.112680.110; Siebel AL, 2010, BIOCHEM PHARMACOL, V80, P1853, DOI 10.1016/j.bcp.2010.06.005; Siegmund KD, 2006, CANCER EPIDEM BIOMAR, V15, P567, DOI 10.1158/1055-9965.EPI-05-0717; Siegmund KD, 2004, BIOINFORMATICS, V20, P1896, DOI 10.1093/bioinformatics/bth176; Siegmund KD, 2011, HUM GENET, V129, P585, DOI 10.1007/s00439-011-0993-x; Sinclair KD, 2000, HUM REPROD, V15, P68; Slatkin M, 2009, GENETICS, V182, P845, DOI 10.1534/genetics.109.102798; Slattery ML, 2001, INT J CANCER, V93, P601, DOI 10.1002/ijc.1370; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, pe3; Sundar IK, 2010, METHOD ENZYMOL, V474, P213, DOI 10.1016/S0076-6879(10)74013-1; Suter CM, 2004, NAT GENET, V36, P497, DOI 10.1038/ng1342; Swan SH, 2000, APMIS, V108, P793, DOI 10.1111/j.1600-0463.2000.tb00001.x; Tal O, 2010, GENETICS, V184, P1037, DOI 10.1534/genetics.109.112466; Talens RP, 2011, INT J EPIDEMIOL, V40, P1; Talens RP, 2010, FASEB J, V24, P3135, DOI 10.1096/fj.09-150490; Tanay A, 2007, P NATL ACAD SCI USA, V104, P5521, DOI 10.1073/pnas.0609746104; Tarantini L, 2009, ENVIRON HEALTH PERSP, V117, P217, DOI 10.1289/ehp.11898; Tarutani Y, 2011, CURR OPIN PLANT BIOL, V14, P608, DOI 10.1016/j.pbi.2011.07.001; Taylor PD, 2007, EXP PHYSIOL, V92, P287, DOI 10.1113/expphysiol.2005.032854; Terry MB, 2011, EPIGENETICS-US, V6, P828, DOI 10.4161/epi.6.7.16500; Teschendorff AE, 2010, GENOME RES, V20, P440, DOI 10.1101/gr.103606.109; Thomson JP, 2010, NATURE, V464, P1082, DOI 10.1038/nature08924; Tierling S, 2011, CLIN GENET, V79, P546, DOI 10.1111/j.1399-0004.2010.01482.x; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Trasler JM, 2009, MOL CELL ENDOCRINOL, V306, P33, DOI 10.1016/j.mce.2008.12.018; Tycko B, 2010, AM J HUM GENET, V86, P109, DOI 10.1016/j.ajhg.2010.01.021; Valinluck V, 2004, NUCLEIC ACIDS RES, V32, P4100, DOI 10.1093/nar/gkh739; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; van den Donk M, 2007, CANCER EPIDEM BIOMAR, V16, P327, DOI 10.1158/1055-9965.EPI-06-0810; Van Guelpen B, 2010, CANCER CAUSE CONTROL, V21, P557, DOI 10.1007/s10552-009-9484-y; van Montfoort APA, 2012, HUM REPROD UPDATE, V18, P171, DOI 10.1093/humupd/dmr047; Vermeulen SH, 2009, GENET EPIDEMIOL, V33, P136, DOI 10.1002/gepi.20365; VESSEY MP, 1983, BRIT J OBSTET GYNAEC, V90, P1007, DOI 10.1111/j.1471-0528.1983.tb06438.x; Wark PA, 2005, CANCER EPIDEM BIOMAR, V14, P1619, DOI 10.1158/1055-9965.EPI-05-0109; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Waterland RA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001252; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834; Weth O, 2011, BIOCHEM CELL BIOL, V89, P459, DOI [10.1139/o11-033, 10.1139/O11-033]; White GP, 2002, J IMMUNOL, V168, P2820; WHITEHEAD ED, 1981, J UROLOGY, V125, P47; Wierda RJ, 2010, J CELL MOL MED, V14, P1225, DOI 10.1111/j.1582-4934.2010.01022.x; Wilker EH, 2010, ENVIRON HEALTH PERSP, V118, P943, DOI 10.1289/ehp.0901440; Wong CCY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017873; Wong CCY, 2010, EPIGENETICS-US, V5, DOI 10.4161/epi.5.6.12226; Wright RO, 2007, J NUTR, V137, P2809; Wright RO, 2010, ENVIRON HEALTH PERSP, V118, P790, DOI 10.1289/ehp.0901429; Wu HC, 2011, EPIGENETICS-US, V6, P76, DOI 10.4161/epi.6.1.13391; Yauk C, 2008, P NATL ACAD SCI USA, V105, P605, DOI 10.1073/pnas.0705896105; Yauk CL, 2007, CANCER RES, V67, P5103, DOI 10.1158/0008-5472.CAN-07-0279; Zhang L, 2012, CELL RES, V22, P107, DOI 10.1038/cr.2011.158; Zhou ZH, 2011, TOXICOL SCI, V125, P412	256	98	103	2	85	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-6717			HUM GENET	Hum. Genet.	OCT	2012	131	10			SI		1565	1589		10.1007/s00439-012-1189-8		25	Genetics & Heredity	Genetics & Heredity	998OH	WOS:000308249300005	22740325	
J	Roy, S; Byrne, J; Pickering, C				Roy, Sudipto; Byrne, Jason; Pickering, Catherine			A systematic quantitative review of urban tree benefits, costs, and assessment methods across cities in different climatic zones	URBAN FORESTRY & URBAN GREENING			English	Review						Cities; Ecosystem services; Ecosystem disservices; Land use policy; Trees	VALUING ECOSYSTEM SERVICES; STREET TREE; CARBON STORAGE; FOREST STRUCTURE; SHADE TREES; DECISION-MAKING; GREEN SPACE; AIR-QUALITY; POLLUTION MITIGATION; UNITED-STATES	Urban trees can potentially mitigate environmental degradation accompanying rapid urbanisation via a range of tree benefits and services. But uncertainty exists about the extent of tree benefits and services because urban trees also impose costs (e.g. asthma) and may create hazards (e.g. windthrow). Few researchers have systematically assessed how urban tree benefits and costs vary across different cities, geographic scales and climates. This paper provides a quantitative review of 115 original urban tree studies, examining: (i) research locations, (ii) research methods, and (iii) assessment techniques for tree services and disservices. Researchers published findings in 33 journals from diverse disciplines including: forestry, land use planning, ecology, and economics. Research has been geographically concentrated (64% of studies were conducted in North America). Nearly all studies (91.3%) used quantitative research, and most studies (60%) employed natural science methods. Demonstrated tree benefits include: economic, social, health, visual and aesthetic benefits; identified ecosystem services include: carbon sequestration, air quality improvement, storm water attenuation, and energy conservation. Disservices include: maintenance costs, light attenuation, infrastructure damage and health problems, among others. Additional research is required to better inform public policy, including comparative assessment of tree services and disservices, and assessment of urban residents and land managers' understanding of tree benefits and costs. (c) 2012 Elsevier GmbH. All rights reserved.	[Roy, Sudipto] Griffith Univ, Urban Res Program, Griffith Sch Environm, Brisbane, Qld 4111, Australia; [Byrne, Jason; Pickering, Catherine] Griffith Univ, Environm Futures Res Ctr, Griffith Sch Environm, Gold Coast, Qld 4222, Australia	Byrne, J (reprint author), Griffith Univ, Environm Futures Res Ctr, Griffith Sch Environm, Room 3-06,Bldg G 31,Gold Coast Campus, Gold Coast, Qld 4222, Australia.	sudipto.roy@griffith.edu.au; Jason.Byrne@griffith.edu.au; c.pickering@griffith.edu.au	Byrne, Jason/L-7140-2013	Byrne, Jason/0000-0001-8733-0333; Roy, Sudipto/0000-0003-2097-8551			Akbari H, 2002, ENVIRON POLLUT, V116, pS119, DOI 10.1016/S0269-7491(01)00264-0; Akbari H, 2001, SOL ENERGY, V70, P295, DOI 10.1016/S0038-092X(00)00089-X; Alberti Marina, 2004, Urban Ecosystems, V7, P241, DOI 10.1023/B:UECO.0000044038.90173.c6; AMIR S, 1990, LANDSCAPE URBAN PLAN, V19, P203, DOI 10.1016/0169-2046(90)90022-T; ANDERSON LM, 1988, LANDSCAPE URBAN PLAN, V15, P153, DOI 10.1016/0169-2046(88)90023-0; Arthur T.E., 1981, STREET TREE DIRECTOR; BEATTY RA, 1981, URBAN ECOL, V5, P81, DOI 10.1016/0304-4009(81)90002-4; Benjamin MT, 1998, ATMOS ENVIRON, V32, P53, DOI 10.1016/S1352-2310(97)00176-3; Benjamin MT, 1996, ATMOS ENVIRON, V30, P1437, DOI 10.1016/1352-2310(95)00439-4; Bolund P, 1999, ECOL ECON, V29, P293, DOI 10.1016/S0921-8009(99)00013-0; Boyd J, 2007, ECOL ECON, V63, P616, DOI 10.1016/j.ecolecon.2007.01.002; Brack CL, 2002, ENVIRON POLLUT, V116, pS195, DOI 10.1016/S0269-7491(01)00251-2; Broadhead JS, 2003, AGR FOREST METEOROL, V115, P151, DOI 10.1016/S0168-1923(02)00212-5; Brown TC, 2007, NAT RESOUR J, V47, P329; Bruns D., 2008, J CONT WATER RES ED, V138, P29; Burden D., 2006, 22 BENEFITS URBAN ST; Byrne J, 2010, AUSTR PLANNER, V47, P162, DOI [10.1080/07293682.2010.508204, DOI 10.1080/07293682.2010.508204]; Carver AD, 2004, ENVIRON MANAGE, V34, P650, DOI 10.1007/s00267-002-7003-y; Cavanagh JAE, 2009, URBAN FOR URBAN GREE, V8, P21, DOI 10.1016/j.ufug.2008.10.002; Chee YE, 2004, BIOL CONSERV, V120, P549, DOI 10.1016/j.biocon.2004.03.028; Chen SS, 2008, SPRINGER SER ENV MAN, P259, DOI 10.1007/978-0-387-71425-7_16; CORCHNOY SB, 1992, ATMOS ENVIRON B-URB, V26, P339, DOI 10.1016/0957-1272(92)90009-H; Costanza R, 2002, ECOL ECON, V41, P367, DOI 10.1016/S0921-8009(02)00087-3; Daily GC, 2009, FRONT ECOL ENVIRON, V7, P21, DOI 10.1890/080025; de Groot R, 2006, LANDSCAPE URBAN PLAN, V75, P175, DOI 10.1016/j.landurbplan.2005.02.016; de Groot RS, 2010, ECOL COMPLEX, V7, P260, DOI 10.1016/j.ecocom.2009.10.006; de Groot RS, 2002, ECOL ECON, V41, P393, DOI 10.1016/S0921-8009(02)00089-7; Dick JM, 2011, ENVIRONMETRICS, V22, P598, DOI 10.1002/env.1085; Dobbs C, 2011, LANDSCAPE URBAN PLAN, V99, P196, DOI 10.1016/j.landurbplan.2010.11.004; Donovan GH, 2011, URBAN FOR URBAN GREE, V10, P163, DOI 10.1016/j.ufug.2011.05.007; Donovan GH, 2010, LANDSCAPE URBAN PLAN, V94, P77, DOI 10.1016/j.landurbplan.2009.07.019; Donovan GH, 2009, ENERG BUILDINGS, V41, P662, DOI 10.1016/j.enbuild.2009.01.002; DWYER J F, 1991, Journal of Arboriculture, V17, P276; Dwyer J. F., 1992, Journal of Arboriculture, V18, P227; Dwyer John F., 2003, Journal of Arboriculture, V29, P49; Escobedo F. J., 2008, Journal of Environmental Management, V86, P148, DOI 10.1016/j.jenvman.2006.11.029; Escobedo F, 2010, ENVIRON SCI POLICY, V13, P362, DOI 10.1016/j.envsci.2010.03.009; Escobedo Francisco J., 2006, Urban Forestry & Urban Greening, V4, P105, DOI 10.1016/j.ufug.2005.12.002; Escobedo FJ, 2011, ENVIRON POLLUT, V159, P2078, DOI 10.1016/j.envpol.2011.01.010; Escobedo FJ, 2009, LANDSCAPE URBAN PLAN, V90, P102, DOI 10.1016/j.landurbplan.2008.10.021; Fahmy M, 2010, BUILD ENVIRON, V45, P345, DOI 10.1016/j.buildenv.2009.06.014; Farber SC, 2002, ECOL ECON, V41, P375, DOI 10.1016/S0921-8009(02)00088-5; Fisher B, 2009, ECOL ECON, V68, P643, DOI 10.1016/j.ecolecon.2008.09.014; Folke C, 1997, AMBIO, V26, P167; Frank Stephen, 2006, Arboriculture & Urban Forestry, V32, P155; Galvin Michael F., 1999, Journal of Arboriculture, V25, P124; Gao XL, 2007, LANDSCAPE URBAN PLAN, V81, P155, DOI 10.1016/j.landurbplan.2006.11.007; Girardet H, 1996, GAIA ATLAS CITIES NE; Gomez-Munoz VM, 2010, LANDSCAPE URBAN PLAN, V94, P149, DOI 10.1016/j.landurbplan.2009.09.002; Good T., 2008, BENEFITS TREES; Gorman J., 2004, Journal of Arboriculture, V30, P36; Gregg JW, 2003, NATURE, V424, P183, DOI 10.1038/nature01728; Hamada S, 2010, URBAN FOR URBAN GREE, V9, P15, DOI 10.1016/j.ufug.2009.10.002; HEISLER G M, 1986, Journal of Arboriculture, V12, P113; HEISLER GM, 1986, URBAN ECOL, V9, P337, DOI 10.1016/0304-4009(86)90008-2; Hildebrandt EW, 1998, ATMOS ENVIRON, V32, P85, DOI 10.1016/S1352-2310(97)00183-0; Hough M, 2004, CITIES NATURAL PROCE; Howarth RB, 2002, ECOL ECON, V41, P421, DOI 10.1016/S0921-8009(02)00091-5; JAENSON R, 1992, Journal of Arboriculture, V18, P171; James P, 2009, URBAN FOR URBAN GREE, V8, P65, DOI 10.1016/j.ufug.2009.02.001; Jim CY, 2008, J ENVIRON MANAGE, V88, P665, DOI 10.1016/j.jenvman.2007.03.035; Jim CY, 2009, APPL GEOGR, V29, P577, DOI 10.1016/j.apgeog.2009.01.002; Jim CY, 2009, CITIES, V26, P187, DOI 10.1016/j.cities.2009.03.003; JIM CY, 1992, ENVIRON CONSERV, V19, P209; JO HK, 1995, J ENVIRON MANAGE, V45, P109, DOI 10.1006/jema.1995.0062; Johnson Andra D., 2003, Urban Forestry & Urban Greening, V2, P65, DOI 10.1078/1618-8667-00024; Jonsson P, 2004, INT J CLIMATOL, V24, P1307, DOI 10.1002/joc.1064; Jutras P, 2009, COMPUT ELECTRON AGR, V67, P9, DOI 10.1016/j.compag.2009.02.008; Kaya LG, 2009, SCI RES ESSAYS, V4, P1100; Kirkpatrick JB, 2011, LANDSCAPE URBAN PLAN, V101, P244, DOI 10.1016/j.landurbplan.2011.02.029; Kong FH, 2007, LANDSCAPE URBAN PLAN, V79, P240, DOI 10.1016/j.landurbplan.2006.02.013; Kooten G.C.V., 2002, LAND ECON, V78, P559; Kottek M, 2006, METEOROL Z, V15, P259, DOI 10.1127/0941-2948/2006/0130; Kroeger T, 2007, ECOL ECON, V64, P321, DOI 10.1016/j.ecolecon.2007.07.021; Kumar M, 2008, ECOL ECON, V64, P808, DOI 10.1016/j.ecolecon.2007.05.008; Liu CF, 2012, URBAN FOR URBAN GREE, V11, P121, DOI 10.1016/j.ufug.2011.03.002; Liu S, 2010, ANN NY ACAD SCI, V1185, P54, DOI 10.1111/j.1749-6632.2009.05167.x; Lohmann Ulrike, 1993, Climate Research, V3, P177, DOI 10.3354/cr003177; Lohr Virginia I., 2004, Journal of Arboriculture, V30, P28; Longcore T, 2004, URBAN GEOGR, V25, P173, DOI 10.2747/0272-3638.25.2.173; Low N., 2005, GREEN CITY SUSTAINAB; Lyytimaki J, 2009, URBAN FOR URBAN GREE, V8, P309, DOI 10.1016/j.ufug.2009.09.003; MA = Millenium Ecosystem Assessment, 2005, EC HUM WELL BEING FR; Maco Scott E., 2002, Journal of Arboriculture, V28, P270; Maco Scott E., 2003, Journal of Arboriculture, V29, P84; Mansfield C, 2005, J FOREST ECON, V11, P177, DOI 10.1016/j.jfe.2005.08.002; Martin C. W., 1989, Journal of Arboriculture, V15, P72; McPherson E. G., 1997, Urban Ecosystems, V1, P49, DOI 10.1023/A:1014350822458; McPherson E. Gregory, 2003, Journal of Arboriculture, V29, P1; McPherson EG, 2011, LANDSCAPE URBAN PLAN, V99, P40, DOI 10.1016/j.landurbplan.2010.08.011; McPherson E. Gregory, 2010, Arboriculture & Urban Forestry, V36, P230; McPherson EG, 1998, ATMOS ENVIRON, V32, P75, DOI 10.1016/S1352-2310(97)00180-5; McPherson E. G., 1989, LANDSCAPE J, V8, P13; McPherson G, 2005, J FOREST, V103, P411; Miller R. W., 1997, URBAN FORESTRY PLANN; Millward AA, 2011, LANDSCAPE URBAN PLAN, V100, P177, DOI 10.1016/j.landurbplan.2010.11.013; Morani A, 2011, ENVIRON POLLUT, V159, P1040, DOI 10.1016/j.envpol.2010.11.022; Myeong S, 2006, REMOTE SENS ENVIRON, V101, P277, DOI 10.1016/j.rse.2005.12.001; Nagendra H, 2010, URBAN FOR URBAN GREE, V9, P129, DOI 10.1016/j.ufug.2009.12.005; Newman P., 2008, CITIES SUSTAINABLE E; Ng E, 2012, BUILD ENVIRON, V47, P256, DOI 10.1016/j.buildenv.2011.07.014; Nowak D. J., 1990, Journal of Arboriculture, V16, P231; Nowak D. J., 1993, Journal of Arboriculture, V19, P173; Nowak D. J., 1990, Journal of Arboriculture, V16, P124; Nowak David J., 2007, Arboriculture & Urban Forestry, V33, P220; Nowak David J., 2006, Urban Forestry & Urban Greening, V4, P115, DOI 10.1016/j.ufug.2006.01.007; Nowak David J., 2002, Journal of Arboriculture, V28, P113; Nowak David J., 2002, Journal of Arboriculture, V28, P194; Nowak David J., 2008, Arboriculture & Urban Forestry, V34, P347; Nowak David J., 2008, Arboriculture & Urban Forestry, V34, P391; Nowak David J., 2008, Arboriculture & Urban Forestry, V34, P386; Nowak DJ, 2005, J FOREST, V103, P377; Nowak DJ, 1996, FOREST SCI, V42, P504; Nowak DJ, 1996, LANDSCAPE URBAN PLAN, V36, P49, DOI 10.1016/S0169-2046(96)00324-6; Nowak DJ, 2000, ATMOS ENVIRON, V34, P1601, DOI 10.1016/S1352-2310(99)00394-5; Nowak DJ, 2002, ENVIRON POLLUT, V116, P381, DOI 10.1016/S0269-7491(01)00214-7; Nowak DJ, 2001, J FOREST, V99, P37; Nowak D.J., 2000, HDB URBAN COMMUNITY, P11; Oikonomou V, 2011, ENVIRON MANAGE, V47, P77, DOI 10.1007/s00267-010-9575-2; Pandit Ram, 2010, Arboriculture & Urban Forestry, V36, P73; Pandit R, 2010, ECOL ECON, V69, P1324, DOI 10.1016/j.ecolecon.2010.01.009; Pataki DE, 2006, GLOBAL CHANGE BIOL, V12, P2092, DOI 10.1111/j.1365-2486.2006.01242.x; Peel MC, 2007, HYDROL EARTH SYST SC, V11, P1633; PENG L., 2008, FRONTIERS FORESTRY C, V3, P177, DOI 10.1007/s11461-008-0035-6; Peper Paula J., 2001, Journal of Arboriculture, V27, P306; Petticrew M, 2001, BRIT MED J, V322, P98, DOI 10.1136/bmj.322.7278.98; Pittman J., 2010, ENV RISK ASSESSMENT, P361; Poudyal NC, 2011, URBAN FOR URBAN GREE, V10, P223, DOI 10.1016/j.ufug.2011.05.005; PROFOUS G V, 1992, Journal of Arboriculture, V18, P145; Randrup T. B., 2005, URBAN FORESTS TREES, P9, DOI 10.1007/3-540-27684-X_2; Register R., 2006, ECOCITIES REBUILDING, P9; RICHARDS NA, 1983, URBAN ECOL, V7, P159, DOI 10.1016/0304-4009(83)90034-7; Roberts L, 2011, SCIENCE, V333, P540, DOI 10.1126/science.333.6042.540; Roloff A, 2009, URBAN FOR URBAN GREE, V8, P295, DOI 10.1016/j.ufug.2009.08.002; ROWNTREE R A, 1991, Journal of Arboriculture, V17, P269; Sagoff M, 2011, ECOL ECON, V70, P497, DOI 10.1016/j.ecolecon.2010.10.006; Sander H, 2010, ECOL ECON, V69, P1646, DOI 10.1016/j.ecolecon.2010.03.011; SANDERS RA, 1984, URBAN ECOL, V8, P13, DOI 10.1016/0304-4009(84)90004-4; SANDERS RA, 1981, URBAN ECOL, V5, P33, DOI 10.1016/0304-4009(81)90019-X; Seppelt R, 2011, J APPL ECOL, V48, P630, DOI 10.1111/j.1365-2664.2010.01952.x; Shashua-Bar L, 2000, ENERG BUILDINGS, V31, P221, DOI 10.1016/S0378-7788(99)00018-3; Shashua-Bar L, 2004, BUILD ENVIRON, V39, P1087, DOI 10.1016/j.buildenv.2003.11.007; Simpson JR, 2011, ENVIRON POLLUT, V159, P2088, DOI 10.1016/j.envpol.2011.02.034; Soares AL, 2011, URBAN FOR URBAN GREE, V10, P69, DOI 10.1016/j.ufug.2010.12.001; Stern H, 2000, AUST METEOROL MAG, V49, P87; Stoffberg GH, 2010, URBAN FOR URBAN GREE, V9, P9, DOI 10.1016/j.ufug.2009.09.004; Stoffberg GH, 2009, SOUTH FORESTS, V71, P273, DOI 10.2989/SF.2009.71.4.4.1031; Stoffberg G. H., 2008, Urban Forestry & Urban Greening, V7, P259, DOI 10.1016/j.ufug.2008.05.002; Sudha P, 2000, LANDSCAPE URBAN PLAN, V47, P47, DOI 10.1016/S0169-2046(99)00067-5; SUN WQ, 1991, LANDSCAPE URBAN PLAN, V20, P277, DOI 10.1016/0169-2046(91)90001-3; Sundar I., 2005, ECOLOGY ENV CONSERVA, V11, P173; Swyngedouw E, 2003, ANTIPODE, V35, P898, DOI 10.1111/j.1467-8330.2003.00364.x; Swyngedouw E, 2010, URBAN LAND PERSPECT, P185, DOI 10.1007/978-90-481-3106-8_11; Taha H, 1997, ENERG BUILDINGS, V25, P169, DOI 10.1016/S0378-7788(96)01006-7; Tallis M, 2011, LANDSCAPE URBAN PLAN, V103, P129, DOI 10.1016/j.landurbplan.2011.07.003; Thaiutsa Bunvong, 2008, Urban Forestry & Urban Greening, V7, P219, DOI 10.1016/j.ufug.2008.03.002; Tiwary A, 2009, ENVIRON POLLUT, V157, P2645, DOI 10.1016/j.envpol.2009.05.005; Todorova A, 2004, LANDSCAPE URBAN PLAN, V69, P403, DOI 10.1016/j.landurbplan.2003.11.001; Tratalos J, 2007, LANDSCAPE URBAN PLAN, V83, P308, DOI 10.1016/j.landurbplan.2007.05.003; Tsiros IX, 2010, RENEW ENERG, V35, P1866, DOI 10.1016/j.renene.2009.12.021; Tyrvainen L, 1997, LANDSCAPE URBAN PLAN, V37, P211, DOI 10.1016/S0169-2046(97)80005-9; Tyrvainen L, 1998, LANDSCAPE URBAN PLAN, V43, P105, DOI 10.1016/S0169-2046(98)00103-0; Tyrvainen L., 2005, URBAN FORESTS TREES, P81, DOI DOI 10.1007/3-540-27684-X; TZILKOWSKI WM, 1986, URBAN ECOL, V9, P387, DOI 10.1016/0304-4009(86)90011-2; United Nations, 2010, WORLD URB PROSP; Vesely ET, 2007, ECOL ECON, V63, P605, DOI 10.1016/j.ecolecon.2006.12.019; Wallace KJ, 2007, BIOL CONSERV, V139, P235, DOI 10.1016/j.biocon.2007.07.015; Walton Jeffrey T., 2008, Arboriculture & Urban Forestry, V34, P334; Watson Gary, 2002, Journal of Arboriculture, V28, P11; WELCH JM, 1994, LANDSCAPE URBAN PLAN, V29, P131, DOI 10.1016/0169-2046(94)90023-X; Yang J, 2005, URBAN FORESTRY URBAN, V3, P65, DOI 10.1016/j.ufug.2004.09.001; Young RF, 2010, URBAN FOR URBAN GREE, V9, P313, DOI 10.1016/j.ufug.2010.06.007; ZHANG K, 2006, CHIN J APPL ECOL, V17, P1918; Zhang W, 2007, ECOL ECON, V64, P253, DOI 10.1016/j.ecolecon.2007.02.024; [赵煜 ZHAO Yu], 2009, [生态学报, Acta Ecologica Sinica], V29, P6723; Zipperer WC, 1997, URBAN ECOSYST, V1, P229, DOI DOI 10.1023/A:1018587830636	176	98	104	45	378	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1618-8667			URBAN FOR URBAN GREE	Urban For. Urban Green.		2012	11	4					351	363		10.1016/j.ufug.2012.06.006		13	Plant Sciences; Environmental Studies; Forestry; Urban Studies	Plant Sciences; Environmental Sciences & Ecology; Forestry; Urban Studies	062LY	WOS:000312922500001		
J	Mealing, NM; Banks, E; Jorm, LR; Steel, DG; Clements, MS; Rogers, KD				Mealing, Nicole M.; Banks, Emily; Jorm, Louisa R.; Steel, David G.; Clements, Mark S.; Rogers, Kris D.			Investigation of relative risk estimates from studies of the same population with contrasting response rates and designs	BMC MEDICAL RESEARCH METHODOLOGY			English	Article							SURVEY NONRESPONSE; PSYCHOLOGICAL DISTRESS; COHORT PROFILE; FOLLOW-UP; BIAS; HEALTH; SCORES	Background: There is little empirical evidence regarding the generalisability of relative risk estimates from studies which have relatively low response rates or are of limited representativeness. The aim of this study was to investigate variation in exposure-outcome relationships in studies of the same population with different response rates and designs by comparing estimates from the 45 and Up Study, a population-based cohort study (self-administered postal questionnaire, response rate 18%), and the New South Wales Population Health Survey (PHS) (computer-assisted telephone interview, response rate similar to 60%). Methods: Logistic regression analysis of questionnaire data from 45 and Up Study participants (n = 101,812) and 2006/2007 PHS participants (n = 14,796) was used to calculate prevalence estimates and odds ratios (ORs) for comparable variables, adjusting for age, sex and remoteness. ORs were compared using Wald tests modelling each study separately, with and without sampling weights. Results: Prevalence of some outcomes (smoking, private health insurance, diabetes, hypertension, asthma) varied between the two studies. For highly comparable questionnaire items, exposure-outcome relationship patterns were almost identical between the studies and ORs for eight of the ten relationships examined did not differ significantly. For questionnaire items that were only moderately comparable, the nature of the observed relationships did not differ materially between the two studies, although many ORs differed significantly. Conclusions: These findings show that for a broad range of risk factors, two studies of the same population with varying response rate, sampling frame and mode of questionnaire administration yielded consistent estimates of exposure-outcome relationships. However, ORs varied between the studies where they did not use identical questionnaire items.	[Mealing, Nicole M.; Banks, Emily; Jorm, Louisa R.; Rogers, Kris D.] Sax Inst, Broadway, NSW 2007, Australia; [Mealing, Nicole M.; Jorm, Louisa R.; Clements, Mark S.] Univ Western Sydney, Sch Med, Penrith, NSW 1797, Australia; [Banks, Emily] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; [Steel, David G.] Univ Wollongong, Ctr Stat & Survey Methodol, N Wollongong, NSW 2522, Australia	Mealing, NM (reprint author), Sax Inst, POB 123, Broadway, NSW 2007, Australia.	Nicole.Mealing@saxinstitute.org.au		Steel, David/0000-0002-3137-9952	National Health and Medical Research Council [402810]	The authors are grateful to Ms Margo Barr and Mrs Sandra Carlson for their expert assistance and advice on the NSW Population Health Survey and use of the NSW Population Health Survey data. We thank the men and women participating in the 45 and Up Study, and the NSW Department of Health for permitting use of the 2006 and 2007 NSW Population Health Survey Datasets. The 45 and Up Study is run by The Sax Institute in collaboration with the Cancer Council of New South Wales; the New South Wales Division of the National Heart Foundation of Australia; the New South Wales Department of Health; beyondblue: the national depression initiative and the New South Wales Department of Ageing, Disability and Home Care. This work was also supported by the National Health and Medical Research Council [402810]. NM was employed by the NSW Department of Health on the NSW Biostatistical Officer Training Program at the time this work was conducted.	Andrews G, 2001, AUST NZ J PUBL HEAL, V25, P494, DOI 10.1111/j.1467-842X.2001.tb00310.x; AUSTIN MA, 1981, AM J EPIDEMIOL, V114, P137; Australian Institute of Health and Welfare, 2004, RUR REG REM HLTH GUI; Banks E, 2008, INT J EPIDEMIOL, V37, P941, DOI 10.1093/ije/dym184; Barr M, 2008, NSW POPULATION HLTH; Brehm John, 1993, PHANTOM RESPONDENT O; Breslow NE, 1987, IARC SCI PUBL, V82, P1; Burkell J, 2003, LIBR INFORM SCI RES, V25, P239, DOI 10.1016/S0740-8188(03)00029-X; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; CRIQUI MH, 1979, AM J EPIDEMIOL, V109, P394; Centre for Epidemiology and Research, 2008, 2007 REP AD HLTH NEW; Centre for Epidemiology and Research, 2007, 2006 REP AD HLTH NEW; Day N, 1999, BRIT J CANCER, V80, P95; *DEP HLTH AG CAR G, 2001, MEAS REM ACC REM IND; Doll R, 2004, BRIT MED J, V328, P1519, DOI 10.1136/bmj.38142.554479.AE; Eastwood BJ, 1996, INT J EPIDEMIOL, V25, P763, DOI 10.1093/ije/25.4.763; Goodman R, 2007, SOC PSYCH PSYCH EPID, V42, P322, DOI 10.1007/s00127-007-0169-0; GREENLAND S, 1977, AM J EPIDEMIOL, V106, P184; HEILBRUN LK, 1991, INT J EPIDEMIOL, V20, P328, DOI 10.1093/ije/20.2.328; KALTON G, 1982, J ROY STAT SOC A STA, V145, P42, DOI 10.2307/2981421; Kessler RC, 2002, PSYCHOL MED, V32, P959, DOI 10.1017/S0033291702006074; Lee C, 2005, INT J EPIDEMIOL, V34, P987, DOI 10.1093/ije/dyi098; Martikainen P, 2007, SCAND J PUBLIC HEALT, V35, P212, DOI 10.1080/14034940600996563; MELTON LJ, 1993, J CLIN EPIDEMIOL, V46, P341, DOI 10.1016/0895-4356(93)90148-T; Miettinen OS, 1985, THEORETICAL EPIDEMIO; Nohr EA, 2006, EPIDEMIOLOGY, V17, P413, DOI 10.1097/01.ede.0000220549.14177.60; Perkins JJ, 1998, J CLIN EPIDEMIOL, V51, P969, DOI 10.1016/S0895-4356(98)00088-2; Picavet HSJ, 1996, J EPIDEMIOL COMMUN H, V50, P86, DOI 10.1136/jech.50.1.86; Ponsonby AL, 1996, AUST NZ J PUBL HEAL, V20, P54, DOI 10.1111/j.1467-842X.1996.tb01336.x; Population Health Division, HLTH PEOPL NEW S WAL; RAO JNK, 2003, ANAL SURVEY DATA, P92; *SAS I INC, SAS VERS 9NC; SCOTT AJ, 1986, J ROY STAT SOC B MET, V48, P170; SIEMIATYCKI J, 1984, AM J EPIDEMIOL, V120, P291; Van Goor H, 1999, QUAL QUANT, V33, P411; Van Loon AJM, 2003, ANN EPIDEMIOL, V13, P105, DOI 10.1016/S1047-2797(02)00257-0; Watts G, 2007, BRIT MED J, V334, P659, DOI 10.1136/bmj.39167.407616.DB; *WHO IASO IOTE, 2000, AS PAC PERSP RED OB	38	98	98	0	5	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2288			BMC MED RES METHODOL	BMC Med. Res. Methodol.	APR 1	2010	10								26	10.1186/1471-2288-10-26		12	Health Care Sciences & Services	Health Care Sciences & Services	603IV	WOS:000278203100001	20356408	
J	Horak, F; Zieglmayer, P; Zieglmayer, R; Lemell, P; Devillier, P; Montagut, A; Melac, M; Galvain, S; Jean-Alphonse, S; Van Overtvelt, L; Moingeon, P; Le Gall, M				Horak, Friedrich; Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick; Devillier, Philippe; Montagut, Armelle; Melac, Michel; Galvain, Sylvie; Jean-Alphonse, Stephanie; Van Overtvelt, Laurence; Moingeon, Philippe; Le Gall, Martine			Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Grass pollen; tablets; sublingual immunotherapy; allergen challenge chamber; Vienna Challenge Chamber	GRASS-POLLEN; RHINITIS; EXPOSURE; EFFICACY; PLACEBO; SYMPTOMS; RHINOCONJUNCTIVITIS; SAFETY; FLOW	Background: The efficacy and safety of a 5-grass-pollen sublingual immunotherapy (SLIT) tablet (Stallergenes SA, Antony, France) have been evaluated in clinical studies during the pollen season. The allergen challenge chamber (ACC) has been developed as a pharmacodynamic assessment tool to control the environmental allergens and to avoid all problems associated with unpredictable pollen seasons. Objective: We sought to evaluate the onset of action and efficacy of 300-IR (index of reactivity) SLIT tablets by using an ACC. Methods: Patients with grass pollen-induced rhinoconjunctivitis were randomized into the active or placebo groups. A standardized allergen challenge with grass pollen and symptom evaluation every 15 minutes was performed at baseline, 1 week, and 1, 2, and 4 months of treatment. The primary end point was the average rhinoconjunctivitis total symptom score (ARTSS). Allergen-specific basophil activation, T-cell proliferation, and plasmatic IgE and IgG responses were assessed before and after treatment. Results: In the intention-to-treat population (n = 89) a significant treatment effect was achieved after the first month (P = .0042) and second month (P = .0203) and was maintained through to the fourth month (P = .0007). In the active group the ARTSS (means +/- SDs) decreased at each challenge: week 1, 7.40 +/- 2.682; month 1, 5.89 +/- 2.431; month 2, 5.09 +/- 2.088; and month 4, 4.85 +/- 1.999. An improvement (vs placebo) of 29.3% for the mean ARTSS ( median, 33.3%) was observed at end point. Furthermore, the induction of grass pollen allergen specific IgGs was associated with clinical response. The most frequent adverse reactions were local: oral pruritus, ear pruritus, and throat irritation. Conclusions: In this ACC study the 300-IR 5-grass-pollen SLIT tablets had a significant effect on rhinoconjunctivitis symptoms (vs placebo) from the first month of treatment onward. (J Allergy Clin Immunol 2009;124:471-7.)	[Horak, Friedrich] Med Univ Vienna, ENT Dept, Vienna, Austria; [Zieglmayer, Petra; Zieglmayer, Rene; Lemell, Patrick] Allergy Ctr Vienna W, Dept Vienna Challenge Chamber, Vienna, Austria; [Devillier, Philippe] Univ Versailles St Quentin, Foch Hosp, UPRES EA 220, Suresnes, France; [Montagut, Armelle] Delta Consultants, Meylan, France; [Melac, Michel; Galvain, Sylvie; Jean-Alphonse, Stephanie; Van Overtvelt, Laurence; Moingeon, Philippe; Le Gall, Martine] Stallergenes SA, Antony, France	Horak, F (reprint author), AKH, Univ Klin, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.	friedrich.horak@vienna.at			GlaxoSmithKline; Oxagen; Allergy Therapeutics; Altana-Nycomed; Boehringer-Ingelheim; Schering-Plough; Pierre Fabre; Servier; Novartis	F. Horak has received honoraria for lectures from Allergy Therapeutics, UCB, Schering-Plough, and Stallergenes and has received research support from GlaxoSmithKline, Oxagen, and Allergy Therapeutics. P. Devillier has received consulting fees from Stallergenes and has received research grants from Altana-Nycomed, Boehringer-Ingelheim, Schering-Plough, Pierre Fabre, Servier, and Novartis. The rest of the authors have declared that they have no conflict of interest.	ALVAREZCUESTA E, 2006, ALLERGY S82, V61, pS1; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Day J. H., 2006, Clinical and Experimental Allergy Reviews, V6, P31, DOI 10.1111/j.1365-2222.2005.00099.x; Didier A, 2009, ALLERGY, V64, P166, DOI 10.1111/j.1398-9995.2008.01767.x; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74; DOYLE WJ, 1995, ANN ALLERG ASTHMA IM, V74, P171; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; European Medicines Agency. Committee for Medicinal Products for Human Use, GUID CLIN DEV PROD S; Gomes DD, 2008, RHINOLOGY, V46, P276; Horak F, 1998, J INVEST ALLERG CLIN, V8, P165; Horak F, 2003, ALLERGY, V58, P481, DOI 10.1034/j.1398-9995.2003.00148.x; Horak F, 2009, CLIN EXP ALLERGY, V39, P394, DOI 10.1111/j.1365-2222.2008.03153.x; HORAK F, 1987, WIEN KLIN WOCHENSCHR, V99, P509; Jaeger S., 2008, Clinical and Experimental Allergy Reviews, V8, P2, DOI 10.1111/j.1472-9733.2008.00125.x; Krug N, 2003, CLIN EXP ALLERGY, V33, P1667, DOI 10.1111/j.1365-2222.2003.01810.x; Nathan Robert A, 2005, J Allergy Clin Immunol, V115, pS442, DOI 10.1016/j.jaci.2004.12.015; Stuebner P, 2006, ANN ALLERG ASTHMA IM, V96, P37; Wahn U, 2009, J ALLERGY CLIN IMMUN, V123, P160, DOI 10.1016/j.jaci.2008.10.009; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Zieglmayer P, 2008, CURR MED RES OPIN, V24, P1833, DOI 10.1185/03007990802155792	21	98	99	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2009	124	3					471	U126		10.1016/j.jaci.2009.06.006		8	Allergy; Immunology	Allergy; Immunology	552TG	WOS:000274315900011	19647862	
J	Kim, JL; Elfman, L; Mi, Y; Wieslander, G; Smedje, G; Norback, D				Kim, J. L.; Elfman, L.; Mi, Y.; Wieslander, G.; Smedje, G.; Norback, D.			Indoor molds, bacteria, microbial volatile organic compounds and plasticizers in schools - associations with asthma and respiratory symptoms in pupils	INDOOR AIR			English	Article						asthma; microbial volatile organic compounds (MVOCs); plasticizer; pupil; respiratory symptoms; school	BUILDING-DAMPNESS; AIR-QUALITY; YOUNG-CHILDREN; RISK-FACTORS; EXPOSURE; ENVIRONMENT; SCHOOLCHILDREN; HEALTH; FORMALDEHYDE; METABOLITES	We investigated asthma and atopy in relation to microbial and plasticizer exposure. Pupils in eight primary schools in Uppsala (Sweden) answered a questionnaire, 1014 (68%) participated. Totally, 7.7% reported doctor-diagnosed asthma, 5.9% current asthma, and 12.2% allergy to pollen/pets. Wheeze was reported by 7.8%, 4.5% reported daytime breathlessness, and 2.0% nocturnal breathlessness. Measurements were performed in 23 classrooms (May-June), 74% had < 1000 ppm CO2 indoors. None had visible mold growth or dampness. Mean total microbial volatile organic compound (MVOC) concentration was 423 ng/m(3) indoors and 123 ng/m(3) outdoors. Indoor concentration of TMPD-MIB (2,2,4-trimethyl-1,3-pentanediol monoisobutyrate, Texanol) and TMPD-DIB (2,2,4-trimethyl-1,3-pentanediol diisobutyrate, TXIB), two common plasticizers, were 0.89 and 1.64 mu g/m(3), respectively. MVOC and plasticizer concentration were correlated (r = 0.5; P < 0.01). Mold concentration was 360 cfu/m(3) indoors and 980 cfu/m(3) outdoors. At higher indoor concentrations of total MVOC, nocturnal breathlessness (P < 0.01) and doctor-diagnosed asthma (P < 0.05) were more common. Moreover, there were positive associations between nocturnal breathlessness and 3-methylfuran (P < 0.01), 3-methyl-1-butanol (P < 0.05), dimethyldisulfide (P < 0.01), 2-heptanone (P < 0.01), 1-octen-3-ol (P < 0.05), 3-octanone (P < 0.05), TMPD-MIB (P < 0.05), and TMPD-DIB (P < 0.01). TMPD-DIB was positively associated with wheeze (P < 0.05), daytime breathlessness (P < 0.05), doctor-diagnosed asthma (P < 0.05), and current asthma (P < 0.05). In conclusion, exposure to MVOC and plasticizers at school may be a risk factor for asthmatic symptoms in children.	Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; Univ Hosp, Uppsala, Sweden	Kim, JL (reprint author), Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden.	jeong-lim.kim@medsci.uu.se		Norback, Dan/0000-0002-5174-6668			ANDERSSON K, 1981, SCAND J WORK ENV HEA, V7, P282; Anundi H, 1992, P 41 NORD M WORK ENV, P227; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Braun-Fahrlander Charlotte, 2003, Curr Opin Allergy Clin Immunol, V3, P325, DOI 10.1097/00130832-200310000-00001; Cain WS, 2005, INDOOR AIR, V15, P445, DOI 10.1111/j.1600-0668.2005.00390.x; Claeson AS, 2002, J ENVIRON MONITOR, V4, P667, DOI 10.1039/b202571j; Daisey JM, 2003, INDOOR AIR, V13, P53, DOI 10.1034/j.1600-0668.2003.00153.x; DOUWES J, 2004, J ALLERGY CLIN IMMUN, V115, P1325; Dsikowitzky L, 2004, CHEMOSPHERE, V57, P1289, DOI 10.1016/j.chemosphere.2004.08.053; Elke K, 1999, J ENVIRON MONITOR, V1, P445, DOI 10.1039/a903034d; Fischer G, 2003, ARCH MICROBIOL, V179, P75, DOI 10.1007/s00203-002-0495-2; Forsberg B, 1997, INT J EPIDEMIOL, V26, P610, DOI 10.1093/ije/26.3.610; Fox A, 2003, J ENVIRON MONITOR, V5, P246, DOI 10.1039/b212341j; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Kamijima M, 2002, J OCCUP HEALTH, V44, P186, DOI 10.1539/joh.44.186; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Korpi A, 1999, ARCH ENVIRON HEALTH, V54, P347; KOSTIAINEN R, 1995, ATMOS ENVIRON, V29, P693, DOI 10.1016/1352-2310(94)00309-9; Lee SC, 2000, CHEMOSPHERE, V41, P109, DOI 10.1016/S0045-6535(99)00396-3; Martinez FD, 1999, LANCET S2, V354, pSII12; Meklin T, 2005, INDOOR AIR, V15, P40, DOI 10.1111/j.1600-0668.2005.00357.x; Meyer HW, 2004, INDOOR AIR, V14, P65, DOI 10.1046/j.1600-0668.2003.00213.x; Mommers M, 2005, INT J HYG ENVIR HEAL, V208, P373, DOI 10.1016/j.ijheh.2005.04.007; MORGAN WJ, 1992, PEDIATR CLIN N AM, V39, P1185; Muniz G. C. B., 1993, U FEDERAL PERNAMBUCO, V1, P1; Nalli S, 2006, ENVIRON POLLUT, V140, P181, DOI 10.1016/j.envpol.2005.06.018; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; Norback D, 1999, INT J TUBERC LUNG D, V3, P368; Norback D, 2000, INT J TUBERC LUNG D, V4, P1016; NORBACK D, 2002, IND AIR 02 P 9 INT C, V3, P410; NORBACK D, 1993, VOLATILE ORGANIC COM, P377; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; PALMGREN U, 1986, J APPL BACTERIOL, V61, P401, DOI 10.1111/j.1365-2672.1986.tb04303.x; Pasanen AL, 1998, ENVIRON INT, V24, P703, DOI 10.1016/S0160-4120(98)00065-8; Plaschke PP, 2000, AM J RESP CRIT CARE, V162, P920; Putus T, 2004, ARCH ENVIRON HEALTH, V59, P194, DOI 10.3200/AEOH.59.4.194-201; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Ronmark E, 1998, RESP MED, V92, P316, DOI 10.1016/S0954-6111(98)90115-9; Schleibinger H, 2005, INDOOR AIR, V15, P98, DOI 10.1111/j.1600-0668.2005.00349.x; Sennhauser Felix H, 2005, Paediatr Respir Rev, V6, P2, DOI 10.1016/j.prrv.2004.11.001; Shea KM, 2003, PEDIATRICS, V111, P1467, DOI 10.1542/peds.111.6.1467; Simoni M, 2005, OCCUP ENVIRON MED, V62, P616, DOI 10.1136/oem.2004.018291; SKOV P, 1990, SCAND J WORK ENV HEA, V16, P363; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Smedje G, 2001, INT J TUBERC LUNG D, V5, P1059; SMEDJE G, 1996, INDOOR AIR 96, V1, P611; Sparks LE, 1999, INDOOR AIR, V9, P18, DOI 10.1111/j.1600-0668.1999.t01-3-00004.x; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Taskinen T, 1997, ACTA PAEDIATR, V86, P1181, DOI 10.1111/j.1651-2227.1997.tb14841.x; Tortolero SR, 2002, J SCHOOL HEALTH, V72, P33; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Walinder R, 2005, ENVIRON HEALTH PERSP, V113, P1775, DOI 10.1289/ehp.8193; Walinder R, 1998, INT J TUBERC LUNG D, V2, P1037; Wessen B, 1996, ANALYST, V121, P1203, DOI 10.1039/an9962101203; Wieslander G, 1999, INT ARCH OCC ENV HEA, V72, P451, DOI 10.1007/s004200050398; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115	61	98	101	2	31	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0905-6947			INDOOR AIR	Indoor Air	APR	2007	17	2					153	163		10.1111/j.1600-0668.2006.00466.x		11	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	149OG	WOS:000245155700008	17391238	
J	Wichmann, HE				Wichmann, H.-E.			Diesel exhaust particles	INHALATION TOXICOLOGY			English	Article; Proceedings Paper	10th International Inhalation Symposium	MAY 31-JUN 03, 2006	Hannover, GERMANY	German Soc Toxicol, Fraunhofer Inst Toxicol & Expt Med, Natl Hlth & Environm Effects Res Lab, US EPA			LUNG-CANCER; AIR-POLLUTION; EXPOSURE	Diesel motor emission is a complex mixture of hundreds of constituents in either gas or particle form. Diesel particulate matter (DPM) is composed of a center core of elemental carbon and adsorbed organic compounds including PAHs and nitro-PAHs, and small amounts of sulfate, nitrate, metals, and other trace elements. DPM consists of fine particles including a high number of ultrafine particles. These particles are highly respirable and have a large surface area where organics can adsorb easily. Exposure to DPM can cause acute irritation and neurophysiological, respiratory, and asthma-like symptoms and can exacerbate allergenic responses to known allergens. Consistently, lung cancer risk is elevated among workers in occupations where diesel engines have been used. However, quantification of the cancer risk with respect to DPM concentrations is not possible. Furthermore, ambient fine and ultrafine particles, of which DPM is an important component, contribute to cardiopulmonary morbidity and mortality and lung cancer. In conclusion, diesel exhaust poses a cancer risk greater than that of any other air pollutant, as well as causing other short- and long-term health problems. One effective way to effectively reduce emission of DPM is the use of particle traps.	GSF, Inst Epidemiol, D-85764 Neuherberg, Germany	Wichmann, HE (reprint author), GSF, Inst Epidemiol, Ingolstaedter Landstr 1, D-85764 Neuherberg, Germany.	wichmann@gsf.de					*AM LUNG ASS, 2003, CLOS DIES DIV PROT P; Bhatia R, 1998, EPIDEMIOLOGY, V9, P84, DOI 10.1097/00001648-199801000-00017; Bruske-Hohlfeld I, 1999, AM J IND MED, V36, P405, DOI 10.1002/(SICI)1097-0274(199910)36:4<405::AID-AJIM1>3.0.CO;2-W; Cohen AJ, 2000, ENVIRON HEALTH PERSP, V108, P743, DOI 10.2307/3454411; Garshick E, 2004, ENVIRON HEALTH PERSP, V112, P1539; HEI, 1999, DIES EM LUNG CANC EP; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Lipsett M, 1999, AM J PUBLIC HEALTH, V89, P1009, DOI 10.2105/AJPH.89.7.1009; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Wichmann H-E, 2004, UMWELTMED FORSCH PRA, V9, P85	11	98	105	0	19	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	0895-8378			INHAL TOXICOL	Inhal. Toxicol.		2007	19			1			241	244		10.1080/08958370701498075		4	Toxicology	Toxicology	210CM	WOS:000249434300031	17886072	
J	Flinterman, AE; Knulst, AC; Meijer, Y; Bruijnzeel-Koomen, CAFM; Pasmans, SGMA				Flinterman, AE; Knulst, AC; Meijer, Y; Bruijnzeel-Koomen, CAFM; Pasmans, SGMA			Acute allergic reactions in children with AEDS after prolonged cow's milk elimination diets	ALLERGY			English	Article						allergic reactions; atopic dermatitis; cow's milk; elimination; tolerance	ATOPIC-DERMATITIS; FOOD ALLERGY; DOUBLE-BLIND; ANAPHYLACTIC SHOCK; HYPERSENSITIVITY; CHALLENGES; IGE; DESENSITIZATION; INFANTS	Background: Food allergy is not always correctly diagnosed in children with atopic eczema dermatitis syndrome (AEDS) and treatment with an avoidance diet is not without danger. Methods: After admission to our clinic, 11 children with a prolonged cow's milk (CM) elimination diet because of AEDS and sensitization underwent double-blind placebo-controlled food challenge (DBPCFC). Retrospectively, the exposure to CM, sensitization and reactions to accidental ingestion were carefully documented. The DBPCFC was used to evaluate the childrens' current status. Results: Before the elimination period (median 2.3 years; started before the admission) all 11 children with AEDS were sensitized and had ingested CM (four bottle-fed; seven breast-fed without CM diet of the mother) without the development of acute reactions. The diagnosis of CM allergy was not confirmed by DBPCFC previously. After elimination the AEDS had not improved, but nevertheless the diet was continued. During the elimination period, eight of 11 children developed severe acute allergic reactions to CM after accidental ingestion. In evaluation, in our clinic all 11 children experienced acute allergic reactions to CM during DBPCFC. Conclusion: There is a considerable chance of developing acute allergic reactions to CM after elimination in children with AEDS without previous problems after CM intake.	Univ Med Ctr Utrecht, Dept Dermatol Allergol, NL-3508 GA Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Pediat, NL-3508 GA Utrecht, Netherlands	Pasmans, SGMA (reprint author), Univ Med Ctr Utrecht, Dept Dermatol Allergol, G-02-124,POB 85500, NL-3508 GA Utrecht, Netherlands.						Bahna SL, 2002, ANN ALLERG ASTHMA IM, V89, P56; Barbi E, 2004, ALLERGY, V59, P668, DOI 10.1111/j.1398-9995.2004.00398.x; Bauer A, 1999, ALLERGY, V54, P894, DOI 10.1034/j.1398-9995.1999.00228.x; Bindslev-Jensen C, 2004, ALLERGY, V59, P690, DOI 10.1111/j.1398-9995.2004.00466.x; BJORKSTEN B, 1983, ALLERGY, V38, P119, DOI 10.1111/j.1398-9995.1983.tb01595.x; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Christie L, 2002, J AM DIET ASSOC, V102, P1648, DOI 10.1016/S0002-8223(02)90351-2; DAVID TJ, 1984, ARCH DIS CHILD, V59, P983; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; HANIFIN JM, 1984, J ALLERGY CLIN IMMUN, V73, P211, DOI 10.1016/S0091-6749(84)80008-1; Heine RG, 2002, CURR OPIN ALLERGY CL, V2, P217, DOI 10.1097/00130832-200206000-00011; Jarvinen KM, 2001, CLIN EXP ALLERGY, V31, P978, DOI 10.1046/j.1365-2222.2001.01151.x; LARRAMENDI CH, 1992, ALLERGY, V47, P490, DOI 10.1111/j.1398-9995.1992.tb00670.x; LIFSCHITZ CH, 1988, J PEDIATR GASTR NUTR, V7, P141, DOI 10.1097/00005176-198801000-00026; MARTIN EM, 1988, ALLERG IMMUNOL PARIS, V20, P55; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; MORISSET M, 2004, 9 INT S IMM CHEM CLI; Novembre E, 2001, ALLERGY, V56, P105, DOI 10.1034/j.1398-9995.2001.00931.x; Osterballe M, 2003, J ALLERGY CLIN IMMUN, V112, P196, DOI 10.1067/mai.2003.1603; Patriarca G, 2003, ALIMENT PHARM THERAP, V17, P459, DOI 10.1046/j.0269-2813.2003.01468.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Rolinck-Werninghaus C, 2005, ALLERGY, V60, P1320, DOI 10.1111/j.1398-9995.2005.00882.x; Sampson HA, 2003, CLIN DERMATOL, V21, P183, DOI 10.1016/S0738-081X(02)00363-2; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Schade R P, 2002, Ned Tijdschr Geneeskd, V146, P1739; Seidenari S, 2003, ALLERGY, V58, P495, DOI 10.1034/j.1398-9995.2003.00153.x; Sicherer SH, 2002, CURR OPIN ALLERGY CL, V2, P207, DOI 10.1097/00130832-200206000-00009; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941	29	98	101	1	2	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	MAR	2006	61	3					370	374		10.1111/j.1398-9995.2006.01018.x		5	Allergy; Immunology	Allergy; Immunology	005VX	WOS:000234853900016	16436148	
J	Clark, S; Long, AA; Gaeta, TJ; Camargo, CA				Clark, S; Long, AA; Gaeta, TJ; Camargo, CA			Multicenter study of emergency department visits for insect sting allergies	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						insect sting allergy; emergency department; epinephrine; referral to allergist	UNITED-STATES; ANAPHYLAXIS; EPIDEMIOLOGY; HYPERSENSITIVITY; HYMENOPTERA; MANAGEMENT; SENSITIVITY; POPULATION; SEVERITY; DISEASE	Background: An earlier study of food-related anaphylaxis in the emergency department (ED) suggested low concordance with national guidelines for anaphylaxis management. Objective: To extend these findings, we performed a chart review study to describe current ED management of insect sting allergy. Methods: The Multicenter Airway Research Collaboration performed a chart review study in 15 North American EDs. Investigators reviewed 617 charts of patients with insect sting allergy. Patients were identified by using International Classification of Diseases, 9th Revision, codes 989.5 (toxic effect of venom), 995.0 (other anaphylactic shock), and 995.3 (allergy, unspecified). Results: The cohort was 42% female and 61% white, with a mean age of 36 +/- 19 years. In this cohort, 58% had local reactions, 11% had mild systemic reactions, and 31% had anaphylactic reactions, as defined by multisystem organ involvement or hypotension. Among patients with systemic reactions (mild or anaphylaxis), most (75%) were stung within 6 hours of ED arrival. While in the ED, 69% of systemic reaction patients received antihistamines, 50% systemic corticosteroids, and 12% epinephrine. Almost all systemic reaction patients (95%) were discharged to home. At ED discharge, 27% (95% CI, 22% to 33%) of systemic reaction patients received a prescription for self-injectable epinephrine. Only 20% (95% CI, 15% to 26%) had documentation of referral to an allergist. Conclusions: Although guidelines suggest specific approaches for the emergency management of insect sting allergy, concordance with these guidelines appears low in patients with a severe insect sting reaction.	Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Rheumatol Allergy & Immunol, Boston, MA 02114 USA; New York Methodist Hosp, Dept Emergency Med, Brooklyn, NY USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02138 USA	Clark, S (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.	sclark3@partners.org			NIAID NIH HHS [AI52338]; NIEHS NIH HHS [T32 ES07069]		Bohlke K, 2004, J ALLERGY CLIN IMMUN, V113, P536, DOI 10.1016/j.jaci.2003.11.033; Brown AFT, 2001, J ALLERGY CLIN IMMUN, V108, P861, DOI 10.1067/mai.2001.119028; BROWN H, 1970, ARCH INTERN MED, V125, P665, DOI 10.1001/archinte.125.4.665; Brown SGA, 2004, J ALLERGY CLIN IMMUN, V114, P371, DOI 10.1016/j.jaci.2004.04.029; *CACI, 2000, SOURC ZIP COD DEM; Clark S, 2004, J ALLERGY CLIN IMMUN, V113, P347, DOI 10.1016/j.jaci.2003.10.053; GAETA TJ, 2001, ACAD EMERG MED, V8, P449; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI 10.1067/mai.2003.1606; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; HERBERT FA, 1982, ANN ALLERGY, V48, P12; *HLTH CAN, 1996, FED CAUS DAT STAT CA; Hosmer DW, 1989, APPL LOGISTIC REGRES; Jerrard DA, 1996, AM J EMERG MED, V14, P429, DOI 10.1016/S0735-6757(96)90067-4; KLEIN JS, 1995, J ALLERGY CLIN IMMUN, V95, P637, DOI 10.1016/S0091-6749(95)70329-2; Lieberman P, 2005, J ALLERGY CLIN IMMUN, V115, pS483, DOI 10.1016/j.jaci.2005.01.010; Matasar MJ, 2003, CURR ALLERGY ASTHM R, V3, P30, DOI 10.1007/s11882-003-0007-8; McDougle Leon, 1995, Journal of Emergency Medicine, V13, P9, DOI 10.1016/0736-4679(94)00105-7; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Neugut AI, 2001, ARCH INTERN MED, V161, P15, DOI 10.1001/archinte.161.1.15; O'Brien J, 2000, EMERG MED PRACT, V2, P1; Peng MM, 2004, ARCH INTERN MED, V164, P317, DOI 10.1001/archinte.164.3.317; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI [10.1016/j.jaci.2005.01.008, 10.1016/j.jaci.2005.01.009]; SCHWARTZ HJ, 1995, ALLERGY PROC, V16, P247, DOI 10.2500/108854195778702639; SETTIPANE GA, 1970, ACTA ALLERGOL, V25, P286, DOI 10.1111/j.1398-9995.1970.tb01264.x; SETTIPANE GA, 1972, J ALLERGY CLIN IMMUN, V50, P146, DOI 10.1016/0091-6749(72)90045-0; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; *STATA, 1985, STATA REF MAN; Stewart AG, 1996, QJM-MON J ASSOC PHYS, V89, P859; Valentine M D, 1992, JAMA, V268, P2830; YOCUM MW, 1996, MED PRACTICING PHYS	30	98	100	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2005	116	3					643	649		10.1016/j.jaci.2005.06.026		7	Allergy; Immunology	Allergy; Immunology	017IE	WOS:000235686500027	16159637	
J	Gueders, MM; Balbin, M; Rocks, N; Foidart, JM; Gosset, P; Louis, R; Shapiro, S; Lopez-Otin, C; Noel, W; Cataldo, DD				Gueders, MM; Balbin, M; Rocks, N; Foidart, JM; Gosset, P; Louis, R; Shapiro, S; Lopez-Otin, C; Noel, W; Cataldo, DD			Matrix metalloproteinase-8 deficiency promotes granulocytic allergen-induced airway inflammation	JOURNAL OF IMMUNOLOGY			English	Article							HUMAN NEUTROPHIL COLLAGENASE; BRONCHOALVEOLAR LAVAGE FLUID; ASTHMATIC-PATIENTS; MMP-8 EXPRESSION; TISSUE INHIBITOR; EPITHELIAL-CELLS; MATRIX-METALLOPROTEINASE-9; DISEASE; CANCER; HYPERRESPONSIVENESS	Matrix metalloproteinases (MMPs) are involved in inflammatory reaction, including asthma-related airway inflammation. MMP-8, mainly produced by neutrophils, has recently been reported to be increased in the bronchoalveolar lavage fluid (BALF) from asthmatic patients. To evaluate the role of MMP-8 in asthma, we measured MMP-8 expression in lung tissue in an OVAsensitized mouse model of asthma and addressed the effect of MMP-8 deletion on allergen-induced bronchial inflammation. MMP-8 production was increased in lungs from C57BL/6 mice exposed to allergens. After allergen exposure, MMP-8-1-mice developed an airway inflammation characterized by an increased neutrophilic inflammation in BALF and an increased neutrophilic and eosinophilic infiltration in the airway walls. MMP-8 deficiency was associated with increased levels of IL-4 and antiOVA IgE and IgG1 in BALF and serum, respectively. Although allergen exposure induced an enhancement of LPS-induced CXC chemokine, KC, and MIP-2 levels in BALF and lung parenchyma, no difference was observed between the two genotypes. Inflammatory cell apoptosis was reduced in the lungs from MMP-8(-/-) mice. For the first time, our study evidences an important role of MMP-8 in the control of neutrophilic and eosinophilic infiltration during allergen-induced lung inflammation, and demonstrates that the anti-inflammatory effect of MMP-8 is partly due to a regulation of inflammatory cell apoptosis.	Univ Liege, Dept Pneumol, B-4000 Liege, Belgium; Univ Liege, Dept Biol Tumors & Dev, Ctr Biomed Integrat Genoprot, B-4000 Liege, Belgium; Univ Oviedo, Inst Univ Oncol, Dept Bioquim & Biol Mol, Oviedo, Spain; INSERM, Unite 416, Inst Pasteur, F-59045 Lille, France; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pulm Med, Boston, MA 02115 USA	Univ Liege, Dept Pneumol, Tower Pathol B23, B-4000 Liege, Belgium.	Didier.Cataldo@ulg.ac.be	Balbin, Milagros/I-4206-2015; Lopez-Otin, Carlos/C-6657-2013	Lopez-Otin, Carlos/0000-0001-6964-1904; Noel, Agnes/0000-0002-7670-6179; Cataldo, Didier/0000-0002-3079-7941			Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; Anticevich SZ, 1996, CLIN EXP ALLERGY, V26, P549, DOI 10.1046/j.1365-2222.1996.d01-341.x; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Betsuyaku T, 1999, AM J RESP CRIT CARE, V159, P1985; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Cataldo D, 2001, ALLERGY, V56, P145, DOI 10.1034/j.1398-9995.2001.056002145.x; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; Cataldo DD, 2004, LAB INVEST, V84, P418, DOI 10.1038/labinvest.3700063; Cataldo DD, 2002, AM J PATHOL, V161, P491, DOI 10.1016/S0002-9440(10)64205-8; Cataldo DD, 2002, CHEST, V122, P1553, DOI 10.1378/chest.122.5.1553; Corry DB, 2002, NAT IMMUNOL, V3, P347, DOI 10.1038/ni773; Ding Y, 1996, J DENT RES, V75, P1986; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fukuda T, 1996, AM J RESP CELL MOL, V14, P84; Girard D, 1997, BIOCHEM J, V325, P147; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; HASTY KA, 1987, J BIOL CHEM, V262, P10048; HASTY KA, 1986, J BIOL CHEM, V261, P5645; Henderson WR, 2002, AM J RESP CRIT CARE, V165, P108; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Johnson S, 1999, AM J PHYSIOL-LUNG C, V277, pL1109; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394; Mautino G, 1997, AM J RESP CELL MOL, V17, P583; McMillan SJ, 2004, J IMMUNOL, V172, P2586; Meyer-Hoffert U, 2003, INT ARCH ALLERGY IMM, V131, P264, DOI 10.1159/000072138; MICHAELIS J, 1990, BIOCHEM J, V270, P809; Montel V, 2004, CANCER RES, V64, P1687, DOI 10.1158/0008-5472.CAN-03-2047; MURPHY G, 1977, BIOCHEM J, V162, P195; [Anonymous], 2000, J CELL BIOL; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; Owen CA, 2004, J IMMUNOL, V172, P7791; PAGGIARO PL, 1993, J INVEST ALLERG CLIN, V3, P237; Prikk K, 2002, LAB INVEST, V82, P1535, DOI 10.1097/01.LAB.0000035023.53893.B6; Prikk K, 2001, J PATHOL, V194, P232, DOI 10.1002/path.849; ROCHE WR, 1989, LANCET, V1, P520; SEPPER R, 1995, CHEST, V107, P1641, DOI 10.1378/chest.107.6.1641; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; [Anonymous], 2004, MATRIX METALLOPROTEI; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2	41	98	99	0	2	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767	1550-6606		J IMMUNOL	J. Immunol.	AUG 15	2005	175	4					2589	2597				9	Immunology	Immunology	966HJ	WOS:000232010400070	16081833	
J	Currie, J; Neidell, M				Currie, J; Neidell, M			Air pollution and infant health: What can we learn from California's recent experience?	QUARTERLY JOURNAL OF ECONOMICS			English	Article							LOW-BIRTH-WEIGHT; UTAH VALLEY; SOUTHERN CALIFORNIA; CHILDHOOD ASTHMA; PM(10) POLLUTION; CHILDREN BORN; MORTALITY; AMBIENT; EXPOSURE; QUALITY	We examine the impact of air pollution on infant death in California over the 1990s. Our work offers several innovations: first, most previous studies examine populations subject to far greater levels of pollution. Second, many studies examine a single pollutant in isolation. We examine three "criteria" pollutants in a common framework. Third, we use rich individual-level data and pollution measured at the weekly level. Our most novel finding is a significant effect of CO on infant mortality: we find that reductions in carbon monoxide over the 1990s saved approximately 1000 infant lives in California.	Univ Calif Los Angeles, Los Angeles, CA 90024 USA; Natl Bur Econ Res, Cambridge, MA 02138 USA; Columbia Univ, New York, NY 10027 USA	Currie, J (reprint author), Univ Calif Los Angeles, Los Angeles, CA 90024 USA.						ALLISON PD, 1982, SOCIOL METHODOL, V12, P61; ALMOND D, 2002, COST LOW BIRTH WEIGH; Chay K., 2003, 10053 NBER; Chay KY, 2003, Q J ECON, V118, P1121, DOI 10.1162/00335530360698513; COFFEY B, 2003, REEXAMINATION AIR PO; Currie J, 1996, J POLIT ECON, V104, P1263, DOI 10.1086/262059; CURRIE J, 2004, 10251 NBER; *ENV DEF, 1993, 400F92005 EPA OFF MO; *ENV DEF, 2003, PRES CLEAR SKIES IN; *ENV DEF, 2003, 2 PROSP AN PLAN MAY; *ENV DEF, 2002, NAT AMB AIR QUAL STA; *ENV DEF, 2003, CRIT POLL; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Greenstone M, 2002, J POLIT ECON, V110, P1175, DOI 10.1086/342808; HUEL G, 1993, J EXPO ANAL ENV EPID, V3, P187; IMBENS G, 1992, ECONOMETRICA, V150, P1187; LOGAN W P D, 1953, Lancet, V1, P336; LUBIN J, 1984, BIOMETRICS, V90, P63; LUI SL, 2003, ENVIRON HEALTH PERSP, V111, P1773; Maisonet M, 2001, ENVIRON HEALTH PERSP, V109, P351, DOI 10.2307/3434782; MANSKI CF, 1977, ECONOMETRICA, V45, P1977, DOI 10.2307/1914121; MANTEL N, 1973, BIOMETRICS, V29, P479, DOI 10.2307/2529171; NEIDELL M, 2005, 25 CISES; NEIDELL M, 2005, 24 CICES; Neidell MJ, 2004, J HEALTH ECON, V23, P1209, DOI 10.1016/j.jhealeco.2004.05.002; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; PRENTICE RL, 1978, BIOMETRIKA, V65, P153, DOI 10.2307/2335290; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; SAMET J, 1997, ENV RES A, V127, P9; Schwartz J, 2000, AM J EPIDEMIOL, V151, P440; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SEIGER H, 2000, 7744 NBER; Spengler JD, 2000, INDOOR AIR QUALITY H; STAFFORD RT, 2001, UPHILL DRIVE; VISCUSI WK, 1993, J ECON LIT, V31, P1912; Wilson WE, 2000, J AIR WASTE MANAGE, V50, P1167	39	98	99	4	23	M I T PRESS	CAMBRIDGE	238 MAIN STREET, STE 500, CAMBRIDGE, MA 02142-1046 USA	0033-5533			Q J ECON	Q. J. Econ.	AUG	2005	120	3					1003	1030		10.1093/qje/120.3.1003		28	Economics	Business & Economics	969HF	WOS:000232224500006		
J	Rook, GAW; Adams, V; Hunt, J; Palmer, R; Martinelli, R; Brunet, LR				Rook, GAW; Adams, V; Hunt, J; Palmer, R; Martinelli, R; Brunet, LR			Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders	SPRINGER SEMINARS IN IMMUNOPATHOLOGY			English	Review						regulatory T cell; allergies; regulatory antigen-presenting cell; innate immunity; autoimmunity	REGULATORY T-CELLS; MONOCLONAL-ANTIBODY TREATMENT; INFLAMMATORY-BOWEL-DISEASE; TOLL-LIKE RECEPTORS; IN-VIVO; MULTIPLE-SCLEROSIS; INTERFERON-GAMMA; ALLERGIC-ASTHMA; DENDRITIC CELLS; AIRWAY HYPERREACTIVITY	In the rich, developed parts of the world there has been a steady and simultaneous increase in at least three groups of disease: (1) allergies, (2) inflammatory bowel diseases (IBD; e.g. Crohn's disease and ulcerative colitis) and (3) autoimmunity (e.g. type 1 diabetes and multiple sclerosis). Because the medical world is so compartmentalised it was some time before the connection between these increases was noticed and understood. There is now evidence that the simultaneous increase in these diseases of immunodysregulation is at least partly attributable to malfunction of regulatory T cells (Treg). This paper provides an overview of relevant work in each of these fields of medicine (though with emphasis on the allergic disorders), and concludes that the increasing failure of Treg is a consequence of diminished exposure to certain micro-organisms that are "old friends", because of their continuous presence throughout mammalian evolution. These organisms, which include saprophytic mycobacteria, helminths and lactobacilli, are recognised by the innate immune system as harmless, and as adjuvants for Treg induction. Polymorphisms of components of the innate immune system such as TLR2 and NOD2 appear to define subsets of the population that will develop immunoregulatory disorders when living in the modern environment. A further role of the "old friends" and of the Treg that they induce might be to maintain the levels of regulatory IL-10 secreting macrophages and antigen-presenting cells, which are depleted in asthma and Crohn's disease. These concepts are leading to novel therapies based on harmless organisms or their components. Phase I/II clinical trials have yielded some statistically significant results, and phase II trials are in progress.	UCL Royal Free & Univ Coll, Windeyer Inst Med Sci, Sch Med, Dept Med Microbiol, London W1P 6DB, England	Rook, GAW (reprint author), UCL Royal Free & Univ Coll, Windeyer Inst Med Sci, Sch Med, Dept Med Microbiol, 46 Cleveland St, London W1P 6DB, England.	g.rook@ucl.ac.uk		Martinelli, Roberta/0000-0003-0784-5973; Rook, Graham/0000-0002-8041-8110			Akdis CA, 2001, INT ARCH ALLERGY IMM, V124, P180, DOI 10.1159/000053704; Alm JS, 2002, GENES IMMUN, V3, P71, DOI 10.1038/sj/gene/6363834; Ancuta P, 2000, EUR J IMMUNOL, V30, P1872, DOI 10.1002/1521-4141(200007)30:7<1872::AID-IMMU1872>3.0.CO;2-2; Arbour NC, 2000, NAT GENET, V25, P187; Arkwright PD, 2001, J ALLERGY CLIN IMMUN, V107, P531, DOI 10.1067/mai.20001.113081; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barclay AN, 2002, TRENDS IMMUNOL, V23, P285, DOI 10.1016/S1471-4906(02)02223-8; Bashir MEH, 2002, J IMMUNOL, V169, P3284; BAXTER AG, 1994, IMMUNOLOGY, V83, P227; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown E, 2001, J CLIN INVEST, V107, P1499, DOI 10.1172/JCI13315; Brunkow ME, 2001, NAT GENET, V27, P68, DOI 10.1038/83784; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Camporota L, 2003, EUR RESPIR J, V21, P287, DOI 10.1183/09031936.03.00042103; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Clynes RA, 2000, NAT MED, V6, P443; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Coles AJ, 1999, LANCET, V354, P1691, DOI 10.1016/S0140-6736(99)02429-0; Dieli F, 1999, IMMUNOLOGY, V98, P71; Douek IF, 1999, LANCET, V353, P1850, DOI 10.1016/S0140-6736(99)00988-5; du Bois RM, 1999, NEW ENGL J MED, V341, P1302; Dutronc Y, 2002, TISSUE ANTIGENS, V60, P337, DOI 10.1034/j.1399-0039.2002.600501.x; Elliott DE, 2000, FASEB J, V14, P1848, DOI 10.1096/fj.99-0885hyp; Esposito K, 2003, J CLIN ENDOCR METAB, V88, P1055, DOI 10.1210/jc.2002-021437; Farooqi IS, 1998, THORAX, V53, P927; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; Frings W, 2002, FEBS LETT, V526, P93, DOI 10.1016/S0014-5793(02)03142-3; Geijtenbeek TBH, 2003, J EXP MED, V197, P7, DOI 10.1084/jem.20021229; Genain CP, 1996, SCIENCE, V274, P2054, DOI 10.1126/science.274.5295.2054; Gerosa F, 1999, CLIN IMMUNOL, V92, P224, DOI 10.1006/clim.1999.4752; Gerosa F, 1996, J EXP MED, V183, P2559, DOI 10.1084/jem.183.6.2559; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Grohmann U, 2002, NAT IMMUNOL, V3, P1097, DOI 10.1038/ni846; Groux H, 1997, NATURE, V389, P737; Hanngren A, 1987, Sarcoidosis, V4, P101; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Heldwein KA, 2002, MICROBES INFECT, V4, P937, DOI 10.1016/S1286-4579(02)01611-8; HERNANDEZPANDO R, 1994, IMMUNOLOGY, V82, P591; Hogg KG, 2003, INFECT IMMUN, V71, P3563, DOI 10.1128/IAI.71.6.3563-3571.2003; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Hutter C, 1992, FEMS Microbiol Immunol, V5, P309; Huynh MLN, 2002, J CLIN INVEST, V109, P41, DOI 10.1172/JCI11638; Kabesch M, 2003, J ALLERGY CLIN IMMUN, V111, P813, DOI 10.1067/mai.2003.1336; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003; KAM JC, 1993, J IMMUNOL, V151, P3460; Kang TJ, 2002, CYTOKINE, V20, P56, DOI 10.1006/cyto.2002.1982; KATZ JD, 1995, SCIENCE, V268, P1185, DOI 10.1126/science.7761837; Kezuka T, 2000, INVEST OPHTH VIS SCI, V41, P1410; KHORUTS A, 1995, J IMMUNOL, V155, P5011; KOHASHI O, 1985, MICROBIOL IMMUNOL, V29, P487; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Krug N, 1996, AM J RESP CELL MOL, V14, P319; Lammas DA, 2000, CLIN EXP IMMUNOL, V121, P417, DOI 10.1046/j.1365-2249.2000.01284.x; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Lawrence CE, 1998, EUR J IMMUNOL, V28, P2672, DOI 10.1002/(SICI)1521-4141(199809)28:09<2672::AID-IMMU2672>3.0.CO;2-F; LEITER EH, 2003, INFLAMM BOWEL DIS S1, V9, pS6; Lindberg E, 2000, J PEDIATR GASTR NUTR, V30, P259, DOI 10.1097/00005176-200003000-00009; Mallat Z, 1999, ARTERIOSCL THROM VAS, V19, P611; Mallat Z, 1999, CIRC RES, V85, P17; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; McIntire JJ, 2001, NAT IMMUNOL, V2, P1109, DOI 10.1038/ni739; Moudgil KD, 2001, J IMMUNOL, V166, P4237; Munn DH, 2002, SCIENCE, V297, P1867, DOI 10.1126/science.1073514; Nouri-Aria KT, 2002, J ALLERGY CLIN IMMUN, V109, pS171, DOI 10.1016/S0091-6749(02)81642-6; O'Brien PE, 2002, AM J SURG, V184, p4S; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Pasare C, 2003, SCIENCE, V299, P1033, DOI 10.1126/science.1078231; Pinderski LJ, 2002, CIRC RES, V90, P1064, DOI 10.1161/01.RES.0000018941.10726.FA; Pinderski Oslund Laura J., 1999, Arteriosclerosis Thrombosis and Vascular Biology, V19, P2847; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Rachmilewitz D, 2002, GASTROENTEROLOGY, V122, P1428, DOI 10.1053/gast.2002.32994; Read S, 2001, CURR OPIN IMMUNOL, V13, P644, DOI 10.1016/S0952-7915(01)00273-4; Renz H, 2002, J ALLERGY CLIN IMMUN, V109, P338, DOI 10.1067/mai.2002.121459; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Roncarolo MG, 2000, CURR OPIN IMMUNOL, V12, P676, DOI 10.1016/S0952-7915(00)00162-X; Sawczenko A, 2001, LANCET, V357, P1093, DOI 10.1016/S0140-6736(00)04309-9; Schultz M, 2002, INFLAMM BOWEL DIS, V8, P71, DOI 10.1097/00054725-200203000-00001; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Smit JJ, 2003, FASEB J, V17, P958, DOI 10.1096/fj.02-0985fje; Smith DA, 2001, CIRCULATION, V104, P746, DOI 10.1161/hc3201.094973; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Sulahian TH, 2000, CYTOKINE, V12, P1312, DOI 10.1006/cyto.2000.0720; Terrazas LI, 2001, J IMMUNOL, V167, P5294; Tormey VJ, 1998, CLIN EXP ALLERGY, V28, P992; Tremlett HL, 2002, QJM-INT J MED, V95, P753, DOI 10.1093/qjmed/95.11.753; Ulyanova T, 2001, J BIOL CHEM, V276, P14451; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; Verdu EF, 2000, CLIN EXP IMMUNOL, V120, P46, DOI 10.1046/j.1365-2249.2000.01170.x; Voll RE, 1997, NATURE, V390, P350, DOI 10.1038/37022; Wakkach A, 2003, IMMUNITY, V18, P605, DOI 10.1016/S1074-7613(03)00113-4; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; WYNN TA, 1995, NATURE, V376, P594, DOI 10.1038/376594a0; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	106	98	109	3	20	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-4325			SPRINGER SEMIN IMMUN	Springer Semin. Immunopathol.	FEB	2004	25	3-4					237	255		10.1007/s00281-003-0148-9		19	Immunology; Pathology	Immunology; Pathology	801IP	WOS:000220089900002	15007629	
J	Epstein, MM				Epstein, MM			Do mouse models of allergic asthma mimic clinical disease?	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Review						allergic asthma, pathophysiology; allergic asthma, pathology; allergic asthmam, therapy; immunoglobulin E; eosinophilic lung inflammation; immunological memory; Th2 cells; airway resistance; allergens, administration and dosage; mice, congenic	INDUCED AIRWAY HYPERREACTIVITY; CELL-DEFICIENT MICE; HOUSE-DUST MITE; TRACT DENDRITIC CELLS; REGULATORY T-CELLS; MURINE STRAIN DIFFERENCES; DIESEL EXHAUST PARTICLES; RECEPTOR TRANSGENIC MICE; BIRCH POLLEN ALLERGEN; TOLL-LIKE RECEPTOR-4	Experimental mouse models of allergic asthma established almost 10 years ago offered new opportunities to study disease pathogenesis and to develop new therapeutics. These models focused on the factors governing the allergic immune response, on modeling clinical behavior of allergic asthma, and led to insights into pulmonary pathophysiology. Although mouse models rarely completely reproduce all the features of human disease, after sensitization and respiratory tract challenges with antigen, wild-type mice develop a clinical syndrome that closely resembles allergic asthma, characterized by eosinophilic lung inflammation, airway hyperresponsiveness (AHR), increased IgE, mucus hypersecretion, and eventually, airway remodeling. There are, however, differences between mouse and human physiology that threaten to limit the value of mouse models. Three examples of such differences relate to both clinical manifestations of disease and underlying pathogenesis. First, in contrast to patients who have increased methacholine-induced AHR even when they are symptom-free, mice exhibit only transient methacholine-induced AHR following allergen exposure. Second, chronic allergen exposure in patients leads to chronic allergic asthma, whereas repeated exposures in sensitized mice causes suppression of disease. Third, IgE and mast cells, in humans, mediate early- and late-phase allergic responses, though both are unnecessary for the generation of allergic asthma in mice. Taken together, these observations suggest that mouse models of allergic asthma are not exact replicas of human disease and thus, question the validity of these models. However, observations from mouse models of allergic asthma support many existing paradigms, although some novel discoveries in mice have yet to be verified in patients. This review presents an overview of the clinical aspects of disease in mouse models of allergic asthma emphasizing ( 1) the factors influencing the pathophysiological responses during the initiation and perpetuation of disease, ( 2) the utility of mouse models for studying clinical manifestations of disease, and ( 3) the applicability of mouse models for testing new treatments for allergic asthma. Copyright (C) 2004 S. Karger AG, Basel.	Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, AT-1235 Vienna, Austria	Epstein, MM (reprint author), Univ Vienna, Dept Dermatol DIAID, VIRCC, Brunner Str 59, AT-1235 Vienna, Austria.	Michelle.Epstein@univie.ac.at					Adel-Patient K, 2003, CLIN EXP ALLERGY, V33, P376, DOI 10.1046/j.1365-2222.2003.01613.x; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Akbari O, 2003, NAT MED, V9, P582, DOI 10.1038/nm851; Alkan SS, 1996, ANN NY ACAD SCI, V796, P82, DOI 10.1111/j.1749-6632.1996.tb32569.x; Allakhverdi Z, 2000, AM J RESP CRIT CARE, V162, P1123; Barrett EG, 2002, AM J RESP CRIT CARE, V165, P1410, DOI 10.1164/rccm.2106029; Batanero E, 2002, INT ARCH ALLERGY IMM, V127, P269, DOI 10.1159/000057743; Bates CA, 2003, J ALLERGY CLIN IMMUN, V111, P256, DOI 10.1067/mai.2003.103; Bauer L, 1997, CLIN EXP IMMUNOL, V107, P536, DOI 10.1046/j.1365-2249.1997.d01-953.x; BILYK N, 1995, IMMUNOLOGY, V86, P231; Blyth DI, 2000, AM J RESP CELL MOL, V23, P241; Borchers MT, 2001, AM J PHYSIOL-LUNG C, V280, pL813; Braun-Fahrlander Charlotte, 2003, Curr Opin Allergy Clin Immunol, V3, P325, DOI 10.1097/00130832-200310000-00001; Brewer JP, 1999, AM J RESP CRIT CARE, V160, P1150; BRUSSELLE GG, 1994, CLIN EXP ALLERGY, V24, P73, DOI 10.1111/j.1365-2222.1994.tb00920.x; Buckley TL, 1996, ANN NY ACAD SCI, V796, P149, DOI 10.1111/j.1749-6632.1996.tb32576.x; Busse WW, 2001, NEW ENGL J MED, V344, P350; Busse WW, 2001, AM J RESP CRIT CARE, V164, pS12; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; CHENG KC, 1998, J ALLERGY CLIN IMMUN, V101, P1; Cheng XM, 2003, IMMUNOL LETT, V89, P31, DOI 10.1016/S0165-2478(03)00107-X; Chu HW, 2003, INFECT IMMUN, V71, P1520, DOI 10.1128/IAI.71.3.1520-1526.2003; Cohn L, 2002, NOVART FDN SYMP, V248, P201; Cohn L, 1999, J IMMUNOL, V162, P6178; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Constant SL, 2000, EUR J IMMUNOL, V30, P840, DOI 10.1002/1521-4141(200003)30:3<840::AID-IMMU840>3.3.CO;2-C; Corry DB, 1998, MOL MED, V4, P344; Coyle AJ, 1996, J IMMUNOL, V156, P2680; Cross ML, 2001, INT ARCH ALLERGY IMM, V125, P112, DOI 10.1159/000053804; CUI ZH, IN PRESS AM J RESP C; Dabbagh K, 2002, J IMMUNOL, V168, P4524; Damiani G, 1989, Eur Respir J Suppl, V6, p469s; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; De Sanctis GT, 1999, AM J PHYSIOL-LUNG C, V277, pL1118; DeBie JJ, 1996, BRIT J PHARMACOL, V119, P1484; Depuydt PO, 2002, CLIN EXP ALLERGY, V32, P391, DOI 10.1046/j.1365-2222.2002.01364.x; DeSanctis GT, 1997, NAT MED, V3, P460, DOI 10.1038/nm0497-460; DESANCTIS GT, 1995, NAT GENET, V11, P150, DOI 10.1038/ng1095-150; deSiqueira ALP, 1997, J ALLERGY CLIN IMMUN, V100, P383, DOI 10.1016/S0091-6749(97)70253-7; Dohi M, 1999, LAB INVEST, V79, P1559; Drazen JM, 1999, ANNU REV PHYSIOL, V61, P593, DOI 10.1146/annurev.physiol.61.1.593; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Erb KJ, 1996, IMMUNOL CELL BIOL, V74, P206, DOI 10.1038/icb.1996.29; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Ferreira M Branco, 2002, Allerg Immunol (Paris), V34, P10; Finotto S, 2002, SCIENCE, V295, P336, DOI 10.1126/science.1065544; Foster PS, 2003, CLIN EXP ALLERGY, V33, P688, DOI 10.1046/j.1365-2222.2003.01647.x; Foster PS, 2002, PHARMACOL THERAPEUT, V94, P253, DOI 10.1016/S0163-7258(02)00220-6; GARLISI CG, 1995, CLIN IMMUNOL IMMUNOP, V75, P75, DOI 10.1006/clin.1995.1055; Garssen J, 1997, INHAL TOXICOL, V9, P581; GAVETT SH, 1994, AM J RESP CELL MOL, V10, P587; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Goldsmith CAW, 2002, INHAL TOXICOL, V14, P325; Graffi SJ, 2002, CLIN IMMUNOL, V103, P176, DOI 10.1006/clim.2002.5190; Hadeiba H, 2000, J IMMUNOL, V164, P4933; Hahn YS, 2003, J IMMUNOL, V171, P3170; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hamelmann E, 1996, J EXP MED, V183, P1719, DOI 10.1084/jem.183.4.1719; Hamelmann E, 1997, P NATL ACAD SCI USA, V94, P1350, DOI 10.1073/pnas.94.4.1350; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hantos Z, 2002, J APPL PHYSIOL, V93, P1196, DOI 10.1152/japplphysiol.00526.2002; Harris N, 1997, EUR J IMMUNOL, V27, P155, DOI 10.1002/eji.1830270123; Hayashi T, 2003, SCAND J IMMUNOL, V57, P562, DOI 10.1046/j.1365-3083.2003.01269.x; Hayashi T, 2002, INT J EXP PATHOL, V83, P81, DOI 10.1046/j.1365-2613.2002.00218.x; Henderson WR, 2000, J IMMUNOL, V164, P1086; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; Herz U, 1998, CLIN EXP ALLERGY, V28, P625; Herz U, 1996, ADV EXP MED BIOL, V409, P25; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210; Holgate Stephen T., 2003, Journal of Allergy and Clinical Immunology, V111, pS18, DOI 10.1067/mai.2003.25; HOLT PG, 1981, INT ARCH ALLER A IMM, V65, P42; HOLT PG, 1985, CLIN EXP IMMUNOL, V62, P586; HOLT PG, 1981, IMMUNOLOGY, V42, P409; HOLT PG, 1994, J IMMUNOL, V153, P256; Holt PG, 2000, J AEROSOL MED, V13, P361, DOI 10.1089/jam.2000.13.361; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Hoshino A, 2003, EUR J IMMUNOL, V33, P861, DOI 10.1002/eji.200323455; Hsu C, 1996, IMMUNOL LETT, V52, P129, DOI 10.1016/0165-2478(96)02599-0; Huh JC, 2003, J EXP MED, V198, P19, DOI 10.1084/jem.20021328; Hussain I, 2001, Curr Opin Investig Drugs, V2, P914; Ichinose T, 2003, TOXICOL APPL PHARM, V187, P29, DOI 10.1016/S0041-008X(02)00038-8; Ichinose T, 1997, TOXICOLOGY, V122, P183, DOI 10.1016/S0300-483X(97)00096-6; Irvin CG, 2003, RESPIR RES, V4, DOI 10.1186/rr199; Iwamoto I, 1995, IMMUNOL RES, V14, P263, DOI 10.1007/BF02935624; Jahn-Schmid B, 1999, J ALLERGY CLIN IMMUN, V104, P1015; Jain VV, 2003, AM J PHYSIOL-LUNG C, V285, pL1137, DOI 10.1152/ajplung.00073.2003; Janssen EM, 2002, AM J RESP CELL MOL, V27, P257; JEFFERY PK, 1992, AM REV RESPIR DIS, V145, P890; Jones HP, 2001, J IMMUNOL, V167, P4518; Julia V, 2002, IMMUNITY, V16, P271, DOI 10.1016/S1074-7613(02)00276-5; Jungsuwadee P, 2002, CLIN IMMUNOL, V102, P145, DOI 10.1006/clim.2001.5157; JUNGSUWADEE P, IN PRESS INT ARCH AL; JUNGSUWADEE P, IN PRESS CLIN IMMUNO; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL302; Kannan MS, 2003, AM J PHYSIOL-LUNG C, V285, pL29, DOI 10.1152/ajplung.00085.2003; Kasai M, 2001, INT ARCH ALLERGY IMM, V125, P59, DOI 10.1159/000053856; Keramidaris E, 2001, J ALLERGY CLIN IMMUN, V107, P734, DOI 10.1067/mai.2001.114050; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kibe A, 2003, AM J RESP CRIT CARE, V167, P50, DOI 10.1164/rccm.2110084; Kim J, 2001, J IMMUNOL, V167, P2808; KIPS JC, 1995, INT ARCH ALLERGY IMM, V107, P115; Knott PG, 2000, AM J RESP CRIT CARE, V161, P1340; Kobayashi T, 2000, J IMMUNOL, V164, P3855; Komai M, 2003, BRIT J PHARMACOL, V138, P912, DOI 10.1038/sj.bjp.0705105; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; Kuchroo VK, 2003, NAT REV IMMUNOL, V3, P454, DOI 10.1038/nri1111; Kumar RK, 2002, AM J RESP CELL MOL, V27, P267, DOI 10.1165/rcmb.F248; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404; KUNG TT, 1994, INT ARCH ALLERGY IMM, V105, P83; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; Kuribayashi K, 2002, CLIN EXP ALLERGY, V32, P641, DOI 10.1046/j.0954-7894.2002.01346.x; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 2001, INT ARCH ALLERGY IMM, V124, P432, DOI 10.1159/000053778; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; Lee KS, 2003, J ALLERGY CLIN IMMUN, V111, P1278, DOI 10.1067/mai.2003.1501; Lee SC, 1999, J IMMUNOL, V162, P6867; Leonard P, 2003, BIODRUGS, V17, P1, DOI 10.2165/00063030-200317010-00001; Li L, 1998, J IMMUNOL, V161, P3128; Li XM, 1998, J IMMUNOL, V160, P1378; Lima C., 2002, Clinical and Experimental Allergy, V32, P1659, DOI 10.1046/j.1365-2222.2002.01506.x; Lisbonne M, 2003, J IMMUNOL, V171, P1637; Lobb RR, 1996, ANN NY ACAD SCI, V796, P113, DOI 10.1111/j.1749-6632.1996.tb32573.x; Lukacs NW, 1996, J LEUKOCYTE BIOL, V59, P13; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526; Lundblad LKA, 2002, J APPL PHYSIOL, V93, P1198, DOI 10.1152/japplphysiol.00080.2002; MacLean JA, 1999, AM J RESP CELL MOL, V20, P379; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580; MCMENAMIN C, 1994, SCIENCE, V265, P1869, DOI 10.1126/science.7916481; MCMENAMIN C, 1993, J EXP MED, V178, P889, DOI 10.1084/jem.178.3.889; MCWILLIAM AS, 1995, IMMUNOL CELL BIOL, V73, P405, DOI 10.1038/icb.1995.63; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Mitzner W, 2003, J APPL PHYSIOL, V94, P828, DOI 10.1152/japplphysiol.00815.2002; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; Miyata S, 1999, CLIN EXP ALLERGY, V29, P114; Mojtabavi N, 2002, J IMMUNOL, V169, P4788; Nagai H, 1996, ANN NY ACAD SCI, V796, P91, DOI 10.1111/j.1749-6632.1996.tb32570.x; OBrien RM, 1996, IMMUNOL CELL BIOL, V74, P174, DOI 10.1038/icb.1996.24; Ormstad H, 2003, TOXICOLOGY, V188, P309, DOI 10.1016/S0300-483X(03)00078-7; Ormstad H, 2000, TOXICOLOGY, V152, P53, DOI 10.1016/S0300-483X(00)00292-4; Pynaert G, 2003, AM J RESP CELL MOL, V29, P634, DOI 10.1165/rcmb.2003-0014OC; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Roche WR, 1998, AM J RESP CRIT CARE, V157, pS191; Rodriguez D, 2003, J IMMUNOL, V171, P1001; Rook Graham A W, 2003, Curr Opin Allergy Clin Immunol, V3, P337, DOI 10.1097/00130832-200310000-00003; Russo M, 2001, AM J RESP CELL MOL, V24, P518; Russo M, 1998, IMMUNOL LETT, V61, P15, DOI 10.1016/S0165-2478(97)00155-7; Sadakane K, 2002, INT ARCH ALLERGY IMM, V128, P220, DOI 10.1159/000064255; Sakai K, 2001, INT ARCH ALLERGY IMM, V126, P126, DOI 10.1159/000049503; Schipf A, 2003, EUR J IMMUNOL, V33, P1697, DOI 10.1002/eji.200323809; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Schramm CM, 2000, AM J RESP CELL MOL, V22, P218; SEDGWICK JD, 1985, IMMUNOLOGY, V56, P635; Seymour BWP, 1997, J IMMUNOL, V159, P6169; Seymour BWP, 1998, J EXP MED, V187, P721, DOI 10.1084/jem.187.5.721; Sheppard D, 2003, PHYSIOL REV, V83, P673, DOI 10.1152/physrev.00033.2002; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; Shinagawa K, 2003, AM J RESP CRIT CARE, V168, P959, DOI 10.1164/rccm.200210-1188OC; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Stumbles PA, 2003, APMIS, V111, P741, DOI 10.1034/j.1600-0463.2003.11107806.x; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Stumbles PA, 2001, J IMMUNOL, V167, P228; Stumbles PA, 1999, IMMUNOL CELL BIOL, V77, P428, DOI 10.1046/j.1440-1711.1999.00850.x; Suzuki T, 1996, J CLIN LAB IMMUNOL, V48, P187; Swirski FK, 2002, J IMMUNOL, V169, P3499; Takeda K, 2001, AM J PHYSIOL-LUNG C, V281, pL394; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; Tang CB, 2001, J IMMUNOL, V166, P1471; Tategaki A, 2002, INT ARCH ALLERGY IMM, V129, P204, DOI 10.1159/000066774; Taube C, 2002, J IMMUNOL, V169, P6482; Temelkovski J, 1998, THORAX, V53, P849; THEPEN T, 1991, EUR J IMMUNOL, V21, P2845, DOI 10.1002/eji.1830211128; Townley RG, 2003, CLIN REV ALLERG IMMU, V24, P85, DOI 10.1385/CRIAI:24:1:85; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120; Tsitoura DC, 2002, INT IMMUNOL, V14, P659, DOI 10.1093/intimm/dxf032; Tulic MK, 2002, INT ARCH ALLERGY IMM, V129, P119, DOI 10.1159/000065881; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Untersmayr E, 2003, J ALLERGY CLIN IMMUN, V112, P616, DOI 10.1016/mai.2003.1681; Upham JW, 2003, PHARMACOL THERAPEUT, V100, P75, DOI 10.1016/S0163-7258(03)00094-9; Valenta R, 2002, CURR OPIN IMMUNOL, V14, P718, DOI 10.1016/S0952-7915(02)00402-8; Van Rijt LS, 2001, MICROSC RES TECHNIQ, V53, P256, DOI 10.1002/jemt.1092; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674; Vermaelen K, 2003, AM J RESP CELL MOL, V29, P405, DOI 10.1165/rcmb.2003-0008OC; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; *WHO, 2000, WHO FACT SHEET BRONC; Wiedermann U, 1998, CLIN EXP IMMUNOL, V111, P144; Wilder JA, 2001, J LEUKOCYTE BIOL, V69, P538; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Wilson RA, 1996, IMMUNOLOGY, V87, P275, DOI 10.1046/j.1365-2567.1996.465550.x; Wolyniec WW, 1998, AM J RESP CELL MOL, V18, P777; Yiamouyiannis CA, 1999, AM J PATHOL, V154, P1911, DOI 10.1016/S0002-9440(10)65449-1; Yssel H, 2001, MICROBES INFECT, V3, P899, DOI 10.1016/S1286-4579(01)01450-2; Yu CK, 1996, J IMMUNOL, V156, P1923; Yu CK, 1999, J ALLERGY CLIN IMMUN, V104, P228, DOI 10.1016/S0091-6749(99)70140-5; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang Y, 1997, AM J RESP CRIT CARE, V155, P661; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; Zuany-Amorim C, 1998, SCIENCE, V280, P1265, DOI 10.1126/science.280.5367.1265	208	98	103	1	23	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.		2004	133	1					84	100		10.1159/000076131		17	Allergy; Immunology	Allergy; Immunology	800KZ	WOS:000220028500010	14726635	
J	Ichiura, H; Kitaoka, T; Tanaka, H				Ichiura, H; Kitaoka, T; Tanaka, H			Removal of indoor pollutants under UV irradiation by a composite TiO2-zeolite sheet prepared using a papermaking technique	CHEMOSPHERE			English	Article						photocatalyst; adsorbent; composite TiO2-zeolite sheet; papermaking technique; indoor pollution	VOLATILE ORGANIC-COMPOUNDS; PHOTOCATALYTIC OXIDATION; INCREMENTAL REACTIVITIES; FILM PHOTOCATALYST; AIR-QUALITY; TIO2; ZEOLITE; ILLUMINATION; ACETALDEHYDE; DEGRADATION	Toluene and formaldehyde are malodorous and cause indoor pollution. These materials have received much attention as hazardous and malodorous substances. It is well known that long-term exposure to even fairly low levels of toluene and formaldehyde brings about the risk of asthma, and eczema. In this study, a composite TiO2-zeolite (ZE) sheet prepared using a papermaking technique was applied to remove toluene and formaldehyde under UV irradiation. The optimum composition of the TiO2 (Ti)-ZE sheet was studied in detail with regard to the effective removal of various indoor pollutants. Gaseous toluene and formaldehyde were removed by a composite TiO2-ZE sheet with different efficiencies depending upon the ratio of Ti/ZE in the composite sheet. The composite sheets could decompose formaldehyde and toluene repeatedly after being recharged. It was shown that the sheets are potentially applicable as highly functional materials to be placed on walls and ceilings of houses for the removal of various indoor pollutants. (C) 2002 Elsevier Science Ltd. All rights reserved.	Kyushu Univ, Dept Forest & Forest Prod Sci, Fukuoka 8128581, Japan	Ichiura, H (reprint author), Kyushu Univ, Dept Forest & Forest Prod Sci, Fukuoka 8128581, Japan.		U-ID, Kyushu/C-5291-2016				Augugliaro V, 1999, APPL CATAL B-ENVIRON, V20, P15, DOI 10.1016/S0926-3373(98)00088-5; Chang TY, 1999, ATMOS ENVIRON, V33, P4695, DOI 10.1016/S1352-2310(99)00232-0; Ichiura H, 2002, J MATER SCI, V37, P2937, DOI 10.1023/A:1016060729376; Ichiura H, 2001, J MATER SCI, V36, P4921, DOI 10.1023/A:1011840405043; Ichiura H, 2001, J MATER SCI, V36, P913, DOI 10.1023/A:1004851101749; ICHIURA H, 2000, P INT S ENV FRIENDL, P42; Jones AP, 1998, SOC SCI MED, V47, P755, DOI 10.1016/S0277-9536(98)00151-8; Kelly NA, 1999, ATMOS ENVIRON, V33, P2101, DOI 10.1016/S1352-2310(98)00273-8; Lee SC, 2000, CHEMOSPHERE, V41, P109, DOI 10.1016/S0045-6535(99)00396-3; LINSEBIGLER AL, 1995, CHEM REV, V95, P735, DOI 10.1021/cr00035a013; MATSUBARA H, 1995, CHEM LETT, P767, DOI 10.1246/cl.1995.767; Mendez-Roman R, 1998, CATAL TODAY, V40, P353, DOI 10.1016/S0920-5861(98)00064-9; Ohko Y, 1997, J PHYS CHEM A, V101, P8057, DOI 10.1021/jp972002k; Rak ZS, 1997, REACT KINET CATAL L, V60, P303, DOI 10.1007/BF02475693; Rappengluck B, 1999, ATMOS ENVIRON, V33, P3843, DOI 10.1016/S1352-2310(98)00394-X; Sopyan I, 1996, J PHOTOCH PHOTOBIO A, V98, P79, DOI 10.1016/1010-6030(96)04328-6; SOPYAN J, 1994, CHEM LETT, P723; TABATA T, 1995, B CHEM SOC JPN, V68, P1905, DOI 10.1246/bcsj.68.1905; Takeda H, 1996, B CHEM SOC JPN, V69, P2735, DOI 10.1246/bcsj.69.2735; TANAKA H, 1993, J POLYM SCI POL CHEM, V31, P2687, DOI 10.1002/pola.1993.080311103; TANAKA H, 1994, LANGMUIR, V10, P3466, DOI 10.1021/la00022a018; Wolkoff P, 1998, SCI TOTAL ENVIRON, V215, P135, DOI 10.1016/S0048-9697(98)00110-7; Yu C, 1998, BUILD ENVIRON, V33, P357, DOI 10.1016/S0360-1323(97)00055-3	23	98	105	4	33	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0045-6535			CHEMOSPHERE	Chemosphere	JAN	2003	50	1					79	83	PII S0045-6535(02)00604-5	10.1016/S0045-6535(02)00604-5		5	Environmental Sciences	Environmental Sciences & Ecology	629XH	WOS:000180077300011	12656232	
J	van Rijt, LS; Prins, JB; Leenen, PJM; Thielemans, K; de Vries, VC; Hoogsteden, HC; Lambrecht, BN				van Rijt, LS; Prins, JB; Leenen, PJM; Thielemans, K; de Vries, VC; Hoogsteden, HC; Lambrecht, BN			Allergen-induced accumulation of airway dendritic cells is supported by an increase in CD31(hi)Ly6C(neg) bone marrow precursors in a mouse model of asthma	BLOOD			English	Article							COLONY-STIMULATING FACTOR; LUNG INFLAMMATION; INHALED ANTIGEN; MURINE MODEL; LYMPH-NODES; ER-MP12; MICE; EOSINOPHILIA; RESPONSES; CHALLENGE	Airway dendritic cells (DCs) are held responsible for inducing sensitization to Inhaled antigen, leading to eosinophilic airway inflammation, typical of asthma. However, less information is available about the role of these cells in ongoing inflammation. In a mouse model of asthma, sensitization to ovalbumin (OVA) was induced by intratracheal injection of myeloid OVA-pulsed DCs. Upon OVA aerosol challenge and induction of eosinophilic airway inflammation in sensitized mice, there was a time-dependent and almost 100-fold increase In the number of MHCII+ CD11b(+) CD11c(+) endogenous air-way DCs as well as CD11b(+) blood DCs. The mechanism of this increase was studied. Adoptive transfer experiments demonstrated that accumulation of airway DCs was not due to reduced migration to the mediastinal lymph nodes. Rather, the massive increase in airway and lymph node DCs was supported by an almost 3-fold expansion of myeloid CD31(hi)Ly-6C(neg) hematopoietic precursor cells in the bone marrow (BM). There was no change in any of the other 5 populations revealed by CD31/Ly-6C staining. When these CD31(hi)Ly-6C(neg) BM precursors were sorted and grown in granulocyte macro-phage-colony-stimulating factor, they differentiated into MHCII+ CD11c(+) DCs. The same CD31(hi)Ly-6C(neg) precursors also expressed the eotaxin receptor CCR3 and differentiated into eosinophils when grown in interleukin 5. Serum levels of eotaxin were doubled in mice with inflammation. These findings in an animal model of asthma suggest that the BM increases its output of myeloid precursors to meet the enhanced demand for DCs and eosinophils in inflamed airways. (C) 2002 by The American Society of Hematology.	Erasmus Univ, Med Ctr, Dept Pulm & Crit Care Med, Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Immunol, Rotterdam, Netherlands; Free Univ Brussels, Dept Physiol, B-1050 Brussels, Belgium	van Rijt, LS (reprint author), Erasmus Univ, Dept Pulm Med, Room Ee2263,Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.		Lambrecht, Bart/K-2484-2014; Leenen, Pieter/I-5839-2013	Lambrecht, Bart/0000-0003-4376-6834; Leenen, Pieter/0000-0001-9860-2920			Asselin-Paturel C, 2001, NAT IMMUNOL, V2, P1144, DOI 10.1038/ni736; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Brasel K, 2000, BLOOD, V96, P3029; Bruno L, 2001, EUR J IMMUNOL, V31, P3403, DOI 10.1002/1521-4141(200111)31:11<3403::AID-IMMU3403>3.0.CO;2-T; de Bruijn MFTR, 1998, J IMMUNOL METHODS, V217, P27, DOI 10.1016/S0022-1759(98)00080-5; deBruijn MFTR, 1996, EUR J IMMUNOL, V26, P2850, DOI 10.1002/eji.1830261208; DEBRUIJN MFTR, 1994, EUR J IMMUNOL, V24, P2279, DOI 10.1002/eji.1830241003; Elsas MICG, 1997, AM J RESP CELL MOL, V17, P404; Ford JG, 2001, J IMMUNOL, V167, P1769; Ganzalo J A, 1996, Immunity, V4, P1; Grimaldi JC, 1999, J LEUKOCYTE BIOL, V65, P846; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; HOLT PG, 1994, J IMMUNOL, V153, P256; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Iezzi G, 2001, J EXP MED, V193, P987, DOI 10.1084/jem.193.8.987; INABA K, 1992, J EXP MED, V176, P1693, DOI 10.1084/jem.176.6.1693; Inman MD, 1999, AM J RESP CELL MOL, V21, P473; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lambrecht BN, 2001, CLIN EXP ALLERGY, V31, P206, DOI 10.1046/j.1365-2222.2001.01061.x; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; Ling V, 1997, EUR J IMMUNOL, V27, P509, DOI 10.1002/eji.1830270223; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Manz MG, 2001, BLOOD, V97, P3333, DOI 10.1182/blood.V97.11.3333; Nakano H, 2001, J EXP MED, V194, P1171, DOI 10.1084/jem.194.8.1171; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510; Peled A, 1998, BLOOD, V91, P1909; Randolph GJ, 1998, SCIENCE, V282, P480, DOI 10.1126/science.282.5388.480; Saito H, 2001, IMMUNOLOGY, V104, P226, DOI 10.1046/j.1365-2567.2001.01253.x; Schlueter AJ, 2001, CYTOMETRY, V43, P297, DOI 10.1002/1097-0320(20010401)43:4<297::AID-CYTO1062>3.0.CO;2-9; SLIEKER WAT, 1993, INT IMMUNOL, V5, P1099, DOI 10.1093/intimm/5.9.1099; Sung SSJ, 2001, J IMMUNOL, V166, P1261; Throsby M, 2000, J IMMUNOL, V165, P1965; Tomaki M, 2000, J IMMUNOL, V165, P4040; VANDERLOO JCM, 1995, BLOOD, V85, P952; Vermaelen KY, 2001, J EXP MED, V193, P51; XIA WJ, 1995, J EXP MED, V181, P1275, DOI 10.1084/jem.181.4.1275	38	98	99	1	1	AMER SOC HEMATOLOGY	WASHINGTON	1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA	0006-4971			BLOOD	Blood	NOV 15	2002	100	10					3663	3671		10.1182/blood-2002-03-0673		9	Hematology	Hematology	613YE	WOS:000179158500031	12393720	
J	Burch, M; Levetin, E				Burch, M; Levetin, E			Effects of meteorological conditions on spore plumes	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						spore plumes; fungal spores; asthma; hay fever; meteorological conditions	ALTERNARIA-ALTERNATA; RISK FACTOR; ASTHMA; WEATHER	Fungal spores are an ever-present component of the atmosphere, and have long been known to trigger asthma and hay fever symptoms in sensitive individuals. The atmosphere around Tulsa has been monitored for airborne spores and pollen with Burkard spore traps at several sampling stations. This study involved the examination of the hourly spore concentrations on days that had average daily concentrations near 50,000 spores/m(3) or greater. Hourly concentrations of Cladosporium, Alternaria, Epicoccum, Curvularia, Pithomyces, Drechslera, smut spores, ascospores, basidiospores, other, and total spores were determined on 4 days at three sites and then correlated with hourly meteorological data including temperature, rainfall, wind speed, dew point, air pressure, and wind direction. On each of these days there was a spore plume, a phenomenon in which spore concentrations increased dramatically over a very short period of time. Spore plumes generally occurred near midday, and concentrations were seen to increase from lows around 20,000 total spores/m(3) to highs over 170,000 total spores/m(3) in 2 h. Multiple regression analysis of the data indicated that increases in temperature, dew point, and air pressure correlated with the increase in spore concentrations, but no single weather variable predicted the appearance of a spore plume. The proper combination of changes in these meteorological parameters that result in a spore plume may be due to the changing weather conditions associated with thunderstorms, as on 3 of the 4 days when spore plumes occurred there were thunderstorms later that evening. The occurrence of spore plumes may have clinical significance, because other studies have shown that sensitization to certain spore types can occur during exposure to high spore concentrations.	Univ Tulsa, Fac Biol Sci, Tulsa, OK 74104 USA	Levetin, E (reprint author), Univ Tulsa, Fac Biol Sci, 600 S Coll Ave, Tulsa, OK 74104 USA.						AHRENS CD, 1998, METEOROLOGY; Allitt U, 2000, AEROBIOLOGIA, V16, P397, DOI 10.1023/A:1026503500730; AYLOR DE, 1990, ANNU REV PHYTOPATHOL, V28, P73, DOI 10.1146/annurev.py.28.090190.000445; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Dales RE, 2000, AM J RESP CRIT CARE, V162, P2087; Dixit A, 2000, GRANA, V39, P209, DOI 10.1080/00173130051084368; HASNAIN SM, 1993, GRANA, V32, P184; HIRST J. M., 1953, TRANS BRIT MYCOL SOC, V36, P375; HJELMROOS M, 1993, GRANA, V32, P40; Ingold C. T., 1971, FUNGAL SPORES THEIR; LEVETIN E, 1991, GRANA, V30, P123; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Rosas I, 1998, ALLERGY, V53, P394, DOI 10.1111/j.1398-9995.1998.tb03911.x; Sterling M., 1999, Aerobiologia, V15, P9, DOI 10.1023/A:1007561201541; Timmer LW, 1998, PHYTOPATHOLOGY, V88, P1218, DOI 10.1094/PHYTO.1998.88.11.1218	16	98	100	1	12	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0020-7128			INT J BIOMETEOROL	Int. J. Biometeorol.	AUG	2002	46	3					107	117		10.1007/s00484-002-0127-1		11	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	591TH	WOS:000177896000001	12194003	
J	D'Ambrosio, D; Mariani, M; Panina-Bordignon, P; Sinigaglia, F				D'Ambrosio, D; Mariani, M; Panina-Bordignon, P; Sinigaglia, F			Chemokines and their receptors guiding T lymphocyte recruitment in lung inflammation	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review						lymphocyte homing; T cell; chemokines; asthma; COPD	MONOCYTE CHEMOATTRACTANT PROTEIN; OBSTRUCTIVE PULMONARY-DISEASE; ALLERGIC INFLAMMATION; AIRWAY HYPERRESPONSIVENESS; DENDRITIC CELLS; ATOPIC ASTHMA; L-SELECTIN; TH2 CELLS; BRONCHOALVEOLAR LAVAGE; NEUTROPHIL EMIGRATION		Roche Milano Ric, I-20132 Milan, Italy	Sinigaglia, F (reprint author), Roche Milano Ric, Via Olgettina 58, I-20132 Milan, Italy.						Agostini C, 1998, J IMMUNOL, V161, P6413; Alon R, 1998, P NATL ACAD SCI USA, V95, P11631, DOI 10.1073/pnas.95.20.11631; Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Baggiolini M, 1997, J EXP MED, V186, P1189, DOI 10.1084/jem.186.8.1189; Baluk P, 1998, AM J PATHOL, V152, P1463; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Blease K, 2000, J IMMUNOL, V165, P1564; Bonecchi R, 1998, J EXP MED, V187, P129, DOI 10.1084/jem.187.1.129; BRYAN SA, 2001, NEW DRUGS ASTHMA ALL, V31, P288, DOI 10.1159/000062158; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell JJ, 2000, CURR OPIN IMMUNOL, V12, P336, DOI 10.1016/S0952-7915(00)00096-0; Campbell JJ, 2001, J IMMUNOL, V166, P2842; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Cassatella MA, 1997, EUR J IMMUNOL, V27, P111, DOI 10.1002/eji.1830270117; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chvatchko Y, 2000, J EXP MED, V191, P1755, DOI 10.1084/jem.191.10.1755; CRONSTEIN BN, 1993, ARTHRITIS RHEUM, V36, P147; Cyster JG, 2000, CURR BIOL, V10, pR30, DOI 10.1016/S0960-9822(99)00253-5; Cyster JG, 1999, J EXP MED, V189, P447, DOI 10.1084/jem.189.3.447; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; D'Ambrosio D, 2000, IMMUNOL TODAY, V21, P183, DOI 10.1016/S0167-5699(00)01590-5; de Oca RM, 2000, INFECT IMMUN, V68, P1746, DOI 10.1128/IAI.68.3.1746-1751.2000; Dilulio NA, 1999, EUR J IMMUNOL, V29, P3485, DOI 10.1002/(SICI)1521-4141(199911)29:11<3485::AID-IMMU3485>3.0.CO;2-B; DOERSCHUK CM, 1987, J APPL PHYSIOL, V63, P1806; Doerschuk CM, 2000, AM J RESP CELL MOL, V23, P133; Frenette PS, 1997, THROMB HAEMOSTASIS, V78, P60; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; GarciaZepeda EA, 1996, NAT MED, V2, P449, DOI 10.1038/nm0496-449; Gasperini S, 1999, J IMMUNOL, V162, P4928; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gerber BO, 1997, CURR BIOL, V7, P836, DOI 10.1016/S0960-9822(06)00371-X; Gonzalez-Amaro R, 1999, CRIT REV IMMUNOL, V19, P389; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Gonzalo JA, 1996, J CLIN INVEST, V98, P2332, DOI 10.1172/JCI119045; Gu L, 2000, NATURE, V404, P407, DOI 10.1038/35006097; Gutierrez-Ramos JC, 2000, IMMUNOL REV, V177, P31, DOI 10.1034/j.1600-065X.2000.17713.x; Hesselgesser J, 1998, J BIOL CHEM, V273, P15687, DOI 10.1074/jbc.273.25.15687; HOGG N, 1995, IMMUNOL TODAY, V16, P327, DOI 10.1016/0167-5699(95)80147-2; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Holt PG, 1999, J LEUKOCYTE BIOL, V66, P272; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Iida K, 1997, THORAX, V52, P431; Jia GQ, 1996, J EXP MED, V184, P1939, DOI 10.1084/jem.184.5.1939; Kawasaki S, 2001, J IMMUNOL, V166, P2055; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kim Y, 2001, J IMMUNOL, V166, P5183; Kodama N, 1998, AM J RESP CELL MOL, V18, P526; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lanzavecchia A, 2000, SCIENCE, V290, P92, DOI 10.1126/science.290.5489.92; Lawrence MB, 1999, CURR OPIN CHEM BIOL, V3, P659, DOI 10.1016/S1367-5931(99)00023-X; Lichtman AH, 1997, CURR BIOL, V7, P242; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Loetscher P, 1998, NATURE, V391, P344, DOI 10.1038/34814; Lu B, 1998, J EXP MED, V187, P601, DOI 10.1084/jem.187.4.601; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Luster AD, 1998, NEW ENGL J MED, V338, P436; Luster AD, 1997, J LEUKOCYTE BIOL, V62, P620; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Mizgerd JP, 1996, J EXP MED, V184, P639, DOI 10.1084/jem.184.2.639; Mizgerd JP, 1997, J EXP MED, V186, P1357, DOI 10.1084/jem.186.8.1357; Moller DR, 1996, J IMMUNOL, V156, P4952; Murphy KM, 2000, ANNU REV IMMUNOL, V18, P451, DOI 10.1146/annurev.immunol.18.1.451; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.immunol.12.1.593; Nagata K, 1999, J IMMUNOL, V162, P1278; Nocker RET, 1999, INT ARCH ALLERGY IMM, V119, P45, DOI 10.1159/000024174; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; PICKER LJ, 1992, ANNU REV IMMUNOL, V10, P561, DOI 10.1146/annurev.immunol.10.1.561; Randolph DA, 1999, J IMMUNOL, V162, P2375; ROBINSON BWS, 1985, J CLIN INVEST, V75, P1488, DOI 10.1172/JCI111852; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Rollins BJ, 1997, BLOOD, V90, P909; Romagnani P, 1999, AM J PATHOL, V155, P1195, DOI 10.1016/S0002-9440(10)65222-4; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Rothenberg ME, 1997, J EXP MED, V185, P785, DOI 10.1084/jem.185.4.785; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; SAETTA M, 2001, INCREASED EXPRESSION; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Salmi M, 1997, ADV IMMUNOL, V64, P139, DOI 10.1016/S0065-2776(08)60889-5; Sekiya T, 2000, J IMMUNOL, V165, P2205; Sinigaglia F, 1999, IMMUNOL REV, V170, P65, DOI 10.1111/j.1600-065X.1999.tb01329.x; Sinigaglia F, 2000, SARCOIDOSIS VASC DIF, V17, P122; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stellato C, 2001, J IMMUNOL, V166, P1457; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Thelen M, 2001, NAT IMMUNOL, V2, P129, DOI 10.1038/84224; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020; Wagner JG, 2000, PHARMACOL REV, V52, P349; White JR, 1998, J BIOL CHEM, V273, P10095, DOI 10.1074/jbc.273.17.10095; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Yang Y, 1998, BLOOD, V92, P3912; Ying S, 1997, EUR J IMMUNOL, V27, P3507, DOI 10.1002/eji.1830271252; Zhang P, 2000, IMMUNOL REV, V173, P39, DOI 10.1034/j.1600-065X.2000.917306.x; Zingoni A, 1998, J IMMUNOL, V161, P547; Zlotnik A, 2000, IMMUNITY, V12, P121, DOI 10.1016/S1074-7613(00)80165-X	105	98	101	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT 1	2001	164	7					1266	1275				10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	489VM	WOS:000172013200036	11673221	
J	Arlian, LG; Platts-Mills, TAE				Arlian, LG; Platts-Mills, TAE			The biology of dust mites and the remediation of mite allergens in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite abatement; allergen remediation; mite allergy; dust mite biology	DERMATOPHAGOIDES-PTERONYSSINUS ACARI; SOLIDIFIED BENZYL BENZOATE; HOUSE-DUST; FARINAE ACARI; BRONCHIAL HYPERREACTIVITY; RELATIVE HUMIDITIES; EUROGLYPHUS-MAYNEI; ASTHMATIC-CHILDREN; BEDDING ENCASEMENT; SEASONAL-VARIATION	In most temperate humid areas of the world, house dust mites are a major source of multiple allergens in house dust Mite allergens sensitize and induce perennial rhinitis, asthma, or atopic dermatitis in a large portion of patients with allergic disease. There is convincing evidence that avoidance of mite allergen can effectively reduce allergic symptoms, Patients can be moved to a mite allergen-free environment, or mite and mite allergen abatement can be performed to reduce exposure in existing residences. Some knowledge of the biology of house dust mites is essential to understand the basis of the recommendations for reducing mites and mite allergens in homes and to appreciate the difficulty of eliminating house dust mites and mite allergens from homes. This article reviews key aspects of the biology of dust mites, the properties of mite allergens, recommendations for reducing mite and mite allergen concentrations in homes, and practical recommendations for treatment.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Arlian, LG (reprint author), Wright State Univ, Dept Biol Sci, 235 Biol Sci Bldg, Dayton, OH 45435 USA.						ANTONICELLI L, 1991, ALLERGY, V46, P594, DOI 10.1111/j.1398-9995.1991.tb00629.x; Arlian L. G., 1996, The immunology of host-ectoparasitic arthropod relationships., P232; Arlian LG, 1999, ANN ALLERG ASTHMA IM, V83, P529, DOI 10.1016/S1081-1206(10)62864-5; Arlian LG, 2000, ANN ALLERG ASTHMA IM, V85, P161; Arlian LG, 1999, J ALLERGY CLIN IMMUN, V104, P852; ARLIAN LG, 1992, EXP APPL ACAROL, V16, P15, DOI 10.1007/BF01201490; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; Arlian LG, 1998, J MED ENTOMOL, V35, P46; ARLIAN LG, 1981, J MED ENTOMOL, V18, P351; ARLIAN LG, 1990, J MED ENTOMOL, V27, P1035; ARLIAN LG, 1989, IMMUNOL ALLERGY CLIN, V9, P339; ARLIAN LG, 1975, J MED ENTOMOL, V12, P437; ARLIAN LG, 1974, J INSECT PHYSIOL, V20, P1063, DOI 10.1016/0022-1910(74)90148-6; ARLIAN LG, 1983, J MED ENTOMOL, V20, P99; Arlian LG, 1999, J MED ENTOMOL, V36, P457; Arlian LG, 1998, J MED ENTOMOL, V35, P962; Arlian LG, 1996, J MED ENTOMOL, V33, P257; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, J ALLERGY CLIN IMMUN, V107, P699; Arlian L, 1981, PHYSIOL ZOOL, V55, P344; Bischoff ERC, 1996, CLIN EXP ALLERGY, V26, P945, DOI 10.1111/j.1365-2222.1996.tb00631.x; Bischoff ERC, 1998, CLIN EXP ALLERGY, V28, P60; BONER AL, 1985, ANN ALLERGY, V54, P42; BRANDT RL, 1976, J MED ENTOMOL, V13, P327; Chang JCS, 1998, INDOOR AIR, V8, P34, DOI 10.1111/j.1600-0668.1998.t01-3-00005.x; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; COLLOFF MJ, 1995, CLIN EXP ALLERGY, V25, P1061, DOI 10.1111/j.1365-2222.1995.tb03252.x; Custovic A, 1998, J ALLERGY CLIN IMMUN, V101, pS81; Custovic A, 1999, ALLERGY, V54, P612, DOI 10.1034/j.1398-9995.1999.00062.x; DIETEMANN A, 1993, J ALLERGY CLIN IMMUN, V91, P738, DOI 10.1016/0091-6749(93)90193-J; DILWORTH RJ, 1991, CLIN EXP ALLERGY, V21, P25, DOI 10.1111/j.1365-2222.1991.tb00800.x; DOBSON RM, 1979, ACAROLOGIA, V21, P482; DODIN A, 1993, J MED ENTOMOL, V30, P810; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; ELLINGSON AR, 1995, J ALLERGY CLIN IMMUN, V96, P473, DOI 10.1016/S0091-6749(95)70289-X; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; HALLAM C, 1998, ALLERGY S, V54, P407; Hart BJ, 1998, ALLERGY, V53, P13; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; HUSS R, 1992, J ALLERGY CLIN IMMUN, V94, P27; Juhas KM, 1998, J ALLERGY CLIN IMMUN, V101, pS28; KALRA S, 1993, THORAX, V48, P10, DOI 10.1136/thx.48.1.10; Kemp TJ, 1996, BRIT MED J, V313, P916; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P1285; KOEKKOEK HH, 1972, ENTOMOL EXP APPL, V15, P438; LANG JD, 1978, ENVIRON ENTOMOL, V7, P281; LARSON DG, 1969, THESIS OHIO STATE U; LAUSCHADENDORF S, 1991, J ALLERGY CLIN IMMUN, V87, P41, DOI 10.1016/0091-6749(91)90211-6; Lewis RD, 1998, AM IND HYG ASSOC J, V59, P606, DOI 10.1202/0002-8894(1998)059<0606:FATROD>2.0.CO;2; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; MANJRA A, 1994, S AFR MED J, V84, P278; Matsumoto K., 1986, Japanese Journal of Sanitary Zoology, V37, P79; MCDONALD LG, 1992, J ALLERGY CLIN IMMUN, V90, P599, DOI 10.1016/0091-6749(92)90132-L; Miller J. D., 1996, Journal of Allergy and Clinical Immunology, V97, P423, DOI 10.1016/S0091-6749(96)81180-8; Morgan MS, 1997, J ALLERGY CLIN IMMUN, V100, P222, DOI 10.1016/S0091-6749(97)70228-8; Munir A K, 1993, Pediatr Allergy Immunol, V4, P136, DOI 10.1111/j.1399-3038.1993.tb00082.x; MURRAY AB, 1979, J ALLERGY CLIN IMMUN, V64, P266, DOI 10.1016/0091-6749(79)90142-8; NELSON HS, 1988, J ALLERGY CLIN IMMUN, V82, P661, DOI 10.1016/0091-6749(88)90980-3; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; NORTON RA, 1992, EVOLUTION DIVERSITY, P8; OCONNOR BM, 1982, ANNU REV ENTOMOL, V27, P385, DOI 10.1146/annurev.en.27.010182.002125; OCONNOR BM, 1982, SYNOPSIS CLASSIFICAT, P46; OROURKE MK, 1996, AEROBIOLOGY, P67; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; PLATTSMILLS TAE, 1982, LANCET, V2, P675; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Rains N, 1999, CLIN EXP ALLERGY, V29, P182; Sakaki I., 1991, Japanese Journal of Sanitary Zoology, V42, P93; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Shakib F, 1998, IMMUNOL TODAY, V19, P313, DOI 10.1016/S0167-5699(98)01284-5; Siebers RW, 1996, J ALLERGY CLIN IMMUN, V98, P853, DOI 10.1016/S0091-6749(96)70141-0; SPIEKSMA FTM, 1967, THESIS LEIDEN STATE; STEWART GA, 1995, CLIN REV ALLERG IMMU, V13, P135; Suto C., 1990, Japanese Journal of Sanitary Zoology, V41, P375; THOMAS B, 1991, INT ARCH ALLER A IMM, V94, P365; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; TOVEY E, 1993, MED J AUSTRALIA, V158, P579; TOVEY ER, 1990, J MED ENTOMOL, V27, P368; Tovey ER, 1997, J ALLERGY CLIN IMMUN, V100, P464; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Tsay A, 2000, J ALLERGY CLIN IMMUN, V105, pS271, DOI 10.1016/S0091-6749(00)91229-6; VANBRONSWIJK JE, 1971, J ALLERGY, V47, P31, DOI 10.1016/S0091-6749(71)80315-9; VANDENHOVE T, 1993, ALLERGY, V48, P264, DOI 10.1111/j.1398-9995.1993.tb00726.x; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; VARELA J, 1994, EUR J BIOCHEM, V225, P93, DOI 10.1111/j.1432-1033.1994.00093.x; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V103, P227, DOI 10.1016/S0091-6749(99)70495-1; Vaughan JW, 1999, J ALLERGY CLIN IMMUN, V104, P1079, DOI 10.1016/S0091-6749(99)70092-8; VOORHORS.R, 1967, J ALLERGY, V39, P325, DOI 10.1016/0021-8707(67)90045-7; VYSZENSKIMOHER DL, 2000, ANN ALLERG ASTHMA IM, V84, P136; WALZL MG, 1992, EXP APPL ACAROL, V16, P85, DOI 10.1007/BF01201494; WHARTON G W, 1977, Acarologia (Paris), V19, P112; WHARTON GW, 1976, J MED ENTOMOL, V12, P577; WOODFOLK JA, 1994, J ALLERGY CLIN IMMUN, V94, P19, DOI 10.1016/0091-6749(94)90066-3; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214	96	98	108	4	19	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3		S			S406	S413		10.1067/mai.2001.113670		8	Allergy; Immunology	Allergy; Immunology	418KR	WOS:000167891800002	11242601	
J	Koziel, JA; Odziemkowski, M; Pawliszyn, J				Koziel, JA; Odziemkowski, M; Pawliszyn, J			Sampling and analysis of airborne particulate matter and aerosols using in-needle trap and SPME fiber devices	ANALYTICAL CHEMISTRY			English	Article							SOLID-PHASE MICROEXTRACTION; PERFORMANCE LIQUID-CHROMATOGRAPHY; POLYCYCLIC AROMATIC-HYDROCARBONS; CAPILLARY-ELECTROPHORESIS; GAS-CHROMATOGRAPHY; AIR; SPECTROSCOPY; SEPARATION	A needle trap device (NTD) and commercial poly(dimethylsiloxane) (PDMS) 7-mum film thickness solid-phase microextraction (SPME) fibers were used for the sampling and analysis of aerosols and airborne particulate matter (PM) from an inhaler-administered drag, spray insect repellant, and tailpipe diesel exhaust. The NTD consisted of a 0.53-mm o.d. stainless steel needle having 5 mm of quartz wool packing section near the needle tip. Samples were collected by drawing air across the NTD with a Luer-tip syringe or via direct exposure of the SPME fiber. The mass loading of PM was varied by adjusting the volume of air pulled through the NTD or by varying the sampling time for the SPME fiber. The air volumes ranged from 0.1 to 50 mt, and sampling times varied from 10 s to 16 min; Particulates were either trapped on the needle packing or sorbed onto the SPME fiber, The devices were introduced to a chromatograph/mass spectrometer (GC/MS) injector for 5 min desorption, In the case of the NTD, 10 muL of clean air was delivered by a gas-tight syringe to aid the introduction of desorbed analytes. The compounds sorbed onto particles extracted by the SPME fiber or trapped in the needle device were desorbed in the injector and no carry-over was observed, Both devices performed well in extracting airborne polycyclic aromatic hydrocarbons: (PAHs) in diesel exhaust, triamcinolone acetonide in a dose of asthma drug and BEET in a dose of insect repellant spray, Results suggest that the NTDs and PDMS 7-mum fibers can be used for airborne particulate sampling and analysis, providing a simple, fast, reusable, and cost-effective screening tool, The advantage of the SPME fiber is the open-bed geometry allowing spectroscopic investigations of particulates; for example, with Raman microspectroscopy.	Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada; Univ Waterloo, Dept Earth Sci, Waterloo, ON N2L 3G1, Canada	Pawliszyn, J (reprint author), Univ Waterloo, Dept Chem, Waterloo, ON N2L 3G1, Canada.		Koziel, Jacek/B-5483-2014	Koziel, Jacek/0000-0002-2387-0354			Bernal JL, 1998, J CHROMATOGR A, V823, P423, DOI 10.1016/S0021-9673(98)00451-8; CHAI M, 1995, ENVIRON SCI TECHNOL, V29, P693, DOI 10.1021/es00003a017; Doppenschmitt SA, 1996, J CHROMATOGR B, V682, P79, DOI 10.1016/0378-4347(96)00060-6; HARRISON RM, 1986, HDB AIR POLLUTION AN; Kleeman MJ, 2000, ENVIRON SCI TECHNOL, V34, P1132, DOI 10.1021/es981276y; KNIGHT DS, 1989, J MATER RES, V4, P385, DOI 10.1557/JMR.1989.0385; Koziel J, 1999, ANAL CHIM ACTA, V400, P153, DOI 10.1016/S0003-2670(99)00614-5; KOZIEL J, IN PRESS J AIR WASTE; LESPADE P, 1982, CARBON, V20, P427, DOI 10.1016/0008-6223(82)90043-4; Lodge J. P., 1989, METHODS AIR SAMPLING; Martos PA, 1997, ANAL CHEM, V69, P402, DOI 10.1021/ac960633p; Martos PA, 1998, ANAL CHEM, V70, P2311, DOI 10.1021/ac9711394; Martos PA, 1999, ANAL CHEM, V71, P1513, DOI 10.1021/ac981028k; Martos PA, 1997, ANAL CHEM, V69, P206, DOI 10.1021/ac960415w; Mastral AM, 2000, ENVIRON SCI TECHNOL, V34, P3051, DOI 10.1021/es001028d; Nguyen AL, 1997, ANAL CHEM, V69, P1726, DOI 10.1021/ac960986o; ODZIEMKOWSKI M, UNPUB J ANAL CHEM; Offenberg JH, 1999, ENVIRON SCI TECHNOL, V33, P3324, DOI 10.1021/es990089c; Pawliszyn J., 1999, APPL SOLID PHASE MIC; Pawliszyn J., 1997, SOLID PHASE MICROEXT; RASCHDORF F, 1978, CHIMIA, V32, P478; SANTOSMONTES A, 1993, J CHROMATOGR-BIOMED, V620, P15, DOI 10.1016/0378-4347(93)80046-7; Seinfeld J. H., 1986, ATMOSPHERIC CHEM PHY; SHACKLETON CHL, 1986, J CHROMATOGR, V379, P91, DOI 10.1016/S0378-4347(00)80683-0; Shi JP, 2000, ENVIRON SCI TECHNOL, V34, P748, DOI 10.1021/es990530z; Shurmer B, 2000, ANAL CHEM, V72, P3660, DOI 10.1021/ac991395b; *US DEP HHS, 1994, NIOSH MAN AN METH; *US EPA, 1996, COMP METH DET TOX OR; YOUNG RJ, 1989, BRIT POLYM J, V21, P17, DOI 10.1002/pi.4980210104	29	98	101	1	61	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0003-2700			ANAL CHEM	Anal. Chem.	JAN 1	2001	73	1					47	54		10.1021/ac000835s		8	Chemistry, Analytical	Chemistry	389WW	WOS:000166262500017	11195511	
J	Gollwitzer, ES; Saglani, S; Trompette, A; Yadava, K; Sherburn, R; McCoy, KD; Nicod, LP; Lloyd, CM; Marsland, BJ				Gollwitzer, Eva S.; Saglani, Sejal; Trompette, Aurelien; Yadava, Koshika; Sherburn, Rebekah; McCoy, Kathy D.; Nicod, Laurent P.; Lloyd, Clare M.; Marsland, Benjamin J.			Lung microbiota promotes tolerance to allergens in neonates via PD-L1	NATURE MEDICINE			English	Article							REGULATORY T-CELLS; IMMUNE-SYSTEM; EARLY-LIFE; CHILDHOOD ASTHMA; COLONIZATION; FARM; INFLAMMATION; PREGNANCY; BACTERIUM; EXPOSURE	Epidemiological data point toward a critical period in early life during which environmental cues can set an individual on a trajectory toward respiratory health or disease(1-8). The neonatal immune system matures during this period(9), although little is known about the signals that lead to its maturation. Here we report that the formation of the lung microbiota is a key parameter in this process. Immediately following birth, neonatal mice were prone to develop exaggerated airway eosinophilia, release type 2 helper T cell cytokines and exhibit airway hyper-responsiveness following exposure to house dust mite allergens, even though their lungs harbored high numbers of natural CD4(+)Foxp3(+)CD25(+)Helios(+) regulatory T (T-reg cells. During the first 2 weeks after birth, the bacterial load in the lungs increased, and representation of the bacterial phyla shifts from a predominance of Gammaproteobacteria and Firmicutes towards Bacteroidetes. The changes in the microbiota were associated with decreased aeroallergen responsiveness and the emergence of a Helios(-) T-reg cell subset that required interaction with programmed death ligand 1 (PD-L1) for development. Absence of microbial colonization(10) or blockade of PD-L1 during the first 2 weeks postpartum maintained exaggerated responsiveness to allergens through to adulthood. Adoptive transfer of Treg cells from adult mice to neonates before aeroallergen exposure ameliorated disease. Thus, formation of the airway microbiota induces regulatory cells early in life, which, when dysregulated, can lead to sustained susceptibility to allergic airway inflammation in adulthood.	[Gollwitzer, Eva S.; Trompette, Aurelien; Yadava, Koshika; Nicod, Laurent P.; Marsland, Benjamin J.] Univ Lausanne, Fac Biol & Med, Ctr Hosp Univ Vaudois CHUV BH19206, Serv Pneumol, Lausanne, Switzerland; [Saglani, Sejal; Sherburn, Rebekah; Lloyd, Clare M.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Natl Heart & Lung Inst, London, England; [McCoy, Kathy D.] Univ Bern, Univ Clin Visceral Surg & Med, Maurice Muller Labs, Bern, Switzerland	Marsland, BJ (reprint author), Univ Lausanne, Fac Biol & Med, Ctr Hosp Univ Vaudois CHUV BH19206, Serv Pneumol, Lausanne, Switzerland.	benjamin.marsland@chuv.ch		Lloyd, Clare/0000-0001-8977-6726; Saglani, Sejal/0000-0001-5192-6418	Leenaards Foundation in Lausanne; Swiss National Science Foundation [310030_146983]; Wellcome Trust [087618/Z/08/Z, 083586/Z/07/Z]	This work is supported by the Leenaards Foundation in Lausanne and the Swiss National Science Foundation grant 310030_146983, awarded to B.J.M. B.J.M. is a Cloetta Medical Research Fellow and, by holding this title, receives financial support. B.J.M. and C.M.L. are part of the European Cooperation in Science and Technology Action BM1201, Developmental Origins of Chronic Lung Disease. S.S. and C.M.L. are supported by the Wellcome Trust grants 087618/Z/08/Z and 083586/Z/07/Z. C.M.L. is a Wellcome Senior Fellow in Basic Biomedical Science and, by holding this title, receives financial support. We thank D. Pinschewer and S. Kallert for valuable discussions and critical feedback.	Burke H, 2012, PEDIATRICS, V129, P735, DOI 10.1542/peds.2011-2196; Cahenzli J, 2013, CELL HOST MICROBE, V14, P559, DOI 10.1016/j.chom.2013.10.004; de Lafaille MAC, 2009, IMMUNITY, V30, P626, DOI 10.1016/j.immuni.2009.05.002; Curotto de Lafaille M. A., 2008, IMMUNITY, V29, P114; Erb-Downward JR, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016384; Francisco LM, 2009, J EXP MED, V206, P3015, DOI 10.1084/jem.20090847; Gem JE, 2005, J ALLERGY CLIN IMMUN, V115, P668; Geuking MB, 2011, IMMUNITY, V34, P794, DOI 10.1016/j.immuni.2011.03.021; Hagner S, 2013, ALLERGY, V68, P322, DOI 10.1111/all.12094; Herbst T, 2011, AM J RESP CRIT CARE, V184, P198, DOI 10.1164/rccm.201010-1574OC; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Hooper LV, 2012, SCIENCE, V336, P1268, DOI 10.1126/science.1223490; Huang YJ, 2011, J ALLERGY CLIN IMMUN, V127, P372, DOI 10.1016/j.jaci.2010.10.048; Jackson DJ, 2010, CURR OPIN ALLERGY CL, V10, P133, DOI 10.1097/ACI.0b013e3283352f7c; Lee SL, 2012, SCI WORLD J, DOI 10.1100/2012/542983; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Marsland BJ, 2013, CHEST, V144, P632, DOI 10.1378/chest.12-2854; Nembrini C, 2011, THORAX, V66, P755, DOI 10.1136/thx.2010.152512; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Pragman AA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047305; Rangel-Moreno J, 2011, NAT IMMUNOL, V12, P639, DOI 10.1038/ni.2053; Round JL, 2010, P NATL ACAD SCI USA, V107, P12204, DOI 10.1073/pnas.0909122107; Stensballe LG, 2013, J PEDIATR-US, V162, P832, DOI 10.1016/j.jpeds.2012.09.049; Trompette A, 2014, NAT MED, V20, P159, DOI 10.1038/nm.3444; Twigg HL, 2013, LANCET RESP MED, V1, P354, DOI 10.1016/S2213-2600(13)70117-6; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Wang L, 2008, P NATL ACAD SCI USA, V105, P9331, DOI 10.1073/pnas.0710441105; Wu PS, 2011, EXPERT REV ANTI-INFE, V9, P731, DOI [10.1586/eri.11.92, 10.1586/ERI.11.92]	30	97	100	5	33	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956	1546-170X		NAT MED	Nat. Med.	JUN	2014	20	6					642	647		10.1038/nm.3568		6	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	AI7LB	WOS:000337071000026	24813249	
J	Savinko, T; Matikainen, S; Saarialho-Kere, U; Lehto, M; Wang, GY; Lehtimaki, S; Karisola, P; Reunala, T; Wolff, H; Lauerma, A; Alenius, H				Savinko, Terhi; Matikainen, Sampsa; Saarialho-Kere, Ulpu; Lehto, Maili; Wang, Guoying; Lehtimaki, Sari; Karisola, Piia; Reunala, Timo; Wolff, Henrik; Lauerma, Antti; Alenius, Harri			IL-33 and ST2 in Atopic Dermatitis: Expression Profiles and Modulation by Triggering Factors	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							T-CELLS; MAST-CELLS; HUMAN MACROPHAGES; FAMILY CYTOKINE; MURINE MODEL; FLAKY TAIL; FILAGGRIN; DISEASE; RNA; SENSITIZATION	In the acute phase of atopic dermatitis (AD), T-helper type 2 (Th2) cytokines characterize the inflammatory response in the skin. IL-33 is a new tissue-derived cytokine, which is mainly expressed by cells of barrier tissues, and is known to activate Th2 lymphocytes, mast cells, and eosinophils. IL-33 signals through a receptor complex consisting of IL-33-specific receptor ST2 and a co-receptor IL-1RAcP. As IL-33 is known to promote Th2-type immunity, we examined expression profiles of IL-33 and its receptor components in human AD skin, in the murine model of AD, and in various cell models. We found increased expression of IL-33 and ST2 in AD skin after allergen or staphylococcal enterotoxin B (SEB) exposure, as well as in the skin of 22-week-old filaggrin-deficient mice. In addition, skin fibroblasts, HaCaT keratinocytes, primary macrophages, and HUVEC endothelial cells efficiently produced IL-33 in response to the combined stimulation of tumor necrosis factor-alpha and IFN-gamma, which was further enhanced by a mimetic of double-stranded RNA. Finally, the increased expression of IL-33 and ST2 caused by irritant, allergen, or SEB challenge was suppressed by topical tacrolimus treatment. These results suggest an important role for IL-33-ST2 interaction in AD and highlight the fact that bacterial and viral infections may increase the production of IL-33.	[Savinko, Terhi; Matikainen, Sampsa; Lehto, Maili; Lehtimaki, Sari; Karisola, Piia; Alenius, Harri] Finnish Inst Occupat Hlth, Unit Immunotoxicol, FIN-00250 Helsinki, Finland; [Saarialho-Kere, Ulpu; Lauerma, Antti] Univ Helsinki, Dept Dermatol Allergol & Venereol, Helsinki, Finland; [Wang, Guoying] Qingdao Univ, Dept Immunol, Coll Med, Qingdao 266071, Peoples R China; [Reunala, Timo; Lauerma, Antti] Univ Tampere, Dept Dermatol & Venereol, FIN-33101 Tampere, Finland	Alenius, H (reprint author), Finnish Inst Occupat Hlth, Unit Immunotoxicol, Topeliuksenkatu 41 AA, FIN-00250 Helsinki, Finland.	harri.alenius@ttl.fi	Lauerma, Antti/J-8180-2016		Academy of Finland; European Union [HEALTH-F2-2011-261366]	We kindly thank Sauli Savukoski for his expertise in immunohistological work. We also thank Paivi Alander and Santtu Hirvikorpi for their excellent technical assistance. This research was funded by the Academy of Finland and the European Union's FP7, grant agreement number HEALTH-F2-2011-261366.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Allakhverdi Z, 2007, J IMMUNOL, V179, P2051; Bieber T, 2010, ANN DERMATOL, V22, P125, DOI 10.5021/ad.2010.22.2.125; Boguniewicz M, 2011, IMMUNOL REV, V242, P233, DOI 10.1111/j.1600-065X.2011.01027.x; Breuer K, 2000, ALLERGY, V55, P551, DOI 10.1034/j.1398-9995.2000.00432.x; Carmi-Levy I, 2011, CLIN REV ALLERG IMMU, V41, P245, DOI 10.1007/s12016-010-8239-6; Cherry WB, 2008, J ALLERGY CLIN IMMUN, V121, P1484, DOI 10.1016/j.jaci.2008.04.005; Chustz RT, 2011, AM J RESP CELL MOL, V45, P145, DOI 10.1165/rcmb.2010-0075OC; Darsow U, 2000, CLIN EXP DERMATOL, V25, P544, DOI 10.1046/j.1365-2230.2000.00695.x; Dickel H, 2010, CONTACT DERMATITIS, V63, P215, DOI 10.1111/j.1600-0536.2010.01769.x; Gombert M, 2005, J IMMUNOL, V174, P5082; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; HANIFIN, 1980, ACTA DERM-VENEREOL, V92, P44; Hong J, 2010, J BIOL CHEM, V286, P20078; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Hsu CL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011944; IRANI AMA, 1989, ALLERGY, V44, P31; Kankkunen P, 2010, J IMMUNOL, V184, P6335, DOI 10.4049/jimmunol.0903019; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kurowska-Stolarska M, 2008, J IMMUNOL, V181, P4780; LANE PW, 1972, J HERED, V63, P135; Lehto M, 2010, INT IMMUNOPHARMACOL, V10, P377, DOI 10.1016/j.intimp.2010.01.001; Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; Moritz DR, 1998, J IMMUNOL, V161, P4866; Nomura I, 2003, J IMMUNOL, V171, P3262; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pirhonen J, 1999, J IMMUNOL, V162, P7322; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Rintahaka J, 2008, J IMMUNOL, V180, P1749; Savinko T, 2005, J IMMUNOL, V175, P8320; Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Smith DE, 2009, CLIN EXP ALLERGY, V40, P200; SOTER NA, 1989, ALLERGY, V44, P16, DOI 10.1111/j.1398-9995.1989.tb02449.x; Vakirlis E, 2010, J EUR ACAD DERMATOL, V25, P409; Wang G, 2007, CLIN EXP ALLERGY, V37, P151, DOI 10.1111/j.1365-2222.2006.02621.x; Weber F, 2006, J VIROL, V80, P5059, DOI 10.1128/JVI.80.10.5059-5064.2006; Wollenberg A, 2003, J ALLERGY CLIN IMMUN, V112, P667, DOI 10.1067/mai.2003.1775; Wollenberg A, 2011, CLIN REV ALLERG IMMU, V41, P272, DOI 10.1007/s12016-010-8227-x; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787	44	97	100	3	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X			J INVEST DERMATOL	J. Invest. Dermatol.	MAY	2012	132	5					1392	1400		10.1038/jid.2011.446		9	Dermatology	Dermatology	926UA	WOS:000302856200015	22277940	
J	Clayton, EMR; Todd, M; Dowd, JB; Aiello, AE				Clayton, Erin M. Rees; Todd, Megan; Dowd, Jennifer Beam; Aiello, Allison E.			The Impact of Bisphenol A and Triclosan on Immune Parameters in the U.S. Population, NHANES 2003-2006	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						allergies; bisphenol A; cytomegalovirus; endocrine-disrupting compounds; NHANES; triclosan	NUTRITION EXAMINATION SURVEY; HUMAN CYTOMEGALOVIRUS; ENDOCRINE DISRUPTERS; NATIONAL-HEALTH; US POPULATION; ANTIBODIES; EXPOSURE; URINARY; SYSTEM; CELLS	BACKGROUND: Exposure to environmental toxicants is associated with numerous disease outcomes, many of which involve underlying immune and inflammatory dysfunction. OBJECTIVES: To address the gap between environmental exposures and immune dysfunction, we investigated the association of two endocrine-disrupting compounds (EDCs) with markers of immune function. METHODS: Using data from the 2003-2006 National Health and Nutrition Examination Survey, we compared urinary bisphenol A (BPA) and triclosan levels with serum cytomegalovirus (CMV) antibody levels and diagnosis of allergies or hay fever in U. S. adults and children >= 6 years of age. We used multivariate ordinary least squares linear regression models to examine the association of BPA and triclosan with CMV antibody titers, and multivariate logistic regression models to investigate the association of these chemicals with allergy or hay fever diagnosis. Statistical models were stratified by age (< 18 years and >= 18 years). RESULTS: In analyses adjusted for age, sex, race, body mass index, creatinine levels, family income, and educational attainment, in the >= 18-year age group, higher urinary BPA levels were associated with higher CMV antibody titers (p < 0.001). In the < 18-year age group, lower levels of BPA were associated with higher CMV antibody titers (p < 0.05). However, triclosan, but not BPA, showed a positive association with allergy or hay fever diagnosis. In the < 18-year age group, higher levels of triclosan were associated with greater odds of having been diagnosed with allergies or hay fever (p < 0.01). CONCLUSIONS: EDCs such as BPA and triclosan may negatively affect human immune function as measured by CMV antibody levels and allergy or hay fever diagnosis, respectively, with differential consequences based on age. Additional studies should be done to investigate these findings.	[Clayton, Erin M. Rees; Aiello, Allison E.] Univ Michigan, Sch Publ Hlth, Ctr Social Epidemiol & Populat Hlth, Ann Arbor, MI 48109 USA; [Clayton, Erin M. Rees; Aiello, Allison E.] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA; [Todd, Megan; Dowd, Jennifer Beam] CUNY, Inst Demog Res, New York, NY 10021 USA; [Todd, Megan] Princeton Univ, Woodrow Wilson Sch Publ & Int Affairs, Princeton, NJ 08544 USA; [Todd, Megan] Princeton Univ, Off Populat Res, Princeton, NJ 08544 USA; [Dowd, Jennifer Beam] CUNY, Hunter Coll, Sch Publ Hlth, New York, NY 10021 USA	Aiello, AE (reprint author), Univ Michigan, Sch Publ Hlth, Ctr Social Epidemiol & Populat Hlth, 1415 Washington Hts,Room 3663, Ann Arbor, MI 48109 USA.	aielloa@umich.edu	Dowd, Jennifer/C-1127-2012; Osborne, Nicholas/N-4915-2015	Dowd, Jennifer/0000-0003-2006-5656; Osborne, Nicholas/0000-0002-6700-2284	National Institutes of Health [1R21NR011181-01]; University of Michigan	This project was supported by an grant from the National Institutes of Health (1R21NR011181-01. E. M. R. C. acknowledges funding from the University of Michigan Robert Wood Johnson Health and Society Scholars Program during the writing of the manuscript.	Ahmed SR, 2000, TOXICOLOGY, V150, P191; Andres A, 2009, J NUTR BIOCHEM, V20, P563, DOI 10.1016/j.jnutbio.2009.04.004; Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Barr DB, 2007, REPROD TOXICOL, V23, P260, DOI 10.1016/j.reprotox.2007.03.003; Bate SL, 2010, CLIN INFECT DIS, V50, P1439, DOI 10.1086/652438; Bureau of Labor and Statistics, 2011, CONS PRIC IND INFL C; *BUR LAB STAT, 2011, ANN DEM SURV MARCH S; Calafat AM, 2008, ENVIRON HEALTH PERSP, V116, P303, DOI 10.1289/ehp.10768; CDC, 2010, NAT REP HUM EXP ENV; CDC, 2011, NAT HLTH NUTR EX SUR; CDC, 2003, NAT HLTH NUTR EX SUR; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Coulborn RM, 2010, ACS SYM SER, V1048, P367; Diamanti-Kandarakis E, 2009, ENDOCR REV, V30, P293, DOI 10.1210/er.2009-0002; Dietert RR, 2010, ENVIRON HEALTH PERSP, V118, P1091, DOI 10.1289/ehp.1001971; Donner KJ, 1999, CYTOMETRY, V35, P80, DOI 10.1002/(SICI)1097-0320(19990101)35:1<80::AID-CYTO11>3.0.CO;2-8; Dowd JB, 2009, EPIDEMIOLOGY, V20, P902, DOI 10.1097/EDE.0b013e3181bb5302; *END SOC, 2009, END SOC POS STAT END; GLASER A, 2004, PESTICIDES YOU, V24, P12; GROSSMAN CJ, 1984, ENDOCR REV, V5, P435; Ishibashi H, 2004, AQUAT TOXICOL, V67, P167, DOI 10.1016/j.aquatox.2003.12.005; Katsel P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007642; KEPNER J, 2004, PESTICIDES YOU, V24, P9; Keri RA, 2007, REPROD TOXICOL, V24, P240, DOI 10.1016/j.reprotox.2007.06.008; Koch S, 2006, MECH AGEING DEV, V127, P538, DOI 10.1016/j.mad.2006.01.011; LaKind J. S., 2011, Journal of Exposure Science and Environmental Epidemiology, V21, P272, DOI 10.1038/jes.2010.9; Lee MH, 2003, IMMUNOLOGY, V109, P76, DOI 10.1046/j.1365-2567.2003.01631.x; Levy SB, 2001, EMERG INFECT DIS, V7, P512; Litonjua AA, 2005, J ALLERGY CLIN IMMUN, V115, P751, DOI 10.1016/j.jaci.2004.12.1138; MCCONNACHIE PR, 1992, ARCH ENVIRON HEALTH, V47, P295; McDade TW, 2000, PSYCHOSOM MED, V62, P560; McHugh MK, 2009, J ASTHMA, V46, P759, DOI 10.3109/02770900903067895; Meeker JD, 2010, REPROD TOXICOL, V30, P532, DOI 10.1016/j.reprotox.2010.07.005; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Roberts ET, 2010, AM J EPIDEMIOL, V172, P363, DOI 10.1093/aje/kwq177; Rosenberg AM, 1999, J TOXICOL ENV HEAL A, V57, P225, DOI 10.1080/009841099157674; Segura JJ, 1999, J ENDODONT, V25, P341, DOI 10.1016/S0099-2399(06)81168-4; Smith Rick, 2009, SLOW DEATH RUBBER DU; Stahlhut RW, 2009, ENVIRON HEALTH PERSP, V117, P784, DOI 10.1289/ehp.0800376; Stowe RP, 2007, EXP GERONTOL, V42, P563, DOI 10.1016/j.exger.2007.01.005; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Straube E, 1999, TOXICOL LETT, V107, P225, DOI 10.1016/S0378-4274(99)00051-X; TAYLORWIEDEMAN J, 1991, J GEN VIROL, V72, P2059, DOI 10.1099/0022-1317-72-9-2059; *US EPA, 2010, RER EL DEC RISK ASS; Vandenberg LN, 2007, ENDOCRINOLOGY, V148, P116, DOI 10.1210/en.2006-0561; Vandenberg LN, 2010, ENVIRON HEALTH PERSP, V118, P1055, DOI 10.1289/ehp.0901716; Veldhoen N, 2006, AQUAT TOXICOL, V80, P217, DOI 10.1016/j.aquatox.2006.08.010; Verthelyi DI, 1998, CELL IMMUNOL, V189, P125, DOI 10.1006/cimm.1998.1372; Welshons WV, 2006, ENDOCRINOLOGY, V147, pS56, DOI 10.1210/en.2005-1159; WIRA CR, 1987, J IMMUNOL, V138, P4159; Ye XY, 2005, ANAL CHEM, V77, P5407, DOI 10.1021/ac050390d	51	97	98	6	38	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2011	119	3					390	396		10.1289/ehp.1002883		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	729CU	WOS:000287926700030	21062687	
J	Lee, RU; Stevenson, DD				Lee, Rachel U.; Stevenson, Donald D.			Aspirin-Exacerbated Respiratory Disease: Evaluation and Management	ALLERGY ASTHMA & IMMUNOLOGY RESEARCH			English	Review						Aspirin-exacerbated respiratory disease; aspirin desensitization; aspirin sensitivity; chronic sinusitis; asthma; nasal polyps; Samter's triad	LEUKOTRIENE-MODIFIER DRUGS; LONG-TERM TREATMENT; INDUCED ASTHMA; DESENSITIZATION-TREATMENT; SENSITIVE ASTHMATICS; INTOLERANT ASTHMA; CONTROLLED-TRIAL; NATURAL-HISTORY; LYSINE-ASPIRIN; CHALLENGE	The clinical syndrome of aspirin-exacerbated respiratory disease (AERD) is a condition where inhibition of cyclooxygenase-1 (COX-1) induces attacks of upper and lower airway reactions, including rhinorrhea and varying degrees of bronchospasm and laryngospasm. Although the reaction is not IgE-mediated, patients can also present with anaphylactic hypersensitivity reactions, including hypotension, after exposure to COX-1 inhibiting drugs. All patients with AERD have underlying nasal polyps and intractable sinus disease which may be difficult to treat with standard medical and surgical interventions. This review article focuses on the management of AERD patients with a particular emphasis on aspirin desensitization and continuous treatment with aspirin.	[Stevenson, Donald D.] Scripps Clin, Div Allergy Asthma & Immunol, San Diego, CA 92130 USA; [Lee, Rachel U.] Naval Med Ctr Portsmouth, Div Allergy Asthma & Immunol, Portsmouth, VA USA	Stevenson, DD (reprint author), Scripps Clin, Div Allergy Asthma & Immunol, 3811 Valley Ctr Dr,S99, San Diego, CA 92130 USA.	DStevemd@aol.com					Berges-Gimeno MP, 2003, ANN ALLERG ASTHMA IM, V90, P338; Berges-Gimeno MP, 2003, J ALLERGY CLIN IMMUN, V111, P180, DOI 10.1067/mai.2003.7; Berges-Gimeno MP, 2002, CLIN EXP ALLERGY, V32, P1491, DOI 10.1046/j.1365-2745.2002.01501.x; Berges-Gimeno MP, 2002, ANN ALLERG ASTHMA IM, V89, P474; Casadevall J, 2000, THORAX, V55, P921, DOI 10.1136/thorax.55.11.921; CHRISTIE PE, 1991, AM REV RESPIR DIS, V143, P1025; Daffern PJ, 1999, J ALLERGY CLIN IMMUN, V104, P559, DOI 10.1016/S0091-6749(99)70324-6; Dahlen SE, 2002, AM J RESP CRIT CARE, V165, P9; DELANEY JC, 1976, CLIN ALLERGY, V6, P177, DOI 10.1111/j.1365-2222.1976.tb01896.x; Dursun AB, 2008, ANN ALLERG ASTHMA IM, V100, P420, DOI 10.1016/S1081-1206(10)60465-6; Gyllfors P, 2003, J ALLERGY CLIN IMMUN, V111, P1116, DOI 10.1067/mai.2003.1450; Hope AP, 2009, J ALLERGY CLIN IMMUN, V123, P406, DOI 10.1016/j.jaci.2008.09.048; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447; Jenkins C, 2004, BMJ-BRIT MED J, V328, P434, DOI 10.1136/bmj.328.7437.434; Klimek L, 2009, IMMUNOL ALLERGY CLIN, V29, P669, DOI 10.1016/j.iac.2009.07.008; KOWALSKI ML, 1986, EUR J RESPIR DIS, V69, P219; Lee JY, 2007, J ALLERGY CLIN IMMUN, V119, P157, DOI 10.1016/j.jaci.2006.09.011; Lee RU, 2010, ANN ALLERG ASTHMA IM, V105, P130, DOI 10.1016/j.anai.2010.05.020; Macy E, 2007, ANN ALLERG ASTHMA IM, V98, P172; Mascia K, 2005, ANN ALLERG ASTHMA IM, V94, P652; MCDONALD JR, 1972, J ALLERGY CLIN IMMUN, V50, P198, DOI 10.1016/0091-6749(72)90014-0; McMains KC, 2006, AM J RHINOL, V20, P573, DOI 10.2500/ajr.2006.20.2913; Milewski M, 1998, J ALLERGY CLIN IMMUN, V101, P581; Nizankowska E, 2000, EUR RESPIR J, V15, P863, DOI 10.1034/j.1399-3003.2000.15e09.x; Parikh AA, 2005, LARYNGOSCOPE, V115, P1385, DOI 10.1097/01.MLG.0000166702.38850.1B; Patriarca G, 1991, ANN ALLERGY, V67, P588; Pfaar O, 2006, J PHYSIOL PHARMACOL, V57, P5; Rozsasi A, 2008, ALLERGY, V63, P1228, DOI 10.1111/j.1398-9995.2008.01658.x; SAMTER M, 1968, ANN INTERN MED, V68, P975; Shaker M, 2008, J ALLERGY CLIN IMMUN, V121, P81, DOI 10.1016/j.jaci.2007.06.047; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Stevenson DD, 2001, J ALLERGY CLIN IMMUN, V108, P47, DOI 10.1067/mai.2001.116290; Stevenson DD, 1996, J ALLERGY CLIN IMMUN, V98, P751, DOI 10.1016/S0091-6749(96)70123-9; Stevenson DD, 2003, CLIN REV ALLERG IMMU, V24, P159, DOI 10.1385/CRIAI:24:2:159; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P773, DOI 10.1016/j.jaci.2006.07.024; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P801, DOI 10.1016/j.jaci.2006.06.019; Stevenson DD, 2009, CURR ALLERGY ASTHM R, V9, P155, DOI 10.1007/s11882-009-0023-4; Szczeklik A, 2000, EUR RESPIR J, V16, P432, DOI 10.1034/j.1399-3003.2000.016003432.x; Szczeklik A, 2009, MIDDLETONS ALLERGY P, P1227; WEBER BW, 1979, J ALLERGY CLIN IMMUN, V64, P32; White AA, 2005, ANN ALLERG ASTHMA IM, V95, P330; White A, 2006, ANN ALLERG ASTHMA IM, V97, P688; White A, 2006, ANN ALLERG ASTHMA IM, V97, P190; Widal MF, 1922, PRESSE MED, V30, P189; Williams AN, 2007, J ALLERGY CLIN IMMUN, V120, P273, DOI 10.1016/j.jaci.2007.03.020; Woessner KM, 2002, ARTHRITIS RHEUM, V46, P2201, DOI 10.1002/art.10426	46	97	99	2	5	KOREAN ACAD ASTHMA ALLERGY & CLINICAL IMMUNOLOGY	JONGNO-GU	RM 1705, KUMHO BLDG 327-2, CHANGSINDONG, JONGNO-GU, SEOUL 110-540, SOUTH KOREA	2092-7355			ALLERGY ASTHMA IMMUN	Allergy Asthma Immunol. Res.	JAN	2011	3	1					3	10		10.4168/aair.2011.3.1.3		8	Allergy; Immunology	Allergy; Immunology	776ZU	WOS:000291581600002	21217919	
J	Gurjar, BR; Jain, A; Sharma, A; Agarwal, A; Gupta, P; Nagpure, AS; Lelieveld, J				Gurjar, B. R.; Jain, A.; Sharma, A.; Agarwal, A.; Gupta, P.; Nagpure, A. S.; Lelieveld, J.			Human health risks in megacities due to air pollution	ATMOSPHERIC ENVIRONMENT			English	Article						Criteria pollutants; Mortality; Morbidity; Relative risk; Cardiovascular; Respiratory; Hospital admissions	UNITED-STATES; HOSPITAL ADMISSIONS; APHEA PROJECT; POLLUTANTS; MORTALITY; EXPOSURE; EMISSIONS; CITIES; ASTHMA	This study evaluates the health risks in megacities in terms of mortality and morbidity due to air pollution. A new spreadsheet model, Risk of Mortality/Morbidity due to Air Pollution (Ri-MAP), is used to estimate the excess numbers of deaths and illnesses. By adopting the World Health Organization (WHO) guideline concentrations for the air pollutants SO(2), NO(2) and total suspended particles (TSP), concentration-response relationships and a population attributable-risk proportion concept are employed. Results suggest that some megacities like Los Angeles, New York, Osaka Kobe, Sao Paulo and Tokyo have very low excess cases in total mortality from these pollutants. In contrast, the approximate numbers of cases is highest in Karachi (15,000/yr) characterized by a very high concentration of total TSP (similar to 670 mu g m(-3)). Dhaka (7000/yr), Beijing (5500/yr), Karachi (5200/yr), Cairo (5000/yr) and Delhi (3500/yr) rank highest with cardiovascular mortality. The morbidity (hospital admissions) due to Chronic Obstructive Pulmonary Disease (COPD) follows the tendency of cardiovascular mortality. Dhaka and Karachi lead the rankings, having about 2100/yr excess cases, while Osaka-Kobe (similar to 20/yr) and Sao Paulo (similar to 50/yr) are at the low end of all megacities considered. Since air pollution is increasing in many megacities, and our database of measured pollutants is limited to the period up to 2000 and does not include all relevant components (e.g. O(3)), these numbers should be interpreted as lower limits. South Asian megacities most urgently need improvement of air quality to prevent excess mortality and morbidity due to exceptionally high levels of air pollution. The risk estimates obtained from Ri-MAP present a realistic baseline evaluation for the consequences of ambient air pollution in comparison to simple air quality indices, and can be expanded and improved in parallel with the development of air pollution monitoring networks. (C) 2010 Elsevier Ltd. All rights reserved.	[Gurjar, B. R.; Jain, A.; Sharma, A.; Agarwal, A.; Gupta, P.] Indian Inst Technol, Dept Civil Engn, Roorkee 247667, Uttar Pradesh, India; [Nagpure, A. S.] Indian Inst Technol, Ctr Transportat Syst, Roorkee 247667, Uttar Pradesh, India; [Gurjar, B. R.; Lelieveld, J.] Max Planck Inst Chem, Div Atmospher Chem, D-55128 Mainz, Germany; [Lelieveld, J.] Cyprus Inst, Energy Environm & Water Res Ctr, CY-1645 Nicosia, Cyprus	Gurjar, BR (reprint author), Indian Inst Technol, Dept Civil Engn, Roorkee 247667, Uttar Pradesh, India.	brgurjar@gmail.com	Lelieveld, Johannes/A-1986-2013; Gurjar, Bhola Ram/L-1357-2013	Gurjar, Bhola Ram/0000-0002-7224-1802	Max Planck Society, Munich; Max Planck Institute for Chemistry, Mainz, Germany; Cyprus Institute	The Max Planck Society, Munich, and the Max Planck Institute for Chemistry, Mainz, Germany, have supported this study through the Max Planck Partner Group for Megacities and Global Change established at Indian Institute of Technology Roorkee, India. We thank the anonymous reviewers whose constructive suggestions have helped improve the manuscript. Support received from The Cyprus Institute during revision of the manuscript is gratefully acknowledged (ERC grant for the C8 project).	Abbey DE, 1999, AM J RESP CRIT CARE, V159, P373; Breitner S, 2009, ENVIRON HEALTH PERSP, V117, P448, DOI 10.1289/ehp.11711; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Burret RT, 1997, EPIDEMIOLOGY, V8, P162; Butler TM, 2008, ATMOS ENVIRON, V42, P703, DOI 10.1016/j.atmosenv.2007.09.060; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; *ESD, 2008, EC SURV DELH ESD 200, pCH8; Gurjar BR, 2008, ATMOS ENVIRON, V42, P1593, DOI 10.1016/j.atmosenv.2007.10.048; Gurjar BR, 2005, ATMOS ENVIRON, V39, P391, DOI 10.1016/j.atmosenv.2004.11.002; Gurjar BR, 2004, ATMOS ENVIRON, V38, P5663, DOI 10.1016/j.atmosenv.2004.05.057; Kyle AD, 2002, ENVIRON HEALTH PERSP, V110, P95; Lawrence MG, 2007, ATMOS CHEM PHYS, V7, P3969; Madronich S, 2006, ATMOS ENVIRON, V40, P6012, DOI 10.1016/j.atmosenv.2005.08.047; Mage D, 1996, ATMOS ENVIRON, V30, P681, DOI 10.1016/1352-2310(95)00219-7; MOLINA LT, 2004, J AIR WASTE MANAGE A; Molina MJ, 2004, J AIR WASTE MANAGE, V54, P644; Ostro B, 2009, ENVIRON HEALTH PERSP, V117, P475, DOI 10.1289/ehp.11848; Poloniecki JD, 1997, OCCUP ENVIRON MED, V54, P535; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Rothman K. J, 2008, MODERN EPIDEMIOLOGY, p[758, 53, 136, 160, 214]; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; Sunyer J, 1997, THORAX, V52, P760; Touloumi G, 1997, AM J EPIDEMIOL, V146, P177; United Nations, 2004, WORLD URB PROSP 2003; VOSTAL JJ, 1994, ENVIRON HEALTH PERSP, V102, P101, DOI 10.2307/3431937; World Health Organization, 2000, WHO REG PUBL EUR SER, V91; *WHO, 1997, ENV HLTH CRIT 188 NI; WHO, 2003, HLTH ASP AIR POLL PA; WHO, 2006, WHO AIR QUAL GUID PA; The World Health Organization, 1987, WHO EUR SER, V23; WHO (World Health Organization), 1999, WH REG PUBL EUR SER, V85, P43; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608	33	97	98	12	86	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	NOV	2010	44	36					4606	4613		10.1016/j.atmosenv.2010.08.011		8	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	672FO	WOS:000283568600010		
J	Simons, FER				Simons, F. Estelle R.			Anaphylaxis: Recent advances in assessment and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Anaphylaxis; systemic allergic reaction; food allergy; medication allergy; insect venom allergy; epinephrine; adrenaline	INDOLENT SYSTEMIC MASTOCYTOSIS; EPINEPHRINE AUTO-INJECTORS; ORAL TOLERANCE INDUCTION; LONG-TERM MANAGEMENT; INSECT STING ALLERGY; OF-THE-LITERATURE; FOOD ALLERGY; HYPERSENSITIVITY REACTIONS; EMERGENCY-DEPARTMENT; VENOM IMMUNOTHERAPY	The incidence rate of anaphylaxis is increasing, particularly during the first 2 decades of life. Common triggers include foods, medications, and insect stings. Clinical diagnosis is based on a meticulous history of an exposure or event preceding characteristic symptoms and signs, sometimes but not always supported by a laboratory test such as an elevated serum total tryptase level. Physician-initiated investigation of patients with anaphylaxis whose symptoms and signs are atypical sometimes leads to important insights into previously unrecognized triggers and mechanisms. In idiopathic anaphylaxis, in which no trigger can be confirmed by means of skin testing or measurement of specific IgE, the possibility of mastocytosis or a clonal mast cell disorder must be considered in addition to the possibility of a previously unrecognized trigger. Long-term risk reduction in patients with anaphylaxis focuses on optimal management of relevant comorbidities such as asthma and other respiratory diseases, cardiovascular disease, and mastocytosis or a clonal mast cell disorder; avoidance of the relevant confirmed allergen trigger; and relevant immunomodulation such as medication desensitization, venom immunotherapy, and possibly in the future, immunotherapy with food. Emergency preparedness for recurrence of anaphylaxis in community settings includes having epinephrine (adrenaline) autoinjectors available, knowing when and how to use them, and having a written, personalized anaphylaxis emergency action plan and up-to-date medical identification. Randomized controlled trials of the pharmacologic interventions used in an acute anaphylaxis episode are needed. (J Allergy Clin Immunol 2009;124:625-36.)	[Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; [Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3T 2N2, Canada	Simons, FER (reprint author), FAAAAI,Room FE125,820 Sherbrook St, Winnipeg, MB R3A 1R9, Canada.	lmcniven@hsc.mb.ca			Canadian Institutes of Health Research	Dr. Simons has received research support from the Canadian Institutes of Health Research, and is a member of advisory boards for the Food Allergy and Anaphylaxis Network, Dey, Intelliject, ALK-Abello, and Sciele.	Alrasbi M, 2007, ALLERGY, V62, P838, DOI 10.1111/j.1398-9995.2007.01434.x; Astier C, 2009, ALLERGY, V64, P819, DOI 10.1111/j.1398-9995.2009.01980.x; Basagana M, 2008, J ALLERGY CLIN IMMUN, V121, P233, DOI 10.1016/j.jaci.2007.10.008; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; BONADONNA P, 2009, J ALLERGY CLIN IMMUN, V123, P690; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Brockow K, 2008, ALLERGY, V63, P226, DOI 10.1111/j.1398-9995.2007.01569.x; Brotherton JML, 2008, CAN MED ASSOC J, V179, P525, DOI 10.1503/cmaj.080916; Burks AW, 2008, J ALLERGY CLIN IMMUN, V121, P1344, DOI 10.1016/j.jaci.2008.02.037; Carter MC, 2007, J ALLERGY CLIN IMMUN, V119, P1550, DOI 10.1016/j.jaci.2007.03.032; Castells MC, 2008, J ALLERGY CLIN IMMUN, V122, P574, DOI 10.1016/j.jaci.2008.02.044; Celik W, 2009, MIDDLETONS ALLERGY P, P1205; Cerecedo I, 2008, J ALLERGY CLIN IMMUN, V122, P589, DOI 10.1016/j.jaci.2008.06.040; Chaudhuri K, 2008, INT J OBSTET ANESTH, V17, P350, DOI 10.1016/j.ijoa.2008.05.002; Cheifetz A, 2003, AM J GASTROENTEROL, V98, P1315, DOI 10.1016/S0002-9270(03)00231-4; Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943; Clark S, 2007, IMMUNOL ALLERGY CLIN, V27, P145, DOI 10.1016/j.iac.2007.03.002; Clark S, 2006, ANN EPIDEMIOL, V16, P696, DOI 10.1016/j.annepidem.2005.12.003; Commins SP, 2009, J ALLERGY CLIN IMMUN, V123, P426, DOI 10.1016/j.jaci.2008.10.052; Cox L, 2007, J ALLERGY CLIN IMMUN, V120, P1373, DOI 10.1016/j.jaci.2007.09.032; de Graaf DC, 2009, J PROTEOMICS, V72, P145, DOI 10.1016/j.jprot.2009.01.017; de Olano DG, 2007, CLIN EXP ALLERGY, V37, P1547, DOI 10.1111/j.1365-2222.2007.02804.x; De Olano DG, 2008, J ALLERGY CLIN IMMUN, V121, P519, DOI 10.1016/j.jaci.2007.11.010; Decker WW, 2008, J ALLERGY CLIN IMMUN, V122, P1161, DOI 10.1016/j.jaci.2008.09.043; Du Toit G, 2007, PEDIATR ALLERGY IMMU, V18, P455, DOI 10.1111/j.1399-3038.2007.00599.x; Estelle F, 2006, J ALLERGY CLIN IMMUN, V117, P367, DOI 10.1016/j.jaci.2005.12.002; Fernando Suran L, 2009, J Pediatr, V154, P148, DOI 10.1016/j.jpeds.2008.06.033; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Freeman TM, 2004, NEW ENGL J MED, V351, P1978, DOI 10.1056/NEJMcp042013; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 1997, J ALLERGY CLIN IMMUN, V100, P760, DOI 10.1016/S0091-6749(97)70270-7; Greenberger PA, 2007, IMMUNOL ALLERGY CLIN, V27, P273, DOI 10.1016/j.iac.2007.03.009; Greenberger PA, 2007, ANN ALLERG ASTHMA IM, V98, P252; Greenhawt MJ, 2009, J ALLERGY CLIN IMMUN, V124, P323, DOI 10.1016/j.jaci.2009.05.028; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, p[292, 300, e1]; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Kontou-Fili K, 2008, ALLERGY, V63, P376, DOI 10.1111/j.1398-9995.2007.01604.x; Korhonen H, 2009, J EXP MED, V206, P411, DOI 10.1084/jem.20082150; Kuehn A, 2009, J ALLERGY CLIN IMMUN, V123, P708, DOI 10.1016/j.jaci.2008.12.012; Lang DM, 2008, CURR ALLERGY ASTHM R, V8, P37, DOI 10.1007/s11882-008-0008-8; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Lieberman P, 2005, ANN ALLERG ASTHMA IM, V95, P217; Lieberman P, 2007, ANN ALLERG ASTHMA IM, V98, P519; Lieberman PL, 2009, MIDDLETONS ALLERGY P, P1027; LIEW WK, 2009, J ALLERGY CLIN IMMUN, V123, P43442; Limb SL, 2007, J ALLERGY CLIN IMMUN, V120, P1378, DOI 10.1016/j.jaci.2007.09.022; Lin RY, 2008, ANN ALLERG ASTHMA IM, V101, P387, DOI 10.1016/S1081-1206(10)60315-8; Longo G, 2008, J ALLERGY CLIN IMMUN, V121, P343, DOI 10.1016/j.jaci.2007.10.029; Mehr S, 2007, PEDIATR ALLERGY IMMU, V18, P448, DOI 10.1111/j.1399-3038.2006.00529.x; Moore LM, 2007, ANN ALLERG ASTHMA IM, V98, P92; Muller UR, 2009, CLIN EXP ALLERGY, V39, P620, DOI 10.1111/j.1365-2222.2009.03251.x; Mueller UR, 2007, CURR OPIN ALLERGY CL, V7, P337, DOI 10.1097/ACI.0b013e328259c328; Nishitani N, 2009, INT J DERMATOL, V48, P522, DOI 10.1111/j.1365-4632.2009.03926.x; Nowak-Wegrzyn A, 2009, J ALLERGY CLIN IMMUN, V123, pS365, DOI 10.1016/j.jaci.2009.03.042; Nurmatov U, 2008, J ALLERGY CLIN IMMUN, V122, P353, DOI 10.1016/j.jaci.2008.05.028; Ono E, 2009, CLIN EXP ALLERGY, V39, P72, DOI 10.1111/j.1365-2222.2008.03104.x; Elberink JNG, 2006, CURR OPIN ALLERGY CL, V6, P298, DOI 10.1097/01.all.0000235906.95300.3e; PEAVY RD, 2009, CURR OPIN ALLERGY CL, V8, P310; Peng ZK, 2004, J ALLERGY CLIN IMMUN, V114, P1189, DOI 10.1016/j.jaci.2004.08.014; Pereira B, 2005, J ALLERGY CLIN IMMUN, V116, P884, DOI 10.1016/j.jaci.2005.05.047; Pumphrey RSH, 2007, J ALLERGY CLIN IMMUN, V119, P1018, DOI 10.1016/j.jaci.2007.01.021; Pushparaj PN, 2009, P NATL ACAD SCI USA, V106, P9773, DOI 10.1073/pnas.0901206106; Rawas-Qalaji MM, 2006, J ALLERGY CLIN IMMUN, V117, P398, DOI 10.1016/j.jaci.2005.12.1310; Rezvani M, 2007, IMMUNOL ALLERGY CLIN, V27, P295, DOI 10.1016/j.jac.2007.03.010; SAMPSON HA, 1984, NEW ENGL J MED, V311, P372, DOI 10.1056/NEJM198408093110605; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson Hugh A, 2006, J Allergy Clin Immunol, V117, P391, DOI 10.1016/j.jaci.2005.12.1303; Schwartz LB, 2008, NEW ENGL J MED, V358, P2505, DOI 10.1056/NEJMe0803599; Schwartz LB, 2006, IMMUNOL ALLERGY CLIN, V26, P451, DOI 10.1016/j.iac.2006.05.010; Sheikh A, 2007, ALLERGY, V62, P830, DOI 10.1111/j.1398-9995.2007.01435.x; Sheikh A, 2009, ALLERGY, V64, P204, DOI 10.1111/j.1398-9995.2008.01926.x; Sheikh A, 2008, J ROY SOC MED, V101, P139, DOI 10.1258/jrsm.2008.070306; Sicherer SH, 2009, ANNU REV MED, V60, P261, DOI 10.1146/annurev.med.60.042407.205711; Simons FER, 2008, BRIT MED J, V336, P1141, DOI 10.1136/bmj.39547.452153.80; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, pS2, DOI 10.1016/j.jaci.2007.05.001; Simons FER, 2007, J ALLERGY CLIN IMMUN, V120, P537, DOI 10.1016/j.jaci.2007.06.025; Simons FER, 2007, IMMUNOL ALLERGY CLIN, V27, P231, DOI 10.1016/j.iac.2007.03.007; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P403, DOI 10.1016/S1081-1206(10)60512-1; Simons FER, 2009, ANN ALLERG ASTHMA IM, V102, P282, DOI 10.1016/S1081-1206(10)60332-8; Simons FER, 2009, J ALLERGY CLIN IMMUN, V124, P301, DOI 10.1016/j.jaci.2009.03.050; Simons FER, 2008, J ALLERGY CLIN IMMUN, V122, P1166, DOI 10.1016/j.jaci.2008.10.019; Simons F. E., 2008, J ALLERGY CLIN IMM S, V121, pS402, DOI 10.1016/j.jaci.2007.08.061; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P837, DOI 10.1016/j.jaci.2004.01.079; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Soar J, 2008, RESUSCITATION, V77, P157, DOI 10.1016/j.resuscitation.2008.02.001; Song TT, 2005, ANN ALLERG ASTHMA IM, V94, P539; Srivastava KD, 2009, J ALLERGY CLIN IMMUN, V123, P443, DOI 10.1016/j.jaci.2008.12.1107; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x; Stecher D, 2009, PEDIATRICS, V124, P65, DOI 10.1542/peds.2008-3388; STURM GJ, 2009, ALLERGY; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Vadas P, 2008, NEW ENGL J MED, V358, P28, DOI 10.1056/NEJMoa070030; Wang J, 2008, J ALLERGY CLIN IMMUN, V121, P1219, DOI 10.1016/j.jaci.2007.12.1150; Yamashita Y, 2007, J IMMUNOL, V179, P740; Zanoni G, 2008, J ALLERGY CLIN IMMUN, V122, P1233, DOI 10.1016/j.jaci.2008.09.015	99	97	104	1	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2009	124	4					625	636		10.1016/j.jaci.2009.08.025		12	Allergy; Immunology	Allergy; Immunology	506UV	WOS:000270802800001	19815109	
J	Stieb, DM; Szyszkowicz, M; Rowe, BH; Leech, JA				Stieb, David M.; Szyszkowicz, Mieczyslaw; Rowe, Brian H.; Leech, Judith A.			Air pollution and emergency department visits for cardiac and respiratory conditions: a multi-city time-series analysis	ENVIRONMENTAL HEALTH			English	Article							HEART-RATE-VARIABILITY; ROOM VISITS; HOSPITAL ADMISSIONS; ASTHMA EMERGENCY; PARTICULATE MATTER; PULMONARY-DISEASE; CHILDHOOD ASTHMA; DAILY MORTALITY; SAINT-JOHN; ASSOCIATION	Background: Relatively few studies have been conducted of the association between air pollution and emergency department (ED) visits, and most of these have been based on a small number of visits, for a limited number of health conditions and pollutants, and only daily measures of exposure and response. Methods: A time-series analysis was conducted on nearly 400,000 ED visits to 14 hospitals in seven Canadian cities during the 1990s and early 2000s. Associations were examined between carbon monoxide (CO), nitrogen dioxide (NO(2)), ozone (O(3)), sulfur dioxide (SO(2)), and particulate matter (PM(10) and PM(2.5)), and visits for angina/myocardial infarction, heart failure, dysrhythmia/conduction disturbance, asthma, chronic obstructive pulmonary disease (COPD), and respiratory infections. Daily and 3-hourly visit counts were modeled as quasi-Poisson and analyses controlled for effects of temporal cycles, weather, day of week and holidays. Results: 24-hour average concentrations of CO and NO(2) lag 0 days exhibited the most consistent associations with cardiac conditions (2.1% (95% CI, 0.0-4.2%) and 2.6% (95% CI, 0.2-5.0%) increase in visits for myocardial infarction/angina per 0.7 ppm CO and 18.4 ppb NO(2) respectively; 3.8% (95% CI, 0.7-6.9%) and 4.7% (95% CI, 1.2-8.4%) increase in visits for heart failure). Ozone (lag 2 days) was most consistently associated with respiratory visits (3.2% (95% CI, 0.3-6.2%), and 3.7% (95% CI,-0.5-7.9%) increases in asthma and COPD visits respectively per 18.4 ppb). Associations tended to be of greater magnitude during the warm season (April-September). In particular, the associations of PM(10) and PM(2.5) with asthma visits were respectively nearly three-and over fourfold larger vs. all year analyses (14.4% increase in visits, 95% CI, 0.2-30.7, per 20.6 mu g/m(3) PM(10) and 7.6% increase in visits, 95% CI, 5.1-10.1, per 8.2 mu g/m(3) PM(2.5)). No consistent associations were observed between three hour average pollutant concentrations and same-day three hour averages of ED visits. Conclusion: In this large multicenter analysis, daily average concentrations of CO and NO(2) exhibited the most consistent associations with ED visits for cardiac conditions, while ozone exhibited the most consistent associations with visits for respiratory conditions. PM(10) and PM(2.5) were strongly associated with asthma visits during the warm season.	[Stieb, David M.; Szyszkowicz, Mieczyslaw; Leech, Judith A.] Hlth Canada, Healthy Environm & Consumer Safety Branch, Populat Studies Div, Ottawa, ON K1A 0K9, Canada; [Stieb, David M.] Univ Ottawa, Dept Epidemiol & Community Hlth, Ottawa, ON K1H 8M5, Canada; [Rowe, Brian H.] Univ Alberta, Dept Emergency Med, Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada; [Leech, Judith A.] Univ Ottawa, Ottawa Hosp, Dept Med, Ottawa, ON K1Y 4E9, Canada	Stieb, DM (reprint author), Hlth Canada, Healthy Environm & Consumer Safety Branch, Populat Studies Div, Postal Locator 4903C,269 Laurier Ave W, Ottawa, ON K1A 0K9, Canada.	dave_stieb@hc-sc.gc.ca; mietek_szyszkowicz@hc-sc.gc.ca; brian.rowe@ualberta.ca; jleech@ottawahospital.on.ca	Wang, Linden/M-6617-2014		Health Canada and Environment Canada	Drs. Robert Beveridge, Eric Grafstein, Simon Kingsley, Michael Schull, Douglas Sinclair and Bernard Unger provided emergency department visit data. Serge Beaulieu of Atlantic Health Sciences Corporation, Stacey Ackroyd of Dalhousie University, Chris Houston from Information Services, Capital Health and Virginia Willis, from the Emergency Medicine Research Group (EMeRG), assisted with data access. Anne Smith-Doiron assisted with the air pollution data. The study was funded by Health Canada and Environment Canada.	Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dockery DW, 2005, ENVIRON HEALTH PERSP, V113, P670, DOI 10.1289/ehp.7767; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Erbas B, 2005, INT J ENVIRON HEAL R, V15, P11, DOI 10.1080/09603120400018717; Farhat SCL, 2005, BRAZ J MED BIOL RES, V38, P227, DOI 10.1590/S0100-879X2005000200011; Galan I, 2003, EUR RESPIR J, V22, P802, DOI 10.1183/09031936.03.00013003; Goldberg MS, 2003, ENVIRON RES, V91, P8, DOI 10.1016/S0013-9351(02)00022-1; Jaffe DH, 2003, ENVIRON RES, V91, P21, DOI 10.1016/S0013-9351(02)00004-X; Jalaludin Bin, 2006, J Expo Sci Environ Epidemiol, V16, P225, DOI 10.1038/sj.jea.7500451; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; Lin CA, 2003, ENVIRON RES, V92, P57, DOI 10.1016/S0013-9351(02)00054-3; Metzger KB, 2004, EPIDEMIOLOGY, V15, P46, DOI 10.1097/01.EDE.0000101748.28283.97; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 2004, NEW ENGL J MED, V351, P1721, DOI 10.1056/NEJMoa040203; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Pope CA, 2004, ENVIRON HEALTH PERSP, V112, P339, DOI 10.1289/ehp.6588; Rowe Brian H, 2006, CJEM, V8, P417; Samoli E, 2008, ENVIRON HEALTH PERSP, V116, P1480, DOI 10.1289/ehp.11345; Slaughter JC, 2005, J EXPO ANAL ENV EPID, V15, P153, DOI 10.1038/sj.jea.7500382; Stieb D M, 2000, Can J Public Health, V91, P107; Stieb DM, 1998, AM J EPIDEMIOL, V148, P666; Stieb DM, 2000, J EXPO ANAL ENV EPID, V10, P461, DOI 10.1038/sj.jea.7500112; Stieb DM, 2002, J AIR WASTE MANAGE, V52, P470; Stieb DM, 1996, ENVIRON HEALTH PERSP, V104, P1354, DOI 10.2307/3432974; Tenias JM, 2002, ARCH ENVIRON HEALTH, V57, P41; Tolbert PE, 2007, J EXPO SCI ENV EPID, V17, pS29, DOI 10.1038/sj.jes.7500625; *US EPA, 2008, LIST DES REF EQ METH; Villeneuve PJ, 2006, EUR J EPIDEMIOL, V21, P689, DOI 10.1007/s10654-006-9050-9; Villeneuve PJ, 2005, INT J BIOMETEOROL, V50, P48, DOI 10.1007/s00484-005-0262-6; Wheeler A, 2006, ENVIRON HEALTH PERSP, V114, P560, DOI 10.1289/ehp.8337; Wilson AM, 2005, ENVIRON RES, V97, P312, DOI 10.1016/j.envres.2004.07.010	36	97	101	7	33	BIOMED CENTRAL LTD	LONDON	CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1476-069X			ENVIRON HEALTH-GLOB	Environ. Health	JUN 10	2009	8								25	10.1186/1476-069X-8-25		13	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	472XE	WOS:000268165500001	19515235	
J	Schildcrout, JS; Sheppard, L; Lumley, T; Slaughter, JC; Koenig, JQ; Shapiro, GG				Schildcrout, Jonathan S.; Sheppard, Lianne; Lumley, Thomas; Slaughter, James C.; Koenig, Jane Q.; Shapiro, Gail G.			Ambient air pollution and asthma exacerbations in children: An eight-city analysis	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						air pollution; asthma; carbon monoxide; nitrogen dioxide; ozone; pediatrics; sulfur dioxide	LONGITUDINAL DATA-ANALYSIS; AFRICAN-AMERICAN CHILDREN; PARTICULATE MATTER; RESPIRATORY HEALTH; INHALED ALLERGEN; SYMPTOM SEVERITY; NITROGEN-DIOXIDE; OZONE EXPOSURE; MEDICATION USE; MEXICO-CITY	The authors investigated the relation between ambient concentrations of five of the Environmental Protection Agency's criteria pollutants and asthma exacerbations (daily symptoms and use of rescue inhalers) among 990 children in eight North American cities during the 22-month prerandomization phase (November 1993-September 1995) of the Childhood Asthma Management Program. Short-term effects of carbon monoxide, nitrogen dioxide, particulate matter less than 10 mu m in aerodynamic diameter (PM10), sulfur dioxide, and warm-season ozone were examined in both one-pollutant and two-pollutant models, using lags of up to 2 days. Lags in carbon monoxide and nitrogen dioxide were positively associated with both measures of asthma exacerbation, and the 3-day moving sum of sulfur dioxide levels was marginally related to asthma symptoms. PM10 and ozone were unrelated to exacerbations. The strongest effects tended to be seen with 2-day lags, where a 1-parts-per-million change in carbon monoxide and a 20-parts-per-billion change in nitrogen dioxide were associated with symptom odds ratios of 1.08 (95% confidence interval (CI): 1.02, 1.15) and 1.09 (95% CI: 1.03, 1.15), respectively, and with rate ratios for rescue inhaler use of 1.06 (95% CI: 1.01, 1.10) and 1.05 (95% CI: 1.01, 1.09), respectively. The authors believe that the observed carbon monoxide and nitrogen dioxide associations can probably be attributed to mobile-source emissions, though more research is required.	Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA; Univ Washington, Sch Publ Hlth, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Environm Protect Agcy, NW Res Ctr Particulate Air Pollut & Hlth, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth, Dept Environm Hlth, Seattle, WA 98195 USA; Univ N Carolina, Sch Publ Hlth, Dept Biostat, Chapel Hill, NC USA; Univ N Carolina, Sch Med, Dept Pediat, Chapel Hill, NC USA	Schildcrout, JS (reprint author), Vanderbilt Univ, Sch Med, Dept Biostat, S-2323 Med Ctr N, Nashville, TN 37232 USA.	jonathan.schildcrout@vanderbilt.edu		Slaughter, James/0000-0002-8770-980X	NHLBI NIH HHS [N01-HR-16047, N01-HR-16044, N01-HR-16045, N01-HR-16046, N01-HR-16048, N01-HR-16049, N01-HR-16050, N01-HR-16051, N01-HR-16052]		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bernstein JA, 2004, J ALLERGY CLIN IMMUN, V114, P1116, DOI 10.1016/j.jaci.2004.08.030; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Dey Achintya N., 2005, VITAL HLTH STAT, V10, P1; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; LUMLEY T, 2005, RMETA META ANAL R PA; LUMLEY T, 2004, MITOOLS TOOLS MULTIP; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Neuhaus JM, 1998, BIOMETRICS, V54, P638, DOI 10.2307/3109770; Norris G, 2000, THORAX, V55, P466, DOI 10.1136/thorax.55.6.466; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; OSTRO BD, 1995, INHAL TOXICOL, V7, P711, DOI 10.3109/08958379509014475; PEPE MS, 1994, COMMUN STAT SIMULAT, V23, P939, DOI 10.1080/03610919408813210; Peters A, 1996, AM J EPIDEMIOL, V144, P570; R Development Core Team, 2006, R LANG ENV STAT COMP; Romieu I, 1997, ARCH ENVIRON HEALTH, V52, P368; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Rubin DB, 1987, MULTIPLE IMPUTATION; Sarnat JA, 2005, EPIDEMIOLOGY, V16, P385, DOI 10.1097/01.ede.0000155505.04775.33; SAS Institute Inc, 2001, SAS STAT US GUID REL; Schildcrout JS, 2005, BIOSTATISTICS, V6, P633, DOI 10.1093/biostatistics/kxi033; Sheppard L, 2003, BIOSTATISTICS, V4, P265, DOI 10.1093/biostatistics/4.2.265; Slaughter JC, 2005, J EXPO ANAL ENV EPID, V15, P153, DOI 10.1038/sj.jea.7500382; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Szefler S, 2000, NEW ENGL J MED, V343, P1054; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Timonen KL, 1997, AM J RESP CRIT CARE, V156, P546; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; Vedal S, 1998, AM J RESP CRIT CARE, V157, P1034; Wang Li Yan, 2005, Prev Chronic Dis, V2, pA11; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; Weiss KB, 2001, J ALLERGY CLIN IMMUN, V107, P3, DOI 10.1067/mai.2001.112262; Yan J, 2004, STAT MED, V23, P859, DOI 10.1002/sim.1650; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	41	97	100	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	SEP 15	2006	164	6					505	517		10.1093/aje/kwj225		13	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	085FG	WOS:000240588300001	16798793	
J	Zock, JP; Heinrich, J; Jarvis, D; Verlato, G; Norback, D; Plana, E; Sunyer, J; Chinn, S; Olivieri, M; Soon, A; Villani, S; Ponzio, M; Dahlman-Hoglund, A; Svanes, C; Luczynska, C				Zock, Jan-Paul; Heinrich, Joachim; Jarvis, Deborah; Verlato, Giuseppe; Norback, Dan; Plana, Estel; Sunyer, Jordi; Chinn, Susan; Olivieri, Mario; Soon, Argo; Villani, Simona; Ponzio, Michela; Dahlman-Hoglund, Anna; Svanes, Cecilie; Luczynska, Christina		Indoor Working Grp European Comm	Distribution and determinants of house dust mite allergens in Europe: the European Community Respiratory Health Survey II	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mites; allergens; housing; risk factors; geographic; ECRHS	ASTHMA; PREVALENCE; DER-P-1; HOMES; MATTRESSES; SYMPTOMS; HUMIDITY; EXPOSURE	Background: Several studies in European homes have described allergen levels from the house dust mite species Dermatophagoides pteronyssinus and to a lesser extent Dermatophagoides farinae, but geographic comparisons of exposure levels and risk factors have been hampered by a lack of standardized methods. Objective: To study the distribution and determinants of the major house dust mite allergens Der p 1 and Der f 1 in 10 European countries using a common protocol. Methods: During home visits with 3580 participants of the European Community Respiratory Health Survey II from 22 study centers, mattress dust was sampled and analyzed for Der p 1, Der f 1, and Der 2 allergen. Information on housing characteristics was obtained by both observations and interview. Results: Der 1 and Der 2 allergens were detectable (>= 0.1 mu g/g) in 68% and 53% of the samples, respectively. Large differences in allergen levels between study centers were observed, and geographic patterns for Der p 1 and Der f 1 were different. Low winter temperatures reduced Der p 1 rather than Der f 1. Important risk factors for high allergen levels included an older mattress, a lower floor level of the bedroom, limited ventilation of the bedroom, and dampness for Der p 1 but not for Der f 1. Conclusion: There are large qualitative and quantitative differences of house dust mite allergen levels in Europe, which can partly be explained by geographic and housing characteristics. Clinical implications: Mite allergen exposure may be reduced by replacing the mattress regularly and increasing ventilation of the bedroom, particularly in winter.	Municipal Inst Med Res, Ctr Res Environm Epidemiol, Barcelona, Spain; Inst Epidemiol, Natl Res Ctr Environm & Hlth, Neuherberg, Germany; Univ London Imperial Coll Sci & Technol, Resp Epidemiol & Publ Hlth Grp, Natl Heart & Lung Inst, London, England; Univ Verona, Dept Med & Publ Hlth, I-37100 Verona, Italy; Uppsala Univ, Dept Med Sci Occupat & Environm Med, Uppsala, Sweden; Kings Coll London, Dept Publ Hlth Sci, London WC2R 2LS, England; Univ Verona, Unit Occupat Med, I-37100 Verona, Italy; Univ Tartu, Dept Publ Hlth, EE-50090 Tartu, Estonia; Univ Pavia, Dept Hlth Sci, Sect Epidemiol & Med Stat, I-27100 Pavia, Italy; Sahlgrens Univ Hosp, Dept Occupat & Environm Med, Gothenburg, Sweden; Univ Bergen, Dept Thorac Med, Inst Med, Bergen, Norway	Zock, JP (reprint author), IMIM, Dr Aiguader 80, E-08003 Barcelona, Spain.	jpzock@imim.es	; SESM, SESM/C-1440-2008; Jarvis, Deborah/E-6494-2011; Hervas, Daniel/H-4854-2011; Sanchez-Ramos, Jose Luis/G-1259-2011; Ciccone, Giovannino/K-3136-2016; Burgos, Felip/E-5734-2015; Sunyer, J/G-6909-2014	Rolla, Giovanni/0000-0001-5997-7172; Norback, Dan/0000-0002-5174-6668; /0000-0003-2517-6515; Sanchez-Ramos, Jose Luis/0000-0001-7187-9989; Ciccone, Giovannino/0000-0001-7644-9574; Burgos, Felip/0000-0002-4938-4581; Sunyer, J/0000-0002-2602-4110; ROMANO, Canzio/0000-0001-5294-9793; Bono, Roberto/0000-0002-2471-6594; Basagana, Xavier/0000-0002-8457-1489; Corsico, Angelo Guido/0000-0002-8716-4694	NHLBI NIH HHS [R01 HL62633-01]; NIEHS NIH HHS [5P30 ES07048]		Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Arlian LG, 2003, IMMUNOL ALLERGY CLIN, V23, P443, DOI 10.1016/S0889-8561(03)00005-5; Brunekreef B, 2005, ALLERGY, V60, P1083, DOI 10.1111/j.1398-9995.2005.00881.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P461; El Sharif N, 2004, ALLERGY, V59, P623, DOI 10.1111/j.1398-9995.2004.00441.x; Gehring U, 2005, ALLERGY, V60, P1079, DOI 10.1111/j.1398-9995.2005.00872.x; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Bleda Hernandez M.J., 2002, GAC SANIT, V16, P188; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; LINTNER TJ, 1993, J ALLERGY CLIN IMMUN, V91, P862, DOI 10.1016/0091-6749(93)90343-E; Lubin JH, 2004, ENVIRON HEALTH PERSP, V112, P1691, DOI 10.1289/ehp.7199; Luczynska C, 1998, CLIN EXP ALLERGY, V28, P1201; Macan J, 2003, ALLERGY, V58, P780, DOI 10.1034/j.1398-9995.2003.00210.x; Melki IS, 2004, J EPIDEMIOL COMMUN H, V58, P476, DOI 10.1136/jech.2003.012690; Mihrshahi S, 2002, ALLERGY, V57, P137, DOI 10.1034/j.1398-9995.2002.5720999.x; Moscato G, 2000, ALLERGY, V55, P873, DOI 10.1034/j.1398-9995.2000.00584.x; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628; O'Connor GT, 2005, J ALLERGY CLIN IMMUN, V116, P26, DOI 10.1016/j.jaci.2005.02.013; Recer GM, 2004, CLIN EXP ALLERGY, V34, P268, DOI 10.1111/j.1365-2222.2004.01863.x; Schei MA, 2002, ALLERGY, V57, P538, DOI 10.1034/j.1398-9995.2002.23433.x; Sidenius KE, 2002, ANN AGR ENV MED, V9, P33; Simpson A, 2001, CLIN EXP ALLERGY, V31, P803, DOI 10.1046/j.1365-2222.2001.01110.x; van Strien RT, 2004, ALLERGY, V59, P645, DOI 10.1111/j.1398-9995.2004.00470.x; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P843; Warner A, 1998, ALLERGY, V53, P698, DOI 10.1111/j.1398-9995.1998.tb03956.x; Wickens K, 2004, PEDIATR ALLERGY IMMU, V15, P55, DOI 10.1046/j.0905-6157.2003.00100.x; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383	29	97	105	0	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2006	118	3					682	690		10.1016/j.jaci.2006.04.060		9	Allergy; Immunology	Allergy; Immunology	086BV	WOS:000240649000022	16950288	
J	Nigo, YI; Yamashita, M; Hirahara, K; Shinnakasu, R; Inami, M; Kimura, M; Hasegawa, A; Kohno, Y; Nakayama, T				Nigo, YI; Yamashita, M; Hirahara, K; Shinnakasu, R; Inami, M; Kimura, M; Hasegawa, A; Kohno, Y; Nakayama, T			Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						cytokine; GATA1; mast cell; lipopolysaccharide; bone-marrow-derived mast cells	ENDOTOXIN EXPOSURE; GENE LOCUS; HISTONE HYPERACETYLATION; INNATE IMMUNITY; CUTTING EDGE; TNF-ALPHA; T-CELLS; ASTHMA; DIFFERENTIATION; LIPOPOLYSACCHARIDE	In a mouse experimental asthma model, the administration of bacterial lipopolysaccharide (LIPS), particularly at low doses, enhances the levels of ovalbumin (OVA)-induced eosinophilic airway inflammation. In an effort to clarify the cellular and molecular basis for the LPS effect, we demonstrate that the OVA-induced eosinophilic inflammation in the lung is dramatically increased by the administration of LPS in wild-type mice, whereas such increase was not observed in mast-cell-deficient mice or Toll-like receptor (TLR)4-deficient mice. Adoptive transfer of bone-marrow-derived mast cells (BMMCs) from wild-type, but not from TLR4-deficient, mice restored the increased eosinophilic inflammation in mast-cell-deficient mice. Wild-type BMMCs pretreated with LPS in vitro also reconstituted the eosinophilic inflammation. Moreover, in vitro analysis revealed that the treatment of BMMCs with LPS resulted in NF-kappa B activation, sustained up-regulation of GATA1 and -2 expression, and increased the capability to produce IL-5 and -13. Dramatic increases in the expression of IL-5 and -13 and Eotaxin 2 were detected in LIPS-treated BMMCs after costimulation with LIPS and IgE/Ag. Overexpression of GATA1, but not GATA2, in MC9 mast cells resulted in increased transcriptional activity of IL-4, -5, and -13. Furthermore, the levels of transcription of Th2 cytokines in BMMCs were decreased by the introduction of small interfering RNA for GATA1. Thus, mast cells appear to control allergic airway inflammation after their activation and modulation through TLR4-mediated induction of GATA1 and subsequent increase in Th2 cytokine production.	Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, Chiba 2608670, Japan; Chiba Univ, Grad Sch Med, Dept Pediat, Chuo Ku, Chiba 2608670, Japan	Nakayama, T (reprint author), Chiba Univ, Grad Sch Med, Dept Immunol, Chuo Ku, H3,1-8-1 Inohana, Chiba 2608670, Japan.	tnakayama@faculty.chiba-u.jp	Nakayama, Toshinori/E-1067-2017; Hirahara, Kiyoshi/E-2460-2017	Nakayama, Toshinori/0000-0002-1434-2007; Hirahara, Kiyoshi/0000-0002-9128-9449			Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Boyce JA, 2003, PROSTAG LEUKOTR ESS, V69, P195, DOI 10.1016/S0952-3278(03)00081-4; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brightling CE, 2003, CLIN EXP ALLERGY, V33, P550, DOI 10.1046/j.1365-2222.2003.01636.x; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Echtenacher B, 1996, NATURE, V381, P75, DOI 10.1038/381075a0; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; Gern JE, 2000, J ALLERGY CLIN IMMUN, V105, pS497; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Harigae H, 1998, GENES CELLS, V3, P39, DOI 10.1046/j.1365-2443.1998.00166.x; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Hoshino K, 1999, J IMMUNOL, V162, P3749; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Kamata T, 2003, J CLIN INVEST, V111, P109, DOI 10.1172/JCI200315719; Kimura M, 2001, IMMUNITY, V15, P275, DOI 10.1016/S1074-7613(01)00182-0; Kimura MY, 2005, J EXP MED, V201, P397, DOI 10.1084/jem.20040733; KITAMURA Y, 1978, BLOOD, V52, P447; Lee HJ, 1998, J IMMUNOL, V160, P2343; Lefort J, 1998, J IMMUNOL, V161, P474; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Malaviya R, 1996, NATURE, V381, P77, DOI 10.1038/381077a0; Masuda A, 2002, J IMMUNOL, V169, P3801; McCurdy JD, 2001, J LEUKOCYTE BIOL, V70, P977; McLachlan JB, 2003, NAT IMMUNOL, V4, P1199, DOI 10.1038/ni1005; Medzhitov R, 2001, NAT REV IMMUNOL, V1, P135, DOI 10.1038/35100529; METCALFE DD, 1981, CRC CR REV IMMUNOL, V3, P23; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Migliaccio AR, 2003, J EXP MED, V197, P281, DOI 10.1084/jem.20021149; Okumura S, 2003, BLOOD, V102, P2547, DOI 10.1182/blood-2002-12-3929; Omori M, 2003, IMMUNITY, V19, P281, DOI 10.1016/S1074-7613(03)00210-3; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; SCHWARTZ LB, 1984, PROG ALLERGY, V34, P271; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; Shibata Y, 2002, J IMMUNOL, V169, P2134; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; Supajatura V, 2001, J IMMUNOL, V167, P2250; Takeda K, 1996, NATURE, V380, P627, DOI 10.1038/380627a0; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Weiss DL, 2001, IMMUNOL REV, V179, P35, DOI 10.1034/j.1600-065X.2001.790104.x; Yamasaki S, 2004, BLOOD, V103, P3093, DOI 10.1182/blood-2003-08-2944; Yamashita M, 2005, J BIOL CHEM, V280, P29409, DOI 10.1074/jbc.M502333200; Yamashita M, 2002, J BIOL CHEM, V277, P42399, DOI 10.1074/jbc.M205876200; Zhang DH, 1998, J IMMUNOL, V161, P3817	52	97	110	1	5	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	FEB 14	2006	103	7					2286	2291		10.1073/pnas.0510685103		6	Multidisciplinary Sciences	Science & Technology - Other Topics	013LU	WOS:000235411600052	16461458	
J	Prussin, C; Metcalfe, DD				Prussin, C; Metcalfe, DD			IgE, mast cells, basophils, and eosinophils	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						IgE; IgE receptor; mast cell; basophil; eosinophil	FC-EPSILON-RI; HOST-DEFENSE; HYPEREOSINOPHILIC SYNDROME; ASTHMA; RECEPTOR; ACTIVATION; EXPRESSION; DEFICIENT; SECRETION; ROLES	IgE, mast cells, basophils, and eosinophils constitute essential elements in allergic inflammation. Allergen-specific IgE, synthesized in response to allergens in the environment, becomes fixed to Fc epsilon RI on the membranes of mast cells and basophils. Aggregation of receptor-bound IgE molecules on re-exposure to specific allergen results in the production of mediators that produce the allergic response. Principal among the cells drawn to sites of mediator release is the eosinophil.	NIAID, LAD, NIH, Bethesda, MD 20892 USA	Metcalfe, DD (reprint author), NIAID, LAD, NIH, Bldg 10,Room 11C205,10 Ctr Dr,MSC 1881, Bethesda, MD 20892 USA.	dmetcalfe@niaid.nih.gov		Prussin, Calman/0000-0002-3917-3326			Adamko D, 2003, CURR OPIN PHARMACOL, V3, P227, DOI 10.1016/S1471-4892(03)00040-7; Akin C, 2004, ANNU REV MED, V55, P419, DOI 10.1146/annurev.med.55.091902.103822; Bieneman AP, 2005, J ALLERGY CLIN IMMUN, V115, P295, DOI 10.1016/j.jaci.2004.10.018; Bochner BS, 2001, IMMUNOL REV, V179, P5, DOI 10.1034/j.1600-065X.2001.790101.x; Bochner BS, 2000, J ALLERGY CLIN IMMUN, V106, P292; CAMERON L, 2003, MIDDLETONS ALLERGY P, P87; Devouassoux G, 1999, J ALLERGY CLIN IMMUN, V104, P811; Galli SJ, 2002, INT J HEMATOL, V75, P363, DOI 10.1007/BF02982125; GALLI SJ, 2001, WILLIAMS HEMATOLOGY, P801; Garman SC, 1999, ANNU REV IMMUNOL, V17, P973, DOI 10.1146/annurev.immunol.17.1.973; Gotlib J, 2004, BLOOD, V103, P2879, DOI 10.1182/blood-2003-06-1824; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; HAMILTON RG, 2001, CLIN IMMUNOLOGY, DOI UNSP 124.1-124.14; Humbles AA, 2004, SCIENCE, V305, P1776, DOI 10.1126/science.1100283; Kay AB, 2004, IMMUNOL ALLERGY CLIN, V24, P645, DOI 10.1016/j.iac.2004.06.007; Kepley CL, 2000, J IMMUNOL, V165, P5913; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; KITA H, 2001, CLIN IMMUNOLOGY PRIN; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Kulka M, 2004, J ALLERGY CLIN IMMUN, V114, P174, DOI 10.1016/j.jaci.2004.03.049; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Marone G, 2005, TRENDS IMMUNOL, V26, P25, DOI 10.1016/j.it.2004.10.010; Mattes Joerg, 2003, Current Drug Targets - Inflammation and Allergy, V2, P169, DOI 10.2174/1568010033484214; Mitre E, 2004, J IMMUNOL, V172, P2439; Odemuyiwa SO, 2004, J IMMUNOL, V173, P5909; Oettgen HC, 2001, J ALLERGY CLIN IMMUN, V107, P429, DOI 10.1067/mai.2001.113759; Phillips C, 2003, J LEUKOCYTE BIOL, V73, P165, DOI 10.1189/jlb.0702356; Rosenberg HF, 2001, J LEUKOCYTE BIOL, V70, P691; Saini SS, 2000, J ALLERGY CLIN IMMUN, V106, P514, DOI 10.1067/mai.2000.108431; Saini SS, 2002, CURR OPIN IMMUNOL, V14, P694, DOI 10.1016/S0952-7915(02)00404-1; Schroeder JT, 2001, ADV IMMUNOL, V77, P93, DOI 10.1016/S0065-2776(01)77015-0; Schwartz LB, 2002, CL ALLER IM, V16, P3; Shi HZ, 2004, J LEUKOCYTE BIOL, V76, P520, DOI 10.1189/jlb.0404228; Tkaczyk C, 2002, MOL IMMUNOL, V38, P1289, DOI 10.1016/S0161-5890(02)00077-9	34	97	107	1	9	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2006	117	2		1			S450	S456		10.1016/j.jaci.2005.11.016		7	Allergy; Immunology	Allergy; Immunology	019VS	WOS:000235865400006	16455345	
J	Schram-Bijkerk, D; Doekes, G; Douwes, J; Boeve, M; Riedler, J; Ublagger, E; Mutius, E; Benz, MR; Pershagen, G; Hage, M; Scheynius, A; Braun-Fahrlander, C; Waser, M; Brunekreef, B				Schram-Bijkerk, D; Doekes, G; Douwes, J; Boeve, M; Riedler, J; Ublagger, E; Mutius, E; Benz, MR; Pershagen, G; Hage, M; Scheynius, A; Braun-Fahrlander, C; Waser, M; Brunekreef, B		PARSIFAL Study Grp	Bacterial and fungal agents in house dust and wheeze in children: the PARSIFAL study	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; beta(1,3)-glucans; endotoxin; farm; fungal extracellular polysaccharides	EXTRACELLULAR POLYSACCHARIDES; ALLERGIC SENSITIZATION; CULTURABLE FUNGI; HAY-FEVER; ASTHMA; FARM; ENDOTOXIN; EXPOSURE; ATOPY; (1->3)-BETA-D-GLUCAN	Background Growing up on a farm and an anthroposophic lifestyle are associated with a lower prevalence of allergic diseases in childhood. This might be related to increased inhalatory exposure to microbial agents. Objective To assess the association between microbial agents in house dust and atopic wheeze in farm children, Steiner school children and reference children. Methods Levels of bacterial endotoxin, fungal beta(1,3)-glucans and fungal extracellular polysaccharides (EPS) in mattress and living room floor dust were measured in a population of 270 atopic (=Phadiatop-positive) children with self-reported wheezing, including 168 current atopic wheezers, and 441 non-atopic, non-symptomatic controls. These children were selected from a cross-sectional study in five European countries. Results In the study population as a whole, average levels of mattress dust endotoxin, EPS and glucans were slightly (1.1-1.2-fold; P < 0.10) higher in control children than in atopic wheezers. Atopic wheeze was related to mattress levels of endotoxin, EPS and glucans in farm and farm-reference children. However, when adjusting for group (farm vs. farm-reference children), the associations became non-significant whereas the group effect remained. No associations between atopic wheeze and microbial agents were observed in Steiner and Steiner-reference children. For current atopic wheeze, the farm effect became non-significant after adjustment for microbial agent levels. Conclusion Not only bacterial endotoxin but also mould components might offer some protection against atopic wheeze in children. However, the protective effect of being raised on a farm was largely unexplained by the mattress microbial agent levels measured in this study.	Univ Utrecht, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand; Childrens Hosp, Salzburg, Austria; Univ Munich, Childrens Hosp, D-8000 Munich, Germany; Karolinska Inst, Ctr Allergy Res, Inst Environm Med, Div Environm Epidemiol, Stockholm, Sweden; Karolinska Inst, Dept Med, Clin Immunol & Allergy Unit, Stockholm, Sweden; St Gorans Univ Hosp, S-11281 Stockholm, Sweden; Karolinska Inst, Dept Med, Clin Allergy Res Unit, Stockholm, Sweden; Univ Basel, Inst Social & Prevent Med, Basel, Switzerland	Schram-Bijkerk, D (reprint author), Univ Utrecht, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.	d.schram@iras.uu.nl	; van Hage, Marianne/A-9678-2017	brunekreef, bert/0000-0001-9908-0060; Douwes, Jeroen/0000-0003-3599-4036; van Hage, Marianne/0000-0003-3091-1596			ADACHI Y, 1994, BIOL PHARM BULL, V17, P1554; ALFVEN T, IN PRESS ALLERGY; Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Arbes SJ, 2005, ENVIRON HEALTH PERSP, V113, P665, DOI 10.1289/ehp.7648; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chew GL, 2001, INDOOR AIR, V11, P171, DOI 10.1034/j.1600-0668.2001.011003171.x; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Douwes J, 2003, AM J EPIDEMIOL, V158, P203, DOI 10.1093/aje/kwg149; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GOTO H, 1994, AM J IND MED, V25, P81, DOI 10.1002/ajim.4700250121; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; SAKURAI T, 1994, BIOL PHARM BULL, V17, P617; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; STONE BA, 1992, CHEM BIOL 1 3BETAGLU; SUZUKI T, 1992, J PHARMACOBIO-DYNAM, V15, P277; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; ZHANG K, 1994, J CELL BIOCHEM, V56, P225, DOI 10.1002/jcb.240560217	31	97	99	1	12	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2005	35	10					1272	1278		10.1111/j.1365-2222.2005.02339.x		7	Allergy; Immunology	Allergy; Immunology	976ZK	WOS:000232772000004	16238785	
J	Ersu, R; Arman, AR; Save, D; Karadag, B; Karakoc, F; Berkem, M; Dagli, E				Ersu, R; Arman, AR; Save, D; Karadag, B; Karakoc, F; Berkem, M; Dagli, E			Prevalence of snoring and symptoms of sleep-disordered breathing in primary school children in Istanbul	CHEST			English	Article						children; hyperactivity; passive smoke exposure; prevalence; snoring	APNEA SYNDROME; NOCTURNAL HYPOXEMIA; PRESCHOOL-CHILDREN; PERFORMANCE; DISTURBANCE; ASSOCIATION; BEHAVIOR; SMOKING	Study objectives: Snoring during sleep is an important manifestation of obstructive sleep apnea syndrome (OSAS). Although clinical history is not sufficiently sensitive and specific to distinguish primary snoring from OSAS, snoring is indicative of upper airway obstruction and may be associated with the presence of diurnal symptoms. Our study aims were to determine the prevalence of snoring in primary school children in Istanbul, and to evaluate the diurnal symptoms and conditions that may be associated with sleep problems. Design, setting, and subjects: A parental questionnaire was used to assess the sleep and wake behavioral patterns in children. Eight representative schools in each of 9 school districts randomly selected from the 32 school districts in Istanbul were visited. Results: The response rate was 78.1%; 2,147 of 2,746 questionnaires were fully completed, returned, and analyzed. The prevalence of habitual snoring was 7.0%. Habitual snorers had significantly more nighttime symptoms, such as observed apneas (odds ratio [OR], 16.9; 95% confidence interval [CI], 10.0 to 28.8; p < 0.0001), difficulty breathing (OR, 17.8; CI, 10.9 to 29.2; p < 0.0001), restless sleep, parasomnias, and nocturnal enuresis, compared to occasional and nonsnorers. There were also increased prevalence of daytime symptoms, such as falling asleep while watching television (OR, 1.8; CI, 0.9 to 3.7; p = 0.01) and in public places (OR, 2.1; CI, 1.2 to 3.8; p = 0.03), and hyperactivity (OR, 2.7; CI, 1.8 to 3.9; p < 0.0001). Exposure to cigarette smoke and the presence of asthma and hay fever increased the likelihood of habitual snoring. Children with a higher risk for OSAS (habitual snoring, apnea, and difficulty breathing during sleep) were also compared to nonsnorers. Although nighttime symptoms were more likely in the high-risk group, the risk of daytime symptoms increased as well. Conclusions: Habitual snoring is a significant problem for children and may be associated with diurnal symptoms. Exposure to cigarette smoke at home and the presence of asthma and hay fever increase the likelihood of habitual snoring.	Marmara Univ, Atkatlar Istanbul, Turkey	Ersu, R (reprint author), Selcuklar Sokak,Elvan Apartmani 26-12, Atkatlar Istanbul, Turkey.	rersu@yahoo.com					ALI NJ, 1993, ARCH DIS CHILD, V68, P360; BILIR N, 1997, SMOKING BEHAV ATTITU, P17; Blunden S, 2000, J CLIN EXP NEUROPSYC, V22, P554, DOI 10.1076/1380-3395(200010)22:5;1-9;FT554; Brooks LJ, 2003, J PEDIATR-US, V142, P515, DOI 10.1067/mpd.2003.158; BROUILETTE R, 1984, J PEDIATR-US, V105, P10, DOI 10.1016/S0022-3476(84)80348-0; BROUILLETTE RT, 1982, J PEDIATR-US, V100, P31, DOI 10.1016/S0022-3476(82)80231-X; Brunetti L, 2001, CHEST, V120, P1930, DOI 10.1378/chest.120.6.1930; CARROLL JL, 1995, CHEST, V108, P610, DOI 10.1378/chest.108.3.610; Castronovo V, 2003, J PEDIATR-US, V142, P377, DOI 10.1067/mpd.2003.118; CORBO GM, 1989, BRIT MED J, V299, P1491; DELASNERIELAUPRETRE N, 1993, J SLEEP RES, V2, P138; Ferreira AM, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.5.e64; GISLASON T, 1995, CHEST, V107, P963, DOI 10.1378/chest.107.4.963; Goh DYT, 2000, AM J RESP CRIT CARE, V162, P682; Gozal D, 1998, PEDIATRICS, V102, P616, DOI 10.1542/peds.102.3.616; GUILLEMINAULT C, 1990, Pediatrician, V17, P46; HULTCRANTZ E, 1995, INT J PEDIATR OTORHI, V32, pS63, DOI 10.1016/0165-5876(94)01144-M; Larsson LG, 2003, CHEST, V124, P204, DOI 10.1378/chest.124.1.204; Lu LR, 2003, CHEST, V124, P587, DOI 10.1378/chest.124.2.587; Marcus CL, 2002, PEDIATRICS, V109, P704; MILLER AJ, 1982, AM J ORTHOD DENTOFAC, V81, P99, DOI 10.1016/0002-9416(82)90033-1; OWEN GO, 1995, CLIN OTOLARYNGOL, V20, P402, DOI 10.1111/j.1365-2273.1995.tb00070.x; Redline S, 1999, AM J RESP CRIT CARE, V159, P1527; Rosen CL, 1999, PEDIATR PULM, V27, P403, DOI 10.1002/(SICI)1099-0496(199906)27:6<403::AID-PPUL7>3.0.CO;2-8; STRADLING JR, 1990, LANCET, V335, P249, DOI 10.1016/0140-6736(90)90068-G; Strohl KP, 1996, AM J RESP CRIT CARE, V154, P279; TECULESCU DB, 1992, PEDIATR PULM, V13, P239, DOI 10.1002/ppul.1950130412; Urschitz MS, 2003, AM J RESP CRIT CARE, V168, P464, DOI 10.1164/rccm.200212-1397OC	28	97	100	1	14	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUL	2004	126	1					19	24		10.1378/chest.126.1.19		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	841XP	WOS:000222965900007	15249437	
J	Smith, KR; Mehta, S				Smith, KR; Mehta, S			The burden of disease from indoor air pollution in developing countries: comparison of estimates	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Article						indoor air pollution; developing countries; household solid fuel use; risk assessment; global burden of disease	RESPIRATORY-INFECTIONS; DAILY MORTALITY; EXPOSURE; CHILDREN; HEALTH	Four different methods have been applied to estimate the burden of disease due to indoor air pollution from household solid fuel use in developing countries (LDCs). The largest number of estimates involves applying exposure-response information from urban ambient air pollution studies to estimate indoor exposure concentrations of particulate air pollution. Another approach is to construct child survival curves using the results of large-scale household surveys, as has been done for India. A third approach involves cross-national analyses of child survival and household fuel use. The fourth method, referred to as the 'fuel-based' approach, which is explored in more depth here, involves applying relative risk estimates from epidemiological studies that use exposure surrogates, such as fuel type, to estimates of household solid fuel use to determine population attributable fractions by disease and age group. With this method and conservative assumptions about relative risks, 4-5 percent of the global LDC totals for both deaths and DALYs (disability adjusted life years) from acute respiratory infections, chronic obstructive pulmonary disease, tuberculosis, asthma, lung cancer, ischaemic heart disease, and blindness can be attributed to solid fuel use in developing countries. Acute respiratory infections in children under five years of age are the largest single category of deaths (64%) and DALYs (81%) from indoor air pollution, apparently being responsible globally for about 1.2 million premature deaths annually in the early 1990s.	Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Smith, KR (reprint author), Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA.	krksmith@uclink.berkeley.edu					Bennett DH, 2002, ENVIRON SCI TECHNOL, V36, p206A, DOI 10.1021/es0222770; BLOOM D, 2000, INT C ENV OCC RESP D; Bloom D., 2002, QUALITY LIFE RURAL A; BRANDON C, 1995, C SUST FUT GLOB SYST; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; COHEN AJ, 2003, IN PRESS COMP QUANTI; FLORIG HK, 1997, ENVIRON SCI TECHNOL, V31, pA276; Hong CJ, 1995, GLOBAL BURDEN DIS AI; HUGHES G, 2000, WHY BABIES YOUNG CHI; KUMAR P, 1997, DOWN EARTH, V6, P29; McMichael AJ, 1998, INT J EPIDEMIOL, V27, P450, DOI 10.1093/ije/27.3.450; Murray CJL, 1996, GLOBAL BURDEN DIS IN; Romieu I, 2002, J OCCUP ENVIRON MED, V44, P640, DOI 10.1097/01.jom.0000023383.41727.32; SAKSENA S, 1997, ENERGY ENV MONITOR, V13, P93; SCHWARTZ J, 1994, ENVIRON RES, V64, P36, DOI 10.1006/enrs.1994.1005; Schwela D, 1996, TOXICOL LETT, V86, P131, DOI 10.1016/0378-4274(96)03684-3; SINTON J, 1996, WHOEHG958; Smith KR, 2000, P NATL ACAD SCI USA, V97, P13286, DOI 10.1073/pnas.97.24.13286; Smith KR, 2000, THORAX, V55, P518, DOI 10.1136/thorax.55.6.518; SMITH KR, 1993, ANNU REV ENERG ENV, V18, P529, DOI 10.1146/annurev.energy.18.1.529; Smith K.R., 1988, ENVIRONMENT, V30, P10; Smith K.R., 2003, COMP QUANTIFICATION; SMITH KR, 1994, WORKSH EN ENV NEX IN; Smith K. R., 1987, BIOFUELS AIR POLLUTI; World Health Organization, 2002, WORLD HLTH REP RED R; *WHO, 1997, HTLH ENV SUST DEV; *WHO, 1979, ENV HLTH CRIT, V8; WHO, 1999, GLOB AIR QUAL GUID; World Health Organization, 2001, WORLD HLTH REP; *WORLD BANK, 1997, CLEAR WAT BLUE SKIES, P114	30	97	105	3	24	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1438-4639			INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.	AUG	2003	206	4-5					279	289		10.1078/1438-4639-00224		11	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	716JD	WOS:000185024300004	12971683	
J	Delfino, RJ; Zeiger, RS; Seltzer, JM; Street, DH; McLaren, CE				Delfino, RJ; Zeiger, RS; Seltzer, JM; Street, DH; McLaren, CE			Association of asthma symptoms with peak particulate air pollution and effect modification by anti-inflammatory medication use	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; epidemiology; longitudinal data analysis; ozone; panel study; particulate air pollution	NITROGEN-DIOXIDE; INHALED ALLERGEN; SOUTHERN-CALIFORNIA; OZONE EXPOSURE; HOSPITAL ADMISSIONS; CHILDREN; RESPONSES; POLLUTANTS; EMERGENCY; MORTALITY	Maxima of hourly data from outdoor monitors may capture adverse effects of outdoor particulate matter (PM) exposures in asthmatic children better than do 24-hr PM averages, which form the basis of current regulations in the United States. Also, asthmatic children on anti-inflammatory medications may be protected against the proinflammatory effects of air pollutants and aeroallergens. We examined strengths of pollutant associations with asthma symptoms between subgroups of asthmatic children who were on versus not on regularly scheduled anti-inflammatory medications, and tested associations for different particle averaging times. This is a daily panel study of 22 asthmatic children (9-19 years of age) followed March through April 1996 (1,248 person-days). They lived in nonsmoking households in a semirural area of Southern California within the air inversion mixing zone (range, 1,200-2,100 feet) with transported air pollution from urban areas of Southern California. The dependent variable derived from diary ordinal scores is episodes of asthma symptoms that interfered with daily activities. Minimum to 90th-percentile levels of exposures at the outdoor monitoring site were 12-63 mug/m(3) for 1-hr PM < 10 mum in aerodynamic diameter (PM10); 8-46 mug/m(3) for 8-hr PM10; 7-32 mug/m(3) for 24-hr PM10; 45-88 ppb for 1-hr O-3; 6-26 ppb for 8-hr NO2; 70-4,714 particles/m(3) for 12-hr daytime fungi; and 12-744 particles/m(3) for 24-hr pollen. Data were analyzed with generalized estimating equations controlling for autocorrelation. There was no confounding by weather, day of week, or linear time trend. Associations were notably stronger in 12 asthmatic children who were not taking anti-inflammatory medications versus 10 subjects who were. Odds ratios (95% confidence intervals) for asthma episodes in relation to lag 0 minimum to 90th-percentile pollutant changes were, respectively, 1-hr maximum PM10, 1.92 (1.22-3.02) versus 0.96 (0.25-3.69); 8-hr maximum PM10, 1.68 (0.91-3.09) versus 0.75 (0.18-3.04); 24-hr average PM10, 1.35 (0.82-2.22) versus 0.80 (0.24-2.69); 1-hr maximum O-3, 1.28 (0.75-2.17) versus 0.76 (0.24-2.44); 8-hr maximum NO2, 1.91 (1.07-3.39) versus 1.08 (0.30-3.93); 12-hr fungi, 1.89 (1.24-2.89) versus 0.90 (0.35-2.30); 24-hr pollen, 1.90 (0.99-3.67) versus 0.85 (0.18-3.91). Pollutant associations were stronger during respiratory infections in subjects not on anti-inflammatory medications. Although lag 0 1-hr maximum PM10 showed the strongest association, the most robust associations were for lag 0 and 3-day moving averages (lags 0-2) of 8-hr maximum and 24-hr mean PM10 in sensitivity analyses testing for thresholds. Most pollutant effects were largely driven by concentrations in the upper quintile. The divergence of exposure-response relationships by anti-inflammatory medication use is consistent with experimental data on inflammatory mechanisms of airborne pollutants and allergens.	Univ Calif Irvine, Div Epidemiol, Dept Med, Coll Med, Irvine, CA 92697 USA; Univ Calif San Diego, Dept Pediat, Sch Med, La Jolla, CA 92093 USA; So Calif Permanente Med Grp, Dept Allergy, San Diego, CA 92120 USA; Indoor Hyg Technol Corp, Rancho Santa Fe, CA USA; Hollistier Stier Labs LLC, Allergy Prod, Independence, OR USA	Delfino, RJ (reprint author), Univ Calif Irvine, Div Epidemiol, Dept Med, Coll Med, 224 Irvine Hall, Irvine, CA 92697 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIEHS NIH HHS [ES06214]		Allen G, 1997, J AIR WASTE MANAGE, V47, P682; Anderson HR, 1998, THORAX, V53, P842; Balmes J. R., 1997, RES REP HLTH EFF I, V78, P1; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Blomberg A, 1999, AM J RESP CRIT CARE, V159, P536; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Chauhan A. J., 1998, Reviews on Environmental Health, V13, P73; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 1997, ENVIRON HEALTH PERSP, V105, P622; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; ELLIS MH, 1989, IMMUNOL ALLERGY CLIN, V9, P365; Garty BZ, 1998, ANN ALLERG ASTHMA IM, V81, P563, DOI 10.1016/S1081-1206(10)62707-X; HAHON N, 1985, ENVIRON RES, V37, P44, DOI 10.1016/0013-9351(85)90048-9; HATCH GE, 1985, ENVIRON RES, V36, P67, DOI 10.1016/0013-9351(85)90008-8; Jamason PF, 1997, AM J RESP CRIT CARE, V156, P1781; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; LAST JA, 1990, 38 HLTH EFF I; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P1724, DOI 10.1046/j.1365-2222.2000.00947.x; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Linaker CH, 2000, THORAX, V55, P930, DOI 10.1136/thorax.55.11.930; Liu LJS, 1997, ENVIRON HEALTH PERSP, V105, P58, DOI 10.1289/ehp.9710558; LIU MC, 1991, AM REV RESPIR DIS, V144, P51; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; METZGER WJ, 1987, AM REV RESPIR DIS, V135, P433; Michaels RA, 1996, AEROSOL SCI TECH, V25, P437, DOI 10.1080/02786829608965408; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; Morgan G, 1998, AM J PUBLIC HEALTH, V88, P1761, DOI 10.2105/AJPH.88.12.1761; Mortimer KM, 2000, AM J RESP CRIT CARE, V162, P1838; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; *NHLBI, 1997, 974051 NHLBI; O'Byrne PM, 1999, AM J RESP CRIT CARE, V159, pS41; OBYRNE PM, 1987, AM REV RESPIR DIS, V136, P740; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; PATASHNICK H, 1991, J AIR WASTE MANAGE, V41, P1079; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; QUAKENBOSS JJ, 1991, J EXPO ANAL ENV EPID, V1, P83; Quintana PJE, 2000, J EXPO ANAL ENV EPID, V10, P437, DOI 10.1038/sj.jea.7500105; Roemer W, 1999, OCCUP ENVIRON MED, V56, P86; Roorda-Knape MC, 1998, ATMOS ENVIRON, V32, P1921, DOI 10.1016/S1352-2310(97)00496-2; Rossi G, 1999, ARCH ENVIRON HEALTH, V54, P158; ROSSI GA, 1991, AM REV RESPIR DIS, V144, P379; ROSSI OVJ, 1993, THORAX, V48, P244, DOI 10.1136/thx.48.3.244; SAMET JM, 2000, HLTH EFFECTS I RES 2, V94, P5; *SANDAG, 1999, SAN DIEG REG AV WEEK; Scannell C, 1996, AM J RESP CRIT CARE, V154, P24; Schierhorn K, 1999, AM J RESP CELL MOL, V20, P1013; SCHWARTZ J, 1991, ENVIRON RES, V56, P1, DOI 10.1016/S0013-9351(05)80104-5; SCHWARTZ J, 1992, AM REV RESPIR DIS, V145, P600; SCHWARTZ J, 1994, ENVIRON HEALTH PERSP, V102, P186, DOI 10.2307/3431609; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; SPEKTOR DM, 1991, ENVIRON RES, V55, P107, DOI 10.1016/S0013-9351(05)80167-7; Stieb DM, 2000, J EXPO ANAL ENV EPID, V10, P461, DOI 10.1038/sj.jea.7500112; Strand V, 1998, EUR RESPIR J, V12, P6, DOI 10.1183/09031936.98.12010006; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Sunyer J, 1997, THORAX, V52, P760; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; *US EPA, 1990, NAT AIR QUAL EM TREN; *US EPA, 1996, EPA600P95001AFCF NAT; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; Weiss ST, 1996, AM J RESP CRIT CARE, V154, pS208	61	97	99	1	9	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2002	110	10					A607	A617				11	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	600VE	WOS:000178411800042	12361942	
J	Ghaemmaghami, AM; Gough, L; Sewell, HF; Shakib, F				Ghaemmaghami, AM; Gough, L; Sewell, HF; Shakib, F			The proteolytic activity of the major dust mite allergen Der p 1 conditions dendritic cells to produce less interleukin-12: allergen-induced Th2 bias determined at the dendritic cell level	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergen; dendritic cells; Der p 1; Th1/Th2	CYSTEINE PROTEASE ACTIVITY; T-HELPER CELL; FLOW-CYTOMETRY; ANTIGEN; DER-P-1; IL-12; LYMPHOCYTES; CAPACITY; CYTOKINE; REQUIRES	Background The proteolytic activity of the house dust mite allergen Der p 1 has recently been shown to bias Th cell subset development in favour of Th2. Apart from its direct effect on T cells, it is conceivable that the proteolytic activity of Der p 1 may induce the generation of dendritic cells (DCs) that favour a Th2 response. Objective To study the effect of the proteolytic activity of Der p 1 on DC functions; namely cell surface phenotype, IL-12 production and ability to favour a Th2 response. Methods We have generated immature DCs from peripheral blood monocytes, matured them with LPS in the presence of either proteolytically active or inactive Der p 1 and compared their functions using flow cytometric analysis. Results Here we demonstrate for the first time that DCs that have been matured in the presence of proteolytically active Der p 1 produce significantly less IL-12, compared to DCs that have been matured in the presence of proteolytically inactive Der p 1. The suppression of IL-12 production was due to the cleavage of CD40 by the proteolytic activity of Der p 1, hence rendering the DCs less responsive to stimulation through the CD40L-CD40 pathway. Furthermore, we demonstrate that DCs that have been matured in the presence of proteolytically active Der p 1 induce the production of significantly less IFN-gamma and more IL-4 by CD4 T cells, compared to DCs that have been matured in the presence of proteolytically inactive Der p 1. Conclusions Collectively, our data provide compelling evidence for the role of the proteolytic activity of Der p 1 in directing DCs to induce Th2 subset development.	Univ Nottingham, Queens Med Ctr, Fac Med & Hlth Sci, Div Mol & Clin Immunol, Nottingham NG7 2UH, England	Shakib, F (reprint author), Univ Nottingham, Queens Med Ctr, Fac Med & Hlth Sci, Div Mol & Clin Immunol, Nottingham NG7 2UH, England.			Fairclough, Lucy/0000-0003-4581-9741			Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Bell D, 1999, ADV IMMUNOL, V72, P255, DOI 10.1016/S0065-2776(08)60023-1; Cella M, 1996, J EXP MED, V184, P747, DOI 10.1084/jem.184.2.747; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Ghaemmaghami AM, 2001, EUR J IMMUNOL, V31, P1211, DOI 10.1002/1521-4141(200104)31:4<1211::AID-IMMU1211>3.0.CO;2-R; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Grunvald E, 1996, INFECT IMMUN, V64, P2010; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; Kalinski P, 1998, J IMMUNOL, V161, P2804; Mascher B, 1999, J IMMUNOL METHODS, V223, P115, DOI 10.1016/S0022-1759(98)00200-2; O'Garra A, 1998, IMMUNITY, V8, P275, DOI 10.1016/S1074-7613(00)80533-6; Ohshima Y, 1997, J IMMUNOL, V158, P629; PORCELLI S, 1992, NATURE, V360, P593, DOI 10.1038/360593a0; Prussin C, 1995, J IMMUNOL METHODS, V188, P117, DOI 10.1016/0022-1759(95)00209-X; Reis E Sousa Caetano, 1997, Journal of Experimental Medicine, V186, P1819; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Schulz O, 2000, IMMUNITY, V13, P453, DOI 10.1016/S1074-7613(00)00045-5; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Schulz O, 1998, J CLIN PATHOL-MOL PA, V51, P222; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; Trinchieri G, 1998, ADV IMMUNOL, V70, P83, DOI 10.1016/S0065-2776(08)60387-9; Vieira PL, 2000, J IMMUNOL, V164, P4507	24	97	99	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2002	32	10					1468	1475		10.1046/j.1365-2745.2002.01504.x		8	Allergy; Immunology	Allergy; Immunology	601ZJ	WOS:000178479300014	12372127	
J	Jakob, T; Ring, J; Udey, MC				Jakob, T; Ring, J; Udey, MC			Multistep navigation of Langerhans/dendritic cells in and out of the skin	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Langerhans cells; dendritic cells; migration-trafficking; adhesion; chemokines; skin; allergy; immune regulation	HUMAN PERIPHERAL-BLOOD; CPG-CONTAINING OLIGODEOXYNUCLEOTIDES; INFLAMMATORY PROTEIN 3-ALPHA; CADHERIN-MEDIATED ADHESION; CUTANEOUS DENDRITIC CELLS; NECROSIS-FACTOR-ALPHA; DRAINING LYMPH-NODES; CONTACT HYPERSENSITIVITY; CHEMOKINE RECEPTORS; TH1 RESPONSES	Langerhans cells (LCs) are specialized antigen-presenting cells that reside in the epidermis as sentinels of the immune system. LCs constantly monitor the epidermal microenvironment by taking up antigen and processing it into fragments that can be recognized by cells of the adaptive immune response. Because of their unique migratory ability, LCs can transport antigen from the epidermis to regional lymph nodes, where they can initiate systemic immune responses. The mechanisms of LC trafficking thus seem to be of particular relevance for the induction and maintenance of cutaneous immunity. LCs or their putative precursors express surface molecules that allow them to home to skin and localize in the epidermis for prolonged periods of time. Tissue injury, microbial infection, and other perturbants of epidermal homeostasis (eg, contact allergens) provide danger signals, leading to a local production of proinflammatory cytokines that induce LC mobilization to the lymphoid tissue. At the same time, signals are generated that recruit LC precursors into the skin to maintain the epidermal LC population. Distinct pairs of chemokines and their receptors control the migration from blood to epidermis and from there to the regional lymphatics. In addition, trafficking is controlled at the level of cell adhesion, where LCs downregulate some adhesion molecules to exit the epidermis and upregulate others to migrate across the extracellular matrix and home to T-cell areas of regional lymphoid tissue. The improved understanding of mechanisms that regulate LC trafficking might offer new opportunities for therapeutic interventions to suppress, stimulate, or deviate cutaneous immune responses.	Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Div Environm Dermatol & Allergy GSF TUM, D-80802 Munich, Germany; GSF, Natl Res Ctr Environm & Hlth, Div Environm Dermatol & Allergy GSF TUM, Neuherberg, Germany; NCI, Dermatol Branch, NIH, Bethesda, MD 20892 USA	Jakob, T (reprint author), Tech Univ Munich, Dept Dermatol & Allergy Biederstein, Div Environm Dermatol & Allergy GSF TUM, Biedersteiner Str 29, D-80802 Munich, Germany.		Jakob, Thilo/J-1621-2012				AIBA S, 1993, J INVEST DERMATOL, V100, P143, DOI 10.1111/1523-1747.ep12462783; AIBA S, 1990, J IMMUNOL, V145, P2791; Antonopoulos C, 2001, J Immunol, V166, P3672; BORKOWSKI TA, 1994, EUR J IMMUNOL, V24, P2767, DOI 10.1002/eji.1830241129; Borkowski TA, 1997, J CLIN INVEST, V100, P575, DOI 10.1172/JCI119567; Borkowski TA, 1996, J EXP MED, V184, P2417, DOI 10.1084/jem.184.6.2417; BRAND CU, 1992, J INVEST DERMATOL, V99, pS109, DOI 10.1111/1523-1747.ep12669997; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; CHEN HD, 1986, J INVEST DERMATOL, V86, P630, DOI 10.1111/1523-1747.ep12275627; CRUZ PD, 1990, J IMMUNOL, V144, P2486; Cumberbatch M, 2000, IMMUNOLOGY, V100, P21, DOI 10.1046/j.1365-2567.2000.00014.x; CUMBERBATCH M, 1992, IMMUNOLOGY, V75, P257; Cumberbatch M, 1999, ARCH DERMATOL RES, V291, P357, DOI 10.1007/s004030050422; Cumberbatch M, 1997, ARCH DERMATOL RES, V289, P277, DOI 10.1007/s004030050193; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; ENK AH, 1993, J IMMUNOL, V150, P3698; ENK AH, 1992, P NATL ACAD SCI USA, V89, P1398, DOI 10.1073/pnas.89.4.1398; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Geissmann F, 1998, J EXP MED, V187, P961, DOI 10.1084/jem.187.6.961; Geissmann F, 1999, J IMMUNOL, V162, P4567; GIROLOMONI G, 1993, J INVEST DERMATOL, V100, P282, DOI 10.1111/1523-1747.ep12469769; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; HOLT PG, 1994, J IMMUNOL, V153, P256; Jakob T, 1999, J INVEST DERMATOL, V112, P102, DOI 10.1046/j.1523-1747.1999.00475.x; Jakob T, 1999, INT ARCH ALLERGY IMM, V118, P457, DOI 10.1159/000024163; Jakob T, 1997, J IMMUNOL, V159, P2693; Jakob T, 1998, J IMMUNOL, V161, P3042; Jakob T, 1998, J IMMUNOL, V160, P4067; Jakob T, 1999, Adv Dermatol, V14, P209; Jenne L, 2001, TRENDS IMMUNOL, V22, P102, DOI 10.1016/S1471-4906(00)01813-5; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; KATZ SI, 1979, NATURE, V282, P324, DOI 10.1038/282324a0; Kobayashi Y, 1997, IMMUNOLOGY, V90, P496, DOI 10.1046/j.1365-2567.1997.00212.x; Kobayashi Y, 1999, J IMMUNOL, V163, P5989; KOSZIK F, 1994, J INVEST DERMATOL, V102, P773, DOI 10.1111/1523-1747.ep12377706; LESSARD RJ, 1968, J INVEST DERMATOL, V50, P1471; Lin CL, 1998, EUR J IMMUNOL, V28, P4114, DOI 10.1002/(SICI)1521-4141(199812)28:12<4114::AID-IMMU4114>3.0.CO;2-C; Lutz MB, 2000, EUR J IMMUNOL, V30, P1048, DOI 10.1002/(SICI)1521-4141(200004)30:4<1048::AID-IMMU1048>3.0.CO;2-W; Nestle FO, 1998, NAT MED, V4, P328, DOI 10.1038/nm0398-328; PICKER LJ, 1990, J IMMUNOL, V145, P3247; Price AA, 1997, J EXP MED, V186, P1725, DOI 10.1084/jem.186.10.1725; Randolph GJ, 1998, P NATL ACAD SCI USA, V95, P6924, DOI 10.1073/pnas.95.12.6924; Riedl E, 2000, J IMMUNOL, V165, P1381; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; Saeki H, 1999, J IMMUNOL, V162, P2472; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Sato K, 2000, J IMMUNOL, V164, P2285; Schuler G, 1997, J EXP MED, V186, P1183, DOI 10.1084/jem.186.8.1183; Schwarzenberger K, 1996, J INVEST DERMATOL, V106, P553, DOI 10.1111/1523-1747.ep12344019; SHIBAKI A, 1995, J INVEST DERMATOL, V104, P42, DOI 10.1111/1523-1747.ep12613476; STINGL G, 1980, IMMUNOL REV, V53, P149, DOI 10.1111/j.1600-065X.1980.tb01043.x; Strunk D, 1997, J EXP MED, V185, P1131, DOI 10.1084/jem.185.6.1131; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; TANG AM, 1993, NATURE, V361, P82, DOI 10.1038/361082a0; Thurner B, 1999, J EXP MED, V190, P1669, DOI 10.1084/jem.190.11.1669; Vassileva G, 1999, J EXP MED, V190, P1183, DOI 10.1084/jem.190.8.1183; Wang B, 1999, J IMMUNOL, V162, P277; Wang BH, 1997, J IMMUNOL, V159, P6148; Wang M, 1999, P NATL ACAD SCI USA, V96, P6885, DOI 10.1073/pnas.96.12.6885; Weiss JM, 1997, J CELL BIOL, V137, P1137, DOI 10.1083/jcb.137.5.1137; WOLFF K, 1991, EPIDERMAL LANGERHANS, P1; Wollenberg A, 1996, J INVEST DERMATOL, V106, P446, DOI 10.1111/1523-1747.ep12343596; Yanagihara S, 1998, J IMMUNOL, V161, P3096; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	66	97	105	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2001	108	5					688	696				9	Allergy; Immunology	Allergy; Immunology	498RG	WOS:000172523800005	11692090	
J	Rahman, I; Mulier, B; Gilmour, PS; Watchorn, T; Donaldson, K; Jeffery, PK; MacNee, W				Rahman, I; Mulier, B; Gilmour, PS; Watchorn, T; Donaldson, K; Jeffery, PK; MacNee, W			Oxidant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor-kappaB	BIOCHEMICAL PHARMACOLOGY			English	Article						GSH; NF-kappa B; hyperoxia; tolerance; 16HBE; A549	NECROSIS-FACTOR-ALPHA; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; INDUCED APOPTOSIS; OXIDATIVE STRESS; B ACTIVATION; INFLAMMATION; ASTHMA; INTERLEUKIN-8; DEXAMETHASONE	The airway epithelium is injured by oxidants inhaled as atmospheric pollutants or produced during inflammatory responses. We studied the effect of modulating the antioxidant intracellular glutathione, both using thiol compounds and by the adaptive effect of hyperoxia, on oxidant-induced injury and activation of the nuclear factor-kappaB (NF-kappaB) in two cell lines: the human bronchial (16HBE) and type II alveolar epithelial cells (A549). The thiol antioxidants glutathione (GSH) and glutathione monoethyl ester (GSH-MEE) [2 mM] increased GSH levels (nmol/mg protein) in A549 cells (GSH 383 +/- 26 and GSH-MEE 336 +/- 23 vs control 171 +/- 13, P < 0.001) and in 16HBE cells (GSH 405 +/- 33, GSH-MEE 362 +/- 37 vs control 198 +/- 12, P < 0.001, N = 3). Treatment of hyperoxia (95% oxygen) also increased GSH levels between 4 and 24 hr exposure compared with control (P < 0.01). Hydrogen peroxide (H2O2) (0.01 mM) induced NF-kappaB activation, whereas hyperoxia exposure did not affect NF-kappaB activation in either cell line. Pretreatment with DL-buthionine (SR)sulfoximine, which decreased intracellular glutathione, increased NF-kappaB binding induced by H2O2 and increased lactate dehydrogenase (LDH) release (P < 0.001). Pretreatment with the thiol compounds and hyperoxia totally inhibited H2O2-induced NF-kappaB binding and cell injury as measured by LDH release. These data indicate the importance of intracellular glutathione and inhibition of NF-kappaB in both protection/tolerance against oxidant-induced epithelial cell injury, and NF-kappaB activation in response to oxidative stress which may be important in lung inflammation. Thus, increasing intracellular glutathione may be of therapeutic relevance if able to modulate NF-kappaB activation and hence attenuate inflammation. (C) 2001 Elsevier Science Inc. All rights reserved.	Univ Edinburgh, Sch Med, Resp Med Unit, ELEGI & Colt Res Lab, Edinburgh EH8 9AG, Midlothian, Scotland; Univ London, Natl Lung & Heart Inst, Lung Pathol Unit, London, England; Napier Univ, Dept Biol Sci, Edinburgh EH14 1DJ, Midlothian, Scotland	Rahman, I (reprint author), Univ Edinburgh, Sch Med, Resp Med Unit, ELEGI & Colt Res Lab, Wilkie Bldg,Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland.						Allen GL, 2000, AM J PHYSIOL-LUNG C, V278, pL253; Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; BAILEY AF, 1991, BIOCHEM PHARMACOL, V42, pS47; Barnes PJ, 1997, TRENDS PHARMACOL SCI, V18, P46, DOI 10.1016/S0165-6147(97)89796-9; Blackwell TS, 1996, J IMMUNOL, V157, P1630; Bonizzi G, 2000, BIOCHEM PHARMACOL, V59, P7, DOI 10.1016/S0006-2952(99)00290-7; Brown LAS, 1996, AM J PHYSIOL-LUNG C, V270, pL446; BROWN LAS, 1994, AM J PHYSIOL, V266, pL172; CANTIN AM, 1987, J APPL PHYSIOL, V63, P152; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38; CROSS CE, 1994, ENVIRON HEALTH PERSP, V102, P185, DOI 10.2307/3432237; DENEKE SM, 1985, J APPL PHYSIOL, V58, P571; DROGE W, 1994, FASEB J, V8, P1131; DROST EM, 2000, EUR RESPIR J, V16, pA260; Flohe L, 1997, FREE RADICAL BIO MED, V22, P1115, DOI 10.1016/S0891-5849(96)00501-1; Franek WR, 2001, J BIOL CHEM, V276, P569; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Haddad JJE, 2000, J BIOL CHEM, V275, P21130, DOI 10.1074/jbc.M000737200; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585; Hehner SP, 1998, J BIOL CHEM, V273, P18117, DOI 10.1074/jbc.273.29.18117; JANY B, 1995, EUR RESPIR J, V8, P387, DOI 10.1183/09031936.95.08030387; Jimenez LA, 2000, TOXICOL APPL PHARM, V166, P101, DOI 10.1006/taap.2000.8957; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Manna SK, 1999, ONCOGENE, V18, P4371, DOI 10.1038/sj.onc.1202811; Mulier B, 1998, EUR RESPIR J, V11, P384, DOI 10.1183/09031936.98.11020384; Pietarinen-Runtti P, 1998, AM J RESP CELL MOL, V19, P286; Rahman I, 1998, AM J PHYSIOL-LUNG C, V275, pL80; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Rahman I, 1999, AM J PHYSIOL-LUNG C, V277, pL1067; Rahman I, 1999, J BIOL CHEM, V274, P5088, DOI 10.1074/jbc.274.8.5088; Rahman I, 1998, THORAX, V53, P601; RAHMAN I, 1995, AM J PHYSIOL-LUNG C, V269, pL285; Rahman I, 2000, FREE RADICAL BIO MED, V28, P1405, DOI 10.1016/S0891-5849(00)00215-X; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Suzuki YJ, 1997, FREE RADICAL BIO MED, V22, P269, DOI 10.1016/S0891-5849(96)00275-4; Teramoto S, 1999, JPN J PHARMACOL, V79, P33, DOI 10.1254/jjp.79.33; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WROBLEWSKI F, 1955, P SOC EXP BIOL MED, V90, P210	38	97	105	1	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0006-2952			BIOCHEM PHARMACOL	Biochem. Pharmacol.	SEP 15	2001	62	6					787	794		10.1016/S0006-2952(01)00702-X		8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	463HB	WOS:000170470100016	11551525	
J	Kamps, AWA; Roorda, RJ; Brand, PLP				Kamps, AWA; Roorda, RJ; Brand, PLP			Peak flow diaries in childhood asthma are unreliable	THORAX			English	Article						asthma; children; home monitoring; peak expiratory flow; compliance	HOME MANAGEMENT; INNER-CITY; CHILDREN	Background-A study was undertaken to investigate the compliance with and accuracy of peak flow diaries in childhood asthma. Methods-Forty asthmatic children (5-16 years) were asked to perform peak flow measurements twice daily for 4 weeks by means of an electronic peak flow meter and to record values in a written diary. Patients and parents were unaware that the device stored the peak flow values on a microchip. In random order, half of the patients were only told that the device allowed for more accurate assessment of peak flow while the other half were told that accurate recording of peak flow was important because the results would be used in guiding adjustments to treatment. Data in the written diary (reported data) were compared with those from the electronic diary tactual data). Results-In the entire study population the mean (SD) actual compliance (77.1 (20.5)%) was much lower than the mean reported compliance (95.7 (9.1)%) (95% CI for difference 12.7% to 24.4%) The percentage of correct peak flow entries decreased from 56% to <50% from the first to the last study week (p<0.04), mainly as a result of an increase in self-invented peak flow entries. Results were comparable for both groups. For incorrect peak flow entries the mean difference between written and electronically recorded entries ranged from -72 to 34 l/min per patient. Conclusions-Peak how diaries kept by asthmatic children are unreliable. Electronic peak flow meters should be used if peak how monitoring is required in children with asthma.	Weezenlanden Hosp, Isala Klinieken, Dept Paediat, Div Pulm, NL-8000 GM Zwolle, Netherlands	Brand, PLP (reprint author), Weezenlanden Hosp, Isala Klinieken, Dept Paediat, Div Pulm, POB 10500, NL-8000 GM Zwolle, Netherlands.						British Thoracic Society, 1997, THORAX S1, V52, pS1, DOI DOI 10.1136/THX.52.2008.S1]; CHARLTON I, 1994, ARCH DIS CHILD, V70, P313; Cote J, 1998, CHEST, V113, P968, DOI 10.1378/chest.113.4.968; Eggleston PA, 1998, PEDIATRICS, V101, P349, DOI 10.1542/peds.101.3.349; HYLAND ME, 1993, BRIT MED J, V306, P487; Madge P, 1997, THORAX, V52, P223; MALO JL, 1995, J ALLERGY CLIN IMMUN, V96, P601, DOI 10.1016/S0091-6749(95)70258-X; Redline S, 1996, PEDIATR PULM, V21, P203; SHEFFER AL, 1992, EUR RESPIR J, V5, P601; Verschelden P, 1996, EUR RESPIR J, V9, P880, DOI 10.1183/09031936.96.09050880	10	97	98	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2001	56	3					180	182		10.1136/thorax.56.3.180		3	Respiratory System	Respiratory System	406WL	WOS:000167239100006	11182008	
J	Linneberg, A; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T				Linneberg, A; Nielsen, NH; Madsen, F; Frolund, L; Dirksen, A; Jorgensen, T			Increasing prevalence of specific IgE to aeroallergens in an adult population: Two cross-sectional surveys 8 years apart - The Copenhagen Allergy Study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adult; epidemiology; prevalence; respiratory hypersensitivity; specific IgE positivity; specific IgE stability	SKIN-TEST REACTIVITY; CHANGING PREVALENCE; DANISH POPULATION; HAY-FEVER; RHINITIS; ASTHMA; CHILDREN; ANTIBODIES; DIAGNOSIS; SYMPTOMS	Background: There is evidence that the prevalence of respiratory allergy has increased in children in many countries. However, this evidence is largely based on questionnaire data, and little is known about similar trends in adults. Objective: We investigated whether the prevalence of specific IgE to aeroallergens had increased in an adult general population over an 8-year period. Methods: Two cross-sectional surveys were carried out in 1990 and 1998, A mailed screening questionnaire on respiratory symptoms sent to random samples of 15- to 41-year-old subjects living in Copenhagen (Denmark) preceded both surveys. Random samples of responders were invited to a health examination, including assessment of specific IgE to 6 common aeroallergens. Totals of 312 (74.6% of the invited subjects) and 482 (53.4% of the invited subjects) subjects were examined in 1990 and 1998, respectively, Analyses of serum samples from both surveys were performed in 1999, Results: The prevalence of specific IgE to at least one allergen increased significantly from 1990 to 1998 (26.5% vs 33.9%; odds ratio adjusted for sex, age, and season of examination, 1.63; 95% confidence interval, 1.15-2.32; P = .006), This increase remained unexplained after adjustment for changes in questionnaire variables on lifestyle and home environment, The clinical significance of this increase was underlined by a corresponding increase in the prevalence of allergic rhinitis symptoms associated with specific IgE positivity, Conclusion: We found that the prevalence of specific IgE positivity to aeroallergens increased in an adult Danish general population from 1990 and 1998.	Glostrup Hosp, Ctr Prevent Med, Dept Internal Med M, DK-2600 Glostrup, Denmark; Gentofte Hosp, Dept Dermatol, Gentofte, Denmark; Frederiksberg Hosp, Dept Internal Med B, Frederiksberg, Denmark; Bispebjerg Hosp, Clin Unit Prevent Med & Hlth Promot, Bispebjerg, Denmark; Univ Copenhagen, Rigshosp, Dept Resp Med, DK-2100 Copenhagen, Denmark	Linneberg, A (reprint author), Glostrup Hosp, Ctr Prevent Med, Dept Internal Med M, 57 Ndr Ringvej,Entrance 8,7th Floor, DK-2600 Glostrup, Denmark.			Jorgensen, Torben/0000-0001-9453-2830; Linneberg, Allan/0000-0002-0994-0184			Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BLAND JM, 1986, LANCET, V1, P307; Burney P, 1996, EUR RESPIR J, V9, P687; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; Butland BK, 1997, BRIT MED J, V315, P717; Crobach MJJS, 1998, SCAND J PRIM HEALTH, V16, P30; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Henderson CE, 1998, J IMMUNOL METHODS, V213, P99, DOI 10.1016/S0022-1759(98)00014-3; Johansen N., 1998, Allergy (Copenhagen), V53, P193; Linneberg A, 1999, ALLERGY, V54, P1194, DOI 10.1034/j.1398-9995.1999.00180.x; Magnus P, 1997, BRIT MED J, V314, P1795; Mygind N, 1996, PEDIATR ALLERGY IMMU, V7, P57, DOI 10.1111/j.1399-3038.1996.tb00397.x; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; NIELSEN NH, 1994, ALLERGY, V49, P86, DOI 10.1111/j.1398-9995.1994.tb00805.x; Paganelli R, 1998, ALLERGY, V53, P763; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; PEAT JK, 1994, BRIT MED J, V308, P1591; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45	20	97	98	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2000	106	2					247	252		10.1067/mai.2000.108312		6	Allergy; Immunology	Allergy; Immunology	343NH	WOS:000088708100005	10932066	
J	Rodrigo, CJ; Rodrigo, C				Rodrigo, CJ; Rodrigo, C			First-line therapy for adult patients with acute asthma receiving a multiple-bose protocol of ipratropium bromide plus albuterol in the emergency department	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; NEBULIZED IPRATROPIUM; SALBUTAMOL; CHILDREN; METAANALYSIS; MANAGEMENT; EFFICACY; BRONCHODILATOR; CHILDHOOD; AGONISTS	We designed a larger, double-blind, randomized, prospective trial to test our hypothesis that patients with acute asthma given combination high dose therapy with ipratropium bromide (IB) and beta(2)-agonists will have greater improvement in pulmonary function and fewer hospital admissions than those given beta(2)-agonists alone. One hundred eighty patients (mean age +/- SD, 34.3 +/- 10.5 yr) who presented to an emergency department (ED) for treatment of an exacerbation of asthma (baseline FEV1 < 50% of predicted) were assigned in a randomized, double-blind fashion to receive albuterol and placebo (n = 92) or albuterol and IB (n = 88). Both drugs were administered through a metered-dose inhaler and spacer at 10-min intervals for 3 h (24 puffs or 2,880 mu g of albuterol and 504 mu g of IB each hour). Primary outcome measures were improvement in pulmonary function (FEV1 or peak expiratory flow [PEF]), and hospital admission rates. In both groups, pulmonary function improved significantly over baseline values (p < 0.01). Subjects who received IB had an overall 20.5% (95% CI: 2.6 to 38.4%) (p = 0.02) greater improvement in PEF and a 48.1% (95% CI: 19.8 to 76.4%) (p = 0.001) greater improvement in FEV1 from the control group. At the end of protocol (3 h), 39% (n = 36) of patients in the control group and 20% (n = 18) in the IB group were admitted (p = 0.01). The use of high doses of is reduced the risk of hospital admission 49% (relative risk = 0.51, 95% CI: 0.31 to 0.83). Five (95% CI: 3 to 17) patients would need to be treated with high doses of IB to prevent a single admission. Kaplan-Meier-estimated curves of the proportion of patients who reached the discharge threshold during the 3 h of treatment, showed a significant difference in favor of the IB group (log-rank test = 0.005). A subgroup analysis showed that patients most likely to benefit from the addition of high doses of IB were those with more severe obstruction (FEV1 less than or equal to 30% of predicted) and long duration of symptoms before the ED presentation (greater than or equal to 24 h). On the contrary, previous use of inhaled beta(2)-agonists did not modify the admission rate and the pulmonary function response to IB. In conclusion, our data support a substantial therapeutic benefit from the addition of IB to albuterol administered in high doses through MDI plus spacer, particularly in patients with FEV1 less than 30%, and with long duration of symptoms before the ED presentation (greater than or equal to 24 h).	Hosp Cent FF AA, Dept Emergencia, Montevideo 11600, Uruguay; Asociac Espanola 1 Socorros Mutuos, Unidad Cuidado Intens, Montevideo, Uruguay	Rodrigo, CJ (reprint author), Hosp Cent FF AA, Dept Emergencia, Av 8 Octubre 3020, Montevideo 11600, Uruguay.						American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; BRYANT DH, 1985, CHEST, V88, P24, DOI 10.1378/chest.88.1.24; FitzGerald JM, 1997, CHEST, V111, P311, DOI 10.1378/chest.111.2.311; Garrett JE, 1997, J ALLERGY CLIN IMMUN, V100, P165, DOI 10.1016/S0091-6749(97)70219-7; GROSS NJ, 1988, NEW ENGL J MED, V319, P486; HIGGINS RM, 1988, CHEST, V94, P718, DOI 10.1378/chest.94.4.718; Karpel JP, 1996, CHEST, V110, P611, DOI 10.1378/chest.110.3.611; Lin RY, 1998, ANN EMERG MED, V31, P208, DOI 10.1016/S0196-0644(98)70308-7; MCFADDEN ER, 1973, NEW ENGL J MED, V288, P221, DOI 10.1056/NEJM197302012880501; ODRISCOLL BR, 1989, LANCET, V1, P1418; Plotnick LH, 1998, BRIT MED J, V317, P971; Qureshi F, 1997, ANN EMERG MED, V29, P205, DOI 10.1016/S0196-0644(97)70269-5; Qureshi F, 1998, NEW ENGL J MED, V339, P1030, DOI 10.1056/NEJM199810083391503; REBUCK AS, 1987, AM J MED, V82, P59, DOI 10.1016/0002-9343(87)90378-0; REISMAN J, 1988, J ALLERGY CLIN IMMUN, V81, P16, DOI 10.1016/0091-6749(88)90214-X; Rodrigo C, 1998, CHEST, V113, P593, DOI 10.1378/chest.113.3.593; RODRIGO C, 1996, AM J RESP CRIT CARE, V153, pA60; Rodrigo G, 1996, AM J EMERG MED, V14, P144, DOI 10.1016/S0735-6757(96)90121-7; Rodrigo G, 1999, AM J MED, V107, P363, DOI 10.1016/S0002-9343(99)00243-0; Rodrigo G, 1998, AM J RESP CRIT CARE, V157, P698; SACKETT D, 1998, EVIDENCE BASED MED H; SCHUH S, 1995, J PEDIATR-US, V126, P639, DOI 10.1016/S0022-3476(95)70368-3; Stoodley RG, 1999, ANN EMERG MED, V34, P8, DOI 10.1016/S0196-0644(99)70266-0; SUMMERS QA, 1990, CHEST, V97, P430; Turner MO, 1997, ARCH INTERN MED, V157, P1736, DOI 10.1001/archinte.157.15.1736; WARD MJ, 1981, BRIT MED J, V282, P598; WATSON WTA, 1988, J ALLERGY CLIN IMMUN, V82, P1012, DOI 10.1016/0091-6749(88)90138-8; Weber EJ, 1999, CHEST, V115, P937, DOI 10.1378/chest.115.4.937	29	97	97	0	0	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN	2000	161	6					1862	1868				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	325KV	WOS:000087675500021		
S	Broeckaert, F; Clippe, A; Knoops, B; Hermans, C; Bernard, A		Mukherjee, AB; Chilton, BS		Broeckaert, F; Clippe, A; Knoops, B; Hermans, C; Bernard, A			Clara cell secretory protein (CC16): Features as a peripheral lung biomarker	UTEROGLOBIN/CLARA CELL PROTEIN FAMILY	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	Conference on Uteroglobin/Calra Cell Protein Family	APR 14-16, 2000	BETHESDA, MARYLAND	NICHHD, NHLBI, New York Acad Sci			BRONCHOALVEOLAR LAVAGE; BIOLOGICAL-FLUIDS; 10-KDA PROTEIN; SERUM LEVELS; ASTHMA; EPITHELIUM; PERMEABILITY; POLYMORPHISM; UTEROGLOBIN; MARKER	Clara cell protein (CC16 or CC10) is a 15.8-kDa protein secreted all along the tracheobronchial tree and especially in the terminal bronchioles where Clara cells are localized. Even though the exact in vivo function of CC16 remains to be clarified, evidence is accumulating that CC16 plays an important protective role in the respiratory tract against oxidative stress and inflammatory response. CC16, however, presents also a major interest as a peripheral lung marker for assessing the cellular integrity or the permeability of the lung epithelium. The serum concentrations of CC16 are decreased in subjects with chronic lung damage caused by tobacco smoke and other air pollutants as a consequence of the destruction of Clara cells. By contrast, serum CC16 in. creases in acute or chronic lung disorders characterized by an increased airways permeability. The sensitivity of serum CC16 to an increased leakiness of the lung allows for the detection of defects of the epithelial barrier at ozone levels below current air-quality guidelines. Although the clinical significance of these early epithelial changes detected by serum CC16 remains to be determined, these results clearly show that the assay in serum of lung secretory proteins such as CC16 represents a new noninvasive approach to evaluate the integrity of the respiratory tract.	Univ Catholique Louvain, Sch Publ Hlth, Fac Med, Ind Toxicol & Occupat Med Unit, B-1200 Brussels, Belgium	Bernard, A (reprint author), Univ Catholique Louvain, Sch Publ Hlth, Fac Med, Ind Toxicol & Occupat Med Unit, 30-54 Clos Chapelle Champs, B-1200 Brussels, Belgium.		BERNARD, Alfred/A-6511-2010	BERNARD, Alfred/0000-0003-3171-3743			Arsalane K, 2000, AM J RESP CRIT CARE, V161, P1624; Arsalane K, 1999, TOXICOL APPL PHARM, V159, P169, DOI 10.1006/taap.1999.8738; BERNARD A, 1994, PEDIATR RES, V36, P771, DOI 10.1203/00006450-199412000-00015; BERNARD A, 1992, EUR RESPIR J, V5, P1231; BERNARD A, 1993, CLIN CHIM ACTA, V223, P189, DOI 10.1016/0009-8981(93)90077-H; Bernard A, 1997, OCCUP ENVIRON MED, V54, P63; BERNARD A, 1998, BIOMARKERS MED WORKP, P273; Buchet JP, 1993, ENVIRON RES, V66, P96; Bernard A M, 1994, Kidney Int Suppl, V47, pS34; BERNARD AM, 1994, EUR RESPIR J, V7, P1932; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Broeckaert F, 2000, CLIN EXP ALLERGY, V30, P469; DODGE DE, 1993, J HISTOCHEM CYTOCHEM, V41, P1171; FLOPPER CG, 1997, LUNG, P517; Halatek T, 1998, EUR RESPIR J, V11, P726; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; Hermans C, 1999, EUR RESPIR J, V13, P1014, DOI 10.1034/j.1399-3003.1999.13e14.x; JACKSON PJ, 1988, J CHROMATOGR, V452, P359, DOI 10.1016/S0021-9673(01)81460-6; JENSEN SM, 1994, INT J CANCER, V58, P629, DOI 10.1002/ijc.2910580503; KABANDA A, 1995, KIDNEY INT, V48, P1946, DOI 10.1038/ki.1995.495; Laing IA, 1998, J MED GENET, V35, P463, DOI 10.1136/jmg.35.6.463; Laing IA, 2000, AM J RESP CRIT CARE, V161, P124; NIETO A, 1982, COMP BIOCHEM PHYS B, V71, P511, DOI 10.1016/0305-0491(82)90417-5; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Shijubo N, 1999, LUNG, V177, P45, DOI 10.1007/PL00007626; SINGH G, 1988, J HISTOCHEM CYTOCHEM, V36, P73; Stripp BR, 1995, AM J PHYSIOL-LUNG C, V269, pL791; VANVYVE T, 1995, J ALLERGY CLIN IMMUN, V95, P60, DOI 10.1016/S0091-6749(95)70153-2	29	97	101	0	6	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-293-2	ANN NY ACAD SCI	Ann.NY Acad.Sci.		2000	923						68	77				10	Biochemistry & Molecular Biology; Multidisciplinary Sciences	Biochemistry & Molecular Biology; Science & Technology - Other Topics	BT10P	WOS:000171966400006	11193780	
J	Lange, P; Celli, B; Agusti, A; Jensen, GB; Divo, M; Faner, R; Guerra, S; Marott, JL; Martinez, FD; Martinez-Camblor, P; Meek, P; Owen, CA; Petersen, H; Pinto-Plata, V; Schnohr, P; Sood, A; Soriano, JB; Tesfaigzi, Y; Vestbo, J				Lange, Peter; Celli, Bartolome; Agusti, Alvar; Jensen, Gorm Boje; Divo, Miguel; Faner, Rosa; Guerra, Stefano; Marott, Jacob Louis; Martinez, Fernando D.; Martinez-Camblor, Pablo; Meek, Paula; Owen, Caroline A.; Petersen, Hans; Pinto-Plata, Victor; Schnohr, Peter; Sood, Akshay; Soriano, Joan B.; Tesfaigzi, Yohannes; Vestbo, Jorgen			Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; FORCED EXPIRATORY VOLUME; FUNCTION DECLINE; NATURAL-HISTORY; INHALED BUDESONIDE; CHILDHOOD ASTHMA; CONTROLLED-TRIAL; COHORT; COPD; SMOKING	BACKGROUND Chronic obstructive pulmonary disease (COPD) is thought to result from an accelerated decline in forced expiratory volume in 1 second (FEV1) over time. Yet it is possible that a normal decline in FEV1 could also lead to COPD in persons whose maximally attained FEV1 is less than population norms. METHODS We stratified participants in three independent cohorts (the Framingham Offspring Cohort, the Copenhagen City Heart Study, and the Lovelace Smokers Cohort) according to lung function (FEV1 >= 80% or <80% of the predicted value) at cohort inception (mean age of patients, approximately 40 years) and the presence or absence of COPD at the last study visit. We then determined the rate of decline in FEV1 over time among the participants according to their FEV1 at cohort inception and COPD status at study end. RESULTS Among 657 persons who had an FEV1 of less than 80% of the predicted value before 40 years of age, 174 (26%) had COPD after 22 years of observation, whereas among 2207 persons who had a baseline FEV1 of at least 80% of the predicted value before 40 years of age, 158 (7%) had COPD after 22 years of observation (P<0.001). Approximately half the 332 persons with COPD at the end of the observation period had had a normal FEV1 before 40 years of age and had a rapid decline in FEV1 thereafter, with a mean (+/- SD) decline of 53 +/- 21 ml per year. The remaining half had had a low FEV1 in early adulthood and a subsequent mean decline in FEV1 of 27 +/- 18 ml per year (P<0.001), despite similar smoking exposure. CONCLUSIONS Our study suggests that low FEV1 in early adulthood is important in the genesis of COPD and that accelerated decline in FEV1 is not an obligate feature of COPD. (Funded by an unrestricted grant from GlaxoSmithKline and others.)	[Lange, Peter] Univ Copenhagen, Inst Publ Hlth, Sect Social Med, DK-1014 Copenhagen K, Denmark; [Lange, Peter] Univ Copenhagen, Resp Sect, Hvidovre Hosp, DK-1014 Copenhagen K, Denmark; [Lange, Peter; Jensen, Gorm Boje; Marott, Jacob Louis; Schnohr, Peter] Univ Copenhagen, Copenhagen City Heart Study, Frederiksberg Hosp, DK-1014 Copenhagen K, Denmark; [Vestbo, Jorgen] Univ Copenhagen, Dept Resp Med, Gentofte Hosp, DK-1014 Copenhagen K, Denmark; [Jensen, Gorm Boje] Univ Southern Denmark, Odense, Denmark; [Celli, Bartolome; Divo, Miguel; Owen, Caroline A.; Pinto-Plata, Victor] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; [Agusti, Alvar] Univ Barcelona, Inst Invest Biomed August Pi & Sunyer, Hosp Clin, Serv Pneumol,Thorax Inst, Barcelona, Spain; [Faner, Rosa] Fundacio Clin Recerca Biomed, Barcelona, Spain; [Agusti, Alvar; Faner, Rosa] Ctr Invest Biomed Red Enfermedades Resp, Madrid, Spain; [Soriano, Joan B.] Univ Autonoma Madrid, Catedra UAM Linde, Inst Invest Hosp Univ Princesa, Madrid, Spain; [Guerra, Stefano; Martinez, Fernando D.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Martinez-Camblor, Pablo] Univ Autonoma Chile, Santiago, Chile; [Meek, Paula] Univ Colorado, Denver, CO 80202 USA; [Petersen, Hans; Tesfaigzi, Yohannes] Lovelace Resp Res Inst, Albuquerque, NM USA; [Sood, Akshay] Univ New Mexico, Albuquerque, NM 87131 USA; [Vestbo, Jorgen] Univ Manchester, Manchester Acad Hlth Sci Ctr, Resp & Allergy Res Grp, Manchester, Lancs, England	Lange, P (reprint author), Univ Copenhagen, Inst Publ Hlth, Sect Social Med, POB 2099,Oster Farimagsgade 5, DK-1014 Copenhagen K, Denmark.	peter.lange@sund.ku.dk	Martinez-Camblor, Pablo/Q-1715-2015; SMIRE+CODIRE, Research Group /E-7657-2017	SMIRE+CODIRE, Research Group /0000-0002-8871-4942; Faner, Rosa/0000-0002-8159-0115	GlaxoSmithKline	Funded by an unrestricted grant from GlaxoSmithKline and others.	Altose MD, 2000, NEW ENGL J MED, V343, P1902; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Baughman P, 2012, EUR J EPIDEMIOL, V27, P933, DOI 10.1007/s10654-012-9750-2; Bisgaard H, 2012, AM J RESP CRIT CARE, V185, P1183, DOI 10.1164/rccm.201110-1922OC; BLAND JM, 1994, BRIT MED J, V309, P780; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; BURROWS B, 1977, AM REV RESPIR DIS, V115, P751; BURROWS B, 1986, AM REV RESPIR DIS, V133, P974; Casanova C, 2011, AM J RESP CRIT CARE, V184, P1015, DOI 10.1164/rccm.201105-0831OC; Celli BR, 2008, AM J RESP CRIT CARE, V178, P332, DOI 10.1164/rccm.200712-1869OC; Decramer M, 2005, LANCET, V365, P1552, DOI 10.1016/S0140-6736(05)66456-2; FLETCHER C, 1977, BRIT MED J, V1, P1645; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hnizdo E, 2006, J OCCUP ENVIRON MED, V48, P625, DOI 10.1097/01.jom.0000214351.18905.48; Hoesein FAAM, 2012, CHEST, V142, P1530, DOI 10.1378/chest.11-2837; Kerstjens HAM, 1997, THORAX, V52, P820; Kohansal R, 2009, AM J RESP CRIT CARE, V180, P3, DOI 10.1164/rccm.200901-0047OC; Kohansal R, 2009, CHEST, V135, P1330, DOI 10.1378/chest.08-1750; Lokke A, 2012, CLIN RESPIR  J, V7, P153; Pauwels RA, 1999, NEW ENGL J MED, V340, P1948, DOI 10.1056/NEJM199906243402503; Petersen H, 2014, CHEST, V145, P695, DOI 10.1378/chest.13-0799; Postma DS, 2015, LANCET, V385, P899, DOI 10.1016/S0140-6736(14)60446-3; Sanchez-Salcedo P, 2014, EUR RESPIR J, V44, P324, DOI 10.1183/09031936.00208613; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; SHERRILL DL, 1992, EUR RESPIR J, V5, P452; Stern DA, 2007, LANCET, V370, P758, DOI 10.1016/S0140-6736(07)61379-8; Stocks J, 2013, LANCET RESP MED, V1, P728, DOI 10.1016/S2213-2600(13)70118-8; Svanes C, 2010, THORAX, V65, P14, DOI 10.1136/thx.2008.112136; Tai A, 2014, THORAX, V69, P805, DOI 10.1136/thoraxjnl-2013-204815; Tantucci C, 2012, INT J CHRONIC OBSTR, V7, P95, DOI 10.2147/COPD.S27480; Tashkin DP, 2008, NEW ENGL J MED, V359, P1543, DOI 10.1056/NEJMoa0805800; Tashkin DP, 2013, CURR OPIN PULM MED, V19, P116, DOI 10.1097/MCP.0b013e32835d8ea4; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vestbo J, 2013, AM J RESP CRIT CARE, V187, P347, DOI 10.1164/rccm.201204-0596PP; Vestbo J, 2011, NEW ENGL J MED, V365, P1184, DOI 10.1056/NEJMoa1105482; Weiss ST, 1996, AM J RESP CRIT CARE, V154, pS208	36	96	97	5	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 9	2015	373	2					111	122		10.1056/NEJMoa1411532		12	Medicine, General & Internal	General & Internal Medicine	CM3QP	WOS:000357598600004	26154786	
J	Agache, I; Ciobanu, C; Agache, C; Anghel, M				Agache, Ioana; Ciobanu, Cristina; Agache, Costel; Anghel, Mariana			Increased serum IL-17 is an independent risk factor for severe asthma	RESPIRATORY MEDICINE			English	Article						IL-17; Severe asthma; Risk factors	C-REACTIVE PROTEIN; AIR-FLOW LIMITATION; CELLS; TH17; INFLAMMATION; SPUTUM	Background: IL-17 expression was found to be associated with many inflammatory diseases in humans, such as rheumatoid arthritis, asthma, systemic lupus erythematosus and allograft rejection and many in vitro studies have indicated a proinflammatory function for IL-17. Objective: Prognostic value of increased serum IL-17 in asthma patients. Methods: Serum IL-17 (ELISA) was measured in 85 asthma patients (pts), mean age 46.99 +/- 14.1 years, 61% females, 23 mild persistent, 26 moderate persistent and 36 severe persistent asthma. Using multiple regression analysis (STATISTICA 7), increased serum IL-17 (>20 pg/ml) was tested as risk factor for severe asthma in comparison with "traditional" risk factors: smoke, NSAID intolerance, obesity, chronic rhinosinusitis, blood eosinophilia, FEV(1) at baseline < 50% predicted (low FEV(1)). Results: Medium serum IL-17 values were 14.21 pg/ml in mild asthma, 12.22 pg/ml in moderate asthma and 24.72 pg/ml in severe asthma. IL-17 values > 20 pg/ml were encountered in 3(13%) mild asthma pts (p < 0.001 vs. severe asthma), 2(8%) moderate asthma pts. (p < 0.001 vs. severe asthma), and in 11(31%) severe asthma pts. For severe asthma multiple regression analysis revealed as independent risk factors IL-17 (p = 0.000290), NSAID intolerance (p = 0.000585) and low FEV(1) (p = 0.000059). Conclusions: IL-17 is increased in severe asthma compared to mild/moderate forms of the disease and values above 20 pg/ml are an independent risk factor for severe asthma. (C) 2010 Elsevier Ltd. All rights reserved.	[Agache, Ioana] Transylvania Univ, Fac Med, Dept Allergy & Clin Immunol, Brasov 500036, Romania; [Ciobanu, Cristina; Agache, Costel] Theramed Med Ctr, Dept Allergy & Clin Immunol, Brasov 500112, Romania; [Anghel, Mariana] Brasov Cty Hosp, Immunol Lab, Brasov 500326, Romania	Agache, I (reprint author), Spatarul Luca Arbore 16, Brasov 500112, Romania.	ibrumaru@unitbv.ro					Barczyk A, 2003, RESP MED, V97, P726, DOI 10.1053/rmed.2003.1507; Bullens DMA, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-135; Kaminska M, 2009, J ALLERGY CLIN IMMUN, V124, P45, DOI 10.1016/j.jaci.2009.03.049; Kasayama S, 2009, CLIN CHIM ACTA, V399, P79, DOI 10.1016/j.cca.2008.09.013; Laan M, 2001, BRIT J PHARMACOL, V133, P200, DOI 10.1038/sj.bjp.0704063; Lee JH, 2007, CHEST, V132, P1882, DOI 10.1378/chest.07-0713; Molet S, 2001, J ALLERGY CLIN IMMUN, V108, P430, DOI 10.1067/mai.2001.117929; Pene J, 2008, J IMMUNOL, V180, P7423; Qian FH, 2008, RESPIROLOGY, V13, P664, DOI 10.1111/j.1440-1843.2008.01314.x; Saito H, 2009, INT ARCH ALLERGY IMM, V149, P61, DOI 10.1159/000210656; Tato CM, 2006, NATURE, V441, P166, DOI 10.1038/441166a; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Wakashin H, 2008, AM J RESP CRIT CARE, V178, P1023, DOI 10.1164/rccm.200801-086OC; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x; Zietkowski Z, 2009, RESP MED, V103, P379, DOI 10.1016/j.rmed.2008.10.003	15	96	103	0	16	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111			RESP MED	Respir. Med.	AUG	2010	104	8					1131	1137		10.1016/j.rmed.2010.02.018		7	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	629EX	WOS:000280178900006	20338742	
J	Olivry, T; DeBoer, DJ; Favrot, C; Jackson, HA; Mueller, RS; Nuttall, T; Prelaud, P				Olivry, Thierry; DeBoer, Douglas J.; Favrot, Claude; Jackson, Hilary A.; Mueller, Ralf S.; Nuttall, Tim; Prelaud, Pascal		Int Task Force Canine Atopic Derma	Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis	VETERINARY DERMATOLOGY			English	Article							ALLERGEN-SPECIFIC IMMUNOTHERAPY; HOUSE-DUST MITES; TYPE-1 HYPERSENSITIVITY REACTIONS; ADVERSE FOOD REACTIONS; DOUBLE-BLIND; TACROLIMUS OINTMENT; HEALTHY DOGS; CONTROLLED-TRIAL; MALASSEZIA-PACHYDERMATIS; FLUTICASONE PROPIONATE	Atopic dermatitis (AD) is a common chronic relapsing pruritic skin disease of dogs for which treatment has varied over time and geographical location. Recent high quality randomized controlled trials and systematic reviews have established which drugs are likely to offer consistent benefit. The International Task Force for Canine AD currently recommends a multifaceted approach to treat dogs with AD. Acute flares should be treated with a combination of nonirritating baths and topical glucocorticoids, once an attempt has been made to identify and remove the suspected causes of the flare. Oral glucocorticoids and antimicrobial therapy must be added when needed. In dogs with chronic AD, a combination of interventions should be considered. Again, factors that trigger flares of AD must be identified and, if possible, avoided. Currently recognized flare factors include food, flea and environmental allergens, Staphylococcus bacteria and Malassezia yeast. Skin and coat hygiene and care must be improved by bathing with nonirritating shampoos and dietary supplementation with essential fatty acids. The severity of pruritus and skin lesions can be reduced with a combination of anti-inflammatory drugs. Currently, medications with good evidence of high efficacy include topical and oral glucocorticoids, and calcineurin inhibitors such as oral ciclosporin and topical tacrolimus. The dose and frequency of administration of these drugs should be tailored to each patient considering each drug's efficacy, adverse effects and cost. Allergen-specific immunotherapy should be offered, whenever feasible, in an attempt to prevent recurrence of clinical signs upon further exposure to environmental allergens to which the patient is hypersensitive.	[Olivry, Thierry] N Carolina State Univ, Coll Vet Med, Dept Clin Sci, Raleigh, NC 27606 USA; [Olivry, Thierry; Int Task Force Canine Atopic Derma] N Carolina State Univ, Coll Vet Med, Ctr Comparat Med & Translat Res, Raleigh, NC 27606 USA; [DeBoer, Douglas J.] Univ Wisconsin, Sch Vet Med, Dept Med Sci, Madison, WI 53706 USA; [Favrot, Claude] Univ Zurich, Vetsuisse Fac, Dept Dermatol, Clin Small Anim Internal Med, Zurich, Switzerland; [Jackson, Hilary A.] Dermatol Referral Serv, Glasgow, Lanark, Scotland; [Mueller, Ralf S.] Univ Munich, Med Klin, Munich, Germany; [Nuttall, Tim] Univ Liverpool, Sch Vet Sci, Small Anim Teaching Hosp, Neston, England; [Prelaud, Pascal] Clin Advetia, Paris, France	Olivry, T (reprint author), N Carolina State Univ, Coll Vet Med, Dept Clin Sci, Res Bldg,4700 Hillsborough St, Raleigh, NC 27606 USA.	thierry_olivry@ncsu.edu	Olivry, Thierry/E-3289-2013	Mueller, Ralf/0000-0001-5835-5910			Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; BADDAKYTAUGBOL B, 2005, ADV VET DERMATOLOGY, V5, P173; Bensignor E, 2005, VET DERMATOL, V16, P52, DOI 10.1111/j.1365-3164.2005.00419.x; Berth-Jones J, 2003, BRIT MED J, V326, P1367, DOI 10.1136/bmj.326.7403.1367; Bizikova P, 2008, VET DERMATOL, V19, P348, DOI 10.1111/j.1365-3164.2008.00697.x; Bizikova P, 2010, VET DERMATOL, V21, P70, DOI 10.1111/j.1365-3164.2009.00782.x; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Bryden SL, 2008, VET DERMATOL, V19, P40; Carlotti DN, 2004, VET DERMATOLOGY S1, V1, P32, DOI 10.1111/j.1365-3164.2004.411_37.x; Carr MN, 2009, VET DERMATOL, V20, P105, DOI 10.1111/j.1365-3164.2008.00716.x; DeBoer DJ, 2002, AM J VET RES, V63, P408, DOI 10.2460/ajvr.2002.63.408; DeBoer DJ, 2001, VET IMMUNOL IMMUNOP, V81, P239, DOI 10.1016/S0165-2427(01)00345-2; DeBoer DJ, 2001, VET IMMUNOL IMMUNOP, V81, P271, DOI 10.1016/S0165-2427(01)00312-9; DeBoer DJ, 2001, VET IMMUNOL IMMUNOP, V81, P277, DOI 10.1016/S0165-2427(01)00304-X; DEVOS C, 1987, ANN ALLERGY, V59, P278; Ewert G, 2001, PRAT MED CHIR ANIM, V36, P401; Farver K, 2005, VET DERMATOL, V16, P261, DOI 10.1111/j.1365-3164.2005.00463.x; Favrot C, 2010, VET DERMATOL, V21, P23, DOI 10.1111/j.1365-3164.2009.00758.x; Glos K, 2008, VET DERMATOL, V19, P280, DOI 10.1111/j.1365-3164.2008.00688.x; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Griffin CE, 2001, VET IMMUNOL IMMUNOP, V81, P255, DOI 10.1016/S0165-2427(01)00346-4; Griffin CE, 2001, VET IMMUNOL IMMUNOP, V81, P363, DOI 10.1016/S0165-2427(01)00348-8; Gross TL, 1997, VET DERMATOL, V8, P127, DOI 10.1046/j.1365-3164.1997.d01-3.x; Gutgesell C, 2001, BRIT J DERMATOL, V145, P70, DOI 10.1046/j.1365-2133.2001.04283.x; Halliwell R., 2006, VET IMMUNOL IMMUNOP, V114, P2007; Hanifin J, 2002, BRIT J DERMATOL, V147, P528, DOI 10.1046/j.1365-2133.2002.05006.x; Hansson H, 2004, VET DERMATOL, V15, P152, DOI 10.1111/j.1365-3164.2004.00367.x; Hill PB, 2001, VET IMMUNOL IMMUNOP, V81, P159; Hillier A, 2001, VET IMMUNOL IMMUNOP, V81, P289, DOI 10.1016/S0165-2427(01)00313-0; Hofmeister EH, 2005, JAVMA-J AM VET MED A, V226, P1092, DOI 10.2460/javma.2005.226.1092; Horvath-Ungerboeck C, 2009, VET DERMATOL, V20, P233, DOI 10.1111/j.1365-3164.2009.00739.x; Iwasaki T, 2006, VET DERMATOL, V17, P195, DOI 10.1111/j.1365-3164.2006.00519.x; Kimura T, 1999, TOXICOL PATHOL, V27, P528, DOI 10.1177/019262339902700506; Leung DYM, 2004, ANN ALLERG ASTHMA IM, V93, pS1; Loewenstein C, 2009, VET DERMATOL, V20, P84, DOI 10.1111/j.1365-3164.2008.00727.x; Loflath A, 2007, Vet Dermatol, V18, P427, DOI 10.1111/j.1365-3164.2007.00639.x; Marsella R, 2006, VET DERMATOL, V17, P24, DOI 10.1111/j.1365-3164.2005.00496.x; Marsella R, 2006, VET DERMATOL, V17, P306, DOI 10.1111/j.1365-3164.2006.00541.x; Marsella R, 2004, VET DERMATOL, V15, P294, DOI 10.1111/j.1365-3164.2004.00397.x; Marsella R, 2009, VET DERMATOL, V20, P533, DOI 10.1111/j.1365-3164.2009.00809.x; Marsh KA, 2000, VET DERMATOL, V11, P277, DOI 10.1046/j.1365-3164.2000.00202.x; MORALES CA, 1994, VET IMMUNOL IMMUNOP, V42, P137, DOI 10.1016/0165-2427(94)90003-5; Morris DO, 2003, AM J VET RES, V64, P262, DOI 10.2460/ajvr.2003.64.262; Morris DO, 1998, AM J VET RES, V59, P836; Carlotti DN, 2009, VET DERMATOL, V20, P405, DOI 10.1111/j.1365-3164.2009.00848.x; Nuttall T, 2006, VET DERMATOL, V17, P348, DOI 10.1111/j.1365-3164.2006.00537.x; Nuttall T, 2009, VET DERMATOL, V20, P191, DOI 10.1111/j.1365-3164.2009.00756.x; Nuttall TJ, 2001, VET DERMATOL, V12, P327, DOI 10.1046/j.0959-4493.2001.00261.x; Olivry T, 2001, VET IMMUNOL IMMUNOP, V81, P347, DOI 10.1016/S0165-2427(01)00316-6; Olivry T, 2001, VET IMMUNOL IMMUNOP, V81, P143, DOI 10.1016/S0165-2427(01)00343-9; Olivry T, 2005, ADV VET DERMATOLOGY, V5, P10; Olivry T, 2007, VET DERMATOL, V18, P390, DOI 10.1111/j.1365-3164.2007.00625.x; Olivry T, 2010, VET DERMATOL, V21, P31, DOI 10.1111/j.1365-3164.2009.00761.x; Olivry T, 2010, VET DERMATOL, V21, P4, DOI 10.1111/j.1365-3164.2009.00784.x; Paller AS, 2008, PEDIATRICS, V122, pE1210, DOI 10.1542/peds.2008-1343; PARADIS M, 1991, J AM ANIM HOSP ASSOC, V27, P44; Piekutowska A, 2008, J COMP PATHOL, V138, P197, DOI 10.1016/j.jcpa.2008.01.006; Plant JD, 2008, VET REC, V162, P624; Pucheu-Haston CM, 2008, CLIN EXP ALLERGY, V38, P667, DOI 10.1111/j.1365-2222.2008.02949.x; Raffan E, 2005, VET DERMATOL, V16, P253, DOI 10.1111/j.1365-3164.2005.00461.x; REME CA, 2008, VET DERMATOLOGY S1, V19, P47; ROUDEBUSH P, 2001, ANN M AM AC VET DERM; ROUDEBUSH P, 1997, AAVD ACVD M NASHV TN, P10; Saevik B, 2004, VET DERMATOL, V15, P137, DOI 10.1111/j.1365-3164.2004.00378.x; Schmidt V, 2010, VET DERMATOL, V21, P91; Schnabl B, 2006, VET REC, V158, P81; Sousa CA, 2001, VET IMMUNOL IMMUNOP, V81, P233, DOI 10.1016/S0165-2427(01)00344-0; Steffan J, 2006, VET DERMATOL, V17, P3, DOI 10.1111/j.1365-3164.2005.00491.x; Swinnen C, 2004, VET DERMATOL, V15, P31, DOI 10.1111/j.1365-3164.2004.00365.x; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Thaci D, 2008, BRIT J DERMATOL, V159, P1348, DOI 10.1111/j.1365-2133.2008.08813.x; Watson AL, 2006, EXP DERMATOL, V15, P74, DOI 10.1111/j.0906-6705.2005.00385.x; Yasukawa K, 2010, VET DERMATOL, V21, P41, DOI 10.1111/j.1365-3164.2009.00764.x; Zur G, 2002, VET DERMATOL, V13, P103, DOI 10.1046/j.1365-3164.2002.00286.x	74	96	96	4	56	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0959-4493			VET DERMATOL	Vet. Dermatol.	JUN	2010	21	3					233	248		10.1111/j.1365-3164.2010.00889.x		16	Dermatology; Veterinary Sciences	Dermatology; Veterinary Sciences	596WF	WOS:000277715500001	20456716	
J	Bornehag, CG; Nanberg, E				Bornehag, C. G.; Nanberg, E.			Phthalate exposure and asthma in children	INTERNATIONAL JOURNAL OF ANDROLOGY			English	Article; Proceedings Paper	5th Copenhagen Workshop on Endocrine Disruptgers - Ubiquitous Endocrine Disrupters and Possible Human Health Effects	MAY 20-22, 2009	Copenhagen, DENMARK			asthma; endocrine disrupters; environmental factors; epidemiology; immunology	SUBCUTANEOUS INJECTION MODEL; ENDOCRINE-DISRUPTING CHEMICALS; IN-HOUSE DUST; DI-N-BUTYL; DI-(2-ETHYLHEXYL) PHTHALATE; BALB/C MICE; DI(2-ETHYLHEXYL) PHTHALATE; AIRWAY INFLAMMATION; YOUNG-CHILDREN; MONO-2-ETHYLHEXYL PHTHALATE	P>During the last decades more than 100 000 new chemicals have been introduced to the environment. Many of these new chemicals and many common consumer products that include these have been shown to be toxic in animal studies and an increasing body of evidence suggests that they are also impacting human health. Among the suspect chemicals, the endocrine disrupting chemicals (EDCs) are of particular concern. One such chemical group is the phthalates, used in soft poly vinyl chloride (PVC) material and in a huge number of consumer products. During the same period of time that the prevalence of these modern chemicals has increased, there has been a remarkable increase in several chronic illnesses, including asthma and allergy in children. In this article we outline the scientific knowledge on phthalate exposure for asthma and airway diseases in children by examining epidemiological and experimental peer review data for potential explanatory mechanisms. Epidemiological data point to a possible correlation between phthalate exposure and asthma and airway diseases in children. Experimental studies present support for an adjuvant effect on basic mechanisms in allergic sensitization by several phthalates. Despite variations in the experimental design and reported result in the individual studies, a majority of published reports have identified adjuvant effects on Th2 differentiation, production of Th2 cytokines and enhanced levels of Th2 promoted immunoglobulins (mainly IgG1 but also IgE) in mice. A limited amount of data do also suggest phthalate-induced enhancement of mast cell degranulation and eosinophilic infiltration which are important parts in the early inflammation phase. Thus, some of the early key mechanisms in the pathology of allergic asthma could possibly be targeted by phthalate exposure. But the important questions of clinical relevance of real life exposure and identification of molecular targets that can explain interactions largely remain to be answered.	[Bornehag, C. G.; Nanberg, E.] Karlstad Univ, Dept Chem & Biomed Sci, SE-65188 Karlstad, Sweden	Bornehag, CG (reprint author), Karlstad Univ, Dept Chem & Biomed Sci, SE-65188 Karlstad, Sweden.	carl-gustaf.bornehag@kau.se					Adibi JJ, 2008, ENVIRON HEALTH PERSP, V116, P467, DOI 10.1289/ehp.10749; Adibi JJ, 2003, ENVIRON HEALTH PERSP, V111, P1719, DOI 10.1289/ehp.6235; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; BALLY MB, 1980, TOXICOLOGY, V18, P49, DOI 10.1016/0300-483X(80)90037-2; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2005, ENVIRON HEALTH PERSP, V113, P1399, DOI 10.1289/ehp.7809; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Butala JH, 2004, TOXICOLOGY, V201, P77, DOI 10.1016/j.tox.2004.04.004; Calafat AM, 2006, TOXICOLOGY, V217, P22, DOI 10.1016/j.tox.2005.08.013; Calafat AM, 2005, ENVIRON HEALTH PERSP, V113, P391; Calafat AM, 2007, ENVIRON HEALTH PERSP, V115, P1596, DOI 10.1289/ehp.10598; Chalubinski M, 2006, ALLERGY, V61, P1326, DOI 10.1111/j.1398-9995.2006.01135.x; Clement LT, 2008, AM J MED SCI, V335, P260, DOI 10.1097/MAJ.0b013e318169031c; COFFMAN RL, 1993, ADV IMMUNOL, V54, P229, DOI 10.1016/S0065-2776(08)60536-2; Dearman RJ, 2008, TOXICOLOGY, V244, P231, DOI 10.1016/j.tox.2007.11.017; Dearman RJ, 2009, J APPL TOXICOL, V29, P118, DOI 10.1002/jat.1388; Deutschle T, 2008, ENVIRON HEALTH PERSP, V116, P1487, DOI 10.1289/ehp.11474; Engel SM, 2006, REPROD TOXICOL, V21, P110, DOI 10.1016/j.reprotox.2005.07.007; Epstein MM, 2004, INT ARCH ALLERGY IMM, V133, P84, DOI 10.1159/000076131; Fischer FP, 1998, PERITON DIALYSIS INT, V18, P620; Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Glue C, 2005, BASIC CLIN PHARMACOL, V96, P140, DOI 10.1111/j.1742-7843.2005.pto960208.x; Glue C, 2002, TOXICOL IN VITRO, V16, P657, DOI 10.1016/S0887-2333(02)00082-6; Gourlay T, 2003, ARTIF ORGANS, V27, P256, DOI 10.1046/j.1525-1594.2003.07107.x; Hansen JS, 2007, TOXICOLOGY, V232, P79, DOI 10.1016/j.tox.2006.12.011; Heudorf U, 2007, INT J HYG ENVIR HEAL, V210, P623, DOI 10.1016/j.ijheh.2007.07.011; Hogberg J, 2008, ENVIRON HEALTH PERSP, V116, P334, DOI 10.1289/ehp.10788; Hong CC, 2004, BIOL PHARM BULL, V27, P1136, DOI 10.1248/bpb.27.1136; Huang PC, 2009, ENVIRON INT, V35, P14, DOI 10.1016/j.envint.2008.05.012; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P560, DOI 10.2105/AJPH.94.4.560; Jepsen KF, 2004, TOXICOL IN VITRO, V18, P265, DOI 10.1016/j.tiv.2003.09.008; Kato T, 2006, EUR J IMMUNOL, V36, P1199, DOI 10.1002/eji.200535140; Koike E, 2009, TOXICOLOGY, V259, P54, DOI 10.1016/j.tox.2009.02.002; Kolarik B, 2008, ENVIRON HEALTH PERSP, V116, P98, DOI 10.1289/ehp.10498; Krug N, 2008, CURR DRUG TARGETS, V9, P438, DOI 10.2174/138945008784533598; Kumar RK, 2008, CURR DRUG TARGETS, V9, P485, DOI 10.2174/138945008784533561; Larsen ST, 2007, TOXICOL LETT, V170, P223, DOI 10.1016/j.toxlet.2007.03.009; Larsen ST, 2007, TOXICOLOGY, V235, P119, DOI 10.1016/j.tox.2007.03.010; Larsen ST, 2004, HUM EXP TOXICOL, V23, P537, DOI 10.1191/0960327104ht486oa; Larsen ST, 2003, FOOD CHEM TOXICOL, V41, P439, DOI 10.1016/S0278-6915(02)00248-X; Larsen ST, 2002, PHARMACOL TOXICOL, V91, P264, DOI 10.1034/j.1600-0773.2002.910508.x; Larsen ST, 2001, TOXICOL LETT, V125, P11; Larsen ST, 2001, TOXICOLOGY, V169, P37, DOI 10.1016/S0300-483X(01)00484-X; LARSSON M, 2009, PVC FLOORING I UNPUB; Lee MH, 2004, INT ARCH ALLERGY IMM, V134, P213, DOI 10.1159/000078768; Manning P J, 2007, Ir Med J, V100, P614; McLeish S, 2007, ARCH DIS CHILD, V92, P1032, DOI 10.1136/adc.2006.112185; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Nakamura R, 2002, IMMUNOL LETT, V80, P119, DOI 10.1016/S0165-2478(01)00318-2; Oh PS, 2009, N-S ARCH PHARMACOL, V380, P115, DOI 10.1007/s00210-009-0423-y; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Sakai K, 2001, INT ARCH ALLERGY IMM, V126, P126, DOI 10.1159/000049503; Schettler T, 2006, INT J ANDROL, V29, P134, DOI 10.1111/j.1365-2605.2005.00567.x; SHERTZER HG, 1985, ARCH ENVIRON CON TOX, V14, P605; SNAPPER CM, 1988, IMMUNOL REV, V102, P51, DOI 10.1111/j.1600-065X.1988.tb00741.x; STEVENS TL, 1988, NATURE, V334, P255, DOI 10.1038/334255a0; Taube C, 2004, INT ARCH ALLERGY IMM, V135, P173, DOI 10.1159/000080899; Tsutsumi O, 2005, J STEROID BIOCHEM, V93, P325, DOI 10.1016/j.jsbmb.2004.12.008; Vandenberg LN, 2007, REPROD TOXICOL, V24, P139, DOI 10.1016/j.reprotox.2007.07.010; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Yang GT, 2008, FOOD AGR IMMUNOL, V19, P351, DOI 10.1080/09540100802545869	64	96	102	6	52	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-6263			INT J ANDROL	Int. J. Androl.	APR	2010	33	2					333	345		10.1111/j.1365-2605.2009.01023.x		13	Andrology	Endocrinology & Metabolism	569XO	WOS:000275636400017	20059582	
J	Marra, F; Marra, CA; Richardson, K; Lynd, LD; Kozyrskyj, A; Patrick, DM; Bowie, WR; FitzGerald, JM				Marra, Fawziah; Marra, Carlo A.; Richardson, Kathryn; Lynd, Larry D.; Kozyrskyj, Anita; Patrick, David M.; Bowie, William R.; FitzGerald, J. Mark			Antibiotic Use in Children Is Associated With Increased Risk of Asthma	PEDIATRICS			English	Article						asthma; antibiotics; epidemiology; children; pediatrics	EARLY-CHILDHOOD; ALLERGIC DISEASE; BIRTH COHORT; 1ST YEAR; LIFE; INFECTIONS; CAUSATION; COMMITTEE; RHINITIS; EXPOSURE	BACKGROUND. Antibiotic exposure in early childhood is a possible contributor to the increasing asthma prevalence in industrialized countries. Although a number of published studies have tested this hypothesis, the results have been conflicting. OBJECTIVE. To explore the association between antibiotic exposure before 1 year of age and development of childhood asthma. METHODS. Using administrative data, birth cohorts from 1997 to 2003 were evaluated (N = 251 817). Antibiotic exposure was determined for the first year of life. After the first 24 months of life, the incidence of asthma was determined in both those exposed and not exposed to antibiotics in the first 12 months of life. Cox proportional hazards models were used to adjust for potential confounders and determine the hazard ratios associated with antibiotic exposure for the development of asthma. RESULTS. Antibiotic exposure in the first year of life was associated with a small risk of developing asthma in early childhood after adjusting for gender, socioeconomic status at birth, urban or rural address at birth, birth weight, gestational age, delivery method, frequency of physician visits, hospital visit involving surgery, visits to an allergist, respirologist, or immunologist, congenital anomalies, and presence of otitis media, acute, or chronic bronchitis, and upper and lower respiratory tract infections during the first year of life. As the number of courses of antibiotics increased, this was associated with increased asthma risk, with the highest risk being in children who received > 4 courses. All antibiotics were associated with an increased risk of developing asthma, with the exception of sulfonamides. CONCLUSIONS. This study provides evidence that the use of antibiotics in the first year of life is associated with a small risk of developing asthma, and this risk increases with the number of courses of antibiotics prescribed. Pediatrics 2009;123:1003-1010	[Marra, Fawziah; Marra, Carlo A.; Richardson, Kathryn; Lynd, Larry D.; Patrick, David M.; Bowie, William R.; FitzGerald, J. Mark] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC V6Z 1Y6, Canada; [Marra, Fawziah; Patrick, David M.] BC Ctr Dis Control, Dept Vaccine & Pharm, Vancouver, BC, Canada; [Kozyrskyj, Anita] Univ Manitoba, Dept Pharm, Winnipeg, MB, Canada; [FitzGerald, J. Mark] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada	Marra, CA (reprint author), Univ British Columbia, Fac Pharmaceut Sci, Ctr Hlth Evaluat & Outcomes Sci, St Pauls Hosp, 620-1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	carlo.marra@ubc.ca			BC Lung Association (British Columbia, Canada)	We thank data analysts at the Centre for Health Services and Policy Research, Data Access Services in the BC Ministry of Health, and the BC College of Pharmacists for providing these data.	Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Centers for Disease Control and Prevention, 2000, MMWR-MORBID MORTAL W, V49, P908; *CDCP, 2006, NAT HLTH INT SURV RA; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; HILL AB, 1965, P ROY SOC MED, V58, P295; *HLTH CAN, HLTH 4 KIDS; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; KOZYRSKYJ AL, 2009, ALLERGY IN PRESS; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Masoli M, 2004, ALLERGY, V59, P469, DOI 10.1111/j.1398-9995.2004.00526.x; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; MOREAU T, 1985, APPL STAT-J ROY ST C, V34, P212, DOI 10.2307/2347465; SCHOENFELD D, 1982, BIOMETRIKA, V69, P239, DOI 10.1093/biomet/69.1.239; Sharland M, 2007, J ANTIMICROB CHEMOTH, V60, pI15, DOI 10.1093/jac/dkm153; STRACHAN DP, 1989, BRIT MED J, V299, P1259; van Reekum R, 2001, J NEUROPSYCH CLIN N, V13, P318, DOI 10.1176/appi.neuropsych.13.3.318; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wjst M, 2001, EUR J MED RES, V6, P263	23	96	114	0	17	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2009	123	3					1003	1010		10.1542/peds.2008-1146		8	Pediatrics	Pediatrics	413XH	WOS:000263825500037	19255032	
J	Ostro, B; Roth, L; Malig, B; Marty, M				Ostro, Bart; Roth, Lindsey; Malig, Brian; Marty, Melanie			The Effects of Fine Particle Components on Respiratory Hospital Admissions in Children	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						children; EC; hospital admissions; OC; PM(2.5); respiratory; species	PARTICULATE AIR-POLLUTION; DIESEL EXHAUST PARTICLES; 9 CALIFORNIA COUNTIES; AMBIENT AIR; SOURCE-APPORTIONMENT; DAILY MORTALITY; RISK-ASSESSMENT; CASE-CROSSOVER; UTAH VALLEY; GAS-PHASE	BACKGROUND: Epidemiologic studies have demonstrated an association between acute exposure to ambient fine particles and both mortality and morbidity. Less is known about the relative impacts of the specific chemical constituents of particulate matter < 2.5 mu m in aerodynamic diameter (PM(2.5)) on hospital admissions. OBJECTIVE: This study was designed to estimate the risks of exposure to PM(2.5) and several species on hospital admissions for respiratory diseases among children. DATA AND METHODS: We obtained data on daily counts of hospitalizations for children < 19 and < 5 years of age for total respiratory diseases and several subcategories including pneumonia, acute bronchitis, and asthma for six California counties from 2000 through 2003, as well as ambient concentrations Of PM2.5 and its constituents, including elemental carbon (EC), organic carbon (OC), and nitrates (NO(3)). We used Poisson regression to estimate risks while controlling for important covariates. RESULTS: We observed associations between several components of PM(2.5) and hospitalization for all of the respiratory outcomes examined. For example, for total respiratory admissions for children < 19 years of age, the interquartile range for a 3-day lag of PM(2.5), EC, OC, NO(3), and sulfates was associated with an excess risk of 4.1% [95% confidence interval (CI), 1.8-6.4], 5.4% (95% CI, 0.8-10-3), 3.4% (95% CI, 1.1-5-7), 3.3% (95% CI, 1.1-5.5), and 3.0% (95% CI, 0.4-5-7), respectively. We also observed associations for several metals. Additional associations with several of the species, including potassium, were observed in the cool season. CONCLUSION: Components of PM(2.5) were associated with hospitalization for several childhood respiratory diseases including pneumonia, bronchitis, and asthma. Because exposure to components (e.g., EC, OC, NO(3), and K) and their related sources, including diesel and gasoline exhaust, wood smoke, and other combustion sources, are ubiquitous in the urban environment, it likely represents an identifiable and preventable risk factor for hospitalization for children.	[Ostro, Bart; Roth, Lindsey; Malig, Brian; Marty, Melanie] Calif EPA, OEHHA, Oakland, CA 94612 USA	Ostro, B (reprint author), Calif EPA, OEHHA, 1515 Clay St,16th Floor, Oakland, CA 94612 USA.	bostro@oehha.ca.gov					Andersen ZJ, 2007, J EXPO SCI ENV EPID, V17, P625, DOI 10.1038/sj.jes.7500546; Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Basu R, 2008, EPIDEMIOLOGY, V19, P138, DOI 10.1097/EDE.0b013e31815c1da7; Bell ML, 2007, ENVIRON HEALTH PERSP, V115, P989, DOI 10.1289/ehp.9621; Braga ALF, 2001, J OCCUP ENVIRON MED, V43, P927; BURNETT RT, 1995, AM J EPIDEMIOL, V142, P15; Burnett RT, 2000, INHAL TOXICOL, V12, P15, DOI 10.1080/089583700750019495; *CA AIR RES BOARD, 2007, 2007 ALM DAT OX SULF; CHALUPA D, 2000, ENV HLTH PERSPECT, V112, P879; Delfino RJ, 2006, ENVIRON HEALTH PERSP, V114, P1736, DOI 10.1289/ehp.9141; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dietert RR, 2000, ENVIRON HEALTH PERSP, V108, P483, DOI 10.2307/3454540; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Franklin M, 2008, EPIDEMIOLOGY, V19, P680, DOI 10.1097/EDE.0b013e3181812bb7; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Ghio AJ, 2004, J AEROSOL MED, V17, P157, DOI 10.1089/0894268041457200; Ginsberg GL, 2005, J TOXICOL ENV HEAL A, V68, P573, DOI 10.1080/15287390590921793; Gottipolu RR, 2008, INHAL TOXICOL, V20, P473, DOI 10.1080/08958370701858427 ; Hertz-Picciotto I, 2007, ENVIRON HEALTH PERSP, V115, P1510, DOI 10.1289/ehp.9617; Hirshon JM, 2008, ENVIRON HEALTH PERSP, V116, P826, DOI 10.1289/ehp.10759; Hiura TS, 2000, J IMMUNOL, V165, P2703; Kaewamatawong T, 2006, TOXICOL PATHOL, V34, P958, DOI 10.1080/01926230601094552; Khalil MAK, 2003, ATMOS ENVIRON, V37, P1211, DOI 10.1016/S1352-2310(02)01014-2; Kodavanti UP, 2002, TOXICOL SCI, V70, P73, DOI 10.1093/toxsci/70.1.73; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; Mar TF, 2004, INHAL TOXICOL, V16, P809, DOI 10.1080/08958370490506646; Mar TF, 2000, ENVIRON HEALTH PERSP, V108, P347, DOI 10.2307/3454354; Marcazzan GM, 2001, ATMOS ENVIRON, V35, P4639, DOI 10.1016/S1352-2310(01)00124-8; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Miller MD, 2002, INT J TOXICOL, V21, P403, DOI 10.1080/10915810290096630; Naeher LP, 2007, INHAL TOXICOL, V19, P67, DOI 10.1080/08958370600985875; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Ostro B, 2006, ENVIRON HEALTH PERSP, V114, P29, DOI 10.1289/ehp.8335; Ostro B, 2007, ENVIRON HEALTH PERSP, V115, P13, DOI 10.1289/ehp.9281; Peel JL, 2005, EPIDEMIOLOGY, V16, P164, DOI 10.1097/01.ede.0000152905.42113.db; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Pritchard RJ, 1996, INHAL TOXICOL, V8, P457, DOI 10.3109/08958379609005440; R Development Core Team, 2006, LANG ENV STAT COMP; RUBIN JI, 2006, STI906201063103FR; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Sarnat JA, 2008, ENVIRON HEALTH PERSP, V116, P459, DOI 10.1289/ehp.10873; SCHAUER J, 2006, RES REPORT CHARACTER; Schauer JJ, 2000, ENVIRON SCI TECHNOL, V34, P1821, DOI 10.1021/es981312t; Schlesinger RB, 2006, INHAL TOXICOL, V18, P95, DOI 10.1080/08958370500306016; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2004, PEDIATRICS, V113, P1037; Sinclair AH, 2004, J AIR WASTE MANAGE, V54, P1212; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; van der Zee SC, 1999, OCCUP ENVIRON MED, V56, P802; World Health Organization, 1975, INT CLASS DIS 9 REV; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P841, DOI 10.2307/3434991; Zeka A, 2005, OCCUP ENVIRON MED, V62, P718, DOI 10.1136/oem.2004.017012; Zelikoff JT, 2002, ENVIRON HEALTH PERSP, V110, P871	59	96	104	5	36	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2009	117	3					475	480		10.1289/ehp.11848		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	415KV	WOS:000263933600038	19337525	
J	Williams, DR; Sternthal, M; Wright, RJ				Williams, David R.; Sternthal, Michelle; Wright, Rosalind J.			Social Determinants: Taking the Social Context of Asthma Seriously	PEDIATRICS			English	Article; Proceedings Paper	Conference on the State of Childhood Asthma and Future Directions	DEC, 2006	Washington, DC	Merck Childhood Asthma Network		childhood asthma prevalence; low-income population; poverty; race; risk factors	RACIAL RESIDENTIAL SEGREGATION; AIR-POLLUTION; COLLECTIVE EFFICACY; LUNG-FUNCTION; URBAN ASTHMA; ATHEROSCLEROSIS RISK; SOCIOECONOMIC-STATUS; CHILDHOOD ASTHMA; SPATIAL DYNAMICS; CHILDRENS HEALTH	Although asthma has emerged as a major contributor to disease and disability among US children, the burden of this disease is unevenly distributed within the population. This article provides a brief overview of social-status variables that predict variations in asthma risks and social exposures, such as stress and violence, that are emerging as important risk factors. The central focus of the article is on the distal social variables that have given rise to unhealthy residential environments in which the risk factors for asthma and other diseases are clustered. Effective initiatives for the prevention and treatment of childhood asthma need to address these nonmedical determinants of the prevalence of asthma. Pediatrics 2009; 123:S174-S184	[Williams, David R.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Cambridge, MA 02138 USA; [Williams, David R.] Harvard Univ, Dept African & African Amer Studies, Cambridge, MA 02138 USA; [Williams, David R.] Harvard Univ, Dept Sociol, Cambridge, MA 02138 USA; [Sternthal, Michelle; Wright, Rosalind J.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Wright, Rosalind J.] Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA USA; [Wright, Rosalind J.] Harvard Univ, Sch Med, Boston, MA 02115 USA	Williams, DR (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave,6th Floor, Boston, MA 02115 USA.	dwilliam@hsph.harvard.edu			NHLBI NIH HHS [R01 HL080674, R01HL080674]; NIEHS NIH HHS [R01 ES10932, R01 ES010932]; NIMH NIH HHS [5 T32 MH16806, R01 MH 59575, R01 MH059575, T32 MH016806]		Adler NE, 2003, CURR DIR PSYCHOL SCI, V12, P119, DOI 10.1111/1467-8721.01245; Austin JB, 2005, ARCH DIS CHILD, V90, P253, DOI 10.1136/adc.2004.049346; Bach PB, 2004, NEW ENGL J MED, V351, P575, DOI 10.1056/NEJMsa040609; Baicker K, 2004, HLTH AFF MILLWOOD S, pVAR33; BARBARIN OA, 1981, I RACISM COMMUNITY C; Bauman K. J., 1998, DIRECT MEASURES POVE; Bentley ME, 2003, J NUTR, V133, p305S; Brisbon N, 2005, J ALLERGY CLIN IMMUN, V115, P1024, DOI 10.1016/j.jaci.2005.02.020; Buchmueller TC, 2004, 10700 NAT BUR EC RES; Byrd RS, 2006, CURR OPIN PULM MED, V12, P68, DOI 10.1097/01.mcp.0000199001.68908.45; Cabana MD, 2007, CHEST, V132, p810S, DOI 10.1378/chest.07-1910; Cagney KA, 2004, J GEN INTERN MED, V19, P229, DOI 10.1111/j.1525-1497.2004.30359.x; Carroll CL, 2007, PEDIATRICS, V120, P734, DOI 10.1542/peds.2007-0409; Cell J. W., 1982, HIGHEST STAGE WHITE; Charles CZ, 2003, ANNU REV SOCIOL, V29, P167, DOI 10.1146/annurev.soc.29.010202.100002; CHEADLE A, 1991, PREV MED, V20, P250, DOI 10.1016/0091-7435(91)90024-X; Chen E, 2002, PSYCHOL BULL, V128, P295, DOI 10.1037/0033-2909.128.2.295; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; Chung CJ, 1999, J CONSUM AFF, V33, P276; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; COLE RE, 1988, CALIF MANAGE REV, V31, P9; Cutler DM, 1997, Q J ECON, V112, P827, DOI 10.1162/003355397555361; de Luis DA, 2005, NUTRITION, V21, P320, DOI 10.1016/j.nut.2004.06.027; DENAVASWALT C, 2002, P60213 US CENS BUR; DeNavas-Walt C, 2006, INCOME POVERTY HLTH; Ellison CG, 2001, SOC FORCES, V80, P215, DOI 10.1353/sof.2001.0063; Evans GW, 2004, AM PSYCHOL, V59, P77, DOI 10.1037/0003-066X.59.2.77; Ferris TG, 2006, MED CARE, V44, P81, DOI 10.1097/01.mlr.0000188914.47033.cd; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Fisher EB, 2004, PEDIATRICS, V114, P116, DOI 10.1542/peds.114.1.116; Fix ME, 1993, CLEAR CONVINCING EVI; Gee GC, 2004, ENVIRON HEALTH PERSP, V112, P1645, DOI 10.1289/ehp.7074; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Glaeser Edward L., 2001, RACIAL SEGREGATION 2; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Greene J, 2006, MILBANK Q, V84, P239, DOI 10.1111/j.1468-0009.2006.00447.x; Halm EA, 2005, CHEST, V128, P1943, DOI 10.1378/chest.128.4.1943; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Harik-Khan RI, 2004, AM J EPIDEMIOL, V159, P351, DOI 10.1093/aje/kwh053; Helling A, 2003, HOUS POLICY DEBATE, V14, P69; Hernandez L. M., 2006, GENES BEHAV SOCIAL E; Hicks LS, 2006, HEALTH AFFAIR, V25, P1712, DOI 10.1377/hlthaff.25.6.1712; Horton NJ, 2008, STAT MED, V27, P4992, DOI 10.1002/sim.3324; Jackson B, 2004, INT J EPIDEMIOL, V33, P271, DOI 10.1093/ije/dyh003; Katz LF, 2001, Q J ECON, V116, P607, DOI 10.1162/00335530151144113; Kawachi I, 1999, ANN NY ACAD SCI, V896, P120, DOI 10.1111/j.1749-6632.1999.tb08110.x; Kennedy BP, 1998, SOC SCI MED, V47, P7, DOI 10.1016/S0277-9536(98)00097-5; KLING JR, 2005, DISCOVERING SUCCESSF; KRIEGER N, 1994, SOC SCI MED, V39, P887, DOI 10.1016/0277-9536(94)90202-X; Lewis TC, 2005, ENVIRON HEALTH PERSP, V113, P1068, DOI 10.1289/ehp.7533; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; Lucas SR, 2006, PAEDIATR RESPIR REV, V7, P233, DOI 10.1016/j.prrv.2006.08.001; Massey Douglas S., 1993, AM APARTHEID SEGREGA; Massey D., 2004, BOIS REV, V1, P7; *MED, 2000, CLEAR AIR ASTHM IND; MITCHELL RE, 1981, AM J COMMUN PSYCHOL, V9, P233, DOI 10.1007/BF00896061; Morenoff JD, 2001, CRIMINOLOGY, V39, P517, DOI 10.1111/j.1745-9125.2001.tb00932.x; Morland K, 2002, AM J PUBLIC HEALTH, V92, P1761, DOI 10.2105/AJPH.92.11.1761; Morland K, 2006, AM J PREV MED, V30, P333, DOI 10.1016/j.amepre.2005.11.003; Morrison RS, 2000, NEW ENGL J MED, V342, P1023, DOI 10.1056/NEJM200004063421406; Myrdal G., 1944, AM DILEMMA NEGRO PRO; *NAT I HLTH, 2003, SUMM S GEN VAR GEN E; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; ORTEGA AN, 2002, PEDIATRICS, V109; ORZECHOWSKI SSP, 2003, NEW WORTH ASSET OWNE; Pamuk E., 1998, SOCIOECONOMIC STATUS; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323; RICCIONI G, 2006, DRUG DISCOV TODAY, V3, P293, DOI 10.1016/j.ddstr.2006.09.010; Sampson RJ, 1999, AM SOCIOL REV, V64, P633, DOI 10.2307/2657367; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sampson R.J., 2003, PERSPECT BIOL MED S, V46, pS53; Sampson R.J., 1995, CRIME INEQUALITY, P37; Sandel M, 2006, ARCH DIS CHILD, V91, P942, DOI 10.1136/adc.2006.098376; Schwartz J, 2004, PEDIATRICS, V113, P1037; Sharpe Rochelle, 1993, WALL STREET J   0914, pA1; Smedley B., 2003, UNEQUAL TREATMENT CO; Smith LA, 2005, PUBLIC HEALTH REP, V120, P109; Sonn CC, 1998, J COMMUNITY PSYCHOL, V26, P457, DOI 10.1002/(SICI)1520-6629(199809)26:5<457::AID-JCOP5>3.0.CO;2-O; Taylor SE, 1997, ANNU REV PSYCHOL, V48, P411, DOI 10.1146/annurev.psych.48.1.411; U.S. House of Representatives Select Committee on Hunger, 1987, OBT FOOD SHOPP CONST; *US NAT ADV COMM C, 1968, REP US NAT ADV COMM; Wade S, 1997, PEDIATR PULM, V24, P263, DOI 10.1002/(SICI)1099-0496(199710)24:4<263::AID-PPUL5>3.0.CO;2-L; Wang MC, 2007, J EPIDEMIOL COMMUN H, V61, P491, DOI 10.1136/jech.2006.051680; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7; Wilson William J., 1996, WHEN WORK DISAPPEARS; Wilson W. J, 1987, TRULY DISADVANTAGED; Wright AL, 1999, J ALLERGY CLIN IMMUN, V104, P589, DOI 10.1016/S0091-6749(99)70328-3; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2003, NEIGHBORHOODS HLTH, P233; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; Wright RJ, 2006, CLIN CHEST MED, V27, P413, DOI 10.1016/j.ccm.2006.04.003; Zenk SN, 2005, AM J PUBLIC HEALTH, V95, P660, DOI 10.2105/AJPH.2004.042150; Zuckerman B, 2004, PEDIATRICS, V114, P224, DOI 10.1542/peds.114.1.224	94	96	96	4	10	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAR	2009	123						S174	S184		10.1542/peds.2008-2233H		11	Pediatrics	Pediatrics	413XL	WOS:000263826000007	19221161	
J	Liebers, V; Raulf-Heimsoth, M; Bruning, T				Liebers, V.; Raulf-Heimsoth, M.; Bruening, T.			Health effects due to endotoxin inhalation (review)	ARCHIVES OF TOXICOLOGY			English	Review						endotoxin; health effects; LAL-test; whole blood assay-allergy	DOSE-RESPONSE RELATIONSHIPS; ORGANIC DUST; LUNG-FUNCTION; FOLLOW-UP; OCCUPATIONAL-EXPOSURE; AIRBORNE ENDOTOXIN; CYTOKINE RESPONSES; LPS INHALATION; COTTON DUST; IN-VIVO	Endotoxins are ubiquitous in the environment and represent important components of bioaerosols. High exposure occurs in rural environment and at several workplaces (e.g. waste collecting, textile industry etc.). Adverse effects on human health induced by inhalation of endotoxin are described in several studies. Up to now the endotoxin levels are mainly measured using the Limulus amoebocyte-lysate (LAL) assay. This assay is well established, but for a suitable characterization of bioaerosols more parameters are necessary. Additional information, e.g. concerning the pyrogenic activity of organic dust samples may be delivered by whole blood assay. Whereas on the one hand protection measures at workplaces are demanded to avoid lung function impairment due to endotoxin exposure, on the other hand a protective effect of exposure to microbial agents like endotoxins with regard to allergy development has been observed. On the cellular level toll-like receptor 4 (TLR4) and IL-1 receptor as well as surface molecules like CD14 have been shown to play a pivotal role in the endotoxin activation cascade. In this review we summarize the mechanism of endotoxin recognition and its manifold effects on human health.	[Liebers, V.; Raulf-Heimsoth, M.; Bruening, T.] Ruhr Univ Bochum, Res Inst Occupat Med, German Social Accident Insurance, BGFA, D-44793 Bochum, Germany	Liebers, V (reprint author), Ruhr Univ Bochum, Res Inst Occupat Med, German Social Accident Insurance, BGFA, Allergol Immunol,Burkle Camp Pl 1, D-44793 Bochum, Germany.	liebers@bgfa.de	Bruning, Thomas/G-8120-2015	Bruning, Thomas/0000-0001-9560-5464			Acevedo F, 2005, INFLAMMATION, V29, P39, DOI 10.1007/s10753-006-8968-0; Alexis N, 2001, J ALLERGY CLIN IMMUN, V107, P31, DOI 10.1067/mai.2001.111594; Alexis NE, 2005, J ALLERGY CLIN IMMUN, V115, P345, DOI 10.1016/j.jaci.2004.11.040; Alexis NE, 2004, J ALLERGY CLIN IMMUN, V114, P1325, DOI 10.1016/j.jaci.2004.09.002; Aulock Sonja Von, 2006, J Interferon Cytokine Res, V26, P887, DOI 10.1089/jir.2006.26.887; Bakirci N, 2007, J OCCUP ENVIRON MED, V49, P853, DOI 10.1097/JOM.0b013e3180dca598; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Binding N, 2004, J ENVIRON MONITOR, V6, P65, DOI 10.1039/b309237b; Bottcher MF, 2004, J ALLERGY CLIN IMMUN, V114, P561, DOI 10.1016/j.jaci.2004.04.050; Brass DM, 2007, J ALLERGY CLIN IMMUN, V120, P121, DOI 10.1016/j.jaci.2007.03.051; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Bunger J, 2007, INT ARCH OCC ENV HEA, V80, P306, DOI 10.1007/s00420-006-0135-2; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chun DTW, 2006, AM J IND MED, V49, P301, DOI 10.1002/ajim.20266; Debarry J, 2007, J ALLERGY CLIN IMMUN, V119, P1514, DOI 10.1016/j.jaci.2007.03.023; Donham KJ, 2000, J OCCUP ENVIRON MED, V42, P260, DOI 10.1097/00043764-200003000-00006; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Douwes J, 1997, INT J OCCUP ENV HEAL, V3, pS26; Eder W, 2005, J ALLERGY CLIN IMMUN, V116, P601, DOI 10.1016/j.jaci.2005.05.003; Eduard W, 2004, AM J IND MED, V46, P396, DOI 10.1002/ajim.20088; FANG Z, 2007, CHINA MICROB ECOL; Gehring U, 2004, ALLERGY, V59, P946, DOI 10.1111/j.1398-9995.2004.00551.x; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Goulding John, 2007, Proc Am Thorac Soc, V4, P618, DOI 10.1513/pats.200706-066TH; Heederik D, 2007, ENVIRON HEALTH PERSP, V115, P298, DOI 10.1289/ehp.8835; JACOBSEN G, 2007, EUR RESP J; Kindinger I, 2005, J IMMUNOL METHODS, V298, P143, DOI 10.1016/j.jim.2005.01.006; Kitz R, 2006, J ENDOTOXIN RES, V12, P367, DOI 10.1179/096805106X153934; LAAKKONEN A, 2007, OCCUP ENV MED; Lange JH, 2000, MED HYPOTHESES, V55, P383, DOI 10.1054/mehy.2000.1072; Larsson L, 2004, INDOOR AIR, V14, P421, DOI 10.1111/j.1600-0668.2004.00290.x; Liebers V, 2006, AM J IND MED, V49, P474, DOI 10.1002/ajim.20310; LIEBERS V, 2007, ASU, V42, P469; LIEBERS V, 2002, J TOXICOL ENV HEAL A, V70, P1798; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; Madsen AM, 2006, ANN AGR ENV MED, V13, P81; Mandryk J, 1999, AM J IND MED, V35, P481, DOI 10.1002/(SICI)1097-0274(199905)35:5<481::AID-AJIM5>3.0.CO;2-N; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; Mastrangelo G, 2005, AM J EPIDEMIOL, V161, P1037, DOI 10.1093/aje/kwi138; Mathiak G, 2003, INT J MOL MED, V11, P41; Mueller M, 2004, J BIOL CHEM, V279, P26307, DOI 10.1074/jbc.M401231200; Nieuwenhuijsen MJ, 1999, ANN OCCUP HYG, V43, P35, DOI 10.1016/S0003-4878(98)00068-4; O'Neill LAJ, 2004, TRENDS IMMUNOL, V25, P687, DOI 10.1016/j.it.2004.10.006; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; Radon K, 2006, OCCUP ENVIRON MED, V63, P73, DOI 10.1136/oem.2004.017616; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; RUSCA S, 2007, INT ARCH OCCUP ENV H; Rylander R, 2006, CURR OPIN ALLERGY CL, V6, P62, DOI 10.1097/01.all.0000202356.83509.f7; Rylander R, 2005, AM J IND MED, V48, P302, DOI 10.1002/ajim.20205; SCHIERL R, 2007, BAVARIA ANN AGRIC EN, V14, P129; Schulze A, 2006, ANN AGR ENV MED, V13, P87; Schulze J, 2003, GEFAHRST REINHALT L, V63, P99; Sebastian A, 2006, J ENVIRON MONITOR, V8, P519, DOI 10.1039/b600706f; Sigsgaard T, 2004, AM J IND MED, V46, P327, DOI 10.1002/ajim.20068; Simpson A, 2006, AM J RESP CRIT CARE, V174, P386, DOI 10.1164/rccm.200509-1380OC; Smit LAM, 2006, OCCUP ENVIRON MED, V63, P59, DOI 10.1136/oem.2005.021527; Spaan S, 2007, APPL ENVIRON MICROB, V73, P6134, DOI 10.1128/AEM.00851-07; Thorn J, 2001, INFLAMM RES, V50, P254, DOI 10.1007/s000110050751; Trivedi Bhavini, 2003, Journal of Allergy and Clinical Immunology, V111, P777, DOI 10.1067/mai.2003.1338; VANDENBULCKE L, 2005, INT ARCH ALLERGY IMM, V139, P159; Vercelli D, 2003, CLIN EXP ALLERGY, V33, P153, DOI 10.1046/j.1365-2222.2003.01606.x; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Walusiak J, 2004, ALLERGY, V59, P1294, DOI 10.1111/j.1398-9995.2004.00560.x; Wang XR, 2002, AM J IND MED, V41, P111, DOI 10.1002/ajim.10042; West MA, 2002, CRIT CARE MED, V30, pS64, DOI 10.1097/00003246-200201001-00009; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wouters IM, 2002, TOXICOL IND HEALTH, V18, P15, DOI 10.1191/0748233702th126oa; Wurfel MM, 2005, J IMMUNOL, V175, P2570	68	96	100	3	26	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0340-5761			ARCH TOXICOL	Arch. Toxicol.	APR	2008	82	4					203	210		10.1007/s00204-008-0290-1		8	Toxicology	Toxicology	280BW	WOS:000254400900001	18322674	
J	Wheeler, AJ; Smith-Doiron, M; Xu, X; Gilbert, NL; Brook, JR				Wheeler, Amanda J.; Smith-Doiron, Marc; Xu, Xiaohong; Gilbert, Nicolas L.; Brook, Jeffrey R.			Intra-urban variability of air pollution in Windsor, Ontario - Measurement and modeling for human exposure assessment	ENVIRONMENTAL RESEARCH			English	Article						air pollution; land-use regression (LUR); geographic information systems (GIS); road traffic; exposure assessment	AMBIENT NITROGEN-DIOXIDE; CHILDHOOD ASTHMA; SPATIAL VARIABILITY; MORTALITY; ASSOCIATION; CHILDREN; INDICATORS; SYMPTOMS; CITIES; SULFUR	There are acknowledged difficulties in epidemiological studies to accurately assign exposure to air pollution for large populations, and large, long-term cohort studies have typically relied upon data from central monitoring stations. This approach has generally been adequate when populations span large areas or diverse cities. However, when the effects of intra-urban differences in exposure are being studied, the use of these existing central sites are likely to be inadequate for representing spatial variability that exists within an urban area. As part of the Border Air Quality Strategy (BAQS), an international agreement between the governments of Canada and the United States, a number of air health effects studies are being undertaken by Health Canada and the US EPA. Health Canada's research largely focuses on the chronic exposure of elementary school children to air pollution. The exposure characterization for this population to a variety of air pollutants has been assessed using land-use regression (LUR) models. This approach has been applied in several cities to nitrogen dioxide (NO2), as an assumed traffic exposure marker. However, the models have largely been developed from limited periods of saturation monitoring data and often only represent one or two seasons. Two key questions from these previous efforts, which are examined in this paper, are: If NO2 is a traffic marker, what other pollutants, potentially traffic related, might it actually represent? How well is the within city spatial variability of NO2, and other traffic-related pollutants, characterized by a single saturation monitoring campaign. Input data for the models developed in this paper were obtained across a network of 54 monitoring sites situated across Windsor, Ontario. The pollutants studied were NO2, sulfur dioxide (SO2) and volatile organic compounds, which were measured in all four seasons by deploying passive samplers for 2-week periods. Correlations among these pollutants were calculated to assess what other pollutants NO2 might represent, and correlations across seasons for a given pollutant were determined to assess how much the within-city spatial pattern varies with time. LUR models were then developed for NO2, SO2, benzene, and toluene. A multiple regression model including proximity to the Ambassador Bridge (the main Canada-US border crossing point), and proximity to highways and major roads, predicted NO2 concentrations with an R-2 = 0.77. The SO2 model predictors included distance to the Ambassador Bridge, dwelling density within 1500 in, and Detroit-based SO2 emitters within 3000 in resulting in a model with an R-2 = 0.69. Benzene and toluene LUR models included traffic predictors as well as point source emitters resulting in R-2 = 0.73 and 0.46, respectively. Between season pollutant correlations were all significant although actual concentrations for each site varied by season. This suggests that if one season were to be selected to represent the annual concentrations for a specific site this may lead to a potential under or overestimation in exposure, which could be significant for health research. All pollutants had strong inter-pollutant correlations suggesting that NO2 could represent SO2, benzene, and toluene. Crown Copyright (c) 2007 Published by Elsevier Inc. All rights reserved.	[Wheeler, Amanda J.; Smith-Doiron, Marc; Gilbert, Nicolas L.] Hlth Canada, Air Hlth Effects Div, Ottawa, ON K1A 0K9, Canada; [Xu, Xiaohong] Univ Windsor, Windsor, ON N9B 3P4, Canada; [Brook, Jeffrey R.] Environm Canada, Air Qual Res Branch, Toronto, ON M3H 5T4, Canada	Wheeler, AJ (reprint author), Hlth Canada, Air Hlth Effects Div, 3rd Floor,269 Laurier Ave W,PL 4903C, Ottawa, ON K1A 0K9, Canada.	Amanda_Wheeler@hc-sc.gc.ca	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Gilbert, Nicolas/0000-0001-6985-8046; Wheeler, Amanda/0000-0001-9288-8163			Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Briggs DJ, 1997, INT J GEOGR INF SCI, V11, P699, DOI 10.1080/136588197242158; Briggs DJ, 2000, SCI TOTAL ENVIRON, V253, P151, DOI 10.1016/S0048-9697(00)00429-0; BROOK JR, 2007, IN PRESS J EXPO SCI; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; Gilbert NL, 2005, J AIR WASTE MANAGE, V55, P1059; Hoek G, 2001, J EXPO ANAL ENV EPID, V11, P459, DOI 10.1038/sj.jea.7500189; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Kanaroglou PS, 2005, ATMOS ENVIRON, V39, P2399, DOI 10.1016/j.atmosenv.2004.06.049; Kuenzli Nino, 2005, Environmental Health Perspectives, V113, P201; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Luginaah Isaac, 2006, International Journal of Environmental Studies, V63, P487, DOI 10.1080/00207230600802122; Pikhart H, 2000, EPIDEMIOLOGY, V11, P153, DOI 10.1097/00001648-200003000-00012; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; SCHAUG J, 1993, ATMOS ENVIRON A-GEN, V27, P831, DOI 10.1016/0960-1686(93)90005-J; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	23	96	96	3	48	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	JAN	2008	106	1					7	16		10.1016/j.envres.2007.09.004		10	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	257PP	WOS:000252811300002	17961539	
J	Hammer, KA; Carson, CF; Riley, TV; Nielsen, JB				Hammer, KA; Carson, CF; Riley, TV; Nielsen, JB			A review of the toxicity of Melaleuca alternifolia (tea tree) oil	FOOD AND CHEMICAL TOXICOLOGY			English	Review						essential oil; terpene; allergy; ecotoxicity	PLANT ESSENTIAL OILS; ALLERGIC CONTACT-DERMATITIS; BETA-MYRCENE; IN-VITRO; INSECTICIDAL ACTIVITY; RAINBOW-TROUT; SALMONELLA/MICROSOME ASSAY; FUMIGANT TOXICITY; ALPHA-TERPINENE; HUMAN MONOCYTES	The essential oil of Melaleuca alternifolia, also known as tea tree or melaleuca oil, is widely available and has been investigated as an alternative antimicrobial, anti-inflammatory and anti-cancer agent. While these properties are increasingly well characterised, relatively limited data are available on the safety and toxicity of the oil. Anecdotal evidence from almost 80 years of use suggests that the topical use of the oil is relatively safe, and that adverse events are minor, self-limiting and occasional. Published data indicate that TTO is toxic if ingested in higher doses and can also cause skin irritation at higher concentrations. Allergic reactions to TTO occur in predisposed individuals and may be due to the various oxidation products that are formed by exposure of the oil to light and/or air. Adverse reactions may be minimised by avoiding ingestion, applying only diluted oil topically and using oil that has been stored correctly. Data from individual components suggest that TTO has the potential to be developmentally toxic if ingested at higher doses, however, TTO and its components are not genotoxic. The limited ecotoxicity data available indicate that TTO is toxic to some insect species but more studies are required. (c) 2005 Elsevier Ltd. All rights reserved.	Univ Western Australia, Sch Biomed & Chem Sci, Nedlands, WA 6009, Australia; Queen Elizabeth II Med Ctr, Western Australian Ctr Pathol & Med Res, Nedlands, WA 6009, Australia; Univ So Denmark, DK-5000 Odense, Denmark	Hammer, KA (reprint author), Univ Western Australia, Sch Biomed & Chem Sci, M502,35 Stirling Hwy, Nedlands, WA 6009, Australia.	khammer@cyllene.uwa.edu.au	Hammer, Katherine/B-7023-2012; Carson, Christine/F-1521-2013	Hammer, Katherine/0000-0001-7878-4851; Carson, Christine/0000-0003-3669-1651			Apted J H, 1991, Australas J Dermatol, V32, P177; Araujo IB, 1996, FOOD CHEM TOXICOL, V34, P477, DOI 10.1016/0278-6915(96)87358-3; Aspres N., 2003, Exogenous Dermatology, V2, P258, DOI 10.1159/000078694; Aydin S, 2005, MUTAT RES-GEN TOX EN, V581, P43, DOI 10.1016/j.mrgetnox.2004.10.017; Belaiche P., 1985, PHYTOTHERAPY, V15, P13; Bhushan M, 1997, CONTACT DERMATITIS, V36, P117, DOI 10.1111/j.1600-0536.1997.tb00435.x; Bischoff K, 1998, J VET DIAGN INVEST, V10, P208; BLACKWELL R, 1991, BR J PHYTOTHER, V2, P26; Boon PI, 1997, ARCH HYDROBIOL, V138, P433; Brand C, 2001, INFLAMM RES, V50, P213, DOI 10.1007/s000110050746; Brenan J A, 1996, Australas J Dermatol, V37, P40, DOI 10.1111/j.1440-0960.1996.tb00993.x; BROPHY JJ, 1989, J AGR FOOD CHEM, V37, P1330, DOI 10.1021/jf00089a027; Cal K, 2003, J CONTROL RELEASE, V93, P369, DOI 10.1016/j.jconrel.2003.09.002; Campbell RE, 2001, AQUAC RES, V32, P223, DOI 10.1046/j.1365-2109.2001.00551.x; Choi WI, 2003, J ECON ENTOMOL, V96, P1479, DOI 10.1603/0022-0493-96.5.1479; COATS JR, 1991, ACS SYM SER, V449, P305; CONNOR TH, 1985, TOXICOL LETT, V25, P33, DOI 10.1016/0378-4274(85)90097-9; COUTTS I, 2002, BR J DERMATOL S62, V147, P70; DEGROOT AC, 1992, CONTACT DERMATITIS, V27, P279; DeGroot AC, 1996, CONTACT DERMATITIS, V35, P304; DELBECCARO MA, 1995, VET HUM TOXICOL, V37, P557; DELGADO IF, 1993, FOOD CHEM TOXICOL, V31, P623, DOI 10.1016/0278-6915(93)90044-Y; Draize J. H., 1955, FOOD DRUG COSMET LAW, V10, P722; ELLIOTT C, 1993, MED J AUSTRALIA, V159, P830; Ellis MD, 1997, J ECON ENTOMOL, V90, P1087; Evandri MG, 2005, FOOD CHEM TOXICOL, V43, P1381, DOI 10.1016/j.fct.2005.03.013; Fletcher J. P., 2005, International Journal of Aromatherapy, V15, P81, DOI 10.1016/j.ijat.2005.03.004; Florin I, 1980, TOXICOLOGY, V18, P219; Fritz TM, 2001, ANN DERMATOL VENER, V128, P123; Gomes-Carneiro MR, 2005, FOOD CHEM TOXICOL, V43, P247, DOI 10.1016/j.fct.2004.09.011; Gomes-Carneiro MR, 1998, MUTAT RES-GEN TOX EN, V416, P129, DOI 10.1016/S1383-5718(98)00077-1; Grodnitzky JA, 2002, J AGR FOOD CHEM, V50, P4576, DOI 10.1021/jf0201475; Hart PH, 2000, INFLAMM RES, V49, P619, DOI 10.1007/s000110050639; Hausen B M, 1999, Am J Contact Dermat, V10, P68, DOI 10.1016/S1046-199X(99)90002-7; Hausen Bjorn M, 2004, Dermatitis, V15, P213, DOI 10.2310/6620.2004.04034; Hayes A. J., 1997, Journal of Essential Oil Research, V9, P575; HEITMULLER PT, 1981, B ENVIRON CONTAM TOX, V27, P596; HENSYL WR, 1990, STEDMANS MED DICT; HOGG C, 2001, INT J AROMATHER, V11, P144, DOI 10.1016/S0962-4562(01)80050-3; Hummelbrunner LA, 2001, J AGR FOOD CHEM, V49, P715, DOI 10.1021/jf000749t; International Organisation for Standardisation, 1996, 47301996 ISO; ISHIDATE M, 1984, FOOD CHEM TOXICOL, V22, P623, DOI 10.1016/0278-6915(84)90271-0; JACOBS MR, 1994, J TOXICOL-CLIN TOXIC, V32, P461; JUHNKE I, 1978, Z WASSER ABWASS FOR, V11, P161; KARR LL, 1988, J PESTIC SCI, V13, P287; KAUDERER B, 1991, ENVIRON MOL MUTAGEN, V18, P28, DOI 10.1002/em.2850180106; KIM D, 2002, TEA TREE OIL ADM OR, P114; KNIGHT TE, 1994, J AM ACAD DERMATOL, V30, P423; KORTING HC, 1994, LIFE SCI, V55, P533, DOI 10.1016/0024-3205(94)00746-2; LEBLANC GA, 1980, B ENVIRON CONTAM TOX, V24, P684; Lee BH, 2004, J STORED PROD RES, V40, P553, DOI 10.1016/j.jspr.2003.09.001; Lee BH, 2001, CROP PROT, V20, P317, DOI 10.1016/S0261-2194(00)00158-7; Lee S, 1997, J ECON ENTOMOL, V90, P883; LISI P, 2000, ANN ITAL DERMATOL AL, V54, P141; MARKING LL, 1994, PROG FISH CULT, V56, P225, DOI 10.1577/1548-8640(1994)056<0225:AFSEOA>2.3.CO;2; McCage CM, 2002, PHYTOMEDICINE, V9, P743, DOI 10.1078/094471102321621377; Mikus J, 2000, PLANTA MED, V66, P366, DOI 10.1055/s-2000-8548; Mills C, 2004, J PHARM PHARMACOL, V56, P375, DOI 10.1211/0022357022773; Morris MC, 2003, PEDIATR EMERG CARE, V19, P169, DOI 10.1097/00006565-200306000-00008; Mozelsio NB, 2003, ALLERGY ASTHMA PROC, V24, P73; ODA Y, 1978, SHOKUHIN EISEI HEN, V9, P177; PARKE D V, 1974, Biochemical Society Transactions, V2, P612; PASSINOREADER DR, 1995, J GREAT LAKES RES, V21, P373; Paumgartten FJR, 1998, BRAZ J MED BIOL RES, V31, P955; RegnaultRoger C, 1995, J STORED PROD RES, V31, P291, DOI 10.1016/0022-474X(95)00025-3; RICE PJ, 1994, J ECON ENTOMOL, V87, P1172; Rockwell P, 1979, NUTR CANCER, V1, P10; RUSSELL M, 1999, TEA TREE GENUS MELAL, P191; Sammataro D, 1998, AM BEE J, V138, P681; SASAKI YF, 1989, MUTAT RES, V226, P103, DOI 10.1016/0165-7992(89)90051-1; Schnitzler P, 2001, PHARMAZIE, V56, P343; SEAWRIGHT A, 1993, MED J AUSTRALIA, V159, P831; SELVAAG E, 1994, CONTACT DERMATITIS, V31, P124, DOI 10.1111/j.1600-0536.1994.tb01940.x; Shin S, 2003, ARCH PHARM RES, V26, P389, DOI 10.1007/BF02976696; Soderberg TA, 1996, TOXICOLOGY, V107, P99, DOI 10.1016/0300-483X(95)03242-8; Southwell I. A., 1997, Journal of Essential Oil Research, V9, P47; Stroh J, 1998, B ENVIRON CONTAM TOX, V60, P923; van der Valk P G, 1994, Ned Tijdschr Geneeskd, V138, P823; Veien NK, 2004, CONTACT DERMATITIS, V50, P378, DOI 10.1111/j.0105-1873.2004.0350f.x; VILLAR D, 1994, VET HUM TOXICOL, V36, P139; Vokou D, 2003, J CHEM ECOL, V29, P2281, DOI 10.1023/A:1026274430898; WATABE T, 1981, XENOBIOTICA, V11, P333; Watson WA, 2004, AM J EMERG MED, V22, P335, DOI 10.1016/j.ajem.2004.06.001; WEBB M, 1976, WATER RES, V10, P303, DOI 10.1016/0043-1354(76)90171-8; Yang YC, 2004, J MED ENTOMOL, V41, P699, DOI 10.1603/0022-2585-41.4.699; YOO Y S, 1985, Journal of the Osaka City Medical Center, V34, P267; ZAMITH HPS, 1993, BRAZ J MED BIOL RES, V26, P93; Zhang SY, 2000, AUDIOL NEURO-OTOL, V5, P64, DOI 10.1159/000013869	88	96	106	6	46	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0278-6915			FOOD CHEM TOXICOL	Food Chem. Toxicol.	MAY	2006	44	5					616	625		10.1016/j.fct.2005.09.001		10	Food Science & Technology; Toxicology	Food Science & Technology; Toxicology	048FD	WOS:000237932100002	16243420	
J	Ray, P; Birolleau, S; Lefort, Y; Becquemin, MH; Beigelman, C; Isnard, R; Teixeira, A; Arthaud, M; Riou, B; Boddaert, J				Ray, Patrick; Birolleau, Sophie; Lefort, Yannick; Becquemin, Marie-Helene; Beigelman, Catherine; Isnard, Richard; Teixeira, Antonio; Arthaud, Martine; Riou, Bruno; Boddaert, Jacques			Acute respiratory failure in the elderly: etiology, emergency diagnosis and prognosis	CRITICAL CARE			English	Article; Proceedings Paper	Annual Congress Urgences	MAY   18, 2005	Paris, FRANCE				CONGESTIVE-HEART-FAILURE; COMMUNITY-ACQUIRED PNEUMONIA; CARDIOGENIC PULMONARY-EDEMA; QUALITY-OF-CARE; NATRIURETIC PEPTIDE; SURVEY PROGRAM; ACUTE DYSPNEA; MANAGEMENT; PATIENT; GUIDELINES	Introduction Our objectives were to determine the causes of acute respiratory failure (ARF) in elderly patients and to assess the accuracy of the initial diagnosis by the emergency physician, and that of the prognosis. Method In this prospective observational study, patients were included if they were admitted to our emergency department, aged 65 years or more with dyspnea, and fulfilled at least one of the following criteria of ARF: respiratory rate at least 25 minute(-1); arterial partial pressure of oxygen (PaO2) 70 mmHg or less, or peripheral oxygen saturation 92% or less in breathing room air; arterial partial pressure of CO2 (PaCO2) >= 45 mmHg, with pH <= 7.35. The final diagnoses were determined by an expert panel from the completed medical chart. Results A total of 514 patients ( aged ( mean +/- standard deviation) 80 +/- 9 years) were included. The main causes of ARF were cardiogenic pulmonary edema (43%), community-acquired pneumonia (35%), acute exacerbation of chronic respiratory disease (32%), pulmonary embolism (18%), and acute asthma (3%); 47% had more than two diagnoses. Inhospital mortality was 16%. A missed diagnosis in the emergency department was noted in 101 (20%) patients. The accuracy of the diagnosis of the emergency physician ranged from 0.76 for cardiogenic pulmonary edema to 0.96 for asthma. An inappropriate treatment occurred in 162 (32%) patients, and lead to a higher mortality (25% versus 11%; p < 0.001). In a multivariate analysis, inappropriate initial treatment ( odds ratio 2.83, p < 0.002), hypercapnia > 45 mmHg ( odds ratio 2.79, p < 0.004), clearance of creatinine < 50 ml minute(-1) ( odds ratio 2.37, p < 0.013), elevated NT-pro-B-type natriuretic peptide or B-type natriuretic peptide ( odds ratio 2.06, p < 0.046), and clinical signs of acute ventilatory failure ( odds ratio 1.98, p < 0.047) were predictive of death. Conclusion Inappropriate initial treatment in the emergency room was associated with increased mortality in elderly patients with ARF.	Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Emergency Med & Surg, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Pneumol, F-75651 Paris, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Resp Intens Care Unit, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Lab Pulm Funct Test, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, UPRES 2397, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Radiol, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Cardiol, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Internal Med, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Lab Emergency Biol, F-75651 Paris 13, France; Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Geriatry, F-75651 Paris 13, France	Ray, P (reprint author), Univ Paris 06, CHU Pitie Salpetriere, Assistance Publ Hop Paris, Dept Emergency Med & Surg, F-75651 Paris 13, France.	patrick.ray@psl.ap-hop-paris.fr	Beigelman-Aubry, Catherine/F-4305-2017	Beigelman-Aubry, Catherine/0000-0001-7092-6448			American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; BARR RG, 2003, AM J RESP CRIT CARE, V167, pA84; Boumendil A, 2004, INTENS CARE MED, V30, P647, DOI 10.1007/s00134-003-2150-z; CHAKKO S, 1991, AM J MED, V90, P353, DOI 10.1016/0002-9343(91)90576-J; Chin MH, 1999, ANN EMERG MED, V34, P595, DOI 10.1016/S0196-0644(99)70161-7; Cleland JGF, 2003, EUR HEART J, V24, P442, DOI 10.1016/S0195-668X(02)00823-0; ERIKSSON H, 1987, EUR HEART J, V8, P1007; Gottdiener JS, 2000, J AM COLL CARDIOL, V35, P1628, DOI 10.1016/S0735-1097(00)00582-9; GROSS JS, 1988, ARCH INTERN MED, V148, P173, DOI 10.1001/archinte.148.1.173; HANLEY JA, 1982, RADIOLOGY, V143, P29; HO KKL, 1993, J AM COLL CARDIOL, V22, pA6; Hood S, 2000, BRIT J GEN PRACT, V50, P559; Hunt SA, 2001, J AM COLL CARDIOL, V38, P2101, DOI 10.1016/S0735-1097(01)01683-7; KATZ S, 1970, GERONTOLOGIST, V10, P20; Komajda M, 2003, EUR HEART J, V24, P464, DOI 10.1016/S0195-668X(02)00700-5; L'Her E, 2004, INTENS CARE MED, V30, P882, DOI 10.1007/s00134-004-2183-y; LANDAHL S, 1980, ACTA MED SCAND, V207, P225; Le Manach Y, 2005, ANESTHESIOLOGY, V102, P885, DOI 10.1097/00000542-200505000-00004; LEMESHOW S, 1982, AM J EPIDEMIOL, V115, P92; Lien CTC, 2002, EUR J HEART FAIL, V4, P91, DOI 10.1016/S1388-9842(01)00200-8; Marrie TJ, 2000, CLIN INFECT DIS, V31, P1066, DOI 10.1086/318124; McCullough PA, 2002, CIRCULATION, V106, P416, DOI 10.1161/01.CIR.0000025242.79963.4C; Metlay JP, 1997, ARCH INTERN MED, V157, P1453, DOI 10.1001/archinte.157.13.1453; Mueller C, 2005, J INTERN MED, V258, P77, DOI 10.1111/j.1365-2796.2005.01503.x; Mueller C, 2004, NEW ENGL J MED, V350, P647, DOI 10.1056/NEJMoa031681; MULROW CD, 1993, J GEN INTERN MED, V8, P383, DOI 10.1007/BF02600079; MUSTCHIN CP, 1982, LANCET, V1, P907; PEARSON SB, 1981, POSTGRAD MED J, V57, P419; PRATTER MR, 1989, ARCH INTERN MED, V149, P2277, DOI 10.1001/archinte.149.10.2277; Ray P, 2005, J AM GERIATR SOC, V53, P643, DOI 10.1111/j.1532-5415.2005.53213.x; Rich MW, 2001, J GERONTOL A-BIOL, V56, pM88; SCHMITT BP, 1986, J GEN INTERN MED, V1, P386, DOI 10.1007/BF02596424; Torbicki A, 2000, EUR HEART J, V21, P1301; WUERZ RC, 1992, ANN EMERG MED, V21, P669, DOI 10.1016/S0196-0644(05)82777-5	34	96	100	1	2	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1466-609X			CRIT CARE	Crit. Care		2006	10	3							R82	10.1186/cc4926		12	Critical Care Medicine	General & Internal Medicine	083DQ	WOS:000240436500013	16723034	
J	Bai, TR; Knight, DA				Bai, TR; Knight, DA			Structural changes in the airways in asthma: observations and consequences	CLINICAL SCIENCE			English	Review						airway smooth muscle; asthma; corticosteroid; fibrosis; lung function; matrix; remodelling	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW LIMITATION; RETICULAR BASEMENT-MEMBRANE; SMOOTH-MUSCLE-CELLS; LONG-TERM TREATMENT; 30-YEAR FOLLOW-UP; LUNG-FUNCTION; FATAL ASTHMA; RISK-FACTORS; BRONCHIAL-ASTHMA	Structural changes reported in the airways of asthmatics include epithelial fragility, goblet cell hyperplasia, enlarged submucosal mucus glands, angiogenesis, increased matrix deposition in the airway wall, increased airway smooth muscle mass, wall thickening and abnormalities in elastin. Genetic influences, as well as fetal and early life exposures, may contribute to structural changes such as subepithelial fibrosis from an early age. Other structural alterations are related to duration of disease and/or long-term uncontrolled inflammation. The increase in smooth muscle mass in both large and small airways probably occurs via multiple mechanisms, and there are probably changes in the phenotype of smooth muscle cells, some showing enhanced synthetic capacity, others enhanced proliferation or contractility. Fixed airflow limitation is probably due to remodelling, whereas the importance of structural changes to the phenomenon of airways hyperresponsiveness may be dependent on the specific clinical phenotype of asthma evaluated. Reduced compliance of the airway wall secondary to enhanced matrix deposition may protect against airway narrowing. Conversely, in severe asthma, disruption of alveolar attachments and adventitial thickening may augment airway narrowing. The encroachment upon luminal area by submucosal thickening may be disadvantageous by increasing the risk of airway closure in the presence of the intraluminal cellular and mucus exudate associated with asthma exacerbations. Structural changes may increase airway narrowing by alteration of smooth muscle dynamics through limitation of the ability of the smooth muscle to periodically lengthen.	Univ British Columbia, St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada	Bai, TR (reprint author), Univ British Columbia, St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, 1081 Burrard St, Vancouver, BC V6Z 1Y6, Canada.	tbai@mrl.ubc.ca					Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Altraja A, 1996, AM J RESP CELL MOL, V15, P482; Amin K, 2000, AM J RESP CRIT CARE, V162, P2295; Apostol GG, 2002, AM J RESP CRIT CARE, V166, P166, DOI 10.1164/rccm.2007035; AZZAWI M, 1992, AM REV RESPIR DIS, V145, P1477; Bai TR, 2000, AM J RESP CRIT CARE, V162, P663; BAI TR, 1990, AM REV RESPIR DIS, V141, P552; Bai TR, 2004, J APPL PHYSIOL, V97, P2029, DOI 10.1152/japplphysiol.00884.2004; Baluk P, 2004, AM J PATHOL, V165, P1071, DOI 10.1016/S0002-9440(10)63369-X; Balzar S, 2002, EUR RESPIR J, V20, P254, DOI 10.1183/09031936.020.0261102; BALZAR S, 2004, AM J RESP CRIT CARE; Barbato A, 2003, AM J RESP CRIT CARE, V168, P798, DOI 10.1164/rccm.200305-650OC; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Benayoun L, 2003, AM J RESP CRIT CARE, V167, P1360, DOI 10.1164/rccm.200209-1030OC; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; Boulet LP, 2003, AM J RESP CRIT CARE, V167, P371, DOI 10.1164/rccm.200111-184PP; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Bousquet J, 1996, AM J RESP CRIT CARE, V153, P1648; Brackel HJL, 2000, AM J RESP CRIT CARE, V162, P896; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Brown RH, 1997, J APPL PHYSIOL, V83, P366; Brusasco V, 2003, J APPL PHYSIOL, V95, P1305, DOI 10.1152/japplphysiol.00001.2003; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Carroll N, 1997, EUR RESPIR J, V10, P292, DOI 10.1183/09031936.97.10020292; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Carroll NG, 2002, THORAX, V57, P677, DOI 10.1136/thorax.57.8.677; Carroll NG, 2000, AM J RESP CRIT CARE, V161, P244; Carroll NG, 1997, AM J RESP CRIT CARE, V155, P689; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; Chetta A, 2003, AM J RESP CRIT CARE, V167, P751, DOI 10.1164/rccm.200207.710OC; Choe MM, 2003, AM J PHYSIOL-LUNG C, V285, pL427, DOI 10.1152/ajplung.00005.2003; COLEBATCH HJ, 1973, J APPL PHYSIOL, V34, P143; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-11740C; DEMOLY P, 1994, AM J RESP CRIT CARE, V150, P214; Duguet A, 2000, AM J RESP CRIT CARE, V161, P839; DUNNILL MS, 1969, THORAX, V24, P176, DOI 10.1136/thx.24.2.176; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; Evans MJ, 1999, AM J RESP CELL MOL, V21, P655; Faul JL, 1997, EUR RESPIR J, V10, P301, DOI 10.1183/09031936.97.10020301; FREW AJ, 1995, AM J RESP CRIT CARE, V151, P340; Gelb AF, 2004, CHEST, V126, P1138, DOI 10.1378/chest.126.4.1138; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gillis HL, 1999, J APPL PHYSIOL, V86, P2001; Green RH, 2002, THORAX, V57, P875, DOI 10.1136/thorax.57.10.875; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Groneberg DA, 2002, HISTOPATHOLOGY, V40, P367, DOI 10.1046/j.1365-2559.2002.01378.x; Gronke L, 2002, CLIN EXP ALLERGY, V32, P57, DOI 10.1046/j.0022-0477.2001.01297.x; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; HAITCHI HH, 2004, AM J RESP CRIT CARE, V169, pA546; Halayko AJ, 2004, AM J RESP CELL MOL, V31, P266, DOI 10.1165/rcmb.2003-02720C; Haley KJ, 1998, AM J RESP CRIT CARE, V158, P565; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267; Haraguchi M, 1999, AM J RESP CRIT CARE, V159, P1005; Hirst Stuart J, 2004, J Allergy Clin Immunol, V114, pS2, DOI 10.1016/j.jaci.2004.04.039; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hoshino M, 1998, THORAX, V53, P21; Huang J, 1999, AM J RESP CRIT CARE, V160, P725; Huber HL, 1922, ARCH INTERN MED, V30, P689; in 't Veen Johannes C. C. M., 2000, American Journal of Respiratory and Critical Care Medicine, V161, P1902; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; James AL, 2002, AM J RESP CRIT CARE, V166, P1590, DOI 10.1164/rccm.2108069; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Jongepier H, 2004, CLIN EXP ALLERGY, V34, P757, DOI 10.1111/j.1365-2222.2004.01938.x; Kaminsky DA, 1997, AM J RESP CRIT CARE, V155, P1260; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kay AB, 2004, TRENDS IMMUNOL, V25, P477, DOI 10.1016/j.it.2004.07.006; King GG, 1998, AM J RESP CRIT CARE, V158, P1900; Kinsella MG, 2004, CRIT REV EUKAR GENE, V14, P203, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.40; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Kuyper LM, 2003, AM J MED, V115, P6, DOI 10.1016/S0002-9343(03)00241-9; Lackie PM, 1997, AM J RESP CELL MOL, V16, P14; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; LAMBERT RK, 1993, J APPL PHYSIOL, V74, P2771; Lange P, 1996, LANCET, V347, P1285; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; LIESKER JJW, 2000, EUR RESP J S31, V16, pS72; Lutchen KR, 2001, AM J RESP CRIT CARE, V164, P207; Ma XF, 2002, AM J PHYSIOL-LUNG C, V283, pL1181, DOI 10.1152/ajplung.00389.2001; Martin JG, 2003, RESP PHYSIOL NEUROBI, V137, P251, DOI 10.1016/D1569-9048(03)00151-4; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Mauad T, 2004, AM J RESP CRIT CARE, V170, P857, DOI 10.1164/rccm.200403-305OC; Mauad Thais, 1999, American Journal of Respiratory and Critical Care Medicine, V160, P968; McParland BE, 2003, J APPL PHYSIOL, V95, P426, DOI 10.1152/japplphysiol.00159.2003; Merkus PJFM, 2004, EUR RESPIR J, V23, P861, DOI 10.1183/09031936.04.00031504; Milanese M, 2001, J APPL PHYSIOL, V91, P1035; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; MONTEFORT S, 1993, CLIN EXP ALLERGY, V23, P185, DOI 10.1111/j.1365-2222.1993.tb00880.x; Nakano Y, 2005, AM J RESP CRIT CARE, V171, P142, DOI 10.1164/rccm.200407-874OC; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211.1268OC; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Oshita Y, 2003, THORAX, V58, P757, DOI 10.1136/thorax.58.9.757; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734; Pauwels RA, 2003, LANCET, V361, P1071, DOI 10.1016/S0140-6736(03)12891-7; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Payne DNR, 2004, THORAX, V59, P862, DOI 10.1136/thx.2003.017244; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; Pitchford S, 2003, BRIT J PHARMACOL, V138, P1181, DOI 10.1038/sj.bjp.0705136; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; Rasmussen F, 2002, J ALLERGY CLIN IMMUN, V110, P220, DOI 10.1067/mai.2002.125295; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246; Robertson D G, 2001, Cardiovasc Toxicol, V1, P7, DOI 10.1385/CT:1:1:07; SAETTA M, 1991, AM REV RESPIR DIS, V143, P138; Salome CM, 2003, EUR RESPIR J, V22, P62, DOI 10.1183/09031936.03.00117502; Schmidt M, 2003, J IMMUNOL, V171, P380; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sherrill D, 2003, EUR RESPIR J, V21, P95, DOI 10.1183/09031936.03.00017103; SLATS AM, 2004, AM J RESP CRIT CARE, V169, pA248; SOBONYA RE, 1984, AM REV RESPIR DIS, V130, P289; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; SUR S, 1993, AM REV RESPIR DIS, V148, P713; Synek M, 1996, AM J RESP CRIT CARE, V154, P224; ten Brinke A, 2004, AM J RESP CRIT CARE, V170, P601, DOI 10.1164/rccm.200404-440OC; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Tran MUT, 2004, CLIN EXP ALLERGY, V34, P1627, DOI 10.1111/j.1365-2222.2004.02057.x; Tschumperlin DJ, 2004, NATURE, V429, P83, DOI 10.1038/nature02543; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Turner DJ, 2002, J APPL PHYSIOL, V93, P1296, DOI 10.1152/japplphysiol.00150.2002; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674; VANDIEMEN CC, 2005, AM J RESP CRIT CARE, V171, pA16; VANRENSEN E, 2004, EUR RESPIR J, V23, P3348; Vignola AM, 2003, EUR RESPIR J, V22, P795, DOI 10.1183/09031936.03.00112302; Vignola AM, 1998, AM J RESP CRIT CARE, V157, P403; Vonk JM, 2004, THORAX, V59, P925, DOI 10.1136/thx.2003.016246; Vonk JM, 2003, THORAX, V58, P322, DOI 10.1136/thorax.58.4.322; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; Wagers SS, 2004, J CLIN INVEST, V114, P104, DOI 10.1172/JC1200419569; Wagner EM, 1998, AM J RESP CRIT CARE, V157, P447; WAGNER EM, 1990, AM REV RESPIR DIS, V141, P584; Wang RD, 2003, AM J RESP CRIT CARE, V168, P1232, DOI 10.1164/rccm.200307-1006OC; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Ward C, 2001, AM J RESP CRIT CARE, V164, P1718; Wenzel SE, 2003, J ALLERGY CLIN IMMUN, V111, P1345, DOI 10.1067/mai.2003.1464; Westergren-Thorsson G, 2002, INT J BIOCHEM CELL B, V34, P1256, DOI 10.1016/S1357-2725(02)00058-4; WILSON JW, 1993, AM REV RESPIR DIS, V148, P806; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Xuan W, 2002, THORAX, V57, P104, DOI 10.1136/thorax.57.2.104; YANAI M, 1992, J APPL PHYSIOL, V72, P1016; Zeiger RS, 1999, J ALLERGY CLIN IMMUN, V103, P376, DOI 10.1016/S0091-6749(99)70460-4; ZHANG X, 2004, AM J PHYSIOL-LUNG C, V287, pL1165; Zhou DY, 2003, BRIT J PHARMACOL, V140, P1237, DOI 10.1038/sj.bjp.0705562; Zhou LM, 2004, AM J RESP CRIT CARE, V169, P703, DOI 10.1164/rccm.200307-964OC	155	96	100	3	8	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	0143-5221			CLIN SCI	Clin. Sci.	JUN	2005	108	6					463	477				15	Medicine, Research & Experimental	Research & Experimental Medicine	936OX	WOS:000229866400001	15896192	
J	Almqvist, C; Pershagen, G; Wickman, M				Almqvist, C; Pershagen, G; Wickman, M			Low socioeconomic status as a risk factor for asthma, rhinitis and sensitization at 4 years in a birth cohort	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy and immunology; asthma; child; primary prevention; rhinitis; socioeconomy	CHILDHOOD ASTHMA; ALLERGIC SENSITIZATION; BRONCHIAL-ASTHMA; CHILDREN; BAMSE; SEVERITY; STRESS; ADULTS; ATOPY	Background The relation between socioeconomic status and allergic diseases in childhood is controversial. Some studies have proposed childhood asthma to be more common in families with low socioeconomic status, while sensitization to airborne allergens seems to be more frequent in individuals with higher socioeconomic status in childhood. Objective To assess the relation between socioeconomic status and asthma, rhinitis and sensitization in an unselected prospective birth cohort. Methods Four thousand and eighty-nine families with children born 1994-1996 in predefined areas of Stockholm answered questionnaires on environmental factors, socioeconomic status (parental occupation), and symptoms of allergic disease at birth, 1, 2 and 4 years of age. Blood samples taken at 4 years from 2614 children were analysed for specific IgE to common airborne and food allergens. Odds ratios (OR) and 95% confidence intervals (CI) for various outcomes in relation to socioeconomic status were estimated with a multiple logistic regression model, adjusting for potential confounders such as heredity for allergic diseases, maternal smoking, short duration of breastfeeding and house construction. Results There was a decreasing risk of asthma and rhinitis with increasing socioeconomic status. The OR for asthma was 0.33 (95% CI 0.17-0.66) and for rhinitis 0.50 (0.32-0.79) comparing the highest and the lowest socioeconomic groups, with a tendency to stronger effects in those with heredity for allergic disease. The risk of sensitization to food allergens also decreased with increasing socioeconomic status; OR 0.65 (0.41-1.02) in the highest socioeconomic group (P-trend=0.03), which was not clearly seen for airborne allergens. Conclusion Asthma, rhinitis and sensitization is more common in lower than in higher socioeconomic groups after adjustment for traditional risk factors. This may be related to additional uncontrolled differences in life style and environmental exposures between the groups, and calls for further studies.	Karolinska Hosp, Dept Environm & Occupat Hlth, S-17176 Stockholm, Sweden; Astrid Lindgren Childrens Hosp, Karolinska Inst, Dept Woman & Child Hlth, Stockholm, Sweden; Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; Karolinska Inst, Ctr Allergy Res, Stockholm, Sweden	Almqvist, C (reprint author), Karolinska Hosp, Dept Environm & Occupat Hlth, Norrbacka 3rd Floor, S-17176 Stockholm, Sweden.	catarina.almqvist@kbh.ki.se	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Pershagen, Goran/0000-0002-9701-1130			Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Amre DK, 2002, J ASTHMA, V39, P625, DOI 10.1081/JAS-120014927; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bergmann RL, 2000, CLIN EXP ALLERGY, V30, P1740, DOI 10.1046/j.1365-2222.2000.00927.x; Boudreaux ED, 2003, PEDIATRICS, V111, P615; Cesaroni G, 2003, EUR RESPIR J, V22, P619, DOI 10.1183/09031936.03.00091202; Emenius G, 2004, ACTA PAEDIATR, V93, P899, DOI 10.1080/08035250410025582; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Gilliland FD, 2003, AM J EPIDEMIOL, V158, P576, DOI 10.1093/aje/kwg181; Koopman LP, 2002, ARCH DIS CHILD, V87, P482, DOI 10.1136/adc.87.6.482; Kozyrskyj AL, 2003, PEDIATR PULM, V36, P241, DOI 10.1002/ppul.10335; Lannero E, 2002, PEDIATR ALLERGY IMMU, V13, P182, DOI 10.1034/j.1399-3038.2002.01055.x; Lindbaek M, 2003, EUR RESPIR J, V21, P105, DOI 10.1183/09031936.02.00241802; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; Poyser MA, 2002, EUR RESPIR J, V19, P892, DOI 10.1183/09031936.02.00238402; Rona RJ, 1999, J EPIDEMIOL COMMUN H, V53, P15; Schaffer T, 2001, ALLERGY, V56, P1206, DOI 10.1034/j.1398-9995.2001.00208.x; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358	23	96	96	1	12	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2005	35	5					612	618		10.1111/j.1365-2222.2005.02243.x		7	Allergy; Immunology	Allergy; Immunology	927ES	WOS:000229175800012	15898983	
J	Berkman, N; Avital, A; Breuer, R; Bardach, E; Springer, C; Godfrey, S				Berkman, N; Avital, A; Breuer, R; Bardach, E; Springer, C; Godfrey, S			Exhaled nitric oxide in the diagnosis of asthma: comparison with bronchial provocation tests	THORAX			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; EXERCISE; CHILDREN; METHACHOLINE; AIR; CHALLENGES; RECOMMENDATIONS; RESPONSIVENESS; EOSINOPHILS; ADENOSINE	Background: Bronchial provocation tests such as exercise, methacholine (MCH), and adenosine-5'-monophosphate ( AMP) challenges are used extensively in the diagnosis of asthma. A study was undertaken to determine whether exhaled nitric oxide (eNO) can be used to diagnose asthma in patients with non-specific respiratory symptoms and to compare this test with conventional provocation tests. Methods: Patients with non-specific respiratory symptoms and normal spirometric parameters were included in the study. eNO was measured and exercise, MCH and AMP challenges performed in all subjects. Patients were defined as asthmatic based on clinical follow up 24 months after testing. Results: Forty patients were considered asthmatic and 45 were not. The area under receiver operating characteristic curves gave values of 0.896 for eNO, 0.781 for exercise, 0.924 for MCH, and 0.939 for AMP (p = 0.033, 0.575 and 0.085 for eNO v exercise, MCH and AMP respectively). From our data, a cut off value of NO>7 ppb at a flow rate of 250 ml/s best differentiates between asthmatics and nonasthmatics (sensitivity 82.5%, specificity 88.9%). Optimal cut off values for other tests were exercise: Delta FEV1 >= 10% (sensitivity 57.9%, specificity 100%); PC20-MCH: <= 3 mg/ml (sensitivity 87.5%, specificity 86.7%); and PC20-AMP: <= 150 mg/ml (sensitivity 89.5%, specificity 95.6%). Conclusions: Measurement of eNO can be used as a safe, simple and rapid test for the diagnosis of asthma and is as good as bronchial provocation tests.	Hadassah Hebrew Univ Med Ctr, Inst Pulmonol, Jerusalem, Israel	Berkman, N (reprint author), Hadassah Univ Hosp, Inst Pulmonol, POB 12000, IL-91120 Jerusalem, Israel.	neville@hadassah.org.il					Al-Ali MK, 1998, RESP MED, V92, P701, DOI 10.1016/S0954-6111(98)90000-2; Al-Ali MK, 1998, RESP MED, V92, P908, DOI 10.1016/S0954-6111(98)90189-5; ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; AVITAL A, 1995, THORAX, V50, P511, DOI 10.1136/thx.50.5.511; Avital A, 2000, PEDIATR PULM, V30, P207, DOI 10.1002/1099-0496(200009)30:3<207::AID-PPUL5>3.0.CO;2-Z; BENTLEY AM, 1992, AM REV RESPIR DIS, V146, P500; Byrnes CA, 1997, THORAX, V52, P697; Chatkin JM, 1999, AM J RESP CRIT CARE, V159, P1810; Crapo RO, 2000, AM J RESP CRIT CARE, V161, P309; Deykin A, 1998, AM J RESP CRIT CARE, V157, P769; DEYKIN A, 2003, AM J RESP CRIT CARE, V165, P1597; Dotsch J, 1996, EUR RESPIR J, V9, P2537, DOI 10.1183/09031936.96.09122537; Dupont LJ, 2003, CHEST, V123, P751, DOI 10.1378/chest.123.3.751; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; GUSTAFSSON LE, 1991, BIOCHEM BIOPH RES CO, V181, P852, DOI 10.1016/0006-291X(91)91268-H; HANLEY JA, 1983, RADIOLOGY, V148, P839; Jatakanon A, 1998, THORAX, V53, P91; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, EUR RESPIR J, V8, P295, DOI 10.1183/09031936.95.08020295; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V152, P609; Lim S, 2000, THORAX, V55, P184, DOI 10.1136/thorax.55.3.184; Maziak W, 1998, AM J RESP CRIT CARE, V157, P998; NIH National Asthma Education and Prevention Program, 1997, GUID DIAGN MAN ASTHM; PERSSON MG, 1993, AM REV RESPIR DIS, V148, P1210; Silkoff PE, 1998, AM J RESP CRIT CARE, V157, P1822; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smith AD, 2004, AM J RESP CRIT CARE, V169, P473, DOI 10.1164/rccm.200310-1376OC; VAN RE, 1999, THORAX, V54, P403; ZWEIG MH, 1993, CLIN CHEM, V39, P561	31	96	108	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY	2005	60	5					383	388		10.1136/thx.2004.031104		6	Respiratory System	Respiratory System	920YH	WOS:000228730900009	15860713	
J	Bahceciler, NN; Arikan, C; Taylor, A; Akdis, M; Blaser, K; Barlan, IB; Akdis, CA				Bahceciler, NN; Arikan, C; Taylor, A; Akdis, M; Blaser, K; Barlan, IB; Akdis, CA			Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						asthma; house dust mites; specific IgA; sublingual immunotherapy	PLACEBO-CONTROLLED EVALUATION; DOUBLE-BLIND; SWALLOW IMMUNOTHERAPY; INDUCED RHINITIS; ORAL TOLERANCE; POLLEN EXTRACT; EFFICACY; RHINOCONJUNCTIVITIS; TRIAL; SLIT	Objective: To evaluate the clinical outcome and changes in allergen-specific antibodies during sublingual immunotherapy ( SLIT) in house dust mite (HDM)-allergic asthma patients and to compare levels of allergen-specific antibodies in HDM-allergic patients before and after treatment with that of healthy controls. Method: Thirty-one asthma patients allergic to HDM were studied. Patients in groups I ( n = 17) and II ( n = 14) received SLIT with a standardized Dermatophagoides pteronyssinus plus Dermatophagoides farinae 50/50 extract for 6 and 12 months, respectively. A group of healthy children ( n = 8) were enrolled as controls. Patients in both groups were evaluated at the start and at the end of treatment according to daily symptom and medication scores, lung function and skin prick tests, PC20, blood eosinophil count, and Der-p-1-specific IgE, IgA, IgG1 and IgG4 levels. Results: Drug consumption decreased significantly in both groups. Furthermore, PC20 and forced expiratory flow between 25 and 75% of vital capacity of patients in group II improved significantly. Although specific IgA, IgG1 and IgG4 levels did not change throughout the treatment period, total eosinophil count and specific IgE decreased significantly in both groups. According to baseline measurements, specific IgA levels of patients in groups I and II were significantly lower than that of controls. This difference disappeared at the end of the treatment period in both groups. Conclusion: SLIT seems to be effective in ameliorating clinical symptoms, drug consumption and bronchial hyperreactivity, and results in downregulation of Der-p-1-specific IgE production. Furthermore, at the end of SLIT, specific IgA levels, which were decreased compared to healthy controls initially, did no longer differ between patients and controls. Copyright (C) 2005 S. Karger AG, Basel.	Marmara Univ Hosp, Div Pediat Allergy & Immunol, TR-34335 Istanbul, Turkey; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	Bahceciler, NN (reprint author), Marmara Univ Hosp, Div Pediat Allergy & Immunol, Nilufer Sokak 5,Gazeteciler Sitesi C-5 Blok D42, TR-34335 Istanbul, Turkey.	aonder@attglobal.net					Akdis CA, 1996, J CLIN INVEST, V98, P1676, DOI 10.1172/JCI118963; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; BAHCECILER NN, 2001, PEDIAT PULMONOL, V22, P618; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; CASANOVAS M, 1994, J INVEST ALLERG CLIN, V4, P305; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; COCKROFT DW, 1998, J ALLERGY CLIN IMMUN, V81, P111; Groux H, 1997, NATURE, V389, P737; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; HEDLIN G, 1990, CLIN EXP ALLERGY, V20, P491, DOI 10.1111/j.1365-2222.1990.tb03141.x; HOLT PG, 1994, IMMUNOL TODAY, V15, P484, DOI 10.1016/0167-5699(94)90194-5; HOWARD LW, 2001, IMMUNOL REV, V182, P207; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Ledford DK, 2000, IMMUNOL ALLERGY CLIN, V20, P503, DOI 10.1016/S0889-8561(05)70163-6; MACHIELS JJ, 1986, BRIT MED J, V293, P948; Mohapatra SS, 2000, IMMUNOL ALLERGY CLIN, V20, P625, DOI 10.1016/S0889-8561(05)70170-3; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; *NAT HEART LUNG BL, 1992, PUBL US DEP HLTH HUM; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Passalacqua G, 1998, ALLERGY, V53, P477, DOI 10.1111/j.1398-9995.1998.tb04084.x; Polgar P, 1971, PULMONARY TESTING CH, P100; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Sterk PJ, 1993, EUR RESPIR J S, V16, P53; STROBEL S, 1998, IMMUNOL TODAY, V12, P156; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VANWILSEM EJG, 1994, IMMUNOLOGY, V83, P128; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WARNER JO, 1978, LANCET, V2, P912; WIEDERMANN U, 2002, RES TRENDS, P17; WILLIAMS PV, 1998, IMMUNOL ALLERGY CLIN, V18, P133	34	96	106	0	3	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.		2005	136	3					287	294		10.1159/000083956		8	Allergy; Immunology	Allergy; Immunology	907CY	WOS:000227694100010	15722639	
J	Bornehag, CG; Sundell, J; Sigsgaard, T				Bornehag, CG; Sundell, J; Sigsgaard, T			Dampness in buildings and health (DBH): Report from an ongoing epidemiological investigation on the association between indoor environmental factors and health effects among children in Sweden	INDOOR AIR			English	Article						asthma; allergy; home; dampness; ventilation; pets; plasticisers	SCIENTIFIC EVIDENCE; ASTHMA; EXPOSURE; PREVALENCE	With the aim of identifying health-relevant exposures in buildings, an epidemiological study "Dampness in Buildings and Health" (DBH) started in the year 2000 in Sweden. The health focus of the study is on asthma and allergic symptoms among small children and their parents. The first step in the study was an epidemiological cross-sectional questionnaire on housing and health involving 14,077 preschool children in the county of Varmland in Sweden (March-April 2000). Self-reported moisture-related problems in the building were strongly associated with asthma, allergic symptoms, and airway infections among children and adults. Other factors associated with symptoms among the children were allergic heredity, smoking in the family, male sex, urban living, short breast feeding, pet keeping, daycare attendance, non-farming life and some food habits. The second step in the study was a nested case-control study including 198 children with symptoms and 202 healthy controls. A detailed clinical examination by physicians in parallel with extensive inspections and measurements in the subjects' homes were conducted from October 2001 to April 2002. The influence of selection bias in case-control studies has been studied, and questionnaires on self-reported symptoms and building characteristics have been validated. Identified risk factors for allergic symptoms are, e.g., inspector-observed dampness, a low ventilation rate, endotoxin, Penicillium and phthalates in dust. In the third phase, a 5-year follow-up study will be carried out during 2005. The same questionnaire as used in DBH-phase 1 will be distributed to the 10,852 children/parents who responded to the first questionnaire in 2000. Finally, in a fourth phase, controlled experimental studies in climate chambers and in vitro tests regarding findings from DBH-Phase 2 are planned to be conducted during 2004-08.	Tech Univ Denmark, Int Ctr Indoor Environm & Energy, DK-2800 Lyngby, Denmark; Karlstad Univ, Div Publ Hlth Sci, Karlstad, Sweden; Karlstad Univ, Swedish Natl Testing & Res Inst, Karlstad, Sweden; Aarhus Univ, Inst Environm & Occupat Med, DK-8000 Aarhus C, Denmark	Sundell, J (reprint author), Tech Univ Denmark, Int Ctr Indoor Environm & Energy, Niels Koppels Alle,Bldg 402, DK-2800 Lyngby, Denmark.	jas@mek.dtu.dk	Sundell, Jan/B-2857-2012				Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; Andersson K, 1997, INDOOR AIR, V7, P78, DOI 10.1111/j.1600-0668.1997.t01-2-00002.x; Beasley R, 2003, PEDIATR CLIN N AM, V50, P539, DOI 10.1016/S0031-3955(03)00050-6; BERNER A, 2004, P ANN M AM AC ALL AS; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, ALLERGY, V59, P554, DOI 10.1111/j.1398-9995.2004.00496.x; Bornehag CG, 2003, ALLERGY, V58, P939, DOI 10.1034/j.1398-9995.2003.00050.x; BORNEHAG CG, 2004, IN PRESS EPIDEMIOLOG; BORNEHAG CG, 2003, P 7 INT C HLTH BUILD; BORNEHAG CG, 2003, P COLD CLIM HVAC 200; BORNEHAG CG, 2004, IN PRESS INDOOR AIR; BORNEHAG CG, 2004, IN PRESS ENV HLTH PE; BORNEHAG CG, 2002, P 9 INT C IND AIR QU, V3; BORNEHAG CG, 2004, UNPUB PHTHALATES IND; BORNEHAG CG, 2002, P 9 INT C IND AIR QU, V3, P431; BORNHEAG CG, 2004, IN PRESS INDOOR AIR; ENGSTROM M, 2001, DIFFERENCES POSSIBLE; Etzel RA, 2003, PEDIATRICS, V112, P233; FORSMAN G, 2001, DIFFERENCES PREVALEN; Hagerhed L., 2002, P 9 INT C IND AIR QU, VV, P7; Hederos CA, 2002, ACTA PAEDIATR, V91, P1246, DOI 10.1080/080352502320777504; JANSSON A, 2004, USE ELECT EQUIPMENT; LAZZARI P, 2002, FOOD HABITS FAMILIES; LUNDGREN B, 2002, P 9 INT C IND AIR QU, V4, P153; NILSSON A, 2004, IN PRESS ATMOSPHERIC; Schneider T, 2003, INDOOR AIR, V13, P38, DOI 10.1034/j.1600-0668.2003.02025.x; Strachan DP, 2000, BRIT MED BULL, V56, P865, DOI 10.1258/0007142001903562; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wargocki P, 2002, INDOOR AIR, V12, P113, DOI 10.1034/j.1600-0668.2002.01145.x	29	96	105	6	29	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air	AUG	2004	14			7			59	66		10.1111/j.1600-0668.2004.00274.x		8	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	850DF	WOS:000223590700008	15330773	
J	Reefer, AJ; Carneiro, RM; Custis, NJ; Platts-Mills, TAE; Sung, SSJ; Hammer, J; Woodfolk, JA				Reefer, AJ; Carneiro, RM; Custis, NJ; Platts-Mills, TAE; Sung, SSJ; Hammer, J; Woodfolk, JA			A role for IL-10-mediated HLA-DR7-restricted T cell-dependent events in development of the modified Th2 response to cat allergen	JOURNAL OF IMMUNOLOGY			English	Article							DELAYED-TYPE HYPERSENSITIVITY; LATE ASTHMATIC REACTIONS; FEL-D-I; MONOCLONAL-ANTIBODIES; POSITIVE ASSOCIATION; SEQUENCE-ANALYSIS; DENDRITIC CELLS; IGG4 ANTIBODIES; MAJOR ALLERGEN; DOMESTIC CAT	Although high dose exposure to inhaled cat allergen (Fel d 1) can cause a form of tolerance (modified Th2 response), the T cell mechanism for this phenomenon has not been studied. T cell responses to Fel d 1 were characterized in both allergic (IgE(pos)) and modified Th2 (IgE(neg)IgG(pos)) responders as well as serum Ab-negative controls (IgE(neg)IgG(neg)). Fel d 1 stimulated high levels of IL-10 in PBMC cultures from all individuals, with evidence of Th2 and Th1 cytokine skewing in allergic and control subjects, respectively. Using overlapping peptides, epitopes at the N terminus of Fel d 1 chain 2 were shown to stimulate strong T cell proliferation and to preferentially induce IL-10 (peptide 2:1 (P2:1)) or IFN-gamma (P2:2) regardless of the allergic status of the donor. Injection of cat extract during conventional immunotherapy stimulated expansion of IL-10- and IFN-gamma-producing chain 2 epitope-specific T cells along with increased Fel d 1-specific serum IgG and IgG4 Ab. Six of 12 modified responders expressed the major HLA-DRB1 allele, *0701, and both P2:1 and P2:2 were predicted ligands for this allele. Cultures from DR7-positive modified responders produced the highest levels of IL-10 to P2:1 in addition to other major and minor epitopes within chains 1 and 2. In the presence of anti-IL-10 mAb, both T cell proliferation and IFN-gamma production were enhanced in a Fel d 1- and epitope-specific manner. We conclude that IL-10-producing T cells specific for chain 2 epitopes are relevant to tolerance induction, and that DR7-restricted recognition of these epitopes favors a modified Th2 response.	Univ Virginia, Dept Internal Med, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Univ Virginia, Dept Rheumatol, Charlottesville, VA 22908 USA; Hoffmann La Roche Inc, Dept Genome & Informat Sci, Nutley, NJ 07110 USA	Woodfolk, JA (reprint author), Univ Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	jaw4m@virginia.edu			NIAID NIH HHS [AI50989, AI20565]		AALBERSE RC, 1983, J IMMUNOL, V130, P722; Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis CA, 1998, J CLIN INVEST, V102, P98, DOI 10.1172/JCI2250; Alexius B, 2002, INT J LAW PSYCHIAT, V25, P109, DOI 10.1016/S0160-2527(01)00114-5; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; Blumenthal MN, 2002, ANN ALLERG ASTHMA IM, V88, P147; Brossart P, 2000, BLOOD, V96, P3102; CAMEIRO R, IN PRESS J INVEST DE; Cardaba B, 1996, CLIN EXP ALLERGY, V26, P316; CHAPMAN MD, 1988, J IMMUNOL, V140, P812; Cho SH, 2000, CLIN EXP ALLERGY, V30, P1568, DOI 10.1046/j.1365-2222.2000.00915.x; Counsell CM, 1996, J ALLERGY CLIN IMMUN, V98, P884, DOI 10.1016/S0091-6749(96)80004-2; DEGROOT H, 1988, J ALLERGY CLIN IMMUN, V82, P778, DOI 10.1016/0091-6749(88)90079-6; Disis ML, 1999, CLIN CANCER RES, V5, P1289; DJURUP R, 1984, ALLERGY, V39, P433, DOI 10.1111/j.1398-9995.1984.tb01965.x; DURHAM SR, 1995, INT ARCH ALLERGY IMM, V107, P282; Ebner C, 1997, CLIN EXP ALLERGY, V27, P1007, DOI 10.1111/j.1365-2222.1997.tb01252.x; Erwin E. A., 2003, Journal of Allergy and Clinical Immunology, V111, pS273, DOI 10.1016/S0091-6749(03)80980-6; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V281, pL1130; Hammer J, 1997, ADV IMMUNOL, V66, P67, DOI 10.1016/S0065-2776(08)60596-9; Hamzaoui A, 2000, MEDIAT INFLAMM, V9, P147; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Jeal H, 2003, J ALLERGY CLIN IMMUN, V111, P795, DOI 10.1067/mai.2003.176; Jeannin P, 1998, J IMMUNOL, V160, P3555; Johnson R. A., 1998, APPL MULTIVARIATE ST; Jutel M, 1995, J IMMUNOL, V154, P4178; LEHMANN PV, 1992, NATURE, V358, P155, DOI 10.1038/358155a0; MacDonald AJ, 2002, J INFECT DIS, V185, P720, DOI 10.1086/339340; Magnan A, 1998, ANAE, V10, P53; Maguire P, 1999, CLIN IMMUNOL, V93, P222, DOI 10.1006/clim.1999.4795; Makela MJ, 2000, P NATL ACAD SCI USA, V97, P6007, DOI 10.1073/pnas.100118997; Bibby J. M., 1994, MULTIVARIATE ANAL; Mark PG, 1996, CLIN EXP ALLERGY, V26, P1316, DOI 10.1046/j.1365-2222.1996.d01-283.x; Meissner N, 1999, CLIN EXP ALLERGY, V29, P618; MORGENSTERN JP, 1991, P NATL ACAD SCI USA, V88, P9690, DOI 10.1073/pnas.88.21.9690; NOURIARIA KT, 2002, J ALLERGY CLIN IMMUN, V1069, pS171; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Oldfield WLG, 2002, J ALLERGY CLIN IMMUN, V109, pS261, DOI 10.1016/S0091-6749(02)81932-7; Oldfield WLG, 2001, J IMMUNOL, V167, P1734; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Robinson DS, 1996, AM J RESP CELL MOL, V14, P113; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; Senechal H, 1999, J ALLERGY CLIN IMMUN, V104, P395, DOI 10.1016/S0091-6749(99)70384-2; Sturniolo T, 1999, NAT BIOTECHNOL, V17, P555; SVEJGAARD E, 1985, ACTA DERM-VENER    S, V114, P72; Tabatabai NM, 1999, HUM IMMUNOL, V60, P105, DOI 10.1016/S0198-8859(98)00102-5; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Woodfolk JA, 2000, J IMMUNOL, V165, P4379; Woodfolk JA, 2001, J IMMUNOL, V167, P5412; Zeibecoglou K, 2000, J ALLERGY CLIN IMMUN, V106, P697, DOI 10.1067/mai.2000.109824	55	96	99	0	0	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	MAR 1	2004	172	5					2763	2772				10	Immunology	Immunology	777PD	WOS:000189186000010	14978075	
J	Neaville, WA; Tisler, C; Bhattacharya, A; Anklam, K; Gilbertson-White, S; Hamilton, R; Adler, K; DaSilva, DF; Roberg, KA; Carlson-Dakes, KT; Anderson, E; Yoshihara, D; Gangnon, R; Mikus, LD; Rosenthal, LA; Gern, JE; Lemanske, RF				Neaville, WA; Tisler, C; Bhattacharya, A; Anklam, K; Gilbertson-White, S; Hamilton, R; Adler, K; DaSilva, DF; Roberg, KA; Carlson-Dakes, KT; Anderson, E; Yoshihara, D; Gangnon, R; Mikus, LD; Rosenthal, LA; Gern, JE; Lemanske, RF			Developmental cytokine response profiles and the clinical and immunologic expression of atopy during the first year of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cytokines; T(H)2; immune development; allergy; IgE	INTERFERON-GAMMA PRODUCTION; COMMON FOOD PROTEINS; SUBSEQUENT DEVELOPMENT; IGE RESPONSES; T-CELLS; CHILDREN; ALLERGEN; ASTHMA; BLOOD; SYMPTOMS	Background: Allergic diseases have been linked to abnormal patterns of immune development, and this has stimulated efforts to define the precise patterns of cytokine dysregulation that are associated with specific atopic phenotypes. Objective: Cytokine-response profiles were prospectively analyzed over the first year of life and compared with the clinical and immunologic expressions of atopy. Methods: Umbilical cord and 1-year PBMCs were obtained from 285 subjects from allergic families. PHA-stimulated cytokine-response profiles (IL-5, IL-10, IL-13, and IFN-gamma) were compared with blood eosinophil counts and total and specific IgE levels (dust mites, cat, egg, Alternaria species, peanut, milk, and dog) at age 1 year and at the development of atopic dermatitis and food allergy. Results: For the cohort as a whole, cytokine responses did not evolve according to a strict T(H)1 or T(H)2 polarization pattern. PHA-stimulated cord blood cells secreted low levels of IL-5 (2.1 pg/mL), moderate levels of IFN-gamma (57.4 pg/mL), and greater amounts of IL-13 (281.8 pg/mL). From birth to 1 year, IL-5 responses dramatically increased, whereas IL-13 and IFN-gamma responses significantly decreased. Reduced cord blood secretion of IL-10 and IFN-gamma was associated with subsequent sensitization to egg. In addition, there was evidence of T(H)2 polarization (increased IL-5 and IL-13 levels) associated with blood eosinophilia and increased total IgE levels by age 1 year. Conclusion: These findings demonstrate that cytokine responses change markedly during the first year of life and provide further evidence of a close relationship between T(H)2 skewing of immune responses and the incidence of atopic manifestations in children.	Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI USA; Univ Wisconsin, Gen Clin Res Ctr, Madison, WI USA	Neaville, WA (reprint author), Univ Wisconsin Hosp, K4-916,600 Highland Ave, Madison, WI 53792 USA.		Rosenthal, Louis/A-8868-2008		NCRR NIH HHS [2 M01 RR03186-16]; NHLBI NIH HHS [1P01HL70831-01, 1R01HL61879-01]		Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Gern JE, 1999, J CLIN INVEST, V104, P837, DOI 10.1172/JCI8272; Halonen M, 1997, CLIN EXP ALLERGY, V27, P1234; HATTEVIG G, 1987, CLIN ALLERGY, V17, P571, DOI 10.1111/j.1365-2222.1987.tb02053.x; HATTEVIG G, 1984, CLIN ALLERGY, V14, P551, DOI 10.1111/j.1365-2222.1984.tb02243.x; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Jeannin P, 1998, J IMMUNOL, V160, P3555; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Matsui E, 2000, CLIN EXP ALLERGY, V30, P1250, DOI 10.1046/j.1365-2222.2000.00931.x; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P39; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 1998, CLIN EXP ALLERGY, V28, P1313; Sampson H.A., 1998, ALLERGY PRINCIPLES P, P1162; SHAW RA, 1990, ARCH DIS CHILD, V65, P1319; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Williams TJ, 2000, J ALLERGY CLIN IMMUN, V105, P951, DOI 10.1067/mai.2000.106211; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	27	96	98	0	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2003	112	4					740	746		10.1067/mai.2003.1716		7	Allergy; Immunology	Allergy; Immunology	730LA	WOS:000185831200014	14564354	
J	Langley, SJ; Goldthorpe, S; Craven, M; Morris, J; Woodcock, A; Custovic, A				Langley, SJ; Goldthorpe, S; Craven, M; Morris, J; Woodcock, A; Custovic, A			Exposure and sensitization to indoor allergens: Association with lung function, bronchial reactivity, and exhaled nitric oxide measures in asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma severity and control; allergen exposure-sensitization; bronchial reactivity; lung function	DUST-MITE ANTIBODIES; CHILDHOOD ASTHMA; RISK-FACTORS; F-I; ADULTS; CHILDREN; COMMUNITY; DECLINE; HYPERRESPONSIVENESS; RESPONSIVENESS	Background: Exposure to high levels of allergens in sensitized asthmatic patients causes worsening of pulmonary function in experimental studies. Chronic exposure to lower, naturally occurring levels of allergens might increase the severity of asthma. Objective: We sought to study the associations between sensitization and exposure to common indoor allergens (dust mite, cat; and dog) in the home on pulmonary function, exhaled nitric oxide (eNO), and airway reactivity in asthmatic patients. Methods: Dust samples were collected from the living room carpet and mattress of 311 subject's homes, and Der p 1, Fel d 1, and Can f 1 concentrations were measured by using ELISAs. Spirometry, nonspecific bronchial reactivity, and eNO were measured. Results: Subjects both sensitized and exposed to high levels of sensitizing allergen had significantly lower FEV1 percent predicted values (mean, 83.7% vs 89.3%; mean difference, 5.6%; 95% CI, 0.6% -10.6%; P = .03), higher eNO values (geometric mean [GM], 12.8 vs 8.7 ppb; GM ratio, 0.7; 95% CI, 0.5-0.8; P = .001), and more severe airways reactivity (PD20 GM, 0.25 vs 0.73 mg; GM ratio, 2.9; 95% CI, 1.6-5.0; P < .001) compared with subjects not sensitized and exposed. No significant effect of the interaction between sensitization and exposure was found for FEV1 percent predicted and eNO values. However, there was a significant effect of the interaction between sensitization and exposure to any allergen (P = .05) and between sensitization and exposure to cat allergen (P = .04) for nonspecific bronchial reactivity. Conclusion: Asthmatic subjects who are exposed in their homes to allergens to which they are sensitized have a more severe form of the disease.	Wythenshawe Hosp, NW Lung Ctr, Med Evaluat Unit, Manchester M23 9LT, Lancs, England; Wythenshawe Hosp, Dept Stat, Manchester M23 9LT, Lancs, England	Langley, SJ (reprint author), Wythenshawe Hosp, NW Lung Ctr, Med Evaluat Unit, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578			CHAPMAN MD, 1988, J IMMUNOL, V140, P812; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P503, DOI 10.1111/j.1365-2222.1977.tb01481.x; Custovic A, 1998, THORAX, V53, P63; Custovic A, 2001, Curr Opin Allergy Clin Immunol, V1, P133; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P434; Frank TL, 1998, AM J RESP CRIT CARE, V158, P1032; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gottlieb DJ, 1996, AM J RESP CRIT CARE, V153, P561; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Henriksen AH, 2000, EUR RESPIR J, V15, P849, DOI 10.1034/j.1399-3003.2000.15e07.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; JUNIPER EF, 1978, THORAX, V33, P705, DOI 10.1136/thx.33.6.705; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1995, AM J RESP CRIT CARE, V151, P1894; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Omenaas E, 1996, EUR RESPIR J, V9, P919, DOI 10.1183/09031936.96.09050919; OMENAAS E, 1995, AM J RESP CRIT CARE, V152, P1158; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Piacentini GL, 1999, J ALLERGY CLIN IMMUN, V104, P1323; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; QUANJER PH, 1993, EUR RESPIR J, V6, P5; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SALOME CM, 1980, CLIN ALLERGY, V10, P541, DOI 10.1111/j.1365-2222.1980.tb02135.x; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; Simpson A, 1999, AM J RESP CRIT CARE, V160, P45; Sunyer J, 2000, INT J EPIDEMIOL, V29, P125, DOI 10.1093/ije/29.1.125; Tracey M, 1995, Am J Respir Crit Care Med, V151, P656; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; WOODFOLK JA, 1992, ANN ALLERGY, V69, P273; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	36	96	96	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					362	368		10.1067/mai.2003.1654		7	Allergy; Immunology	Allergy; Immunology	709WY	WOS:000184650600021	12897743	
J	Svanes, C; Heinrich, J; Jarvis, D; Chinn, S; Omenaas, E; Gulsvik, A; Kunzli, N; Burney, P				Svanes, C; Heinrich, J; Jarvis, D; Chinn, S; Omenaas, E; Gulsvik, A; Kunzli, N; Burney, P			Pet-keeping in childhood and adult asthma and hay fever: European Community Respiratory Health Survey	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cats; dogs; birds; asthma; hay fever; sensitization; tolerance; hygiene hypothesis; ECRHS	HOUSE-DUST ENDOTOXIN; ALLERGEN EXPOSURE; CAT ALLERGENS; SENSITIZATION; CHILDREN; SYMPTOMS; LIFE; ATOPY; RISK; ENVIRONMENT	Background: Whether pet-keeping early in life protects against or promotes allergy remains unclear. Objective: Our aim was to examine the effects of childhood pet-keeping on adult allergic disease in a large international population-based study, including information on sensitization, adult pet-keeping, and pet prevalence in the populations. Methods: We used information from structured interviews (n = 18,530) and specific IgE to common aeroallergens in blood samples (n = 13,932) from participants in the European Community Respiratory Health Survey (ECRHS) to analyze the associations between keeping pets and adult asthma and hay fever. Results: Keeping cats in childhood was associated with asthma only among atopic subjects, an association that varied between centers (P = .002) and was stronger where cats where less common (< 40% cats: odds ratio(wheeze) [ORwheeze] = 1.84, 95% CI = 1.31-2.57; 40%-60% cats: ORwheeze = 1.33, 95% CI = 1.10-1.61; greater than or equal to60% cats: ORwheeze = 0.98, 95% CI = 0.73-1.33). Dogs owned in childhood or adulthood were associated with asthma among nonatopic subjects (childhood: ORwheeze = 1.28, 95% CI = 1.13-1.46; adulthood: ORwheeze = 1.31, 95% CI = 1.14-1.51; both: ORwheeze = 1.69, 95% CI = 1.40-2.04). In atopic subjects, those who had owned dogs in childhood had less hay fever (OR = 0.85; 95% CI = 0.73-0.98) and no increased risk of asthma (ORwheeze = 1.01, 95 % CI = 0.87-1.17). Respiratory symptoms were more common in subjects who had owned birds during childhood (ORwheeze = 1.12; 95 % CI = 1.02-1.23) independent of sensitization. Conclusions: The effects of pet-keeping in childhood varied according to the type of pet, the allergic sensitization of the individual, and the wider environmental exposure to allergen. Cats owned in childhood were associated with more asthma in sensitized adults who grew up in areas with a low community prevalence of cats. Dogs owned in childhood seemed to protect against adult allergic disease but promote nonallergic asthma.	Haraldsplass Hosp, Dept Med, N-5009 Bergen, Norway; Univ Bergen, Inst Med, Sect Resp Med, N-5009 Bergen, Norway; GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; Univ London Kings Coll, Dept Publ Hlth Sci, London WC2R 2LS, England; Univ So Calif, Los Angeles, CA USA; Univ Basel, Basel, Switzerland	Svanes, C (reprint author), Haraldsplass Hosp, Dept Med, N-5009 Bergen, Norway.		Jarvis, Deborah/E-6494-2011; Kunzli, Nino/F-7195-2014	Kunzli, Nino/0000-0001-8360-080X	NCRR NIH HHS [2 S07 RR05521-28]		Anyo G, 2002, CLIN EXP ALLERGY, V32, P361, DOI 10.1046/j.1365-2222.2002.01254.x; Apelberg BJ, 2001, J ALLERGY CLIN IMMUN, V107, P455, DOI 10.1067/mai.2001.113240; *AVMA COMM HUM AN, 1995, J AM VET MED ASSOC, V206, P961; Baldini M, 2002, ALLERGY, V57, P188, DOI 10.1034/j.1398-9995.2002.1r152.x; Braback L, 2001, PEDIATR ALLERGY IMMU, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; BUIJS J, 1995, AM J RESP CRIT CARE, V151, P873; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Chan PWK, 2001, PEDIATR INT, V43, P350, DOI 10.1046/j.1442-200X.2001.01421.x; COPPERMAN SM, 1982, NEW YORK STATE J MED, V82, P1685; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gehring U, 2001, EUR RESPIR J, V18, P555, DOI 10.1183/09031936.01.00096801; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Henriksen AH, 2001, RESP MED, V95, P122, DOI 10.1053/rmed.2000.1004; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hesselmar B, 2001, PEDIATR ALLERGY IMMU, V12, P208, DOI 10.1034/j.1399-3038.2001.012004208.x; HOLSCHER B, 2002, PEDIAT ALLERGY IMMUN, V13; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Martinez FD, 1999, LANCET S2, V354, pSII12; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Noertjojo K, 1999, J ALLERGY CLIN IMMUN, V103, P60, DOI 10.1016/S0091-6749(99)70526-9; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Prescott SL, 2001, CLIN EXP ALLERGY, V31, P1653, DOI 10.1046/j.1365-2222.2001.01258.x; Radon K, 2001, EUR RESPIR J, V17, P747, DOI 10.1183/09031936.01.17407470; Rees D, 1998, S AFR MED J, V88, P1110; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ronmark E, 2001, PEDIATRICS, V107, DOI 10.1542/peds.107.3.e37; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Sporik R, 2001, THORAX, V56, P58; Stata Corp, STAT STAT SOFTW REL; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sunyer J., 1997, European Respiratory Journal, V10, P2490, DOI 10.1183/09031936.97.10112490; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tan JS, 1997, ARCH INTERN MED, V157, P1933, DOI 10.1001/archinte.157.17.1933; Tariq SM, 1998, J ALLERGY CLIN IMMUN, V101, P587; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Withers NJ, 1998, AM J RESP CRIT CARE, V158, P352; 1980, CLASS OCC LOND OFF P	51	96	99	0	12	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					289	300		10.1067/mai.2003.1596		12	Allergy; Immunology	Allergy; Immunology	709WY	WOS:000184650600012	12897734	
J	Staples, JA; Ponsonby, AL; Lim, LLY; McMichael, AJ				Staples, JA; Ponsonby, AL; Lim, LLY; McMichael, AJ			Ecologic analysis of some immune-related disorders, including type 1 diabetes, in Australia: Latitude, regional ultraviolet radiation, and disease prevalence	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; Australia; autoimmune disease; ecologic analysis; eczema/dermatitis; immune disorders; latitude; rheumatoid arthritis; type 1 diabetes; ultraviolet radiation	VITAMIN-D DEFICIENCY; MULTIPLE-SCLEROSIS; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASE; MOLECULAR MIMICRY; BIRTH-COHORT; EXPOSURE; MECHANISMS; RESPONSES; ASTHMA	The apparent immune-suppressive effect of ultraviolet radiation (UVR) has suggested that this environmental exposure may influence the development of immune-related disorders. Self-reported prevalence rates of type 1 diabetes mellitus, rheumatoid arthritis (RA), eczema/dermatitis, and asthma, from the 1995 Australian National Health Survey, were therefore examined by latitude and ambient level of UVR. A positive association of type I diabetes mellitus prevalence was found with both increasing southern latitude of residence (r = 0.77; P = 0.026) and decreasing regional annual ambient UVR (r = -0.80; p = 0.018); a 3-fold increase in prevalence from the northernmost region to the southernmost region was evident. In contrast, asthma correlated negatively with latitude (r = -0.72; p = 0.046), although the change in asthma prevalence from the north to the south of Australia was only 0.7-fold. For both RA and eczema/dermatitis, there were no statistically significant associations between latitude/UVR and disease prevalence. These ecologic data provide some support for a previously proposed beneficial effect of UVR on T-helper 1-mediated autoimmune disorders such as type 1 diabetes. The inverse association of type 1 diabetes prevalence with UVR is consistent with that previously reported for another autoimmune disease, multiple sclerosis, in Australia, and also with type I diabetes latitudinal gradients in the Northern Hemisphere. The finding also accords with photoimmunologic evidence of UVR-induced immunosuppression and may suggest a beneficial effect of UVR in reducing the incidence of such autoimmune conditions. In light of this study, analytic epidemiologic studies investigating risk of immune disorders in relation to personal UVR exposure in humans are required.	Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia	Staples, JA (reprint author), Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT, Australia.						*ABS, 1995, 43680 ABS; *ABS, 1995, 43630001 ABS; *ABS, 1995, 43630 ABS; Albert LJ, 1999, NEW ENGL J MED, V341, P2068, DOI 10.1056/NEJM199912303412707; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Blasi F, 2001, Monaldi Arch Chest Dis, V56, P276; Cantorna MT, 2000, P SOC EXP BIOL MED, V223, P230, DOI 10.1046/j.1525-1373.2000.22333.x; Clydesdale GJ, 2001, IMMUNOL CELL BIOL, V79, P547, DOI 10.1046/j.1440-1711.2001.01047.x; Couper D, 1998, CLIN EXP ALLERGY, V28, P715; Dahlquist G, 1999, DIABETOLOGIA, V42, P51; Dahlquist G, 1998, Acta Paediatr Suppl, V425, P5; Damian DL, 1998, J INVEST DERMATOL, V110, P824, DOI 10.1046/j.1523-1747.1998.00176.x; Davidson A, 2001, NEW ENGL J MED, V345, P340; Duthie MS, 1999, BRIT J DERMATOL, V140, P995; Ebringer A, 2000, J MED MICROBIOL, V49, P305; EURODIAB, 2000, DIABETOLOGIA, V43, P47, DOI DOI 10.1007/S001250050006; Garssen J, 1999, IMMUNOLOGY, V97, P506; GIES HP, 1999, TRENDS SUN PROTECTIO, P1; Grover SR, 2001, MED J AUSTRALIA, V175, P251; Hammond SR, 2000, BRAIN, V123, P968, DOI 10.1093/brain/123.5.968; Haverkos HW, 1997, DIABETOLOGIA, V40, P1235, DOI 10.1007/s001250050813; Hayes CE, 1997, P SOC EXP BIOL MED, V216, P21; HERSEY P, 1983, J IMMUNOL, V131, P1471; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; Kamradt T, 2001, NEW ENGL J MED, V344, P655; KARGES WJP, 1995, MOL ASPECTS MED, V16, P79, DOI 10.1016/0098-2997(95)00001-W; KARVONEN M, 1993, DIABETOLOGIA, V36, P883, DOI 10.1007/BF02374468; Kelly DA, 1998, J PHOTOCH PHOTOBIO B, V44, P130, DOI 10.1016/S1011-1344(98)00136-5; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Lemus-Deschamps L, 1999, METEOROL APPL, V6, P241, DOI 10.1017/S1350482799001188; Mackay IR, 2000, BRIT MED J, V321, P93, DOI 10.1136/bmj.321.7253.93; Mason RS, 2001, MED J AUSTRALIA, V175, P236; McGrath JJ, 2001, MED J AUSTRALIA, V174, P150; MCLEOD JG, 1994, MED J AUSTRALIA, V160, P117; McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005; McMichael AJ, 2001, NEUROEPIDEMIOLOGY, V20, P165, DOI 10.1159/000054782; McNally NJ, 2000, BRIT J DERMATOL, V142, P712, DOI 10.1046/j.1365-2133.2000.03416.x; MILLER DH, 1990, J NEUROL NEUROSUR PS, V53, P903, DOI 10.1136/jnnp.53.10.903; Nghiem DX, 2001, J INVEST DERMATOL, V117, P1193, DOI 10.1046/j.0022-202x.2001.01503.x; Norris JM, 2001, LANCET, V358, P1476, DOI 10.1016/S0140-6736(01)06570-9; Notkins AL, 2001, J CLIN INVEST, V108, P1247, DOI 10.1172/JCI14257; Pasco JA, 2001, MED J AUSTRALIA, V175, P401; Pearce N, 1999, THORAX, V54, P268; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills Thomas A E, 2002, Curr Allergy Asthma Rep, V2, P175, DOI 10.1007/s11882-002-0013-2; Ponsoby AL, 2002, TOXICOLOGY, V181, P71, DOI 10.1016/S0300-483X(02)00257-3; REWERS M, 1988, DIABETES, V37, P1113; Reynolds NJ, 2001, LANCET, V357, P2012, DOI 10.1016/S0140-6736(00)05114-X; Selgrade MJK, 1997, ENVIRON HEALTH PERSP, V105, P332, DOI 10.1289/ehp.97105332; Sleijffers A, 2001, J INVEST DERMATOL, V117, P1144, DOI 10.1046/j.0022-202x.2001.01542.x; Stene LC, 2000, DIABETOLOGIA, V43, P1093, DOI 10.1007/s001250051499; van der Mei IAF, 2001, NEUROEPIDEMIOLOGY, V20, P168, DOI 10.1159/000054783; Weinshenker BG, 1996, NEUROL CLIN, V14, P291, DOI 10.1016/S0733-8619(05)70257-7; Wilson C, 2000, MICROBES INFECT, V2, P1489, DOI 10.1016/S1286-4579(00)01303-4; Yang Z, 1998, DIABETES CARE, V21, P525, DOI 10.2337/diacare.21.4.525	55	96	103	0	9	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2003	111	4					518	523		10.1289/ehp.5941		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	665WM	WOS:000182144300041	12676609	
J	Mendell, MJ; Fisk, WJ; Kreiss, K; Levin, H; Alexander, D; Cain, WS; Girman, JR; Hines, CJ; Jensen, PA; Milton, DK; Rexroat, LP; Wallingford, KM				Mendell, MJ; Fisk, WJ; Kreiss, K; Levin, H; Alexander, D; Cain, WS; Girman, JR; Hines, CJ; Jensen, PA; Milton, DK; Rexroat, LP; Wallingford, KM			Improving the health of workers in indoor environments: Priority research needs for a national occupational research agenda	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							SICK-BUILDING-SYNDROME; AIR EXCHANGE-RATE; OFFICE BUILDINGS; RESPIRATORY-DISEASES; RHINOVIRUS COLDS; VENTILATION; RISK; TRANSMISSION; ASTHMA; INFECTIONS	Indoor nonindustrial work environments were designated a priority research area through the nationwide stakeholder process that created the National Occupational Research Agenda. A multidisciplinary research team used member consensus and quantitative estimates, with extensive external review, to develop a specific research agenda. The team outlined the following priority research topics: building-influenced communicable respiratory infections, building-related asthma/allergic diseases, and nonspecific building-related symptoms; indoor environmental science; and methods for increasing implementation of healthful building practices. Available data suggest that improving building environments may result in health benefits for more than 15 million of the 89 million US indoor workers, with estimated economic benefits of $5 to $75 billion annually. Research on these topics, requiring new collaborations and resources, offers enormous potential health and economic returns.	Lawrence Berkeley Natl Lab, Berkeley, CA 94720 USA; NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH USA; NIOSH, Div Resp Dis Studies, Cincinnati, OH USA; Bldg Ecol Res Grp, San Diego, CA USA; Amer Federat Teachers, Washington, DC USA; Univ Calif San Diego, Dept Surg, Sch Med, San Diego, CA 92103 USA; US Environm Protect Agcy, Indoor Environm Div, Washington, DC USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; US Gen Serv Adm, Publ Bldg Serv, Ft Worth, TX USA	Mendell, MJ (reprint author), Lawrence Berkeley Natl Lab, 1 Cyclotron Rd,MS 90-3058, Berkeley, CA 94720 USA.		Milton, Donald/G-3286-2010	Milton, Donald/0000-0002-0550-7834			*AM SOC HEAT REFR, 1996, PROP AM NAT STAND VE; Apte M., 1999, P IND AIR 99 8 INT C, V1, P117; Bluyssen PM, 1996, INDOOR AIR, V6, P221, DOI 10.1111/j.1600-0668.1996.00002.x; BRIGHTMAN HS, 1999, P IND AIR 99 8 INT C, P847; Brosseau LM, 1994, ASHRAE T, V100, P368; BRUNDAGE JF, 1988, JAMA-J AM MED ASSOC, V259, P2108, DOI 10.1001/jama.259.14.2108; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; CHEN A, 2000, ENV SCI POLICY, V2, P457; COMETTOMUNIZ JE, 1994, INDOOR AIR, V4, P140, DOI 10.1111/j.1600-0668.1994.t01-1-00002.x; COUCH RB, 1981, B NEW YORK ACAD MED, V57, P907; COUCH RB, 1966, BACTERIOL REV, V30, P517; *CUTT INF CORP, 1996, INDOOR AIR QUALITY U, V9, P2; Dales R, 1998, ARCH ENVIRON HEALTH, V53, P190; DICK EC, 1987, J INFECT DIS, V156, P442; Drinka PJ, 1996, J AM GERIATR SOC, V44, P910; EPA (Environment Protection Authority), 1991, EPA PUBL, V168; Environmental Protection Agency, 1998, EPA PUBL; Fisk WJ, 1997, INDOOR AIR, V7, P158, DOI 10.1111/j.1600-0668.1997.t01-1-00002.x; Fisk WJ, 1993, INDOOR AIR, V3, P246, DOI DOI 10.1111/J.1600-0668.1993.00005.X; Fisk WJ, 2000, INDOOR AIR QUALITY H, P41; *GAO, 1999, GAO PUBL, P70; GWALTNEY JM, 1978, ANN INTERN MED, V88, P463; GWALTNEY JM, 1982, AM J EPIDEMIOL, V116, P828; GYNTELBERG F, 1994, INDOOR AIR, V4, P223, DOI 10.1111/j.1600-0668.1994.00003.x; HODGSON MJ, 1987, AM J EPIDEMIOL, V125, P631; HOFFMAN RE, 1993, AM J PUBLIC HEALTH, V83, P89; HOGE CW, 1994, NEW ENGL J MED, V331, P643, DOI 10.1056/NEJM199409083311004; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; HUSMAN T, 1993, P IND AIR 93 6 INT C, P171; Institute of Medicine Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; JAAKKOLA JJK, 1995, EUR J EPIDEMIOL, V11, P213, DOI 10.1007/BF01719490; JENNINGS LC, 1987, EUR J EPIDEMIOL, V3, P327, DOI 10.1007/BF00145641; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Kemp PC, 1998, INDOOR AIR, V8, P153, DOI 10.1111/j.1600-0668.1998.t01-1-00003.x; Knight V, 1980, Ann N Y Acad Sci, V353, P147, DOI 10.1111/j.1749-6632.1980.tb18917.x; KREISS K, 1989, OCCUP MED, V4, P1; LAFORCE F M, 1986, Environment International, V12, P137, DOI 10.1016/0160-4120(86)90024-3; LANGMUIR AD, 1948, AM J HYG, V48, P240; LEINSTER P, 1981, P IND AIR 90 5 INT C, P97; Mendell MJ, 1996, EPIDEMIOLOGY, V7, P583, DOI 10.1097/00001648-199611000-00004; Mendell MJ, 1993, INDOOR AIR, V3, P227, DOI 10.1111/j.1600-0668.1993.00003.x; Menzies D, 2000, ANN INTERN MED, V133, P779; Milton DK, 2000, INDOOR AIR, V10, P212, DOI 10.1034/j.1600-0668.2000.010004212.x; Milton DK, 1998, AM J IND MED, V33, P1, DOI 10.1002/(SICI)1097-0274(199801)33:1<1::AID-AJIM1>3.0.CO;2-2; NARDELL EA, 1991, AM REV RESPIR DIS, V144, P302; NELSON NA, 1995, SCAND J WORK ENV HEA, V21, P51; *NEW YORK STAT COM, 1923, VENT REP NEW YORK ST, P417; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; *REG ALT DEV CORP, 1993, PROM APPR IMP IAQ; RICHARDS AL, 1993, AM J PUBLIC HEALTH, V83, P1326, DOI 10.2105/AJPH.83.9.1326; RILEY RL, 1974, AM J MED, V57, P466, DOI 10.1016/0002-9343(74)90140-5; Rosenstock L, 1998, AM J PUBLIC HEALTH, V88, P353, DOI 10.2105/AJPH.88.3.353; Rylander R, 1992, INDOOR ENVIRON, V1, P263, DOI 10.1177/1420326X9200100502; SATTAR SA, 1987, CRIT REV ENV CONTR, V17, P89; SAWYER MH, 1994, J INFECT DIS, V169, P91; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; Seuri M, 2000, INDOOR AIR, V10, P138, DOI 10.1034/j.1600-0668.2000.010003138.x; Sieber W.K., 1996, APPL OCCUP ENV HYG, V11, P1387; SKOV P, 1987, ENVIRON INT, V13, P339, DOI 10.1016/0160-4120(87)90190-5; STENBERG B, 1994, INT J EPIDEMIOL, V23, P1190, DOI 10.1093/ije/23.6.1190; TEEUW KB, 1994, ARCH INTERN MED, V154, P2339, DOI 10.1001/archinte.154.20.2339; Ten Brinke J, 1998, INDOOR AIR, V8, P140; *US CDCP, 1998, MMWR-MORBID MORTAL W, V44, P1022; *US EPA, 1989, EPA PUBL; *US EPA OFF RAD IN, 1994, 3434 HR US EPA OFF; Walinder R, 1997, INDOOR AIR, V7, P198, DOI 10.1111/j.1600-0668.1997.t01-1-00005.x; Walinder R, 1998, INT ARCH OCC ENV HEA, V71, P479, DOI 10.1007/s004200050309; WARSHAUER DM, 1989, AM J EPIDEMIOL, V129, P319; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Weschler CJ, 2000, INDOOR AIR, V10, P92, DOI 10.1034/j.1600-0668.2000.010002092.x; Wolkoff P, 2000, INDOOR AIR, V10, P82, DOI 10.1034/j.1600-0668.2000.010002082.x; WYON DP, 1992, ENVIRON TECHNOL, V13, P313	73	96	98	1	15	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	SEP	2002	92	9					1430	1440		10.2105/AJPH.92.9.1430		11	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	587UM	WOS:000177661900016	12197969	
J	Sagi, HC; Beutler, W; Carroll, E; Connolly, PJ				Sagi, HC; Beutler, W; Carroll, E; Connolly, PJ			Airway complications associated with surgery on the anterior cervical spine	SPINE			English	Article						airway; respiratory; complications; anterior cervical surgery	VOCAL CORD PARALYSIS; CASPAR INSTRUMENTATION; PLATE FIXATION; FUSION; OBSTRUCTION; INJURY; STABILIZATION; DISKECTOMY; CORPECTOMY; DYSPHAGIA	Study Design. Retrospective chart review of 311 anterior cervical procedures. Objectives. To assess the incidence and variables that predispose to an airway complication in a large series of anterior cervical surgical procedures. Summary of Background Data. A rare but potentially lethal complication after anterior cervical spine surgery is respiratory compromise and airway obstruction, Some risk factors are thought to include two-level corpectomy in myelopathic patients with a history of heavy smoking and asthma. No previous study in the literature has been directed at examining the factors specifically related to airway complications after anterior cervical spine surgery, Methods. Each chart was examined for patient characteristics and pathology, anesthetic parameters and problems, operative procedure, and postoperative course and management. Statistical analysis was performed. Results. Nineteen patients (6.1%) had an airway complication and six (1.9%) required reintubation. One patient died. Symptoms developed on average 36 hours postoperatively. All complications except for two were attributable to pharyngeal edema. Variables that were found to be statistically associated with an airway complication (P < 0.05) were exposing more than three vertebral bodies, a blood loss >300 mL, exposures involving C2, C3, or C4, and an operative time >5 hours. A history of myelopathy, spinal cord injury, pulmonary problems, smoking, anesthetic risk factors, and the absence of a drain did not correlate with an airway complication, Conclusions. Patients with prolonged procedures (i.e., >5 hours) exposing more than three vertebral levels that include C2, C3, or C4 with more than 300-mL blood loss should be watched carefully for respiratory insufficiency.	Univ Calif San Francisco, Fresno Med Educ Program, Fresno, CA USA; SUNY Upstate Med Univ, Syracuse, NY USA	Sagi, HC (reprint author), Calif State Univ Fresno, Dept Orthopaed, Ctr Med, 445 S Cedar Ave, Fresno, CA 93702 USA.	eversosaggy@cs.com					ANDERSON PA, 1992, J BONE JOINT SURG AM, V74A, P683; ANDREWS ET, 1971, CLIN ORTHOP RELAT R, P15; BERTALANFFY H, 1989, ACTA NEUROCHIR, V99, P41, DOI 10.1007/BF01407775; Bookvar JA, 2001, J NEUROSURG, V94, P12; Bose B, 1998, SURG NEUROL, V49, P25, DOI 10.1016/S0090-3019(97)00306-6; BROWN JA, 1988, SPINE, V13, P236, DOI 10.1097/00007632-198803000-00003; Daniels SK, 1998, ENT-EAR NOSE THROAT, V77, P473; Drompp B W, 1964, Clin Orthop Relat Res, V34, P42; EMERY SE, 1991, J BONE JOINT SURG AM, V73A, P544; Henry AD, 1999, J BONE JOINT SURG BR, V81B, P472, DOI 10.1302/0301-620X.81B3.9109; Jellish WS, 1999, J NEUROSURG, V91, P170, DOI 10.3171/spi.1999.91.2.0170; Jonsson B, 1994, Eur Spine J, V3, P76, DOI 10.1007/BF02221444; Kirshblum S, 1999, ARCH PHYS MED REHAB, V80, P1101, DOI 10.1016/S0003-9993(99)90068-0; Krnacik MJ, 1997, SPINE, V22, P2188, DOI 10.1097/00007632-199709150-00019; Malca SA, 1996, SPINE, V21, P685, DOI 10.1097/00007632-199603150-00004; Manski TJ, 1998, J NEUROSURG, V89, P839, DOI 10.3171/jns.1998.89.5.0839; Morpeth JF, 2000, LARYNGOSCOPE, V110, P43, DOI 10.1097/00005537-200001000-00009; Muzumdar DP, 2000, SURG NEUROL, V53, P586, DOI 10.1016/S0090-3019(00)00245-7; Penberthy A, 1998, ANAESTH INTENS CARE, V26, P305; RIEW DK, 1999, J BONE JOINT SURG AM, V81, P950; Riew KD, 1999, SPINE, V24, P2404, DOI 10.1097/00007632-199911150-00019; ROBINSON RA, 1955, B JOHNS HOPKINS HOSP, V96, P223; STONE JL, 1989, J NEUROSURG, V70, P879, DOI 10.3171/jns.1989.70.6.0879; SUH PB, 1990, SPINE, V15, P1079, DOI 10.1097/00007632-199015100-00018; Swank M L, 1997, Eur Spine J, V6, P138, DOI 10.1007/BF01358747; Swank ML, 1997, SPINE, V22, P274, DOI 10.1097/00007632-199702010-00009; Tew J M Jr, 1976, Clin Neurosurg, V23, P424; TIPPETS RH, 1988, NEUROSURGERY, V22, P1008; Winslow CP, 1999, AM J OTOLARYNG, V20, P16, DOI 10.1016/S0196-0709(99)90046-7; Winslow CP, 2001, ARCH OTOLARYNGOL, V127, P51; Zeidman SM, 1997, J SPINAL DISORD, V10, P523	31	96	103	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436			SPINE	SPINE	MAY 1	2002	27	9					949	953		10.1097/00007632-200205010-00013		5	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	548ZL	WOS:000175420000012	11979168	
J	Hoppin, JA; Umbach, DM; London, SJ; Alavanja, MCR; Sandler, DP				Hoppin, JA; Umbach, DM; London, SJ; Alavanja, MCR; Sandler, DP			Chemical predictors of wheeze among farmer pesticide applicators in the agricultural health study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						wheeze; pesticides; organophosphates; paraquat; agricultural exposure	RESPIRATORY SYMPTOMS; OCCUPATIONAL ASTHMA; PARAQUAT; WORKERS; INSECTICIDE; POPULATION; PREVALENCE; SELECTION; EXPOSURE; INDUSTRY	Pesticides may contribute to respiratory symptoms among farmers. Using the Agricultural Health Study, a large cohort of certified pesticide applicators in Iowa and North Carolina, we explored the association between wheeze and pesticide use in the past year. Self-administered questionnaires contained items on 40 currently used pesticides and pesticide application practices. A total of 20,468 applicators, ranging in age from 16 to 88 years, provided complete information; 19% reported wheezing in the past year. Logistic regression models controlling for age, state, smoking, and history of asthma or atopy were used to evaluate associations between individual pesticides and wheeze. Among pesticides suspected to contribute to wheeze, paraquat, three organophosphates (parathion, malathion, and chlorpyrifos), and one thiocarbamate (S-ethyl-dipropylthiocarbamate [EPTC]) had elevated odds ratios (OR). Parathion had the highest OR (1.5, 95% confidence interval [CI] 1.0, 2.2). Chlorpyrifos, EPTC, paraquat, and parathion demonstrated significant dose-response trends. The herbicides, atrazine and alachlor, but not 2,4-D, were associated with wheeze. Atrazine had a significant dose-response trend with participants applying atrazine more than 20 days/year having an OR of 1.5 (95% CI 1.2, 1.9). Inclusion of crops and animals into these models did not significantly alter the observed OR. These associations, though small, suggest an independent role for specific pesticides in respiratory symptoms of farmers.	NIEHS, Epidemiol Branch, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Biostat Branch, NIH, Res Triangle Pk, NC 27709 USA; NCI, Occupat Epidemiol Branch, NIH, Rockville, MD USA	Hoppin, JA (reprint author), NIEHS, Epidemiol Branch, NIH, MD A3-05,POB 12233, Res Triangle Pk, NC 27709 USA.			Sandler, Dale/0000-0002-6776-0018; London, Stephanie/0000-0003-4911-5290			Alavanja MCR, 1996, ENVIRON HEALTH PERSP, V104, P362, DOI 10.2307/3432672; BLAIR A, 1993, EPIDEMIOLOGY, V4, P55, DOI 10.1097/00001648-199301000-00011; BRYANT DH, 1985, AUST NZ J MED, V15, P66, DOI 10.1111/j.1445-5994.1985.tb02740.x; Castro-Gutierrez N, 1997, SCAND J WORK ENV HEA, V23, P421; *CHEM PHARM PRESS, 1995, CROP PROT REF; CONE JE, 1994, CHEST, V106, P500, DOI 10.1378/chest.106.2.500; Dalvie MA, 1999, OCCUP ENVIRON MED, V56, P391; DESCHAMPS D, 1994, LANCET, V344, P1712, DOI 10.1016/S0140-6736(94)90498-7; DOSMAN JA, 1987, J OCCUP ENVIRON MED, V29, P38; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; HONDA I, 1992, THORAX, V47, P760, DOI 10.1136/thx.47.9.760; HONORE P, 1994, ACTA CLIN BELG, V49, P220; Karjalainen A, 2000, AM J IND MED, V37, P451, DOI 10.1002/(SICI)1097-0274(200005)37:5<451::AID-AJIM1>3.0.CO;2-U; Kimbell-Dunn M, 1999, AM J IND MED, V35, P51, DOI 10.1002/(SICI)1097-0274(199901)35:1<51::AID-AJIM7>3.0.CO;2-F; Masley M L, 2000, J Agric Saf Health, V6, P103; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262; Nathell L, 2000, SCAND J WORK ENV HEA, V26, P382; Ohayo-Mitoko GJA, 2000, OCCUP ENVIRON MED, V57, P195, DOI 10.1136/oem.57.3.195; POPENDORF W, 1985, AM IND HYG ASSOC J, V46, P154, DOI 10.1202/0002-8894(1985)046<0154:ASOARH>2.3.CO;2; Post W, 1998, OCCUP ENVIRON MED, V55, P349; ROYCE S, 1993, CHEST, V103, P295, DOI 10.1378/chest.103.1.295; SCHENKER M, 1991, OCCUP MED, V6, P415; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; Schwartz DA, 1999, ENVIRON HEALTH PERSP, V107, P393; SENTHILSELVAN A, 1992, AM REV RESPIR DIS, V146, P884; Sprince NL, 2000, AM J IND MED, V38, P455; Tarone RE, 1997, AM J IND MED, V31, P233; Tupi K, 1987, Eur J Respir Dis Suppl, V152, P206; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; WEINER A, 1961, ANN ALLERGY, V19, P397; Wilkins JR, 1999, AM J IND MED, V35, P150, DOI 10.1002/(SICI)1097-0274(199902)35:2<150::AID-AJIM7>3.0.CO;2-5; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	32	96	97	1	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR 1	2002	165	5					683	689		10.1164/rccm.2106074		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	526LD	WOS:000174131200013	11874814	
J	Danahay, H; Atherton, H; Jones, G; Bridges, RJ; Poll, CT				Danahay, H; Atherton, H; Jones, G; Bridges, RJ; Poll, CT			Interleukin-13 induces a hypersecretory ion transport phenotype in human bronchial epithelial cells	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article						calcium-activated chloride channel; hypersecretion; asthma; interleukin-4	TRANSMEMBRANE CONDUCTANCE REGULATOR; AIRWAY EPITHELIUM; WILD-TYPE; EXPRESSION; ASTHMA; CHANNEL; DIFFERENTIATION; MODULATION; MEDIATORS; IL-13	Interleukin (IL)-13 has been associated with asthma, allergic rhinitis, and chronic sinusitis, all conditions where an imbalance in epithelial fluid secretion and absorption could impact upon the disease. We have investigated the effects of IL-13 on the ion transport characteristics of human bronchial epithelial cells cultured at an apical-air interface. Ussing chamber studies indicated that 48 h pretreatment with IL-13 or IL-4 significantly reduced the basal short-circuit current (I-sc) and inhibited the amiloride-sensitive current by >98%. Furthermore, the I-sc responses were increased by more than six- and twofold over control values when stimulated with UTP or forskolin, respectively, after cytokine treatment. The IL-13-enhanced response to UTP/ionomycin was sensitive to bumetanide and DIDS and was reduced in a low-chloride, bicarbonate-free solution. Membrane permeablization studies indicated that IL-13 induced the functional expression of an apical Ca2+-activated anion conductance and that changes in apical or basolateral K+ conductances could not account for the increased I-sc responses to UTP or ionomycin. The results indicate that IL-13 converts the human bronchial epithelium from an absorptive to a secretory phenotype that is the result of loss of amiloride-sensitive current and an increase in a DIDS-sensitive apical anion conductance.	Novartis Resp Res Ctr, Horsham RH12 5AB, W Sussex, England; Univ Pittsburgh, Dept Cell Biol & Physiol, Pittsburgh, PA 15261 USA	Danahay, H (reprint author), Novartis Resp Res Ctr, Wimblehurst Rd, Horsham RH12 5AB, W Sussex, England.						Alpert SE, 1995, AM J PHYSIOL-LUNG C, V269, pL734; BESANCON F, 1994, AM J PHYSIOL-CELL PH, V267, pC1398; Borok Z, 1998, AM J PHYSIOL-LUNG C, V274, pL149; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271; Brouillard F, 2001, J BIOL CHEM, V276, P9486, DOI 10.1074/jbc.M006636200; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; Chang MMJ, 1998, AM J PHYSIOL-LUNG C, V275, pL524; CHRISTOFFERSEN GRJ, 1975, COMP BIOCHEM PHYS A, V52, P317, DOI 10.1016/S0300-9629(75)80094-6; Devor DC, 2000, AM J PHYSIOL-CELL PH, V279, pC461; Devor DC, 1999, AM J PHYSIOL-CELL PH, V276, pC827; Fukuda N, 2001, AM J PHYSIOL-LUNG C, V280, pL1258; Fuller CM, 2000, CLIN EXP PHARMACOL P, V27, P906, DOI 10.1046/j.1440-1681.2000.03359.x; Galietta LJV, 2000, AM J PHYSIOL-LUNG C, V278, pL1186; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Gray TE, 1996, AM J RESP CELL MOL, V14, P104; HAMILOS DL, 1996, AM J RESP CELL MOL B, V15, P433; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; HUANG SK, 1995, J IMMUNOL, V155, P2688; Humbert M, 1997, J ALLERGY CLIN IMMUN, V99, P657, DOI 10.1016/S0091-6749(97)70028-9; Iwase N, 1997, J CLIN INVEST, V99, P1651, DOI 10.1172/JCI119328; Kerem E, 1999, NEW ENGL J MED, V341, P156, DOI 10.1056/NEJM199907153410304; Kotsimbos TC, 1996, P ASSOC AM PHYSICIAN, V108, P368; Kunzelmann K, 2000, PFLUG ARCH EUR J PHY, V440, P193, DOI 10.1007/s004240000255; Kunzelmann K, 2000, P NATL ACAD SCI USA, V97, P10282, DOI 10.1073/pnas.160041997; Martin LD, 1997, EUR RESPIR J, V10, P2139, DOI 10.1183/09031936.97.10092139; Martin LD, 2000, CHEST, V117, p267S, DOI 10.1378/chest.117.5_suppl_1.267S; NAKAMURA H, 1992, FEBS LETT, V314, P366, DOI 10.1016/0014-5793(92)81507-I; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nettesheim P, 1996, TOXICOL LETT, V88, P35, DOI 10.1016/0378-4274(96)03715-0; Paradiso AM, 2001, J GEN PHYSIOL, V117, P53; PAWANKAR RU, 1995, AM J RESP CRIT CARE, V152, P2059; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Schultz B. D., 1999, Physiological Reviews, V79, pS109; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; Van den Berg JG, 2000, J AM SOC NEPHROL, V11, P413; Wang YB, 1999, J APPL PHYSIOL, V87, P1852; ZegarraMoran O, 1997, J MEMBRANE BIOL, V156, P297, DOI 10.1007/s002329900209; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909; Zund G, 1996, J BIOL CHEM, V271, P7460	39	96	101	0	1	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	FEB	2002	282	2					L226	L236				11	Physiology; Respiratory System	Physiology; Respiratory System	511YA	WOS:000173292100009	11792627	
J	Li, YF; Gilliland, FD; Berhane, K; McConnell, R; Gauderman, WJ; Rappaport, EB; Peters, JM				Li, YF; Gilliland, FD; Berhane, K; McConnell, R; Gauderman, WJ; Rappaport, EB; Peters, JM			Effects of in utero and environmental tobacco smoke exposure on lung function in boys and girls with and without asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SOUTHERN CALIFORNIA COMMUNITIES; MATERNAL SMOKING; PULMONARY-FUNCTION; CIGARETTE-SMOKING; PARENTAL SMOKING; PASSIVE SMOKING; RESPIRATORY ILLNESS; DIFFERING LEVELS; AIR-POLLUTION; CHILDREN	To investigate whether the effects of in utero exposure to maternal smoking and environmental tobacco smoke (ETS) exposure on lung function vary by sex or asthma status, we examined medical history and tobacco smoke exposure data for 5,263 participants in the Children's Health Study. At study enrollment, parents or guardians of each subject completed a questionnaire, and lung function was measured spirometrically with maximum forced expiratory flow-volume maneuvers. To assess the in utero effects of maternal smoking and ETS exposure on lung function, we used regression splines that accounted for the nonlinear relationship between pulmonary function, height, and age. In utero exposure to maternal smoking was independently associated with deficits in lung function that were larger for children with asthma. Boys and girls with a history of in utero exposure to maternal smoking showed deficits in maximum midexpiratory flow (MMEF) and a decrease in the FEV1/FVC ratio. As compared with children without asthma, boys with asthma had significantly larger deficits from in utero exposure in FVC, MMEF, and FEV1/FVC, and girls with asthma had larger decreases in FEV1/FVC. The effect of ETS exposure varied by children's gender and asthma status. Deficits in flows associated with current ETS exposure were present in children with and without asthma but were significant only among children without asthma. Past ETS exposure was associated with reduced FEV1, MMEF, and FEV1/FVC among boys with asthma. In contrast, past ETS exposure was associated with decreased flow rates in girls without asthma. In summary, both in utero exposure to maternal smoking and ETS exposure were associated with persistent deficits in lung function. The effects of in utero exposure were greatest among children with asthma.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.		LI, YU-FEN/F-4770-2010		NHLBI NIH HHS [1 R01 HL61768-01]; NIEHS NIH HHS [5P30 ES07048-02, 1P01 ES09581-05]		Becker R. A., 1988, NEW S LANGUAGE; BURR ML, 1975, THORAX, V30, P663, DOI 10.1136/thx.30.6.663; BURROWS B, 1980, AM REV RESPIR DIS, V122, P813; *CA EPA, 1997, HLTH EFFECTS EXPOSUR; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; Cook DG, 1998, THORAX, V53, P884; COULTAS DB, 1989, AM J EPIDEMIOL, V130, P338; COULTAS DB, 1990, AM REV RESPIR DIS, V142, P602; CUNNINGHAM J, 1995, AM J RESP CRIT CARE, V152, P565; CUNNINGHAM J, 1994, AM J EPIDEMIOL, V139, P1139; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Dezateux C, 1997, BRIT MED BULL, V53, P40; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172; DODGE RR, 1980, AM REV RESPIR DIS, V122, P567; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; HABY MM, 1994, PEDIATR PULM, V18, P323, DOI 10.1002/ppul.1950180510; Hanrahan J P, 1998, Eur Respir J Suppl, V27, p46s; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; HASTIE T, 1993, J ROY STAT SOC B MET, V55, P757; Jedrychowski W, 1996, Przegl Epidemiol, V50, P457; Joad JP, 1999, TOXICOL APPL PHARM, V155, P253, DOI 10.1006/taap.1998.8612; KNIGHT A, 1985, MED J AUSTRALIA, V142, P194; MURRAY AB, 1988, CHEST, V94, P701, DOI 10.1378/chest.94.4.701; ORYSZCZYN MP, 1991, J ALLERGY CLIN IMMUN, V87, P1169, DOI 10.1016/0091-6749(91)92163-U; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; RONCHETTI R, 1994, EUR RESPIR J, V7, P472, DOI 10.1183/09031936.94.07030472; SHERRILL DL, 1992, AM REV RESPIR DIS, V145, P1136; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; TAGER IB, 1983, NEW ENGL J MED, V309, P699, DOI 10.1056/NEJM198309223091204; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TAGER IB, 1987, AM REV RESPIR DIS, V136, P1366; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; *US DEP HHS, 1986, PHS PUBL; U. S. Environmental Protection Agency, 1992, RESP HLTH EFF PASS S; WANG XB, 1994, AM J RESP CRIT CARE, V149, P1420; WEITZMAN M, 1990, PEDIATRICS, V85, P505; WYPIJ D, 1993, STAT SINICA, V3, P329	42	96	102	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC	2000	162	6					2097	2104				8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	381ZV	WOS:000165794700023	11112121	
J	Shima, M; Adachi, M				Shima, M; Adachi, M			Effect of outdoor and indoor nitrogen dioxide on respiratory symptoms in schoolchildren	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						nitrogen dioxide; air pollution; indoor environment; wheeze; asthma; cohort study	AIR-POLLUTION; CHILDHOOD ASTHMA; INHALED ALLERGEN; LUNG-FUNCTION; EAST-GERMANY; CHILDREN; EXPOSURE; HEALTH; ASSOCIATION; PREVALENCE	Background Nitrogen dioxide (NO2), an oxidant gas that contaminates both outdoor and indoor air, is considered to be a potential risk factor for asthma. We investigated concurrently the effects of outdoor and indoor NO2 on the prevalence and incidence of respiratory symptoms among children. Methods A cohort study was carried out over 3 years on 842 schoolchildren living in seven different communities in Japan. Indoor NO2. concentrations over 24 hours were measured in both winter and summer in. the homes of the subjects, and a 3-year average of the outdoor NO2 concentration was determined for each community. Respiratory symptoms were evaluated every year from responses to questionnaires. Results The prevalence of bronchitis, wheeze, and asthma significantly increased with increases of indoor NO2 concentrations among girls, but not among boys. In neither boys nor girls were there significant differences in the prevalence of respiratory symptoms among urban, suburban, and rural districts. The incidence of asthma increased among children living in areas with high concentrations of outdoor NO2 Multiple logistic regression analysis showed that a 10 parts per billion (ppb) increase of outdoor NO2 concentration was associated with an increased incidence of wheeze and asthma (odds ratios [OR] = 1.76, 95% CI : 1.04-3.23 and OR = 2.10, 95% CI: 1.10-4.75, respectively), but that no such associations were found with indoor NO2 concentration (OR = 0.73, 95% CI:0.45-1.14 and OR = 0.87, 95% CI:0.51-1.43,respectively). Conclusions These findings suggest that outdoor NO2 air pollution may be particularly important for the development of wheeze and asthma among children. Indoor NO2 concentrations were associated with the prevalence of respiratory symptoms only among girls. Girls may be more susceptible to indoor air pollution than boys.	Chiba Univ, Sch Med, Dept Publ Hlth, Chuo Ku, Chiba 2608670, Japan	Shima, M (reprint author), Chiba Univ, Sch Med, Dept Publ Hlth, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ANTO JM, 1995, LANCET, V345, P402, DOI 10.1016/S0140-6736(95)90395-X; ARMITAGE P, 1994, STAT METHODS MED RES, P402; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRAUNFAHRLANDER C, 1992, AM REV RESPIR DIS, V145, P42; CHINN S, 1991, J EPIDEMIOL COMMUN H, V45, P188, DOI 10.1136/jech.45.3.188; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; Ferris B., 1978, AM REV RESPIR DIS, V118, P7; Forastiere F, 1996, AM J RESP CRIT CARE, V153, P1098; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891; HOEK G, 1984, INT ARCH OCC ENV HEA, V55, P79, DOI 10.1007/BF00378070; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; *JAP ENV AG, 1992, ANN REP QUAL ENV JAP, P2; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; KOREN HS, 1995, ENVIRON HEALTH PERSP, V103, P235, DOI 10.2307/3432379; Kramer U, 1999, INT J EPIDEMIOL, V28, P865, DOI 10.1093/ije/28.5.865; Krishna MT, 1996, J ROY COLL PHYS LOND, V30, P61; Magnus P, 1998, INT J EPIDEMIOL, V27, P995, DOI 10.1093/ije/27.6.995; MELIA RJW, 1977, BRIT MED J, V2, P149; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Pershagen G, 1995, INT J EPIDEMIOL, V24, P1147, DOI 10.1093/ije/24.6.1147; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Pilotto LS, 1997, INT J EPIDEMIOL, V26, P788, DOI 10.1093/ije/26.4.788; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258; SAMET JM, 1987, AM REV RESPIR DIS, V136, P1486; SAMET JM, 1978, AM J EPIDEMIOL, V108, P435; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Shima M, 1998, OCCUP ENVIRON MED, V55, P428; SHIMA M, 1994, J EPIDEMIOL, V4, P137; Strachan DP, 1996, BRIT MED J, V312, P1195; Strand V, 1997, AM J RESP CRIT CARE, V155, P881; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; TUNNICLIFFE WS, 1994, LANCET, V344, P1733, DOI 10.1016/S0140-6736(94)92886-X; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Wilson AC, 1998, BRIT MED J, V316, P21	41	96	98	0	11	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	OCT	2000	29	5					862	870		10.1093/ije/29.5.862		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	376DX	WOS:000165443900014	11034970	
J	Szepfalusi, Z; Loibichler, C; Pichler, J; Reisenberger, K; Ebner, C; Urbanek, R				Szepfalusi, Z; Loibichler, C; Pichler, J; Reisenberger, K; Ebner, C; Urbanek, R			Direct evidence for transplacental allergen transfer	PEDIATRIC RESEARCH			English	Article							CELL PROLIFERATIVE RESPONSES; PERFUSED HUMAN PLACENTA; ENVIRONMENTAL ALLERGENS; BABIES BORN; RESPONSIVENESS; CHILDHOOD; PROTEINS; NEWBORNS; ANTIGENS; PATTERNS	Allergies are increasing, and despite deeper insights into the immunologic basis of these diseases, preventive measures are not yet efficient. As the induction of allergic diseases is often triggered in early childhood, perinatal or prenatal preventive strategies would be beneficial. We investigated the transfer of inhalant and nutritive allergens across the human placenta. For this purpose, the maternal side of a placental cotyledon was perfused in vitro with an allergen-containing medium, and a specific ELISA was used to detect the allergens on the fetal side. Both allergens evaluated, birch pollen major allergen Bet vl and the milk allergen beta-lactoglobulin, could be shown to cross the placenta. The nutritive allergen beta-lactoglobulin was not only transferred across the placenta in all eight experiments, but was also detectable within the first minutes of perfusion. The peak allergen concentration on the fetal side could be increased by addition of human immunoglobulin. Far the inhalant allergen Bet v1, transfer was observed in two of 10 placental experiments, and only if human immunoglobulin was added. a pulsatility wave with a frequency of 30-35 min suggested tin active transfer mechanism We conclude that allergens are actively and selectively transferred across the placenta. Therefore, controlled maternal allergen exposure might offer new ways to induce tolerance to specific allergens in the fetus.	Univ Vienna, AKH, Dept Pediat, A-1090 Vienna, Austria; Univ Vienna, Dept Gynecol & Obstet, A-1090 Vienna, Austria; Univ Vienna, Inst Gen & Expt Pathol, A-1090 Vienna, Austria	Szepfalusi, Z (reprint author), Univ Vienna, AKH, Dept Pediat, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.						ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; BJORKSTEN F, 1980, CLIN ALLERGY, V10, P585, DOI 10.1111/j.1365-2222.1980.tb02140.x; BROWNBILL P, 1995, J CLIN INVEST, V96, P2220, DOI 10.1172/JCI118277; DAHL GMK, 1984, COMP BIOCHEM PHYS A, V77, P199, DOI 10.1016/0300-9629(84)90046-X; FORTUNATO SJ, 1992, AM J OBSTET GYNECOL, V167, P1595; HAHNZORIC M, 1992, PEDIATR RES, V32, P150, DOI 10.1203/00006450-199208000-00005; Holt PG, 1998, ENVIRON HEALTH PERSP, V106, P795, DOI 10.2307/3434191; Jones AC, 1996, PEDIATR ALLERGY IMMU, V7, P109, DOI 10.1111/j.1399-3038.1996.tb00117.x; Jones CA, 1998, LANCET, V351, P1859, DOI 10.1016/S0140-6736(05)78805-X; KONDO N, 1992, ARCH DIS CHILD, V67, P1003; Miles EA, 1996, CLIN EXP ALLERGY, V26, P780, DOI 10.1046/j.1365-2222.1996.d01-383.x; MILES EA, 1995, J ALLERGY CLIN IMMUN, V95, P381; PIASTRA M, 1994, INT ARCH ALLERGY IMM, V104, P358; PICINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; Prescott SL, 1997, INT ARCH ALLERGY IMM, V113, P75; Prescott SL, 1998, J IMMUNOL, V160, P4730; Reisenberger K, 1996, AM J OBSTET GYNECOL, V174, P1450, DOI 10.1016/S0002-9378(96)70587-2; SCHNEIDE.H, 1972, AM J OBSTET GYNECOL, V114, P822; Schneider H, 1985, Contrib Gynecol Obstet, V13, P40; SHAHEEN SO, 1995, CLIN EXP ALLERGY, V25, P1034; Szepfalusi Z, 1997, CLIN EXP ALLERGY, V27, P28, DOI 10.1046/j.1365-2222.1997.d01-417.x; Van Duren-Schmidt K, 1997, PEDIATR RES, V41, P1; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; WICHMANN HE, 1996, CLIN EXP ALLERGY, V25, P1034; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261	25	96	101	0	1	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	SEP	2000	48	3					404	407				4	Pediatrics	Pediatrics	345ZQ	WOS:000088845900025	10960510	
J	Lopuhaa, CE; Roseboom, TJ; Osmond, C; Barker, DJP; Ravelli, ACJ; Bleker, OP; van der Zee, JS; van der Meulen, JHP				Lopuhaa, CE; Roseboom, TJ; Osmond, C; Barker, DJP; Ravelli, ACJ; Bleker, OP; van der Zee, JS; van der Meulen, JHP			Atopy, lung function, and obstructive airways disease after prenatal exposure to famine	THORAX			English	Article						fetal origins of disease; atopy; obstructive airways disease; famine	BIRTH-WEIGHT; RISK-FACTORS; FETAL GROWTH; ADULT-RATS; ASTHMA; CHILDHOOD; IGE; ADOLESCENCE; PREVALENCE; ALLERGENS	Background-Associations have been found between a large head size at birth and atopy, and between low birth weight and obstructive airways disease. A study was undertaken of people born around the time of the Dutch famine in 1944-5 to determine the effects of maternal malnutrition during specific periods of gestation on the prevalence of obstructive airways disease and atopy. Methods-Nine hundred and twelve people aged about 50, born at term between November 1943 and February 1947 in Amsterdam, were asked about their medical history. Lung function was measured in 733 and serum concentrations of total IgE and specific IgE against mite, pollen and cat were measured in 726. Those exposed in late, mid, and early gestation (exposed participants) were compared with those born before or conceived after the famine (non-exposed participants). Results-Exposure to famine during gestation affected neither the concentrations of total or specific IgE nor lung function values. The prevalence of obstructive airways disease was increased in people exposed to famine in mid gestation (odds ratio adjusted for sex 1.7, 95% confidence interval (CI) 1.1 to 2.6) and tended to be higher in those exposed in early gestation (odds ratio 1.5, 95% CI: 0.9 to 2.6). Conclusions The observed increase in the prevalence of obstructive airways disease in people exposed to famine in mid and early gestation was not parallelled by effects on IgE concentrations or lung function. The link between exposure to famine in mid and early gestation and obstructive airways disease in adulthood suggests that fetal lungs can be permanently affected by nutritional challenges during periods of rapid growth.	Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands; Univ Southampton, Dept Biostat & Epidemiol, Southampton SO9 5NH, Hants, England; Univ Southampton, Dept Obstet & Gynaecol, Southampton SO9 5NH, Hants, England; Univ Southampton, MRC, Environm Epidemiol Unit, Southampton SO9 5NH, Hants, England	van der Meulen, JHP (reprint author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, Keppel St, London WC1E 7HT, England.		van der Zee, jaring/M-8462-2013				AALBERSE RC, 1992, CLIN EXP ALLERGY, V22, P1003, DOI 10.1111/j.1365-2222.1992.tb03028.x; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; ARSHAD SH, 1993, CLIN EXP ALLERGY, V23, P504, DOI 10.1111/j.1365-2222.1993.tb03238.x; Bakker B., 1997, SOCIALE WETENSCHAPPE, V40, P1; BARKER DJP, 1991, BRIT MED J, V303, P671; Barker DJP, 1998, MOTHERS BABIES HLTH; Bloomfield F., 1998, FETAL MAT MED REV, V10, P91, DOI 10.1017/S0965539597000235; Burger GCE, 1948, MALNUTRITION STARVAT; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; Holt PG, 1997, THORAX, V52, P1; KELLY YJ, 1995, THORAX, V50, P525, DOI 10.1136/thx.50.5.525; LANGLEY SC, 1994, J NUTR, V124, P1588; LangleyEvans SC, 1997, J NUTR, V127, P202; MATTHES JWA, 1995, ARCH DIS CHILD, V73, P231; MCCANCE RA, 1974, PROC R SOC SER B-BIO, V185, P1, DOI 10.1098/rspb.1974.0001; Medical Research Council, 1986, QUEST RESP SYMPT; MULAY S, 1980, FED PROC, V39, P261; Oliveti JF, 1996, AM J EPIDEMIOL, V143, P570; Oryszczyn MP, 1999, CLIN EXP ALLERGY, V29, P334; Ravelli ACJ, 1998, LANCET, V351, P173, DOI 10.1016/S0140-6736(97)07244-9; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; RONA RJ, 1993, BRIT MED J, V306, P817; Schaubel D, 1996, J ASTHMA, V33, P255, DOI 10.3109/02770909609055366; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Sears MR, 1996, ARCH DIS CHILD, V75, P392; SEIDMAN DS, 1991, ARCH DIS CHILD, V66, P584; SHAHEEN S, 1994, THORAX, V49, P533, DOI 10.1136/thx.49.6.533; Shaheen SO, 1998, THORAX, V53, P549; Shaheen SO, 1999, THORAX, V54, P396; Slezak JA, 1998, J ASTHMA, V35, P203, DOI 10.3109/02770909809068208; Stein CE, 1997, THORAX, V52, P895; Stein Z. A., 1975, FAMINE HUMAN DEV DUT; Witteman AM, 1996, J ALLERGY CLIN IMMUN, V97, P16, DOI 10.1016/S0091-6749(96)70278-6	36	96	100	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUL	2000	55	7					555	561		10.1136/thorax.55.7.555		7	Respiratory System	Respiratory System	328EF	WOS:000087835400006	10856314	
J	Fujimura, KE; Demoor, T; Rauch, M; Faruqi, AA; Jang, S; Johnson, CC; Boushey, HA; Zoratti, E; Ownby, D; Lukacs, NW; Lynch, SV				Fujimura, Kei E.; Demoor, Tine; Rauch, Marcus; Faruqi, Ali A.; Jang, Sihyug; Johnson, Christine C.; Boushey, Homer A.; Zoratti, Edward; Ownby, Dennis; Lukacs, Nicholas W.; Lynch, Susan V.			House dust exposure mediates gut microbiome Lactobacillus enrichment and airway immune defense against allergens and virus infection	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						house environment; airway adaptive immunity; gastrointestinal bacterial community; Lactobacilliaceae	T-CELLS; CHILDHOOD; RISK; MICE; SUPPRESSES; METABOLISM; BACTERIA; INFANCY	Exposure to dogs in early infancy has been shown to reduce the risk of childhood allergic disease development, and dog ownership is associated with a distinct house dust microbial exposure. Here, we demonstrate, using murine models, that exposure of mice to dog-associated house dust protects against ovalbumin or cockroach allergen-mediated airway pathology. Protected animals exhibited significant reduction in the total number of airway T cells, down-regulation of Th2-related airway responses, as well as mucin secretion. Following dog-associated dust exposure, the cecal microbiome of protected animals was extensively restructured with significant enrichment of, amongst others, Lactobacillus johnsonii. Supplementation of wild-type animals with L. johnsonii protected them against both airway allergen challenge or infection with respiratory syncytial virus. L. johnsonii-mediated protection was associated with significant reductions in the total number and proportion of activated CD11c(+)/CD11b(+) and CD11c(+)/CD8(+) cells, as well as significantly reduced airway Th2 cytokine expression. Our results reveal that exposure to dog-associated household dust results in protection against airway allergen challenge and a distinct gastrointestinal microbiome composition. Moreover, the study identifies L. johnsonii as a pivotal species within the gastrointestinal tract capable of influencing adaptive immunity at remote mucosal surfaces in a manner that is protective against a variety of respiratory insults.	[Fujimura, Kei E.; Rauch, Marcus; Faruqi, Ali A.; Lynch, Susan V.] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA; [Boushey, Homer A.] Univ Calif San Francisco, Div Pulm & Crit Care Med, San Francisco, CA 94143 USA; [Demoor, Tine; Jang, Sihyug; Lukacs, Nicholas W.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Johnson, Christine C.] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI 48202 USA; [Zoratti, Edward] Henry Ford Hlth Syst, Div Allergy & Clin Immunol, Detroit, MI 48202 USA; [Ownby, Dennis] Med Coll Georgia, Dept Pediat, Augusta, GA 30912 USA	Lukacs, NW (reprint author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.	nlukacs@umich.edu; susan.lynch@ucsf.edu			National Institutes of Health, National Institute of Allergy and Infectious Diseases [P01AI089473-01A1]	This study was supported by the National Institutes of Health, National Institute of Allergy and Infectious Diseases P01AI089473-01A1.	Abreu NA, 2012, SCI TRANSL MED, V4; Adams VC, 2004, EUR J IMMUNOL, V34, P631, DOI 10.1002/eji.200324659; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; de Vrese M, 2005, CLIN NUTR, V24, P481, DOI 10.1016/j.clnu.2005.02.006; DeAngelis KM, 2009, ISME J, V3, P168, DOI 10.1038/ismej.2008.103; Forsythe P, 2007, AM J RESP CRIT CARE, V175, P561, DOI 10.1164/rccm.200606-821OC; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Furet JP, 2004, INT J FOOD MICROBIOL, V97, P197, DOI 10.1016/j.ijfoodmicro.2004.04.020; Hamady M, 2010, ISME J, V4, P17, DOI 10.1038/ismej.2009.97; Hansen CHF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034043; Havstad S, 2011, J ALLERGY CLIN IMMUN, V128, P880, DOI 10.1016/j.jaci.2011.06.039; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; Inoue R, 2007, FEMS IMMUNOL MED MIC, V50, P67, DOI 10.1111/j.1574-695X.2007.00233.x; Ivanov II, 2009, CELL, V139, P485, DOI 10.1016/j.cell.2009.09.033; Joffe TH, 2009, J PEDIATR, V154, P154, DOI 10.1016/j.jpeds.2008.08.039; Johnson CC, 2005, J ALLERGY CLIN IMMUN, V115, P1218, DOI 10.1016/j.jaci.2005.04.020; Kwon HK, 2010, P NATL ACAD SCI USA, V107, P2159, DOI 10.1073/pnas.0904055107; Lance G.N., 1967, AUST COMPUT J, V1, P15; Nistal E, 2012, BIOCHIMIE, V94, P1724, DOI 10.1016/j.biochi.2012.03.025; Orsmark-Pietrast C, 2013, EUR RESPIR J, V42, P65, DOI 10.1183/09031936.00077712; Ott W.R., 1989, P RES PLANN C HUM AC, P3; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Regnier SA, 2013, PEDIATR INFECT DIS J, V32, P820, DOI 10.1097/INF.0b013e31829061e8; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Szabo Shelagh M, 2013, Paediatr Respir Rev, V13 Suppl 2, pS9, DOI 10.1016/S1526-0542(12)70161-6; Tregoning JS, 2010, CLIN MICROBIOL REV, V23, P74, DOI 10.1128/CMR.00032-09; Tremaroli V, 2012, NATURE, V489, P242, DOI 10.1038/nature11552; Valladares R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010507; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871	30	95	99	8	44	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JAN 14	2014	111	2					805	810		10.1073/pnas.1310750111		6	Multidisciplinary Sciences	Science & Technology - Other Topics	288LW	WOS:000329614500057	24344318	
J	Bisgaard, H; Jensen, SM; Bonnelykke, K				Bisgaard, Hans; Jensen, Signe M.; Bonnelykke, Klaus			Interaction between Asthma and Lung Function Growth in Early Life	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; lung function; young child; infant; neonate	1ST 6 YEARS; AIRWAY RESPONSIVENESS; PRESCHOOL-CHILDREN; CHILDHOOD ASTHMA; BIRTH COHORT; HIGH-RISK; BRONCHIAL RESPONSIVENESS; INHALED CORTICOSTEROIDS; YOUNG INFANTS; LONG-TERM	Rationale: The causal direction between asthma and lung function deficit is unknown, but important for the focus of preventive measures and research into the origins of asthma. Objectives: To analyze the interaction between lung function development and asthma from birth to 7 years of age. Methods: The Copenhagen Prospective Studies on Asthma in Childhood is a prospective clinical study of a birth cohort of 411 at-risk children. Spirometry was completed in 403 (98%) neonates and again by age 7 in 317 children (77%). Measurements and Main Results: Neonatal spirometry and bronchial responsiveness to methacholine was measured during sedation by forced flow-volume measurements. Asthma was diagnosed prospectively from daily diary cards and clinic visits every 6 months. Children with asthma by age 7(14%) already had a significant airflow deficit as neonates (forced expiratory flow at 50% of vital capacity second in neonates reduced by 0.34 z score by 1 mo; P = 0.03). This deficit progressed significantly during early childhood (forced expiratory flow at 0.5 seconds in neonates at age 7 reduced by 0.82 z score by age 7; P < 0.0001), suggesting that approximately 40% of the airflow deficit associated with asthma is present at birth, whereas 60% develops with clinical disease. Environmental tobacco exposure, but not allergic sensitization, also hampered airflow growth. Bronchial responsiveness to methacholine in the neonates was associated with the development of asthma (P = 0.01). Conclusions: Children developing asthma by age 7 had a lung function deficit and increased bronchial responsiveness as neonates. This lung function deficit progressed to age 7. Therefore, research into the origins and prevention of asthma should consider early life before and after birth.	[Bisgaard, Hans; Jensen, Signe M.; Bonnelykke, Klaus] Univ Copenhagen, Danish Pediat Asthma Ctr, Copenhagen, Denmark; [Bisgaard, Hans; Jensen, Signe M.; Bonnelykke, Klaus] Copenhagen Univ Hosp, Copenhagen, Denmark	Bisgaard, H (reprint author), Univ Copenhagen, Danish Pediat Asthma Ctr, Copenhagen, Denmark.	bisgaard@copsac.com	Kronow, Joern/B-1054-2011; Jensen, Signe/G-1026-2016; Bisgaard, Hans/N-4761-2016	Jensen, Signe/0000-0002-7738-5231; Bisgaard, Hans/0000-0003-4131-7592			Bisgaard H, 2004, ANN ALLERG ASTHMA IM, V93, P381; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bisgaard H, 2007, NEW ENGL J MED, V357, P1487, DOI 10.1056/NEJMoa052632; Bisgaard H, 2011, J ALLERGY CLIN IMMUN, V127, P1155, DOI 10.1016/j.jaci.2011.02.007; Bisgaard H, 2010, J ALLERGY CLIN IMMUN, V126, P187, DOI 10.1016/j.jaci.2010.07.011; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P1355, DOI 10.1016/j.jaci.2009.03.046; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Brand PLP, 2008, EUR RESPIR J, V32, P1096, DOI 10.1183/09031936.00002108; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Chawes BLK, 2010, J ALLERGY CLIN IMMUN, V126, P567, DOI 10.1016/j.jaci.2010.06.026; CLARKE JR, 1995, AM J RESP CRIT CARE, V151, P1434; Giwercman C, 2010, J ALLERGY CLIN IMMUN, V125, P866, DOI 10.1016/j.jaci.2010.01.026; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Halkjaer LB, 2006, ARCH DERMATOL, V142, P561, DOI 10.1001/archderm.142.5.561; Henderson J, 2008, THORAX, V63, P974, DOI 10.1136/thx.2007.093187; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Loland L, 2006, CHEST, V129, P669, DOI 10.1378/chest.129.3.669; Loland L, 2008, CHEST, V133, P115, DOI 10.1378/chest.07-1328; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lowe LA, 2005, AM J RESP CRIT CARE, V171, P231, DOI 10.1164/rccm.200406-695OC; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Paganelli R, 1998, ALLERGY, V53, P763; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Phelan PD, 2002, J ALLERGY CLIN IMMUN, V109, P189, DOI 10.1067/mai.2001.120951; S. American Thoracic and S. European Respiratory, 2005, AM J RESP CRIT CARE, V171, P912; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sorensen M, 2007, BIOMARKERS, V12, P38, DOI 10.1080/13547500600943148; Turner SW, 2004, AM J RESP CRIT CARE, V169, P921, DOI 10.1164/rccm.200307-891OC; Wilson NM, 2004, PEDIATR PULM, V38, P75, DOI 10.1002/ppul.20049	33	95	95	0	6	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN 1	2012	185	11					1183	1189		10.1164/rccm.201110-1922OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	946VC	WOS:000304384600011	22461370	
J	Zeiger, RS; Mauger, D; Bacharier, LB; Guilbert, TW; Martinez, FD; Lemanske, RF; Strunk, RC; Covar, R; Szefler, SJ; Boehmer, S; Jackson, DJ; Sorkness, CA; Gern, JE; Kelly, HW; Friedman, NJ; Mellon, MH; Schatz, M; Morgan, WJ; Chinchilli, VM; Raissy, HH; Bade, E; Malka-Rais, J; Beigelman, A; Taussig, LM				Zeiger, Robert S.; Mauger, David; Bacharier, Leonard B.; Guilbert, Theresa W.; Martinez, Fernando D.; Lemanske, Robert F., Jr.; Strunk, Robert C.; Covar, Ronina; Szefler, Stanley J.; Boehmer, Susan; Jackson, Daniel J.; Sorkness, Christine A.; Gern, James E.; Kelly, H. William; Friedman, Noah J.; Mellon, Michael H.; Schatz, Michael; Morgan, Wayne J.; Chinchilli, Vernon M.; Raissy, Hengameh H.; Bade, Elizabeth; Malka-Rais, Jonathan; Beigelman, Avraham; Taussig, Lynn M.		CARE Network Natl Heart Lung	Daily or Intermittent Budesonide in Preschool Children with Recurrent Wheezing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED FLUTICASONE PROPIONATE; RANDOMIZED CONTROLLED-TRIAL; 2 YEARS OLD; YOUNG-CHILDREN; INHALATION SUSPENSION; PERSISTENT ASTHMA; ORAL PREDNISOLONE; DOUBLE-BLIND; INFANTS; CORTICOSTEROIDS	BACKGROUND Daily inhaled glucocorticoids are recommended for young children at risk for asthma exacerbations, as indicated by a positive value on the modified asthma predictive index (API) and an exacerbation in the preceding year, but concern remains about daily adherence and effects on growth. We compared daily therapy with intermittent therapy. METHODS We studied 278 children between the ages of 12 and 53 months who had positive values on the modified API, recurrent wheezing episodes, and at least one exacerbation in the previous year but a low degree of impairment. Children were randomly assigned to receive a budesonide inhalation suspension for 1 year as either an intermittent high-dose regimen (1 mg twice daily for 7 days, starting early during a predefined respiratory tract illness) or a daily low-dose regimen (0.5 mg nightly) with corresponding placebos. The primary outcome was the frequency of exacerbations requiring oral glucocorticoid therapy. RESULTS The daily regimen of budesonide did not differ significantly from the intermittent regimen with respect to the frequency of exacerbations, with a rate per patient-year for the daily regimen of 0.97 (95% confidence interval [CI], 0.76 to 1.22) versus a rate of 0.95 (95% CI, 0.75 to 1.20) for the intermittent regimen (relative rate in the intermittent-regimen group, 0.99; 95% CI, 0.71 to 1.35; P = 0.60). There were also no significant between-group differences in several other measures of asthma severity, including the time to the first exacerbation, or adverse events. The mean exposure to budesonide was 104 mg less with the intermittent regimen than with the daily regimen. CONCLUSIONS A daily low-dose regimen of budesonide was not superior to an intermittent high-dose regimen in reducing asthma exacerbations. Daily administration led to greater exposure to the drug at 1 year. (Funded by the National Heart, Lung, and Blood Institute and others; MIST ClinicalTrials.gov number, NCT00675584.)	[Zeiger, Robert S.; Friedman, Noah J.; Mellon, Michael H.; Schatz, Michael] Kaiser Permanente So Calif, Dept Allergy, San Diego, CA USA; [Zeiger, Robert S.; Schatz, Michael] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA; [Mauger, David; Boehmer, Susan; Chinchilli, Vernon M.] Penn State Univ, Dept Publ Hlth Sci, Hershey, PA USA; [Bacharier, Leonard B.; Strunk, Robert C.; Beigelman, Avraham] Washington Univ, Dept Pediat, St Louis, MO 63130 USA; [Bacharier, Leonard B.; Strunk, Robert C.; Beigelman, Avraham] St Louis Childrens Hosp, St Louis, MO USA; [Guilbert, Theresa W.; Lemanske, Robert F., Jr.; Jackson, Daniel J.; Sorkness, Christine A.; Gern, James E.] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Med, Madison, WI USA; [Guilbert, Theresa W.; Lemanske, Robert F., Jr.; Jackson, Daniel J.; Sorkness, Christine A.; Gern, James E.] Univ Wisconsin Madison, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA; [Guilbert, Theresa W.; Lemanske, Robert F., Jr.; Jackson, Daniel J.; Sorkness, Christine A.; Gern, James E.] Univ Wisconsin Madison, Sch Pharm, Madison, WI USA; [Martinez, Fernando D.; Morgan, Wayne J.] Univ Arizona, Arizona Resp Ctr, Tucson, AZ USA; [Covar, Ronina; Szefler, Stanley J.; Malka-Rais, Jonathan; Taussig, Lynn M.] Natl Jewish Hlth, Dept Pediat, Div Pediat Clin Pharmacol, Denver, CO USA; [Covar, Ronina; Szefler, Stanley J.; Malka-Rais, Jonathan; Taussig, Lynn M.] Natl Jewish Hlth, Dept Pediat, Div Allergy & Immunol, Denver, CO USA; [Covar, Ronina; Szefler, Stanley J.; Malka-Rais, Jonathan; Taussig, Lynn M.] Univ Colorado, Sch Med, Denver, CO USA; [Kelly, H. William; Raissy, Hengameh H.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Bade, Elizabeth] Univ Wisconsin Milwaukee, Sch Med & Publ Hlth, Dept Family Med, Milwaukee, WI USA	Zeiger, RS (reprint author), Kaiser Permanente, Dept Allergy, 7060 Clairemont Mesa Blvd, San Diego, CA 92111 USA.	robert.s.zeiger@kp.org		Guilbert, Theresa/0000-0002-6932-712X	National Heart, Lung, and Blood Institute [5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, 5U10HL064313]; Washington University School of Medicine [5UL1RR02499204]; Madison CTSA [1UL1RR025011]; National Center for Research Resources, National Institutes of Health [UL1RR025780];  [M01 RR00036];  [M01 RR00051];  [5M01 RR00997]	Supported by grants (5U10HL064287, 5U10HL064288, 5U10HL064295, 5U10HL064307, 5U10HL064305, and 5U10HL064313) from the National Heart, Lung, and Blood Institute; a grant (5UL1RR02499204) from the Washington University School of Medicine Clinical and Translational Science Awards (CTSA) Infrastructure for Pediatric Research; a grant (1UL1RR025011) from the Madison CTSA; a grant (UL1RR025780) to the Colorado CTSA from the National Center for Research Resources, National Institutes of Health; and grants to the General Clinical Research Centers at Washington University School of Medicine (M01 RR00036), National Jewish Health (M01 RR00051), and the University of New Mexico (5M01 RR00997).	Bacharier LB, 2007, J ALLERGY CLIN IMMUN, V119, P604, DOI 10.1016/j.jaci.2006.12.607; Bacharier LB, 2009, J ALLERGY CLIN IMMUN, V123, P1077, DOI 10.1016/j.jaci.2008.12.1120; Bacharier LB, 2008, J ALLERGY CLIN IMMUN, V122, P1127, DOI 10.1016/j.jaci.2008.09.029; Baker JW, 1999, PEDIATRICS, V103, P414, DOI 10.1542/peds.103.2.414; Beigelman A, 2009, ANN ALLERG ASTHMA IM, V103, P108, DOI 10.1016/S1081-1206(10)60162-7; Bisgaard H, 1999, AM J RESP CRIT CARE, V160, P126; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Castro-Rodriguez JA, 2009, PEDIATRICS, V123, pe519, DOI 10.1542/peds.2008-2867; CONNETT G, 1993, ARCH DIS CHILD, V68, P85; Ducharme FM, 2009, NEW ENGL J MED, V360, P339, DOI 10.1056/NEJMoa0808907; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Global Initiative for Asthma, GLOB STRAT DIAGN MAN; Guilbert TW, 2004, CONTROL CLIN TRIALS, V25, P286, DOI 10.1016/j.cct.2004.03.002; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Horner CC, 2007, CURR OPIN ALLERGY CL, V7, P180, DOI 10.1097/ACI.0b013e32807fafd2; Kemp JP, 1999, ANN ALLERG ASTHMA IM, V83, P231, DOI 10.1016/S1081-1206(10)62646-4; Leflein JG, 2002, PEDIATRICS, V109, P866, DOI 10.1542/peds.109.5.866; Lemanske RF, 2005, J ALLERGY CLIN IMMUN, V116, P571, DOI 10.1016/j.jaci.2005.06.024; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; *NAT ASTHM ED PREV, EXP PAN REP 3 GUID D; Oommen A, 2003, LANCET, V362, P1433, DOI 10.1016/S0140-6736(03)14685-5; Panickar J, 2009, NEW ENGL J MED, V360, P329, DOI 10.1056/NEJMoa0804897; Pao CS, 2002, AM J RESP CRIT CARE, V166, P945, DOI 10.1164/rccm.200203-265OC; Papi A, 2009, ALLERGY, V64, P1463, DOI 10.1111/j.1398-9995.2009.02134.x; Raat H, 2007, QUAL LIFE RES, V16, P445, DOI 10.1007/s11136-006-9134-8; Rivera-Spoljaric K, 2009, J PEDIATR-US, V154, P877, DOI 10.1016/j.jpeds.2008.12.029; Roorda RJ, 2001, J ALLERGY CLIN IMMUN, V108, P540, DOI 10.1067/mai.2001.118789; Santanello NC, 2000, J ALLERGY CLIN IMMUN, V106, P861, DOI 10.1067/mai.2000.110478; Scott MB, 2001, ANN ALLERG ASTHMA IM, V87, P488; Shapiro G, 1998, J ALLERGY CLIN IMMUN, V102, P789, DOI 10.1016/S0091-6749(98)70019-3; Shapiro G, 1999, DRUGS, V58, P43, DOI 10.2165/00003495-199958004-00006; Svedmyr J, 1999, ACTA PAEDIATR, V88, P42; Szefler SJ, 2002, J ALLERGY CLIN IMMUN, V109, P730, DOI 10.1067/mai.2002.122712; Szefler SJ, 2007, J ALLERGY CLIN IMMUN, V120, P1043, DOI 10.1016/j.jaci.2007.08.063; Teper AM, 2005, AM J RESP CRIT CARE, V171, P587, DOI 10.1164/rccm.200408-10880C; Teper AM, 2004, PEDIATR PULM, V37, P111, DOI 10.1002/ppul.10400; Wasserman RL, 2006, ANN ALLERG ASTHMA IM, V96, P808	39	95	108	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 24	2011	365	21					1990	2001				12	Medicine, General & Internal	General & Internal Medicine	851PF	WOS:000297282600009	22111718	
J	Islam, SA; Chang, DS; Colvin, RA; Byrne, MH; McCully, ML; Moser, B; Lira, SA; Charo, IF; Luster, AD				Islam, Sabina A.; Chang, Daniel S.; Colvin, Richard A.; Byrne, Mike H.; McCully, Michelle L.; Moser, Bernhard; Lira, Sergio A.; Charo, Israel F.; Luster, Andrew D.			Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5(+) T(H)2 cells	NATURE IMMUNOLOGY			English	Article							CHEMOKINE RECEPTOR CCR8; T-CELLS; DENDRITIC CELLS; AIRWAY INFLAMMATION; IMMUNE-RESPONSES; CUTTING EDGE; TH1 CELLS; IN-VIVO; EXPRESSION; DIFFERENTIATION	Mouse CCL8 is a CC chemokine of the monocyte chemoattractant protein (MCP) family whose biological activity and receptor usage have remained elusive. Here we show that CCL8 is highly expressed in the skin, where it serves as an agonist for the chemokine receptor CCR8 but not for CCR2. This distinguishes CCL8 from all other MCP chemokines. CCL8 responsiveness defined a population of highly differentiated, CCR8-expressing inflammatory T helper type 2 (T(H)2) cells enriched for interleukin (IL)-5. Ccr8- and Ccl8-deficient mice had markedly less eosinophilic inflammation than wild-type or Ccr4-deficient mice in a model of chronic atopic dermatitis. Adoptive transfer studies established CCR8 as a key regulator of T(H)2 cell recruitment into allergen-inflamed skin. In humans, CCR8 expression also defined an IL-5-enriched T(H)2 cell subset. The CCL8-CCR8 chemokine axis is therefore a crucial regulator of T(H)2 cell homing that drives IL-5-mediated chronic allergic inflammation.	[Islam, Sabina A.; Chang, Daniel S.; Colvin, Richard A.; Byrne, Mike H.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Ctr Immunol & Inf, Boston, MA 02163 USA; [McCully, Michelle L.; Moser, Bernhard] Cardiff Univ, Dept Infect Immun & Biochem, Cardiff, S Glam, Wales; [Lira, Sergio A.] Mt Sinai Sch Med, Inst Immunol, New York, NY USA; [Charo, Israel F.] Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94143 USA	Luster, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Ctr Immunol & Inf, Boston, MA 02163 USA.	aluster@mgh.harvard.edu	McCully, Michelle/A-7705-2013	McCully, Michelle/0000-0003-1543-3629	US National Institutes of Health (Harvard Skin Disease Research Center Pilot & Feasibility Study) [K08-AI556663, P30AR042689, R37-AI040618]; Infectious Diseases Society of America	This work is funded by US National Institutes of Health grants K08-AI556663 and P30AR042689 (Harvard Skin Disease Research Center Pilot & Feasibility Study) to S. A. I. and R37-AI040618 to A. D. L., and the Infectious Diseases Society of America Young Investigator Award to S. A. I. The authors thank P. Murphy (National Institutes of Health) for 4DE4 cells, J. Pease (Imperial College London) for human CCR8 receptor transfectants, P. Shrikant (Roswell Park Cancer Institute) for transgenic Thy1.1 OTII mice, L. Lefrancois (University of Connecticut School of Medicine) for transgenic Thy1.2 OTII mice, C. Sanderson (National Institute for Medical Research, London) for Il5-transgenic mice, S. Thomas for assistance with calcium flux studies and T. Means for assistance with design and validation of QPCR primers.	Ahmed R, 1996, SCIENCE, V272, P54, DOI 10.1126/science.272.5258.54; Ansel KM, 2006, ANNU REV IMMUNOL, V24, P607, DOI 10.1146/annurev.immunol.23.021704.115821; Bernardini G, 1998, EUR J IMMUNOL, V28, P582, DOI 10.1002/(SICI)1521-4141(199802)28:02<582::AID-IMMU582>3.0.CO;2-A; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Croft M, 2010, ANNU REV IMMUNOL, V28, P57, DOI 10.1146/annurev-immunol-030409-101243; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; Dairaghi DJ, 1999, J BIOL CHEM, V274, P21569, DOI 10.1074/jbc.274.31.21569; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Ebert LM, 2006, J IMMUNOL, V176, P4331; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Fox JM, 2006, J BIOL CHEM, V281, P36652, DOI 10.1074/jbc.M605584200; Gombert M, 2005, J IMMUNOL, V174, P5082; GONG JH, 1995, J EXP MED, V181, P631, DOI 10.1084/jem.181.2.631; Gong XQ, 1997, J BIOL CHEM, V272, P11682, DOI 10.1074/jbc.272.18.11682; Gonzalo JA, 2007, J IMMUNOL, V179, P1740; Goya I, 2003, J IMMUNOL, V170, P2138; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Hoshino A, 2007, J IMMUNOL, V178, P5296; Iellem A, 2000, EUR J IMMUNOL, V30, P1030, DOI 10.1002/(SICI)1521-4141(200004)30:4<1030::AID-IMMU1030>3.3.CO;2-#; Inami M, 2004, J BIOL CHEM, V279, P23123, DOI 10.1074/jbc.M401248200; Islam SA, 2006, BLOOD, V107, P444, DOI 10.1182/blood-2005-06-2362; Jacobsen EA, 2008, J EXP MED, V205, P699, DOI 10.1084/jem.20071840; Jin HL, 2009, J INVEST DERMATOL, V129, P31, DOI 10.1038/jid.2008.106; Kremer L, 2001, J IMMUNOL, V166, P218; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Luttichau HR, 2000, J EXP MED, V191, P171, DOI 10.1084/jem.191.1.171; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Mutalithas K, 2010, CLIN EXP ALLERGY, V40, P1175, DOI 10.1111/j.1365-2222.2010.03504.x; Nomiyama H, 2003, J INTERF CYTOK RES, V23, P37, DOI 10.1089/10799900360520432; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Qu CF, 2004, J EXP MED, V200, P1231, DOI 10.1084/jem.20032152; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Shinnakasu R, 2006, J IMMUNOL, V177, P5801; Sigmundsdottir H, 2008, NAT IMMUNOL, V9, P981, DOI 10.1038/ni.f.208; SPANGRUDE GJ, 1985, J IMMUNOL, V135, P4135; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; Tsou CL, 2007, J CLIN INVEST, V117, P902, DOI 10.1172/JCI29919; VanSnick J, 1996, J IMMUNOL, V157, P2570; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wang G, 2007, CLIN EXP ALLERGY, V37, P151, DOI 10.1111/j.1365-2222.2006.02621.x; Wang YH, 2007, J EXP MED, V204, P1837, DOI 10.1084/jem.20070406; Wei L, 2010, IMMUNITY, V32, P840, DOI 10.1016/j.immuni.2010.06.003; Xie JF, 2006, TRANSPLANTATION, V82, P1501, DOI 10.1097/01.tp.0000243167.11566.eb; Zheng Y, 2009, NATURE, V458, P351, DOI 10.1038/nature07674; Zingoni A, 1998, J IMMUNOL, V161, P547; Zlotnik A, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-12-243	50	95	100	3	7	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1529-2908			NAT IMMUNOL	Nat. Immunol.	FEB	2011	12	2					167	U86		10.1038/ni.1984		13	Immunology	Immunology	708QF	WOS:000286378400011	21217759	
J	Ho, SM				Ho, Shuk-Mei			Environmental epigenetics of asthma: An update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Pulmonary disorder; traffic-related pollutants; polycyclic aromatic hydrocarbons; microbial and viral infection; lipopoly-saccharide; endotoxin; oxidant early-life programming; nutrition; maternal exposure; T-H cells; dendritic cells; macrophages; lung epithelial cells; phenotype plasticity; developmental basis of disease; gene-environment interaction; DNA methylation; histone modification; microRNA; chromatin remodeling; allergen; inflammatory response	ADULT LUNG-FUNCTION; REGULATORY T-CELLS; MAMMALIAN DNA METHYLTRANSFERASES; DIESEL EXHAUST PARTICLES; TOBACCO-SMOKE EXPOSURE; EARLY-CHILDHOOD ASTHMA; BREAST-CANCER CELLS; IFN-GAMMA GENE; AIR-POLLUTION; DENDRITIC CELLS	Asthma, a chronic inflammatory disorder of the airway, is influenced by interplay between genetic and environmental factors now known to be mediated by epigenetics. Aberrant DNA methylation, altered histone modifications, specific microRNA expression, and other chromatin alterations orchestrate a complex early-life reprogramming of immune T-cell response, dendritic cell function, macrophage activation, and a breach of airway epithelial barrier that dictates asthma risk and severity in later life. Adult-onset asthma is under analogous regulation. The sharp increase in asthma prevalence over the past 2 or 3 decades and the large variations among populations of similar racial/ethnic background but different environmental exposures favors a strong contribution of environmental factors. This review addresses the fundamental question of whether environmental influences on asthma risk, severity, and steroid resistance are partly due to differential epigenetic modulations. Current knowledge on the epigenetic effects of tobacco smoke, microbial allergens, oxidants, airborne particulate matter, diesel exhaust particles, polycyclic aromatic hydrocarbons, dietary methyl donors and other nutritional factors, and dust mites is discussed. Exciting findings have been generated by rapid technological advances and well-designed experimental and population studies. The discovery and validation of epigenetic biomarkers linked to exposure, asthma, or both might lead to better epigenotyping of risk, prognosis, treatment prediction, and development of novel therapies. (J Allergy Clin Immunol 2010;126:453-65.)	[Ho, Shuk-Mei] Univ Cincinnati, Coll Med, Dept Environm Hlth, Ctr Environm Genet, Cincinnati, OH 45267 USA	Ho, SM (reprint author), 3223 Eden Ave,Kettering Complex,Suite 130, Cincinnati, OH 45267 USA.	shuk-mei.ho@uc.edu			National Institutes of Health [P30ES006096, R01ES015584, RC2ES018758, RC2ES018789, P50ES015905]	Supported by National Institutes of Health grants P30ES006096, R01ES015584, RC2ES018758, RC2ES018789, and P50ES015905.	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Androulidaki A, 2009, IMMUNITY, V31, P220, DOI 10.1016/j.immuni.2009.06.024; Anttila S, 2003, CANCER RES, V63, P8623; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Backdahl L, 2009, INT J BIOCHEM CELL B, V41, P176, DOI 10.1016/j.biocel.2008.08.023; Bakirtas Arzu, 2009, Inflammation & Allergy Drug Targets, V8, P353; Barker D J, 2001, Med Health Care Philos, V4, P31, DOI 10.1023/A:1009934412988; BARKER DJP, 1991, BRIT MED J, V303, P671; Barnes PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1055, DOI 10.1016/j.jaci.2007.01.015; Bateson P, 2004, NATURE, V430, P419, DOI 10.1038/nature02725; Beach J, 2007, CHEST, V131, P569, DOI 10.1378/chest.06-0492; Belderbos M, 2009, CURR OPIN PEDIATR, V21, P762, DOI 10.1097/MOP.0b013e3283325e3a; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Bird A, 2007, NATURE, V447, P396, DOI 10.1038/nature05913; Biswas S, 2008, MOL NUTR FOOD RES, V52, P987, DOI 10.1002/mnfr.200700259; Biswas SK, 2009, TRENDS IMMUNOL, V30, P475, DOI 10.1016/j.it.2009.07.009; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Boezen H Marike, 2009, Proc Am Thorac Soc, V6, P701, DOI 10.1513/pats.200907-058DP; Bogdanovic O, 2009, CHROMOSOMA, V118, P549, DOI 10.1007/s00412-009-0221-9; Bouzigon E, 2007, EUR RESPIR J, V30, P253, DOI 10.1183/09031936.00162206; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander Charlotte, 2003, Curr Opin Allergy Clin Immunol, V3, P325, DOI 10.1097/00130832-200310000-00001; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Breton CV, 2009, AM J RESP CRIT CARE, V180, P462, DOI 10.1164/rccm.200901-0135OC; Busse WW, 2007, J ALLERGY CLIN IMMUN, V119, P43, DOI 10.1016/j.jaci.2006.10.021; Cannell IG, 2008, BIOCHEM SOC T, V36, P1224, DOI 10.1042/BST0361224; Carlsen Kai-Hakon, 2005, Treat Respir Med, V4, P337, DOI 10.2165/00151829-200504050-00005; Carroll KN, 2009, J ALLERGY CLIN IMMUN, V123, P1055, DOI 10.1016/j.jaci.2009.02.021; Chan C, 2005, J IMMUNOL, V175, P461; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Choudhry S, 2008, HUM GENET, V123, P455, DOI 10.1007/s00439-008-0495-7; Clapier CR, 2009, ANNU REV BIOCHEM, V78, P273, DOI 10.1146/annurev.biochem.77.062706.153223; Cook JD, 2005, P NATL ACAD SCI USA, V102, P8644, DOI 10.1073/pnas.0503218102; Cooney Craig A, 2002, J Nutr, V132, p2393S; D'Amato G, 2010, J INVEST ALLERG CLIN, V20, P95; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, P573; Dietert RR, 2008, BIRTH DEFECTS RES B, V83, P547, DOI 10.1002/bdrb.20170; Digel W, 2005, CRIT REV ONCOL HEMAT, V55, P1, DOI 10.1016/j.critrevonc.2005.02.002; Dimeloe S, 2010, J STEROID BIOCHEM, V120, P86, DOI 10.1016/j.jsbmb.2010.02.029; Doherty SP, 2009, BIOMARKERS, V14, P97, DOI 10.1080/13547500902965898; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; Dykewicz MS, 2009, J ALLERGY CLIN IMMUN, V123, P519, DOI 10.1016/j.jaci.2009.01.061; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Edwards CA, 2003, THORAX, V58, P1061, DOI 10.1136/thorax.58.12.1061; Elliott L, 2008, J ALLERGY CLIN IMMUN, V122, P49, DOI 10.1016/j.jaci.2008.04.001; Fields PE, 2002, J IMMUNOL, V169, P647; Finch CE, 2004, SCIENCE, V305, P1736, DOI 10.1126/science.1092556; Foster SL, 2007, NATURE, V447, P972, DOI 10.1038/nature05836; Fujino T, 1996, J BIOL CHEM, V271, P16748; Gilliland FD, 2001, EPIDEMIOLOGY, V12, P43, DOI 10.1097/00001648-200101000-00009; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Gilmour P.S., 2003, AM J PHYSIOL-LUNG C, V284, P533; Giri DK, 1998, J IMMUNOL, V161, P4834; Goldberg AD, 2007, CELL, V128, P635, DOI 10.1016/j.cell.2007.02.006; Gonzalgo ML, 1997, NUCLEIC ACIDS RES, V25, P2529, DOI 10.1093/nar/25.12.2529; Gorman S, 2010, PHOTOCH PHOTOBIO SCI, V9, P571, DOI 10.1039/b9pp00136k; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; Hammad H, 2008, NAT REV IMMUNOL, V8, P193, DOI 10.1038/nri2275; Hammad H, 2006, J ALLERGY CLIN IMMUN, V118, P331, DOI 10.1016/j.jaci.2006.03.041; Hermann A, 2004, CELL MOL LIFE SCI, V61, P2571, DOI 10.1007/s00018-004-4201-1; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Hunt JS, 2005, FASEB J, V19, P681, DOI 10.1096/fj.04-2078rev; Ito K, 2006, J ALLERGY CLIN IMMUN, V117, P522, DOI 10.1016/j.jaci.2006.01.032; Ito K., 2001, FASEB Journal, V15, P1110; Ito T, 2006, TOXICOL LETT, V165, P66, DOI 10.1016/j.toxlet.2006.01.015; Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Jones B, 2006, EMBO J, V25, P2443, DOI 10.1038/sj.emboj.7601148; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kim DH, 2001, CANCER RES, V61, P3419; Kim DH, 2003, CANCER RES, V63, P3743; Kim JS, 2004, CARCINOGENESIS, V25, P2165, DOI 10.1093/carcin/bgh217; Kim JH, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-49; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; Kondo Y, 2009, YONSEI MED J, V50, P455, DOI 10.3349/ymj.2009.50.4.455; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Kuehni CE, 2009, AM J RESP CRIT CARE, V179, P1079, DOI 10.1164/rccm.200904-0567ED; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kumar RK, 2009, DIS MODEL MECH, V2, P549, DOI 10.1242/dmm.001719; Lal G, 2009, BLOOD, V114, P3727, DOI 10.1182/blood-2009-05-219584; Landrigan PJ, 2004, ENVIRON HEALTH PERSP, V112, P731, DOI 10.1289/ehp.6702; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Launay JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007959; Lawlor DA, 2005, THORAX, V60, P851, DOI 10.1136/thx.2005.042408; Lee DU, 2002, IMMUNITY, V16, P649, DOI 10.1016/S1074-7613(02)00314-X; Lemanske RF, 2010, J ALLERGY CLIN IMMUN, V125, pS95, DOI 10.1016/j.jaci.2009.10.047; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lillienberg L, 2008, ANN OCCUP HYG, V52, P107, DOI 10.1093/annhyg/mem063; Ling C, 2009, DIABETES, V58, P2718, DOI 10.2337/db09-1003; Litonjua AA, 2007, J ALLERGY CLIN IMMUN, V120, P1031, DOI 10.1016/j.jaci.2007.08.028; Liu J, 2008, TOXICOL SCI, V102, P76, DOI 10.1093/toxsci/kfm290; Liu XD, 2009, BIOCHEM BIOPH RES CO, V380, P177, DOI 10.1016/j.bbrc.2009.01.066; Locksley RM, 2009, J EXP MED, V206, P1643, DOI 10.1084/jem.20091442; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Los H, 2001, Twin Res, V4, P81, DOI 10.1375/1369052012191; Macaubas Claudia, 2003, Current Drug Targets - Inflammation and Allergy, V2, P175, DOI 10.2174/1568010033484304; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; Mashek DG, 2004, J LIPID RES, V45, P1958, DOI 10.1194/jlr.E4000002-JLR200; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; Maziak Wasim, 2005, BMC Pulm Med, V5, P5, DOI 10.1186/1471-2466-5-5; Mcleish AC, 2010, J ASTHMA, V47, P345, DOI 10.3109/02770900903556413; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Millman A, 2008, PEDIATRICS, V122, P620, DOI 10.1542/peds.2007-3143; Minekura H, 2001, GENE, V278, P185, DOI 10.1016/S0378-1119(01)00714-4; Miremadi A, 2007, HUM MOL GENET, V16, P28, DOI DOI 10.1093/HMG/DDM021); Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nahid MA, 2009, J BIOL CHEM, V284, P34590, DOI 10.1074/jbc.M109.056317; Nouri-Aria KT, 2009, ADV EXP MED BIOL, V665, P180; Nuttall SL, 2000, LANCET, V355, P1648, DOI 10.1016/S0140-6736(05)72556-3; Orfei L, 2008, ARCH DIS CHILD, V93, P570, DOI 10.1136/adc.2006.112201; OU TX, 2009, J IMMUNOL, V182, P4994; Patel MM, 2009, CURR OPIN PEDIATR, V21, P235, DOI 10.1097/MOP.0b013e3283267726; Patra SK, 2009, BIOCHEMISTRY-MOSCOW+, V74, P613, DOI 10.1134/S0006297909060042; Pauley KM, 2008, ANN NY ACAD SCI, V1143, P226, DOI 10.1196/annals.1443.009; Peden D, 2010, J ALLERGY CLIN IMMUN, V125, pS150, DOI 10.1016/j.jaci.2009.10.073; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Perera F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004488; Peters-Golden M, 2004, AM J RESP CELL MOL, V31, P3, DOI 10.1165/rcmb.f279; Ponsonby AL, 2001, CLIN EXP ALLERGY, V31, P1544, DOI 10.1046/j.1365-2222.2001.01163.x; Rahman I, 2003, J BIOCHEM MOL BIOL, V36, P95; Ray A, 2010, MUCOSAL IMMUNOL, V3, P216, DOI 10.1038/mi.2010.4; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ribeiro M, 2009, AM J IND MED, V52, P261, DOI 10.1002/ajim.20669; Robays LJ, 2009, MUCOSAL IMMUNOL, V2, P206, DOI 10.1038/mi.2009.7; Rodriguez A, 2004, GENOME RES, V14, P1902, DOI 10.1101/gr.2722704; Sadikovic B, 2008, J BIOL CHEM, V283, P4051, DOI 10.1074/jbc.M707506200; Sadikovic B, 2007, TOXICOL APPL PHARM, V225, P300, DOI 10.1016/j.taap.2007.08.013; Sadikovic B, 2006, TOXICOL APPL PHARM, V216, P458, DOI 10.1016/j.taap.2006.06.012; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schweizer M, 1999, J GEN VIROL, V80, P1147; SHAHEEN SO, 1994, AM J RESP CRIT CARE, V149, P616; Shankar SL, 2003, J NEUROSCI, V23, P4208; Siedlecki P, 2006, ACTA BIOCHIM POL, V53, P245; Sigurs N, 2005, AM J RESP CRIT CARE, V171, P137, DOI 10.1164/rccm.200406-730OC; Simon Rupert, 2008, Anal Bioanal Chem, V391, P1397, DOI 10.1007/s00216-007-1771-4; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stepanek L, 2005, J NEUROSCI, V25, P3813, DOI 10.1523/NEUROSCI-4531-04.2005; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Strachan DP, 2000, THORAX S1, V55, pS2; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, P57, DOI 10.1016/j.jaci.2007.09.004; Sun LY, 2006, ENDOCRINOLOGY, V147, P5480, DOI 10.1210/en.2006-0586; Szyf M, 2009, ANNU REV PHARMACOL, V49, P243, DOI 10.1146/annurev-pharmtox-061008-103102; TAKIZAWA H, 1990, AM J RESP CELL MOL, V2, P245; Tan Z, 2007, AM J HUM GENET, V81, P829, DOI 10.1086/521200; Tang WY, 2007, REV ENDOCR METAB DIS, V8, P173, DOI 10.1007/s11154-007-9042-4; Tiwari VK, 2008, PLOS BIOL, V6, P2911, DOI 10.1371/journal.pbio.0060306; Tykocinski LO, 2005, J BIOL CHEM, V280, P28177, DOI 10.1074/jbc.M502038200; Vaag A, 2007, CURR OPIN CLIN NUTR, V10, P591, DOI 10.1097/MCO.0b013e3282ab9ea6; Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5772.CAN-06-3123; VAN PN, 2008, TISSUE ANTIGENS, V72, P91; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vercelli D, 2008, J ALLERGY CLIN IMMUN, V122, P267, DOI 10.1016/j.jaci.2008.06.008; von Mutius E, 2009, J ALLERGY CLIN IMMUN, V123, P3, DOI 10.1016/j.jaci.2008.10.046; Wang LQ, 2009, IMMUNOL CELL BIOL, V87, P195, DOI 10.1038/icb.2008.106; Waterland RA, 2003, MOL CELL BIOL, V23, P5293, DOI 10.1128/MCB.23.15.5293-5300.2003; Wei G, 2009, IMMUNITY, V30, P155, DOI 10.1016/j.immuni.2008.12.009; Weisenberger DJ, 1999, J BIOL CHEM, V274, P23948, DOI 10.1074/jbc.274.34.23948; Weiss ST, 2009, CURR OPIN GENET DEV, V19, P279, DOI 10.1016/j.gde.2009.05.001; White GP, 2002, J IMMUNOL, V168, P2820; *WHO, 2000, 206 WHO; WILSON VL, 1983, CELL, V32, P239, DOI 10.1016/0092-8674(83)90514-7; WILSON VL, 1984, CARCINOGENESIS, V5, P1027, DOI 10.1093/carcin/5.8.1027; Windham GC, 2000, EPIDEMIOLOGY, V11, P427, DOI 10.1097/00001648-200007000-00011; Wong GWK, 2008, PEDIATR PULM, V43, P107, DOI 10.1002/ppul.20755; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yanagawa N, 2002, JPN J CANCER RES, V93, P1107; YOUNG HA, 1994, J IMMUNOL, V153, P3603; Zhang N, 2005, J MOL BIOL, V346, P951, DOI 10.1016/j.jmb.2004.12.027; Zhu JF, 2008, BLOOD, V112, P1557, DOI 10.1182/blood-2008-05-078154; [Anonymous], 1998, EUR RESP J, V12, P315	176	95	101	5	37	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2010	126	3					453	465		10.1016/j.jaci.2010.07.030		13	Allergy; Immunology	Allergy; Immunology	646CF	WOS:000281512500007	20816181	
J	Gearry, RB; Richardson, AK; Frampton, CM; Dodgshun, AJ; Barclay, ML				Gearry, Richard B.; Richardson, Ann K.; Frampton, Christopher M.; Dodgshun, Andrew J.; Barclay, Murray L.			Population-based cases control study of inflammatory bowel disease risk factors	JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY			English	Article						Crohn's disease; epidemiology; inflammatory bowel diseases; risk factors; ulcerative colitis	ONSET CROHNS-DISEASE; ULCERATIVE-COLITIS; INTESTINAL MICROFLORA; CHILDHOOD EXPOSURE; HYGIENE HYPOTHESIS; CHINESE POPULATION; PASSIVE SMOKING; TOBACCO-SMOKE; NEW-ZEALAND; SUSCEPTIBILITY	Background and Aim: The rapid increase in inflammatory bowel disease (IBD) incidence confirms the importance of environment in its etiology. We aimed to assess the role of childhood and other environmental risk factors in IBD. Methods: A population-based case-control study was carried out in Canterbury, New Zealand. Participants comprised 638 prevalent Crohn's disease (CD) cases, 653 prevalent ulcerative colitis (UC) cases and 600 randomly-selected sex and age matched controls. Exposure rates to environmental risk factors were compared. Unadjusted and adjusted odds ratios (OR) with 95% confidence intervals (CI) are presented. Results: A family history of IBD (CD OR 3.06 [2.18-4.30], UC OR 2.52 [1.90-3.54]), cigarette smoking at diagnosis (CD OR 1.99 [1.48-2.68], UC OR 0.67 [0.48-0.94]), high social class at birth (CD and UC trend, P < 0.001) and Caucasian ethnicity (CD OR 2.04 [1.05-4.38], UC OR 1.47 [1.01-2.14]) were significantly associated with IBD. City living was associated with CD (P < 0.01). Being a migrant was associated with UC (UC OR 1.40 [1.14-2.01]). Having a childhood vegetable garden was protective against IBD (CD OR 0.52 [0.36-0.76], UC OR 0.65 [0.45-0.94]) as was having been breast-fed (CD OR 0.55 [0.41-0.74], UC OR 0.71 [0.52-0.96]) with a duration-response effect. Appendicectomy, tonsillectomy, infectious monomucleosis and asthma were more common in CD patients than controls (P < 0.01). Conclusions: The importance of childhood factors in the development of IBD is confirmed. The duration-response protective association between breast-feeding and subsequent development of IBD requires further evaluation, as does the protective effect associated with a childhood vegetable garden.	[Gearry, Richard B.; Frampton, Christopher M.; Dodgshun, Andrew J.; Barclay, Murray L.] Univ Otago, Dept Med, Christchurch 8140, New Zealand; [Gearry, Richard B.; Barclay, Murray L.] Christchurch Hosp, Dept Gastroenterol, Christchurch, New Zealand; [Richardson, Ann K.] Canterbury Dist Hlth Board, Christchurch, New Zealand	Gearry, RB (reprint author), Univ Otago, Dept Med, POB 4345, Christchurch 8140, New Zealand.	Richard.gearry@cdhb.govt.nz		Gearry, Richard/0000-0002-2298-5141	Canterbury Medical Research Foundation; Bowel and Liver Trust, Canterbury; Canterbury Gastroenterology Research Trust	This research was funded by the Canterbury Medical Research Foundation, Bowel and Liver Trust, Canterbury and the Canterbury Gastroenterology Research Trust. The researchers wish to thank people in Canterbury with and without inflammatory bowel disease who acted as cases and controls for this study.	Amre DK, 2006, AM J GASTROENTEROL, V101, P1005, DOI 10.1111/j.1572-0241.2006.00526.x; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Baron S, 2005, GUT, V54, P357, DOI 10.1136/gut.2004.054353; BERGSTRAND O, 1983, SCAND J GASTROENTERO, V18, P903; Bernstein CN, 2005, GASTROENTEROLOGY, V129, P827, DOI 10.1053/j.gastro.2005.06.021; Bernstein CN, 2006, AM J GASTROENTEROL, V101, P993, DOI 10.1111/j.1572-0241.2006.00381.x; Binder V, 2004, BEST PRACT RES CL GA, V18, P463, DOI 10.1016/j.bpg.2003.13.002; BOYKO EJ, 1987, NEW ENGL J MED, V316, P707, DOI 10.1056/NEJM198703193161202; Card T, 2004, GUT, V53, P246, DOI 10.1136/gut.2003.025239; de Ridder L, 2007, INFLAMM BOWEL DIS, V13, P1083, DOI 10.1002/ibd.20171; Economou M, 2004, AM J GASTROENTEROL, V99, P2393, DOI 10.1111/j.1572-0241.2004.40304.x; Ehlin AGC, 2003, GUT, V52, P1117, DOI 10.1136/gut.52.8.1117; EKBOM A, 1990, AM J EPIDEMIOL, V132, P1111; Eliakim R, 2000, EUR J GASTROEN HEPAT, V12, P975, DOI 10.1097/00042737-200012090-00002; ELLEY WB, 1985, NEW ZEAL J EDUC STUD, V20, P115; Fanaro S, 2003, ACTA PAEDIATR, V92, P48; Gasche C, 2000, INFLAMM BOWEL DIS, V6, P8; Gearry RB, 2006, GUT, V55, P580, DOI 10.1136/gut.2005.085464; Gearry RB, 2007, INFLAMM BOWEL DIS, V13, P1220, DOI 10.1002/ibd.20190; Gearry RB, 2006, INFLAMM BOWEL DIS, V12, P936, DOI 10.1097/01.mib.0000231572.88806.b9; Gibson PR, 2005, ALIMENT PHARM THERAP, V21, P1399, DOI 10.1111/j.1365-2036.2005.02506.x; GILAT T, 1987, SCAND J GASTROENTERO, V22, P1009, DOI 10.3109/00365528708991950; GODET PG, 1995, GUT, V37, P668, DOI 10.1136/gut.37.5.668; Goldman Armond S, 2007, Adv Pediatr, V54, P275, DOI 10.1016/j.yapd.2007.03.014; Klement E, 2004, AM J CLIN NUTR, V80, P1342; Koutroubakis IE, 1999, DIS COLON RECTUM, V42, P225, DOI 10.1007/BF02237133; LASHNER BA, 1993, AM J GASTROENTEROL, V88, P356; LEIBOWITZ U, 1966, J NEUROL NEUROSUR PS, V29, P60, DOI 10.1136/jnnp.29.1.60; Lennard-Jones J E, 1989, Scand J Gastroenterol Suppl, V170, P2; Leong RWL, 2004, INFLAMM BOWEL DIS, V10, P646, DOI 10.1097/00054725-200409000-00022; Leong RWL, 2003, ALIMENT PHARM THERAP, V17, P1465, DOI 10.1046/j.0269-2813.2003.01607.x; MIDTVEDT AC, 1992, J PEDIATR GASTR NUTR, V15, P395, DOI 10.1097/00005176-199211000-00005; Montgomery SM, 2002, CURR OPIN GASTROEN, V18, P416, DOI 10.1097/01.MOG.0000014653.49814.2A; Montgomery SM, 1999, GASTROENTEROLOGY, V116, P796, DOI 10.1016/S0016-5085(99)70062-4; MORITA N, 1995, J GASTROENTEROL, V30, P1; PERSSON PG, 1990, GUT, V31, P1377, DOI 10.1136/gut.31.12.1377; Radford-Smith GL, 2002, GUT, V51, P808, DOI 10.1136/gut.51.6.808; Reif S, 2001, AM J GASTROENTEROL, V96, P829; Rigas A, 1993, Ann Epidemiol, V3, P387; Rook Graham A W, 2002, Biologist (London), V49, P145; ROTHMAN KJ, 1998, MOD EPIDEMIOL, pS97; Russell RK, 2005, GUT, V54, P1500; RUSSELL RK, 2005, GUT, V54, P1501; SANDLER RS, 1992, AM J EPIDEMIOL, V135, P603; SOMERVILLE KW, 1984, BRIT MED J, V289, P954; SONNENBERG A, 1990, GUT, V31, P1037, DOI 10.1136/gut.31.9.1037; Sood A, 2003, GUT, V52, P1587, DOI 10.1136/gut.52.11.1587; Tannock GW, 2002, EUR J CLIN NUTR, V56, pS44, DOI 10.1038/sj.ejcn.1601661; Targan SR, 2005, GASTROENTEROLOGY, V128, P2020, DOI 10.1053/j.gastro.2005.03.046; Tarrant KM, 2008, AM J GASTROENTEROL, V103, P3082, DOI 10.1111/j.1572-0241.2008.02212.x; Tibbs T, 2001, J AM DIET ASSOC, V101, P535, DOI 10.1016/S0002-8223(01)00134-1; TOBIN MV, 1987, GASTROENTEROLOGY, V93, P316; Van Kruiningen HJ, 2005, INFLAMM BOWEL DIS, V11, P360, DOI 10.1097/01.MIB.0000158536.31557.90; WURZELMANN JI, 1994, DIGEST DIS SCI, V39, P555, DOI 10.1007/BF02088342; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	55	95	97	0	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0815-9319	1440-1746		J GASTROEN HEPATOL	J. Gastroenterol. Hepatol.	FEB	2010	25	2					325	333		10.1111/j.1440-1746.2009.06140.x		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	551CX	WOS:000274184500019	20074146	
J	Knol, AB; de Hartog, JJ; Boogaard, H; Slottje, P; van der Sluijs, JP; Lebret, E; Cassee, FR; Wardekker, A; Ayres, JG; Borm, PJ; Brunekreef, B; Donaldson, K; Forastiere, F; Holgate, ST; Kreyling, WG; Nemery, B; Pekkanen, J; Stone, V; Wichmann, HE; Hoek, G				Knol, Anne B.; de Hartog, Jeroen J.; Boogaard, Hanna; Slottje, Pauline; van der Sluijs, Jeroen P.; Lebret, Erik; Cassee, Flemming R.; Wardekker, Arjan; Ayres, Jon G.; Borm, Paul J.; Brunekreef, Bert; Donaldson, Kenneth; Forastiere, Francesco; Holgate, Stephen T.; Kreyling, Wolfgang G.; Nemery, Benoit; Pekkanen, Juha; Stone, Vicky; Wichmann, H-Erich; Hoek, Gerard			Expert elicitation on ultrafine particles: likelihood of health effects and causal pathways	PARTICLE AND FIBRE TOXICOLOGY			English	Article							PARTICULATE AIR-POLLUTION; CORONARY-HEART-DISEASE; DIESEL-EXHAUST INHALATION; LONG-TERM EXPOSURE; URBAN AIR; CARDIOPULMONARY MORTALITY; AMBIENT FINE; NANOPARTICLES; ASSOCIATION; ASTHMA	Background: Exposure to fine ambient particulate matter (PM) has consistently been associated with increased morbidity and mortality. The relationship between exposure to ultrafine particles (UFP) and health effects is less firmly established. If UFP cause health effects independently from coarser fractions, this could affect health impact assessment of air pollution, which would possibly lead to alternative policy options to be considered to reduce the disease burden of PM. Therefore, we organized an expert elicitation workshop to assess the evidence for a causal relationship between exposure to UFP and health endpoints. Methods: An expert elicitation on the health effects of ambient ultrafine particle exposure was carried out, focusing on: 1) the likelihood of causal relationships with key health endpoints, and 2) the likelihood of potential causal pathways for cardiac events. Based on a systematic peernomination procedure, fourteen European experts (epidemiologists, toxicologists and clinicians) were selected, of whom twelve attended. They were provided with a briefing book containing key literature. After a group discussion, individual expert judgments in the form of ratings of the likelihood of causal relationships and pathways were obtained using a confidence scheme adapted from the one used by the Intergovernmental Panel on Climate Change. Results: The likelihood of an independent causal relationship between increased short-term UFP exposure and increased all-cause mortality, hospital admissions for cardiovascular and respiratory diseases, aggravation of asthma symptoms and lung function decrements was rated medium to high by most experts. The likelihood for long-term UFP exposure to be causally related to all cause mortality, cardiovascular and respiratory morbidity and lung cancer was rated slightly lower, mostly medium. The experts rated the likelihood of each of the six identified possible causal pathways separately. Out of these six, the highest likelihood was rated for the pathway involving respiratory inflammation and subsequent thrombotic effects. Conclusion: The overall medium to high likelihood rating of causality of health effects of UFP exposure and the high likelihood rating of at least one of the proposed causal mechanisms explaining associations between UFP and cardiac events, stresses the importance of considering UFP in future health impact assessments of (transport-related) air pollution, and the need for further research on UFP exposure and health effects.	[Knol, Anne B.; de Hartog, Jeroen J.; Slottje, Pauline; Lebret, Erik; Cassee, Flemming R.] Dutch Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands; [de Hartog, Jeroen J.; Boogaard, Hanna; van der Sluijs, Jeroen P.; Lebret, Erik; Brunekreef, Bert; Hoek, Gerard] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [van der Sluijs, Jeroen P.; Wardekker, Arjan] Univ Utrecht, Copernicus Inst, Utrecht, Netherlands; [Ayres, Jon G.] Univ Birmingham, Inst Occupat & Environm Med, Birmingham, W Midlands, England; [Borm, Paul J.] Hogesch Zuyd, Ctr Expertise Life Sci, Heerlen, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Donaldson, Kenneth] Univ Edinburgh, Ctr Inflammat Res, Edinburgh, Midlothian, Scotland; [Forastiere, Francesco] Hlth Author Rome, Dept Epidemiol, Rome, Italy; [Holgate, Stephen T.] Univ Southampton, Sch Med, Southampton SO9 5NH, Hants, England; [Kreyling, Wolfgang G.; Wichmann, H-Erich] Helmholtz Ctr Munich, Inst Lung Biol & Focus Network Nanoparticles & Hl, Neuherberg, Germany; [Nemery, Benoit] Katholieke Univ Leuven, Lung Toxicol Res Unit, Leuven, Belgium; [Pekkanen, Juha] Natl Publ Hlth Inst, Environm Epidemiol Unit, Kuopio, Finland; [Stone, Vicky] Napier Univ, Sch Life Sci, Edinburgh EH14 1DJ, Midlothian, Scotland	Knol, AB (reprint author), Dutch Natl Inst Publ Hlth & Environm RIVM, Bilthoven, Netherlands.	anne.knol@rivm.nl; J.J.deHartog@uu.nl; J.M.C.Boogaard@uu.nl; Pauline.Slottje@uu.nl; J.P.vanderSluijs@uu.nl; Erik.Lebret@rivm.nl; Flemming.cassee@rivm.nl; J.A.Wardekker@uu.nl; j.g.ayres@bham.ac.uk; p.borm@hszuyd.nl; B.Brunekreef@uu.nl; ken.donaldson@ed.ac.uk; forastiere@asplazio.it; S.Holgate@soton.ac.uk; Kreyling@gsf.de; Ben.Nemery@med.kuleuven.be; Juha.Pekkanen@thl.fi; V.Stone@napier.ac.uk; wichmann@gsf.de; G.Hoek@uu.nl	van der Sluijs, Jeroen/B-6302-2008; Nemery, Benoit/D-1224-2013; Forastiere, Francesco/J-9067-2016	van der Sluijs, Jeroen/0000-0002-1346-5953; Forastiere, Francesco/0000-0002-9162-5684; brunekreef, bert/0000-0001-9908-0060; Kreyling, Wolfgang/0000-0002-0702-6567	EU 6th Framework research project INTARESE; Dutch National Institute for Public Health and the Environment (RIVM)	Anthony Seaton, as valuable member of the expert panel who chose ( from the onset) not be co-author of the paper. The study was performed within the framework of EU 6th Framework research project INTARESE and the strategic research project IQARUS of the Dutch National Institute for Public Health and the Environment (RIVM).	Andersen DF, 1997, SYST DYNAM REV, V13, P107, DOI 10.1002/(SICI)1099-1727(199722)13:2<107::AID-SDR120>3.0.CO;2-7; Barclay JL, 2009, OCCUP ENVIRON MED, V66, P325, DOI 10.1136/oem.2008.039032; Beelen R, 2008, ENVIRON HEALTH PERSP, V116, P196, DOI 10.1289/ehp.10767; Berger A, 2006, J OCCUP ENVIRON MED, V48, P1149, DOI 10.1097/01.jom.0000245921.15916.03; BeruBe K, 2007, CLIN EXP PHARMACOL P, V34, P1044, DOI 10.1111/j.1440-1681.2007.04733.x; Borm Paul J A, 2006, Part Fibre Toxicol, V3, P11, DOI 10.1186/1743-8977-3-11; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Chan CC, 2004, ENVIRON HEALTH PERSP, V112, P1063, DOI 10.1289/chp.6897; Cooke RM, 2007, ENVIRON SCI TECHNOL, V41, P6598, DOI 10.1021/es0714078; de Hartog JJ, 2003, AM J EPIDEMIOL, V157, P613, DOI 10.1093/aje/kwg021; Delfino RJ, 2005, ENVIRON HEALTH PERSP, V113, P934, DOI 10.1289/ehp.7938; Donaldson K, 2001, ENVIRON HEALTH PERSP, V109, P523, DOI 10.2307/3454663; Donaldson K, 2007, J NANOSCI NANOTECHNO, V7, P4607, DOI 10.1166/jun.2007.003; Duffin R, 2007, YONSEI MED J, V48, P561, DOI 10.3349/ymj.2007.48.4.561; Finkelstein MM, 2004, AM J EPIDEMIOL, V160, P173, DOI 10.1093/aje/kwh181; Forastiere F, 2005, AM J RESP CRIT CARE, V172, P1549, DOI 10.1164/rccm.200412-1726OC; Gehring U, 2006, EPIDEMIOLOGY, V17, P545, DOI 10.1097/01.ede.0000224541.38258.87; GODLESKI JJ, 2000, 91 HEI; GROUP M, 2002, SYST DYNAM REV, V18, P5; Gwinn MR, 2006, ENVIRON HEALTH PERSP, V114, P1818; Halonen JI, 2008, THORAX, V63, P635, DOI 10.1136/thx.2007.091371; Henneberger A, 2005, ENVIRON HEALTH PERSP, V113, P440, DOI 10.1289/ehp.7579; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Ibald-Mulli A, 2002, J AEROSOL MED, V15, P189, DOI 10.1089/089426802320282310; Kandlikar M, 2007, J NANOPART RES, V9, P137, DOI 10.1007/s11051-006-9154-x; Kreyling WG, 2004, J AEROSOL MED, V17, P140, DOI 10.1089/0894268041457147; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Linstone H., 1975, DELPHI METHOD TECHNI; Lucking AJ, 2008, EUR HEART J, V29, P3043, DOI 10.1093/eurheartj/ehn464; MANNING M, 2006, ADV CLIM CHANGE RES, V2, P18; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Mills NL, 2007, NEW ENGL J MED, V357, P1075, DOI 10.1056/NEJMoa066314; Mills NL, 2005, CIRCULATION, V112, P3930, DOI 10.1161/CIRCULATIONAHA.105.588962; MohanKumar SMJ, 2008, NEUROTOXICOLOGY, V29, P479, DOI 10.1016/j.neuro.2007.12.004; Nel A, 2006, SCIENCE, V311, P622, DOI 10.1126/science.1114397; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Oberdorster G, 2005, ENVIRON HEALTH PERSP, V113, P823, DOI 10.1289/ehp.7339; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 1999, AM J EPIDEMIOL, V150, P1094; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Peters Annette, 2006, Part Fibre Toxicol, V3, P13, DOI 10.1186/1743-8977-3-13; Pope CA, 2006, J AIR WASTE MANAGE, V56, P709; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Pope CA, 1999, AM J RESP CRIT CARE, V159, P365; Roman HA, 2008, ENVIRON SCI TECHNOL, V42, P2268, DOI 10.1021/es0713882; Routledge HC, 2005, OCCUP MED-OXFORD, V55, P439, DOI 10.1093/occmed/kqi136; Ruckerl R, 2006, AM J RESP CRIT CARE, V173, P432, DOI 10.1164/rccm.200507-1123OC; Ruckerl R, 2007, ENVIRON HEALTH PERSP, V115, P1072, DOI 10.1289/ehp.10021; Schulz H, 2005, J AEROSOL MED, V18, P1, DOI 10.1089/jam.2005.18.1; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Stolzel M., 2007, Journal of Exposure Science and Environmental Epidemiology, V17, P458, DOI 10.1038/sj.jes.7500538; Utell MJ, 2002, INHAL TOXICOL, V14, P1231, DOI 10.1080/08958370290084881; Vennix J. A. M., 1996, GROUP MODEL BUILDING; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Wichmann H E, 2000, Res Rep Health Eff Inst, P5	57	95	97	2	47	BIOMED CENTRAL LTD	LONDON	CURRENT SCIENCE GROUP, MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1743-8977			PART FIBRE TOXICOL	Part. Fibre Toxicol.	JUL 24	2009	6								19	10.1186/1743-8977-6-19		16	Toxicology	Toxicology	487TH	WOS:000269298600001	19630955	
J	Fedulov, AV; Leme, A; Yang, Z; Dahl, M; Lim, R; Mariani, TJ; Kobzik, L				Fedulov, Alexey V.; Leme, Adriana; Yang, Zhiping; Dahl, Morten; Lim, Robert; Mariani, Thomas J.; Kobzik, Lester			Pulmonary exposure to particles during pregnancy causes increased neonatal asthma susceptibility	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						maternal asthma; environmental particles; titanuim dioxide; diesel exhaust particles; susceptibility	STEROID SEX-HORMONES; ALLERGIC AIRWAY INFLAMMATION; DIESEL EXHAUST; MATERNAL TRANSMISSION; ALVEOLAR MACROPHAGES; LANGERHANS CELLS; DENDRITIC CELLS; MURINE MODEL; MICE; RISK	Maternal immune responses can promote allergy development in offspring, as shown in a model of increased susceptibility to asthma in babies of ovalbumin (OVA)-sensitized and -challenged mother mice. We investigated whether inflammatory responses to air pollution particles (diesel exhaust particles, DEP) or control "Inert" titanium dioxide (TiO2) particles are enhanced during pregnancy and whether exposure to particles can cause increased neonatal susceptibility to asthma. Pregnant BALB/c mice (or nonpregnant controls) received particle suspensions intranasally at Day 14 of pregnancy. Lung inflammatory responses were evaluated 48 hours after exposure. Offspring of particle- or buffer-treated mothers were sensitized and aerosolized with OVA, followed by assays of airway hyperresponsiveness (AHR) and allergic inflammation (AI). Nonpregnant females had the expected minimal response to "inert" TiO2. In contrast, pregnant mice showed robust and persistent acute inflammation after both TiO2 and DEP. Genomic profiling identified genes differentially expressed in pregnant lungs exposed to TiO2 center dot Neonates of mothers exposed to TiO2 (and DEP, but not PBS) developed AHR and All, indicating that pregnancy exposure to both "inert" TiO2 and DEP caused increased asthma susceptibility in offspring. We conclude that (1) pregnancy enhances lung inflammatory responses to otherwise relatively innocuous inert particles; and (2) exposures of nonallergic pregnant females to inert or toxic environmental air particles can cause increased allergic susceptibility in offspring.	[Fedulov, Alexey V.; Leme, Adriana; Yang, Zhiping; Dahl, Morten; Lim, Robert; Kobzik, Lester] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, Boston, MA 02115 USA; [Mariani, Thomas J.] Harvard Univ, Sch Med, Lung Biol Ctr, Boston, MA USA	Fedulov, AV (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Mol & Integrat Physiol Sci Program, 665 Huntington Ave,HSP 12,Room 1313, Boston, MA 02115 USA.	afedulov@hsph.harvard.edu	Dahl, Morten/F-4219-2014	Dahl, Morten/0000-0002-6686-312X	NHLBI NIH HHS [HL69760]		Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Ahn MH, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-34; Albrecht ED, 2000, AM J OBSTET GYNECOL, V182, P432, DOI 10.1016/S0002-9378(00)70235-3; Arredondo F, 2006, SEMIN REPROD MED, V24, P33, DOI 10.1055/s-2006-931799; Baron RM, 2004, FASEB J, V18, P1276, DOI 10.1096/fj.04-1518fje; Bommel H, 2000, J ALLERGY CLIN IMMUN, V105, P796, DOI 10.1067/mai.2000.105124; Cahill M., 1995, HDB DIAGNOSTIC TESTS; Chao TC, 1996, AM J REPROD IMMUNOL, V35, P106; CHAO TC, 1995, CELL IMMUNOL, V160, P43, DOI 10.1016/0008-8749(95)80007-6; CHAO TC, 1994, AM J REPROD IMMUNOL, V32, P43; Chao TC, 2000, AM J REPROD IMMUNOL, V44, P310, DOI 10.1111/j.8755-8920.2000.440511.x; Cohn L, 2001, J IMMUNOL, V166, P2760; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Dohi M, 1999, LAB INVEST, V79, P1559; Drumm K, 1999, LUNG, V177, P9, DOI 10.1007/PL00007628; Fedulov A, 2005, J IMMUNOL, V175, P4292; Fujimaki H, 1997, TOXICOLOGY, V116, P227, DOI 10.1016/S0300-483X(96)03539-1; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; Gomes RFM, 2000, J APPL PHYSIOL, V89, P908; GUNNISON AF, 1992, FUND APPL TOXICOL, V19, P607, DOI 10.1016/0272-0590(92)90100-V; Hamada K, 2003, J IMMUNOL, V170, P1683; HAMADA K, 2006, IN PRESS J TOXICOL E; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; Hubeau C, 2006, AM J PATHOL, V168, P1931, DOI 10.2353/ajpati.7.2006.051231; Huffman LJ, 2004, J TOXICOL ENV HEAL A, V67, P125, DOI 10.1080/15287390490264776; Ivanova E, 2005, AM J REPROD IMMUNOL, V53, P199, DOI 10.1111/j.1600-0897.2005.00266.x; Kang CM, 2005, AM J RESP CELL MOL, V33, P290, DOI 10.1165/rcmb.2005-0003OC; Leme AS, 2006, J IMMUNOL, V176, P762; LIN H, 1993, J IMMUNOL, V151, P4562; Lomax R, 2001, STAT CONCEPTS 2 COUR; LUTCHEN KR, 1993, J APPL PHYSIOL, V75, P478; Mao A, 2005, J IMMUNOL, V175, P5146; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; Miyake Yoshihiro, 2002, J Epidemiol, V12, P418; Pauwels RA, 1998, CLIN EXP ALLERGY, V28, P1; Piccinni MP, 2000, J NEUROIMMUNOL, V109, P30, DOI 10.1016/S0165-5728(00)00299-X; Prescott SL, 2006, CURR ALLERGY ASTHM R, V6, P75, DOI 10.1007/s11882-006-0014-7; Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227; Southam DS, 2002, AM J PHYSIOL-LUNG C, V282, pL833, DOI 10.1152/ajplung.00173.2001; Suzuki Takahito, 1993, Japanese Journal of Allergology, V42, P963; Takano H, 1998, IMMUNOPHARM IMMUNOT, V20, P329, DOI 10.3109/08923979809038548; van Zijverden M, 2000, TOXICOL APPL PHARM, V168, P131, DOI 10.1006/taap.2000.9013; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; Von Mutius E, 2000, ARCH DIS CHILD S, V2, P112; Warheit DB, 2005, TOXICOL SCI, V88, P514, DOI 10.1093/toxsci/kfi331; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; Weiss ST, 2001, ANN ALLERG ASTHMA IM, V87, P5; Wieser F, 2001, FERTIL STERIL, V75, P1234, DOI 10.1016/S0015-0282(01)01796-4; Wills-Karp M, 2000, IMMUNOPHARMACOLOGY, V48, P263, DOI 10.1016/S0162-3109(00)00223-X	53	95	98	1	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	JAN	2008	38	1					57	67		10.1165/rcmb.2007-0124OC		11	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	244DC	WOS:000251845200008	17656681	
J	Lundblad, LKA; Thompson-Figueroa, J; Allen, GB; Rinaldi, L; Norton, RJ; Irvin, CG; Bates, JHT				Lundblad, Lennart K. A.; Thompson-Figueroa, John; Allen, Gilman B.; Rinaldi, Lisa; Norton, Ryan J.; Irvin, Charles G.; Bates, Jason H. T.			Airway hyperresponsiveness in allergically inflamed mice - The role of airway closure	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; micro-computed tomography; input impedance; lung derecruitment; lung volume	SMOOTH-MUSCLE CONTRACTION; TEMPORAL DYNAMICS; ASTHMA; LUNG; DOGS; HYPEROXIA; RAT; BRONCHOCONSTRICTION; VENTILATION; CHALLENGE	Rationale: Allergically inflamed mice exhibit airway hyper-responsiveness to inhaled methacholine, which computer simulations of lung impedance suggest is due to enhanced lung derecruitment and which we sought to verify in the present study. Methods: BALB/c mice were sensitized and challenged with ovalbumin to induce allergic inflammation; the control mice were sensitized but received no challenge. The mice were then challenged with inhaled methacholine and respiratory system impedance tracked for the following 10 minutes. Respiratory elastance (H) was estimated from each impedance measurement. One group of mice was ventilated with 100% O-2 during this procedure and another group was ventilated with air. After the procedure, the mice were killed and ventilated with pure N-2, after which the trachea was tied off and the lungs were imaged with micro-computed tomography (micro-CT). Results: H was significantly higher in allergic mice than in control animals after methacholine challenge. The ratio of H at the end of the measurement period between allergic and nonallergic mice ventilated with O-2 was 1.36, indicating substantial derecruitment in the allergic animals. The ratio between lung volumes determined by micro-CT in the control and the allergic mice was also 1.36, indicative of a corresponding volume loss due to absorption atelectasis. Micro-CT images and histograms of Hounsfield units from the lungs also showed increased volume loss in the allergic mice compared with control animals after methacholine challenge. Conclusions: These results support the conclusion that airway closure is a major component of hyperresponsiveness in allergically inflamed mice.	Univ Vermont, Coll Med, Vermont Lung Ctr, Burlington, VT 05405 USA	Lundblad, LKA (reprint author), Univ Vermont, Coll Med, Vermont Lung Ctr, HSRF 230,149 Beaumont Ave, Burlington, VT 05405 USA.	lennart.lundblad@uvm.edu			NCRR NIH HHS [P20 RR15557]; NHLBI NIH HHS [R01 HL67273]		BATES JHT, 1994, J APPL PHYSIOL, V76, P616; Bates JHT, 1997, J APPL PHYSIOL, V82, P55; BECKETT WS, 1988, J APPL PHYSIOL, V64, P1683; Belik J, 2003, J APPL PHYSIOL, V94, P2303, DOI 10.1152/japplphysiol.00820.2002; Brusasco V, 2003, J APPL PHYSIOL, V95, P1305, DOI 10.1152/japplphysiol.00001.2003; DOMINO KB, 1989, J APPL PHYSIOL, V67, P730; Fredberg JJ, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-2; HANTOS Z, 1992, J APPL PHYSIOL, V72, P168; Harris RS, 2006, AM J RESP CRIT CARE, V174, P245, DOI 10.1164/rccm.200510-1634OC; Hohlfeld JM, 1999, AM J RESP CRIT CARE, V159, P1803; King GG, 1998, AM J RESP CRIT CARE, V158, P1900; Lakshminrusimha S, 2006, J APPL PHYSIOL, V101, P135, DOI 10.1152/japplphysiol.01382.2005; Laurent F, 2000, EUR RADIOL, V10, P1404, DOI 10.1007/s003300000504; Lauzon AM, 2000, J APPL PHYSIOL, V89, P2023; Lundblad LKA, 2004, ANN BIOMED ENG, V32, P1420, DOI 10.1114/B:ABME.0000042229.41098.6a; Lundblad LKA, 2005, AM J RESP CRIT CARE, V171, P1363, DOI 10.1164/rccm.200410-1349OC; LUNDBLAD LKA, 2006, P AM THORAC SOC, V3, pA789; Mann CM, 1998, J APPL PHYSIOL, V84, P2010; MITZNER W, 1992, J APPL PHYSIOL, V72, P158; MORGAN JJ, 1984, RESP PHYSIOL, V55, P309, DOI 10.1016/0034-5687(84)90053-7; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211.1268OC; Pare PD, 2003, AM J RESP CRIT CARE, V168, P913, DOI 10.1164/rccm.2307005; Petak F, 2001, J APPL PHYSIOL, V90, P2221; Ricciardolo FLM, 2003, THORAX, V58, P175, DOI 10.1136/thorax.58.2.175; Venegas JG, 2005, NATURE, V434, P777, DOI 10.1038/nature03490; Wagers S, 2004, J APPL PHYSIOL, V96, P2019, DOI 10.1152/japplphysiol.00924.2003; Wagers S, 2002, J APPL PHYSIOL, V92, P1802, DOI 10.1152/japplphysiol.00883.2001; Wagers SS, 2004, J CLIN INVEST, V114, P104, DOI 10.1172/JC1200419569; WOLLNER A, 1991, ALLERGY, V46, P35, DOI 10.1111/j.1398-9995.1991.tb00540.x	29	95	98	0	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 15	2007	175	8					768	774		10.1164/rccm.200610-1410OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	157MR	WOS:000245724700007	17255559	
J	Adam, E; Hansen, KK; Astudillo, OF; Coulon, L; Bex, F; Duhant, X; Jaumotte, E; Hollenberg, MD; Jacquet, A				Adam, E; Hansen, KK; Astudillo, OF; Coulon, L; Bex, F; Duhant, X; Jaumotte, E; Hollenberg, MD; Jacquet, A			The house dust mite allergen Der p 1, unlike Der p 3, stimulates the expression of interleukin-8 in human airway epithelial cells via a proteinase-activated receptor-2-independent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TUMOR-NECROSIS-FACTOR; CYSTEINE PROTEASE ACTIVITY; INDUCE CYTOKINE RELEASE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; INFLAMMATORY CYTOKINES; TIGHT JUNCTIONS; GM-CSF; RECEPTOR-2	We investigated and compared the mechanisms by which two dust mite proteolytic allergens, Der p 1 and Der p 3, and a peptide agonist of proteinase-activated receptor 2 (PAR(2)AP) trigger interleukin (IL)-8 release from human pulmonary epithelial cells (A549). Although all three stimuli tested induced the up-regulation of IL-8 ( mRNA and protein), the Der p 1-mediated signaling events did not exactly match those induced by PAR(2)AP and Der p 3. First, Der p 1 was less effective in stimulating IL-8 gene transcriptional activity than PAR(2)AP and Der p 3. Second, Der p 1-mediated IL-8 expression was mainly dependent on NF-kappa B, whereas Der p 3 and PAR(2)AP regulated IL-8 expression through the activation of both NF-kappa B and AP-1. Third, although all three MAP kinases, ERK1/2, p38, and JNK, were activated, Der p 1 induced IL-8 release exclusively via the ERK1/2 signaling pathway, whereas PAR(2)AP and Der p 3 also involved the other kinases. Fourth, in HeLa cells, Der p 1 was able to up-regulate IL-8 secretion independent of PAR(2) expression, and in contrast with PAR(2)AP and Der p 3, Der p 1 was unable to affect calcium signaling via PAR(2) in PAR(2)-expressing KNRK cells. Finally, cleavage by Der p 1 of a synthetic peptide representing the N-terminal activation-cleavage site of PAR(2) did not release a high potency activator of PAR(2) as does Der p 3. We conclude that Der p 1 ( but not Der p 3)-induced IL-8 production in A549 epithelial cells is independent of PAR(2) activation.	Univ Libre Bruxelles, Inst Biol & Med Mol, Dept Appl Genet, B-6041 Gosselies, Belgium; Univ Calgary, Dept Pharmacol & Therapeut, Canadian Inst Hlth Res Prot & Inflammat Network, Calgary, AB T2N 4N1, Canada; Univ Calgary, Dept Med, Canadian Inst Hlth Res Prot & Inflammat Network, Calgary, AB T2N 4N1, Canada; Univ Libre Bruxelles, Inst CERIA, Microbiol Lab, B-1060 Brussels, Belgium; Univ Libre Bruxelles, Erasme Hosp, Dept Immunol, Sch Med,Inst Interdisciplinary Res, B-1060 Brussels, Belgium	Jacquet, A (reprint author), Univ Libre Bruxelles, Inst Biol & Med Mol, Dept Appl Genet, B-6041 Gosselies, Belgium.	alain.jacquet@ulb.ac.be					Adam E, 2003, MOL CELL BIOL, V23, P6200, DOI 10.1128/MCB.23.17.6200-6209.2003; Al-Ani B, 2003, J PHARMACOL EXP THER, V304, P1120, DOI 10.1124/jpet.102.043844; Al-Ani B, 1999, J PHARMACOL EXP THER, V290, P753; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Asokananthan N, 2002, J IMMUNOL, V169, P4572; Belham CL, 1996, BIOCHEM J, V320, P939; BERNSTEIN LR, 1994, J BIOL CHEM, V269, P9401; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Bretschneider E, 1999, BRIT J PHARMACOL, V126, P1735, DOI 10.1038/sj.bjp.0702509; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; Busse William W., 2003, Journal of Allergy and Clinical Immunology, V111, pS799, DOI 10.1067/mai.2003.158; Cocks TM, 1999, NATURE, V398, P156, DOI 10.1038/18223; Compton SJ, 2001, BRIT J PHARMACOL, V134, P705, DOI 10.1038/sj.bjp.0704303; Davies D E, 2001, Curr Opin Allergy Clin Immunol, V1, P67, DOI 10.1097/00130832-200102000-00012; Fahy JV, 2001, AM J RESP CRIT CARE, V164, pS46; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P728, DOI 10.1046/j.1365-2222.2002.01374.x; Hewitt CRA, 1997, CLIN EXP ALLERGY, V27, P201, DOI 10.1111/j.1365-2222.1997.tb00694.x; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hoffmann E, 2005, J BIOL CHEM, V280, P9706, DOI 10.1074/jbc.M407071200; Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847; Hollenberg MD, 2002, PHARMACOL REV, V54, P203, DOI 10.1124/pr.54.2.203; Hollenberg MD, 1996, MOL PHARMACOL, V49, P229; Holtmann H, 2001, J BIOL CHEM, V276, P3508, DOI 10.1074/jbc.M004376200; HOSHI H, 1995, CLIN EXP ALLERGY, V25, P720, DOI 10.1111/j.1365-2222.1995.tb00009.x; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757; Kawabata A, 1999, J PHARMACOL EXP THER, V288, P358; King C, 1998, J IMMUNOL, V161, P3645; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lamblin C, 1998, AM J RESP CRIT CARE, V157, P394; Li J, 2002, AM J PHYSIOL-LUNG C, V283, pL690, DOI 10.1152/ajplung.00060.2002; LINDLEY I, 1988, P NATL ACAD SCI USA, V85, P9199, DOI 10.1073/pnas.85.23.9199; Lourbakos A, 2001, INFECT IMMUN, V69, P5121, DOI 10.1128/IAI.69.8.5121-5130.2001; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; Massaer M, 2001, INT ARCH ALLERGY IMM, V125, P32, DOI 10.1159/000053794; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Miike S, 2003, J ALLERGY CLIN IMMUN, V111, P704, DOI 10.1067/mai.2003.1332; MINTA A, 1989, J BIOL CHEM, V264, P8171; Mori N, 1999, INFECT IMMUN, V67, P3872; Mukaida N, 2000, INT J HEMATOL, V72, P391; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1994, J LEUKOCYTE BIOL, V56, P554; Mukaida N, 2003, AM J PHYSIOL-LUNG C, V284, P566; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; OKAMOTO SI, 1994, J BIOL CHEM, V269, P8582; Ricciardolo FLM, 2000, AM J RESP CRIT CARE, V161, P1672; Riewald M, 2001, BLOOD, V97, P3109, DOI 10.1182/blood.V97.10.3109; Saccani S, 2002, NAT IMMUNOL, V3, P69, DOI 10.1038/ni748; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Sharma S, 2003, CLIN EXP ALLERGY, V33, P163, DOI 10.1046/j.1365-2222.2003.01605.x; Shpacovitch VM, 2002, J INVEST DERMATOL, V118, P380, DOI 10.1046/j.0022-202x.2001.01658.x; Simeonova PP, 1996, AM J RESP CELL MOL, V15, P787; Stacey MA, 1997, BIOCHEM BIOPH RES CO, V236, P522, DOI 10.1006/bbrc.1997.6997; Sun G, 2001, J IMMUNOL, V167, P1014; Takai T, 2005, BIOCHEM BIOPH RES CO, V328, P944, DOI 10.1016/j.bbrc.2005.01.051; Tancharoen S, 2005, J IMMUNOL, V174, P5796; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vinciguerra M, 2004, J BIOL CHEM, V279, P9634, DOI 10.1074/jbc.M308721200; Vliagoftis H, 2001, J ALLERGY CLIN IMMUN, V107, P679, DOI 10.1067/mai.2001.114245; Vliagoftis Harissios, 2000, Journal of Allergy and Clinical Immunology, V106, P537; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang XL, 2002, J BIOL CHEM, V277, P23620, DOI 10.1074/jbc.M202242200; Wardlaw AJ, 2002, CLIN SCI, V103, P201; Winton HL, 1998, CLIN EXP ALLERGY, V28, P1273; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969	67	95	101	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 17	2006	281	11					6910	6923		10.1074/jbc.M507140200		14	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	022BY	WOS:000236030900003	16293628	
J	Lucas, SR; Platts-Mills, TAE				Lucas, SR; Platts-Mills, TAE			Physical activity and exercise in asthma: Relevance to etiology and treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma exercise; conditioning; etiology; pathophysiology; sedentary lifestyle; activity; therapy; incidence; severity	AIRWAY SMOOTH-MUSCLE; DEEP INSPIRATION; CHILDREN; PROGRAM; OBESITY; HYPERRESPONSIVENESS; OVERWEIGHT; INTENSITY; RISK	There is little doubt that the cause of the increased prevalence and severity of asthma is multifactorial. Although the factors of allergen exposure and hygiene are almost certainly necessary for its development, there is a growing body of literature that implicates lifestyle change, specifically decreased physical activity, as a contributor to the increase in asthma prevalence and severity. Several literature reviews of exercise conditioning in patients with asthma have been published. These reviews and recent controlled trials emphasize that although many of the studies of exercise conditioning in asthmatic patients involved different methods and outcome measures, the overwhelming majority of studies demonstrated the capacity for asthmatic subjects to exercise safely and significantly improve their cardiovascular fitness and quality of life. There are several proposed pathophysiologic mechanisms responsible for the effects of decreased activity on the lung function of patients with asthma. A prescription for exercise has been endorsed for all asthmatic subjects by the American College of Sports Medicine and the American Thoracic Society. The allergy community has placed emphasis on medical therapy and allergen avoidance; in addition, exercise avoidance has not been formally incorporated into the National Asthma Education and Prevention Program guidelines. It is our belief that an exercise prescription should be part of the treatment for all cases of asthma. The real question is whether prolonged physical activity and, in particular, outdoor play of children plays a role in prophylaxis against persistent wheezing. If so, the decrease in physical activity might have played a major role in recent increases in asthma prevalence and severity.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA	Platts-Mills, TAE (reprint author), Univ Virginia, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.	tap2z@virginia.edu			NIAID NIH HHS [P01-AI-50989, AI-20565]		American College of Sports Medicine, 2000, ACSMS GUID EX TEST P; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; Biring MS, 1999, AM J MED SCI, V318, P293, DOI 10.1097/00000441-199911000-00002; BUTTON B, 2004, PEDIATR PULM, V27, P213; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Cambach W, 1997, EUR RESPIR J, V10, P104, DOI 10.1183/09031936.97.10010104; Clark C. J., 1993, PRINCIPLES PRACTICE, P424; COCHRANE LM, 1990, THORAX, V45, P345, DOI 10.1136/thx.45.5.345; Crater Scott E., 1998, Current Opinion in Pediatrics, V10, P594; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985; Figueroa-Munoz JI, 2001, THORAX, V56, P133, DOI 10.1136/thorax.56.2.133; FIRRINCIELI V, 2004, IN PRESS PEDIAT PULM; FISH JE, 1981, J APPL PHYSIOL, V50, P1079; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959; Hallstrand TS, 2000, CHEST, V118, P1460, DOI 10.1378/chest.118.5.1460; Hark WT, 2005, ANN ALLERG ASTHMA IM, V94, P247; Huovinen E, 2001, THORAX, V56, P234, DOI 10.1136/thorax.56.3.234; Kapsali T, 2000, J APPL PHYSIOL, V89, P711; MALMBERG P, 1993, EUR RESPIR J, V6, P680; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; NADEL JA, 1961, J APPL PHYSIOL, V16, P717; National Asthma Education and Prevention Program. National Asthma Education and Prevention Program, 2002, J ALLERGY CLIN IMMUN, V110, pS141; National Center for Health Statistics, 2000, AD HLTH CHARTB; Nystad W, 2001, EUR J EPIDEMIOL, V17, P209, DOI 10.1023/A:1017926403763; Orenstein DM, 2002, PEDIATR CLIN N AM, V49, P709, DOI 10.1016/S0031-3955(02)00023-8; ORENSTEIN DM, 1996, CHILD ADOLESCENT ATH, V5, P433; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; Rasmussen F, 2000, EUR RESPIR J, V16, P866, DOI 10.1183/09031936.00.16586600; Ricciardolo FLM, 2001, AM J MED, V111, P18, DOI 10.1016/S0002-9343(01)00816-6; ROBINSON DM, 1992, NEW ZEAL MED J, V105, P253; Salter HH, 1882, ASTHMA ITS PATHOLOGY; SASAKI H, 1979, J APPL PHYSIOL, V47, P1251; Satta A, 2000, J SPORT MED PHYS FIT, V40, P277; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; SKLOOT G, 1995, J CLIN INVEST, V96, P2393, DOI 10.1172/JCI118296; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tantisira KG, 2001, THORAX, V56, P64; Thomson RJ, 1996, AM J RESP CRIT CARE, V154, P749; VARRAY AL, 1991, CHEST, V99, P579, DOI 10.1378/chest.99.3.579; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131; Visser M, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.1.e13; Westerterp KR, 2001, NATURE, V410, P539, DOI 10.1038/35069142	44	95	101	2	24	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					928	934		10.1016/j.jaci.2005.01.033		7	Allergy; Immunology	Allergy; Immunology	925LR	WOS:000229055100005	15867847	
J	Pichavant, M; Charbonnier, AS; Taront, S; Brichet, AB; Wallaert, B; Pestel, J; Tonnel, AB; Gosset, P				Pichavant, M; Charbonnier, AS; Taront, S; Brichet, AB; Wallaert, B; Pestel, J; Tonnel, AB; Gosset, P			Asthmatic bronchial epithelium activated by the proteolytic allergen Der p 1 increases selective dendritic cell recruitment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						epithelial cells; dendritic cells; chemokines; allergy; lung	INFLAMMATORY PROTEIN 3-ALPHA; BRONCHOALVEOLAR LAVAGE FLUID; NECROSIS-FACTOR-ALPHA; ATOPIC ASTHMA; PROINFLAMMATORY CYTOKINES; INTESTINAL EPITHELIUM; RESPIRATORY-TRACT; AIRWAY EPITHELIUM; ANATOMIC SITES; UP-REGULATION	Background: Airway dendritic cells (DCs) are crucial for allergen-induced sensitization and inflammation in allergic asthma. After allergen challenge, an increased number of DCs is observed in airway epithelium from patients with allergy. Objective: Because Der p 1, a cysteine protease allergen from Dermatophagoides pteronyssinus, induces chemokine production by bronchial epithelial cells (BECs), the purpose of this investigation was to evaluate the capacity of BEC exposed to Der p 1 to recruit DCs. Methods: Chemotactic activity of BEAS-2B, a bronchial epithelial cell line, and BECs from nonatopic controls and patients with allergic asthma was evaluated on the migration of precursors, immature and mature monocyte-derived DCs (MDDCs), and CD34(+)-derived Langerhans cells (LCs). Results: C-C chemokine ligand (CCL)-2, CCL5, and C-X-C chemokine ligand 10 production by BEAS-2B and BEC was increased after Der p 1 exposure, whereas the proenzyme proDer p 1 devoid of enzymatic activity had no effect. Der p I stimulation of BEAS-2B and BEC from both groups increased significantly the recruitment of MDDC precursors, depending on CCL2, CCL5, and C-X-C chemokine ligand 10 production. In a reconstituted polarized epithelium, apical application of Der p I enhanced MDDC precursor migration into the epithelial layer. Moreover, Der p 1 stimulation of BEC from patients with asthma but not from controls increased the migration of LC precursors, mainly dependent on CCL20 secretion. No migration of immature and mature DCs was observed. Conclusion: These data confirmed that BECs participate in the homeostasis of the DC network present within the bronchial epithelium through the secretion of chemokines. In allergic asthma, upregulation of CCL20 production induced LC recruitment, the role of which remains to be determined.	Inst Pasteur, INSERM, U416, IFR 17, F-59019 Lille, France	Gosset, P (reprint author), Inst Pasteur, INSERM, U416, IFR 17, 1 Rue Prof Calmette,BP 245, F-59019 Lille, France.	Philippe.Gosset@pasteur-lille.fr					Alam R, 1996, AM J RESP CRIT CARE, V153, P1398; Allam JP, 2003, J ALLERGY CLIN IMMUN, V112, P141, DOI 10.1067/mai.2003.1607; Asokananthan N, 2002, J IMMUNOL, V169, P4572; BELLINI A, 1993, CHEST, V103, P997, DOI 10.1378/chest.103.4.997; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; Caux C, 2000, SPRINGER SEMIN IMMUN, V22, P345, DOI 10.1007/s002810000053; Caux C, 1997, BLOOD, V90, P1458; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Dieu MC, 1998, J EXP MED, V188, P373, DOI 10.1084/jem.188.2.373; Dieu-Nosjean MC, 2000, J EXP MED, V192, P705, DOI 10.1084/jem.192.5.705; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; GOSSET P, 1991, J ALLERGY CLIN IMMUN, V88, P561, DOI 10.1016/0091-6749(91)90149-I; Gosset P, 1999, J ALLERGY CLIN IMMUN, V103, P289, DOI 10.1016/S0091-6749(99)70504-X; Grassi F, 1998, J LEUKOCYTE BIOL, V64, P484; Hammad H, 2002, J IMMUNOL, V169, P1524; Hammad H, 2000, LAB INVEST, V80, P605; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; HOLT PG, 1989, CLIN EXP ALLERGY, V19, P255, DOI 10.1111/j.1365-2222.1989.tb02380.x; Holt PG, 2000, J AEROSOL MED, V13, P361, DOI 10.1089/jam.2000.13.361; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P421, DOI 10.1067/mai.2000.105010; Homey B, 2000, J IMMUNOL, V164, P6621; Izadpanah A, 2001, AM J PHYSIOL-GASTR L, V280, pG710; Jahnsen FL, 2001, THORAX, V56, P823, DOI 10.1136/thorax.56.11.823; Kheradmand F, 2002, J IMMUNOL, V169, P5904; King C, 1998, J IMMUNOL, V161, P3645; Knight DA, 2001, J ALLERGY CLIN IMMUN, V108, P797; Lambrecht BN, 2003, NAT REV IMMUNOL, V3, P994, DOI 10.1038/nri1249; Lanzavecchia A, 2001, CELL, V106, P263, DOI 10.1016/S0092-8674(01)00455-X; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1046/j.1365-2222.1996.d01-337.x; Novak N, 2004, ALLERGY, V59, P5, DOI 10.1046/j.1398-9995.2003.00337.x; Pichavant M, 2003, J IMMUNOL, V171, P6697; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Rozyk KJ, 1997, IMMUNOL LETT, V58, P47; SCHONHEGRAD MA, 1991, J EXP MED, V173, P1345, DOI 10.1084/jem.173.6.1345; Stumbles PA, 2001, J IMMUNOL, V167, P228; Tanaka Y, 1999, EUR J IMMUNOL, V29, P633, DOI 10.1002/(SICI)1521-4141(199902)29:02<633::AID-IMMU633>3.0.CO;2-I; Tillie-Leblond I, 1999, AM J RESP CRIT CARE, V159, P487; Vanbervliet Beatrice, 2002, European Journal of Immunology, V32, P231, DOI 10.1002/1521-4141(200201)32:1<231::AID-IMMU231>3.0.CO;2-8; Vermaelen KY, 2001, J EXP MED, V193, P51; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844	42	95	97	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	APR	2005	115	4					771	778		10.1016/j.jaci.2004.11.043		8	Allergy; Immunology	Allergy; Immunology	916GM	WOS:000228373400016	15805997	
J	Cullinan, P; MacNeill, SJ; Harris, JM; Moffat, S; White, C; Mills, P; Taylor, AJN				Cullinan, P; MacNeill, SJ; Harris, JM; Moffat, S; White, C; Mills, P; Taylor, AJN			Early allergen exposure, skin prick responses, and atopic wheeze at age 5 in English children: a cohort study	THORAX			English	Article							HOUSE-DUST MITE; ASTHMA; SENSITIZATION; CHILDHOOD; ENVIRONMENT; RISK	Background: For many years it has been assumed that the risk of childhood respiratory allergies is related to allergen exposures in early life. There are, however, few prospective data in support. We aimed to examine this relationship in a representative cohort of children born in Ashford, Kent (UK). Methods: 625 children (94% of those eligible) were followed from birth to the age of 5.5 years at which time 552 underwent skin prick testing to extracts of house dust mite and cat fur allergens. Maternal reports of wheeze in the last year were collected by interview. These outcomes were related to individual domestic concentrations of Der p 1 and Fel d I allergens estimated from dust collection at the age of 8 weeks. Results: 10% of children were sensitised to house dust mite or cat at age 5.5 years; 7% had atopic wheeze. No significant relationships between allergen exposure and either sensitisation or wheeze were found but, on examination, the exposure-response relationships for both allergens and for each outcome rose steeply at low levels of exposure and were attenuated at high levels of exposure. These patterns were modified by paternal atopy and by birth order. Conclusions: There are no linear relationships between early allergen exposure and the induction of childhood respiratory allergy; rather, the risks of IgE sensitisation and asthma rise at very low levels of exposure and are attenuated thereafter. These patterns are influenced by parental atopy and birth order. These findings suggest important gene-environment interactions in the development of atopy and asthma and imply that reductions in domestic allergen exposure alone are unlikely to have a major impact in decreasing the incidence of these diseases in childhood.	Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Occupat & Environm Med, London SW3 6LR, England	Cullinan, P (reprint author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dept Occupat & Environm Med, Manresa Rd, London SW3 6LR, England.	p.cullinan@ic.ac.uk					Atkinson W, 1999, EUR RESPIR J, V13, P583, DOI 10.1183/09031936.99.13358599; CHECKOWAY H, 1989, RES METHODS OCCUPATI, P244; Cullinan P, 1999, EUR RESPIR J, V13, P1139, DOI 10.1034/j.1399-3003.1999.13e33.x; Heinrich J, 2003, J EXPO ANAL ENV EPID, V13, P152, DOI 10.1038/sj.jea.7500267; KALRA S, 1992, THORAX, V47, P928, DOI 10.1136/thx.47.11.928; KUEHR J, 1994, CLIN EXP ALLERGY, V24, P229, DOI 10.1111/j.1365-2222.1994.tb00224.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stayner L, 2003, SCAND J WORK ENV HEA, V29, P317; Sunyer J, 2001, CLIN EXP ALLERGY, V31, P1352, DOI 10.1046/j.1365-2222.2001.01187.x; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	15	95	100	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	OCT	2004	59	10					855	861		10.1136/thx.2003.019877		7	Respiratory System	Respiratory System	858FC	WOS:000224175200009	15454651	
J	Gruber, A; Mancek, M; Wagner, H; Kirschning, CJ; Jerala, R				Gruber, A; Mancek, M; Wagner, H; Kirschning, CJ; Jerala, R			Structural model of MD-2 and functional role of its basic amino acid clusters involved in cellular lipopolysaccharide recognition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-4; DUST-MITE ALLERGEN; SIGNAL-TRANSDUCTION; CRYSTAL-STRUCTURE; GM2-ACTIVATOR PROTEIN; TERTIARY STRUCTURE; INNATE IMMUNITY; DISULFIDE BONDS; RESPONSIVENESS; COMPLEX	The receptor complex resulting from association of MD-2 and the ectodomain of Toll-like receptor 4 (TLR4) mediates lipopolysaccharide (LPS) signal transduction across the cell membrane. We prepared a tertiary structure model of MD-2, based on the known structures of homologous lipid-binding proteins. Analysis of circular dichroic spectra of purified bacterially expressed MD-2 indicates high content of beta-type secondary structure, in agreement with the structural model. Bacterially expressed MD-2 was able to confer LPS responsiveness to cells expressing TLR4 despite lacking glycosylation. We identified several clusters of basic residues on the surface of MD-2. Mutation of each of two clusters encompassing the residues Lys(89)-Arg(90)-Lys(91) and Lys(125)-Lys(125) significantly decreased the signal transduction of the respective MD-2 mutants either upon co-expression with TLR4 or upon addition as soluble protein into the supernatant of cells overexpressing TLR4. These basic clusters lie at the edge of the beta-sheet sandwich, which in cholesterol-binding protein connected to Niemann-Pick disease C2 (NPC2), dust mite allergen Der p2, and ganglioside GM2-activator protein form a hydrophobic pocket. In contrast, mutation of another basic cluster composed of Arg(69)-Lys(72), which according to the model lies further apart from the hydrophobic pocket only weakly decreased MD-2 activity. Furthermore, addition of the peptide, comprising the surface loop between Cys(95) and Cys(105), predicted by model, particularly in oxidized form, decreased LPS-induced production of tumor necrosis factor alpha and interleukin-8 upon application to monocytic cells and fibroblasts, respectively, supporting its involvement in LPS signaling. Our structural model of MD-2 is corroborated by biochemical analysis and contributes to the unraveling of molecular interactions in LPS recognition.	Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia; Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany	Jerala, R (reprint author), Natl Inst Chem, Biotechnol Lab, Ljubljana 1000, Slovenia.	roman.jerala@ki.si		Jerala, Roman/0000-0002-6337-5251			Akashi S, 2003, J EXP MED, V198, P1035, DOI 10.1084/jem.20031076; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Andreeva A, 2004, NUCLEIC ACIDS RES, V32, pD226, DOI 10.1093/nar/gkh039; da Silva CJ, 2002, J BIOL CHEM, V277, P1845, DOI DOI 10.1074/JBC.M109910200; Derewenda U, 2002, J MOL BIOL, V318, P189, DOI 10.0000/S0022-2836(02)00027-X; Ferguson AD, 1998, SCIENCE, V282, P2215, DOI 10.1126/science.282.5397.2215; Ferguson AD, 2000, STRUCT FOLD DES, V8, P585; Fiser A, 2003, BIOINFORMATICS, V19, P2500, DOI 10.1093/bioinformatics/btg362; Frecer V, 2000, EUR J BIOCHEM, V267, P837, DOI 10.1046/j.1432-1327.2000.01069.x; Friedland N, 2003, P NATL ACAD SCI USA, V100, P2512, DOI 10.1073/pnas.0437840100; Ginalski K, 2003, PROTEINS, V53, P410, DOI 10.1002/prot.10548; Gioannini TL, 2004, P NATL ACAD SCI USA, V101, P4186, DOI 10.1073/pnas.0306906101; Guyard-Dangremont V, 1999, PROTEIN SCI, V8, P2392; Inohara N, 2002, TRENDS BIOCHEM SCI, V27, P219, DOI 10.1016/S0968-0004(02)02084-4; Kawasaki K, 2003, J IMMUNOL, V170, P413; Kawasaki K, 2000, J BIOL CHEM, V275, P2251, DOI 10.1074/jbc.275.4.2251; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Latz E, 2002, J BIOL CHEM, V277, P47834, DOI 10.1074/jbc.M207873200; Lee HK, 2004, J BIOL CHEM, V279, P10564, DOI 10.1074/jbc.M311564200; Mancek M, 2002, BIOCHEM BIOPH RES CO, V292, P880, DOI 10.1006/bbrc.2002.6748; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Meng GX, 2003, J BIOL CHEM, V278, P39822, DOI 10.1074/jbc.M304766200; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mullen GED, 2003, P NATL ACAD SCI USA, V100, P3919, DOI 10.1073/pnas.0630495100; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Ohnishi T, 2003, CLIN DIAGN LAB IMMUN, V10, P405, DOI 10.1128/CDLI.10.3.405-410.2003; Ohnishi T, 2001, J IMMUNOL, V167, P3354; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pristovsek P, 1999, J MED CHEM, V42, P4604, DOI 10.1021/jm991031b; Re F, 2003, J IMMUNOL, V171, P5272; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rost B, 2003, NUCLEIC ACIDS RES, V31, P3300, DOI 10.1093/nar/gkg508; SALI A, 1995, PROTEINS, V23, P318, DOI 10.1002/prot.340230306; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schubert WD, 2001, J MOL BIOL, V312, P783, DOI 10.1006/jmbi.2001.4989; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THANNHAUSER TW, 1984, ANAL BIOCHEM, V138, P181, DOI 10.1016/0003-2697(84)90786-3; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; Visintin A, 2003, J BIOL CHEM, V278, P48313, DOI 10.1074/jbc.M306802200; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Wright CS, 2003, J MOL BIOL, V331, P951, DOI 10.1016/S0022-2836(03)00794-0; Wright CS, 2000, J MOL BIOL, V304, P411, DOI 10.1006/jmbi.2000.4225; ZHANG KYJ, 1994, PROTEIN SCI, V3, P687	47	95	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 2	2004	279	27					28475	28482		10.1074/jbc.M400993200		8	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	832KC	WOS:000222265400082	15111623	
J	Jaakkola, JJK; Parise, H; Kislitsin, V; Lebedeva, NI; Spengler, JD				Jaakkola, JJK; Parise, H; Kislitsin, V; Lebedeva, NI; Spengler, JD			Asthma, wheezing, and allergies in Russian schoolchildren in relation to new surface materials in the home	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							YOUNG-CHILDREN; SYMPTOMS; HEALTH	In a cross-sectional study of 5951 Russian 8-12-year-old schoolchildren, risks of current asthma, wheezing, and allergy were related to recent renovation and the installation of materials with potential chemical emissions. New linoleum flooring, synthetic carpeting, particleboard, wall coverings, and furniture and recent painting were determinants of 1 or several of these 3 health outcomes. These findings warrant further attention to the type of materials used in interior design.	Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England; Univ Helsinki, Dept Publ Hlth, Helsinki, Finland; Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; Ctr Preparat & Implementat Int Tech Assistance Pr, Moscow, Russia; Harvard Univ, Sch Publ Hlth, Environm Sci & Engn Program, Boston, MA 02115 USA	Jaakkola, JJK (reprint author), Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England.	j.jaakkola@bham.ac.uk	Jaakkola, Jouni/G-4314-2012				FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2000, ENVIRON HEALTH PERSP, V108, P589, DOI 10.2307/3434876; Mastrangelo G, 1995, Med Lav, V86, P503; Spengler JD, 2004, AM J PUBLIC HEALTH, V94, P657, DOI 10.2105/AJPH.94.4.657; Ucgun I, 1998, ALLERGY, V53, P1096, DOI 10.1111/j.1398-9995.1998.tb03822.x; WIESLANDER G, 1994, INT ARCH OCC ENV HEA, V66, P261, DOI 10.1007/BF00454365	9	95	101	0	9	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	APR	2004	94	4					560	562		10.2105/AJPH.94.4.560		3	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	807IC	WOS:000220494200016	15054004	
J	Mueller-Anneling, L; Avol, E; Peters, JM; Thorne, PS				Mueller-Anneling, L; Avol, E; Peters, JM; Thorne, PS			Ambient endotoxin concentrations in PM10 from Southern California	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; bioaerosol; endotoxin; lipopolysaccharide; particulate matter	PARTICULATE AIR-POLLUTION; LUNG-FUNCTION GROWTH; ALVEOLAR MACROPHAGE RESPONSES; IN-HOUSE DUST; AIRBORNE ENDOTOXIN; DAILY MORTALITY; INSOLUBLE COMPONENTS; EXPOSURE-RESPONSE; INHALED ENDOTOXIN; COARSE PARTICLES	Concentrations of endotoxin in urban air pollution have not previously been extensively characterized. We measured 24-hr levels of PM10 (particulate matter < 10 mum in aerodynamic diameter) and the associated endotoxin component once every 6 weeks for 1 year in 13 communities in Southern California. All the samples collected had detectable PM10 and endotoxin levels. The geometric mean PM10 was 34.6 mug/m(3) [geometric SD (GSD), 2.1; range, 3.0-135]. By volume, the endotoxin geometric mean was 0.44 endotoxin units (EU)/m(3) (GSD, 3.1; range, 0.03-5.44). Per unit material collected, the geometric mean of endotoxin collected was 13.6 EU/mg (GSD, 3.2; range, 0.7-96.8). No correlation was found between endotoxin concentrations and other ambient pollutants concurrently measured [ozone, nitrogen dioxide, total acids, or PM2.5 (particulate matter < 2.5 put in aerodynamic diameter]. PM10 and endotoxin concentrations were significantly correlated, most strongly in summer. Samples collected in more rural and agricultural areas had lower PM10 and mid-range endotoxin levels. The high desert and mountain communities had lower PM10 levels but endotoxin levels comparable with or higher than the rural agricultural sites. By volume, endotoxin levels were highest at sites downwind of Los Angeles, California, which were also the locations of highest PM10. Endotoxin concentrations measured in this study were all < 5.5 EU/m(3), which is lower than recognized thresholds for acute adverse health effects for occupational exposures but in the same range as indoor household concentrations. This study provides the first extensive characterization of endotoxin concentration across a large metropolitan area in relation to PM10 and other pollutant monitoring, and supports the need for studies of the role of endotoxin in childhood asthma in urban settings.	Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, Iowa City, IA 52242 USA; Univ So Calif, Dept Prevent Med, Los Angeles, CA USA	Thorne, PS (reprint author), Univ Iowa, Coll Publ Hlth, Dept Occupat & Environm Hlth, 100 Oakdale Campus,IREH, Iowa City, IA 52242 USA.	peter-thorne@uiowa.edu			NIEHS NIH HHS [P30 ES 007048, P30 ES 05605]		Bonner JC, 1998, AM J RESP CELL MOL, V19, P672; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; CLAPP WD, 1994, AM J RESP CRIT CARE, V150, P611; Dockery DW, 2001, ENVIRON HEALTH PERSP, V109, P483, DOI 10.2307/3454657; Donaldson K, 2001, INT J HYG ENVIR HEAL, V203, P411, DOI 10.1078/1438-4639-00059; DONHAM K, 1989, BRIT J IND MED, V46, P31; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 2003, ANN OCCUP HYG, V47, P187, DOI 10.1093/annhyg/meg032; Douwes J, 2002, THORAX, V57, P86, DOI 10.1136/thorax.57.1.86; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1997, INT J OCCUP ENV HL S, V3, pS26; DOUWES J, 2003, MODERN IND HYGIENE, V2, P219; Fairley D, 1999, ENVIRON HEALTH PERSP, V107, P637, DOI 10.2307/3434455; Gauderman WJ, 2000, AM J RESP CRIT CARE, V162, P1383; Gauderman WJ, 2002, AM J RESP CRIT CARE, V166, P76, DOI 10.1164/rccm.2111021; HEEDERIK D, 2003, MODERN IND HYGIENE, V2, P293; Heinrich J, 2001, CLIN EXP ALLERGY, V31, P1839, DOI 10.1046/j.1365-2222.2001.01220.x; Imrich A, 1999, TOXICOL APPL PHARM, V159, P117, DOI 10.1006/taap.1999.8731; Imrich A, 2000, TOXICOL APPL PHARM, V167, P140, DOI 10.1006/taap.2000.9002; Jagielo PJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1052; Jedrychowski W, 1999, ENVIRON HEALTH PERSP, V107, P669, DOI 10.2307/3434460; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Li XY, 1997, ENVIRON HEALTH PERSP, V105, P1279, DOI 10.2307/3433547; Lippmann M, 2000, ANNU REV PUBL HEALTH, V21, P309, DOI 10.1146/annurev.publhealth.21.1.309; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; Menetrez MY, 2001, J AIR WASTE MANAGE, V51, P1436, DOI 10.1080/10473289.2001.10464365; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.0.CO;2-V; Monn C, 1999, TOXICOL APPL PHARM, V155, P245, DOI 10.1006/taap.1998.8591; Ning YY, 2000, J TOXICOL ENV HEAL A, V59, P165, DOI 10.1080/009841000156952; Ostro BD, 1999, ENVIRON RES, V81, P231, DOI 10.1006/enrs.1999.3978; Ostro BD, 2000, J EXPO ANAL ENV EPID, V10, P412, DOI 10.1038/sj.jea.7500094; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; Plopper CG, 2000, ENVIRON HEALTH PERSP, V108, pA252, DOI 10.1289/ehp.108-a252; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; Pope CA, 1999, ENVIRON HEALTH PERSP, V107, P613, DOI 10.2307/3434450; POPE CA, 1995, ENVIRON HEALTH PERSP, V103, P472, DOI 10.2307/3432586; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; Rylander R., 1997, INT J OCCUP ENV HL S, V3, P32; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; Soukup JM, 2001, TOXICOL APPL PHARM, V171, P20, DOI 10.1006/taap.2000.9096; Thorne PS, 2000, TOXICOLOGY, V152, P13, DOI 10.1016/S0300-483X(00)00287-0; THORNE PS, 2003, AM J RESP CRIT CARE, V167, pA470; THORNE PS, 2001, AM J RESP CRIT CARE, V163, pA844; THORNE PS, 2003, AM J RESP CRIT CARE, V167, pA972; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Zock JP, 1998, AM J IND MED, V33, P384, DOI 10.1002/(SICI)1097-0274(199804)33:4<384::AID-AJIM9>3.0.CO;2-U	54	95	96	3	21	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2004	112	5					583	588		10.1289/ehp.6552		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	811KI	WOS:000220770400046	15064165	
J	Green, BJ; Mitakakis, TZ; Tovey, ER				Green, BJ; Mitakakis, TZ; Tovey, ER			Allergen detection from 11 fungal species before and after germination	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; fungi; germination; halogen; immunoassay	ASP-F-I; ASPERGILLUS-FUMIGATUS; ALTERNARIA-ALTERNATA; BINDING PROTEIN; DIFFERENT MEDIA; MAJOR ALLERGEN; IGE ANTIBODIES; RISK FACTOR; EXPRESSION; ASTHMA	Background: Allergens dispersed by airborne fungal spores play an important but poorly understood role in the underlying cause and exacerbation of asthma. Previous studies suggest that spores of Alternaria and Aspergillus release greater quantities of allergen after germination than before germination. It is unknown whether this is true of other allergenic fungi. Objective: Our purpose was to investigate the release of allergen from a range of individual fungal-spores before and after germination. Methods: Allergen expression from spores of Alternaria alternata, Cladosporium herbarum, Aspergillius fumigatus, Botrytis cinerea, Epicoccum nigrum, Exserohilum rostralum, Penicillium chrysogenum, Stemphylium botryosum, Curvularia lunata, Trichoderma viride, and Bipolaris spicifera was examined by halogen immunoassays through the use of pooled serum IgE from patients allergic to fungus. Spores were deposited onto proteinbinding membranes direct, from culture. To germinate spores, samples were incubated in high humidity at room temperature for 48 hours. Ungerminated and germinated samples were then laminated with an adhesive film and immunostained by the halogen assay. The samples were examined by light microscopy, and positive counts (haloed particles) were expressed as percentages of total spores. Results: For 9 of 11 species, between 5.7% and 92% of spores released allergen before germination. Spores of Penicillium and Trichodemia did not release detectable allergen. After germination, all spores that germinated had allergen elution from their hyphae. Eight of I I species showed a significant increase (P <.05) in the percentage of spores eluting detectable allergen. Localization of allergen along the hyphae varied with species, such that some eluted allergen mainly from hyphal tips and septal junctions whereas others eluted allergen along the entire length. Conclusions: Increased elution of allergen after germination might be a common feature of many species of allergenic fungi. Although allergens from both spores and hyphae were recognized by human IgE, the extent to which human exposure occurs to allergens eluted from inhaled spores or from hyphae that germinate after deposition in the respiratory tract remains to be explored. The patterns of allergen expression might affect the clinical response to such exposure. (J Allergy Clin Immunol 2003;111:285-9.).	Univ Sydney, Fac Med, Woolcock Allergen Unit, Sydney, NSW 2006, Australia; Royal Prince Alfred Hosp, Woolcock Inst Med Res, Sydney, NSW, Australia	Green, BJ (reprint author), Univ Sydney, Fac Med, Woolcock Allergen Unit, Room 461,Blackburn Bldg D06, Sydney, NSW 2006, Australia.		Tovey, Euan/G-8604-2017	Tovey, Euan/0000-0002-1802-7266			Achatz G, 1996, ADV EXP MED BIOL, V409, P157; AMITANI R, 1995, INFECT IMMUN, V63, P3266; ARRUDA LK, 1990, J EXP MED, V172, P1529, DOI 10.1084/jem.172.5.1529; ARRUDA LK, 1992, J IMMUNOL, V149, P3354; AUKRUST L, 1985, Allergy (Copenhagen), V40, P43, DOI 10.1111/j.1398-9995.1985.tb04298.x; Bisht V, 2000, ALLERGY, V55, P274, DOI 10.1034/j.1398-9995.2000.00371.x; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; Breitenbach M, 2002, CHEM IMMUNOL, V81, P48; Bush R., 2001, J ALLERGY CLIN IMMUN, V107, P430, DOI 10.1067/mai.2001.113669; Cody DT, 1997, LARYNGOSCOPE, V107, P1511, DOI 10.1097/00005537-199711000-00016; Crameri R, 2002, CHEM IMMUNOL, V81, P73; DeVouge MW, 1996, INT ARCH ALLERGY IMM, V111, P385; Downs SH, 2001, AM J RESP CRIT CARE, V164, P455; EINARSSON R, 1992, CLIN REV ALLERG, V10, P165; Gupta R, 1999, J ALLERGY CLIN IMMUN, V104, P857; HOFFMAN DR, 1981, ANN ALLERGY, V46, P310; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; KARLSSONBORGA A, 1989, ANN ALLERGY, V63, P521; LAKE FR, 1991, AUST NZ J MED, V21, P871, DOI 10.1111/j.1445-5994.1991.tb01410.x; MIAKAKIS TZ, 2002, IN PRESS GRANA; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; Neukirch C, 1999, J ALLERGY CLIN IMMUN, V103, P709, DOI 10.1016/S0091-6749(99)70247-2; NOBLE WC, 1963, J GEN MICROBIOL, V32, P397; NOBLE WC, 1967, AIRBORNE MICROBES, P81; PARIS S, 1990, INT ARCH ALLER A IMM, V92, P1; REIJULA KE, 1991, J ALLERGY CLIN IMMUN, V87, P683, DOI 10.1016/0091-6749(91)90389-6; Shen HD, 2001, CLIN EXP ALLERGY, V31, P295, DOI 10.1046/j.1365-2222.2001.01026.x; SPORIK RB, 1993, CLIN EXP ALLERGY, V23, P326, DOI 10.1111/j.1365-2222.1993.tb00330.x; Supajatura V, 2002, J CLIN INVEST, V109, P1351, DOI 10.1172/JCI200214704; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tomee JFC, 2000, CLIN EXP ALLERGY, V30, P476, DOI 10.1046/j.1365-2222.2000.00796.x; Tovey E.R., 1989, Advances in the Biosciences, V74, P33; Tronchin G, 1997, INFECT IMMUN, V65, P9; Wang JE, 2001, INFECT IMMUN, V69, P2402, DOI 10.1128/IAI.69.4.2402-2406.2001; Yang Z, 2000, THORAX, V55, P579, DOI 10.1136/thorax.55.7.579; ZHANG L, 1995, J IMMUNOL, V154, P710	36	95	98	5	15	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2003	111	2					285	289		10.1067/mai.2003.57		5	Allergy; Immunology	Allergy; Immunology	644WF	WOS:000180942700010	12589346	
J	Allmers, H; Schmengler, J; Skudlik, C				Allmers, H; Schmengler, J; Skudlik, C			Primary prevention of natural rubber latex allergy in the German health care system through education and intervention	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						occupational asthma; natural rubber latex allergy; powder free latex gloves; latex allergens; primary prevention	IGE ANTIBODIES; GLOVES; SENSITIZATION; PREVALENCE; WORKERS; NURSES	Background: The development of occupational asthma and allergic skin reactions caused by natural rubber latex (NRL) allergy are risks for health care workers. There are few published studies to suggest that intervention programs to reduce exposure will lead to primary prevention of sensitization. Objective: This study assesses the effects of intervention to reduce the incidence of NRL allergy in personnel working in health care facilities insured by the German statutory accident insurance company for health care workers, Berufsgenossenschaft fur Gesundheitsdienst und Wohlfahrtspflege, with approximately 3 million insured employees, by switching to powder-free NRL gloves. Methods: The timing of introduction of intervention strategies, such as education of both physicians and administrators, together with regulations demanding that health care facilities only purchase low-protein, powder-free NRL gloves are reported. We reviewed the annual numbers of reported suspected cases of NRL-caused occupational allergies and the amount and type of gloves used in German acute-care hospitals since 1986. Results: The purchase of powder-free NRL examination gloves exceeded that of powdered gloves for the first time in 1998. This only became true for powder-free NRL sterile gloves 2 years later in 2000. The incidence of suspected occupational NRL allergy cases rose until 1998 and has declined steadily since. There was a 2-year lag between the beginning of the decline in the purchase of powdered NRL examination gloves and the beginning of a decline in suspected NRL-caused occupational asthma cases. Conclusions: Despite the effect of increased recognition of NRL allergies, education about NRL allergies in health care facilities combined with the introduction of powder-free gloves with reduced protein levels has been associated with a decline in the number of suspected cases of occupational allergies caused by NRL in Germany on a nationwide scale. These results clearly indicate that primary prevention of occupational NRL allergies can be achieved if these straightforward and practical interventions are properly carried out and maintained.	Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, D-49090 Osnabruck, Germany; Harvard Sch Publ Hlth, Boston, MA USA; Berufsgenossenschaft & Gesundheitsdienst & Wohlfa, Delmenhorst, Germany	Allmers, H (reprint author), Univ Osnabruck, Dept Dermatol Environm Med & Hlth Sci, Sedanstr 115, D-49090 Osnabruck, Germany.						Allmers H, 1997, DEUT MED WOCHENSCHR, V122, P1308, DOI 10.1055/s-2008-1047764; Allmers H, 1998, J ALLERGY CLIN IMMUN, V102, P841, DOI 10.1016/S0091-6749(98)70026-0; Allmers H, 1996, DEUT MED WOCHENSCHR, V121, P823, DOI 10.1055/s-2008-1043073; ARELLANO R, 1992, ANESTHESIOLOGY, V77, P905, DOI 10.1097/00000542-199211000-00011; Baur X, 1998, J ALLERGY CLIN IMMUN, V101, P24, DOI 10.1016/S0091-6749(98)70188-5; Baur X, 1996, ANAESTHESIST, V45, P653, DOI 10.1007/s001010050299; Grzybowski M, 1996, J ALLERGY CLIN IMMUN, V98, P535, DOI 10.1016/S0091-6749(96)70087-8; HAAMANN F, 2001, ERFOLGREICHE PRAVENT; KELLY KJ, 1993, J ALLERGY CLIN IMMUN, V91, P1140, DOI 10.1016/0091-6749(93)90316-8; LAGIER F, 1992, J ALLERGY CLIN IMMUN, V90, P319, DOI 10.1016/S0091-6749(05)80009-0; Levy DA, 1999, JAMA-J AM MED ASSOC, V281, P988, DOI 10.1001/jama.281.11.988; Liss GM, 2001, AM J IND MED, V40, P347, DOI 10.1002/ajim.1108; Liss GM, 1997, OCCUP ENVIRON MED, V54, P335; Roy A, 1997, J Can Dent Assoc, V63, P297; SAARY J, 2001, AM J RESP CRIT CARE, V163, pA809; Shoup A J, 1997, AORN J, V66, P729, DOI 10.1016/S0001-2092(06)62931-1; Shoup AJ, 1997, AORN J, V66, P729; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V102, P333; TARLO SM, 1994, J ALLERGY CLIN IMMUN, V93, P985, DOI 10.1016/S0091-6749(94)70045-1; Tarlo SM, 2001, J ALLERGY CLIN IMMUN, V108, P628; TUJANMAA K, 2000, J ALLERGY CLIN IMMUN, V104; TURJANMAA K, 1987, CONTACT DERMATITIS, V17, P270, DOI 10.1111/j.1600-0536.1987.tb01476.x; WITT S, 1999, TECHNICAL INFORMATIO; YASSIN MS, 1994, ANN ALLERGY, V85, P626	24	95	98	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2002	110	2					318	323	UNSP 1/87/126461	10.1067/mai.2002.126461		6	Allergy; Immunology	Allergy; Immunology	585DY	WOS:000177509800019	12170275	
J	Koopman, LP; van Strien, RT; Kerkhof, M; Wijga, A; Smit, HA; de Jongste, JC; Gerritsen, J; Aalberse, RC; Brunekreef, B; Neijens, HJ				Koopman, LP; van Strien, RT; Kerkhof, M; Wijga, A; Smit, HA; de Jongste, JC; Gerritsen, J; Aalberse, RC; Brunekreef, B; Neijens, HJ		Prevention Incidence Asthma Mite	Placebo-controlled trial of house dust mite-impermeable mattress covers - Effect on symptoms in early childhood	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						mite control; wheezing; asthma; atopy; allergens	DER-P-I; RESPIRATORY SYMPTOMS; ALLERGEN EXPOSURE; EARLY-LIFE; HIGH-RISK; ASTHMA; INFANTS; IGE; SENSITIZATION; SENSITIVITY	We investigated the effect of house dust mite (HDM)-allergen avoidance on the development of respiratory Symptoms, atopic dermatitis, and atopic sensitization by performing a double blind, placebo-controlled trial. In total, 1,282 allergic pregnant women were selected (416 received HDM allergen-impermeable mattress covers for the parents' and child's mattress in the third trimester of pregnancy [active], 394 received placebo covers, 472 received no intervention). Data on allergen exposure, clinical symptoms, and immunoglobulin E were collected prospectively. The prevalence of night cough without a cold in the second year of life was lower in the group with active covers compared with the group with placebo covers (adjusted odds ratio 0.65; 95% confidence interval 0.4-1.0). No effect of the intervention was seen on other respiratory symptoms, atopic dermatitis, and total and specific immunoglobulin E. It can be concluded that application of HDM-impermeable mattress covers on the child's and parents' beds reduced night cough, but not other respiratory symptoms, atopic dermatitis, and atopic sensitization in the first 2 years of life. Follow-up will determine the long-term effect of the intervention on the development of atopic disease.	Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat, NL-3000 CB Rotterdam, Netherlands; Univ Utrecht, Inst Risk Assessment, Dept Environm & Occupat Hlth, Utrecht, Netherlands; Univ Groningen, Dept Epidemiol & Stat, Groningen, Netherlands; Natl Inst Publ Hlth & Environm, Dept Chron Dis Epidemiol, Groningen, Netherlands; Univ Groningen, Beatrix Childrens Hosp, Dept Pediat Pulmonol, Groningen, Netherlands; Blood Transfus Serv, Cent Lab, Amsterdam, Netherlands	Neijens, HJ (reprint author), Erasmus Univ, Sophia Childrens Hosp, Med Ctr, Dept Pediat, POB 2060, NL-3000 CB Rotterdam, Netherlands.		Kerkhof, Marjan/A-8846-2008	brunekreef, bert/0000-0001-9908-0060			ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BURR ML, 1989, J EPIDEMIOL COMMUN H, V43, P125, DOI 10.1136/jech.43.2.125; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Koopman LP, 2001, PEDIATR ALLERGY IMMU, V12, P118, DOI 10.1034/j.1399-3038.2001.012003118.x; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Moher D, 2001, BMC Med Res Methodol, V1, P2, DOI 10.1186/1471-2288-1-2; Nishioka K, 1998, J ALLERGY CLIN IMMUN, V101, P28, DOI 10.1016/S0091-6749(98)70189-7; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; PEAT JK, 1994, AUST NZ J MED, V24, P270, DOI 10.1111/j.1445-5994.1994.tb02171.x; PEAT JK, 1991, CLIN EXP ALLERGY, V21, P573, DOI 10.1111/j.1365-2222.1991.tb00849.x; PLATTSMILLS TAE, 1995, J ALLERGY CLIN IMMUN, V96, P435, DOI 10.1016/S0091-6749(95)70284-9; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STALLMAN PJ, 1977, INT ARCH ALLER A IMM, V54, P443; vanStrien RT, 1995, CLIN EXP ALLERGY, V25, P1184; vanStrien RT, 1996, EUR RESPIR J, V9, P926, DOI 10.1183/09031936.96.09050926; VANSTRIEN RT, 1994, CLIN EXP ALLERGY, V24, P853; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x	28	95	97	0	5	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2002	166	3					307	313		10.1164/rccm.2106026		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	580QV	WOS:000177246000012	12153962	
J	Giguere, S; Viel, L; Lee, E; MacKay, EJ; Hernandez, J; Franchini, M				Giguere, S; Viel, L; Lee, E; MacKay, EJ; Hernandez, J; Franchini, M			Cytokine induction in pulmonary airways of horses with heaves and effect of therapy with inhaled fluticasone propionate	VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY			English	Article						cytokine; chemokine; heaves; COPD; horse; fluticasone	BRONCHOALVEOLAR LAVAGE FLUID; NF-KAPPA-B; OBSTRUCTION HEAVES; BRONCHIAL HYPERRESPONSIVENESS; PHENOTYPIC ANALYSIS; STRAW CHALLENGES; PERIPHERAL-BLOOD; ATOPIC ASTHMA; ANIMAL-MODEL; NATURAL HAY	Work in humans and laboratory animals has identified a central role for cytokines and chemokines in development and persistence of lower airway inflammation. The objectives of this study were to determine interleukin (IL)-1beta, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha induction in bronchoalveolar lavage (BAL) of control horses and horses with heaves both during remission and exacerbation of the disease, and to determine the effect of therapy with inhaled fluticasone propionate on the cytokine profile of horses with heaves. IL-1beta and TNF-alpha mRNA expression was significantly higher in horses with heaves after exposure to moldy hay compared to either values obtained during clinical remission or to healthy controls. IL-8 mRNA expression and protein concentrations were significantly higher in horses with heaves than in controls. Both IL-4 and IFN-gamma mRNA expression was increased at various times in heaves-susceptible horses compared to controls. IL-2, IL-5 and IL-10 mRNA expression was not detected in BAL cells of either group. Therapy with inhaled fluticasone propionate after induction of a severe heaves exacerbation resulted in complete resolution of clinical signs, normalization of pulmonary function tests, and significant decrease in BAL neutrophilia. This was associated with a significant decrease in IL-4 mRNA expression and increase in IFN-gamma/IL-4 ratio in horses with heaves. These results demonstrate the clinical efficacy of inhaled fluticasone propionate for the treatment of heaves and suggest a role for cytokines in the development of lower airway inflammation in heaves-susceptible horses. (C) 2002 Elsevier Science B.V. All rights reserved.	Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA; Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada; Univ Zurich, Inst Virol, Fac Vet, CH-8057 Zurich, Switzerland	Giguere, S (reprint author), Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, POB 100136, Gainesville, FL 32610 USA.						Baeuerle PA, 1997, ADV IMMUNOL, V65, P111, DOI 10.1016/S0065-2776(08)60742-7; Barnes PJ, 1996, J ALLERGY CLIN IMMUN, V97, P159, DOI 10.1016/S0091-6749(96)80216-8; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Bureau F, 2000, J IMMUNOL, V165, P5822; Bureau F, 2000, AM J RESP CRIT CARE, V161, P1314; CARGILE JL, 1995, AM J VET RES, V56, P1445; Chung KF, 1999, THORAX, V54, P825; Cohn L, 2000, PHARMACOL THERAPEUT, V88, P187, DOI 10.1016/S0163-7258(00)00091-7; Franchini M, 2000, AM J VET RES, V61, P1369, DOI 10.2460/ajvr.2000.61.1369; Giguere S, 1999, VET IMMUNOL IMMUNOP, V67, P1, DOI 10.1016/S0165-2427(98)00212-8; GRAY PR, 1989, AM REV RESPIR DIS, V140, P154; Hare JE, 1999, AM J VET RES, V60, P841; Horohov DW, 2000, VET CLIN N AM-EQUINE, V16, P1; KIPS JC, 1992, AM REV RESPIR DIS, V145, P332; Kleiber C, 1999, J VET MED A, V46, P177, DOI 10.1046/j.1439-0442.1999.00210.x; MACKAY RJ, 1991, AM J VET RES, V52, P533; MACKAY RJ, 1992, AM J VET RES, V53, P1258; MCGORUM BC, 1993, VET IMMUNOL IMMUNOP, V36, P223, DOI 10.1016/0165-2427(93)90021-U; MCGORUM BC, 1993, VET IMMUNOL IMMUNOP, V36, P207, DOI 10.1016/0165-2427(93)90020-5; Mosmann TR, 1996, IMMUNOL TODAY, V17, P138, DOI 10.1016/0167-5699(96)80606-2; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; PETSCHE VM, 1994, AM J VET RES, V55, P885; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Riffo-Vasquez Y, 2000, INT J BIOCHEM CELL B, V32, P833, DOI 10.1016/S1357-2725(00)00029-7; ROBINSON D, 1993, AM REV RESPIR DIS, V148, P401; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Robinson NE, 1996, BRIT VET J, V152, P283, DOI 10.1016/S0007-1935(96)80101-1; Tesarowski DB, 1996, AM J VET RES, V57, P1214; TOSI MF, 1992, AM J RESP CELL MOL, V7, P214; TSUKAGOSHI H, 1994, J ALLERGY CLIN IMMUN, V93, P464, DOI 10.1016/0091-6749(94)90355-7; VIEL L, 1985, HIPPIATRIKA S, P41; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; WATSON ED, 1992, EQUINE VET J, V24, P379; Watson JL, 1997, VET PATHOL, V34, P108; Willoughby R A, 1979, Vet Clin North Am Large Anim Pract, V1, P171; YING S, 1991, Clinical and Experimental Allergy, V21, P745, DOI 10.1111/j.1365-2222.1991.tb03205.x	38	95	95	0	10	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-2427			VET IMMUNOL IMMUNOP	Vet. Immunol. Immunopathol.	MAR	2002	85	3-4					147	158	PII S0165-2427(01)00420-2	10.1016/S0165-2427(01)00420-2		12	Immunology; Veterinary Sciences	Immunology; Veterinary Sciences	551HW	WOS:000175555500004	11943316	
J	Douwes, J; Pearce, N; Heederik, D				Douwes, J; Pearce, N; Heederik, D			Does environmental endotoxin exposure prevent asthma?	THORAX			English	Review							ANIMAL FEED-INDUSTRY; LUNG-FUNCTION CHANGES; IN-HOUSE DUST; INFLAMMATORY RESPONSE; HAY-FEVER; AIRBORNE ENDOTOXIN; INHALED ENDOTOXIN; ALLERGIC SENSITIZATION; RESPIRATORY SYMPTOMS; BRONCHIAL REACTIVITY	The evidence as to whether exposure to environmental airborne endotoxin plays a protective or an inducing role in the development of asthma is reviewed. Studies of endotoxin and atopy, endotoxin and asthma, and farming and asthma are considered and, in each instance, a distinction is made between evidence of primary causation and evidence of secondary causation. It is concluded that, although it is plausible that bacterial endotoxin may protect against the development of asthma, there is considerable reason for caution regarding this hypothesis.	Univ Utrecht, Inst Risk Assessment Sci, Div Environm & Occupat Hlth, NL-3508 TD Utrecht, Netherlands; Massey Univ, Ctr Publ Hlth Res, Wellington, New Zealand	Douwes, J (reprint author), Univ Utrecht, Inst Risk Assessment Sci, Div Environm & Occupat Hlth, POB 80176, NL-3508 TD Utrecht, Netherlands.			Douwes, Jeroen/0000-0003-3599-4036			Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Becker S, 1999, AM J RESP CRIT CARE, V160, P1309; Bjorksten B, 2000, AM J RESP CRIT CARE, V162, pS105; BLAINEY AD, 1988, THORAX, V43, P697, DOI 10.1136/thx.43.9.697; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; CASTELLAN RM, 1987, NEW ENGL J MED, V317, P605, DOI 10.1056/NEJM198709033171005; Christiani DC, 2001, AM J RESP CRIT CARE, V163, P847; *DECOS, 1998, END HLTH BAS REC EXP; DONHAM K, 1989, BRIT J IND MED, V46, P31; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; Douwes J, 1997, INT J OCCUP ENV HL S, V3, pS26; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Fishwick D, 1997, OCCUP ENVIRON MED, V54, P301; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; HAGMAR L, 1990, INT ARCH OCC ENV HEA, V62, P159, DOI 10.1007/BF00383592; HEEDERIK D, 1991, INT ARCH OCC ENV HEA, V62, P595, DOI 10.1007/BF00381114; Heederik D, 1997, ANN AGR ENV MED, V4, P17; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; IVERSEN M, 1990, ALLERGY, V45, P347, DOI 10.1111/j.1398-9995.1990.tb00510.x; Jacobs R., 1997, INT J OCCUP ENV HL S, V3, P3; KENNEDY SM, 1987, AM REV RESPIR DIS, V135, P194; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; KIMPBELLDUNN M, 1999, AM J IND MED, V35, P51; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Kogevinas M, 1999, LANCET, V353, P1750, DOI 10.1016/S0140-6736(98)07397-8; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P153; Liu AH, 2000, CLIN EXP ALLERGY, V30, P1535, DOI 10.1046/j.1365-2222.2000.01012.x; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Martinez FD, 1999, LANCET S2, V354, pSII12; Melbostad E, 1998, SCAND J WORK ENV HEA, V24, P262; Melsom T, 2001, THORAX, V56, P477, DOI 10.1136/thorax.56.6.477; Michaelis AR, 2000, INTERDISCIPL SCI REV, V25, P73; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1992, THORAX, V47, P288, DOI 10.1136/thx.47.4.288; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; MICHEL O, 1989, J APPL PHYSIOL, V66, P1059; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157; Michel O., 1997, INT J OCCUP ENV HL S, V3, P18; Milton DK, 1996, AM J IND MED, V29, P3, DOI 10.1002/(SICI)1097-0274(199601)29:1<3::AID-AJIM2>3.0.CO;2-V; MILTON DK, 1995, AM J IND MED, V28, P469, DOI 10.1002/ajim.4700280404; Morrison D C, 1979, Adv Immunol, V28, P293; NEIJARI C, 1996, RESP MED, V90, P401; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Park JH, 2000, ENVIRON HEALTH PERSP, V108, P1023, DOI 10.2307/3434953; Pearce N, 1999, THORAX, V54, P268; PERNIS B, 1961, BRIT J IND MED, V18, P120; PETERSON RD, 1964, J ALLERGY, V35, P134, DOI 10.1016/0021-8707(64)90027-9; Post W, 1998, OCCUP ENVIRON MED, V55, P349; Preller L, 1996, EUR RESPIR J, V9, P1407, DOI 10.1183/09031936.96.09071407; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; RYLANDER R, 1993, ANN OCCUP HYG, V37, P57, DOI 10.1093/annhyg/37.1.57; Rylander R., 1997, INT J OCCUP ENV HL S, V3, P32; SANDSTROM T, 1992, EUR RESPIR J, V5, P992; Schenker MB, 1998, AM J RESP CRIT CARE, V158, pS1; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V152, P603; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47; Shaheen SO, 1996, BRIT MED J, V313, P969; SIGSGAARD T, 1992, AM J IND MED, V22, P163, DOI 10.1002/ajim.4700220204; SMID T, 1992, AM REV RESPIR DIS, V146, P1474; SMID T, 1994, AM J IND MED, V25, P877, DOI 10.1002/ajim.4700250611; STELLMAN SD, 1988, AM J IND MED, V13, P43, DOI 10.1002/ajim.4700130104; STERLING TD, 1978, ARCH ENVIRON HEALTH, V33, P313; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; THOMAS I, 1974, LIVES CELL NOTES BIO, P78; Thorn J, 1998, THORAX, V53, P1047; TOREN K, 1991, BRIT J IND MED, V48, P323; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Ulmer AJ, 1997, INT J OCCUP ENV HEAL, V3, pS8; VANDERZWAN JC, 1982, CLIN ALLERGY, V12, P547; VANHAGEHAMSTEN M, 1987, CLIN ALLERGY, V17, P417; Vogelzang PFJ, 1998, AM J RESP CRIT CARE, V157, P15; Vogelzang PFJ, 1999, EUR RESPIR J, V13, P187, DOI 10.1034/j.1399-3003.1999.13a34.x; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; WRIGHT SD, 1990, SCIENCE, V249, P143; ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49; Zhiping Wang, 1996, American Journal of Respiratory and Critical Care Medicine, V154, P1261; Zock JP, 1999, AM J RESP CRIT CARE, V159, P137; Zock JP, 1998, AM J IND MED, V33, P384, DOI 10.1002/(SICI)1097-0274(199804)33:4<384::AID-AJIM9>3.0.CO;2-U	89	95	100	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JAN	2002	57	1					86	90		10.1136/thorax.57.1.86		5	Respiratory System	Respiratory System	511WG	WOS:000173288100020	11809997	
J	Litonjua, AA; Carey, VJ; Burge, HA; Weiss, ST; Gold, DR				Litonjua, AA; Carey, VJ; Burge, HA; Weiss, ST; Gold, DR			Exposure to cockroach allergen in the home is associated with incident doctor-diagnosed asthma and recurrent wheezing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article; Proceedings Paper	Annual Meeting of the American-Thoracic-Society	APR 24-29, 1998	CHICAGO, ILLINOIS	Amer Thorac Soc		cockroach; indoor allergens; asthma; wheeze	INNER-CITY CHILDREN; CHILDHOOD ASTHMA; RESPIRATORY ILLNESS; UNITED-STATES; RISK FACTOR; SENSITIZATION; SMOKING; RACE; RESPONSIVENESS; PREVALENCE	Background: Indoor inhaled allergens have been repeatedly demonstrated to worsen asthma In sensitized individual, but their role in incident asthma is more controversial, Objective: We investigated the relationship between exposure to allergens (dust mite, cat, and cockroach) measured in the home and incident doctor-diagnosed asthma and recurrent wheezing in children born to parents with asthma, allergies, or both. Methods: From an ongoing longitudinal family and birth cohort study, rye identified 222 siblings (median age, 2.87 years) of the index children. Allergen levels in the home were measured from dust samples obtained at the beginning of the study. Incident doctor-diagnosed asthma and recurrent wheezing were determined from questionnaires administered at 14 months and 22 months after the initial questionnaire, Results: Thirteen (5.9%) children were reported to have Incident asthma, twenty (9.0%) children had recurrent asthmatic wheezing, and 18 (8.1%) had recurrent wheezing without asthma, Compared with children living in homes with Bla g 1 or 2 levels of less than 0.05 U/g, children exposed to Bra g 1 or 2 levels of 0.05 to less than 2 U/g had a relative risk for incident asthma of 8.27 (95% confidence interval, 1.04-66.04), whereas children exposed to Bla g 1 or 2 levels of 2 U/g or greater bad a relative risk for incident asthma of 35.87 (95% confidence Interval, 4.49-286.62). Cockroach allergen exposure was likewise a significant predictor for recurrent asthmatic wheezing. Neither dust mite nor cat allergen levels were significantly associated with either outcome. These findings remained after control for several covariates, Conclusion: Exposure to cockroach allergen early in life may contribute to the development of asthma in susceptible children.	Brigham & Womens Hosp, Dept Med, Channing Lab, Boston, MA 02115 USA	Litonjua, AA (reprint author), Brigham & Womens Hosp, Dept Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [HL07427]; NIAID NIH HHS [AI35786]		BJORKSTEN B, 1987, CLIN REV ALLERG, V5, P339; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; INFANTERIVARD C, 1995, EPIDEMIOLOGY, V6, P178, DOI 10.1097/00001648-199503000-00016; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KANG B, 1976, J ALLERGY CLIN IMMUN, V58, P357, DOI 10.1016/0091-6749(76)90115-9; Kattan M, 1997, PEDIATR PULM, V24, P253, DOI 10.1002/(SICI)1099-0496(199710)24:4<253::AID-PPUL4>3.0.CO;2-L; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Litonjua AA, 1999, PEDIATR PULM, V28, P394, DOI 10.1002/(SICI)1099-0496(199912)28:6<394::AID-PPUL2>3.0.CO;2-6; Litonjua AA, 1998, AM J RESP CRIT CARE, V158, P176; MARTINEZ FD, 1988, AM REV RESPIR DIS, V138, P518; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Martinez FD, 1998, EUR RESPIR J, V12, p3S; OPENSHAW PJM, 1994, THORAX, V49, P101, DOI 10.1136/thx.49.2.101; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWNTREE S, 1987, J ALLERGY CLIN IMMUN, V80, P622, DOI 10.1016/0091-6749(87)90017-0; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SHERMAN CB, 1993, AM REV RESPIR DIS, V148, P98; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; TOLLERUD DJ, 1995, J CLIN LAB ANAL, V9, P37, DOI 10.1002/jcla.1860090107; WEISS KB, 1992, CHEST, V101, pS362, DOI 10.1378/chest.101.6_Supplement.362S; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	29	95	95	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2001	107	1					41	47		10.1067/mai.2001.111143		7	Allergy; Immunology	Allergy; Immunology	394PW	WOS:000166533300008	11149989	
J	KleinJan, A; Vinke, JG; Severijnen, LWFM; Fokkens, WJ				KleinJan, A; Vinke, JG; Severijnen, LWFM; Fokkens, WJ			Local production and detection of (specific) IgE in nasal B-cells and plasma cells of allergic rhinitis patients	EUROPEAN RESPIRATORY JOURNAL			English	Article						allergic rhinitis; B-cells; biotinylated allergen; nasal mucosa; plasma cells; specific IgE	MESSENGER-RNA; MAST-CELLS; MUCOSA; EXPRESSION; IL-4; ANTIBODIES; CHALLENGE; INDUCTION; POLYPS; LUNG	Allergic diseases are characterized by allergic complaints in the shock organ and specific immunoglobulin (Ig)E in serum. Literature data indicate that the nasal mucosa itself could produce at least a large part of the specific IgE in allergic rhinitis patients. In order to investigate this hypothesis, nasal mucosal biopsies from the inferior turbinate were taken from symptomatic grass pollen allergic rhinitis patients, symptomatic house dust mite allergic rhinitis patients and nonallergic healthy controls, confirmed by radioallergosorbent test and skin-prick test, Immunohistochemical double-staining was performed for B-cells (CD19) with IgE, plasma cells (CD138) with IgE and plasma cells with biotinylated allergens. Significantly more IgE-positive B-cells and IgE-positive plasma cells were found in biotinylated a the nasal mucosa of allergic patients than in that of nonallergic controls. Double staining with biotinylated allergens and plasma cells showed allergen-positive plasma cells in the nasal mucosa of allergic patients and no allergen-positive plasma cells in the nasal mucosa of nonallergic patients. Blocking experiments using polyclonal antibodies directed against IgE showed a significant reduction in the number of allergen-positive cells in contrast to experiments using polyclonal antibodies directed against IgG, IgA or IgM. This study describes new evidence that specific immunoglobulin E is produced locally in the nasal mucosa in patients with seasonal allergic rhinitis and perennial allergic rhinitis, but not in nonallergic controls.	Erasmus Univ, Dept Otorhinolaryngol, Med Ctr, NL-3015 GD Rotterdam, Netherlands	KleinJan, A (reprint author), Erasmus Univ, Dept Otorhinolaryngol, Med Ctr, Room Ee1655,Dr Molewaterpl 50, NL-3015 GD Rotterdam, Netherlands.						Abbas AK, 1997, CELLULAR MOL IMMUNOL; ALI M, 1979, ARCH PATHOL LAB MED, V103, P274; BOUWHUIJSEN ECA, 1996, ALLERGOLOGIE, V19, P56; BRADDING P, 1993, J IMMUNOL, V151, P3853; Brandtzaeg P, 1996, ACTA OTO-LARYNGOL, V116, P149, DOI 10.3109/00016489609137812; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; COCKS BG, 1993, INT IMMUNOL, V5, P657, DOI 10.1093/intimm/5.6.657; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DRAKELEE AB, 1984, J LARYNGOL OTOL, V98, P795, DOI 10.1017/S0022215100147474; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128; Durham SR, 1997, EUR J IMMUNOL, V27, P2899, DOI 10.1002/eji.1830271123; DURHAM SR, 1992, J IMMUNOL, V148, P2390; ELSHAMI AS, 1989, ALLERGY MOL BIOL, P191; FOKKENS W J, 1988, Rhinology (Utrecht), V26, P293; FOKKENS WJ, 1990, INT ARCH ALLER A IMM, V93, P66; GANZER U, 1988, ORL J OTO-RHINO-LARY, V50, P257; GAUCHAT JF, 1993, NATURE, V365, P340, DOI 10.1038/365340a0; Ghaffar O, 1997, AM J RESP CELL MOL, V17, P17; GILLON J, 1981, IMMUNOL TODAY, V2, P80, DOI 10.1016/0167-5699(81)90035-9; HUGGINS KG, 1975, LANCET, V2, P148; KleinJan A, 1997, J ALLERGY CLIN IMMUN, V99, P515, DOI 10.1016/S0091-6749(97)70079-4; KleinJan A, 1999, J ALLERGY CLIN IMMUN, V103, P441, DOI 10.1016/S0091-6749(99)70469-0; LeGros G, 1996, EUR J IMMUNOL, V26, P3042, DOI 10.1002/eji.1830261233; MCMENAMIN C, 1992, IMMUNOLOGY, V77, P592; MERRETT TG, 1976, CLIN ALLERGY, V6, P69, DOI 10.1111/j.1365-2222.1976.tb01413.x; MYGIND N, 1975, LANCET, V2, P502; Pawankar R, 1997, J CLIN INVEST, V99, P1492, DOI 10.1172/JCI119311; PLATTSMILLS TAE, 1979, J IMMUNOL, V122, P2218; Savelkoul H F, 1996, Eur Respir J Suppl, V22, p67s; Vinke JG, 1999, INT J PEDIATR OTORHI, V51, P73, DOI 10.1016/S0165-5876(99)00244-X; Yanagihara Y, 1997, CLIN EXP IMMUNOL, V108, P295, DOI 10.1046/j.1365-2249.1997.d01-1001.x; ZOLA H, 1987, IMMUNOL TODAY, V8, P308, DOI 10.1016/0167-5699(87)90018-1; Zurcher AW, 1996, INT ARCH ALLERGY IMM, V111, P77	34	95	97	0	7	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2000	15	3					491	497		10.1034/j.1399-3003.2000.15.11.x		7	Respiratory System	Respiratory System	295JG	WOS:000085962500011	10759442	
J	Kabashima, K				Kabashima, Kenji			New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity	JOURNAL OF DERMATOLOGICAL SCIENCE			English	Review						Atopic dermatitis; Skin barrier; Filaggrin; Langerhans cells; Pruritus; Hapten-atopy hypothesis	REGULATORY T-CELLS; LANGERIN(+) DENDRITIC CELLS; STROMAL LYMPHOPOIETIN EXPRESSION; OF-FUNCTION VARIANTS; LANGERHANS CELLS; IMMUNE-RESPONSES; NC/NGA MICE; CONTACT-DERMATITIS; SKIN INFLAMMATION; TH17 CELLS	Atopic dermatitis (AD) is a common skin condition, characterized by a complex, heterogeneous pathogenesis, including skin barrier dysfunctions, allergy/immunology, and pruritus. When the skin barrier is disrupted by, for example, the filaggrin gene mutation and/or environmental factors, the skin is predisposed to being penetrated by external stimuli. Foreign antigens can be subdivided into two subsets by size: haptens (including metals) and protein antigens. It is known that a single hapten challenge provokes Th1 initially, but that repeated elicitation with haptens results in a shift toward Th2-dominated responses. On the other hand, exposure to protein antigens directly induces Th2-dominant conditions via the thymic stromal lymphopoietin (TSLP) receptor on Langerhans cells. Recently, it has been revealed that Th2 cells produce IL-31, which provokes pruritus, and that Th2 cytokines decrease filaggrin expressions by keratinocytes. These findings suggest that Th2 conditions lead to pruritus and barrier dysfunctions. In this review, we will examine the highly complex interplay among skin barrier abnormality, allergy/immunology, and pruritus as a trinity in the development of AD. (C) 2013 Japanese Society for Investigative Dermatology. Published by Elsevier Ireland Ltd. All rights reserved.	Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, Kyoto 6068507, Japan	Kabashima, K (reprint author), Kyoto Univ, Grad Sch Med, Dept Dermatol, Sakyo Ku, 54 Shogoin Kawara, Kyoto 6068507, Japan.	kaba@kuhp.kyoto-u.ac.jp	Kabashima, Kenji/G-2521-2014	Kabashima, Kenji/0000-0002-0773-0554	Ministries of Education, Culture, Sports, Science and Technology	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministries of Education, Culture, Sports, Science and Technology.	Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; Arita K, 2008, AM J HUM GENET, V82, P73, DOI 10.1016/j.ajhg.2007.09.002; Baumgrass R, 2010, J ALLERGY CLIN IMMUN, V126, P184; Baumgrass R, 2010, J ALLERGY CLIN IMMUN, V126, P183, DOI 10.1016/j.jaci.2010.04.032; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Boniface K, 2005, J IMMUNOL, V174, P3695; Brandt C, 2009, ALLERGY, V64, P1588, DOI 10.1111/j.1398-9995.2009.02054.x; Briot A, 2009, J EXP MED, V206, P1135, DOI 10.1084/jem.20082242; Brown SJ, 2012, J INVEST DERMATOL, V132, P98, DOI 10.1038/jid.2011.342; Brown SJ, 2011, J ALLERGY CLIN IMMUN, V127, P661, DOI 10.1016/j.jaci.2011.01.031; Bursch LS, 2007, J EXP MED, V204, P3147, DOI 10.1084/jem.20071966; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Caproni M, 2006, J CLIN IMMUNOL, V26, P370, DOI 10.1007/s10875-006-9034-2; Cheung PFY, 2008, J IMMUNOL, V180, P5625; Di Cesare A, 2008, J INVEST DERMATOL, V128, P2569, DOI 10.1038/jid.2008.283; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Dudda JC, 2008, J EXP MED, V205, P1559, DOI 10.1084/jem.20072594; Egawa G, 2011, J INVEST DERMATOL, V131, P2178, DOI 10.1038/jid.2011.198; Elentner A, 2009, J CELL MOL MED, V13, P2658, DOI 10.1111/j.1582-4934.2009.00797.x; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fukamachi S, 2011, J DERMATOL SCI, V61, P118, DOI 10.1016/j.jdermsci.2010.11.012; Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122; Ginhoux F, 2007, J EXP MED, V204, P3133, DOI 10.1084/jem.20071733; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Gutowska-Owsiak D, 2012, EXP DERMATOL, V21, P104, DOI 10.1111/j.1600-0625.2011.01412.x; Hadj-Rabia S, 2004, GASTROENTEROLOGY, V127, P1386, DOI 10.1053/j.gast.2004.07.022; Hattori K, 2010, J IMMUNOL, V184, P2729, DOI 10.4049/jimmunol.0900215; He R, 2007, P NATL ACAD SCI USA, V104, P15817, DOI 10.1073/pnas.0706942104; Heimall J, 2012, EXPERT REV CLIN IMMU, V8, P189, DOI [10.1586/eci.11.100, 10.1586/ECI.11.100]; Hijnen D, 2009, J ALLERGY CLIN IMMUN, V124, P856, DOI 10.1016/j.jaci.2009.07.056; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Honda T, 2013, J INVEST DERMATOL, V133, P303, DOI 10.1038/jid.2012.284; Honda T, 2011, J DERMATOL SCI, V63, P75, DOI 10.1016/j.jdermsci.2011.06.004; Honda T, 2011, J DERMATOL SCI, V61, P144, DOI 10.1016/j.jdermsci.2010.11.001; Honda Tetsuya, 2010, Recent Pat Inflamm Allergy Drug Discov, V4, P85; Honda T, 2010, J ALLERGY CLIN IMMUN, V125, P1154, DOI 10.1016/j.jaci.2009.12.005; Howell MD, 2007, J ALLERGY CLIN IMMUN, V120, P150, DOI 10.1016/j.jaci.2007.04.031; Johansson O, 1998, J DERMATOL SCI, V17, P24, DOI 10.1016/S0923-1811(97)00066-2; Kabashima K, 2012, DERMATOL SIN, V30, P142, DOI 10.1016/j.dsi.2012.07.003; Kabashima-Kubo R, 2012, J DERMATOL SCI, V67, P37, DOI 10.1016/j.jdermsci.2012.04.004; Kamo A, 2011, J DERMATOL SCI, V62, P91, DOI 10.1016/j.jdermsci.2011.01.004; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Kawasaki H, 2012, J ALLERGY CLIN IMMUN, V129, P1538, DOI 10.1016/j.jaci.2012.01.068; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; KITAGAKI H, 1995, J INVEST DERMATOL, V105, P749, DOI 10.1111/1523-1747.ep12325538; Kitagaki H, 1997, J IMMUNOL, V159, P2484; Koga C, 2008, J INVEST DERMATOL, V128, P2625, DOI 10.1038/jid.2008.111; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; Listwan P, 2004, METHOD CELL BIOL, V78, P817; Liu Q, 2009, CELL, V139, P1353, DOI 10.1016/j.cell.2009.11.034; Loser K, 2009, INT IMMUNOPHARMACOL, V9, P587, DOI 10.1016/j.intimp.2009.01.024; McFadden JP, 2011, CLIN EXP ALLERGY, V41, P327, DOI 10.1111/j.1365-2222.2010.03684.x; Mitsuishi T, 2011, J DERMATOL SCI, V63, P184, DOI 10.1016/j.jdermsci.2011.05.007; Moniaga Catharina Sagita, 2011, Inflammation & Allergy Drug Targets, V10, P477; Moniaga CS, 2011, J DERMATOL SCI, V61, P79, DOI 10.1016/j.jdermsci.2010.11.005; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Moniaga CS, AM J PATHOL IN PRESS; Mori T, 2010, BRIT J DERMATOL, V162, P83, DOI 10.1111/j.1365-2133.2009.09440.x; Murota H, 2012, J ALLERGY CLIN IMMUN, V130; Nakajima S, 2012, J ALLERGY CLIN IMMUN, V129; Negi O, 2012, J DERMATOL SCI, V66, P37, DOI 10.1016/j.jdermsci.2012.01.007; Nickel R, 1999, J ALLERGY CLIN IMMUN, V104, P723; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Nomura I, 2003, J IMMUNOL, V171, P3262; Novak N, 2007, ADV EXP MED BIOL, V601, P97; Ochs HD, 2005, IMMUNOL REV, V203, P156, DOI 10.1111/j.0105-2896.2005.00231.x; Ohsawa Y, 2012, ALLERGY, V67, P1014, DOI 10.1111/j.1398-9995.2012.02854.x; Onoue A, 2009, EXP DERMATOL, V18, P1036, DOI 10.1111/j.1600-0625.2009.00899.x; Otsuka A, 2011, EUR J DERMATOL, V21, P816, DOI 10.1684/ejd.2011.1470; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Poulin LF, 2007, J EXP MED, V204, P3119, DOI 10.1084/jem.20071724; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Reefer AJ, 2008, J ALLERGY CLIN IMMUN, V121, P415, DOI 10.1016/j.jaci.2007.11.003; Rippke F, 2004, AM J CLIN DERMATOL, V5, P217, DOI 10.2165/00128071-200405040-00002; Rokhsar CK, 1998, J AM ACAD DERMATOL, V39, P751, DOI 10.1016/S0190-9622(98)70048-9; Sather BD, 2007, J EXP MED, V204, P1335, DOI 10.1084/jem.20070081; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Schnopp C, 2007, PHOTODERMATOL PHOTO, V23, P81, DOI 10.1111/j.1600-0781.2007.00284.x; SHANON J, 1965, DERMATOLOGICA, V131, P176; Shimada Y, 2004, J DERMATOL SCI, V34, P201, DOI 10.1016/j.jdermsci.2004.01.001; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Soumelis V, 2002, NAT IMMUNOL, V3, P673, DOI 10.1038/ni805; Spergel JM, 1998, J CLIN INVEST, V101, P1614, DOI 10.1172/JCI1647; Stander S, 2002, EXP DERMATOL, V11, P12, DOI 10.1034/j.1600-0625.2002.110102.x; Stary G, 2011, J IMMUNOL, V186, P103, DOI 10.4049/jimmunol.1002485; Sun YG, 2007, NATURE, V448, P700, DOI 10.1038/nature06029; Tesmer LA, 2008, IMMUNOL REV, V223, P87, DOI 10.1111/j.1600-065X.2008.00628.x; Thyssen JP, 2012, BRIT J DERMATOL, V166, P1255, DOI 10.1111/j.1365-2133.2012.10852.x; Toda M, 2003, J ALLERGY CLIN IMMUN, V111, P875, DOI 10.1067/mai.2003.1414; Tokura Y, 2010, J DERMATOL SCI, V58, P1, DOI 10.1016/j.jdermsci.2010.02.008; Tominaga M, 2008, BRIT J DERMATOL, V158, P842, DOI 10.1111/j.1365-2133.2007.08410.x; Tominaga M, 2007, J DERMATOL SCI, V48, P103, DOI 10.1016/j.jdermsci.2007.06.003; Tominaga M, 2007, J DERMATOL SCI, V46, P199, DOI 10.1016/j.jdermsci.2007.02.002; Tomura M, 2010, J CLIN INVEST, V120, P883, DOI 10.1172/JCI40926; Urashima R, 1998, VIRCHOWS ARCH, V432, P363, DOI 10.1007/s004280050179; Verhagen J, 2006, J ALLERGY CLIN IMMUN, V117, P176, DOI 10.1016/j.jaci.2005.10.040; Vijayanand P, 2012, IMMUNITY, V36, P175, DOI 10.1016/j.immuni.2011.12.014; Wang LC, 2008, J IMMUNOL, V180, P4722; Yoo J, 2005, J EXP MED, V202, P541, DOI 10.1084/jem.20041503	102	94	95	4	24	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0923-1811			J DERMATOL SCI	J. Dermatol. Sci.	APR	2013	70	1					3	11		10.1016/j.jdermsci.2013.02.001		9	Dermatology	Dermatology	136RF	WOS:000318380400001	23473856	
J	Kawasaki, H; Nagao, K; Kubo, A; Hata, T; Shimizu, A; Mizuno, H; Yamada, T; Amagai, M				Kawasaki, Hiroshi; Nagao, Keisuke; Kubo, Akiharu; Hata, Tsuyoshi; Shimizu, Atsushi; Mizuno, Hideaki; Yamada, Taketo; Amagai, Masayuki			Altered stratum corneum barrier and enhanced percutaneous immune responses in filaggrin-null mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Filaggrin; filaggrin-null mice; atopic dermatitis; ichthyosis vulgaris; barrier function; flaky tail mice; stratum corneum; percutaneous immune response	OF-FUNCTION MUTATIONS; ICHTHYOSIS-VULGARIS; ATOPIC-DERMATITIS; SKIN-BARRIER; HOUSE-MOUSE; FLAKY TAIL; CLINICAL SEVERITY; KERATIN FILAMENTS; LANGERHANS CELLS; DISEASE	Background: Loss-of-function mutations in filaggrin are major predisposing factors for atopic dermatitis. Although various reports suggest a critical role for filaggrin in stratum corneum (SC) barrier formation, the lack of filaggrin-null (Flg(-/-)) mice has hampered detailed in vivo analysis of filaggrin's functions. Objective: We sought to generate Flg(-/-) mice and to assess the effect of filaggrin loss on SC barrier function and percutaneous immune responses. Methods: We generated Flg(-/-) mice using gene targeting and assessed the morphology, hydration, mechanical strength, and antigen permeability of their SC. Percutaneous immune responses were evaluated through irritant-and hapten-induced contact hypersensitivity studies and by measuring humoral responses to epicutaneous sensitization with protein antigen. Results: Newborn Flg(-/-) mice exhibited dry scaly skin. Despite marked decreases in natural moisturizing factor levels, which are filaggrin degradation products, SC hydration and transepidermal water loss were normal. Microscopic analyses suggested premature shedding of SC layers, and indeed, increased desquamation under mechanical stress was demonstrated. Loss of keratin patterns, which are critical for corneocyte stabilization, is likely attributable to fragility in the Flg(-/-) SC. Antigens penetrated the Flg(-/-) SC more efficiently, leading to enhanced responses in hapten-induced contact hypersensitivity and higher serum levels of anti-ovalbumin IgG(1) and IgE. Conclusion: Complete filaggrin deficiency led to altered barrier integrity and enhanced sensitization, which are important factors in early-phase atopic dermatitis. Flg(-/-) mice should provide a valuable tool to further explore additional factors the dysfunction of which leads to uncontrolled inflammation in patients with atopic diseases. (J Allergy Clin Immunol 2012;129:1538-46.)	[Amagai, Masayuki] Keio Univ, Sch Med, Dept Dermatol, Shinjyuku Ku, Tokyo, Japan; [Kubo, Akiharu] Keio Univ, Sch Med, Ctr Integrated Med Res, Tokyo, Japan; [Yamada, Taketo] Keio Univ, Sch Med, Dept Pathol, Tokyo 160, Japan; [Hata, Tsuyoshi] KOSE Corp, Fundamental Res Labs, Tokyo, Japan; [Mizuno, Hideaki] RIKEN, Brain Sci Inst, Wako, Saitama, Japan	Amagai, M (reprint author), Keio Univ, Sch Med, Dept Dermatol, Shinjyuku Ku, 35 Shinanomachi, Tokyo, Japan.	amagai@a7.keio.jp	Nagao, Keisuke/J-5116-2013; Amagai, Masayuki/K-5325-2013; Kubo, Akiharu/I-2711-2014	Nagao, Keisuke/0000-0002-7005-3138; Amagai, Masayuki/0000-0003-3314-7052; Kubo, Akiharu/0000-0003-0902-3586	Ministry of Health, Labour and Welfare of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; Keio University	Supported by a Health Labour Sciences Research Grant for Research on Allergic Diseases and Immunology from the Ministry of Health, Labour and Welfare of Japan; Grants-in-Aid for Scientific Research; the "Promotion of Environmental Improvement for Independence of Young Researchers" program and a Matching Fund Subsidy for Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan; Research Grants for Life Sciences and Medicine from Keio University Medical Science Fund; and a Keio University Grant-in-Aid for Encouragement of Young Medical Scientists.	Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; BRODY I, 1959, J ULTRA MOL STRUCT R, V2, P482, DOI 10.1016/S0022-5320(59)90007-3; BRODY I, 1960, J ULTRA MOL STRUCT R, V4, P264, DOI 10.1016/S0022-5320(60)80023-8; Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x; DALE BA, 1978, NATURE, V276, P729, DOI 10.1038/276729a0; DALE BA, 1985, ANN NY ACAD SCI, V455, P330, DOI 10.1111/j.1749-6632.1985.tb50420.x; El Maghraby G M, 2008, Eur J Pharm Sci, V34, P203, DOI 10.1016/j.ejps.2008.05.002; ElGammal C, 1996, CLIN EXP DERMATOL, V21, P338; Elias PM, 2009, CURR OPIN ALLERGY CL, V9, P437, DOI 10.1097/ACI.0b013e32832e7d36; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fluhr JW, 2010, J INVEST DERMATOL, V130, P2141, DOI 10.1038/jid.2010.74; Gruber R, 2011, AM J PATHOL, V178, P2252, DOI 10.1016/j.ajpath.2011.01.053; HOU SYE, 1991, J INVEST DERMATOL, V96, P215; Irvine AD, 2007, J INVEST DERMATOL, V127, P504, DOI 10.1038/sj.jid.5700695; JARRETT A, 1957, J EMBRYOL EXP MORPH, V5, P103; Kamata Y, 2009, J BIOL CHEM, V284, P12829, DOI 10.1074/jbc.M807908200; Kawamoto T, 2003, ARCH HISTOL CYTOL, V66, P123, DOI 10.1679/aohc.66.123; Kezic S, 2008, J INVEST DERMATOL, V128, P2117, DOI 10.1038/jid.2008.29; Kubo A, 2009, J EXP MED, V206, P2937, DOI 10.1084/jem.20091527; LANE PW, 1972, J HERED, V63, P135; Larson RP, 2010, J IMMUNOL, V184, P2974, DOI 10.4049/jimmunol.0803478; MANABE M, 1991, DIFFERENTIATION, V48, P43, DOI 10.1111/j.1432-0436.1991.tb00241.x; McGrath JA, 2008, TRENDS MOL MED, V14, P20, DOI 10.1016/j.molmed.2007.10.006; Moniaga CS, 2010, AM J PATHOL, V176, P2385, DOI 10.2353/ajpath.2010.090957; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Nemoto-Hasebe I, 2009, J INVEST DERMATOL, V129, P682, DOI 10.1038/jid.2008.280; Norlen L, 2004, J INVEST DERMATOL, V123, P715, DOI 10.1111/j.0022-202X.2004.23213.x; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V126, P574, DOI 10.1016/j.jaci.2010.04.038; Ouchi T, 2011, J EXP MED, V208, P2607, DOI 10.1084/jem.20111718; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, P485, DOI 10.1016/j.jaci.2009.05.042; Oyoshi MK, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Presland RB, 2000, J INVEST DERMATOL, V115, P1072, DOI 10.1046/j.1523-1747.2000.00178.x; Proksch E, 2006, J DERMATOL SCI, V43, P159, DOI 10.1016/j.jdermsci.2006.06.003; Rawlings A V, 2004, Dermatol Ther, V17 Suppl 1, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, pe1; Scharschmidt TC, 2009, J ALLERGY CLIN IMMUN, V124, P496, DOI 10.1016/j.jaci.2009.06.046; SEARLE AG, 1957, J EMBRYOL EXP MORPH, V5, P93; Segre JA, 2006, J CLIN INVEST, V116, P1150, DOI 10.1172/JCI28521; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Soma Y, 2005, INT J DERMATOL, V44, P197, DOI 10.1111/j.1365-4632.2004.02375.x; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P4097, DOI 10.1073/pnas.78.7.4097; SYBERT VP, 1985, J INVEST DERMATOL, V84, P191, DOI 10.1111/1523-1747.ep12264813; Tomita Y, 2005, EXP DERMATOL, V14, P619, DOI 10.1111/j.0906-6705.2005.00341.x; Weerheim A, 2001, ARCH DERMATOL RES, V293, P191, DOI 10.1007/s004030100212; Ya-Xian Zhen, 1999, Archives of Dermatological Research, V291, P555, DOI 10.1007/s004030050453; YAMAMOTO Y, 1994, ACTA DERM-VENEREOL, P34	48	94	93	0	11	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2012	129	6					1538	+		10.1016/j.jaci.2012.01.068		15	Allergy; Immunology	Allergy; Immunology	952BL	WOS:000304764600014	22409988	
J	Oschatz, C; Maas, C; Lecher, B; Jansen, T; Bjorkqvist, J; Tradler, T; Sedlmeier, R; Burfeind, P; Cichon, S; Hammerschmidt, S; Muller-Esterl, W; Wuillemin, WA; Nilsson, G; Renne, T				Oschatz, Chris; Maas, Coen; Lecher, Bernd; Jansen, Thomas; Bjorkqvist, Jenny; Tradler, Thomas; Sedlmeier, Reinhard; Burfeind, Peter; Cichon, Sven; Hammerschmidt, Sven; Mueller-Esterl, Werner; Wuillemin, Walter A.; Nilsson, Gunnar; Renne, Thomas			Mast Cells Increase Vascular Permeability by Heparin-Initiated Bradykinin Formation In Vivo	IMMUNITY			English	Article							COAGULATION-FACTOR-XII; ADVERSE CLINICAL EVENTS; CHONDROITIN SULFATE-E; HEREDITARY ANGIOEDEMA; CONTACT SYSTEM; ALLERGIC REACTIONS; ACTIVATION; MECHANISMS; RECEPTOR; ENZYME	Activated mast cells trigger edema in allergic and inflammatory disease. We report a paracrine mechanism by which mast cell-released heparin increases vascular permeability in vivo. Heparin activated the protease factor XII, which initiates bradykinin formation in plasma. Targeting factor XII or kinin B2 receptors abolished heparin-triggered leukocyte-endothelium adhesion and interfered with a mast cell-driven drop in blood pressure in rodents. Intravital laser scanning microscopy and tracer measurements showed heparin-driven fluid extravasation in mouse skin microvessels. Ablation of factor XII or kinin B2 receptors abolished heparin-induced skin edema and protected mice from allergen-activated mast cell-driven leakage. In contrast, heparin and activated mast cells induced excessive edema in mice deficient in the major inhibitor of factor XII, Cl esterase inhibitor. Allergen exposure triggered edema attacks in hereditary angioedema patients, lacking Cl esterase inhibitor. The data indicate that heparin-initiated bradykinin formation plays a fundamental role in mast cell-mediated diseases.	[Oschatz, Chris; Maas, Coen; Jansen, Thomas; Bjorkqvist, Jenny; Renne, Thomas] Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden; [Oschatz, Chris; Maas, Coen; Jansen, Thomas; Bjorkqvist, Jenny; Renne, Thomas] Karolinska Inst, Ctr Mol Med, S-17176 Stockholm, Sweden; [Nilsson, Gunnar] Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, S-17176 Stockholm, Sweden; [Lecher, Bernd] Mfd Diagnost GmbH, D-55234 Wendelsheim, Germany; [Jansen, Thomas] Univ Med Ctr Mainz, Dept Med 2, D-55131 Mainz, Germany; [Tradler, Thomas] Scil Prot GmbH, D-06120 Halle, Germany; [Sedlmeier, Reinhard] Ingenium Pharmaceut GmbH, D-82152 Martinsried, Germany; [Burfeind, Peter] Univ Gottingen, Inst Human Genet, D-37073 Gottingen, Germany; [Cichon, Sven] Univ Bonn, Life & Brain Ctr, Dept Genom, D-53105 Bonn, Germany; [Cichon, Sven] Univ Bonn, Inst Human Genet, D-53105 Bonn, Germany; [Cichon, Sven] Res Ctr Julich, Inst Neurosci & Med, D-52425 Julich, Germany; [Hammerschmidt, Sven] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Dept Genet Microorganisms, D-17487 Greifswald, Germany; [Mueller-Esterl, Werner] Goethe Univ Frankfurt, Inst Biochem 2, D-60590 Frankfurt, Germany; [Wuillemin, Walter A.] Luzerner Kantonsspital, Div Hematol, CH-6000 Luzern, Switzerland; [Wuillemin, Walter A.] Luzerner Kantonsspital, Cent Hematol Lab, CH-6000 Luzern, Switzerland; [Wuillemin, Walter A.] Univ Bern, CH-3010 Bern, Switzerland	Renne, T (reprint author), Karolinska Inst, Dept Mol Med & Surg, S-17176 Stockholm, Sweden.	thomas@renne.net	Cichon, Sven/H-8803-2013; Cichon, Sven/B-9618-2014	Cichon, Sven/0000-0002-9475-086X; Cichon, Sven/0000-0002-9475-086X; Nilsson, Gunnar/0000-0001-6795-5512; Maas, Coen/0000-0003-4593-0976	Vetenskapsradet [K2010-64X-21462-01-3]; Hjart Lungfonden [20090642]; Stockholms lans landsting (ALF) [20090540]; Stiftung fur Pathobiochemie und Molekulare Diagnostik of the DGKL,; Cancerfonden [100615]; Federal Ministry of Education and Research (BMBF); Rubicon fellowship [825-10-012]; Netherlands Organisation for Scientific Research (NWO); Margarete Waitz-foundation, Mainz	This work was supported in part by grants from Vetenskapsradet (K2010-64X-21462-01-3), Hjart Lungfonden (20090642), Stockholms lans landsting (ALF, 20090540), Stiftung fur Pathobiochemie und Molekulare Diagnostik of the DGKL, Cancerfonden (100615), and the Federal Ministry of Education and Research (BMBF)-funded ERARE program to T.R. C.M. is supported by a Rubicon fellowship (825-10-012), provided by the Netherlands Organisation for Scientific Research (NWO). T.J. holds a scholarship of the Margarete Waitz-foundation, Mainz. Part of the work of T.T. was performed at Jerini AG, Berlin. We thank L. Kjellen (Uppsala University, Uppsala, Sweden) for providing Ndst2<SUP>-/-</SUP> mice.	Akcali C, 2008, J EUR ACAD DERMATOL, V22, P83, DOI 10.1111/j.1468-3083.2007.02353.x; BELTRAMI E, 1995, P NATL ACAD SCI USA, V92, P8744, DOI 10.1073/pnas.92.19.8744; Bork K, 2009, J ALLERGY CLIN IMMUN, V124, P129, DOI 10.1016/j.jaci.2009.03.038; Brunnee T, 1997, CLIN EXP ALLERGY, V27, P653; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Cichon S, 2006, AM J HUM GENET, V79, P1098, DOI 10.1086/509899; COCHRANE CG, 1982, ADV IMMUNOL, V33, P241, DOI 10.1016/S0065-2776(08)60837-8; Davis AE, 2008, ANN ALLERG ASTHMA IM, V100, pS7; Dlamini Z, 2005, J CLIN PATHOL, V58, P915, DOI 10.1136/jcp.2004.021444; Donelan J, 2006, P NATL ACAD SCI USA, V103, P7759, DOI 10.1073/pnas.0602210103; Eriksson EE, 2001, FASEB J, V15, P1149, DOI 10.1096/fj.00-0537com; FAREED J, 1989, SEMIN THROMB HEMOST, V15, P440, DOI 10.1055/s-2007-1002744; Forsberg E, 1999, NATURE, V400, P773; Galli SJ, 2008, NAT REV IMMUNOL, V8, P478, DOI 10.1038/nri2327; Greenhawt M, 2007, CURR OPIN ALLERGY CL, V7, P387; Guerrini M, 2008, NAT BIOTECHNOL, V26, P669, DOI 10.1038/nbt1407; Han ED, 2002, J CLIN INVEST, V109, P1057, DOI 10.1172/JCI200214211; HOJIMA Y, 1984, BLOOD, V63, P1453; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; ISHIZAKA T, 1985, J IMMUNOL, V134, P1880; Johne J, 2006, BIOL CHEM, V387, P173, DOI 10.1515/BC.2006.023; Jorpes E, 1935, Biochem J, V29, P1817; Kalesnikoff J, 2008, NAT IMMUNOL, V9, P1215, DOI 10.1038/ni.f.216; Kaplan AP, 2010, MOL IMMUNOL, V47, P2161, DOI 10.1016/j.molimm.2010.05.010; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Kleinschnitz C, 2006, J EXP MED, V203, P513, DOI 10.1084/jem.20052458; Leeb-Lundberg LMF, 2005, PHARMACOL REV, V57, P27, DOI 10.1124/pr.57.1.2; LINKER A, 1972, BIOCHEMISTRY-US, V11, P563, DOI 10.1021/bi00754a013; LOMBARDINI C, 2009, AM J EMERG MED, V27, pE1171; Maas C, 2008, J CLIN INVEST, V118, P3208, DOI [10.1172/JCI35424, 10.1172/JC135424]; MacLaughlin EJ, 2002, PHARMACOTHERAPY, V22, P1511, DOI 10.1592/phco.22.16.1511.33688; Marshall JS, 2004, NAT REV IMMUNOL, V4, P787, DOI 10.1038/nri1460; MASS C, 2011, SEMIN THROM IN PRESS; MAZZI G, 1994, HAEMATOLOGICA, V79, P283; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228; Muller F, 2009, CELL, V139, P1143, DOI 10.1016/j.cell.2009.11.001; Noga O, 1999, INT ARCH ALLERGY IMM, V120, P310, DOI 10.1159/000024284; Nzeako UC, 2001, ARCH INTERN MED, V161, P2417, DOI 10.1001/archinte.161.20.2417; Pauer HU, 2004, THROMB HAEMOSTASIS, V92, P503, DOI 10.1160/TH04-04-0250; PROUD D, 1988, ANNU REV IMMUNOL, V6, P49; Renne T, 2005, J IMMUNOL, V175, P3377; Renne T, 2005, J EXP MED, V202, P271, DOI 10.1084/jem.20050664; Schmaier AH, 2008, J CLIN INVEST, V118, P3006, DOI 10.1172/JCI36617; Schwartz LB, 2008, NEW ENGL J MED, V358, P2505, DOI 10.1056/NEJMe0803599; SIEBECK M, 1994, J APPL PHYSIOL, V77, P2675; Siebenhaar F, 2008, J ALLERGY CLIN IMMUN, V121, P955, DOI 10.1016/j.jaci.2007.11.013; STEVENS RL, 1988, P NATL ACAD SCI USA, V85, P2284, DOI 10.1073/pnas.85.7.2284; Summers CW, 2008, J ALLERGY CLIN IMMUN, V121, P632, DOI 10.1016/j.jaci.2007.12.003; Theoharides TC, 2006, ANN NY ACAD SCI, V1088, P78, DOI 10.1196/annals.1366.025; Ullrich Melanie, 2009, Methods Mol Biol, V561, P145, DOI 10.1007/978-1-60327-019-9_10; Warkentin TE, 2009, EXPERT OPIN DRUG SAF, V8, P129, DOI [10.1517/14740330902778180 , 10.1517/14740330902778180]; WIRTH K, 1991, BRIT J PHARMACOL, V102, P774; Zuraw BL, 2008, NEW ENGL J MED, V359, P1027, DOI 10.1056/NEJMcp0803977	53	94	95	0	9	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613			IMMUNITY	Immunity	FEB 25	2011	34	2					258	268		10.1016/j.immuni.2011.02.008		11	Immunology	Immunology	729YD	WOS:000287989500015	21349432	
J	Wright, RJ; Visness, CM; Calatroni, A; Grayson, MH; Gold, DR; Sandel, MT; Lee-Parritz, A; Wood, RA; Kattan, M; Bloomberg, GR; Burger, M; Togias, A; Witter, FR; Sperling, RS; Sadovsky, Y; Gern, JE				Wright, Rosalind J.; Visness, Cynthia M.; Calatroni, Agustin; Grayson, Mitchell H.; Gold, Diane R.; Sandel, Megan T.; Lee-Parritz, Aviva; Wood, Robert A.; Kattan, Meyer; Bloomberg, Gordon R.; Burger, Melissa; Togias, Alkis; Witter, Frank R.; Sperling, Rhoda S.; Sadovsky, Yoel; Gern, James E.			Prenatal Maternal Stress and Cord Blood Innate and Adaptive Cytokine Responses in an Inner-City Cohort	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						psychological stress; cord blood; cytokines; innate; adaptive	RESPIRATORY SYNCYTIAL VIRUS; T-REGULATORY CELLS; IMMUNE-RESPONSES; AIRWAY INFLAMMATION; DENDRITIC CELLS; ASTHMA; MATURATION; PREGNANCY; ALLERGENS; CHILDREN	Rationale: Stress-elicited disruption of immunity begins in utero. Objectives: Associations among prenatal maternal stress and cord blood mononuclear cell (CBMC) cytokine responses were prospectively examined in the Urban Environment and Childhood Asthma Study (n = 557 families). Methods: Prenatal maternal stress included financial hardship, difficult life circumstances, community violence, and neighborhood/block and housing conditions. Factor analysis produced latent variables representing three contexts: individual stressors and ecological-level strains (housing problems and neighborhood problems), which were combined to create a composite cumulative stress indicator. CBMCs were incubated with innate (lipopolysaccharide, polyinosinic-polycytidylic acid, cytosine-phosphate-guanine dinucleotides, peptidoglycan) and adaptive (tetanus, dust mite, cockroach) stimuli, respiratory syncytial virus, phytohemagglutinin, or medium alone. Cytokines were measured using multiplex ELISAs. Using linear regression, associations among increasing cumulative stress and cytokine responses were examined, adjusting for sociodemographic factors, parity, season of birth, maternal asthma and steroid use, and potential pathway variables (prenatal smoking, birth weight for gestational age). Measurements and Main Results Mothers were primarily minorities (Black [71%], Latino [19%]) with an income less than $15,000 (69%). Mothers with the highest cumulative stress were older and more likely to have asthma and deliver lower birth weight infants. Higher prenatal stress was related to increased IL-8 production after microbial (CpG, PIC, peptidoglycan) stimuli and increased tumor necrosis factor-a to microbial stimuli (CpG, PIC). In the adaptive panel, higher stress was associated with increased IL-13 after dust mite stimulation and reduced phytohemagglutinin-induced Conclusions Prenatal stress was associated with altered innate and adaptive immune responses in CBMCs. Stress-induced perinatal immunomodulation may impact the expression of allergic disease in these children.	[Wright, Rosalind J.; Gold, Diane R.] Harvard Univ, Brigham & Womens Hosp, Channing Lab, Dept Med,Med Sch, Boston, MA 02115 USA; [Wright, Rosalind J.; Gold, Diane R.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [Visness, Cynthia M.; Calatroni, Agustin] Rho Inc, Chapel Hill, NC USA; [Sandel, Megan T.; Lee-Parritz, Aviva] Boston Univ, Sch Med, Boston, MA 02118 USA; [Grayson, Mitchell H.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Kattan, Meyer] Columbia Univ, Med Ctr, New York, NY USA; [Wood, Robert A.; Witter, Frank R.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Burger, Melissa; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Madison, WI USA; [Bloomberg, Gordon R.] Washington Univ, St Louis Sch Med, St Louis, MO USA; [Sperling, Rhoda S.] Mt Sinai Sch Med, New York, NY USA; [Sadovsky, Yoel] Magee Womens Res Inst, Pittsburgh, PA USA; [Togias, Alkis] NIAID, Bethesda, MD 20892 USA	Wright, RJ (reprint author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	rerjw@channing.harvard.edu		Lee-Parritz, Aviva/0000-0003-4655-7720	National Institute of Allergy and Infectious Diseases, National Institutes of Health [NO1-AI-25496, NO1-AI-25482]; National Center for Research Resources, National Institutes of Health [RR00052, M01RR00533, M01RR00071, 5 UL1RR024992-02]; National Institutes of Health [R01 HL080674]; Genentech	Supported by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contracts NO1-AI-25496 and NO1-AI-25482, and by the National Center for Research Resources, National Institutes of Health grants RR00052, M01RR00533, M01RR00071, and 5 UL1RR024992-02. During preparation of this manuscript R.J.W. was also supported by National Institutes of Health grant R01 HL080674.; R.J.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. C.M.V. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. A.C. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.H.G. received 550,001-$100,000 from Genentech as an investigator-initiated research grant. D.R.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.T.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. At-P. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.A.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.K. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. G.R.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. M.B. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. AT. is an employee of the National Institutes of Health. F.R.W. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. R.S.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. Y.S. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript. J.E.G. does not have a financial relationship with a commercial entity that has an interest in the subject of this manuscript.	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; BOOTH CL, 1989, DEV PSYCHOL, V25, P403, DOI 10.1037/0012-1649.25.3.403; Coe CL, 1999, BIOL NEONATE, V76, P301, DOI 10.1159/000014172; de Weerth C, 2005, NEUROSCI BIOBEHAV R, V29, P295, DOI 10.1016/j.neubiorev.2004.10.005; Devereux G, 2002, CLIN EXP ALLERGY, V32, P43, DOI 10.1046/j.0022-0477.2001.01267.x; Dunn JR, 2002, J EPIDEMIOL COMMUN H, V56, P671, DOI 10.1136/jech.56.9.671; Elenkov IJ, 1999, TRENDS ENDOCRIN MET, V10, P359, DOI 10.1016/S1043-2760(99)00188-5; Evans J, 2000, J EPIDEMIOL COMMUN H, V54, P677, DOI 10.1136/jech.54.9.677; Friedlander Samuel L, 2005, Pediatr Infect Dis J, V24, pS170, DOI 10.1097/01.inf.0000187273.47390.01; Galli E, 2007, ALLERGY ASTHMA PROC, V28, P540, DOI 10.2500/aap2007.28.3048; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Haynes LM, 2001, J VIROL, V75, P10730, DOI 10.1128/JVI.75.22.10730-10737.2001; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HEMMI H, 2000, NAT IMMUNOL, V4088, P740; Holloway JA, 2000, LANCET, V356, P1900, DOI 10.1016/S0140-6736(00)03265-7; Holt PG, 2005, J ALLERGY CLIN IMMUN, V116, P16, DOI 10.1016/j.jaci.2005.04.017; Iwamura C, 2008, CURR ALLERGY ASTHM R, V8, P7, DOI 10.1007/s11882-008-0003-0; Joachim RA, 2008, AM J PATHOL, V173, P1379, DOI 10.2353/ajpath.2008.080105; Jolliffe IT, 2002, PRINCIPAL COMPONENT; Kleinbaum D. G., 1998, APPL REGRESSION ANAL; Lobel M, 2008, HEALTH PSYCHOL, V27, P604, DOI 10.1037/a0013242; Lutgendorf SK, 2005, BRAIN BEHAV IMMUN, V19, P185, DOI 10.1016/j.bbi.2004.11.003; Macaubas C, 2003, LANCET, V362, P1192, DOI 10.1016/S0140-6736(03)14542-4; Martinez FD, 1999, J ALLERGY CLIN IMMUN, V103, P355, DOI 10.1016/S0091-6749(99)70456-2; Merlot E, 2008, BRAIN BEHAV IMMUN, V22, P42, DOI 10.1016/j.bbi.2007.05.007; Morales JR, 2006, CHILD DEV, V77, P907, DOI 10.1111/j.1467-8624.2006.00910.x; MOSSMAN TR, 1996, IMMUNOL TODAY, V17, P138; Murawski MR, 2009, J VIROL, V83, P1492, DOI 10.1128/JVI.00671-08; Myers HF, 2009, J BEHAV MED, V32, P9, DOI 10.1007/s10865-008-9181-4; Oken Emily, 2003, BMC Pediatr, V3, P6, DOI 10.1186/1471-2431-3-6; Oya H, 2000, CLIN EXP IMMUNOL, V121, P384, DOI 10.1046/j.1365-2249.2000.01310.x; PASCOE JM, 1995, ARCH PEDIAT ADOL MED, V149, P1325; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; Peters JL, 2009, J ALLERGY CLIN IMMUN, V123, P1041, DOI 10.1016/j.jaci.2009.02.027; PICCINNI MP, 1993, INT ARCH ALLERGY IMM, V102, P301; Pincus-Knackstedt MK, 2006, J IMMUNOL, V177, P8484; Powell ND, 2009, BRAIN BEHAV IMMUN, V23, P225, DOI 10.1016/j.bbi.2008.09.010; Prescott SL, 2003, ALLERGY, V58, P1187, DOI 10.1034/j.1398-9995.2003.00263.x; Prescott SL, 1998, J IMMUNOL, V160, P4730; Prescott SL, 2006, PAEDIATR RESPIR REV, V7, P89, DOI 10.1016/j.prrv.2006.03.001; Ritter C, 2000, HEALTH PSYCHOL, V19, P576, DOI 10.1037/0278-6133.19.6.576; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Schonberger HJ, 2005, PEDIATR ALLERGY IMMU, V16, P27, DOI 10.1111/j.1399-3038.2005.00243.x; SCHREFFLER WG, 2006, BMC IMMUNOL, V7, P29; Stock P, 2004, NAT IMMUNOL, V5, P1149, DOI 10.1038/ni1122; Suarez CJ, 2008, CURR ALLERGY ASTHM R, V8, P451, DOI 10.1007/s11882-008-0085-8; Team R. D. C. R., LANG ENV STAT COMP; Thornton CA, 2004, J IMMUNOL, V173, P3084; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; von Hertzen LC, 2002, J ALLERGY CLIN IMMUN, V109, P923, DOI 10.1067/mai.2002.124776; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wright RJ, 2005, J ALLERGY CLIN IMMUN, V116, P1301, DOI 10.1016/j.jaci.2005.09.050; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2007, PAEDIATR PERINAT EP, V21, P8, DOI 10.1111/j.1365-3016.2007.00879.x; ZHANG Y, 2008, J NEUROIMMUNOL, V204, P139	59	94	95	4	12	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 1	2010	182	1					25	33		10.1164/rccm.200904-0637OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	623AP	WOS:000279709200007	20194818	
J	Cho, HY; Kleeberger, SR				Cho, Hye-Youn; Kleeberger, Steven R.			Nrf2 protects against airway disorders	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						ARE; Keap1; Lung; Knockout mice; Oxidant; Polymorphism; Mutation	RESPIRATORY SYNCYTIAL VIRUS; ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; INDUCED LUNG INJURY; GLUTATHIONE-S-TRANSFERASE; EXTRACELLULAR-SUPEROXIDE DISMUTASE; IDIOPATHIC PULMONARY-FIBROSIS; TRANSPEPTIDASE-DEFICIENT MICE; INDUCED INFLAMMATORY RESPONSE; ADENOVIRUS-MEDIATED TRANSFER	Nuclear factor-erythroid 2 related factor 2 (Nrf2) is a ubiquitous master transcription factor that regulates antioxidant response elements (AREs)-mediated expression of antioxidant enzyme and cytoprotective proteins. In the unstressed condition, Kelch-like ECH-associated protein 1 (Keap1) suppresses cellular Nrf2 in cytoplasm and drives its proteasomal degradation. Nrf2 can be activated by diverse stimuli including oxidants, pro-oxidants, antioxidants, and chemopreventive agents. Nrf2 induces cellular rescue pathways against oxidative injury, abnormal inflammatory and immune responses, apoptosis, and carcinogenesis. Application of Nrf2 germ-line mutant mice has identified an extensive range of protective roles for Nrf2 in experimental models of human disorders in the liver, gastrointestinal tract, air-way, kidney, brain, circulation, and immune or nerve system. In the lung, lack of Nrf2 exacerbated toxicity caused by multiple oxidative insults including supplemental respiratory therapy (e.g., hyperoxia, mechanical ventilation), cigarette smoke, allergen, virus, bacterial endotoxin and other inflammatory agents (e.g., carrageenin), environmental pollution (e.g., particles), and a fibrotic agent bleomycin. Microarray analyses and bioinformatic studies elucidated functional AREs and Nrf2-directed genes that are critical components of signaling mechanisms in pulmonary protection by Nrf2. Association of loss of function with promoter polymorphisms in NRF2 or somatic and epigenetic mutations in KEAP1 and NRF2 has been found in cohorts of patients with acute lung injury/acute respiratory distress syndrome Or lung cancer, which further supports the role for NRF2 in these lung diseases. In the Current review, we address the role of Nrf2 in airways based on emerging evidence from experimental oxidative disease models and human studies. Published by Elsevier Inc.	[Cho, Hye-Youn; Kleeberger, Steven R.] Natl Inst Environm Hlth Sci, Lab Resp Biol, NIH, Res Triangle Pk, NC 27709 USA	Cho, HY (reprint author), Natl Inst Environm Hlth Sci, Lab Resp Biol, NIH, Bldg 101,MD D-201,111 TW Alexander Dr, Res Triangle Pk, NC 27709 USA.	cho2@niehs.nih.gov					Adair-Kirk TL, 2008, AM J RESP CELL MOL, V39, P400, DOI 10.1165/rcmb.2007-0295OC; Aleyasin H, 2007, P NATL ACAD SCI USA, V104, P18748, DOI 10.1073/pnas.0709379104; Angus DC, 2001, CRIT CARE MED, V29, P1303, DOI 10.1097/00003246-200107000-00002; Aoki Y, 2001, TOXICOL APPL PHARM, V173, P154, DOI 10.1006/taap.2001.9176; Arisawa T, 2008, ONCOL REP, V19, P211; Asikainen TM, 2004, ANTIOXID REDOX SIGN, V6, P155, DOI 10.1089/152308604771978462; Asikainen TM, 2002, FREE RADICAL BIO MED, V32, P175, DOI 10.1016/S0891-5849(01)00776-6; Bakin AV, 2005, FREE RADICAL BIO MED, V38, P375, DOI 10.1016/j.freeradbiomed.2004.10.033; Baraldi E, 2007, NEW ENGL J MED, V357, P1946, DOI 10.1056/NEJMra067279; Barrios R, 2001, LUNG, V179, P319, DOI 10.1007/s0040800000071; Becker Y, 2006, VIRUS GENES, V33, P235, DOI 10.1007/s11262-006-0064-x; Beeh KM, 2002, EUR RESPIR J, V19, P1119, DOI 10.1183/09031936.02.00262402; Behera AK, 2001, BIOCHEM BIOPH RES CO, V280, P188, DOI 10.1006/bbrc.2000.4098; Bland RD, 2005, BIOL NEONATE, V88, P181, DOI 10.1159/000087581; Boelen A, 2002, J MED VIROL, V66, P552, DOI 10.1002/jmv.2180; Bowler RP, 2002, AM J PHYSIOL-LUNG C, V282, pL719, DOI 10.1152/ajplung.0058.2001; CANADA AT, 1995, AM J PHYSIOL-LUNG C, V268, pL539; CANTIN AM, 1987, J CLIN INVEST, V79, P1665, DOI 10.1172/JCI113005; Casola A, 2001, J BIOL CHEM, V276, P19715, DOI 10.1074/jbc.M101526200; Castro SM, 2006, AM J RESP CRIT CARE, V174, P1361, DOI 10.1164/rccm.200603-319OC; Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Cho HY, 2004, FASEB J, V18, P1258; Cho HY, 2005, FREE RADICAL BIO MED, V38, P325, DOI 10.1016/j.freeradbiomed.2004.10.013; Cho HY, 2002, AM J RESP CELL MOL, V26, P175; Cho HY, 2002, AM J RESP CELL MOL, V26, P42; Cho HY, 2009, AM J RESP CRIT CARE, V179, P138, DOI 10.1164/rccm.200804-535OC; Clements CM, 2006, P NATL ACAD SCI USA, V103, P15091, DOI 10.1073/pnas.0607260103; Cohen J, 2002, NATURE, V420, P885, DOI 10.1038/nature01326; Cortijo J, 2001, EUR RESPIR J, V17, P1228, DOI 10.1183/09031936.01.00049701; CRAPO JD, 1986, ANNU REV PHYSIOL, V48, P721; CRAPO JD, 1984, J TOXICOL ENV HEALTH, V13, P301; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; Deger Y, 2007, CELL BIOCHEM FUNCT, V25, P633, DOI 10.1027/cbf.1362; Denu JM, 1998, BIOCHEMISTRY-US, V37, P5633, DOI 10.1021/bi973035t; Devling TWP, 2005, P NATL ACAD SCI USA, V102, P7280, DOI 10.1073/pnas.0501475102; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Dinkova-Kostova AT, 2002, P NATL ACAD SCI USA, V99, P11908, DOI 10.1073/pnas.172398899; Erickson AM, 2002, J BIOL CHEM, V277, P30730, DOI 10.1074/jbc.M205225200; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Fahey JW, 2002, P NATL ACAD SCI USA, V99, P7610, DOI 10.1073/pnas.112203099; Fattman CL, 2003, FREE RADICAL BIO MED, V35, P763, DOI 10.1016/S0891-5849(03)00402-7; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; FOY HM, 1973, AM J EPIDEMIOL, V97, P80; FRACICA PJ, 1988, EXP LUNG RES, V14, P869, DOI 10.3109/01902148809064180; Fridovich I, 1998, J EXP BIOL, V201, P1203; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Gebel S, 2004, CARCINOGENESIS, V25, P169, DOI 10.1093/carcin/bgg193; Gerhauser C, 1997, CANCER RES, V57, P272; Goss CH, 2003, CRIT CARE MED, V31, P1607, DOI 10.1097/01.CCM.0000063475.65751.1D; Hackett NR, 2003, AM J RESP CELL MOL, V29, P331, DOI 10.1165/rcmb.2002-0321OC; Hall C B, 1999, J Pediatr, V135, P2; HALLIWELL B, 1992, J LAB CLIN MED, V119, P598; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; HE LS, 1990, AM J PHYSIOL, V259, pL451; Hirota K, 2002, ANN NY ACAD SCI, V957, P189; Ho YS, 1998, AM J RESP CELL MOL, V18, P538; Hoshino T, 2003, AM J RESP CRIT CARE, V168, P1075, DOI 10.1164/rccm.200209-982OC; HUDAK BB, 1993, PHARMACOGENETICS, V3, P135, DOI 10.1097/00008571-199306000-00003; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; Iizuka T, 2005, GENES CELLS, V10, P1113, DOI 10.1111/j.1365-2443.2005.00905.x; Inden M, 2006, NEUROBIOL DIS, V24, P144, DOI 10.1016/j.nbd.2006.06.004; ISHIDA R, 1975, BIOCHEM BIOPH RES CO, V66, P1432, DOI 10.1016/0006-291X(75)90519-7; Ishii T, 1999, FREE RADICAL RES, V31, P351, DOI 10.1080/10715769900300921; Ishii T, 2004, CIRC RES, V94, P609, DOI 10.1161/01.RES.0000119171.44657.45; Ishii Y, 2005, J IMMUNOL, V175, P6968; Itoh K, 2004, FREE RADICAL BIO MED, V36, P1208, DOI 10.1016/j.freeradbiomed.2004.02.075; Itoh K, 2003, GENES CELLS, V8, P379, DOI 10.1046/j.1365-2443.2003.00640.x; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jardine H, 2002, J BIOL CHEM, V277, P21158, DOI 10.1074/jbc.M112145200; Jean JC, 2002, AM J PHYSIOL-LUNG C, V283, pL766, DOI 10.1152/ajplung.00250.2000; Jeyapaul J, 2000, BIOCHEM PHARMACOL, V59, P1433, DOI 10.1016/S0006-2952(00)00256-2; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; Johnston CJ, 1998, EXP LUNG RES, V24, P189; Kang GH, 2003, LAB INVEST, V83, P519, DOI 10.1097/01.LAB.0000064704.53132.65; Kang KW, 2002, MOL PHARMACOL, V62, P1001, DOI 10.1124/mol.62.5.1001; Kang MI, 2004, P NATL ACAD SCI USA, V101, P2046, DOI 10.1073/pnas.0308347100; Katoh Y, 2005, ARCH BIOCHEM BIOPHYS, V433, P342, DOI 10.1016/j.abb.2004.10.012; Katsuoka F, 2005, J BIOL CHEM, V280, P4483, DOI 10.1074/jbc.M411451200; KAYANOKI Y, 1994, J BIOL CHEM, V269, P15488; Khor TO, 2008, CANCER PREV RES, V1, P187, DOI 10.1158/1940-6207.CAPR-08-0028; Kim HS, 2003, AM J PHYSIOL-LUNG C, V285, pL363, DOI 10.1152/ajplung.00078.2003; Kobayashi M, 2002, GENES CELLS, V7, P807, DOI 10.1046/j.1365-2443.2002.00561.x; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; LEDWOZYW A, 1991, ACTA PHYSIOL HUNG, V78, P157; LEFF JA, 1992, AM REV RESPIR DIS, V146, P985; Li N, 2004, J IMMUNOL, V173, P3467; Li YJ, 2008, CLIN IMMUNOL, V128, P366, DOI 10.1016/j.clim.2008.05.005; Lin PP, 2003, LUNG CANCER-J IASLC, V40, P123, DOI 10.1016/S0169-5002(03)00027-8; Liu RM, 2004, AM J PHYSIOL-LUNG C, V286, pL121, DOI 10.1152/ajplung.00231.2003; Liu TS, 2004, J BIOL CHEM, V279, P2461, DOI 10.1074/jbc.M307251200; Liu WR, 2004, CIRCULATION, V110, P1276, DOI 10.1161/01.CIR.0000141803.41217.B6; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; Machtay M, 2006, RADIOTHER ONCOL, V81, P196, DOI 10.1016/j.radonc.2006.09.013; Malhotra D, 2008, AM J RESP CRIT CARE, V178, P592, DOI 10.1164/rccm.200803-380OC; Mapp CE, 2002, J ALLERGY CLIN IMMUN, V109, P867, DOI 10.1067/mai.2002.123234; Markart P, 2009, ANTIOXID REDOX SIGN, V11, P227, DOI 10.1089/ARS.2008.2105; Marzec JM, 2007, FASEB J, V21, P2237, DOI 10.1096/fj.06-7759com; Mata M, 2003, EUR RESPIR J, V22, P900, DOI 10.1183/09031936.03.00018003; Matthay MA, 2003, AM J RESP CRIT CARE, V167, P1027, DOI 10.1164/rccm.200208-966WS; Matthews BD, 2001, PEDIATR PULM, V32, P459, DOI 10.1002/ppul.1159; Matthias C, 1998, PHARMACOGENETICS, V8, P91; MCCLELLAN RO, 1987, ANNU REV PHARMACOL, V27, P279; McMahon M, 2003, J BIOL CHEM, V278, P21592, DOI 10.1074/jbc.M300931200; McMahon M, 2006, J BIOL CHEM, V281, P24756, DOI 10.1074/jbc.M601119200; Meulener MC, 2006, P NATL ACAD SCI USA, V103, P12517, DOI 10.1073/pnas.0601891103; MEYER A, 1995, AM J RESP CRIT CARE, V152, P1055; Mochizuki M, 2005, AM J RESP CRIT CARE, V171, P1260, DOI 10.1164/rccm.200406-755OC; Moore ML, 2006, PHARMACOL THERAPEUT, V112, P405, DOI 10.1016/j.pharmthera.2006.04.008; Moss M, 1996, JAMA-J AM MED ASSOC, V275, P50, DOI 10.1001/jama.275.1.50; Nguyen T, 2000, J BIOL CHEM, V275, P15466, DOI 10.1074/jbc.M000361200; NORTHWAY WH, 1967, NEW ENGL J MED, V276, P357, DOI 10.1056/NEJM196702162760701; Ockenga J, 2003, GASTROENTEROLOGY, V124, P1802, DOI 10.1016/S0016-5085(03)00294-4; Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Oue N, 2001, PATHOBIOLOGY, V69, P143, DOI 10.1159/000048769; Padmanabhan B, 2006, MOL CELL, V21, P689, DOI 10.1016/j.molcel.2006.01.013; Papaiahgari S, 2004, J BIOL CHEM, V279, P42302, DOI 10.1074/jbc.M408275200; Papaiahgari S, 2007, AM J RESP CRIT CARE, V176, P1222, DOI 10.1164/rccm.200701-060OC; Pardo A, 2003, AM J RESP CRIT CARE, V167, P925, DOI 10.1164/rccm.200209-1007OC; Powers KA, 2006, J EXP MED, V203, P1951, DOI 10.1084/jem.20060913; Rahman I, 1996, BIOCHEM BIOPH RES CO, V229, P832, DOI 10.1006/bbrc.1996.1888; Rahman I, 2006, BIOCHEM PHARMACOL, V72, P1439, DOI 10.1016/j.bcp.2006.07.004; Rahman I, 1999, ANTIOXID REDOX SIGN, V1, P425, DOI 10.1089/ars.1999.1.4-425; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Ramos-Gomez M, 2003, CARCINOGENESIS, V24, P461, DOI 10.1093/carcin/24.3.461; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; Reddy NM, 2007, PHYSIOL GENOMICS, V32, P74, DOI 10.1152/physiolgenomics.00126.2007; REPINE JE, 1992, LANCET, V339, P466; RUSHMORE TH, 1991, J BIOL CHEM, V266, P11632; Sadowska AM, 2007, PULM PHARMACOL THER, V20, P9, DOI 10.1016/j.pupt.2005.12.007; Saugstad Ola Didrik, 2003, Semin Neonatol, V8, P39, DOI 10.1016/S1084-2756(02)00194-X; Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105; Shih AY, 2003, J NEUROSCI, V23, P3394; Sieger D, 2000, FREE RADICAL BIO MED, V29, P246, DOI 10.1016/S0891-5849(00)00310-5; Singh A, 2008, CANCER RES, V68, P7975, DOI 10.1158/0008-5472.CAN-08-1401; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2009, FREE RADICAL BIO MED, V46, P376, DOI 10.1016/j.freeradbiomed.2008.10.026; Spiteri MA, 2000, ALLERGY, V55, P15, DOI 10.1034/j.1398-9995.2000.00502.x; Sriram N, 2008, PULM PHARMACOL THER, V22, P221; STENZEL JD, 1993, FREE RADICAL BIO MED, V14, P531, DOI 10.1016/0891-5849(93)90110-G; Suzuki M, 2008, AM J RESP CELL MOL, V39, P673, DOI 10.1165/rcmb.2007-0424OC; Talalay P, 2001, J NUTR, V131, p3027S; Tan XL, 2009, LUNG CANCER, V65, P129, DOI 10.1016/j.lungcan.2009.01.002; Taylor JL, 1998, AM J PHYSIOL-LUNG C, V274, pL582; Taylor RC, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000166; Terui K, 2000, TOHOKU J EXP MED, V192, P259, DOI 10.1620/tjem.192.259; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thimmulappa RK, 2007, ANTIOXID REDOX SIGN, V9, P1963, DOI 10.1089/ars.2007.1745; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1127/JCI25790; Thompson K, 2003, J NEUROSCI RES, V71, P46, DOI 10.1002/jnr.10463; Tian LC, 1998, AM J PHYSIOL-CELL PH, V275, pC740; Tirumalai R, 2002, TOXICOL LETT, V132, P27, DOI 10.1016/S0378-4274(02)00055-3; Tripp RA, 2001, NAT IMMUNOL, V2, P732, DOI 10.1038/90675; Uings IJ, 2000, J CLIN PATHOL-MOL PA, V53, P295; Vallyathan V, 1998, ENVIRON HEALTH PERSP, V106, P1151, DOI 10.2307/3433978; van Schaik SM, 2000, J MED VIROL, V62, P257, DOI 10.1002/1096-9071(200010)62:2<257::AID-JMV19>3.0.CO;2-M; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Walter Nicholas, 2006, Proc Am Thorac Soc, V3, P330, DOI 10.1513/pats.200602-016TK; Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004; Wang XT, 2007, HUM MOL GENET, V16, P1188, DOI 10.1093/hmg/ddm066; Wang Y, 2004, FREE RADICAL BIO MED, V37, P1736, DOI 10.1016/j.freeradbiomed.2004.09.006; Wang Y, 2004, AM J PHYSIOL-LUNG C, V286, pL1188, DOI 10.1152/ajplung.00288.2003; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Ware LB, 2006, AM J PHYSIOL-LUNG C, V291, pL307, DOI 10.1152/ajplung.00157.2006; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; WHITNEY PL, 1993, BIOCHIM BIOPHYS ACTA, V1156, P275, DOI 10.1016/0304-4165(93)90042-7; Williams MA, 2008, J IMMUNOL, V181, P4545; Yamamoto M, 2003, J CLIN INVEST, V112, P1395, DOI 10.1172/JCI200317700; Yamamoto T, 2004, BIOCHEM BIOPH RES CO, V321, P72, DOI 10.1016/j.bbrc.2004.06.112; Zhang DD, 2003, MOL CELL BIOL, V23, P8137, DOI 10.1128/MCB.23.22.8137-8151.2003; ZHANG YS, 1994, P NATL ACAD SCI USA, V91, P3147, DOI 10.1073/pnas.91.8.3147; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944; Zipper LM, 2002, J BIOL CHEM, V277, P36544, DOI 10.1074/jbc.M206530200	183	94	100	3	25	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X			TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	APR 1	2010	244	1			SI		43	56		10.1016/j.taap.2009.07.024		14	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	573DU	WOS:000275889400007	19646463	
J	Prescott, SL; Clifton, V				Prescott, Susan L.; Clifton, Vicki			Asthma and pregnancy: emerging evidence of epigenetic interactions in utero	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergic disease; asthma; cord blood; cytokines; epigenetics; fetus; folate; maternal diet; pregnancy	REGULATORY T-CELLS; POPULATION-BASED REGISTER; TOBACCO-SMOKE EXPOSURE; MATERNAL ASTHMA; CORD BLOOD; CHILDHOOD ASTHMA; CESAREAN-SECTION; FETAL SEX; ALLERGIC SENSITIZATION; GENE-EXPRESSION	Purpose of review Pregnancy is arguably the most critical period of developmental programming. Here, we particularly focus on the emerging paradigm that disease propensity is epigenetically determined by maternal exposures that have the capacity to activate or silence fetal genes through alterations in DNA and histone methylation, histone acetylation, and chromatin structure. Recent findings The most notable recent candidate to emerge in this role has been dietary folate, a methyl donor clearly associated with changes in gene expression and disease susceptibility through gene hypermethylation. Animal studies also provide the first evidence that the allergy protective effects of microbial exposure in pregnancy may be mediated by changes in methylation of Th1 genes of the offspring. There is also emerging evidence that perinatal differences in immune function of allergy-prone newborns extend beyond previously recognized differences in effector T cell (Th1/Th2) function, to also include differences in neonatal regulatory T cell (Treg) and Th17 function, and moreover, that these pathways are also epigenetically regulated. Summary New studies reinforce the importance of in-utero exposures (including dietary nutrients, microbial products, cigarette smoking, and certain maternal mediations) in fetal immune development and in programming the susceptibility to asthma and allergic disease.	[Prescott, Susan L.] Univ Western Australia, Sch Paediat & Child Hlth Res, Perth, WA 6001, Australia; [Clifton, Vicki] Univ Adelaide, Robinson Inst, Adelaide, SA, Australia	Prescott, SL (reprint author), Univ Western Australia, Princess Margaret Hosp, Sch Paediat & Child Hlth Res, POB D184, Perth, WA 6001, Australia.	sprescott@meddent.uwa.edu.au	Prescott, Susan/H-5665-2014; Clifton, Vicki/A-1445-2012	Clifton, Vicki/0000-0002-4892-6748			Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99; Bager P, 2008, CLIN EXP ALLERGY, V38, P634, DOI 10.1111/j.1365-2222.2008.02939.x; Bakhireva LN, 2008, ANN ALLERG ASTHMA IM, V101, P137, DOI 10.1016/S1081-1206(10)60201-3; Bakhireva LN, 2008, J ASTHMA, V45, P403, DOI 10.1080/02770900801971826; Bernsen RM, 2008, J ALLERGY CLIN IMMUN, V122, P841, DOI 10.1016/j.jaci.2008.07.046; Bhavsar P, 2008, J ALLERGY CLIN IMMUN, V121, P580, DOI 10.1016/j.jaci.2007.12.1156; Bisgaard H, 2009, J ALLERGY CLIN IMMUN, V123, P651, DOI 10.1016/j.jaci.2008.11.036; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Bousquet J, 2004, ALLERGY, V59, P138, DOI 10.1046/j.1398-9995.2003.00359.x; Boyle RJ, 2008, CLIN EXP ALLERGY, V38, P1882, DOI 10.1111/j.1365-2222.2008.03100.x; BRECKLER L, 2009, PEDIAT ALLERGY IMMUN; Breckler LA, 2008, ALLERGY, V63, P1473, DOI 10.1111/j.1398-9995.2008.01718.x; Breton MC, 2009, THORAX, V64, P101, DOI 10.1136/thx.2008.102970; Castro-Rodriguez JA, 2008, J PEDIATR, V152, P823, DOI 10.1016/j.jpeds.2008.01.003; Cazzola M, 2008, THORAX, V63, P944, DOI 10.1136/thx.2008.104463; Chatzi L, 2008, THORAX, V63, P507, DOI 10.1136/thx.2007.081745; Christensson C, 2008, DRUG SAFETY, V31, P965, DOI 10.2165/00002018-200831110-00002; Clifton VL, 2005, CELL TISSUE RES, V322, P63, DOI 10.1007/s00441-005-1117-5; Clifton VL, 2004, PLACENTA, V25, pS45, DOI 10.1016/j.placenta.2004.01.004; Dehlink E, 2009, CLIN EXP ALLERGY, V39, P246, DOI 10.1111/j.1365-2222.2008.03125.x; Douwes J, 2008, EUR RESPIR J, V32, P603, DOI 10.1183/09031936.00033707; Ege MJ, 2008, ALLERGY, V63, P1505, DOI 10.1111/j.1398-9995.2008.01793.x; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Fox AT, 2009, J ALLERGY CLIN IMMUN, V123, P417, DOI 10.1016/j.jaci.2008.12.014; Fujimaki W, 2008, CLIN DEV IMMUNOL, DOI 10.1155/2008/305859; Garcia-Marcos L, 2008, INT ARCH ALLERGY IMM, V149, P33; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Greer FR, 2008, PEDIATRICS, V121, P183, DOI 10.1542/peds.2007-3022; Haberg SE, 2009, ARCH DIS CHILD, V94, P180, DOI 10.1136/adc.2008.142448; HAN YY, 2009, PEDIAT ALLERGY IMMUN; Hertz-Picciotto I, 2008, BASIC CLIN PHARMACOL, V102, P146, DOI 10.1111/j.1742-7843.2007.00190.x; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holt PG, 2008, J ALLERGY CLIN IMMUN, V122, P717, DOI 10.1016/j.jaci.2008.08.019; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; JANSON PC, 2008, BIOCH BIOPHYS ACTA; Janson PCJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001612; Joffe TH, 2009, J PEDIATR, V154, P154, DOI 10.1016/j.jpeds.2008.08.039; Karmaus W, 2008, J ASTHMA, V45, P688, DOI 10.1080/02770900802178306; Keil T, 2009, ALLERGY, V64, P445, DOI 10.1111/j.1398-9995.2008.01867.x; Kenyon Sara, 2008, BMC Pregnancy Childbirth, V8, P14, DOI 10.1186/1471-2393-8-14; Koenen HJPM, 2008, BLOOD, V112, P2340, DOI 10.1182/blood-2008-01-133967; KRAUSSETSCHMANN S, 2008, J ALLERGY CLIN IMMUN, V121; Mattes E, 2009, BRAIN BEHAV IMMUN, V23, P380, DOI 10.1016/j.bbi.2008.12.004; Mayhew TM, 2008, PLACENTA, V29, P366, DOI 10.1016/j.placenta.2008.01.011; Metsala J, 2008, AM J EPIDEMIOL, V168, P170, DOI 10.1093/aje/kwn105; Miller RL, 2008, J CLIN INVEST, V118, P3265, DOI 10.1172/JCI37171; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Mold JE, 2008, SCIENCE, V322, P1562, DOI 10.1126/science.1164511; Murphy VE, 2006, RESPIROLOGY, V11, P41, DOI 10.1111/j.1440-1843.2006.00782.x; Murphy VE, 2006, THORAX, V61, P169, DOI 10.1136/thx.2005.049718; Murphy VE, 2005, OBSTET GYNECOL, V106, P1046, DOI 10.1097/01.AOG.0000185281.21716.02; Murphy VE, 2003, PLACENTA, V24, P739, DOI 10.1016/S0143-4004(03)00103-6; Noakes PS, 2006, CHEMOSPHERE, V63, P1304, DOI 10.1016/j.chemosphere.2005.09.008; Olsen SF, 2008, AM J CLIN NUTR, V88, P167; Osborn DA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006475.pub2; Osei-Kumah A, 2006, PLACENTA, V27, P847, DOI 10.1016/j.placenta.2005.08.007; Osei-Kumah A, 2008, CYTOKINE, V43, P187, DOI 10.1016/j.cyto.2008.05.008; Persky V, 2008, ANN ALLERG ASTHMA IM, V101, P271, DOI 10.1016/S1081-1206(10)60492-9; Pfefferle PI, 2008, J ALLERGY CLIN IMMUN, V122, P711, DOI 10.1016/j.jaci.2008.06.035; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Polansky JK, 2008, EUR J IMMUNOL, V38, P1654, DOI 10.1002/eji.200838105; Polte T, 2008, CLIN EXP ALLERGY, V38, P1950, DOI 10.1111/j.1365-2222.2008.03096.x; Polte T, 2008, J ALLERGY CLIN IMMUN, V122, P1022, DOI 10.1016/j.jaci.2008.09.014; Prescott SL, 2008, CLIN EXP ALLERGY, V38, P1606, DOI 10.1111/j.1365-2222.2008.03061.x; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Prescott SL, 2008, J ALLERGY CLIN IMMUN, V122, P391, DOI [10.1016/j.jaci.2008.04.042, 10.1016/j.jaci.2008.04.0422]; Prescott SL, 2007, J ALLERGY CLIN IMMUN, V120, P200, DOI 10.1016/j.jaci.2007.03.045; Prescott Susan L, 2003, Curr Opin Allergy Clin Immunol, V3, P125, DOI 10.1097/00130832-200304000-00006; Rebordosa C, 2008, INT J EPIDEMIOL, V37, P583, DOI 10.1093/ije/dyn070; ROBERTSON SA, 2009, BIOL REPROD; Sala-Vila A, 2008, CLIN EXP ALLERGY, V38, P1432, DOI 10.1111/j.1365-2222.2008.03072.x; SANDBERG M, 2008, PEDIAT ALLERGY IMMUN; Sanders VM, 2006, BRAIN BEHAV IMMUN, V20, P317, DOI 10.1016/j.bbi.2005.08.005; Schaub B, 2008, ALLERGY, V63, P1438, DOI 10.1111/j.1398-9995.2008.01685.x; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; Scott NM, 2009, J IMMUNOL, V182, P1411; Shaheen SO, 2009, THORAX, V64, P411, DOI 10.1136/thx.2008.104703; Shaheen SO, 2008, THORAX, V63, P483, DOI 10.1136/thx.2007.090019; Shaheen SO, 2002, THORAX, V57, P958, DOI 10.1136/thorax.57.11.958; Shanks N, 2000, P NATL ACAD SCI USA, V97, P5645, DOI 10.1073/pnas.090571897; Simpson JL, 2008, PAEDIATR RESPIR REV, V9, P263, DOI 10.1016/j.prrv.2008.05.007; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Snijders BEP, 2008, PEDIATRICS, V122, pE115, DOI 10.1542/peds.2007-1651; Stencel-Gabriel K, 2007, PEDIATR ALLERGY IMMU, V18, P659, DOI 10.1111/j.1399-3038.2007.00571.x; Su RC, 2008, J ALLERGY CLIN IMMUN, V121, P57, DOI 10.1016/j.jaci.2007.09.004; Tanaka K, 2008, J ASTHMA, V45, P833, DOI 10.1080/02770900802339742; Tata LJ, 2008, THORAX, V63, P981, DOI 10.1136/thx.2008.098244; Thavagnanam S, 2008, CLIN EXP ALLERGY, V38, P629, DOI 10.1111/j.1365-2222.2007.02780.x; Tollanes MC, 2008, J PEDIATR-US, V153, P112, DOI 10.1016/j.jpeds.2008.01.029; VENTER C, 2009, PEDIAT ALLERGY IMMUN; Waterland RA, 2007, ANNU REV NUTR, V27, P363, DOI 10.1146/annurev.nutr.27.061406.093705; White GP, 2002, J IMMUNOL, V168, P2820; Wickens K, 2008, J ALLERGY CLIN IMMUN, V122, P788, DOI 10.1016/j.jaci.2008.07.011; Willers SM, 2008, AM J RESP CRIT CARE, V178, P124, DOI 10.1164/rccm.200710-1544OC; Williamson AC, 1930, AM J OBSTET GYNECOL, V20, P192	97	94	99	2	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1528-4050			CURR OPIN ALLERGY CL	Curr. Opin. Allergy Clin. Immunol.	OCT	2009	9	5					417	426		10.1097/ACI.0b013e328330634f		10	Allergy; Immunology	Allergy; Immunology	490OT	WOS:000269511100005	19652594	
J	Riedl, MA; Saxon, A; Diaz-Sanchez, D				Riedl, Marc A.; Saxon, Andrew; Diaz-Sanchez, David			Oral sulforaphane increases Phase II antioxidant enzymes in the human upper airway	CLINICAL IMMUNOLOGY			English	Article						Oxidative stress; Antioxidants; Asthma; Allergic inflammation; Sulforaphane; Phase II enzymes; Air pollution	DIESEL EXHAUST PARTICLES; OXIDATIVE STRESS; BROCCOLI SPROUTS; QUANTITATIVE-DETERMINATION; CRUCIFEROUS VEGETABLES; NASAL CHALLENGE; IGE PRODUCTION; IN-VIVO; ISOTHIOCYANATES; ASTHMA	Background: Cellular oxidative stress is an important factor in asthma and is thought to be the principle mechanism by which oxidant pollutants such as ozone and particulates mediate their pro-inflammatory effects. Endogenous Phase II enzymes abrogate oxidative stress through the scavenging of reactive oxygen species and metabolism of reactive chemicals. Objective: We conducted a placebo-controlled dose escalation trial to investigate the in vivo effects of sulforaphane, a naturally occurring potent inducer of Phase II enzymes, on the expression of glutathione-s-transferase M1 (GSTM1), glutathione-s-transferase P1 (GSTP1), NADPH quinone oxidoreductase (NQO1), and hemoxygenase-1 (HO-1) in the upper airway of human subjects. Methods: Study subjects consumed oral sulforaphane doses contained in a standardized broccoli sprout homogenate (BSH). RNA expression for selected Phase II enzymes was measured in nasal lavage cells by RT-PCR before and after sulforaphane dosing. Results: All subjects tolerated oral sulforaphane dosing without significant adverse events. Increased Phase II enzyme expression in nasal lavage cells occurred in a dose-dependent manner with maximal enzyme induction observed at the highest dose of 200 g broccoli sprouts prepared as BSH. Significant increases were seen in all sentinel Phase II enzymes RNA expression compared to baseline. Phase II enzyme induction was not seen with ingestion of non-sulforaphane containing alfalfa sprouts.	[Riedl, Marc A.; Saxon, Andrew] Univ Calif Los Angeles, David Geffen Sch Med, Hart & Louis Lab, Dept Med, Los Angeles, CA 90095 USA; [Diaz-Sanchez, David] US EPA, Human Studies Div, Chapel Hill, NC 27599 USA	Riedl, MA (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Ctr Hlth Sci 37 131, 10833 Conte Ave, Los Angeles, CA 90095 USA.	mriedl@mednet.ucla.edu			NCRR NIH HHS [K12 RR017611, K12 RR017611-05]; NIAID NIH HHS [P01 AI050495, P01 AI050495-05]; NIEHS NIH HHS [5P01ES09581-10, P01 ES009581]; PHS HHS [K12 R011 7611]		BAUTIG A, 2003, LUNG CELL MOL PHYSL, V285, pL671; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Bowler RP, 2002, J ALLERGY CLIN IMMUN, V110, P349, DOI 10.1067/mai.2002.126780; Cho HY, 2006, ANTIOXID REDOX SIGN, V8, P76, DOI 10.1089/ars.2006.8.76; Cho HY, 2002, AM J RESP CELL MOL, V26, P175; Cornblatt BS, 2007, CARCINOGENESIS, V28, P1485, DOI 10.1093/carcin/bgm049; Davies RJ, 1997, ALLERGY, V52, P59; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Diaz-Sanchez D, 1999, CLIN IMMUNOL, V90, P313, DOI 10.1006/clim.1998.4676; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Diaz-Sanchez D, 2006, J ALLERGY CLIN IMMUN, V118, P441, DOI 10.1016/j.jaci.2006.04.047; DIAZSANCHEZ D, 1994, J CLIN INVEST, V94, P1417, DOI 10.1172/JCI117478; Fahey JW, 1997, P NATL ACAD SCI USA, V94, P10367, DOI 10.1073/pnas.94.19.10367; Fahey JW, 2001, PHYTOCHEMISTRY, V56, P5, DOI 10.1016/S0031-9422(00)00316-2; Fahey JW, 1999, FOOD CHEM TOXICOL, V37, P973, DOI 10.1016/S0278-6915(99)00082-4; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1335, DOI 10.1164/rccm.200509-1424OC; Gurgueira SA, 2002, ENVIRON HEALTH PERSP, V110, P749; Kensler TW, 2005, CANCER EPIDEM BIOMAR, V14, P2605, DOI 10.1158/1055-9965.EPI-05-0368; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Lee JS, 2005, CANCER LETT, V224, P171, DOI 10.1016/j.canlet.2004.09.042; Li N, 2006, ANTIOXID REDOX SIGN, V8, P88, DOI 10.1089/ars.2006.8.88; Li N, 2004, J IMMUNOL, V173, P3467; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li N, 2000, J IMMUNOL, V165, P3393; Lim HB, 1998, FREE RADICAL BIO MED, V25, P635, DOI 10.1016/S0891-5849(98)00073-2; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; Marwick JA, 2004, AM J RESP CELL MOL, V31, P633, DOI 10.1165/rcmb.2004-0006OC; Morimitsu Y, 2002, J BIOL CHEM, V277, P3456, DOI 10.1074/jbc.M110244200; Munday R, 2008, CANCER RES, V68, P1593, DOI 10.1158/0008-5472.CAN-07-5009; Pereira B, 1995, BIOCHEM PHARMACOL, V50, P2093, DOI 10.1016/0006-2952(95)02116-7; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Riedl MA, 2008, CURR OPIN ALLERGY CL, V8, P49, DOI 10.1097/ACI.0b013e3282f3d913; RITZ SA, 2007, LUNG CELLULAR MOL PH, V292, pL33; Romieu I, 2004, THORAX, V59, P8; Sadowska AM, 2007, STEROIDS, V72, P1, DOI 10.1016/j.steroids.2006.10.007; SANDERS SP, 1995, AM J RESP CRIT CARE, V151, P1725; Scandalios JG, 2005, BRAZ J MED BIOL RES, V38, P995, DOI 10.1590/S0100-879X2005000700003; Shapiro TA, 2001, CANCER EPIDEM BIOMAR, V10, P501; Shapiro TA, 1998, CANCER EPIDEM BIOMAR, V7, P1091; Shapiro TA, 2006, NUTR CANCER, V55, P53, DOI 10.1207/s15327914nc5501_7; Talalay P, 2007, P NATL ACAD SCI USA, V104, P17500, DOI 10.1073/pnas.0708710104; Thimmulappa RK, 2002, CANCER RES, V62, P5196; Troyer JK, 2001, J CHROMATOGR A, V919, P299, DOI 10.1016/S0021-9673(01)00842-1; Wan JX, 2007, INHAL TOXICOL, V19, P177, DOI 10.1080/08958370701496145; Wan JX, 2006, J IMMUNOL, V177, P3477; Ye LX, 2002, CLIN CHIM ACTA, V316, P43, DOI 10.1016/S0009-8981(01)00727-6; Zhang YS, 1996, ANAL BIOCHEM, V239, P160, DOI 10.1006/abio.1996.0311	48	94	99	0	8	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1521-6616			CLIN IMMUNOL	Clin. Immunol.	MAR	2009	130	3					244	251		10.1016/j.clim.2008.10.007		8	Immunology	Immunology	409UD	WOS:000263530400002	19028145	
J	Julvez, J; Ribas-Fito, N; Torrent, M; Forns, M; Garcia-Esteban, R; Sunyer, J				Julvez, Jordi; Ribas-Fito, Nuria; Torrent, Maties; Forns, Maria; Garcia-Esteban, Raquel; Sunyer, Jordi			Maternal smoking habits and cognitive development of children at age 4 years in a population-based birth cohort	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						maternal smoking habits; smoking during pregnancy; paternal smoking habits; cognitive development; neurocognitive functions; pre-school children; populatin based study; birth cohort	FOLLOW-UP; PREGNANT-WOMEN; IN-UTERO; EXPOSURE; ALCOHOL; TOBACCO; CIGARETTES; MARIJUANA; RISK; NEURODEVELOPMENT	Background Active maternal smoking during pregnancy has been associated with a higher risk of behavioural disorders in children, but a few cohort studies measuring smoking data prospectively have studied its specific effects on the cognitive abilities of pre-schoolers. Method A birth cohort was set up in Menorca Island in 1997 within the Asthma Multicenter Infants Cohort Study. A total of 420 (87% of those eligible) children had complete data for final analyses at age 4 years. Interviewer-administered questionnaires were completed by mothers during the third trimester of pregnancy and then every year up to age 4 years of their child. A standardized version of the McCarthy Scales of Children's Abilities (MCSA) was used to evaluate the child's motor and cognitive capabilities. Multivariable regressions were used with MCSA`s assessed outcomes adjusting for: home location, maternal alcohol consumption, mother's social class and level of education during pregnancy, parity, marital status, father's education level, child's gender, birth weight and height, breastfeeding duration, passive smoking, school season, age during test administration and evaluator (psychologist). Results A high global consistency in maternal smoking habits was found (total agreement= 88.7%). Maternal social class and education level were inversely associated with maternal smoking behaviour. Maternal smoking during pregnancy (in cig./day) was associated with a decrease (in points) of children's global cognitive score [beta=-0.60, (95% CI: -1.10; -0.09)]; as wen as global cognitive sub-areas like verbal score [beta = -0.59, (95% CI: -1.11; -0.07)]; quantitative score [beta=-0.57, (95% CI: -1.08; -0.06)]; executive function score [beta = -0.71, (95% CI: -1.23; -0.20)]; and working memory score [beta=-0.46, (95% CI: -0.92; -0.01)]. Conclusion Our findings suggest an association with maternal smoking during pregnancy and lowered cognitive development in children at age 4 years.	Ctr Res Environm Epidemiol, Inst Municipal Invest Med, E-08003 Barcelona, Spain; Menorca Hlth Area, Menorca, Spain; Univ Barcelona, Dept Personality Evaluat & Psychol Treatment, E-08007 Barcelona, Spain; Univ Pompeu Fabra, Dept Expt Hlth Sci, Barcelona, Spain	Julvez, J (reprint author), Ctr Res Environm Epidemiol, Inst Municipal Invest Med, C Dr Aiguader,88, E-08003 Barcelona, Spain.	jjulvez@imim.es	Forns, Maria/F-9549-2010; Sunyer, J/G-6909-2014	Sunyer, J/0000-0002-2602-4110			Barkley RA, 2001, NEUROPSYCHOL REV, V11, P1, DOI 10.1023/A:1009085417776; Baron SI, 2004, NEUROPSYCHOLOGICAL E; Batstra L, 2003, EARLY HUM DEV, V75, P21, DOI 10.1016/j.earlhumdev.2003.09.001; Batty GD, 2006, PEDIATRICS, V118, P943, DOI 10.1542/peds.2006-0168; Breslau N, 2005, INT J EPIDEMIOL, V34, P1047, DOI 10.1093/ije/dyi163; Buka SL, 2003, AM J PSYCHIAT, V160, P1978, DOI 10.1176/appi.ajp.160.11.1978; Cornelius MD, 2001, J DEV BEHAV PEDIATR, V22, P217; Cornelius MD, 2000, ALCOHOL RES HEALTH, V24, P242; ESKENAZI B, 1995, AM J EPIDEMIOL, V142, pS19; Espy K A, 2001, J Pediatr Psychol, V26, P1, DOI 10.1093/jpepsy/26.1.1; Fergusson DM, 1998, ARCH GEN PSYCHIAT, V55, P721, DOI 10.1001/archpsyc.55.8.721; Fried PA, 2001, NEUROTOXICOL TERATOL, V23, P1, DOI 10.1016/S0892-0362(00)00119-7; FRIED PA, 1992, J DEV BEHAV PEDIATR, V13, P383; FRIED PA, 1988, NEUROTOXICOL TERATOL, V10, P305, DOI 10.1016/0892-0362(88)90032-3; FRIED PA, 1992, NEUROTOXICOL TERATOL, V14, P299, DOI 10.1016/0892-0362(92)90036-A; Fried PA, 1998, NEUROTOXICOL TERATOL, V20, P293, DOI 10.1016/S0892-0362(97)00091-3; Haynes G, 2003, NEUROTOXICOL TERATOL, V25, P659, DOI 10.1016/j.ntt.2003.07.003; HELLSTROMLINDAH.E, 1998, BRAIN RES DEV BRAIN, V108, P147; Huizink AC, 2006, NEUROSCI BIOBEHAV R, V30, P24, DOI 10.1016/j.neubiorev.2005.04.005; JACOBSEN SW, 1992, LONGITUDINAL STUDIE; Jacobson JL, 2005, NEUROTOXICOL TERATOL, V27, P395, DOI 10.1016/j.ntt.2005.01.009; JULVEZ J, 2007, IN PRESS ACTA PAEDIA; Kolb B, 1996, FUNDAMENTALS HUMAN N; Lawlor DA, 2007, AM J EPIDEMIOL, V165, P418, DOI 10.1093/aje/kwk030; Levin ED, 1998, HANDBOOK OF DEVELOPMENTAL NEUROTOXICOLOGY, P587; LEZAK MD, 2004, NEUROPSYCHOLOGICAL A; Li Y, 2004, PHARMACOL RES, V49, P467, DOI 10.1016/j.phrs.2003.11.002; Linnet KM, 2003, AM J PSYCHIAT, V160, P1028, DOI 10.1176/appi.ajp.160.6.1028; Lynch ME, 2003, J STUD ALCOHOL, V64, P678; McCarthy D., 1996, MANUAL MCCARTHY SCAL; Mortensen EL, 2002, JAMA-J AM MED ASSOC, V287, P2365, DOI 10.1001/jama.287.18.2365; OLDS D, 1997, MENTAL RETARDATION D, V3, P357; Paule MG, 2000, NEUROTOXICOL TERATOL, V22, P631, DOI 10.1016/S0892-0362(00)00095-7; Perera FP, 2006, ENVIRON HEALTH PERSP, V114, P1287, DOI 10.1289/ehp.9084; Ramsay MC, 2000, NEUROPSYCHOL REV, V10, P1, DOI 10.1023/A:1009065713389; Roy TS, 2002, J PHARMACOL EXP THER, V300, P124, DOI 10.1124/jpet.300.1.124; SUZUKI K, 1980, AM J OBSTET GYNECOL, V136, P1009; Trasti N, 1999, EARLY HUM DEV, V55, P137, DOI 10.1016/S0378-3782(99)00017-1; Walker A, 1999, CHILD ADOL PSYCH CL, V8, P845; Watson R, 1998, BRIT MED J, V316, P9; Weissman MM, 1999, J AM ACAD CHILD PSY, V38, P892, DOI 10.1097/00004583-199907000-00020; Weitzman M, 2002, NEUROTOXICOL TERATOL, V24, P397, DOI 10.1016/S0892-0362(02)00201-5; Wisborg K, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.4.e46; Yuan KH, 1998, BRIT J MATH STAT PSY, V51, P289	44	94	95	3	18	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	AUG	2007	36	4					825	832		10.1093/ije/dym107		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	218XW	WOS:000250050300024	17550944	
J	Blumer, N; Sel, S; Virna, S; Patrascan, CC; Zimmermann, S; Herz, U; Renz, H; Garn, H				Blumer, N.; Sel, S.; Virna, S.; Patrascan, C. C.; Zimmermann, S.; Herz, U.; Renz, H.; Garn, H.			Perinatal maternal application of Lactobacillus rhamnosus GG suppresses allergic airway inflammation in mouse offspring	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						airway inflammation; allergy; materno-fetal interaction; mice; probiotics	PLACEBO-CONTROLLED TRIAL; DENDRITIC CELL-FUNCTION; CD4(+) T-CELLS; MURINE MODEL; PROBIOTIC BACTERIA; ATOPIC DISEASE; EXPERIMENTAL ASTHMA; HYGIENE HYPOTHESIS; IMMUNE-SYSTEM; FOOD ALLERGY	Clinical studies indicate that maternal exposure to probiotic bacteria may protect from the development of allergic disease later in life. The purpose of this study was to analyse the effects of a perinatal Lactobacillus rhamnosus GG (LGG) supplementation on the development of allergic disorders in offspring. Female BALB/c mice received intragastric LGG every other day before conception, during pregnancy and lactation (perinatal supplementation group) or before conception and during pregnancy only (prenatal supplementation group). Cytokine expression of placental tissues was examined. Offspring of LGG-supplemented and sham-exposed mothers were sensitized to Ovalbumin (OVA), followed by aerosol allergen challenges. Development of experimental asthma was assessed by bronchoalveolar lavage analysis, lung histology and lung function measurement. Cytokine production of splenic mononuclear cells was analysed following in vitro stimulation. Intestinal colonization with LGG was observed in mother mice only, but not in the offspring. However, a reduced expression of TNF-alpha, IFN-gamma, IL-5 as well as IL-10 was observed in mice derived from perinatally LGG-supplemented mothers, whereas IL-13 and IL-4 expression remained unchanged. Moreover, in offspring of prenatally or perinatally LGG-supplemented mothers allergic airway and peribronchial inflammation as well as goblet cell hyperplasia were significantly reduced as compared with mice derived from non-supplemented mothers. In contrast, airway hyperresponsiveness to methacholine was not affected. Exposure to LGG during pregnancy only shifted the placental cytokine expression pattern with a markedly increased TNF-alpha level. Our data suggest that LGG may exert beneficial effects on the development of experimental allergic asthma, when applied in a very early phase of life. Immunological effects are, at least in parts, mediated via the placenta, probably by induction of pro-inflammatory cell signals.	Hosp Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Berlin, Germany; Hosp Philipps Univ Marburg, Dept Med Microbiol, Berlin, Germany; Bristol Myers Squibb Co, Mead Johnson Nutrit, Evanston, IL USA	Blumer, N (reprint author), Hosp Philipps Univ Marburg, Dept Clin Chem & Mol Diagnost, Berlin, Germany.	bluemer@mailer.uni-marburg.de					Atasoy U, 2003, J IMMUNOL, V171, P4369; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Braat H, 2004, AM J CLIN NUTR, V80, P1618; Bunder R, 2004, J ALLERGY CLIN IMMUN, V114, P422, DOI 10.1016/j.jaci.2004.05.029; de Vrese M, 2002, BRIT J NUTR, V88, pS59, DOI 10.1079/BJN2002630; Erickson KL, 2000, J NUTR, V130, P403; Foster PS, 2000, LAB INVEST, V80, P655; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FULLER R, 1989, J APPL BACTERIOL, V66, P365; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Helin T, 2002, ALLERGY, V57, P243, DOI 10.1034/j.1398-9995.2002.1s3299.x; Hessle C, 1999, CLIN EXP IMMUNOL, V116, P276; Ishida Y, 2003, BIOSCI BIOTECH BIOCH, V67, P951, DOI 10.1271/bbb.67.951; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki Marko, 2003, Curr Opin Allergy Clin Immunol, V3, P15, DOI 10.1097/00130832-200302000-00003; Kerzel S, 2003, AM J RESP CELL MOL, V28, P170, DOI 10.1165/rcmb.4811; Kirjavainen PV, 2003, J PEDIATR GASTR NUTR, V36, P223, DOI 10.1097/00005176-200302000-00012; Kirjavainen PV, 1999, ALLERGY, V54, P909, DOI 10.1034/j.1398-9995.1999.00103.x; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Matricardi PM, 2002, ALLERGY, V57, P185, DOI 10.1034/j.1398-9995.2002.1a3299.x; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; Mohamadzadeh M, 2005, P NATL ACAD SCI USA, V102, P2880, DOI 10.1073/pnas.0500098102; Noverr MC, 2004, TRENDS MICROBIOL, V12, P562, DOI 10.1016/j.tim.2004.10.008; Ohno H, 2005, BIOL PHARM BULL, V28, P1462, DOI 10.1248/bpb.28.1462; PERDIGON G, 1995, J DAIRY SCI, V78, P1597; RENZ H, 1992, J ALLERGY CLIN IMMUN, V89, P1127, DOI 10.1016/0091-6749(92)90296-E; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Schrezenmeir J., 2001, AM J CLIN NUTR, V73, P361; Smits HH, 2005, J ALLERGY CLIN IMMUN, V115, P1260, DOI 10.1016/j.jaci.2005.03.036; Solomon A, 2005, CLIN EXP ALLERGY, V35, P941, DOI 10.1111/j.1365-2222.2005.02285.x; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Vaarala O, 2003, CLIN EXP ALLERGY, V33, P1634, DOI 10.1111/j.1365-2222.2003.01835.x; Viljanen M, 2005, J ALLERGY CLIN IMMUN, V115, P1254, DOI 10.1016/j.jaci.2005.03.047; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; von der Weid T, 2001, CLIN DIAGN LAB IMMUN, V8, P695, DOI 10.1128/CDLI.8.4.695-701.2001; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579	43	94	100	0	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2007	37	3					348	357		10.1111/j.1365-2222.2007.02671.x		10	Allergy; Immunology	Allergy; Immunology	144DO	WOS:000244776000007	17359385	
J	Bernard, A; Carbonnelle, S; de Burbure, C; Michel, O; Nickmilder, M				Bernard, Alfred; Carbonnelle, Sylviane; de Burbure, Claire; Michel, Olivier; Nickmilder, Marc			Chlorinated pool attendance, atopy, and the risk of asthma during childhood	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						aeroallergens; atopy; childhood asthma; chlorine; exercise-induced asthma; exhaled nitric oxide; nitrogen trichloride; swimming pool; total IgE; trichloramine	SERUM IMMUNOGLOBULIN-E; NITROGEN TRICHLORIDE; HYGIENE HYPOTHESIS; SWIMMING POOLS; SODIUM-HYPOCHLORITE; TIGHT JUNCTIONS; NITRIC-OXIDE; LUNG; SCHOOLCHILDREN; CHLORAMINES	The pool chlorine hypothesis postulates that the rise in childhood asthma in the developed world could result at least partly from the increasing exposure of children to toxic gases and aerosols contaminating the air of indoor chlorinated pools. To further assess this hypothesis, we explored the relationships between childhood asthma, atopy, and cumulated pool attendance (CPA). We studied 341 schoolchildren 10-13 years of age who attended at a variable rate the same public pool in Brussels (trichloramine in air, 0.3-0.5 mg/m(3)). Examination of the children included a questionnaire, an exercise-induced bronchoconstriction (EIB) test, and the measurement of exhaled nitric oxide (eNO) and total and aeroallergen-specific serum IgE. CPA by children (range, 0-1,818 hr) emerged among the most consistent predictors of asthma (doctor diagnosed or screened with the EIB test) and of elevated eNO, ranking immediately after atopy and family history of asthma or hay fever. Although the risk of elevated eNO increased with CPA [odds ratio (OR) = 1.30; 95% confidence interval (CI), 1.10-1.43] independently of total or specific serum IgE, the probability of developing asthma increased with CPA only in children with serum IgE > 100 kIU/L (OR for each 100-hr increase in CPA = 1.79; 95% CI, 1.07-2.72). All these effects were dose related and most strongly linked to pool attendance before 6-7 years of age. Use of indoor chlorinated pools especially by young children interacts with atopic status to promote the development of childhood asthma. These findings further support the hypothesis implicating pool chlorine in the rise of childhood asthma in industrialized countries. Key words: aeroallergens, atopy, childhood asthma, chlorine, exercise-induced asthma, exhaled nitric oxide, nitrogen trichloride, swimming pool, total IgE, trichloramine.	Univ Catholique Louvain, Toxicol Unit, Dept Publ Hlth, B-1200 Brussels, Belgium; Free Univ Brussels, Clin Allergol, Brussels, Belgium; Free Univ Brussels, Clin Resp Dis, Brussels, Belgium	Bernard, A (reprint author), Univ Catholique Louvain, Toxicol Unit, Dept Publ Hlth, 30-54 Clos Chapelle aux Champs, B-1200 Brussels, Belgium.	bernard@toxi.ucl.ac.be	Nickmilder, Marc/A-9060-2010; BERNARD, Alfred/A-6511-2010	BERNARD, Alfred/0000-0003-3171-3743; michel, olivier/0000-0002-1528-1277			Allison PD, 1999, LOGISTIC REGRESSION; *AM LUNG ASS, 2004, TRENDS ASTHM MORB MO; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Beeh KM, 2000, EUR RESPIR J, V16, P609, DOI 10.1034/j.1399-3003.2000.16d07.x; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Chen P, 2001, CLIN EXP ALLERGY, V31, P1086, DOI 10.1046/j.1365-2222.2001.01127.x; EXON JH, 1987, TOXICOLOGY, V44, P257, DOI 10.1016/0300-483X(87)90028-X; Finkelstein JN, 2004, PEDIATRICS, V113, P1092; GAGNAIRE F, 1994, J APPL TOXICOL, V14, P405, DOI 10.1002/jat.2550140604; Gilmour I. M., 2006, ENV HLTH PERSPECT, V114, P627; Johnson CC, 2002, EPIDEMIOL REV, V24, P154, DOI 10.1093/epirev/mxf013; Klinnert M. D., 2001, PEDIATRICS, V108, P69; Kramer MS, 2004, CLIN EXP ALLERGY, V34, P753, DOI 10.1111/j.1365-2222.2004.01940.x; Lagerkvist BJ, 2004, ENVIRON HEALTH PERSP, V112, P1768, DOI 10.1289/ehp.7027; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; MCFADDEN ER, 1994, NEW ENGL J MED, V330, P1362, DOI 10.1056/NEJM199405123301907; MCGEADY SJ, 2004, PEDIATRICS, V112, P1107; Michel O, 1999, AM J RESP CRIT CARE, V159, pA145; Schuetze G, 1999, PEDIATR ALLERGY IMMU, V10, P138, DOI 10.1034/j.1399-3038.1999.00025.x; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; Silkoff PE, 2004, J ALLERGY CLIN IMMUN, V114, P1241, DOI 10.1016/j.jaci.2004.08.042; Skoner DP, 2002, PEDIATRICS, V109, P393; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; Tulic MK, 2003, CHEST, V123, p348S, DOI 10.1378/chest.123.3_suppl.348S; Umetsu DT, 2004, NAT MED, V10, P232, DOI 10.1038/nm0304-232; von Mutius E, 2001, CLIN EXP ALLERGY, V31, P1651, DOI 10.1046/j.1365-2222.2001.01272.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; WHO, 2000, EUR SER WHO, V91	35	94	95	0	11	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	OCT	2006	114	10					1567	1573		10.1289/ehp.8461		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	090RW	WOS:000240969700035	17035144	
J	Cruse, G; Duffy, SM; Brightling, CE; Bradding, P				Cruse, G.; Duffy, S. M.; Brightling, C. E.; Bradding, P.			Functional K(Ca)3.1 K+ channels are required for human lung mast cell migration	THORAX			English	Article							ACTIVATED POTASSIUM CHANNEL; AIRWAY SMOOTH-MUSCLE; SELECTIVE INHIBITOR; EPITHELIAL-CELLS; ION CHANNELS; BONE-MARROW; EXPRESSION; PROLIFERATION; IMMUNOMODULATION; INFILTRATION	Background: Mast cell recruitment and activation are critical for the initiation and progression of inflammation and fibrosis. Mast cells infiltrate specific structures in many diseased tissues such as the airway smooth muscle (ASM) in asthma. This microlocalisation of mast cells is likely to be key to disease pathogenesis. Human lung mast cells (HLMC) express the Ca2+ activated K+ channel K(Ca)3.1 which modulates mediator release, and is proposed to facilitate the retraction of the cell body during migration of several cell types. A study was undertaken to test the hypothesis that blockade of K(Ca)3.1 would attenuate HLMC proliferation and migration. Methods: HLMC were isolated and purified from lung material resected for bronchial carcinoma. HLMC proliferation was assessed by cell counts at various time points following drug exposure. HLMC chemotaxis was assayed using standard Transwell chambers (8 mm pore size). Ion currents were measured using the single cell patch clamp technique. Results: K(Ca)3.1 blockade with triarylmethane-34 (TRAM-34) did not inhibit HLMC proliferation and clotrimazole had cytotoxic effects. In contrast, HLMC migration towards the chemokine CXCL10, the chemoattractant stem cell factor, and the supernatants from tumour necrosis factor a stimulated asthmatic ASM was markedly inhibited with both the non-selective K(Ca)3.1 blocker charybdotoxin and the highly specific K(Ca)3.1 blocker TRAM-34 in a dose dependent manner. Although K(Ca)3.1 blockade inhibits HLMC migration, K(Ca)3.1 is not opened by the chemotactic stimulus, suggesting that it must be involved downstream of the initial receptor-ligand interactions. Conclusions: Since modulation of K(Ca)3.1 can inhibit HLMC chemotaxis to diverse chemoattractants, the use of K(Ca)3.1 blockers such as TRAM-34 could provide new therapeutic strategies for mast cell mediated diseases such as asthma.	Univ Leicester, Dept Resp Med, Glenfield Gen Hosp, Inst Lung Hlth,Dept Infect Immun & Inflammat,Sch, Leicester LE3 9QP, Leics, England	Cruse, G (reprint author), Univ Leicester, Dept Resp Med, Glenfield Gen Hosp, Inst Lung Hlth,Dept Infect Immun & Inflammat,Sch, Groby Rd, Leicester LE3 9QP, Leics, England.	glenncruse@hotmail.com	Cruse, Glenn/B-4597-2012	Bradding, Peter/0000-0001-8403-0319	Wellcome Trust [, 076264]		Aktas H, 1998, P NATL ACAD SCI USA, V95, P8280, DOI 10.1073/pnas.95.14.8280; Berger P, 2003, FASEB J, V17, P2139, DOI 10.1096/fj.03-0041fje; Bradding P, 2005, CHEM IMMUNOL ALLERGY, V87, P163; Bradding P, 1999, CRIT REV ONCOL HEMAT, V31, P119, DOI 10.1016/S1040-8428(99)00010-4; Bradding P, 2003, J LEUKOCYTE BIOL, V73, P614, DOI 10.1189/jlb.1202602; Brightling CE, 2005, AM J RESP CRIT CARE, V171, P1103, DOI 10.1164/rccm.200409-1220OC; Brightling CE, 2005, J LEUKOCYTE BIOL, V77, P759, DOI 10.1189/jlb.0904511; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; Duffy SM, 2005, FASEB J, V19, P1006, DOI 10.1096/fj.04-3439fie; Duffy SM, 2004, J ALLERGY CLIN IMMUN, V114, P66, DOI 10.1016/j.jaci.2004.04.005; Duffy SM, 2003, J ALLERGY CLIN IMMUN, V112, P965, DOI 10.1067/mai.2003.1779; Duffy SM, 2001, J IMMUNOL, V167, P4261; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; GIMENEZGALLEGO G, 1988, P NATL ACAD SCI USA, V85, P3329, DOI 10.1073/pnas.85.10.3329; Grgic I, 2005, ARTERIOSCL THROM VAS, V25, P704, DOI 10.1161/01.ATV.0000156399.12787.5c; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Jensen BS, 1999, P NATL ACAD SCI USA, V96, P10917, DOI 10.1073/pnas.96.19.10917; Jones SE, 2003, KIDNEY INT, V64, P906, DOI 10.1046/j.1523-1755.2003.00183.x; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kaur D, 2005, CLIN EXP ALLERGY, V35, P226, DOI 10.1111/j.1365-2222.2005.02161.x; Kohler R, 2003, CIRCULATION, V108, P1119, DOI 10.1161/01.CIR.0000086464.04719.DD; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; PENSO J, 2002, EUR J PHARMACOL, V45, P227; Schilling T, 2004, EUR J NEUROSCI, V19, P1469, DOI 10.1111/j.1460-9568.2004.03265.x; Schneider SW, 2000, PFLUG ARCH EUR J PHY, V439, P297, DOI 10.1007/s004240050943; Schwab A, 2006, J CELL PHYSIOL, V206, P86, DOI 10.1002/jcp.20434; Schwab A, 1999, PFLUG ARCH EUR J PHY, V438, P330, DOI 10.1007/s004240050917; TETLOW LC, 1995, ANN RHEUM DIS, V54, P549, DOI 10.1136/ard.54.7.549; URBAHNS K, 2005, BIOORG MED CHEM LETT, V13, P2637; WOJTULEWSKI JA, 1980, ANN RHEUM DIS, V39, P469, DOI 10.1136/ard.39.5.469; Wulff H, 2000, P NATL ACAD SCI USA, V97, P8151, DOI 10.1073/pnas.97.14.8151; Wulff H, 2001, J BIOL CHEM, V276, P32040, DOI 10.1074/jbc.M105231200; Wulff H, 2004, J IMMUNOL, V173, P776; Zhang WJ, 2002, DRUG METAB DISPOS, V30, P314, DOI 10.1124/dmd.30.3.314	35	94	96	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	OCT	2006	61	10					880	885		10.1136/thx.2006.060319		6	Respiratory System	Respiratory System	088YO	WOS:000240847200012	16809411	
J	Johnston, NW; Sears, MR				Johnston, N. W.; Sears, M. R.			Asthma exacerbations center dot 1: Epidemiology	THORAX			English	Review							INHALED CORTICOSTEROIDS; RESPIRATORY-INFECTIONS; INDUSTRIAL POPULATION; RHINOVIRUS INFECTIONS; HOSPITAL ADMISSIONS; AIR-POLLUTION; UNITED-STATES; CHILDREN; SYMPTOMS; ILLNESS	Asthma exacerbations may be triggered by a number of atmospheric and domiciliary environmental factors as well as by those encountered in schools and workplaces. The majority of exacerbations, particularly in children, coincide with respiratory viral infections, most commonly rhinovirus. As most respiratory viruses and many aeroallergens appear in seasonal patterns, asthma exacerbations, particularly those requiring emergency treatment, show analogous seasonal cycles which differ in form in children and adults. While similar in form between the sexes, they differ in amplitude, with boys having higher risks of exacerbation in childhood and women in adult life. Simultaneous exposure of asthmatics with respiratory viral infections to allergens or air pollutants may significantly increase the risks of exacerbation. Access to and compliance with inhaled corticosteroid treatment is an important predictor of the likelihood of asthma exacerbations occurring, including those that occur during respiratory viral infections. Epidemiologically, the degree of asthma control achieved by asthmatics is an important predictor of the likelihood of disease exacerbation including respiratory failure, death, and health service consumption.	St Josephs Healthcare, Firestone Inst Resp Hlth, Hamilton, ON L8N 4A6, Canada	Johnston, NW (reprint author), St Josephs Healthcare, Firestone Inst Resp Hlth, 50 Charlton Ave E, Hamilton, ON L8N 4A6, Canada.	njohnsto@sympatico.ca					ANDERSSON F, 2003, J ASTHMA, V5, P615; ANTO JM, 1989, NEW ENGL J MED, V320, P1097, DOI 10.1056/NEJM198904273201701; ATKINSON RW, 2004, THORAX, V569, P277; Brenner BE, 2005, THORAX, V60, P806, DOI 10.1136/thx.2004.033928; Campbell MJ, 1997, BRIT MED J, V315, P1012; Cerveri I, 1999, EUR RESPIR J, V14, P288, DOI 10.1034/j.1399-3003.1999.14b09.x; Chauhan AJ, 2003, BRIT MED BULL, V68, P95, DOI 10.1093/bmb/ldg022; Dales RE, 2004, J ALLERGY CLIN IMMUN, V113, P303, DOI 10.1016/j.jaci.2003.11.016; Dales RE, 1996, EUR RESPIR J, V9, P72, DOI 10.1183/09031936.96.09010072; Dales RE, 2003, CHEST, V123, P745, DOI 10.1378/chest.123.3.745; Doull IJM, 1997, BRIT MED J, V315, P858; FLOYER JA, TREATISE ASTHMA, P1717; Friedlander SL, 2005, J ALLERGY CLIN IMMUN, V116, P267, DOI 10.1016/j.jaci.2005.06.003; Gern JE, 2002, AM J MED, V112, p19S; Getahun D, 2005, J ASTHMA, V42, P373, DOI 10.1081/JAS-200062995; Grunberg K, 2001, AM J RESP CRIT CARE, V164, P1816; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; Hales S, 1998, ENVIRON HEALTH PERSP, V106, P607, DOI 10.1289/ehp.98106607; HENDLEY JO, 1969, AM J EPIDEMIOL, V89, P184; Hersoug LG, 2005, INDOOR AIR, V15, P363, DOI 10.1111/j.1600-0668.2005.00382.x; Higham J, 1997, J EPIDEMIOL COMMUN H, V51, P233, DOI 10.1136/jech.51.3.233; HYNDMAN SJ, 1994, BRIT MED J, V308, P1596; Ivey Marsha A., 2001, Allergology International, V50, P29, DOI 10.1046/j.1440-1592.2001.00198.x; Jamason PF, 1997, AM J RESP CRIT CARE, V156, P1781; Johnston NW, 2006, J ALLERGY CLIN IMMUN, V117, P557, DOI 10.1016/j.jaci.2005.11.034; JOHNSTON NW, 2006, IN PRESS EXACERBATIO; JOHNSTON NW, 2005, J ALLERGY CLIN IMMUN, V112, P132; Johnston Sebastian L, 2005, Proc Am Thorac Soc, V2, P150, DOI 10.1513/pats.200502-018AW; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654; Jones C, 2003, J ASTHMA, V40, P93, DOI 10.1081/JAS-120017212; Kimbell-Dunn M, 2000, Respirology, V5, P241, DOI 10.1046/j.1440-1843.2000.00255.x; Lane S, 2006, RESP MED, V100, P434, DOI 10.1016/j.rmed.2005.06.012; LISTER S, 2001, AUST NZ J PUBL HEAL, V255, P14; Maimonides Moses, 1963, TREATISE ASTHMA, P1; Manfreda J, 2001, CAN MED ASSOC J, V164, P995; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; McKean M, 2000, COCHRANE DB SYST REV, V1; Murray Clare S, 2004, Proc Am Thorac Soc, V1, P99, DOI 10.1513/pats.2306027; MURRAY CS, 2005, THORAX, V61, P376; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Panickar JR, 2005, THORAX, V60, P1035, DOI 10.1136/thx.2005.044750; Parameswaran K, 2003, J ASTHMA, V40, P107, DOI 10.1081/JAS-120017980; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Peden DB, 2005, J ALLERGY CLIN IMMUN, V115, P213, DOI 10.1016/j.jaci.2004.12.003; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Reddel H, 1999, LANCET, V353, P364, DOI 10.1016/S0140-6736(98)06128-5; Rennard Stephen I, 2004, Proc Am Thorac Soc, V1, P88, DOI 10.1513/pats.2306026; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Salter HH, 1860, ASTHMA ITS PATHOLOGY; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Skrepnek GH, 2004, AM J MANAG CARE, V10, pS129; Suissa S, 2001, J ALLERGY CLIN IMMUN, V107, P937, DOI 10.1067/mai.2001.115653; TAN WC, 2004, CURR OPIN PULM MED, V11, P21; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Tattersfield AE, 1999, AM J RESP CRIT CARE, V160, P594; THOMAS KE, 1991, BRIT J IND MED, V48, P314; UNGER L, 1974, ANN ALLERGY, V32, P214; Vermeire PA, 2002, RESP MED, V96, P142, DOI 10.1053/rmed.2001.1241; Weiland SK, 2004, OCCUP ENVIRON MED, V61, P609, DOI 10.1136/oem.2002.006809; Weinberger M, 2003, J PEDIATR-US, V142, pS34, DOI 10.1067/mpd.2003.24; WEISS KB, 1990, JAMA-J AM MED ASSOC, V263, P2323	61	94	97	1	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	AUG	2006	61	8					722	728		10.1136/thx.2005.045161		7	Respiratory System	Respiratory System	068JL	WOS:000239369700017	16877691	
J	Purvis, DJ; Thompson, JMD; Clark, PM; Robinson, E; Black, PN; Wild, CJ; Mitchell, EA				Purvis, DJ; Thompson, JMD; Clark, PM; Robinson, E; Black, PN; Wild, CJ; Mitchell, EA			Risk factors for atopic dermatitis in New Zealand children at 3.5 years of age	BRITISH JOURNAL OF DERMATOLOGY			English	Article						allergic diseases; atopic dermatitis; atopy; breastfeeding; eczema; hygiene hypothesis	ALLERGIC DISEASE; HAY-FEVER; CHILDHOOD ECZEMA; BIRTH COHORT; EARLY-LIFE; ASTHMA; EXPOSURE; SYMPTOMS; INFANTS; HYGIENE	Background The prevalence of atopic dermatitis (AD) is increasing in Western societies. The hygiene hypothesis proposes that this is due to reduced exposure to environmental allergens and infections during early life. Objectives To examine factors associated with a diagnosis of AD at 3.5 years of age, especially those factors implicated by the hygiene hypothesis. Methods The Auckland Birthweight Collaborative study is a case-control study of risk factors for small for gestational age babies. Cases were born at term with birthweight <= 10th centile; controls were appropriate for gestational age, with birthweight > 10th centile. The infants were assessed at birth, 1 year and 3.5 years of age. Data were collected by parental interview and examination of the child. AD was defined as the presence of an itchy rash in the past 12 months with three or more of the following: history of flexural involvement; history of generally dry skin; history of atopic disease in parents or siblings; and visible flexural dermatitis as per photographic protocol. Statistical analyses took into account the disproportionate sampling of the study population. Results Analysis was restricted to European subjects. Eight hundred and seventy-one children were enrolled at birth, 744 (85.4%) participated at 1 year, and 550 (63.2%) at 3.5 years. AD was diagnosed in 87 (15.8%) children seen at 3.5 years. The prevalence of AD did not differ by birthweight. AD at 3.5 years was associated with raised serum IgE > 200 kU L-1, and wheezing, asthma, rash or eczema at 1 year. In multivariate analysis, adjusted for parental atopy and breastfeeding, AD at 3.5 years was associated with atopic disease in the parents: maternal atopy only, adjusted odds ratio (OR) 3.83, 95% confidence interval (CI) 1.20-12.23; paternal atopy only, adjusted OR 3.59, 95% CI 1.09-11.75; both parents atopic, adjusted OR 6.12, 95% CI 2.02-18.50. There was a higher risk of AD with longer duration of breastfeeding: < 6 months, adjusted OR 6.13, 95% CI 1.45-25.86; >= 6 months, adjusted OR 9.70, 95% CI 2.47-38.15 compared with never breastfed. These findings remained significant after adjusting for environmental factors and a personal history of atopy. AD at 3.5 years was associated with owning a cat at 3.5 years (adjusted OR 0.45, 95% CI 0.21-0.97) but not with owning a dog at 3.5 years, pets at 1 year, nor with older siblings. Furthermore, AD at 3.5 years was not associated with gender, socioeconomic status, maternal smoking, parity, damp, mould, immunizations, body mass index or antibiotic use in first year of life. Conclusions A personal and a parental history of atopic disease are risk factors for AD at 3.5 years. Duration of breastfeeding was associated with an increased risk of AD. No association was found with those factors implicated by the hygiene hypothesis. This study suggests that breastfeeding should not be recommended for the prevention of AD.	Univ Auckland, Dept Paediat, Auckland, New Zealand; Univ Auckland, Sch Populat Hlth, Auckland 1, New Zealand; Univ Auckland, Dept Med, Auckland, New Zealand; Univ Auckland, Dept Stat, Auckland 1, New Zealand	Mitchell, EA (reprint author), Univ Auckland, Dept Paediat, Private Bag 92019, Auckland, New Zealand.	e.mitchell@auckland.ac.nz	Wild, Christopher/A-1449-2012	Wild, Christopher/0000-0003-0115-6448			Asher MI, 2001, NEW ZEAL MED J, V114, P114; Bergmann RL, 2002, CLIN EXP ALLERGY, V32, P205, DOI 10.1046/j.1365-2222.2002.01274.x; Bottcher MF, 2002, CLIN EXP ALLERGY, V32, P159, DOI 10.1046/j.1365-2222.2002.01343.x; Braback L, 2001, PEDIATR ALLERGY IMMU, V12, P4, DOI 10.1034/j.1399-3038.2001.012001004.x; BRAUNFAHRLANDER C, 2002, CURR OPIN ALLERGY CL, V3, P325; Butland BK, 1997, BRIT MED J, V315, P717; Farooqi IS, 1998, THORAX, V53, P927; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; FERGUSSON DM, 1982, J EPIDEMIOL COMMUN H, V36, P118, DOI 10.1136/jech.36.2.118; Gdalevich M, 2001, J AM ACAD DERMATOL, V45, P520, DOI 10.1067/mjd.2001.114741; HARPER J, 2000, TXB PEDIAT DERMATOLO, V1, P161; Harris JM, 2001, BRIT J DERMATOL, V144, P795, DOI 10.1046/j.1365-2133.2001.04135.x; Holscher B, 2002, PEDIATR ALLERGY IMMU, V13, P334, DOI 10.1034/j.1399-3038.2002.02063.x; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; Kramer MS, 2001, JAMA-J AM MED ASSOC, V285, P413, DOI 10.1001/jama.285.4.413; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Leadbitter P, 1999, THORAX, V54, P905; Lewis SA, 1998, RESP MED, V92, P1237, DOI 10.1016/S0954-6111(98)90427-9; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; McKeever TM, 2001, THORAX, V56, P758, DOI 10.1136/thorax.56.10.758; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Olesen AB, 1997, BRIT MED J, V314, P1003; Oranje AP, 2002, CURR OPIN PEDIATR, V14, P410, DOI 10.1097/01.MOP.0000021894.75794.BE; OWNBY DR, 2004, CURR OPIN ALLERGY CL, V3, P517; Ponsonby AL, 1998, ARCH DIS CHILD, V79, P328; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Sherriff A, 2002, ARCH DIS CHILD, V87, P26, DOI 10.1136/adc.87.1.26; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Thompson JMD, 2001, J PAEDIATR CHILD H, V37, P369, DOI 10.1046/j.1440-1754.2001.00684.x; Williams H, 1999, J ALLERGY CLIN IMMUN, V103, P125, DOI 10.1016/S0091-6749(99)70536-1; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; WILLIAMS HC, DO I MAKE DIAGNOSIS	34	94	96	1	7	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	APR	2005	152	4					742	749		10.1111/j.1365-2133.2005.06540.x		8	Dermatology	Dermatology	915NC	WOS:000228309900020	15840107	
J	Lehrer, PM; Vaschillo, E; Vaschillo, B; Lu, SE; Scardella, A; Siddique, M; Habib, RH				Lehrer, PM; Vaschillo, E; Vaschillo, B; Lu, SE; Scardella, A; Siddique, M; Habib, RH			Biofeedback treatment for asthma	CHEST			English	Article						airway resistance; alternative and complementary medicine; disease severity; heart rate variability; oscillation mechanics; psychology; self-regulation	HEART-RATE-VARIABILITY; RESPIRATORY SINUS ARRHYTHMIA; BONE-MINERAL DENSITY; INHALED CORTICOSTEROIDS; CONTROLLED TRIAL; IMPEDANCE; THERAPY; COMPLEMENTARY; RELAXATION; AGONISTS	Study objectives: We evaluated the effectiveness of heart rate variability (HRV) biofeedback as a complementary treatment for asthma. Patients: Ninety-four adult outpatient paid volunteers with asthma. Setting: The psychophysiology laboratory at The University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, and the private outpatient offices of participating asthma physicians. Interventions: The interventions were as follows: (1) a full protocol (ie, HRV biofeedback and abdominal breathing through pursed lips and prolonged exhalation); (2) HRV biofeedback alone; (3) placebo EEG biofeedback; and (4) a waiting list control. Design: Subjects were first prestabilized using controller medication and then were randomly assigned to experimental groups. Medication was titrated biweekly by blinded asthma specialists according to a protocol based on National Heart, Lung, and Blood Institute guidelines, according to symptoms, spirometry, and home peak flows. Measurements: Subjects recorded daily asthma symptoms and twice-daily peak expiratory flows. Spirometry was performed before and after each weekly treatment session under the HRV and placebo biofeedback conditions, and at triweekly assessment sessions under the waiting list condition. Oscillation resistance was measured approximately triweekly. Results: Compared with the two control groups, subjects in both of the two HRV biofeedback groups were prescribed less medication, with minimal differences between the two active treatments. Improvements averaged one full level of asthma severity. Measures from forced oscillation pneumography similarly showed improvement in pulmonary function. A placebo effect influenced an improvement in asthma symptoms, but not in pulmonary function. Groups did not differ in the occurrence of severe asthma flares. Conclusions: The results suggest that HRV biofeedback may prove to be a useful adjunct to asthma treatment and may help to reduce dependence on steroid medications. Further evaluation of this method is warranted.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurosci, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Biometr, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Div Biometr, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Sch Publ Hlth, Piscataway, NJ 08854 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Med, Piscataway, NJ 08854 USA; Childrens Mercy Hosp, Toledo, OH USA	Lehrer, PM (reprint author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Psychiat, 671 Hoes Ln, Piscataway, NJ 08854 USA.	lehrer@umdnj.edu			NHLBI NIH HHS [R01 HL058805-03, R01 HL58805]		AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Baldwin CM, 2002, ARCH INTERN MED, V162, P1697, DOI 10.1001/archinte.162.15.1697; Barnes PJ, 2001, RESP PHYSIOL, V125, P145, DOI 10.1016/S0034-5687(00)00210-3; Birrell MA, 2002, BRIT J PHARMACOL, V136, P620, DOI 10.1038/sj.bjp.0704758; BORKOVEC TD, 1972, J BEHAV THER EXP PSY, V3, P257, DOI 10.1016/0005-7916(72)90045-6; Camm AJ, 1996, CIRCULATION, V93, P1043; Chan PWK, 2000, PEDIATR INT, V42, P547, DOI 10.1046/j.1442-200x.2000.01278.x; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; HABIB RH, 1993, J APPL PHYSIOL, V74, P1045; Hand CH, 1996, J ASTHMA, V33, P331, DOI 10.3109/02770909609055374; Kazuma N, 1997, CHRONOBIOL INT, V14, P597, DOI 10.3109/07420529709001450; KELLOWAY JS, 1994, ARCH INTERN MED, V154, P1349; Lee E. T., 1992, STAT METHODS SURVIVA; Lehrer P, 1997, APPL PSYCHOPHYS BIOF, V22, P95, DOI 10.1023/A:1026224211993; Lehrer P, 2000, APPL PSYCHOPHYS BIOF, V25, P193, DOI 10.1023/A:1009506909815; LEHRER PM, 1994, J BEHAV MED, V17, P1, DOI 10.1007/BF01856879; Lehrer PM, 2003, PSYCHOSOM MED, V65, P796, DOI 10.1097/01.PSY.0000089200.81962.19; LEHRER PM, 1986, J PSYCHOSOM RES, V30, P13, DOI 10.1016/0022-3999(86)90061-9; Lehrer PM, 2000, APPL PSYCHOPHYS BIOF, V25, P177, DOI 10.1023/A:1009554825745; Lemanske RF, 2001, JAMA-J AM MED ASSOC, V285, P2594, DOI 10.1001/jama.285.20.2594; Lofdahl CG, 1999, BRIT MED J, V319, P87; LUTCHEN KR, 1990, J APPL PHYSIOL, V68, P2139; LUTCHEN KR, 1987, J APPL PHYSIOL, V62, P403; Martin RM, 1998, THORAX, V53, P558; Matsumoto H, 2001, CHEST, V120, P1468, DOI 10.1378/chest.120.5.1468; NAGELS J, 1980, J APPL PHYSIOL, V49, P408; National Asthma Education and Prevention Program, 2002, EXP PAN REP GUID DIA; RUBIN DB, 1976, BIOMETRIKA, V63, P581, DOI 10.1093/biomet/63.3.581; Simon RA, 1999, ALLERGY ASTHMA PROC, V20, P161, DOI 10.2500/108854199778552993; Singh V, 2002, RESP MED, V96, P835, DOI 10.1053/rmed.2002.1368; Sivri A, 2001, Respirology, V6, P131, DOI 10.1046/j.1440-1843.2001.00323.x; Tsugeno H, 2002, OSTEOPOROSIS INT, V13, P650, DOI 10.1007/s001980200088; VANDENELSHOUT FJJ, 1990, CHEST, V98, P358, DOI 10.1378/chest.98.2.358; Wong CA, 2000, LANCET, V355, P1399, DOI 10.1016/S0140-6736(00)02138-3	35	94	109	1	15	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	AUG	2004	126	2					352	361		10.1378/chest.126.2.352		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	846CZ	WOS:000223293900011	15302717	
J	Deveci, SE; Deveci, F; Acik, Y; Ozan, AT				Deveci, SE; Deveci, F; Acik, Y; Ozan, AT			The measurement of exhaled carbon monoxide in healthy smokers and non-smokers	RESPIRATORY MEDICINE			English	Article						exhaled carbon monoxide; smoking; passive smoking	EXPIRED-AIR; SMOKING CESSATION; PASSIVE SMOKING; CYSTIC-FIBROSIS; BREATH; EXPOSURE; ADOLESCENTS; ASTHMA; TRIAL	The measurement of exhaled carbon monoxide (CO) level may provide an immediate, non-invasive method of assessing smoking status. The aims of this study were to use a portable CO monitor to compare the exhaled CO levels in established smokers and non-smokers. The exhaled CO levels were measured in 322 subjects (243 healthy smokers, 55 healthy non-smokers, 24 passive smokers) who applied to healthy stand during the spring student activity of Firat University in Elazig. Exhaled CO concentration was measured using the EC50 Smokerlyser. The mean exhaled CO level was 17.13 +/- 8.50 parts per million (ppm) for healthy smokers and 3.61 +/- 2.15 ppm for healthy non-smokers, and 5.20 +/- 3.38 ppm for passive smokers. There were significant positive correlation between CO levels and daily cigarette consumption, and CO levels and duration of smoking in healthy smokers (r = +0.550, P<0.001, r = +0.265, P<0.001, respectively. Spearman's test). When smokers and non-smokers were looked at as a whole, a cutoff of 6.5 ppm had a sensitivity of 90% and specificity of 83%. In conclusion, exhaled CO level provides an easy, an immediate way of assessing a subject's smoking status. (C) (C) 2004 Elsevier Ltd. All rights reserved.	Firat Univ, Fac Med, Dept Publ Hlth, TR-23119 Elazig, Turkey; Firat Univ, Fac Med, Dept Chest Dis, TR-23119 Elazig, Turkey	Deveci, F (reprint author), Firat Univ, Fac Med, Dept Publ Hlth, TR-23119 Elazig, Turkey.	drfigen@hotmail.com					Antuni JD, 2000, THORAX, V55, P138, DOI 10.1136/thorax.55.2.138; Bonita R, 1999, TOB CONTROL, V8, P156; CROWLEY TJ, 1989, ADDICT BEHAV, V14, P493, DOI 10.1016/0306-4603(89)90069-5; Cunnington AJ, 2002, POSTGRAD MED J, V78, P233, DOI 10.1136/pmj.78.918.233; Ece A, 2000, Allergol Immunopathol (Madr), V28, P255; Gourgoulianis KI, 2002, ACTA PAEDIATR, V91, P712, DOI 10.1080/080352502760069160; Hewat VN, 1998, NEW ZEAL MED J, V111, P343; Horvath I, 1999, CLIN EXP ALLERGY, V29, P1276; IRVING JM, 1988, PREV MED, V17, P109, DOI 10.1016/0091-7435(88)90076-X; JAMROZIK K, 1984, BRIT MED J, V288, P1499; JARVIS M, 1984, J EPIDEMIOL COMMUN H, V38, P335, DOI 10.1136/jech.38.4.335; JARVIS MJ, 1987, AM J PUBLIC HEALTH, V77, P1435, DOI 10.2105/AJPH.77.11.1435; JARVIS MJ, 1986, THORAX, V41, P886, DOI 10.1136/thx.41.11.886; JARVIS MJ, 1980, BRIT MED J, V281, P484; Jimenez-Ruiz CA, 2001, CHEST, V119, P1365, DOI 10.1378/chest.119.5.1365; JONES RH, 1958, J LAB CLIN MED, V51, P553; JORENBY DE, 1995, JAMA-J AM MED ASSOC, V274, P1347, DOI 10.1001/jama.274.17.1347; LARENJEIRA R, 2000, SAO PAULO MED J, V118, P89; LeSon S, 1995, Allergol Immunopathol (Madr), V23, P235; Mastora I, 2001, RADIOLOGY, V218, P695; Middleton ET, 2000, CHEST, V117, P758, DOI 10.1378/chest.117.3.758; Montuschi P, 2001, CHEST, V120, P496, DOI 10.1378/chest.120.2.496; Nakayama T, 1998, J Epidemiol, V8, P140; REA JN, 1973, BRIT J PREV SOC MED, V27, P114; RINGOLD A, 1962, ARCH ENVIRON HEALTH, V5, P308; Ruiz JMG, 1998, REV CLIN ESP, V198, P440; TONNESEN P, 1993, JAMA-J AM MED ASSOC, V269, P1268, DOI 10.1001/jama.269.10.1268; VOGT TM, 1977, AM J PUBLIC HEALTH, V67, P545, DOI 10.2105/AJPH.67.6.545; WALD NJ, 1981, THORAX, V36, P366, DOI 10.1136/thx.36.5.366; Yamaya M, 1998, AM J RESP CRIT CARE, V158, P311; Yamaya M, 2001, CLIN EXP ALLERGY, V31, P417, DOI 10.1046/j.1365-2222.2001.01013.x; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140; Zetterquist W, 2002, EUR RESPIR J, V20, P92, DOI 10.1183/09031936.02.00245302	33	94	97	2	17	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111			RESP MED	Respir. Med.	JUN	2004	98	6					551	556		10.1016/j.rmed.2003.11.018		6	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	825HH	WOS:000221746400011	15191041	
J	Braback, L; Hjern, A; Rasmussen, F				Braback, L; Hjern, A; Rasmussen, F			Trends in asthma, allergic rhinitis and eczema among Swedish conscripts from farming and non-farming environments. A nationwide study over three decades	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergic rhinitis; asthma; conscripts; eczema; epidemiology; farm environment; rural; time trend; urban	HAY-FEVER; RESPIRATORY SYMPTOMS; ATOPIC-DERMATITIS; YOUNG MEN; PREVALENCE; CHILDREN; SENSITIZATION; ADULTS; DISEASES; EXPOSURE	Background Asthma and allergies are less common in children who have been raised in farming environments. Objectives To assess whether children who grow up in a farming environment have been protected against the general increase in atopic disorders in Sweden and whether other rural environments could also be protective. Method Linkage at an individual level of three national registers in Sweden: The Swedish Military Service Conscription Register (MSCR), the Register of the Total Population (RTP) and the Population and Housing Censuses (PHC). Asthma, allergic rhinitis and eczema at conscription were analysed in relation to area of residence, parental occupation, maternal age, family size and being the first born for 1 309 652 male conscripts in three successive cohorts born between 1952 and 1981. Results Allergic rhinitis and eczema displayed a continuous increase throughout the study period, whereas the rise in asthma mainly occurred in conscripts born after 1961. Farming environments and rural living already provided protection from allergic rhinitis in conscripts born during the 1950s, but the protective effect was greater in later cohorts. An inverse association was observed between farm living and asthma, but mainly in conscripts born after 1970. The adjusted risk ratios for asthma in conscripts from farming vs. non-farming families were 1.00 (95% CI 0.93-1.07), 0.94 (95% CI 0.88-1.01) and 0.85 (95% CI 0.79-0.91) in conscripts born in 1952-1961, 1962-1971 and 1972-1981, respectively. Rural living per se had no effect on the occurrence of asthma. Eczema was less common in rural areas, but the time trend was similar in urban and rural areas. Conclusions Our findings suggest that environmental changes affecting the whole of society have promoted an increase in asthma, allergic rhinitis and eczema in both farming and non-farming environments. A lower risk of allergic rhinitis in conscripts whose parents were involved in farming was observed in all birth cohorts, whereas the protective effect of growing up on a farm on the risk of asthma appears to be a fairly recent phenomenon.	Karolinska Inst, Dept Publ Hlth Sci, Epidemiol Res Grp, Epidemiol Res Unit, SE-17176 Stockholm, Sweden; Sundsvall Hosp, Mid Sweden Res & Dev Ctr, Sundsvall, Sweden; Uppsala Univ, Dept Womens & Childrens Hlth, Unit Paediat, Uppsala, Sweden; Swedish Natl Board Hlth & Welf, Ctr Epidemiol, Stockholm, Sweden	Rasmussen, F (reprint author), Karolinska Inst, Dept Publ Hlth Sci, Epidemiol Res Grp, Epidemiol Res Unit, SE-17176 Stockholm, Sweden.	finn.rasmussen@phs.ki.se					ABERG N, 1989, CLIN EXP ALLERGY, V19, P59, DOI 10.1111/j.1365-2222.1989.tb02345.x; Braback L, 1998, CLIN EXP ALLERGY, V28, P936; Braback L, 1991, PEDIATR ALLERGY IMMU, V2, P14, DOI 10.1111/j.1399-3038.1991.tb00174.x; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Court CS, 2002, THORAX, V57, P951, DOI 10.1136/thorax.57.11.951; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Heinrich J, 1998, ALLERGY, V53, P89, DOI 10.1111/j.1398-9995.1998.tb03779.x; Herd RM, 1996, BRIT J DERMATOL, V135, P18; Hjern A, 1999, PEDIATR ALLERGY IMMU, V10, P101, DOI 10.1034/j.1399-3038.1999.00023.x; Horak F, 2002, CLIN EXP ALLERGY, V32, P1155, DOI 10.1046/j.1365-2745.2002.01448.x; Jogi R, 1996, ALLERGY, V51, P331, DOI 10.1111/j.1398-9995.1996.tb00094.x; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Magnus P, 1997, BRIT MED J, V314, P1795; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; Pearce N, 2000, EUR RESPIR J, V16, P420, DOI 10.1183/9031936.00.16337700; Pearce N, 1999, THORAX, V54, P268; Radon K, 2001, EUR RESPIR J, V17, P747, DOI 10.1183/09031936.01.17407470; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P270; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149	32	94	95	1	8	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2004	34	1					38	43		10.1111/j.1365-2222.2004.01841.x		6	Allergy; Immunology	Allergy; Immunology	763LF	WOS:000188086500007	14720260	
J	Zhang, JF; Hu, W; Wei, FS; Wu, GP; Korn, LR; Chapman, RS				Zhang, JF; Hu, W; Wei, FS; Wu, GP; Korn, LR; Chapman, RS			Children's respiratory morbidity prevalence in relation to air pollution in four Chinese cities	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; children; China; particulate matter; respiratory health	LONG-TERM EXPOSURE; PARTICULATE MATTER; PASSIVE SMOKING; HEALTH; COMMUNITIES; CALIFORNIA; PARTICLES; SYMPTOMS; PM10	We examined respiratory health effects of long-term exposure to ambient air pollution in 7,621 schoolchildren residing in eight districts of four Chinese cities. The four cities exhibited wide between-city and within-city gradients in ambient levels of four size fractions of particulate matter [less than or equal to 2.5 pro in aerodynamic diameter (PM2.5), between 2.5 and 10 mum (PM10-2.5), less than or equal to 10 mum (PM10), and total suspended particulates (TSP)] and two gaseous pollutants (SO2 and NOx). Informed consent and written responses to questionnaires about children's personal, residential, and family information, as well as their health histories and status, were obtained with the help of the parents and the school personnel. We used a two-stage regression approach in data analyses. In the first-stage logistic regressions, we obtained logits of district-specific prevalence of wheeze, asthma, bronchitis, hospitalization for respiratory diseases, persistent cough, and persistent phlegm, adjusted for covariates representing personal, household, and family parameters. Some of these covariates were found to be risk factors of children's respiratory health, including being younger in the study group, being male, having been breast-fed, sharing bedrooms, sharing beds, room being smoky during cooking, eye irritation during cooking, parental smoking, and a history of parental asthma. In several of the second-stage variance-weighted linear regressions, we examined associations between district-specific adjusted prevalence rates and district-specific ambient levels of each pollutant. We found positive associations between morbidity prevalence and outdoor levels of PM of all size fractions, but the association appeared to be stronger for coarse particles (PM10-2.5). The results also present some evidence that ambient levels of NOx and SO2 were positively associated with children's respiratory symptoms, but the evidence for these two gaseous pollutants appeared to be weaker than that for the PM.	EOHSI, Piscataway, NJ 08854 USA; Rutgers State Univ, Piscataway, NJ USA; China Natl Environm Monitoring Ctr, Beijing, Peoples R China; US EPA, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA; Univ Med & Dent New Jersey, Piscataway, NJ 08854 USA	Zhang, JF (reprint author), EOHSI, Room 358,170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.		Hu, Wei/M-3524-2013				Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FORASTIERE F, 1992, INT J EPIDEMIOL, V21, P66, DOI 10.1093/ije/21.1.66; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; Health Effects Institute, 2001, AIRB PART HLTH HEI E; Hruba F, 2001, J EXPO ANAL ENV EPID, V11, P33, DOI 10.1038/sj.jea.7500141; NEAS LM, 1994, AM J EPIDEMIOL, V139, P1088; Ostro BD, 1999, ENVIRON RES, V81, P231, DOI 10.1006/enrs.1999.3978; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Pikhart H, 2000, EPIDEMIOLOGY, V11, P153, DOI 10.1097/00001648-200003000-00012; Pope CA, 2000, AEROSOL SCI TECH, V32, P4, DOI 10.1080/027868200303885; Qian ZM, 2001, J EXPO ANAL ENV EPID, V11, P341, DOI 10.1038/sj.jea.7500170; Qian ZM, 2000, ARCH ENVIRON HEALTH, V55, P126; *SEPA, 1992, STAND ENV MON AN MET; Shen S, 1992, Biomed Environ Sci, V5, P136; WARE JH, 1986, AM REV RESPIR DIS, V133, P834; WARE JH, 1984, AM REV RESPIR DIS, V129, P366; Wei F, 1999, ENVIRON SCI TECHNOL, V33, P4188, DOI 10.1021/es9904944; Wilson R., 1996, PARTICLES OUR AIR CO; Zhang JFJ, 1999, ARCH ENVIRON HEALTH, V54, P373	25	94	110	3	30	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2002	110	9					961	967				7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	591RJ	WOS:000177893800040	12204833	
J	Gerhold, K; Blumchen, K; Bock, A; Seib, C; Stock, P; Kallinich, T; Lohning, M; Wahn, U; Hamelmann, E				Gerhold, K; Blumchen, K; Bock, A; Seib, C; Stock, P; Kallinich, T; Lohning, M; Wahn, U; Hamelmann, E			Endotoxins prevent murine IgE production,T(H)2 immune responses, and development of airway eosinophilia but not airway hyperreactivity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mice; eosinophils; T(H)1/T(H)2 cells; cytokines; lipopolysaccharides	TOLL-LIKE RECEPTOR-4; DENDRITIC CELLS; BACTERIAL LIPOPOLYSACCHARIDE; INFLAMMATORY RESPONSE; ALLERGEN CHALLENGE; SENSITIZED MICE; TNF-ALPHA; TH2 CELLS; ASTHMA; MACROPHAGES	Background: Contact with immunomodulatory factors, such as LPS, in early infancy is associated with decreased allergen sensitization. Objective: We sought to study the effects of systemic or airway exposure with LPS on the development of allergen sensitization, eosinophilic airway inflammation, and increased in vivo airway reactivity (AR) in a mouse model. Methods: BALB/c mice were systemically sensitized with ovalbumin (OVA) plus adjuvant on days 1 and W and challenged through the airways with allergen on days 34 to 36. We performed measurement of OVA-specific IgE serum levels, in vitro T(H)2 cytokine production, differential cell counts in bronchoalveolar lavage fluids, and assessment of in vivo AR to inhaled methacholine by means of barometric whole-body plethysmography. Results: Systemic LPS administration before OVA sensitization reduced OVA-specific IgE serum levels (426 76 is 880 104 U/mL, P <.01), T(H)2 cytokine production by splenic mononuclear cells (IL-4: 0.08 +/- 0.01 vs 0.17 +/- 0.01 ng/mL; IL-5: 1.98 +/- 0.52 vs 4.11 +/- 0.54 ng/mL; P <.01), and extent of airway eosinophilia (total cell counts: 93 vs 376 x 10(3)/mL, eosinophils: 23% vs 51%; P <.01) compared with that in OVA-sensitized mice. Local LPS administration to sensitized mice before airway allergen challenges particularly induced IFN-gamma production by peribronchial lymph node cells in vitro (1718 +/- 315 vs 483 +/- 103 ng/mL, P <.01) associated with reduced airway eosinophilia compared with that seen in OVA-sensitized mice. Development of increased AR was not affected by systemic or local LPS exposure. Inhibitory effects of LPS on allergen sensitization and eosinophilic airway inflammation were inhibited bY administration of anti-IL-12 antibodies before LPS exposure. Conclusion: These data indicate that local and systemic application of LPS modulates systemic and local T(H)1/T(H)2 immune responses in a distinct but similarly IL-12-dependent mode.	Univ Hosp Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Deutsch Rheuma Forschungszentrum, Berlin, Germany	Hamelmann, E (reprint author), Univ Hosp Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Blunck R, 2001, J IMMUNOL, V166, P1009; BORCHERS MT, 2001, AM J PHYSIOL, V281, P1653; Desmedt M, 1998, J IMMUNOL, V160, P5300; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Henderson WR, 2000, J IMMUNOL, V164, P1086; Hilkens CMU, 1997, BLOOD, V90, P1920; HOLT PG, 1981, INT ARCH ALLER A IMM, V65, P42; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Levitt RC, 1999, J ALLERGY CLIN IMMUN, V103, pS485, DOI 10.1016/S0091-6749(99)70165-X; LeyvaCobian F, 1997, CLIN IMMUNOL IMMUNOP, V85, P1, DOI 10.1006/clin.1997.4426; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; MARTINEZ FD, 1995, AM J RESP CRIT CARE, V151, P1644; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Moreland JG, 2001, AM J PHYSIOL-LUNG C, V280, pL173; Nomura F, 2000, J IMMUNOL, V164, P3476; Ogata H, 2000, J EXP MED, V192, P23, DOI 10.1084/jem.192.1.23; Ohmori Y, 2001, J LEUKOCYTE BIOL, V69, P598; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schwarze J, 1998, J ALLERGY CLIN IMMUN, V102, P86, DOI 10.1016/S0091-6749(98)70058-2; Snijders A, 1998, INT IMMUNOL, V10, P1593, DOI 10.1093/intimm/10.11.1593; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Szabo SJ, 1997, J EXP MED, V185, P817, DOI 10.1084/jem.185.5.817; Tang CB, 2001, J IMMUNOL, V166, P1471; Tournoy KG, 2001, J ALLERGY CLIN IMMUN, V107, P483, DOI 10.1067/mai.2001.112693; Tsan MF, 2001, AM J PHYSIOL-CELL PH, V280, pC1422; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Yang M, 2001, AM J RESP CELL MOL, V25, P522	40	94	98	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2002	110	1					110	116		10.1067/mai.2002.125831		7	Allergy; Immunology	Allergy; Immunology	574CF	WOS:000176870300021	12110829	
J	Smart, JM; Kemp, AS				Smart, JM; Kemp, AS			Increased Th1 and Th2 allergen-induced cytokine responses in children with atopic disease	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergens; atopy; childhood; cytokines; house dust mite; interferon-gamma; interleukins-4/-5/-13; rye grass pollen; superantigens	BLOOD MONONUCLEAR-CELLS; INTERFERON-GAMMA PRODUCTION; MESSENGER-RNA EXPRESSION; PERIPHERAL-BLOOD; IFN-GAMMA; NONATOPIC CHILDREN; INTERLEUKIN-4 PRODUCTION; MITE ALLERGEN; T-CELLS; ASTHMA	Background Polyclonal cytokine responses following stimulation of T cells with mitogens or superantigens provides information on cytokine production from a wide range of T cells. Alternatively allergen-induced T cell responses can provide information on cytokine production by allergen-reactive T cells. While there is evidence of increased Th2 and reduced Th1 cytokine production following T cell stimulation with non-specific mitogens and superantigens, the evidence that Th1 cytokine production to allergens is decreased in line with a postulated imbalance in Th1/Th2 responses is unclear, with studies finding decreased, no difference or increased IFN-gamma responses to allergens in atopic subjects. Objecgive To examine childhood polyclonal and allergen-induced cytokine responses in parallel to evaluate cytokine imbalances in childhood atopic disease. Methods PBMC cytokine responses were examined in response to a polyclonal stimulus, staphylococcal superantigen (SEB), in parallel with two inhalant allergens, house dust mite (HDM) and rye grass pollen (RYE), and an ingested allergen, ovalbumin (OVA), in (a) 35 healthy children (non-atopic) and (b) 36 children with atopic disease (asthma, eczema and/or rhinitis) (atopic). Results Atopic children had significantly reduced IFN-gamma and increased IL-4 and IL-5 but not IL13 production to SEB superantigen stimulation when compared with non-atopic children. HDM and RYE allergens stimulated significantly increased IFN-gamma, IL-5 and IL-13, while OVA stimulated significantly increased IFN-gamma production in atopic children. Conclusion We show that a polyclonal stimulus induces a reduced Th1 (IFN-gamma) and increased Th2 (IL-4 and IL-5) cytokine pattern. In contrast, the allergen-induced cytokine responses in atopic children were associated with both increased Th1 (INF-gamma) and Th2 (IL-5 and IL-13) cytokine production. The increased Th1 response to allergen is likely to reflect prior sensitization and indicates that increases in both Th1 and Th2 cytokine production to allergens exists concomitantly with a decreased Th1 response to a polyclonal stimulus in atopic children.	Royal Childrens Hosp, Dept Immunol, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia	Kemp, AS (reprint author), Royal Childrens Hosp, Dept Immunol, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.						Campbell DE, 1999, CLIN EXP IMMUNOL, V115, P377; Campbell DE, 1997, CLIN EXP IMMUNOL, V107, P392, DOI 10.1111/j.1365-2249.1997.278-ce1172.x; Chang JH, 1996, J ALLERGY CLIN IMMUN, V98, P922, DOI 10.1016/S0091-6749(96)80008-X; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; Devereux G, 2000, J IMMUNOL METHODS, V234, P13, DOI 10.1016/S0022-1759(99)00185-4; Dunbar PR, 1998, CURR BIOL, V8, P413, DOI 10.1016/S0960-9822(98)70161-7; Gabrielsson S, 1998, SCAND J IMMUNOL, V48, P429; GREWE M, 1994, LANCET, V343, P25, DOI 10.1016/S0140-6736(94)90879-6; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hoekstra MO, 1997, CLIN EXP ALLERGY, V27, P1254; Holt PG, 2000, J ALLERGY CLIN IMMUN, V105, P1117, DOI 10.1067/mai.2000.105804; Holt PG, 1999, CLIN EXP ALLERGY, V29, P8, DOI 10.1046/j.1365-2222.1999.00003.x-i2; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; JUJO K, 1992, J ALLERGY CLIN IMMUN, V90, P323, DOI 10.1016/S0091-6749(05)80010-7; Kimura M, 2000, J ALLERGY CLIN IMMUN, V105, P327, DOI 10.1016/S0091-6749(00)90083-6; Kimura M, 1998, J ALLERGY CLIN IMMUN, V102, P238, DOI 10.1016/S0091-6749(98)70092-2; Klimek L, 1999, CLIN EXP ALLERGY, V29, P1326; KONIG B, 1995, INT ARCH ALLERGY IMM, V106, P124; Koning H, 1997, CYTOKINE, V9, P416, DOI 10.1006/cyto.1996.0184; Laan MP, 1998, EUR CYTOKINE NETW, V9, P75; Li Y, 1998, J IMMUNOL, V161, P7007; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; Noma T, 1996, CLIN EXP ALLERGY, V26, P1298; NOMA T, 1995, PEDIATR RES, V38, P187, DOI 10.1203/00006450-199508000-00009; Nurse B, 2000, J ALLERGY CLIN IMMUN, V106, P84, DOI 10.1067/mai.2000.107397; Nurse B, 1997, J ALLERGY CLIN IMMUN, V100, P662, DOI 10.1016/S0091-6749(97)70171-4; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Rook GAW, 2001, LANCET, V357, P2137, DOI 10.1016/S0140-6736(00)05210-7; Shinbara M, 1996, ANN ALLERG ASTHMA IM, V77, P60; Smart JM, 2001, PEDIATR ALLERGY IMMU, V12, P181, DOI 10.1034/j.1399-3038.2001.012004181.x; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; SUPHIOGLU C, 1993, ALLERGY, V48, P273, DOI 10.1111/j.1398-9995.1993.tb00728.x; Tang C, 1997, EUR RESPIR J, V10, P624; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; TANG MLK, 1995, CLIN EXP ALLERGY, V25, P515, DOI 10.1111/j.1365-2222.1995.tb01088.x; Tau GZ, 2000, J EXP MED, V192, P977, DOI 10.1084/jem.192.7.977; Thepen T, 1996, J ALLERGY CLIN IMMUN, V97, P828, DOI 10.1016/S0091-6749(96)80161-8; VANASPEREN PP, 1980, MED J AUSTRALIA, V2, P266; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Werfel T, 1996, J INVEST DERMATOL, V107, P871, DOI 10.1111/1523-1747.ep12331164; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; WILSON CB, 1991, J PEDIATR-US, V118, pS4, DOI 10.1016/S0022-3476(05)82182-1	45	94	106	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAY	2002	32	5					796	802		10.1046/j.1365-2222.2002.01391.x		7	Allergy; Immunology	Allergy; Immunology	549GP	WOS:000175436400024	11994108	
J	Burnett, RT; Smith-Doiron, M; Stieb, D; Raizenne, ME; Brook, JR; Dales, RE; Leech, JA; Cakmak, S; Krewski, D				Burnett, RT; Smith-Doiron, M; Stieb, D; Raizenne, ME; Brook, JR; Dales, RE; Leech, JA; Cakmak, S; Krewski, D			Association between ozone and hospitalization for acute respiratory diseases in children less than 2 years of age	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						air pollution; child; hospitalization; ozone; respiratory tract diseases	AIR-POLLUTION; DAILY MORTALITY; UPPER AIRWAYS; ADMISSIONS; ASTHMA; PARTICULATE; TORONTO; EMERGENCY; ILLNESSES; MONTREAL	To clarify the health effects of ozone exposure in young children, the authors studied the association between air pollution and hospital admissions for acute respiratory problems in children less than 2 years of age during the 15-year period from 1980 to 1994 in Toronto, Canada. The daily time series of admissions was adjusted for the influences of day of the week, season, and weather. A 35% (95% confidence interval: 19%, 52%) increase in the daily hospitalization rate for respiratory problems was associated with a 5-day moving average of the daily 1-hour maximum ozone concentration of 45 parts per billion, the May-August average value. The ozone effect persisted after adjustment for other ambient air pollutants or weather variables. Ozone was not associated with hospital admissions during the September-April period. Ambient ozone levels in the summertime should be considered a risk factor for respiratory problems in children less than 2 years of age.	Hlth Canada, Environm Hlth Directorate, Ottawa, ON K1A 0L2, Canada; Environm Canada, Meteorol Serv Canada, Downsview, ON, Canada; Univ Ottawa, Fac Med, Dept Epidemiol & Community Med, Ottawa, ON, Canada	Burnett, RT (reprint author), Hlth Canada, Environm Hlth Directorate, 200 Environm Hlth Ctr, Ottawa, ON K1A 0L2, Canada.			Cakmak, Sabit/0000-0001-9921-2107			Anderson HR, 1998, THORAX, V53, P842; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BorjaAburto VH, 1997, AM J EPIDEMIOL, V145, P258; Burnett RT, 1999, ARCH ENVIRON HEALTH, V54, P130; Burnett RT, 1997, ENVIRON RES, V72, P24, DOI 10.1006/enrs.1996.3685; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; BURNETT RT, 1994, ENVIRON RES, V65, P172, DOI 10.1006/enrs.1994.1030; Burnett RT, 1998, J AIR WASTE MANAGE, V48, P689; CAMPBELL ME, 1995, CAN J PUBLIC HEALTH, V86, P351; CHITANO P, 1995, EUR RESPIR J, V8, P1357, DOI 10.1183/09031936.95.08081357; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Dab W, 1996, J EPIDEMIOL COMMU S1, V50, ps42; DELEON P, 1996, J EPIDEMIOL COMMU S1, V50, pS63; DELFINO RJ, 1994, ENVIRON RES, V67, P1, DOI 10.1006/enrs.1994.1061; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; FRISCHER TM, 1993, AM REV RESPIR DIS, V148, P961; GERRITY TR, 1988, J APPL PHYSIOL, V65, P393; HARKEMA JR, 1987, AM J PATHOL, V128, P129; Hastie T, 1990, GEN ADDITIVE MODELS; KNOBEL HH, 1995, PEDIATRICS, V96, P1106; Leech J A, 1996, Chronic Dis Can, V17, P118; MCBRIDE DE, 1994, AM J RESP CRIT CARE, V149, P1192; Ponka A, 1996, J EPIDEMIOL COMMUN H, V50, pS59, DOI 10.1136/jech.50.Suppl_1.s59; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; PRIESTLEY MB, 1981, SPECTRAL ANAN TIME S; SALDIVA PHN, 1994, ENVIRON RES, V65, P218, DOI 10.1006/enrs.1994.1033; Schouten JP, 1996, J EPIDEMIOL COMMUN H, V50, pS22, DOI 10.1136/jech.50.Suppl_1.s22; SCHWARTZ J, 1991, ENVIRON RES, V56, P1, DOI 10.1016/S0013-9351(05)80104-5; SCHWARTZ J, 1994, ARCH ENVIRON HEALTH, V49, P366; Schwartz J, 1996, EPIDEMIOLOGY, V7, P20, DOI 10.1097/00001648-199601000-00005; SCHWARTZ J, 1995, THORAX, V50, P531, DOI 10.1136/thx.50.5.531; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P648; SCHWARTZ J, 1994, AM J EPIDEMIOL, V139, P589; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Spix C, 1998, ARCH ENVIRON HEALTH, V53, P54; SPREM N, 1993, INT J PEDIATR OTORHI, V26, P245, DOI 10.1016/0165-5876(93)90094-J; *STAT SCI INC, 1993, S PLUS MAN; Steib DM, 2000, CAN J PUBLIC HEALTH, V91, P107; TAKAHASHI N, 1995, J APPL PHYSIOL, V79, P1753; THURSTON GD, 1992, J EXPO ANAL ENV EPID, V2, P429; THURSTON GD, 1994, ENVIRON RES, V65, P271, DOI 10.1006/enrs.1994.1037; TSENG RYM, 1992, ANN ALLERGY, V68, P425; Vigotti MA, 1996, J EPIDEMIOL COMMUN H, V50, pS71, DOI 10.1136/jech.50.Suppl_1.s71; WYZGA RE, 1995, PARTICULATE MATTER H, P3	46	94	98	1	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	MAR 1	2001	153	5					444	452		10.1093/aje/153.5.444		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	405YZ	WOS:000167189300006	11226976	
J	Simpson, BM; Custovic, A; Simpson, A; Hallam, CL; Walsh, D; Marolia, H; Campbell, J; Woodcock, A				Simpson, BM; Custovic, A; Simpson, A; Hallam, CL; Walsh, D; Marolia, H; Campbell, J; Woodcock, A			NAC Manchester Asthma and Allergy Study ((NAC)MAAS): risk factors for asthma and allergic disorders in adults	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; eczema; hay fever; allergens; skin prick tests	HOUSE-DUST MITE; RESPIRATORY HEALTH SURVEY; CHILDHOOD ASTHMA; EXPOSURE; SENSITIZATION; CHILDREN; POPULATION; CAT; SENSITIVITY; ENVIRONMENT	Background Asthma and atopic disorders are the most common chronic diseases in the developed countries. Knowledge of the risk factors for these disorders may facilitate the development of preventive strategies aimed at reducing prevalence rates. Objectives To investigate the risk factors for asthma and allergic diseases in a large number of adults who are the parents of children in the National Asthma Campaign Manchester Asthma and Allergy Study. Methods All pregnant women and their partners attending 'Booking' antenatal clinics were invited to take part in the study. Questionnaire data were collected including the history of asthma and other atopic diseases, pet ownership and smoking habits, and skin prick tests were performed. The prevalence of atopy and the risk factors for asthma and allergic disorders were investigated in all subjects who completed the questionnaire and underwent skin testing. Statistical analysis was carried out using logistic regression. Initially, risk factors were assessed by univariate analysis to see how each potential explanatory variable affected the probability of having allergic disease. Variables were then tested in a forward stepwise multivariate analysis. Results In 5687 adult subjects there was a very high (48.2%) prevalence of atopy, and 9.7% of subjects had a diagnosis of asthma. In a multivariate regression analysis sensitization to dust mite, cat, dog and mixed grasses were all independently associated with asthma. The odds ratios for current asthma increased with the increasing number of positive skin tests (any two allergens - OR 4.3, 95% CI 3.3-5.5; any three allergens - OR 7.0 95% CI 5.3-9.3; all four allergens - OR 10.4, 95% CI 7.7-14; P < 0.00001). Dog ownership (OR 1.31, 95% CI 1.10-1.57; P = 0.003) and current smoking (OR 1.36, 95% CI 1.15-1.62; P = 0.0004) were significantly and directly associated with 'asthma ever'. Thirteen per cent of participants reported a history of eczema. In the multivariate analysis the strongest independent associate of eczema was sensitization to dog (OR 1.37, 95% CI 1.14-1.63, P < 0.0001). Apart from dog, the strength of the association between sensitization to common allergens and eczema appeared to be much lower than in the case of asthma. The prevalence of hay fever was high (20.6%), and in the multivariate analysis the association between sensitization to pollen and hay fever was extremely strong (OR 13.6, 95% CI 11.3-16.3; P < 0.0001). Conclusions The results of the current study emphasize the importance of sensitization to indoor allergens in asthma. However, evidence of a possible direct role of allergen exposure in asthma causation remains unclear.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Custovic, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Southmoor Rd, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578; Simpson, Angela/0000-0003-2733-6666			ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; BECKLAKE MR, 1990, RESPIRATION, V57, P137; Bodner CH, 1998, AM J RESP CRIT CARE, V157, P35; Brown MA, 1997, CLIN EXP ALLERGY, V27, P4, DOI 10.1046/j.1365-2222.1997.d01-430.x; Burr ML, 1997, CLIN EXP ALLERGY, V27, P1247; BURROWS B, 1995, J ALLERGY CLIN IMMUN, V95, P548, DOI 10.1016/S0091-6749(95)70317-9; CHARPIN D, 1988, CHEST, V93, P758, DOI 10.1378/chest.93.4.758; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; CHAVARRIA JF, 1992, INT ARCH ALLERGY IMM, V99, P466; Custovic A, 1998, THORAX, V53, P63; Eisner MD, 1998, AM J RESP CRIT CARE, V158, P170; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Hopkin JM, 1999, CLIN EXP ALLERGY, V29, P733; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; MILLS TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS1; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; PEAT JK, 1994, AUST NZ J MED, V24, P473; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SEATON A, 1994, THORAX, V49, P171, DOI 10.1136/thx.49.2.171; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P235; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Tan JS, 1997, ARCH INTERN MED, V157, P1933, DOI 10.1001/archinte.157.17.1933; Tunnicliffe WS, 1999, EUR RESPIR J, V13, P654, DOI 10.1183/09031936.99.13365499; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79	30	94	97	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2001	31	3					391	399		10.1046/j.1365-2222.2001.01050.x		9	Allergy; Immunology	Allergy; Immunology	417UB	WOS:000167851600009	11260150	
J	Martinez, FD				Martinez, FD			The coming-of-age of the hygiene hypothesis	RESPIRATORY RESEARCH			English	Editorial Material						atopy; CD14; endotoxin; genetics; hygiene	HAY-FEVER; ALLERGIC SENSITIZATION; EARLY-LIFE; ASTHMA; ATOPY; CHILDREN; EXPOSURE; ASSOCIATION; ENDOTOXIN; RISK	The hygiene hypothesis, as originally proposed, postulated an inverse relation between the incidence of infectious diseases in early life and the subsequent development of allergies and asthma. New evidence from epidemiological, biological and genetic studies has significantly enlarged the scope of the hypothesis. It now appears probable that environmental 'danger' signals regulate the pattern of immune responses in early life. Microbial burden in general, and not any single acute infectious illness, is the main source of these signals. The latter interact with a sensitive and complex receptor system, and genetic variations in this receptor system may be an important determinant of inherited susceptibility to asthma and allergies.	Univ Arizona, Resp Sci Ctr, Tucson, AZ USA	Martinez, FD (reprint author), 1501 N Campbell Ave,Suite 2349, Tucson, AZ 85725 USA.				NHLBI NIH HHS [HL 66800, HL 56177, HL 61892, HL 64307, HL 66447, R01 HL056177, R01 HL066447, U10 HL064307]		AMELUNG PJ, 2000, AM J RESP CRIT CARE, V161, pA927; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; CELEDON JC, 2000, AM J RESP CRIT CARE, V161, pA927; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Holt PG, 2000, ALLERGY, V55, P688, DOI 10.1034/j.1398-9995.2000.00118.x; Hubacek JA, 1999, CIRCULATION, V99, P3218; JOOS L, 2000, AM J RESP CRIT CARE, V161, pA928; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; MARTINEZ FD, 1995, THORAX, V50, P1067, DOI 10.1136/thx.50.10.1067; MARTINEZ FD, 1999, LANCET S2, V354; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; ODONNELL AR, 2000, AM J RESP CRIT CARE, V161, pA928; Paunio M, 2000, JAMA-J AM MED ASSOC, V283, P343, DOI 10.1001/jama.283.3.343; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; PUGIN J, 1994, IMMUNITY, V1, P509, DOI 10.1016/1074-7613(94)90093-0; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; ROMAGNANI S, 1992, IMMUNOL TODAY, V13, P379, DOI 10.1016/0167-5699(92)90083-J; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Sherrill D, 1999, CLIN EXP ALLERGY, V29, P905; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Woolcock AJ, 1997, CIBA F SYMP, V206, P122	29	94	96	0	6	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1465-993X			RESPIR RES	Respir. Res.		2001	2	3					129	132		10.1186/rr48		4	Respiratory System	Respiratory System	443VC	WOS:000169361500002	11686875	
J	Gautrin, D; Ghezzo, H; Infante-Rivard, C; Malo, JL				Gautrin, D; Ghezzo, H; Infante-Rivard, C; Malo, JL			Incidence and determinants of IgE-mediated sensitization in apprentices - A prospective study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							EXPOSURE-RESPONSE RELATIONSHIPS; LABORATORY-ANIMAL WORKERS; OCCUPATIONAL ASTHMA; GENERAL-POPULATION; LATEX; ALLERGY; SYMPTOMS; ATOPY; RATS; FLOUR	We investigated prospectively the incidence and determinants of work-related specific skin sensitization in a cohort of 769 apprentices, including 417 in animal health technology, 230 in pastry-making, and 122 in dental-hygiene technology. Subjects were recruited when starting exposure to laboratory animals, flour, or latex. A questionnaire and skin-prick tests with common and work-related allergens were administered on entry and at follow-up visits from 8 to 44 mo; information on number of hours of exposure to specific allergens was obtained. Among 769 apprentices, 698 attended greater than or equal to 1 follow-up visit. A total of 111 subjects developed specific sensitization over the study period. The incidence of work-related sensitization (per person-year) was 8.9% (95% CI 7.3 to 11.0%) in the animal-health program, 4.2% (95% CI 1.8 to 8.2%) in the pastry-making program, and 2.5% (95% CI = 0.7 to 4.3%) in the dental-hygiene program. In the animal health group, Cox regression analyses showed that atopy, nasal, and respiratory symptoms in the pollen season, and exposure assessed by the school attended or by duration of exposure to rodents were the most significant predictors of sensitization. In the dental-hygiene program, atopy and asthma were significant determinants. This study shows that: (1) an apprenticeship in animal-health technology carries a greater risk of developing specific sensitization than do apprenticeships in pastry-making and dental-hygiene; (2) atopy, respiratory symptoms in the pollen season, and number of hours in contact with rodents determine the risk of sensitization in apprentices in the animal health program.	Hop Sacre Coeur, Dept Chest Med, Montreal, PQ H4J 1C5, Canada; McGill Univ, Joint Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Joint Dept Occupat Hlth, Montreal, PQ, Canada	Gautrin, D (reprint author), Hop Sacre Coeur, Dept Chest Med, 5400 Gouin Blvd W, Montreal, PQ H4J 1C5, Canada.						AOYAMA K, 1992, BRIT J IND MED, V49, P41; BALDO BA, 1982, PROG ALLERGY, V30, P1; BARBEE RA, 1976, ANN INTERN MED, V84, P129; BRITTON J, 1994, EUR RESPIR J, V7, P881; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; Chan-Yeung M., 1999, ASTHMA WORKPLACE, P129; COCKCROFT A, 1981, LANCET, V1, P827; Cockcroft DW, 1984, ANN ALLERGY, V53, P26; COOKSON WOCM, 1986, CLIN ALLERGY, V16, P425, DOI 10.1111/j.1365-2222.1986.tb01977.x; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P579; DUFRESNE A, 1997, ANN OCCUP HYG, V41, P621; Gautrin D, 1997, AM J RESP CRIT CARE, V155, P1841; Gordon S, 1997, J ALLERGY CLIN IMMUN, V99, P716, DOI 10.1016/S0091-6749(97)70036-8; Heederik D, 1999, J ALLERGY CLIN IMMUN, V103, P678, DOI 10.1016/S0091-6749(99)70242-3; HEEDERIK D, 1999, ASTHMA WORKPLACE, P377; HERXHEIMER H, 1967, LANCET, V1, P83; Hollander A, 1997, AM J RESP CRIT CARE, V155, P562; MCDONALD JC, 1995, EPIDEMIOLOGY WORK RE, P325; MUSK AW, 1989, BRIT J IND MED, V46, P636; Newman-Taylor Anthony, 1995, P117; NEWMANTAYLOR AJ, 1999, ASTHMA WORKPLACE, P399; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P505, DOI 10.1016/0091-6749(87)90369-1; Sussman GL, 1998, J ALLERGY CLIN IMMUN, V101, P171; Tarlo SM, 1997, J ALLERGY CLIN IMMUN, V99, P396, DOI 10.1016/S0091-6749(97)70058-7; TARLO SM, 1990, J ALLERGY CLIN IMMUN, V85, P626, DOI 10.1016/0091-6749(90)90103-B; THIEL H, 1983, P INV S 11 INT C ALL, P429; VANDENPLAS O, 1995, AM J RESP CRIT CARE, V151, P54; VANDENPLAS O, 1995, EUR RESPIR J, V8, P1957, DOI 10.1183/09031936.95.08111957; VENABLES KM, 1988, BRIT J IND MED, V45, P660	31	94	96	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	OCT	2000	162	4					1222	1228				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	364RD	WOS:000089905900005	11029321	
J	Blease, K; Mehrad, B; Standiford, TJ; Lukacs, NW; Kunkel, SL; Chensue, SW; Lu, B; Gerard, CJ; Hogaboam, CM				Blease, K; Mehrad, B; Standiford, TJ; Lukacs, NW; Kunkel, SL; Chensue, SW; Lu, B; Gerard, CJ; Hogaboam, CM			Airway remodeling is absent in CCR1(-/-) mice during chronic fungal allergic airway disease	JOURNAL OF IMMUNOLOGY			English	Article							HUMAN LUNG FIBROBLASTS; BRONCHOPULMONARY ASPERGILLOSIS; SUBEPITHELIAL FIBROSIS; CHEMOKINE RECEPTORS; TH1 RESPONSES; MURINE MODEL; HOST-DEFENSE; INFLAMMATION; ASTHMA; HYPERREACTIVITY	Asthmatic-like reactions characterized by elevated IgE, Th2 cytokines, C-C chemokines, eosinophilic inflammation, and persistent airway hyperresponsiveness follow pulmonary exposure to the spores or conidia from Aspergillus fumigatus fungus in sensitized individuals. In addition to these features, subepithelial fibrosis and goblet cell hyperplasia characterizes fungal-induced allergic airway disease in mice. Because lung concentrations of macrophage inflammatory protein-1 alpha and RANTES were significantly elevated after A. fumigatus-sensitized mice received an intrapulmonary challenge with A. fumigatus spores or conidia, the present study addressed the role of their receptor, C-C chemokine receptor 1 (CCR1), in this model. A. fumigatus-sensitized CCR1 wild-type (+/+) and CCR1 knockout (-/-) mice exhibited similar increases in serum IgE and polymorphonuclear leukocyte numbers in the bronchoalveolar lavage, Airway hyperresponsiveness was prominent in both groups of mice at 30 days after an intrapulmonary challenge with A. fumigatus spores or conidia, However, whole lung levels of IFN-gamma were significantly higher whereas IL-4, IL-13, and Th2-inducible chemokines such as C10, eotaxin, and macrophage-derived chemokine were significantly lower in whole lung samples from CCR1(-/-) mice compared with CCR1(+/+) mice at 30 days after the conidia challenge. Likewise, significantly fewer goblet cells and less subepithelial fibrosis were observed around large airways in CCR1-/- mice at the same time after the conidia challenge. Thus, these findings demonstrate that CCR1 is a major contributor to the airway remodeling responses that arise from A. fumigatus-induced allergic airway disease.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Div Pulm & Crit Care, Ann Arbor, MI 48109 USA; Vet Affairs Med Ctr, Dept Pathol, Ann Arbor, MI 48105 USA; Childrens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Hogaboam, CM (reprint author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine Rd, Ann Arbor, MI 48109 USA.		Mehrad, Borna/D-9363-2015	Mehrad, Borna/0000-0001-5198-065X	NHLBI NIH HHS [1P50-HL60289, HL35276, P01-HL31963]		Alam R, 1996, AM J RESP CRIT CARE, V153, P1398; Barnes PJ, 1996, BRIT J CLIN PHARMACO, V42, P3, DOI 10.1046/j.1365-2125.1996.03721.x; Boulet L P, 1998, Can Respir J, V5, P16; Campbell EM, 1998, J IMMUNOL, V161, P7047; Chu HW, 1998, AM J RESP CRIT CARE, V158, P1936; Cockrill BA, 1999, ANNU REV MED, V50, P303; Cohn L, 1999, J EXP MED, V190, P1309, DOI 10.1084/jem.190.9.1309; Corry DB, 1998, MOL MED, V4, P344; Doucet C, 1998, INT IMMUNOL, V10, P1421, DOI 10.1093/intimm/10.10.1421; Doucet C, 1998, J CLIN INVEST, V101, P2129, DOI 10.1172/JCI741; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Drazen JM, 1999, CLIN EXP ALLERGY, V29, P37; EVANOFF HL, 1992, IMMUNOL INVEST, V21, P39, DOI 10.3109/08820139209069361; Gao JL, 1997, J EXP MED, V185, P1959, DOI 10.1084/jem.185.11.1959; Garlisi CG, 1997, AM J RESP CELL MOL, V17, P642; Gerard C, 1997, J CLIN INVEST, V100, P2022, DOI 10.1172/JCI119734; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Gonzalo JA, 1998, J EXP MED, V188, P157, DOI 10.1084/jem.188.1.157; Hofstra CL, 1998, J IMMUNOL, V161, P5054; Hogaboam CM, 1999, J IMMUNOL, V162, P6071; Hogaboam CM, 2000, AM J PATHOL, V156, P723, DOI 10.1016/S0002-9440(10)64775-X; Holgate ST, 1997, AM J RESP CRIT CARE, V156, P1377; Holgate ST, 1997, CIBA F SYMP, V206, P5; Holt PG, 1999, NATURE, V402, pB12; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; JEFFERY PK, 1991, AM REV RESPIR DIS, V143, P1152; JEFFERY PK, 1992, RESPIRATION S1, V5, P13; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; Keane MP, 1999, J IMMUNOL, V162, P5511; KRISHNASWAMY G, 1999, VETERANS HLTH SYSTEM, V4, P44; Li L, 1998, J IMMUNOL, V161, P3128; Lukacs NW, 1999, J CLIN INVEST, V104, P995, DOI 10.1172/JCI8125; Lukacs NW, 1996, J LEUKOCYTE BIOL, V60, P573; Lukacs NW, 1997, J IMMUNOL, V158, P4478; MALO JL, 1979, CLIN ALLERGY, V9, P377, DOI 10.1111/j.1365-2222.1979.tb02496.x; Mehrad B, 1999, J IMMUNOL, V162, P1633; Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; ROCHE WR, 1989, LANCET, V1, P520; SCHAFFNER A, 1982, J CLIN INVEST, V69, P617, DOI 10.1172/JCI110489; SMITH RE, 1995, J LEUKOCYTE BIOL, V57, P782; Smith RE, 1996, BIOL SIGNAL, V5, P223; Stafford S, 1997, J IMMUNOL, V158, P4953; Taramelli D, 1996, J MED VET MYCOL, V34, P49; Topham PS, 1999, J CLIN INVEST, V104, P1549, DOI 10.1172/JCI7707; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53; Zhu Zhou, 1999, Journal of Clinical Investigation, V103, P779, DOI 10.1172/JCI5909	47	94	101	0	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	AUG 1	2000	165	3					1564	1572				9	Immunology	Immunology	337CV	WOS:000088340600053	10903765	
J	Zollner, TM; Wichelhaus, TA; Hartung, A; Von Mallinckrodt, C; Wagner, TOF; Brade, V; Kaufmann, R				Zollner, TM; Wichelhaus, TA; Hartung, A; Von Mallinckrodt, C; Wagner, TOF; Brade, V; Kaufmann, R			Colonization with superantigen-producing Staphylococcus aureus is associated with increased severity of atopic dermatitis	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopic dermatitis; cutaneous lymphocyte-associated antigen; Staphylococcus aureus; SCORAD; specific IgE against SEA/SEB; staphylococcal enterotoxins; superantigen; T cell skin homing	SHOCK SYNDROME TOXIN-1; LYMPHOCYTE-ASSOCIATED ANTIGEN; BLOOD MONONUCLEAR-CELLS; HUMAN T-LYMPHOCYTES; BACTERIAL SUPERANTIGENS; IGE ANTIBODIES; UP-REGULATION; SKIN; ENTEROTOXINS; EXPRESSION	Background Atopic dermatitis (AD) is a chronic inflammatory skin disease associated with colonization of the skin with Staphylococcus aureus known to produce toxins with superantigen (SAg) activity. Besides T-cell activation these toxins induce T-cell skin homing in vitro. This may contribute to the observed induction or enhancement of skin inflammation. Objective The aim of this study was to determine whether colonization with SAg-producing S. aureus isolates modulates the intensity of AD. If so, it was of interest whether this may be primarily due to the toxins' effects as SAgs or as allergens. Methods In AD patients, healthy controls, and atopic controls SAg production by S. aureus isolated from skin or mucous membranes was investigated and correlated to the severity of the disease. Total IgE, SAg-specific IgE, and T-cell activation and recirculation markers were analysed and correlated with SAg production. Results Fifty-seven percent of S. aureus strains isolated from AD patients produced SAgs. This frequency was higher compared to healthy controls (33%). SAg production by S. aureus was correlated with a significantly higher scoring of AD (SCORAD index, 58 +/- 19 in SAg-producing vs 41 +/- 7 in non-SAg-producing germs; P < 0.05). However, the severity of the disease was not associated with sensitization against the SAgs staphylococcal enterotoxin A (SEA) and staphylococcal enterotoxin B (SEB). Furthermore, SAg production by S. aureus was inversely correlated with total IgE concentration (P < 0.05) and positively correlated with T-cell activation (as measured by HLA-DR and CD69 expression) and the expression of the T-cell skin homing phenotype cutaneous lymphocyte-associated antigen. Conclusion SAg production by S. aureus is suggested to be associated with an increased severity of atopic dermatitis. Since SAg production was found neither exclusively in AD patients nor in all patients, other pathogenic factors may be additionally effective.	Univ Frankfurt, Sch Med, Dept Dermatol, D-60590 Frankfurt, Germany; Univ Frankfurt, Sch Med, Dept Med Microbiol, D-60590 Frankfurt, Germany; Univ Frankfurt, Sch Med, Dept Pulmonol, D-60590 Frankfurt, Germany	Zollner, TM (reprint author), Univ Frankfurt, Sch Med, Dept Dermatol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.						Akiyama H, 1996, ARCH DERMATOL RES, V288, P418, DOI 10.1007/BF02507115; Boehncke WH, 1996, NATURE, V379, P777, DOI 10.1038/379777a0; Boehncke WH, 1999, HAUTARZT, V50, P91, DOI 10.1007/s001050050870; Boehncke WH, 1996, TRENDS MICROBIOL, V4, P485, DOI 10.1016/S0966-842X(97)82910-1; Boehncke WH, 1997, J CUTAN PATHOL, V24, P1, DOI 10.1111/j.1600-0560.1997.tb00778.x; Bunikowski R, 1999, J ALLERGY CLIN IMMUN, V103, P119, DOI 10.1016/S0091-6749(99)70535-X; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Grewe M, 1998, IMMUNOL TODAY, V19, P359, DOI 10.1016/S0167-5699(98)01285-7; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Herz U, 1998, J INVEST DERMATOL, V110, P224, DOI 10.1046/j.1523-1747.1998.00119.x; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Hofer MF, 1995, CLIN EXP ALLERGY, V25, P1218, DOI 10.1111/j.1365-2222.1995.tb03046.x; Jabara HH, 1996, INT IMMUNOL, V8, P1503, DOI 10.1093/intimm/8.10.1503; Jappe U, 1998, J INVEST DERMATOL, V110, P844; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505; KONIG B, 1995, INT ARCH ALLERGY IMM, V106, P124; LESTER MR, 1995, CLIN IMMUNOL IMMUNOP, V77, P332, DOI 10.1006/clin.1995.1160; Leung DYM, 1998, BRIT J DERMATOL, V139, P17; LEUNG DYM, 1995, J EXP MED, V181, P747, DOI 10.1084/jem.181.2.747; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MCFADDEN JP, 1993, BRIT J DERMATOL, V128, P631, DOI 10.1111/j.1365-2133.1993.tb00257.x; Michie CA, 1996, LANCET, V347, P324, DOI 10.1016/S0140-6736(96)90498-5; Miller J. Michael, 1995, P19; NEUBER K, 1995, INT ARCH ALLERGY IMM, V107, P179; Nissen D, 1997, ANN ALLERG ASTHMA IM, V79, P403; Piletta PA, 1996, ARCH DERMATOL, V132, P1171, DOI 10.1001/archderm.132.10.1171; PODDA M, 1999, ARCH DERMATOL RES, V291, pA108; Reekers R, 1999, J ALLERGY CLIN IMMUN, V104, P466, DOI 10.1016/S0091-6749(99)70395-7; SALOGA J, 1996, J INVEST DERMATOL, V107, P603; SCHMIDT A, 1996, MUNCH MED WSCHR, V138, P432; STALDER JF, 1993, DERMATOLOGY, V186, P23; Strange P, 1996, ARCH DERMATOL, V132, P27, DOI 10.1001/archderm.132.1.27; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; Tada J, 1996, EUR J DERMATOL, V6, P552; Torres MJ, 1998, CLIN EXP ALLERGY, V28, P1264; Zollner TM, 1996, IMMUNOL LETT, V49, P111, DOI 10.1016/0165-2478(95)02491-3; Zollner TM, 1999, J INVEST DERMATOL, V112, P118; Zollner TM, 1997, EXP DERMATOL, V6, P161, DOI 10.1111/j.1600-0625.1997.tb00200.x	39	94	101	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUL	2000	30	7					994	1000				7	Allergy; Immunology	Allergy; Immunology	334CP	WOS:000088167800013	10848922	
J	Muraro, A; Halken, S; Arshad, SH; Beyer, K; Dubois, AEJ; Du Toit, G; Eigenmann, PA; Grimshaw, KEC; Hoest, A; Lack, G; O'Mahony, L; Papadopoulos, NG; Panesar, S; Prescott, S; Roberts, G; de Silva, D; Venter, C; Verhasselt, V; Akdis, AC; Sheikh, A				Muraro, A.; Halken, S.; Arshad, S. H.; Beyer, K.; Dubois, A. E. J.; Du Toit, G.; Eigenmann, P. A.; Grimshaw, K. E. C.; Hoest, A.; Lack, G.; O'Mahony, L.; Papadopoulos, N. G.; Panesar, S.; Prescott, S.; Roberts, G.; de Silva, D.; Venter, C.; Verhasselt, V.; Akdis, A. C.; Sheikh, A.		EAACI Food Allergy Anaphylaxis	EAACI Food Allergy and Anaphylaxis Guidelines. Primary prevention of food allergy	ALLERGY			English	Article						primary prevention; food allergy; children; EAACI; guidelines	RANDOMIZED CONTROLLED-TRIAL; HYDROLYZED INFANT FORMULAS; FISH-OIL SUPPLEMENTATION; PLACEBO-CONTROLLED TRIAL; BRIEF NEONATAL EXPOSURE; HIGH-RISK CHILDREN; COWS MILK ALLERGY; ATOPIC DISEASE; FOLLOW-UP; BIRTH COHORT	Food allergy can have significant effects on morbidity and quality of life and can be costly in terms of medical visits and treatments. There is therefore considerable interest in generating efficient approaches that may reduce the risk of developing food allergy. This guideline has been prepared by the European Academy of Allergy and Clinical Immunology's (EAACI) Taskforce on Prevention and is part of the EAACI Guidelines for Food Allergy and Anaphylaxis. It aims to provide evidence-based recommendations for primary prevention of food allergy. A wide range of antenatal, perinatal, neonatal, and childhood strategies were identified and their effectiveness assessed and synthesized in a systematic review. Based on this evidence, families can be provided with evidence-based advice about preventing food allergy, particularly for infants at high risk for development of allergic disease. The advice for all mothers includes a normal diet without restrictions during pregnancy and lactation. For all infants, exclusive breastfeeding is recommended for at least first 4-6months of life. If breastfeeding is insufficient or not possible, infants at high-risk can be recommended a hypoallergenic formula with a documented preventive effect for the first 4months. There is no need to avoid introducing complementary foods beyond 4months, and currently, the evidence does not justify recommendations about either withholding or encouraging exposure to potentially allergenic foods after 4months once weaning has commenced, irrespective of atopic heredity. There is no evidence to support the use of prebiotics or probiotics for food allergy prevention.	[Muraro, A.] Univ Padua, Dept Mother & Child Hlth, Referral Ctr Food Allergy Diag & Treatment, I-35128 Padua, Italy; [Halken, S.; Hoest, A.] Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, DK-5000 Odense, Denmark; [Arshad, S. H.; Grimshaw, K. E. C.; Roberts, G.] Univ Southampton, Fac Med, Clin & Expt Sci Acad Unit, Southampton SO9 5NH, Hants, England; [Arshad, S. H.; Roberts, G.; Venter, C.] St Marys Hosp, David Hide Asthma & Allergy Res Ctr, Newport, Wight, England; [Arshad, S. H.; Roberts, G.] Univ Hosp Southampton NHS Fdn Trust, NIHR Resp Biomed Res Unit, Southampton, Hants, England; [Beyer, K.] Charite, Clin Pediat Pneumol & Immunol, D-13353 Berlin, Germany; [Dubois, A. E. J.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pediat Pulmonol & Paediat Allergy, Groningen, Netherlands; [Du Toit, G.; Lack, G.] Kings Coll London, Guys & St Thomas NHS Fdn Trust, Dept Paediat Allergy, MRC,Div Asthma Allergy & Lung Biol, London WC2R 2LS, England; [Du Toit, G.; Lack, G.] Kings Coll London, Guys & St Thomas NHS Fdn Trust, Asthma UK Ctr Allerg Mechanisms Asthma, London WC2R 2LS, England; [Eigenmann, P. A.] Univ Hosp Geneva, Dept Child & Adolescent, Allergy Unit, Geneva, Switzerland; [O'Mahony, L.] Univ Zurich, Swiss Inst Allergy & Asthma Res, Zurich, Switzerland; [Papadopoulos, N. G.] Univ Manchester, Inst Human Dev, Manchester, Lancs, England; [Papadopoulos, N. G.] Univ Athens, Dept Allergy, Pediat Clin 2, Athens, Greece; [Panesar, S.; de Silva, D.] Evidence Based Hlth Care Ltd, Edinburgh, Midlothian, Scotland; [Prescott, S.] Univ Western Australia, Sch Paediat & Child Hlth Res, Perth, WA 6009, Australia; [Venter, C.] Univ Portsmouth, Sch Hlth Sci & Social Work, Portsmouth, Hants, England; [Verhasselt, V.] Univ Nice Sophia Antipolis, Hop Archet, EA Tolerance Immunitaire 6302, F-06189 Nice, France; [Akdis, A. C.] Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Sheikh, A.] Univ Edinburgh, Ctr Populat Hlth Sci, Allergy & Resp Res Grp, Edinburgh EH8 9YL, Midlothian, Scotland; [Sheikh, A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gen Internal Med & Primary Care, Boston, MA 02115 USA	Muraro, A (reprint author), Univ Padua, Dept Mother & Child Hlth, Referral Ctr Food Allergy Diag & Treatment, Via Giustiniani 3, I-35128 Padua, Italy.	muraro@centroallergiealimentari.eu	Sheikh, Aziz /D-2818-2009; Prescott, Susan/H-5665-2014; Eigenmann, Philippe/A-6569-2017	Sheikh, Aziz /0000-0001-7022-3056; Eigenmann, Philippe/0000-0003-1738-1826; Grimshaw, Kate/0000-0003-3649-7963	Medical Research Council [G1000758]		Anandan C, 2009, ALLERGY, V64, P840, DOI 10.1111/j.1398-9995.2009.02042.x; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; BARDARE M, 1993, ANN ALLERGY, V71, P366; Brouwers MC, 2010, PREV MED, V51, P421, DOI 10.1016/j.ypmed.2010.08.005; BRUNO G, 1993, ALLERGY PROC, V14, P181, DOI 10.2500/108854193778878682; Chirico G, 1997, ALLERGY, V52, P82, DOI 10.1111/j.1398-9995.1997.tb02549.x; D'Agata A, 1996, Pediatr Med Chir, V18, P469; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; de Silva D, 2014, ALLERGY, V69, P581, DOI 10.1111/all.12334; de Silva Debra, 2013, Clin Transl Allergy, V3, P10, DOI 10.1186/2045-7022-3-10; de SL, 1994, PEDIAT MED CHIR, V16, P251; Denburg JA, 2005, PEDIATR RES, V57, P276, DOI 10.1203/01.PDR.0000148279.72611.1D; Du Toit G, 2008, J ALLERGY CLIN IMMUN, V122, P984, DOI 10.1016/j.jaci.2008.08.039; Du Toit G, 2013, J ALLERGY CLIN IMMUN, V131, P135, DOI 10.1016/j.jaci.2012.09.015; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; FALTHMAGNUSSON K, 1992, J ALLERGY CLIN IMMUN, V89, P709, DOI 10.1016/0091-6749(92)90378-F; Furuhjelm C, 2011, PEDIAT ALLERG IMM-UK, V22, P505, DOI 10.1111/j.1399-3038.2010.01096.x; Grimshaw KEC, 2013, PEDIATRICS, V132, pE1529, DOI 10.1542/peds.2012-3692; Gruber C, 2010, J ALLERGY CLIN IMMUN, V126, P791, DOI 10.1016/j.jaci.2010.07.022; Halken S, 1993, Pediatr Allergy Immunol, V4, P173, DOI 10.1111/j.1399-3038.1993.tb00088.x; HALKEN S, 1992, ALLERGY, V47, P545, DOI 10.1111/j.1398-9995.1992.tb00680.x; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Halmerbauer G, 2003, PEDIATR ALLERGY IMMU, V14, P10, DOI 10.1034/j.1399-3038.2003.02069.x; HATTEVIG G, 1989, CLIN EXP ALLERGY, V19, P27, DOI 10.1111/j.1365-2222.1989.tb02339.x; Hays T, 2005, ARCH PEDIAT ADOL MED, V159, P810, DOI 10.1001/archpedi.159.9.810; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; Howick J, 2011, 2011 OXFORD CEBM LEV; Huurre A, 2008, CLIN EXP ALLERGY, V38, P1342, DOI 10.1111/j.1365-2222.2008.03008.x; Joseph CLM, 2011, J ALLERGY CLIN IMMUN, V127, P1203, DOI 10.1016/j.jaci.2011.02.018; Kajosaari M, 1994, Pediatr Allergy Immunol, V5, P26, DOI 10.1111/j.1399-3038.1994.tb00344.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kjaer HF, 2008, PEDIAT ALLERG IMM-UK, V19, P737, DOI 10.1111/j.1399-3038.2008.00733.x; Kjaer HF, 2009, PEDIATR ALLERGY IMMU, V20, P726, DOI 10.1111/j.1399-3038.2009.00862.x; KJELLMAN NIM, 1979, CLIN ALLERGY, V9, P347, DOI 10.1111/j.1365-2222.1979.tb02493.x; Klemens CM, 2011, BJOG-INT J OBSTET GY, V118, P916, DOI 10.1111/j.1471-0528.2010.02846.x; Koplin JJ, 2010, J ALLERGY CLIN IMMUN, V126, P807, DOI 10.1016/j.jaci.2010.07.028; Kramer MS, 2007, BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kramer MS, 2009, AM J CLIN NUTR, V90, P1070, DOI 10.3945/ajcn.2009.28021; Kramer M.S., 2012, COCHRANE DATABASE SY, V9; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen AK, 2011, CLIN EXP ALLERGY, V41, P1414, DOI 10.1111/j.1365-2222.2011.03821.x; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Kull I, 2006, J ALLERGY CLIN IMMUN, V118, P1299, DOI 10.1016/j.jaci.2006.08.022; Kull I, 2010, J ALLERGY CLIN IMMUN, V125, P1013, DOI 10.1016/j.jaci.2010.01.051; Kunz C, 2008, ADV EXP MED BIOL, V606, P455, DOI 10.1007/978-0-387-74087-4_18; LILJA G, 1991, CLIN EXP ALLERGY, V21, P195, DOI 10.1111/j.1365-2222.1991.tb00830.x; LINDFORS ATB, 1992, ALLERGY, V47, P207, DOI 10.1111/j.1398-9995.1992.tb00652.x; Linehan MF, 2014, J ALLERGY CLIN IMMUN, V133, P688, DOI 10.1016/j.jaci.2013.08.007; LOVEGROVE JA, 1994, BRIT J NUTR, V71, P223, DOI 10.1079/BJN19940129; Lowe AJ, 2011, J ALLERGY CLIN IMMUN, V128, P360, DOI 10.1016/j.jaci.2010.05.006; LUCAS A, 1990, BRIT MED J, V300, P837; MALLET E, 1992, J PEDIATR-US, V121, pS95, DOI 10.1016/S0022-3476(05)81415-5; Manley BJ, 2011, PEDIATRICS, V128, pE71, DOI 10.1542/peds.2010-2405; Marini A, 1996, ACTA PAEDIATR, V85, P1, DOI 10.1111/j.1651-2227.1996.tb14267.x; Marmsjo K, 2009, AM J CLIN NUTR, V90, P1693, DOI 10.3945/ajcn.2009.27963; Marschan E, 2008, CLIN EXP ALLERGY, V38, P611, DOI 10.1111/j.1365-2222.2008.02942.x; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Matricardi PM, 2008, CLIN EXP ALLERGY, V38, P493, DOI 10.1111/j.1365-2222.2007.02912.x; Matricardi PM, 2009, CLIN EXP ALLERGY, V39, P1551, DOI 10.1111/j.1365-2222.2009.03348.x; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Morisset M, 2011, EUR J CLIN NUTR, V65, P175, DOI 10.1038/ejcn.2010.250; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P103, DOI 10.1046/j.1399-3038.2003.00129.x; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Odelram H, 1996, ALLERGY, V51, P192, DOI 10.1111/j.1398-9995.1996.tb04587.x; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; Osborn DA, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003664.pub3; Osborn DA, 2006, COCHRANE DATABASE SY, V4; Osborn DA, 2007, COCHRANE DATABASE SY, V4; Osborn DA, 2013, COCHRANE DATABASE SY, V3; Palmer DJ, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e184; Pesonen M, 2006, CLIN EXP ALLERGY, V36, P1011, DOI 10.1111/j.1365-2222.2006.02526.x; POYSA L, 1991, ALLERGY PROC, V12, P107, DOI 10.2500/108854191779011800; Prescott SL, 2008, ALLERGY, V63, P1481, DOI 10.1111/j.1398-9995.2008.01778.x; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P457, DOI 10.1016/S0091-6749(99)70393-3; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; Sausenthaler S, 2007, AM J CLIN NUTR, V85, P530; Sausenthaler S, 2011, AM J CLIN NUTR, V94, p2012S, DOI 10.3945/ajcn.110.001180; Schoetzau A, 2002, PEDIATR ALLERGY IMMU, V13, P234, DOI 10.1034/j.1399-3038.2002.01050.x; Scott M, 2012, THORAX, V67, P1046, DOI 10.1136/thoraxjnl-2012-202150; Sjogren YM, 2007, PEDIATR ALLERGY IMMU, V18, P20, DOI 10.1111/j.1399-3038.2006.00486.x; Szajewska H, 2010, CURR MED RES OPIN, V26, P423, DOI 10.1185/03007990903510317; Tang Lu-jing, 2012, Zhonghua Er Ke Za Zhi, V50, P504; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; Venter C, 2006, PEDIATR ALLERGY IMMU, V17, P356, DOI 10.1111/j.1399-3038.2006.00428.x; Venter C, 2009, PEDIATR ALLERGY IMMU, V20, P320, DOI 10.1111/j.1399-3038.2008.00832.x; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; von Berg A, 2008, J ALLERGY CLIN IMMUN, V121, P1442, DOI 10.1016/j.jaci.2008.04.021; Wetzig H, 2000, INT J HYG ENVIR HEAL, V203, P17, DOI 10.1078/S1438-4639(04)70003-6; Yu G, 1998, ACTA PAEDIATR, V87, P729; Zachariassen G, 2011, PEDIAT ALLERG IMM-UK, V22, P515, DOI 10.1111/j.1399-3038.2010.01102.x; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zeiger R, 1992, PEDIATR ALLERGY IMMU, V3, P110, DOI 10.1111/j.1399-3038.1992.tb00035.x	97	93	101	6	43	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	MAY	2014	69	5					590	601		10.1111/all.12398		12	Allergy; Immunology	Allergy; Immunology	AE2QB	WOS:000333816900006	24697491	
J	Soroosh, P; Doherty, TA; Duan, W; Mehta, AK; Choi, H; Adams, YF; Mikulski, Z; Khorram, N; Rosenthal, P; Broide, DH; Croft, M				Soroosh, Pejman; Doherty, Taylor A.; Duan, Wei; Mehta, Amit Kumar; Choi, Heonsik; Adams, Yan Fei; Mikulski, Zbigniew; Khorram, Naseem; Rosenthal, Peter; Broide, David H.; Croft, Michael			Lung-resident tissue macrophages generate Foxp3(+) regulatory T cells and promote airway tolerance	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							HOUSE-DUST MITE; ALVEOLAR MACROPHAGES; DENDRITIC CELLS; RETINOIC-ACID; ALLERGIC INFLAMMATION; INHALED ANTIGEN; TGF-BETA; ASPERGILLUS-FUMIGATUS; IMMUNE-RESPONSE; FLOW-CYTOMETRY	Airway tolerance is the usual outcome of inhalation of harmless antigens. Although T cell deletion and anergy are likely components of tolerogenic mechanisms in the lung, increasing evidence indicates that antigen-specific regulatory T cells (inducible T-reg cells [iT(reg) cells]) that express Foxp3 are also critical. Several lung antigen-presenting cells have been suggested to contribute to tolerance, including alveolar macrophages (Mempty sets), classical dendritic cells (DCs), and plasmacytoid DCs, but whether these possess the attributes required to directly promote the development of Foxp3(+) iT(reg) cells is unclear. Here, we show that lung-resident tissue Mempty sets coexpress TGF-beta and retinal dehydrogenases (RALDH1 and RALDH 2) under steady-state conditions and that their sampling of harmless airborne antigen and presentation to antigen-specific CD4 T cells resulted in the generation of Foxp3(+) T-reg cells. T-reg cell induction in this model depended on both TGF-beta and retinoic acid. Transfer of the antigen-pulsed tissue Mempty sets into the airways correspondingly prevented the development of asthmatic lung inflammation upon subsequent challenge with antigen. Moreover, exposure of lung tissue Mempty sets to allergens suppressed their ability to generate iT(reg) cells coincident with blocking airway tolerance. Suppression of T-reg cell generation required proteases and TLR-mediated signals. Therefore, lung-resident tissue Mempty sets have regulatory functions, and strategies to target these cells might hold promise for prevention or treatment of allergic asthma.	[Soroosh, Pejman; Duan, Wei; Mehta, Amit Kumar; Choi, Heonsik; Adams, Yan Fei; Croft, Michael] La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA 92037 USA; [Mikulski, Zbigniew] La Jolla Inst Allergy & Immunol, Div Inflammat Biol, La Jolla, CA 92037 USA; [Doherty, Taylor A.; Khorram, Naseem; Rosenthal, Peter; Broide, David H.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	Croft, M (reprint author), La Jolla Inst Allergy & Immunol, Div Immune Regulat, La Jolla, CA 92037 USA.	mick@liai.org	Mehta, Amit Kumar/D-7585-2016	Mikulski, Zbigniew/0000-0002-1918-9216	National Institutes of Health [CA91837, AI70535]	This work was supported by National Institutes of Health grants CA91837 and AI70535 to M. Croft. This is manuscript number # 1534 from the La Jolla Institute for Allergy and Immunology.	Akbari O, 2001, NAT IMMUNOL, V2, P725, DOI 10.1038/90667; Akdis M, 2006, CURR OPIN IMMUNOL, V18, P738, DOI 10.1016/j.coi.2006.06.003; Bakocevic N, 2010, J IMMUNOL, V184, P1317, DOI 10.4049/jimmunol.0902277; Bang BR, 2011, EXP MOL MED, V43, P275, DOI 10.3858/emm.2011.43.5.028; Beaty SR, 2007, J IMMUNOL, V178, P1882; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; BILYK N, 1993, J EXP MED, V177, P1773, DOI 10.1084/jem.177.6.1773; Blumenthal RL, 2001, J ALLERGY CLIN IMMUN, V107, P258, DOI 10.1067/mai.2001.112845; Braedel S, 2004, BRIT J HAEMATOL, V125, P392, DOI 10.1111/j.1365-2141.2004.04922.x; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Cose S, 2006, EUR J IMMUNOL, V36, P1423, DOI 10.1002/eji.200535539; de Heer HJ, 2004, J EXP MED, V200, P89, DOI 10.1084/jem.20040035; de Lafaille MAC, 2008, IMMUNITY, V29, P114, DOI 10.1016/j.immuni.2008.05.010; Denning TL, 2007, NAT IMMUNOL, V8, P1086, DOI 10.1038/ni1511; Denning TL, 2011, J IMMUNOL, V187, P733, DOI 10.4049/jimmunol.1002701; Doganci A, 2005, J CLIN INVEST, V115, P313, DOI 10.1172/JCI200522433; Doherty T, 2007, CURR OPIN IMMUNOL, V19, P676, DOI 10.1016/j.coi.2007.07.017; Duan W, 2011, J IMMUNOL, V187, P6499, DOI 10.4049/jimmunol.1101398; Duan W, 2010, J ALLERGY CLIN IMMUN, V126, P1284, DOI 10.1016/j.jaci.2010.09.021; Duan W, 2008, J IMMUNOL, V181, P8650; Furuhashi Kazuki, 2012, Am J Respir Cell Mol Biol, V46, P165, DOI 10.1165/rcmb.2011-0070OC; Futterer A, 1998, IMMUNITY, V9, P59, DOI 10.1016/S1074-7613(00)80588-9; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326; Gajewska BU, 2001, J CLIN INVEST, V108, P577, DOI 10.1172/JCI12627; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Halwani R, 2011, AM J RESP CELL MOL, V44, P127, DOI 10.1165/rcmb.2010-0027TR; Hamann A, 2000, EUR J IMMUNOL, V30, P3207, DOI 10.1002/1521-4141(200011)30:11<3207::AID-IMMU3207>3.0.CO;2-L; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harp JR, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010973; Hawrylowicz CM, 2005, NAT REV IMMUNOL, V5, P271, DOI 10.1038/nri1589; Hintzen G, 2006, J IMMUNOL, V177, P7346; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; Josefowicz SZ, 2012, NATURE, V482, P395, DOI 10.1038/nature10772; Kamada N, 2005, J IMMUNOL, V175, P6900; Kauffman Henk F, 2006, Clin Mol Allergy, V4, P5, DOI 10.1186/1476-7961-4-5; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kirby AC, 2009, J IMMUNOL, V183, P1983, DOI 10.4049/jimmunol.0901089; Larche M, 2007, CHEST, V132, P1007, DOI 10.1378/chest.06-2434; Lekkerkerker AN, 2012, CURR PHARM DESIGN, V18, P4093; Lipscomb Mary F., 1993, Regional Immunology, V5, P151; Lloyd CM, 2009, IMMUNITY, V31, P438, DOI 10.1016/j.immuni.2009.08.007; Mambula SS, 2002, J BIOL CHEM, V277, P39320, DOI 10.1074/jbc.M201683200; Mucida D, 2005, J CLIN INVEST, V115, P1923, DOI 10.1172/JCI24487; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Nakano H, 2012, MUCOSAL IMMUNOL, V5, P53, DOI 10.1038/mi.2011.47; Neveu WA, 2009, J IMMUNOL, V183, P1732, DOI 10.4049/jimmunol.0802923; Ostroukhova M, 2004, J CLIN INVEST, V114, P28, DOI 10.1172/JC1200420509; ROTH MD, 1993, J LEUKOCYTE BIOL, V53, P366; Stevens WW, 2007, J IMMUNOL METHODS, V327, P63, DOI 10.1016/j.jim.2007.07.011; Strickland D, 1996, IMMUNOLOGY, V87, P250, DOI 10.1046/j.1365-2567.1996.459542.x; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; THEPEN T, 1993, ADV EXP MED BIOL, V329, P305; THEPEN T, 1992, CLIN EXP ALLERGY, V22, P1107, DOI 10.1111/j.1365-2222.1992.tb00137.x; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Tsitoura DC, 1999, J IMMUNOL, V163, P2592; Umetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007; UPHAM JW, 1995, IMMUNOLOGY, V84, P142; Vermaelen K, 2004, CYTOM PART A, V61A, P170, DOI 10.1002/cyto.a.20064; Wikstrom ME, 2010, IMMUNOL CELL BIOL, V88, P658, DOI 10.1038/icb.2010.18; Willart MAM, 2012, J EXP MED, V209, P1505, DOI 10.1084/jem.20112691; Zaslona Z, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-2; Zheng Y, 2010, NATURE, V463, P808, DOI 10.1038/nature08750	64	93	93	2	18	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	APR 8	2013	210	4					775	788		10.1084/jem.20121849		14	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	121ZP	WOS:000317284900012	23547101	
J	Ramasamy, A; Curjuric, I; Coin, LJ; Kumar, A; McArdle, WL; Imboden, M; Leynaert, B; Kogevinas, M; Schmid-Grendelmeier, P; Pekkanen, J; Wjst, M; Bircher, AJ; Sovio, U; Rochat, T; Hartikainen, AL; Balding, DJ; Jarvelin, MR; Probst-Hensch, N; Strachan, DP; Jarvis, DL				Ramasamy, Adaikalavan; Curjuric, Ivan; Coin, Lachlan J.; Kumar, Ashish; McArdle, Wendy L.; Imboden, Medea; Leynaert, Benedicte; Kogevinas, Manolis; Schmid-Grendelmeier, Peter; Pekkanen, Juha; Wjst, Matthias; Bircher, Andreas J.; Sovio, Ulla; Rochat, Thierry; Hartikainen, Anna-Liisa; Balding, David J.; Jarvelin, Marjo-Riitta; Probst-Hensch, Nicole; Strachan, David P.; Jarvis, Deborah L.			A genome-wide meta-analysis of genetic variants associated with allergic rhinitis and grass sensitization and their interaction with birth order	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Hay fever; IgE sensitization to grass; hygiene hypothesis; older siblings; gene-environment interaction; genome-wide association study; European Community Respiratory Health Survey; British 1958 Birth Cohort; Northern Finland Birth Cohort of 1966; Swiss Study on Air Pollution and Lung Disease in Adults	RESPIRATORY-HEALTH-SURVEY; HAY-FEVER; ENVIRONMENT INTERACTION; FILAGGRIN MUTATIONS; CHILDHOOD ECZEMA; CHROMOSOME 11Q13; ASTHMA; COHORT; EXPOSURE; DISEASES	Background: Hay fever or seasonal allergic rhinitis (AR) is a chronic disorder associated with IgE sensitization to grass. The underlying genetic variants have not been studied comprehensively. There is overwhelming evidence that those who have older siblings have less AR, although the mechanism for this remains unclear. Objective: We sought to identify common genetic variant associations with prevalent AR and grass sensitization using existing genome-wide association study (GWAS) data and to determine whether genetic variants modify the protective effect of older siblings. Method: Approximately 2.2 million genotyped or imputed single nucleotide polymorphisms were investigated in 4 large European adult cohorts for AR (3,933 self-reported cases vs 8,965 control subjects) and grass sensitization (2,315 cases vs 10,032 control subjects). Results: Three loci reached genome-wide significance for either phenotype. The HLAvariant rs7775228, which cis-regulates HLA-DRB4, was strongly associated with grass sensitization and weakly with AR (P-grass = 1.6 x 10(-9); P-AR = 8.0 x 10(-3)). Variants in a locus near chromosome 11 open reading frame 30 (C11orf30) and leucine-rich repeat containing 32 (LRRC32), which was previously associated with atopic dermatitis and eczema, were also strongly associated with both phenotypes (rs2155219; P-grass = 9.4 x 10(-9); P-AR = 3.8 x 10(-8))(.) The third genome-wide significant variant was rs17513503 (P-grass = 1.2 x 10(-8); PAR = 7.4 x 10(-7)) which was located near transmembrane protein 232 (TMEM232) and solute carrier family 25, member 46 (SLC25A46). Twelve further loci with suggestive associations were also identified. Using a candidate gene approach, where we considered variants within 164 genes previously thought to be important, we found variants in 3 further genes that may be of interest: thymic stromal lymphopoietin (TSLP), Toll-like receptor 6 (TLR6) and nucleotide-binding oligomerization domain containing 1 (NOD1/CARD4). We found no evidence for variants that modified the effect of birth order on either phenotype. Conclusions: This relatively large meta-analysis of GWASs identified few loci associated with AR and grass sensitization. No birth order interaction was identified in the current analyses. (J Allergy Clin Immunol 2011;128:996-1005.)	[Ramasamy, Adaikalavan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London SW3 6LR, England; [Curjuric, Ivan; Kumar, Ashish; Imboden, Medea; Probst-Hensch, Nicole] Swiss Trop & Publ Hlth Inst, Basel, Switzerland; [Curjuric, Ivan; Imboden, Medea; Bircher, Andreas J.; Probst-Hensch, Nicole] Univ Basel, CH-4003 Basel, Switzerland; [Coin, Lachlan J.; Sovio, Ulla; Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London SW3 6LR, England; [Kumar, Ashish] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX1 2JD, England; [Kumar, Ashish] Univ Oxford, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX1 2JD, England; [McArdle, Wendy L.] Univ Bristol, Dept Social & Community Med, Avon Longitudinal Study Parents & Children ALSPAC, Bristol BS8 1TH, Avon, England; [Leynaert, Benedicte] INSERM, U700, Paris, France; [Kogevinas, Manolis] Ctr Res Environm Epidemiol, Barcelona, Spain; [Kogevinas, Manolis] IMIM Hosp del Mar, Municipal Inst Med Res, Barcelona, Spain; [Kogevinas, Manolis] CIBER Epidemiol & Salud Publ, Barcelona, Spain; [Kogevinas, Manolis] Univ Crete, Sch Med, Dept Social Med, Iraklion, Greece; [Schmid-Grendelmeier, Peter] Univ Zurich Hosp, Dept Dermatol, Allergy Unit, Zurich, Switzerland; [Pekkanen, Juha] Natl Inst Hlth & Welf THL, Dept Environm Hlth, Helsinki, Finland; [Pekkanen, Juha] Univ Eastern Finland, Inst Publ Hlth & Clin Nutr, Kuopio, Finland; [Wjst, Matthias] Helmholtz Zentrum Munchen German Res Ctr Environm, Munich, Germany; [Bircher, Andreas J.] Univ Basel Hosp, Dept Dermatol, Allergy Unit, Basel, Switzerland; [Sovio, Ulla] London Sch Hyg & Trop Med, Dept Med Stat, London, England; [Rochat, Thierry] Univ Hosp Geneva, Div Pulm Med, Geneva, Switzerland; [Hartikainen, Anna-Liisa] Univ Oulu, Inst Clin Med, Dept Clin Sci Obstet & Gynecol, Oulu, Finland; [Balding, David J.] UCL, Inst Genet, London WC1E 6BT, England; [Jarvelin, Marjo-Riitta; Jarvis, Deborah L.] Univ London Imperial Coll Sci Technol & Med, MRC HPA Ctr Environm & Hlth, London SW3 6LR, England; [Strachan, David P.] Univ London, Div Community Hlth Sci, London WC1E 7HU, England	Jarvis, DL (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Emmanuel Kaye Bldg,Manressa Rd, London SW3 6LR, England.	d.jarvis@imperial.ac.uk	Balding, David/G-9898-2011; Ramasamy, Adaikalavan/G-2632-2010; Coin, Lachlan/A-9001-2014; Kogevinas, Manolis/C-3918-2017	Balding, David/0000-0002-1480-6115; Ramasamy, Adaikalavan/0000-0002-7598-2892; Coin, Lachlan/0000-0002-4300-455X; Kumar, Ashish/0000-0002-7075-5930; Jarvelin, Marjo-Riitta/0000-0002-2149-0630	European Commission [018996]; Department of Health, United Kingdom; Medical Research Council [G0500539]; Helmholtz Center; EU Project European; Swiss National Foundation for Scientific Research	Details of the many charities, governmental bodies, and scientific funding organizations that supported the epidemiologic study, including phenotyping, DNA collection, and genotyping for the British 1958 Birth Cohort (B58C), the European Community Respiratory Health Survey (ECRHS2), the Northern Finland Birth Cohort of 1966 (NFBC1966), and the Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA), can be found in this article's Online Repository at www.jacionline.org. A. R. has received research support from the European Commission (through project GABRIEL, contract no. 018996 under the Integrated Program LSH-2004-1.2.5-1) and the Department of Health, United Kingdom. U.S. was supported by Medical Research Council studentship grant G0500539.; Disclosure of potential conflict of interest: M. Wjst receives research support from the Helmholtz Center and EU Project European. T. Rochat receives research support from the Swiss National Foundation for Scientific Research. The rest of the authors have declared that they have no conflict of interest.	Ackermann-Liebrich U, 2005, SOZ PRAVENTIV MED, V50, P245, DOI 10.1007/s00038-005-4075-5; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Cramer C, 2010, J ALLERGY CLIN IMMUN, V125, P1254, DOI 10.1016/j.jaci.2010.03.036; Dixon AL, 2007, NAT GENET, V39, P1202, DOI 10.1038/ng2109; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Duetsch G, 2002, HUM MOL GENET, V11, P613, DOI 10.1093/hmg/11.6.613; Ege MJ, 2011, J ALLERGY CLIN IMMUN, V127, P138, DOI 10.1016/j.jaci.2010.09.041; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fang CL, 2010, ARCH IMMUNOL THER EX, V58, P81, DOI 10.1007/s00005-010-0064-3; Haider S, 2009, NUCLEIC ACIDS RES, V37, pW23, DOI 10.1093/nar/gkp265; Hunninghake GM, 2010, ALLERGY, V65, P1566, DOI 10.1111/j.1398-9995.2010.02415.x; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Karmaus W, 2002, J EPIDEMIOL COMMUN H, V56, P209, DOI 10.1136/jech.56.3.209; KOIVIKKO A, 1986, ALLERGY, V41, P233, DOI 10.1111/j.1398-9995.1986.tb02023.x; LEVINE BB, 1972, SCIENCE, V178, P1201, DOI 10.1126/science.178.4066.1201; Marenholz I, 2011, HUM MOL GENET, V20, P2443, DOI 10.1093/hmg/ddr117; Michel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013894; Moffatt MF, 2010, NEW ENGL J MED, V363, P1211, DOI 10.1056/NEJMoa0906312; Murcray CE, 2009, AM J EPIDEMIOL, V169, P219, DOI 10.1093/aje/kwn353; NINAN TK, 1992, BRIT MED J, V304, P873; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, P170, DOI 10.1016/j.jaci.2009.10.046; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; O'Regan GM, 2010, J ALLERGY CLIN IMMUN, V125, pe1; R Development Core Team, 2008, R LANG ENV STAT COMP; Rantakallio P., 1969, ACTA PAEDIAT SC S193, V193; Strachan DP, 2007, INT J EPIDEMIOL, V36, P522, DOI 10.1093/ije/dyl309; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, THORAX S1, V55, pS2; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wan YI, 2011, J ALLERGY CLIN IMMUN, V127, pe1; Wan YZI, 2011, J ALLERGY CLIN IMMUN, V127, P223, DOI 10.1016/j.jaci.2010.10.006; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Weinmayr G, 2010, ALLERGY, V65, P766, DOI 10.1111/j.1398-9995.2009.02283.x; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; [Anonymous], GENOME WIDE EVALUATI; [Anonymous], 1997, AM J RESP CRIT CARE, V156, P1773; [Anonymous], HUGE LIT FINDER HUGE	38	93	94	4	18	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2011	128	5					996	1005		10.1016/j.jaci.2011.08.030		10	Allergy; Immunology	Allergy; Immunology	842FJ	WOS:000296578200012	22036096	
J	Apeagyei, E; Bank, MS; Spengler, JD				Apeagyei, Eric; Bank, Michael S.; Spengler, John D.			Distribution of heavy metals in road dust along an urban-rural gradient in Massachusetts	ATMOSPHERIC ENVIRONMENT			English	Article						Heavy metal; Road dust; Tire wear; Brake wear; Traffic-related emissions	PARTICULATE MATTER; HONG-KONG; PARTICLE RESUSPENSION; SOURCE PROFILES; AIR-POLLUTION; STREET DUSTS; CONTAMINATION; ASTHMA; SOILS; EMISSIONS	Human exposures to particulate matter emitted from on-road motor vehicles include complex mixtures of metals from tires, brakes, parts wear and resuspended road dust. The aim of this study was to assess road dust for metals associated with motor vehicle traffic, particularly those metals coming from brake and tire wears. We hypothesized that the road dust would show significant difference in both composition and concentration by traffic type, road class and by location. X-ray fluorescence (XRF) analyses of 115 parked car tires showed Zn and Ca were likely associated with tire wear dust. XRF results of three used brake pads indicated high concentrations of Fe, Ti, Cu, Ba, Mo and Zr. To assess heavy metal exposures associated with tires and brake wear adjacent to roads of varying traffic and functional classes, 85 samples of road dust were collected from road surfaces adjacent to the curb and analyzed by XRF. Median concentrations for Fe. Ca and K were greater than Ti (1619 ppm), with concentration ratios of Fe: Ca: K: Ti [16:5:3:1]. Cumulative frequency distribution graphs showed distribution of Fe, Ba, Cu, and Mo were similar regardless of road traffic rating. However, Zn, Ti, and Zr varied significantly (p < 0.05) with traffic ratings of roadways (heavy > moderate > low traffic). Fe, Ba, Cu, and Mo also had similar distributions regardless of road class while composition of Zn, Ti, and Zr varied significantly across road class (p < 0.05) (Major roads > Minor roads > highway). In comparing urban road dust to rural road dust, we observed Fe, Ca, K, and Ti were significantly greater in urban road dust (p < 0.05). In urban road dust the Fe: Ca: K: Ti relationship with median Ti of 2216 ppm was 12: 6: 3.5: 1. These results indicate that roadway dust may be important sources of metals for runoff water and localized resuspended particulate matter. (C) 2010 Elsevier Ltd. All rights reserved.	[Spengler, John D.] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr W, Boston, MA 02215 USA	Spengler, JD (reprint author), Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Landmark Ctr W, Room 406,401 Pk Dr, Boston, MA 02215 USA.	spengler@hsph.harvard.edu			Harvard NIEHS Center for Environmental Health [ES00002]	The authors gratefully acknowledge Dr. James Shine, Yongmei Shen, Jose Vallerino and Steve Melly of the Harvard School of Public Health for their help with XRF analyses, sample preparation, and traffic classification of roads, respectively. We wish to thank David Moscaritolo and Derick Brain for their road dust sampling work at the early stage of the project. This research was supported by the Harvard NIEHS Center for Environmental Health grant (ES00002).	Adachi K, 2004, ENVIRON INT, V30, P1009, DOI 10.1016/j.envint.2004.04.004; Amato F, 2009, ATMOS ENVIRON, V43, P2770, DOI 10.1016/j.atmosenv.2009.02.039; BAGLEY SH, 2007, JUST CASE MYSTIC VIE; BANERJEE A, 1983, INT J ENVIRON STUD, V20, P239, DOI 10.1080/00207238308710040; Basta NT, 2005, J ENVIRON QUAL, V34, P49; Blau PJ, 2001, ORNLTM200164; Cadle SH, 1999, ENVIRON SCI TECHNOL, V33, P2328, DOI 10.1021/es9810843; Chang SH, 2009, SOIL SEDIMENT CONTAM, V18, P669, DOI 10.1080/15320380903085691; Chen TB, 1997, ENVIRON POLLUT, V96, P61, DOI 10.1016/S0269-7491(97)00003-1; Chow JC, 2003, ATMOS ENVIRON, V37, P1317, DOI 10.1016/S1352-2310(02)01021-X; Claiborn CS, 2002, ENVIRON HEALTH PERSP, V110, P547; CULBARD EB, 1988, J ENVIRON QUAL, V17, P226; Duong TTT, 2009, ATMOS ENVIRON, V43, P3502, DOI 10.1016/j.atmosenv.2009.04.036; Farago ME, 1996, FRESEN J ANAL CHEM, V354, P660; Fauser P, 1999, RUBBER CHEM TECHNOL, V72, P969, DOI 10.5254/1.3538846; FUKUZAKI N, 1986, ATMOS ENVIRON, V20, P377, DOI 10.1016/0004-6981(86)90041-7; Garg BD, 2000, ENVIRON SCI TECHNOL, V34, P4463, DOI 10.1021/es001108h; HAQUS MD, 1986, J BIOL SCI RES, V17, P151; Hirshon JM, 2008, ENVIRON HEALTH PERSP, V116, P826, DOI 10.1289/ehp.10759; Ho KF, 2003, ATMOS ENVIRON, V37, P1023, DOI 10.1016/S1352-2310(02)01028-2; Jarosz Wanda, 1994, Medycyna Weterynaryjna, V50, P23; Kumar AV, 2001, ATMOS ENVIRON, V35, P4245, DOI 10.1016/S1352-2310(01)00258-8; KUPIAINEN K, 2007, MONOGRAPHS BOREAL EN, V26, P8; LEHARNE S, 1992, ENVIRON INT, V18, P263, DOI 10.1016/0160-4120(92)90109-H; Li XD, 2001, APPL GEOCHEM, V16, P1361, DOI 10.1016/S0883-2927(01)00045-2; Lin S, 2002, ENVIRON RES, V88, P73, DOI 10.1006/enrs.2001.4303; Manno E, 2006, ATMOS ENVIRON, V40, P5929, DOI 10.1016/j.atmosenv.2006.05.020; MURAKAMI M, 2006, RWHM WORKSH IWA 5 WO, V5, P124; NICHOLSON KW, 1988, ATMOS ENVIRON, V22, P2639, DOI 10.1016/0004-6981(88)90433-7; *NITON, 2009, THERM SCI NITON; PANKO J, 2008, METHODS COLLECTING T; Peden DB, 2002, ENVIRON HEALTH PERSP, V110, P565; Prieditis H, 2002, EXP LUNG RES, V28, P563, DOI 10.1080/01902140290096782; ROGGE WF, 1993, ENVIRON SCI TECHNOL, V27, P636, DOI 10.1021/es00041a007; Sagebiel JC, 1997, ENVIRON SCI TECHNOL, V31, P75, DOI 10.1021/es960137i; Schauer JJ, 2002, ENVIRON SCI TECHNOL, V36, P1169, DOI 10.1021/es0108077; Schauer J.J., 2006, HLTH EFFECT I, V133, P1; SEHMEL GA, 1973, ATMOS ENVIRON, V7, P291, DOI 10.1016/0004-6981(73)90078-4; Sinclair AH, 2004, J AIR WASTE MANAGE, V54, P1212; Tsai FC, 2000, INHAL TOXICOL, V12, P121, DOI 10.1080/08958378.2000.11463204; Wong JWC, 1997, ENVIRON TECHNOL, V18, P109, DOI 10.1080/09593331808616518; WOODCOCK ST, 2004, ENVIRON MONIT ASSESS, V93, P229	42	93	102	5	103	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1352-2310			ATMOS ENVIRON	Atmos. Environ.	APR	2011	45	13					2310	2323		10.1016/j.atmosenv.2010.11.015		14	Environmental Sciences; Meteorology & Atmospheric Sciences	Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences	753ZG	WOS:000289819200016		
J	Heinrich, J				Heinrich, Joachim			Influence of indoor factors in dwellings on the development of childhood asthma	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Review						Asthma; Children; Incidence; Indoor factor; Epidemiology	POLYCYCLIC AROMATIC-HYDROCARBONS; VOLATILE ORGANIC-COMPOUNDS; HOUSE-DUST MITE; ENVIRONMENTAL TOBACCO-SMOKE; NITROGEN-DIOXIDE EXPOSURE; CHILDRENS RESPIRATORY HEALTH; OUTDOOR AIR-POLLUTION; SCHOOL-AGE-CHILDREN; 1ST 5 YEARS; YOUNG-CHILDREN	Asthma has become the most common, childhood chronic disease in the industrialized world, and it is also increasing in developing regions. There are huge differences in the prevalence of childhood asthma across countries and continents, and there is no doubt that the prevalence of asthma was strongly increasing during the past decades worldwide. Asthma, as a complex disease, has a broad spectrum of potential determinants ranging from genetics to life style and environmental factors. Environmental factors are likely to be important in explaining the regional differences and the overall increasing trend towards asthma's prevalence. Among the environmental conditions, indoor factors are of particular interest because people spend more than 80% of their time indoors globally. Increasing prices for oil, gas and other sources of primary energy will further lead to better insulation of homes, and ultimately to reduced energy costs. This will decrease air exchange rates and will lower the dilution of indoor air mass with ambient air. Indoor air quality and potential health effects will therefore be an area for future research and for gaining a better understanding of asthma epidemics. This strategic review will summarize the current knowledge of the effects of a broad spectrum of indoor factors on the development of asthma in childhood in Western countries based on epidemiological studies. In conclusion, several epidemiological studies point out, that indoor factors might cause asthma in childhood. Stronger and more consistent findings are seen when exposure to these indoor factors is assessed by surrogates for the source of the actual toxicants. Measurement-based exposure assessments for several indoor factors are less common than using surrogates of the exposure. These studies, however, mainly showed heterogeneous results. The most consistent finding for an induction of asthma in childhood is related to exposure to environmental tobacco smoke, to living in homes close to busy roads, and in damp homes where are visible moulds at home. The causing agents of the increased risk of living in damp homes remained uncertain and needs clarification. Exposure to pet-derived allergens and house dust mites are very commonly investigated and thought to be related to asthma onset. The epidemiological evidence is not sufficient to recommend avoidance measures against pet and dust mites as preventive activities against allergies. More research is also needed to clarify the potential risk for exposure to volatile and semi-volatile organic compounds due to renovation activities, phthalates and chlorine chemicals due to cleaning. (C) 2010 Elsevier GmbH. All rights reserved.	[Heinrich, Joachim] Helmholtz Zentrum Munchen, Natl Res Ctr Environm Hlth, Inst Epidemiol, Munich, Germany	Heinrich, J (reprint author), Helmholtz Zentrum Munchen, Inst Epidemiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	joachim.heinrich@helmholtz-muenchen.de			European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC)	This literature review was supported by a contract from the European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC). The views expressed and conclusions drawn are those of the author.	Aalberse RC, 2002, IMMUNOLOGY, V105, P9, DOI 10.1046/j.0019-2805.2001.01341.x; Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Antova T, 2008, J EPIDEMIOL COMMUN H, V62, P708, DOI 10.1136/jech.2007.065896; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BATES DV, 1992, ENVIRON RES, V59, P336, DOI 10.1016/S0013-9351(05)80040-4; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Binkovda B, 2003, MUTAT RES-FUND MOL M, V525, P43, DOI 10.1016/S0027-5107(02)00312-3; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Bornehag CG, 2005, INDOOR AIR, V15, P48, DOI 10.1111/j.1600-0668.2005.00306.x; Bornehag CG, 2001, INDOOR AIR, V11, P72; Bornehag CG, 2004, ENVIRON HEALTH PERSP, V112, P1393, DOI 10.1289/ehp.7187; Bornehag CG, 2004, INDOOR AIR, V14, P59, DOI 10.1111/j.1600-0668.2004.00274.x; BORNEHAG CG, 2010, INT J ANDROL    0104; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; Bousquet J, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2008.01954.x; Braback L, 2009, ENVIRON HEALTH-GLOB, V8, DOI 10.1186/1476-069X-8-17; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Brown SK, 2002, INDOOR AIR, V12, P55, DOI 10.1034/j.1600-0668.2002.120107.x; BRUNEKREEF B, 1990, J AIR WASTE MANAGE, V40, P1252; Brunekreef B, 2001, CLIN EXP ALLERGY, V31, P1170, DOI 10.1046/j.1365-2222.2001.01208.x; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; *CA EPA, 1997, HLTH EFF EXP ENV TOB; Cain WS, 2005, INDOOR AIR, V15, P445, DOI 10.1111/j.1600-0668.2005.00390.x; Campo P, 2006, J ALLERGY CLIN IMMUN, V118, P1271, DOI 10.1016/j.jaci.2006.08.008; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Celedon JC, 2007, J ALLERGY CLIN IMMUN, V120, P144, DOI 10.1016/j.jaci.2007.03.037; Chang KF, 2006, ENVIRON POLLUT, V142, P388, DOI 10.1016/j.envpol.2005.09.025; Chen CM, 2007, INDOOR AIR, V17, P384, DOI 10.1111/j.1600-0668.2007.00486.x; Chen CM, 2008, EUR RESPIR J, V31, P963, DOI 10.1183/09031936.00092807; Chen CM, 2010, INT J HYG ENVIR HEAL, V213, P1, DOI 10.1016/j.ijheh.2009.12.003; Choi H, 2006, ENVIRON HEALTH PERSP, V114, P1744, DOI 10.1289/ehp.8982; *CICAD, 2002, 40 CICAD IPCS; Clarisse B, 2003, ENVIRON RES, V92, P245, DOI 10.1016/S0013-9351(03)00039-2; Clark K, 2003, HANDB ENVIRON CHEM, V3, P125; Clark NA, 2010, ENVIRON HEALTH PERSP, V118, P284, DOI 10.1289/ehp.0900916; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; Cook DG, 1997, THORAX, V52, P1081; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53; Custovic A, 2001, J ALLERGY CLIN IMMUN, V108, P537, DOI 10.1067/mai.2001.118599; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; Dales R, 2006, ENVIRON HEALTH PERSP, V114, P610, DOI 10.1289/ehp.8142; Dales R, 2004, J ASTHMA, V41, P259, DOI 10.1081/JAS-120026082; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; Destaillats H, 2008, ATMOS ENVIRON, V42, P1371, DOI 10.1016/j.atmosenv.2007.10.080; Diette GB, 2007, ENVIRON HEALTH PERSP, V115, P1665, DOI 10.1289/ehp.10088; Diez U, 2003, INT J HYG ENVIR HEAL, V206, P173, DOI 10.1078/1438-4639-00218; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; DIJKSTRA L, 1990, AM REV RESPIR DIS, V142, P1172; Dodson RE, 2008, ATMOS ENVIRON, V42, P1569, DOI 10.1016/j.atmosenv.2007.10.088; Dong GH, 2008, INT J ENVIRON HEAL R, V18, P267, DOI 10.1080/09603120701842864; Douwes J, 2006, J ALLERGY CLIN IMMUN, V117, P1067, DOI 10.1016/j.jaci.2006.02.002; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Dubowski KM, 1999, J ANAL TOXICOL, V23, P386; *EC, 2005, 21501 EC JRC EU EN; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Edwards RD, 2001, ATMOS ENVIRON, V35, P1411, DOI 10.1016/S1352-2310(00)00359-9; Emenius G, 2004, ACTA PAEDIATR, V93, P899, DOI 10.1080/08035250410025582; Emenius G, 2004, INDOOR AIR, V14, P34, DOI 10.1046/j.1600-0668.2003.00207.x; *EUROSTAT STAT OFF, 2007, EUR FIG EUROSTATE YB; EZEONU IM, 1994, APPL ENVIRON MICROB, V60, P4172; Ferro AR, 2004, J EXPO ANAL ENV EPID, V14, pS34, DOI 10.1038/sj.jea.7500356; Ferro AR, 2004, ENVIRON SCI TECHNOL, V38, P1759, DOI 10.1021/es0263893; Fisk WJ, 2007, INDOOR AIR, V17, P284, DOI 10.1111/j.1600-0668.2007.00475.x; Foto M, 2004, ANAL BIOANAL CHEM, V379, P156, DOI 10.1007/s00216-004-2583-4; FRANKLIN P, 2000, AM J RESP CRIT CARE, V161, P1559; Fromme H, 1998, SCI TOTAL ENVIRON, V217, P165, DOI 10.1016/S0048-9697(98)00189-2; Garrett MH, 1999, ALLERGY, V54, P330, DOI 10.1034/j.1398-9995.1999.00763.x; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891; Gehring U, 2002, EUR RESPIR J, V19, P690, DOI 10.1183/09031936.02.01182001; Gehring U, 2007, EUR RESPIR J, V29, P1144, DOI 10.1183/09031936.00118806; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; GEHRING U, 2009, AM J RESP CRIT CARE; Gem JE, 2004, J ALLERGY CLIN IMMUN, V113, P307; Gent JF, 2002, ENVIRON HEALTH PERSP, V110, pA781; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gilbert NL, 2006, ENVIRON RES, V102, P1, DOI 10.1016/j.envres.2006.02.007; Giovannangelo M, 2007, INDOOR AIR, V17, P70, DOI 10.1111/j.1600-0668.2006.00461.x; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; GOtzsche PC, 2008, COCHRANE DB SYST REV, V16; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Guo H, 2009, INDOOR AIR, V19, P206, DOI 10.1111/j.1600-0668.2008.00580.x; Gustafson P, 2008, ENVIRON SCI TECHNOL, V42, P5074, DOI 10.1021/es800304y; Haas D, 2007, ATMOS ENVIRON, V41, P5192, DOI 10.1016/j.atmosenv.2006.07.062; Haghighat F, 1998, BUILD ENVIRON, V33, P261, DOI 10.1016/S0360-1323(97)00060-7; HASSELBLAD V, 1981, AM REV RESPIR DIS, V123, P479; Health Effects Institute (HEI) Air Toxics Review Panel, 2007, 16 HEI; HEI (Health Effects Institute), 2010, 17 HEI; Heinrich J, 2005, J EXPO ANAL ENV EPID, V15, P74, DOI 10.1038/sj.jea.7500373; Heissenhuber A, 2003, ALLERGY, V58, P154, DOI 10.1034/j.1398-9995.2003.00037.x; HILL AB, 1965, P ROY SOC MED, V58, P295; Hodgson A. T., 2003, VOLATILE ORGANIC COM; HOEK G, 1984, INT ARCH OCC ENV HEA, V55, P79, DOI 10.1007/BF00378070; Hyvarinen A, 2006, ARCH ENVIRON OCCUP H, V61, P149, DOI 10.3200/AEOH.61.4.149-157; International Agency for Research on Cancer (IARC) Monographs on the evaluation of carcinogenic risks to humans, 2006, FORM 2 BUT 1 TERT BU, V88; *IEH, 1999, R12 IEH MRC; Ilgen E, 2001, ATMOS ENVIRON, V35, P1235, DOI 10.1016/S1352-2310(00)00388-5; Ilgen E, 2001, ATMOS ENVIRON, V35, P1253, DOI 10.1016/S1352-2310(00)00490-8; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; IOM (Institute of Medicine), 2004, DAMP IND SPAC HLTH; Iossifova YY, 2007, ALLERGY, V62, P504, DOI 10.1111/j.1398-9995.2007.01340.x; Iossifova YY, 2009, ANN ALLERG ASTHMA IM, V102, P131, DOI 10.1016/S1081-1206(10)60243-8; Jaakkola JJK, 2005, ENVIRON HEALTH PERSP, V113, P357, DOI 10.1289/ehp.7242; Jaakkola JJK, 1999, AM J PUBLIC HEALTH, V89, P188, DOI 10.2105/AJPH.89.2.188; Jaakkola JJK, 2000, AM J PUBLIC HEALTH, V90, P797, DOI 10.2105/AJPH.90.5.797; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P560, DOI 10.2105/AJPH.94.4.560; Jaakkola JJK, 2008, ENVIRON HEALTH PERSP, V116, P845, DOI 10.1289/ehp.10846; Jaakkola MS, 1997, EUR RESPIR J, V10, P2384, DOI 10.1183/09031936.97.10102384; Jantunen MJ, 1998, J EXPO ANAL ENV EPID, V8, P495; Jarvis D, 1998, EUR RESPIR J, V11, P651; Jarvis D, 1996, LANCET, V347, P426, DOI 10.1016/S0140-6736(96)90009-4; Jarvis D, 2007, J ALLERGY CLIN IMMUN, V119, P697, DOI 10.1016/j.jaci.2006.10.042; Jarvis DL, 2005, THORAX, V60, P474, DOI 10.1136/thx.2004.032177; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Jia C, 2008, ATMOS ENVIRON, V42, P2101, DOI 10.1016/j.atmosenv.2007.11.047; Jurvelin J, 2001, J AIR WASTE MANAGE, V51, P17; Karvonen AM, 2009, PEDIATRICS, V124, pE329, DOI 10.1542/peds.2008-1590; Kelly TJ, 1999, ENVIRON SCI TECHNOL, V33, P81, DOI 10.1021/es980592+; Kim JL, 2007, INDOOR AIR, V17, P153, DOI 10.1111/j.1600-0668.2006.00466.x; Kim YM, 2001, ENVIRON SCI TECHNOL, V35, P997, DOI 10.1021/es000192y; Knol AB, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-19; KOO LC, 1990, AM REV RESPIR DIS, V141, P1119; Kotzias D., 2005, INDEX PROJECT CRITIC; Krakowiak A, 1998, AM J IND MED, V33, P274, DOI 10.1002/(SICI)1097-0274(199803)33:3<274::AID-AJIM9>3.0.CO;2-W; Krauss-Etschmann S, 2009, J ALLERGY CLIN IMMUN, V123, P1176, DOI 10.1016/j.jaci.2009.01.054; KRZYZANOWSKI M, 1990, ENVIRON RES, V52, P117, DOI 10.1016/S0013-9351(05)80247-6; *KUS, 2008, VERGL FLUCHT ORG VER; Lang I, 2008, REGUL TOXICOL PHARM, V50, P23, DOI 10.1016/j.yrtph.2007.08.012; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Larsson M, 2008, ACTA PAEDIATR, V97, P1210, DOI 10.1111/j.1651-2227.2008.00910.x; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lee CW, 2006, ENVIRON RES, V100, P139, DOI 10.1016/j.envres.2005.05.003; Lehmann I, 2001, INT J HYG ENVIR HEAL, V204, P211, DOI 10.1078/1438-4639-00100; Leung R, 1998, CLIN EXP ALLERGY, V28, P585; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Long CM, 2000, J AIR WASTE MANAGE, V50, P1236; Lung SCC, 2003, INDOOR AIR, V13, P194, DOI 10.1034/j.1600-0668.2003.00197.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; McGwin G, 2010, ENVIRON HEALTH PERSP, V118, P313, DOI 10.1289/ehp.0901143; Meklin T, 2005, INDOOR AIR, V15, P40, DOI 10.1111/j.1600-0668.2005.00357.x; Melen E, 2008, ENVIRON HEALTH PERSP, V116, P1077, DOI 10.1289/ehp.11117; Mendell MJ, 2007, INDOOR AIR, V17, P259, DOI 10.1111/j.1600-0668.2007.00478.x; MENZIE CA, 1992, ENVIRON SCI TECHNOL, V26, P1278, DOI 10.1021/es00031a002; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; MITRA S, 1995, ATMOS ENVIRON, V29, P3345, DOI 10.1016/1352-2310(95)00214-J; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Morgenstern V, 2008, AM J RESP CRIT CARE, V177, P1331, DOI 10.1164/rccm.200701-036OC; Naumova YY, 2002, ENVIRON SCI TECHNOL, V36, P2552, DOI 10.1021/es015727h; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; Nickmilder M, 2007, PEDIATR ALLERGY IMMU, V18, P27, DOI 10.1111/j.1399-3038.2006.00487.x; Nielsen GD, 2007, INDOOR AIR, V17, P236, DOI 10.1111/j.1600-0668.2006.00468.x; Nitschke M, 1999, INT J ENVIRON HEAL R, V9, P39, DOI 10.1080/09603129973344; Nordling E, 2008, EPIDEMIOLOGY, V19, P401, DOI [10.1097/EDE.0b013e31816a1ce3, 10.1097/EDE.0b013e31816alce3]; Oftedal B, 2007, CLIN EXP ALLERGY, V37, P1632, DOI 10.1111/j.1365-2222.2007.02823.x; Oftedal B, 2009, ENVIRON HEALTH PERSP, V117, P839, DOI 10.1289/ehp.11491; Ohura T, 2004, ENVIRON SCI TECHNOL, V38, P77, DOI 10.1021/es030512o; Oie L, 1997, ENVIRON HEALTH PERSP, V105, P972; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; *OQAI, 2006, DDDSB200657 OQAI; Pandit GG, 2001, SCI TOTAL ENVIRON, V279, P159, DOI 10.1016/S0048-9697(01)00763-X; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Pekkanen J, 2007, EUR RESPIR J, V29, P509, DOI 10.1183/09031936.00040806; Perera FP, 1998, AM J EPIDEMIOL, V147, P309; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Pirkle James L., 1996, JAMA (Journal of the American Medical Association), V275, P1233, DOI 10.1001/jama.275.16.1233; *PLAST INF CTR, 2007, WHAT AR PLAST; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Ponsonby AL, 2000, EPIDEMIOLOGY, V11, P128, DOI 10.1097/00001648-200003000-00008; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Pujades-Rodriguez M, 2009, OCCUP ENVIRON MED, V66, P679, DOI 10.1136/oem.2008.043885; Raw GJ, 2004, J EXPO ANAL ENV EPID, V14, pS85, DOI 10.1038/sj.jea.7500363; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; Rumchev KB, 2002, EUR RESPIR J, V20, P403, DOI 10.1183/09031936.02.00245002; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; Sahakian NM, 2008, IMMUNOL ALLERGY CLIN, V28, P485, DOI 10.1016/j.iac.2008.03.009; Salthammer T, 2010, CHEM REV, V110, P2536, DOI 10.1021/cr800399g; SAMET JM, 1993, AM REV RESPIR DIS, V148, P1258; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schneider P, 2001, SCI TOTAL ENVIRON, V267, P41, DOI 10.1016/S0048-9697(00)00766-X; Schram-Bijkerk D, 2005, CLIN EXP ALLERGY, V35, P1272, DOI 10.1111/j.1365-2222.2005.02339.x; Sexton K, 2007, J TOXICOL ENV HEAL A, V70, P465, DOI 10.1080/15287390600870858; Sherriff A, 2005, THORAX, V60, P45, DOI 10.1136/thx.2004.021154; Shima M, 2003, J EPIDEMIOL, V13, P108; Shima M, 2000, INT J EPIDEMIOL, V29, P862, DOI 10.1093/ije/29.5.862; Singer BC, 2003, ATMOS ENVIRON, V37, P5551, DOI 10.1016/j.atmosenv.2003.07.015; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; SPICER CW, 1993, J AIR WASTE MANAGE, V43, P1479; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Srivastava PK, 2000, SCI TOTAL ENVIRON, V255, P161, DOI 10.1016/S0048-9697(00)00465-4; Stark PC, 2005, ENVIRON HEALTH PERSP, V113, P1405, DOI 10.1289/ehp.7844; STRACHAN DP, 1995, BRIT MED J, V311, P1053; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sunyer J, 2004, INT J EPIDEMIOL, V33, P116, DOI 10.1093/ije/dyh037; Tang DL, 2008, ENVIRON HEALTH PERSP, V116, P674, DOI 10.1289/ehp.10471; THOMAS B, 1991, INT ARCH ALLER A IMM, V94, P365; Topp R, 2004, J ENVIRON MONITOR, V6, P807, DOI 10.1039/b405537c; Torrent M, 2007, AM J RESP CRIT CARE, V176, P446, DOI 10.1164/rccm.200607-916OC; TOVEY ER, 2008, J ALLERGY CLIN IMMUN, V122, pE111; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; Trevillian LF, 2005, AM J PUBLIC HEALTH, V95, P2238, DOI 10.2105/AJPH.2004.047191; van Strien RT, 2004, EPIDEMIOLOGY, V15, P471, DOI 10.1097/01.ede.0000129511.61698.d8; van Strien RT, 2004, ALLERGY, V59, P645, DOI 10.1111/j.1398-9995.2004.00470.x; VOLKMER RE, 1995, J PAEDIATR CHILD H, V31, P116, DOI 10.1111/j.1440-1754.1995.tb00758.x; World Health Organization, 2009, WHO GUID IND QUAL DA; WHO, 2007, GLOB YOUTH TOB SURV; *WHO, 2005, HLTH EFF TRANSP REAL; *WHO, 2007, 2 TECHN M QUANT DIS; *WHO EUR CTR ENV H, 2003, EXP ENV TOB SMOK EUR; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; Wieslander G, 1997, ANN OCCUP HYG, V41, P155, DOI 10.1016/S0003-4878(96)00039-7; Wolkoff P, 1995, INDOOR AIR, P1, DOI 10.1111/j.1600-0668.1995.tb00017.x; Wormuth M, 2006, RISK ANAL, V26, P803, DOI 10.1111/j.1539-6924.2006.00770.x; Yu CWF, 2003, INDOOR BUILT ENVIRON, V12, P299, DOI 10.1177/142032603035502; Zhao ZH, 2008, ENVIRON HEALTH PERSP, V116, P90, DOI 10.1289/ehp.10576; Zock JP, 2007, AM J RESP CRIT CARE, V176, P735, DOI 10.1164/rccm.200612-17930C; Zock JP, 2006, J ALLERGY CLIN IMMUN, V118, P682, DOI 10.1016/j.jaci.2006.04.060; Zock JP, 2002, J ALLERGY CLIN IMMUN, V110, P285, DOI 10.1067/mai.2002.126383; ZOCK JP, 2009, ALLERGY CLIN IMMUNOL, V24; Zuraimi MS, 2006, BUILD ENVIRON, V41, P316, DOI 10.1016/j.buildenv.2005.01.028	228	93	95	14	78	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1438-4639	1618-131X		INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.	JAN	2011	214	1					3	27		10.1016/j.ijheh.2010.08.009		25	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	739BL	WOS:000288687200001	20851050	
J	Zuberbier, T; Bachert, C; Bousquet, PJ; Passalacqua, G; Canonica, GW; Merk, H; Worm, M; Wahn, U; Bousquet, J				Zuberbier, T.; Bachert, C.; Bousquet, P. J.; Passalacqua, G.; Canonica, G. Walter; Merk, H.; Worm, M.; Wahn, U.; Bousquet, J.			GA(2)LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma	ALLERGY			English	Article						allergen; European Academy of Allergy and Immunology (EAACI); Global Allergy and Asthma European Network (GA(2)LEN); immunotherapy; subcutaneous; sublingual	HOUSE-DUST MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; CONSORT STATEMENT; GRASS-POLLEN; FOLLOW-UP; SUBLINGUAL IMMUNOTHERAPY; RANDOMIZED-TRIALS; CLINICAL-EFFICACY; DOUBLE-BLIND; 2008 UPDATE	This pocket guide is the result of a consensus reached during several GA(2)LEN and EAACI meetings. The aim of the current pocket guide is to offer a comprehensive set of recommendations on the use of immunotherapy in allergic rhinoconjunctivitis and asthma in daily practice. This pocket guide is meant to give simple answers to the most frequent questions of practitioners in Europe, including 'practising allergists', general practitioners and any other physicians with special interest in allergen-specific immunotherapy (SIT). It is not a long or detailed scientific review of the topic. However, the recommendations in this pocket guide were compiled following an in-depth review of existing guidelines and publications, including the 1998 EAACI position paper, the 1998 WHO Position Paper on SIT and the 2001 Allergic Rhinitis and its Impact on Asthma (ARIA). It is also based on the ARIA update 2008 (prepared in collaboration with GA(2)LEN), the 'Sub-lingual Immunotherapy: WAO Position Paper 2009' (from the World Allergy Organisation) and the Methodology paper of ARIA. The recommendations cover patient selection, allergen extract to be used, route of administration of SIT (in particular, sublingual and subcutaneous immunotherapy), and necessary precautions to be followed in using SIT.	[Zuberbier, T.; Worm, M.; Wahn, U.] Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Bachert, C.] Ghent Univ Hosp, Dept Otorhinolaryngol, B-9000 Ghent, Belgium; [Bousquet, P. J.; Bousquet, J.] CHU Montpellier, Montpellier, France; [Passalacqua, G.; Canonica, G. Walter] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; [Merk, H.] Rhein Westfal TH Aachen, Univ Clin, Dept Dermatol & Allergol, Aachen, Germany; [Bousquet, J.] INSERM, CSEP, F-1018 Villejuif, France	Zuberbier, T (reprint author), Charite, Dept Dermatol & Allergy, D-13353 Berlin, Germany.	torsten.zuberbier@charite.de					Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Bousquet J, 2008, ALLERGY, V63, P8, DOI 10.1111/j.1398-9995.2007.01620.x; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet J, 2009, J ALLERGY CLIN IMMUN, V124, P428, DOI 10.1016/j.jaci.2009.06.027; Bousquet PJ, 2009, ALLERGY, V64, P1737, DOI 10.1111/j.1398-9995.2009.02232.x; Boutron I, 2008, ANN INTERN MED, V148, P295; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; Canonica GW, 2009, ALLERGY, V64, P1, DOI 10.1111/j.1398-9995.2009.02309.x; Casanovas M, 2005, CLIN EXP ALLERGY, V35, P1377, DOI 10.1111/j.1365-2222.2005.02343.x; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Didier A, 2007, J ALLERGY CLIN IMMUN, V120, P1338, DOI 10.1016/j.jaci.2007.07.046; DURHAM SR, 1999, NEW ENGL J MED, V12, P341; Durham SR, 2010, J ALLERGY CLIN IMMUN, V125, P131, DOI 10.1016/j.jaci.2009.10.035; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; *EUR MED AG, 2008, HMPEWP85042006 EUR M; Inal A, 2007, J INVEST ALLERG CLIN, V17, P85; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274; Moher D, 2001, LANCET, V357, P1191, DOI 10.1016/S0140-6736(00)04337-3; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x	27	93	111	0	5	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy	DEC	2010	65	12					1525	1530		10.1111/j.1398-9995.2010.02474.x		6	Allergy; Immunology	Allergy; Immunology	673UG	WOS:000283688400003	21039596	
J	Holgate, ST; Arshad, HS; Roberts, GC; Howarth, PH; Thurner, P; Davies, DE				Holgate, Stephen T.; Arshad, Hasan S.; Roberts, Graham C.; Howarth, Peter H.; Thurner, Philipp; Davies, Donna E.			A new look at the pathogenesis of asthma	CLINICAL SCIENCE			English	Review						allergen; asthma; inflammation; remodelling; T-cell; virus infection	AIRWAY EPITHELIAL-CELLS; RESOLUTION COMPUTED-TOMOGRAPHY; THYMIC STROMAL LYMPHOPOIETIN; SMOOTH-MUSCLE; CHILDHOOD ASTHMA; BRONCHIAL HYPERRESPONSIVENESS; BARRIER FUNCTION; LUNG-FUNCTION; PERSISTENT ASTHMA; ATOPIC ASTHMA	Asthma is an inflammatory disorder of the conducting airways that has strong association with allergic sensitization. The disease is characterized by a polarized Th-2 (T-helper-2)-type T-cell response, but in general targeting this component of the disease with selective therapies has been disappointing and most therapy still relies on bronchodilators and corticosteroids rather than treating underlying disease mechanisms. With the disappointing outcomes of targeting individual Th-2 cytokines or manipulating T-cells, the time has come to re-evaluate the direction of research in this disease. A case is made that asthma has its origins in the airways themselves involving defective structural and functional behaviour of the epithelium in relation to environmental insults. Specifically, a defect in barrier function and an impaired innate immune response to viral infection may provide the substrate upon which allergic sensitization takes place. Once sensitized, the repeated allergen exposure will lead to disease persistence. These mechanisms could also be used to explain airway wall remodelling and the susceptibility of the asthmatic lung to exacerbations provoked by respiratory viruses, air pollution episodes and exposure to biologically active allergens. Variable activation of this epithelial mesenchymal trophic unit could also lead to the emergence of different asthma phenotypes and a more targeted approach to the treatment of these. It also raises the possibility of developing treatments that increase the lung's resistance to the inhaled environment rather than concentrating all efforts on trying to suppress inflammation once it has become established.	[Holgate, Stephen T.; Arshad, Hasan S.; Roberts, Graham C.; Howarth, Peter H.; Davies, Donna E.] Univ Southampton, Div Infect Inflammat & Immun, Southampton Gen Hosp, Southampton S016 6YD, Hants, England; [Thurner, Philipp] Univ Southampton, Bioengn Sci Res Grp, Southampton S017 1BJ, Hants, England	Holgate, ST (reprint author), Univ Southampton, Div Infect Inflammat & Immun, Southampton Gen Hosp, Southampton S016 6YD, Hants, England.	sth@soton.ac.uk	Thurner, Philipp/A-3887-2012; Davies, Donna/H-2993-2012	Thurner, Philipp/0000-0001-7588-9041	Medical Research Council (MRC), Asthma UK, Asthma; Allergy Inflammation and Repair (AAIR); British Lung Foundation	We wish to acknowledge the Medical Research Council (MRC), Asthma UK, Asthma, Allergy Inflammation and Repair (AAIR), and the British Lung Foundation for supporting research that underpins this review. S.T.H. is an MRC Clinical Professor.	An SS, 2007, CAN J PHYSIOL PHARM, V85, P700, DOI 10.1139/Y07-059; An SS, 2009, BIOCHEM BIOPH RES CO, V382, P697, DOI 10.1016/j.bbrc.2009.03.118; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; Austen K F, 1979, Harvey Lect, V73, P93; Barbato A, 2006, AM J RESP CRIT CARE, V174, P975, DOI 10.1164/rccm.200602-189OC; Barnes PJ, 1996, AM J RESP CRIT CARE, V154, P1227; Begueret H, 2007, THORAX, V62, P8, DOI 10.1136/thx.2006.062141; Bjerg-Backlund A, 2006, Allergy, V61, P549; Bossios A, 2008, CLIN EXP ALLERGY, V38, P1615, DOI 10.1111/j.1365-2222.2008.03058.x; Bourdin A, 2007, J ALLERGY CLIN IMMUN, V119, P1367, DOI 10.1016/j.jaci.2007.01.055; Boushey HA, 2005, NEW ENGL J MED, V352, P1519, DOI 10.1056/NEJMoa042552; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Bucchieri F, 2002, AM J RESP CELL MOL, V27, P179; Choe MM, 2006, AM J RESP CELL MOL, V35, P306, DOI 10.1165/rcmb.2005-0443OC; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; de Blic J, 2005, J ALLERGY CLIN IMMUN, V116, P750, DOI 10.1016/j.jaci.2005.07.009; de Boer WI, 2008, CAN J PHYSIOL PHARM, V86, P105, DOI 10.1139/y08-004; Dharmage SC, 2009, EUR RESPIR J, V33, P237, DOI 10.1183/09031936.00062907; Dijkstra A, 2006, THORAX, V61, P105, DOI 10.1136/thx.2004.039271; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Fedorov IA, 2005, THORAX, V60, P389, DOI 10.1136/thx.2004.030262; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Groschwitz KR, 2009, J ALLERGY CLIN IMMUN, V124, P3, DOI 10.1016/j.jaci.2009.05.038; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hackett TL, 2009, AM J RESP CRIT CARE, V180, P122, DOI 10.1164/rccm.200811-1730OC; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Haldar P, 2009, NEW ENGL J MED, V360, P973, DOI 10.1056/NEJMoa0808991; Hara Johsuke, 2008, Allergol Int, V57, P211, DOI 10.2332/allergolint.O-06-461; Haselden BM, 2001, J ALLERGY CLIN IMMUN, V108, P394, DOI 10.1067/mai.2001.117460; Haughney J, 2008, RESP MED, V102, P1681, DOI 10.1016/j.rmed.2008.08.003; Holgate S, 2008, EUR RESPIR J, V32, P1433, DOI 10.1183/09031936.00053108; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Holgate ST, 2007, J ALLERGY CLIN IMMUN, V120, P1233, DOI 10.1016/j.jaci.2007.10.025; Holgate Stephen T, 2002, Curr Opin Allergy Clin Immunol, V2, P27, DOI 10.1097/00130832-200202000-00005; Holgate ST, 2009, CURR OPIN PULM MED, V15, P63, DOI 10.1097/MCP.0b013e32831da867; Horne Rob, 2007, BMC Pulm Med, V7, P8, DOI 10.1186/1471-2466-7-8; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; Jackson DJ, 2008, AM J RESP CRIT CARE, V178, P667, DOI 10.1164/rccm.200802-309OC; James AL, 2009, EUR RESPIR J, V34, P1040, DOI 10.1183/09031936.00181608; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; Kim ES, 2007, ALLERGY, V62, P635, DOI 10.1111/j.1398-9995.2007.01375.x; Kurukulaaratchy RJ, 2003, J ALLERGY CLIN IMMUN, V112, P311, DOI 10.1067/mai.2003.1623; Lancet editorial, 2008, LANCET, V372, P1009; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Law L, 2005, J HEART LUNG TRANSPL, V24, P1571, DOI 10.1016/j.healun.2005.01.007; Liu YJ, 2007, J ALLERGY CLIN IMMUN, V120, P238, DOI 10.1016/j.jaci.2007.06.004; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-15830C; Malavia NK, 2009, AM J RESP CELL MOL, V41, P297, DOI 10.1165/rcmb.2008-0358OC; Martinez FD, 2002, PEDIATRICS, V109, P362; Matricardi PM, 2008, EUR RESPIR J, V32, P585, DOI 10.1183/09031936.00066307; Matzinger P, 2007, NAT IMMUNOL, V8, P11, DOI 10.1038/ni0107-11; Mehr S, 2009, J PEDIATR-US, V155, P289, DOI 10.1016/j.jpeds.2009.01.058; Mendis S, 2007, B WORLD HEALTH ORGAN, V85, P279, DOI 10.2471/BLT.06.033647; Morgan WJ, 2005, AM J RESP CRIT CARE, V172, P1253, DOI 10.1164/rccm.200504-525OC; Murray CS, 2006, LANCET, V368, P754, DOI 10.1016/S0140-6736(06)69285-4; Nadeem Ahmed, 2008, Ther Adv Respir Dis, V2, P215, DOI 10.1177/1753465808094971; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; O'Regan GM, 2008, J ALLERGY CLIN IMMUN, V122, P689, DOI 10.1016/j.jaci.2008.08.002; Obase Y, 2003, ALLERGY, V58, P213, DOI 10.1034/j.1398-9995.2003.00053.x; Panettieri RA, 2008, J ALLERGY CLIN IMMUN, V121, P607, DOI 10.1016/j.jaci.2008.01.006; Pearce N, 1999, THORAX, V54, P268; Pedersen SE, 2007, J ALLERGY CLIN IMMUN, V120, P1036, DOI 10.1016/j.jaci.2007.07.016; Postma DS, 2007, GENDER MED, V4, pS133, DOI 10.1016/S1550-8579(07)80054-4; Puddicombe SM, 2003, AM J RESP CELL MOL, V28, P61, DOI 10.1165/rcmb.4715; Raza A, 2008, THORAX, V63, P842; Rochman Y, 2008, CURR OPIN PHARMACOL, V8, P249, DOI 10.1016/j.coph.2008.03.002; Rothen-Rutishauser BM, 2005, AM J RESP CELL MOL, V32, P281, DOI 10.1165/rcmb.2004-0187OC; Rothenberg ME, 2008, NEW ENGL J MED, V358, P1215, DOI 10.1056/NEJMoa070812; Rusznak C, 2001, CLIN EXP ALLERGY, V31, P226, DOI 10.1046/j.1365-2222.2001.01000.x; Saglani S, 2005, AM J RESP CRIT CARE, V171, P722, DOI 10.1164/rccm.200410-14040C; Sajjan U, 2008, AM J RESP CRIT CARE, V178, P1271, DOI 10.1164/rccm.200801-136OC; Saunders R, 2009, J ALLERGY CLIN IMMUN, V123, P376, DOI 10.1016/j.jaci.2008.10.048; Scadding GK, 2008, CLIN EXP ALLERGY, V38, P19, DOI 10.1111/j.1365-2222.2007.02888.x; Sears MR, 2008, J ALLERGY CLIN IMMUN, V122, P662, DOI 10.1016/j.jaci.2008.08.003; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Shaw TJ, 2004, EUR RESPIR J, V23, P813, DOI 10.1183/09031936.04.00119904; Siddiqui S, 2008, J ALLERGY CLIN IMMUN, V122, P335, DOI 10.1016/j.jaci.2008.05.020; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stern DA, 2008, LANCET, V372, P1058, DOI 10.1016/S0140-6736(08)61447-6; Stevens PT, 2008, CLIN EXP ALLERGY, V38, P1901, DOI 10.1111/j.1365-2222.2008.03093.x; Swindle EJ, 2009, J ALLERGY CLIN IMMUN, V124, P23, DOI 10.1016/j.jaci.2009.05.037; ten Brinke A, 2008, CURR OPIN ALLERGY CL, V8, P63, DOI 10.1097/ACI.0b013e3282f3b5b5; Tieu DD, 2009, J ALLERGY CLIN IMMUN, V124, P37, DOI 10.1016/j.jaci.2009.04.045; To T, 2007, ARCH PEDIAT ADOL MED, V161, P1197, DOI 10.1001/archpedi.161.12.1197; Tschernig T, 2001, THORAX, V56, P427, DOI 10.1136/thorax.56.6.427; Tschumperlin DJ, 2003, AM J RESP CELL MOL, V28, P142, DOI 10.1165/rcmb.2002-0121OC; Turato G, 2008, AM J RESP CRIT CARE, V178, P476, DOI 10.1164/rccm.200712-1818OC; Turner SW, 2007, CLIN EXP ALLERGY, V37, P163, DOI 10.1111/j.1365-2222.2007.02661.x; Ueda T, 2006, J ALLERGY CLIN IMMUN, V118, P1019, DOI 10.1016/j.jaci.2006.07.032; Van den Toorn LM, 2001, AM J RESP CRIT CARE, V164, P2107; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wang JX, 2005, J BIOL CHEM, V280, P7273, DOI 10.1074/jbc.M410819200; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Wennergren G, 2009, ACTA PAEDIATR, V98, P1085, DOI 10.1111/j.1651-2227.2009.01342.x; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wicks J, 2006, THORAX, V61, P313, DOI 10.1136/thx.2005.050005; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Wu PS, 2008, AM J RESP CRIT CARE, V178, P1123, DOI 10.1164/rccm.200804-579OC; Yamane-Ohnuki N, 2004, BIOTECHNOL BIOENG, V87, P614, DOI 10.1002/bit.20151	105	93	99	0	20	PORTLAND PRESS LTD	LONDON	THIRD FLOOR, EAGLE HOUSE, 16 PROCTER STREET, LONDON WC1V 6 NX, ENGLAND	0143-5221			CLIN SCI	Clin. Sci.	APR 10	2010	118	7-8					439	450		10.1042/CS20090474		12	Medicine, Research & Experimental	Research & Experimental Medicine	585MM	WOS:000276829600001	20025610	
J	Holloway, JW; Yang, IA; Holgate, ST				Holloway, John W.; Yang, Ian A.; Holgate, Stephen T.			Genetics of allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Heritability; genetics; genetic testing; pharmacogenetics; epigenetics	GENOME-WIDE ASSOCIATION; DIISOCYANATE-INDUCED ASTHMA; SEVERE PERSISTENT ASTHMA; IMPROVED LUNG-FUNCTION; OF-FUNCTION MUTATIONS; DUST-MITE EXPOSURE; HYPER-IGE SYNDROME; CHILDHOOD ASTHMA; FILAGGRIN MUTATIONS; ATOPIC-DERMATITIS	Allergic diseases are complex genetic diseases resulting from the effect of multiple genetic and interacting environmental factors on their pathophysiology. Recent years have seen considerable progress in unraveling the contribution of these factors to an individual subject's susceptibility to, subsequent development of, and severity of disease. This has resulted in increasing insight into novel areas of allergic disease pathophysiology, for example the significant role played by locally acting tissue susceptibility factors like epithelial/epidermal barrier function and remodeling, such as filaggrin, ADAM33, and GSDML/ORMDL3, in patients with atopic dermatitis and asthma. Furthermore, studies of gene-environment interactions and Mendelian randomization approaches have led to increased insight into the importance of environmental triggers for allergic disease. Studies of the timing of action of genetic variants in determining disease susceptibility have highlighted the importance of in utero development and early life in determining susceptibility to allergic disease. In the future, genetic discoveries in allergic disease will potentially lead to better endophenotyping, prognostication, prediction of treatment response, and insights into molecular pathways to develop more targeted therapy for these conditions. (J Allergy Clin Immunol 2010;125:S81-94.)	[Holloway, John W.; Holgate, Stephen T.] Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Immun, Southampton SO16 6YD, Hants, England; [Holloway, John W.] Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England; [Yang, Ian A.] Univ Queensland, Dept Thorac Med, Prince Charles Hosp, Brisbane, Qld, Australia; [Yang, Ian A.] Univ Queensland, Sch Med, Brisbane, Qld, Australia	Holloway, JW (reprint author), Southampton Gen Hosp, Sch Med, Div MP810 3, Southampton SO16 6YD, Hants, England.	J.W.Holloway@southampton.ac.uk	Holloway, John/B-5424-2009; Yang, Ian/B-9609-2008	Holloway, John/0000-0001-9998-0464; Yang, Ian/0000-0001-8338-1993	Medical Research Council [G19/34, G0400473, G0800766]		Allen M, 2003, NAT GENET, V35, P258, DOI 10.1038/ng1256; Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Altshuler D, 2008, SCIENCE, V322, P881, DOI 10.1126/science.1156409; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Baccarelli A, 2009, AM J RESP CRIT CARE, V179, P572, DOI 10.1164/rccm.200807-1097OC; Balaci L, 2007, AM J HUM GENET, V80, P1103, DOI 10.1016/518259; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, P1391, DOI 10.1016/j.jaci.2009.03.014; Barton SJ, 2009, J ALLERGY CLIN IMMUN, V123, pe17; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Benn CS, 2001, CLIN EXP ALLERGY, V31, P1862, DOI 10.1046/j.1365-2222.2001.01128.x; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Bierbaum S, 2005, AM J RESP CRIT CARE, V172, P1505, DOI 10.1164/rccm.200506-890OC; Bisgaard H, 2009, AM J RESP CRIT CARE, V179, P179, DOI 10.1164/rccm.200809-1436OC; BLAKEY JD, 1958, THORAX, V64, P381; Bleecker ER, 2006, J ALLERGY CLIN IMMUN, V118, P809, DOI 10.1016/j.jaci.2006.06.036; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Breton CV, 2009, AM J RESP CRIT CARE, V179, P601, DOI 10.1164/rccm.200809-1384OC; Brown SJ, 2009, J INVEST DERMATOL, V129, P543, DOI 10.1038/jid.2008.413; Burke W, 2003, AM J PREV MED, V24, P160, DOI 10.1016/S0749-3797(02)00589-5; Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Busse WW, 2008, AM J RESP CRIT CARE, V178, P1002, DOI 10.1164/rccm.200708-1200OC; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; Chavanas S, 2000, NAT GENET, V25, P141; Choi JH, 2004, ANN ALLERG ASTHMA IM, V93, P293; COOKSON WOCM, 1989, LANCET, V1, P1292; Daley D, 2009, HUM GENET, V125, P445, DOI 10.1007/s00439-009-0643-8; Denham S, 2008, RESP RES, V9, DOI 10.1186/1465-9921-9-38; Dezateux C, 1997, BRIT MED BULL, V53, P40; Dijkstra A, 2008, J ALLERGY CLIN IMMUN, V121, P1510, DOI 10.1016/j.jaci.2008.04.015; Duroudier NP, 2009, ALLERGY, V64, P823, DOI 10.1111/j.1398-9995.2009.02015.x; Esparza-Gordillo J, 2009, NAT GENET, V41, P596, DOI 10.1038/ng.347; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fergusson DM, 1997, CLIN EXP ALLERGY, V27, P1394, DOI 10.1046/j.1365-2222.1997.1430947.x; Flood-Page P, 2007, AM J RESP CRIT CARE, V176, P1062, DOI 10.1164/rccm.200701-085OC; Frazer KA, 2009, NAT REV GENET, V10, P241, DOI 10.1038/nrg2554; Galanter J, 2008, AM J RESP CRIT CARE, V177, P1194, DOI 10.1164/rccm.200711-1644OC; GODFREY KM, 1994, CLIN EXP ALLERGY, V24, P641, DOI 10.1111/j.1365-2222.1994.tb00968.x; Gudbjartsson DF, 2009, NAT GENET, V41, P342, DOI 10.1038/ng.323; Haitchi HM, 2005, AM J RESP CRIT CARE, V171, P958, DOI 10.1164/rccm.200409-1251OC; Haland G, 2006, NEW ENGL J MED, V355, P1682, DOI 10.1056/NEJMoa052885; Haldar P, 2008, AM J RESP CRIT CARE, V178, P218, DOI [10.1164/rccm.200711-1754OC, 10.1164/rccm.200711-17540C]; Hancock DB, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000623; HANSON B, 1991, AM J HUM GENET, V48, P873; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, pe7; Hawkins GA, 2008, PHARMACOGENOMICS, V9, P349, DOI 10.2217/14622416.9.3.349; Hawkins GA, 2009, J ALLERGY CLIN IMMUN, V123, P1376, DOI 10.1016/j.jaci.2009.01.049; Henderson J, 2008, J ALLERGY CLIN IMMUN, V121, P872, DOI 10.1016/j.jaci.2008.01.026; Henrichsen CN, 2009, HUM MOL GENET, V18, pR1, DOI 10.1093/hmg/ddp011; Hersh CP, 2007, AM J RESP CRIT CARE, V176, P849, DOI 10.1164/rccm.200704-592OC; Himes BE, 2009, AM J HUM GENET, V84, P581, DOI 10.1016/j.ajhg.2009.04.006; Hindorff LA, CATALOG PUBLISHED GE; Holgate ST, 2007, EUR RESPIR J, V29, P793, DOI 10.1183/09031936.00087506; Hollingsworth JW, 2008, J CLIN INVEST, V118, P3462, DOI 10.1172/JCI34378; Holloway JW, 2008, NEW ENGL J MED, V359, P2043, DOI 10.1056/NEJMe0807576; Holloway JW, 2008, J ALLERGY CLIN IMMUN, V121, P573, DOI 10.1016/j.jaci.2008.01.007; Holloway JW, 2007, CURR OPIN ALLERGY CL, V7, P69, DOI 10.1097/ACI.0b013e328013d51b; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, P93, DOI 10.1016/j.jaci.2008.03.015; Hunninghake GM, 2008, J ALLERGY CLIN IMMUN, V122, pe1; Islam T, 2009, THORAX, V64, P197, DOI 10.1136/thx.2008.099366; Janssens ACJW, 2006, GENET MED, V8, P395, DOI 10.1097/01.gim.0000229689.18263.f4; Jirtle RL, 2007, NAT REV GENET, V8, P253, DOI 10.1038/nrg2045; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kim SH, 2009, CLIN EXP ALLERGY, V39, P203, DOI 10.1111/j.1365-2222.2008.03117.x; Kim Y, 2007, GENES IMMUN, V8, P369, DOI 10.1038/sj.gene.6364394; Klotsman M, 2007, PHARMACOGENET GENOM, V17, P189, DOI 10.1097/FPC.0b013e3280120043; Koppelman GH, 2008, EUR RESPIR J, V32, P775, DOI 10.1183/09031936.00093608; Koppelman GH, 2009, AM J RESP CRIT CARE, V180, P929, DOI 10.1164/rccm.200810-1621OC; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; Leung TF, 2009, ALLERGY, V64, P621, DOI 10.1111/j.1398-9995.2008.01873.x; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Lima JJ, 2006, AM J RESP CRIT CARE, V173, P379, DOI 10.1164/rccm.200509-1412OC; Lima JJ, 2009, CURR OPIN PULM MED, V15, P57, DOI 10.1097/MCP.0b013e32831da8be; Litonjua AA, 2008, AM J RESP CRIT CARE, V178, P688, DOI 10.1164/rccm.200709-1363OC; London SJ, 2009, ANNU REV PUBL HEALTH, V30, P55, DOI 10.1146/annurev.publhealth.031308.100151; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Lucas JS, 2004, AM J RESP CRIT CARE, V170, P534, DOI 10.1164/rccm.200311-15830C; Lyssenko V, 2008, NEW ENGL J MED, V359, P2220, DOI 10.1056/NEJMoa0801869; Maher B, 2008, NATURE, V456, P18, DOI 10.1038/456018a; Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494; Marenholz I, 2006, J ALLERGY CLIN IMMUN, V118, P866, DOI 10.1016/j.jaci.2006.07.026; Marenholz I, 2009, J ALLERGY CLIN IMMUN, V123, P911, DOI 10.1016/j.jaci.2009.01.051; Martinez Fernando D, 2007, Proc Am Thorac Soc, V4, P221, DOI 10.1513/pats.200702-035AW; McCarroll SA, 2008, NAT GENET, V40, P1166, DOI 10.1038/ng.238; McCarthy MI, 2008, NAT REV GENET, V9, P356, DOI 10.1038/nrg2344; McCarthy MI, 2008, HUM MOL GENET, V17, pR156, DOI 10.1093/hmg/ddn289; Meigs JB, 2008, NEW ENGL J MED, V359, P2208, DOI 10.1056/NEJMoa0804742; Miller RL, 2008, AM J RESP CRIT CARE, V177, P567, DOI 10.1164/rccm.200710-1511PP; Milner JD, 2008, NATURE, V452, P773, DOI 10.1038/nature06764; Minegishi Y, 2007, NATURE, V448, P1058, DOI 10.1038/nature06096; Moffatt MF, 2007, NATURE, V448, P470, DOI 10.1038/nature06014; Nair P, 2009, NEW ENGL J MED, V360, P985, DOI 10.1056/NEJMoa0805435; NARAYAN KM, 2009, NEW ENGL J MED, V360, P136; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Ober C, 2001, Curr Allergy Asthma Rep, V1, P174, DOI 10.1007/s11882-001-0085-4; Ober C, 2008, NEW ENGL J MED, V358, P1682, DOI 10.1056/NEJMoa0708801; Obermayer-Pietsch BM, 2004, J BONE MINER RES, V19, P42, DOI 10.1359/JBMR.0301207; Oguma T, 2004, NEW ENGL J MED, V351, P1752, DOI 10.1056/NEJMoa031785; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Palmer CNA, 2007, J ALLERGY CLIN IMMUN, V120, P64, DOI 10.1016/j.jaci.2007.04.001; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Presland RB, 2004, J INVEST DERMATOL, V123, P603, DOI 10.1111/j.0022-202X.2004.23226.x; Pykalainen M, 2005, J ALLERGY CLIN IMMUN, V115, P80, DOI 10.1016/j.jaci.2004.10.006; Reijmerink NE, 2008, J ALLERGY CLIN IMMUN, V122, P651, DOI 10.1016/j.jaci.2008.06.030; Rogers AJ, 2009, AM J RESP CRIT CARE, V179, P1084, DOI 10.1164/rccm.200812-1860OC; SALAM MT, 2009, J ALLERGY CLIN IMMUN, V123, pE1; Salam MT, 2009, J ALLERGY CLIN IMMUN, V123, P596, DOI 10.1016/j.jaci.2008.12.020; Salter HH, 1860, ASTHMA ITS PATHOLOGY; Sandilands A, 2009, J CELL SCI, V122, P1285, DOI 10.1242/jcs.033969; Schroer K.T., 2008, J PEDIAT, V154, P401; SCHROER KT, 2008, J PEDIAT, V154, pE1; Sharma S, 2009, AM J RESP CRIT CARE, V179, P356, DOI 10.1164/rccm.200808-1268OC; Sheehan NA, 2008, PLOS MED, V5, P1205, DOI 10.1371/journal.pmed.0050177; Shimizu M, 2005, HUM MOL GENET, V14, P2919, DOI 10.1093/hmg/ddi323; Simpson A, 2005, AM J RESP CRIT CARE, V172, P55, DOI 10.1164/rccm.200412-1708OC; Skadhauge LR, 1999, EUR RESPIR J, V13, P8, DOI 10.1183/09031936.99.13100899; Smit LAM, 2009, AM J RESP CRIT CARE, V179, P363, DOI 10.1164/rccm.200810-1533OC; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; Smith GD, 2005, BRIT MED J, V330, P1076, DOI 10.1136/bmj.330.7499.1076; SMITH M, 2008, J ALLERGY CLIN IMMUN, V121, pE1; Smith M, 2008, J ALLERGY CLIN IMMUN, V121, P1460, DOI 10.1016/j.jaci.2008.03.025; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Sutherland TE, 2009, CLIN EXP ALLERGY, V39, P943, DOI 10.1111/j.1365-2222.2009.03243.x; SUTTNER K, 2009, J ALLERGY CLIN IMMUN, V123, pE1; Suttner K, 2009, J ALLERGY CLIN IMMUN, V123, P1062, DOI 10.1016/j.jaci.2009.02.025; Tantisira KG, 2009, PHARMACOGENET GENOM, V19, P244, DOI 10.1097/FPC.0b013e328326e0b1; Tantisira KG, 2004, HUM MOL GENET, V13, P1353, DOI 10.1093/hmg/ddh149; Tavendale R, 2008, J ALLERGY CLIN IMMUN, V121, P860, DOI 10.1016/j.jaci.2008.01.015; Van Eerdewegh P, 2002, NATURE, V418, P426, DOI 10.1038/nature00878; Vercelli D, 2008, NAT REV IMMUNOL, V8, P169, DOI 10.1038/nri2257; Wechsler ME, 2006, AM J RESP CRIT CARE, V173, P519, DOI 10.1164/rccm.200509-15190C; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Weidinger S, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000166; Wenzel SE, 2007, J ALLERGY CLIN IMMUN, V119, P14, DOI 10.1016/j.jaci.2006.10.025; Wenzel SE, 2009, AM J RESP CRIT CARE, V179, P549, DOI 10.1164/rccm.200809-1512OC; Wu H, 2009, ALLERGY, V64, P629, DOI 10.1111/j.1398-9995.2008.01912.x; Wu H, 2007, ENVIRON HEALTH PERSP, V115, P616, DOI 10.1289/ehp.9740; Yang IA, 2008, THORAX, V63, P555, DOI 10.1136/thx.2007.079426; Yang IA, 2007, CLIN EXP ALLERGY, V37, P1264, DOI 10.1111/j.1365-2222.2007.02798.x; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Zhang YM, 2003, NAT GENET, V34, P181, DOI 10.1038/ng1166; 1000 GENOMES DEEP CA	143	93	97	2	16	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2		2			S81	S94		10.1016/j.jaci.2009.10.071		14	Allergy; Immunology	Allergy; Immunology	629CC	WOS:000280170600008	20176270	
J	Pettipher, R				Pettipher, R.			The roles of the prostaglandin D-2 receptors DP1 and CRTH2 in promoting allergic responses	BRITISH JOURNAL OF PHARMACOLOGY			English	Article; Proceedings Paper	Joint Life Science Meeting of the British-Pharmacological-Society/Physiological-Society/Biochemical-Society	JUL, 2007	Glasgow, SCOTLAND	British Pharmacol Soc, Physiol Soc, Biochem Soc		prostaglandin D-2; DP1; CRTH2; mast cells; Th2 lymphocytes; eosinophils; PI3K; allergic rhinitis; asthma	EOSINOPHILIC AIRWAY INFLAMMATION; D-PROSTANOID RECEPTOR-1; HUMAN DENDRITIC CELLS; HELPER TYPE-2 CELLS; CHEMOATTRACTANT RECEPTOR; TH2 CELLS; IN-VIVO; MAST-CELLS; ANTAGONIST BAY-U-3405; CYTOKINE PRODUCTION	Prostaglandin D-2 (PGD(2)) is produced by mast cells, Th2 lymphocytes and dendritic cells and has been detected in high concentrations at sites of allergic inflammation. PGD2 exerts its inflammatory effects through high affinity interactions with the G protein coupled receptors DP1 and chemoattractant-homologous receptor expressed on Th2 cells (CRTH2, also known as DP2). DP1 and CRTH2 act in concert to promote a number of biological effects associated with the development and maintenance of the allergic response. During the process of allergen sensitization, DP1 activation may enhance polarization of Th0 cells to Th2 cells by inhibiting production of interleukin 12 by dendritic cells. Upon exposure to allergen in sensitized individuals, activation of DP1 may contribute to the long lasting blood flow changes in the target organ. CRTH2 is expressed by Th2 lymphocytes, eosinophils and basophils and may mediate the recruitment of these cell types during the late phase allergic response. The role played by CRTH2 in promoting the production of Th2 cytokines and IgE make antagonism of this receptor a particularly attractive approach to the treatment of chronic allergic disease.	Oxagen Ltd, Abingdon OX14 4RY, Oxon, England	Pettipher, R (reprint author), Oxagen Ltd, 91 Milton Pk, Abingdon OX14 4RY, Oxon, England.	r.pettipher@oxagen.co.uk					Ajuebor MN, 2000, AM J PHYSIOL-GASTR L, V279, pG238; Almishri W, 2005, J PHARMACOL EXP THER, V313, P64, DOI 10.1124/jpet.104.079079; ALSINAWI LAH, 1985, PROSTAGLANDINS, V29, P99; ALVING K, 1991, BRIT J PHARMACOL, V104, P452; Angeli W, 2004, J IMMUNOL, V172, P3822; Arimura A, 2001, J PHARMACOL EXP THER, V298, P411; Armer RE, 2005, J MED CHEM, V48, P6174, DOI 10.1021/jm050519b; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Bohm E, 2004, J BIOL CHEM, V279, P7663, DOI 10.1074/jbc.M310270200; Busse W, 2001, J ALLERGY CLIN IMMUN, V107, P461, DOI 10.1067/mai.2001.114657; Caron G, 2001, J IMMUNOL, V167, P3682; CHARLESWORTH EN, 1991, J IMMUNOL, V146, P671; Cheng K, 2006, P NATL ACAD SCI USA, V103, P6682, DOI 10.1073/pnas.0601574103; Cossette C, 2007, J PHARMACOL EXP THER, V320, P173, DOI 10.1124/jpet.106.111062; Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641; DOYLE WJ, 1990, J ALLERGY CLIN IMMUN, V86, P924, DOI 10.1016/S0091-6749(05)80156-3; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Faith A, 2005, J ALLERGY CLIN IMMUN, V116, P1136, DOI 10.1016/j.jaci.2005.08.002; Faveeuw C, 2003, EUR J IMMUNOL, V33, P889, DOI 10.1002/eji.200323330; Fujitani Y, 2002, J IMMUNOL, V168, P443; Gazi L, 2005, PROSTAG OTH LIPID M, V75, P153, DOI 10.1016/j.prostaglandins.2004.11.003; Gervais FG, 2005, MOL PHARMACOL, V67, P1834, DOI 10.1124/mol.104.009068; Gervais FG, 2001, J ALLERGY CLIN IMMUN, V108, P982, DOI 10.1067/mai.2001.119919; GILES H, 1989, BRIT J PHARMACOL, V96, P291; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Gonzalo J, 2005, AM J RESP CRIT CARE, V163, pA811; Gosset P, 2005, EUR J IMMUNOL, V35, P1491, DOI 10.1002/eji.200425319; Gyles SL, 2006, IMMUNOLOGY, V119, P362, DOI 10.1111/j.1365-2567.2006.02440.x; Hahn EL, 2005, IMMUNOL ALLERGY CLIN, V25, P231, DOI 10.1016/j.iac.2005.02.004; HAMIDBLOOMFIELD S, 1989, BRIT J PHARMACOL, V96, P307; Hammad H, 2003, J IMMUNOL, V171, P3936; Hammad H, 2007, J EXP MED, V204, P357, DOI 10.1084/jem.20061196; HEAVEY DJ, 1984, PROSTAGLANDINS, V28, P755, DOI 10.1016/0090-6980(84)90033-9; Heinemann A, 2003, J IMMUNOL, V170, P4752; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Hirai H, 2002, J IMMUNOL, V168, P981; HOWARTH P, 1991, ADV PROSTAG THROMB L, V21, P449; Howarth PH, 1997, ALLERGY, V52, P12; Kitawaki T, 2006, INT IMMUNOL, V18, P1789, DOI 10.1093/intimm/dxl113; Kostenis E, 2006, TRENDS MOL MED, V12, P148, DOI 10.1016/j.molmed.2006.02.005; Lambrecht BN, 2005, ALLERGY, V60, P271, DOI 10.1111/j.1398-9995.2005.00708.x; LEWIS RA, 1982, J IMMUNOL, V129, P1627; Maciejewski-Lenoir D, 2006, J INVEST DERMATOL, V126, P2637, DOI 10.1038/sj.jid.5700586; Maezawa Y, 2004, CLIN EXP IMMUNOL, V135, P12, DOI 10.1046/j.1365-2249.2004.02337.x; Maezawa Y, 2003, INT ARCH ALLERGY IMM, V131, P2, DOI 10.1159/1000070473; Matsuoka T, 2000, SCIENCE, V287, P2013, DOI 10.1126/science.287.5460.2013; Mazzoni A, 2001, J CLIN INVEST, V108, P1865, DOI 10.1172/JCI13930; MCKENNIFF MG, 1991, BRIT J PHARMACOL, V104, P585; Mimura H, 2005, J PHARMACOL EXP THER, V314, P244, DOI 10.1124/jpet.104.081539; Monneret G, 2002, J IMMUNOL, V168, P3563; Monneret G, 2001, BLOOD, V98, P1942, DOI 10.1182/blood.V98.6.1942; MURRAY JJ, 1986, NEW ENGL J MED, V315, P800, DOI 10.1056/NEJM198609253151304; NACLERIO RM, 1983, AM REV RESPIR DIS, V128, P597; NAGAI H, 1995, PROSTAGLANDINS, V50, P75, DOI 10.1016/0090-6980(95)00111-5; Nagata K, 1999, FEBS LETT, V459, P195, DOI 10.1016/S0014-5793(99)01251-X; Nagata K, 1999, J IMMUNOL, V162, P1278; Narita S, 1996, INT ARCH ALLERGY IMM, V109, P161; OSullivan S, 1996, J ALLERGY CLIN IMMUN, V98, P421, DOI 10.1016/S0091-6749(96)70167-7; Peters S P, 1982, Trans Assoc Am Physicians, V95, P221; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Reddy ST, 1999, BIOCHEM BIOPH RES CO, V265, P205, DOI 10.1006/bbrc.1999.1658; Sandig H, 2006, FEBS LETT, V580, P373, DOI 10.1016/j.febslet.2005.11.052; Sandig H, 2007, J LEUKOCYTE BIOL, V81, P372, DOI 10.1189/jlb.0706424; Satoh T, 2006, J IMMUNOL, V177, P2621; Sawyer N, 2002, BRIT J PHARMACOL, V137, P1163, DOI 10.1038/sj.bjp.0704973; Schuligoi R, 2007, BIOCHEM PHARMACOL, V74, P107, DOI 10.1016/j.bcp.2007.03.023; Shiraishi Y, 2005, J PHARMACOL EXP THER, V312, P954, DOI 10.1124/jpet.104.078212; Sihra BS, 1997, THORAX, V52, P447; Sousa AR, 1997, THORAX, V52, P940; Spik I, 2005, J IMMUNOL, V174, P3703; Stubbs VEL, 2002, J BIOL CHEM, V277, P26012, DOI 10.1017/jbc.M201803200; Sturino CF, 2007, J MED CHEM, V50, P794, DOI 10.1021/jm0603668; Sugimoto H, 2003, J PHARMACOL EXP THER, V305, P347, DOI 10.1124/jpet.102.046748; Takeshita K, 2004, INT IMMUNOL, V16, P947, DOI 10.1093/intimm/dxh096; Tanaka K, 2004, BIOCHEM BIOPH RES CO, V316, P1009, DOI 10.1016/j.bbrc.2004.02.151; Tanaka K, 2000, J IMMUNOL, V164, P2277; Terada N, 1998, ACTA OTO-LARYNGOL, P32; Theiner G, 2006, IMMUNOBIOLOGY, V211, P463, DOI 10.1016/j.imbio.2006.05.020; Trivedi SG, 2006, P NATL ACAD SCI USA, V103, P5179, DOI 10.1073/pnas.0507175103; Uller L, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-16; Ulven T, 2005, J MED CHEM, V48, P897, DOI 10.1021/jm049036i; van Neerven RJ, 2006, INT ARCH ALLERGY IMM, V141, P119, DOI 10.1159/000094714; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; Vinall SL, 2007, IMMUNOLOGY, V121, P577, DOI 10.1111/j.1365-2567.2007.02606.x; Walch L, 1999, BRIT J PHARMACOL, V126, P859, DOI 10.1038/sj.bjp.0702393; Wang YH, 2006, IMMUNITY, V24, P827, DOI 10.1016/j.immuni.2006.03.019; WHITTLE BJR, 1983, PROSTAGLANDINS, V25, P205, DOI 10.1016/0090-6980(83)90105-3; WIDDICOMBE JG, 1990, RESP MED, V84, P3, DOI 10.1016/S0954-6111(08)80001-7; Wright DH, 2000, BRIT J PHARMACOL, V131, P1537, DOI 10.1038/sj.bjp.0703688; Xue LZ, 2007, BIOCHEM PHARMACOL, V73, P843, DOI 10.1016/j.bcp.2006.11.021; Xue LZ, 2005, J IMMUNOL, V175, P6531; Ying S, 2005, J IMMUNOL, V174, P8183	93	93	95	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.	MAR	2008	153			1			S191	S199		10.1038/sj.bjp.0707488		9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	268OA	WOS:000253587900023	17965752	
J	Kessler, R; Stahl, E; Vogelmeier, C; Haughney, J; Trudeau, E; Lofdahl, CG				Kessler, Romain; Stahl, Elisabeth; Vogelmeier, Claus; Haughney, John; Trudeau, Elyse; Lofdahl, Claes-Goran			Patient understanding, detection, and experience of COPD exacerbations - An observational, interview-based study	CHEST			English	Article						burden; COPD; exacerbation; patient's perspective	OBSTRUCTIVE PULMONARY-DISEASE; QUALITY-OF-LIFE; CHRONIC-BRONCHITIS; HEALTH-STATUS; LUNG-FUNCTION; TIME-COURSE; ASTHMA; IMPACT; HOSPITALIZATION; SALMETEROL	Study objectives: This study was conducted to gain insight into patients' comprehension, recognition, and experience of exacerbations of COPD, and to explore the patient burden associated with these events. Design: A qualitative, multinational, cross-sectional, interview-based study. Setting: Patients' homes. Patients: Patients (n = 125) with predominantly moderate-to-very severe COPD (age >= 50 years; with two or more exacerbations during the previous year). Interventions: Patients underwent a 1-h face-to-face interview with a trained interviewer. Measurements and results: During the preceding year, patients experienced a mean +/- SD of 4.6 +/- 5.4 exacerbations, after which 19.2% (n = 24) believed they had not fully recovered. Although commonly used by physicians, only 1.6% (n = 2) of patients understood the term exacerbation, preferring to use simpler terms, such as chest infection (16.0%; n = 20) or crisis (16.0%; n = 20) instead. Approximately two thirds of patients stated that they were aware of when an exacerbation was imminent and, in most cases, patients recounted that symptoms were consistent from one exacerbation to another. Some patients (32.8%; n = 41), however, reported no recognizable warning signs. At the onset of an exacerbation, 32.8% of patients (n = 41) stated that they reacted by self-administering their medication. Some patients spontaneously mentioned a fear of dying (12.0%; n = 15) or suffocating (9.6%; n = 12) during exacerbations, and effects on activities, mood, and personal/family relationships were frequently reported. Physicians tended to underestimate the psychological impact of exacerbations compared with patient reports. Conclusions: This study shows that patients with frequent exacerbations have a poor understanding of the term exacerbation. Patient recollections suggest that exacerbation profiles vary enormously between patients but that symptoms/warning signs are fairly consistent within individuals, and are generally recognizable. Exacerbations appear to have a significant impact on patient well-being, including psychological well-being, and this may be underestimated by physicians.	Hop Univ Strasbourg, Hop Hautpierre, Dept Pulmonol, Strasbourg, France; Univ Aberdeen, Aberdeen, Scotland; Marburg Univ Hosp, Marburg, Germany; Mapi Values, Lyon, France; Univ Lund Hosp, S-22185 Lund, Sweden; Univ London Imperial Coll Sci & Technol, London, England	Kessler, R (reprint author), Hop Univ Strasbourg, Hop Hautpierre, Dept Pulmonol, Strasbourg, France.	romain.kessler@chru-strasbourg.fr		kessler, romain/0000-0002-5798-5715			Andersson F, 2003, J ASTHMA, V40, P615, DOI 10.1081/JAS-120019032; Andersson F, 2002, RESP MED, V96, P700, DOI 10.1053/rmed.2002.1334; Breslin E, 1998, CHEST, V114, P958, DOI 10.1378/chest.114.4.958; Burge S, 2003, Eur Respir J Suppl, V41, p46s; Calverley P, 2003, LANCET, V361, P449, DOI 10.1016/S0140-6736(03)12459-2; Calverley PM, 2003, EUR RESPIR J, V22, P912, DOI 10.1183/09031936.03.00027003; Casaburi R, 2002, EUR RESPIR J, V19, P217, DOI 10.1183/09031936.02.00269802; Connors AF, 1996, AM J RESP CRIT CARE, V154, P959; Doll H, 2005, PHARMACOECONOMICS, V23, P345, DOI 10.2165/00019053-200523040-00005; Doll H, 2002, RESP MED, V96, P39, DOI 10.1053/rmed.2001.1208; Donaldson GC, 2002, THORAX, V57, P847, DOI 10.1136/thorax.57.10.847; Donohue JF, 2002, CHEST, V122, P47, DOI 10.1378/chest.122.1.47; Engstrom CP, 2001, EUR RESPIR J, V18, P69, DOI 10.1183/09031936.01.00044901; Eriksen Nanna, 2003, Ugeskr Laeger, V165, P3499; Garcia-Aymerich J, 2001, AM J RESP CRIT CARE, V164, P1002; Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459; Miravitlles M, 2004, THORAX, V59, P387, DOI 10.1136/thx.2003.008730; Nguyen BP, 1996, ANN ALLERG ASTHMA IM, V77, P209; Nicolson P, 2000, J ANTIMICROB CHEMOTH, V45, P25, DOI 10.1093/jac/45.suppl_2.25; Oliver SM, 2001, FAM PRACT, V18, P430, DOI 10.1093/fampra/18.4.430; Partridge MR, 2000, EUR RESPIR J, V16, P333, DOI 10.1183/09031936.00.16233400; Patil SP, 2003, ARCH INTERN MED, V163, P1180, DOI 10.1001/archinte.163.10.1180; Pauwels R, 2004, RESP MED, V98, P99, DOI 10.1016/j.med.2003.09.001; PEACH H, 1981, THORAX, V36, P585, DOI 10.1136/thx.36.8.585; Perfetto EM, 2001, CLIN THER, V23, P1747, DOI 10.1016/S0149-2918(01)80142-9; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rennard S, 2002, EUR RESPIR J, V20, P799, DOI 10.1183/09031936.02.03242002; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; Seemungal TAR, 2000, AM J RESP CRIT CARE, V161, P1608; Spencer S, 2004, EUR RESPIR J, V23, P698, DOI 10.1183/09031936.04.00121404; Spencer S, 2003, THORAX, V58, P589, DOI 10.1136/thorax.58.7.589; Szafranski W, 2003, EUR RESPIR J, V21, P74, DOI 10.1183/09031936.03.00031402; *US DEP HHS, NIH PUBL, V2701; Vestbo J, 2004, EUR RESPIR REV, V13, P6; Wilkinson TMA, 2004, AM J RESP CRIT CARE, V169, P1298, DOI 10.1164/rccm.200310-1443OC; Wouters EFM, 2003, RESP MED, V97, pS3, DOI 10.1016/S0954-6111(03)80020-3	36	93	102	1	6	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUL	2006	130	1					133	142		10.1378/chest.130.1.133		10	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	066HC	WOS:000239219300023	16840393	
J	Perzanowski, MS; Miller, RL; Thorne, PS; Barr, RG; Divjan, A; Sheares, BJ; Garfinkel, RS; Perera, FP; Goldstein, IF; Chew, GL				Perzanowski, MS; Miller, RL; Thorne, PS; Barr, RG; Divjan, A; Sheares, BJ; Garfinkel, RS; Perera, FP; Goldstein, IF; Chew, GL			Endotoxin in inner-city homes: Associations with wheeze and eczema in early childhood	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						endotoxin; asthma; allergy; hygiene hypothesis; wheeze; inner-city; eczema	HOUSE-DUST ENDOTOXIN; HYGIENE HYPOTHESIS; ALLERGIC DISEASES; INDOOR ALLERGENS; NATIONAL-SURVEY; BIRTH COHORT; HIGH-RISK; EXPOSURE; ASTHMA; CHILDREN	Background: An inverse association between domestic exposure to endotoxin and atopy in childhood has been observed. The relevance of this aspect of the hygiene hypothesis to US inner-city communities that have disproportionately high asthma prevalence has not been determined. Objectives: To measure endotoxin in the dust from inner-city homes, evaluate associations between endotoxin and housing/lifestyle characteristics, and determine whether endotoxin exposure predicted wheeze, allergic rhinitis, and eczema over the first 3 years of life. Methods: As part of an ongoing prospective birth cohort study, children of Dominican and African-American mothers living in New York City underwent repeated questionnaire measures. Dust samples collected from bedroom floors at age 12 or 36 months were assayed for endotoxin. Results: Among the samples collected from 301 participants' homes, the geometric mean endotoxin concentration (95% CI) was 75.9 EU/mg (66-87), and load was 3892 EU/m(2) (3351-4522). Lower endotoxin concentrations were associated with wet mop cleaning and certain neighborhoods. Endotoxin concentration correlated weakly with cockroach (Bla g 2: r = 0.22, P < .001) and mouse (mouse urinary protein: r = 0.28; P < .001) allergens in the dust. Children in homes with higher endotoxin concentration were less likely to have eczema at age 1 year (odds ratio, 0.70 [0.53-0.93]) and more likely to wheeze at age 2 years (odds ratio, 1.34 [1.01-1.78]). These associations were stronger among children with a maternal history of asthma. Conclusion: Endotoxin levels in this inner-city community are similar to those in nonfarm homes elsewhere. In this community, domestic endotoxin exposure was inversely associated with eczema at age 1 year, but positively associated with wheeze at age 2 years. Clinical implications: Endotoxin exposure in the inner-city community may be related to wheeze in the early life; however, given the inverse association seen with eczema, the long-term development of allergic disease is still in question.	Columbia Univ, Mailman Sch Publ Hlth, Columbias Ctr Childrens Environm Hlth, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Data Coordinating Ctr, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Div Pulm Allergy & Crit Care Med, New York, NY USA; Columbia Univ, Coll Phys & Surg, Div Gen Med, Dept Med, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY USA; Univ Iowa, Dept Environm & Occupat Hlth, Iowa City, IA USA	Chew, GL (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Columbias Ctr Childrens Environm Hlth, 60 Haven Ave,B-1, New York, NY 10032 USA.	cg2gg@columbia.edu			NCRR NIH HHS [M01 RR000645, RR00645]; NIEHS NIH HHS [P30 ES009089-09, 5 P30 ES009089, 5 R01 ES08977, P01 ES009600, P01 ES009600-09, P30 ES005605, P30 ES005605-17, P30 ES009089, P30 ES05605, P50 ES009600, P50 ES09600, R01 ES008977, R01 ES008977-10, R01 ES011158, R01 ES011158-03, R01 ES012468, R01 ES012468-03, R01ES111158]		Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bischof W, 2002, INDOOR AIR, V12, P2, DOI 10.1034/j.1600-0668.2002.120102.x; Bolte G, 2003, CLIN EXP ALLERGY, V33, P770, DOI 10.1046/j.1365-2222.2003.01665.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Chrischilles E, 2004, J ALLERGY CLIN IMMUN, V113, P66, DOI 10.1016/j.jaci.2003.09.037; *CIT NEW YORK DEP, 2003, ASTHM FACTS; Douwes J, 2000, AM J RESP CRIT CARE, V162, P1348; Douwes J, 1998, INDOOR AIR, V8, P255, DOI 10.1111/j.1600-0668.1998.00006.x; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gehring U, 2002, AM J RESP CRIT CARE, V166, P939, DOI 10.1164/rccm.200203-256OC; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LUCZYNSKA CM, 1989, J IMMUNOL METHODS, V118, P227, DOI 10.1016/0022-1759(89)90010-0; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Meyer IH, 2003, J ASTHMA, V40, P545, DOI 10.1081/JAS-120018789; Miller RL, 2004, CHEST, V126, P1071, DOI 10.1378/chest.126.4.1071; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995; Mueller-Anneling L, 2004, ENVIRON HEALTH PERSP, V112, P583, DOI 10.1289/ehp.6552; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Phipatanakul W, 2004, PEDIATRICS, V114, P13, DOI 10.1542/peds.114.1.13; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; Rauh VA, 2002, ENVIRON HEALTH PERSP, V110, P323; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 2000, THORAX S1, V55, pS2; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Thorne PS, 2000, TOXICOLOGY, V152, P13, DOI 10.1016/S0300-483X(00)00287-0; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Wickens K, 2004, INDOOR AIR, V14, P217, DOI 10.1111/j.1600-0668.2004.00253.x; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	39	93	95	0	4	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1082	1089		10.1016/j.jaci.2005.12.1348		8	Allergy; Immunology	Allergy; Immunology	041EM	WOS:000237436300016	16675336	
J	Fischer, G; Braun, S; Thissen, R; Dott, W				Fischer, G; Braun, S; Thissen, R; Dott, W			FT-IR spectroscopy as a tool for rapid identification and intra-species characterization of airborne filamentous fungi	JOURNAL OF MICROBIOLOGICAL METHODS			English	Article						FT-IR; fungi; identification; Penicillium; Aspergillus; Conidia; chemotaxonomy	TRANSFORM-INFRARED-SPECTROSCOPY; PERFORMANCE LIQUID-CHROMATOGRAPHY; PYROLYSIS MASS-SPECTROMETRY; SECONDARY METABOLITES; VOLATILE METABOLITES; TYPING METHODS; MYCOTOXINS; STRAINS; DIFFERENTIATION; CLASSIFICATION	Identification of microfungi is time-consuming due to cultivation and microscopic examination and can be influenced by the interpretation of the macro- and micro-morphological characters observed. Fungal conidia contain mycotoxins that may be present in bioaerosols and thus the capacity for production of mycotoxins (and allergens) needs to be investigated to create a basis for reliable risk assessment in environmental and occupational hygiene. The present investigation aimed to create a simple but sophisticated method for the preparation of samples and the identification of airborne fungi by FT-IR spectroscopy. The method was suited to reproducibly differentiate Aspergillus and Penicillium species on the generic, the species.. and the strain level. There are strong indications that strains of one taxon differing in metabolite production can be reliably distinguished by FT-IR spectroscopy (e.g. Aspergillus parasiticus). On the other hand, species from different taxa being similar in secondary metabolite production showed comparably higher similarities. The results obtained here can serve as a basis for the development of a database for species identification and strain characterization of microfungi. The method presented here will improve and facilitate the risk assessment in case of bioaerosol exposure, as strains with different physiological properties (e.g. toxic, non-toxic) could be differentiated. Moreover, it has the potential to significantly improve the identification of microfungi in various fields of applied microbiological research, e.g. high throughput screening in view of specific physiological properties, biodiversity studies, inventories in environmental microbiology, and quality control measures. (c) 2005 Elsevier B.V. All rights reserved.	Univ Hosp RWTH Aachen, Inst Hyg & Environm Med, D-52057 Aachen, Germany	Fischer, G (reprint author), Univ Hosp RWTH Aachen, Inst Hyg & Environm Med, Pauwelsstr 30, D-52057 Aachen, Germany.	Guido.Fischer@post.rwth-aachen.de					Bondy GS, 2000, J TOXICOL ENV HEAL B, V3, P109, DOI 10.1080/109374000281113; Fischer G, 1999, CHEMOSPHERE, V38, P1745, DOI 10.1016/S0045-6535(98)00391-9; Fischer G, 1999, CHEMOSPHERE, V39, P795; Fischer G, 2000, INT J HYG ENVIR HEAL, V203, P97, DOI 10.1078/S1438-4639(04)70014-0; Fischer G, 2003, ARCH MICROBIOL, V179, P75, DOI 10.1007/s00203-002-0495-2; Fischer G, 2002, INT J HYG ENVIR HEAL, V205, P433, DOI 10.1078/1438-4639-00190; Fischer G, 2000, INT J HYG ENVIR HEAL, V203, P105, DOI 10.1078/S1438-4639(04)70015-2; FRISVAD JC, 1987, J CHROMATOGR, V404, P195, DOI 10.1016/S0021-9673(01)86850-3; FRISVAD JC, 1998, THESIS TU DENMARK; Frisvad JC, 1990, MODERN CONCEPTS PENI, P159; FRISVAD JC, 1993, J CHROMATOGR LIBR, V54, P253; Goodacre R, 1998, MICROBIOL-UK, V144, P1157; Haag H, 1996, J MICROBIOL METH, V27, P157, DOI 10.1016/S0167-7012(96)00943-8; HELM D, 1991, J GEN MICROBIOL, V137, P69; HENDRY KM, 1993, J TOXICOL ENV HEALTH, V38, P183; Kirschner C, 2001, J CLIN MICROBIOL, V39, P1763, DOI 10.1128/JCM.39.5.1763-1770.2001; Klich M.A., 2002, IDENTIFICATION COMMO; Kummerle M, 1998, APPL ENVIRON MICROB, V64, P2207; LACEY J, 1994, J AEROSOL SCI, V25, P1371, DOI 10.1016/0021-8502(94)90215-1; LARSEN TO, 1995, MYCOL RES, V99, P1153; LARSEN TO, 1995, MYCOL RES, V99, P1167; Miller J. D., 1994, ORGANIC DUSTS EXPOSU, P87; Mitchell Julian I., 1995, Mycologist, V9, P67; Mohacek-Grosev V, 2001, SPECTROCHIM ACTA A, V57, P2815, DOI 10.1016/S1386-1425(01)00584-4; NAUMANN D, 1991, NATURE, V351, P81, DOI 10.1038/351081a0; Naumann D., 1990, BUNDESGESUNDHEITSBLA, V33, P387; NICHOLS PD, 1985, J MICROBIOL METH, V4, P79, DOI 10.1016/0167-7012(85)90023-5; Orsini F, 2000, J MICROBIOL METH, V42, P17, DOI 10.1016/S0167-7012(00)00168-8; Pitt JI, 1979, GENUS PENICILLIUM; Pitt JI, 1985, FUNGI FOOD SPOILAGE; Pitt JL, 1988, LAB GUIDE COMMON PEN; Raper K B, 1977, GENUS ASPERGILLUS; Riedel A, 1996, PHARM IND, V58, P853; Robbins C A, 2000, Appl Occup Environ Hyg, V15, P773; Rozynek P, 2004, INT J HYG ENVIR HEAL, V207, P297, DOI 10.1078/1438-4639-00289; Samson RA, 2000, INTRO FOOD AIRBORNE; Sandt C, 2003, J CLIN MICROBIOL, V41, P954, DOI 10.1128/JCM.41.3.954-959.2003; Schmalreck AF, 2000, MYCOSES, V43, P61; Schmitt J, 1998, INT BIODETER BIODEGR, V41, P1, DOI 10.1016/S0964-8305(98)80002-4; SELTMANN G, 1995, ZBL BAKT-INT J MED M, V282, P372; SELTMANN G, 1994, EPIDEMIOL INFECT, V113, P411; SOCKALINGUM GW, 1997, BIOCHEM BIOPH RES CO, V23, P240; Sugiyama Junta, 1998, Mycoscience, V39, P487, DOI 10.1007/BF02460912; SVENDSEN A, 1994, MYCOL RES, V98, P1317; Timmins EM, 1998, J CLIN MICROBIOL, V36, P367; Timmins EM, 1998, YEAST, V14, P885, DOI 10.1002/(SICI)1097-0061(199807)14:10<885::AID-YEA286>3.0.CO;2-G; Tintelnot K, 2000, J CLIN MICROBIOL, V38, P1599; Wenning M, 2002, APPL ENVIRON MICROB, V68, P4717, DOI 10.1128/AEM.68.10.4717-4721.2002	48	93	97	2	21	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-7012			J MICROBIOL METH	J. Microbiol. Methods	JAN	2006	64	1					63	77		10.1016/j.mimet.2005.04.005		15	Biochemical Research Methods; Microbiology	Biochemistry & Molecular Biology; Microbiology	003PU	WOS:000234694900006	16229914	
J	Matura, M; Skold, M; Borje, A; Andersen, KE; Bruze, M; Frosch, P; Goossens, A; Johansen, JD; Svedman, C; White, IR; Karlberg, AT				Matura, M; Skold, M; Borje, A; Andersen, KE; Bruze, M; Frosch, P; Goossens, A; Johansen, JD; Svedman, C; White, IR; Karlberg, AT			Selected oxidized fragrance terpenes are common contact allergens	CONTACT DERMATITIS			English	Article						allergic contact dermatitis; autoxidation; caryophyllene; fragrance allergy; fragrance mix; hydroperoxides; linalool; myrcene; oxidation products; patch testing	AIRBORNE COMPOSITAE DERMATITIS; D-LIMONENE; HAND ECZEMA; COLOPHONY; OIL; SENSITIZATION; LINALOOL; HYDROPEROXIDE; MONOTERPENES; TURPENTINE	Terpenes are widely used fragrance compounds in fine fragrances, but also in domestic and occupational products. Terpenes oxidize easily due to autoxidation on air exposure. Previous studies have shown that limonene, linalool and caryophyllene are not allergenic themselves but readily form allergenic products on air-exposure. This study aimed to determine the frequency and characteristics of allergic reactions to selected oxidized fragrance terpenes other than limonene. In total 1511 consecutive dermatitis patients in 6 European dermatology centres were patch tested with oxidized fragrance terpenes and some oxidation fractions and compounds. Oxidized linalool and its hydroperoxide fraction were found to be common contact allergens. Of the patients tested, 1.3% showed a positive reaction to oxidized linalool and 1.1% to the hydroperoxide fraction. About 0.5% of the patients reacted to oxidized caryophyllene whereas 1 patient reacted to oxidized myrcene. Of the patients reacting to the oxidized terpenes, 58% had fragrance-related contact allergy and/or a positive history for adverse reaction to fragrances. Autoxidation of fragrance terpenes contributes greatly to fragrance allergy, which emphasizes the need of testing with compounds that patients are actually exposed to and not only with the ingredients originally applied in commercial formulations.	Gothenburg Univ, Dept Chem, SE-41296 Gothenburg, Sweden; Sahlgrenska Univ Hosp, Dept Dermatol, Gothenburg, Sweden; Univ So Denmark, Odense Univ Hosp, Dept Dermatol, Odense, Denmark; Univ Hosp, Dept Occupat & Environm Dermatol, Malmo, Sweden; Dept Dermatol, Dortmund, Germany; Univ Witten Herdecke, Dortmund, Germany; Catholic Univ Leuven, Univ Hosp, Dept Dermatol, Louvain, Belgium; Univ Copenhagen, Gentofte Hosp, Dept Dermatol, Natl Allergy Res Ctr, Copenhagen, Denmark; St Thomas Hosp, St Johns Inst Dermatol, London, England	Matura, M (reprint author), Gothenburg Univ, Dept Chem, SE-41296 Gothenburg, Sweden.	mihaly.matura@chem.gu.se	Borje, Anna/A-7581-2010; Karlberg, Ann-Therese/A-7706-2010; andersen, klaus/H-2117-2011				Al-Malaika S., 1993, ATMOSPHERIC OXIDATIO, VI, P45, DOI 10.1016/B978-0-444-89615-5.50006-8; Andersen KE, 1998, CONTACT DERMATITIS, V38, P222, DOI 10.1111/j.1600-0536.1998.tb05718.x; BRUZE M, 1986, CONTACT DERMATITIS, V14, P119, DOI 10.1111/j.1600-0536.1986.tb01178.x; Christensen LP, 1999, ARCH DERMATOL RES, V291, P425, DOI 10.1007/s004030050433; CRONIN E, 1979, CONTACT DERMATITIS, V5, P308, DOI 10.1111/j.1600-0536.1979.tb04884.x; DeGroot AC, 1997, CONTACT DERMATITIS, V36, P57; DEGROOT AC, 1983, CONTACT DERMATITIS, V9, P230; DOOMSGOOSSENS A, 1977, CONTACT DERMATITIS, V3, P304, DOI 10.1111/j.1600-0536.1977.tb03692.x; Farm G, 1996, CONTACT DERMATITIS, V34, P93, DOI 10.1111/j.1600-0536.1996.tb02137.x; Fregert S, 1969, CONTACT DERMATITIS N, V5, P85; Frosch PJ, 2005, CONTACT DERMATITIS, V52, P207, DOI 10.1111/j.0105-1873.2005.00565.x; Frosch PJ, 1999, BRIT J DERMATOL, V141, P1076, DOI 10.1046/j.1365-2133.1999.03208.x; GROOT A, 1994, UNWANTED EFFECTS COS; HELLERSTROM S, 1955, J INVEST DERMATOL, V24, P217; Heydorn S, 2003, CONTACT DERMATITIS, V48, P317, DOI 10.1034/j.1600-0536.2003.00133.x; Heydorn S, 2003, CONTACT DERMATITIS, V48, P59, DOI 10.1034/j.1600-0536.2003.480201.x; Johansen JD, 2001, CONTACT DERMATITIS, V44, P304, DOI 10.1034/j.1600-0536.2001.440510.x; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; Johansen Jeanne Duus, 2002, Contact Dermatitis, V46, P1; KARLBERG AT, 1994, ARCH DERMATOL RES, V286, P97, DOI 10.1007/BF00370734; KARLBERG AT, 1992, CONTACT DERMATITIS, V26, P332, DOI 10.1111/j.1600-0536.1992.tb00129.x; KARLBERG AT, 1985, BRIT J DERMATOL, V113, P475, DOI 10.1111/j.1365-2133.1985.tb02363.x; Karlberg AT, 1996, CONTACT DERMATITIS, V35, P201, DOI 10.1111/j.1600-0536.1996.tb02358.x; Karlberg AT, 1997, CONTACT DERMATITIS, V36, P201, DOI 10.1111/j.1600-0536.1997.tb00270.x; Matura M, 2002, J AM ACAD DERMATOL, V47, P709, DOI 10.1067/mjd.2002.124817; Matura M, 2003, CONTACT DERMATITIS, V49, P15, DOI 10.1111/j.0105-1873.2003.00135.x; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; OPDYKE DLJ, 1976, FOOD COSMET TOXICOL, V14, P615, DOI 10.1016/S0015-6264(76)80022-3; PAULSEN E, 1993, CONTACT DERMATITIS, V29, P138, DOI 10.1111/j.1600-0536.1993.tb03511.x; Paulsen E, 2002, CONTACT DERMATITIS, V47, P14, DOI 10.1034/j.1600-0536.2002.470103.x; Rastogi SC, 1998, CONTACT DERMATITIS, V39, P293, DOI 10.1111/j.1600-0536.1998.tb05944.x; Rastogi SC, 1998, CONTACT DERMATITIS, V38, P29, DOI 10.1111/j.1600-0536.1998.tb05633.x; Rastogi SC, 2001, CONTACT DERMATITIS, V45, P221, DOI 10.1034/j.1600-0536.2001.450406.x; RYCROFT RJG, 1980, CONTACT DERMATITIS, V6, P325, DOI 10.1111/j.1600-0536.1980.tb04957.x; SCHALLER M, 1995, CLIN EXP DERMATOL, V20, P143; Schnuch A, 2004, CONTACT DERMATITIS, V50, P117, DOI 10.1111/j.0105-1873.2004.0313.x; Skold M, 2004, CHEM RES TOXICOL, V17, P1697, DOI 10.1021/tx049831z; Skold M, 2002, CONTACT DERMATITIS, V46, P267, DOI 10.1034/j.1600-0536.2002.460504.x; SKOLD M, 2005, UNPUB FRAGRANCE CHEM; Sugiura M, 2000, CONTACT DERMATITIS, V43, P157, DOI 10.1034/j.1600-0536.2000.043003157.x; Verghese J., 1994, PAFAI J, V16, P21; VESTEY JP, 1986, CONTACT DERMATITIS, V15, P119, DOI 10.1111/j.1600-0536.1986.tb01310.x; Wahlberg J, 1995, TXB CONTACT DERMATIT, P241; Wakelin SH, 1998, CONTACT DERMATITIS, V38, P164, DOI 10.1111/j.1600-0536.1998.tb05686.x; Wohrl S, 2001, BRIT J DERMATOL, V145, P268, DOI 10.1046/j.1365-2133.2001.04345.x	45	93	96	3	28	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	JUN	2005	52	6					320	328		10.1111/j.0105-1873.2005.00605.x		9	Allergy; Dermatology	Allergy; Dermatology	931OS	WOS:000229495200007	15932583	
J	Brussee, JE; Smit, HA; van Strien, RT; Corver, K; Kerkhof, M; Wijga, AH; Aalberse, RC; Postma, D; Gerritsen, J; Grobbee, DE; de Jongste, JC; Brunekreef, B				Brussee, JE; Smit, HA; van Strien, RT; Corver, K; Kerkhof, M; Wijga, AH; Aalberse, RC; Postma, D; Gerritsen, J; Grobbee, DE; de Jongste, JC; Brunekreef, B			Allergen exposure in infancy and the development of sensitization, wheeze, and asthma at 4 years	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						cohort studies; child; preschool; allergens; house dust mites; cats; dogs; sensitization; wheezing; asthma	HOUSE-DUST MITE; BIRTH COHORT; MATERNAL HISTORY; INDOOR ALLERGENS; RISK-FACTOR; 1ST YEAR; LIFE; CHILDHOOD; ATOPY; PET	Background: The relationship between mite and pet allergen exposure in infancy and the subsequent development of sensitization and asthma is complex. Objective: We prospectively investigated the effect of allergen exposure at 3 months of age on the development of sensitization, wheeze, and physician-diagnosed asthma in the first 4 years of life in a birth cohort of children with and without an atopic mother. Methods: Children participated in the Prevention and Incidence of Asthma and Mite Allergy study. Allergen exposure at 3 months of age was determined from mattress dust samples. Specific IgE to inhalant allergens was measured at 4 years of age, and information about wheeze and physician-diagnosed asthma was collected with yearly questionnaires. Results: Mite and cat allergen exposure in infancy were associated with an increased risk of specific sensitization to house dust mite and cat, respectively, at 4 years of age. There were borderline significant associations between cat allergen exposure and persistent wheeze in the total study population and between dog allergen exposure and persistent wheeze in children with a nonatopic mother. In children with an atopic mother, there was some indication of a positive association between mite allergen exposure and physician-diagnosed asthma. Conclusion: Early house dust mite and cat allergen exposure might lead to sensitization and, in case of cat allergen exposure, to persistent wheeze. Early mite and dog allergen exposure might lead to asthma and persistent wheeze, respectively, but only in subgroups defined by maternal atopy.	Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; Univ Munich, Inst Occupat & Environm Med, Munich, Germany; Erasmus MC, Dept Pediat, Div Resp Med, Rotterdam, Netherlands; Univ Groningen, Dept Epidemiol & Stat, Groningen, Netherlands; Sanquin Res CLB, Dept Immunopathol, Amsterdam, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Groningen Hosp, Dept Paediat Resp Med, Groningen, Netherlands; Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands	Smit, HA (reprint author), Natl Inst Publ Hlth & Environm, Ctr Prevent & Hlth Serv Res, POB 1, NL-3720 BA Bilthoven, Netherlands.	jet.smit@rivm.nl	Kerkhof, Marjan/A-8846-2008; Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468; brunekreef, bert/0000-0001-9908-0060			Almqvist C, 2003, CLIN EXP ALLERGY, V33, P1190, DOI 10.1046/j.1365-2222.2003.01764.x; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Belanger K, 2003, AM J EPIDEMIOL, V158, P195, DOI 10.1093/aje/kwg148; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Brussee JE, 2004, AM J RESP CRIT CARE, V169, P209, DOI 10.1164/rccm.200306-800OC; Carter PM, 2003, ANN ALLERG ASTHMA IM, V90, P41; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; COLLOFF MJ, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb01763.x; Crestani E, 2004, J ALLERGY CLIN IMMUN, V113, P284, DOI 10.1016/j.jaci.2003.11.009; Cullinan P, 2004, THORAX, V59, P855, DOI 10.1136/thx.2003.019877; Gehring U, 2004, ENVIRON HEALTH PERSP, V112, P834, DOI 10.1289/ehp.6685; Johnson CC, 2004, J ALLERGY CLIN IMMUN, V114, P105, DOI 10.1016/j.jaci.2004.04.007; Lakwijk N, 1998, CLIN EXP ALLERGY, V28, P454; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Murray C S, 2001, Curr Opin Allergy Clin Immunol, V1, P407, DOI 10.1097/00130832-200110000-00005; Nafstad P, 2001, ALLERGY, V56, P307, DOI 10.1034/j.1398-9995.2001.00881.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Pearce N, 2000, THORAX, V55, P424, DOI 10.1136/thorax.55.5.424; Platts-Mills TA, 2000, J ALLERGY CLIN IMMUN, V105, P503; Polk S, 2004, AM J RESP CRIT CARE, V170, P273, DOI 10.1164/rccm.200310-1348OC; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Sandin A, 2004, PEDIATR ALLERGY IMMU, V15, P316, DOI 10.1111/j.1399-3038.2004.00166.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; van Strien RT, 2003, CLIN EXP ALLERGY, V33, P490, DOI 10.1046/j.1365-2222.2003.01626.x; van Strien RT, 2002, ENVIRON HEALTH PERSP, V110, pA693; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7	29	93	97	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2005	115	5					946	952		10.1016/j.jaci.2005.02.035		7	Allergy; Immunology	Allergy; Immunology	925LR	WOS:000229055100008	15867850	
J	Velasco, G; Campo, M; Manrique, OJ; Bellou, A; He, HZ; Arestides, RSS; Schaub, B; Perkins, DL; Finn, PW				Velasco, G; Campo, M; Manrique, OJ; Bellou, A; He, HZ; Arestides, RSS; Schaub, B; Perkins, DL; Finn, PW			Toll-like receptor 4 or 2 agonists decrease allergic inflammation	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						innate; immunity; asthma; Toll-like receptor 4; Toll-like receptor 2; allergy	AIRWAY HYPERRESPONSIVENESS; PULMONARY INFLAMMATION; IMMUNE-RESPONSES; MURINE MODEL; BACTERIAL LIPOPOLYSACCHARIDE; DENDRITIC CELLS; TH2 RESPONSES; T-CELLS; ASTHMA; ENDOTOXIN	Toll-like receptors (TLRs) recognize highly conserved microbial molecular patterns, such as found in endotoxin. This study tested whether TLR4 and TLR2 stimulation in vivo would modulate subsequent adaptive (allergic) immune responses. We analyzed the effects of pulmonary administration of a TLR4 agonist, lipid A (LpA), and two TLR2 agonists, peptidoglycan (Ppg) and PamCys, in a murine model of allergic inflammation. The TLR agonists were administered during allergen sensitization or challenge. Both TLR agonists decreased the allergen-induced pulmonary recruitment of eosinophils when administered at sensitization or challenge. When given before sensitization, the TLR4 and TLR2 agonists decreased additional allergen-induced parameters of inflammation (pulmonary eosinophilia, bronchoalveolar lavage IL-13, total serum IgE, and airway hyperresponsiveness). Interestingly, TLR4 and TLR2 agonists decreased the number of CD4+ cells in the lung. Also, at the site of local allergen stimulation, the draining thoracic lymph nodes, allergen-induced lymphocyte proliferation, and IL-13 secretion were decreased by administration of LpA and Ppg. These data provide a distinct example of the modulation of adaptive (allergic) responses by non-antigen-dependent stimuli. Our findings also demonstrate that both TLR4 and TLR2 agonists decrease allergic responses, supporting the concept that exposure to bacterial components under defined conditions may protect against allergic disease.	Brigham & Womens Hosp, Div Resp & Crit Care, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Lab Immunogenet & Transplant, Boston, MA 02115 USA	Finn, PW (reprint author), Brigham & Womens Hosp, Div Resp & Crit Care, 75 Francis St, Boston, MA 02115 USA.	pwfinn@rics.bwh.harvard.edu			NHLBI NIH HHS [HL 56723, HL 67684]		Adler A, 2004, J APPL PHYSIOL, V97, P286, DOI 10.1152/japplphysiol.00821.2003; Akdis CA, 2003, EUR J IMMUNOL, V33, P2717, DOI 10.1002/eji.200323329; Arestides RSS, 2002, EUR J IMMUNOL, V32, P2874, DOI 10.1002/1521-4141(2002010)32:10<2874::AID-IMMU2874>3.0.CO;2-4; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Banerjee B, 2004, INFECT IMMUN, V72, P6087, DOI 10.1128/IAI.72.10.6087-6094.2004; Bellou Abdelouahab, 2003, Curr Opin Allergy Clin Immunol, V3, P487, DOI 10.1097/00130832-200312000-00011; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Broide DH, 2001, J CLIN IMMUNOL, V21, P175, DOI 10.1023/A:1011078930363; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chisholm D, 2004, J ALLERGY CLIN IMMUN, V113, P448, DOI 10.1016/j.jaci.2003.12.011; Dabbagh K, 2003, CURR OPIN INFECT DIS, V16, P199, DOI 10.1097/01.qco.0000073767.11390.47; Dodge IL, 2003, J IMMUNOL, V170, P4457; Donovan CE, 1999, J IMMUNOL, V163, P6827; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Gelman AE, 2004, J IMMUNOL, V172, P6065; Gerhold K, 2003, J ALLERGY CLIN IMMUN, V112, P389, DOI 10.1067/mai.2003.1646; Gerhold K, 2002, J ALLERGY CLIN IMMUN, V110, P110, DOI 10.1067/mai.2002.125831; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Krinzman SJ, 1996, AM J PHYSIOL-LUNG C, V271, pL476; Krinzman SJ, 1996, J CLIN INVEST, V98, P2693, DOI 10.1172/JCI119093; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; LIO J, 2000, INT ARCH ALLERGY IMM, V127, P217; Mark DA, 2000, AM J RESP CELL MOL, V22, P265; Mark DA, 1998, INT IMMUNOL, V10, P1647, DOI 10.1093/intimm/10.11.1647; Redecke V, 2004, J IMMUNOL, V172, P2739; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Rodriguez D, 2003, J IMMUNOL, V171, P1001; Schwartz DA, 2001, AM J RESP CRIT CARE, V163, P305; Schwartz DA, 1994, AM J PHYSIOL, V267, P609; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Tulic MK, 2000, AM J RESP CELL MOL, V22, P604; Wan GH, 2000, CLIN EXP ALLERGY, V30, P426; Watanabe J, 2003, J BIOL CHEM, V278, P42361, DOI 10.1074/jbc.M307752200; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648	38	93	99	1	13	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAR	2005	32	3					218	224		10.1165/rcmb.2003-0435OC		7	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	900DS	WOS:000227196200007	15576672	
J	Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Friedman, W; Zeldin, DC				Arbes, SJ; Cohn, RD; Yin, M; Muilenberg, ML; Friedman, W; Zeldin, DC			Dog allergen (Can f 1) and cat allergen (Fel d 1) in US homes: Results from the National Survey of Lead and Allergens in Housing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergens; asthma; cat allergen; Can f 1; dog allergen; epidemiology; Fel d 1; survey	DUST MITE; D-I; COCKROACH ALLERGENS; DOMESTIC ALLERGENS; PUBLIC PLACES; PARTICLE-SIZE; RISK-FACTORS; LOS-ALAMOS; NEW-MEXICO; F I	Background: Exposures to dog and cat allergens are believed to play important roles in the etiology of asthma; however, the levels of these allergens have never been assessed in a representative sample of US homes. Objective: The objective of this study was to estimate and characterize exposures to Can f 1 (dog allergen) and Fell d 1 (cat allergen) in US homes. Methods: Data were obtained from the National Survey of Lead and Allergens in Housing, a nationally representative survey of 831 US homes. Vacuumed-collected dust samples from the bed, bedroom floor, living room floor, and living room sofa were analyzed for concentrations of Can f 1 and Fel d 1 (micrograms of allergen per gram of dust). Results: Although a dog or cat had lived in only 49.1% of homes in the previous 6 months, Can f 1 and Fel d 1 were detected in 100% and 99.9% of homes, respectively. Averaged over the sampled sites, geometric mean concentrations (mug/g) were 4.69 for Can f 1 and 4.73 for Fel d 1. Among homes with an indoor dog and cat, respectively, geometric mean concentrations were 69 for Can f 1 and 200 for Fel d 1. Among homes without the indoor pet, geometric mean concentrations were above 1.0. The independent predictors of elevated concentrations in homes without pets were all demographic variables that were also linked to a higher prevalence of pet ownership. Conclusions: Can f 1 and Fel d 1 are universally present in US homes. Levels that have been associated with an increased risk of allergic sensitization were found even in homes without pets. Because of the transportability of these allergens on clothing, elevated levels in homes without pets, particularly among demographic groups in which pet ownership is more prevalent, implicate the community as an important source of these pet allergens.	NIEHS, NIH, Res Triangle Pk, NC 27709 USA; Constella Grp Inc, Durham, NC USA; Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; US Dept Housing & Urban Dev, Off Healthy Homes & Lead Hazard Control, Washington, DC USA	Zeldin, DC (reprint author), NIEHS, NIH, POB 12233,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.						Almqvist C, 1999, J ALLERGY CLIN IMMUN, V103, P1012, DOI 10.1016/S0091-6749(99)70172-7; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Berge M, 1998, PEDIATR ALLERGY IMMU, V9, P25, DOI 10.1111/j.1399-3038.1998.tb00296.x; Bollinger ME, 1996, J ALLERGY CLIN IMMUN, V97, P907, DOI 10.1016/S0091-6749(96)80064-9; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53; Custovic A, 1996, CLIN EXP ALLERGY, V26, P1246, DOI 10.1046/j.1365-2222.1996.d01-278.x; Custovic A, 1997, AM J RESP CRIT CARE, V155, P94; DEBLAY F, 1991, AM REV RESPIR DIS, V143, P1334; EGGLESTON PA, 1992, ALLERGY PROC, V13, P289, DOI 10.2500/108854192778816942; ENBERG RN, 1993, ANN ALLERGY, V70, P471; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GERGEN PJ, 1992, J ALLERGY CLIN IMMUN, V90, P579, DOI 10.1016/0091-6749(92)90130-T; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Jacobs DE, 2002, ENVIRON HEALTH PERSP, V110, pA599; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361; MUNIR AKM, 1993, J ALLERGY CLIN IMMUN, V91, P1067, DOI 10.1016/0091-6749(93)90221-Z; Nelson RP, 1996, J ALLERGY CLIN IMMUN, V98, P258, DOI 10.1016/S0091-6749(96)70148-3; Partti-Pellinen K, 2000, ALLERGY, V55, P65, DOI 10.1034/j.1398-9995.2000.00226.x; Patchett K, 1997, J ALLERGY CLIN IMMUN, V100, P755, DOI 10.1016/S0091-6749(97)70269-0; Plaschke P, 1999, ALLERGY, V54, P843, DOI 10.1034/j.1398-9995.1999.00162.x; Platts-Mills TA, 1997, J ALLERGY CLIN IMM S, V100, P2; PLATTSMILLS TAE, 1995, INT ARCH ALLERGY IMM, V107, P301; Pope A. M., 1993, INDOOR ALLERGENS ASS; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; SCHOU C, 1991, J ALLERGY CLIN IMMUN, V88, P847, DOI 10.1016/0091-6749(91)90240-O; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527; WOOD RA, 1992, J ALLERGY CLIN IMMUN, V89, P126, DOI 10.1016/S0091-6749(05)80049-1	32	93	97	1	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2004	114	1					111	117		10.1016/j.jaci.2004.04.036		7	Allergy; Immunology	Allergy; Immunology	836DA	WOS:000222534300016	15241352	
J	Svanes, C; Omenaas, E; Jarvis, D; Chinn, S; Gulsvik, A; Burney, P				Svanes, C; Omenaas, E; Jarvis, D; Chinn, S; Gulsvik, A; Burney, P			Parental smoking in childhood and adult obstructive lung disease: results from the European Community Respiratory Health Survey	THORAX			English	Article							MATERNAL SMOKING; TOBACCO-SMOKE; CIGARETTE-SMOKING; YOUNG-ADULTS; ASTHMA; EXPOSURE; LIFE; PREVALENCE; PREGNANCY; POPULATION	Background: Early exposure to parental smoking appears to influence the development of the airways and predispose to respiratory symptoms. A study was undertaken to determine whether the consequences of parental smoking could be traced in adulthood. Methods: Information from interviewer-led questionnaires was available for 18922 subjects aged 20-44 years from random population samples in 37 areas participating in the European Community Respiratory Health Survey. Lung function data were available for 15-901 subjects. Results: In men, father's smoking in childhood was associated with more respiratory symptoms (ORwheeze 1.13 (95% CI 1.00 to 1.28); never smokers: ORwheeze 1.21 (95% CI 0.96 to 1.50)) and there was a dose-dependent association between number of parents smoking and wheeze (one: OR 1.08 (95% CI 0.94 to 1.24); both: OR 1.24 (95% CI 1.05 to 1.47); p(trend)=0.010). A reduced ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC) was related to father's smoking (-0.3% (95% CI -0.6 to 0)) and number of parents smoking (p(trend)<0.001) among men. In women, mother's smoking was associated with more respiratory symptoms and poorer lung function (ORwheeze 1.15 (95% CI 1.01 to 1.31), never smokers: ORwheeze 1.21 (95% CI 0.98-1.51); FEV1-24 ml (95% CI -45 to -3); FEV1/FVC ratio -0.6% (95% CI -0.9 to -0.3)). These effects were possibly accounted for by maternal smoking in pregnancy (ORwheeze 1.39 (95% CI 1.17 to 1.65); FEV1-23 ml (95% CI -52 to 7); FEV1/FVC ratio -0.9% (95% CI -1.3 to -0.4)) as there was no association with paternal smoking among women (interaction by sex, p<0.05). These results were homogeneous across centres. Conclusion: Both intrauterine and environmental exposure to parental tobacco smoking was related to more respiratory symptoms and poorer lung function in adulthood in this multicultural study. The age window of particular vulnerability appeared to differ by sex, postnatal exposure being important only in men and a role for prenatal exposure being more evident in women.	Haraldsplass Hosp, Dept Med, N-5009 Bergen, Norway; Haukeland Univ Hosp, Dept Thorac Med, N-5021 Bergen, Norway; Univ London Kings Coll, Dept Publ Hlth Sci, London SE1 3QD, England	Svanes, C (reprint author), Haraldsplass Hosp, Dept Med, N-5009 Bergen, Norway.	cecilie.svanes@med.uib.no	Jarvis, Deborah/E-6494-2011		NCRR NIH HHS [S07 RR05521-28]		Becklake MR, 1999, THORAX, V54, P1119; Burney P, 1997, J ALLERGY CLIN IMMUN, V99, P314, DOI 10.1016/S0091-6749(97)70048-4; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Carlsen KCL, 1997, EUR RESPIR J, V10, P1774; Chinn S, 1997, EUR RESPIR J, V10, P2495, DOI 10.1183/09031936.97.10112495; COLLINS MH, 1985, PEDIATR RES, V19, P408; Cook DG, 1997, THORAX, V52, P1081; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; ESCOLAR JD, 1995, EXP LUNG RES, V21, P255, DOI 10.3109/01902149509068831; *EUR COMM RESP HLT, 1994, MED HLTH EC DIR GEN, V13; Gold DR, 1996, NEW ENGL J MED, V335, P931, DOI 10.1056/NEJM199609263351304; HANRAHAN JP, 1992, AM REV RESPIR DIS, V145, P1129; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; JENKINS MA, 1994, BRIT MED J, V309, P90; Larsson ML, 2001, CHEST, V120, P711, DOI 10.1378/chest.120.3.711; Leynaert B, 1997, AM J RESP CRIT CARE, V156, P1413; MASI MA, 1988, AM REV RESPIR DIS, V138, P296; Morgan WJ, 1998, AM J RESP CRIT CARE, V158, P689; Office of Population Censuses and Surveys, 1980, CLASS OCC; POLGAR G, 1979, AM REV RESPIR DIS, V120, P625; Prescott E, 1997, EUR RESPIR J, V10, P822; Roca J, 1998, EUR RESPIR J, V11, P1354, DOI 10.1183/09031936.98.11061354; RONA RJ, 1993, THORAX, V48, P21, DOI 10.1136/thx.48.1.21; Stein RT, 1999, AM J EPIDEMIOL, V149, P1030; Stick SM, 1996, LANCET, V348, P1060, DOI 10.1016/S0140-6736(96)04446-7; Strachan DP, 1996, BRIT MED J, V312, P1195; Strachan DP, 1998, THORAX, V53, P204; TAGER IB, 1995, AM J RESP CRIT CARE, V152, P977; Upton MN, 1998, LANCET, V352, P453, DOI 10.1016/S0140-6736(05)79187-X; Wasowicz Marcin, 1994, Polish Journal of Pathology, V45, P155	30	93	95	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	APR 1	2004	59	4					295	302		10.1136/thx.2003.009746		8	Respiratory System	Respiratory System	807CT	WOS:000220480300007	15047948	
J	Dales, RE; Cakmak, S; Judek, S; Dann, T; Coates, F; Brook, JR; Burnett, RT				Dales, RE; Cakmak, S; Judek, S; Dann, T; Coates, F; Brook, JR; Burnett, RT			Influence of outdoor aeroallergens on hospitalization for asthma in Canada	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; fungus; pollen; air pollution; epidemiology	INHALED ALLERGEN; AIRWAY RESPONSE; OZONE EXPOSURE; POLLEN	Background: The risk of hospitalization for asthma caused by outdoor aeroallergens is largely unknown. Objective: The objective of this study was to determine the association between changes in outdoor aeroallergens and hospitalizations for asthma from the Pacific coast to the Atlantic coast of Canada. Methods: A daily time series analysis was done to test the association between daily changes in aeroallergens and daily changes in hospitalizations for asthma during a 7-year period between 1993 and 2000 in 10 of the largest cities in Canada. Results were adjusted for long-term trends, day of the week, climate, and air pollution. Results: A daily increase, equivalent to the mean value of each allergen, was associated with the following percentage increase in asthma hospitalizations: 3.3% (95% CI, 2.3 to 4.1) for basidiomycetes, 3.1 % (95 % CI, 2.8 to 5.7) for ascomycetes, 3.2% (95% CI, 1.6 to 4.8) for deuteromycetes, 3.0% (95% CI, 1.1 to 4.9) for weeds, 2.9 % (95 % CI, 0.9 to 5.0) for trees, and 2.0% (95% CI, 1.1 to 2.8) for grasses. After accounting for the independent effects of trees and ozone, the combination of the 2 was associated with an additional 0.22% increase in admissions averaged across cities (P < .05). Conclusion: These findings provide evidence for the hypothesis that aeroallergens are an important cause of severe asthma morbidity across Canada,, and in some situations there might be a modest synergistic adverse effect of ozone and aeroallergens combined.	Univ Ottawa, Ottawa, ON K1N 6N5, Canada; Ottawa Hlth Res Inst, Ottawa, ON, Canada; Hlth Canada, Ottawa, ON, Canada	Dales, RE (reprint author), Ottawa Gen Hosp, Gen Campus,501 Smyth Rd,Box 211, Ottawa, ON K1H 8L6, Canada.			Cakmak, Sabit/0000-0001-9921-2107			AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; Hoog GSde, 2000, ATLAS CLIN FUNGI, P1; Delfino RJ, 1996, AM J RESP CRIT CARE, V154, P633; Delfino RJ, 1997, AM J RESP CRIT CARE, V155, P568; Epton MJ, 1997, THORAX, V52, P528; HASTIE T, 1990, GEN ADDICTIVE MODELS; Hoek G, 1997, ARCH ENVIRON HEALTH, V52, P455; Jenkins HS, 1999, AM J RESP CRIT CARE, V160, P33; LEHRER SB, 1994, ALLERGY, V49, P460, DOI 10.1111/j.1398-9995.1994.tb00840.x; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P1724, DOI 10.1046/j.1365-2222.2000.00947.x; Lierl MB, 2003, ANN ALLERG ASTHMA IM, V90, P28; LOPEZ M, 1989, J ALLERGY CLIN IMMUN, V84, P246; McCallagh P, 1989, GEN LINEAR MODELS; MOLFINO NA, 1991, LANCET, V338, P199, DOI 10.1016/0140-6736(91)90346-Q; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; PLATTSMILLS T, 1999, ASTHAM LINK ENV IMMU; SALVAGGIO J, 1971, J ALLERGY CLIN IMMUN, V48, P96, DOI 10.1016/0091-6749(71)90091-1; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633; Schappi GF, 1999, ALLERGY, V54, P478, DOI 10.1034/j.1398-9995.1999.00838.x; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; Vagaggini B, 2002, AM J RESP CRIT CARE, V166, P1073, DOI 10.1164/rccm.2201013; von Mutius E, 2000, J ALLERGY CLIN IMMUN, V105, P9, DOI 10.1016/S0091-6749(00)90171-4	23	93	93	4	8	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2004	113	2					303	306		10.1016/j.jaci.2003.11.016		4	Allergy; Immunology	Allergy; Immunology	773EX	WOS:000188885700019	14767446	
J	Buentke, E; Heffler, LC; Wilson, JL; Wallin, RPA; Lofman, C; Chambers, BJ; Ljunggren, HG; Scheynius, A				Buentke, E; Heffler, LC; Wilson, JL; Wallin, RPA; Lofman, C; Chambers, BJ; Ljunggren, HG; Scheynius, A			Natural killer and dendritic cell contact in lesional atopic dermatitis skin - Malassezia-influenced cell interaction	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article						cell communication; cell death; eczema	NK CELLS; PITYROSPORUM ORBICULARE; MEDIATED LYSIS; HUMAN BLOOD; IN-VIVO; EXPRESSION; RECEPTORS; SUBSETS; FURFUR; MATURATION	The regulation of dendritic cells is far from fully understood. Interestingly, several recent reports have suggested a role for natural killer cells in affecting dendritic cell maturation and function upon direct contact between the cells. It is not known if this interaction takes place also in vivo, or if a potential interaction of natural killer cells and dendritic cells would be affected by allergen exposure of the dendritic cells. The yeast Malassezia can act as an allergen in atopic eczema/dermatitis syndrome, and induce maturation of dendritic cells. Our aims were to study the distribution of natural killer cells in the skin from atopic eczema/dermatitis syndrome patients with the emphasis on possible natural killer cell-dendritic cell interaction, and to assess whether the interaction of Malassezia with dendritic cells would affect subsequent interaction between dendritic cells and natural killer cells. A few scattered natural killer (CD56(+)/CD3(-)) cells were found in the dermis of healthy individuals and in nonlesional skin from atopic eczema/dermatitis syndrome patients. In lesional skin and in biopsies from Malassezia atopy-patch-test-positive skin, however, natural killer cells were differentially distributed and for the first time we could show close contact between natural killer cells and CD1a(+) dendritic cells. Dendritic cells preincubated with Malassezia became less susceptible to natural-killer-cell-induced cell death, suggesting a direct effect imposed by Malassezia upon interaction of dendritic cells with natural killer cells. These findings indicate that natural killer cells and dendritic cells can interact in the skin and that Malassezia affects the interaction between natural killer cells and dendritic cells. Our data suggest that natural killer cells may play a role in regulating dendritic cells in atopic eczema/dermatitis syndrome.	Karolinska Hosp, Karolinska Inst, Dept Med, Unit Clin Allergy Res, S-17176 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, Stockholm, Sweden; Uppsala Univ, Dept Anim Dev & Genet, Uppsala, Sweden	Buentke, E (reprint author), Karolinska Hosp, Karolinska Inst, Dept Med, Unit Clin Allergy Res, L2-04, S-17176 Stockholm, Sweden.			Chambers, Benedict/0000-0003-0437-8441			Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bouloc A, 2000, J INVEST DERMATOL, V115, P1160, DOI 10.1046/j.1523-1747.2000.0202a-4.x; Buentke E, 2000, CLIN EXP ALLERGY, V30, P1759, DOI 10.1046/j.1365-2222.2000.00937.x; Buentke E, 2001, CLIN EXP ALLERGY, V31, P1583, DOI 10.1046/j.1365-2222.2001.01199.x; Carbone E, 1999, EUR J IMMUNOL, V29, P4022, DOI 10.1002/(SICI)1521-4141(199912)29:12<4022::AID-IMMU4022>3.0.CO;2-O; Chambers BJ, 1996, IMMUNITY, V5, P311, DOI 10.1016/S1074-7613(00)80257-5; CHIARELLI F, 1987, BRIT J DERMATOL, V116, P651, DOI 10.1111/j.1365-2133.1987.tb05898.x; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; Eriksson M, 1999, J EXP MED, V190, P1005, DOI 10.1084/jem.190.7.1005; Faergemann J, 1999, ALLERGY, V54, P413, DOI 10.1034/j.1398-9995.1999.00089.x; Ferlazzo G, 2002, J EXP MED, V195, P343, DOI 10.1084/jem.20011149; Ferlazzo G, 2001, IMMUNOL LETT, V76, P37, DOI 10.1016/S0165-2478(00)00323-0; Fernandez NC, 1999, NAT MED, V5, P405; Geldhof AB, 1998, BLOOD, V91, P196; Gerosa F, 2002, J EXP MED, V195, P327, DOI 10.1084/jem.20010938; Goodier MR, 2000, J IMMUNOL, V165, P139; Granucci F, 2001, NAT IMMUNOL, V2, P882, DOI 10.1038/ni0901-882; Grufman P, 2000, EUR J IMMUNOL, V30, P1088, DOI 10.1002/(SICI)1521-4141(200004)30:4<1088::AID-IMMU1088>3.0.CO;2-O; Hashiro M, 1998, J DERMATOL SCI, V16, P231, DOI 10.1016/S0923-1811(97)00074-1; Johansson C, 2002, J INVEST DERMATOL, V118, P1044, DOI 10.1046/j.1523-1747.2002.01758.x; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; JOHNSON GD, 1982, J IMMUNOL METHODS, V55, P231, DOI 10.1016/0022-1759(82)90035-7; Kaburagi Y, 2001, ARCH DERMATOL RES, V293, P350, DOI 10.1007/s004030100230; Korsgren M, 1999, J EXP MED, V189, P553, DOI 10.1084/jem.189.3.553; LESKO MJ, 1989, CLIN EXP ALLERGY, V19, P633, DOI 10.1111/j.1365-2222.1989.tb02759.x; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Linder MT, 2000, CLIN EXP ALLERGY, V30, P122, DOI 10.1046/j.1365-2222.2000.00702.x; Mayser P, 2000, ACTA DERM-VENEREOL, V80, P357, DOI 10.1080/000155500459303; Minter RM, 2001, P NATL ACAD SCI USA, V98, P277, DOI 10.1073/pnas.250489297; Moretta A, 2001, ANNU REV IMMUNOL, V19, P197, DOI 10.1146/annurev.immunol.19.1.197; NAKAMURA S, 1995, AM J SURG PATHOL, V19, P284, DOI 10.1097/00000478-199503000-00006; Piccioli D, 2002, J EXP MED, V195, P335, DOI 10.1084/jem.20010934; ROMANI N, 1994, J EXP MED, V180, P83, DOI 10.1084/jem.180.1.83; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Scheynius A, 2002, INT ARCH ALLERGY IMM, V127, P161, DOI 10.1159/000053860; Spaggiari GM, 2001, EUR J IMMUNOL, V31, P1656, DOI 10.1002/1521-4141(200106)31:6<1656::AID-IMMU1656>3.0.CO;2-V; STRANNEGAARD IL, 1980, ACTA DERM-VENER    S, V92, P48; Vulcano M, 2001, EUR J IMMUNOL, V31, P812, DOI 10.1002/1521-4141(200103)31:3<812::AID-IMMU812>3.0.CO;2-L; WEHRMANN W, 1990, INT ARCH ALLER A IMM, V92, P318; Werfel T, 1998, ALLERGY, V53, P731; Wilson JL, 1999, J IMMUNOL, V163, P6365; ZACHARY CB, 1985, BRIT J DERMATOL, V112, P149, DOI 10.1111/j.1365-2133.1985.tb00078.x; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	46	93	101	0	2	BLACKWELL PUBLISHING INC	MALDEN	350 MAIN ST, MALDEN, MA 02148 USA	0022-202X			J INVEST DERMATOL	J. Invest. Dermatol.	OCT	2002	119	4					850	857		10.1046/j.1523-1747.2002.00132.x		8	Dermatology	Dermatology	612KC	WOS:000179072800013	12406330	
J	Jarvis, D; Chinn, S; Potts, J; Burney, P				Jarvis, D; Chinn, S; Potts, J; Burney, P		European Community Resp Hlth Surve	Association of body mass index with respiratory symptoms and atopy: results from the European Community Respiratory Health Survey	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article							YOUNG-ADULTS; ASTHMA; OBESITY; WEIGHT; OVERWEIGHT; CHILDREN; WHEEZE; LEPTIN; RISK	Background There are several reports showing that obese adults report more respiratory symptoms suggestive of asthma than those who are not obese. Objective To determine the association of body mass index with respiratory symptoms and atopy in young adults Method Information collected from 15 454 participants in the European Community Respiratory Health Survey, a multicentre cross-sectional survey of young adults, was analysed to determine the association of body mass index with respiratory symptoms and atopy. Results Men and women with a body mass index of greater than 30 were at an increased risk of wheeze with shortness of breath compared with those with a body mass of 20-24.99 (OR in men 1.85, 95% confidence interval 1.41-2.42; OR in women 2.03, 95% confidence interval 1.59-2.58). Similar associations were observed for other symptoms suggestive or asthma, Body mass index was not associated with 'hayfever or nasal allergies', specific IgE to house dust mite. grass or cat or with total IgE in men or women. Conclusion Reported associations of body mass index with symptoms suggestive of asthma are unlikely to be explained by a higher risk of atopy in the obese. Alternative explanations must be sought.	Dept Publ Hlth Sci, London SE1 3QD, England	Jarvis, D (reprint author), Dept Publ Hlth Sci, Capital House,42 Weston St, London SE1 3QD, England.		Jarvis, Deborah/E-6494-2011				Bodner C, 1999, EUR RESPIR J, V13, P22, DOI 10.1183/09031936.99.13102299; BURNEY PGJ, 1989, INT J EPIDEMIOL, V18, P165, DOI 10.1093/ije/18.1.165; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; Chen Y, 1999, AM J EPIDEMIOL, V150, P255; Chinn S, 2001, THORAX, V56, P845, DOI 10.1136/thorax.56.11.845; Clement K, 1999, DIABETES, V48, P398, DOI 10.2337/diabetes.48.2.398; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Grievink L, 1999, EUR J CLIN NUTR, V53, P813, DOI 10.1038/sj.ejcn.1600854; Hu GZ, 2000, AM J EPIDEMIOL, V151, P975; Huang SL, 1999, CLIN EXP ALLERGY, V29, P323; Isidori AM, 1999, J CLIN ENDOCR METAB, V84, P3673, DOI 10.1210/jc.84.10.3673; JANSON C, 1995, J INTERN MED, V237, P277; Janson C, 1997, EUR RESPIR J, V10, P1795, DOI 10.1183/09031936.97.10081795; Luder E, 1998, J PEDIATR-US, V132, P699, DOI 10.1016/S0022-3476(98)70363-4; Patterson P E, 1999, Curr Opin Pulm Med, V5, P63, DOI 10.1097/00063198-199901000-00011; Schachter LM, 2001, THORAX, V56, P4, DOI 10.1136/thorax.56.1.4; SEIDELL JC, 1986, AM J PUBLIC HEALTH, V76, P264, DOI 10.2105/AJPH.76.3.264; Shaheen SO, 1999, THORAX, V54, P396; SOMERVILLE SM, 1984, ARCH DIS CHILD, V59, P940; Spicer LJ, 1997, ENDOCRINOLOGY, V138, P3374, DOI 10.1210/en.138.8.3374; Stenius-Aarniala B, 2000, BRIT MED J, V320, P827, DOI 10.1136/bmj.320.7238.827; Tantisira K, 2001, THORAX S2, V56; VALDIVIA GS, 1999, EUR RESPIR J, V14, P143; WHEELDON NM, 1994, BRIT J CLIN PHARMACO, V37, P583; Xu BZ, 2000, J ALLERGY CLIN IMMUN, V105, P393, DOI 10.1016/S0091-6749(00)90095-2	26	93	94	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2002	32	6					831	837		10.1046/j.1365-2222.2002.01380.x		7	Allergy; Immunology	Allergy; Immunology	568NL	WOS:000176548400006	12047427	
J	Rauh, VA; Chew, GL; Garfinkel, RS				Rauh, VA; Chew, GL; Garfinkel, RS			Deteriorated housing contributes to high cockroach allergen levels in inner-city households	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						childhood asthma; cockroach allergens; housing problems; inner-city minority populations	INDOOR ALLERGENS; SOCIOECONOMIC-STATUS; RISK-FACTORS; BLACK-WOMEN; ASTHMA; EXPOSURE; CHILDREN; CHILDHOOD; HEALTH; SENSITIZATION	The high prevalence of childhood asthma in low-income, inner-city populations is not fully understood but has been at least partly attributed to the disproportionate exposures associated with socioeconomic disadvantage. The contribution of indoor allergens to asthma is well documented, but links between socioeconomic disadvantage and indoor allergen levels are not clear. We investigated levels of cockroach allergens (Bla g 2) in a sample of 132 Dominican or African American low-income households with young children in northern Manhattan in New York City (40% were receiving public assistance) to determine whether the distribution of allergens is a function of housing deterioration. Deterioration was measured by the presence and number of physical housing problems (holes in the ceilings and walls, water damage, etc.). More than 50% of the sample had two or more types of housing dilapidation, and 67% of the sample reported cockroach sightings in their homes. Samples of dust were collected from kitchen and bedroom surfaces. We hypothesized that the greater the dilapidation, the higher the allergen levels, independent of income, sociocultural factors, and pest-control methods. In addition, we hypothesized that the homes of families characterized by frequent moves (23.5%) would have higher allergen levels than more stable families. Results showed significant positive associations between housing deterioration and allergen levels in kitchens, after adjusting for income and ethnicity, with independent effects of residential stability (p < 0.05). Bedroom allergen levels were associated with housing instability (p < 0.01) and etlinicity (p < 0.01). Findings demonstrated that indoor household allergen levels are related to degree of household disrepair, after adjusting for individual family attributes, suggesting that social-structural aspects of housing may be appropriate targets for public health interventions designed to reduce allergen exposure.	Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Ctr Populat & Family Hlth, New York, NY 10032 USA; Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA	Rauh, VA (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Heilbrunn Ctr Populat & Family Hlth, 60 Haven Ave,B-2, New York, NY 10032 USA.				NIEHS NIH HHS [5 RO1 ES08977, P50 ES09600]		BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; *CIT COMM CHILDR N, 1995, KEEP TRACK NEW YORK; Claudio L, 2000, Environ Health Perspect, V108, pA450, DOI 10.1289/ehp.108-a450; Dunn JR, 1999, ANN NY ACAD SCI, V896, P399, DOI 10.1111/j.1749-6632.1999.tb08153.x; Duran-Tauleria E, 1999, THORAX, V54, P476; Fullilove M T, 1998, J Am Med Womens Assoc (1972), V53, P72; Fullilove MT, 1996, AM J PSYCHIAT, V153, P1516; GARFIELD R, 1994, WASHINGTON HEIGHTS I; Garrett MH, 1998, AM J RESP CRIT CARE, V158, P891; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Geronimus AT, 2000, AM J PUBLIC HEALTH, V90, P867, DOI 10.2105/AJPH.90.6.867; GOLDSTEIN IF, 1987, ADV AEROBIOL, V51, P133; Hernandez Ramona, 1997, DOMINICAN NEW YORKER; Jones AP, 1998, SOC SCI MED, V47, P755, DOI 10.1016/S0277-9536(98)00151-8; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Klepeis NE, 2001, J EXPO ANAL ENV EPID, V11, P231, DOI 10.1038/sj.jea.7500165; LITTLEJOHNS P, 1993, RESP MED, V87, P139, DOI 10.1016/0954-6111(93)90142-M; MANFREDI C, 1992, AM J PUBLIC HEALTH, V82, P267, DOI 10.2105/AJPH.82.2.267; MAYER SE, 1989, J HUM RESOUR, V24, P88, DOI 10.2307/145934; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; *NY AC MED, 1989, WORKSH HOUS HLTH INT; PLATTSMILLS TAE, 1994, ANN ALLERGY, V72, P381; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; REEB KG, 1987, SOC SCI MED, V25, P1321, DOI 10.1016/0277-9536(87)90130-4; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; ROWLEY DL, 1993, AM J PREV MED, V9, P1; Sampson RJ, 1997, SCIENCE, V277, P918, DOI 10.1126/science.277.5328.918; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; Sexton K, 1988, AIR POLLUTION AUTOMO, P207; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STOKOLS D, 1992, AM PSYCHOL, V47, P6, DOI 10.1037/0003-066X.47.1.6; STRACHAN DP, 1990, J EPIDEMIOL COMMUN H, V44, P231, DOI 10.1136/jech.44.3.231; WALLACE R, 1990, B N Y ACAD MED, V66, P351; 1996, B N Y ACAD MED, V66, P379	39	93	95	2	4	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	APR	2002	110			2			323	327				5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	542WE	WOS:000175066600026	11929744	
J	Fahy, JV				Fahy, JV			Remodeling of the airway epithelium in asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article; Proceedings Paper	16th Annual Transatlantic Airway Conference (TAC)	JAN, 2001	SAN FRANCISCO, CALIFORNIA			asthma; desquamation; epithelium; goblet cell; mucin	GOBLET CELL METAPLASIA; BRONCHOALVEOLAR LAVAGE FLUID; GLAND SEROUS CELLS; MILD ASTHMA; BRONCHIAL EPITHELIUM; MUCUS PRODUCTION; INDUCED SPUTUM; PLASMA EXUDATION; MURINE MODEL; INFLAMMATION	Several pathologic changes occur in the airway epithelium in asthma, but the relationship between these changes and the initiation and progression of asthma remains poorly understood. One possibility is that changes in the structure and function of the epithelium induced by environmental exposure in genetically susceptible subjects represent primary pivotal events that occur early in the pathogenesis of asthma. Alternatively, these epithelial changes may occur simply as a consequence of pivotal early events in other systems, such as immune deviation in childhood to a helper T cell type 2 (Th2) subtype of CD4* cells. Epithelial desquamation in asthma represents a pathologic change that is frequently cited as important for the mechanisms of airway remodeling and airway hyperresponsiveness. Desquamation of the epithelium may not represent true pathology, however, but may instead be an artifact of tissue sampling and handling. Evidence is more firm for other pathologic changes in the epithelium. For example, goblet cell numbers are increased in asthma, leading to increases in stored mucins in the epithelium and in secreted mucins in sputum. The functional consequences of these changes include sputum production and airway narrowing, which lead to asthma exacerbations. Currently available data suggest that an important mechanism for goblet cell hyperplasia in asthma is the action of Th2 cytokines. Improved understanding of epithelial goblet cell abnormalities in asthma will hopefully lead to novel therapies for mucin hypersecretion, which is an important cause of morbidity and mortality.	Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Fahy, JV (reprint author), Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, Box 0111,505 Parnassus Ave, San Francisco, CA 94143 USA.				NHLBI NIH HHS [P50 HL 56385, R01 HL61662]		Agusti C, 1998, AM J RESP CRIT CARE, V158, P1253; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; AIZAWA H, 1988, BRIT J PHARMACOL, V93, P139; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Blyth DI, 1996, AM J RESP CELL MOL, V14, P425; BLYTH DI, 1997, AM J RESP CRIT CARE, V155, pA291; BOLENDER RP, 1993, AM J PHYSIOL, V265, pL521; Boulet LP, 1997, CHEST, V112, P45, DOI 10.1378/chest.112.1.45; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Chanez P, 1999, AM J RESP CRIT CARE, V159, P588; CHUNG KF, 1990, EUR RESPIR J, V3, P329; COCKCROFT DW, 1987, J ALLERGY CLIN IMMUN, V79, P734, DOI 10.1016/0091-6749(87)90204-1; Cohn L, 1998, J IMMUNOL, V161, P3813; Cohn L, 1999, J IMMUNOL, V162, P6178; Cohn L, 1997, J EXP MED, V186, P1737, DOI 10.1084/jem.186.10.1737; Dabbagh K, 1999, J IMMUNOL, V162, P6233; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; FAHY JV, 1993, AM REV RESPIR DIS, V147, pA551; FAHY JV, 2000, AM J RESP CRIT CARE, V161, pA741; FAHY JV, 1998, ALLERGY PRINCIPLES P, P520; FORESI A, 1990, CHEST, V98, P528, DOI 10.1378/chest.98.3.528; GLEICH GJ, 1988, J ALLERGY CLIN IMMUN, V81, P776, DOI 10.1016/0091-6749(88)90931-1; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Henderson WR, 1996, J EXP MED, V184, P1483, DOI 10.1084/jem.184.4.1483; HOUSTON JC, 1953, THORAX, V8, P207, DOI 10.1136/thx.8.3.207; Howard C. V, 1998, UNBIASED STEREOLOGY; Huber HL, 1922, ARCH INTERN MED, V30, P689; JAYAWICKREME SP, 1999, AM J PHYSIOL, V276, pL159; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; KHASHAYAR R, 2000, AM J RESP CRIT CARE, V161, pA204; KIRBY JG, 1987, AM REV RESPIR DIS, V136, P379; Kuperman D, 1998, J EXP MED, V187, P939, DOI 10.1084/jem.187.6.939; LAITINEN LA, 1985, AM REV RESPIR DIS, V131, P599; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lee HM, 2000, AM J PHYSIOL-LUNG C, V278, pL185; Lee JJ, 1997, J EXP MED, V185, P2143, DOI 10.1084/jem.185.12.2143; Li X, 1997, AM J RESP CRIT CARE, V156, P229; Longphre M, 1999, J CLIN INVEST, V104, P1375, DOI 10.1172/JCI6097; Louahed J, 2000, AM J RESP CELL MOL, V22, P649; LOZEWICZ S, 1990, THORAX, V45, P12, DOI 10.1136/thx.45.1.12; LUNDGREN JD, 1991, J ALLERGY CLIN IMMUN, V87, P689, DOI 10.1016/0091-6749(91)90390-A; MAROM Z, 1983, J CLIN INVEST, V72, P122, DOI 10.1172/JCI110949; MONTEFORT S, 1993, EUR RESPIR J, V6, P1257; MONTEFORT S, 1992, CLIN EXP ALLERGY, V22, P511, DOI 10.1111/j.1365-2222.1992.tb00159.x; NAYLOR BERNARD, 1962, THORAX, V17, P69, DOI 10.1136/thx.17.1.69; Ohkawara Y, 1997, AM J RESP CELL MOL, V16, P510; OPPENSHAW PJM, 1989, RESP MED, V83, P25; Ordonez C, 2000, AM J RESP CRIT CARE, V162, P2324; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Peebles RS, 1998, J APPL PHYSIOL, V84, P1500; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PERSSON CGA, 1986, LANCET, V2, P1126; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Polito AJ, 1998, J ALLERGY CLIN IMMUN, V102, P714, DOI 10.1016/S0091-6749(98)70008-9; REDINGTON AE, 1995, AM J RESP CRIT CARE, V151, P1034; ROSE MC, 1997, AIRWAY MUCUS BASIC M; Shim JJ, 2001, AM J PHYSIOL-LUNG C, V280, pL134; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; SODERBERG M, 1990, EUR RESPIR J, V3, P261; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; Trifilieff A, 2000, AM J PHYSIOL-LUNG C, V279, pL1120; VANHOUTTE PM, 1988, AM REV RESPIR DIS, V138, pS24; VANVYVE T, 1992, CHEST, V102, P356, DOI 10.1378/chest.102.2.356; Vinall LE, 2000, AM J RESP CELL MOL, V23, P678; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2000, AM J RESP CELL MOL, V22, P637; Woltmann G, 1999, THORAX, V54, P124	75	93	96	0	10	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV 15	2001	164	10		S			S46	S51				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	504AH	WOS:000172833700005	11734466	
J	ten Brinke, A; van Dissel, JT; Sterk, PJ; Zwinderman, AH; Rabe, KF; Bel, EH				ten Brinke, A; van Dissel, JT; Sterk, PJ; Zwinderman, AH; Rabe, KF; Bel, EH			Persistent airflow limitation in adult-onset nonatopic asthma is associated with serologic evidence of Chlamydia pneumoniae infection	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; severity of illness index; airway obstruction; prognosis; chronic disease; phenotype; Chlamydia pneumoniae; infection; immunology; human	AIR-FLOW OBSTRUCTION; BRONCHOALVEOLAR LAVAGE; LUNG-FUNCTION; PULMONARY-DISEASE; INTRINSIC ASTHMA; PERIPHERAL-BLOOD; BRONCHIAL-ASTHMA; FOLLOW-UP; ANTIBODIES; IMMUNOPATHOLOGY	Background: Persistent airflow limitation may develop in patients with asthma, particularly in adults with nonatopic (intrinsic) disease. Although the underlying mechanisms are still unknown, respiratory infections might be involved. Objective: We investigated the annual loss of lung function in relation to seropositivity to Chlamydia pneumoniae in different subgroups of patients with severe asthma according to age at onset of asthma and atopic status. Methods: One hundred one nonsmoking outpatients with a pulmonologist's diagnosis of severe asthma (32 men and 69 women; mean age, 46.0 years; range, 18-75 years) were included in a cross-sectional study. C pneumoniae-specific serum IgG and IgA were measured by means of ELISA. The estimated decline in lung function was calculated from the relationship between postbronchodilator FEV1/vital capacity (percent predicted) and the duration of asthma and expressed as the slope of the regression line. Results: Patients with adult-onset nonatopic asthma and positive IgG antibodies to C pneumoniae had a significantly steeper slope of the regression line compared with the other subgroups of asthmatic patients (P = .001), being indicative of a 4-fold greater estimated decline in postbronchodilator FEV1/vital capacity (2.3% vs 0.5% predicted per year of asthma duration). Conclusion: These results suggest that C pneumoniae infection might promote the development of persistent airflow limitation in patients with nonatopic adult-onset asthma. It remains to be established whether viable pathogens that are accessible for therapeutic intervention are still present in the lower airways.	Leiden Univ, Med Ctr, Dept Pulm Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Infect Dis, NL-2300 RC Leiden, Netherlands; Leiden Univ, Med Ctr, Dept Med Stat, NL-2300 RC Leiden, Netherlands	ten Brinke, A (reprint author), Leiden Univ, Med Ctr, Dept Pulm Dis, C3-P,POB 9600, NL-2300 RC Leiden, Netherlands.						Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Black PN, 2000, EUR RESPIR J, V15, P254, DOI 10.1034/j.1399-3003.2000.15b06.x; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Cook PJ, 1998, THORAX, V53, P254; Cunningham AF, 1998, EUR RESPIR J, V11, P345, DOI 10.1183/09031936.98.11020345; Hahn DL, 1996, EPIDEMIOL INFECT, V117, P513; HAHN DL, 1991, JAMA-J AM MED ASSOC, V266, P225, DOI 10.1001/jama.266.2.225; Hansen EF, 1999, AM J RESP CRIT CARE, V159, P1267; Humbert M, 1999, IMMUNOL TODAY, V20, P528, DOI 10.1016/S0167-5699(99)01535-2; Humbert M, 1996, AM J RESP CRIT CARE, V154, P1497; Kroegel C, 1997, EUR RESPIR J, V10, P513; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; MABEY DCW, 1987, LANCET, V2, P1491; MACEK V, 1994, AM J RESP CRIT CARE, V150, P7; MCINTOSH JC, 1992, INFECT IMMUN, V60, P2936; Miyashita N, 1998, ANN ALLERG ASTHMA IM, V80, P405; MOORE DE, 1982, LANCET, V2, P574; Quanjer PH, 1993, EUR RESPIR J, V6, P16; RACKEMANN FM, 1947, AM J MED, V3, P601, DOI 10.1016/0002-9343(47)90204-0; Reed CE, 1999, J ALLERGY CLIN IMMUN, V103, P539, DOI 10.1016/S0091-6749(99)70221-6; Tang C, 1997, EUR RESPIR J, V10, P624; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; Ulrik CS, 1999, EUR RESPIR J, V13, P904, DOI 10.1034/j.1399-3003.1999.13d35.x; ULRIK CS, 1994, AM J RESP CRIT CARE, V150, P629; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; Virchow JC, 1996, J ALLERGY CLIN IMMUN, V98, pS27; von Hertzen L, 1999, CLIN EXP ALLERGY, V29, P522; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; Ward ME, 1995, APMIS, V103, P769; Wong YK, 1999, HEART, V81, P232; Wu L, 2000, AM J RESP CRIT CARE, V162, P1148; YAMADA K, 2000, AM J RESP CRIT CARE, V161, pA606	33	93	96	0	0	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2001	107	3					449	454		10.1067/mai.2001.113047		6	Allergy; Immunology	Allergy; Immunology	416RE	WOS:000167793300005	11240944	
J	Su, HJ; Wu, PC; Chen, HL; Lee, FC; Lin, LL				Su, HJ; Wu, PC; Chen, HL; Lee, FC; Lin, LL			Exposure assessment of indoor allergens, endotoxin, and airborne fungi for homes in southern Taiwan	ENVIRONMENTAL RESEARCH			English	Article						airborne fungi; allergen; endotoxin; Der p 1; Der p 2	DUST MITE ALLERGENS; RESIDENTIAL CHARACTERISTICS; CONTROL CHILDREN; RISK-FACTORS; ENVIRONMENTAL EXPOSURE; DOMESTIC INTERIORS; CHILDHOOD ASTHMA; YOUNG-ADULTS; SENSITIZATION; PREVALENCE	This study was undertaken to examine the seasonal variations of domestic Der p 1, Der p 2, and endotoxin on mattress and airborne fungal concentrations in homes of asthmatic and nonasthmatic children in southern Taiwan, where temperature and relative humidity are usually high throughout the year. A group of asthmatic children (10-12 years old) were selected randomly based on a citywide questionnaire survey. The nonasthmatic children were chosen to be in the comparison group by matching in age, gender, and proximity of residence. Environmental sampling of domestic microbes was conducted once a month for a year, Twelve calendar months were grouped into spring, summer, fall, and winter according to weather data (mainly average temperature and humidity) from the Central Weather Bureau. Dust samples from a child's mattress and airborne samples fi om a child's bedroom were collected and analyzed for allergens of Der p 1 and Der p 2, endotoxin, and fungi respectively. Results show that about 65% of children's mattresses in our region have Der p 1 levels greater than 2 mug/g. It is also apparent that most airborne fungal concentrations found in homes of either asthmatic or nonasthmatic children are higher than the recommended levels of concern. The predominant genera are Cladosporium, Aspergillus, Penicillium, Alternaria, and yeast, In addition, seasonal effects seem to be a critical factor for the concentrations and distributions of domestic endotoxin in these study homes. The implication of long-term exposure to these high levels of environmental microbes and how their effects vary with seasons remain to be further characterized. (C) 2001 Academic Press.	Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, Tainan 70428, Taiwan	Wu, PC (reprint author), Natl Cheng Kung Univ, Coll Med, Dept Environm & Occupat Hlth, 138 Sheng Li Rd, Tainan 70428, Taiwan.			Su, Huey-Jen/0000-0003-3589-9987			ACGIH American Conference of Governmental Industrial Hygienists, 1999, BIOAER ASS CONTR; ACGIH, 1986, GUID ASS BIOAER IND; ACGIH, 1989, GUID ASS BIOAER IND; AIHA, 1996, FIELD GUID DET BIOL; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; ARRUDA LK, 1991, CLIN EXP ALLERGY, V21, P433, DOI 10.1111/j.1365-2222.1991.tb01683.x; Barnett H. L., 1987, ILLUSTRATED GENERA I; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; CHAPMAN MD, 1989, CURR OPIN IMMUNOL, V1, P647, DOI 10.1016/0952-7915(89)90035-6; Charlet L.D., 1978, International Journal of Acarology, V4, P23; CHARPIN D, 1991, AM REV RESPIR DIS, V143, P983; Colloff M. J., 1991, Review of Medical and Veterinary Entomology, V79, P611; CUIJPERS CEJ, 1995, ENVIRON RES, V68, P11, DOI 10.1006/enrs.1995.1003; DEKKER C, 1991, CHEST, V100, P922, DOI 10.1378/chest.100.4.922; DOWSE GK, 1985, J ALLERGY CLIN IMMUN, V75, P75, DOI 10.1016/0091-6749(85)90016-8; EBNER MR, 1992, MYCOL RES, V96, P117; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HENDRY KM, 1993, J TOXICOL ENV HEALTH, V38, P183; HORK B, 1996, ANN ALLERG ASTHMA IM, V76, P41; HSIEH KH, 1988, J ASTHMA, V25, P73, DOI 10.3109/02770908809071357; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; HUNTER CA, 1988, INT BIODETERIOR, V24, P81, DOI 10.1016/0265-3036(88)90052-8; INFANTERIVARD C, 1993, AM J EPIDEMIOL, V137, P834; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109; KAUFFMAN HF, 1994, CLIN SIGNIFICANCE FU, P221; KORPP M, 1988, ANN CLIN RES, V141, P361; LACEY J., 1991, FRONTIERS MYCOLOGY; Larone D. H., 1987, MED IMPORTANT FUNGI; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; LUCZYNSKA CM, 1990, AM REV RESPIR DIS, V141, P361; MACHER JM, 1991, ARCH ENVIRON HEALTH, V46, P25; Macher JM, 1995, AIR SAMPLING INSTRUM, P589; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MICHEL O, 1992, AM REV RESPIR DIS, V146, P352; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; MILTON D K, 1990, American Industrial Hygiene Association Journal, V51, P331, DOI 10.1202/0002-8894(1990)051<0331:EMASAA>2.0.CO;2; MOUBASHER AH, 1990, FOLIA MICROBIOL, V35, P298, DOI 10.1007/BF02821282; NORDVALL SL, 1988, ACTA PAEDIATR SCAND, V77, P716, DOI 10.1111/j.1651-2227.1988.tb10736.x; Peat JK, 1987, CLIN ALLERGY, V17, P297; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V80, P755, DOI 10.1016/S0091-6749(87)80261-0; PLATTSMILLS TAE, 1989, J ALLERGY CLIN IMMUN, V83, P416, DOI 10.1016/0091-6749(89)90128-0; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; SALVAGGIO J, 1981, J ALLERGY CLIN IMMUN, V68, P327, DOI 10.1016/0091-6749(81)90131-7; Sandford A, 1996, AM J RESP CRIT CARE, V153, P1749; SARASFIELD JK, 1974, ARCH DIS CHILD, V49, P711; SCHWARTZ DA, 1995, AM J RESP CRIT CARE, V151, P47; SHADZI S, 1993, MYCOSES, V36, P69; SMID T, 1992, AM REV RESPIR DIS, V146, P474; Smith J. M., 1969, BRIT MED J, V1, P723; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181; SWANSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P724, DOI 10.1016/0091-6749(85)90678-5; TANG RB, 1986, J ASTHMA, V23, P245, DOI 10.3109/02770908609073168; Tirimanna PRS, 1996, BRIT J GEN PRACT, V46, P277; TOVEY ER, 1981, NATURE, V289, P592, DOI 10.1038/289592a0; TSAI LC, 1988, J ASTHMA, V5, P7; TUNER K, 1974, CLIN ALLERGY, V4, P149; VERHOEFF AP, 1992, ALLERGY, V38, P85; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WALTERS M, 1994, APPL ENVIRON MICROB, V60, P996; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E	72	93	94	0	14	ACADEMIC PRESS INC	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	FEB	2001	85	2					135	144		10.1006/enrs.2000.4113		10	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	403DT	WOS:000167027900009	11161663	
J	Buckley, DA; Wakelin, SH; Seed, PT; Holloway, D; Rycroft, RJG; White, IR; McFadden, JP				Buckley, DA; Wakelin, SH; Seed, PT; Holloway, D; Rycroft, RJG; White, IR; McFadden, JP			The frequency of fragrance allergy in a patch-test population over a 17-year period	BRITISH JOURNAL OF DERMATOLOGY			English	Article						allergic contact dermatitis; cosmetic allergy; fragrances; patch testing; perfumes	CONTACT-DERMATITIS; CONSTITUENTS; MIX; PERFUMES	Fragrances are widely encountered in our daily environment and are known to be a common cause of allergic contact dermatitis. We have reviewed our patch test data from 1980 to 1996 to establish whether the pattern of fragrance allergy has changed with time. During this period, 25,545 patients (10,450 male, 15,005 female) were patch tested with the European standard series, The mean annual frequency of positive reactions to the fragrance mix was 8.5% in females (range 6.1-10.9) and 6.7% in males (range 5.1-12.9). Females were 1.3 times more Likely to be allergic to fragrance (P < 0.001, 95% confidence interval, CI 1.17-1.41). Males with fragrance allergy were older than females by 5.6 years (mean age 48.2 vs. 42.6 years; P ( 0.001, 95% CI 3.9-7.3). The incidence of a concomitant positive patch test to balsam of Peru in fragrance-sensitive patients showed wide variation. suggesting that it is not a reliable marker of fragrance allergy, There was a positive correlation between the isomers isoeugenol and eugenol, Oak moss remained the most common overall allergen throughout the study, positive in 38.3% of females and 35.6% of males who were tested to the constituents of the fragrance mix. During the period of the study the incidence of positive tests to oak moss increased by 5% yearly (P = 0.001, 95% CI 3.2-8.7). The frequency of allergic reactions to eugenol and geraniol remained relatively constant. Isoeugenol and alpha-amyl cinnamic aldehyde sensitivity increased and hydroxycitronellal showed a slow decline. There was a striking reduction in the frequency of sensitivity to cinnamic aldehyde (by 18% yearly; P < 0.001, 95% CI 14.3-21.0) and cinnamic alcohol. (by 9% yearly; P < 0.001, 95% CI 5.2-12.9): these are now uncommon fragrance allergens. These data show temporal trends which may reflect the frequency of population exposure to individual fragrances.	St Thomas Hosp, Inst Dermatol, London SE1 7EH, England; Kings Coll London, Guys Kings & St Thomas Sch Med, Dept Publ Hlth Med, London SE1 3QD, England	St Thomas Hosp, Inst Dermatol, London SE1 7EH, England.	j.mcfadden@umds.ac.uk	Seed, Paul/C-4435-2008	Seed, Paul/0000-0001-7904-7933			BASKETTER DA, 1991, CONTACT DERMATITIS, V25, P160, DOI 10.1111/j.1600-0536.1991.tb01822.x; BECKER K, 1994, CONTACT DERMATITIS, V30, P185, DOI 10.1111/j.1600-0536.1994.tb00713.x; CALNAN CD, 1980, CONTACT DERMATITIS, V6, P500, DOI 10.1111/j.1600-0536.1980.tb05581.x; DEGROOT AC, 1993, CONTACT DERMATITIS, V28, P139, DOI 10.1111/j.1600-0536.1993.tb03373.x; DeGroot AC, 1997, CONTACT DERMATITIS, V36, P57; EDMAN B, 1994, CONTACT DERMATITIS, V31, P291, DOI 10.1111/j.1600-0536.1994.tb02021.x; EDMAN B, 1985, CONTACT DERMATITIS, V13, P129, DOI 10.1111/j.1600-0536.1985.tb02524.x; ENDERS F, 1989, CONTACT DERMATITIS, V20, P237; FROSCH PJ, 1995, CONTACT DERMATITIS, V33, P333, DOI 10.1111/j.1600-0536.1995.tb02048.x; Huber P. J., 1967, P 5 BERK S MATH STAT, P221; JOHANSEN JD, 1995, CONTACT DERMATITIS, V32, P18, DOI 10.1111/j.1600-0536.1995.tb00834.x; Johansen JD, 1996, BRIT J DERMATOL, V135, P419, DOI 10.1111/j.1365-2133.1996.tb01506.x; Larsen W G, 1987, Acta Derm Venereol Suppl (Stockh), V134, P83; LARSEN WG, 1985, J AM ACAD DERMATOL, V12, P1, DOI 10.1016/S0190-9622(85)70001-1; LARSEN WG, 1977, ARCH DERMATOL, V113, P623, DOI 10.1001/archderm.113.5.623; LEYDEN JJ, 1977, CONTACT DERMATITIS, V3, P333, DOI 10.1111/j.1600-0536.1977.tb03698.x; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; Scheinman P L, 1996, Am J Contact Dermat, V7, P65, DOI 10.1016/S1046-199X(96)90077-9; SCHNUCH A, 1993, DERMATOS BER UMWELT, V41, P60; SHEHADE S A, 1991, Contact Dermatitis, V24, P119, DOI 10.1111/j.1600-0536.1991.tb01663.x; VESTEY JP, 1986, CONTACT DERMATITIS, V15, P119, DOI 10.1111/j.1600-0536.1986.tb01310.x	21	93	94	1	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-0963	1365-2133		BRIT J DERMATOL	Br. J. Dermatol.	FEB	2000	142	2					279	283		10.1046/j.1365-2133.2000.03298.x		5	Dermatology	Dermatology	291LX	WOS:000085737300014	10730761	
J	Montuschi, P; Santonico, M; Mondino, C; Pennazza, G; Mantini, G; Martinelli, E; Capuano, R; Ciabattoni, G; Paolesse, R; Di Natale, C; Barnes, PJ; D'Amico, A				Montuschi, Paolo; Santonico, Marco; Mondino, Chiara; Pennazza, Giorgio; Mantini, Giulia; Martinelli, Eugenio; Capuano, Rosamaria; Ciabattoni, Giovanni; Paolesse, Roberto; Di Natale, Corrado; Barnes, Peter J.; D'Amico, Arnaldo			Diagnostic Performance of an Electronic Nose, Fractional Exhaled Nitric Oxide, and Lung Function Testing in Asthma	CHEST			English	Article							VOLATILE ORGANIC-COMPOUNDS; SENSOR ARRAY; BREATH; IDENTIFICATION; CANCER; METALLOPORPHYRINS; DISCRIMINATION; CHILDREN	Background: Analysis of exhaled breath by biosensors discriminates between patients with asthma and healthy subjects. An electronic nose consists of a chemical sensor array for the detection of volatile organic compounds (VOCs) and an algorithm for pattern recognition. We compared the diagnostic performance of a prototype of an electronic nose with lung function tests and fractional exhaled nitric oxide (FENO) in patients with atopic asthma. Methods: A cross-sectional study was undertaken in 27 patients with intermittent and persistent mild asthma and in 24 healthy subjects. Two procedures for collecting exhaled breath were followed to study the differences between total and alveolar air. Seven patients with asthma and seven healthy subjects participated in a study with mass spectrometry (MS) fingerprinting as an independent technique for assessing between group discrimination. Classification was based on principal component analysis and a feed-forward neural network. Results: The best results were obtained when the electronic nose analysis was performed on alveolar air. Diagnostic performance for electronic nose, FENO, and lung function testing was 87.5%, 79.2%, and 70.8%, respectively. The combination of electronic nose and FENO had the highest diagnostic performance for asthma (95.8%). MS fingerprints of VOCs could discriminate between patients with asthma and healthy subjects. Conclusions: The electronic nose has a high diagnostic performance that can be increased when combined with FENO. Large studies are now required to definitively establish the diagnostic performance of the electronic nose. Whether this integrated noninvasive approach will translate into an early diagnosis of asthma has to be clarified. Trial registration: EUDRACT https://eudralink.emea.europa.eu; Identifier: 2007-000890-51; and clinicaltrials.gov; Identifier: NCT00819676. CHEST 2010; 137(4):790-796	[Montuschi, Paolo] Univ Cattolica Sacro Cuore, Fac Med, Dept Pharmacol, I-00168 Rome, Italy; [Santonico, Marco; Mantini, Giulia; Martinelli, Eugenio; Capuano, Rosamaria; Paolesse, Roberto; Di Natale, Corrado; D'Amico, Arnaldo] Univ Roma Tor Vergata, Dept Elect Engn, I-00173 Rome, Italy; [Pennazza, Giorgio] Univ Campus Biomed, Fac Engn, Rome, Italy; [Mondino, Chiara] IDI, Dept Immunodermatol, Rome, Italy; [Ciabattoni, Giovanni] Univ G dAnnunzio, Fac Pharm, Dept Drug Sci, Chieti, Italy; [Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Sch Med, Airway Dis Sect, Natl Heart & Lung Inst, London, England	Montuschi, P (reprint author), Univ Cattolica Sacro Cuore, Fac Med, Dept Pharmacol, Largo F Vito 1, I-00168 Rome, Italy.	pmontuschi@rm.unicatt.it	Paolesse, Roberto/B-8966-2013; Santonico, Marco/K-4465-2016; Capuano, Rosamaria/K-9258-2016	Paolesse, Roberto/0000-0002-2380-1404; Santonico, Marco/0000-0002-3755-6198; MONTUSCHI, Paolo/0000-0001-5589-1750; Di Natale, Corrado/0000-0002-0543-4348; Pennazza, Giorgio/0000-0003-4843-9445	Merck; Sharp; Dohme; Catholic University of the Sacred Heart [2008-2009]	Supported by Merck, Sharp, and Dohme, and Catholic University of the Sacred Heart academic grant 2008-2009.	Bishop CM, 2006, PATTERN RECOGNITION; D'Amico A, 2008, SKIN RES TECHNOL, V14, P226, DOI 10.1111/j.1600-0846.2007.00284.x; D'Amico A, 2008, SENSOR ACTUAT B-CHEM, V130, P458, DOI 10.1016/j.snb.2007.09.044; D'Amico A, 2000, SENSOR ACTUAT B-CHEM, V65, P209, DOI 10.1016/S0925-4005(99)00342-1; Di Natale C, 2003, BIOSENS BIOELECTRON, V18, P1209, DOI 10.1016/S0956-5663(03)00086-1; Di Natale C, 2007, SENSOR ACTUAT B-CHEM, V121, P238, DOI 10.1016/j.snb.2006.09.038; Dragonieri S, 2007, J ALLERGY CLIN IMMUN, V120, P856, DOI 10.1016/j.jaci.2007.05.043; Dragonieri S, 2009, LUNG CANCER, V64, P166, DOI 10.1016/j.lungcan.2008.08.008; GARDNER JW, 1994, SENSOR ACTUAT B-CHEM, V18, P211; Johnson R. A., 1992, APPL MULTIVARIATE ST; Kusch P, 2004, J POLYM ENVIRON, V12, P83, DOI 10.1023/B:JOOE.0000010053.20382.d7; Machado RF, 2005, AM J RESP CRIT CARE, V171, P1286, DOI 10.1164/rccm.200409-1184OC; Malerba M, 2008, CHEST, V134, P733, DOI 10.1378/chest.08-0763; Montuschi P, 2006, J ALLERGY CLIN IMMUN, V118, P347, DOI 10.1016/j.jaci.2006.04.010; National Asthma Education and Prevention Program, 2007, NIH PUBL; Paredi P, 2000, AM J RESP CRIT CARE, V162, P1450; Pavon JLP, 2006, TRAC-TREND ANAL CHEM, V25, P257, DOI 10.1016/j.trac.2005.09.003; Petsky HL, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005603.pub2; Phillips M, 1999, J CHROMATOGR B, V729, P75, DOI 10.1016/S0378-4347(99)00127-9; Phillips M, 1997, ANAL BIOCHEM, V247, P272, DOI 10.1006/abio.1997.2069; Rock F, 2008, CHEM REV, V108, P705, DOI 10.1021/cr068121q; Sivan Y, 2009, J PEDIATR-US, V155, P211, DOI 10.1016/j.jpeds.2009.02.034; Turner APF, 2004, NAT REV MICROBIOL, V2, P161, DOI 10.1038/nrmicro823; van den Velde S, 2007, ANAL CHEM, V79, P3425, DOI 10.1021/ac062009a; [Anonymous], 1999, AM J RESP CRIT CARE, V160, P2104	25	92	95	1	20	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	APR	2010	137	4					790	796		10.1378/chest.09-1836		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	582XA	WOS:000276632400009	20081096	
J	Abramson, MJ; Puy, RM; Weiner, JM				Abramson, Michael J.; Puy, Robert M.; Weiner, John M.			Injection allergen immunotherapy for asthma	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review						*Desensitization, Immunologic; Allergens [administration & dosage; immunology]; Asthma [immunology; *therapy]; Injections, Subcutaneous; Randomized Controlled Trials as Topic; Humans	HOUSE-DUST-MITE; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND PLACEBO; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; GRASS-POLLEN IMMUNOTHERAPY; 3-YEAR DOUBLE-BLIND; STANDARDIZED 5-GRASS-POLLEN EXTRACT; ENZYME-POTENTIATED DESENSITIZATION; RANDOMIZED CONTROLLED-TRIAL	Background Allergen specific immunotherapy has long been a controversial treatment for asthma. Although beneficial effects upon clinically relevant outcomes have been demonstrated in randomised controlled trials, there remains a risk of severe and sometimes fatal anaphylaxis. The recommendations of professional bodies have ranged from cautious acceptance to outright dismissal. With increasing interest in new allergen preparations and methods of delivery, we updated the systematic review of allergen specific immunotherapy for asthma. Objectives The objective of this review was to assess the effects of allergen specific immunotherapy for asthma. Search strategy We searched the Cochrane Airways Group Trials Register up to 2005, Dissertation Abstracts and Current Contents. Selection criteria Randomised controlled trials using various forms of allergen specific immunotherapy to treat asthma and reporting at least one clinical outcome. Data collection and analysis Three authors independently assessed eligibility of studies for inclusion. Two authors independently performed quality assessment of studies. Main results Eighty-eight trials were included (13 new trials). There were 42 trials of immunotherapy for house mite allergy; 27 pollen allergy trials; 10 animal dander allergy trials; two Cladosporium mould allergy, two latex and six trials looking at multiple allergens. Concealment of allocation was assessed as clearly adequate in only 16 of these trials. Significant heterogeneity was present in a number of comparisons. Overall, there was a significant reduction in asthma symptoms and medication, and improvement in bronchial hyper-reactivity following immunotherapy. There was a significant improvement in asthma symptom scores (standardised mean difference -0.59, 95% confidence interval -0.83 to -0.35) and it would have been necessary to treat three patients (95% CI 3 to 5) with immunotherapy to avoid one deterioration in asthma symptoms. Overall it would have been necessary to treat four patients (95% CI 3 to 6) with immunotherapy to avoid one requiring increased medication. Allergen immunotherapy significantly reduced allergen specific bronchial hyper-reactivity, with some reduction in non-specific bronchial hyper-reactivity as well. There was no consistent effect on lung function. If 16 patients were treated with immunotherapy, one would be expected to develop a local adverse reaction. If nine patients were treated with immunotherapy, one would be expected to develop a systemic reaction (of any severity). Authors' conclusions Immunotherapy reduces asthma symptoms and use of asthma medications and improves bronchial hyper-reactivity. One trial found that the size of the benefit is possibly comparable to inhaled steroids. The possibility of local or systemic adverse effects (such as anaphylaxis) must be considered.	[Abramson, Michael J.] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia; [Puy, Robert M.] Dept Allergy Immunol & Resp Med, Melbourne, Vic, Australia; [Weiner, John M.] AllergyNet Australia, Melbourne, Vic, Australia	Abramson, MJ (reprint author), Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic 3004, Australia.	Michael.Abramson@monash.edu			Reckitt Benckiser; GarfieldWeston Foundation, UK	MJA received an honorarium from Boehringer Ingelheim for speaking at the Airways 2006 meeting. he was awarded a grant from Reckitt Benckiser for a study of NSAID induced asthma.; External sources; GarfieldWeston Foundation, UK.	AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; Abramson M, 1999, ALLERGY, V54, P1022, DOI 10.1034/j.1398-9995.1999.00102.x; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; ABRAMSON MJ, 1998, COCHRANE DATABASE SY; Abramson M. J., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001186; ABRAMSON MJ, 1999, IMMUNOTHERAPY ASTHMA, P207; Adamek-Guzik T, 1979, Pol Tyg Lek, V34, P1111; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Akmanlar N, 2000, Allergol Immunopathol (Madr), V28, P213; Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Altintas D, 1999, Allergol Immunopathol (Madr), V27, P309; Altman DG, 2001, ANN INTERN MED, V134, P663; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; AMARAL MR, 1978, ALLERGOL IMMUNOPATH, V6, P231; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ARAGONES AM, 1980, AN ESP PEDIATR, V13, P87; ARBESMAN CE, 1964, J ALLERGY, V35, P12, DOI 10.1016/0021-8707(64)90044-9; ARBESMAN CE, 1965, J ALLERGY, V36, P29, DOI 10.1016/0021-8707(65)90030-4; Ariano R, 1997, Allergol Immunopathol (Madr), V25, P23; ARIANO R, 1993, PEDIATR ASTHMA ALLER, V7, P227, DOI 10.1089/pai.1993.7.227; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; ARIANO R, 2005, ALLERG IMMUNOL PARIS, V37, P103; ARMENTIA A, 1992, ANN ALLERGY, V69, P441; Armentia A, 1997, J INVEST ALLERG CLIN, V7, P325; ARMENTIA A, 1990, ANN ALLERGY, V65, P265; Armentia-Medina A, 1995, Allergol Immunopathol (Madr), V23, P211; ARMENTIAMEDINA A, 1989, ANN ALLERGY, V63, P127; Arvidsson MB, 2004, ALLERGY, V59, P74, DOI 10.1046/j.1398-9995.2003.00334.x; Arvidsson MB, 2002, J ALLERGY CLIN IMMUN, V109, P777, DOI 10.1067/mai.2002.123868; Asaoku Y, 2000, Nihon Kokyuki Gakkai Zasshi, V38, P92; Astarita C, 1996, J INVEST ALLERG CLIN, V6, P248; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Basomba A, 2002, J ALLERGY CLIN IMMUN, V109, P943, DOI 10.1067/mai.2002.124465; BAUR X, 1989, MED KLIN, V84, P439; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BESSOT JC, 1980, ALLERGOL IMMUNOPATH, V8, P351; Bodtger U, 2003, CLIN EXP ALLERGY, V33, P496, DOI 10.1046/j.1365-2222.2003.01611.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; BOTEY J, 1981, Allergie et Immunologie (Paris), V13, P18; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; BOUSQUET J, 1985, CLIN ALLERGY, V15, P179, DOI 10.1111/j.1365-2222.1985.tb02272.x; BOUSQUET J, 1987, REV MAL RESPIR, V4, pR25; BOUSQUET J, 1999, ALLERGY, V54, P349; BRETON A, 1961, Sem Hop, V37, P3676; *BRIT THOR ASS, 1979, BR J DIS CHEST, V73, P260; *BRIT TUB ASS, 1968, BRIT MED J, V3, P774; BRUCE CA, 1977, J ALLERGY CLIN IMMUN, V59, P449, DOI 10.1016/0091-6749(77)90009-4; BRUUN E, 1950, Acta Med Scand Suppl, V239, P332; BRUUN EGON, 1957, ACTA ALLERGOL, V11, P142, DOI 10.1111/j.1398-9995.1957.tb03018.x; BUCHANAN DJ, 1981, MED J ZAMBIA, V15, P14; BUCUR J, 1989, ANN ALLERGY, V62, P355; Bufe A, 2004, ALLERGY, V59, P498, DOI 10.1111/j.1398-9995.2004.00457.x; Caffarelli C, 2000, ALLERGY, V55, P1142, DOI 10.1034/j.1398-9995.2000.00655.x; Calamita Z, 2006, ALLERGY, V61, P1162, DOI 10.1111/j.1395-9995.2006.01205.x; CANTANI A, 1984, ANN ALLERGY, V53, P79; Cantani A, 1996, J INVEST ALLERG CLIN, V6, P270; Cantani A, 2005, Eur Rev Med Pharmacol Sci, V9, P103; Caramia G, 1996, Allerg Immunol (Paris), V28, P308; Carbone R, 2005, Eur Rev Med Pharmacol Sci, V9, P125; Casanovas M, 2005, CLIN EXP ALLERGY, V35, P1377, DOI 10.1111/j.1365-2222.2005.02343.x; Casanovas M, 2004, ALERGOLOGIA INMUNOLO, V19, P43; CATES CJ, 2008, VISUAL RX VER 3 0 3; CHOOVORAVECH P, 1980, J MED ASSOC THAILAND, V63, P506; Choovoravech P, 1976, Curr Med Res Opin, V4, P330, DOI 10.1185/03007997609109325; CHOOVORAVECH P, 1974, J MED ASSOC THAILAND, V57, P445; Chowdhury I, 1999, ANN AGR ENV MED, V6, P91; CHU JCL, 1981, ANN ALLERGY, V47, P107; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; CLEVELAND CH, 1992, IMMUNOL ALLERGY CLIN, V12, P39; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; COOPER PJ, 1984, CLIN ALLERGY, V14, P541, DOI 10.1111/j.1365-2222.1984.tb02242.x; CORBETTA L, 1992, ALLERGOL IMMUNOPATH, V21, P61; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Costa JCT, 1996, ALLERGY, V51, P238, DOI 10.1111/j.1398-9995.1996.tb04599.x; Creticos P. S., 2003, Journal of Allergy and Clinical Immunology, V111, pS201, DOI 10.1016/S0091-6749(03)80689-9; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRIMI E, 1991, J ALLERGY CLIN IMMUN, V87, P721, DOI 10.1016/0091-6749(91)90395-5; Crimi Nunzio, 2004, Ann Ital Med Int, V19, P98; D'Ambrosio F P, 1996, Allergol Immunopathol (Madr), V24, P146; D'SOUZA M F, 1973, Clinical Allergy, V3, P177, DOI 10.1111/j.1365-2222.1973.tb01320.x; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; DAMATO G, 1995, CLIN EXP ALLERGY, V25, P149, DOI 10.1111/j.1365-2222.1995.tb01020.x; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; DURIEU H, 1961, Brux Med, V41, P209; EBNER H, 1989, WIEN KLIN WOCHENSCHR, V101, P504; Echechipia S, 1995, J INVEST ALLERG CLIN, V5, P325; ENGSTROM I, 1957, Acta Paediatr, V46, P81, DOI 10.1111/j.1651-2227.1957.tb08634.x; ERIKSSON NE, 1979, ALLERGY, V34, P233, DOI 10.1111/j.1398-9995.1979.tb01704.x; FANTI A, 1988, LOTTO TUBERCULOSI MA, V58, P658; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Ferreira N, 1993, Allergol Immunopathol (Madr), V21, P185; Ferrer A, 2003, J INVEST ALLERG CLIN, V13, P244; FORMGREN H, 1984, Journal of Allergy and Clinical Immunology, V73, P140; FOUCARD T, 1984, MOULD ALL WORKSH UPP, P105; Franco C, 1995, Allergol Immunopathol (Madr), V23, P58; FRANKLAND AW, 1954, LANCET, V1, P1055; FROSTAD AB, 1983, CLIN ALLERGY, V13, P337, DOI 10.1111/j.1365-2222.1983.tb02609.x; GADDIE J, 1976, BRIT MED J, V2, P561; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; GARCIA AN, 1997, PEDIAT INTEGRAL, V2, P397; GARCIAORTEGA P, 1993, CHEST, V103, P183, DOI 10.1378/chest.103.1.183; Garde Garde J M, 1999, Allergol Immunopathol (Madr), V27, P46; GERRARD J W, 1989, Clinical Ecology, V6, P43; Gillis D, 1997, MED J AUSTRALIA, V167, P540; GIOVANE AL, 1994, CLIN EXP ALLERGY, V24, P53, DOI 10.1111/j.1365-2222.1994.tb00917.x; GOLDSTEIN GL, 1981, ANN ALLERGY, V47, P333; Gonzalez P, 2002, J INVEST ALLERG CLIN, V12, P263; GOOR W, 1971, SCHWEIZ MED WSCHR, V101, P1217; GORDON VH, 1972, ANN ALLERGY, V30, P507; Gozalo F, 1997, Allergol Immunopathol (Madr), V25, P219; GRAMMER LC, 1983, J ALLERGY CLIN IMMUN, V72, P448, DOI 10.1016/0091-6749(83)90580-8; GRAMMER LC, 1982, J ALLERGY CLIN IMMUN, V69, P494, DOI 10.1016/0091-6749(82)90173-7; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; Gruber W, 1999, CLIN EXP ALLERGY, V29, P176; Guardia P, 2004, Allergol Immunopathol (Madr), V32, P271, DOI 10.1157/13066304; Guerra F, 2003, J INVEST ALLERG CLIN, V13, P108; HAAHTELA T, 1984, ANN ALLERGY, V52, P355; Hakansson L, 1998, CLIN EXP ALLERGY, V28, P791; HANNEUSE Y, 1982, ALLERGOL IMMUNOPATH, V10, P289; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; Hedlin G, 1995, J ALLERGY CLIN IMMUN, V96, P879, DOI 10.1016/S0091-6749(95)70223-7; HENOCQ E, 1973, CLIN ALLERGY, V3, P461, DOI 10.1111/j.1365-2222.1973.tb01353.x; HENRY R, 1990, J PAEDIATR CHILD H, V26, P72, DOI 10.1111/j.1440-1754.1990.tb02389.x; HERXHEIMER H, 1952, INT ARCH ALLER A IMM, V3, P189; HERXHEIMER H, 1951, INT ARCH ALLER A IMM, V2, P40; HERXHEIMER H, 1950, J PHYSL, V3, P37; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HILL DJ, 1982, BRIT MED J, V284, P306; Hirokawa Y, 1996, TOHOKU J EXP MED, V178, P371, DOI 10.1620/tjem.178.371; HIRSCH SR, 1982, J ALLERGY CLIN IMMUN, V70, P183, DOI 10.1016/0091-6749(82)90040-9; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; Hurley C., 2003, Journal of Allergy and Clinical Immunology, V111, pS201, DOI 10.1016/S0091-6749(03)80692-9; IIKURA Y, 1997, FISCHER VERLAG, V91, P45; IPSEN H, 1988, ALLERGY, V43, P370, DOI 10.1111/j.1398-9995.1988.tb00431.x; Jacobsen L., 1996, Journal of Allergy and Clinical Immunology, V97, P232, DOI 10.1016/S0091-6749(96)80416-7; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JARISCH R, 1979, HAUTARZT, V30, P365; JOHNSTONE D, 1961, PEDIATRICS, V27, P39; JOHNSTONE DE, 1957, AMA J DIS CHILD, V94, P1; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; JYO T, 1989, J ALLERGY CLIN IMMUN, V83, P386, DOI 10.1016/0091-6749(89)90123-1; Kalla M, 1979, Pol Tyg Lek, V34, P865; KANG BC, 1988, J ASTHMA, V25, P205; KERR JAMES W., 1963, SCOT MED JOUR, V8, P485; Kohno Y, 1998, J ALLERGY CLIN IMMUN, V102, P927, DOI 10.1016/S0091-6749(98)70330-6; Solodun AK, 1979, PEDIAT AKUSHERSTVO G, V3, P5; KRAEPELIEN S, 1963, Acta Paediatr Suppl, V140, P92; KUNA P, 1989, J ALLERGY CLIN IMMUN, V83, P816, DOI 10.1016/0091-6749(89)90020-1; LAETSCH C, 1973, SCHWEIZ MED WSCHR, V103, P342; Lau J, 1997, ANN INTERN MED, V127, P820; LEJARAZU DM, 1993, J INVEST ALLERG CLIN, V3, P210; LENG X, 1990, ANN ALLERGY, V64, P27; LEVIN SJ, 1959, PEDIATR CLIN N AM, V6, P698; Lewith GT, 2002, BRIT MED J, V324, P520, DOI 10.1136/bmj.324.7336.520; Leynadier F, 2000, J ALLERGY CLIN IMMUN, V106, P585; LICHTENSTEIN LM, 1971, ANN INTERN MED, V75, P663; LILJA G, 1989, J ALLERGY CLIN IMMUN, V83, P37, DOI 10.1016/0091-6749(89)90475-2; Lizaso M.T., 2003, Anales Sis San Navarra, V26, P129, DOI 10.4321/s1137-66272003000400016; Lombardi C, 2005, J ALLERGY CLIN IMMUN, V115, pS207, DOI 10.1016/j.jaci.2004.12.841; LOZANO RM, 1992, ALLERGOL IMMUNOPATH, V20, P230; Lu FM, 1998, ANN ALLERG ASTHMA IM, V80, P419; MACHIELS JJ, 1993, AM REV RESPIR DIS, V147, P1407; MACHIELS JJ, 1991, ALLERGY, V46, P335, DOI 10.1111/j.1398-9995.1991.tb00596.x; MACHIELS JJ, 1990, J CLIN INVEST, V85, P1024, DOI 10.1172/JCI114532; MACHIELS JJ, 1990, CLIN EXP ALLERGY, V20, P653, DOI 10.1111/j.1365-2222.1990.tb02704.x; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Majori M, 1998, EUR RESPIR J, V11, P1263, DOI 10.1183/09031936.98.11061263; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; MALLET A, 1994, ALLERGOL IMMUNOPATH, V22, P226; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1990, DAN MED BULL, V37, P12; MALLING HJ, 1987, ALLERGY, V42, P305, DOI 10.1111/j.1398-9995.1987.tb02214.x; Marcucci F, 2005, PEDIATR ALLERGY IMMU, V16, P519, DOI 10.1111/j.1399-3038.2005.00301.x; Marogna M, 2005, J ALLERGY CLIN IMMUN, V115, P1184, DOI 10.1016/j.jaci.2005.02.031; Marogna M, 2004, ALLERGY, V59, P1205, DOI 10.1111/j.1398-9995.2004.00508.x; Martin N, 1996, ACTA HYDROCH HYDROB, V24, P68, DOI 10.1002/aheh.19960240203; Maruo H, 1990, Arerugi, V39, P662; MATOGA S, 1989, Pediatria Polska, V64, P167; Matsumoto Tomoaki, 1998, Allergology International, V47, P213, DOI 10.2332/allergolint.47.213; Matsuoka Hiroyuki, 1998, Allergology International, V47, P123, DOI 10.2332/allergolint.47.123; MAUNSELL K, 1971, LANCET, V1, P967; MCALLEN MK, 1967, BRIT MED J, V1, P22; METZGER WJ, 1983, J ALLERGY CLIN IMMUN, V71, P119, DOI 10.1016/0091-6749(83)90245-2; MILLER DL, 1971, ANN ALLERGY, V29, P178; MILLER FF, 1964, J ALLERGY, V35, P7, DOI 10.1016/0021-8707(64)90043-7; Mirone C, 2004, CLIN EXP ALLERGY, V34, P1408, DOI 10.1111/j.1365-2222.2004.02056.x; MISCHLER TW, 1981, CURR THER RES CLIN E, V29, P745; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; MOLLER C, 1986, ALLERGY, V41, P271, DOI 10.1111/j.1398-9995.1986.tb02028.x; MOSBECH H, 1985, ANN ALLERGY, V55, P389; MOSBECH H, 1990, ALLERGY, V45, P142, DOI 10.1111/j.1398-9995.1990.tb00472.x; MOSBECH H, 1989, ALLERGY, V44, P499, DOI 10.1111/j.1398-9995.1989.tb04189.x; MOSBECH H, 1989, ALLERGY, V44, P487, DOI 10.1111/j.1398-9995.1989.tb04188.x; MOSBECH H, 1990, ALLERGY, V45, P209, DOI 10.1111/j.1398-9995.1990.tb00485.x; MOSCATO G, 1991, J INVEST ALLERG CLIN, V1, P383; MOSHKEVICH VS, 1985, ALLERGOL IMMUNOPATH, V13, P317; Moverare R, 1998, ALLERGY, V53, P275, DOI 10.1111/j.1398-9995.1998.tb03887.x; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Munoz-Lopez F, 1994, Allergol Immunopathol (Madr), V22, P132; MUNOZLOPEZ F, 1981, ALLERGOLOGIA IMMU S9, P171; MUNROASHMAN D, 1976, ANN ALLERGY, V36, P95; MURRAY AB, 1985, ANN ALLERGY, V54, P541; NAGATA M, 1993, INTERNAL MED, V32, P702, DOI 10.2169/internalmedicine.32.702; Nagata M, 1993, Arerugi, V42, P628; Nagata M, 1998, INT ARCH ALLERGY IMM, V117, P20, DOI 10.1159/000053565; NAGATA M, 1989, Japanese Journal of Allergology, V38, P1319; Negro J M, 1999, Allergol Immunopathol (Madr), V27, P153; NEWTON D A G, 1978, British Journal of Diseases of the Chest, V72, P21, DOI 10.1016/0007-0971(78)90004-9; NORMAN PS, 1978, J ALLERGY CLIN IMMUN, V61, P370, DOI 10.1016/0091-6749(78)90116-1; *NORT COCHR CTR CO, 2008, REV MAN REVMAN 5 0; NOVEMBRE E, 1991, RIV ITAL PED, V17, P75; Oda N, 1998, CELL IMMUNOL, V190, P43, DOI 10.1006/cimm.1998.1391; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; ORTOLANI C, 1984, J ALLERGY CLIN IMMUN, V73, P283, DOI 10.1016/S0091-6749(84)80021-4; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; OSTERBALLE O, 1982, ALLERGY, V37, P379, DOI 10.1111/j.1398-9995.1982.tb02316.x; OSTERBALLE O, 1982, ALLERGY, V37, P169, DOI 10.1111/j.1398-9995.1982.tb01893.x; OSTERBALLE O, 1982, ALLERGY, V37, P209, DOI 10.1111/j.1398-9995.1982.tb01898.x; OSVATH P, 1976, MONATSSCHR KINDERH, V124, P110; Pajno B, 2003, J ALLERGY CLIN IM S2, V111, pS200; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2004, ALLERGY, V59, P883, DOI 10.1111/j.1398-9995.2004.00578.x; PAJNO GB, 2002, ASTHMA IMMUNOLOGY S1, V109, pA599; PALACIOS AS, 1989, ALLERGOL IMMUNOPATH, V17, P323; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; Paranos S, 1997, J INVEST ALLERG CLIN, V7, P588; Park HS, 2001, ANN ALLERG ASTHMA IM, V86, P444; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Paul K, 1998, EUR J PEDIATR, V157, P109, DOI 10.1007/s004310050780; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; Pene J, 1998, J ALLERGY CLIN IMMUN, V102, P571, DOI 10.1016/S0091-6749(98)70294-5; PEREZ AO, 2000, REV ESPANOLA PEDIAT, V56, P253; PERONI DG, 1995, ALLERGY, V50, P925, DOI 10.1111/j.1398-9995.1995.tb02500.x; PETERSEN BN, 1988, ALLERGY, V43, P353, DOI 10.1111/j.1398-9995.1988.tb00429.x; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Pradalier A, 1999, ALLERGY, V54, P819, DOI 10.1034/j.1398-9995.1999.00077.x; PRICE JF, 1984, CLIN ALLERGY, V14, P209, DOI 10.1111/j.1365-2222.1984.tb02200.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; RAK S, 1993, ALLERGY, V48, P125, DOI 10.1111/j.1398-9995.1993.tb04714.x; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; RAK S, 1991, J ALLERGY CLIN IMMUN, V88, P878, DOI 10.1016/0091-6749(91)90244-I; Rak S, 2001, J ALLERGY CLIN IMMUN, V108, P921, DOI 10.1067/mai.2001.119743; RAK S, 1990, J ALLERGY CLIN IMMUN, V86, P706, DOI 10.1016/S0091-6749(05)80174-5; RAK S, 1993, ALLERGY, V48, P460, DOI 10.1111/j.1398-9995.1993.tb00745.x; REBIEN W, 1980, Allergologie, V3, P101; REID MJ, 1986, J ALLERGY CLIN IMMUN, V78, P590, DOI 10.1016/0091-6749(86)90076-X; REILLY DT, 1993, COMPLEMENTARY THE S1, V1, P24; REINERT M, 1983, PRAX KLIN PNEUMOL, V37, P228; REINERT M, 1981, PRAX KLIN PNEUMOL, V35, P71; Rocha E M, 1986, Allerg Immunol (Paris), V18, P29; ROHATGI N, 1988, J ALLERGY CLIN IMMUN, V82, P389, DOI 10.1016/0091-6749(88)90010-3; Rose G, 1996, J ALLERGY CLIN IMMUN, V97, P1071, DOI 10.1016/S0091-6749(96)70260-9; SABBAH A, 1991, Allergie et Immunologie (Paris), V23, P58; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SANDERS S, 1966, PRACTITIONER, V196, P811; Rodriguez Santos O, 2005, PEDIATRIKA, V25, P18; SANTOS OR, 2004, REV ALERG MEX, V51, P177; Saraclar Y, 1998, J INVEST ALLERG CLIN, V8, P98; Sastre J, 2003, J ALLERGY CLIN IMMUN, V111, P985, DOI 10.1067/mai.2003.1390; Scordamaglia A., 1997, European Respiratory Journal Supplement, V10, p441S; Shaikh WA, 1997, CLIN EXP ALLERGY, V27, P1279; SHEN H, 1998, EUROPEAN RESP J S25, V3, pA69; Shore L, 1980, ALLERGOL IMMUNOPATH, V8, P288; *SILK SCI CORP, 1996, UN SCAN IT V4 0; Simons FER, 1996, INT IMMUNOL, V8, P1937, DOI 10.1093/intimm/8.12.1937; Sin B, 1996, J INVEST ALLERG CLIN, V6, P341; SMITH AP, 1971, BRIT MED J, V4, P204; Smith TRF, 2004, ALLERGY, V59, P1097, DOI 10.1111/j.1398-9995.2004.00601.x; Smits William, 2003, Ear Nose Throat J, V82, P881; SUNDIN B, 1986, J ALLERGY CLIN IMMUN, V77, P478, DOI 10.1016/0091-6749(86)90183-1; SWINEFORD O, 1955, J ALLERGY, V26, P305, DOI 10.1016/0021-8707(55)90060-5; Sychlowy A, 1979, Pediatr Pol, V54, P1295; SYKORA T, 2004, CZE ALERGIE, V6, P170; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tabar AI, 1999, J INVEST ALLERG CLIN, V9, P155; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; TARI MG, 1992, J INVEST ALLERG CLIN, V2, P59; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Tari MG, 1997, ALLERGY, V52, P65, DOI 10.1111/j.1398-9995.1997.tb02547.x; TASKAPAN O, 1998, DERI HASTALIKLARI VE, V32, P164; Taub S J, 1969, IMJ Ill Med J, V135, P706; TAUDORF E, 1985, ALLERGY, V40, P321, DOI 10.1111/j.1398-9995.1985.tb00243.x; TAUDORF E, 1987, J ALLERGY CLIN IMMUN, V80, P153, DOI 10.1016/0091-6749(87)90124-2; TAUDORF E, 1983, ALLERGY, V38, P561, DOI 10.1111/j.1398-9995.1983.tb04140.x; TAYLOR B, 1974, CLIN ALLERGY, V4, P35, DOI 10.1111/j.1365-2222.1974.tb01360.x; TAYLOR WW, 1978, J ALLERGY CLIN IMMUN, V61, P283, DOI 10.1016/0091-6749(78)90048-9; TINKELMAN DG, 1995, J ALLERGY CLIN IMMUN, V95, P8, DOI 10.1016/S0091-6749(95)70146-X; Tsai YG, 2005, PEDIATR ALLERGY IMMU, V16, P602, DOI 10.1111/j.1399-3038.2005.00313.x; TUCHINDA M, 1973, J ALLERGY CLIN IMMUN, V51, P131, DOI 10.1016/0091-6749(73)90018-3; TURNER MW, 1984, CLIN ALLERGY, V14, P221, DOI 10.1111/j.1365-2222.1984.tb02201.x; URBANEK R, 1982, MONATSSCHR KINDERH, V130, P150; Valovirta E, 1997, J INVEST ALLERG CLIN, V7, P369; Valovirta E, 1999, Wien Med Wochenschr, V149, P442; VALOVIRTA E, 1984, ANN ALLERGY, V53, P85; VALOVIRTA E, 1986, ANN ALLERGY, V57, P173; Van Bever HP, 1998, CLIN EXP ALLERGY, V28, P943; VANBEVER HP, 1990, J ALLERGY CLIN IMMUN, V86, P141, DOI 10.1016/S0091-6749(05)80058-2; VANBEVER HP, 1992, EUR RESPIR J, V5, P318; VANBEVER HP, 1988, ALLERGY, V43, P378; VANBEVER HP, 1989, CLIN EXP ALLERGY, V19, P399; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; Varney VA, 2003, CLIN EXP ALLERGY, V33, P1076, DOI 10.1046/j.1365-2222.2003.01735.x; VARNEY VA, 1991, BRIT MED J, V302, P265; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VIDAL C, 1999, ALERGOLOGIA INMUNOLO, V14, P289; Villalmanzo IG, 1999, J INVEST ALLERG CLIN, V9, P321; Voltolini S, 2001, Allergol Immunopathol (Madr), V29, P103; Vooren P H, 1969, Ned Tijdschr Geneeskd, V113, P2127; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; WAHN U, 1980, J ALLERGY CLIN IMMUN, V65, P413, DOI 10.1016/0091-6749(80)90233-X; WAHN U, 1988, J ALLERGY CLIN IMMUN, V82, P360, DOI 10.1016/0091-6749(88)90007-3; Walker S. M., 2003, Journal of Allergy and Clinical Immunology, V111, pS267, DOI 10.1016/S0091-6749(03)80958-2; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; WANG H, 2004, RESPIROLOGY S, V9, pA79; Wang JA, 1999, VACCINE, V17, P1, DOI 10.1016/S0264-410X(98)00153-4; WARNER JO, 1978, LANCET, V2, P912; Weeke B, 1991, Clin Exp Allergy, V21 Suppl 1, P86, DOI 10.1111/j.1365-2222.1991.tb01711.x; WEYER A, 1981, ALLERGY, V36, P309, DOI 10.1111/j.1398-9995.1981.tb01582.x; WIHL JA, 1988, ALLERGY, V43, P363, DOI 10.1111/j.1398-9995.1988.tb00430.x; Wilson DR, 2001, CLIN EXP ALLERGY, V31, P1705, DOI 10.1046/j.1365-2222.2001.01231.x; Wilson DR, 2003, COCHRANE DB SYST REV, DOI [10.1016/S1081-1206(10)60004-X, DOI 10.1002/14651858.CD002893]; WUTHRICH B, 1980, SCHWEIZ MED WSCHR, V110, P281; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305; Zenner HP, 1997, J ALLERGY CLIN IMMUN, V100, P23; Zietkowski Z, 1999, Pol Merkur Lekarski, V6, P236	349	92	98	0	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1469-493X	1361-6137		COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2010		8							CD001186	10.1002/14651858.CD001186.pub2		111	Medicine, General & Internal	General & Internal Medicine	634RZ	WOS:000280603600025	20687065	
J	Annesi-Maesano, I; Moreau, D; Caillaud, D; Lavaud, F; Le Moullec, Y; Taytard, A; Pauli, G; Charpin, D				Annesi-Maesano, Isabella; Moreau, David; Caillaud, Denis; Lavaud, Francois; Le Moullec, Yvon; Taytard, Andre; Pauli, Gabrielle; Charpin, Denis			Residential proximity fine particles related to allergic sensitisation and asthma in primary school children	RESPIRATORY MEDICINE			English	Article						air pollution; asthma; allergic rhinitis; traffic; NO2; PM2.5	DIESEL EXHAUST PARTICLES; AIR-POLLUTION; RESPIRATORY HEALTH; EXPOSURE; POLLUTANTS; ATOPY; IGE; SCHOOLCHILDREN; INFLAMMATION; PARTICULATE	Background: Fine particulate matter has been linked to allergies by experimental and epidemiological data having used aggregated data or concentrations provided by fixed-site monitoring stations, which may have led to misclassification of individual exposure to air pollution. Methods: A semi-individual design was employed to relate individual data on asthma and allergy of 5338 school children (10.4 +/- 0.7 years) attending 108 randomly chosen schools in 6 French cities to the concentrations of PM2.5 (fine particles with aerodynamic diameter <= 2.5 mu m) assessed in proximity of their homes. Children underwent a medical visit including skin prick test (SPT) to common allergens, exercise-induced bronchial (EIB) reactivity and skin examination for flexural dermatitis. Their parents fitted in a standardised health questionnaire. Results: After adjustment for confounders and NO2 as a potential modifier, the odds of suffering from EIB and flexural dermatitis at the period of the survey, past year atopic asthma and SPT positivity to indoor allergens were significantly increased in residential settings with PM2.5 concentrations exceeding 10 mu g/m(3) (WHO air quality limit values). The relationships were strengthened in long-term residents (current address for at least 8 years). Conclusions: Findings support the hypothesis that changes in allergy prevalence observed in recent decades might be partly related to interactions between traffic-related air pollution and allergens. Further longitudinal investigations are needed to corroborate such results. (c) 2007 Elsevier Ltd. All rights reserved.	Univ Paris 06, INSERM, UMR S 707, EPAR,Med Sch St Antoine, F-75571 Paris, France; Hop Maison Blanche, Reims, France; Lab Hyg Paris, Paris, France; Hop Haut Leveque Bordeaux, Bordeaux, France; Hop Civils, Strasbourg, France; Hop Nord Marseille, Marseille, France	Annesi-Maesano, I (reprint author), Univ Paris 06, INSERM, UMR S 707, EPAR,Med Sch St Antoine, 27 Rue Chaligny, F-75571 Paris, France.	annesi@u707.jussieu.fr	Wang, Linden/M-6617-2014; Annesi-Maesano, Isabella/D-9173-2016; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Annesi-Maesano I, 2007, EUR RESPIR J, V29, P428, DOI 10.1183/09031936.00129506; Annesi-Maesano I, 2004, CLIN EXP ALLERGY, V34, P1017, DOI 10.1111/j.1365-2222.2004.02002.x; ANNESIMAESANO I, 2001, WORLD CLEAN AIR ENV, P1; Behrendt H, 1997, INT ARCH ALLERGY IMM, V113, P69; BROOK JR, 1995, AIR WASTE MANAGE ASS, V45, P709; Brunekreef B, 1997, EPIDEMIOLOGY, V8, P298, DOI 10.1097/00001648-199705000-00012; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; Festy B, 1997, B ACAD NAT MED PARIS, V181, P461; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gilmour MI, 1995, TOXICOLOGY, V105, P335, DOI 10.1016/0300-483X(95)03230-D; Hirsch T, 1999, EUR RESPIR J, V14, P669, DOI 10.1034/j.1399-3003.1999.14c29.x; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Kunzli N, 2000, LANCET, V356, P795, DOI 10.1016/S0140-6736(00)02653-2; Lee E., 1980, STAT METHODS SURVIVA; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.1093/biomet/73.1.13; Mastrangelo G, 2003, INT ARCH OCC ENV HEA, V76, P63, DOI 10.1007/s00420-002-0373-x; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Miyake Yoshihiro, 2002, J Epidemiol, V12, P418; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Nordenhall C, 2000, EUR RESPIR J, V15, P1046, DOI 10.1034/j.1399-3003.2000.01512.x; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; POPP W, 1989, ALLERGY, V44, P572, DOI 10.1111/j.1398-9995.1989.tb04202.x; Priftanji A, 2001, LANCET, V358, P1426, DOI 10.1016/S0140-6736(01)06521-7; Steerenberg PA, 2003, J TOXICOL ENV HEAL A, V66, P1421, DOI 10.1080/15287390390202054; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; TAKENAKA H, 1995, J ALLERGY CLIN IMMUN, V95, P103, DOI 10.1016/S0091-6749(95)70158-3; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Weiland Stephan K., 1994, Annals of Epidemiology, V4, P243; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; WJST M, 1993, BRIT MED J, V307, P596; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015	38	92	93	1	21	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111			RESP MED	Respir. Med.	AUG	2007	101	8					1721	1729		10.1016/j.rmed.2007.02.022		9	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	195IW	WOS:000248406900016	17442561	
J	Luebke, RW; Chen, DH; Dietert, R; Yang, Y; King, M; Luster, MI				Luebke, RW; Chen, DH; Dietert, R; Yang, Y; King, M; Luster, MI			The comparative immunotoxicity of five selected compounds following developmental or adult exposure	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS			English	Review							DELAYED-TYPE HYPERSENSITIVITY; DEVELOPING IMMUNE-SYSTEM; TETRACHLORODIBENZO-P-DIOXIN; PRENATAL DIAZEPAM EXPOSURE; NATURAL-KILLER-CELLS; HUMORAL IMMUNITY; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; PERINATAL EXPOSURE; HOST-RESISTANCE; LEAD-EXPOSURE	It is well established that human diseases associated with abnormal immune function, including some common infectious diseases and asthma, are considerably more prevalent at younger ages. Although not established absolutely, it is generally believed that development constitutes a period of increased immune system susceptibility to xenobiotics, since adverse effects may occur at lower doses and/or immunomodulation may be more persistent, thus increasing the relative risk of xenobiotic exposure to the immunologically immature organism. To address this issue, a brief overview of immune maturation in humans is provided to demonstrate that functional immaturity alone predisposes the young to infection. Age-dependent differences in the immunotoxic effects of five diverse compounds, diethylstilbestrol (DES), diazepam (DZP), lead (Pb), 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), and tributyltin oxide (TBTO), which have undergone adult and developmental immunotoxicity testing in rodents, are then reviewed, as are human data when available. For all five chemicals, the developing immune system was found to be at greater risk than that of the adult, either because lower doses produced immunotoxicity, adverse effects were more persistent, or both.	US EPA, Immunotoxicol Branch, Expt Toxicol Div, Natl Hlth & Environm Effects Res Lab,Off Res & De, Res Triangle Pk, NC 27711 USA; US EPA, Off Childrens Hlth Protect, Washington, DC 20460 USA; Cornell Univ, Dept Microbiol & Immunol, Ithaca, NY USA; Cornell Univ, Inst Comparat & Environm Toxicol, Ithaca, NY 14853 USA; US EPA, Off Pesticides Program, Washington, DC 20460 USA; US EPA, Off Pollut Prevent & Tox, Washington, DC 20460 USA; NIOSH, Toxicol & Mol Biol Branch, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV USA	Luebke, RW (reprint author), US EPA, Immunotoxicol Branch, Expt Toxicol Div, Natl Hlth & Environm Effects Res Lab,Off Res & De, Res Triangle Pk, NC 27711 USA.	luebke.robert@epi.gov					AMBRUSO DR, 1984, PEDIATR RES, V18, P1148, DOI 10.1203/00006450-198411000-00019; Anetor J I, 1998, Afr J Med Med Sci, V27, P169; Baccarelli A, 2002, ENVIRON HEALTH PERSP, V110, P1169; Baird DD, 1996, J CLIN EPIDEMIOL, V49, P263, DOI 10.1016/0895-4356(95)00521-8; BALEY JE, 1985, J IMMUNOL, V134, P3042; Birnbaum LS, 2000, FOOD ADDIT CONTAM, V17, P275, DOI 10.1080/026520300283351; BLAKLEY BR, 1981, TOXICOL APPL PHARM, V61, P18, DOI 10.1016/0041-008X(81)90003-X; BLAYLOCK BL, 1992, TOXICOL APPL PHARM, V112, P207, DOI 10.1016/0041-008X(92)90189-Y; Bunn TL, 2001, TOXICOL SCI, V64, P57; Bunn TL, 2001, TOXICOL METHOD, V11, P41; Bunn TL, 2001, J TOXICOL ENV HEAL A, V64, P101; Cavalcante NJF, 2001, CLIN INFECT DIS, V33, P1842, DOI 10.1086/324160; Chen SP, 2004, J TOXICOL ENV HEAL A, V67, P495, DOI 10.1080/15287390490276520; CICCIMARRA F, 1994, J PERINAT MED, V22, P84, DOI 10.1515/jpme.1994.22.s1.84; COSCIA G C, 1987, Medicina del Lavoro, V78, P360; Covelli V, 1998, IMMUNOPHARM IMMUNOT, V20, P199, DOI 10.3109/08923979809038539; DEAN JH, 1980, J RETICULOENDOTH SOC, V28, P571; DESCOTES J, 1982, J IMMUNOPHARMACOL, V4, P279; DESCOTES J, 1982, IMMUNOL LETT, V5, P41, DOI 10.1016/0165-2478(82)90089-X; DOSTAL M, 1995, REPROD TOXICOL, V9, P115, DOI 10.1016/0890-6238(94)00061-1; Dragan YP, 2000, FOOD ADDIT CONTAM, V17, P289, DOI 10.1080/026520300283360; Dyatlov VA, 2002, BRAIN BEHAV IMMUN, V16, P477, DOI 10.1006/brbi.2001.0641; Ewers U, 1982, ENVIRON RES, V29, P352; Faden H, 2001, EUR J PEDIATR, V160, P407, DOI 10.1007/s004310100754; FAITH RE, 1979, CLIN EXP IMMUNOL, V35, P413; FAITH RE, 1977, J TOXICOL ENV HEALTH, V3, P451; FISCHBEIN A, 1993, CLIN IMMUNOL IMMUNOP, V66, P163, DOI 10.1006/clin.1993.1020; FORSBERG JG, 1984, ARCH TOXICOL, V55, P7; Gehrs BC, 1997, TOXICOLOGY, V122, P219, DOI 10.1016/S0300-483X(97)00098-X; Gehrs BC, 1997, TOXICOLOGY, V122, P229, DOI 10.1016/S0300-483X(97)00099-1; Gehrs BC, 1999, TOXICOLOGY, V134, P79, DOI 10.1016/S0300-483X(99)00024-4; Geyer HJ, 2002, CHEMOSPHERE, V48, P631, DOI 10.1016/S0045-6535(02)00030-9; GEYER HJ, 1990, TOXICOLOGY, V65, P97, DOI 10.1016/0300-483X(90)90081-Q; Heo Y, 1996, TOXICOL APPL PHARM, V138, P149, DOI 10.1006/taap.1996.0108; HOLLADAY SD, 1993, CELL IMMUNOL, V152, P131, DOI 10.1006/cimm.1993.1273; HOLLADAY SD, 1991, TERATOLOGY, V44, P385, DOI 10.1002/tera.1420440405; Holladay SD, 2000, ENVIRON HEALTH PERSP, V108, P463, DOI 10.2307/3454538; HOLSAPPLE MP, 1991, TOXICOLOGY, V69, P219, DOI 10.1016/0300-483X(91)90184-3; Holsapple MP, 2003, TOXICOLOGY, V185, P193, DOI 10.1016/S0300-483X(02)00609-1; ISHAAYA I, 1976, PESTIC BIOCHEM PHYS, V6, P270, DOI 10.1016/0048-3575(76)90070-5; KALLAND T, 1980, CELL IMMUNOL, V51, P55, DOI 10.1016/0008-8749(80)90237-3; KALLAND T, 1978, CANCER LETT, V4, P141, DOI 10.1016/S0304-3835(78)94017-X; KALLAND T, 1981, CANCER RES, V41, P5134; KALLAND T, 1984, IMMUNOPHARMACOLOGY, V7, P127, DOI 10.1016/0162-3109(84)90062-6; KALLAND T, 1979, J NATL CANCER I, V63, P413; KALLAND T, 1980, J IMMUNOL, V124, P194; Karmaus W, 2001, ARCH ENVIRON HEALTH, V56, P485; Kellogg CK, 1999, PHARMACOL BIOCHEM BE, V64, P673, DOI 10.1016/S0091-3057(99)00137-9; Kerkvliet NI, 2002, INT IMMUNOPHARMACOL, V2, P277, DOI 10.1016/S1567-5769(01)00179-5; KIMBER I, 1986, INT ARCH OCC ENV HEA, V57, P117, DOI 10.1007/BF00381379; KOLLER LD, 1983, J TOXICOL ENV HEALTH, V12, P173; KOLLER LD, 1977, TOXICOL APPL PHARM, V42, P621, DOI 10.1016/S0041-008X(77)80050-1; KRAJNC EI, 1984, TOXICOL APPL PHARM, V75, P363, DOI 10.1016/0041-008X(84)90176-5; LASCHI A, 1983, TOXICOL LETT, V16, P281, DOI 10.1016/0378-4274(83)90188-1; Levy O, 1999, PEDIATRICS, V104, P1327, DOI 10.1542/peds.104.6.1327; LIVEZEY GT, 1986, NEUROTOXICOL TERATOL, V8, P433; LU YC, 1985, ENVIRON HEALTH PERSP, V59, P17, DOI 10.2307/3429869; LUEBKE RW, 1984, INT J IMMUNOPHARMACO, V6, P609, DOI 10.1016/0192-0561(84)90072-9; LUSTER MI, 1978, J ENVIRON PATHOL TOX, V1, P397; LUSTER MI, 1979, TOXICOL APPL PHARM, V47, P279, DOI 10.1016/0041-008X(79)90322-3; LUSTER MI, 1980, INT J IMMUNOPHARMACO, V2, P301, DOI 10.1016/0192-0561(80)90030-2; LUSTER MI, 1978, B ENVIRON CONTAM TOX, V20, P433; LUSTER MI, 1984, J IMMUNOL, V133, P110; Luster Michael I., 2003, Environmental Health Perspectives, V111, P579; Lutz PM, 1999, TOXICOLOGY, V134, P63, DOI 10.1016/S0300-483X(99)00036-0; McCabe MJ, 1999, TOXICOLOGY, V139, P255, DOI 10.1016/S0300-483X(99)00147-X; Miller TE, 1998, TOXICOL SCI, V42, P129, DOI 10.1006/toxs.1998.2424; MISRA KP, 2003, TOXICOLOGY, V188, P251; MOCARELLI P, 1986, JAMA-J AM MED ASSOC, V256, P2687, DOI 10.1001/jama.256.19.2687; MULLER S, 1977, EXPERIENTIA, V33, P667; NAKANISHI Y, 1985, ENVIRON HEALTH PERSP, V59, P31, DOI 10.2307/3429870; National Research Council, 1993, PEST DIETS INF CHILD; NEILAN BA, 1980, CLIN EXP IMMUNOL, V39, P746; PENNINKS AH, 1983, ADV IMMUNOPHARMACOL, V2, P41; Pinkerton LE, 1998, AM J IND MED, V33, P400, DOI 10.1002/(SICI)1097-0274(199804)33:4<400::AID-AJIM11>3.0.CO;2-2; Pocchiari F, 1979, Ann N Y Acad Sci, V320, P311, DOI 10.1111/j.1749-6632.1979.tb13157.x; PRICE HV, 1976, TRANSPLANTATION, V21, P294, DOI 10.1097/00007890-197604000-00004; QUEIROZ MLS, 1994, IMMUNOPHARM IMMUNOT, V16, P115, DOI 10.3109/08923979409029904; Sandler J, 2002, HUM EXP TOXICOL, V21, P469; Sata F, 1998, ENVIRON RES, V76, P61, DOI 10.1006/enrs.1997.3790; Schell LM, 2004, ENVIRON RES, V96, P264, DOI 10.1016/j.envres.2004.02.008; Schena FP, 2002, TRANSPL IMMUNOL, V9, P161, DOI 10.1016/S0966-3274(02)00028-X; SCHLUMPF M, 1992, DEV PHARMACOL THERAP, V18, P145; SCHLUMPF M, 1990, DEV PHARMACOL THERAP, V15, P178; SCHLUMPF M, 1989, LIFE SCI, V44, P493, DOI 10.1016/0024-3205(89)90465-7; SCHLUMPF M, 1994, TOXICOLOGY, V94, P223, DOI 10.1016/0300-483X(94)90040-X; SCHLUMPF M, 1993, PHARMACOL TOXICOL, V73, P335; SCHREIBER AA, 1993, AGENTS ACTIONS, V38, P265, DOI 10.1007/BF01976219; SCHREIBER AA, 1993, AGENTS ACTIONS, V39, P166, DOI 10.1007/BF01998970; SIMMONS RD, 1983, TERATOLOGY, V28, P181, DOI 10.1002/tera.1420280206; SMIALOWICZ RJ, 1989, TOXICOLOGY, V57, P97, DOI 10.1016/0300-483X(89)90037-1; SMIALOWICZ RJ, 1994, TOXICOL APPL PHARM, V124, P248, DOI 10.1006/taap.1994.1029; Snyder JE, 2000, TOXICOL SCI, V57, P87, DOI 10.1093/toxsci/57.1.87; Staples JE, 1999, J IMMUNOL, V163, P4168; STIEHM ER, 1966, PEDIATRICS, V37, P715; Sugimoto M, 2003, COM S COLL LEARN, V2, P3; Tendron A, 2002, PEDIATR NEPHROL, V17, P121; TOGNONI G, 1982, DRUG METAB REV, V13, P447, DOI 10.3109/03602538209029989; Tryphonas H., 2004, FOOD CHEM TOXICOL, V42, P227; Ugaz EMA, 1999, IMMUNOPHARMACOLOGY, V41, P209, DOI 10.1016/S0162-3109(99)00031-4; Undeger U, 1996, TOXICOLOGY, V109, P167, DOI 10.1016/0300-483X(96)03333-1; Upham JW, 2002, INFECT IMMUN, V70, P6583, DOI 10.1128/IAI.70.12.6583-6588.2002; VALENTINO M, 1991, ARCH TOXICOL, V65, P685, DOI 10.1007/BF02098038; Van Loveren H, 1998, Arch Toxicol Suppl, V20, P285; Van Loveren H, 2003, TOXICOLOGY, V185, P185, DOI 10.1016/S0300-483X(02)00608-X; Vandebriel RJ, 1998, TOXICOL APPL PHARM, V148, P126, DOI 10.1006/taap.1997.8294; VERDIER F, 1991, J TOXICOL ENV HEALTH, V32, P307; Villagra R, 1997, B ENVIRON CONTAM TOX, V58, P190; VOS JG, 1974, INT ARCH ALLER A IMM, V47, P777; VOS JG, 1990, TOXICOL APPL PHARM, V105, P144, DOI 10.1016/0041-008X(90)90366-3; Weisglas-Kuperus N, 2000, ENVIRON HEALTH PERSP, V108, P1203, DOI 10.2307/3434834; WEISGLASKUPERUS N, 1995, PEDIATR RES, V38, P404, DOI 10.1203/00006450-199509000-00022; Whalen MM, 1999, ENVIRON RES, V81, P108, DOI 10.1006/enrs.1999.3968; Whalen MM, 2002, ENVIRON RES, V88, P19, DOI 10.1006/enrs.2001.4318; WILSON CB, 1986, J PEDIATR-US, V108, P1, DOI 10.1016/S0022-3476(86)80761-2; WOLACH B, 1994, ISRAEL J MED SCI, V30, P331	116	92	96	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1093-7404			J TOXICOL ENV HEAL B	J. Toxicol. Env. Health-Pt b-Crit. Rev.	JAN-FEB	2006	9	1					1	26		10.1080/15287390500194326		26	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	998AO	WOS:000234290500001	16393867	
J	Liao, SC; Cheng, YC; Wang, YC; Wang, CW; Yang, SM; Yu, CK; Shieh, CC; Cheng, KC; Lee, MF; Chiang, SR; Shieh, JM; Chang, MS				Liao, SC; Cheng, YC; Wang, YC; Wang, CW; Yang, SM; Yu, CK; Shieh, CC; Cheng, KC; Lee, MF; Chiang, SR; Shieh, JM; Chang, MS			IL-19 induced Th2 cytokines and was up-regulated in asthma patients	JOURNAL OF IMMUNOLOGY			English	Article							HUMAN INTERLEUKIN-10; STIMULATORY FACTOR; TRANSGENIC MICE; MURINE MODEL; T-CELLS; INFLAMMATION; RESPONSES; DETERMINES; INDUCTION; EFFECTORS	IL-19 belongs to the IL-10 family, which includes IL-10, IL-19, IL-20, IL-22, melanoma differentiation-associated gene-7 (IL-24), and AK155 (IL-26). IL-10 has been shown to inhibit allergen-induced airway hyperreactivity and inflammation. To determine whether IL-19 was also associated with asthma, we used ELISA to analyze the serum level of IL-19 in patients with asthma and found that their serum IL-19 levels were twice those of healthy controls. Patients with a high level of IL-19 also had high levels of IL-4 and IL-13. In a dust mite-induced murine model of asthma, we found that IL-19 level in asthmatic BALB/cJ mice was also twice that of healthy control mice. IL-19 transcript was also induced in the lungs of asthmatic mice. Electroporation i.m. of the IL-19 gene into healthy mice up-regulated IL-4 and IL-5, but not IL-13. However, IL-19 up-regulated IL-13 in asthmatic mice. In vitro, IL-19 induced IL-4, IL-5, IL-10, and IL-13 production by activated T cells. Activation of T cells was required for induction of IL-13 because IL-19 did not induce IL-13 production on nonstimulated T cells. Taken together, these results demonstrated that IL-19 up-regulates Th2 cytokines on activated T cells and might play an important role in the pathogenesis of asthma.	Natl Cheng Kung Univ, Coll Med, Grant Inst Biochem, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Grad Inst Microbiol & Immunol, Tainan 701, Taiwan; Chi Mei Med Ctr, Tainan, Taiwan	Chang, MS (reprint author), Natl Cheng Kung Univ, Coll Med, Grant Inst Biochem, 1 Dahsueh Rd, Tainan 701, Taiwan.	mschang@mail.ncku.edu.tw					Aihara H, 1998, NAT BIOTECHNOL, V16, P867, DOI 10.1038/nbt0998-867; CLUTTERBUCK EJ, 1989, BLOOD, V73, P1504; DEWAAL MR, 1998, CYTOKINE, P151; de Waal Malefyt R., 1991, J EXP MED, V174, P1209, DOI DOI 10.1084/JEM.174.5.1209; Ding YZ, 2000, J EXP MED, V191, P213, DOI 10.1084/jem.191.2.213; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; Gallagher G, 2004, INT IMMUNOPHARMACOL, V4, P615, DOI 10.1016/j.intimp.2004.01.005; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; Gesser B, 1997, P NATL ACAD SCI USA, V94, P14620, DOI 10.1073/pnas.94.26.14620; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Grunig G, 1997, J EXP MED, V185, P1089, DOI 10.1084/jem.185.6.1089; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUNG TT, 1995, AM J RESP CELL MOL, V13, P360; Liao YC, 2002, J IMMUNOL, V169, P4288; McKenzie GJ, 1998, IMMUNITY, V9, P423, DOI 10.1016/S1074-7613(00)80625-1; Parronchi P, 1999, J IMMUNOL, V163, P5946; ROUSSET F, 1992, P NATL ACAD SCI USA, V89, P1890, DOI 10.1073/pnas.89.5.1890; SEDER RA, 1992, J EXP MED, V176, P1091, DOI 10.1084/jem.176.4.1091; SWAIN SL, 1990, J IMMUNOL, V145, P3796; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; VANOOSTERHOUT AJM, 1995, J ALLERGY CLIN IMMUN, V96, P104, DOI 10.1016/S0091-6749(95)70039-0; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yu CK, 1999, J ALLERGY CLIN IMMUN, V104, P228, DOI 10.1016/S0091-6749(99)70140-5	25	92	101	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	DEC 1	2004	173	11					6712	6718				7	Immunology	Immunology	873UV	WOS:000225307500027	15557163	
J	Chan, HK; Chew, NYK				Chan, HK; Chew, NYK			Novel alternative methods for the delivery of drugs for the treatment of asthma	ADVANCED DRUG DELIVERY REVIEWS			English	Review						dry powder aerosol formulation; powder production process; spray drying; solvent precipitation; milling; powder properties; carrier blend; dry powder inhaler	SALBUTAMOL SULFATE; POROUS PARTICLES; INHALATION; FORMULATIONS; POWDERS; CARRIER; LACTOSE	Successful delivery of dry powder aerosols to the lung requires careful consideration of the powder production process, formulation and inhaler device. Newer production methods are emerging to prepare powders with desirable characteristics for inhalational administration. The conventional formulation approach of adding coarse lactose carriers to the drug to form binary powder systems to enhance powder flow and dispersion properties has been expanded to using finer carrier particles and hydrophobic materials, as well as ternary systems. Particle morphology and surface properties have also been explored to enhance powder performance. For the inhaler device, the new generation inhalers are designed to reduce or completely decouple the influence of air flow on the aerosol generation. Each of these determinants for powder aerosol delivery is reviewed with a strong focus on the patent literature that contains enormous information about the latest development in this field. (C) 2003 Elsevier Science B.V. All rights reserved.	Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia	Chan, HK (reprint author), Univ Sydney, Fac Pharm, A15, Sydney, NSW 2006, Australia.						Bot AI, 2000, PHARMACEUT RES, V17, P275, DOI 10.1023/A:1007544804864; Buccellati C, 2002, FARMACO, V57, P235, DOI 10.1016/S0014-827X(02)01209-0; Chan HK, 1997, PHARMACEUT RES, V14, P431, DOI 10.1023/A:1012035113276; CHAWLA A, 1994, INT J PHARM, V108, P233, DOI 10.1016/0378-5173(94)90132-5; Chew NYK, 2001, PHARMACEUT RES, V18, P1570, DOI 10.1023/A:1013082531394; CHEW NYK, 2001, KONA POWDER PARTICLE, V19, P46; CHEW NYK, 2000, RESP DRUG DELIVERY, V2, P615; CHEW NYK, 2002, IN PRESS ENCY PHARM; CHEW NYK, 2002, P RESP DRUG DELIVERY, V2, P619; Staniforth JN, 2000, US Patent, Patent No. 6153224; Dellamary LA, 2000, PHARMACEUT RES, V17, P168, DOI 10.1023/A:1007513213292; Diamant Z, 2000, PULM PHARMACOL THER, V13, P1, DOI 10.1006/pupt.1999.0222; Edwards DA, 1997, SCIENCE, V276, P1868, DOI 10.1126/science.276.5320.1868; Fults K A, 1997, Pharm Dev Technol, V2, P67, DOI 10.3109/10837459709022610; KELLER M, 2000, P RESP DRUG DELIVERY, V2, P511; Larhrib H, 1999, INT J PHARM, V191, P1, DOI 10.1016/S0378-5173(99)00164-7; LIGOTKE MW, 2002, P RESP DRUG DELIVERY, V2, P419; Lucas P, 1999, PHARMACEUT RES, V16, P1643, DOI 10.1023/A:1011981326827; Lucas P, 1996, P RESP DRUG DELIVERY, VIL, P243; Maa YF, 1999, PHARMACEUT RES, V16, P249, DOI 10.1023/A:1018828425184; Maa Yuh-Fun, 2000, Current Pharmaceutical Biotechnology, V1, P283, DOI 10.2174/1389201003378898; Masters K, 1979, SPRAY DRYING HDB; MATZER WJ, 1999, BIODRUGS, V12, P237; MUMENTHALER M, 1991, INT J PHARM, V72, P97, DOI 10.1016/0378-5173(91)90047-R; OSTRANDER KD, 2000, P RESP DRUG DELIVERY, V7, P447; Sakagami M, 2002, J CONTROL RELEASE, V80, P207, DOI 10.1016/S0168-3659(02)00034-2; Sievers RE, 2000, 219 ACS NAT M SAN FR; VIDGREN MT, 1987, INT J PHARM, V35, P139, DOI 10.1016/0378-5173(87)90082-2; VILLAX P, 2002, P RESP DRUG DELIVERY, V2, P459; [Anonymous], 2002, P RESP DRUG DELIVERY; WEERS J, 2000, INNOVATIONS PHARM TE, V1, P114; Weers J., 2000, INNOV PHARM TECH, V1, P111; WEERS JG, 2000, P RESP DRUG DELIVERY, P91; YAMASHITA C, 1996, P RESP DRUG DELIVERY, P483; York P., 1996, P RESP DRUG DELIVERY, P231; Zeng XM, 2001, J PHARM SCI, V90, P1424, DOI 10.1002/jps.1094; STANIFORTH JN, 2001, Patent No. 0178695; Staniforth JN, 1997, International Patent, Patent No. [WO 97/03649, 9703649, WO/97/03649]; Clark AR, 1996, WO patent, Patent No. 9631221; GANDERTON D, 1994, Patent No. 5376386; Lechuga-Ballesteros D, 2001, WO patent, Patent No. 0132144; Briggner LE, 1999, US Patent, Patent No. 5874063; Edwards DA, 2001, WO patent, Patent No. 0195874; Begon D, 2001, WO patent, Patent No. 0114036; MUSA R, 2000, Patent No. 0053158; MUSA R, 2000, Patent No. 0053157; Kusssendrager KD, 2002, Carrier material for dry powder inhalation, Patent No. [WO 0207705, 0207705]; Cundy K. C., 1992, US Patent, Patent No. 5145684; Chickering DA III, 2001, US patent, Patent No. 6223455; KELLER M, 2000, Patent No. 0028979; LANCASTER RW, 2000, Patent No. 0038811; WARD G, 2001, Patent No. 0176560; WEERS JG, 1998, Patent No. 6309623; Staniforth J.N., 2002, WO IPO, Patent No. [0243702 A2, 0243702]; BELL J, 1979, Patent No. 416516; Chiesi P., 1980, DE patent, Patent No. 3018550; Nilsson L.G, 2000, DOI 6, 089, 227, Patent No. 6089227; NILSSON T, 2002, Patent No. 0211801; Watanabe W, 2001, WO patent, Patent No. 0149263; Forrester R. B., 1986, US patent, Patent No. [US4590206, 4590206]; Morton DAV, 2001, WO patent, Patent No. 0187277; WARD G, 2001, Patent No. 01701698; STANIFORTH JN, 2002, Patent No. 0200197; Maa Y-F, 2001, US patent, Patent No. 6284282; Woolfe AJ, 2001, WO patent, Patent No. 0113885; JOHNSON KA, 2000, Patent No. 6103270; VEMURI N, 2000, Patent No. 0032165; Staniforth JN, 1996, International Patent, Patent No. [WO 96/23485, 9623485]; Banholzer R, 2002, WO patent, Patent No. 0230928	69	92	95	0	29	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-409X			ADV DRUG DELIVER REV	Adv. Drug Deliv. Rev.	JUL 18	2003	55	7					793	805		10.1016/S0169-409X(03)00078-4		13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	702FV	WOS:000184212500003	12842601	
J	Clarisse, B; Laurent, AM; Seta, N; Le Moullec, Y; El Hasnaoui, A; Momas, I				Clarisse, B; Laurent, AM; Seta, N; Le Moullec, Y; El Hasnaoui, A; Momas, I			Indoor aldehydes: measurement of contamination levels and identification of their determinants in Paris dwellings	ENVIRONMENTAL RESEARCH			English	Article						aldehyde; indoor air quality; determinants; passive sampling; ventilation	FORMALDEHYDE CONCENTRATIONS; EXPOSURE; AIR; ENVIRONMENTS; TOBACCO; HEALTH	The recent increased prevalence of childhood asthma and atopy has brought into question the impact of outdoor pollutants and indoor air quality. The contributory role of aldehydes to this problem and the fact that they are mainly derived from the domestic environment make them of particular interest. This study therefore measures six different aldehyde levels in Paris dwellings from potentially different sources and identifies their indoor determinants. The study was carried out in the three principal rooms of 61 flats with no previous history of complaint for olfactory nuisance or specific symptoms, two-thirds of the flats having been recently refurbished. Aldehydes were sampled in these rooms using passive samplers, and a questionnaire on potential aldehyde sources was filled out at the same time. A multiple linear regression model was used to investigate indoor aldehyde determinants. Our study revealed that propionaldehyde and benzaldehyde were of minor importance compared to formaldehyde, acetaldehyde, pentanal, and hexanal. We found that levels of these last four compounds depended on the age of wall or floor coverings (renovations less than I year old), smoking, and ambient parameters (carbon dioxide levels, temperature). These results could help in the assessment of ndoor aldehyde emissions. (C) 2003 Elsevier Science (USA). All rights reserved.	Univ Paris 05, Lab Hyg & Sante Publ, Fac Sci Pharmaceut & Biol, F-75270 Paris 6, France; Hyge Lab Ville Paris, Paris, France; Epidemiol Unit, Lab GlaxoSmithKline, Marly Le Roi, France; Direct Act Sociale Enfance & Sante Mairie Paris, Paris, France	Momas, I (reprint author), Univ Paris 05, Lab Hyg & Sante Publ, Fac Sci Pharmaceut & Biol, 4 Ave Observ, F-75270 Paris 6, France.						Andreini BP, 2000, MICROCHEM J, V67, P11, DOI 10.1016/S0026-265X(00)00087-4; Baumann MGD, 2000, FOREST PROD J, V50, P75; BROWN V, 1996, 299 BRE BUILD RES ES; *CAL EPA, 1997, 979 CAL EPA; *COMM COST CONC CO, 1990, 13219 EUR COMM EUR C; DALLY KA, 1981, ARCH ENVIRON HEALTH, V36, P277; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GODISH T, 1989, AM J PUBLIC HEALTH, V79, P1044, DOI 10.2105/AJPH.79.8.1044; Gonzalez-Flesca N, 1999, ENVIRON SCI POLLUT R, V6, P95, DOI 10.1007/BF02987560; GOUPIL G, 2001, QUALITE AIR PARIS 20, P1; IARC Monographs on the evaluation of the carcinogenic risk of chemicals to humans, 1998, IARC MON, V1-29; *ITS, 1996, RES IND AIR QUAL GUI; Koeck M, 1997, Cent Eur J Public Health, V5, P127; Krieger P, 1998, REV MAL RESPIR, V15, P11; KUSKE M, POLLUTIONS AIR INTER, P1; *NAT RES COUNC COM, 1980, FORM ASS ITS HLTH DI; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; *OFF SMOK HLTH, 1979, DHEW PHS PUBLLL, P14; SAMET JM, 1988, AM REV RESPIR DIS, V137, P221; Schleibinger H, 2001, GEFAHRST REINHALT L, V61, P26; SEXTON K, 1986, JAPCA J AIR WASTE MA, V36, P698; SEXTON K, 1989, ENVIRON SCI TECHNOL, V23, P985, DOI 10.1021/es00066a009; VANNETTEN C, 1983, CAN J PUBLIC HEALTH, V74, P55; WHO, 2000, GUID AIR QUAL; Wiglusz R, 1990, Bull Inst Marit Trop Med Gdynia, V41, P73; Wiglusz R, 1990, Bull Inst Marit Trop Med Gdynia, V41, P79	26	92	94	1	17	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	JUL	2003	92	3					245	253		10.1016/S0013-9351(03)00039-2		9	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	693WG	WOS:000183740900009	12804521	
J	Yeatts, K; Davis, KJ; Sotir, M; Herget, C; Shy, C				Yeatts, K; Davis, KJ; Sotir, M; Herget, C; Shy, C			Who gets diagnosed with asthma? Frequent wheeze among adolescents with and without a diagnosis of asthma	PEDIATRICS			English	Article						asthma; adolescents; wheezing; diagnosis; demographics; allergies	CHILDHOOD ASTHMA; VIDEO QUESTIONNAIRE; PERSISTENT WHEEZE; AFRICAN-AMERICAN; HEALTH-SERVICES; UNITED-STATES; GREAT-BRITAIN; RISK-FACTORS; CHILDREN; PREVALENCE	Objective. 1) To describe the factors associated with not receiving an asthma diagnosis among children with frequent wheezing symptoms and 2) to determine risk factors for frequent wheezing in the population. Methods. The North Carolina School Asthma Survey provided self-reported questionnaire data on respiratory health from 122 829 children ages 12 to 18 years enrolled in 499 public middle schools in North Carolina during the 1999 - 2000 school year. Questions from the International Survey of Allergies and Asthma in Childhood were used to estimate the prevalence of asthma and wheezing-related illness and associated factors. Results. Factors independently associated with undiagnosed frequent wheezing versus asymptomatic children included female gender ( odds ratio [ OR]: 1.45; 95% confidence interval [CI]: 1.35-1.54), current smoking ( OR: 2.60; 95% CI: 2.43-2.79), exposure to household smoke ( OR: 1.59; 95% CI: 1.50-1.70), low socioeconomic status ( OR: 1.52; 95% CI: 1.42-1.63), and African American ( OR: 1.25; 95% CI: 1.15-1.34), Native American ( OR: 1.35; 95% CI: 1.11-1.62), and Mexican American ( OR: 1.32; 95% CI: 1.17-1.48) race/ethnicity. Urban residence showed a weak negative association ( OR: 0.91; 95% CI: 0.85-0.96). A similar pattern of results was observed for analyses comparing odds of undiagnosed frequent wheeze versus diagnosed asthmatics. Report of allergies was less likely in frequent wheezers (70%) compared with diagnosed asthmatics (86%), but much higher than in asymptomatic children (36%). Thirty-three percent of children with undiagnosed frequent wheezing reported 1 or more physician visits in the last year for wheezing or breathing problems compared with 71% of children with diagnosed asthma, and 4% in asymptomatic children. The prevalence of any inhaler use in the past 12 months was 12% for undiagnosed frequent wheezers versus 78% for diagnosed asthmatics. The proportion of undiagnosed frequent wheezers with fair or poor self-rated health (23%) was slightly higher than diagnosed asthmatics (20%) and much higher than asymptomatic children ( 4%). Conclusions. In one of the largest adolescent asthma surveys ever reported in the United States, undiagnosed frequent wheezing was independently associated with female gender, current smoking, exposure to household smoke, low socioeconomic status, allergies, and African American, Native American, and Mexican American race/ ethnicity. Children with undiagnosed frequent wheezing were not receiving adequate health care for their asthma-like illness. Clinicians who treat adolescents should consider asking adolescents specifically about wheezing. This information may assist primary care physicians in identifying children with undiagnosed asthma in need of treatment.	Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Worldwide Epidemiol, Res Triangle Pk, NC USA; N Carolina Dept Hlth & Human Serv, Div Publ Hlth, Raleigh, NC USA	Yeatts, K (reprint author), Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Campus Box 7435,McGavran Greenberg Hall, Chapel Hill, NC 27599 USA.						Adams P. F., 1995, VITAL HLTH STAT, V10; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; ANDERSON HR, 1981, LANCET, V2, P1030; Asher MI, 1998, EUR RESPIR J, V12, P315; Beasley R, 1998, CLIN EXP ALLERGY, V28, P8; BOSCO LA, 1993, CHEST, V104, P1727, DOI 10.1378/chest.104.6.1727; Braun-Fahrlander C, 1998, PEDIATR PULM, V25, P159, DOI 10.1002/(SICI)1099-0496(199803)25:3<159::AID-PPUL5>3.0.CO;2-H; Castro-Rodriguez LA, 2001, AM J RESP CRIT CARE, V163, P1344; Cook DG, 1999, THORAX, V54, P357; CRAIN EF, 1994, PEDIATRICS, V94, P356; Cunningham J, 1996, AM J PUBLIC HEALTH, V86, P1406, DOI 10.2105/AJPH.86.10.1406; Cunningham J, 1996, AM J RESP CRIT CARE, V153, P218; Diaz T, 2000, PEDIATRICS, V105, P1188, DOI 10.1542/peds.105.6.1188; Fagan JK, 2001, ANN ALLERG ASTHMA IM, V86, P177; Fuso L, 2000, RESP MED, V94, P397, DOI 10.1053/rmed.1999.0747; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; HALFON N, 1993, PEDIATRICS, V91, P56; Halterman JS, 2000, PEDIATRICS, V105, P272; Kaur B, 1998, BRIT MED J, V316, P118; Lowe GL, 2001, BRIT J GEN PRACT, V51, P664; LOZANO P, 1995, JAMA-J AM MED ASSOC, V274, P469, DOI 10.1001/jama.274.6.469; Lwebuga-Mukasa JS, 2000, J URBAN HEALTH, V77, P745, DOI 10.1007/BF02344035; Maier WC, 1998, J CLIN EPIDEMIOL, V51, P557, DOI 10.1016/S0895-4356(98)00027-4; MITCHELL EA, 1991, SOC SCI MED, V32, P831, DOI 10.1016/0277-9536(91)90309-Z; MITCHELL EA, 1989, INT J EPIDEMIOL, V18, P888, DOI 10.1093/ije/18.4.888; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; NORMAN F, 1993, EUR RESPIR J, V6, P834; ORTEGA AN, 2002, PEDIATRICS, V109; Pearce N, 2000, J Epidemiol Biostat, V5, P5; Renzoni E, 1999, EUR RESPIR J, V14, P597, DOI 10.1034/j.1399-3003.1999.14c19.x; Institute SAS, 2000, SAS STAT US GUID VER; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SENNHAUSER FH, 1995, PEDIATR PULM, V19, P161, DOI 10.1002/ppul.1950190304; Siersted HC, 1998, BRIT MED J, V316, P651; SILVER E, 1998, J ASTHMA, V35, P37; SPEIGHT ANP, 1983, BRIT MED J, V286, P1253; STRACHAN DP, 1994, ARCH DIS CHILD, V70, P174; TAYLOR WR, 1992, PEDIATRICS, V90, P657; Venn A, 1998, BRIT MED J, V316, P1945; Warner JO, 2000, CLIN EXP ALLERGY, V30, P70; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; Yeatts K, 2000, J ASTHMA, V37, P425, DOI 10.3109/02770900009055468; Yeatts KB, 2001, J ADOLESCENT HEALTH, V29, P314, DOI 10.1016/S1054-139X(01)00256-7; Zoratti EM, 1998, AM J RESP CRIT CARE, V158, P371	44	92	92	1	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	MAY 1	2003	111	5					1046	1054		10.1542/peds.111.5.1046		9	Pediatrics	Pediatrics	673KC	WOS:000182579300036	12728087	
J	Jones, CA; Holloway, JA; Popplewell, EJ; Diaper, ND; Holloway, JW; Vance, GHS; Warner, JA; Warner, JO				Jones, CA; Holloway, JA; Popplewell, EJ; Diaper, ND; Holloway, JW; Vance, GHS; Warner, JA; Warner, JO			Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						soluble CD14; amniotic fluid; breast milk; eczema	EARLY-CHILDHOOD; IGE PRODUCTION; IMMUNE-SYSTEM; CUTTING EDGE; HAY-FEVER; LIPOPOLYSACCHARIDE; CHILDREN; ASTHMA; RECOGNITION; MICROFLORA	Background: Exposure to various microbial products in early life reduces the risk of atopy. Such exposure induces down-regulation of T(H)2 allergy-biased responses by means of pattern recognition molecules, such as CD14, an LPS receptor. Objective: We sought to determine whether infant and maternal levels of soluble CD14 (sCD14) are associated with the atopic outcomes of infants. Methods: Levels of sCD14 in plasma, amniotic fluid, and breast milk were measured with a specific ELISA in different cohorts. Expression of toll-like receptors in the fetal gut was examined by using RT-PCR. Results: Soluble CD14 levels increased during fetal development and postnatally, attaining adult levels by around 4 months of age, with an overshoot of adult levels from 6 months of age. There was no difference in plasma sCD14 levels at birth of children with a high compared with those with a low risk of development of atopy. Amniotic fluid sCD14 levels at midgestation (16-17 weeks) were significantly lower when the child was subsequently atopic (P < .05). Soluble CD14 levels in breast milk collected 3 months postpartum were significantly lower in children with eczema at 6 months of age, irrespective of whether they were atopic (P = .003). Transcripts for toll-like receptor 4, which would enable transmembrane signaling for LPS/sCD14 complexes, were expressed within fetal gut and skin. Conclusion: Exposure to reduced levels of sCD14 in the fetal and neonatal gastrointestinal tract is associated with the development of atopy, eczema, or both. Thus the exogenous supply of sCD14 might influence immunologic reactivity both locally and systemically in early life and thereby influence disease outcome.	Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Southampton SO16 6YD, Hants, England; Southampton Gen Hosp, Sch Med, Div Human Genet, Southampton SO16 6YD, Hants, England	Jones, CA (reprint author), Southampton Gen Hosp, Sch Med, Div Infect Inflammat & Repair, Level G Mailpoint 803, Southampton SO16 6YD, Hants, England.		Holloway, Judith/A-1757-2010; Holloway, John/B-5424-2009	Holloway, Judith/0000-0002-2268-3071; Holloway, John/0000-0001-9998-0464	NHLBI NIH HHS [HL61858]		Arias MA, 2000, J IMMUNOL, V164, P3480; Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Beutler B, 2000, CURR OPIN IMMUNOL, V12, P20, DOI 10.1016/S0952-7915(99)00046-1; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; ETAC Study Group, 1998, ALLERGY IMMUNOL, V9, P116; Farooqi IS, 1998, THORAX, V53, P927; FREY EA, 1992, J EXP MED, V176, P1665, DOI 10.1084/jem.176.6.1665; HAZIOT A, 1988, J IMMUNOL, V141, P547; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; Horrobin DF, 2000, AM J CLIN NUTR, V71, p367S; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Jiang QQ, 2000, J IMMUNOL, V165, P3541; Jones A C, 1994, Pediatr Allergy Immunol, V5, P230, DOI 10.1111/j.1399-3038.1994.tb00245.x; Jones CA, 2001, J ALLERGY CLIN IMMUN, V108, P235, DOI 10.1067/mai.2001.117178; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Labeta MO, 2000, J EXP MED, V191, P1807, DOI 10.1084/jem.191.10.1807; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Roos T, 1997, AM J OBSTET GYNECOL, V177, P1230, DOI 10.1016/S0002-9378(97)70044-9; SPENCER J, 1986, CLIN EXP IMMUNOL, V64, P536; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; Sudo N, 1997, J IMMUNOL, V159, P1739; Sugiyama T, 2001, J IMMUNOL, V166, P826; TALEUCHI O, 1999, IMMUNITY, V11, P443; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766	32	92	103	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2002	109	5					858	866		10.1067/mai.2002.123535		9	Allergy; Immunology	Allergy; Immunology	553QW	WOS:000175687800018	11994712	
J	Anyo, G; Brunekreef, B; de Meer, G; Aarts, F; Janssen, NAH; van Vliet, P				Anyo, G; Brunekreef, B; de Meer, G; Aarts, F; Janssen, NAH; van Vliet, P			Early, current and past pet ownership: associations with sensitization, bronchial responsiveness and allergic symptoms in school children	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						pets; cats; dogs; sensitization; bronchial responsiveness; asthma	HAY-FEVER; EARLY EXPOSURE; RISK FACTOR; ASTHMA; ATOPY; FARM; LIFE; CAT; ENVIRONMENT; INFECTIONS	Background Studies have suggested that early contact with pets may prevent the development of allergy and asthma. Objective To study the association between early, current and past pet ownership and sensitization, bronchial responsiveness and allergic symptoms in school children. Methods A population of almost 3000 primary school children was investigated using protocols of the International Study on Asthma and Allergies in Childhood (ISAAC). Allergic symptoms were measured using the parent-completed ISAAC questionnaire. Sensitization to common allergens was measured using skin prick tests (SPT)s and/or serum immunoglobulin (Ig)E determinations. Bronchial responsiveness was tested using a hypertonic saline challenge. Pet ownership was investigated by questionnaire. Current, past and early exposure to pets was documented separately for cats, dogs, rodents and birds. The data on current, past and early pet exposure were then related to allergic symptoms, sensitization and bronchial responsiveness. Results Among children currently exposed to pets, there was significantly less sensitization to cat (odds ratio (OR) = 0.69) and dog (OR = 0.63) allergens, indoor allergens in general (OR = 0.64), and outdoor allergens (OR = 0.60) compared to children who never had pets in the home. There was also less hayfever (OR=0.66) and rhinitis (OR=0.76). In contrast, wheeze, asthma and bronchial responsiveness were not associated with current pet ownership. Odds ratios associated with past pet ownership were generally above unity, and significant for asthma in the adjusted analysis (OR= 1.85), suggesting selective avoidance in families with sensitized and/or symptomatic children. Pet ownership in the first two years of life only showed an inverse association with sensitization to pollen: OR = 0.71 for having had furry or feathery pets in general in the first two years of life, and OR = 0.73 for having had cats and/or dogs in the first two years of life, compared to not having had pets in the first two years of life. Conclusion These results suggest that the inverse association between current pet ownership and sensitization and hayfever symptoms was partly due to the removal of pets in families with sensitized and/or symptomatic children. Pet ownership in the first two years of life only seemed to offer some protection against sensitization to pollen.	IRAS, Div Environm & Occupat Hlth, NL-3508 TD Utrecht, Netherlands	Brunekreef, B (reprint author), IRAS, Div Environm & Occupat Hlth, POB 80176, NL-3508 TD Utrecht, Netherlands.			brunekreef, bert/0000-0001-9908-0060			Ahlbom A, 1998, INDOOR AIR, V8, P219, DOI 10.1111/j.1600-0668.1998.00003.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28; BRUNEKREEF B, 1992, INT J EPIDEMIOL, V21, P338, DOI 10.1093/ije/21.2.338; DUC J, 1988, ALLERGY, V43, P332, DOI 10.1111/j.1398-9995.1988.tb00426.x; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Subcommitte on Skin Tests of the European Academy of Allergology and Clinical Immunology, 1989, ALLERGY S10, V44, P1; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; *ISAAC STEER COMM, 1998, PHAS 2 MOD INT STUD, P1; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kulig M, 2000, J ALLERGY CLIN IMMUN, V105, P274, DOI 10.1016/S0091-6749(00)90076-9; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1998, J ALLERGY CLIN IMMUN, V101, P439, DOI 10.1016/S0091-6749(98)70350-1; Nystad W, 1998, ALLERGY, V53, P1189, DOI 10.1111/j.1398-9995.1998.tb03840.x; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Roost HP, 1999, J ALLERGY CLIN IMMUN, V104, P941, DOI 10.1016/S0091-6749(99)70072-2; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Svanes C, 1999, J ALLERGY CLIN IMMUN, V103, P415, DOI 10.1016/S0091-6749(99)70465-3; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Wijga A, 2001, CLIN EXP ALLERGY, V31, P576, DOI 10.1046/j.1365-2222.2001.01072.x	26	92	94	0	7	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	MAR	2002	32	3					361	366		10.1046/j.1365-2222.2002.01254.x		6	Allergy; Immunology	Allergy; Immunology	541QB	WOS:000174994300008	11940064	
J	Sicherer, SH; Furlong, TJ; DeSimone, J; Sampson, HA				Sicherer, SH; Furlong, TJ; DeSimone, J; Sampson, HA			The US Peanut and Tree Nut Allergy Registry: Characteristics of reactions in schools and day care	JOURNAL OF PEDIATRICS			English	Article							DOUBLE-BLIND; FOOD; CHILDREN; ANAPHYLAXIS; LIFE	Objective: Severe food-allergic reactions occur in schools, but. the features have not been described. Study design: Participants in the US Peanut and Tree Nut Allergy Registry (PAR) who indicated that their child experienced an allergic reaction in school or day care were randomly selected for a telephone interview conducted with a structured questionnaire. Results: Of 4586 participants in the PAR, 750 (16%) indicated a reaction in school or day care, and 100 subjects or parental surrogates described 124 reactions to peanut (115) or tree nuts (9); 64% of the reactions occurred in day care or preschool, and the remainder in elementary school or higher grades. Reactions were reported from ingestion (60%), skin contact/possible ingestion (24%), and inhalation/possible skin contact or ingestion (16%). In the majority of reactions caused by inhalation, concomitant ingestion/skin contact could not be ruled out. Various foods caused by ingestion, but peanut butter crab projects were commonly responsible for the skin contact (44%) or inhalation (41%) reactions. For 90% of reactions, medications were given (86% antihistamines, 28% epinephrine). Epinephrine was given in school by teachers in 4 cases, nurses in 7, and parents or others in the remainder. Treatment delays were attributed to delayed recognition of reactions, calling parents, not following emergency plans, and an unsuccessful attempt to administer epinephrine. Conclusions: School personnel must be educated to recognize and treat food-allergic reactions. Awareness must be increased to avoid accidental exposures, including exposure from peanut butter craft projects.	CUNY Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Pediat Allergy Immunol, New York, NY 10029 USA; Food Allergy Network, Fairfax, VA USA	Sicherer, SH (reprint author), CUNY Mt Sinai Sch Med, Elliot & Roslyn Jaffe Food Allergy Inst, Dept Pediat, Div Pediat Allergy Immunol, Box 1198,1 Gustave L Levy Pl, New York, NY 10029 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NICHD NIH HHS [5 P30 HD28822]		AAAAI Board of Directors, 1998, J ALLERGY CLIN IMMUN, V102, P173; BOCK SA, 1987, PEDIATRICS, V79, P683; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; Frazier C A, 1993, Pediatrics, V91, P516; Furlong TJ, 1998, J ALLERGY CLIN IMMUN, V101, pS104; GERN JE, 1991, NEW ENGL J MED, V324, P976, DOI 10.1056/NEJM199104043241407; HAY GH, 1994, J SCHOOL HEALTH, V64, P119; Hourihane JO, 1998, BRIT MED J, V316, P1271; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; IGEA JM, 1994, J ALLERGY CLIN IMMUN, V94, P33, DOI 10.1016/0091-6749(94)90068-X; Kalogeromitros D, 1996, ANN ALLERG ASTHMA IM, V77, P480; Mudd K E, 1995, J Sch Nurs, V11, P30; Novembre E, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.4.e8; Polasani R, 1997, ANN ALLERG ASTHMA IM, V78, P35; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sicherer SH, 2000, J ALLERGY CLIN IMMUN, V105, P582, DOI 10.1067/mai.2000.104941; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sicherer SH, 1999, J ALLERGY CLIN IMMUN, V103, P559, DOI 10.1016/S0091-6749(99)70224-1; SICHERER SH, 1999, J ALLERGY CLIN IMMUN, V103, P186; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; YUNGINGER JW, 1988, JAMA-J AM MED ASSOC, V260, P1450, DOI 10.1001/jama.260.10.1450	22	92	93	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	APR	2001	138	4					560	565		10.1067/mpd.2001.111821		6	Pediatrics	Pediatrics	423KL	WOS:000168175400025	11295721	
J	Kulig, M; Klettke, U; Wahn, V; Forster, J; Bauer, CP; Wahn, U				Kulig, M; Klettke, U; Wahn, V; Forster, J; Bauer, CP; Wahn, U		MAS Study Grp	Development of seasonal allergic rhinitis during the first 7 years of life	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						seasonal allergic rhinitis; allergic sensitization; atopic family history; children	SCHOOL-CHILDREN; EAST-GERMANY; LATE-ONSET; PREVALENCE; ASTHMA; SENSITIZATION; ATOPY; RISK; ISAAC; ADOLESCENTS	Background: Against the background of the controversial discussion about an increase in allergic rhinitis in recent years, intraindividual longitudinal data is lacking for IgE-mediated seasonal allergic rhinitis (SAR), Little is known about the development of SAR in terms of prevalence and incidence rates from birth to school age. Objective: In a prospective birth cohort, we investigated the development of sensitization and symptoms of SAR. SAR should be defined with high specificity, and associated risk factors should be determined. Methods: Annual longitudinal data about seasonal allergic symptoms and sensitization was available for 587 children from birth to their seventh birthday The definition of SAR was based on a combination of exposure-related symptoms and sensitization. Results: Up to 7 years of age, SAR developed in 15% of the children. Incidence and prevalence of symptoms and sensitization were low during early childhood (<2%) and increased steadily with age. Children in which SAR had already developed in the second year all were born in spring or early summer, resulting in at least two seasons of pollen exposure before manifestation of SAR. Risk factors assessed by multiple logistic regression analysis were male sex (odds ratio [OR] = 2.4), atopic mothers (OR = 2.6) and fathers (OR = 3.6) having allergic rhinitis themselves, first-born child (OR = 2.0), early sensitization to food (OR = 3.3), and atopic dermatitis (OR = 2.5), whereas early wheezing was not associated with SAR. Conclusion: The development of SAR is characterized by a marked increase in prevalence and incidence after the second year of life. Our longitudinal data further indicate that in combination with the risk of allergic predisposition, at least 2 seasons of pollen allergen exposure are needed before allergic rhinitis becomes clinically manifest.	Tech Univ, Childrens Hosp, Munich, Germany; Univ Freiburg, Childrens Hosp, Freiburg, Germany; Humboldt Univ, Dept Pediat Pneumol & Immunol, Berlin, Germany; Humboldt Univ, Charite Hosp, Inst Social Med & Epidemiol, Berlin, Germany	Kulig, M (reprint author), Univ Klinikum Charite, Inst Arbeitsmed Sozialmed & Epidemiol, D-10098 Berlin, Germany.						ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; BENER A, 1994, EUR J EPIDEMIOL, V10, P271, DOI 10.1007/BF01719349; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Duhme H, 1998, EUR RESPIR J, V11, P840, DOI 10.1183/09031936.98.11040840; Hosmer DW, 1989, APPL LOGISTIC REGRES; Jones NS, 1998, J LARYNGOL OTOL, V112, P1019; KUEHR J, 1995, J ALLERGY CLIN IMMUN, V95, P655, DOI 10.1016/S0091-6749(95)70168-0; LAU S, 1989, J ALLERGY CLIN IMMUN, V84, P718, DOI 10.1016/0091-6749(89)90300-X; LUCK W, 1985, J PEDIATR, V99, P763; Martinez F D, 1998, Eur Respir J Suppl, V27, p3s; MEINERT R, 1994, ALLERGY, V49, P526, DOI 10.1111/j.1398-9995.1994.tb01124.x; POYSA L, 1991, ALLERGY, V46, P161, DOI 10.1111/j.1398-9995.1991.tb00564.x; Remes ST, 1998, ALLERGY, V53, P682, DOI 10.1111/j.1398-9995.1998.tb03954.x; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; SCHAFER T, 1993, ALLERGY, V48, P291, DOI 10.1111/j.1398-9995.1993.tb00731.x; Sherrill DL, 1999, J ALLERGY CLIN IMMUN, V104, P28, DOI 10.1016/S0091-6749(99)70110-7; Strachan DP, 1997, PEDIATR ALLERGY IMMU, V8, P161, DOI 10.1111/j.1399-3038.1997.tb00156.x; VARONIER HS, 1984, HELV PAEDIATR ACTA, V39, P129; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; Weeke E R, 1992, Rhinol Suppl, V13, P5; Wright A L, 1998, Eur Respir J Suppl, V27, p17s; WRIGHT AL, 1994, PEDIATRICS, V94, P895; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9	26	92	98	2	5	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	NOV	2000	106	5					832	839		10.1067/mai.2000.110098		8	Allergy; Immunology	Allergy; Immunology	417ZK	WOS:000167865200005	11080703	
J	Jorres, RA; Holz, O; Zachgo, W; Timm, P; Koschyk, S; Muller, B; Grimminger, F; Seeger, W; Kelly, FJ; Dunster, C; Frischer, T; Lubec, G; Waschewski, M; Niendorf, A; Magnussen, H				Jorres, RA; Holz, O; Zachgo, W; Timm, P; Koschyk, S; Muller, B; Grimminger, F; Seeger, W; Kelly, FJ; Dunster, C; Frischer, T; Lubec, G; Waschewski, M; Niendorf, A; Magnussen, H			The effect of repeated ozone exposures on inflammatory markers in bronchoalveolar lavage fluid and mucosal biopsies	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							AIRWAY INFLAMMATION; NITROGEN-DIOXIDE; HUMANS; LUNG; RESPONSES; ALLERGEN; RESPONSIVENESS; ADAPTATION; POLLUTION; FIBROSIS	The aim of this study was to investigate the cellular and biochemical events associated with repeated exposures to ozone. Twenty-three healthy subjects underwent single exposures to 200 ppb ozone and to filtered air (FA), as well as repeated exposures to 200 ppb ozone on 4 consecutive days, each for 4 h of intermittent exercise. Bronchoalveolar lavage was performed and mucosal biopsies were taken 20 h after the single or the last of the repeated exposures. As compared with FA, the single exposure to ozone caused a decrease in FEV1, an increase in the percentages of neutrophils and lymphocytes, the concentrations of total protein, IL-6, IL-8, reduced glutathione, urate, and ortho-tyrosine in BAL fluid (BALF), but no changes in the cellular composition of biopsy. After the repeated exposure, the effect on lung function was abolished and differential cell counts in BALF were not significantly different from those after FA. However, the concentrations of total protein, IL-6, IL-8, reduced glutathione, and ortho-tyrosine were still increased. IL-10 could only be detected in BALF after repeated ozone exposures. Furthermore, macroscopic scores for bronchitis, erythema, and hypervulnerability of airway mucosa were increased, as well as numbers of neutrophils in bronchial mucosal biopsies. Our data demonstrate that airway inflammation persists after repeated ozone exposure, despite attenuation of some inflammatory markers in BALF and adaptation of lung function.	Krankenhaus Grosshansdorf, Zentrum Pneumol & Thoraxchirurg, D-22927 Grosshansdorf, Germany; Univ Marburg, Policlin Dept Internal Med, Lab Resp Cell Biol, D-3550 Marburg, Germany; Univ Giessen, Zentrum Innere Med, Giessen, Germany; Univ Hamburg, Krankenhaus Eppendorf, Inst Pathol, D-2000 Hamburg, Germany; St Thomas Hosp, Rayne Inst, London SE1 7EH, England; Univ Vienna, Childrens Hosp, Vienna, Austria	Jorres, RA (reprint author), Krankenhaus Grosshansdorf, Zentrum Pneumol & Thoraxchirurg, D-22927 Grosshansdorf, Germany.		Kelly, Frank/C-6125-2009	Kelly, Frank/0000-0003-2558-8392			ARIS RM, 1993, AM REV RESPIR DIS, V148, P1363; Balmes JR, 1996, AM J RESP CRIT CARE, V153, P904; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANG LY, 1992, TOXICOL APPL PHARM, V115, P241, DOI 10.1016/0041-008X(92)90329-Q; Christian DL, 1998, AM J RESP CRIT CARE, V158, P532; Devlin RB, 1997, INHAL TOXICOL, V9, P211; DEVRIES JE, 1995, ANN MED, V27, P537, DOI 10.3109/07853899509002465; FARRELL BP, 1979, AM REV RESPIR DIS, V119, P725; FOLINSBEE LJ, 1994, AM J RESP CRIT CARE, V149, P98; Holz O, 1999, AM J RESP CRIT CARE, V159, P776; Holz O, 1999, AM J RESP CRIT CARE, V159, pA493; HURD SZ, 1991, J ALLERGY CLIN IMMUN, V88, P808; Jorres R, 1996, AM J RESP CRIT CARE, V153, P56; JORRES R, 1995, EUR RESPIR J, V8, P416, DOI 10.1183/09031936.95.08030416; Kelly FJ, 1996, AM J RESP CRIT CARE, V154, P1700; LUBEC G, 1994, FASEB J, V8, P1166; MAGNUSSEN H, 1998, EUR RESPIR REV, V8, P141; MCDONNELL WF, 1991, ARCH ENVIRON HEALTH, V46, P145; MULLER B, 1994, LUNG, V172, P61; PEDEN DB, 1995, AM J RESP CRIT CARE, V151, P1336; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; SCHELEGLE ES, 1991, AM REV RESPIR DIS, V143, P1353; Sun J, 1997, RESP MED, V91, P47, DOI 10.1016/S0954-6111(97)90136-0; Tellez-Rojo MM, 1997, SALUD PUBLICA MEXICO, V39, P513, DOI 10.1590/S0036-36341997000600004; TEPPER JS, 1989, AM REV RESPIR DIS, V140, P493; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527; Torres A, 1997, AM J RESP CRIT CARE, V156, P728; Ward PA, 1998, AM J RESP CRIT CARE, V157, pS123	29	92	93	0	2	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN	2000	161	6					1855	1861				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	325KV	WOS:000087675500020	10852757	
J	Johnson, SB; Riley, AW; Granger, DA; Riis, J				Johnson, Sara B.; Riley, Anne W.; Granger, Douglas A.; Riis, Jenna			The Science of Early Life Toxic Stress for Pediatric Practice and Advocacy	PEDIATRICS			English	Article						toxic stress; health disparities; social determinants of health	CHILDHOOD SOCIOECONOMIC-STATUS; INNER-CITY COHORT; IMMUNE-SYSTEM; MATERNAL-CARE; EARLY EXPERIENCE; SOCIAL-ENVIRONMENT; METABOLIC SYNDROME; INDOOR ALLERGENS; CORTISOL-LEVELS; CHILDREN	Young children who experience toxic stress are at high risk for a number of health outcomes in adulthood, including cardiovascular disease, cancers, asthma, and depression. The American Academy of Pediatrics has recently called on pediatricians, informed by research from molecular biology, genomics, immunology, and neuroscience, to become leaders in science-based strategies to build strong foundations for children's life-long health. In this report, we provide an overview of the science of toxic stress. We summarize the development of the neuroendocrine-immune network, how its function is altered by early life adversity, and how these alterations then increase vulnerability to disease. The fact that early environments shape and calibrate the functioning of biological systems very early in life is both a cautionary tale about overlooking critical periods in development and reason for optimism about the promise of intervention. Even in the most extreme cases of adversity, well-timed changes to children's environments can improve outcomes. Pediatricians are in a unique position to contribute to the public discourse on health and social welfare by explaining how factors that seem distal to child health may be the key to some of the most intractable public health problems of our generation. We consider the challenges and opportunities for preventing toxic stress in the context of contemporary pediatric practice. Pediatrics 2013;131:319-327	[Johnson, Sara B.; Riley, Anne W.] Johns Hopkins Sch Med, Dept Pediat, Baltimore, MD USA; [Johnson, Sara B.; Granger, Douglas A.; Riis, Jenna] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Populat Family & Reprod Hlth, Baltimore, MD USA; [Granger, Douglas A.] Johns Hopkins Sch Nursing, Ctr Interdisciplinary Salivary Biosci Res, Dept Acute & Chron Care, Baltimore, MD USA	Johnson, SB (reprint author), 200 N Wolfe St,Room 2017, Baltimore, MD 21287 USA.	sjohnson@jhsph.edu			National Institute on Drug Abuse [K01DA027229]	Dr Johnson is supported by a Career Development Award sponsored by the National Institute on Drug Abuse (K01DA027229).	ADER R, 1983, DEV PSYCHOBIOL, V16, P251, DOI 10.1002/dev.420160402; Anda RF, 2008, AM J PREV MED, V34, P396, DOI 10.1016/j.amepre.2008.02.002; Beijers R, 2010, PEDIATRICS, V126, pE401, DOI 10.1542/peds.2009-3226; Bjorntorp P, 2000, BRIT J NUTR, V83, pS49, DOI 10.1017/S0007114500000957; Blalock JE, 2007, BRAIN BEHAV IMMUN, V21, P23, DOI 10.1016/j.bbi.2006.09.004; Blalock JE, 2005, J INTERN MED, V257, P126, DOI 10.1111/j.1365-2796.2004.01441.x; BOYCE WT, 1995, PSYCHOSOM MED, V57, P411; Brower V, 2011, NATURE, V471, pS12, DOI 10.1038/471S12a; Carroll JE, 2011, BRAIN BEHAV IMMUN, V25, P1468, DOI 10.1016/j.bbi.2011.05.016; Champagne FA, 2003, PHYSIOL BEHAV, V79, P359, DOI 10.1016/S0031-9384(03)00149-5; Chen E, 2006, SOC SCI MED, V62, P2161, DOI 10.1016/j.socscimed.2005.08.054; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Chen E, 2008, IMMUNOL ALLERGY CLIN, V28, P649, DOI 10.1016/j.iac.2008.03.007; Chen E, 2007, AM J RESP CRIT CARE, V176, P644, DOI 10.1164/rccm.200610-1473OC; Coe CL, 2007, PSYCHONEUROIMMUNOLOGY, VOLS I AND II, 4TH EDITION, P455, DOI 10.1016/B978-012088576-3/50027-7; Coe CL, 2000, HEALTH PSYCHOL, V19, P554, DOI 10.1037//0278-6133.19.6.554; Coe CL, 2005, NEUROSCI BIOBEHAV R, V29, P39, DOI 10.1016/j.neubiorev.2004.11.003; Coe CL, 2003, BRAIN BEHAV IMMUN, V17, P3, DOI 10.1016/S0889-1591(02)00099-5; COE CL, 1992, PEDIATRICS, V90, P505; Cohen S, 2010, ANN NY ACAD SCI, V1186, P37, DOI 10.1111/j.1749-6632.2009.05334.x; Danese A, 2008, ARCH GEN PSYCHIAT, V65, P409, DOI 10.1001/archpsyc.65.4.409; Danese A, 2007, P NATL ACAD SCI USA, V104, P1319, DOI 10.1073/pnas.0610362104; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Fisher PA, 2007, PSYCHONEUROENDOCRINO, V32, P892, DOI 10.1016/j.psyneuen.2007.06.008; Fox NA, 2010, CHILD DEV, V81, P23, DOI 10.1111/j.1467-8624.2009.01379.x; Francis D, 1999, SCIENCE, V286, P1155, DOI 10.1126/science.286.5442.1155; Francis Darlene D, 2009, Pediatrics, V124 Suppl 3, pS196, DOI 10.1542/peds.2009-1100G; Francis DD, 1999, ANN NY ACAD SCI, V896, P66, DOI 10.1111/j.1749-6632.1999.tb08106.x; Fries ABW, 2008, DEV PSYCHOBIOL, V50, P588, DOI 10.1002/dev.20319; Gabbay V, 2009, J AFFECT DISORDERS, V115, P177, DOI 10.1016/j.jad.2008.07.022; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Garner AS, 2012, PEDIATRICS, V129, pE224, DOI 10.1542/peds.2011-2662; Gould S. J., 1977, ONTOGENY PHYLOGENY; Granger D. A., 2006, DEV PSYCHOPATHOL, V2, P677; Gunnar M, 2007, ANNU REV PSYCHOL, V58, P145, DOI 10.1146/annurev.psych.58.110405.085605; Gunnar MR, 2001, DEV PSYCHOPATHOL, V13, P611, DOI 10.1017/S095457940100311X; Hanson LA, 2001, PEDIAT ALLERG IMM-UK, V12, P15, DOI 10.1034/j.1399-3038.2001.121404.x; Hennessy MB, 2010, NEUROSCI BIOBEHAV R, V34, P782, DOI 10.1016/j.neubiorev.2009.03.012; Hertz-Picciotto I, 2008, BASIC CLIN PHARMACOL, V102, P146, DOI 10.1111/j.1742-7843.2007.00190.x; Hertzman C, 1999, ANN NY ACAD SCI, V896, P85, DOI 10.1111/j.1749-6632.1999.tb08107.x; Hotamisligil GS, 2006, NATURE, V444, P860, DOI 10.1038/nature05485; Hurtado A, 2005, KIDNEY INT S, V97, pS62, DOI DOI 10.1111/J.1523-1755.2005.09711.X; Janeway C. A., 2005, IMMUNOBIOLOGY IMMUNE; Keller PS, 2010, PHYSIOL BEHAV, V101, P705, DOI 10.1016/j.physbeh.2010.08.012; Kertes DA, 2008, DEV PSYCHOPATHOL, V20, P473, DOI 10.1017/S0954579408000230; Krieger J, 2002, ENVIRON HEALTH PERSP, V110, P311; Lendor C, 2008, ANN ALLERG ASTHMA IM, V101, P193, DOI 10.1016/S1081-1206(10)60209-8; Lewis-Morrarty E, 2012, J ADOLESCENT HEALTH, V51, pS17, DOI 10.1016/j.jadohealth.2012.05.005; Liu D, 1997, SCIENCE, V277, P1659, DOI 10.1126/science.277.5332.1659; LUBACH GR, 1995, BRAIN BEHAV IMMUN, V9, P31, DOI 10.1006/brbi.1995.1004; Marsland AL, 2008, BRAIN BEHAV IMMUN, V22, P753, DOI 10.1016/j.bbi.2007.11.008; Maughan A, 2007, J ABNORM CHILD PSYCH, V35, P685, DOI 10.1007/s10802-007-9129-0; McAfoose J, 2009, NEUROSCI BIOBEHAV R, V33, P355, DOI 10.1016/j.neubiorev.2008.10.005; McEwen BS, 1998, NEW ENGL J MED, V338, P171; Meaney MJ, 2010, CHILD DEV, V81, P41, DOI 10.1111/j.1467-8624.2009.01381.x; Miller GE, 2011, PSYCHOL SCI, V22, P1591, DOI 10.1177/0956797611419170; Miller RL, 2001, AM J RESP CRIT CARE, V164, P995; Misener VL, 2008, NEUROPSYCHOBIOLOGY, V58, P71, DOI 10.1159/000159775; Nelson CA, 1999, CURR DIR PSYCHOL SCI, V8, P42, DOI 10.1111/1467-8721.00010; Pervanidou P, 2007, PSYCHONEUROENDOCRINO, V32, P991, DOI 10.1016/j.psyneuen.2007.07.001; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Rhen T, 2005, NEW ENGL J MED, V353, P1711, DOI 10.1056/NEJMra050541; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Ruiz RJ, 2005, ADV NURS SCI, V28, P345; Shirtcliff E, 2009, P NATL ACAD SCI USA, V106, P2863; Shonkoff JP, 2012, PEDIATRICS, V129, pE232, DOI 10.1542/peds.2011-2663; Shonkoff JP, 2009, JAMA-J AM MED ASSOC, V301, P2252, DOI 10.1001/jama.2009.754; SOLOMON GF, 1968, NATURE, V220, P821, DOI 10.1038/220821a0; Sternthal MJ, 2009, J ALLERGY CLIN IMMUN, V124, P954, DOI 10.1016/j.jaci.2009.07.030; Suglia SF, 2010, J EPIDEMIOL COMMUN H, V64, P636, DOI 10.1136/jech.2008.082842; Suglia SF, 2009, ARCH PEDIAT ADOL MED, V163, P244, DOI 10.1001/archpediatrics.2008.555; Szyf M, 2005, FRONT NEUROENDOCRIN, V26, P139, DOI 10.1016/j.yfrne.2005.10.002; Tonelli L, 2001, IMMUNOL REV, V184, P203, DOI 10.1034/j.1600-065x.2001.1840118.x; Tottenham N, 2012, J ADOLESCENT HEALTH, V51, pS29, DOI 10.1016/j.jadohealth.2012.04.004; Vanderwert RE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011415; Vedhara K., 2005, HUMAN PSYCHONEUROIMM; Weaver ICG, 2006, P NATL ACAD SCI USA, V103, P3480, DOI 10.1073/pnas.0507526103; Webster JI, 2002, ANNU REV IMMUNOL, V20, P125, DOI 10.1146/annurev.immunol.20.082401.104914; Wordsworth W, 1888, MY HEART LEAPS I BEH; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; ZEVELOFF SI, 1982, AM NAT, V120, P537, DOI 10.1086/284010	82	91	91	9	45	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	FEB	2013	131	2					319	327		10.1542/peds.2012-0469		9	Pediatrics	Pediatrics	081XG	WOS:000314355100059	23339224	
J	Islam, SA; Luster, AD				Islam, Sabina A.; Luster, Andrew D.			T cell homing to epithelial barriers in allergic disease	NATURE MEDICINE			English	Review							CUTANEOUS LYMPHOCYTE ANTIGEN; CHEMOKINE RECEPTORS CCR4; ACTIVATION-REGULATED CHEMOKINE; SMOOTH-MUSCLE-CELLS; ATOPIC-DERMATITIS; DENDRITIC CELLS; RETINOIC-ACID; T(H)2 CELLS; MOUSE MODEL; TH2 CELLS	Allergic inflammation develops in tissues that have large epithelial surface areas that are exposed to the environment, such as the lung, skin and gut. In the steady state, antigen-experienced memory T cells patrol these peripheral tissues to facilitate swift immune responses against invading pathogens. In at least two allergy-prone organs, the skin and the gut, memory T cells are programmed during the initial antigen priming to express trafficking receptors that enable them to preferentially home to these organs. In this review we propose that tissue-specific memory and inflammation-specific T cell trafficking facilitates the development of allergic disease in these organs. We thus review recent advances in our understanding of tissue-specific T cell trafficking and how regulation of T cell trafficking by the chemokine system contributes to allergic inflammation in mouse models and in human allergic diseases of the skin, lung and gut. Inflammation-and tissue-specific T lymphocyte trafficking pathways are currently being targeted as new treatments for non-allergic inflammatory diseases and may yield effective new therapeutics for allergic diseases.	[Islam, Sabina A.; Luster, Andrew D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02115 USA	Luster, AD (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Immunol & Inflammatory Dis,Div Rheumatol Alle, Boston, MA 02115 USA.	aluster@mgh.harvard.edu			US National Institutes of Health [R37AI040618, U19AI095261]	The authors were supported by US National Institutes of Health grants R37AI040618 and U19AI095261 to A.D.L.	Abe H, 1999, GENE, V227, P71, DOI 10.1016/S0378-1119(98)00599-X; ABERNATHYCARVER KJ, 1995, J CLIN INVEST, V95, P913, DOI 10.1172/JCI117743; Adorini L, 2003, ANN NY ACAD SCI, V987, P258; Agace WW, 2006, NAT REV IMMUNOL, V6, P682, DOI 10.1038/nri1869; Al-Shami A, 2005, J EXP MED, V202, P829, DOI 10.1084/jem.20050199; Annacker O, 2005, J EXP MED, V202, P1051, DOI 10.1084/jem.20040662; Ansel KM, 2003, NAT IMMUNOL, V4, P616, DOI 10.1038/ni0703-616; BABI LFS, 1995, J EXP MED, V181, P1935; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bentley AM, 1997, CLIN EXP ALLERGY, V27, P71, DOI 10.1111/j.1365-2222.1997.tb01830.x; BERG EL, 1991, J EXP MED, V174, P1461, DOI 10.1084/jem.174.6.1461; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P688, DOI 10.1067/mai.2002.123235; Blazquez AB, 2010, GASTROENTEROLOGY, V138, P275, DOI 10.1053/j.gastro.2009.09.016; Boonstra A, 2001, J IMMUNOL, V167, P4974; Boyman O, 2004, J EXP MED, V199, P731, DOI 10.1084/jem.20031482; Briskin M, 1997, AM J PATHOL, V151, P97; Bromley SK, 2008, NAT IMMUNOL, V9, P970, DOI 10.1038/ni.f.213; CAHILL RNP, 1977, J EXP MED, V145, P420, DOI 10.1084/jem.145.2.420; Cameron L, 2009, ALLERGY, V64, P1478, DOI 10.1111/j.1398-9995.2009.02053.x; Campbell JJ, 2007, J IMMUNOL, V178, P3358; Campbell JJ, 2001, J IMMUNOL, V166, P2842; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; Carson KR, 2009, LANCET ONCOL, V10, P816, DOI 10.1016/S1470-2045(09)70161-5; Charbonnier AS, 1999, J EXP MED, V190, P1755, DOI 10.1084/jem.190.12.1755; Chensue SW, 2001, J EXP MED, V193, P573, DOI 10.1084/jem.193.5.573; Chung CD, 2003, J IMMUNOL, V170, P581; Clark RA, 2006, J IMMUNOL, V176, P4431; Conrad C, 2007, NAT MED, V13, P836, DOI 10.1038/nm1605; Conroy DM, 2003, J LEUKOCYTE BIOL, V74, P558, DOI 10.1189/jlb.0103030; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Corren J, 2011, NEW ENGL J MED, V365, P1088, DOI 10.1056/NEJMoa1106469; D'Ambrosio D, 1998, J IMMUNOL, V161, P5111; de Bree GJ, 2005, J EXP MED, V202, P1433, DOI 10.1084/jem.20051365; DeLong JH, 2011, J ALLERGY CLIN IMMUN, V127, P1211, DOI 10.1016/j.jaci.2011.02.028; DePaolo RW, 2011, NATURE, V471, P220, DOI 10.1038/nature09849; Duhen T, 2009, NAT IMMUNOL, V10, P857, DOI 10.1038/ni.1767; Echigo T, 2004, J ALLERGY CLIN IMMUN, V113, P940, DOI 10.1016/S0091-6749(04)01061-9; Edele F, 2008, J IMMUNOL, V181, P3745; Eigenmann PA, 1999, J ALLERGY CLIN IMMUN, V103, P931, DOI 10.1016/S0091-6749(99)70441-0; Eiwegger T, 2011, EUR J IMMUNOL, V41, P1535, DOI 10.1002/eji.201141668; El-Shazly A, 2006, J IMMUNOL, V176, P1860; Fairs A, 2010, AM J RESP CRIT CARE, V182, P1362, DOI 10.1164/rccm.201001-0087OC; Fort MM, 2001, IMMUNITY, V15, P985, DOI 10.1016/S1074-7613(01)00243-6; Fuhlbrigge RC, 1997, NATURE, V389, P978; Fulkerson PC, 2004, J IMMUNOL, V173, P7565; Gebhardt T, 2009, NAT IMMUNOL, V10, P524, DOI 10.1038/ni.1718; Gombert M, 2005, J IMMUNOL, V174, P5082; Gonzalo JA, 2007, J IMMUNOL, V179, P1740; Goya I, 2003, J IMMUNOL, V170, P2138; Gunther C, 2005, J IMMUNOL, V174, P1723; Hadis U, 2011, IMMUNITY, V34, P237, DOI 10.1016/j.immuni.2011.01.016; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Harper EG, 2008, J INVEST DERMATOL, V128, P1173, DOI 10.1038/sj.jid.5701169; Harris NL, 2002, J EXP MED, V195, P317, DOI 10.1084/jem.20011558; Hegazy AN, 2010, IMMUNITY, V32, P116, DOI 10.1016/j.immuni.2009.12.004; Hijnen D, 2005, J INVEST DERMATOL, V125, P1149, DOI 10.1111/j.0022-202X.2005.23932.x; Hijnen DJ, 2004, J ALLERGY CLIN IMMUN, V113, P334, DOI 10.1016/j.jaci.2003.12.007; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Homey B, 2002, NAT MED, V8, P157, DOI 10.1038/nm0202-157; Huang JL, 2004, HUM MOL GENET, V13, P2691, DOI 10.1093/hmg/ddh279; Hvid M, 2011, J INVEST DERMATOL, V131, P150, DOI 10.1038/jid.2010.277; Iellem A, 2001, J EXP MED, V194, P847, DOI 10.1084/jem.194.6.847; Islam SA, 2011, NAT IMMUNOL, V12, P167, DOI 10.1038/ni.1984; Iwata M, 2004, IMMUNITY, V21, P527, DOI 10.1016/j.immuni.2004.08.011; Iwata M, 2003, INT IMMUNOL, V15, P1017, DOI 10.1093/intimm/dxg101; Kakinuma T, 2003, J ALLERGY CLIN IMMUN, V111, P592, DOI 10.1067/mai.2003.114; Kawai T, 2001, J IMMUNOL, V167, P5887; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kim CH, 2003, J IMMUNOL, V171, P152; Kim CH, 2001, J CLIN INVEST, V108, P1331, DOI 10.1172/JCI13543; Klonowski KD, 2004, IMMUNITY, V20, P551, DOI 10.1016/S1074-7613(04)00103-7; Knight AK, 2007, AM J PHYSIOL-GASTR L, V293, pG1234, DOI 10.1152/ajpgi.00323.2007; Koelle DM, 2002, J CLIN INVEST, V110, P537, DOI 10.1172/JCI200215537; Kraft M, 2011, NEW ENGL J MED, V365, P1141, DOI 10.1056/NEJMe1108666; Kunkel EJ, 2000, J EXP MED, V192, P761, DOI 10.1084/jem.192.5.761; Lambrecht BN, 2009, IMMUNITY, V31, P412, DOI 10.1016/j.immuni.2009.08.008; Lamhamedi-Cherradi SE, 2008, J IMMUNOL, V180, P6000; Leung DYM, 2003, LANCET, V361, P151, DOI 10.1016/S0140-6736(03)12193-9; Leung TF, 2002, J ALLERGY CLIN IMMUN, V110, P404, DOI 10.1067/mai.2002.126378; Lin XP, 2002, J ALLERGY CLIN IMMUN, V109, P879, DOI 10.1067/mai.2002.123238; Johansson-Lindbom B., 2005, J EXP MED, V202, P1063; Lloyd CM, 2010, NAT REV IMMUNOL, V10, P838, DOI 10.1038/nri2870; Lonsdorf AS, 2009, J INVEST DERMATOL, V129, P2552, DOI 10.1038/jid.2009.122; Lukacs NW, 2001, J EXP MED, V194, P551, DOI 10.1084/jem.194.4.551; Lundy SK, 2005, J IMMUNOL, V174, P2054; Luster AD, 2005, NAT IMMUNOL, V6, P1182, DOI 10.1038/ni1275; Masopust D, 2010, J EXP MED, V207, P553, DOI 10.1084/jem.20090858; Mathew A, 2002, J IMMUNOL, V169, P651; Mathew A, 2001, J EXP MED, V193, P1087, DOI 10.1084/jem.193.9.1087; McLachlan JB, 2009, IMMUNITY, V30, P277, DOI 10.1016/j.immuni.2008.11.013; Medoff BD, 2006, AM J PHYSIOL-LUNG C, V290, pL170, DOI 10.1152/ajplung.00212.2005; Medoff BD, 2002, J IMMUNOL, V168, P5278; Medoff BD, 2008, ANNU REV IMMUNOL, V26, P205, DOI 10.1146/annurev.immunol.26.021607.090312; Medoff BD, 2009, J IMMUNOL, V182, P623; Meisel C, 2001, J IMMUNOL, V166, P3143; Mikhak Z, 2009, J ALLERGY CLIN IMMUN, V123, P67, DOI 10.1016/j.jaci.2008.09.049; Mionnet C, 2010, NAT MED, V16, P1305, DOI 10.1038/nm.2253; Monney L, 2002, NATURE, V415, P536, DOI 10.1038/415536a; Mora JR, 2005, J EXP MED, V201, P303, DOI 10.1084/jem.20041645; Mora JR, 2003, NATURE, V424, P88, DOI 10.1038/nature01726; Morales J, 1999, P NATL ACAD SCI USA, V96, P14470, DOI 10.1073/pnas.96.25.14470; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Muro S, 2000, CLIN CHEST MED, V21, P225, DOI 10.1016/S0272-5231(05)70263-X; Mutalithas K, 2010, CLIN EXP ALLERGY, V40, P1175, DOI 10.1111/j.1365-2222.2010.03504.x; Nouri-Aria KT, 2002, EUR J IMMUNOL, V32, P1933, DOI 10.1002/1521-4141(200207)32:7<1933::AID-IMMU1933>3.0.CO;2-R; Ohmichi Y, 2011, J EXP MED, V208, P1015, DOI 10.1084/jem.20101786; Oliveira SHP, 2001, INFLAMM RES, V50, P168, DOI 10.1007/s000110050741; Oyoshi MK, 2011, J CLIN INVEST, V121, P2210, DOI 10.1172/JCI43586; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perros F, 2009, ALLERGY, V64, P995, DOI 10.1111/j.1398-9995.2009.02095.x; Pettipher R, 2007, NAT REV DRUG DISCOV, V6, P313, DOI 10.1038/nrd2266; Pichavant M, 2005, J ALLERGY CLIN IMMUN, V115, P771, DOI 10.1016/j.jaci.2004.11.043; PICKER LJ, 1990, J IMMUNOL, V145, P3247; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; Pilette C, 2004, EUR RESPIR J, V23, P876, DOI 10.1183/09031936.04.00102504; Pivarcsi A, 2004, J IMMUNOL, V173, P5810; Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387; Prussin C, 2009, J ALLERGY CLIN IMMUN, V124, P1326, DOI 10.1016/j.jaci.2009.09.048; Purwar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016245; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Reekers R, 1996, BRIT J DERMATOL, V135, P935, DOI 10.1046/j.1365-2133.1996.d01-1098.x; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Reinhardt RL, 2001, NATURE, V410, P101, DOI 10.1038/35065111; Robinson DS, 2010, J ALLERGY CLIN IMMUN, V126, P1081, DOI 10.1016/j.jaci.2010.06.025; Rodriguez E, 2009, J ALLERGY CLIN IMMUN, V123, P1361, DOI 10.1016/j.jaci.2009.03.036; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Sallusto F, 2004, CURR OPIN IMMUNOL, V16, P724, DOI 10.1016/j.coi.2004.09.012; Sallusto F, 1998, J EXP MED, V187, P875, DOI 10.1084/jem.187.6.875; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Sallusto F, 1998, IMMUNOL TODAY, V19, P568, DOI 10.1016/S0167-5699(98)01346-2; Schaerli P, 2004, J EXP MED, V199, P1265, DOI 10.1084/jem.20032177; Schuh JM, 2002, FASEB J, V16, P1313, DOI 10.1096/fj.02-0193fje; Schulten V, 2009, J ALLERGY CLIN IMMUN, V124, P100, DOI 10.1016/j.jaci.2009.02.010; Sheridan B.S., 2011, NAT IMMUNOL, V121, P485; Shimada Y, 2004, J DERMATOL SCI, V34, P201, DOI 10.1016/j.jdermsci.2004.01.001; Siegmund K, 2005, BLOOD, V106, P3097, DOI 10.1182/blood-2005-05-1864; Sigmundsdottir H, 2008, NAT IMMUNOL, V9, P981, DOI 10.1038/ni.f.208; Sigmundsdottir H, 2007, NAT IMMUNOL, V8, P285, DOI 10.1038/ni1433; Spergel JM, 1999, J CLIN INVEST, V103, P1103, DOI 10.1172/JCI5669; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Tager AM, 2003, NAT IMMUNOL, V4, P982, DOI 10.1038/ni970; Takatsu K, 2008, CURR OPIN IMMUNOL, V20, P288, DOI 10.1016/j.coi.2008.04.001; Thomas SY, 2007, J IMMUNOL, V179, P1901; Tremblay K, 2006, GENES IMMUN, V7, P632, DOI 10.1038/sj.gene.6364340; Trifari S, 2009, NAT IMMUNOL, V10, P864, DOI 10.1038/ni.1770; Upadhyaya B, 2011, J IMMUNOL, V187, P3111, DOI 10.4049/jimmunol.1101283; VanSnick J, 1996, J IMMUNOL, V157, P2570; Vestergaard C, 2003, BRIT J DERMATOL, V149, P457, DOI 10.1046/j.1365-2133.2003.05505.x; Vezys V, 2009, NATURE, V457, P196, DOI 10.1038/nature07486; Vijayanand P, 2010, J IMMUNOL, V184, P4568, DOI 10.4049/jimmunol.0901342; Voehringer D, 2006, J EXP MED, V203, P1435, DOI 10.1084/jem.20052448; Wakim LM, 2008, SCIENCE, V319, P198, DOI 10.1126/science.1151869; Wang YH, 2010, J EXP MED, V207, P2479, DOI 10.1084/jem.20101376; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wei L, 2010, IMMUNITY, V32, P840, DOI 10.1016/j.immuni.2010.06.003; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; Woodward AL, 2001, J ALLERGY CLIN IMMUN, V107, P359, DOI 10.1067/mai.2001.112695; Worbs T, 2006, J EXP MED, V203, P519, DOI 10.1084/jem.20052016; Worbs T, 2007, TRENDS IMMUNOL, V28, P274, DOI 10.1016/j.it.2007.04.002; Zammit DJ, 2006, IMMUNITY, V24, P439, DOI 10.1016/j.immuni.2006.01.015; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212; Zhu JF, 2010, IMMUNITY, V32, P11, DOI 10.1016/j.immuni.2010.01.001	167	91	94	1	20	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	1078-8956			NAT MED	Nat. Med.	MAY	2012	18	5					705	715		10.1038/nm.2760		11	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	938WE	WOS:000303763500038	22561834	
J	Murk, W; Risnes, KR; Bracken, MB				Murk, William; Risnes, Kari R.; Bracken, Michael B.			Prenatal or Early-Life Exposure to Antibiotics and Risk of Childhood Asthma: A Systematic Review	PEDIATRICS			English	Review						antibiotics; asthma; meta-analysis; systematic review	BIRTH COHORT; ALLERGIC DISEASE; 1ST YEAR; RESPIRATORY ILLNESS; AIRWAY INFLAMMATION; SCHOOL-AGE; CHILDREN; ECZEMA; INFECTIONS; PREVALENCE	CONTEXT: The increasing prevalence of childhood asthma has been associated with low microbial exposure as described by the hygiene hypothesis. OBJECTIVE: We sought to evaluate the evidence of association between antibiotic exposure during pregnancy or in the first year of life and risk of childhood asthma. METHODS: PubMed was systematically searched for studies published between 1950 and July 1, 2010. Those that assessed associations between antibiotic exposure during pregnancy or in the first year of life and asthma at ages 0 to 18 years (for pregnancy exposures) or ages 3 to 18 years (for first-year-of-life exposures) were included. Validity was assessed according to study design, age at asthma diagnosis, adjustment for respiratory infections, and consultation rates. RESULTS: For exposure in the first year of life, the pooled odds ratio (OR) for all studies (N = 20) was 1.52 (95% confidence interval [CI]: 1.30-1.77). Retrospective studies had the highest pooled risk estimate for asthma (OR: 2.04 [95% CI: 1.83-2.27]; n = 8) compared with database and prospective studies (OR: 1.25 [95% CI: 1.08-1.45]; n = 12). Risk estimates for studies that adjusted for respiratory infections (pooled OR: 1.16 [95% CI: 1.08-1.25]; n = 5) or later asthma onset (pooled OR for asthma at or after 2 years: OR: 1.16 [95% CI: 1.06-1.25]; n = 3) were weaker but remained significant. For exposure during pregnancy (n = 3 studies), the pooled OR was 1.24 (95% CI: 1.02-1.50). CONCLUSIONS: Antibiotics seem to slightly increase the risk of childhood asthma. Reverse causality and protopathic bias seem to be possible confounders for this relationship. Pediatrics 2011;127:1125-1138	[Murk, William; Risnes, Kari R.; Bracken, Michael B.] Yale Univ, Sch Publ Hlth, Ctr Perinatal Pediat & Environm Epidemiol, New Haven, CT 06510 USA; [Risnes, Kari R.] Norwegian Univ Sci & Technol, Dept Publ Hlth, N-7034 Trondheim, Norway	Bracken, MB (reprint author), Yale Univ, Sch Publ Hlth, Ctr Perinatal Pediat & Environm Epidemiol, 1 Church St, New Haven, CT 06510 USA.	michael.bracken@yale.edu			Liaison Committee; Central Norway Regional Health Authority; Norwegian University of Science and Technology	Dr Risnes was financially supported by a grant from the Liaison Committee between the Central Norway Regional Health Authority and the Norwegian University of Science and Technology.	Aberg N, 1996, ALLERGY, V51, P232, DOI 10.1111/j.1398-9995.1996.tb04598.x; Ahn KM, 2005, J ASTHMA, V42, P745, DOI 10.1080/02770900500308023; Altman DG, 2003, BRIT MED J, V326, P219, DOI 10.1136/bmj.326.7382.219; Bashir MEH, 2004, J IMMUNOL, V172, P6978; Benn CS, 2002, J ALLERGY CLIN IMMUN, V110, P72, DOI 10.1067/mai.2002.125833; BIZAL CL, 1991, J LEUKOCYTE BIOL, V50, P240; Blumer N, 2007, CLIN EXP ALLERGY, V37, P348, DOI 10.1111/j.1365-2222.2007.02671.x; Blumer N, 2005, CLIN EXP ALLERGY, V35, P397, DOI 10.1111/j.1365-2222.2005.02184.x; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; CHARLTON I, 1991, ARCH DIS CHILD, V66, P633; Cohet C, 2004, J EPIDEMIOL COMMUN H, V58, P852, DOI 10.1136/jech.2003.019182; Droste JHJ, 2000, CLIN EXP ALLERGY, V30, P1547; Egger M, 1997, BRIT MED J, V315, P629; Farooqi IS, 1998, THORAX, V53, P927; Floistrup H, 2006, J ALLERGY CLIN IMMUN, V117, P59, DOI 10.1016/j.jaci.2005.09.039; Foliaki S, 2004, INT J EPIDEMIOL, V33, P558, DOI 10.1093/ije/dyh031; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Joffe TH, 2009, J PEDIATR, V154, P154, DOI 10.1016/j.jpeds.2008.08.039; Karadag B, 2007, ALLERGY, V62, P1387, DOI 10.1111/j.1398-9995.2007.01505.x; Karimi M, 2009, IRAN J PEDIATR, V19, P141; Kozyrskyj AL, 2007, CHEST, V131, P1753, DOI 10.1378/chest.06-3008; Kumar R, 2008, J ALLERGY CLIN IMMUN, V121, P878, DOI 10.1016/j.jaci.2008.01.030; Kummeling I, 2008, CLIN EXP ALLERGY, V38, P1249, DOI 10.1111/j.1365-2222.2008.03047.x; Kusel MMH, 2008, CLIN EXP ALLERGY, V38, P1921, DOI 10.1111/j.1365-2222.2008.03138.x; Lai CKW, 2009, THORAX, V64, P476, DOI 10.1136/thx.2008.106609; Mai XM, 2010, CLIN EXP ALLERGY, V40, P1230, DOI 10.1111/j.1365-2222.2010.03532.x; Majkowska-Wojciechowska BM, 2007, ALLERGY, V62, P1044, DOI 10.1111/j.1398-9995.2007.01457.x; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Marra F, 2009, PEDIATRICS, V123, P1003, DOI 10.1542/peds.2008-1146; Martel MJ, 2009, AM J EPIDEMIOL, V169, P195, DOI 10.1093/aje/kwn309; McKeever TM, 2002, J ALLERGY CLIN IMMUN, V109, P43, DOI 10.1067/mai.2002.121016; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; Molis WE, 2008, ALLERGY, V63, P1529, DOI 10.1111/j.1398-9995.2008.01749.x; Mullooly JP, 2007, PHARMACOEPIDEM DR S, V16, P275, DOI 10.1002/pds.1272; Murray CS, 2002, THORAX, V57, P388, DOI 10.1136/thorax.57.5.388; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; Ponsonby AL, 1999, THORAX, V54, P664; Prescott SL, 2009, CURR OPIN ALLERGY CL, V9, P417, DOI 10.1097/ACI.0b013e328330634f; SIGURS N, 1995, PEDIATRICS, V95, P500; Sobko T, 2010, PAEDIATR PERINAT EP, V24, P88, DOI 10.1111/j.1365-3016.2009.01080.x; Stallworth Leila E, 2005, J Manag Care Pharm, V11, P657; Su Y, 2010, CLIN EXP ALLERGY, V40, P1222, DOI 10.1111/j.1365-2222.2010.03539.x; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Thomas M, 2003, EXPERT OPIN PHARMACO, V4, P351; Thomsen SF, 2006, ALLERGY ASTHMA PROC, V27, P110; von Elm E, 2008, J CLIN EPIDEMIOL, V61, P344, DOI 10.1016/j.jclinepi.2007.11.008; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; Wickens K, 2008, CLIN EXP ALLERGY, V38, P1318, DOI 10.1111/j.1365-2222.2008.03024.x; Wickens K, 1999, CLIN EXP ALLERGY, V29, P766; Wjst M, 2001, EUR J MED RES, V6, P263; Xu BZ, 1999, INT J EPIDEMIOL, V28, P723, DOI 10.1093/ije/28.4.723; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	54	91	94	1	13	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUN	2011	127	6					1125	1138		10.1542/peds.2010-2092		14	Pediatrics	Pediatrics	771GV	WOS:000291146100054	21606151	
J	Varshney, P; Steele, PH; Vickery, BP; Bird, JA; Thyagarajan, A; Scurlock, AM; Perry, TT; Jones, SM; Burks, AW				Varshney, Pooja; Steele, Pamela H.; Vickery, Brian P.; Bird, J. Andrew; Thyagarajan, Ananth; Scurlock, Amy M.; Perry, Tamara T.; Jones, Stacie M.; Burks, A. Wesley			Adverse reactions during peanut oral immunotherapy home dosing	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							COWS MILK ALLERGY; CHILDREN		[Varshney, Pooja; Steele, Pamela H.; Vickery, Brian P.; Bird, J. Andrew; Thyagarajan, Ananth; Burks, A. Wesley] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Scurlock, Amy M.; Perry, Tamara T.; Jones, Stacie M.] Univ Arkansas Med Sci, Arkansas Childrens Hosp, Dept Pediat, Little Rock, AR 72205 USA	Varshney, P (reprint author), Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.	wesley.burks@duke.edu		Bird, John/0000-0003-3772-6078	NIAID NIH HHS [R01 AI068074-02, R01 AI068074, R01 AI068074-01A1, R01 AI068074-03, T32 AI007062, T32 AI007062-28A2, T32 AI007062-29, T32 AI007062-30, T32 AI007062-31]		Cox L, 2007, J ALLERGY CLIN IMMUN, V120, pS25, DOI 10.1016/j.jaci.2007.06.019; Hofmann AM, 2009, J ALLERGY CLIN IMMUN, V124, P286, DOI 10.1016/j.jaci.2009.03.045; Jones SM, 2009, J ALLERGY CLIN IMMUN, V124, P292, DOI 10.1016/j.jaci.2009.05.022; Meglio P, 2004, ALLERGY, V59, P980, DOI 10.1111/j.1398-9995.2004.00542.x; Skripak JM, 2008, J ALLERGY CLIN IMMUN, V122, P1154, DOI 10.1016/j.jaci.2008.09.030; Staden U, 2007, ALLERGY, V62, P1261, DOI 10.1111/j.1398-9995.2007.01501.x	6	91	91	2	6	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2009	124	6					1351	1352		10.1016/j.jaci.2009.09.042		2	Allergy; Immunology	Allergy; Immunology	536VH	WOS:000273071500030	19913285	
J	Cooper, PJ				Cooper, Philip J.			Interactions between helminth parasites and allergy	CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; asthma; geohelminths; helminths	SKIN-TEST REACTIVITY; ASCARIS-IMMUNOGLOBULIN-E; SOUTH-AFRICAN CHILDREN; INDUCED INTERLEUKIN-10; RISK-FACTORS; RURAL AREA; GABONESE SCHOOLCHILDREN; GEOHELMINTH INFECTIONS; ANTHELMINTIC TREATMENT; ATOPIC SENSITIZATION	Purpose of review To review the findings of recent human studies of the association between helminth parasite infections and allergy and discuss their potential relevance to public health. Recent findings Different helminth parasites may have different effects on allergy that may depend on the timing or intensity of the exposure or host genetic factors. Infections with Trichuris trichiura in early life are associated with a reduced prevalence of allergen skin test reactivity later in life and infants of helminth-infected mothers have been reported to have a reduced prevalence of eczema. Hookworm infection has been associated with a reduced prevalence of asthma in Ethiopia. Several studies have reported that anti-Ascaris IgE is an important risk factor for asthma, but this could be explained by an enhanced ability of atopics to produce IgE. Toxocara infections may be associated with an increased risk of wheeze in some populations that may be caused by the host response to the parasite or by parasite-enhanced Th2 responses to aeroallergens. Summary Although helminth infections can modulate the host inflammatory response directed against the parasite, a causal association between helminths and atopic diseases remains uncertain.	[Cooper, Philip J.] St Georges Univ London, Ctr Infect, London, England; [Cooper, Philip J.] Univ San Francisco Quito, Inst Microbiol, Quito, Ecuador; [Cooper, Philip J.] Hosp Padre Alberto Buffoni, Ctr Invest FEPIS, Quininde, Esmeraldas Prov, Ecuador	Cooper, PJ (reprint author), Casilla 17-14-39, Carcelen, Quito, Ecuador.	pcooper@sgul.ac.uk			Wellcome Trust [074679, 072405]		Anthony RM, 2007, NAT REV IMMUNOL, V7, P975, DOI 10.1038/nri2199; Araujo MI, 2006, CHEM IMMUNOL ALLERGY, V90, P29; Araujo MIAS, 2004, J INFECT DIS, V190, P1797, DOI 10.1086/425017; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P399, DOI 10.1097/01.all.0000182536.55650.d0; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Audicana MT, 2008, CLIN MICROBIOL REV, V21, P360, DOI 10.1128/CMR.00012-07; Bayraktar MR, 2005, ACTA TROP, V95, P116, DOI 10.1016/j.actatropica.2005.05.006; Bethony J, 2006, LANCET, V367, P1521, DOI 10.1016/S0140-6736(06)68653-4; Camara AA, 2004, J ALLERGY CLIN IMMUN, V113, P551, DOI 10.1016/j.jaci.2003.11.027; Cooper PJ, 2008, CLIN EXP ALLERGY, V38, P551, DOI 10.1111/j.1365-2222.2008.02934.x; Cooper PJ, 2006, BRIT MED BULL, V79-80, P203, DOI 10.1093/bmb/ldl015; Cooper PJ, 2008, J INFECT DIS, V198, P1237, DOI 10.1086/591945; Cooper PJ, 2008, J INFECT DIS, V197, P1333, DOI 10.1086/586904; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830; Cooper PJ, 2002, J INFECT DIS, V186, P1307, DOI 10.1086/344318; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Cooper PJ, 2001, INFECT IMMUN, V69, P1574, DOI 10.1128/IAI.69.3.1574-1580.2001; Cooper PJ, 2002, IGE ANTIIGE THERAPY, V164, P409; COOPER PJ, 2009, ALLERGY IN PRESS; da Silva ER, 2008, PEDIATR PULM, V43, P662, DOI 10.1002/ppul.20833; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Davey G, 2005, CLIN EXP ALLERGY, V35, P301, DOI 10.1111/j.1365-2222.2005.02181.x; Dold S, 1998, J ALLERGY CLIN IMMUN, V102, P414, DOI 10.1016/S0091-6749(98)70129-0; Ege MJ, 2008, J ALLERGY CLIN IMMUN, V122, P407, DOI 10.1016/j.jaci.2008.06.011; Elliott AM, 2005, JAMA-J AM MED ASSOC, V294, P2032, DOI 10.1001/jama.294.16.2032-c; Falcone FH, 2005, TRENDS PARASITOL, V21, P157, DOI 10.1016/j.pt.2005.02.002; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Ferreira MU, 2007, J TROP PEDIATRICS, V53, P119, DOI 10.1093/tropej/fml083; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Garn H, 2007, IMMUNOBIOLOGY, V212, P441, DOI 10.1016/j.imbio.2007.03.006; Geiger SM, 2004, CLIN EXP IMMUNOL, V136, P334, DOI 10.1111/j.1365-2249.2004.02449.x; Hagel I, 2007, ACTA TROP, V103, P231, DOI 10.1016/j.actatropica.2007.06.010; Haileamlak A, 2005, J ALLERGY CLIN IMMUN, V115, P370, DOI 10.1016/j.jaci.2004.10.024; Heukelbach J, 2008, LANCET INFECT DIS, V8, P302, DOI 10.1016/S1473-3099(08)70098-7; Hoerauf A, 2005, PARASITE IMMUNOL, V27, P417, DOI 10.1111/j.1365-3024.2005.00792.x; Hunninghake GM, 2007, J ALLERGY CLIN IMMUN, V119, P654, DOI 10.1016/j.jaci.2006.12.609; Karadag B, 2006, ALLERGY, V61, P996, DOI 10.1111/j.1398-9995.2006.01107.x; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; Maruyama H, 1996, LANCET, V347, P1766, DOI 10.1016/S0140-6736(96)90844-2; Moller M, 2007, HUM MOL GENET, V16, P1828, DOI 10.1093/hmg/ddm131; Nash T.E., 2005, PRINCIPLES PRACTICE, P3293; Nicolaou N, 2005, ALLERGY, V60, P1357, DOI 10.1111/j.1398-9995.2005.00961.x; Nieuwenhuizen N, 2006, J ALLERGY CLIN IMMUN, V117, P1098, DOI 10.1016/j.jaci.2005.12.1357; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P640, DOI 10.1111/j.1365-2222.2006.02479.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Pearce N, 2007, THORAX, V62, P758, DOI 10.1136/thx.2006.070169; Peisong G, 2004, GENES IMMUN, V5, P58, DOI 10.1038/sj.gene.6364030; Pereira MU, 2007, EUR RESPIR J, V29, P1154, DOI 10.1183/09031936.00127606; Ponte EV, 2006, ANN ALLERG ASTHMA IM, V96, P713; Rodrigues LC, 2008, CLIN EXP ALLERGY, V38, P1769, DOI 10.1111/j.1365-2222.2008.03027.x; Santos ABR, 2008, J ALLERGY CLIN IMMUN, V121, P1040, DOI 10.1016/j.jaci.2007.12.1147; Schafer T, 2005, ALLERGY, V60, P1014, DOI 10.1111/j.1398-9995.2005.00801.x; SPILLMANN RK, 1975, AM J TROP MED HYG, V24, P791; Steinman HA, 2003, PEDIATR ALLERGY IMMU, V14, P383, DOI 10.1034/j.1399-3038.2003.00062.x; Takeuchi H, 2008, CLIN EXP ALLERGY, V38, P276, DOI 10.1111/j.1365-2222.2007.02890.x; Turner JD, 2005, MICROBES INFECT, V7, P990, DOI 10.1016/j.micinf.2005.03.036; Turner JD, 2008, J INFECT DIS, V197, P1204, DOI 10.1086/586717; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Riet E, 2007, IMMUNOBIOLOGY, V212, P475, DOI 10.1016/j.imbio.2007.03.009; von Mutius Erika, 2007, Proc Am Thorac Soc, V4, P212, DOI 10.1513/pats.200701-028AW; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wilson MS, 2007, IMMUNOL CELL BIOL, V85, P148, DOI 10.1038/sj.icb.7100014; Wordemann M, 2008, TROP MED INT HEALTH, V13, P180, DOI 10.1111/j.1365-3156.2007.01988.x	70	91	105	4	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1528-4050			CURR OPIN ALLERGY CL	Curr. Opin. Allergy Clin. Immunol.	FEB	2009	9	1					29	37		10.1097/ACI.0b013e32831f44a6		9	Allergy; Immunology	Allergy; Immunology	400SH	WOS:000262888400006	19106698	
J	Flohr, C; Quinnell, RJ; Britton, J				Flohr, C.; Quinnell, R. J.; Britton, J.			Do helminth parasites protect against atopy and allergic disease?	CLINICAL AND EXPERIMENTAL ALLERGY			English	Review							SCHISTOSOMA-MANSONI INFECTION; NECATOR-AMERICANUS INFECTION; SKIN-TEST REACTIVITY; IGE ANTIBODY-LEVELS; HOUSE-DUST MITE; ASCARIS-LUMBRICOIDES; RURAL AREA; GABONESE SCHOOLCHILDREN; INDUCED INTERLEUKIN-10; INTESTINAL PARASITES	Allergic diseases are rare in areas with high helminth parasite exposure and common where helminth exposure is lacking or significantly reduced, such as urban areas of developing countries and industrialized nations. Studies suggest that helminths induce a systemic immuno-modulatory network, including regulatory T cells and anti-inflammatory IL-10, which might play a key role in the protection against the allergic phenotype. Here, we review the current cross-sectional, birth cohort, and intervention study evidence for a protective effect of helminth infection on allergy. There is increasing evidence for a causal relationship between helminth infection and reduced skin prick test responsiveness to allergens. Cross-sectional studies have shown a consistent negative relationship, and these results have been confirmed in several, although not all, intervention studies. The immunological basis for this protective effect is less clear. Recent studies do not support the mast-cell IgE saturation hypothesis, but suggest that protection is associated with IL-10 production. As for allergic disease, cross-sectional studies support a negative relationship between clinical asthma and infection with some helminth species, particularly hookworm, but more studies are required to draw conclusions for eczema and rhinitis. In addition, none of the few intervention studies to date have demonstrated an increase in clinical allergy after helminth treatment, and further studies are needed. Furthermore, we are only beginning to understand the host genetic factors that are potentially involved. A genetically predetermined T-helper type 2 cell-dominated cytokine milieu reduces parasite burden and may enhance host survival in an environment where helminth parasites are prevalent. Lack of parasite exposure in such hosts might lead to hypersensitivity to seemingly minor environmental allergen stimuli. Large birth cohort studies in helminth-endemic areas that use epidemiological, genetic, and immunological tools are required to further examine how helminth parasites affect the development of atopy and allergic disease. Intervention studies with hookworm in parasite-naive allergic individuals are currently ongoing in the United Kingdom to test the above hypotheses further.	[Flohr, C.] Univ Nottingham, Inst Clin Res, Nottingham NG7 2UH, England; [Quinnell, R. J.] Univ Leeds, Fac Biol Sci, Inst Integrat & Comparat Biol, Leeds, W Yorkshire, England; [Britton, J.] Univ Nottingham, Dept Epidemiol & Publ Hlth, Nottingham NG7 2RD, England; [Flohr, C.] Univ Nottingham, Ctr Evidence Based Dermatol, Nottingham NG7 2UH, England	Flohr, C (reprint author), Univ Nottingham, Inst Clin Res, Nottingham NG7 2UH, England.	carsten.flohr@nottingham.ac.uk					ALSHISHTAWY MM, 1991, INT ARCH ALLER A IMM, V96, P348; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Araujo MIAS, 2004, J INFECT DIS, V190, P1797, DOI 10.1086/425017; Arruda LK, 2005, CURR OPIN ALLERGY CL, V5, P399, DOI 10.1097/01.all.0000182536.55650.d0; Babu S, 2006, J IMMUNOL, V176, P3248; Barnes KC, 2005, CURR OPIN ALLERGY CL, V5, P379, DOI 10.1097/01.all.0000182543.37724.7b; Bashir MEH, 2002, J IMMUNOL, V169, P3284; BAZARAL M, 1973, CLIN EXP IMMUNOL, V14, P117; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURRELMORRIS C, 2000, EPIDEMIOLOGY CAUSE P, P169; CARSWELL F, 1977, CLIN ALLERGY, V7, P445, DOI 10.1111/j.1365-2222.1977.tb01475.x; Collins A, 2000, GENET MOL BIOL, V23, P1; Contopoulos-Ioannidis DG, 2005, J ALLERGY CLIN IMMUN, V115, P963, DOI 10.1016/j.jaci.2004.12.1119; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cooper PJ, 2008, J INFECT DIS, V197, P1333, DOI 10.1086/586904; Cooper PJ, 2006, LANCET, V367, P1598, DOI 10.1016/S0140-6736(06)68697-2; Cooper PJ, 2004, J INFECT DIS, V190, P1338, DOI 10.1086/423944; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 2000, J INFECT DIS, V182, P1207, DOI 10.1086/315830; Cooper PJ, 2004, CLIN EXP ALLERGY, V34, P845, DOI 10.1111/j.1365-2222.2004.01958.x; Cooper PJ, 2004, CLIN REV ALLERG IMMU, V26, P5, DOI 10.1385/CRIAI:26:1:5; Cooper PJ, 2003, AM J RESP CRIT CARE, V168, P313, DOI 10.1164/rccm.200211-1320OC; Crompton DWT, 1999, J PARASITOL, V85, P397, DOI 10.2307/3285768; Dagoye D, 2003, AM J RESP CRIT CARE, V167, P1369, DOI 10.1164/rccm.200210-1204OC; Das PK, 1997, T ROY SOC TROP MED H, V91, P677, DOI 10.1016/S0035-9203(97)90521-6; Davey G, 2005, CLIN EXP ALLERGY, V35, P301, DOI 10.1111/j.1365-2222.2005.02181.x; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Elliott AM, 2005, JAMA-J AM MED ASSOC, V294, P2032, DOI 10.1001/jama.294.16.2032-c; Erb KJ, 2007, EUR J IMMUNOL, V37, P1170, DOI 10.1002/eji.200737314; Fallon PG, 2007, NAT REV IMMUNOL, V7, P220, DOI 10.1038/nri2039; Flohr C, 2003, BRIT J DERMATOL, V148, P871, DOI 10.1046/j.1365-2133.2003.05403.x; Flohr C, 2007, CLIN EXP ALLERGY, V37, P1880; Flohr C, 2006, J ALLERGY CLIN IMMUN, V118, P1305, DOI 10.1016/j.jaci.2006.08.035; Flohr C, 2008, J ALLERGY CLIN IMMUN, V121, P141, DOI 10.1016/j.jaci.2007.08.066; Geiger SM, 2007, PARASITE IMMUNOL, V29, P347, DOI 10.1111/j.1365-3024.2007.00950.x; Geiger SM, 2004, CLIN EXP IMMUNOL, V136, P334, DOI 10.1111/j.1365-2249.2004.02449.x; GERRARD JW, 1976, ANN ALLERGY, V37, P91; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; Golding J, 1987, Paediatr Perinat Epidemiol, V1, P67, DOI 10.1111/j.1365-3016.1987.tb00091.x; GROVE DI, 1974, CLIN ALLERGY, V4, P295, DOI 10.1111/j.1365-2222.1974.tb01388.x; GROVE DI, 1975, MED J AUSTRALIA, V1, P336; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209; Haileamlak A, 2005, J ALLERGY CLIN IMMUN, V115, P370, DOI 10.1016/j.jaci.2004.10.024; Heinrich J, 1998, AM J PUBLIC HEALTH, V88, P1319, DOI 10.2105/AJPH.88.9.1319; HERRICK WW, 1913, ARCH INTERN MED, V11, P163; Huang SL, 2002, CLIN EXP ALLERGY, V32, P1029, DOI 10.1046/j.1365-2745.2002.01424.x; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; King CL, 1998, J IMMUNOL, V160, P3578; King CL, 1996, J IMMUNOL, V156, P4715; Kitagaki K, 2006, J IMMUNOL, V177, P1628; Kouriba B, 2005, J IMMUNOL, V174, P6274; Kraan TCTMV, 1999, GENES IMMUN, V1, P61; LARRICK JW, 1983, J ALLERGY CLIN IMMUN, V71, P184, DOI 10.1016/0091-6749(83)90097-0; Le Souef PN, 2000, LANCET, V356, P242; Leonardi-Bee J, 2006, AM J RESP CRIT CARE, V174, P514, DOI 10.1164/rccm.200603-331OC; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; LYNCH NR, 1984, J ALLERGY CLIN IMMUN, V73, P229, DOI 10.1016/S0091-6749(84)80012-3; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; LYNCH NR, 1983, INT ARCH ALLER A IMM, V72, P369; MACFARLANE JT, 1979, CLIN ALLERGY, V9, P333, DOI 10.1111/j.1365-2222.1979.tb02491.x; Mahanty S, 1996, J INFECT DIS, V173, P769; Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Mangan NE, 2006, J IMMUNOL, V176, P138; Markell EK, 1999, MED PARASITOLOGY; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; MASTERS S, 1985, EPIDEMIOL REV, V7, P49; Medeiros M, 2003, J ALLERGY CLIN IMMUN, V111, P947, DOI 10.1067/mai.2003.1381; Melendez AJ, 2007, NAT MED, V13, P1375, DOI 10.1038/nm1654; Mitre E, 2005, INFECT IMMUN, V73, P4106, DOI 10.1128/IAI.73.7.4106-4111.2005; Mitre E, 2008, J INFECT DIS, V197, P94, DOI 10.1086/524301; Moller M, 2007, HUM MOL GENET, V16, P1828, DOI 10.1093/hmg/ddm131; Mortimer K, 2006, AM J TROP MED HYG, V75, P914; NEAME RL, 1995, BRIT J DERMATOL, V132, P772; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Obihara CC, 2006, CLIN EXP ALLERGY, V36, P640, DOI 10.1111/j.1365-2222.2006.02479.x; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Ponte EV, 2006, ANN ALLERG ASTHMA IM, V96, P713; Pritchard DI, 2007, AM J TROP MED HYG, V77, P860; Pritchard DI, 2001, TRENDS PARASITOL, V17, P169, DOI 10.1016/S1471-4922(01)01941-9; Quinnell RJ, 2003, INT J PARASITOL, V33, P1219, DOI 10.1016/S0020-7519(03)00175-9; Ramsay CE, 1999, HUM GENET, V104, P269, DOI 10.1007/s004390050947; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Schafer T, 2005, ALLERGY, V60, P1014, DOI 10.1111/j.1398-9995.2005.00801.x; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; Soboslay PT, 2006, MICROBES INFECT, V8, P238, DOI 10.1016/j.micinf.2005.06.019; STEEL C, 1994, LANCET, V343, P890, DOI 10.1016/S0140-6736(94)90009-4; Terhell AJ, 2002, T ROY SOC TROP MED H, V96, P334, DOI 10.1016/S0035-9203(02)90117-3; TULLIS DCH, 1970, NEW ENGL J MED, V282, P370, DOI 10.1056/NEJM197002122820706; Turner JD, 2003, J INFECT DIS, V188, P1768, DOI 10.1086/379370; Turner JD, 2008, J INFECT DIS, V197, P1204, DOI 10.1086/586717; TURTON JA, 1976, LANCET, V2, P686; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van den Biggelaar AHJ, 2007, J ALLERGY CLIN IMMUN, V120, P973, DOI 10.1016/j.jaci.2007.06.044; VANDELLEN RG, 1971, NEW ENGL J MED, V285, P146, DOI 10.1056/NEJM197107152850304; WAITE DA, 1980, CLIN ALLERGY, V10, P71, DOI 10.1111/j.1365-2222.1980.tb02082.x; WARRELL DA, 1975, Q J MED, V44, P325; WEIL GJ, 1983, J CLIN INVEST, V71, P1124, DOI 10.1172/JCI110862; Weiss ST, 2000, J ALLERGY CLIN IMMUN, V105, P205, DOI 10.1016/S0091-6749(00)90067-8; World Health Organization, 2002, WHO TECHN REP SER, V912; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; Williams-Blangero S, 2008, J INFECT DIS, V197, P1198, DOI 10.1086/533493; Williams-Blangero S, 2008, J INFECT DIS, V197, P66, DOI 10.1086/524060; Wilson MS, 2004, CLIN REV ALLERG IMMU, V26, P35, DOI 10.1385/CRIAI:26:1:35; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Wohlleben G, 2004, INT IMMUNOL, V16, P585, DOI 10.1093/intimm/dxh062; Yazdanbakhsh M, 2004, CLIN REV ALLERG IMMU, V26, P15, DOI 10.1385/CRIAI:26:1:15; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	114	91	99	2	14	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2009	39	1					20	32		10.1111/j.1365-2222.2008.03134.x		13	Allergy; Immunology	Allergy; Immunology	392DE	WOS:000262282300006	19128351	
J	O'Connor, GT; Neas, L; Vaughn, B; Kattan, M; Mitchell, H; Crain, EF; Evans, R; Gruchalla, R; Morgan, W; Stout, J; Adams, GK; Lippmann, M				O'Connor, George T.; Neas, Lucas; Vaughn, Benjamin; Kattan, Meyer; Mitchell, Herman; Crain, Ellen F.; Evans, Richard, III; Gruchalla, Rebecca; Morgan, Wayne; Stout, James; Adams, G. Kenneth; Lippmann, Morton			Acute respiratory health effects of air pollution on children with asthma in US inner cities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						nitrogen dioxide; ozone; sulfur dioxide; carbon monoxide; fine particle emissions; asthma in children	PEAK EXPIRATORY FLOW; FINE PARTICLES; DAILY MORTALITY; ENVIRONMENTAL INTERVENTION; HOSPITAL ADMISSIONS; CHILDHOOD ASTHMA; SYMPTOM SEVERITY; MEDICATION USE; MEXICO-CITY; URBAN AIR	Background: Children with asthma in inner-city communities may be particularly vulnerable to adverse effects of air pollution because of their airways disease and exposure to relatively high levels of motor vehicle emissions. Objective: To investigate the association between fluctuations in outdoor air pollution and asthma morbidity among inner-city children with asthma. Methods: We analyzed data from 861 children with persistent asthma in 7 US urban communities who performed 2-week periods of twice-daily pulmonary function testing every 6 months for 2 years. Asthma symptom data were collected every 2 months. Daily pollution measurements were obtained from the Aerometric Information Retrieval System. The relationship of lung function and symptoms to fluctuations in pollutant concentrations was examined by using mixed models. Results: Almost all pollutant concentrations measured were below the National Ambient Air Quality Standards. In single-pollutant models, higher 5-day average concentrations of NO(2), sulfur dioxide, and particles smaller than 2.5 mu m were associated with significantly lower pulmonary function. Higher pollutant levels were independently associated with reduced lung function in a 3-pollutant model. Higher concentrations of NO(2) and particles smaller than 2.5 mu m were associated with asthma-related missed school days, and higher NO(2) concentrations were associated with asthma symptoms. Conclusion: Among inner-city children with asthma, short-term increases in air pollutant concentrations below the National Ambient Air Quality Standards were associated with adverse respiratory health effects. The associations with NO(2) suggest that motor vehicle emissions may be causing excess morbidity in this population.	[O'Connor, George T.] Boston Univ, Sch Med, Ctr Pulm, Dept Med, Boston, MA 02118 USA; [Neas, Lucas; Mitchell, Herman] US EPA, Res Triangle Pk, NC 27711 USA; [Vaughn, Benjamin] Rho Fed Syst Div Inc, Chapel Hill, NC USA; [Kattan, Meyer] Mt Sinai Sch Med, Dept Pediat, New York, NY USA; [Crain, Ellen F.] Albert Einstein Coll Med, Dept Pediat Emergency Med, Jacobi Med Ctr, Bronx, NY 10467 USA; [Evans, Richard, III] Northwestern Univ, Sch Med, Dept Pediat & Med, Chicago, IL 60611 USA; [Gruchalla, Rebecca] Univ Texas SW Med Ctr Dallas, Dept Med, Dallas, TX 75390 USA; [Gruchalla, Rebecca] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Morgan, Wayne] Univ Arizona, Coll Med, Resp Sci Ctr, Tucson, AZ 85721 USA; [Stout, James] Univ Washington, Sch Med, Dept Pediat, Seattle, WA 98195 USA; [Adams, G. Kenneth] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Lippmann, Morton] NYU, Sch Med, Dept Environm Med, Tuxedo Pk, NY USA	O'Connor, GT (reprint author), Boston Univ, Sch Med, Ctr Pulm, Dept Med, 715 Albany St,Room 304, Boston, MA 02118 USA.	goconnor@bu.edu	Neas, Lucas/J-9378-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; O'Connor, George/0000-0002-6476-3926	NCRR NIH HHS [M01RR00533]; NIAID NIH HHS [AI-39902, AI-39761, AI-39769, AI-39776, AI-39785, AI-39789, AI-39900, AI-39901]		Barnett AG, 2005, AM J RESP CRIT CARE, V171, P1272, DOI 10.1164/rccm.200411-1586OC; Belanger K, 2006, AM J RESP CRIT CARE, V173, P297, DOI 10.1164/rccm.200408-1123OC; Burnett RT, 2000, INHAL TOXICOL, V12, P15, DOI 10.1080/089583700750019495; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; Gauderman WJ, 2004, NEW ENGL J MED, V351, P1057, DOI 10.1056/NEJMoa040610; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; HSU KHK, 1979, J PEDIATR-US, V95, P14, DOI 10.1016/S0022-3476(79)80075-X; ITO K, 2005, J EXPO ANAL ENV EPID, V15, P173; Krewski D, 2007, J TOXICOL ENV HEAL A, V70, P275, DOI 10.1080/15287390600884859; Laden F, 2000, ENVIRON HEALTH PERSP, V108, P941, DOI 10.2307/3435052; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Neas LM, 1999, EPIDEMIOLOGY, V10, P550, DOI 10.1097/00001648-199909000-00015; NEAS LM, 1995, AM J EPIDEMIOL, V141, P111; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Peters A, 1997, EUR RESPIR J, V10, P872; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Phalen R., 2002, PARTICULATE AIR POLL; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Sarnat JA, 2000, J AIR WASTE MANAGE, V50, P1184; Schwartz J, 1996, J AIR WASTE MANAGE, V46, P927, DOI 10.1080/10473289.1996.10467528; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Sinclair AH, 2004, J AIR WASTE MANAGE, V54, P1212; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346; SPEKTOR DM, 1988, AM REV RESPIR DIS, V137, P313; Thurston GD, 1997, AM J RESP CRIT CARE, V155, P654; Tiittanen P, 1999, EUR RESPIR J, V13, P266, DOI 10.1034/j.1399-3003.1999.13b08.x; U. S. Environmental Protection Agency, 2004, EPA600P99002AF; [Anonymous], TECHN TRANSF NETW AI; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; Ward DJ, 2002, THORAX, V57, P489, DOI 10.1136/thorax.57.6.489; WHITE MC, 1994, ENVIRON RES, V65, P56, DOI 10.1006/enrs.1994.1021; Zanobetti A, 2000, ENVIRON HEALTH PERSP, V108, P1071, DOI 10.2307/3434961	44	91	99	3	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2008	121	5					1133	1139		10.1016/j.jaci.2008.02.020		7	Allergy; Immunology	Allergy; Immunology	302IJ	WOS:000255961700009	18405952	
J	Bello, D; Herrick, CA; Smith, TJ; Woskie, SR; Streicher, RP; Cullen, MR; Liu, YC; Redlich, CA				Bello, Dhimiter; Herrick, Christina A.; Smith, Thomas J.; Woskie, Susan R.; Streicher, Robert P.; Cullen, Mark R.; Liu, Youcheng; Redlich, Carrie A.			Skin exposure to isocyanates: Reasons for concern	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Review						asthma; dermal exposure; isocyanates; sensitization; skin	ALLERGIC CONTACT-DERMATITIS; METHYLENE DIPHENYL DIISOCYANATE; TOLUENE DIISOCYANATE; OCCUPATIONAL ASTHMA; POLYURETHANE FOAM; BODY REPAIR; IN-VIVO; 1,6-HEXAMETHYLENE DIISOCYANATE; TRIMELLITIC ANHYDRIDE; RESPIRATORY ALLERGY	OBJECTIVE: Isocyanates (di- and poly-), important chemicals used worldwide to produce polyurethane products, are a leading cause of occupational asthma. Respiratory exposures have been reduced through improved hygiene controls and the use of less-volatile isocyanates. Yet isocyanate asthma continues to occur, not uncommonly in settings with minimal inhalation exposure but opportunity for skin exposure. In this review we evaluate the potential role of skin exposure in the development of isocyanate asthma. DATA SOURCES: We reviewed the published animal and human literature on isocyanate skin-exposure methods, workplace skin exposure, skin absorption, and the role of skin exposure in isocyanate sensitization and asthma. DATA EXTRACTION: We selected relevant articles from computerized searches on Medline, U.S. Environmental Protection Agency, Occupational Safety and Health Administration, National Institute for Occupational Safety and Health, and Google databases using the keywords "isocyanate," "asthma," "skin," "sensitization," and other synonymous terms, and our own extensive collection of isocyanate publications. DATA SYNTHESIS: Isocyanate production and use continues to increase as the polyurethane industry expands. There is substantial opportunity for isocyanate skin exposure in many work settings, but such exposure is challenging to quantify and continues to be underappreciated. Isocyanate skin exposure can occur at work, even with the use of personal protective equipment, and may also occur with consumer use of certain isocyanate products. In animals, isocyanate skin exposure is an efficient route to induce sensitization, with subsequent inhalation challenge resulting in asthma-like responses. Several lines of evidence support a similar role for human isocyanate skin exposure, namely, that such exposure occurs and can contribute to the development of isocyanate asthma in certain settings, presumably by inducing systemic sensitization. CONCLUSIONS: Integrated animal and human research is needed to better understand the role of skin exposure in human isocyanate asthma and to improve diagnosis and prevention. In spite of substantial research needs, sufficient evidence already exists to justify greater emphasis on the potential risks of isocyanate skin exposure and the importance of preventing such exposures at work and during consumer use of certain isocyanate products.	Univ Massachusetts, Dept Work Environm, Lowell, MA 01854 USA; Harvard Univ, Sch Publ Hlth, Exposure Epidemiol & Risk Program, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA; Yale Univ, Sch Med, Occupat & Environm Med Program, New Haven, CT USA	Bello, D (reprint author), Univ Massachusetts, Dept Work Environm, KI 200,1 Univ Ave, Lowell, MA 01854 USA.	dhimiter_bello@uml.edu			NIEHS NIH HHS [K24 ES00355, K24 ES000355, T32 ES007069, T32 ES07069]; NIOSH CDC HHS [5 R01 OH004246, R01 OH004246, R01 OH3457]		ABBAS A. K., 2000, CELLULAR MOL IMMUNOL; ACGIH, 2006, 2006 TLVS BEIS THRES; *ALL POL IND, 2005, HANDL HEAT POL THERM; ALLPORT D, 2003, MDI TDI SAF HLTH ENV; ALOMAR A, 1986, CONTACT DERMATITIS, V15, P44, DOI 10.1111/j.1600-0536.1986.tb01267.x; BAKKE J, 2006, INT CONSENSUS REPORT; Ban M, 2006, TOXICOLOGY, V218, P39, DOI 10.1016/j.tox.2005.09.013; Basketter DA, 2006, CONTACT DERMATITIS, V55, P178, DOI 10.1111/j.1600-0536.2006.00906.x; BAU X, 2003, ANN ALLERGY ASTHM S2, V90, P11; BAUR X, 1994, INT ARCH OCC ENV HEA, V66, P141, DOI 10.1007/BF00380772; Bello D, 2006, J ENVIRON MONITOR, V8, P523, DOI 10.1039/b517948c; Bello D, 2004, AM J IND MED, V46, P480, DOI 10.1002/ajim.20076; Bello D, 2005, J ENVIRON MONITOR, V7, P716, DOI 10.1039/b503807c; BELLO D, IN PRESS J OCCUP ENV; BERNSTEIN DI, 1993, J ALLERGY CLIN IMMUN, V92, P387, DOI 10.1016/0091-6749(93)90117-X; Bernstein JA, 1996, TOXICOLOGY, V111, P181, DOI 10.1016/0300-483X(96)03375-6; Boman A, 2000, Int J Occup Environ Health, V6, P93; Boukhman MP, 2001, FOOD CHEM TOXICOL, V39, P1125, DOI 10.1016/S0278-6915(01)00062-X; Boutin M, 2006, ANN OCCUP HYG, V50, P385, DOI 10.1093/annhyg/mei075; CARROLL KB, 1976, CLIN ALLERGY, V6, P99, DOI 10.1111/j.1365-2222.1976.tb01886.x; COLLINHANSEN I, 2006, AM IND HYG ASS C 206; Creely KS, 2006, ANN OCCUP HYG, V50, P609, DOI [10.1093/annhyg/mel024, 10.1093/annhyg/me1024]; Cummings KJ, 2007, OCCUP ENVIRON MED, V64, P134, DOI 10.1136/oem.2006.027987; Darcey D, 2002, ARCH ENVIRON HEALTH, V57, P239; De Zotti R, 2000, OCCUP ENVIRON MED, V57, P837, DOI 10.1136/oem.57.12.837; DIETEMANNMOLARD A, 1991, LANCET, V338, P953, DOI 10.1016/0140-6736(91)91825-F; Donnelly R, 2004, OCCUP MED-OXFORD, V54, P432, DOI 10.1093/occmed/kqg133; ERJEFALT I, 1992, CLIN EXP ALLERGY, V22, P854, DOI 10.1111/j.1365-2222.1992.tb02831.x; Fent KW, 2006, SCAND J WORK ENV HEA, V32, P225; Frick M, 2004, CONTACT DERMATITIS, V51, P73, DOI 10.1111/j.0105-1873.2004.00404.x; Frick M, 2003, CONTACT DERMATITIS, V48, P305, DOI 10.1034/j.1600-0536.2003.00123.x; Gagne S, 2003, ANALYST, V128, P1447, DOI 10.1039/b310463j; Goossens A, 2002, CONTACT DERMATITIS, V47, P304, DOI 10.1034/j.1600-0536.2002.470509.x; Herrick CA, 2002, J ALLERGY CLIN IMMUN, V109, P873, DOI 10.1067/mai.2002.123533; Herrick CA, 2003, J IMMUNOL, V170, P2488; Kaaria K, 2001, ANALYST, V126, P476, DOI 10.1039/b009549o; KANERVA L, 2001, CONTACT DERMATITIS, V44, P246; KAROL MH, 1981, TOXICOL APPL PHARM, V58, P221, DOI 10.1016/0041-008X(81)90426-9; Kimber I, 2002, TOXICOLOGY, V181, P311, DOI 10.1016/S0300-483X(02)00299-8; Krone CA, 2005, PEDIATR ALLERGY IMMU, V16, P368, DOI 10.1111/j.1399-3038.2005.00295.x; Krone CA, 2003, B ENVIRON CONTAM TOX, V70, P328, DOI 10.1007/s00128-002-0195-2; Lack G, 2003, NEW ENGL J MED, V348, P977, DOI 10.1056/NEJMoa013536; LEGRIS M, 1995, EXPOSURE ISOCYANATES; LEIBOLD E, 1999, MDI STUDY ADSORPTION; LENAERTSLANGANK.H, 1992, ZBL ARBEITSMEDIZIN, V42, P2; LISS DJ, 2006, P AM THOR SOC, V2, pA816; LISS GM, 1988, J ALLERGY CLIN IMMUN, V82, P55, DOI 10.1016/0091-6749(88)90051-6; Littorin M, 2002, INT ARCH OCC ENV HEA, V75, P468, DOI 10.1007/s00420-002-0337-1; Liu YC, 2000, AM J IND MED, V37, P265, DOI 10.1002/(SICI)1097-0274(200003)37:3<265::AID-AJIM4>3.0.CO;2-O; MAITRE A, 1996, INT S BIOL MON OCC E; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; Moody RP, 2006, FOOD CHEM TOXICOL, V44, P1783, DOI 10.1016/j.fct.2006.05.020; Morgan CJ, 2003, CONTACT DERMATITIS, V48, P224, DOI 10.1034/j.1600-0536.2003.00064.x; MUNN A., 1965, ANN OCCUP HYG, V8, P163; MUSK AW, 1988, AM J IND MED, V13, P331, DOI 10.1002/ajim.4700130304; NEMERY B, 1993, LANCET, V341, P318, DOI 10.1016/0140-6736(93)92682-J; Nicholson PJ, 2005, OCCUP ENVIRON MED, V62, P290, DOI 10.1136/oem.2004.016287; National Institute for Occupational Safety and Health (NIOSH), 2005, NIOSH POCK GUID CHEM; *NIOSH, 1999, HETA9901962860; *NIOSH, 1998, 9800112801 HETA; *NIOSH, 1996, PREV ASTH DEATH DIIS; Orloff KG, 1998, ENVIRON HEALTH PERSP, V106, P665, DOI 10.2307/3434095; PETERS JM, 1971, AM REV RESPIR DIS, V104, P432; Petsonk EL, 2000, CHEST, V118, P1183, DOI 10.1378/chest.118.4.1183; Pronk A, 2006, OCCUP ENVIRON MED, V63, P624, DOI 10.1136/oem.2005.023226; RATTRAY NJ, 1994, TOXICOLOGY, V88, P15, DOI 10.1016/0300-483X(94)90108-2; Redlich CA, 2001, AM J IND MED, V39, P587, DOI 10.1002/ajim.1058; Saloga J, 2000, ALLERGY, V55, P905, DOI 10.1034/j.1398-9995.2000.00126.x; Scheerens H, 1999, AM J RESP CRIT CARE, V159, P1074; SHEAARER WT, 2003, ALLERGY PRINCIPLES P, P1; Smith D, 1996, CLIN ELECTROENCEPHAL, V27, P4; Sommer B G, 2000, Ugeskr Laeger, V162, P505; STOWE M, 2006, P AM THOR SOC, V3, pA250; STREICHER RP, 1994, ANALYST, V119, P89, DOI 10.1039/an9941900089; Strid J, 2005, CLIN EXP ALLERGY, V35, P757, DOI 10.1111/j.1365-2222.2005.02260.x; Tarlo SM, 1997, AM J IND MED, V32, P517, DOI 10.1002/(SICI)1097-0274(199711)32:5<517::AID-AJIM12>3.0.CO;2-5; Tarlo SM, 2005, OCCUP MED-OXFORD, V55, P588, DOI 10.1093/occmed/kqi182; Tinkle SS, 2003, ENVIRON HEALTH PERSP, V111, P1202, DOI 10.1289/ehp.5999; Valks R, 2003, CONTACT DERMATITIS, V49, P166, DOI 10.1111/j.0105-1873.2003.0185j.x; Vanoirbeek JAJ, 2006, J ALLERGY CLIN IMMUN, V117, P1090, DOI 10.1016/j.jaci.2006.01.027; Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155; VILAPLANA J, 1987, CONTACT DERMATITIS, V16, P113, DOI 10.1111/j.1600-0536.1987.tb01397.x; Vock EH, 1997, TOXICOL LETT, V92, P93, DOI 10.1016/S0378-4274(97)00041-6; WELINDER H, 1988, CLIN ALLERGY, V18, P85, DOI 10.1111/j.1365-2222.1988.tb02847.x; Wester RC, 1999, TOXICOL SCI, V48, P1; WILKINSON SM, 1991, CONTACT DERMATITIS, V25, P94, DOI 10.1111/j.1600-0536.1991.tb01795.x; Wisnewski AV, 2004, J ALLERGY CLIN IMMUN, V113, P1178, DOI 10.1016/j.jaci.2004.03.009; Wisnewski AV, 1999, J ALLERGY CLIN IMMUN, V104, P341, DOI 10.1016/S0091-6749(99)70377-5; Wisnewski AV, 2000, AM J RESP CRIT CARE, V162, P2330; Wisnewski AV, 2006, ASTHMA WORKPLACE, P481; Woskie SR, 2004, ANN OCCUP HYG, V48, P393, DOI 10.1093/annhyg/meh021; Ye YM, 2006, J ALLERGY CLIN IMMUN, V118, P885, DOI 10.1016/j.jaci.2006.06.026; ZAMMITTABONA M, 1983, AM REV RESPIR DIS, V128, P226; Zhang XD, 2004, J ALLERGY CLIN IMMUN, V113, P320, DOI 10.1016/j.jaci.2003.11.047	94	91	92	3	20	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	MAR	2007	115	3					328	335		10.1289/ehp.9557		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	142LN	WOS:000244651500022	17431479	
J	Maantay, J				Maantay, Juliana			Asthma and air pollution in the Bronx: Methodological and data considerations in using GIS for environmental justice and health research	HEALTH & PLACE			English	Article; Proceedings Paper	Workshop on New Approaches to Researching Environmental Justice	OCT, 2003	Univ British Columbia, Vancouver, CANADA		Univ British Columbia	asthma; air pollution; Geographic Information Systems (GIS); environmental justice; environmental health; proximity analysis	GEOGRAPHIC INFORMATION-SYSTEMS; DISPARITIES GEOCODING PROJECT; CHRONIC RESPIRATORY SYMPTOMS; PUBLIC-HEALTH; CHILDHOOD ASTHMA; CHILDREN; EQUITY; EPIDEMIOLOGY; ROAD; POLLUTANTS	This paper examines methods of environmental justice assessment with Geographic Information Systems, using research on the spatial correspondence between asthma and air pollution in the Bronx, New York City as a case study. Issues of spatial extent and resolution, the selection of environmental burdens to analyze, data and methodological limitations, and different approaches to delineating exposure are discussed in the context of the asthma study, which, through proximity analysis, found that people living near (within specified distance buffers) noxious land uses were up to 66 percent more likely to be hospitalized for asthma, and were 30 percent more likely to be poor and 13 percent more likely to be a minority than those outside the buffers. (c) 2005 Elsevier Ltd. All rights reserved.	CUNY Herbert H Lehman Coll, Dept Environm Geog & Geol Sci, Bronx, NY 10468 USA	Maantay, J (reprint author), CUNY Herbert H Lehman Coll, Dept Environm Geog & Geol Sci, 250 Bedford Pk Blvd W, Bronx, NY 10468 USA.	juliana.maantay@lehman.cuny.edu					ANDERTON DL, 1994, DEMOGRAPHY, V31, P229, DOI 10.2307/2061884; Becker KM, 1998, AM J EPIDEMIOL, V147, P709; Boer JT, 1997, SOC SCI QUART, V78, P793; Bowen WM, 1995, ANN ASSOC AM GEOGR, V85, P641, DOI 10.1111/j.1467-8306.1995.tb01818.x; BOWMAN JD, 2000, PUBLIC HLTH GIS NEWS, V32, P7; BRUNEKREEF B, 1995, ENVIRON HEALTH PERSP, V103, P3, DOI 10.2307/3432443; BRYANT B., 1995, ENV JUSTICE ISSUES P; Bullard R. D., 1994, UNEQUAL PROTECTION E; Bullen N, 1996, SOC SCI MED, V42, P801, DOI 10.1016/0277-9536(95)00180-8; BURKE LM, 1993, ISSUES SERIES TITLE, P44; Chakraborty J., 1995, COMPUTERS ENV URBAN, V19, P1; Chakraborty J, 1997, CARTOGR GEOGR INF SC, V24, P145, DOI 10.1559/152304097782476951; Chakraborty J., 1999, T GIS, V3, P239, DOI 10.1111/1467-9671.00020; Chen FM, 1998, AM J EPIDEMIOL, V148, P1212; Ciccone G, 1998, OCCUP ENVIRON MED, V55, P771; Clarke KC, 1996, EMERG INFECT DIS, V2, P85; CROMLEY E, 1997, ACCURACY RESIDENTIAL; Cromley EK, 2002, GIS PUBLIC HLTH; CROMLEY EK, 2001, GETTING STARTED GEOG, P257; Cutter SL, 1996, RISK ANAL, V16, P517, DOI 10.1111/j.1539-6924.1996.tb01097.x; Delfino RJ, 2003, ENVIRON HEALTH PERSP, V111, P647, DOI 10.1289/ehp.5992; Devasundaram JK, 1998, AM J PUBLIC HEALTH, V88, P1406, DOI 10.2105/AJPH.88.9.1406-a; Dunn CE, 2001, HEALTH PLACE, V7, P1, DOI 10.1016/S1353-8292(00)00033-2; EDWARDS J, 1994, ARCH ENVIRON HEALTH, V49, P223; English P, 1999, ENVIRON HEALTH PERSP, V107, P761, DOI 10.2307/3434663; FITZGERALD M, 2004, CARTOGRAPHICA, V39, P29; Flowerdew R., 1994, SPATIAL ANAL GIS, P121; Friedman MS, 2001, JAMA-J AM MED ASSOC, V285, P897, DOI 10.1001/jama.285.7.897; GLASS GE, 1992, GEO INF SYST, V3, P65; Glickman T., 1995, 9513 RES FUT; GOODCHILD MF, 1980, GEO-PROCESSING, V1, P297; Green RS, 2004, ENVIRON HEALTH PERSP, V112, P61, DOI 10.1289/ehp.6566; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P1001; GUTHE WG, 1992, ENVIRON RES, V59, P318, DOI 10.1016/S0013-9351(05)80038-6; Hitchins J, 2000, ATMOS ENVIRON, V34, P51, DOI 10.1016/S1352-2310(99)00304-0; Ihrig MM, 1998, EPIDEMIOLOGY, V9, P290, DOI 10.1097/00001648-199805000-00013; Jackson Kenneth, 1995, ENCY NEW YORK CITY; Jacquez GM, 2000, J GEOGR SYST, V2, P91, DOI DOI 10.1007/S101090050035; Jia Charles Q., 1996, Environmental Science and Technology, V30, P86; JOHNSTON BR, 1994, PAYS PRICE SOCIOCULT; KINGHAM SP, 1995, ENVIRON PLANN A, V27, P809, DOI 10.1068/a270809; Kohli S, 1997, COMPUT METH PROG BIO, V53, P105, DOI 10.1016/S0169-2607(97)01811-7; Krieger N, 2003, AM J PUBLIC HEALTH, V93, P1655, DOI 10.2105/AJPH.93.10.1655; Krieger N, 1999, INT J HEALTH SERV, V29, P295, DOI 10.2190/M11W-VWXE-KQM9-G97Q; Krieger N, 2002, AM J EPIDEMIOL, V156, P471, DOI 10.1093/aje/kwf068; Kulldorff M, 1997, AM J EPIDEMIOL, V146, P161; Kulldorff M, 1999, J Public Health Manag Pract, V5, P100; *LAK ENV, 2004, IND SOURC COMPL AERM; Livingstone AE, 1996, BRIT MED J, V312, P676; LOVE D, 1995, HEALTH SERV RES, V29, P629; Maantay J, 2002, ENVIRON HEALTH PERSP, V110, P161; Maantay J, 2001, AM J PUBLIC HEALTH, V91, P1033, DOI 10.2105/AJPH.91.7.1033; MAANTAY JA, 2001, PLANNERS NETWORK, V145, P6; MAANTAY JA, 2002, J LAW MED ETHICS, P572; MacEachren AM, 1998, ENVIRON PLANN A, V30, P1547, DOI 10.1068/a301547; McMaster R. B., 1997, CARTOGR GEOGR INF SC, V24, P172, DOI 10.1559/152304097782476933; MELIKER JR, 2001, AMBULATORY CHILD HLT, P297; Moore DA, 1999, EPIDEMIOL REV, V21, P143; Morello-Frosch R, 2001, URBAN AFF REV, V36, P551, DOI 10.1177/10780870122184993; Neumann CM, 1998, ENVIRON HEALTH PERSP, V106, P217; *NEW YORK CIT DEP, 1993, CIT IND STUD GEOGR A; *NEW YORK CIT DEP, 1999, ASTHM FACTS; *NEW YORK CIT DEP, 2002, TRAFF RUL REG; *NEW YORK CIT DEP, 2003, ASTHM FACTS; *NEW YORK CIT MAYO, 2001, CIT ENV QUAL REV CEQ; *NEW YORK STAT DEP, 2003, TECHN DOC; NITTA H, 1993, ARCH ENVIRON HEALTH, V48, P53; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; Oosterlee A, 1996, OCCUP ENVIRON MED, V53, P241; Openshaw S., 1984, CONCEPTS TECHNIQUES, V38; Parker EB, 1998, HEALTH PLACE, V4, P183, DOI 10.1016/S1353-8292(98)00010-0; PERLIN K, 1995, COMPUTER GRAPHICS, V29, P1; Pine JC, 2000, J ENVIRON HEALTH, V62, P9; POLLOCK PH, 1995, SOC SCI QUART, V76, P294; Richards TB, 1999, PUBLIC HEALTH REP, V114, P359, DOI 10.1093/phr/114.4.359; ROMIEU I, 1995, AM J EPIDEMIOL, V141, P546; ROSENBAUM A, 2000, MODELING CUMULATIVE; Rushton G., 2000, URISA Journal, V12; Schulz AJ, 2002, MILBANK Q, V80, P677, DOI 10.1111/1468-0009.00028; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; Sheppard E, 1999, J EXPO ANAL ENV EPID, V9, P18, DOI 10.1038/sj.jea.7500023; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Sunyer J, 1997, THORAX, V52, P760; Tobler W. R., 1979, PHILOS GEOGRAPHY; Towers G, 2000, PROF GEOGR, V52, P23, DOI 10.1111/0033-0124.00202; *US DEP COMM BUR C, 2000, SUMM TAP FIL 1; *US DEP COMM BUR C, 2000, TIGER FIL; *US EPA, 2002, TOX REL INV TRI; *US EPA, 2002, NAT EM INV NEI DAT; *US EPA, 2002, AIR MON LOC CRIT AIR; vanVliet P, 1997, ENVIRON RES, V74, P122, DOI 10.1006/enrs.1997.3757; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P2177, DOI 10.1164/rccm2106126; Vine MF, 1997, ENVIRON HEALTH PERSP, V105, P598, DOI 10.1289/ehp.97105598; WALL P., 2000, J GEOGR SYST, V2, P243, DOI 10.1007/PL00011457; Whitsel EA, 2004, AM J EPIDEMIOL, V160, P1023, DOI 10.1093/aje/kwh310; Wilkinson P, 1999, THORAX, V54, P1070; WYST JH, 1993, BRIT MED J, V307, P596; Yasnoff W A, 1999, J Public Health Manag Pract, V5, pix; Zhu YF, 2002, J AIR WASTE MANAGE, V52, P1032; Zimmerman R., 1994, FORDHAM URBAN LAW J, V21, P633	100	91	91	3	41	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1353-8292			HEALTH PLACE	Health Place	MAR	2007	13	1					32	56		10.1016/j.healthplace.2005.09.009		25	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	120ZK	WOS:000243125500004	16311064	
J	Ciprandi, G; Fenoglio, D; Cirillo, I; Vizzaccaro, A; Ferrera, A; Tosca, MA; Puppo, F				Ciprandi, G; Fenoglio, D; Cirillo, I; Vizzaccaro, A; Ferrera, A; Tosca, MA; Puppo, F			Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							REGULATORY T-CELLS; GRASS-POLLEN IMMUNOTHERAPY; CLINICAL IMMUNOLOGY; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION; ALLERGIC RHINITIS; ORAL TOLERANCE; IL-10; SUPPRESSION; DISEASE	Background: Subcutaneous specific immunotherapy has been demonstrated to be capable of inducing T-cell regulatory response. Interleukin 10 (IL-10) plays a crucial role in inducing allergen-specific tolerance; however, no previous studies have examined IL-10 production after sublingual immunotherapy (SLIT). Objective: To evaluate T-cell proliferation and IL-10 production in patients successfully treated with SLIT for house dust mites (HDMs). Methods: Peripheral blood mononuclear cells were isolated from patients after at least 3 years of successful HDM SLIT and from matched untreated allergic patients and healthy control subjects. After 3 and 6 days of in vitro stimulation with phytohemagglutinin (PHA), Candida albicans, and Dermatophagoides farinae, proliferation and production of IL-10 were measured. Results: Patients treated with SLIT showed a significant reduction of proliferation induced by C albicans compared with untreated atopic patients (P < .001), but a significant reduction was also demonstrated in healthy controls compared with untreated atopic patients (P < .001). Patients treated with SLIT also showed a significant increase of IL-10 production after Candida and PHA stimuli compared with patients with untreated rhinitis (P < .001 for both). Patients with untreated rhinitis did not produce IL-10. Conclusion: This preliminary study confirms reduced T-cell proliferation and preliminarily provides the first evidence, to our knowledge, of peripheral IL-10 production in allergic patients successfully treated with HDM SLIT.	Azienda Osped Univ San Marino, Genoa, Italy; Univ Genoa, DIMI, CEBR, I-16126 Genoa, Italy; Osped Marina Milit, La Spezia, Italy; Ist Giannina Gaslini, I-16148 Genoa, Italy	Ciprandi, G (reprint author), Osped San Martino Genova, Dipartimento Reg Testa Coll, Largo R Benzi 10, I-16132 Genoa, Italy.	gio.cip@libero.it					Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Bachert C, 1999, INT ARCH ALLERGY IMM, V118, P375, DOI 10.1159/000024141; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Bousquet J, 1998, ALLERGY S, V53, P44; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, P147, DOI DOI 10.1067/MAI.2001.118891; Bullens DMA, 2004, CLIN EXP ALLERGY, V34, P879, DOI 10.1111/j.1365-2222.2004.01955.x; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Fanta C, 1999, INT ARCH ALLERGY IMM, V120, P218, DOI 10.1159/000024270; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; Frew Anthony J., 2003, Journal of Allergy and Clinical Immunology, V111, pS712; Frieri M, 1999, ALLERGY ASTHMA PROC, V20, P281, DOI 10.2500/108854199778251988; Giannarini L, 1998, CLIN EXP ALLERGY, V28, P404; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Herrick CA, 2003, NAT REV IMMUNOL, V3, P1; HOLT PG, 1988, CLIN ALLERGY, V18, P229, DOI 10.1111/j.1365-2222.1988.tb02864.x; HSU CH, 2004, J AM COLL IMMUNOL, V115, P1084; HUSBY S, 1994, J IMMUNOL, V152, P4663; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Kon OM, 1999, INT ARCH ALLERGY IMM, V118, P133, DOI 10.1159/000024049; Lima MT, 2002, CLIN EXP ALLERGY, V32, P507, DOI 10.1046/j.0954-7894.2002.01327.x; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; Malling HJ, 1998, ALLERGY, V53, P933, DOI 10.1111/j.1398-9995.1998.tb03793.x; Montagnoli C, 2002, J IMMUNOL, V169, P6298; MOWAT AM, 1987, IMMUNOL TODAY, V8, P93, DOI 10.1016/0167-5699(87)90853-X; Norman PS, 2004, J ALLERGY CLIN IMMUN, V113, P1013, DOI 10.1016/j.jaci.2004.03.020; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Passalacqua Giovanni, 2004, Curr Opin Allergy Clin Immunol, V4, P31, DOI 10.1097/00130832-200402000-00007; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; SCHANDENE L, 1994, J IMMUNOL, V152, P4368; Sheikh S, 1996, PEDIATR ASTHMA ALLER, V10, P161, DOI 10.1089/pai.1996.10.161; TAKANASKI S, 1994, J EXP MED, V180, P711, DOI 10.1084/jem.180.2.711; Tang CB, 2001, J IMMUNOL, V166, P1471; TePas EC, 2004, ANN ALLERG ASTHMA IM, V92, P25; TEPAS EC, 2004, ANN ALLERG ASTHMA IM, V92, P1; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; WEINER L, 1997, IMMUNOL TODAY, V18, P335; Wilson DR, 2003, COCHRANE DB SYST REV, V2	45	91	98	0	1	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	JUL	2005	95	1					38	44				7	Allergy; Immunology	Allergy; Immunology	949IO	WOS:000230778800008	16095140	
J	Voynow, JA; Fischer, BM; Malarkey, DE; Burch, LH; Wong, T; Longphre, M; Ho, SB; Foster, WM				Voynow, JA; Fischer, BM; Malarkey, DE; Burch, LH; Wong, T; Longphre, M; Ho, SB; Foster, WM			Neutrophil elastase induces mucus cell metaplasia in mouse lung	AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY			English	Article; Proceedings Paper	100th International Conference of the American-Thoracic-Society	MAY 21-26, 2004	Orlando, FL	Amer Thorac Soc		neutrophil elastase; goblet cell metaplasia; Muc5ac	AIRWAY EPITHELIAL-CELLS; FACTOR RECEPTOR ACTIVATION; INDUCED MUC5AC EXPRESSION; RAT BRONCHIAL EPITHELIUM; MUCIN GENE-EXPRESSION; GLAND SEROUS CELLS; NASAL EPITHELIUM; PROTEIN EXPRESSION; MESSENGER-RNA; ASTHMA	Goblet cell hyperplasia in the superficial airway epithelia is a signature pathological feature of chronic bronchitis and cystic fibrosis. In these chronic inflammatory airway diseases, neutrophil elastase (NE) is found in high concentrations in the epithelial lining fluid. NE has been reported to trigger mucin secretion and increase mucin gene expression in vitro. We hypothesized that chronic NE exposure to murine airways in vivo would induce goblet cell metaplasia. Human NE (50 mug) or PBS saline was aspirated intratracheally by male Balb/c (6 wk of age) mice on days 1, 4, and 7. On days 8, 11, and 14, lung tissues for histology and bronchoalveolar lavage (BAL) samples for cell counts and cytokine levels were obtained. NE induced Muc5ac mRNA and protein expression and goblet cell metaplasia on days 8, 11, and 14. These cellular changes were the result of proteolytic activity, since the addition of an elastase inhibitor, methoxysuccinyl Ala-Ala-Pro-Val chloromethylketone (AAPV-CMK), blocked NE-induced Muc5ac expression and goblet cell metaplasia. NE significantly increased keratinocyte-derived chemokine and IL-5 in BAL and increased lung tissue inflammation and BAL leukocyte counts. The addition of AAPV-CMK reduced these measures of inflammation to control levels. These experiments suggest that NE proteolytic activity initiates an inflammatory process leading to goblet cell metaplasia.	Duke Univ, Med Ctr, Div Pediat Pulm Med, Dept Pediat, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; NIEHS, Lab Expt Pathol, Res Triangle Pk, NC 27709 USA; Bayer Biotechnol, Dept Cell & Analyt Biol, Berkeley, CA 94710 USA; Univ Minnesota, Vet Affairs Med Ctr, Dept Med, Minneapolis, MN 55417 USA	Voynow, JA (reprint author), Duke Univ, Med Ctr, Div Pediat Pulm Med, Dept Pediat, Box 2994, Durham, NC 27710 USA.	voyno001@mc.duke.edu			NHLBI NIH HHS [HL-62641, HL-65611]		ABBINANTENISSEN JM, 1993, AM J PHYSIOL, V265, pL286; Alimam MZ, 2000, AM J RESP CELL MOL, V22, P253; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL556; Boers JE, 1999, AM J RESP CRIT CARE, V159, P1585; Borchers MT, 1998, AM J PHYSIOL-LUNG C, V274, pL573; Borchers MT, 1999, AM J PHYSIOL-LUNG C, V277, pL489; BREUER R, 1985, EXP LUNG RES, V9, P167, DOI 10.3109/01902148509061535; Cho HY, 2000, AM J RESP CRIT CARE, V162, P629; Christensen TG, 1996, EUR RESPIR J, V9, P535, DOI 10.1183/09031936.96.09030535; Culley FJ, 2002, J EXP MED, V196, P1381, DOI 10.1084/jem.20020943; Devaney JM, 2003, FEBS LETT, V544, P129, DOI 10.1016/S0014-5793(03)00482-4; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Engelhardt JF, 2001, AM J RESP CELL MOL, V24, P649; EVANS CM, 2003, AM J RESP CRIT CARE, V167, pA17; FAHY JV, 1992, AM REV RESPIR DIS, V146, P1430; Fischer BM, 2003, AM J PHYSIOL-LUNG C, V284, pL671, DOI 10.1152/ajplung.00220.2002; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447; Foster WM, 2001, J APPL PHYSIOL, V90, P1111; Giangreco A, 2002, AM J PATHOL, V161, P173, DOI 10.1016/S0002-9440(10)64169-7; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HARKEMA JR, 1989, TOXICOL PATHOL, V17, P525; Hotchkiss JA, 1998, AM J RESP CELL MOL, V18, P91; HYDE DM, 1992, AM J RESP CELL MOL, V6, P481; JEFFERY PK, 1981, J PATHOL, V133, P341, DOI 10.1002/path.1711330406; Justice JP, 2002, AM J PHYSIOL-LUNG C, V282, pL1066, DOI 10.1152/ajplung.00195.2001; KIM KC, 1987, P NATL ACAD SCI USA, V84, P9304, DOI 10.1073/pnas.84.24.9304; KLINGER JD, 1984, J CLIN INVEST, V74, P1669, DOI 10.1172/JCI111583; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; LAMB D, 1968, J PATHOL BACTERIOL, V96, P97, DOI 10.1002/path.1700960111; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Liu H, 1999, AM J PHYSIOL-LUNG C, V276, pL28; LUNDGREN JD, 1994, RESP MED, V88, P511, DOI 10.1016/S0954-6111(05)80333-6; Miller LM, 2002, EXP LUNG RES, V28, P435, DOI 10.1080/01902140290096728; Nadel JA, 2001, RESPIR RES, V2, P85, DOI 10.1186/rr43; NAKAMURA H, 1992, J CLIN INVEST, V89, P1478, DOI 10.1172/JCI115738; Oh SW, 2002, J IMMUNOL, V168, P1992; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; QUI Y, 2003, AM J RESP CRIT CARE, V168, P968; Reynolds SD, 2000, AM J PATHOL, V156, P269, DOI 10.1016/S0002-9440(10)64727-X; Rose MC, 2000, J AEROSOL MED, V13, P245, DOI 10.1089/jam.2000.13.245; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733; SELTZER J, 1984, AM REV RESPIR DIS, V129, P790; Senior RM, 1998, FISHMANS PULMONARY D, P659; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; SHEKELS LL, 1995, BIOCHEM J, V311, P775; Shimizu T, 1996, AM J RESP CRIT CARE, V153, P1412; Snedecor G. W., 1980, STAT METHODS; SOMMERHOFF CP, 1990, J CLIN INVEST, V85, P682, DOI 10.1172/JCI114492; SOMMERHOFF CP, 1989, J IMMUNOL, V142, P2450; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; STOCKLEY RA, 1979, AM REV RESPIR DIS, V120, P1081; Temann UA, 2002, J CLIN INVEST, V109, P29, DOI 10.1172/JCI13696; Temann UA, 1997, AM J RESP CELL MOL, V16, P471; VANOOSTERHOUT AJM, 1995, AM J RESP CRIT CARE, V151, P177; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; Wagner JG, 2001, TOXICOL SCI, V60, P338, DOI 10.1093/toxsci/60.2.338; Walter MJ, 2002, J CLIN INVEST, V110, P165, DOI 10.1172/JCI200214345; Wan HJ, 2004, DEVELOPMENT, V131, P953, DOI 10.1242/dev.00966; Welsh M. J., 2001, METABOLIC MOL BASES, P5121; Whitehead GS, 2003, AM J PHYSIOL-LUNG C, V285, pL32, DOI 10.1152/ajplung.00390.2002; Whittaker L, 2002, AM J RESP CELL MOL, V27, P593, DOI 10.1165/rcmb.4838; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yamaguchi Y, 1998, TRANSPLANTATION, V65, P1622, DOI 10.1097/00007890-199806270-00014; Yanagihara K, 2001, AM J RESP CELL MOL, V24, P66	65	91	98	1	4	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	1040-0605			AM J PHYSIOL-LUNG C	Am. J. Physiol.-Lung Cell. Mol. Physiol.	DEC	2004	287	6					L1293	L1302		10.1152/ajplung.00140.2004		10	Physiology; Respiratory System	Physiology; Respiratory System	869BI	WOS:000224956900029	15273079	
J	Bisgaard, H				Bisgaard, H			The Copenhagen Prospective Study on Asthma in Childhood (COPSAC): design, rationale, and baseline data from a longitudinal birth cohort study	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							RESPIRATORY SYNCYTIAL VIRUS; ATOPIC-DERMATITIS; INCREASING PREVALENCE; PERSONAL EXPOSURE; HEALTHY-CHILDREN; HAY-FEVER; 1ST YEAR; AGE; POPULATION; SYMPTOMS	Background: The atopic diseases asthma, atopic dermatitis, and allergic rhinitis are the most common chronic diseases in children, and their prevalence has increased recently in industrialized nations. Little is known about the genetic-environmental interaction factors driving such proliferation. Objective: To investigate the relationships among genetic, environmental, and lifestyle factors in the development of atopic diseases in high-risk children with the aim of developing evidence-based prevention strategies. Methods: The Copenhagen Prospective Study on Asthma in Childhood is a single-center, birth cohort study of children of asthmatic mothers. Objective assessments begin at birth, with scheduled visits every 6 months and when acute symptoms manifest. Clinical outcomes comprise preasthma, asthma, atopic dermatitis, allergic rhinitis, allergy, lung function, and bronchial responsiveness. Exposure assessments comprise respiratory, intestinal, and skin microbiology; the child's diet; indoor and outdoor air quality; allergens; and indicators of lifestyle. Genetic characteristics of probands and parents are evaluated. Quality assurance follows Good Clinical Practice guidelines. Results: Four hundred eleven infants of asthmatic mothers were enrolled at the age of I month. The children were born between August 2, 1998, and December 28, 2001. Compared with the Copenhagen population, mothers of the cohort population were less likely to have given natural childbirth. The households were slightly less affluent, with fewer children and fewer pets. Whites may be overrepresented. At age 2 years, 93% of the infants were still actively participating in the cohort. Conclusions: This longitudinal birth cohort study of high-risk Danish infants consists of objective phenotyping, detailed information on exposure, high data quality, and a high participant retention rate.	Copenhagen Univ Hosp, Dept Pediat, COPSAC Clin Res Unit L213, DK-2100 Copenhagen, Denmark	Bisgaard, H (reprint author), Copenhagen Univ Hosp, Dept Pediat, COPSAC Clin Res Unit L213, DK-2100 Copenhagen, Denmark.	Bisgaard@copsac.dk	Kronow, Joern/B-1054-2011; Bisgaard, Hans/N-4761-2016	Bisgaard, Hans/0000-0003-4131-7592			Al-Delaimy W. K., 2002, Journal of Epidemiology and Community Health, V56, P66, DOI 10.1136/jech.56.1.66; ANDERSON HR, 1994, BRIT MED J, V308, P1600; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Backer V, 2002, ANN ALLERG ASTHMA IM, V89, P148; Baraldi E, 2002, EUR RESPIR J, V20, P223, DOI 10.1183/09031936.02.00293102; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; BISGAARD H, 1987, ACTA PAEDIATR SCAND, V76, P719, DOI 10.1111/j.1651-2227.1987.tb10555.x; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Bisgaard Hans, 2004, Pediatrics, V113, pe87, DOI 10.1542/peds.113.2.e87; Bohme M, 2001, ACTA DERM-VENEREOL, V81, P193, DOI 10.1080/000155501750376294; BraunFahrlander C, 1997, PEDIATR ALLERGY IMMU, V8, P75, DOI 10.1111/j.1399-3038.1997.tb00147.x; Brunekreef B, 2002, PEDIAT ALLERG IMM-UK, V13, P55, DOI 10.1034/j.1399-3038.13.s.15.1.x; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Cane RS, 2001, ARCH DIS CHILD, V84, P31, DOI 10.1136/adc.84.1.31; Chauhan AJ, 2003, LANCET, V361, P1939, DOI 10.1016/S0140-6736(03)13582-9; Custovic A, 2002, PEDIATR ALLERGY IMMU, V13, P32, DOI 10.1034/j.1399-3038.13.s.15.3.x; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; DRUZIK CM, 1990, INT J ENVIRON AN CH, V38, P495, DOI 10.1080/03067319008026952; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hilberg O, 2002, ALLERGY, V57, P5, DOI 10.1046/j.0908-665x.2001.all.doc.x; Hjern A, 1999, PEDIATR ALLERGY IMMU, V10, P209, DOI 10.1034/j.1399-3038.1999.00014.x; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JOHNSTON SL, 1993, J CLIN MICROBIOL, V31, P111; JOHNSTON SL, 1995, BRIT MED J, V310, P1225; Karmaus W, 2001, ARCH ENVIRON HEALTH, V56, P485; KOHRMAN A, 1995, PEDIATRICS, V95, P314; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Kunz B, 1997, DERMATOLOGY, V195, P10; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Le Souef P, 2002, PEDIATR ALLERGY IMMU, V13, P44, DOI 10.1034/j.1399-3038.13.s.15.9.x; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Leung DYM, 2001, J AM ACAD DERMATOL, V45, pS13, DOI 10.1067/mjd.2001.117024; Linneberg A, 2000, J ALLERGY CLIN IMMUN, V106, P247, DOI 10.1067/mai.2000.108312; McConnell R, 2003, AM J RESP CRIT CARE, V168, P790, DOI 10.1164/rccm.200304-466OC; Melnik B, 1992, Acta Derm Venereol Suppl (Stockh), V176, P77; Mielck A, 1996, INT J EPIDEMIOL, V25, P388, DOI 10.1093/ije/25.2.388; Nickel Renate, 2002, Paediatr Respir Rev, V3, P169, DOI 10.1016/S1526-0542(02)00190-2; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; Nielsen KG, 2001, AM J RESP CRIT CARE, V164, P554; Olsen J, 2001, SCAND J PUBLIC HEALT, V29, P300, DOI 10.1177/14034948010290040201; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; PALMES ED, 1986, AM IND HYG ASSOC J, V47, P418, DOI 10.1202/0002-8894(1986)047<0418:ASMMFD>2.3.CO;2; Reginster JY, 1998, INT J GYNECOL OBSTET, V63, P21, DOI 10.1016/S0020-7292(98)00113-1; Sears MR, 2003, NEW ENGL J MED, V349, P1414, DOI 10.1056/NEJMoa022363; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; Sigurs N, 2001, AM J RESP CRIT CARE, V163, pS2; Smyth RL, 1999, LANCET S2, V354, pSII21; Soderstrom L, 2003, ALLERGY, V58, P921, DOI 10.1034/j.1398-9995.2003.00227.x; Sorensen M, 2003, CANCER EPIDEM BIOMAR, V12, P191; SOYSETH V, 1995, LANCET, V345, P217; Stein R, 1999, LANCET, V354, P541, DOI 10.1016/S0140-6736(98)10321-5; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; *SUBC SKIN TESTS E, 1989, ALLERGY S10, V44, P1; Taussig LM, 2003, J ALLERGY CLIN IMMUN, V111, P661, DOI 10.1067/mai.2003.162; TAYLOR B, 1984, LANCET, V2, P1255; ten Tusscher GW, 2001, ACTA PAEDIATR, V90, P1292; TURNER DJ, 1995, AM J RESP CRIT CARE, V151, P1441; VILLA MP, 1990, PEDIATR PULM, V9, P199, DOI 10.1002/ppul.1950090403; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1994, BRIT MED J, V308, P692; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; WILLIAMS HC, 1994, BRIT MED J, V308, P1132; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x	66	91	92	3	8	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	OCT	2004	93	4					381	389				9	Allergy; Immunology	Allergy; Immunology	864TL	WOS:000224655700013	15521375	
J	Susitaival, P; Flyvholm, MA; Meding, B; Kanerva, L; Lindberg, M; Svensson, A; Olafsson, JH				Susitaival, P; Flyvholm, MA; Meding, B; Kanerva, L; Lindberg, M; Svensson, A; Olafsson, JH			Nordic Occupational Skin Questionnaire (NOSQ-2002): a new tool for surveying occupational skin diseases and exposure	CONTACT DERMATITIS			English	Review						eczema; epidemiology; exposure; hand dermatitis; NOSQ-2002; occupational; questionnaire design; questionnaire methods; skin diseases	PARTY DIAGNOSTIC-CRITERIA; REPORTED HAND ECZEMA; ALLERGIC CONTACT SENSITIZATION; ATOPIC-DERMATITIS; DANISH POPULATION; GLOSTRUP ALLERGY; PREVALENCE; DERMATOSES; VALIDATION; NETHERLANDS	Occupational skin diseases are among the most frequent work-related diseases in industrialized countries. Good occupational skin disease statistics exist in few countries. Questionnaire studies are needed to get more data on the epidemiology of occupational skin diseases. The Nordic Occupational Skin Questionnaire Group has developed a new questionnaire tool - Nordic Occupational Skin Questionnaire (NOSQ-2002) - for surveys on work-related skin disease and exposures to environmental factors. The 2 NOSQ-2002 questionnaires have been compiled by using existing questionnaires and experience. NOSQ-2002/SHORT is a ready-to-use 4-page questionnaire for screening and monitoring occupational skin diseases, e.g. in a population or workplace. All the questions in the short questionnaire (NOSQ-2002/SHORT) are included in the long version, NOSQ-2002/LONG, which contains a pool of questions to be chosen according to research needs and tailored to specific populations. The NOSQ-2002 report includes, in addition to the questionnaires, a comprehensive manual for researchers on planning and conducting a questionnaire survey on hand eczema and relevant exposures. NOSQ-2002 questionnaires have been compiled in English and translated into Danish, Swedish, Finnish and Icelandic. The use of NOSQ-2002 will benefit research on occupational skin diseases by providing more standardized data, which can be compared between studies and countries.	Natl Inst Occupat Hlth, DK-2100 Copenhagen, Denmark; N Karelia Cent Hosp, Dept Dermatol, Joensuu, Finland; Natl Inst Working Life, Stockholm, Sweden; Finnish Inst Occupat Hlth, Helsinki, Finland; Stockholm Cty Council, Stockholm, Sweden; Univ Hosp, Dept Dermatol, Malmo, Sweden; Univ Hosp, Landspitali, Dept Dermatol, Reykjavik, Iceland	Flyvholm, MA (reprint author), Natl Inst Occupat Hlth, Lerso Parkalle 105, DK-2100 Copenhagen, Denmark.						BAKKE P, 1990, ALLERGY, V45, P515, DOI 10.1111/j.1398-9995.1990.tb00527.x; BERG M, 1990, CONTACT DERMATITIS, V22, P71, DOI 10.1111/j.1600-0536.1990.tb01520.x; BORG V, 1997, WORK ENV HLTH DANISH; Brisman J, 1998, OCCUP ENVIRON MED, V55, P750; Burr H, 2003, SCAND J WORK ENV HEA, V29, P270; BURR H, 2001, INT J OCCUP ENV HEAL, V7, pS33; COENRAADS PJ, 1983, CLIN EXP DERMATOL, V8, P495, DOI 10.1111/j.1365-2230.1983.tb01816.x; COENRAADS PJ, 1984, CLIN EXP DERMATOL, V9, P149, DOI 10.1111/j.1365-2230.1984.tb00776.x; FLYVHOLM MA, 2001, WORK ENV DENMARK 200; FLYVHOLM MA, 2003, STUDY PROTOCOLCOORDI, P1; FLYVHOLM MA, 2002, INT C OCC ENV EXP SK; FLYVHOLM MA, 2003, 1 WORLD C WORK REL E, pO70; Flyvhholm MA, 2002, TEMANORD, V518, P1; KALLUNKI H, 2002, EXPOSURE HLTH EFFECT; KAVLI G, 1984, CONTACT DERMATITIS, V10, P174, DOI 10.1111/j.1600-0536.1984.tb00027.x; KAVLI G, 1987, CONTACT DERMATITIS, V17, P156, DOI 10.1111/j.1600-0536.1987.tb02697.x; Meding B, 1990, Acta Derm Venereol Suppl (Stockh), V153, P1; Meding B, 2002, J INVEST DERMATOL, V118, P719, DOI 10.1046/j.1523-1747.2002.01718.x; Meding B, 2001, CONTACT DERMATITIS, V45, P341, DOI 10.1034/j.1600-0536.2001.450604.x; Meding B, 2001, CONTACT DERMATITIS, V45, P99, DOI 10.1034/j.1600-0536.2001.045002099.x; MEDING B, 1987, BRIT J DERMATOL, V116, P627, DOI 10.1111/j.1365-2133.1987.tb05895.x; MEDING B, 1994, CONTACT DERMATITIS, V30, P129, DOI 10.1111/j.1600-0536.1994.tb00692.x; NIELSEN NH, 1992, ACTA DERM-VENEREOL, V72, P456; NIELSEN NH, 1993, ALLERGY, V48, P319, DOI 10.1111/j.1398-9995.1993.tb02400.x; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; Ortengren U, 1999, EUR J ORAL SCI, V107, P496, DOI 10.1046/j.0909-8836.1999.eos107612.x; PELTONEN L, 1979, CONTACT DERMATITIS, V5, P27, DOI 10.1111/j.1600-0536.1979.tb05531.x; Popescu CM, 1998, BRIT J DERMATOL, V138, P436; SMIT HA, 1993, INT J EPIDEMIOL, V22, P288, DOI 10.1093/ije/22.2.288; SMIT HA, 1992, CONTACT DERMATITIS, V26, P11, DOI 10.1111/j.1600-0536.1992.tb00861.x; SUSITAIVAL P, 1994, SCAND J WORK ENV HEA, V20, P206; Susitaival P, 2001, Am J Contact Dermat, V12, P103, DOI 10.1053/ajcd.2001.19631; SUSITAIVAL P, 1995, SCAND J WORK ENV HEA, V21, P30; SUSITAIVAL P, 1996, PEOPLE WORK RES REPO, V10; SUSITAIVAL P, 1996, MED SCI, V93, P1; SUSITAIVAL P, 2003, 1 WORLD C WORK REL E, pP34; SUSITAIVAL P, 2001, ALLERGIA JA TYOPAIVA, P35; SUSITAIVAL P, 2000, ALLERGY RISKS DENT P, P41; Svensson A, 2002, BRIT J DERMATOL, V147, P281, DOI 10.1046/j.1365-2133.2002.04799.x; Vermeulen R, 2000, CONTACT DERMATITIS, V42, P202, DOI 10.1034/j.1600-0536.2000.042004202.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P397, DOI 10.1111/j.1365-2133.1994.tb08531.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams HC, 1996, BRIT J DERMATOL, V135, P12; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Williams HC, 1995, BRIT J DERMATOL, V133, P941, DOI 10.1111/j.1365-2133.1995.tb06930.x; Yngveson M, 1997, ACTA DERM-VENEREOL, V77, P455	46	91	92	0	4	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	AUG	2003	49	2					70	76		10.1111/j.0105-1873.2003.00159.x		7	Allergy; Dermatology	Allergy; Dermatology	748ZC	WOS:000186892100002	14641353	
J	Buhl, R; Hanf, G; Soler, M; Bensch, G; Wolfe, J; Everhard, F; Champain, K; Fox, H; Thirlwell, J				Buhl, R; Hanf, G; Soler, M; Bensch, G; Wolfe, J; Everhard, F; Champain, K; Fox, H; Thirlwell, J			The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						allergic asthma; anti-immunoglobulin E; omalizumab; quality of life	OF-LIFE; AIRWAY HYPERRESPONSIVENESS; CLINICAL-TRIALS; DISEASE; QUESTIONNAIRE; INFLAMMATION; INHIBITION; SEVERITY; THERAPY	The aim of the present study was to determine the effect of treatment with omalizumab, an anti-immunoglobulin E antibody, on asthma-related quality of life (AQoL) in patients with moderate-to-severe allergic asthma. A total of 546 patients with allergic asthma were randomised to double-blind subcutaneous treatment with either placebo or omalizumab for 52 weeks. A constant beclomethasone dipropionate dose was maintained during the first 16 weeks (steroid-stable phase). This was followed by a 12-week steroid-reduction phase. The core study was followed by a 24-week double-blind extension phase. AQoL was evaluated at baseline and at the end of the steroid-stable (week 16), steroid-reduction (week 28) and extension phases (week 52) using the Juniper Asthma Quality of Life Questionnaire (AQLQ). Baseline AQLQ scores were comparable for the two treatment groups. Relative to placebo, omalizumab-treated patients demonstrated statistically significant improvements from baseline across all four AQLQ domains, as well as overall AQoL score, at weeks 16 (except environmental exposure), 28 and 52. Patients on omalizumab were also more likely to achieve clinically significant improvements in AQoL during the course of the study. Overall, almost 70% of patients and investigators rated treatment with omalizumab as "excellent/good", compared with similar to40% of placebo recipients. Clinical studies show that omalizumab enhances disease control whilst reducing corticosteroid consumption in patients with allergic asthma. The results of the present study show that these changes are paralleled by improvements in asthma-related quality of life that are meaningful to such patients.	Univ Hosp, Div Pulm, D-55131 Mainz, Germany; Charite Berlin, Allergy & Asthma Clin, Berlin, Germany; Univ Basel Hosp, Div Pulm, CH-4031 Basel, Switzerland; Allergy Immunol & Asthma Med Grp, Stockton, CA USA; Allergy & Asthma Associates, San Jose, CA USA; Novartis Pharma AG, Basel, Switzerland; Novartis Horsham Res Ctr, Horsham, W Sussex, England	Buhl, R (reprint author), Univ Hosp, Div Pulm, Langenbeckstr 1, D-55131 Mainz, Germany.						Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Drazen JM, 1996, J EXP MED, V183, P1, DOI 10.1084/jem.183.1.1; Easthope S, 2001, DRUGS, V61, P253, DOI 10.2165/00003495-200161020-00008; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Hamelmann E, 1999, ALLERGY, V54, P297, DOI 10.1034/j.1398-9995.1999.00085.x; Holt PG, 1999, NATURE, V402, pB12; Israel E, 2001, NEW ENGL J MED, V345, P941, DOI 10.1056/NEJMoa002304; Jardieu PM, 1999, INT ARCH ALLERGY IMM, V118, P112, DOI 10.1159/000024043; Joyce DP, 2000, J ASTHMA, V37, P303, DOI 10.3109/02770900009055454; Juniper E F, 1998, Can Respir J, V5 Suppl A, p77A; Juniper EF, 2000, AM J RESP CRIT CARE, V162, P1330; Juniper EF, 1997, ALLERGY, V52, P971, DOI 10.1111/j.1398-9995.1997.tb02416.x; JUNIPER EF, 1995, AM J RESP CRIT CARE, V151, P66; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; JUNIPER EF, 1992, THORAX, V47, P76, DOI 10.1136/thx.47.2.76; JUNIPER EF, 1993, AM REV RESPIR DIS, V147, P832; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Moy ML, 2001, AM J RESP CRIT CARE, V163, P924; PRESTA LG, 1993, J IMMUNOL, V151, P2623; SHIELDS RL, 1995, INT ARCH ALLERGY IMM, V107, P412; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Spector SL, 1999, ANN ALLERG ASTHMA IM, V83, P435, DOI 10.1016/S1081-1206(10)62848-7; Thompson WG, 2000, AM J GASTROENTEROL, V95, P1637; Wijnhoven HAH, 2001, CHEST, V119, P1034, DOI 10.1378/chest.119.4.1034; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255	29	91	98	0	4	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	NOV	2002	20	5					1088	1094		10.1183/09031936.02.00016502		7	Respiratory System	Respiratory System	614EZ	WOS:000179176500004	12449159	
J	Schneider, P; Gebefugi, I; Richter, K; Wolke, G; Schnelle, J; Wichmann, HE; Heinrich, J				Schneider, P; Gebefugi, I; Richter, K; Wolke, G; Schnelle, J; Wichmann, HE; Heinrich, J		INGA Study Grp	Indoor and outdoor BTX levels in German cities	SCIENCE OF THE TOTAL ENVIRONMENT			English	Article						volatile organic compounds; BTX; passive sampling; indoor air quality; homes	VOLATILE ORGANIC-COMPOUNDS; EASTERN GERMANY; AIR; HAMBURG; ERFURT; HOMES; EMISSIONS	On the basis of the ongoing study INGA (INdoor exposure and Genetics in Asthma), Germany's most detailed and standardized epidemiological study on indoor exposure to both allergens in house dust and volatile compounds in the air of the home environment has been performed. The purpose of this paper is to describe the spatial and seasonal variability of indoor and outdoor BTX (Benzene, toluene, ethyl benzene, ortho-xylene, meta- and para-xylene) concentrations for the study period from June 1995 to November 1996. Within this framework, air concentrations of volatile organic compounds (BTX) were measured in 204 households in Erfurt (Eastern Germany) and 201 households in Hamburg (Western Germany). BTX sampling was conducted over one week using OVM 3500 passive diffusion sampling devices in the indoor (living room and bedroom) and outdoor environment (outside the window of the living room). Indoor and outdoor median BTX concentrations in Erfurt were slightly, but significantly higher than those in Hamburg. This gap was most pronounced in the levels of indoor toluene (37.3 mug/m(3) for Erfurt and 20.5 mug/m(3) for Hamburg, P < 0.0001). In both cities, winter indoor and outdoor concentrations for the five compounds exceeded the summer values. Outdoor concentrations of ethyl benzene and ortho-xylene were very low (50% < L.D.). In general, the indoor BTX air concentrations were significantly higher than the outdoor concentrations, the lowest I/O ratios were found in the case of benzene. Living room and bedroom values for the five compounds were highly correlated (Spearman coefficient 0.5-0.9). Despite the better insulation of the homes in West Germany, no indication for the expected higher indoor concentrations of BTX in the West could be found. The strong and yet undiscovered indoor source for toluene in East Germany might lead to a further increase in the indoor air load in those homes in the East, which undergo renovations which will lead to improved insulation (C) 2001 Elsevier Science B.V. All rights reserved.	GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany; GSF, Natl Res Ctr Environm & Hlth, Inst Ecol Chem, Neuherberg, Germany; Grosshansdorf Hosp, Ctr Pneumol & Thorac Surg, Hamburg, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Dept Epidemiol, Munich, Germany	Heinrich, J (reprint author), GSF, Natl Res Ctr Environm & Hlth, Inst Epidemiol, D-85764 Oberschleissheim, Germany.		Schnelle-Kreis, Jurgen/M-9845-2014	Schnelle-Kreis, Jurgen/0000-0003-4846-2303			BEGEROW J, 1995, FRESEN J ANAL CHEM, V351, P549, DOI 10.1007/BF00322731; BISCHOF W, 2000, P HLTH BUILD, V1, P151; Cyrys J, 2000, SCI TOTAL ENVIRON, V250, P51, DOI 10.1016/S0048-9697(00)00361-2; DEBORTOLI M, 1986, ENVIRON INT, V12, P343, DOI 10.1016/0160-4120(86)90048-6; EIKMANN T, 1992, HDB UMWELTMEDIZIN; FAHLBUSCH B, 1999, ALLERGY 2000, V54, P1; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; HEILEMANN KJ, 1999, GESUNDHEITS INGENIEU, V120, P239; Heinrich J, 1998, ALLERGY, V53, P89, DOI 10.1111/j.1398-9995.1998.tb03779.x; HERBARTH O, 1994, UMWELTMED FORSCH PRA, V5, P281; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; KRAUSE C, 1991, UMWELT SURVEY WOHN C, V3; LEBRET E, 1986, Environment International, V12, P323, DOI 10.1016/0160-4120(86)90046-2; LEVSEN W, 1999, BELASTUNG MENSCHEN D; OTSON R, 1996, P 7 INT C IND AIR 1, V21, P565; PORSTMANN F, 1994, STAUB REINHALT LUFT, V54, P147; RANFT U, 1997, EPIDEMIOLOGISCHE UNT; Richter K, 1999, ALLERGOLOGIE, V22, P14; Rosner B, 1990, FUNDAMENTALS BIOSTAT; *SAS I, 1996, VERSION 6 12; SCHLIPKOTER HW, 1994, DESKRIPTION SCHULANF; Schneider P, 1998, GEFAHRST REINHALT L, V58, P191; SCHNEIDER P, 1995, ALLERGOLOGIE, V18, P518; Schneider P, 1999, J EXPO ANAL ENV EPID, V9, P282, DOI 10.1038/sj.jea.7500030; SEIFERT B, 1992, ECOMED VERLAG LANDSB; SOLLINGER S, 1993, ATMOS ENVIRON B-URB, V27, P183, DOI 10.1016/0957-1272(93)90004-P; Wallace L, 1991, J Expo Anal Environ Epidemiol, V1, P157; WALLACE LA, 1988, ATMOS ENVIRON, V22, P2141, DOI 10.1016/0004-6981(88)90125-4; WALLACE LA, 1987, ATMOS ENVIRON, V21, P385, DOI 10.1016/0004-6981(87)90017-5; WARE JH, 1993, AM J EPIDEMIOL, V137, P1287; WICHMANN HE, 1991, RISIKOGRUPPENBEZOGEN; YOCOM JE, 1982, JAPCA J AIR WASTE MA, V32, P500	32	91	95	2	16	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0048-9697			SCI TOTAL ENVIRON	Sci. Total Environ.	FEB 21	2001	267	1-3					41	51		10.1016/S0048-9697(00)00766-X		11	Environmental Sciences	Environmental Sciences & Ecology	412DC	WOS:000167537900004	11286215	
J	Gilliland, FD; Berhane, K; Rapaport, EB; Thomas, DC; Avol, E; Gauderman, WJ; London, SJ; Margolis, HG; McConnell, R; Islam, KT; Peters, JM				Gilliland, FD; Berhane, K; Rapaport, EB; Thomas, DC; Avol, E; Gauderman, WJ; London, SJ; Margolis, HG; McConnell, R; Islam, KT; Peters, JM			The effects of ambient air pollution on school absenteeism due to respiratory illnesses	EPIDEMIOLOGY			English	Article						air pollution; ozone; respiratory illnesses and children; school absenteeism	SOUTHERN CALIFORNIA COMMUNITIES; PULMONARY-FUNCTION; DIFFERING LEVELS; MEXICO-CITY; CHILDREN; ASTHMA; PARTICULATE; EXPOSURES; MORBIDITY; SYMPTOMS	We investigated the relations between ozone (O-3), nitrogen dioxide (NO2), and respirable particles less than 10 mum in diameter (PM10) and school absenteeism in a cohort of 4th-grade school children who resided in 12 southern California communities. An active surveillance system ascertained the numbers and types of absences during the first 6 months of 1996. Pollutants were measured hourly at central-site monitors in each of the 12 communities. To examine acute effects of air pollution on absence rates, we fitted a two-stage time series model to the absence count data that included distributed lag effects of exposure adjusted for long-term pollutant levels. Short-term change in O-3, but not NO2 or PM10, was associated with a substantial increase in school absences from both upper and lower respiratory illness. An increase of 20 ppb of O-3 was associated with an increase of 62.9% [95% confidence interval (95% CI) = 18.4-124.1%] for illness-related absence rates, 82.9% (95% CI = 3.9-222.0%) for respiratory illnesses, 45.1% (95% CI = 21.3-73.7%) for upper respiratory illnesses, and 173.9% (95% CI = 91.3-292.3%) for lower respiratory illnesses with wet cough. The short-term effects of a 20-ppb change of O-3 on illness-related absenteeism were larger in communities with lower long-term average PM10 [223.5% (95% CI = 90.4-449.7)] compared with communities with high average levels [38.1% (95% CI = 8.5-75.8)]. Increased school absenteeism from O-3 exposure in children is an important adverse effect of ambient air pollution worthy of public policy consideration.	Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA; NIEHS, Res Triangle Pk, NC 27709 USA; Calif Air Resources Board, Sacramento, CA USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,CHP 236, Los Angeles, CA 90033 USA.			London, Stephanie/0000-0003-4911-5290	NHLBI NIH HHS [1R01 HL61768]; NIEHS NIH HHS [5 P30 ES07048-02, 5ES09581-01]		AKAIKE H, 1970, ANN I STAT MATH, V22, P203, DOI 10.1007/BF02506337; ALMON S, 1965, ECONOMETRICA, V33, P178, DOI 10.2307/1911894; AVOL E, 1997, AM J RESP CRIT CARE, V155, pA747; Bascom R, 1996, AM J RESP CRIT CARE, V153, P477; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432345; Bateson TF, 1999, EPIDEMIOLOGY, V10, P539, DOI 10.1097/00001648-199909000-00013; BLOOM B, 1981, CURRENT ESTIMATES NA; CELANO MP, 1993, J LEARN DISABIL, V26, P23; Dominici F, 2000, J ROY STAT SOC A STA, V163, P263, DOI 10.1111/1467-985X.00170; FERRIS BG, 1970, AM REV RESPIR DIS, V102, P591; Gauderman J.W., 2000, AM J RESP CRIT CARE, V162, P1383; Gold DR, 1999, EPIDEMIOLOGY, V10, P8, DOI 10.1097/00001648-199901000-00004; Hastie T, 1990, GEN ADDITIVE MODELS; LINN WS, 1988, TOXICOL IND HEALTH, V4, P505; Linn WS, 1996, J EXPO ANAL ENV EPID, V6, P449; LIPPMANN M, 2000, ENV TOXICANTS HUMAN, P655; LUMLEY T, IN PRESS ENVIRONMETR; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; McCullagh P., 1989, GEN LINEAR MODELS; Navidi W., 1999, RES REP HLTH EFF I, V86, P1; NEAS LM, 1991, AM J EPIDEMIOL, V134, P204; OSTRO B, 1993, ENVIRON RES, V50, P238; OSTRO BD, 1990, RISK ANAL, V10, P421, DOI 10.1111/j.1539-6924.1990.tb00525.x; OSTRO BD, 1984, SCI TOTAL ENVIRON, V39, P111, DOI 10.1016/0048-9697(84)90029-9; PARCEL GS, 1979, PEDIATRICS, V64, P878; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; Peters JM, 1999, AM J RESP CRIT CARE, V159, P768; PONKA A, 1990, ENVIRON RES, V52, P34, DOI 10.1016/S0013-9351(05)80149-5; Pope CA, 1996, AM J RESP CRIT CARE, V154, pS229; Raizenne M, 1998, CAN J PUBLIC HEALTH, V89, pS43; RANSOM MR, 1992, ENVIRON RES, V58, P204, DOI 10.1016/S0013-9351(05)80216-6; ROGERS KD, 1965, AM J DIS CHILD, V109, P9; ROMIEU I, 1992, AM J EPIDEMIOL, V136, P1524; ROZELLE RM, 1968, EDUC PSYCHOL MEAS, V28, P1151, DOI 10.1177/001316446802800415; SAMET JM, 1993, ENVIRON HEALTH PERSP, V101, P149, DOI 10.2307/3431671; Samet J. M., 1995, PARTICULATE AIR POLL; SCHIFFER CG, 1963, ILLNESS CHILDREN DAT; SCHLESINGER R, 2000, ENV TOXICANTS HUMAN, P595; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; SCHWARTZ J, 1993, AM J EPIDEMIOL, V137, P1136; *US EPA, 1996, AIR QUAL CRIT OZ REL, V3; WAYNE WS, 1969, ARCH ENVIRON HEALTH, V19, P315; WEITZMAN M, 1986, J CHRON DIS, V39, P799, DOI 10.1016/0021-9681(86)90082-2; Zeger SL, 2000, ENVIRON HEALTH PERSP, V108, P419, DOI 10.2307/3454382	45	91	98	3	22	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	JAN	2001	12	1					43	54		10.1097/00001648-200101000-00009		12	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	385LR	WOS:000166006400009	11138819	
J	Kanehiro, A; Ikemura, T; Makela, MJ; Lahn, M; Joetham, A; Dakhama, A; Gelfand, EW				Kanehiro, A; Ikemura, T; Makela, MJ; Lahn, M; Joetham, A; Dakhama, A; Gelfand, EW			Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							HUMAN NEUTROPHIL FUNCTIONS; MURINE MODEL; PDE INHIBITORS; ATOPIC ASTHMA; TYPE-4; LUNG; EOSINOPHILIA; RESPONSES; ROLIPRAM; CAMP	We compared for the first time the therapeutic potential of a specific phosphodiesterase 4 (PDE4) inhibitor, rolipram, with anti-VLA-4 and anti-IL-5 in a model of secondary allergen exposure of previously sensitized and challenged mice. To address these issues, mice were sensitized and challenged with ovalbumin (OVA) (primary challenge). Six weeks later, sensitized/challenged mice were reexposed to OVA (secondary challenge) and airway response (resistance [RL] and dynamic compliance [Cdyn]) to inhaled methacholine was monitored. After secondary OVA challenge, Rr significantly increased as did the number of lung inflammatory cells and IL-4 and IL-5 production in bronchoalveolar lavage fluid (BALF). Administration of rolipram, in a dose-dependent manner, significantly prevented both changes in Rr and Cdyn, as well as eosinophil, lymphocyte, and neutrophil accumulation in the BALF; IL-4 and IL-5 levels in BALF were also significantly reduced. In contrast, treatment with anti-VLA-4 and anti-IL-5 only prevented changes in RL and eosinophil numbers and IL-5 production in BALF. Further, goblet cell hyperplasia was suppressed only by treatment with rolipram. None of the treatments affected OVA-specific antibody levels. These studies confirm that IL-5 dependent eosinophilic inflammation plays an essential role in the development of certain aspects of airway function after rechallenge of sensitized mice and that lymphocytes and neutrophils are also important in the development of altered airway function. The use of agents that inhibit PDE4 may have an important role in the treatment of asthma in previously sensitized mice.	Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Immunol, Denver, CO 80206 USA	Gelfand, EW (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, Div Basic Sci, 1400 Jackson St, Denver, CO 80206 USA.		KANEHIRO, Arihiko/B-1926-2011		NHLBI NIH HHS [HL-36577, HL-61005]		AZZAWI M, 1990, AM REV RESPIR DIS, V142, P1407; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38; Danahay H, 1997, BRIT J PHARMACOL, V120, P289, DOI 10.1038/sj.bjp.0700901; DERIAN CK, 1995, J IMMUNOL, V154, P308; Essayan DM, 1997, BIOCHEM PHARMACOL, V53, P1055, DOI 10.1016/S0006-2952(97)00102-0; Foissier L, 1996, J PHARMACOL EXP THER, V278, P1484; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; FRIGAS E, 1986, J ALLERGY CLIN IMMUN, V77, P527, DOI 10.1016/0091-6749(86)90341-6; Gozzard N, 1996, BRIT J PHARMACOL, V117, P1405; Hamelmann E, 1997, AM J RESP CRIT CARE, V155, P819; HATZELMANN A, 1995, BRIT J PHARMACOL, V114, P821; Howell RE, 1995, PULM PHARMACOL, V8, P83, DOI 10.1006/pulp.1995.1010; Kanehiro A, 2000, AM J RESP CRIT CARE, V162, P1132; KANEKO T, 1995, CELL SIGNAL, V7, P527, DOI 10.1016/0898-6568(95)00023-I; KLEMM P, 1995, EUR J PHARMACOL, V281, P69, DOI 10.1016/0014-2999(95)00232-A; LAGENTE V, 1994, EUR J PHARMACOL, V255, P253, DOI 10.1016/0014-2999(94)90107-4; LAVNIKOVA N, 1993, AM J RESP CELL MOL, V8, P384; MARTIN TR, 1988, J APPL PHYSIOL, V64, P2318; Miotla JM, 1998, AM J RESP CELL MOL, V18, P411; Moy ML, 1998, SEM RESP CRIT CARE M, V19, P349, DOI 10.1055/s-2007-1009412; OTTONELLO L, 1995, CLIN EXP IMMUNOL, V101, P502; POBER JS, 1993, J IMMUNOL, V150, P5114; Schudt C, 1999, PULM PHARMACOL THER, V12, P123, DOI 10.1006/pupt.1999.0182; SCHUDT C, 1991, N-S ARCH PHARMACOL, V344, P682; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takeda K, 1997, J EXP MED, V186, P449, DOI 10.1084/jem.186.3.449; TEMANN U, 1997, AM J RESP CELL MOL B, V13, P54; Tomkinson A, 1999, AM J RESP CRIT CARE, V160, P1283; TORPHY TJ, 1993, J PHARMACOL EXP THER, V265, P1213; TURNER CR, 1994, AM J RESP CRIT CARE, V149, P1153; UNDERWOOD DC, 1993, J PHARMACOL EXP THER, V264, P609; WOOLCOCK AJ, 1969, J CLIN INVEST, V48, P1097, DOI 10.1172/JCI106066; WRIGHT CD, 1990, BIOCHEM PHARMACOL, V40, P699, DOI 10.1016/0006-2952(90)90304-4	33	91	93	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JAN	2001	163	1					173	184				12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	394TV	WOS:000166540100033	11208644	
J	Diez, U; Kroessner, T; Rehwagen, M; Richter, M; Wetzig, H; Schulz, R; Borte, M; Metzner, G; Krumbiegel, P; Herbarth, O				Diez, U; Kroessner, T; Rehwagen, M; Richter, M; Wetzig, H; Schulz, R; Borte, M; Metzner, G; Krumbiegel, P; Herbarth, O			Effects of indoor painting and smoking on airway symptoms in atopy risk children in the first year of life - results of the LARS-study	INTERNATIONAL JOURNAL OF HYGIENE AND ENVIRONMENTAL HEALTH			English	Article; Proceedings Paper	7th Congress of the Society-of-Hygiene-and-Environmental-Medicine	1999	LEIPZIG, GERMANY	Soc Hygiene & Environm Med		atopy risk children; air pollution; VOC; restoration; smoking; pulmonary infections	VOLATILE ORGANIC-COMPOUNDS; ASTHMA	Introduction: The Leipzig Allergy High-Risk Children Study (LARS) is a prospective nested cohort control study about the influence of chemical indoor exposure in dwellings on the health outcome of atopy-risk children during the first years of life. Design and Methods: 475 premature children and children with allergic risk factors have been selected out of the 1995/1996 birth cohort in the city of Leipzig. Twenty-five volatile organic compounds (VOC) were measured in the infant's bedrooms using passive sampling systems for 4 weeks after birth. The babies underwent a medical examination at the age of sis weeks and 1 year. The parents answered a questionnaire. Results: Correlations between VOC exposures and infections were calculated by multiple logistic regression. Selected VOC show a direct association to actually painted dwellings (OR = 2.4; 95 % Cl 1.1-5.3). An increase of risk of pulmonary infections was observed in infants aged 6 weeks if restoration (painting OR 5.6; 95 % Cl 1.3-24.0) or flooring connected with painting had occurred during the pregnancy period. Higher concentration of styrene (>2.0 mu g/m(3), indicator for flooring) elevated the risk of pulmonary infections in six-week-old infants (OR = 2.1; 95 % Cl 1.1-4.2). Environmental benzene > 5.6 mu g/m(3) increased the risk of airway infections in six-week-old babies (OR = 2.4; 95 % Cl 1.28-4.48). Smoking in the dwelling (OR = 2.0; 95 % Cl 1.1-3.5) as well as restoration (OR = 1.9; 95 % Cl 1.1-3.5) are also risk factors of the development of wheezing in the one-year-old child. Conclusions: The data give indications in order to prevent allergies and chronic lung diseases in atopy risk children exposure to chemicals from indoor air should be minimised from birth on.	UFZ Helmholtz Ctr Environm Res, Dept Human Exposure Res & Epidemiol, D-04318 Leipzig, Germany; Univ Leipzig, Childrens Hosp, Fac Med, Leipzig, Germany; Univ Leipzig, Fac Med, Inst Clin Immunol & Transfus Med, Leipzig, Germany	Diez, U (reprint author), UFZ Helmholtz Ctr Environm Res, Dept Human Exposure Res & Epidemiol, Permoser Str 15, D-04318 Leipzig, Germany.	diez@expo.ufz.de					Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Carswell F, 1995, CLIN EXP ALLERGY, V25, P52, DOI 10.1111/j.1365-2222.1995.tb00044.x; DIEZ U, 1996, PADIATR GRENZGEB, V34, P507; DIEZ U, 1998, PADIATR GRENZGEB, V36, P375; FERGUSSON DM, 1981, J EPIDEMIOL COMMUN H, V35, P180, DOI 10.1136/jech.35.3.180; HANRAHAN JP, 1998, AM REV RESPIR DIS, V141, pA282; Hempel-Jorgensen A, 1998, INT ARCH OCC ENV HEA, V71, P225, DOI 10.1007/s004200050274; Herbarth O, 1998, ADV AIR POLLUT SER, V6, P619; Jones AP, 1998, SOC SCI MED, V47, P755, DOI 10.1016/S0277-9536(98)00151-8; Karaman O, 1999, PEDIATR INT, V41, P147; MERRETT TG, 1988, ANN ALLERGY, V61, P13; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; MUTIUS E, 1994, KINDERARZT UMWELT JA, P90; REINHARDT D, 1997, THERAPIE KRANKHEITEN; SEIFERT B, 1986, BUNDESGESUNDHBL, V29, P417; TAGER IB, 1993, AM REV RESPIR DIS, V147, P811; WALLACE L, 1987, ARCH ENVIRON HEALTH, V42, P272; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; 1998, BUNDESGESUNDHBL, V9, P392	19	91	93	1	12	ELSEVIER GMBH, URBAN & FISCHER VERLAG	JENA	OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY	1438-4639			INT J HYG ENVIR HEAL	Int. J. Hyg. Environ. Health.	MAR	2000	203	1					23	28		10.1078/S1438-4639(04)70004-8		6	Public, Environmental & Occupational Health; Infectious Diseases	Public, Environmental & Occupational Health; Infectious Diseases	317HG	WOS:000087219500004	10956586	
J	Eyerich, K; Novak, N				Eyerich, K.; Novak, N.			Immunology of atopic eczema: overcoming the Th1/Th2 paradigm	ALLERGY			English	Review						dendritic cell; dermatitis; eczema; immunology; T cell	THYMIC STROMAL LYMPHOPOIETIN; FC-EPSILON-RI; ANTI-CD20 RITUXIMAB TREATMENT; IFN-GAMMA RESPONSE; ALLERGIC CONTACT; DENDRITIC CELLS; PATCH TEST; IN-SITU; T-CELLS; KERATINOCYTE DIFFERENTIATION	Atopic eczema (AE) is a challenge for modern medicine, because it is prevalent, severely affects quality of life of patients and their families, and causes high socioeconomic costs. The pathogenesis of AE is complex. While initial studies suggested a Th2 deviation as primary reason for the disease, numerous studies addressed a genetically predetermined impaired epidermal barrier as leading cause in a subgroup of patients. Recently, immune changes beyond the initial Th2 concept were defined in AE, with a role for specialized dendritic cells as well as newly identified T helper cell subsets such as Th17 and Th22 cells. Furthermore, trigger factors are expanded beyond classical Th2 allergens such as pollen or house dust mites to microbial products as well as self-antigens. This review pieces together our current understanding of immune as well as barrier abnormalities into the pathogenesis mosaic of AE.	[Eyerich, K.] Tech Univ Munich, Dept Dermatol & Allergy, D-80290 Munich, Germany; [Eyerich, K.] Helmholtz Ctr, ZAUM Ctr Allergy & Environm, Munich, Germany; [Eyerich, K.] Tech Univ Munich, D-80290 Munich, Germany; [Novak, N.] Univ Bonn, Med Ctr, Dept Dermatol & Allergy, Bonn, Germany	Eyerich, K (reprint author), Dept Dermatol & Allergy, Biedersteiner Str 29, D-80802 Munich, Germany.	kilian.eyerich@lrz.tum.de					Antoniu SA, 2010, CURR OPIN INVEST DR, V11, P1286; Barnes KC, 2010, J ALLERGY CLIN IMMUN, V125, P16, DOI 10.1016/j.jaci.2009.11.008; Baurecht H, 2007, J ALLERGY CLIN IMMUN, V120, P1406, DOI 10.1016/j.jaci.2007.08.067; Belloni B, 2007, J ALLERGY CLIN IMMUN, V120, P1223, DOI 10.1016/j.jaci.2007.08.060; Bieber T, 2012, ALLERGY, V67, P969, DOI 10.1111/j.1398-9995.2012.02845.x; Bieber T, 2012, ALLERGY, V67, P1475, DOI 10.1111/all.12049; Bieber T, 2008, NEW ENGL J MED, V358, P1483, DOI 10.1056/NEJMra074081; Bisgaard H, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050131; Brandt EB, 2011, J CLIN CELL IMMUNOL, V2; Buka RL, 2005, J AM ACAD DERMATOL, V53, P358, DOI 10.1016/j.jaad.2005.03.013; Bunikowski R, 2000, J ALLERGY CLIN IMMUN, V105, P814, DOI 10.1067/mai.2000.105528; Chiou YL, 2009, J CELL PHYSIOL, V220, P311, DOI 10.1002/jcp.21764; Compalati E, 2012, CURR OPIN ALLERGY CL, V12, P427, DOI 10.1097/ACI.0b013e328354e540; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; DARSOW U, 1995, J ALLERGY CLIN IMMUN, V95, P677, DOI 10.1016/S0091-6749(95)70172-9; De Benedetto A, 2008, J INVEST DERMATOL, V128, P1594, DOI 10.1038/sj.jid.5701208; Deleuran M, 2012, CHEM IMMUNOL ALLERGY, V96, P45, DOI 10.1159/000331871; Eyerich K, 2008, INT ARCH ALLERGY IMM, V145, P213, DOI 10.1159/000109290; Eyerich K, 2010, EXP DERMATOL, V19, P511, DOI 10.1111/j.1600-0625.2009.00980.x; Eyerich K, 2009, J ALLERGY CLIN IMMUN, V123, P59, DOI [10.1016/j.jaci.2008.10.031, 10.1016/j.jaci.2009.10.031]; Eyerich S, 2011, NEW ENGL J MED, V365, P231, DOI 10.1056/NEJMoa1104200; Eyerich S, 2010, TRENDS IMMUNOL, V31, P354, DOI 10.1016/j.it.2010.06.004; Eyerich S, 2009, J CLIN INVEST, V119, P3573, DOI 10.1172/JCI40202; Fallon PG, 2009, NAT GENET, V41, P602, DOI 10.1038/ng.358; Fischer-Stabauer M, 2012, EUR J DERMATOL, V22, P781, DOI 10.1684/ejd.2012.1854; Fujita H, 2011, J ALLERGY CLIN IMMUN, V128, P574, DOI 10.1016/j.jaci.2011.05.016; Gao PS, 2012, J INVEST DERMATOL, V132, P650, DOI 10.1038/jid.2011.374; Garmhausen D, 2013, ALLERGY, V68, P498, DOI 10.1111/all.12112; Gittler JK, 2012, J ALLERGY CLIN IMMUN, V130, P1344, DOI 10.1016/j.jaci.2012.07.012; GREWE M, 1995, J INVEST DERMATOL, V105, P407, DOI 10.1111/1523-1747.ep12321078; Gros E, 2011, J ALLERGY CLIN IMMUN, V128, P1015, DOI 10.1016/j.jaci.2011.05.043; Gros E, 2009, J ALLERGY CLIN IMMUN, V124, P753, DOI 10.1016/j.jaci.2009.07.004; Gschwandtner M, 2013, ALLERGY, V68, P37, DOI 10.1111/all.12051; HANIFIN JM, 1993, J AM ACAD DERMATOL, V28, P189, DOI 10.1016/0190-9622(93)70026-P; Heil PM, 2010, J DTSCH DERMATOL GES, V8, P990, DOI 10.1111/j.1610-0387.2010.07497.x; HENSELER T, 1995, J AM ACAD DERMATOL, V32, P982, DOI 10.1016/0190-9622(95)91336-X; Heratizadeh A, 2011, BRIT J DERMATOL, V164, P316, DOI 10.1111/j.1365-2133.2010.10090.x; Herrmann N, 2013, ALLERGY, V68, P621, DOI 10.1111/all.12145; Hinz D, 2012, ALLERGY, V67, P380, DOI 10.1111/j.1398-9995.2011.02767.x; Howell MD, 2008, J INVEST DERMATOL, V128, P2248, DOI 10.1038/jid.2008.74; Howell MD, 2009, J ALLERGY CLIN IMMUN, V124, pR7, DOI 10.1016/j.jaci.2009.07.012; Ibler K, 2010, J EUR ACAD DERMATOL, V24, P837, DOI 10.1111/j.1468-3083.2009.03202.x; Imaizumi A, 2003, J DERMATOL SCI, V33, P23, DOI 10.1016/S0923-1811(03)00132-4; Irvine AD, 2011, NEW ENGL J MED, V365, P1315, DOI 10.1056/NEJMra1011040; Jacobi A, 2005, J AM ACAD DERMATOL, V52, P522, DOI 10.1016/j.jaad.2004.11.022; Jang IG, 2000, J AM ACAD DERMATOL, V42, P1033, DOI 10.1016/S0190-9622(00)90300-1; Jee SJ, 2011, ALLERGY ASTHMA IMMUN, V3, P89, DOI 10.4168/aair.2011.3.2.89; Jiang H, 2012, ALLERGY, V67, P1078, DOI 10.1111/j.1398-9995.2012.02857.x; Kasperkiewicz M, 2011, J ALLERGY CLIN IMMUN, V127, p270 e1; Kasraie S, 2012, ALLERGY, V67, P41, DOI 10.1111/j.1398-9995.2011.02710.x; Kasraie S, 2011, ALLERGY, V66, P845, DOI 10.1111/j.1398-9995.2011.02545.x; Kinoshita H, 2009, J ALLERGY CLIN IMMUN, V123, P179, DOI 10.1016/j.jaci.2008.10.008; Kong HDH, 2012, GENOME RES, V22, P850, DOI 10.1101/gr.131029.111; Kortekangas-Savolainen O, 2004, ALLERGY, V59, P168, DOI 10.1046/j.1398-9995.2003.00330.x; Krathen RA, 2005, J AM ACAD DERMATOL, V53, P338, DOI 10.1016/j.jaad.2005.02.014; Kwiek B, 2008, J ALLERGY CLIN IMMUN, V122, P126, DOI 10.1016/j.jaci.2008.05.005; Lane JE, 2006, J AM ACAD DERMATOL, V54, P68, DOI 10.1016/j.jaad.2005.09.030; Lau S, 2012, J ALLERGY CLIN IMMUN, V129, P1040, DOI 10.1016/j.jaci.2012.02.005; Leung DYM, 2011, J ALLERGY CLIN IMMUN, V127, P965, DOI 10.1016/j.jaci.2011.02.010; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Macias ES, 2011, J AM ACAD DERMATOL, V64, P455, DOI 10.1016/j.jaad.2010.03.044; Martin SF, 2011, ALLERGY, V66, P1152, DOI 10.1111/j.1398-9995.2011.02652.x; Mayser P, 2000, ACTA DERM-VENEREOL, V80, P357, DOI 10.1080/000155500459303; McLean WHI, 2008, J ALLERGY CLIN IMMUN, V121, P1294, DOI 10.1016/j.jaci.2008.02.039; Metz M, 2011, J INVEST DERMATOL, V131, P987, DOI 10.1038/jid.2010.419; Morizane S, 2012, J ALLERGY CLIN IMMUN, V130, P259, DOI 10.1016/j.jaci.2012.03.006; Moul DK, 2008, J AM ACAD DERMATOL, V58, P984, DOI 10.1016/j.jaad.2008.02.007; Navarini AA, 2011, J ALLERGY CLIN IMMUN, V128, P1128, DOI 10.1016/j.jaci.2011.09.009; Niebuhr M, 2012, J ALLERGY CLIN IMMUN, V126, P1176; Nograles KE, 2009, J ALLERGY CLIN IMMUN, V123, P1244, DOI 10.1016/j.jaci.2009.03.041; Novak N, 2013, ALLERGY, V68, P454, DOI 10.1111/all.12109; Novak N, 2011, ALLERGY, V66, P830, DOI 10.1111/j.1398-9995.2011.02571.x; Novak N, 2009, ALLERGY, V64, P265, DOI 10.1111/j.1398-9995.2008.01922.x; Novak N, 2008, J INVEST DERMATOL, V128, P1430, DOI 10.1038/sj.jid.5701190; Oldhoff JM, 2005, ALLERGY, V60, P693, DOI 10.1111/j.1398-9995.2005.00791.x; Ong PY, 2002, NEW ENGL J MED, V347, P1151, DOI 10.1056/NEJMoa021481; Oyoshi MK, 2010, J ALLERGY CLIN IMMUN, V126, P976, DOI 10.1016/j.jaci.2010.08.041; Peng WM, 2011, ALLERGY, V66, P605, DOI 10.1111/j.1398-9995.2010.02524.x; Pennino D, 2010, J IMMUNOL, V184, P4880, DOI 10.4049/jimmunol.0901767; Pilette C, 2013, ALLERGY, V68, P312, DOI 10.1111/all.12090; Puya R, 2012, INT J DERMATOL, V51, P115, DOI 10.1111/j.1365-4632.2011.05195.x; Roduit C, 2012, J ALLERGY CLIN IMMUN, V130, P130, DOI 10.1016/j.jaci.2012.02.043; Samrao A, 2012, ARCH DERMATOL, V148, P890, DOI 10.1001/archdermatol.2012.812; Schmidt M, 2010, NAT IMMUNOL, V11, P814, DOI 10.1038/ni.1919; Schultz Larsen F, 1993, J Am Acad Dermatol, V28, P719; Schuttelaar MLA, 2009, ALLERGY, V64, P1758, DOI 10.1111/j.1398-9995.2009.02080.x; Sediva A, 2008, J ALLERGY CLIN IMMUN, V121, P1515, DOI 10.1016/j.jaci.2008.03.007; Sheinkopf LE, 2008, ALLERGY ASTHMA PROC, V29, P530, DOI 10.2500/aap.2008.29.3160; Simon D, 2008, J ALLERGY CLIN IMMUN, V122, P423, DOI 10.1016/j.jaci.2008.06.010; Simon D, 2008, J ALLERGY CLIN IMMUN, V121, P122, DOI 10.1016/j.jaci.2007.11.016; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Strachan DR, 2001, J ALLERGY CLIN IMMUN, V108, P901, DOI 10.1067/mai.2001.119408; Suarez-Farinas M, 2011, J ALLERGY CLIN IMMUN, V127, P954, DOI 10.1016/j.jaci.2010.12.1124; Takiguchi R, 2007, J AM ACAD DERMATOL, V56, P222, DOI 10.1016/j.jaad.2006.08.031; Tintle S, 2011, J ALLERGY CLIN IMMUN, V128, P583, DOI 10.1016/j.jaci.2011.05.042; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Volf EM, 2012, J DRUGS DERMATOL, V11, P341; Vu AT, 2010, J ALLERGY CLIN IMMUN, V126, P985, DOI 10.1016/j.jaci.2010.09.002; Walley AJ, 2001, NAT GENET, V29, P175, DOI 10.1038/ng728; Zeller S, 2009, J ALLERGY CLIN IMMUN, V124, P278, DOI 10.1016/j.jaci.2009.05.015	102	90	96	1	29	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538			ALLERGY	Allergy	AUG	2013	68	8					974	982		10.1111/all.12184		9	Allergy; Immunology	Allergy; Immunology	204SV	WOS:000323390500005	23889510	
J	Leuppi, JD; Schuetz, P; Bingisser, R; Bodmer, M; Briel, M; Drescher, T; Duerring, U; Henzen, C; Leibbrandt, Y; Maier, S; Miedinger, D; Muller, B; Scherr, A; Schindler, C; Stoeckli, R; Viatte, S; von Garnier, C; Tamm, M; Rutishauser, J				Leuppi, Joerg D.; Schuetz, Philipp; Bingisser, Roland; Bodmer, Michael; Briel, Matthias; Drescher, Tilman; Duerring, Ursula; Henzen, Christoph; Leibbrandt, Yolanda; Maier, Sabrina; Miedinger, David; Mueller, Beat; Scherr, Andreas; Schindler, Christian; Stoeckli, Rolf; Viatte, Sebastien; von Garnier, Christophe; Tamm, Michael; Rutishauser, Jonas			Short-term vs Conventional Glucocorticoid Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease The REDUCE Randomized Clinical Trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SYSTEMIC GLUCOCORTICOIDS; ORAL PREDNISONE; COPD; MORTALITY	Importance International guidelines advocate a 7- to 14-day course of systemic glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease (COPD). However, the optimal dose and duration are unknown. Objective To investigate whether a short-term (5 days) systemic glucocorticoid treatment in patients with COPD exacerbation is noninferior to conventional (14 days) treatment in clinical outcome and whether it decreases the exposure to steroids. Design, Setting, and Patients REDUCE (Reduction in the Use of Corticosteroids in Exacerbated COPD), a randomized, noninferiority multicenter trial in 5 Swiss teaching hospitals, enrolling 314 patients presenting to the emergency department with acute COPD exacerbation, past or present smokers (>= 20 pack-years) without a history of asthma, from March 2006 through February 2011. Interventions Treatment with 40 mg of prednisone daily for either 5 or 14 days in a placebo-controlled, double-blind fashion. The predefined noninferiority criterion was an absolute increase in exacerbations of at most 15%, translating to a critical hazard ratio of 1.515 for a reference event rate of 50%. Main Outcome and Measure Time to next exacerbation within 180 days. Results Of 314 randomized patients, 289 (92%) of whom were admitted to the hospital, 311 were included in the intention-to-treat analysis and 296 in the per-protocol analysis. Hazard ratios for the short-term vs conventional treatment group were 0.95 (90% CI, 0.70 to 1.29; P=.006 for noninferiority) in the intention-to-treat analysis and 0.93 (90% CI, 0.68 to 1.26; P=.005 for noninferiority) in the per-protocol analysis, meeting our noninferiority criterion. In the short-term group, 56 patients (35.9%) reached the primary end point; 57 (36.8%) in the conventional group. Estimates of reexacerbation rates within 180 days were 37.2% (95% CI, 29.5% to 44.9%) in the short-term; 38.4% (95% CI, 30.6% to 46.3%) in the conventional, with a difference of -1.2% (95% CI, -12.2% to 9.8%) between the short-term and the conventional. Among patients with a reexacerbation, the median time to event was 43.5 days (interquartile range [IQR], 13 to 118) in the short-term and 29 days (IQR, 16 to 85) in the conventional. There was no difference between groups in time to death, the combined end point of exacerbation, death, or both and recovery of lung function. In the conventional group, mean cumulative prednisone dose was significantly higher (793 mg [95% CI, 710 to 876 mg] vs 379 mg [95% CI, 311 to 446 mg], P<.001), but treatment-associated adverse reactions, including hyperglycemia and hypertension, did not occur more frequently. Conclusions and Relevance In patients presenting to the emergency department with acute exacerbations of COPD, 5-day treatment with systemic glucocorticoids was noninferior to 14-day treatment with regard to reexacerbation within 6 months of follow-up but significantly reduced glucocorticoid exposure. These findings support the use of a 5-day glucocorticoid treatment in acute exacerbations of COPD.	[Leuppi, Joerg D.; Drescher, Tilman; Maier, Sabrina; Miedinger, David; Scherr, Andreas] Univ Basel Hosp, Clin Internal Med, Basel, Switzerland; [Bingisser, Roland; Bodmer, Michael] Univ Basel Hosp, Interdisciplinary Emergency Dept, Basel, Switzerland; [Briel, Matthias] Univ Basel Hosp, Basel Inst Clin Epidemiol & Biostat, Basel, Switzerland; [Drescher, Tilman; Duerring, Ursula; Stoeckli, Rolf] Univ Basel Hosp, Clin Endocrinol Diabetol & Metab, Basel, Switzerland; [Scherr, Andreas; Tamm, Michael] Univ Basel Hosp, Clin Pneumol, Basel, Switzerland; [Schuetz, Philipp; Mueller, Beat] Kantonsspital, Med Univ Clin, Aarau, Switzerland; [Henzen, Christoph] Kantonsspital, Dept Internal Med, Luzern, Switzerland; [Rutishauser, Jonas] Univ Basel, Biozentrum, CH-4003 Basel, Switzerland; [Schindler, Christian] Univ Basel, Swiss Trop & Publ Hlth Inst, CH-4003 Basel, Switzerland; [Viatte, Sebastien] Univ Manchester, Arthrit Res UK Epidemiol Unit, Manchester Acad Hlth Sci Ctr, Manchester M13 9PL, Lancs, England; [von Garnier, Christophe] Inselspital Bern, Univ Hosp Bern, Resp Med Clin, Bern, Switzerland; [Leibbrandt, Yolanda; Viatte, Sebastien; Rutishauser, Jonas] Hosp Ctr Biel Bienne, Clin Internal Med, Dept Med, Biel, Switzerland	Rutishauser, J (reprint author), Ctr Hosp, Clin Internal Med, Dept Med, Vogelsang 84, CH-2501 Biel, Switzerland.	j.rutishauser@unibas.ch	Bodmer, Michael/K-1873-2013; Schindler, Christian/D-3472-2015	Bingisser, Roland/0000-0001-8223-9792; Briel, Matthias/0000-0002-2070-5230	Department of Medicine, University Hospital Basel; Clinic of Internal Medicine, Hospital Center of Biel-Bienne; Freie Akademische Gesellschaft; Fonds fur Lehre und Forschung; AstraZeneca; Viollier Laboratory; Gottfried und Julia Bangerter-Rhyner-Stiftung fur Medizinische Forschung	The REDUCE trial was an investigator-initiated study supported by the Department of Medicine, University Hospital Basel; the Clinic of Internal Medicine, Hospital Center of Biel-Bienne; Freie Akademische Gesellschaft; Fonds fur Lehre und Forschung; AstraZeneca; Viollier Laboratory; Gottfried und Julia Bangerter-Rhyner-Stiftung fur Medizinische Forschung.	Aaron SD, 2003, NEW ENGL J MED, V348, P2618, DOI 10.1056/NEJMoa023161; ANTHONISEN NR, 1987, ANN INTERN MED, V106, P196; Bestall JC, 1999, THORAX, V54, P581; Bridevaux PO, 2010, EUR RESPIR J, V36, P1259, DOI 10.1183/09031936.00004110; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; Christ-Crain M, 2004, LANCET, V363, P600, DOI 10.1016/S0140-6736(04)15591-8; Davies L, 1999, LANCET, V354, P456, DOI 10.1016/S0140-6736(98)11326-0; Evans AT, 2002, LANCET, V359, P1648, DOI 10.1016/S0140-6736(02)08597-5; Global Initiative for Chronic Obstructive Lung Disease, GLOB STRAT DIAGN MAN; Groenewegen KH, 2003, CHEST, V124, P459, DOI 10.1378/chest.124.2.459; Hansel TT, 2009, LANCET, V374, P744, DOI 10.1016/S0140-6736(09)61342-8; Jochmann A, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13567; Jochmann A, 2010, SWISS MED WKLY, V140, DOI 10.4414/smw.2010.13053; Lindenauer PK, 2010, JAMA-J AM MED ASSOC, V303, P2359, DOI 10.1001/jama.2010.796; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Piaggio G, 2012, JAMA-J AM MED ASSOC, V308, P2594, DOI 10.1001/jama.2012.87802; Rodriguez-Roisin R, 2000, CHEST, V117, p398S, DOI 10.1378/chest.117.5_suppl_2.398S; Sayiner A, 2001, CHEST, V119, P726, DOI 10.1378/chest.119.3.726; Schuetz P, 2010, SWISS MED WKLY, V140, DOI 10.4414/smw.2010.13109; Soler-Cataluna JJ, 2005, THORAX, V60, P925, DOI 10.1136/thx.2005.040527; Stolz D, 2007, CHEST, V131, P9, DOI 10.1378/chest.06-1500; Thompson WH, 1996, AM J RESP CRIT CARE, V154, P407; Walters JAE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006897.pub2; Wouters EFM, 2004, LANCET, V364, P883, DOI 10.1016/S0140-6736(04)16984-5	25	90	94	2	22	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 5	2013	309	21					2223	2231		10.1001/jama.2013.5023		9	Medicine, General & Internal	General & Internal Medicine	156YC	WOS:000319859200026	23695200	
J	Mugler, JP; Altes, TA; Ruset, IC; Dregely, IM; Mata, JF; Miller, GW; Ketel, S; Ketel, J; Hersman, FW; Ruppert, K				Mugler, John P., III; Altes, Talissa A.; Ruset, Iulian C.; Dregely, Isabel M.; Mata, Jaime F.; Miller, G. Wilson; Ketel, Stephen; Ketel, Jeffrey; Hersman, F. William; Ruppert, Kai			Simultaneous magnetic resonance imaging of ventilation distribution and gas uptake in the human lung using hyperpolarized xenon-129	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						gas exchange; pulmonary function; pulmonary ventilation	AIR SPACES; HE-3 GAS; IN-VIVO; MRI; DYNAMICS; NMR	Despite a myriad of technical advances in medical imaging, as well as the growing need to address the global impact of pulmonary diseases, such as asthma and chronic obstructive pulmonary disease, on health and quality of life, it remains challenging to obtain in vivo regional depiction and quantification of the most basic physiological functions of the lung-gas delivery to the airspaces and gas uptake by the lung parenchyma and blood-in a manner suitable for routine application in humans. We report a method based on MRI of hyperpolarized xenon-129 that permits simultaneous observation of the 3D distributions of ventilation (gas delivery) and gas uptake, as well as quantification of regional gas uptake based on the associated ventilation. Subjects with lung disease showed variations in gas uptake that differed from those in ventilation in many regions, suggesting that gas uptake as measured by this technique reflects such features as underlying pathological alterations of lung tissue or of local blood flow. Furthermore, the ratio of the signal associated with gas uptake to that associated with ventilation was substantially altered in subjects with lung disease compared with healthy subjects. This MRI-based method provides a way to quantify relationships among gas delivery, exchange, and transport, and appears to have significant potential to provide more insight into lung disease.	[Mugler, John P., III; Altes, Talissa A.; Mata, Jaime F.; Miller, G. Wilson; Ruppert, Kai] Univ Virginia, Dept Radiol, Ctr Vivo Hyperpolarized Gas MR Imaging, Charlottesville, VA 22908 USA; [Ruset, Iulian C.; Ketel, Stephen; Ketel, Jeffrey; Hersman, F. William] Xemed LLC, Durham, NH 03824 USA; [Ruset, Iulian C.; Dregely, Isabel M.; Hersman, F. William] Univ New Hampshire, Dept Phys, Durham, NH 03824 USA	Mugler, JP (reprint author), Univ Virginia, Dept Radiol, Ctr Vivo Hyperpolarized Gas MR Imaging, Charlottesville, VA 22908 USA.	John.Mugler@virginia.edu	Mugler, John/B-9432-2013	Mugler, John/0000-0002-4140-308X; Dregely, Isabel/0000-0003-4146-7363	National Institutes of Health [R41 HL091578, R01 EB003202, R01 HL079077]; Siemens Medical Solutions	This work was supported by National Institutes of Health Grants R41 HL091578, R01 EB003202, and R01 HL079077 and by a research grant from Siemens Medical Solutions.	ABRAHAM MH, 1985, J MED CHEM, V28, P865, DOI 10.1021/jm00145a004; Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; BROWN TR, 1982, P NATL ACAD SCI-BIOL, V79, P3523, DOI 10.1073/pnas.79.11.3523; Cleveland ZI, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012192; de Lange EE, 1999, RADIOLOGY, V210, P851; Driehuys B, 2006, P NATL ACAD SCI USA, V103, P18278, DOI 10.1073/pnas.0608458103; Fichele S, 2004, J MAGN RESON IMAGING, V20, P331, DOI 10.1002/jmri.20104; Hersman FW, 2008, ACAD RADIOL, V15, P683, DOI 10.1016/j.acra.2007.09.020; Hu S, 2008, J MAGN RESON, V192, P258, DOI 10.1016/j.jmr.2008.03.003; Kauczor HU, 1996, RADIOLOGY, V201, P564; Lustig M, 2007, MAGN RESON MED, V58, P1182, DOI 10.1002/mrm.21391; MacFall JR, 1996, RADIOLOGY, V200, P553; MATA J, 2010, P INT SOC MAGN RESON, V18, P989; MILLER KW, 1981, P NATL ACAD SCI-BIOL, V78, P4946, DOI 10.1073/pnas.78.8.4946; Moller HE, 2002, MAGN RESON MED, V47, P1029, DOI 10.1002/mrm.10173; Mugler JP, 1997, MAGNET RESON MED, V37, P809, DOI 10.1002/mrm.1910370602; POSSE S, 1995, MAGN RESON MED, V33, P34, DOI 10.1002/mrm.1910330106; Reeder SB, 2007, J MAGN RESON IMAGING, V26, P1145, DOI 10.1002/jmri.21089; Ruppert K, 2000, NMR BIOMED, V13, P220, DOI 10.1002/1099-1492(200006)13:4<220::AID-NBM638>3.0.CO;2-F; Ruppert K, 2000, MAGNET RESON MED, V44, P349, DOI 10.1002/1522-2594(200009)44:3<349::AID-MRM2>3.0.CO;2-J; Sakai K, 1996, J MAGN RESON SER B, V111, P300, DOI 10.1006/jmrb.1996.0098; Swanson SD, 1999, MAGNET RESON MED, V42, P1137, DOI 10.1002/(SICI)1522-2594(199912)42:6<1137::AID-MRM19>3.3.CO;2-W; Wagshul ME, 1996, MAGNET RESON MED, V36, P183, DOI 10.1002/mrm.1910360203; Wakayama Tetsuya, 2008, Magn Reson Med Sci, V7, P65, DOI 10.2463/mrms.7.65	24	90	90	2	32	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	DEC 14	2010	107	50					21707	21712		10.1073/pnas.1011912107		6	Multidisciplinary Sciences	Science & Technology - Other Topics	697NY	WOS:000285521500087	21098267	
J	Wagner, E; Frank, MM				Wagner, Eric; Frank, Michael M.			Therapeutic potential of complement modulation	NATURE REVIEWS DRUG DISCOVERY			English	Review							HEMOLYTIC-UREMIC SYNDROME; MANNOSE-BINDING LECTIN; ELEVATION MYOCARDIAL-INFARCTION; ENTIRE C1QR(2)S(2) COMPLEX; TRAUMATIC BRAIN-INJURY; TH2 EFFECTOR FUNCTIONS; ALTERNATIVE PATHWAY; FACTOR-H; C1 INHIBITOR; FACTOR-B	The complement system is an essential component of innate immunity that has been more recently recognized as an unexpected player in various pathological states. These include age-related macular degeneration, atypical haemolytic uraemic syndrome, allergy, foetal loss, and axonal and myelin degradation after trauma. Its importance has also been recognized in physiological processes including haematopoietic stem cell homing to the bone marrow, liver regeneration and modulation of adaptive immune responses. Although the complement system has long been known to be involved in autoimmune and inflammatory diseases, few agents that target the complement system are currently approved for clinical use. However, renewed interest in modulating this system in various pathological conditions has emerged, and several agents are now in development.	[Frank, Michael M.] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; [Wagner, Eric] Univ Laval, Ctr Rech Rhumatol & Immunol, Ctr Hosp Univ Quebec, Quebec City, PQ, Canada; [Wagner, Eric] Univ Laval, Dept Microbiol Infectiol & Immunol, Quebec City, PQ, Canada; [Frank, Michael M.] Duke Univ, Med Ctr, Dept Immunol, Durham, NC 27710 USA	Frank, MM (reprint author), Duke Univ, Med Ctr, Dept Pediat, Box 2611, Durham, NC 27710 USA.	frank007@mc.duke.edu					Agostoni A, 2004, J ALLERGY CLIN IMMUN, V114, pS51, DOI 10.1016/j.jaci.2004.06.047; Arumuciam T, 2008, P NATL ACAD SCI USA, V104, P14104; Asghar SS, 2000, FRONT BIOSCI, V5, pE63, DOI 10.2741/asghar; Atkinson C, 2008, J IMMUNOL, V180, P1231; Atkinson JP, 2006, J CLIN INVEST, V116, P1215, DOI 10.1172/JCI28622; BAIG K, 2007, ANN THORACIC CARDIOV, V84, P1477; Baldwin WM, 2004, AM J TRANSPLANT, V4, P311, DOI 10.1111/j.1600-6143.2004.00348.x; BASTA M, 1994, J CLIN INVEST, V94, P1729, DOI 10.1172/JCI117520; Basta M, 2008, MOL IMMUNOL, V45, P4073, DOI 10.1016/j.molimm.2008.07.012; Beinrohr L, 2008, TRENDS MOL MED, V14, P511, DOI 10.1016/j.molmed.2008.09.009; Bergmann-Leitner ES, 2007, VACCINE, V25, P7732, DOI 10.1016/j.vaccine.2007.08.030; Bergmann-Leitner ES, 2006, CLIN IMMUNOL, V121, P177, DOI 10.1016/j.clim.2006.07.001; Biesecker G, 1999, IMMUNOPHARMACOLOGY, V42, P219, DOI 10.1016/S0162-3109(99)00020-X; Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007; Bureeva S, 2005, DRUG DISCOV TODAY, V10, P1535, DOI 10.1016/S1359-6446(05)03592-0; Caliezi C, 2002, CRIT CARE MED, V30, P1722, DOI 10.1097/00003246-200208000-00008; Carroll MC, 2004, NAT IMMUNOL, V5, P981, DOI 10.1038/ni1113; Casanova JL, 2004, J EXP MED, V199, P1295, DOI 10.1084/jem.20040537; Chen CH, 1998, IMMUNOLOGY, V95, P648; Chen CH, 1998, CLIN IMMUNOL IMMUNOP, V87, P68, DOI 10.1006/clin.1997.4515; Cicardi M, 2005, SPRINGER SEMIN IMMUN, V27, P286, DOI 10.1007/s00281-005-0001-4; Cole DS, 2003, CLIN SCI, V104, P455, DOI 10.1042/CS20020362; Cugno M, 2009, TRENDS MOL MED, V15, P69, DOI 10.1016/j.molmed.2008.12.001; Davis AE, 2008, MOL IMMUNOL, V45, P4057, DOI 10.1016/j.molimm.2008.06.028; de Cordoba SR, 2004, MOL IMMUNOL, V41, P355, DOI 10.1016/j.molimm.2004.02.005; Dommett RM, 2006, TISSUE ANTIGENS, V68, P193, DOI 10.1111/j.1399-0039.2006.00649.x; Dragon-Durey MA, 2005, SPRINGER SEMIN IMMUN, V27, P359, DOI 10.1007/s00281-005-0003-2; Dragon-Durey MA, 2005, J AM SOC NEPHROL, V16, P555, DOI 10.1681/ASN.2004050380; Drouin SM, 2002, J IMMUNOL, V169, P5926; Drouin SM, 2001, J IMMUNOL, V167, P4141; EISEN DP, 2003, CLIN INFECT DIS, V37, P1996; Epstein TG, 2008, DRUGS, V68, P2561, DOI 10.2165/0003495-200868180-00003; Fang CJ, 2008, BRIT J HAEMATOL, V143, P336, DOI 10.1111/j.1365-2141.2008.07324.x; Fattouch K, 2007, EUR J CARDIO-THORAC, V32, P326, DOI 10.1016/j.ejcts.2007.04.038; Frank MM, 2000, IMMUNOL RES, V22, P137, DOI 10.1385/IR:22:2-3:137; Frank M. M., 1998, HUMAN COMPLEMENT SYS, P1; Fritzinger DC, 2009, DEV COMP IMMUNOL, V33, P105, DOI 10.1016/j.dci.2008.07.006; Garred P, 2003, MOL IMMUNOL, V40, P73, DOI 10.1016/S0161-5890(03)00104-4; Gruppo RA, 2009, NEW ENGL J MED, V360, P544, DOI 10.1056/NEJMc0809959; Hamilton SR, 2006, SCIENCE, V313, P1441, DOI 10.1126/science.1130256; Harris CL, 2002, CLIN EXP IMMUNOL, V129, P198, DOI 10.1046/j.1365-2249.2002.01924.x; Helmy KY, 2006, CELL, V124, P915, DOI 10.1016/j.cell.2005.12.039; Hepburn NJ, 2008, MOL IMMUNOL, V45, P395, DOI 10.1016/j.molimm.2007.06.144; Herbert AP, 2007, J BIOL CHEM, V282, P18960, DOI 10.1074/jbc.M609636200; Holers VM, 2008, IMMUNOL REV, V223, P300, DOI 10.1111/j.1600-065X.2008.00641.x; Holland M Claire H, 2004, Curr Opin Investig Drugs, V5, P1164; HOLMER M, 2007, NAT BIOTECHNOL, V25, P4; Huang YX, 2008, J IMMUNOL, V181, P8068; Inal JM, 2005, J IMMUNOL, V174, P356; Janssen BJC, 2007, J BIOL CHEM, V282, P29241, DOI 10.1074/jbc.M704587200; Jarva H, 2003, MOL IMMUNOL, V40, P95, DOI 10.1016/S0161-5890(03)00108-1; Jiang HX, 2001, J EXP MED, V194, P1609, DOI 10.1084/jem.194.11.1609; Jokiranta TS, 2007, MOL IMMUNOL, V44, P3889, DOI 10.1016/j.molimm.2007.06.003; Jolles S, 2005, CLIN EXP IMMUNOL, V142, P1, DOI 10.1111/j.1365-2249.2005.02834.X; Jongerius I, 2007, J EXP MED, V204, P2461, DOI 10.1084/jem.20070818; Katschke KJ, 2007, J EXP MED, V204, P1319, DOI 10.1084/jem.20070432; Katschke KJ, 2009, J BIOL CHEM, V284, P10473, DOI 10.1074/jbc.M809106200; Kavanagh D, 2008, ANNU REV MED, V59, P293, DOI 10.1146/annurev.med.59.060106.185110; Kemper C, 2007, NAT REV IMMUNOL, V7, P9, DOI 10.1038/nri1994; Kemper C, 2008, MOL IMMUNOL, V45, P4048, DOI 10.1016/j.molimm.2008.06.034; Kim DD, 2006, CLIN IMMUNOL, V118, P127, DOI 10.1016/j.clim.2005.10.014; Kohl Jorg, 2006, Curr Opin Mol Ther, V8, P529; Lambris JD, 2008, NAT REV MICROBIOL, V6, P132, DOI 10.1038/nrmicro1824; Lazar H. L., 2004, CIRCULATION S1, V110, pII274, DOI 10.1161/01.CIR.0000138315.99788.eb; Leinhase I, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-13; Leinhase I, 2006, EXP NEUROL, V199, P454, DOI 10.1016/j.expneurol.2006.01.033; LI JS, 2006, EXPERT REV CARDIOVAS, V4, P659; Lin T, 2007, TRANSPL INT, V20, P481, DOI 10.1111/j.1432-2277.2006.00448.x; LISZEWSKI MK, 2009, J IMMUNOL, V181, P4199; LOCKE JE, 2009, AM J TRANSPLANT, V9, P23123; Makrides SC, 1998, PHARMACOL REV, V50, P59; Manderson AP, 2004, ANNU REV IMMUNOL, V22, P431, DOI 10.1146/annurev.immunol.22.012703.104549; Markiewski MM, 2007, AM J PATHOL, V171, P715, DOI 10.2353/ajpath.2007.070166; MAROM Z, 1985, J EXP MED, V161, P657, DOI 10.1084/jem.161.4.657; Mathieu MC, 2005, IMMUNOL LETT, V100, P139, DOI 10.1016/j.imlet.2005.03.003; Mitchell DA, 2007, MOL IMMUNOL, V44, P2997, DOI 10.1016/j.molimm.2006.12.027; Mocco J, 2006, J NEUROSURG, V105, P595, DOI 10.3171/jns.2006.105.4.595; Mollnes TE, 2006, MOL IMMUNOL, V43, P107, DOI 10.1016/j.molimm.2005.06.014; Monk PN, 2007, BRIT J PHARMACOL, V152, P429, DOI 10.1038/sj.bjp.0707332; Nielsen EW, 2007, MOL IMMUNOL, V44, P1819, DOI 10.1016/j.molimm.2006.10.003; Nurnberger J, 2009, NEW ENGL J MED, V360, P542, DOI 10.1056/NEJMc0808527; OSOFSKY SG, 1977, J PEDIATR-US, V90, P180, DOI 10.1016/S0022-3476(77)80626-4; Parker C, 2009, LANCET, V373, P759, DOI 10.1016/S0140-6736(09)60001-5; Patel H, 2006, J AM SOC NEPHROL, V17, P1102, DOI 10.1681/ASN.200610116; Petersen KA, 2006, J CLIN IMMUNOL, V26, P465, DOI 10.1007/s10875-006-9037-z; Pickering MC, 2008, CLIN EXP IMMUNOL, V151, P210, DOI 10.1111/j.1365-2249.2007.03574.x; Ratajczak J, 2004, BLOOD, V103, P2071, DOI 10.1182/blood-2003-06-2099; Reis ES, 2006, SCAND J IMMUNOL, V63, P155, DOI 10.1111/j.1365-3083.2006.01729.x; Ricklin D, 2007, NAT BIOTECHNOL, V25, P1265, DOI 10.1038/nbt1342; Roth A, 2009, BLOOD, V113, P3885, DOI 10.1182/blood-2009-01-196329; Rother RP, 2007, NAT BIOTECHNOL, V25, P1256, DOI 10.1038/nbt1344; Sjoberg AP, 2009, TRENDS IMMUNOL, V30, P83, DOI 10.1016/j.it.2008.11.003; Song HB, 2003, J CLIN INVEST, V111, P1875, DOI 10.1172/JCI200317348; Speth C, 2008, FUNDAMENTAL IMMUNOLO, P1047; Sprong T, 2003, BLOOD, V102, P3702, DOI 10.1182/blood-2003-03-0703; STEGALL M, 2009, AM SOC TRANSPL WINT; Struber M, 1999, INTENS CARE MED, V25, P1315, DOI 10.1007/s001340051065; Sullivan K, 2004, IMMUNOLOGIC DISORDER, P652; Taube C, 2006, P NATL ACAD SCI USA, V103, P8084, DOI 10.1073/pnas.0602357103; Testa L, 2008, J THORAC CARDIOV SUR, V136, P884, DOI 10.1016/j.jtcvs.2007.12.062; Thiel S, 2007, MOL IMMUNOL, V44, P3875, DOI 10.1016/j.molimm.2007.06.005; Thielmann M, 2006, EUR J CARDIO-THORAC, V30, P285, DOI 10.1016/j.ejcts.2006.04.022; Thorgersen EB, 2008, INFECT IMMUN, V77, P725; Thurman JM, 2006, J AM SOC NEPHROL, V17, P707, DOI 10.1681/ASN.2005070698; TRAPP RG, 1987, J RHEUMATOL, V14, P135; Trouw LA, 2001, MOL IMMUNOL, V38, P199, DOI 10.1016/S0161-5890(01)00043-8; Valdimarsson H, 2003, BIOCHEM SOC T, V31, P768, DOI 10.1042/BST0310768; Vergunst CE, 2007, RHEUMATOLOGY, V46, P1773, DOI 10.1093/rheumatology/kem222; VONZABERN I, 1993, ACTIVATORS INHIBITOR, P127; WAGNER E, 2001, MED IMMUNOLOGY, P341; WAGNER E, 2001, CLIN DIAGNOSIS MANAG, P892; WAGNER E, 1998, HUMAN COMPLEMENT SYS, P527; Walport MJ, 2001, NEW ENGL J MED, V344, P1058; Walport MJ, 2001, NEW ENGL J MED, V344, P1140; Ward PA, 2004, NAT REV IMMUNOL, V4, P133, DOI 10.1038/nri1269; WEISMAN HF, 1990, SCIENCE, V249, P146, DOI 10.1126/science.2371562; Whipple EC, 2007, MOL IMMUNOL, V44, P377, DOI 10.1016/j.molimm.2006.02.032; Wiesmann C, 2006, NATURE, V444, P217, DOI 10.1038/nature05263; Wills-Karp Marsha, 2007, Proc Am Thorac Soc, V4, P247, DOI 10.1513/pats.200704-046AW; Yazdanbakhsh K, 2005, TRANSFUSION, V45, p122S, DOI 10.1111/j.1537-2995.2005.00526.x; Younger JG, 2001, J APPL PHYSIOL, V90, P2289; Zipfel PF, 2006, MOL IMMUNOL, V43, P97, DOI 10.1016/j.molimm.2005.06.015	122	90	100	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1474-1776			NAT REV DRUG DISCOV	Nat. Rev. Drug Discov.	JAN	2010	9	1					43	56		10.1038/nrd3011		14	Biotechnology & Applied Microbiology; Pharmacology & Pharmacy	Biotechnology & Applied Microbiology; Pharmacology & Pharmacy	566GD	WOS:000275357200023	19960015	
J	Blanc, PD; Iribarren, C; Trupin, L; Earnest, G; Katz, PP; Balmes, J; Sidney, S; Eisner, MD				Blanc, P. D.; Iribarren, C.; Trupin, L.; Earnest, G.; Katz, P. P.; Balmes, J.; Sidney, S.; Eisner, M. D.			Occupational exposures and the risk of COPD: dusty trades revisited	THORAX			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; WORK DISABILITY; HEALTH OUTCOMES; US POPULATION; LUNG-FUNCTION; ASTHMA; BURDEN; ASSOCIATION; PREVALENCE; LIMITATION	Background: The contribution of occupational exposures to chronic obstructive pulmonary disease (COPD) and, in particular, their potential interaction with cigarette smoking remains underappreciated. Methods: Data from the FLOW study of 1202 subjects with COPD (of which 742 had disease classified as stage II or above by Global Obstructive Lung Disease (GOLD) criteria) and 302 referent subjects matched by age, sex and race recruited from a large managed care organisation were analysed. Occupational exposures were assessed using two methods: self-reported exposure to vapours, gas, dust or fumes on the longest held job (VGDF) and a job exposure matrix (JEM) for probability of exposure based on occupation. Multivariate analysis was used to control for age, sex, race and smoking history. The odds ratio (OR) and adjusted population attributable fraction (PAF) associated with occupational exposure were calculated. Results: VGDF exposure was associated with an increased risk of COPD (OR 2.11; 95% CI 1.59 to 2.82) and a PAF of 31% (95% CI 22% to 39%). The risk associated with high probability of workplace exposure by JEM was similar (OR 2.27; 95% CI 1.46 to 3.52), although the PAF was lower (13%; 95% CI 8% to 18%). These estimates were not substantively different when the analysis was limited to COPD GOLD stage II or above. Joint exposure to both smoking and occupational factors markedly increased the risk of COPD (OR 14.1; 95% CI 9.33 to 21.2). Conclusions: Workplace exposures are strongly associated with an increased risk of COPD. On a population level, prevention of both smoking and occupational exposure, and especially both together, is needed to prevent the global burden of disease.	[Blanc, P. D.; Earnest, G.; Balmes, J.; Eisner, M. D.] Univ San Francisco, Div Occupat & Environm Med, San Francisco, CA 94117 USA; [Blanc, P. D.; Earnest, G.; Balmes, J.; Eisner, M. D.] Univ San Francisco, Dept Med, Div Pulm & Crit Care Med, San Francisco, CA 94117 USA; [Iribarren, C.; Sidney, S.; Eisner, M. D.] Kaiser Permanente, Div Res, Oakland, CA USA; [Trupin, L.; Katz, P. P.] Univ San Francisco, Dept Med, Inst Hlth Policy Studies, San Francisco, CA 94117 USA	Eisner, MD (reprint author), Univ San Francisco, Div Occupat & Environm Med, 350 Parnassus Ave,Ste 609, San Francisco, CA 94117 USA.	mark.eisner@ucsf.edu			NHLBI/NIH [R01HL077618]	NHLBI/NIH R01HL077618.	American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BECKLAKE MR, 1985, CHEST, V88, P608, DOI 10.1378/chest.88.4.608; Benke G, 2008, ANN EPIDEMIOL, V18, P23, DOI 10.1016/j.annepidem.2007.06.007; Bergdahl IA, 2004, EUR RESPIR J, V23, P402, DOI 10.1183/09031936.04.00034304; Blanc P D, 2007, Int J Tuberc Lung Dis, V11, P251; Blanc PD, 2005, AM J IND MED, V48, P110, DOI 10.1002/ajim.20187; Blanc PD, 2004, OCCUP ENVIRON MED, V61, P661, DOI 10.1136/oem.2003.010058; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; Boggia B, 2008, J OCCUP ENVIRON MED, V50, P366, DOI 10.1097/JOM.0b013e318162f601; Buist AS, 2007, LANCET, V370, P741, DOI 10.1016/S0140-6736(07)61377-4; Calfee CS, 2006, CHEST, V130, P1312, DOI 10.1378/chest.130.5.1312; de Meer Gea, 2004, Environ Health, V3, P6; *ECRHS INV, 1993, PROT EUR COMM RESP H; Eisner MD, 2007, RESP RES, V8, DOI 10.1186/1465-9921-8-7; Eisner MD, 2006, AM J MED, V119, P884, DOI 10.1016/j.amjmed.2006.01.016; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Eisner MD, 2002, AM J PUBLIC HEALTH, V92, P1506, DOI 10.2105/AJPH.92.9.1506; Fabbri LM, 2003, EUR RESPIR J, V22, P1, DOI 10.1183/09031936.03.00063703; GREENLAND S, 1993, BIOMETRICS, V49, P865, DOI 10.2307/2532206; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Harber P, 2007, AM J RESP CRIT CARE, V176, P994, DOI 10.1164/rccm.200605-730OC; Hnizdo E, 2002, AM J EPIDEMIOL, V156, P738, DOI 10.1093/aje/kwf105; Karter AJ, 2002, JAMA-J AM MED ASSOC, V287, P2519, DOI 10.1001/jama.287.19.2519; Kennedy SM, 2000, OCCUP ENVIRON MED, V57, P635, DOI 10.1136/oem.57.9.635; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Mak GK, 2001, AM J MED SCI, V322, P121, DOI 10.1097/00000441-200109000-00002; Mannino D. M., 2002, MMWR-MORBID MORTAL W, V51, P1; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Perez-Padilla R, 2006, RESPIR CARE, V51, P1167; Sidney S, 2005, CHEST, V128, P2068, DOI 10.1378/chest.128.4.2068; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; *US BUR CENS, 2000, IND OCC CLASS SYST; Walters JAE, 2006, RESPIROLOGY, V11, P306, DOI 10.1111/j.1440-1843.2006.00842.x; Weinmann S, 2008, J OCCUP ENVIRON MED, V50, P561, DOI 10.1097/JOM.0b013e3181651556; Whitney E, 2008, AM J RESP CRIT CARE, V177, P1172; Zock JP, 2001, AM J RESP CRIT CARE, V163, P1572; 1999, MMWR MORBIDITY MORTA, V48, P993	39	90	94	1	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JAN	2009	64	1					6	12		10.1136/thx.2008.099390		7	Respiratory System	Respiratory System	387CF	WOS:000261928600004	18678700	
J	Wang, CH; Huang, CD; Lin, HC; Lee, KY; Lin, SM; Liu, CY; Huang, KH; Ko, YS; Chung, KF; Kuo, HP				Wang, Chun-Hua; Huang, Chien-Da; Lin, Horng-Chyuan; Lee, Kang-Yun; Lin, Shu-Min; Liu, Chien-Ying; Huang, Kuo-Hsiung; Ko, Yu-Shien; Chung, Kian Fan; Kuo, Han-Pin			Increased circulating fibrocytes in asthma with chronic airflow obstruction	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; fibrocytes; myofibroblasts; transforming growth factor-beta; airway remodeling	PERIPHERAL-BLOOD FIBROCYTES; RETICULAR BASEMENT-MEMBRANE; TISSUE-REPAIR; CELLS; DIFFERENTIATION; EXPRESSION; FIBROSIS; GROWTH; ANGIOGENESIS; INFLAMMATION	Rationale A proportion of patients with asthma present with chronic airflow obstruction (CAO). We hypothesized that this effect may result from increased activity of circulating fibroblast-like progenitor cells (fibrocytes) that could home to the airway mucosal wall. Objectives: To compare the proportion, proliferation, and differentiation of circulating fibrocytes from patients with asthma with CAO or no airflow obstruction (NOA) and control subjects. Methods: We investigated circulating fibrocytes in 11 patients with asthma with CAO and a rapid decline in FEV(1), 9 patients with asthma with NOA, and 10 nonasthmatic control subjects. Blood nonadherent non-T (NANT) cells were incubated with fetal calf serum or each patient's own serum and fibrocytes expressing CD34, CD45, and collagen I with a-smooth muscle actin were identified by flow cytometry. Measurements and Main Results: A higher percentage of circulating fibrocytes in NANT cells was found in patients with CAO when compared with patients with NOA and control subjects. In CAO, the slope of the yearly decline in FEV(1) correlated with circulating fibrocytes (r = -0.756, n = 11, P < 0.01). When NANT cells from patients with CAO were cultured in the patients' own sera, more fibrocytes were detected than when cultured in sera from patients with NOA or from normal subjects. An anti-transforming growth factor (TGF)-beta(1)-neutralizing antibody inhibited a-smooth muscle actin-positive fibrocyte transformation from NANT cells of patients with CAO. Serum TGF-beta(1) levels were higher in patients with CAO than in patients with NOA or in normal subjects. Conclusions: Circulating fibrocytes are increased in patients with asthma with CAO and can be transformed by TGF-beta(1) to myofibroblasts. Fibrocytes may contribute to airway obstruction in asthma.	[Wang, Chun-Hua; Huang, Chien-Da; Lin, Horng-Chyuan; Lee, Kang-Yun; Lin, Shu-Min; Liu, Chien-Ying; Huang, Kuo-Hsiung; Kuo, Han-Pin] Chang Gung Mem Hosp, Dept Thorac Med, Taipei 10591, Taiwan; [Wang, Chun-Hua; Lin, Horng-Chyuan] Chang Gung Univ, Dept Chinese Med, Tao Yuan, Taiwan; [Huang, Chien-Da; Lee, Kang-Yun; Liu, Chien-Ying; Kuo, Han-Pin] Chang Gung Univ, Dept Med, Tao Yuan, Taiwan; [Ko, Yu-Shien] Chang Gung Mem Hosp, Cardiovasc Div 1, Taipei 10591, Taiwan; [Chung, Kian Fan] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Kuo, HP (reprint author), Chang Gung Mem Hosp, Dept Thorac Med, 199 Tung Hwa N Rd, Taipei 10591, Taiwan.	q8828@ms11.hinet.net		Wang, Chun-Hua/0000-0002-3514-9353			Abe R, 2001, J IMMUNOL, V166, P7556; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Balzar S, 2005, J ALLERGY CLIN IMMUN, V115, P110, DOI 10.1016/j.jaci.2004.09.034; BLANC PD, 1993, CHEST, V104, P1371, DOI 10.1378/chest.104.5.1371; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BUCALA R, 1994, MOL MED, V1, P71; Chesney J, 1997, BIOCHEM SOC T, V25, P520; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; Hartlapp I, 2001, FASEB J, V15, P2215, DOI 10.1096/fj.01-0049com; Hong KM, 2007, J BIOL CHEM, V282, P22910, DOI 10.1074/jbc.M703597200; Hoshino M, 2003, EUR RESPIR J, V21, P804, DOI 10.1183/09031936.03.00082002; Huang J, 1999, AM J RESP CRIT CARE, V160, P725; Ko YS, 2004, CIRCULATION, V109, P1172, DOI 10.1161/01.CIR.0000117233.57190.BD; Kuo HP, 2001, BRIT J PHARMACOL, V134, P1539, DOI 10.1038/sj.bjp.0704389; Marini M, 1996, BIOCHEM BIOPH RES CO, V220, P896, DOI 10.1006/bbrc.1996.0502; Metz CN, 2003, CELL MOL LIFE SCI, V60, P1342, DOI 10.1007/s00018-003-2328-0; Moore BB, 2005, AM J PATHOL, V166, P675, DOI 10.1016/S0002-9440(10)62289-4; Mori L, 2005, EXP CELL RES, V304, P81, DOI 10.1016/j.yexcr.2004.11.011; Murdoch C, 2000, IMMUNOL REV, V177, P175, DOI 10.1034/j.1600-065X.2000.17715.x; Nihlberg K, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-50; Pascual RM, 2005, J ALLERGY CLIN IMMUN, V116, P477, DOI 10.1016/j.jaci.2005.07.011; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Phillips RJ, 2004, J CLIN INVEST, V114, P438, DOI 10.1172/jci200420997; Quan TE, 2004, INT J BIOCHEM CELL B, V36, P598, DOI 10.1016/j.biocel.2003.10.005; Redington AE, 2000, CLIN EXP ALLERGY, V30, P42; Redington AE, 1997, THORAX, V52, P310; Schmidt M, 2003, J IMMUNOL, V171, P380; Torrego A, 2007, THORAX, V62, P307, DOI 10.1136/thx.2006.063487; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, pS514, DOI 10.1016/S0091-6749(00)90053-8; Wang CH, 1999, J ALLERGY CLIN IMMUN, V104, P803; Wang JF, 2007, WOUND REPAIR REGEN, V15, P113, DOI 10.1111/j.1524-475X.2006.00192.x; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631	36	90	91	0	1	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	SEP 15	2008	178	6					583	591		10.1164/rccm.200710-1557OC		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	347RL	WOS:000259158600008	18583572	
J	Marschan, E; Kuitunen, M; Kukkonen, K; Poussa, T; Sarnesto, A; Haahtela, T; Korpela, R; Savilahti, E; Vaarala, O				Marschan, E.; Kuitunen, M.; Kukkonen, K.; Poussa, T.; Sarnesto, A.; Haahtela, T.; Korpela, R.; Savilahti, E.; Vaarala, O.			Probiotics in infancy induce protective immune profiles that are characteristic for chronic low-grade inflammation	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopic; CRP; IgA; IgE; IL-10; oral tolerance; probiotic; regulatory cells	PLACEBO-CONTROLLED TRIAL; ORAL TOLERANCE INDUCTION; COWS MILK ALLERGY; ATOPIC-DERMATITIS; DOUBLE-BLIND; ANTIBODY-RESPONSES; HYGIENE HYPOTHESIS; T-CELLS; CHILDREN; PREVENTION	Background Probiotics are widely studied both in the treatment and prevention of allergic diseases, but their mode of action is poorly known. Objective Our aim was to examine the effect of probiotic bacteria on in vivo cytokine, antibody, and inflammatory responses in allergy-prone infants. Methods In a randomized double-blind study, probiotic bacteria or placebo were given for 1 month before delivery to mothers and for 6 months to infants with a family history of allergy. Plasma samples were analysed for C-reactive protein (CRP), total IgA and IgE, food-specific IgA, IgG, and IgE, IL-2, IL-4, IL-6, IL-10, TNF-alpha, and IFN-gamma. We analysed the associations of immunological and inflammatory parameters at age 6 months with probiotic treatment and allergic phenotype at 2 years. Results Infants receiving probiotic bacteria had higher plasma levels of CRP (P=0.008), total IgA (P=0.016), total IgE (P=0.047), and IL-10 (P=0.002) than infants in the placebo group. Increased plasma CRP level at age 6 months was associated with a decreased risk of eczema [odds ratio (OR) 0.41 [95% confidence interval (CI) 0.17-0.99], P=0.046], and with a decreased risk of allergic disease [OR 0.38 (95% CI 0.16-0.87), P=0.023] at age 2 years, when adjusted with probiotic use. Conclusion The association of CRP with a decreased risk of eczema at 2 years of age in allergy-prone children supports the view that chronic, low-grade inflammation protects from eczema. Probiotic-induced low-grade inflammation was characterized by elevation of IgE, IgA, and IL-10, the changes typically observed in helminth infection-associated induction of regulatory mechanisms. The findings emphasize the role of chronic microbial exposure as an immune modulator protecting from allergy.	[Marschan, E.; Sarnesto, A.; Savilahti, E.] Univ Helsinki, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland; [Kuitunen, M.; Kukkonen, K.; Haahtela, T.] Univ Helsinki, Skin & Allergy Hosp, FIN-00029 Helsinki, Finland; [Poussa, T.] STAT Consulting, Tampere, Finland; [Korpela, R.] Valio Res & Dev, Helsinki, Finland; [Korpela, R.] Univ Helsinki, Inst Biomed, FIN-00029 Helsinki, Finland; [Vaarala, O.] Natl Publ Hlth Inst, Dept Viral Dis & Immunol, Helsinki, Finland	Marschan, E (reprint author), Univ Helsinki, Hosp Children & Adolescents, Haartmaninkatu 8,POB 700, FIN-00029 Helsinki, Finland.	emma.marschan@hus.fi					BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Dreborg S, 1989, ALLERGY S10, V44, P1; Fang H, 2000, FEMS IMMUNOL MED MIC, V29, P47, DOI 10.1016/S0928-8244(00)00187-5; Harris NL, 2006, J IMMUNOL, V177, P6256; HEUMANN D, 1994, INFECT IMMUN, V62, P2715; *INT RHIN MAN WORK, 1994, ALLERGY, V49, pS1; ISOLAURI E, 1995, VACCINE, V13, P310, DOI 10.1016/0264-410X(95)93319-5; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Kukkonen K, 2006, PEDIATR ALLERGY IMMU, V17, P416, DOI 10.1111/j.1399-3038.2006.00420.x; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; Maeda Y, 2001, IMMUNOBIOLOGY, V204, P442, DOI 10.1078/0171-2985-00054; Maizels RM, 2005, CURR OPIN IMMUNOL, V17, P656, DOI 10.1016/j.coi.2005.09.001; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; Miettinen M, 1998, INFECT IMMUN, V66, P6058; *NAT ASTHM ED PREV, 2002, J ALLERGY CLIN IMMUN, V110, pS147; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Rodriguez OL, 2004, J TROP PEDIATRICS, V50, P68, DOI 10.1093/tropej/50.2.68; Rosenfeldt V, 2004, J PEDIATR-US, V145, P612, DOI 10.1016/j.jpeds.2004.06.068; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; Saarinen KM, 1999, J ALLERGY CLIN IMMUN, V104, P1093, DOI 10.1016/S0091-6749(99)70094-1; Sanders ME, 2003, NUTR REV, V61, P91, DOI 10.1301/nr.2003.marr.91-99; SAVILAHTI E, 1993, DIABETES CARE, V16, P984, DOI 10.2337/diacare.16.7.984; STALDER JF, 1993, DERMATOLOGY, V186, P23; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Sudo N, 1997, J IMMUNOL, V159, P1739; Umetsu DT, 2004, NAT MED, V10, P232, DOI 10.1038/nm0304-232; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Vartiainen E, 2002, J ALLERGY CLIN IMMUN, V109, P643, DOI 10.1067/mai.2002.123307; Viljanen M, 2005, J ALLERGY CLIN IMMUN, V115, P1254, DOI 10.1016/j.jaci.2005.03.047; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; Voor T, 2005, CLIN EXP ALLERGY, V35, P153, DOI 10.1111/j.1365-2222.2005.02157.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	40	90	94	1	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2008	38	4					611	618		10.1111/j.1365-2222.2008.02942.x		8	Allergy; Immunology	Allergy; Immunology	275ET	WOS:000254055400009	18266878	
J	Michils, A; Baldassarre, S; Van Muylem, A				Michils, A.; Baldassarre, S.; Van Muylem, A.			Exhaled nitric oxide and asthma control: a longitudinal study in unselected patients	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma control; exhaled nitric oxide; lung function	RANDOMIZED CONTROLLED-TRIAL; GUIDE; QUESTIONNAIRE; EXACERBATIONS; MARKERS; AIR	Controlled studies have shown that monitoring of the exhaled nitric oxide fraction (FeNO) improves asthma management. However, the studies seldom consider the full range of patients seen in clinical practise. In the present study, the ability of FeNO to reflect asthma control over time is investigated in a regular clinical setting, and meaningful FeNO cut-off points and changes are identified. Answers to the Asthma Control Questionnaire and FeNO were recorded at least once in 341 unselected asthma patients. The whole population and subgroups were considered, i.e. both inhaled corticosteroid (ICS)-naive and low or high-to-medium (<= or >500 mu g beclomethasone dipropionate equivalents(.)day(-1)) ICS-dose groups. An FeNo decrease <40% or increase <30% precludes asthma control optimisation or deterioration, respectively (negative predictive value 79 and 82%, respectively). In the present study's low-dose group, a decrease >40% indicated asthma control optimisation (positive predictive value (PPV) 83%). In ICS-naive patients, FeNO >35 ppb predicted asthma control improvement in response to ICS (PPV 68%). In most cases, forced expiratory volume in one second assessments were not useful. In conclusion, in a given patient, exhaled nitric oxide fraction was found to be significantly related to asthma control over time. The overall ability of exhaled nitric oxide fraction to reflect asthma control was reduced in patients using high doses of inhaled corticosteroids. Forced expiratory volume in one second had little additional value in assessing asthma control.	[Michils, A.; Baldassarre, S.; Van Muylem, A.] Erasme Univ Hosp, Chest Dept, B-1070 Brussels, Belgium	Van Muylem, A (reprint author), CUB Erasme, Chest Dept, 808 Route de Lennik, B-1070 Brussels, Belgium.	avmuylem@ulb.ac.be					ALVING K, 1993, EUR RESPIR J, V6, P1368; American Thoracic Society, 2005, AM J RESP CRIT CARE, V171, P912, DOI DOI 10.1164/RCCM.200406-710ST; CRATER SE, 1999, AM RESP CRIT CARE ME, V158, P806; [Anonymous], 1993, EUR RESP J S16, V6, P5; Gelb AF, 2006, CHEST, V129, P1492, DOI 10.1378/chest.129.6.1492; *GLOB IN ASTHM, 2002, NHLBI PUBL; Green RH, 2002, LANCET, V360, P1715, DOI 10.1016/S0140-6736(02)11679-5; Jatakanon A, 1999, THORAX, V54, P108; Jatakanon A, 2000, AM J RESP CRIT CARE, V161, P64; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Juniper EF, 1999, EUR RESPIR J, V14, P902, DOI 10.1034/j.1399-3003.1999.14d29.x; JUNIPER EF, 2006, RESP MED, V73, P296; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406; Lopes C, 2006, J ALLERGY CLIN IMMUN, V117, pS177, DOI 10.1016/j.jaci.2005.12.705; McSharry CP, 2005, J ALLERGY CLIN IMMUN, V116, P88, DOI 10.1016/j.jaci.2005.03.025; Senna G, 2007, ALLERGY, V62, P207, DOI 10.1111/j.1398-9995.2006.01250.x; Shaw DE, 2007, AM J RESP CRIT CARE, V176, P231, DOI 10.1164/rccm.200610-14270C; Silkoff PE, 2005, J ALLERGY CLIN IMMUN, V116, P1249, DOI 10.1016/j.jaci.2005.09.029; Smith AD, 2005, AM J RESP CRIT CARE, V172, P453, DOI 10.1164/rccm.200411-1498OC; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Szefler SJ, 2005, J ALLERGY CLIN IMMUN, V115, P233, DOI 10.1016/j.jaci.2004.11.014; TAYLOR RD, 2006, THORAX, V61, P817; Teeter JG, 1998, CHEST, V113, P272, DOI 10.1378/chest.113.2.272; Travers J, 2007, THORAX, V62, P219, DOI 10.1136/thx.2006.066837; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	30	90	97	0	3	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	MAR	2008	31	3					539	546		10.1183/09031936.00020407		8	Respiratory System	Respiratory System	272RA	WOS:000253876000010	18057062	
J	Schulte, PA; Wagner, GR; Ostry, A; Blanciforti, LA; Icutlip, RG; Krajnak, KM; Luster, M; Munson, AE; O'Callaghan, JP; Parks, CG; Simeonova, PP; Miller, DB				Schulte, Paul A.; Wagner, Gregory R.; Ostry, Aleck; Blanciforti, Laura A.; Icutlip, Robert G.; Krajnak, Kristine M.; Luster, Michael; Munson, Albert E.; O'Callaghan, James P.; Parks, Christine G.; Simeonova, Petia P.; Miller, Diane B.			Work, obesity, and occupational safety and health	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Review							BODY-MASS INDEX; CARDIOVASCULAR RISK-FACTORS; CARPAL-TUNNEL SYNDROME; DIET-INDUCED OBESITY; PHYSICAL-ACTIVITY; FAT DISTRIBUTION; UNITED-STATES; WEIGHT-GAIN; NUTRITION EXAMINATION; PARKINSONS-DISEASE	There is increasing evidence that obesity and overweight may be related, in part, to adverse work conditions. In particular, the risk of obesity may increase in high-demand, low-control work environments, and for those who work long hours. In addition, obesity may modify the risk for vibration-induced injury and certain occupational musculoskeletal disorders. We hypothesized that obesity may also be a co-risk factor for the development of occupational asthma and cardiovascular disease that and it may modify the worker's response to occupational stress, immune response to chemical exposures, and risk of disease from occupational neurotoxins. We developed 5 conceptual models of the interrelationship of work, obesity, and occupational safety and health and highlighted the ethical, legal, and social issues related to fuller consideration of obesity's role in occupational health and safety.	NIOSH, Educ & Informat Div, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA; Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Schulte, PA (reprint author), NIOSH, Educ & Informat Div, Ctr Dis Control & Prevent, 4676 Columbia Pkwy, Cincinnati, OH 45226 USA.	pas4@cdc.gov	O'Callaghan, James/O-2958-2013	Parks, Christine/0000-0002-5734-3456			Abbott RD, 2002, NEUROLOGY, V59, P1051; ALBANES D, 1987, Nutrition and Cancer, V9, P199; Aldana SG, 2001, J OCCUP ENVIRON MED, V43, P36, DOI 10.1097/00043764-200101000-00009; AYDIN N, 2003, TURKISH J SURG, V19, P133; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; BARBEAU EM, 2004, PREV CHRONIC DIS JUL; Baur X, 1998, AM J IND MED, V33, P114; Bernard B.P., 1997, DHHS NIOSH PUBLICATI, V97B141; Bhatia J Y, 2003, Indian J Med Microbiol, V21, P246; Bhattacherjee A, 2003, J OCCUP HEALTH, V45, P382, DOI 10.1539/joh.45.382; Brisson C, 2000, J OCCUP ENVIRON MED, V42, P40, DOI 10.1097/00043764-200001000-00011; Brown Norman DePaul, 2003, AAOHN J, V51, P470; Bungum T, 2003, AM J HEALTH BEHAV, V27, P456; Burton W N, 1999, Bus Health, V17, P34; Burton WN, 1998, J OCCUP ENVIRON MED, V40, P786, DOI 10.1097/00043764-199809000-00007; CARNARGO CA, 1999, ARCH INTERN MED, V159, P2582; Carr D, 2005, J HEALTH SOC BEHAV, V46, P244; CASSELL JA, 1995, J AM DIET ASSOC, V95, P424, DOI 10.1016/S0002-8223(95)00114-X; CHAU N, 2004, J OCCUP HEALTH, V465, P272; Chen Y, 2002, AM J EPIDEMIOL, V155, P191, DOI 10.1093/aje/155.3.191; CHENOWETH D, 2004, OB BUILT ENV IMPR PU; Chung NK, 1996, MIL MED, V161, P739; Collins S, 2004, PHYSIOL BEHAV, V81, P243, DOI 10.1016/j.physbeh.2004.02.006; *CTR MED MED SERV, 2004, MM3502 CTR MED MED S; DEJOY DM, 1993, J OCCUP ENVIRON MED, V35, P1221; Di Lorenzo L, 2003, INT J OBESITY, V27, P1353, DOI 10.1038/sj.ijo.0802419; Dirx MJM, 2003, INT J CANCER, V106, P766, DOI 10.1002/ijc.11277; Drewnowski A, 2004, AM J CLIN NUTR, V79, P6; Edwards M, 1996, AVIAT SPACE ENVIR MD, V67, P1144; Egger G, 2003, Obes Rev, V4, P115, DOI 10.1046/j.1467-789X.2003.00100.x; Epel ES, 2000, PSYCHOSOM MED, V62, P623; FINE LJ, 2005, TXB CLIN OCCUPATIONA, P563; Flegal KM, 2002, JAMA-J AM MED ASSOC, V288, P1723, DOI 10.1001/jama.288.14.1723; Froom P, 1996, OCCUP ENVIRON MED, V53, P832; Geliebter A, 2000, NUTRITION, V16, P27, DOI 10.1016/S0899-9007(99)00228-2; GEORGES E, 1992, AM J HUM BIOL, V4, P657, DOI 10.1002/ajhb.1310040512; Griffin M., 1990, HDB HUMAN VIBRATION; Hayne CL, 2004, J PUBLIC HEALTH POL, V25, P391, DOI 10.1057/palgrave.jphp.3190038; Hellerstedt WL, 1997, INT J EPIDEMIOL, V26, P575, DOI 10.1093/ije/26.3.575; HENSCHEL A, 1967, C J PUBLIC HEALTH, V58, P491; Hill JO, 2003, SCIENCE, V299, P853, DOI 10.1126/science.1079857; Holmberg S, 2005, SCAND J RHEUMATOL, V34, P59, DOI 10.1080/03009740510017922; HOUSE JS, 1986, J HEALTH SOC BEHAV, V27, P62, DOI 10.2307/2136503; Hsiao HW, 2003, ERGONOMICS, V46, P1233, DOI 10.1080/00140130310001593595; Hsiao HW, 2002, ERGONOMICS, V45, P136, DOI 10.1080/00140130110115372; Ilmarinen Raija, 2004, Int J Occup Saf Ergon, V10, P215; *INS INF I, OB LIAB INS; JAYO JM, 1993, INT J OBESITY, V17, P597; Jedrychowski W, 2001, Cent Eur J Public Health, V9, P126; Jedrychowski W, 1998, PUBLIC HEALTH, V112, P189, DOI 10.1038/sj.ph.1900438; Jonsson D, 1999, J CARDIOVASC RISK, V6, P379; Theorell Tores, 2000, OCCUP MED, V15, P78; Katz David L., 2005, Morbidity and Mortality Weekly Report, V54, P1; KNUTSSON A, 1992, WORK STRESS, V6, P163, DOI 10.1080/02678379208260350; Koleva M, 2003, Cent Eur J Public Health, V11, P9; KORNITZER M, 1986, POSTGRAD MED J, V62, P695; Kortt Michael, 2002, Aust Health Rev, V25, P207; Kritchevsky D, 1986, Adv Exp Med Biol, V206, P55; Kuczmarski RJ, 2000, AM J CLIN NUTR, V72, P1074; La Cava Antonio, 2003, Curr Opin Investig Drugs, V4, P1327; Laitinen J, 2002, INT J OBESITY, V26, P1329, DOI 10.1038/sj.ijo.08021314; Leigh JP, 2000, COSTS OCCUPATIONAL I; LICHTENSTEIN MJ, 1989, AM J MED SCI, V297, P233; Logroscino G, 1996, ANN NEUROL, V39, P89, DOI 10.1002/ana.410390113; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; LUSTER MI, 1993, FUND APPL TOXICOL, V21, P71, DOI 10.1006/faat.1993.1074; Marcos A, 2003, EUR J CLIN NUTR, V57, pS66, DOI 10.1038/cj.ejcn.1601819; MARONEY D, 1992, PERCEPT MOTOR SKILL, V75, P387; Marszalek Anna, 2004, Int J Occup Saf Ergon, V10, P361; Martikainen PT, 1999, AM J CLIN NUTR, V69, P719; Mayeux R, 1999, NEUROLOGY, V52, pA296; McEwen BS, 2005, METABOLISM, V54, P20, DOI 10.1016/j.metabol.2005.01.008; Mead MN, 2004, ENVIRON HEALTH PERSP, V112, pA344; Miller DB, 2005, AGEING RES REV, V4, P123, DOI 10.1016/j.arr.2005.03.002; Miranda H, 2001, OCCUP ENVIRON MED, V58, P528, DOI 10.1136/oem.58.8.528; Mito N, 2002, METABOLISM, V51, P1241, DOI 10.1053/meta.2002.35196; Mock CN, 2002, ACCIDENT ANAL PREV, V34, P221, DOI 10.1016/S0001-4575(01)00017-3; Mokdad AH, 2000, JAMA-J AM MED ASSOC, V284, P1650, DOI 10.1001/jama.284.13.1650; Moorman AM, 2005, ACSMS HEALTH FIT J, V9, P29; Moreau M, 2004, INT J OBESITY, V28, P574, DOI 10.1038/sj.ijo.0802600; NETTERSTROM B, 1991, BRIT J IND MED, V48, P684; Neumark-Sztainer D, 1999, J NUTR EDUC, V31, P3, DOI 10.1016/S0022-3182(99)70378-X; Niedhammer I, 1996, INT J OBESITY, V20, P625; Health effects of occupational exposure to respirable crystalline silica, NIOSH PUBL, V2002-129; NRC (National Research Council and the Institute of Medicine), 2001, MUSC DIS WORKPL LOW; Nystad W, 2004, AM J EPIDEMIOL, V160, P969, DOI 10.1093/aje/kwh303; OLSEN O, 1991, J EPIDEMIOL COMMUN H, V45, P4, DOI 10.1136/jech.45.1.4; Ostry AS, 2006, BMC PUBLIC HEALTH, V6, DOI 10.1186/1471-2458-6-53; OTTMAN R, 1990, GENET EPIDEMIOL, V7, P177, DOI 10.1002/gepi.1370070302; Paul R. J., 1995, EMPLOYEE RESPONSIBIL, V8, P133, DOI [10.1007/BF02621279, DOI 10.1007/BF02621279]; Perbellini L, 2004, Med Lav, V95, P211; Petro AE, 2004, METABOLISM, V53, P454, DOI 10.1016/j.metabol.2003.11.018; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Poulain M, 2006, CAN MED ASSOC J, V174, P1293, DOI 10.1503/cmaj.051299; PRIMACK A, 2002, OBES RES S, V1, pS82; Pronk NP, 2004, J OCCUP ENVIRON MED, V46, P19, DOI 10.1097/01.jom.0000105910.69449.b7; Puhl Rebecca, 2003, Eat Behav, V4, P53, DOI 10.1016/S1471-0153(02)00096-X; REED DM, 1989, AM J EPIDEMIOL, V129, P495; RISSANEN A, 1990, BRIT MED J, V301, P835; Rivera-Sanchez YM, 2004, J APPL PHYSIOL, V96, P2200, DOI 10.1152/japplphysiol.00960.2003; Roehling MV, 1999, PERS PSYCHOL, V52, P969, DOI 10.1111/j.1744-6570.1999.tb00186.x; Roquelaure Y, 2001, Int J Occup Med Environ Health, V14, P357; Rosmond R, 1999, INT J OBESITY, V23, P138, DOI 10.1038/sj.ijo.0800782; Schmier JK, 2006, SCAND J WORK ENV HEA, V32, P5; Schulte PA, 2005, J OCCUP ENVIRON MED, V47, P607, DOI 10.1097/01.jom.0000165086.25595.9d; Shaheen SO, 1999, THORAX, V54, P396; Shields M, 1999, Health Rep, V11, P33; Siegrist J., 2000, OCCUPATIONAL MED STA, V15, P83; Simeonova PP, 2004, TOXICOL APPL PHARM, V198, P444, DOI 10.1016/j.taap.2003.10.018; Simeonova PP, 2003, ENVIRON HEALTH PERSP, V111, P1744, DOI 10.1289/ehp.6332; Snijder MB, 2006, INT J EPIDEMIOL, V35, P83, DOI 10.1093/ije/dyi253; Sorensen G, 2006, Med Lav, V97, P240; Sorensen G, 2005, AM J PUBLIC HEALTH, V95, P1389, DOI 10.2105/AJPH.2004.038745; Sriram K, 2002, NEUROSCIENCE, V115, P1335, DOI 10.1016/S0306-4522(02)00306-8; Steenland K, 2003, AM J IND MED, V43, P461, DOI 10.1002/ajim.10216; STOOHS RA, 1994, SLEEP, V17, P619; Stoyneva Z, 2003, CARDIOVASC RES, V57, P615, DOI 10.1016/S0008-6363(02)00728-9; Sturm R, 2002, HEALTH AFFAIR, V21, P245, DOI 10.1377/hlthaff.21.2.245; Sturm R, 2001, PUBLIC HEALTH, V115, P229, DOI 10.1016/S0033-3506(01)00449-8; Suadicani P, 2002, J CARDIOVASC RISK, V9, P191, DOI 10.1097/00043798-200208000-00003; Swinburn B, 2002, Obes Rev, V3, P289, DOI 10.1046/j.1467-789X.2002.00082.x; Tanaka S, 1997, AM J IND MED, V32, P550, DOI 10.1002/(SICI)1097-0274(199711)32:5<550::AID-AJIM18>3.3.CO;2-H; TILLETT S, 1993, AM J IND MED, V23, P143, DOI 10.1002/ajim.4700230120; Tsai SP, 2006, J OCCUP ENVIRON MED, V48, P22, DOI 10.1097/01.jom.0000184866.49000.e5; Tucker LA, 1998, AM J HEALTH PROMOT, V12, P202; TURNER N, 1999, INT SOC RESP PROT C; van Amelsvoort LGMP, 1999, INT J OBESITY, V23, P973, DOI 10.1038/sj.ijo.0801028; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; von Mutius E, 2001, THORAX, V56, P835, DOI 10.1136/thorax.56.11.835; Waage HP, 1997, AM J IND MED, V31, P705; Walker-Bone KE, 2003, SEMIN ARTHRITIS RHEU, V33, P185, DOI 10.1016/S0049-0172(03)00128-8; Walters GA, 2002, OBES RES, V10, p84S, DOI 10.1038/oby.2002.197; Wamala SP, 1997, PREV MED, V26, P734, DOI 10.1006/pmed.1997.0199; Wang FF, 2004, J OCCUP ENVIRON MED, V46, P428, DOI 10.1097/01.jom.0000126022.25149.bf; Wardle J, 2000, J PSYCHOSOM RES, V48, P195, DOI 10.1016/S0022-3999(00)00076-3; WHITTINGTON G, 2005, MON LAB REV      JAN, P28; World Health Organization, 2002, WORLD HLTH REP 2002; World Health Organization, 1998, OB PREV MAN GLOB EP; WIESLANDER G, 1989, BRIT J IND MED, V46, P43; Wisse BE, 2004, J AM SOC NEPHROL, V15, P2792, DOI 10.1097/01.ASN.0000141966.69934.21; Wolf AM, 1998, OBES RES, V6, P97; Xu BZ, 2002, EUR J PUBLIC HEALTH, V12, P166, DOI 10.1093/eurpub/12.3.166; Yamada Y, 2002, J OCCUP HEALTH, V44, P373, DOI 10.1539/joh.44.373; Yamada Y, 2001, SCAND J WORK ENV HEA, V27, P318; Yancey AK, 2004, PREV MED, V38, P848, DOI 10.1016/j.ypmed.2003.12.019; YOUNG LM, 1985, J HEALTH SOC BEHAV, V26, P233, DOI 10.2307/2136755; 2000, FED REG, V65, P31039	147	90	94	0	19	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	MAR	2007	97	3					428	436		10.2105/AJPH.2006.086900		9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	142GD	WOS:000244636500016	17267711	
J	Maneechotesuwan, K; Xin, Y; Ito, K; Jazrawi, E; Lee, KY; Usmani, OS; Barnes, PJ; Adcock, IM				Maneechotesuwan, Kittipong; Xin, Yao; Ito, Kazuhiro; Jazrawi, Elen; Lee, Kang-Yun; Usmani, Omar S.; Barnes, Peter J.; Adcock, Ian M.			Regulation of Th2 cytokine genes by p38 MAPK-mediated phosphorylation of GATA-3	JOURNAL OF IMMUNOLOGY			English	Article							ACTIVATED PROTEIN-KINASE; NUCLEAR-LOCALIZATION SEQUENCE; CD4(+) T-CELLS; AIRWAY INFLAMMATION; SIGNAL INTEGRATION; IL-4 PRODUCTION; EXPRESSION; ASTHMA; LYMPHOCYTES; INHIBITION	GATA-3 plays a critical role in allergic diseases by regulating the release of cytokines from Th2 lymphocytes. However, the molecular mechanisms involved in the regulation of GATA-3 in human T lymphocytes are not yet understood. Using small interfering RNA to knock down GATA-3, we have demonstrated its critical role in regulating IL-4, IL-5, and IL-13 release from a human T cell line. Specific stimulation of T lymphocytes by costimulation of CD3 and CD28 to mimic activation by APCs induces translocation of GATA-3 from the cytoplasm to the nucleus, with binding to the promoter region of Th2 cytokine genes, as determined by chromatin immunoprecipitation. GATA-3 nuclear translocation is dependent on its phosphorylation on serine residues by p38 MAPK, which facilitates interaction with the nuclear transporter protein importin-a. This provides a means whereby allergen exposure leads to the expression of Th2 cytokines, and this novel mechanism may provide new approaches to treating allergic diseases.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Airway Dis, London SW3 6LY, England	Barnes, PJ (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Sect Airway Dis, Dovehouse St, London SW3 6LY, England.	p.j.barnes@imperial.ac.uk		Adcock, Ian/0000-0003-2101-8843			Barnes PJ, 2006, PHARMACOL THERAPEUT, V109, P238, DOI 10.1016/j.pharmthera.2005.08.001; Barnes PJ, 2004, NAT REV DRUG DISCOV, V3, P831, DOI 10.1038/nrd1524; Caramori G, 2001, EUR RESPIR J, V18, P466, DOI 10.1183/09031936.01.00040701; Chen CH, 2000, J IMMUNOL, V165, P5597; Chialda L, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-36; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Duan W, 2005, AM J RESP CRIT CARE, V171, P571, DOI 10.1164/rccm.200408; England Karen, 2003, Methods Mol Biol, V233, P217; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Goldfarb DS, 2004, TRENDS CELL BIOL, V14, P505, DOI 10.1016/j.tcb.2004.07.016; GOOTENBERG JE, 1981, J EXP MED, V154, P1403, DOI 10.1084/jem.154.5.1403; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2001, J BIOL CHEM, V276, P30208, DOI 10.1074/jbc.M103604200; Ito K, 2001, FASEB J, V15, P1100; Koprak S, 1999, CELL IMMUNOL, V192, P87, DOI 10.1006/cimm.1998.1448; Lavenu-Bombled C, 2002, J BIOL CHEM, V277, P18313, DOI 10.1074/jbc.M110013200; Lee CY, 2001, J SCHED, V4, P3, DOI 10.1002/1099-1425(200101/02)4:1<3::AID-JOS57>3.0.CO;2-D; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Mori A, 1999, J IMMUNOL, V163, P4763; Nakamura Yutaka, 2005, Current Drug Targets - Inflammation and Allergy, V4, P267, DOI 10.2174/1568010053586273; Nunes JA, 1996, MOL IMMUNOL, V33, P63, DOI 10.1016/0161-5890(95)00121-2; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Pahl A, 2002, BRIT J PHARMACOL, V135, P1915, DOI 10.1038/sj.bjp.0704656; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Salmon RA, 1997, J IMMUNOL, V159, P5309; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Schafer PH, 1999, J IMMUNOL, V162, P7110; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; Staples KJ, 2000, BIOCHEM BIOPH RES CO, V273, P811, DOI 10.1006/bbrc.2000.3023; STOCHAJ U, 1992, EUR J CELL BIOL, V59, P1; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Takemoto N, 2002, J IMMUNOL, V169, P4103; Torgerson TR, 1998, J IMMUNOL, V161, P6084; Underwood DC, 2000, J PHARMACOL EXP THER, V293, P281; Xiao CY, 1997, J BIOL CHEM, V272, P22191, DOI 10.1074/jbc.272.35.22191; Yagi R, 2002, INT IMMUNOL, V14, P1, DOI 10.1093/intimm/14.1.1; Yamane H, 2005, J EXP MED, V202, P793, DOI 10.1084/jem.20051304; Yamashita M, 2004, J BIOL CHEM, V279, P26983, DOI 10.1074/jbc.M403688200; YANG ZY, 1994, MOL CELL BIOL, V14, P2201; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhu JF, 2004, NAT IMMUNOL, V5, P1157, DOI 10.1038/ni1128	44	90	100	1	3	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	FEB 15	2007	178	4					2491	2498				8	Immunology	Immunology	133QF	WOS:000244026800059	17277157	
J	de Haar, C; Hassing, I; Bol, M; Bleumink, R; Pieters, R				de Haar, C.; Hassing, I.; Bol, M.; Bleumink, R.; Pieters, R.			Ultrafine but not fine particulate matter causes airway inflammation and allergic airway sensitization to co-administered antigen in mice	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						adjuvant; airway; allergic; inflammation; intranasal; mouse; particulate matter; sensitization; ultrafine particles	DIESEL EXHAUST PARTICLES; CARBON-BLACK PARTICLES; ADJUVANT ACTIVITY; POLLEN ALLERGENS; TRANSITION-METALS; AMBIENT PARTICLES; OXIDATIVE STRESS; DENDRITIC CELLS; IGE PRODUCTION; IN-VITRO	Background Airborne particulate matter (PM) is an important factor associated with the enhanced prevalence of respiratory allergy. The PM adjuvant activity on allergic sensitization is a possible mechanism of action involved, and the induction of airway inflammation is suggested to be of importance in PM-induced adjuvant activity. Objective Because differently sized PM have different toxic potentials, we studied the role of particle size in the induction of airway inflammation and allergic sensitization. This was done using fine (0.250 and 0.260 mu m) and ultrafine (0.029 and 0.014 mu m) titanium dioxide (TiO2) and carbon black particles (CBP) with known differences in airway toxicity. Methods Mice were intranasally exposed to ovalbumin (OVA) alone or in combination with one of the different particles. The induction of airway inflammation and the immune adjuvant activity were studied in the lungs and lung-draining peribronchial lymph nodes (PBLN) at day 8. OVA-specific antibodies were measured at day 21, and the development of allergic airway inflammation was studied after OVA challenges (day 28). Results When administered at the same total particle mass (200 mu g), exposure to ultrafine TiO2 and CBP-induced airway inflammation, and had immune adjuvant activity. The latter was shown by increasing both the PBLN cell numbers and the production of OVA-specific T-helper type 2 (Th2) cytokines (IL-4, IL-5, IL-10 and IL-13). Whereas OVA-specific IgE and IgG1 levels in serum were only increased in animals exposed to the ultrafine TiO2, allergic airway inflammation could be detected in both ultrafine TiO2- and CBP-treated groups after challenges with OVA. Conclusion Our data show that only the ultrafine particles, with a small diameter and a large total surface area/mass, cause airway inflammation and have immune adjuvant activity in the current model supporting the hypothesis that particle toxicity is site-dependent and related to adjuvant activity.	Univ Utrecht, Inst Risk Assessment Sci, Dept Immunotoxicol, NL-3508 TC Utrecht, Netherlands	de Haar, C (reprint author), Erasmus MC, Div Gastroenterol & Nutr, Pediat Lab, Ee 1571,Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.	c.dehaar@erasmusmc.nl					AMATO GD, 1998, PULM PHARMACOL THER, V11, P369; AMATO GD, 2002, ALLERGY S7I, V57, P30; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Bevan D R, 1985, Toxicol Ind Health, V1, P57; Borm PJA, 2005, TOXICOL APPL PHARM, V205, P157, DOI 10.1016/j.taap.2004.10.020; Brown DM, 2004, AM J PHYSIOL-LUNG C, V286, pL344, DOI 10.1152/ajplung.00139.2003; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Brown DM, 2000, OCCUP ENVIRON MED, V57, P685, DOI 10.1136/oem.57.10.685; Chvatchko Y, 1996, J EXP MED, V184, P2353, DOI 10.1084/jem.184.6.2353; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; de Haar C, 2005, TOXICOL SCI, V87, P409, DOI 10.1093/toxsci/kfi255; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; DiazSanchez D, 1997, ALLERGY, V52, P52; Elder ACP, 2000, INHAL TOXICOL, V12, P227, DOI 10.1080/089583700750019585; Englert N, 2004, TOXICOL LETT, V149, P235, DOI 10.1016/j.toxlet.2003.12.035; Foged C, 2005, INT J PHARM, V298, P315, DOI 10.1016/j.ijpharm.2005.03.035; Ford JG, 2001, J IMMUNOL, V167, P1769; FUJIMAKI H, 1994, TOXICOLOGY, V92, P261, DOI 10.1016/0300-483X(94)90182-1; Gallucci S, 2001, CURR OPIN IMMUNOL, V13, P114, DOI 10.1016/S0952-7915(00)00191-6; Gilmour PS, 2004, TOXICOL APPL PHARM, V195, P35, DOI 10.1016/j.taap.2003.10.003; Granum B, 2002, TOXICOL SCI, V65, P7, DOI 10.1093/toxsci/65.1.7; Greenwell LL, 2002, FREE RADICAL BIO MED, V32, P898, DOI 10.1016/S0891-5849(02)00782-7; Gupta RK, 1998, ADV DRUG DELIVER REV, V32, P155, DOI 10.1016/S0169-409X(98)00008-8; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 2000, AM J RESP CELL MOL, V23, P327; Hofstra CL, 1999, INFLAMM RES, V48, P602, DOI 10.1007/s000110050510; Johnson RL, 2004, CIRCULATION, V109, P5, DOI 10.1161/01.CIR.0000110643.19575.79; Korsgren M, 1997, J EXP MED, V185, P885, DOI 10.1084/jem.185.5.885; KUBO S, 2003, J IMMUNOL, V17, P775; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Lambert AL, 2000, TOXICOL APPL PHARM, V165, P84, DOI 10.1006/taap.2000.8932; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Maejima K, 1997, J TOXICOL ENV HEALTH, V52, P231, DOI 10.1080/009841097159674; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; Nightingale JA, 2000, AM J RESP CRIT CARE, V162, P161; Nilsen A, 1997, TOXICOLOGY, V124, P225, DOI 10.1016/S0300-483X(97)00150-9; Peters A, 1997, EUR RESPIR J, V10, P872; Peterson B, 1996, ANN ALLERG ASTHMA IM, V77, P263; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Renwick LC, 2004, OCCUP ENVIRON MED, V61, P442, DOI 10.1136/oem.2003.008227; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633; Schaumann F, 2004, AM J RESP CRIT CARE, V170, P898, DOI 10.1164/rccm.200403-423OC; Steerenberg PA, 2003, J TOXICOL ENV HEAL A, V66, P1421, DOI 10.1080/15287390390202054; Tumas DB, 2001, J ALLERGY CLIN IMMUN, V107, P1025, DOI 10.1067/mai.2001.115625; Van Rijt LS, 2001, MICROSC RES TECHNIQ, V53, P256, DOI 10.1002/jemt.1092; Whitekus MJ, 2002, J IMMUNOL, V168, P2560; Wilson MR, 2002, TOXICOL APPL PHARM, V184, P172, DOI 10.1006/taap.2002.9501; Zielinski H, 1999, AM J PHYSIOL-LUNG C, V277, pL719	50	90	92	0	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2006	36	11					1469	1479		10.1111/j.1365-2222.2006.02586.x		11	Allergy; Immunology	Allergy; Immunology	101IK	WOS:000241734300016	17083358	
J	Fritsch, M; Uxa, S; Horak, F; Putschoegl, B; Dehlink, E; Szepfalusi, Z; Frischer, T				Fritsch, Maria; Uxa, Sabine; Horak, Friedrich, Jr.; Putschoegl, Bettina; Dehlink, Eleonora; Szepfalusi, Zsoit; Frischer, Thomas			Exhaled nitric oxide in the management of childhood asthma: A prospective 6-months study	PEDIATRIC PULMONOLOGY			English	Article						airway inflammation; childhood asthma; fractional exhaled nitric oxide; exhaled air; exacerbations; inhaled corticosteroids	DOSE-RESPONSE RELATIONSHIP; CHILDREN; HEALTHY; REPRODUCIBILITY; RECOMMENDATIONS; REDUCTION; THERAPY; ADULTS; AIR	Fractional exhaled nitric oxide (FeNO) is elevated in asthma and reflects eosinophilic airway inflammation. The aim of this prospective, randomized, single-blind study was to examine whether the inclusion of repeated FeNO measurements into asthma monitoring leads to an improvement in asthma outcome. Forty-seven children with mild to moderate asthma were allocated to a FeNO group (n = 22) and to a control group (n = 25). In the FeNO group therapy was based on symptoms, beta-agonist use, lung function, and FeNO whereas in the control group therapy was based on symptoms, beta-agonist use and lung function only Patients performed five visits in 6 weeks intervals. Frequency of respiratory symptoms, beta-agonist use, FEV1% predicted and the frequency of exacerbations were similar between groups. Patients in the FeNO group received higher doses of inhaled corticosteroids (ICS) (control group: median (interquartile range): 241 mu g (26-607 mu g); FeNo group: 316 mu g (200-500 mu g) and had significantly higher MEF,50% predicted (control group: median (interquartile range): 68.5% (55.8-83.1%); FeNO group: 83.2% (62.9%-98.3%). At a cut-off point of 22.9 ppb FeNO the best predictive value for exacerbations with a sensitivity of 80% and specificity of 60% was found. Significant relationships were observed between FeNO and dose of ICS (beta = 8.77; P < 0.002), beta-agonist use 2 weeks prior to a visit (beta = 0.11; P < 0.05), asthma symptoms (beta = 0.02; P < 0.0001), and bronchial hyperresponsiveness (beta = 0.04; P = 0.02). In conclusion, FeNO was related to important markers of asthma control. A therapy regimen aimed at lowering FeNO in children with asthma improved parameters of small airway function, but was not able to improve clinical markers of asthma control.	Univ Vienna, Childrens Hosp, Dept Gen Paediat, A-1090 Vienna, Austria	Frischer, T (reprint author), Univ Vienna, Childrens Hosp, Dept Gen Paediat, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	thomas.frischer@meduniwien.ac.at		Fritsch, Maria/0000-0001-5304-673X			American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Bratton DL, 1999, PEDIATR PULM, V28, P402, DOI 10.1002/(SICI)1099-0496(199912)28:6<402::AID-PPUL3>3.0.CO;2-V; Buchvald F, 2005, J ALLERGY CLIN IMMUN, V115, P1130, DOI 10.1016/j.jaci.2005.03.020; Covar RA, 2003, J PEDIATR-US, V142, P469, DOI 10.1067/mpd.2003.187; Franklin PJ, 1999, AM J RESP CRIT CARE, V159, P69; Frischer T, 1999, WIEN KLIN WOCHENSCHR, V111, P900; Horak F, 2002, EUR RESPIR J, V19, P838, DOI 10.1183/09031936.02.00512001; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Jones SL, 2002, EUR RESPIR J, V20, P601, DOI 10.1183/09031936.02.00285302; Kharitonov SA, 2003, EUR RESPIR J, V21, P433, DOI 10.1183/09031936.03.00066903; Kharitonov SA, 2002, THORAX, V57, P889, DOI 10.1136/thorax.57.10.889; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; Leuppi JD, 2001, AM J RESP CRIT CARE, V163, P406; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Pijnenburg MW, 2005, THORAX, V60, P215, DOI 10.1136/thx.2004.023374; PIJNENBURG MW, 2005, AM J RESP CRIT CARE, V173, P831; Pijnenburg MWH, 2005, CLIN EXP ALLERGY, V35, P920, DOI 10.1111/j.1365-2222.2005.02279.x; RIEDLER J, 1994, AM J RESP CRIT CARE, V150, P1632; Silkoff PE, 2001, CHEST, V119, P1322, DOI 10.1378/chest.119.5.1322; Silvestri M, 2001, THORAX, V56, P857, DOI 10.1136/thorax.56.11.857; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Smith AD, 2005, NEW ENGL J MED, V352, P2163, DOI 10.1056/NEJMoa043596; Sont JK, 1996, THORAX, V51, P496, DOI 10.1136/thx.51.5.496; WALLS AF, 1992, CLIN EXP ALLERGY, V22, P1, DOI 10.1111/j.1365-2222.1992.tb00106.x; Zacharasiewicz A, 2005, AM J RESP CRIT CARE, V171, P1077, DOI 10.1164/rccm.200409-1242OC; ZAPLETAL A, 1987, LUNG FUNCTION CHILDR, P174	27	90	94	0	1	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	SEP	2006	41	9					855	862		10.1002/ppul.20455		8	Pediatrics; Respiratory System	Pediatrics; Respiratory System	077NC	WOS:000240035300008	16850457	
J	Hales, BJ; Martin, AC; Pearce, LJ; Laing, IA; Hayden, CM; Goldblatt, J; Le Souef, PN; Thomas, WR				Hales, Belinda J.; Martin, Andrew C.; Pearce, Leigh J.; Laing, Ingrid A.; Hayden, Catherine M.; Goldblatt, Jack; Le Souef, Peter N.; Thomas, Wayne R.			IgE and IgG anti-house dust mite specificities in allergic disease	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						house dust mite allergens; IgE; IgG(4); IgG(1); asthma	MODIFIED TH2 RESPONSE; DERMATOPHAGOIDES-PTERONYSSINUS; CHILDREN; ASTHMA; ANTIBODIES; EXTRACT; DER-P-2; BINDING; POPULATION; CHILDHOOD	Background: There are few studies that quantitatively compare IgE and IgG antibody binding to the major and minor house dust mite allergens. Objective: To measure the IgE and IgG antibody specificities produced by adults and children, including children admitted to an emergency department for asthma. Methods: Antibodies were measured by solid-phase microliter assays. Results: Children recruited from the emergency department had similar titers and patterns of IgE antibody binding compared with children without acute disease. Der p 1 and 2 bound 50 % to 65 % of the IgE antibody, and most of the remaining binding was to Der p 4, 5, and 7. Der p 3, 8, 10, and 20 induced low titers. The pattern was similar across a wide range of antibouse.dust mite titers. IgG(1) and IgG(4) antibodies predominantly bound the major and midrange allergens and were mainly found in children with allergy. Children recruited in the emergency department had lower titers. Conclusion: The same IgE antibody-binding pattern and predominant contribution of Der p 1 and 2 was found across a wide range of total IgE antibody titers and for children admitted to an emergency department. IgG, and IgG(4) antibodies bound to the more allergenic specificities and were largely found in children with allergy. The IgG antibody titers were lower in sera from children admitted to the emergency department for asthma exacerbations. Clinical implications: Der p 1 and 2 and possibly Der p 4, 5, and 7 provide a formulation suitable for immunotherapy and diagnosis. Low IgG antibodies were a feature of acute disease.	Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Mol Biotechnol, Subiaco, WA 6008, Australia; Univ Western Australia, Sch Paediat & Child Hlth, Nedlands, WA 6009, Australia	Hales, BJ (reprint author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Div Mol Biotechnol, 100 Roberts Rd, Subiaco, WA 6008, Australia.	belinda@ichr.uwa.edu.au	Hales, Belinda/C-3858-2013; Laing, Ingrid/I-7092-2013	Hales, Belinda/0000-0003-2193-3996; Laing, Ingrid/0000-0002-1641-9899			Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; CHAPMAN MD, 1978, CLIN EXP IMMUNOL, V34, P126; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P1029, DOI 10.1016/j.jaci.2004.12.1131; Hales BJ, 2004, INT ARCH ALLERGY IMM, V135, P101, DOI 10.1159/000080652; Heaton T, 2005, LANCET, V365, P142, DOI 10.1016/S0140-6736(05)17704-6; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; O'Brien RM, 2000, CLIN EXP ALLERGY, V30, P333; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Pittner G, 2004, CLIN EXP ALLERGY, V34, P597, DOI 10.1111/j.1365-2222.2004.1930.x; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Satinover SM, 2005, J ALLERGY CLIN IMMUN, V115, P803, DOI 10.1016/j.jaci.2005.01.018; Schuurman J, 1997, CLIN EXP ALLERGY, V27, P1095, DOI 10.1111/j.1365-2222.1997.tb01262.x; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Smith AM, 1998, CLIN IMMUNOL IMMUNOP, V86, P102, DOI 10.1006/clin.1997.4454; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Thomas WR, 2002, INT ARCH ALLERGY IMM, V129, P1, DOI 10.1159/000065179; Trombone APF, 2002, CLIN EXP ALLERGY, V32, P1323, DOI 10.1046/j.1365-2745.2002.01455.x; Van Der Veen MJ, 2001, CLIN EXP ALLERGY, V31, P705, DOI 10.1046/j.1365-2222.2001.01120.x; VANDERHEIJDEN FL, 1995, CLIN EXP IMMUNOL, V99, P289; Weghofer M, 2005, CLIN EXP ALLERGY, V35, P1384, DOI 10.1111/j.1365-2222.2005.02345.x	23	90	97	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					361	367		10.1016/j.jaci.2006.04.001		7	Allergy; Immunology	Allergy; Immunology	075IH	WOS:000239877700010	16890759	
J	Bousquet, J; Anto, JM; Bachert, C; Bousquet, PJ; Colombo, P; Crameri, R; Daeron, M; Fokkens, W; Leynaert, B; Lahoz, C; Maurer, M; Passalacqua, G; Valenta, R; van Hage, M; van Ree, R				Bousquet, J; Anto, JM; Bachert, C; Bousquet, PJ; Colombo, P; Crameri, R; Daeron, M; Fokkens, W; Leynaert, B; Lahoz, C; Maurer, M; Passalacqua, G; Valenta, R; van Hage, M; van Ree, R			Factors responsible for differences between asymptomatic subjects and patients presenting an IgE sensitization to allergens. A GA(2)LEN project	ALLERGY			English	Review						allergy; asthma; basophil; IgE; IgG; rhinitis	FC-EPSILON-RI; REGULATORY T-CELLS; HOUSE-DUST MITE; GENERAL-POPULATION SAMPLE; STAPHYLOCOCCUS-AUREUS ENTEROTOXINS; HUMAN BASOPHIL RELEASABILITY; MOUNTAIN CEDAR POLLINOSIS; BIRCH POLLEN ALLERGEN; SKIN-TEST REACTIVITY; TOTAL SERUM IGE	The synthesis of allergen-specific IgE is required for the development of allergic diseases including allergic rhinitis and allergic asthma (patients), but many individuals with allergen-specific IgE do not develop symptoms (asymptomatic subjects). Differences may exist between asymptomatic subjects and patients. Whether the presence of allergen-specific IgE translates into clinical allergy most likely depends on a complex interplay of multiple factors. These include a family history of atopy, the levels of total serum IgE and, allergen-specific IgE or IgG, epitope-specificity of IgE and their degree of polyclonality (mono- vs polysensitized), as yet unidentified serum factors, the balance of T regulatory cells (Treg) and Th1/Th2 cells, the polymorphisms of the high affinity receptor for IgE (Fc epsilon RI) and other factors regulating the activation of Fc epsilon RI-bearing cells. Asymptomatic subjects may be more often monosensitized than patients who may be more often polysensitized. There are many unanswered important questions that need to be addressed in order to better understand how IgE sensitization translates into clinical allergy. The assessment of differences between the asymptomatic and symptomatic groups of subjects represent one of the scientific programs of Global Allergy and Asthma European Network funded by the European Union and the hypotheses underlying these differences are presented in this paper.	Univ Hosp Montpellier, INSERM, Serv Maladies Resp, U454, Montpellier, France; Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; State Univ Ghent Hosp, ENT Dept, B-9000 Ghent, Belgium; CNR, Ist Biomed & Immunol Mol, Palermo, Italy; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland; Inst Pasteur, Unite Allergol Mol & Cellulaire, Paris, France; Univ Amsterdam, Dept Otorhinolaryngol, Amsterdam, Netherlands; INSERM, U700, Paris, France; Univ Autonoma Madrid, Dept Immunol, Fdn Jimenez Diaz, E-28049 Madrid, Spain; Univ Med Berlin, Klin Dermatol Venerol & Allergol, Berlin, Germany; Dept Internal Med Padiglione Maragliano, Genoa, Italy; Med Univ Vienna, Ctr Physiol & Pathophysiol, Dept Pathophysiol, Div Immunopathol, Vienna, Austria; Karolinska Inst, Dept Med, Allergy & Clin Immunol Unit, Stockholm, Sweden; Karolinska Univ Hosp, Stockholm, Sweden; Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	Bousquet, J (reprint author), Univ Hosp Montpellier, INSERM, Serv Maladies Resp, U454, Montpellier, France.		Colombo, Paolo/G-2200-2013; van Hage, Marianne/A-9678-2017; Anto, J/H-2676-2014	van Hage, Marianne/0000-0003-3091-1596; Anto, J/0000-0002-4736-8529; Bousquet, Philippe Jean/0000-0002-0217-5483; Colombo, Paolo/0000-0002-0908-1359			Addo Yobo Emmanuel O. D., 1997, Thorax, V52, P161; Aghayan-Ugurluoglu R, 2000, J ALLERGY CLIN IMMUN, V105, P803, DOI 10.1067/mai.2000.104782; AHLSTEDT S, 1977, INT ARCH ALLER A IMM, V55, P400; Akbari O, 2003, CURR OPIN IMMUNOL, V15, P627, DOI 10.1016/j.coi.2003.09.012; Akdis M, 2004, J EXP MED, V199, P1567, DOI 10.1084/jem.20032058; Ali K, 2004, NATURE, V431, P1007, DOI 10.1038/nature02991; Almqvist C, 2003, J ALLERGY CLIN IMMUN, V111, P800, DOI 10.1067/mai.2003.1334; Asero R, 2002, ALLERGY, V57, P1063, DOI 10.1034/j.1398-9995.2002.23766.x; ATMADJA AK, 1995, J INFECT DIS, V172, P1567; Bachert C, 2003, J ALLERGY CLIN IMMUN, V111, P1131, DOI 10.1067/mai.2003.1389; Bachert C, 2001, J ALLERGY CLIN IMMUN, V107, P607, DOI 10.1067/mai.2001.112374; BACKER V, 1992, ANN ALLERGY, V69, P116; Balaban N, 2000, INT J FOOD MICROBIOL, V61, P1, DOI 10.1016/S0168-1605(00)00377-9; Baldacci S, 1996, ALLERGY, V51, P149, DOI 10.1111/j.1398-9995.1996.tb04579.x; BARBEE RA, 1976, ANN INTERN MED, V84, P129; BENHAMOU M, 1990, J IMMUNOL, V144, P3071; BERNSTEIN IL, 1977, INT ARCH ALLER A IMM, V55, P215; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Borkow G, 2000, J CLIN INVEST, V106, P1053, DOI 10.1172/JCI10182; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; BOUSQUET J, 1982, ALLERGY, V37, P397, DOI 10.1111/j.1398-9995.1982.tb02318.x; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V87, P737, DOI 10.1016/0091-6749(91)90397-7; BOYANO T, 1994, J INVEST ALLERG CLIN, V4, P158; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; BRYCESON ADM, 1977, BRIT MED J, V1, P742; Cardaba B, 2000, J ALLERGY CLIN IMMUN, V105, P292, DOI 10.1016/S0091-6749(00)90079-4; Cardaba B, 1998, CLIN EXP ALLERGY, V28, P413; CASOLARO V, 1990, AM REV RESPIR DIS, V142, P1108; Celedon JC, 2002, LANCET, V360, P781, DOI 10.1016/S0140-6736(02)09906-3; Cox HE, 1998, BRIT J DERMATOL, V138, P182; D'Amato M, 1999, HUM IMMUNOL, V60, P1250, DOI 10.1016/S0198-8859(99)00112-3; DAERON M, 1995, J CLIN INVEST, V95, P577, DOI 10.1172/JCI117701; DAERON M, 1995, IMMUNITY, V3, P635, DOI 10.1016/1074-7613(95)90134-5; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; DAmato M, 1996, HUM IMMUNOL, V46, P100, DOI 10.1016/0198-8859(96)00012-2; Doherty DG, 1998, J IMMUNOL, V161, P3527; EBNER C, 1995, J IMMUNOL, V154, P1932; FISCHER GF, 1992, HUM IMMUNOL, V33, P259, DOI 10.1016/0198-8859(92)90333-I; Flicker S, 2003, INT ARCH ALLERGY IMM, V132, P13, DOI 10.1159/000073260; Foster B, 2003, J ALLERGY CLIN IMMUN, V112, P1132, DOI 10.1016/j.jaci.2003.09.011; Geller-Bernstein C, 2002, ALLERGY, V57, P37, DOI 10.1034/j.1398-9995.2002.057s71037.x; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GOULD HJ, 2002, ANNU REV IMMUNOL, V18, P18; Grindebacke H, 2004, CLIN EXP ALLERGY, V34, P1364, DOI 10.1111/j.1365-2222.2004.02067.x; HAGEL I, 1993, CLIN EXP IMMUNOL, V94, P80; HAGY GW, 1976, J ALLERGY CLIN IMMUN, V58, P330, DOI 10.1016/0091-6749(76)90139-1; Haider MZ, 1998, CLIN GENET, V54, P166; HILL MR, 1995, BRIT MED J, V311, P776; Hiller R, 2002, FASEB J, V16, P414, DOI 10.1096/fj.01-0711fje; Hofer MF, 1999, J INVEST DERMATOL, V112, P171, DOI 10.1046/j.1523-1747.1999.00492.x; Holt PG, 2000, LANCET, V356, P1699, DOI 10.1016/S0140-6736(00)03198-6; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Ishizawa M, 1999, J HUM GENET, V44, P308, DOI 10.1007/s100380050166; Jansen DF, 1999, AM J RESP CRIT CARE, V159, P924; Johansson SGO, 2004, J ALLERGY CLIN IMMUN, V113, P832, DOI 10.1016/j.jaci.2003.12.591; Joshi SK, 2001, J IMMUNOL, V166, P6693; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Karlsson MR, 2004, J EXP MED, V199, P1679, DOI 10.1084/jem.20032121; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kepley CL, 2003, CLIN IMMUNOL, V108, P89, DOI 10.1016/S1521-6616(03)00155-4; KEPLEY CL, 2004, J BIOL CHEM; Kerkhof M, 2000, CLIN EXP ALLERGY, V30, P1387, DOI 10.1046/j.1365-2222.2000.00907.x; KURNIAWAN A, 1993, J IMMUNOL, V150, P3941; Lagier B, 1995, J ALLERGY CLIN IMMUN, V96, P932, DOI 10.1016/S0091-6749(95)70231-8; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; LINBLAD J, 1961, J ALLERGY, V332, P392; Ling EM, 2004, LANCET, V363, P608, DOI 10.1016/S0140-6736(04)15592-X; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; LYNCH NR, 1987, CLIN ALLERGY, V17, P199, DOI 10.1111/j.1365-2222.1987.tb02004.x; MacGlashan D, 1998, BLOOD, V91, P1633; MACGLASHAN DW, 1993, J ALLERGY CLIN IMMUN, V91, P605, DOI 10.1016/0091-6749(93)90266-I; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; MacIntyre UE, 2001, S AFR MED J, V91, P667; MARONE G, 1986, J ALLERGY CLIN IMMUN, V78, P974, DOI 10.1016/0091-6749(86)90288-5; MARSH DG, 1979, P NATL ACAD SCI USA, V76, P2903, DOI 10.1073/pnas.76.6.2903; Martinez TB, 2001, CLIN EXP ALLERGY, V31, P1464; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Melen E, 2001, ALLERGY, V56, P646, DOI 10.1034/j.1398-9995.2001.00387.x; MERRETT TG, 1976, CLIN ALLERGY, V6, P131, DOI 10.1111/j.1365-2222.1976.tb01890.x; Mitchell AJ, 2002, SCAND J IMMUNOL, V55, P33, DOI 10.1046/j.1365-3083.2002.01012.x; NG'Ang'A LW, 1997, E AFR MED J, V74, P694; Niederberger V, 2004, P NATL ACAD SCI USA, V101, P14677, DOI 10.1073/pnas.0404735101; Niederberger V, 2001, J INVEST DERMATOL, V117, P848, DOI 10.1046/j.0022-202x.2001.01470.x; Novak N, 2004, ALLERGY, V59, P5, DOI 10.1046/j.1398-9995.2003.00337.x; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Odhiambo JA, 1998, EUR RESPIR J, V12, P1105, DOI 10.1183/09031936.98.12051105; OTTESEN EA, 1985, J IMMUNOL, V134, P2707; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Paris-Kohler A, 2000, J ALLERGY CLIN IMMUN, V105, P339, DOI 10.1016/S0091-6749(00)90085-X; Pastorello EA, 1998, J ALLERGY CLIN IMMUN, V102, P1021, DOI 10.1016/S0091-6749(98)70341-0; PASTORELLO EA, 1995, J ALLERGY CLIN IMMUN, V96, P580, DOI 10.1016/S0091-6749(95)70255-5; Pauli G, 2000, INT ARCH ALLERGY IMM, V123, P183, DOI 10.1159/000024443; PEAT JK, 1990, J ALLERGY CLIN IMMUN, V85, P65, DOI 10.1016/0091-6749(90)90223-Q; PENE J, 1994, IMMUNOLOGY, V81, P58; PEPYS J, 1973, CLIN ALLERGY, V3, P491, DOI 10.1111/j.1365-2222.1973.tb03057.x; PEPYS J, 1994, ALLERGY, V49, P397, DOI 10.1111/j.1398-9995.1994.tb00830.x; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Purohit A, 2005, CLIN EXP ALLERGY, V35, P186, DOI 10.1111/j.1365-2222.2005.02156.x; RAMIREZ DA, 1984, J ALLERGY CLIN IMMUN, V73, P88, DOI 10.1016/0091-6749(84)90489-5; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Rasmussen F, 2000, CHEST, V117, P1330, DOI 10.1378/chest.117.5.1330; REID MJ, 1988, NEW ENGL REG ALLERGY, V9, P225; ROANE J, 1968, ANN ALLERGY, V26, P443; Rohde G, 2004, RESP MED, V98, P858, DOI 10.1016/j.rmed.2004.02.012; Rohrbach M, 1998, DIS MARKERS, V14, P177; Roncarolo Maria Grazia, 2003, Novartis Found Symp, V252, P115; Roncarolo M.G., 2003, NOVART FDN SYMP, V252, P127; Roncarolo M.G., 2003, NOVART FDN SYMP, V252, P203; Rudin A, 2001, ALLERGY, V56, P1042, DOI 10.1034/j.1398-9995.2001.00991.x; Sakaguchi S, 2004, ANNU REV IMMUNOL, V22, P531, DOI 10.1146/annurev.immunol.21.120601.141122; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Satti Mohamed Z., 2004, BMC Immunology, V5, P1, DOI 10.1186/1471-2172-5-6; Saxon A, 1997, BIOCHEM SOC T, V25, P383; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Scrivener S, 2000, CLIN EXP ALLERGY, V30, P304; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; Seneviratne SL, 2002, J CLIN INVEST, V110, P1283, DOI 10.1172/JCI200215753; Shiomori T, 2000, J ALLERGY CLIN IMMUN, V105, P449, DOI 10.1067/mai.2000.104256; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; SOLA JL, 1995, ACTA ANAESTH SCAND, V39, P273; Soriano JB, 1997, AM J RESP CRIT CARE, V156, P1394; Sunyer J, 2000, ALLERGY, V55, P762, DOI 10.1034/j.1398-9995.2000.00657.x; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Takai T, 1996, NATURE, V379, P346, DOI 10.1038/379346a0; TAUTZ C, 1994, J ALLERGY CLIN IMMUN, V93, P918, DOI 10.1016/0091-6749(94)90386-7; Tkaczyk C, 2004, INT ARCH ALLERGY IMM, V133, P305, DOI 10.1159/000077213; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; Valenta R, 1999, CLIN EXP ALLERGY, V29, P896; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van Hage-Hamsten M, 2002, CLIN EXP ALLERGY, V32, P838, DOI 10.1046/j.1365-2222.2002.01402.x; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 1999, J ALLERGY CLIN IMMUN, V103, P1000, DOI 10.1016/S0091-6749(99)70169-7; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; VANREE R, 1999, IMMUNOTHERAPY ASTHMA, P848; Vercelli D, 1998, INT ARCH ALLERGY IMM, V116, P1, DOI 10.1159/000023918; von Bubnoff D, 2004, ALLERGY, V59, P933, DOI 10.1111/j.1398-9995.2004.00546.x; Vuitton DA, 2004, CLIN REV ALLERG IMMU, V26, P93, DOI 10.1385/CRIAI:26:2:093; Vuitton DA, 2003, ACTA TROP, V85, P119, DOI 10.1016/S0001-706X(02)00230-9; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; Walraven GEL, 2001, CLIN EXP ALLERGY, V31, P1679, DOI 10.1046/j.1365-2222.2001.01094.x; Westritschnig K, 2003, CLIN EXP ALLERGY, V33, P22, DOI 10.1046/j.1365-2222.2003.01540.x; Woodfolk JA, 2002, INT ARCH ALLERGY IMM, V129, P277, DOI 10.1159/000067595; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; YSSEL H, 1992, J IMMUNOL, V148, P738	152	90	92	0	11	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	JUN	2006	61	6					671	680		10.1111/j.1398-9995.2006.01048.x		10	Allergy; Immunology	Allergy; Immunology	040AB	WOS:000237349300004	16677235	
J	van der Deen, M; de Vries, EGE; Timens, W; Scheper, RJ; Timmer-Bosscha, H; Postma, DS				van der Deen, M; de Vries, EGE; Timens, W; Scheper, RJ; Timmer-Bosscha, H; Postma, DS			ATP-binding cassette (ABC) transporters in normal and pathological lung	RESPIRATORY RESEARCH			English	Review							MULTIDRUG-RESISTANCE PROTEIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; P-GLYCOPROTEIN EXPRESSION; DENSITY-LIPOPROTEIN DEFICIENCY; BRONCHIAL EPITHELIAL-CELLS; ORGANIC ANION TRANSPORTER; CYSTIC-FIBROSIS PATIENTS; DEPENDENT EXPORT PUMP; NITRIC-OXIDE SYNTHASE; BLOOD-BRAIN-BARRIER	ATP-binding cassette ( ABC) transporters are a family of transmembrane proteins that can transport a wide variety of substrates across biological membranes in an energy-dependent manner. Many ABC transporters such as P-glycoprotein ( P-gp), multidrug resistance-associated protein 1 ( MRP1) and breast cancer resistance protein ( BCRP) are highly expressed in bronchial epithelium. This review aims to give new insights in the possible functions of ABC molecules in the lung in view of their expression in different cell types. Furthermore, their role in protection against noxious compounds, e. g. air pollutants and cigarette smoke components, will be discussed as well as the ( mal) function in normal and pathological lung. Several pulmonary drugs are substrates for ABC transporters and therefore, the delivery of these drugs to the site of action may be highly dependent on the presence and activity of many ABC transporters in several cell types. Three ABC transporters are known to play an important role in lung functioning. Mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR) gene can cause cystic fibrosis, and mutations in ABCA1 and ABCA3 are responsible for respectively Tangier disease and fatal surfactant deficiency. The role of altered function of ABC transporters in highly prevalent pulmonary diseases such as asthma or chronic obstructive pulmonary disease ( COPD) have hardly been investigated so far. We especially focused on polymorphisms, knock-out mice models and in vitro results of pulmonary research. Insight in the function of ABC transporters in the lung may open new ways to facilitate treatment of lung diseases.	Dept Pulm Med, NL-9713 GZ Groningen, Netherlands; Univ Groningen, Univ Med Ctr Groningen, Dept Internal Med, NL-9713 GZ Groningen, Netherlands; Dept Pathol & Lab Med, NL-9713 GZ Groningen, Netherlands; Free Univ Amsterdam, Dept Pathol, NL-1081 HV Amsterdam, Netherlands	Postma, DS (reprint author), Dept Pulm Med, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.	m.van.der.deen@int.umcg.nl; e.g.e.de.vries@int.umcg.nl; w.timens@path.umcg.nl; rj.scheper@vumc.nl; h.timmer-bosscha@int.umcg.nl; d.s.postma@int.umcg.nl	Timens, Wim/K-5570-2013	Timens, Wim/0000-0002-4146-6363			Agassandian M, 2004, AM J RESP CELL MOL, V31, P227, DOI 10.1165/rcmb.2004-0038OC; Bain LJ, 2003, XENOBIOTICA, V33, P1173, DOI 10.1080/00498250310001609138; Bandi N, 2002, EUR J PHARMACOL, V437, P9, DOI 10.1016/S0014-2999(02)01267-0; Baudouin-Legros M, 2003, AM J PHYSIOL-CELL PH, V284, pC620, DOI 10.1152/ajpcell.00457.2002; Bebok Z, 2002, J BIOL CHEM, V277, P43041, DOI 10.1074/jbc.M203154200; Beck K, 2003, J HISTOCHEM CYTOCHEM, V51, P887; Beer TW, 1996, THORAX, V51, P526, DOI 10.1136/thx.51.5.526; Biernacki WA, 2003, THORAX, V58, P294, DOI 10.1136/thorax.58.4.294; Booth CL, 1998, CANCER RES, V58, P3641; Borst P, 2000, J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Brady JM, 2002, DRUG METAB DISPOS, V30, P838, DOI 10.1124/dmd.30.7.838; Brechot JM, 1998, J HISTOCHEM CYTOCHEM, V46, P513; Brezillon S, 1997, HUM PATHOL, V28, P944, DOI 10.1016/S0046-8177(97)90010-1; BREZILLON S, 1995, LAB INVEST, V72, P191; Brooks-Wilson A, 1999, NAT GENET, V22, P336; Buchler M, 1996, J BIOL CHEM, V271, P15091; Campbell L, 2003, J PHARMACOL EXP THER, V304, P441, DOI 10.1124/jpet.102.042994; Chen ZS, 2005, MOL PHARMACOL, V67, P545, DOI 10.1124/mol.104.007138; Chen ZS, 2001, J BIOL CHEM, V276, P33747, DOI 10.1074/jbc.M104833200; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; Conrad S, 2002, PHARMACOGENETICS, V12, P321, DOI 10.1097/00008571-200206000-00008; CORDONCARDO C, 1990, J HISTOCHEM CYTOCHEM, V38, P1277; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38; Crapo J D, 1982, Am Rev Respir Dis, V125, P740; Crooks SW, 2000, EUR RESPIR J, V15, P274, DOI 10.1034/j.1399-3003.2000.15b09.x; Croop JM, 1997, GENE, V185, P77, DOI 10.1016/S0378-1119(96)00633-6; Cui YH, 1999, MOL PHARMACOL, V55, P929; Dean M, 2001, J LIPID RES, V42, P1007; DEGREEF C, 1995, BIOCHEM J, V307, P713; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; Diestra JE, 2002, J PATHOL, V198, P213, DOI 10.1002/path.1203; Doubre Helene, 2005, International Journal of Cancer, V113, P568, DOI 10.1002/ijc.20617; DOYAL LA, 1998, P NATL ACAD SCI USA, V95, P15665; Drobnik W, 2001, GASTROENTEROLOGY, V120, P1203, DOI 10.1053/gast.2001.23250; Ehrhardt C, 2003, PHARMACEUT RES, V20, P545, DOI 10.1023/A:1023230328687; Eichelbaum M, 2004, THER DRUG MONIT, V26, P180, DOI 10.1097/00007691-200404000-00017; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; ENGELHARDT JF, 1994, J CLIN INVEST, V93, P737, DOI 10.1172/JCI117028; Flens MJ, 1996, AM J PATHOL, V148, P1237; Forbes Ben, 2000, Pharmaceutical Science and Technology Today, V3, P18, DOI 10.1016/S1461-5347(99)00231-X; GIANGRECO A, 2003, AM J PHYSL LUNG CELL; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706; Grauer MT, 2004, J PSYCHOPHARMACOL, V18, P66, DOI 10.1177/0269881104042831; Hamilton KO, 2002, CURR DRUG METAB, V3, P1, DOI 10.2174/1389200023338170; Hamilton KO, 2001, INT J PHARM, V228, P171, DOI 10.1016/S0378-5173(01)00836-5; Hamilton KO, 2001, J PHARMACOL EXP THER, V298, P1199; Hayashi A, 2003, BIOCHEM BIOPH RES CO, V310, P824, DOI 10.1016/j.bbrc.2003.09.086; Hendrikse NH, 1999, CANCER RES, V59, P2411; Hickman-Davis J, 1999, P NATL ACAD SCI USA, V96, P4953, DOI 10.1073/pnas.96.9.4953; Hickman-Davis JM, 2002, AM J PHYSIOL-LUNG C, V282, pL944, DOI 10.1152/ajplung.00216.2001; HIGGINS CF, 1995, J BIOENERG BIOMEMBR, V27, P63, DOI 10.1007/BF02110332; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; HOLLAND IB, 2003, ABC PROTEINS BACTERI, P427; Hollande E, 1998, EUR J CELL BIOL, V76, P220; Hooijberg JH, 1999, CANCER RES, V59, P2532; Hopper-Borge E, 2004, CANCER RES, V64, P4927, DOI 10.1158/0008-5472.CAN-03-3111; HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27; Hu XF, 2003, SURV OPHTHALMOL, V48, P424, DOI 10.1016/S0039-6257(03)00053-5; Hurbain I, 2003, PEDIATR RES, V54, P627, DOI 10.1203/01.PDR.0000090926.16166.3F; Isla D, 2004, ANN ONCOL, V15, P1194, DOI 10.1093/annonc/mdh319; Ito K, 2001, J BIOL CHEM, V276, P15616, DOI 10.1074/jbc.M011246200; Ito S, 2001, PHARMACOGENETICS, V11, P175, DOI 10.1097/00008571-200103000-00008; JACKSON A, 1980, HISTOPATHOLOGY, V4, P607, DOI 10.1111/j.1365-2559.1980.tb02956.x; Jedlitschky G, 2000, J BIOL CHEM, V275, P30069, DOI 10.1074/jbc.M005463200; Johannesson M, 1997, BIOCHEM BIOPH RES CO, V239, P606, DOI 10.1006/bbrc.1997.7519; Johnson DR, 2001, CANCER RES, V61, P1469; Jonker JW, 2002, P NATL ACAD SCI USA, V99, P15649, DOI 10.1073/pnas.202607599; Kalin N, 1999, J CLIN INVEST, V103, P1379, DOI 10.1172/JCI5731; Kamisako T, 1999, HEPATOLOGY, V30, P485, DOI 10.1002/hep.510300220; Kerb R, 2001, PHARMACOGENOMICS, V2, P51, DOI 10.1517/14622416.2.1.51; Kiuchi Y, 1998, FEBS LETT, V433, P149, DOI 10.1016/S0014-5793(98)00899-0; Kogan I, 2003, EMBO J, V22, P1981, DOI 10.1093/emboj/cdg194; KOMATANI H, CANC RES, V61, P2827; Kool M, 1999, P NATL ACAD SCI USA, V96, P6914, DOI 10.1073/pnas.96.12.6914; Kool M, 1997, CANCER RES, V57, P3537; KUNZELMANN K, 1994, J CELL PHYSIOL, V161, P393, DOI 10.1002/jcp.1041610302; Kuroda M, 2004, J GASTROEN HEPATOL, V19, P146, DOI 10.1111/j.1440-1746.2004.03275.x; Langmann T, 2003, CLIN CHEM, V49, P230, DOI 10.1373/49.2.230; LechaptZalcman E, 1997, EUR RESPIR J, V10, P1837, DOI 10.1183/09031936.97.10081837; Lehmann T, 2001, TOXICOLOGY, V167, P59, DOI 10.1016/S0300-483X(01)00458-9; LEIER I, 1994, EUR J BIOCHEM, V220, P599, DOI 10.1111/j.1432-1033.1994.tb18661.x; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Linsdell P, 1999, BRIT J PHARMACOL, V126, P1471, DOI 10.1038/sj.bjp.0702458; Loe DW, 1997, MOL PHARMACOL, V51, P1034; Loe DW, 1998, CANCER RES, V58, P5130; Lorico A, 2002, TOXICOLOGY, V171, P201, DOI 10.1016/S0300-483X(01)00584-4; Lorico A, 1997, CANCER RES, V57, P5238; McNeish J, 2000, P NATL ACAD SCI USA, V97, P4245, DOI 10.1073/pnas.97.8.4245; Meng QH, 2000, J PATHOL, V190, P126, DOI 10.1002/(SICI)1096-9896(200002)190:2<126::AID-PATH500>3.0.CO;2-#; MORRIS AP, 1992, J BIOL CHEM, V267, P5575; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; MULLER M, HUMAN ABC TRANSPORTE; Muramatsu T, 2004, ONCOL RES, V14, P331; Nagayoshi Keiko, 2004, Drug Metab Pharmacokinet, V19, P407, DOI 10.2133/dmpk.19.407; Neuringer IP, 2004, RESP RES, V5, DOI 10.1186/1465-9921-5-6; Oguri T, 2001, INT J CANCER, V93, P584, DOI 10.1002/ijc.1369; Oselin K, 2003, EUR J CLIN PHARMACOL, V59, P347, DOI 10.1007/s00228-003-0625-z; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Penque D, 2000, LAB INVEST, V80, P857; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Prehm P, 2004, BIOCHEM PHARMACOL, V68, P1401, DOI 10.1016/j.bcp.2004.06.017; PUCHELLE E, 1992, AM J RESP CELL MOL, V7, P485; Puddu P, 1999, LAB INVEST, V79, P1299; PUNJABI CJ, 1994, AM J RESP CELL MOL, V11, P165; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; RATCLIFF R, 1993, NAT GENET, V4, P35, DOI 10.1038/ng0593-35; REID G, 2003, P NATL ACAD SCI US; Renes J, 1999, BRIT J PHARMACOL, V126, P681, DOI 10.1038/sj.bjp.0702360; RIORDAN JR, 1989, SCIENCE, V245, P1066; Roerig DL, 2004, DRUG METAB DISPOS, V32, P953, DOI 10.1124/dmd.104.000042; Saito S, 2002, J HUM GENET, V47, P147, DOI 10.1007/s100380200018; Savaraj N, 2003, INT J ONCOL, V23, P173; Scheffer GL, 2002, J CLIN PATHOL, V55, P332; Scheffer GL, 2002, LAB INVEST, V82, P515; Scheffer GL, 2002, LAB INVEST, V82, P193; Schinkel AH, 1997, P NATL ACAD SCI USA, V94, P4028, DOI 10.1073/pnas.94.8.4028; Schultz MJ, 2001, J IMMUNOL, V166, P4059; Seree E, 1998, BIOCHEM BIOPH RES CO, V252, P392, DOI 10.1006/bbrc.1998.9662; Shen B.-Q., 1994, American Journal of Physiology, V266, pL493; Shulenin S, 2004, NEW ENGL J MED, V350, P1296, DOI 10.1056/NEJMoa032178; Sinues B, 2003, ONCOLOGY-BASEL, V64, P183, DOI 10.1159/000067770; Summer R, 2003, AM J PHYSIOL-LUNG C, V285, pL97, DOI 10.1152/ajplung.00009.2003; Suzuki T, 2001, CURR DRUG METAB, V2, P367, DOI 10.2174/1389200013338289; Szakacs G, 2004, CANCER CELL, V6, P129, DOI 10.1016/j.ccr.2004.06.026; THOMAS GA, 1994, EUR J CANCER, V30A, P1705, DOI 10.1016/0959-8049(94)00290-L; Torky ARW, 2005, TOXICOLOGY, V207, P437, DOI 10.1016/j.tox.2004.10.014; Trezise AEO, 1997, HUM MOL GENET, V6, P527, DOI 10.1093/hmg/6.4.527; Trompier D, 2004, CANCER RES, V64, P4950, DOI 10.1158/0008-5472.CAN-04-0143; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; Van Aubel RAMH, 2002, J AM SOC NEPHROL, V13; van den Berge M, 2004, J ALLERGY CLIN IMMUN, V114, P737, DOI 10.1016/j.jaci.2004.05.071; VANDERDEEN M, 2003, AM J RESP CRIT CARE, V167, pA397; VANDERDEEN M, 2004, P AM ASSOC CANC RES, V45, pA508; VANDERVALK P, 1990, ANN ONCOL, V1, P56; Verbon A, 2002, CLIN EXP IMMUNOL, V130, P32, DOI 10.1046/j.1365-2249.2002.01952.x; VOLM M, 1992, CANCER, V70, P764, DOI 10.1002/1097-0142(19920815)70:4<764::AID-CNCR2820700408>3.0.CO;2-M; VOLM M, 1991, BRIT J CANCER, V64, P700, DOI 10.1038/bjc.1991.384; Wang N, 2003, J BIOL CHEM, V278, P42906, DOI 10.1074/jbc.M307831200; Waters CM, 2000, ANESTHESIOLOGY, V93, P825, DOI 10.1097/00000542-200009000-00033; Weinberger B, 1999, PHARMACOL THERAPEUT, V84, P401, DOI 10.1016/S0163-7258(99)00044-3; Wielinga PR, 2003, J BIOL CHEM, V278, P17664, DOI 10.1074/jbc.M212723200; Wijnholds J, 2000, J CLIN INVEST, V105, P279, DOI 10.1172/JCI8267; Wijnholds J, 1997, NAT MED, V3, P1275, DOI 10.1038/nm1197-1275; Wijnholds J, 1998, J EXP MED, V188, P797, DOI 10.1084/jem.188.5.797; Wioland MA, 2000, J HISTOCHEM CYTOCHEM, V48, P1215, DOI 10.1177/002215540004800905; Wood L, 1998, BRIT J CANCER, V77, P627, DOI 10.1038/bjc.1998.100; Yamamoto T, 2004, BIOCHEM BIOPH RES CO, V321, P72, DOI 10.1016/j.bbrc.2004.06.112; Yamano G, 2001, FEBS LETT, V508, P221, DOI 10.1016/S0014-5793(01)03056-3; Yoh K, 2004, CLIN CANCER RES, V10, P1691, DOI 10.1158/1078-0432.CCR-0937-3; Young LC, 1999, CLIN CANCER RES, V5, P673; Zelcer N, 2003, BIOCHEM J, V371, P361, DOI 10.1042/BJ20021886; Zheng HX, 2004, J CLIN PHARMACOL, V44, P135, DOI 10.1177/0091270003262108	155	90	92	0	3	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1465-993X			RESP RES	Respir. Res.	JUN 20	2005	6								59	10.1186/1465-9921-6-59		16	Respiratory System	Respiratory System	960AW	WOS:000231563600001	15967026	
J	Halvorsen, T; Skadberg, BT; Eide, GE; Roksund, OD; Carlsen, KH; Bakke, P				Halvorsen, T; Skadberg, BT; Eide, GE; Roksund, OD; Carlsen, KH; Bakke, P			Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study	ACTA PAEDIATRICA			English	Article						infant; premature; bronchopulmonary dysplasia; lung diseases; obstructive; cohort studies	LUNG-FUNCTION; BRONCHOPULMONARY DYSPLASIA; RESPIRATORY HEALTH; WEIGHT; DISEASE; RESPONSIVENESS; SEQUELAE; CHILDREN; AGE; METHACHOLINE	Aims: The pulmonary outcome of extreme prematurity remains to be established in adults. We determined respiratory health and lung function status in a population-based, complete cohort of young preterms approaching adulthood. Methods. Forty-six preterms with gestational age less than or equal to28 wk or birthweight less than or equal to1000 g, born between 1982 and 1985, were compared to the temporally nearest term-born subject of equal gender. Spirometry, plethysmography, reversibility test to salbutamol and methacholine bronchial provocation test were performed. Neonatal data were obtained from hospital records and current symptoms from validated questionnaires. Results: When entering the study at a mean age of 17.7 (SD: 1.2) y, a doctor's diagnosis of asthma and use of asthma inhalers were significantly more prevalent among preterms than controls (one asthmatic control compared to nine preterms, all but one using asthma inhalers). Peak expiratory flow (PEF) and forced expiratory volume in 1 s (FEV1) were decreased and the discrepancies relative to controls increased parallel to increased severity of neonatal lung disease. Parameters of increased neonatal oxygen exposure significantly predicted FEV1. Adjusted for height, gender and age, FEV1 was reduced by a mean of 580 ml/s in subjects with a history of bronchopulmonary dysplasia. Fifty-six percent of preterms had a positive methacholine provocation test compared to 26% of controls. Conclusion: A substantially decreased FEV1, increased bronchial hyperresponsiveness and a number of established risk factors for steeper age-related decline in lung function were observed in preterms. A potential for early onset chronic obstructive pulmonary disease is present in subsets of this group.	Haukeland Univ Hosp, Dept Paediat, NO-5021 Bergen, Norway; Univ Bergen, Inst Clin & Mol Med, N-5020 Bergen, Norway; Haukeland Univ Hosp, Clin Res Ctr, NO-5021 Bergen, Norway; Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Sect Epidemiol & Med Stat, N-5020 Bergen, Norway; Voksentoppen Natl Hosp, Oslo, Norway; Res Inst Asthma Allergy & Chron Lung Dis Children, Oslo, Norway; Haukeland Univ Hosp, Dept Thorac Med, NO-5021 Bergen, Norway; Univ Bergen, Inst Med, N-5020 Bergen, Norway	Halvorsen, T (reprint author), Haukeland Univ Hosp, Dept Paediat, NO-5021 Bergen, Norway.	thornas.halvorsen@helse-bergen.no	Halvorsen, Thomas/P-6741-2015	Halvorsen, Thomas/0000-0003-1471-0225			Anand D, 2003, ARCH DIS CHILD, V88, P135, DOI 10.1136/adc.88.2.135; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; CUNNINGHAM CK, 1991, PEDIATRICS, V88, P527; DEKLEINE MJK, 1990, THORAX, V45, P941, DOI 10.1136/thx.45.12.941; Doyle LW, 2001, ARCH DIS CHILD, V84, P40, DOI 10.1136/adc.84.1.40; Eber E, 2001, THORAX, V56, P317, DOI 10.1136/thorax.56.4.317; [Anonymous], 1993, ALLERGY, V48, P48; Godfrey S, 1999, EUR RESPIR J, V14, P659, DOI 10.1034/j.1399-3003.1999.14c28.x; Gross SJ, 1998, J PEDIATR-US, V133, P188, DOI 10.1016/S0022-3476(98)70219-7; Jacob SV, 1998, J PEDIATR-US, V133, P193, DOI 10.1016/S0022-3476(98)70220-3; Jobe Alan H., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1723; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; McLeod A, 1996, ARCH DIS CHILD, V74, P188; *MED BIRTH REG, 1997, BIRTHS NORW 30 YEARS; NIEMINEN MM, 1988, THORAX, V43, P896, DOI 10.1136/thx.43.11.896; NORTHWAY WH, 1990, NEW ENGL J MED, V323, P1793, DOI 10.1056/NEJM199012273232603; NTP Technical Report, 2002, NIH PUBLICATION; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; Palta M, 2001, AM J EPIDEMIOL, V154, P521, DOI 10.1093/aje/154.6.521; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pelkonen AS, 1997, AM J RESP CRIT CARE, V156, P1178; Pelkonen AS, 2001, RESP MED, V95, P565, DOI 10.1053/rmed.2001.1104; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; QUANJER PH, 1995, PEDIATR PULM, V19, P135, DOI 10.1002/ppul.1950190209; Rijcken B, 1996, AM J RESP CRIT CARE, V154, pS246; SHAHEEN SO, 1995, AM J RESP CRIT CARE, V151, P1649; Skjaerven R, 2000, ACTA OBSTET GYN SCAN, V79, P440, DOI 10.1034/j.1600-0412.2000.079006440.x; Stevenson DK, 1998, AM J OBSTET GYNECOL, V179, P1632, DOI 10.1016/S0002-9378(98)70037-7; STEWART AL, 1981, LANCET, V1, P1038; Weiss ST, 2000, AM J RESP CRIT CARE, V162, pS134; Weiss ST, 1996, AM J RESP CRIT CARE, V154, pS208; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760; YUDKIN PL, 1987, EARLY HUM DEV, V15, P45, DOI 10.1016/0378-3782(87)90099-5; 2001, SPSS WINDOWS RELEASE, P136	34	90	94	0	5	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0803-5253			ACTA PAEDIATR	Acta Paediatr.	OCT	2004	93	10					1294	1300		10.1080/08035250410028101		7	Pediatrics	Pediatrics	859GT	WOS:000224252100006	15499947	
J	Kramer, U; Lemmen, CH; Behrendt, H; Link, E; Schafer, T; Gostomzyk, J; Scherer, G; Ring, J				Kramer, U; Lemmen, CH; Behrendt, H; Link, E; Schafer, T; Gostomzyk, J; Scherer, G; Ring, J			The effect of environmental tobacco smoke on eczema and allergic sensitization in children	BRITISH JOURNAL OF DERMATOLOGY			English	Article						eczema; parental atopy; predisposition; respiratory allergies; sensitization; tobacco smoke	PARENTAL SMOKING; PASSIVE-SMOKING; EARLY-CHILDHOOD; RESPIRATORY HEALTH; ATOPIC-DERMATITIS; URINARY COTININE; RISK-FACTORS; EXPOSURE; ASSOCIATION; ASTHMA	Background The negative impact of environmental tobacco smoke (ETS) on airway diseases in children is well known. Whether there is an effect on atopic eczema is not clear. Objectives To determine the impact of ETS on atopic eczema, allergic sensitization and allergic airway diseases in 1669 school beginners. Methods The prevalence of atopy-related health outcomes was assessed by questionnaire, dermatological examination, skin prick testing and specific immunoglobulin E measurement. Exposure assessments were based on measurement of cotinine [expressed as cotinine to creatine ratio (CCR)] in spot urine samples (n = 1220) together with questionnaire and interview data on smoking behaviour of the parents. Results In the total study group, prevalence of atopic eczema diagnosed on examination was significantly associated with urinary CCR values. The odds ratio (OR) and 95% confidence interval (CI), calculated for an increase of 100 ng mg(-1) CCR was 1.97 (95% CI 1.23-3.16). The prevalence of skin manifestations according to questionnaire data as well as a history of asthma, wheezing, and hay fever were positively although not significantly associated with ETS exposure. When genetically predisposed children (defined by the presence of parental atopy) were compared with children whose parents had no atopy, the ORs of allergic outcome variables were generally higher in the first group. In the group of predisposed children, significant associations with urinary CCR were found for allergic sensitization against house dust mites as measured by skin prick test (OR 3.10, 95% CI 1.63-5.90). Conclusions Children are at a higher risk of developing an atopic eczema when exposed to ETS and genetically predisposed children are at higher risk of developing a sensitization against house dust mites.	Univ Dusseldorf, Inst Umweltmed Forsch, D-40225 Dusseldorf, Germany; Tech Univ Munich, Natl Res Ctr Environm & Hlth GSF, Div Environm Dermatol & Allergol, D-8000 Munich, Germany; Med Univ Lubeck, Dept Social Med, D-23538 Lubeck, Germany; Dept Publ Hlth, Augsburg, Germany; Analyt Biol Res Lab ABF, Munich, Germany; Tech Univ Munich, Clin Dermatol & Allergol, D-8000 Munich, Germany	Kramer, U (reprint author), Univ Dusseldorf, Inst Umweltmed Forsch, Hennekamp 50, D-40225 Dusseldorf, Germany.	kraemeru@uni-duesseldorf.de					Agabiti N, 1999, EPIDEMIOLOGY, V10, P692, DOI 10.1097/00001648-199911000-00008; ARSHAD SH, 1992, J ALLERGY CLIN IMMUN, V90, P235, DOI 10.1016/0091-6749(92)90077-F; BAKOULA CG, 1995, LANCET, V346, P280, DOI 10.1016/S0140-6736(95)92167-2; BRABACK L, 1995, ARCH DIS CHILD, V72, P487; CHILMONCZYK BA, 1993, NEW ENGL J MED, V328, P1665, DOI 10.1056/NEJM199306103282303; Cook DG, 1999, THORAX, V54, P357; DOMINO EF, 1995, CLIN PHARMACOL THER, V57, P479, DOI 10.1016/0009-9236(95)90219-8; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HALKEN S, 1995, ALLERGY, V50, P97; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; JAAKKOLA N, 1994, SCAND J SOC MED, V22, P107; Jarvis D, 1999, J ALLERGY CLIN IMMUN, V104, P934, DOI 10.1016/S0091-6749(99)70071-0; Kabesch M., 2000, ACI INT, V12, P146, DOI 10.1027/0838-1925.12.4.146; Kulig M, 1999, HUM EXP TOXICOL, V18, P241, DOI 10.1191/096032799678839987; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; Lindfors A, 1999, J ALLERGY CLIN IMMUN, V104, P755; Nafstad P, 1997, EPIDEMIOLOGY, V8, P293, DOI 10.1097/00001648-199705000-00011; REESE AC, 1992, AM REV RESPIR DIS, V146, P66; RYLANDER E, 1995, EPIDEMIOLOGY, V6, P289, DOI 10.1097/00001648-199505000-00017; SAMET MJ, 2000, INDOOR AIR QUALITY H; Schafer T, 1997, J AM ACAD DERMATOL, V36, P550, DOI 10.1016/S0190-9622(97)70242-1; Scherer G, 1999, HUM EXP TOXICOL, V18, P297, DOI 10.1191/096032799678840075; SCHERER G, 1988, KLIN WOCHENSCHR, V66, P5; Seymour BWP, 1997, J IMMUNOL, V159, P6169; STALDER JF, 1993, DERMATOLOGY, V186, P23; Strachan DP, 1998, THORAX, V53, P117; Strachan DP, 1997, THORAX, V52, P905; Strachan DP, 1998, THORAX, V53, P204; U.S. Environmental Protection Agency, 1992, EPA600690006F; Wardlaw AJ, 1995, CLIN EXP ALLERGY, V25, P56, DOI 10.1111/j.1365-2222.1995.tb00045.x; Weaver VM, 1996, CANCER EPIDEM BIOMAR, V5, P135; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; WJST M, 1994, ALLERGY, V49, P766, DOI 10.1111/j.1398-9995.1994.tb02100.x	33	90	92	0	2	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	JAN	2004	150	1					111	118		10.1111/j.1365-2133.2004.05710.x		8	Dermatology	Dermatology	766YA	WOS:000188410300012	14746624	
J	Bryld, LE; Hindsberger, C; Kyvik, KO; Agner, T; Menne, T				Bryld, LE; Hindsberger, C; Kyvik, KO; Agner, T; Menne, T			Risk factors influencing the development of hand eczema in a population-based twin sample	BRITISH JOURNAL OF DERMATOLOGY			English	Article						atopy; contact allergy; hand eczema; twins; wet work	CONTACT-DERMATITIS; ATOPIC-DERMATITIS; NICKEL ALLERGY; SENSITIZATION; ASSOCIATION; OCCUPATION; WORKERS	Background A population-based twin study has recently shown that genetic factors are of significance for hand eczema. Objectives To characterize further a sample of this twin material with regard to contact allergy, atopic dermatitis and wet work. Methods In total, 1076 individual twins were examined clinically and patch tested. The diagnosis of atopic dermatitis was based on the U.K. Working Party criteria. The decision concerning wet work was based on the individual job description, taking into account the later introduced definition of at least 2 h of water exposure daily. The data were analysed by a newly developed statistical method which makes it possible to analyse the individual risk factor and at the same time discriminate between genetic and environmental factors. Results The statistical analysis confirmed atopic dermatitis as an important risk factor for hand eczema. Contact allergy was also confirmed as a significant risk factor for hand eczema, and the risk was related to strength (+ to + + +) of contact allergy. The results indicated that the high frequency of hand eczema in women in comparison with men was caused by environmental and not genetic factors. Aggregation of hand eczema within twin pairs was only to a minor degree explained by atopic dermatitis and nickel allergy (or other contact allergies). Conclusions We suggest that a hitherto unrecognized genetic risk factor for hand eczema independent of atopic dermatitis and contact allergy is probably of importance for the development of irritant contact dermatitis on the hands.	Copenhagen Univ Hosp, Dept Dermatol, DK-2900 Hellerup, Denmark; Univ Copenhagen, Dept Biostat, DK-1168 Copenhagen, Denmark; Univ So Denmark, Inst Publ Hlth, Danish Twin Registry, DK-5000 Odense, Denmark	Agner, T (reprint author), Copenhagen Univ Hosp, Dept Dermatol, DK-2900 Hellerup, Denmark.			Kyvik, Kirsten Ohm/0000-0003-2981-0245			Agner T, 1992, Acta Derm Venereol Suppl (Stockh), V173, P1; Andersen KE, 2001, TOXICOL APPL PHARM, V170, P166, DOI 10.1006/taap.2000.9095; Berndt U, 1999, BRIT J DERMATOL, V140, P922, DOI 10.1046/j.1365-2133.1999.02827.x; Betensky RA, 2001, GENET EPIDEMIOL, V20, P228; Bryld LE, 2000, BRIT J DERMATOL, V142, P298, DOI 10.1046/j.1365-2133.2000.03301.x; Buckley DA, 2000, CONTACT DERMATITIS, V43, P304; CHRISTENSEN OB, 1982, CONTACT DERMATITIS, V8, P7, DOI 10.1111/j.1600-0536.1982.tb04127.x; COENRAADS PJ, 1983, CLIN EXP DERMATOL, V8, P495, DOI 10.1111/j.1365-2230.1983.tb01816.x; Coenraads PJ, 1998, INT ARCH OCC ENV HEA, V71, P7, DOI 10.1007/s004200050243; Diepgen TL, 1999, INT ARCH OCC ENV HEA, V72, P496, DOI 10.1007/s004200050407; Hindsberger C, 2003, GENET EPIDEMIOL, V25, P225, DOI 10.1002/gepi.10253; LAMMINTAUSTA K, 1981, CONTACT DERMATITIS, V7, P301, DOI 10.1111/j.1600-0536.1981.tb04085.x; MEDING B, 1990, CONTACT DERMATITIS, V23, P154, DOI 10.1111/j.1600-0536.1990.tb04776.x; MEDLING B, 1990, CONTACT DERMATITIS, V23, P6; Menne T, 1979, Derm Beruf Umwelt, V27, P129; MENNE T, 1982, ACTA DERM-VENEREOL, V62, P35; MENNE T, 1997, CONTACT DERMATITIS, V24, P375; Mortz CG, 2002, ACTA DERM-VENEREOL, V82, P359, DOI 10.1080/000155502320624096; NIELSEN MH, 2002, CONTACT DERMATITIS, V46, P71; Nielsen NH, 2001, ACTA DERM-VENEREOL, V81, P31, DOI 10.1080/000155501750208155; NILSSON E, 1985, CONTACT DERMATITIS, V13, P216, DOI 10.1111/j.1600-0536.1985.tb02553.x; RYCROFT RJG, 1981, THESIS U CAMBRIDGE U; Rystedt I, 1985, Acta Derm Venereol Suppl (Stockh), V117, P1; Skytthe A, 2002, TWIN RES, V5, P352; Svensson A, 2002, BRIT J DERMATOL, V147, P281, DOI 10.1046/j.1365-2133.2002.04799.x; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Willis CM, 2002, CONTACT DERMATITIS, V47, P267, DOI 10.1034/j.1600-0536.2002.470503.x	27	90	91	0	4	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	DEC	2003	149	6					1214	1220		10.1111/j.1365-2133.2003.05678.x		7	Dermatology	Dermatology	752HE	WOS:000187154400014	14674899	
J	Lane, SE; Watts, RA; Bentham, G; Innes, NJ; Scott, DGI				Lane, SE; Watts, RA; Bentham, G; Innes, NJ; Scott, DGI			Are environmental factors important in primary systemic vasculitis? A case-control study	ARTHRITIS AND RHEUMATISM			English	Article							CHURG-STRAUSS-SYNDROME; RHEUMATOLOGY 1990 CRITERIA; WEGENER GRANULOMATOSIS; OCCUPATIONAL EXPOSURE; HYDROCARBON EXPOSURE; SILICA EXPOSURE; UNITED-KINGDOM; DISEASE; GLOMERULONEPHRITIS; ANTIBODIES	Objective. To investigate the association between primary systemic vasculitis (PSV) and environmental risk factors. Methods. Seventy-five PSV cases and 273 controls (220 nonvasculitis, 19 secondary vasculitis and 34 asthma controls) were interviewed using a structured questionnaire. Factors investigated were social class, occupational and residential history, smoking, pets, allergies, vaccinations, medications, hepatitis, tuberculosis, and farm exposure in the year before symptom onset (index year). The Standard Occupational Classification 2000 and job-exposure matrices were used to assess occupational silica, solvent, and metal exposure. Stepwise multiple logistic regression was used to calculate the odds ratio (OR) and 95% confidence interval (95% CI) adjusted for potential confounders. Total PSV, subgroups (47 Wegener's granulomatosis [WG], 12 microscopic polyangiitis, 16 Churg-Strauss syndrome [CSS]), and antineutrophil cytoplasmic antibody (ANCA)-positive cases were compared with control groups. Results. Farming in the index year was significantly associated with PSV (OR 2.3 [95% CI 1.2-4.6]), with WG (2.7 [1.2-5.8]), with MPA (6.3 [1.9-21.6]), and with perinuclear ANCA (pANCA) (4.3 [1.5-12.7]). Farming during working lifetime was associated with PSV (2.2 [1.2-3.81) and with WG (2.7 [1.3-5.7]). Significant associations were found for high occupational silica exposure in the index year (with PSV 3.0 [1.0-8.4], with CSS 5.6 [1.3-23.5], and with ANCA 4.9 [1.3-18.6]), high occupational solvent exposure in the index year (with PSV 3.4 [0.9-12.5], with WG 4.8 [1.2-19.8], and with classic ANCA [cANCA] 3.9 [1.6-9.5]), high occupational solvent exposure during working lifetime (with PSV 2.7 [1.1-6.6], with WG 3.4 [1.3-8.9], and with cANCA 3.3 [1.0-10.8]), drug allergy (with PSV 3.6 [1.8-7.0], with WG 4.0 [1.8-8.7], and with cANCA 4.7 [1.9-11.7]), and allergy overall (with PSV 2.2 [1.2-3.9], with WG 2. 7 [1.4-5.7]). No other significant associations were found. Conclusion. A significant association between farming and PSV has been identified for the first time. Results also support previously reported associations with silica, solvents, and allergy.	Norfolk & Norwich Univ Hosp, Norwich, Norfolk, England; Ipswich Hosp, NHS Trust, Ipswich, Suffolk, England; Univ E Anglia, Norwich NR4 7TJ, Norfolk, England	Lane, SE (reprint author), Addenbrookes Hosp, Dept Rheumatol, Hills Rd,POB 204, Cambridge CB2 2QQ, England.						BOUJEMAA W, 1994, SCAND J WORK ENV HEA, V20, P180; CHEVAILLER A, 1994, ANN RHEUM DIS, V53, P781, DOI 10.1136/ard.53.11.781-b; CHUA KB, 1999, LANCET, V354, P1222; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; CUADRADO MJ, 1994, BRIT J RHEUMATOL, V33, P749; Duna GE, 1998, CLIN EXP RHEUMATOL, V16, P669; GOCKE DJ, 1970, LANCET, V2, P1149; GREGORINI G, 1993, ADV EXP MED BIOL, V336, P435; Guillevin Loic, 1997, Current Opinion in Rheumatology, V9, P31, DOI 10.1097/00002281-199701000-00006; Hilliquin P, 2000, RHEUMATOLOGY, V39, P1020, DOI 10.1093/rheumatology/39.9.1020; Hogan SL, 2001, J AM SOC NEPHROL, V12, P134; HOTZ P, 1995, NEPHRON, V70, P438; JENNETTE JC, 1994, ARTHRITIS RHEUM, V37, P187, DOI 10.1002/art.1780370206; Kinoshita M, 1999, J ALLERGY CLIN IMMUN, V103, P534, DOI 10.1016/S0091-6749(99)70483-5; Lane SE, 2000, NEPHROL DIAL TRANSPL, V15, P23, DOI 10.1093/ndt/15.1.23; LANHAM JG, 1984, MEDICINE, V63, P65; LARSSON H, 1984, ACTA MED SCAND, V216, P541; LEAVITT RY, 1990, ARTHRITIS RHEUM, V33, P1101; Lewis RL, 1997, OCCUPATIONAL ENV MED, V2nd, P405; Mandell Brian F., 1998, Current Opinion in Rheumatology, V10, P51, DOI 10.1097/00002281-199801000-00008; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094; MOCSARI E, 1989, VET MICROBIOL, V19, P245, DOI 10.1016/0378-1135(89)90070-9; NUYTS GD, 1995, NEPHROL DIAL TRANSPL, V10, P1162; *OFF NAT STAT, 2000, STAT STAND OCC CLASS, V1; Pai P, 1998, NEPHROL DIAL TRANSPL, V13, P1321; Pai P, 1998, POSTGRAD MED J, V74, P225; Parks CG, 1999, ENVIRON HEALTH PERSP, V107, P793, DOI 10.2307/3434342; Rosenman KD, 1999, AM J IND MED, V35, P375, DOI 10.1002/(SICI)1097-0274(199904)35:4<375::AID-AJIM8>3.0.CO;2-I; SOMER T, 1995, CLIN INFECT DIS, V20, P1010; STEENLAND NK, 1990, AM J PUBLIC HEALTH, V80, P153, DOI 10.2105/AJPH.80.2.153; SYMMONS DPM, 1994, BRIT J RHEUMATOL, V33, P735; Tervaert Jan Willem Cohen, 1998, Current Opinion in Rheumatology, V10, P12, DOI 10.1097/00002281-199801000-00003; Tomer Y, 1999, CLIN EXP RHEUMATOL, V17, P521; van Gurp E. A. F. J., 2000, Clinical and Experimental Immunology, V120, P60; VOZNESENSKII NK, 1995, GIG SANIT, V6, P20; Watts R. A., 1998, Clinical and Experimental Immunology, V112, P30; Watts RA, 2000, ARTHRITIS RHEUM, V43, P414, DOI 10.1002/1529-0131(200002)43:2<414::AID-ANR23>3.0.CO;2-0; Wichmann I, 1996, ANN RHEUM DIS, V55, P205, DOI 10.1136/ard.55.3.205; WITTE KW, 1982, PHARMACOTHERAPY, V2, P54; Yashiro M, 2000, AM J KIDNEY DIS, V35, P889, DOI 10.1016/S0272-6386(00)70260-5	40	90	94	1	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	0004-3591			ARTHRITIS RHEUM	Arthritis Rheum.	MAR	2003	48	3					814	823		10.1002/art.10830		10	Rheumatology	Rheumatology	653LY	WOS:000181438800031	12632437	
J	Liu, AH; Murphy, JR				Liu, AH; Murphy, JR			Hygiene hypothesis: Fact or fiction?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						hygiene; allergy; atopy; asthma; autoimmunity; childhood; endotoxin; epidemiology type 1diabetes; celiac disease; inflammatory bowel disease; rheumatoid arthritis; microbiology	HOUSE-DUST ENDOTOXIN; DAY-CARE ATTENDANCE; ATOPIC DISEASE; CHILDHOOD ASTHMA; UNITED-STATES; SCHOOL-AGE; EARLY-LIFE; EXPOSURE; CHILDREN; RISK	The hygiene hypothesis of asthma and allergy has recently received a swell of popularity and published supporting evidence, and has been extended to autoimmune conditions of childhood. Broadly stated, naturally occurring infections and microbial exposures might essentially immunize against the development of asthma and allergic and autoimmune diseases. If true, then reductions in nature's immunotherapy over the past century might be a major factor in the global increase of these conditions (eg, the higher prevalence of asthma and allergies in urban metropolitan areas compared with rural and farm communities) and might lead to new therapies for these conditions. Although such a unifying hypothesis has great appeal, currently it is only speculation about what might be at the end of the investigative road. How close are the current studies to establishing a causal relationship between microbial exposures and a reduction in allergic, asthmatic, and autoimmune disease prevalence? A systematic epidemiologic appraisal of the current hygiene hypothesis evidence can provide a critical analysis of what is currently known and an investigative blueprint for future studies that can ultimately prove causation and improve recommendations, interventions, and therapies. (J Allergy Clin Immunol 2003;111:471-8.).	Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Dept Pediat, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Div Biostat, Denver, CO 80206 USA; Univ Colorado, Ctr Hlth Sci, Dept Prevent Med & Biometr, Boulder, CO 80309 USA	Liu, AH (reprint author), Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, 1400 Jackson St K1023, Denver, CO 80206 USA.				NHLBI NIH HHS [K23-HL-0472]		Akinbami LJ, 2002, PEDIATRICS, V110, P315, DOI 10.1542/peds.110.2.315; Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Arbour NC, 2000, NAT GENET, V25, P187; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Ball TM, 2002, ARCH PEDIAT ADOL MED, V156, P121; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cottrez F, 2000, J IMMUNOL, V165, P4848; FEDERICO MJ, IN PRESS PEDIAT CLIN; Gehring U, 2001, J ALLERGY CLIN IMMUN, V108, P847, DOI 10.1067/mai.2001.119026; Gereda JE, 2000, JAMA-J AM MED ASSOC, V284, P1652, DOI 10.1001/jama.284.13.1652; Gereda JE, 2001, J ALLERGY CLIN IMMUN, V107, P790, DOI 10.1067/mai.2001.115245; HURWITZ ES, 1991, PEDIATRICS, V87, P62; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Jeannin P, 1998, J IMMUNOL, V160, P3555; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Litonjua AA, 2002, J ALLERGY CLIN IMMUN, V110, P736, DOI 10.1067/mai.2002.128948; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LOUHIALA PJ, 1995, AM J PUBLIC HEALTH, V85, P1109, DOI 10.2105/AJPH.85.8_Pt_1.1109; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 2002, J ALLERGY CLIN IMMUN, V110, P381, DOI 10.1067/mai.2002.126658; McHugh RS, 2002, J ALLERGY CLIN IMMUN, V110, P693, DOI 10.1067/mai.2002.129339; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Rautava S, 2002, J ALLERGY CLIN IMMUN, V109, P119, DOI 10.1067/mai.2002.120273; Reed CE, 2001, J ALLERGY CLIN IMMUN, V108, P157, DOI 10.1067/mai.2001.116862; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Salvi SS, 2001, AM J RESP CRIT CARE, V164, P1343; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; SHEIKH A, IN PRESS J ALLERGY C; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; WALD ER, 1991, J PEDIATR-US, V118, P509, DOI 10.1016/S0022-3476(05)83370-0; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	41	90	94	4	33	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2003	111	3					471	478		10.1067/mai.2003.172		8	Allergy; Immunology	Allergy; Immunology	656YW	WOS:000181639500005	12642824	
J	Sengler, C; Haider, A; Sommerfeld, C; Lau, S; Baldini, M; Martinez, F; Wahn, U; Nickel, R				Sengler, C; Haider, A; Sommerfeld, C; Lau, S; Baldini, M; Martinez, F; Wahn, U; Nickel, R		German Multicenter Allergy Study c	Evaluation of the CD14 C-159 T polymorphism in the German Multicenter Allergy Study cohort	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						atopy; CD14; genetics; IgE	ENDOTOXIN; EXPOSURE; ASTHMA; ATOPY; GENE	Background Multiple genetic studies have shown linkage of atopy-related phenotypes to chromosome 5q31. In this region several candidate genes for atopy are localized such as the Th2 cytokines IL-4, IL-5 and IL-13, but also CD14, a receptor for LPS. Recently, a functional CD14 promoter polymorphism was related to total and specific IgE responsiveness. Objective The aim of our study was to evaluate the role of this single nucleotide polymorphism (SNP) in a large German birth cohort. Methods Atopy-related phenotypes were longitudinally carefully evaluated in over 800 children from birth to the age of 10 years. Yearly visits included standardized interviews, physical examinations and determination of total and specific IgE antibodies. Pulmonary function tests and histamine provocations were performed at the age of seven. Eight-hundred and seventy-two children of the Multicenter Allergy Study (MAS) cohort were genotyped using melting curve and restriction digest analyses. Results CD14-159 allele frequencies were consistent with previous reports, however, no association of the SNP with asthma, atopic dermatitis, allergic rhinitis, total or specific IgE levels could be observed. Conclusion The CD14-159 SNP might not play a major role in the development of atopy in German children.	Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, D-13353 Berlin, Germany; Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA	Nickel, R (reprint author), Humboldt Univ, Charite, Dept Pediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.						Baldini M, 1999, AM J RESP CELL MOL, V20, P976; Bergmann RL, 1998, CLIN EXP ALLERGY, V28, P965; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Kulig M, 2000, J ALLERGY CLIN IMMUN, V106, P832, DOI 10.1067/mai.2000.110098; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LeVan TD, 2001, J IMMUNOL, V167, P5838; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Sengler Claudia, 2002, Respir Res, V3, P7, DOI 10.1186/rr179; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Vercelli D, 2001, INT ARCH ALLERGY IMM, V124, P20, DOI 10.1159/000053658; Verhasselt V, 1997, J IMMUNOL, V158, P2919; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230	13	90	90	0	3	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	FEB	2003	33	2					166	169		10.1046/j.1365-2222.2003.01549.x		4	Allergy; Immunology	Allergy; Immunology	644PN	WOS:000180927400005	12580907	
J	Redd, SC				Redd, SC			Asthma in the United States: Burden and current theories	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						asthma; epidemiology; hygiene; incidence; indoor environment; obesity	BODY-MASS INDEX; FAMILY-SIZE; WEIGHT; CHILDHOOD; ADULTS; RISK	Asthma has emerged as a major public health problem in the United States over the past 20 years. Currently, nearly 15 million Americans have asthma, including almost 5 million children. The number of asthma cases has more than doubled since 1980. Approximately 5,500 persons die from asthma each year, and rates have increased over the past 20 years. Rates of death, hospitalization, and emergency department visits are 2-3 times higher among African Americans than among white Americans. The costs of asthma have also increased to $12.7 billion in 1998. Both lifestyle and environmental hypotheses have been invoked to explain the increase in asthma prevalence. Several studies have examined the relationship of obesity and asthma and found associations suggesting that obesity predisposes to the development of asthma. Some studies have found that day care attendance and having older siblings protect against the development of asthma. This observation has led investigators to hypothesize that increased exposure to microbial agents might protect against asthma (the hygiene hypothesis). Environmental exposures found to predispose to asthma include house dust mite allergen and environmental tobacco smoke. Although current knowledge does not permit definitive conclusions about the causes of asthma onset, better adherence to current recommendations for medical therapy and environmental management of asthma would reduce the burden of this disease.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Air Pollut & Resp Hlth Branch, Atlanta, GA 30341 USA	Redd, SC (reprint author), CDC, 6 Execut Pk Dr,Bldg 6,Room 1019, Atlanta, GA 30329 USA.						Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Bernstein DI, 1997, JAMA-J AM MED ASSOC, V278, P1907, DOI 10.1001/jama.278.22.1907; Bodner C, 1998, THORAX, V53, P28; Busse WW, 2001, NEW ENGL J MED, V344, P350; Camargo CA, 1999, ARCH INTERN MED, V159, P2582, DOI 10.1001/archinte.159.21.2582; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P682; CHEN Y, 1993, THORAX, V48, P375, DOI 10.1136/thx.48.4.375; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Homa DM, 2000, AM J RESP CRIT CARE, V161, P504; IOM (Committee on the Assessment of Asthma and Indoor Air of the Institute of Medicine), 2000, CLEAR AIR ASTHM IND; Jatulis DE, 1998, ANN ALLERG ASTHMA IM, V81, P82; Linn W S, 1999, Curr Opin Pulm Med, V5, P21, DOI 10.1097/00063198-199901000-00004; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; Mokdad AH, 1999, JAMA-J AM MED ASSOC, V282, P1519, DOI 10.1001/jama.282.16.1519; National Asthma Education Prevention Program (NAEPP), 1997, NIH PUBL; Peters JM, 1999, AM J RESP CRIT CARE, V159, P760; PLATTSMILLS TA, 2001, AM J RESP CRIT CARE, V164, P1106; Rona RJ, 1997, J ALLERGY CLIN IMMUN, V99, P454, DOI 10.1016/S0091-6749(97)70070-8; Salvi SS, 2001, AM J RESP CRIT CARE, V164, P1343; Shaheen SO, 1999, THORAX, V54, P396; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; *US EPA NAT AIR QU, 2001, 454R01004 EPA NAT AI; Weiss KB, 2000, J ALLERGY CLIN IMMUN, V106, P493; WEISS KB, 1992, NEW ENGL J MED, V326, P862, DOI 10.1056/NEJM199203263261304; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	28	90	92	2	7	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	AUG	2002	110			4			557	560				4	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	586ER	WOS:000177572100008	12194886	
J	De Meer, G; Heederik, D; Postma, DS				De Meer, G; Heederik, D; Postma, DS			Bronchial responsiveness to adenosine 5 '-monophosphate (AMP) and methacholine differ in their relationship with airway allergy and baseline FEV	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						adenosine; bronchial hyperresponsiveness; methacholine; airway allergy	NITRIC-OXIDE LEVELS; ASTHMA; HYPERRESPONSIVENESS; INFLAMMATION; RHINITIS; MARKERS; NONASTHMATICS; EOSINOPHILS; PREVALENCE; POPULATION	Bronchial hyperresponsiveness (BHR) and inflammation are central hallmarks of asthma. Studies in patients with asthma suggest that BHR to adenosine 5'-monophosphate (AMP) is a better marker of bronchial inflammation than BHR to methacholine. The association between markers of airway inflammation and BHR to methacholine and AMP in a population of young adults, with mild symptoms if any, was evaluated. A total of 230 subjects who participated in a follow-up study on occupational allergy were included. Before exposure to occupational allergens, subjects completed a questionnaire on respiratory symptoms and were tested for atopy, blood eosinophilia (greater than or equal to 275/mm(3)), and BHR to methacholine and AMP (greater than or equal to 15% fall in FEV1). Risk estimates were expressed as prevalence ratios (PR) and 95% confidence intervals (95% CI). Dose-response slopes (DRS) for methacholine and AMP were compared between healthy control subjects, self-reported allergic rhinitis, and allergic asthma. BHR to AMP was associated with allergic rhinitis (PR 2.51, 95% Cl: 1.22;5.17), allergic asthma (PR 4.38, 95% Cl: 1.98;9.66), with atopy (PR 3.87, 95% Cl: 1.76;8.52), and blood eosinophilia (PR 3.57, 95% Cl: 1.48;8.77), but not with baseline FEV1. BHR to methacholine was inversely related to prechallenge FEV1 (PR 0.97, 95% Cl: 0.96;0.99). For both methacholine and AMP the geometric mean DRS increased along the axis asymptomatic-allergic rhinitis-allergic asthma, but for AMP the increase was the strongest. In this population study among young adults, BHR to AMP refers to allergic background of airway lability and BHR to methacholine is related to a diminished airway caliber.	Univ Utrecht, Div Environm & Occupat Hlth, Inst Risk Assessment Sci, NL-3508 TD Utrecht, Netherlands; Univ Groningen Hosp, Dept Pulmonol, Groningen, Netherlands	De Meer, G (reprint author), Univ Utrecht, Div Environm & Occupat Hlth, Inst Risk Assessment Sci, POB 80176, NL-3508 TD Utrecht, Netherlands.						Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; Crimi E, 1998, AM J RESP CRIT CARE, V157, P4; De Meer G, 2001, THORAX, V56, P362, DOI 10.1136/thorax.56.5.362; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; HOLGATE ST, 1986, ARCH INT PHARMACOD T, V280, P240; Ichinose M, 2000, EUR RESPIR J, V15, P248, DOI 10.1034/j.1399-3003.2000.15b05.x; IHRE E, 1993, CLIN EXP ALLERGY, V23, P298, DOI 10.1111/j.1365-2222.1993.tb00326.x; MENSINGA TT, 1990, J ALLERGY CLIN IMMUN, V86, P99, DOI 10.1016/S0091-6749(05)80129-0; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; OOSTERHOFF Y, 1993, AM REV RESPIR DIS, V147, P512; PEACHELL PT, 1988, AM REV RESPIR DIS, V138, P1143; PHILLIPS GD, 1990, AM REV RESPIR DIS, V141, P9; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1183/09031936.00.15103000; POLOSA R, 1995, AM J RESP CRIT CARE, V151, P624; PRIETO L, 1993, CLIN EXP ALLERGY, V23, P172, DOI 10.1111/j.1365-2222.1993.tb00878.x; PRIETO L, 1994, ANN ALLERGY, V72, P534; Rutgers SR, 2000, CLIN EXP ALLERGY, V30, P657; SEPPALA OP, 1991, RESP MED, V85, P365, DOI 10.1016/S0954-6111(06)80179-4; Thompson ML, 1998, OCCUP ENVIRON MED, V55, P272; van den Toorn LM, 2000, AM J RESP CRIT CARE, V162, P953; Van dn Berge M, 2001, AM J RESP CRIT CARE, V163, P1546; van Rensen ELJ, 1999, THORAX, V54, P403; vanVelzen E, 1996, THORAX, V51, P582, DOI 10.1136/thx.51.6.582; Weersink EJM, 1997, AM J RESP CRIT CARE, V155, P1241	25	90	92	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 1	2002	165	3					327	331				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	517PA	WOS:000173618100005	11818315	
J	Taylor, SL; Hefle, SL				Taylor, SL; Hefle, SL			Will genetically modified foods be allergenic?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						biotechnology; allergy; food; sequence homology; digestion; exposure; classification; heat stability	BREAST-FED INFANTS; COWS MILK ALLERGY; BETA-LACTOGLOBULIN; HYPERSENSITIVITY REACTIONS; BACILLUS-THURINGIENSIS; PEANUT PROTEIN; DOUBLE-BLIND; IN-VITRO; CHILDREN; IDENTIFICATION	Foods produced through agricultural biotechnology, including such staples as corn, soybeans, canola, and potatoes, are already reaching the consumer marketplace. Agricultural biotechnology offers the promise to produce crops with improved agronomic characteristics (eg, insect resistance, herbicide tolerance, disease resistance, and climatic tolerance) and enhanced consumer benefits (eg, better taste and texture, longer shelf life, and more nutritious). Certainly, the products of agricultural biotechnology should be subjected to a careful and complete safety assessment before commercialization. Because the genetic modification ultimately results in the introduction of new proteins into the food plant, the safety, including the potential allergenicity, of the newly introduced proteins must be assessed. Although most allergens are proteins, only a few of the many proteins found in foods are allergenic under the typical circumstances of exposure. The potential allergenicity of the introduced proteins call be evaluated by focusing on the source of the gene, the sequence homology of the newly introduced protein to known allergens, the expression level of the novel protein in the modified crop, the functional classification of the novel protein, the reactivity of the novel protein with IgE from the serum of individuals with known allergies to the source of the transferred genetic material, and various physicochemical properties of the newly introduced protein, such as heat stability and digestive stability. Few products of agricultural biotechnology (and none of the current products) will involve the transfer of genes from known allergenic sources, Applying such criteria provides reasonable assurance that the newly introduced protein has limited capability to become an allergen.	Univ Nebraska, Food Allergy Res & Resource Program, Lincoln, NE 68588 USA	Taylor, SL (reprint author), 143 Food Ind Complex, Lincoln, NE 68583 USA.						Aalberse RC, 1997, ENVIRON TOXICOL PHAR, V4, P55, DOI 10.1016/S1382-6689(97)10042-4; ARSHAD SH, 1991, CLIN EXP ALLERGY, V21, P373, DOI 10.1111/j.1365-2222.1991.tb01671.x; Astwood JD, 1996, NAT BIOTECHNOL, V14, P1269, DOI 10.1038/nbt1096-1269; Beever D. E., 2000, Nutrition Abstracts and Reviews. Series B, Livestock Feeds and Feeding, V70, P175; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V84, P701, DOI 10.1016/0091-6749(89)90298-4; Betz FS, 2000, REGUL TOXICOL PHARM, V32, P156, DOI 10.1006/rtph.2000.1426; BOCK SA, 1977, CLIN ALLERGY, V7, P375, DOI 10.1111/j.1365-2222.1977.tb01466.x; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; *FAO UN, 1995, REP FAO TECHN CONS F; FAO/WHO consultation, 2000, SAF ASP GEN MOD FOOD; *FAO WHO CONS, 1996, 61 FAOWHO CONS; Fukushima Y, 1997, AM J CLIN NUTR, V65, P30; Harrison LA, 1996, J NUTR, V126, P728; HEFTE SL, 1996, CRIT REV FOOD SCI S, V36, pS69; HOST A, 1990, CLIN EXP ALLERGY, V20, P383, DOI 10.1111/j.1365-2222.1990.tb02798.x; Houben GF, 1997, ENVIRON TOXICOL PHAR, V4, P127, DOI 10.1016/S1382-6689(97)10053-9; Hourihane JO, 1997, J ALLERGY CLIN IMMUN, V100, P596, DOI 10.1016/S0091-6749(97)70161-1; *IFT, 2000, FOOD TECHNOL, V54, P62; *IFT, 2000, FOOD TECHNOL, V54, P61; *IFT, 2000, FOOD TECHNOL, V54, P124; Knippels LMJ, 1999, FOOD CHEM TOXICOL, V37, P881, DOI 10.1016/S0278-6915(99)00064-2; Knippels LMJ, 1998, CLIN EXP ALLERGY, V28, P368, DOI 10.1046/j.1365-2222.1998.00242.x; MACHTINGER S, 1986, J ALLERGY CLIN IMMUN, V77, P341, DOI 10.1016/S0091-6749(86)80115-4; MAY CD, 1976, J ALLERGY CLIN IMMUN, V58, P500, DOI 10.1016/0091-6749(76)90194-9; Metcalfe DD, 1996, CRIT REV FOOD SCI, V36, pS165; Moneret-Vautrin D A, 1995, Allerg Immunol (Paris), V27, P2; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nordlee JA, 1996, NEW ENGL J MED, V334, P688, DOI 10.1056/NEJM199603143341103; Rance F, 1998, J ALLERGY CLIN IMMUN, V101, pS88; Redenbaugh K., 1992, SAFETY ASSESSMENT GE, P267; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Schnepf E, 1998, MICROBIOL MOL BIOL R, V62, P775; Shin DS, 1998, J BIOL CHEM, V273, P13753, DOI 10.1074/jbc.273.22.13753; SORVA R, 1994, J ALLERGY CLIN IMMUN, V93, P787, DOI 10.1016/0091-6749(94)90259-3; Taylor SL, 1997, ENVIRON TOXICOL PHAR, V4, P121, DOI 10.1016/S1382-6689(97)10052-7; Taylor SL, 1996, CRIT REV FOOD SCI, V36, pS91; Underwood BA, 1994, RETINOIDS BIOL CHEM, P217; VANASPEREN PP, 1983, ARCH DIS CHILD, V58, P253; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; Wal JM, 1998, INT DAIRY J, V8, P413, DOI 10.1016/S0958-6946(98)00064-8; WARNER JO, 1980, CLIN ALLERGY, V10, P133, DOI 10.1111/j.1365-2222.1980.tb02090.x; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303	43	90	95	9	93	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2001	107	5					765	771				7	Allergy; Immunology	Allergy; Immunology	434JX	WOS:000168812300001	11344340	
J	Whigham, LD; Cook, EB; Stahl, JL; Saban, R; Bjorling, DE; Pariza, MW; Cook, ME				Whigham, LD; Cook, EB; Stahl, JL; Saban, R; Bjorling, DE; Pariza, MW; Cook, ME			CLA reduces antigen-induced histamine and PGE(2) release from sensitized guinea pig tracheae	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						type I hypersensitivity; conjugated linoleic acid; immunity; allergies; asthma	CONJUGATED LINOLEIC-ACID; 3T3-L1 PREADIPOCYTES; BODY-COMPOSITION; FATTY-ACIDS; LYMPHOCYTE; MODULATION; GROWTH; RATS; MICE; PROLIFERATION	Conjugated linoleic acid (CLA) has been shown to enhance immune reactions such as lymphocyte blastogenesis and delayed-type hypersensitivity. We investigated the role of CLA in type I (immediate) hypersensitivity, using a guinea pig tracheal superfusion model for measuring antigen-induced airway smooth muscle contraction and inflammatory mediator release. Female Hartley guinea pigs were fed a diet supplemented with 0.25 g corn oil or linoleic acid/100 g of diet (control) or 0.25 g CLA/100 g of diet for at least 1 wk before and during active sensitization to ovalbumin antigen. Tracheae from sensitized guinea pigs were suspended in air-filled water-jacketed (37 degrees C) tissue chambers in a superfusion apparatus. Tracheae were superfused with buffer containing antigen, and tissue contraction was recorded. Superfusate was collected at 90-s intervals for evaluation of histamine and PGE(2) release. CLA did not affect antigen-induced tracheal contractions when expressed as gram contraction per gram tissue. CLA significantly reduced antigen-induced histamine and PGE(2) release. CLA appears to decrease release of some inflammatory mediators during type I hypersensitivity reactions.	Univ Wisconsin, Coll Agr & Life Sci, Dept Anim Sci, Madison, WI 53706 USA; Univ Wisconsin, Coll Agr & Life Sci, Dept Nutr Sci, Madison, WI 53706 USA; Univ Wisconsin, Sch Med, Dept Med, Madison, WI 53706 USA; Univ Wisconsin, Sch Vet Med, Dept Surg Sci, Madison, WI 53706 USA; Univ Wisconsin, Food Res Inst, Madison, WI 53706 USA; Univ Texas, Dept Internal Med, Galveston, TX 77555 USA	Cook, ME (reprint author), Univ Wisconsin, Coll Agr & Life Sci, Dept Anim Sci, 1675 Observ Dr, Madison, WI 53706 USA.						*AM AC ALL ASTHM I, 1998, EX SUMM; Banni S, 1996, J NUTR BIOCHEM, V7, P150, DOI 10.1016/0955-2863(95)00193-X; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Black PN, 1999, J ALLERGY CLIN IMMUN, V103, P351, DOI 10.1016/S0091-6749(99)70513-0; Brodie AE, 1999, J NUTR, V129, P602; Chew BP, 1997, ANTICANCER RES, V17, P1099; Chin S. F., 1992, Journal of Food Composition and Analysis, V5, P185, DOI 10.1016/0889-1575(92)90037-K; CHIN SF, 1994, J NUTR, V124, P2344; CONSTANTINE JW, 1965, J PHARM PHARMACOL, V17, P384; COOK ME, 1993, POULTRY SCI, V72, P1301; FISHLEDER RI, 1984, J PHARMACOL EXP THER, V230, P534; GOLD KN, 1994, ARTHRITIS RHEUM, V37, P925, DOI 10.1002/art.1780370623; HA YL, 1987, CARCINOGENESIS, V8, P1881, DOI 10.1093/carcin/8.12.1881; KLEEBERGER SR, 1995, ASTHMA RHINITIS, P825; LEE KN, 1994, ATHEROSCLEROSIS, V108, P19, DOI 10.1016/0021-9150(94)90034-5; Lee KN, 1998, BIOCHEM BIOPH RES CO, V248, P817, DOI 10.1006/bbrc.1998.8994; Li Y, 1998, LIPIDS, V33, P417, DOI 10.1007/s11745-998-0223-9; Liu KL, 1997, LIPIDS, V32, P725, DOI 10.1007/s11745-997-0092-2; MILLER CC, 1994, BIOCHEM BIOPH RES CO, V198, P1107, DOI 10.1006/bbrc.1994.1157; NUGTEREN DH, 1970, BIOCHIM BIOPHYS ACTA, V210, P171, DOI 10.1016/0005-2760(70)90072-X; Park Y, 1997, LIPIDS, V32, P853, DOI 10.1007/s11745-997-0109-x; Park Y, 1999, LIPIDS, V34, P235, DOI 10.1007/s11745-999-0358-8; Park Y., 1996, THESIS U WISCONSIN M; ROPER RL, 1992, J IMMUNOL, V149, P2984; Satory DL, 1999, J NUTR, V129, P92; Sebedio JL, 1997, BBA-LIPID LIPID MET, V1345, P5, DOI 10.1016/S0005-2760(97)00015-5; Sugano M, 1997, J NUTR BIOCHEM, V8, P38, DOI 10.1016/S0955-2863(96)00150-7; Sugano M, 1998, LIPIDS, V33, P521, DOI 10.1007/s11745-998-0236-4; SUNSHINE C, 1994, BBA-BIOMEMBRANES, V1191, P59, DOI 10.1016/0005-2736(94)90233-X; UNDEM BJ, 1985, AM REV RESPIR DIS, V131, P260; WONG DTO, 1976, INT ARCH ALLER A IMM, V50, P155; Wong MW, 1997, ANTICANCER RES, V17, P987; WOODBAKER R, 1995, ASTHMA RHINITIS, P791	33	90	92	0	2	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119			AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	MAR	2001	280	3					R908	R912				5	Physiology	Physiology	401FQ	WOS:000166917900038	11171673	
J	Brenner, AV; Wang, ZY; Kleinerman, RA; Wang, LD; Zhang, SZ; Metayer, C; Chen, K; Lei, SW; Cui, HX; Lubin, JH				Brenner, AV; Wang, ZY; Kleinerman, RA; Wang, LD; Zhang, SZ; Metayer, C; Chen, K; Lei, SW; Cui, HX; Lubin, JH			Previous pulmonary diseases and risk of lung cancer in Gansu Province, China	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						case-control studies; lung neoplasms; tuberculosis; pulmonary; bronchitis; pulmonary emphysema; asthma; pneumonia	NONSMOKING WOMEN; FAMILY HISTORY; TUBERCULOSIS PATIENTS; RESPIRATORY-DISEASE; MORTALITY; SMOKING; COHORT; EXPOSURE; ASTHMA; MINERS	Backgrounds Although active smoking is well established as the main cause of lung cancer, there is accumulating evidence that history of prior lung diseases may be an independent risk factor for lung cancer. Methods A population-based case-control study in Gansu Province, China identified 886 lung cancer cases (656 male, 230 female) diagnosed between January 1994 and April 1998. A standardized interview collected information on a variety of potential risk factors including a history of physician-diagnosed non-malignant lung diseases (pulmonary tuberculosis, chronic bronchitis/emphysema, asthma, pneumonia), age and year in which each condition was first diagnosed, and any therapy or hospitalization received. Results Pulmonary tuberculosis (odds ratio [OR] = 2.1, 95% CI:1.4-3.1) and chronic bronchitis/emphysema (OR = 1.4 95% CI : 1.1-1.8) were associated with increased risk of lung cancer, after adjustment for active smoking and socioeconomic status. The OR for asthma (OR = 1.4, 95% CI : 0.9-2.1) and pneumonia (OR = 1.5, 95% CI: 1.0-2.3) were also elevated. The risk of lung cancer remained significant for pulmonary tuberculosis and chronic bronchitis/emphysema when analysis was limited to the pathologically confirmed cases and self-responders. Conclusions This study provides additional evidence that previous pulmonary tuberculosis and chronic bronchitis/emphysema are causally related to lung cancer, although the precise mechanism is still unclear. The results for asthma and pneumonia, while suggestive of a positive association, did not reach the traditional level of statistical significance and should be interpreted with caution.	NCI, Div Canc Epidemiol & Genet, Radiat Epidemiol Branch, Bethesda, MD 20892 USA	Brenner, AV (reprint author), NCI, Div Canc Epidemiol & Genet, Radiat Epidemiol Branch, 6120 Execut Blvd,MSC 7362, Bethesda, MD 20892 USA.			Kleinerman, Ruth/0000-0001-7415-2478	NCI NIH HHS [N01-CP-50509]		ALAVANJA MCR, 1992, AM J EPIDEMIOL, V136, P623; BAKRIS GL, 1983, CANCER, V52, P493, DOI 10.1002/1097-0142(19830801)52:3<493::AID-CNCR2820520319>3.0.CO;2-Y; Blot WJ, 1996, CANC EPIDEMIOLOGY PR, P637; Breslow N. E, 1980, STAT METHODS CANC RE, V1; CAMPBELL A H, 1970, British Journal of Diseases of the Chest, V64, P141, DOI 10.1016/S0007-0971(70)80002-X; COHEN BH, 1978, LANCET, V2, P1024; COHEN BH, 1977, LANCET, V2, P523; DAVIS FG, 1989, CANCER RES, V49, P6130; GAO YT, 1987, INT J CANCER, V40, P604, DOI 10.1002/ijc.2910400505; HOWE GR, 1979, INT J EPIDEMIOL, V8, P305, DOI 10.1093/ije/8.4.305; Huovinen E, 1997, THORAX, V52, P49; Ko YC, 1997, INT J EPIDEMIOL, V26, P24, DOI 10.1093/ije/26.1.24; KODOLOVA IM, 1986, ARK PATOL, V48, P52; Liu Qing, 1993, American Journal of Epidemiology, V137, P145; LIU ZY, 1992, INT J EPIDEMIOL, V21, P197, DOI 10.1093/ije/21.2.197; LUBIN JH, 1984, J NATL CANCER I, V73, P383; LUBIN JH, 1995, J NATL CANCER I, V87, P817, DOI 10.1093/jnci/87.11.817; Lubin JH, 1997, RADIAT RES, V147, P126, DOI 10.2307/3579412; Luo RX, 1996, LUNG CANCER-J IASLC, V14, pS113, DOI 10.1016/S0169-5002(96)90217-2; Magnussen H, 1998, CLIN EXP ALLERGY, V28, P187; Markewitz BA, 1999, AM J MED SCI, V318, P74, DOI 10.1097/00000441-199908000-00002; Matsushita H, 1995, PATHOL INT, V45, P925, DOI 10.1111/j.1440-1827.1995.tb03417.x; Mayne ST, 1999, AM J EPIDEMIOL, V149, P13; Ogura T, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P294; OHSHIMA H, 1994, MUTAT RES, V305, P253, DOI 10.1016/0027-5107(94)90245-3; OSANN KE, 1991, CANCER RES, V51, P4893; SAMET JM, 1986, AM REV RESPIR DIS, V134, P466; Shen XB, 1996, LUNG CANCER-J IASLC, V14, pS107, DOI 10.1016/S0169-5002(96)90216-0; SKILLRUD DM, 1986, ANN INTERN MED, V105, P503; *STAT AN SYST I IN, 1996, US GUID STAT VERS 6; TOCKMAN MS, 1987, ANN INTERN MED, V106, P512; VENA JE, 1985, AM J EPIDEMIOL, V122, P66; Wang ZY, 1996, HEALTH PHYS, V70, P192, DOI 10.1097/00004032-199602000-00006; WU AH, 1995, AM J EPIDEMIOL, V141, P1023; WU AH, 1988, CANCER RES, V48, P7279; WUWILLIAMS AH, 1990, BRIT J CANCER, V62, P982, DOI 10.1038/bjc.1990.421; ZHENG W, 1987, BRIT J CANCER, V56, P501, DOI 10.1038/bjc.1987.233; ZHINGEL IP, 1989, PROBL TUBERK, V6, P26	38	90	97	0	1	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	FEB	2001	30	1					118	124		10.1093/ije/30.1.118		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	413AG	WOS:000167587300032	11171871	
J	Bugajska-Schretter, A; Grote, M; Vangelista, L; Valent, P; Sperr, WR; Rumpold, H; Pastore, A; Reichelt, R; Valenta, R; Spitzauer, S				Bugajska-Schretter, A; Grote, M; Vangelista, L; Valent, P; Sperr, WR; Rumpold, H; Pastore, A; Reichelt, R; Valenta, R; Spitzauer, S			Purification, biochemical, and immunological characterisation of a major food allergen: different immunoglobulin E recognition of the apo- and calcium-bound forms of carp parvalbumin	GUT			English	Article						food allergy; parvalbumin; circular dichroism; epitopes; antibodies; immunochemistry	BINDING PROTEIN PARVALBUMIN; BIRCH POLLEN ALLERGEN; FISH HYPERSENSITIVITY; MUSCULAR PARVALBUMINS; ADVERSE REACTIONS; IGE-BINDING; MUSCLE; SITES; EXPRESSION; CHALLENGE	Background-Almost 4% of the population suffer from food allergy which is an adverse reaction to food with an underlying immunological mechanism. Aims-To characterise one of the most frequent IgE defined food allergens, fish parvalbumin. Methods-Tissue and subcellular distribution of carp parvalbumin was analysed by immunogold electron microscopy and cell fractionation. Parvalbumin was purified to homogeneity, analysed by mass spectrometry and circular dichroism (CD) spectroscopy, and its allergenic activity was analysed by IgE binding and basophil histamine release tests. Results-The isoelectric point (pI) 4.7 form of carp parvalbumin, a three EF-hand calcium-binding protein, was purified to homogeneity. CD analysis revealed a remarkable stability and refolding capacity of calcium-bound parvalbumin. This may explain why parvalbumin, despite cooking and exposure to the gastrointestinal tract, can sensitise patients. Purified parvalbumin reacted with IgE of more than 95% of individuals allergic to fish, induced dose-dependent basophil histamine release and contained, on average, 83% of the IgE epitopes present in other fish species. Calcium depletion reduced the IgE binding capacity of parvalbumin which, according to CD analysis, may be due to conformation-dependent IgE recognition. Conclusions-Purified carp parvalbumin represents an important cross reactive food allergen. It can be used for in vitro and in vivo diagnosis of fish-induced food allergy. Our finding that the ape-form of parvalbumin had a greatly reduced IgE binding capacity indicates that this form may be a candidate for safe immunotherapy of fish-related food allergy.	Univ Vienna, AKH, Inst Med & Chem Lab, A-1090 Vienna, Austria; Univ Munster, Inst Med Phys & Biophys, D-4400 Munster, Germany; European Mol Biol Lab, Heidelberg, Germany; Univ Vienna, AKH, Dept Internal Med 1, Div Haematol, A-1090 Vienna, Austria; Natl Inst Med Res, Mol Struct Div, London NW7 1AA, England; Univ Vienna, AKH, Dept Pathophysiol, A-1090 Vienna, Austria	Valenta, R (reprint author), Univ Vienna, Vienna Gen Hosp, Dept Pathophysiol, Immunopathol Grp, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.				Medical Research Council [MC_U117584256]		AAS K, 1969, J ALLERGY, V44, P333, DOI 10.1016/0021-8707(69)90025-2; ATKINS FM, 1985, J ALLERGY CLIN IMMUN, V75, P348, DOI 10.1016/0091-6749(85)90071-5; BERCHTOLD MW, 1989, BIOCHIM BIOPHYS ACTA, V1009, P201, DOI 10.1016/0167-4781(89)90104-8; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; BINDSLEV JC, 1998, ALLERGY, V53, P725; Bischoff SC, 1997, GUT, V40, P745; Bischoff SC, 1996, ALLERGY, V51, P811; BLUM HE, 1977, J BIOL CHEM, V252, P2834; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BREITENEDER H, 1989, EMBO J, V8, P1935; BRUIJNZEELKOOMEN C, 1995, ALLERGY, V50, P623, DOI 10.1111/j.1398-9995.1995.tb02579.x; Bugajska-Schretter A, 1998, J ALLERGY CLIN IMMUN, V101, P67, DOI 10.1016/S0091-6749(98)70195-2; CELIO MR, 1981, NATURE, V293, P300, DOI 10.1038/293300a0; CELIO MR, 1988, CELL CALCIUM, V9, P81, DOI 10.1016/0143-4160(88)90027-9; COFFEE CJ, 1973, J BIOL CHEM, V248, P3305; CRESPO JF, 1992, J ALLERGY CLIN IMMUN, V89, P192; DECLERCQ JP, 1991, J MOL BIOL, V220, P1017, DOI 10.1016/0022-2836(91)90369-H; DEMARTINO M, 1990, J ALLERGY CLIN IMMUN, V86, P909, DOI 10.1016/S0091-6749(05)80154-X; DUBUSKE LM, 1993, ALLERGY PROC, V14, P243, DOI 10.2500/108854193778811955; ELSAYED S, 1975, SCAND J IMMUNOL, V4, P203, DOI 10.1111/j.1365-3083.1975.tb02618.x; ENDO T, 1985, ENDOCRINOLOGY, V117, P527; Etesamifar M, 1998, ALLERGOLOGIE, V21, P451; GOODMAN M, 1977, J MOL EVOL, V9, P131, DOI 10.1007/BF01732745; GOODMAN M, 1979, J MOL EVOL, V13, P331, DOI 10.1007/BF01731373; HAIECH J, 1979, BIOCHEMISTRY-US, V18, P2752, DOI 10.1021/bi00580a010; HEIZMANN CW, 1991, TRENDS BIOCHEM SCI, V16, P98, DOI 10.1016/0968-0004(91)90041-S; HEIZMANN CW, 1982, P NATL ACAD SCI-BIOL, V79, P7243, DOI 10.1073/pnas.79.23.7243; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; KRETSINGER RH, 1973, J BIOL CHEM, V248, P3313; Laberge M, 1997, BIOCHEMISTRY-US, V36, P5363, DOI 10.1021/bi962436q; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHKY P, 1974, J BIOL CHEM, V249, P4332; LEVY JH, 1989, J THORAC CARDIOV SUR, V98, P200; ONEIL C, 1993, CLIN REV ALLERG, V11, P183; Pascual C, 1992, J PEDIATR, V121, P29; PAULS TL, 1994, BIOCHEMISTRY-US, V33, P10393, DOI 10.1021/bi00200a021; PECHERE JF, 1971, BIOCHIM BIOPHYS ACTA, V236, P391, DOI 10.1016/0005-2795(71)90220-0; PECHERE JF, 1971, EUR J BIOCHEM, V23, P421, DOI 10.1111/j.1432-1033.1971.tb01636.x; Sampson HA, 1997, JAMA-J AM MED ASSOC, V278, P1888, DOI 10.1001/jama.278.22.1888; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; SEIBERLER S, 1994, EMBO J, V13, P3481; Strynadka N.C.J., 1991, CURR OPIN STRUC BIOL, V1, P905, DOI 10.1016/0959-440X(91)90085-8; SUDHAKAR K, 1995, BIOCHEMISTRY-US, V34, P1355, DOI 10.1021/bi00004a030; Tan RY, 1996, J BIOL CHEM, V271, P7479; Teitelbaum JE, 1998, CURR OPIN GASTROEN, V14, P498, DOI 10.1097/00001574-199811000-00014; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; Valenta R, 1999, BIOL CHEM, V380, P815, DOI 10.1515/BC.1999.101; Valenta R, 1998, ALLERGY, V53, P552, DOI 10.1111/j.1398-9995.1998.tb03930.x; WESIERSKAGADEK J, 1985, EUR J BIOCHEM, V153, P421, DOI 10.1111/j.1432-1033.1985.tb09319.x	52	90	95	4	14	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0017-5749			GUT	Gut	MAY	2000	46	5					661	669		10.1136/gut.46.5.661		9	Gastroenterology & Hepatology	Gastroenterology & Hepatology	308HQ	WOS:000086704900017	10764710	
J	Guez, S; Vatrinet, C; Fadel, R; Andre, C				Guez, S; Vatrinet, C; Fadel, R; Andre, C			House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study	ALLERGY			English	Article						house-dust mite; perennial rhinitis; sublingual immunotherapy	CONTROLLED TRIAL; ALLERGIC RHINITIS; POLLEN EXTRACT; ASTHMA; RHINOCONJUNCTIVITIS; EFFICACY; CHILDREN; EXPOSURE; IGE	Background: The safety and efficacy of sublingual-swallow immunotherapy (SLIT) in rhinitis caused by house-dust mite were evaluated in a double-blind, placebo-controlled study including 75 patients for 24 months. Methods: Patients received either placebo or SLIT with a standardized Dermatophagoides pteronyssinus (D.pt.) - D. farinae (D.f.) 50/50 extract. The mean cumulative dose was 90 000 IR, equivalent to 2.2 mg of Der p 1 and 1.7 mg of Der f I. Symptom and medication scores were assessed throughout the study. Exposure to house-dust mite, skin sensitivity, and serum specific IgE and IgG4 were assessed before starting treatment and after 12 and 24 months. Results: Seventy-two patients (36 active-36 placebo) were eligible for intent-to-treat analysis. Thirty-six patients dropped out of the study. The number of patients who dropped out due to lack of efficacy was eight out of 37 (21.6%) in the active treatment group compared to 15 out of 38 (39.5%) in the placebo group (chi-square = 2.81, P = 0.09). Total symptom and medication scores decreased significantly after 12 and 24 months (P < 0.05) of treatment in both groups, but no significant difference was observed between the active and placebo groups. After 24 months, the number of patients with high levels of indoor allergenic load decreased significantly in both groups compared to baseline data (P = 0.01). Specific IgE (D.pt. and D.f.) increased significantly in the active treatment group after 12 and 24 months, while no change was observed in the placebo group. Specific IgG4 levels were not significantly modified in either group. Two patients in each group reported mild adverse effects. No severe adverse effects were reported. Conclusions: We conclude that SLIT in rhinitis caused by house-dust mite was safe, but there was a lack of consistent clinical benefit compared to placebo, probably due to the impact of the allergen avoidance measures that lowered the allergen burden.	Stallergenes SA, Sci & Med Dept, F-92183 Antony, France; Assoc Promot Allergol Aquitaine, Bordeaux, France	Andre, C (reprint author), Stallergenes SA, Sci & Med Dept, 6 Rue Alexis Tocqueville, F-92183 Antony, France.						ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Bousquet J, 1999, ALLERGY, V54, P249, DOI 10.1034/j.1398-9995.1999.00916.x; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V86, P292, DOI 10.1016/S0091-6749(05)80091-0; BOUSQUET J, 1992, ALLERGIC NONALLERGIC, P136; Clavel R, 1998, ALLERGY, V53, P493, DOI 10.1111/j.1398-9995.1998.tb04086.x; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; Feliziani V, 1995, Allergol Immunopathol (Madr), V23, P224; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; MALLING HJ, 1993, ALLERGY, V48, P9; Malling HJ, 1998, ALLERGY, V53, P461; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Passalacqua G, 1998, LANCET, V351, P629, DOI 10.1016/S0140-6736(97)07055-4; Platts-Mills Thomas A. E., 1997, Journal of Allergy and Clinical Immunology, V100, pS1; QUOIX E, 1993, ALLERGY, V48, P306, DOI 10.1111/j.1398-9995.1993.tb02397.x; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; SABBAH A, 1994, ALLERGY, V49, P309, DOI 10.1111/j.1398-9995.1994.tb02273.x; SENSI LG, 1994, CLIN EXP ALLERGY, V24, P377, DOI 10.1111/j.1365-2222.1994.tb00250.x; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; TROISE C, 1995, J INVEST ALLERG CLIN, V5, P25; VARNEY VA, 1991, BRIT MED J, V302, P265; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x	25	90	92	0	4	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	APR	2000	55	4					369	375		10.1034/j.1398-9995.2000.00413.x		7	Allergy; Immunology	Allergy; Immunology	300WT	WOS:000086277300008	10782522	
J	Jefferson, T; Jones, M; Doshi, P; Spencer, EA; Onakpoya, I; Heneghan, CJ				Jefferson, Tom; Jones, Mark; Doshi, Peter; Spencer, Elizabeth A.; Onakpoya, Igho; Heneghan, Carl J.			Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments	BMJ-BRITISH MEDICAL JOURNAL			English	Article							NEUROPSYCHIATRIC ADVERSE EVENTS; PROPHYLAXIS	Objective To describe the potential benefits and harms of oseltamivir by reviewing all clinical study reports (or similar document when no clinical study report exists) of randomised placebo controlled trials and regulatory comments ("regulatory information"). Design Systematic review of regulatory information. Data sources Clinical study reports, trial registries, electronic databases, regulatory archives, and correspondence with manufacturers. Eligibility criteria for selecting studies Randomised placebo controlled trials on adults and children who had confirmed or suspected exposure to natural influenza. Main outcome measures Time to first alleviation of symptoms, influenza outcomes, complications, admissions to hospital, and adverse events in the intention to treat population. Results From the European Medicines Agency and Roche, we obtained clinical study reports for 83 trials. We included 23 trials in stage 1 (reliability and completeness screen) and 20 in stage 2 (formal analysis). In treatment trials on adults, oseltamivir reduced the time to first alleviation of symptoms by 16.8 hours (95% confidence interval 8.4 to 25.1 hours, P<0.001). There was no effect in children with asthma, but there was an effect in otherwise healthy children (mean difference 29 hours, 95% confidence interval 12 to 47 hours, P=0.001). In treatment trials there was no difference in admissions to hospital in adults (risk difference 0.15%, 95% confidence interval -0.91% to 0.78%, P=0.84) and sparse data in children and for prophylaxis. In adult treatment trials, oseltamivir reduced investigator mediated unverified pneumonia (risk difference 1.00%, 0.22% to 1.49%; number needed to treat to benefit (NNTB) 100, 95% confidence interval 67 to 451). The effect was not statistically significant in the five trials that used a more detailed diagnostic form for "pneumonia," and no clinical study reports reported laboratory or diagnostic confirmation of "pneumonia." The effect on unverified pneumonia in children and for prophylaxis was not significant. There was no significant reduction in risk of unverified bronchitis, otitis media, sinusitis, or any complication classified as serious or that led to study withdrawal. 14 of 20 trials prompted participants to self report all secondary illnesses to an investigator. Oseltamivir in the treatment of adults increased the risk of nausea (risk difference 3.66%, 0.90% to 7.39%; number needed to treat to harm (NNTH) 28, 95% confidence interval 14 to 112) and vomiting (4.56%, 2.39% to 7.58%; 22, 14 to 42). In treatment of children, oseltamivir induced vomiting (5.34%, 1.75% to 10.29%; 19, 10 to 57). In prophylaxis trials, oseltamivir reduced symptomatic influenza in participants by 55% (3.05%, 1.83% to 3.88%; NNTB 33, 26 to 55) and households (13.6%, 9.52% to 15.47%; NNTB 7, 6 to 11) based on one study, but there was no significant effect on asymptomatic influenza and no evidence of a reduction in transmission. In prophylaxis studies, oseltamivir increased the risk of psychiatric adverse events during the combined "on-treatment" and "off-treatment" periods (risk difference 1.06%, 0.07% to 2.76%; NNTH 94, 36 to 1538) and there was a dose-response effect on psychiatric events in two "pivotal" treatment trials of oseltamivir, at 75 mg (standard dose) and 150 mg (high dose) twice daily (P=0.038). In prophylaxis studies, oseltamivir increased the risk of headaches on-treatment (risk difference 3.15%, 0.88% to 5.78%; NNTH 32, 18 to 115), renal events with treatment (0.67%, -0.01% to 2.93%), and nausea while receiving treatment (4.15%, 0.86% to 9.51%; NNTH 25, 11 to 116). Conclusions In prophylactic studies oseltamivir reduces the proportion of symptomatic influenza. In treatment studies it also modestly reduces the time to first alleviation of symptoms, but it causes nausea and vomiting and increases the risk of headaches and renal and psychiatric syndromes. The evidence of clinically significant effects on complications and viral transmission is limited because of rarity of such events and problems with study design. The trade-off between benefits and harms should be borne in mind when making decisions to use oseltamivir for treatment, prophylaxis, or stockpiling.	[Jefferson, Tom] Cochrane Acute Resp Infect Grp, I-00187 Rome, Italy; [Jones, Mark] Univ Queensland, Sch Populat Hlth, Brisbane, Qld, Australia; [Doshi, Peter] Univ Maryland, Sch Pharm, Dept Pharmaceut Hlth Serv Res, Baltimore, MD 21201 USA; [Spencer, Elizabeth A.; Onakpoya, Igho; Heneghan, Carl J.] Univ Oxford, Nuffield Dept Primary Care Hlth Sci, Oxford, England	Jefferson, T (reprint author), Cochrane Acute Resp Infect Grp, Via Puglie 23, I-00187 Rome, Italy.	jefferson.tom@gmail.com		Spencer, Elizabeth/0000-0002-9079-8006	NIHR Health Technology Assessment programme	This project was funded by the NIHR Health Technology Assessment programme and will be published in full in the Health Technology Assessment journal series (more details are available at www.nets.nihr.ac.uk/projects/hta/108001). The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health. The study sponsor had no role in study design; the collection, analysis, and interpretation of data; the writing of the article; and the decision to submit the article for publication. All the authors have no ties to the manufacturer or the sponsor (apart from those disclosed) and had access to all parts of the deidentified clinical study reports from the oseltamivir trial programme.	Donaldson L, 2006, J ROY SOC MED, V99, P222, DOI 10.1258/jrsm.99.5.222; Doshi P., 2013, BMJ OPEN, V3, DOI [DOI 10.1136/BMJOPEN-2012-002496, 10.1136/bmjopen-2012-002496]; Doshi P, 2012, BRIT MED J, V344, DOI 10.1136/bmj.d7898; European Medicines Agency, 2010, EUROPEAN MEDICINES A; Food and Drug Administration, 2000, MEDICAL REVIEW PART; Food and Drug Administration, 2000, DRUG APPROVAL PACKAG; Godlee F, 2012, BMJ-BRIT MED J, V345, pe7304; F Hoffmann-La Roche, 2013, ROCHE GLOBAL POLICY; Hrobjartsson A, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e1119; Jefferson T, 2011, BMJ-BRIT MED J, V342, pc7258; Jefferson T., 2014, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD008965.PUB4; Jefferson T, 2009, BRIT MED J, V339, DOI 10.1136/bmj.b5106; Jones M, 2012, DRUG SAFETY, V35, P1187, DOI 10.2165/11641690-000000000-00000; Shun-Shin M, 2009, BRIT MED J, V339, pb3172; Toovey S, 2012, DRUG SAFETY, V35, P1188; Toovey S, 2008, DRUG SAFETY, V31, P1097, DOI 10.2165/0002018-200831120-00006; US Department of Health and Human Services, 2005, HHS PANDEMIC INFLUEN; [Anonymous], 2013, WHO MODEL LIST OF ES; World Health Organization, 2007, WHO INTERIM PROTOCOL; [Anonymous], 2009, INVESTIGATORS GUIDE	20	89	97	1	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	APR 9	2014	348								g2545	10.1136/bmj.g2545		18	Medicine, General & Internal	General & Internal Medicine	AE9SE	WOS:000334348700012	24811411	
J	Ly, NP; Litonjua, A; Gold, DR; Celedon, JC				Ly, Ngoc P.; Litonjua, Augusto; Gold, Diane R.; Celedon, Juan C.			Gut microbiota, probiotics, and vitamin D: Interrelated exposures influencing allergy, asthma, and obesity?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						Microbiota; asthma; obesity; allergic; eczema; vitamin D; probiotics; cytokines	PLACEBO-CONTROLLED TRIAL; DIET-INDUCED OBESITY; RANDOMIZED CONTROLLED-TRIAL; BODY-MASS INDEX; AGE 5 YEARS; ANTIBIOTIC USE; INTESTINAL MICROFLORA; EARLY-LIFE; 1ST YEAR; AIRWAY INFLAMMATION	Current evidence supports a role for gut colonization in promoting and maintaining a balanced immune response in early life. An altered or less diverse gut microbiota composition has been associated with atopic diseases, obesity, or both. Moreover, certain gut microbial strains have been shown to inhibit or attenuate immune responses associated with chronic inflammation in experimental models. However, there has been no fully adequate longitudinal study of the relation between the neonatal gut microbiota and the development of allergic diseases (eg, atopic asthma) and obesity. The emergence of promising experimental studies has led to several clinical trials of probiotics (live bacteria given orally that allow for intestinal colonization) in human subjects. Probiotic trials thus far have failed to show a consistent preventive or therapeutic effect on asthma or obesity. Previous trials of probiotics have been limited by small sample size, short duration of follow-up, or lack of state-of-the art analyses of the gut microbiota. Finally, there is emerging evidence that the vitamin D pathway might be important in gut homeostasis and in signaling between the microbiota and the host. Given the complexity of the gut micriobiota, additional research is needed before we can confidently establish whether its manipulation in early life can prevent or treat asthma, obesity, or both. (J Allergy Clin Immunol 2011;127:1087-94.)	[Ly, Ngoc P.] Univ Calif San Francisco, Dept Pediat, Div Pediat Pulm Med, San Francisco, CA 94143 USA; [Litonjua, Augusto; Gold, Diane R.] Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; [Litonjua, Augusto; Gold, Diane R.] Harvard Univ, Sch Med, Boston, MA USA; [Celedon, Juan C.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, UPMC, Pittsburgh, PA USA	Ly, NP (reprint author), 521 Parnassus Ave,C344, San Francisco, CA 94143 USA.	lyn@peds.ucsf.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Litonjua, Augusto/0000-0003-0422-5875	NIAID NIH HHS [R01 AI035786-17, R01 AI035786]		Adlerberth I, 2009, ACTA PAEDIATR, V98, P229, DOI 10.1111/j.1651-2227.2008.01060.x; Adlerberth I, 2007, J ALLERGY CLIN IMMUN, V120, P343, DOI 10.1016/j.jaci.2007.05.018; Adorini L, 2009, HUM IMMUNOL, V70, P345, DOI 10.1016/j.humimm.2009.01.016; Antonio MAD, 2005, J INFECT DIS, V192, P394, DOI 10.1086/430926; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; *ASTHM AM LUNG ASS, 2008, ASTHM AM LUNG ASS LU; Backhed F, 2004, P NATL ACAD SCI USA, V101, P15718, DOI 10.1073/pnas.0407076101; Backhed F, 2007, P NATL ACAD SCI USA, V104, P979, DOI 10.1073/pnas.0605374104; Benyshek DC, 2007, COLLEGIUM ANTROPOL, V31, P11; Bergeron C, 2005, J ALLERGY CLIN IMMUN, V115, P1102, DOI 10.1016/j.jaci.2005.03.018; Beuther DA, 2005, J ALLERGY CLIN IMMUN, V115, P1100, DOI 10.1016/j.jaci.2004.12.1141; Bjorksten B, 2004, SPRINGER SEMIN IMMUN, V25, P257, DOI 10.1007/s00281-003-0142-2; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Black PN, 2005, CHEST, V128, P3792, DOI 10.1378/chest.128.6.3792; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Borriello SP, 2003, CLIN INFECT DIS, V36, P775, DOI 10.1086/368080; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1590; Boulet LP, 2007, RESP MED, V101, P2240, DOI 10.1016/j.rmed.2007.06.031; Boyle RJ, 2009, CLIN EXP ALLERGY, V39, P1117, DOI 10.1111/j.1365-2222.2009.03305.x; Brehm JM, 2010, J ALLERGY CLIN IMMUN, V126, P52, DOI 10.1016/j.jaci.2010.03.043; Brehm JM, 2009, AM J RESP CRIT CARE, V179, P765, DOI 10.1164/rccm.200808-1361OC; Cani PD, 2008, DIABETES, V57, P1470, DOI 10.2337/db07-1403; Cani PD, 2007, DIABETES, V56, P1761, DOI 10.2337/db06-1491; Cani PD, 2009, CURR PHARM DESIGN, V15, P1546, DOI 10.2174/138161209788168164; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Celedon JC, 2004, CLIN EXP ALLERGY, V34, P1011, DOI 10.1111/j.1365-2222.2004.01994.x; Celedon JC, 2002, AM J RESP CRIT CARE, V166, P72, DOI 10.1164/rccm.2109074; Celedon JC, 2006, CHEST, V130, P1624, DOI 10.1378/chest.130.5.1624; Celedon Juan C, 2004, Treat Respir Med, V3, P291, DOI 10.2165/00151829-200403050-00003; Dethlefsen L, 2007, NATURE, V449, P811, DOI 10.1038/nature06245; Dethlefsen L, 2008, PLOS BIOL, V6, P2383, DOI 10.1371/journal.pbio.0060280; Devereux G, 2005, J ALLERGY CLIN IMMUN, V115, P1109, DOI 10.1016/j.jaci.2004.12.11.39; Dominguez-Bello MG, 2010, P NATL ACAD SCI USA, V107, P11971, DOI 10.1073/pnas.1002601107; ELMOHANDES AE, 1993, AM J INFECT CONTROL, V21, P231; Feleszko W, 2007, CLIN EXP ALLERGY, V37, P498, DOI 10.1111/j.1365-2222.2006.02629.x; Forno Erick, 2008, Clin Mol Allergy, V6, P11, DOI 10.1186/1476-7961-6-11; Forsythe P, 2007, AM J RESP CRIT CARE, V175, P561, DOI 10.1164/rccm.200606-821OC; Gale CR, 2008, EUR J CLIN NUTR, V62, P68, DOI 10.1038/sj.ejcn.1602680; Griffin MD, 2003, ANNU REV NUTR, V23, P117, DOI 10.1146/annurev.nutr.23.011702.073114; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Guarner F, 2003, LANCET, V361, P512, DOI 10.1016/S0140-6736(03)12489-0; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P1235, DOI 10.1016/j.jaci.2005.09.016; Hallstrom M, 2004, EUR J CLIN MICROBIOL, V23, P463, DOI 10.1007/s10096-004-1146-0; Harmsen HJM, 2000, J PEDIATR GASTR NUTR, V30, P61, DOI 10.1097/00005176-200001000-00019; Harris JM, 2007, THORAX, V62, P631, DOI 10.1136/thx.2006.072124; Hessle C, 1999, CLIN EXP IMMUNOL, V116, P276; Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, pe1, DOI 10.1053/j.gastro.2009.08.042; Hildebrandt MA, 2009, GASTROENTEROLOGY, V137, P1716, DOI 10.1053/j.gastro.2009.08.042; Hill G B, 1984, Scand J Urol Nephrol Suppl, V86, P23; HILTON E, 1992, ANN INTERN MED, V116, P353; Holick MF, 2006, MAYO CLIN PROC, V81, P353; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; James WPT, 2008, J INTERN MED, V263, P336, DOI 10.1111/j.1365-2796.2008.01922.x; Jernberg C, 2007, ISME J, V1, P56, DOI 10.1038/ismej.2007.3; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kalliomaki M, 2008, AM J CLIN NUTR, V87, P534; Kalliomaki M, 2007, J ALLERGY CLIN IMMUN, V119, P1019, DOI 10.1016/j.jaci.2006.12.608; Karimi K, 2009, AM J RESP CRIT CARE, V179, P186, DOI 10.1164/rccm.200806-951OC; Kelly D, 2007, MUTAT RES-FUND MOL M, V622, P58, DOI 10.1016/j.mrfmmm.2007.03.011; Kero J, 2002, PEDIATR RES, V52, P6, DOI 10.1023/01.PDR.0000017263.01840.F0; Keski-Nisula L, 2009, J ALLERGY CLIN IMMUN, V123, P1305, DOI 10.1016/j.jaci.2009.03.021; Kopp MV, 2008, PEDIATRICS, V121, pE850, DOI 10.1542/peds.2007-1492; Kuitunen M, 2009, J ALLERGY CLIN IMMUN, V123, P335, DOI 10.1016/j.jaci.2008.11.019; Kukkonen K, 2007, J ALLERGY CLIN IMMUN, V119, P192, DOI 10.1016/j.jaci.2006.09.009; Kumar J, 2009, PEDIATRICS, V124, pE362, DOI 10.1542/peds.2009-0051; Laitinen K, 2009, BRIT J NUTR, V101, P1679, DOI 10.1017/S0007114508111461; Ley RE, 2005, P NATL ACAD SCI USA, V102, P11070, DOI 10.1073/pnas.0504978102; Ley RE, 2006, NATURE, V444, P1022, DOI 10.1038/nature4441022a; Litonjua AA, 2008, J ALLERGY CLIN IMMUN, V121, P1075, DOI 10.1016/j.jaci.2008.03.005; Liu PT, 2007, J IMMUNOL, V179, P2060; LONG SS, 1977, J PEDIATR-US, V91, P298, DOI 10.1016/S0022-3476(77)80836-6; Lotz M, 2006, J EXP MED, V203, P973, DOI 10.1084/jem.20050625; Luoto R, 2010, INT J OBESITY, V34, P1531, DOI 10.1038/ijo.2010.50; Luoto R, 2010, BRIT J NUTR, V103, P1792, DOI 10.1017/S0007114509993898; Mai V, 2009, NUTR J, V8, DOI 10.1186/1475-2891-8-49; Mai XM, 2010, CLIN EXP ALLERGY, V40, P1230, DOI 10.1111/j.1365-2222.2010.03532.x; Marra F, 2006, CHEST, V129, P610, DOI 10.1378/chest.129.3.610; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; McKeever TM, 2002, AM J RESP CRIT CARE, V166, P827, DOI 10.1164/rccm.200202-158OC; McLachlan CR, 2007, J ALLERGY CLIN IMMUN, V119, P634, DOI 10.1016/j.jaci.2006.10.029; McLoughlin RM, 2011, J ALLERGY CLIN IMMUN, V127, P1097, DOI 10.1016/j.jaci.2011.02.012; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Melen E, 2010, J ALLERGY CLIN IMMUN, V126, P631, DOI 10.1016/j.jaci.2010.06.030; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; Murphy A, 2009, AM J HUM GENET, V85, P87, DOI 10.1016/j.ajhg.2009.06.011; Murray CS, 2005, CLIN EXP ALLERGY, V35, P741, DOI 10.1111/j.1365.2005.02259.x; Musso G, 2010, CURR OPIN LIPIDOL, V21, P76, DOI 10.1097/MOL.0b013e3283347ebb; Oyama N, 2001, J ALLERGY CLIN IMMUN, V107, P153, DOI 10.1067/mai.2001.111142; Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177; Parikh SJ, 2004, J CLIN ENDOCR METAB, V89, P1196, DOI 10.1210/jc.2003-031398; Parsons TJ, 1999, INT J OBESITY, V23, pS1; Penders J, 2007, GUT, V56, P661, DOI 10.1136/gut.2006.100164; Penders J, 2006, PEDIATRICS, V118, P511, DOI 10.1542/peds.2005-2824; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Peters-Golden M, 2006, EUR RESPIR J, V27, P495, DOI 10.1183/09031936.06.00077205; Pistiner M, 2008, J ALLERGY CLIN IMMUN, V122, P274, DOI 10.1016/j.jaci.2008.05.007; Prescott SL, 2005, CLIN EXP ALLERGY, V35, P1557, DOI 10.1111/j.1365-2222.2005.02376.x; Rask C, 2005, SCAND J IMMUNOL, V61, P529, DOI 10.1111/j.1365-3083.2005.01598.x; Reid G, 2001, FEMS IMMUNOL MED MIC, V30, P49, DOI 10.1016/S0928-8244(00)00233-9; Rusconi F, 2007, AM J RESP CRIT CARE, V175, P16, DOI 10.1164/rccm.200512-1978OC; Salam MT, 2006, ANN EPIDEMIOL, V16, P341, DOI 10.1016/j.annepidem.2005.06.054; Salminen S, 1998, BRIT J NUTR, V80, pS147; Sepp E, 1997, ACTA PAEDIATR, V86, P956, DOI 10.1111/j.1651-2227.1997.tb15178.x; SHERMAN CB, 1990, AM J EPIDEMIOL, V132, P83; Shida K, 2002, CLIN EXP ALLERGY, V32, P563, DOI 10.1046/j.0954-7894.2002.01354.x; Shore SA, 2008, J ALLERGY CLIN IMMUN, V121, P1087, DOI 10.1016/j.jaci.2008.03.004; Sood A, 2005, J ALLERGY CLIN IMMUN, V115, P921, DOI 10.1016/j.jaci.2005.02.033; Su Y, 2010, CLIN EXP ALLERGY, V40, P1222, DOI 10.1111/j.1365-2222.2010.03539.x; Sudo N, 2002, CLIN EXP ALLERGY, V32, P1112, DOI 10.1046/j.1365-2222.2002.01430.x; Sudo N, 1997, J IMMUNOL, V159, P1739; Sutherland ER, 2009, J ALLERGY CLIN IMMUN, V123, P1328, DOI 10.1016/j.jaci.2009.04.005; Sutherland TJT, 2008, AM J RESP CRIT CARE, V178, P469, DOI 10.1164/rccm.200802-301OC; Turnbaugh PJ, 2008, CELL HOST MICROBE, V3, P213, DOI 10.1016/j.chom.2008.02.015; Turnbaugh PJ, 2009, SCI TRANSL MED, V1, DOI 10.1126/scitranslmed.3000322; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Verhulst SL, 2008, J ASTHMA, V45, P828, DOI 10.1080/02770900802339734; Vickers MH, 2007, CURR DRUG TARGETS, V8, P923; Weber G, 2005, J INVEST DERMATOL, V124, P1080, DOI 10.1111/j.0022-202X.2005.23687.x; Weston S, 2005, ARCH DIS CHILD, V90, P892, DOI 10.1136/adc.2004.060673; Wortsman J, 2000, AM J CLIN NUTR, V72, P690; Wu SP, 2010, AM J PATHOL, V177, P686, DOI 10.2353/ajpath.2010.090998; Xu B, 2001, J ALLERGY CLIN IMMUN, V107, P732; Yim S, 2007, J CYST FIBROS, V6, P403, DOI 10.1016/j.jcf.2007.03.003; Yoshioka T, 2001, J INT MED RES, V29, P409; Young SL, 2004, CLIN DIAGN LAB IMMUN, V11, P686, DOI 10.1128/CDLI.11.4.686-690.2004; Yu SH, 2008, P NATL ACAD SCI USA, V105, P20834, DOI 10.1073/pnas.0808700106; Zoetendal EG, 2006, MOL MICROBIOL, V59, P1639, DOI 10.1111/j.1365-2958.20006.05056.x	130	89	96	4	50	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2011	127	5					1087	1094		10.1016/j.jaci.2011.02.015		8	Allergy; Immunology	Allergy; Immunology	756NG	WOS:000290018600001	21419479	
J	Rook, GAW				Rook, G. A. W.			99th Dahlem Conference on Infection, Inflammation and Chronic Inflammatory Disorders: Darwinian medicine and the 'hygiene' or 'old friends' hypothesis	CLINICAL AND EXPERIMENTAL IMMUNOLOGY			English	Article						Darwinian medicine; dendritic cells; 'hygiene hypothesis'; 'old friends' hypothesis; T(reg)	INNATE IMMUNITY; HAY-FEVER; DISEASE; ASTHMA; VIRUSES; PATHOGENESIS; ASSOCIATION; EVOLUTION; PARASITES; LESSONS	P>The current synthesis of the 'hygiene hypothesis' suggests that the recent increase in chronic inflammatory disorders is at least partly attributable to immunodysregulation resulting from lack of exposure to microorganisms that have evolved an essential role in the establishment of the immune system. This document provides a background for discussion of the following propositions. The essential role of these organisms is an example of 'evolved dependence'. The most relevant organisms are those that co-evolved with mammals, and already accompanied early hominids in the Paleolithic. More recently evolved 'childhood infections' are not likely to have evolved this role, and recent epidemiology supports this contention. This mechanism is interacting with other modern environmental changes that also lead to enhanced inflammatory responses [inappropriate diet, obesity, psychological stress, vitamin D deficiency, pollution (dioxins), etc.]. The range of chronic inflammatory disorders that is affected is potentially larger than usually assumed [allergies, autoimmunity, inflammatory bowel disease, but also vascular disease, some cancers, depression/anxiety (when accompanied by raised inflammatory cytokines), and perhaps neurodegenerative disorders and type 2 diabetes].	UCL, Dept Infect, London W1T 4JF, England	Rook, GAW (reprint author), UCL, Dept Infect, London W1T 4JF, England.	g.rook@ucl.ac.uk	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Rook, Graham/0000-0002-8041-8110			Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029; AITOUFELLA H, 2009, DARWINIAN MED HYGIEN, P221; Aliouat-Denis CM, 2008, INFECT GENET EVOL, V8, P708, DOI 10.1016/j.meegid.2008.05.001; Armelagos GJ, 2005, EVOL ANTHROPOL, V14, P109, DOI 10.1002/evan.20048; Armelagos GJ, 2005, SOC SCI MED, V61, P755, DOI 10.1016/j.socscimed.2004.08.066; Barnes KC, 2005, CURR OPIN ALLERGY CL, V5, P379, DOI 10.1097/01.all.0000182543.37724.7b; Belkaid Y, 2010, CLIN EXP IMMUNOL, V160, P35, DOI 10.1111/j.1365-2249.2010.04131.x; Bienenstock J, 2010, CLIN EXP IMMUNOL, V160, P85, DOI 10.1111/j.1365-2249.2010.04124.x; Blount D, 2009, AM J TROP MED HYG, V81, P911, DOI 10.4269/ajtmh.2009.09-0237; Bowlby J., 1971, ATTACHMENT LOSS, V1; Bremner SA, 2008, ALLERGY, V63, P274, DOI 10.1111/j.1398-9995.2007.01599.x; Caldwell JC, 2001, B WORLD HEALTH ORGAN, V79, P159; Compton WM, 2006, AM J PSYCHIAT, V163, P2141, DOI 10.1176/appi.ajp.163.12.2141; De Mazancourt C, 2005, J ECOL, V93, P305, DOI 10.1111/j.0022-0477.2004.00952.x; Ehses JA, 2008, BIOCHEM SOC T, V36, P340, DOI 10.1042/BST0360340; Ewald PW, 2010, CLIN EXP IMMUNOL, V160, P27, DOI 10.1111/j.1365-2249.2010.04127.x; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fredericks CA, 2010, BRAIN BEHAV IMMUN, V24, P350, DOI 10.1016/j.bbi.2009.10.014; Fumagalli M, 2009, J EXP MED, V206, P1395, DOI 10.1084/jem.20082779; Gagneux S, 2007, LANCET INFECT DIS, V7, P328, DOI 10.1016/S1473-3099(07)70108-1; Getts MT, 2010, CLIN EXP IMMUNOL, V160, P15, DOI 10.1111/j.1365-2249.2010.04132.x; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Harrison LC, 2008, J AUTOIMMUN, V31, P306, DOI 10.1016/j.jaut.2008.04.026; HARRISON T, 2009, PRINCIPLES PRACTICE, P269; Hawks J, 2007, P NATL ACAD SCI USA, V104, P20753, DOI 10.1073/pnas.0707650104; Hoberg EP, 2006, PARASITOL INT, V55, pS23, DOI 10.1016/j.parint.2005.11.049; JEON KW, 1972, SCIENCE, V176, P1122, DOI 10.1126/science.176.4039.1122; Kidgell C, 2002, INFECT GENET EVOL, V2, P39, DOI 10.1016/S1567-1348(02)00089-8; Kuiper J, 2007, CURR OPIN LIPIDOL, V18, P521; Linz B, 2007, NATURE, V445, P915, DOI 10.1038/nature05562; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Mazmanian SK, 2008, NATURE, V453, P620, DOI 10.1038/nature07008; Mazmanian SK, 2006, NAT REV IMMUNOL, V6, P849, DOI 10.1038/nri1956; Mira A, 2006, TRENDS MICROBIOL, V14, P200, DOI 10.1016/j.tim.2006.03.001; Mortimer K, 2006, AM J TROP MED HYG, V75, P914; Okada H, 2010, CLIN EXP IMMUNOL, V160, P1, DOI 10.1111/j.1365-2249.2010.04139.x; Pelosi U, 2005, ALLERGY, V60, P626, DOI 10.1111/j.1398-9995.2005.00747.x; Perez PF, 2007, PEDIATRICS, V119, pE724, DOI 10.1542/peds.2006-1649; ROOK GAW, 2009, PROGR INFLAMMATION R, P317; Rook GAW, 2008, TRENDS IMMUNOL, V29, P150, DOI 10.1016/j.it.2008.01.002; Rook GAW, 2009, IMMUNOLOGY, V126, P3, DOI 10.1111/j.1365-2567.2008.03007.x; Schroder NWJ, 2009, CURR OPIN ALLERGY CL, V9, P38, DOI 10.1097/ACI.0b013e32831d0f99; Seiskari T, 2007, CLIN EXP IMMUNOL, V148, P47, DOI 10.1111/j.1365-2249.2007.03333.x; Sibley LD, 2008, ANNU REV MICROBIOL, V62, P329, DOI 10.1146/annurev.micro.62.081307.162925; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Summers RW, 2005, GUT, V54, P87, DOI 10.1136/gut.2004.041749; Turnbaugh PJ, 2009, NATURE, V457, P480, DOI 10.1038/nature07540; Umetsu DT, 2010, CLIN EXP IMMUNOL, V160, P125, DOI 10.1111/j.1365-2249.2010.04136.x; Umetsu Dale T, 2005, J Pediatr Gastroenterol Nutr, V40 Suppl 1, pS43, DOI 10.1097/00005176-200504001-00026; Van Blerkom LM, 2003, YEARB PHYS ANTHROPOL, V46, P14, DOI 10.1002/ajpa.10384; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; von Herrath M, 2009, DIABETES, V58, P2, DOI 10.2337/db08-9027; Wen L, 2008, NATURE, V455, P1109, DOI 10.1038/nature07336; Whitlock DR, 2009, PROG INFLAMM RES SER, P103, DOI 10.1007/978-3-7643-8903-1_6; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Xystrakis E, 2006, J CLIN INVEST, V116, P146, DOI 10.1172/JCI21759	56	89	96	4	65	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0009-9104			CLIN EXP IMMUNOL	Clin. Exp. Immunol.	APR	2010	160	1					70	79		10.1111/j.1365-2249.2010.04133.x		10	Immunology	Immunology	567JN	WOS:000275443000011	20415854	
J	Siebenhaar, F; Degener, F; Zuberbier, T; Martus, P; Maurer, M				Siebenhaar, Frank; Degener, Franziska; Zuberbier, Torsten; Martus, Peter; Maurer, Marcus			High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Urticaria; cold; chronic; objective; antihistamine; desloratadine	CHRONIC IDIOPATHIC URTICARIA; DOUBLE-BLIND; EAACI/GA(2)LEN/EDF GUIDELINE; MULTICENTER; DIAGNOSIS; EFFICACY; SAFETY; ADULTS; TRIAL	Background: Increased dosing of nonsedating antihistamines is recommended by the current European Academy of Allergology and Clinical Immunology/Global Allergy and Asthma European Network/European Dermatology Forum guidelines on patients with acquired cold urticaria (ACU) who do not respond satisfactorily to the standard dose. Prospective data supporting this recommendation are scant. Objective: We sought to assess the effects of 5 and 20 mg of desloratadine and placebo on cold-induced urticarial reactions in patients with ACU. Methods: In this prospective, randomized, double-blind, 3-way crossover trial, patients with ACU (n = 30) received placebo, 5 mg of desloratadine, and 20 mg of desloratadine every day each for 7 days separated by 14-day washout periods. At the end of each treatment, patients underwent cold provocation with the TempTest 2.0/2.1 system, and urticarial reactions were assessed by using digital 3-dimensional time-lapse photography and thermography; the critical temperature threshold (CTT) and critical stimulation time threshold (CSTT) were measured. Adverse events (AEs) reported during the study were assessed. Results: Compared with placebo, 7 days of desloratadine at 5 and 20 mg/d significantly reduced the volume of cold-induced wheals and areas of hyperthermic skin and improved CTT and CSTT results. Desloratadine at 20 mg/d significantly reduced cold-induced wheal volume and CTT and CSTT values versus desloratadine at 5 mg/d. Desloratadine was well tolerated, with no increased rate of somnolence or other AEs with 20 mg of desloratadine. Conclusions: Desloratadine at standard and high doses significantly improved objective signs of ACU provoked by cold exposure. Desloratadine at 4 times the standard dose significantly reduced ACU lesion severity versus 5 mg of desloratadine without an increase in AEs. This study supports current guidelines that increased desloratadine dosing might benefit patients with urticaria who do not respond to standard doses. (J Allergy Clin Immunol 2009;123:672-9.)	[Siebenhaar, Frank; Degener, Franziska; Zuberbier, Torsten; Maurer, Marcus] Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, D-10117 Berlin, Germany; [Martus, Peter] Charite Univ Med Berlin, Inst Biostat & Clin Epidemiol, D-10117 Berlin, Germany	Maurer, M (reprint author), Charite Univ Med Berlin, Dept Dermatol & Allergy, Allergie Ctr Charite, Charitepl 1, D-10117 Berlin, Germany.	marcus.maurer@charite.de			DFG; Schering-Plough; Novartis; Leti; Stallergenes; Bayer Schering; Ansell; Kryolan; UCB; MSD; Proctor Gamble	F Siebenhaar has received research support from DFG and Schering-Plough. T. Zuberbier has received research grants from Schering-Plough, Novartis, Leti, Stallergenes, Bayer Schering, Ansell, Kryolan, UCB, MSD, and Proctor & Gamble; has been affiliated with the Editorial Board of the Journal of Allergy, the Scientific Advisory Board of the German Society for Allergy and Clinical Immunology, and the Expert Commission "Novel Food" of the German Federal Ministry of Consumer Protection; has served as the Chairman of the European Academy of Allergology and Clinical Immunology Dermatology Section, the Head of the European Centre for Allergy Research Foundation, a committee member of the World Health Organization Initiative Allergic Rhinitis and its Impact on Asthma, a member of the World Allergy Organisation Communications Council, and Secretary General of the Global Allergy and Asthma European Network and has provided expert testimony for the US Food and Drug Administration. M. Maurer is or recently was an investigator, speaker, and/or advisor for Almirall Hermal, Bayer Schering Pharma, Biofrontera, Essex Pharma, Genentech, JADO Technologies, Jerini, Novartis, Schering-Plough, Symbiopharm, UCB, and Uriach. The rest of the authors have declared that they have no conflict of interest.	Boyce JA, 2006, J ALLERGY CLIN IMMUN, V117, P1415, DOI 10.1016/j.jaci.2006.04.003; Grob JJ, 2008, J EUR ACAD DERMATOL, V22, P87, DOI 10.1111/j.1468-3083.2007.02385.x; Henz BM, 2001, ALLERGY, V56, P7, DOI 10.1034/j.1398-9995.2001.00101.x; Juhlin L, 2004, J Dermatolog Treat, V15, P51; Lippert U, 1995, Exp Dermatol, V4, P272, DOI 10.1111/j.1600-0625.1995.tb00257.x; Monroe E, 2003, J AM ACAD DERMATOL, V48, P535, DOI 10.1067/mjd.2003.143; Neven B, 2004, BLOOD, V103, P2809, DOI 10.1182/blood-2003-07-2531; Ortonne JP, 2007, AM J CLIN DERMATOL, V8, P37, DOI 10.2165/00128071-200708010-00005; Ring J, 2001, INT J DERMATOL, V40, P72, DOI 10.1046/j.1365-4362.2001.00186.x; Siebenhaar F, 2007, CLIN EXP DERMATOL, V32, P241, DOI 10.1111/j.1365-2230.2007.02376.x; Siebenhaar F, 2004, J ALLERGY CLIN IMMUN, V114, P1224; Wanderer AA, 2004, IMMUNOL ALLERGY CLIN, V24, P259, DOI 10.1016/j.iac.2004.01.001; Wang YH, 2005, ALLERGY, V60, P117, DOI 10.1111/j.1398-9995.2004.00641.x; Zhao Y, 2004, INFLAMM RES, V53, P664, DOI 10.1007/s00011-004-1309-6; Zuberbier T, 2006, ALLERGY, V61, P321, DOI 10.1111/j.1398-9995.2006.00962.x; Zuberbier T, 2006, ALLERGY, V61, P316, DOI 10.1111/j.1398-9995.2005.00964.x	16	89	95	0	1	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					672	679		10.1016/j.jaci.2008.12.008		8	Allergy; Immunology	Allergy; Immunology	426TQ	WOS:000264731200029	19201016	
J	Cazzola, M; Matera, MG				Cazzola, M.; Matera, M. G.			Novel long-acting bronchodilators for COPD and asthma	BRITISH JOURNAL OF PHARMACOLOGY			English	Review						aclidinium; asthma; bronchodilators; carmoterol; chronic obstructive pulmonary disease; combination therapy; indacaterol; long-acting antimuscarinic agents; NVA237; ultra-long-acting beta-agonists	OBSTRUCTIVE PULMONARY-DISEASE; AIR-FLOW OBSTRUCTION; BETA(2)-ADRENOCEPTOR AGONIST; GUINEA-PIGS; PHARMACOLOGICAL CHARACTERIZATION; ADRENOCEPTOR AGONIST; POSITIVE INTERACTION; GLOBAL STRATEGY; STABLE COPD; TIOTROPIUM	An important step in simplifying asthma and chronic obstructive pulmonary disease (COPD) management and improving adherence with prescribed therapy is to reduce the dose frequency to the minimum necessary to maintain disease control. Therefore, the incorporation of once-daily dose administration is an important strategy to improve adherence and is a regimen preferred by most patients, which may also lead to enhancement of compliance, and may have advantages leading to improved overall clinical outcomes. Once-daily beta(2)-agonists or ultra long-acting beta(2)-agonists (LABAs) such as carmoterol, indacaterol, GSK-159797, GSK-597901, GSK-159802, GSK-642444 and GSK-678007 are under development for the treatment of asthma and COPD. Also some new long-acting antimuscarinic agents (LAMAs) such as aclidinium, LAS-35201, GSK656398, GSK233705, NVA-237 (glycopyrrolate) and OrM3 are under development. In any case, the current opinion is that it will be advantageous to develop inhalers containing combination of several classes of long-acting bronchodilator drugs in an attempt to simplify treatment regimens as much as possible. Consequently, several options for once-daily dual-action ultra LABA+LAMA combination products are currently being evaluated. A different approach is to have a dimer molecule in which both pharmacologies are present (these molecules are known as M(3) antagonist-beta(2) agonist (MABA) bronchodilators). The advent of a successful MABA product will revolutionize the field and open the door for a new range of combination products.	[Matera, M. G.] Univ Naples 2, Dept Expt Med, Pharmacol Unit, Naples, Italy; [Cazzola, M.] Univ Roma Tor Vergata, Dipartimento Med Interna, Unit Resp Dis, I-00133 Rome, Italy	Cazzola, M (reprint author), Univ Roma Tor Vergata, Dipartimento Med Interna, Unit Resp Dis, Via Montpellier 1, I-00133 Rome, Italy.	mario.cazzola@uniroma2.it	Cazzola, Mario/G-9397-2012		AstraZeneca; Boehringer Ingelheim; Chiesi Farmaceutici; Dey; GSK; Menarini Farmaceutici; Novartis; Nycomed; Pfizer; Sanovel	Mario Cazzola has received honoraria for speaking and consulting and/or financial support for attending meetings from AstraZeneca, Boehringer Ingelheim, Chiesi Farmaceutici, Dey, GSK, Menarini Farmaceutici, Novartis, Nycomed (former Altana), Pfizer and Sanovel. Maria Gabriella Matera has received honoraria for consulting and/or financial support for attending meetings from Altana, AstraZeneca, Boehringer Ingelheim, GSK, Novartis and Pfizer. No funding has been provided for this article.	Aaron SD, 2007, ANN INTERN MED, V146, P545; Acerbi D, 2007, PULM PHARMACOL THER, V20, P290, DOI 10.1016/j.pupt.2006.05.005; ARIEVICH H, 2006, EUR RESPIR J, V28, pS430; Aubier M, 2005, EUR RESP J S49, V26, p287S; Barnes PJ, 2004, AM J MED, V117, p24S, DOI 10.1016/j.amjmed.2004.10.018; Bateman ED, 2008, EUR RESPIR J, V31, P143, DOI 10.1183/09031936.00138707; Battram C, 2006, J PHARMACOL EXP THER, V317, P762, DOI 10.1124/jpet.105.098251; Beeh KM, 2007, EUR RESPIR J, V29, P871, DOI 10.1183/09031936.00060006; Beier J, 2007, PULM PHARMACOL THER, V20, P740, DOI 10.1016/j.pupt.2006.09.001; Bender BG, 2002, J ALLERGY CLIN IMMUN, V109, pS554, DOI 10.1067/mai.2002.124570; Brookman LJ, 2007, CURR MED RES OPIN, V23, P3113, DOI 10.1185/030079907X242863; Brown AD, 2007, BIOORG MED CHEM LETT, V17, P4012, DOI 10.1016/j.bmcl.2007.04.081; Campbell LM, 1999, DRUGS, V58, P25, DOI 10.2165/00003495-199958004-00004; Cazzola M, 2005, EXPERT OPIN INV DRUG, V14, P775, DOI 10.1517/13543784.14.7.775; Cazzola M, 2004, RESP MED, V98, P1214, DOI 10.1016/j.rmed.2004.05.003; Cazzola M, 2004, PULM PHARMACOL THER, V17, P35, DOI 10.1016/j.pupt.2003.09.001; CAZZOLA M, 2006, DRUG DISCOV TODAY TH, V3, P277, DOI 10.1016/j.ddstr.2006.09.009; Cazzola M, 2007, PULM PHARMACOL THER, V20, P556, DOI 10.1016/j.pupt.2006.06.001; Cazzola M, 2007, RESP MED, V101, P957, DOI 10.1016/j.rmed.2006.09.012; Cazzola Mario, 2004, Chest, V125, P9, DOI 10.1378/chest.125.1.9; Celli BR, 2004, EUR RESPIR J, V23, P932, DOI 10.1183/09031936.04.00014304; *CHIES FARM, 2004, 4226 CHF; Chuchalin AG, 2007, RESP MED, V101, P2065, DOI 10.1016/j.rmed.2007.06.002; Claxton AJ, 2001, CLIN THER, V23, P1296, DOI 10.1016/S0149-2918(01)80109-0; Cooper N, 2006, P AM THOR SOC, V3, pA117; Fitzgerald MF, 2007, DRUG DISCOV TODAY, V12, P472, DOI 10.1016/j.drudis.2007.04.003; Gavalda A, 2007, EUR RESP J S51, V30, p209S; GUNAWARDENA KA, 2006, P AM THOR SOC, V3, pA117; Haeussermann S, 2006, EUR RESPIR J, V28, p211s; JOOS G, 2007, EUR RESPIR J, V30, pS210; KIKKAWA H, 1994, BIOL PHARM BULL, V17, P1047; KIKKAWA H, 1991, JPN J PHARMACOL, V57, P175, DOI 10.1254/jjp.57.175; Kottakis I, 2006, EUR RESPIR J, V28, p665s; KUNA P, 2007, EUR RESPIR J, V30, pS354; LaForce C, 2008, ALLERGY, V63, P103, DOI 10.1111/j.1398-9995.2007.01555.x; Lipworth BJ, 1997, BRIT J CLIN PHARMACO, V43, P9, DOI 10.1111/j.1365-2125.1997.tb00025.x; Lu S, 2006, EUR RESPIR J, V28, P772, DOI 10.1183/09031936.06.00126005; Magnussen H, 2008, RESP MED, V102, P50, DOI 10.1016/j.rmed.2007.08.003; Martinez FD, 2005, NEW ENGL J MED, V353, P2637, DOI 10.1056/NEJMp058299; Matera MG, 2007, DRUGS, V67, P503, DOI 10.2165/00003495-200767040-00002; MIRALPEIX M, 2007, EUR RESPIR J, V30, pS359; Naline E, 2007, EUR RESPIR J, V29, P575, DOI 10.1183/09031936.00032806; Nandeuil A, 2006, EUR RESPIR J, V28, p665s; National Asthma Education and Prevention Program, 2007, J ALLERGY CLIN IMMUN, V120, pS94, DOI [DOI 10.1016/J.JACI.2007.09.029, 10.1016/j.jaci.2007.09.043]; PATACCHINI R, 2007, EUR RESPIR J, V30, pS25; RABE K, 2008, CHEST; Rabe KF, 2007, AM J RESP CRIT CARE, V176, P532, DOI 10.1164/rccm.200703-456SO; Rennard S, 2008, RESP MED, V102, P1033, DOI 10.1016/j.rmed.2008.02.001; Rodrigo GJ, 2007, PULM PHARMACOL THER, V20, P495, DOI 10.1016/j.pupt.2006.02.003; Rossoni G, 2005, BRIT J PHARMACOL, V144, P422, DOI 10.1038/sj.bjp.0706096; Rossoni G, 2007, PULM PHARMACOL THER, V20, P250, DOI 10.1016/j.pupt.2006.01.004; Garcia Gil E, 2007, EUR RESP J S51, V30, p356S; Sin DD, 2006, EUR J PHARMACOL, V533, P28, DOI 10.1016/j.ejphar.2005.12.049; Singh D, 2008, THORAX; Singh D, 2006, P AM THOR SOC, V3, pA113; Sturton RG, 2008, J PHARMACOL EXP THER, V324, P270, DOI 10.1124/jpet.107.129296; Tamura G, 2007, RESP MED, V101, P1895, DOI 10.1016/j.rmed.2007.05.001; Tashkin DP, 2008, RESP MED, V102, P479, DOI 10.1016/j.rmed.2007.12.019; Thomas R., 2006, P AM THOR SOC, V3, pA725; van Noord JA, 2006, CHEST, V129, P509, DOI 10.1378/chest.129.3.509; van Noord JA, 2005, EUR RESPIR J, V26, P214, DOI 10.1183/09031936.05.00140404; VILLETTI G, 2007, EUR RESPIR J, V30, pS26; Vogelmeier CF, 2006, EUR RESP J S50, V28, p429s; VOSS HP, 1992, EUR J PHARM-MOLEC PH, V227, P403, DOI 10.1016/0922-4106(92)90158-R; Walters JAE, 2005, RESP MED, V99, P384, DOI 10.1016/j.rmed.2005.01.003; Wise RA, 2007, AM J MED, V120, pS4, DOI 10.1016/j.amjmed.2007.04.007; Yang Shi-jun, 2007, Jishou Daxue Xuebao (Ziran Kexue Ban), V28, P99; 2007, THERAVANCE INC THRX	68	89	90	0	15	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0007-1188			BRIT J PHARMACOL	Br. J. Pharmacol.	OCT	2008	155	3					291	299		10.1038/bjp.2008.284		9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	354RE	WOS:000259655900003	18604231	
J	Snijders, BEP; Thijs, C; van Ree, R; van den Brandt, PA				Snijders, Bianca E. P.; Thijs, Carel; van Ree, Ronald; van den Brandt, Piet A.			Age at first introduction of cow milk products and other food products in relation to infant atopic manifestations in the first 2 years of life: The KOALA birth cohort study	PEDIATRICS			English	Article						cow milk; solids; atopy; reverse causation; oral tolerance; infant	BRIEF NEONATAL EXPOSURE; ASTHMA; ALLERGY; CHILDREN; SENSITIZATION; PREVENTION; ECZEMA; RISK; ASSOCIATION; DERMATITIS	OBJECTIVES. Scientific evidence is scarce about timing of solid-food introduction and its association with the development of atopy. We aimed to evaluate any associations between the introduction of cow milk products/other solid food products and infant atopic manifestations in the second year of life, taking into account reverse causation. METHODS. Data from 2558 infants in an ongoing prospective birth cohort study in the Netherlands were analyzed. Data on the main determinants (introduction of cow milk products and other food products), outcomes (eczema; atopic dermatitis [United Kingdom Working Party criteria]; recurrent wheeze; any sensitization; sensitization against cow milk, hen egg, peanut, and at least 1 inhalant allergen), and confounders were collected by repeated questionnaires at 34 weeks of gestation and 3, 7, 12, and 24 months postpartum. Information on sensitization was gathered by venous blood collections performed during home visits at age 2. Analyses were performed by multiple logistic regression analyses. RESULTS. More delay in introduction of cow milk products was associated with a higher risk for eczema. In addition, a delayed introduction of other food products was associated with an increased risk for atopy development at the age of 2 years. Exclusion of infants with early symptoms of eczema and recurrent wheeze (to avoid reverse causation) did not essentially change our results. DISCUSSION. Delaying the introduction of cow milk or other food products may not be favorable in preventing the development of atopy.	[Snijders, Bianca E. P.; Thijs, Carel; van den Brandt, Piet A.] Maastricht Univ, Dept Epidemiol, Care & Publ Hlth Res Inst, NL-6200 MD Maastricht, Netherlands; [Thijs, Carel; van den Brandt, Piet A.] Maastricht Univ, Dept Epidemiol, Nutr & Toxicol Res Inst, NL-6200 MD Maastricht, Netherlands; [van Ree, Ronald] Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, NL-1105 AZ Amsterdam, Netherlands	Snijders, BEP (reprint author), Maastricht Univ, Dept Epidemiol, Care & Publ Hlth Res Inst, POB 616, NL-6200 MD Maastricht, Netherlands.	bep.snijders@epid.unimaas.nl					AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Andreasyan K, 2007, PEDIATR ALLERGY IMMU, V18, P250, DOI 10.1111/j.1399-3038.2006.00509.x; Arshad SH, 2005, J ALLERGY CLIN IMMUN, V116, P3, DOI 10.1016/j.jaci.2005.03.043; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; de Jong MH, 1998, ARCH DIS CHILD, V79, P126; de Jong MH, 2002, ARCH DIS CHILD, V86, P365, DOI 10.1136/adc.86.5.365; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Ivarsson A, 2002, AM J CLIN NUTR, V75, P914; Khakoo GA, 2004, ARCH DIS CHILD, V89, P295, DOI 10.1136/adc.2003.039016; Kummeling I, 2005, PEDIATR ALLERGY IMMU, V16, P679, DOI 10.1111/j.1399-3038.2005.00333.x; Liem JJ, 2007, J ALLERGY CLIN IMMUN, V119, P1203, DOI 10.1016/j.jaci.2006.12.671; Magnus P, 1997, BRIT MED J, V314, P1795; Mihrshahi S, 2007, CLIN EXP ALLERGY, V37, P671, DOI 10.1111/j.1365-2222.2007.02696.x; Morgan J, 2004, ARCH DIS CHILD, V89, P309, DOI 10.1136/adc.2002.020065; Oddy WH, 1999, BRIT MED J, V319, P815; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Siltanen M, 2001, J ALLERGY CLIN IMMUN, V107, P229, DOI 10.1067/mai.2001.112128; SNIJDERS BE, 2007, PEDIATRICS, V119; Snijders BFP, 2007, J PEDIATR-US, V151, P347, DOI 10.1016/j.jpeds.200703.022; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; van Wijk F, 2007, BIOMED PHARMACOTHER, V61, P8, DOI 10.1016/j.biopha.2006.11.003; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; Wood RA, 2006, ARCH PEDIAT ADOL MED, V160, P552, DOI 10.1001/archpedi.160.5.552; Zeiger RS, 2003, PEDIATRICS, V111, P1662; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353	26	89	92	0	5	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2008	122	1					E115	E122		10.1542/peds.2007-1651		8	Pediatrics	Pediatrics	320YN	WOS:000257271200075	18595956	
J	Salam, MT; Islam, T; Gilliland, FD				Salam, Muhammad T.; Islam, Talat; Gilliland, Frank D.			Recent evidence for adverse effects of residential proximity to traffic sources on asthma	CURRENT OPINION IN PULMONARY MEDICINE			English	Article						air pollution; asthma; freeway; traffic; wheeze	VOLATILE ORGANIC-COMPOUNDS; 3 EUROPEAN AREAS; AIR-POLLUTION; RESPIRATORY SYMPTOMS; NITROGEN-DIOXIDE; ADULT ASTHMA; EXPOSURE; CHILDREN; ASSOCIATION; COHORT	There is consistent evidence that living near traffic sources is associated with asthma occurrence and exacerbations. Future studies have the opportunity to improve exposure estimates by measuring traffic-related pollutants near homes and schools and including time/activity patterns in prediction models. Further research is also warranted to investigate the differential impact of traffic by genetic and other susceptibility factors and to identify specific pollutants that underlie the adverse effect of traffic on asthma.	[Salam, Muhammad T.; Islam, Talat; Gilliland, Frank D.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA	Gilliland, FD (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St, Los Angeles, CA 90033 USA.	gillilan@usc.edu		Salam, Muhammad/0000-0002-3565-8916			ANDERSEN ZJ, 2007, J EXPO SCI ENV  0509; Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; Arif AA, 2007, INT ARCH OCC ENV HEA, V80, P711, DOI 10.1007/s00420-007-0183-2; Bayer-Oglesby L, 2006, AM J EPIDEMIOL, V164, P1190, DOI 10.1093/aje/kwj338; Beck JP, 2007, SCI TOTAL ENVIRON, V372, P440, DOI 10.1016/j.scitotenv.2006.10.009; Benhamou S, 1998, CANCER RES, V58, P5291; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Brugge D, 2007, ENVIRON HEALTH-UK, V6, DOI 10.1186/1476-069X-6-13; Chardon B, 2007, OCCUP ENVIRON MED, V64, P320, DOI 10.1136/oem.2005.026187; Chen CH, 2006, J ASTHMA, V43, P287, DOI 10.1080/02770900600622935; Gauderman WJ, 2007, LANCET, V369, P571, DOI 10.1016/S0140-6736(07)60037-3; Gordian ME, 2006, J EXPO SCI ENV EPID, V16, P49, DOI 10.1038/sj.jea.7500436; Ho WC, 2007, ENVIRON RES, V104, P402, DOI 10.1016/j.envres.2007.01.007; Hoek G, 2002, ATMOS ENVIRON, V36, P4077, DOI 10.1016/S1352-2310(02)00297-2; HOLGUIN F, 2007, AM J RESP CRIT  0719; Kan HD, 2007, THORAX, V62, P873, DOI 10.1136/thx.2006.073015; Kim Sun-Young, 2006, J Prev Med Public Health, V39, P309; Kim SY, 2007, INT ARCH OCC ENV HEA, V80, P701, DOI 10.1007/s00420-007-0182-3; Kuehni CE, 2006, INT J EPIDEMIOL, V35, P779, DOI 10.1093/ije/dyl022; Lee SL, 2006, CLIN EXP ALLERGY, V36, P1138, DOI 10.1111/j.1365-2222.2006.02555.x; Lewne M, 2004, SCI TOTAL ENVIRON, V332, P217, DOI 10.1016/j.scitotenv.2004.04.014; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; Meng YY, 2007, ANN ALLERG ASTHMA IM, V98, P455; MENG YY, 2006, LIVING NEAR HEAVY TR, P1; Mi YH, 2006, INDOOR AIR, V16, P454, DOI 10.1111/j.1600-0668.2006.00439.x; Modig L, 2006, EUR RESPIR J, V28, P75, DOI 10.1183/09031936.06.00071505; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Nitschke M, 2006, J OCCUP ENVIRON MED, V48, P462, DOI 10.1097/01.jom.0000215802.43229.62; Pattenden S, 2006, OCCUP ENVIRON MED, V63, P828, DOI 10.1136/oem.2006.025213; Ramos RG, 2006, J ENVIRON HEALTH, V68, P26; Ryan PH, 2007, ENVIRON HEALTH PERSP, V115, P278, DOI 10.1289/ehp.9480; Ryan PH, 2005, J ALLERGY CLIN IMMUN, V116, P279, DOI 10.1016/j.jaci.2005.014; SALAM MT, 2007, THORAX          0821; SALAM MT, 2007, AM J RESP CRIT  0802; Sole D, 2007, J INVEST ALLERG CLIN, V17, P6; Tavernier G, 2006, J ALLERGY CLIN IMMUN, V117, P656, DOI 10.1016/j.jaci.2005.12.1311; Yang CY, 2007, J TOXICOL ENV HEAL A, V70, P111, DOI 10.1080/15287390600755059; Yen IH, 2006, AM J PUBLIC HEALTH, V96, P873, DOI 10.2105/AJPH.2004.059253	39	89	94	1	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1070-5287			CURR OPIN PULM MED	Curr. Opin. Pulm. Med.	JAN	2008	14	1					3	8		10.1097/MCP.0b013e3282f1987a		6	Respiratory System	Respiratory System	242AU	WOS:000251697700002	18043269	
J	Wang, HB; Ghiran, I; Matthaei, K; Weller, PF				Wang, Hai-Bin; Ghiran, Ionita; Matthaei, Klaus; Weller, Peter F.			Airway eosinophils: Allergic inflammation recruited professional antigen-presenting cells	JOURNAL OF IMMUNOLOGY			English	Article							CD4 T-CELLS; DENDRITIC CELLS; IN-VIVO; HLA-DR; RESPIRATORY-TRACT; LYMPH-NODES; HUMAN LUNG; ASTHMA; EXPRESSION; CHALLENGE	The capacity of airway eosinophils, potentially pertinent to allergic diseases of the upper and lower airways, to function as professional APCs, those specifically able to elicit responses from unprimed, Ag-naive CD4(+) T cells has been uncertain. We investigated whether airway eosinophils are capable of initiating naive T cell responses in vivo. Eosinophils, isolated free of other APCs from the spleens of IL-5 transgenic mice, following culture with GM-CSF expressed MHC class 11 and the costimulatory proteins, CD40, CD80, and CD86. Eosinophils, incubated with OVA Ag in vitro, were instilled intratracheally into wild-type recipient mice that adoptively received i.v. infusions of OVA Ag-specific CD4(+) T cells from OVA TCR transgenic mice. OVA-exposed eosinophils elicited activation (CD69 expression), proliferation (BrdU incorporation), and IL-4, but not IFN-gamma, cytokine production by OVA-specific CD4(+) T cells in paratracheal lymph nodes (LN). Exposure of eosinophils to lysosomotropic NH4Cl which inhibits Ag processing, blocked each of these eosinophil-mediated activation responses of CD4(+) T cells. By three-color fluorescence microscopy, OVA Ag-loaded eosinophil APCs were physically interacting with naive OVA-specific CD4(+) T cells in paratracheal LN after eosinophil airway instillation. Thus, recruited luminal airway eosinophils are distinct allergic "inflammatory" professional APCs able to activate primary CD4(+) T cell responses in regional LNs.	Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Allergy, Boston, MA 02115 USA; Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Div Inflammat & Infect Dis, Boston, MA 02115 USA; Australian Natl Univ, John Curtin Sch Med Res, Div Mol Biosci, Gene Targeting Lab, Canberra, ACT 2601, Australia	Weller, PF (reprint author), Beth Israel Deaconess Med Ctr, Dept Med, DA-617,330 Brookline Ave, Boston, MA 02215 USA.	pweller@bidmc.harvard.edu	Klaus, Matthaei/D-8691-2011		NHLBI NIH HHS [HL70270, R01 HL070270, R01 HL070270-03, R01 HL070270-04]; NIAID NIH HHS [R01 AI020241, AI051645, AI20241, R01 AI020241-21A1, R01 AI020241-22, R01 AI020241-23, R01 AI051645, R01 AI051645-03, R01 AI051645-04, R01 AI051645-05, R01 AI051645-06A1, R37 AI020241, U19 AI041995, U19 AI041995-040003]		Burg J, 2002, AM J PHYSIOL-LUNG C, V283, pL460, DOI 10.1152/ajplung.00249.2001; Busse WW, 2001, NEW ENGL J MED, V344, P350; Byersdorfer CA, 2001, J IMMUNOL, V167, P6756; DELPOZO V, 1992, EUR J IMMUNOL, V22, P1919; Duez C, 2004, J ALLERGY CLIN IMMUN, V114, P820, DOI 10.1016/j.jaci.2004.08.011; Freeman GL, 1995, J PARASITOL, V81, P1010, DOI 10.2307/3284059; Fulkerson PC, 2006, P NATL ACAD SCI USA, V103, P16418, DOI 10.1073/pnas.0607863103; Geissmann F, 2007, NAT IMMUNOL, V8, P558, DOI 10.1038/nio607-558; Grayson MH, 1998, J EXP MED, V188, P2187, DOI 10.1084/jem.188.11.2187; GREGSON N, 2003, EUROPEAN URBAN REGIO, V3, P5; GUIDA L, 1994, BLOOD, V84, P2733; HANSEL TT, 1991, CLIN EXP IMMUNOL, V86, P271; Hmama Z, 1998, J IMMUNOL, V161, P4882; Ingulli E, 2002, J IMMUNOL, V169, P2247; Itano AA, 2003, NAT IMMUNOL, V4, P733, DOI 10.1038/ni957; Jacobsen EA, 2007, J ALLERGY CLIN IMMUN, V119, P1313, DOI 10.1016/j.jaci.2007.03.043; Jenkins MK, 2001, ANNU REV IMMUNOL, V19, P23, DOI 10.1146/annurev.immunol.19.1.23; Kato M, 1998, ANAT REC, V252, P418, DOI 10.1002/(SICI)1097-0185(199811)252:3<418::AID-AR10>3.0.CO;2-1; Klion AD, 2004, J ALLERGY CLIN IMMUN, V113, P30, DOI 10.1016/j.jaci.2003.10.050; Kuipers H, 2004, CURR OPIN IMMUNOL, V16, P702, DOI 10.1016/j.coi.2004.09.010; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Liu LY, 2002, J IMMUNOL, V169, P6452; LOSS GE, 1993, J IMMUNOL, V150, P3187; LUCEY DR, 1989, P NATL ACAD SCI USA, V86, P1348, DOI 10.1073/pnas.86.4.1348; MacKenzie JR, 2001, J IMMUNOL, V167, P3146; Masten BJ, 2006, J IMMUNOL, V177, P7784; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; MENGELERS HJ, 1994, AM J RESP CRIT CARE, V149, P345; Mishra A, 1999, J CLIN INVEST, V103, P1719, DOI 10.1172/JCI6560; Moqbel R., 2006, SCI STKE, V2006, ppe26; Padigel UM, 2006, INFECT IMMUN, V74, P3232, DOI 10.1128/IAI.02067-05; Rothenberg ME, 2006, ANNU REV IMMUNOL, V24, P147, DOI 10.1146/annurev.immunol.24.021605.090720; SEDGWICK JB, 1992, J IMMUNOL, V149, P3710; Shi HZ, 2000, J CLIN INVEST, V105, P945, DOI 10.1172/JCI8945; Throsby M, 2000, J IMMUNOL, V165, P1965; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; van Rijt LS, 2005, J EXP MED, V201, P981, DOI 10.1084/jem.20042311; van Rijt LS, 2004, J IMMUNOL METHODS, V288, P111, DOI 10.1016/j.jim.2004.03.004; van Rijt LS, 2003, J IMMUNOL, V171, P3372; Varol C, 2007, J EXP MED, V204, P171, DOI 10.1084/jem.20061011; Voehringer D, 2004, IMMUNITY, V20, P267, DOI 10.1016/S1074-7613(04)00026-3; Voehringer D, 2007, J LEUKOCYTE BIOL, V81, P1434, DOI 10.1189/jlb.1106686; von Garnier C, 2005, J IMMUNOL, V175, P1609; WELLER PF, 1993, J IMMUNOL, V150, P2554; Wikstrom ME, 2007, IMMUNOL CELL BIOL, V85, P182, DOI 10.1038/sj.icb.7100039; Yamamoto H, 2000, AM J RESP CELL MOL, V23, P379; ZIEGLER HK, 1982, P NATL ACAD SCI-BIOL, V79, P175, DOI 10.1073/pnas.79.1.175	48	89	92	2	7	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	DEC 1	2007	179	11					7585	7592				8	Immunology	Immunology	237MK	WOS:000251378300047	18025204	
J	Rees, VW; Connolly, GN				Rees, Vaughan W.; Connolly, Gregory N.			Measuring air quality to protect children from secondhand smoke in cars	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; NUTRITION EXAMINATION SURVEY; INFANT-DEATH-SYNDROME; 3RD NATIONAL-HEALTH; PASSIVE SMOKING; EXPOSURE; ASTHMA; HOME; HOUSEHOLDS; CHILDHOOD	Background: Secondhand tobacco smoke (SHS) is a major, preventable contributor to acute and chronic adverse health outcomes that affect children disproportionately. The predominant source of SHS among children is domestic exposure, and while up to two thirds of U.S. households have car smoking bans, an unacceptable number of children remain vulnerable. To help promote more effective protection through legislation, health communication strategies, or behavioral interventions, data demonstrating the adverse effect of SHS on air quality in cars are needed. Methods: Secondhand tobacco smoke in a motor vehicle under actual driving conditions was monitored by measuring respirable suspended particles (RSPs) of less than 2.5 microns in diameter, and carbon monoxide. Forty-five driving trials were conducted, using teams of volunteer drivers and smokers recruited from the general community. Three smoking conditions (nonsmoking baseline, active smoking, and immediate post-smoking period, each 5 minutes) were crossed with two ventilation conditions (windows open, closed) in a 3 x 2 within-sessions factorial design. Results: The highest mean observed RSP level was 271 mu g/m(3), which is unsafe, particularly for children. Peak RSP levels were considerably higher. RSPs and carbon monoxide increased significantly from baseline after smoking, and these increases were greatest during the closed ventilation condition, compared with open ventilation. Conclusions: Private passenger cars are a domestic environment with the potential to yield unsafe levels of SHS contaminants. These data may assist policymakers and health advocates to promote protective strategies to ensure smoke-free domestic environments for children.	Harvard Univ, Sch Publ Hlth, Div Publ Hlth Practice, Boston, MA 02115 USA	Rees, VW (reprint author), Harvard Univ, Sch Publ Hlth, Div Publ Hlth Practice, Landmark Bldg,Level 3 E,677 Huntington Ave, Boston, MA 02115 USA.	vrees@hsph.harvard.cdu					Adair-Bischoff CE, 1998, ARCH PEDIAT ADOL MED, V152, P127; *AM LEG FDN, 2006, DONT PASS GAS; BAUMAN A, 1995, BRIT MED J, V311, P1164; *CAL ENV PROG AG, 1997, HLTH EFF EXP ENV TOB; Connolly GN, 2005, EVALUATION MASSACHUS; CROCKER P J, 1985, Journal of Emergency Medicine, V3, P443, DOI 10.1016/0736-4679(85)90002-2; EMMONS KM, 1994, HEALTH PSYCHOL, V13, P516, DOI 10.1037//0278-6133.13.6.516; EMMONS KM, 1992, AM J PUBLIC HEALTH, V82, P24, DOI 10.2105/AJPH.82.1.24; Emmons KM, 2001, PEDIATRICS, V108, P18, DOI 10.1542/peds.108.1.18; Gehrman CA, 2003, NICOTINE TOB RES, V5, P289, DOI 10.1080/1462220031000094231; Gergen P.J, 1998, PEDIATRICS, P101; Gilpin E A, 1999, Nicotine Tob Res, V1, P153, DOI 10.1080/14622299050011261; Gurkan F, 2000, EUR J EPIDEMIOL, V16, P465, DOI 10.1023/A:1007658411953; Halterman JS, 2006, AMBUL PEDIATR, V6, P115, DOI 10.1016/j.ambp.2005.10.004; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P579, DOI 10.2307/3455031; Jedrychowski W, 1997, ENVIRON HEALTH PERSP, V105, P302, DOI 10.1289/ehp.97105302; Keppel G., 1991, DESIGN ANAL RES HDB; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P795, DOI 10.1001/jama.273.10.795; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; Matt GE, 2000, HEALTH PSYCHOL, V19, P232, DOI 10.1037//0278-6133.19.3.232; Matt GE, 2004, TOB CONTROL, V13, P29, DOI 10.1136/tc.2003.003889; MITCHELL EA, 1993, PEDIATRICS, V91, P893; Nardini S, 2004, Monaldi Arch Chest Dis, V61, P183; *NEW YORK STAT DEP, 2005, NEW YORK STAT DEP HL; Norman GJ, 1999, PREV MED, V29, P581, DOI 10.1006/pmed.1999.0574; Ott W, 1992, J EXPO ANAL ENV EPID, V2, P175; Park JH, 1998, J EXPO ANAL ENV EPID, V8, P65; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; REPACE JL, 1980, SCIENCE, V208, P464, DOI 10.1126/science.7367873; Roberts LM, 1996, MED J AUSTRALIA, V165, P350; SCHUSTER MA, 2002, ARCH PEDIAT ADOLESC, V156, P1095; Strachan DP, 1997, THORAX, V52, P905; Thaqi A, 2005, INDOOR AIR, V15, P302, DOI 10.1111/j.1600-0668.2005.00361.x; Travers M. J., 2004, Morbidity and Mortality Weekly Report, V53, P1040; U.S. DHHS, 2000, RED TOB US REP SURG; *US EPA, 1993, RESP HLTH EFF PASS S, V4; *US EPA, AIR QUAL GUID PART P; *US EPA, 2005, AIR QUAL CRIT PART M; Wakefield M, 2000, AM J PREV MED, V19, P188, DOI 10.1016/S0749-3797(00)00197-5; YIOW L, 2005, CAR HOME SMOKE FREE; Zhou RQ, 2000, MUTAT RES-GEN TOX EN, V465, P191, DOI 10.1016/S1383-5718(99)00229-6	41	89	89	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0749-3797			AM J PREV MED	Am. J. Prev. Med.	NOV	2006	31	5					363	368		10.1016/j.ampere.2006.07.021		6	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	098RX	WOS:000241541600002	17046406	
J	Ribas-Fito, N; Ramon, R; Ballester, F; Grimalt, J; Marco, A; Olea, N; Posada, M; Rebagliato, M; Tardon, A; Torrent, M; Sunyer, J				Ribas-Fito, Nuria; Ramon, Rosa; Ballester, Ferran; Grimalt, Joan; Marco, Alfredo; Olea, Nicolas; Posada, Manuel; Rebagliato, Marisa; Tardon, Adonina; Torrent, Maties; Sunyer, Jordi		INMA Study Grp	Child health and the environment: The INMA spanish study	PAEDIATRIC AND PERINATAL EPIDEMIOLOGY			English	Article						longitudinal cohort study; prenatal exposures; pollution; diet; genetics; study design; biological samples; childhood growth; child development; endocrine disruptors	OXIDATIVE STRESS; POLYCHLORINATED-BIPHENYLS; PRENATAL EXPOSURE; ARACHIDONIC-ACID; AIR-POLLUTANTS; BIRTH-WEIGHT; ASTHMA; PREECLAMPSIA; SUPPLEMENTATION; PREGNANCY	The INMA (INfancia y Medio Ambiente [Environment and Childhood]) is a population-based cohort study in different Spanish cities, that focuses on prenatal environmental exposures and growth, development and health from early fetal life until childhood. The study focuses on five primary areas of research: (1) growth and physical development; (2) behavioural and cognitive development; (3) asthma and allergies; (4) sexual and reproductive development; and (5) environmental exposure pathways. The general aims of the project are: (1) to describe the degree of individual prenatal exposure to environmental pollutants, and the internal dose of chemicals during pregnancy, at birth and during childhood in Spain; (2) to evaluate the impact of the exposure to different contaminants on fetal and infant growth, health and development; (3) to evaluate the role of diet on fetal and infant growth, health and development; and (4) to evaluate the interaction between persistent pollutants, nutrients and genetic determinants on fetal and infant growth, health and development. Extensive assessments will be carried out on 3100 pregnant women and children. Data will be collected by physical examinations, questionnaires, interviews, ultrasound and biological samples. Pregnant women are being assessed at 12, 20 and 32 weeks of gestation to collect information about environmental exposures and fetal growth. The children will be followed until the age of 4 years.	Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, E-08003 Barcelona, Spain; Inst Invest Quim & Ambientals, Barcelona, Spain; Univ Pompeu Fabra, Barcelona, Spain; Univ Alicante, Dept Salud Publ, E-03080 Alicante, Spain; Escola Valenciana Estudis Salut CS GV, Valencia, Spain; Hosp Univ La Fe, CS GV, Valencia, Spain; Hosp Univ San Cecilio SAS UGR, Granada, Spain; Inst Invest Enfermedades Raras ISCIII, Madrid, Spain; Univ Oviedo, Oviedo, Spain; Area Salut Menorca IB Salut, Mao, Spain	Ribas-Fito, N (reprint author), Inst Municipal Invest Med, Resp & Environm Hlth Res Unit, C Dr Aiguader,80, E-08003 Barcelona, Spain.	nribas@imim.es	Grimalt, Joan/E-2073-2011; Olea, Nicolas/H-3198-2014; Sunyer, J/G-6909-2014	Grimalt, Joan/0000-0002-7391-5768; Olea, Nicolas/0000-0002-8938-3743; Sunyer, J/0000-0002-2602-4110; Posada, Manuel/0000-0002-8372-4180			Birch EE, 1998, PEDIATR RES, V44, P201, DOI 10.1203/00006450-199808000-00011; Chappell LC, 2002, AM J OBSTET GYNECOL, V187, P777, DOI 10.1067/mob.2002.125735; Counter SA, 2004, TOXICOL APPL PHARM, V198, P209, DOI 10.1016/j.taap.2003.11.032; Daniels JL, 2004, EPIDEMIOLOGY, V15, P394, DOI 10.1097/01.ede.0000129514.46451.ce; Grandjean P, 2003, AM J CLIN NUTR, V77, P715; Helland I. B., 2003, PEDIATRICS, V111, P39; Hornstra G., 2000, AM J CLIN NUTR, V71, P1262; Hubbard R, 2004, THORAX, V59, P3; Hubel CA, 1999, P SOC EXP BIOL MED, V222, P222, DOI 10.1046/j.1525-1373.1999.d01-139.x; Jacobson JL, 2003, J PEDIATR-US, V143, P780, DOI 10.1067/S0022-3476(03)00577-8; Lacasana M, 2005, EUR J EPIDEMIOL, V20, P183, DOI 10.1007/s10654-004-3005-9; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; Nieuwenhuijsen MJ, 2002, EPIDEMIOLOGY, V13, P725, DOI 10.1097/01.EDE.0000030722.16351.91; Ribas-Fito N, 2003, PEDIATRICS, V111, pE580, DOI 10.1542/peds.111.5.e580; Roberts JM, 1999, LANCET, V354, P788; Romieu I, 2002, AM J RESP CRIT CARE, V166, P703, DOI 10.1164/rccm.2112074; Rumchev K, 2004, THORAX, V59, P746, DOI 10.1136/thx.2003.013680; Vreugdenhil HJI, 2004, DEV MED CHILD NEUROL, V46, P398, DOI 10.1017/S0012162204000647; Weiss B, 2000, ENVIRON HEALTH PERSP, V108, P375, DOI 10.2307/3454523; WEISSKOPF MG, 2005, ENVIRON RES, V97, P148; Williams C, 2001, AM J CLIN NUTR, V73, P316; Wright JM, 2004, ENVIRON HEALTH PERSP, V112, P920, DOI 10.1289/ehp.6779	22	89	89	2	14	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0269-5022			PAEDIATR PERINAT EP	Paediatr. Perinat. Epidemiol.	SEP	2006	20	5					403	410		10.1111/j.1365-3016.2006.00745.x		8	Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics	Public, Environmental & Occupational Health; Obstetrics & Gynecology; Pediatrics	073YA	WOS:000239777400005	16911019	
J	Yu, JW; Kagan, R; Verreault, N; Nicolas, N; Joseph, L; Pierre, YS; Clarke, A				Yu, Joyce W.; Kagan, Rhoda; Verreault, Nina; Nicolas, Nathalie; Joseph, Lawrence; Pierre, Yvan St.; Clarke, Ann			Accidental ingestions in children with peanut allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						peanut allergy; accidental ingestion; treatment; peanut safe policies	TREE-NUT-ALLERGY; SKIN PRICK TESTS; NATURAL-HISTORY; FOOD ALLERGY; HYPERSENSITIVITY REACTIONS; ANAPHYLACTIC REACTIONS; IGE CONCENTRATIONS; PREVALENCE; ADOLESCENTS; RESOLUTION	Background: Accidental exposure to peanut has been reported to occur frequently. Total avoidance of peanut is difficult because of its widespread use, manufacturing and labeling errors, utensil contamination, and label misinterpretation. Objective: Given the apparent increased awareness of peanut allergy by both consumers and food manufacturers, we aimed to determine the current frequency of accidental exposures occurring in peanut allergic children in Quebec and to identify factors associated with exposure. Methods: The parents of children with peanut allergy diagnosed at the Montreal Children's Hospital completed questionnaires about accidental exposure to peanut occurring over the period of the preceding year. Logistic regression was used to identify associated factors. Results: Of 252 children, 62% were boys, with a mean age of 8.1 years (SD, 2.9). The mean age at diagnosis was 2.0 years (SD, 2.1). Thirty-five accidental exposures occurred in 29 children over a period of 244 patient-years, yielding an annual incidence rate of 14.3% (95% CI, 10.0% to 19.9%). Fifteen reactions were mild, 16 moderate, and 4 severe. Of 20 reactions that were moderate to severe, only 4 received epinephrine. Eighty percent of children attended schools prohibiting peanut, and only 1 accidental exposure occurred at school. No associated factors were identified. Conclusion: Accidental exposure to peanut occurs at a lower frequency than previously reported, but most reactions are managed inappropriately. Clinical implications: Enhanced awareness, access to safer environments, and good food manufacturing practices may have contributed to a lower incidence of inadvertent peanut exposure, but a further reduction and better education on allergy management are desirable.	McGill Univ, Div Clin Immunol & Allergy, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Div Pediat Allergy & Clin Immunol, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Div Clin Epidemiol, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ H3G 1A4, Canada	Clarke, A (reprint author), McGill Univ, Div Clin Immunol & Allergy, Ctr Hlth, 1650 Cedar Ave,L10-413, Montreal, PQ H3G 1A4, Canada.	ann.clarke@mcgill.ca					Al-Muhsen S, 2003, CAN MED ASSOC J, V168, P1279; Avery NJ, 2003, PEDIATR ALLERGY IMMU, V14, P378, DOI 10.1034/j.1399-3038.2003.00072.x; Banerjee D. K., 2004, Journal of Allergy and Clinical Immunology, V113, pS152, DOI 10.1016/j.jaci.2003.12.556; Banerjee DK, 2006, J ALLERGY CLIN IMMUN, V117, pS36, DOI 10.1016/j.jaci.2005.12.146; BANERJEE DK, 2005, J ALLERGY CLIN IMMUN, V115, pS36, DOI 10.1016/j.jaci.2004.12.161; Bock SA, 2001, J ALLERGY CLIN IMMUN, V107, P191, DOI 10.1067/mai.2001.112031; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; BOCK SA, 1988, J ALLERGY CLIN IMMUN, V82, P986; *CAN FOOD INSP AG, 2004, UND ALL FOOD; *CAN FOOD INSP AG, 2005, FOOD ALL; *CAN FOOD INSP AG, 2001, NAT SECT ASS 2000 IM; *CAN SOC ALL CLIN, 2005, AN SCH OTH SETT 2005; Eigenmann PA, 1998, PEDIATR ALLERGY IMMU, V9, P186, DOI 10.1111/j.1399-3038.1998.tb00371.x; Ewan PW, 2005, CLIN EXP ALLERGY, V35, P751, DOI 10.1111/j.1365-2222.2005.02266.x; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Grundy J, 2002, J ALLERGY CLIN IMMUN, V110, P784, DOI 10.1067/mai.2002.128802; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Hourihane JO, 1998, BRIT MED J, V316, P1271; Joshi P, 2002, J ALLERGY CLIN IMMUN, V109, P1019, DOI 10.1067/mai.2002.123305; Kagan RS, 2003, J ALLERGY CLIN IMMUN, V112, P1223, DOI 10.1016/j.jaci.2003.09.026; McKenna C, 1997, ANN ALLERG ASTHMA IM, V79, P234; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790; Primeau MN, 2000, CLIN EXP ALLERGY, V30, P1135, DOI 10.1046/j.1365-2222.2000.00889.x; Pucar F, 2001, CLIN EXP ALLERGY, V31, P40, DOI 10.1046/j.1365-2222.2001.00962.x; Rance F, 2002, J ALLERGY CLIN IMMUN, V109, P1027, DOI 10.1067/mai.2002.124775; Roberts G, 2005, J ALLERGY CLIN IMMUN, V115, P1291, DOI 10.1016/j.jaci.2005.02.038; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; SAMPSON HA, 1992, NEW ENGL J MED, V327, P380, DOI 10.1056/NEJM199208063270603; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Schappi GF, 2001, ALLERGY, V56, P1216, DOI 10.1034/j.1398-9995.2001.00280.x; Sicherer SH, 2000, CURR OPIN PEDIATR, V12, P567, DOI 10.1097/00008480-200012000-00010; Sicherer SH, 2000, PEDIATRICS, V105, P359, DOI 10.1542/peds.105.2.359; Sicherer SH, 2005, J ALLERGY CLIN IMMUN, V116, P153, DOI 10.1016/j.jaci.2005.03.017; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P118, DOI 10.1016/j.jaci.2004.03.056; Sicherer SH, 2003, J ALLERGY CLIN IMMUN, V112, P1203, DOI 10.1016/S0091-6749(03)02026-8; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350; Simons E, 2005, ANN ALLERG ASTHMA IM, V95, P426; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473; Vadas P, 2003, J FOOD PROTECT, V66, P1932; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Vierk K, 2002, J ALLERGY CLIN IMMUN, V109, P1022, DOI 10.1067/mai.2002.124500	46	89	89	0	7	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2006	118	2					466	472		10.1016/j.jaci.2006.04.024		7	Allergy; Immunology	Allergy; Immunology	075IH	WOS:000239877700024	16890773	
J	Bleck, B; Tse, DB; Jaspers, I; de Lafaille, MAC; Reibman, J				Bleck, B; Tse, DB; Jaspers, I; de Lafaille, MAC; Reibman, J			Diesel exhaust particle-exposed human bronchial epithelial cells induce dendritic cell maturation	JOURNAL OF IMMUNOLOGY			English	Article							COLONY-STIMULATING FACTOR; AMBIENT PARTICULATE MATTER; REGULATORY T-CELLS; GM-CSF; INFLAMMATORY RESPONSE; TRANSGENE EXPRESSION; ASTHMA; ANTIGEN; SENSITIZATION; TOLERANCE	Increased exposure to air pollutants such as diesel exhaust particles (DEP) has been proposed as one mechanism to explain the rise in allergic disorders. However, the immunologic mechanisms by which DEP enhance allergic sensitization and asthma remain unclear. We hypothesized that DEP act as an adjuvant for immature dendritic cell (DC) maturation via its effect on airway epithelial cell-derived microenvironment for DC. Immature monocyte-derived DC (iMDDC) failed to undergo phenotypic (CD80, CD83, CD86) or functional (T cell activation) maturation in response to exposure to DEP (0.001-100 mu g/ml). In contrast, primary cultures of human bronchial epithelial cells (HBEC) treated with DEP induced iMDDC phenotypic maturation (2.6 +/- 0.1-fold increase in CD83 expression, n = 4, p < 0.05) and functional maturation (2.6 +/- 0.2-fold increase in T cell activation, n = 4, p < 0.05). Functional maturation of iMDDC was induced by conditioned medium derived from DEP-treated HBEC, and was inhibited in cultures with DEP-treated HBEC and blocking Abs against GM-CSF, or GM-CSF-targeted small interfering RNA. These data suggest that DEP induce Ag-independent DC maturation via epithelial cell-DC interactions mediated by HBEC-derived GM-CSF. Although additional signals may be required for polarization of DC, these data suggest a novel mechanism by which environmental pollutants alter airway immune responses.	NYU, Sch Med, Dept Med, New York, NY 10016 USA; NYU, Sch Med, Div Pulm & Crit Care Med, New York, NY 10016 USA; NYU, Sch Med, Div Infect Dis, New York, NY 10016 USA; NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA; NYU, Sch Med, Dept Pathol, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Pathogenesis Program, New York, NY 10016 USA; Univ N Carolina, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27599 USA	Reibman, J (reprint author), NYU, Sch Med, Dept Med, 550 1st Ave,Room NB7N24, New York, NY 10016 USA.	reibmj01@gcrc.med.nyu.edu			NCRR NIH HHS [M01RR00096]; NIAID NIH HHS [AI27742-129007, AI44729]; NIEHS NIH HHS [ES013611]		Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Becker S, 2005, TOXICOL APPL PHARM, V203, P45, DOI 10.1016/j.taap.2004.07.007; Beckwith CI, 2002, BRILLS TIBET STU LIB, V2, P27; Boisleve F, 2005, TOXICOLOGY, V206, P233, DOI 10.1016/j.tox.2004.08.015; Boland S., 1999, AM J PHYSIOL, V276, P604; Bonvallot V, 2002, BIOFACTORS, V16, P15; Byrd RS, 2006, CURR OPIN PULM MED, V12, P68, DOI 10.1097/01.mcp.0000199001.68908.45; Cates EC, 2003, J ALLERGY CLIN IMMUN, V111, P1076, DOI 10.1067/mai.2003.1460; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38; de Jong EC, 2005, SPRINGER SEMIN IMMUN, V26, P289, DOI 10.1007/s00281-004-0167-1; de Lafaille MAC, 2001, J EXP MED, V194, P1349, DOI 10.1084/jem.194.9.1349; DeMarini DM, 2004, ENVIRON HEALTH PERSP, V112, P814; Dhodapkar MV, 2001, J EXP MED, V193, P233, DOI 10.1084/jem.193.2.233; Diaz-Sanchez D, 2005, AM J PHYSIOL-LUNG C, V289, pL722, DOI 10.1152/ajplung.00217.2005; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hauben E, 2005, MICROBES INFECT, V7, P1023, DOI 10.1016/j.micinf.2005.03.027; HOLT PG, 1990, INT ARCH ALLER A IMM, V91, P155; Holt PG, 2000, J AEROSOL MED, V13, P361, DOI 10.1089/jam.2000.13.361; Kalia R, 1999, COMPUT SCI ENG, V1, P2; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Lei XF, 1998, CLIN EXP IMMUNOL, V113, P157; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; MCWILLIAM AS, 1994, J EXP MED, V179, P1331, DOI 10.1084/jem.179.4.1331; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Ohtoshi T, 1998, J ALLERGY CLIN IMMUN, V101, P778, DOI 10.1016/S0091-6749(98)70307-0; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Pourazar J, 2005, AM J PHYSIOL-LUNG C, V289, pL724, DOI 10.1152/ajplung.00055.2005; Reddy A, 1997, BLOOD, V90, P3640; Reibman J, 2000, J IMMUNOL, V165, P1618; Reibman J, 2003, AM J RESP CELL MOL, V28, P648, DOI 10.1165/rcmb.2002-00950C; Reibman J, 2002, AM J RESP CELL MOL, V27, P455, DOI 10.1165/rcmb.2001-0005OC; Rescigno M, 2001, NAT IMMUNOL, V2, P361, DOI 10.1038/86373; Riedl M, 2005, J ALLERGY CLIN IMMUN, V115, P221, DOI 10.1016/j.jaci.2004.11.047; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Singh P, 2004, ENVIRON HEALTH PERSP, V112, P820, DOI 10.1289/ehp.6579; Stampfli MR, 1998, J CLIN INVEST, V102, P1704, DOI 10.1172/JCI4160; Steinman RM, 2003, PATHOL BIOL, V51, P59, DOI 10.1016/S0369-8114(03)00096-8; Steinman RM, 2002, P NATL ACAD SCI USA, V99, P351, DOI 10.1073/pnas.231606698; Swirski FK, 2002, J IMMUNOL, V169, P3499; Takizawa Hajime, 2004, Curr Opin Allergy Clin Immunol, V4, P355, DOI 10.1097/00130832-200410000-00005; Upham JW, 2005, CURR OPIN ALLERGY CL, V5, P167, DOI 10.1097/01.all.0000162310.79555.ed; Van Rijt LS, 2005, CLIN EXP ALLERGY, V35, P1125, DOI 10.1111/j.1365-2222.2005.02321.x; von Boehmer H, 2005, NAT IMMUNOL, V6, P338, DOI 10.1038/ni1180	47	89	93	1	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUN 15	2006	176	12					7431	7437				7	Immunology	Immunology	050QA	WOS:000238101800034	16751388	
J	Spurzem, JR; Rennard, SI				Spurzem, JR; Rennard, SI			Pathogenesis of COPD	SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE			English	Review						bronchitis; emphysema; peribronchiolar fibrosis; cigarette smoking; protease; antioxidant; repair	OBSTRUCTIVE-PULMONARY-DISEASE; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; BRONCHOALVEOLAR LAVAGE FLUID; BRONCHIAL EPITHELIAL-CELLS; COLLAGEN GEL CONTRACTION; FIBROBLAST-MEDIATED CONTRACTION; HUMAN NEUTROPHIL ELASTASE; LOWER RESPIRATORY-TRACT; HUMAN LUNG FIBROBLASTS	Chronic obstructive pulmonary disease (COPD) is characterized and defined by limitation of expiratory airflow. This can result from several types of anatomical lesions, including loss of lung elastic recoil and fibrosis and narrowing of small airways. Inflammation, edema, and secretions also contribute variably to airflow limitation. Smoking can cause COPD through several mechanisms. First, smoke is a powerful inducer of an inflammatory response. Inflammatory mediators, including oxidants and proteases, are believed to play a major role in causing lung damage. Smoke can also alter lung repair responses in several ways. Inhibition of repair may lead to tissue destruction that characterizes emphysema, whereas abnormal repair can lead to the peribronchiolar fibrosis that causes airflow limitation in small airways. Genetic factors likely play a major role and probably account for much of the heterogeneity susceptibility to smoke and other factors. Many factors may play a role, but to date, only alpha-1 protease inhibitor deficiency has been unambiguously identified. Exposures other than cigarette smoke can contribute to the development of COPD. Inflammation of the lower respiratory tract that results from asthma or other chronic disorders may also contribute to the development of fixed airway obstruction. COPD is not only a disease of the lungs but is also a systemic inflammatory disorder. Muscular weakness, increased risk for atherosclerotic vascular disease, depression, osteoporosis, and abnormalities in fluids and electrolyte balance may all be consequences of COPD. Advances in understanding the pathogenesis of COPD have the potential for identifying new therapeutic targets that could alter the natural history of this devastating disorder.	Univ Nebraska, Med Ctr, Omaha, NE 68198 USA	Spurzem, JR (reprint author), Univ Nebraska, Med Ctr, 600 S 42nd St, Omaha, NE 68198 USA.	jspurzem@unmc.edu					Agusti AGN, 2002, AM J RESP CRIT CARE, V166, P485, DOI 10.1164/rccm.2108013; ANTHONISEN NR, 1994, JAMA-J AM MED ASSOC, V272, P1497, DOI 10.1001/jama.272.19.1497; Aoshiba K, 2001, AM J PHYSIOL-LUNG C, V281, pL1392; Aoshiba K, 2003, AM J RESP CELL MOL, V28, P555, DOI 10.1165/rcmb.2002.0090OC; ASHLEY F, 1975, ANN INTERN MED, V82, P739; Balbi B, 2003, CHEST, V123, P983, DOI 10.1378/chest.123.4.983; BARKER DJP, 1991, BRIT MED J, V303, P671; Beeh KM, 2003, CHEST, V123, P778, DOI 10.1378/chest.123.3.778; BITTERMAN PB, 1986, J CLIN INVEST, V77, P700, DOI 10.1172/JCI112364; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; BUIST AS, 1976, AM REV RESPIR DIS, V114, P115; BUSIT AS, 1994, TXB RESP MED, P1259; Calikoglu M, 2004, RESPIRATION, V71, P45, DOI 10.1159/000075648; Campbell EJ, 1999, J CLIN INVEST, V104, P337, DOI 10.1172/JCI6092; Carnevali S, 2003, AM J PHYSIOL-LUNG C, V284, pL955, DOI 10.1152/ajplung.00466.2001; Carnevali S, 1998, AM J PHYSIOL-LUNG C, V274, pL591; Casaburi R, 2000, CHEST, V117, p267S, DOI 10.1378/chest.117.5_suppl_1.267S-a; Cataldo D, 2000, INT ARCH ALLERGY IMM, V123, P259, DOI 10.1159/000024452; Chailleux E, 1996, CHEST, V109, P741, DOI 10.1378/chest.109.3.741; Chapman HA, 1997, ANNU REV PHYSIOL, V59, P63, DOI 10.1146/annurev.physiol.59.1.63; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9; Churg A, 2003, AM J RESP CRIT CARE, V167, P1083, DOI 10.1164/rccm.200212-1396OC; COMSTOCK GW, 1988, AM J EPIDEMIOL, V127, P114; Culpitt SV, 2002, AM J RESP CRIT CARE, V165, P1371, DOI 10.1164/rccm.2105106; D'Angelo M, 2001, J BONE MINER RES, V16, P2339, DOI 10.1359/jbmr.2001.16.12.2339; DAUGHTON DM, 2004, SMOKING CESSATION RE; de Boer WI, 2000, J PATHOL, V190, P619, DOI 10.1002/(SICI)1096-9896(200004)190:5<619::AID-PATH555>3.0.CO;2-6; Debigare R, 2003, CHEST, V124, P83, DOI 10.1378/chest.124.1.83; DIFRANCIA M, 1994, AM J RESP CRIT CARE, V150, P1453; Eid AA, 2001, AM J RESP CRIT CARE, V164, P1414; FINE A, 1987, J BIOL CHEM, V262, P3897; Floreani AA, 2003, AM J RESP CELL MOL, V29, P472, DOI 10.1165/rcmb.2002-0143OC; FUJITA J, 1990, AM REV RESPIR DIS, V142, P57; Fujita M, 2004, THORAX, V59, P224, DOI 10.1136/thx.2003.010785; GADEK JE, 1979, SCIENCE, V206, P1315, DOI 10.1126/science.316188; Gosker HR, 2003, EUR RESPIR J, V22, P280, DOI 10.1183/09031936.03.00012803; Grashoff WFH, 1997, AM J PATHOL, V151, P1785; GROSS P, 1964, J Occup Med, V6, P481; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grumelli S, 2004, PLOS MED, V1, P75, DOI 10.1371/journal.pmed.0010008; Hargreave FE, 1999, AM J RESP CRIT CARE, V160, pS53; Hautamaki RD, 1997, SCIENCE, V277, P2002, DOI 10.1126/science.277.5334.2002; Hind M, 2004, EUR RESPIR J, V23, P20, DOI 10.1183/09031936.03.00119103; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Ionescu A A, 2003, Eur Respir J Suppl, V46, p64s; Ito K, 2000, MOL CELL BIOL, V20, P6891, DOI 10.1128/MCB.20.18.6891-6903.2000; Ito K, 2004, BIOCHEM BIOPH RES CO, V315, P240, DOI 10.1016/j.bbrc.2004.01.046; JANOFF A, 1977, AM REV RESPIR DIS, V115, P461; JANOFF A, 1982, AM REV RESPIR DIS, V126, P25; KALENDERIAN R, 1988, CHEST, V94, P119, DOI 10.1378/chest.94.1.119; Karadag F, 2004, RESPIROLOGY, V9, P70, DOI 10.1111/j.1440-1843.2003.00533.x; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kasahara Y, 2001, AM J RESP CRIT CARE, V163, P737; Keatings VM, 1996, AM J RESP CRIT CARE, V153, P530; Kim HJ, 2004, AM J RESP CELL MOL, V31, P483, DOI 10.1165/rcmb.2002-0300OC; Kohri K, 2002, AM J PHYSIOL-LUNG C, V283, pL531, DOI 10.1152/ajplung.00455.2001; Kohyama T, 2002, AM J RESP CELL MOL, V26, P694; Kohyama T, 2001, AM J PHYSIOL-LUNG C, V281, pL1257; KUHN C, 1976, LAB INVEST, V34, P372; LACOSTE JY, 1993, J ALLERGY CLIN IMMUN, V92, P537, DOI 10.1016/0091-6749(93)90078-T; Lams BEA, 2000, EUR RESPIR J, V15, P512, DOI 10.1034/j.1399-3003.2000.15.14.x; LANG MR, 1994, THORAX, V49, P319, DOI 10.1136/thx.49.4.319; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Laudanna C, 1997, J BIOL CHEM, V272, P24141, DOI 10.1074/jbc.272.39.24141; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; Lee HM, 2000, AM J PHYSIOL-LUNG C, V278, pL185; LIEBOW AA, 1959, AM REV RESPIR DIS, V80, P67; Liu XD, 2002, AM J PHYSIOL-LUNG C, V282, pL1049, DOI 10.1152/ajplung.00321.2001; Liu XD, 2003, CELL MOTIL CYTOSKEL, V54, P248, DOI 10.1002/cm.10098; Louis RE, 2002, EUR RESPIR J, V20, P325, DOI 10.1183/09031936.02.00286302; LUCAS PA, 1988, CONNECT TISSUE RES, V18, P1, DOI 10.3109/03008208809019068; Lucey EC, 2003, RESPIRATION, V70, P200, DOI 10.1159/000070068; MacNee W, 2001, NOVART FDN SYMP, V234, P169; MacNee W., 2000, CHEST, V117, P303; Maestrelli P, 2003, EUR RESPIR J, V21, P971, DOI 10.1183/09031936.03.00098203; Maestrelli P, 2001, AM J RESP CRIT CARE, V164, P1508; Maltais F, 2000, THORAX, V55, P848, DOI 10.1136/thorax.55.10.848; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; March TH, 2004, EXP LUNG RES, V30, P383, DOI 10.1080/01902140490463142; Massaro D, 2001, NOVART FDN SYMP, V234, P229; Massaro GD, 1997, NAT MED, V3, P675, DOI 10.1038/nm0697-675; Massaro GD, 2000, AM J PHYSIOL-LUNG C, V278, pL955; Massaro GD, 1996, AM J PHYSIOL, V270, P305; Mio T, 1996, AM J PHYSIOL-LUNG C, V270, pL829; Mio T, 1998, AM J PHYSIOL-LUNG C, V274, pL119; Miotto D, 2003, EUR RESPIR J, V22, P602, DOI 10.1183/09031936.03.00046402; Monick MM, 2003, ANNU REV PHYSIOL, V65, P643, DOI 10.1146/annurev.physiol.65.092101.142440; Monick MM, 2001, J IMMUNOL, V166, P2681; Montano M, 2004, CHEST, V125, P466, DOI 10.1378/chest.125.2.466; Morse D, 2002, AM J RESP CELL MOL, V27, P8; NAKAMURA Y, 1995, AM J RESP CRIT CARE, V151, P1497; Nguyen LT, 1999, CLIN NUTR, V18, P269, DOI 10.1016/S0261-5614(98)80023-X; NIEWOEHNER DE, 1974, NEW ENGL J MED, V291, P755, DOI 10.1056/NEJM197410102911503; NIEWOEHNER DE, 1994, TXB PULMONARY DIS, V2, P973; NOLTE H, 1988, AGENTS ACTIONS, V23, P173, DOI 10.1007/BF02142532; OKADA Y, 1988, FEBS LETT, V229, P157, DOI 10.1016/0014-5793(88)80817-2; OShaughnessy TC, 1997, AM J RESP CRIT CARE, V155, P852; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Page K, 2003, J IMMUNOL, V170, P5681; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Pesci A, 1998, EUR RESPIR J, V12, P380, DOI 10.1183/09031936.98.12020380; PIERCE JA, 1961, ANN INTERN MED, V55, P210; PIQUETTE CA, 2000, TXB RESP MED, V2, P1187; PRYZWANSKY KB, 1995, BLOOD, V85, P222; RAGHOW R, 1987, J CLIN INVEST, V79, P1285, DOI 10.1172/JCI112950; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; RAHMAN I, 1995, AM J PHYSIOL, V269, P285; RENNARD SI, 2003, CHRONIC OBSTRUCTIVE, P139; Rennard SI, 1990, EUR RESPIR J, V3, p116S; Rennard SI, 1998, PULMONARY DIS DISORD, P697; Ries AL, 1997, CHEST, V112, P1363; Roberts AB, 1998, MINER ELECTROL METAB, V24, P111, DOI 10.1159/000057358; Romberger DJ, 2002, J APPL PHYSIOL, V93, P289, DOI 10.1152/japplphysiol.00815.2001; Rutgers SR, 2000, EUR RESPIR J, V15, P109, DOI 10.1183/09031936.00.15110900; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Saeta M, 1999, AM J RESP CRIT CARE, V160, P711; SAETTA M, 1993, AM REV RESPIR DIS, V147, P301; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1046/j.1365-2222.1996.d01-386.x; Saetta M, 2003, SARCOIDOSIS VASC DIF, V20, P28; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Saito A, 2003, INT ARCH ALLERGY IMM, V132, P168, DOI 10.1159/000073718; Schiller M, 2004, J DERMATOL SCI, V35, P83, DOI 10.1016/j.jdermsci.2003.12.006; Schols AMWJ, 1999, AM J RESP CRIT CARE, V160, P1220; Schols AMWJ, 1998, AM J RESP CRIT CARE, V157, P1791; SCHOLS AMWJ, 1991, THORAX, V46, P695, DOI 10.1136/thx.46.10.695; Schunemann HJ, 2001, AM J RESP CRIT CARE, V163, P1246; Segura-Valdez L, 2000, CHEST, V117, P684, DOI 10.1378/chest.117.3.684; SENIOR RM, 1977, AM REV RESPIR DIS, V116, P469; Shaheen SO, 1998, THORAX, V53, P549; Shapiro SD, 1999, AM J RESP CELL MOL, V20, P1100; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17; Silverman EK, 2001, NOVART FDN SYMP, V234, P45; Sin DD, 2003, AM J MED, V114, P10, DOI 10.1016/S0002-9343(02)01297-4; Sin DD, 2003, CIRCULATION, V107, P1514, DOI 10.1161/01.CIR.0000056767.69054.B3; Skold CM, 1999, AM J RESP CRIT CARE, V159, P1138; SKOLD CM, 1992, CHEST, V101, P989, DOI 10.1378/chest.101.4.989; Sullivan P F, 1999, Nicotine Tob Res, V1 Suppl 2, pS51; Sullivan PF, 1999, NICOTINE TOB RES S2, V1, pS69; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; Taggart CC, 2001, J BIOL CHEM, V276, P33345, DOI 10.1074/jbc.M103220200; Takabatake N, 2000, AM J RESP CRIT CARE, V161, P1179; Takeyabu K, 1998, EUR RESPIR J, V12, P1033, DOI 10.1183/09031936.98.12051033; Takeyama K, 2000, J IMMUNOL, V164, P1546; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165; Tang KC, 2004, J APPL PHYSIOL, V97, P1559, DOI 10.1152/japplphysiol.00221.2004; Tanino M, 2002, THORAX, V57, P405, DOI 10.1136/thorax.57.5.405; THOMPSON AB, 1992, AM REV RESPIR DIS, V146, P389; THOMPSON AB, 1989, AM REV RESPIR DIS, V140, P1527; Traves SL, 2002, THORAX, V57, P590, DOI 10.1136/thorax.57.7.590; TRAVIS J, 1988, AM J MED, V84, P37; Tsao PN, 2004, AM J RESP CRIT CARE, V169, P505, DOI 10.1164/rccm.200306-774OC; TURATO G, 1995, AM J RESP CRIT CARE, V152, P1262; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; VERRA F, 1995, AM J RESP CRIT CARE, V151, P630; Vignola AM, 2004, RESP MED, V98, P495, DOI 10.1016/j.rmed.2003.12.012; Wang HJ, 2003, AM J PHYSIOL-LUNG C, V284, pL205, DOI 10.1152/ajplung.00042.2002; Wang ZD, 2000, J EXP MED, V192, P1587, DOI 10.1084/jem.192.11.1587; Wickenden JA, 2003, AM J RESP CELL MOL, V29, P562, DOI 10.1165/rcmb.2002-0235OC; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; Wouters EF, 2002, CHEST, V121, P127; Wouters EFM, 2002, THORAX, V57, P1067, DOI 10.1136/thorax.57.12.1067; Wyatt TA, 1999, AM J RESP CELL MOL, V21, P283; Yamada N, 2000, AM J HUM GENET, V66, P187, DOI 10.1086/302729; Yamamoto C, 1997, Nihon Kyobu Shikkan Gakkai Zasshi, V35, P1191; Zheng T, 2000, J CLIN INVEST, V106, P1081, DOI 10.1172/JCI10458	166	89	99	1	7	THIEME MEDICAL PUBL INC	NEW YORK	333 SEVENTH AVE, NEW YORK, NY 10001 USA	1069-3424			SEM RESP CRIT CARE M	Semin. Respir. Crit. Care Med.	APR	2005	26	2					142	153		10.1055/s-2005-869535		12	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	922UU	WOS:000228866200003	16088433	
J	Smith, LA; Hatcher-Ross, JL; Wertheimer, R; Kahn, RS				Smith, LA; Hatcher-Ross, JL; Wertheimer, R; Kahn, RS			Rethinking race/ethnicity, income, and childhood asthma: Racial/ethnic disparities concentrated among the very poor	PUBLIC HEALTH REPORTS			English	Article							INNER-CITY CHILDREN; SOCIOECONOMIC-STATUS; PEDIATRIC ASTHMA; INDOOR ALLERGENS; MEDICATION-USE; RISK-FACTORS; MANAGEMENT-PRACTICES; COCKROACH ALLERGEN; ETHNIC-DIFFERENCES; HEALTH-SERVICES	Objective. Past studies of the prevalence of childhood asthma have yielded conflicting findings as to whether racial/ethnic disparities remain after other factors such as, income, are taken into account. The objective of this study was to examine the association of race/ethnicity and family income with the prevalence of childhood asthma and to assess whether racial/ethnic disparities vary by income strata. Methods. Cross-sectional data on 14,244 children aged < 18 years old in the 1997 National Health Interview Survey were examined. The authors used logistic regression to analyze the independent and joint effects of race/ethnicity and income-to-federal poverty level (FPL) ratio, adjusting for demographic covariates. The main outcome measure was parental report of the child having ever been diagnosed with asthma. Results. Bivariate analyses, based on weighted percentages, revealed that asthma was more prevalent among non-Hispanic black children (13.6%) than among non-Hispanic white children (11.2%; p < 0.01), but the prevalence of asthma did not differ significantly between Hispanic children (10.1%) and non-Hispanic white children (11.2%; p = 0.13). Overall, non-Hispanic black children were at higher risk for asthma than non-Hispanic white children (adjusted odds ratio [OR]= 1.20; 95% confidence interval [CI] 1.03, 1.40), after adjustment for sociodemographic variables, including the ratio of annual family income to the FPL. Asthma prevalence did not differ between Hispanic children and non-Hispanic white children in adjusted analyses (adjusted OR = 0.85; 95% CI 0.71, 1.02). Analyses stratified by income revealed that only among children from families with incomes less than half the FPL did non-Hispanic black children have a higher risk of asthma than non-Hispanic white children (adjusted OR = 1.99; 95% CI 1.09, 3.64). No black vs. white differences existed at other income levels. Subsequent analyses of these very poor children that took into account additional potentially explanatory variables did not attenuate the higher asthma risk for very poor non-Hispanic black children relative to very poor non-Hispanic white children. Conclusions. Non-Hispanic black children were at substantially higher risk of asthma than non-Hispanic white children only among the very poor. The concentration of racial/ethnic differences only among the very poor suggests that patterns of social and environmental exposures must overshadow any hypothetical genetic risk.	Boston Univ, Med Ctr, Div Gen Pediat, Dept Pediat, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Univ Minnesota, Dept Educ Psychol, Counseling & Student Personnel Psychol Program, Minneapolis, MN 55455 USA; Child Trends Inc, Washington, DC USA; Childrens Hosp, Med Ctr, Div Gen & Community Pediat, Cincinnati, OH 45229 USA	Smith, LA (reprint author), Boston Univ, Med Ctr, Div Gen Pediat, Dept Pediat, Matern Bldg,4th Floor,91 E Concord St, Boston, MA 02118 USA.	lauren.smith@bmc.org			NICHD NIH HHS [K23 HD40362-01]		Akinbami LJ, 2002, AMBUL PEDIATR, V2, P382, DOI 10.1367/1539-4409(2002)002<0382:RAIDIC>2.0.CO;2; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Braveman P, 2001, PUBLIC HEALTH REP, V116, P449, DOI 10.1016/S0033-3549(04)50073-0; Butz AM, 2000, ARCH PEDIAT ADOL MED, V154, P984; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; Cooper RS, 2003, NEW ENGL J MED, V348, P1166, DOI 10.1056/NEJMsb022863; Cooper WO, 2001, ARCH PEDIAT ADOL MED, V155, P1111; *CPS, ANN DEM SURV MARCH S; CRAIN EF, 1994, PEDIATRICS, V94, P356; Crain EF, 1998, ARCH PEDIAT ADOL MED, V152, P333; Cunningham J, 1996, AM J PUBLIC HEALTH, V86, P1406, DOI 10.2105/AJPH.86.10.1406; Diette GB, 2001, J PEDIATR-US, V138, P59, DOI 10.1067/mpd.2001.109600; DUNCAN GJ, 1994, CHILD DEV, V65, P296, DOI 10.1111/j.1467-8624.1994.tb00752.x; EDWARDS SW, 1994, VITAL HLTH STAT, P120; Finkelstein JA, 2002, ARCH PEDIAT ADOL MED, V156, P562; FINKELSTEIN JA, 1995, PEDIATRICS, V95, P389; Flores G, 1999, AM J PUBLIC HEALTH, V89, P1066, DOI 10.2105/AJPH.89.7.1066; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; Grant EN, 2000, AM J PUBLIC HEALTH, V90, P1923, DOI 10.2105/AJPH.90.12.1923; HAHN BA, 1995, PEDIATRICS, V95, P727; Halterman JS, 2000, PEDIATRICS, V105, P272; Halterman JS, 2001, AMBUL PEDIATR, V1, P275, DOI 10.1367/1539-4409(2001)001<0275:MUAHCC>2.0.CO;2; Jones CP, 2001, AM J EPIDEMIOL, V154, P299, DOI 10.1093/aje/154.4.299; Kaplan JB, 2003, JAMA-J AM MED ASSOC, V289, P2709, DOI 10.1001/jama.289.20.2709; Kaufman JS, 1997, EPIDEMIOLOGY, V8, P621, DOI 10.1097/00001648-199710000-00002; Krieger N, 2001, PUBLIC HEALTH REP, V116, P419, DOI 10.1016/S0033-3549(04)50070-5; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LaVeist TA, 2000, INT J HEALTH SERV, V30, P217, DOI 10.2190/LKDF-UJQ5-W1KU-GLR1; Lester LA, 2001, J ALLERGY CLIN IMMUN, V108, P357, DOI 10.1067/mai.2001.117796; Lieu TA, 2002, PEDIATRICS, V109, P857, DOI 10.1542/peds.109.5.857; MARDER D, 1992, CHEST S, V101, P426; MASSEY DS, 1990, AM J SOCIOL, V96, P329, DOI 10.1086/229532; Massey D., 2004, DU BOIS REV, V1, P7, DOI DOI 10.1017/S1742058X04040032; Miller JE, 2000, AM J PUBLIC HEALTH, V90, P428, DOI 10.2105/AJPH.90.3.428; *NAT CTR HLTH STAT, 1997, NHIS COD; Newacheck PW, 2000, ARCH PEDIAT ADOL MED, V154, P287; Ortega AN, 2001, MED CARE, V39, P1065, DOI 10.1097/00005650-200110000-00004; Pachter LM, 2002, J ASTHMA, V39, P119, DOI 10.1081/JAS-120002193; PLATTSMILLS TAE, 1991, INT ARCH ALLER A IMM, V94, P339; PLATTSMILLS TAE, 1994, ANN ALLERGY, V72, P381; Raghunathan TE, IVEWARE IMPUTATION V; *RES TRIANGL I, 2000, SUDAAN REL 7 5 4A; Rivara FP, 2001, ARCH PEDIAT ADOL MED, V155, P119; Roberts EM, 2003, ARCH PEDIAT ADOL MED, V157, P449, DOI 10.1001/archpedi.157.5.449; Roberts EM, 2002, J NATL MED ASSOC, V94, P215; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHENKER N, 2004, MULTIPLE IMPUTATION; Schleicher NC, 2000, J ASTHMA, V37, P259, DOI 10.3109/02770900009055448; Smedley B., 2003, UNEQUAL TREATMENT CO; SMITH LA, 2000, ASTHMAS IMPACT SOC S, P219; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Stassen HH, 2001, GENET EPIDEMIOL, V21, pS284; *US DHHS, 2000, HEALTH PEOPL 2010 UN; *US NAT CTR HLTH S, 2000, DAT FIL DOC; *US NAT CTR HLTH S, NCHS DEV; VACH W, 1991, AM J EPIDEMIOL, V134, P895; Warman KL, 1999, PEDIATRICS, V103, P422, DOI 10.1542/peds.103.2.422; Weiss KB, 1992, CHEST, V101, P362; WEITZMAN M, 1992, JAMA-J AM MED ASSOC, V268, P2673, DOI 10.1001/jama.268.19.2673; WEITZMAN M, 1990, AM J DIS CHILD, V144, P1189; Williams DR, 1997, ANN EPIDEMIOL, V7, P322, DOI 10.1016/S1047-2797(97)00051-3; Williams DR, 2001, PUBLIC HEALTH REP, V116, P404, DOI 10.1016/S0033-3549(04)50068-7; WILLIESJACOBO LJ, 1993, J ALLERGY CLIN IMMUN, V92, P630, DOI 10.1016/0091-6749(93)90090-3; WISSOW LS, 1988, AM J PUBLIC HEALTH, V78, P777, DOI 10.2105/AJPH.78.7.777; Wright RJ, 2001, ENVIRON HEALTH PERSP, V109, P1085, DOI 10.2307/3454965; Xie HG, 1999, PHARMACOGENETICS, V9, P511; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	70	89	91	0	4	ASSOC SCHOOLS PUBLIC HEALTH	WASHINGTON	1101 15TH ST NW, STE 910, WASHINGTON, DC 20005 USA	0033-3549			PUBLIC HEALTH REP	Public Health Rep.	MAR-APR	2005	120	2					109	116				8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	915JW	WOS:000228301500003	15842111	
J	Marotta, A; Klinnert, MD; Price, MR; Larsen, GL; Liu, AH				Marotta, A; Klinnert, MD; Price, MR; Larsen, GL; Liu, AH			Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopy; children; early intervention; lung function; bronchodilator response; impulse oscillometry; spirometry	FORCED OSCILLATION TECHNIQUE; CHILDHOOD ASTHMA; AIRWAY-OBSTRUCTION; METHACHOLINE RESPONSIVENESS; INTERRUPTER TECHNIQUE; RESPIRATORY SYMPTOMS; PRESCHOOL-CHILDREN; YOUNG-CHILDREN; PEAK FLOW; COLD-AIR	Background: Objective lung function measurements are routinely used to diagnose and manage asthma, but their utility for young children has not been defined. Objective: Bronchodilator responses were measured by means of impulse oscillometry (IOS) and compared with conventional spirometry to determine the value of lung function measures in 4-year-old asthma-prone children. Methods: The study participants were in the Childhood Asthma Prevention Study (National Institute of Health/National Institute of Allergy and Infectious Diseases) and at risk for asthma. At age 4 years, concurrent asthma was determined by using a previously validated modified American Thoracic Society questionnaire. Children performed IOS and spirometry before and after albuterol administration and underwent skin prick testing to 13 common allergens to assess atopy. IOS measures were as follows: airways resistance at 5 Hz and 10 Hz, airways reactance at 5 Hz and 10 Hz, and resonant frequency. Results: Asthmatic patients versus nonasthmatic patients significantly differed in their IOS-assessed bronchodilator responses through Delta resistance at 5 Hz (medians, 27% vs 17%; P = .02) and Delta resistance at 10 Hz (24% vs 16%; P = .03). Because atopic children who have frequent wheezing are at risk for persistent asthma, the data were analyzed in regard to atopic patients with or without asthma. IOS strongly distinguished atopic asthmatic children through A resistance at 5 Hz (36% vs 13 %, P = .007), Delta resistance at 10 Hz (25% vs 11%, P = .02), and Delta reactance at 10 Hz (47 % vs 12 %, P = .03). Conventional spirometry did not establish similar statistically significant findings. Conclusion: IOS bronchodilator responses are remarkably abnormal in 4-year-old children, who are most likely to have persistent asthma. IOS is a useful diagnostic tool in early asthma development and might be a helpful objective outcome measure of early interventions.	Natl Jewish Med & Res Ctr, Div Pediat Allergy & Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Pediat Behav Hlth, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Boulder, CO 80309 USA; Univ Colorado, Hlth Sci Ctr, Dept Psychiat, Boulder, CO 80309 USA; Natl Jewish Med & Res Ctr, Div Pediat Pulm Med, Denver, CO 80206 USA	Liu, AH (reprint author), Natl Jewish Med & Res Ctr, Dept Pediat, 1400 Jackson St,K1023, Denver, CO 80206 USA.				NCRR NIH HHS [M01-RR00051]; NHLBI NIH HHS [HL-67818, K23-HL04272]; NIAID NIH HHS [R18-AI41137]		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Arets HGM, 2001, EUR RESPIR J, V18, P655, DOI 10.1183/09031936.01.00204301; Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; BROOKE AM, 1995, AM J RESP CRIT CARE, V152, P1872; CARR W, 1992, AM J PUBLIC HEALTH, V82, P59, DOI 10.2105/AJPH.82.1.59; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Delacourt C, 2000, AM J RESP CRIT CARE, V161, P730; Delacourt C, 2001, AM J RESP CRIT CARE, V164, P965; DUIVERMAN EJ, 1986, B EUR PHYSIOPATH RES, V22, P433; Eigen H, 2001, AM J RESP CRIT CARE, V163, P619; GLEASON M, 2001, P WORLD ASTHM M CHIC; Goodman DC, 1998, PEDIATRICS, V101, P208, DOI 10.1542/peds.101.2.208; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hellinckx J, 1998, EUR RESPIR J, V12, P438, DOI 10.1183/09031936.98.12020438; Illi S, 2001, J ALLERGY CLIN IMMUN, V108, P709, DOI 10.1067/mai.2001.118786; Joseph CLM, 1999, J ASTHMA, V36, P565, DOI 10.3109/02770909909087293; Klinnert MD, 2002, AM J PUBLIC HEALTH, V92, P792, DOI 10.2105/AJPH.92.5.792; Klug B, 1999, EUR RESPIR J, V14, P1185, DOI 10.1183/09031936.99.14511859; Klug B, 1996, PEDIATR PULM, V21, P290; KONIG P, 1984, CHEST, V86, P884, DOI 10.1378/chest.86.6.884; Kulig M, 1998, PEDIAT ALLERG IMM-UK, V9, P61, DOI 10.1111/j.1399-3038.1998.tb00305.x; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Leone FT, 2001, CHEST, V119, P1027, DOI 10.1378/chest.119.4.1027; MARDER D, 1992, CHEST S, V101, P426; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MAZUREK HK, 1995, CHEST, V107, P996, DOI 10.1378/chest.107.4.996; Nielsen KG, 2000, AM J RESP CRIT CARE, V162, P1500; Nielsen KG, 2000, AM J RESP CRIT CARE, V161, P1805; Oswald H, 1997, PEDIATR PULM, V23, P14, DOI 10.1002/(SICI)1099-0496(199701)23:1<14::AID-PPUL2>3.0.CO;2-P; Palmer LJ, 2001, AM J RESP CRIT CARE, V163, P37; Remes ST, 2002, THORAX, V57, P120, DOI 10.1136/thorax.57.2.120; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; Stein RT, 1997, THORAX, V52, P946; Szefler S, 2000, NEW ENGL J MED, V343, P1054; TARGONSKI PV, 1994, AM J PUBLIC HEALTH, V84, P1830, DOI 10.2105/AJPH.84.11.1830; Wolfe R, 2000, AM J RESP CRIT CARE, V162, P2177	37	89	96	0	3	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2003	112	2					317	322		10.1067/mai.2003.1627		6	Allergy; Immunology	Allergy; Immunology	709WY	WOS:000184650600015	12897737	
J	Perez-Machado, MA; Ashwood, P; Thomson, MA; Latcham, F; Sim, R; Walker-Smith, JA; Murch, SH				Perez-Machado, MA; Ashwood, P; Thomson, MA; Latcham, F; Sim, R; Walker-Smith, JA; Murch, SH			Reduced transforming growth factor-beta 1-producing T cells in the duodenal mucosa of children with food allergy	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						food allergy; lymphocytes; TGF-beta; celiac disease	INFLAMMATORY-BOWEL-DISEASE; ATOPIC DISEASE; EXPRESSION; BETA; PROBIOTICS; INDUCTION; IMMUNITY; INFANTS; ANTIGEN; PROTEIN	Infant food allergies are increasing, and many breast-fed infants now sensitize to maternally-ingested antigens. As low-dose oral tolerance requires generation of suppressor lymphocytes producing TGF-beta1 (Th3 cells), we studied these cells in duodenal biopsies after diagnostic endoscopy. Spontaneous production of Th1, Th2 and Th3 cytokines by duodenal lymphocytes was studied using flow cytometry in 20 children with no eventual clinicopathological diagnosis (controls), 30 children with multiple food allergy, nine with celiac disease and six with inflammatory enteropathies. Immunohistochemistry and in situ hybridization were used to localize TGF-beta1 protein and mRNA in matched biopsies. We found no significant Th1/Th2 skewing amongst mucosal lymphocytes in allergic children compared to controls, although celiac and inflammatory enteropathy patients showed increased Th1 responses. By contrast, the allergic children showed reduction of TGF-beta1(+) lymphocytes in both epithelial and lamina propria compartments. Reduction of TGF-beta1 expression was also seen in mononuclear cells and epithelium in food allergy by immunohistochemistry and in situ hybridization. The dominant mucosal abnormality in food allergic children was, thus, not Th2 deviation but impaired generation of Th3 cells. As generation of these cells requires innate immune response to enteric bacteria, we suggest that changing infectious exposures may inhibit primary establishment of basic oral tolerance mechanisms.	UCL Royal Free & Univ Coll, Sch Med, Ctr Paediat Gastroenterol, London NW3 2PF, England; UCL Royal Free & Univ Coll, Sch Med, Dept Histopathol, London, England	Murch, SH (reprint author), UCL Royal Free & Univ Coll, Sch Med, Ctr Paediat Gastroenterol, Royal Free Campus,Rowland Hill St, London NW3 2PF, England.	s.murch@rfc.ucl.ac.uk					Beyer K, 2002, J ALLERGY CLIN IMMUN, V109, P707, DOI 10.1067/mai.2002.122503; Bonen DK, 2003, GASTROENTEROLOGY, V124, P140, DOI 10.1053/gast.2003.50019; CAMPBELL DI, 2003, IN PRESS PEDIAT RES; Chung HL, 2002, J ALLERGY CLIN IMMUN, V109, P150, DOI 10.1067/mai.2002.120562; Forsthuber T, 1996, SCIENCE, V271, P1728, DOI 10.1126/science.271.5256.1728; Garba ML, 2001, J IMMUNOL METHODS, V258, P193, DOI 10.1016/S0022-1759(01)00491-4; Groux H, 1999, IMMUNOL TODAY, V20, P442, DOI 10.1016/S0167-5699(99)01510-8; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Hill DJ, 1999, ANN MED, V31, P272, DOI 10.3109/07853899908995890; Hooper LV, 2001, SCIENCE, V292, P1115, DOI 10.1126/science.1058709; Isolauri E, 1999, J PEDIATR-US, V134, P27, DOI 10.1016/S0022-3476(99)70368-9; JUNG T, 1993, J IMMUNOL METHODS, V159, P197, DOI 10.1016/0022-1759(93)90158-4; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; LATCHAM F, 2003, IN PRESS J PEDIAT; LINDFORS A, 1988, ALLERGY, V43, P11, DOI 10.1111/j.1398-9995.1988.tb02038.x; Lionetti P, 1999, J PEDIATR GASTR NUTR, V29, P308, DOI 10.1097/00005176-199909000-00013; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Mayer L, 2000, J PEDIATR GASTR NUTR, V30, pS4, DOI 10.1097/00005176-200001001-00002; MILLER A, 1994, EUR J IMMUNOL, V24, P1026, DOI 10.1002/eji.1830240503; Murch S, 1996, LANCET, V348, P1656, DOI 10.1016/S0140-6736(05)65716-9; Murch SH, 2000, CURR OPIN GASTROEN, V16, P552, DOI 10.1097/00001574-200011000-00016; Murch SH, 2001, LANCET, V357, P1057, DOI 10.1016/S0140-6736(00)04305-1; Newberry RD, 1999, NAT MED, V5, P900; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Ridge JP, 1996, SCIENCE, V271, P1723, DOI 10.1126/science.271.5256.1723; Strober W, 1998, GASTROENTEROLOGY, V114, P214, DOI 10.1016/S0016-5085(98)70649-3; Sudo N, 1997, J IMMUNOL, V159, P1739; Taams LS, 2001, EUR J IMMUNOL, V31, P1122, DOI 10.1002/1521-4141(200104)31:4<1122::AID-IMMU1122>3.0.CO;2-P; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; WALKERSMITH JA, 1999, DIS SMALL INTESTINE, P205; Weiner HL, 1997, IMMUNOL TODAY, V18, P335, DOI 10.1016/S0167-5699(97)01053-0; Xian CJ, 1999, SCAND J GASTROENTERO, V34, P591; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490	33	89	93	0	3	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	AUG	2003	33	8					2307	2315		10.1002/eji.200323308		9	Immunology	Immunology	709WC	WOS:000184648700028	12884306	
J	Stark, PC; Burge, HA; Ryan, LM; Milton, DK; Gold, DR				Stark, PC; Burge, HA; Ryan, LM; Milton, DK; Gold, DR			Fungal levels in the home and lower respiratory tract illnesses in the first year of life	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						fungi; respiratory tract infections; infants; public health	INDOOR ALLERGEN LEVELS; CHILDHOOD ASTHMA; CHILDREN; DAMPNESS; HEALTH; SPORES; ASSOCIATIONS; PREDICTORS; ACTIVATION; DISEASES	The association between home dampness and lower respiratory symptoms in children has been well documented. Whether fungal exposures contribute to this association is uncertain. In a prospective birth cohort of 499 children of parents with asthma/allergies, we examined in-home fungal concentrations as predictors of lower respiratory illnesses (LRI) (croup, pneumonia, bronchitis, and bronchiolitis) in the first year. In multivariate analyses, we found a significant increased relative risk (RR) between LRI and high levels (more than the 90th percentile) of airborne Penicillium (RR = 1.73, 95% confidence interval [CI], 1.23, 2.43), dust-borne Clodosporium (RR = 1.52; Cl, 1.02, 2.25), Zygornycetes (RR = 1.96; CI, 1.35, 2.83), and Alternaria (RR = 1.51; CI, 1.00, 2.28), after controlling for sex, presence of water damage or visible mold/mildew, born in winter, breastfeeding, and being exposed to other children through siblings. In a multivariate analysis, the RR of LRI was elevated in households with any fungal level at more than the 90th percentile (RR = 1.86; CI, 1.21, 2.88). Exposure to high fungal levels increased the risk of LRI in infancy, even for infants with nonwheezing LRI. Actual mechanisms remain unknown, but fungi and their components (glucans, mycotoxins, and proteins) may increase the risk of LRI by acting as irritants or through increasing susceptibility to infection.	Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Cambridge, MA 02138 USA; Tufts New England Med Ctr, Dept Med, Div Clin Care Res, Biostat Res Ctr, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Biostat, Cambridge, MA 02138 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA	Gold, DR (reprint author), Channing Labs, 181 Longwood Ave, Boston, MA 02115 USA.		Milton, Donald/G-3286-2010; Ryan, Louise/A-4562-2009	Milton, Donald/0000-0002-0550-7834; Ryan, Louise/0000-0001-5957-2490	NIAID NIH HHS [AI/EHS35786]		ANDERSEN AA, 1958, J BACTERIOL, V76, P471; BRUNEKREEF B, 1989, AM REV RESPIR DIS, V140, P1363; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Chew GL, 1998, AM J RESP CRIT CARE, V157, P1536; Clark NM, 1999, ENVIRON HEALTH PERSP, V107, P421; Dales RE, 1999, ENVIRON HEALTH PERSP, V107, P481; Dharmage S, 2001, AM J RESP CRIT CARE, V164, P65; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GERBERICK GF, 1984, ENVIRON RES, V33, P246, DOI 10.1016/0013-9351(84)90021-5; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Gold DR, 2000, ENVIRON HEALTH PERSP, V108, P643, DOI 10.2307/3454400; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; Hegele RG, 2001, J PEDIATR-US, V138, P831, DOI 10.1067/mpd.2001.114479; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; JAAKKOLA JJK, 1993, J EXPO ANAL ENV EPID, V3, P129; Johnston R, 2000, CLEARING AIR ASTHMA; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; Koskinen OM, 1999, INT J ENVIRON HEAL R, V9, P143; MACHER J, 2000, BIOAEROSOLS ASSESSME; Nikulin M, 1997, FUND APPL TOXICOL, V35, P182, DOI 10.1006/faat.1996.2274; Oie L, 1999, EPIDEMIOLOGY, V10, P294, DOI 10.1097/00001648-199905000-00018; Park JH, 2001, ENVIRON HEALTH PERSP, V109, P859, DOI 10.2307/3454831; POPE AM, 1993, INDOOR ALLERGENS; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rylander R, 1998, AM J RESP CRIT CARE, V158, P1685; Sorenson WG, 1999, ENVIRON HEALTH PERSP, V107, P469; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3; WEEMS JJ, 1987, J CLIN MICROBIOL, V25, P1459; WELLIVER RC, 1993, PEDIATR PULM, V15, P19, DOI 10.1002/ppul.1950150104	31	89	93	2	8	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2003	168	2					232	237		10.1164/rccm.200207-730OC		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	699XL	WOS:000184082000018	12724122	
J	Medeiros, M; Figueiredo, JP; Almeida, MC; Matos, MA; Araujo, MI; Cruz, AA; Atta, AM; Rego, MAV; de Jesus, AR; Taketomi, EA; Carvalho, EM				Medeiros, M; Figueiredo, JP; Almeida, MC; Matos, MA; Araujo, MI; Cruz, AA; Atta, AM; Rego, MAV; de Jesus, AR; Taketomi, EA; Carvalho, EM			Schistosoma mansoni infection is associated with a reduced course of asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; skin prick test; dust mites; helminths; Schistosoma mansoni; IL-10; IgE	INVERSE ASSOCIATION; ATOPY; REACTIVITY; EXPOSURE; ACTIVATION; ALLERGENS; CHILDREN; IL-10	Background: Helminthic infections decrease skin reactivity to indoor allergens, but data on whether they influence asthma severity are lacking. Objective: This study evaluated the course of asthma in patients with and without Schistosoma mansoni infection. Methods: Asthmatic subjects were enrolled from 3 low-socioeconomic areas: a rural area endemic for schistosomiasis (group 1) in addition to a rural area (group 2) and a slum area (group 3), both of which were not endemic for schistosomiasis. A questionnaire on the basis of the International Study of Asthma and Allergies in Childhood study was applied in these 3 areas, and from each area, 21 age- and sex-matched asthmatic subjects were selected for a prospective 1-year study. Pulmonary function tests, skin prick tests with indoor allergens, stool examinations, and serum evaluations were performed in these subjects. Every 3 months, the subjects were evaluated for asthma exacerbation through physical examination, and a questionnaire regarding asthma symptoms and use of antiasthma medicine was administered. Results: The prevalence of S mansoni infection was greater in group I compared with in groups 2 and 3 (P < .0001), whereas the frequency of other helminth and protozoa infections was similar among the 3 groups. The frequency of positive skin test responses to indoor allergens was less (19.0%) in group I subjects relative to those in group 2 (76.2%) and group 3 (57.1%; P < .001). The frequencies of symptoms, use of antiasthma drugs, and pulmonary abnormal findings at physical examination were less in group 1 subjects than in group 2 and 3 subjects (P = .0001). Conclusion: Our results suggest that S mansoni infection is associated with a milder course of asthma.	Hosp Univ Prof Edgar Santos, Serv Imunol, BR-40110160 Salvador, BA, Brazil; Inst Saude Coletiva, Salvador, BA, Brazil; Univ Fed Bahia, Dept Anal Clin & Toxicol, Salvador, BA, Brazil; Escola Baiana Med & Saude Publ, Salvador, BA, Brazil; Univ Fed Uberlandia, Dept Microbiol Immunol & Parasitol, BR-38400 Uberlandia, MG, Brazil	Medeiros, M (reprint author), Hosp Univ Prof Edgar Santos, Serv Imunol, Rua Joao Botas S-N,5 Andar, BR-40110160 Salvador, BA, Brazil.		Cruz, Alvaro/I-1676-2012	Cruz, Alvaro/0000-0002-7403-3871			Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Araujo MI, 1996, EUR J IMMUNOL, V26, P1399, DOI 10.1002/eji.1830260633; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Catapani WR, 1997, J ALLERGY CLIN IMMUN, V100, P142; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; Cooper PJ, 2002, CLIN EXP IMMUNOL, V128, P398, DOI 10.1046/j.1365-2249.2002.01908.x; Howard TD, 2000, J ALLERGY CLIN IMMUN, V105, pS477, DOI 10.1016/S0091-6749(00)90046-0; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; KATZ N, 1968, Revista do Instituto de Medicina Tropical de Sao Paulo, V10, P295; KATZ N, 1970, J PARASITOL, V56, P1032, DOI 10.2307/3277532; King CL, 1996, J IMMUNOL, V156, P4715; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LINCH NR, 1998, J ALLERGY CLIN IMMUN, V101, P217; Liu AH, 2002, J ALLERGY CLIN IMMUN, V109, P379, DOI 10.1067/mai.2002.122157; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P401; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Medeiros M, 2002, J ALLERGY CLIN IMMUN, V109, pS139, DOI 10.1016/S0091-6749(02)81542-1; MOREL AM, 1988, J ALLERGY CLIN IMMUN, V82, P646, DOI 10.1016/0091-6749(88)90978-5; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; Velupillai P, 2000, HUM IMMUNOL, V61, P225, DOI 10.1016/S0198-8859(99)00136-6; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; Weiss ST, 2000, J ALLERGY CLIN IMMUN, V105, P205, DOI 10.1016/S0091-6749(00)90067-8	28	89	97	1	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					947	951		10.1067/mai.2003.1381		5	Allergy; Immunology	Allergy; Immunology	679DA	WOS:000182904500006	12743556	
J	Morafo, V; Srivastava, K; Huang, CK; Kleiner, G; Lee, SY; Sampson, HA; Li, XM				Morafo, V; Srivastava, K; Huang, CK; Kleiner, G; Lee, SY; Sampson, HA; Li, XM			Genetic susceptibility to food allergy is linked to differential T(H)2-T(H)1 responses in C3H/HeJ and BALB/c mice	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						marine strains; food allergy susceptibility; T(H)2-T(H)1 cytokines	MAJOR PEANUT ALLERGEN; HOUSE-DUST ENDOTOXIN; T-CELL; IFN-GAMMA; MURINE MODEL; ATOPIC-DERMATITIS; IMMUNE-RESPONSES; INTERFERON-GAMMA; ORAL TOLERANCE; IL-10	Background: Although food allergy is a serious health problem in westernized countries, factors influencing the development of food allergy are largely unknown. Appropriate marine models of food allergy would be useful in understanding the mechanisms underlying food allergy in human subjects. Objective: We sought to determine the susceptibility of different strains of mice to food hypersensitivity. Methods: C3H/HeJ and BALB/c mice were sensitized to cow's milk (CM) or peanut by means of intragastric administration, with cholera toxin as a mucosal adjuvant. Mice were then challenged with CM or peanut Antigen-specific IgE levels, anaphylactic symptoms, plasma histamine levels, and splenocyte cytokine profiles of these 2 strains were compared. Results: CM-specific IgE levels were significantly increased only in the C3HMeJ strain, 87% of which exhibited systemic anaphylactic reactions accompanied by significantly increased plasma histamine levels in response to challenge. BALB/c mice exhibited no significant CM-specific IgE response, increased plasma histamine levels, or anaphylactic symptoms. After peanut challenge, 100% of peanut-sensitized C3H/HeJ mice exhibited high levels of peanut-specific IgE and anaphylactic symptoms. In contrast, no hypersensitivity reactions were detected in BALB/c mice, despite the presence of significant serum peanut-specific IgE levels. Splenocytes from CM- and peanut-sensitized C3H/HeJ mice exhibited significantly increased IL-4 and IL-10 secretion, whereas splenocytes from BALB/c mice exhibited significantly increased IFN-gamma secretion. Conclusion: induction of food-induced hypersensitivity reactions in mice is strain dependent, with C3H/HeJ mice being susceptible and BALB/c mice being resistant. This strain-dependent susceptibility to food allergy is associated with differential T(H)2-T(H)1 responses after intragastric food allergen sensitization.	CUNY Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA	Morafo, V (reprint author), CUNY Mt Sinai Sch Med, Dept Pediat, 1 Gustave L Levy Pl, New York, NY 10029 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NIAID NIH HHS [P01-AI44236-01]		Atherton KT, 2002, ANN NY ACAD SCI, V964, P163; Barnes PJ, 2001, CLIN EXP ALLERGY, V31, P667, DOI 10.1046/j.1365-2222.2001.01118.x; Bashir MEH, 2002, J IMMUNOL, V169, P3284; BISSONNETTE EY, 1990, J IMMUNOL, V145, P3385; Bjorksten B, 2001, Curr Opin Allergy Clin Immunol, V1, P225, DOI 10.1097/01.all.0000011018.32315.1d; BURKS AW, 1992, J ALLERGY CLIN IMMUN, V90, P962, DOI 10.1016/0091-6749(92)90469-I; Dabbagh K, 2002, J IMMUNOL, V168, P4524; Daser A, 1998, INT ARCH ALLERGY IMM, V117, P239, DOI 10.1159/000024017; De Jong EC, 1998, CLIN EXP ALLERGY, V28, P743; DONON BJ, 1994, J ALLERGY CLIN IMMUN, V93, P93; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; HEINZEL FP, 1994, INFECT IMMUN, V62, P4244; Helm RM, 2002, ANN NY ACAD SCI, V964, P139; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; HSU DH, 1992, INT IMMUNOL, V4, P563, DOI 10.1093/intimm/4.5.563; *I LAB AN RES COMM, 1996, GUID CAR US LAB AN; JOHANSSON SGO, 1984, ANN ALLERGY, V53, P665; Lee HO, 2000, GASTROENTEROLOGY, V119, P129, DOI 10.1053/gast.2000.8542; Lee SY, 2001, CLIN IMMUNOL, V101, P220, DOI 10.1006/clim.2001.5122; Lewkowich IP, 2002, EUR J IMMUNOL, V32, P3536, DOI 10.1002/1521-4141(200212)32:12<3536::AID-IMMU3536>3.0.CO;2-U; Li XM, 1999, J ALLERGY CLIN IMMUN, V103, P206, DOI 10.1016/S0091-6749(99)70492-6; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Li XM, 1999, J IMMUNOL, V162, P3045; Lin CC, 2000, IMMUNOL LETT, V73, P57, DOI 10.1016/S0165-2478(00)00200-5; MacDonald TT, 2000, INFLAMM BOWEL DIS, V6, P116; Maitland AL, 2001, J ALLERGY CLIN IMMUN, V107, pS140; Morafo V, 2002, J ALLERGY CLIN IMMUN, V109, pS287, DOI 10.1016/S0091-6749(02)82014-0; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; MOWAT AM, 1986, IMMUNOLOGY, V58, P677; Nilsen EM, 1998, GASTROENTEROLOGY, V115, P551, DOI 10.1016/S0016-5085(98)70134-9; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Park JH, 2001, AM J RESP CRIT CARE, V163, P322; Pierkes M, 1999, J ALLERGY CLIN IMMUN, V103, P326, DOI 10.1016/S0091-6749(99)70509-9; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Romagnani S, 2000, J ALLERGY CLIN IMMUN, V105, P399, DOI 10.1067/mai.2000.104575; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Ruffilli A, 1997, ALLERGY, V52, P256, DOI 10.1111/j.1398-9995.1997.tb00990.x; Sampson HA, 1997, J ALLERGY CLIN IMMUN, V100, P444; Sampson HA, 2002, NEW ENGL J MED, V346, P1294, DOI 10.1056/NEJMcp012667; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P717, DOI 10.1016/S0091-6749(99)70411-2; Schade RP, 2000, J ALLERGY CLIN IMMUN, V106, P1155, DOI 10.1067/mai.2000.110802; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350; Strobel S, 2002, ANN NY ACAD SCI, V958, P47; VANNIER E, 1991, J CLIN INVEST, V87, P1936, DOI 10.1172/JCI115219; VOGEL SN, 1994, INFECT IMMUN, V62, P4454; Wong CK, 2001, CLIN EXP IMMUNOL, V125, P177, DOI 10.1046/j.1365-2249.2001.01602.x	47	89	94	1	6	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2003	111	5					1122	1128		10.1067/mai.2003.1463		7	Allergy; Immunology	Allergy; Immunology	679DA	WOS:000182904500030	12743580	
J	Phillips, C; Coward, WR; Pritchard, DI; Hewitt, CRA				Phillips, C; Coward, WR; Pritchard, DI; Hewitt, CRA			Basophils express a type 2 cytokine profile on exposure to proteases from helminths and house dust mites	JOURNAL OF LEUKOCYTE BIOLOGY			English	Article						hookworm; allergy; Dermatophagoides pteronyssinus	PERIPHERAL-BLOOD BASOPHILS; DER-P-I; ACTIVATED RECEPTORS; ENZYMATIC-ACTIVITY; TIGHT JUNCTIONS; IL-4 PRODUCTION; ALLERGEN; INTERLEUKIN-4; RELEASE; IGE	The proteolytic activities frequently associated with sources of allergens and parasite secretions have been suggested as important immunomodulators. We have investigated whether the protease activity of the house dust mite allergen Der p1. and the secreted proteases of the hookworm Necator americanus are able to directly induce type 2 cytokine production by basophils. Der p1 and the secretions of N. americanus induced interleukin (IL)-4, IL-5, and IL-13 but not interferon-gamma mRNA in KU812 basophils. Enzyme-linked immunosorbent assay confirmed that IL-4 and IL-13 were secreted. A nonproteolytic antigen failed to induce cytokine expression, and preincubation of Der p1. or N. americanus secretions with protease inhibitors inhibited cytokine expression. Data were confirmed using basophils purified from human peripheral blood. We speculate that this innate mechanism may contribute to the development of a cytokine milieu that could promote immunoglobulin E synthesis, eosinophil recruitment, and the development of type 2 T cells.	Univ Leicester, Dept Microbiol & Immunol, Inst Lung Hlth, Leicester LE1 9HN, Leics, England; Univ Nottingham, Sch Pharm, Sch Pharmaceut Sci, Nottingham, England	Hewitt, CRA (reprint author), Univ Leicester, Dept Microbiol & Immunol, Inst Lung Hlth, POB 138,Univ Rd, Leicester LE1 9HN, Leics, England.						Agis H, 1996, IMMUNOLOGY, V87, P535, DOI 10.1046/j.1365-2567.1996.493578.x; BROWN A, 1995, PARASITOLOGY, V110, P555; BRUNNER T, 1993, J EXP MED, V177, P605, DOI 10.1084/jem.177.3.605; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Culley FJ, 2000, J IMMUNOL, V165, P6447; Dahinden CA, 1997, INT ARCH ALLERGY IMM, V113, P134; DEMEURE CE, 1994, J IMMUNOL, V152, P4775; Falcone FH, 1996, EUR J IMMUNOL, V26, P1147, DOI 10.1002/eji.1830260528; Gibbs BF, 1996, EUR J IMMUNOL, V26, P2493, DOI 10.1002/eji.1830261033; Haas H, 1999, INT ARCH ALLERGY IMM, V119, P86, DOI 10.1159/000024182; Haas H, 1999, EUR J IMMUNOL, V29, P918, DOI 10.1002/(SICI)1521-4141(199903)29:03<918::AID-IMMU918>3.3.CO;2-K; Hara T, 1998, BIOCHEM BIOPH RES CO, V247, P542, DOI 10.1006/bbrc.1998.8816; Hewitt CRA, 1997, CLIN EXP ALLERGY, V27, P201, DOI 10.1111/j.1365-2222.1997.tb00694.x; Hewitt CRA, 1998, ALLERGY, V53, P60; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Kasaian MT, 1996, INT IMMUNOL, V8, P1287, DOI 10.1093/intimm/8.8.1287; KISHI K, 1985, LEUKEMIA RES, V9, P381, DOI 10.1016/0145-2126(85)90060-8; Li HM, 1996, J IMMUNOL, V156, P4833; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; MACGLASHAN D, 1994, J IMMUNOL, V152, P3006; Machado DC, 1996, EUR J IMMUNOL, V26, P2972, DOI 10.1002/eji.1830261224; MAGGI E, 1992, J IMMUNOL, V148, P2142; MUELLER R, 1994, EUR J IMMUNOL, V24, P2935, DOI 10.1002/eji.1830241203; Ochensberger B, 1996, BLOOD, V88, P3028; PRITCHARD DI, 1997, PULMONARY DEFENCES, P305; Redrup AC, 1998, J IMMUNOL, V160, P1957; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1046/j.1365-2222.1997.d01-415.x; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; SEN HG, 1967, NATURE, V214, P609, DOI 10.1038/214609b0; Stewart GA, 1996, CLIN EXP ALLERGY, V26, P1020, DOI 10.1046/j.1365-2222.1996.d01-405.x; van Oort E, 2002, EUR J BIOCHEM, V269, P671, DOI 10.1046/j.0014-2956.2001.02700.x; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Wang M, 1999, CLIN IMMUNOL, V90, P47, DOI 10.1006/clim.1998.4628; Yamashita M, 1996, J IMMUNOL, V157, P714	37	89	96	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0741-5400			J LEUKOCYTE BIOL	J. Leukoc. Biol.	JAN	2003	73	1					165	171		10.1189/jlb.0702356		7	Cell Biology; Hematology; Immunology	Cell Biology; Hematology; Immunology	636MY	WOS:000180460900017	12525574	
J	Carbonnelle, S; Francaux, M; Doyle, I; Dumont, X; De Burbure, C; Morel, G; Michel, O; Bernard, A				Carbonnelle, S; Francaux, M; Doyle, I; Dumont, X; De Burbure, C; Morel, G; Michel, O; Bernard, A			Changes in serum pneumoproteins caused by short-term exposures to nitrogen trichloride in indoor chlorinated swimming pools	BIOMARKERS			English	Article						nitrogen trichloride; exercise; pneumoproteins; swimming; lung epithelium; Clara cell protein; surfactant-associated proteins; chlorine-based disinfectants; chlorine	CLARA CELL PROTEIN; BRONCHIAL RESPONSIVENESS; RESPIRATORY SYMPTOMS; FAILURE; BARRIER; ASTHMA; INJURY; OZONE; GAS	Nitrogen trichloride (NCl3) is an irritant gas released in the air of indoor pools sanitized with chlorine-based disinfectants. In the present study we investigated the effects of NCl3 on the pulmonary epithelium of pool attendees by measuring the leakage into serum of three lung-specific proteins (pneumoproteins): the alveolar surfactant-associated proteins A and B (SP-A and SP-B) and the bronchiolar 16 kDa Clara cell protein (CC16). These pneumoproteins were measured in the serum of 29 recreational swimmers (16 children and 13 adults) before and after attending a chlorinated pool with a mean NCl3 concentration of 490 mug m(-3). Pneumoprotein changes in serum were also studied in 14 trained swimmers performing an intensive 45 min standardized swimming session in a chlorinated pool (mean NCl3 concentration of 355 mug m(-1)) and for the purposes of comparison in a non-chlorinated pool sanitized by the copper silver method. Serum CC16 was not increased in recreational swimmers, but in trained swimmers serum levels of this protein peaked immediately after strenuous exercise, both in the copper/silver pool and in the chlorinated pool. This acute increase in airway permeability is probably the consequence of the mechanical stress on the epithelial barrier caused by overinflation and, or hyperventilation during intense exercise. Serum levels of SP-A and SP-B were unaffected by strenuous exercise in the copper silver pool. The two proteins were, however, significantly increased in a time-dependent manner in recreational and trained swimmers attending the chlorinated pool. The intravascular leakage of SP-A and SP-B was already statistically significant after only 1 h of exposure to pool air without exercising and remained elevated for 12 h after. These changes were knot associated with decrements in lung function. The ability of NCl3 to acutely disrupt the lung epithelium barrier was confirmed in mice using serum CC16 and plasma proteins in bronchoalveolar lavage fluid as permeability markers. The significance of these permeability changes induced by NCl3 in the deep lung is presently unknown. In view of the increasing and widespread human exposure to this gas not only in indoor pools but also in a variety of other situations, these findings warrant further study.	Catholic Univ Louvain, Ind Toxicol Unit, B-1200 Brussels, Belgium; Catholic Univ Louvain, Fac Med, Unit Phys Educ, B-1200 Brussels, Belgium; Flinders Univ S Australia, Sch Med, Dept Human Physiol & Crit Care Med, Adelaide, SA 5001, Australia; Inst Natl Rech & Secur, F-54501 Vandoeuvre Les Nancy, France; Free Univ Brussels, St Pierre Univ Hosp, Clin Allergol & Resp Dis, B-1000 Brussels, Belgium	Bernard, A (reprint author), Catholic Univ Louvain, Toxicol Unit, 30-54 Clos Chapelle Aux Champs, B-1200 Brussels, Belgium.		Francaux, Marc/C-5594-2008; BERNARD, Alfred/A-6511-2010	BERNARD, Alfred/0000-0003-3171-3743; michel, olivier/0000-0002-1528-1277; Francaux, Marc/0000-0001-8182-1588			Agabiti N, 2001, OCCUP ENVIRON MED, V58, P399, DOI 10.1136/oem.58.6.399; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Arsalane K, 1999, TOXICOL APPL PHARM, V159, P169, DOI 10.1006/taap.1999.8738; BARBEE SJ, 1983, AM IND HYG ASSOC J, V44, P145, DOI 10.1202/0002-8894(1983)044<0145:AITONT>2.3.CO;2; BERNARD A, 1992, EUR RESPIR J, V5, P1231; Bernard A, 1996, CLIN CHEM, V42, P1120; BERNARD AM, 1994, ENVIRON RES, V66, P96, DOI 10.1006/enrs.1994.1047; BERNARD AM, 1994, EUR RESPIR J, V7, P1932; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; DOYLE IR, 1995, AM J RESP CRIT CARE, V152, P307; Doyle IR, 1997, AM J RESP CRIT CARE, V156, P1217; GAGNAIRE F, 1994, J APPL TOXICOL, V14, P405, DOI 10.1002/jat.2550140604; Halatek T, 1998, EUR RESPIR J, V11, P726; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hermans C, 1998, CLIN CHIM ACTA, V272, P101, DOI 10.1016/S0009-8981(98)00006-0; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; HERMANS C, 1996, BIOMARKERS, V1, P1; HERY M, 1995, ANN OCCUP HYG, V39, P437; Hopkins SR, 1997, AM J RESP CRIT CARE, V155, P1090; JENSEN HJ, 1988, ZEITUNG GESAMTE HYGI, V34, P248; Karnak I, 1996, CLIN PEDIATR, V35, P471, DOI 10.1177/000992289603500908; Massin N, 1998, OCCUP ENVIRON MED, V55, P258; Musch MW, 1999, GASTROENTEROLOGY, V117, P115, DOI 10.1016/S0016-5085(99)70557-3; NAKAMURA TY, 1995, J CELL BIOL, V131, P509, DOI 10.1083/jcb.131.2.509; Nanson CJ, 2001, RESP PHYSIOL, V127, P259, DOI 10.1016/S0034-5687(01)00251-1; Newman D J, 1994, Kidney Int Suppl, V47, pS20; ROBIN M, 2002, IN PRESS EUROPEAN RE; Shijubo N, 1997, EUR RESPIR J, V10, P1108, DOI 10.1183/09031936.97.10051108; Tanen DA, 1999, NEW ENGL J MED, V341, P848, DOI 10.1056/NEJM199909093411115; TATSUMI T, 1994, AM J PHYSIOL-HEART C, V267, pH1597; Weiler JM, 1998, J ALLERGY CLIN IMMUN, V102, P722, DOI 10.1016/S0091-6749(98)70010-7; WEST JB, 1991, J APPL PHYSIOL, V70, P1731; WHO, 2000, GUID SAF RECR WAT EN, V2	35	89	89	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK,, ABINGDON OX14 4RN, OXON, ENGLAND	1354-750X			BIOMARKERS	Biomarkers	NOV-DEC	2002	7	6					464	478		10.1080/13547500210166612		15	Biotechnology & Applied Microbiology; Toxicology	Biotechnology & Applied Microbiology; Toxicology	630QV	WOS:000180120600003	12581482	
J	Grenier, PA; Beigelman-Aubry, C; Fetita, C; Preteux, F; Brauner, MW; Lenoir, S				Grenier, PA; Beigelman-Aubry, C; Fetita, C; Preteux, F; Brauner, MW; Lenoir, S			New frontiers in CT imaging of airway disease	EUROPEAN RADIOLOGY			English	Review						chronic obstructive pulmonary disease; airways; helical CT; 3D images	THIN-SECTION CT; RESOLUTION COMPUTED-TOMOGRAPHY; PULMONARY-FUNCTION TESTS; DIFFUSE ASPIRATION BRONCHIOLITIS; EXPIRATORY CT; SPIRAL CT; TRACHEOBRONCHIAL TREE; LUNG TRANSPLANTATION; VIRTUAL BRONCHOSCOPY; HELICAL CT	Combining helical volumetric CT acquisition and thin-slice thickness during breath hold provides an accurate assessment of both focal and diffuse airway diseases. With multiple detector rows, compared with single-slice helical CT, multislice CT can cover a greater volume, during a simple breath hold, and with better longitudinal and in-plane spatial resolution and improved temporal resolution. The result in data set allows the generation of superior multiplanar and 3D images of the airways, including those obtained from techniques developed specifically for airway imaging, such as virtual bronchography and virtual bronchoscopy. Complementary CT evaluation at suspended or continuous full expiration is mandatory to detect air trapping that is a key finding for depicting an obstruction on the small airways. Indications for CT evaluation of the airways include: (a) detection of endobronchial lesions in patients with an unexplained hemoptysis; (b) evaluation of extent of tracheobronchial stenosis for planning treatment and follow-up; (c) detection of congenital airway anomalies revealed by hemoptysis or recurrent infection; (d) detection of postinfectious or postoperative airway fistula or dehiscence, and (e) diagnosis and assessment of extent of bronchiectasis and small airway disease. Improvement in image analysis technique and the use of spirometrically control Of lung Volume acquisition have made possible accurate and reproducible quantitative assessment of airway wall and lumen areas and lung density. This contributes to better insights in physiopathology of obstructive lung disease, particularly in chronic obstructive pulmonary disease and asthma.	Univ Paris 06, Pitie Salpetriere Hosp, Dept Radiol, Assistance Publ Hop Paris, F-75651 Paris, France; Inst Natl Telecommun, Dept ARTEMIS, F-91011 Evry, France; UFR SMBH Paris XIII, Avicenne Hosp, Bobigny, France; Inst Mutualiste Montsouris, Paris, France	Grenier, PA (reprint author), Univ Paris 06, Pitie Salpetriere Hosp, Dept Radiol, Assistance Publ Hop Paris, 47-83 Blvd Hop, F-75651 Paris, France.		Beigelman-Aubry, Catherine/F-4305-2017	Beigelman-Aubry, Catherine/0000-0001-7092-6448			AHN JM, 1994, AM J ROENTGENOL, V163, P49; Akira M, 1998, AM J ROENTGENOL, V170, P291; AKIRA M, 1993, RADIOLOGY, V189, P559; AMIRAV I, 1993, J APPL PHYSIOL, V75, P2239; Aquino SL, 1996, J COMPUT ASSIST TOMO, V20, P594, DOI 10.1097/00004728-199607000-00018; Arakawa H, 1998, RADIOLOGY, V206, P89; Bartz RR, 2000, J THORAC IMAG, V15, P285, DOI 10.1097/00005382-200010000-00009; Beigelman C, 1998, EUR RADIOL, V8, P79, DOI 10.1007/s003300050343; BEIGELMANAUBRY C, IN PRESS RADIOLOGY; BROWN R, 1997, J APPL PHYSIOL, V2, P491; Brown RH, 1998, AM J RESP CRIT CARE, V157, P491; Cartier Y, 1999, AM J ROENTGENOL, V173, P47; CONCES DJ, 1991, AM J ROENTGENOL, V157, P249; DAVIS SD, 1989, AM J ROENTGENOL, V153, P953; Ferretti GR, 2001, EUR RESPIR J, V18, P381, DOI 10.1183/09031936.01.00217701; FETITA CI, 2000, EUR RADIOL, V122, P394; Fotheringham T, 1999, J COMPUT ASSIST TOMO, V23, P385, DOI 10.1097/00004728-199905000-00012; Franquet T, 2000, AM J ROENTGENOL, V174, P528; GAETA M, 1993, RADIOLOGY, V187, P535; Gevenois PA, 1996, RADIOLOGY, V199, P825; GEVENOIS PA, 1995, AM J RESP CRIT CARE, V152, P653; Gilkeson RC, 2001, AM J ROENTGENOL, V176, P205; Gleeson FV, 1996, AM J ROENTGENOL, V166, P1052; Gotway MB, 2000, J THORAC IMAG, V15, P168, DOI 10.1097/00005382-200007000-00003; GRENIER P, 1986, RADIOLOGY, V161, P95; Grenier P, 1996, EUR RADIOL, V6, P199; Grenier P, 1993, J Thorac Imaging, V8, P213, DOI 10.1097/00005382-199322000-00006; GRENIER P, 1996, MED RADIOLOGY SPIRAL; Gruden JF, 1999, RADIOLOGY, V210, P711; HANSELL DM, 1991, CLIN RADIOL, V43, P8, DOI 10.1016/S0009-9260(05)80345-9; Hansell DM, 1996, RADIOLOGY, V199, P123; Hansell DM, 1997, RADIOLOGY, V203, P721; Heyneman LE, 1999, AM J ROENTGENOL, V173, P1617; Hopper KD, 1998, RADIOLOGY, V209, P872; Howling SJ, 1999, RADIOLOGY, V212, P637; IM JG, 1988, J COMPUT ASSIST TOMO, V12, P792, DOI 10.1097/00004728-198809010-00014; IM JG, 1991, CLIN RADIOL, V43, P380, DOI 10.1016/S0009-9260(05)80564-1; Johnson JL, 1998, RADIOLOGY, V206, P95; KALENDER WA, 1990, RADIOLOGY, V175, P265; KANG EY, 1995, RADIOLOGY, V195, P649; Kauczor HU, 1996, AM J ROENTGENOL, V167, P419; Kim JS, 1997, AM J ROENTGENOL, V168, P751; King GG, 1999, AM J RESP CRIT CARE, V159, P992; King GG, 2000, AM J RESP CRIT CARE, V161, P574; LAMERS RJ, 1994, RADIOLOGY, V193, P109; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; LEE KS, 1994, AM J ROENTGENOL, V162, P543; Lee KW, 2000, RADIOLOGY, V214, P831; Leung AN, 1998, CHEST, V113, P365, DOI 10.1378/chest.113.2.365; Lucidarme O, 1998, AM J ROENTGENOL, V170, P301; Lucidarme O, 2000, RADIOLOGY, V216, P768; Lucidarme O, 1996, RADIOLOGY, V200, P673; LYNCH DA, 1993, RADIOLOGY, V188, P829; Lynch DA, 2001, RADIOL CLIN N AM, V39, P1153, DOI 10.1016/S0033-8389(05)70336-5; Lynch DA, 1998, RADIOL CLIN N AM, V36, P129, DOI 10.1016/S0033-8389(05)70010-5; Matsuse T, 1996, CHEST, V110, P1289, DOI 10.1378/chest.110.5.1289; Matsuse T, 1998, CHEST, V114, P350, DOI 10.1378/chest.114.1.350-a; McAdams HP, 1998, AM J ROENTGENOL, V170, P1361; McAdams HP, 1998, RADIOLOGY, V209, P689; MCGUINNESS G, 1993, AM J ROENTGENOL, V160, P253; MCGUINNESS G, 1994, CHEST, V105, P1155, DOI 10.1378/chest.105.4.1155; MCGUINNESS G, 1993, RADIOLOGY, V189, P563; MCNAMARA AE, 1992, J APPL PHYSIOL, V73, P307; MILLAR AB, 1992, RESP MED, V86, P39; MILLER RR, 1995, AM J SURG PATHOL, V19, P653, DOI 10.1097/00000478-199506000-00005; MOORE ADA, 1992, AM J ROENTGENOL, V158, P1211; MULLER NL, 1990, AM J ROENTGENOL, V154, P983; MULLER NL, 1995, RADIOLOGY, V196, P3; NAIDICH DP, 1995, RADIOLOGY, V197, P1; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Ng CS, 1999, J THORAC IMAG, V14, P279, DOI 10.1097/00005382-199910000-00008; NIMI A, 2000, AM J RESP CRIT CARE, V162, P1518; PADLEY SPG, 1993, CLIN RADIOL, V47, P236, DOI 10.1016/S0009-9260(05)81129-8; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084; Park CS, 1997, RADIOLOGY, V203, P361; PEROT V, 2001, J RADIOL, V82, P1213; Preteux F, 1999, J ELECTRON IMAGING, V8, P36, DOI 10.1117/1.482682; QUINT LE, 1995, RADIOLOGY, V194, P871; REIFF DB, 1995, AM J ROENTGENOL, V165, P261; Remy J, 1998, EUR RADIOL, V8, P335, DOI 10.1007/s003300050391; Remy-Jardin M, 1998, RADIOLOGY, V208, P393; Remy-Jardin M, 2002, RADIOLOGY, V222, P261; Remy-Jardin M, 1998, RADIOLOGY, V208, P761; REMYJARDIN M, 1993, RADIOLOGY, V186, P107; RemyJardin M, 1996, EUR RADIOL, V6, P807; REMYJARDIN M, 1989, DIAGN INTERVENT RADI, V1, P45; Roberts HR, 2000, THORAX, V55, P198, DOI 10.1136/thorax.55.3.198; RUBIN GD, 1996, MED RADIOLOGY SPIRAL, P101; SCHLUETER FJ, 1999, RADIOLOGY, P849; Schoepf UJ, 1999, RADIOLOGY, V212, P649; SEMENKOVICH JW, 1995, RADIOLOGY, V194, P205; SET PAK, 1993, RADIOLOGY, V189, P677; SHAEFFERPROKOP C, 1996, MED RADIOLOGY SPIRAL, P161; Stark P, 1998, RADIOL CLIN N AM, V36, P91, DOI 10.1016/S0033-8389(05)70008-7; STERN EJ, 1993, RADIOLOGY, V187, P27; STERN EJ, 1994, AM J ROENTGENOL, V163, P37; Summers RM, 1998, AM J ROENTGENOL, V170, P947; TAGASUKI JE, 1998, RADIOL CLIN N AM, V36, P39; Verschakelen JA, 1998, EUR RADIOL, V8, P1391, DOI 10.1007/s003300050558; WEBB WR, 1984, INVEST RADIOL, V19, P394, DOI 10.1097/00004424-198409000-00011; WESTCOTT JL, 1995, RADIOLOGY, V196, P175; WOLLMER P, 1986, CHEST, V90, P387, DOI 10.1378/chest.90.3.387; WOOD SA, 1995, J APPL PHYSIOL, V79, P1687; Worthy SA, 1997, RADIOLOGY, V205, P465; Worthy SA, 1997, AM J ROENTGENOL, V169, P673; Yang CF, 1997, AM J ROENTGENOL, V168, P1045	106	89	91	1	5	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0938-7994			EUR RADIOL	Eur. Radiol.	MAY	2002	12	5					1022	1044		10.1007/s00330-002-1342-1		23	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	552HJ	WOS:000175613700006	11976844	
J	van den Biggelaar, AHJ; Lopuhaa, C; van Ree, R; van der Zee, JS; Jans, J; Hoek, A; Migombet, B; Borrmann, S; Luckner, D; Kremsner, PG; Yazdanbakhsh, M				van den Biggelaar, AHJ; Lopuhaa, C; van Ree, R; van der Zee, JS; Jans, J; Hoek, A; Migombet, B; Borrmann, S; Luckner, D; Kremsner, PG; Yazdanbakhsh, M			The prevalence of parasite infestation and house dust mite sensitization in Gabonese schoolchildren	INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY			English	Article						atopy; skin test reactivity; malaria; helminth; schistosomiasis; filariasis; IgE; Africa	HUMAN LYMPHATIC FILARIASIS; SCHISTOSOMA-HAEMATOBIUM; ALLERGIC REACTIVITY; INTERFERON-GAMMA; ATOPY; IGE; INFECTION; MALARIA; ASTHMA; CHILDREN	Background: Allergic diseases seem less prevalent in communities in less developed parts of the world, where parasite infections are highly prevalent. Altogether not much is known about the association between chronic infections with tissue and blood-dwelling parasites and atopy. Methods: In an area in Gabon endemic for blood and tissue parasites, 520 schoolchildren were parasitologically examined and skin prick-tested for a set of common environmental aeroallergens. Levels of allergen-specific IgE and polyclonal IgE were measured. Results: In schoolchildren schistosome and filarial infections increased with age, whereas malaria was more prevalent in younger children. In contrast to allergen sensitization that increased with age, skin test reactivity tended to decline. The number of children with mite-specific IgE antibodies (47%) by far exceeded the number responding to skin prick testing (11%). Mite sensitization was found to be the highest in children infected with schistosomes and/or filariae whereas skin test reactivity was lowest. The multiple logistic regression showed that the risk of a positive skin test was 8-fold higher with increasing levels of mite-specific IgE but was reduced by 72% when infected with blood stage helminths. Conclusions: Chronic blood and tissue parasite infections that are often capable of modulating immune responses in the host are negatively associated with skin test reactivity in a sensitized population. Copyright (C) 2001 S. Karger AG, Basel.	Leiden Univ, Med Ctr P4, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Pulmonol, NL-1105 AZ Amsterdam, Netherlands; Cent Lab Blood Transfus, Dept Allergy, Amsterdam, Netherlands; Albert Schweitzer Hosp, Res Unit, Lambarene, Gabon; Univ Tubingen, Inst Trop Med, Dept Parasitol, D-72074 Tubingen, Germany	Yazdanbakhsh, M (reprint author), Leiden Univ, Med Ctr P4, Dept Parasitol, POB 9605, NL-2300 RC Leiden, Netherlands.		Borrmann, Steffen/G-1838-2013; van der Zee, jaring/M-8462-2013	Borrmann, Steffen/0000-0001-9189-4393; 			AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Allen JE, 1996, INT ARCH ALLERGY IMM, V109, P3; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Cookson WOCM, 1997, SCIENCE, V275, P41, DOI 10.1126/science.275.5296.41; DREBORG S, 1993, ALLERGY, V48, P49, DOI 10.1111/j.1398-9995.1993.tb04756.x; Faniran AO, 1999, THORAX, V54, P606; GODFREY RC, 1976, NATURE, V259, P484, DOI 10.1038/259484a0; Grogan JL, 1998, J INFECT DIS, V177, P1433; HAGEL I, 1993, PARASITE IMMUNOL, V15, P311, DOI 10.1111/j.1365-3024.1993.tb00615.x; Holgate ST, 1999, NATURE, V402, pB2; JAKOBSEN PH, 1995, PARASITE IMMUNOL, V17, P223, DOI 10.1111/j.1365-3024.1995.tb01019.x; Katz N, 1972, Rev Inst Med Trop Sao Paulo, V14, P397; KING CL, 1991, J IMMUNOL, V146, P1478; Kurtzhals JAL, 1998, LANCET, V351, P1768, DOI 10.1016/S0140-6736(97)09439-7; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Matricardi PM, 1997, BRIT MED J, V314, P999; Mordmuller BG, 1997, EUR CYTOKINE NETW, V8, P29; PRITCHARD DI, 1993, PARASITE IMMUNOL, V15, P5, DOI 10.1111/j.1365-3024.1993.tb00566.x; SARTONO E, 1995, J INFECT DIS, V171, P1683; Schuurman J, 1997, J ALLERGY CLIN IMMUN, V99, P545, DOI 10.1016/S0091-6749(97)70083-6; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Terhell AJ, 1996, T ROY SOC TROP MED H, V90, P196, DOI 10.1016/S0035-9203(96)90140-6; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; VANREE R, 1994, ALLERGY, V49, P254; WILDLING E, 1995, TROP MED PARASITOL, V46, P77; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56; YAZDANBAKHSH M, 1993, EUR J IMMUNOL, V23, P3312, DOI 10.1002/eji.1830231238; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Yobo EODA, 1997, THORAX, V52, P161	33	89	92	2	6	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1018-2438			INT ARCH ALLERGY IMM	Int. Arch. Allergy Immunol.	NOV	2001	126	3					231	238		10.1159/000049519		8	Allergy; Immunology	Allergy; Immunology	508WD	WOS:000173112000009	11752881	
J	Giembycz, MA				Giembycz, MA			Cilomilast: a second generation phosphodiesterase 4 inhibitor for asthma and chronic obstructive pulmonary disease	EXPERT OPINION ON INVESTIGATIONAL DRUGS			English	Review						airways inflammation; asthma; Ariflo; cilomilast; chronic obstructive pulmonary disease; cyclic AMP; phosphodiesterase 4; SB-207439	HUMAN-LIVER-MICROSOMES; AFFINITY ROLIPRAM BINDING; SELECTIVE PDE4 INHIBITOR; THEOPHYLLINE METABOLISM; ARIFLO(TM) SB-207499; INHALED CORTICOSTEROIDS; CATALYTIC ACTIVITY; CIGARETTE-SMOKING; SE-207499 ARIFLO; HUMAN MONOCYTES	Cilomilast (Ariflo(TM), SE-207499) is an orally-active, second generation phosphodiesterase (PDE) inhibitor that may be effective in the treatment of asthma and chronic obstructive pulmonary disease (COPD). It has high selectivity for the cyclic AMP-specific, or PDE4, isoenzyme that predominates in pro-inflammatory and immune cells and is ten-fold more selective for PDE4D than for PDE4A, B and C. In vitro, cilomilast suppresses the activity of many pro-inflammatory and immune cells that have been implicated in the pathogenesis of asthma and COPD and is highly active in animal models of these diseases. Cilomilast demonstrates a markedly improved side effect profile over the archetypal PDE4 inhibitor, rolipram, which has been attributed to its inability to discriminate between the high affinity rolipram binding site and the catalytic domain of the enzyme, and the fact that it is negatively charged which at physiological pH should limit its penetration in to the CNS. In humans cilomilast is rapidly absorbed after oral administration, providing dose-proportional systemic exposure up to 4 mg, completely bioavailable, has a half-life of similar to 7 h and is subject to negligible first pass hepatic metabolism. Cilomilast is extensively metabolised with decyclopentylation, acyl glucuronidation and 3-hydroxylation of the cyclopentyl ring representing the principal routes. Most of the drug is excreted in the urine (similar to 90%) and faeces (6-7%) with unchanged cilomilast accounting for less than 1% of the administered dose. Cilomilast has been evaluated in Phase I, Phase II and Phase III trials and dose-response experiments have demonstrated a clinically significant increase in lung function and a perceived improvement in quality of life in patients with COPD. Trials of cilomilast in asthma have been less impressive although a trend towards improved lung function has been reported. Cilomilast is safe and well-tolerated at doses up to 15 mg in both short- and long-term dosing trials with a low incidence of adverse effects. No evidence for drug-drug interactions with commonly prescribed medications for COPD and asthma such as digoxin, corticosteroids, salbutamol, theophylline or warfarin has been found. Moreover, the pharmacokinetics of cilomilast are essentially the same in smokers and non-smokers, indicating that no dose adjustments of cilomilast will be required in patients with COPD. Thus, cilomilast displays a promising clinical profile in the treatment of inflammatory airway diseases, in particular COPD and the results of further Phase III trials are awaited with interest.	Imperial Coll, Sch Med, Natl Heart & Lung Inst, London SW3 6LY, England	Giembycz, MA (reprint author), Imperial Coll, Sch Med, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.						Ammit AJ, 2000, AM J RESP CELL MOL, V23, P794; American Thoracic Society (ATS), 1995, AM J RESP CRIT CARE, V152, pS77; Au BT, 1998, BRIT J PHARMACOL, V123, P1260, DOI 10.1038/sj.bjp.0701723; BAGCHI I, 2001, AM J RESP CRIT CARE, V163, pA507; Barnes PJ, 1996, EUR RESPIR J, V9, P636, DOI 10.1183/09031936.96.09040636; Barnette MS, 1996, BIOCHEM PHARMACOL, V51, P949; Barnette MS, 1998, J PHARMACOL EXP THER, V284, P420; BARNETTE MS, 1995, J PHARMACOL EXP THER, V273, P1396; BARNETTE MS, 1995, J PHARMACOL EXP THER, V273, P674; Barnette M.S., 1996, PHARM REV COMMUN, V8, P65; BARNETTE MS, 1994, AM J RESP CRIT CARE, V149, pA209; Brown W, 1999, IDrugs, V2, P915; Bundschuh DS, 2001, J PHARMACOL EXP THER, V297, P280; BUTLER MA, 1992, PHARMACOGENETICS, V2, P116, DOI 10.1097/00008571-199206000-00003; Calverley PMA, 2000, AM J RESP CRIT CARE, V161, P341; CAMPBELL ME, 1987, DRUG METAB DISPOS, V15, P237; CAMPBELL ME, 1987, CLIN PHARMACOL THER, V42, P157; CHIPAPPARA G, 2001, AM J RESP CRIT CARE, V163, pA278; Christensen SB, 1998, J MED CHEM, V41, P821, DOI 10.1021/jm970090r; Compten CH, 1999, AM J RESP CRIT CARE, V159, pA806; Compton C, 1999, AM J RESP CRIT CARE, V159, pA624; COMPTON C, 2000, AM J RESP CRIT CARE, V161, pA200; Compton C, 2000, AM J RESP CRIT CARE, V161, pA505; Compton CH, 1999, AM J RESP CRIT CARE, V159, pA522; COMPTON CH, 2001, AM J RESP CRIT CARE, V163, pA909; COMPTON CH, 1999, EUR RESPIR J, V14, pS331; COMPTON CH, 1999, EUR RESPIR J, V14, pS288; Culpitt S V, 2000, Expert Opin Pharmacother, V1, P1007, DOI 10.1517/14656566.1.5.1007; DEMARSH PL, 2001, AM J RESP CRIT CARE, V163, pA381; Dent G, 1998, PULM PHARMACOL THER, V11, P13, DOI 10.1006/pupt.1998.0111; Duplantier AJ, 1996, J MED CHEM, V39, P120, DOI 10.1021/jm9505066; EDELSON JD, 2001, AM J RESP CRIT CARE, V163, pA277; EDELSON JD, 2001, AM J RESP CRIT CARE, V163, pA771; FUHR U, 1992, BIOCHEM PHARMACOL, V43, P225, DOI 10.1016/0006-2952(92)90282-N; Giembycz MA, 2000, DRUGS, V59, P193, DOI 10.2165/00003495-200059020-00004; Griswold DE, 1998, J PHARMACOL EXP THER, V287, P705; GRISWOLD DE, 1999, AM J RESP CRIT CARE, V160, pA90; GU L, 1992, PHARMACOGENETICS, V2, P72; HA HR, 1995, BRIT J CLIN PHARMACO, V39, P321; Hansen G, 2000, P NATL ACAD SCI USA, V97, P6751, DOI 10.1073/pnas.97.12.6751; Hatzelmann A, 2001, J PHARMACOL EXP THER, V297, P267; HOPPE H, 2001, AM J RESP CRIT CARE, V163, pA994; Houslay MD, 1998, ADV PHARMACOL, V44, P225, DOI 10.1016/S1054-3589(08)60128-3; Hughes B, 1997, DRUG DISCOV TODAY, V2, P89, DOI 10.1016/S1359-6446(97)01000-3; HUNT SN, 1976, CLIN PHARMACOL THER, V19, P546; Hurd Suzanne, 2000, Chest, V117, p1S, DOI 10.1378/chest.117.2_suppl.1S; IRANI C, 2001, AM J RESP CRIT CARE, V163, pA778; Jeffery PK, 1999, CLIN EXP ALLERGY, V29, P14, DOI 10.1046/j.1365-2222.1999.00004.x-i2; JONES H, 2001, AM J RESP CRIT CARE, V163, pA993; Jusko W J, 1978, Clin Pharmacol Ther, V24, P405; JUSKO WJ, 1979, DRUG METAB REV, V9, P221, DOI 10.3109/03602537908993892; Kelly J, 1999, AM J RESP CRIT CARE, V159, pA807; KELLY J, 2000, AM J RESP CRIT CARE, V161, pA573; KELLY J, 2001, AM J RESP CRIT CARE, V163, pA278; KELLY J, 2001, AM J RESP CRIT CARE, V163, pA79; KOHYAMA T, 2000, AM J RESP CRIT CARE, V161, pA440; KOHYAMA T, 2000, EUR RESPIR J, V16, pS250; KUEHL FA, 1987, AM REV RESPIR DIS, V136, P210; Laliberte F, 2000, BIOCHEMISTRY-US, V39, P6449; Lazzeri N, 2001, AM J RESP CELL MOL, V24, P44; LIU Q, 2000, EUR RESPIR J, V16, pS539; MALUS E, 2001, IN PRESS AM J RESP C, V163; Manning CD, 1999, BRIT J PHARMACOL, V128, P1393, DOI 10.1038/sj.bjp.0702911; MANNINO DM, 1998, MMWR-MORBID MORTAL W, V47, P11; MARIVET MC, 1989, J MED CHEM, V32, P1450, DOI 10.1021/jm00127a009; MINNICOZZI M, 2000, AM J RESP CRIT CARE, V161, pA183; MORCILLO EJ, 2001, AM J RESP CRIT CARE, V163, pA993; MUHSIN M, 1998, IDEAL DATA BASE; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; Murdoch R., 1998, European Respiratory Journal, V12, p362S; Murdoch RD, 1999, AM J RESP CRIT CARE, V159, pA525; MURDOCH RD, 2000, AM J RESP CRIT CARE, V161, pA572; MURDOCH RD, 1998, AM J RESP CRIT CARE, V157, pA409; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; Nieman RB, 1998, AM J RESP CRIT CARE, V157, pA413; NIEMAN RB, 1999, EUR RESPIR J, V14, pS331; Norman P, 1999, EXPERT OPIN THER PAT, V9, P1101, DOI 10.1517/13543776.9.8.1101; Norman P, 2000, EXPERT OPIN THER PAT, V10, P1415, DOI 10.1517/13543776.10.9.1415; Norman P, 1998, EXPERT OPIN THER PAT, V8, P771, DOI 10.1517/13543776.8.7.771; NORMAN P, 1999, FINANCIAL TIMES BUSI; OSBORN RR, 2001, AM J RESP CRIT CARE, V163, pA144; OWEN CA, 2001, AM J RESP CRIT CARE, V163, pA348; PANETTIERI RA, 2000, AM J RESP CRIT CARE, V161, pA697; PANETTIERI RA, 2000, EUR RESPIR J, V16, pS370; PILLING D, 2000, FINANCIAL TIMES 1101; PLANQUOIS JMS, 2000, AM J RESP CRIT CARE, V161, pA326; POWELL JR, 1977, AM REV RESPIR DIS, V116, P17; POWELL JR, 1978, AM REV RESPIR DIS, V118, P229; PRUNIAUX MP, 2001, AM J RESP CRIT CARE, V163, pA991; ROBSON RA, 1987, BRIT J CLIN PHARMACO, V24, P293; ROBSON RA, 1988, BIOCHEM PHARMACOL, V37, P1651, DOI 10.1016/0006-2952(88)90423-6; RUSH AK, 2000, EUR RESPIR J, V16, pS74; SARKAR MA, 1992, DRUG METAB DISPOS, V20, P31; Sears MR, 1997, LANCET, V350, P1; SHIMADA T, 1989, CANCER RES, V49, P3218; SIAFAKAS NM, 1996, EUR RESPIR REV, V6, P270; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; *SMITHKL BEEC, 1995, RES DEV REV SB PHARM; *SMITHKL BEECH SEI, 1998, PHARM JAP, V16, P17; *SMITHKL BEECH SEI, 1997, PHARM JAP, V15, P17; Souness JE, 1997, CELL SIGNAL, V9, P227, DOI 10.1016/S0898-6568(96)00173-8; Souness JE, 1996, BRIT J PHARMACOL, V118, P649; Souness JE, 1997, BRIT J PHARMACOL, V121, P743, DOI 10.1038/sj.bjp.0701200; SPICER D, 2000, AM J RESP CRIT CARE, V161, pA578; Sullivan S D, 2000, Chest, V117, p5S, DOI 10.1378/chest.117.2_suppl.5S; Teixeira MM, 1997, TRENDS PHARMACOL SCI, V18, P164, DOI 10.1016/S0165-6147(97)01049-3; Tjia JF, 1996, J PHARMACOL EXP THER, V276, P912; Torphy T. J., 1997, European Respiratory Journal Supplement, V10, p313S; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351; Torphy TJ, 1999, PULM PHARMACOL THER, V12, P131, DOI 10.1006/pupt.1999.0181; TORPHY TJ, 1992, J BIOL CHEM, V267, P1798; UNDEM B, 2000, EUR RESPIR J, V16, pS539; Underwood DC, 1998, J PHARMACOL EXP THER, V287, P988; UNDERWOOD DC, 2000, AM J RESP CRIT CARE, V161, pA492; UNDERWOOD DC, 1998, AM J RESP CRIT CARE, V157, pA827; VISTISEN K, 1992, CARCINOGENESIS, V13, P1561, DOI 10.1093/carcin/13.9.1561; Wang P, 1999, MOL PHARMACOL, V56, P170; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; World Health Organziation (WHO), 1998, LIF 21 CENT VIS ALL; WOOLLEY ST, 2000, EUR RESPIR J, V16, pS539; Zussman B, 1999, EUR RESPIR J, V14, p331s; ZUSSMAN B, 2000, AM J RESP CRIT CARE, V161, pA574; Zussman B, 2000, AM J RESP CRIT CARE, V161, pA492; SCHMIECHEN R, 1977, Patent No. 4012495	125	89	91	0	3	ASHLEY PUBLICATIONS LTD	LONDON	UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE FINCHLEY CENTRAL, LONDON N3 1QB, ENGLAND	1354-3784			EXPERT OPIN INV DRUG	Expert Opin. Investig. Drugs	JUL	2001	10	7					1361	1379		10.1517/13543784.10.7.1361		19	Pharmacology & Pharmacy	Pharmacology & Pharmacy	450YL	WOS:000169772400014	11772257	
J	Kimber, I; Basketter, DA; Berthold, K; Butler, M; Garrigue, JL; Lea, L; Newsome, C; Roggeband, R; Steiling, W; Stropp, G; Waterman, S; Wiemann, C				Kimber, I; Basketter, DA; Berthold, K; Butler, M; Garrigue, JL; Lea, L; Newsome, C; Roggeband, R; Steiling, W; Stropp, G; Waterman, S; Wiemann, C			Skin sensitization testing in potency and risk assessment	TOXICOLOGICAL SCIENCES			English	Article						skin sensitization; sensitization potency; risk assessment; guinea pig tests; local lymph node assay; human sensitization	LYMPH-NODE ASSAY; PIG MAXIMIZATION TEST; ALLERGIC CONTACT SENSITIZATION; FALSE-POSITIVE RESPONSES; PREDICTIVE TEST METHODS; GUINEA-PIG; CELL; PRODUCTS; AGENTS; SENSITIVITY	The purpose of this article is to review, and make recommendations for, the use of relevant skin sensitization test methods, for the purposes of determination of relative potency and the threshold dose necessary for the induction of skin sensitization, and for risk assessment, In addressing the first area, the utility of three guinea pig tests (the guinea pig maximization test, the occluded patch test, and the open epicutaneous test) of the local lymph node assay (LLNA) and of human volunteer testing for the assessment of relative potency and identification of thresholds for sensitization were considered. The following conclusions were drawn. (1) Although attempts have been made to modify the guinea pig maximization test for the purposes of deriving dose-response relationships, this method is usually unsuitable for determination of relative sensitizing potency. (2) Guinea pig methods that do not require the use of adjuvant and which employ a relevant route of exposure (the occluded patch test and the open epicutaneous test) are more appropriate for the assessment of relative skin-sensitizing potency. (3) The LLNA is suitable for the determination of relative skin sensitizing potency, and the adaptation of this method for derivation of comparative criteria such as EC3 values (the estimated concentration of test chemical required to induce a stimulation index of 3 in the LLNA) provides an effective and quantitative basis for such measurements, (4) For all the methods identified above, potency is assessed relative to other chemical allergens of known skin sensitizing potential. The estimation of likely threshold concentrations is dependent upon the availability of suitable benchmark chemicals of known potency for human sensitization. (5) Human testing (and specifically, the Human Repeat Insult Patch Test) can provide information of value in confirming the absence of skin sensitizing activity of formulations and products under specific conditions of use and exposure. Based on the above, the following recommendations are made. (1) If results are already available from suitable guinea pig tests, then judicious interpretation of the data may provide information of value in assessing relative skin sensitizing potency. This option should be explored before other analyses are conducted. (2) The LLNA is the recommended method for new assessments of relative potency, and/or for the investigation of the influence of vehicle or formulation on skin sensitizing potency. (3) Whenever available, human skin sensitization data should be incorporated into an assessment of relative potency. With respect to risk assessment, the conclusion drawn is that all the available data on skin-sensitizing activity in animals and man should be integrated into the risk-assessment process. Appropriate interpretation of existing data from suitable guinea pig studies can provide valuable information with respect to potency, as the first step in the development of a risk assessment. However, for de novo investigations, the LLNA is the method favored for providing quantitative estimations of skin-sensitizing potency that are best suited to the risk assessment process. Finally, human testing is of value in the risk assessment process, but is performed only for the purposes of confirming product safety.	Zeneca Cent Toxicol Lab, Macclesfield SK10 4TJ, Cheshire, England; Unilever Res Colworth, SEAC Toxicol Unit, Sharnbrook MK44 1LQ, Beds, England; Asta Med, D-33790 Halle An Der Saale, Germany; ECETOC, B-1160 Brussels, Belgium; LOreal Rech, F-93601 Aulnay Sous Bois, France; Union Carbide Benelux NV, B-2030 Antwerp, Belgium; Procter & Gamble Co, B-1853 Strombeek Bever, Belgium; Henkel KGAA, D-40191 Dusseldorf, Germany; Bayer AG, D-42096 Wuppertal, Germany; Exxon Biomed Sci Inc, E Millstone, NJ 08875 USA; BASF Aktiengessell, D-67056 Ludwigshafen, Germany	Zeneca Cent Toxicol Lab, Alderley Pk, Macclesfield SK10 4TJ, Cheshire, England.	Ian.Kimber@CTL.zeneca.com					ANDERSEN KE, 1984, CONTACT DERMATITIS, V11, P11, DOI 10.1111/j.1600-0536.1984.tb00163.x; Andersen KE, 1995, ACTA DERM-VENEREOL, V75, P463; ANDERSEN KE, 1985, CONTACT ALLERGY PRED, P59; BARRATT MD, 1992, CONTACT DERMATITIS, V27, P98, DOI 10.1111/j.1600-0536.1992.tb05217.x; Basketter D. A., 1998, International Journal of Cosmetic Science, V20, P141, DOI 10.1046/j.1467-2494.1998.171746.x; Basketter DA, 1996, CONTACT DERMATITIS, V35, P146, DOI 10.1111/j.1600-0536.1996.tb02332.x; Basketter DA, 2000, CONTACT DERMATITIS, V42, P344, DOI 10.1034/j.1600-0536.2000.042006344.x; Basketter DA, 1997, FOOD CHEM TOXICOL, V35, P417, DOI 10.1016/S0278-6915(97)00129-4; Basketter DA, 1999, CONTACT DERMATITIS, V40, P150, DOI 10.1111/j.1600-0536.1999.tb06013.x; Basketter DA, 1999, FOOD CHEM TOXICOL, V37, P1167, DOI 10.1016/S0278-6915(99)00112-X; Basketter DA, 1997, CONTACT DERMATITIS, V36, P97, DOI 10.1111/j.1600-0536.1997.tb00421.x; Basketter DA, 1999, J APPL TOXICOL, V19, P261, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<261::AID-JAT572>3.0.CO;2-5; Basketter DA, 1998, FOOD CHEM TOXICOL, V36, P327, DOI 10.1016/S0278-6915(97)00158-0; Basketter DA, 1996, FOOD CHEM TOXICOL, V34, P985, DOI 10.1016/S0278-6915(96)00059-2; BASKETTER DA, 1992, CONTACT DERMATITIS, V27, P209, DOI 10.1111/j.1600-0536.1992.tb03247.x; BASKETTER DA, 1992, ACTA DERM-VENEREOL, V72, P264; BASKETTER DA, 1999, TOXICOLOGY CONTACT C; Robinson M., 1996, TOXICOLOGY CONTACT H, P152; BOTHAM PA, 1991, FOOD CHEM TOXICOL, V29, P275, DOI 10.1016/0278-6915(91)90025-3; Buehler EV, 1996, CONTACT DERMATITIS, V34, P111, DOI 10.1111/j.1600-0536.1996.tb02140.x; BUEHLER EV, 1965, ARCH DERMATOL, V91, P171; CALVIN G, 1992, RISK MANAGEMENT OF CHEMICALS, P120; CARDIN CW, 1986, CONTACT DERMATITIS, V15, P10, DOI 10.1111/j.1600-0536.1986.tb01254.x; Dearman RJ, 1998, J APPL TOXICOL, V18, P281, DOI 10.1002/(SICI)1099-1263(199807/08)18:4<281::AID-JAT506>3.0.CO;2-4; Fewings J, 1999, CONTACT DERMATITIS, V41, P1, DOI 10.1111/j.1600-0536.1999.tb06200.x; Frankild S, 1996, CONTACT DERMATITIS, V35, P135, DOI 10.1111/j.1600-0536.1996.tb02330.x; Friedmann P S, 1990, Adv Dermatol, V5, P175; FRIEDMANN P S, 1985, P275; FRIEDMANN PS, 1996, TOXICOLOGY CONTACT H, P26; FROSCH PJ, 1995, CONTACT DERMATITIS, V32, P210, DOI 10.1111/j.1600-0536.1995.tb00671.x; Gerberick G F, 2000, Am J Contact Dermat, V11, P65, DOI 10.1053/AC.2000.3191; Gerberick G F, 2000, Am J Contact Dermat, V11, P3; GERBERICK GF, 1993, AM J CONTACT DERMATI, V4, P205; HANNUKSELA M, 1986, CONTACT DERMATITIS, V15, P211, DOI 10.1111/j.1600-0536.1986.tb01338.x; Heylings JR, 1996, TOXICOLOGY, V109, P57, DOI 10.1016/0300-483X(96)03304-5; Hilton J, 1998, Am J Contact Dermat, V9, P29, DOI 10.1016/S1046-199X(98)90142-7; KERO M, 1980, CONTACT DERMATITIS, V6, P341, DOI 10.1111/j.1600-0536.1980.tb04960.x; KIMBER I, 1990, INT ARCH ALLER A IMM, V93, P47; Kimber I, 1997, CLIN REV ALLERG IMMU, V15, P145, DOI 10.1007/BF02826584; KIMBER I, 1989, FOOD CHEM TOXICOL, V27, P755, DOI 10.1016/0278-6915(89)90081-1; KIMBER I, 1992, TOXICOL APPL PHARM, V117, P137, DOI 10.1016/0041-008X(92)90230-P; KIMBER I, 1994, TOXICOLOGY, V93, P13, DOI 10.1016/0300-483X(94)90193-7; KIMBER I, 1992, FOOD CHEM TOXICOL, V30, P165, DOI 10.1016/0278-6915(92)90153-C; Kimber I, 1995, TOXICOLOGY, V103, P63, DOI 10.1016/0300-483X(95)03114-U; KIMBER I, 1991, FOOD CHEM TOXICOL, V29, P125, DOI 10.1016/0278-6915(91)90167-6; Kimber I, 1997, HUM ECOL RISK ASSESS, V3, P385; Kimber I, 1999, FOOD CHEM TOXICOL, V37, P553, DOI 10.1016/S0278-6915(99)00048-4; Kimber I, 1996, TOXICOLOGY CONTACT H, P4; KIMBER I, 1996, DERMATOTOXICOLOGY, P469; KINNAIRD A, 1989, INT ARCH ALLER A IMM, V89, P202; Klecak G, 1985, Curr Probl Dermatol, V14, P152; KLIGMAN AM, 1995, CONTACT DERMATITIS, V32, P129, DOI 10.1111/j.1600-0536.1995.tb00801.x; Lea L J, 1999, Am J Contact Dermat, V10, P213, DOI 10.1016/S1046-199X(99)90071-4; Loveless SE, 1996, TOXICOLOGY, V108, P141, DOI 10.1016/0300-483X(95)03279-O; MAGNUSSON B, 1969, J INVEST DERMATOL, V52, P268; MAGNUSSON B, 1970, ALLERGIC CONTACT DER; MERK HF, 1998, ALLERGIC CONTACT DER, P81; Momma J, 1998, TOXICOLOGY, V126, P75, DOI 10.1016/S0300-483X(97)00181-9; NAKAMURA A, 1994, CONTACT DERMATITIS, V31, P72, DOI 10.1111/j.1600-0536.1994.tb01921.x; *NIH, 1999, NIH PUBL, V99; REES JL, 1990, BRIT J DERMATOL, V122, P29, DOI 10.1111/j.1365-2133.1990.tb08236.x; ROBERTS DW, 1982, J THEOR BIOL, V99, P807, DOI 10.1016/0022-5193(82)90199-0; ROBERTS DW, 1990, CONTACT DERMATITIS, V23, P331, DOI 10.1111/j.1600-0536.1990.tb05167.x; Robinson MK, 1996, FOOD CHEM TOXICOL, V34, P495, DOI 10.1016/0278-6915(96)87361-3; ROBINSON MK, 1990, TOXICOL APPL PHARM, V104, P106, DOI 10.1016/0041-008X(90)90286-4; Robinson MK, 2000, CONTACT DERMATITIS, V42, P251, DOI 10.1034/j.1600-0536.2000.042005251.x; ROBINSON MK, 1989, FOOD CHEM TOXICOL, V27, P479, DOI 10.1016/0278-6915(89)90036-7; Robinson MK, 1999, CONTACT DERMATITIS, V41, P65; ROBINSON MK, 1991, FUND APPL TOXICOL, V17, P103, DOI 10.1016/0272-0590(91)90243-W; ROBINSON MK, 1990, TOXICOLOGY, V61, P91, DOI 10.1016/0300-483X(90)90012-6; Roggeband R, 1999, HUM EXP TOXICOL, V18, P591, DOI 10.1191/096032799678839491; Seidenari S, 1996, CONTACT DERMATITIS, V34, P88, DOI 10.1111/j.1600-0536.1996.tb02136.x; Stotts J., 1980, CURRENT CONCEPTS CUT, P41; Warbrick EV, 1999, CONTACT DERMATITIS, V41, P325; Warbrick EV, 1999, J APPL TOXICOL, V19, P255, DOI 10.1002/(SICI)1099-1263(199907/08)19:4<255::AID-JAT573>3.0.CO;2-S; WHITE SI, 1986, BRIT J DERMATOL, V115, P663, DOI 10.1111/j.1365-2133.1986.tb06646.x	76	89	93	0	2	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1096-6080	1096-0929		TOXICOL SCI	Toxicol. Sci.	FEB	2001	59	2					198	208		10.1093/toxsci/59.2.198		11	Toxicology	Toxicology	396LR	WOS:000166638300003	11158712	
J	Ross, MA; Curtis, L; Scheff, PA; Hryhorczuk, DO; Ramakrishnan, V; Wadden, RA; Persky, VW				Ross, MA; Curtis, L; Scheff, PA; Hryhorczuk, DO; Ramakrishnan, V; Wadden, RA; Persky, VW			Association of asthma symptoms and severity with indoor bioaerosols	ALLERGY			English	Article						allergens; asthma; bacteria; dampness; dust mites; flooding; mold spores	DUST-MITE-ALLERGEN; ENDOTOXIN EXPOSURE; RESPIRATORY HEALTH; CONTROL CHILDREN; RISK FACTOR; HOUSE; HOME; CHILDHOOD; FUNGI	Background: In this study, repeated measurements were made of levels of mold spores, bacteria, and dust-mite allergens over a 7-month period in the homes of asthmatics, and relationships with measures of asthma severity were evaluated. Methods: A sample of 57 asthmatic individuals, living in 44 homes in East Moline, Illinois, and nearby communities, participated in a panel study. The homes were visited up to nine times during the study to collect air and dust samples. Asthma severity indicators were derived from questionnaire data and from the daily health records from the panel study. Associations between indoor levels of mold spores, bacteria, and dust-mite allergens were tested with several asthma severity indicators. Results: There was evidence of associations between all asthma severity measures and levels of total and Gram-negative bacteria, but mold-spore abundance was associated only with emergency room (ER) visits for asthma. No significant associations were found with house-dust-mite allergen and any of the asthma severity indicators, but the levels of dust-mite allergen were low, with median concentrations of 0.18 mu g/g dust Der f 1 and 0.19 mu g/g dust Der p 1. Conclusions: Some evidence was found for associations of increased concentrations of Gram-negative bacteria and mold spores with asthma severity, particularly with ER visits. No association was found between house-dust-mite allergen and asthma severity indicators; however, the mite-allergen levels in the study homes were generally well below the proposed threshold level of 2 mu g/g dust.	US EPA, Off Air Qual Planning & Stand, Hlth & Ecosyst Effects Grp, Res Triangle Pk, NC 27711 USA; Univ Illinois, Sch Publ Hlth, Chicago, IL USA	Ross, MA (reprint author), US EPA, Off Air Qual Planning & Stand, Hlth & Ecosyst Effects Grp, Mail Code 15, Res Triangle Pk, NC 27711 USA.				NIOSH CDC HHS [2T15OH07104]; PHS HHS [94IA0025]		BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; Curtis L, 1997, ALLERGY, V52, P642, DOI 10.1111/j.1398-9995.1997.tb01043.x; CURTIS L, 2000, IN PRESS INDOOR BUIL; Custovic A, 1996, J ALLERGY CLIN IMMUN, V98, P64, DOI 10.1016/S0091-6749(96)70227-0; DEKOSTER JA, 1995, AM IND HYG ASSOC J, V56, P573, DOI 10.1202/0002-8894(1995)056<0573:BCINCA>2.0.CO;2; LI CS, 1995, ARCH ENVIRON HEALTH, V50, P38; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; MICHEL O, 1991, CLIN EXP ALLERGY, V21, P441, DOI 10.1111/j.1365-2222.1991.tb01684.x; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; RIZZO M, 1997, P 90 ANN M EXH AIR W; Rizzo MC, 1997, PEDIATR ALLERGY IMMU, V8, P121; SAS Institute Inc, 1990, SAS STAT US GUID VER; Smedje G, 1997, CLIN EXP ALLERGY, V27, P1270, DOI 10.1111/j.1365-2222.1997.tb01171.x; Sporik R, 1999, THORAX, V54, P675; SPORIK R, 1995, AM J RESP CRIT CARE, V151, P1388; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Squillace SP, 1997, AM J RESP CRIT CARE, V156, P1760; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181; vanStrien RT, 1996, EUR RESPIR J, V9, P926, DOI 10.1183/09031936.96.09050926; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; ZOCK JP, 1994, EUR RESPIR J, V7, P1254, DOI 10.1183/09031936.94.07071254	23	89	98	0	6	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	AUG	2000	55	8					705	711		10.1034/j.1398-9995.2000.00551.x		7	Allergy; Immunology	Allergy; Immunology	341JE	WOS:000088586600004	10955695	
J	Collison, A; Mattes, J; Plank, M; Foster, PS				Collison, Adam; Mattes, Joerg; Plank, Maximilian; Foster, Paul S.			Inhibition of house dust mite-induced allergic airways disease by antagonism of microRNA-145 is comparable to glucocorticoid treatment	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						miRNA; asthma; allergy; inflammation; dexamethasone; glucocorticoid; HDM; antagomir	EXPERIMENTAL ASTHMA; EOSINOPHIL RECRUITMENT; IMMUNE-SYSTEM; T(H)2 CELLS; IN-VIVO; EXPRESSION; MODULATION; INFLAMMATION; MECHANISMS; MODEL	Background: Glucocorticoids are used as mainstay therapy for asthma, but some patients remain resistant to therapy. MicroRNAs (miRNAs) are important regulators of the immune system by promoting the catabolism of their target transcripts as well as attenuating their translation. The role of miRNA in regulating allergic inflammation remains largely unknown. Blocking miRNA function may provide a new nonsteroidal anti-inflammatory approach to treatment. Objectives: To (1) determine the role of specific miRNAs in the regulation of hallmark features of allergic airways inflammation and (2) compare the efficacy of antagonizing miRNA function with that of steroid treatment. Methods: Mice were sensitized and then aeroallergen-challenged with house dust mite to induce allergic airways disease, and alterations in the expression of miRNAs were characterized. Next mice were treated with antagomirs that inhibited the function of specific miRNAs in the lung or treated with dexamethasone and inflammatory lesions, and airway hyperresponsiveness was measured. Results: miR-145, miR-21, and let-7b have been implicated in airway smooth muscle function, inflammation, and airways epithelial cell function, respectively. Inhibition of miR-145, but not miR-21 or lethal-7b, inhibited eosinophilic inflammation, mucus hypersecretion, T(H)2 cytokine production, and airway hyperresponsiveness. The anti-inflammatory effects of miR-145 antagonism were comparable to steroid treatment. Conclusion: Our study highlights the importance of understanding the contribution of miRNAs to pathogenesis of human allergic disease and their potential as novel anti-inflammatory targets. (J Allergy Clin Immunol 2011; 128: 160-7.)	[Collison, Adam; Plank, Maximilian; Foster, Paul S.] Univ Newcastle, Cooperat Res Ctr Asthma & Airways, Ctr Asthma & Resp Dis, Sch Biomed Sci & Pharm,Fac Hlth, Newcastle, NSW 2300, Australia; [Collison, Adam; Mattes, Joerg] Univ Newcastle, Cooperat Res Ctr Asthma & Airways, Expt & Translat Resp Grp, Sch Biomed Sci & Pharm,Fac Hlth, Newcastle, NSW 2300, Australia	Foster, PS (reprint author), Univ Newcastle, Cooperat Res Ctr Asthma & Airways, Ctr Asthma & Resp Dis, Sch Biomed Sci & Pharm,Fac Hlth, 5th Floor David Maddison Clin Sci Bldg, Newcastle, NSW 2300, Australia.	joerg.mattes@newcastle.edu.au; paul.foster@newcastle.edu.au	Foster, Paul/G-5057-2013		National Health and Medical Research Council; Cooperative Research Centre for Asthma and Airways	Supported by a National Health and Medical Research Council project grant (to J.M. and P.S.F.), a National Health and Medical Research Council Health Professional Research Fellowship (to J.M.), and the Cooperative Research Centre for Asthma and Airways (to J.M. and P.S.F.).	Aberdam D, 2008, TRENDS BIOCHEM SCI, V33, P583, DOI 10.1016/j.tibs.2008.09.002; Adcock IM, 2008, CURR ALLERGY ASTHM R, V8, P171, DOI 10.1007/s11882-008-0028-4; Anderson GP, 2008, LANCET, V372, P1107, DOI 10.1016/S0140-6736(08)61452-X; Barnes PJ, 2009, LANCET, V373, P1905, DOI 10.1016/S0140-6736(09)60326-3; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Barnes PJ, 2006, EUR RESPIR J, V27, P413, DOI 10.1183/09031936.06.00125404; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Cohn L, 2004, ANNU REV IMMUNOL, V22, P789, DOI 10.1146/annurev.immunol.22.012703.104716; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Currie GP, 2005, RESP MED, V99, P683, DOI 10.1016/j.rmed.2004.11.008; Fabani MM, 2010, NUCLEIC ACIDS RES, V38, P4466, DOI 10.1093/nar/gkq160; Fanta CH, 2009, NEW ENGL J MED, V360, P1002, DOI 10.1056/NEJMra0804579; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; He Tao, 2009, Bioinformation, V4, P112; Herbert C, 2008, CLIN EXP ALLERGY, V38, P847, DOI 10.1111/j.1365-2222.2008.02950.x; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kay AB, 2001, NEW ENGL J MED, V344, P30; Krutzfeldt J, 2005, NATURE, V438, P685, DOI 10.1038/nature04303; La Rocca G, 2011, J CELL PHYSIOL, V226, P602, DOI 10.1002/jcp.22368; Loffler D, 2007, BLOOD, V110, P1330, DOI 10.1182/blood-2007-03-081133; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Mattes J, 2002, J EXP MED, V195, P1433, DOI 10.1084/jem.20020009; Mattes J, 2008, CURR OPIN MOL THER, V10, P150; Mattes J, 2009, P NATL ACAD SCI USA, V106, P18704, DOI 10.1073/pnas.0905063106; O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708; Polikepahad S, 2010, J BIOL CHEM, V285, P30139, DOI 10.1074/jbc.M110.145698; Riggi N, 2010, GENE DEV, V24, P916, DOI 10.1101/gad.1899710; ROBINSON D, 1993, J ALLERGY CLIN IMMUN, V92, P313, DOI 10.1016/0091-6749(93)90175-F; Rodriguez A, 2007, SCIENCE, V316, P608, DOI 10.1126/science.1139253; Sachdeva M, 2010, CANCER RES, V70, P378, DOI 10.1158/0008-5472.CAN-09-2021; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Sonkoly E, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000610; Sonkoly E, 2009, INT REV IMMUNOL, V28, P535, DOI 10.3109/08830180903208303; Sont JK, 1999, AM J RESP CRIT CARE, V159, P1043; Sur S, 1996, J ALLERGY CLIN IMMUN, V97, P1272, DOI 10.1016/S0091-6749(96)70195-1; Ulrich K, 2008, PULM PHARMACOL THER, V21, P637, DOI 10.1016/j.pupt.2008.02.006; Weckmann M, 2007, NAT MED, V13, P1308, DOI 10.1038/nm1660; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Witwer KW, 2010, J IMMUNOL, V184, P2369, DOI 10.4049/jimmunol.0902712; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Zhang JG, 2010, CLIN CHIM ACTA, V411, P846, DOI 10.1016/j.cca.2010.02.074	45	88	98	1	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2011	128	1					160	U251		10.1016/j.jaci.2011.04.005		12	Allergy; Immunology	Allergy; Immunology	785RE	WOS:000292245600021	21571357	
J	Barrett, NA; Rahman, OM; Fernandez, JM; Parsons, MW; Xing, W; Austen, KF; Kanaoka, Y				Barrett, Nora A.; Rahman, Opu M.; Fernandez, James M.; Parsons, Matthew W.; Xing, Wei; Austen, K. Frank; Kanaoka, Yoshihide			Dectin-2 mediates Th2 immunity through the generation of cysteinyl leukotrienes	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article							HUMAN POLYMORPHONUCLEAR LEUKOCYTES; PATTERN-RECOGNITION RECEPTOR; MANSONI EGG ANTIGENS; DUST MITE ALLERGEN; DENDRITIC CELLS; INHALED ANTIGEN; VASCULAR-PERMEABILITY; AIRWAY INFLAMMATION; SCHISTOSOMA-MANSONI; MICE LACKING	The innate signaling pathways for Th2 immunity activated by inhaled antigens are not well defined. We previously identified Dectin-2 as a receptor for glycans in allergen extracts from the house dust mite Dermatophagoides farinae (Df) that mediates cysteinyl leukotriene (cys-LT) generation from pulmonary CD11c(+) cells and from GM-CSF-cultured bone marrow cells (BMCsGM-CSF) Using lentiviral knockdown of Dectin-2 in BMCsGM-CSF and adoptive transfer of Df-pulsed BMCsGm-csF to sensitize naive mice, we now report that Dectin-2 is critical for the development of Df-elicited eosinophilic and neutrophilic pulmonary inflammation and Th2 cytokine generation in the lungs and restimulated lymph nodes. Sensitization with Df-pulsed BMCsGM-CSF from LTC4 synthase(LTC,S)-deficient mice or type 1 cys-LT receptor (CysLT,R)-deficient mice demonstrated that both proteins were required for Df-elicited eosinophilic pulmonary inflammation and Th2 cytokine generation in the lungs and restimulated lymph nodes. Direct sensitization and challenge of Ltc4s(-/-) and Cysitr1(-/-) mice confirmed that cys-LTs mediate these parameters of Df-elicited Th2 pulmonary inflammation. Thus, the Dectin-2-cys-LT pathway is critical for the induction of Th2 immunity to a major allergen, in part through CysLT(1)R. These findings identify a previously unrecognized link between a myeloid C-type lectin receptor and Th2 immunity.	[Barrett, Nora A.; Rahman, Opu M.; Fernandez, James M.; Parsons, Matthew W.; Xing, Wei; Austen, K. Frank; Kanaoka, Yoshihide] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Barrett, Nora A.; Rahman, Opu M.; Fernandez, James M.; Parsons, Matthew W.; Xing, Wei; Austen, K. Frank; Kanaoka, Yoshihide] Brigham & Womens Hosp, Div Rheumatol Immunol & Allergy, Boston, MA 02115 USA	Kanaoka, Y (reprint author), Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.	ykanaoka@rics.bwh.harvard.edu			National Institutes of Health [101HL36110, R01HL090630, K08A1080948]; Joycelyn C. Austen Fund for the Career Development of Women Physician Scientists	This work is supported by National Institutes of Health grants 101HL36110, RO1HL090630 (to Y. Kanaoka), and K08A1080948 (to. NA. Barrett). N.A. Barrett is supported by the Joycelyn C. Austen Fund for the Career Development of Women Physician Scientists.	Altmann F, 2007, INT ARCH ALLERGY IMM, V142, P99, DOI 10.1159/000096114; Aragane Y, 2003, J IMMUNOL, V171, P3801; Ariizumi K, 2000, J BIOL CHEM, V275, P11957, DOI 10.1074/jbc.275.16.11957; Barrett NA, 2009, J IMMUNOL, V182, P1119; Boehmler AM, 2009, J IMMUNOL, V182, P6789, DOI 10.4049/jimmunol.0801525; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Cates EC, 2004, J IMMUNOL, V173, P6384; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hammad H, 2009, NAT MED, V15, P410, DOI 10.1038/nm.1946; Inoue K, 2009, RESP RES, V10, DOI 10.1186/1465-9921-10-68; Instanes C, 2004, CLIN EXP ALLERGY, V34, P1634, DOI 10.1111/j.1365-2222.2004.02076.x; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Kanaoka Y, 2001, J BIOL CHEM, V276, P22608, DOI 10.1074/jbc.M103562200; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lambrecht BN, 2000, CLIN EXP ALLERGY, V30, P214; Lambrecht BN, 2000, J IMMUNOL, V164, P2937; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; Lutz MB, 1999, J IMMUNOL METHODS, V223, P77, DOI 10.1016/S0022-1759(98)00204-X; Machida I, 2004, J IMMUNOL, V172, P1833; Madsen L, 1999, P NATL ACAD SCI USA, V96, P10338, DOI 10.1073/pnas.96.18.10338; Maekawa A, 2002, J BIOL CHEM, V277, P20820, DOI 10.1074/jbc.M203163200; Meliton AY, 2010, EUR RESPIR J, V35, P402, DOI 10.1183/09031936.00009309; Meyer S, 2007, GLYCOBIOLOGY, V17, P1104, DOI 10.1093/glyco/cwm073; Okano M, 2001, J IMMUNOL, V167, P442; Okano M, 1999, J IMMUNOL, V163, P6712; Okunishi K, 2004, J IMMUNOL, V173, P6393; Olynych TJ, 2006, J ALLERGY CLIN IMMUN, V118, P837, DOI 10.1016/j.jaci.2006.06.008; Peng J, 2010, CELL RES, V20, P62, DOI 10.1038/cr.2009.128; Phipps S, 2009, AM J RESP CRIT CARE, V179, P883, DOI 10.1164/rccm.200806-974OC; Rincon M, 1997, J EXP MED, V185, P461, DOI 10.1084/jem.185.3.461; Robbiani DF, 2000, CELL, V103, P757, DOI 10.1016/S0092-8674(00)00179-3; Robinson MJ, 2009, J EXP MED, V206, P2037, DOI 10.1084/jem.20082818; Saijo S, 2010, IMMUNITY, V32, P681, DOI 10.1016/j.immuni.2010.05.001; Sato K, 2006, J BIOL CHEM, V281, P38854, DOI 10.1074/jbc.M606542200; Shreffler WG, 2006, J IMMUNOL, V177, P3677; Suram S, 2006, J BIOL CHEM, V281, P5506, DOI 10.1074/jbc.M509824200; Thivierge M, 2006, J ALLERGY CLIN IMMUN, V117, P1155, DOI 10.1016/j.jaci.2005.12.1342; Valera I, 2007, J LEUKOCYTE BIOL, V81, P925, DOI 10.1189/jlb.0706451; Wills-Karp M, 2010, MUCOSAL IMMUNOL, V3, P104, DOI 10.1038/mi.2009.138; Yamasaki S, 2008, NAT IMMUNOL, V9, P1179, DOI 10.1038/ni.1651	42	88	91	0	8	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	MAR 14	2011	208	3					593	604		10.1084/jem.20100793		12	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	735ZW	WOS:000288460300015	21357742	
J	Andersen, ZJ; Hvidberg, M; Jensen, SS; Ketzel, M; Loft, S; Sorensen, M; Tjonneland, A; Overvad, K; Raaschou-Nielsen, O				Andersen, Zorana J.; Hvidberg, Martin; Jensen, Steen S.; Ketzel, Matthias; Loft, Steffen; Sorensen, Mette; Tjonneland, Anne; Overvad, Kim; Raaschou-Nielsen, Ole			Chronic Obstructive Pulmonary Disease and Long-Term Exposure to Traffic-related Air Pollution A Cohort Study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						COPD; air pollution; hospital admission; asthma; diabetes	LUNG-FUNCTION; RESPIRATORY SYMPTOMS; NITROGEN-DIOXIDE; HEALTH; RISK; COPD; CANCER; ATHEROSCLEROSIS; INFLAMMATION; POPULATION	Rationale: Short-term exposure to air pollution has been associated with exacerbation of chronic obstructive pulmonary disease (COPD), whereas the role of long-term exposures on the development of COPD is not yet fully understood. Objectives: We assessed the effect of exposure to traffic-related air pollution over 35 years on the incidence of COPD in a prospective cohort study. Methods: We followed 57,053 participants in the Danish Diet, Cancer, and Health cohort in the Hospital Discharge Register for their first hospital admission for COPD between 1993 and 2006. We estimated the annual mean levels of nitrogen dioxide (NO(2)) and nitrogen oxides (NO(x)) at all residential addresses of the cohort participants since 1971 to an event or 2006 and used indicators of traffic near the residential address at recruitment. We assessed the association between exposure to air pollution and COPD incidence by Cox regression analyses for the full cohort, and for participants with and without comorbid conditions, including asthma, diabetes, or cardiovascular disease. Measurements and Main Results: A first hospital admission for COPD was recorded for 1,786 (3.4%) of 52,799 eligible subjects between recruitment (1993-1997) and 2006. COPD incidence was associated with the 35-year mean NO(2) level (hazard ratio, 1.08; 95% confidence interval, 1.02-1.14, per interquartile range of 5.8 mu g/m(3)), with stronger associations in subjects with diabetes (1.29; 1.05-1.50) and asthma (1.19; 1.03-1.38). Conclusions: Long-term exposure to traffic-related air pollution may contribute to the development of COPD with possibly enhanced susceptibility in people with diabetes and asthma.	[Andersen, Zorana J.; Sorensen, Mette; Tjonneland, Anne; Raaschou-Nielsen, Ole] Danish Canc Soc, Inst Canc Epidemiol, DK-2100 Copenhagen O, Denmark; [Hvidberg, Martin; Jensen, Steen S.; Ketzel, Matthias] Aarhus Univ, Natl Environm Res Inst, Roskilde, Denmark; [Loft, Steffen] Univ Copenhagen, Dept Environm Hlth, Copenhagen, Denmark; [Overvad, Kim] Aarhus Univ, Sch Publ Hlth, Aarhus, Denmark; [Overvad, Kim] Aarhus Univ Hosp, Aalborg Hosp, Ctr Cardiovasc Res, Aalborg, Denmark	Andersen, ZJ (reprint author), Danish Canc Soc, Inst Canc Epidemiol, Strandboulevarden 49, DK-2100 Copenhagen O, Denmark.	zorana@cancer.dk	Andersen, Zorana /P-4983-2014; Ketzel, Matthias/K-4246-2015	Andersen, Zorana /0000-0003-4138-9828; Ketzel, Matthias/0000-0001-9519-1935; Hvidberg, Martin/0000-0003-3991-2667; Sorensen, Mette/0000-0002-7302-4789; Loft, Steffen/0000-0001-9552-8518	Danish Research Council	Supported by The Danish Research Council.	Berkowicz R, 2008, ENVIRON MODELL SOFTW, V23, P296, DOI 10.1016/j.envsoft.2007.04.007; Downs SH, 2007, NEW ENGL J MED, V357, P2338, DOI 10.1056/NEJMoa073625; Eriksen Nanna, 2003, Ugeskr Laeger, V165, P3499; Gotschi T, 2008, INT J EPIDEMIOL, V37, P1349, DOI 10.1093/ije/dyn136; Hart JE, 2010, AM J RESP CRIT CARE, V183, P73; Hesterberg TW, 2009, CRIT REV TOXICOL, V39, P195, DOI 10.1080/10408440802220603; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hogg JC, 2009, RESPIROLOGY, V14, P336, DOI 10.1111/j.1440-1843.2009.01497.x; Ingebrigtsen T, 2010, RESP MED, V104, P1890, DOI 10.1016/j.rmed.2010.05.004; Jensen SS, 2001, TRANSPORT RES D-TR E, V6, P229, DOI 10.1016/S1361-9209(00)00026-2; Jensen SS, 2009, ATMOS ENVIRON, V43, P4544, DOI 10.1016/j.atmosenv.2009.06.042; Kan HD, 2007, THORAX, V62, P873, DOI 10.1136/thx.2006.073015; Karakatsani A, 2003, EUR J EPIDEMIOL, V18, P45; Kunzli N, 2009, THORAX, V64, P664, DOI 10.1136/thx.2008.110031; Kurmi OP, 2010, THORAX, V65, P221, DOI 10.1136/thx.2009.124644; Lindgren A, 2009, INT J HEALTH GEOGR, V8, DOI 10.1186/1476-072X-8-2; Ling Sean H, 2009, Int J Chron Obstruct Pulmon Dis, V4, P233; Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802; Naess O, 2007, AM J EPIDEMIOL, V165, P435, DOI 10.1093/aje/kwk016; Probst-Hensch NM, 2010, THORAX, V65, P150, DOI 10.1136/thx.2009.115063; Pujades-Rodriguez Mar, 2009, BMC Pulm Med, V9, P42, DOI 10.1186/1471-2466-9-42; Raaschou-Nielsen O, 2001, AM J EPIDEMIOL, V153, P433, DOI 10.1093/aje/153.5.433; Raaschou-Nielsen O, 2000, J EXPO ANAL ENV EPID, V10, P4, DOI 10.1038/sj.jea.7500070; Raaschou-Nielsen O, 2010, CANCER EPIDEM BIOMAR, V19, P1284, DOI 10.1158/1055-9965.EPI-10-0036; Salvi SS, 2009, LANCET, V374, P733, DOI 10.1016/S0140-6736(09)61303-9; Schikowski T, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-152; Schindler C, 2009, AM J RESP CRIT CARE, V179, P579, DOI 10.1164/rccm.200803-388OC; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Sint T, 2008, INHAL TOXICOL, V20, P25, DOI 10.1080/08958370701758759 ; Sun QH, 2009, CIRCULATION, V119, P538, DOI 10.1161/CIRCULATIONAHA.108.799015; Sunyer J, 2009, THORAX, V64, P645, DOI 10.1136/thx.2009.115071; Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986; VESTBO J, 1989, EUR RESPIR J, V2, P710; Viegi G, 2006, RESPIROLOGY, V11, P523, DOI 10.1111/j.1400-1843.2006.00886.x; Wegmann M, 2005, EXP TOXICOL PATHOL, V56, P341, DOI 10.1016/j.etp.2004.12.004	35	88	91	2	29	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	FEB 15	2011	183	4					455	461		10.1164/rccm.201006-0937OC		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	724IE	WOS:000287568500009	20870755	
J	Norval, M; Lucas, RM; Cullen, AP; de Gruijl, FR; Longstreth, J; Takizawa, Y; van der Leun, JC				Norval, M.; Lucas, R. M.; Cullen, A. P.; de Gruijl, F. R.; Longstreth, J.; Takizawa, Y.; van der Leun, J. C.			The human health effects of ozone depletion and interactions with climate change	PHOTOCHEMICAL & PHOTOBIOLOGICAL SCIENCES			English	Review							NONMELANOMA SKIN-CANCER; BASAL-CELL CARCINOMA; VITAMIN-D STATUS; TYPE-1 DIABETES-MELLITUS; CUTANEOUS MALIGNANT-MELANOMA; POLYMORPHIC LIGHT ERUPTION; HEPATITIS-B VACCINATION; REGULATORY-T-CELLS; CIRCULATING 25-HYDROXYVITAMIN-D LEVELS; RADIATION-INDUCED IMMUNOSUPPRESSION	Depletion of the stratospheric ozone layer has led to increased solar UV-B radiation (280-315 nm) at the surface of the Earth. This change is likely to have had an impact on human exposure to UV-B radiation with consequential detrimental and beneficial effects on health, although behavioural changes in society over the past 60 years or so with regard to sun exposure are of considerable importance. The present report concentrates on information published since our previous report in 2007. The adverse effects of UV radiation are primarily on the eye and the skin. While solar UV radiation is a recognised risk factor for some types of cataract and for pterygium, the evidence is less strong, although increasing, for ocular melanoma, and is equivocal at present for age-related macular degeneration. For the skin, the most common harmful outcome is skin cancer, including melanoma and the non-melanoma skin cancers, basal cell carcinoma and squamous cell carcinoma. The incidence of all three of these tumours has risen significantly over the past five decades, particularly in people with fair skin, and is projected to continue to increase, thus posing a significant world-wide health burden. Overexposure to the sun is the major identified environmental risk factor in skin cancer, in association with various genetic risk factors and immune effects. Suppression of some aspects of immunity follows exposure to UV radiation and the consequences of this modulation for the immune control of infectious diseases, for vaccination and for tumours, are additional concerns. In a common sun allergy (polymorphic light eruption), there is an imbalance in the immune response to UV radiation, resulting in a sun-evoked rash. The major health benefit of exposure to solar UV-B radiation is the production of vitamin D. Vitamin D plays a crucial role in bone metabolism and is also implicated in protection against a wide range of diseases. Although there is some evidence supporting protective effects for a range of internal cancers, this is not yet conclusive, but strongest for colorectal cancer, at present. A role for vitamin D in protection against several autoimmune diseases has been studied, with the most convincing results to date for multiple sclerosis. Vitamin D is starting to be assessed for its protective properties against several infectious and coronary diseases. Current methods for protecting the eye and the skin from the adverse effects of solar UV radiation are evaluated, including seeking shade, wearing protective clothing and sunglasses, and using sunscreens. Newer possibilities are considered such as creams that repair UV-induced DNA damage, and substances applied topically to the skin or eaten in the diet that protect against some of the detrimental effects of sun exposure. It is difficult to provide easily understandable public health messages regarding "safe" sun exposure, so that the positive effects of vitamin D production are balanced against the negative effects of excessive exposure. The international response to ozone depletion has included the development and deployment of replacement technologies and chemicals. To date, limited evidence suggests that substitutes for the ozone-depleting substances do not have significant effects on human health. In addition to stratospheric ozone depletion, climate change is predicted to affect human health, and potential interactions between these two parameters are considered. These include altering the risk of developing skin tumours, infectious diseases and various skin diseases, in addition to altering th efficiency by which pathogenic microorganisms are inactivated in the environment.	[Norval, M.] Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland; [Lucas, R. M.] Australian Natl Univ, Natl Ctr Epidemiol & Populat Hlth, Canberra, ACT 0200, Australia; [Cullen, A. P.] Univ Waterloo, Sch Optometry, Waterloo, ON N2L 5T6, Canada; [de Gruijl, F. R.] Leiden Univ, Med Ctr, Dept Dermatol, NL-2300 RC Leiden, Netherlands; [Longstreth, J.] Inst Global Risk Res, Bethesda, MD 20817 USA; [Takizawa, Y.] Natl Inst Minamata Dis, Minamata, Kumamoto 8670008, Japan; [van der Leun, J. C.] Ecofys, NL-3526 KL Utrecht, Netherlands	Norval, M (reprint author), Univ Edinburgh, Sch Med, Edinburgh EH8 9AG, Midlothian, Scotland.	Mary.Norval@ed.ac.uk					ACHESON ED, 1960, AM J HYG, V72, P88; Ahn J, 2008, J NATL CANCER I, V100, P796, DOI 10.1093/jnci/djn152; AIHW (Australian Institute of Health and Welfare), 2008, CANC SER, V46; Alamartine E, 2003, J INVEST DERMATOL, V120, P99, DOI 10.1046/j.1523-1747.2003.12016.x; Almquist M, 2010, INT J CANCER, V127, P2159, DOI 10.1002/ijc.25215; Aloia JF, 2007, EPIDEMIOL INFECT, V135, P1095; Applebaum KM, 2007, ENVIRON HEALTH PERSP, V115, P1231, DOI 10.1289/ehp.10096; Armstrong B K, 1997, Australas J Dermatol, V38 Suppl 1, pS1; Ascherio A, 2007, ANN NEUROL, V61, P504, DOI 10.1002/ana.21141; Asgari M, 2010, J INVEST DERMATOL, V130, pS58; Asgari MM, 2008, J INVEST DERMATOL, V128, P1409, DOI 10.1038/sj.jid.5701227; Ateenyi-Agaba C, 2004, BRIT J CANCER, V90, P1777, DOI 10.1038/sj.bjc.6601743; Atkinson MA, 2001, LANCET, V358, P221, DOI 10.1016/S0140-6736(01)05415-0; Australasian Paediatric Endocrine Group, CLIN PRACT GUID TYP; Autier P, 2009, BRIT J DERMATOL, V161, P40, DOI 10.1111/j.1365-2133.2009.09448.x; Autier P, 2007, ARCH INTERN MED, V167, P1730, DOI 10.1001/archinte.167.16.1730; Autier P, 2007, INT J CANCER, V121, P1, DOI 10.1002/ijc.22745; Ayala M, 2007, INVEST OPHTH VIS SCI, V48, P4187, DOI 10.1167/iovs.06-0660; Bahlo M, 2009, NAT GENET, V41, P824, DOI 10.1038/ng.396; Barnetson RS, 2006, J INVEST DERMATOL, V126, P1869, DOI 10.1038/sj.jid.5700317; Bath-Hextall F, 2007, INT J CANCER, V121, P2105, DOI 10.1002/ijc.22952; Becklund BR, 2010, P NATL ACAD SCI USA, V107, P6418, DOI 10.1073/pnas.1001119107; Beissert S, 2008, PHOTOCHEM PHOTOBIOL, V84, P29, DOI 10.1111/j.1751-1097.2007.00231.x; Benitez-Aguirre PZ, 2009, MED J AUSTRALIA, V190, P426; Bennett MF, 2008, J INVEST DERM SYMP P, V13, P15, DOI 10.1038/jidsymp.2008.3; Berkhout RJM, 2000, J CLIN MICROBIOL, V38, P2087; Bialek-Szymanska Anna, 2007, Klin Oczna, V109, P127; Bikle DD, 2004, J NUTR, V134, p3472S; Bimczok R, 2007, SKIN PHARMACOL PHYS, V20, P57, DOI 10.1159/000096173; Birt B, 2007, J PHOTOCH PHOTOBIO B, V87, P27, DOI 10.1016/j.jphotobiol.2006.12.008; Bischoff-Ferrari HA, 2006, AM J CLIN NUTR, V84, P18; Blum M, 2008, ENDOCRINE, V33, P90, DOI 10.1007/s12020-008-9051-4; Bodiwala D, 2003, CANCER LETT, V200, P141, DOI 10.1016/S0304-3835(03)00416-6; Boehm AB, 2009, ENVIRON SCI TECHNOL, V43, P8046, DOI 10.1021/es9015124; Bogh MKB, 2010, J INVEST DERMATOL, V130, P546, DOI 10.1038/jid.2009.323; Bono A, 2008, TUMORI, V94, P11; Box NF, 2001, J INVEST DERMATOL, V116, P224, DOI 10.1046/j.1523-1747.2001.01224.x; Braff MH, 2006, CURR TOP MICROBIOL, V306, P91; Brekke HK, 2007, PEDIATR DIABETES, V8, P11, DOI 10.1111/j.1399-5448.2006.00223.x; Brewster DH, 2007, BRIT J DERMATOL, V156, P1295, DOI 10.1111/j.1365-2133.2007.07892.x; Brudnik U, 2009, EXP DERMATOL, V18, P167, DOI 10.1111/j.1600-0625.2008.00760.x; BRULS WAG, 1984, PHOTOCHEM PHOTOBIOL, V40, P485, DOI 10.1111/j.1751-1097.1984.tb04622.x; Byers T, 2010, AM J EPIDEMIOL, V172, P1, DOI 10.1093/aje/kwq112; Camouse MM, 2009, EXP DERMATOL, V18, P522, DOI 10.1111/j.1600-0625.2008.00818.x; Campbell-Stokes PL, 2005, DIABETOLOGIA, V48, P643, DOI 10.1007/s00125-005-1697-3; Cancer Council Australia, RISKS BEN SUN EXP PO; Cannell JJ, 2006, EPIDEMIOL INFECT, V134, P1129, DOI 10.1017/S0950268806007175; Cannell JJ, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-29; Cannell JJ, 2008, ALTERN MED REV, V13, P6; Cantorna MT, 2008, MOL ASPECTS MED, V29, P369, DOI 10.1016/j.mam.2008.04.004; Carless MA, 2008, BRIT J DERMATOL, V159, P804, DOI 10.1111/j.1365-2133.2008.08745.x; Carter OBJ, 2007, J HEALTH COMMUN, V12, P41, DOI 10.1080/10810730601093371; Casimiro E, 2006, ENVIRON HEALTH PERSP, V114, P1950, DOI 10.1289/ehp.8431; Chandler HL, 2010, INVEST OPHTH VIS SCI, V51, P172, DOI 10.1167/iovs.09-3996; Chang YM, 2009, INT J EPIDEMIOL, V38, P814, DOI 10.1093/ije/dyp166; Charkaluk ML, 2002, PEDIATR RES, V52, P859, DOI 10.1203/01.PDR.0000034261.44203.26; Chen ACH, 2008, J GEN VIROL, V89, P2891, DOI 10.1099/vir.0.2008/003665-0; Chlebowski RT, 2008, J NATL CANCER I, V100, P1581, DOI 10.1093/jnci/djn360; CHOU BR, 1986, CAN J OPTOM, V48, P17; Christian JB, 2008, J NATL CANCER I, V100, P1223, DOI 10.1093/jnci/djn262; CIE, 2006, 1742006 CIE; Cinek O, 2003, EUR J PEDIATR, V162, P428, DOI 10.1007/s00431-003-1211-1; Clark RA, 2008, J EXP MED, V205, P2221, DOI 10.1084/jem.20071190; CLEMENS TL, 1982, LANCET, V1, P74; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Connelly SJ, 2007, ENVIRON SCI TECHNOL, V41, P7101, DOI 10.1021/es071324r; Coohill TP, 2009, PHOTOCHEM PHOTOBIOL, V85, P1043, DOI 10.1111/j.1751-1097.2009.00586.x; Coory M, 2006, CANCER CAUSE CONTROL, V17, P21, DOI 10.1007/s10552-005-3637-4; Dahlquist G, 1999, DIABETOLOGIA, V42, P51; Dal H, 2008, J DERMATOL, V35, P55, DOI 10.1111/j.1346-8138.2008.00416.x; Dal H, 2007, EUR J DERMATOL, V17, P428, DOI 10.1684/ejd.2007.0242; Dalmas M, 2007, EUR J CANCER, V43, P1604, DOI 10.1016/j.ejca.2007.04.013; Damian DL, 2008, J INVEST DERMATOL, V128, P447, DOI 10.1038/sj.jid.5701058; Damian DL, 1998, J INVEST DERMATOL, V110, P824, DOI 10.1046/j.1523-1747.1998.00176.x; Davies CM, 2009, WATER RES, V43, P643, DOI 10.1016/j.watres.2008.11.016; DAVIES PDO, 1985, TUBERCLE, V66, P301, DOI 10.1016/0041-3879(85)90068-6; Dawson-Hughes B, 2005, OSTEOPOROSIS INT, V16, P713, DOI 10.1007/s00198-005-1867-7; De Fabo EC, 2004, CANCER RES, V64, P6372, DOI 10.1158/0008-5472.CAN-04-1454; de Feraudy S, 2010, AM J PATHOL, V177, P555, DOI 10.2353/ajpath.2010.090925; de Gruijl FR, 2010, INT J CANCER, V127, P796, DOI 10.1002/ijc.25097; de Gruijl FR, 2003, PHOTOCH PHOTOBIO SCI, V2, P16, DOI 10.1039/b211156j; de Gruijl FR, 2008, PHOTOCHEM PHOTOBIOL, V84, P2, DOI 10.1111/j.1751-1097.2007.00211.x; de Koning Maurits Nc, 2008, Infect Agent Cancer, V3, P12, DOI 10.1186/1750-9378-3-12; Dennis LK, 2008, ANN EPIDEMIOL, V18, P614, DOI 10.1016/j.annepidem.2008.04.006; Dennis LK, 2003, ANN INTERN MED, V139, P966; Detorakis ET, 2009, INT J MOL MED, V23, P439, DOI 10.3892/ijmm_00000149; Diffey B, 2000, BRIT MED J, V320, P176, DOI 10.1136/bmj.320.7228.176; Diffey BL, 2010, BRIT J DERMATOL, V162, P1342, DOI 10.1111/j.1365-2133.2010.09697.x; Diffey BL, 2009, BRIT J DERMATOL, V161, P25, DOI 10.1111/j.1365-2133.2009.09445.x; Diffey BL, 2002, METHODS, V28, P4, DOI 10.1016/S1046-2023(02)00204-9; Diffey B, 2008, PHOTOCHEM PHOTOBIOL, V84, P371, DOI 10.1111/j.1751-1097.2007.00271.x; Diffey BL, 2010, PHOTODERMATOL PHOTO, V26, P172, DOI 10.1111/j.1600-0781.2010.00518.x; Dobbinson S, 2008, J AM ACAD DERMATOL, V59, P602, DOI 10.1016/j.jaad.2008.06.011; Dobbinson SJ, 2008, AM J PREV MED, V34, P94, DOI 10.1016/j.amepre.2007.09.024; Dobbinson SJ, 2009, BRIT MED J, V338, DOI 10.1136/bmj.b95; Dobnig H, 2008, ARCH INTERN MED, V168, P1340, DOI 10.1001/archinte.168.12.1340; Dong XQ, 2007, EXP EYE RES, V84, P200, DOI 10.1016/j.exer.2006.09.017; Dongre AM, 2007, INDIAN J DERMATOL VE, V73, P26; DURRUTY P, 1979, DIABETOLOGIA, V17, P357, DOI 10.1007/BF01236269; Elliott JC, 2010, PEDIATR DIABETES, V11, P394, DOI 10.1111/j.1399-5448.2009.00620.x; Ellison TI, 2008, J INVEST DERMATOL, V128, P2508, DOI 10.1038/jid.2008.131; Ema M, 2010, REPROD TOXICOL, V29, P125, DOI 10.1016/j.reprotox.2009.11.005; Ema M, 2010, REPROD TOXICOL, V29, P1, DOI 10.1016/j.reprotox.2009.09.005; Faurschou A, 2007, BRIT J DERMATOL, V156, P716, DOI 10.1111/j.1365-2133.2006.07684.x; FELDMAN D, 1995, ADV EXP MED BIOL, V375, P53; Fernandez Anthony, 2008, J Invest Dermatol, V128, P2352, DOI 10.1038/jid.2008.260; Fioletov VE, 2010, J PHOTOCH PHOTOBIO B, V100, P57, DOI 10.1016/j.jphotobiol.2010.05.002; Fisman DN, 2007, ANNU REV PUBL HEALTH, V28, P127, DOI 10.1146/annurev.publhealth.28.021406.144128; Fletcher AE, 2008, ARCH OPHTHALMOL-CHIC, V126, P1396, DOI 10.1001/archopht.126.10.1396; Forslund O, 2007, J INFECT DIS, V196, P876, DOI 10.1086/521031; Freedman DM, 2007, J NATL CANCER I, V99, P1594, DOI 10.1093/jnci/djm204; Freedman DM, 2002, OCCUP ENVIRON MED, V59, P257, DOI 10.1136/oem.59.4.257; Fris M, 2008, GRAEF ARCH CLIN EXP, V246, P551, DOI 10.1007/s00417-007-0747-6; Fris M, 2007, GRAEF ARCH CLIN EXP, V245, P1705, DOI 10.1007/s00417-007-0620-7; Fronczak CM, 2003, DIABETES CARE, V26, P3237, DOI 10.2337/diacare.26.12.3237; Fukazawa T, 1999, J NEUROL SCI, V166, P47, DOI 10.1016/S0022-510X(99)00112-4; Gallagher RDP, 2000, JAMA-J AM MED ASSOC, V283, P2955, DOI 10.1001/jama.283.22.2955; Gambichler T, 2006, ARCH DERMATOL RES, V298, P139, DOI 10.1007/s00403-006-0673-1; Gandini S, 2009, EUR J CANCER, V45, P634, DOI 10.1016/j.ejca.2008.10.003; Garland CF, 2007, J STEROID BIOCHEM, V103, P708, DOI 10.1016/j.jsbmb.2006.12.007; Garland CF, 2009, ANN EPIDEMIOL, V19, P468, DOI 10.1016/j.annepidem.2009.03.021; Geller AC, 1997, J AM ACAD DERMATOL, V37, P935, DOI 10.1016/S0190-9622(97)70068-9; Gies P, 2007, PHOTODERMATOL PHOTO, V23, P264, DOI 10.1111/j.1600-0781.2007.00309.x; Gies P, 2007, PHOTOCHEM PHOTOBIOL, V83, P1465, DOI 10.1111/j.1751-1097.2007.00188.x; Ginde AA, 2009, J AM GERIATR SOC, V57, P1595, DOI 10.1111/j.1532-5415.2009.02359.x; Ginde AA, 2009, CURR ALLERGY ASTHM R, V9, P81, DOI 10.1007/s11882-009-0012-7; Ginde AA, 2009, ARCH INTERN MED, V169, P626, DOI 10.1001/archinternmed.2008.604; Ginde AA, 2009, ARCH INTERN MED, V169, P384, DOI 10.1001/archinternmed.2008.560; Giovannucci E, 1998, CANCER CAUSE CONTROL, V9, P567, DOI 10.1023/A:1008835903714; Giovannucci E, 2008, ARCH INTERN MED, V168, P1174, DOI 10.1001/archinte.168.11.1174; Glasser R, 2009, J ALLERGY CLIN IMMUN, V123, P1117, DOI 10.1016/j.jaci.2009.01.043; Gordon LG, 2009, J INVEST DERMATOL, V129, P2766, DOI 10.1038/jid.2009.141; Gorham ED, 2009, DIABETOLOGIA, V52, P2087, DOI 10.1007/s00125-009-1449-x; Gorham ED, 2007, AM J PREV MED, V32, P210, DOI 10.1016/j.amepre.2006.11.004; Grant WB, 2002, CANCER, V94, P1867, DOI 10.1002/cncr.10427; Grant WB, 2006, ANTICANCER RES, V26, P2687; Grant WB, 2010, J STEROID BIOCHEM, V121, P456, DOI 10.1016/j.jsbmb.2010.03.089; Grant William B, 2009, Dermatoendocrinol, V1, P25; Grant WB, 2009, ANN EPIDEMIOL, V19, P446, DOI 10.1016/j.annepidem.2008.12.014; Green A, 1999, LANCET, V354, P723, DOI 10.1016/S0140-6736(98)12168-2; Green AC, 2007, CANCER EPIDEM BIOMAR, V16, P1921, DOI 10.1158/1055-9965.EPI-07-0477; Gudbjartsson DF, 2008, NAT GENET, V40, P886, DOI 10.1038/ng.161; Hagenau T, 2009, OSTEOPOROSIS INT, V20, P133, DOI 10.1007/s00198-008-0626-y; Haines A, 2000, CAN MED ASSOC J, V163, P729; Hanwell HEC, 2010, J STEROID BIOCHEM, V121, P334, DOI 10.1016/j.jsbmb.2010.03.023; Harrison SL, 2008, CANCER EPIDEM BIOMAR, V17, P2318, DOI 10.1158/1055-9965.EPI-07-2801; Harrison SL, 2005, AM J EPIDEMIOL, V161, P536, DOI 10.1093/aje/kwi081; Harwood CA, 2000, J MED VIROL, V61, P289, DOI 10.1002/1096-9071(200007)61:3<289::AID-JMV2>3.0.CO;2-Z; Hawk JLM, 2004, PHOTODERMATOL PHOTO, V20, P312, DOI 10.1111/j.1600-0781.2004.00129.x; Heitzer E, 2007, J INVEST DERMATOL, V127, P2872, DOI 10.1038/sj.jid.5700923; Hirakawa M, 2008, BRIT J OPHTHALMOL, V92, P630, DOI 10.1136/bjo.2007.130575; Hirani V, 2010, AGE AGEING, V39, P62, DOI 10.1093/ageing/afp195; Holick MF, 2003, J CELL BIOCHEM, V88, P296, DOI 10.1002/jcb.10338; Holick MF, 2008, MOL ASPECTS MED, V29, P361, DOI 10.1016/j.mam.2008.08.008; Hollis BW, 2005, J NUTR, V135, P317; HOLLY EA, 1990, CANCER RES, V50, P5773; Hu DN, 2008, PHOTOCHEM PHOTOBIOL, V84, P639, DOI 10.1111/j.1751-1097.2008.00316.x; Hu DN, 2005, AM J OPHTHALMOL, V140, P612, DOI 10.1016/j.ajo.2005.05.034; Hughes DA, 2009, CLIN EXP IMMUNOL, V158, P20, DOI 10.1111/j.1365-2249.2009.04001.x; Huncharek M, 2002, AM J PUBLIC HEALTH, V92, P1173, DOI 10.2105/AJPH.92.7.1173; Hypponen E, 2001, LANCET, V358, P1500, DOI 10.1016/S0140-6736(01)06580-1; IARC, 2008, IARC WORK GROUP REP, V5; *IARC, 2001, 9283230051 WHO IARC; Iftner T, 2002, EMBO J, V21, P4741, DOI 10.1093/emboj/cdf443; Ilyas M, 2007, CURR SCI INDIA, V93, P1604; Jeevan A, 2009, TUBERCULOSIS, V89, P431, DOI 10.1016/j.tube.2009.09.004; Jeffery LE, 2009, J IMMUNOL, V183, P5458, DOI 10.4049/jimmunol.0803217; JENAB M, 2010, BRIT MED J, V340, pNIL10; John EM, 2004, J STEROID BIOCHEM, V89-90, P549, DOI 10.1016/j.jsbmb.2004.03.067; Kannengiesser C, 2008, MOL ONCOL, V1, P425, DOI 10.1016/j.molonc.2008.01.002; Kaporis HG, 2007, J INVEST DERMATOL, V127, P2391, DOI 10.1038/sj.jid.5700884; Karatekin G, 2009, EUR J CLIN NUTR, V63, P473, DOI 10.1038/sj.ejcn.1602960; Karlsson PM, 2007, INT J CANCER, V121, P323, DOI 10.1002/ijc.22692; Kazantzidis A, 2009, PHOTOCH PHOTOBIO SCI, V8, P45, DOI 10.1039/b811216a; Ke MS, 2008, PHOTOCHEM PHOTOBIOL, V84, P180, DOI 10.1111/j.1751-1097.2007.00217.x; Kimlin MG, 2004, PHOTOCH PHOTOBIO SCI, V3, P1067, DOI 10.1039/b404957h; King BJ, 2008, J APPL MICROBIOL, V104, P1311, DOI 10.1111/j.1365-2672.2007.03658.x; Kinlin LM, 2009, AM J EPIDEMIOL, V169, P588, DOI 10.1093/aje/kwn383; Konety B R, 1999, Semin Urol Oncol, V17, P77; Krause R, 1998, LANCET, V352, P709, DOI 10.1016/S0140-6736(05)60827-6; KRIPKE ML, 1974, J NATL CANCER I, V53, P1333; Kristal AR, 2002, CANCER EPIDEM BIOMAR, V11, P719; Kuchuk NO, 2009, J BONE MINER RES, V24, P693, DOI [10.1359/jbmr.081209, 10.1359/JBMR.081209]; Kyle JW, 2008, PEDIATRICS, V121, pE1074, DOI 10.1542/peds.2007-1400; Kyu-Won C, 2009, PHOTODERMATOL PHOTO, V25, P286, DOI 10.1111/j.1600-0781.2009.00464.x; Laaksi I, 2007, AM J CLIN NUTR, V86, P714; Lam LT, 2007, INT J ENVIRON HEAL R, V17, P1, DOI 10.1080/09603120601124264; Lange JR, 2007, J CLIN ONCOL, V25, P1363, DOI 10.1200/JCO.2006.08.8310; Lautenschlager S, 2007, LANCET, V370, P528, DOI 10.1016/S0140-6736(07)60638-2; Lea CS, 2007, ANN EPIDEMIOL, V17, P447, DOI 10.1016/j.annepidem.2007.01.030; Leiter U, 2008, ADV EXP MED BIOL, V624, P89, DOI 10.1007/978-0-387-77574-6_8; Lembo S, 2008, BRIT J DERMATOL, V159, P1342, DOI 10.1111/j.1365-2133.2008.08734.x; Levell NJ, 2009, BRIT J DERMATOL, V161, P630, DOI 10.1111/j.1365-2133.2009.09299.x; Li XH, 2000, BIOMED ENVIRON SCI, V13, P263; Linder N, 2011, J TROP PEDIATRICS, V57, P299, DOI 10.1093/tropej/fmp104; Linos E, 2009, J INVEST DERMATOL, V129, pS59; Lipozencic J, 2008, ACTA DERMATOVENER CR, V16, P193; Lips P, 2001, J CLIN ENDOCR METAB, V86, P1212, DOI 10.1210/jc.86.3.1212; Longstreth J, 1998, J PHOTOCH PHOTOBIO B, V46, P20, DOI 10.1016/S1011-1344(98)00183-3; Lucas Chere R, 2008, J Cosmet Dermatol, V7, P132, DOI 10.1111/j.1473-2165.2008.00376.x; Mabruk MJEMF, 2009, J CUTAN PATHOL, V36, P760, DOI 10.1111/j.1600-0560.2008.01164.x; Macdonald HM, 2008, BONE, V42, P996, DOI 10.1016/j.bone.2008.01.011; MACLAUGHLIN J, 1985, J CLIN INVEST, V76, P1536, DOI 10.1172/JCI112134; MACLAUGHLIN JA, 1982, SCIENCE, V216, P1001, DOI 10.1126/science.6281884; Mainster MA, 2009, AM J OPHTHALMOL, V147, P8, DOI 10.1016/j.ajo.2008.08.020; Martineau AR, 2007, J STEROID BIOCHEM, V103, P793, DOI 10.1016/j.jsbmb.2006.12.052; Matsui MS, 2009, J INVEST DERM SYMP P, V14, P56, DOI 10.1038/jidsymp.2009.14; McKenzie RL, 2011, PHOTOCH PHOTOBIO SCI, V10, P182, DOI 10.1039/c0pp90034f; McKenzie RL, 2009, PHOTOCHEM PHOTOBIOL, V85, P88, DOI 10.1111/j.1751-1097.2008.00400.x; MCLEOD JG, 1994, MED J AUSTRALIA, V160, P117; McMichael AJ, 1997, EPIDEMIOLOGY, V8, P642, DOI 10.1097/00001648-199710000-00005; MCMICHAEL AJ, 2010, LANCET, V374, P2123; Meyer LM, 2008, EXP EYE RES, V86, P282, DOI 10.1016/j.exer.2007.10.019; Mitchell DL, 2010, P NATL ACAD SCI USA, V107, P9329, DOI 10.1073/pnas.1000324107; Mnich CD, 2009, EXP DERMATOL, V18, P69, DOI 10.1111/j.1600-0625.2008.00765.x; Mody VC, 2008, ACTA OPHTHALMOL, V86, P188, DOI 10.1111/j.1600-0420.2007.01022.x; Moehrie M, 2008, CLIN DERMATOL, V26, P12, DOI 10.1016/j.clindermatol.2007.10.001; Mohr SB, 2008, DIABETOLOGIA, V51, P1391, DOI 10.1007/s00125-008-1061-5; Mohr SB, 2008, BREAST J, V14, P255, DOI 10.1111/j.1524-4741.2008.00571.x; Moise AF, 1999, INT J BIOMETEOROL, V43, P128, DOI 10.1007/s004840050128; Mokady E, 2000, NUTR CANCER, V38, P65, DOI 10.1207/S15327914NC381_10; Montella A, 2009, EUR J CANCER, V45, P2360, DOI 10.1016/j.ejca.2009.03.004; MULLER HK, 2007, PHOTOCHEM PHOTOBIOL, V84, P47; Munger KL, 2006, JAMA-J AM MED ASSOC, V296, P2832, DOI 10.1001/jama.296.23.2832; Munger KL, 2004, NEUROLOGY, V62, P60; Murray JC, 2008, J AM ACAD DERMATOL, V59, P418, DOI 10.1016/j.jaad.2008.05.004; NAGANO T, 2007, PHOTOCHEM PHOTOBIOL, V84, P63; Narbutt J, 2005, PHOTOCH PHOTOBIO SCI, V4, P517, DOI 10.1039/b503166d; Neale RE, 2007, J AM ACAD DERMATOL, V56, P380, DOI 10.1016/j.jaad.2006.08.039; Ng K, 2008, J CLIN ONCOL, V26, P2984, DOI 10.1200/JCO.2007.15.1027; Nicol I, 2007, J INVEST DERMATOL, V127, P41, DOI 10.1038/sj.jid.5700509; Nikolaou VA, 2008, CANCER CAUSE CONTROL, V19, P671, DOI 10.1007/s10552-008-9130-0; Nikolova PN, 2007, CANCER IMMUNOL IMMUN, V56, P371, DOI 10.1007/s00262-006-0193-z; Nnoaham KE, 2008, INT J EPIDEMIOL, V37, P113, DOI 10.1093/ije/dym247; Nohynek GJ, 2010, TOXICOL APPL PHARM, V243, P239, DOI 10.1016/j.taap.2009.12.001; Norval M, 2007, PHOTOCH PHOTOBIO SCI, V6, P232, DOI 10.1039/b700018a; Norval M, 2009, BRIT J DERMATOL, V161, P732, DOI 10.1111/j.1365-2133.2009.09332.x; Norval M, 2008, PHOTOCHEM PHOTOBIOL, V84, P19, DOI 10.1111/j.1751-1097.2007.00239.x; Norval M, 2010, PHOTOCH PHOTOBIO SCI, V9, P11, DOI 10.1039/b9pp00012g; Oberyszyn TM, 2008, CANCER LETT, V261, P127, DOI 10.1016/j.canlet.2008.01.009; Olsen CM, 2009, INT J CANCER, V124, P937, DOI 10.1002/ijc.24011; Onkamo P, 1999, DIABETOLOGIA, V42, P1395, DOI 10.1007/s001250051309; Oriowo OM, 2001, INVEST OPHTH VIS SCI, V42, pS282; Orton SM, 2008, AM J CLIN NUTR, V88, P441; Ostman J, 2008, J INTERN MED, V263, P386, DOI 10.1111/j.1365-2796.2007.01896.x; Pakker H, 2000, J PHYCOL, V36, P334, DOI 10.1046/j.1529-8817.2000.99087.x; Patz JA, 2008, MED CLIN N AM, V92, P1473, DOI 10.1016/j.mcna.2008.07.007; Peehl DM, 1999, EUR UROL, V35, P392, DOI 10.1159/000019914; Peguet-Navarro J, 2008, EUR J DERMATOL, V18, P504, DOI 10.1684/ejd.2008.0496; Pellacani G, 2008, J EUR ACAD DERMATOL, V22, P213, DOI 10.1111/j.1468-3083.2007.02388.x; Pettijohn KJ, 2009, CANCER EPIDEM BIOMAR, V18, P454, DOI 10.1158/1055-9965.EPI-08-0634; Pham TQ, 2009, OPHTHAL EPIDEMIOL, V16, P136, DOI 10.1080/09286580701299395; Pinto AV, 2010, MUTAT RES-FUND MOL M, V688, P3, DOI 10.1016/j.mrfmmm.2010.02.003; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Ponsonby AL, 2008, AM J EPIDEMIOL, V168, P358, DOI 10.1093/aje/kwn142; Pope SJ, 2008, PHOTOCHEM PHOTOBIOL, V84, P1277, DOI 10.1111/j.1751-1097.2008.00373.x; Pruthi DK, 2009, J AM ACAD DERMATOL, V61, P44, DOI 10.1016/j.jaad.2009.01.020; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; Qureshi AA, 2008, ARCH INTERN MED, V168, P501, DOI 10.1001/archinte.168.5.501; Ramagopalan SV, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000369; Reddy KK, 2010, J INVEST DERMATOL, V130, P321, DOI 10.1038/jid.2009.353; Reich A, 2009, PHOTODERMATOL PHOTO, V25, P242, DOI 10.1111/j.1600-0781.2009.00450.x; RHODES LE, 2010, J INVEST DERMATOL, V25, P1411; Rhodes LE, 2010, J INVEST DERMATOL, V130, P626, DOI 10.1038/jid.2009.250; Richardson Ann, 2008, N Z Med J, V121, P18; Richmond-Sinclair NM, 2009, J INVEST DERMATOL, V129, P323, DOI 10.1038/jid.2008.234; Richtig E, 2007, DERMATOLOGY, V214, P246, DOI 10.1159/000099590; Robinson ES, 2000, PHOTOCHEM PHOTOBIOL, V71, P743, DOI 10.1562/0031-8655(2000)071<0743:TMMMIR>2.0.CO;2; Roche EF, 2003, J PEDIATR ENDOCR MET, V16, P779; Rostand SG, 1997, HYPERTENSION, V30, P150; Rothwell PM, 1999, BRIT MED J, V319, P887; SACN (Scientific Advisory Committee on Nutrition), 2007, UPD VIT D POS STAT S; Sagripanti JL, 2009, PHOTOCHEM PHOTOBIOL, V85, P978, DOI 10.1111/j.1751-1097.2008.00518.x; Salmon PJM, 2007, AUSTRALAS J DERMATOL, V48, P208, DOI 10.1111/j.1440-0960.2007.00388.x; Samuelsson U, 2007, DIABETES RES CLIN PR, V76, P75, DOI 10.1016/j.diabres.2006.07.023; Santos JL, 2001, REV SAUDE PUBL, V35, P96, DOI 10.1590/S0034-89102001000100014; Sastre-Garau X, 2009, J PATHOL, V218, P48, DOI 10.1002/path.2532; Sathyanarayana UG, 2007, CANCER LETT, V245, P112, DOI 10.1016/j.canlet.2005.12.042; Scelo G, 2007, INT J CANCER, V120, P152, DOI 10.1002/ijc.22159; Schmidt-Pokrzywniak A, 2009, OPHTHALMOLOGY, V116, P340, DOI 10.1016/j.ophtha.2008.09.040; Schoof N, 2009, GENES IMMUN, V10, P586, DOI 10.1038/gene.2009.40; Schwarz T, 2008, PHOTOCHEM PHOTOBIOL, V84, P10, DOI 10.1111/j.1751-1097.2007.00223.x; Scully M, 2008, AUST NZ J PUBL HEAL, V32, P461, DOI 10.1111/j.1753-6405.2008.00280.x; SEDDON JM, 1990, ARCH OPHTHALMOL-CHIC, V108, P1274; Segerback D, 2008, CANCER EPIDEM BIOMAR, V17, P2388, DOI 10.1158/1055-9965.EPI-08-0248; Sekelj S, 2007, COLLEGIUM ANTROPOL, V31, P45; Semba RD, 2010, EUR J CLIN NUTR, V64, P203, DOI 10.1038/ejcn.2009.140; SETLOW RB, 1993, P NATL ACAD SCI USA, V90, P6666, DOI 10.1073/pnas.90.14.6666; Shah CP, 2005, OPHTHALMOLOGY, V112, P1599, DOI 10.1016/j.ophtha.2005.04.020; Shih STF, 2009, PREV MED, V49, P449, DOI 10.1016/j.ypmed.2009.09.008; Sinclair C, 2009, BRIT J DERMATOL, V161, P116, DOI 10.1111/j.1365-2133.2009.09459.x; Sinton LW, 2002, APPL ENVIRON MICROB, V68, P1122, DOI 10.1128/AEM.68.3.1122-1131.2002; Sivapirabu G, 2009, BRIT J DERMATOL, V161, P1357, DOI 10.1111/j.1365-2133.2009.09244.x; Sleijffers A, 2003, J IMMUNOL, V170, P3423; Sleijffers A, 2003, PHOTOCHEM PHOTOBIOL, V77, P271, DOI 10.1562/0031-8655(2003)077<0271:ECUALC>2.0.CO;2; Sleijffers A, 2001, J INVEST DERMATOL, V117, P1144, DOI 10.1046/j.0022-202x.2001.01542.x; Sliney DH, 2006, PROG BIOPHYS MOL BIO, V92, P150, DOI 10.1016/j.pbiomolbio.2006.02.007; Sloka JS, 2008, CAN J NEUROL SCI, V35, P69; Smolders J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006635; Sneyd MJ, 2009, CANCER EPIDEM BIOMAR, V18, P1706, DOI 10.1158/1055-9965.EPI-08-0682; Staples J. A., 2002, ENV HLTH PERSPECT, V111, P518, DOI 10.1289/ehp.5941; Staples J, 2010, BRIT MED J, V340, DOI 10.1136/bmj.c1640; Staples MP, 2006, MED J AUSTRALIA, V184, P6; Stene LC, 2000, DIABETOLOGIA, V43, pA94; Stolzenberg-Solomon RZ, 2010, AM J EPIDEMIOL, V172, P81, DOI 10.1093/aje/kwq120; Struijk L, 2008, J GEN VIROL, V89, P2303, DOI 10.1099/vir.0.83317-0; Suarez-Martinez Edu B, 2007, P R Health Sci J, V26, P349; Sugie N, 2002, PHOTODERMATOL PHOTO, V18, P163, DOI 10.1034/j.1600-0781.2002.00765.x; Swann MH, 2007, SEMIN ONCOL, V34, P51, DOI 10.1053/j.seminoncol.2006.10.021; Tang X, 2011, PHOTOCH PHOTOBIO SCI, V10, P280, DOI 10.1039/c0pp90039g; Taylor BV, 2010, MULT SCLER J, V16, P398, DOI 10.1177/1352458509359724; TAYLOR BV, 2010, MULT SCLER; Thieden E, 2009, PHOTOCHEM PHOTOBIOL, V85, P1480, DOI 10.1111/j.1751-1097.2009.00612.x; THOMPSON SC, 1993, NEW ENGL J MED, V329, P1147, DOI 10.1056/NEJM199310143291602; TOEWS GB, 1980, J IMMUNOL, V124, P445; Tommasi S, 1997, CANCER RES, V57, P4727; Tornesello ML, 2006, BRIT J CANCER, V94, P446, DOI 10.1038/sj.bjc.6602921; Travis RC, 2009, AM J EPIDEMIOL, V169, P1223, DOI 10.1093/aje/kwp022; Tremlett H, 2008, NEUROEPIDEMIOLOGY, V31, P271, DOI 10.1159/000166602; Triay E, 2009, BRIT J OPHTHALMOL, V93, P1524, DOI 10.1136/bjo.2009.157933; Tsai WT, 2007, J HAZARD MATER, V139, P185, DOI 10.1016/j.jhazmat.2006.10.025; Tsai WT, 2010, J ENVIRON SCI HEAL C, V28, P125, DOI 10.1080/10590501.2010.481806; Tsai WT, 2009, ENVIRON INT, V35, P418, DOI 10.1016/j.envint.2008.08.009; Tsai WT, 2005, J HAZARD MATER, V119, P69, DOI 10.1016/j.jhazmat.2004.12.018; Underbrink MP, 2008, J VIROL, V82, P10408, DOI 10.1128/JVI.00902-08; Urashima M, 2010, AM J CLIN NUTR, V91, P1255, DOI 10.3945/ajcn.2009.29094; Vaiserman AM, 2007, DIABETOLOGIA, V50, P32, DOI 10.1007/s00125-006-0456-4; Vajdic CM, 2002, INT J CANCER, V101, P175, DOI 10.1002/ijc.10646; van Doorn R, 2005, SEMIN ONCOL, V32, P479, DOI 10.1053/j.seminoncol.2005.07.001; van Hattem S, 2009, BRIT J DERMATOL, V161, P840, DOI 10.1111/j.1365-2133.2009.09222.x; VAN IA, 2003, BRIT MED J, V327, P316; VAN JC, 2006, CANCER EPIDEM BIOMAR, V15, P2546; VAN JC, 2002, PHOTOCHEM PHOTOBIOL, V1, P324; VAN JC, 2008, PHOTOCHEM PHOTOBIOL, V7, P730; van Schanke A, 2006, CANCER RES, V66, P2608, DOI 10.1158/0008-5472.CAN-05-2476; Vojnikovic B, 2007, COLLEGIUM ANTROPOL, V31, P43; Vollmer RT, 2007, AM J CLIN PATHOL, V128, P260, DOI 10.1309/7MHX96XH3DTY32TQ; Wakita D, 2009, CARCINOGENESIS, V30, P1408, DOI 10.1093/carcin/bgp144; Walsh James E, 2007, Eye Contact Lens, V33, P58, DOI 10.1097/01.icl.0000240515.57520.a6; Wang GS, 2009, LUPUS, V18, P1037, DOI 10.1177/0961203309106181; WANG L, 2007, INT IMMUNOL, V20, P57, DOI 10.1093/intimm/dxm124; Wang LE, 2007, CLIN CANCER RES, V13, P6532, DOI 10.1158/1078-0432.CCR-07-0969; Wang LN, 2010, IMMUNOBIOLOGY, V215, P124, DOI 10.1016/j.imbio.2009.01.013; Wang SQ, 2009, BRIT J DERMATOL, V161, P28, DOI 10.1111/j.1365-2133.2009.09446.x; Wang TJ, 2010, LANCET, V376, P180, DOI 10.1016/S0140-6736(10)60588-0; Waster PK, 2009, J INVEST DERMATOL, V129, P1769, DOI 10.1038/jid.2008.421; Wayse V, 2004, EUR J CLIN NUTR, V58, P563, DOI 10.1038/sj.ejcn.1601845; Wei MY, 2008, CANCER EPIDEM BIOMAR, V17, P2958, DOI 10.1158/1055-9965.EPI-08-0402; Weis E, 2006, ARCH OPHTHALMOL-CHIC, V124, P54, DOI 10.1001/archopht.124.1.54; Wejse C, 2009, AM J RESP CRIT CARE, V179, P843, DOI 10.1164/rccm.200804-567OC; Welsh MM, 2008, CARCINOGENESIS, V29, P1950, DOI 10.1093/carcin/bgn160; Welsh MM, 2009, CANCER RES, V69, P6158, DOI 10.1158/0008-5472.CAN-09-0415; White ANJ, 2009, BMC INFECT DIS, V9, DOI 10.1186/1471-2334-9-196; White JH, 2008, INFECT IMMUN, V76, P3837, DOI 10.1128/IAI.00353-08; Whiteman DC, 2008, EUR J CANCER PREV, V17, P243, DOI 10.1097/CEJ.0b013e3282b6fe3f; Whiteman DC, 2007, CANCER CAUSE CONTROL, V18, P485, DOI 10.1007/s10552-007-0123-1; Widyarini S, 2006, P NATL ACAD SCI USA, V103, P12837, DOI 10.1073/pnas.0603642103; Willer CJ, 2005, BRIT MED J, V330, P120, DOI 10.1136/bmj.38301.686030.63; Willis JA, 2002, J PEDIATR ENDOCR MET, V15, P645; Wolf P, 2009, EXP DERMATOL, V18, P350, DOI 10.1111/j.1600-0625.2009.00859.x; Woolcott CG, 2010, CANCER EPIDEM BIOMAR, V19, P130, DOI 10.1158/1055-9965.EPI-09-0475; Xiao TZ, 2009, J INVEST DERMATOL, V129, pS32; Yamshchikov AV, 2009, ENDOCR PRACT, V15, P438, DOI 10.4158/EP09101.ORR; Yang G, 2007, CANCER RES, V67, P5649, DOI 10.1158/0008-5472.CAN-06-3806; Yarak S, 2009, CLIN EXP DERMATOL, V35, P581; Yesudian PD, 2008, PHOTODERMATOL PHOTO, V24, P97, DOI 10.1111/j.1600-0781.2008.00339.x; Yetley EA, 2008, AM J CLIN NUTR, V88, p558S; Yiasemides E, 2009, CARCINOGENESIS, V30, P101, DOI 10.1093/carcin/bgn248; Yin L, 2010, EUR J CANCER, V46, P2196, DOI 10.1016/j.ejca.2010.03.037; Yin L, 2009, CANCER EPIDEMIOL, V33, P435, DOI 10.1016/j.canep.2009.10.014; Yin M, 2009, INT J CLIN EXP MED, V2, P159; Youl PH, 2009, INT J CANCER, V124, P1963, DOI 10.1002/ijc.24154; Yu GP, 2006, PHOTOCHEM PHOTOBIOL, V82, P1621, DOI 10.1562/2006-07-17-RA-970; Yusuf N, 2007, PHOTODERMATOL PHOTO, V23, P48, DOI 10.1111/j.1600-0781.2007.00262.x; Zanetti R, 2006, BRIT J CANCER, V94, P743, DOI 10.1038/sj.bjc.6602982; Zhou L, 2009, INVEST OPHTH VIS SCI, V50, P2077, DOI 10.1167/iovs.08-2604	376	88	93	6	100	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1474-905X			PHOTOCH PHOTOBIO SCI	Photochem. Photobiol. Sci.		2011	10	2					199	225		10.1039/c0pp90044c		27	Biochemistry & Molecular Biology; Biophysics; Chemistry, Physical	Biochemistry & Molecular Biology; Biophysics; Chemistry	714UV	WOS:000286835400002	21253670	
J	Penard-Morand, C; Raherison, C; Charpin, D; Kopferschmitt, C; Lavaud, F; Caillaud, D; Annesi-Maesano, I				Penard-Morand, C.; Raherison, C.; Charpin, D.; Kopferschmitt, C.; Lavaud, F.; Caillaud, D.; Annesi-Maesano, I.			Long-term exposure to close-proximity air pollution and asthma and allergies in urban children	EUROPEAN RESPIRATORY JOURNAL			English	Article						Air pollution; allergic rhinitis; allergic sensitisation; asthma; eczema; exposure assessment	RESPIRATORY HEALTH; CHILDHOOD ASTHMA; NITROGEN-DIOXIDE; DIESEL EXHAUST; PARTICLES; SCHOOLCHILDREN; SYMPTOMS; OUTDOOR; COHORT; ISAAC	The aim of this study was to evaluate the impact of urban air pollution, assessed through reliable indicators of exposure, on asthma and allergies in schoolchildren. A validated dispersion model combining data on traffic conditions, topography, meteorology and background pollution was used to relate 3-yrs averaged concentrations of major urban pollutants at the sites of schools to skin prick tests, exercise-induced asthma and reported asthma and allergies in 6,683 children (9-11 yrs) attending 108 schools randomly selected in six French communities. For the 4,907 children who had resided at their current address for the past 3 yrs, asthma (exercise induced, past year and lifetime) was significantly positively associated with benzene, SO(2), particles with a 50% cut-off aerodynamic diameter of 10 mm (PM(10)), nitrogen oxides (NO(x)) and CO. In the same children, eczema (lifetime and past year) was significantly positively associated with benzene, PM(10), NO(2), NO x and CO, lifetime allergic rhinitis with PM(10) and sensitisation to pollens with benzene and PM(10). Among the 2,213 children residing at their current address since birth, the associations persisted for lifetime asthma with benzene (adjusted OR per interquartile range (95% CI) 1.3 (1.0-1.9)) and PM10 (1.4 (1.0-2.0)), and for sensitisation to pollens with volatile organic compounds (1.3 (1.0-1.9)) and PM10 (1.2 (1.0-1.9)). Accurately modelled urban air pollution was associated with some measures of childhood asthma and allergies.	[Penard-Morand, C.; Annesi-Maesano, I.] INSERM, UMR S 707, F-75654 Paris 13, France; [Penard-Morand, C.; Annesi-Maesano, I.] Univ Paris 06, UMR S 707, F-75252 Paris 05, France; [Penard-Morand, C.] AgroParisTech, Inst Sci & Ind Vivant & Environm, ENGREF, Paris, France; [Raherison, C.] Hop Haut Leveque, Ctr Francois Magendie, Pessac, France; [Raherison, C.] Univ Bordeaux 2, Inst Publ Hlth, EA 3672, F-33076 Bordeaux, France; [Charpin, D.] Hop Nord Marseille, Serv Pneumol, Marseille, France; [Kopferschmitt, C.] Nouvel Hop Civil, Serv Pneumol, Strasbourg, France; [Lavaud, F.] CHU Reims, Hop Maison Blanche, Serv Pneumol, Reims, France; [Caillaud, D.] CHU Clermont Ferrand, Hop Gabriel Montpied, Serv Pneumol, Clermont Ferrand, France	Penard-Morand, C (reprint author), INSERM UPMC Paris 6, Med Sch St Antoine, UMR S 707, 27 Rue Chaligny, F-75571 Paris 12, France.	celine.morand@polytechnique.org	Annesi-Maesano, Isabella/D-9173-2016; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Annesi-Maesano I, 2007, RESP MED, V101, P1721, DOI 10.1016/j.rmed.2007.02.022; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Brauer M, 2007, EUR RESPIR J, V29, P879, DOI 10.1183/09031936.00083406; Brauer M, 2003, EPIDEMIOLOGY, V14, P228, DOI 10.1097/00001648-200303000-00019; Carr D, 2002, ENVIRON RES, V90, P111, DOI 10.1006/enrs.2002.4393; Chen TM, 2007, AM J MED SCI, V333, P249, DOI 10.1097/MAJ.0b013e31803b900f; CORBO GM, 1993, J ALLERGY CLIN IMMUN, V92, P616, DOI 10.1016/0091-6749(93)90086-U; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Fenger J, 1999, ATMOS ENVIRON, V33, P4877, DOI 10.1016/S1352-2310(99)00290-3; Fischer PH, 2000, ATMOS ENVIRON, V34, P3713, DOI 10.1016/S1352-2310(00)00067-4; Gauderman WJ, 2005, EPIDEMIOLOGY, V16, P737, DOI 10.1097/01.ede.00001813087.51440.75; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Janssen NAH, 2003, ENVIRON HEALTH PERSP, V111, P1512, DOI 10.1289/ehp.6243; Jerrett M, 2005, J EXPO ANAL ENV EPID, V15, P185, DOI 10.1038/sj.jea.7500388; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Kim JJ, 2004, AM J RESP CRIT CARE, V170, P520, DOI 10.1164/rccm.200403-2810C; Kramer U, 2000, EPIDEMIOLOGY, V11, P64, DOI 10.1097/00001648-200001000-00014; Morgenstern V, 2007, OCCUP ENVIRON MED, V64, P8, DOI 10.1136/oem.2006.028241; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Penard-Morand C, 2008, REV MAL RESPIR, V25, P1013, DOI 10.1019/200820019; Penard-Morand C, 2005, CLIN EXP ALLERGY, V35, P1279, DOI 10.1111/j.1365-2222.2005.02336.x; Penard-Morand C, 2006, ATMOS ENVIRON, V40, P2274, DOI 10.1016/j.atmosenv.2005.11.057; Reungoat P, 2005, J EXPO ANAL ENV EPID, V15, P524, DOI 10.1038/sj.jea.7500430; Salvi S, 1999, AM J RESP CRIT CARE, V159, P702; Sunyer J, 1997, THORAX, V52, P760; Weiland SK, 2004, EUR RESPIR J, V24, P406, DOI 10.1183/09031936.04.00090303; Wilkinson P, 1999, THORAX, V54, P1070; WJST M, 1993, BRIT MED J, V307, P596; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18; 1998, LANCET, V351, P1225	32	88	92	2	22	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUL	2010	36	1					33	40		10.1183/09031936.00116109		8	Respiratory System	Respiratory System	618YY	WOS:000279394100009	20075054	
J	Senti, G; Johansen, P; Haug, S; Bull, C; Gottschaller, C; Muller, P; Pfister, T; Maurer, P; Bachmann, MF; Graf, N; Kundig, TM				Senti, G.; Johansen, P.; Haug, S.; Bull, C.; Gottschaller, C.; Muller, P.; Pfister, T.; Maurer, P.; Bachmann, M. F.; Graf, N.; Kundig, T. M.			Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a phase I/IIa clinical trial	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; house dust mite; specific immunotherapy; Type A CpG; virus-like particles	HOUSE-DUST-MITE; MONOPHOSPHORYL-LIPID-A; DERMATOPHAGOIDES-PTERONYSSINUS; BRONCHIAL HYPERREACTIVITY; IMMUNOSTIMULATORY DNA; POLLEN IMMUNOTHERAPY; ASTHMATIC-CHILDREN; DENDRITIC CELLS; RAGWEED ALLERGY; BACTERIAL-DNA	B-type CpG oligodeoxynucleotides (ODN) is currently used in clinical trials because of its prolonged half-life, which is due to its phosphorothioate backbone. A-type CpG ODN is a stronger inducer of IFN but has an unstable phosphodiester backbone that has so far prohibited its clinical use. However, upon association with virus-like particles (VLP) consisting of the bacteriophage Q beta coat protein, A-type CpG ODN can be stabilized and can become an efficient adjuvant in mice. Therefore, the phase I/IIa study presented represents the first test of A-type CpGs in humans. To test the safety, tolerability and clinical efficacy of QbG10 as an adjuvant for subcutaneous immunotherapy with a house dust mite (HDM) allergen extract in allergic patients. A single centre, open-label phase I/IIa study evaluated the safety, tolerability and clinical efficacy of QbG10 as an adjuvant to immunotherapy with a subcutaneous HMD allergen extract in 20 patients suffering from HDM allergy. Twenty-one patients were enrolled between March and July 2005. Individual immunotherapy lasted 10 weeks. Clinical end-points included questionnaires, conjunctival provocation, skin prick tests and the measurement of allergen-specific IgG and IgE. QbG10 was well tolerated. Almost complete tolerance to the allergen was observed in conjunctival provocation testing after treatment with QbG10, and symptoms of rhinitis and allergic asthma were significantly reduced. Within 10 weeks of therapy, patients were nearly symptom-free and this amelioration lasted for at least 38 weeks post-treatment. Following injections of QbG10 and HDM allergen extract, allergen-specific IgG increased, while there was a transient increase in allergen-specific IgE titres. Skin reactivity to HDM was reduced. The subcutaneous application of HDM allergen, together with A-type CpG ODN packaged into VLP, was safe. All patients achieved practically complete alleviation of allergy symptoms after 10 weeks of immunotherapy. This promising clinical outcome calls for larger placebo-controlled phase II studies. G. Senti, P. Johansen, S. Haug, C. Bull, C. Gottschaller, P. Muller, T. Pfister, P. Maurer, M. F. Bachmann, N. Graf and T. M. Kundig, Clinical & Experimental Allergy, 2009 (39) 562-570.	[Senti, G.; Johansen, P.; Haug, S.; Bull, C.; Gottschaller, C.; Kundig, T. M.] Univ Zurich Hosp, Dept Dermatol, Unit Expt Immunotherapy, CH-8091 Zurich, Switzerland; [Senti, G.; Graf, N.] Univ Zurich Hosp, Clin Res Ctr, CH-8091 Zurich, Switzerland; [Muller, P.; Pfister, T.; Maurer, P.; Bachmann, M. F.] Cytos Biotechnol AG, Schlieren, Switzerland	Kundig, TM (reprint author), Univ Zurich Hosp, Dept Dermatol, Unit Expt Immunotherapy, Gloriastr 31, CH-8091 Zurich, Switzerland.	thomas.kuendig@usz.ch	Johansen, Pal/A-1403-2013				Arbes SJ, 2005, J ALLERGY CLIN IMMUN, V116, P377, DOI 10.1016/j.jaci.2005.05.017; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; CASTELAIN PY, 1988, CONTACT DERMATITIS, V19, P58, DOI 10.1111/j.1600-0536.1988.tb02869.x; Comoy EE, 1997, INT IMMUNOL, V9, P523, DOI 10.1093/intimm/9.4.523; Cox JC, 1997, VACCINE, V15, P248, DOI 10.1016/S0264-410X(96)00183-1; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; Drachenberg KJ, 2001, ALLERGY, V56, P498, DOI 10.1034/j.1398-9995.2001.056006498.x; DREBORG S, 1993, ALLERGY, V48, P473, DOI 10.1111/j.1398-9995.1993.tb01102.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Gauvreau GM, 2006, AM J RESP CRIT CARE, V174, P15, DOI 10.1164/rccm.200601-057OC; Guez S, 2000, ALLERGY, V55, P369, DOI 10.1034/j.1398-9995.2000.00413.x; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; Kline Joel N, 2007, Proc Am Thorac Soc, V4, P283, DOI 10.1513/pats.200701-019AW; Klinman Dennis M, 2004, Nat Rev Immunol, V4, P249, DOI 10.1038/nri1329; Kohama Y, 1999, J ALLERGY CLIN IMMUN, V104, P1231; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Manolova V, 2008, EUR J IMMUNOL, V38, P1404, DOI 10.1002/eji.200737984; Marshall JD, 2001, J ALLERGY CLIN IMMUN, V108, P191, DOI 10.1067/mai.2001.116984; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Mothes N, 2003, CLIN EXP ALLERGY, V33, P1198, DOI 10.1046/j.1365-2222.2003.01699.x; Mutwiri GK, 2004, J CONTROL RELEASE, V97, P1, DOI 10.1016/j.jcornel.2004.02.022; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OSTERBALLE O, 1982, ALLERGY, V37, P553, DOI 10.1111/j.1398-9995.1982.tb02340.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Pajno GB, 2007, J ALLERGY CLIN IMMUN, V119, P796, DOI 10.1016/j.jaci.2007.01.009; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Pierson-Mullany LK, 2000, ANN ALLERG ASTHMA IM, V84, P241, DOI 10.1016/S1081-1206(10)62761-5; Pifferi M, 2002, ALLERGY, V57, P785, DOI 10.1034/j.1398-9995.2002.23498.x; Rothenfusser S, 2002, HUM IMMUNOL, V63, P1111, DOI 10.1016/S0198-8859(02)00749-8; Rueff F, 2004, ALLERGY, V59, P589, DOI 10.1111/j.1398-9995.2004.00505.x; SANDS H, 1994, MOL PHARMACOL, V45, P932; Senti Gabriela, 2006, Inflammation & Allergy Drug Targets, V5, P243, DOI 10.2174/187152806779010963; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Sledge RF, 1938, US NAVAL MED B, V36, P18; Sparwasser T, 1997, NATURE, V386, P336, DOI 10.1038/386336a0; Storni T, 2004, J IMMUNOL, V172, P1777; SUSSMAN GL, 1982, ANN ALLERGY, V48, P75; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Tighe H, 2000, J ALLERGY CLIN IMMUN, V106, P124, DOI 10.1067/mai.2000.107927; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; VARNEY VA, 1991, BRIT MED J, V302, P265; Verthelyi D, 2002, J IMMUNOL, V168, P1659; Verthelyi D, 2001, J IMMUNOL, V166, P2372; Vissers JLM, 2004, J ALLERGY CLIN IMMUN, V113, P1204, DOI 10.1016/j.jaci.2004.02.041; von Beust BR, 2005, EUR J IMMUNOL, V35, P1869, DOI 10.1002/eji.200526124; Wheeler AW, 2004, EXPERT OPIN BIOL TH, V4, P1473, DOI 10.1517/14712598.4.9.1473; Wilcock LK, 2004, CLIN EXP ALLERGY, V34, P1373, DOI 10.1111/j.1365-2222.2004.02052.x; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175	52	88	93	1	10	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	APR	2009	39	4					562	570		10.1111/j.1365-2222.2008.03191.x		9	Allergy; Immunology	Allergy; Immunology	418YA	WOS:000264184800015	19226280	
J	Matricardi, PM; Illi, S; Gruber, C; Keil, T; Nickel, R; Wahn, U; Lau, S				Matricardi, P. M.; Illi, S.; Grueber, C.; Keil, T.; Nickel, R.; Wahn, U.; Lau, S.			Wheezing in childhood: incidence, longitudinal patterns and factors predicting persistence	EUROPEAN RESPIRATORY JOURNAL			English	Article						asthma; atopic dermatitis; children; epidemiology; prediction of persistence; wheezing	BIRTH COHORT; INHALED CORTICOSTEROIDS; ASTHMA-TREATMENT; FOLLOW-UP; HIGH-RISK; CHILDREN; PREVENTION; LIFE; AGE; SENSITIZATION	Childhood asthma is frequently perceived as a disease with uniform clinical pathways. This perception might be an oversimplification. The aim of the present study was to investigate the incidence and natural course of wheeze over the first 13 yrs of life and analyse the risk factors predicting wheeze at 11-13 yrs of age. The Multicentre Allergy Study, a German birth cohort, recruited 1,314 children in 1990. Physical examinations, interviews on atopic diseases, immunoglobulin (Ig)E and lung function tests were performed up to 13 yrs of age. Complete data on the course of wheeze were available for 441 children. It was found that incidence of wheezing declined with age. The first wheezing episode was reported by 299 9 and 9% of participants at <= 3 (early wheezers), 3-6 (late wheezers), and >6 yrs (very late wheezers) of age, respectively. Wheezing at the age of 13 yrs was associated with parental atopy, and with IgE sensitisation to common allergens, elevated total IgE and exposure to high levels of indoor allergens in early life. All these associations were remarkably stronger among early wheezers than among early nonwheezers. In conclusion, the relevance of an early expression of atopy as a predictor of wheezing at age 13 yrs declines with increasing age of wheezing onset.	[Keil, T.] Charite Univ Med Ctr, Inst Social Med Epidemiol & Hlth Econ, Berlin, Germany; [Illi, S.] Univ Childrens Hosp, Munich, Germany; [Matricardi, P. M.; Grueber, C.; Nickel, R.; Wahn, U.; Lau, S.] Charite Univ Med Ctr, Dept Paediat Pneumol & Immunol, Berlin, Germany	Matricardi, PM (reprint author), Charite Univ Med Berlin, Dept Paediat Pneumol & Immunol, Augustenburger Pl 1, D-13353 Berlin, Germany.	paolo.matricardi@charite.de			German Ministry of Education and Research (BMBF) [O1EE9406]	The present study was supported by the German Ministry of Education and Research (BMBF), grant number O1EE9406.	Asher I, 2004, INT ARCH ALLERGY IMM, V135, P83, DOI 10.1159/000080524; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Balemans WAF, 2006, J CLIN EPIDEMIOL, V59, P1207, DOI 10.1016/j.jclinepi.2006.02.011; Bergmann R L, 1994, Pediatr Allergy Immunol, V5, P19, DOI 10.1111/j.1399-3038.1994.tb00343.x; Bisgaard H, 2006, NEW ENGL J MED, V354, P1998, DOI 10.1056/NEJMoa054692; Castro-Rodriguez JA, 2000, AM J RESP CRIT CARE, V162, P1403; Eid NS, 2004, CLIN PEDIATR, V43, P793, DOI 10.1177/000992280404300903; Eysink PED, 2005, BRIT J GEN PRACT, V55, P125; Guerra S, 2004, AM J RESP CRIT CARE, V170, P78, DOI 10.1164/rccm.200309-1224OC; Guilbert TW, 2006, NEW ENGL J MED, V354, P1985, DOI 10.1056/NEJMoa051378; Hyvarinen MK, 2005, PEDIATR PULM, V40, P316, DOI 10.1002/ppul.20273; Illi S, 2001, BRIT MED J, V322, P390, DOI 10.1136/bmj.322.7283.390; Illi S, 2004, J ALLERGY CLIN IMMUN, V113, P925, DOI 10.1016/j.jaci.2004.01.778; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Lieu TA, 1998, AM J RESP CRIT CARE, V157, P1173; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Martinez FD, 2007, J ALLERGY CLIN IMMUN, V119, P30, DOI 10.1016/j.jaci.2006.10.020; Rhodes HL, 2002, AM J RESP CRIT CARE, V165, P176; Simpson A, 2005, CURR OPIN ALLERGY CL, V5, P223, DOI 10.1097/01.all.0000168785.51711.27; Toelle BG, 2004, EUR RESPIR J, V23, P66, DOI 10.1183/09031936.03.00046903; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; [Anonymous], 2006, LANCET, V368, P705	25	88	92	1	6	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	SEP	2008	32	3					585	592		10.1183/09031936.00066307		8	Respiratory System	Respiratory System	351OG	WOS:000259433100010	18480107	
J	Bousquet, J; Boulet, LP; Peters, MJ; Magnussen, H; Quiralte, J; Martinez-Aguilarf, NE; Carlsheimer, A				Bousquet, Jean; Boulet, Louis-Philippe; Peters, Matthew J.; Magnussen, Helgo; Quiralte, Joaquin; Martinez-Aguilarf, Nora E.; Carlsheimer, Asa			Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone	RESPIRATORY MEDICINE			English	Article						asthma control; exacerbations; hospitatisations; combination therapy; maintenance plus as needed	RANDOMIZED CONTROLLED-TRIAL; INHALED BUDESONIDE; SINGLE INHALER; FORMOTEROL; EXACERBATIONS; COMBINATION; THERAPY; SALMETEROL; METAANALYSIS; MEDICATION	Background: Budesonide/formoterol maintenance and reliever therapy (Symbicort SMART (R)) improves asthma control compared with fixed-dose inhaled corticosteroid/ long-acting beta(2)-agonist (ICS/LABA) regimens, but its efficacy has not been assessed in comparison with sustained high-dose satmeterol/fluticasone (Seretide(TM)) plus a short-acting beta(2)-agonist (SABA). Methods: Patients (N = 2309) with symptomatic asthma (aged _> 12 years; forced expiratory volume in 1 s > 50% predicted), who had experienced an asthma exacerbation in the previous year, were randomised to receive budesonide/formoterol 160/4.5 mu g two inhalations twice daily and as needed, or one inhalation of salmeterot/fluticasone 50/500 mu g twice daily plus terbutaline as needed, for 6 months. Results: Time to first severe exacerbation, the pre-specified primary outcome, was not significantly prolonged (risk ratio 0.82; 95% confidence interval 0.63, 1.05). Budesonide/ formoterol maintenance and reliever therapy reduced total exacerbations from 31 to 25 events/100 patients/year (P=0.039), and exacerbations requiring hospitalisation/ emergency room (ER) treatment from 13 to 9 events/100 patients/year (P=0.046). The treatments showed no difference in measures of lung function or asthma symptoms. The mean dose of ICS received was lower using budesonide/formoterol maintenance and reliever therapy (792 mu g/day budesonide [1238 mu g/day beclomethasone dipropionate (BDP) equivalent] versus 1000 mu g/day fluticasone [2000 mu g/day BDP equivalent] with salmeterol/ fluticasone therapy; P<0.0001). Both treatments were well tolerated. Conclusion: In the treatment of uncontrolled asthma, budesonide/formoterol maintenance and reliever therapy reduces the incidence of severe asthma exacerbations and hospitalisation/ER treatment with similar daily symptom control compared with sustained high-dose salmeterol/fluticasone plus SABA. This benefit is achieved with substantially less ICS exposure. (C) 2007 Published by Elsevier Ltd.	Hop Arnaud Villeneuve, F-34000 Montpellier, France; Hop Laval, Inst Cardiol & Pneumol, Quebec City, PQ, Canada; Concord Hosp, Concord, Australia; Krankenhaus Grosshansdorf, Zentrum Pneumol & Thoraxchirurg, Lehrstuhl Innere Med Pneumol, Grosshansdorf, Germany; Complejo Hosp Jaen, Unidad Alergia, Jaen, Spain; AstraZeneca, Lund, Sweden	Bousquet, J (reprint author), Hop Arnaud Villeneuve, 371 Ave Doyen Gaston Giraud, F-34000 Montpellier, France.	jean.bousquet@orange.fr	IBIS, ALERGICAS/C-1733-2016				Anderson HR, 2005, BRIT MED J, V330, P117, DOI 10.1136/bmj.38316.729907.8F; Angus R, 2005, INT J CLIN PRACT, V59, P156, DOI 10.1111/j.1368-5031.2004.00455.x; Barnes PJ, 2007, EUR RESPIR J, V29, P587, DOI 10.1183/09031936.00080306; Bateman ED, 2004, AM J RESP CRIT CARE, V170, P836, DOI 10.1164/rccm.200401-033OC; Bousquet J, 2007, ALLERGY, V62, P102, DOI 10.1111/j.1398-9995.2006.01305.x; *BRIT5 THOR SOC SC, 2005, BRIT GUID MAN ASTHM; Duong M, 2007, J ALLERGY CLIN IMMUN, V119, P322, DOI 10.1016/j.jaci.2006.10.018; Edwards SJ, 2007, CURR MED RES OPIN, V23, P1809, DOI 10.1185/030079907X210697; FitzGerald JM, 2006, THORAX, V61, P992, DOI 10.1136/thx.2005.045195; FitzGerald JM, 2004, THORAX, V59, P550, DOI 10.1136/thx.2003.014936; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32; Global Initiative for Asthma, 2006, GLOB STRAT ASTHM MAN; Harrison TW, 2004, LANCET, V363, P271, DOI 10.1016/S0140-6736(03)15384-6; Humbert M, 2007, ALLERGY, V62, P95, DOI 10.1111/j.1398-9995.2006.01308.x; Juniper EF, 2005, RESP MED, V99, P553, DOI 10.1016/j.rmed.2004.10.008; Kuna P, 2007, INT J CLIN PRACT, V61, P725, DOI 10.1111/j.1742-1241.2007.01338.x; Lai CKW, 2003, J ALLERGY CLIN IMMUN, V111, P263, DOI 10.1067/mai.2003.30; Lanes SF, 2002, THORAX, V57, P683, DOI 10.1136/thorax.57.8.683; Mendes ES, 2003, EUR RESPIR J, V21, P989, DOI 10.1183/09031936.03.00072402; *NIH, 974051 NIH PUBL; O'Byrne PM, 2001, AM J RESP CRIT CARE, V164, P1392; O'Byrne PM, 2005, AM J RESP CRIT CARE, V171, P129, DOI 10.1164/rccm.200407-884OC; Palmqvist M, 1997, EUR RESPIR J, V10, P2484, DOI 10.1183/09031936.97.10112489; Palmqvist M, 1999, AM J RESP CRIT CARE, V160, P244; Paredi P, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-15; Partridge Martyn R, 2006, BMC Pulm Med, V6, P13, DOI 10.1186/1471-2466-6-13; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pauwels RA, 2003, EUR RESPIR J, V22, P787, DOI 10.1183/09031936.03.00055803; Rabe KF, 2004, J ALLERGY CLIN IMMUN, V114, P40, DOI 10.1016/j.jaci.2004.04.042; Rabe KF, 2006, LANCET, V368, P744, DOI 10.1016/S0140-6736(06)69284-2; Sin DD, 2004, JAMA-J AM MED ASSOC, V292, P367, DOI 10.1001/jama.292.3.367; Tattersfield AE, 2001, LANCET, V357, P257, DOI 10.1016/S0140-6736(00)03611-4; Tintinger GR, 2000, INFLAMMATION, V24, P239, DOI 10.1023/A:1007013530072; van Veen A, 2003, PULM PHARMACOL THER, V16, P153, DOI 10.1016/S1094-5539(03)00003-8; Vogelmeier C, 2005, EUR RESPIR J, V26, P819, DOI 10.1183/09031936.05.00028305	35	88	91	1	12	W B SAUNDERS CO LTD	LONDON	32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND	0954-6111			RESP MED	Respir. Med.	DEC	2007	101	12					2437	2446		10.1016/j.rmed.2007.07.014		10	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	235DC	WOS:000251212700002	17905575	
J	Lee, JH; Haselkorn, T; Borish, L; Rasouliyan, L; Chipps, BE; Wenzel, SE				Lee, June H.; Haselkorn, Tmirah; Borish, Larry; Rasouliyan, Lawrence; Chipps, Bradley E.; Wenzel, Sally E.			Risk factors associated with persistent airflow limitation in severe or difficult-to-treat asthma	CHEST			English	Article						airway remodeling; difficult-to-treat asthma; irreversible airway obstruction; persistent airflow limitation; severe asthma	ETHNICALLY DIVERSE POPULATIONS; TREATMENT REGIMENS TENOR; LUNG-FUNCTION; BETA(2)-ADRENERGIC RECEPTOR; COMPUTED-TOMOGRAPHY; SUSCEPTIBILITY LOCI; CIGARETTE-SMOKING; NATURAL-HISTORY; WALL THICKNESS; MILD ASTHMA	Background: The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens study is among the largest to assess persistent airflow limitation and the first to evaluate a wide range of potential risk factors in high-risk patients with severe or difficult-to-treat asthma. A better understanding is needed regarding factors associated with persistent airway obstruction; this study was performed to determine demographic and clinical characteristics associated with persistent airflow limitation. Methods: Data from adult patients (>= 18 years old) with severe or difficult-to-treat asthma were evaluated. Patients with COPD, obesity with a restrictive respiratory pattern, or a >= 30 pack-year history of smoking were excluded. Patients with persistent airflow limitation (postbronchodilator FEV1/FVC ratio <= 70% at two annual consecutive visits) and normal postbronchodilator FEV1/ FVC ratio (75 to 85%) were compared. Multivariate analysis identified factors independently associated with persistent airflow limitation. Results: Of 1,017 patients, 612 patients (60%) showed evidence of persistent airflow limitation. Risk factors were as follows: older age (odds ratio [OR] per 10 years, 1.4; 95 % confidence interval [CI], 1.3 to 1.6); male gender (OR, 4.5; 95% CI, 2.3 to 8.5); black ethnicity (OR, 2.2; 95% CI, 1.3 to 3.8); current or past smoking (OR, 3.9; 95% CI, 1.8 to 8.6; and OR, 1.6; 95% CI, 1.2 to 2.3, respectively); aspirin sensitivity (OR, 1.5; 95% CI, 1.0 to 2.4); and longer asthma duration (OR per 10 years, 1.6; 95% CI, 1.4 to 1.8). Protective factors were Hispanic ethnicity, higher education, family history of atopic dermatitis, pet(s) in the home, and dust sensitivity. Conclusions: Persistent airflow limitation is prevalent in patients with severe or difficult-to-treat asthma and is associated with identifiable clinical and demographic characteristics.	[Lee, June H.; Haselkorn, Tmirah] Genentech Inc, San Francisco, CA 94080 USA; [Borish, Larry] Univ Virginia Hlth Syst, Charlottesville, VA USA; [Rasouliyan, Lawrence] ICON Clin Res, San Francisco, CA USA; [Chipps, Bradley E.] Capital Allergy & Resp Dis Ctr, Sacramento, CA USA; [Wenzel, Sally E.] Univ Pittsburgh, Pittsburgh, PA USA	Lee, JH (reprint author), Genentech Inc, 1 DNA Way,MS 453B, San Francisco, CA 94080 USA.	lee.june@gene.com	panduru, mihaela/H-2411-2011; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			Abraham B, 2003, EUR RESPIR J, V22, P470, DOI 10.1183/09031936.03.00261903; American Lung Association Epidemiology and Statistics Unit Research and Scientific Affairs, 2006, TRENDS ASTHM MORB MO; American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Bleecker Eugene R, 2004, Chest, V126, p93S, DOI 10.1378/chest.126.2_suppl_1.93S; Bumbacea D, 2004, EUR RESPIR J, V24, P122, DOI 10.1183/09031936.04.00077803; Chalmers GW, 2002, THORAX, V57, P226, DOI 10.1136/thorax.57.3.226; Covar RA, 2004, AM J RESP CRIT CARE, V170, P234, DOI 10.1164/rccm.200308-11740C; Dolan CM, 2004, ANN ALLERG ASTHMA IM, V92, P32; Federico MJ, 2005, CHEST, V127, P571, DOI 10.1378/chest.127.2.571; Fuhlbrigge AL, 2002, IMMUNOL ALLERGY CLIN, V22, P753, DOI 10.1016/S0889-8561(02)00022-X; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Grol MH, 1999, AM J RESP CRIT CARE, V160, P1830; Hansen JE, 2007, CHEST, V131, P349, DOI 10.1378/chest.06-1349; Hunninghake GM, 2006, AM J RESP CRIT CARE, V173, P143, DOI 10.1164/rccm.200508-1232SO; Israel E, 2000, AM J RESP CRIT CARE, V162, P75; James AL, 2005, AM J RESP CRIT CARE, V171, P109, DOI 10.1164/rccm.200402-230OC; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; Lee JH, 2006, J ASTHMA, V43, P179, DOI 10.1080/02770900600566405; Marsh DG, 1997, NAT GENET, V15, P389; Mascia K, 2005, J ALLERGY CLIN IMMUN, V116, P970, DOI 10.1016/j.jaci.2005.08.035; Miranda C, 2004, J ALLERGY CLIN IMMUN, V113, P101, DOI 10.1016/j.jaci.2003.10.041; *NAT HEART LUNG BL, 1997, 974051 NIH; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518; Ober C, 2000, AM J HUM GENET, V66, P517, DOI 10.1086/302781; Orie NGM, 1961, BRONCHITIS, P43; Pepe C, 2005, J ALLERGY CLIN IMMUN, V116, P544, DOI 10.1016/j.jaci.2005.06.011; Rasmussen F, 2002, AM J RESP CRIT CARE, V165, P1480, DOI 10.1164/rccm.2108009; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Taylor DR, 2000, THORAX, V55, P762, DOI 10.1136/thorax.55.9.762; ten Brinke A, 2001, AM J RESP CRIT CARE, V164, P744; Tomlinson JEM, 2005, THORAX, V60, P282, DOI 10.1136/thx.2004.033688; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; Vignola AM, 1998, AM J RESP CRIT CARE, V158, P1945; Vignola A. M., 2003, CHEST, V123, P417; Weir TD, 1998, AM J RESP CRIT CARE, V158, P787; Wenzel S, 2005, AM J RESP CRIT CARE, V172, P149, DOI 10.1164/rccm.200409-1181PP; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	38	88	91	0	2	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	DEC	2007	132	6					1882	1889		10.1378/chest.07-0713		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	246HA	WOS:000251996900029	18079222	
J	Nieuwenhuizen, N; Lopata, AL; Jeebhay, MLF; Herbert, DR; Robins, TG; Brombacher, F				Nieuwenhuizen, N; Lopata, AL; Jeebhay, MLF; Herbert, DR; Robins, TG; Brombacher, F			Exposure to the fish parasite Anisakis causes allergic airway hyperreactivity and dermatitis	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						anisakis; nematode; parasitc; gene-deficient mice; food allergy; dermatitis; asthma; occupational allergy; IL4; IL-13	LEISHMANIA-MAJOR INFECTION; FOOD ALLERGY; GASTROALLERGIC ANISAKIASIS; LARVAL ANTIGENS; SEAFOOD ALLERGY; UNITED-STATES; T-CELLS; SIMPLEX; ASTHMA; RESPONSES	Background: Several case reports show allergy and anaphylactic reactions to the fish parasite Anisakis in the domestic and occupational setting. Further research is needed on the prevalence and mechanisms of disease. Objective: To determine the prevalence of Anisakis sensitization and related symptoms among workers in 2 fish-processing factories, and to use gene-deficient mice to determine the working mechanisms of Anisakis allergy. Methods: A modified version of the European Community Respiratory Health Survey was used to interview 578 South African fish-processing workers. Sensitization to Anisakis, seafood, and common aeroallergens was determined by skin prick test. Lung function was measured by spirometry and methacholine challenge. Serum eicosapentaenoic acid levels were used as an index of seafood consumption. Sensitized wildtype, IL-4, or IL-4 receptor alpha-deficient mice were challenged orally with Anisakis extract. Allergic reactions, lung pathology, antibodies, cytokines, mast cell proteases, and histamine were evaluated. Results: The prevalence of sensitization to Anisakis was higher than the prevalence of sensitization to fish (8% vs 6%). Anisakis-specific IgE reactivity was associated with bronchial hyperreactivity and dermatitis, and significantly increased with fish consumption. In mice, Anisakis infective larvae (1,3) induced a striking T(H)2/type 2 response. Food-allergic-type reactions induced by oral challenge with Anisakis extract were absent in IL-4 receptor a knockout mice. Conclusion: Anisakis sensitization in fish-processing workers is associated with allergic symptoms and correlates with high levels of fish consumption. Anisakis proteins induce allergic reactions in sensitized mice by IL-4/IL-13-mediated mechanisms. Clinical implications: Anisakis allergy should be considered in fish-processing workers with allergic symptoms.	Univ Cape Town, Observ, Div Immunol, IIDMM,Fac Hlth Sci,Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa; Univ Cape Town, Occupat & Environm Hlth Res Unit, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa; Univ Michigan, Dept Environm Hlth Sci, Ann Arbor, MI 48109 USA	Brombacher, F (reprint author), Univ Cape Town, Observ, Div Immunol, IIDMM,Fac Hlth Sci,Natl Hlth Lab Serv, ZA-7925 Cape Town, South Africa.	fbrombac@mweb.co.za	Lopata, Andreas/C-8160-2009; Lopata, Andreas/C-3831-2012; Herbert, De'Broski/J-7357-2012	Lopata, Andreas/0000-0002-2940-9235; Herbert, De'Broski/0000-0002-2449-5365	PHS HHS [R01 F002304]		Alonso-Gomez A, 2004, PARASITOL RES, V93, P378, DOI 10.1007/s00436-004-1085-9; Araujo MIAS, 2004, J INFECT DIS, V190, P1797, DOI 10.1086/425017; Armentia A, 1998, J ALLERGY CLIN IMMUN, V102, P831, DOI 10.1016/S0091-6749(98)70024-7; Audicana MT, 2002, TRENDS PARASITOL, V18, P20, DOI 10.1016/S1471-4922(01)02152-3; AUDICANA MT, 1995, J ALLERGY CLIN IMMUN, V96, P558, DOI 10.1016/S0091-6749(95)70301-2; Bashir MEH, 2002, J IMMUNOL, V169, P3284; Brewer JM, 1999, J IMMUNOL, V163, P6448; Buhl R, 2005, CURR OPIN PULM MED, V11, P27; Caballero ML, 2004, PARASITOL RES, V93, P248, DOI 10.1007/s00436-004-1099-3; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Couture C, 2003, AM J SURG PATHOL, V27, P1167, DOI 10.1097/00000478-200308000-00017; Daschner A, 2002, PARASITE IMMUNOL, V24, P243, DOI 10.1046/j.1365-3024.2002.00458.x; Daschner A, 2000, J ALLERGY CLIN IMMUN, V105, P176, DOI 10.1016/S0091-6749(00)90194-5; Daschner A, 2001, ALLERGY, V56, P1003, DOI 10.1034/j.1398-9995.2001.00207.x; Davey G, 2005, CLIN EXP ALLERGY, V35, P301, DOI 10.1111/j.1365-2222.2005.02181.x; del Pozo V, 1999, J ALLERGY CLIN IMMUN, V104, P637, DOI 10.1016/S0091-6749(99)70336-2; Dominguez-Ortega J, 2001, INT ARCH ALLERGY IMM, V125, P86, DOI 10.1159/000053801; Falcao H, 2002, ALLERGY, V57, P44, DOI 10.1034/j.1398-9995.2002.13429.x; GarciaPalacios L, 1996, J HELMINTHOL, V70, P281; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Heinzmann A, 2000, HUM MOL GENET, V9, P549, DOI 10.1093/hmg/9.4.549; IGLESIAS R, 1993, PARASITE IMMUNOL, V15, P243, DOI 10.1111/j.1365-3024.1993.tb00607.x; James JM, 2003, PEDIATRICS, V111, P1625; Jeebhay MF, 2004, OCCUP ENVIRON MED, V61, P471, DOI 10.1136/oem.2002.001099; Jeebhay MF, 2001, OCCUP ENVIRON MED, V58, P553, DOI 10.1136/oem.58.9.553; Jung SK, 2000, J IMMUNOL, V165, P1491; KASUYA S, 1990, LANCET, V335, P665, DOI 10.1016/0140-6736(90)90455-E; Kimura S, 2001, Rinsho Byori, V49, P376; KLIKS MM, 1983, AM J TROP MED HYG, V32, P526; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Leung DYM, 2003, NEW ENGL J MED, V348, P986, DOI 10.1056/NEJMoa022613; Li XM, 2000, J ALLERGY CLIN IMMUN, V106, P150, DOI 10.1067/mai.2000.107395; Mohrs M, 2000, INFECT IMMUN, V68, P1773, DOI 10.1128/IAI.68.4.1773-1780.2000; Murase T, 1998, BLOOD, V92, P2182; NobenTrauth N, 1996, SCIENCE, V271, P987, DOI 10.1126/science.271.5251.987; OSHIMA T, 1987, PARASITOL TODAY, V3, P44, DOI 10.1016/0169-4758(87)90212-2; Palmer LJ, 2002, AM J RESP CRIT CARE, V165, P1489, DOI 10.1164/rccm.2107020; Perteguer MJ, 2001, PARASITOL RES, V87, P396, DOI 10.1007/s004360000362; Pichler WJ, 1999, CLIN EXP ALLERGY, V29, P1161, DOI 10.1046/j.1365-2222.1999.00646.x; Ring Johannes, 2004, Novartis Found Symp, V257, P6; SAKANARI JA, 1990, PARASITOL TODAY, V6, P323, DOI 10.1016/0169-4758(90)90176-5; Sampson HA, 2004, J ALLERGY CLIN IMMUN, V113, P805, DOI 10.1016/j.jaci.2004.03.014; Scala E, 2001, EUR J DERMATOL, V11, P249; Sicherer SH, 2004, J ALLERGY CLIN IMMUN, V114, P159, DOI 10.1016/j.jaci.2004.04.018; Sicherer SH, 2002, LANCET, V360, P701, DOI 10.1016/S0140-6736(02)09831-8; van den Biggelaar AHJ, 2004, J INFECT DIS, V189, P892, DOI 10.1086/381767; VANTHIEL PH, 1966, TROP GEOGR MED, V18, P310; Webb DC, 2000, J IMMUNOL, V165, P108; Wills-Karp M, 2004, IMMUNOL REV, V202, P175, DOI 10.1111/j.0105-2896.2004.00215.x; Wilson MS, 2005, J EXP MED, V202, P1199, DOI 10.1084/jem.20042572; Yazdanbakhsh M, 2005, CURR OPIN ALLERGY CL, V5, P386, DOI 10.1097/01.all.0000182541.52971.eb; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	52	88	91	2	14	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2006	117	5					1098	1105		10.1016/j.jaci.2005.12.1357		8	Allergy; Immunology	Allergy; Immunology	041EM	WOS:000237436300018	16675338	
J	Walker, S; Monteil, M; Phelan, K; Lasserson, TJ; Walters, EH				Walker, S; Monteil, M; Phelan, K; Lasserson, TJ; Walters, EH			Anti-IgE for chronic asthma in adults and children	COCHRANE DATABASE OF SYSTEMATIC REVIEWS			English	Review						anti-asthmatic agents [therapeutic use]; antibodies, anti-idiotypic [*therapeutic use]; antibodies, monoclonal [*therapeutic use]; asthma [*drug therapy; immunology]; chronic disease; immunoglobulin E [blood; immunology]; randomized controlled trials	SEVERE ALLERGIC-ASTHMA; QUALITY-OF-LIFE; ANTIIMMUNOGLOBULIN-E ANTIBODY; HUMANIZED MONOCLONAL-ANTIBODY; COMPLEX-FORMATION; SERUM IGE; E THERAPY; OMALIZUMAB; EFFICACY; DISEASE	Background Omalizumab is a recombinant humanised monoclonal antibody directed against immunoglobulin E (anti-IgE) to inhibit the immune system's response to allergen exposure. Omalizumab is directed against the binding site of IgE for its high affinity Fc receptor. It prevents free serum IgE from attaching to mast cells and other effector cells and prevents IgE mediated inflammatory changes. Objectives To determine the efficacy of anti-IgE compared with placebo in patients with allergic asthma. Search strategy We searched the Cochrane Airways Group Asthma trials register for potentially relevant studies (February 2006). Selection criteria Randomised controlled trials examining anti-IgE administered in any manner for any duration. Trials with co-interventions were included as long as they were the same in each arm. Data collection and analysis Two reviewers independently assessed study quality and extracted and entered data. Three modes of administration were identified from the published literature (inhaled, intravenous and subcutaneous injection). Subgroup analysis was performed by asthma severity. Data were extracted from published and unpublished sources. Main results Fourteen trials (15 group comparisons) were included in the review, contributing a total of 3143 mild to severe allergic asthmatic participants with high levels of IgE. Treatment with intravenous and subcutaneous Omalizumab significantly reduced free IgE compared with placebo. Omalizumab led to a significant reduction in inhaled steroid (ICS) consumption compared with placebo (-119 mcg/day (95% CI -154 to -83, three trials)). There were significant increases in the number of participants who were able to reduce ICS by over 50% (odds ratio (OR) 2.50, 95% confidence interval (CI) 2.02 to 3.10 (four trials)); or completely withdraw their daily ICS intake (OR 2.50 (95% CI 2.00 to 3.13; four trials)). Participants treated with Omalizumab were less likely to suffer an asthma exacerbation with treatment as an adjunct to ICS (OR 0.52, 95% CI 0.41 to 0.65, five trials), or as an ICS tapering agent (OR 0.47, 95% CI 0.37 to 0.60, four trials). Authors' conclusions Omalizumab was significantly more effective than placebo at increasing the numbers of patients who were able to reduce or withdraw their inhaled steroids, but the clinical value of the reduction in steroid consumption has be considered in the light of the high cost of Omalizumab. The impressive placebo effects observed in control groups bring into question the true effect of Omalizumab. Omalizumab was effective in reducing asthma exacerbations as an adjunctive therapy to inhaled steroids, and during steroid tapering phases of clinical trials. Omalizumab was generally well tolerated, although there were more injection site reactions with Omalizumab. Patient and physician assessments of the drug were positive. Further assessment in paediatric populations is necessary, as is direct double-dummy comparison with ICS.	Natl Resp Training Ctr, Warwick CV34 4AB, England	Walker, S (reprint author), Natl Resp Training Ctr, 10 Church St, Warwick CV34 4AB, England.	s.walker@educationforhealth.org.uk	Walker, Samantha/B-9740-2013	Walker, Samantha/0000-0001-5503-8258			ARSHAD SH, 2001, ANTI IGE THERAPY AST; Ayres J. G., 2003, Journal of Allergy and Clinical Immunology, V111, pS202, DOI 10.1016/S0091-6749(03)80693-0; Ayres JG, 2004, ALLERGY, V59, P701, DOI 10.1111/j.1398-9995.2004.00533.x; Babu KS, 2001, ALLERGY, V56, P1121, DOI 10.1034/j.1398-9995.2001.00019.x; Berger W, 2003, ANN ALLERG ASTHMA IM, V91, P182; Berger WE, 2002, ANN ALLERG ASTHMA IM, V88, P152; Bisberg D, 1996, J CLIN PHARMACOL, V36, P859; Boulet LP, 2003, CHEST, V124, p105S; Boulet LP, 1997, AM J RESP CRIT CARE, V155, P1835; Bousquet J, 2004, CHEST, V125, P1378, DOI 10.1378/chest.125.4.1378; Bousquet J, 2004, EUROPEAN RESP J S48, V24, p220s; Bousquet J, 2003, EUROPEAN RESP J S45, V22; BRUNO L, 2005, 19 WORLD ALL ORG C M; *BTS, 2005, BRIT GUID MAN ASHM; Buhl R, 2002, EUR RESPIR J, V20, P1088, DOI 10.1183/09031936.02.00016502; Buhl R, 2002, EUR RESPIR J, V20, P73, DOI 10.1183/09031936.02.00278102; Buhl R, 2001, P ANN THOR SOC 97 IN, P186; BUHL R, 2001, P ATS 97 INT C MAY 1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 1997, J ALLERGY CLIN IMMUN, V100, P110; Chilvers E, 2003, AM THOR SOC 99 INT C, pC104; Chipps B., 2003, Journal of Allergy and Clinical Immunology, V111, pS144, DOI 10.1016/S0091-6749(03)80461-X; CHUNG F, 2002, P AAAI M; Chung F, 2003, EUROPEAN RESP J S45, V22; Dahl R., 2004, Journal of Allergy and Clinical Immunology, V113, pS37, DOI 10.1016/j.jaci.2003.12.090; Demoly P, 1997, AM J RESP CRIT CARE, V155, P1825; Djukanovic R, 2004, AM J RESP CRIT CARE, V170, P583, DOI 10.1164/rccm.200312-1651OC; Djukanovic R, 2003, AM THOR SOC 99 INT C; DJUKANOVIC R, 2003, ALLERGY CLIN IMMUNOL; Emmrich P, 2001, MONATSSCHRIFT KINDER, V149, P506; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828; Fahy JV, 1999, AM J RESP CRIT CARE, V160, P1023; Fernandez C, 2005, AM THOR SOC 2005 INT; Finn A, 2003, J ALLERGY CLIN IMMUN, V111, P278, DOI 10.1067/mai.2003.54; Fox JA, 1996, J PHARMACOL EXP THER, V279, P1000; Frew AJ, 1998, THORAC S, V53, P52; Global initiative for asthma (GINA), 2002, NHLBI WHO WORKSH; HANF G, 2005, AM SOC 2005 INT C MA; Harnest U, 2004, J ALLERGY CLIN IM S2, V113, pS175; Higgins B., 2003, Journal of Allergy and Clinical Immunology, V111, pS144, DOI 10.1016/S0091-6749(03)80459-1; Holgate S, 2001, CURR MED RES OPIN, V17, P233; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Holgate ST, 2001, P ATS 97 INT C MAY 1, P159; HOLGATE ST, 2001, P ATS 97 INT C 2001, P184; Howes T, 2003, AM THOR SOC 99 INT C, pC104; Hughes ATD, 2000, JAMA-J AM MED ASSOC, V284, P2859, DOI 10.1001/jama.284.22.2859; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Israel E., 2003, Journal of Allergy and Clinical Immunology, V111, pS146, DOI 10.1016/S0091-6749(03)80469-4; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JUNIPER EF, 1994, J CLIN EPIDEMIOL, V47, P81, DOI 10.1016/0895-4356(94)90036-1; KAISER J, 2003, MED OFF EFF REV, P99; Korenblat P, 2005, J ALLERGY CLIN IM S2, V115, pS76; Korenblat P, 2005, AM THOR SOC 2005 INT; KORENBLAT PE, 2004, AM THOR SOC 100 INT, pG88; LANIER RQ, 2001, ATS INT C MAY 18 23; Lemanske RF, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.5.e55; LIU J, 1995, BIOCHEMISTRY-US, V34, P10474, DOI 10.1021/bi00033a020; MASSANARI M, 2005, 19 WORLD ALL ORG C M; MASSARARI M, 2005, 19 WORLD ALL ORG C M; Matz J, 2005, AM THOR SOC 2005 INT, pB36; Metzger WJ, 1998, J ALLERGY CLIN IMMUN, V101, P231; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, P36; MILGROM H, 2005, AM THOR SOC 2005 INT; Moulton D, 2000, CAN MED ASSOC J, V162, P864; Nayak A, 2000, AM J RESP CRIT CARE, V161, pA504; NOGA O, 2005, AM THOR SOC 2005 INT; Ong YE, 2005, J ALLERGY CLIN IMMUN, V116, P558, DOI 10.1016/j.jaci.2005.05.035; Qureshi F, 1998, NEW ENGL J MED, V339, P1030, DOI 10.1056/NEJM199810083391503; SEARS MR, 1991, NEW ENGL J MED, V325, P1067, DOI 10.1056/NEJM199110103251504; Shrewsbury S, 2000, BRIT MED J, V320, P1368, DOI 10.1136/bmj.320.7246.1368; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; SOLER M, 2001, P ATS 97 INT C MAY 1; Soler M, 2000, EUR RESPIR J, V16, p10s; Spector SL, 1999, ANN ALLERG ASTHMA IM, V83, P435, DOI 10.1016/S1081-1206(10)62848-7; van Rensen ELJ, 2005, AM THOR SOC 2005 INT, pC12; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; Vignola M, 2003, EUROPEAN RESP J S45, V22; WENZEL S, 2002, SEVERE ALLERGIC ASTH; Wijnhoven HAH, 2001, CHEST, V119, P1034, DOI 10.1378/chest.119.4.1034; Wilding P, 1997, BRIT MED J, V314, P1441; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; WRENN K, 1991, ANN INTERN MED, V115, P241; [Anonymous], 2000, DTSCH APOTHEKER ZEIT, V140, P1289; [Anonymous], 2000, HOSP PRACTICE, V24, P27	86	88	90	0	5	WILEY-LISS	HOBOKEN	DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA	1469-493X			COCHRANE DB SYST REV	Cochrane Database Syst Rev.		2006		2							CD003559	10.1002/14651858.CD003559.pub3		94	Medicine, General & Internal	General & Internal Medicine	034MC	WOS:000236932100113		
J	Sathe, SK; Teuber, SS; Roux, KH				Sathe, SK; Teuber, SS; Roux, KH			Effects of food processing on the stability of food allergens	BIOTECHNOLOGY ADVANCES			English	Review						food allergy; processing; stability; epitope	DOUBLE-BLIND; PROTEINS; CHALLENGE; FISH; KIWI; NUT	The ubiquitous presence of allergens in the human food supply coupled with increased awareness of food allergies warrants undertaking appropriate preventive measures to protect sensitive consumers from unwanted exposure to offending food allergens. Attempts to reduce or eliminate food allergenicity through food processing have met with mixed results. The rationale for using food processing to reduce/eliminate allergenicity and limitations to using this approach are discussed. (C) 2005 Elsevier Inc. All rights reserved.	Florida State Univ, Coll Human Sci, Dept Nutr Food & Exercise Sci, Tallahassee, FL 32306 USA; Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Genome & Biomed Sci Facil, Davis, CA 95616 USA; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA	Sathe, SK (reprint author), Florida State Univ, Coll Human Sci, Dept Nutr Food & Exercise Sci, 402 Sandels Bldg, Tallahassee, FL 32306 USA.	ssathe@mailer.fsu.edu					Aleman A, 2004, J ALLERGY CLIN IMMUN, V113, P543, DOI 10.1016/j.jaci.2003.11.043; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V90, P622, DOI 10.1016/0091-6749(92)90135-O; Brenna O, 2000, J AGR FOOD CHEM, V48, P493, DOI 10.1021/jf9906681; DAUSSANT J, 1976, J AGR FOOD CHEM, V24, P103, DOI 10.1021/jf60203a029; Dube M, 2004, J AGR FOOD CHEM, V52, P3938, DOI 10.1021/jf030792r; EHN BM, 2004, J AGR FOOD CHEM, V52, P398; Fiocchi A, 2004, PEDIATR ALLERGY IMMU, V15, P454, DOI 10.1111/j.1399-3038.2004.00186.x; Gruber P, 2004, J AGR FOOD CHEM, V52, P4002, DOI 10.1021/jf035458+; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; HEFLE SL, 2005, J ALLERGY CLIN IMMUN, V115, pS32, DOI 10.1016/j.jaci.2004.12.143; Leduc V, 2003, J ALLERGY CLIN IMMUN, V111, P897, DOI 10.1067/mai.2003.1345; Malanin K, 1995, ALLERGY, V50, P988, DOI 10.1111/j.1398-9995.1995.tb02513.x; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Sanchez C, 2003, REV FR ALLERGOL, V43, P13, DOI 10.1016/S0335-7457(02)00003-5; Sen M, 2002, J IMMUNOL, V169, P882; SPIES JR, 1974, J AGR FOOD CHEM, V22, P30, DOI 10.1021/jf60191a005; Su M, 2004, J SCI FOOD AGR, V84, P1119, DOI 10.1002/jsfa.1748; Taylor SL, 2004, J FOOD SCI, V69, pR175; Varjonen E, 1996, CLIN EXP ALLERGY, V26, P436, DOI 10.1046/j.1365-2222.1996.d01-328.x	19	88	98	2	28	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0734-9750			BIOTECHNOL ADV	Biotechnol. Adv.	SEP	2005	23	6					423	429		10.1016/j.biotechadv.2005.05.008		7	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	954PS	WOS:000231167600005	15978770	
J	Meyers, DA; Postma, DS; Stine, OC; Koppelman, GH; Ampleford, EJ; Jongepier, H; Howard, TD; Bleecker, ER				Meyers, DA; Postma, DS; Stine, OC; Koppelman, GH; Ampleford, EJ; Jongepier, H; Howard, TD; Bleecker, ER			Genome screen for asthma and bronchial hyperresponsiveness: Interactions with passive smoke exposure	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						smoking; bronchial hyperresponsiveness; asthma; lung function; linkage; genome-wide sereen	ENVIRONMENTAL TOBACCO-SMOKE; WIDE SEARCH; RESPIRATORY SYMPTOMS; CHROMOSOME 5Q31-Q33; SUSCEPTIBILITY LOCI; FOUNDER POPULATION; LINKAGE ANALYSIS; LUNG-FUNCTION; SERUM IGE; GENE	Background: Asthma is a common respiratory disease caused by the interaction of genetic susceptibility and exposure to various environmental factors. Passive smoke exposure, characterized by parental smoking, has been shown to be a risk factor for the development of atopy and asthma. Objective: We sought to perform a genome-wide linkage screen for asthma and bronchial hyperresponsiveness (BHR) and to determine the influence of passive tobacco smoke exposure during childhood on the results of genetic linkage studies to investigate gene-environment interactions. Methods: A genome-wide linkage screen for asthma and BHR was performed in 200 families ascertained through a parent with asthma. Analyses were performed separately for the entire sample and for the smoking-exposed and nonexposed families. Results: For asthma and BHR, the strongest evidence for linkage was observed for chromosomes 3p and 5q. The families in which the children were exposed to passive smoking accounted for the evidence for linkage of BHR to 5q (P < .001), but evidence for linkage to 3p was found in both sets of families. Similar results were observed for asthma. However, there was no observed difference in the frequency of asthma or BHR in the offspring from the smoke-exposed compared with the nonexposed families. Conclusion: The results from this study demonstrate that the influence of susceptibility genes for a common disease such as asthma might not be apparent unless there is the appropriate exposure to environmental stimuli, such as passive exposure to cigarette smoke. This approach should be useful for identification of asthma susceptibility genes.	Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat, Winston Salem, NC 27157 USA; Wake Forest Univ, Sch Med, Dept Med, Winston Salem, NC USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Winston Salem, NC USA; Univ Hosp, Dept Pulmonol, Groningen, Netherlands; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA	Meyers, DA (reprint author), Wake Forest Univ, Sch Med, Ctr Human Genom, Dept Pediat, Med Ctr Blvd, Winston Salem, NC 27157 USA.	dmeyers@wfubmc.edu	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	NHLBI NIH HHS [R01 HL 48341, R01 HL 66393]		BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; Carey VJ, 1996, AM J RESP CRIT CARE, V153, P356; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; DEVRIES K, 1962, INT ARCH ALLERGY, V20, P63; Dizier MH, 2000, AM J RESP CRIT CARE, V162, P1812; Ehrlich F, 1906, BIOCHEM Z, V1, P8; Gilliland FD, 2003, AM J EPIDEMIOL, V157, P861, DOI 10.1093/aje/kwg037; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Hakonarson H, 2002, AM J HUM GENET, V71, P483, DOI 10.1086/342205; HIRSCHHORN JN, 2005, J CLIN ENDOCR METAB, V87, P4438; Howard TD, 2002, J ALLERGY CLIN IMMUN, V110, P743, DOI 10.1067/mai.2002.128723; Howard TD, 2001, AM J RESP CELL MOL, V25, P377; Howard TD, 2002, AM J HUM GENET, V70, P230, DOI 10.1086/338242; Koppelman GH, 2001, AM J RESP CRIT CARE, V163, P965; Kruglyak L, 1996, AM J HUM GENET, V58, P1347; LAITINEN T, 2001, NAT GENET, V28, P89; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Lux AL, 2000, ARCH DIS CHILD, V83, P307, DOI 10.1136/adc.83.4.307; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Martinez FD, 1998, AM J RESP CRIT CARE, V158, P1739; MARTINEZ FD, 1992, PEDIATRICS, V89, P21; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MORTON NE, 1956, AM J HUM GENET, V8, P80; Noguchi E, 1997, AM J RESP CRIT CARE, V156, P1390; Ober C, 2000, AM J HUM GENET, V67, P1154, DOI 10.1016/S0002-9297(07)62946-2; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Panhuysen CIM, 1998, AM J RESP CRIT CARE, V157, P1734; PEAT JK, 1993, EUR RESPIR J, V6, P662; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; VANDERLENDE R, 1972, SCAND J RESPIR DIS, V53, P218; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033; XU J, 2001, AM J HUM GENET, V69, P1271; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589; Xu JF, 2000, AM J HUM GENET, V67, P1163, DOI 10.1086/321190; Yokouchi Y, 2000, GENOMICS, V66, P152, DOI 10.1006/geno.2000.6201; Young S, 2000, PEDIATR PULM, V29, P331, DOI 10.1002/(SICI)1099-0496(200005)29:5<331::AID-PPUL1>3.0.CO;2-A	39	88	91	1	1	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2005	115	6					1169	1175		10.1016/j.jaci.2005.01.070		7	Allergy; Immunology	Allergy; Immunology	935WZ	WOS:000229815400010	15940130	
J	Sugimoto, T; Ishikawa, Y; Yoshimoto, T; Hayashi, N; Fujimoto, J; Nakanishi, K				Sugimoto, T; Ishikawa, Y; Yoshimoto, T; Hayashi, N; Fujimoto, J; Nakanishi, K			Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse	JOURNAL OF EXPERIMENTAL MEDICINE			English	Article						IL-9; IL-13; IL-18; Th1; bronchial asthma	ALLERGEN-SPECIFIC TH1; IFN-GAMMA PRODUCTION; MAST-CELL; BRONCHIAL HYPERRESPONSIVENESS; MONOCLONAL-ANTIBODY; EPITHELIAL-CELLS; IL-18 RECEPTOR; MURINE MODEL; ASTHMA; EXPRESSION	Interleukin (IL)-18 was originally regarded to induce T helper cell (Th)1-related cytokines. In general, factors favoring interferon (IFN)-gamma production are believed to abolish allergic diseases. Thus, we tested the role of IL-18 in regulation of bronchial asthma. To avoid a background response of host-derived T cells, we administered memory type Th1 or Th2 cells into unsensitized mice and examined their role in induction of bronchial asthma. Administration of antigen (Ag) induced both air-way inflammation and airway hyperresponsiveness (AHR) in mice receiving memory Th2 cells. In contrast, the same treatment induced only airway inflammation but not AHR in mice receiving memory Th1 cells. However, these mice developed striking AHR when they were coadministered with IL-18. Furthermore, mice having received IFN-gamma-expressing Th1 cells sorted from polarized Th1 cells developed severe airway inflammation and AHR after intranasal administration of Ag and IL-18. Thus, Th1 cells become harmful when they are stimulated with Ag and IL-18. Newly polarized Th1 cells and IFN-gamma-expressing Th1 cells, both of which express IL-18 receptor alpha chain strongly, produce IFN-gamma, IL-9, IL-13, granulocyte/macrophage colony-stimulating factor, tumor necrosis factor alpha, regulated on activation, normal T cell expressed and secreted, and macrophage inflammatory protein 1alpha upon stimulation with Ag, IL-2, and IL-18 in vitro. Thus, Ag and IL-18 stimulate memory Th1 cells to induce severe airway inflammation and AHR in the naive host.	Hyogo Med Univ, Dept Immunol & Med Zool, Nishinomiya, Hyogo 6638501, Japan; Hyogo Med Univ, Dept Surg, Nishinomiya, Hyogo 6638501, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawagoe, Saitama 3320012, Japan	Nakanishi, K (reprint author), Hyogo Med Univ, Dept Immunol & Med Zool, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.	nakaken@hyo-med.ac.jp					Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; ASANO Y, 1985, J EXP MED, V162, P413, DOI 10.1084/jem.162.2.413; Barnes PJ, 1999, NATURE, V402, pB31; BOCHNER BS, 1994, ANNU REV IMMUNOL, V12, P295; Busse WW, 2001, NEW ENGL J MED, V344, P350; Cameron LA, 1999, EUR RESPIR J, V14, P553, DOI 10.1034/j.1399-3003.1999.14c12.x; Davies DE, 2003, J ALLERGY CLIN IMMUN, V111, P215, DOI 10.1067/mai.2003.128; Del Prete G, 1998, Int Rev Immunol, V16, P427, DOI 10.3109/08830189809043004; Elias JA, 2003, J CLIN INVEST, V111, P291, DOI 10.1172/JCI200317748; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; Ford JG, 2001, J IMMUNOL, V167, P1769; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hayashi N, 2002, P NATL ACAD SCI USA, V99, P6187, DOI 10.1073/pnas.092129899; Hoshino T, 1999, J IMMUNOL, V162, P5070; Huang TJ, 2001, J IMMUNOL, V166, P207; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; Hyodo Y, 1999, J IMMUNOL, V162, P1662; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kohno K, 1997, J IMMUNOL, V158, P1541; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; Li L, 1998, J IMMUNOL, V161, P3128; Louahed J, 2000, AM J RESP CELL MOL, V22, P649; Luster AD, 1998, NEW ENGL J MED, V338, P436; McKenzie GJ, 1998, CURR BIOL, V8, P339, DOI 10.1016/S0960-9822(98)70134-4; MOSMANN TR, 1986, P NATL ACAD SCI USA, V83, P5654, DOI 10.1073/pnas.83.15.5654; Murphy S A, 1990, Holist Nurs Pract, V4, P1; Nakanishi K, 2001, ANNU REV IMMUNOL, V19, P423, DOI 10.1146/annurev.immunol.19.1.423; Okamura H, 1998, ADV IMMUNOL, V70, P281, DOI 10.1016/S0065-2776(08)60389-2; OKAMURA H, 1995, NATURE, V378, P88, DOI 10.1038/378088a0; Pizarro TT, 1999, J IMMUNOL, V162, P6829; Randolph DA, 1999, J CLIN INVEST, V104, P1021, DOI 10.1172/JCI7631; Randolph DA, 1999, J IMMUNOL, V162, P2375; Ray A, 1999, J CLIN INVEST, V104, P985, DOI 10.1172/JCI8204; Renauld JC, 2001, J CLIN PATHOL, V54, P577, DOI 10.1136/jcp.54.8.577; Ritz SA, 2002, TRENDS IMMUNOL, V23, P396, DOI 10.1016/S1471-4906(02)02278-0; SEDER RA, 1994, ANNU REV IMMUNOL, V12, P635, DOI 10.1146/annurev.immunol.12.1.635; Sugawara S, 2001, J IMMUNOL, V167, P6568; Takaoka A, 2001, J IMMUNOL, V167, P2349; Takeuchi M, 1997, CELL TISSUE RES, V289, P499, DOI 10.1007/s004410050895; TAMURA T, 1992, J IMMUNOL, V148, P2370; Temann UA, 1998, J EXP MED, V188, P1307, DOI 10.1084/jem.188.7.1307; Tominaga K, 2000, INT IMMUNOL, V12, P151, DOI 10.1093/intimm/12.2.151; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; Urban JF, 1998, IMMUNITY, V8, P255, DOI 10.1016/S1074-7613(00)80477-X; Vermeer PD, 2003, AM J RESP CELL MOL, V28, P286, DOI 10.1165/rcmb.4887; Wild JS, 2000, J IMMUNOL, V164, P2701; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yoshimoto T, 1999, P NATL ACAD SCI USA, V96, P13962, DOI 10.1073/pnas.96.24.13962; Yoshimoto T, 2000, NAT IMMUNOL, V1, P132, DOI 10.1038/77811; Yoshimoto T, 2003, J EXP MED, V197, P997, DOI 10.1084/jem.20021701; Yoshimoto T, 1998, J IMMUNOL, V161, P3400; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3	60	88	94	0	0	ROCKEFELLER UNIV PRESS	NEW YORK	1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA	0022-1007			J EXP MED	J. Exp. Med.	FEB 16	2004	199	4					535	545		10.1084/jem.20031368		11	Immunology; Medicine, Research & Experimental	Immunology; Research & Experimental Medicine	777NZ	WOS:000189185600010	14970180	
J	Burge, PS				Burge, PS			Sick building syndrome	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							INDOOR AIR-QUALITY; DIFFERENT VENTILATION SYSTEMS; 2 OFFICE BUILDINGS; OCCUPATIONAL ASTHMA; SYNDROME SBS; PERSONAL FACTORS; SKIN SYMPTOMS; CASE-REFERENT; RISK-FACTORS; WORKERS		Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Birmingham B9 5SS, W Midlands, England	Burge, PS (reprint author), Birmingham Heartlands Hosp, Occupat Lung Dis Unit, Bordesley Green E, Birmingham B9 5SS, W Midlands, England.	sherwood.burge@heartsol.wmids.nhs.uk					ANDERSEN I, 1973, ARCH ENVIRON HEALTH, V26, P22; BERGLUND B, 2002, ARCH CTR SENSORY RES, V7, P83; BLASCO A, 1992, J INVEST ALLERG CLIN, V2, P167; Brasche S, 2001, INDOOR AIR, V11, P217, DOI 10.1034/j.1600-0668.2001.110402.x; Brasche S, 2001, INT J HYG ENVIR HEAL, V203, P311, DOI 10.1078/1438-4639-00042; BURGE PS, 1994, THORAX, V49, P842, DOI 10.1136/thx.49.8.842; BURGE PS, 1993, INDOOR AIR 93, P731; Burge PS, 1990, INDOOR AIR 90, V1, P479; BURGE PS, 1990, P 5 INT C IND AIR QU, V1, P575; BURGE S, 1987, ANN OCCUP HYG, V31, P493, DOI 10.1093/annhyg/31.4A.493; CARMICHAEL AJ, 1992, CONTACT DERMATITIS, V26, P63, DOI 10.1111/j.1600-0536.1992.tb00881.x; CLARK EG, 1987, J SOC OCCUP MED, V37, P30; Costa MDB, 2000, ARCH ENVIRON HEALTH, V55, P279; Curran AD, 1996, ALLERGY, V51, P826; DESCHAMPS D, 1994, CHEST, V105, P1895, DOI 10.1378/chest.105.6.1895; FANGER PO, 1988, ENERG BUILDINGS, V12, P7, DOI 10.1016/0378-7788(88)90052-7; FANGER PO, 1988, ENERG BUILDINGS, V12, P1, DOI 10.1016/0378-7788(88)90051-5; FINNEGAN MJ, 1984, BRIT MED J, V289, P1573; FLETCHER AM, 1990, THORAX, V46, P313; FRANCK C, 1986, ACTA OPHTHALMOL, V64, P306; FRANCK C, 1989, ACTA OPHTHALMOL, V67, P61; Franck C, 1991, INDOOR AIR, V1, P5, DOI 10.1111/j.1600-0668.1991.01-11.x; GANNON PFG, 1995, THORAX, V50, P156, DOI 10.1136/thx.50.2.156; GUBERAN E, 1978, SCHWEIZ MED WSCHR, V108, P827; GYNTELBERG F, 1994, INDOOR AIR, V4, P223, DOI 10.1111/j.1600-0668.1994.00003.x; Harrison J., 1987, INDOOR AIR 87, V2, P487; HEDGE A, 1989, ENVIRON INT, V15, P143, DOI 10.1016/0160-4120(89)90020-2; HEDGE A, 1989, ENVIRON INT, V15, P115, DOI 10.1016/0160-4120(89)90017-2; HEDGE A, 1993, INDOOR AIR 93, P517; HEDGE A, 1993, INDOOR AIR 93, P383; HEDGE A, 1993, INDOOR AIR 93, P345; HEDGE A, 1993, INDOOR AIR, V3, P328, DOI 10.1111/j.1600-0668.1993.00016.x; JAAKKOLA JJK, 1995, OCCUP ENVIRON MED, V52, P709; JAAKKOLA JJK, 1989, ENVIRON INT, V15, P163, DOI 10.1016/0160-4120(89)90022-6; Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223; LEINSTER P, 1990, INDOOR AIR 90, V1, P287; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P68; MENDELL MJ, 1990, AM J PUBLIC HEALTH, V80, P1193, DOI 10.2105/AJPH.80.10.1193; Mendell MJ, 2002, EPIDEMIOLOGY, V13, P296, DOI 10.1097/00001648-200205000-00010; Menzies D, 1997, ARCH ENVIRON HEALTH, V52, P360; MENZIES RI, 1990, INDOOR AIR 90, V1, P519; MIKATAVAGE MA, 1995, AM IND HYG ASSOC J, V56, P1141; Mizoue T, 2001, AM J EPIDEMIOL, V154, P803, DOI 10.1093/aje/154.9.803; MUSTCHIN CP, 1979, THORAX, V34, P682, DOI 10.1136/thx.34.5.682; Muzi G, 1998, AM J IND MED, V34, P79, DOI 10.1002/(SICI)1097-0274(199807)34:1<79::AID-AJIM11>3.0.CO;2-1; Nagorka R, 1990, Offentl Gesundheitswes, V52, P168; Niven RM, 2000, OCCUP ENVIRON MED, V57, P627, DOI 10.1136/oem.57.9.627; NORBACK D, 1988, AM IND HYG ASSOC J, V49, P117; NORDSTROM K, 1995, OCCUP ENVIRON MED, V52, P170; NORDSTROM K, 1995, INDOOR ENVIRON, V4, P37, DOI 10.1177/1420326X9500400105; Ooi PL, 1998, OCCUP ENVIRON MED, V55, P188; Pan ZW, 2000, INDOOR AIR, V10, P237, DOI 10.1034/j.1600-0668.2000.010004237.x; PRELLER L, 1990, DIRECTORAAT GEN ARBE, V83, P1; RAW GJ, 1990, P 5 INT C IND AIR QU, V1, P231; RAYNAL A, 1995, INDOOR AIR, V5, P22, DOI 10.1111/j.1600-0668.1995.t01-3-00004.x; RAYNAL A, 1993, INDOOR AIR 93, P639; REINIKAINEN LM, 1990, INDOOR AIR 90, V1, P775; ROBERTSON AS, 1985, BRIT MED J, V291, P373; ROBERTSON AS, 1990, INDOOR AIR 90, V1, P237; ROBERTSON AS, 1988, INDOOR AMBIENT AIR Q, P320; ROSSKAMP E, 1990, BUNDESGESUNDHBL, V3, P117; RYCROFT RJG, 1985, AM J IND MED, V8, P371, DOI 10.1002/ajim.4700080417; Seppanen OA, 1999, INDOOR AIR, V9, P226, DOI 10.1111/j.1600-0668.1999.00003.x; SKOV P, 1987, ENVIRON INT, V13, P339, DOI 10.1016/0160-4120(87)90190-5; SKOV P, 1989, SCAND J WORK ENV HEA, V15, P286; STENBERG B, 1994, INT J EPIDEMIOL, V23, P1190, DOI 10.1093/ije/23.6.1190; STENBERG B, 1993, INDOOR AIR 93, P399; STENBERG B, 1990, INDOOR AIR 90, V4, P627; SUNDELL J, 1994, ENVIRON INT, V20, P239, DOI 10.1016/0160-4120(94)90141-4; SUNDELL J, 1994, INDOOR AIR, V4, P83, DOI 10.1111/j.1600-0668.1994.t01-2-00003.x; TAW GJ, 1995, 695 TCR BUILD RES ES; TECELESCU DB, 1998, INT ARCH OCC ENV HEA, V71, P353; Thickett KM, 2002, EUR RESPIR J, V19, P827, DOI 10.1183/09031936.02.00232802; WACLAWSKI ER, 1989, BRIT MED J, V298, P929; Wargocki P, 2000, INDOOR AIR, V10, P222, DOI 10.1034/j.1600-0668.2000.010004222.x; Wessen B, 1996, ANALYST, V121, P1203, DOI 10.1039/an9962101203; *WHO, 1990, EUR SER, V3, P1; Zweers T, 1992, INDOOR AIR, V2, P127, DOI 10.1111/j.1600-0668.1992.00001.x	78	88	92	0	21	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	FEB 1	2004	61	2					185	190		10.1136/oem.2003.008813		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	766DJ	WOS:000188329900018	14739390	
J	Fung, F; Clark, RF				Fung, F; Clark, RF			Health effects of mycotoxins: A toxicological overview	JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY			English	Review						mycotoxins; toxicological; gastrointestinal; fungi; mycotoxicosis; indoor; agricultural	VOLATILE ORGANIC MIXTURE; STACHYBOTRYS-CHARTARUM; PULMONARY HEMORRHAGE; OCHRATOXIN-A; T-2 TOXIN; TRICHOTHECENE MYCOTOXINS; ESOPHAGEAL CANCER; FUNGAL TOXINS; CELL-LINES; EXPOSURE	Diseases caused by fungi are spread by direct implantation or inhalation of spores. Fungi can cause adverse human health effects to many organ systems. In addition to infection and allergy, fungi can produce mycotoxins and organic chemicals that are responsible for various toxicologic effects. We reviewed the published literature on important mycotoxins and systemic effects of mycotoxins. Scientific literature revealed a linkage between ingesting mycotoxin contaminated food and illness, especially hepatic, gastrointestinal, and carcinogenic diseases. Issues related to mycotoxin exposure, specific diseases, and management are discussed. Although there is agreement that diet is the main source of mycotoxin exposure, specific health effects and risk assessment from indoor nonagricultural exposure are limited by the paucity of scientific evidence currently available. Further research on the health effects of inhaling mycotoxins in indoor settings is needed.	Univ Calif San Diego, Sharp Rees Stealy Med Grp, San Diego, CA 92101 USA; Univ Calif San Diego, Div Med Toxicol, San Diego, CA 92101 USA	Fung, F (reprint author), Univ Calif San Diego, Sharp Rees Stealy Med Grp, 2001 4th Ave, San Diego, CA 92101 USA.	fred.fung@sharp.com					Baldo Juliana V, 2002, Appl Neuropsychol, V9, P193, DOI 10.1207/S15324826AN0904_1; BAREL S, 1990, J PHARM SCI, V79, P548, DOI 10.1002/jps.2600790619; BEASLEY VR, 1986, TOXICON, V24, P13, DOI 10.1016/0041-0101(86)90161-3; BERGMANN F, 1988, TOXICON, V26, P923, DOI 10.1016/0041-0101(88)90257-7; Bhat RV, 1997, J TOXICOL-CLIN TOXIC, V35, P249; Bondy GS, 2000, J TOXICOL ENV HEAL B, V3, P109, DOI 10.1080/109374000281113; Breton P, 1998, TOXICON, V36, P645, DOI 10.1016/S0041-0101(97)00084-6; Broussard Crystal N., 2001, American Journal of Gastroenterology, V96, P3195, DOI 10.1016/S0002-9270(01)03845-X; CASTEGNARO M, 1991, IARC SCI PUBL, V113, P9; CHANG FC, 1977, FOOD COSMET TOXICOL, V15, P199, DOI 10.1016/S0015-6264(77)80390-8; CHAO TC, 1991, J PATHOL, V164, P225, DOI 10.1002/path.1711640307; Chapman JA, 2003, ALLERGY ASTHMA PROC, V24, P1; Chu F S, 1974, CRC Crit Rev Toxicol, V2, P499; CHU FS, 1994, APPL ENVIRON MICROB, V60, P847; CHU FS, 1992, J ANIM SCI, V70, P3950; CORRIER DE, 1991, VET IMMUNOL IMMUNOP, V30, P73, DOI 10.1016/0165-2427(91)90010-A; CREPPY EE, 1984, FOOD CHEM TOXICOL, V22, P883, DOI 10.1016/0278-6915(84)90170-4; CROFT WA, 1986, ATMOS ENVIRON, V20, P549, DOI 10.1016/0004-6981(86)90096-X; Dales R, 1998, ARCH ENVIRON HEALTH, V53, P190; Dalton P, 2003, TOXICOL LETT, V140, P239, DOI 10.1016/S0378-4274(02)00510-6; Dees C, 1997, ENVIRON HEALTH PERSP, V105, P633, DOI 10.2307/3433382; DENNING DW, 1987, ADVERSE DRUG REACT T, V6, P175; DIPAOLO N, 1993, NEPHRON, V64, P621, DOI 10.1159/000187411; Domijan Ana-Marija, 1999, Arhiv za Higijenu Rada i Toksikologiju, V50, P263; Drobotko V. G., 1945, AMER REV SOVIET MED, V2, P238; DVRORACKOVA I, 1977, ANN NUTR ALIMENT, V31, P977; DVRORACKOVA I, 1976, BRIT MED J, V1, P691; EICHNER RD, 1984, AUST J EXP BIOL MED, V62, P479, DOI 10.1038/icb.1984.45; Elidemir O, 1999, PEDIATRICS, V104, P964, DOI 10.1542/peds.104.4.964; EMANUEL DA, 1975, CHEST, V67, P293, DOI 10.1378/chest.67.3.293; *FAO UN WHO, 2001, JOINT FAO WHO EXP CO; *FDA, 1999, FDA CFSAN FOOD COMPL; *FDA OFF PLANT DAI, 2000, APPL JUIC CONC APPL; Fischer G, 2002, INT J HYG ENVIR HEAL, V205, P433, DOI 10.1078/1438-4639-00190; Flappan SM, 1999, ENVIRON HEALTH PERSP, V107, P927; FORGACS J, 1966, SCIENCE, V152, P1634, DOI 10.1126/science.152.3729.1634; FRANK HK, 1992, Z ERNAHRUNGSWISS, V31, P164, DOI 10.1007/BF01611139; FUKUI Y, 1987, FOOD CHEM TOXICOL, V25, P17, DOI 10.1016/0278-6915(87)90302-4; Fung F, 1998, J TOXICOL-CLIN TOXIC, V36, P79; Fung Frederick, 2003, Appl Occup Environ Hyg, V18, P535, DOI 10.1080/10473220301451; GIAMBRONE JJ, 1978, AM J VET RES, V39, P305; GILBERT J, 1993, FOOD ADDIT CONTAM, V10, P37; GREATOREX JC, 1974, J REPROD FERTIL, V37, P33; Guyatt GH, 2000, JAMA-J AM MED ASSOC, V284, P1290, DOI 10.1001/jama.284.10.1290; HADIDANE R, 1985, HUM TOXICOL, V4, P491; HARDIN BD, 2002, ACOEM EVIDENCE BASED; HAYES RB, 1984, FOOD CHEM TOXICOL, V22, P39, DOI 10.1016/0278-6915(84)90050-4; Hodgson MJ, 1998, J OCCUP ENVIRON MED, V40, P241, DOI 10.1097/00043764-199803000-00006; HSIEH DPH, 1982, ADV EXP MED BIOL, V136, P847; HUDNELL HK, 1992, ARCH ENVIRON HEALTH, V47, P31; Hussain SP, 2000, MUTAT RES-REV MUTAT, V462, P311, DOI 10.1016/S1383-5742(00)00015-6; *INT AG RES CANC, 1984, IARC MON EV CARC RIS, V40, P83; JELINEK CF, 1989, J ASSOC OFF ANA CHEM, V72, P223; JOHANNING E, 1996, INT ARCH OCC ENV HEA, V68, P206; Juranic Z, 1998, J EXP CLIN CANC RES, V17, P33; KELLERMAN TS, 1990, ONDERSTEPOORT J VET, V57, P269; KEMPPAINEN BW, 1984, FOOD CHEM TOXICOL, V22, P893, DOI 10.1016/0278-6915(84)90172-8; Kendrick B., 1992, 5 KINGDOM, P316; KENDRICK B, 1992, 5 KINGDOM, P1; KHACHATOURIANS GG, 1990, CAN J PHYSIOL PHARM, V68, P1004; Knapp JF, 1999, PEDIATR EMERG CARE, V15, P288; KORPINEN EL, 1972, NORD VET MED, V24, P62; KROGH P, 1974, Acta Pathologica et Microbiologica Scandinavica Supplementum, V246, P1; Kuhn DM, 2003, CLIN MICROBIOL REV, V16, P144, DOI 10.1128/CMR.16.1.144-172.2003; Kuiper-Goodman T, 1989, Biomed Environ Sci, V2, P179; KUMAGAI S, 1988, FOOD CHEM TOXICOL, V26, P753, DOI 10.1016/0278-6915(88)90210-4; LACEY J, 1987, ANN OCCUP HYG, V31, P1, DOI 10.1093/annhyg/31.1.1; LAFARGEFRAYSSINET C, 1981, MUTAT RES, V88, P115, DOI 10.1016/0165-1218(81)90010-0; LESHALEY PR, IN PRESS SCI REV MEN; Liu X, 1992, Biomed Environ Sci, V5, P161; LUDOLPH AC, 1991, CAN J NEUROL SCI, V18, P492; MADHYASTHA MS, 1994, TOXICON, V32, P1147, DOI 10.1016/0041-0101(94)90398-0; MALMBERG P, 1993, CHEST, V103, P1202, DOI 10.1378/chest.103.4.1202; MANGLE PG, 1971, J REPROD FERTIL, V24, P441; MANTLE PG, 1969, J REPROD FERTIL, V18, P81; MCCLUSKY OE, 2002, 1I02 CSA TX MED ASS; MCPARTLAND JM, 1997, AM FAM PHYSICIAN, V55, P791; MILLER RV, 2001, MYCOTOXIN PHYTOTOXIN, P123; MONATANA E, 1997, PEDIATRICS, V99, P117; Nam KS, 2001, LIFE SCI, V69, P229, DOI 10.1016/S0024-3205(01)01125-0; Nikulin M, 1997, FUND APPL TOXICOL, V35, P182, DOI 10.1006/faat.1996.2274; Novotny WE, 2000, ARCH PEDIAT ADOL MED, V154, P271; OLSEN JH, 1988, BRIT J CANCER, V58, P392, DOI 10.1038/bjc.1988.226; OMAR RF, 1991, J BIOCHEM TOXICOL, V6, P203, DOI 10.1002/jbt.2570060306; OTTO DA, 1992, ARCH ENVIRON HEALTH, V47, P23; PATTEN RC, 1981, AM J TROP MED HYG, V30, P422; Peraica M, 1999, B WORLD HEALTH ORGAN, V77, P754; PESTKA JJ, 1988, J ASSOC OFF ANA CHEM, V71, P1075; PIER AC, 1980, J AM VET MED ASSOC, V176, P719; Pohland A E, 2001, Methods Mol Biol, V157, P3; POHLAND AE, 1993, FOOD ADDIT CONTAM, V10, P17; RAO BL, 1985, MYCOPATHOLOGIA, V89, P177, DOI 10.1007/BF00447028; Rao CY, 2000, MYCOPATHOLOGIA, V149, P27, DOI 10.1023/A:1007239017018; RILEY RT, 1985, J TOXICOL ENV HEALTH, V15, P769; ROOD HD, 1986, J CHROMATOGR, V378, P375, DOI 10.1016/S0378-4347(00)80733-1; *RTECS, 1996, YD0100000 RTECS NAT; RYAN NJ, 1979, PEDIATRICS, V64, P71; SELIM MI, 1997, AIHA J-J SCI OCCUP E, V59, P252; Smela ME, 2001, CARCINOGENESIS, V22, P535, DOI 10.1093/carcin/22.4.535; SMITH RD, 1985, J CHROMATOGR SCI, V23, P192; SOBOTKA TJ, 1978, PHARMACOLOGY, V16, P287, DOI 10.1159/000136781; SOLOMON WR, 1993, ALLERGY PRINCIPLES P, P469; SORENSON WG, 1987, APPL ENVIRON MICROB, V53, P1470; STOLOFF L, 1991, FOOD ADDIT CONTAM, V8, P213; Sudakin DL, 2003, TOXICOL LETT, V143, P97, DOI 10.1016/S0378-4274(03)00116-4; THIEL PG, 1992, MYCOPATHOLOGIA, V117, P3, DOI 10.1007/BF00497272; Tripi PA, 2000, PAEDIATR ANAESTH, V10, P92, DOI 10.1046/j.1460-9592.2000.00452.x; Trout D, 2001, ENVIRON HEALTH PERSP, V109, P641, DOI 10.2307/3455040; UENO Y, 1977, ANN NUTR ALIMENT, V31, P885; UENO Y, 1985, CRC CR REV TOXICOL, V14, P99, DOI 10.3109/10408448509089851; *US ARM MED RES I, 2001, USAMRIIDS MED MAN BI; Verardi Giuseppe, 1995, Natural Toxins, V3, P337, DOI 10.1002/nt.2620030433; Wang JS, 1999, MUTAT RES-FUND MOL M, V424, P167, DOI 10.1016/S0027-5107(99)00017-2; WEAVER GA, 1978, VET REC, V103, P531; WENTZEL CA, 1992, MYCOPATHOLOGIA, V117, P11; WHO, 1990, WHO ENV HLTH CRIT; Wilkins CK, 1998, PHARMACOL TOXICOL, V83, P112; WILKINSON AP, 1988, FOOD ADDIT CONTAM A, V5, P609; WILLIAMS SR, 2004, MED TOXICOLOGY, pCH102; WILLIS RM, 1980, LANCET, V1, P1198; Withanage GSK, 2001, VET HUM TOXICOL, V43, P6; WOGAN GN, 1992, PROG CLIN BIOL RES, V374, P123; YOSHIZAWA T, 1994, APPL ENVIRON MICROB, V60, P1626; YOSHIZAWA T, 1985, APPL ENVIRON MICROB, V50, P67; Yu MC, 2000, CAN J GASTROENTEROL, V14, P703; Zavaleta EG, 2001, ANGIOLOGY, V52, P349, DOI 10.1177/000331970105200509; 1997, MORB MORT WKLY REP, V46, P33; 2000, MORB MORT WKLY REP, V49, P180	128	88	100	4	26	MARCEL DEKKER INC	NEW YORK	270 MADISON AVE, NEW YORK, NY 10016 USA	0731-3810			J TOXICOL-CLIN TOXIC	J. Toxicol.-Clin. Toxicol.		2004	42	2					217	234		10.1081/CLT-120030947		18	Toxicology	Toxicology	828YM	WOS:000222009700014	15214629	
J	Woodruff, TJ; Parker, JD; Kyle, AD; Schoendorf, KC				Woodruff, TJ; Parker, JD; Kyle, AD; Schoendorf, KC			Disparities in exposure to air pollution during pregnancy	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; birth outcomes; criteria air pollutants; environmental justice	LOW-BIRTH-WEIGHT; EMERGENCY ROOM VISITS; NORTH-AMERICAN CHILDREN; UNITED-STATES; SOUTHERN CALIFORNIA; RESPIRATORY SYMPTOMS; INDUSTRIAL SOURCES; INFANT-MORTALITY; ACID AEROSOLS; ASTHMA	Previous research shows poorer birth outcomes for racial and ethnic minorities and for persons with low socioeconomic status (SES). We evaluated whether mothers in groups at higher risk for poor birth outcomes live in areas of higher air pollution and whether higher exposure to air pollution contributes to poor birth outcomes. An index representing long-term exposure to criteria air pollutants was matched with birth certificate data at the county level for the United States in 1998-1999. We used linear regression to estimate associations between the air pollution index and maternal race and educational attainment, a marker for SES of the mother, controlling for age, Parity, marital status, and region of the country. Then we used logistic regression models both to estimate likelihood of living in counties with the highest levels of air pollution for different racial groups and by educational attainment, adjusting for other maternal risk factors, and to estimate the effect of living in counties with higher levels of air pollution on preterm delivery and births small for gestational age (SGA). Hispanic, African-American, and Asian/Pacific Islander mothers experienced higher mean levels of air pollution and were more than twice as likely to live in the most polluted counties compared with white mothers after controlling for maternal risk factors, region, and educational status [Hispanic mothers: adjusted odds ratio (AOR) = 4.66; 95% confidence interval (95% CI), 1.92-11.32; African-American mothers: AOR = 2.58; 95% CI, 1.00-6.62; Asian/Pacific Islander mothers: AOR = 2.82; 95% CI, 1.07-7.39]. Educational attainment was not associated with living in counties with highest levels of the air pollution index (AOR = 0.95; 95% CI, 0.40-2.26) after adjusting for maternal risk factors, region of the country, and race/ethnicity. There was a small increase in the odds of preterm delivery (AOR = 1.05; 95% CI, 0.99-1.12) but not SGA (AOR = 0.96; 95% CI, 0.86-1-07) in a county with high air pollution. Additional risk of residing in areas with poor air, quality may exacerbate health problems of infants and children already at increased risk for poor health.	US EPA, Natl Ctr Environm Econ, San Francisco, CA 94105 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Infant & Child Hlth Studies Branch, Hyattsville, MD 20782 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA	Woodruff, TJ (reprint author), US EPA, Natl Ctr Environm Econ, 75 Hawthorne St,SPE-1, San Francisco, CA 94105 USA.		Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ANDERTON DL, 1994, DEMOGRAPHY, V31, P229, DOI 10.2307/2061884; Avol EL, 2001, AM J RESP CRIT CARE, V164, P2067; BATES DV, 1995, ENVIRON HEALTH PERSP, V103, P49, DOI 10.2307/3432345; Bobak M, 1999, OCCUP ENVIRON MED, V56, P539; Bobak M, 2000, ENVIRON HEALTH PERSP, V108, P173, DOI 10.2307/3454517; Bobak M, 2001, EPIDEMIOLOGY, V12, P358, DOI 10.1097/00001648-200105000-00018; Council of Economic Advisers for the President's Initiative on Race, 1998, CHANG AM IND SOC EC; Dejmek J, 1999, ENVIRON HEALTH PERSP, V107, P475, DOI 10.2307/3434630; DOCKERY DW, 1989, AM REV RESPIR DIS, V139, P587; Dockery DW, 1996, ENVIRON HEALTH PERSP, V104, P500, DOI 10.2307/3432990; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; *FED INT FOR CHILD, 2002, AM CHILDR KEY NAT IN; Ha EH, 2001, EPIDEMIOLOGY, V12, P643, DOI 10.1097/00001648-200111000-00011; Institute of Medicine, 1999, ENV JUST RES ED HLTH; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; Kramer MS, 2000, PAEDIATR PERINAT EP, V14, P194, DOI 10.1046/j.1365-3016.2000.00266.x; Kyle AD, 2002, ENVIRON HEALTH PERSP, V110, P95; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Loomis D, 1999, EPIDEMIOLOGY, V10, P118, DOI 10.1097/00001648-199903000-00006; Maisonet M, 2001, ENVIRON HEALTH PERSP, V109, P351, DOI 10.2307/3434782; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 1999, ENVIRON HEALTH PERSP, V107, P757, DOI 10.2307/3434662; *NAT CTR HLTH STAT, 2003, NAT DAT PUBL US DAT; National Center for Health Statistics, 2001, HLTH US 2001 URB RUR; Norris G, 1999, ENVIRON HEALTH PERSP, V107, P489, DOI 10.2307/3434632; Pamuk E., 1998, SOCIOECONOMIC STATUS; Perlin SA, 1999, J EXPO ANAL ENV EPID, V9, P29, DOI 10.1038/sj.jea.7500024; Perlin SA, 2001, J AIR WASTE MANAGE, V51, P406; PICKLE L, 1999, STAT MED, V18, P3221; Raizenne M, 1996, ENVIRON HEALTH PERSP, V104, P506, DOI 10.2307/3432991; Ritz B, 2000, EPIDEMIOLOGY, V11, P502, DOI 10.1097/00001648-200009000-00004; Ritz B, 1999, ENVIRON HEALTH PERSP, V107, P17, DOI 10.2307/3434285; Rogers JF, 2000, AM J EPIDEMIOL, V151, P602; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Samet J.M., 2000, NATL MORBIDITY MORTA; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1994, AM J RESP CRIT CARE, V150, P1234; *STAT CORP, 1999, STAT STAT SOFTW; Studnicka M, 1997, EUR RESPIR J, V10, P2275, DOI 10.1183/09031936.97.10102275; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; *US EPA, 2003, AM CHILD ENV MEAS CO; *US EPA, 2000, AER INF RETR SYST; Wang XB, 1997, ENVIRON HEALTH PERSP, V105, P514, DOI 10.1289/ehp.97105514; Woodruff TJ, 1997, ENVIRON HEALTH PERSP, V105, P608	44	88	88	0	10	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2003	111	7					942	+		10.1289/ehp.5317		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	689ND	WOS:000183498900033	12782496	
J	Halken, S; Host, A; Niklassen, U; Hansen, LG; Nielsen, F; Pedersen, S; Osterballe, O; Veggerby, C; Poulsen, LK				Halken, S; Host, A; Niklassen, U; Hansen, LG; Nielsen, F; Pedersen, S; Osterballe, O; Veggerby, C; Poulsen, LK			Effect of mattress and pillow encasings on children with asthma and house dust mite allergy	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						mattress encasing; house dust mite allergy; childhood asthma; inhaled steroids	CHILDHOOD ASTHMA; AIRBORNE ALLERGENS; AVOIDANCE MEASURES; EXPOSURE; SENSITIZATION; MANAGEMENT; ANTIGEN	Background: House dust mite (HDM) allergy is a frequent cause of allergic asthma in children. Reduction of exposure seems to be the most logical way to treat these patients. Objective: Our aim was to investigate whether mattress and pillow encasings resulted in an effective long-term control of HDM allergen levels, thereby reducing the need for asthma medication in children with asthma and HDM allergy. Methods: In a prospective, double-blind, placebo-controlled study 60 children (age range, 6-15 years) with asthma and HDM allergy were randomized to active (allergy control) or placebo mattress and pillow encasings. After a 2-week baseline period, follow-up was performed every 3 months for I year. During the entire study period, the dose of inhaled steroids was tapered off to the lowest effective dose according to well-defined criteria. Results: Fifty-two patients completed the trial, and 5 were excluded, leaving data from 47 children (26 in the active treatment group and 21 in the placebo group) for analysis. A significant perennial reduction in HDM allergen concentrations was seen only for the active treatment group. Also, a significant decrease in the dose of inhaled steroids (mean, 408 to 227 mug/d; P <.001) was found for the active treatment group only, with significant differences between groups after 9 and 12 months. After 1 year, the dose of inhaled steroids was reduced by at least 50% in significantly more children in the active treatment group than in the placebo group (73% vs 24%, P <.01). Conclusion: Encasing of mattresses and pillows resulted in a significant long-term reduction in HDM allergen concentrations in mattresses and in the need for inhaled steroids in children with asthma and HDM allergy.	Sonderborg Hosp, Dept Pediat, DK-6400 Sonderberg, Denmark; Lab Med Allergol, Copenhagen, Denmark; Viborg Hosp, Dept Pediat, Viborg, Denmark; Kolding Cty Hosp, Dept Pediat, Kolding, Denmark; Odense Univ Hosp, Dept Pediat, Odense, Denmark	Halken, S (reprint author), Sonderborg Hosp, Dept Pediat, DK-6400 Sonderberg, Denmark.						Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; Boulet LP, 1997, CLIN EXP ALLERGY, V27, P52, DOI 10.1046/j.1365-2222.1997.d01-418.x; Carswell F, 1999, CLIN EXP ALLERGY, V29, P193; Cloosterman SGM, 1999, CLIN EXP ALLERGY, V29, P1336, DOI 10.1046/j.1365-2222.1999.00627.x; Custovic A, 2000, CLIN REV ALLERG IMMU, V18, P397, DOI 10.1385/CRIAI:18:3:397; EHNERT B, 1992, J ALLERGY CLIN IMMUN, V90, P135, DOI 10.1016/S0091-6749(06)80024-2; Frederick JM, 1997, EUR RESPIR J, V10, P361, DOI 10.1183/09031936.97.10020361; Gotzsche PC, 1998, BRIT MED J, V317, P1105; Host A, 2000, ALLERGY, V55, P600, DOI 10.1034/j.1398-9995.2000.00122.x; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Jirapongsananuruk O, 2000, ANN ALLERG ASTHMA IM, V84, P305, DOI 10.1016/S1081-1206(10)62778-0; MATTHYS H, 1993, RESPIRATION, V60, P343; OWEN S, 1990, LANCET, V335, P396, DOI 10.1016/0140-6736(90)90219-U; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Shapiro GG, 1999, J ALLERGY CLIN IMMUN, V103, P1069, DOI 10.1016/S0091-6749(99)70181-8; Silvestri M, 1996, ANN ALLERG ASTHMA IM, V76, P239; SPORIK R, 1993, CLIN EXP ALLERGY, V23, P740, DOI 10.1111/j.1365-2222.1993.tb00361.x; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; Vanlaar CH, 2000, J ALLERGY CLIN IMMUN, V105, P1130, DOI 10.1067/mai.2000.106213; VERVLOET D, 1991, ALLERGY, V46, P554, DOI 10.1111/j.1398-9995.1991.tb00620.x; Weeks J, 1995, CLIN EXP ALLERGY, V25, P1179, DOI 10.1111/j.1365-2222.1995.tb03041.x; WICKMAN M, 1991, J ALLERGY CLIN IMMUN, V88, P89, DOI 10.1016/0091-6749(91)90305-8	22	88	91	0	2	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JAN	2003	111	1					169	176		10.1067/mai.2003.5		8	Allergy; Immunology	Allergy; Immunology	636PR	WOS:000180465500026	12532114	
J	Apostol, GG; Jacobs, DR; Tsai, AW; Crow, RS; Williams, OD; Townsend, MC; Beckett, WS				Apostol, GG; Jacobs, DR; Tsai, AW; Crow, RS; Williams, OD; Townsend, MC; Beckett, WS			Early life factors contribute to the decrease in lung function between ages 18 and 40 - The coronary artery risk development in young adults study	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						lung development; family smoking; smoking; asthma	OBSTRUCTIVE PULMONARY-DISEASE; FORCED EXPIRATORY VOLUME; TOBACCO-SMOKE EXPOSURE; RESPIRATORY SYMPTOMS; CIGARETTE-SMOKING; REFERENCE VALUES; FUNCTION DECLINE; CHILDREN; ASTHMA; CARDIA	Early life factors may influence pulmonary function. We measured forced expiratory volume in 1 second (FEV1) in 1985-1986 and 2, 5, and 10 years later in approximately 4,000 black and white men and women initially aged 18-30 years. We estimated the age pattern of FEV1 according to family smoking status, early diagnosis of asthma, early smoking initiation, adult asthma, and cigarette smoking. FEV1 followed a quadratic pattern from age of peak through age 40. The pattern varied by race and sex. Early smoking initiation was associated with a faster decrease in FEV1. Smoking by family members was related to early life asthma and may have contributed to faster FEV1 decrease by encouraging behaviors such as heavier smoking or earlier smoking initiation. Prevalence of smoking was 28% when no family member smoked, compared with 59% when four or more members smoked. The FEV1 decline was 8.5% in never-smokers without asthma; 10.1% in nonsmoking individuals diagnosed with asthma; and 11.1% in baseline smokers who smoked 15 or more cigarettes per day. The combination of asthma and heavier smoking was synergistic (17.8% decline). This study delineates an increased rate of decline in those with asthma or in those who smoke cigarettes and implicates early life exposures as contributing to the faster rate of FEV1 decline.	Univ Minnesota, Sch Publ Hlth, Div Epidemiol, Minneapolis, MN 55454 USA; Univ Oslo, Inst Nutr Res, Oslo, Norway; Ingenix Pharmaceut Serv, Eden Prairie, MN USA; Univ Alabama, Div Prevent Med, Birmingham, AL USA; MC Townsend Associates, Pittsburgh, PA USA; Univ Rochester, Dept Environm Med, Occupat Med Div, Rochester, NY USA	Jacobs, DR (reprint author), Univ Minnesota, Sch Publ Hlth, Div Epidemiol, 1300 S 2nd St,Suite 300, Minneapolis, MN 55454 USA.						American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; BECKETT WS, 2001, AM J RESP CRIT CARE, V164, P23045; BINDER RE, 1976, AM REV RESPIR DIS, V114, P955; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; Brandli O, 1996, THORAX, V51, P277, DOI 10.1136/thx.51.3.277; BURROWS B, 1986, AM REV RESPIR DIS, V133, P974; *CDC, 1999, ASTHM AT A GLANC 199, P2; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; FRIEDMAN GD, 1988, J CLIN EPIDEMIOL, V41, P1105, DOI 10.1016/0895-4356(88)90080-7; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gold DR, 1996, NEW ENGL J MED, V335, P931, DOI 10.1056/NEJM199609263351304; GOLD DR, 1994, AM J RESP CRIT CARE, V149, P1198; GOLD DR, 1993, AM REV RESPIR DIS, V148, P10; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Harik-Khan RI, 2001, AM J RESP CRIT CARE, V164, P1647; HIGGINS M, 1991, CHEST, V99, P315, DOI 10.1378/chest.99.2.315; HONIG E, 1989, HEART, P2078; Humerfelt S, 1998, CLIN PHYSIOL, V18, P387, DOI 10.1046/j.1365-2281.1998.00115.x; JAAKKOLA MS, 1991, EUR RESPIR J, V4, P643; JAAKKOLA MS, 1993, AM REV RESPIR DIS, V147, P359; Jacobs DR, 1999, STAT MED, V18, P655, DOI 10.1002/(SICI)1097-0258(19990330)18:6<655::AID-SIM62>3.3.CO;2-L; JACOBS DR, 1992, AM REV RESPIR DIS, V146, P644; Jedrychowski W, 2001, Med Sci Monit, V7, P293; KELLER J, 1989, American Review of Respiratory Disease, V139, pA24; KEYS A, 1972, AM J PUBLIC HEALTH N, V62, P1506, DOI 10.2105/AJPH.62.11.1506; KNUDSON RJ, 1983, AM REV RESPIR DIS, V127, P725; Knuiman MW, 1999, ANN EPIDEMIOL, V9, P297, DOI 10.1016/S1047-2797(98)00066-0; KRZYZANOWSKI M, 1990, CHEST, V98, P62, DOI 10.1378/chest.98.1.62; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Louis R, 2000, AM J RESP CRIT CARE, V161, P9; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; RENZETTI AD, 1979, AM REV RESPIR DIS, V119, P693; RODRIGUEZ BL, 1994, AM J EPIDEMIOL, V140, P398; Samet JM, 1996, AM J RESP CRIT CARE, V154, pS257; Scanlon PD, 2000, AM J RESP CRIT CARE, V161, P381; SCHOENBERG JB, 1978, RESP PHYSIOL, V33, P367, DOI 10.1016/0034-5687(78)90063-4; SHERMAN CB, 1992, AM REV RESPIR DIS, V146, P855; SHERRILL DL, 1991, AM REV RESPIR DIS, V144, P17; SOBOL B, 1974, CHEST, V64, P148; TAGER IB, 1985, AM REV RESPIR DIS, V131, P752; TAGER IB, 1988, AM REV RESPIR DIS, V138, P837; VANPELT W, 1994, AM J RESP CRIT CARE, V149, P1218; Vestbo J, 1999, LANCET, V353, P1819, DOI 10.1016/S0140-6736(98)10019-3; Vestbo J, 1991, Ugeskr Laeger, V153, P2292; VOLLMER WM, 1993, OCCUP MED, V8, P339; WEISS ST, 1992, AM REV RESPIR DIS, V145, P58; Weiss ST, 1996, AM J RESP CRIT CARE, V154, pS208; XU XP, 1992, AM REV RESPIR DIS, V146, P1345	49	88	90	1	4	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUL 15	2002	166	2					166	172		10.1164/rccm.2007035		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	571XX	WOS:000176745400010	12119228	
J	Kero, J; Gissler, M; Gronlund, MM; Kero, P; Koskinen, O; Hemminki, E; Isolauri, E				Kero, J; Gissler, M; Gronlund, MM; Kero, P; Koskinen, O; Hemminki, E; Isolauri, E			Mode of delivery and asthma - Is there a connection?	PEDIATRIC RESEARCH			English	Article							FOLLOW-UP; BIRTH COHORT; CHILDREN; PREVALENCE; ATOPY; CHILDHOOD; INFANTS; LIFE; MICROFLORA; HEALTH	Genetic factors cannot explain the recent rapid increase in the incidence of atopic diseases. The phenomenon has been explained by environmental factors, and there are data for and against the hypothesis that a decline in the pressure of microbial stimulation early in life could be behind the allergy epidemic. Changes have also occurred in maternity care, among them a rise in the caesarean section rate, which could diminish initial microbial exposure and thereby alter T helper 1 cell/T helper-2 cell development and affect the risk of developing atopy. In this study, we sought to establish whether mode of delivery does influence the development of atopic asthma, Finnish 1987 Medical Birth Register (n = 59,927 Live births) information was linked between several national health registers to obtain information on asthma and mode of delivery in children registered. The data were adjusted for maternal age, previous deliveries, child's sex, and birth size. Atopy was evaluated in the second study (Turku Birth Cohort), which involved 219 children born by vaginal delivery (n = 106) or caesarean section (n = 113); history of atopic symptoms was established by questionnaire and a clinical examination was conducted, including skin prick testing and determination of total and allergen-specific I-E in serum, The register study showed the Cumulative incidence of asthma at the age of seven to be significantly higher in children born by caesarean section (4.2%) than in those vaginally delivered (3.3%), the adjusted odds ratio (OR) for confounding variables being 1.21 (1.08-1.36), p < 0.01, In the second study, significantly more positive allergy tests were reported in questionnaires in the caesarean (22%) than in the vaginal delivery group (I M, OR 2.22 (1.06-4.64), p < 0.01, and a trend toward more positive skin prick reactions was documented at clinical examination; 41% versits 29%, OR 1.31 (0.65-2.65), p = 0.11. In conclusion, these results suggest that caesarean section delivery may be associated with an increased prevalence of atopic asthma.	Univ Turku, Cent Hosp, Dept Paediat, FIN-20520 Turku, Finland; Univ Turku, Cent Hosp, Dept Clin Chem, FIN-20520 Turku, Finland; Natl Res & Dev Ctr Welf & Hlth, FIN-00531 Helsinki, Finland	Kero, J (reprint author), Univ Heidelberg, Inst Pharmakol, Neuenheimer Feld 366,Room 309, D-69120 Heidelberg, Germany.		kero, jukka/G-3448-2014	kero, jukka/0000-0001-8767-7222			Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BENNET R, 1987, INFECTION, V15, P332, DOI 10.1007/BF01647733; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; Chirico G, 1999, BIOL NEONATE, V75, P294, DOI 10.1159/000014107; Dashe JS, 2000, OBSTET GYNECOL, V96, P321, DOI 10.1016/S0029-7844(00)00943-1; Duran-Tauleria E, 1999, THORAX, V54, P476; ESKEW PN, 1994, J REPROD MED, V39, P809; Forastiere F, 1997, EPIDEMIOLOGY, V8, P566, DOI 10.1097/00001648-199709000-00015; Gissler M, 1998, PAEDIATR PERINAT EP, V12, P437; GISSLER M, 1995, SCAND J SOC MED, V23, P75; Gissler M, 2000, EUR J EPIDEMIOL, V16, P59, DOI 10.1023/A:1007639230040; GISSLER M, 1999, ADM REGISTERS HLTH R, P73; Gregory A, 1999, CLIN EXP ALLERGY, V29, P330; Gronlund MM, 1999, CLIN EXP IMMUNOL, V116, P521; Gronlund MM, 1999, J PEDIATR GASTR NUTR, V28, P19, DOI 10.1097/00005176-199901000-00007; Gronlund MM, 2000, ARCH DIS CHILD, V83, pF186, DOI 10.1136/fn.83.3.F186; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Jana N, 1995, J Obstet Gynaecol (Tokyo 1995), V21, P227; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Keskimaki I, 1991, INT J HLTH SCI, V2, P15; KINOSHITA Y, 1991, J PEDIATR-US, V118, P115, DOI 10.1016/S0022-3476(05)81861-X; Kulig M, 1999, J PEDIATR-US, V134, P453, DOI 10.1016/S0022-3476(99)70203-9; LANG DM, 1994, NEW ENGL J MED, V331, P1542, DOI 10.1056/NEJM199412083312302; LAWOYIN TO, 1993, J TROP MED HYG, V96, P352; Macfarlane A, 1998, BRIT MED J, V316, P566; MacKenzie IZ, 1999, BRIT MED J, V318, P1070; Matricardi PM, 1997, BRIT MED J, V314, P999; NAKAGOMI T, 1994, LANCET, V343, P121, DOI 10.1016/S0140-6736(94)90854-0; Oddy WH, 1999, BRIT MED J, V319, P815; PEAT JK, 1994, BRIT MED J, V308, P1591; PERLOW JH, 1992, AM J OBSTET GYNECOL, V167, P963; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; Remes ST, 1996, ACTA PAEDIATR, V85, P59, DOI 10.1111/j.1651-2227.1996.tb13891.x; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAMPSON HA, 1984, J ALLERGY CLIN IMMUN, V74, P26, DOI 10.1016/0091-6749(84)90083-6; Sanfilippo L, 2000, CLIN EXP IMMUNOL, V119, P456, DOI 10.1046/j.1365-2249.2000.01155.x; SCOLOZZI R, 1989, ANN ALLERGY, V62, pA193; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Sly RM, 1997, ANN ALLERG ASTHMA IM, V78, P427; Stewart AW, 1997, INT J EPIDEMIOL, V26, P126, DOI 10.1093/ije/26.1.126; Sudo N, 1997, J IMMUNOL, V159, P1739; TAYLOR B, 1984, LANCET, V2, P1255; THILAGANATHAN R, 1994, AM J OBSTET GYNECOL, V171, P1271; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; VONMUTIUS E, 1992, BRIT MED J, V305, P1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692; *WHO, 1977, MAN INT CLASS DIS IN, V1; *WHO, 1977, MAN INT CLASS DIS, V2	51	88	91	1	14	INT PEDIATRIC RESEARCH FOUNDATION, INC	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436 USA	0031-3998			PEDIATR RES	Pediatr. Res.	JUL	2002	52	1					6	11		10.1023/01.PDR.0000017263.01840.F0		6	Pediatrics	Pediatrics	564ZT	WOS:000176344000002	12084840	
J	Derewenda, U; Li, J; Derewenda, Z; Dauter, Z; Mueller, GA; Rule, GS; Benjamin, DC				Derewenda, U; Li, J; Derewenda, Z; Dauter, Z; Mueller, GA; Rule, GS; Benjamin, DC			The crystal structure of a major dust mite allergen Der p 2, and its biological implications	JOURNAL OF MOLECULAR BIOLOGY			English	Article						allergen; asthma; X-ray structure; immunoglobulin fold; hydrophobic cavity	MACROMOLECULAR STRUCTURES; IMMUNOGLOBULIN FOLD; PROTEIN; DER-P-2; FAMILY; RHOGDI; BINDS; DERMATOPHAGOIDES; REFINEMENT; ASTHMA	The crystal structure of the common house mite (Dermatophagoides sp.) Der p 2 allergen was solved at 2.15 Angstrom resolution using the MAD phasing technique, and refined to an R-factor of 0.209. The refined atomic model, which reveals an immunoglobulin-like tertiary fold, differs in important ways from the previously described NMR structure, because the two beta-sheets are significantly further apart and create an internal cavity, which is occupied by a hydrophobic ligand. This interaction is structurally reminiscent of the binding of a prenyl group by a regulatory protein, the Rho guanine nucleotide exchange inhibitor. The crystal structure suggests that binding of non-polar molecules may be essential to the physiological function of the Der p 2 protein, (C) 2002 Elsevier Science Ltd. All rights reserved.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA; Brookhaven Natl Lab, Upton, NY 11973 USA; Beirne Carter Ctr Immunol Res, Charlottesville, VA 22908 USA; Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA 22908 USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Derewenda, U (reprint author), Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA.		Rule, Gordon/Q-2422-2015; Mueller, Geoffrey/I-2909-2017	Rule, Gordon/0000-0002-4396-3363; Mueller, Geoffrey/0000-0001-8361-5323	NIAID NIH HHS [AI-34607]		Asero R, 2001, ANN ALLERG ASTHMA IM, V87, P65; BORK P, 1994, J MOL BIOL, V242, P309, DOI 10.1016/S0022-2836(84)71582-8; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Halaby DM, 1999, PROTEIN ENG, V12, P563, DOI 10.1093/protein/12.7.563; HENDERSON IC, 1990, ANN ONCOL, V1, P9; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Hoffman GR, 2000, CELL, V100, P345, DOI 10.1016/S0092-8674(00)80670-4; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keep NH, 1997, STRUCTURE, V5, P623, DOI 10.1016/S0969-2126(97)00218-9; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KLEYWEGT GJ, 1994, FIRST MAP FINAL MODE, P59; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; Longenecker K, 1999, ACTA CRYSTALLOGR D, V55, P1503, DOI 10.1107/S090744499900801X; Mantyjarvi R, 2000, BBA-PROTEIN STRUCT M, V1482, P308, DOI 10.1016/S0167-4838(00)00139-4; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Mueller GA, 2001, J BIOL CHEM, V276, P9359, DOI 10.1074/jbc.M010812200; Mueller GA, 1997, J BIOL CHEM, V272, P26893, DOI 10.1074/jbc.272.43.26893; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAURECKIENE S, 2000, SCIENCE, V290, P2227; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Okamura N, 1999, BBA-MOL CELL BIOL L, V1438, P377, DOI 10.1016/S1388-1981(99)00070-0; Otwinowski Z., 1991, DARESBURY STUDY WEEK, P80; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; POWTAN KD, 1993, ACTA CRYSTALLOGR D, V49, P148; SHAKIB F, 2001, J CLIN PATHOL, V54, P155; SHELDRICK G, 1991, DARESBURY STUDY WEEK, P23; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; 1994, ACTA CRSYSTALLOG D, V50, P760	32	88	93	0	3	ACADEMIC PRESS LTD ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0022-2836			J MOL BIOL	J. Mol. Biol.	APR 19	2002	318	1					189	197		10.0000/S0022-2836(02)00027-X		9	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	548MY	WOS:000175392800016	12054778	
J	Arlian, LG				Arlian, LG			Arthropod allergens and human health	ANNUAL REVIEW OF ENTOMOLOGY			English	Review						allergic reactions to arthropods; allergic reactions to insects and mites	HOUSE-DUST-MITE; IMPORTED FIRE ANT; AMERICAN PERIPLANETA-AMERICANA; COCKROACH BLATTELLA-GERMANICA; ANTIGENIC CROSS-REACTIVITY; IGE ANTIBODY-RESPONSES; AMINO-ACID-SEQUENCES; INNER-CITY CHILDREN; DERMATOPHAGOIDES-PTERONYSSINUS ACARI; GLUTATHIONE-S-TRANSFERASE	Many species of arthropods are the sources of potent allergens that sensitize and induce IgE-mediated allergic reactions in humans. Most of these arthropod allergens are proteins, and the allergic response mechanism to these allergens is the same as it is for allergens from other sources such as plant pollens, molds, and foods. Aside from ingestion of crustaceans (shrimp, lobster), among arthropods, humans have the greatest contact with insects and mites, and as a result allergies to these two groups of arthropods have been the most frequently reported. Because of the large number of people affected by allergic reactions to stinging insects, cockroaches, and dust mites. Many allergens of these organisms have been extensively studied, purified, and characterized and for some recombinant allergens, produced. Cocktails of these recombinant allergens have the potential for use in diagnosis and immunotherapy. In this chapter, we review the insects and mites that induce allergic reactions. Where the information exists, the immunobiochemical characterization of the allergens and the frequency, of sensitivity or clinical reactivity in the human population are also reviewed. As background, the beginning of this review includes sections that define allergens, explain the allergic reaction mechanism, and describe the methods for naming allergens.	Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA	Arlian, LG (reprint author), Wright State Univ, Dept Biol Sci, Dayton, OH 45435 USA.						Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; ACERO S, 2000, ALLERGY, V55, P207; AKI T, 1995, J ALLERGY CLIN IMMUN, V96, P74, DOI 10.1016/S0091-6749(95)70035-8; AKI T, 1994, INT ARCH ALLERGY IMM, V103, P349; Alanko K, 2000, ALLERGY, V55, P879, DOI 10.1034/j.1398-9995.2000.00572.x; Alp H, 2001, ANN ALLERG ASTHMA IM, V86, P51; Annila IT, 1996, ANN ALLERG ASTHMA IM, V77, P423; Arlian LG, 1999, ANN ALLERG ASTHMA IM, V83, P529, DOI 10.1016/S1081-1206(10)62864-5; Arlian LG, 2000, ANN ALLERG ASTHMA IM, V85, P161; ARLIAN LG, 1991, J INVEST DERMATOL, V96, P349, DOI 10.1111/1523-1747.ep12465257; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1051, DOI 10.1016/0091-6749(93)90219-6; ARLIAN LG, 1988, J MED ENTOMOL, V25, P240; ARLIAN LG, 1982, J ALLERGY CLIN IMMUN, V69, P527, DOI 10.1016/0091-6749(82)90178-6; Arlian LG, 1997, ANN ALLERG ASTHMA IM, V79, P525; ARLIAN LG, 1992, J ALLERGY CLIN IMMUN, V90, P292, DOI 10.1016/S0091-6749(05)80006-5; ARLIAN LG, 1993, J ALLERGY CLIN IMMUN, V91, P1042, DOI 10.1016/0091-6749(93)90218-5; ARLIAN LG, 1983, J MED ENTOMOL, V20, P99; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, pS406, DOI 10.1067/mai.2001.113670; ARLIAN LG, 1984, J ALLERGY CLIN IMMUN, V74, P172, DOI 10.1016/0091-6749(84)90282-3; ARLIAN LG, 1987, J MED ENTOMOL, V24, P252; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P457, DOI 10.1016/0091-6749(87)90363-0; ARLIAN LG, 1987, J ALLERGY CLIN IMMUN, V79, P467, DOI 10.1016/0091-6749(87)90364-2; Arruda L K, 2001, Curr Opin Pulm Med, V7, P14, DOI 10.1097/00063198-200101000-00003; Arruda LK, 1997, J BIOL CHEM, V272, P20907, DOI 10.1074/jbc.272.33.20907; Arruda LK, 1995, J BIOL CHEM, V270, P31196; ARRUDA LK, 1995, J BIOL CHEM, V270, P19563; Arruda LK, 1997, AM J RESP CRIT CARE, V155, P343; ARRUDA LK, 1999, ALLERGY CLIN IMMUNOL, V11, P167, DOI 10.1027/0838-1925.11.5.167; Asturias JA, 1998, BBA-GENE STRUCT EXPR, V1397, P27, DOI 10.1016/S0167-4781(98)00006-2; BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278; BARNARD JH, 1966, NEW YORK STATE J MED, V66, P1206; BAUR X, 1992, INT ARCH OCC ENV HEA, V64, P185, DOI 10.1007/BF00380907; BAUR X., 1982, J ALLERGY CLIN IMMUN, V68, P66; BENAIMPINTO C, 1990, INT J DERMATOL, V29, P600, DOI 10.1111/j.1365-4362.1990.tb03479.x; BENJAMINI E, 1960, NATURE, V138, P959; BERNTON HS, 1964, J ALLERGY, V35, P506, DOI 10.1016/0021-8707(64)90082-6; BIRNBAUM J, 1995, J ALLERGY CLIN IMMUN, V96, P561, DOI 10.1016/S0091-6749(95)70303-9; Blanco C, 1997, J ALLERGY CLIN IMMUN, V99, P308, DOI 10.1016/S0091-6749(97)70047-2; BOORMAN J, 1987, MED VET ENTOMOL, V1, P211, DOI 10.1111/j.1365-2915.1987.tb00346.x; BOUSQUET J, 1984, J ALLERGY CLIN IMMUN, V73, P332, DOI 10.1016/0091-6749(84)90405-6; BOUSQUET J, 1982, CLIN ALLERGY, V12, P331, DOI 10.1111/j.1365-2222.1982.tb02537.x; Brown AFT, 1998, J ACCID EMERG MED, V15, P111; Brown HM, 2000, ALLERGY, V55, P901; BULLOCK RJ, 1994, MED J AUSTRALIA, V160, P44; CALL RS, 1992, J PEDIATR-US, V121, P862, DOI 10.1016/S0022-3476(05)80329-4; Caraballo L, 1998, J INVEST ALLERG CLIN, V8, P281; Caraballo L, 1997, INT ARCH ALLERGY IMM, V112, P341; Caraballo L, 1996, J ALLERGY CLIN IMMUN, V98, P573, DOI 10.1016/S0091-6749(96)70091-X; CHAN-YEUNG M, 1986, American Review of Respiratory Disease, V133, P686; Chapman MD, 2000, J ALLERGY CLIN IMMUN, V106, P409; Chapman MD, 1997, ALLERGY, V52, P374, DOI 10.1111/j.1398-9995.1997.tb01014.x; Chapman MD, 1996, ALLERGY ALLERGIC DIS, P942; CHAPMAN MD, 2000, INT ALLERGY CLIN I S, V1, P77; Chew FT, 1999, CLIN EXP ALLERGY, V29, P982, DOI 10.1046/j.1365-2222.1999.00543.x; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; CRANSTON PS, 1983, ANN TROP MED PARASIT, V77, P527; CUTHBERT OD, 1979, CLIN ALLERGY, V9, P229, DOI 10.1111/j.1365-2222.1979.tb01547.x; DAUL CB, 1994, INT ARCH ALLERGY IMM, V105, P49; De Lucca SD, 1999, J ALLERGY CLIN IMMUN, V104, P672, DOI 10.1016/S0091-6749(99)70341-6; deBlay F, 1997, J ALLERGY CLIN IMMUN, V99, P107, DOI 10.1016/S0091-6749(97)81051-2; DONNOVAN BJ, 1978, NZ ENTOMOL, V6, P385; DUCOMBS G, 1981, CONTACT DERMATITIS, V7, P287; Dunlop K, 1997, Australas J Dermatol, V38, P193, DOI 10.1111/j.1440-0960.1997.tb01695.x; EBNER C, 1994, CLIN EXP ALLERGY, V24, P347, DOI 10.1111/j.1365-2222.1994.tb00245.x; Eggleston P., 1996, Journal of Allergy and Clinical Immunology, V97, P301, DOI 10.1016/S0091-6749(96)80694-4; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Eggleston PA, 2001, J ALLERGY CLIN IMMUN, V107, pS422, DOI 10.1067/mai.2001.113671; Eich-Wanger C, 1998, CLIN EXP ALLERGY, V28, P1292; ELRAB MOG, 1980, J ALLERGY CLIN IMMUN, V66, P190, DOI 10.1016/0091-6749(80)90038-X; Epton MJ, 1999, INT ARCH ALLERGY IMM, V120, P185, DOI 10.1159/000024266; ERBEN AM, 1993, J ALLERGY CLIN IMMUN, V92, P846, DOI 10.1016/0091-6749(93)90062-K; ERIKSSON NE, 1989, ALLERGY, V44, P305, DOI 10.1111/j.1398-9995.1989.tb00451.x; Eriksson TLJ, 1998, EUR J BIOCHEM, V251, P443, DOI 10.1046/j.1432-1327.1998.2510443.x; Ewan PW, 1998, BRIT MED J, V316, P1365; FALK ES, 1980, BRIT J DERMATOL, V103, P283, DOI 10.1111/j.1365-2133.1980.tb07245.x; FERNANDEZCALDAS E, 1994, J ALLERGY CLIN IMMUN, V94, P404, DOI 10.1016/0091-6749(94)90106-6; FERNANDEZCALDAS E, 1988, NEW ENGL REG ALLERGY, V9, P283; FERRANDIZ R, 1995, CLIN EXP ALLERGY, V25, P929, DOI 10.1111/j.1365-2222.1995.tb00394.x; FEWTRELL C, 1980, J IMMUNOL, V125, P701; Finn PW, 2000, J ALLERGY CLIN IMMUN, V105, P933, DOI 10.1067/mai.2000.106546; Freeman TM, 1997, ANN ALLERG ASTHMA IM, V78, P369; Fujikawa A, 1998, CLIN EXP ALLERGY, V28, P1549; Fujikawa A, 1996, MOL IMMUNOL, V33, P311, DOI 10.1016/0161-5890(95)00127-1; Galindo P A, 1998, Allergol Immunopathol (Madr), V26, P251; Garcia Robaina J C, 1996, Allergol Immunopathol (Madr), V24, P135; GAUCI M, 1989, INT ARCH ALLER A IMM, V85, P190; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573; Gergen PJ, 1999, J ALLERGY CLIN IMMUN, V103, P501, DOI 10.1016/S0091-6749(99)70477-X; GLUCK JC, 1986, ANN ALLERGY, V56, P492; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; HAMILTON S, 1992, NEW ENGL REV-MIDDLEB, V14, P96; Helm R, 1996, J ALLERGY CLIN IMMUN, V98, P172, DOI 10.1016/S0091-6749(96)70240-3; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154; HEYMANN PW, 1989, J ALLERGY CLIN IMMUN, V83, P1055, DOI 10.1016/0091-6749(89)90447-8; Hirabayashi K, 1997, ALLERGY, V52, P188, DOI 10.1111/j.1398-9995.1997.tb00973.x; Hirsch T, 2000, CLIN EXP ALLERGY, V30, P529, DOI 10.1046/j.1365-2222.2000.00785.x; HOFFMAN D, 1982, Journal of Allergy and Clinical Immunology, V69, P139; Hoffman D. R., 1997, Journal of Allergy and Clinical Immunology, V99, pS377; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V92, P707, DOI 10.1016/0091-6749(93)90014-7; HOFFMAN DR, 1981, ANN ALLERGY, V46, P304; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P828, DOI 10.1016/0091-6749(88)90085-1; HOFFMAN DR, 1980, ANN ALLERGY, V45, P276; HOFFMAN DR, 1994, INT ARCH ALLERGY IMM, V104, P184; HOFFMAN DR, 1977, J ALLERGY CLIN IMMUN, V59, P364, DOI 10.1016/0091-6749(77)90019-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V82, P818, DOI 10.1016/0091-6749(88)90084-X; HOFFMAN DR, 1987, CLIN REV ALLERG, V5, P177; Hoffman DR, 1996, J ALLERGY CLIN IMMUN, V97, P812, DOI 10.1016/S0091-6749(96)80159-X; HOFFMAN DR, 1993, J ALLERGY CLIN IMMUN, V91, P71, DOI 10.1016/0091-6749(93)90298-T; Hoffman DR, 1999, J ALLERGY CLIN IMMUN, V103, pS164; HUDSON A, 1960, SCIENCE, V131, P1730, DOI 10.1126/science.131.3415.1730; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; INGRAM CG, 1979, LANCET, V2, P1330; Ito K, 1987, Arerugi, V36, P30; ITO K, 1986, ANN ALLERGY, V57, P199; JAMES AA, 1991, MOL BIOCHEM PARASIT, V44, P245, DOI 10.1016/0166-6851(91)90010-4; JAMIESON HC, 1938, J ALLERGY, V9, P273, DOI 10.1016/S0021-8707(38)90220-5; Jeep S, 1996, ALLERGY, V51, P540; Johansson E, 1997, CLIN EXP ALLERGY, V27, P691; JOHANSSON E, 1991, CLIN EXP ALLERGY, V21, P511, DOI 10.1111/j.1365-2222.1991.tb01693.x; JOHANSSON E, 1994, CLIN EXP ALLERGY, V24, P743, DOI 10.1111/j.1365-2222.1994.tb00985.x; Johansson SGO, 2000, EUR J ALLERGY CLIN I, V55, P1073; Jorge PPO, 2000, J ALLERGY CLIN IMMUN, V105, pS169, DOI 10.1016/S0091-6749(00)90943-6; KAGEN S L, 1984, Journal of Allergy and Clinical Immunology, V73, P187; KANG B, 1979, J ALLERGY CLIN IMMUN, V63, P80, DOI 10.1016/0091-6749(79)90196-9; KANG B, 1989, ANN ALLERGY, V62, P30; KANG BC, 1993, J ALLERGY CLIN IMMUN, V92, P802, DOI 10.1016/0091-6749(93)90057-M; Kang BC, 1996, INT ARCH ALLERGY IMM, V111, P299; KANG BC, 1995, INT ARCH ALLERGY IMM, V107, P569; KANG BC, 1991, J ALLERGY CLIN IMMUN, V87, P1073, DOI 10.1016/0091-6749(91)92152-Q; KAY AB, 1978, CLIN EXP IMMUNOL, V34, P106; KAY AB, 1983, J ALLERGY CLIN IMMUN, V71, P345, DOI 10.1016/0091-6749(83)90090-8; KERSTEN W, 1998, ALLERGO J, V7, P317; KIISTALA R, 1995, ALLERGY, V50, P844; Kim YK, 1999, J ALLERGY CLIN IMMUN, V104, P1285; KIMURA JY, 1990, ALLERGY, V45, P167, DOI 10.1111/j.1398-9995.1990.tb00479.x; KINET JP, 1990, CURR OPIN IMMUNOL, V2, P499, DOI 10.1016/0952-7915(90)90002-X; King C, 1996, J ALLERGY CLIN IMMUN, V98, P739, DOI 10.1016/S0091-6749(96)70121-5; KING TP, 1978, BIOCHEMISTRY-US, V17, P5165, DOI 10.1021/bi00617a016; KING TP, 1995, J ALLERGY CLIN IMMUN, V96, P5, DOI 10.1016/S0091-6749(95)70027-7; King TP, 1996, TOXICON, V34, P1455, DOI 10.1016/S0041-0101(96)00088-8; KING TP, 1976, ARCH BIOCHEM BIOPHYS, V172, P661, DOI 10.1016/0003-9861(76)90121-1; King TP, 1996, J ALLERGY CLIN IMMUN, V98, P588, DOI 10.1016/S0091-6749(96)70093-3; KING TP, 1984, J IMMUNOL, V133, P2668; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; KINO T, 1987, J ALLERGY CLIN IMMUN, V79, P857, DOI 10.1016/0091-6749(87)90233-8; KINO T, 1979, J ALLERGY CLIN IMMUN, V64, P131, DOI 10.1016/0091-6749(79)90047-2; KOCHUYT AM, 1993, CLIN EXP ALLERGY, V23, P190, DOI 10.1111/j.1365-2222.1993.tb00881.x; Komase Y, 1997, ALLERGY, V52, P75, DOI 10.1111/j.1398-9995.1997.tb02548.x; KORSGAARD J, 1985, ALLERGOL IMMUNOPATH, V13, P143; KROIDL R, 1992, CLIN EXP ALLERGY, V22, P958, DOI 10.1111/j.1365-2222.1992.tb02070.x; LAKE FR, 1991, J ALLERGY CLIN IMMUN, V87, P1035, DOI 10.1016/0091-6749(91)92147-S; LAMY M, 1986, TOXICON, V24, P347, DOI 10.1016/0041-0101(86)90194-7; LAMY M, 1983, EXPERIENTIA, V39, P299, DOI 10.1007/BF01955314; Larsen JN, 1996, J ALLERGY CLIN IMMUN, V97, P577; Lee MH, 2000, ANN ALLERG ASTHMA IM, V85, P200; LEHRER SB, 1991, J ALLERGY CLIN IMMUN, V87, P574, DOI 10.1016/0091-6749(91)90017-I; LEUNG PSC, 1994, J ALLERGY CLIN IMMUN, V94, P882, DOI 10.1016/0091-6749(94)90156-2; Leung R, 1997, J ALLERGY CLIN IMMUN, V99, P594, DOI 10.1016/S0091-6749(97)70018-6; Liccardi G, 2000, RESP MED, V94, P1109, DOI 10.1053/rmed.2000.0922; LIERL MB, 1994, ANN ALLERGY, V72, P45; LIGHT W C, 1975, Clinical Allergy, V5, P389, DOI 10.1111/j.1365-2222.1975.tb01878.x; LIN KL, 1994, J ALLERGY CLIN IMMUN, V94, P989, DOI 10.1016/0091-6749(94)90117-1; LIND P, 1985, J ALLERGY CLIN IMMUN, V76, P753, DOI 10.1016/0091-6749(85)90682-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; LLERENA LP, 1991, J ALLERGY CLIN IMMUN, V88, P943, DOI 10.1016/0091-6749(91)90252-J; Lombardi C, 1998, Allergol Immunopathol (Madr), V26, P288; LU G, 1993, J IMMUNOL, V150, P2823; LUCZYNSKA C, 1990, CLIN EXP ALLERGY, V2, P403; MACGLASHAN D, 1983, J IMMUNOL, V130, P2330; MARSHALL NA, 1986, J ALLERGY CLIN IMMUN, V78, P430, DOI 10.1016/0091-6749(86)90029-1; Martinez A, 1997, Allergol Immunopathol (Madr), V25, P118; MARX JJ, 1993, AM REV RESPIR DIS, V147, P354; Matsumoto T, 1996, INT ARCH ALLERGY IMM, V109, P197; MCCORMACK DR, 1995, ANN ALLERG ASTHMA IM, V74, P39; McKIEL J. A., 1959, Canadian Journal of Zoology, V37, P341, DOI 10.1139/z59-038; MCKIEL JA, 1961, CAN J ZOOLOG, V39, P597, DOI 10.1139/z61-064; Melen E, 1999, J ALLERGY CLIN IMMUN, V103, P859, DOI 10.1016/S0091-6749(99)70430-6; MENDOZA J, 1970, ANN ALLERGY, V28, P159; MENON P, 1991, ANN ALLERGY, V67, P573; Moffitt JE, 1997, ANN ALLERG ASTHMA IM, V79, P125; Mollet JA, 1997, J MED ENTOMOL, V34, P307; MORGAN MS, 1994, FOLIA PARASIT, V41, P223; Morgan MS, 1997, AM J TROP MED HYG, V57, P190; Morgan MS, 1997, J ALLERGY CLIN IMMUN, V100, P222, DOI 10.1016/S0091-6749(97)70228-8; Morsy Tosson A., 2000, Journal of the Egyptian Society of Parasitology, V30, P83; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; NELSON DR, 1990, J ALLERGY CLIN IMMUN, V85, P80, DOI 10.1016/0091-6749(90)90225-S; NORDVALL SL, 1988, J ALLERGY CLIN IMMUN, V82, P567, DOI 10.1016/0091-6749(88)90966-9; OKA K, 1989, Journal of Dermatology (Tokyo), V16, P341; ONEILL GM, 1994, BBA-GENE STRUCT EXPR, V1219, P521, DOI 10.1016/0167-4781(94)90080-9; OVSYANNIKOVA IG, 1994, J ALLERGY CLIN IMMUN, V94, P537, DOI 10.1016/0091-6749(94)90211-9; PAULL BR, 1983, J ALLERGY CLIN IMMUN, V71, P448, DOI 10.1016/0091-6749(83)90460-8; Peng Z, 1998, J ALLERGY CLIN IMMUN, V101, pS32; Peng ZK, 1996, ANN ALLERG ASTHMA IM, V77, P238; Peng ZK, 1998, J ALLERGY CLIN IMMUN, V101, P498, DOI 10.1016/S0091-6749(98)70357-4; Peng ZK, 1997, J ALLERGY CLIN IMMUN, V100, P192, DOI 10.1016/S0091-6749(97)70224-0; Peng ZK, 1996, INT ARCH ALLERGY IMM, V110, P46; PERLMAN F, 1962, CALIF MED, V96, P1; Peruzzi M, 1999, ANN ALLERG ASTHMA IM, V83, P167, DOI 10.1016/S1081-1206(10)62631-2; PINAS JL, 1986, J ALLERGY CLIN IMMUN, V77, P364; Pitetti RD, 1999, PEDIATR EMERG CARE, V15, P33, DOI 10.1097/00006565-199902000-00010; Platts-Mills TAE, 2000, J ALLERGY CLIN IMMUN, V106, P787, DOI 10.1067/mai.2000.110548; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P511, DOI 10.1016/0091-6749(91)90010-L; POLLART SM, 1991, J ALLERGY CLIN IMMUN, V87, P505, DOI 10.1016/0091-6749(91)90009-D; Pomes A, 2000, J ALLERGY CLIN IMMUN, V105, pS168, DOI 10.1016/S0091-6749(00)90938-2; Puerta L, 1996, J ALLERGY CLIN IMMUN, V98, P932, DOI 10.1016/S0091-6749(96)80009-1; PUERTA L, 1993, J INVEST ALLERG CLIN, V3, P198; QUILL H, 1998, NIH PUB; RACIOPPI JV, 1987, INSECT BIOCHEM, V17, P503, DOI 10.1016/0020-1790(87)90010-2; Reese G, 1999, INT ARCH ALLERGY IMM, V119, P247, DOI 10.1159/000024201; REISMAN RE, 1982, J ALLERGY CLIN IMMUN, V69, P268, DOI 10.1016/S0091-6749(82)80003-1; REUNALA T, 1994, INT ARCH ALLERGY IMM, V104, P366; RIBEIRO JMC, 1984, COMP BIOCHEM PHYS B, V79, P81, DOI 10.1016/0305-0491(84)90081-6; ROCKWELL EVELYN M., 1952, ANN ALLERGY, V10, P404; Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; RUDOLP R, 1987, ASTHMA ALLERGY CLI S, V51, P177; SANCHEZ PA, 1991, J INVEST ALLERG CLIN, V1, P179; SanchezBorges M, 1997, J ALLERGY CLIN IMMUN, V99, P738, DOI 10.1016/S0091-6749(97)80005-X; Santos ABR, 1999, J ALLERGY CLIN IMMUN, V104, P329, DOI 10.1016/S0091-6749(99)70375-1; Sarpong SB, 1997, J ALLERGY CLIN IMMUN, V99, P486, DOI 10.1016/S0091-6749(97)70074-5; Sarpong SB, 1996, J ALLERGY CLIN IMMUN, V97, P1393, DOI 10.1016/S0091-6749(96)70209-9; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; SCHULANER FA, 1970, PEDIATRICS, V45, P465; SCHULTZEWERNING.G, 1987, ALLERGOLOGIE, V10, P416; SCHULTZEWERNINGHAUS G, 1991, INT ARCH ALLER A IMM, V94, P371; SCHUMACHER MJ, 1990, AM J TROP MED HYG, V43, P79; SCHUMACHER MJ, 1995, ARCH INTERN MED, V155, P2038, DOI 10.1001/archinte.155.19.2038; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SHANTI KN, 1993, J IMMUNOL, V151, P5354; SHEN HD, 1993, CLIN EXP ALLERGY, V23, P934, DOI 10.1111/j.1365-2222.1993.tb00278.x; SHEN HD, 1989, ANN ALLERGY, V63, P143; Shen HD, 1997, CLIN EXP ALLERGY, V27, P824, DOI 10.1046/j.1365-2222.1997.650890.x; Smith E.H., 1992, NPCA FIELD GUIDE STR; Soto-Quiros ME, 1998, ALLERGY, V53, P499, DOI 10.1111/j.1398-9995.1998.tb04087.x; Spiegel W. A, 1994, ANN ALLERGY, V72, P56; Sporik R, 1999, THORAX, V54, P675; STEWART GA, 1992, IMMUNOLOGY, V75, P29; STEWART GA, 1995, CLIN REV ALLERG IMMU, V13, P135; Straumann F, 2000, INT ARCH ALLERGY IMM, V123, P268, DOI 10.1159/000024453; STROM GB, 1980, J ALLERGY CLIN IMMUN, V65, P202; SUZUKI S, 1976, ACTA ALLERGOL, V31, P428, DOI 10.1111/j.1398-9995.1976.tb01493.x; TAGER A, 1969, INT ARCH ALLER A IMM, V36, P408; TERANISHI H, 1995, INT ARCH ALLERGY IMM, V106, P271; THIEN FCK, 1993, MED J AUSTRALIA, V159, P639; Thien FCK, 1996, CLIN EXP ALLERGY, V26, P216, DOI 10.1111/j.1365-2222.1996.tb00082.x; THOMAS B, 1991, INT ARCH ALLER A IMM, V94, P365; Thomas WR, 1998, ALLERGY, V53, P821, DOI 10.1111/j.1398-9995.1998.tb03987.x; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; TOPHAM CM, 1994, PROTEIN ENG, V7, P869, DOI 10.1093/protein/7.7.869; Tovey E, 1999, J ALLERGY CLIN IMMUN, V103, P179, DOI 10.1016/S0091-6749(99)70488-4; TOVEY ER, 1990, J MED ENTOMOL, V27, P368; TOVEY ER, 1989, J EXP MED, V170, P1457, DOI 10.1084/jem.170.4.1457; TRUDEAU WL, 1993, CLIN EXP ALLERGY, V23, P377, DOI 10.1111/j.1365-2222.1993.tb00342.x; TRUDEAU WL, 1990, AM J ASTHMA ALLERGY, V3, P222; Tsai LC, 1998, J ALLERGY CLIN IMMUN, V102, P295, DOI 10.1016/S0091-6749(98)70099-5; Vailes LD, 1998, J ALLERGY CLIN IMMUN, V101, P274; van Hage-Hamsten M, 1998, ALLERGY, V53, P49; VANHAGEHAMSTEN M, 1985, CLIN ALLERGY, V15, P555; van Hage-Hamsten M, 2000, ALLERGY, V55, P30; vanRee R, 1996, ALLERGY, V51, P387; vanWijnen JH, 1997, ALLERGY, V52, P460; VANWYE JE, 1991, NEW ENGL J MED, V324, P777; VANWYE JE, 1991, J ALLERGY CLIN IMMUN, V88, P968, DOI 10.1016/0091-6749(91)90257-O; VARELA J, 1994, EUR J BIOCHEM, V225, P93, DOI 10.1111/j.1432-1033.1994.00093.x; Vega JM, 1997, ALLERGY, V52, P1244, DOI 10.1111/j.1398-9995.1997.tb02532.x; Vovolis V, 1999, ALLERGY ASTHMA PROC, V20, P107, DOI 10.2500/108854199778612626; Wahl R, 1997, ALLERGY, V52, P236, DOI 10.1111/j.1398-9995.1997.tb00987.x; WILBUR RD, 1975, J ALLERGY CLIN IMMUN, V55, P72; WITTEMAN AM, 1995, INT ARCH ALLERGY IMM, V108, P165; XU W, 1997, J ALLERGY CLIN IMMUN, V99, pS512; YAMAMOTO K, 1978, MOD PROBL PAEIDAT, V20, P163; YASUEDA H, 1986, INT ARCH ALLER A IMM, V81, P214; YASUEDA H, 1993, CLIN EXP ALLERGY, V23, P384, DOI 10.1111/j.1365-2222.1993.tb00343.x; YOUNG JD, 1963, EXP PARASITOL, V13, P155, DOI 10.1016/0014-4894(63)90065-1; YUNGINGER JW, 1998, ALLERGY PRINCIPLES P, V2, P1063; Zhang L, 1997, CLIN EXP ALLERGY, V27, P876	280	88	96	3	20	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA	0066-4170			ANNU REV ENTOMOL	Annu. Rev. Entomol.		2002	47						395	433		10.1146/annurev.ento.47.091201.145224		39	Entomology	Entomology	514DC	WOS:000173421900014	11729080	
J	Binder, M; Mahler, V; Hayek, B; Sperr, WR; Scholler, M; Prozell, S; Wiedermann, G; Valent, P; Valenta, R; Duchene, M				Binder, M; Mahler, V; Hayek, B; Sperr, WR; Scholler, M; Prozell, S; Wiedermann, G; Valent, P; Valenta, R; Duchene, M			Molecular and immunological characterization of arginine kinase from the indianmeal moth, Plodia interpunctella, a novel cross-reactive invertebrate pan-allergen	JOURNAL OF IMMUNOLOGY			English	Article							REAGINIC SENSITIVITY; COCKROACH ALLERGEN; BRONCHIAL-ASTHMA; IGE ANTIBODIES; SILKWORM MOTH; HOUSE-DUST; SEQUENCE; INSECTS; CLONING; SITES	IgE recognition of indoor allergens represents a major cause of allergic asthma in atopic individuals. We found that 52 of 102 patients suffering from allergic symptoms indoors contained IgE Abs against allergens from the Indianmeal moth (Plodia interpunctella), a ubiquitous food pest. Using serum IgE from a moth-sensitized patient we screened an expression cDNA library constructed from A interpunctella larvae. cDNAs coding for arginine kinase (EC 2.7.3.3), a 40-kDa enzyme commonly occurring in invertebrates that is involved in the storage of such high-energy phosphate bonds as phosphoarginine, were isolated. Recombinant moth arginine kinase, designated Plo i 1, was expressed in Escherichia coli as a histidine-tagged protein with enzymatic activity, and purified to homogeneity by nickel chelate affinity chromatography. Purified recombinant arginine kinase induced specific basophil histamine release and immediate as well as late-phase skin reactions. It reacted with serum IgE from 13 of the 52 (25%) moth-allergic patients and inhibited the binding of allergic patients' IgE to an immunologically related 40-kDa allergen present in house dust mite, cockroach, king prawn, lobster, and mussel. Our results indicate that arginine kinases represent a new class of cross-reactive invertebrate pan-allergens. Recombinant arginine kinase may be used to identify a group of polysensitized indoor allergic patients and for immunotherapy of these individuals.	Univ Vienna, Dept Pathophysiol, Div Specif Prophylaxis & Trop Med, AKH, A-1090 Vienna, Austria; Univ Vienna, Div Immunopathol, Dept Pathophysiol, A-1090 Vienna, Austria; Univ Vienna, Div Hematol & Hemostaseol, Dept Internal Med 1, A-1090 Vienna, Austria; Biol Res Ctr Agr & Forestry, Inst Stored Prod Protect, Berlin, Germany	Duchene, M (reprint author), Univ Vienna, Dept Pathophysiol, Div Specif Prophylaxis & Trop Med, AKH, Wahringer Gurtel 18-20, A-1090 Vienna, Austria.						ANOSIKE EO, 1975, BIOCHEM J, V145, P535; ARRUDA LK, 1995, INT ARCH ALLERGY IMM, V107, P295; BALDO BA, 1988, INT ARCH ALLER A IMM, V85, P278; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; DUMAS C, 1993, J BIOL CHEM, V268, P21599; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kay A. B., 1997, ALLERGY ALLERGIC DIS; King TP, 2000, INT ARCH ALLERGY IMM, V123, P99, DOI 10.1159/000024440; KINO T, 1978, J ALLERGY CLIN IMMUN, V61, P10, DOI 10.1016/0091-6749(78)90467-0; KINO T, 1979, J ALLERGY CLIN IMMUN, V64, P131, DOI 10.1016/0091-6749(79)90047-2; Komase Y, 1997, ALLERGY, V52, P75, DOI 10.1111/j.1398-9995.1997.tb02548.x; Kucharski R, 1998, GENE, V211, P343, DOI 10.1016/S0378-1119(98)00114-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN RY, 1993, J ALLERGY CLIN IMMUN, V92, P837, DOI 10.1016/0091-6749(93)90061-J; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Pereira CA, 2000, J BIOL CHEM, V275, P1495, DOI 10.1074/jbc.275.2.1495; REDDY SRR, 1992, EUR J BIOCHEM, V206, P251, DOI 10.1111/j.1432-1033.1992.tb16923.x; REICHMUTH CM, 1997, VORRATSSCHADLINGE GE, P119; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEVENSON DD, 1967, J ALLERGY, V39, P274, DOI 10.1016/0021-8707(67)90091-3; SUZUKI M, 1995, ALLERGY, V50, P23, DOI 10.1111/j.1398-9995.1995.tb02479.x; Thomas WR, 1999, CLIN EXP ALLERGY, V29, P1583, DOI 10.1046/j.1365-2222.1999.00670.x; URBACH ERIC, 1941, JOUR ALLERGY, V12, P485, DOI 10.1016/S0021-8707(41)90227-7; VALENT P, 1989, P NATL ACAD SCI USA, V86, P5542, DOI 10.1073/pnas.86.14.5542; vanWijnen JH, 1997, ALLERGY, V52, P460; Vaughan WT, 1928, J LAB CLIN MED, V13, P955; Wang YME, 1998, J NEUROSCI, V18, P987; WITTICH F. W., 1940, JOUR LANCET, V60, P418; WYSS M, 1995, BIOCHEM J, V309, P255; Zhou GF, 1998, P NATL ACAD SCI USA, V95, P8449, DOI 10.1073/pnas.95.15.8449	36	88	96	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	NOV 1	2001	167	9					5470	5477				8	Immunology	Immunology	487DN	WOS:000171858500088	11673567	
J	Marks, GB; Colquhoun, JR; Girgis, ST; Koski, MH; Treloar, ABA; Hansen, P; Downs, SH; Car, NG				Marks, GB; Colquhoun, JR; Girgis, ST; Koski, MH; Treloar, ABA; Hansen, P; Downs, SH; Car, NG			Thunderstorm outflows preceding epidemics of asthma during spring and summer	THORAX			English	Article						asthma; thunderstorms; season	GRASS-POLLEN; AIR-POLLUTION; AUSTRALIA; MORTALITY; ENGLAND; CITY	Background-A study was undertaken to assess the importance of thunderstorms as a cause of epidemics of asthma exacerbations and to investigate the underlying mechanism. Methods-A case control study was performed in six towns in south eastern Australia. Epidemic case days (n = 48) and a random sample of control days (n = 191) were identified by reference to the difference between the observed and expected number of emergency department attendances for asthma. The occurrence of thunderstorms, their associated outflows and cold fronts were ascertained, blind to case status, for each of these days. In addition, the relation of hourly pollen counts to automatic weather station data was examined in detail for the period around one severe epidemic of asthma exacerbations. The main outcome measure was the number of epidemics of asthma exacerbations. Results-Thunderstorm outflows were detected on 33% of epidemic days and only 3% of control days (odds ratio 15.0, 95% confidence interval 6.0 to 37.6). The association was strongest in late spring and summer. Detailed examination of one severe epidemic showed that its onset coincided with the arrival of the thunderstorm outflow and a 4-12 fold increase in the ambient concentration of grass pollen grains. Conclusions-These findings are consistent with the hypothesis that some epidemics of exacerbations of asthma are caused by high concentrations of allergenic particles produced by an outflow of colder air, associated with the downdraught from a thunderstorm, sweeping up pollen grains and particles and then concentrating them in a shallow band of air at ground level. This is a common cause of exacerbations of asthma during the pollen season.	Univ Sydney, Inst Resp Med, Sydney, NSW 2050, Australia; Bur Meteorol, NSW Reg Off, Sydney, NSW, Australia; Charles Sturt Univ, Sch Biomed Sci, Wagga Wagga, NSW, Australia	Marks, GB (reprint author), Univ Sydney, Inst Resp Med, Sydney, NSW 2050, Australia.		Downs, Sara/D-8478-2011; Osborne, Nicholas/N-4915-2015	Downs, Sara/0000-0003-1044-3182; Osborne, Nicholas/0000-0002-6700-2284			BELLOMO R, 1992, MED J AUSTRALIA, V156, P834; Celenza A, 1996, BRIT MED J, V312, P604; Davidson AC, 1996, BRIT MED J, V312, P601; Epton MJ, 1997, THORAX, V52, P528; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; Jamason PF, 1997, AM J RESP CRIT CARE, V156, P1781; KAPYLA M, 1981, Grana, V20, P131; Katsouyanni K, 1996, J EPIDEMIOL COMMUN H, V50, pS12, DOI 10.1136/jech.50.Suppl_1.S12; MACKENBACH JP, 1993, J EPIDEMIOL COMMUN H, V47, P121, DOI 10.1136/jech.47.2.121; Newson R, 1997, THORAX, V52, P680; Newson R, 1998, EUR RESPIR J, V11, P694; ODGEN E, 1974, MANUAL SAMPLING AIRB; PACKE GE, 1985, LANCET, V2, P199; ROSENBERG GL, 1983, J ALLERGY CLIN IMMUN, V71, P302, DOI 10.1016/0091-6749(83)90084-2; Simpson RW, 1997, ARCH ENVIRON HEALTH, V52, P442; SUPHIOGLU C, 1992, LANCET, V339, P569, DOI 10.1016/0140-6736(92)90864-Y; TOBIAS A, 1998, STATA TECH B, V46, P33; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x	19	88	89	2	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	JUN	2001	56	6					468	471		10.1136/thorax.56.6.468		4	Respiratory System	Respiratory System	438XL	WOS:000169079500011	11359963	
J	Yoshimura, S; Bondeson, J; Brennan, FM; Foxwell, BMJ; Feldmann, M				Yoshimura, S; Bondeson, J; Brennan, FM; Foxwell, BMJ; Feldmann, M			Role of NF kappa B in antigen presentation and development of regulatory T cells elucidated by treatment of dendritic cells with the proteasome inhibitor PSI	EUROPEAN JOURNAL OF IMMUNOLOGY			English	Article						antigen presentation; NF kappa B; tolerance	NECROSIS-FACTOR-ALPHA; PROINFLAMMATORY CYTOKINES; FUNCTIONAL-HETEROGENEITY; BLOOD MONOCYTES; ACTIVATION; TOLERANCE; INDUCTION; EXPRESSION; APOPTOSIS; UNRESPONSIVENESS	Dendritic cells (DC) are the most potent antigen-presenting cells for naive T cells, due to their high expression of MHC and costimulatory molecules, but relatively little is known about the biochemical pathways that regulate this function. We used the proteasome inhibitor N-benzyloxycarbonyl-IIe-Glu(O-tert-butyl)-Ala-leucinal (PSI) to demonstrate that DC antigen presentation is NF kappaB dependent. As PSI is not a specific inhibitor of NF kappaB, we reproduced this finding using a very specific approach, namely adenoviral gene transfer of I kappaB alpha, the naturally occurring inhibitor of NF kappaB. The mechanism for this inhibition of DC antigen presentation involves at least three aspects of antigen presenting function: down-regulation of HLA class II, down-regulation of CD86, and inhibition of the immunostimulatory cytokines IL-12 and TNF-alpha. In the light of the marked down-regulation of antigen-presentation cell function, it was of interest to investigate what effects exposure to PSI-treated DC might have on T cell function. It was found that immunological tolerance was induced, as challenge of T cells previously exposed to PSI-treated DC, with normal DG from the same donor did not restore their response, despite the presence of viable T cells. There were also changes in T cell surface markers, with down-regulation of CD3 and CD25 expression, and inhibition of the production of Th1 cytokines like IL-2 and IFN-gamma. These results demonstrates that NF kappaB is an effective target for blocking DC antigen presentation and inhibiting T cell-dependent immune responses, and this has implications for the development of therapeutic agents for use in multiple conditions, including transplantation, allergy and autoimmune diseases.	Imperial Coll Sch Med, Div Rheumatol, Kennedy Inst, London, England	Feldmann, M (reprint author), Imperial Coll Sch Med, Div Rheumatol, Kennedy Inst, 1 Aspenlea Rd, London, England.						Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bender A, 1996, J IMMUNOL METHODS, V196, P121, DOI 10.1016/0022-1759(96)00079-8; Bondeson J, 1999, J IMMUNOL, V162, P2939; Bondeson J, 2000, J RHEUMATOL, V27, P2078; Bondeson J, 1999, P NATL ACAD SCI USA, V96, P5668, DOI 10.1073/pnas.96.10.5668; Brand K, 1997, ARTERIOSCL THROM VAS, V17, P1901; Butler DM, 1995, EUR CYTOKINE NETW, V6, P225; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CLARKE CJP, 1995, EUR J IMMUNOL, V25, P2961, DOI 10.1002/eji.1830251037; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; Foxwell B, 1998, P NATL ACAD SCI USA, V95, P8211, DOI 10.1073/pnas.95.14.8211; GRAHAM FL, 1995, MOL BIOTECHNOL, V3, P207, DOI 10.1007/BF02789331; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Haas M, 1998, J LEUKOCYTE BIOL, V63, P395; Ivanov VN, 1998, INT IMMUNOL, V10, P1807, DOI 10.1093/intimm/10.12.1807; Janeway CA, 1996, CURR BIOL, V6, P519, DOI 10.1016/S0960-9822(02)00531-6; Kupatt C, 1997, J MOL CELL CARDIOL, V29, P2599, DOI 10.1006/jmcc.1997.0439; LAMB JR, 1984, NATURE, V308, P72, DOI 10.1038/308072a0; LAMB JR, 1987, EUR J IMMUNOL, V17, P1641, DOI 10.1002/eji.1830171118; LAMB JR, 1986, IMMUNOLOGY, V57, P331; LING P, 1995, J IMMUNOL, V154, P116; Liu LM, 1998, J IMMUNOL, V161, P1146; Masurier C, 1999, IMMUNOLOGY, V96, P569; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.immunol.12.1.991; McDade TP, 1999, SURGERY, V126, P371, DOI 10.1016/S0039-6060(99)70179-0; Meierhoff G, 1998, IMMUNOBIOLOGY, V198, P501; Miller SD, 1995, IMMUNITY, V3, P739, DOI 10.1016/1074-7613(95)90063-2; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Park W, 1997, EUR J IMMUNOL, V27, P1082, DOI 10.1002/eji.1830270507; Pearson TC, 1996, TRANSPLANTATION, V61, P997, DOI 10.1097/00007890-199604150-00002; Reddy A, 1997, BLOOD, V90, P3640; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; Romani N, 1996, J IMMUNOL METHODS, V196, P137, DOI 10.1016/0022-1759(96)00078-6; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sato M, 2000, INT IMMUNOL, V12, P335, DOI 10.1093/intimm/12.3.335; SMITH RM, 1994, IMMUNOLOGY, V83, P1; STEINMAN RM, 1973, J EXP MED, V137, P1142, DOI 10.1084/jem.137.5.1142; Traenckner E B, 1995, J Cell Sci Suppl, V19, P79; TRAENCKNER EBM, 1994, EMBO J, V13, P5433; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Waldmann H, 1998, ANNU REV IMMUNOL, V16, P619, DOI 10.1146/annurev.immunol.16.1.619; Wang XC, 2000, J UROLOGY, V163, P993, DOI 10.1016/S0022-5347(05)67870-6; Webb LMC, 1996, EUR J IMMUNOL, V26, P2320, DOI 10.1002/eji.1830261008; WHITESIDE ST, 1992, NUCLEIC ACIDS RES, V20, P1531, DOI 10.1093/nar/20.7.1531; YOSHIMURA S, 2001, IN PRESS INT IMMUNOL; ZANDERS ED, 1983, NATURE, V303, P625, DOI 10.1038/303625a0; ZANDERS ED, 1985, EUR J IMMUNOL, V15, P302, DOI 10.1002/eji.1830150318; Zhou LJ, 1996, P NATL ACAD SCI USA, V93, P2588, DOI 10.1073/pnas.93.6.2588	49	88	94	0	1	WILEY-V C H VERLAG GMBH	BERLIN	PO BOX 10 11 61, D-69451 BERLIN, GERMANY	0014-2980			EUR J IMMUNOL	Eur. J. Immunol.	JUN	2001	31	6					1883	1893		10.1002/1521-4141(200106)31:6<1883::AID-IMMU1883>3.0.CO;2-V		11	Immunology	Immunology	442TY	WOS:000169302100027	11433385	
J	Wechsler, ME; Grasemann, H; Deykin, A; Silverman, EK; Yandava, CN; Israel, E; Wang, M; Drazen, JM				Wechsler, ME; Grasemann, H; Deykin, A; Silverman, EK; Yandava, CN; Israel, E; Wang, M; Drazen, JM			Exhaled nitric oxide in patients with asthma - Association with NOS1 genotype	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SYNTHASE GENE NOS1; APOLIPOPROTEIN-E; POPULATION; POLYMORPHISMS; INFLAMMATION; MUTATIONS; DISORDERS; LINKAGE; MARKERS; LOCUS	An increased concentration of nitric oxide (NO) in exhaled air (FENO) is now recognized as a critical component of the asthmatic phenotype. When we identified patients with asthma on the basis of a standard case definition alone, we found that they were remarkably heterogeneous with respect to their FENO. However, when we included genotype at a prominent asthma candidate gene (i.e., NOS1) in the case definition, and determined the number of AAT repeats in intron 20, we identified a remarkably homogenous cohort of patients with respect to FENO. Both mean FENO (p = 0.00008) and variability around the mean (p = 0.000002) were significantly lower in asthmatic individuals with a high number (greater than or equal to 12) of AAT repeats at this locus than in those with fewer repeats. These data provide a biologically tenable link between genotype at a candidate gene in a region of linkage, NOS1, and an important component of the asthmatic phenotype, FENO. We show that addition of NOS1 genotype to the case definition of asthma allows the identification of a uniform cohort of patients, with respect to FENO, that would have been indistinguishable by other physiologic criteria. Our isolation of this homogenous cohort of patients ties together the well-established associations among asthma, increased concentrations of NO in the exhaled air of asthmatic individuals, and variations of trinucleotide repeat sequences as identified in several neurologic conditions.	Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Med, Boston, MA 02115 USA	Drazen, JM (reprint author), Brigham & Womens Hosp, Div Pulm & Crit Care Med, 75 Francis St,Tower 4B, Boston, MA 02115 USA.		Drazen, Jeffrey/E-5841-2012; Wechsler, Michael /B-3979-2013; Wand, Matt /F-9413-2012	Wechsler, Michael /0000-0003-3505-2946; Wand, Matt /0000-0003-2555-896X	NHLBI NIH HHS [P50-HL-56383]		American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P225, DOI DOI 10.1164/AJRCCM/136.1.225; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; BARNES PJ, 1995, CHEST, V107, pS119, DOI 10.1378/chest.107.3_Supplement.119S; BARNES PJ, 1993, EUR RESPIR J, V6, P163; Barnes PJ, 1996, THORAX, V51, P233, DOI 10.1136/thx.51.3.233; BOERWINKLE E, 1986, AM J HUM GENET, V39, P137; BOERWINKLE E, 1988, AM J HUM GENET, V42, P104; Chung E, 1996, AM J HUM GENET, V58, P363; De Sanctis GT, 1999, J EXP MED, V189, P1621, DOI 10.1084/jem.189.10.1621; DeSanctis GT, 1997, AM J PHYSIOL-LUNG C, V273, pL883; Deykin A, 1998, AM J RESP CRIT CARE, V157, P769; FERNANDES L, 1995, AM J RESP CRIT CARE, V151, P1689; Grasemann H, 1999, HUM HERED, V49, P139, DOI 10.1159/000022861; Grasemann H, 1999, CLIN EXP ALLERGY, V29, P39; HALL AV, 1994, J BIOL CHEM, V269, P33082; Hedenstierna G, 1998, EUR RESPIR J, V12, P1248, DOI 10.1183/09031936.98.12061248; HUANG PL, 1993, CELL, V75, P1273, DOI 10.1016/0092-8674(93)90615-W; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; KHARITONOV SA, 1995, CHEST, V107, pS156, DOI 10.1378/chest.107.3_Supplement.156S; Marsh DG, 1997, NAT GENET, V15, P389; Martin JB, 1999, NEW ENGL J MED, V340, P1970; Massaro AF, 1996, AM J RESP CRIT CARE, V153, P1510; MASSARO AF, 1995, AM J RESP CRIT CARE, V152, P800; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Pearson CE, 1998, CURR OPIN STRUC BIOL, V8, P321, DOI 10.1016/S0959-440X(98)80065-1; REILLY SL, 1991, AM J HUM GENET, V49, P1155; Ricciardolo FLM, 1998, LANCET, V351, P449, DOI 10.1016/S0140-6736(05)78400-2; Robbins RA, 1996, AM J RESP CRIT CARE, V153, P1631; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911; Silkoff PE, 1999, CHEST, V116, P754, DOI 10.1378/chest.116.3.754; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Timchenko LT, 1999, CELL MOL LIFE SCI, V55, P1432, DOI 10.1007/s000180050383; Togashi H, 1997, P NATL ACAD SCI USA, V94, P2676, DOI 10.1073/pnas.94.6.2676; TWELLS R, 1995, AM J HUM GENET, V56, P336; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21; WEBER JL, 1989, AM J HUM GENET, V44, P388	39	88	93	0	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC	2000	162	6					2043	2047				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	381ZV	WOS:000165794700013	11112111	
J	Gelb, AF; Zamel, N				Gelb, AF; Zamel, N			Unsuspected pseudophysiologic emphysema in chronic persistent asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							AIR-FLOW OBSTRUCTION; TOTAL LUNG CAPACITY; SMALL-AIRWAYS; FOLLOW-UP; DIAPHRAGM; DISEASE; HYPERINFLATION; MECHANISM; MUSCLE; ADULTS	The current literature emphasizes the role of airway remodeling in chronic persistent asthma and its putative effect on causing fixed expiratory airflow limitation. We studied 18 adults with chronic persistent asthma; 12 men, six women, age 59 +/- 15 yr (mean +/- SD) with fixed expiratory airflow obstruction. We measured lung elastic recoil and examined the mechanism of expiratory airflow limitation. Diaphragmatic strength was also measured in six asthmatics, using both sniff and partially occluded airway technique. All 18 asthmatics had markedly abnormal maximal expiratory flow-volume curves at both high and low lung volumes. Hyperinflation was present at residual volume (RV), FRC, and TLC in all subjects. Diffusing capacity was normal or elevated and lung computed tomography (CT) was normal in all 18 asthmatic subjects. There was a significant loss of lung elastic recoil in three of four asthmatics age 30 to 49, all five age 51 to 60 yr, and seven of nine age 61 to 82 yr. Maximal expiratory airflow limitation in only four elderly asthmatics and only at low lung volumes was due completely to loss of lung elastic recoil. In the others, we estimate the reduction in lung elastic recoil was responsible for 35% reduction in maximal expiratory airflow at 80% of TLC, and 55% at 70% of TLC. Despite hyperinflation, transdiaphragmatic pressures and strength were normal. The mechanisms responsible for loss of lung elastic recoil remain elusive. The high incidence of loss of lung elastic recoil in chronic persistent asthma was unexpected, and its contribution to abnormal lung function needs to be emphasized.	Univ Calif Los Angeles, Sch Med, Div Pulm, Dept Med, Los Angeles, CA USA; Univ Calif Los Angeles, Sch Med, Lakewood Reg Med Ctr, Los Angeles, CA USA; Univ Toronto, Fac Med, Toronto, ON, Canada	Gelb, AF (reprint author), 3650 E South St,Suite 308, Lakewood, CA 90712 USA.						BEALE HD, 1952, J ALLERGY, V23, P1, DOI 10.1016/0021-8707(52)90067-1; BECKMAN KS, 1997, CHEST, V112, P1234; Biernacki W, 1997, EUR RESPIR J, V10, P2455, DOI 10.1183/09031936.97.10112455; BLACK LF, 1969, AM REV RESPIR DIS, V99, P696; BLACKIE SP, 1990, AM REV RESPIR DIS, V142, P79; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; CADE JF, 1973, AUST NZ J MED, V3, P545, DOI 10.1111/j.1445-5994.1973.tb04293.x; Chetta A, 1997, CHEST, V111, P852, DOI 10.1378/chest.111.4.852; FINUCANE KE, 1969, J APPL PHYSIOL, V26, P330; GELB AF, 1975, CHEST, V68, P538, DOI 10.1378/chest.68.4.538; Gelb AF, 1998, AM J RESP CRIT CARE, V158, P815; Gelb AF, 1996, AM J RESP CRIT CARE, V154, P945; Gelb AF, 1996, CHEST, V109, P353, DOI 10.1378/chest.109.2.353; GOLD WM, 1967, J APPL PHYSIOL, V23, P433; KINSELLA M, 1988, CHEST, V94, P286, DOI 10.1378/chest.94.2.286; KNOX AJ, 1994, CLIN SCI, V86, P647; Laghi F, 1998, AM J RESP CRIT CARE, V157, P475; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; MANWELL A, 1974, J APPL PHYSIOL, V37, P297; MCCARTHY DS, 1980, THORAX, V35, P298, DOI 10.1136/thx.35.4.298; MILLER JM, 1985, CLIN SCI, V69, P91; MULLER N, 1980, J APPL PHYSIOL, V49, P869; MULLER N, 1981, J APPL PHYSIOL, V50, P279; PALMER KNV, 1975, BRIT MED J, V1, P485; Pellegrino R, 1996, J APPL PHYSIOL, V81, P964; PERESS L, 1976, AM J MED, V61, P165, DOI 10.1016/0002-9343(76)90165-0; PRIDE NB, 1967, J APPL PHYSIOL, V23, P646; Redington AE, 1997, THORAX, V52, P310; RODARTE JR, 1999, J APPL PHYSIOL, V81, P964; SIMILOWSKI T, 1991, NEW ENGL J MED, V325, P917, DOI 10.1056/NEJM199109263251304; Ulrik CS, 1999, EUR RESPIR J, V14, P892, DOI 10.1034/j.1399-3003.1999.14d27.x; ULRIK CS, 1992, THORAX, V47, P14, DOI 10.1136/thx.47.1.14; WOOLCOCK AJ, 1968, AM REV RESPIR DIS, V98, P788; WOOLCOCK AJ, 1971, AM REV RESPIR DIS, V104, P703; ZAMEL N, 1976, AM REV RESPIR DIS, V113, P337	37	88	88	0	1	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV	2000	162	5					1778	1782				5	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	371WU	WOS:000165202900032	11069812	
J	Wakefield, M; Banham, D; Martin, J; Ruffin, R; McCaul, K; Badcock, N				Wakefield, M; Banham, D; Martin, J; Ruffin, R; McCaul, K; Badcock, N			Restrictions on smoking at home and urinary cotinine levels among children with asthma	AMERICAN JOURNAL OF PREVENTIVE MEDICINE			English	Article						asthma; child; cotinine; family relations; tobacco smoke pollution; smoking	ENVIRONMENTAL TOBACCO-SMOKE; PARENTAL SMOKING; PASSIVE SMOKING; EXPOSURE; HOUSEHOLD	Objectives: The purpose of this study was to determine the extent to which various levels of restrictions on smoking in the home may be associated with children's exposure to environmental tobacco smoke (ETS). Methods: The methodology consisted of a cross-sectional survey involving 249 children with asthma aged 1 to 11 attending hospital outpatient clinics, with at least one parent who smoked, linked to the child's urinary cotinine to creatinine rations (CCR). Results: After adjustment for child's age, mother's smoking status, and total parental daily cigarette consumption, a total ban was associated with significantly lower urinary CCR levels (7.6 nmol/mmol) than bans with exceptions or limited smoking in the home. Where exceptions to bans were made (14.9 nmol/mmol), children's urinary CCR levels were no different from homes in which smoking was allowed in rooms the child rarely frequented (14.1 nmol/mmol). These two intermediate levels of restriction were in turn associated with significantly lower CCR levels than unrestricted smoking in the home (26.0 nmol/mmol). Conclusions: Making exceptions to bans on smoking at home measurably undermines the protective effect of a ban. However, making some exceptions to a ban and limiting smoking to rooms where the child rarely goes may result in reduced exposure to ETS, compared with unrestricted smoking.	Univ Illinois, Hlth Res Ctr, Chicago, IL 60607 USA; Univ Illinois, Policy Ctr, Chicago, IL 60607 USA; Womens & Childrens Hosp, Dip Food Technol, Adelaide, SA, Australia; Queen Elizabeth Hosp, Adelaide, SA, Australia; S Australian Dept Human Serv, Adelaide, SA, Australia	Wakefield, M (reprint author), Univ Illinois, Hlth Res Ctr, 850 W jackson Blvd,Suite 400, Chicago, IL 60607 USA.		McCaul, Kieran/B-8751-2008				Abulhosn RS, 1997, ARCH PEDIAT ADOL MED, V151, P135; Ashley MJ, 1998, TOB CONTROL, V7, P61; Bakoula CG, 1997, CANCER CAUSE CONTROL, V8, P73, DOI 10.1023/A:1018487222533; Benowitz NL, 1999, ENVIRON HEALTH PERSP, V107, P349, DOI 10.2307/3434427; Benowitz NL, 1996, EPIDEMIOL REV, V18, P188; Cook DG, 1999, THORAX, V54, P357; COOK DG, 1994, BRIT MED J, V308, P384; COULTAS DB, 1990, AM REV RESPIR DIS, V142, P602; DELLORCO V, 1995, AM J EPIDEMIOL, V142, P419; EMERSON JA, 1994, ADDICT BEHAV, V19, P677, DOI 10.1016/0306-4603(94)90022-1; EVANS D, 1987, AM REV RESPIR DIS, V135, P567; Farkas AJ, 1999, TOB CONTROL, V8, P261; FRIED PA, 1995, CLIN BIOCHEM, V28, P415, DOI 10.1016/0009-9120(94)00092-A; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; Henschen M, 1997, ENVIRON RES, V72, P65, DOI 10.1006/enrs.1996.3688; Irvine L, 1999, BRIT MED J, V318, P1456; Jaakkola MS, 1997, EUR RESPIR J, V10, P2384, DOI 10.1183/09031936.97.10102384; Lofroth G, 1993, TOB CONTROL, V2, P222, DOI 10.1136/tc.2.3.222; McBride SJ, 1999, J EXPO ANAL ENV EPID, V9, P602, DOI 10.1038/sj.jea.7500057; Oddoze C, 1999, CLIN CHEM, V45, P505; Ott WR, 1999, ENVIRON HEALTH PERSP, V107, P375, DOI 10.2307/3434430; RONCHETTI R, 1994, EUR RESPIR J, V7, P472, DOI 10.1183/09031936.94.07030472; ROSIER MJ, 1994, AM J RESP CRIT CARE, V149, P1431; STRECHER V J, 1989, Health Education Research, V4, P225, DOI 10.1093/her/4.2.225; Tabachnick B. G., 1996, USING MULTIVARIATE S; THOMPSON SG, 1990, CLIN CHIM ACTA, V187, P289, DOI 10.1016/0009-8981(90)90114-8; WAKEFIELD M, IN PRESS HLTH PROM J; Winkelstein ML, 1997, ANN ALLERG ASTHMA IM, V78, P419	28	88	89	2	2	ELSEVIER SCIENCE INC	NEW YORK	655 AVENUE OF THE AMERICAS, NEW YORK, NY 10010 USA	0749-3797			AM J PREV MED	Am. J. Prev. Med.	OCT	2000	19	3					188	192		10.1016/S0749-3797(00)00197-5		5	Public, Environmental & Occupational Health; Medicine, General & Internal	Public, Environmental & Occupational Health; General & Internal Medicine	361ME	WOS:000089726200008	11020596	
J	Bodner, C; Anderson, WJ; Reid, TS; Godden, DJ				Bodner, C; Anderson, WJ; Reid, TS; Godden, DJ		Aberdeen WHEASE Study Grp	Childhood exposure to infection and risk of adult onset wheeze and atopy	THORAX			English	Article						childhood infections; family size; adult onset wheeze; asthma; atopy	FAMILY-SIZE; HAY-FEVER; PREVALENCE; ASSOCIATION; SYMPTOMS; CHILDREN; ASTHMA	Background-The prevalence of asthma and allergic diseases in children and young adults is inversely associated with family size. It has been suggested that more frequent exposure to infections in a large family group, particularly those spread by the faecal-oral route, may protect against atopic diseases, although not all published data support this hypothesis. Whether similar considerations apply to adult onset wheeze is unknown. The relationship between adult onset wheezing and atopy measured in adulthood and childhood exposure to a range of infections was investigated. Methods-A nested case control study of participants in a 30 year follow up survey was conducted. Questionnaire data on childhood infections had been obtained in a 1964 survey. In 1995 a further questionnaire on respiratory symptoms and other risk factors for wheezing illness was administered, total IgE, skin and RAST tests were performed, and serum was stored. In 1999 serological tests for hepatitis A, Helicobacter pylori, and Toxoplasma gondii were performed on the stored samples. Information from the 1964 questionnaires was available for 97 cases and 208 controls and serological tests were obtained for 85 cases and 190 controls. The potential risk factors were examined for all cases, those who reported doctor diagnosed asthma, those who described persistent cough and phlegm with wheeze, and subjects stratified by atopic status. Results-The sibship structure was similar in cases and controls. In univariate analysis of all cases, childhood infections reported by parents as acquired either before or after the age of three years did not influence case:control or atopic status. Seropositivity was also similar for all cases and controls, but cases in the subgroup with chronic cough and phlegm were more likely to be seropositive for hepatitis A and H pylori. Seropositivity was unrelated to atopic status. In multivariate analyses both the effect of having two or more younger siblings (OR 0.1, 95% CI 0.03 to 0.8) and of acquiring measles up to the age of three (OR 0.2, CI 0.03 to 0.8) were significantly related to a lower risk of doctor diagnosed asthma. Conclusions-In these well characterised subjects, exposure to infections as measured by parental reports obtained at age 10-14 years and by serological tests obtained in adulthood did not influence the development of wheezing symptoms or atopic status in adulthood. However, early exposure to measles and family size may be associated with a lower risk of adult onset doctor diagnosed asthma.	Univ Aberdeen, Dept Environm & Occupat Med, Aberdeen AB25 2ZD, Scotland; Aberdeen Royal Infirm, Dept Thorac Med, Aberdeen AB25 2ZN, Scotland; Grampian Univ Hosp Trust, Dept Med Microbiol, Aberdeen AB25 2ZN, Scotland	Godden, DJ (reprint author), Univ Aberdeen, Dept Environm & Occupat Med, Aberdeen AB25 2ZD, Scotland.						Bodner C, 1998, THORAX, V53, P28; Bodner C, 1997, BRIT MED J, V314, P792; Bodner CH, 1998, AM J RESP CRIT CARE, V157, P35; DAWSON B, 1969, LANCET, V1, P827; GODDEN DJ, 1994, AM J RESP CRIT CARE, V149, P106; GOLDING J, 1986, STUDY HLTH BEHAV BRI, P171; Jarvis D, 1997, CLIN EXP ALLERGY, V27, P240; Matricardi PM, 1997, BRIT MED J, V314, P999; MATRICARDI PM, 1997, LANCET, V349, P67; Omran M, 1996, BRIT MED J, V312, P34; PEAT JK, 1994, BRIT MED J, V308, P1591; ROMAGNANI S, 1992, INT ARCH ALLERGY IMM, V98, P279; Shaheen SO, 1996, LANCET, V347, P1792, DOI 10.1016/S0140-6736(96)91617-7; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strachan DP, 1997, CLIN EXP ALLERGY, V27, P151; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strachan DP, 1997, J ALLERGY CLIN IMMUN, V99, P6, DOI 10.1016/S0091-6749(97)81038-X; Strachan DP, 1996, ARCH DIS CHILD, V74, P422; von Mutius E, 1999, EUR RESPIR J, V14, P4, DOI 10.1034/j.1399-3003.1999.14a03.x; VONMUTIUS E, 1994, BRIT MED J, V308, P692	20	88	88	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAY	2000	55	5					383	387		10.1136/thorax.55.5.383		5	Respiratory System	Respiratory System	310GD	WOS:000086817400009	10770819	
J	Fleischer, DM; Perry, TT; Atkins, D; Wood, RA; Burks, AW; Jones, SM; Henning, AK; Stablein, D; Sampson, HA; Sicherer, SH				Fleischer, David M.; Perry, Tamara T.; Atkins, Dan; Wood, Robert A.; Burks, A. Wesley; Jones, Stacie M.; Henning, Alice K.; Stablein, Donald; Sampson, Hugh A.; Sicherer, Scott H.			Allergic Reactions to Foods in Preschool-Aged Children in a Prospective Observational Food Allergy Study	PEDIATRICS			English	Article						food allergy; IgE-mediated allergic reaction; epinephrine	TREE-NUT-ALLERGY; PEANUT ALLERGY; UNITED-STATES; EPINEPHRINE; IGE; ANAPHYLAXIS; CHALLENGES; PREVALENCE; FEATURES; REGISTRY	OBJECTIVE: To examine circumstances of allergic reactions to foods in a cohort of preschool-aged children. METHODS: We conducted a prospective, 5-site observational study of 512 infants aged 3 to 15 months with documented or likely allergy to milk or egg, and collected data prospectively examining allergic reactions. RESULTS: Over a median follow-up of 36 months (range: 0-48.4), the annualized reaction rate was 0.81 per year (367/512 subjects reporting 1171 reactions [95% confidence interval: 0.76-0.85]). Overall, 269/512 (52.5%) reported >1 reaction. The majority of reactions (71.2%) were triggered by milk (495 [42.3%]), egg (246 [21.0%]), and peanut (93 [7.9%]), with accidental exposures attributed to unintentional ingestion, label-reading errors, and cross-contact. Foods were provided by persons other than parents in 50.6% of reactions. Of 834 reactions to milk, egg, or peanut, 93 (11.2%) were attributed to purposeful exposures to these avoided foods. A higher number of food allergies (P < .0001) and higher food-specific immunoglobulin E (P < .0001) were associated with reactions. Of the 11.4% of reactions (n = 134) that were severe, 29.9% were treated with epinephrine. Factors resulting in undertreatment included lack of recognition of severity, epinephrine being unavailable, and fears about epinephrine administration. CONCLUSIONS: There was a high frequency of reactions caused by accidental and nonaccidental exposures. Undertreatment of severe reactions with epinephrine was a substantial problem. Areas for improved education include the need for constant vigilance, accurate label reading, avoidance of nonaccidental exposure, prevention of cross-contamination, appropriate epinephrine administration, and education of all caretakers. Pediatrics 2012;130:e25-e32	[Fleischer, David M.; Atkins, Dan] Natl Jewish Hlth, Denver, CO 80206 USA; [Perry, Tamara T.; Jones, Stacie M.] Univ Arkansas Med Sci, Little Rock, AR 72205 USA; [Wood, Robert A.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Burks, A. Wesley] Duke Univ, Med Ctr, Durham, NC USA; [Henning, Alice K.; Stablein, Donald] EMMES Corp, Rockville, MD USA; [Burks, A. Wesley] Univ N Carolina, Chapel Hill, NC USA; [Sampson, Hugh A.; Sicherer, Scott H.] Mt Sinai Sch Med, Jaffe Food Allergy Inst, New York, NY USA	Fleischer, DM (reprint author), Natl Jewish Hlth, 1400 Jackson St,J321, Denver, CO 80206 USA.	fleischerd@njhealth.org			National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) [U19AI066738, U01AI066560]; National Center for Research Resources, a component of the NIH [UL1 RR025780, UL1 RR029887, UL1 RR029884, UL1 RR024128, UL1 RR025005]; NIH-NIAID; NIH-National Heart, Lung, and Blood Institute; Marion B. Lyon Award; Food Allergy & Anaphylaxis Network; Wallace Research Foundation; National Peanut Board; Food Allergy Initiative; Dyax Corp.; National Institutes of Health (NIH)	Supported by the National Institutes of Health (NIH)-National Institute of Allergy and Infectious Diseases (NIAID) U19AI066738 and U01AI066560. The project was also supported by grants UL1 RR025780 (National Jewish Health), UL1 RR029887 (Mount Sinai School of Medicine), UL1 RR029884 (University of Arkansas for Medical Sciences), UL1 RR024128 (Duke University Medical Center), and UL1 RR025005 (Johns Hopkins University School of Medicine) from the National Center for Research Resources, a component of the NIH. Dr Fleischer received grant support from the NIH-NIAID. Dr Perry received research support from the NIH-National Heart, Lung, and Blood Institute and the Marion B. Lyon Award. Dr Atkins received grant support from the NIH. Dr Wood received grant support from the NIH. Dr Burks received grant support from the NIH, the Food Allergy & Anaphylaxis Network, and the Wallace Research Foundation. Dr Jones received research support from the National Peanut Board, the NIH-NIAID, the Food Allergy Initiative, and Dyax Corp. Dr Stablein received grant support from the NIH. Dr Sampson received research support from the NIH-NIAID and the Food Allergy Initiative. Dr Sicherer received research support from the NIH-NIAID and the Food Allergy Initiative. Funded by the National Institutes of Health (NIH).	American Academy of Pediatrics, 2000, PEDIATRICS 1, V106, P346; Bock SA, 2007, J ALLERGY CLIN IMMUN, V119, P1016, DOI 10.1016/j.jaci.2006.12.622; Boyano-Martinez T, 2009, J ALLERGY CLIN IMMUN, V123, P883, DOI 10.1016/j.jaci.2008.12.1125; Boyce J. A., 2010, Journal of Allergy and Clinical Immunology, V126, pS1; Branum AM, 2009, PEDIATRICS, V124, P1549, DOI 10.1542/peds.2009-1210; Eigenmann PA, 1998, PEDIATRICS, V101, DOI 10.1542/peds.101.3.e8; Eigenmann PA, 2002, ALLERGY, V57, P449, DOI 10.1034/j.1398-9995.2002.13494.x; Furlong TJ, 2001, J ALLERGY CLIN IMMUN, V108, P867, DOI 10.1067/mai.2001.119157; Greenhawt MJ, 2009, J ALLERGY CLIN IMMUN, V124, P598, DOI 10.1016/j.jaci.2009.06.039; Gupta RS, 2011, PEDIATRICS, V128, pE9, DOI 10.1542/peds.2011-0204; Hourihane JO, 1997, CLIN EXP ALLERGY, V27, P634, DOI 10.1046/j.1365-2222.1997.d01-559.x; Jarvinen KM, 2008, J ALLERGY CLIN IMMUN, V122, P133, DOI 10.1016/j.jaci.2008.04.031; Jarvinen KM, 2009, J ALLERGY CLIN IMMUN, V124, P1267, DOI 10.1016/j.jaci.2009.10.006; Kemp SF, 2008, ALLERGY, V63, P1061, DOI 10.1111/j.1398-9995.2008.01733.x; Monks H, 2010, CLIN EXP ALLERGY, V40, P1533, DOI 10.1111/j.1365-2222.2010.03586.x; Nowak-Wegrzyn A, 2001, ARCH PEDIAT ADOL MED, V155, P790; Perry TT, 2004, J ALLERGY CLIN IMMUN, V114, P1164, DOI 10.1016/j.jaci.2004.07.063; Perry TT, 2004, J ALLERGY CLIN IMMUN, V113, P973, DOI 10.1016/j.jaci.2004.02.035; Ross MP, 2008, J ALLERGY CLIN IMMUN, V121, P166, DOI 10.1016/j.jaci.2007.10.012; Rudders SA, 2010, PEDIATRICS, V125, pE711, DOI 10.1542/peds.2009-2832; Sampson HA, 2001, J ALLERGY CLIN IMMUN, V107, P891, DOI 10.1067/mai.2001.114708; Sampson MA, 2006, J ALLERGY CLIN IMMUN, V117, P1440, DOI 10.1016/j.jaci.2006.03.009; Sicherer SH, 2012, J PEDIATR-US, V160, P651, DOI 10.1016/j.jpeds.2011.09.056; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V126, P1191, DOI 10.1016/j.jaci.2010.08.036; Sicherer SH, 2010, J ALLERGY CLIN IMMUN, V125, P1077, DOI 10.1016/j.jaci.2010.02.038; Sicherer SH, 2001, J PEDIATR-US, V138, P560, DOI 10.1067/mpd.2001.111821; Sicherer SH, 1998, PEDIATRICS, V102, part. no., DOI 10.1542/peds.102.1.e6; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P128, DOI 10.1067/mai.2001.115755; Simonte SJ, 2003, J ALLERGY CLIN IMMUN, V112, P180, DOI 10.1067/mai.2003.1486; Vander Leek TK, 2000, J PEDIATR-US, V137, P749, DOI 10.1067/mpd.2000.109376; Yu JW, 2006, J ALLERGY CLIN IMMUN, V118, P466, DOI 10.1016/j.jaci.2006.04.024	31	87	88	2	14	AMER ACAD PEDIATRICS	ELK GROVE VILLAGE	141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA	0031-4005			PEDIATRICS	Pediatrics	JUL	2012	130	1					E25	E32		10.1542/peds.2011-1762		8	Pediatrics	Pediatrics	967KH	WOS:000305905900004	22732173	
J	Bowers, RM; Sullivan, AP; Costello, EK; Collett, JL; Knight, R; Fierer, N				Bowers, Robert M.; Sullivan, Amy P.; Costello, Elizabeth K.; Collett, Jeff L., Jr.; Knight, Rob; Fierer, Noah			Sources of Bacteria in Outdoor Air across Cities in the Midwestern United States	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							RIBOSOMAL-RNA GENE; MICROBIAL COMMUNITIES; BIOLOGICAL PARTICLES; AIRBORNE BACTERIAL; DIVERSITY; SEQUENCES; ATMOSPHERE; ECOLOGY; BIODIVERSITY; VARIABILITY	Bacteria are abundant in the atmosphere, where they often represent a major portion of the organic aerosols. Potential pathogens of plants and livestock are commonly dispersed through the atmosphere, and airborne bacteria can have important effects on human health as pathogens or triggers of allergic asthma and seasonal allergies. Despite their importance, the diversity and biogeography of airborne microorganisms remain poorly understood. We used high-throughput pyrosequencing to analyze bacterial communities present in the aerosol fraction containing fine particulate matter of <= 2.5 mu m from 96 near-surface atmospheric samples collected from cities throughout the midwestern United States and found that the communities are surprisingly diverse and strongly affected by the season. We also directly compared the airborne communities to those found in hundreds of samples representing potential source environments. We show that, in addition to the more predictable sources (soils and leaf surfaces), fecal material, most likely dog feces, often represents an unexpected source of bacteria in the atmosphere at more urbanized locations during the winter. Airborne bacteria are clearly an important, but understudied, component of air quality that needs to be better integrated into efforts to measure and model pollutants in the atmosphere.	[Bowers, Robert M.; Fierer, Noah] Univ Colorado, Dept Ecol & Evolutionary Biol, Boulder, CO 80309 USA; [Sullivan, Amy P.; Collett, Jeff L., Jr.] Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; [Costello, Elizabeth K.] Stanford Univ, Sch Med, Dept Microbiol & Immunol, Stanford, CA 94305 USA; [Knight, Rob] Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA; [Knight, Rob] Howard Hughes Med Inst, Boulder, CO 80309 USA; [Fierer, Noah] Univ Colorado, Cooperat Inst Res Environm Sci, Boulder, CO 80309 USA	Fierer, N (reprint author), Univ Colorado, Dept Ecol & Evolutionary Biol, UCB 216, Boulder, CO 80309 USA.	noah.fierer@colorado.edu	Collett, Jeffrey/F-2862-2010; Knight, Rob/D-1299-2010	Collett, Jeffrey/0000-0001-9180-508X; 	CIRES IRP program; U.S. Environmental Protection Agency; National Science Foundation; Howard Hughes Medical Institute; National Institutes of Health	Support for this work was provided by grants from the CIRES IRP program (to N.F.), the U.S. Environmental Protection Agency (to N.F.), the National Science Foundation (to N.F.), the Howard Hughes Medical Institute, and the National Institutes of Health, and aerosol sample collection for this project was supported by the Lake Michigan Air Directors Consortium (LADCO).	Albrecht A, 2007, ANN AGR ENV MED, V14, P81; American Lung Association, 2007, TRENDS ASTHM MORB MO; American Veterinary Medical Association, 1997, US PET OWN DEM SOURC; Bibby K, 2010, WATER RES, V44, P4252, DOI 10.1016/j.watres.2010.05.039; Bowers RM, 2010, ISME J, V5, P601; Bowers RM, 2009, APPL ENVIRON MICROB, V75, P5121, DOI 10.1128/AEM.00447-09; Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104; Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303; Caporaso JG, 2010, BIOINFORMATICS, V26, P266, DOI 10.1093/bioinformatics/btp636; Christner BC, 2008, SCIENCE, V319, P1214, DOI 10.1126/science.1149757; CHRISTOFF C, 2011, DETROIT WONT BITE DI; Clarke KR, 2001, MAR ECOL PROG SER, V216, P265, DOI 10.3354/meps216265; Costello EK, 2009, SCIENCE, V326, P1694, DOI 10.1126/science.1177486; D'Amato G, 2002, ALLERGY, V57, P30, DOI 10.1034/j.1398-9995.57.s72.5.x; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Durso LM, 2010, APPL ENVIRON MICROB, V76, P4858, DOI 10.1128/AEM.00207-10; Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461; Fierer N, 2008, APPL ENVIRON MICROB, V74, P200, DOI 10.1128/AEM.01467-07; Fierer N, 2008, P NATL ACAD SCI USA, V105, P17994, DOI 10.1073/pnas.0807920105; HIRANO SS, 1983, ANNU REV PHYTOPATHOL, V21, P243, DOI 10.1146/annurev.py.21.090183.001331; Humbert JF, 2009, ENVIRON MICROBIOL, V11, P2339, DOI 10.1111/j.1462-2920.2009.01960.x; Jaenicke R, 2005, SCIENCE, V308, P73, DOI 10.1126/science.1106335; Kim H, 1998, J APPL MICROBIOL, V85, P731, DOI 10.1111/j.1365-2672.1998.00586.x; Lange JL, 1997, APPL ENVIRON MICROB, V63, P1557; Lauber CL, 2009, APPL ENVIRON MICROB, V75, P5111, DOI 10.1128/AEM.00335-09; Lee JE, 2011, ISME J, V5, P362, DOI 10.1038/ismej.2010.120; Ley RE, 2008, SCIENCE, V320, P1647, DOI 10.1126/science.1155725; Lighthart B, 1997, FEMS MICROBIOL ECOL, V23, P263, DOI 10.1016/S0168-6496(97)00036-6; Lighthart B., 2000, AEROBIOLOGIA, V16, P7, DOI DOI 10.1023/A:1007694618888; LINDEMANN J, 1982, APPL ENVIRON MICROB, V44, P1059; Liu ZZ, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn491; Lozupone CA, 2007, APPL ENVIRON MICROB, V73, P1576, DOI 10.1128/AEM.01996-06; Middelbos IS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009768; Mohler O, 2007, BIOGEOSCIENCES, V4, P1059; Moorman Jeanne E., 2011, Morbidity and Mortality Weekly Report, V60, P84; Murakami Y, 2010, MICROBES ENVIRON, V25, P183, DOI 10.1264/jsme2.ME10114; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Pillai SD, 2002, CAN J MICROBIOL, V48, P681, DOI 10.1139/W02-070; Price MN, 2009, MOL BIOL EVOL, V26, P1641, DOI 10.1093/molbev/msp077; Redford AJ, 2010, ENVIRON MICROBIOL, V12, P2885, DOI 10.1111/j.1462-2920.2010.02258.x; Rinsoz T, 2008, ATMOS ENVIRON, V42, P6767, DOI 10.1016/j.atmosenv.2008.05.018; Ritchie LE, 2008, FEMS MICROBIOL ECOL, V66, P590, DOI 10.1111/j.1574-6941.2008.00609.x; Wang Q, 2007, APPL ENVIRON MICROB, V73, P5261, DOI 10.1128/AEM.00062-07; Wiedinmyer C, 2009, ATMOS ENVIRON, V43, P4278, DOI 10.1016/j.atmosenv.2009.06.012; Womack AM, 2010, PHILOS T R SOC B, V365, P3645, DOI 10.1098/rstb.2010.0283; Zhang HH, 2010, MOL BIOL REP, V37, P4013, DOI 10.1007/s11033-010-0060-z; Zwart G, 2002, AQUAT MICROB ECOL, V28, P141, DOI 10.3354/ame028141	47	87	90	5	66	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240			APPL ENVIRON MICROB	Appl. Environ. Microbiol.	SEP	2011	77	18					6350	6356		10.1128/AEM.05498-11		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	817RJ	WOS:000294691400005	21803902	
J	Andersen, B; Frisvad, JC; Sondergaard, I; Rasmussen, IS; Larsen, LS				Andersen, Birgitte; Frisvad, Jens C.; Sondergaard, Ib; Rasmussen, Ib S.; Larsen, Lisbeth S.			Associations between Fungal Species and Water-Damaged Building Materials	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							DANISH HOMES; RESIDENTIAL CHARACTERISTICS; STACHYBOTRYS-CHARTARUM; MOLDY HOMES; MICRO-FUNGI; HOUSE DUST; INDOOR AIR; AIRBORNE; MOISTURE; IDENTIFICATION	Fungal growth in damp or water-damaged buildings worldwide is an increasing problem, which has adverse effects on both the occupants and the buildings. Air sampling alone in moldy buildings does not reveal the full diversity of fungal species growing on building materials. One aim of this study was to estimate the qualitative and quantitative diversity of fungi growing on damp or water-damaged building materials. Another was to determine if associations exist between the most commonly found fungal species and different types of materials. More than 5,300 surface samples were taken by means of V8 contact plates from materials with visible fungal growth. Fungal identifications and information on building material components were analyzed using multivariate statistic methods to determine associations between fungi and material components. The results confirmed that Penicillium chrysogenum and Aspergillus versicolor are the most common fungal species in water-damaged buildings. The results also showed Chaetomium spp., Acremonium spp., and Ulocladium spp. to be very common on damp building materials. Analyses show that associated mycobiotas exist on different building materials. Associations were found between (i) Acremonium spp., Penicillium chrysogenum, Stachybotrys spp., Ulocladium spp., and gypsum and wallpaper, (ii) Arthrinium phaeospermum, Aureobasidium pullulans, Cladosporium herbarum, Trichoderma spp., yeasts, and different types of wood and plywood, and (iii) Aspergillus fumigatus, Aspergillus melleus, Aspergillus niger, Aspergillus ochraceus, Chaetomium spp., Mucor racemosus, Mucor spinosus, and concrete and other floor-related materials. These results can be used to develop new and resistant building materials and relevant allergen extracts and to help focus research on relevant mycotoxins, microbial volatile organic compounds (MVOCs), and microparticles released into the indoor environment.	[Andersen, Birgitte; Frisvad, Jens C.; Sondergaard, Ib] Tech Univ Denmark, CMB, DTU Syst Biol, DK-2800 Lyngby, Denmark; [Rasmussen, Ib S.; Larsen, Lisbeth S.] Danish Technol Inst, DK-2630 Taastrup, Denmark	Andersen, B (reprint author), Tech Univ Denmark, CMB, DTU Syst Biol, Bldg 221, DK-2800 Lyngby, Denmark.	ba@bio.dtu.dk	Andersen, Birgitte/F-3922-2012	Andersen, Birgitte/0000-0002-4544-9886	Villum Fonden	We thank Villum Fonden for financial support.	Andersen B, 2003, MYCOLOGIA, V95, P1227, DOI 10.2307/3761923; Andersen B, 2000, INT BIODETER BIODEGR, V46, P111, DOI 10.1016/S0964-8305(00)00092-5; Andersen B, 2008, INT J FOOD MICROBIOL, V126, P172, DOI 10.1016/j.ijfoodmicro.2008.05.036; Bellanger AP, 2009, LETT APPL MICROBIOL, V49, P260, DOI 10.1111/j.1472-765X.2009.02653.x; Chao HJ, 2002, ENVIRON HEALTH PERSP, V110, P777; de Hoog G. S., 2000, ATLAS CLIN FUNGI; Domsch KH, 1980, COMPENDIUM SOIL FUNG; FRISVAD JC, 1994, AIR QUAL MG, V2, P281; Frisvad JC, 2008, MYCOL RES, V112, P231, DOI 10.1016/j.mycres.2007.08.018; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GRANT C, 1989, INT BIODETERIOR, V25, P259, DOI 10.1016/0265-3036(89)90002-X; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505; GRAVESEN S, 1972, ACTA ALLERGOL, V27, P337, DOI 10.1111/j.1398-9995.1972.tb01433.x; GRAVESEN S, 1978, ALLERGY, V33, P268, DOI 10.1111/j.1398-9995.1978.tb01547.x; Greenacre MJ, 1984, THEORY APPL CORRES A; GRISHKAN I, 2003, ISRAEL MYCOL PROG, V2, P19; Holme J, 2010, INDOOR AIR, V20, P329, DOI 10.1111/j.1600-0668.2010.00658.x; HORNER WE, 1995, CLIN MICROBIOL REV, V8, P161; Hyvarinen A, 2002, INT BIODETER BIODEGR, V49, P27, DOI 10.1016/S0964-8305(01)00103-2; Jarvis J Q, 2001, Appl Occup Environ Hyg, V16, P380, DOI 10.1080/104732201750154242; Kildeso J, 2003, INDOOR AIR, V13, P148, DOI 10.1034/j.1600-0668.2003.00172.x; LARSEN L, 1991, GRANA, V30, P467; Lee TG, 2003, ARCH ENVIRON HEALTH, V58, P442; Miller JD, 2010, CHEM-BIOL INTERACT, V183, P113, DOI 10.1016/j.cbi.2009.09.023; Mitchell CS, 2007, ENVIRON HEALTH PERSP, V115, P958, DOI 10.1289/ehp.8987; Nielsen K, 2002, THESIS TU DENMARK LY; Nielsen KF, 2004, INT BIODETER BIODEGR, V54, P325, DOI 10.1016/j.ibiod.2004.05.002; Nielsen KF, 1998, INT BIODETER BIODEGR, V42, P9, DOI 10.1016/S0964-8305(98)00038-9; Niemeier RT, 2006, J OCCUP ENVIRON HYG, V3, P262, DOI 10.1080/15459620600637333; PARK D, 1982, T BRIT MYCOL SOC, V79, P174; Picart P, 2008, ANTON LEEUW INT J G, V94, P307, DOI 10.1007/s10482-008-9248-9; Polizzi V, 2009, J ENVIRON MONITOR, V11, P1849, DOI 10.1039/b906856b; Rand TG, 2005, TOXICOL SCI, V87, P213, DOI 10.1093/toxsci/kfi223; Rand TG, 2010, ARCH TOXICOL, V84, P205, DOI 10.1007/s00204-009-0481-4; Samson R, 2002, INTRO FOOD AIRBORNE; SAMSON RA, 1994, AIR QUAL MG, V2, P541; Samson R. A., 2010, FOOD INDOOR FUNGI; Sautour M, 2002, J IND MICROBIOL BIOT, V28, P311, DOI 10.1038/sj/jim/7000248; Sen B, 2009, ENVIRON MONIT ASSESS, V151, P209, DOI 10.1007/s10661-008-0262-1; Simon-Nobbe Birgit, 2008, Int Arch Allergy Immunol, V145, P58, DOI 10.1159/000107578; Sivasubramani SK, 2004, INDOOR AIR, V14, P405, DOI 10.1111/j.1600-0668.2004.00262.x; Sneath PHA, 1973, NUMERICAL TAXONOMY; Solovyeva IV, 1999, SYST APPL MICROBIOL, V22, P546; Steiman R, 2004, ANTON LEEUW INT J G, V85, P69, DOI 10.1023/B:ANTO.0000020150.91058.4d; Tucker K, 2007, FUNGAL GENET BIOL, V44, P641, DOI 10.1016/j.fgb.2006.12.007; Tuomi T, 2000, APPL ENVIRON MICROB, V66, P1899, DOI 10.1128/AEM.66.5.1899-1904.2000; VANREENENHOEKSTRA ES, 1991, GRANA, V30, P418; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; Viitanen H, 2010, J BUILD PHYS, V33, P201, DOI 10.1177/1744259109343511; Vijay HM, 2005, AEROBIOLOGIA, V21, P95, DOI 10.1007/s10453-005-4179-7; Walinder R, 2005, ENVIRON HEALTH PERSP, V113, P1775, DOI 10.1289/ehp.8193; *WHO REG OFF EUR, WHO GUID IND QUAL DA; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E	53	87	88	7	50	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240			APPL ENVIRON MICROB	Appl. Environ. Microbiol.	JUN	2011	77	12					4180	4188		10.1128/AEM.02513-10		9	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	773WI	WOS:000291341800032	21531835	
J	Eden, T				Eden, Tim			Aetiology of childhood leukaemia	CANCER TREATMENT REVIEWS			English	Review						Aetiology; Childhood leukaemia	ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDRENS-CANCER-GROUP; NON-HODGKINS-LYMPHOMA; DAY-CARE ATTENDANCE; PARENTAL ALCOHOL-CONSUMPTION; ACUTE LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; VOLTAGE POWER-LINES; VITAMIN-K; IONIZING-RADIATION	The acute leukaemias account for about 30% of all malignancy seen in childhood across the Western world. A peak incidence of precursor B cell ALL has emerged as socio-economic conditions have improved in countries worldwide. From twin studies and the use of neonatal blood spots it has been possible to back track the first initiating genetic events within critical haemopoietic cells to foetal development in utero for most precursor B cell ALL and some cases of AML These events may occur as part of normal foetal development. Whether other factors (environmental or constitutional) are involved to increase the chance of these first genetic changes happening is unclear. For some leukaemias (e.g. infant MLL positive ALL) the first event appears adequate to create a malignant clone but for the majority of ALL and AML further 'genetic' changes are required, probably postnatal. Many environmental factors have been proposed as causative for leukaemia but only ionising irradiation and certain chemicals, e.g. benzene and cytotoxics (alkylators and topoisomerase II inhibitors) have been confirmed and then principally for acute myeloid leukaemia. It appears increasingly likely that delayed. dysregulated responses to 'common' infectious agents play a major part in the conversion of pre-leukaemic clones into overt precursor B cell ALL the most common form of childhood leukaemia. Constitutional polymorphic alleleic variants in immune response genes (especially the HLA Class II proteins) and cytokines may play a role in determining the type of immune response. High penetrance germ-line mutations are involved in only about 5% of childhood leukaemias (more in AML than ALL). There is little evidence to support any role of viral transformation in causation, unlike in animals. Other environmental factors for which some evidence exists include non-ionising electromagnetic radiation and electric fields, although their mode of action in leukaemogenesis remains unclear. There is no single cause for childhood leukaemia and for most individuals a combination of factors appears to be necessary; all involving gene-environment interactions. To date few clear preventative measures have emerged, except the complete avoidance of first trimester X-rays in pregnancy; a healthy diet with adequate oral folic acid intake both preconception and early in pregnancy; and the early exposure of children to other children outside the home to facilitate stimulation and maturation of the natural immune system. Here then are clear echoes of the "hygiene hypothesis" regarding the initiation of allergies, autoimmune disease and type I diabetes mellitus in children and young people. (C) 2010 Published by Elsevier Ltd.	Univ Manchester, Christie Hosp NHS Fdn Trust, Acad Unit Paediat & Adolescent Oncol, Teenage Canc Trust Young Oncol Unit, Manchester M20 4BX, Lancs, England	Eden, T (reprint author), Univ Manchester, Christie Hosp NHS Fdn Trust, Acad Unit Paediat & Adolescent Oncol, Teenage Canc Trust Young Oncol Unit, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	Tim.eden@manchester.ac.uk			Teenage Cancer Trust	T.E. is funded by the Teenage Cancer Trust. The author would wish to acknowledge the long term collaboration and friendship of the team with who he has been involved over the last 30 years in epidemiological research especially Jill Birch, Mel Greaves, Richard McNally and Malcolm Taylor.	Adelman AS, 2007, BRIT J CANCER, V97, P140, DOI 10.1038/sj.bjc.6603793; Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; ALEXANDER FE, 1996, IARC SCI PUBL, V135, P21; ALVORD EC, 1987, J CHILD NEUROL, V2, P313; ANSELL P, 2004, BR J MIDWIFERY, V12, P38; Axelson O, 2002, EPIDEMIOLOGY, V13, P146, DOI 10.1097/00001648-200203000-00008; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; BENDER AP, 1988, CANCER RES, V48, P2919; Beral V, 2001, BRIT J CANCER, V85, P1685; Bogdanovic G, 2004, BRIT J CANCER, V91, P913, DOI 10.1038/sj.bjc.6602099; BUCKLEY JD, 1994, LEUKEMIA, V8, P856; Chen J, 1996, CANCER RES, V56, P4862; Cheng KK, 1999, LANCET, V354, P1925; CNATTINGIUS S, 1995, J NATL CANCER I, V87, P908, DOI 10.1093/jnci/87.12.908; Costas K, 2002, SCI TOTAL ENVIRON, V300, P23, DOI 10.1016/S0048-9697(02)00169-9; Crosignani P, 2004, INT J CANCER, V108, P596, DOI 10.1002/ijc.11597; Dickinson HO, 2005, BRIT MED J, V330, P1279, DOI 10.1136/bmj.330.7503.1279; DOCHERTY JD, 1999, BRIT J CANCER, V80, P1483; Doll R, 1997, BRIT J RADIOL, V70, P130; Dorak MT, 1999, BLOOD, V94, P694; Draper G, 2005, BRIT MED J, V330, P1290, DOI 10.1136/bmj.330.7503.1290; Fear NT, 2003, BRIT J CANCER, V89, P1228, DOI 10.1038/sj.bjc.6601278; Felix CA, 1998, P NATL ACAD SCI USA, V95, P13176, DOI 10.1073/pnas.95.22.13176; Fews AP, 1999, INT J RADIAT BIOL, V75, P1523; Feychting M, 1998, SCAND J WORK ENV HEA, V24, P8; FEYCHTING M, 1993, AM J EPIDEMIOL, V138, P467; FORD AM, 1993, NATURE, V363, P358, DOI 10.1038/363358a0; Ford AM, 1997, BLOOD, V89, P281; FORD AM, 2004, BLOOD, V104, P566; Gale KB, 1997, P NATL ACAD SCI USA, V94, P13950, DOI 10.1073/pnas.94.25.13950; Gilham C, 2005, BRIT MED J, V330, P1294, DOI 10.1136/bmj.38428.521042.8F; GOLDING J, 1992, BRIT MED J, V305, P341; Greaves M, 2002, BRIT MED J, V324, P283, DOI 10.1136/bmj.324.7332.283; Greaves M, 2006, NAT REV CANCER, V6, P193, DOI 10.1038/nrc1816; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Greaves MF, 1997, LANCET, V349, P344, DOI 10.1016/S0140-6736(96)09412-3; Greaves MF, 2003, BLOOD, V102, P2321, DOI 10.1182/blood-2002-12-3817; GREAVES MF, 1988, LEUKEMIA, V2, P120; Greenland S, 2000, EPIDEMIOLOGY, V11, P624, DOI 10.1097/00001648-200011000-00003; Groves FD, 1999, BRIT J CANCER, V81, P175, DOI 10.1038/sj.bjc.6690668; Hasle H, 2001, Lancet Oncol, V2, P429, DOI 10.1016/S1470-2045(00)00435-6; Hatch EE, 1998, EPIDEMIOLOGY, V9, P234, DOI 10.1097/00001648-199805000-00006; Heegaard ED, 2001, BRIT J HAEMATOL, V114, P810, DOI 10.1046/j.1365-2141.2001.03021.x; Henshaw DL, 1996, INT J RADIAT BIOL, V69, P25, DOI 10.1080/095530096146156; Hjalgrim LL, 2002, BRIT J CANCER, V87, P994, DOI 10.1038/sj.bjc.6600601; Hughes AM, 2007, INT J CANCER, V121, P819, DOI 10.1002/ijc.22702; Infante-Rivard C, 2000, BRIT J CANCER, V83, P1559, DOI 10.1054/bjoc.2000.1495; Infante-Rivard C, 2003, HEALTH PHYS, V85, P60, DOI 10.1097/00004032-200307000-00012; Infante-Rivard C, 2002, EPIDEMIOLOGY, V13, P277, DOI 10.1097/00001648-200205000-00007; Infante-Rivard C, 2001, EPIDEMIOLOGY, V12, P13, DOI 10.1097/00001648-200101000-00004; Isa A, 2004, PEDIATR BLOOD CANCER, V42, P357, DOI 10.1002/pbc.20001; ISHIKAWA K, 1995, J PEDIAT HEMATOL ONC, V17, P270, DOI 10.1097/00043426-199508000-00010; Jensen CD, 2004, CANCER CAUSE CONTROL, V15, P559, DOI 10.1023/B:CACO.0000036161.98734.17; Kaletsch U, 1999, RADIAT ENVIRON BIOPH, V38, P211, DOI 10.1007/s004110050158; Kelsey KT, 1997, BRIT J CANCER, V76, P852, DOI 10.1038/bjc.1997.474; Kerr JR, 2003, J CLIN PATHOL, V56, P873, DOI 10.1136/jcp.56.11.873; Kersey JH, 1997, BLOOD, V90, P4243; Kheifets L, 2008, RADIAT PROT DOSIM, V132, P139, DOI 10.1093/rpd/ncn260; Kim YI, 2006, GUT, V55, P1387, DOI 10.1136/gut.2006.095463; Kinlen L, 2004, BRIT J CANCER, V91, P1, DOI 10.1038/sj.bjc.6601982; KINLEN L, 1988, LANCET, V2, P1323; KINLEN LJ, 1990, LANCET, V336, P577, DOI 10.1016/0140-6736(90)93389-7; KINLEN LJ, 1991, BRIT MED J, V303, P1357; KINLEN LJ, 1994, BRIT MED J, V309, P1197; Kinlen LJ, 2001, LANCET, V357, P858, DOI 10.1016/S0140-6736(00)04208-2; KOLB H, 1994, DIABETOLOGIA, V37, P729, DOI 10.1007/BF00417700; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939; Law GR, 2003, AM J EPIDEMIOL, V158, P328, DOI 10.1093/aje/kwg165; Lehtinen M, 2003, AM J EPIDEMIOL, V158, P207, DOI 10.1093/aje/kwg137; Little J, 1999, IARC SCI PUBLICATION, V149; Ma X, 2002, BRIT J CANCER, V86, P1419, DOI 10.1038/sj/bjc/6600274; Ma XM, 2005, CANCER EPIDEM BIOMAR, V14, P1928, DOI 10.1158/1055-9965.EPI-05-0115; MacKenzie J, 1999, BRIT J CANCER, V81, P898, DOI 10.1038/sj.bjc.6690783; MacKenzie J, 2001, LEUKEMIA, V15, P415, DOI 10.1038/sj.leu.2402049; Maia AT, 2001, BLOOD, V98, P478, DOI 10.1182/blood.V98.2.478; Mason JB, 2009, NUTR REV, V67, P206, DOI 10.1111/j.1753-4887.2009.00190.x; McKinney PA, 1999, BRIT J CANCER, V80, P1844, DOI 10.1038/sj.bjc.6690609; McKinney PA, 2000, DIABETIC MED, V17, P236, DOI 10.1046/j.1464-5491.2000.00220.x; MCKINNEY PA, 1987, ARCH DIS CHILD, V62, P279; McNally RJQ, 2004, BRIT J HAEMATOL, V127, P243, DOI 10.1111/j.1365-2141.2004.05166.x; Meinert R, 1999, CANCER EPIDEM BIOMAR, V8, P793; Meinert R, 2000, AM J EPIDEMIOL, V151, P639; Meinert R, 2000, AM J EPIDEMIOL, V151, P647; Mori H, 2002, P NATL ACAD SCI USA, V99, P8242, DOI 10.1073/pnas.112218799; Naumburg E, 2002, MED PEDIATR ONCOL, V38, P391, DOI 10.1002/mpo.10084; NISHI M, 1989, J EPIDEMIOL COMMUN H, V43, P352, DOI 10.1136/jech.43.4.352; Pang D, 2003, BRIT J CANCER, V88, P373, DOI 10.1038/sj.bjc.6600774; Parker L, 1998, BRIT MED J, V316, P189; Parkin D. M., 1998, IARC SCI PUBLICATION, V144; Parslow RC, 2002, EUR J CANCER, V38, P2033, DOI 10.1016/S0959-8049(02)00316-7; Passmore SJ, 1998, BRIT MED J, V316, P178; Perrillat F, 2002, EUR J PEDIATR, V161, P235, DOI 10.1007/s00431-001-0906-4; Petridou E, 1997, BRIT J CANCER, V76, P1241, DOI 10.1038/bjc.1997.541; POYNTON FJ, 1992, BRIT J CHILD DIS, V19, P128; Priftakis P, 2003, MED PEDIATR ONCOL, V40, P219, DOI 10.1002/mpo.10246; Pui C, 2004, NEW ENGL J MED, V350, P1535, DOI 10.1056/NEJMra023001; Reynolds P, 2002, AM J EPIDEMIOL, V155, P603, DOI 10.1093/aje/155.7.603; Roman E, 1997, BRIT J CANCER, V76, P406, DOI 10.1038/bjc.1997.399; Roman E, 2005, EUR J CANCER, V41, P749, DOI 10.1016/j.ejca.2004.11.006; Roman E, 2002, BRIT J CANCER, V86, P63, DOI 10.1038/sj/bjc/6600007; ROSS JA, 1994, J NATL CANCER I, V86, P1678, DOI 10.1093/jnci/86.22.1678; Ross JA, 1996, CANCER CAUSE CONTROL, V7, P581, DOI 10.1007/BF00051700; Savitz DA, 1997, AM J IND MED, V31, P287; Schuz J, 1999, BRIT J CANCER, V80, P585, DOI 10.1038/sj.bjc.6690395; Schuz J, 2000, CANCER EPIDEM BIOMAR, V9, P835; SENATOR H, 1882, BERLINER KLIN WOCHEN, V35, P533; SEVERSON RK, 1993, CANCER EPIDEM BIOMAR, V2, P433; Shiramizu B, 2002, PEDIATR HEMAT ONCOL, V19, P543, DOI 10.1080/08880010290097396; Shu XO, 1999, CANCER EPIDEM BIOMAR, V8, P783; SHU XO, 1988, CANCER, V62, P635, DOI 10.1002/1097-0142(19880801)62:3<635::AID-CNCR2820620332>3.0.CO;2-3; Shu XO, 1996, JNCI-J NATL CANCER I, V88, P24, DOI 10.1093/jnci/88.1.24; Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810; Skinner J, 2002, BRIT J CANCER, V87, P1257, DOI 10.1068/sj.bjc.6606602; Smith MA, 1998, CANCER CAUSE CONTROL, V9, P285, DOI 10.1023/A:1008873103921; Smith MA, 1999, MED PEDIATR ONCOL, V33, P441, DOI 10.1002/(SICI)1096-911X(199911)33:5<441::AID-MPO1>3.0.CO;2-P; Smith MT, 2002, BLOOD, V100, P4590, DOI 10.1182/blood-2001-12-0264; Sorahan T, 1997, BRIT J CANCER, V76, P1525, DOI 10.1038/bjc.1997.589; STEWART A, 1958, BRIT MED J, V1, P1495; Stiller CA, 2008, BRIT J CANCER, V98, P1006, DOI 10.1038/sj.bjc.6604237; Stiller CA, 1996, BRIT MED J, V313, P1297; Strachan David P., 2000, Thorax, V55, pS2, DOI 10.1136/thorax.55.suppl_1.S2; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Strick R, 2000, P NATL ACAD SCI USA, V97, P4790, DOI 10.1073/pnas.070061297; Taylor GM, 2002, HUM MOL GENET, V11, P1585; Taylor GM, 1998, BRIT J CANCER, V78, P561, DOI 10.1038/bjc.1998.540; Birch JM., 1996, LEUKEMIA, P210; Thompson JR, 2001, LANCET, V358, P1935, DOI 10.1016/S0140-6736(01)06959-8; Thornton AJ, 1998, INDOOR BUILT ENVIRON, V7, P65, DOI 10.1159/000024566; Twisselmann B, 2005, BRIT MED J, V331, P636, DOI 10.1136/bmj.331.7517.636; Urayama KY, 2008, RADIAT PROT DOSIM, V132, P259, DOI 10.1093/rpd/ncn271; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; Westerbeek RMC, 1998, BRIT J CANCER, V78, P119, DOI 10.1038/bjc.1998.452; Wiemels JL, 1999, CANCER RES, V59, P4095; Wiemels JL, 2001, P NATL ACAD SCI USA, V98, P4004, DOI 10.1073/pnas.061408298; Wiemels JL, 1999, LANCET, V354, P1499, DOI 10.1016/S0140-6736(99)09403-9; Wiemels JL, 2002, BLOOD, V99, P3801, DOI 10.1182/blood.V99.10.3801; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; 2002, BRIT J CANC, V86, P1727; 2002, BRIT J CANC, V86, P1721; 2000, BRIT J CANC, V82, P1073	142	87	92	3	37	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0305-7372			CANCER TREAT REV	Cancer Treat. Rev.	JUN	2010	36	4			SI		286	297		10.1016/j.ctrv.2010.02.004		12	Oncology	Oncology	614XZ	WOS:000279094400002	20223594	
J	Eifan, AO; Akkoc, T; Yildiz, A; Keles, S; Ozdemir, C; Bahceciler, NN; Barlan, IB				Eifan, A. O.; Akkoc, T.; Yildiz, A.; Keles, S.; Ozdemir, C.; Bahceciler, N. N.; Barlan, I. B.			Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/rhinitis children sensitized to house dust mite: an open randomized controlled trial	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; cytokines; nasal provocation; rhinitis; sublingual-subcutaneous immunotherapy	GRASS-POLLEN IMMUNOTHERAPY; ALLERGEN-SPECIFIC IMMUNOTHERAPY; T-REGULATORY CELLS; DOUBLE-BLIND; PEDIATRIC-PATIENTS; DOUBLE-DUMMY; ASTHMA; RHINITIS; CHILDHOOD; METAANALYSIS	Background In children, the clinical efficacy and immunological mechanisms of sublingual immunotherapy (SLIT) compared with subcutaneous immunotherapy (SCIT) is still to be elucidated. Objectives To compare SLIT, SCIT and pharmacotherapy in relation to clinical efficacy and immunological mechanisms that govern its effect in asthmatic/rhinitis children who were sensitized to house dust mite (HDM). Methods In this single centre, prospective, randomized, controlled, open labelled, three parallel group trial, 48 patients mono-sensitized to HDM were randomized to receive either SLIT (n = 16), SCIT (n = 16) or pharmacotherapy alone (n = 16). Symptom, medication and visual analogue score (VAS) were collected and bronchial-nasal hyper-reactivity, skin prick tests, total-specific IgE were performed at baseline and 12 months after treatment. In addition, peripheral blood mononuclear cells were cultured with recombinant Der p 1 and Bet v 1 extracts and allergen-specific IL-4, IL-5, IL-13, IFN-gamma, IL-10, and TGF-beta secretions were measured. Results SLIT and SCIT demonstrated a significant reduction of total rhinitis and asthma symptom score, total medication score, VAS and skin reactivity to HDM (P<0.05) when compared with pharmacotherapy. A significant reduction of serum-specific HDM-IgE in SCIT and SLIT were observed. Moreover, titrated nasal provocative dose significantly increased in both immunotherapy groups when compared with the pharmacotherapy group. No adverse effects were reported in SLIT, while two patients demonstrated serious adverse events in SCIT. After 1 year of treatment, Der p 1-driven IL-10 significantly increased in SLIT compared with pharmacotherapy, whereas Bet v 1-driven TGF-beta (negative control) increased significantly in SLIT only. No changes were observed for Th1-Th2 cytokines. Conclusion Both SLIT and SCIT demonstrated clinical improvement compared with pharmacotherapy in asthma/rhinitis children sensitized to HDM.	[Eifan, A. O.; Akkoc, T.; Yildiz, A.; Keles, S.; Ozdemir, C.; Bahceciler, N. N.; Barlan, I. B.] Marmara Univ, Fac Med, Div Pediat Allergy & Immunol, Istanbul, Turkey; [Eifan, A. O.] Univ London Imperial Coll Sci Technol & Med, Fac Med, NHLI, Allergy & Clin Immunol Sect, London SW7 2AZ, England	Eifan, AO (reprint author), Marmara Univ, Fac Med, Div Pediat Allergy & Immunol, Istanbul, Turkey.	a.eifan@imperial.ac.uk		Eifan, Aarif/0000-0003-4098-4211	The Marmara University Scientific Research Committee [TIP/SAG-TUS-140607-0114]	We express our appreciation to Aysegul Izgi, M.Sc. and Ayzer Tevetoglu, M.Sc., for their contributions to the study. This work was supported by The Marmara University Scientific Research Committee (BAPKO no. TIP/SAG-TUS-140607-0114, 2007).	Abramson M. J., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001186; Ait-Khaled N, 2007, ALLERGY, V62, P247, DOI 10.1111/j.1398-9995.2007.01325.x; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; Amar SM, 2009, J ALLERGY CLIN IMMUN, V124, P150, DOI 10.1016/j.jaci.2009.04.037; Antunez C, 2008, PEDIATR ALLERGY IMMU, V19, P210, DOI 10.1111/j.1399-3038.2007.00604.x; Arikan C, 2004, CLIN EXP ALLERGY, V34, P398, DOI 10.1111/j.1365-2222.2004.01869.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Bacharier LB, 2008, ALLERGY, V63, P5, DOI 10.1111/j.1398-9995.2007.01586.x; Bahceciler NN, 2005, INT ARCH ALLERGY IMM, V136, P287, DOI 10.1159/000083956; Bohle B, 2007, J ALLERGY CLIN IMMUN, V120, P707, DOI 10.1016/j.jaci.2007.06.013; Bousquet J., 1998, Allergy (Copenhagen), V53, P1; Calderon MA, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001936.pub2; Cosmi L, 2006, CLIN EXP ALLERGY, V36, P261, DOI 10.1111/j.1365-2222.2006.02429.x; Dehlink E, 2006, CLIN EXP ALLERGY, V36, P32, DOI 10.1111/j.1365-2222.2006.02400.x; Di Lorenzo G, 2009, J ALLERGY CLIN IMMUN, V123, P1103, DOI 10.1016/j.jaci.2009.02.012; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Francis JN, 2008, J ALLERGY CLIN IMMUN, V121, P1120, DOI 10.1016/j.jaci.2008.01.072; Gafvelin G, 2005, INT ARCH ALLERGY IMM, V138, P59, DOI 10.1159/000087358; Gardner LM, 2004, CLIN EXP ALLERGY, V34, P1209, DOI 10.1111/j.1365-2222.2004.02009.x; Global Initiative for Asthma Management and Prevention, 2006, NHLBI WHO WORKSH REP; JUTEL M, 1995, J IMMUNOL, V154, P4187; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Majori M, 2000, CLIN EXP ALLERGY, V30, P341, DOI 10.1046/j.1365-2222.2000.00701.x; Mauro M, 2007, Eur Ann Allergy Clin Immunol, V39, P119; Mungan D, 1999, ANN ALLERG ASTHMA IM, V82, P485, DOI 10.1016/S1081-1206(10)62726-3; Novak N, 2008, TRENDS MOL MED, V14, P191, DOI 10.1016/j.molmed.2008.03.001; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Ozdemir C, 2007, PEDIATR ALLERGY IMMU, V18, P508, DOI 10.1111/j.1399-3038.2007.00549.x; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; Quirino T, 1996, CLIN EXP ALLERGY, V26, P1253, DOI 10.1046/j.1365-2222.1996.d01-280.x; Roberts G, 2006, J ALLERGY CLIN IMMUN, V117, P263, DOI 10.1016/j.jaci.2005.09.054; Tahamiler R, 2008, ORL J OTO-RHINO-LARY, V70, P144, DOI 10.1159/000124286; Wachholz PA, 2002, IMMUNOLOGY, V105, P56, DOI 10.1046/j.1365-2567.2002.01338.x; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x	36	87	101	2	15	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JUN	2010	40	6					922	932		10.1111/j.1365-2222.2009.03448.x		11	Allergy; Immunology	Allergy; Immunology	592TE	WOS:000277402400013	20100188	
J	Juhn, YJ; Kita, H; Yawn, BP; Boyce, TG; Yoo, KH; McGree, ME; Weaver, AL; Wollan, P; Jacobson, RM				Juhn, Young J.; Kita, Hirohito; Yawn, Barbara P.; Boyce, Thomas G.; Yoo, Kwang H.; McGree, Michaela E.; Weaver, Amy L.; Wollan, Peter; Jacobson, Robert M.			Increased risk of serious pneumococcal disease in patients with asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; invasive pneumococcal disease; epidemiology; risk; microbial infection; pneumococcal pneumonia; adults; Rochester Epidemiology Project	IMMUNE-RESPONSE; VACCINE; EPIDEMIOLOGY; COMMUNITY; MICE; INFECTIONS; PNEUMONIAE; CHILDHOOD; CLEARANCE; SYMPTOMS	Background: Individuals with asthma have been reported to be at increased risk of invasive pneumococcal disease (IPD). These findings need to be confirmed in a different population-based study setting. Objective: We assessed whether serious pneumococcal disease (SPD), defined as an IPD, pneumococcal pneumonia, or both, was associated with asthma status. Methods: This is a retrospective case-control study using criteria-based methods for ascertaining SPD, as well as asthma. Subjects were residents of Rochester, Minnesota, who had SPD between 1964 and 1983 (the primarily pre-pneumococcal vaccine era) and their age-and sex-matched control subjects using 1:2 matching. Potential cases and control subjects were identified by using the Rochester Epidemiology project database and confirmed by medical record reviews. All cases and control subjects were merged with the database comprising the entire pool of Rochester residents with and without asthma between 1964 and 1983. Results: A total of 3941 records of potential patients with SPD were reviewed, and we identified 174 cases of SPD (51% male subjects and 94% white subjects). SPD was associated with a history of asthma among all ages (odds ratio, 2.4; 95% CI, 0.96.6; P = .09) and among adults (odds ratio, 6.7; 95% CI, 1.627.3; P = .01), controlling for high-risk conditions for IPD and smoking exposure. The population-attributable risk percentage was 17% in the adult population. Conclusion: Adults with asthma might be at increased risk of SPD.	[Juhn, Young J.] Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, Rochester, MN 55905 USA; [Yawn, Barbara P.; Wollan, Peter] Olmsted Med Ctr, Dept Res, Rochester, MN USA; [Yoo, Kwang H.] Konkuk Univ, Sch Med, Dept Internal Med, Seoul, South Korea; [McGree, Michaela E.; Weaver, Amy L.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA	Juhn, YJ (reprint author), Mayo Clin, Dept Pediat & Adolescent Med, Div Community Pediat & Adolescent Med, 200 1st St SW, Rochester, MN 55905 USA.	juhn.young@mayo.edu		Jacobson, Robert/0000-0002-6355-8752	National Institutes of Health [R01 AI 56133]	Supported by a National Institutes of Health grant (R01 AI 56133) from the National Institute of Allergy and Infectious Diseases.	*AM AC PED, 2006, RED BOOK 2006; Arkwright PD, 2000, CLIN EXP IMMUNOL, V122, P16, DOI 10.1046/j.1365-2249.2000.01338.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; BEARD CM, 1992, J CLIN EPIDEMIOL, V45, P1013; BRODER I, 1974, J ALLERGY CLIN IMMUN, V54, P100, DOI 10.1016/0091-6749(74)90038-4; BUSSE WW, 1991, REV INFECT DIS, V13, pS477; *CDC, 1997, ACT BACT COR SURV RE; Chaplin DD, 2007, J ALLERGY CLIN IMMUN, V119, pS132, DOI 10.1016/j.jaci.2006.11.647; Chinn S, 2004, THORAX, V59, P646, DOI 10.1136/thx.2004.021642; Contoli M, 2006, NAT MED, V12, P1023, DOI 10.1038/nm1462; Fahy J V, 2000, Curr Opin Pulm Med, V6, P15, DOI 10.1097/00063198-200001000-00004; Fischer JE, 1997, J VIROL, V71, P8672; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GROVE DI, 1975, J ALLERGY CLIN IMMUN, V55, P152, DOI 10.1016/0091-6749(75)90011-1; Juhn YJ, 2006, ANN ALLERG ASTHMA IM, V97, P469; Katusic SK, 1998, MAYO CLIN PROC, V73, P1053; Kelsey JL, 1996, METHODS OBSERVATIONA; KincyCain T, 1996, INFECT IMMUN, V64, P1437; KURLAND LT, 1981, SCI AM, V245, P54; LAHOOD N, 1993, ANN ALLERGY, V70, P289; LEE HJ, 1995, VACCINE, V13, P1533; Lethbridge-Cejku M, 2005, VITAL HLTH STAT, V10, P1; Nuorti JP, 2000, NEW ENGL J MED, V342, P681, DOI 10.1056/NEJM200003093421002; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Talbot TR, 2005, NEW ENGL J MED, V352, P2082, DOI 10.1056/NEJMoa044113; TSIGRELIS C, 1999, 45 ANN INF DIS SOC A; *US BUR CENS, 1980, PHC802305 US BUR CEN; Wark PAB, 2005, J EXP MED, V201, P937, DOI 10.1084/jem.20041901; *WHO, 2005, N307 WHO; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; [Anonymous], 1998, MMWR MORB MORTAL WKL, V47, P1022	31	87	88	0	4	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2008	122	4					719	723		10.1016/j.jaci.2008.07.029		5	Allergy; Immunology	Allergy; Immunology	359LU	WOS:000259989000014	18790525	
J	Bousquet, J; Fokkens, W; Burney, P; Durham, SR; Bachert, C; Akdis, CA; Canonica, GW; Dahlen, SE; Zuberbier, T; Bieber, T; Bonini, S; Bousquet, PJ; Brozek, JL; Cardell, LO; Crameri, R; Custovic, A; Demoly, P; van Wijk, RG; Gjomarkaj, M; Holland, C; Howarth, P; Humbert, M; Johnston, SL; Kauffmann, F; Kowalski, ML; Lambrecht, B; Lehmann, S; Leynaert, B; Lodrup-Carlsen, K; Mullol, J; Niggemann, B; Nizankowska-Mogilnicka, E; Papadopoulos, N; Passalacqua, G; Schunemann, HJ; Simon, HU; Todo-Bom, A; Toskala, E; Valenta, R; Wickman, M; Zock, JP				Bousquet, J.; Fokkens, W.; Burney, P.; Durham, S. R.; Bachert, C.; Akdis, C. A.; Canonica, G. W.; Dahlen, S. -E.; Zuberbier, T.; Bieber, T.; Bonini, S.; Bousquet, P. J.; Brozek, J. L.; Cardell, L. -O.; Crameri, R.; Custovic, A.; Demoly, P.; van Wijk, R. G.; Gjomarkaj, M.; Holland, C.; Howarth, P.; Humbert, M.; Johnston, S. L.; Kauffmann, F.; Kowalski, M. L.; Lambrecht, B.; Lehmann, S.; Leynaert, B.; Lodrup-Carlsen, K.; Mullol, J.; Niggemann, B.; Nizankowska-Mogilnicka, E.; Papadopoulos, N.; Passalacqua, G.; Schuenemann, H. J.; Simon, H. -U.; Todo-Bom, A.; Toskala, E.; Valenta, R.; Wickman, M.; Zock, J. P.			Important research questions in allergy and related diseases: nonallergic rhinitis: a GA(2)LEN paper	ALLERGY			English	Review						asthma; epidemiology; GA(2)LEN; inflammation; nonallergic; rhinitis	NONINFECTIOUS PERENNIAL RHINITIS; RESPIRATORY-HEALTH-SURVEY; QUALITY-OF-LIFE; INDEPENDENT RISK-FACTOR; EUROPEAN BIRTH COHORT; LOCAL IGE PRODUCTION; SKIN-TEST REACTIVITY; NASAL-MUCOSA; AIR-POLLUTION; EOSINOPHIL APOPTOSIS	Nonallergic rhinitis (NAR) can be defined as a chronic nasal inflammation which is not caused by systemic IgE-dependent mechanisms. It is common and probably affects far more than 200 million people worldwide. Both children and adults are affected. However, its exact prevalence is unknown and its phenotypes need to be evaluated using appropriate methods to better understand its pathophysiology, diagnosis and management. It is important to differentiate between infectious rhinitis, allergic/NAR and chronic rhinosinusitis, as management differs for each of these cases. Characterization of the phenotype, mechanisms and management of NAR represents one of the major unmet needs in allergic and nonallergic diseases. Studies on children and adults are required in order to appreciate the prevalence, phenotype, severity and co-morbidities of NAR. These studies should compare allergic and NAR and consider different age group populations including elderly subjects. Mechanistic studies should be carried out to better understand the disease(s) and risk factors and to guide towards an improved diagnosis and therapy. These studies need to take the heterogeneity of NAR into account. It is likely that neuronal mechanisms, T cells, innate immunity and possibly auto-immune responses all play a role in NAR and may also contribute to the symptoms of allergic rhinitis.	[Bousquet, J.; Bousquet, P. J.; Demoly, P.] Univ Hosp, Montpellier, France; [Bousquet, J.; Bousquet, P. J.; Demoly, P.] CNRS, INSERM, Montpellier, France; [Fokkens, W.; Holland, C.] Univ Amsterdam, Dept Otorhinolaryngol, NL-1012 WX Amsterdam, Netherlands; [Burney, P.; Durham, S. R.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England; [Bachert, C.; Johnston, S. L.] Ghent Univ Hosp, URL, B-9000 Ghent, Belgium; [Akdis, C. A.; Crameri, R.] Swiss Inst Allergy & Asthma Res SIAF, Davos, Switzerland; [Canonica, G. W.; Passalacqua, G.] Univ Genoa, Dept Internal Med, I-16126 Genoa, Italy; [Dahlen, S. -E.] Karolinska Inst, Stockholm, Sweden; [Zuberbier, T.] Charite Univ Med Berlin, Dept Dermatol & Allergy, D-13353 Berlin, Germany; [Bieber, T.] Univ Bonn, Dept Dermatol & Allergy, D-5300 Bonn, Germany; [Bonini, S.] Univ Naples 2, INMM CNR, Rome, Italy; [Brozek, J. L.; Schuenemann, H. J.] Italian Natl Canc Inst Regina Elena, CLARITY Res Grp, Dept Epidemiol, Rome, Italy; [Cardell, L. -O.] Karolinska Inst, Inst Clin Sci Intervent & Technol, Div ENT Dis, Stockholm, Sweden; [Custovic, A.] Univ Manchester, Manchester, Lancs, England; [Demoly, P.] CNRS, INSERM, U657, Montpellier, France; [van Wijk, R. G.] Erasmus MC, Rotterdam, Netherlands; [Gjomarkaj, M.] CNR, Ist Biomed & Immunol Mol, Palermo, Italy; [Howarth, P.] Univ Southampton, Inflammat Repair Sch Med, Div Infect, Southampton, Hants, England; [Humbert, M.] Univ Paris Sud, Hop Antoine Beclere, Serv Pneumol, Clamart, France; [Kauffmann, F.] INSERM, U780, Villejuif, France; [Kowalski, M. L.] Med Univ Lodz, Dept Immunol Rheumatol & Allergy, Lodz, Poland; [Lehmann, S.] Univ Hosp, Montpellier, France; [Lehmann, S.] CNRS, Montpellier, France; [Leynaert, B.] INSERM, U700, Paris, France; [Lodrup-Carlsen, K.] Ullevel Univ Hosp, Dept Paediat, Oslo, Norway; [Lodrup-Carlsen, K.] Univ Oslo, Fac Med, Oslo, Norway; [Mullol, J.] IDIBAPS, Hosp Clin, ENT Dept, Barcelona, Catalunya, Spain; [Niggemann, B.] German Red Cross Hosp, Berlin, Germany; [Nizankowska-Mogilnicka, E.] Jagiellonian Univ, Sch Med, Dept Pulm Dis, Krakow, Poland; [Papadopoulos, N.] Univ Athens, Pediat Clin 2, Dept Allergy, Athens, Greece; [Simon, H. -U.] Univ Bern, Inst Pharmacol, Bern, Switzerland; [Todo-Bom, A.] Coimbra Univ Hosp, Immunoallergol Dept, Coimbra, Portugal; [Toskala, E.] Finnish Inst Occupat Hlth, Dept Otorhinolaryngol, Helsinki, Finland; [Valenta, R.] Med Univ Vienna, Div Immunopathol, Vienna, Austria; [Wickman, M.] Sachs Childrens Hosp, Stockholm, Sweden; [Wickman, M.] Karolinska Inst, Inst Environm Med, S-10401 Stockholm, Sweden; [Zock, J. P.] IMIM, Unitat Recerca Resp & Ambiental, Barcelona, Spain	Bousquet, J (reprint author), Univ Hosp, F-34295 Montpellier 5, France.		Johnston, Sebastian/I-2423-2012; Custovic, Adnan/A-2435-2012; Papadopoulos, Nikolaos/L-8670-2013; Lambrecht, Bart/K-2484-2014	Custovic, Adnan/0000-0001-5218-7071; Papadopoulos, Nikolaos/0000-0002-4448-3468; Lambrecht, Bart/0000-0003-4376-6834; Papadopoulos, Nikolaos/0000-0002-2508-3872; Bousquet, Philippe Jean/0000-0002-0217-5483; Bonini, Sergio/0000-0003-0079-3031; Simon, Hans-Uwe/0000-0002-9404-7736			Ait-Khaled N, 2007, ALLERGY, V62, P247, DOI 10.1111/j.1398-9995.2007.01325.x; Akdis CA, 2006, ALLERGY, V61, P11, DOI 10.1111/j.1398-9995.2006.01159.x; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Almqvist C, 2008, ALLERGY, V63, P47, DOI 10.1111/j.1398-9995.2007.01524.x; ANNESIMAESANO I, 2003, UPPER LOWER RESP DIS, P105; Arshad SH, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.2.e33; Bachert C, 2006, ALLERGY, V61, P693, DOI 10.1111/j.1398-9995.2006.1054.x; Bateman ED, 2007, ALLERGY, V62, P213, DOI 10.1111/j.1398-9995.2007.01324.x; Beck JP, 2007, SCI TOTAL ENVIRON, V372, P440, DOI 10.1016/j.scitotenv.2006.10.009; Benson M, 2007, ALLERGY, V62, P178, DOI 10.1111/j.1398-9995.2006.01264.x; Benson M, 2002, CLIN EXP ALLERGY, V32, P301, DOI 10.1046/j.1365-2222.2002.01300.x; Benson M, 2002, CYTOKINE, V18, P20, DOI 10.1006/cyto.2002.1012; BENTLEY AM, 1992, J ALLERGY CLIN IMMUN, V89, P877, DOI 10.1016/0091-6749(92)90444-7; Biagini JM, 2006, PEDIATR ALLERGY IMMU, V17, P278, DOI 10.1111/j.1399-3038.2006.00386.x; Blom HM, 1997, J ALLERGY CLIN IMMUN, V100, P739, DOI 10.1016/S0091-6749(97)70267-7; Blom HM, 1997, CLIN EXP ALLERGY, V27, P796, DOI 10.1046/j.1365-2222.1997.670842.x; Blom HM, 1998, CLIN EXP ALLERGY, V28, P1351; Bodtger U, 2006, ALLERGY, V61, P712, DOI 10.1111/j.1398-9995.2006.01140.x; Bonini S, 2007, ALLERGY, V62, P683, DOI 10.1111/j.1398-9995.2007.01382.x; Bousquet J, 2008, ALLERGY, V63, P1, DOI 10.1111/j.1398-9995.2007.01594.x; Bousquet J, 2006, ALLERGY, V61, P671, DOI 10.1111/j.1398-9995.2006.01048.x; Bousquet J, 2006, J ALLERGY CLIN IMMUN, V117, P158, DOI 10.1016/j.jaci.2005.09.047; BOUSQUET J, 1994, J ALLERGY CLIN IMMUN, V94, P182, DOI 10.1016/0091-6749(94)90038-8; BOUSQUET J, 1993, ALLERGY, V48, P183, DOI 10.1111/j.1398-9995.1993.tb00711.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; Bousquet PJ, 2007, ALLERGY, V62, P367, DOI 10.1111/j.1398-9995.2006.01276.x; Braat JPM, 1998, AM J RESP CRIT CARE, V157, P1748; Brandt D, 2006, ANN ALLERG ASTHMA IM, V96, P526; Bresciani M, 2001, J ALLERGY CLIN IMMUN, V107, P73, DOI 10.1067/mai.2001.111593; Brozek JL, 2008, ALLERGY, V63, P38, DOI 10.1111/j.1398-9995.2007.01560.x; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; Calderon-Garciduenas L, 2003, PEDIATR PULM, V36, P148, DOI 10.1002/ppul.10338; CALDERONGARCIDUENAS L, 1992, AM J PATHOL, V140, P225; CALDERONGARCIDUENAS L, 1994, ENVIRON HEALTH PERSP, V102, P1074, DOI 10.2307/3431995; Campana R, 2008, J ALLERGY CLIN IMMUN, V121, P528, DOI 10.1016/j.jaci.2007.09.014; Canonica GW, 2007, ALLERGY, V62, P17, DOI 10.1111/j.1398-9995.2007.01549.x; Canonica GW, 2007, ALLERGY, V62, P668, DOI 10.1111/j.1398-9995.2007.01352.x; Casado B, 2005, PROTEOMICS, V5, P2949, DOI 10.1002/pmic.200401172; Casado B, 2004, CURR ALLERGY ASTHM R, V4, P224, DOI 10.1007/s11882-004-0030-4; Chiappara G, 2007, ALLERGY, V62, P787, DOI 10.1111/j.1398-9995.2007.01417.x; Cirillo I, 2007, ALLERGY, V62, P1087, DOI 10.1111/j.1398-9995.2007.01401.x; Cruz AA, 2007, ALLERGY, V62, P1, DOI 10.1111/j.1398-9995.2007.01551.x; de Benedictis FM, 1999, CHEST, V115, P550, DOI 10.1378/chest.115.2.550; Droste JHJ, 1996, J ALLERGY CLIN IMMUN, V97, P922, DOI 10.1016/S0091-6749(96)80066-2; Durham SR, 1997, INT ARCH ALLERGY IMM, V113, P128; Durr DG, 2001, J OTOLARYNGOL, V30, P93, DOI 10.2310/7070.2001.20813; FLUCKIGER S, 2004, RECENT RES DEV ALLER, V5, P57; Fokkens W.J., 2007, RHINOLOGY S20, V45, P1; Fokkens Wytske J, 2002, Curr Allergy Asthma Rep, V2, P203, DOI 10.1007/s11882-002-0020-3; Forsberg B, 2005, AMBIO, V34, P11, DOI 10.1639/0044-7447(2005)034[0011:CHIAOL]2.0.CO;2; Franchi M, 2006, ALLERGY, V61, P864, DOI 10.1111/j.1398-9995.2006.01106.x; Gevaert P, 2006, J ALLERGY CLIN IMMUN, V118, P1133, DOI 10.1016/j.jaci.2006.05.031; Ghafouri B, 2006, J PROTEOME RES, V5, P330, DOI 10.1021/pr050341h; Giovannangelo M, 2007, INDOOR AIR, V17, P70, DOI 10.1111/j.1600-0668.2006.00461.x; Giovannangelo M, 2007, J EXPO SCI ENV EPID, V17, P134, DOI 10.1038/sj.jes.7500482; Goetzel RZ, 2003, J OCCUP ENVIRON MED, V45, P5, DOI 10.1097/01.jom.0000048178.88600.6e; Graudenz GS, 2006, J ALLERGY CLIN IMMUN, V118, P1126, DOI 10.1016/j.jaci.2006.07.005; Greiner AN, 2006, J ALLERGY CLIN IMMUN, V118, P985, DOI 10.1016/j.jaci.2006.06.029; Guerra S, 2005, ALLERGY, V60, P343, DOI 10.1111/j.1398-9995.2005.00717.x; Heinzerling L, 2005, ALLERGY, V60, P1287, DOI 10.1111/j.1398-9995.2005.00895.x; Howarth Peter H, 2005, J Allergy Clin Immunol, V115, pS414, DOI 10.1016/j.jaci.2004.12.1134; HUGGINS KG, 1975, LANCET, V2, P148; Humbert M, 2007, ALLERGY, V62, P95, DOI 10.1111/j.1398-9995.2006.01308.x; International Consensus Report on Diagnosis and Management of Rhinitis, 1994, ALLERGY S, V49, P1; Iwasaki A, 2007, ANNU REV IMMUNOL, V25, P381, DOI 10.1146/annurev.immunol.25.022106.141634; Jarvis D, 2002, EUR RESPIR J, V20, P1071, DOI 10.1183/09031936.02.00046802; Jones MG, 2006, J ALLERGY CLIN IMMUN, V117, P663, DOI 10.1016/j.jaci.2005.09.053; Juniper EF, 2007, ALLERGY, V62, P1091, DOI 10.1111/j.1398-9995.2007.01370.x; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, pS742, DOI 10.1016/S0091-6749(97)90000-2; Jutel M, 2006, ALLERGY, V61, P796, DOI 10.1111/j.1398-9995.2006.01175.x; KAUFFMANN F, 1995, CLIN EXP ALLERGY, V25, P19, DOI 10.1111/j.1365-2222.1995.tb00413.x; Keil T, 2006, ALLERGY, V61, P1104, DOI 10.1111/j.1398-9995.2006.01167.x; Keil T, 2006, ALLERGY, V61, P221, DOI 10.1111/j.1398-9995.2006.00989.x; Kim Dennis, 2007, Curr Opin Otolaryngol Head Neck Surg, V15, P268, DOI 10.1097/MOO.0b013e328259c372; KOENIG JQ, 1988, J ALLERGY CLIN IMMUN, V81, P1055, DOI 10.1016/0091-6749(88)90180-7; Koga T, 2006, RESP MED, V100, P273, DOI 10.1016/j.rmed.2005.05.017; Kowalski Marek L, 2007, Clin Allergy Immunol, V19, P147; Leger D, 2006, ARCH INTERN MED, V166, P1744, DOI 10.1001/archinte.166.16.1744; Leroyer C, 1999, OCCUP ENVIRON MED, V56, P334; Leynaert B, 1999, J ALLERGY CLIN IMMUN, V104, P301, DOI 10.1016/S0091-6749(99)70370-2; Limacher A, 2007, J IMMUNOL, V178, P389; Lund VJ, 1997, ENT J S, V76, P1; Lundback B, 2007, ALLERGY, V62, P611, DOI 10.1111/j.1398-9995.2007.01399.x; Mamessier E, 2007, ALLERGY, V62, P162, DOI 10.1111/j.1398-9995.2006.01288.x; Marinho S, 2007, ALLERGY, V62, P1379, DOI 10.1111/j.1398-9995.2007.01502.x; Marinho S, 2007, ALLERGY, V62, P385, DOI 10.1111/j.1398-9995.2006.01294.x; Mavale-Manuel S, 2007, ALLERGY, V62, P265, DOI 10.1111/j.1398-9995.2006.01251.x; Mayer C, 1999, J EXP MED, V189, P1507, DOI 10.1084/jem.189.9.1507; *MED HLTH EUR COMM, 1994, EUR COMM RESP HLTH S; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Molgaard E, 2007, ALLERGY, V62, P1033, DOI 10.1111/j.1398-9995.2007.01355.x; Nassef M, 2006, CURR MED RES OPIN, V22, P2541, DOI 10.1185/030079906X158057; Natter S, 1998, FASEB J, V12, P1559; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V272, P852; NEWMAN LJ, 1994, JAMA-J AM MED ASSOC, V271, P363, DOI 10.1001/jama.271.5.363; Nicholas B, 2006, PROTEOMICS, V6, P4390, DOI 10.1002/pmic.200600011; Nikasinovic L, 2006, J ALLERGY CLIN IMMUN, V117, P1382, DOI 10.1016/j.jaci.2006.03.023; NIZANKOWSKA M, 2007, ALLERGY, V62, P1111; Papadopoulos NG, 2007, ALLERGY, V62, P457, DOI 10.1111/j.1398-9995.2007.01341.x; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; Pattenden S, 2006, OCCUP ENVIRON MED, V63, P828, DOI 10.1136/oem.2006.025213; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; Powe DG, 2004, ALLERGY, V59, P204, DOI 10.1046/j.1398-9995.2003.00315.x; Powe DG, 2003, CLIN EXP ALLERGY, V33, P1374, DOI 10.1046/j.1365-2222.2003.01737.x; Ray NF, 1999, J ALLERGY CLIN IMMUN, V103, P408, DOI 10.1016/S0091-6749(99)70464-1; REYNES C, 2008, CLIN PROTEO IN PRESS; Rolla G, 2007, CHEST, V131, P1345, DOI 10.1378/chest.06-2618; Rondon C, 2007, J ALLERGY CLIN IMMUN, V119, P899, DOI 10.1016/j.jaci.2007.01.006; Salonen RO, 2008, ENVIRON INT, V34, P51, DOI 10.1016/j.envint.2007.06.012; Sanderson EG, 2006, J TOXICOL ENV HEAL A, V69, P1819, DOI 10.1080/15287390600631557; Sanderson EG, 2006, ENVIRON HEALTH PERSP, V114, P1108, DOI 10.1289/ehp.8524; Sandstrom Thomas, 2005, Toxicol Appl Pharmacol, V207, P261, DOI 10.1016/j.taap.2005.03.031; Sanico AM, 2000, AM J RESP CRIT CARE, V161, P1631; Sarin S, 2006, J ALLERGY CLIN IMMUN, V118, P999, DOI 10.1016/j.jaci.2006.09.013; Schatz M, 2007, ALLERGY, V62, P9, DOI 10.1111/j.1398-9995.2007.01548.x; Schleimer R P, 2007, Clin Allergy Immunol, V20, P51; Schmid-Grendelmeier P, 2005, J ALLERGY CLIN IMMUN, V115, P1068, DOI 10.1016/j.jaci.2005.01.065; Schmidt-Weber CB, 2007, J ALLERGY CLIN IMMUN, V120, P247, DOI 10.1016/j.jaci.2007.06.039; Schunemann HJ, 2006, AM J RESP CRIT CARE, V174, P605, DOI 10.1164/rccm.200602-197ST; Schwarze PE, 2007, INHAL TOXICOL, V19, P17, DOI 10.1080/08958370701490445; SHAPIRO GG, 1992, J ALLERGY CLIN IMMUN, V90, P417, DOI 10.1016/0091-6749(92)90160-4; Sheehan David, 2007, Reviews on Environmental Health, V22, P175; SHEEHAN JK, 2006, NOVART FDN SYMP, V9, P216; Shiio Y, 2006, NAT PROTOC, V1, P139, DOI 10.1038/nprot.2006.22; Shusterman D, 2004, NEUROPEPTIDES, V38, P351, DOI 10.1016/j.npep.2004.08.002; Shusterman D, 2003, CURR ALLERGY ASTHM R, V3, P258, DOI 10.1007/s11882-003-0048-z; Shusterman Dennis, 2007, Clin Allergy Immunol, V19, P249; Simon HU, 2006, CHEM IMMUNOL ALLERGY, V91, P49; Simon HU, 1997, J IMMUNOL, V158, P3902; Simoni M, 2007, RESP MED, V101, P531, DOI 10.1016/j.rmed.2006.06.021; SLAVIN RG, 1988, J ALLERGY CLIN IMMUN, V82, P950, DOI 10.1016/0091-6749(88)90038-3; Stevenson DD, 2006, J ALLERGY CLIN IMMUN, V118, P87; Tahamiler R, 2007, ALLERGY, V62, P1029, DOI 10.1111/j.1398-9995.2007.01397.x; Takhar P, 2005, J IMMUNOL, V174, P5024; Takhar P, 2007, J ALLERGY CLIN IMMUN, V119, P213, DOI 10.1016/j.jaci.2006.09.045; ten Brinke A, 2002, J ALLERGY CLIN IMMUN, V109, P621, DOI 10.1067/mai.2002.122458; TOLLERUD DJ, 1991, AM REV RESPIR DIS, V144, P776; VALENTA R, 1991, SCIENCE, V253, P557, DOI 10.1126/science.1857985; VALERO A, 2007, J ALLERGY CLIN IMMUN, V120, P365; van Bree L, 2007, J TOXICOL ENV HEAL A, V70, P377, DOI 10.1080/15287390600885088; Van Cauwenberge P, 2005, ALLERGY, V60, P858, DOI 10.1111/j.1398-9995.2005.00822.x; Van Hoecke H, 2006, ALLERGY, V61, P705, DOI 10.1111/j.1398-9995.2006.01057.x; van Ree Ronald, 2004, Allergy, V59, P571; van Rijswijk JB, 2005, ALLERGY, V60, P1471, DOI 10.1111/j.1398-9995.2005.00975.x; van Rijswijk JB, 2003, RHINOLOGY, V41, P25; Varga EM, 1999, EUR RESPIR J, V14, P610, DOI 10.1034/j.1399-3003.1999.14c21.x; VERVLOET D, 1991, CLIN EXP ALLERGY, V21, P733, DOI 10.1111/j.1365-2222.1991.tb03203.x; Webb DR, 2002, ANN ALLERG ASTHMA IM, V88, P385; Wedback A, 2005, RHINOLOGY, V43, P86; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; Xepapadaki P, 2007, IMMUNOBIOLOGY, V212, P453, DOI 10.1016/j.imbio.2007.03.008; Zacharasiewicz A, 2003, J CLIN EPIDEMIOL, V56, P385, DOI 10.1016/S089504356(03)00043-X; ZELLER S, 2007, INT ARCH ALLERGY IMM, V145, P87; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455	154	87	90	2	13	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0105-4538	1398-9995		ALLERGY	Allergy	JUL	2008	63	7					842	853		10.1111/j.1398-9995.2008.01715.x		12	Allergy; Immunology	Allergy; Immunology	313DA	WOS:000256720100006	18588549	
J	Kormann, MSD; Depner, M; Harti, D; Klopp, N; Illig, T; Adamski, J; Vogelberg, C; Weiland, SK; von Mutius, E; Kabesch, M				Kormann, Michael S. D.; Depner, Martin; Harti, Dominik; Klopp, Norman; Illig, Thomas; Adamski, Jerzy; Vogelberg, Christian; Weiland, Stephan K.; von Mutius, Erika; Kabesch, Michael			Toll-like receptor heterodimer variants protect from childhood asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						asthma; atopic asthma; toll-like receptor; heterodimer; polymorphism	HAY-FEVER; CHILDREN; CELLS; ATOPY; POLYMORPHISMS; POPULATION; PREVALENCE; MECHANISMS; EXPRESSION; HAPLOTYPES	Background: Early exposure to microbes reduces the risk for asthma. Toll-like receptors (TLRs) represent a major group of receptors for the specific recognition of pathogen-associated molecular patterns of microbes capable of activating innate and adaptive immunity. Objective: Because TLRs can influence key events in the induction and perpetuation of asthma and atopy, we sought to determine whether genetic alterations in TLR genes affect asthma risk. Methods: We systematically evaluated putatively functional genetic variants in all 10 human TLR genes for their association with different asthma phenotypes in a case-control study (n = 1872) by using matrix-assisted laser desorption/ionization time-of-flight genotyping. For polymorphisms showing association with atopic asthma, effects on gene and protein expression were studied by means of RT-PCR and flow cytometry ex vivo. T-cell cytokine production was evaluated by means of ELISA after stimulation of the respective TLRs with specific ligands. Results: Protective effects on atopic asthma were identified for single nucleotide polymorphisms in TLR1 (odds ratio [OR], 0.54; 95% CI, 0.37-0.81; P =.002), TLR6 (OR, 0.54; 95% CI, 0.37-0.79; P =.003), and TLR10 (OR, 0.58; 95% CI, 0.39-0.86; P =.006), all capable of forming heterodimers with TLR2. Effects remained significant after correction for multiple comparisons. PBMCs of minor allele carriers showed increased levels of the respective TLR mRNA and proteins, augmented inflammatory responses, increased T(H)1 cytokine expression, and reduced T(H)2-associated IL-4 production after specific stimulation. Conclusion: These results suggest that functional relevant TLR1 and TLR6 variants are directly involved in asthma development.	[Kormann, Michael S. D.; Depner, Martin; Harti, Dominik; Klopp, Norman; Illig, Thomas; von Mutius, Erika; Kabesch, Michael] Univ Munich, Univ Childrens Hosp, D-80337 Munich, Germany; [Weiland, Stephan K.] Univ Ulm, Inst Epidemiol, D-89069 Ulm, Germany; [Vogelberg, Christian] Univ Childrens Hosp, Dresden, Germany; [Adamski, Jerzy] GSF Natl Res Ctr Environm & Hlth, Inst Expt Genet, Neuherberg, Germany; [Klopp, Norman; Illig, Thomas] GSF Natl Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany	Kabesch, M (reprint author), Univ Munich, Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	Michael.Kabesch@med.uni-muenchen.de	Kormann, Michael/C-7723-2014	von Mutius, Erika/0000-0002-8893-4515			Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Bourke E, 2003, BLOOD, V102, P956, DOI 10.1182/blood-2002-11-3355; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Cohn L, 1998, J IMMUNOL, V161, P3813; Dudbridge F, 2003, GENET EPIDEMIOL, V25, P115, DOI 10.1002/gepi.10252; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Hasan U, 2005, J IMMUNOL, V174, P2942; HOMUNG V, 2002, J IMMUNOL, V168, P4531; Ishii KJ, 2005, J CLIN IMMUNOL, V25, P511, DOI 10.1007/s10875-005-7829-1; Kormann MSD, 2005, AM J RESP CRIT CARE, V171, P1358, DOI 10.1164/rccm.200410-1312OC; Lazarus R, 2004, AM J RESP CRIT CARE, V170, P594, DOI 10.1164/rccm.200404-491OC; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Medzhitov R, 1997, NATURE, V388, P394; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Raby BA, 2002, AM J RESP CRIT CARE, V166, P1449, DOI 10.1164/rrcm.200207-634OC; Renner ED, 2005, J CLIN IMMUNOL, V25, P321, DOI 10.1007/s10875-005-4183-2; Sasieni PD, 1997, BIOMETRICS, V53, P1253, DOI 10.2307/2533494; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Vaidya SA, 2003, CURR OPIN IMMUNOL, V15, P402, DOI 10.1016/S0952-7915(03)00070-0; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Weiland SK, 1999, EUR RESPIR J, V14, P862, DOI 10.1034/j.1399-3003.1999.14d23.x; Yuan HY, 2006, NUCLEIC ACIDS RES, V34, pW635, DOI 10.1093/nar/gkl236; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; INNATE IMMUNITY PGA	29	87	89	0	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUL	2008	122	1					86	92		10.1016/j.jaci.2008.04.039		7	Allergy; Immunology	Allergy; Immunology	325RD	WOS:000257605100014	18547625	
J	Fiocchi, A; Assa'ad, A; Bahna, S				Fiocchi, Alessandro; Assa'ad, Amal; Bahna, Sami		Amer Coll Allergy Asthma Immunolog	Food allergy and the introduction of solid foods to infants: a consensus document	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Review							BOVINE SERUM-ALBUMIN; BREAST-FED INFANTS; COWS MILK ALLERGY; HIGH-RISK INFANTS; PARTIAL WHEY HYDROLYSATE; HOUSE-DUST-MITE; PEANUT ALLERGY; NATURAL-HISTORY; ATOPIC DISEASE; CROSS-REACTIVITY	Objective: To make recommendations based on a critical review of the evidence for the timing of the introduction of solid foods and its possible role in the development of food allergy. Data Sources: MEDLINE searches using the following search algorithm: [weaning AND infant AND allergy]/[food allergy AND sensitization]/[dietary prevention AND food allergy OR allergens]/[Jan 1980-Feb 2006]. Study Selection: Using the authors' clinical experience and research expertise, 52 studies were retrieved that satisfied the following conditions: English language, journal impact factor above I or scientific society, expert, or institutional publication, and appraisable using the World Health Organization categories of evidence. Results: Available information suggests that early introduction can increase the risk of food allergy, that avoidance of solids can prevent the development of specific food allergies, that some foods are more allergenic than others, and that some food allergies are more persistent than others. Conclusions: Pediatricians and allergists should cautiously individualize the introduction of solids into the infants' diet. With assessed risk of allergy, the optimal age for the introduction of selected supplemental foods should be 6 months, dairy products 12 months, hen's egg 24 months, and peanut, tree nuts, fish, and seafood at least 36 months. For all infants, complementary feeding can be introduced from the sixth month, and egg, peanut, tree nuts, fish, and seafood introduction require caution. Foods should be introduced one at a time in small amounts. Mixed foods containing various food allergens should not be given unless tolerance to every ingredient has been assessed.	Univ Milan, Melloni Hosp, Sch Med, Amer Coll Allergy Asthma & Immunol Mellini Paedia, I-20129 Milan, Italy	Fiocchi, A (reprint author), Univ Milan, Melloni Hosp, Sch Med, Amer Coll Allergy Asthma & Immunol Mellini Paedia, Via Melloni 52, I-20129 Milan, Italy.	allerg@tin.it		Fiocchi, Alessandro/0000-0002-2549-0523			Anandan C, 2005, BRIT MED J, V331, P1155, DOI 10.1136/bmj.331.7526.1155; Garcia Ara M. C., 1996, ALLERGOL IMMUNOPA S1, V24, P31; Armentia A, 2001, CLIN EXP ALLERGY, V31, P1250, DOI 10.1046/j.1365-2222.2001.01142.x; ARSHAD SH, 1992, LANCET, V339, P1493, DOI 10.1016/0140-6736(92)91260-F; Ayuso R, 1999, ANN ALLERG ASTHMA IM, V83, P399, DOI 10.1016/S1081-1206(10)62837-2; Ayuso R, 2000, ALLERGY, V55, P348, DOI 10.1034/j.1398-9995.2000.00285.x; Ayuso R, 2002, INT ARCH ALLERGY IMM, V129, P38, DOI 10.1159/000065172; Bahna SL, 2001, ANN ALLERG ASTHMA IM, V86, P414; Baker SS, 2000, PEDIATRICS, V106, P346; Ballmer-Weber BK, 2000, J ALLERGY CLIN IMMUN, V106, P373, DOI 10.1067/mai.2000.107196; Ballmer-Weber BK, 2002, ALLERGY, V57, P228, DOI 10.1034/j.1398-9995.2002.1o3319.x; BERNHISELBROADBENT J, 1989, J ALLERGY CLIN IMMUN, V83, P435, DOI 10.1016/0091-6749(89)90130-9; BERNHISELBROADBENT J, 1992, J ALLERGY CLIN IMMUN, V89, P730, DOI 10.1016/0091-6749(92)90381-B; Beyer KB, 2001, J ALLERGY CLIN IMMUN, V107, P1077, DOI 10.1067/mai.2001.115480; Bjorksten B, 2004, CLIN EXP ALLERGY, V34, P673, DOI [10.1111/j.1365-2222.2004.1936.x, 10.1111/j.1365-2222.2004.01936.x]; Bjornsson E, 1996, ANN ALLERG ASTHMA IM, V77, P327; BOCK SA, 1982, J ALLERGY CLIN IMMUN, V69, P173, DOI 10.1016/0091-6749(82)90096-3; BOCK SA, 1989, J ALLERGY CLIN IMMUN, V83, P900, DOI 10.1016/0091-6749(89)90103-6; Bousquet J, 1998, ALLERGY, V53, P3; Boyano-Martinez T, 2002, J ALLERGY CLIN IMMUN, V110, P304, DOI 10.1067/mai.2002.126081; Brandtzaeg P, 2002, ANN NY ACAD SCI, V964, P13; BROWN WM, 1989, NUCLEIC ACIDS RES, V17, P10495, DOI 10.1093/nar/17.24.10495; BURKS AW, 1991, ADV EXP MED BIOL, V289, P295; Burks AW, 1998, J PEDIATR-US, V132, P132, DOI 10.1016/S0022-3476(98)70498-6; Busse PJ, 2002, NEW ENGL J MED, V347, P1535, DOI 10.1056/NEJM200211073471921; Caffarelli C, 1997, ALLERGY ASTHMA PROC, V18, P245, DOI 10.2500/108854197778594007; CHANDRA RK, 1991, ANN ALLERGY, V67, P129; CHANDRA RK, 1989, ANN ALLERGY, V63, P102; Chandra RK, 1997, J PEDIATR GASTR NUTR, V24, P380, DOI 10.1097/00005176-199704000-00005; Chapman JA, 2006, ANN ALLERGY ASTHM S3, V96, P1; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Codina R, 1998, INT ARCH ALLERGY IMM, V117, P120, DOI 10.1159/000023998; CRESPO JF, 1995, ALLERGY, V50, P257, DOI 10.1111/j.1398-9995.1995.tb01143.x; Dalal I, 2002, ALLERGY, V57, P362, DOI 10.1034/j.1398-9995.2002.1s3412.x; De Frutos C, 2002, J ALLERGY CLIN IMMUN, V109, pS306; De Luca L, 1987, Pediatr Med Chir, V9, P449; Department of Health, 1994, WEAN WEAN DIET REP H; Dewey KG, 1999, AM J CLIN NUTR, V69, P679; Diaz-Perales A, 2000, CLIN EXP ALLERGY, V30, P1403, DOI 10.1046/j.1365-2222.2000.00909.x; Donzelli F, 1990, Pediatr Med Chir, V12, P71; DYBENDAL T, 1990, ANN OCCUP HYG, V34, P215, DOI 10.1093/annhyg/34.2.215; EGGLESTON PA, 1987, ANN ALLERGY, V59, P179; Escudero C, 2003, ALLERGY, V58, P616, DOI 10.1034/j.1398-9995.2003.00201.x; Ewan PW, 1996, BRIT MED J, V312, P1074; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FIOCCHI A, 1995, J AM COLL NUTR, V14, P245; Fiocchi A, 2004, PEDIATR ALLERGY IMMU, V15, P454, DOI 10.1111/j.1399-3038.2004.00186.x; Fiocchi A, 2003, ANN ALLERG ASTHMA IM, V91, P3; Fiocchi A, 2003, J ALLERGY CLIN IMMUN, V111, P193, DOI 10.1067/mai.2003.12; Fiocchi A, 1999, CLIN EXP ALLERGY, V29, P402, DOI 10.1046/j.1365-2222.1999.00495.x; Fiocchi A, 1998, ALLERGY, V53, P798; Fleischer DM, 2003, J ALLERGY CLIN IMMUN, V112, P183, DOI 10.1067/mai.2003.1517; FORD RPK, 1982, ARCH DIS CHILD, V57, P649; FORSYTH JS, 1993, BRIT MED J, V306, P1572; Franck P, 2002, INT ARCH ALLERGY IMM, V128, P212, DOI 10.1159/000064254; Garcia-Ara MC, 2004, CLIN EXP ALLERGY, V34, P866, DOI 10.1111/j.1365-2222.2004.01976.x; Gartner LM, 2005, PEDIATRICS, V115, P496, DOI 10.1542/peds.2004-2491; GIAMPIETRO PG, 1992, ANN ALLERGY, V69, P143; Greiner T, 1996, J Hum Lact, V12, P123, DOI 10.1177/089033449601200216; Halken S, 2000, PEDIATR ALLERGY IMMU, V11, P149, DOI 10.1034/j.1399-3038.2000.00081.x; Hansen KS, 2003, ALLERGY, V58, P132, DOI 10.1034/j.1398-9995.2003.23959.x; Helm RM, 1996, CEREAL FOOD WORLD, V41, P839; HIDE DW, 1994, J ALLERGY CLIN IMMUN, V93, P842, DOI 10.1016/0091-6749(94)90375-1; Hide DW, 1996, ALLERGY, V51, P89, DOI 10.1111/j.1398-9995.1996.tb04563.x; Hill DJ, 1997, ENVIRON TOXICOL PHAR, V4, P101, DOI 10.1016/S1382-6689(97)10049-7; HIRAYAMA K, 1990, BIOCHEM BIOPH RES CO, V173, P639, DOI 10.1016/S0006-291X(05)80083-X; Host A, 1999, ARCH DIS CHILD, V81, P80; HOST A, 1988, ACTA PAEDIATR SCAND, V77, P663, DOI 10.1111/j.1651-2227.1988.tb10727.x; Host A, 2001, PEDIATR ALLERGY IMMU, V12, P78, DOI 10.1034/j.1399-3038.2001.121418.x; Host A, 1994, PEDIATR ALLERGY IMMU, V5, P5, DOI 10.1111/j.1399-3038.1994.tb00352.x; Hourihane JO, 1996, BRIT MED J, V313, P518; Hourihane JO, 1998, BRIT MED J, V316, P1271; Humieres J, 2004, ALLERGY, V59, P1259, DOI 10.1111/j.1398-9995.2004.00618.x; JAMES JM, 1992, J PEDIATR-US, V121, P371, DOI 10.1016/S0022-3476(05)81788-3; KAJOSAARI M, 1983, ACTA PAEDIATR SCAND, V72, P411, DOI 10.1111/j.1651-2227.1983.tb09738.x; Kanny G, 2001, J ALLERGY CLIN IMMUN, V108, P133, DOI 10.1067/mai.2001.116427; Kleinman RE, 2000, PEDIATRICS, V106, P1274; Kleinman RE, 2003, PEDIAT NUTR HDB; Koletzko B, 2000, PEDIATRICS, V106, P1285; KORENBLAT PE, 1968, J ALLERGY, V41, P226, DOI 10.1016/0021-8707(68)90046-4; Kramer M. S., 2002, COCHRANE DATABASE SY, V1, DOI 10.1002/14651858; Kull I, 1999, PEDIATR ALLERGY IMMU, V10, P21, DOI 10.1034/j.1398-9995.1999.101019.x; Lanigan JA, 2001, EUR J CLIN NUTR, V55, P309, DOI 10.1038/sj.ejcn.1601168; Lehto M, 2003, CLIN EXP ALLERGY, V33, P90, DOI 10.1046/j.1365-2222.2003.01568.x; Leser C, 2001, J INVEST ALLERG CLIN, V11, P89; LUCAS A, 1990, BRIT MED J, V300, P837; Lucas JSA, 2004, CLIN EXP ALLERGY, V34, P1115, DOI 10.1111/j.1365-2222.2004.01982.x; MacDonald A, 2003, J R SOC PROMO HEALTH, V123, P169, DOI 10.1177/146642400312300314; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Martelli A, 2002, ANN ALLERG ASTHMA IM, V89, P38; *MIN PUBL WORKS GO, 1998, NUTR HEALTH TERM INF; Moneret-Vautrin D A, 1994, Pediatr Allergy Immunol, V5, P184, DOI 10.1111/j.1399-3038.1994.tb00236.x; Muller U, 1998, Z LEBENSM UNTERS F A, V207, P341, DOI 10.1007/s002170050343; Muraro A, 2004, PEDIATR ALLERGY IMMU, V15, P291, DOI 10.1111/j.1399-3038.2004.00127.x; Naylor AJ, 2001, DEV READINESS NORMAL; Norris JM, 2005, JAMA-J AM MED ASSOC, V293, P2343, DOI 10.1001/jama.293.19.2343; Oldaeus G, 1997, ARCH DIS CHILD, V77, P4; OSBORN DA, 2003, FORMULAS CONTAINING; Osterballe M, 2005, ALLERGY, V60, P218, DOI 10.1111/j.1398-9995.2005.00674.x; Palosuo Kati, 2003, Curr Opin Allergy Clin Immunol, V3, P205, DOI 10.1097/00130832-200306000-00009; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V109, P563, DOI 10.1067/mai.2002.121946; Pastorello EA, 2002, J ALLERGY CLIN IMMUN, V110, P310, DOI 10.1067/mai.2002.125830; PASTORELLO EA, 1989, J ALLERGY CLIN IMMUN, V84, P475, DOI 10.1016/0091-6749(89)90360-6; Poltronieri P, 2002, INT ARCH ALLERGY IMM, V128, P97, DOI 10.1159/000059399; Poole JA, 2006, PEDIATRICS, V117, P2175, DOI 10.1542/peds.2005-1803; Poulsen LK, 2001, ALLERGY, V56, P39, DOI 10.1034/j.1398-9995.2001.00912.x; Quirce S, 2001, ALLERGY, V56, P754, DOI 10.1034/j.1398-9995.2001.056008754.x; Reche M, 2001, ALLERGY, V56, P1197, DOI 10.1034/j.1398-9995.2001.00279.x; Reilly JJ, 2005, BRIT J NUTR, V94, P869, DOI 10.1079/BJN20051601; RESTANI P, 1997, J AM COLL NUTR, V16, P565; Romeira AM, 2003, ALLERGY, V58, P533, DOI 10.1034/j.1398-9995.2003.00154.x; Roux KH, 2003, INT ARCH ALLERGY IMM, V131, P234, DOI 10.1159/000072135; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SAARINEN UM, 1980, LANCET, V1, P166; Sampson HA, 1996, BRIT MED J, V312, P1050; Sampson HA, 1999, J ALLERGY CLIN IMMUN, V103, P981, DOI 10.1016/S0091-6749(99)70167-3; SAMPSON HA, 1989, J PEDIATR-US, V115, P23, DOI 10.1016/S0022-3476(89)80323-3; Sanchez-Monge R, 2000, J ALLERGY CLIN IMMUN, V106, P190, DOI 10.1067/mai.2000.107599; Scurlock AM, 2004, ANN ALLERG ASTHMA IM, V93, pS12; Seppala U, 1999, J ALLERGY CLIN IMMUN, V103, P165, DOI 10.1016/S0091-6749(99)70541-5; Shek LPC, 2004, J ALLERGY CLIN IMMUN, V114, P387, DOI 10.1016/j.jaci.2004.04.032; Sicherer SH, 2001, J ALLERGY CLIN IMMUN, V108, P881, DOI 10.1067/mai.2001.118515; Sicherer SH, 2002, ANN ALLERG ASTHMA IM, V88, P350; SIGURS N, 1992, PEDIATRICS, V89, P735; Simonato B, 2001, J AGR FOOD CHEM, V49, P5668, DOI 10.1021/jf0104984; Skolnick HS, 2001, J ALLERGY CLIN IMMUN, V107, P367, DOI 10.1067/mai.2001.112129; Solensky R, 2003, ANN ALLERG ASTHMA IM, V91, P411; Spergel JM, 2000, ANN ALLERG ASTHMA IM, V85, P473; Tarini BA, 2006, ARCH PEDIAT ADOL MED, V160, P502, DOI 10.1001/archpedi.160.5.502; Tariq SM, 1996, BRIT MED J, V313, P514; Thompson D., 1996, CONCISE OXFORD DICT; *UNICEF, 1999, BREASTF FDN HEALTH F; VANDENPLAS Y, 1992, ANN ALLERGY, V68, P419; VANDENPLAS Y, 1995, EUR J PEDIATR, V154, P488, DOI 10.1007/s004310050330; vanRee R, 1996, ALLERGY, V51, P387; vanRee R, 1996, ALLERGY, V51, P108; Vieths Stefan, 1995, Lebensmittelchemie, V49, P29; von Berg A, 2003, J ALLERGY CLIN IMMUN, V111, P533, DOI 10.1067/mai.2003.101; WERFEL S, 1992, J ALLERGY CLIN IMMUN, V89, P228; WHO, 2001, WHONHD0108; *WHO, 2001, COMPLEMENTARY FEEDIN; *WHO, 2001, WORLD HLTH ASS RES I; World Health Organization/United Nations International Children Fund (WHO/UNICEF), 1998, COMPL FEED YOUNG CHI; Wild LG, 2005, CURR ALLERGY ASTHM R, V5, P74, DOI 10.1007/s11882-005-0059-z; WITTEMAN AM, 1994, INT ARCH ALLERGY IMM, V105, P56; Woods RK, 2001, EUR J CLIN NUTR, V55, P298, DOI 10.1038/sj.ejcn.1601159; WUTHRICH B, 1993, ALLERGOLOGIE, V16, P280; ZEIGER RS, 1995, J ALLERGY CLIN IMMUN, V95, P1179, DOI 10.1016/S0091-6749(95)70074-9; ZEIGER RS, 1989, J ALLERGY CLIN IMMUN, V84, P72, DOI 10.1016/0091-6749(89)90181-4; Zimmerman B, 2001, J ALLERGY CLIN IMMUN, V107, P558, DOI 10.1067/mai.2001.113526; Zlotkin S, 2000, PEDIATRICS, V106, P1272; Zuberbier T, 2004, ALLERGY, V59, P338, DOI 10.1046/j.1398-9995.2003.00403.x; Zutavern A, 2006, PEDIATRICS, V117, P401, DOI 10.1542/peds.2004-2521; Zutavern A, 2004, ARCH DIS CHILD, V89, P303, DOI 10.1136/adc.2002.025353; [Anonymous], 2003, DIETARY GUIDELINES C	155	87	92	2	14	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	JUL	2006	97	1					10	20				11	Allergy; Immunology	Allergy; Immunology	065TA	WOS:000239181000006	16892776	
J	Taramarcaz, P; Lambelet, C; Clot, B; Keimer, C; Hauser, C				Taramarcaz, P; Lambelet, C; Clot, B; Keimer, C; Hauser, C			Ragweed (Ambrosia) progression and its health risks: will Switzerland resist this invasion?	SWISS MEDICAL WEEKLY			English	Review						Ambrosia; allergy; health risk; allergic rhinits; asthma; Switzerland	ALLERGIC RHINITIS; POLLEN ALLERGY; HAY-FEVER; LATE SUMMER; IMMUNOTHERAPY; SENSITIZATION; EFFICACY; ASTHMA; OMALIZUMAB; EXPOSURE	The purpose of this article is to alert physicians for the environmental and health threats of Ambrosia artemisiifolia (common ragweed) in Switzerland. Switzerland borders several heavily ragweed colonised areas. Up to 12% of the population suffers from allergies (hay fever, asthma) to ragweed pollen in these areas. Switzerland is beginning to be invaded by this plant. Currently, the ragweed pollen counts are still low but can reach local peaks that induce symptoms in allergic individuals. Ragweed allergy, however, is still rare in Switzerland. Because the amount of ragweed pollen was increasing in the last few years, identification and surveillance of ragweed plant foci was started. Colonisation is currently systematically monitored in Geneva and southern Tessin. Major accumulation of ragweed foci have been detected in the canton of Geneva, the western shore of the lake of Geneva belonging to the canton of Vaud, and in the southern part of the canton of Tessin, aside from minor foci registered all over Switzerland. The routes of ragweed invasion are presented and discussed. Current measures of ragweed containment and needs for the future are presented. The urge for these measures at an early stage of ragweed spread is underlined by the impracticability of eradication in highly colonised areas. The costs of preventing ragweed spread in Switzerland are likely to be several magnitudes lower than the treatment of a significant percentage of the Swiss population for ragweed pollen allergy. Because areas can change from low to heavy ragweed colonisation within a few years, the current window of opportunity to prevent further colonisation by ragweed should not be missed.	Univ Hosp Geneva, Serv Allergol & Immunol, CH-1211 Geneva, Switzerland; Univ Geneva, Sch Med, CH-1211 Geneva, Switzerland; Conservatoire & Jardin Bot Ville Geneve, Geneva, Switzerland; MeteoSuisse, Biometeorol & Environm, Stn Aerol, Payerne, Switzerland; Serv Agr, Stn Phytosanit, Geneva, Switzerland; Geneva Ambrosia Grp, Geneva, Switzerland	Hauser, C (reprint author), Univ Hosp Geneva, Serv Allergol & Immunol, 24 Rue Micheli du Crest, CH-1211 Geneva, Switzerland.	Conrad.Hauser@medecine.unige.ch	Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284			ANDERSON LB, 1970, J ALLERGY, V45, P310, DOI 10.1016/0021-8707(70)90037-7; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; ARIA Workshop Group, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI DOI 10.1067/MAI.2001.118891; Asero R, 2004, INT ARCH ALLERGY IMM, V133, P49, DOI 10.1159/000075253; BANKEN R, 1992, Allergie et Immunologie (Paris), V24, P91; Barnes C, 2001, ANN ALLERG ASTHMA IM, V86, P166; Bass DJ, 2000, ANN ALLERG ASTHMA IM, V85, P374; BASSETT IJ, 1975, CAN J PLANT SCI, V55, P463; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; BRUNET C, 1992, J ALLERGY CLIN IMMUN, V89, P87, DOI 10.1016/S0091-6749(05)80044-2; Burton WN, 2001, J OCCUP ENVIRON MED, V43, P64, DOI 10.1097/00043764-200101000-00013; CAMPAGNA E, 1940, PROBLEME HERBE GASPE; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; CIOTTI V, 2004, AMBROSIA ARTEMISIIFO; Clot B., 2002, EUROPEAN ANN ALLERGY, V34, P126; CLOT B, 2003, OEKOSKOP, V3, P7; Clot Bernard, 2003, Aerobiologia, V19, P227, DOI 10.1023/B:AERO.0000006572.53105.17; Comtois P., 1992, Allergie et Immunologie (Paris), V24, P22; Corsico R, 2000, J INVEST ALLERG CLIN, V10, P155; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; D'Amato G, 1998, ALLERGY, V53, P567, DOI 10.1111/j.1398-9995.1998.tb03932.x; Dahl A., 1999, AEROBIOLOGIA, V15, P293, DOI DOI 10.1023/A:1007678107552; Dechamp C, 1995, Allerg Immunol (Paris), V27, P332; Dechamp C, 1995, Allerg Immunol (Paris), V27, P323; DECHAMP C, 2002, AMBROISIES POLLUANTS; Dechamp C, 1990, ALLERGY CLIN IMMUNOL, V2, P78; Defila C, 2001, INT J BIOMETEOROL, V45, P203, DOI 10.1007/s004840100101; Delabays N., 2005, Revue Suisse d'Agriculture, V37, P17; DELABAYS N, 2002, REV SUISSE AGR, V34, P21; Dervaderics M, 2002, IMMUNOL INVEST, V31, P29, DOI 10.1081/IMM-120003220; Donovan JP, 1996, ANN ALLERG ASTHMA IM, V77, P74; ENBERG RN, 1987, J ALLERGY CLIN IMMUN, V79, P867, DOI 10.1016/0091-6749(87)90234-X; FELBER F, 2003, PLANTES POLLENS ALLE, V3, P184; FERNANDEZ C, 1993, J ALLERGY CLIN IMMUN, V92, P660, DOI 10.1016/0091-6749(93)90008-4; Fischer S, 1996, J ALLERGY CLIN IMMUN, V98, P189, DOI 10.1016/S0091-6749(96)70242-7; Frenz DA, 1999, ANN ALLERG ASTHMA IM, V82, P41, DOI 10.1016/S1081-1206(10)62658-0; GALLESIO MT, 1991, G IT ALLERGOL IMMUNO, V5, P467; GEHRIG R, 2004, 11 MET SCHWEIZ; GILARDI S, 1994, SCHWEIZ MED WSCHR, V124, P1841; GUMOWSKI PI, 2002, SWISS MED WEEKLY, V132, pS40; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196; Holgate ST, 2004, CLIN EXP ALLERGY, V34, P632, DOI 10.1111/j.1365-2222.2004.1916.x; Houghton JT, 1996, CLIMATE CHANGE 1995; Humbert M, 2005, ALLERGY, V60, P309, DOI 10.1111/j.1398-9995.2004.00772.x; Jager S, 2000, AEROBIOLOGIA, V16, P149, DOI 10.1023/A:1007603321556; Jager S, 1991, ALLERGENIC POLLEN PO, P125; Jarai-Komlodi M., 1993, AEROBIOLOGIA, V9, P75, DOI 10.1007/BF02311373; JEANMONOD D, 2002, SAUSSUREA, V32, P132; KOHLER B, 2004, KLIMAERWARMUNG FORDE; Laaidi M, 2003, ANN ALLERG ASTHMA IM, V91, P195; LAIIDI M, 2003, INT J BIOMETEREOL, V48, P65; LEUSCHNER R M, 1978, Bauhinia, V6, P265; LEUSCHNER RM, 1985, ALLERG IMMUNOL, V17, P431; Mandrioli P., 1998, AEROBIOLOGIA, V14, P13, DOI DOI 10.1007/BF02694590; MAURER A, 2003, THESIS U GENEVE; MERINEY DK, 1986, ANN ALLERGY, V56, P34; *NHLBI WHO, 1998, GLOB STRAT ASTHM MAN; Peeters A.G., 2000, AEROBIOLOGIA, V16, P295, DOI 10.1023/A:1007656405322; PHAM NH, 1995, CLIN EXP ALLERGY, V25, P599, DOI 10.1111/j.1365-2222.1995.tb01107.x; ROLL A, 2005, SWISS MED WKLY S144, V135, pS19; Rybnicek O., 2000, AEROBIOLOGIA, V16, P287, DOI DOI 10.1023/A:1007611715820; Rybncek O, 2001, ALLERGY CLIN IMMUNOL, V13, P60, DOI 10.1027/0838-1925.13.2.60; Saar M., 2000, AEROBIOLOGIA, V16, P101, DOI DOI 10.1023/A:1007670229308; SADO M, 1990, P 4 INT C AER, P59; *SAPALDIA STUD, 1995, INT ARCH ALLERGY, V106, P149; Schmid-Grendelmeier P, 2001, Ther Umsch, V58, P285, DOI 10.1024/0040-5930.58.5.285; SCHNEITER D, 2002, EUROPEAN ANN ALLERGY, V34, P113; SOLOMON WR, 1984, J ALLERGY CLIN IMMUN, V74, P449, DOI 10.1016/0091-6749(84)90376-2; TEMESVARI E, 1993, CONTACT DERMATITIS, V28, P185, DOI 10.1111/j.1600-0536.1993.tb03385.x; Thibaudon M, 2003, Eur Ann Allergy Clin Immunol, V35, P87; THOMMEN E, 1943, B SOC BOT GENEVA, V2, P131; Tutin TG, 1964, FLORA EUROPAEA, V1; VanDeusen MA, 1997, ANN ALLERG ASTHMA IM, V78, P573; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VARONIER HS, 1969, ACTA ALLERGOL, V24, P410, DOI 10.1111/j.1398-9995.1969.tb03755.x; Verini M, 2001, SCI TOTAL ENVIRON, V270, P63, DOI 10.1016/S0048-9697(00)00798-1; Vignola AM, 2004, ALLERGY, V59, P709, DOI 10.1111/j.1398-9995.2004.00550.x; VINCENT G, 1992, Allergie et Immunologie (Paris), V24, P84; WANG SY, 1985, NATURE, V316, P386; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425; *WHO ICIS EPN, 2003, WHO M REP 2003; Wilken JA, 2002, ANN ALLERG ASTHMA IM, V89, P372; Wilson DR, 2003, COCHRANE DB SYST REV, V2; Wyler C, 2000, EPIDEMIOLOGY, V11, P450, DOI 10.1097/00001648-200007000-00015; Yankova R., 2000, AEROBIOLOGIA, V16, P299, DOI 10.1023/A:1007690116728; Zanon P, 2002, Monaldi Arch Chest Dis, V57, P144; 2005, BAG B, V30, P528	90	87	96	2	18	E M H SWISS MEDICAL PUBLISHERS LTD	BASEL	STEINENTORSTRASSE 13, CH-4-10 BASEL, SWITZERLAND	1424-7860			SWISS MED WKLY	Swiss Med. Wkly.	SEP 17	2005	135	37-38					538	548				11	Medicine, General & Internal	General & Internal Medicine	984FU	WOS:000233288700001	16333764	
J	de Jong, PA; Muller, NL; Pare, PD; Coxson, HO				de Jong, PA; Muller, NL; Pare, PD; Coxson, HO			Computed tomographic imaging of the airways: relationship to structure and function	EUROPEAN RESPIRATORY JOURNAL			English	Review						airways; asthma; chronic obstructive pulmonary disease; computed tomography; cystic fibrosis; lung structure and function	THIN-SECTION CT; HIGH-RESOLUTION CT; OBSTRUCTIVE PULMONARY-DISEASE; CYSTIC-FIBROSIS LUNG; BRONCHIAL-WALL THICKNESS; PLACEBO-CONTROLLED TRIAL; ATOMIC-BOMB SURVIVORS; AIR-FLOW OBSTRUCTION; YOUNG-CHILDREN; ASYMPTOMATIC SUBJECTS	Alterations in the structure of the airways, collectively termed airway remodelling, contribute to airflow obstruction in a variety of chronic lung diseases. While histology has provided valuable insights into the structure of airway wall remodelling, this technique is invasive and does not allow the longitudinal analysis of airway wall dimensions. Technical advances in computed tomography allow the assessment of airway wall dimensions, and are ideally suited for the noninvasive investigation of the pathogenesis of airway wall remodelling and the evaluation of new therapeutic interventions. The aim of this article is to review the use of computed tomography in the investigation of airway structure and function in health and disease.	Univ British Columbia, Vancouver Gen Hosp, Dept Radiol, Vancouver, BC V5Z 1M9, Canada; Erasmus MC Sophia, Dept Paediat Pulmonol, Rotterdam, Netherlands; St Pauls Hosp, James Hogg iCAPTURE Ctr Cardiovasc & Pulm Res, Vancouver, BC V6Z 1Y6, Canada	Coxson, HO (reprint author), Univ British Columbia, Vancouver Gen Hosp, Dept Radiol, 855 W 12th Ave,Room 3350 JPN, Vancouver, BC V5Z 1M9, Canada.	harvey.coxson@vch.ca	Pare, Peter/C-7425-2011; de Jong, Pim/G-7220-2014; Coxson, Harvey/A-9861-2017	de Jong, Pim/0000-0003-4840-6854; Coxson, Harvey/0000-0001-5750-9711			Aurora P, 2004, THORAX, V59, P1068, DOI 10.1136/thx.2004.022590; Austin JHM, 1996, RADIOLOGY, V200, P327; Awadh N, 1998, THORAX, V53, P248; BAI TR, 1990, AM REV RESPIR DIS, V141, P552; Bankier AA, 1996, RADIOLOGY, V199, P831; BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; Beigelman-Aubry C, 2002, RADIOLOGY, V223, P181, DOI 10.1148/radiol.2231010779; BHALLA M, 1991, RADIOLOGY, V179, P783; Bonnel AS, 2004, PEDIATR PULM, V38, P396, DOI 10.1002/ppul.20091; BOULET LP, 1995, AM J RESP CRIT CARE, V152, P865; Brackel HJL, 2000, AM J RESP CRIT CARE, V162, P896; Brenner DJ, 2002, PEDIATR RADIOL, V32, P228, DOI 10.1007/s00247-002-0671-1; Brenner DJ, 2001, AM J ROENTGENOL, V176, P289; Brody AS, 1998, PEDIATRICS, V101, P1071, DOI 10.1542/peds.101.6.1071; Brody AS, 2004, J PEDIATR-US, V144, P145, DOI 10.1016/j.jpeds.2003.11.008; Brody AS, 1999, PEDIATR RADIOL, V29, P731, DOI 10.1007/s002470050684; Brody AS, 2001, J THORAC IMAG, V16, P259, DOI 10.1097/00005382-200110000-00007; BRODY AS, 2004, PEDIAT PULMONOL S27, V38, pA321; BRODY AS, 2003, PEDIAT PULMONOL S25, V36, pA389; BRODY AS, 2003, PEDIAT PULMONOL, V36, pA388; Brown RH, 2000, AM J RESP CRIT CARE, V161, P1256; Brown RH, 1997, J APPL PHYSIOL, V82, P491; Brown RH, 2001, AM J RESP CRIT CARE, V163, P994; CHOW CW, 1982, EUR J PEDIATR, V139, P240, DOI 10.1007/BF00442171; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; COXSON H, 2003, AM J RESP CRIT CARE, V167, pA81; Dakin CJ, 2002, PEDIATR PULM, V33, P475, DOI 10.1002/ppul.10109; Dakin CJ, 2002, AM J RESP CRIT CARE, V165, P904, DOI 10.1164/rccm.2010139; de Jong PA, 2003, EUR RESPIR J, V22, P235, DOI 10.1183/09031936.03.00089702; de Jong PA, 2004, EUR RESPIR J, V23, P93, DOI 10.1183/09031936.03.00006603; de Jong PA, 2004, RADIOLOGY, V231, P434, DOI 10.1148/radiol.2312021393; DEJONG PA, 2005, IN PRESS AM J RESP C; Demirkazik FB, 2001, EUR J RADIOL, V37, P54, DOI 10.1016/S0720-048X(00)00236-9; Diederich S, 1996, EUR RADIOL, V6, P801; Donnelly LF, 1997, PEDIATR RADIOL, V27, P920, DOI 10.1007/s002470050272; Doring Gerd, 2004, J Cyst Fibros, V3, P67, DOI 10.1016/j.jcf.2004.03.008; Dorlochter L, 2003, EUR J RADIOL, V47, P193, DOI 10.1016/S0720-048X(02)00097-9; DOVEY M, 1989, J SUBMICR CYTOL PATH, V21, P521; Drent M, 2003, EUR RADIOL, V13, P2462, DOI 10.1007/s00330-003-1965-x; Edwards EA, 2003, PEDIATR PULM, V36, P87, DOI 10.1002/ppul.10339; Ferretti GR, 1996, J COMPUT ASSIST TOMO, V20, P777, DOI 10.1097/00004728-199609000-00018; Ferretti GR, 2001, EUR RESPIR J, V18, P381, DOI 10.1183/09031936.01.00217701; Gevenois PA, 1996, RADIOLOGY, V199, P825; GEVENOIS PA, 1995, AM J RESP CRIT CARE, V152, P653; Gibson RL, 2003, AM J RESP CRIT CARE, V168, P918, DOI 10.1164/rccm.200304-505SO; Goldin JG, 1998, RADIOLOGY, V208, P321; GOLDIN JG, 1999, J ALLERGY CLIN IMM S, V104, P258; Gono H, 2003, EUR RESPIR J, V22, P965, DOI 10.1183/09031936.03.00085302; Goris ML, 2003, CHEST, V123, P1655, DOI 10.1378/chest.123.5.1655; Grenier P, 1996, EUR RADIOL, V6, P199; Grenier PA, 2002, EUR RADIOL, V12, P1022, DOI 10.1007/s00330-002-1342-1; Gustafsson PM, 2003, EUR RESPIR J, V22, P972, DOI 10.1183/09031936.03.00049502; Hamutcu R, 2002, AM J RESP CRIT CARE, V165, P1172, DOI 10.1164/rccm.2104090; HANSELL DM, 1989, BRIT J RADIOL, V62, P1; HAYHURST MD, 1984, LANCET, V2, P320; Helbich TH, 1999, RADIOLOGY, V213, P537; Helbich TH, 1999, AM J ROENTGENOL, V173, P81; Hoffman EA, 2003, ACAD RADIOL, V10, P1104, DOI 10.1016/S1076-6332(03)00330-1; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; HOGG JC, 1970, NEW ENGL J MED, V282, P1283, DOI 10.1056/NEJM197006042822302; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Hogg JC, 2004, LANCET, V364, P709, DOI 10.1016/S0140-6736(04)16900-6; Hubert Dominique, 2004, J Cyst Fibros, V3, P15, DOI 10.1016/j.jcf.2003.12.004; Ikonen T, 1996, J HEART LUNG TRANSPL, V15, P587; Karp CL, 2004, NAT IMMUNOL, V5, P388, DOI 10.1038/ni1056; Kasahara K, 2002, THORAX, V57, P242, DOI 10.1136/thorax.57.3.242; Kazerooni EA, 1997, AM J ROENTGENOL, V169, P977; Ketai L, 2001, ACAD RADIOL, V8, P257, DOI 10.1016/S1076-6332(03)80535-4; Kim JS, 1997, J COMPUT ASSIST TOMO, V21, P306, DOI 10.1097/00004728-199703000-00028; King GG, 2004, EUR RESPIR J, V24, P211, DOI 10.1183/09031936.04.00047503; King GG, 2000, AM J RESP CRIT CARE, V161, P574; KINSELLA M, 1988, CHEST, V94, P286, DOI 10.1378/chest.94.2.286; Kubota J, 1998, Radiat Med, V16, P167; Kulich M, 2003, J PEDIATR-US, V142, P631, DOI 10.1067/mpd.2003.197; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Labiris NR, 2003, EUR RESPIR J, V21, P848, DOI 10.1183/09031936.03.00065102; LEIGH MW, 1995, AM J RESP CELL MOL, V12, P605; Little SA, 2002, THORAX, V57, P247, DOI 10.1136/thorax.57.3.247; Logan PM, 1996, IRISH J MED SCI, V165, P27; Long FR, 1999, RADIOLOGY, V212, P588; Long FR, 2004, J PEDIATR-US, V144, P154, DOI 10.1016/j.jpeds.2003.09.026; Long FR, 2001, PEDIATR RADIOL, V31, P413, DOI 10.1007/s002470100462; Long FR, 2001, J THORAC IMAG, V16, P251, DOI 10.1097/00005382-200110000-00006; Loubeyre P, 1996, CHEST, V109, P360, DOI 10.1378/chest.109.2.360; Lucidarme O, 1998, AM J ROENTGENOL, V170, P301; Lucidarme O, 1996, RADIOLOGY, V200, P673; Lugo-Olivieri CH, 1998, CLIN IMAG, V22, P346, DOI 10.1016/S0899-7071(98)00031-X; LYNCH DA, 1993, RADIOLOGY, V188, P829; Maffessanti M, 1996, J THORAC IMAG, V11, P27, DOI 10.1097/00005382-199601110-00002; Manson D, 1997, PEDIATR RADIOL, V27, P794, DOI 10.1007/s002470050235; Marchant JM, 2001, PEDIATR PULM, V31, P24, DOI 10.1002/1099-0496(200101)31:1<24::AID-PPUL1003>3.0.CO;2-D; Matsuoka S, 2005, RADIOLOGY, V234, P595, DOI 10.1148/radiol.2342031466; Mayo JR, 2003, RADIOLOGY, V228, P15, DOI 10.1148/radiol.2281020874; MCNAMARA AE, 1992, J APPL PHYSIOL, V73, P307; McNittGray MF, 1997, J COMPUT ASSIST TOMO, V21, P939, DOI 10.1097/00004728-199711000-00017; MELLINS RB, 1969, PEDIATRICS, V44, P315; Mishima M, 1999, P NATL ACAD SCI USA, V96, P8829, DOI 10.1073/pnas.96.16.8829; Mitsunobu F, 2003, EUR RESPIR J, V22, P106, DOI 10.1183/09031936.03.00081702; Mitsunobu F, 2003, AM J RESP CRIT CARE, V167, P411, DOI 10.1164/rccm.2112070; Moss RB, 2004, CHEST, V125, P509, DOI 10.1378/chest.125.2.509; MULLER NL, 1988, CHEST, V94, P782, DOI 10.1378/chest.94.4.782; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; Nakano Y, 2005, AM J RESP CRIT CARE, V171, P142, DOI 10.1164/rccm.200407-874OC; Nakano Y, 2002, P SOC PHOTO-OPT INS, V4683, P460, DOI 10.1117/12.463615; Nasr SZ, 2001, PEDIATR PULM, V31, P377, DOI 10.1002/ppul.1061; NASR SZ, 2004, PEDIAT PULMONOL S27, V38, pA323; NATHANSON I, 1991, PEDIATR PULM, V11, P81, DOI 10.1002/ppul.1950110112; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Niimi A, 2000, AM J RESP CRIT CARE, V162, P1518; Niimi A, 2003, AM J RESP CRIT CARE, V168, P983, DOI 10.1164/rccm.200211.1268OC; Niimi A, 2004, AM J MED, V116, P725, DOI 10.1016/j.amjmed.2003.11.026; Ogrinc G, 1998, HUM PATHOL, V29, P65, DOI 10.1016/S0046-8177(98)90392-6; Oikonomou A, 2002, EUR RADIOL, V12, P2229, DOI 10.1007/s00330-002-1340-3; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557; Ooi GC, 2002, RADIOLOGY, V225, P663, DOI 10.1148/radiol.2253011575; OPPENHEIMER EH, 1981, HUM PATHOL, V12, P36, DOI 10.1016/S0046-8177(81)80240-7; Orlandi I, 2005, RADIOLOGY, V234, P604, DOI 10.1148/radiol.2342040013; ORNOY A, 1987, AM J MED GENET, V28, P935, DOI 10.1002/ajmg.1320280420; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; PAGANIN F, 1992, AM REV RESPIR DIS, V146, P1084; Park CS, 1997, RADIOLOGY, V203, P361; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PHILLIPS MS, 1986, CLIN RADIOL, V37, P321, DOI 10.1016/S0009-9260(86)80261-6; Pierce DA, 1996, SCIENCE, V272, P632; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Preston DL, 2003, RADIAT RES, V160, P381, DOI 10.1667/RR3049; PRESTON DL, 1987, RADIAT RES, V111, P151, DOI 10.2307/3577030; Quan JM, 2001, J PEDIATR-US, V139, P813, DOI 10.1067/mpd.2001.118570; Reid L, 1967, Bibl Paediatr, V86, P195; REID LM, 1950, THORAX, V5, P233, DOI 10.1136/thx.5.3.233; Reinhardt JM, 1997, IEEE T MED IMAGING, V16, P820, DOI 10.1109/42.650878; RemyJardin M, 1996, RADIOLOGY, V200, P665; Robinson PJ, 2002, PEDIATR PULM, V34, P237, DOI 10.1002/ppul.10136; Robinson TE, 2001, J PEDIATR-US, V138, P553, DOI 10.1067/mpd.2001.111820; Robinson TE, 2003, AM J RESP CRIT CARE, V168, P588, DOI 10.1164/rccm.200209-1093OC; Saba OI, 2003, J APPL PHYSIOL, V95, P1063, DOI 10.1152/japplphysiol.00962.2002; Santamaria F, 1998, PEDIATRICS, V101, P908, DOI 10.1542/peds.101.5.908; SANTIS G, 1991, CLIN RADIOL, V44, P20, DOI 10.1016/S0009-9260(05)80220-X; Schidlow Daniel V, 2004, J Cyst Fibros, V3, P63, DOI 10.1016/j.jcf.2004.05.044; SENETERRE E, 1994, EUR RESPIR J, V7, P596, DOI 10.1183/09031936.94.07030596; Shah RM, 1997, AM J ROENTGENOL, V169, P375; Shaw TJ, 2004, EUR RESPIR J, V23, P813, DOI 10.1183/09031936.04.00119904; Silva CIS, 2004, AM J ROENTGENOL, V183, P817; SILVERMAN PM, 1987, J COMPUT ASSIST TOMO, V11, P52, DOI 10.1097/00004728-198701000-00010; SOBONYA RE, 1986, AM REV RESPIR DIS, V134, P290; STIGLBAUER R, 1992, ACTA RADIOL, V33, P548; STURGESS J, 1982, AM J PATHOL, V106, P303; TACCONE A, 1992, EUR J RADIOL, V15, P125, DOI 10.1016/0720-048X(92)90137-X; Tanaka N, 2003, RADIOLOGY, V227, P776, DOI 10.1148/; Terasaki Hiroshi, 2004, Radiat Med, V22, P179; Tiddens H, 2000, AM J RESP CRIT CARE, V162, pS7; Tiddens HAWM, 2000, EUR RESPIR J, V15, P735, DOI 10.1034/j.1399-3003.2000.15d18.x; TIDDENS HAWM, 1995, AM J RESP CRIT CARE, V152, P260; Tiddens HAWM, 2002, PEDIATR PULM, V34, P228, DOI 10.1002/ppul.10134; Tirouvanziam R, 2002, AM J PHYSIOL-LUNG C, V283, pL445, DOI 10.1152/ajplung.00419.2001; TOMASHEFSKI JF, 1986, AM REV RESPIR DIS, V133, P535; Tooker AC, 2003, RADIOLOGY, V227, P575, DOI 10.1148/radiol.2272012146; van Beek EJR, 2004, J MAGN RESON IMAGING, V20, P540, DOI 10.1002/jmri.20154; Vignola AM, 2004, EUR RESPIR J, V24, P910, DOI 10.1183/09031936.04.00032603; WEBB WR, 1984, INVEST RADIOL, V19, P394, DOI 10.1097/00004424-198409000-00011; WENTWORTH P, 1968, THORAX, V23, P582, DOI 10.1136/thx.23.6.582; WOOD SA, 1995, J APPL PHYSIOL, V79, P1687; Yamasaki A, 2003, LUNG, V181, P115, DOI 10.1007/s00408-003-1012-3; YOUNG K, 1991, ACTA RADIOL, V32, P439; ZUELZER WW, 1949, PEDIATRICS, V4, P53	166	87	90	4	12	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUL	2005	26	1					140	152		10.1183/09031936.05.00007105		13	Respiratory System	Respiratory System	945JG	WOS:000230498200022	15994401	
J	Jarvis, J; Seed, MJ; Elton, RA; Sawyer, L; Agius, RM				Jarvis, J; Seed, MJ; Elton, RA; Sawyer, L; Agius, RM			Relationship between chemical structure and the occupational asthma hazard of low molecular weight organic compounds	OCCUPATIONAL AND ENVIRONMENTAL MEDICINE			English	Article							RESPIRATORY SENSITIZATION; SUBSTANCES; IDENTIFICATION; ALLERGENS; TOXICITY; EXPOSURE; DISEASE	Aims: To investigate quantitatively, relationships between chemical structure and reported occupational asthma hazard for low molecular weight (LMW) organic compounds; to develop and validate a model linking asthma hazard with chemical substructure; and to generate mechanistic hypotheses that might explain the relationships. Methods: A learning dataset used 78 LMW chemical asthmagens reported in the literature before 1995, and 301 control compounds with recognised occupational exposures and hazards other than respiratory sensitisation. The chemical structures of the asthmagens and control compounds were characterised by the presence of chemical substructure fragments. Odds ratios were calculated for these fragments to determine which were associated with a likelihood of being reported as an occupational asthmagen. Logistic regression modelling was used to identify the independent contribution of these substructures. A post-1995 set of 21 asthmagens and 77 controls were selected to externally validate the model. Results: Nitrogen or oxygen containing functional groups such as isocyanate, amine, acid anhydride, and carbonyl were associated with an occupational asthma hazard, particularly when the functional group was present twice or more in the same molecule. A logistic regression model using only statistically significant independent variables for occupational asthma hazard correctly assigned 90% of the model development set. The external validation showed a sensitivity of 86% and specificity of 99%. Conclusions: Although a wide variety of chemical structures are associated with occupational asthma, bifunctional reactivity is strongly associated with occupational asthma hazard across a range of chemical substructures. This suggests that chemical cross-linking is an important molecular mechanism leading to the development of occupational asthma. The logistic regression model is freely available on the internet and may offer a useful but inexpensive adjunct to the prediction of occupational asthma hazard.	Univ Manchester, Ctr Environm & Occupat Hlth, Manchester M13 9PL, Lancs, England; Univ Edinburgh, Univ Comp Serv, Edinburgh EH8 9YL, Midlothian, Scotland; Univ Edinburgh, Sch Biol Sci, Edinburgh EH8 9YL, Midlothian, Scotland	Agius, RM (reprint author), Univ Manchester, Ctr Environm & Occupat Hlth, Oxford Rd, Manchester M13 9PL, Lancs, England.	agius@manchester.ac.uk	Seed, Martin/A-2132-2013				AGIUS RM, 1994, OCCUP MED-OXFORD, V44, P34, DOI 10.1093/occmed/44.1.34; AGIUS RM, 1991, ANN OCCUP HYG, V35, P129, DOI 10.1093/annhyg/35.2.129; Agius RM, 2000, OCCUP MED, V15, P369; *AM C GOV IND HYG, 2002, THRESH LIM VAL BIOL; Armitage P, 1994, STAT METHODS MED RES, P443; Avashia B, 1996, J OCCUP ENVIRON MED, V38, P625, DOI 10.1097/00043764-199606000-00015; Barratt MD, 2001, CURR OPIN CHEM BIOL, V5, P383, DOI 10.1016/S1367-5931(00)00218-0; Bernstein DI, 2003, IMMUNOL ALLERGY CLIN, V23, P221, DOI 10.1016/S0889-8561(02)00084-X; DALBY A, 1992, J CHEM INF COMP SCI, V32, P244, DOI 10.1021/ci00007a012; Dearman RJ, 2003, J APPL TOXICOL, V23, P199, DOI 10.1002/jat.907; *ECETOC, 2003, 89 ECETOC QSARS; Fairhurst S, 2003, FOOD CHEM TOXICOL, V41, P1453, DOI 10.1016/S0278-6915(03)00193-5; Graham C, 1997, REGUL TOXICOL PHARM, V26, P296, DOI 10.1006/rtph.1997.1170; *HLTH SAF EX, 1994, EH4094 HLTH SAF EX; *HLTH SAF EX, 2002, EH402002 HLTH SAF EX; Karol MH, 2001, ANN ALLERG ASTHMA IM, V87, P28; Karol MH, 1996, TOXICOL LETT, V86, P187, DOI 10.1016/0378-4274(96)03689-2; Kimber I, 2001, TOXICOL IN VITRO, V15, P307, DOI 10.1016/S0887-2333(01)00027-3; MENARD S, 1995, APPL LOGISTIC REGRES, P54; Meyer JD, 1999, OCCUP MED-OXFORD, V49, P485, DOI 10.1093/occmed/49.8.485; Nasser SMS, 2001, CLIN EXP ALLERGY, V31, P1014, DOI 10.1046/j.1365-2222.2001.01090.x; Pearl Greg M., 2001, Current Topics in Medicinal Chemistry, V1, P247, DOI 10.2174/1568026013395074; Piipari R, 1998, CLIN EXP ALLERGY, V28, P358; SARLO K, 1997, TOXICOLOGY CHEM RESP, P107; SAVONIUS B, 1993, CLIN EXP ALLERGY, V23, P416, DOI 10.1111/j.1365-2222.1993.tb00348.x; TERPSTRA GK, 1981, EUR J PHARMACOL, V73, P107, DOI 10.1016/0014-2999(81)90154-0; van Kampen V, 2000, AM J IND MED, V38, P164, DOI 10.1002/1097-0274(200008)38:2<164::AID-AJIM7>3.0.CO;2-2; Vandenplas O, 2003, EUR RESPIR J, V21, P706, DOI 10.1183/09031936.03.00113303; VENABLES KM, 1989, BRIT J IND MED, V46, P222; Wild LG, 2003, IMMUNOL ALLERGY CLIN, V23, P235, DOI 10.1016/S088908561(02)00083-8; Zeiss C Raymond, 2002, Curr Opin Allergy Clin Immunol, V2, P89, DOI 10.1097/00130832-200204000-00001	31	87	88	2	10	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1351-0711			OCCUP ENVIRON MED	Occup. Environ. Med.	APR	2005	62	4					243	250		10.1136/oem.2004.016402		8	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	907TC	WOS:000227739900008	15778257	
J	Graham-Bermann, SA; Seng, J				Graham-Bermann, SA; Seng, J			Violence exposure and traumatic stress symptoms as additional predictors of health problems in high-risk children	JOURNAL OF PEDIATRICS			English	Article							POSTTRAUMATIC-STRESS; COMMUNITY VIOLENCE; DOMESTIC VIOLENCE; ABUSE; WOMEN; DISORDER; PTSD; AGGRESSION; DEPRESSION; WITNESSES	Objective To test the hypotheses that both violence and traumatic stress symptoms are associated with negative health status among poor preschool children. Study design This cross-sectional analysis of a Head Start preschool age cohort (n = 160) studied health outcomes parallel to those assessed in the 2001 National Health Interview Survey of child health (asthma, allergy, attention deficit hyperactivity disorder, global appraisal) its well as two stress-related somatic complaints, gastrointestinal problems and headache. Risk factors include sociodemographics, mothers' health factors, extent of exposure to violence and maltreatment, and mother- and teacher-reported traumatic stress symptoms. Results Compared with poor children in the National Health Interview Survey and their Head Start peers, children exposed to violence and those with high levels of traumatic stress had significantly, worse outcomes, in a dose-response relation. Being abused, exposed to domestic violence, and having a mother using substances were associated with a higher number of health problems. The hierarchical model established the mother's own poor physical health and the child's level of traumatic stress as the strongest predictors of poor child health. Conclusions These two risk factors are amenable to intervention by health care providers who treat children.	Univ Michigan, Dept Psychol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Nursing, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Obstet & Gynecol, Ann Arbor, MI 48109 USA	Graham-Bermann, SA (reprint author), Univ Michigan, Dept Psychol, 525 E Univ Ave, Ann Arbor, MI 48109 USA.			Graham-Bermann, Sandra A/0000-0002-3811-7330; Seng, Julia/0000-0002-7066-6348	PHS HHS [90-YD-0066]		Achenbach T. M., 1991, MANUAL TEACHERS REPO; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Applegate B, 1997, J AM ACAD CHILD PSY, V36, P1211, DOI 10.1097/00004583-199709000-00013; Bassuk E L, 2001, J Am Med Womens Assoc (1972), V56, P79; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561; BECK AT, 1988, CLIN PSYCHOL REV, V8, P77, DOI 10.1016/0272-7358(88)90050-5; BLOOM B, 2004, SUMMARY HLTH STAT US; Felitti VJ, 1998, AM J PREV MED, V14, P245, DOI 10.1016/S0749-3797(98)00017-8; Friedman Matthew J., 1995, P507; Graham-Bermann SA, 1998, J INTERPERS VIOLENCE, V13, P111, DOI 10.1177/088626098013001007; GrahamBermann SA, 1996, J CLIN CHILD PSYCHOL, V25, P280, DOI 10.1207/s15374424jccp2503_4; GRAHAMBERMANN SA, IN PRESS VIOLENCE WO; Graham-Bermann S. A., 1994, J FAMILY PSYCHOL, V8, P224, DOI 10.1037//0893-3200.8.2.224; GRAHAMBERMANN SA, 2001, PRESCHOOL POSTTRAUMA; Holden GW, 2003, CLIN CHILD FAM PSYCH, V6, P151, DOI 10.1023/A:1024906315255; JOURILES EN, 1995, J FAM PSYCHOL, V9, P69, DOI 10.1037//0893-3200.9.1.69; Kilpatrick KL, 1998, CHILD ABUSE NEGLECT, V22, P319, DOI 10.1016/S0145-2134(97)00178-6; Kimerling R, 2000, J TRAUMA STRESS, V13, P115, DOI 10.1023/A:1007729116133; Kimerling R, 2002, GENDER PTSD, P271; Klinnert MD, 2001, PEDIATRICS, V108, part. no., DOI 10.1542/peds.108.4.e69; Litrownik AJ, 2003, J FAM VIOLENCE, V18, P59, DOI 10.1023/A:1021405515323; MARTINEZ P, 1993, PSYCHIATRY, V56, P22; O'Brien M, 1994, Violence Vict, V9, P45; OSOFSKY JD, 1993, PSYCHIATRY, V56, P36; RICHTERS JE, 1993, PSYCHIATRY, V56, P7; Richters J. E., 1990, SURVEY CHILDRENS EXP; Rossman BBR, 1997, J AM ACAD CHILD PSY, V36, P1089; Roth S, 1997, J TRAUMA STRESS, V10, P539, DOI 10.1002/jts.2490100403; Sadler AG, 2000, OBSTET GYNECOL, V96, P473, DOI 10.1016/S0029-7844(00)00919-4; Seng JS, 2002, J MIDWIFERY WOM HEAL, V47, P337, DOI 10.1016/S1526-9523(02)00275-1; STRAUS MA, 1979, J MARRIAGE FAM, V41, P75, DOI 10.2307/351733; Straus M. M. A., 1980, CLOSED DOORS VIOLENC; Vogel LCM, 2001, J TRAUMA STRESS, V14, P569, DOI 10.1023/A:1011116824613; WOLFE VV, 1989, BEHAV THER, V20, P215, DOI 10.1016/S0005-7894(89)80070-X; Wright RJ, 2004, J ALLERGY CLIN IMMUN, V113, P1051, DOI 10.1016/j.jaci.2004.03.032	35	87	87	2	22	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAR	2005	146	3					349	354		10.1016/j.jpeds.2004.10.065		6	Pediatrics	Pediatrics	906SI	WOS:000227662600015	15756218	
J	Ishida, Y; Nakamura, F; Kanzato, H; Sawada, D; Hirata, H; Nishimura, A; Kajimoto, O; Fujiwara, S				Ishida, Y; Nakamura, F; Kanzato, H; Sawada, D; Hirata, H; Nishimura, A; Kajimoto, O; Fujiwara, S			Clinical effects of Lactobacillus acidophilus strain L-92 on perennial allergic rhinitis: A double-blind, placebo-controlled study	JOURNAL OF DAIRY SCIENCE			English	Article						Lactobacillus acidophilus; perennial allergic rhinitis; double-blind placebo-controlled study	LACTIC-ACID BACTERIA; REGULATORY-CELLS; CONTROLLED TRIAL; DENDRITIC CELLS; ATOPIC DISEASE; T-CELLS; CHILDREN; ASTHMA; MICE; PREVENTION	Studies in animals have suggested that lactic acid bacteria alleviate allergic diseases, however, little information is available on their clinical effect on allergy in humans. Thus, we examined the efficacy of orally administered Lactobacillus acidophilus strain L-92 (L-92) on perennial allergic rhinitis. In a randomized, double-blind, placebo-controlled clinical trial, 49 patients with perennial allergic rhinitis were randomized to receive either 100 mL of heat-treated fermented milk containing L-92 (n = 25) or acidified milk without lactic acid bacteria (placebo; n = 24) for 8 wk. The severity of symptoms was evaluated based on the changes in the scores of clinical symptoms. Oral administration of milk fermented with L-92 resulted in a statistically significant improvement of nasal symptom-medication scores. Ocular symptom-medication scores of patients in the L-92 intervention group tended to improve compared with those in the placebo group. In addition, clear decreases of the scores of swelling and color of the nasal mucosa were observed in the L-92 intervention group at 6 and 8 wk after the start of ingestion of fermented milk. There were no significant differences in serum antihouse dust mite immunoglobulin E levels nor in T helper type 1/T helper type 2 ratio between the 2 groups. These results suggest that oral administration of L-92 can alleviate the symptoms of perennial allergic rhinitis, however, statistically significant changes were not shown in blood parameters.	Calpis Co Ltd, Ctr Res & Dev, Kanagawa, Japan; Okayama Univ, Sch Med, Dept Internal Med 3, Okayama 700, Japan; Soiken Inc, Osaka, Japan	Fujiwara, S (reprint author), Calpis Co Ltd, Ctr Res & Dev, Kanagawa, Japan.	shigeru.fujiwara@calpis.co.jp					Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; CHEN YH, 1994, SCIENCE, V265, P1237, DOI 10.1126/science.7520605; Cross ML, 2001, INT IMMUNOPHARMACOL, V1, P891, DOI 10.1016/S1567-5769(01)00025-X; de Lafaille MAC, 2002, CURR OPIN IMMUNOL, V14, P771; Groux H, 1997, NATURE, V389, P737; Helin T, 2002, ALLERGY, V57, P243, DOI 10.1034/j.1398-9995.2002.1s3299.x; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P59, DOI 10.1111/j.1399-3038.1995.tb00261.x; Ishida Y, 2003, BIOSCI BIOTECH BIOCH, V67, P951, DOI 10.1271/bbb.67.951; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, LANCET, V357, P1076, DOI 10.1016/S0140-6736(00)04259-8; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Levings MK, 2002, INT ARCH ALLERGY IMM, V129, P263, DOI 10.1159/000067596; Matsuzaki T, 1998, J DAIRY SCI, V81, P48; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Miettinen M, 1998, INFECT IMMUN, V66, P6058; Murosaki S, 1998, J ALLERGY CLIN IMMUN, V102, P57, DOI 10.1016/S0091-6749(98)70055-7; OKUDA M, 2002, CLIN GUIDELINES ALLE, P24; Pessi T, 2000, CLIN EXP ALLERGY, V30, P1804, DOI 10.1046/j.1365-2222.2000.00948.x; ROMAGNANI S, 1994, CURR OPIN IMMUNOL, V6, P838, DOI 10.1016/0952-7915(94)90002-7; Rosenfeldt V, 2003, J ALLERGY CLIN IMMUN, V111, P389, DOI 10.1067/mai.2003.389; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Weiner HL, 2001, NAT IMMUNOL, V2, P671, DOI 10.1038/90604; Wheeler JG, 1997, ANN ALLERG ASTHMA IM, V79, P229	24	87	91	0	2	AMER DAIRY SCIENCE ASSOC	SAVOY	1111 N DUNLAP AVE, SAVOY, IL 61874 USA	0022-0302			J DAIRY SCI	J. Dairy Sci.	FEB	2005	88	2					527	533				7	Agriculture, Dairy & Animal Science; Food Science & Technology	Agriculture; Food Science & Technology	892QQ	WOS:000226665500010	15653517	
J	Meystre, S				Meystre, S			The current state of telemonitoring: A comment on the literature	TELEMEDICINE JOURNAL AND E-HEALTH			English	Editorial Material							MONITORING-SYSTEM; TELEMEDICINE; INTERNET; CARE; MANAGEMENT; TELEMETRY; PATIENT; EVEREST; TOP	Telemonitoring, is defined as the use of information technology to monitor patients at a distance. This literature review suggests that the most promising applications for telemonitoring is for chronic illnesses such as cardiopulmonary disease, asthma, and heart failure in the home. Fetal heart rate monitoring and infant cardiopulmonary functions have also been monitored at a distance, as well as coagulation, or the level of activity of elderly people, assessed by the intelligent home monitoring devices. Hospitals, clinics, and prisons all have used telemonitoring, as have ambulances equipped with systems connected to the receiving hospital. Telemonitoring allows reduction of chronic disease complications thanks to a better followup; provides health care services without using hospital beds; and reduces patient travel, time off from work, and overall costs. Several systems have proven to be cost effective. Telemonitoring is also a way of responding to the new needs of home care in an ageing population. Real- time monitoring of patients in ambulances reduces the time to initiate treatment and allows the emergency crew to be better prepared. The obstacles to telemonitoring development include the initial costs of systems, physician licensing, and reimbursement. In the future, virtual reality, immersive environments, haptic feedback and nanotechnology promise new ways in improving the capabilities of telemonitoring.	Univ Utah, Sch Med, Dept Med Informat, Salt Lake City, UT 84132 USA	Meystre, S (reprint author), Univ Utah, Sch Med, Dept Med Informat, 30 North 1900 East,Room AB 193, Salt Lake City, UT 84132 USA.	s.meystre@utah.edu					Anagnostaki A, 2001, MEDINFO, V10, P77; Anantharaman V, 2001, INT J MED INFORM, V61, P147, DOI 10.1016/S1386-5056(01)00137-X; Angood PB, 2000, TELEMED J E-HEALTH, V6, P315, DOI 10.1089/153056200750040174; Artinian NT, 2001, HEART LUNG, V30, P191, DOI 10.1067/mhl.2001.112684; *ASS TEL SERV PROV, 1999, 1999 REP US TEL ACT; Barbaro V, 1997, J Telemed Telecare, V3, P96, DOI 10.1258/1357633971930931; Barro S, 1999, IEEE ENG MED BIOL, V18, P80, DOI 10.1109/51.775492; Belmont J M, 1995, Telemed J, V1, P133, DOI 10.1089/tmj.1.1995.1.133; Cai J, 2000, Proc AMIA Symp, P116; CALAGAN J, 2001, TELEMED J E HLTH, V7, P174; *CEN WORK GROUP 4, 2000, PRENV1064 CEN WORK G; *CMS, 2002, MED TEL; *CMS, 2003, MED INT MAN 3; Cordisco ME, 1999, AM J CARDIOL, V84, P860, DOI 10.1016/S0002-9149(99)00452-X; CORDISCO ME, 1999, AM J CARDIOL, V84, pA8; de Lusignan S, 2000, J Telemed Telecare, V6 Suppl 1, pS119; Einthoven W., 1906, ARCH INT PHYSIOL, V4, P132; Field MJ, 2002, JAMA-J AM MED ASSOC, V288, P423, DOI 10.1001/jama.288.4.423; Finkelstein J, 2000, CHEST, V117, P148, DOI 10.1378/chest.117.1.148; FITZGERALD J, 1996, BUSINESS DATA COMMUN, V19, P562; Frim DM, 2000, J NEUROSURG, V92, P927, DOI 10.3171/jns.2000.92.6.0927; Gandsas A, 2000, AVIAT SPACE ENVIR MD, V71, P68; Gomez EJ, 2002, COMPUT METH PROG BIO, V69, P163, DOI 10.1016/S0169-2607(02)00039-1; Gray JE, 2000, PEDIATRICS, V106, P1318, DOI 10.1542/peds.106.6.1318; Guler Nihal Fatma, 2002, J Med Syst, V26, P199, DOI 10.1023/A:1015010316958; Guler Nihal Fatma, 2002, J Med Syst, V26, P159, DOI 10.1023/A:1014862027454; Harnett BM, 2001, AVIAT SPACE ENVIR MD, V72, P1125; HINES J, 1999, BIOTELEMETRY USING I; *I MED US COMM EV, 1996, TEL GUID ASS TEL HLT, V14, P271; Johnson P, 1996, J Telemed Telecare, V2, P107, DOI 10.1258/1357633961929871; JOHNSON P, 1998, J TELEMED TELECARE, V18, P86; Jovanov E, 2001, Biomed Sci Instrum, V37, P373; Karlsten R, 2000, J TELEMED TELECARE, V6, P1, DOI 10.1258/1357633001933835; LEITNER P, 1999, TELEMEDICINE WILL GR; Maree DM, 2001, RESPIRATION, V68, P400, DOI 10.1159/000050534; Morlion B, 2002, AM J RESP CRIT CARE, V165, P694, DOI 10.1164/rccm.2107059; Naef R W 3rd, 1998, J Perinatol, V18, P226; *NAT RES COUNC, 2000, NETW HLTH PRESCR INT, V18, P358; Nicogossian AE, 2001, TELEMED J E-HEALTH, V7, P1, DOI 10.1089/153056201300093813; Oohashi T, 2002, CLIN NEUROPHYSIOL, V113, P435, DOI 10.1016/S1388-2457(02)00002-0; Orlov OI, 2001, TELEMED J E-HEALTH, V7, P33, DOI 10.1089/153056201300093877; Quemere M P, 2000, J Gynecol Obstet Biol Reprod (Paris), V29, P571; Satava R, 2000, TELEMED J E-HEALTH, V6, P303, DOI 10.1089/153056200750040165; Sixsmith AJ, 2000, J TELEMED TELECARE, V6, P63, DOI 10.1258/1357633001935059; Tsang MW, 2001, J TELEMED TELECARE, V7, P47, DOI 10.1258/1357633011936138; Vincent JA, 1997, PEDIATR CARDIOL, V18, P86, DOI 10.1007/s002469900121; 2002, WPSM WARFIGHTER PHYS; 2002, HLTH LEVEL 7; 2001, VITALINK 1200	49	87	89	3	13	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED J E-HEALTH	Telemed. J. e-Health	FEB	2005	11	1					63	69		10.1089/tmj.2005.11.63		7	Health Care Sciences & Services	Health Care Sciences & Services	912RK	WOS:000228096900023	15785222	
J	Ostojic, V; Cvoriscec, B; Ostojic, SB; Reznikoff, D; Stipic-Markovic, A; Tudjman, Z				Ostojic, V; Cvoriscec, B; Ostojic, SB; Reznikoff, D; Stipic-Markovic, A; Tudjman, Z			Improving asthma control through telemedicine: A study of short-message service	TELEMEDICINE JOURNAL AND E-HEALTH			English	Article							PEAK EXPIRATORY FLOW; SELF-MANAGEMENT; OBSTRUCTION; MEDICATION; EDUCATION; SYMPTOMS; PROGRAM; HEALTH; COSTS; DIARY	Home peak expiratory flow ( PEF) measurement is recommended by asthma guidelines. In a 16-week randomized controlled study on there exists 6 subjects with asthma ( 24.6 +/- 6.5 years old, asthma duration. 6 months), we examined Global System for Mobile Communications ( GSM) mobile telephone short- message service ( SMS) as a novel means of telemedicine in PEF monitoring. All subjects received asthma education, self- management plan, and standard treatment. All measured PEF three times daily and kept a symptom diary. In the study group, therapy was adjusted weekly by an asthma specialist according to PEF values received daily from the patients. There was no significant difference between the groups in absolute PEF, but PEF variability was significantly smaller in the study group ( 16.12 +/- 6.93% vs. 27.24 +/- 10.01%, p = 0.049). forced expiratory flow in 1 second ( FEV(1); % predicted) in the study group was slightly but significantly increased ( 81.25 +/- 17.31 vs. 77.63 +/- 14.80, p = 0.014) and in the control group, unchanged ( 78.25 +/- 21.09 vs. 78.88 +/- 22.02, p = 0.497). Mean FEV(1) was similar in the two groups both before and after the study. Controls had significantly higher scores for cough ( 1.85 +/- 0.43 vs. 1.42 +/- 0.28, p < 0.05) and night symptoms ( 1.22 +/- 0.23 vs. 0.85 +/- 0.32, p < 0.05). There was no significant difference between the groups in daily consumption of inhaled medicine, forced vital capacity, or compliance. Per patient, per week, the additional cost of follow- up by SMS was A E1.67 ( equivalent to approximately $ 1.30 per 1 Euro), and SMS transmission required 11.5 minutes. Although a study group of 40 patients is needed for the follow- up study to achieve the power of 80% within the 95% confidence interval, we conclude that SMS is a convenient, reliable, affordable, and secure means of telemedicine that may improve asthma control when added to a written action plan and standard follow- up.	Univ Zagreb, Gen Hosp Sveti Duh, Dept Internal Dis, Div Clin Immunol & Pulmonol, Zagreb, Croatia; Winthrop Univ Hosp, Dept Internal Med, Mineola, NY 11501 USA	Ostojic, V (reprint author), Univ Zagreb, Dept Internal Med, Div Clin Immunol & Pulmonol, HR-10000 Zagreb, Croatia.	vostojic@astma.hr					Anderson K, 2001, LANCET, V358, P1343, DOI 10.1016/S0140-6736(01)06451-0; ARCHER LNJ, 1985, ARCH DIS CHILD, V60, P473; BAGG LR, 1980, EUR J RESPIR DIS, V61, P298; BARNES PJ, 1986, AM REV RESPIR DIS, V134, P1289; Bousquet J, 2002, CLIN THER, V24, P1, DOI 10.1016/S0149-2918(02)85002-0; BREWIS RAL, 1991, RESP MED, V85, P457, DOI 10.1016/S0954-6111(06)80262-3; Bruderman I, 1997, Telemed J, V3, P127, DOI 10.1089/tmj.1.1997.3.127; Burney P, 1996, EUR RESPIR J, V9, P687; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; CHMELIK F, 1994, ANN ALLERGY, V73, P527; CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618; COUTTS JAP, 1992, ARCH DIS CHILD, V67, P332; Cowie RL, 1997, CHEST, V112, P1534, DOI 10.1378/chest.112.6.1534; CROSS D, 1991, J ALLERGY CLIN IMMUN, V87, P120, DOI 10.1016/0091-6749(91)90223-B; ENRIGHT P, 1992, AM REV RESPIR DIS, V146, P1367; Enright PL, 1994, AM J RESP CRIT CAR S, V149, P9; Finkelstein J, 2000, CHEST, V117, P148, DOI 10.1378/chest.117.1.148; FINKELSTEIN J, 1998, MEDINFO 1, V9, P272; Finkelstein J, 2001, MEDINFO 1, V10, P810; HORN CR, 1984, LANCET, V1, P1143; IGNACIOGARCIA JM, 1995, AM J RESP CRIT CARE, V151, P353; JONES KP, 1995, THORAX, V50, P851, DOI 10.1136/thx.50.8.851; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; LEBOWITZ MD, 1982, CHEST, V81, P566, DOI 10.1378/chest.81.5.566; MALO JL, 1993, J ALLERGY CLIN IMMUN, V91, P702, DOI 10.1016/0091-6749(93)90189-M; National Asthma Education and Prevention Program, 1997, PUBL NIH; National Institutes of Health, 2002, GLOB STRAT ASTHM MAN; Ostojic V, 2000, J TELEMED TELECARE, V6, P172, DOI 10.1258/1357633001935176; Rietveld S, 1997, J ASTHMA, V34, P133, DOI 10.3109/02770909709075658; RUBINFELD AR, 1976, LANCET, V1, P882; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; TAITEL MS, 1995, J ALLERGY CLIN IMMUN, V95, P672, DOI 10.1016/S0091-6749(95)70171-0; TURNERWARWICK M, 1977, BRIT J DIS CHEST, V71, P73, DOI 10.1016/0007-0971(77)90086-9	34	87	88	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1530-5627			TELEMED J E-HEALTH	Telemed. J. e-Health	FEB	2005	11	1					28	35		10.1089/tmj.2005.11.28		8	Health Care Sciences & Services	Health Care Sciences & Services	912RK	WOS:000228096900019	15785218	
J	Olaguibel, JM; Puebla, MJA				Olaguibel, JM; Puebla, MJA			Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis	JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY			English	Article						sublingual allergen vaccination; immunotherapy; rhinitis; asthma; children; efficacy; meta-analysis	HOUSE-DUST MITE; PLACEBO-CONTROLLED EVALUATION; DOUBLE-BLIND; POSTMARKETING SURVEILLANCE; SWALLOW IMMUNOTHERAPY; PEDIATRIC-PATIENTS; GRASS-POLLEN; ASTHMA; SAFETY; EXTRACT	Background. Sunlingual route, that allows the safe administration of allergen vaccination at home and without injections, is highly attractive alternative to parential delivery, especially amongthe youngest population. However, it's efficiacy in children has been questioned. Objuctive. To evaluate the efficiacy (symptom and medication scores) of sublingual allergen vaccination compared to placebo in pediatric patients. Search strategy: MEDLINE, EMBASE, ISI and the Cochrane Central Register of Controlled trials were explored (completed in january/04) for potentially relevant studies. Selection Criteria: Randomized double blind placebo-controlled clinical trials involving children <= 14 years-old with either rhinitis or asthma of proved allergic aetiology. Data collection and analysis. Two reviewers analyzed independently the eligiblility of studies for inclusions. The combined standardized mean difference (SMD) method was used the random effect model to obtain SMD. However, we also present the SMD values from the fixed effect model. The main outcomes were clinical symptom (asthma, rhinitis and conjunctivitis) and drug requirement scores. Safely, immunological and clinical changes were also reviewed. Results. Seven double blind placebo-controlled trials, enrolling 256 children (129 treatment and 127 placebo recipients), wee analyzed. We observed decreases in symptom (SMD: -1.42 for asthma, -0.44 for rhinitis and -1.49 for conjunctivitis) and medication requirement (SMD - 1.01) scores. Only reductions in asthma (p = 0.01) and drug dosage (p = 0.06) scores reached statistical significance with the random effect model but changes in rhinitis fixed effect model were similar in magnitude (SMD: - 1.60 for asthma, SMD: -0.47 for rhinitis, SMD: -1.09 for conjunctivitis and SMD: 0.54 for drug intake). Safety was constant in all the studies, neither severe nor systemic reactions were observed and oral and gastrointestinal complaints complaints were the most common adverse effects. Conclusion: In children, sublingual delivery of allergen vaccination constitutes a safe and effective alternative to the sublingual route to reduce allergy respiratory symptoms and drug intake. Further studies in this group of age are required to establish the optimal conditions for sublingual allergen vaccination.	Hosp Virgen Del Camino, Secc Alergol, Pamplona, Spain	Olaguibel, JM (reprint author), Secc Alergol, Plaza de la Paz S-N, Pamplona 31003, Spain.	jmolaguibel@telefonica.net					Alderson P, 2003, COCHRANE LIB; Almagro E, 1995, Allergol Immunopathol (Madr), V23, P153; Andre C, 2000, INT ARCH ALLERGY IMM, V121, P229, DOI 10.1159/000024322; Bahceciler NN, 2001, PEDIATR PULM, V32, P49, DOI 10.1002/ppul.1088; Bernardis P, 1996, J INVEST ALLERG CLIN, V6, P55; Bousquet J, 1998, ALLERGY S, V53, P44; Canonica GW, 2003, J ALLERGY CLIN IMMUN, V111, P437, DOI 10.1067/mai.2003.129; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; Di Rienzo V, 2003, CLIN EXP ALLERGY, V33, P206, DOI 10.1046/j.1365-2222.2003.01587.x; Di Rienzo V, 1999, Allergol Immunopathol (Madr), V27, P145; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; FREW AJ, 1993, BRIT MED J, V307, P919; Grosclaude M, 2002, INT ARCH ALLERGY IMM, V129, P248, DOI 10.1159/000066779; Hirsch T, 1997, PEDIATR ALLERGY IMMU, V8, P21, DOI 10.1111/j.1399-3038.1997.tb00138.x; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; Lombardi C, 2001, ALLERGY, V56, P989, DOI 10.1034/j.1398-9995.2001.00181.x; LOPEZ S, 1994, CONTACT DERMATITIS, V31, P37, DOI 10.1111/j.1600-0536.1994.tb01903.x; Malling HJ, 2002, CURR OPIN ALLERGY CL, V2, P523, DOI 10.1097/01.all.0000044538.45448.80; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Olaguibel JM, 1997, ALLERGY, V52, P168, DOI 10.1111/j.1398-9995.1997.tb00971.x; OLAGUIBEL JM, MISCLASIFICATION CLI; Pajno GB, 2000, ALLERGY, V55, P842, DOI 10.1034/j.1398-9995.2000.00495.x; Pajno GB, 2003, CLIN EXP ALLERGY, V33, P1641, DOI 10.1111/j.1365-2222.2003.01809.x; Passalacqua G, 1996, J INVEST ALLERG CLIN, V6, P81; TABAR AI, 1993, ALLERGY, V48, P450, DOI 10.1111/j.1398-9995.1993.tb00743.x; Tari M G, 1994, Allergol Immunopathol (Madr), V22, P209; TARI MG, 1990, ALLERGOL IMMUNOPATH, V18, P277; Vourdas D, 1998, ALLERGY, V53, P662, DOI 10.1111/j.1398-9995.1998.tb03952.x; Wilson DR, 2003, COCHRANE DB SYST REV, V2; Wuthrich B, 2003, J INVEST ALLERG CLIN, V13, P145; Yuksel H, 1999, J INVEST ALLERG CLIN, V9, P305	33	87	94	0	1	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY	1018-9068			J INVEST ALLERG CLIN	J. Invest. Allergol. Clin. Immunol.		2005	15	1					9	16				8	Allergy; Immunology	Allergy; Immunology	919JA	WOS:000228613100002	15864877	
J	Platts-Mills, TAE; Erwin, E; Heymann, P; Woodfolk, J				Platts-Mills, TAE; Erwin, E; Heymann, P; Woodfolk, J			Is the hygiene hypothesis still a viable explanation for the increased prevalence of asthma?	ALLERGY			English	Article; Proceedings Paper	Conference on Addressing the Allergy Epidemic	MAY, 2004	Uppsala, SWEDEN			allergen exposure; asthma; hygiene; lifestyle; prevalence	MODIFIED TH2 RESPONSE; DOG OWNERSHIP; CAT ALLERGEN; CHILDREN; EXPOSURE; SENSITIZATION; RISK; ATOPY; AGE; MORBIDITY	The hygiene hypothesis states that a reduced exposure to allergens in early life is solely implicated in the growing propensity for allergy sensitization. Important elements of the hypothesis include helminth infection, exposure to endotoxins, exposure to pets and growing up on a farm. However, the hygiene hypothesis alone does not provide an adequate explanation for the observed increase in allergic disease. For example, in North American inner cities, asthma is increasing among children who live in very poor housing, which might be assumed to be somewhat dirty. In order to explain the increase in asthma, we need to take a broader view and also consider alterations related to the adoption of a western lifestyle. It has been suggested that lifestyle changes related to obesity (e.g. a change in diet) are associated with asthma. Other changes include a progressive decrease in physical activity. This lifestyle factor seems to correlate best with the recent increase in asthma. Clearly, the link between physical activity and asthma needs to be investigated in more detail.	Univ Virginia, Asthma & Allerg Dis Ctr, Charlottesville, VA USA	Platts-Mills, TAE (reprint author), Univ Virginia Hlth Syst, Asthma & Allerg Dis Ctr, POB 801355, Charlottesville, VA 22908 USA.						Bach JF, 2003, ANN NY ACAD SCI, V998, P161, DOI 10.1196/annals.1254.017; Beasley R, 2000, J ALLERGY CLIN IMMUN, V105, pS466, DOI 10.1016/S0091-6749(00)90044-7; Berkey CS, 2000, PEDIATRICS, V105, DOI 10.1542/peds.105.4.e56; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Crater DD, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.6.e97; Custis N., 2004, Journal of Allergy and Clinical Immunology, V113, pS259, DOI 10.1016/j.jaci.2004.01.400; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; FIRINCIELLI V, 2005, IN PRESS PEDIAT PULM; Fredberg JJ, 1999, AM J RESP CRIT CARE, V159, P959; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Green RM, 2002, BRIT MED J, V324, P763, DOI 10.1136/bmj.324.7340.763; HAAHTELA T, 1990, BRIT MED J, V301, P266; HARK WT, 2004, IN PRESS ANN ALLERGY; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hesselmar B, 1999, CLIN EXP ALLERGY, V29, P611; Heymann PW, 2004, J ALLERGY CLIN IMMUN, V114, P239, DOI 10.1016/j.jaci.2004.04.006; LUCAS S, 2005, IN PRESS J ALLERGY C; Luder E, 2004, RESP MED, V98, P29, DOI 10.1016/j.rmed.2003.08.004; Matricardi PM, 2003, CLIN EXP ALLERGY, V33, P717, DOI 10.1046/j.1365-2222.2003.01695.x; McLean DE, 2004, ARCH PEDIAT ADOL MED, V158, P244, DOI 10.1001/archpedi.158.3.244; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Perzanowski MS, 2002, AM J RESP CRIT CARE, V166, P696, DOI 10.1164/rccm.2201035; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2002, CLIN EXP ALLERGY, V32, P335, DOI 10.1046/j.1365-2222.2002.01352.x; Platts-Mills TA, 1997, J ALLERGY CLIN IMM S, V100, P2; PlattsMills TAE, 1997, CIBA F SYMP, V206, P173; PLATTSMILLS TAE, 1982, CLIN ASPECTS IMMUNOL, P579; Reefer AJ, 2004, J IMMUNOL, V172, P2763; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SKLOOT G, 1995, J CLIN INVEST, V96, P393; SMITH JM, 1976, BRIT J DIS CHEST, V70, P73; SPORIK R, 1992, CLIN EXP ALLERGY, V22, P897, DOI 10.1111/j.1365-2222.1992.tb02062.x; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; WALZER M, 1956, J ALLERGY, V27, P113, DOI 10.1016/0021-8707(56)90002-8; WEISS KB, 1993, ANNU REV PUBL HEALTH, V14, P491, DOI 10.1146/annurev.pu.14.050193.002423; Westerterp KR, 2001, NATURE, V410, P539, DOI 10.1038/35069142	39	87	88	1	23	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-4538			ALLERGY	Allergy		2005	60			79			25	31		10.1111/j.1398-9995.2005.00854.x		7	Allergy; Immunology	Allergy; Immunology	915NX	WOS:000228312000006	15842230	
J	Phipps, S; Benyahia, F; Ou, TT; Barkans, J; Robinson, DS; Kay, AB				Phipps, S; Benyahia, F; Ou, TT; Barkans, J; Robinson, DS; Kay, AB			Acute allergen-induced airway remodeling in atopic asthma	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							BASEMENT-MEMBRANE; TGF-BETA; BRONCHIAL BIOPSIES; EPITHELIAL-CELLS; GENE-EXPRESSION; MODERATE ASTHMA; INFLAMMATION; MILD; ACTIVATION; EOSINOPHILS	Studies in animals and in human atopic skin suggest that allergen challenge may activate acute tissue remodeling changes via transforming growth factor-beta pathways. We determined whether inhalational allergen challenge in subjects with mild asthma induces similar acute changes to the airway epithelial mesenchymal trophic unit (EMTU). Endobronchial mucosal biopsies obtained before and 24 h after challenge were examined by confocal microscopy for extracellular matrix deposition in the reticular basement membrane (RBM). Cells actively involved in extracellular matrix synthesis were identified as immunoreactive to heat shock protein 47, a chaperone of Collagen synthesis. Interleukin-4/13 and transforming growth factor-beta-activated cells were identified by specific antibodies to phosphorylated (phospho-) signal transducer and activator of transcription 6 and phospho-Smad2, respectively. After allergen challenge, there was a significant increase in the number of heat shock protein 47-positive airway fibroblasts (P = 0.003) and in the thickness of tenascin in the RBM (P = 0.031). There were also increases in the number of phospho-Smad2+ epithelial cells (P = 0.04) and nuclear phospho-Smad2+ fibroblasts (P = 0.03), as well as phospho-signal transducer and activator of transcription 6+ epithelial cells (P = 0.03), after allergen challenge. Thus, allergen challenge in patients with mild asthma induces activation of epithelial cells and fibroblasts in the EMTU as well as increased tenascin deposition within the RBM. Airway remodeling in asthma may, in part, result from repeated acute activation of the EMTU by allergen exposure.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, Div Biomed Sci,Fac Med, London SW3 6LY, England	Kay, AB (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Leukocyte Biol Sect, Div Biomed Sci,Fac Med, Guy Scadding Bldg,Dovehouse St, London SW3 6LY, England.	a.b.kay@imperial.ac.uk	Phipps, Simon/F-9170-2010	Phipps, Simon/0000-0002-7388-3612			Buckley CD, 2001, TRENDS IMMUNOL, V22, P199, DOI 10.1016/S1471-4906(01)01863-4; CHAI H, 1975, J ALLERGY CLIN IMMUN, V56, P323, DOI 10.1016/0091-6749(75)90107-4; Cho JY, 2004, J CLIN INVEST, V113, P551, DOI 10.1172/JCI200419133; Davies DE, 2002, INT J BIOCHEM CELL B, V34, P1520, DOI 10.1016/S1357-2725(02)00048-1; Evans MJ, 1999, AM J RESP CELL MOL, V21, P655; Flood-Page P, 2003, J CLIN INVEST, V112, P1029, DOI 10.1172/JCI200317974; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664; Goumans MJ, 2002, EMBO J, V21, P1743, DOI 10.1093/emboj/21.7.1743; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hoshino M, 1998, J ALLERGY CLIN IMMUN, V102, P783, DOI 10.1016/S0091-6749(98)70018-1; Khan LN, 2000, AM J RESP CRIT CARE, V162, P1377; Kuperman DA, 2002, NAT MED, V8, P885, DOI 10.1038/nm734; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; Li X, 1997, AM J RESP CRIT CARE, V156, P229; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Payne DNR, 2003, AM J RESP CRIT CARE, V167, P78, DOI 10.1164/rccm.200205-414OC; Phipps S, 2004, J INVEST DERMATOL, V122, P1406, DOI 10.1111/j.0022-202X.2004.22619.x; Phipps S, 2002, J IMMUNOL, V169, P4604; Redington AE, 1998, J PATHOL, V186, P410, DOI 10.1002/(SICI)1096-9896(199812)186:4<410::AID-PATH198>3.0.CO;2-9; Rosendahl A, 2002, AM J RESP CELL MOL, V27, P160; Rosendahl A, 2001, AM J RESP CELL MOL, V25, P60; Sagara H, 2002, J ALLERGY CLIN IMMUN, V110, P249, DOI 10.1067/mai.2002.126078; Sasaki H, 2002, J IMMUNOL, V168, P5178; Venkayya R, 2002, AM J RESP CELL MOL, V26, P202; Wenzel SE, 2002, J IMMUNOL, V169, P4613; WONG DTW, 1993, AM J PATHOL, V143, P130; Woodruff PG, 2004, AM J RESP CRIT CARE, V169, P1001, DOI 10.1164/rccm.200311-1529OC; Ying S, 1999, J IMMUNOL, V163, P6321	29	87	92	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	DEC	2004	31	6					626	632		10.1165/rcmb.2004-0193OC		7	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	877BA	WOS:000225541600007	15333330	
J	Wilson, MS; Maizels, RM				Wilson, MS; Maizels, RM			Regulation of allergy and autoimmunity in helminth infection	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY			English	Review						cytokines; asthma; immunoregulation; parasites	INDUCED AIRWAY HYPERREACTIVITY; KILLED MYCOBACTERIUM-VACCAE; T-CELL RESPONSES; DEPENDENT DIABETES-MELLITUS; MODIFIED TH2 RESPONSE; HOUSE-DUST MITE; SCHISTOSOMA-MANSONI; MAST-CELLS; IMMUNE-RESPONSES; EOSINOPHILIC INFLAMMATION	Parasitic infections are a major theme in the "hygiene hypothesis", as allergies and autoimmune diseases are less prevalent in countries with higher burdens of helminths and other parasitic organisms. Helminths"-the grouping of multicellular worm parasistes including nematodes, cestodes and trematodes-tend to establish long-lived, chronic infections indicating successful down-modulation of the host immune system. In this review, we describe the intricate immunology of host-helminth interactions and how parasites manipulate immune responses to enhance their survival. In so doing, they often minimise immunopathology and, it is suggested, reduce host susceptibility to, and severity of allergic and autoimmune diseases. Studies on helminth-infected communities and individuals support the hypothesis that an immuno-regulatory network promoted by parasites extends its influence to limiting allergies. Experimental models are now probing more deeply into the area of immune modulation by helminths, and we discuss the likely mechanisms by which helminths could be establishing a strongly regulatory environment. Understanding and harnessing the modulatory capacity of helminths may uncover novel therapeutic interventions, mimicking and exploiting their evolution for our benefit. Parasitic infections are a major theme in the-"hygiene hypothesis", as allergies and autoimmune diseases are less prevalent in countries with higher burdens of helminths and other parasitic organisms. Helminths"-the grouping of multicellular worm parasistes including nematodes, cestodes and trematodes-tend to establish long-lived, chronic infections indicating successful down-modulation of the host immune system. In this review, we describe the intricate immunology of host-helminth interactions and how parasites manipulate immune responses to enhance their survival. In so doing, they often minimise immunopathology and, it is suggested, reduce host susceptibility to, and severity of allergic and autoimmune diseases. Studies on helminth-infected communities and individuals support the hypothesis that an immuno-regulatory network promoted by parasites extends its influence to limiting allergies. Experimental models are now probing more deeply into the area of immune modulation by helminths, and we discuss the likely mechanisms by which helminths could be establishing a strongly regulatory environment. Understanding and harnessing the modulatory capacity of helminths may uncover novel therapeutic interventions, mimicking and exploiting their evolution for our benefit.	Univ Edinburgh, Inst Cell Anim & Populat Biol, Edinburgh, Midlothian, Scotland	Maizels, RM (reprint author), Univ Edinburgh, Inst Cell Anim & Populat Biol, W Mains Rd, Edinburgh, Midlothian, Scotland.	rick.maizels@ed.ac.uk					ACTOR JK, 1993, P NATL ACAD SCI USA, V90, P948, DOI 10.1073/pnas.90.3.948; Akbari O, 2003, INT ARCH ALLERGY IMM, V130, P108, DOI 10.1159/000069012; Akbari O, 2002, NAT MED, V8, P1024, DOI 10.1038/nm745; Al-Qaoud KM, 2000, INT IMMUNOL, V12, P899, DOI 10.1093/intimm/12.6.899; ALI NMH, 1984, PARASITOLOGY, V88, P153; Allen JE, 1997, IMMUNOL TODAY, V18, P387, DOI 10.1016/S0167-5699(97)01102-X; ANDERSEN E, 1981, ACTA NEUROL SCAND, V63, P131; Angeli W, 2001, EUR J IMMUNOL, V31, P2751; Apostolou I, 2002, NAT IMMUNOL, V3, P756, DOI 10.1038/ni816; Araujo MI, 2000, INT ARCH ALLERGY IMM, V123, P145, DOI 10.1159/000024433; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Barthlott T, 2003, J EXP MED, V197, P451, DOI 10.1084/jem.20021387; Bashir MEH, 2002, J IMMUNOL, V169, P3284; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Belkaid Y, 2002, NATURE, V420, P502, DOI 10.1038/nature01152; Ben-Smith A, 2003, J HELMINTHOL, V77, P133, DOI 10.1079/JOH2003173; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bilenki L, 2002, CLIN IMMUNOL, V102, P28, DOI 10.1006/clim.2001.5144; Boitelle A, 2003, J IMMUNOL, V171, P447; Borkow G, 2001, SCAND J INFECT DIS, V33, P568, DOI 10.1080/00365540110026656; Brown T R, 1898, J Exp Med, V3, P315, DOI 10.1084/jem.3.3.315; Chiaramonte MG, 1999, J CLIN INVEST, V104, P777, DOI 10.1172/JCI7325; Chiaramonte MG, 2003, J EXP MED, V197, P687, DOI 10.1084/jem.20020903; Cooke A, 1999, PARASITE IMMUNOL, V21, P169, DOI 10.1046/j.1365-3024.1999.00213.x; Cooper PJ, 2003, J ALLERGY CLIN IMMUN, V111, P995, DOI 10.1067/mai.2003.1348; Cooper PJ, 1998, J INFECT DIS, V178, P1133, DOI 10.1086/515661; Cooper PJ, 2002, CLIN EXP IMMUNOL, V128, P398, DOI 10.1046/j.1365-2249.2002.01908.x; Culley FJ, 2000, J IMMUNOL, V165, P6447; DEHLAWI MS, 1987, PARASITE IMMUNOL, V9, P187, DOI 10.1111/j.1365-3024.1987.tb00499.x; Doetze A, 2000, INT IMMUNOL, V12, P623, DOI 10.1093/intimm/12.5.623; Elliott DE, 2003, AM J PHYSIOL-GASTR L, V284, pG385, DOI 10.1152/ajpgi.00049.2002; Elliott DE, 2000, FASEB J, V14, P1848, DOI 10.1096/fj.99-0885hyp; ELSE KJ, 1994, J EXP MED, V179, P347, DOI 10.1084/jem.179.1.347; Erb KJ, 1998, J EXP MED, V187, P561, DOI 10.1084/jem.187.4.561; Farooqi IS, 1998, THORAX, V53, P927; Fontenot JD, 2003, NAT IMMUNOL, V4, P330, DOI 10.1038/ni904; Fox JG, 2000, NAT MED, V6, P536, DOI 10.1038/75015; Gale EAM, 2002, DIABETOLOGIA, V45, P588, DOI 10.1007/s00125-002-0801-1; Goodridge HS, 2001, J IMMUNOL, V167, P940; Green A, 2000, LANCET, V355, P873; Groux H, 1997, NATURE, V389, P737; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hadeiba H, 2003, J IMMUNOL, V170, P5502; HAGEL I, 1993, INT ARCH ALLERGY IMM, V101, P209; Hall LR, 1999, J IMMUNOL, V163, P4970; Hamelmann E, 1999, AM J RESP CRIT CARE, V160, P934; Hamelmann E, 2001, IMMUNOL REV, V179, P182, DOI 10.1034/j.1600-065X.2001.790118.x; Hansen G, 1999, J CLIN INVEST, V103, P175, DOI 10.1172/JCI5155; Hansen G, 2000, J CLIN INVEST, V105, P61, DOI 10.1172/JCI7589; Harvey HA, 2001, J AUTOIMMUN, V16, P257, DOI 10.1006/jaut.2000.0477; Herrick CA, 2003, NAT REV IMMUNOL, V3, P405, DOI 10.1038/nri1084; Herrick CA, 2003, J IMMUNOL, V170, P2488; Hoffmann KF, 2000, J IMMUNOL, V164, P6406; Holland MJ, 2000, EUR J IMMUNOL, V30, P1977, DOI 10.1002/1521-4141(200007)30:7<1977::AID-IMMU1977>3.0.CO;2-3; Holt PG, 1996, J EXP MED, V183, P1297, DOI 10.1084/jem.183.4.1297; Hopfenspirger MT, 2002, J IMMUNOL, V168, P2516; Hopkin JM, 1997, CURR OPIN IMMUNOL, V9, P788, DOI 10.1016/S0952-7915(97)80179-3; HUSSAIN R, 1992, J IMMUNOL, V148, P2731; Imai S, 2001, BIOCHEM BIOPH RES CO, V286, P1051, DOI 10.1006/bbrc.2001.5471; Irvine EJ, 2001, SCAND J GASTROENTERO, V36, P2; Jeannin P, 1998, J IMMUNOL, V160, P3555; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; Kawakami T, 2002, NAT REV IMMUNOL, V2, P773, DOI 10.1038/nri914; Kennedy MW, 2000, PARASITOL TODAY, V16, P373, DOI 10.1016/S0169-4758(00)01743-9; Kero J, 2001, J ALLERGY CLIN IMMUN, V108, P781, DOI 10.1067/mai.2001.119557; Khan WI, 2002, INFECT IMMUN, V70, P5931, DOI 10.1128/IAI.70.11.5931-5937.2002; Khattri R, 2003, NAT IMMUNOL, V4, P337, DOI 10.1038/ni909; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Kohm AP, 2002, J IMMUNOL, V169, P4712; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; KULLBERG MC, 1992, J IMMUNOL, V148, P3264; KURNIAWAN A, 1993, J IMMUNOL, V150, P3941; Ledingham DL, 1996, TRANSPLANTATION, V61, P184, DOI 10.1097/00007890-199601270-00003; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Lima C., 2002, Clinical and Experimental Allergy, V32, P1659, DOI 10.1046/j.1365-2222.2002.01506.x; Liu ZG, 2002, J IMMUNOL, V169, P6959; Lukacs NW, 2001, NAT REV IMMUNOL, V1, P108, DOI 10.1038/35100503; LYNCH NR, 1993, J ALLERGY CLIN IMMUN, V92, P404, DOI 10.1016/0091-6749(93)90119-Z; Lynch NR, 1999, THORAX, V54, P659; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; Mahanty S, 1996, J INFECT DIS, V173, P769; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; Maizels RM, 2003, NAT REV IMMUNOL, V3, P733, DOI 10.1038/nri1183; Maloy KJ, 2001, NAT IMMUNOL, V2, P816, DOI 10.1038/ni0901-816; MANDRELL RE, 1992, INFECT IMMUN, V60, P1322; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; Mao XQ, 2000, PARASITOL TODAY, V16, P186, DOI 10.1016/S0169-4758(00)01642-2; Matricardi P M, 2000, Respir Res, V1, P129, DOI 10.1186/rr22; Matricardi PM, 2000, CLIN EXP ALLERGY, V30, P1506, DOI 10.1046/j.1365-2222.2000.00994.x; McDermott JR, 2003, P NATL ACAD SCI USA, V100, P7761, DOI 10.1073/pnas.1231488100; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; McKinney PA, 2000, DIABETIC MED, V17, P236, DOI 10.1046/j.1464-5491.2000.00220.x; Meeusen ENT, 2000, PARASITOL TODAY, V16, P95, DOI 10.1016/S0169-4758(99)01607-5; Mehlhop PD, 1997, P NATL ACAD SCI USA, V94, P1344, DOI 10.1073/pnas.94.4.1344; Moran AP, 2001, J AUTOIMMUN, V16, P241, DOI 10.1006/jaut.2000.0490; MURRAY J, 1978, AM J CLIN NUTR, V31, P1363; MURRAY MJ, 1977, AM J CLIN NUTR, V30, P2117; Nacher M, 2000, PARASITE IMMUNOL, V22, P107, DOI 10.1046/j.1365-3024.2000.00284.x; Nacher M, 2001, AM J TROP MED HYG, V65, P834; Nakae S, 2003, INT IMMUNOL, V15, P483, DOI 10.1093/intimm/dxg054; Negrao-Correa D, 2003, INFECT IMMUN, V71, P2607, DOI 10.1128/IAI.71.5.2607-2614.2003; Nyan OA, 2001, CLIN EXP ALLERGY, V31, P1672, DOI 10.1046/j.1365-2222.2001.00987.x; Oh JW, 2002, J ALLERGY CLIN IMMUN, V110, P460, DOI 10.1067/mai.2002.127512; Paterson JCM, 2002, INFECT IMMUN, V70, P6058, DOI 10.1128/IAI.70.11.6058-6067.2002; Pearce EJ, 2002, NAT REV IMMUNOL, V2, P499, DOI 10.1038/nri843; Pearce EJ, 1996, EXP PARASITOL, V84, P295, DOI 10.1006/expr.1996.0116; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Platts-Mills TAE, 2001, INT ARCH ALLERGY IMM, V124, P126, DOI 10.1159/000053689; Robbie-Ryan M, 2002, CURR OPIN IMMUNOL, V14, P728, DOI 10.1016/S0952-7915(02)00394-1; ROCKEN M, 1992, NATURE, V359, P79, DOI 10.1038/359079a0; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; ROSATI G, 1988, NEUROLOGY, V38, P384; Royer B, 2001, CLIN EXP ALLERGY, V31, P694, DOI 10.1046/j.1365-2222.2001.01069.x; Sabin EA, 1996, J INFECT DIS, V173, P269; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; Sakaguchi S, 2001, IMMUNOL REV, V182, P18, DOI 10.1034/j.1600-065X.2001.1820102.x; Sartono E, 1995, PARASITE IMMUNOL, V17, P587, DOI 10.1111/j.1365-3024.1995.tb01002.x; Satoguina J, 2002, MICROBES INFECT, V4, P1291, DOI 10.1016/S1286-4579(02)00014-X; Schonemeyer A, 2001, J IMMUNOL, V167, P3207; Schopf LR, 2002, J IMMUNOL, V168, P2383; Scrivener S, 2001, LANCET, V358, P1493, DOI 10.1016/S0140-6736(01)06579-5; Sears MR, 1997, LANCET, V350, P1015, DOI 10.1016/S0140-6736(97)01468-2; Selassie FG, 2000, CLIN EXP ALLERGY, V30, P356, DOI 10.1046/j.1365-2222.2000.00706.x; Sewell D, 2003, INT IMMUNOL, V15, P59, DOI 10.1093/intimm/dxg012; Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1; SHER A, 1992, ANNU REV IMMUNOL, V10, P385, DOI 10.1146/annurev.immunol.10.1.385; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Silveira MR, 2002, INFECT IMMUN, V70, P6263, DOI 10.1128/IAI.70.11.6263-6272.2002; Simpson CR, 2002, CLIN EXP ALLERGY, V32, P37, DOI 10.1046/j.0022-0477.2001.01250.x; Stene LC, 2001, LANCET, V357, P607, DOI 10.1016/S0140-6736(00)04067-8; Sternberg JM, 1996, EUR J IMMUNOL, V26, P539, DOI 10.1002/eji.1830260306; Stockinger B, 2001, NAT IMMUNOL, V2, P757, DOI 10.1038/ni0901-757; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tsitoura DC, 2000, J ALLERGY CLIN IMMUN, V106, P239; Umetsu DT, 2002, NAT IMMUNOL, V3, P715, DOI 10.1038/ni0802-715; URBAN JF, 1992, IMMUNOL REV, V127, P205, DOI 10.1111/j.1600-065X.1992.tb01415.x; van den Biggelaar AHJ, 2001, INT ARCH ALLERGY IMM, V126, P231, DOI 10.1159/000049519; van den Biggelaar AHJ, 2000, LANCET, V356, P1723, DOI 10.1016/S0140-6736(00)03206-2; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; von Mutius E, 2001, AM J RESP CRIT CARE, V164, P1106; Walter DM, 2001, J IMMUNOL, V167, P4668; Wang CC, 2001, CLIN EXP ALLERGY, V31, P495, DOI 10.1046/j.1365-2222.2001.01044.x; Wang CC, 1998, IMMUNOLOGY, V93, P307; Williams CMM, 2000, J EXP MED, V192, P455, DOI 10.1084/jem.192.3.455; Williams CMM, 2000, J ALLERGY CLIN IMMUN, V105, P847, DOI 10.1067/mai.2000.106485; Wills-Karp M, 2003, CURR OPIN PULM MED, V9, P21, DOI 10.1097/00063198-200301000-00004; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Woolcock AJ, 1997, CIBA F SYMP, V206, P122; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Wynn TA, 2003, ANNU REV IMMUNOL, V21, P425, DOI 10.1146/annurev.immunol.21.120601.141142; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Yang X, 1999, IMMUNOLOGY, V98, P329; YAZDANBAKHSH M, 1993, J INFECT DIS, V167, P925; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Zaccone P, 2003, EUR J IMMUNOL, V33, P1439, DOI 10.1002/eji.200323910; Zuany-Amorim C, 2002, J IMMUNOL, V169, P1492; Zuany-Amorim C, 2002, NAT MED, V8, P625, DOI 10.1038/nm0602-625	161	87	93	2	21	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1080-0549			CLIN REV ALLERG IMMU	Clin. Rev. Allergy Immunol.	FEB	2004	26	1					35	50		10.1385/CRIAI:26:1:35		16	Allergy; Immunology	Allergy; Immunology	778MF	WOS:000189244800005	14755074	
J	Pitchford, SC; Riffo-Vasquez, Y; Sousa, A; Momi, S; Gresele, P; Spina, D; Page, CP				Pitchford, SC; Riffo-Vasquez, Y; Sousa, A; Momi, S; Gresele, P; Spina, D; Page, CP			Platelets are necessary for airway wall remodeling in a murine model of chronic allergic inflammation	BLOOD			English	Article							SMOOTH-MUSCLE-CELLS; GROWTH-FACTOR; BRONCHIAL-ASTHMA; MUCOSAL BIOPSIES; MOUSE MODEL; MILD ASTHMA; IN-VIVO; PROLIFERATION; HYPERPLASIA; MICE	Asthma is associated with airway remodeling. Evidence of platelet recruitment to the lungs of asthmatics after allergen exposure suggests platelets participate in various aspects of asthma; although their importance is unknown in the context of airway remodeling, their involvement in atherosclerosis is established. Studies from our laboratory have shown a requirement for platelets in pulmonary leukocyte recruitment in a murine model of allergic lung inflammation. Presently, the effects of platelet depletion and corticosteroid administration on airway remodeling and lung function were examined. Ovalbumin (OVA)-sensitized mice, exposed to aerosolized OVA for 8 weeks, demonstrated epithelial and smooth muscle thickening, and subepithelial reticular fiber deposition in the distal airways. The depletion of platelets via an immunologic (antiplatelet antisera) or nonimmunologic (busulfan) method, markedly reduced airway remodeling. In contrast, dexamethasone administration did not affect epithelial thickening or subepithelial fibrosis, despite significantly inhibiting leukocyte recruitment. Thus, pathways leading to certain aspects of airway remodeling may not depend on leukocyte recruitment, whereas platelet activation is obligatory. OVA-sensitized mice exhibited airway hyperresponsiveness (AHR) compared with sham-sensitized mice following chronic OVA exposure. Neither platelet depletion nor dexamethasone administration inhibited chronic AHR; thus, mechanisms other than inflammation and airway remodeling may be involved in the pathogenesis of chronic AHR.	Kings Coll London, Sackler Inst Pulm Pharmacol, GKT Sch Biomed Sci, London SE1 1UL, England; Univ Perugia, Dept Internal Med, Sect Internal & Cardiovasc Med, I-06100 Perugia, Italy	Spina, D (reprint author), Kings Coll London, Sackler Inst Pulm Pharmacol, GKT Sch Biomed Sci, 5th Fl,Hodgkin Bldg,Guys Campus, London SE1 1UL, England.	domenico.spina@kci.ac.uk	Gresele, Paolo/F-6775-2013	Gresele, Paolo/0000-0001-5365-8445; Spina, Domenico/0000-0002-6815-1564			Anderson HV, 2001, CIRCULATION, V104, P2331, DOI 10.1161/hc4401.098434; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Bonacci JV, 2003, BRIT J PHARMACOL, V138, P1203, DOI 10.1038/sj.bjp.0705135; Bonner JC, 1998, AM J PHYSIOL-LUNG C, V274, pL72; BOULET LP, 1995, EUR RESPIR J, V8, P913; Boulet LP, 2000, AM J RESP CRIT CARE, V162, P1308; BRECHER G, 1950, J APPL PHYSIOL, V3, P365; Burger PC, 2003, BLOOD, V101, P2661, DOI 10.1182/blood-2002-07-2209; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Ciferri S, 2000, THROMB HAEMOSTASIS, V83, P157; EBINA M, 1993, AM REV RESPIR DIS, V148, P720; FALCINELLI E, 2001, THROMB HAEMOST S, V86, pOC916; FINGERLE J, 1989, P NATL ACAD SCI USA, V86, P8412, DOI 10.1073/pnas.86.21.8412; Foster PS, 2000, LAB INVEST, V80, P655; Foster PS, 2002, LAB INVEST, V82, P455; Golino P, 1997, THROMB HAEMOSTASIS, V77, P783; Gresele P, 1987, Agents Actions Suppl, V21, P119; GRESELE P, 1993, J ALLERGY CLIN IMMUN, V91, P894, DOI 10.1016/0091-6749(93)90347-I; HIRST SJ, 1992, AM J RESP CELL MOL, V7, P574; HOGEVOLD HE, 1990, THROMB RES, V57, P21, DOI 10.1016/0049-3848(90)90192-F; Holgate ST, 2000, AM J RESP CRIT CARE, V162, pS113; Hoyle GW, 1999, AM J PATHOL, V154, P1763, DOI 10.1016/S0002-9440(10)65432-6; Ichii T, 2002, ARTERIOSCL THROM VAS, V22, P1286, DOI 10.1161/01.ATV.0000024684.67566.45; IHNATOWYCZ IO, 1981, ARTERY, V9, P316; IP JH, 1991, J AM COLL CARDIOL, V17, pB77; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; Kawasaki T, 2000, BLOOD, V96, P153; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Leigh R, 2002, AM J RESP CELL MOL, V27, P526, DOI 10.1165/rcmb.2002-0048OC; LELLOUCHTUBIANA A, 1985, BRIT J EXP PATHOL, V66, P345; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; MAKILA UM, 1984, PROSTA LEUKOTR MED, V16, P11, DOI 10.1016/0262-1746(84)90081-7; MARTIN JF, 1983, LANCET, V1, P793; Massberg S, 2002, J EXP MED, V196, P887, DOI 10.1084/jem.20012044; MEHRI Y, 1997, ARTERIOSCLER THROMB, V17, P1185; Metzger W J, 1987, Agents Actions Suppl, V21, P151; Minshall EM, 1997, AM J RESP CELL MOL, V17, P326; MORLEY J, 1984, LANCET, V2, P1142; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; Okona-Mensah KB, 1998, BRIT J PHARMACOL, V125, P599, DOI 10.1038/sj.bjp.0702046; Pitchford SC, 2003, J ALLERGY CLIN IMMUN, V112, P109, DOI 10.1067/mai.2003.1514; Pitchford SC, 2002, PLATELETS THROMBOTIC, P852, DOI 10.1017/CBO9780511545283.057; PLATTSMILLS TAE, 1987, J ALLERGY CLIN IMMUN, V79, P781, DOI 10.1016/0091-6749(87)90211-9; Puddicombe SM, 2000, FASEB J, V14, P1362, DOI 10.1096/fj.14.10.1362; ROCHE WR, 1989, LANCET, V1, P520; Ross R, 1999, NEW ENGL J MED, V340, P115; Sakai K, 2001, INT ARCH ALLERGY IMM, V126, P126, DOI 10.1159/000049503; Sanner SM, 2002, STEROIDS, V67, P715; SHURE D, 1992, BIOCHEM BIOPH RES CO, V186, P1510, DOI 10.1016/S0006-291X(05)81577-3; Spina D, 2002, TRENDS PHARMACOL SCI, V23, P311, DOI 10.1016/S0165-6147(02)02022-9; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219; Tomioka S, 2002, J APPL PHYSIOL, V93, P263, DOI 10.1152/japplphysiol.01129.2001; Ulfman LH, 2003, AM J RESP CELL MOL, V28, P512, DOI 10.1165/rcmb.4806; Vanacker NJ, 2001, AM J RESP CRIT CARE, V163, P674; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; Vignola AM, 2000, J ALLERGY CLIN IMMUN, V105, P1041, DOI 10.1067/mai.2000.107195; Ward C, 2002, THORAX, V57, P309, DOI 10.1136/thorax.57.4.309; Weber AA, 1999, BIOCHEM BIOPH RES CO, V259, P341, DOI 10.1006/bbrc.1999.0793; Yamashita N, 2001, J ALLERGY CLIN IMMUN, V107, P135, DOI 10.1067/mai.2001.111433; Yoshida A, 2002, BRIT J PHARMACOL, V137, P146, DOI 10.1038/sj.bjp.0704852	60	87	93	2	6	AMER SOC HEMATOLOGY	WASHINGTON	1900 M STREET. NW SUITE 200, WASHINGTON, DC 20036 USA	0006-4971			BLOOD	Blood	JAN 15	2004	103	2					639	647		10.1182/blood-2003-05-1707		9	Hematology	Hematology	762CY	WOS:000187954000050	14504080	
J	Gono, H; Fujimoto, K; Kawakami, S; Kubo, K				Gono, H; Fujimoto, K; Kawakami, S; Kubo, K			Evaluation of airway wall thickness and air trapping by HRCT in asymptomatic asthma	EUROPEAN RESPIRATORY JOURNAL			English	Article						air trapping; airflow obstruction; airway remodelling; airway wall; bronchial asthma; high-resolution computed tomography	RESOLUTION COMPUTED-TOMOGRAPHY; OBSTRUCTIVE PULMONARY-DISEASE; FLOW OBSTRUCTION; BRONCHIAL-ASTHMA; FUNCTION TESTS; FATAL ASTHMA; EMPHYSEMA; CT; HYPERRESPONSIVENESS; DIMENSIONS	The aim of this study was to examine the relationship between the structural changes in large and small airways in asymptomatic asthmatics quantified by high-resolution computed tomography (HRCT) and airflow obstruction. The bronchial wall thickness at the trunk of the apical bronchus (B1) of the right upper lobe was used for assessment of the large airways. Air trapping, evaluated by the ratio of the average. CT-determined values for the bilateral upper and lower lung segments at full expiration to that at full inspiration (E/I ratio), was used for assessment of the small airways. Measurements were obtained with a helical HRCT in 24 asymptomatic asthmatics followed by optimal treatment with inhaled and/or oral corticosteroids for >6 months. Prior (20-30 min) to the HRCT examination, all patients were given an inhaled bronchodilator. The ratio of airway wall thickness to outer diameter (T/D) and the percentage wall area (WA%) at the B1 bronchus and the E/I ratio were significantly greater for the 14 asthmatics with deficient reversible airflow obstruction (forced expiratory volume in one second (FEV1) <80% prediced or FEV1/forced vital capacity <70% after bronchodilator inhalation) than for the 10 asthmatics with normal spirometry and seven normal subjects. T/D, WA%, and E/I ratio showed significant negative correlations with FEV1 % pred after bronchodilator inhalation. The E/I ratio also showed significant positive correlations with T/D, WA%, and residual volume/total lung capacity. These findings suggest that, in spite of optimal treatment, structural changes in both large and small airways may simultaneously occur in asthmatics with deficient reversible airflow obstruction.	Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano 3908621, Japan; Shinshu Univ, Sch Med, Dept Radiol, Matsumoto, Nagano 3908621, Japan	Fujimoto, K (reprint author), Shinshu Univ, Sch Med, Dept Internal Med 1, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.						Arakawa H, 1998, AM J ROENTGENOL, V170, P1349; Awadh N, 1998, THORAX, V53, P248; BALDWIN ED, 1948, MEDICINE, V27, P243; BERGLUND E, 1963, ACTA MED SCAND, V173, P185; BOULET L, 1995, AM J RESP CRIT CARE, V153, P865; BOULET LP, 1994, CHEST, V105, P1024, DOI 10.1378/chest.105.4.1024; BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; Carr DH, 1998, RESP MED, V92, P448, DOI 10.1016/S0954-6111(98)90290-6; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; Eda S, 1997, AM J RESP CRIT CARE, V155, P1290; FERGUSON AC, 1988, J ALLERGY CLIN IMMUN, V82, P19, DOI 10.1016/0091-6749(88)90045-0; Hudon C, 1997, ANN ALLERG ASTHMA IM, V78, P195; JAMES AL, 1989, AM REV RESPIR DIS, V139, P242; James AL, 1997, AIRWAY WALL REMODELI, P1; King GG, 1999, AM J RESP CRIT CARE, V159, P992; Kubo K, 1998, AM J RESP CRIT CARE, V158, P979; KUWANO K, 1993, AM REV RESPIR DIS, V148, P1220; Macklem PT, 1996, AM J RESP CRIT CARE, V153, P83; Mochizuki T, 1997, CHEST, V112, P1522, DOI 10.1378/chest.112.6.1522; Nakano Y, 2000, AM J RESP CRIT CARE, V162, P1102; NEWMAN KB, 1994, CHEST, V106, P105, DOI 10.1378/chest.106.1.105; Nishida O, 1976, JPN J CLIN PATHOL, V24, P941; Okazawa M, 1996, AM J RESP CRIT CARE, V154, P1557; Paganin F, 1996, AM J RESP CRIT CARE, V153, P110; Park JW, 1997, J INVEST ALLERG CLIN, V7, P186; Rennard SI, 1996, J ALLERGY CLIN IMMUN, V98, pS278, DOI 10.1016/S0091-6749(96)70076-3	27	87	89	0	2	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	DEC	2003	22	6					965	971		10.1183/09031936.03.00085302		7	Respiratory System	Respiratory System	750RA	WOS:000187009900020	14680087	
J	Tschumperlin, DJ; Shively, JD; Kikuchi, T; Drazen, JM				Tschumperlin, DJ; Shively, JD; Kikuchi, T; Drazen, JM			Mechanical stress triggers selective release of fibrotic mediators from bronchial epithelium	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article							GROWTH-FACTOR-BETA; BRONCHOALVEOLAR LAVAGE FLUID; INDUCED CARDIOMYOCYTE HYPERTROPHY; ENDOTHELIN-1 GENE-EXPRESSION; AIR-FLOW OBSTRUCTION; PROTEIN-KINASE-C; LATENT TGF-BETA; EXTRACELLULAR-MATRIX; TRANSFORMING GROWTH-FACTOR-BETA-1; CELL-PROLIFERATION	Transforming growth factor-beta (TGF-beta) and endothelin (ET) are found in elevated amounts in the airways of individuals with asthma. The cellular source of these peptides and their role in mediating the airway fibrosis of chronic asthma are unknown. In response to mechanical stresses similar to those occurring in vivo during airway constriction, bronchial epithelial cells increase the steady-state level of mRNA for both ET-1 and ET-2, followed by increased release of ET protein. Mechanical stress also enhances release of TGF-beta2 from a preformed cell-associated pool. TGF-beta2 and ET act individually and, more importantly, synergistically to promote fibrotic protein synthesis in reporter fibroblasts. To confirm the role of these intermediates in stress-induced fibrosis, conditioned medium from mechanically stressed bronchial epithelial cells was shown to elicit fibrotic protein synthesis in reporter fibroblasts; this effect was significantly inhibited by combined treatment with ET receptor antagonists and a neutralizing antibody to TGF-beta2. These data are consistent with a primary pathogenic role for mechanical stress-induced release of both TGF-beta2 and ET in the subepithelial fibrosis that characterizes chronic asthma.	Harvard Univ, Pulm & Crit Care Div, Dept Med, Brigham & Womens Hosp,Sch Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Phys Programs, Dept Environm Hlth, Boston, MA USA	Drazen, JM (reprint author), Harvard Univ, Pulm & Crit Care Div, Dept Med, Brigham & Womens Hosp,Sch Med, 75 Francis St, Boston, MA 02115 USA.	jdrazen@nejm.org	Drazen, Jeffrey/E-5841-2012		NHLBI NIH HHS [HL-33009]		Aoki S K, 1994, J Viral Hepat, V1, P73, DOI 10.1111/j.1365-2893.1994.tb00064.x; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BROEKELMANN TJ, 1991, P NATL ACAD SCI USA, V88, P6642, DOI 10.1073/pnas.88.15.6642; CHEN J, 2001, J PHYSL CELL PHYSL, V280, pC1475; DALLAS SL, 1995, J CELL BIOL, V131, P539, DOI 10.1083/jcb.131.2.539; Eickelberg O, 1999, AM J PHYSIOL-LUNG C, V276, pL814; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; ENDO T, 1992, BIOCHEM BIOPH RES CO, V186, P1594, DOI 10.1016/S0006-291X(05)81590-6; FINE A, 1987, J BIOL CHEM, V262, P3897; Fish JE, 1999, J ALLERGY CLIN IMMUN, V104, P509, DOI 10.1016/S0091-6749(99)70315-5; Gandhi CR, 2000, EUR J PHARMACOL, V406, P311, DOI 10.1016/S0014-2999(00)00683-X; Gonzalez W, 2001, J CARDIOVASC PHARM, V37, P219, DOI 10.1097/00005344-200102000-00009; Huang M, 2002, J CLIN INVEST, V109, P931, DOI 10.1172/JCI14685; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Kakinuma Y, 1999, LIFE SCI, V65, P1671, DOI 10.1016/S0024-3205(99)00416-6; KAWANA M, 1995, MOL CELL BIOL, V15, P4225; Khalil MK, 1996, CAN J OPHTHALMOL, V31, P32; KURIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P1435, DOI 10.1016/0006-291X(89)92270-5; Lambert GL, 2000, J MOL ENDOCRINOL, V24, P273, DOI 10.1677/jme.0.0240273; Lauth M, 2000, J MOL MED-JMM, V78, P441, DOI 10.1007/s001090000129; Lee CG, 2001, J EXP MED, V194, P809, DOI 10.1084/jem.194.6.809; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; MAGNAN A, 1994, THORAX, V49, P789, DOI 10.1136/thx.49.8.789; MALEK AM, 1993, P NATL ACAD SCI USA, V90, P5999, DOI 10.1073/pnas.90.13.5999; MATTOLI S, 1991, J ALLERGY CLIN IMMUN, V88, P376, DOI 10.1016/0091-6749(91)90100-3; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; O'Callaghan CJ, 2000, HYPERTENSION, V36, P319; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; PELTON RW, 1991, AM J RESP CELL MOL, V5, P522; RAGHOW R, 1989, J CLIN INVEST, V84, P1836; REDINGTON AE, 1995, AM J RESP CRIT CARE, V151, P1034; Redington AE, 1997, AM J RESP CRIT CARE, V156, P642; Ressler B, 2000, AM J PHYSIOL-LUNG C, V278, pL1264; Richter A, 2001, AM J RESP CELL MOL, V25, P385; Riser BL, 1996, AM J PATHOL, V148, P1915; Ruwhof C, 2000, MOL CELL BIOCHEM, V208, P89, DOI 10.1023/A:1007046105745; Sharma P, 1998, BIOCHEM BIOPH RES CO, V245, P709, DOI 10.1006/bbrc.1998.8507; Sime PJ, 1997, J CLIN INVEST, V100, P768, DOI 10.1172/JCI119590; SPRINGALL DR, 1991, LANCET, V337, P697, DOI 10.1016/0140-6736(91)90279-X; Swartz MA, 2001, P NATL ACAD SCI USA, V98, P6180, DOI 10.1073/pnas.111133298; TAIPALE J, 1995, J BIOL CHEM, V270, P4689; TAIPALE J, 1994, J CELL BIOL, V124, P171, DOI 10.1083/jcb.124.1.171; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Tschumperlin DJ, 2002, AM J PHYSIOL-LUNG C, V282, pL904, DOI 10.1152/ajplung.00270.2001; Ueba H, 1997, ARTERIOSCL THROM VAS, V17, P1512; van Wamel AJET, 2001, MOL CELL BIOCHEM, V218, P113, DOI 10.1023/A:1007279700705; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; Vignola AM, 1996, CLIN EXP IMMUNOL, V106, P114, DOI 10.1046/j.1365-2249.1996.d01-811.x; VITTORI E, 1992, AM REV RESPIR DIS, V146, P1320; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; WANG DL, 1993, BIOCHEM BIOPH RES CO, V195, P1050, DOI 10.1006/bbrc.1993.2150; Wiggs BR, 1997, J APPL PHYSIOL, V83, P1814; Yamazaki T, 1996, J BIOL CHEM, V271, P3221; Yasuda T, 1996, J CLIN INVEST, V98, P1991, DOI 10.1172/JCI119003	55	87	89	0	2	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	FEB	2003	28	2					142	149		10.1165/rcmb.2002-0121OC		8	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	643HG	WOS:000180855400005	12540481	
J	Mortz, CG; Lauritsen, JM; Bindslev-Jensen, C; Andersen, KE				Mortz, CG; Lauritsen, JM; Bindslev-Jensen, C; Andersen, KE			Nickel sensitization in adolescents and association with ear piercing, use of dental braces and hand eczema. The Odense Adolescence Cohort Study on Atopic Diseases and Dermatitis (TOACS)	ACTA DERMATO-VENEREOLOGICA			English	Article						schoolchildren; atopic dermatitis; inhalant allergy; hand eczema; multivariate graphical analysis	NORTH NORWEGIAN SCHOOLCHILDREN; ALLERGIC CONTACT-DERMATITIS; CHILDREN; SENSITIVITY; POPULATION; PREVALENCE; HISTORY; TESTS	The prevalence of nickel allergy (sensitization) and the associations with ear piercing, use of dental braces and hand eczema were assessed in a cohort of 1, 501 8th grade schoolchildren (aged 12-16 years) in Odense, Denmark. Nickel allergy was found in 8.6% and was clinically relevant in 69% of cases. Nickel allergy was found most frequently in girls and the association with ear piercing was confirmed. Application of dental braces (oral nickel exposure) prior to ear piercing (cutaneous nickel exposure) was associated with a significantly reduced prevalence of nickel allergy. In adolescents a significant association was found between hand eczema and nickel allergy. A follow-up study of this population is planned in order to assess the course and development of contact dermatitis, hand eczema and atopic diseases in adulthood and after choice of occupation.	Odense Univ Hosp, Dept Dermatol, DK-5000 Odense C, Denmark	Mortz, CG (reprint author), Odense Univ Hosp, Dept Dermatol, DK-5000 Odense C, Denmark.		andersen, klaus/H-2117-2011; Bindslev-Jensen, Carsten/H-1877-2011	Bindslev-Jensen, Carsten/0000-0002-8940-038X			Agresti A, 1984, ANAL ORDINAL CATEGOR; ANDERSEN KE, 1993, BRIT J DERMATOL, V129, P50, DOI 10.1111/j.1365-2133.1993.tb03311.x; AYALA F, 1992, CONTACT DERMATITIS, V26, P307; BALATO N, 1989, CONTACT DERMATITIS, V20, P305, DOI 10.1111/j.1600-0536.1989.tb03153.x; BARROS MA, 1991, CONTACT DERMATITIS, V25, P156; Brasch J, 1997, CONTACT DERMATITIS, V37, P286, DOI 10.1111/j.1600-0536.1997.tb02466.x; BRUNE D, 1986, BIOMATERIALS, V7, P163, DOI 10.1016/0142-9612(86)90097-9; Christensen O B, 1975, Contact Dermatitis, V1, P129, DOI 10.1111/j.1600-0536.1975.tb05353.x; DOTTERUD LK, 1994, CONTACT DERMATITIS, V31, P308, DOI 10.1111/j.1600-0536.1994.tb02025.x; DOTTERUD LK, 1995, ACTA PAEDIATR, V84, P402, DOI 10.1111/j.1651-2227.1995.tb13659.x; FISCHER TI, 1985, BRIT J DERMATOL, V112, P63, DOI 10.1111/j.1365-2133.1985.tb02292.x; GAWKRODGER DJ, 1986, CONTACT DERMATITIS, V14, P165, DOI 10.1111/j.1600-0536.1986.tb01198.x; GONCALO S, 1992, CONTACT DERMATITIS, V26, P112, DOI 10.1111/j.1600-0536.1992.tb00894.x; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; Katsarou A, 1996, CONTACT DERMATITIS, V34, P70, DOI 10.1111/j.1600-0536.1996.tb02125.x; Kerosuo H, 1996, AM J ORTHOD DENTOFAC, V109, P148, DOI 10.1016/S0889-5406(96)70175-0; KIEFFER M, 1979, CONTACT DERMATITIS, V5, P398, DOI 10.1111/j.1600-0536.1979.tb04913.x; KLEIN JP, 1995, STAT MED, V14, P1265, DOI 10.1002/sim.4780141202; LARSSONSTYMNE B, 1985, CONTACT DERMATITIS, V13, P289, DOI 10.1111/j.1600-0536.1985.tb02580.x; MCDONAGH AJG, 1992, BRIT J DERMATOL, V126, P16, DOI 10.1111/j.1365-2133.1992.tb08396.x; MEIJER C, 1995, CONTACT DERMATITIS, V32, P147, DOI 10.1111/j.1600-0536.1995.tb00804.x; Menne T, 1996, ANN CLIN LAB SCI, V26, P133; MENNE T, 1982, ACTA DERM-VENEREOL, V62, P35; MENNE T, 1983, CONTACT DERMATITIS, V9, P289, DOI 10.1111/j.1600-0536.1983.tb04393.x; MOLLER H, 1986, CONTACT DERMATITIS, V14, P57, DOI 10.1111/j.1600-0536.1986.tb01154.x; Mortz CG, 2002, ACTA DERM-VENEREOL, V82, P352, DOI 10.1080/000155502320624087; Mortz CG, 2001, BRIT J DERMATOL, V144, P523, DOI 10.1046/j.1365-2133.2001.04078.x; Mortz CG, 1999, CONTACT DERMATITIS, V41, P121, DOI 10.1111/j.1600-0536.1999.tb06102.x; NIELSEN NH, 1993, CONTACT DERMATITIS, V29, P16; PAMBOR M, 1992, CONTACT DERMATITIS, V27, P326, DOI 10.1111/j.1600-0536.1992.tb03292.x; PEVNY I, 1984, CONTACT DERMATITIS, V11, P201, DOI 10.1111/j.1600-0536.1984.tb00983.x; RADEMAKER M, 1989, CONTACT DERMATITIS, V20, P104, DOI 10.1111/j.1600-0536.1989.tb03116.x; ROMAGUERA C, 1985, CONTACT DERMATITIS, V12, P283, DOI 10.1111/j.1600-0536.1985.tb01140.x; Rudzki E, 1996, CONTACT DERMATITIS, V34, P66, DOI 10.1111/j.1600-0536.1996.tb02121.x; Rycroft RJG, 1995, TXB CONTACT DERMATIT; SEVILA A, 1994, CONTACT DERMATITIS, V30, P292, DOI 10.1111/j.1600-0536.1994.tb00601.x; Susitaival P, 1996, PEOPLE WORK, V10, P1; VANHOOGSTRATEN IMW, 1991, CLIN EXP IMMUNOL, V85, P441; VEIEN NK, 1993, J AM ACAD DERMATOL, V29, P1002; VEIEN NK, 1982, CONTACT DERMATITIS, V8, P373, DOI 10.1111/j.1600-0536.1982.tb04261.x; WAHLBERG JE, 1971, BRIT J DERMATOL, V85, P97, DOI 10.1111/j.1365-2133.1971.tb07192.x; WESTON WL, 1986, PEDIATRICS, V78, P1070	42	87	88	1	5	TAYLOR & FRANCIS AS	OSLO	CORT ADELERSGT 17, PO BOX 2562, SOLLI, 0202 OSLO, NORWAY	0001-5555			ACTA DERM-VENEREOL	Acta Derm.-Venereol.	SEP	2002	82	5					359	364		10.1080/000155502320624096		6	Dermatology	Dermatology	604UL	WOS:000178639400008	12430735	
J	Jacob, B; Ritz, B; Gehring, U; Koch, A; Bischof, W; Wichmann, HE; Heinrich, J				Jacob, B; Ritz, B; Gehring, U; Koch, A; Bischof, W; Wichmann, HE; Heinrich, J		INGA-Study Grp	Indoor exposure to molds and allergic sensitization	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						allergic sensitization; house dust; indoor allergen exposure; molds	IN-HOUSE DUST; REPORTED HOME DAMPNESS; RESPIRATORY SYMPTOMS; BRONCHIAL HYPERRESPONSIVENESS; RESIDENTIAL CHARACTERISTICS; CHILDHOOD ASTHMA; HEALTH; CHILDREN; FUNGI; PROPAGULES	Evidence that indoor dampness and mold growth are associated with respiratory health has been accumulating, but few studies have been able to examine health risks in relation to measured levels of indoor mold exposure. In particular, little is known about the contribution of indoor molds to the development of allergic sensitization. As a part of an ongoing study examining the effects of ambient air pollutants on respiratory health and atopic diseases in German school children, we examined the relation between viable mold levels indoors and allergic sensitization in 272 children. We examined whether allergic sensitization in children is associated with higher fungal spore count in settled house dust sampled from living room floors. Adjusting for age, sex, parental education, region of residency, and parental history of atopy, we found that mold spore counts for Cladosporium and Aspergillus were associated with an increased risk of allergic sensitization. Sensitized children exposed to high levels of mold spores (> 90th percentile) were more likely to suffer from symptoms of rhinoconjunctivitis. We conclude that elevated indoor concentrations of molds in wintertime might play a role in increasing the risk of developing atopic symptoms and allergic sensitization not only to molds but also to other common, inhaled allergens. These effects were strongest in the group of children who had lived in the same home since birth.	GSF, Inst Epidemiol, Munich, Germany; Univ Munich, Inst Med Data Management Biometr & Epidemiol, Munich, Germany; Univ Calif Los Angeles, Sch Publ Hlth, Ctr Environm & Occupat Hlth, Los Angeles, CA 90024 USA; Univ Jena, Dept Indoor Climatol, Erfurt, Germany	Jacob, B (reprint author), GSF, Inst Epidemiol, Ingolstadter Landstr 1, D-85758 Neuherberg, Germany.		Ritz, Beate/E-3043-2015	Gehring, Ulrike/0000-0003-3612-5780			BJORNSSON E, 1995, CLIN EXP ALLERGY, V25, P423, DOI 10.1111/j.1365-2222.1995.tb01073.x; BURR ML, 1988, J ROY SOC HEALTH, V108, P99, DOI 10.1177/146642408810800311; COREY JP, 1994, OTOLARYNG HEAD NECK, V111, P340; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; DAMATO G, 1995, ALLERGY, V50, P870, DOI 10.1111/j.1398-9995.1995.tb02492.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GRAVESEN S, 1979, ALLERGY, V34, P135, DOI 10.1111/j.1398-9995.1979.tb01562.x; Gross I, 2000, CLIN EXP ALLERGY, V30, P376, DOI 10.1046/j.1365-2222.2000.00780.x; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Katz Y, 1999, CLIN EXP ALLERGY, V29, P186; Koch A, 2000, ALLERGY, V55, P176, DOI 10.1034/j.1398-9995.2000.00233.x; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; LIAPPRIS N, 1993, ALLERGO J S3, V2, P133; MARTIN CJ, 1987, BRIT MED J, V294, P1125; Munir AKM, 1997, J ALLERGY CLIN IMMUN, V100, P177, DOI 10.1016/S0091-6749(97)70221-5; Nelson HS, 1999, J ALLERGY CLIN IMMUN, V104, P775; Nowak D, 1996, EUR RESPIR J, V9, P2541, DOI 10.1183/09031936.96.09122541; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; PLATT SD, 1989, BRIT MED J, V298, P1673; Richter K, 1999, ALLERGOLOGIE, V22, P14; Senkpiel K, 1996, ZBL HYG UMWELTMED, V198, P191; Sporik R, 1999, THORAX, V54, P675; STRACHAN DP, 1990, THORAX, V45, P382, DOI 10.1136/thx.45.5.382; SU HJ, 1992, APPL ENVIRON MICROB, V58, P181; Verhoeff AP, 1997, ANN ALLERG ASTHMA IM, V78, P544; VERHOEFF AP, 1994, ALLERGY, V49, P533, DOI 10.1111/j.1398-9995.1994.tb01125.x; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; VERHOEFF AP, 1992, ALLERGY, V47, P83; VERHOEFF AP, 1995, AM J EPIDEMIOL, V141, P103; WAEGEMAEKERS M, 1989, ALLERGY, V44, P192, DOI 10.1111/j.1398-9995.1989.tb02261.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WARNER JA, 1991, PEDIATR ALLERGY IMMU, V1, P79; WICKMAN M, 1992, J ALLERGY CLIN IMMUN, V89, P752, DOI 10.1016/0091-6749(92)90384-E; WOOD RA, 1988, AM REV RESPIR DIS, V137, P358	37	87	94	0	12	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUL	2002	110	7					647	653				7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	585VZ	WOS:000177546400024	12117641	
J	Wichmann, G; Herbarth, O; Lehmann, I				Wichmann, G; Herbarth, O; Lehmann, I			The mycotoxins citrinin, gliotoxin, and patulin affect interferon-gamma rather than interleukin-4 production in human blood cells	ENVIRONMENTAL TOXICOLOGY			English	Article; Proceedings Paper	10th International Symposium on Toxicity Assessment (ISTA 10)	AUG 26-31, 2001	QUEBEC CITY, CANADA			mycotoxins; citrinin; gliotoxin; patulin; Th1 cells; Th2 cells; IL-4; IFN-gamma; cytokine immunotoxicity	RESPIRATORY HEALTH; KAPPA-B; FUNGI; RISK; PROLIFERATION; CHILDREN; DAMP	Exposure to molds diminishes the numbers of T-helper type 1 (Th1) cells in the peripheral blood of children and is a risk factor for the development of allergic diseases (results of LARS: Leipzig Allergy Risk Children Study, Mueller et al. 2002). We hypothesized that mycotoxins are responsible for this effect and therefore investigated the influence of citrinin, gliotoxin, and patulin on human peripheral blood mononuclear cells (PBMC). CD3/CD28-stimulated PBMC of healthy donors were incubated for 24 h with the mycotoxins in serial dilutions and triplicates. Vitality and proliferation were tested using the MTT assay and T-cell function by the expression of cytokines (ELISA, intracellular cytokine staining, and real-time polymerase chain reaction (RT-PCR) for interferon-gamma (IFN-gamma) and interleukin-4 (IL-4). The cytokine secretion was inhibited at concentrations 2-130 times lower compared to vitality (ELISA versus MTT assay). The strongest inhibition of cytokine expression was found for IFN-gamma: 8.3 mug/mL citrinin, 34.2 ng/mL gliotoxin, and 64.8 ng/mL patulin caused a 50% inhibition of the IFN-gamma release (50% inhibitory dose, ID50). For IL-4 release the corresponding ID50 values were 21.6 mug/mL citrinin, 82.8 ng/mL gliotoxin, and 243.2 ng/mL patulin. Furthermore, 3 ng/mL patulin caused a significant increase of IL-4 but a significant suppression of IFN-gamma. On the mRNA level, after 24 h an unaltered or enhanced IL-4 was observed compared to a reduced IFN-gamma expression. Using a method of intracellular cytokine staining, we were able to show that the described effects are caused by a reduction of the number of IFN-gamma-producing T lymphocytes rather than by a reduced functional capacity of the single cell. We suggest that mycotoxins primarily cause stronger inhibition of IFN-gamma-producing Th1 cells, which may lead to T-cell polarization toward the Th2 phenotype and may raise the risk for the development of allergies. (C) 2002 Wiley Periodicals, Inc.	UFZ Helmholtz Ctr Environm Res, Ctr Environm Res Leipzig Halle, Dept Human Exposure Res & Epidemiol, D-04318 Leipzig, Germany; Univ Leipzig, Fac Med, Dept Environm Hyg, Leipzig, Germany	Wichmann, G (reprint author), UFZ Helmholtz Ctr Environm Res, Ctr Environm Res Leipzig Halle, Dept Human Exposure Res & Epidemiol, Permoser Str 15, D-04318 Leipzig, Germany.	guwich@expo.xfz.de					Charoenpornsook K, 1998, MYCOPATHOLOGIA, V143, P105, DOI 10.1023/A:1006971724678; Diez U, 2000, INT J HYG ENVIR HEAL, V203, P23, DOI 10.1078/S1438-4639(04)70004-8; Fischer G, 2000, INT J HYG ENVIR HEAL, V203, P105, DOI 10.1078/S1438-4639(04)70015-2; Flannigan B, 1991, Soc Appl Bacteriol Symp Ser, V20, p61S; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; Gravesen S, 1999, ENVIRON HEALTH PERSP, V107, P505; Herbarth O., 2000, P HLTH BUILDINGS, V1, P281; Herfarth H, 2000, CLIN EXP IMMUNOL, V120, P59, DOI 10.1046/j.1365-2249.2000.01184.x; HORAK B, 1987, ALLERGOL IMMUNOPATH, V15, P161; Husman T, 1996, SCAND J WORK ENV HEA, V22, P5; Lehmann I., 2001, Allergy (Copenhagen), V56, P43; LEHMANN I, 2001, INT J HYG ENVIR HEAL, V204, P1; LICORISH K, 1985, J ALLERGY CLIN IMMUN, V76, P19; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MUELLER A, 2002, IN PRESS INT J HYG E; Pahl HL, 1996, J EXP MED, V183, P1829, DOI 10.1084/jem.183.4.1829; Peat JK, 1998, ALLERGY, V53, P120, DOI 10.1111/j.1398-9995.1998.tb03859.x; ROMAGNANI S, 1997, IGE REGULATION MOL M, P1; Rossano F, 1999, RES MICROBIOL, V150, P13, DOI 10.1016/S0923-2508(99)80042-4; Sutton P, 1995, BIOCHEM PHARMACOL, V50, P2009, DOI 10.1016/0006-2952(95)02101-9; SUTTON P, 1994, INFECT IMMUN, V62, P1192; TARGONSKI PV, 1995, J ALLERGY CLIN IMMUN, V95, P955, DOI 10.1016/S0091-6749(95)70095-1; TOBIN RS, 1987, CAN J PUBLIC HLTH S, V78, P1	23	87	92	0	10	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1520-4081			ENVIRON TOXICOL	Environ. Toxicol.	JUN	2002	17	3			SI		211	218		10.1002/tox.10050		8	Environmental Sciences; Toxicology; Water Resources	Environmental Sciences & Ecology; Toxicology; Water Resources	571KW	WOS:000176717400008	12112629	
J	Hancox, RJ; Subbarao, P; Kamada, D; Watson, RM; Hargreave, FE; Inman, MD				Hancox, RJ; Subbarao, P; Kamada, D; Watson, RM; Hargreave, FE; Inman, MD			B-2-agonist tolerance and exercise-induced bronchospasm	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; exercise-induced; adrenergic beta-agonists; tolerance	REGULAR INHALED ALBUTEROL; INDUCED BRONCHOCONSTRICTION; ASTHMATIC SUBJECTS; BRONCHODILATOR; SALMETEROL; SUBSENSITIVITY; TERBUTALINE; BUDESONIDE; SALBUTAMOL; RESPONSES	The effect of regular inhaled beta-agonist on the treatment of exercise-induced bronchoconstriction was studied. Eight subjects with exercise-induced bronchoconstriction took 1 week each of salbutamol 200 mug qid or placebo in a random-order, double-blind, crossover study. They then withheld this treatment for 8 hours before performing a dry-air, sub-maximal exercise challenge at a work-rate previously shown to induce a 15% fall in forced expiratory volume in 1 second (FEV1). Five minutes after exercise, they inhaled salbutamol 100, 100, and 200 mug at 5-minute intervals. The mean pre-exercise FEV1 was similar on both study days. However, pretreatment for 1 week with salbutamol led to a significantly greater fall in FEV1 after exercise. The FEV1 remained lower than during the placebo arm despite the administration of salbutamol after exercise. This difference persisted 25 minutes after exercise. It is concluded that regular beta-agonist treatment leads to Increased exercise-induced bronchoconstriction and a suboptimal bronchodilator response to beta-agonist. The data suggest that previous regular beta-agonist treatment may lead to a failure to respond to emergency bronchodilator treatment during an acute asthma attack and support current opinion that regular short-acting beta-agonist therapy should not be used to treat asthma.	St Josephs Hosp, Firestone Inst Resp Hlth, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada	Inman, MD (reprint author), St Josephs Hosp, Firestone Inst Resp Hlth, Asthma Res Grp, Hamilton, ON L8N 4A6, Canada.		Hancox, Robert/G-4746-2011				Aldridge RE, 2000, AM J RESP CRIT CARE, V161, P1459; Cockcroft DW, 1996, THORAX, V51, P1051, DOI 10.1136/thx.51.10.1051; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738; GROVE A, 1995, LANCET, V346, P201, DOI 10.1016/S0140-6736(95)91265-7; Hancox RJ, 1999, EUR RESPIR J, V14, P283, DOI 10.1034/j.1399-3003.1999.14b08.x; Inman MD, 1996, AM J RESP CRIT CARE, V153, P65; Jones SL, 2001, EUR RESPIR J, V17, P368, DOI 10.1183/09031936.01.17303680; LARSSON K, 1992, CHEST, V101, P953, DOI 10.1378/chest.101.4.953; NEWNHAM DM, 1995, THORAX, V50, P497, DOI 10.1136/thx.50.5.497; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; RAMAGE L, 1994, RESP MED, V88, P363, DOI 10.1016/0954-6111(94)90042-6; ROBERTSON CF, 1990, MED J AUSTRALIA, V152, P511; Taylor DR, 1998, THORAX, V53, P744; Wraight JM, 2001, RESPIROLOGY, V6, pA48	14	87	91	1	8	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	APR 15	2002	165	8					1068	1070		10.1164/rccm.200111-091BC		3	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	542CX	WOS:000175026900009	11956046	
J	Gerberick, GF; Robinson, MK; Felter, SP; White, IR; Basketter, DA				Gerberick, GF; Robinson, MK; Felter, SP; White, IR; Basketter, DA			Understanding fragrance allergy using an exposure-based risk assessment approach	CONTACT DERMATITIS			English	Article						skin; allergic contact sensitization; fragrances; exposure; potency; risk assessment; margin of safety	LYMPH-NODE ASSAY; SODIUM LAURYL SULFATE; SKIN SENSITIZATION RISK; CONTACT SENSITIZATION; CINNAMIC-ALDEHYDE; GUINEA-PIG; ACTIVATION; DERMATITIS; RESPONSES; TESTS	Conducting a sound skin sensitization risk assessment prior to the introduction of new ingredients and products into the market place is essential. The process by which low-molecular-weight chemicals induce and elicit skin sensitization is dependent on many factors, including the ability of the chemical to penetrate the skin, react with protein, and trigger a cell-mediated immune response. Based on our chemical, cellular and molecular understanding of allergic contact dermatitis, it is possible to carry out a quantitative risk assessment. Specifically, by estimating the exposure to the allergen and its allergenic potency, it is feasible to assess quantitatively the sensitization risk of an ingredient in a particular product type. This paper focuses on applying exposure-based risk assessment tools to understanding fragrance allergy for 2 hypothetical products containing the fragrance allergen cinnamic aldehyde. The risk assessment process predicts that an eau de toilette leave-on product containing 1000 ppm or more cinnamic aldehyde would pose an unacceptable risk of induction of skin sensitization, while a shampoo, containing the same level of cinnamic aldehyde, would pose an acceptable risk of induction of skin sensitization, based on limited exposure to the ingredient from a rinse-off product application.	Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH USA; St Thomas Hosp, St Johns Inst Dermatol, London SE1 7EH, England; Unilever, SEAC Toxicol Unit, Sharnbrook, Beds, England	Gerberick, GF (reprint author), Procter & Gamble Co, Miami Valley Labs, Cincinnati, OH USA.			Robinson, Michael/0000-0002-6914-8543			Andersen KE, 1995, ACTA DERM-VENEREOL, V75, P463; Andersen K. E., 1985, CURRENT PROBLEMS DER, V14, P59; Basketter D. A., 1998, International Journal of Cosmetic Science, V20, P141, DOI 10.1046/j.1467-2494.1998.171746.x; Basketter DA, 2000, CONTACT DERMATITIS, V42, P344, DOI 10.1034/j.1600-0536.2000.042006344.x; Basketter DA, 1999, CONTACT DERMATITIS, V40, P150, DOI 10.1111/j.1600-0536.1999.tb06013.x; Basketter DA, 1996, FOOD CHEM TOXICOL, V34, P985, DOI 10.1016/S0278-6915(96)00059-2; BASKETTER DA, 1999, COMMENTS TOXICOL, V7, P79; Robinson M., 1996, TOXICOLOGY CONTACT H, P152; BOTHAM PA, 1991, FOOD CHEM TOXICOL, V29, P275, DOI 10.1016/0278-6915(91)90025-3; Buckley DA, 2000, BRIT J DERMATOL, V142, P279, DOI 10.1046/j.1365-2133.2000.03298.x; CUMBERBATCH M, 1993, TOXICOLOGY, V77, P181, DOI 10.1016/0300-483X(93)90148-L; DANNEMAN PJ, 1983, FOOD CHEM TOXICOL, V21, P721, DOI 10.1016/0278-6915(83)90203-X; Dearman RJ, 1999, J APPL TOXICOL, V19, P299, DOI 10.1002/(SICI)1099-1263(199909/10)19:5<299::AID-JAT591>3.0.CO;2-C; DeGroot AC, 1997, CONTACT DERMATITIS, V36, P57; European Centre for Ecotoxicology and Toxicology of Chemicals (ECETOC), 1994, 58 ECETOC; Effendy I, 1996, BRIT J DERMATOL, V135, P428; Environmental Protection Agency (EPA), 1999, EXP FACT HDB; EPA, 1992, US EPA PUBL; *EPA, 1998, US EPA PUBL; FRIEDMANN PS, 1983, CLIN EXP IMMUNOL, V53, P709; FRIEDMANN PS, 1983, BRIT J DERMATOL, V109, P86; FUNK JO, 1994, CONTACT DERMATITIS, V31, P236, DOI 10.1111/j.1600-0536.1994.tb01995.x; Gerberick G F, 2000, Am J Contact Dermat, V11, P65, DOI 10.1053/AC.2000.3191; Gerberick G F, 2000, Am J Contact Dermat, V11, P3; GERBERICK GF, 1993, AM J CONTACT DERMATI, V4, P205; GERBERICK GF, IN PRESS AM J CONTAC; Heylings JR, 1996, TOXICOLOGY, V109, P57, DOI 10.1016/0300-483X(96)03304-5; Hilton J, 1998, Am J Contact Dermat, V9, P29, DOI 10.1016/S1046-199X(98)90142-7; Johansen JD, 1996, CONTACT DERMATITIS, V34, P165, DOI 10.1111/j.1600-0536.1996.tb02167.x; Johansen JD, 2000, BRIT J DERMATOL, V142, P490, DOI 10.1046/j.1365-2133.2000.03362.x; KIMBER I, 1992, FOOD CHEM TOXICOL, V30, P165, DOI 10.1016/0278-6915(92)90153-C; KIMBER I, 1989, ARCH TOXICOL, V63, P274, DOI 10.1007/BF00278640; Kimber I, 1997, HUM ECOL RISK ASSESS, V3, P385; KLIGMAN AM, 1966, J INVEST DERMATOL, V47, P393, DOI 10.1038/jid.1966.160; Larsen W, 1996, Am J Contact Dermat, V7, P77, DOI 10.1016/S1046-199X(96)90078-0; LARSEN W, 1977, ARCH DERMATOL, V12, P623; LARSEN WG, 1985, J AM ACAD DERMATOL, V12, P1, DOI 10.1016/S0190-9622(85)70001-1; Lunder T, 2000, CONTACT DERMATITIS, V43, P107, DOI 10.1034/j.1600-0536.2000.043002107.x; MALTEN KE, 1984, CONTACT DERMATITIS, V11, P1, DOI 10.1111/j.1600-0536.1984.tb00162.x; McFadden JP, 1998, CONTACT DERMATITIS, V39, P79, DOI 10.1111/j.1600-0536.1998.tb05837.x; REES JL, 1990, BRIT J DERMATOL, V122, P29, DOI 10.1111/j.1365-2133.1990.tb08236.x; *RES I FRAGR MAT F, UNPUB ASS DAT; Robinson MK, 1996, FOOD CHEM TOXICOL, V34, P495, DOI 10.1016/0278-6915(96)87361-3; Robinson MK, 2000, CONTACT DERMATITIS, V42, P251, DOI 10.1034/j.1600-0536.2000.042005251.x; ROBINSON MK, 1989, FOOD CHEM TOXICOL, V27, P479, DOI 10.1016/0278-6915(89)90036-7; ROBINSON MK, 1991, FUND APPL TOXICOL, V17, P103, DOI 10.1016/0272-0590(91)90243-W; *SCI COMM COSM PRO, 1999, SCCNFP011999; *SCI COMM COSM PRO, 1999, SCCNFP001798; Seidenari S, 1996, CONTACT DERMATITIS, V34, P88, DOI 10.1111/j.1600-0536.1996.tb02136.x; WHITE SI, 1986, BRIT J DERMATOL, V115, P663, DOI 10.1111/j.1365-2133.1986.tb06646.x	50	87	87	1	8	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-1873			CONTACT DERMATITIS	Contact Dermatitis	DEC	2001	45	6					333	340		10.1034/j.1600-0536.2001.450603.x		8	Allergy; Dermatology	Allergy; Dermatology	512WP	WOS:000173346800003	11846748	
J	Vanacker, NJ; Palmans, E; Kips, JC; Pauwels, RA				Vanacker, NJ; Palmans, E; Kips, JC; Pauwels, RA			Fluticasone inhibits but does not reverse allergen-induced structural airway changes	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							BROWN-NORWAY RATS; INHALED CORTICOSTEROIDS; SMOOTH-MUSCLE; MURINE MODEL; MILD ASTHMA; SUBEPITHELIAL FIBROSIS; BASEMENT-MEMBRANE; ANTIGEN CHALLENGE; BRONCHIAL-ASTHMA; TERM TREATMENT	Ethical and technical reasons limit the possibility of evaluating the effects of inhaled corticosteroids on structural changes in airways of humans with asthma. We therefore evaluated whether fluticasone propionate (FP) modifies airway remodeling, induced by repeated allergen exposure in rats. Sensitized EN-rats were exposed to aerosolized ovalbumin (OA) for 2 wk. To assess the effect of FP on the development of or on established airway remodeling, animals were treated with aerosolized FP or placebo during allergen exposure or for 2 wk afterward. Compared with animals exposed to phosphate-buffered saline (PBS), OA-challenged animals developed an increase in total airway wall area, enhanced fibronectin deposition, epithelial cell proliferation, goblet cell hyperplasia, and airway hyperresponsiveness. Concomitant treatment with FP decreased all allergen-induced structural changes without being able to reverse them to normal. Initiating FP treatment after the allergen exposure had no effect on any of the OA-induced structural airway changes. The increase in total airway wall area, enhanced fibronectin deposition, and epithelial cell proliferation persisted. The goblet cell hyperplasia disappeared spontaneously. In conclusion, concomitant treatment with FP partly inhibits structural airway changes as well as hyperresponsiveness induced by OA exposure. Post hoc treatment fails to reverse established airway remodeling.	State Univ Ghent Hosp, Dept Resp Dis, B-9000 Ghent, Belgium	Vanacker, NJ (reprint author), State Univ Ghent Hosp, Dept Resp Dis, De Pintelaan 185, B-9000 Ghent, Belgium.						AGERTOFT L, 1994, RESP MED, V88, P373, DOI 10.1016/0954-6111(94)90044-2; Anstead G M, 1998, Adv Wound Care, V11, P277; Blyth DI, 1998, AM J RESP CELL MOL, V19, P38; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507; Brieva JL, 2000, AM J RESP CRIT CARE, V161, P293; Chakir J, 1996, LAB INVEST, V75, P735; Cui ZH, 1999, ALLERGY, V54, P1074, DOI 10.1034/j.1398-9995.1999.00133.x; Druilhe A, 1998, AM J RESP CELL MOL, V19, P747; DUBAYBO BA, 1991, RES COMMUN CHEM PATH, V71, P365; HAAHTELA T, 1994, NEW ENGL J MED, V331, P700, DOI 10.1056/NEJM199409153311103; Herard AL, 1996, AM J PHYSIOL-LUNG C, V271, pL726; Hirst SJ, 1998, AM J RESP CRIT CARE, V158, pS201; Holgate ST, 2000, J ALLERGY CLIN IMMUN, V105, P193, DOI 10.1016/S0091-6749(00)90066-6; Hoshino M, 1999, J ALLERGY CLIN IMMUN, V104, P356, DOI 10.1016/S0091-6749(99)70379-9; Hoshino M, 1998, CLIN EXP ALLERGY, V28, P568; IGNOTZ RA, 1986, J BIOL CHEM, V261, P4337; Laitinen A, 1997, AM J RESP CRIT CARE, V156, P951; LUNDGREN R, 1988, EUR RESPIR J, V1, P883; Mathur M, 1999, AM J RESP CRIT CARE, V159, P580; Meerschaert J, 1999, AM J RESP CRIT CARE, V159, P619; Olivieri D, 1997, AM J RESP CRIT CARE, V155, P1864; Overbeek SE, 1996, CHEST, V110, P35, DOI 10.1378/chest.110.1.35; Palmans E, 2000, AM J RESP CRIT CARE, V161, P627; Pavlovic D, 1998, EUR RESPIR J, V11, P575; Pedersen S, 1997, Pediatr Pulmonol Suppl, V15, P22; ROCHE WR, 1989, LANCET, V1, P520; Salmon M, 1999, EUR RESPIR J, V14, P633, DOI 10.1034/j.1399-3003.1999.14c25.x; SAPIENZA S, 1991, AM REV RESPIR DIS, V144, P423; SELROOS O, 1995, CHEST, V108, P1228, DOI 10.1378/chest.108.5.1228; Shiels IA, 1999, INFLAMMATION, V23, P321; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557; Stewart AG, 1995, BRIT J PHARMACOL, V116, P3219; Temelkovski J, 1998, THORAX, V53, P849; Tournoy KG, 2000, CLIN EXP ALLERGY, V30, P79; TRIGG CJ, 1994, AM J RESP CRIT CARE, V150, P17; Warshamana GS, 1998, AM J PHYSIOL-LUNG C, V274, pL499; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; YOUNG PG, 1995, EUR J PHARMACOL, V273, P137, DOI 10.1016/0014-2999(94)00679-2	39	87	104	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	MAR	2001	163	3					674	679				6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	419HW	WOS:000167944100017	11254522	
J	Davis, PJ; Smales, CM; James, DC				Davis, PJ; Smales, CM; James, DC			How can thermal processing modify the antigenicity of proteins?	ALLERGY			English	Article; Proceedings Paper	Symposium on Immunological, Chemical and Clinical Problems of Food Allergy	MAR 11-13, 2001	VENICE, ITALY			antigenicity; thermal processing	HEATED PECAN NUT; MAILLARD REACTION; NEOALLERGENS; GLYCATION; N-EPSILON-(CARBOXYMETHYL)LYSINE; ANTIBODIES; PRODUCTS	This paper is a brief review of thermally induced covalent modifications to proteins in foods, focussing mainly on the advanced glycation end-products (AGE) of the Maillard reaction. Most foods are subjected to thermal processing, either in the home or during their production/manufacture. Thermal processing provides many beneficial effects, but also brings about major changes in allergenicity. Far from being a general way to decrease allergenic risk, thermal processing is as likely to increase allergenicity as to reduce it, through the introduction of neoantigens. These changes are highly complex and not easily predictable, but there are a number of major chemical pathways that lead to distinct patterns of modification. Perhaps the most important of these is through the reaction of protein amino groups with sugars, leading to an impressive cocktail of AGE-modified protein derivatives. These are antigenic and many of the important neoantigens found in cooked or stored foods are probably such Maillard reaction products. A deeper understanding of thermally induced chemical changes is essential for more advanced risk assessments, more effective QC protocols, production of more relevant diagnostic allergen extracts and the development of novel protein engineering and therapeutic approaches to minimise allergenic risk.	Unilever Res, Colworth Lab, Sharnbrook MK44 1LQ, Beds, England; Univ Kent, Res Sch Biosci, Canterbury, Kent, England	Davis, PJ (reprint author), Unilever Res, Colworth Lab, Sharnbrook MK44 1LQ, Beds, England.		James, David/N-3794-2015				BERENS L, 1974, CLIN EXP IMMUNOL, V17, P703; Berrens L, 1996, ALLERGY, V51, P277, DOI 10.1111/j.1398-9995.1996.tb00085.x; BLEUMINK E, 1966, NATURE, V212, P541, DOI 10.1038/212541a0; BUCALA R, 1996, DIAGN ENDOCRIN METAB, V14, P99; Codina R, 1998, INT ARCH ALLERGY IMM, V117, P120, DOI 10.1159/000023998; Davis PJ, 1998, ALLERGY, V53, P102; DOKE S, 1989, AGR BIOL CHEM TOKYO, V53, P1231; Ikeda K, 1998, J IMMUNOL METHODS, V215, P95, DOI 10.1016/S0022-1759(98)00064-7; Ikeda K, 1996, BIOCHEMISTRY-US, V35, P8075, DOI 10.1021/bi9530550; Kalluri R, 2000, J BIOL CHEM, V275, P20027, DOI 10.1074/jbc.M904549199; Kilara Arun, 1996, P71; Malanin K, 1995, ALLERGY, V50, P988, DOI 10.1111/j.1398-9995.1995.tb02513.x; Maleki SJ, 2000, J ALLERGY CLIN IMMUN, V106, P763, DOI 10.1067/mai.2000.109620; Prausnitz C, 1921, ZBL BAKT           1, V86, P160; Prowse CV, 1998, BLOOD REV, V12, P99, DOI 10.1016/S0268-960X(98)90021-2; REDDY S, 1995, BIOCHEMISTRY-US, V34, P10872, DOI 10.1021/bi00034a021; ROSEN JP, 1994, J ALLERGY CLIN IMMUN, V93, P1068, DOI 10.1016/S0091-6749(94)70056-7; Smales CM, 2000, BIOTECHNOL APPL BIOC, V32, P109, DOI 10.1042/BA20000032; SUAREZ G, 1989, J BIOL CHEM, V264, P3674; Urisu A, 1997, J ALLERGY CLIN IMMUN, V100, P171, DOI 10.1016/S0091-6749(97)70220-3	20	87	97	1	18	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy		2001	56			67			56	60		10.1034/j.1398-9995.2001.00918.x		5	Allergy; Immunology	Allergy; Immunology	448PA	WOS:000169634200015	11298011	
J	Mallol, J; Sole, D; Asher, I; Clayton, T; Stein, R; Soto-Quiroz, M				Mallol, J; Sole, D; Asher, I; Clayton, T; Stein, R; Soto-Quiroz, M		Latin Amer ISAAC Collaborators Grp	Prevalence of asthma symptoms in Latin America: The International Study of Asthma and Allergies in Childhood (ISAAC)	PEDIATRIC PULMONOLOGY			English	Article						asthma; children; epidemiology; Latin America; ISAAC; prevalence	CHILDREN; AUSTRALIA; GERMANY	The prevalence of respiratory symptoms indicative of asthma in children from Latin America has been largely ignored. As part of the International Study of Asthma and Allergies in Childhood (ISAAC), 17 centers in 9 different Latin American countries participated in the study, and data from 52,549 written questionnaires (WQ) in children aged 13-14 years and from 36,264 WQ in 6-7 year olds are described here. In children aged 13-14 years, the prevalence of asthma ever ranged from 5.5-28%, and the prevalence of wheezing in the last 12 months from 6.6-27%. In children aged 6-7 years, the prevalence of asthma ever ranged from 4.1-26.9%, and the prevalence of wheezing in the last 12 months ranged from 8.6-32.1%. The lower prevalence in centers with higher levels of atmospheric pollution suggests that chronic inhalation of polluted air in children does not contribute to asthma. Furthermore, the high figures for asthma in a region with a high level of gastrointestinal parasite infestation, and a high burden of acute respiratory infections occurring early in life, suggest that these factors, considered as protective in other regions, do not have the same effect in this region. The present study indicates that the prevalence of asthma and related symptoms in Latin America is as high and variable as described in industrialized or developed regions of the world. Pediatr Pulmonol. 2000; 30:439-444. (C) 2000 Wiley-Liss. Inc.	Univ Santiago Chile, Dept Pediat Resp Med, Santiago, Chile; Univ Fed Sao Paulo, Div Allergy, Sao Paulo, Brazil; Univ Auckland, Dept Paediat, Auckland 1, New Zealand; Catholic Univ, Pediat Pulm Unit, Porto Alegre, RS, Brazil	Mallol, J (reprint author), Univ Santiago Chile, Dept Pediat Resp Med, Clasificador 23,Correo 9, Santiago, Chile.		Clayton, Tadd/B-7914-2009; Sole, Dirceu/D-7789-2013; Stein, Renato/K-2568-2014; Jones, Marcus/A-3580-2011; Asher, Innes/O-2604-2016	Jones, Marcus/0000-0002-8263-1265; Asher, Innes/0000-0003-1768-3832			Asher MI, 1998, EUR RESPIR J, V12, P315; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; ASHER MI, 1988, AM REV RESPIR DIS, V138, P524; Burney P, 1996, EUR RESPIR J, V9, P687; BURNEY PGJ, 1994, EUR RESPIR J, V7, P954; BURR ML, 1994, INT J EPIDEMIOL, V23, P341, DOI 10.1093/ije/23.2.341; CARRASCO E, 1987, CHEST S, V91, P93; CARTERPOKRAS OD, 1993, AM J PUBLIC HEALTH, V83, P580, DOI 10.2105/AJPH.83.4.580; DENNY FW, 1995, AM J RESP CRIT CAR S, V152, P5; KEELEY DJ, 1991, THORAX, V46, P549, DOI 10.1136/thx.46.8.549; LEUNG R, 1994, THORAX, V49, P1205, DOI 10.1136/thx.49.12.1205; LOPEZANTUNANOF J, 1997, RESP INFECT CHILDREN, P3; Lynch NR, 1997, AM J RESP CRIT CARE, V156, P50; OYARZUN M, 1993, AM REV RESPIR DIS, V147, P826; PEARCE N, 1993, EUR RESPIR J, V6, P1455; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; ROBERTSON CF, 1993, PEDIATR PULM, V16, P219, DOI 10.1002/ppul.1950160403; ROBERTSON CF, 1995, CLIN PAEDIAT ASTHMA, P253; SOTOQUIROS M, 1994, CLIN EXP ALLERGY, V24, P1130; VONMUTIUS E, 1992, BRIT MED J, V305, P1395	20	87	101	0	4	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012 USA	8755-6863			PEDIATR PULM	Pediatr. Pulmonol.	DEC	2000	30	6					439	444		10.1002/1099-0496(200012)30:6<439::AID-PPUL1>3.0.CO;2-E		6	Pediatrics; Respiratory System	Pediatrics; Respiratory System	380CN	WOS:000165680900001	11109054	
J	Thorne, PS				Thorne, PS			Inhalation toxicology models of endotoxin- and bioaerosol-induced inflammation	TOXICOLOGY			English	Article; Proceedings Paper	Symposium on Indoor Environmental Factors Enhancing Allergic Immune Response: Focus on Endotoxin and Particles	JUN   26, 1999	OSLO, NORWAY	EUROTOX, Immunotoxicol & Chem Allergy Special Sect		inhalation toxicology; exposure chambers; bioaerosols; endotoxin; glucans	PULMONARY HYPERSENSITIVITY RESPONSES; POLYMERASE CHAIN-REACTION; MURINE MODEL; GUINEA-PIGS; COTTON DUST; RAT NASAL; (1->3)-BETA-D-GLUCAN; BACTERIA; SYSTEM; HYBRIDIZATION	Inhalation toxicology studies in rodents have proven their usefulness for furthering our understanding of the causal agents, mechanisms, and pathology associated with exposures to environmental endotoxins and bioaerosols. Inhalation animal models are used to determine which components of a mixture are the most important toxicants for inducing the observed adverse outcome. They are used to obtain exposure-response relationships for allergens and pro-inflammatory agents to help elucidate disease mechanisms and contribute quantitative data to the risk assessment process. Inhalation models serve as important adjuncts to epidemiology studies and human exposure studies. They are also useful for establishing phenotype in studies of genetic polymorphisms and disease susceptibility and are widely applied for evaluation of safety and efficacy for potential therapeutic agents. In order to produce reliable data, rigorous exposure chamber design, aerosol generation systems, exposure quantitation and experimental protocols must be utilized. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.	Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA	Thorne, PS (reprint author), Univ Iowa, Coll Publ Hlth, Dept Environm & Occupat Hlth, Iowa City, IA 52242 USA.						Deetz DC, 1997, AM J RESP CRIT CARE, V155, P254; DENIS M, 1991, AM J RESP CELL MOL, V5, P477; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Douwes J, 1996, APPL ENVIRON MICROB, V62, P3176; ELLAKKANI MA, 1987, TOXICOL APPL PHARM, V88, P354, DOI 10.1016/0041-008X(87)90211-0; ELLAKKANI MA, 1984, TOXICOL APPL PHARM, V74, P267, DOI 10.1016/0041-008X(84)90152-2; Fanucchi MV, 1998, TOXICOL APPL PHARM, V152, P1, DOI 10.1006/taap.1998.8484; Fogelmark B, 1997, MEDIAT INFLAMM, V6, P263; GEORGE CLS, 2000, IN PRESS AM J PHYSL; GILMOUR MI, 1993, TOXICOL APPL PHARM, V123, P211, DOI 10.1006/taap.1993.1239; GORDON T, 1994, AM J RESP CELL MOL, V10, P177; GREENBERGER MJ, 1995, J IMMUNOL, V155, P722; HEEDERIK D, 2000, IN PRESS OCCUPATIONA; Hsieh TH, 1999, AEROSOL SCI TECH, V31, P358, DOI 10.1080/027868299304084; IWANAGA S, 1993, CURR OPIN IMMUNOL, V5, P74, DOI 10.1016/0952-7915(93)90084-6; Jagielo PJ, 1996, AM J PHYSIOL-LUNG C, V270, pL1052; Jagielo PJ, 1998, AM J PHYSIOL-LUNG C, V274, pL26; KAROL MH, 1986, CRIT REV TOXICOL, V16, P349, DOI 10.3109/10408448609037467; KAROL MH, 1989, TOXICOL APPL PHARM, V100, P234, DOI 10.1016/0041-008X(89)90310-4; Kline JN, 1998, J IMMUNOL, V160, P2555; Lambert AL, 1998, AM J RESP CRIT CARE, V157, P1991; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Lange JL, 1997, APPL ENVIRON MICROB, V63, P1557; LIVAK KJ, 1995, PCR METH APPL, V4, P357; LUKACS NW, 1994, AM J RESP CELL MOL, V10, P526; McBride J. T., 1992, COMPR TREAT, V1, P49; McCray PB, 1999, AM J PHYSIOL-LUNG C, V277, pL183; MORITA T, 1981, FEBS LETT, V129, P318, DOI 10.1016/0014-5793(81)80192-5; NAGI N, 1993, BIOL PHARM BULL, V16, P822; OBAYASHI T, 1995, LANCET, V345, P17, DOI 10.1016/S0140-6736(95)91152-9; OShaughnessy PT, 1996, AEROSOL SCI TECH, V25, P292, DOI 10.1080/02786829608965397; OSHAUGHNESSY PT, 1994, INHAL TOXICOL, V6, P95, DOI 10.3109/08958379409029698; PIATAK M, 1993, BIOTECHNIQUES, V14, P70; PICARD C, 1992, APPL ENVIRON MICROB, V58, P2717; ROSLANSKY PF, 1991, J CLIN MICROBIOL, V29, P2477; ROY C, UNPUB GLUCAN SOYBEAN; SCHWARTZ DA, 1994, AM J PHYSIOL-LUNG C, V267, pL609; STEIGER D, 1995, AM J RESP CELL MOL, V12, P307; Tamura H, 1997, J CLIN LAB ANAL, V11, P104, DOI 10.1002/(SICI)1098-2825(1997)11:2<104::AID-JCLA6>3.0.CO;2-B; THORNE PS, 1994, AM J IND MED, V25, P109, DOI 10.1002/ajim.4700250129; THORNE PS, 1988, TOXICOLOGY, V52, P141, DOI 10.1016/0300-483X(88)90201-6; THORNE PS, 1989, TOXICOL APPL PHARM, V100, P247, DOI 10.1016/0041-008X(89)90311-6; Thorne PS, 1997, AM IND HYG ASSOC J, V58, P792, DOI 10.1202/0002-8894(1997)058<0792:FEOEAS>2.0.CO;2; Thorne PS, 1999, AM J RESP CELL MOL, V20, P1155; THORNE PS, 1999, ORGANIC INDOOR AIR P, P85, DOI 10.1002/9783527613663.ch07; THORNE PS, 1999, ORGANIC INDOOR AIR P, P275, DOI 10.1002/9783527613663.ch20; Tyler W. S., 1992, COMP BIOL NORMAL LUN, P37	47	87	89	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	0300-483X			TOXICOLOGY	Toxicology	NOV 2	2000	152	1-3					13	23		10.1016/S0300-483X(00)00287-0		11	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	379EC	WOS:000165627100003	11090935	
J	Farr, BM; Bartlett, CLR; Wadsworth, J; Miller, DL				Farr, BM; Bartlett, CLR; Wadsworth, J; Miller, DL		British Thoracic Soc Pneumonia Stu	Risk factors for community-acquired pneumonia diagnosed upon hospital admission	RESPIRATORY MEDICINE			English	Article						case-control study; chronic obstructive pulmonary disease; congestive heart failure; epidemiology; occupational; pneumonia; risk factors; smoking	BACTERIAL PNEUMONIA; ETIOLOGY; MORTALITY; EPIDEMIOLOGY; INFECTION; SMOKING	A case-control study of risk factors for community-acquired pneumonia in adults admitted to hospital is reported. Cases were surviving patients (n = 178) admitted to 14 hospitals in England. Controls were individuals (n = 385) randomly selected from the electoral registers of the areas served by the hospitals. The two groups were compared with regard to risk factors for pneumonia using a standardized postal questionnaire. Independent risk factors associated with cases in log-linear regression analysis were age, heart disease (as indicated by congestive heart Failure and/or digitalis treatment), lifetime smoking history, chronic airway disease (chronic bronchitis and/or asthma), occupational dust exposure, pneumonia as a child, single marital status and unemployment. Corticosteroid and bronchodilator therapy were also independent risk factors in the log-linear regression analysis, but may reflect the severity of underlying lung disease for which these drugs were prescribed. These data suggest that cigarette smoking is the major avoidable risk factor for acute pneumonia in adults.	Univ Virginia, Sch Med, Dept Internal Med, Charlottesville, VA 22908 USA; Univ London, St Marys Hosp, Sch Med, Dept Epidemiol & Publ Hlth, London, England; Publ Hlth Lab Serv, Ctr Communicable Dis Surveillance, London NW9 5EQ, England	Farr, BM (reprint author), Univ Virginia, Sch Med, Dept Internal Med, Box 800743, Charlottesville, VA 22908 USA.						Aguirre I, 1993, Aten Primaria, V12, P359; ANDREWS BE, 1987, Q J MED, V62, P195; AUSTRIAN R, 1964, ANN INTERN MED, V60, P759; BAKER RJ, 1978, OXFORD NUMERICAL ALG; BATES JH, 1992, CHEST, V101, P1005, DOI 10.1378/chest.101.4.1005; BATH JCJL, 1964, BRIT J DIS CHEST, V58, P1, DOI 10.1016/S0007-0971(64)80017-6; BERKSON J, 1946, BIOMETRICS BULL, V2, P47, DOI 10.2307/3002000; Broome C V, 1979, Epidemiol Rev, V1, P1; CAIAFFA WT, 1993, AM J EPIDEMIOL, V138, P909; Centers for disease control and prevention (CDC), 1988, MMWR-MORBID MORTAL W, V37, P593; CHARLTON JRH, 1983, LANCET, V1, P691; COLBY JRT, 1974, LANCET, V2, P1031; DOLL R, 1976, BRIT MED J, V2, P1525; FANG GD, 1990, MEDICINE, V69, P307; Farr BM, 2000, RESP MED, V94, P422, DOI 10.1053/rmed.1999.0743; FARR BM, 1991, ANN INTERN MED, V115, P428; Fekety F R Jr, 1971, Am Rev Respir Dis, V104, P499; FERGUSSON DM, 1981, J EPIDEMIOL COMMUN H, V35, P180, DOI 10.1136/jech.35.3.180; JAY SJ, 1975, NEW ENGL J MED, V293, P798, DOI 10.1056/NEJM197510162931604; JOKINEN C, 1993, AM J EPIDEMIOL, V137, P977; KLIMEK JJ, 1983, AM J INFECT CONTROL, V11, P79, DOI 10.1016/0196-6553(83)90117-7; KOIVULA I, 1994, AM J MED, V96, P313, DOI 10.1016/0002-9343(94)90060-4; LACROIX AZ, 1989, PUBLIC HEALTH REP, V104, P350; LANGE P, 1995, EUR RESPIR J, V8, P1695; LIM I, 1989, MED J AUSTRALIA, V151, P87; LIPSKY BA, 1986, ARCH INTERN MED, V146, P2179, DOI 10.1001/archinte.146.11.2179; MACFARLANE JT, 1982, LANCET, V2, P255; Marrie T J, 1990, Semin Respir Infect, V5, P260; MCNABB WR, 1984, J ROY SOC MED, V77, P550; MERCER J, 1985, POSTGRAD MED J, V61, P713; MOINE P, 1994, CHEST, V105, P1487, DOI 10.1378/chest.105.5.1487; MOORE MA, 1977, JOHNS HOPKINS MED J, V140, P9; MORRIS K, 1990, AM J DIS CHILD, V144, P105; MUFSON MA, 1967, AM J EPIDEMIOL, V86, P526; *OFF NAT STAT, 1998, STAT OFF DH2, V23; ORT S, 1983, JAMA-J AM MED ASSOC, V249, P214, DOI 10.1001/jama.249.2.214; PROUT S, 1983, S AFR MED J, V64, P443; SAS, 1985, SAS US GUID STAT; SULLIVAN RJ, 1972, ARCH INTERN MED, V129, P935, DOI 10.1001/archinte.129.6.935; TORRES A, 1991, AM REV RESPIR DIS, V144, P312; US Department of Health and Human Services, 1984, DHHS PUBL; WHITE RJ, 1981, THORAX, V36, P566, DOI 10.1136/thx.36.8.566; WOODHEAD MA, 1987, LANCET, V1, P671; 1988, MMWR, V37, P249; 1995, MMWR, V44, P535	45	87	93	0	3	W B SAUNDERS CO LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0954-6111			RESP MED	Respir. Med.	OCT	2000	94	10					954	963		10.1053/rmed.2000.0865		10	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	366RE	WOS:000090017700005	11059948	
J	Palmer, LJ; Burton, PR; Faux, JA; James, AL; Musk, AW; Cookson, WOCM				Palmer, LJ; Burton, PR; Faux, JA; James, AL; Musk, AW; Cookson, WOCM			Independent inheritance of serum immunoglobulin E concentrations and airway responsiveness	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							SKIN-TEST REACTIVITY; COMMUNITY POPULATION-SAMPLE; BRONCHIAL RESPONSIVENESS; QUANTITATIVE TRAIT; GENERAL-POPULATION; ASTHMA; IGE; PREVALENCE; ATOPY; TWINS	Elevated serum Immunoglobulin E (IgE) levels and increased airway responsiveness (AR) are correlated traits that are characteristic of asthma. It is not known to what extent these traits arise from distinct or shared genetic determinants. We investigated the genetic and environmental components of variance of serum total and specific IgE levels and AR in an Australian population-based sample of 232 Caucasian nuclear families. The inter-relationships of the genetic determinants of these traits were also investigated. Log, total serum IgE levels had a narrow-sense heritability (h(N)(2)) of 47.3% (SE = 10.0%). Specific serum IgE levels against house dust mite and timothy grass, measured as a RAST Index, ad a h(N)(2) Of 33.8% (SE = 7.3%). AR, quantified by the log, dose-response slope to methacholine (DRS), had a h(N)(2) of 30.0% (SE = 12.3%). Extended modeling demonstrated an approximate 70% overlap in the genetic determinants of total and specific serum IgE levels. The genetic determinants of serum IgE levels and AR exhibited less than 30% sharing. These data are consistent with the existence of multiple genetic determinants of the pathophysiologic traits associated with asthma, and suggest that AR is genetically distinct from atopy. These results have implications for gene discovery programs.	Case Western Reserve Univ, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Univ Leicester, Dept Epidemiol & Publ Hlth, Genet Epidemiol Unit, Leicester, Leics, England; John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Univ Perth, Dept Med, Dept Pulm Physiol, Perth, WA, Australia; Sir Charles Gairdiner Hosp, Dept Resp Med, Perth, WA, Australia; TVW Telethon Inst Child Hlth Res, Div Populat Sci, Genet Epidemiol Unit, Perth, WA, Australia	Palmer, LJ (reprint author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.		Palmer, Lyle/K-3196-2014; Burton, Paul/H-7527-2016	Palmer, Lyle/0000-0002-1628-3055; 	NCRR NIH HHS [RR-03655]		American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; BARBEE RA, 1981, J ALLERGY CLIN IMMUN, V68, P106, DOI 10.1016/0091-6749(81)90167-6; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; BROWN WG, 1979, J ALLERGY CLIN IMMUN, V63, P328, DOI 10.1016/0091-6749(79)90127-1; BURROWS B, 1992, J ALLERGY CLIN IMMUN, V90, P376, DOI 10.1016/S0091-6749(05)80018-1; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Clayton D, 1993, STAT MODELS EPIDEMIO; CLOUGH JB, 1993, CLIN EXP ALLERGY, V23, P883, DOI 10.1111/j.1365-2222.1993.tb00272.x; Cookson WOCM, 1998, CLIN EXP ALLERGY, V28, P88; CROCKETT AJ, 1995, J PAEDIATR CHILD H, V31, P213, DOI 10.1111/j.1440-1754.1995.tb00788.x; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; HANSON B, 1991, AM J HUM GENET, V48, P873; HILL DJ, 1995, AUST J PUBLIC HEALTH, V19, P305; HILL DJ, 1993, MED J AUSTRALIA, V158, P228; HILL MR, 1995, BRIT MED J, V311, P776; HOPP RJ, 1984, J ALLERGY CLIN IMMUN, V73, P265, DOI 10.1016/S0091-6749(84)80018-4; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; Hopper J. L., 1994, AUST J STAT, V36, P153, DOI DOI 10.1111/J.1467-842X.1994.TB00859.X; Jansen DF, 1997, RESP MED, V91, P121, DOI 10.1016/S0954-6111(97)90048-2; Khoury MJ, 1993, FUNDAMENTALS GENETIC; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; Medical Research Council Committee on the Aetiology of Chronic Bronchitis, 1965, LANCET, V1, P775; MEYERS DA, 1987, AM J HUM GENET, V41, P51; OCONNOR G, 1987, AM REV RESPIR DIS, V136, P1412; PAOLETTI P, 1995, AM J RESP CRIT CARE, V151, P1770; POSTMA DS, 1995, NEW ENGL J MED, V333, P894, DOI 10.1056/NEJM199510053331402; RISCH N, 1990, AM J HUM GENET, V46, P222; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Robertson CF, 1998, MED J AUSTRALIA, V168, P434; RYAN G, 1982, THORAX, V37, P423, DOI 10.1136/thx.37.6.423; SCHORK NJ, 1993, HUM HERED, V43, P1, DOI 10.1159/000154106; SEARS MR, 1989, CLIN EXP ALLERGY, V19, P419, DOI 10.1111/j.1365-2222.1989.tb02408.x; SUNYER J, 1995, J ALLERGY CLIN IMMUN, V95, P699, DOI 10.1016/S0091-6749(95)70175-3; WUTHRICH B, 1981, CLIN ALLERGY, V11, P147, DOI 10.1111/j.1365-2222.1981.tb01578.x; YAN K, 1983, THORAX, V38, P760, DOI 10.1136/thx.38.10.760	35	87	88	0	3	AMER LUNG ASSOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	JUN	2000	161	6					1836	1843				8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	325KV	WOS:000087675500017	10852754	
J	Violari, A; Lindsey, JC; Hughes, MD; Mujuru, HA; Barlow-Mosha, L; Kamthunzi, P; Chi, BH; Cotton, MF; Moultrie, H; Khadse, S; Schimana, W; Bobat, R; Purdue, L; Eshleman, SH; Abrams, EJ; Millar, L; Petzold, E; Mofenson, LM; Jean-Philippe, P; Palumbo, P				Violari, Avy; Lindsey, Jane C.; Hughes, Michael D.; Mujuru, Hilda A.; Barlow-Mosha, Linda; Kamthunzi, Portia; Chi, Benjamin H.; Cotton, Mark F.; Moultrie, Harry; Khadse, Sandhya; Schimana, Werner; Bobat, Raziya; Purdue, Lynette; Eshleman, Susan H.; Abrams, Elaine J.; Millar, Linda; Petzold, Elizabeth; Mofenson, Lynne M.; Jean-Philippe, Patrick; Palumbo, Paul			Nevirapine versus Ritonavir-Boosted Lopinavir for HIV-Infected Children	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SINGLE-DOSE NEVIRAPINE; RANDOMIZED CONTROLLED-TRIAL; ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR; DRUG-RESISTANCE; GROWTH; INITIATION; DYNAMICS; EXPOSURE; FAILURE	BACKGROUND Nevirapine-based antiretroviral therapy is the predominant (and often the only) regimen available for children in resource-limited settings. Nevirapine resistance after exposure to the drug for prevention of maternal-to-child human immunodeficiency virus (HIV) transmission is common, a problem that has led to the recommendation of ritonavir-boosted lopinavir in such settings. Regardless of whether there has been prior exposure to nevirapine, the performance of nevirapine versus ritonavir-boosted lopinavir in young children has not been rigorously established. METHODS In a randomized trial conducted in six African countries and India, we compared the initiation of HIV treatment with zidovudine, lamivudine, and either nevirapine or ritonavir-boosted lopinavir in HIV-infected children 2 to 36 months of age who had no prior exposure to nevirapine. The primary end point was virologic failure or discontinuation of treatment by study week 24. RESULTS A total of 288 children were enrolled; the median percentage of CD4+ T cells was 15%, and the median plasma HIV type 1 (HIV-1) RNA level was 5.7 log(10) copies per milliliter. The percentage of children who reached the primary end point was significantly higher in the nevirapine group than in the ritonavir-boosted lopinavir group (40.8% vs. 19.3%; P < 0.001). Among the nevirapine-treated children with virologic failure for whom data on resistance were available, more than half (19 of 32) had resistance at the time of virologic failure. In addition, the time to a protocol-defined toxicity end point was shorter in the nevirapine group (P=0.04), as was the time to death (P=0.06). CONCLUSIONS Outcomes were superior with ritonavir-boosted lopinavir among young children with no prior exposure to nevirapine. Factors that may have contributed to the suboptimal results with nevirapine include elevated viral load at baseline, selection for nevirapine resistance, background regimen of nucleoside reverse-transcriptase inhibitors, and the standard ramp-up dosing strategy. The results of this trial present policymakers with difficult choices. (Funded by the National Institute of Allergy and Infectious Diseases and others; P1060 ClinicalTrials.gov number, NCT00307151.)	[Violari, Avy] Univ Witwatersrand, Perinatal HIV Res Unit, ZA-2050 Johannesburg, South Africa; [Mujuru, Hilda A.] Univ Witwatersrand, Reprod Hlth & HIV Inst, Fac Hlth Sci, Johannesburg, South Africa; [Cotton, Mark F.] Univ Stellenbosch, Tygerberg Childrens Hosp, ZA-7505 Tygerberg, South Africa; [Bobat, Raziya] Univ KwaZulu Natal, Nelson R Mandela Sch Med, Durban, South Africa; [Lindsey, Jane C.; Hughes, Michael D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; [Mujuru, Hilda A.] Univ Zimbabwe, Coll Hlth Sci, Dept Paediat & Child Hlth, Harare, Zimbabwe; [Barlow-Mosha, Linda] Johns Hopkins Univ, Res Collaborat, Makerere Univ, Kampala, Uganda; [Kamthunzi, Portia] Univ N Carolina Project, Lilongwe, Malawi; [Chi, Benjamin H.] Ctr Infect Dis Res Zambia, Lusaka, Zambia; [Khadse, Sandhya] BJ Med Coll & Sassoon Gen Hosp, Dept Pediat, Pune, Maharashtra, India; [Schimana, Werner] Duke Univ, Kilimanjaro Christian Med Ctr Collaborat, Moshi, Tanzania; [Purdue, Lynette] NIAID, NIH, Div Aids, Pharmaceut Affairs Branch, Bethesda, MD 20892 USA; [Jean-Philippe, Patrick] NIAID, NIH, Div Aids, Henry Jackson Fdn, Bethesda, MD 20892 USA; [Petzold, Elizabeth] Social & Sci Syst, Silver Spring, MD USA; [Mofenson, Lynne M.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Pediat Adolescent & Maternal AIDS Branch, NIH, Rockville, MD USA; [Eshleman, Susan H.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA; [Abrams, Elaine J.] Columbia Univ, Sch Publ Hlth, Int Ctr AIDS Care Program, New York, NY USA; [Abrams, Elaine J.] Columbia Univ, Sch Publ Hlth, Treatment Program, New York, NY USA; [Abrams, Elaine J.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; [Millar, Linda] Frontier Sci & Technol Res Fdn Inc, Amherst, NY USA; [Palumbo, Paul] Dartmouth Med Sch, Lebanon, NH USA	Palumbo, P (reprint author), Dartmouth Hitchcock Med Ctr, Int Pediat HIV Program, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	paul.e.palumbo@dartmouth.edu		Mofenson, Lynne/0000-0002-2818-9808	National Institute of Allergy and Infectious Diseases (NIAID) [U01 AI068632]; Eunice Kennedy Shriver National Institute of Child Health and Human Development; National Institute of Mental Health [U01 AI068632, 5 U01 AI41110, 1 U01 AI068616]; NIAID [HHSN272200800014C]; Abbott; Tibotec; Boehringer Ingelheim; Pfizer; Medicines Development; GlaxoSmithKline; ViiV Healthcare	Supported by a grant [U01 AI068632] from the National Institute of Allergy and Infectious Diseases (NIAID), the Eunice Kennedy Shriver National Institute of Child Health and Human Development, and the National Institute of Mental Health to the Pediatric AIDS Clinical Trials Group (PACTG) and the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) Group; the Statistical and Data Analysis Center at Harvard School of Public Health under NIAID cooperative agreements (5 U01 AI41110 with the PACTG and 1 U01 AI068616 and U01 AI068632 with the IMPAACT Group); and by a contract from the NIAID (HHSN272200800014C).; Dr. Avy Violari reports receiving lecture fees from Abbott, consulting fees from Tibotec, and trial drugs from GlaxoSmithKline; Dr. Hughes, consulting fees from Boehringer Ingelheim, Pfizer, Medicines Development, and Tibotec and support for a scientific workshop from Merck; Dr. Cotton, lecture fees from Abbott; and Dr. Moultrie, grants from GlaxoSmithKline, ViiV Healthcare, and Tibotec. No other potential conflict of interest relevant to this article was reported.	Aldrovandi GM, 2009, AIDS, V23, P661, DOI 10.1097/QAD.0b013e3283269dfb; Babiker A, 2011, LANCET INFECT DIS, V11, P273, DOI 10.1016/S1473-3099(10)70313-3; Boltz VF, 2011, P NATL ACAD SCI USA, V108, P9202, DOI 10.1073/pnas.1105688108; Buchacz K, 2001, PEDIATRICS, V108, DOI 10.1542/peds.108.4.e72; Coovadia A, 2010, JAMA-J AM MED ASSOC, V304, P1082, DOI 10.1001/jama.2010.1278; Dreimane D, 2001, PEDIATR INFECT DIS J, V20, P315, DOI 10.1097/00006454-200103000-00020; Hunt GM, 2011, AIDS, V25, P1461, DOI 10.1097/QAD.0b013e3283492180; Li JZ, 2011, JAMA-J AM MED ASSOC, V305, P1327, DOI 10.1001/jama.2011.375; Lockman S, 2010, NEW ENGL J MED, V363, P1499, DOI 10.1056/NEJMoa0906626; Luzuriaga K, 1999, J VIROL, V73, P362; Mulenga V, 2010, CLIN INFECT DIS, V51, P1081, DOI 10.1086/656628; Nachman SA, 2002, ARCH PEDIAT ADOL MED, V156, P497; Palumbo P, 2007, J INFECT DIS, V196, P23, DOI 10.1086/518508; Palumbo P, 2010, NEW ENGL J MED, V363, P1510, DOI 10.1056/NEJMoa1000931; Violari A, 2008, NEW ENGL J MED, V359, P2233, DOI 10.1056/NEJMoa0800971; [Anonymous], 2010, ANT THER HIV INF INF	16	86	88	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2012	366	25					2380	2389				10	Medicine, General & Internal	General & Internal Medicine	961GH	WOS:000305451700007	22716976	
J	Ko, TM; Chung, WH; Wei, CY; Shih, HY; Chen, JK; Lin, CH; Chen, YT; Hung, SI				Ko, Tai-Ming; Chung, Wen-Hung; Wei, Chun-Yu; Shih, Han-Yu; Chen, Jung-Kuei; Lin, Chia-Hsien; Chen, Yuan-Tsong; Hung, Shuen-Iu			Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Drug hypersensitivity; T-cell receptor; HLA; third complementarity-determining region; Stevens-Johnson syndrome; toxic epidermal necrolysis	TOXIC EPIDERMAL NECROLYSIS; HLA-B-ASTERISK-1502 ALLELE; DRUG HYPERSENSITIVITY; LIVER-INJURY; HAN CHINESE; OXCARBAZEPINE; RISK; ASSOCIATION; ACTIVATION; CLONES	Background: Stevens-Johnson syndrome (SJS) and its related disease, toxic epidermal necrolysis (TEN), are life-threatening drug hypersensitivities with robust immune responses to drugs. Despite the strong HLA predisposition to drug hypersensitivities, such as HLA-B*1502 to carbamazepine (CBZ)-induced SJS/TEN, it remains unknown whether particular T-cell receptors (TCRs) participate in recognition of small drug/peptide-HLA complexes. Objective: Using the strong HLA predisposition in patients with CBZ-induced SJS/TEN as a model, we aimed to study the use of TCR repertoire in patients with drug hypersensitivity. Method: We enrolled patients with CBZ-SJS/TEN, tolerant control subjects, and healthy subjects who had no history of CBZ exposure. We isolated PBMCs from the subjects, cultured CBZ-specific T cells, and globally investigated the expression level and third complementarity-determining region length distribution of the TCR profile. We further assessed the pathogenic role of the disease-specific clonotype using real-time PCR-based tests and functional analysis. Results: On drug stimulation, CBZ-specific CD8(+) T cells were expanded in vitro and activated to release granulysin. Notably, VB-11-ISGSY was identified as the most predominant clonotype and shared among different subjects. This clonotype was present in 16 (84%) of 19 patients with SJS/TEN, absent in all 17 tolerant patients, and present at a low frequency in healthy subjects (4/29 [14%]). CBZ-specific cytotoxicity could be primed in vitro in the PBMCs of healthy subjects who are carriers of HLA-B*1502 and VB-11-ISGSY; this cytotoxicity could be blocked by an anti-TCR-VB-11 antibody. Furthermore, a single T-cell clone expressing VA-22-FISGTY/VB-11-ISGSY showed significant cytotoxicity against HLA-B*1502-positive antigen-presenting cells and CBZ. Conclusion: This study establishes the key role of the TCR in the pathogenic mechanism of SJS/TEN, explains why some HLA-B*1502 carriers are tolerant to CBZ, and provides a biomarker profile for drug hypersensitivity. (J Allergy Clin Immunol 2011;128:1266-76.)	[Hung, Shuen-Iu] Natl Yang Ming Univ, Inst Pharmacol, Sch Med, Taipei 11221, Taiwan; [Ko, Tai-Ming; Shih, Han-Yu; Chen, Yuan-Tsong] Natl Taiwan Univ, Coll Med, Grad Inst Microbiol, Taipei 10764, Taiwan; [Ko, Tai-Ming; Wei, Chun-Yu; Shih, Han-Yu; Chen, Jung-Kuei; Lin, Chia-Hsien; Chen, Yuan-Tsong; Hung, Shuen-Iu] Acad Sinica, Inst Biomed Sci, Taipei 11529, Taiwan; [Chung, Wen-Hung] Chang Gung Mem Hosp, Dept Dermatol, Taipei 10591, Taiwan; [Hung, Shuen-Iu] Natl Yang Ming Univ, Infect & Immun Res Ctr, Taipei 11221, Taiwan	Hung, SI (reprint author), Natl Yang Ming Univ, Inst Pharmacol, Sch Med, 155 Linong St,Sect 2, Taipei 11221, Taiwan.	chen0010@ibms.sinica.edu.tw; sihung@ym.edu.tw			National Science Council, Taiwan [NSC95-2314-B-010-096, 95-2314-B-182A-048, 95-3112-B-001-010, 95-3112-B-001-011, 96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2, NSC 97-2745-B-010-001, 98-2320-B-010-002-MY3, 98-2314-B-182A-027-MY3]; Taiwanese Ministry of Education; Academia Sinica Thematic Research Program [AS 99 TP B12]; Chang-Gung Memorial Hospital	Supported by grants from the National Science Council, Taiwan (NSC95-2314-B-010-096, 95-2314-B-182A-048, 95-3112-B-001-010, 95-3112-B-001-011, 96-2320-B-010-021-MY2, 96-2628-B-182A-065-MY2, NSC 97-2745-B-010-001, 98-2320-B-010-002-MY3, 98-2314-B-182A-027-MY3); the Taiwanese Ministry of Education (Aim for the Top University Plan, National Yang-Ming University); the Academia Sinica Thematic Research Program (AS 99 TP B12); and Chang-Gung Memorial Hospital.	BERAN RG, 1993, EPILEPSIA, V34, P163, DOI 10.1111/j.1528-1157.1993.tb02392.x; Bousso P, 1998, IMMUNITY, V9, P169, DOI 10.1016/S1074-7613(00)80599-3; Buggy Y, 2010, EPILEPSIA, V51, P818, DOI 10.1111/j.1528-1167.2009.02489.x; Chen P, 2011, NEW ENGL J MED, V364, P1126, DOI 10.1056/NEJMoa1009717; Chessman D, 2008, IMMUNITY, V28, P822, DOI 10.1016/j.immuni.2008.04.020; Chung WH, 2008, NAT MED, V14, P1343, DOI 10.1038/nm.1884; Chung WH, 2004, NATURE, V428, P486, DOI 10.1038/428486a; Currier JR, 2001, CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735.IM1028S38; Daly AK, 2009, NAT GENET, V41, P816, DOI 10.1038/ng.379; Dogan EA, 2008, EPILEPSY BEHAV, V13, P156, DOI 10.1016/j.yebeh.2008.02.001; Ferrell PB, 2008, PHARMACOGENOMICS, V9, P1543, DOI 10.2217/14622416.9.10.1543; Guglielmi L, 2006, CURR PHARM DESIGN, V12, P3309, DOI 10.2174/138161206778194088; Hallmayer J, 2009, NAT GENET, V41, P708, DOI 10.1038/ng.372; Hermansson A, 2010, J EXP MED, V207, P1081, DOI 10.1084/jem.20092243; Hirsch LJ, 2008, NEUROLOGY, V71, P1527, DOI 10.1212/01.wnl.0000334295.50403.4c; Hovhannisyan Z, 2008, NATURE, V456, P534, DOI 10.1038/nature07524; Hunder NN, 2008, NEW ENGL J MED, V358, P2698, DOI 10.1056/NEJMoa0800251; Hung SI, 2010, PHARMACOGENOMICS, V11, P349, DOI [10.2217/pgs.09.162, 10.2217/PGS.09.162]; Hung SL, 2005, P NATL ACAD SCI USA, V102, P4134, DOI 10.1073/pnas.0409500102; Aceves-Avila FJ, 2008, JCR-J CLIN RHEUMATOL, V14, P261, DOI 10.1097/RHU.0b013e31817a241a; Le Louet H, 2008, EUR J NEUROL, V15, pE43, DOI 10.1111/j.1468-1331.2008.02111.x; Locharernkul C, 2008, EPILEPSIA, V49, P2087, DOI 10.1111/j.1528-1167.2008.01719.x; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Man CBL, 2007, EPILEPSIA, V48, P1015, DOI 10.1111/j.1528-1167.2007.01022.x; May TW, 2003, CLIN PHARMACOKINET, V42, P1023, DOI 10.2165/00003088-200342120-00002; Mehta TY, 2009, INDIAN J DERMATOL VE, V75, P579, DOI 10.4103/0378-6323.57718; Morel E, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Morel E, 2010, J ALLERGY CLIN IMMUN, V125, P703, DOI 10.1016/j.jaci.2009.10.030; Mueller DL, 2010, NAT IMMUNOL, V11, P21, DOI 10.1038/ni.1817; Nassif A, 2004, J ALLERGY CLIN IMMUN, V114, P1209, DOI 10.1016/j.jaci.2004.07.047; Ochsenreither S, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-34; PADOVAN E, 1993, SCIENCE, V262, P422, DOI 10.1126/science.8211163; Pichler Werner J, 2006, Allergol Int, V55, P17, DOI 10.2332/allergolint.55.17; Risitano AM, 2004, LANCET, V364, P355, DOI 10.1016/S0140-6736(04)16724-X; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Roujeau Jean-Claude, 2006, Allergol Int, V55, P27, DOI 10.2332/allergolint.55.27; Singer JB, 2010, NAT GENET, V42, P711, DOI 10.1038/ng.632; Wu Y, 2007, J ALLERGY CLIN IMMUN, V119, P973, DOI 10.1016/j.jaci.2006.12.617; Wu Y, 2006, J ALLERGY CLIN IMMUN, V118, P233, DOI 10.1016/j.jaci.2006.03.005; Yang CWO, 2007, J ALLERGY CLIN IMMUN, V120, P870, DOI 10.1016/j.jaci.2007.06.017	40	86	94	1	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2011	128	6					1266	U624		10.1016/j.jaci.2011.08.013		22	Allergy; Immunology	Allergy; Immunology	865WX	WOS:000298342700016	21924464	
J	Kremmyda, LS; Vlachava, M; Noakes, PS; Diaper, ND; Miles, EA; Calder, PC				Kremmyda, Lefkothea-Stella; Vlachava, Maria; Noakes, Paul S.; Diaper, Norma D.; Miles, Elizabeth A.; Calder, Philip C.			Atopy Risk in Infants and Children in Relation to Early Exposure to Fish, Oily Fish, or Long-Chain Omega-3 Fatty Acids: A Systematic Review	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY			English	Review						Atopy; Allergy; Asthma; Eczema; Immune function; Inflammation; Eicosanoid; Cytokine; Fatty acid; Fish oil; Pregnancy	FATTY-ACID-COMPOSITION; RANDOMIZED CONTROLLED-TRIAL; CHILDHOOD ASTHMA PREVENTION; ALLERGIC RHINITIS; DIETARY FACTORS; CORD-BLOOD; EICOSAPENTAENOIC ACID; DOCOSAHEXAENOIC ACID; AIRWAY INFLAMMATION; CYTOKINE PRODUCTION	There are two main families of polyunsaturated fatty acids (PUFAs), the n-6 and the n-3 families. It has been suggested that there is a causal relationship between n-6 PUFA intake and allergic disease, and there are biologically plausible mechanisms, involving eicosanoid mediators of the n-6 PUFA arachidonic acid, that could explain this. Fish and fish oils are sources of long-chain n-3 PUFAs and these fatty acids act to oppose the actions of n-6 PUFAs. Thus, it is considered that n-3 PUFAs will protect against atopic sensitization and against the clinical manifestations of atopy. Evidence to examine this has been acquired from epidemiologic studies investigating associations between fish intake in pregnancy, lactation, infancy, and childhood, and atopic outcomes in infants and children and from intervention studies with fish oil supplements in pregnancy, lactation, infancy, and childhood, and atopic outcomes in infants and children. All five epidemiological studies investigating the effect of maternal fish intake during pregnancy on atopic or allergic outcomes in infants/children of those pregnancies concluded protective associations. One study investigating the effects of maternal fish intake during lactation did not observe any significant associations. The evidence from epidemiological studies investigating the effects of fish intake during infancy and childhood on atopic outcomes in those infants or children is inconsistent, although the majority of the studies (nine of 14) showed a protective effect of fish intake during infancy or childhood on atopic outcomes in those infants/children. Fish oil supplementation during pregnancy and lactation or during infancy or childhood results in a higher n-3 PUFA status in the infants or children. Fish oil provision to pregnant women is associated with immunologic changes in cord blood and such changes may persist. Studies performed to date indicate that provision of fish oil during pregnancy may reduce sensitization to common food allergens and reduce prevalence and severity of atopic dermatitis in the first year of life, with a possible persistence until adolescence with a reduction in eczema, hay fever, and asthma. Fish oil provision to infants or children may be associated with immunologic changes in the blood but it is not clear if these are of clinical significance and whether they persist. Fish oil supplementation in infancy may decrease the risk of developing some manifestations of allergic disease, but this benefit may not persist as other factors come into play. It is not clear whether fish oil can be used to treat children with asthma as the two studies conducted to date give divergent results. Further studies of increased long-chain n-3 PUFA provision in during pregnancy, lactation, and infancy are needed to more clearly identify the immunologic and clinical effects in infants and children and to identify protective and therapeutic effects and their persistence.	[Kremmyda, Lefkothea-Stella; Vlachava, Maria; Noakes, Paul S.; Diaper, Norma D.; Miles, Elizabeth A.; Calder, Philip C.] Univ Southampton, Southampton Gen Hosp MP887, Inst Human Nutr, Southampton SO16 6YD, Hants, England; [Kremmyda, Lefkothea-Stella; Vlachava, Maria; Noakes, Paul S.; Diaper, Norma D.; Miles, Elizabeth A.; Calder, Philip C.] Univ Southampton, Southampton Gen Hosp MP887, Sch Med, Inst Dev Sci, Southampton SO16 6YD, Hants, England	Miles, EA (reprint author), Univ Southampton, Southampton Gen Hosp MP887, Inst Human Nutr, IDS Bldg,Tremona Rd, Southampton SO16 6YD, Hants, England.	E.A.Miles@soton.ac.uk	Calder, Philip/E-9739-2013; Miles, Elizabeth/O-1861-2015	Calder, Philip/0000-0002-6038-710X; Miles, Elizabeth/0000-0002-8643-0655	European Commission [FOOD-CT-2006-16249]	L-SK, MV, PSN, NDD, and EAM are supported by funding from the European Commission under Framework 6 (FOOD-CT-2006-16249).	Alm B, 2009, ARCH DIS CHILD, V94, P11, DOI 10.1136/adc.2008.140418; Almqvist C, 2007, J ALLERGY CLIN IMMUN, V119, P1438, DOI 10.1016/j.jaci.2007.01.046; Andreasyan K, 2005, ALLERGY, V60, P671, DOI 10.1111/j.1398-9995.2005.00757.x; Antova T, 2003, THORAX, V58, P231, DOI 10.1136/thorax.58.3.231; Aoki H, 2008, BIOCHEM BIOPH RES CO, V367, P509, DOI 10.1016/j.bbrc.2008.01.012; Barden AE, 2004, FREE RADICAL RES, V38, P233, DOI 10.1080/10715760310001656722; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; British Nutrition Foundation, 1992, REP TASK FORC UNS FA; Burdge GC, 2006, NUTR RES REV, V19, P26, DOI 10.1079/NRR2005113; Calder PC, 2006, CLIN EXP ALLERGY, V36, P138, DOI 10.1111/j.1365-2222.2006.02433.x; Calder PC, 2000, PEDIATR ALLERGY IMMU, V11, P29, DOI 10.1034/j.1399-3038.2000.00508.x; Calder P. C., 2006, AM J CLIN NUTR, V83, p1505S; Calder PC, 2004, BIOACTIVE LIPIDS, P1; Calder PC, 2007, PROSTAG LEUKOTR ESS, V77, P327, DOI 10.1016/j.plefa.2007.10.015; Calder PC, 2009, BIOFACTORS, V35, P266, DOI 10.1002/biof.42; Calder PC, 2008, PROSTAG LEUKOTR ESS, V79, P101, DOI 10.1016/j.plefa.2008.09.016; Calvani M, 2006, PEDIATR ALLERGY IMMU, V17, P94, DOI 10.1111/j.1399-3038.2005.00367.x; Chatzi L, 2007, PEDIATR ALLERGY IMMU, V18, P480, DOI 10.1111/j.1399-3038.2007.00596.x; Damsgaard CT, 2007, J NUTR, V137, P1031; Demmelmair H, 1998, J LIPID RES, V39, P1389; Denburg JA, 2005, PEDIATR RES, V57, P276, DOI 10.1203/01.PDR.0000148279.72611.1D; Dunder T, 2001, ALLERGY, V56, P425, DOI 10.1034/j.1398-9995.2001.056005425.x; Dunstan JA, 2004, CLIN EXP ALLERGY, V34, P1237, DOI 10.1111/j.1365-2222.2004.02028.x; Dunstan JA, 2004, EUR J CLIN NUTR, V58, P429, DOI 10.1038/sj.ejcn.1601825; Dunstan JA, 2003, CLIN EXP ALLERGY, V33, P442, DOI 10.1046/j.1365-2222.2003.01590.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; Dunstan JA, 2007, PEDIATR RES, V62, P689; Farchi S, 2003, EUR RESPIR J, V22, P772, DOI 10.1183/09031936.03.00006703; Fiore S., 2004, BIOACTIVE LIPIDS, P223; Furuhjelm C, 2009, ACTA PAEDIATR, V98, P1461, DOI 10.1111/j.1651-2227.2009.01355.x; Haworth O, 2008, NAT IMMUNOL, V9, P873, DOI 10.1038/ni.1627; Healy DA, 2000, LIPIDS, V35, P763, DOI 10.1007/s11745-000-0583-1; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Hodge L, 1996, MED J AUSTRALIA, V164, P137; HODGE L, 1994, AUST NZ J MED, V24, P727, DOI 10.1111/j.1445-5994.1994.tb01793.x; Hodge L, 1998, EUR RESPIR J, V11, P361, DOI 10.1183/09031936.98.11020361; Hoppu U, 2005, J PEDIATR GASTR NUTR, V41, P335, DOI 10.1097/01.mpg.0000168992.44428.fa; Huang SL, 2001, CLIN EXP ALLERGY, V31, P259, DOI 10.1046/j.1365-2222.2001.00938.x; Kim JL, 2005, INDOOR AIR, V15, P170, DOI 10.1111/j.1600-0668.2005.00334.x; Krauss-Etschmann S, 2008, J ALLERGY CLIN IMMUN, V121, P464, DOI 10.1016/j.jaci.2007.09.018; Krauss-Etschmann S, 2007, AM J CLIN NUTR, V85, P1392; Kull I, 2006, ALLERGY, V61, P1009, DOI 10.1111/j.1398-9995.2006.01115.x; Larque E, 2006, AM J CLIN NUTR, V84, P853; Lauritzen L, 2005, LIPIDS, V40, P669, DOI 10.1007/s11745-005-1429-6; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTIN JC, 1993, AM J CLIN NUTR, V58, P653; Mihrshahi S, 2003, J ALLERGY CLIN IMMUN, V111, P162, DOI 10.1067/mai.2003.36; Mihrshahi S, 2004, PEDIATR ALLERGY IMMU, V15, P517, DOI 10.1111/j.1399-3038.2004.00187.x; Mihrshahi S, 2001, CONTROL CLIN TRIALS, V22, P333, DOI 10.1016/S0197-2456(01)00112-X; Moore ML, 2006, J ALLERGY CLIN IMMUN, V117, P1036, DOI 10.1016/j.jaci.2005.12.1314; Nafstad P, 2003, J ASTHMA, V40, P343, DOI 10.1081/JAS-120018633; Nagakura T, 2000, EUR RESPIR J, V16, P861, DOI 10.1183/09031936.00.16586100; Prostanoids Nicolaou A., 2004, BIOACTIVE LIPIDS, P197; Olsen SF, 2008, AM J CLIN NUTR, V88, P167; Park GY, 2006, AM J PHYSIOL-LUNG C, V290, pL797, DOI 10.1152/ajplung.00513.2005; Peat JK, 2004, J ALLERGY CLIN IMMUN, V114, P807, DOI 10.1016/j.jaci.2004.06.057; Peterson LD, 1998, LIPIDS, V33, P171, DOI 10.1007/s11745-998-0193-y; Prescott SL, 2007, CLIN SCI, V113, P409, DOI 10.1042/CS20070111; Rees D, 2006, AM J CLIN NUTR, V83, P331; Romieu I, 2007, CLIN EXP ALLERGY, V37, P518, DOI 10.1111/j.1365-2222.2007.02685.x; Salam MT, 2005, J ASTHMA, V42, P513, DOI 10.1081/JAS-200067619; Sausenthaler S, 2007, AM J CLIN NUTR, V85, P530; Serhan CN, 2004, LIPIDS, V39, P1125, DOI 10.1007/s11745-004-1339-7; Serhan CN, 2003, J IMMUNOL, V171, P6856; Takemura Y, 2002, PREV MED, V34, P221, DOI 10.1006/pmed.2001.0978; Tilley SL, 2001, J CLIN INVEST, V108, P15, DOI 10.1172/JCI13416; Vachier I, 2002, BIOCHEM BIOPH RES CO, V290, P219, DOI 10.1006/bbrc.2001.6155; Vaisman N, 2005, EUR CYTOKINE NETW, V16, P194; Warstedt K, 2009, PEDIATR RES, V66, P212, DOI 10.1203/PDR.0b013e3181aabd1c; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Willers S, 2007, THORAX, V62, P746	73	86	87	2	39	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1080-0549			CLIN REV ALLERG IMMU	Clin. Rev. Allergy Immunol.	AUG	2011	41	1					36	66		10.1007/s12016-009-8186-2		31	Allergy; Immunology	Allergy; Immunology	801UZ	WOS:000293467400004	19997989	
J	Forey, BA; Thornton, AJ; Lee, PN				Forey, Barbara A.; Thornton, Alison J.; Lee, Peter N.			Systematic review with meta-analysis of the epidemiological evidence relating smoking to COPD, chronic bronchitis and emphysema	BMC PULMONARY MEDICINE			English	Review								Background: Smoking is a known cause of the outcomes COPD, chronic bronchitis (CB) and emphysema, but no previous systematic review exists. We summarize evidence for various smoking indices. Methods: Based on MEDLINE searches and other sources we obtained papers published to 2006 describing epidemiological studies relating incidence or prevalence of these outcomes to smoking. Studies in children or adolescents, or in populations at high respiratory disease risk or with co-existing diseases were excluded. Study-specific data were extracted on design, exposures and outcomes considered, and confounder adjustment. For each outcome RRs/ORs and 95% CIs were extracted for ever, current and ex smoking and various dose response indices, and meta-analyses and meta-regressions conducted to determine how relationships were modified by various study and RR characteristics. Results: Of 218 studies identified, 133 provide data for COPD, 101 for CB and 28 for emphysema. RR estimates are markedly heterogeneous. Based on random-effects meta-analyses of most-adjusted RR/ORs, estimates are elevated for ever smoking (COPD 2.89, CI 2.63-3.17, n = 129 RRs; CB 2.69, 2.50-2.90, n = 114; emphysema 4.51, 3.38-6.02, n = 28), current smoking (COPD 3.51, 3.08-3.99; CB 3.41, 3.13-3.72; emphysema 4.87, 2.83-8.41) and ex smoking (COPD 2.35, 2.11-2.63; CB 1.63, 1.50-1.78; emphysema 3.52, 2.51-4.94). For COPD, RRs are higher for males, for studies conducted in North America, for cigarette smoking rather than any product smoking, and where the unexposed base is never smoking any product, and are markedly lower when asthma is included in the COPD definition. Variations by sex, continent, smoking product and unexposed group are in the same direction for CB, but less clearly demonstrated. For all outcomes RRs are higher when based on mortality, and for COPD are markedly lower when based on lung function. For all outcomes, risk increases with amount smoked and pack-years. Limited data show risk decreases with increasing starting age for COPD and CB and with increasing quitting duration for COPD. No clear relationship is seen with duration of smoking. Conclusions: The results confirm and quantify the causal relationships with smoking.	[Forey, Barbara A.; Lee, Peter N.] P N Lee Stat & Comp Ltd, Surrey, England	Forey, BA (reprint author), P N Lee Stat & Comp Ltd, Surrey, England.	BarbaraForey@pnlee.co.uk			Philip Morris International, Inc.	This research was funded by Philip Morris International, Inc. However the opinions and conclusions of the authors are their own, and do not necessarily reflect the position of Philip Morris International, Inc. We thank John Fry for assistance with the statistical analysis. We also thank Pauline Wassell, Diana Morris and Yvonne Cooper for assistance in typing the various drafts of the paper and obtaining the relevant literature.	ALDERSON MR, 1985, J EPIDEMIOL COMMUN H, V39, P286, DOI 10.1136/jech.39.4.286; Alderson M.R., 1986, RISK LUNG CANC CHRON; ALESSANDRI C, 1994, THROMB HAEMOSTASIS, V72, P343; Altman DG, 2000, STAT CONFIDENCE; American Thoracic Society, 1991, AM REV RESPIR DIS, V144, P1202, DOI 10.1164/ajrccm/144.5.1202; American Thoracic Society, 1987, AM REV RESPIR DIS, V136, P1285, DOI 10.1164/ajrccm/136.5.1285; American thoracic society, 1995, AM J RESP CRIT CARE, V152, pS77; Amigo H, 2006, REV MED CHILE, V134, P1275, DOI 10.4067/S0034-98872006001000009; ANDERSON AE, 1966, ARCH ENVIRON HEALTH, V12, P569; Anderson D, 1998, MUTAT RES-FUND MOL M, V403, P229, DOI 10.1016/S0027-5107(98)00082-7; Anderson D, 2001, INT J HYG ENVIR HEAL, V204, P55, DOI 10.1078/1438-4639-00073; ANDERSON DO, 1965, CAN MED ASSOC J, V92, P1066; ANDERSON DO, 1962, NEW ENGL J MED, V267, P787, DOI 10.1056/NEJM196210182671601; AUERBACH O, 1974, CHEST, V65, P29, DOI 10.1378/chest.65.1.29; AUERBACH O, 1972, NEW ENGL J MED, V286, P853, DOI 10.1056/NEJM197204202861601; BAKKE PS, 1991, THORAX, V46, P863, DOI 10.1136/thx.46.12.863; BANG K M, 1990, American Journal of Public Health, V80, P1495, DOI 10.2105/AJPH.80.12.1495; BANG KM, 1993, J NATL MED ASSOC, V85, P51; BECK GJ, 1982, AM REV RESPIR DIS, V125, P375; Bednarek M, 2005, RESPIRATION, V72, P142, DOI 10.1159/000084044; Bednarek Michal, 2005, Pneumonol Alergol Pol, V73, P122; Bednarek Michal, 2002, Pneumonol Alergol Pol, V70, P139; BEST EWR, 1967, CAN MED ASSOC J, V96, P1104; BJORNSSON E, 1994, EUR RESPIR J, V7, P2146, DOI 10.1183/09031936.94.07122146; British Thoracic Society, 1997, THORAX S5, V52, P1; Brogger J, 2006, EUR RESPIR J, V27, P682, DOI 10.1183/09031936.06.00057005; BROWN R G, 1957, Br J Prev Soc Med, V11, P162; BURROWS B, 1975, AM REV RESPIR DIS, V112, P365; CAMILLI AE, 1987, AM REV RESPIR DIS, V135, P794; CARSTENSEN JM, 1987, J EPIDEMIOL COMMUN H, V41, P166, DOI 10.1136/jech.41.2.166; Cederlof R, 1975, RELATIONSHIP SMOKING; Cerveri I, 2003, EUR RESPIR J, V22, P413, DOI 10.1183/09031936.03.00121103; Cerveri I, 2001, EUR RESPIR J, V18, P85, DOI 10.1183/09031936.01.00087101; CHAPMAN RS, 1985, AM REV RESPIR DIS, V132, P261; Chen Jiajian, 2003, Health Rep, V14, P9; Chen Y, 2000, J CLIN EPIDEMIOL, V53, P755, DOI 10.1016/S0895-4356(99)00211-5; Chen ZM, 1997, JAMA-J AM MED ASSOC, V278, P1500, DOI 10.1001/jama.278.18.1500; Cheng Xiansheng, 1999, Zhonghua Jiehe He Huxi Zazhi, V22, P290; CLEMENT J, 1982, AM REV RESPIR DIS, V125, P553; COATES EO, 1965, J AMER MED ASSOC, V191, P161; Cocci F, 2002, INT J BIOCHEM CELL B, V34, P594, DOI 10.1016/S1357-2725(02)00015-8; College of General Practitioners, 1961, BMJ-BRIT MED J, V2, P973; Coultas DB, 2001, AM J RESP CRIT CARE, V164, P372; Dahl M, 2001, AM J RESP CRIT CARE, V164, P1008; de Marco R, 2004, THORAX, V59, P120, DOI 10.1136/thorax.2003.011163; de Torres JP, 2006, RESPIRATION, V73, P306, DOI 10.1159/000090051; DEAN G, 1978, J EPIDEMIOL COMMUN H, V32, P86, DOI 10.1136/jech.32.2.86; Dean G, 1978, REPORT 2 RETROSPECTI; Dean G., 1977, 14 TOB RES COUNC; DEANE M, 1965, ARCH ENVIRON HEALTH, V10, P323; DeJong Sandra R, 2004, Clin Nurse Spec, V18, P72, DOI 10.1097/00002800-200403000-00012; Department of National Health and Welfare Canada, 1966, CAN STUD SMOK HLTH C; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; Diaz JIJ, 2003, ARCH BRONCONEUMOL, V39, P554; Dickinson JA, 1999, THORAX, V54, P501; DOCKERY DW, 1988, AM REV RESPIR DIS, V137, P286; DODGE R, 1986, AM REV RESPIR DIS, V133, P981; DOLL R, 1994, BRIT MED J, V309, P901; DOLL R, 1964, BRIT MED J, V1, P1399; DOLL R, 1976, BRIT MED J, V2, P1525; DOLL R, 1980, BRIT MED J, V280, P967; DONTAS AS, 1984, J GERONTOL, V39, P430; DOPICO GA, 1984, AM REV RESPIR DIS, V130, P759; DORN HF, 1959, PUBLIC HEALTH REP, V74, P581, DOI 10.2307/4590516; Dorn HF, 1958, P SOC STAT SECT AM S, P34; Egger M, 1997, BRIT MED J, V315, P629; Ehrlich RI, 2004, INT J TUBERC LUNG D, V8, P369; Eisner Mark D, 2005, Environ Health, V4, P7, DOI 10.1186/1476-069X-4-7; Ekberg-Aronsson M, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-98; ENRIGHT PL, 1994, CHEST, V106, P827, DOI 10.1378/chest.106.3.827; Enstrom JE, 2003, BRIT MED J, V326, P1057, DOI 10.1136/bmj.326.7398.1057; Enstrom JE, 1999, J CLIN EPIDEMIOL, V52, P813; FERRIS BG, 1976, AM REV RESPIR DIS, V113, P475; FERRIS BG, 1973, AM REV RESPIR DIS, V107, P110; FERRIS BG, 1971, AM REV RESPIR DIS, V104, P232; Ferris BJ, 1962, AM REV RESPIR DIS, V864, P165; Fidan F, 2004, TOB CONTROL, V13, P161, DOI 10.1136/tc.2003.003731; Finklea JF, 1974, HLTH CONSEQUENCES SU, P4; FLEISS JL, 1991, J CLIN EPIDEMIOL, V44, P127, DOI 10.1016/0895-4356(91)90261-7; FLETCHER CM, 1959, BRIT MED J, V2, P257; Forastiere F, 1998, AM J RESP CRIT CARE, V157, P1864; Forey B., 2006, INT SMOKING STAT COL; FOXMAN B, 1986, PREV MED, V15, P624, DOI 10.1016/0091-7435(86)90067-8; Fukuchi Y, 2004, RESPIROLOGY, V9, P458, DOI 10.1111/j.1440-1843.2004.00637.x; Gardner MJ, 1989, BRIT MED J; Geijer RMM, 2006, BRIT J GEN PRACT, V56, P656; Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2006, GLOB STRAT DIAGN MAN; Godtfredsen NS, 2002, THORAX, V57, P967, DOI 10.1136/thorax.57.11.967; Goldberg HE, 1974, HLTH CONSEQUENCES SU, P5; Gorecka D, 2001, Pneumonol Alergol Pol, V69, P617; GULSVIK A, 1979, SCAND J RESPIR DIS, V60, P275; GULSVIK A, 1979, SCAND J RESPIR DIS, V60, P286; Gulsvik A, 1979, OBSTRUCTIVE LUNG DIS; HAENSZEL W, 1972, J CHRON DIS, V25, P519, DOI 10.1016/0021-9681(72)90151-8; Hamling J, 2008, STAT MED, V27, P954, DOI 10.1002/sim.3013; HAMMOND E. CUYLER, 1966, NAT CANCER INST MONOGR, V19, P127; HAMMOND EC, 1964, J NATL CANCER I, V32, P1161; Hardie JA, 2005, RESP MED, V99, P186, DOI 10.1016/j.rmed.2004.06.006; Harik-Khan RI, 2002, CHEST, V121, P370, DOI 10.1378/chest.121.2.370; HARRISEZE AOC, 1993, E AFR MED J, V70, P763; HAWTHORNE VM, 1978, J EPIDEMIOL COMMUN H, V32, P260, DOI 10.1136/jech.32.4.260; Hayes CG, 1974, HLTH CONSEQUENCES SU, P3; He Yao, 2002, Zhonghua Liu Xing Bing Xue Za Zhi, V23, P186; Hedlund U, 2004, EUR J EPIDEMIOL, V19, P953, DOI 10.1007/s10654-004-5194-7; Hedman J, 1999, INT J EPIDEMIOL, V28, P717, DOI 10.1093/ije/28.4.717; Henley SJ, 2004, J NATL CANCER I, V96, P853, DOI 10.1093/jnci/djh144; HIGGINS I T, 1958, Tubercle, V39, P296, DOI 10.1016/S0041-3879(58)80092-6; HIGGINS ITT, 1957, BRIT MED J, V2, P1198; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; HIGGINS MW, 1977, AM REV RESPIR DIS, V116, P403; HIGGINS MW, 1982, AM REV RESPIR DIS, V125, P144; HIGGINS MW, 1989, AM REV RESPIR DIS, V140, pS42; Hirayama T, 1982, UICC SMOK CONTR WORK, P2; Hirayama T, 1988, INT C SERIES, V780, P75; Ho SC, 1999, J AM GERIATR SOC, V47, P1445; Holland WW, 1965, AM J EPIDEMIOL, V82, P95; Hollnagel H, 1983, Ugeskr Laeger, V145, P113; Hollnagel H, 1983, Ugeskr Laeger, V145, P118; House DE, 1974, HLTH CONSEQUENCES SU, P2; Hozawa A, 2006, CHEST, V130, P1642, DOI 10.1378/chest.130.6.1642; HRUBEC Z, 1973, ARCH ENVIRON HEALTH, V27, P189; Hrubec Z., 1997, SMOKING TOBACCO CONT, V8, P501; Huchon GJ, 2002, EUR RESPIR J, V20, P806, DOI 10.1183/09031936.02.00042002; HUHTI E, 1980, EUR J RESPIR DIS, V61, P33; HUHTI E, 1978, ANN CLIN RES, V10, P87; Huhti E, 1965, ACTA TUBERC PNEUMO S, P1; Hyman JJ, 2004, J PERIODONTOL, V75, P9, DOI 10.1902/jop.2004.75.1.9; ITABASHI S, 1990, RESPIRATION, V57, P384; Jacobs DR, 1999, ARCH INTERN MED, V159, P733, DOI 10.1001/archinte.159.7.733; Jedrychowski W, 1983, Arch Gerontol Geriatr, V2, P237, DOI 10.1016/0167-4943(83)90027-4; Jensen EJ, 1998, EUR RESPIR J, V11, P670; Jimemez-Ruiz CA, 2004, NICOTINE TOB RES, V6, P649, DOI 10.1080/14622200410001727948; Jimenez-Ruiz CA, 2002, ARCH BRONCONEUMOL, V38, P530; Jindal S K, 2006, Indian J Chest Dis Allied Sci, V48, P23; Johannessen A, 2005, THORAX, V60, P842, DOI 10.1136/thx.2005.043943; Johannessen A, 2005, INT J TUBERC LUNG D, V9, P926; JOSHI RC, 1975, THORAX, V30, P61, DOI 10.1136/thx.30.1.61; Jousilahti P, 1996, LANCET, V348, P567, DOI 10.1016/S0140-6736(96)02374-4; Kachel Tomasz, 2003, Pneumonol Alergol Pol, V71, P428; KAHN HAROLD A., 1966, NAT CANCER INST MONOGR, V19, P1; Kant I. J., 2003, Occupational and Environmental Medicine, V60, pi32, DOI 10.1136/oem.60.suppl_1.i32; Karakatsani A, 2003, EUR J EPIDEMIOL, V18, P45; Katancik JA, 2005, J PERIODONTOL, V76, P2161, DOI 10.1902/jop.2005.76.11-S.2161; KATO I, 1989, INT J EPIDEMIOL, V18, P345, DOI 10.1093/ije/18.2.345; KHOURY MJ, 1986, INT J EPIDEMIOL, V15, P65, DOI 10.1093/ije/15.1.65; Kim DS, 2005, AM J RESP CRIT CARE, V172, P842, DOI 10.1164/rccm.200502-259OC; Kiraz K, 2003, CLIN INVEST MED, V26, P243; KLAYTON R, 1975, AM REV RESPIR DIS, V112, P71; Knuiman MW, 1999, ANN EPIDEMIOL, V9, P297, DOI 10.1016/S1047-2797(98)00066-0; Kojima S, 2005, J EPIDEMIOL, V15, P113, DOI 10.2188/jea.15.113; Kotaniemi J, 2005, COPD, V2, P331, DOI DOI 10.1080/15412550500218122; Kotaniemi Jyrki-Tapani, 2003, Int J Circumpolar Health, V62, P142; KRZYZANOWSKI M, 1986, AM REV RESPIR DIS, V134, P1011; Kubik A, 1984, Czech Med, V7, P25; KULLER LH, 1989, AM REV RESPIR DIS, V140, pS76; Lai CKW, 1995, EUR RESPIR J, V8, P2055, DOI 10.1183/09031936.95.08122055; Lai CKW, 2006, EUR RESPIR J, V27, P846; Lam TH, 1997, JAMA-J AM MED ASSOC, V278, P1505, DOI 10.1001/jama.278.18.1505; Lam TH, 2002, ANN EPIDEMIOL, V12, P316, DOI 10.1016/S1047-2797(01)00258-7; LAMBERT PM, 1970, LANCET, V1, P853; LANGE P, 1990, THORAX, V45, P579, DOI 10.1136/thx.45.8.579; Lange P, 2003, AGE AGEING, V32, P636, DOI 10.1093/ageing/afg108; LANGE P, 1992, EUR RESPIR J, V5, P1111; Langhammer A, 2000, J EPIDEMIOL COMMUN H, V54, P917, DOI 10.1136/jech.54.12.917; LAVECCHIA C, 1988, INT J EPIDEMIOL, V17, P50; LEBOWITZ MD, 1977, AM J EPIDEMIOL, V105, P534; LEBOWITZ MD, 1995, CHEST, V108, P55, DOI 10.1378/chest.108.1.55; LEBOWITZ MD, 1981, AM REV RESPIR DIS, V123, P16; LEBOWITZ MD, 1977, J CHRON DIS, V30, P599, DOI 10.1016/0021-9681(77)90058-3; LEBOWITZ MD, 1977, ENVIRON RES, V14, P59, DOI 10.1016/0013-9351(77)90066-4; LEBOWITZ MD, 1977, INT J EPIDEMIOL, V6, P107, DOI 10.1093/ije/6.2.107; LEE PN, 1981, J EPIDEMIOL COMMUN H, V35, P16, DOI 10.1136/jech.35.1.16; Lee PN, 1999, STAT MED, V18, P1973, DOI 10.1002/(SICI)1097-0258(19990815)18:15<1973::AID-SIM166>3.3.CO;2-7; Lee PN, 1979, MORTALITY SMOKING AS; Lee PN, 2010, BMC MED, V8; Liaw KM, 1998, TOB CONTROL, V7, P141; Lindberg A, 2006, CHEST, V129, P879, DOI 10.1378/chest.129.4.879; Lindberg A, 2006, RESP MED, V100, P264, DOI 10.1016/j.rmed.2005.04.029; Lindstrom M, 2001, CHEST, V119, P852, DOI 10.1378/chest.119.3.852; Liu BQ, 1998, BRIT MED J, V317, P1411; Liu S. M., 2005, ZHONGHUA YI XUE ZA Z, V85, P747; Lokke A, 2006, THORAX, V61, P935, DOI 10.1136/thx.2006.062802; Lundback B, 2003, RESP MED, V97, P115, DOI 10.1053/rmed.2003.1446; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; LUNDBACK B, 1993, EUR J EPIDEMIOL, V9, P123, DOI 10.1007/BF00158781; Mador MJ, 2003, AM J RESP CRIT CARE, V168, P102, DOI 10.1164/rccm.200202-0800OC; Magnusson S, 1999, SCAND J PRIM HEALTH, V17, P100; MANFREDA J, 1989, AM J IND MED, V15, P7, DOI 10.1002/ajim.4700150103; Mannino DM, 2000, ARCH INTERN MED, V160, P1683, DOI 10.1001/archinte.160.11.1683; Mannino DM, 2003, J INTERN MED, V254, P540, DOI 10.1111/j.1365-2796.2003.01211.x; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; Maranetra Khun Nanta, 2002, Journal of the Medical Association of Thailand, V85, P1147; MARCUS EB, 1989, AM REV RESPIR DIS, V140, pS64; Matheson MC, 2006, HUM BIOL, V78, P705, DOI 10.1353/hub.2007.0015; Medical Research Council Committee on the Aetiology of Chronic Bronchitis, 1965, LANCET, V1, P775; Medical Research Council, 1960, BRIT MED J, V2, P1665; MELLSTROM D, 1982, AGE AGEING, V11, P45, DOI 10.1093/ageing/11.1.45; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; MENEZES AMB, 1995, INT J EPIDEMIOL, V24, P95, DOI 10.1093/ije/24.1.95; Menezes Ana Maria Baptista, 2005, Cad. Saúde Pública, V21, P1565, DOI 10.1590/S0102-311X2005000500030; Meren M, 2001, RESP MED, V95, P954, DOI 10.1053/rmed.2001.1188; METZNER HL, 1983, PREV MED, V12, P491, DOI 10.1016/0091-7435(83)90204-9; MILLER A, 1988, CHEST, V94, P1187, DOI 10.1378/chest.94.6.1187; MILNE JS, 1971, BRIT J PREV SOC MED, V25, P37; MILNE JS, 1972, RESPIRATION, V29, P359; Moller W, 2001, EXP LUNG RES, V27, P547, DOI 10.1080/019021401753181827; Montnemery P, 2003, RESP MED, V97, P970, DOI 10.1016/S0954-6111(03)00126-4; Montnemery P, 1998, RESP MED, V92, P1337, DOI 10.1016/S0954-6111(98)90139-1; Montnemery P, 2001, RESP MED, V95, P744, DOI 10.1053/rmed.2001.1129; Moore BA, 2005, J GEN INTERN MED, V20, P33, DOI 10.1111/j.1525-1497.2004.40081.x; MUELLER RE, 1971, AM REV RESPIR DIS, V103, P209; Nawa Takeshi, 2002, Nihon Kokyuki Gakkai Zasshi, V40, P468; Nejjari C, 1996, Monaldi Arch Chest Dis, V51, P373; Niepsuj Grzegorz, 2002, Wiad Lek, V55 Suppl 1, P354; Nihlen U, 2004, RESP MED, V98, P263, DOI 10.1016/j.rmed.2003.10.006; Nihlen U, 1999, SCAND J PRIM HEALTH, V17, P232; Nilsson S, 2001, J EPIDEMIOL COMMUN H, V55, P825, DOI 10.1136/jech.55.11.825; Office of Population Censuses and Surveys, 1980, SER DH2, V5; Ogilvie AG, 1957, CHRONIC BRONCHITIS N; OMENAAS E, 1995, CLIN EXP ALLERGY, V25, P682, DOI 10.1111/j.1365-2222.1995.tb00004.x; Omori H, 2006, RESPIROLOGY, V11, P205, DOI 10.1111/j.1440-1843.2006.00827.x; OSWALD NC, 1955, LANCET, V2, P843; OSWALD NC, 1953, LANCET, V265, P639; PANDEY MR, 1984, THORAX, V39, P331, DOI 10.1136/thx.39.5.331; PANDEY MR, 1984, THORAX, V39, P337, DOI 10.1136/thx.39.5.337; Patel BD, 2004, THORAX, V59, P682, DOI 10.1136/thx.2003.010215; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; PEAT JK, 1990, THORAX, V45, P32, DOI 10.1136/thx.45.1.32; Pelkonen M, 2006, CHEST, V130, P1129, DOI 10.1378/chest.130.4.1129; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701; PETO R, 1983, AM REV RESPIR DIS, V128, P491; POSTMA DS, 1995, ARCH INTERN MED, V155, P1393, DOI 10.1001/archinte.155.13.1393; PRATT PC, 1980, ARCH ENVIRON HEALTH, V35, P133; Prescott E, 1997, EUR RESPIR J, V10, P822; Prescott E I, 1996, Ugeskr Laeger, V158, P6456; Price DB, 2006, RESPIRATION, V73, P285, DOI 10.1159/000090142; REID D. D., 1966, NAT CANCER INST MONOGR, V19, P321; REID DD, 1964, BRIT MED J, V2, P1487; Renwick DS, 1996, THORAX, V51, P164, DOI 10.1136/thx.51.2.164; Riccioni G, 2005, Monaldi Arch Chest Dis, V63, P88; RIMINGTON J, 1974, BRIT J DIS CHEST, V68, P161, DOI 10.1016/S0007-0971(74)80015-X; RIMINGTON J, 1972, BMJ-BRIT MED J, V2, P262; RODRIGUES L, 1990, INT J EPIDEMIOL, V19, P205, DOI 10.1093/ije/19.1.205; ROGOT E, 1989, AM REV RESPIR DIS, V140, pS69; ROGOT E, 1980, PUBLIC HEALTH REP, V95, P213; RYDER RC, 1971, J PATHOL, V104, P59, DOI 10.1002/path.1711040108; Sai Xiao-Yong, 2006, Zhonghua Liu Xing Bing Xue Za Zhi, V27, P765; Sargeant LA, 2000, EUR RESPIR J, V16, P397, DOI 10.1034/j.1399-3003.2000.016003397.x; SAS Institute Inc, GLM PROC SAS STAT US; SAWICKI F, 1972, Epidemiological Review (English Translation of Przeglad Epidemiologiczny), V26, P229; Sawicki F, 1973, USES EPIDEMIOLOGY PL, P652; SCHWARTZ J, 1990, AM J EPIDEMIOL, V132, P67; Shahab L, 2006, THORAX, V61, P1043, DOI 10.1136/thx.2006.064410; SHAHAR E, 1994, NEW ENGL J MED, V331, P228, DOI 10.1056/NEJM199407283310403; Shahar E, 1999, AM J RESP CRIT CARE, V159, P1780; SHARP JT, 1965, AM REV RESPIR DIS, V91, P510; SHARP JT, 1973, AM REV RESPIR DIS, V108, P1066; Shimura S, 1996, EUR RESPIR J, V9, P1395, DOI 10.1183/09031936.96.09071395; Shin C, 2003, CHEST, V123, P1924, DOI 10.1378/chest.123.6.1924; SIAFAKAS NM, 1995, EUR RESPIR J, V8, P1398, DOI 10.1183/09031936.95.08081398; Sichletidis L, 2005, RESPIRATION, V72, P270, DOI 10.1159/000085368; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Sisson JH, 2005, ALCOHOL, V36, P19, DOI 10.1016/j.alcohol.2005.05.002; Sobradillo Pena VS, 2000, CHEST, V118, P981; Sobradillo V, 1999, Arch Bronconeumol, V35, P159; SPEIZER FE, 1989, AM REV RESPIR DIS, V140, pS49; STERLING TD, 1993, AM J EPIDEMIOL, V138, P128; STJERNBERG N, 1985, EUR J RESPIR DIS, V67, P41; Strom K, 1996, Monaldi Arch Chest Dis, V51, P16; Suadicani P, 2001, OCCUP ENVIRON MED, V58, P160, DOI 10.1136/oem.58.3.160; SUTINEN S, 1978, SCAND J RESPIR DIS, V59, P101; TAGER I, 1978, INT J EPIDEMIOL, V7, P55, DOI 10.1093/ije/7.1.55; TAGER IB, 1976, AM REV RESPIR DIS, V113, P619; TANG JL, 1995, BRIT MED J, V311, P1530; Taylor DH, 2002, AM J PUBLIC HEALTH, V92, P990, DOI 10.2105/AJPH.92.6.990; Thun MJ, 1997, SMOKING TOBACCO CONT, P305; Tinkelman DG, 2006, RESPIRATION, V73, P296, DOI 10.1159/000090141; TODD GF, 1978, J EPIDEMIOL COMMUN H, V32, P267, DOI 10.1136/jech.32.4.267; TROISI RJ, 1995, CHEST, V108, P1557, DOI 10.1378/chest.108.6.1557; Trupin L, 2003, EUR RESPIR J, V22, P462, DOI 10.1183/09031936.03.00094203; Tsushima K, 2006, RESP MED, V100, P1360, DOI 10.1016/j.rmed.2005.11.021; TURKELTAUB PC, 1991, ANN ALLERGY, V67, P147; TVERDAL A, 1993, J CLIN EPIDEMIOL, V46, P475, DOI 10.1016/0895-4356(93)90025-V; Tylen U, 2000, RESP MED, V94, P38, DOI 10.1053/rmed.1999.0690; Urrutia Isabel, 2005, Eur J Public Health, V15, P160; U. S. Surgeon General, 1989, DHHS PUBL, VCDC 89-8411; U. S. Surgeon General, 1984, HLTH CONS SMOK CHRON; Vestbo J, 2002, AM J RESP CRIT CARE, V166, P329, DOI 10.1164/rccm.2112048; VIEGI G, 1988, EUR RESPIR J, V1, P311; Viegi G, 2000, CHEST, V117, p339S, DOI 10.1378/chest.117.5_suppl_2.339S; Vikgren J, 2004, ACTA RADIOL, V45, P44, DOI 10.1080/02841850310002970; VIKGREN J, 2003, ACTA RADIOL, V44, P517, DOI 10.1034/j.1600-0455.2003.00105.x; Vineis P, 2005, BRIT MED J, V330, P277, DOI 10.1136/bmj.38327.648472.82; VOLLMER WM, 1989, AM J EPIDEMIOL, V129, P1157; von Hertzen L, 2000, RESP MED, V94, P356, DOI 10.1053/rmed.1999.0715; Wagena EJ, 2004, PSYCHOSOM MED, V66, P729, DOI 10.1097/01.psy.0000138127.00991.ef; Wagena EJ, 2005, PSYCHOSOM MED, V67, P656, DOI 10.1097/01.psy.0000171197.29484.6b; Wald NJ, 1997, BRIT MED J, V314, P1860; Wang Q, 2001, RESPIRATION, V68, P352, DOI 10.1159/000050526; Wang XB, 2005, TRIQUARTERLY, P26; Watson L, 2002, EUR RESPIR J, V20, P313, DOI 10.1183/09031936.02.00256402; WEINKAM JJ, 1992, AM J EPIDEMIOL, V136, P722; WEISS W, 1963, ARCH ENVIRON HEALTH, V7, P538; Wen CP, 2004, PREV MED, V39, P528, DOI 10.1016/j.ypmed.2004.02.010; World Health Organisation, 1967, INT CLASS DIS MAN IN, V1; Wig KL, 1964, INDIAN J CHEST DIS, V6, P183; WILHELMSEN L, 1969, BMJ-BRIT MED J, V3, P553; Wilson David, 2005, Chest, V128, P2035, DOI 10.1378/chest.128.4.2035; Wilson DH, 2004, SOZ PRAVENTIV MED, V49, P406, DOI 10.1007/s00038-004-3075-1; Wojtyniak B, 1984, Z Erkr Atmungsorgane, V163, P274; Woods R K, 2000, Respirology, V5, P257, DOI 10.1046/j.1440-1843.2000.00257.x; WOOLF CR, 1974, CHEST, V66, P652, DOI 10.1378/chest.66.6.652; Xiao D, 2004, CHINESE MED J-PEKING, V117, P661; Xu F, 2005, CHEST, V128, P2818, DOI 10.1378/chest.128.4.2818; XU X, 1994, EUR RESPIR J, V7, P477, DOI 10.1183/09031936.94.07030477; XU XP, 1992, AM REV RESPIR DIS, V146, P1345; Yamaguchi S, 1988, J EPIDEMIOL COMMUNIT, V43, P1; Yuan Jian-Min, 1996, JAMA (Journal of the American Medical Association), V275, P1646, DOI 10.1001/jama.275.21.1646; Zielinski J, 2006, EUR RESPIR J, V27, P833, DOI 10.1183/09031936.06.00025905; Zielinski J, 2001, CHEST, V119, P731, DOI 10.1378/chest.119.3.731; Zielinski Jan, 2005, Pneumonol Alergol Pol, V73, P116; Zietkowski Z, 2005, RESP MED, V99, P816, DOI 10.1016/j.rmed.2004.12.008; Zock JP, 2001, AM J RESP CRIT CARE, V163, P1572; Zoia M C, 1995, Monaldi Arch Chest Dis, V50, P104	324	86	91	3	24	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1471-2466			BMC PULM MED	BMC Pulm. Med.		2011	11								36	10.1186/1471-2466-11-36		61	Respiratory System	Respiratory System	V27DB	WOS:000208592800036	21672193	
J	Fain, S; Schiebler, ML; McCormack, DG; Parraga, G				Fain, Sean; Schiebler, Mark L.; McCormack, David G.; Parraga, Grace			Imaging of Lung Function Using Hyperpolarized Helium-3 Magnetic Resonance Imaging: Review of Current and Emerging Translational Methods and Applications	JOURNAL OF MAGNETIC RESONANCE IMAGING			English	Review						pulmonary MRI; hyperpolarized noble gas; (3)He MRI; COPD; cystic fibrosis asthma	APPARENT DIFFUSION-COEFFICIENT; LONG-RANGE DIFFUSION; OXYGEN-SENSITIVE HE-3-MRI; AIR-FLOW OBSTRUCTION; QUANTITATIVE ASSESSMENT; PROJECTION ACQUISITION; VENTILATION DEFECTS; PULMONARY-FUNCTION; MULTIDETECTOR CT; COLLATERAL PATHS	During the past several years there has been extensive development and application of hyperpolarized helium-3 (HP (3)He) magnetic resonance imaging (MRI) in clinical respiratory indications such as asthma chronic obstructive pulmonary disease cystic fibrosis radiation-induced lung injury and transplantation This review focuses on the state-of-the-art of HP 3He MRI and its application to clinical pulmonary research This is not an overview of the physics of the method as this topic has been covered previously We focus here on the potential of this imaging method and its challenges in demonstrating new types of information that has the potential to influence clinical research and decision making in pulmonary medicine Particular attention is given to functional imaging approaches related to ventilation and diffusion-weighted imaging with applications in chronic obstructive pulmonary disease cystic fibrosis, asthma and radiation-induced lung injury The strengths and challenges of the application of 3He MRI in these indications are discussed along with a comparison to established and emerging imaging techniques	[McCormack, David G.; Parraga, Grace] Robarts Res Inst, Imaging Res Labs, London, ON N6A 5K8, Canada; [McCormack, David G.; Parraga, Grace] Univ Western Ontario, Dept Med Biophys, London, ON, Canada; [McCormack, David G.; Parraga, Grace] Univ Western Ontario, Dept Med Imaging, London, ON, Canada; [McCormack, David G.; Parraga, Grace] Univ Western Ontario, Dept Biomed Engn, London, ON, Canada; [Fain, Sean; Schiebler, Mark L.] Univ Wisconsin, Dept Med Phys, Madison, WI 53706 USA	Parraga, G (reprint author), Robarts Res Inst, Imaging Res Labs, 100 Perth Dr, London, ON N6A 5K8, Canada.		Parraga, Grace/K-6465-2013; Fain, Sean/K-4260-2016	Fain, Sean/0000-0001-5461-0646	Canadian Institutes of Health Research (CIHR) Canadian Lung Association (Ontario Thoracic Society); National Institutes of Health/National Heart Lung and Blood Institute (NHLBI); NHLBI; Hartwell Foundation; Academic Medical Organization of Southwestern Ontario; Canadian Institutes of Health Research Canadian Thoracic Society; Ontario Research Fund	Contract grant sponsors Canadian Institutes of Health Research (CIHR) Canadian Lung Association (Ontario Thoracic Society) National Institutes of Health/National Heart Lung and Blood Institute (NHLBI) SF is supported by the NHLBI the Hartwell Foundation and Sandler Program for Asthma Research GP, is supported by the Academic Medical Organization of Southwestern Ontario Canadian Institutes of Health Research Canadian Thoracic Society and Ontario Research Fund	Abdeen N, 2006, MAGN RESON MED, V56, P255, DOI 10.1002/mrm.20943; ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; Altes TA, 2001, J MAGN RESON IMAGING, V13, P378, DOI 10.1002/jmri.1054; ALTES TA, 2006, P 14 ANN M ISMRM SEA, P1305; Altes Talissa A, 2003, Top Magn Reson Imaging, V14, P231, DOI 10.1097/00002142-200306000-00003; Aysola RS, 2008, CHEST, V134, P1183, DOI 10.1378/chest.07-2779; BACHOFEN H, 1981, ACTA ANAT, V111, P10; Bartel SET, 2008, J APPL PHYSIOL, V104, P1495, DOI 10.1152/japplphysiol.01005.2007; BASSER PJ, 1994, J MAGN RESON SER B, V103, P247, DOI 10.1006/jmrb.1994.1037; Bates EL, 2009, RADIOTHER ONCOL, V93, P32, DOI 10.1016/j.radonc.2009.05.018; Baydur A, 1996, Curr Opin Pulm Med, V2, P370, DOI 10.1097/00063198-199609000-00005; Bear J, 1972, DYNAMICS FLUIDS PORO; BOUCHIAT MA, 1960, PHYS REV LETT, V5, P373, DOI 10.1103/PhysRevLett.5.373; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720; BRADLEY JRO, 2003, J MAGN RESON IMAGING, V17, P142; Brookeman J, 1999, EUR J RADIOL, V9, P21; Cai J, 2007, MAGN RESON MED, V58, P373, DOI 10.1002/mrm.21288; Cai J, 2007, INT J RADIAT ONCOL, V68, P650, DOI 10.1016/j.ijrobp.2007.02.011; Cai J, 2009, INT J RADIAT ONCOL, V75, P276, DOI 10.1016/j.ijrobp.2009.03.051; Chen XJ, 1999, MAGNET RESON MED, V42, P721, DOI 10.1002/(SICI)1522-2594(199910)42:4<721::AID-MRM14>3.0.CO;2-D; Cho A, 2009, SCIENCE, V326, P778, DOI 10.1126/science.326_778; COLEGROVE FD, 1963, PHYS REV, V132, P2561, DOI 10.1103/PhysRev.132.2561; Conradi MS, 2008, ACAD RADIOL, V15, P675, DOI 10.1016/j.acra.2007.09.019; Cox G, 2007, NEW ENGL J MED, V356, P1327, DOI 10.1056/NEJMoa064707; Coxson HO, 2009, AM J RESP CRIT CARE, V180, P588, DOI 10.1164/rccm.200901-0159PP; de Lange EE, 2007, J ALLERGY CLIN IMMUN, V119, P1072, DOI 10.1016/j.jaci.2006.12.659; de Lange EE, 2006, CHEST, V130, P1055, DOI 10.1378/chest.130.4.1055; de Lange EE, 2009, RADIOLOGY, V250, P567, DOI 10.1148/radiol.2502080188; Deninger AJ, 1999, J MAGN RESON, V141, P207, DOI 10.1006/jmre.1999.1902; Deninger AJ, 2002, MAGNET RESON MED, V47, P105, DOI 10.1002/mrm.10032; Diaz S, 2008, J MAGN RESON IMAGING, V27, P763, DOI 10.1002/jmri.21212; Diaz S, 2009, EUR J RADIOL, V71, P257, DOI 10.1016/j.ejrad.2008.04.013; Diaz S, 2009, ACAD RADIOL, V16, P700, DOI 10.1016/j.acra.2008.12.017; Emami Kiarash, 2009, Proc Am Thorac Soc, V6, P431, DOI 10.1513/pats.200902-008AW; Fain SB, 2006, RADIOLOGY, V239, P875, DOI 10.1148/radiol.2393050111; Fain SB, 2005, ACAD RADIOL, V12, P1385, DOI 10.1016/j.acra.2005.08.005; Fain SB, 2008, ACAD RADIOL, V15, P753, DOI 10.1016/j.acra.2007.10.019; Fain SB, 2007, J MAGN RESON IMAGING, V25, P910, DOI 10.1002/jmri.20876; Fazel R, 2009, NEW ENGL J MED, V361, P849, DOI 10.1056/NEJMoa0901249; Fischer MC, 2004, MAGNET RESON MED, V52, P766, DOI 10.1002/mrm.20239; Gast KK, 2008, EUR RADIOL, V18, P530, DOI 10.1007/s00330-007-0778-8; Gee J, 2003, ACAD RADIOL, V10, P1147, DOI 10.1016/S1076-6332(03)00329-5; Gierada DS, 2009, J MAGN RESON IMAGING, V30, P801, DOI 10.1002/jmri.21912; HAPPER W, PHYS REV A, P3092; Hersman FW, 2008, ACAD RADIOL, V15, P683, DOI 10.1016/j.acra.2007.09.020; HODGE CW, 2009, MED DOSIM; Holmes JH, 2008, MAGN RESON MED, V59, P1062, DOI 10.1002/mrm.21437; Holmnes JH, 2009, MAGN RESON MED, V62, P1543, DOI 10.1002/mrm.22150; Ireland RH, 2008, PHYS MED BIOL, V53, P6055, DOI 10.1088/0031-9155/53/21/011; Ireland RH, 2007, INT J RADIAT ONCOL, V68, P273, DOI 10.1016/j.ijrobp.2006.12.068; Jalali A, 2004, MAGNET RESON MED, V51, P291, DOI 10.1002/mrm.10698; Kauczor HU, 1997, JMRI-J MAGN RESON IM, V7, P538, DOI 10.1002/jmri.1880070314; Koumellis P, 2005, J MAGN RESON IMAGING, V22, P420, DOI 10.1002/jmri.20402; Lee EY, 2009, J THORAC IMAG, V24, P110, DOI 10.1097/RTI.0b013e3181909f4a; Lewis TA, 2005, MAGNET RESON MED, V53, P474, DOI 10.1002/mrm.20349; Lutey BA, 2008, RADIOLOGY, V248, P655, DOI 10.1148/radiol.2482071838; MacDonald A, 1978, PHYSL ASPECTS ANAEST; MacFall JR, 1996, RADIOLOGY, V200, P553; Mansson S, 2003, MAGNET RESON MED, V50, P1170, DOI 10.1002/mrm.10649; MATHEW L, 2009, EUR J RADIOL; Mathew L, 2010, MED PHYS, V37, P22, DOI 10.1118/1.3263616; McMahon CJ, 2006, EUR RADIOL, V16, P2483, DOI 10.1007/s00330-006-0311-5; Melo MFV, 2003, J NUCL MED, V44, P1982; MIDDLETON H, 1995, MAGNET RESON MED, V33, P271, DOI 10.1002/mrm.1910330219; Miller GW, 2010, MAGN RESON MED, V63, P127, DOI 10.1002/mrm.22181; Moller HE, 2002, MAGN RESON MED, V47, P1029, DOI 10.1002/mrm.10173; Moore WC, 2007, J ALLERGY CLIN IMMUN, V119, P405, DOI 10.1016/j.jaci.2006.11.639; Morbach AE, 2005, J MAGN RESON IMAGING, V21, P765, DOI 10.1002/jmri.20300; Parraga G, 2008, ACAD RADIOL, V15, P776, DOI 10.1016/j.acra.2008.03.003; Patyal BR, 1997, J MAGN RESON, V126, P58, DOI 10.1006/jmre.1997.1159; Patz S, 2008, ACAD RADIOL, V15, P713, DOI 10.1016/j.acra.2008.01.008; Patz S, 2007, EUR J RADIOL, V64, P335, DOI 10.1016/j.ejrad.2007.08.008; PETERSON E, 2008, P 16 ANN M ISMRM TOR, P26453; Plotkowiak M, 2009, PHILOS T R SOC A, V367, P2347, DOI 10.1098/rsta.2009.0023; Rizi RR, 2004, MAGNET RESON MED, V52, P65, DOI 10.1002/mrm.20136; Ruppert K, 2004, MAGNET RESON MED, V51, P676, DOI 10.1002/mrm.10736; Ruset I. C., 2006, PHYS REV LETT, V96; Saam BT, 2000, MAGNET RESON MED, V44, P174, DOI 10.1002/1522-2594(200008)44:2<174::AID-MRM2>3.3.CO;2-W; Saba OI, 2003, J APPL PHYSIOL, V95, P1063, DOI 10.1152/japplphysiol.00962.2002; Salerno M, 2002, RADIOLOGY, V222, P252; Salerno M, 2001, MAGNET RESON MED, V46, P667, DOI 10.1002/mrm.1244; Samee S, 2003, J ALLERGY CLIN IMMUN, V111, P1205, DOI 10.1067/mai.2003.1544; Sciurba FC., 2004, CHEST, V126, p159S; Sciurba Frank C, 2004, Chest, V126, p117S, DOI 10.1378/chest.126.2_suppl_1.117S; Snell GI, 2003, CHEST, V124, P1073, DOI 10.1378/chest.124.3.1073; Sundaram TA, 2005, MED IMAGE ANAL, V9, P524, DOI 10.1016/j.media.2005.04.002; Tgavalekos NT, 2005, J APPL PHYSIOL, V99, P2388, DOI 10.1152/japplphysiol.00391.2005; Tzeng YS, 2007, MAGN RESON MED, V58, P636, DOI 10.1002/mrm.21285; Tzeng YS, 2009, J APPL PHYSIOL, V106, P813, DOI 10.1152/japplphysiol.01133.2007; van Beek EJR, 2009, EUR RESPIR J, V34, P1311, DOI 10.1183/09031936.00138508; van Beek EJR, 2004, J MAGN RESON IMAGING, V20, P540, DOI 10.1002/jmri.20154; Verbanck S, 2007, J APPL PHYSIOL, V103, P249, DOI 10.1152/japplphysiol.01384.2006; Verbanck S, 2009, J APPL PHYSIOL, V106, P1023, DOI 10.1152/japplphysiol.91479.2008; Voorhees A, 2005, MAGNET RESON MED, V54, P1146, DOI 10.1002/mrm.20682; Walker TG, 1997, REV MOD PHYS, V69, P629, DOI 10.1103/RevModPhys.69.629; Wang C, 2008, MAGN RESON MED, V59, P673, DOI 10.1002/mrm.21543; Wang CB, 2006, MAGN RESON MED, V56, P296, DOI 10.1002/mrm.20944; Wang CB, 2008, J MAGN RESON IMAGING, V28, P80, DOI 10.1002/jmri.21408; Wild JM, 2003, MAGNET RESON MED, V49, P991, DOI 10.1002/mrm.10477; Woodhouse N, 2005, J MAGN RESON IMAGING, V21, P365, DOI 10.1002/jmri.20290; Woods JC, 2006, MAGN RESON MED, V56, P1293, DOI 10.1002/mrm.21076; Woods JC, 2005, J APPL PHYSIOL, V99, P1992, DOI 10.1152/japplphysiol.00185.2005; Yablonskiy DA, 2002, P NATL ACAD SCI USA, V99, P3111, DOI 10.1073/pnas.052594699; Yablonskiy DA, 2009, J APPL PHYSIOL, V107, P1258, DOI 10.1152/japplphysiol.00386.2009	104	86	89	4	38	JOHN WILEY & SONS INC	HOBOKEN	111 RIVER ST, HOBOKEN, NJ 07030 USA	1053-1807			J MAGN RESON IMAGING	J. Magn. Reson. Imaging	DEC	2010	32	6			SI		1398	1408		10.1002/jmri.22375		11	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	691LC	WOS:000285080300013	21105144	
J	Massanari, M; Nelson, H; Casale, T; Busse, W; Kianifard, F; Geba, GP; Zeldin, RK				Massanari, Marc; Nelson, Harold; Casale, Thomas; Busse, William; Kianifard, Farid; Geba, Gregory P.; Zeldin, Robert K.			Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Omalizumab; allergic asthma; immunotherapy; systemic allergic reactions; cluster immunotherapy; cat; dog; house dust mines	ANTI-IGE ANTIBODY; RI EXPRESSION; DOUBLE-BLIND; RHINITIS; CHILDREN	Background: Although specific immunotherapy is a valuable treatment option for patients with allergic asthma, the potential for systemic allergic reactions has limited its use, especially for patients with symptomatic disease. Objective: To evaluate omalizumab's effect on the tolerability of specific immunotherapy in patients with symptomatic persistent asthma not adequately controlled with inhaled corticosteroids. Methods: This multicenter, double-blind, parallel-group study randomized patients to treatment with omalizumab or placebo, after which they received specific immunotherapy to at least I of 3 perennial aeroallergens (cat, dog, and house dust mite) according to a 4-week, 18-injection cluster regimen, followed by 7 weeks of maintenance therapy. The primary efficacy variable, a systemic allergic reaction after immunotherapy, was analyzed by using the Cochrane-Mantel-Haenszel test. Results: A total of 248 randomized patients (126 omalizumab, 122 placebo) received at least I dose of immunotherapy and were evaluated for efficacy. Patients receiving omalizumab experienced significantly fewer systemic allergic reactions to immunotherapy than those receiving placebo (17/126 [13.5%] vs 32/122 [26.2%]; P = .017; 95% CI, 2.91% to 22.56%) and had fewer respiratory-related (grade 3) systemic allergic reactions (6 vs 24, respectively). Grade 4 reactions were reported in 2 patients in each group. More omalizumab patients were able to reach the target maintenance immunotherapy dose (110 [87.3%] vs 88 [72.1%], respectively; P = .004). Conclusion: Use of omalizumab in patients whose asthma was symptomatic despite use of inhaled corticosteroids was associated with fewer systemic allergic reactions to specific immunotherapy and enabled more patients to achieve the target immunotherapy maintenance dose. (J Allergy, Clin Immunol 2010; 125:383-9.)	[Massanari, Marc; Kianifard, Farid; Geba, Gregory P.; Zeldin, Robert K.] Novartis Pharmaceut, E Hanover, NJ 07936 USA; [Nelson, Harold] Natl Jewish Hlth, Denver, CO USA; [Casale, Thomas] Creighton Univ, Omaha, NE 68178 USA; [Busse, William] Univ Wisconsin, Madison, WI 53706 USA	Massanari, M (reprint author), Novartis Pharmaceut, 1 Hlth Plaza,Bldg 419-2326, E Hanover, NJ 07936 USA.	marc.massanari@novartis.com			Novartis Pharmaceuticals Corp; East Hanover, NJ; Genentech. Inc, South San Francisco, Calif; Schering-Plough; Genentech; Ception; AstraZeneca; Novartis; NIH-NIAID; NIH-NHLB1; Centocor; GlaxoSmithKline; MedImmuen	Supported by Novartis Pharmaceuticals Corp, East Hanover, NJ, and Genentech. Inc, South San Francisco, Calif.; Disclosure of potential conflict of interest: M. Massanari, F. Kianifard, and R. K. Zeldin are employed by Novartis. H. Nelson has consultant arrangements with Genentech/Novartis, Abbott Laboratories. MediciNova, AstraZeneca. Amgen, GlaxoSmithKline, Schering-Plough, Dyson, and Sepracor: receives research support from Schering-Plough, Genentech. Ception, and AstraZeneca; and is on the speakers' bureau for GlaxoSmithKline. T. Casale receives research support from Novartis and Genentech. W. Busse has consultant arrangements with Altair. GlaxoSmithKline, Merck. Wyeth, Pfizer, Centocor. Amgen, UCB. Johnson & Johnson, Novartis, AstraZeneca, Eisai. TEVA, CompleWare, KaloBios, Boehringer Ingelheim, and Sandoz and receives research support from the NIH-NIAID, NIH-NHLB1, Novartis, Centocor. GlaxoSmithKline, MedImmuen, and Ception. G. P. Geba is a former employee and current stockholder of Novartis.	Abramson MJ, 2003, COCHRANE DB SYST REV, V4, DOI DOI 10.1002/14651858.CD001186; Adkinson NF, 1999, NEW ENGL J MED, V341, P522, DOI 10.1056/NEJM199908123410710; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; Busse W, 2001, J ALLERGY CLIN IMMUN, V108, P184, DOI 10.1067/mai.2001.117880; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Collet D, 2003, MODELLING SURVIVAL D; Cox L, 2008, J ALLERGY CLIN IMMUN, V122, P432, DOI 10.1016/j.jaci.2008.06.007; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Freedman L S, 1982, Stat Med, V1, P121, DOI 10.1002/sim.4780010204; Global Initiative for Asthma, GINA REP GLOB STRAT; KAMIN W, 2009, PEDIAT ALLE IN PRESS; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; Lachin J. M., 2000, BIOSTATISTICAL METHO; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; MacGlashan DW, 1997, J IMMUNOL, V158, P1438; Muller HL, 1966, J ASTHMA RES, V3, P331; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Prussin C, 2003, J ALLERGY CLIN IMMUN, V112, P1147, DOI 10.1016/j.jaci.2003.10.003; Rolinck-Werninghaus C, 2004, ALLERGY, V59, P973, DOI 10.1111/j.1398-9995.2004.00552.x; Soler M, 2001, EUR RESPIR J, V18, P254, DOI 10.1183/09031936.01.00092101; Stokes M. E., 2000, CATEGORICAL DATA ANA; Walker SM, 2001, J ALLERGY CLIN IMMUN, V107, P87, DOI 10.1067/mai.2001.112027	22	86	88	0	3	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	FEB	2010	125	2					383	389		10.1016/j.jaci.2009.11.022		7	Allergy; Immunology	Allergy; Immunology	558RU	WOS:000274764000016	20159249	
J	Bracken, M; Fleming, L; Hall, P; Van Stiphout, N; Bossley, C; Biggart, E; Wilson, NM; Bush, A				Bracken, M.; Fleming, L.; Hall, P.; Van Stiphout, N.; Bossley, C.; Biggart, E.; Wilson, N. M.; Bush, A.			The importance of nurse-led home visits in the assessment of children with problematic asthma	ARCHIVES OF DISEASE IN CHILDHOOD			English	Article							QUALITY-OF-LIFE; DIFFICULT ASTHMA; RISK-FACTORS; INTERVENTION; SEVERITY; DOCTOR; COSTS	Objective: To evaluate and identify potentially modifiable factors in children with problematic asthma by a nurse-led assessment and home visit. Design: Observational cohort study. Setting: A tertiary paediatric respiratory centre. Patients: 71 children, aged 4.5-17.5 years, with problematic asthma currently under follow-up at a tertiary respiratory centre. Interventions: A nurse-led hospital visit followed by a home visit. Main outcome measures: Identification and attempted change of exacerbating factors so that further investigations and consideration of off-label, potentially toxic, asthma therapies were not necessary. Results: Potentially modifiable factors were identified in 56 (79%) children. Many children had multiple causes for poor control. The most important were ongoing allergen exposure, 22 children (31%); passive or active smoking, 18 children (25%); medication issues including adherence, 34 children (48%); psychosocial factors, 42 families (59%). The home visit contributed valuable information to this assessment. At the home visit house dust mite avoidance measures were found to be inadequate in 84% of those sensitised; medications were not easily available for inspection or were out of date in 23%; 74% of psychology referrals were made after the home visit. In 39 children (55%) the factors identified and the interventions recommended meant that further escalation of treatment was avoided. Conclusions: Nurse-led assessments including a home visit can help identify potentially modifiable factors for poorly controlled symptoms in children with problematic asthma.	[Bracken, M.; Hall, P.; Van Stiphout, N.; Bossley, C.; Biggart, E.; Wilson, N. M.; Bush, A.] Royal Brompton Hosp, Dept Paediat Respirol, London SW3 6NP, England; [Fleming, L.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England	Bush, A (reprint author), Royal Brompton Hosp, Dept Paediat Respirol, Sydney St, London SW3 6NP, England.	a.bush@rbht.nhs.uk					American Thoracic Society, 2000, AM J RESP CRIT CARE, V162, P2341, DOI DOI 10.1164/AJRCCM.162.6.ATS9-00; Barry CA, 2001, SOC SCI MED, V53, P487, DOI 10.1016/S0277-9536(00)00351-8; Bender B, 1997, ANN ALLERG ASTHMA IM, V79, P177; British-Thoracic-Society/ Scottish-Intercollegiate-Guidelines-Network, 2008, THORAX S4, V63, piv1, DOI DOI 10.1136/THX.2008.097741; Bush A, 2008, LANCET, V372, P1019, DOI 10.1016/S0140-6736(08)61422-1; Carter MC, 2001, J ALLERGY CLIN IMMUN, V108, P732, DOI 10.1067/mai.2001.119155; Chung KF, 1999, EUR RESPIR J, V13, P1198; Gotzsche PC, 2008, ALLERGY, V63, P646, DOI 10.1111/j.1398-9995.2008.01690.x; Gotzsche PC, 2007, LANCET, V370, P2100, DOI 10.1016/S0140-6736(07)61899-6; Heaney LG, 2005, RESP MED, V99, P1152, DOI 10.1016/j.rmed.2005.02.013; Horner SD, 2006, J COMMUN HEALTH NURS, V23, P213, DOI 10.1207/s15327655jchn2304_2; Juniper EF, 1996, QUAL LIFE RES, V5, P35, DOI 10.1007/BF00435967; Juniper EF, 1996, QUAL LIFE RES, V5, P27, DOI 10.1007/BF00435966; Milgrom H, 1996, J ALLERGY CLIN IMMUN, V98, P1051, DOI 10.1016/S0091-6749(96)80190-4; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Murray CS, 2006, THORAX, V61, P376, DOI 10.1136/thx.2005.042523; Ogden J, 2004, FAM PRACT, V21, P479, DOI 10.1093/fampra/cmh502; Orrell-Valente JK, 2008, PEDIATRICS, V122, pE1186, DOI 10.1542/peds.2008-0292; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Primomo J, 2006, PUBLIC HEALTH NURS, V23, P234, DOI 10.1111/j.1525-1446.2006.230306.x; Ranganathan SC, 2001, PEDIATR PULM, V31, P114, DOI 10.1002/1099-0496(200102)31:2<114::AID-PPUL1018>3.0.CO;2-O; Richardson LP, 2006, PEDIATRICS, V118, P1042, DOI 10.1542/peds.2006-0249; Serra-Batlles J, 1998, EUR RESPIR J, V12, P1322, DOI 10.1183/09031936.98.12061322; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787; Smith JR, 2005, THORAX, V60, P1003, DOI 10.1136/thx.2005.043877	25	86	88	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0003-9888			ARCH DIS CHILD	Arch. Dis. Child.	OCT	2009	94	10					780	784		10.1136/adc.2008.152140		5	Pediatrics	Pediatrics	497BF	WOS:000270028100007	19546102	
J	Uter, W; Ramsch, C; Aberer, W; Ayala, F; Balato, A; Beliauskiene, A; Fortina, AB; Bircher, A; Brasch, J; Chowdhury, MMU; Coenraads, PJ; Schuttelaar, ML; Cooper, S; Corradin, MT; Elsner, P; English, JSC; Fartasch, M; Mahler, V; Frosch, PJ; Fuchs, T; Gawkrodger, DJ; Gimenez-Arnau, AM; Green, CM; Horne, HL; Jolanki, R; King, CM; Krecisz, B; Kiec-Swierczynska, M; Ormerod, AD; Orton, DI; Peserico, A; Rantanen, T; Rustemeyer, T; Sansom, JE; Simon, D; Statham, BN; Wilkinson, M; Schnuch, A				Uter, Wolfgang; Raemsch, Christiane; Aberer, Werner; Ayala, Fabio; Balato, Anna; Beliauskiene, Aiste; Fortina, Anna Belloni; Bircher, Andreas; Brasch, Jochen; Chowdhury, Mahbub M. U.; Coenraads, Pieter-Jan; Schuttelaar, Marie-Louise; Cooper, Sue; Corradin, Maria Teresa; Elsner, Peter; English, John S. C.; Fartasch, Manige; Mahler, Vera; Frosch, Peter J.; Fuchs, Thomas; Gawkrodger, David J.; Gimenez-Arnau, Ana-Maria; Green, Cathy M.; Horne, Helen L.; Jolanki, Riitta; King, Codagh M.; Krecisz, Beata; Kiec-Swierczynska, Marta; Ormerod, Anthony D.; Orton, David I.; Peserico, Andrea; Rantanen, Tapio; Rustemeyer, Thomas; Sansom, Jane E.; Simon, Dagmar; Statham, Barry N.; Wilkinson, Mark; Schnuch, Axel			The European baseline series in 10 European Countries, 2005/2006-Results of the European Surveillance System on Contact Allergies (ESSCA)	CONTACT DERMATITIS			English	Article						clinical epidemiology; contact allergy; patch testing	PATCH TEST SERIES; MULTIFACTORIAL ANALYSIS; METHYLDIBROMO GLUTARONITRILE; TIXOCORTOL PIVALATE; STANDARD SERIES; RECOMMENDATION; MULTICENTER; FREQUENCY; AGE	Background Continual surveillance based on patch test results has proved useful for the identification of contact allergy. Objectives To provide a current view on the spectrum of contact allergy to important sensitizers across Europe. Patients/Methods Clinical and patch test data of 19 793 patients patch tested in 2005/2006 in the 31 participating departments from 10 European countries (the European Surveillance System on Contact Allergies' (ESSCA) www.essca-dc.org) were descriptively analysed, aggregated to four European regions. Results Nickel sulfate remains the most common allergen with standardized prevalences ranging from 19.7% (central Europe) to 24.4% (southern Europe). While a number of allergens shows limited variation across the four regions, such as Myroxylon pereirae (5.3-6.8%), cobalt chloride (6.2-8.8%) or thiuram mix (1.7-2.4%), the differences observed with other allergens may hint on underlying differences in exposures, for example: dichromate 2.4% in the UK (west) versus 4.5-5.9% in the remaining EU regions, methylchloroisothiazolinone/methylisothiazolinone 4.1% in the South versus 2.1-2.7% in the remaining regions. Conclusions Notwithstanding residual methodological variation (affecting at least some 'difficult' allergens) tackled by ongoing efforts for standardization, a comparative analysis as presented provides (i) a broad overview on contact allergy frequencies and (ii) interesting starting points for further, in-depth investigation.	[Uter, Wolfgang; Raemsch, Christiane] Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, D-91054 Erlangen, Germany; [Aberer, Werner] Med Univ Graz, Dept Dermatol, Graz, Austria; [Ayala, Fabio; Balato, Anna] Univ Naples Federico 2, Dept Dermatol, Naples, Italy; [Beliauskiene, Aiste] Kaunas Univ Med, Dept Skin & Venereal Dis, Kaunas, Lithuania; [Fortina, Anna Belloni] Univ Padua, Dept Pediat, Dermatol Unit, I-35100 Padua, Italy; [Bircher, Andreas] Univ Basel Hosp, Allergy Unit, Dept Dermatol, Basel, Switzerland; [Brasch, Jochen] Univ Schleswig Holstein, Dept Dermatol, Lubeck, Germany; [Chowdhury, Mahbub M. U.] Univ Wales Hosp, Welsh Inst Dermatol, Cardiff CF4 4XW, S Glam, Wales; [Coenraads, Pieter-Jan; Schuttelaar, Marie-Louise] Univ Groningen, Univ Med Ctr Groningen, Dept Dermatol, Groningen, Netherlands; [Cooper, Sue] Slade Hosp, Oxford, England; [Corradin, Maria Teresa] S Maria delgi Angeli Hosp, Dermatol Unit, Pordenone, Italy; [Elsner, Peter] Univ Jena, Dept Dermatol & Allergol, Jena, Germany; [English, John S. C.] Queens Med Ctr, Dept Dermatol, Nottingham NG7 2UH, England; [Fartasch, Manige; Mahler, Vera] Univ Erlangen Nurnberg, Dept Dermatol, D-8520 Erlangen, Germany; [Frosch, Peter J.] Dept Dermatol, Dortmund, Germany; [Frosch, Peter J.] Univ Witten Herdecke, Witten, Germany; [Fuchs, Thomas] Univ Gottingen, Dept Dermatol, D-3400 Gottingen, Germany; [Gawkrodger, David J.] Royal Hallamshire Hosp, Dept Dermatol, Sheffield S10 2JF, S Yorkshire, England; [Gimenez-Arnau, Ana-Maria] Univ Autonoma Barcelona, IMAS, Hosp del Mar, Dept Dermatol, Barcelona, Spain; [Green, Cathy M.] Univ Dundee, Ninewells Hosp & Med Sch, Dept Dermatol, Dundee DD1 9SY, Scotland; [Horne, Helen L.] James Cook Univ Hosp, Middlesbrough, Cleveland, England; [Jolanki, Riitta] FIOH, Helsinki, Finland; [King, Codagh M.] Royal Liverpool Univ Hosp, Liverpool, Merseyside, England; [Krecisz, Beata; Kiec-Swierczynska, Marta] Nofer Inst, Dept Dermatol, Lodz, Poland; [Ormerod, Anthony D.] Aberdeen Royal Infirm, Dept Dermatol, Aberdeen, Scotland; [Peserico, Andrea] Univ Padua, Dept Dermatol, I-35100 Padua, Italy; [Rantanen, Tapio] Paijat Hame Cent Hosp, Dept Dermatol, Lahti, Finland; [Rustemeyer, Thomas] Free Univ Amsterdam, Dept Dermatol, NL-1081 HV Amsterdam, Netherlands; [Sansom, Jane E.] Royal Brisbane Hosp, Dept Dermatol, Brisbane, Qld, Australia; [Simon, Dagmar] Univ Hosp Bern, Dept Dermatol, Inselspital, CH-3010 Bern, Switzerland; [Statham, Barry N.] Abertawe Bromorgannwg Univ NHS Trust, Dept Dermatol, Swansea, W Glam, Wales; [Wilkinson, Mark] Gen Infirm, Dept Dermatol, Leeds LS1 3EX, W Yorkshire, England; [Schnuch, Axel] Univ Gottingen, Informat Network Dept Dermatol IVDK, D-3400 Gottingen, Germany	Uter, W (reprint author), Univ Erlangen Nurnberg, Dept Med Informat Biometry & Epidemiol, Waldstr 6, D-91054 Erlangen, Germany.	wolfgang.uter@imbe.med.uni-erlangen.de	Krecisz, Beata/G-4920-2010; Kiec-Swierczynska, Marta/G-4928-2010; Brasch, Jochen/A-9559-2010	Ayala, Fabio/0000-0002-2596-1268; Balato, Anna/0000-0001-5485-0172; Uter, Wolfgang/0000-0002-4498-3710			Bruze M, 2005, CONTACT DERMATITIS, V52, P24, DOI 10.1111/j.0105-1873.2005.00482.x; Bruze M, 1999, CONTACT DERMATITIS, V41, P241, DOI 10.1111/j.1600-0536.1999.tb06154.x; Bruze M, 2008, CONTACT DERMATITIS, V58, P129, DOI 10.1111/j.1600-0536.2007.01292.x; Buckley DA, 2003, BRIT J DERMATOL, V149, P986, DOI 10.1111/j.1365-2133.2003.05491.x; Hasan T, 2005, CONTACT DERMATITIS, V53, P40, DOI 10.1111/j.0105-1873.2005.00630.x; Hegewald J, 2008, J EUR ACAD DERMATOL, V22, P174; Isaksson M, 2000, CONTACT DERMATITIS, V43, P41; Johansen JD, 2008, CONTACT DERMATITIS, V59, P48, DOI 10.1111/j.1600-0536.2008.01364.x; Jong CT, 2007, CONTACT DERMATITIS, V57, P165, DOI 10.1111/j.1600-0536.2007.01181.x; Kalavala M, 2007, CONTACT DERMATITIS, V57, P44, DOI 10.1111/j.1600-0536.2007.01136.x; Menezes de Padua CA, 2005, PHARMACOEPIDEM DR S, V14, P725, DOI 10.1002/pds.1117; Schnuch A, 1996, CONTACT DERMATITIS, V34, P377, DOI 10.1111/j.1600-0536.1996.tb02236.x; Thyssen JP, 2007, CONTACT DERMATITIS, V56, P185, DOI 10.1111/j.1600-0536.2006.01058.x; Uter W, 2004, CONTACT DERMATITIS, V51, P47, DOI 10.1111/j.0105-1873.2004.00406.x; Uter W, 2005, CONTACT DERMATITIS, V53, P136, DOI 10.1111/j.0105-1873.2005.00673.x; Uter W, 2003, CONTACT DERMATITIS, V49, P270, DOI 10.1111/j.0105-1873.2003.0225n.x; Uter W, 2003, CONTACT DERMATITIS, V48, P33, DOI 10.1034/j.1600-0536.46.s4.29_102.x; Uter W, 2001, OCCUP ENVIRON MED, V58, P392, DOI 10.1136/oem.58.6.392; Uter W, 2008, CONTACT DERMATITIS, V59, P56, DOI 10.1111/j.1600-0536.2007.01313.x; Wahlberg JE, 2006, CONTACT DERMATITIS, P365, DOI 10.1007/3-540-31301-X_22	20	86	88	0	10	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0105-1873			CONTACT DERMATITIS	Contact Dermatitis		2009	61	1					31	38				8	Allergy; Dermatology	Allergy; Dermatology	471IZ	WOS:000268052000004	19659962	
J	von Mutius, E; Radon, K				von Mutius, Erika; Radon, Katja			Living on a farm: Impact on asthma induction and clinical course	IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA			English	Article							COMMUNITY RESPIRATORY HEALTH; YOUNG DANISH FARMERS; TOLL-LIKE RECEPTOR-2; SCHOOL-AGE-CHILDREN; ATOPIC SENSITIZATION; ALLERGIC DISEASES; INVERSE ASSOCIATION; HAY-FEVER; EUROPEAN FARMERS; NONATOPIC ASTHMA	Exposure to a farming environment protects individuals from respiratory allergy The timing and duration of exposure seem to play critical roles. The largest reduction in risk of developing respiratory allergies is seen among those who are exposed prenatally and continuously thereafter. Contact with farm animals, at least in childhood, likely confers protection; other factors have not been completely identified. Also, the consumption of milk directly from the farm during childhood has been shown to be beneficial with respect to childhood asthma and allergies. Increased levels of microbial substances may contribute to the protective effects. The mechanisms by which such environmental exposures confer protection from respiratory allergies are not well understood. A number of gene-by-environment interactions have been observed with polymorphisms in genes of innate immunity receptors and exposure to farming environments. Increased levels of microbial exposures recognized by innate immune responses may affect adaptive immune responses resulting in decreased levels of atopic sensitization and asthma.	[von Mutius, Erika] Univ Childrens Hosp, D-80337 Munich, Germany; [Radon, Katja] Univ Munich, Unit Occupat & Environm Epidemiol & Net Teaching, Inst & Outpatient Clin Occupat Social & Environm, Ctr Clin, D-80336 Munich, Germany	von Mutius, E (reprint author), Univ Childrens Hosp, Lindwurmstr 4, D-80337 Munich, Germany.	erika.von.mutius@med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515			Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; Asher MI, 1998, EUR RESPIR J, V12, P315; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2002, ALLERGY, V57, P1094, DOI 10.1034/j.1398-9995.2002.23644.x; Brightbill HD, 2000, IMMUNOLOGY, V101, P1, DOI 10.1046/j.1365-2567.2000.00093.x; CHANYEUNG M, 2008, PEDIAT ALLERGY IMMUN; Dimich-Ward H, 2006, CLIN EXP ALLERGY, V36, P1122, DOI 10.1111/j.1365-2222.2006.02556.x; Dorevitch S, 2007, ANN ALLERG ASTHMA IM, V98, P440; Douwes J, 2007, ALLERGY, V62, P1158, DOI 10.1111/j.1398-9995.2007.01490.x; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Downs SH, 2001, CLIN EXP ALLERGY, V31, P570, DOI 10.1046/j.1365-2222.2001.01070.x; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, AM J IND MED, V46, P396, DOI 10.1002/ajim.20088; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Eisen E A, 1995, Med Lav, V86, P125; Ernst P, 2000, AM J RESP CRIT CARE, V161, P1563; Erwin EA, 2005, J ALLERGY CLIN IMMUN, V115, P74, DOI 10.1016/j.jaci.2004.10.030; Hersoug LG, 2007, ALLERGY, V62, P1205, DOI 10.1111/j.1398-9995.2007.01506.x; HOPPIN LA, 2008, AM J RESP CRIT CARE, V177, P11; Horak F, 2002, CLIN EXP ALLERGY, V32, P1155, DOI 10.1046/j.1365-2745.2002.01448.x; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; Janson C, 2007, J ALLERGY CLIN IMMUN, V120, P673, DOI 10.1016/j.jaci.2007.05.003; Kilpelainen M, 2000, CLIN EXP ALLERGY, V30, P201; Kilpelainen M, 2002, ALLERGY, V57, P1130, DOI 10.1034/j.1398-9995.2002.23341.x; Kilpelainen M, 2001, RESP MED, V95, P911, DOI 10.1053/rmed.2001.1175; Klintberg B, 2001, EUR RESPIR J, V17, P1151, DOI 10.1183/09031936.01.00027301; Koskela HO, 2005, OCCUP ENVIRON MED, V62, P607, DOI 10.1136/oem.2004.014852; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Le Moual N, 2008, AM J RESP CRIT CARE, V177, P4, DOI 10.1164/rccm.200703-415PP; Leonardi S, 2007, ALLERGY ASTHMA PROC, V28, P410, DOI 10.2500/aap.2007.28.2954; Leynaert B, 2001, AM J RESP CRIT CARE, V164, P1829; Leynaert B, 2006, J ALLERGY CLIN IMMUN, V118, P658, DOI 10.1016/j.jaci.2006.06.015; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Midodzi WK, 2007, RESPIROLOGY, V12, P692, DOI 10.1111/j.1440-1843.2007.01134.x; Monso E, 2000, AM J RESP CRIT CARE, V162, P1246; Monso E, 2003, EUR RESPIR J, V21, P323, DOI 10.1183/09031936.03.00070803; Naleway Allison L, 2004, Clin Med Res, V2, P5; Omland O, 1999, EUR RESPIR J, V13, P31, DOI 10.1183/09031936.99.13103199; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Perzanowski MS, 2006, J ALLERGY CLIN IMMUN, V117, P1082, DOI 10.1016/j.jaci.2005.12.1348; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; Portengen L, 2005, J ALLERGY CLIN IMMUN, V115, P797, DOI 10.1016/j.jaci.2004.11.046; Portengen L, 2002, CLIN EXP ALLERGY, V32, P247, DOI 10.1046/j.1365-2222.2002.01310.x; Radon K, 2006, ALLERGY, V61, P443, DOI 10.1111/j.1398-9995.2006.00995.x; Radon K, 2006, OCCUP ENVIRON MED, V63, P73, DOI 10.1136/oem.2004.017616; Radon K, 2004, AM J IND MED, V46, P349, DOI 10.1002/ajim.20000; Radon K, 2004, CLIN EXP ALLERGY, V34, P1178, DOI 10.1111/j.1365-2222.2004.02005.x; Radon K, 2002, ANN AGR ENV MED, V9, P207; Radon K, 2001, EUR RESPIR J, V17, P747, DOI 10.1183/09031936.01.17407470; RADON K, ALLERGY IN PRESS; Radon K, 2006, J ALLERGY CLIN IMMUN, V118, P1279, DOI 10.1016/j.jaci.2006.08.033; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Schulze A, 2007, EUR RESPIR J, V29, P1169, DOI 10.1183/09031936.00127906; Smit LAM, 2007, CLIN EXP ALLERGY, V37, P1602, DOI 10.1111/j.1365-2222.2007.02831.x; SMIT LA, 2008, EUR RESP J; Smit LAM, 2007, OCCUP ENVIRON MED, V64, P101, DOI 10.1136/oem.2006.028167; STERN DA, 2006, J ALL CLIN IMMUNOL; Sunyer J, 2004, J ALLERGY CLIN IMMUN, V114, P1033, DOI 10.1016/j.jaci.2004.05.072; Takeda K, 2005, INT IMMUNOL, V17, P1, DOI 10.1093/intimm/dxh186; van Strien RT, 2004, J ALLERGY CLIN IMMUN, V113, P860, DOI 10.1016/j.jaci.2004.01.078; Von Ehrenstein OS, 2000, CLIN EXP ALLERGY, V30, P187; von Mutius E, 2007, SEMIN RESP CRIT CARE, V28, P255, DOI 10.1055/s-2007-981646; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358; vonMutius E, 1996, BRIT MED J, V312, P1448; Weinmayr G, 2007, AM J RESP CRIT CARE, V176, P565, DOI 10.1164/rccm.200607-994OC; Wickens K, 2002, ALLERGY, V57, P1171, DOI 10.1034/j.1398-9995.2002.t01-1-23644.x; Zhao TB, 2000, J PAEDIATR CHILD H, V36, P128, DOI 10.1046/j.1440-1754.2000.00457.x	73	86	87	3	20	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0889-8561			IMMUNOL ALLERGY CLIN	Immunol. Allerg. Clin. North Am.	AUG	2008	28	3					631	+		10.1016/j.iac.2008.03.010		19	Allergy; Immunology	Allergy; Immunology	334IF	WOS:000258214800011	18572111	
J	Salo, PM; Arbes, SJ; Crockett, PW; Thorne, PS; Cohn, RD; Zeldin, DC				Salo, Paeivi M.; Arbes, Samuel J.; Crockett, Patrick W.; Thorne, Peter S.; Cohn, Richard D.; Zeldin, Darryl C.			Exposure to multiple indoor allergens in US homes and its relationship to asthma	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						allergen; indoor exposure; asthma; allergy	HOUSE-DUST MITE; INNER-CITY CHILDREN; 1ST NATIONAL-SURVEY; ALTERNARIA-ALTERNATA; MOUSE ALLERGEN; ENVIRONMENTAL INTERVENTION; COCKROACH ALLERGEN; UNITED-STATES; DOG ALLERGEN; SENSITIZATION	Background: The National Survey of Lead and Allergens in Housing was the first population-based study to measure indoor allergen levels in US homes. Objective: We characterized the overall burden to multiple allergens and examined whether increased allergen levels were associated with occupants' asthma status. Methods: This cross-sectional study surveyed a nationally representative sample of 831 housing units in 75 different locations throughout the United States. Information was collected by means of questionnaire and environmental assessment. Allergen concentrations in dust samples were assessed by using immunoassays. The following cutoff points were used to define increased allergen levels: 10 mu g/g for Der p 1, Der f 1, and Can f 1; 8 mu g/g for Fel d 1; 8 U/g for Bla g 1; 1.6 mu g/g for mouse urinary protein; and 7 mu g/g for Alternaria alternata antigens. Allergen burden was considered high when 4 or more allergens exceeded increased levels in any of the sampling locations. Results: Exposure to multiple allergens was common in US homes. Of the surveyed homes, 51.5% had at least 6 detectable allergens and 45.8% had at least 3 allergens exceeding increased levels. Race, income, housing type, absence of children, and presence of smokers, pets, cockroaches, rodents, and mold/moisture-related problems were independent predictors of high allergen burden. Among atopic subjects, high allergen burden increased the odds of having asthma symptoms (odds ratio, 1.81; 95% CI, 1.04-3.15). Conclusion: Increased allergen levels in the home are associated with asthma symptoms in allergic individuals.	[Salo, Paeivi M.; Zeldin, Darryl C.] NIEHS, NIH, Res Triangle Pk, NC 27709 USA; [Arbes, Samuel J.] Rho Inc, Chapel Hill, NC USA; [Crockett, Patrick W.; Cohn, Richard D.] Constella Grp LLC, Durham, NC USA; [Thorne, Peter S.] Univ Iowa, Coll Publ Hlth, Iowa City, IA USA	Zeldin, DC (reprint author), NIEHS, NIH, 111 Alexander Dr,Mail Drop D2-01, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov			Intramural NIH HHS [Z01 ES025041-10]		Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Arbes SJ, 2003, J ALLERGY CLIN IMMUN, V111, P408, DOI 10.1067/mai.2003.16; Barnes C, 2006, ANN ALLERG ASTHMA IM, V97, P350; Breysse PN, 2005, ENVIRON RES, V98, P167, DOI 10.1016/j.envres.2004.07.018; Chew GL, 1999, ALLERGY, V54, P1058, DOI 10.1034/j.1398-9995.1999.00003.x; Cho SH, 2006, SCI TOTAL ENVIRON, V371, P31, DOI 10.1016/j.scitotenv.2006.09.001; Cohn RD, 2006, ENVIRON HEALTH PERSP, V114, P522, DOI 10.1289/ehp.8561; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; Committee on Damp Indoor Spaces and Health, 2004, DAMP IND SPAC HLTH; Crain EF, 2002, ENVIRON HEALTH PERSP, V110, P939; Custovic A, 1998, CLIN EXP ALLERGY, V28, P53; Elliott L, 2007, ENVIRON HEALTH PERSP, V115, P215, DOI 10.1289/ehp.9412; Gergen PJ, 2001, J ALLERGY CLIN IMMUN, V107, pS445, DOI 10.1067/mai.2001.114992; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Huss K, 2001, J ALLERGY CLIN IMMUN, V107, P48, DOI 10.1067/mai.2001.111146; Institute of Medicine Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; Illi S, 2006, LANCET, V368, P763, DOI 10.1016/S0140-6736(06)69286-6; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; Kitch BT, 2000, ENVIRON HEALTH PERSP, V108, P301, DOI 10.2307/3454347; Langley SJ, 2003, J ALLERGY CLIN IMMUN, V112, P362, DOI 10.1067/mai.2003.1654; Leaderer BP, 2002, ENVIRON HEALTH PERSP, V110, P419; Leech JA, 2002, J EXPO ANAL ENV EPID, V12, P427, DOI 10.1038/sj.jea.7500244; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V105, pS628; Perry TT, 2006, ANN ALLERG ASTHMA IM, V97, P628; Peters JL, 2007, J URBAN HEALTH, V84, P185, DOI 10.1007/s11524-006-9146-2; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; Rogers L, 2002, CHEST, V122, P1580, DOI 10.1378/chest.122.5.1580; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Salo PM, 2006, J ALLERGY CLIN IMMUN, V118, P892, DOI 10.1016/j.jaci.2006.07.037; Salo PM, 2005, J ALLERGY CLIN IMMUN, V116, P623, DOI 10.1016/j.jaci.2005.05.030; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; Thorne PS, 2005, AM J RESP CRIT CARE, V172, P1371, DOI 10.1164/rccm.200505-758OC; Vojta PJ, 2002, ENVIRON HEALTH PERSP, V110, P527; 2005, TOBACCO USE ADULTS U; 2000, SELF REPORTED ASTHMA	39	86	90	2	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2008	121	3					678	684		10.1016/j.jaci.2007.12.1164		7	Allergy; Immunology	Allergy; Immunology	273GR	WOS:000253918900021	18255132	
J	Arbex, MA; Martins, LC; de Oliveira, RC; Pereira, LAA; Arbex, FF; Cancado, JED; Saldiva, PHN; Braga, ALF				Arbex, Marcos Abdo; Martins, Lourdes Conceicao; de Oliveira, Regiani Carvalho; Amador Pereira, Luiz Alberto; Arbex, Flavio Ferlin; Delfini Cancado, Jose Eduardo; Nascimento Saldiva, Paulo Hilario; Ferreira Braga, Alfesio Luis			Air pollution from biomass burning and asthma hospital admissions in a sugar cane plantation area in Brazil	JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH			English	Article; Proceedings Paper	ALA/ATS International Conference	MAY, 2005	San Diego, CA	ALA, ATS			EMERGENCY-ROOM VISITS; CYTOKINE PRODUCTION; CHILDREN; POPULATION; CALIFORNIA; SYMPTOMS; EXPOSURE; SEATTLE; HAZE; UTAH	Objective: To evaluate the association between the total suspended particles (TSPs) generated from preharvest sugar cane burning and hospital admission due to asthma ( asthma hospital admissions) in the city of Araraquara. Design: An ecological time-series study. Total daily records of asthma hospital admissions (ICD 10th J15) were obtained from one of the main hospitals in Araraquara, Sao Paulo State, Brazil, from 23 March 2003 to 27 July 2004. The daily concentration of TSP (mu g/m(3)) was obtained using Handi-vol equipment (Energetica, Brazil) placed in downtown Araraquara. The local airport provided the daily mean figures of temperature and humidity. The daily number of asthma hospital admissions was considered as the dependent variable in Poisson's regression models and the daily concentration of TSP was considered the independent variable. The generalised linear model with natural cubic spline was adopted to control for long-time trend. Linear terms were used for weather variables. Results: TSP had an acute effect on asthma admissions, starting 1 day after TSP concentrations increased and remaining almost unchanged for the next four days. A 10 mu g/m(3) increase in the 5-day moving average (lag1-5) of TSP concentrations was associated with an increase of 11.6% (95% CI 5.4 to 17.7) in asthma hospital admissions. Conclusion: Increases in TSP concentrations were definitely associated with asthma hospital admissions in Araraquara and, despite using sugar cane alcohol to reduce air pollution from automotive sources in large Brazilian urban centres, the cities where sugar cane is harvested pay a high toll in terms of public health.	Univ Sao Paulo, Fac Med, Lab Poluicao Atmosfer Expt, Nucleo Estudos Epidemiol Ambiental, Sao Paulo, Brazil; Univ Fed Sao Paulo, Escola Paulista Med, Grp Fisiopatol Resp & Poluicao Ambiental, Sao Paulo, Brazil; Univ Catolica Santos, Programa Posgrad Saude Coletiva, Santos, SP, Brazil; Univ Santo Amaro, Fac Med, Programa Pediat Ambiental, Sao Paulo, Brazil; ABC, Fac Med, Dept Saude Coletividade, Santo Andre, SP, Brazil	Braga, ALF (reprint author), Rua Francisco Octavio Pacca 180,4 Andar, BR-04822030 Sao Paulo, SP, Brazil.	abraga@unisa.br	Carvalho Oliveira, Regiani/B-8471-2012; Saldiva, Paulo/D-7385-2012; Braga, Alfesio/G-6920-2012	Saldiva, Paulo/0000-0003-2005-8253; Braga, Alfesio/0000-0003-3254-3029			Akaike H, 1973, 2 INT S INF THEOR, P267, DOI DOI 10.1007/978-1-4612-1694-0_; Anderson HR, 1998, THORAX, V53, P842; Arbex MA, 2000, J AIR WASTE MANAGE, V50, P1745, DOI 10.1080/10473289.2000.10464211; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Bascom R, 1996, AM J RESP CRIT CARE, V153, P3; BATES DV, 1987, ENVIRON RES, V43, P317, DOI 10.1016/S0013-9351(87)80032-4; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Becker S, 1996, TOXICOL APPL PHARM, V141, P637, DOI 10.1006/taap.1996.0330; Cancado JE, 2006, ENVIRON HEALTH PERSP, V114, P725, DOI 10.1289/ehp.8485; Carter JD, 1997, TOXICOL APPL PHARM, V146, P180, DOI 10.1006/taap.1997.8254; Centers for Disease Control and Prevention, 1998, CDC SURVEILL SUMM, V47, P1; CHEW FT, 1995, LANCET, V346, P1427, DOI 10.1016/S0140-6736(95)92443-4; DUCLOS P, 1990, ARCH ENVIRON HEALTH, V45, P53; Etzel RA, 2003, PEDIATRICS, V112, P233; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; GREEN PJ, 1994, NON PARAMETRIC REGRE; HOSIOKANGAS J, 1995, J AEROSOL SCI, V26, pS423, DOI 10.1016/0021-8502(95)97119-Y; JOHNSTON FH, 2002, MED J AUSTRALIA, V176, P536; Koenig JQ, 1999, J ALLERGY CLIN IMMUN, V104, P717; Lara LBLS, 2001, ATMOS ENVIRON, V35, P4937, DOI 10.1016/S1352-2310(01)00198-4; Lin CA, 2003, ENVIRON RES, V92, P57, DOI 10.1016/S0013-9351(02)00054-3; Lin M, 2002, ENVIRON HEALTH PERSP, V110, P575; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Long WQ, 1998, CHEST, V113, P351, DOI 10.1378/chest.113.2.351; Magnus P, 1997, BRIT MED J, V314, P1795; Martins MCH, 2004, J EPIDEMIOL COMMUN H, V58, P41, DOI 10.1136/jech.58.1.41; MASSAD E, 1986, ENVIRON RES, V40, P479, DOI 10.1016/S0013-9351(86)80123-2; McCullagh P., 1989, GEN LINEAR MODELS; Migliaretti G, 2005, INT ARCH OCC ENV HEA, V78, P164, DOI 10.1007/s00420-004-0569-3; National Academy of Science, 2000, CLEAR AIR ASTHM IND; NORRIS G, 1999, ENV HLTH PERSPECT, V107, P389; PONKA A, 1991, ARCH ENVIRON HEALTH, V46, P262; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Samet J M, 2000, Res Rep Health Eff Inst, V94, P5; Schwartz J, 2000, EPIDEMIOLOGY, V11, P320, DOI 10.1097/00001648-200005000-00016; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWELA DH, 1909, HLTH GUIDELINES VEGE; Sheppard L, 1999, EPIDEMIOLOGY, V10, P23, DOI 10.1097/00001648-199901000-00006; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213; TSENG RYM, 1992, ANN ALLERGY, V68, P425; U.S. EPA, 2004, AIR QUAL CRIT PART M; VICENT R, 1997, AM J PATHOL, V151, P1563; WARD D, 1997, REC CONC C MISS; WARDLAW AJ, 1993, CLIN EXP ALLERGY, V23, P81, DOI 10.1111/j.1365-2222.1993.tb00303.x	45	86	95	2	23	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0143-005X			J EPIDEMIOL COMMUN H	J. Epidemiol. Community Health	MAY	2007	61	5					395	400		10.1136/jech.2005.044743		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	156YM	WOS:000245685800008	17435205	
J	Poulsen, LK; Hummelshoj, L				Poulsen, Lars K.; Hummelshoj, Lone			Triggers of IgE class switching and allergy development	ANNALS OF MEDICINE			English	Review						allergy; asthma; B lymphocytes; class switch recombination; IgE; OX40 ligand; Th2 lymphocytes; TSLP	HUMAN B-CELLS; SINGLE-STRANDED-DNA; ANTI-CD40 MONOCLONAL-ANTIBODIES; IMMUNOGLOBULIN-SECRETING CELLS; EPSILON GERMLINE TRANSCRIPTS; CYTIDINE DEAMINASE AID; REGULATORY T-CELLS; TOTAL SERUM IGE; PLASMA-CELL; IFN-GAMMA	The prevalence of immunoglobulin E (IgE)-mediated allergic diseases has been increasing for the last four decades. In this review determinants for an increased IgE synthesis are discussed on both an epidemiological and on an immunological level with special emphasis on the differentiation of the B cell to an IgE-producing plasma cell. Factors that favor an IgE immune response are low antigen doses and immunization via mucous membranes, but it is highly likely that other environmental factors besides exposure to the allergenic sources play a role. Important factors in the formation of the Thelper type 2 (Th2) T cell subset are the actions of thymic stromal lymphopoietin (TSLP) on dendritic cells and the OX40 ligand on CD4+ T cells. In order for a B lymphocyte to switch to IgE production it needs two signals provided by a Th2 cell in the form of the cytokines interleukin (IL-) 4/IL-13 and ligation of the CD40. In spite of a half-life of only a few days, there is evidence that the IgE response may last for years even without allergen stimulation. This is likely to be caused by long-lived IgE-producing plasma cells, and such cells may be difficult to target therapeutically thus emphasizing the need for more knowledge on preventable causes of IgE- and allergy development.	Natl Univ Hosp, Allergy Clin, Lab Med Allergy, Copenhagen, Denmark	Poulsen, LK (reprint author), Natl Univ Hosp, Allergy Clin, Dept 7551, Lab Med Allergy, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.	lkpallgy@mail.dk					Alm JS, 1999, LANCET, V353, P1485, DOI 10.1016/S0140-6736(98)09344-1; Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462; ARMITAGE RJ, 1993, J IMMUNOL, V150, P3671; Asao H, 2001, J IMMUNOL, V167, P1; Asseman C, 1999, J EXP MED, V190, P995, DOI 10.1084/jem.190.7.995; Bacharier LB, 1998, INT ARCH ALLERGY IMM, V115, P257, DOI 10.1159/000069456; BANCHEREAU J, 1995, BEHR INST MITT, P58; BARBERIS A, 1990, GENE DEV, V4, P849, DOI 10.1101/gad.4.5.849; BEHRINGWERKE AG, 1985, ENZYGNOST IGE ENZYMI; BERCIANO FA, 1987, ALLERGY, V42, P276, DOI 10.1111/j.1398-9995.1987.tb02210.x; BERNFIELD M, 1990, PHILOS T ROY SOC B, V327, P171, DOI 10.1098/rstb.1990.0052; Bhalla RB, 1982, ADV INTERPRETATION C, P295; Bodtger U, 2003, J ALLERGY CLIN IMMUN, V111, P149, DOI 10.1067/mai.2003.37; Bodtger Uffe, 2004, Curr Opin Allergy Clin Immunol, V4, P5, DOI 10.1097/00130832-200402000-00003; Bossen C, 2006, J BIOL CHEM, V281, P13964, DOI 10.1074/jbc.M601553200; BOSSIE A, 1991, CELL IMMUNOL, V135, P95, DOI 10.1016/0008-8749(91)90257-C; Brandt K, 2003, BLOOD, V102, P4090, DOI 10.1182/blood-2003-03-0669; Brandt K, 2003, J INVEST DERMATOL, V121, P1379, DOI 10.1046/j.1523-1747.2003.12603.x; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pns.0730835100; BRIERE F, 1994, J EXP MED, V179, P757, DOI 10.1084/jem.179.2.757; Calame KL, 2003, ANNU REV IMMUNOL, V21, P205, DOI 10.1146/annurev.immunol.21.120601.141138; Calame KL, 2001, NAT IMMUNOL, V2, P1103, DOI 10.1038/ni1201-1103; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Conti P, 2003, IMMUNOL LETT, V86, P123, DOI 10.1016/S0165-2478(03)00002-6; COSMAN D, 1994, STEM CELLS, V12, P440; Daniels GA, 1995, NUCLEIC ACIDS RES, V23, P5006, DOI 10.1093/nar/23.24.5006; deBoer BA, 1997, INFECT IMMUN, V65, P1122; DEFRANCE T, 1992, J EXP MED, V175, P671, DOI 10.1084/jem.175.3.671; Di Noia J, 2002, NATURE, V419, P43, DOI 10.1038/nature00981; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; DRESKIN SC, 1987, J CLIN INVEST, V79, P1764, DOI 10.1172/JCI113017; Duchosal MA, 1997, SEMIN HEMATOL, V34, P2; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Dumoutier L, 2000, J IMMUNOL, V164, P1814; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Fear DJ, 2004, J IMMUNOL, V173, P4529; Fickenscher H, 2002, TRENDS IMMUNOL, V23, P89, DOI 10.1016/S1471-4906(01)02149-4; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; Fujieda S, 1996, MOL IMMUNOL, V33, P1335, DOI 10.1016/S0161-5890(96)00092-2; Garraud O, 1996, B I PASTEUR, V94, P285, DOI 10.1016/S0020-2452(97)87084-4; GASCAN H, 1991, J IMMUNOL, V147, P8; GAUCHAT JF, 1990, J EXP MED, V172, P463, DOI 10.1084/jem.172.2.463; GAUCHAT JF, 1992, INT IMMUNOL, V4, P397, DOI 10.1093/intimm/4.3.397; HAGEL I, 1993, CLIN EXP IMMUNOL, V94, P80; HALLGREN R, 1983, ACTA MED SCAND, V213, P99; Hansen D, 1993, Pediatr Allergy Immunol, V4, P30, DOI 10.1111/j.1399-3038.1993.tb00062.x; Hansen TK., 2004, P 9 INT S IMM CHEM C; Henderson A, 1998, ANNU REV IMMUNOL, V16, P163, DOI 10.1146/annurev.immunol.16.1.163; Heyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487; HOLFORDSTREVENS V, 1984, J ALLERGY CLIN IMMUN, V73, P516, DOI 10.1016/0091-6749(84)90363-4; Holt PG, 2004, NAT IMMUNOL, V5, P695, DOI 10.1038/ni0704-695; Hummelshoj L, 2006, SCAND J IMMUNOL, V64, P40, DOI 10.1111/j.1365-3083.2006.01773.x; Iciek LA, 1997, J IMMUNOL, V158, P4769; Ito T, 2005, J EXP MED, V202, P1213, DOI 10.1084/jem.20051135; Ito T, 2006, P NATL ACAD SCI USA, V103, P13138, DOI 10.1073/pnas.0603107103; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; JABARA HH, 1990, J EXP MED, V172, P1861, DOI 10.1084/jem.172.6.1861; JANEWAY J, 1997, HUMORAL IMMUNE RESPO, V8, P51; Johansson SGO, 2005, ALLERGY, V60, P1192, DOI 10.1111/j.1398-9995.2005.00870.x; Johnsen CR, 1997, OCCUP ENVIRON MED, V54, P671; JUNG S, 1993, SCIENCE, V259, P984, DOI 10.1126/science.8438159; Kampen GT, 1999, ALLERGY, V54, P171, DOI 10.1034/j.1398-9995.1999.00775.x; KARASUYAMA H, 1994, CELL, V77, P133, DOI 10.1016/0092-8674(94)90241-0; KARTASAMITA CB, 1994, J ALLERGY CLIN IMMUN, V94, P981, DOI 10.1016/0091-6749(94)90116-3; Kasaian MT, 2002, IMMUNITY, V16, P559, DOI 10.1016/S1074-7613(02)00295-9; KELSOE G, 1993, CURR OPIN IMMUNOL, V5, P418, DOI 10.1016/0952-7915(93)90062-W; Kenter AL, 2003, CURR OPIN IMMUNOL, V15, P190, DOI 10.1016/S0952-7915(03)00018-9; KINIWA M, 1992, J CLIN INVEST, V90, P262, DOI 10.1172/JCI115846; KITANI A, 1994, J IMMUNOL, V153, P1466; KJELLMAN NIM, 1976, CLIN ALLERGY, V6, P51, DOI 10.1111/j.1365-2222.1976.tb01411.x; KJELLMAN NIM, 1984, ALLERGY, V39, P443, DOI 10.1111/j.1398-9995.1984.tb01966.x; KLINK M, 1990, J ALLERGY CLIN IMMUN, V85, P440, DOI 10.1016/0091-6749(90)90153-U; Kotenko SV, 2002, CYTOKINE GROWTH F R, V13, P223, DOI 10.1016/S1359-6101(02)00012-6; Kovanen PE, 2004, IMMUNOL REV, V202, P67, DOI 10.1111/j.0105-2896.2004.00203.x; Krause TG, 2002, LANCET, V360, P691, DOI 10.1016/S0140-6736(02)09841-0; LEBMAN DA, 1988, J EXP MED, V168, P853, DOI 10.1084/jem.168.3.853; LINDBERG RE, 1986, J ALLERGY CLIN IMMUN, V78, P614, DOI 10.1016/0091-6749(86)90078-3; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; LUTZKER S, 1988, MOL CELL BIOL, V8, P1849; LYNCH NR, 1993, J INVEST ALLERG CLIN, V3, P96; Macpherson AJ, 2004, NAT REV IMMUNOL, V4, P478, DOI 10.1038/nri1373; Malisan F, 1996, J EXP MED, V183, P937, DOI 10.1084/jem.183.3.937; Matricardi PM, 2000, BRIT MED J, V320, P412, DOI 10.1136/bmj.320.7232.412; Matricardi PM, 1997, BRIT MED J, V314, P999; McHeyzer-Williams MG, 1999, CURR OPIN IMMUNOL, V11, P172, DOI 10.1016/S0952-7915(99)80029-6; MCINTYRE TM, 1995, J IMMUNOL, V154, P3156; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Morrison AM, 1998, SEMIN IMMUNOL, V10, P133, DOI 10.1006/smim.1998.0115; MOSMANN TR, 1986, J IMMUNOL, V136, P2348; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nutt S L, 2001, Int Rev Immunol, V20, P65, DOI 10.3109/08830180109056723; Nutt SL, 1999, NATURE, V401, P556; Ober C, 2006, GENES IMMUN, V7, P95, DOI 10.1038/sj.gene.6364284; Oettgen HC, 2000, CURR OPIN IMMUNOL, V12, P618, DOI 10.1016/S0952-7915(00)00153-9; Olesen AB, 2001, LANCET, V357, P1749, DOI 10.1016/S0140-6736(00)04896-0; Ozaki K, 2002, SCIENCE, V298, P1630, DOI 10.1126/science.1077002; Parrish-Novak J, 2000, NATURE, V408, P57; PAULL BR, 1978, J IMMUNOL, V120, P1917; Paulsen E, 1997, ALLERGY, V52, P656, DOI 10.1111/j.1398-9995.1997.tb01045.x; PEDERSEN M, 1990, THESIS KOBENHAVNS U; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; Pene J, 2004, J IMMUNOL, V172, P5154; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; POULSEN LK, 1989, ALLERGY, V44, P178; PUNNONEN J, 1993, ALLERGY, V48, P189, DOI 10.1111/j.1398-9995.1993.tb00712.x; PUNNONEN J, 1994, J IMMUNOL, V152, P1094; QUELLE FW, 1995, MOL CELL BIOL, V15, P3336; Rada C, 2002, CURR BIOL, V12, P1748, DOI 10.1016/S0960-9822(02)01215-0; Ramirez MA, 1919, J AMER MED ASSOC, V73, P984; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; RIDLEY RC, 1993, BLOOD, V81, P767; Riedl MA, 2005, J IMMUNOL, V174, P7440; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; ROLINK A, 1991, EUR J IMMUNOL, V21, P2609, DOI 10.1002/eji.1830211044; Romagnani S, 1997, CURR OPIN IMMUNOL, V9, P773, DOI 10.1016/S0952-7915(97)80176-8; SAVLIWALA MN, 1987, J ALLERGY CLIN IMMUN, V80, P741, DOI 10.1016/0091-6749(87)90296-X; SCHELLENBERG RR, 1975, J IMMUNOL, V115, P1577; SCHINDLER C, 1994, EMBO J, V13, P1350; Seong SY, 2004, NAT REV IMMUNOL, V4, P469, DOI 10.1038/nri1372; Shapiro-Shelef M, 2005, NAT REV IMMUNOL, V5, P230, DOI 10.1038/nri1572; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; Skov PS, 1997, PEDIATR ALLERGY IMMU, V8, P156, DOI 10.1111/j.1399-3038.1997.tb00171.x; Stavnezer J, 1996, CURR OPIN IMMUNOL, V8, P199, DOI 10.1016/S0952-7915(96)80058-6; STAVNEZER J, 1988, P NATL ACAD SCI USA, V85, P7704, DOI 10.1073/pnas.85.20.7704; STAVNEZER J, 1995, J IMMUNOL, V155, P1647; STAVNEZERNORDGREN J, 1986, EMBO J, V5, P95; Steinman L, 2007, NAT MED, V13, P139, DOI 10.1038/nm1551; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Suto A, 2002, BLOOD, V100, P4565, DOI 10.1182/blood-2002-04-1115; Szczeklik A, 1996, CLIN EXP ALLERGY, V26, P303; Takei M, 2007, BIOCHEM BIOPH RES CO, V355, P603, DOI 10.1016/j.bbrc.2007.01.157; Thomas MD, 2006, CELL IMMUNOL, V239, P92, DOI 10.1016/j.cellimm.2006.04.007; Tirosh A, 2006, ANN INTERN MED, V144, P877; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; van der Kleij D, 2002, J BIOL CHEM, V277, P48122, DOI 10.1074/jbc.M206941200; VANVLASSELAER P, 1992, J IMMUNOL, V148, P2062; Wabl M, 1987, Immunol Rev, V96, P91, DOI 10.1111/j.1600-065X.1987.tb00511.x; Wahn U, 1997, J ALLERGY CLIN IMMUN, V99, P763, DOI 10.1016/S0091-6749(97)80009-7; WALDMANN TA, 1970, IMMUNOGLOBULINS BIOL, P33; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; WARREN WD, 1995, J IMMUNOL, V155, P5637; Wick KR, 2000, MOL IMMUNOL, V37, P641, DOI 10.1016/S0161-5890(00)00088-2; Wood N, 2004, CELL IMMUNOL, V231, P133, DOI 10.1016/j.cellimm.2005.01.001; Wu JH, 1996, J IMMUNOL, V157, P3404; XU LX, 1994, INT IMMUNOL, V6, P515, DOI 10.1093/intimm/6.4.515; Yazdanbakhsh M, 2004, CLIN REV ALLERG IMMU, V26, P15, DOI 10.1385/CRIAI:26:1:15; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Yu KF, 2003, NAT IMMUNOL, V4, P442, DOI 10.1038/ni919; ZEISS CR, 1973, J IMMUNOL, V110, P414	159	86	94	1	15	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	0785-3890			ANN MED	Ann. Med.		2007	39	6					440	456		10.1080/07853890701449354		17	Medicine, General & Internal	General & Internal Medicine	222NR	WOS:000250304700004	17852040	
J	Wigle, DT; Arbuckle, TE; Walker, M; Wade, MG; Liu, SL; Krewski, D				Wigle, Donald T.; Arbuckle, Tye E.; Walker, Mark; Wade, Michael G.; Liu, Shiliang; Krewski, Daniel			Environmental hazards: Evidence for effects on child health	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART B-CRITICAL REVIEWS			English	Review							BLOOD LEAD LEVELS; ACUTE LYMPHOBLASTIC-LEUKEMIA; NUTRITION EXAMINATION SURVEY; ADVERSE PREGNANCY OUTCOMES; PARTICULATE AIR-POLLUTION; DISINFECTION BY-PRODUCTS; WASTE LANDFILL SITES; BASAL-CELL CARCINOMA; INTRAUTERINE GROWTH-RETARDATION; PARENTAL OCCUPATIONAL EXPOSURES	The human fetus, child, and adult may experience adverse health outcomes from parental or childhood exposures to environmental toxicants. The fetus and infant are especially vulnerable to toxicants that disrupt developmental processes during relatively narrow time windows. This review summarizes knowledge of associations between child health and development outcomes and environmental exposures, including lead, methylmercury, polychlorinated biphenyls (PCBs), dioxins and related polyhalogenated aromatic hydrocarbons (PHAHs), certain pesticides, environmental tobacco smoke (ETS), aeroallergens, ambient air toxicants (especially particulate matter [PM] and ozone), chlorination disinfection by-products (DBPs), sunlight, power-frequency magnetic fields, radiofrequency (RF) radiation, residential proximity to hazardous waste disposal sites, and solvents. The adverse health effects linked to such exposures include fetal death, birth defects, being small for gestational age (SGA), preterm birth, clinically overt cognitive, neurologic, and behavioral abnormalities, subtle neuropsychologic deficits, childhood cancer, asthma, other respiratory diseases, and acute poisoning. Some environmental toxicants, notably lead, ionizing radiation, ETS, and certain ambient air toxicants, produce adverse health effects at relatively low exposure levels during fetal or child developmental time windows. For the many associations supported by limited or inadequate epidemiologic evidence, major sources of uncertainty include the limited number of studies conducted on specific exposure-outcome relationships and methodologic limitations. The latter include (1) crude exposure indices, (2) limited range of exposure levels, (3) small sample sizes, and (4) limited knowledge and control of potential confounders. Important knowledge gaps include the role of preconceptual paternal exposures, a topic much less studied than maternal or childhood exposures. Large longitudinal studies beginning before or during early pregnancy are urgently needed to accurately measure and assess the relative importance of parental and childhood exposures and evaluate relatively subtle health outcomes such as neuropsychologic and other functional deficits. Large case-control studies are also needed to assess the role of environmental exposures and their interactions with genetic factors in relatively uncommon outcomes such as specific types of birth defects and childhood cancers. There is also an urgent need to accelerate development and use of biomarkers of exposure and genetic susceptibility in epidemiologic studies. This review supports the priority assigned by international agencies to relationships between child health and air quality (indoor and outdoor), lead, pesticides, water contaminants, and ETS. To adequately address such priorities, governments and agencies must strengthen environmental health research capacities and adopt policies to reduce parental and childhood exposures to proven and emerging environmental threats.	Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Ottawa, ON K1N 6N5, Canada; Hlth Canada, Healthy Environm & Consumer Safety Branch, Ottawa, ON K1A 0L2, Canada; Univ Ottawa, Fac Med, Dept Obstet & Gynecol, Ottawa, ON K1N 6N5, Canada; Publ Hlth Agcy Canada, Ctr Hlth Human Dev, Ottawa, ON, Canada	Wigle, DT (reprint author), Univ Ottawa, McLaughlin Ctr Populat Hlth Risk Assessment, Room 318B,1 Stewart St, Ottawa, ON K1N 6N5, Canada.	don.wigle@sympatico.ca		Wade, Michael/0000-0002-7331-3839			Acquavella JF, 2006, EPIDEMIOLOGY, V17, P69, DOI 10.1097/01.ede.0000190603.52867.22; Adams PF, 1999, VITAL HLTH STAT, V10, P1; Agency for Toxic Substances and Disease Registry, 2005, TOX PROF LEAD DRAFT; Agency for Toxic Substances and Disease Registry, 1999, TOX PROF MERC UPD; Ahlbom A, 2000, BRIT J CANCER, V83, P692, DOI 10.1054/bjoc.2000.1376; Ahmad SA, 2001, ENVIRON HEALTH PERSP, V109, P629, DOI 10.2307/3455038; Alaluusua S, 1999, LANCET, V353, P206, DOI 10.1016/S0140-6736(05)77214-7; Aligne CA, 2003, JAMA-J AM MED ASSOC, V289, P1258, DOI 10.1001/jama.289.10.1258; American Academy of Pediatrics Committee on Environmental Health, 2003, PED ENV HLTH; AMINZAKI L, 1979, AM J DIS CHILD, V133, P172; Anderson HR, 1997, THORAX, V52, P1003; Arbuckle TE, 1998, CRIT REV TOXICOL, V28, P229, DOI 10.1080/10408449891344218; Arbuckle TE, 1999, EPIDEMIOLOGY, V10, P752, DOI 10.1097/00001648-199911000-00017; Arbuckle TE, 2004, EPIDEMIOLOGY, V15, P187, DOI 10.1097/01.ede.0000112212.01931.81; Arbuckle TE, 2001, ENVIRON HEALTH PERSP, V109, P851, DOI 10.2307/3454830; Astakhova LN, 1998, RADIAT RES, V150, P349, DOI 10.2307/3579983; Ballew C, 1999, J PEDIATR-US, V134, P623, DOI 10.1016/S0022-3476(99)70250-7; Becker K, 2002, INT J HYG ENVIR HEAL, V205, P297, DOI 10.1078/1438-4639-00155; Bell EM, 2001, EPIDEMIOLOGY, V12, P148, DOI 10.1097/00001648-200103000-00005; BELLINGER D, 1988, NEUROTOXICOL TERATOL, V10, P497, DOI 10.1016/0892-0362(88)90084-0; Bellinger DC, 2003, NEW ENGL J MED, V349, P500; Bellinger DC, 2004, PEDIATRICS, V113, P1016; Berkowitz GS, 2004, ENVIRON HEALTH PERSP, V112, P388, DOI 10.1289/ehp.6414; Berlin CM, 2002, J TOXICOL ENV HEAL A, V65, P1839, DOI 10.1080/00984100290071748; BERNARD AM, 1995, ENVIRON RES, V68, P91, DOI 10.1006/enrs.1995.1012; Bhatia R, 2005, ENVIRON HEALTH PERSP, V113, P220, DOI 10.1289/ehp.7382; Binkova B, 2004, EFFECTS AIR POLLUTIO; Borja-Aburto VH, 1999, AM J EPIDEMIOL, V150, P590; Bove F, 2002, ENVIRON HEALTH PERSP, V110, P61; Brain JD, 2003, ENVIRON HEALTH PERSP, V111, P962, DOI 10.1289/ehp.6020; Branum AM, 2003, ENVIRON HEALTH PERSP, V111, P642, DOI 10.1289/ehp.5781; Brauer M, 2002, AM J RESP CRIT CARE, V166, P1092, DOI 10.1164/rccm.200108-007OC; Brender J, 2002, J OCCUP ENVIRON MED, V44, P650, DOI 10.1097/01.jom.0000023382.41727.7b; Brent RL, 2004, PEDIATRICS, V113, P1158; Briassoulis G, 2001, HUM EXP TOXICOL, V20, P8, DOI 10.1191/096032701676731093; Brouwer A, 1998, CHEMOSPHERE, V37, P1627, DOI 10.1016/S0045-6535(98)00230-6; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; Burnett RT, 2001, AM J EPIDEMIOL, V153, P444, DOI 10.1093/aje/153.5.444; California Environmental Protection Agency, 2005, PROP ID ENV TOB SMOK; *CAL EPA, 2000, AD CAL AMB AIR QUAL; Canfield RL, 2003, NEW ENGL J MED, V348, P1517, DOI 10.1056/NEJMoa022848; Carpenter RG, 2004, LANCET, V363, P185, DOI 10.1016/S0140-6736(03)15323-8; Centers for Disease Control and Prevention (CDC), 2003, 2 NAT REP HUM EXP EN; Centers for Disease Control and Prevention (CDC), 2001, NAT REP HUM EXP ENV; *CDCP, 1990, MORBIDITY MORTALITY, V39, P125; Centers for Disease Control and Prevention (CDC), 2005, 3 NAT REP HUM EXP EN; Cedergren MI, 2002, ENVIRON RES, V89, P124, DOI 10.1006/enrs.2001.4362; Chao WY, 1997, ARCH ENVIRON HEALTH, V52, P257; Chen Z, 2005, CANCER, V103, P1064, DOI 10.1002/cncr.20894; Chia SE, 2004, NEUROTOXICOL TERATOL, V26, P285, DOI 10.1016/j.ntt.2003.10.009; Chia SE, 2003, AM J OBSTET GYNECOL, V188, P425, DOI 10.1067/mob.2003.73; Chiodo LM, 2004, NEUROTOXICOL TERATOL, V26, P359, DOI 10.1016/j.ntt.2004.01.010; Choi SM, 2004, J TOXICOL ENV HEAL B, V7, P1, DOI 10.1080/10937400490253229; Clarkson TW, 1997, CRIT REV CL LAB SCI, V34, P369, DOI 10.3109/10408369708998098; Claudio L, 2000, TOXICOL APPL PHARM, V164, P1, DOI 10.1006/taap.2000.8890; Colt JS, 1998, ENVIRON HEALTH PERSP, V106, P909, DOI 10.2307/3434208; *COMM ENV COOP, 2002, N AM REG ACT PLAN EN; COOK DG, 1993, THORAX, V48, P14, DOI 10.1136/thx.48.1.14; Cordier S, 2004, OCCUP ENVIRON MED, V61, P8; Corona R, 2001, ARCH DERMATOL, V137, P1162; Counter SA, 2004, TOXICOL APPL PHARM, V198, P209, DOI 10.1016/j.taap.2003.11.032; Counter SA, 2003, J OCCUP ENVIRON MED, V45, P87, DOI 10.1097/01.jom.0000048165.87707.fd; Counter SA, 2002, J TOXICOL ENV HEAL A, V65, P149, DOI 10.1080/152873902753396785; Crombie IK, 2001, THORAX, V56, P9, DOI 10.1136/thorax.56.1.9; Crosignani P, 2004, INT J CANCER, V108, P596, DOI 10.1002/ijc.11597; Dallaire F, 2004, ENVIRON HEALTH PERSP, V112, P1359, DOI 10.1289/ehp.7255; Daniels JL, 2004, EPIDEMIOLOGY, V15, P394, DOI 10.1097/01.ede.0000129514.46451.ce; Daniels JL, 1997, ENVIRON HEALTH PERSP, V105, P1068, DOI 10.1289/ehp.971051068; Daniels JL, 2001, EPIDEMIOLOGY, V12, P20, DOI 10.1097/00001648-200101000-00005; Darvill T, 2000, NEUROTOXICOLOGY, V21, P1029; Davidson PW, 2004, PEDIATRICS, V113, P1023; Davidson PW, 1998, JAMA-J AM MED ASSOC, V280, P701, DOI 10.1001/jama.280.8.701; De Roos AJ, 2001, AM J EPIDEMIOL, V154, P106, DOI 10.1093/aje/154.2.106; Dewailly E, 2000, ENVIRON HEALTH PERSP, V108, P205, DOI 10.2307/3454435; DiFranza JR, 2004, PEDIATRICS, V113, P1007; DimichWard H, 1996, SCAND J WORK ENV HEA, V22, P267; Dodds L, 2004, EPIDEMIOLOGY, V15, P179, DOI 10.1097/01.ede.0000112209.47765.d9; Dodds L, 2001, OCCUP ENVIRON MED, V58, P443, DOI 10.1136/oem.58.7.443; Dolk H, 2003, BRIT MED BULL, V68, P25, DOI 10.1093/bmb/ldg024; Dolk H, 1998, LANCET, V352, P423, DOI 10.1016/S0140-6736(98)01352-X; Dulon M, 2002, J CLIN EPIDEMIOL, V55, P1075, DOI 10.1016/S0895-4356(02)00484-5; Dulout FN, 1996, MUTAT RES-GENET TOX, V370, P151; Dummer TJB, 2003, J EPIDEMIOL COMMUN H, V57, P456, DOI 10.1136/jech.57.6.456; Ehrlich RI, 1996, AM J RESP CRIT CARE, V154, P681; Elliott P, 2001, BRIT MED J, V323, P363, DOI 10.1136/bmj.323.7309.363; Elliott RC, 1999, AM J IND MED, V36, P557, DOI 10.1002/(SICI)1097-0274(199911)36:5<557::AID-AJIM8>3.0.CO;2-Q; EMORY E, 2003, AM J OBSTET GYNECOL, V188, P526; Eriksson P, 1997, NEUROTOXICOLOGY, V18, P719; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P409; Eskenazi B, 2004, ENVIRON HEALTH PERSP, V112, P1116, DOI 10.1289/ehp.6789; Etzel RA, 1999, PEDIATRICS, V104, P328; Etzel RA, 1998, PEDIATRICS, V101, P717; *EUR ENV AG WHO RE, 2002, 29 EUR ENV AG WHO RE; Evens CC, 2001, J TOXICOL ENV HEAL A, V64, P521, DOI 10.1080/15287390152627219; Factor-Litvak P, 1999, ENVIRON HEALTH PERSP, V107, P9, DOI 10.2307/3434284; Fels LM, 1998, NEPHROL DIAL TRANSPL, V13, P2248, DOI 10.1093/ndt/13.9.2248; Flores-Luevano S, 2003, SALUD PUBLICA MEXICO, V45, P431, DOI [10.1590/S0036-36342003000600002, 10.1590/s0036-36342003000600002]; Flower KB, 2004, ENVIRON HEALTH PERSP, V112, P631; Freedman DM, 2001, AM J PUBLIC HEALTH, V91, P564, DOI 10.2105/AJPH.91.4.564; Gallagher MD, 1998, EPIDEMIOLOGY, V9, P484, DOI 10.1097/00001648-199809000-00003; Gandini S, 2005, EUR J CANCER, V41, P45, DOI 10.1016/j.ejca.2004.10.016; Gandini S, 2005, EUR J CANCER, V41, P28, DOI 10.1016/j.ejca.2004.10.015; Garry V F, 1996, Environ Health Perspect, V104, P394; Gemmel A, 2002, ENVIRON HEALTH PERSP, V110, pA625; Gibson JL, 1892, P INT MED C AUST, V3, P76; Gilbert ES, 2002, HEALTH PHYS, V82, P726, DOI 10.1097/00004032-200205000-00017; Gilboa SM, 2005, AM J EPIDEMIOL, V162, P238, DOI 10.1093/aje/kwi189; Gladen BC, 2000, J PEDIATR-US, V136, P490, DOI 10.1016/S0022-3476(00)90012-X; Glinianaia SV, 2004, ENVIRON HEALTH PERSP, V112, P1365, DOI 10.1289/ehp.6857; Glinianaia SV, 2004, EPIDEMIOLOGY, V15, P36, DOI 10.1097/01.ede.0000101023.41844.ac; Gocmen A, 1989, Biomed Environ Sci, V2, P36; Golding J, 2001, PAEDIATR PERINAT EP, V15, P74; Goldman LR, 1998, ENVIRON HEALTH PERSP, V106, P875, DOI 10.2307/3434204; Golub MS, 1998, J TOXICOL ENV HEAL B, V1, P199; Gomaa A, 2002, PEDIATRICS, V110, P110, DOI 10.1542/peds.110.1.110; Gouveia N, 2004, J EPIDEMIOL COMMUN H, V58, P11, DOI 10.1136/jech.58.1.11; Grandjean P, 2004, J PEDIATR-US, V144, P169, DOI 10.1016/j.jpeds.2003.10.058; Grandjean P, 2001, NEUROTOXICOL TERATOL, V23, P305, DOI 10.1016/S0892-0362(01)00155-6; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Graves CG, 2001, REGUL TOXICOL PHARM, V34, P103, DOI 10.1006/rtph.2001.1494; Gray LE, 2001, HUM REPROD UPDATE, V7, P248, DOI 10.1093/humupd/7.3.248; Guo YLL, 1999, ENVIRON HEALTH PERSP, V107, P715, DOI 10.2307/3434656; Ha E, 2002, ARCH ENVIRON HEALTH, V57, P207; Halfon N, 1999, J AM ACAD CHILD PSY, V38, P600, DOI 10.1097/00004583-199905000-00023; Hanke W, 2004, INT ARCH OCC ENV HEA, V77, P47, DOI 10.1007/s00420-003-0475-0; Harada M, 1999, SCI TOTAL ENVIRON, V234, P59, DOI 10.1016/S0048-9697(99)00255-7; Harada M., 1977, MINIMATA DIS METHYLM, P209; Heinrich J, 2004, CURR ALLERGY ASTHM R, V4, P302, DOI 10.1007/s11882-004-0075-4; Hertz-Picciotto I, 2005, EPIDEMIOLOGY, V16, P648, DOI 10.1097/01.ede.0000173043.85834.f3; Hertz-Picciotto I, 2000, AM J IND MED, V38, P300, DOI 10.1002/1097-0274(200009)38:3<300::AID-AJIM9>3.0.CO;2-C; Hewitt J B, 1998, J Obstet Gynecol Neonatal Nurs, V27, P521, DOI 10.1111/j.1552-6909.1998.tb02618.x; Hong YC, 2003, J OCCUP ENVIRON MED, V45, P492, DOI 10.1097/01.jom.0000063627.37065.a1; Hooper K, 1999, ENVIRON HEALTH PERSP, V107, P429, DOI 10.2307/3434622; Hopenhayn-Rich C, 2000, ENVIRON HEALTH PERSP, V108, P667, DOI 10.2307/3434889; Hosie S, 2000, EUR J PEDIATR SURG, V10, P304, DOI 10.1055/s-2008-1072381; Hwang BF, 2003, ARCH ENVIRON HEALTH, V58, P83, DOI 10.3200/AEOH.58.2.83-91; Infante-Rivard C, 1999, AM J EPIDEMIOL, V150, P528; Infante-Rivard C, 2002, ENVIRON HEALTH PERSP, V110, P591; Infante-Rivard C, 1999, EPIDEMIOLOGY, V10, P481, DOI 10.1097/00001648-199909000-00004; *INT AG RES CANC, 1987, UPD IARC MON S7, V1; Jaakkola JJK, 2002, SCAND J WORK ENV HEA, V28, P71; Jaakkola JJK, 2001, ENVIRON HEALTH PERSP, V109, P557, DOI 10.2307/3455027; Jacob P, 1999, BRIT J CANCER, V80, P1461, DOI 10.1038/sj.bjc.6690545; Jacobson JL, 2002, ENVIRON HEALTH PERSP, V110, P393; JACOBSON SW, 1985, CHILD DEV, V56, P853, DOI 10.1111/j.1467-8624.1985.tb00158.x; Jamal GA, 2002, TOXICOLOGY, V181, P23, DOI 10.1016/S0300-483X(02)00447-X; Jedrychowski W, 2005, EUR J EPIDEMIOL, V20, P775, DOI 10.1007/s10654-005-1048-1; Jedrychowski W, 2004, ENVIRON HEALTH PERSP, V112, P1398, DOI 10.1289/ehp.7065; Ji BT, 1997, J NATL CANCER I, V89, P238, DOI 10.1093/jnci/89.3.238; Johnston MV, 1998, CURR OPIN NEUROL, V11, P689; Kaiser Reinhard, 2004, Environ Health, V3, P4, DOI 10.1186/1476-069X-3-4; Kallen B, 1998, RADIAT RES, V149, P202, DOI 10.2307/3579931; Karmaus W, 2001, ARCH ENVIRON HEALTH, V56, P485; Karmaus Wilfried, 2004, Environ Health, V3, P1, DOI 10.1186/1476-069X-3-1; Kerr MA, 2000, CANCER CAUSE CONTROL, V11, P635, DOI 10.1023/A:1008951632482; Kharrazi M, 2004, EPIDEMIOLOGY, V15, P660, DOI 10.1097/01.ede.0000142137.39619.60; Khattak S, 1999, JAMA-J AM MED ASSOC, V281, P1106, DOI 10.1001/jama.281.12.1106; Kheifets Leeka, 2005, Bioelectromagnetics, VSuppl 7, pS51; King WD, 2000, ENVIRON HEALTH PERSP, V108, P883, DOI 10.1289/ehp.00108883; Klotz JB, 1999, EPIDEMIOLOGY, V10, P383, DOI 10.1097/00001648-199907000-00008; Koller K, 2004, ENVIRON HEALTH PERSP, V112, P987, DOI 10.1289/ehp.6941; Korrick SA, 2001, ANN EPIDEMIOL, V11, P491, DOI 10.1016/S1047-2797(01)00239-3; Krewski D, 2001, J TOXICOL ENV HEAL B, V4, P1, DOI 10.1080/109374001459458; Krewski D, 2001, J TOXICOL ENV HEAL B, V4, P145, DOI 10.1080/109374001459467; Kristensen P, 1997, Epidemiology, V8, P537, DOI 10.1097/00001648-199709000-00011; Kuehl KS, 2003, BIRTH DEFECTS RES A, V67, P162, DOI 10.1002/bdra.10015; Kundi M, 2004, J TOXICOL ENV HEAL B, V7, P351, DOI 10.1080/10937400490486258; LaKind JS, 2005, J TOXICOL ENV HEAL A, V68, P1713, DOI 10.1080/15287390500225724; Landrigan PJ, 2002, ENVIRON HEALTH PERSP, V110, P721; Landrigan PJ, 1999, ANN NY ACAD SCI, V895, P1, DOI 10.1111/j.1749-6632.1999.tb08073.x; Lanphear BP, 2000, PUBLIC HEALTH REP, V115, P521, DOI 10.1093/phr/115.6.521; Lanphear BP, 2005, ENVIRON HEALTH PERSP, V113, P894, DOI 10.1289/ehp.7688; Lanphear BP, 2001, PEDIATRICS, V107, P505, DOI 10.1542/peds.107.3.505; Lee GM, 2002, EPIDEMIOLOGY, V13, P21, DOI 10.1097/00001648-200201000-00005; Leech J A, 1996, Chronic Dis Can, V17, P118; Levario-Carrillo M, 2004, CHEMOSPHERE, V55, P1421, DOI 10.1016/j.chemosphere.2003.11.027; Li DK, 2002, EPIDEMIOLOGY, V13, P9, DOI 10.1097/00001648-200201000-00004; Lidsky TI, 2003, BRAIN, V126, P5, DOI 10.1093/brain/awg014; Lin M, 2004, AM J EPIDEMIOL, V159, P294, DOI 10.1093/aje/kwh043; LINDBOHM ML, 1991, SCAND J WORK ENV HEA, V17, P95; Linet MS, 2003, PEDIATRICS, V112, P218; Litovitz TL, 2001, AM J EMERG MED, V19, P337, DOI 10.1053/ajem.2001.25272; Liu SL, 2003, ENVIRON HEALTH PERSP, V111, P1773, DOI 10.1289/ehp.6251; Loffredo CA, 2000, AM J MED GENET, V97, P319, DOI 10.1002/1096-8628(200024)97:4<319::AID-AJMG1283>3.0.CO;2-E; Longnecker MP, 1997, ANNU REV PUBL HEALTH, V18, P211, DOI 10.1146/annurev.publhealth.18.1.211; Longnecker MP, 2005, ENVIRON RES, V97, P127, DOI 10.1016/S0013-9351(03)00108-7; Longnecker MP, 2002, AM J EPIDEMIOL, V155, P313, DOI 10.1093/aje/155.4.313; Longnecker MP, 2001, LANCET, V358, P110, DOI 10.1016/S0140-6736(01)05329-6; Longnecker MP, 2003, ENVIRON HEALTH PERSP, V111, P65, DOI 10.1289/ehp.5463; Longnecker MP, 2005, EPIDEMIOLOGY, V16, P641, DOI 10.1097/01.ede.0000172137.45662.85; Lorenzana RM, 2003, J TOXICOL ENV HEAL A, V66, P871, DOI 10.1080/15287390390210532; Ma XM, 2002, ENVIRON HEALTH PERSP, V110, P955; MACMAHON B, 1962, J NATL CANCER I, V28, P1173; Makri A, 2004, J TOXICOL ENV HEAL B, V7, P417, DOI 10.1080/10937400490512465; Mannino DM, 2002, CHEST, V122, P409, DOI 10.1378/chest.122.2.409; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; MARSH DO, 1981, CLIN TOXICOL, V18, P1311; MARSH DO, 1980, ANN NEUROL, V7, P348, DOI 10.1002/ana.410070412; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McKinney Patricia A, 2005, Bioelectromagnetics, VSuppl 7, pS60; McMartin KI, 2002, J PEDIATR-US, V140, P205, DOI 10.1067/mpd.2002.121937; McMartin KI, 1998, AM J IND MED, V34, P288, DOI 10.1002/(SICI)1097-0274(199809)34:3<288::AID-AJIM12>3.0.CO;2-Q; MCMICHAEL AJ, 1986, J EPIDEMIOL COMMUN H, V40, P18, DOI 10.1136/jech.40.1.18; Meza MM, 2005, ENVIRON HEALTH PERSP, V113, P775; Michalek JE, 1998, EPIDEMIOLOGY, V9, P161, DOI 10.1097/00001648-199803000-00010; MILLER RW, 1995, RADIAT RES, V144, P160, DOI 10.2307/3579255; MILLER RW, 1995, ENVIRON HEALTH PERSP, V103, P41, DOI 10.2307/3432343; Morris SE, 2003, SCOT MED J, V48, P105; MOTARELLI P, 2000, LANCET, V3555, P1858; Moya J, 2004, PEDIATRICS, V113, P996; Moysich KB, 2002, LANCET ONCOL, V3, P269, DOI 10.1016/S1470-2045(02)00727-1; Munger R, 1997, ENVIRON HEALTH PERSP, V105, P308, DOI 10.1289/ehp.97105308; Murakami S, 2004, INDOOR AIR, V14, P144, DOI 10.1111/j.1600-0668.2004.00283.x; Murata K, 2002, RISK ANAL, V22, P465, DOI 10.1111/0272-4332.00034; Mylchreest E, 2000, TOXICOL SCI, V55, P143, DOI 10.1093/toxsci/55.1.143; Nakashima E, 2002, RADIAT RES, V158, P346, DOI 10.1667/0033-7587(2002)158[0346:EORDOT]2.0.CO;2; Naldi L, 2000, J AM ACAD DERMATOL, V42, P446, DOI 10.1016/S0190-9622(00)90217-2; *NAT AC SCI, 2003, VET AG OR UPD 2002; National Academy of Sciences, 2000, TOX EFF METH; National Academies of Sciences, 1999, ARS DRINK WAT; National Academy of Science, 2000, CLEAR AIR ASTHM IND; National Academy of Sciences, 1993, PEST DIETS INF CHILD; *NAT I CHILD HLTH, 2002, NAT CHILDR STUD; *NAT I ENV HLTH SC, 1999, REP HLTH EFF EXP POW; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; Newland MC, 2002, ENVIRON TOXICOL PHAR, V12, P119, DOI 10.1016/S1382-6689(02)00030-3; Nieuwenhuijsen MJ, 2002, EPIDEMIOLOGY, V13, P725, DOI 10.1097/01.EDE.0000030722.16351.91; Nieuwenhuijsen MJ, 2000, OCCUP ENVIRON MED, V57, P73, DOI 10.1136/oem.57.2.73; Noshchenko AG, 2002, INT J CANCER, V99, P609, DOI 10.1002/ijc.10406; NURMINEN T, 1995, J OCCUP ENVIRON MED, V37, P935, DOI 10.1097/00043764-199508000-00008; Oken E, 2005, ENVIRON HEALTH PERSP, V113, P1376, DOI 10.1289/ehp.8041; Oliveira LM, 2002, REV SAUDE PUBL, V36, P81, DOI 10.1590/S0034-89102002000100013; Olshan Andrew F, 2003, Adv Exp Med Biol, V518, P147; Orr M, 2002, INT J HYG ENVIR HEAL, V205, P19, DOI 10.1078/1438-4639-00126; Osman K, 1999, ENVIRON RES, V80, P1, DOI 10.1006/enrs.1998.3886; Otake M, 1998, INT J RADIAT BIOL, V74, P159, DOI 10.1080/095530098141555; OTAKE M, 1994, RADIAT RES, V140, P112, DOI 10.2307/3578576; Parker L, 1999, LANCET, V354, P1407, DOI 10.1016/S0140-6736(99)04138-0; Parran Damani K, 2003, Brain Res Dev Brain Res, V141, P71; Pastore LM, 1997, OCCUP ENVIRON MED, V54, P511; Patandin S, 1999, J PEDIATR-US, V134, P33, DOI 10.1016/S0022-3476(99)70369-0; Patandin S, 1998, PEDIATR RES, V44, P538, DOI 10.1203/00006450-199810000-00012; Perera FP, 2004, ENVIRON HEALTH PERSP, V112, P626, DOI 10.1289/ehp.6617; Perera FP, 2003, ENVIRON HEALTH PERSP, V111, P201, DOI 10.1289/ehp.5742; Pesatori AC, 2003, IND HEALTH, V41, P127, DOI 10.2486/indhealth.41.127; Pfeiffer P, 2000, MUTAGENESIS, V15, P289, DOI 10.1093/mutage/15.4.289; Pierce DA, 1996, RADIAT RES, V146, P1, DOI 10.2307/3579391; Pino P, 2004, EPIDEMIOLOGY, V15, P702, DOI 10.1097/01.ede.0000142153.28496.d0; Popovic JR, 2001, VITAL HLTH STAT, V13, P1; RABINOWITZ MB, 1993, CALCIFIED TISSUE INT, V53, P338, DOI 10.1007/BF01351840; Rahman MM, 2001, J TOXICOL-CLIN TOXIC, V39, P683; Ratcliffe HE, 1996, J TOXICOL ENV HEALTH, V49, P221; Rauh VA, 2004, NEUROTOXICOL TERATOL, V26, P373, DOI 10.1016/j.ntt.2004.01.002; Reynolds P, 2003, ENVIRON HEALTH PERSP, V111, P663, DOI 10.1289/ehp.5986; Ribas-Fito N, 2001, J EPIDEMIOL COMMUN H, V55, P537, DOI 10.1136/jech.55.8.537; Ribas-Fito N, 2002, PEDIATR RES, V52, DOI 10.1023/01.PDR.0000023171.89966.8B; Ris MD, 2004, J INT NEUROPSYCH SOC, V10, P261, DOI 10.1017/S1355617704102154; Ritz B, 2002, AM J EPIDEMIOL, V155, P17, DOI 10.1093/aje/155.1.17; ROGAN WJ, 1988, SCIENCE, V241, P334, DOI 10.1126/science.3133768; ROGAN WJ, 1986, J PEDIATR-US, V109, P335, DOI 10.1016/S0022-3476(86)80397-3; ROMAN DD, 1995, INT J RADIAT ONCOL, V31, P983, DOI 10.1016/0360-3016(94)00550-8; RON E, 1982, AM J EPIDEMIOL, V116, P149; Rosso S, 1998, MELANOMA RES, V8, P573, DOI 10.1097/00008390-199812000-00013; Rothenberg SJ, 2000, NEUROTOXICOL TERATOL, V22, P503, DOI 10.1016/S0892-0362(00)00079-9; ROTHENBERG SJ, 1994, NEUROTOXICOLOGY, V15, P695; Ruckart PZ, 2004, ENVIRON HEALTH PERSP, V112, P46, DOI 10.1289/ehp.6430; Rushton L, 2003, BRIT MED BULL, V68, P183, DOI 10.1093/bmb/ldg034; RYAN JJ, 1990, FUND APPL TOXICOL, V15, P722, DOI 10.1016/0272-0590(90)90188-P; Sagiv SK, 2005, ENVIRON HEALTH PERSP, V113, P602, DOI 10.1289/ehp.7646; Saiyed H, 2003, ENVIRON HEALTH PERSP, V111, P1958, DOI 10.1289/ehp.6271; Sarasua SM, 2000, J TOXICOL ENV HEAL A, V60, P1, DOI 10.1080/009841000156556; Savitz D A, 2001, Bioelectromagnetics, VSuppl 5, pS69; SAVITZ DA, 1995, ENVIRON HEALTH PERSP, V103, P592, DOI 10.2307/3432436; Savitz DA, 2002, EPIDEMIOLOGY, V13, P1, DOI 10.1097/00001648-200201000-00001; Schantz SL, 2003, ENVIRON HEALTH PERSP, V111, P357, DOI 10.1289/ehp.5461; SCHEELE J, 1992, EUR J PEDIATR, V151, P802, DOI 10.1007/BF01957928; SCHNAAS L, 2006, ENV HLTH PERSPECT, V11, P791; SCHWARTZ J, 1988, J PEDIATR-US, V112, P12, DOI 10.1016/S0022-3476(88)80111-2; Schwartz J, 2004, PEDIATRICS, V113, P1037; SCHWARTZ J, 1986, PEDIATRICS, V77, P281; Selevan SG, 2003, NEW ENGL J MED, V348, P1527, DOI 10.1056/NEJMoa020880; Selevan SG, 2000, ENVIRON HEALTH PERSP, V108, P451, DOI 10.2307/3454536; SEVER LE, 1988, AM J EPIDEMIOL, V127, P226; Sever LE, 1997, OCCUP MED, V12, P305; Shafer Timothy J, 2002, Brain Res Dev Brain Res, V136, P151; Shannon MW, 2004, PEDIATRICS, V114, P1699, DOI 10.1542/peds.2004-2166; Shaw GM, 2003, AM J EPIDEMIOL, V157, P475, DOI 10.1093/aje/kwg013; Shaw GM, 1999, EPIDEMIOLOGY, V10, P60, DOI 10.1097/00001648-199901000-00011; Shea KM, 2003, PEDIATRICS, V111, P1467, DOI 10.1542/peds.111.6.1467; Shen XM, 1998, ENVIRON RES, V79, P1, DOI 10.1006/enrs.1998.3851; Shenkin JD, 2004, J PUBLIC HEALTH DENT, V64, P184, DOI 10.1111/j.1752-7325.2004.tb02750.x; Shi L, 2001, OCCUP MED-OXFORD, V51, P230, DOI 10.1093/occmed/51.4.230; Shu XO, 2004, CANCER EPIDEM BIOMAR, V13, P1230; Shu XO, 2002, CANCER EPIDEM BIOMAR, V11, P177; Slotkin TA, 2004, TOXICOL APPL PHARM, V198, P132, DOI 10.1016/j.taap.2003.06.001; Sorahan T, 2001, BRIT J CANCER, V84, P141, DOI 10.1054/bjoc.2000.1556; Sorensen N, 1999, EPIDEMIOLOGY, V10, P370; Staessen JA, 2001, LANCET, V357, P1660, DOI 10.1016/S0140-6736(00)04822-4; Steffen C, 2004, OCCUP ENVIRON MED, V61, P773, DOI 10.1136/oem.2003.010868; Stewart A, 1956, LANCET, V2, P447; Swan SH, 2005, ENVIRON HEALTH PERSP, V113, P1056, DOI 10.1289/ehp.8100; Sweeney MH, 2000, FOOD ADDIT CONTAM, V17, P303, DOI 10.1080/026520300283379; Sweet LI, 2001, J TOXICOL ENV HEAL B, V4, P161, DOI 10.1080/10937400117236; Tang HW, 1999, J APPL TOXICOL, V19, P167, DOI 10.1002/(SICI)1099-1263(199905/06)19:3<167::AID-JAT560>3.0.CO;2-8; Taub JW, 2004, LEUKEMIA LYMPHOMA, V45, P19, DOI 10.1080/1042819031000149403; Teague WG, 2001, PEDIATR CLIN N AM, V48, P1167, DOI 10.1016/S0031-3955(05)70367-9; Toledano MB, 2005, ENVIRON HEALTH PERSP, V113, P225, DOI 10.1289/ehp.7111; Torres-Arreola L, 2003, ANN EPIDEMIOL, V13, P158, DOI 10.1016/S1047-2797(02)00424-6; Torres-Sanchez LE, 1999, ENVIRON RES, V81, P297, DOI 10.1006/enrs.1999.3984; Tsai SM, 1998, J TOXICOL ENV HEAL A, V55, P389, DOI 10.1080/009841098158322; United Nations Environment Programme, 2002, GLOB MERC ASS; United Nations Scientific Committee on the Effects of Atomic Radiation, 2000, UNSCEAR 2000 REP SOU; United States Environmental Protection Agency, 2004, EXP HUM HLTH REASS 2; *US EPA, 2004, IN OTH PEST INGR PES; *US EPA, 1997, IRIS SUBST LIST; *US EPA, 2001, LISTS OTH IN PEST IN; U. S. Environmental Protection Agency, 2003, NAT AIR QUAL EM TREN; *US EPA, 1999, PEST IND SAL US 1996; van Dam RM, 1999, AM J EPIDEMIOL, V150, P459; van den Berg M, 2000, FOOD ADDIT CONTAM A, V17, P223; Venners SA, 2005, AM J EPIDEMIOL, V162, P709, DOI 10.1093/aje/kwi275; Ventura SJ, 1999, NATL VITAL STAT REPO, V47, P1; VENTURA SJ, 2001, NATL VITAL STAT REP, V49, P16; Verberk MM, 1996, ARCH ENVIRON HEALTH, V51, P83; Vidair CA, 2004, TOXICOL APPL PHARM, V196, P287, DOI 10.1016/j.taap.2003.12.016; Vreugdenhil HJI, 2002, J PEDIATR-US, V140, P48, DOI 10.1067/mpd.2002.119625; Vrijheid M, 2003, OCCUP ENVIRON MED, V60, P543, DOI 10.1136/oem.60.8.543; Vrijheid M, 2002, OCCUP ENVIRON MED, V59, P768, DOI 10.1136/oem.59.11.768; Vrijheid M, 2000, ENVIRON HEALTH PERSP, V108, P101, DOI 10.2307/3454635; Wakeford R, 2003, INT J RADIAT BIOL, V79, P293, DOI 10.1080/0955300031000114729; Waliszewski SM, 2005, B ENVIRON CONTAM TOX, V75, P952, DOI 10.1007/s00128-005-0842-5; Wang CL, 2002, ENVIRON RES, V89, P12, DOI 10.1006/enrs.2002.4342; Wang Jinping, 2002, Zhonghua Liu Xing Bing Xue Za Zhi, V23, P190; Wang SL, 2003, ENVIRON RES, V93, P131, DOI 10.1016/S0013-9351(03)00040-9; Wang XB, 2002, JAMA-J AM MED ASSOC, V287, P195, DOI 10.1001/jama.287.2.195; Ward DJ, 2004, OCCUP ENVIRON MED, V61, DOI 10.1136/oem.2003.007088; Watson WA, 2003, AM J EMERG MED, V21, P353, DOI 10.1016/S0735-6757(03)00088-3; Weidner IS, 1998, ENVIRON HEALTH PERSP, V106, P793, DOI 10.1289/ehp.98106793; Weisglas-Kuperus N, 2004, TOXICOL LETT, V149, P281, DOI 10.1016/j.toxlet.2003.12.039; Weisskopf MG, 2005, ENVIRON RES, V97, P149, DOI 10.1016/j.envres.2004.01.014; Wennborg H, 2000, J OCCUP ENVIRON MED, V42, P438, DOI 10.1097/00043764-200004000-00022; WERTHEIMER N, 1979, AM J EPIDEMIOL, V109, P273; Wheatley B, 1998, Int J Circumpolar Health, V57 Suppl 1, P586; World Health Organization, 1999, INT CONS ENV TOB SMO; Whyatt RM, 2004, ENVIRON HEALTH PERSP, V112, P1125, DOI 10.1289/ehp.6641; Wigle DT, 2003, CHILD HLTH ENV; WIGLE DT, 2005, CHILD HLTH ENV S; Wilhelm M, 2005, ENVIRON HEALTH PERSP, V113, P1212, DOI 10.1289/ehp.7751; WILKINS JR, 1988, AM J IND MED, V14, P299; Wright JM, 2004, ENVIRON HEALTH PERSP, V112, P920, DOI 10.1289/ehp.6779; Wu TJ, 2003, ENVIRON HEALTH PERSP, V111, P737, DOI 10.1289/ehp.6008; Wulff M, 1996, PAEDIATR PERINAT EP, V10, P22, DOI 10.1111/j.1365-3016.1996.tb00022.x; Yamanaka K, 2004, TOXICOL APPL PHARM, V198, P385, DOI 10.1016/j.taap.2003.10.025; Yanez L, 2003, ENVIRON RES, V93, P231, DOI 10.1016/j.envres.2003.07.005; Yolton K, 2005, ENVIRON HEALTH PERSP, V113, P98; Young JG, 2005, NEUROTOXICOLOGY, V26, P199, DOI 10.1016/j.neuro.2004.10.004; Zahm SH, 1998, ENVIRON HEALTH PERSP, V106, P893, DOI 10.2307/3434207; Zhang HS, 2002, BIOMED ENVIRON SCI, V15, P330; Zou CC, 2003, CHINESE MED J-PEKING, V116, P565	359	86	88	13	75	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1093-7404			J TOXICOL ENV HEAL B	J. Toxicol. Env. Health-Pt b-Crit. Rev.	JAN-MAR	2007	10	1-2					3	39		10.1080/10937400601034563		37	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	125GB	WOS:000243429300002	18074303	
J	Trenga, CA; Sullivan, JH; Schildcrout, JS; Shepherd, KP; Shapiro, GG; Liu, LJS; Kaufman, JD; Koenig, JQ				Trenga, CA; Sullivan, JH; Schildcrout, JS; Shepherd, KP; Shapiro, GG; Liu, LJS; Kaufman, JD; Koenig, JQ			Effect of particulate air, pollution on lung function in adult and pediatric subjects in a Seattle panel study	CHEST			English	Article						adults; asthma; children; COPD; lung function; particulate air pollution	ANTIINFLAMMATORY MEDICATION USE; EXHALED NITRIC-OXIDE; RESPIRATORY HEALTH; ASTHMATIC-CHILDREN; SYMPTOM SEVERITY; SMALL AIRWAYS; PARTICLES; EXPOSURE; MATTER; ASSOCIATION	Study objective: To determine whether increased exposure to particulate matter air pollution (PM), measured with personal, residential, or central site monitoring, was associated with pulmonary function decrements in either adults with COPD or children with asthma. Participants: We studied 57 adults with or without COPD and 17 children aged 6 to 13 years with physician-diagnosed asthma in Seattle during a 3-year panel study. Study design and measurements: Indoor and outdoor PM measurements were made at subjects' homes. The subjects wore personal exposure monitors for 10 consecutive 24-h periods, and PM was also measured at a central outdoor location. We assessed the within-subject effect of particulate exposure on FEV1 and peak expiratory flow (PEF) in adults, and maximal midexpiratory flow (MMEF), PEF, FEV1, and symptoms in children. Results: FEV1 decrements were associated with 1-day lagged central site PM <= 2.5 mu m in diameter (PM2.5) in adult subjects with COPD. In children not receiving antiinflammatory medication, same day indoor, outdoor, and central site exposures to PM2.5 were associated with decrements in MMEF, PEF, and FEV1. Associations with PM2.5 and lung function decrements were also observed for 1-day lagged indoor (MMEF, PEF, FEV1) and personal (PEF only) exposures. Antiinflammatory medication use in children significantly attenuated the PM effect on airflow rates and volumes. Conclusions: This study found consistent decrements in MMEF in children with asthma who were not receiving medications. It is notable that effects were observed even though PM exposures were low for an urban area. These findings suggest the need for future larger studies of PM effects in this susceptible population that repeatedly measure spirometry to include MMEF and potentially more sensitive markers of airway inflammation such as exhaled breath condensate and exhaled nitric oxide.	Univ Washington, Dept Environm Hlth, EPA NW Res Ctr Particulate Air Pollut & Hlth, Seattle, WA 98195 USA; Vanderbilt Univ, Dept Biostat, Nashville, TN USA; Univ Washington, Dept Pediat, Seattle, WA USA	Trenga, CA (reprint author), Univ Washington, Dept Environm Hlth, EPA NW Res Ctr Particulate Air Pollut & Hlth, Box 354695, Seattle, WA 98195 USA.	ctrenga@u.washington.edu	Kaufman, Joel/B-5761-2008	Kaufman, Joel/0000-0003-4174-9037	NIEHS NIH HHS [K24 ES013195, K24 ES013195-01A1, P30ES07033]		ALLEN R, 2003, ENVIRON SCI TECHNOL, V16, P3484; Blomberg A, 2000, CLIN EXP ALLERGY, V30, P310; Brauer M, 2001, J EXPO ANAL ENV EPID, V11, P490, DOI 10.1038/sj.jea.7500195; Delfino RJ, 1998, ENVIRON HEALTH PERSP, V106, P751, DOI 10.1289/ehp.98106751; Delfino RJ, 2004, ENVIRON HEALTH PERSP, V112, P932, DOI 10.1289/ehp.6815; Delfino RJ, 2002, ENVIRON HEALTH PERSP, V110, pA607; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Goswami E, 2002, J AIR WASTE MANAGE, V52, P324; Grievink L, 1999, EUR RESPIR J, V13, P1439, DOI 10.1183/09031936.99.13614479; Guyatt GH, 1997, PEDIATRICS, V99, P165, DOI 10.1542/peds.99.2.165; Hamid Q, 1997, J ALLERGY CLIN IMMUN, V100, P44; Jones SL, 2001, AM J RESP CRIT CARE, V164, P738; Koenig JQ, 2005, ENVIRON HEALTH PERSP, V113, P499, DOI 10.1289/ehp.7511; KOENIG JQ, 1993, ENVIRON RES, V63, P26, DOI 10.1006/enrs.1993.1123; Koenig JQ, 2003, ENVIRON HEALTH PERSP, V111, P1625, DOI 10.1289/ehp.6160; Littell R., 1996, SAS SYSTEM MIXED MOD; Little RJA, 2002, STAT ANAL MISSING DA; Liu LJS, 2003, ENVIRON HEALTH PERSP, V111, P909, DOI 10.1289/ehp.6011; Liu LJS, 2002, ENVIRON SCI TECHNOL, V36, P2977, DOI 10.1021/es0112644; Macklem PT, 1998, AM J RESP CRIT CARE, V157, pS181; Penttinen P, 2001, ENVIRON HEALTH PERSP, V109, P319, DOI 10.2307/3454889; Peters A, 1997, ENVIRON HEALTH PERSP, V105, P430, DOI 10.1289/ehp.97105430; POPE CA, 1992, AM REV RESPIR DIS, V145, P1123; Romieu I, 1996, AM J RESP CRIT CARE, V154, P300; Sarnat JA, 2001, ENVIRON HEALTH PERSP, V109, P1053, DOI 10.2307/3454961; Schwartz J, 2004, ENVIRON HEALTH PERSP, V112, P557; Schwartz J, 2000, EPIDEMIOLOGY, V11, P6, DOI 10.1097/00001648-200001000-00004; Slaughter JC, 2003, ANN ALLERG ASTHMA IM, V91, P346; U.S. EPA, 2004, AIR QUAL CRIT PART M; van der Zee SC, 2000, EUR RESPIR J, V15, P700, DOI 10.1034/j.1399-3003.2000.15d13.x; Yu OC, 2000, ENVIRON HEALTH PERSP, V108, P1209, DOI 10.2307/3434835; [Anonymous], 1995, AM J RESP CRIT CARE, V152, P1107	32	86	95	2	33	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	JUN	2006	129	6					1614	1622		10.1378/chest.129.6.1614		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	054BA	WOS:000238349300036	16778283	
J	Casalino-Matsuda, SM; Monzon, ME; Forteza, RM				Casalino-Matsuda, SM; Monzon, ME; Forteza, RM			Epidermal growth factor receptor activation by epidermal growth factor mediates oxidant-induced goblet cell metaplasia in human airway epithelium	AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY			English	Article						EGFR; goblet cells; hyaluronan; NHBE cells; tissue kallikrein	MUCIN GENE-EXPRESSION; ALPHA-CONVERTING-ENZYME; TISSUE KALLIKREIN ACTIVITY; C-ERBB RECEPTORS; ASTHMATIC SUBJECTS; HYALURONIC-ACID; IN-VITRO; INCREASES MUC5AC; HOST-DEFENSE; MUCUS	Mucus overproduction in inflammatory and obstructive airway diseases is associated with goblet cell (GC) metaplasia in airways. Although the mechanisms involved in GC metaplasia and mucus hypersecretion are not completely understood, association with oxidative stress and epidermal growth factor receptor (EGFIR) signaling has been reported. To explore the mechanisms involved in oxidative stress-induced GC metaplasia, cultures of differentiated normal human bronchial epithelial cells grown at the air-liquid interface were exposed to reactive oxygen species (RIDS) generated by xanthine/xanthine oxidase. EGFIR activation and signaling was assessed by measuring EGF and transforming growth factor-alpha release and EGFIR and (44/42)MAPK phosphorylation. The GC population was evaluated by confocal microscopy. ROS-induced EGFIR activation resulted in GC proliferation and increased MUC5AC gene and protein expression. Signaling was due to pro-EGF processing by tissue kallikrein (TK), which was activated by ROS-induced hyaluronan breakdown. It was inhibited by catalase, a TK inhibitor, and EGF-blocking antibodies. Exposure to recombinant TK mimicked the ROS effects, increasing the expression of MUC5AC and lactoperoxidase. In addition, ROS induced the antiapoptotic factor Bcl-2 in a TK-dependent fashion. In conclusion, ROS-induced GC metaplasia in normal human bronchial epithelial cells is associated with HA depolymerization and EGF processing by TK followed by EGFR signaling, suggesting that increases in TK activity could contribute to GC metaplasia and mucus hypersecretion in diseases such as asthma and chronic bronchitis. The data also suggest that increases in GC population could be sustained by the associated upregulation of Bcl-2 in airway epithelial cells.	Univ Miami, Miller Sch Med, Div Pulm & Crit Care Med, Miami, FL 33136 USA	Forteza, RM (reprint author), Univ Miami, Miller Sch Med, Div Pulm & Crit Care Med, R-47,1600 NW 10th Ave,RMSB 7072A, Miami, FL 33136 USA.	rforteza@miami.edu		Casalino-Matsuda, S Marina/0000-0002-7566-4560	NHLBI NIH HHS [HL-073156, HL-68992]		Adler KB, 2001, AM J RESP CELL MOL, V25, P397; Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; AIKAWA T, 1992, CHEST, V101, P916, DOI 10.1378/chest.101.4.916; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Atherton HC, 2003, AM J PHYSIOL-LUNG C, V285, pL730, DOI 10.1152/ajplung.00089.2003; BALAZS EA, 1967, ARTHRITIS RHEUM, V10, P357, DOI 10.1002/art.1780100407; Basbaum C, 2002, NOVART FDN SYMP, V248, P171; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595; Blanchet S, 2004, AM J RESP CELL MOL, V30, P421, DOI 10.1165/rcmb.2003-0281RC; Booth BW, 2001, AM J RESP CELL MOL, V25, P739; BRAY BA, 1994, EXP LUNG RES, V20, P317, DOI 10.3109/01902149409064390; Cagliari CI, 2003, BIOCHEM BIOPH RES CO, V311, P241, DOI 10.1016/j.bbrc.2003.09.203; Casalino-Matsuda SM, 2004, J BIOL CHEM, V279, P21606, DOI 10.1074/jbc.M309950200; Chan H, 1998, PROTEIN EXPRES PURIF, V12, P361, DOI 10.1006/prep.1997.0854; CHRISTIANSEN SC, 1992, AM REV RESPIR DIS, V145, P900; CHRISTIANSEN SC, 1987, J CLIN INVEST, V79, P188, DOI 10.1172/JCI112782; Clark JA, 2005, AM J PHYSIOL-GASTR L, V288, pG755, DOI 10.1152/ajpgi.00172.2004; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Dohrman A, 1998, BBA-MOL BASIS DIS, V1406, P251, DOI 10.1016/S0925-4439(98)00010-6; DUNNILL MS, 1960, J CLIN PATHOL, V13, P27, DOI 10.1136/jcp.13.1.27; El-Chemaly S, 2003, AM J RESP CRIT CARE, V167, P425, DOI 10.1164/rccm.200206-531OC; FAHY JV, 1992, AM REV RESPIR DIS, V146, P1430; Fischer BM, 2002, AM J RESP CELL MOL, V26, P447; Floros KV, 2003, ANN NY ACAD SCI, V1010, P153, DOI 10.1196/annals.1299.025; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Forteza R, 2001, FASEB J, V15, P2179, DOI 10.1096/fj.01-0036com; Forteza R, 1999, AM J RESP CELL MOL, V21, P666; GEIGER R, 1988, METHOD ENZYMOL, V163, P102; Gerson C, 2000, AM J RESP CELL MOL, V22, P665; HALLIWELL B, 1988, FASEB J, V2, P2867; Harris JF, 2005, AM J RESP CRIT CARE, V171, P764, DOI 10.1164/rccm.200408-1108OC; Harrod KS, 2003, AM J RESP CELL MOL, V28, P451, DOI 10.1165/rcmb.2002-0100OC; Hashimoto K, 2004, AM J RESP CRIT CARE, V170, P306, DOI 10.1164/rccm.200301-030OC; Hauber HP, 2004, EUR RESPIR J, V23, P846, DOI 10.1183/09031936.04.00096504; HUNTER T, 1981, CELL, V24, P741, DOI 10.1016/0092-8674(81)90100-8; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JAHNKE GD, 1994, ENDOCRINOLOGY, V135, P2022, DOI 10.1210/en.135.5.2022; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; JORGENSEN PE, 1991, BIOCHIM BIOPHYS ACTA, V1074, P284, DOI 10.1016/0304-4165(91)90165-D; JORGENSEN PE, 1994, GROWTH FACTORS, V11, P113, DOI 10.3109/08977199409001053; Kasper M, 2002, CLIN EXP ALLERGY, V32, P1251, DOI 10.1046/j.1365-2745.2002.01423.x; Kondo M, 2002, AM J RESP CELL MOL, V27, P536, DOI 10.1165/rcmb.4682; Koo JS, 1999, AM J RESP CELL MOL, V20, P43; Kuwada SK, 1998, AM J PHYSIOL-CELL PH, V275, pC1419; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; LAPSHINA IM, 1984, SOV MEDITISINA, V11, P16; LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267; Lemjabbar H, 2003, J BIOL CHEM, V278, P26202, DOI 10.1074/jbc.M207018200; Lemjabbar H, 2002, NAT MED, V8, P41, DOI 10.1038/nm0102-41; Liu YZ, 1999, NUCLEIC ACIDS RES, V27, P2086, DOI 10.1093/nar/27.10.2086; Markewitz BA, 1999, AM J MED SCI, V318, P74, DOI 10.1097/00000441-199908000-00002; MATSUMURA G, 1966, RADIAT RES, V28, P735, DOI 10.2307/3572179; Miller LA, 1996, J CLIN INVEST, V97, P1429, DOI 10.1172/JCI118564; MONZON ME, 2005, AM J RESP CELL MOL B, V34, P135; Nlend MC, 2002, AM J RESP CELL MOL, V27, P436, DOI 10.1165/rcmb.2002-0012OC; O'Donnell RA, 2004, THORAX, V59, P1032, DOI 10.1136/thx.2004.028043; O' Riordan TG, 2003, LUNG, V181, P237, DOI 10.1007/s00408-003-1019-9; Ordonez CL, 2001, AM J RESP CRIT CARE, V163, P517; Polosa R, 2002, J ALLERGY CLIN IMMUN, V109, P75, DOI 10.1067/mai.2002.120274; Polosa R, 1999, AM J RESP CELL MOL, V20, P914; PROUD D, 1993, AM J RESP CELL MOL, V8, P16; REID L M, 1954, Lancet, V266, P274; Rogers DF, 2003, INT J BIOCHEM CELL B, V35, P1, DOI 10.1016/S1357-2725(02)00083-3; Rose MC, 2006, PHYSIOL REV, V86, P245, DOI 10.1152/physrev.00010.2005; Rose MC, 2001, AM J RESP CELL MOL, V25, P533; Salathe M, 1997, AM J RESP CELL MOL, V17, P97; Shao MXG, 2005, P NATL ACAD SCI USA, V102, P767, DOI 10.1073/pnas.0408932102; Shao MXG, 2003, P NATL ACAD SCI USA, V100, P11618, DOI 10.1073/pnas.1534804100; Strachan L, 2001, J BIOL CHEM, V276, P18265, DOI 10.1074/jbc.M006935200; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Takeyama K, 2000, J IMMUNOL, V164, P1546; Takeyama K, 1999, P NATL ACAD SCI USA, V96, P3081, DOI 10.1073/pnas.96.6.3081; Takeyama K, 2001, AM J RESP CRIT CARE, V163, P511; Takeyama K, 2001, AM J PHYSIOL-LUNG C, V280, pL165; Tesfaigzi Y, 2004, AM J PHYSIOL-LUNG C, V286, pL268, DOI 10.1152/ajplung.00172.2003; Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440; Vignola AM, 2001, J ALLERGY CLIN IMMUN, V108, P738, DOI 10.1067/mai.2001.119160; Voynow JA, 2005, AM J RESP CRIT CARE, V172, P1013, DOI 10.1164/rccm.200410-1398OC; Voynow JA, 1999, AM J PHYSIOL-LUNG C, V276, pL835; WANNER A, 1990, CHEST S, V97, P11; Wijkstrom-Frei C, 2003, AM J RESP CELL MOL, V29, P206, DOI 10.1165/rcmb.2002-0152OC; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yoshisue H, 2004, BIOSCI BIOTECH BIOCH, V68, P2024, DOI 10.1271/bbb.68.2024; Zhang M, 1997, EUR RESPIR J, V10, P1747, DOI 10.1183/09031936.97.10081747	84	86	90	0	7	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1044-1549			AM J RESP CELL MOL	Am. J. Respir. Cell Mol. Biol.	MAY	2006	34	5					581	591		10.1165/rcmb.2005-0386OC		11	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	Biochemistry & Molecular Biology; Cell Biology; Respiratory System	040JD	WOS:000237373900024	16424381	
J	Frampton, MW; Stewart, JC; Oberdorster, G; Morrow, PE; Chalupa, D; Pietropaoli, AP; Frasier, LM; Speers, DM; Cox, C; Huang, LS; Utell, MJ				Frampton, MW; Stewart, JC; Oberdorster, G; Morrow, PE; Chalupa, D; Pietropaoli, AP; Frasier, LM; Speers, DM; Cox, C; Huang, LS; Utell, MJ			Inhalation of ultrafine particles alters blood leukocyte expression of adhesion molecules in humans	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						blood leukocytes; human; monocytes; ultrafine particles	PARTICULATE AIR-POLLUTION; EMERGENCY-ROOM VISITS; BRONCHOALVEOLAR LAVAGE; PERIPHERAL-BLOOD; ATOPIC ASTHMA; ENVIRONMENTAL AEROSOLS; LYMPHOCYTE-ACTIVATION; OXIDATIVE STRESS; MENSTRUAL-CYCLE; CARBON-BLACK	Ultrafine particles (UFPs; aerodynamic diameter < 100 nm) may contribute to the respiratory and cardiovascular morbidity and mortality associated with particulate air pollution. We tested the hypothesis that inhalation of carbon UFPs has vascular effects in healthy and asthmatic subjects, detectable as alterations in blood leukocyte expression of adhesion molecules. Healthy subjects inhaled filtered air and freshly generated elemental carbon particles (count median diameter - 25 nm, geometric standard deviation similar to 1.6), for 2 hr, in three separate protocols: 10 mu g/m(3) at rest, 10 and 25 mu g/m(3) with exercise, and 50 mu g/m(3) with exercise. In a fourth protocol, subjects with asthma inhaled air and 10 mu g/m(3) UFPs with exercise. Peripheral venous blood was obtained before and at intervals after exposure, and leukocyte expression of surface markers was quantitated using multiparameter flow cytometry. In healthy subjects, particle exposure with exercise reduced expression of adhesion molecules CD54 and CD18 on monocytes and CD18 and CD49d on granulocytes. There were also concentration-related reductions in blood monocytes, basophils, and eosinophils and increased lymphocyte expression of the activation marker CD25. In subjects with asthma, exposure with exercise to 10 mu g/m(3) UFPs reduced expression of CD11b on monocytes and eosinophils and CD54 on granulocytes. Particle exposure also reduced the percentage of CD4(+) T cells, basophils, and eosinophils. Inhalation of elemental carbon UFPs alters peripheral blood leukocyte distribution and expression of adhesion molecules, in a pattern consistent with increased retention of leukocytes in the pulmonary vascular bed.	Univ Rochester, Med Ctr, Sch Med, Dept Med, Rochester, NY 14642 USA; Univ Rochester, Dept Environm Med, Sch Med, Rochester, NY 14642 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA; Univ Rochester, Dept Biostat, Sch Med, Rochester, NY 14642 USA	Frampton, MW (reprint author), Univ Rochester, Med Ctr, Sch Med, Dept Med, 601 Elmwood Ave,Box 692, Rochester, NY 14642 USA.	mark_frampton@urmc.rochester.edu			NCRR NIH HHS [M01 RR000044, RR00044]; NIEHS NIH HHS [R01 ES011853, ES01247, P30 ES001247]		Anderson GJ, 2001, J APPL PHYSIOL, V91, P1084; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; Batalha JRF, 2002, ENVIRON HEALTH PERSP, V110, P1191; BRAND P, 1991, ATMOS ENVIRON A-GEN, V25, P581, DOI 10.1016/0960-1686(91)90055-C; BRAND P, 1992, ATMOS ENVIRON A-GEN, V26, P2451, DOI 10.1016/0960-1686(92)90375-U; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Chalupa DC, 2004, ENVIRON HEALTH PERSP, V112, P879, DOI 10.1289/ehp.6851; Chalupa DC, 2002, CRUCIAL ISSUES INHAL, P241; CORRIGAN CJ, 1990, AM REV RESPIR DIS, V141, P970; CORRIGAN CJ, 1995, AM J RESP CELL MOL, V12, P567; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370390205065; De C. R., 1995, J CLIN INVEST, V96, P60; DOERSCHUK CM, 2003, THERAPEUTIC TARGETS, P249; FRAMPTON MW, 2004, AM J RESP CRIT CARE, V169, pA280; GAVRAS JB, 1994, INHAL TOXICOL, V6, P633, DOI 10.3109/08958379409003044; Ibald-Mulli A, 2001, AM J PUBLIC HEALTH, V91, P571, DOI 10.2105/AJPH.91.4.571; Jones B., 1989, DESIGN ANAL CROSS TR; Kim HJ, 2003, AM J RESP CELL MOL, V28, P111, DOI 10.1165/rcmb.4796; KITTELSON DB, 2001, 200112 MN DOT; Kunzli N, 2005, ENVIRON HEALTH PERSP, V113, P201, DOI 10.1289/ehp.7523; Lefer AM, 1997, CIRCULATION, V95, P553; LESLIE CA, 1994, PROSTAGLANDINS, V47, P41, DOI 10.1016/0090-6980(94)90073-6; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li XY, 1999, INHAL TOXICOL, V11, P709; Lipsett M, 1997, ENVIRON HEALTH PERSP, V105, P216, DOI 10.1289/ehp.97105216; Mukae H, 2001, AM J RESP CRIT CARE, V163, P201; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; National Institutes of Health, 1997, NIH PUBL; Oberdorster G, 2002, J TOXICOL ENV HEAL A, V65, P1531, DOI 10.1080/00984100290071658; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; OHKAWARA Y, 1995, AM J RESP CELL MOL, V12, P4; Pekkanen J, 2002, CIRCULATION, V106, P933, DOI 10.1161/01.CIR.0000027561.41736.3C; Pekkanen J, 2000, OCCUP ENVIRON MED, V57, P818, DOI 10.1136/oem.57.12.818; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Peters A, 2001, CIRCULATION, V103, P2810; Peters A, 1997, LANCET, V349, P1582, DOI 10.1016/S0140-6736(97)01211-7; Pietropaoli AP, 2004, INHAL TOXICOL, V16, P59, DOI 10.1080/08958370490443079; Pietropaoli A. P., 2004, EFFECTS AIR CONTAMIN, P181; PIETROPAOLI AP, 2004, AM J RESP CRIT CARE, V169, pA883; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; Schwartz J, 2001, ENVIRON HEALTH PERSP, V109, P405, DOI 10.2307/3434788; Schwarz E, 2000, CYTOKINE, V12, P413, DOI 10.1006/cyto.1999.0570; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; STEARNS RC, 1994, P INT C EL MICR PAR, P763; Tan WC, 2000, AM J RESP CRIT CARE, V161, P1213; Tolbert PE, 2000, AM J EPIDEMIOL, V151, P798; Utell MJ, 2002, INHAL TOXICOL, V14, P1231, DOI 10.1080/08958370290084881; Van Eeden SF, 1999, J APPL PHYSIOL, V86, P970; VIRCHOW JC, 1995, AM J RESP CRIT CARE, V151, P960; WALKER C, 1992, AM REV RESPIR DIS, V146, P109; WALLENSTEIN S, 1977, BIOMETRICS, V33, P261, DOI 10.2307/2529321; WICHMANN HE, 2000, HLTH EFF I RES REP, V98, P1; WILSON JW, 1994, AM J RESP CRIT CARE, V149, P86; WILSON JW, 1992, AM REV RESPIR DIS, V145, P958	57	86	91	0	12	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2006	114	1					51	58		10.1289/ehp.7962		8	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	999NR	WOS:000234396800038	16393658	
J	Prescott, SL; Dunstan, JA; Hale, J; Breckler, L; Lehmann, H; Weston, S; Richmond, P				Prescott, SL; Dunstan, JA; Hale, J; Breckler, L; Lehmann, H; Weston, S; Richmond, P			Clinical effects of probiotics are associated with increased interferon-gamma responses in very young children with atopic dermatitis	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						allergy; cytokines; food allergy; infantile atopic dermatitis; probiotics	PLACEBO-CONTROLLED TRIAL; EUROPEAN TASK-FORCE; INTESTINAL MICROFLORA; CONSENSUS REPORT; LYMPHOID-TISSUE; SCORAD INDEX; INFANTS; ALLERGY; GUT; BACTERIA	We recently demonstrated that administration of probiotics resulted in significant clinical improvement in very young children with moderate-to-severe atopic dermatitis (AD). The purpose of this study was to determine the underlying immunological effects that are associated with these apparent clinical benefits. Peripheral blood mononuclear cells (PBMC) were isolated from children (n=53) at baseline and at the end of an 8-week supplementation period during which they received a probiotic (Lactobacillus fermentum PCC (TM)) (n=26) or a placebo (n=27). A further sample was collected at 16 weeks (8 weeks after ceasing the supplement). Cytokine (IL-5, IL-6, IL-10, IL-13, IFN-gamma and TNF-alpha) responses to allergens (egg ovalbumin (OVA), beta lactoglobulin (BLG), house dust mite (HDM)), vaccines (tetanus toxoid (TT)), diphtheria toxoid (DT)), intestinal flora (heat-killed Lactobacillus (HKLB)), heat-killed Staphylococcus aureus (HKSA), Staphylococcus aureus enterotoxin B (SEB) and mitogen (phytohaemaglutinin (PHA)) were compared. The administration of probiotics was associated with a significant increase in T-helper type 1(Th1-type) cytokine IFN-gamma responses to PHA and SEB at the end of the supplementation period (week 8: P=0.004 and 0.046) as well as 8 weeks after ceasing supplementation (week 16: P=0.005 and 0.021) relative to baseline levels of response. No significant changes were seen in the placebo group. The increase in IFN-gamma responses to SEB was directly proportional to the decrease in the severity of AD (r=-0.445, P=0.026) over the intervention period. At the end of the supplementation period (week 8) children receiving probiotics showed significantly higher TNF-alpha responses to HKLB (P=0.018) and HKSA (P=0.011) but this was no longer evident when supplementation ceased (week 16). Although IL-13 responses to OVA were significantly reduced in children receiving probiotics after 8 weeks (P=0.008), there were no other effects on allergen-specific responses, and this effect was not sustained after ceasing supplementation (week 16). There were no effects on vaccine-specific responses, or on responses to any of the stimuli assessed. The improvement in AD severity with probiotic treatment was associated with significant increases in the capacity for Th1 IFN-gamma responses and altered responses to skin and enteric flora. This effect was still evident 2 months after the supplementation was ceased. The lack of consistent effects on allergen-specific responses suggests that the effects of probiotics may be mediated through other independent pathways, which need to be explored further.	UWA, Sch Paediat & Child Hlth, Princess Margaret Hosp, Perth, WA 6840, Australia	Prescott, SL (reprint author), UWA, Sch Paediat & Child Hlth, Princess Margaret Hosp, POB D184, Perth, WA 6840, Australia.	susanp@ichr.uwa.edu.au	Richmond, Peter/G-3379-2012; Prescott, Susan/H-5665-2014				Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Benyacoub J, 2003, J NUTR, V133, P1158; BIENENSTOCK J, 1982, ADV EXP MED BIOL, V149, P471; BIENENSTOCK J, 1984, AM J ANAT, V170, P437, DOI 10.1002/aja.1001700316; Bjorksten B, 2001, J ALLERGY CLIN IMMUN, V108, P516; Bjorksten B, 1999, CLIN EXP ALLERGY, V29, P342; Bottcher MF, 2000, CLIN EXP ALLERGY, V30, P1591, DOI 10.1046/j.1365-2222.2000.00982.x; Christensen HR, 2002, J IMMUNOL, V168, P171; Dunstan JA, 2005, CLIN EXP ALLERGY, V35, P1309, DOI 10.1111/j.1365-2222.2005.02348.x; Dunstan JA, 2003, J ALLERGY CLIN IMMUN, V112, P1178, DOI 10.1016/j.jaci.2003.09.009; GIACINTO CD, 2005, J IMMUNOL, V174, P3237; Haddeland U, 2005, PEDIATR ALLERGY IMMU, V16, P104, DOI 10.1111/j.1399-3038.2005.00250.x; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hart AL, 2004, GUT, V53, P1602, DOI 10.1136/gut.2003.037325; Holt PG, 1999, ALLERGY, V54, P12, DOI 10.1111/j.1398-9995.1999.tb04382.x; Isolauri E, 2000, CLIN EXP ALLERGY, V30, P1604, DOI 10.1046/j.1365-2222.2000.00943.x; Kalliomaki M, 2003, LANCET, V361, P1869, DOI 10.1016/S0140-6736(03)13490-3; Kalliomaki M, 2001, J ALLERGY CLIN IMMUN, V107, P129, DOI 10.1067/mai.2001.111237; Kunz B, 1997, DERMATOLOGY, V195, P10; Lammers KM, 2003, FEMS IMMUNOL MED MIC, V38, P165, DOI 10.1016/S0928-8244(03)00144-5; Majamaa H, 1997, J ALLERGY CLIN IMMUN, V99, P179, DOI 10.1016/S0091-6749(97)70093-9; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Mastrandrea F., 2004, ALLERG IMMUNOL PARIS, V36, P118; Pohjavuori E, 2004, J ALLERGY CLIN IMMUN, V114, P131, DOI 10.1016/j.jaci.2004.03.036; Rehakova Z, 1998, PHYSIOL RES, V47, P357; Rowe J, 2001, J INFECT DIS, V184, P80, DOI 10.1086/320996; STALDER JF, 1993, DERMATOLOGY, V186, P23; Sudo N, 1997, J IMMUNOL, V159, P1739; UPHAM JW, 1995, CLIN EXP ALLERGY, V25, P634, DOI 10.1111/j.1365-2222.1995.tb01111.x; Viljanen M, 2005, ALLERGY, V60, P494, DOI 10.1111/j.1398-9995.2004.00514.x; WESTON S, 2005, ARCH DIS CHILD	31	86	89	0	7	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	DEC	2005	35	12					1557	1564		10.1111/j.1365-2222.2005.02376.x		8	Allergy; Immunology	Allergy; Immunology	990XT	WOS:000233777400007	16393321	
J	Moscato, G; Pignatti, P; Yacoub, MR; Romano, C; Spezia, S; Perfetti, L				Moscato, G; Pignatti, P; Yacoub, MR; Romano, C; Spezia, S; Perfetti, L			Occupational asthma and occupational rhinitis in hairdressers	CHEST			English	Article						hairdressers; occupational asthma; occupational rhinitis; persulfate	PERSULFATE SALTS; AIRWAY INFLAMMATION; INDUCED SPUTUM; TOLUENE DIISOCYANATE; AMMONIUM PERSULFATE; INHALATION; AGENTS; PREVALENCE; DIAGNOSIS; CELL	Background: Hairdressers are at risk for occupational respiratory diseases, but the risk factors, causal agents, and underlying mechanisms are not completely defined. Aim: To describe the features of a large group of hairdressers consecutively referred to our center for suspected occupational asthma (OA) over an 8-year period, the type of occupational respiratory diseases, the etiologic agents, and the diagnostic tests. Results: Forty-seven hairdressers (mean age, 25 years; range, 17 to 52 years) were studied. On the basis of the response to the specific inhalation challenge (SIC), 24 patients received a diagnosis of OA (51.1%), which was due to persulfate salts in 21 patients (87.5%), permanent hair dyes in 2 patients (8.3%), and latex in 1 patient (4.2%). Thirteen of these 24 patients (54.2%) also received a diagnosis of occupational rhinitis, which was due to persulfate salts in I I patients (84.6%) and to paraphenylenediamine in two patients (15.4%). Patients with persulfate asthma had a long period of exposure to bleaching agents, a long latent period between the start of exposure and the onset of symptoms, and a prevalent eosinophilic airway inflammation in induced sputum. The skin-prick test with ammonium persulfate performed in a subset of patients gave negative results Conclusions: In the present study, we confirmed that persulfate salts are the major agents involved in OA and occupational rhinitis in hairdressers. The positive response to the SIC in only a part of the population of symptomatic exposed workers, the period between the starting of exposure and the onset of symptoms, the type of response to the SIC, and the high frequency of association of asthma with other diseases such as dermatitis and rhinitis suggest an immunologic mechanism that remains to be elucidated.	Fdn Salvatore Maugeri, IRCCS, Serv Allergy & Immunol Clin,Sci Inst Pavia, Allergy & Immunol Unit,Inst Res & Care, I-27100 Pavia, Italy; Univ Turin, Allergy & Pneumol Unit, Dept Traumatol Orthopaed & Occupat Med, Turin, Italy; Fdn Salvatore Maugeri, IRCCS, Sci Inst Pavia, Lab Igiene Ambientale & Tossicol Ind, I-27100 Pavia, Italy	Moscato, G (reprint author), Fdn Salvatore Maugeri, IRCCS, Serv Allergy & Immunol Clin,Sci Inst Pavia, Allergy & Immunol Unit,Inst Res & Care, I-27100 Pavia, Italy.	gmoscato@fsm.it		ROMANO, Canzio/0000-0001-5294-9793			Akpinar-Elci M, 2002, J OCCUP ENVIRON MED, V44, P585, DOI 10.1097/00043764-200206000-00023; Ameille J, 2003, OCCUP ENVIRON MED, V60, P136, DOI 10.1136/oem.60.2.136; Anees W, 2002, THORAX, V57, P231, DOI 10.1136/thorax.57.3.231; BAUR X, 1979, RESPIRATION, V38, P144; BLAINEY AD, 1986, THORAX, V41, P42, DOI 10.1136/thx.41.1.42; Cortona G, 2001, G Ital Med Lav Ergon, V23, P64; Di Franco A, 1998, RESP MED, V92, P550; Djukanovic R, 2002, EUR RESPIR J, V20, p1S, DOI 10.1183/09031936.02.00000102; FABBRI LM, 1987, AM REV RESPIR DIS, V136, P36; FISHER AA, 1976, ARCH DERMATOL, V112, P1407, DOI 10.1001/archderm.112.10.1407; GAMBOA PM, 1989, ALLERGOL IMMUNOPATH, V17, P109; Koch P, 2001, Am J Clin Dermatol, V2, P353, DOI 10.2165/00128071-200102060-00002; Leino T, 1998, SCAND J WORK ENV HEA, V24, P398; Lemiere C, 2000, J ALLERGY CLIN IMMUN, V106, P1163; Lemiere Catherine, 2004, Curr Opin Allergy Clin Immunol, V4, P81, DOI 10.1097/00130832-200404000-00002; Macchioni P, 1999, Med Lav, V90, P776; Malo JL, 1997, EUR RESPIR J, V10, P1513, DOI 10.1183/09031936.97.10071513; MALO JL, 1991, AM REV RESPIR DIS, V143, P528; MALO JL, 1992, J ALLERGY CLIN IMMUN, V90, P937, DOI 10.1016/0091-6749(92)90466-F; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; MEINDL K, 1969, ZBL ARBEITSMED, V3, P75; MEREDITH SK, 1991, BRIT J IND MED, V48, P292; MOSCATO G, 1991, J OCCUP ENVIRON MED, V33, P720, DOI 10.1097/00043764-199106000-00014; Moscato G, 2000, Monaldi Arch Chest Dis, V55, P66; Moscato G, 1999, CHEST, V115, P249, DOI 10.1378/chest.115.1.249; Moscato G, 2003, EUR RESPIR J, V21, P879, DOI 10.1183/09031936.03.00000403; Munoz X, 2004, OCCUP ENVIRON MED, V61, P861, DOI 10.1136/oem.2004.013177; Munoz X, 2003, CHEST, V123, P2124, DOI 10.1378/chest.123.6.2124; *NHLBI WHO, 1995, NHLBI WHO PUBL; Pankow W, 1989, Pneumologie, V43, P173; Parameswaran K, 2000, EUR RESPIR J, V15, P486, DOI 10.1034/j.1399-3003.2000.15.10.x; Park HS, 1999, CLIN EXP ALLERGY, V29, P1395; PARRA FM, 1992, ALLERGY, V47, P656, DOI 10.1111/j.1398-9995.1992.tb02391.x; PARSONS JF, 1979, FOOD COSMET TOXICOL, V17, P129, DOI 10.1016/0015-6264(79)90210-4; Pavord ID, 1997, THORAX, V52, P498; PEPYS J, 1975, AM REV RESPIR DIS, V112, P829; PEPYS J, 1976, CLIN ALLERGY, V6, P399, DOI 10.1111/j.1365-2222.1976.tb01922.x; Perfetti L, 2000, ALLERGY, V55, P94, DOI 10.1034/j.1398-9995.2000.00380.x; Pignatti P, 2002, J ALLERGY CLIN IMMUN, V110, P667, DOI 10.1067/mai.2002.128279; PISATI G, 1988, MED TOR, V10, P79; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; Quanjer PH, 1983, B EUR PHYSIOPATHO S5, V19, P45; Rietschel R. L, 2001, FISHERS CONTACT DERM; Schwaiblmair M, 1997, INT ARCH OCC ENV HEA, V70, P419, DOI 10.1007/s004200050239; SCHWARTZ HJ, 1990, J OCCUP ENVIRON MED, V32, P473, DOI 10.1097/00043764-199005000-00015; Siracusa A, 2000, CLIN EXP ALLERGY, V30, P1519, DOI 10.1046/j.1365-2222.2000.00946.x; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172; Stern BJ, 2001, NEUROLOGIST, V7, P1; *SUBC SKIN TESTS E, 1989, ALLERGY S10, V44, P1; Vandenplas O, 1997, EUR RESPIR J, V10, P2612, DOI 10.1183/09031936.97.10112612; Vandenplas O, 2001, J ALLERGY CLIN IMMUN, V107, P542, DOI 10.1067/mai.2001.113519; WRBITZKY R, 1995, INT ARCH OCC ENV HEA, V67, P413, DOI 10.1007/BF00381054; Yawalkar N, 1999, ANN ALLERG ASTHMA IM, V82, P401	53	86	89	0	5	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	NOV	2005	128	5					3590	3598		10.1378/chest.128.5.3590		9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	987HG	WOS:000233508400075	16304318	
J	Philip, G; Nayak, AS; Berger, WE; Leynadier, F; Vrijens, F; Dass, SB; Reiss, TF				Philip, G; Nayak, AS; Berger, WE; Leynadier, F; Vrijens, F; Dass, SB; Reiss, TF			The effect of montelukast on rhinitis symptoms in patients with asthma and seasonal allergic rhinitis	CURRENT MEDICAL RESEARCH AND OPINION			English	Article						allergic rhinitis; asthma; concomitant allergy and asthma; daily rhinitis symptoms; daytime nasal symptoms; montelukast; upper and lower airway disease	RANDOMIZED CONTROLLED-TRIAL; DOUBLE-BLIND; ORAL MONTELUKAST; PLACEBO; LEUKOTRIENES; INFLAMMATION; MULTICENTER; BUDESONIDE; LORATADINE; AIRWAYS	Objective:The objective of this study was to evaluate montelukast 10 mg daily as treatment for allergic rhinitis in patients with symptomatic allergic rhinitis and active asthma during the allergy season. Methods: This was a multicenter study of 831 patients (ages 15 years-85 years) with seasonal allergen sensitivity, active symptoms of seasonal allergic rhinitis, and active asthma. Following a single-blind, placebo run-in period of 3 days-5 days, patients were randomized to oral montelukast 10 mg (n = 415) or placebo (n = 416) daily during the 2-week, double-blind, active-treatment period. Main outcome measures: The primary endpoint was Daily Rhinitis Symptoms score, average of Daytime Nasal Symptoms and Nighttime Symptoms, as self-rated by patients on a 0-3 scale on daily diaries. Results: Montelukast reduced the Daily Rhinitis Symptoms score: difference between montelukast and placebo in mean change from baseline was -0.12 [95% CI -0.18, -0.06; p < 0.0011. Similar improvements were seen in Daytime Nasal Symptoms (-0.14 [-0.21, -0.07; p:less than or equal to 0.001]) and Nighttime Symptoms (-0.10 [-0.16,-0.04; p less than or equal to 0.001]). Improvements (p < 0.05) were seen in Daytime Eye Symptoms and in the secondary endpoints of Global Evaluations of AIR by Patient and by Physician, and Rhinoconjunctivitis Quality of Life. In exploratory analyses, improvement in rhinitis symptoms was numerically (though not statistically) larger in patients with greater levels of asthma at study start. Montelukast provided benefit in the Global Evaluations of Asthma by Patient and by Physician: mean differences were -0.24 [-0.41, -0.06; p = 0.008] and -0.17 [-0.33,-0.01; p = 0.037). Similarly, as-needed P-agonist use (puffs/day) was reduced with montelukast (p less than or equal to 0.005). Conclusion: Montelukast provides significant relief from symptoms of seasonal allergic rhinitis, while also conferring a benefit for asthma, in patients with both allergic rhinitis and asthma.	Merck Res Labs, Resp & Allergy Dept, Rahway, NJ 07065 USA; Univ Illinois, Peoria, IL 61656 USA; So Calif Res, Mission Viejo, CA USA; Univ Paris, F-75252 Paris, France	Philip, G (reprint author), Merck Res Labs, Resp & Allergy Dept, Mail Code RY34B-344,126 E Lincoln Ave, Rahway, NJ 07065 USA.						Baena-Cagnani CE, 2003, INT ARCH ALLERGY IMM, V130, P307, DOI 10.1159/000070218; Bjermer L, 2003, BRIT MED J, V327, P891, DOI 10.1136/bmj.327.7420.891; Borish L, 2003, J ALLERGY CLIN IMMUN, V112, P1021, DOI 10.1016/j.jaci.2003.90.015; Bousquet J., 2003, Clinical and Experimental Allergy Reviews, V3, P43, DOI 10.1046/j.1472-9725.2003.00063.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BOUSQUET J, 2004, 2004 ANN C EUR AC AL; Braunstahl GJ, 2000, AM J RESP CRIT CARE, V161, P2051; Braunstahl GJ, 2003, ALLERGY, V58, P1235, DOI 10.1046/j.0105-4538.2003.00354.x; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Canonica G. W., 2003, Clinical and Experimental Allergy Reviews, V3, P61, DOI 10.1046/j.1472-9725.2003.00014.x; Casale TB, 1999, AM J RESP CRIT CARE, V160, P1778; Ciprandi G., 2004, ALLERG IMMUNOL, V36, P67; Crystal-Peters J, 2002, J ALLERGY CLIN IMMUN, V109, P57, DOI 10.1067/mai.2002.120554; Dahlen S.-E., 2003, Clinical and Experimental Allergy Reviews, V3, P69, DOI 10.1046/j.1472-9725.2003.00016.x; Howarth PH, 2000, AM J RESP CRIT CARE, V161, pS133; JUNIPER EF, 1991, CLIN EXP ALLERGY, V21, P77, DOI 10.1111/j.1365-2222.1991.tb00807.x; Juniper EF, 1997, J ALLERGY CLIN IMMUN, V99, P742; LAM S, 1988, J ALLERGY CLIN IMMUN, V81, P711, DOI 10.1016/0091-6749(88)91043-3; Leynaert B, 2000, AM J RESP CRIT CARE, V162, P1391; Leynaert B., 2000, J ALLERGY CLIN IMMUN, V106, P201; LIU MC, 1991, AM REV RESPIR DIS, V144, P51; Malmstrom K, 1999, ANN INTERN MED, V130, P487; Meltzer EO, 2000, J ALLERGY CLIN IMMUN, V105, P917, DOI 10.1067/mai.2000.106040; Nathan RA, 1997, J ALLERGY CLIN IMMUN, V99, pS808, DOI 10.1016/S0091-6749(97)80040-1; Nayak AS, 2002, ANN ALLERG ASTHMA IM, V88, P592; Pawankar R., 2003, Clinical and Experimental Allergy Reviews, V3, P74, DOI 10.1046/j.1472-9725.2003.00017.x; PERRY TT, IN PRESS ANN ALLERGY; Philip G, 2002, CLIN EXP ALLERGY, V32, P1020, DOI 10.1046/j.1365-2222.2002.01422.x; Price DB, 2003, THORAX, V58, P211, DOI 10.1136/thorax.58.3.211; PRICE DB, IN PRESS CLIN EXP AL; PRICE DB, 2003, ALLERGY CLIN IMMUN S, V1, P29; Reiss T. F., 2001, Clinical and Experimental Allergy Reviews, V1, P264, DOI 10.1046/j.1472-9725.2001.t01-1-00012.x; Reiss TF, 1998, ARCH INTERN MED, V158, P1213, DOI 10.1001/archinte.158.11.1213; Schramm B, 2003, EUR RESPIR J, V21, P116, DOI 10.1183/09031936.03.00019502; Simons FER, 1999, J ALLERGY CLIN IMMUN, V104, P534, DOI 10.1016/S0091-6749(99)70320-9; TOGIAS A, 2003, J ALLERGY CLIN IMMUN, V1111, P1171; van Adelsberg J, 2003, ALLERGY, V58, P1268, DOI 10.1046/j.1398-9995.2003.00261.x; van Adelsberg J, 2003, ANN ALLERG ASTHMA IM, V90, P214; Vignola A. M., 2003, Clinical and Experimental Allergy Reviews, V3, P63, DOI 10.1046/j.1472-9725.2003.00015.x; Von Mutius E, 1998, CLIN EXP ALLERGY, V28, P45; WENZEL SE, 2003, FATTY ACIDS, V69, P145; Wilson AM, 2001, CLIN EXP ALLERGY, V31, P616, DOI 10.1046/j.1365-2222.2001.01088.x	42	86	94	0	4	LIBRAPHARM	NEWBURY	C/O DR. PETER L CLARKE, 26-32 VENTURE WEST, NEW GREENHAM PARK, NEWBURY RG19 6HX, BERKSHIRE, ENGLAND	0300-7995			CURR MED RES OPIN	Curr. Med. Res. Opin.	OCT	2004	20	10					1549	1558		10.1185/030079904X3348		10	Medicine, General & Internal; Medicine, Research & Experimental	General & Internal Medicine; Research & Experimental Medicine	864MX	WOS:000224638700004	15462688	
J	Antonini, JM; Taylor, MD; Zimmer, AT; Roberts, JR				Antonini, JM; Taylor, MD; Zimmer, AT; Roberts, JR			Pulmonary responses to welding fumes: Role of metal constituents	JOURNAL OF TOXICOLOGY AND ENVIRONMENTAL HEALTH-PART A-CURRENT ISSUES			English	Article; Proceedings Paper	42nd Annual Meeting of the Society-of-Toxicology	MAR   12, 2003	Lake city, UT	Soc Toxicol			OIL FLY-ASH; STAINLESS-STEEL WELDERS; MILD-STEEL; LUNG-CANCER; ARC WELDERS; SHIPYARD WORKERS; PARTICLES; HEALTH; MORTALITY; CHROMIUM	It is estimated that more than 1 million workers worldwide perform some type of welding as part of their work duties. Epidemiology studies have shown that a large number of welders experience some type of respiratory illness. Respiratory effects seen in full-time welders have included bronchitis, siderosis, asthma, and a possible increase in the incidence of lung cancer. Pulmonary infections are increased in terms of severity, duration, and frequency among welders. Inhalation exposure to welding fumes may vary due to differences in the materials used and methods employed. The chemical properties of welding fumes can be quite complex. Most welding materials are alloy mixtures of metals characterized by different steels that may contain iron, manganese, chromium, and nickel. Animal studies have indicated that the presence and combination of different metal constituents is an important determinant in the potential pneumotoxic responses associated with welding fumes. Animal models have demonstrated that stainless steel (SS) welding fumes, which contain significant levels of nickel and chromium, induce more lung injury and inflammation, and are retained in the longs longer than mild steel (MS) welding fumes, which contain mostly iron. In addition, SS fumes generated from welding processes using fluxes to protect the resulting weld contain elevated levels of soluble metals, which may affect respiratory health. Recent animal studies have indicated that the lung injury and inflammation induced by SS welding fumes that contain water-soluble metals are dependent on both the soluble and insoluble fractions of the fume. This article reviews the role that metals play in the pulmonary effects associated with welding fume exposure in workers and laboratory animals.	NIOSH, Hlth Effects Lab Div, Morgantown, WV 26505 USA; NIOSH, Div Appl Res & Technol, Cincinnati, OH 45226 USA	Antonini, JM (reprint author), NIOSH, Hlth Effects Lab Div, 1095 Willowdale Rd,M-S 2015, Morgantown, WV 26505 USA.	jga6@cdc.gov					ACGIH, 2001, DOC THRESH LIM VAL C, V3, P1726; AKBARKHANZADEH F, 1993, INT ARCH OCC ENV HEA, V64, P393, DOI 10.1007/BF00517944; AKBARKHANZADEH F, 1980, J OCCUP ENVIRON MED, V22, P337, DOI 10.1097/00043764-198005000-00007; Antonini JM, 2003, AM J IND MED, V43, P350, DOI 10.1002/ajim.10194; ANTONINI JM, 1994, ENVIRON HEALTH PERSP, V102, P37, DOI 10.2307/3432211; Antonini JM, 2003, CRIT REV TOXICOL, V33, P61, DOI 10.1080/713611032; Antonini JM, 1997, EXP LUNG RES, V23, P205, DOI 10.3109/01902149709087368; Antonini JM, 1996, TOXICOL APPL PHARM, V140, P188, DOI 10.1006/taap.1996.0212; Antonini JM, 1999, J TOXICOL ENV HEAL A, V58, P343, DOI 10.1080/009841099157205; ATTFIELD MD, 1978, BRIT J IND MED, V35, P117; Beach JR, 1996, AM J RESP CRIT CARE, V154, P1394; BECK BD, 1982, TOXICOL APPL PHARM, V66, P9, DOI 10.1016/0041-008X(82)90057-6; Becker N, 1999, J OCCUP ENVIRON MED, V41, P294, DOI 10.1097/00043764-199904000-00012; BOSHNAKOVA E, 1989, Journal of Hygiene Epidemiology Microbiology and Immunology (Prague), V33, P379; Buerke U, 2002, AM J IND MED, V41, P259, DOI 10.1002/ajim.10055; *BUR LAB STAT, 1999, OCC EMPL STAT 1999 N; CLAPP DE, 1977, WELD J, V56, pS380; COGGON D, 1994, LANCET, V344, P41, DOI 10.1016/S0140-6736(94)91056-1; COHEN MD, 1993, CRIT REV TOXICOL, V23, P255, DOI 10.3109/10408449309105012; DANIELSEN TE, 1993, BRIT J IND MED, V50, P1097; Danielsen TE, 2000, J OCCUP ENVIRON MED, V42, P101, DOI 10.1097/00043764-200001000-00023; DOIG A. T., 1964, ANN OCCUP HYG, V7, P223; Dreher KL, 1997, J TOXICOL ENV HEALTH, V50, P285, DOI 10.1080/009841097160492; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; Hansen KS, 1996, AM J IND MED, V30, P373, DOI 10.1002/(SICI)1097-0274(199610)30:4<373::AID-AJIM1>3.0.CO;2-X; Hewitt PJ, 2001, ANN OCCUP HYG, V45, P295, DOI 10.1016/S0003-4878(00)00092-2; *HOB I WELD TECHN, 1977, POCK WELD GUID, P119; IARC, 1990, IARC MON EV CARC RIS, V49, P447; KLEINFEL.M, 1969, ARCH ENVIRON HEALTH, V19, P70; Kodavanti UP, 1998, TOXICOL SCI, V43, P204, DOI 10.1093/toxsci/43.2.204; Lewis AB, 2003, J BIOSCIENCES, V28, P13, DOI 10.1007/BF02970126; LOCKEY JE, 1988, AM REV RESPIR DIS, V138, P1047; Langard S., 1997, CLIN PULM MED, V4, P194, DOI 10.1097/00045413-199707000-00003; MAXILD J, 1978, MUTAT RES, V56, P235, DOI 10.1016/0027-5107(78)90190-2; MINNI E, 1984, J AEROSOL SCI, V15, P57, DOI 10.1016/0021-8502(84)90056-9; MORGAN WKC, 1989, AM IND HYG ASSOC J, V50, P59, DOI 10.1080/15298668991374318; MOULIN JJ, 1993, BRIT J IND MED, V50, P234; Moulin JJ, 1997, SCAND J WORK ENV HEA, V23, P104; MUR JM, 1985, INT ARCH OCC ENV HEA, V57, P1, DOI 10.1007/BF00383541; [Anonymous], 1992, DHHS NIOSH PUBL; OBERDORSTER G, 1992, ENVIRON HEALTH PERSP, V97, P193, DOI 10.2307/3431353; OXHOJ H, 1979, ARCH ENVIRON HEALTH, V34, P211; ROSLER JA, 1996, EUR RESP J S23, V9, pS220; SFERLAZZA SJ, 1991, AM REV RESPIR DIS, V143, P1134; Simonsson B. G., 1995, European Respiratory Journal, V8, p194S; SJOGREN B, 1994, OCCUP ENVIRON MED, V51, P335; SJOGREN B, 1987, SCAND J WORK ENV HEA, V13, P247; Sobaszek A, 2000, J OCCUP ENVIRON MED, V42, P923, DOI 10.1097/00043764-200009000-00016; SREEKANTHAN P, 1997, THESIS MIT CAMBRIDGE; STEENLAND K, 1991, AM J EPIDEMIOL, V133, P220; STERN RM, 1983, ARCH ENVIRON HEALTH, V38, P148; STERN RM, 1981, ENVIRON HEALTH PERSP, V41, P235, DOI 10.2307/3429321; STERN RM, 1977, DANISH WELDING I PUB, V7705; Tuschl H, 1997, J APPL TOXICOL, V17, P377; Ulfarson U., 1981, SCAND J WORK ENV HEA, V2, P1; VILLAUME JE, 1979, EFFECTS WELDING HLTH, V1; Voitkevich V, 1995, WELDING FUMES FORMAT, P18; WANG ZP, 1994, AM J IND MED, V26, P741, DOI 10.1002/ajim.4700260603; Wergeland E, 2001, SCAND J WORK ENV HEA, V27, P353; Zimmer AT, 2001, J AEROSOL SCI, V32, P993, DOI 10.1016/S0021-8502(01)00035-0	60	86	92	2	9	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1528-7394			J TOXICOL ENV HEAL A	J. Toxicol. Env. Health Part A	FEB 13	2004	67	3					233	249		10.1080/15287390490266909		17	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	802BG	WOS:000220138400005	14681078	
J	Ebo, DG; Hagendorens, MM; Bridts, CH; De Clerck, LS; Stevens, WJ				Ebo, DG; Hagendorens, MM; Bridts, CH; De Clerck, LS; Stevens, WJ			Sensitization to cross-reactive carbohydrate determinants and the ubiquitous protein profilin: mimickers of allergy	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						carbohydrate determinants; cross-reactivity; food; hymenoptera venom; IgE; latex; profilin	CORE ALPHA-1,3-LINKED FUCOSE; OLIVE TREE POLLEN; BIRCH POLLEN; IGE-BINDING; CLINICAL RELEVANCE; MAJOR ALLERGEN; GRASS-POLLEN; HEVEA-BRASILIENSIS; FOOD ALLERGENS; LATEX PROFILIN	Background During the last decade, evidence has been provided for profilins and cross-reactive carbohydrate determinants (CCDs) to be capable of inducing cross-reactive IgE antibodies with little clinical relevance. Objective To investigate the prevalence of sensitization to CCD and profilin in isolated allergies (birch, timothy grass, house dust mite, pets (cat and/or dog), natural rubber latex (NRL) and hymenoptera venom). To study the contribution of anti-CCD and anti-profilin IgE antibodies as a cause of clinically irrelevant IgE for NRL and apple. Methods For the first part of the study, 100 patients with inhalant allergy, 17 patients with NRL allergy and 40 patients with venom anaphylaxis were enrolled. Diagnosis was based on a questionnaire and a positive IgE determination and skin test for relevant allergen. Patients were identified as sensitized to CCD if they had a negative prick test and positive IgE for the glycoprotein bromelain. Sensitization to profilin was assessed by IgE for rBet v 2 (recombinant birch profilin). For the second part of the study, sera containing IgE against apple (n=82) or NRL (n=38) were classified as true-negative or false-positive according to the presence or absence of an oral allergy syndrome (OAS) or NRL-induced anaphylaxis. In these patients, sensitization to CCD and profilin was evaluated as described above. Results No sensitization to bromelain-type CCD and profilin was found in isolated birch pollen or NRL allergy. In contrast, sensitization to bromelain-type CCD was found in 4/17 patients with isolated grass pollinosis, 5/24 patients with combined pollinosis (birch, timothy, mugwort) and 7/33 patients with venom anaphylaxis. Sensitization to profilin was almost restricted to patients with combined pollen allergy (5/24). In pollen-allergic individuals with a false-positive IgE against NRL the prevalence of sensitization to bromelain-type CCD and profilin IgE was higher than in NRL-allergic patients (P<0.00001 and P=0.0006, respectively). In pollen-allergic individuals with a false-positive IgE to apple, the frequency of sensitization to bromelain-type CCD was higher than in OAS patients (P=0.004). Clinically irrelevant NRL and apple were also found in four and five out of the seven patients sensitized to venom CCD, respectively. In pollinosis, clinically irrelevant NRL and apple IgE antibodies were inhibited by bromelain and recombinant birch profilin, whereas in isolated venom anaphylaxis these antibodies were inhibited by bromelain. Conclusions Patients monoallergic to NRL or birch pollen showed no sensitization to bromelain-type CCD or profilin. Sensitization to profilin and/or bromelain-type CCD, caused by pollen (timothy grass, mugwort) or hymenoptera venom allergens, can elicit false-positive IgE antibodies against NRL and apple.	Univ Antwerp, Dept Immunol Allergol & Rheumatol, B-2610 Antwerp, Belgium	Stevens, WJ (reprint author), Univ Antwerp, Dept Immunol Allergol & Rheumatol, Univ Pl 1, B-2610 Antwerp, Belgium.	immuno@ua.ac.be	BRIDTS, Chris/M-7933-2016; EBO, Didier/H-4894-2016	BRIDTS, Chris/0000-0002-3324-7320; EBO, Didier/0000-0003-0672-7529			AALBERSE RC, 1981, J ALLERGY CLIN IMMUN, V68, P356, DOI 10.1016/0091-6749(81)90133-0; Aalberse RC, 2001, ALLERGY, V56, P478, DOI 10.1034/j.1398-9995.2001.056006478.x; Batanero E, 1999, J ALLERGY CLIN IMMUN, V103, P147, DOI 10.1016/S0091-6749(99)70538-5; BATANERO E, 1994, MOL IMMUNOL, V31, P31, DOI 10.1016/0161-5890(94)90135-X; BIRCHER AJ, 1994, CLIN EXP ALLERGY, V24, P367, DOI 10.1111/j.1365-2222.1994.tb00248.x; BREITENEDER H, 1989, EMBO J, V8, P1935; CANONICA GW, 1989, ALLERGY, V44, P1, DOI 10.1111/j.1398-9995.1989.tb00438.x; Daschner A, 1998, ALLERGY, V53, P614, DOI 10.1111/j.1398-9995.1998.tb03938.x; Diez-Gomez ML, 1999, ALLERGY, V54, P951, DOI 10.1034/j.1398-9995.1999.00145.x; EBNER C, 1995, J ALLERGY CLIN IMMUN, V95, P962, DOI 10.1016/S0091-6749(95)70096-X; Ebo DG, 2002, ALLERGY, V57, P706, DOI 10.1034/j.1398-9995.2002.23553.x; Elfman L, 1997, INT ARCH ALLERGY IMM, V113, P249; Fotisch K, 1999, INT ARCH ALLERGY IMM, V120, P30, DOI 10.1159/000024217; Fotisch K, 1998, ALLERGY, V53, P1043, DOI 10.1111/j.1398-9995.1998.tb03813.x; Fotisch K, 2001, GLYCOCONJUGATE J, V18, P373, DOI 10.1023/A:1014860030380; Fuchs T, 1997, J ALLERGY CLIN IMMUN, V100, P356, DOI 10.1016/S0091-6749(97)70249-5; GAILHOFER G, 1988, CLIN ALLERGY, V18, P445, DOI 10.1111/j.1365-2222.1988.tb02894.x; Ganglberger E, 2001, INT ARCH ALLERGY IMM, V125, P216, DOI 10.1159/000053819; Hemmer W, 2001, J ALLERGY CLIN IMMUN, V108, P1045, DOI 10.1067/mai.2001.120013; Hirschwehr R, 1998, J ALLERGY CLIN IMMUN, V101, P196; ISHIHARA H, 1979, J BIOL CHEM, V254, P715; KOCHUYT AM, 2000, THESIS U LEUVEN LEUV; Luttkopf D, 2000, J ALLERGY CLIN IMMUN, V106, P390, DOI 10.1067/mai.2000.108711; Mari A, 1999, J ALLERGY CLIN IMMUN, V103, P1005, DOI 10.1016/S0091-6749(99)70171-5; Mari A, 2001, INT ARCH ALLERGY IMM, V125, P57, DOI 10.1159/000053797; Nettis E, 2001, ALLERGY, V56, P257, DOI 10.1034/j.1398-9995.2001.056003257.x; Nieto A, 2000, CLIN EXP ALLERGY, V30, P264; Pauli G, 1996, J ALLERGY CLIN IMMUN, V97, P1100, DOI 10.1016/S0091-6749(96)70264-6; Petersen A, 1996, J ALLERGY CLIN IMMUN, V98, P805, DOI 10.1016/S0091-6749(96)70130-6; PETERSEN A, 1995, ELECTROPHORESIS, V16, P869, DOI 10.1002/elps.11501601144; Pike RN, 1997, INT ARCH ALLERGY IMM, V112, P412; Pridgeon C, 2000, CLIN EXP ALLERGY, V30, P1444, DOI 10.1046/j.1365-2222.2000.00908.x; Rihs HP, 2000, ALLERGY, V55, P712, DOI 10.1034/j.1398-9995.2000.00553.x; Rossi RE, 1996, ALLERGY, V51, P940; Schafer T, 1996, ALLERGY, V51, P372; TRETTER V, 1993, INT ARCH ALLERGY IMM, V102, P259; VALENTA R, 1992, J EXP MED, V175, P377, DOI 10.1084/jem.175.2.377; VALLIER P, 1995, CLIN EXP ALLERGY, V25, P332; van Ree R, 2002, INT ARCH ALLERGY IMM, V129, P189, DOI 10.1159/000066770; van Ree R, 2000, J BIOL CHEM, V275, P11451, DOI 10.1074/jbc.275.15.11451; vanderVeen MJ, 1997, J ALLERGY CLIN IMMUN, V100, P327, DOI 10.1016/S0091-6749(97)70245-8; VANREE R, 1993, J CLIN IMMUNOASSAY, V16, P124; van Ree R, 2000, ALLERGY CLIN IMMUNOL, V12, P7, DOI 10.1027/0838-1925.12.1.7; Vieths S, 2002, ANN NY ACAD SCI, V964, P47; Wensing M, 2002, J ALLERGY CLIN IMMUN, V110, P435, DOI 10.1067/mai.2002.126380; Wilson IBH, 2001, GLYCOBIOLOGY, V11, P261, DOI 10.1093/glycob/11.4.261; Wilson IBH, 1998, GLYCOCONJUGATE J, V15, P1055, DOI 10.1023/A:1006960401562; Yagami T, 2002, INT ARCH ALLERGY IMM, V129, P27, DOI 10.1159/000065180; Yagami T, 1998, J ALLERGY CLIN IMMUN, V101, P379; Yip L, 2000, INT ARCH ALLERGY IMM, V121, P292, DOI 10.1159/000024342	50	86	87	1	5	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	JAN	2004	34	1					137	144		10.1111/j.1365-2222.2004.01837.x		8	Allergy; Immunology	Allergy; Immunology	763LF	WOS:000188086500021	14720274	
J	Shepherd, GM				Shepherd, GM			Hypersensitivity reactions to chemotherapeutic drugs	CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY			English	Review						hypersensitivity; allergy; chemotherapy; desensitization; drug asparaginase; platinum compounds; epipodophyllotoxins; taxanes	ACUTE LYMPHOBLASTIC-LEUKEMIA; PEGYLATED LIPOSOMAL DOXORUBICIN; DESENSITIZATION PROTOCOL; ALLERGIC REACTIONS; CARBOPLATIN; PACLITAXEL; ASPARAGINASE; CANCER; CYCLOPHOSPHAMIDE; DOCETAXEL	There is an ever-increasing number of therapeutics used to treat cancer. A recent publication listed 86 currently available antineoplastic medications. Despite this large number, hypersensitivity reactions are not common except with platinum compounds (cisplatin, carboplatin), epipodophyllotoxins (teniposide, etoposide), asparaginase, taxanes (paclitaxel), and procarbazine. Doxorubicin and 6-mercaptopurine are occasionally associated with hypersensitivity reaction. Comparable reactions with other chemotherapeutic agents are. uncommon; many are only anecdotal reports. Reactions associated with individual drugs are discussed in detail. The mechanisms responsible for most of these reactions are not known, as they have generally not been evaluated. The term "hypersensitivity" is widely used in the chemotherapy literature without a common definition. Hypersensitivity is defined here as an unexpected reaction with signs and symptoms not consistent with known toxicity of the drug. Most reactions are coincident with or within hours of drug administration. Almost all are associated with parenteral administration. Symptoms include flushing, alterations in heart rate and blood pressure, dyspnea and bronchospasm, back pain, fever, pruritus, nausea and all types of rashes. Some cases may be due to non-immune mediated release of histamine or cytokines, as many patients can subsequently tolerate re-exposure after pretreatment with steroids and antihistamine, and slow readministration of the drug. This is more compatible with a graded challenge, than desensitization and is generally successful for taxanes, less so for platinum compounds. In most cases hypersensitivity reactions are associated with the specific chemotherapeutic drug. Reaction rates may vary with different forms of the drugs, e.g. pegylated. Occasionally excipients such as Cremaphor EL may induce hypersensitivity reactions.	Cornell Univ, Weill Med Coll, New York, NY 10021 USA	Shepherd, GM (reprint author), Cornell Univ, Weill Med Coll, New York, NY 10021 USA.						ABRAMOWICZ M, 2000, MED LETT, V42, P83; Alberts DS, 1997, DRUGS, V54, P30; Alkins SA, 1996, CANCER, V77, P2123, DOI 10.1002/(SICI)1097-0142(19960515)77:10<2123::AID-CNCR24>3.0.CO;2-W; BERNSTEIN BJ, 2000, ANN PHARMACOTHER, V11, P1332; Blanca M, 1997, ALLERGY, V52, P1009, DOI 10.1111/j.1398-9995.1997.tb02422.x; Chiara S, 1997, EUR J CANCER, V33, P967, DOI 10.1016/S0959-8049(96)00497-2; CORNWELL GG, 1979, CANCER TREAT REP, V63, P399; COYLE T, 1992, CANCER, V69, P2532, DOI 10.1002/1097-0142(19920515)69:10<2532::AID-CNCR2820691024>3.0.CO;2-I; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V97, P42, DOI 10.1016/S0091-6749(96)70281-6; Fishman A, 1999, INT J GYNECOL CANCER, V9, P156, DOI 10.1046/j.1525-1438.1999.99014.x; FOSSELLA FV, 1994, J CLIN ONCOL, V12, P1238; Gabizon AA, 2001, CANCER INVEST, V19, P424, DOI 10.1081/CNV-100103136; GIGUERE JK, 1988, MED PEDIATR ONCOL, V16, P378, DOI 10.1002/mpo.2950160605; Goldberg A, 1996, J ALLERGY CLIN IMMUN, V98, P841, DOI 10.1016/S0091-6749(96)70134-3; GORAM AL, 2001, PHARMACOTHERAPY, V6, P751; GROSEN E, 2000, LANCET, V354, P288; Hoetelmans RWM, 1996, ANN PHARMACOTHER, V30, P367; HUDSON MM, 1993, J CLIN ONCOL, V11, P1080; KELLIE SJ, 1991, CANCER-AM CANCER SOC, V67, P1070, DOI 10.1002/1097-0142(19910215)67:4<1070::AID-CNCR2820670434>3.0.CO;2-X; Kintzel PE, 2001, ANN PHARMACOTHER, V35, P1114; Koppler H, 2001, ONKOLOGIE, V24, P283, DOI 10.1159/000055093; Korelitz BI, 1999, J CLIN GASTROENTEROL, V28, P341, DOI 10.1097/00004836-199906000-00011; Larson RA, 1998, LEUKEMIA, V12, P660, DOI 10.1038/sj.leu.2401007; Lehmann DF, 1997, CLIN PHARMACOL THER, V62, P225, DOI 10.1016/S0009-9236(97)90071-0; Markman M, 1999, J CLIN ONCOL, V17, P1141; Moon C, 2000, ANTI-CANCER DRUG, V11, P565, DOI 10.1097/00001813-200008000-00007; Mueller Hans-Joachim, 2001, British Journal of Haematology, V114, P794; Myers J S, 2000, Clin J Oncol Nurs, V4, P161; NOLTE H, 1988, AM J PEDIAT HEMATOL, V10, P308; Ozkan A, 2001, PEDIATR DERMATOL, V18, P38, DOI 10.1046/j.1525-1470.2001.018001038.x; PEEREBOOM DM, 1993, J CLIN ONCOL, V11, P885; Polyzos A, 2001, ONCOLOGY-BASEL, V61, P129, DOI 10.1159/000055363; Popescu MA, 1996, J ALLERGY CLIN IMMUN, V97, P26; RHEINHOLDKELLER E, 1992, CLIN INVESTIG, V70, P698; Robinson JB, 2001, GYNECOL ONCOL, V82, P550, DOI 10.1006/gyno.2001.6331; Sandhu H S, 2000, Can Respir J, V7, P491; Shukunami K, 1999, GYNECOL ONCOL, V72, P431, DOI 10.1006/gyno.1998.5273; Stone HD, 1998, J ALLERGY CLIN IMMUN, V101, P429; Szebeni J, 2001, INT IMMUNOPHARMACOL, V1, P721, DOI 10.1016/S1567-5769(01)00006-6; TORRICELLI R, 1995, SCHWEIZ MED WSCHR, V125, P1870; WEISS RB, 1992, SEMIN ONCOL, V19, P458; Woo MH, 2000, J CLIN ONCOL, V18, P1525; Zanotti KM, 2001, J CLIN ONCOL, V19, P3126; Zanotti KM, 2001, DRUG SAFETY, V24, P767, DOI 10.2165/00002018-200124100-00005; ZONZITS E, 1992, ARCH DERMATOL, V128, P80, DOI 10.1001/archderm.128.1.80; 2001, PHYSICIANS DESK REFE, P1925	46	86	93	0	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1080-0549			CLIN REV ALLERG IMMU	Clin. Rev. Allergy Immunol.	JUN	2003	24	3					253	262		10.1385/CRIAI:24:3:253		10	Allergy; Immunology	Allergy; Immunology	674JJ	WOS:000182633400006	12721396	
J	Fisk, WJ; Faulkner, D; Palonen, J; Seppanen, O				Fisk, WJ; Faulkner, D; Palonen, J; Seppanen, O			Performance and costs of particle air filtration technologies	INDOOR AIR			English	Article						allergen; building; concentration; filtration; particle; reduction	TOBACCO-SMOKE PARTICLES; AEROSOL FRACTION; MITE ALLERGEN; DEPOSITION; POLLEN; PENETRATION; EXPOSURE; OUTDOOR	This paper predicts the reductions in the indoor mass concentrations of particles attainable from use of filters in building supply airstreams and also from use of stand-alone fan-filter units. Filters with a wide efficiency range are considered. Predicted concentration reductions are provided for indoor-generated particles containing dust-mite and cat allergen, for environmental tobacco smoke (ETS) particles, and for outdoor air fine-mode particles. Additionally, this paper uses a simple model and available data to estimate the energy and total costs of the filtration options. Predicted reductions in cat and dust-mite allergen concentrations range from 20 to 80%. To obtain substantial, e.g. 50%, reductions in indoor concentrations of these allergens, the rate of airflow through the filter must be at least a few indoor volumes per hour. Increasing filter efficiencies above approximately ASHRAE Dust Spot 65% does not significantly reduce predicted indoor concentrations of these allergens. For ETS particles and outdoor fine-mode particles, calculations indicate that relatively large, e.g. 80%, decreases in indoor concentrations are attainable with practical filter efficiencies and flow rates. Increasing the filter efficiency above ASHRAE 85% results in only modest predicted incremental decreases in indoor concentration. Energy costs and total costs can be similar for filtration using filters with a wide range of efficiency ratings. Total estimated filtration costs of approximately $0.70 to $1.80 per person per month are insignificant relative to salaries, rent, or health insurance costs.	Univ Calif Berkeley, Lawrence Berkeley Lab, Indoor Environm Dept, Berkeley, CA 94720 USA; Helsinki Univ Technol, Lab Heating Ventilating & Air Condittioning, FIN-02150 Espoo, Finland	Fisk, WJ (reprint author), Univ Calif Berkeley, Lawrence Berkeley Lab, Indoor Environm Dept, MS 90-3058, Berkeley, CA 94720 USA.						Abt E, 2000, ENVIRON SCI TECHNOL, V34, P3579, DOI 10.1021/es990348y; *ASHRAE, 1992, 521 ANSIASHRAE; ASHRAE, 1999, 522 ASHRAE; *ASHRAE, 1996, ASHRAE HDB; *CA EPA, 1997, HLTH EFF EXP ENV TOB; Committee on the Assessment of Asthma and Indoor Air, 2000, CLEAR AIR ASTHM IND; COUCH RB, 1981, B NEW YORK ACAD MED, V57, P907; Custovic A, 1998, THORAX, V53, P33; DEBLAY F, 1991, J ALLERGY CLIN IMMUN, V88, P919, DOI 10.1016/0091-6749(91)90249-N; DICK EC, 1987, J INFECT DIS, V156, P442; *DOD, 1987, 8559 NAT TECHN INF S; *DOD, 1987, 4234 DOD TB; *EPA, 1996, EPA600AP95001C; *EPA, 1996, EPA600AP95001A; *EPA, 1992, EPA600690006F; Fogh CL, 1997, ATMOS ENVIRON, V31, P2193, DOI 10.1016/S1352-2310(97)00037-X; HANLEY JT, 1994, INDOOR AIR, V4, P169, DOI 10.1111/j.1600-0668.1994.t01-1-00005.x; Lai ACK, 2000, J AEROSOL SCI, V31, P463; LEWIS S, 1995, J HAZARD MATER, V43, P195, DOI 10.1016/0304-3894(95)00037-U; MEANS RS, 1999, FACILITIES MAINTENAN; Miller SL, 2001, ATMOS ENVIRON, V35, P2053, DOI 10.1016/S1352-2310(00)00506-9; Milton D.K., 1996, INDOOR AIR HUMAN HLT, P179; NAZAROFF WW, 1993, ASTM STANDARD TECHNI, V1205; Ozkaynak H, 1996, J EXPO ANAL ENV EPID, V6, P57; Pope A. M., 1993, INDOOR ALLERGENS ASS; RANTIOLEHTIMAKI A, 1994, CLIN EXP ALLERGY, V24, P23, DOI 10.1111/j.1365-2222.1994.tb00912.x; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; SOOLE BW, 1971, AEROSOL SCI, V2, P1; SOOLE BW, 1971, AEROSOL SCIENCE, V2, P281; SPIEKSMA FTM, 1991, GRANA, V30, P98; SPIEKSMA FTM, 1990, CLIN EXP ALLERGY, V20, P273, DOI 10.1111/j.1365-2222.1990.tb02683.x; THATCHER TL, 1995, ATMOS ENVIRON, V29, P1487, DOI 10.1016/1352-2310(95)00016-R; TOVEY ER, 1981, AM REV RESPIR DIS, V124, P630; TSUBATA R, 1996, P IND AIR 96 SEEC IS, V3, P155; Vette AF, 2001, AEROSOL SCI TECH, V34, P118, DOI 10.1080/027868201300082120; WHITBY KT, 1978, ATMOS ENVIRON, V12, P135, DOI 10.1016/0004-6981(78)90196-8; XU MD, 1994, AEROSOL SCI TECH, V20, P194, DOI 10.1080/02786829408959676	37	86	89	2	36	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6947			INDOOR AIR	Indoor Air	DEC	2002	12	4					223	234		10.1034/j.1600-0668.2002.01136.x		12	Construction & Building Technology; Engineering, Environmental; Public, Environmental & Occupational Health	Construction & Building Technology; Engineering; Public, Environmental & Occupational Health	625CD	WOS:000179798600004	12532754	
J	Burge, HA				Burge, HA			An update on pollen and fungal spore aerobiology	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						pollen; fungi; aerobiology; spores; allergen; immunodetection	IN-HOUSE DUST; THUNDERSTORM-ASSOCIATED ASTHMA; VOLATILE ORGANIC-COMPOUNDS; WATER-DAMAGED BUILDINGS; REPORTED HOME DAMPNESS; GRASS-POLLEN; STACHYBOTRYS-CHARTARUM; RESIDENTIAL CHARACTERISTICS; RESPIRATORY SYMPTOMS; INDOOR AIR	Changes in climate are altering pollen distribution. Predictive modeling can be used to forecast long- and short-term changes in pollen concentrations. Increasing evidence confirms the presence of pollen allergens on small, respirable particles in the air, explaining the occurrence of pollen-season increases in asthma. Like pollens, above ground indoor fungal aerosols primarily reflect outdoor concentrations. Basement spore concentrations might be higher and reflective of local sources. Fungal presence in the indoor or outdoor air can be monitored on an area basis or with personal monitors. The samples can be analyzed by means of microscopy, culture, DNA probes, HPLC, or immunodetection. Total fungal biomass can be estimated on the basis of measurements of ergosterol or glucan in environmental samples. Unfortunately, there are no generally accepted standards for interpretation of fungal levels in indoor or outdoor air. At present, the best approach to indoor fungal control is moisture control in the indoor environment. This will essentially prevent fungal growth, except from extraordinary events.	Harvard Univ, Sch Publ Hlth, Landmark Ctr, Boston, MA 02215 USA	Burge, HA (reprint author), Harvard Univ, Sch Publ Hlth, Landmark Ctr, Room 404M W,401 Pk Dr,POB 15677, Boston, MA 02215 USA.						Ahearn DG, 1997, CURR MICROBIOL, V35, P305, DOI 10.1007/s002849900259; Aizenberg V, 2000, AM IND HYG ASSOC J, V61, P398, DOI 10.1080/15298660008984550; Aizenberg V, 2000, AIHAJ, V61, P855, DOI 10.1202/0002-8894(2000)061<0855:POAOCB>2.0.CO;2; Anderson W, 2001, QJM-MON J ASSOC PHYS, V94, P429, DOI 10.1093/qjmed/94.8.429; Bellin P, 2001, INDOOR AIR, V11, P65, DOI 10.1034/j.1600-0668.2001.011001065.x; Burge HA, 2000, CURR MICROBIOL, V40, P10, DOI 10.1007/s002849910003; Celenza A, 1996, BRIT MED J, V312, P604; Charcosset JY, 2001, APPL ENVIRON MICROB, V67, P2051, DOI 10.1128/AEM.67.5.2051-2055.2001; Cruz-Perez P, 2001, MOL CELL PROBE, V15, P129, DOI 10.1006/mcpr.2001.0347; Dales RE, 1997, INT J EPIDEMIOL, V26, P120, DOI 10.1093/ije/26.1.120; Dales RE, 1999, MYCOPATHOLOGIA, V147, P21, DOI 10.1023/A:1007096704217; Davidson AC, 1996, BRIT MED J, V312, P601; Davis MB, 2001, SCIENCE, V292, P673, DOI 10.1126/science.292.5517.673; Day JP, 2002, APPL ENVIRON MICROB, V68, P37, DOI 10.1128/AEM.68.1.37-45.2002; DE RW, 2002, J ECON ENTOMOL, V95, P36; Degaudenzi ME, 1999, PHYS REV E, V59, P6569, DOI 10.1103/PhysRevE.59.6569; Dharmage S, 1999, INDOOR AIR, V9, P188, DOI 10.1111/j.1600-0668.1999.t01-1-00005.x; Dharmage S, 1999, CLIN EXP ALLERGY, V29, P1481, DOI 10.1046/j.1365-2222.1999.00640.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; Elke K, 1999, J ENVIRON MONITOR, V1, P445, DOI 10.1039/a903034d; Emberlin J, 1999, CLIN EXP ALLERGY, V29, P347; Engvall K, 2001, INT J TUBERC LUNG D, V5, P468; Etzel RA, 1998, ARCH PEDIAT ADOL MED, V152, P757; Fahlbusch B, 2001, ALLERGY, V56, P1081, DOI 10.1034/j.1398-9995.2001.00106.x; Fiorina A, 1998, J INVEST ALLERG CLIN, V8, P85; Fischer G, 1999, Schriftenr Ver Wasser Boden Lufthyg, V104, P183; Freye HB, 2001, ALLERGY ASTHMA PROC, V22, P239; Galan C, 2001, INT J BIOMETEOROL, V45, P8, DOI 10.1007/s004840000081; Garrett MH, 1998, CLIN EXP ALLERGY, V28, P459; GAUTRIN D, 1994, J ALLERGY CLIN IMMUN, V93, P437, DOI 10.1016/0091-6749(94)90352-2; Gehring U, 2001, ENVIRON HEALTH PERSP, V109, P139, DOI 10.2307/3434766; Geiser M, 2000, J ALLERGY CLIN IMMUN, V106, P92, DOI 10.1067/mai.2000.107753; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Hameed AAA, 2001, J ENVIRON MONITOR, V3, P206, DOI 10.1039/b007159p; Hauck BC, 1997, AM IND HYG ASSOC J, V58, P713, DOI 10.1202/0002-8894(1997)058<0713:FTONAS>2.0.CO;2; Hirsch T, 2000, ALLERGY, V55, P79, DOI 10.1034/j.1398-9995.2000.00250.x; Holmquist L, 2001, INDOOR AIR, V11, P241, DOI 10.1034/j.1600-0668.2001.110405.x; Inglis GD, 2002, CAN J MICROBIOL, V48, P60, DOI 10.1139/W01-130; James TY, 2001, MOL ECOL, V10, P471, DOI 10.1046/j.1365-294x.2001.01224.x; Kamata N, 2002, B ENTOMOL RES, V92, P119, DOI 10.1079/BER2002158; Karunasena E, 2001, MYCOPATHOLOGIA, V150, P91, DOI 10.1023/A:1010920611811; Kenny LC, 1999, ANN OCCUP HYG, V43, P393; Kenny LC, 1998, AM IND HYG ASSOC J, V59, P831; Keshri G, 2002, J APPL MICROBIOL, V92, P165, DOI 10.1046/j.1365-2672.2002.01515.x; Khan ZU, 1999, MYCOPATHOLOGIA, V146, P25, DOI 10.1023/A:1007034703398; Kilpelainen M, 2001, THORAX, V56, P462, DOI 10.1136/thorax.56.6.462; KLIRONOMOS JN, 1946, REV CANADIENNE BOT, V75, P1670; Knox RB, 1997, CLIN EXP ALLERGY, V27, P246; Korpi A, 1999, ARCH ENVIRON HEALTH, V54, P347; Laaidi K, 2001, INT J BIOMETEOROL, V45, P124, DOI 10.1007/s004840100096; Leenders ACAP, 1999, J CLIN MICROBIOL, V37, P1752; Levy JI, 1999, AM IND HYG ASSOC J, V60, P317, DOI 10.1080/00028899908984448; Lewis SA, 2000, CLIN EXP ALLERGY, V30, P1724, DOI 10.1046/j.1365-2222.2000.00947.x; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; Li DW, 1995, MYCOPATHOLOGIA, V131, P149, DOI 10.1007/BF01102894; MADELIN TM, 1992, J APPL BACTERIOL, V72, P400, DOI 10.1111/j.1365-2672.1992.tb01853.x; Mahieu LM, 2000, J HOSP INFECT, V45, P191, DOI 10.1053/jhin.2000.0773; MALMBERG P, 1993, CHEST, V103, P1202, DOI 10.1378/chest.103.4.1202; Marks GB, 2001, THORAX, V56, P468, DOI 10.1136/thorax.56.6.468; McGrath JJ, 1999, CURR MICROBIOL, V38, P33, DOI 10.1007/PL00006768; Mehta SK, 2000, AIHAJ, V61, P850, DOI 10.1202/0002-8894(2000)061<0850:EOPASF>2.0.CO;2; Mitakakis TZ, 2000, CLIN EXP ALLERGY, V30, P1733, DOI 10.1046/j.1365-2222.2000.00966.x; Newson R, 1997, THORAX, V52, P680; Nielsen KF, 1999, MYCOPATHOLOGIA, V145, P43, DOI 10.1023/A:1007038211176; Olsson M, 1998, J CLIN MICROBIOL, V36, P1737; Martinez Ordaz VA, 2002, REV ALERG MEX, V49, P2; Pasanen AL, 2000, INDOOR AIR, V10, P111, DOI 10.1034/j.1600-0668.2000.010002111.x; Pessi AM, 2002, APPL ENVIRON MICROB, V68, P963, DOI 10.1128/AEM.68.2.963-967.2002; Peteet D, 2000, P NATL ACAD SCI USA, V97, P1359, DOI 10.1073/pnas.97.4.1359; Pieckenstain FL, 2001, ANTON LEEUW INT J G, V80, P245, DOI 10.1023/A:1013021011328; RANTIOLEHTIMAKI A, 1989, ALLERGY, V44, P18, DOI 10.1111/j.1398-9995.1989.tb00440.x; Rautiala S, 1998, AM IND HYG ASSOC J, V59, P455; Razmovski V, 2000, J ALLERGY CLIN IMMUN, V105, P725, DOI 10.1067/mai.2000.105222; Ren P, 2001, ALLERGY, V56, P419, DOI 10.1034/j.1398-9995.2001.056005419.x; Ren P, 1999, J EXPO ANAL ENV EPID, V9, P560, DOI 10.1038/sj.jea.7500061; Roe JD, 2001, J EXPO ANAL ENV EPID, V11, P12, DOI 10.1038/sj.jea.7500147; Rylander R, 1999, ENVIRON HEALTH PERSP, V107, P501; Schappi GF, 1999, CLIN EXP ALLERGY, V29, P633; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; SNELLER MR, 1979, ANN ALLERGY, V43, P352; Spicer RC, 2000, AM IND HYG ASSOC J, V61, P362, DOI 10.1080/15298660008984544; Stazi MA, 2002, PEDIATR ALLERGY IMMU, V13, P105, DOI 10.1034/j.1399-3038.2002.00070.x; Sterling DA, 1998, ANN ALLERG ASTHMA IM, V80, P279; Su HJJ, 2001, ARCH ENVIRON HEALTH, V56, P144; Szponar B, 2000, INDOOR AIR, V10, P13; Takahashi T, 1997, MYCOPATHOLOGIA, V139, P23, DOI 10.1023/A:1006831111595; Takamura S, 2000, RRD PLASMAS, V1, P41; Thorn J, 2001, MEDIAT INFLAMM, V10, P173; Thrane U, 2001, FEMS MICROBIOL LETT, V203, P249, DOI 10.1016/S0378-1097(01)00361-5; Tiffany JA, 2000, J ENVIRON HEALTH, V62, P9; Troutt C, 2001, INT J BIOMETEOROL, V45, P64, DOI 10.1007/s004840100087; Tuomi T, 2000, APPL ENVIRON MICROB, V66, P1899, DOI 10.1128/AEM.66.5.1899-1904.2000; Venables KM, 1997, CLIN EXP ALLERGY, V27, P725, DOI 10.1046/j.1365-2222.1997.790893.x; VERHOEFF AP, 1994, ALLERGY, V49, P540, DOI 10.1111/j.1398-9995.1994.tb01126.x; Vesper S, 2000, J URBAN HEALTH, V77, P68, DOI 10.1007/BF02350963; Waghorn TS, 2002, VET PARASITOL, V104, P119, DOI 10.1016/S0304-4017(01)00629-X; Wan GH, 1999, ARCH ENVIRON HEALTH, V54, P172; Ward MDW, 2000, TOXICOLOGY, V147, P133, DOI 10.1016/S0300-483X(00)00191-8; Wayne P, 2002, ANN ALLERG ASTHMA IM, V88, P279; Wijnands LM, 2000, ALLERGY, V55, P856, DOI 10.1034/j.1398-9995.2000.00532.x; Wilkins CK, 1998, PHARMACOL TOXICOL, V83, P112; Wilkins K, 2000, CHEMOSPHERE, V41, P437, DOI 10.1016/S0045-6535(99)00273-8; Williams RH, 2001, APPL ENVIRON MICROB, V67, P2453, DOI 10.1128/AEM.67.6.2453-2459.2001; Wouters IM, 2000, APPL ENVIRON MICROB, V66, P627, DOI 10.1128/AEM.66.2.627-631.2000; Wu PC, 2000, ENVIRON RES, V82, P253, DOI 10.1006/enrs.1999.4017; Zacharasiewicz A, 1999, WIEN KLIN WOCHENSCHR, V111, P882; Zhou G, 2000, MOL CELL PROBE, V14, P339, DOI 10.1006/mcpr.2000.0324; Zukowski K, 1998, Rocz Panstw Zakl Hig, V49, P67; Zukowski K, 1996, Rocz Panstw Zakl Hig, V47, P343	110	86	88	4	18	MOSBY, INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2002	110	4					544	552		10.1067/mai.2002.128674		9	Allergy; Immunology	Allergy; Immunology	602JJ	WOS:000178501900001	12373259	
J	Wardlaw, AJ; Brightling, CE; Green, R; Woltmann, G; Bradding, P; Pavord, ID				Wardlaw, AJ; Brightling, CE; Green, R; Woltmann, G; Bradding, P; Pavord, ID			New insights into the relationship between airway inflammation and asthma	CLINICAL SCIENCE			English	Review						airway hyper-responsiveness; airway smooth muscle; asthma; eosinophils; inflammation	SMOOTH-MUSCLE CELLS; OBSTRUCTIVE PULMONARY-DISEASE; EXPIRATORY FLOW VARIABILITY; MAST-CELLS; BRONCHIAL HYPERREACTIVITY; EOSINOPHILIC BRONCHITIS; POPULATION-SAMPLE; NEDOCROMIL SODIUM; DEEP INSPIRATION; INDUCED SPUTUM	Asthma is a condition characterized by variable airflow obstruction, airway hyper-responsiveness (AHR) and airway inflammation which is usually, but not invariably, eosinophilic. Current thoughts on the pathogenesis of asthma are focused on the idea that it is caused by an inappropriate response of the specific immune system to harmless antigens, particularly allergens such as cat dander and house dust mite, that result in Th2-mediated chronic inflammation. However, the relationship between inflammation and asthma is complex, with no good correlation between the severity of inflammation, at least as measured by the number of eosinophils, and the severity of asthma. In addition, there are a number of conditions, such as eosinophilic bronchitis and allergic rhinitis, in which there is a Th2-mediated inflammatory response, but no asthma, as measured by variable airflow obstruction or AHR. Bronchoconstriction can also occur without obvious airway inflammation, and neutrophilic inflammation can in some cases be associated with asthma. When we compared the immunopathology of eosinophilic bronchitis and asthma, the only difference we observed was that, in asthma, the airway smooth muscle (ASM) was infiltrated by mast cells, suggesting that airway obstruction and AHR are due to an ASM mast cell myositis. This observation emphasizes that the features that characterize asthma, as opposed to bronchitis, are due to abnormalities in smooth muscle responsiveness, which could be intrinsic or acquired, and that inflammation is only relevant in that it leads to these abnormalities. It also emphasizes the importance of micro-localization as an organizing principle in physiological responses to airway inflammation. Thus, if inflammation is localized to the epithelium and lamina propria, then the symptoms of bronchitis (cough and mucus hypersecretion) result, and it is only if the ASM is involved -for reasons that remain to be established -that asthma occurs.	Glenfield Hosp, Leicester Warwick Med Sch, Inst Lung Hlth, Dept Resp Med, Leicester LE3 9QP, Leics, England	Wardlaw, AJ (reprint author), Glenfield Hosp, Leicester Warwick Med Sch, Inst Lung Hlth, Dept Resp Med, Groby Rd, Leicester LE3 9QP, Leics, England.						Alvarez MJ, 2000, ALLERGY, V55, P531, DOI 10.1034/j.1398-9995.2000.00534.x; Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; BRIGHTLING CE, 2002, J ALLERGY CLIN IMMUN, V109, P534; Brightling Christopher E., 2000, American Journal of Respiratory and Critical Care Medicine, V162, P878; Britton J, 1998, BRIT MED J, V317, P227; Brown JK, 2001, AM J RESP CELL MOL, V24, P146; Bryan SA, 2000, LANCET, V356, P2149, DOI 10.1016/S0140-6736(00)03497-8; Bryan SA, 2000, EXPERT OPIN INV DRUG, V9, P25; CARROLL N, 1993, AM REV RESPIR DIS, V147, P405; CAUGHEY GH, 1989, AM J PHYSIOL, V257, pL39; CHAPMAN ID, 1993, CLIN EXP ALLERGY, V23, P168, DOI 10.1111/j.1365-2222.1993.tb00877.x; CHOWIENCZYK PJ, 1994, BRIT MED J, V309, P1618; Costello RW, 1997, AM J PHYSIOL-LUNG C, V273, pL93; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; Evans CM, 1997, J CLIN INVEST, V100, P2254, DOI 10.1172/JCI119763; Ewart SL, 1996, AM J RESP CELL MOL, V14, P487; Flood-Page P, 2002, J ALLERGY CLIN IMMUN, V109, P743; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; GIBSON PG, 1989, LANCET, V1, P1346; GREEN RH, 2002, AM J RESP CRIT CARE, V165, pA320; GREEN RH, 2002, IN PRESS THORAX; Grunstein MM, 2001, AM J PHYSIOL-LUNG C, V280, pL229; Hakonarson H, 1999, J CLIN INVEST, V103, P1077, DOI 10.1172/JCI5809; Hakonarson H, 1998, J CLIN INVEST, V102, P1732, DOI 10.1172/JCI4141; Hart PH, 2001, IMMUNOL CELL BIOL, V79, P149, DOI 10.1046/j.1440-1711.2001.00983.x; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Helenius I, 2000, J ALLERGY CLIN IMMUN, V106, P444, DOI 10.1067/mai.2000.107749; Henderson WR, 1997, J CLIN INVEST, V100, P3083, DOI 10.1172/JCI119863; HIGGINS BG, 1992, AM REV RESPIR DIS, V145, P588; Hirst SJ, 2000, CLIN EXP ALLERGY, V30, P54, DOI 10.1046/j.1365-2222.2000.00099.x; Holgate ST, 2000, CLIN EXP ALLERGY, V30, P1; Homer RJ, 2000, CLIN CHEST MED, V21, P331, DOI 10.1016/S0272-5231(05)70270-7; Hunter CJ, 2002, CHEST, V121, P1051, DOI 10.1378/chest.121.4.1051; James A, 2000, EUR RESPIR J, V15, P782, DOI 10.1034/j.1399-3003.2000.15d25.x; Jeffery PK, 1999, CLIN EXP ALLERGY, V29, P14, DOI 10.1046/j.1365-2222.1999.00004.x-i2; John M, 1997, J IMMUNOL, V158, P1841; Kapsali T, 2000, J APPL PHYSIOL, V89, P711; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kay AB, 1996, AM J RESP CRIT CARE, V154, pS66; Kay AB, 1997, CIBA F SYMP, V206, P56; KRAAN J, 1988, AM REV RESPIR DIS, V137, P44; Leckie MJ, 2000, LANCET, V356, P2144, DOI 10.1016/S0140-6736(00)03496-6; LORBER DB, 1978, AM REV RESPIR DIS, V118, P855; Marklund B, 1999, FAM PRACT, V16, P112, DOI 10.1093/fampra/16.2.112; MOQBEL R, 1988, ALLERGY, V43, P268, DOI 10.1111/j.1398-9995.1988.tb00899.x; MURPHY MB, 1984, THORAX, V39, P179, DOI 10.1136/thx.39.3.179; *NAC BTS RCP, 1997, THORAX S1, V52; Nicklas R A, 1997, Curr Opin Pulm Med, V3, P51, DOI 10.1097/00063198-199701000-00008; OKAYAMA Y, 1992, CLIN EXP ALLERGY, V22, P401, DOI 10.1111/j.1365-2222.1992.tb03102.x; Pavord ID, 1999, LANCET, V353, P2213, DOI 10.1016/S0140-6736(99)01813-9; Pavord ID, 1997, THORAX, V52, P498; PIN I, 1992, AM REV RESPIR DIS, V145, P1265; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Schleimer RP, 1998, CLIN EXP ALLERGY, V28, P15; Scichilone N, 2001, AM J RESP CRIT CARE, V163, P413; SIERSTED HC, 1994, AM J RESP CRIT CARE, V149, P598; SILVERMAN M, 1995, NEW ENGL J MED, V332, P181, DOI 10.1056/NEJM199501193320309; SMITH PG, 1994, AM J RESP CELL MOL, V10, P85; Strachan DP, 1999, ALLERGY, V54, P7, DOI 10.1111/j.1398-9995.1999.tb04381.x; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; Wardlaw AJ, 1999, BRIT MED J, V318, P258; WARDLAW AJ, 1988, AM REV RESPIR DIS, V137, P62; Wardlaw AJ, 2000, BRIT MED BULL, V56, P985, DOI 10.1258/0007142001903490; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001; Xu JF, 2001, AM J HUM GENET, V68, P1437, DOI 10.1086/320589	68	86	87	0	3	PORTLAND PRESS	LONDON	59 PORTLAND PLACE, LONDON W1N 3AJ, ENGLAND	0143-5221			CLIN SCI	Clin. Sci.	AUG	2002	103	2					201	211				11	Medicine, Research & Experimental	Research & Experimental Medicine	582PG	WOS:000177359900013	12149112	
J	Darvay, A; White, IR; Rycroft, RJG; Jones, AB; Hawk, JL; McFadden, JP				Darvay, A; White, IR; Rycroft, RJG; Jones, AB; Hawk, JL; McFadden, JP			Photoallergic contact dermatitis is uncommon	BRITISH JOURNAL OF DERMATOLOGY			English	Article						benzophenone-3; photoallergy; photodermatosis; photopatch test; sunscreens; ultraviolet filters	SCANDINAVIAN MULTICENTER PHOTOPATCH; PHOTOCONTACT SENSITIZATION; PHOTOSENSITIVITY; SENSITIVITY; EXPERIENCE; SUNSCREENS; 5-YEAR	Background Despite the enormous increase in sunscreen use, allergic contact (AC) and photoallergic (PA) reactions to ultraviolet (UV) filters are considered rare. Objectives To analyse the data from 2715 patients who underwent photopatch testing at St John's Institute of Dermatology during the period 1983-98. Methods A retrospective analysis of all positive photopatch test episodes was undertaken with the results retrieved from the environmental dermatology database and further verified with the original archived patch test documentation for each individual patient. Results In 111 patients with positive reactions (4.1%), there were 155 AC or PA reactions to allergens in the photopatch test series. Eighty PA reactions were observed in 62 (2.3%) patients (32 men and 30 women, age range 28-75 years), with UV filters accounting for 52 positive reactions (65%). drugs 16 (20%), musk ambrette 11 (14%) and the antiseptic trichlorocarbanilide one (1%). The most common UV filter photoallergen was benzophenone-3 with 14 positive results, followed by benzophenone-10 (n = 9), isopropyl dibenzoylmethane (n = 6), p-aminobenzoic acid (PABA) (n = 5), octyl dimethyl PABA (n = 5), butyl methoxydibenzoylmethane (n = 4), isoamyl methoxycinnamate (n = 2), ethyl methoxycinnamate (n = 2), octyl methoxycinnamate (n = 2). amyl dimethyl PABA (n = 2) and phenylbenzimidazole sulphonic acid (n = 1). A similar number of AC reactions to UV filters was detected in this study. Thus 49 patients (1.8%) had a total of 75 reactions: 51 due to UV filters and 24 as a result of exposure to fragrances and therapeutic agents. Benzophenone-10 accounted for 13 AC reactions and benzophenone-3 for eight reactions. Twenty-two patients had a PA reaction alone, whereas 19 patients had chronic actinic dermatitis and 15 patients polymorphic light eruption (PLE) in addition. Thus, 34 of the 62 patients (55%) had a preceding underlying photodermatosis. Conclusions These results show a low yield of positive photopatch tests. Thus, despite the large increase in the use of UV filters over the last decade, the development of PA reactions remains rare. Furthermore, most of the common UV filter photoallergens identified in this study, including PABA, amyl dimethyl PABA and benzophenone-10. are now rarely used in sunscreen manufacture, while isopropyl dibenzoylmethane was voluntarily removed from the market in 1993. Currently, benzophenone-3 is the commonest contact photoallergen still in widespread use. In contrast, the UVB filter octyl methoxycinnamate, used in a number of sunscreens, produced only two positive PA reactions in 12 years of testing. Nevertheless, although these reactions are extremely rare, patients with photodermatoses such as PIE and chronic actinic dermatitis do represent a group of patients at increased risk of developing photoallergy. Further photopatch test series should be regularly reviewed and updated, as the relevance of individual photoallergens changes over time. Currently, there is no evidence that PA reactions represent a common clinical problem.	St Thomas Hosp, St Johns Inst Dermatol, Dept Environm Dermatol, London SE1 7EH, England	Darvay, A (reprint author), St Thomas Hosp, St Johns Inst Dermatol, Dept Environm Dermatol, Lambeth Palace Rd, London SE1 7EH, England.						ADDO HA, 1987, BRIT J DERMATOL, V117, P555, DOI 10.1111/j.1365-2133.1987.tb07486.x; Ang P, 1998, Am J Contact Dermat, V9, P42, DOI 10.1016/S1046-199X(98)90145-2; Bell HK, 2000, BRIT J DERMATOL, V142, P589, DOI 10.1046/j.1365-2133.2000.03401.x; Berne B, 1998, CONTACT DERMATITIS, V38, P61; CRONIN E, 1984, CONTACT DERMATITIS, V11, P88, DOI 10.1111/j.1600-0536.1984.tb00933.x; DELEO VA, 1992, ARCH DERMATOL, V128, P1513, DOI 10.1001/archderm.128.11.1513; DROMGOOLE SH, 1990, J AM ACAD DERMATOL, V22, P1068, DOI 10.1016/0190-9622(90)70154-A; ENGLISH JSC, 1987, CONTACT DERMATITIS, V17, P159, DOI 10.1111/j.1600-0536.1987.tb02698.x; FISCHER T, 1991, CONTACT DERMATITIS, V25, P319, DOI 10.1111/j.1600-0536.1991.tb01881.x; FOTIADES J, 1995, J AM ACAD DERMATOL, V33, P597, DOI 10.1016/0190-9622(95)91277-0; Fregert S, 1981, MANUAL CONTACT DERMA; HOLZLE E, 1991, J AM ACAD DERMATOL, V25, P59, DOI 10.1016/0190-9622(91)70175-2; Ibbotson SH, 1997, BRIT J DERMATOL, V136, P371, DOI 10.1046/j.1365-2133.1997.5671521.x; Journe F, 1999, ACTA DERM-VENEREOL, V79, P211; KNOBLER E, 1989, ARCH DERMATOL, V125, P801, DOI 10.1001/archderm.125.6.801; MARGUERY MC, 1989, BR J DERMATOL S34, V121, P59, DOI 10.1111/j.1365-2133.1989.tb05965.x; MENAGE HD, 1995, BRIT J DERMATOL, V132, P543; MENZE J, 1998, J AM ACAD DERMATOL, V18, P1044; NATER JP, 1985, UNWANTED EFFECTS COS, P360; Schauder S, 1997, CONTACT DERMATITIS, V37, P221, DOI 10.1111/j.1600-0536.1997.tb02439.x; THUNE P, 1984, CONTACT DERMATITIS, V11, P98, DOI 10.1111/j.1600-0536.1984.tb00935.x; THUNE P, 1988, PHOTODERMATOLOGY, V5, P261; U.S. Food and Drug Administration, 1978, FED REG, V43, P38206; WENNERSTEN G, 1984, CONTACT DERMATITIS, V10, P305, DOI 10.1111/j.1600-0536.1984.tb00149.x; WENNERSTEN G, 1986, SEMIN DERMATOL, V5, P277	25	86	88	0	10	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0007-0963			BRIT J DERMATOL	Br. J. Dermatol.	OCT	2001	145	4					597	601		10.1046/j.1365-2133.2001.04458.x		5	Dermatology	Dermatology	484MF	WOS:000171693600011	11703286	
J	Olesen, C; Sondergaard, C; Thrane, N; Nielsen, GL; de Jong-van den Berg, L; Olsen, J				Olesen, C; Sondergaard, C; Thrane, N; Nielsen, GL; de Jong-van den Berg, L; Olsen, J		EuroMAP Grp	Do pregnant women report use of dispensed medications?	EPIDEMIOLOGY			English	Article						compliance; exposure misclassification; pregnancy; prescription database; risk assessment; validation study	DRUG-USE; CONGENITAL-MALFORMATIONS; PATIENT COMPLIANCE; QUESTIONNAIRE DATA; RECALL BIAS; EXPOSURE; OUTCOMES; RECORDS; ASTHMA; POPULATION	Surveillance of drug safety in pregnancy often draws on administrative prescription registries. Noncompliance in the use of prescribed medication may be frequent among pregnant women owing to their fear of fetotoxic side effects. To estimate compliance in the use of prescription drugs dispensed during pregnancy, we compared prescription data from the North Jutland Prescription Database with information on drug use provided by pregnant women to the Danish National Birth Cohort (DNBC), which is a health inter-view survey. We used the North Jutland Prescription Database to identify all prescription drugs dispensed during pregnancy for the 2,041 women who were enrolled in the DNBC in the County of North Jutland, Denmark. Compliance was defined as the probability of reporting drug use in DNBC after purchasing a dispensed prescription drug. The overall compliance to drugs purchased within 120 days before the interview was 43% (95% confidence interval = 40-46). Drugs used for treating chronic diseases, for example, beta-blockers, insulin, thyroid hormones, and diuretic and antiepileptic drugs, were always reported to be used, but compliance was low for drugs used for local or short-term treatment such as antihistamines, antibiotics, antacids, nonsteroid anti-inflammatory drugs, and gynecologic drugs. Thus, for the latter drug groups the prescription database may provide an incomplete identification of exposure, Neither data source is unbiased regarding actual drug intake. Nevertheless, our results indicate that for some drug groups risk assessment studies based on prescription data may produce false negative results as a result of noncompliance.	Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, DK-8000 Aarhus C, Denmark; Med Res Unit, Ringkobing, Denmark; Aarhus Univ, Dept Clin Epidemiol, Aarhus, Denmark; Aalborg Hosp, Aalborg, Denmark; Univ Groningen, GUIDE, Dept Social Pharm & Pharmacoepidemiol, Groningen, Netherlands	Olesen, C (reprint author), Aarhus Univ, Danish Epidemiol Sci Ctr, Dept Epidemiol & Social Med, Vennelyst Blvd 6, DK-8000 Aarhus C, Denmark.						Bar-Oz B, 1999, LANCET, V354, P1700, DOI 10.1016/S0140-6736(99)04411-6; BOSLEY CM, 1995, EUR RESPIR J, V8, P899; Briggs G, 1994, DRUGS PREGNANCY LACT; BROCKLEBANK JC, 1978, AM J OBSTET GYNECOL, V132, P235; BRYANT HE, 1989, AM J PUBLIC HEALTH, V79, P78, DOI 10.2105/AJPH.79.1.78; CHRISTENSEN DB, 1978, HEALTH SERV RES, V13, P171; CORREY JF, 1991, AUST NZ J OBSTET GYN, V31, P340, DOI 10.1111/j.1479-828X.1991.tb02816.x; CRAMER JA, 1989, JAMA-J AM MED ASSOC, V261, P3273, DOI 10.1001/jama.261.22.3273; Creer TL, 1996, J ASTHMA, V33, P203, DOI 10.3109/02770909609055361; DEJONG PCM, 1991, AM J EPIDEMIOL, V134, P998; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; GRAHAM D J, 1988, American Journal of Preventive Medicine, V4, P15; GREENBERG RN, 1984, CLIN THER, V6, P592; HARLOW SD, 1989, AM J EPIDEMIOL, V129, P233; HAYNES TB, 1979, COMPLIANCE HLTH CARE, P11; HERTZPICCIOTTO I, 1991, AM J EPIDEMIOL, V133, P408; MITCHELL AA, 1986, AM J EPIDEMIOL, V123, P670; Nielsen GL, 1999, ALIMENT PHARM THERAP, V13, P1085; Olesen C, 1999, EUR J CLIN PHARMACOL, V55, P139, DOI 10.1007/s002280050608; OLESEN C, 1999, EUR J OBSTET GYN R B, V78, P1; OLESEN C, 1999, EUR J CLIN PHARMACOL, V55, P145; PIPER JM, 1987, AM J OBSTET GYNECOL, V157, P148; Ruigomez A, 1999, AM J EPIDEMIOL, V150, P476; Sorensen HT, 1999, BRIT J CLIN PHARMACO, V48, P234, DOI 10.1046/j.1365-2125.1999.00989.x; Sorensen HT, 1998, REPROD TOXICOL, V12, P383; SPECTOR SL, 1989, J ALLERGY CLIN IMMUN, V84, P409, DOI 10.1016/0091-6749(89)90434-X; Steffensen FH, 1998, LANCET, V351, P596, DOI 10.1016/S0140-6736(05)78584-6; SWAN SH, 1992, EPIDEMIOLOGY, V3, P356, DOI 10.1097/00001648-199207000-00011; TAKAKI S, 1985, THER DRUG MONIT, V7, P87, DOI 10.1097/00007691-198503000-00015; Van den Berg LTWDJ, 1999, TERATOLOGY, V60, P33; VANDENBERG LTW, 1993, EUR J CLIN PHARMACOL, V45, P9; *WHO, 1993, WHO REG PUBL EUR SER, V45; Wilton LV, 1998, BRIT J OBSTET GYNAEC, V105, P882, DOI 10.1111/j.1471-0528.1998.tb10234.x; YEUNG M, 1994, RESP MED, V88, P31, DOI 10.1016/0954-6111(94)90171-6	34	86	88	1	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1044-3983			EPIDEMIOLOGY	Epidemiology	SEP	2001	12	5					497	501		10.1097/00001648-200109000-00006		5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	465GJ	WOS:000170581000006	11505166	
J	Galan, C; Carinanos, P; Garcia-Mozo, H; Alcazar, P; Dominguez-Vilches, E				Galan, C; Carinanos, P; Garcia-Mozo, H; Alcazar, P; Dominguez-Vilches, E			Model for forecasting Olea europaea L. airborne pollen in South-West Andalusia, Spain	INTERNATIONAL JOURNAL OF BIOMETEOROLOGY			English	Article						aerobiology; forecasting; Olea europaea; pollen index; pollen production	ATMOSPHERE	Data on predicted average and maximum air-borne pollen concentrations and the dates on which these maximum values are expected are of undoubted value to allergists and allergy sufferers, as well as to agronomists. This paper reports on the development of predictive models for calculating total annual pollen output, on the basis of pollen and weather data compiled over the last 19 years (1982-2000) for Cordoba (Spain). Models were tested in order to predict the 2000 pollen season; in addition, and in view of the heavy rainfall recorded in spring 2000, the 1982-1998 data set was used to test the model for 1999. The results of the multiple regression analysis show that the variables exerting the greatest influence on the pollen index were rainfall in March and temperatures over the months prior to the flowering period. For prediction of maximum values and dates on which these values might be expected, the start of the pollen season was used as an additional independent variable. Temperature proved the best variable for this prediction. Results improved when the 5-day moving average was taken into account. Testing of the predictive model for 1999 and 2000 yielded fairly similar results. In both cases, the difference between expected and observed pollen data was no greater than 10%. However, significant differences were recorded between forecast and expected maximum and minimum values, owing to the influence of rainfall during the flowering period.	Univ Cordoba, Dept Bot, E-14071 Cordoba, Spain	Galan, C (reprint author), Univ Cordoba, Dept Bot, Colonia San Jose,Casa 4,Ctra Madrid Km 396, E-14071 Cordoba, Spain.		Carinanos, Paloma/K-5696-2014	Carinanos, Paloma/0000-0002-8955-2383			Alba F, 1998, AEROBIOLOGIA, V14, P191, DOI 10.1007/BF02694205; ARON R, 1983, AGR METEOROL, V28, P351, DOI 10.1016/0002-1571(83)90011-0; CANDAU P, 1981, BOT MACARONESICA, V8, P89; DAMATO G, 1994, CLIN EXP ALLERGY, V24, P210, DOI 10.1111/j.1365-2222.1994.tb00222.x; DELAGUARDIA CD, 1993, J INVEST ALLERG CLIN, V3, P251; DELAGUARDIA CD, 2000, POLEN, V10, P103; DOMINGUEZ E, 1992, MONOGRAFIAS REA EAN, V1; Dominguez Vilches Eugenio, 1993, Journal of Investigational Allergology and Clinical Immunology, V3, P121; *FAO, 1998, CROP EV TRANSP GUID; FLORIDO JF, 1999, INT ARCH ALLERGY IMM, V119, P199; Fornaciari M., 1997, Agricoltura Mediterranea, V127, P134; Fornaciari M, 1998, GRANA, V37, P110; Fornaciari M, 2000, PLANT BIOSYST, V134, P199, DOI 10.1080/11263500012331358474; Frenguelli G, 1989, AEROBIOLOGIA, V5, P64, DOI 10.1007/BF02446489; Galan C, 1998, INT J BIOMETEOROL, V41, P95, DOI 10.1007/s004840050059; Galan C, 2001, INT J BIOMETEOROL, V45, P8, DOI 10.1007/s004840000081; Galan C, 1988, AN ASOC PALINOL LENG, V4, P46; GALAN CD, 1993, J INVEST ALLERG CLIN, V3, P271; GARCIAMOZO H, 2001, IN PRESS GRANA; Gonzalez Minero F J, 1997, Ann Allergy Asthma Immunol, V78, P278; Gonzalez-Minero FJG, 1998, AGR ECOSYST ENVIRON, V69, P201, DOI 10.1016/S0167-8809(98)00105-4; Gonzalez-Minero F. J., 1996, AEROBIOLOGIA, V12, P91, DOI 10.1007/BF02446600; GUTIERREZBUSTIL.M, 2000, BOT MADR, V57, P357; HIRST JM, 1952, ANN APPL BIOL, V39, P257, DOI 10.1111/j.1744-7348.1952.tb00904.x; *I EST AND, 1999, AN EST AND; RALLO L, 1991, J AM SOC HORTIC SCI, V116, P1058; Recio M, 1996, GRANA, V35, P308; RUIZ L, 1998, STUDY SEASONAL DAILY	28	86	89	3	10	SPRINGER-VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010 USA	0020-7128			INT J BIOMETEOROL	Int. J. Biometeorol.	JUL	2001	45	2					59	63		10.1007/s004840100089		5	Biophysics; Environmental Sciences; Meteorology & Atmospheric Sciences; Physiology	Biophysics; Environmental Sciences & Ecology; Meteorology & Atmospheric Sciences; Physiology	457DX	WOS:000170122800002	11513048	
J	Lynch, SV; Wood, RA; Boushey, H; Bacharier, LB; Bloomberg, GR; Kattan, M; O'Connor, GT; Sandel, MT; Calatroni, A; Matsui, E; Johnson, CC; Lynn, H; Visness, CM; Jaffee, KF; Gergen, PJ; Gold, DR; Wright, RJ; Fujimura, K; Rauch, M; Busse, WW; Gern, JE				Lynch, Susan V.; Wood, Robert A.; Boushey, Homer; Bacharier, Leonard B.; Bloomberg, Gordon R.; Kattan, Meyer; O'Connor, George T.; Sandel, Megan T.; Calatroni, Agustin; Matsui, Elizabeth; Johnson, Christine C.; Lynn, Henry; Visness, Cynthia M.; Jaffee, Katy F.; Gergen, Peter J.; Gold, Diane R.; Wright, Rosalind J.; Fujimura, Kei; Rauch, Marcus; Busse, William W.; Gern, James E.			Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Asthma; atopy; allergen exposure; microbial exposure; inner city	HOUSE-DUST MITE; CHILDHOOD ASTHMA; INNER-CITY; IMMUNE DEVELOPMENT; VIRUS-INFECTION; DOG OWNERSHIP; UNITED-STATES; LUNG-FUNCTION; BIRTH-COHORT; CAT ALLERGEN	Background: Wheezing illnesses cause major morbidity in infants and are frequent precursors to asthma. Objective: We sought to examine environmental factors associated with recurrent wheezing in inner-city environments. Methods: The Urban Environment and Childhood Asthma study examined a birth cohort at high risk for asthma (n = 560) in Baltimore, Boston, New York, and St Louis. Environmental assessments included allergen exposure and, in a nested case-control study of 104 children, the bacterial content of house dust collected in the first year of life. Associations were determined among environmental factors, aeroallergen sensitization, and recurrent wheezing at age 3 years. Results: Cumulative allergen exposure over the first 3 years was associated with allergic sensitization, and sensitization at age 3 years was related to recurrent wheeze. In contrast, first-year exposure to cockroach, mouse, and cat allergens was negatively associated with recurrent wheeze (odds ratio, 0.60, 0.65, and 0.75, respectively; P <= .01). Differences in house dust bacterial content in the first year, especially reduced exposure to specific Firmicutes and Bacteriodetes, was associated with atopy and atopic wheeze. Exposure to high levels of both allergens and this subset of bacteria in the first year of life was most common among children without atopy or wheeze. Conclusions: In inner-city environments children with the highest exposure to specific allergens and bacteria during their first year were least likely to have recurrent wheeze and allergic sensitization. These findings suggest that concomitant exposure to high levels of certain allergens and bacteria in early life might be beneficial and suggest new preventive strategies for wheezing and allergic diseases.	[Lynch, Susan V.; Boushey, Homer; Fujimura, Kei; Rauch, Marcus] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Wood, Robert A.; Matsui, Elizabeth] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Bacharier, Leonard B.; Bloomberg, Gordon R.] Washington Univ, St Louis Childrens Hosp, Sch Med, Dept Pediat, St Louis, MO 63110 USA; [Kattan, Meyer] Columbia Univ, Med Ctr, Div Pediat Allergy & Immunol, New York, NY USA; [O'Connor, George T.; Sandel, Megan T.] Boston Univ, Sch Med, Ctr Pulm, Chapel Hill, NC USA; [Calatroni, Agustin; Lynn, Henry; Visness, Cynthia M.; Jaffee, Katy F.] Rho Inc, Chapel Hill, NC USA; [Johnson, Christine C.] Div Allergy & Immunol Henry Ford Hlth Syst, Detroit, MI USA; [Gergen, Peter J.] Natl Inst Allergy & Infect Dis, Bethesda, MD USA; [Gold, Diane R.; Wright, Rosalind J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Channing Lab, Boston, MA 02115 USA; [Busse, William W.; Gern, James E.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Pediat, Madison, WI USA	Wood, RA (reprint author), Johns Hopkins Univ, Sch Med, 600 North Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	rwood@jhmi.edu			National Institute of Allergy and Infectious Diseases; National Institutes of Health [NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, HHSN272201000052I]; National Center for Advancing Translational Sciences, National Institutes of Health [RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, 5UL1RR024992 02]	This project has been supported in whole or in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, under contract numbers NO1-AI-25496, NO1-AI-25482, HHSN272200900052C, and HHSN272201000052I. Additional support was provided by the National Center for Advancing Translational Sciences, National Institutes of Health, under grants RR00052, M01RR00533, 1UL1RR025771, M01RR00071, 1UL1RR024156, and 5UL1RR024992 02.	Abreu NA, 2012, SCI TRANSL MED, V4; Akinbami LJ, 2009, PEDIATRICS, V123, pS131, DOI 10.1542/peds.2008-2233C; Atarashi K, 2011, SCIENCE, V331, P337, DOI 10.1126/science.1198469; Bufford JD, 2008, CLIN EXP ALLERGY, V38, P1635, DOI 10.1111/j.1365-2222.2008.03018.x; Carroll KN, 2008, PEDIATRICS, V122, P58, DOI 10.1542/peds.2007-2087; Castro-Rodriguez JA, 2010, J ALLERGY CLIN IMMUN, V126, P212, DOI 10.1016/j.jaci.2010.06.032; Chen CM, 2007, J ALLERGY CLIN IMMUN, V119, P1148, DOI 10.1016/j.jaci.2007.02.017; COHEN S, 1983, J HEALTH SOC BEHAV, V24, P385, DOI 10.2307/2136404; Corver K, 2006, PEDIATR ALLERGY IMMU, V17, P329, DOI 10.1111/j.1399-3038.2006.00410.x; DeSantis TZ, 2007, MICROB ECOL, V53, P371, DOI 10.1007/s00248-006-9134-9; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, pe1; Fujimura KE, 2012, J MICROBIOL METH, V91, P231, DOI 10.1016/j.mimet.2012.08.016; Fujimura KE, 2010, J ALLERGY CLIN IMMUN, V126, DOI 10.1016/j.jaci.2010.05.042; Gaffin JM, 2009, CURR OPIN ALLERGY CL, V9, P128, DOI 10.1097/ACI.0b013e32832678b0; Gern James E, 2009, BMC Pulm Med, V9, P17, DOI 10.1186/1471-2466-9-17; Gern JE, 2004, J ALLERGY CLIN IMMUN, V113, P307, DOI 10.1016/j.jaci.2003.11.017; Gold DR, 1999, AM J RESP CRIT CARE, V160, P227; Haapakoski R, 2013, J INVEST DERMATOL, V133, P964, DOI 10.1038/jid.2012.356; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hazen TC, 2010, SCIENCE, V330, P204, DOI 10.1126/science.1195979; Hilty M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008578; Horak F, 2004, CLIN EXP ALLERGY, V34, P1220, DOI 10.1111/j.1365-2222.2004.02024.x; Huang YJ, 2010, J ALLERGY CLIN IMMUN, V127, pe1; Huang YJ, 2010, J ALLERGY CLIN IMMUN, V127, P372; Ichinohe T, 2011, P NATL ACAD SCI USA, V108, P5354, DOI 10.1073/pnas.1019378108; KUEHR J, 1994, J ALLERGY CLIN IMMUN, V94, P44, DOI 10.1016/0091-6749(94)90070-1; Lau S, 2003, EUR RESPIR J, V21, P834, DOI 10.1183/09031936.03.00037203; Lau S, 2000, LANCET, V356, P1392, DOI 10.1016/S0140-6736(00)02842-7; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Lopez-Sanchez Maria Jose, 2008, Environmental Microbiology, V10, P3417, DOI 10.1111/j.1462-2920.2008.01776.x; Marks GB, 2006, J ALLERGY CLIN IMMUN, V118, P53, DOI 10.1016/j.jaci.2006.04.004; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Matsui EC, 2008, IMMUNOL ALLERGY CLIN, V28, P665, DOI 10.1016/j.iac.2008.03.004; Oertli M, 2013, P NATL ACAD SCI USA, V110, P3047, DOI 10.1073/pnas.1211248110; Olszak T, 2012, SCIENCE, V336, P489, DOI 10.1126/science.1219328; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Pelletier AJ, 2006, PEDIATRICS, V118, P2418, DOI 10.1542/peds.2006-1193; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Phipatanakul W, 2008, ALLERGY, V63, P1512, DOI 10.1111/j.1398-9995.2008.01679.x; Phipatanakul W, 2005, ANN ALLERG ASTHMA IM, V94, P593; Platts-Mills T, 2001, LANCET, V357, P752, DOI 10.1016/S0140-6736(00)04168-4; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Remes ST, 2001, J ALLERGY CLIN IMMUN, V108, P509, DOI 10.1067/mai.2001.117797; Ries M, 2013, J LEUKOCYTE BIOL, V94, P123, DOI 10.1189/jlb.0612278; Rivas MN, 2013, J ALLERGY CLIN IMMUN, V131, P201, DOI 10.1016/j.jaci.2012.10.026; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, pe1; Tovey ER, 2008, J ALLERGY CLIN IMMUN, V122, P114, DOI 10.1016/j.jaci.2008.05.010; Trompette A, 2009, NATURE, V457, P585, DOI 10.1038/nature07548; Turnbaugh PJ, 2006, NATURE, V444, P1027, DOI 10.1038/nature05414; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, P948, DOI 10.1016/j.jaci.2011.07.027; van Nimwegen FA, 2011, J ALLERGY CLIN IMMUN, V128, pe1; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Vujkovic-Cvijin I, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006438; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Wright RJ, 2010, AM J RESP CRIT CARE, V182, P25, DOI 10.1164/rccm.200904-0637OC; Yasui H, 2004, CLIN DIAGN LAB IMMUN, V11, P675, DOI 10.1128/CDLI.11.4.675-679.2004	60	85	87	6	33	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749	1097-6825		J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2014	134	3					593	+		10.1016/j.jaci.2014.04.018		21	Allergy; Immunology	Allergy; Immunology	AO5GR	WOS:000341372400011	24908147	
J	Kumamoto, Y; Linehan, M; Weinstein, JS; Laidlaw, BJ; Craft, JE; Iwasaki, A				Kumamoto, Yosuke; Linehan, Melissa; Weinstein, Jason S.; Laidlaw, Brian J.; Craft, Joseph E.; Iwasaki, Akiko			CD301b(+) Dermal Dendritic Cells Drive T Helper 2 Cell-Mediated Immunity	IMMUNITY			English	Article							CD4(+) T-CELLS; TRANSCRIPTION FACTOR GATA-3; HELPER TYPE-2 RESPONSE; DUST MITE ALLERGEN; IN-VIVO; LANGERHANS CELLS; MUCOSAL IMMUNIZATION; AIRWAY INFLAMMATION; HELMINTH INFECTION; TH2 CELLS	Unlike other types of T helper (Th) responses, whether the development of Th2 cells requires instruction from particular subset of dendritic cells (DCs) remains unclear. By using an in vivo depletion approach, we have shown that DCs expressing CD301b were required for the generation of Th2 cells after subcutaneous immunization with ovalbumin (OVA) along with papain or alum. CD301b(+) DCs are distinct from epidermal or CD207(+) dermal DCs (DDCs) and were responsible for transporting antigen injected subcutaneously with Th2-type adjuvants. Transient depletion of CD301b(+) DCs resulted in less effective accumulation and decreased expression of CD69 by polyclonal CD4(+) T cells in the lymph node. Moreover, despite intact cell division and interferon-gamma production, CD301b(+) DC depletion led to blunted interleukin-4 production by OVA-specific OT-II transgenic CD4(+) T cells and significantly impaired Th2 cell development upon infection with Nippostrongylus brasiliensis. These results reveal CD301b(+) DDCs as the key mediators of Th2 immunity.	[Kumamoto, Yosuke; Linehan, Melissa; Weinstein, Jason S.; Laidlaw, Brian J.; Craft, Joseph E.; Iwasaki, Akiko] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA; [Craft, Joseph E.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA	Iwasaki, A (reprint author), Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT 06520 USA.	akiko.iwasaki@yale.edu		Kumamoto, Yosuke/0000-0001-9369-4934	National Institutes of Health (NIH) [AI054359, AI062428, AR40072, AR44076]; Yale Rheumatic Diseases Research Core Center, NIH (NIAMS) [P30 AR053495]	We thank D. Kaplan and R. Medzhitov for critical reading of the manuscript and H. Dong for technical support. This work is supported by National Institutes of Health (NIH) grants to A. I. (AI054359 and AI062428) and J.E.C. (AR40072 and AR44076). The study was partly funded by a pilot grant from the Yale Rheumatic Diseases Research Core Center, NIH (NIAMS) P30 AR053495. Y.K. was an Astellas Foundation for Research on Metabolic Disorders fellow.	Baaten BJG, 2010, IMMUNITY, V32, P104, DOI 10.1016/j.immuni.2009.10.011; Besnard AG, 2011, EUR J IMMUNOL, V41, P1675, DOI 10.1002/eji.201041033; Bobr A, 2010, J IMMUNOL, V185, P4724, DOI 10.4049/jimmunol.1001802; Bogunovic M, 2006, J EXP MED, V203, P2627, DOI 10.1084/jem.20060667; Brewig N, 2009, J IMMUNOL, V182, P774; Camberis M, 2003, CURR PROTOC IMMUNOL, DOI DOI 10.1002/0471142735.IM1912S55; Choi YS, 2011, IMMUNITY, V34, P932, DOI 10.1016/j.immuni.2011.03.023; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; Fahlen-Yrlid L, 2009, J IMMUNOL, V183, P5032, DOI 10.4049/jimmunol.0803992; Gao Y, 2013, IMMUNITY, V39, P722, DOI 10.1016/j.immuni.2013.08.028; Ginhoux F, 2007, J EXP MED, V204, P3133, DOI 10.1084/jem.20071733; Guan HB, 2009, J IMMUNOL, V183, P172, DOI 10.4049/jimmunol.0802325; Guilliams M, 2010, BLOOD, V115, P1958, DOI 10.1182/blood-2009-09-245274; Halim TYF, 2012, IMMUNITY, V36, P451, DOI 10.1016/j.immuni.2011.12.020; Hammad H, 2010, J EXP MED, V207, P2097, DOI 10.1084/jem.20101563; Hervouet C, 2010, J IMMUNOL, V184, P4842, DOI 10.4049/jimmunol.0901695; Igyarto BZ, 2011, IMMUNITY, V35, P260, DOI 10.1016/j.immuni.2011.06.005; Ishiwata K, 2010, J IMMUNOL, V184, P2086, DOI 10.4049/jimmunol.0804051; Kaplan DH, 2012, NAT REV IMMUNOL, V12, P114, DOI 10.1038/nri3150; Kim TS, 2010, J EXP MED, V207, P1161, DOI 10.1084/jem.20092017; King IL, 2010, J EXP MED, V207, P953, DOI 10.1084/jem.20091844; Kissenpfennig A, 2005, IMMUNITY, V22, P643, DOI 10.1016/j.immuni.2005.04.004; Kool M., 2012, BIOL REP, V4, P6; Kumamoto Y, 2004, J BIOL CHEM, V279, P49274, DOI 10.1074/jbc.M409300200; Kumamoto Y, 2011, P NATL ACAD SCI USA, V108, P8749, DOI 10.1073/pnas.1100567108; Kumamoto Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005619; Leon B, 2012, NAT IMMUNOL, V13, P681, DOI 10.1038/ni.2309; MacDonald AS, 2002, J IMMUNOL, V168, P537; Magalhaes JG, 2011, P NATL ACAD SCI USA, V108, P14896, DOI 10.1073/pnas.1015063108; Maldonado-Lopez R, 1999, J EXP MED, V189, P587, DOI 10.1084/jem.189.3.587; Matsumoto K, 2008, BIOCHEM BIOPH RES CO, V365, P170, DOI 10.1016/j.bbrc.2007.10.156; Merad M, 2008, NAT REV IMMUNOL, V8, P935, DOI 10.1038/nri2455; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; Nagao K, 2009, P NATL ACAD SCI USA, V106, P3312, DOI 10.1073/pnas.0807126106; Oflazoglu E, 2004, EUR J IMMUNOL, V34, P3326, DOI 10.1002/eji.200425197; Ohnmacht C, 2010, IMMUNITY, V33, P364, DOI 10.1016/j.immuni.2010.08.011; Otsuka A, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2740; Palm NW, 2012, NATURE, V484, P465, DOI 10.1038/nature11047; Paul WE, 2010, NAT REV IMMUNOL, V10, P225, DOI 10.1038/nri2735; Perrigoue JG, 2009, NAT IMMUNOL, V10, P697, DOI 10.1038/ni.1740; Phythian-Adams AT, 2010, J EXP MED, V207, P2089, DOI 10.1084/jem.20100734; Plantinga M, 2013, IMMUNITY, V38, P322, DOI 10.1016/j.immuni.2012.10.016; Pulendran B, 1999, P NATL ACAD SCI USA, V96, P1036, DOI 10.1073/pnas.96.3.1036; Pulendran B, 2012, SCIENCE, V337, P431, DOI 10.1126/science.1221064; Rank MA, 2009, J ALLERGY CLIN IMMUN, V123, P1047, DOI 10.1016/j.jaci.2009.02.026; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Schenten D, 2002, EUR J IMMUNOL, V32, P3152, DOI 10.1002/1521-4141(200211)32:11<3152::AID-IMMU3152>3.0.CO;2-2; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Smith KA, 2012, INFECT IMMUN, V80, P3481, DOI 10.1128/IAI.00436-12; Smith KA, 2011, J IMMUNOL, V186, P7098, DOI 10.4049/jimmunol.1003636; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; Sokol CL, 2009, NAT IMMUNOL, V10, P713, DOI 10.1038/ni.1738; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Tang H, 2010, NAT IMMUNOL, V11, P608, DOI 10.1038/ni.1883; Webster B, 2006, J EXP MED, V203, P1903, DOI 10.1084/jem.20052272; Yoo JK, 2010, J EXP MED, V207, P1435, DOI 10.1084/jem.20091373; Yoshimoto T, 2009, NAT IMMUNOL, V10, P706, DOI 10.1038/ni.1737; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8; Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212	61	85	87	0	16	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	1074-7613	1097-4180		IMMUNITY	Immunity	OCT 17	2013	39	4					733	743		10.1016/j.immuni.2013.08.029		11	Immunology	Immunology	AA2UP	WOS:000330950000014	24076051	
J	Hyson, DA				Hyson, Dianne A.			A Comprehensive Review of Apples and Apple Components and Their Relationship to Human Health	ADVANCES IN NUTRITION			English	Review								There has been an increasing appreciation and understanding of the link between dietary fruit and vegetable intake and improved health in humans. The widespread and growing intake of apples and apple juice/products and their rich phytochemical profile suggest their important potential to affect the health of the populations consuming them. This review summarizes current clinical, in vitro, and in vivo data and builds upon earlier published reports that apple may reduce the risk of chronic disease by various mechanisms, including antioxidant, antiproliferative, and cell signaling effects. Exposure to apples and apple products has been associated with beneficial effects on risk, markers, and etiology of cancer, cardiovascular disease, asthma, and Alzheimer's disease. Recent work suggests that these products may also be associated with improved outcomes related to cognitive decline of normal aging, diabetes, weight management, bone health, pulmonary function, and gastrointestinal protection. Adv. Nutr. 2: 408-420,2011.	Calif State Univ Sacramento, Dept Family & Consumer Sci Nutr & Food Dietet, Sacramento, CA 95819 USA	Hyson, DA (reprint author), Calif State Univ Sacramento, Dept Family & Consumer Sci Nutr & Food Dietet, Sacramento, CA 95819 USA.	dhyson@csus.edu			United States Apple Association; Apple Products Research and Education Council	Supported in part by the United States Apple Association and the Apple Products Research and Education Council.	American Heart Association, HEART DIS STROK STAT; Avci A, 2007, EXP AGING RES, V33, P429, DOI 10.1080/03610730701525352; Barth SW, 2007, J AGR FOOD CHEM, V55, P1181, DOI 10.1021/jf063078t; Barth SW, 2005, CARCINOGENESIS, V26, P1414, DOI 10.1093/carcin/bgi082; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bell JA, 2004, NUTRITION, V20, P492, DOI 10.1016/j.nut.2004.01.015; Boyer J, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-5; Carmona R H, 2004, BONE HLTH OSTEOPOROS; Cefarelli G, 2006, J AGR FOOD CHEM, V54, P803, DOI 10.1021/jf052632g; Chan A, 2009, J ALZHEIMERS DIS, V16, P176; Chan A, 2007, J NEUROCHEM, V102, P753, DOI 10.1111/j.1471-4159.2007.04589.x; Chan A, 2006, J ALZHEIMERS DIS, V10, P353; Chan A, 2006, J ALZHEIMERS DIS, V9, P287; Chun OK, 2007, J NUTR, V137, P1244; Chun OK, 2005, J SCI FOOD AGR, V85, P1715, DOI 10.1002/jsfa.2176; Davis PA, 2006, EXP BIOL MED, V231, P594; de Oliveira MC, 2003, NUTRITION, V19, P253, DOI 10.1016/S0899-9007(02)00850-X; Decorde K, 2008, MOL NUTR FOOD RES, V52, P400, DOI 10.1002/mnfr.200700141; DEVEREUX G, 2005, CLIN IMMUNOL, V115, P1109, DOI DOI 10.1016/J.JACI.2004.12.11.39; Gallus S, 2005, ANN ONCOL, V16, P1841, DOI 10.1093/annonc/mdi361; Garcia V, 2005, EUR RESPIR J, V26, P449, DOI 10.1183/09031936.05.00142104; Gerhauser C, 2008, PLANTA MED, V74, P1608, DOI 10.1055/s-0028-1088300; Gosse F, 2005, CARCINOGENESIS, V26, P1291, DOI 10.1093/carcin/bgi074; Gosse F, 2006, INT J ONCOL, V29, P423; Graziani G, 2005, GUT, V54, P193, DOI 10.1136/gut.2004.046292; He XJ, 2007, J AGR FOOD CHEM, V55, P4366, DOI 10.1021/jf063563o; HERTOG MGL, 1994, NUTR CANCER, V22, P175; HERTOG MGL, 1993, LANCET, V342, P1007, DOI 10.1016/0140-6736(93)92876-U; Jemal A, 2007, CA-CANCER J CLIN, V57, P43; Johnston KL, 2002, J SCI FOOD AGR, V82, P1800, DOI 10.1002/jsfa.1264; Kahle K, 2005, MOL NUTR FOOD RES, V49, P1143, DOI 10.1002/mnfr.200500132; Kern M, 2007, J AGR FOOD CHEM, V55, P4999, DOI 10.1021/jf063158x; Knekt P, 1996, BRIT MED J, V312, P478; Ko SH, 2005, J MED FOOD, V8, P41, DOI 10.1089/jmf.2005.8.41; Lichtenthaler R, 2005, J AGR FOOD CHEM, V53, P103, DOI 10.1021/jf0307550; Linseisen J, 2007, INT J CANCER, V121, P1103, DOI 10.1002/ijc.22807; Liu JR, 2009, J AGR FOOD CHEM, V57, P297, DOI 10.1021/jf801826w; Liu RH, 2005, J AGR FOOD CHEM, V53, P2341, DOI 10.1021/jf058010; Lotito SB, 2004, FREE RADICAL BIO MED, V36, P201; Lotito SB, 2004, FREE RADICAL BIO MED, V37, P251, DOI 10.1016/j.freeradbiomed.2004.04.019; Maffei F, 2007, BRIT J NUTR, V97, P921, DOI 10.1017/S0007114507665192; Marks SC, 2009, J AGR FOOD CHEM, V57, P2009, DOI 10.1021/jf802757x; Molnar P, 2005, PHYTOTHER RES, V19, P700, DOI 10.1002/ptr.1735; Ogino Y, 2007, LIPIDS, V42, P151, DOI 10.1007/s11745-006-3008-2; Okoko BJ, 2007, EUR RESPIR J, V29, P1161, DOI 10.1183/09031936.00097806; Olsson ME, 2004, J AGR FOOD CHEM, V52, P7264, DOI 10.1021/jf030479p; Pajk T, 2006, NUTRITION, V22, P376, DOI 10.1016/j.nut.2005.08.010; Patel BD, 2006, THORAX, V61, P388, DOI 10.1136/thx.2004.024935; Peri L, 2005, FREE RADICAL BIO MED, V39, P668, DOI 10.1016/j.freeradbiomed.2005.04.021; Prynne CJ, 2006, AM J CLIN NUTR, V83, P1420; Puel C, 2005, CALCIFIED TISSUE INT, V77, P311, DOI 10.1007/s00223-005-0060-5; Ramos S, 2007, J NUTR BIOCHEM, V18, P427, DOI 10.1016/j.jnutbio.2006.11.004; Rogers E J, 2004, J Nutr Health Aging, V8, P92; Romieu I, 2006, THORAX, V61, P209, DOI 10.1136/thx.2004.039123; Sampson L, 2002, J AM DIET ASSOC, V102, P1414, DOI 10.1016/S0002-8223(02)90314-7; Schaefer S, 2006, MOL NUTR FOOD RES, V50, P413, DOI 10.1002/mnfr.200500194; Schaefer S, 2006, MOL NUTR FOOD RES, V50, P24, DOI 10.1002/mnfr.200500136; Shaheen SO, 2001, AM J RESP CRIT CARE, V164, P1823; Song YQ, 2005, J AM COLL NUTR, V24, P376; Sun J, 2002, J AGR FOOD CHEM, V50, P7449, DOI 10.1021/jf0207530; Sun J, 2008, J AGR FOOD CHEM, V56, P11661, DOI 10.1021/jf8021223; Sun T, 2007, J FOOD SCI, V72, pR159, DOI 10.1111/j.1750-3841.2007.00552.x; Tabak C, 2006, THORAX, V61, P1048, DOI 10.1136/thx.2005.043034; Tchantchou F, 2004, J Nutr Health Aging, V8, P492; Tchantchou F, 2005, J ALZHEIMERS DIS, V8, P283; Tsao R, 2005, J AGR FOOD CHEM, V53, P4989, DOI 10.1021/jf048289h; U.S. Apple Association, 2010, PROD UT AN; Veeriah S, 2006, MOL CARCINOGEN, V45, P164, DOI 10.1002/mc.20158; Veeriah S, 2007, J AGR FOOD CHEM, V55, P2892, DOI 10.1021/jf063386r; Vidal R, 2005, J LIPID RES, V46, P258, DOI 10.1194/jlr.M400209-JLR200; Viggiano A, 2006, EXP NEUROL, V199, P354, DOI 10.1016/j.expneurol.2006.01.001; Waldecker M, 2008, NUTRITION, V24, P366, DOI 10.1016/j.nut.2007.12.013; Willers SM, 2007, THORAX, V62, P773, DOI 10.1136/thx.2006.074187; Williamson G, 2005, AM J CLIN NUTR, V81, p243S; Wojdylo A, 2008, J AGR FOOD CHEM, V56, P6520, DOI 10.1021/jf800510j; Yoon H, 2007, J AGR FOOD CHEM, V55, P3167, DOI 10.1021/jf0632379	76	85	87	4	68	AMER SOC NUTRITION-ASN	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	2161-8313			ADV NUTR	Adv. Nutr.	SEP	2011	2	5					408	420		10.3945/an.111.000513		13	Nutrition & Dietetics	Nutrition & Dietetics	V27BU	WOS:000208589500005	22332082	
J	Terzano, C; Di Stefano, F; Conti, V; Graziani, E; Petroianni, A				Terzano, C.; Di Stefano, F.; Conti, V.; Graziani, E.; Petroianni, A.			Air pollution ultrafine particles: toxicity beyond the lung	EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES			English	Article						Nanoparticles; Lung injury; Cardiovascular disease; Health effects	DIESEL EXHAUST PARTICLES; CORONARY-HEART-DISEASE; POLYCYCLIC AROMATIC-HYDROCARBONS; AIRBORNE PARTICULATE MATTER; LONG-TERM EXPOSURE; OXIDATIVE STRESS; FINE PARTICLES; CARBON-BLACK; IN-VIVO; HOSPITAL ADMISSIONS	Background: Ultrafine particles or nanoparticles (UFPs or PM0.1) are the fraction of ambient particulates with an aerodynamic diameter smaller than 0.1 mu m. Currently UFPs are emerging as the most abundant particulate pollutants in urban and industrial areas, as their exposures have increased dramatically because of anthropogenic sources such as internal combustion engines, power plants, incinerators and many other sources of thermo-degradation. Ultrafine particles have been less studied than PM2.5 and PM10 particulates, mass concentrations of particles smaller than 2.5 and 10 mu m, respectively. Objective, Evidence and Information Sources: We examined the current scientific literature about the health effects of ultrafine particles exposure. State of the Art: UFPs are able to inhibit phagocytosis, and to stimulate inflammatory responses, damaging epithelial cells and potentially gaining access to the interstitium. They could be responsible for consistent reductions in forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) in patients with asthma. Chronic exposure to UFPs can produce deleterious effects on the lung, also causing oxidative stress and enhancing pro-inflammatory effects in airways of COPD patients. Cardiovascular detrimental consequences due to UFPs exposure have observed in epidemiological studies, and could likely be explained by translocation of UFPs from the respiratory epithelium towards circulation and subsequent toxicity to vascular endothelium; alteration of blood coagulation; triggering of autonomic nervous system reflexes eventually altering the cardiac frequency and function. Once deposited deeply into the lung, UFPs - in contrast to larger-sized particles - appear to access to the blood circulation by different transfer routes and mechanisms, resulting in distribution throughout the body, including the brain, with potential neurotoxic consequences. Perspectives and Conclusions. UFPs represent an area of toxicology of emerging concern. A new concept of environmental medicine would help in understanding not only the environmental mechanisms of disease, but also in developing specific preventive or therapeutic strategies for minimizing the dangerous influence of pollution on health.	[Terzano, C.; Di Stefano, F.; Conti, V.; Graziani, E.; Petroianni, A.] Univ Roma La Sapienza, Dept Cardiovasc & Resp Sci, Resp Dis Unit, Fdn E Lorillard Spencer Cenci, Rome, Italy	Terzano, C (reprint author), Univ Roma La Sapienza, Dept Cardiovasc & Resp Sci, Resp Dis Unit, Fdn E Lorillard Spencer Cenci, Rome, Italy.	cterzano@tin.it					Abbey DE, 1998, AM J RESP CRIT CARE, V158, P289; Akerman ME, 2002, P NATL ACAD SCI USA, V99, P12617, DOI 10.1073/pnas.152463399; Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Annesi-Maesano I, 2007, EUR RESPIR J, V29, P428, DOI 10.1183/09031936.00129506; Araujo JA, 2008, CIRC RES, V102, P589, DOI 10.1161/CIRCRESAHA.107.164970; Barrett EG, 2003, INHAL TOXICOL, V15, P151, DOI 10.1080/08958370390168210; Bell ML, 2008, AM J EPIDEMIOL, V168, P1301, DOI 10.1093/aje/kwn252; Berube KA, 1999, ATMOS ENVIRON, V33, P1599, DOI 10.1016/S1352-2310(98)00384-7; Bhatnagar A, 2006, CIRC RES, V99, P692, DOI 10.1161/01.RES.0000243586.99701.cf; Bouthillier L, 1998, AM J PATHOL, V153, P1873, DOI 10.1016/S0002-9440(10)65701-X; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Brook RD, 2002, CIRCULATION, V105, P1534, DOI 10.1161/01.CIR.0000013838.94747.64; Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240; Brown JS, 2002, AM J RESP CRIT CARE, V166, P1240, DOI 10.1164/rccm.00205-399OC; Calderon-Garciduenas L, 2002, TOXICOL PATHOL, V30, P373, DOI 10.1080/01926230252929954; Campbell A, 2005, NEUROTOXICOLOGY, V26, P133, DOI 10.1016/j.neuro.2004.08.003; Chalupa DC, 2004, ENVIRON HEALTH PERSP, V112, P879, DOI 10.1289/ehp.6851; Committee on the Medical Effects of Air Pollution, 2006, CARD DIS AIR POLL; CONHAIM RL, 1988, J APPL PHYSIOL, V64, P1134; Costa DL, 1997, ENVIRON HEALTH PERSP, V105, P1053, DOI 10.2307/3433509; Daigle CC, 2003, INHAL TOXICOL, V15, P539, DOI 10.1080/08958370390205065; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; de Hartog JJ, 2003, AM J EPIDEMIOL, V157, P613, DOI 10.1093/aje/kwg021; *DEP ENV, 1996, QUARD AIRB PART MATT; DOCKERY DW, 1993, NEW ENGL J MED, V329, P1753, DOI 10.1056/NEJM199312093292401; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; Donaldson K, 2001, OCCUP ENVIRON MED, V58, P211, DOI 10.1136/oem.58.3.211; Donaldson K, 2000, PHILOS T ROY SOC A, V358, P2741; Donaldson Ken, 2005, Part Fibre Toxicol, V2, P10, DOI 10.1186/1743-8977-2-10; Don Porto Carero A., 2001, ENVIRON MOL MUTAGEN, V37, P155; Evans SA, 2006, EXP LUNG RES, V32, P363, DOI 10.1080/01902140600959671; FEIKERT T, 2004, TOXICOLOGIST S1, V78, P435; FERIN J, 1992, AM J RESP CELL MOL, V6, P535; Folino AF, 2009, EUR HEART J, V30, P1614, DOI 10.1093/eurheartj/ehp136; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gatti AM, 2005, J MATER SCI-MATER M, V16, P1213, DOI 10.1007/s10856-005-4731-6; Gatti AM, 2004, J MATER SCI-MATER M, V15, P469, DOI 10.1023/B:JMSM.0000021122.49966.6d; Gianutsos G, 1997, FUND APPL TOXICOL, V37, P102, DOI 10.1006/faat.1997.2306; Gilmour PS, 1996, OCCUP ENVIRON MED, V53, P817; Gilmour PS, 2001, AM J PHYSIOL-LUNG C, V281, pL598; Godleski J. J., 2000, RES REP HLTH EFF I, V91, P5; Godschalk RWL, 2000, CARCINOGENESIS, V21, P87, DOI 10.1093/carcin/21.1.87; Gold DR, 2000, CIRCULATION, V101, P1267; Goldberg MS, 2001, ENVIRON HEALTH PERSP, V109, P487, DOI 10.2307/3454658; Goldberg MS, 2001, ENVIRON RES, V86, P26, DOI 10.1006/enrs.2001.4243; Hermans C, 1999, AM J RESP CRIT CARE, V159, P646; Hildebrandt K, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-25; Hoek G, 2001, EPIDEMIOLOGY, V12, P355, DOI 10.1097/00001648-200105000-00017; Hong YC, 2002, STROKE, V33, P2165, DOI 10.1161/01.STR.0000026865.52610.5B; HOSIOKANGAS J, 1995, J AEROSOL SCI, V26, pS423, DOI 10.1016/0021-8502(95)97119-Y; Inoue K, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-106; Jimenez LA, 2000, TOXICOL APPL PHARM, V166, P101, DOI 10.1006/taap.2000.8957; Johnston CJ, 1996, TOXICOL APPL PHARM, V140, P154, DOI 10.1006/taap.1996.0208; Kennedy PGE, 2002, J NEUROL NEUROSUR PS, V73, P237, DOI 10.1136/jnnp.73.3.237; Kettunen J, 2007, STROKE, V38, P918, DOI 10.1161/01.STR.0000257999.49706.3b; Kim CS, 1997, AM J RESP CRIT CARE, V155, P899; KLEINJANS JCS, 1989, MUTAT RES, V224, P127, DOI 10.1016/0165-1218(89)90011-6; LEVIN ER, 1995, NEW ENGL J MED, V333, P356; LEVSEN K, 1988, FRESEN Z ANAL CHEM, V331, P467, DOI 10.1007/BF00467033; Lewis AB, 2003, J BIOSCIENCES, V28, P13, DOI 10.1007/BF02970126; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Maeng SH, 2003, MUTAT RES-GEN TOX EN, V539, P109, DOI 10.1016/S1383-5718(03)00154-2; McCreanor J, 2007, NEW ENGL J MED, V357, P2348, DOI 10.1056/NEJMoa071535; Mills NL, 2006, AM J RESP CRIT CARE, V173, P426, DOI 10.1164/rccm.200506-865OC; Nel AE, 1998, J ALLERGY CLIN IMMUN, V102, P539, DOI 10.1016/S0091-6749(98)70269-6; Nemmar A, 2002, CIRCULATION, V105, P411, DOI 10.1161/hc0402.104118; Nemmar A, 2004, TOXICOL LETT, V149, P243, DOI 10.1016/j.toxlet.2003.12.061; Nemmar A, 2001, AM J RESP CRIT CARE, V164, P1665; NIKULA KJ, 1995, FUND APPL TOXICOL, V25, P80, DOI 10.1006/faat.1995.1042; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; OBERDORSTER G, 1995, INHAL TOXICOL, V7, P111, DOI 10.3109/08958379509014275; Oberdorster G, 2004, INHAL TOXICOL, V16, P437, DOI 10.1080/08958370490439597; Osier M, 1997, FUND APPL TOXICOL, V40, P220, DOI 10.1006/faat.1997.2390; Ostro B, 2006, ENVIRON HEALTH PERSP, V114, P29, DOI 10.1289/ehp.8335; Pekkanen J, 1997, ENVIRON RES, V74, P24, DOI 10.1006/enrs.1997.3750; Pekkanen J, 2002, CIRCULATION, V106, P933, DOI 10.1161/01.CIR.0000027561.41736.3C; Penttinen P, 2001, EUR RESPIR J, V17, P428, DOI 10.1183/09031936.01.17304280; Peters A, 2000, EPIDEMIOLOGY, V11, P11, DOI 10.1097/00001648-200001000-00005; Peters A, 1997, AM J RESP CRIT CARE, V155, P1376; Peters A, 2001, EUR HEART J, V22, P1198, DOI 10.1053/euhj.2000.2483; Peters A, 2001, CIRCULATION, V103, P2810; Peters Annette, 2006, Part Fibre Toxicol, V3, P13, DOI 10.1186/1743-8977-3-13; Pope CA, 2009, NEW ENGL J MED, V360, P376, DOI 10.1056/NEJMsa0805646; Pope CA, 1999, AM HEART J, V138, P890, DOI 10.1016/S0002-8703(99)70014-1; Pope CA, 2004, CIRCULATION, V109, P71, DOI 10.1161/01.CIR.0000108927.80044.7F; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Renwick LC, 2001, TOXICOL APPL PHARM, V172, P119, DOI 10.1006/taap.2001.9128; Rubes J, 2005, HUM REPROD, V20, P2776, DOI 10.1093/humrep/dei122; Ruckerl Regina, 2007, Part Fibre Toxicol, V4, P1, DOI 10.1186/1743-8977-4-1; Samet JM, 2000, NEW ENGL J MED, V343, P1742, DOI 10.1056/NEJM200012143432401; Schwartz J, 1999, EPIDEMIOLOGY, V10, P17, DOI 10.1097/00001648-199901000-00005; Schwarze PE, 2006, HUM EXP TOXICOL, V25, P559, DOI 10.1177/096032706072520; Seaton A, 1999, THORAX, V54, P1027; Seaton A, 2003, THORAX, V58, P1012, DOI 10.1136/thorax.58.12.1012; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; Somers CM, 2004, SCIENCE, V304, P1008, DOI 10.1126/science.1095815; Somers CM, 2002, P NATL ACAD SCI USA, V99, P15904, DOI 10.1073/pnas.252499499; Squadrito GL, 2001, FREE RADICAL BIO MED, V31, P1132, DOI 10.1016/S0891-5849(01)00703-1; STEARNS RC, 1994, P INT C EL MICR PAR, P763; Stone V, 1998, TOXICOL IN VITRO, V12, P649, DOI 10.1016/S0887-2333(98)00050-2; Stone V, 2000, EUR RESPIR J, V15, P297, DOI 10.1034/j.1399-3003.2000.15b13.x; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Tamaoki J, 2004, AM J PHYSIOL-LUNG C, V287, pL1127, DOI 10.1152/ajplung.00241.2004; Terasaki Shin-Ichiro, 1997, Kurume Medical Journal, V44, P61; Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538; van Eeden SF, 2001, AM J RESP CRIT CARE, V164, P826; Van Lente F, 2000, CLIN CHIM ACTA, V293, P31, DOI 10.1016/S0009-8981(99)00236-3; Vedal S, 1997, J AIR WASTE MANAGE, V47, P551; Venkataraman C, 1998, INHAL TOXICOL, V10, P183; von Klot S, 2002, EUR RESPIR J, V20, P691, DOI 10.1183/09031936.02.01402001; Wellenius GA, 2005, STROKE, V36, P2549, DOI 10.1161/01.STR.0000189687.78760.47; World Health Organization, 2005, WORK GROUP M BONN GE; Wichmann HE, 2007, INHAL TOXICOL, V19, P241, DOI 10.1080/08958370701498075; WICHMANN HE, 2000, 98 HEI, P1; Zanobetti A, 2001, AM J RESP CRIT CARE, V164, P831; PARTICUALTE MATTER P, P63	119	85	91	5	69	VERDUCI PUBLISHER	ROME	VIA GREGORIO VII, ROME, 186-00165, ITALY	1128-3602			EUR REV MED PHARMACO	Eur. Rev. Med. Pharmacol. Sci.	OCT	2010	14	10					809	821				13	Pharmacology & Pharmacy	Pharmacology & Pharmacy	674MS	WOS:000283750900001	21222367	
J	Verma, D; Moghimi, B; LoDuca, PA; Singh, HD; Hoffman, BE; Herzog, RW; Daniell, H				Verma, Dheeraj; Moghimi, Babak; LoDuca, Paul A.; Singh, Harminder D.; Hoffman, Brad E.; Herzog, Roland W.; Daniell, Henry			Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						allergy; chloroplast; genetic disorders; oral tolerance; plant-made therapeutics	HEAT-LABILE ENTEROTOXIN; CHOLERA-TOXIN; TRANSGENIC CHLOROPLASTS; FUNCTIONAL-EVALUATION; TOBACCO CHLOROPLASTS; ESCHERICHIA-COLI; VACCINE ANTIGENS; IMMUNE-RESPONSES; GENE-THERAPY; MOUSE MODEL	To address complications of pathogenic antibody or life-threatening anaphylactic reactions in protein replacement therapy for patients with hemophilia or other inherited protein deficiencies, we have developed a prophylactic protocol using a murine hemophilia B model. Oral delivery of coagulation factor IX fused with cholera toxin beta-subunit (with or without a furin cleavage site; CTB-FFIX or CTB-FIX), expressed in chloroplasts (up to 3.8% soluble protein or 0.4 mg/g leaf tissue), bioencapsulated in plant cells, effectively blocked formation of inhibitory antibodies (undetectable or up to 100-fold less than controls). Moreover, this treatment eliminated fatal anaphylactic reactions that occurred after four to six exposures to intravenous F. IX. Whereas only 20-25% of control animals survived after six to eight F. IX doses, 90-93% of F.IX-fed mice survived 12 injections without signs of allergy or anaphylaxis. Immunostaining confirmed delivery of F. IX to Peyer's patches in the ileum. Within 2-5 h, feeding of CTB-FFIX additionally resulted in systemic delivery of F. IX antigen. This high-responder strain of hemophilia B mice represents a new animal model to study anaphylactic reactions. The protocol was effective over a range of oral antigen doses (equivalent to 5-80 mu g recombinant F.IX/kg), and controlled inhibitor formation and anaphylaxis long-term, up to 7 months (similar to 40% life span of this mouse strain). Oral antigen administration caused a deviant immune response that suppressed formation of IgE and inhibitory antibodies. This cost-effective and efficient approach of antigen delivery to the gut should be applicable to several genetic diseases that are prone to pathogenic antibody responses during treatment.	[Verma, Dheeraj; Singh, Harminder D.; Daniell, Henry] Univ Cent Florida, Coll Med, Dept Mol Biol & Microbiol, Orlando, FL 32816 USA; [Moghimi, Babak; LoDuca, Paul A.; Hoffman, Brad E.; Herzog, Roland W.] Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA	Herzog, RW (reprint author), Univ Florida, Coll Med, Dept Pediat, Gainesville, FL 32610 USA.	rherzog@ufl.edu; daniell@mail.ucf.edu	Verma, Dheeraj/E-1654-2011; Hoffman, Brad/E-8363-2010	Hoffman, Brad/0000-0002-5560-9580; Daniell, Henry/0000-0003-4485-1176	NIH [R21 HL089813, R01 AI/HL51390, R01 GM 63879]	We thank Clive Wasserfall and David Markusic for their help. This work was supported by NIH Grant R21 HL089813 to R. W. H. and H. D., R01 AI/HL51390 to R. W. H., and R01 GM 63879 to H. D.	Arlen PA, 2008, INFECT IMMUN, V76, P3640, DOI 10.1128/IAI.00050-08; Arlen PA, 2007, PLANT BIOTECHNOL J, V5, P511, DOI 10.1111/j.1467-7652.2007.00258.x; Arruda VR, 2009, MOL THER, V17, P1492, DOI 10.1038/mt.2009.150; Cao O, 2006, BLOOD, V108, P480, DOI 10.1182/blood-2005-11-4668; Cao O, 2009, MOL THER, V17, P1733, DOI 10.1038/mt.2009.159; Daniell H, 2001, J MOL BIOL, V311, P1001, DOI 10.1006/jmbi.2001.4921; Daniell H, 2002, NAT BIOTECHNOL, V20, P581, DOI 10.1038/nbt0602-581; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; Daniell H, 2007, P NATL ACAD SCI USA, V104, P6879, DOI 10.1073/pnas.0702219104; Daniell H, 2009, TRENDS PLANT SCI, V14, P669, DOI 10.1016/j.tplants.2009.09.009; Daniell H, 2009, BMC BIOTECHNOL, V9, DOI 10.1186/1472-6750-9-33; Davoodi-Semiromi A, 2010, PLANT BIOTECHNOL J, V8, P223, DOI 10.1111/j.1467-7652.2009.00479.x; Davoodi-Semiromi A, 2009, HUM VACCINES, V5, P488; De Cosa B, 2001, NAT BIOTECHNOL, V19, P71, DOI 10.1038/83559; de Haan L, 1998, IMMUNOL CELL BIOL, V76, P270; Dimichele DM, 2006, HAEMOPHILIA, V12, P37, DOI 10.1111/j.1365-2516.2006.01364.x; DiMichele D, 2007, BRIT J HAEMATOL, V138, P305, DOI 10.1111/j.1365-2141.2007.06657.x; Dioun AF, 1998, J ALLERGY CLIN IMMUN, V102, P113, DOI 10.1016/S0091-6749(98)70061-2; Finkelman FD, 2007, J ALLERGY CLIN IMMUN, V120, P506, DOI 10.1016/j.jaci.2007.07.033; Franchini M, 2009, BLOOD COAGUL FIBRIN, V20, P225, DOI 10.1097/MBC.0b013e328329f265; Ghosh K, 2009, CLIN REV ALLERG IMMU, V37, P58, DOI 10.1007/s12016-009-8118-1; HAQ TA, 1995, SCIENCE, V268, P714, DOI 10.1126/science.7732379; Kadar JG, 2007, HAEMOPHILIA, V13, P104, DOI 10.1111/j.1365-2516.2006.01339.x; Limaye A, 2006, FASEB J, V20, P959, DOI 10.1096/fj.05-5134fje; Lin HF, 1997, BLOOD, V90, P3962; Mason HS, 2002, TRENDS MOL MED, V8, P324, DOI 10.1016/S1471-4914(02)02360-2; Mohrenschlager M, 2008, J EUR ACAD DERMATOL, V22, P692, DOI 10.1111/j.1468-3083.2008.02638.x; Monahan PE, 2008, THROMB HAEMOSTASIS, V100, P563, DOI 10.1160/TH08-04-0262; Nicolino M, 2009, GENET MED, V11, P210, DOI 10.1097/GIM.0b013e31819d0996; Rawle FE, 2006, J THROMB HAEMOST, V4, P2172, DOI 10.1111/j.1538-7836.2006.02118.x; Ruhlman T, 2007, PLANT BIOTECHNOL J, V5, P495, DOI 10.1111/j.1467-7652.2007.00259.x; Ruhlman T, 2010, PLANT PHYSIOL, V152, P2088, DOI 10.1104/pp.109.152017; Singh N. Dolendro, 2009, V483, P163, DOI 10.1007/978-1-59745-407-0_10; Sun BD, 2010, MOL THER, V18, P353, DOI 10.1038/mt.2009.195; Terada K, 2001, VOX SANG, V80, P61, DOI 10.1046/j.1423-0410.2001.00007.x; Thorland EC, 1999, HAEMOPHILIA, V5, P101, DOI 10.1046/j.1365-2516.1999.00303.x; TSUJI T, 1995, MICROBIOL IMMUNOL, V39, P817; Verma D, 2008, NAT PROTOC, V3, P739, DOI 10.1038/nprot.2007.522; Verma D, 2007, PLANT PHYSIOL, V145, P1129, DOI 10.1104/pp.107.106690; von der Weid T, 2001, INT ARCH ALLERGY IMM, V125, P307, DOI 10.1159/000053831; Warrier I, 1997, J PEDIAT HEMATOL ONC, V19, P23, DOI 10.1097/00043426-199701000-00003	41	85	86	0	5	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	APR 13	2010	107	15					7101	7106		10.1073/pnas.0912181107		6	Multidisciplinary Sciences	Science & Technology - Other Topics	583AC	WOS:000276642100096	20351275	
J	Smith-Sivertsen, T; Diaz, E; Pope, D; Lie, RT; Diaz, A; McCracken, J; Bakke, P; Arana, B; Smith, KR; Bruce, N				Smith-Sivertsen, Tone; Diaz, Esperanza; Pope, Dan; Lie, Rolv T.; Diaz, Anaite; McCracken, John; Bakke, Per; Arana, Byron; Smith, Kirk R.; Bruce, Nigel			Effect of Reducing Indoor Air Pollution on Women's Respiratory Symptoms and Lung Function: The RESPIRE Randomized Trial, Guatemala	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						biomass; bronchitis; chronic; carbon monoxide; developing countries; pulmonary disease; chronic obstructive; smoke; spirometry; wood	OBSTRUCTIVE PULMONARY-DISEASE; WOOD SMOKE EXPOSURE; PARTICULATE MATTER; CARBON-MONOXIDE; HIGHLAND GUATEMALA; STOVE INTERVENTION; BIOMASS SMOKE; MEXICAN WOMEN; ASTHMA; RISK	Exposure to household wood smoke from cooking is a risk factor for chronic obstructive lung disease among women in developing countries. The Randomized Exposure Study of Pollution Indoors and Respiratory Effects (RESPIRE) is a randomized intervention trial evaluating the respiratory health effects of reducing indoor air pollution from open cooking fires. A total of 504 rural Mayan women in highland Guatemala aged 15-50 years, all using traditional indoor open fires, were randomized to either receive a chimney woodstove (plancha) or continue using the open fire. Assessments of chronic respiratory symptoms and lung function and individual measurements of carbon monoxide exposure were performed at baseline and every 6 months up to 18 months. Use of a plancha significantly reduced carbon monoxide exposure by 61.6%. For all respiratory symptoms, reductions in risk were observed in the plancha group during follow-up; the reduction was statistically significant for wheeze (relative risk = 0.42, 95% confidence interval: 0.25, 0.70). The number of respiratory symptoms reported by the women at each follow-up point was also significantly reduced by the plancha (odds ratio = 0.7, 95% confidence interval: 0.50, 0.97). However, no significant effects on lung function were found after 12-18 months. Reducing indoor air pollution from household biomass burning may relieve symptoms consistent with chronic respiratory tract irritation.	[Diaz, Esperanza] Univ Bergen, Sect Gen Practice, Dept Publ Hlth & Primary Hlth Care, Fac Med & Dent, N-5018 Bergen, Norway; [Pope, Dan; Bruce, Nigel] Univ Liverpool, Div Publ Hlth, Sch Populat Community & Behav Sci, Fac Med, Liverpool L69 3BX, Merseyside, England; [Diaz, Anaite; Arana, Byron] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala; [McCracken, John] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA; [McCracken, John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA; [Bakke, Per] Haukeland Hosp, Dept Thorac Med, N-5021 Bergen, Norway; [Bakke, Per] Univ Bergen, Inst Med, Fac Med & Dent, N-5018 Bergen, Norway; [Smith, Kirk R.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA	Diaz, E (reprint author), Univ Bergen, Sect Gen Practice, Dept Publ Hlth & Primary Hlth Care, Fac Med & Dent, Kalfarveien 31, N-5018 Bergen, Norway.	esperanza.diaz@isf.uib.no	Pope, Daniel/C-3054-2014		Norwegian Research Council; US National Institute of Environmental Health Sciences	Funding was obtained from the Norwegian Research Council for this supplement to the main randomized trial (RESPIRE), which was funded by the US National Institute of Environmental Health Sciences.	ABRAMSON MJ, 1991, J ASTHMA, V28, P129, DOI 10.3109/02770909109082737; Akhtar T, 2007, CHEST, V132, P1472, DOI 10.1378/chest.06-2529; Albalak R, 2001, ENVIRON SCI TECHNOL, V35, P2650, DOI 10.1021/es001940m; American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; Asher MI, 1998, EUR RESPIR J, V12, P315; Bai J, 1998, CHEST, V114, P1343, DOI 10.1378/chest.114.5.1343; Boy E, 2000, ENERGY SUSTAIN DEV, V4, P21; Bruce N, 2004, J EXPO ANAL ENV EPID, V14, pS26, DOI 10.1038/sj.jea.7500355; Bruce N, 2000, B WORLD HEALTH ORGAN, V78, P1078; Bruce N, 2007, B WORLD HEALTH ORGAN, V85, P535, DOI 10.2471/BLT.06.035832; Chapman RS, 2005, BRIT MED J, V331, P1050, DOI 10.1136/bmj.38628.676088.55; Diaz E, 2007, INT J TUBERC LUNG D, V11, P1372; Diaz Esperanza, 2008, BMC Int Health Hum Rights, V8, P7, DOI 10.1186/1472-698X-8-7; Diaz E, 2007, J EPIDEMIOL COMMUN H, V61, P74, DOI 10.1136/jech.2006.043133; Engle P, 1998, HUM ORGAN, V54, P522; HALLMAN K, 2006, DOUBLY DISADVANTAGED; Kiraz K, 2003, CLIN INVEST MED, V26, P243; Lenfant C, 2005, GLOBAL STRATEGY DIAG; Liu SM, 2007, THORAX, V62, P889, DOI 10.1136/thx.2006.061457; Mannino DM, 2007, LANCET, V370, P765, DOI 10.1016/S0140-6736(07)61380-4; Mathers C, 2006, UPDATED PROJECTIONS; McCracken JP, 2007, ENVIRON HEALTH PERSP, V115, P996, DOI 10.1289/ehp.9888; McCracken JP, 2009, EPIDEMIOLOGY, V20, P127, DOI 10.1097/EDE.0b013e31818ef327; McCracken JP, 1998, ENVIRON INT, V24, P739, DOI 10.1016/S0160-4120(98)00062-2; Menezes AMB, 2005, LANCET, V366, P1875, DOI 10.1016/S0140-6736(05)67632-5; Naeher LP, 2000, INDOOR AIR, V10, P200; Naeher LP, 2001, ENVIRON SCI TECHNOL, V35, P575, DOI 10.1021/es991225g; Orozco-Levi M, 2006, EUR RESPIR J, V27, P542, DOI 10.1183/09031936.06.00052705; Ozbay B, 2001, Respirology, V6, P255, DOI 10.1046/j.1440-1843.2001.00339.x; Pandey M R, 1985, Tokai J Exp Clin Med, V10, P471; PerezPadilla R, 1996, AM J RESP CRIT CARE, V154, P701; Ramirez-Venegas A, 2006, AM J RESP CRIT CARE, V173, P393, DOI 10.1164/rccm.200504-568OC; Regalado J, 2006, AM J RESP CRIT CARE, V174, P901, DOI 10.1164/rccm.200503-479OC; Rehfuess E, 2006, ENVIRON HEALTH PERSP, V114, P373, DOI 10.1289/ehp.8603; Rinne ST, 2006, RESP MED, V100, P1208, DOI 10.1016/j.rmed.2005.10.020; Shrestha IL, 2005, INT J OCCUP ENV HEAL, V11, P150; Smith KR, 2006, EPIDEMIOLOGY, V17, pS44, DOI 10.1097/00001648-200611001-00077; Smith K, 2004, COMP QUANTIFICATION, P1435; Sumer H, 2004, SOZ PRAVENTIV MED, V49, P247, DOI 10.1007/s00038-004-3038-6; Thompson L, 2004, EPIDEMIOLOGY, V15, pS173, DOI 10.1097/00001648-200407000-00462; Thompson L, 2007, SOC SCI MED, V65, P1337, DOI 10.1016/j.socscimed.2007.05.018; TOREN K, 1993, CHEST, V104, P600, DOI 10.1378/chest.104.2.600; Triche EW, 2005, EPIDEMIOLOGY, V16, P377, DOI 10.1097/01.ede.0000158225.44414.85; WHO, 2006, WHO AIR QUAL GUID PA	44	85	87	1	8	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262			AM J EPIDEMIOL	Am. J. Epidemiol.	JUL 15	2009	170	2					211	220		10.1093/aje/kwp100		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	469HU	WOS:000267887900010	19443665	
J	Yang, W; Omaye, ST				Yang, Wei; Omaye, Stanley T.			Air pollutants, oxidative stress and human health	MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS			English	Review						Air pollution; Oxidative stress; Free radicals; Human health; Antioxidants	OBSTRUCTIVE PULMONARY-DISEASE; INHALED NITROGEN-DIOXIDE; MICROSOMAL EPOXIDE HYDROLASE; EMERGENCY ROOM ADMISSIONS; CONGESTIVE-HEART-FAILURE; CARBON-MONOXIDE LEVELS; HOSPITAL ADMISSIONS; LUNG-CANCER; DAILY MORTALITY; AMBIENT AIR	Air pollutants have, and continue to be, major contributing factors to chronic diseases and mortality, subsequently impacting public health. Chronic diseases include: chronic obstructive pulmonary diseases (COPD), cardiovascular diseases (CVD), asthma, and cancer. Byproducts of oxidative stress found in air pollutants are common initiators or promoters of the damage produced in such chronic diseases. Such air pollutants include: ozone, sulfur oxides, carbon monoxide, nitrogen oxides, and particulate matter. Interaction between oxidative stress byproducts and certain genes within our population may modulate the expression of specific chronic diseases. in this brief review we attempt to provide some insight into what we currently know about the health problems associated with various air pollutants and their relationship in promoting chronic diseases through changes in oxidative stress and modulation of gene expression. Such insight eventually may direct the means for effective public health prevention and treatment of diseases associated with air pollution and treatment of diseases associated with air pollution. (C) 2008 Elsevier B.V. All rights reserved.	[Omaye, Stanley T.] Univ Nevada, Dept Nutr, Reno, NV 89557 USA; [Yang, Wei; Omaye, Stanley T.] Univ Nevada, Environm Sci Grad Program, Reno, NV 89557 USA; [Yang, Wei] Univ Nevada, Sch Community Hlth Sci, Reno, NV 89557 USA	Omaye, ST (reprint author), Univ Nevada, Dept Nutr, Reno, NV 89557 USA.	omaye@unr.edu					ADAMS KF, 1988, J AM COLL CARDIOL, V12, P900; ALTSHULLER AP, 1987, JAPCA J AIR WASTE MA, V37, P1409; AMDUR MO, 1980, CASARETT DOULLS TOXI, P608; Atkinson RW, 2001, AM J RESP CRIT CARE, V164, P1860; AVIADO DM, 1968, ARCH ENVIRON HEALTH, V16, P903; BARBONE F, 1995, AM J EPIDEMIOL, V141, P1161; Barnes PJ, 1999, THORAX, V54, P245; BARRY BE, 1988, EXP LUNG RES, V14, P225, DOI 10.3109/01902148809115126; Beelen R, 2008, ENVIRON HEALTH PERSP, V116, P196, DOI 10.1289/ehp.10767; Benhamou S, 1998, CANCER RES, V58, P5291; Bouchardy C, 1998, PHARMACOGENETICS, V8, P291, DOI 10.1097/00008571-199808000-00002; Bouchardy C, 2001, LUNG CANCER-J IASLC, V32, P109, DOI 10.1016/S0169-5002(00)00215-4; BOWLER PJ, 1993, ENV SCI PHILOS ANCIE, P137; Brimblecombe Peter, 1987, BIG SMOKE HIST AIR P; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Burnett RT, 1997, EPIDEMIOLOGY, V8, P162, DOI 10.1097/00001648-199703000-00007; Burnett RT, 1997, ENVIRON HEALTH PERSP, V105, P614, DOI 10.1289/ehp.97105614; CALVERT AF, 1987, AUST NZ J MED, V17, P472, DOI 10.1111/j.1445-5994.1987.tb00100.x; Capasso L, 2000, LANCET, V356, P1774, DOI 10.1016/S0140-6736(05)71971-1; Chen L, 2001, TOXICOL METHOD, V11, P233; CHEN L, 2000, J INHAL TOXICOL, V12, P281; DANIEL H, 2002, HR J NUTR, V87, pS305; Dockery DW, 2001, ENVIRON HEALTH PERSP, V109, P483, DOI 10.2307/3454657; Dominici F, 2006, JAMA-J AM MED ASSOC, V295, P1127, DOI 10.1001/jama.295.10.1127; DRISCOLL KE, 1986, FUND APPL TOXICOL, V7, P264, DOI 10.1016/0272-0590(86)90156-9; ELSOM D, 1992, ENV HLTH PERSPECT, V100, P47; Evelyn J., 1661, FUMIFUGIUM INCONVENI; FAIRLEY D, 1990, ENVIRON HEALTH PERSP, V89, P159, DOI 10.2307/3430912; Fakhrzadeh L, 2004, AM J PHYSIOL-LUNG C, V287, P279; FERIN J, 1977, INHALED PARTICLES, V4, P234; FRANK NR, 1962, J APPL PHYSIOL, V17, P252; Gent JF, 2003, JAMA-J AM MED ASSOC, V290, P1859, DOI 10.1001/jama.290.14.1859; Gilmour M, 2006, ENVIRON HEALTH PERSP, V114, P627, DOI 10.1289/ehp.8380; Goldsmith Carroll-Ann W., 1999, Reviews on Environmental Health, V14, P121; GOLDSTEIN E, 1977, AM REV RESPIR DIS, V115, P403; Halliwell B, 2002, FREE RADICAL BIO MED, V32, P968, DOI 10.1016/S0891-5849(02)00808-0; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Hong YC, 2002, STROKE, V33, P2165, DOI 10.1161/01.STR.0000026865.52610.5B; Hong YC, 2002, ENVIRON HEALTH PERSP, V110, P187; HORSTMAN DH, 1990, AM REV RESPIR DIS, V142, P1158; HORVATH SM, 1989, JAPCA J AIR WASTE MA, V39, P1323; HORVATH SM, 1988, J APPL PHYSIOL, V65, P2696; KINNEY PL, 1991, ENVIRON RES, V54, P99, DOI 10.1016/S0013-9351(05)80094-5; KOENIG JQ, 1987, AM REV RESPIR DIS, V136, P1152; Krishna M. T., 1998, Reviews on Environmental Health, V13, P59; KRISTENSEN TS, 1989, SCAND J WORK ENV HEA, V15, P245; Kunsch C, 1999, CIRC RES, V85, P753; LANNUZZI MC, 2002, RESP RES, V3, P1; Lawrence E., 1998, LONGMAN DICT ENV SCI; LEIKIN JB, 1986, AM J EMERG MED, V4, P126, DOI 10.1016/0735-6757(86)90156-7; LETHBRIDGE-CEJKU M, 2006, VITAL HLTH STAT, V10, P228; LEWIS TR, 1969, ARCH ENVIRON HEALTH, V18, P591; Linder J, 1988, Schweiz Z Sportmed, V36, P5; LINN WS, 1980, AM REV RESPIR DIS, V121, P243; LIPPMANN M, 1992, ENV TOXICANTS HUMAN, P465; London Stephanie J, 2007, Proc Am Thorac Soc, V4, P217, DOI 10.1513/pats.200701-031AW; MacMillan-Crow LA, 2000, ARCH BIOCHEM BIOPHYS, V377, P350, DOI 10.1006/abbi.2000.1799; MacNee W, 2001, TRENDS MOL MED, V7, P55, DOI 10.1016/S1471-4914(01)01912-8; MacNee W, 2007, CLIN CHEST MED, V28, P479, DOI 10.1016/j.ccm.2007.06.008; MATTHAY RA, 1992, CECIL TXB MED, P386; MAZUMDAR S, 1982, ARCH ENVIRON HEALTH, V37, P213; McCunney RJ, 2005, J OCCUP ENVIRON MED, V47, P1285, DOI 10.1097/01.jom.0000188561.75578.bf; Mensink RP, 2002, P NUTR SOC, V61, P401, DOI 10.1079/PNS2002182; MILLER FW, 1993, ENV HAZARDS AIR POLL, P1; Morgan G, 1998, AM J PUBLIC HEALTH, V88, P1761, DOI 10.2105/AJPH.88.12.1761; MORRIS RD, 1995, AM J PUBLIC HEALTH, V85, P1361, DOI 10.2105/AJPH.85.10.1361; Mortimer KM, 2002, EUR RESPIR J, V19, P699, DOI 10.1183/09031936.02.00247102; *NCHS, 2007, CHARTB TRENDS HLTH A; Noble DR, 1999, CHEM COMMUN, P2317, DOI 10.1039/a907891f; NYBERG BF, 2000, SCAND J WORK ENV S1, V26, P49; Oberdorster G, 2001, INT ARCH OCC ENV HEA, V74, P1; Omaye ST, 2002, TOXICOLOGY, V180, P139, DOI 10.1016/S0300-483X(02)00387-6; OSTRO B, 1984, ENVIRON HEALTH PERSP, V58, P397, DOI 10.2307/3429861; PONKA A, 1994, ENVIRON RES, V65, P207, DOI 10.1006/enrs.1994.1032; Pope CA, 2000, ENVIRON HEALTH PERSP, V108, P713, DOI 10.2307/3454408; POPE CA, 1992, ARCH ENVIRON HEALTH, V47, P211; POPE CA, 1995, AM J RESP CRIT CARE, V151, P669; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; POPE CA, 1991, ARCH ENVIRON HEALTH, V46, P90; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132; POSTLETHWAIT EM, 1981, J TOXICOL ENV HEALTH, V7, P861; POSTLETHWAIT EM, 1990, J APPL PHYSIOL, V68, P594; POSTLETHWAIT EM, 1989, J TOXICOL ENV HLTH, V7, P861; QUIRKE S, 1992, BRIT MUSEUM BOOK ANC, P240; Rahman I, 1998, THORAX, V53, P601; REDDY K, 1987, INHAL TOXICOL, P223; REID L, 1963, BRIT J EXP PATHOL, V44, P437; Romieu I, 2006, EUR RESPIR J, V28, P953, DOI 10.1183/09031936.06.00114905; Rossner P, 2008, MUTAT RES-FUND MOL M, V642, P21, DOI 10.1016/j.mrfmmm.2008.03.004; Rossner P, 2007, MUTAT RES-FUND MOL M, V617, P23, DOI 10.1016/j.mrfmmm.2006.11.033; Sakao S, 2001, AM J RESP CRIT CARE, V163, P420; Salvi S, 2001, Curr Opin Allergy Clin Immunol, V1, P35; SCHIMMEL H, 1976, J OCCUP ENVIRON MED, V18, P316, DOI 10.1097/00043764-197605000-00006; SCHLESINGER RB, 1989, ENVIRON HEALTH PERSP, V79, P121, DOI 10.2307/3430538; SCHWARTZ J, 1991, ENVIRON RES, V56, P1, DOI 10.1016/S0013-9351(05)80104-5; SCHWARTZ J, 1995, THORAX, V50, P531, DOI 10.1136/thx.50.5.531; SCHWARTZ J, 1992, AM J EPIDEMIOL, V135, P12; SCHWARTZ J, 1993, AM REV RESPIR DIS, V147, P826; SCHWARTZ J, 1995, AM J EPIDEMIOL, V142, P23; SCHWARTZ J, 1990, AM J EPIDEMIOL, V131, P185; Schwartz J, 1997, EPIDEMIOLOGY, V8, P371, DOI 10.1097/00001648-199707000-00004; Schwartz J, 2008, ENVIRON HEALTH PERSP, V116, P64, DOI 10.1289/ehp.9955; SHEPS DS, 1987, ARCH ENVIRON HEALTH, V42, P108; Silverman EK, 2000, CHEST, V117, p273S, DOI 10.1378/chest.117.5_suppl_1.273S; Smith CAD, 1997, LANCET, V350, P630, DOI 10.1016/S0140-6736(96)08061-0; Sorensen M, 2003, MUTAT RES-REV MUTAT, V544, P255, DOI 10.1016/j.mrrev.2003.06.010; SPEKTOR DM, 1988, AM REV RESPIR DIS, V138, P821; STERN FB, 1988, AM J EPIDEMIOL, V128, P1276; SUNYER J, 1991, AM J EPIDEMIOL, V134, P277; SUNYER J, 1993, AM J EPIDEMIOL, V137, P701; TANGO T, 1994, ENVIRON HEALTH PERSP, V102, P41; Taraseviciene-Stewart L, 2008, J CLIN INVEST, V118, P394, DOI [10.1172/JCI31811, 10.1172/JC131811]; Thom SR, 1997, J APPL PHYSIOL, V82, P1424; Timblin C, 1998, CANCER RES, V58, P4543; van der Vliet A, 1998, J BIOL CHEM, V273, P31860, DOI 10.1074/jbc.273.48.31860; Vedal S, 2002, CLIN CHEST MED, V23, P763, DOI 10.1016/S0272-5231(02)00028-X; VINEIS R, 1999, IARC SCI PUBLICATION; WEB JL, 2001, ADV GENET, V42, P77; WYZGA RE, 1978, J AM STAT ASSOC, V17, P463; Xia Tian, 2006, Clin Occup Environ Med, V5, P817; Yang QY, 2005, ENVIRON RES, V99, P99, DOI 10.1016/j.envres.2004.09.014; YANG W, 1998, J TOXICOL ENV HLTH, V55, P101; ZHANG J, 1992, J CLIN INVEST, V90, P1193, DOI 10.1172/JCI115980	123	85	88	6	35	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1383-5718			MUTAT RES-GEN TOX EN	Mutat. Res. Genet. Toxicol. Environ. Mutagen.	MAR 31	2009	674	1-2					45	54		10.1016/j.mrgentox.2008.10.005		10	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	Biotechnology & Applied Microbiology; Genetics & Heredity; Toxicology	432KX	WOS:000265133000006	19013537	
J	Traidl-Hoffmann, C; Jakob, T; Behrendt, H				Traidl-Hoffmann, Claudia; Jakob, Thilo; Behrendt, Heidrun			Determinants of allergenicity	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergen; structure; intrinsic function; pollen-associated lipid mediators; adjuvant	HOUSE-DUST MITE; SERUM IGE LEVELS; ALLERGIC AIRWAY INFLAMMATION; CYSTEINE PROTEASE ACTIVITY; DIESEL EXHAUST PARTICLES; CD4(+)CD25(+) T-CELLS; AMINO-ACID-SEQUENCE; DER-P-I; DENDRITIC CELLS; PROTEOLYTIC ACTIVITY	The question "What makes an allergen an allergen?" has puzzled generations of researchers, and we still do not have a conclusive answer. Despite increasing knowledge about the molecular and functional characteristics of allergens that have been identified, we still do not fully understand why some proteins are clinically relevant allergens and most are not. Different approaches have been taken to identify the structural and functional features of allergens, aiming at developing methods to predict allergenicity and thus to identify allergens. However, none of these methods has allowed a reliable discrimination between allergenic and nonallergenic compounds on its own. This review sums up diverse determinants that contribute to the phenomenon of allergenicity and outlines that in addition to the structure and function of the allergen, factors derived from allergen carriers, the environment, and the susceptible individual are of importance. (J Allergy Clin Immunol 2009;123:558-66.)	[Traidl-Hoffmann, Claudia; Behrendt, Heidrun] Tech Univ Munich, Div Environm Dermatol & Allergy, Helmholtz Ctr Munich TUM, ZAUM Ctr Allergy & Environm,Dept Dermatol & Aller, D-80802 Munich, Germany; [Jakob, Thilo] Univ Med Ctr Freiburg, Allergy Res Grp, Dept Dermatol, Freiburg, Germany	Traidl-Hoffmann, C (reprint author), Tech Univ Munich, Div Environm Dermatol & Allergy, Helmholtz Ctr Munich TUM, ZAUM Ctr Allergy & Environm,Dept Dermatol & Aller, Biedersteinerstr 29, D-80802 Munich, Germany.	traidl-hoffmann@lrz.tum.de; thilo.jakob@uniklinik-freiburg.de	Jakob, Thilo/J-1621-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284; Traidl-Hoffmann, Claudia/0000-0001-5085-5179	German Ministry of Research and Science; University of Freiburg Medical Faculty; Landesstifung Baden Wuettemberg	Disclosure of potential conflict of interest: T. Jakob receives grant support from the German Ministry of Research and Science, the University of Freiburg Medical Faculty, and the Landesstifung Baden Wuettemberg and is a member of the Executive Committee for the European Academy of Allergy and Clinical Immunology and a board member for the European Immunodermatology Society. The rest of the authors have declared that they have no conflict of interest.	Aalberse RC, 2006, CHEM IMMUNOL ALLERGY, V91, P134; Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Aalberse RC, 2004, J ALLERGY CLIN IMMUN, V113, P983, DOI 10.1016/j.jaci.2004.02.046; Aalberse RC, 2006, MOL NUTR FOOD RES, V50, P625, DOI 10.1002/mnfr.200500270; AKDIS C, 2006, CURR OPIN IMMUNOL, V13, P718; Akdis M, 2003, FASEB J, V17, P1026, DOI 10.1096/fj.02-1070com; Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; Akkoc T, 2008, J ALLERGY CLIN IMMUN, V121, P652, DOI 10.1016/j.jaci.2007.12.1171; Al-Mousawi MSH, 2004, J ALLERGY CLIN IMMUN, V114, P1389, DOI 10.1016/j.jaci.2004.09.005; Alessandrini F, 2006, J ALLERGY CLIN IMMUN, V117, P824, DOI 10.1016/j.jaci.2005.11.046; Antens CJM, 2006, CLIN EXP ALLERGY, V36, P1525, DOI 10.1111/j.1365-2222.2006.02603.x; Asher MI, 2006, LANCET, V368, P733, DOI 10.1016/S0140-6736(06)69283-0; Behrendt H, 2001, INT ARCH ALLERGY IMM, V124, P121, DOI 10.1159/000053688; Behrendt H, 2001, CURR OPIN IMMUNOL, V13, P709, DOI 10.1016/S0952-7915(01)00283-7; Behrendt H, 1999, INT ARCH ALLERGY IMM, V118, P414, DOI 10.1159/000024151; Bellinghausen I, 2003, J ALLERGY CLIN IMMUN, V111, P862, DOI 10.1067/mai.2003.1412; Berin M. C., 2008, Journal of Allergy and Clinical Immunology, V121, P1311, DOI 10.1016/j.jaci.2008.04.023; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Blaser K, 1996, ADV EXP MED BIOL, V409, P295; Blaser K, 1998, INT ARCH ALLERGY IMM, V117, P1, DOI 10.1159/000023984; Boldogh I, 2005, J CLIN INVEST, V115, P2169, DOI 10.1172/JCI24422; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; Buters JTM, 2008, INT ARCH ALLERGY IMM, V145, P122, DOI 10.1159/000108137; Chapman MD, 2007, J ALLERGY CLIN IMMUN, V119, P414, DOI 10.1016/j.jaci.2006.11.001; Charbonnier AS, 2003, J LEUKOCYTE BIOL, V73, P91, DOI 10.1189/jlb.0602289; CHUA KY, 1988, J EXP MED, V167, P175, DOI 10.1084/jem.167.1.175; Cookson W, 2004, NAT REV IMMUNOL, V4, P978, DOI 10.1038/nri1500; Cortes L, 2006, J ALLERGY CLIN IMMUN, V118, P878, DOI 10.1016/j.jaci.2006.05.029; Custis NJ, 2003, CLIN EXP ALLERGY, V33, P986, DOI 10.1046/j.1365-2222.2003.01706.x; De Groot J, 2007, BIOTECHNOL BIOENG, V97, P735, DOI 10.1002/bit.21264; Deb R, 2007, J BIOL CHEM, V282, P36808, DOI 10.1074/jbc.M702336200; Dharajiya N, 2007, J ALLERGY CLIN IMMUN, V119, P646, DOI 10.1016/j.jaci.2006.11.634; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Eisenbarth SC, 2002, J EXP MED, V196, P1645, DOI 10.1084/jem.20021340; Emanuelsson C, 2007, MOL IMMUNOL, V44, P3256, DOI 10.1016/j.molimm.2007.01.019; Franze T, 2005, ENVIRON SCI TECHNOL, V39, P1673, DOI 10.1021/es0488737; Furmonaviciene R, 2007, CLIN EXP ALLERGY, V37, P231, DOI 10.1111/j.1365-2222.2007.02651.x; Furmonaviciene R, 2005, BIOINFORMATICS, V21, P4201, DOI 10.1093/bioinformatics/bti700; Geha RS, 2003, NAT REV IMMUNOL, V3, P721, DOI 10.1038/nri1181; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; GILFILLAN AM, 2008, IMMUNOL RES; Gilliland FD, 2004, LANCET, V363, P119, DOI 10.1016/S0140-6736(03)15262-2; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Gough L, 1999, J EXP MED, V190, P1897, DOI 10.1084/jem.190.12.1897; Gruijthuijsen YK, 2006, INT ARCH ALLERGY IMM, V141, P265, DOI 10.1159/000095296; Gutermuth J, 2007, J ALLERGY CLIN IMMUN, V120, P293, DOI 10.1016/j.jaci.2007.03.017; Hammad H, 2001, BLOOD, V98, P1135, DOI 10.1182/blood.V98.4.1135; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Holloway JW, 2007, CURR OPIN ALLERGY CL, V7, P69, DOI 10.1097/ACI.0b013e328013d51b; Horner AA, 2006, J ALLERGY CLIN IMMUN, V117, P1133, DOI 10.1016/j.jaci.2006.02.035; Ichikawa K, 2001, CLIN EXP ALLERGY, V31, P1279, DOI 10.1046/j.1365-2222.2001.01169.x; Jankovic D, 2006, CHEM IMMUNOL ALLERGY, V90, P65; Kabesch M, 2006, J ALLERGY CLIN IMMUN, V117, P269, DOI 10.1016/j.jaci.2005.10.024; Kaiser L, 2003, INT ARCH ALLERGY IMM, V132, P25, DOI 10.1159/000073261; Kaisho T, 2006, J ALLERGY CLIN IMMUN, V117, P979, DOI 10.1016/j.jaci.2006.02.023; Kato A, 2007, J IMMUNOL, V179, P1080; Kauffman HF, 2006, CLIN MOL ALLERGY, V28, P5; Kikuchi Y, 2006, J IMMUNOL, V177, P1609; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224; Krishnamoorthy N, 2008, NAT MED, V14, P565, DOI 10.1038/nm1766; Laitinen T, 2004, SCIENCE, V304, P300, DOI 10.1126/science.1090010; Larche M, 2006, NAT REV IMMUNOL, V6, P761, DOI 10.1038/nri1934; Lau S, 2005, ALLERGY, V60, P766, DOI 10.1111/j.1398-9995.2005.00781.x; LEUNG DYM, 1993, J CLIN INVEST, V92, P1374, DOI 10.1172/JCI116711; Li YJ, 2008, CLIN IMMUNOL, V128, P366, DOI 10.1016/j.clim.2008.05.005; Maleki SJ, 2000, J IMMUNOL, V164, P5844; Mariani V, 2007, J IMMUNOL, V178, P7623; McCloskey N, 2007, J BIOL CHEM, V282, P24083, DOI 10.1074/jbc.M703195200; Medzhitov R, 1997, NATURE, V388, P394; Meno K, 2005, J IMMUNOL, V175, P3835; Mogensen JE, 2007, BIOCHEMISTRY-US, V46, P3356, DOI 10.1021/bi062058h; Motta AC, 2006, INT ARCH ALLERGY IMM, V139, P294, DOI 10.1159/000091600; Ng N, 2006, J ALLERGY CLIN IMMUN, V117, P1074, DOI 10.1016/j.jaci.2006.03.025; Nouri-Aria KT, 2004, J IMMUNOL, V172, P3252; Ozdemir C, 2006, CLIN EXP ALLERGY, V36, P960, DOI 10.1111/j.1365-2222.2006.02515.x; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Pandiyan P, 2007, NAT IMMUNOL, V8, P1353, DOI 10.1038/ni1536; Perzanowski MS, 2008, J ALLERGY CLIN IMMUN, V121, P1047, DOI 10.1016/j.jaci.2008.02.005; Piggott DA, 2005, J CLIN INVEST, V115, P459, DOI 10.1172/JCI200522462; Platts-Mills TAE, 2004, SPRINGER SEMIN IMMUN, V25, P271, DOI 10.1007/s00281-003-0149-8; Plotz SG, 2004, J ALLERGY CLIN IMMUN, V113, P1152, DOI 10.1016/j.jaci.2004.03.011; Radauer C, 2006, J ALLERGY CLIN IMMUN, V117, P141, DOI 10.1016/j.jaci.2005.09.010; Radauer C, 2008, J ALLERGY CLIN IMMUN, V121, P847, DOI 10.1016/j.jaci.2008.01.025; Radulovic S, 2008, J ALLERGY CLIN IMMUN, V121, P1467, DOI 10.1016/j.jaci.2008.03.013; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; Rhodes HL, 2001, J ALLERGY CLIN IMMUN, V108, P720, DOI 10.1067/mai.2001.119151; Riedl MA, 2005, J IMMUNOL, V174, P7440; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; Sackesen C, 2005, ALLERGY, V60, P1485, DOI 10.1111/j.1398-9995.2005.00874.x; SARFATI M, 1992, IMMUNOLOGY, V76, P662; Saxon A, 2005, NAT IMMUNOL, V6, P223, DOI 10.1038/ni0305-223; Schaub B, 2006, J ALLERGY CLIN IMMUN, V117, P969, DOI 10.1016/j.jaci.2006.03.003; Schaub B, 2008, J ALLERGY CLIN IMMUN, V121, P1491, DOI 10.1016/j.jaci.2008.04.010; SCHULZ O, 1995, EUR J IMMUNOL, V25, P3191, DOI 10.1002/eji.1830251131; Schulz O, 1998, J EXP MED, V187, P271, DOI 10.1084/jem.187.2.271; Sen M, 2002, J IMMUNOL, V169, P882; Shibata Y, 2000, J IMMUNOL, V164, P1314; Shreffler WG, 2006, J IMMUNOL, V177, P3677; Silvanovich A, 2006, TOXICOL SCI, V90, P252, DOI 10.1093/toxsci/kfj068; Sokol CL, 2008, NAT IMMUNOL, V9, P310, DOI 10.1038/ni1558; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STRACHAN DP, 1989, BRIT MED J, V299, P1259; Tai HY, 2006, ALLERGY, V61, P382, DOI 10.1111/j.1398-9995.2005.00958.x; Takai T, 2005, INT ARCH ALLERGY IMM, V137, P194, DOI 10.1159/000086331; Thunberg S, 2007, CLIN EXP ALLERGY, V37, P1127, DOI 10.1111/j.1365-2222.2007.02739.x; Torrent M, 2006, J ALLERGY CLIN IMMUN, V118, P742, DOI 10.1016/j.jaci.2006.04.059; Traidl-Hoffmann C, 2005, J EXP MED, V201, P627, DOI 10.1084/jem.20041065; Traidl-Hoffmann C, 2002, J ALLERGY CLIN IMMUN, V109, P831, DOI 10.1067/mai.2002.124655; Vercelli D, 2006, CURR OPIN IMMUNOL, V18, P733, DOI 10.1016/j.coi.2006.09.002; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Weidinger S, 2004, J MED GENET, V41, P658, DOI 10.1136/jmg.2004.020263; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V122, P560, DOI 10.1016/j.jaci.2008.05.050; Weidinger S, 2008, J ALLERGY CLIN IMMUN, V121, P1203, DOI 10.1016/j.jaci.2008.02.014; Williams MA, 2007, J ALLERGY CLIN IMMUN, V119, P488, DOI 10.1064/j.jaci.2006.10.022; Woodcock A, 2004, AM J RESP CRIT CARE, V170, P433, DOI 10.1164/rccm.200401-083OC; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb; Yang IA, 2007, CURR OPIN ALLERGY CL, V7, P75, DOI 10.1097/ACI.0b013e328012ce39; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Zeller S, 2008, INT ARCH ALLERGY IMM, V145, P87, DOI 10.1159/000108133; Zhang J, 2007, ALLERGY, V62, P1302, DOI 10.1111/j.1397-9995.2007.01492.x	122	85	85	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAR	2009	123	3					558	566		10.1016/j.jaci.2008.12.003		9	Allergy; Immunology	Allergy; Immunology	426TQ	WOS:000264731200011	19152966	
J	Cox, L; Li, JT; Nelson, H; Lockey, R				Cox, Linda; Li, James T.; Nelson, Harold; Lockey, Richard			Allergen immunotherapy: A practice parameter second update	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review							GRASS-POLLEN IMMUNOTHERAPY; HOUSE-DUST-MITE; DERMATOPHAGOIDES-PTERONYSSINUS EXTRACT; PLACEBO-CONTROLLED TRIAL; SUBLINGUAL-SWALLOW IMMUNOTHERAPY; DOUBLE-BLIND PLACEBO; STANDARDIZED CAT EXTRACT; IMPORTED FIRE ANT; LOCAL NASAL IMMUNOTHERAPY; INSECT STING ALLERGY	These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma and Immunology; the American College of Allergy, Asthma and Immunology; and the Joint Council of Allergy, Asthma and Immunology. The American Academy of Allergy, Asthma and Immunology (AAAAI) and the American College of Allergy, Asthma and Immunology (ACAAI) have jointly accepted responsibility for establishing the "Allergen immunotherapy: a practice parameter second update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.	Joint Council Allergy Asthma & Immunol, Palatine, IL 60067 USA; Nova SE Univ, Coll Osteopath Med, Dept Med, Davie, FL USA; Mayo Clin, Div Allerg Dis, Rochester, MN USA; Univ S Florida, Coll Med, Dept Med, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Pediat, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Publ Hlth, James A Haley Vet Hosp,Div Allergy & Immunol, Tampa, FL 33612 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO USA	Cox, L (reprint author), Joint Council Allergy Asthma & Immunol, 50 N Brockway St 3-3, Palatine, IL 60067 USA.						Aaronson DW, 2004, J ALLERGY CLIN IMMUN, V113, P1117, DOI 10.1016/j.jaci.2004.01.756; AAS K, 1971, ACTA PAEDIATR SCAND, V60, P264, DOI 10.1111/j.1651-2227.1971.tb06655.x; ABRAMSON MJ, 1995, AM J RESP CRIT CARE, V151, P969; Abramson M. J., 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001186; Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Adkinson NF, 1997, NEW ENGL J MED, V336, P324, DOI 10.1056/NEJM199701303360502; Agostinis F, 2005, ALLERGY, V60, P133, DOI 10.1111/j.1398-9995.2004.00616.x; Alvarez-Cuesta E, 2006, ALLERGY, V61, P1, DOI 10.1111/j.1398-9995.2006.01219_1.x; ALVAREZCUESTA E, 1994, J ALLERGY CLIN IMMUN, V93, P556, DOI 10.1016/S0091-6749(94)70067-2; American Academy of Allergy Asthma and Immunology (AAAAI), 1997, J ALLERGY CLIN IMMUN, V99, P583; Amin HS, 2006, J ALLERGY CLIN IMMUN, V117, P169, DOI 10.1016/j.jaci.2005.10.010; ANDERSON MC, 1982, J ALLERGY CLIN IMMUN, V69, P3, DOI 10.1016/0091-6749(82)90080-X; Andre C, 2003, INT ARCH ALLERGY IMM, V131, P111, DOI 10.1159/000070926; ANDRI L, 1992, ALLERGY, V47, P318, DOI 10.1111/j.1398-9995.1992.tb02061.x; ANDRI L, 1995, CLIN EXP ALLERGY, V25, P1092, DOI 10.1111/j.1365-2222.1995.tb03256.x; ANDRI L, 1993, J ALLERGY CLIN IMMUN, V91, P987, DOI 10.1016/0091-6749(93)90211-W; ANTICO A, 2006, ALLERGY, P1236; Arbes SJ, 2004, J ALLERGY CLIN IMMUN, V114, P111, DOI 10.1016/j.jaci.2004.04.036; Ariano R, 1999, ALLERGY, V54, P313, DOI 10.1034/j.1398-9995.1999.00900.x; Asero R, 2005, J ALLERGY CLIN IMMUN, V116, P1036, DOI 10.1016/j.jaci.2005.08.019; Asero R, 2004, INT ARCH ALLERGY IMM, V135, P332, DOI 10.1159/000082328; AUKRUST L, 1979, INT ARCH ALLER A IMM, V58, P375; AYUSO R, 1984, ANN ALLERGY, V52, P426; BAER H, 1974, J ALLERGY CLIN IMMUN, V54, P157, DOI 10.1016/0091-6749(74)90052-9; BAER H, 1970, J ALLERGY, V45, P347, DOI 10.1016/0021-8707(70)90043-2; Bagnasco M, 1997, J ALLERGY CLIN IMMUN, V100, P122; Bahima AC, 2004, J INVEST ALLERG CLIN, V14, P17; Bannon GA, 2001, INT ARCH ALLERGY IMM, V124, P70, DOI 10.1159/000053672; Barderas R, 2002, INT ARCH ALLERGY IMM, V127, P47, DOI 10.1159/000048168; Barletta B, 1996, J ALLERGY CLIN IMMUN, V98, P797, DOI 10.1016/S0091-6749(96)70129-X; Bellinghausen I, 1997, EUR J IMMUNOL, V27, P1131, DOI 10.1002/eji.1830270513; BERG TLO, 1974, J ALLERGY CLIN IMMUN, V54, P209, DOI 10.1016/0091-6749(74)90063-3; Bernardini R, 2006, CURR MED RES OPIN, V22, P1515, DOI 10.1185/030079906X115711; Bernardo FP, 2004, COMP AID CH, V18, P151; Bernstein DI, 2004, J ALLERGY CLIN IMMUN, V113, P1129, DOI 10.1016/j.jaci.2004.02.006; BERNSTEIN IL, 1976, J ALLERGY CLIN IMMUN, V57, P141, DOI 10.1016/0091-6749(76)90033-6; BERNSTEIN JA, 1994, ANN ALLERGY, V73, P423; BERTELSEN A, 1989, ALLERGY, V44, P330, DOI 10.1111/j.1398-9995.1989.tb00454.x; BICKELL WH, 1984, ANN EMERG MED, V13, P189, DOI 10.1016/S0196-0644(84)80611-3; BJORKSTEN B, 1986, ALLERGY, V41, P290, DOI 10.1111/j.1398-9995.1986.tb02031.x; Black JH, 1929, J ALLERGY, V1, P71, DOI 10.1016/S0021-8707(29)90084-8; Blaher B, 1996, J ALLERGY CLIN IMMUN, V98, P124, DOI 10.1016/S0091-6749(96)70234-8; Blaser K, 2004, CLIN EXP ALLERGY, V34, P328, DOI 10.1111/j.1365-2222.2004.01909.x; Bodtger U, 2002, ALLERGY, V57, P297, DOI 10.1034/j.1398-9995.2002.1o3532.x; Bonno M, 1996, J ALLERGY CLIN IMMUN, V97, P680, DOI 10.1016/S0091-6749(96)70314-7; BOUSQUET J, 1985, J ALLERGY CLIN IMMUN, V76, P734, DOI 10.1016/0091-6749(85)90680-3; BOUSQUET J, 1985, CLIN ALLERGY, V15, P439, DOI 10.1111/j.1365-2222.1985.tb02293.x; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V83, P797, DOI 10.1016/0091-6749(89)90017-1; BOUSQUET J, 1988, J ALLERGY CLIN IMMUN, V82, P971, DOI 10.1016/0091-6749(88)90133-9; Bousquet J, 1998, ANN ALLERG ASTHMA IM, V81, P401, DOI 10.1016/S1081-1206(10)63136-5; BOUSQUET J, 1987, J ALLERGY CLIN IMMUN, V80, P591, DOI 10.1016/0091-6749(87)90013-3; BOUSQUET J, 1991, J ALLERGY CLIN IMMUN, V88, P43, DOI 10.1016/0091-6749(91)90299-4; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; BOUSQUET J, 1987, ALLERGY, V42, P401, DOI 10.1111/j.1398-9995.1987.tb00355.x; BOUSQUET J, 1986, ANN ALLERGY, V56, P456; Bowen T, 2004, ANN ALLERG ASTHMA IM, V93, P425; Bucher X, 2004, ALLERGY, V59, P1272, DOI 10.1111/j.1398-9995.2004.00626.x; Bussmann C, 2006, J ALLERGY CLIN IMMUN, V118, P1292, DOI 10.1016/j.jaci.2006.07.054; Cabanas R, 2000, J INVEST ALLERG CLIN, V10, P71; Cantani A, 1997, J INVEST ALLERG CLIN, V7, P90; CANTANI A, 2004, EUR REV MED PHARM SC, P139; Casale TB, 2006, J ALLERGY CLIN IMMUN, V117, P134, DOI 10.1016/j.jaci.2005.09.036; Cools M, 2000, ALLERGY, V55, P69, DOI 10.1034/j.1398-9995.2000.00191.x; Corrigan CJ, 2005, ALLERGY, V60, P801, DOI 10.1111/j.1398-9995.2005.00790.x; Cox L, 2006, ANN ALLERG ASTHMA IM, V97, P126; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Creticos PS, 2006, NEW ENGL J MED, V355, P1445, DOI 10.1056/NEJMoa052916; CRETICOS PS, 1984, J ALLERGY CLIN IMMUN, V73, P94, DOI 10.1016/0091-6749(84)90490-1; CRETICOS PS, 1985, J CLIN INVEST, V76, P2247, DOI 10.1172/JCI112233; Creticos PS, 1996, NEW ENGL J MED, V334, P501, DOI 10.1056/NEJM199602223340804; CRETICOS PS, 1989, J ALLERGY CLIN IMMUN, V84, P197, DOI 10.1016/0091-6749(89)90325-4; *CURR STAT ALL IMM, 1989, LANCET, V333, P259; Dahl R, 2006, ALLERGY, V61, P185, DOI 10.1111/j.1398-9995.2005.00949.x; Dahl R, 2006, J ALLERGY CLIN IMMUN, V118, P434, DOI 10.1016/j.jaci.2006.05.003; Des Roches A., 1996, Allergy (Copenhagen), V51, P430; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Di Rienzo V, 1999, ALLERGY, V54, P1110, DOI 10.1034/j.1398-9995.1999.00267.x; DJURUP R, 1987, CLIN ALLERGY, V17, P459, DOI 10.1111/j.1365-2222.1987.tb02040.x; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb04655.x; DREBORG S, 1986, ALLERGY, V41, P131, DOI 10.1111/j.1398-9995.1986.tb00289.x; *DRUGS AN COMM AM, 1998, ANN ALLERG ASTHMA IM, V81, P101; Dunsky EH, 2006, ALLERGY, V61, P1235, DOI 10.1111/j.1398-9995.2006.01137.x; Duplantier JE, 1998, J ALLERGY CLIN IMMUN, V101, P855, DOI 10.1016/S0091-6749(98)70318-5; Durham SR, 1999, CLIN EXP ALLERGY, V29, P1490; Durham SR, 2006, J ALLERGY CLIN IMMUN, V117, P802, DOI 10.1016/j.jaci.2005.12.1358; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Eifan AO, 2007, ALLERGY, V62, P567, DOI 10.1111/j.1398-9995.2006.01301.x; Eng PA, 2006, ALLERGY, V61, P198, DOI 10.1111/j.1398-9995.2006.01011.x; Eng PA, 2002, ALLERGY, V57, P306, DOI 10.1034/j.1398-9995.2002.1o3264.x; Enrique E, 2005, J ALLERGY CLIN IMMUN, V116, P1073, DOI 10.1016/j.jaci.2005.08.027; ERIKSSON NE, 1987, ALLERGY, V42, P205, DOI 10.1111/j.1398-9995.1987.tb02201.x; ESCH RE, 1992, ARB PEI GSH, V85, P171; Esch RE, 2004, J ALLERGY CLIN IMMUN, V113, P210, DOI 10.1016/j.jaci.2003.11.024; Estelle F, 2001, J ALLERGY CLIN IMMUN, V108, P871, DOI 10.1067/mai.2001.119409; Eusebius NP, 2002, INT ARCH ALLERGY IMM, V127, P234, DOI 10.1159/000053868; EVANS R, 1976, J CLIN INVEST, V57, P1378, DOI 10.1172/JCI108406; EWAN PW, 1988, CLIN ALLERGY, V18, P501, DOI 10.1111/j.1365-2222.1988.tb02900.x; EWAN PW, 1993, CLIN EXP ALLERGY, V23, P647, DOI 10.1111/j.1365-2222.1993.tb01791.x; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Fahlbusch B, 1998, CLIN EXP ALLERGY, V28, P799; Ferrer M, 2005, J INVEST ALLERG CLIN, V15, P283; Fiocchi A, 2005, ANN ALLERG ASTHMA IM, V95, P254; Francis JN, 2003, J ALLERGY CLIN IMMUN, V111, P1255, DOI 10.1067/mai.2003.1570; FRANKLIN W, 1967, JAMA-J AM MED ASSOC, V201, P951; Freeman J, 1911, LANCET, V2, P814; Freeman J, 1930, LANCET, V1, P744; FREEMAN TM, 1992, J ALLERGY CLIN IMMUN, V90, P210, DOI 10.1016/0091-6749(92)90073-B; Frew AJ, 2006, J ALLERGY CLIN IMMUN, V117, P319, DOI 10.1016/j.jaci.2005.11.014; GEORGITIS JW, 1984, J ALLERGY CLIN IMMUN, V74, P694, DOI 10.1016/0091-6749(84)90232-X; Gidaro GB, 2005, CLIN EXP ALLERGY, V35, P565, DOI 10.1111/j.1365-2222.2005.02240.x; GLEICH GJ, 1982, J ALLERGY CLIN IMMUN, V70, P261, DOI 10.1016/0091-6749(82)90062-8; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Goldberg A, 2003, ANN ALLERG ASTHMA IM, V91, P405; Golden DBK, 2005, J ALLERGY CLIN IMMUN, V115, P439, DOI 10.1016/j.jaci.2005.01.005; Golden DBK, 2004, NEW ENGL J MED, V351, P668, DOI 10.1056/NEJMoa022952; Golden DBK, 2003, J ALLERGY CLIN IMMUN, V112, P495, DOI 10.1067/mai.2003.1606; Golden DBK, 2000, J ALLERGY CLIN IMMUN, V105, P385, DOI 10.1016/S0091-6749(00)90092-7; Golden DBK, 1998, J ALLERGY CLIN IMMUN, V101, P298; GOLDEN DBK, 1989, JAMA-J AM MED ASSOC, V262, P240, DOI 10.1001/jama.262.2.240; Golden DBK, 2001, J ALLERGY CLIN IMMUN, V107, P897, DOI 10.1067/mai.2001.114706; GOMEZ J, 1989, J ASTHMA, V26, P243, DOI 10.3109/02770908909073256; GONZALEZ RM, 1987, ANN ALLERGY, V59, P149; Graft DF, 1998, J ALLERGY CLIN IMMUN, V101, P573; GREENBERG MA, 1986, J ALLERGY CLIN IMMUN, V77, P865, DOI 10.1016/0091-6749(86)90385-4; GREENERT S, 1971, LANCET, V2, P1121; Grier TJ, 2007, ANN ALLERG ASTHMA IM, V99, P151; Hamid QA, 1997, J ALLERGY CLIN IMMUN, V99, P254, DOI 10.1016/S0091-6749(97)70106-4; Hansen KS, 2004, MOL NUTR FOOD RES, V48, P441, DOI 10.1002/mnfr.200400037; Harvey SM, 2004, ANN ALLERG ASTHMA IM, V92, P414; HAUGAARD L, 1992, ALLERGY, V47, P249, DOI 10.1111/j.1398-9995.1992.tb00658.x; HAUGAARD L, 1993, J ALLERGY CLIN IMMUN, V91, P709, DOI 10.1016/0091-6749(93)90190-Q; HEDLIN G, 1991, J ALLERGY CLIN IMMUN, V87, P955, DOI 10.1016/0091-6749(91)90417-M; Hedlin G, 1999, J ALLERGY CLIN IMMUN, V103, P609, DOI 10.1016/S0091-6749(99)70232-0; HEJJAOUI A, 1990, J ALLERGY CLIN IMMUN, V85, P473, DOI 10.1016/0091-6749(90)90157-Y; HELM RM, 1990, INT ARCH ALLER A IMM, V92, P154; HEPNER MJ, 1990, J ALLERGY CLIN IMMUN, V86, P407, DOI 10.1016/S0091-6749(05)80105-8; HORST M, 1990, J ALLERGY CLIN IMMUN, V85, P460, DOI 10.1016/0091-6749(90)90156-X; HUNT KJ, 1978, NEW ENGL J MED, V299, P157, DOI 10.1056/NEJM197807272990401; Ippoliti F, 2003, PEDIATR ALLERGY IMMU, V14, P216, DOI 10.1034/j.1399-3038.2003.00025.x; JACOBS RL, 1981, J ALLERGY CLIN IMMUN, V68, P125, DOI 10.1016/0091-6749(81)90170-6; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; Jacobsen L, 2001, ANN ALLERG ASTHMA IM, V87, P43; Jain VV, 2003, CLIN EXP ALLERGY, V33, P1330, DOI 10.1046/j.1365-2222.2003.01763.x; Javeed N, 1996, CATHETER CARDIO DIAG, V39, P383, DOI 10.1002/(SICI)1097-0304(199612)39:4<383::AID-CCD13>3.0.CO;2-E; Jeong KY, 2003, ALLERGY, V58, P1059, DOI 10.1034/j.1398-9995.2003.00167.x; JOHNSTONE DE, 1968, PEDIATRICS, V42, P793; *JOINT TASK FORC P, 1995, J ALLERGY CLIN IMMUN, V96, pS707; Jutel M, 2003, EUR J IMMUNOL, V33, P1205, DOI 10.1002/eji.200322919; Jutel M, 2005, J ALLERGY CLIN IMMUN, V116, P608, DOI 10.1016/j.jaci.2005.06.004; Jutel M, 1995, CLIN EXP ALLERGY, V25, P1205, DOI 10.1111/j.1365-2222.1995.tb03044.x; KANG BC, 1988, J ASTHMA, V25, P205; Kanter L, 2006, ANN ALLERG ASTHMA IM, V97, P7; Kanter LJ, 2003, ANN ALLERG ASTHMA IM, V90, P389; Kao N, 2000, ANN ALLERG ASTHMA IM, V84, P273, DOI 10.1016/S1081-1206(10)62769-X; Karl S, 1988, Z Hautkr, V63 Suppl 4, P55; KARLSSON R, 1986, ALLERGY, V41, P141, DOI 10.1111/j.1398-9995.1986.tb00290.x; Katial RK, 1997, ANN ALLERG ASTHMA IM, V79, P340; KEATING MU, 1991, J ALLERGY CLIN IMMUN, V88, P339, DOI 10.1016/0091-6749(91)90095-6; Kelso JM, 2004, ANN ALLERG ASTHMA IM, V92, P225; KERNERMAN SM, 1992, ANN ALLERGY, V69, P493; Khinchi MS, 2004, ALLERGY, V59, P45, DOI 10.1046/j.1398-9995.2003.00387.x; KIVITY S, 1990, J ALLERGY CLIN IMMUN, V85, P669, DOI 10.1016/0091-6749(90)90111-G; Kleine-Tebbe J, 2006, ALLERGY, V61, P181, DOI 10.1111/j.1398-9995.2006.00959.x; Kohno Y, 1998, J ALLERGY CLIN IMMUN, V102, P927, DOI 10.1016/S0091-6749(98)70330-6; KORDASH TR, 1993, ANN ALLERGY, V71, P240; La Rosa M, 1999, J ALLERGY CLIN IMMUN, V104, P425, DOI 10.1016/S0091-6749(99)70388-X; LANG DM, 1991, ANN INTERN MED, V115, P270; LANG DM, 1993, ARCH INTERN MED, V153, P2033, DOI 10.1001/archinte.153.17.2033; LEAVENGOOD DC, 1985, J ALLERGY CLIN IMMUN, V76, P789, DOI 10.1016/0091-6749(85)90749-3; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P140, DOI 10.1016/0091-6749(76)90149-4; LEIFERMAN KM, 1976, J ALLERGY CLIN IMMUN, V58, P129, DOI 10.1016/0091-6749(76)90148-2; Lent AM, 2006, J ALLERGY CLIN IMMUN, V118, P1249, DOI 10.1016/j.jaci.2006.07.055; Lerch E, 1998, J ALLERGY CLIN IMMUN, V101, P606; Lewis W. H., 1983, AIRBORNE ALLERGENIC; Leynadier F, 2001, CLIN EXP ALLERGY, V31, P988, DOI 10.1046/j.1365-2222.2001.01145.x; Li JT, 1998, ANN ALLERG ASTHMA IM, V81, P415, DOI 10.1016/S1081-1206(10)63138-9; LICHTENSTEIN LM, 1973, J CLIN INVEST, V52, P472, DOI 10.1172/JCI107204; LIN MS, 1993, ANN ALLERGY, V71, P557; LIND P, 1984, ALLERGY, V39, P259, DOI 10.1111/j.1398-9995.1984.tb00863.x; Litwin A, 1997, J ALLERGY CLIN IMMUN, V100, P30; Lockey R, 2003, MIDDLETONS ALLERGY P, P573; LOCKEY RF, 1987, J ALLERGY CLIN IMMUN, V79, P660, DOI 10.1016/S0091-6749(87)80164-1; Lockey RF, 2001, ANN ALLERG ASTHMA IM, V87, P47; Lockey RF, 2001, J ALLERGY CLIN IMMUN, V108, P497; LOMBARDERO M, 1988, J IMMUNOL METHODS, V108, P71, DOI 10.1016/0022-1759(88)90404-8; LOWELL FC, 1965, NEW ENGL J MED, V273, P675, DOI 10.1056/NEJM196509232731302; LOWENSTEIN H, 1981, J IMMUNOL, V126, P943; LOWENSTEIN H, 1980, ALLERGY, V35, P198, DOI 10.1111/j.1398-9995.1980.tb01743.x; LOWENSTEIN H, 1980, ALLERGY, V35, P188, DOI 10.1111/j.1398-9995.1980.tb01739.x; LOWENSTEIN H, 1981, J IMMUNOL, V127, P637; Lowenstein H, 1983, 11 INT C ALL CLIN IM, P545; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Malling HJ, 2000, DRUG SAFETY, V23, P323, DOI 10.2165/00002018-200023040-00005; MALLING HJ, 1986, ALLERGY, V41, P342, DOI 10.1111/j.1398-9995.1986.tb00311.x; MALLING HJ, 1986, ALLERGY, V41, P507, DOI 10.1111/j.1398-9995.1986.tb00336.x; MALLING HJ, 1988, ALLERGY, V43, P60, DOI 10.1111/j.1398-9995.1988.tb02045.x; Marcucci F, 2005, ALLERGY, V60, P952, DOI 10.1111/j.1398-9995.2005.00786.x; Marogna M, 2007, ANN ALLERG ASTHMA IM, V98, P274; MARTIN BG, 1985, ANN ALLERGY, V54, P99; MATLOFF SM, 1993, ALLERGY PROC, V14, P347, DOI 10.2500/108854193778774001; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; MAURO M, 2006, ALLERG IMMUNOL, V38, P31; MCHUGH SM, 1990, J ALLERGY CLIN IMMUN, V86, P521, DOI 10.1016/S0091-6749(05)80208-8; Michils A, 2000, ALLERGY, V55, P455, DOI 10.1034/j.1398-9995.2000.00412.x; Michils A, 1998, J ALLERGY CLIN IMMUN, V102, P118, DOI 10.1016/S0091-6749(98)70062-4; Milgrom H, 1999, NEW ENGL J MED, V341, P1966, DOI 10.1056/NEJM199912233412603; Milgrom H, 2001, PEDIATRICS, V108, P36; MILLER DL, 1972, ANN ALLERGY, V29, P178; Modrzynski Marek, 2003, Przegl Lek, V60, P130; Moffitt JE, 2004, J ALLERGY CLIN IMMUN, V114, P869, DOI 10.1016/j.jaci.2004.07.046; Moingeon P, 2006, ALLERGY, V61, P151, DOI 10.1111/j.1398-9995.2006.01002.x; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Moreno C, 2004, CLIN EXP ALLERGY, V34, P527, DOI 10.1111/j.1365-2222.2004.1819.x; Moverare R, 2002, ALLERGY, V57, P423, DOI 10.1034/j.1398-9995.2002.13248.x; Muller U, 2001, J ALLERGY CLIN IMMUN, V107, P81, DOI 10.1067/mai.2001.111852; Muller UR, 2005, J ALLERGY CLIN IMMUN, V115, P606, DOI [10.1016/j.jsci.2004.11.012, 10.1016/j.jaci.2004.11.012]; Nanda A, 2004, J ALLERGY CLIN IMMUN, V114, P1339, DOI 10.1016/j.jaci.2004.08.049; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V98, P382, DOI 10.1016/S0091-6749(96)70162-8; Nelson HS, 1996, J ALLERGY CLIN IMMUN, V97, P1193, DOI 10.1016/S0091-6749(96)70184-7; NELSON HS, 1993, J ALLERGY CLIN IMMUN, V92, P229, DOI 10.1016/0091-6749(93)90166-D; Nelson HS, 1997, J ALLERGY CLIN IMMUN, V99, P744, DOI 10.1016/S0091-6749(97)80006-1; Nelson HS, 2000, J ALLERGY CLIN IMMUN, V106, P41, DOI 10.1067/mai.2000.107197; NEWMAN BR, 1981, ANN ALLERGY, V47, P35; Nguyen SA, 2005, ANN ALLERG ASTHMA IM, V94, P387; Nicklas RA, 1996, J ALLERGY CLIN IMMUN, V98, P1001, DOI 10.1016/S0091-6749(96)80183-7; Niederberger V, 1998, J ALLERGY CLIN IMMUN, V102, P579, DOI 10.1016/S0091-6749(98)70273-8; Nielsen L, 1996, J ALLERGY CLIN IMMUN, V97, P1207, DOI 10.1016/S0091-6749(96)70186-0; Niemeijer NR, 1996, ANN ALLERG ASTHMA IM, V76, P535; NIGGEMANN B, 2006, FIVE YEAR FOLLOW UP, V855, P9; Noon L, 1911, LANCET, V1, P1572; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623; Ohashi Y, 1998, ARCH OTOLARYNGOL, V124, P1337; Ohashi Yoshihiro, 2006, Ann Allergy Asthma Immunol, V96, P600; OHMAN JL, 1984, J ALLERGY CLIN IMMUN, V74, P230, DOI 10.1016/0091-6749(84)90251-3; OHMAN JL, 1987, CLIN REV ALLERG, V5, P37; Olaguibel JM, 2005, J INVEST ALLERG CLIN, V15, P9; Olsen OT, 1997, ALLERGY, V52, P853, DOI 10.1111/j.1398-9995.1997.tb02157.x; OPPENHEIMER J, 1994, J ALLERGY CLIN IMMUN, V93, P61, DOI 10.1016/0091-6749(94)90233-X; OPPENHEIMER JJ, 1992, J ALLERGY CLIN IMMUN, V90, P256, DOI 10.1016/0091-6749(92)90080-L; ORTOLANI C, 1994, ALLERGY, V49, P13, DOI 10.1111/j.1398-9995.1994.tb00767.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; Schamann F, 2001, ALLERGOL IMMUNOPATH, V29, P60; Passalacqua G, 1999, J ALLERGY CLIN IMMUN, V104, P964, DOI 10.1016/S0091-6749(99)70076-X; Passalacqua G, 2005, CLIN EXP ALLERGY, V35, P880, DOI 10.1111/j.1365-2222.2005.02226.x; PASSALACQUA G, 1995, AM J RESP CRIT CARE, V152, P461; Passalacqua G, 1997, CLIN EXP ALLERGY, V27, P904; PAULI G, 1984, J ALLERGY CLIN IMMUN, V74, P524, DOI 10.1016/0091-6749(84)90389-0; Peden D, 2003, ANN ALLERG ASTHMA IM, V90, P1; Penagos M, 2006, ANN ALLERG ASTHMA IM, V97, P141; PENCE HL, 1976, J ALLERGY CLIN IMMUN, V58, P39, DOI 10.1016/0091-6749(76)90105-6; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; PHAM NH, 1994, CLIN EXP ALLERGY, V24, P558, DOI 10.1111/j.1365-2222.1994.tb00953.x; PHILLIPS JW, 1989, ANN ALLERGY, V63, P503; Pichler CE, 1997, ALLERGY, V52, P274, DOI 10.1111/j.1398-9995.1997.tb00991.x; Pichler CE, 2001, ALLERGY, V56, P301, DOI 10.1034/j.1398-9995.2001.00834.x; Polosa R, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-153; Polosa R, 2004, ALLERGY, V59, P1224, DOI 10.1111/j.1398-9995.2004.00537.x; PORTNOY J, 1992, ANN ALLERGY, V68, P493; PORTNOY J, 1994, ANN ALLERGY, V73, P409; Portnoy JM, 2001, ANN ALLERG ASTHMA IM, V87, P28; Portnoy JM, 2001, CLIN REV ALLERG IMMU, V21, P241, DOI 10.1385/CRIAI:21:2-3:241; Pumphrey RSH, 2000, CLIN EXP ALLERGY, V30, P1144, DOI 10.1046/j.1365-2222.2000.00864.x; Purello-D'Ambrosio F, 1999, ALLERGY, V54, P968, DOI 10.1034/j.1398-9995.1999.00203.x; Purello-D'Ambrosio F, 2001, CLIN EXP ALLERGY, V31, P1295, DOI 10.1046/j.1365-2222.2001.01027.x; Radcliffe MJ, 2003, BRIT MED J, V327, P251, DOI 10.1136/bmj.327.7409.251; Ragusa FV, 1997, J INVEST ALLERG CLIN, V7, P151; Ragusa VF, 2004, ALLERG IMMUNOL PARIS, V36, P52; RAK S, 1988, J ALLERGY CLIN IMMUN, V82, P470, DOI 10.1016/0091-6749(88)90021-8; Rance F, 2000, Allerg Immunol (Paris), V32, P366; REID MJ, 1993, J ALLERGY CLIN IMMUN, V92, P6, DOI 10.1016/0091-6749(93)90030-J; Reisman RE, 2001, J ALLERGY CLIN IMMUN, V107, P781, DOI 10.1067/mai.2001.115042; Roll A, 2006, J INVEST ALLERG CLIN, V16, P79; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; Ross RN, 2000, CLIN THER, V22, P329, DOI 10.1016/S0149-2918(00)80037-5; Ross RN, 2000, CLIN THER, V22, P342, DOI 10.1016/S0149-2918(00)80038-7; Ross RN, 2000, CLIN THER, V22, P351, DOI 10.1016/S0149-2918(00)80039-9; Rossi RE, 2005, INT J IMMUNOPATH PH, V18, P277; Roy SR, 2007, ANN ALLERG ASTHMA IM, V99, P82; Rueff F, 2001, J ALLERGY CLIN IMMUN, V108, P1027, DOI 10.1067/mai.2001.119154; SADAN N, 1969, NEW ENGL J MED, V280, P623, DOI 10.1056/NEJM196903202801201; SALVAGGIO JE, 1993, J ALLERGY CLIN IMMUN, V92, P217, DOI 10.1016/0091-6749(93)90164-B; Sampson HA, 2005, J ALLERGY CLIN IMMUN, V115, P584, DOI [10.1016/j.jaci.2005.01.008, 10.1016/j.jaci.2005.01.009]; Sampson HA, 2000, BRIT MED BULL, V56, P925, DOI 10.1258/0007142001903607; Savolainen J, 2004, CLIN EXP ALLERGY, V34, P413, DOI 10.1111/j.1365-2222.2004.01823.x; Schiavino D, 2004, ANN ALLERG ASTHMA IM, V92, P409; SCHOU C, 1990, J ALLERGY CLIN IMMUN, V86, P935, DOI 10.1016/S0091-6749(05)80157-5; Schramm G, 1999, J IMMUNOL, V162, P2406; SHAFIEE A, 1981, J ALLERGY CLIN IMMUN, V67, P472, DOI 10.1016/0091-6749(81)90101-9; Sharkey P, 1996, ANN ALLERG ASTHMA IM, V76, P175; Shekelle PG, 1999, BRIT MED J, V318, P593; SHERMAN MS, 1988, J ALLERGY CLIN IMMUN, V81, P908, DOI 10.1016/0091-6749(88)90949-9; Simons FER, 2001, J ALLERGY CLIN IMMUN, V108, P1040, DOI 10.1067/mai.2001.119916; Simons FER, 2000, PEDIATRICS, V106, P1040, DOI 10.1542/peds.106.5.1040; Simons FER, 2002, J ALLERGY CLIN IMMUN, V109, P171, DOI 10.1067/mai.2002.120758; Simons FER, 1998, J ALLERGY CLIN IMMUN, V101, P33, DOI 10.1016/S0091-6749(98)70190-3; Simons FER, 2000, J ALLERGY CLIN IMMUN, V105, P1025, DOI 10.1067/mai.2000.106042; Smith AM, 1998, J ALLERGY CLIN IMMUN, V101, P423; Smith H, 2004, J ALLERGY CLIN IMMUN, V114, P831, DOI 10.1016/j.jaci.2004.06.058; SRIDHARA S, 1992, ASIAN PAC J ALLERGY, V10, P33; Tabar AI, 2005, J ALLERGY CLIN IMMUN, V116, P109, DOI 10.1016/j.jaci.2005.05.005; Tabar AI, 1999, J INVEST ALLERG CLIN, V9, P155; Tankersley MS, 2002, J ALLERGY CLIN IMMUN, V109, P556, DOI 10.1067/mai.2002.121956; Tankersley MS, 2000, J ALLERGY CLIN IMMUN, V106, P840, DOI 10.1067/mai.2000.110468; Theodoropoulos DS, 2000, ALLERGY ASTHMA PROC, V21, P159, DOI 10.2500/108854100778149007; Thomas M, 2005, EMERG MED J, V22, P272, DOI 10.1136/emj.2005.023507; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Till Stephen J, 2004, Clin Allergy Immunol, V18, P85; TIPTON WR, 1982, J ALLERGY CLIN IMMUN, V69, P194, DOI 10.1016/0091-6749(82)90099-9; TOOGOOD JH, 1988, J ALLERGY CLIN IMMUN, V81, P1, DOI 10.1016/0091-6749(88)90212-6; TRIPLETT RF, 1973, SOUTHERN MED J, V66, P477; Tripodi S, 2006, INT ARCH ALLERGY IMM, V139, P149, DOI 10.1159/000090391; Tulic MK, 2004, J ALLERGY CLIN IMMUN, V113, P235, DOI 10.1016/j.jaci.2003.11.001; Turkeltaub PC, 1988, ALLERGY PRINCIPLES P, P388; Vailes L, 2001, J ALLERGY CLIN IMMUN, V107, P641, DOI 10.1067/mai.2001.114118; VALENTINE MD, 1990, NEW ENGL J MED, V323, P1601, DOI 10.1056/NEJM199012063232305; Valyasevi MA, 1999, ANN ALLERG ASTHMA IM, V83, P132, DOI 10.1016/S1081-1206(10)62624-5; van Halteren HK, 1997, J ALLERGY CLIN IMMUN, V100, P767, DOI 10.1016/S0091-6749(97)70271-9; van Ree R, 1998, J ALLERGY CLIN IMMUN, V102, P184, DOI 10.1016/S0091-6749(98)70084-3; VANDERZEE JS, 1988, J ALLERGY CLIN IMMUN, V82, P270, DOI 10.1016/0091-6749(88)91011-1; VANMETRE TE, 1982, J ALLERGY CLIN IMMUN, V69, P181, DOI 10.1016/0091-6749(82)90098-7; VANMETRE TE, 1988, J ALLERGY CLIN IMMUN, V82, P1055, DOI 10.1016/0091-6749(88)90144-3; VanMetre TE, 1996, J ALLERGY CLIN IMMUN, V97, P1033, DOI 10.1016/S0091-6749(96)70254-3; VANMETRE TE, 1989, J ALLERGY CLIN IMMUN, V83, P888, DOI 10.1016/0091-6749(89)90102-4; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V65, P288, DOI 10.1016/0091-6749(80)90158-X; VANMETRE TE, 1980, J ALLERGY CLIN IMMUN, V66, P500, DOI 10.1016/0091-6749(80)90012-3; Varney VA, 1997, CLIN EXP ALLERGY, V27, P860, DOI 10.1111/j.1365-2222.1997.tb01225.x; VARNEY VA, 1993, J CLIN INVEST, V92, P644, DOI 10.1172/JCI116633; VIJAY HM, 1987, INT ARCH ALLER A IMM, V83, P325; Wachholz PA, 2003, J ALLERGY CLIN IMMUN, V112, P915, DOI [10.1067/mai.2003.1770, 10.1016/S0091-6749(03)02022-0]; Walker Ross F., 2000, Limnology, V1, P107, DOI 10.1007/s102010070016; Walker S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003559.pub3; Wang H, 2006, ALLERGY, V61, P191, DOI 10.1111/j.1398-9995.2005.00913.x; Weber RW, 2004, CURR ALLERGY ASTHM R, V4, P401, DOI 10.1007/s11882-004-0091-4; WEBER RW, 1985, CLIN REV ALLERG, V3, P291, DOI 10.1007/BF02992997; WEBER RW, 1984, ANN ALLERGY, V52, P226; WEBER RW, 1987, ANN ALLERGY, V58, P287; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; White JF, 2003, ANN ALLERG ASTHMA IM, V91, P425; Williams PB, 2003, ANN ALLERG ASTHMA IM, V91, P26; Wilson DR, 2005, ALLERGY, V60, P4, DOI 10.1111/j.1398-9995.2005.00699.x; Wolf BL, 2006, ANN ALLERG ASTHMA IM, V97, P52; Wood RA, 1999, J ALLERGY CLIN IMMUN, V103, P773, DOI 10.1016/S0091-6749(99)70419-7; YOO TJ, 1975, ANN ALLERGY, V34, P87; YUNGINGER JW, 1972, J ALLERGY CLIN IMMUN, V50, P326, DOI 10.1016/0091-6749(72)90036-X; ZETTERST.O, 1972, ACTA ALLERGOL, V27, P15, DOI 10.1111/j.1398-9995.1972.tb01638.x; [Anonymous], 2005, J ALLERGY CLIN IMMUN, V115, pS483; [Anonymous], 1998, ALLERGY S, V53, P1	349	85	88	1	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	SEP	2007	120	3		S			S25	S85		10.1016/j.jaci.2007.06.019		61	Allergy; Immunology	Allergy; Immunology	216OP	WOS:000249888200001		
J	Churg, A; Tai, H; Coulthard, T; Wang, R; Wright, JL				Churg, Andrew; Tai, Hsin; Coulthard, Tonya; Wang, Rona; Wright, Joanne L.			Cigarette smoke drives small airway remodeling by induction of growth factors in the airway wall	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						cigarette smoke; connective tissue growth factor; platelet-derived growth factor; small airway remodeling; transforming growth factor-beta	OBSTRUCTIVE PULMONARY-DISEASE; TRANSFORMING GROWTH-FACTOR-BETA-1; FACTOR BETA(1); FIBROSIS; LUNG; EXPRESSION; ASTHMA; MODEL; ACTIVATION; CELLS	Background: Small airway remodeling (SAR) is an important cause of airflow obstruction in cigarette smokers with chronic obstructive pulmonary disease, but the pathogenesis of SAR is not understood. Objective: To determine whether smoke causes production of profibrotic growth factors in the airway wall. Methods: We exposed C57BI/6 mice to cigarette smoke for up to 6 mo and examined growth factor/procollagen gene expression in laser-capture microdissected small airways by real-time reverse transcription-polymerase chain reaction. Results: With a single smoke exposure, increases in procollagen, connective tissue growth factor (CTGF), transforming growth factor (TGF)-beta(1), platelet-derived growth factor (PDGF)-A and -B expression were seen 2 h after the start of smoking and declined to baseline by 24 h. With repeated exposures and at killing of animals 24 h after the last exposure, increases in procollagen, CTGF, PDGF-B, and (minimally) PDGF-A expression persisted through 1 wk, 1 mo, and 6 mo. TGF-beta(1) gene expression declined over time; however, increased immunochemical staining for phopho-Smad 2 was present at all time points, indicating continuing TGF-beta downstream signaling. Morphometric analysis showed that the small airways in smoke-exposed mice had more Collagen at 6 mo. Conclusions: These findings suggest that smoke can induce growth factor and procollagen production in small airways in a time frame that initially is too short for a significant inflammatory response and that profibrotic growth factor and procollagen gene expression become self-sustaining with repeated smoke exposures. These results imply that the pathogenesis of and possible treatment approaches to emphysema and small airway remodeling might be quite different.	Univ British Columbia, Dept Pathol, Vancouver, BC V6T 2B5, Canada	Churg, A (reprint author), Univ British Columbia, Dept Pathol, 2211 Wesbrook Mail, Vancouver, BC V6T 2B5, Canada.	achurg@interchange.ubc.ca					Abdollahi A, 2005, J EXP MED, V201, P925, DOI 10.1084/jem.20041393; ANTONIADES HN, 1990, J CLIN INVEST, V86, P1055, DOI 10.1172/JCI114808; AUBERT JD, 1994, AM J PHYSIOL, V266, pL655; AUBERT JD, 1994, THORAX, V49, P225, DOI 10.1136/thx.49.3.225; Barnes PJ, 2003, EUR RESPIR J, V22, P672, DOI 10.1183/09031936.03.00040703; Bonner JC, 2004, CYTOKINE GROWTH F R, V15, P255, DOI 10.1016/j.cytogfr.2004.03.006; Bonniaud P, 2004, AM J RESP CELL MOL, V31, P510, DOI 10.1165/rcmb.2004-0158OC; Chambers RC, 2000, J BIOL CHEM, V275, P35584, DOI 10.1074/jbc.M003188200; Chapman HA, 2004, J CLIN INVEST, V113, P148, DOI 10.1172/JCI200420729; Chua F, 2005, AM J RESP CELL MOL, V33, P9, DOI 10.1165/rcmb.2005-0062TR; Chua Felix, 2006, Proc Am Thorac Soc, V3, P424, DOI 10.1513/pats.200603-078AW; CHURG A, 2006, P AM THORAC SOC, V3, pA546; COSIO M, 1978, NEW ENGL J MED, V298, P1277, DOI 10.1056/NEJM197806082982303; Cosio MG, 2002, CHEST, V121, p160S, DOI 10.1378/chest.121.5_suppl.160S; de Boer WI, 1998, AM J RESP CRIT CARE, V158, P1951; Dhami R, 2000, AM J RESP CELL MOL, V22, P244; Gauldie Jack, 2002, Respir Res, V3, P1, DOI 10.1186/rr158; HOGG JC, 1968, NEW ENGL J MED, V278, P1355, DOI 10.1056/NEJM196806202782501; Hogg JC, 2004, NEW ENGL J MED, V350, P2645, DOI 10.1056/NEJMoa032158; Ingram JL, 2004, FASEB J, V18, P1132, DOI 10.1096/fj.03-1492fje; Jeffery PK, 2001, AM J RESP CRIT CARE, V164, P28; Kelly MM, 2005, AM J RESP CELL MOL, V32, P99, DOI 10.1165/rcmb.2004-0190OC; Kenyon NJ, 2003, THORAX, V58, P772, DOI 10.1136/thorax.58.9.772; Kumar RK, 2004, CLIN EXP ALLERGY, V34, P567, DOI 10.1111/j.1365-2222.2004.1917.x; Lewis CC, 2005, J ALLERGY CLIN IMMUN, V115, P534, DOI 10.1016/j.jaci.2004.11.051; Liu JY, 1997, AM J RESP CELL MOL, V17, P129; MacNee W., 2000, CHEST, V117, P303; McCartney-Francis N, 1990, Growth Factors, V4, P27, DOI 10.3109/08977199009011007; NIEWOEHNER DE, 1974, J APPL PHYSIOL, V36, P412; Pare P D, 1997, Monaldi Arch Chest Dis, V52, P589; Saetta M, 1998, AM J RESP CRIT CARE, V157, P822; Selman M, 2001, ANN INTERN MED, V134, P136; Shapiro SD, 2005, AM J RESP CELL MOL, V32, P367, DOI 10.1165/rcmb.F296; Takizawa H, 2001, AM J RESP CRIT CARE, V163, P1476; THURLBECK WM, 1999, THURLBECKS CHRONIC A; Turato G, 2002, AM J RESP CRIT CARE, V166, P105, DOI 10.1164/rccm.2111084; Vignola AM, 1997, AM J RESP CRIT CARE, V156, P591; Wang RD, 2005, AM J RESP CELL MOL, V33, P387, DOI 10.1165/rcmb.2005-02030C; WIGGS BR, 1992, AM REV RESPIR DIS, V145, P1251; WRIGHT JL, 2004, AM J RESPIR CELL MOL, V3, P501; Yoshida K, 2005, AM J PATHOL, V166, P1029, DOI 10.1016/S0002-9440(10)62324-3; YOSHIDA M, 1995, P NATL ACAD SCI USA, V92, P9570, DOI 10.1073/pnas.92.21.9570; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	43	85	90	0	6	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	DEC 15	2006	174	12					1327	1334		10.1164/rccm.200605-585OC		8	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	117RA	WOS:000242889400009	17008639	
J	Bussmann, C; Bockenhoff, A; Henke, H; Werfel, T; Novak, N				Bussmann, Caroline; Boeckenhoff, Anette; Henke, Henning; Werfel, Thomas; Novak, Natalija			Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis?	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						allergy; atopic dermatitis; house dust mite; allergen specific immunotherapy	HOUSE-DUST-MITE; BLIND CONTROLLED TRIAL; DERMATOPHAGOIDES-PTERONYSSINUS; SUBLINGUAL IMMUNOTHERAPY; ASTHMATIC-PATIENTS; HYPOSENSITIZATION; CHILDREN; RHINITIS; IMMUNOLOGY; AVOIDANCE	House dust mite (HDM) allergens are perennial indoor allergens, which may play a role as allergic trigger factors in atopic dermatitis (AD). Facilitated by their high enzymatic activity, HDM allergens are capable of penetrating the impaired epidermal skin barrier in patients with AD, gaining access to immune cells. In this way, HDM allergens induce both allergic reactions of the immediate type and allergic reactions of the delayed type, which contribute to impairment of AD. Because allergen reduction achieved by encasing strategies does not always lead to significant improvement of clinical symptoms, specific immunotherapy (SIT) might represent an attractive therapeutic option for long-time treatment of this subgroup of patients with AD. However, systematic studies on the effectiveness of SIT in patients with AD are rare. Furthermore, data on the immunologic changes induced by SIT in patients with AD are not well studied. In this review, we provide an overview of the pathogenic impact of HDM allergens as an example for aeroallergens on the course of AD. In addition, we discuss prophylactic and therapeutic options for the treatment of HDM allergy in patients with AD, including a summary of the current data available on SIT as a potential therapeutic option for patients with AD.	Univ Bonn, Dept Dermatol, D-53127 Bonn, Germany; Univ Dortmund, Dept Stat, D-44221 Dortmund, Germany; Hannover Med Sch, Dept Dermatol, D-3000 Hannover, Germany	Novak, N (reprint author), Univ Bonn, Dept Dermatol, Siegmund Freud Str 25, D-53127 Bonn, Germany.	Natalija.Novak@ukb.uni-bonn.de					Akdis CA, 2006, J ALLERGY CLIN IMMUN, V118, P152, DOI 10.1016/j.jaci.2006.03.045; ARLIAN LG, 1991, EXP APPL ACAROL, V10, P167, DOI 10.1007/BF01198649; Arlian LG, 2001, J ALLERGY CLIN IMMUN, V107, P406, DOI 10.1067/mai.2001.113670; Boguniewicz M, 2006, J ALLERGY CLIN IMMUN, V118, P40, DOI 10.1016/j.jaci.2006.04.044; Bousquet J, 2001, ANN ALLERG ASTHMA IM, V87, P38; Brown A, 2003, AM J RESP CELL MOL, V29, P381, DOI 10.1165/rcmb.2003-0060OC; BRUUN EGON, 1949, ACTA ALLERGOL, V2, P122, DOI 10.1111/j.1398-9995.1949.tb03295.x; CHAIT I, 1985, PRACTITIONER, V229, P609; Cork MJ, 2006, J ALLERGY CLIN IMMUN, V118, P3, DOI 10.1016/j.jaci.2006.04.042; Cork Michael J, 2005, Community Pract, V78, P440; CORRADO OJ, 1989, ALLERGY, V44, P108, DOI 10.1111/j.1398-9995.1989.tb02233.x; Cox LS, 2006, J ALLERGY CLIN IMMUN, V117, P1021, DOI 10.1016/j.jaci.2006.02.040; Di Prisco de Fuenmayor MC, 1979, BRIT J DERMATOL, V101, P697; Des RA, 1997, J ALLERGY CLIN IMMUN, V99, P450; Engelhart S, 2002, INT J HYG ENVIR HEAL, V205, P453, DOI 10.1078/1438-4639-00192; Fleiss J L, 1993, Stat Methods Med Res, V2, P121, DOI 10.1177/096228029300200202; Galli E, 1994, Allergol Immunopathol (Madr), V22, P18; GLOVER MT, 1992, CLIN EXP ALLERGY, V22, P440, DOI 10.1111/j.1365-2222.1992.tb00145.x; Grembiale RD, 2000, AM J RESP CRIT CARE, V162, P2048; GREWER M, 2000, ALLERGO J, V9, P351; HEDGES LV, 1985, STAT METHODS META; Heijer A., 1993, ALLERGO J, V2, P3; Johansson SGO, 2001, ALLERGY, V56, P813, DOI 10.1034/j.1398-9995.2001.t01-1-00001.x; KAUFMAN HS, 1974, ANN ALLERGY, V32, P321; Kawabata A, 2005, J PHARMACOL SCI, V97, P20, DOI 10.1254/jphs.FMJ04005X4; Kleine-Tebbe J, 2006, ALLERGO J, V15, P56; LEROY BP, 1993, J AM ACAD DERMATOL, V28, P232, DOI 10.1016/0190-9622(93)70033-P; Leung DYM, 2004, J CLIN INVEST, V113, P651, DOI 10.1172/JCI200421060; Maestrelli P, 2004, J ALLERGY CLIN IMMUN, V113, P643, DOI 10.1016/j.jaci.2003.12.586; Malling HJ, 2006, ALLERGY, V61, P24, DOI 10.1111/j.1398-9995.2006.01158.x; Mastrandrea F, 2000, Allergol Immunopathol (Madr), V28, P54; MICHILS A, 1994, BRIT J DERMATOL, V130, P134, DOI 10.1111/j.1365-2133.1994.tb06908.x; Morar N, 2006, J ALLERGY CLIN IMMUN, V118, P24, DOI 10.1016/j.jaci.2006.03.037; Mosca M, 1993, ITAL DERMATOL VENERE, V128, P79; Noh GW, 1998, ALLERGY, V53, P1202, DOI 10.1111/j.1398-9995.1998.tb03842.x; Pacor Maria Luisa, 1994, Recenti Progressi in Medicina, V85, P273; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Petrova SI, 2006, ZH MIKROBIOL EPIDEMI, V1, P33; PLATTSMILLS TAE, 1992, J ALLERGY CLIN IMMUN, V89, P1046, DOI 10.1016/0091-6749(92)90228-T; Rijssenbeek-Nouwens LHM, 2002, CLIN EXP ALLERGY, V32, P117, DOI 10.1046/j.0022-0477.2001.01256.x; RING J, 1982, BRIT J DERMATOL, V107, P597, DOI 10.1111/j.1365-2133.1982.tb00412.x; Schmid P, 2001, ALLERGY, V56, P841, DOI 10.1034/j.1398-9995.2001.00144.x; SEIDENARI S, 1986, DERMATOLOGICA, V172, P229; Silny W, 2006, ALLERGOLOGIE, V29, P171; Silny Wojciech, 2005, Wiad Lek, V58, P47; SMITH AP, 1971, BRIT MED J, V4, P204; Tan BB, 1996, LANCET, V347, P15, DOI 10.1016/S0140-6736(96)91556-1; Terreehorst I, 2003, NEW ENGL J MED, V349, P237, DOI 10.1056/NEJMoa023171; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; Trofimowicz A, 1995, Rocz Akad Med Bialymst, V40, P414; Tupker RA, 1996, J ALLERGY CLIN IMMUN, V97, P1064, DOI 10.1016/S0091-6749(96)70259-2; Verhagen J, 2005, INT REV IMMUNOL, V24, P533, DOI 10.1080/08830180500371173; Warner A, 1999, ALLERGY, V54, P681, DOI 10.1034/j.1398-9995.1999.00850.x; WARNER JO, 1978, LANCET, V2, P912; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; Werfel T, 2006, ALLERGY, V61, P202, DOI 10.1111/j.1398-9995.2006.00974.x; Wills-Karp M, 2001, NAT REV IMMUNOL, V1, P69, DOI 10.1038/35095579; Woodcock A, 2003, NEW ENGL J MED, V349, P225, DOI 10.1056/NEJMoa023175; Zachariae H, 1985, Acta Derm Venereol Suppl (Stockh), V114, P48; Zwacka G, 1996, ALLERGOLOGIE, V19, P580	60	85	94	0	5	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	DEC	2006	118	6					1292	1298		10.1016/j.jaci.2006.07.054		7	Allergy; Immunology	Allergy; Immunology	117NP	WOS:000242880300013	17157659	
J	Grize, L; Gassner, M; Wuthrich, B; Bringolf-Isler, B; Takken-Sahli, K; Sennhauser, FH; Stricker, T; Eigenmann, PA; Braun-Fahrlander, C				Grize, L; Gassner, M; Wuthrich, B; Bringolf-Isler, B; Takken-Sahli, K; Sennhauser, FH; Stricker, T; Eigenmann, PA; Braun-Fahrlander, C		Swiss Surveillance Programme	Trends in prevalence of asthma, allergic rhinitis and atopic dermatitis in 5-7-year old Swiss children from 1992 to 2001	ALLERGY			English	Article						allergic rhinitis; asthma; atopic dermatitis; children; trend	ISAAC PHASE-I; INCREASING PREVALENCE; RESPIRATORY HEALTH; AIR-POLLUTION; HAY-FEVER; HONG-KONG; SCHOOLCHILDREN; ADOLESCENTS; CHILDHOOD; GERMANY	Background: Changing occurrence rates of asthma, allergic rhinitis and atopic dermatitis are of public health concern and require surveillance. Changes in prevalence rates of these atopic diseases were monitored during 10 years and their trend with time was determined taking into account the influence of personal and environmental risk factors. Methods: Four cross-sectional surveys in 5-7-year old children were performed in seven different communities in Switzerland between 1992 and 2001. Prevalence of respiratory and allergic symptoms and of affecting risk factors including parental environmental concern were assessed using a standardized parental questionnaire. Results: A total of 988 (74.1%), 1778 (79.0%), 1406 (82.6%) and 1274 (78.9%) children participated, respectively, in the 1992, 1995, 1998 and 2001 surveys. Prevalence rates of asthma and hay fever symptoms remained quite stable over time (wheeze/past year: 8.8%, 7.8%, 6.4% and 7.4%, sneezing attack during pollen season: 5.0%, 5.6%, 5.4% and 4.6%). Rates of reported atopic dermatitis symptoms (specific skin rash/past year: 4.6%, 6.5%,7.4% and 7.6%) showed an increase over time, but those of diagnosis of eczema did not show a clear pattern (18.4%, 15.7%, 14.0% and 15.2%). Stratified analysis by parental environmental concern and by parental atopy showed similar trends. Rates of atopic dermatitis symptoms showed significant increase in girls but stayed stable in boys. Conclusion: Results of these four consecutive surveys suggest that the increase in prevalence of asthma and hay fever in 5-7-year old children living in Switzerland may have ceased. However, symptoms of atopic dermatitis may still be on the rise, especially among girls.	Univ Basel, Inst Social & Prevent Med, CH-4051 Basel, Switzerland; Univ Hosp, Dept Dermatol, Zurich, Switzerland; Sch Hlth Serv, Zurich, Switzerland; Univ Childrens Hosp, Zurich, Switzerland; Paediat Univ Hosp, Allergy Clin, Geneva, Switzerland	Grize, L (reprint author), Univ Basel, Inst Social & Prevent Med, Steinengraben 49, CH-4051 Basel, Switzerland.		Eigenmann, Philippe/A-6569-2017	Eigenmann, Philippe/0000-0003-1738-1826			Anthracopoulos M, 2001, THORAX, V56, P569, DOI 10.1136/thorax.56.7.569; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bayer-Oglesby L, 2005, ENVIRON HEALTH PERSP, V113, P1632, DOI 10.1289/ehp.8159; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; BraunFahrlander C, 1997, AM J RESP CRIT CARE, V155, P1042; D'Amato G, 2000, J INVEST ALLERG CLIN, V10, P123; Downs SH, 2001, ARCH DIS CHILD, V84, P20, DOI 10.1136/adc.84.1.20; Garcia-Marcos L, 2004, ALLERGY, V59, P1301, DOI 10.1111/j.1398-9995.2004.00562.x; Haileamlak A, 2005, BRIT J DERMATOL, V152, P735, DOI 10.1111/j.1365-2133.2005.06511.x; Kramer U, 1998, BRIT J DERMATOL, V139, P1040; KUEHNI CE, 1999, EUR RESPIR J, V14, pS440; Kwong GNM, 2001, THORAX, V56, P312, DOI 10.1136/thorax.56.4.312; Lee SL, 2004, PEDIATR ALLERGY IMMU, V15, P72, DOI 10.1046/j.0905-6157.2003.00109.x; Maziak W, 2003, ALLERGY, V58, P572, DOI 10.1034/j.1398-9995.2003.00161.x; Mommers M, 2005, THORAX, V60, P97, DOI 10.1136/thx.2004.024786; NELDER JA, 1972, J R STAT SOC SER A-G, V135, P370, DOI 10.2307/2344614; *SAS INC, 2001, REL 8 02; Selnes A, 2005, ALLERGY, V60, P894, DOI 10.1111/j.1398-9995.2005.00797.x; Strachan DP, 1998, THORAX, V53, P204; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; von Hertzen L, 2005, ALLERGY, V60, P283, DOI 10.1111/j.1398-9995.2005.00769.x; von Hertzen LC, 2004, ALLERGY, V59, P124, DOI 10.1046/j.1398-9995.2003.00433.x; von Mutius E, 2001, AM J RESP CRIT CARE, V164, P1106; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; von Mutius E, 2001, AM J RESP CRIT CARE, V164, P1108; Williams HC, 1996, BRIT J DERMATOL, V135, P12; Wong GWK, 2004, CLIN EXP ALLERGY, V34, P1550, DOI 10.1111/j.1365-2222.2004.02064.x; Zollner IK, 2005, THORAX, V60, P545, DOI 10.1136/thx.2004.029561	29	85	90	2	6	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	MAR	2006	61	5					556	562		10.1111/j.1398-9995.2006.01030.x		7	Allergy; Immunology	Allergy; Immunology	027CY	WOS:000236392500008	16629784	
J	Nicolaou, N; Siddique, N; Custovic, A				Nicolaou, N; Siddique, N; Custovic, A			Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization	ALLERGY			English	Editorial Material							EXERCISE-INDUCED BRONCHOSPASM; CHILDHOOD ASTHMA; LIFE-STYLE; HAY-FEVER; CHILDREN; ATOPY; SENSITIZATION; RHINITIS; ADOLESCENTS; EXPOSURE		Univ Manchester, Wythenshawe Hosp, NW Lung Ctr, Acad Div Med & Surg Hlth, Manchester M23 9LT, Lancs, England; Royal Bournemouth Hosp, Dept Thorac Med, Bournemouth, Dorset, England	Nicolaou, N (reprint author), Univ Manchester, Wythenshawe Hosp, NW Lung Ctr, Acad Div Med & Surg Hlth, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071			Adler A, 2005, J ALLERGY CLIN IMMUN, V115, P67, DOI 10.1016/j.jaci.2004.10.008; Aligne CA, 2000, AM J RESP CRIT CARE, V162, P873; Braback L, 2004, CLIN EXP ALLERGY, V34, P38, DOI 10.1111/j.1365-2222.2004.01841.x; Braun-Fahrlander C, 2004, EUR RESPIR J, V23, P407, DOI 10.1183/09031936.04.00074004; Eder W, 2004, J ALLERGY CLIN IMMUN, V113, P482, DOI 10.1016/j.jaci.2003.12.374; Eduard W, 2004, THORAX, V59, P381, DOI 10.1136/thx.2004.013326; Filipiak B, 2001, CLIN EXP ALLERGY, V31, P1829, DOI 10.1046/j.1365-2222.2001.01246.x; Heinrich Joachim, 2004, Curr Opin Allergy Clin Immunol, V4, P341, DOI 10.1097/00130832-200410000-00003; Hijazi N, 2000, THORAX, V55, P775, DOI 10.1136/thorax.55.9.775; Kim YK, 2002, CLIN EXP ALLERGY, V32, P1305, DOI 10.1046/j.1365-2745.2002.01478.x; Linneberg A, 2005, ALLERGY, V60, P538, DOI 10.1111/j.1398-9995.2005.00721.x; Mercer MJ, 2004, PEDIATR ALLERGY IMMU, V15, P234, DOI 10.1111/j.1399-3038.2004.00125.x; Mistry R, 2004, EUR J PEDIATR, V163, P145, DOI 10.1007/s00431-003-1393-6; Miyamoto T, 1997, ALLERGY, V52, P30; Ng'ang'a LW, 1998, THORAX, V53, P919; Nicolai T, 2003, EUR RESPIR J, V21, P956, DOI 10.1183/09031936.03.00041103; Perzanowski MS, 2002, J PEDIATR-US, V140, P582, DOI 10.1067/mpd.2002.122937; Platts-Mills TAE, 2005, ALLERGY, V60, P25, DOI 10.1111/j.1398-9995.2005.00854.x; Platts-Mills TAE, 2005, PLOS MED, V2, P122, DOI 10.1371/journal.pmed.0020034; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Shapiro GG, 2002, PEDIATR PULM, V33, P47, DOI 10.1002/ppul.10029; Singh Meenu, 2005, Paediatr Respir Rev, V6, P14, DOI 10.1016/j.prrv.2004.11.003; Steinman HA, 2003, PEDIATR ALLERGY IMMU, V14, P383, DOI 10.1034/j.1399-3038.2003.00062.x; Sudhir P, 2003, J TROP PEDIATRICS, V49, P104, DOI 10.1093/tropej/49.2.104; VANNIEKERK CH, 1979, CLIN ALLERGY, V9, P319; Venn AJ, 2001, AM J RESP CRIT CARE, V164, P1660; Verlato G, 2003, J ALLERGY CLIN IMMUN, V111, P1232, DOI 10.1067/mai.2003.1484; Viinanen A, 2005, ALLERGY, V60, P1370, DOI 10.1111/j.1398-9995.2005.00877.x; Walraven GEL, 2001, CLIN EXP ALLERGY, V31, P1679, DOI 10.1046/j.1365-2222.2001.01094.x; Wong GWK, 2004, BRIT MED J, V329, P486, DOI 10.1136/bmj.329.7464.486; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3; Yobo EODA, 1997, THORAX, V52, P161	32	85	88	3	9	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0105-4538			ALLERGY	Allergy	NOV	2005	60	11					1357	1360		10.1111/j.1398-9995.2005.00961.x		4	Allergy; Immunology	Allergy; Immunology	969NS	WOS:000232241600004	16197466	
J	Wheeler, BW; Ben-Shlomo, Y				Wheeler, BW; Ben-Shlomo, Y			Environmental equity, air quality, socioeconomic status, and respiratory health: a linkage analysis of routine data from the Health Survey for England	JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH			English	Article							POLLUTION; JUSTICE; ASTHMA; ASSOCIATION; MORTALITY; EXPOSURE; COHORT	Study objective: To assess relations between socioeconomic status and local air quality, and combined effects on respiratory health, in the context of environmental and health inequality. Design: Data on people taking part in the Health Survey for England were attributed with a small area index of air pollution using annual mean concentrations of nitrogen dioxide, sulphur dioxide, benzene, and particulates (PM10). Regression models were used to measure associations between social class, air quality, forced expiratory volume in one second (FEV1), and self reported asthma. Participants: Participants aged 16 - 79 in the Health Survey for England 1995, 1996, and 1997. Main results: Urban lower social class households were more likely to be located in areas of poor air quality, but the association in rural areas was, if anything reversed. Low social class and poor air quality were independently associated with decreased lung function (FEV1), but not asthma prevalence, after adjustment for a number of potential confounders. Social class effects were not attenuated by adjustment for air quality. In men, a differential effect of air pollution on FEV1 was found, with its effect in social classes III to V about double that in social classes I and II ( p value for interaction = 0.04). This effect modification was not seen for women. Conclusions: Further evidence of environmental inequity in the UK is provided. The association between FEV1 and local air quality is of similar magnitude to that with social class, and the adverse effects of air pollution seem to be greater in men in lower social classes.	Univ Sheffield, Dept Geog, Sheffield S10 2TN, S Yorkshire, England; Univ Bristol, Dept Social Med, Bristol BS8 1TH, Avon, England	Wheeler, BW (reprint author), Univ Sheffield, Dept Geog, Winter St, Sheffield S10 2TN, S Yorkshire, England.	b.w.wheeler@sheffield.ac.uk	Wheeler, Benedict/G-1711-2012	Wheeler, Benedict/0000-0001-9404-5936			AckermannLiebrich U, 1997, AM J RESP CRIT CARE, V155, P122; Ben-Shlomo Y, 2002, INT J EPIDEMIOL, V31, P285, DOI 10.1093/ije/31.2.285; Bowen WM, 1995, ANN ASSOC AM GEOGR, V85, P641, DOI 10.1111/j.1467-8306.1995.tb01818.x; Brainard JS, 2002, ENVIRON PLANN A, V34, P695, DOI 10.1068/a34184; BROWN P, 1995, ENVIRON RES, V69, P15, DOI 10.1006/enrs.1995.1021; Brunekreef B, 2002, LANCET, V360, P1233, DOI 10.1016/S0140-6736(02)11274-8; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; Bullard R. D., 1994, DUMPING DIXIE RACE C; CLINTON WJ, FEDERAL ACTIONS ADDR; Davis DL, 2002, ENVIRON HEALTH PERSP, V110, pA734, DOI 10.1289/ehp.110-a734; Department of Health, HLTH SURV ENGL; Ecob R, 1999, SOC SCI MED, V48, P693, DOI 10.1016/S0277-9536(98)00385-2; Elliott MR, 2004, J EPIDEMIOL COMMUN H, V58, P24, DOI 10.1136/jech.58.1.24; *ENV AG, POS STAT ADDR ENV IN; Hoek G, 2002, LANCET, V360, P1203, DOI 10.1016/S0140-6736(02)11280-3; Janssen NAH, 2000, J AIR WASTE MANAGE, V50, P1133; Jerrett M, 2004, J EPIDEMIOL COMMUN H, V58, P31, DOI 10.1136/jech.58.1.31; *JOINT HLTH SURV U, 2000, SN3979 JOINT HLTH SU; *JOINT HLTH SURV U, 2001, SN3796 JOINT HLTH SU; *JOINT HLTH SURV U, 2001, SN3886 JOINT HLTH SU; Martins MCH, 2004, J EPIDEMIOL COMMUN H, V58, P41, DOI 10.1136/jech.58.1.41; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McLaren D., 1999, POLLUTION INJUSTICE; Mitchell G, 2003, ENVIRON PLANN A, V35, P909, DOI 10.1068/a35240; NOBLE M, 2004, ENGLISH INDICES DEPR, P180; O'Neill MS, 2003, ENVIRON HEALTH PERSP, V111, P1861, DOI 10.1289/ehp.6334; PYE S., 2001, FURTHER ANAL NO2 PM1; Rene AA, 2000, J NATL MED ASSOC, V92, P275; STRACHAN DP, 2004, LIFE COURSE APPROACH; Szasz A., 1997, CURR SOCIOL, V45, P99, DOI 10.1177/001139297045003006; TUDORHART J, 1971, LANCET, V1, P406; University of Essex, UK DAT ARCH; *USEPA, ENV JUST FREQ ASK QU; Walker G., 2000, CRITICAL URBAN STUDI; Wheeler BW, 2004, ENVIRON PLANN A, V36, P803, DOI 10.1068/a3691; Zemp E, 1999, AM J RESP CRIT CARE, V159, P1257; Zmirou D, 2004, J EPIDEMIOL COMMUN H, V58, P18, DOI 10.1136/jech.58.1.18	37	85	85	3	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0143-005X			J EPIDEMIOL COMMUN H	J. Epidemiol. Community Health	NOV	2005	59	11					948	954		10.1136/jech.2005.036418		7	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	975HO	WOS:000232651800009	16234422	
J	Franze, T; Weller, MG; Niessner, R; Poschl, U				Franze, T; Weller, MG; Niessner, R; Poschl, U			Protein nitration by polluted air	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; BET V 1; LIQUID-CHROMATOGRAPHY; PARTICULATE MATTER; AQUEOUS-SOLUTION; FINE PARTICLES; GRASS-POLLEN; ALLERGENS; IGE; GAS	The effects of air pollution on allergic diseases are not yet well-understood. Here, we show that proteins, in particular birch pollen proteins including the allergen Bet v 1, are efficiently nitrated by polluted air. This posttranslational modification of proteins is likely to trigger immune reactions and provides a molecular rationale for the promotion of allergies by traffic-related air pollution. Enzyme immunoassays have been used to determine equivalent degrees of nitration (EDN) for protein samples exposed to urban outdoor air and synthetic gas mixtures. The observed rates of nitration were governed by the abundance of nitrogen oxides and ozone, and concentration levels typical for summer smog conditions led to substantial nitration within a few hours to days (EDN up to 20%). Moreover, nitrated proteins were detected in urban road dust, window dust, and fine air particulate matter (EDN up to 0.1%).	Tech Univ Munich, Inst Hydrochem, D-81377 Munich, Germany	Poschl, U (reprint author), Tech Univ Munich, Inst Hydrochem, Marchioninistr 17, D-81377 Munich, Germany.	ulrich.poeschl@ch.tum.de	Weller, Michael G./B-5015-2008; Poschl, Ulrich/A-6263-2010; Niessner, Reinhard/C-1414-2010; Niessner, Reinhard/D-1502-2010; Osborne, Nicholas/N-4915-2015	Weller, Michael G./0000-0003-2767-2029; Poschl, Ulrich/0000-0003-1412-3557; Osborne, Nicholas/0000-0002-6700-2284			Barzaghi P, 2002, PHYS CHEM CHEM PHYS, V4, P3669, DOI 10.1039/b201652d; BECKMAN JS, 1992, ARCH BIOCHEM BIOPHYS, V298, P438, DOI 10.1016/0003-9861(92)90432-V; Belloli R, 1999, J CHROMATOGR A, V846, P277, DOI 10.1016/S0021-9673(99)00030-8; Berrens L, 1997, INT ARCH ALLERGY IMM, V113, P236; Birnboim HC, 2003, J IMMUNOL, V171, P528; Bolzacchini E, 2001, ENVIRON SCI TECHNOL, V35, P1791, DOI 10.1021/es001290m; Brunekreef B, 2001, CLIN EXP ALLERGY, V31, P1170, DOI 10.1046/j.1365-2222.2001.01208.x; Brunekreef B, 2003, EUR RESPIR J, V21, P913, DOI 10.1183/09031936.03.00014903; Doyle HA, 2001, TRENDS IMMUNOL, V22, P443, DOI 10.1016/S1471-4906(01)01976-7; FALL BI, 2001, BIOS S TUB GERM; FinlaysonPitts BJ, 1997, SCIENCE, V276, P1045, DOI 10.1126/science.276.5315.1045; FINLAYSONPITTS BJ, 2000, CHEM LOWER ATMOSPHER; Franze T, 2004, ANALYST, V129, P589, DOI 10.1039/b402624a; Franze T, 2003, ANALYST, V128, P824, DOI 10.1039/b303132b; Franze T, 2003, J AEROSOL SCI, V34, pS777; GOSCHNICK J, 1996, J AEROSOL SCI, V27, P229; GRAHAM A, 1993, FEBS LETT, V330, P181, DOI 10.1016/0014-5793(93)80269-Z; Greenacre SAB, 2001, FREE RADICAL RES, V34, P541, DOI 10.1080/10715760100300471; HOLT PG, 1987, IMMUNOLOGY, V60, P97; Huby RDJ, 2000, TOXICOL SCI, V55, P235, DOI 10.1093/toxsci/55.2.235; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JAROLIM E, 1989, ALLERGY, V44, P385, DOI 10.1111/j.1398-9995.1989.tb04169.x; KNOX RB, 1993, CLIN EXP ALLERGY, V23, P354, DOI 10.1111/j.1365-2222.1993.tb00339.x; Kramer U, 1999, INT J EPIDEMIOL, V28, P865, DOI 10.1093/ije/28.5.865; Landsteiner K, 1935, J EXP MED, V61, P643, DOI 10.1084/jem.61.5.643; Lin JK, 2000, CHEM-BIOL INTERACT, V127, P219, DOI 10.1016/S0009-2797(00)00181-2; Miguel AG, 1999, ENVIRON SCI TECHNOL, V33, P4159, DOI 10.1021/es9904890; Mikhailov E, 2004, ATMOS CHEM PHYS, V4, P323; Neuhaus-Steinmetz U, 2000, AM J RESP CELL MOL, V23, P228; Petersen A, 1998, CLIN EXP ALLERGY, V28, P315; POSCHL U, 1982, J AEROSOL MED, V15, P203; Rehwagen M, 1999, ENVIRON TOXICOL, V14, P321, DOI 10.1002/(SICI)1522-7278(199907)14:3<321::AID-TOX5>3.0.CO;2-L; RIEDEL F, 1995, PEDR ALLERGY, V8, P65; Riediker M, 2001, ANN ALLERG ASTHMA IM, V87, P311; Ring J, 2001, ANN ALLERG ASTHMA IM, V87, P2; Ring J, 2001, CURR OPIN IMMUNOL, V13, P701, DOI 10.1016/S0952-7915(01)00282-5; Schappi GF, 1997, J ALLERGY CLIN IMMUN, V100, P656, DOI 10.1016/S0091-6749(97)70170-2; Schappi GF, 1997, SEX PLANT REPROD, V10, P315, DOI 10.1007/s004970050105; Schauer C, 2004, ANAL BIOANAL CHEM, V378, P725, DOI 10.1007/s00216-003-2449-1; SCHINKO HAE, 1994, ALLERGOLOGIE, V17, P514; Svartengren M, 2000, EUR RESPIR J, V15, P716, DOI 10.1034/j.1399-3003.2000.15d15.x; Umschlag T, 2002, PHYS CHEM CHEM PHYS, V4, P2975, DOI 10.1039/b110263j; Wahn U, 2000, ALLERGY, V55, P591, DOI 10.1034/j.1398-9995.2000.00111.x; Walcher W, 2003, J PROTEOME RES, V2, P534, DOI 10.1021/pr034034s; WUTHRICH B, 1995, INT ARCH ALLERGY IMM, V106, P149; Zhang Q, 2003, ATMOS ENVIRON, V37, P2247, DOI 10.1016/S1352-2310(03)00127-4	46	85	87	1	36	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X			ENVIRON SCI TECHNOL	Environ. Sci. Technol.	MAR 15	2005	39	6					1673	1678		10.1021/es0488737		6	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	906JF	WOS:000227636300044	15819224	
J	Pilette, C; Francis, JN; Till, SJ; Durham, SR				Pilette, C; Francis, JN; Till, SJ; Durham, SR			CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge	EUROPEAN RESPIRATORY JOURNAL			English	Article						allergen challenge; asthma; C-C chemokine receptor 4; chemokines; cytokines	BRONCHIAL EPITHELIAL-CELLS; CHEMOKINE RECEPTOR CXCR3; T-CELLS; IN-VIVO; TH2 CELLS; BRONCHOALVEOLAR LAVAGE; RESPIRATORY-DISEASE; EXPRESSION; LYMPHOCYTES; LUNG	T-helper (Th) 2 cytokines; are thought to mediate most features of allergic inflammation in atopic asthma. However, it remains unclear whether chemokine pathways direct selective recruitment of Th2 cells to the airways during human allergic responses. Bronchoalveolar lavage (BAL) was performed in 15 nonsmoking mild atopic asthmatics before and 24 h after a fibreoptic segmental allergen challenge, and chemokines related to T-cell recruitment were assayed by ELISA. The Th2-related C-C chemokine (CCR)4 ligands, macrophage-derived chemokine/C-C chemokine ligand (CCL)22 and thymus and activation-regulated chemokine/CCL17, were increased in BAL after challenge. These chemokines correlated significantly with lymphocyte numbers and with interleukin (IL)-5 and IL-13 in post-challenge B L. In contrast, two out of three putative Th1-related chemokines; did not change. There were no alterations in monokine induced by interferon (IFN)-gamma/CXC chemokine ligand (CXCL)9 or macrophage inflammatory protein-1alpha/CCL3; whereas a significant increase in IFN-induced protein-10kDa/CXCL 10 was observed, which did not correlate with the T-cell influx. In peripheral mononuclear cells from atopic donors, CCL22 and CCL17 were induced by IL-4 and IL-13, further supporting the relationship between CCL22/CCL17 and Th2 cytokines. Finally, CCL22 was able to trigger actin polymerisation in peripheral CD4+ T-cells expressing CCR4. Thus, C-C chemokine receptor 4 ligands are up-regulated in the airways of atopic asthmatics following allergen exposure, contribute to the T-cell influx to the airways and are closely related to the Th2-cytokine response.	Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, London SW3 6LY, England	Pilette, C (reprint author), Univ London Imperial Coll Sci & Technol, Natl Heart & Lung Inst, Dovehouse St, London SW3 6LY, England.	s.durham@imperial.ac.uk					Agostini C, 1998, J IMMUNOL, V161, P6413; Albanesi C, 2001, J LEUKOCYTE BIOL, V70, P617; Andrew DP, 2001, J IMMUNOL, V166, P103; Andrew DP, 1998, J IMMUNOL, V161, P5027; Annunziato F, 1999, J LEUKOCYTE BIOL, V65, P691; BENTLEY AM, 1993, AM J RESP CELL MOL, V8, P35; BRIGHTLING CE, 2003, EUR RESPIR J, pA187; Busse William W., 2003, Journal of Allergy and Clinical Immunology, V111, pS799, DOI 10.1067/mai.2003.158; CHO SH, 2002, CLIN EXP ALLERGY, V32, P1790; Ferrero E, 2003, IMMUNOLOGY, V108, P365, DOI 10.1046/j.1365-2567.2003.01600.x; Foussat A, 2000, EUR J IMMUNOL, V30, P87, DOI 10.1002/1521-4141(200001)30:1<87::AID-IMMU87>3.0.CO;2-7; Gallo SA, 2003, BBA-BIOMEMBRANES, V1614, P36, DOI 10.1016/S0005-2736(03)00161-5; Gonzalo JA, 1999, J IMMUNOL, V163, P403; Holt PG, 1998, IMMUNOL CELL BIOL, V76, P119; Kroegel C, 1996, EUR RESPIR J, V9, P899, DOI 10.1183/09031936.96.09050899; Kunkel EJ, 2002, AM J PATHOL, V160, P347, DOI 10.1016/S0002-9440(10)64378-7; Larche M, 2003, J ALLERGY CLIN IMMUN, V111, P450, DOI 10.1067/mai.2003.169; Lilly CM, 2001, AM J RESP CRIT CARE, V163, P1669; Lloyd CM, 2000, J EXP MED, V191, P265, DOI 10.1084/jem.191.2.265; Loetscher M, 1998, EUR J IMMUNOL, V28, P3696, DOI 10.1002/(SICI)1521-4141(199811)28:11<3696::AID-IMMU3696>3.0.CO;2-W; Magnan AO, 2000, AM J RESP CRIT CARE, V161, P1790; Medoff BD, 2002, J IMMUNOL, V168, P5278; Miotto D, 2001, J ALLERGY CLIN IMMUN, V107, P664, DOI 10.1067/mai.2001.113524; Nouri-Aria KT, 2002, EUR J IMMUNOL, V32, P1933, DOI 10.1002/1521-4141(200207)32:7<1933::AID-IMMU1933>3.0.CO;2-R; Panina-Bordignon P, 2001, J CLIN INVEST, V107, P1357, DOI 10.1172/JCI12655; PARRONCHI P, 1992, EUR J IMMUNOL, V22, P1615, DOI 10.1002/eji.1830220640; RENNARD SI, 1986, J APPL PHYSIOL, V60, P532; ROBINSON DS, 1993, J ALLERGY CLIN IMMUN, V92, P397, DOI 10.1016/0091-6749(93)90118-Y; Sabroe I, 2002, EUR RESPIR J, V19, P350, DOI 10.1183/09031936.02.00253602; Saetta M, 2002, AM J RESP CRIT CARE, V165, P1404, DOI 10.1164/rccm.2107139; Sallusto F, 1997, SCIENCE, V277, P2005, DOI 10.1126/science.277.5334.2005; Sauty A, 1999, J IMMUNOL, V162, P3549; Schipf A, 2003, EUR J IMMUNOL, V33, P1697, DOI 10.1002/eji.200323809; Schweitzer B, 2002, NAT BIOTECHNOL, V20, P359, DOI 10.1038/nbt0402-359; Sekiya T, 2000, J IMMUNOL, V165, P2205; Stephens R, 2002, J IMMUNOL, V169, P5458; Thomas MS, 2002, J IMMUNOL, V169, P7045; Till SJ, 1998, AM J RESP CRIT CARE, V158, P404	38	85	87	0	4	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	JUN	2004	23	6					876	884		10.1183/09031936.04.00102504		9	Respiratory System	Respiratory System	828TP	WOS:000221996500017	15219001	
J	Singh, P; DeMarini, DM; Dick, CAJ; Tabor, DG; Ryan, JV; Linak, WP; Kobayashi, T; Gilmour, MI				Singh, P; DeMarini, DM; Dick, CAJ; Tabor, DG; Ryan, JV; Linak, WP; Kobayashi, T; Gilmour, MI			Sample characterization of automobile and forklift diesel exhaust particles and comparative pulmonary toxicity in mice	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						automobile; diesel exhaust particles; forklift; mice; pulmonary toxicity; SRM 2975	AIRWAY INFLAMMATION; IGE PRODUCTION; EMISSIONS; PARTICULATE; EXPOSURE; HEALTH; HYPERRESPONSIVENESS; MUTAGENICITY; EXPRESSION; COMPONENTS	Two samples of diesel exhaust particles (DEPs) predominate in health effects research: an automobile-derived DEP (A-DEP) sample and the National Institute of Standards Technology standard reference material (SRM 2975) generated from a forklift engine. A-DEPs have been tested extensively for their effects on pulmonary inflammation and exacerbation of allergic asthma-like responses. In contrast, SRM 2975 has been tested thoroughly for its genotoxicity. In the present study, we combined physical and chemical analyses of both DEP samples with pulmonary toxicity testing in CD-I mice to compare the two materials and to make associations between their physicochemical properties and their biologic effects. A-DEPs had more than 10 times the amount of extractable organic material and less than one-sixth the amount of elemental carbon compared with SRM 2975. Aspiration of 100 mug of either DEP sample in saline produced mild acute lung injury; however, A-DEPs induced macrophage influx and activation, whereas SIRM 2975 enhanced polymorphonuclear cell inflammation. A-DEPs stimulated an increase in interleukin-6 (IL-6), tumor necrosis factor a, macrophage inhibitory protein-2, and the T(H)2 cytokine IL-5, whereas SRM 2975 only induced significant levels of IL-6. Fractionated organic extracts of the same quantity of DEPs (100 mug) did not have a discernable effect on lung responses and will require further study. The disparate results obtained highlight the need for chemical, physical, and source characterization of particle samples under investigation. Multidisciplinary toxicity testing of diesel emissions derived from a variety of generation and collection conditions is required to meaningfully assess the health hazards associated with exposures to DEPs.	US EPA, Natl Hlth & Environm Effects Res Lab, Res Triangle Pk, NC 27711 USA; Univ N Carolina, Ctr Environm Med & Lung Biol, Chapel Hill, NC USA; US EPA, Natl Risk Management Res Lab, Res Triangle Pk, NC 27711 USA; Natl Inst Environm Studies, Environm Hlth Sci Div, Tsukuba, Ibaraki, Japan	Singh, P (reprint author), US EPA, Natl Hlth & Environm Effects Res Lab, MD B143-01, Res Triangle Pk, NC 27711 USA.	singh.pramila@epa.gov					Boland S., 1999, AM J PHYSIOL, V276, P604; Claxton L, 1992, MUTAT RES, V276, P1; CLAXTON LD, 1983, ENVIRON MUTAGEN, V5, P609, DOI 10.1002/em.2860050410; DeMarini DM, 2004, ENVIRON HEALTH PERSP, V112, P814; DiazSanchez D, 1997, ALLERGY, V52, P52; Dick CAJ, 2003, INHAL TOXICOL, V15, P39, DOI 10.1080/08958370304454; Donaldson K, 1996, TOXICOL LETT, V88, P293, DOI 10.1016/0378-4274(96)03752-6; Driscoll KE, 2000, TOXICOL SCI, V55, P24, DOI 10.1093/toxsci/55.1.24; Foster WM, 2001, J APPL PHYSIOL, V90, P1111; Granum B, 2002, TOXICOL SCI, V65, P7, DOI 10.1093/toxsci/65.1.7; Heo Y, 2001, TOXICOLOGY, V159, P143, DOI 10.1016/S0300-483X(00)00418-2; Hughes TJ, 1997, MUTAT RES-GEN TOX EN, V391, P243, DOI 10.1016/S1383-5718(97)00075-2; Kawasaki S, 2001, AM J RESP CELL MOL, V24, P419; KOBAYASHI T, 1995, FUND APPL TOXICOL, V27, P195, DOI 10.1006/faat.1995.1124; Lewtas J., 1982, TOXICOLOGICAL EFFECT; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Lovik M, 1997, TOXICOLOGY, V121, P165, DOI 10.1016/S0300-483X(97)00075-9; Madden MC, 2000, TOXICOL APPL PHARM, V168, P140, DOI 10.1006/taap.2000.9024; Mauderly JL, 2001, TOXICOL SCI, V62, P6, DOI 10.1093/toxsci/62.1.6; METZGER JM, 1988, IMMUNOPHARMACOLOGY, V15, P103, DOI 10.1016/0162-3109(88)90057-4; MILLER NJ, 1993, CLIN SCI, V84, P407; Miyabara Y, 1998, AM J RESP CRIT CARE, V157, P1138; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; National Institute for Occupational Safety and Health (NIOSH), 1994, DHHS NIOSH PUBL; *NIST, 2000, CERT AN STAND REF MA; Pope CA, 2002, JAMA-J AM MED ASSOC, V287, P1132, DOI 10.1001/jama.287.9.1132; Rosenkranz HS, 1996, MUTAT RES-GENET TOX, V367, P65, DOI 10.1016/0165-1218(95)00066-6; SAGAI M, 1993, FREE RADICAL BIO MED, V14, P37, DOI 10.1016/0891-5849(93)90507-Q; Salvi SS, 2000, AM J RESP CRIT CARE, V161, P550; SCHUETZLE D, 1983, ENVIRON HEALTH PERSP, V47, P65, DOI 10.2307/3429500; Seagrave J, 2002, TOXICOL SCI, V70, P212, DOI 10.1093/toxsci/70.2.212; Sydbom A, 2001, EUR RESPIR J, V17, P733, DOI 10.1183/09031936.01.17407330; Takano H, 1997, AM J RESP CRIT CARE, V156, P36; Tsien A, 1997, TOXICOL APPL PHARM, V142, P256, DOI 10.1006/taap.1996.8063; Weir E, 2002, CAN MED ASSOC J, V167, P505; Wilhelm M, 2003, ENVIRON HEALTH PERSP, V111, P207, DOI 10.1289/ehp.5688	36	85	85	3	15	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JUN	2004	112	8					820	825		10.1289/ehp.6579		6	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	829BO	WOS:000222018200028	15175167	
J	Monninkhof, E; van der Valk, P; van der Palen, J; van Herwaarden, C; Zielhuis, G				Monninkhof, E; van der Valk, P; van der Palen, J; van Herwaarden, C; Zielhuis, G			Effects of a comprehensive self-management programme in patients with chronic obstructive pulmonary disease	EUROPEAN RESPIRATORY JOURNAL			English	Article						chronic obstructive lung disease; patient education; quality of life; randomised controlled trial; self-management	QUALITY-OF-LIFE; AIR-FLOW LIMITATION; 6-MINUTE WALK TEST; FLUTICASONE PROPIONATE; CONTROLLED TRIAL; HEALTH-STATUS; LUNG-DISEASE; EDUCATION; ASTHMA; COPD	The aim of this study was to assess the effects of a comprehensive self-management intervention on health-related quality of life (HRQoL), symptoms and walking distance in patients with stable moderately severe chronic obstructive pulmonary disease (COPD). This study was part of the overall COPD study of the Dept of Pulmonary Medicine, Enschede, which consisted of an inhaled corticosteroid (ICS) trial and a self-management trial. After the ICS trial, all patients were randomised again to a self-management and a control group. The self-management intervention consisted of a skill-oriented patient education programme and a near-home fitness programme, on top of usual care. The control group received usual care by the treating chest physician. HRQoL was measured by the St George's Respiratory Questionnaire (SGRQ) and walking distance by the 6-min walking test. Patients recorded their symptoms in diaries and graded their health status from 1-10 in a weekly report. Altogether, 248 COPD patients were randomly allocated to either an intervention (127) or control (121) group. No differences in the SGRQ scores within and between both groups were observed over I yr. Similarly, no differences in symptom scores and 6-min walking distance were found within and between groups. The intervention group reported more exacerbations than the control group. The majority (69%) of the exacerbations in the intervention group were self-treated at home. This study failed to show positive effects of a self-management programme among moderately severe chronic obstructive pulmonary disease patients.	Med Spectrum Twente, Dept Pulm Med, NL-7500 KA Enschede, Netherlands; Univ Nijmegen, Med Ctr, Dept Epidemiol & Biostat, Nijmegen, Netherlands; Univ Nijmegen, Med Ctr, Dept Pulm Med, Nijmegen, Netherlands	Monninkhof, E (reprint author), Med Spectrum Twente, Dept Pulm Med, POB 50000, NL-7500 KA Enschede, Netherlands.		Zielhuis, Gerhard/D-4229-2009; Zielhuis, Gerhard/H-8123-2014				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P77; American Thoracic Society, 1999, AM J RESP CRIT CARE, V159, P1666; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Bourbeau J, 2003, ARCH INTERN MED, V163, P585, DOI 10.1001/archinte.163.5.585; BRAND PLP, 1992, THORAX, V47, P429, DOI 10.1136/thx.47.6.429; Burge PS, 2000, BRIT MED J, V320, P1297, DOI 10.1136/bmj.320.7245.1297; BUTLAND RJA, 1982, BRIT MED J, V284, P1607; CASABURI R, 1991, AM REV RESPIR DIS, V143, P9; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Gallefoss F, 1999, AM J RESP CRIT CARE, V160, P2000; Gallefoss F, 1999, AM J RESP CRIT CARE, V159, P812; GIBSON PG, 2000, COCHRANE DATABASE SY; Gosselink R, 1996, AM J RESP CRIT CARE, V153, P976; JONES PW, 1992, AM REV RESPIR DIS, V145, P1321; Jones PW, 1997, AM J RESP CRIT CARE, V155, P1283; Jones PW, 2002, EUR RESPIR J, V19, P398, DOI 10.1183/09031936.02.00063702; Klein JJ, 2001, EUR RESPIR J, V17, P386, DOI 10.1183/09031936.01.17303860; LITTLEJOHNS P, 1991, THORAX, V46, P559, DOI 10.1136/thx.46.8.559; LORIG KR, 1993, ARTHRITIS RHEUM, V36, P439, DOI 10.1002/art.1780360403; MONNINKHOF E, 2003, IN PRESS PATIENT ED; MONNINKHOF EM, 2003, COCHRANE DATABASE SY; Norris SL, 2001, DIABETES CARE, V24, P561, DOI 10.2337/diacare.24.3.561; Paggiaro PL, 1998, LANCET, V351, P773, DOI 10.1016/S0140-6736(97)03471-5; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Redelmeier DA, 1997, AM J RESP CRIT CARE, V155, P1278; SCHOLS AMWJ, 1991, THORAX, V46, P695, DOI 10.1136/thx.46.10.695; Seemungal TAR, 1998, AM J RESP CRIT CARE, V157, P1418; SuperioCabuslay E, 1996, ARTHRIT CARE RES, V9, P292, DOI 10.1002/1529-0131(199608)9:4<292::AID-ANR1790090414>3.0.CO;2-4; van der Valk P, 2002, AM J RESP CRIT CARE, V166, P1358, DOI 10.1164/rccm.200206-512OC; Watson PB, 1997, EUR RESPIR J, V10, P1267, DOI 10.1183/09031936.97.10061267; Wouters EF, 2002, CHEST, V121, P127; WOUTERS EFM, 1999, EUR RESPIR REV, V9, P189	32	85	88	0	7	EUROPEAN RESPIRATORY SOC JOURNALS LTD	SHEFFIELD	146 WEST ST, STE 2.4, HUTTONS BLDG, SHEFFIELD S1 4ES, ENGLAND	0903-1936			EUR RESPIR J	Eur. Resp. J.	NOV	2003	22	5					815	820		10.1183/09031936.03.00047003		6	Respiratory System	Respiratory System	739UE	WOS:000186364200019	14621090	
J	Gavett, SH; Haykal-Coates, N; Copeland, LB; Heinrich, J; Gilmour, MI				Gavett, SH; Haykal-Coates, N; Copeland, LB; Heinrich, J; Gilmour, MI			Metal composition of ambient PM2.5 influences severity of allergic airways disease in mice	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						air pollution; airway hyperresponsiveness; allergic sensitization; asthma; epidemiology; inflammation; metals	OIL FLY-ASH; HOUSE-DUST MITE; AIR-POLLUTION; RESPIRATORY SYMPTOMS; PULMONARY TOXICITY; INTERFERON-GAMMA; UTAH VALLEY; LUNG INJURY; SENSITIZATION; ASTHMA	Children living in Hettstedt in eastern Germany have been reported to have a higher prevalence of sensitization to common aeroallergens than another cohort living in the neighboring city of Zerbst; these differences correlated with the presence of industrial air pollution. Samples of fine particulate matter (< 2.5 mum aerodynamic diameter; PM2.5) collected in Hettstedt in 1999 had several-fold higher levels of zinc, magnesium, lead, copper, and cadmium than samples from Zerbst. To determine if the results from epidemiologic studies could be repeated in an animal model, we administered PM2.5 from Hettstedt and Zerbst to ovalbumin-allergic mice. In Balb/c mice, PM2.5 from Hettstedt, but not PM2.5 from Zerbst or control filter extract, caused a significant increase in immediate responses to ovalbumin challenge when aspirated 2 hr before challenge, but not when aspirated immediately before sensitization 2 weeks earlier. Antigen-specific IgE was increased by Flettstedt PM2.5 whether administered before sensitization or challenge. Airway responsiveness to methacholine aerosol and lung inflammatory cell numbers were significantly increased only, in allergic mice exposed to Hettstedt PM2.5 before challenge. Both Hettstedt and Zerbst PM2.5 significantly increased lung injury parameters and proinflammatory cytokines. These results are consistent with epidemiologic findings and show that metal composition of ambient PM, 5 influences the severity of allergic respiratory disease.	US EPA, Div Environm Toxicol, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA; GSF, Res Ctr Environm & Hlth, Inst Epidemiol, Neuherberg, Germany	Gavett, SH (reprint author), US EPA, Div Environm Toxicol, Natl Hlth & Environm Effects Res Lab, Off Res & Dev, B143-02, Res Triangle Pk, NC 27711 USA.						Biran R, 1996, INT J ENVIRON AN CH, V63, P315, DOI 10.1080/03067319608028327; Chew FT, 1999, ALLERGY, V54, P320, DOI 10.1034/j.1398-9995.1999.00012.x; Chung F, 2001, MEDIAT INFLAMM, V10, P51, DOI 10.1080/09629350120054518; Diaz-Sanchez D, 1999, J ALLERGY CLIN IMMUN, V104, P1183; Dye JA, 2001, ENVIRON HEALTH PERSP, V109, P395, DOI 10.2307/3434787; Dye JA, 1999, AM J PHYSIOL-LUNG C, V277, pL498; Foster WM, 2001, J APPL PHYSIOL, V90, P1111; Gavett SH, 1999, AM J RESP CRIT CARE, V160, P1897; Gavett SH, 1997, ENVIRON RES, V72, P162, DOI 10.1006/enrs.1997.3732; Ghio AJ, 2002, ENVIRON HEALTH PERSP, V110, P89; Ghio AJ, 2001, AM J RESP CRIT CARE, V164, P704; Hamelmann E, 1997, AM J RESP CRIT CARE, V156, P766; Heinrich J, 1999, ENVIRON HEALTH PERSP, V107, P53, DOI 10.2307/3434289; Heinrich J, 2002, EUR RESPIR J, V19, P1040, DOI 10.1183/09031936.02.00261802; Heinrich J, 2002, EPIDEMIOLOGY, V13, P394, DOI 10.1097/01.EDE.00000016977.59359.B6; Heinrich J, 2000, AM J RESP CRIT CARE, V161, P1930; HENDERSON RF, 1985, FUND APPL TOXICOL, V5, P451, DOI 10.1016/0272-0590(85)90092-2; Hylkema MN, 2002, AM J RESP CELL MOL, V27, P244; Kobayashi T, 2000, AM J RESP CRIT CARE, V162, P352; Lambert AL, 2001, EXP LUNG RES, V27, P617, DOI 10.1080/019021401753181863; Lambert AL, 1999, TOXICOL APPL PHARM, V158, P269, DOI 10.1006/taap.1999.8709; Lambert AL, 2000, TOXICOL APPL PHARM, V165, P84, DOI 10.1006/taap.2000.8932; Medoff BD, 2002, J IMMUNOL, V168, P5278; Ostro B, 2001, EPIDEMIOLOGY, V12, P200, DOI 10.1097/00001648-200103000-00012; Patton L, 2002, ALLERGY ASTHMA PROC, V23, P9; Peden DB, 2001, ANN ALLERG ASTHMA IM, V87, P12; POPE CA, 1989, AM J PUBLIC HEALTH, V79, P623, DOI 10.2105/AJPH.79.5.623; Salvi S, 2001, Curr Opin Allergy Clin Immunol, V1, P35; Steerenberg PA, 1999, INHAL TOXICOL, V11, P1109; *US EPA, 2002, 6020A US EPA; *US EPA, 2002, EPA600491010; *US EPA, 2002, AIR TRENDS 6 PRINC P; Yoshida M, 2002, AM J RESP CRIT CARE, V166, P451, DOI 10.1164/rccm.200202-0950C	33	85	91	5	37	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	SEP	2003	111	12					1471	1477		10.1289/ehp.6300		7	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	733HZ	WOS:000185995500027	12948886	
J	Duits, LA; Nibbering, PH; van Strijen, E; Vos, JB; Mannesse-Lazeroms, SPG; van Sterkenburg, MAJA; Hiemstra, PS				Duits, LA; Nibbering, PH; van Strijen, E; Vos, JB; Mannesse-Lazeroms, SPG; van Sterkenburg, MAJA; Hiemstra, PS			Rhinovirus increases human beta-defensin-2 and -3 mRNA expression in cultured bronchial epithelial cells	FEMS IMMUNOLOGY AND MEDICAL MICROBIOLOGY			English	Article						antimicrobial peptide; defensin; epithelium; rhinovirus; respiratory infection	DOUBLE-STRANDED-RNA; HUMAN AIRWAY EPITHELIA; NITRIC-OXIDE SYNTHASE; BETA-DEFENSINS; DENDRITIC CELLS; CYSTIC-FIBROSIS; INHIBITION; INTERFERON; GENE; REPLICATION	Human beta-defensins (hBDs) are antimicrobial peptides that play important roles in host defense against infection, inflammation and immunity. Previous studies showed that micro-organisms and proinflammatory mediators regulate the expression of these peptides in airway epithelial cells. The aim of the present study was to investigate the modulation of expression of hBDs in cultured primary bronchial epithelial cells (PBEC) by rhinovirus-16 (RV16), a respiratory virus responsible for the common cold and associated with asthma exacerbations. RV16 was found to induce expression of hBD-2 and -3 mRNA in PBEC, but did not affect hBD-1 mRNA. Viral replication appeared essential for rhinovirus-induced beta-defensin mRNA expression, since UV-inactivated rhinovirus did not increase expression of hBD-2 and hBD-3 mRNA. Exposure to synthetic double-stranded RNA (dsRNA) molecule polyinosinic:polycytidylic acid had a similar effect as RV16 on mRNA expression of these peptides in PBEC. In line with this, PBEC were found to express TLR3, a Toll-like receptor involved in recognition of dsRNA. This study shows that rhinovirus infection of PBEC leads to increased hBD-2 and hBD-3 mRNA expression, which may play a role in both the uncomplicated common cold and in virus-associated exacerbations of asthma. (C) 2003 Federation of European Microbiological Societies. Published by Elsevier Science B.V. All rights reserved.	Leiden Univ, Ctr Med, Dept Pulmonol, NL-2300 RC Leiden, Netherlands; Leiden Univ, Ctr Med, Dept Infect Dis, NL-2300 RC Leiden, Netherlands	Hiemstra, PS (reprint author), Leiden Univ, Ctr Med, Dept Pulmonol, POB 9600, NL-2300 RC Leiden, Netherlands.			Vos, Joost/0000-0003-0088-4275			Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Birchler T, 2001, EUR J IMMUNOL, V31, P3131, DOI 10.1002/1521-4141(200111)31:11<3131::AID-IMMU3131>3.0.CO;2-G; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DAHER KA, 1986, J VIROL, V60, P1068; Dauletbaev N, 2002, RESPIRATION, V69, P46, DOI 10.1159/000049369; DEGOUW HWF, 2000, EUR RESPIR J, V15, pS219; Duits LA, 2002, IMMUNOLOGY, V106, P517, DOI 10.1046/j.1365-2567.2002.01430.x; Duits LA, 2001, BIOCHEM BIOPH RES CO, V280, P522, DOI 10.1006/bbrc.2000.4157; FORSBERG K, 1988, J CELL PHYSIOL, V136, P266, DOI 10.1002/jcp.1041360208; Ganz T, 2001, Semin Respir Infect, V16, P4; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Gern JE, 1996, J IMMUNOL, V157, P1605; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Gropp R, 1999, HUM GENE THER, V10, P957, DOI 10.1089/10430349950018355; Harder J, 2000, AM J RESP CELL MOL, V22, P714; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; HEINZEL R, 1986, EUR J BIOCHEM, V160, P61, DOI 10.1111/j.1432-1033.1986.tb09940.x; HUSSAIN IR, 2000, AM J RESP CRIT CARE, V161, pA349; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Jia HP, 2001, GENE, V263, P211; KARUPIAH G, 1993, SCIENCE, V261, P1445, DOI 10.1126/science.7690156; Krug A, 2001, EUR J IMMUNOL, V31, P3026, DOI 10.1002/1521-4141(2001010)31:10<3026::AID-IMMU3026>3.0.CO;2-H; Lee J.-L., 1995, ETRI Journal, V16; Lehrer RI, 2002, CURR OPIN IMMUNOL, V14, P96, DOI 10.1016/S0952-7915(01)00303-X; MARAN A, 1990, MOL CELL BIOL, V10, P4424; McCray PB, 1997, AM J RESP CELL MOL, V16, P343; MELKOVA Z, 1995, J IMMUNOL, V155, P5711; Moser C, 2002, INFECT IMMUN, V70, P3068, DOI 10.1128/IAI.70.6.3068-3072.2002; NAKASHIMA H, 1993, AIDS, V7, P1129, DOI 10.1097/00002030-199308000-00019; NICHOLSON KG, 1993, BRIT MED J, V307, P982; Niyonsaba F, 2001, EUR J IMMUNOL, V31, P1066, DOI 10.1002/1521-4141(200104)31:4<1066::AID-IMMU1066>3.0.CO;2-#; O'Neil DA, 1999, J IMMUNOL, V163, P6718; PROUD D, 2001, AM J RESP CRIT CARE, V163, pA466; Rueckert R., 1996, FIELDS VIROLOGY, P609; SALLENAVE JM, 1994, AM J RESP CELL MOL, V11, P733; Schutte BC, 2002, P NATL ACAD SCI USA, V99, P2129, DOI 10.1073/pnas.042692699; Singh PK, 2000, AM J PHYSIOL-LUNG C, V279, pL799; Singh PK, 1998, P NATL ACAD SCI USA, V95, P14961, DOI 10.1073/pnas.95.25.14961; Snell JC, 1997, J LEUKOCYTE BIOL, V62, P369; STOLK J, 1998, MOL BIOL LUNG, V1, P55; SUBAUSTE MC, 1995, J CLIN INVEST, V96, P549, DOI 10.1172/JCI118067; TOKUNAGA K, 1987, CANCER RES, V47, P5616; Van Wetering S, 2000, AM J PHYSIOL-LUNG C, V278, pL51; VILCEK J, 1987, J CELL PHYSIOL, V130, P37, DOI 10.1002/jcp.1041300107; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525; Yang D, 2001, J LEUKOCYTE BIOL, V69, P691; Yasin B, 2000, EUR J CLIN MICROBIOL, V19, P187, DOI 10.1007/s100960050457	48	85	95	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0928-8244			FEMS IMMUNOL MED MIC	FEMS Immunol. Med. Microbiol.	AUG 18	2003	38	1					59	64		10.1016/S0928-8244(03)00106-8		6	Immunology; Infectious Diseases; Microbiology	Immunology; Infectious Diseases; Microbiology	711GE	WOS:000184730600009	12900056	
J	Steerenberg, PA; Janssen, NAH; de Meer, G; Fischer, PH; Nierkens, S; van Loveren, H; Opperhuizen, A; Brunekreef, B; van Amsterdam, JGC				Steerenberg, PA; Janssen, NAH; de Meer, G; Fischer, PH; Nierkens, S; van Loveren, H; Opperhuizen, A; Brunekreef, B; van Amsterdam, JGC			Relationship between exhaled NO, respiratory symptoms, lung function, bronchial hyperresponsiveness, and blood eosinophilia in school children	THORAX			English	Article							NASAL NITRIC-OXIDE; ASTHMATIC-PATIENTS; ALLERGIC RHINITIS; AIR-POLLUTION; MILD ASTHMA; RESPONSIVENESS; INHIBITOR; SYNTHASE; SEASON; SAMPLE	Background: Exhaled nitric oxide (eNO) may serve as a non-invasive marker of airway inflammation but its relationship with other commonly used measures has not been evaluated. Methods: Levels of eNO in a sample of 450 children aged 7-12 years out of a total sample of 2504 school children living in different urban areas near motorways were determined. The aim of this cross-sectional study was to explore the relationship between eNO, impairment of lung function (PEF, FVC, FEV1 and MMEF), bronchial hyperresponsiveness (BHR), and blood eosinophilia in children with and without atopy as assessed by skin prick testing. Results: Regression analysis showed that wheezing and nasal discharge and conjunctivitis that had occurred during the previous 12 months were positively associated with eNO levels in atopic children (relative increase of 1.48 and 1.41, respectively; p<0.05) but not in non-atopic children. Similarly, BHR and the number of blood eosinophils per ml were positively associated with eNO levels in atopic children (relative increase of 1.55 and 2.29, respectively; p<0.05) but not in non-atopic children. The lung function indices PEF, FVC, FEV, and MMEF were not associated with eNO levels. Conclusions: In addition to conventional lung function tests and symptom questionnaires, eNO is a suitable measure of airway inflammation and its application may reinforce the power of epidemiological surveys on respiratory health.	Natl Inst Publ Hlth & Environm, RIVM, Lab Pathol & Immunobiol, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Dept Chron Dis & Environm Epidemiol, NL-3720 BA Bilthoven, Netherlands; Natl Inst Publ Hlth & Environm, Hlth Effects Res Lab, NL-3720 BA Bilthoven, Netherlands; Univ Utrecht, Inst Risk Assessment Sci, Environm & Occupat Hlth Div, Utrecht, Netherlands	Steerenberg, PA (reprint author), Natl Inst Publ Hlth & Environm, RIVM, Lab Pathol & Immunobiol, POB 1, NL-3720 BA Bilthoven, Netherlands.			brunekreef, bert/0000-0001-9908-0060			ABERG N, 1989, CLIN EXP ALLERGY, V19, P643, DOI 10.1111/j.1365-2222.1989.tb02761.x; ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; Adisesh LA, 1998, CLIN EXP ALLERGY, V28, P876; ALVING K, 1993, EUR RESPIR J, V6, P1368; Arnal JF, 1997, CLIN EXP ALLERGY, V27, P358; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Barnes PJ, 1996, THORAX, V51, P218, DOI 10.1136/thx.51.2.218; Berlyne G, 2000, LANCET, V355, P1029, DOI 10.1016/S0140-6736(00)02027-4; Boezen HM, 1996, AM J RESP CRIT CARE, V154, P30; BRUSASCO V, 1990, J APPL PHYSIOL, V69, P2209; DURHAM SR, 1985, CLIN ALLERGY, V15, P411, DOI 10.1111/j.1365-2222.1985.tb02290.x; Fischer PH, 2002, INT ARCH OCC ENV HEA, V75, P348, DOI 10.1007/s00420-002-0320-x; Frangova V, 1996, CHEST, V110, P1236, DOI 10.1378/chest.110.5.1236; Garnier P, 1996, EUR RESPIR J, V9, P1134, DOI 10.1183/09031936.96.09061134; Gratziou C, 2001, CLIN EXP ALLERGY, V31, P409, DOI 10.1046/j.1365-2222.2001.01001.x; GUSTAFSSON LE, 1998, EUR RESPIR J, V11, P49; Hoekstra MO, 1998, PEDIATR ALLERGY IMMU, V9, P143, DOI 10.1111/j.1399-3038.1998.tb00361.x; Jatakanon A, 1998, THORAX, V53, P91; Jobsis Q, 2001, THORAX, V56, P285, DOI 10.1136/thorax.56.4.285; KARTASAMITA CB, 1994, J ALLERGY CLIN IMMUN, V94, P981, DOI 10.1016/0091-6749(94)90116-3; Kharitonov S, 1997, EUR RESPIR J, V10, P1683, DOI 10.1183/09031936.97.10071683; KHARITONOV SA, 1994, LANCET, V343, P133, DOI 10.1016/S0140-6736(94)90931-8; Kharitonov SA, 1996, AM J RESP CRIT CARE, V153, P454; KUEHR J, 1994, EUR J PEDIATR, V153, P739, DOI 10.1007/BF01954491; MacPherson JC, 2001, J IMMUNOL, V166, P5763; Martin U, 1996, J ALLERGY CLIN IMMUN, V97, P768, DOI 10.1016/S0091-6749(96)80154-0; Quanjer PH, 1993, EUR RESPIR J S, V16, P5, DOI 10.1183/09041950.005s1693; Salome CM, 1999, AM J RESP CRIT CARE, V159, P911; Silvestri M, 1999, ANN ALLERG ASTHMA IM, V83, P335, DOI 10.1016/S1081-1206(10)62674-9; Slutsky AS, 1999, AM J RESP CRIT CARE, V160, P2104; Steerenberg PA, 1999, EUR RESPIR J, V13, P334, DOI 10.1034/j.1399-3003.1999.13b19.x; Steerenberg PA, 2000, NITRIC OXIDE-BIOL CH, V4, P168, DOI 10.1006/niox.2000.0282; van Amsterdam JGC, 1999, NITRIC OXIDE-BIOL CH, V3, P492, DOI 10.1006/niox.1999.0258; van Amsterdam JGC, 1999, INT ARCH OCC ENV HEA, V72, P404, DOI 10.1007/s004200050392; VANAMSTERDAM JGC, 2003, IN PRESS CLIN EXP AL; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892; Yates DH, 1996, AM J RESP CRIT CARE, V154, P247; [Anonymous], 1993, ALLERGY, V48, P48	38	85	90	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	MAR	2003	58	3					242	245		10.1136/thorax.58.3.242		4	Respiratory System	Respiratory System	654AV	WOS:000181470900013	12612304	
J	Schuster, MA; Franke, T; Pham, CB				Schuster, MA; Franke, T; Pham, CB			Smoking patterns of household members and visitors in homes with children in the United States	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; NUTRITION EXAMINATION SURVEY; INFANT-DEATH-SYNDROME; PASSIVE SMOKING; PARENTAL SMOKING; MATERNAL SMOKING; CIGARETTE-SMOKING; CHILDHOOD ASTHMA; URINARY COTININE; NATIONAL-HEALTH	Background: Environmental tobacco smoke (ETS), also called passive smoking, has been shown to have adverse effects on the health of children. Objective: To determine the prevalence and pattern of ETS exposure in US homes with children younger than 18 years. Design: We analyzed data from the 1994 National Health Interview Survey and Year 2000 Objectives supplement. A multistage sample design was used to represent the civilian, noninstitutionalized population of the United States. Main Outcome Measures: Frequency of smoking by household residents and visitors in homes with children. Results: Thirty-five percent of children in the United States-21 million children-live in homes where residents or visitors smoke in the home on a regular basis (greater than or equal to I d/wk). From the household perspective, regular smoking by residents and visitors occurs in 36% of homes in which children reside. in 92% of homes with children where residents smoke at home, they do so every day of the week. Sixteen percent of nonsmoking respondents with children report that other residents or visitors smoke in the home. In 6% of the homes where no residents smoke, there is nevertheless regular smoking by visitors. In multivariate regression analysis, the prevalence of regular smoking in homes with children varies by age of youngest child, race/ethnicity, number of parents in the home, parental educational level, income, and region of the country. Conclusions: Many children live in homes with ETS. Most respondents who smoke report that smoking occurs in the home every day. Visitors are an additional source of ETS in homes, including some homes where residents do not smoke. Clinicians who take care of children can advise parents, whether or not they smoke, on how to limit their children's ETS exposure.	RAND Corp, Santa Monica, CA 90407 USA; Univ Calif Los Angeles, Sch Med, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Sch Social Welf, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA; Univ Calif Los Angeles, Dept Hlth Serv, Los Angeles, CA 90024 USA	Schuster, MA (reprint author), RAND Corp, 1700 Main St, Santa Monica, CA 90407 USA.				ODCDC CDC HHS [U48/CCU915773]		Adair-Bischoff CE, 1998, ARCH PEDIAT ADOL MED, V152, P127; *AM MED ASS COUNC, 1994, ARCH FAM MED, V3, P865; Ashley MJ, 1998, TOB CONTROL, V7, P61; Ashley MJ, 1998, AM J PUBLIC HEALTH, V88, P797, DOI 10.2105/AJPH.88.5.797; BAKER, 1997, WASHINGTON POST 0805, pA1; Bal DG, 2001, J CLIN ONCOL, V19, p69S; BECHER H, 1992, EPIDEMIOLOGY, V3, P509, DOI 10.1097/00001648-199211000-00008; Biener L, 1997, PREV MED, V26, P358, DOI 10.1006/pmed.1997.0152; Burnett KF, 1999, CLIN PEDIATR, V38, P339, DOI 10.1177/000992289903800604; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P1038; Centers for Disease Control and Prevention, STAT TOB ACT TRACK E; Chan-Yeung M, 2000, ARCH PEDIAT ADOL MED, V154, P657; Christakis DA, 2001, ARCH PEDIAT ADOL MED, V155, P15; CLAIRBORNE W, 1998, WASHINGTON POST 0217, V17, pA3; COGHLIN J, 1989, AM J EPIDEMIOL, V130, P696; EY JL, 1995, PEDIATRICS, V95, P670; EZRA DB, 1994, ST LOUIS U PUB L REV, V13, P547; Farkas AJ, 2000, JAMA-J AM MED ASSOC, V284, P717, DOI 10.1001/jama.284.6.717; Farkas AJ, 1999, TOB CONTROL, V8, P261; Fergusson D M, 1985, Pediatr Pulmonol, V1, P99, DOI 10.1002/ppul.1950010208; Fiore MC, 2000, JAMA-J AM MED ASSOC, V283, P3244; Gergen PJ, 1998, PEDIATRICS, V101, part. no., DOI 10.1542/peds.101.2.e8; Gergen PJ, 2001, RESP PHYSIOL, V128, P39, DOI 10.1016/S0034-5687(01)00263-8; Gilpin E A, 1999, Nicotine Tob Res, V1, P153, DOI 10.1080/14622299050011261; Gilpin EA, 2000, AM J EPIDEMIOL, V152, P727, DOI 10.1093/aje/152.8.727; Glantz SA, 2000, PEDIATRICS, V106, part. no., DOI 10.1542/peds.106.6.e82; Golding J, 1997, PAEDIATR PERINAT EP, V11, P67, DOI 10.1046/j.1365-3016.1997.d01-12.x; Groner JA, 2000, PEDIATRICS, V105, P267; Hopper JA, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.4.e47; Hovell MF, 2000, BRIT MED J, V321, P337, DOI 10.1136/bmj.321.7257.337; Hovell M, 2000, Tobacco Control, V9, P1140; Ilicali OC, 1999, ARCH OTOLARYNGOL, V125, P758; King G, 1998, Conn Med, V62, P531; KLEIN JD, 1995, PEDIATRICS, V96, P326; Kline RL, 2000, TOB CONTROL, V9, P201, DOI 10.1136/tc.9.2.201; KLONOFFCOHEN HS, 1995, JAMA-J AM MED ASSOC, V273, P795, DOI 10.1001/jama.273.10.795; KOSOWER E, 1995, ARCH PEDIAT ADOL MED, V149, P430; Lam TH, 2001, PEDIATRICS, V107, part. no., DOI 10.1542/peds.107.6.e91; Leech JA, 1999, CAN J PUBLIC HEALTH, V90, P244; Li JS, 1999, PEDIATR PULM, V27, P5, DOI 10.1002/(SICI)1099-0496(199901)27:1<5::AID-PPUL3>3.0.CO;2-5; Mannino D M, 1996, Tob Control, V5, P13, DOI 10.1136/tc.5.1.13; Mannino DM, 2001, ARCH PEDIAT ADOL MED, V155, P36; MCMARTIN KI, 2002, J PEDIATR, V104, P205; Moskowitz WB, 1999, ARCH PEDIAT ADOL MED, V153, P446; NAVARRO M, 1997, NEW YORK TIMES A, V1, pA1; NEUSPIEL DR, 1989, AM J PUBLIC HEALTH, V79, P168, DOI 10.2105/AJPH.79.2.168; Norman GJ, 1999, PREV MED, V29, P581, DOI 10.1006/pmed.1999.0574; Overpeck MD, 1991, ADV DATA, V202, P1; Ownby DR, 2000, ARCH PEDIAT ADOL MED, V154, P1237; PEDREIRA FA, 1985, PEDIATRICS, V75, P594; Perez-Stable EJ, 2001, ARCH PEDIAT ADOL MED, V155, P25; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233; *PUBL HLTH SERV US, 1991, HLTH PEOPL 2000; RIBOLI E, 1990, CANCER CAUSE CONTROL, V1, P243, DOI 10.1007/BF00117476; RIGOTTI NA, 1991, JAMA-J AM MED ASSOC, V266, P3162; Schwartz J, 2000, AM J RESP CRIT CARE, V161, P802; SCHYDLOWER M, 1994, PEDIATRICS, V93, P866; Sciacca JP, 1996, J COMMUN HEALTH, V21, P133, DOI 10.1007/BF01682304; Siegel M, 2000, AM J PUBLIC HEALTH, V90, P372, DOI 10.2105/AJPH.90.3.372; STEIN RJ, 2000, PEDIATRICS; U. S. Department of Health and Human Services, 2000, HLTH PEOPL 2010; Wahlgren DR, 1997, CHEST, V111, P81, DOI 10.1378/chest.111.1.81; Wakefield MA, 2000, BRIT MED J, V321, P333, DOI 10.1136/bmj.321.7257.333; WALL MA, 1995, PEDIATRICS, V96, P622; WEITZMAN M, 1990, PEDIATRICS, V85, P505; Whitlock G, 1998, TOB CONTROL, V7, P276; *WHO DIV NONC DIS, INT CONS ENV TOB SMO; WILLERS S, 1995, ARCH ENVIRON HEALTH, V50, P130; WILLERS S, 1991, ALLERGY, V46, P330, DOI 10.1111/j.1398-9995.1991.tb00595.x; AM NONSM RIGHTS WEB	70	85	89	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	1072-4710			ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	NOV	2002	156	11					1094	1100				7	Pediatrics	Pediatrics	612AJ	WOS:000179050700006	12413336	
J	Faergemann, J				Faergemann, J			Atopic dermatitis and fungi	CLINICAL MICROBIOLOGY REVIEWS			English	Review							IGE-MEDIATED HYPERSENSITIVITY; YEAST MALASSEZIA-FURFUR; CANDIDA-ALBICANS MANNAN; CROSS-REACTING IGE; PITYROSPORUM-OVALE; STAPHYLOCOCCUS-AUREUS; SEBORRHEIC DERMATITIS; PITYRIASIS-VERSICOLOR; HUMAN-SKIN; THERAPEUTIC IMPLICATIONS	Atopic dermatitis (AD) is a chronic, itching, inflammatory skin disease which is associated with asthma and/or hay fever and a familial occurrence of these conditions. Genetic factors are important in the development of AD, but the exact hereditary pathway is still unknown. Dry skin and the weakened barrier function in patients with AD is very important for the patient's reactions to irritants and other external trigger factors including microorganisms. The standard treatments are topical corticosteroids, topical immunomodulating agents, and emollients. If AD cannot be controlled by this type of treatment, systemic immunomodulating agents may be used. UVB, UVA, or psoralen-UVA may also be used for widespread severe lesions. However, some patients do not respond to these standard treatment, and then it is important to consider the role of microorganisms, house dust mites or food. The role of the Malassezia yeasts in AD, especially AD located to the head and neck region, is now documented in several papers. There are also several papers indicating the role of Candida as an aggravating factor in AD. Patients with AD also develop chronic dermatophyte infections more easily, and patients with AD and chronic dermatophyte infections may show improvement in their AD when treated with antifungal drugs.	Sahlgrens Univ Hosp, Dept Dermatol, S-41345 Gothenburg, Sweden	Faergemann, J (reprint author), Sahlgrens Univ Hosp, Dept Dermatol, S-41345 Gothenburg, Sweden.						Abeck D, 1998, BRIT J DERMATOL, V139, P13; Adachi A, 1999, Arerugi, V48, P719; Akiyama H, 1997, J DERMATOL SCI, V16, P23, DOI 10.1016/S0923-1811(97)00616-6; Arzumanian VG, 2001, VESTN ROS AKAD MED+, V2, P29; Arzumanyan VG, 2000, B EXP BIOL MED+, V129, P601, DOI 10.1007/BF02434889; Ashbee H R, 1994, Exp Dermatol, V3, P106, DOI 10.1111/j.1600-0625.1994.tb00267.x; BACK O, 1995, ARCH DERMATOL RES, V287, P448, DOI 10.1007/BF00373427; Back O, 2001, J EUR ACAD DERMATOL, V15, P34, DOI 10.1046/j.1468-3083.2001.00207.x; BACK O, 1985, J AM ACAD DERMATOL, V12, P56, DOI 10.1016/S0190-9622(85)70009-6; Baillon H, 1889, TRAITE BOT MED CRYPT, P234; Banfield CC, 2001, BRIT J DERMATOL, V144, P940, DOI 10.1046/j.1365-2133.2001.04179.x; BARNETT JA, 1990, YEASTS CHARACTERISTI, P22; BERGBRANT IM, 1988, ACTA DERM-VENEREOL, V68, P537; BERGBRANT IM, 1994, ACTA DERM-VENEREOL, V74, P260; BERGBRANT IM, 1990, SEMIN DERMATOL, V9, P262; BERGKHOUT CM, 1923, THESIS U UTRECHT UTR; BINGHAM EA, 2000, TXB PEDIAT DERMATOLO, P215; Brehler RBS, 2001, J EUR ACAD DERMATOL, V15, P5, DOI 10.1046/j.1468-3083.2001.00211.x; BROBERG A, 1995, ACTA DERM-VENEREOL, V75, P46; BROBERG A, 1992, ACTA DERM-VENEREOL, V72, P187; Brook I, 1996, INT J DERMATOL, V35, P791, DOI 10.1111/j.1365-4362.1996.tb02975.x; Bruijnzeel-Koomen CAFM, 1986, ARCH DERMATOL RES, V278, P199; Buentke E, 2000, CLIN EXP ALLERGY, V30, P1759, DOI 10.1046/j.1365-2222.2000.00937.x; BUSLAU M, 1990, MYCOSES, V33, P90; Castellani A, 1913, MANUAL TROPICAL MED; Clemmensen O., 1983, SEMIN DERMATOL, V2, P26; COOKSON WO, 1999, J AM ACAD DERMATOL S, V45, pS7; COX H, 2000, PEDIAT DERMATOLOGY, P169; Devos SA, 2000, ALLERGY, V55, P1056, DOI 10.1034/j.1398-9995.2000.00782.x; DOEKES G, 1993, ALLERGY, V48, P401, DOI 10.1111/j.1398-9995.1993.tb00737.x; DOEKES G, 1993, ALLERGY, V48, P394, DOI 10.1111/j.1398-9995.1993.tb00736.x; Eichstedt E., 1846, FRORIEP NEUE NOTIZ N, V39, P270; Erchiga VC, 2000, BRIT J DERMATOL, V143, P799; Faergemann J, 1997, MYCOSES, V40, P29; FAERGEMANN J, 1983, ACTA DERM-VENEREOL, V63, P346; FAERGEMANN J, 1981, J INVEST DERMATOL, V77, P314, DOI 10.1111/1523-1747.ep12482488; FAERGEMANN J, 1985, SEMIN DERMATOL, V4, P173; FAERGEMANN J, 1987, MYCOSES, V30, P298; Faergemann J, 2000, Am J Clin Dermatol, V1, P75, DOI 10.2165/00128071-200001020-00001; Faergemann J, 2001, BRIT J DERMATOL, V144, P549, DOI 10.1046/j.1365-2133.2001.04082.x; FAERGEMANN J, 1980, ACTA DERM-VENEREOL, V60, P531; Faergemann J, 1999, ALLERGY, V54, P413, DOI 10.1034/j.1398-9995.1999.00089.x; FAERGEMANN J, 1995, CLIN DERMATOL, V3, P1; FAERGEMANN J, 1999, TREATMENT ATOPIC DER, P98; Goh CL, 1997, INT J DERMATOL, V36, P653, DOI 10.1046/j.1365-4362.1997.00290.x; GORDON MA, 1951, MYCOLOGIA, V43, P524, DOI 10.2307/3755426; GORDON MA, 1951, J INVEST DERMATOL, V17, P267, DOI 10.1038/jid.1951.93; GRUBY M, 1842, CR HEBD ACAD SCI, V14, P634; Gueho E, 1996, ANTON LEEUW INT J G, V69, P337, DOI 10.1007/BF00399623; Guillot J, 1996, J MYCOL MED, V6, P103; Gupta AK, 2001, MED MYCOL, V39, P243; Gupta AK, 2001, MED MYCOL, V39, P199; Gupta AK, 2000, BRIT J DERMATOL, V142, P758, DOI 10.1046/j.1365-2133.2000.03294.x; HANIFEN J, 2001, J AM ACAD DERM S1, V45, P1; Hanifin JM, 2001, EXP DERMATOL, V10, P11, DOI 10.1034/j.1600-0625.2001.100102.x; Hanifin JM, 1980, ACTA DERM-VENEREOL S, V92, P44; Hanifin J. M., 2001, J AM ACAD DERMATOL, V44, P28; HAY RJ, 1982, BRIT J DERMATOL, V106, P191, DOI 10.1111/j.1365-2133.1982.tb00928.x; HAY RJ, 1998, ROOK WILKINSON EBLIN, V2, P1277; Herz U, 1999, INT ARCH ALLERGY IMM, V118, P240, DOI 10.1159/000024085; HOEGER PH, 1992, J INFECT DIS, V165, P1064; HOOG G, 2000, ATLAS CLIN FUNGI, P144; HUANG X, 1995, ALLERGY, V50, P648, DOI 10.1111/j.1398-9995.1995.tb02581.x; HUGHES H, 1958, BR MED J         AUG, P542; ISHIGURO A, 1992, INFECT IMMUN, V60, P1550; JEKLER J, 1992, ACTA DERM-VENEREOL, V72, P33; JENSENJAROLIM E, 1992, J ALLERGY CLIN IMMUN, V89, P44, DOI 10.1016/S0091-6749(05)80039-9; Johansson C, 1999, SCAND J IMMUNOL, V49, P293, DOI 10.1046/j.1365-3083.1999.00506.x; JOHANSSON S, 1991, ACTA DERM-VENEREOL, V71, P11; JOHNSSON C, IN PRESS BR J DERMAT; JONES HE, 1974, ARCH DERMATOL, V110, P213, DOI 10.1001/archderm.110.2.213; JONES HE, 1973, ARCH DERMATOL, V108, P61, DOI 10.1001/archderm.108.1.61; Kane J., 1997, LAB HDB DERMATOPHYTE; Kawamura MS, 1998, ARCH DERMATOL RES, V290, P603, DOI 10.1007/s004030050359; KIEFFER M, 1990, J AM ACAD DERMATOL, V22, P739, DOI 10.1016/0190-9622(90)70100-V; Kim SC, 2000, KOREAN J MED MYCOL, V5, P120; Kim TY, 1999, CLIN EXP DERMATOL, V24, P226, DOI 10.1046/j.1365-2230.1999.00460.x; Kimura M, 1999, CLIN EXP IMMUNOL, V118, P192; Kimura M, 2000, INT ARCH ALLERGY IMM, V122, P195, DOI 10.1159/000024397; Klein PA, 1999, CUTIS, V63, P171; Klubal R, 1997, J INVEST DERMATOL, V108, P336, DOI 10.1111/1523-1747.ep12286482; KORTEKANGASSAVOLAINEN O, 1993, CLIN EXP ALLERGY, V23, P179, DOI 10.1111/j.1365-2222.1993.tb00879.x; Koyama T, 2000, MICROBIOL IMMUNOL, V44, P373; KROGER S, 1995, ACTA DERM-VENEREOL, V75, P357; KUNZ R, 2000, TXB PEDIAT DERMATOLO, P199; LACOUR M, 1993, CLIN REV ALLERG, V11, P491; LANGENBECK B., 1839, NEUE NOT GEB NATUR H, V12, P145; LARKO O, 1999, TREATMENT ATOPIC DER, P147; LEEMING JP, 1987, J CLIN MICROBIOL, V25, P2017; LEEMING JP, 1989, J APPL BACTERIOL, V67, P47, DOI 10.1111/j.1365-2672.1989.tb04953.x; Leung DYM, 1998, BRIT J DERMATOL, V139, P17; Leung DYM, 2001, J AM ACAD DERMATOL, V44, pS1, DOI 10.1067/mjd.2001.109815; Leung DYM, 1999, ALLERGY, V54, P39; Leung D.Y.M., 1995, J INVEST DERMATOL, V105, P37; LEVER R, 1988, BRIT J DERMATOL, V119, P189, DOI 10.1111/j.1365-2133.1988.tb03201.x; Lever R, 1996, DERMATOL THER, V1, P32; LEYDEN JJ, 1974, BRIT J DERMATOL, V90, P525, DOI 10.1111/j.1365-2133.1974.tb06447.x; Lindborg M, 1999, J INVEST DERMATOL, V113, P156, DOI 10.1046/j.1523-1747.1999.00661.x; LINDGREN L, 1995, ACTA DERM-VENEREOL, V75, P300; Lintu P, 1997, CLIN EXP ALLERGY, V27, P87, DOI 10.1046/j.1365-2222.1997.d01-425.x; Lintu P, 2001, ALLERGY, V56, P512, DOI 10.1034/j.1398-9995.2001.056006512.x; Lintu P, 1999, ALLERGY, V54, P1067, DOI 10.1034/j.1398-9995.1999.00091.x; Lintu P, 1998, CLIN EXP ALLERGY, V28, P486; Matsumura N, 1997, ACTA DERM-VENEREOL, V77, P388; Mayser P, 2000, ACTA DERM-VENEREOL, V80, P357, DOI 10.1080/000155500459303; MCGREGOR JM, 1992, BRIT J DERMATOL, V127, P233, DOI 10.1111/j.1365-2133.1992.tb00120.x; MITTAG H, 1995, MYCOSES, V38, P13; Morita Eishin, 1999, Journal of Dermatology (Tokyo), V26, P282; Nakabayashi A, 2000, MED MYCOL, V38, P337, DOI 10.1080/714030958; Nermes M, 1996, CLIN EXP ALLERGY, V26, P164, DOI 10.1111/j.1365-2222.1996.tb00075.x; Nissen D, 1998, ANN ALLERG ASTHMA IM, V81, P247; NOBLE WC, 1996, J EUR ACAD DERMATO S, V7, P12; Odds FC, 1994, J AM ACAD DERMATOL, V31, pS2; Odds FC, 1988, CANDIDA CANDIDOSIS; OKUDAIRA H, 1983, ANN ALLERGY, V50, P51; Onishi Y, 1999, EUR J BIOCHEM, V261, P148, DOI 10.1046/j.1432-1327.1999.00247.x; PLATTSMILLS TAE, 1986, ANN ALLERGY, V56, P454; RAJKA G, 1979, ACTA DERM-VENEREOL, V59, P45; RAJKA G, 1975, ATOPIC DERMATITIS; RAMSAY CA, 1996, J EUR ACAD DERMAT S1, V7, P15; Rasool O, 2000, EUR J BIOCHEM, V267, P4355, DOI 10.1046/j.1432-1327.2000.01475.x; REDLINE RW, 1981, NEW ENGL J MED, V305, P1395, DOI 10.1056/NEJM198112033052307; RIVOLTA S, 1874, PARASSITI VEGETALI; ROBERTS SOB, 1969, BRIT J DERMATOL, V81, P264, DOI 10.1111/j.1365-2133.1969.tb13978.x; ROBERTS SOB, 1969, BRIT J DERMATOL, V81, P315, DOI 10.1111/j.1365-2133.1969.tb13990.x; ROKUGO M, 1990, ARCH DERMATOL, V126, P627, DOI 10.1001/archderm.126.5.627; Romani L, 1997, CHEM IMMUNOL, V68, P110; RUBIN CP, 1853, HIST NATURELLE VEGET; SABOURAUD R, 1904, MALASIES CUIR CHEVUL; SALKIN I F, 1977, Canadian Journal of Microbiology, V23, P471; Samaranayake YH, 2001, CLIN MICROBIOL REV, V14, P398, DOI 10.1128/CMR.14.2.398-429.2001; Sampson H A, 1989, J Allergy Clin Immunol, V84, P1062, DOI 10.1016/0091-6749(89)90154-1; Savolainen J, 1998, ALLERGY, V53, P506, DOI 10.1111/j.1398-9995.1998.tb04088.x; SAVOLAINEN J, 1992, CLIN EXP ALLERGY, V22, P469, DOI 10.1111/j.1365-2222.1992.tb00149.x; SAVOLAINEN J, 1993, CLIN EXP ALLERGY, V23, P332, DOI 10.1111/j.1365-2222.1993.tb00331.x; Savolainen J, 2001, CLIN EXP ALLERGY, V31, P125, DOI 10.1046/j.1365-2222.2001.00958.x; Savolainen J, 1999, CLIN EXP ALLERGY, V29, P824, DOI 10.1046/j.1365-2222.1999.00555.x; Scalabrin DMF, 1999, J ALLERGY CLIN IMMUN, V104, P1273, DOI 10.1016/S0091-6749(99)70024-2; Schmidt M, 1997, EUR J BIOCHEM, V246, P181, DOI 10.1111/j.1432-1033.1997.00181.x; SKOV L, 1996, J EUR ACAD DERMATO S, V7, P8; SLOOFF W, 1971, YEASTS TAXONOMIC STU, P1167; SORENSEN LH, 1999, TREATMENT ATOPIC DER, P126; STALDER JF, 1993, DERMATOLOGY, V186, P23; Strickland I, 1999, J INVEST DERMATOL, V112, P249, DOI 10.1046/j.1523-1747.1999.00502.x; SVEJGAARD E, 1990, SEMIN DERMATOL, V9, P255; SVEJGAARD E, 1989, ACTA DERM-VENEREOL S, V144, P140; SVENSSON A, 1999, TREATMENT ATOPIC DER, P37; Tanaka M, 1996, ARCH DERMATOL RES, V288, P495, DOI 10.1007/BF02505243; TANAKA M, 1994, ARCH DERMATOL, V130, P1393, DOI 10.1001/archderm.130.11.1393; Tengvall Linder M., 1996, Clinical and Experimental Allergy, V26, P1286, DOI 10.1046/j.1365-2222.1996.d01-281.x; Tengvall Linder M, 2000, Clin Exp Allergy, V30, P122; Tengvall Linder M., 1998, Scandinavian Journal of Immunology, V47, P152; THESTRUPPEDERSE.K, 1996, J EUR ACAD DERMATO S, V7, P3; UNNA PG, 1891, PRAKT DERMATOL, V13, P225; VONSEHLEN, 1880, TEGEBL VERSAMML DTSC, V600; Waersted A, 1985, Acta Derm Venereol Suppl (Stockh), V114, P146; WARD GW, 1989, LANCET, V1, P859; Watanabe S, 2001, J INVEST DERMATOL, V116, P769, DOI 10.1046/j.1523-1747.2001.01321.x; WESSELS MW, 1991, BRIT J DERMATOL, V125, P227, DOI 10.1111/j.1365-2133.1991.tb14745.x; WHITE I, 1983, BR J CLIN PRACT  JUN, P215; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Williams HC, 2000, CLIN EXP DERMATOL, V25, P522, DOI 10.1046/j.1365-2230.2000.00698.x; Williams HC, 2000, ATOPIC DERMATITIS EP, P41, DOI 10.1017/CBO9780511545771.005; WILSON BB, 1993, CUTIS, V51, P191; Wollenberg A, 2000, CLIN EXP DERMATOL, V25, P530, DOI 10.1046/j.1365-2230.2000.00699.x; Yasueda H, 1998, BIOCHEM BIOPH RES CO, V248, P240, DOI 10.1006/bbrc.1998.8944; ZARGARI A, 1994, ALLERGY, V49, P50, DOI 10.1111/j.1398-9995.1994.tb00773.x; Zargari A, 1995, CLIN EXP ALLERGY, V25, P1235, DOI 10.1111/j.1365-2222.1995.tb03048.x; Zollner TM, 2000, CLIN EXP ALLERGY, V30, P994	169	85	90	1	5	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0893-8512			CLIN MICROBIOL REV	Clin. Microbiol. Rev.	OCT	2002	15	4					545	+		10.1128/CMR.15.4.545-563.2002		20	Microbiology	Microbiology	647MT	WOS:000181097200002	12364369	
J	Oshikawa, K; Yanagisawa, K; Tominaga, S; Sugiyama, Y				Oshikawa, K; Yanagisawa, K; Tominaga, S; Sugiyama, Y			Expression and function of the ST2 gene in a murine model of allergic airway inflammation	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; allergy; gene therapy; type-2 helper T cell; T1/ST2	HELPER T-CELLS; INTERLEUKIN-1 RECEPTOR; EFFECTOR FUNCTION; RESPONSIVE GENE; PROMOTER USAGE; IL-1 RECEPTOR; MAST-CELLS; ASTHMA; PROTEIN; T1/ST2	Background We have recently reported that soluble ST2 protein levels are elevated in the sera of patients with asthma, and correlate well with the severity of asthma exacerbation. However, the role, function, and kinetics of soluble ST2 expression in asthma remain unclear. Objective The objective of the present study was to clarify the function and kinetics of soluble murine (m) ST2 expression in a murine asthma model. Methods We analyzed the kinetics of gene and protein expression of mST2 in sera or lung tissue after allergen (ovalbumin; OVA) challenge in a murine model of allergic airway inflammation, the effects of mST2 protein on OVA-induced Th2 cytokine production in vitro from splenocytes of sensitized mice, and the effects of soluble mST2 on Th2-dependent allergic airway inflammation by in vivo gene transfer of mST2. Results Serum mST2 protein levels increased to the maximal level 3 h after the allergen challenge, before serum IL-5 levels peaked. The mRNA expression of mST2 in lung tissue was induced after the allergen challenge, while that in the spleen was constitutively detected. Furthermore, pre-treatment with mST2 protein significantly inhibited the production of IL-4 and IL-5, but not IFN-gamma, from OVA-stimulated splenocytes in vitro, and intravenous mST2 gene transfer resulted in a drastic reduction in the number of eosinophils and in the levels of IL-4 and IL-5 in bronchoalveolar lavage fluid, compared with those in response to transfer of non-coding plasmid vector or of lipid alone. Conclusion These results suggest that increases in endogenous mST2 protein after allergen exposure may modulate Th2-mediated airway inflammation, and that in vivo gene transfer of mST2 can be applicable to use in a novel immunotherapy for allergic diseases.	Jichi Med Sch, Dept Med, Div Pulm Med, Minami Kawachi, Tochigi 3290498, Japan; Jichi Med Sch, Dept Biochem, Minami Kawachi, Tochigi, Japan	Oshikawa, K (reprint author), Jichi Med Sch, Dept Med, Div Pulm Med, 3311-1 Minamikawachi, Minami Kawachi, Tochigi 3290498, Japan.						BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERGERS G, 1994, EMBO J, V13, P1176; BOUSQUET J, 1990, NEW ENGL J MED, V323, P1033, DOI 10.1056/NEJM199010113231505; Corry DB, 1998, MOL MED, V4, P344; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Dow SW, 1999, HUM GENE THER, V10, P1905, DOI 10.1089/10430349950017266; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; Freimark BD, 1998, J IMMUNOL, V160, P4580; Gajewska BU, 2001, AM J RESP CELL MOL, V25, P326; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Iwahana H, 1999, EUR J BIOCHEM, V264, P397, DOI 10.1046/j.1432-1327.1999.00615.x; Kuroiwa K, 2000, HYBRIDOMA, V19, P151, DOI 10.1089/02724570050031194; Lambrecht BN, 2000, J CLIN INVEST, V106, P551, DOI 10.1172/JCI8107; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Moritz DR, 1998, HYBRIDOMA, V17, P107, DOI 10.1089/hyb.1998.17.107; Moritz DR, 1998, J IMMUNOL, V161, P4866; Oshikawa K, 2001, AM J RESP CRIT CARE, V164, P277; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROSSLER U, 1993, ONCOGENE, V8, P609; Sato Y, 1996, SCIENCE, V273, P352, DOI 10.1126/science.273.5273.352; TAKAGI T, 1993, BIOCHIM BIOPHYS ACTA, V1178, P194, DOI 10.1016/0167-4889(93)90009-E; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Tominaga S, 1996, HUM GENET, V97, P561; TOMINAGA S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P1; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yanagisawa K, 1997, J BIOCHEM-TOKYO, V121, P95	33	85	91	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	OCT	2002	32	10					1520	1526		10.1046/j.1365-2745.2002.01494.x		7	Allergy; Immunology	Allergy; Immunology	601ZJ	WOS:000178479300022	12372135	
J	Gibson, PG; Fujimura, M; Niimi, A				Gibson, PG; Fujimura, M; Niimi, A			Eosinophilic bronchitis: clinical manifestations and implications for treatment	THORAX			English	Review							OBSTRUCTIVE PULMONARY-DISEASE; COUGH-VARIANT ASTHMA; CHRONIC NONPRODUCTIVE COUGH; AIR-FLOW OBSTRUCTION; SPUTUM EOSINOPHILIA; ALLERGIC RHINITIS; INFLAMMATION; HYPERRESPONSIVENESS; RESPONSIVENESS; CHILDREN	Airway inflammation with eosinophils is now reported to occur not only in asthma but in other airway diseases such as cough variant asthma, chronic cough, atopic cough, episodic symptoms without asthma, allergic rhinitis, and COPD. Although the prevalence of eosinophilic bronchitis (EB) is less than in asthma, the causes, mechanisms and treatment of EB in these conditions appears to be similar to asthma where allergen induced IL-5 secretion and symptoms are readily responsive to inhaled corticosteroids. The prognosis of EB without asthma is not known but it may be a precursor for asthma and, if so, recognition of this syndrome may permit effective treatment and reduction in the rising prevalence of asthma. Induced sputum analysis allows recognition of EB in clinical practice. The place of the asthma treatment paradigm with early and sustained corticosteroid treatment needs to be defined in EB without asthma. Airway wall remodelling can occur in rhinitis, COPD, and cough variant asthma with EB. The mechanisms and long term implications of this complication in EB without asthma need to be clarified.	Kanazawa Univ, Sch Med, Dept Internal Med 3, Kanazawa, Ishikawa 9208641, Japan; Kyoto Univ, Grad Sch Med, Dept Resp Med, Sakyo Ku, Kyoto 6068507, Japan							Alvarez MJ, 2000, ALLERGY, V55, P355, DOI 10.1034/j.1398-9995.2000.00312.x; Balzano G, 1999, AM J RESP CRIT CARE, V160, P1486; Belda J, 2000, AM J RESP CRIT CARE, V161, P475; Bhowmik A, 2000, THORAX, V55, P114, DOI 10.1136/thorax.55.2.114; BOULET LP, 1989, ANN ALLERGY, V63, P114; BRAMAN SS, 1985, PRIMARY CARE, V12, P217; Braunstahl GJ, 2001, J ALLERGY CLIN IMMUN, V107, P469, DOI 10.1067/mai.2001.113046; Brightling CE, 2000, LANCET, V356, P1480, DOI 10.1016/S0140-6736(00)02872-5; Brightling CE, 1999, EUR RESPIR J, V14, P1228, DOI 10.1183/09031936.99.14512289; Brightling CE, 2000, EUR RESPIR J, V15, P682, DOI 10.1034/j.1399-3003.2000.15d10.x; Brightling CE, 1999, AM J RESP CRIT CARE, V160, P406; Brightling CE, 1999, THORAX, V54, P563; Brightling Christopher E., 2000, American Journal of Respiratory and Critical Care Medicine, V162, P878; BROWN LF, 1984, AM J SURG PATHOL, V8, P809; Cai Y, 1998, EUR RESPIR J, V11, P848, DOI 10.1183/09031936.98.11040848; Carney IK, 1997, AM J RESP CRIT CARE, V156, P211; Chakir J, 2000, J ALLERGY CLIN IMMUN, V106, P904, DOI 10.1067/mai.2000.110100; Chanez P, 1997, AM J RESP CRIT CARE, V155, P1529; CHERIYAN S, 1994, ANN ALLERGY, V73, P478; Cockcroft DW, 2000, CHEST, V118, P277, DOI 10.1378/chest.118.1.277; CORRAO WM, 1979, NEW ENGL J MED, V300, P633, DOI 10.1056/NEJM197903223001201; DJUKANOVIC R, 1992, EUR RESPIR J, V5, P538; DOAN T, 1992, ANN ALLERGY, V69, P505; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58; Forsythe P, 2000, CLIN EXP ALLERGY, V30, P225; FUJIMOTO K, CHEST, V155, P697; Fujimura M, 2000, CLIN EXP ALLERGY, V30, P41; Fujimura M, 1997, J ASTHMA, V34, P119, DOI 10.3109/02770909709075656; FUJIMURA M, 1992, INTERNAL MED, V31, P447, DOI 10.2169/internalmedicine.31.447; FUJIMURA M, 2001, IN PRESS RECENT RES; Fujimura Masaki, 2000, Allergology International, V49, P135, DOI 10.1046/j.1440-1592.2000.00171.x; Gibson PG, 1999, THORAX, V54, P656; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; GIBSON PG, 1989, LANCET, V1, P1346; Gibson PG, 1998, J ALLERGY CLIN IMMUN, V101, P320; GIBSON PG, 1995, CLIN EXP ALLERGY, V25, P127, DOI 10.1111/j.1365-2222.1995.tb01017.x; Gibson PG, 1999, PEDIATR PULM, V28, P261, DOI 10.1002/(SICI)1099-0496(199910)28:4<261::AID-PPUL5>3.0.CO;2-I; Gibson PG, 2001, AM J RESP CRIT CARE, V163, P32; Girgis ST, 2000, EUR RESPIR J, V16, P3, DOI 10.1034/j.1399-3003.2000.16a02.x; Gollash H, 1889, FORTSCHR MED, V7, P361; Gutierrez V, 1998, ANN ALLERG ASTHMA IM, V81, P143; Hamelmann E, 1999, INT ARCH ALLERGY IMM, V120, P8, DOI 10.1159/000024215; Harrison AM, 1999, AM J RESP CRIT CARE, V159, P1918; Hospers JJ, 1999, AM J RESP CRIT CARE, V160, P1869; Hsu JY, 1997, J FORMOS MED ASSOC, V96, P330; Inman MD, 2001, AM J RESP CRIT CARE, V164, P569; IRWIN RS, 1990, AM REV RESPIR DIS, V141, P640; Iwanaga T, 1998, Arerugi, V47, P457; Keatings VM, 1997, AM J RESP CRIT CARE, V155, P542; Lams BEA, 2000, EUR RESPIR J, V15, P512, DOI 10.1034/j.1399-3003.2000.15.14.x; Lams BEA, 1998, AM J RESP CRIT CARE, V158, P1518; Lemiere C, 1997, J ALLERGY CLIN IMMUN, V100, P852, DOI 10.1016/S0091-6749(97)70286-0; Leone C, 1997, J ALLERGY CLIN IMMUN, V100, P775, DOI 10.1016/S0091-6749(97)70273-2; Matsumoto H, 2001, CLIN EXP ALLERGY, V31, P637, DOI 10.1046/j.1365-2222.2001.01034.x; McGarvey L, 2000, AM J RESP CRIT CARE, V161, P1763; McGarvey LPA, 1999, EUR RESPIR J, V13, P59; Morikawa A., 1994, Acta Paediatrica Japonica, V36, P223; National Institutes of Health, 1997, NIH PUBL; Niimi A, 2000, LANCET, V356, P564, DOI 10.1016/S0140-6736(00)02584-8; Niimi A, 1998, EUR RESPIR J, V11, P1064, DOI 10.1183/09031936.98.11051064; NIIMI A, 1991, American Review of Respiratory Disease, V143, pA30; OGAWA H, 1995, RESP MED, V89, P219, DOI 10.1016/0954-6111(95)90251-1; Ogawa H, 1998, INT ARCH ALLERGY IMM, V116, P162, DOI 10.1159/000023940; Ohgou T, 1999, Arerugi, V48, P23; Papi A, 2000, AM J RESP CRIT CARE, V162, P1773; Pavord ID, 1997, THORAX, V52, P498; Pizzichini E, 1998, AM J RESP CRIT CARE, V158, P1511; Pizzichini M M, 1999, Can Respir J, V6, P323; Polosa R, 2000, EUR RESPIR J, V15, P30, DOI 10.1183/09031936.00.15103000; PUOLIJOKI H, 1987, EUR J RESPIR DIS, V71, P77; Remes ST, 1998, ACTA PAEDIATR, V87, P165, DOI 10.1080/08035259850157606; Rosi E, 2000, CLIN EXP ALLERGY, V30, P577; Rutgers SR, 2000, CLIN EXP ALLERGY, V30, P657; Rutgers SR, 2000, THORAX, V55, P12, DOI 10.1136/thorax.55.1.12; Rytila P, 2000, EUR RESPIR J, V16, P824, DOI 10.1183/09031936.00.16582400; SACHA RF, 1985, ANN ALLERGY, V54, P195; Saetta M, 1996, CLIN EXP ALLERGY, V26, P766, DOI 10.1046/j.1365-2222.1996.d01-386.x; Spanevello A, 2000, AM J RESP CRIT CARE, V162, P1172; SYED A, 1991, CLIN INVEST MED, V14, P28; ULRIK CS, 1995, CHEST, V108, P10, DOI 10.1378/chest.108.1.10; Wark P A, 2000, Respirology, V5, P51, DOI 10.1046/j.1440-1843.2000.00226.x; Wenzel SE, 1999, AM J RESP CRIT CARE, V160, P1001	82	85	109	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0040-6376			THORAX	Thorax	FEB	2002	57	2					178	182		10.1136/thorax.57.2.178		5	Respiratory System	Respiratory System	520FF	WOS:000173769800018	11828051	
J	Custovic, A; Simpson, BM; Murray, CS; Lowe, L; Woodcock, A				Custovic, A; Simpson, BM; Murray, CS; Lowe, L; Woodcock, A		NAC Manchester Asthma Allergy Stu	The National Asthma Campaign Manchester Asthma and Allergy Study	PEDIATRIC ALLERGY AND IMMUNOLOGY			English	Article; Proceedings Paper	Congress of the European-Academy-of-Allergy-and-Clinical-Immunology	JUN, 2001	BERLIN, GERMANY	European Acad Allergy & Clin Immunol		allergens; asthma; atopy; prevention; sensitization	YOUNG-CHILDREN; EARLY-LIFE; PREGNANCY	The (NAC)Manchester Asthma and Allergy Study is a prospective study of the development of asthma and allergies in childhood. The subjects (995 children at age 3 years) were recruited in utero by screening parents in the antenatal clinic using skin prick testing and a questionnaire regarding allergic diseases. Children were assigned to risk groups according to parental atopic status (high risk, both parents atopic; medium risk, one parent atopic; low risk, neither parent atopic). A subgroup of those at high risk (with no pets in the home) was randomized to stringent environmental control (allergen impermeable covers for the parental and infant bed, hot washing of bedding weekly, HEPA vacuum cleaner, hard floor for the nursery), and the remainder followed a normal regime. The children have been followed prospectively. The environmental influences are very clearly defined. Measurements of environmental exposures include levels of house dust mite; cat and dog allergens during pregnancy and early life; pet ownership and exposure; childcare arrangements; number of siblings; vaccination uptake; thorough dietary questionnaire and endotoxin exposure. Further unique objective outcome in the cohort is the assessment of lung function in preschool children using specific airways resistance, which at age 3 years clearly reflects both genetic and environmental influences.	Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Custovic, A (reprint author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.		Custovic, Adnan/A-2435-2012	Custovic, Adnan/0000-0001-5218-7071; Woodcock, Ashley/0000-0002-5428-8578			Bisgaard H, 1995, EUR RESPIR J, V8, P2067, DOI 10.1183/09031936.95.08122067; Custovic A, 2001, LANCET, V358, P188, DOI 10.1016/S0140-6736(01)05406-X; Custovic A, 2000, J ALLERGY CLIN IMMUN, V105, P252, DOI 10.1016/S0091-6749(00)90073-3; Klug B, 1997, EUR RESPIR J, V10, P1599, DOI 10.1183/09031936.97.10071599; Lowe L, 2002, LANCET, V359, P1904, DOI 10.1016/S0140-6736(02)08781-0; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Simpson BM, 2001, CLIN EXP ALLERGY, V31, P391, DOI 10.1046/j.1365-2222.2001.01050.x; SMILLIE FI, 2001, CLIN EXP ALLERGY, V311, P1194	8	85	87	1	3	BLACKWELL MUNKSGAARD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0905-6157			PEDIATR ALLERGY IMMU	Pediatr. Allergy Immunol.		2002	13			15			32	37		10.1034/j.1399-3038.13.s.15.3.x		6	Allergy; Immunology; Pediatrics	Allergy; Immunology; Pediatrics	638KW	WOS:000180571000008	12688622	
J	Sherriff, A; Peters, TJ; Henderson, J; Strachan, D				Sherriff, A; Peters, TJ; Henderson, J; Strachan, D		ALSPAC Study Team	Risk factor associations with wheezing patterns in children followed longitudinally from birth to 3 1/2 years	INTERNATIONAL JOURNAL OF EPIDEMIOLOGY			English	Article						ALSPAC; infant wheeze; risk factors	LOWER RESPIRATORY-TRACT; DAY-CARE ATTENDANCE; MATERNAL SMOKING; PARENTAL SMOKING; ASTHMA; ATOPY; LIFE; INFECTIONS; PERSISTENT; ILLNESSES	Background There is a paucity of detailed longitudinal data on wheeze in early childhood. Not. all children who wheeze in early infancy will continue to wheeze into childhood and beyond. This study aims to investigate possible risk factors for different patterns of wheeze in the pre-school years. Subjects and Study participants. were part of.the.Avon Longitudinal Study of.Parents.and Methods Children (ALSPAC). Maternal reports of child wheeze between birth and 6 months and again between 30 and 42 months were gathered prospectively. Children were categorized into early wheeze, persistent wheeze or late onset wheeze. A large number of risk factors were assessed for each wheezing phenotype using multivariable logistic regression models. Results Over 70% of children who wheezed in the first 6 months did not wheeze 3 years later. Wheezing between 0-6 months was independently associated with the presence of older siblings, male sex, delivery between April and December, bottle feeding, young maternal age, prenatal tobacco smoke exposure, atopy and parental history of asthma. From within this group of early wheezers, risk factors for wheeze that persisted beyond 6 months included pre-term delivery; young maternal age, living in rented local authority housing, atopy and a maternal (not paternal) history of asthma. Atopy and a family history of asthma emerged as the main predictors of wheeze that developed after 6 months of age. Conclusion It is clear that a number of wheezing syndromes exist by 3 1/2 years, albeit with some degree of overlap. Detailed follow-up of this cohort is underway to determine whether risk factor associations determined in the first 3 1/2 years have long-term significance for the clinical entity termed 'asthma'.	Univ Bristol, Unit Paediat & Perinatal Epidemiol, Inst Child Hlth, Bristol BS8 1TQ, Avon, England; Univ Bristol, Dept Social Med, Bristol BS8 1TQ, Avon, England; Univ Bristol, Royal Hosp Sick Children, Inst Child Hlth, Bristol BS8 1TQ, Avon, England; St George Hosp, Med Sch, Dept Publ Hlth Sci, London, England	Sherriff, A (reprint author), Univ Bristol, Unit Paediat & Perinatal Epidemiol, Inst Child Hlth, 24 Tyndall Ave, Bristol BS8 1TQ, Avon, England.			Peters, Tim/0000-0003-2881-4180			Burney P, 1997, AM J RESP CRIT CARE, V156, P1773; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Cook DG, 1998, THORAX, V53, P884; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Doull IJM, 1997, BRIT MED BULL, V53, P71; Doull IJM, 1996, CLIN EXP ALLERGY, V26, P613; Hernandez SF, 1999, ARCH MED RES, V30, P216, DOI 10.1016/S0188-0128(99)00008-1; HILL MR, 1995, BRIT MED J, V311, P776; HIZAWA N, 1995, J MED GENET, V32, P363, DOI 10.1136/jmg.32.5.363; Leach AJ, 1999, INT J PEDIATR OTORHI, V49, pS173; LIEBERMAN E, 1994, AM J PUBLIC HEALTH, V84, P1127, DOI 10.2105/AJPH.84.7.1127; LUX AL, IN PRESS ARCH DIS CH; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; MARTINEZ FD, 1992, AM J EPIDEMIOL, V136, P1258; Nystad W, 1999, INT J EPIDEMIOL, V28, P882, DOI 10.1093/ije/28.5.882; Oddy WH, 1999, BRIT MED J, V319, P815; Rahman M M, 1997, Bangladesh Med Res Counc Bull, V23, P47; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617; SAARINEN UM, 1995, LANCET, V346, P1065, DOI 10.1016/S0140-6736(95)91742-X; SCHWARTZ J, 1990, AM REV RESPIR DIS, V142, P555; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; TAYLOR B, 1987, ARCH DIS CHILD, V62, P786; WILCOX AJ, 1993, AM J EPIDEMIOL, V137, P1098; YOUNG S, 1991, NEW ENGL J MED, V324, P1168, DOI 10.1056/NEJM199104253241704	24	85	89	2	9	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0300-5771			INT J EPIDEMIOL	Int. J. Epidemiol.	DEC	2001	30	6					1473	1484		10.1093/ije/30.6.1473		12	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	520NC	WOS:000173787100055	11821366	
J	Kassel, O; De Blay, F; Duvernelle, C; Olgart, C; Israel-Biet, D; Krieger, P; Moreau, L; Muller, C; Pauli, G; Frossard, N				Kassel, O; De Blay, F; Duvernelle, C; Olgart, C; Israel-Biet, D; Krieger, P; Moreau, L; Muller, C; Pauli, G; Frossard, N			Local increase in the number of mast cells and expression of nerve growth factor in the bronchus of asthmatic patients after repeated inhalation of allergen at low-dose	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						neurotrophin; asthma; airway; mast cell; NGF; tryptase; allergy; bronchus; bronchoalveolar lavage; bronchial biopsy	AIRWAY MUCOSAL INFLAMMATION; SURVIVAL PROMOTION; PERIPHERAL-BLOOD; FUNCTIONAL TRKA; UP-REGULATION; MILD ASTHMA; PROGENITORS; EXPOSURE; RECEPTOR; MODEL	Background Repeated inhalation of allergen at low-dose induces an increase in bronchial hyper-responsiveness, without any associated symptom. The concomitant events in the bronchus have not been described. Objective We have studied the dynamic number of mast cells in the airways of patients with mild asthma before and after repeated inhalation of allergen at low-dose and the expression of nerve growth factor (NGF), which is reported to promote growth and survival of mast cells. Methods Twelve patients with mild asthma to cat allergen were enrolled at random in a blind placebo-controlled study, and submitted to repeated low-dose allergen exposure (1/5 of the provocative dose). Mast cells were immunolocalized using an antibody against mast cell tryptase. NGF and its high affinity receptor, TrkA, were immunolocalized using anti-NGF and anti-TrkA antibodies, respectively. NGF mRNA was quantified by competitive polymerase chain reaction (PCR) after reverse transcription of total RNA extracted from bronchial biopsy. NGF protein levels were measured by ELISA in bronchoalveolar lavage (BAL) fluid. Results Bronchial mast cell number was increased significantly after allergen exposure as compared with before. NGF expression in the bronchus was immunolocalized mainly to epithelial cells, but also to fibroblasts, blood vessels, and a few infiltrated cells. NGF mRNA levels in bronchial biopsies were increased significantly after allergen exposure. The high affinity receptor for NGF, TrkA, was immunolocalized to the infiltrated mast cell membrane. Conclusion Our study shows that the increase in the number of mast cells and in the expression of NGF induced by allergen exposure in the bronchus of asthmatic patients is occurring before the onset of symptoms. In addition, our finding of the presence of the TrkA receptor on the membrane of the infiltrated mast cell in situ brings evidence of the mast cell as a target cell for the growth factor activity of NGF in the airways in asthma.	Univ Strasbourg 1, Fac Pharm, INSERM, U425, F-67401 Illkirch Graffenstaden, France; Hop Univ Strasbourg, Serv Pneumol, Strasbourg, France; Hop Laennec, Immunol Pulm Lab, Paris, France; Fac Pharm, CNRS, UMR 7034, F-67401 Illkirch Graffenstaden, France	Frossard, N (reprint author), Univ Strasbourg 1, Fac Pharm, INSERM, U425, 74 Route Rhin,BP 24, F-67401 Illkirch Graffenstaden, France.		Kassel, Olivier/H-2117-2013; Frossard, Nelly/F-8301-2013	Kassel, Olivier/0000-0002-8616-3091; MULLER, Christian/0000-0002-3463-1025			ALOE L, 1977, BRAIN RES, V133, P358, DOI 10.1016/0006-8993(77)90772-7; ALOE L, 1994, NEUROREPORT, V5, P1030, DOI 10.1097/00001756-199405000-00003; Arshad SH, 1998, AM J RESP CRIT CARE, V157, P1900; BEASLEY R, 1989, AM REV RESPIR DIS, V139, P806; Bonini S, 1996, P NATL ACAD SCI USA, V93, P10955, DOI 10.1073/pnas.93.20.10955; BRADDING P, 1994, AM J RESP CELL MOL, V10, P471; Braun A, 1998, EUR J IMMUNOL, V28, P3240, DOI 10.1002/(SICI)1521-4141(199810)28:10<3240::AID-IMMU3240>3.0.CO;2-U; Bullock ED, 1996, J BIOL CHEM, V271, P27500; Campbell E, 1999, AM J PATHOL, V154, P1259, DOI 10.1016/S0002-9440(10)65377-1; CRIMI E, 1991, AM REV RESPIR DIS, V144, P1282; de Blay F, 1999, INT ARCH ALLERGY IMM, V120, P158, DOI 10.1159/000024234; de Vries A, 1999, AM J RESP CRIT CARE, V159, P1541; DENBURG JA, 1985, J ALLERGY CLIN IMMUN, V76, P466, DOI 10.1016/0091-6749(85)90728-6; FOX A, 1997, AM J RESP CRIT CARE, V155, pA157; Frew AJ, 1996, J ALLERGY CLIN IMMUN, V98, P133, DOI 10.1016/S0091-6749(96)70235-X; GALLI SJ, 1990, LAB INVEST, V62, P5; GIBSON PG, 1991, AM REV RESPIR DIS, V143, P331; HORIGOME K, 1994, J BIOL CHEM, V269, P2695; ISHIZAKA T, 1993, CURR OPIN IMMUNOL, V5, P937, DOI 10.1016/0952-7915(93)90109-6; KANNAN Y, 1993, INT ARCH ALLERGY IMM, V102, P362; Kassel O, 1999, EUR RESPIR J, V13, P951, DOI 10.1034/j.1399-3003.1999.13e04.x; Kassel O, 1998, MOL PHARMACOL, V54, P1073; KAWAMOTO K, 1995, BLOOD, V86, P4638; LAITINEN LA, 1993, AM REV RESPIR DIS, V147, P697; LEON A, 1994, P NATL ACAD SCI USA, V91, P3739, DOI 10.1073/pnas.91.9.3739; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LOZEWICZ S, 1988, BRIT MED J, V297, P1515; MATSUDA H, 1991, J EXP MED, V174, P7, DOI 10.1084/jem.174.1.7; MONTEFORT S, 1994, J CLIN INVEST, V93, P1411, DOI 10.1172/JCI117118; Murakami M, 1997, J IMMUNOL, V159, P439; Nilsson G, 1997, EUR J IMMUNOL, V27, P2295, DOI 10.1002/eji.1830270925; OHNISHI M, 1988, J ALLERGY CLIN IMMUN, V81, P1149, DOI 10.1016/0091-6749(88)90883-4; Olgart C, 2001, EUR RESPIR J, V18, P115, DOI 10.1183/09031936.01.00069901; OLLERENSHAW SL, 1992, AM REV RESPIR DIS, V145, P922; Palmqvist M, 1998, RESP MED, V92, P1223, DOI 10.1016/S0954-6111(98)90425-5; PESCI A, 1993, AM REV RESPIR DIS, V147, P684; PURCELL WM, 1994, HUM EXP TOXICOL, V13, P429; Roquet A, 1998, APMIS, V106, P293; SAETTA M, 1992, AM REV RESPIR DIS, V145, P160; SANTAMBROGIO L, 1994, J IMMUNOL, V153, P4488; Sehmi R, 1996, AM J RESP CELL MOL, V15, P645; Solomon A, 1998, J ALLERGY CLIN IMMUN, V102, P454, DOI 10.1016/S0091-6749(98)70135-6; Tam SY, 1997, BLOOD, V90, P1807; Valent P, 1995, Exp Dermatol, V4, P255, DOI 10.1111/j.1600-0625.1995.tb00254.x; Virchow JC, 1998, AM J RESP CRIT CARE, V158, P2002; Welker P, 1998, IMMUNOLOGY, V94, P310; Wood Lorna J., 1998, American Journal of Respiratory and Critical Care Medicine, V157, P99	47	85	89	0	3	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	0954-7894			CLIN EXP ALLERGY	Clin. Exp. Allergy	SEP	2001	31	9					1432	1440		10.1046/j.1365-2222.2001.01177.x		9	Allergy; Immunology	Allergy; Immunology	473CF	WOS:000171021400015	11591194	
J	Quirce, S; Maranon, F; Umpierrez, A; de las Heras, M; Fernandez-Caldas, E; Sastre, J				Quirce, S; Maranon, F; Umpierrez, A; de las Heras, M; Fernandez-Caldas, E; Sastre, J			Chicken serum albumin (Gal d 5*) is a partially heat-labile inhalant and food allergen implicated in the bird-egg syndrome	ALLERGY			English	Article						allergic asthma; bird-egg syndrome; chicken albumin; egg allergy; feathers	OCCUPATIONAL ASTHMA; CROSS-REACTIVITY; ALPHA-LIVETIN; PROTEINS; YOLK; IDENTIFICATION; DISEASE; WHITE; BEEF	Background: Chicken serum albumin (alpha -livetin) has been implicated as the causative allergen of the bird-egg syndrome. However, the clinical relevance of sensitization to this allergen has not been confirmed by specific challenge tests and environmental sampling. We investigated whether chicken albumin can be detected in air samples collected in a home with birds, and whether sensitization to this protein may cause respiratory and food allergy symptoms. The heat resistance of chicken albumin and the possible cross-reactivity with conalbumin were also investigated. Methods: We studied eight patients with food allergy to egg yolk who also suffered from respiratory symptoms (rhinitis and/or asthma) caused by exposure to birds. Sensitization to egg yolk and bird antigens was investigated by skin and serologic tests. Hypersensitivity to chicken albumin was confirmed by specific bronchial, conjunctival, and oral provocation tests. Results. All patients had positive skin tests and serum IgE against egg yolk, chicken serum, chicken meat, bird feathers, and chicken albumin. The presence of airborne chicken albumin in the domestic environment was confirmed. Specific bronchial challenge to chicken albumin elicited early asthmatic responses in six patients with asthma. An oral challenge with chicken albumin provoked digestive and systemic allergic symptoms in the two patients challenged. IgE reactivity to chicken albumin was reduced by 88% after heating at 90 degreesC for 30 min. ELISA inhibition demonstrated only partial cross-reactivity between chicken albumin and conalbumin. Conclusions: Chicken albumin (Gal d 5) is a partially heat-labile allergen that may cause both respiratory and food-allergy symptoms in patients with the bird-egg syndrome.	Fdn Jimenez Diaz, Serv Alergia, Dept Allergy, E-28040 Madrid, Spain; CBF LETI SA, Madrid, Spain	Quirce, S (reprint author), Fdn Jimenez Diaz, Serv Alergia, Dept Allergy, Av Reyes Catolicos 2, E-28040 Madrid, Spain.						AGARWAL MK, 1981, J ALLERGY CLIN IMMUN, V68, P194, DOI 10.1016/0091-6749(81)90183-4; ALKABELLO SAS, 1995, ALERGOLOGICA FACTORE, P281; BARR SE, 1961, J ALLERGY, V32, P17, DOI 10.1016/0021-8707(61)90034-X; BAUSELA BA, 1991, ALLERGY, V46, P614, DOI 10.1111/j.1398-9995.1991.tb00632.x; BERNSTEIN DI, 1987, J ALLERGY CLIN IMMUN, V80, P791, DOI 10.1016/S0091-6749(87)80267-1; BERNSTEIN JA, 1993, CHEST, V103, P532, DOI 10.1378/chest.103.2.532; BERRENS L, 1986, CLIN ALLERGY, V16, P355, DOI 10.1111/j.1365-2222.1986.tb01968.x; BERRENS L, 1987, CLIN ALLERGY, V17, P405, DOI 10.1111/j.1365-2222.1987.tb02033.x; Blanco Carmona J G, 1992, Allergy, V47, P190; Breiteneder H, 2000, J ALLERGY CLIN IMMUN, V106, P27, DOI 10.1067/mai.2000.106929; Calvert JE, 1999, CLIN EXP ALLERGY, V29, P166; COCKCROFT DW, 1977, CLIN ALLERGY, V7, P235, DOI 10.1111/j.1365-2222.1977.tb01448.x; CRAIG TJ, 1992, ANN ALLERGY, V69, P510; DEBLAY F, 1994, ALLERGY PROC, V15, P77, DOI 10.2500/108854194778703017; DEMAATBLEEKER F, 1985, ANN ALLERGY, V54, P245; Eigenmann PA, 2000, J ALLERGY CLIN IMMUN, V105, P587, DOI 10.1067/mai.2000.104255; FAUX J A, 1971, Clinical Allergy, V1, P159, DOI 10.1111/j.1365-2222.1971.tb03015.x; Fernandez-Caldas E, 1998, J ALLERGY CLIN IMMUN, V101, P554, DOI 10.1016/S0091-6749(98)70364-1; Fiocchi A, 1998, ALLERGY, V53, P798; HARGREAVE FE, 1972, J ALLERGY CLIN IMMUN, V50, P157, DOI 10.1016/0091-6749(72)90047-4; HOFFMAN DR, 1983, J ALLERGY CLIN IMMUN, V71, P481, DOI 10.1016/0091-6749(83)90465-7; HOFFMAN DR, 1988, J ALLERGY CLIN IMMUN, V81, P484, DOI 10.1016/0091-6749(88)90921-9; KING TP, 1994, INT ARCH ALLERGY IMM, V105, P224; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MANDALLAZ M, 1991, ALLERGOLOGIE, V7, P275; MANDALLAZ MM, 1988, INT ARCH ALLER A IMM, V87, P143; MARKS MB, 1984, ANN ALLERGY, V52, P56; MOLLER C, 1984, ALLERGY, V39, P37, DOI 10.1111/j.1398-9995.1984.tb01931.x; OUCHTERLONY O, 1953, ACTA PATHOL MIC SC, V32, P231; Powrie W. D., 1985, FOOD CHEM, P829; Quirce S, 1998, CLIN EXP ALLERGY, V28, P478, DOI 10.1046/j.1365-2222.1998.00253.x; QUIRCE S, 1994, J ALLERGY CLIN IMMUN, V93, P44, DOI 10.1016/0091-6749(94)90231-3; Restani P, 1998, INT ARCH ALLERGY IMM, V117, P113, DOI 10.1159/000023997; SMITH AB, 1990, CHEST, V98, P398, DOI 10.1378/chest.98.2.398; SMITH AB, 1987, AM J IND MED, V12, P205, DOI 10.1002/ajim.4700120209; Spitzauer S, 1999, INT ARCH ALLERGY IMM, V120, P259, DOI 10.1159/000024278; Spitzauer S, 1995, J ALLERGY CLIN IMMUN, V96, P951, DOI 10.1016/S0091-6749(95)70233-4; SZEPFALUSI Z, 1994, J ALLERGY CLIN IMMUN, V93, P932, DOI 10.1016/0091-6749(94)90388-3; TAUERREICH I, 1994, ALLERGY, V49, P448, DOI 10.1111/j.1398-9995.1994.tb00838.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Werfel SJ, 1997, J ALLERGY CLIN IMMUN, V99, P293, DOI 10.1016/S0091-6749(97)70045-9; WILLIAMS J, 1962, BIOCHEM J, V83, P346; Zacharasiewicz A, 1999, WIEN KLIN WOCHENSCHR, V111, P882	43	85	87	0	3	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	AUG	2001	56	8					754	762		10.1034/j.1398-9995.2001.056008754.x		9	Allergy; Immunology	Allergy; Immunology	459CU	WOS:000170234200007	11488669	
J	Al Frayh, AR; Shakoor, Z; El Rab, MOG; Hasnain, SM				Al Frayh, AR; Shakoor, Z; El Rab, MOG; Hasnain, SM			Increased prevalence of asthma in saudi Arabia	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							SWEDISH SCHOOL-CHILDREN; SKIN-TEST REACTIVITY; RESPIRATORY SYMPTOMS; CHANGING PREVALENCE; ALLERGIC DISEASES; BRONCHIAL-ASTHMA; SCHOOLCHILDREN; ATOPY; EPIDEMIOLOGY; ADOLESCENTS	Background: Branchial asthma is among the most common chronic illnesses of childhood. A number of reports in the recent past suggest that the prevalence of asthma is increasing globally. Objective: To investigate the changing prevalence of asthma in the Kingdom of Saudi Arabia. Subjects and Methods: Two populations of schoolchildren between the ages of 8 and 16 years were studied using an internationally designed protocol in 1986 and 1995. The questionnaire used in these studies was very similar to the one used in the International Study of Allergy and Asthma in Childhood. A total of 2,123 schoolchildren in 1986 (Jeddah and Riyadh) and 1,008 schoolchildren in 1995 (Hail and Gizan) were enrolled in the surveys. These cross-sectional studies of randomly selected schoolchildren were statistically analyzed using ANOVA and a Z test. Results: The comparison of data between Riyadh versus Hail (inland desert dry environment) and Jeddah versus Gizan (coastal humid environment) revealed that the prevalence of asthma in the similar populations increased significantly from 8% in 1986 to 23% in 1995 (P < .0001). Likewise, the prevalence of allergic rhinitis also increased from 20% to 25% (P < .003) since 1986. However, no significant change in the prevalence of eczema (from 12% to 13%) was noted between 1986 and 1995. Conclusions: The study indicates that there was a significant increase in the prevalence of bronchial asthma and, to a lesser extent, in the prevalence of allergic rhinitis in the Kingdom of Saudi Arabia during this 9-year period. The study also revealed increased exposure to environmental factors such as tobacco smoke and indoor animals in Saudi houses. It seems that the continuing changes in contemporary life may well have contributed to the increased prevalence of asthma in the country.	King Saud Univ, Coll Med, Dept Pediat, Riyadh 11461, Saudi Arabia; King Khalid Univ Hosp, Riyadh 11461, Saudi Arabia; King Saud Univ, Dept Pathol, Riyadh 11451, Saudi Arabia; King Faisal Specialist Hosp & Res Ctr, Dept Biol & Med Res, Riyadh 11211, Saudi Arabia	Al Frayh, AR (reprint author), King Saud Univ, Coll Med, Dept Pediat, Riyadh 11461, Saudi Arabia.						ABERG N, 1989, ACTA PAEDIATR SCAND, V78, P246, DOI 10.1111/j.1651-2227.1989.tb11064.x; al Frayh A R, 1989, Allerg Immunol (Paris), V21, P389; AL-NAHDI M, 1989, Allergie et Immunologie (Paris), V21, P278; ALFRAYH A, 1992, SAUDI MED J, V13, P521; ALFRAYH A, 1990, J ASTHMA, V27, P315, DOI 10.3109/02770909009073344; ALFRAYH AR, 1989, ALLERG IMMUNOL S, V89, P16; ALFRAYH AR, 1990, 9 INT C EG SOC ALL C, P3; BAUMAN A, 1992, MED J AUSTRALIA, V156, P827; BENER A, 1991, J ASTHMA, V28, P281, DOI 10.3109/02770909109073385; BESNIER E, 1892, ANN DERMATOL SYPHIL, V23, P634; BOUSQUET J, 1986, J ALLERGY CLIN IMMUN, V78, P1019, DOI 10.1016/0091-6749(86)90296-4; Brabin BJ, 1998, ANN TROP PAEDIATR, V18, pS33; BUIST AS, 1990, JAMA-J AM MED ASSOC, V264, P1719, DOI 10.1001/jama.264.13.1719; BURNEY PGJ, 1990, BRIT MED J, V300, P1306; GERGEN PJ, 1988, PEDIATRICS, V81, P1; GREGG I, 1983, ASTHMA, P242; HAAHTELA T, 1980, ALLERGY, V35, P433, DOI 10.1111/j.1398-9995.1980.tb01790.x; HATTEVIG G, 1987, ACTA PAEDIATR SCAND, V76, P349, DOI 10.1111/j.1651-2227.1987.tb10473.x; Hayashi T, 1995, ANN ALLERG ASTHMA IM, V75, P525; HOPPER JL, 1995, AUST J PUBLIC HEALTH, V19, P120; HURRY VM, 1988, AUST NZ J MED, V18, P745, DOI 10.1111/j.1445-5994.1988.tb00173.x; INGRAM JM, 1995, J ALLERGY CLIN IMMUN, V96, P449, DOI 10.1016/S0091-6749(95)70286-5; KJELLMAN NIM, 1977, ACTA PAEDIATR SCAND, V66, P465, DOI 10.1111/j.1651-2227.1977.tb07928.x; KORENYIBOTH AL, 1992, MIL MED, V157, P452; KORSGAARD J, 1982, AM REV RESPIR DIS, V125, P80; Lenney W, 1997, Pediatr Pulmonol Suppl, V15, P13; Lundback B, 1998, CLIN EXP ALLERGY, V28, P3; *NHLBI, 1995, NIH PUBL; NINAN TK, 1992, BRIT MED J, V304, P873; Nystad W, 1997, EUR RESPIR J, V10, P1046, DOI 10.1183/09031936.97.10051046; PEARCE N, 1995, EPIDEMIOLOGY, V6, P190, DOI 10.1097/00001648-199503000-00020; PEAT JK, 1994, EUR RESPIR J, V7, P1805, DOI 10.1183/09031936.94.07101805; PEAT JK, 1994, BRIT MED J, V308, P1591; ROBERTSON CF, 1991, BRIT MED J, V302, P1116; ROBIN ED, 1988, CHEST, V93, P614, DOI 10.1378/chest.93.3.614; SKARPAAS IJK, 1985, ALLERGY, V40, P295, DOI 10.1111/j.1398-9995.1985.tb00235.x; Sly RM, 1999, ANN ALLERG ASTHMA IM, V82, P233, DOI 10.1016/S1081-1206(10)62603-8; VARJONEN E, 1992, ALLERGY, V47, P243, DOI 10.1111/j.1398-9995.1992.tb00657.x; *WHO, 1975, B WORLD HEALTH ORGAN, V52, P251; Yemaneberhan H, 1997, LANCET, V350, P85, DOI 10.1016/S0140-6736(97)01151-3	40	85	91	0	1	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	MAR	2001	86	3					292	296				5	Allergy; Immunology	Allergy; Immunology	416GZ	WOS:000167773100009	11289327	
J	Lim, S; Groneberg, D; Fischer, A; Oates, T; Caramori, G; Mattos, W; Adcock, I; Barnes, PJ; Chung, KF				Lim, S; Groneberg, D; Fischer, A; Oates, T; Caramori, G; Mattos, W; Adcock, I; Barnes, PJ; Chung, KF			Expression of heme oxygenase isoenzymes 1 and 2 in normal and asthmatic airways - Effect of inhaled corticosteroids	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article							PARTICULATE AIR-POLLUTION; HUMAN-SKIN FIBROBLASTS; NITRIC-OXIDE SYNTHASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; MESSENGER-RNA; EPITHELIAL-CELLS; GENE-EXPRESSION; CARBON-MONOXIDE; IN-VITRO	Heme oxygenase (HO) is considered to be an antioxidant enzyme that catabolizes heme to produce carbon monoxide (CO) and biliverdin. We determined the expression and distribution of HO-1 and HO-2, two isoenzymes of HO, in the airways of patients with asthma, and determined the effect of inhaled corticosteroid therapy. Immunostaining for both enzymes was widely distributed in the airways' submucosa, particularly in airway epithelium and submucosal macrophages (CD68(+)) as determined by double immunostaining. There was no difference in intensity and extent of staining in biopsies from normal subjects (n = 10) and subjects with asthma (n = 10). Following 1 mo of treatment with inhaled corticosteroids (budesonide 1,600 mug/d), there was no significant change in the expression and distribution of either HO-1 or HO-2 in the airways' submucosa in eight subjects with mild asthma, despite a significant reduction in airway eosinophils and a reduction in bronchial responsiveness to methacholine. Levels of exhaled nitric oxide were significantly reduced, but exhaled CO levels remained unchanged by the treatment. Treatment with a placebo inhaler (n = 8) had no effects on these parameters. Thus, both HO-1 and HO-2 are extensively distributed equally in normal subjects and subjects with asthma, and are not modulated by inhaled corticosteroid therapy in subjects with asthma. HO may be an important endogenous antioxidant enzyme.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England; Univ Giessen, Inst Anat & Cell Biol, Giessen, Germany	Chung, KF (reprint author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, Dovehouse St, London SW3 6LY, England.			Adcock, Ian/0000-0003-2101-8843; Groneberg, David/0000-0001-8551-6556; Chung, Kian Fan/0000-0001-7101-1426			ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; Antczak A, 1997, EUR RESPIR J, V10, P1235, DOI 10.1183/09031936.97.10061235; Barnes PJ, 1998, PHARMACOL REV, V50, P515; BAUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63; Berkman N, 1996, AM J RESP CRIT CARE, V154, P1804; CAMHI SL, 1995, AM J RESP CELL MOL, V13, P387; CANTONI L, 1991, BIOCHEM J, V279, P891; Datta PK, 1999, KIDNEY INT, V55, P1734, DOI 10.1046/j.1523-1755.1999.00429.x; Dennery PA, 1996, PEDIATR RES, V40, P815, DOI 10.1203/00006450-199612000-00007; Dennery PA, 1996, AM J PHYSIOL-LUNG C, V271, pL672; Foresti R, 1999, BIOCHEM J, V339, P729, DOI 10.1042/0264-6021:3390729; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; HAMID Q, 1993, LANCET, V342, P1510, DOI 10.1016/S0140-6736(05)80083-2; Hart LA, 1998, AM J RESP CRIT CARE, V158, P1585; Horvath I, 1998, AM J RESP CRIT CARE, V158, P1042; Horvath I, 1998, THORAX, V53, P668; ISHIZAWA S, 1983, J BIOL CHEM, V258, P4220; JARJOUR NN, 1992, AM REV RESPIR DIS, V146, P905; KEYSE SM, 1990, MOL CELL BIOL, V10, P4967; KEYSE SM, 1989, P NATL ACAD SCI USA, V86, P99, DOI 10.1073/pnas.86.1.99; KINNULA VL, 1995, LAB INVEST, V73, P3; Lamkhioued B, 1997, J IMMUNOL, V159, P4593; Lavrovsky Y, 1996, BIOCHEM BIOPH RES CO, V218, P759, DOI 10.1006/bbrc.1996.0135; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Lee PJ, 1996, AM J RESP CELL MOL, V14, P556; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; LUTTON JD, 1992, J CELL BIOCHEM, V49, P259, DOI 10.1002/jcb.240490308; MAINES MD, 1988, FASEB J, V2, P2557; Poss KD, 1997, P NATL ACAD SCI USA, V94, P10925, DOI 10.1073/pnas.94.20.10925; Raju VS, 1997, BBA-GENE STRUCT EXPR, V1351, P89, DOI 10.1016/S0167-4781(96)00183-2; Saleh D, 1998, FASEB J, V12, P929; SEATON A, 1995, LANCET, V345, P176, DOI 10.1016/S0140-6736(95)90173-6; SOUSA AR, 1993, AM REV RESPIR DIS, V147, P1557; VACHIER I, 1994, EUR RESPIR J, V7, P1585, DOI 10.1183/09031936.94.07091585; VILE GF, 1994, P NATL ACAD SCI USA, V91, P2607, DOI 10.1073/pnas.91.7.2607; Zayasu K, 1997, AM J RESP CRIT CARE, V156, P1140	36	85	87	0	0	AMER THORACIC SOC	NEW YORK	1740 BROADWAY, NEW YORK, NY 10019-4374 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	NOV	2000	162	5					1912	1918				7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	371WU	WOS:000165202900054	11069834	
J	Alvarez, MJ; Olaguibel, JM; Garcia, BE; Rodriguez, A; Tabar, AI; Urbiola, E				Alvarez, MJ; Olaguibel, JM; Garcia, BE; Rodriguez, A; Tabar, AI; Urbiola, E			Airway inflammation in asthma and perennial allergic rhinitis. Relationship with nonspecific bronchial responsiveness and maximal airway narrowing	ALLERGY			English	Article						airway inflammation; asthma; eosinophil cationic protein; eosinophils; induced sputum; maximal response plateau; nonspecific bronchial hyperresponsiveness; rhinitis; tryptase	INDUCED SPUTUM; MAST-CELLS; BRONCHOALVEOLAR LAVAGE; HEALTHY-SUBJECTS; EOSINOPHILS; BLOOD; HYPERRESPONSIVENESS; REPRODUCIBILITY; CHALLENGE; BIOPSIES	Background: Eosinophilic airway inflammation is the hallmark of asthma, but it has also been reported in other conditions such as allergic rhinitis. We have tested whether the analysis of cells and chemicals in sputum can distinguish between patients with mild allergic asthma, those with allergic rhinitis, and healthy controls. The relationship between inflammation markers in sputum and nonspecific bronchial hyperresponsiveness to methacholine (BHR) (PD20 and maximal response plateau [MRP] values) was also evaluated. Methods: We selected 31 mild asthmatics and 15 rhinitis patients sensitized to house-dust mite. As a control group, we studied 10 healthy subjects. Every subject underwent the methacholine bronchial provocation test (M-BPT) and sputum induction. Blood eosinophils and serum ECP levels were measured. Sputum cell differentials were assessed, and eosinophil cationic protein (ECP), tryptase, albumin, and interleukin (IL)-5 levels were measured in the entire sputum supernatant. Results: Blood eosinophils and serum ECP levels were higher in asthma patients and rhinitis than in healthy controls, but no difference: between asthma patients and rhinitis patients was found. Asthmatics had higher eosinophil counts and higher ECP and tryptase levels in sputum than rhinitis patients or control subjects. Sputum albumin levels were higher in asthmatics than in controls. Rhinitis patients exhibited higher sputum eosinophils than healthy controls. An association between sputum eosinophil numbers and MPR values (r = -0.57) was detected, and a trend toward correlation between sputum ECP levels and PD20 values (r = -0.47) was found in the rhinitis group, but not in asthmatics. No correlation between blood eosinophilic inflammation and lung functional indices was found. Conclusions: Induced sputum is an accurate method to study bronchial inflammation, allowing one to distinguish between rhinitis patients and mildly asthmatic patients. The fact that no relationship was detected between sputum inflammation and BHR suggests that other factors, such as airway remodeling, may be at least partly responsible for BHR in asthma.	Hosp Virgen Camino, Serv Alergol, Pamplona, Spain; Hosp Virgen Camino, Serv Patol, Pamplona, Spain	Olaguibel, JM (reprint author), Plaza La Paz SN, Pamplona 31002, Spain.						BOUSQUET J, 1992, ALLERGY, V47, P3, DOI 10.1111/j.1398-9995.1992.tb02242.x; BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; CLAMAN DM, 1994, J ALLERGY CLIN IMMUN, V94, P861, DOI 10.1016/0091-6749(94)90154-6; CORRIGAN CJ, 1993, ALLERGY PRINCIPLES P, P206; CRAPO RO, 1981, AM REV RESPIR DIS, V123, P659; CRIMI E, 1988, AM J CRIT CARE MED, V157, P4; DJUKANOVIC R, 1990, AM REV RESPIR DIS, V142, P863; DURHAM SR, 1989, J ALLERGY CLIN IMMUN, V84, P931, DOI 10.1016/0091-6749(89)90391-6; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53; FAHY JV, 1993, AM REV RESPIR DIS, V147, P1126; Foresi A, 1997, J ALLERGY CLIN IMMUN, V100, P58; GALLI SJ, 1995, ALLERGY, V50, P851, DOI 10.1111/j.1398-9995.1995.tb02490.x; Gershman NH, 1996, EUR RESPIR J, V9, P2448, DOI 10.1183/09031936.96.09122448; Grootendorst DC, 1997, CLIN EXP ALLERGY, V27, P769, DOI 10.1046/j.1365-2222.1997.890900.x; IREDALE MJ, 1994, CLIN EXP ALLERGY, V24, P940, DOI 10.1111/j.1365-2222.1994.tb02725.x; JEFFERY PK, 1989, AM REV RESPIR DIS, V140, P1745; LAM S, 1991, J ALLERGY CLIN IMMUN, V87, P842, DOI 10.1016/0091-6749(91)90131-7; Louis R, 1997, AM J RESP CRIT CARE, V155, P466; Monteseirin J, 1993, Allergol Immunopathol (Madr), V21, P97; MORENO RH, 1986, AM REV RESPIR DIS, V133, P272; National Heart Lung and Blood Institute, 1991, J ALLERGY CLIN IMMUN, V88, P425; PIN I, 1992, THORAX, V47, P25, DOI 10.1136/thx.47.1.25; Pizzichini E, 1998, EUR RESPIR J, V11, P828, DOI 10.1183/09031936.98.11040828; Pizzichini E, 1997, J ALLERGY CLIN IMMUN, V99, P539, DOI 10.1016/S0091-6749(97)70082-4; Pizzichini E, 1996, AM J RESP CRIT CARE, V154, P308; POPOV T, 1994, CLIN EXP ALLERGY, V24, P778, DOI 10.1111/j.1365-2222.1994.tb00990.x; PRIETO L, 1990, ALLERGOL IMMUNOPATH, V18, P285; PRIETO L, 1990, REV ESP ALERGOL IMMU, V5, P57; Ronchi MC, 1997, EUR RESPIR J, V10, P1809, DOI 10.1183/09031936.97.10081809; SEDGWICK JB, 1991, AM REV RESPIR DIS, V144, P1274; Spanevello A, 1997, CLIN EXP ALLERGY, V27, P1138; STERK PJ, 1989, EUR RESPIR J, V2, P267; SUR S, 1993, ALLERGY PRINCIPLES P, P169	33	85	88	0	1	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy	APR	2000	55	4					355	362		10.1034/j.1398-9995.2000.00312.x		8	Allergy; Immunology	Allergy; Immunology	300WT	WOS:000086277300006	10782520	
J	Spiteri, MA; Bianco, A; Strange, RC; Fryer, AA				Spiteri, MA; Bianco, A; Strange, RC; Fryer, AA			Polymorphisms at the glutathione S-transferase, GSTP1 locus: a novel mechanism for susceptibility and development of atopic airway inflammation	ALLERGY			English	Article; Proceedings Paper	International Meeting on Experimental and Clinical-Therapeutic Features of Asthma	JUN 07-08, 1999	NAPLES, ITALY			airway inflammation; atopy; bronchial hyperresponsiveness; GSTP1 polymorphisms	POLYCYCLIC AROMATIC-HYDROCARBONS; HUMAN-LUNG; NITROGEN-DIOXIDE; DIOL EPOXIDES; EXPRESSION; EXPOSURE; ASTHMA; OZONE; PURIFICATION; ASSOCIATION	A common feature of environmental irritants is their ability to cause local inflammation which could alter airway function. The principal targets of such injury are the epithelial cells lining the airway passages and the lower respiratory gas-exchange areas. While host atopy is a recognized risk factor for airway inflammation, atopy alone cannot cause asthma. We hypothesize that susceptibility to persistent airway inflammation in atopic individuals is characterized by an inherited deficiency in the effectiveness of detoxification of inhaled irritants and products of oxidative stress such as reactive oxygen species (ROS). Our case-control studies show that polymorphisms at the glutathione S-transferase, GSTP1, locus on chromosome 11q13 may account for variation in host response to oxidative stress, a key component of airway inflammation. Frequency of the GSTP1 Val/Val genotype is reduced in atopic subjects compared with nonatopic subjects. Trend analysis also shows a significant decrease of GSTP1 Val/Val (with parallel increase of GSTP1 Ile/Ile) genotype frequency with increasing severity of airflow obstruction/bronchial hyperresponsiveness. The implication of specific polymorphisms at the GSTP1 locus in airway inflammation is entirely novel: however, GST are recognized as a supergene family of enzymes critical in 1) cell protection from the toxic products of ROS-mediated reactions, 2) modulation of eicosanoid synthesis.	Univ Keele, Dept Resp Med, Lung Injury & Inflammat Grp, Keele ST5 5BG, Staffs, England; Univ Keele, Ctr Cell & Mol Med, Clin Biochem Res Lab, Keele ST5 5BG, Staffs, England	Spiteri, MA (reprint author), N Staffordshire Hosp, Dept Resp Med, Lung Injury & Inflammat Grp, Stoke On Trent ST4 6QG, Staffs, England.						AliOsman F, 1997, J BIOL CHEM, V272, P10004; ANTTILA S, 1993, CANCER RES, V53, P5643; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; BECKETT GJ, 1990, BIOCHIM BIOPHYS ACTA, V1036, P176, DOI 10.1016/0304-4165(90)90031-Q; FRYER AA, 1986, BIOCHIM BIOPHYS ACTA, V883, P448, DOI 10.1016/0304-4165(86)90283-7; FRYER AA, 2000, IN PRESS AM J RESP C; GREENE LS, 1995, J AM COLL NUTR, V14, P317; Harries LW, 1997, CARCINOGENESIS, V18, P641, DOI 10.1093/carcin/18.4.641; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; HAZUCHA MJ, 1987, J APPL PHYSIOL, V62, P1671; Hu X, 1997, BIOCHEM BIOPH RES CO, V238, P397, DOI 10.1006/bbrc.1997.7311; Kelly FJ, 1996, AM J RESP CRIT CARE, V154, P1700; KELLY FJ, 1995, RESP MED, V89, P647, DOI 10.1016/0954-6111(95)90131-0; KOSKELO K, 1981, SCAND J CLIN LAB INV, V41, P683, DOI 10.3109/00365518109090515; Krishna MT, 1996, J ROY COLL PHYS LOND, V30, P61; LIU DX, 1995, FREE RADICAL BIO MED, V18, P571, DOI 10.1016/0891-5849(94)00154-C; Martinez J, 1996, ARCH BIOCHEM BIOPHYS, V336, P191, DOI 10.1006/abbi.1996.0549; Mattey DL, 1999, ANN RHEUM DIS, V58, P164, DOI 10.1136/ard.58.3.164; NINAN TK, 1992, BRIT MED J, V304, P873; PARTRIDGE CA, 1984, LUNG, V162, P27, DOI 10.1007/BF02715625; REITJENS IMC, 1986, J TOXICOL ENV HLTH, V19, P555; SPITERI MA, 1994, EUR RESPIR J, V7, P1431, DOI 10.1183/09031936.94.07081431; STRANGE RC, 1990, GLUTATHIONE S-TRANSFERASES AND DRUG RESISTANCE, P262; Sundberg K, 1998, CARCINOGENESIS, V19, P433, DOI 10.1093/carcin/19.3.433; Thomas NS, 1997, AM J RESP CRIT CARE, V156, pS144; Watson MA, 1998, CARCINOGENESIS, V19, P275, DOI 10.1093/carcin/19.2.275; Willey JC, 1996, AM J RESP CELL MOL, V14, P262	27	85	90	0	2	MUNKSGAARD INT PUBL LTD	COPENHAGEN	35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK	0105-4538			ALLERGY	Allergy		2000	55			61			15	20		10.1034/j.1398-9995.2000.00502.x		6	Allergy; Immunology	Allergy; Immunology	331NH	WOS:000088024800004	10919500	
J	Cao, C; Jiang, WJ; Wang, BY; Fang, JH; Lang, JD; Tian, G; Jiang, JK; Zhu, TF				Cao, Chen; Jiang, Wenjun; Wang, Buying; Fang, Jianhuo; Lang, Jidong; Tian, Geng; Jiang, Jingkun; Zhu, Ting F.			Inhalable Microorganisms in Beijing's PM2.5 and PM10 Pollutants during a Severe Smog Event	ENVIRONMENTAL SCIENCE & TECHNOLOGY			English	Article							AIRBORNE BACTERIAL COMMUNITIES; PARTICULATE MATTER; OXIDATIVE DAMAGE; AIR-POLLUTION; UNITED-STATES; CLEAN-AIR; HEALTH; CHINA; VARIABILITY; SIZE	Particulate matter (PM) air pollution poses a formidable public health threat to the city of Beijing. Among the various hazards of PM pollutants, microorganisms in PM2.5 and PM10 are thought to be responsible for various allergies and for the spread of respiratory diseases. While the physical and chemical properties of PM pollutants have been extensively studied, much less is known about the inhalable microorganisms. Most existing data on airborne microbial communities using 16S or 18S rRNA gene sequencing to categorize bacteria or fungi into the family or genus levels do not provide information on their allergenic and pathogenic potentials. Here we employed metagenomic methods to analyze the microbial composition of Beijing's PM pollutants during a severe January smog event. We show that with sufficient sequencing depth, airborne microbes including bacteria, archaea, fungi, and dsDNA viruses can be identified at the species level. Our results suggested that the majority of the inhalable microorganisms were soil-associated and nonpathogenic to human. Nevertheless, the sequences of several respiratory microbial allergens and pathogens were identified and their relative abundance appeared to have increased with increased concentrations of PM pollution. Our findings may serve as an important reference for environmental scientists, health workers, and city planners.	[Cao, Chen; Jiang, Wenjun; Zhu, Ting F.] Tsinghua Univ, Sch Life Sci,TNLIST, MOE Key Lab Bioinformat,Ctr Synth & Syst Biol, PTN Peking Univ Tsinghua Univ Natl Inst Biol Sci, Beijing 100084, Peoples R China; [Cao, Chen; Jiang, Wenjun; Zhu, Ting F.] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou 310003, Zhejiang, Peoples R China; [Cao, Chen] Peking Univ, Grad Program Sch Life Sci, Beijing 100871, Peoples R China; [Wang, Buying; Jiang, Jingkun] Tsinghua Univ, Sch Environm, State Key Joint Lab Environm Simulat & Pollut Con, Beijing 100084, Peoples R China; [Jiang, Jingkun] State Environm Protect Key Lab Sources & Control, Beijing 100084, Peoples R China; [Fang, Jianhuo; Lang, Jidong; Tian, Geng] Tsinghua Univ, Sch Life Sci, Ctr Biomed Anal, Beijing 100084, Peoples R China	Zhu, TF (reprint author), Tsinghua Univ, Sch Life Sci,TNLIST, MOE Key Lab Bioinformat,Ctr Synth & Syst Biol, PTN Peking Univ Tsinghua Univ Natl Inst Biol Sci, Beijing 100084, Peoples R China.	tiangeng@biomed.tsinghua.edu.cn; jiangjk@tsinghua.edu.cn; tzhu@biomed.tsinghua.edu.cn	Jiang, Jingkun/A-1076-2010		Tsinghua University-Peking University Center for Life Sciences (CLS); Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases; Science and Technology Major Project of the Ministry of Science and Technology of China [2013ZX10003003]; National Natural Science Foundation of China [21190054, 21107060, 21221004]; Center for Marine Medicine and Rescue of Tsinghua University; Tsinghua Qian Ren Tuan Dui funding	We thank Gong Cheng, Lei Huang, Babak Javid, Masood Kayani, Yigong Shi, Melody Toosky, Hongwei Wang, Zhen Xie, Nieng Yan, Li Yu, Jingren Zhang, and Michael Q Zhang for helpful discussions and comments on the manuscript, and Qingran Bai, He Chen, Siyu Chen, Zhen Cheng, Hongliang Fu, Ru He, Long Hu, Dongfang Li, Junxiang Li, Cuihua Liu, Kaigui Luo, Peng Liang, Yu Liang, Yongbin Li, Zhixun Shen, Shuxiao Wang, Tingting Wang, Zhiying Xie, Siyin Zhang, and Wei Zhou for their assistance with the experiments. BGI-Shenzhen provided the sequencing platforms used in this study and assistance in preliminary sequence analysis. NSCC-TJ (D.L.) and Tsinghua University School of Information Science and Technology provided computational facilities and assistance with the data analysis. This work was supported in part by funding from the Tsinghua University-Peking University Center for Life Sciences (CLS), Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the Science and Technology Major Project of the Ministry of Science and Technology of China (Grant No. 2013ZX10003003 to Z.Z.), National Natural Science Foundation of China (Grant No. 21190054, 21107060, and 21221004), Center for Marine Medicine and Rescue of Tsinghua University, and Tsinghua Qian Ren Tuan Dui funding (to M.Q.Z.).	Acinas SG, 2005, APPL ENVIRON MICROB, V71, P8966, DOI 10.1128/AEM.71.12.8966-8969.2005; Bertolini V, 2013, APPL MICROBIOL BIOT, V97, P6561, DOI 10.1007/s00253-012-4450-0; Bowers RM, 2013, ENVIRON SCI TECHNOL, V47, P12097, DOI 10.1021/es402970s; Bowers RM, 2011, APPL ENVIRON MICROB, V77, P6350, DOI 10.1128/AEM.05498-11; Bowers RM, 2011, ISME J, V5, P601, DOI 10.1038/ismej.2010.167; Bowers RM, 2009, APPL ENVIRON MICROB, V75, P5121, DOI 10.1128/AEM.00447-09; Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104; Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8; Cheng Z, 2013, ATMOS ENVIRON, V65, P186, DOI 10.1016/j.atmosenv.2012.10.022; Clifton Ian J, 2010, Expert Rev Respir Med, V4, P519, DOI 10.1586/ers.10.42; Deacon LJ, 2009, ATMOS ENVIRON, V43, P5698, DOI 10.1016/j.atmosenv.2009.07.042; DeLeon-Rodriguez N, 2013, P NATL ACAD SCI USA, V110, P2575, DOI 10.1073/pnas.1212089110; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Duhaime MB, 2012, ENVIRON MICROBIOL, V14, P2526, DOI 10.1111/j.1462-2920.2012.02791.x; Eames I, 2009, J R SOC INTERFACE, V6, pS697, DOI 10.1098/rsif.2009.0407.focus; Ferroni A, 2008, J CYST FIBROS, V7, P477, DOI 10.1016/j.jcf.2008.05.001; Fowler D., 2013, RES FINDINGS SUPPORT; Haddad SH, 2004, INT J INFECT DIS, V8, P210, DOI 10.1016/j.ijid.2003.10.007; Hanzalova K, 2010, MUTAT RES-GEN TOX EN, V696, P114, DOI 10.1016/j.mrgentox.2009.12.018; He KB, 2001, ATMOS ENVIRON, V35, P4959, DOI 10.1016/S1352-2310(01)00301-6; Hunt A, 2003, ENVIRON HEALTH PERSP, V111, P1209, DOI 10.1289/ehp.6114; Jaenicke R, 2005, SCIENCE, V308, P73, DOI 10.1126/science.1106335; Lee SA, 2014, SCI TOTAL ENVIRON, V466, P725, DOI 10.1016/j.scitotenv.2013.07.104; Lee T, 2006, INDOOR AIR, V16, P37, DOI 10.1111/j.1600-0668.2005.00396.x; Li RQ, 2009, BIOINFORMATICS, V25, P1966, DOI 10.1093/bioinformatics/btp336; Lim WS, 2001, THORAX, V56, P296, DOI 10.1136/thorax.56.4.296; Menzies D, 2000, ANN INTERN MED, V133, P779; Meyer F., 2008, BMC BIOINFORMATICS, V9, P1, DOI DOI 10.1186/1471-2105-9-S10-01.PUBMED:18173834; Nierman WC, 2005, NATURE, V438, P1151, DOI 10.1038/nature04332; Ouyang YD, 2013, LANCET RESP MED, V1, P12, DOI 10.1016/S2213-2600(12)70065-6; Parrish DD, 2009, SCIENCE, V326, P674, DOI 10.1126/science.1176064; Pope CA, 2009, NEW ENGL J MED, V360, P376, DOI 10.1056/NEJMsa0805646; Qin JJ, 2012, NATURE, V490, P55, DOI 10.1038/nature11450; Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821; Reponen T, 1996, ATMOS ENVIRON, V30, P3967, DOI 10.1016/1352-2310(96)00128-8; Robertson CE, 2013, APPL ENVIRON MICROB, V79, P3485, DOI 10.1128/AEM.00331-13; Segata N, 2012, NAT METHODS, V9, P811, DOI [10.1038/nmeth.2066, 10.1038/NMETH.2066]; Shike H, 2005, PEDIATR INFECT DIS J, V24, P29, DOI 10.1097/01.inf.0000148882.97399.79; Sjoling A, 2007, J CLIN MICROBIOL, V45, P3295, DOI 10.1128/JCM.00471-07; Stanier CO, 2004, AEROSOL SCI TECH, V38, P215, DOI 10.1080/02786820390229525; Valavanidis A, 2008, J ENVIRON SCI HEAL C, V26, P339, DOI 10.1080/10590500802494538; Wang SX, 2010, ENVIRON SCI TECHNOL, V44, P2490, DOI 10.1021/es9028167; Yang F, 2011, ATMOS CHEM PHYS, V11, P5207, DOI 10.5194/acp-11-5207-2011; Zhang JF, 2010, LANCET, V375, P1110, DOI 10.1016/S0140-6736(10)60062-1; Zhang Q, 2012, NATURE, V484, P161, DOI 10.1038/484161a	45	84	101	49	285	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	0013-936X	1520-5851		ENVIRON SCI TECHNOL	Environ. Sci. Technol.	FEB 4	2014	48	3					1499	1507		10.1021/es4048472		9	Engineering, Environmental; Environmental Sciences	Engineering; Environmental Sciences & Ecology	AA3TL	WOS:000331015100020	24456276	
J	Loss, G; Apprich, S; Waser, M; Kneifel, W; Genuneit, J; Buchele, G; Weber, J; Sozanska, B; Danielewicz, H; Horak, E; van Neerven, RJJ; Heederik, D; Lorenzen, PC; von Mutius, E; Braun-Fahrlander, C				Loss, Georg; Apprich, Silvia; Waser, Marco; Kneifel, Wolfgang; Genuneit, Jon; Buechele, Gisela; Weber, Juliane; Sozanska, Barbara; Danielewicz, Hanna; Horak, Elisabeth; van Neerven, R. J. Joost; Heederik, Dick; Lorenzen, Peter C.; von Mutius, Erika; Braun-Fahrlaender, Charlotte		GABRIELA Study Grp	The protective effect of farm milk consumption on childhood asthma and atopy: The GABRIELA study	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Allergic diseases; asthma; atopy; children; farming; hay fever; microorganism; farm milk; risk; whey protein	SCHOOL-AGE-CHILDREN; INVERSE ASSOCIATION; INNATE IMMUNITY; EXPOSURE; ALLERGY; HEALTH; BETA; LIFE; PREVALENCE; EXPRESSION	Background: Farm milk consumption has been identified as an exposure that might contribute to the protective effect of farm life on childhood asthma and allergies. The mechanism of action and the role of particular constituents of farm milk, however, are not yet clear. Objective: We sought to investigate the farm milk effect and determine responsible milk constituents. Methods: In rural regions of Germany, Austria, and Switzerland, a comprehensive questionnaire about farm milk consumption and other farm-related exposures was completed by parents of 8334 school-aged children, and 7606 of them provided serum samples to assess specific IgE levels. In 800 cow's milk samples collected at the participants' homes, viable bacterial counts, whey protein levels, and total fat content were analyzed. Asthma, atopy, and hay fever were associated to reported milk consumption and for the first time to objectively measured milk constituents by using multiple regression analyses. Results: Reported raw milk consumption was inversely associated to asthma (adjusted odds ratio [aOR], 0.59; 95% CI, 0.46-0.74), atopy (aOR, 0.74; 95% CI, 0.61-0.90), and hay fever (aOR, 0.51; 95% CI, 0.37-0.69) independent of other farm exposures. Boiled farm milk did not show a protective effect. Total viable bacterial counts and total fat content of milk were not significantly related to asthma or atopy. Increased levels of the whey proteins BSA (aOR for highest vs lowest levels and asthma, 0.53; 95% CI, 0.30-0.97), alpha-lactalbumin (aOR for interquartile range and asthma, 0.71; 95% CI, 0.52-0.97), and beta-lactoglobulin (aOR for interquartile range and asthma, 0.62; 95% CI, 0.39-0.97), however, were inversely associated with asthma but not with atopy. Conclusions: The findings suggest that the protective effect of raw milk consumption on asthma might be associated with the whey protein fraction of milk. (J Allergy Clin Immunol 2011;128:766-73.)	[Loss, Georg; Waser, Marco; Braun-Fahrlaender, Charlotte] Swiss Trop & Publ Hlth Inst, CH-4002 Basel, Switzerland; [Loss, Georg; Waser, Marco; Braun-Fahrlaender, Charlotte] Univ Basel, CH-4003 Basel, Switzerland; [Apprich, Silvia; Kneifel, Wolfgang] Univ Nat Resources & Life Sci, BOKU Vienna, Dept Food Sci & Technol, Vienna, Austria; [Genuneit, Jon; Buechele, Gisela] Univ Ulm, Inst Epidemiol & Med Biometry, D-89069 Ulm, Germany; [Weber, Juliane; von Mutius, Erika] Ludwig Maximilians Univ Munchen, Univ Childrens Hosp, Munich, Germany; [Sozanska, Barbara; Danielewicz, Hanna] Wroclaw Med Univ, Dept Paediat Allergol & Cardiol 1, Wroclaw, Poland; [Horak, Elisabeth] Innsbruck Med Univ, Dept Pediat & Adolescents, Div Cardiol & Pulmonol, Innsbruck, Austria; [van Neerven, R. J. Joost] Friesland Campina Res, Deventer, Netherlands; [Heederik, Dick] Univ Utrecht, IRAS, Div Environm Epidemiol, NL-3508 TC Utrecht, Netherlands; [Lorenzen, Peter C.] Max Rubner Inst, Fed Res Inst Nutr & Food, Dept Safety & Qual Milk & Fish Prod, Kiel, Germany	Loss, G (reprint author), Swiss Trop & Publ Hlth Inst, Socinstr 57,POB, CH-4002 Basel, Switzerland.	georg.loss@unibas.ch	Loss, Georg/F-1557-2013; Genuneit, Jon/I-9323-2012; Lauener, Roger/O-8612-2016	Genuneit, Jon/0000-0001-5764-1528; Lauener, Roger/0000-0002-8412-606X; Ege, Markus/0000-0001-6643-3923; von Mutius, Erika/0000-0002-8893-4515	European Union [LSH-2004-1.2.5-1, 018996]; European Commission; InfectoPharm; Airsonett AB; Deutsche Forschungsgemeinschaft (DFG); BMBF	Supported by a European Union Research grant under the FP6-LifeSCIHEALTH Integrated Program LSH-2004-1.2.5-1 (contract no. 018996).; J. Weber, B. Sozanska, H. Danielewicz, A Boznanski, A. Debinska, M. Depner, A. Kosmeda, and C. Strunz-Lehner have received research support from the European Commission. D. Heederik and I. M. Wouters have received research support from the European Union. E. von Mutius is a consultant for Novartis, GlaxoSmithKline, ALK-Abello, and Protectimmun; has received a speaker's fee from InfectoPharm; has received research support from Airsonett AB; is a member of the Expert Panel for UK Research Excellence Framework; and is an Associate Editor for the Journal of Allergy and Clinical Immunology. M. Ege has received research support from the European Commission and the Deutsche Forschungsgemeinschaft (DFG). M. Kabesch has financial interests in Roxall, GlaxoSmithKline, Novartis, Sanofi-Aventis, Allergopharma, and AstraZeneca GmbH and has received research support from DFG, BMBF, and the European Union. The rest of the authors have declared that they have no conflict of interest.	Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bieli C, 2007, J ALLERGY CLIN IMMUN, V120, P1308, DOI 10.1016/j.jaci.2007.07.034; Black PN, 1997, EUR RESPIR J, V10, P6, DOI 10.1183/09031936.97.10010006; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Conroy ME, 2009, CURR OPIN ALLERGY CL, V9, P197, DOI 10.1097/ACI.0b013e32832b3f1d; Desmasures N, 1997, J APPL MICROBIOL, V83, P53, DOI 10.1046/j.1365-2672.1997.00166.x; Eder W, 2006, NEW ENGL J MED, V355, P2226, DOI 10.1056/NEJMra054308; Ege MJ, 2011, NEW ENGL J MED, V364, P701, DOI 10.1056/NEJMoa1007302; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Genuneit J, 2011, PAEDIATR PERINAT EP, V25, P436, DOI 10.1111/j.1365-3016.2011.01223.x; International Dairy Federation, 1991, 100B IDF; Krissansen GW, 2007, J AM COLL NUTR, V26, p713S; Li MO, 2006, ANNU REV IMMUNOL, V24, P99, DOI 10.1146/annurev.immunol.24.021605.090737; Lorenzen PC, 2011, INT J DAIRY TECHNOL, V64, P166, DOI 10.1111/j.1471-0307.2010.00656.x; Mosconi E, 2010, MUCOSAL IMMUNOL, V3, P461, DOI 10.1038/mi.2010.23; Oddy WH, 2010, PEDIATR ALLERGY IMMU, V21, P47, DOI 10.1111/j.1399-3038.2009.00913.x; Perkin MR, 2007, CLIN EXP ALLERGY, V37, P627, DOI 10.1111/j.1365-2222.2007.02715.x; Perkin MR, 2006, J ALLERGY CLIN IMMUN, V117, P1374, DOI 10.1016/j.jaci.2006.03.008; Peroni DG, 2010, PEDIAT ALLERG IMM-UK, V21, P977, DOI 10.1111/j.1399-3038.2010.00995.x; Peroni DG, 2009, PEDIAT ALLERG IMM-UK, V20, P42, DOI 10.1111/j.1399-3038.2008.00737.x; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, P108, DOI 10.1016/j.jaci.2009.09.019; Pfefferle PI, 2010, J ALLERGY CLIN IMMUN, V125, pe1; Puddu P, 2009, BIOCHIMIE, V91, P11, DOI 10.1016/j.biochi.2008.05.005; Remes ST, 2003, CLIN EXP ALLERGY, V33, P427, DOI 10.1046/j.1365-2222.2003.01566.x; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Rusu D, 2009, J NUTR, V139, P386, DOI 10.3945/jn.108.098459; Sly PD, 2008, LANCET, V372, P1100, DOI 10.1016/S0140-6736(08)61451-8; Thijs C, 2010, ALLERGY, V66, P58; von Mutius E, 2010, NAT REV IMMUNOL, V10, P861, DOI 10.1038/nri2871; Waser M, 2007, CLIN EXP ALLERGY, V37, P661, DOI 10.1111/j.1365-2222.2006.02640.x; Wijga AH, 2003, THORAX, V58, P567, DOI 10.1136/thorax.58.7.567; Yoshida T, 2005, J AGR FOOD CHEM, V53, P6851, DOI 10.1021/jf050772k	32	84	85	2	34	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	OCT	2011	128	4					766	U432		10.1016/j.jaci.2011.07.048		12	Allergy; Immunology	Allergy; Immunology	841UA	WOS:000296538100010	21875744	
J	Henneberger, PK; Redlich, CA; Callahan, DB; Harber, P; Lemiere, C; Martin, J; Tarlo, SM; Vandenplas, O; Toren, K				Henneberger, Paul K.; Redlich, Carrie A.; Callahan, David B.; Harber, Philip; Lemiere, Catherine; Martin, James; Tarlo, Susan M.; Vandenplas, Olivier; Toren, Kjell		ATS Ad Hoc Comm Work Exacerbated	An Official American Thoracic Society Statement: Work-Exacerbated Asthma	AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE			English	Article						asthma; occupational diseases; work-related asthma; exacerbation; work-exacerbated asthma	QUALITY-OF-LIFE; DIAGNOSING OCCUPATIONAL ASTHMA; WORKPLACE EXACERBATION; LUNG-FUNCTION; AIRWAY INFLAMMATION; CHRONIC-BRONCHITIS; RESPIRATORY-TRACT; SIGNALING CASCADE; SULFUR-DIOXIDE; INDUCED SPUTUM	Rationale: Occupational exposures can contribute to the exacerbation as well as the onset of asthma. However, work-exacerbated asthma (WEA) has received less attention than occupational asthma (OA) that is caused by work. Objectives: The purpose of this Statement is to summarize current knowledge about the descriptive epidemiology, clinical characteristics, and management and treatment of WEA; propose a case definition for WEA; and discuss needs for prevention and research. Methods: Information about WEA was identified primarily by systematic searches of the medical literature. Statements about prevention and research needs were reached by consensus. Measurements and Main Results: WEA is defined as the worsening of asthma due to conditions at work. WEA is common, with a median prevalence of 21.5% among adults with asthma. Different types of agents or conditions at work may exacerbate asthma. WEA cases with persistent work-related symptoms can have clinical characteristics (level of severity, medication needs) and adverse socioeconomic outcomes (unemployment, reduction in income) similar to those of OA cases. Compared with adults with asthma unrelated to work, WEA cases report more days with symptoms, seek more medical care, and have a lower quality of life. WEA should be considered in any patient with asthma that is getting worse or who has work-related symptoms. Management of WEA should focus on reducing work exposures and optimizing standard medical management, with a change in jobs only if these measures are not successful. Conclusions: WEA is a common and under recognized adverse outcome resulting from conditions at work. Additional research is needed to improve the understanding of the risk factors for, and mechanisms and outcomes of, WEA, and to inform and evaluate preventive interventions.						e Donaghue Research Foundation; American Conference Institute; BNSF Foundation; International Carbon Black Association; Kaiser Permanente; Astra Zeneca; Boehringer Ingelheim; Ception Therapeutics; MedImmune; Wyeth; Merck; Novartis; Allergen; British Columbia Workers Compensation Board; Manitoba Workers Compensation Board; Ontario Workplace Safety and Insurance Board	P.K.H., K.T., and O.V. reported that they received no payments or services from a third party for the work submitted, and had no relevant financial activities outside the submitted work. C. A. R. reported serving on an advisory board for Firmenich S. A. ($5,001-$10,000), receiving author royalties from Elsevier Medical Publishing ($1,000 or less), and a research grant from the Donaghue Research Foundation ($50,001-$100,000). She also reported review of medical records for law firms related to workers compensation, disability, or occupational issues ($1,001-$5,000). D. B. C. reported stock holdings in General Electric ($1,001-$5,000), 3M ($1,001-$5,000), Microsoft ($1,001-$5,000), and Proctor and Gamble ($5,001-$10,000). P. H. reported lecture fees from American Conference Institute ($1,000 or less), fees paid to his institution for medical evaluations and expert testimony regarding individuals with occupational issues ($50,001-$100,000), and research grants paid to his institution from BNSF Foundation ($50,001-$100,000), International Carbon Black Association ($50,001-$100,000), and Kaiser Permanente ($100,001 or more). C. L. reported consultancies for Glaxo Smith Kline ($5,001-$10,000) and Topigen ($1,001-$5,000), and advisory board service for Altana ($1,001-$5,000), Astra Zeneca (up to $1,000), Merck Frosst (up to $1,000), and Novartis (up to $1,000). She received lecture fees from Astra Zeneca ($1,001-$5,000) and Novartis (up to $1,000), and research grants from Astra Zeneca ($10,001-$50,000), Boehringer Ingelheim ($10,001-$50,000), Ception Therapeutics ($10,001-$50,000), MedImmune ($5001-$10,000), and Wyeth ($10,001-$50,000). J. M. received lecture fees from Merck ($1,001-$5,000) and Novartis ($1,001-$5,000), and a research grant from Merck ($50,001-$100,000). S. M. T. reported fees paid to her institution for patient medical assessments for workers compensation systems, their appeals tribunals, and insurance companies ($50,001-$100,000). She also reported research grants from Allergen ($100,001 or more), the British Columbia Workers Compensation Board ($10,001-$50,000), the Manitoba Workers Compensation Board ($100,001 or more), and the Ontario Workplace Safety and Insurance Board ($100,001 or more).	ABRAMSON MJ, 1995, MED J AUSTRALIA, V162, P78; AXON EJ, 1995, OCCUP MED-OXFORD, V45, P109, DOI 10.1093/occmed/45.2.109; Bai TR, 2007, EUR RESPIR J, V30, P452, DOI 10.1183/09031936.00165106; Balder B, 1998, RESP MED, V92, P729, DOI 10.1016/S0954-6111(98)90003-8; Balmes J, 2003, AM J RESP CRIT CARE, V167, P787, DOI 10.1164/rccm.167.5.787; Berger Z, 2006, J OCCUP ENVIRON MED, V48, P833, DOI 10.1097/01.jom.0000225169.45337.97; Bessac BF, 2008, J CLIN INVEST, V118, P1899, DOI 10.1172/JCI34192; Bessac BF, 2008, PHYSIOLOGY, V23, P360, DOI 10.1152/physiol.00026.2008; Bianchi ME, 2007, J LEUKOCYTE BIOL, V81, P1, DOI 10.1189/jlb.0306164; Blanc PD, 2003, CHEST, V124, P1153, DOI 10.1378/chest.124.3.1153; Blanc PD, 1999, AM J RESP CRIT CARE, V160, P2028; Bolen AR, 2007, OCCUP ENVIRON MED, V64, P343, DOI 10.1136/oem.028662; Bresnitz EA, 2004, AM J RESP CRIT CARE, V169, P873, DOI 10.1164/rccm.169.7.873; Breton CV, 2006, OCCUP ENVIRON MED, V63, P411, DOI 10.1136/oem.2005.025064; Caldeira RD, 2006, OCCUP ENVIRON MED, V63, P694, DOI 10.1136/oem.2005.025916; CANNON J, 1995, BRIT MED J, V311, P602; Chiry S, 2007, CHEST, V132, P483, DOI 10.1378/chest.07-0460; Demnati R., 1995, Journal of Environmental Pathology Toxicology and Oncology, V14, P15; Depuydt PO, 2002, CLIN EXP ALLERGY, V32, P391, DOI 10.1046/j.1365-2222.2002.01364.x; Gassert TH, 1998, J OCCUP ENVIRON MED, V40, P481, DOI 10.1097/00043764-199805000-00011; Gilmour MI, 1996, FUND APPL TOXICOL, V31, P65, DOI 10.1006/faat.1996.0076; Girard F, 2004, AM J RESP CRIT CARE, V170, P845, DOI 10.1164/rccm.200403-380OC; Goe SK, 2004, OCCUP ENVIRON MED, V61, P512, DOI 10.1136/oem.2003.008177; Goh L. G., 1994, Singapore Medical Journal, V35, P190; Hao MQ, 2003, J ALLERGY CLIN IMMUN, V112, P905, DOI 10.1067/mai.2003.1780; HARBER P, 1994, CHEST, V105, P1564, DOI 10.1378/chest.105.5.1564; HARBER P, 1991, CHEST, V100, P340, DOI 10.1378/chest.100.2.340; Hashimoto KI, 2001, AM J RESP CRIT CARE, V164, P1957; Henneberger PK, 2006, OCCUP ENVIRON MED, V63, P551, DOI 10.1136/oem.2005.024786; Henneberger PK, 2003, ARCH ENVIRON HEALTH, V58, P781; Henneberger PK, 2002, INT J OCCUP ENV HEAL, V8, P291; Holt PG, 2008, NAT REV IMMUNOL, V8, P142, DOI 10.1038/nri2236; Jajosky R A, 1999, MMWR CDC Surveill Summ, V48, P1; Johnson A, 2006, OCCUP MED-OXFORD, V56, P258, DOI 10.1093/occmed/kql020; Johnson AR, 2000, AM J RESP CRIT CARE, V162, P2058; KOENIG JQ, 1992, J ALLERGY CLIN IMMUN, V89, P789, DOI 10.1016/0091-6749(92)90432-2; Koff JL, 2006, J IMMUNOL, V177, P8693; Larbanois A, 2002, EUR RESPIR J, V19, P1107, DOI 10.1183/09031936.02.00272202; Lemiere C, 2001, J ALLERGY CLIN IMMUN, V107, P1063, DOI 10.1067/mai.2001.115486; Lemiere C, 1999, EUR RESPIR J, V13, P482, DOI 10.1183/09031936.99.13348299; Lemiere C, 2007, J ALLERGY CLIN IMMUN, V120, P1354, DOI 10.1016/j.jaci.2007.07.043; Long NC, 1999, EUR RESPIR J, V14, P46, DOI 10.1034/j.1399-3003.1999.14a10.x; Lowery EP, 2007, QUAL LIFE RES, V16, P1605, DOI 10.1007/s11136-007-9274-5; MAESTRELLI P, 1994, CLIN EXP ALLERGY, V24, P29, DOI 10.1111/j.1365-2222.1994.tb00913.x; Malo JL, 2001, J ALLERGY CLIN IMMUN, V108, P317, DOI 10.1067/mai.2001.116432; Mancuso CA, 2003, AM J IND MED, V44, P236, DOI 10.1002/ajim.10257; Mapp CE, 2005, AM J RESP CRIT CARE, V172, P280, DOI 10.1164/rccm.200311-1575SO; MARKS GB, 1993, J CLIN EPIDEMIOL, V46, P1103, DOI 10.1016/0895-4356(93)90109-E; MARKS GB, 1992, J CLIN EPIDEMIOL, V45, P461, DOI 10.1016/0895-4356(92)90095-5; MCCLELLAN VE, 1990, NEW ZEAL MED J, V103, P399; McGovern T, 2010, AM J PHYSIOL-LUNG C, V299, pL808, DOI 10.1152/ajplung.00438.2009; Michel O, 2000, ANN ALLERG ASTHMA IM, V85, P305; Moorman Jeanne E., 2007, Morbidity and Mortality Weekly Report, V56, P1; Nakanaga T, 2007, AM J PHYSIOL-LUNG C, V292, pL1289, DOI 10.1152/ajplung.00356.2006; National Center for Health Statistics, 2007, ASTHM PREV HLTH CAR; O'Byrne PM, 2009, AM J RESP CRIT CARE, V179, P19, DOI 10.1164/rccm.200807-1126OC; Obata H, 1999, EUR RESPIR J, V13, P489, DOI 10.1183/09031936.99.13348999; Pelissier Sherley, 2006, J Occup Environ Med, V48, P656; Pellegrino R, 2005, EUR RESPIR J, V26, P948, DOI 10.1183/09031936.05.00035205; Piirila PL, 2005, J OCCUP HEALTH, V47, P112, DOI 10.1539/joh.47.112; Radon K, 2002, CHEST, V122, P1086, DOI 10.1378/chest.122.3.1086; Ramos-Barbon D, 2004, CLIN REV ALLERG IMMU, V27, P3, DOI 10.1385/CRIAI:27:1:003; Reed PL, 2007, AM J IND MED, V50, P646, DOI 10.1002/ajim.20504; Saarinen K, 2003, EUR RESPIR J, V22, P305, DOI 10.1183/09031936.03.00100102; Santos MS, 2007, CHEST, V131, P1768, DOI 10.1378/chest.06-2787; Schelegle ES, 2003, TOXICOL APPL PHARM, V186, P127, DOI 10.1016/S0041-008X(02)00026-1; Song MY, 2011, ANTIOXID REDOX SIGN, V15, P1549, DOI 10.1089/ars.2010.3648; Tager IB, 2005, EPIDEMIOLOGY, V16, P751, DOI 10.1097/01.ede.0000183166.68809.b0; Tarlo SM, 2003, CAN MED ASSOC J, V168, P867; TARLO SM, 1995, CHEST, V107, P634, DOI 10.1378/chest.107.3.634; Tarlo SM, 2000, CHEST, V118, P1309, DOI 10.1378/chest.118.5.1309; Tarlo SM, 2008, CHEST, V134, p1S, DOI 10.1378/chest.08-0201; Vandenplas O, 2003, EUR RESPIR J, V22, P689, DOI 10.1183/09031936.03.00053203; Wang PS, 2003, J OCCUP ENVIRON MED, V45, P1303, DOI 10.1097/01.jom.0000100200.90573.df; Wheeler S, 1998, WESTERN J MED, V168, P98; WIEBICKE W, 1990, J ALLERGY CLIN IMMUN, V86, P915, DOI 10.1016/S0091-6749(05)80155-1; ZEJDA JE, 1994, J OCCUP ENVIRON MED, V36, P49	77	84	84	0	13	AMER THORACIC SOC	NEW YORK	61 BROADWAY, FL 4, NEW YORK, NY 10006 USA	1073-449X			AM J RESP CRIT CARE	Am. J. Respir. Crit. Care Med.	AUG 1	2011	184	3					368	378		10.1164/rccm.812011ST		11	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	808EE	WOS:000293958800016	21804122	
J	Fujimura, KE; Johnson, CC; Ownby, DR; Cox, MJ; Brodie, EL; Havstad, SL; Zoratti, EM; Woodcroft, KJ; Bobbitt, KR; Wegienka, G; Boushey, HA; Lynch, SV				Fujimura, Kei E.; Johnson, Christine C.; Ownby, Dennis R.; Cox, Michael J.; Brodie, Eoin L.; Havstad, Suzanne L.; Zoratti, Edward M.; Woodcroft, Kimberley J.; Bobbitt, Kevin R.; Wegienka, Ganesa; Boushey, Homer A.; Lynch, Susan V.			Man's best friend? The effect of pet ownership on house dust microbial communities	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Letter							EXPOSURE; ALLERGY		[Fujimura, Kei E.; Cox, Michael J.; Lynch, Susan V.] Univ Calif San Francisco, Div Gastroenterol, Colitis & Crohns Dis Ctr, San Francisco, CA 94143 USA; [Boushey, Homer A.] Univ Calif San Francisco, Dept Med, Div Pulm & Crit Care, San Francisco, CA USA; [Johnson, Christine C.; Havstad, Suzanne L.; Woodcroft, Kimberley J.; Bobbitt, Kevin R.; Wegienka, Ganesa] Henry Ford Hosp, Dept Biostat & Res Epidemiol, Detroit, MI 48202 USA; [Zoratti, Edward M.] Henry Ford Hosp, Dept Internal Med, Div Allergy & Immunol, Detroit, MI 48202 USA; [Ownby, Dennis R.] Med Coll Georgia, Dept Pediat, Div Allergy Immunol, Augusta, GA 30912 USA; [Brodie, Eoin L.] Lawrence Berkeley Natl Lab, Ctr Environm Biotechnol, Berkeley, CA USA	Fujimura, KE (reprint author), Univ Calif San Francisco, Div Gastroenterol, Colitis & Crohns Dis Ctr, San Francisco, CA 94143 USA.	susan.lynch@ucsf.edu	Cox, Michael/A-6959-2010; Brodie, Eoin/A-7853-2008	Brodie, Eoin/0000-0002-8453-8435; Johnson, Christine Cole/0000-0002-6864-6604; Cox, Michael/0000-0002-4002-1506	NIAID NIH HHS [R01 AI059415-05, R01 AI050681, R01 AI050681-05, R01 AI059415]; PHS HHS [A150681, A159415]		Aichbhaumik N, 2008, CLIN EXP ALLERGY, V38, P1787, DOI 10.1111/j.1365-2222.2008.03079.x; Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; Bergmann RL, 1997, CLIN EXP ALLERGY, V27, P752, DOI 10.1046/j.1365-2222.1997.310899.x; Brodie EL, 2006, APPL ENVIRON MICROB, V72, P6288, DOI 10.1128/AEM.00246-06; Havaux X, 2005, CLIN EXP IMMUNOL, V139, P179, DOI 10.1111/j.1365-2249.2004.02679.x; Ownby DR, 2002, JAMA-J AM MED ASSOC, V288, P963, DOI 10.1001/jama.288.8.963; Penders J, 2006, CLIN EXP ALLERGY, V36, P1602, DOI 10.1111/j.1365-2222.2006.02599.x; Reese TA, 2007, NATURE, V447, P92, DOI 10.1038/nature05746; von Mutius E, 2008, IMMUNOL ALLERGY CLIN, V28, P631, DOI 10.1016/j.iac.2008.03.010	9	84	84	6	24	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2010	126	2								10.1016/j.jaci.2010.05.042		3	Allergy; Immunology	Allergy; Immunology	642IL	WOS:000281203800038	20633927	
J	Kull, I; Melen, E; Alm, J; Hallberg, J; Svartengren, M; van Hage, M; Pershagen, G; Wickman, M; Bergstrom, A				Kull, Inger; Melen, Erik; Alm, Johan; Hallberg, Jenny; Svartengren, Magnus; van Hage, Marianne; Pershagen, Goran; Wickman, Magnus; Bergstrom, Anna			Breast-feeding in relation to asthma, lung function, and sensitization in young schoolchildren	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						Breast-feeding; asthma; sensitization; lung function; infant feeding; prevention; BAMSE	PROSPECTIVE BIRTH COHORT; ALLERGIC DISEASES; CHILDHOOD ASTHMA; ATOPIC DISEASE; RISK; CHILDREN; WHEEZE; LIFE; PREVENTION; PHENOTYPES	Background: The evidence from previous studies on beneficial effects of breast-feeding in relation to development of asthma is conflicting. Objective: To investigate the relation between breast-feeding and asthma and/or sensitization during the first 8 years of life. Method: In a birth cohort, children were followed up to 8 years by questionnaires at ages 2 months and 1, 2, 4, and 8 years to collect information on exposures and health effects. Determination of serum IgE antibodies to common inhalant and food allergens was performed at 4 and 8 years. Longitudinal analyses were applied by using general estimated equations. The study population consisted of 3825 children (93% of the original cohort), of whom 2370 gave blood and 2564 performed lung function measurements at 8 years. Results: Children exclusively breast-fed 4 months or more had a reduced risk of asthma during the first 8 years of life (adjusted odds ratio [OR], 0.63; 95% CI, 0.50-0.78) compared with children breast-fed less than 4 months. At 8 years, reduced risks of sensitization (adjusted OR, 0.79; 95% CI, 0.64-0.99) and asthma in combination with sensitization (adjusted OR, 0.59; 95% CI, 0.37-0.93) were seen among children exclusively breast-fed 4 months or more. This group also had a significantly better lung function measured with peak expiratory flow. Conclusion: Breast-feeding for 4 months or more seems to reduce the risk of asthma up to 8 years. At this age, a reduced risk was observed particularly for asthma combined with sensitization. Furthermore, breast-feeding seems to have a beneficial effect on lung function. (J Allergy Clin Immunol 2010;125:1013-9.)	[Kull, Inger; Melen, Erik; Pershagen, Goran; Wickman, Magnus; Bergstrom, Anna] Karolinska Inst, Inst Environm Med, SE-17176 Stockholm, Sweden; [Kull, Inger] Karolinska Inst, Ctr Allergy Res, SE-17176 Stockholm, Sweden; [Svartengren, Magnus] Karolinska Inst, Dept Publ Hlth Sci, SE-17176 Stockholm, Sweden; [Melen, Erik] Karolinska Univ Hosp, Astrid Lindgren Childrens Hosp, Stockholm, Sweden; [Alm, Johan; Hallberg, Jenny; Wickman, Magnus] Sachs Childrens Hosp, Dept Pediat, Stockholm, Sweden; [Alm, Johan] Soder Sjukhuset, Dept Clin Sci & Educ, Karolinska Inst, Stockholm, Sweden; [van Hage, Marianne] Karolinska Inst & Univ Hosp, Clin Immunol & Allergy Unit, Dept Med Solna, Stockholm, Sweden	Kull, I (reprint author), Karolinska Inst, Inst Environm Med, Norrbacka 3rd Level, SE-17176 Stockholm, Sweden.	inger.kull@ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Alm, Johan/0000-0002-9062-4479; Pershagen, Goran/0000-0002-9701-1130; Kull, Inger/0000-0001-6096-3771	Swedish Asthma and Allergy Association's Research Foundation; Vardal Foundation for Health Care Sciences and Allergy Research; Swedish Heart and Lung Foundation, the Swedish Research Council; Stockholm County Council	Supported by the Swedish Asthma and Allergy Association's Research Foundation, the Vardal Foundation for Health Care Sciences and Allergy Research, the Swedish Heart and Lung Foundation, the Swedish Research Council, and the Stockholm County Council.	Agostoni C, 2008, J PEDIATR GASTR NUTR, V46, P99; Arshad SH, 2007, J ALLERGY CLIN IMMUN, V119, P307, DOI 10.1016/j.jaci.2006.12.621; Burgess S, 2006, PEDIATRICS, V117, P787; Duncan JM, 2008, CURR OPIN ALLERGY CL, V8, P398, DOI 10.1097/ACI.0b013e32830d82ed; Elliott L, 2008, J ALLERGY CLIN IMMUN, V122, P49, DOI 10.1016/j.jaci.2008.04.001; Fitzmaurice G, 2004, APPL LONGITUDINAL AN; Friedman NJ, 2005, J ALLERGY CLIN IMMUN, V115, P1238, DOI 10.1016/j.jaci.2005.01.069; Gdalevich M, 2001, J PEDIATR-US, V139, P261, DOI 10.1067/mpd.2001.117006; Guilbert TW, 2007, AM J RESP CRIT CARE, V176, P843, DOI 10.1164/rccm.200610-1507OC; Hallberg J, 2006, ACTA PAEDIATR, V95, P1191, DOI 10.1080/08035250600584794; Host A, 2008, PEDIATR ALLERGY IMMU, V19, P1, DOI 10.1111/j.1399-3038.2007.00680.x; HOWIE PW, 1990, BRIT MED J, V300, P11; Kramer MS, 2007, BRIT MED J, V335, P815, DOI 10.1136/bmj.39304.464016.AE; Kull I, 2004, J ALLERGY CLIN IMMUN, V114, P755, DOI 10.1016/j.jaci.2004.07.036; Kull I, 2005, J ALLERGY CLIN IMMUN, V116, P657, DOI 10.1016/j.jaci.2005.04.028; Kull I, 2002, ARCH DIS CHILD, V87, P478, DOI 10.1136/adc.87.6.478; Kurukulaaratchy RJ, 2006, ANN ALLERG ASTHMA IM, V97, P84; Lodge CJ, 2008, AM J RESP CRIT CARE, V178, P994; LODGE CJ, 2008, AM J RESP CRIT CARE, V178, P5; Lowe AJ, 2006, J ALLERGY CLIN IMMUN, V117, P682, DOI 10.1016/j.jaci.2005.10.027; Mai XM, 2007, J ALLERGY CLIN IMMUN, V120, P551, DOI 10.1016/j.jaci.2007.05.004; Mandhane PJ, 2007, J ALLERGY CLIN IMMUN, V119, P1359, DOI 10.1016/j.jaci.2007.01.043; Matheson MC, 2007, J ALLERGY CLIN IMMUN, V120, P1051, DOI 10.1016/j.jaci.2007.06.030; Miller MR, 2005, EUR RESPIR J, V26, P319, DOI 10.1183/09031936.05.00034805; Nagel G, 2009, EUR RESPIR J, V33, P993, DOI 10.1183/09031936.00075708; Oddy Wendy H, 2003, J Hum Lact, V19, P250, DOI 10.1177/0890334403255516; ODDY WH, 2003, J HUM LACT, V19, P62; Ogbuanu IU, 2009, THORAX, V64, P62, DOI 10.1136/thx.2008.101543; Ostblom E, 2008, CLIN EXP ALLERGY, V38, P1325, DOI 10.1111/j.1365-2222.2008.03010.x; Prescott SL, 2008, PEDIAT ALLERG IMM-UK, V19, P375, DOI 10.1111/j.1399-3038.2008.00718.x; Quanjer PH, 1997, PEDIATR PULM, V24, P2, DOI 10.1002/(SICI)1099-0496(199707)24:1<2::AID-PPUL2>3.3.CO;2-U; Ronmark E, 1999, ALLERGY, V54, P926, DOI 10.1034/j.1398-9995.1999.00044.x; Rothman KJ, 1998, MODERN EPIDEMIOLOGY; SCHOLTENS S, 2008, BREASTFEEDING OVERWE; Sears MR, 2002, LANCET, V360, P901, DOI 10.1016/S0140-6736(02)11025-7; Thomsen SF, 2006, ALLERGY ASTHMA PROC, V27, P110; van Odijk J, 2003, ALLERGY, V58, P833, DOI 10.1034/j.1398-9995.2003.00264.x; Wickman M, 2002, PEDIATR ALLERGY IMMU, V13, P11, DOI 10.1034/j.1399-3038.13.s.15.10.x; Wright AL, 2002, CLIN REV ALLERG IMMU, V22, P33, DOI 10.1385/CRIAI:22:1:033	39	84	89	4	25	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	MAY	2010	125	5					1013	1019		10.1016/j.jaci.2010.01.051		7	Allergy; Immunology	Allergy; Immunology	596LO	WOS:000277686700009	20392479	
J	Shankardass, K; McConnell, R; Jerrett, M; Milam, J; Richardson, J; Berhane, K				Shankardass, Ketan; McConnell, Rob; Jerrett, Michael; Milam, Joel; Richardson, Jean; Berhane, Kiros			Parental stress increases the effect of traffic-related air pollution on childhood asthma incidence	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						socioeconomic status; tobacco smoke	ENVIRONMENTAL TOBACCO-SMOKE; DIESEL EXHAUST PARTICLES; MATERNAL SMOKING; SOCIOECONOMIC-STATUS; LUNG-FUNCTION; IN-VIVO; RESPIRATORY HEALTH; PROSPECTIVE COHORT; RISK-FACTORS; CHILDREN	Exposure to traffic-related pollution (TRP) and tobacco smoke have been associated with new onset asthma in children. Psychosocial stress-related susceptibility has been proposed to explain social disparities in asthma. We investigated whether low socioeconomic status (SES) or high parental stress modified the effect of TRP and in utero tobacco smoke exposure on new onset asthma. We identified 2,497 children aged 5-9 years with no history of asthma or wheeze at study entry (2002-2003) into the Children's Health Study, a prospective cohort study in southern California. The primary outcome was parental report of doctor-diagnosed new onset asthma during 3 years of follow-up. Residential exposure to TRP was assessed using a line source dispersion model. Information about maternal smoking during pregnancy, parental education (a proxy for SES), and parental stress were collected in the study baseline questionnaire. The risk of asthma attributable to TRP was significantly higher for subjects with high parental stress (HR 1.51 across the interquartile range for TRP; 95% CI 1.16-1.96) than for subjects with low parental stress (HR 1.05, 95% CI 0.74-1.49; interaction P value 0.05). Stress also was associated with larger effects of in utero tobacco smoke. A similar pattern of increased risk of asthma was observed among children from low SES families who also were exposed to either TRP or in utero tobacco smoke. These results suggest that children from stressful households are more susceptible to the effects of TRP and in utero tobacco smoke on the development of asthma.	[McConnell, Rob; Milam, Joel; Richardson, Jean; Berhane, Kiros] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90089 USA; [Shankardass, Ketan] St Michaels Hosp, Li Ka Shing Knowledge Inst, Ctr Res Inner City Hlth, Toronto, ON M5B 1W8, Canada; [Jerrett, Michael] Univ Calif Berkeley, Div Environm Hlth Sci, Sch Publ Hlth, Berkeley, CA 94720 USA	McConnell, R (reprint author), Univ So Calif, Keck Sch Med, Dept Prevent Med, 1540 Alcazar St,Suite 236, Los Angeles, CA 90089 USA.	rmcconne@usc.edu	Reis, Aline/G-9573-2012; Osborne, Nicholas/N-4915-2015	Osborne, Nicholas/0000-0002-6700-2284	National Institute of Environmental Health Sciences [5R03ES014046, 1R01ES016535, 5P01ES009581, 5P01ES011627, 5P30ES007048]	This work was supported by National Institute of Environmental Health Sciences Grants 5R03ES014046,1R01ES016535, 5P01ES009581, 5P01ES011627, and 5P30ES007048; U. S. Environmental Protection Agency Grants R831845, RD831861, and R826708; National Cancer Institute Grant 1U54CA116848-01; the Hastings Foundation; and the Canadian Institutes of Health Research.	ALPERN L, 1993, DEV PSYCHOPATHOL, V5, P371, DOI 10.1017/S0954579400004478; Blomberg A, 1998, FREE RADICAL RES, V28, P59, DOI 10.3109/10715769809097876; Boulet LP, 2006, CHEST, V129, P661, DOI 10.1378/chest.129.3.661; BURNEY PGJ, 1989, EUR RESPIR J, V2, P940; BURR ML, 1992, CLIN EXP ALLERGY, V22, P509, DOI 10.1111/j.1365-2222.1992.tb00158.x; Burra TA, 2009, ENVIRON RES, V109, P567, DOI 10.1016/j.envres.2009.03.004; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chen E, 2003, PSYCHOSOM MED, V65, P984, DOI 10.1097/01.PSY.0000097340.54195.3C; Clougherty JE, 2007, ENVIRON HEALTH PERSP, V115, P1140, DOI 10.1289/ehp.9863; COHEN S, 1988, CLAR SYMP, P31; Cummings E. M., 1994, CHILDREN MARITAL CON; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; Diaz-Sanchez D, 2000, J ALLERGY CLIN IMMUN, V106, P1140, DOI 10.1067/mai.2000.111144; DiazSanchez D, 1997, J IMMUNOL, V158, P2406; Ehrlich RI, 1995, INT J EPIDEMIOL, V24, P1138, DOI 10.1093/ije/24.6.1138; Fujieda S, 1998, AM J RESP CELL MOL, V19, P507; Gilliland FD, 2000, THORAX, V55, P271, DOI 10.1136/thorax.55.4.271; Gilliland FD, 2002, AM J RESP CRIT CARE, V166, P457, DOI 10.1164/rccm.2112064; Gilliland FD, 2003, AM J RESP CRIT CARE, V167, P917, DOI 10.1164/rccm.200206-616OC; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gilliland FD, 2006, AM J RESP CRIT CARE, V174, P1094, DOI DOI 10.1164/RCCM.200605-722OC; Gold DR, 2005, ANNU REV PUBL HEALTH, V26, P89, DOI 10.1146/annurev.publhealth.26.021304.144528; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; HEWITT PL, 1992, J PSYCHOPATHOL BEHAV, V14, P247, DOI 10.1007/BF00962631; HODGES WF, 1990, J DIVORCE REMARRIAGE, V14, P63, DOI 10.1300/J087v14n01_06; Jerrett M, 2005, EPIDEMIOLOGY, V16, P727, DOI 10.1097/01.ede.0000181630.15826.7d; Jerrett M, 2008, ENVIRON HEALTH PERSP, V116, P1433, DOI 10.1289/ehp.10968; Kilpelainen M, 2002, CLIN EXP ALLERGY, V32, P256, DOI 10.1046/j.1365-2222.2002.01282.x; King ME, 2004, PANMINERVA MED, V46, P97; Kumagai Y, 1997, FREE RADICAL BIO MED, V22, P479, DOI 10.1016/S0891-5849(96)00341-3; Li N, 2003, CLIN IMMUNOL, V109, P250, DOI 10.1016/j.clim.2003.08.006; Li XY, 1996, THORAX, V51, P1216, DOI 10.1136/thx.51.12.1216; Li YF, 2005, CHEST, V127, P1232, DOI 10.1378/chest.127.4.1232; Li YF, 2000, AM J RESP CRIT CARE, V162, P2097; Li YF, 2008, ENVIRON HEALTH PERSP, V116, P409, DOI 10.1289/ehp.10655; Liu LY, 2002, AM J RESP CRIT CARE, V165, P1062, DOI 10.1164/rccm.2109065; Lu Y, 2001, HEALTH PROMOT INT, V16, P355, DOI 10.1093/heapro/16.4.355; Ma RJ, 2003, BIOMETRIKA, V90, P157, DOI 10.1093/biomet/90.1.157; Marshall GD, 2000, ALLERGY ASTHMA PROC, V21, P241, DOI 10.2500/108854100778248917; McConnell R, 2002, LANCET, V359, P386, DOI 10.1016/S0140-6736(02)07597-9; McConnell R, 2006, ENVIRON HEALTH PERSP, V114, P766, DOI 10.1289/ehp.8594; MCCONNELL R, 2007, AM J RESP CRIT CARE, V175, pA304; MCCONNELL R, 2005, AM J RESP CRIT CARE, V2, pA605; Milam J, 2008, J ASTHMA, V45, P319, DOI 10.1080/02770900801930277; Nel A, 2005, SCIENCE, V308, P804, DOI 10.1126/science.1108752; Nel A E, 2001, Curr Opin Pulm Med, V7, P20, DOI 10.1097/00063198-200101000-00004; Pattenden S, 2006, TOB CONTROL, V15, DOI 10.1136/tc.2005.015065; PBERT L, 1992, J PSYCHOPATHOL BEHAV, V14, P363, DOI 10.1007/BF00960780; Pearce N, 2006, INT J TUBERC LUNG D, V10, P125; Pearce N, 1999, THORAX, V54, P268; PEAT JK, 1992, CHEST, V102, P153, DOI 10.1378/chest.102.1.153; Pourazar J, 2005, AM J PHYSIOL-LUNG C, V289, pL724, DOI 10.1152/ajplung.00055.2005; R DEVELOPMENT CORE TEAM, 2005, R FDN STAT COMP; RUSSELL G, 1987, CHILD DEV, V58, P1573, DOI 10.1111/j.1467-8624.1987.tb03867.x; Salam MT, 2004, ENVIRON HEALTH PERSP, V112, P760, DOI 10.1289/ehp.6662; Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Sarnat JA, 2007, CURR OPIN PULM MED, V13, P63, DOI 10.1097/MCP.0b013e3280117d25; Schildcrout JS, 2006, AM J EPIDEMIOL, V164, P505, DOI 10.1093/aje/kwj225; SCHUMACHER J, 2006, WOMENS HLTH FINDINGS; Shalowitz MU, 2001, AMBUL PEDIATR, V1, P185, DOI 10.1367/1539-4409(2001)001<0185:TROLSA>2.0.CO;2; Skinner EA, 2007, ANNU REV PSYCHOL, V58, P119, DOI 10.1146/annurev.psych.58.11405.085705; Steptoe A, 2001, ANN BEHAV MED, V23, P177, DOI 10.1207/S15324796ABM2303_5; Strachan DP, 1998, THORAX, V53, P204; Tatum AJ, 2005, IMMUNOL ALLERGY CLIN, V25, P15, DOI 10.1016/j.iac.2004.09.003; Taylor SE, 2000, PSYCHOL REV, V107, P411, DOI 10.1037/0033-295X.107.3.411; Umetsu DT, 2006, CURR OPIN IMMUNOL, V18, P727, DOI 10.1016/j.coi.2006.09.007; Wheeler BW, 2005, J EPIDEMIOL COMMUN H, V59, P948, DOI 10.1136/jech.2005.036418; Wright RJ, 2005, CURR OPIN ALLERGY CL, V5, P23, DOI 10.1097/00130832-200502000-00006; Wright RJ, 1998, THORAX, V53, P1066; Wright RJ, 2004, AM J PUBLIC HEALTH, V94, P625, DOI 10.2105/AJPH.94.4.625; Wright RJ, 2002, AM J RESP CRIT CARE, V165, P358	72	84	86	7	25	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	JUL 28	2009	106	30					12406	12411		10.1073/pnas.0812910106		6	Multidisciplinary Sciences	Science & Technology - Other Topics	476KV	WOS:000268440200038	19620729	
J	Nemoto-Hasebe, I; Akiyama, M; Nomura, T; Sandilands, A; McLean, WHI; Shimizu, H				Nemoto-Hasebe, Ikue; Akiyama, Masashi; Nomura, Toshifumi; Sandilands, Aileen; McLean, W. H. Irwin; Shimizu, Hiroshi			Clinical Severity Correlates with Impaired Barrier in Filaggrin-Related Eczema	JOURNAL OF INVESTIGATIVE DERMATOLOGY			English	Article							STRATUM-CORNEUM HYDRATION; CAUSE ICHTHYOSIS VULGARIS; ATOPIC-DERMATITIS; UNINVOLVED SKIN; GENE; MUTATIONS; PENETRATION; DISEASE	Mutations in the gene-encoding filaggrin (FLG), a key molecule involved in skin barrier function, have been shown to be a major predisposing factor for atopic dermatitis (AD; eczema). To elucidate the pathomechanisms underlying filaggrin-related AD, we investigated stratum corneum (SC) hydration and transepidermal water loss (TEWL) as parameters of barrier function in AD patients harboring FLG mutations compared to AD patients without any FLG mutation. In filaggrin-related AD, SC hydration was both significantly reduced ( P < 0.01-0.05) and thicker (P < 0.01-0.05) than that in healthy controls. TEWL was demonstrably increased in non-filaggrin AD compared to healthy controls ( P < 0.01-0.05). The objective score of atopic dermatitis (OSCORAD), a disease clinical severity index, significantly correlated with TEWL (r = 0.81, P < 0.005), SC hydration (r = -0.65, P < 0.05), and SC thickness (r = 0.59, P < 0.05) in filaggrin-related AD. On the contrary, there was no correlation between these parameters and the OSCORAD in non-filaggrin AD. Furthermore, a significant correlation was obtained between the OSCORAD and specific IgE for house dust (r = 0.66, P < 0.05), mite allergen (r = 0.53, P < 0.05), and cat dander (r = 0.64, P < 0.05) in filaggrin-related AD, but not in non-filaggrin AD. All these data suggest that experimentally demonstrable skin barrier defects due to FLG mutations may play a crucial role in the pathogenesis of AD.	[Nemoto-Hasebe, Ikue; Akiyama, Masashi; Nomura, Toshifumi; Shimizu, Hiroshi] Hokkaido Univ, Grad Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan; [Sandilands, Aileen; McLean, W. H. Irwin] Univ Dundee, Coll Life Sci & Med, Div Mol Med, Epithelial Genet Grp, Dundee, Scotland; [Sandilands, Aileen; McLean, W. H. Irwin] Univ Dundee, Coll Dent & Nursing, Div Mol Med, Epithelial Genet Grp, Dundee, Scotland	Akiyama, M (reprint author), Hokkaido Univ, Grad Sch Med, Dept Dermatol, North 15 West 7, Sapporo, Hokkaido 0608638, Japan.	akiyama@med.hokudai.ac.jp; shimizu@med.hokudai.ac.jp	McLean, William/C-6352-2009	McLean, William Henry Irwin/0000-0001-5539-5757	British Skin Foundation; National Eczema Society (UK); UK Medical Research Council [G0700314]; Ministry of Education, Science, Sports, and Culture of Japan [18390310, 20390304]	We thank Dr James R. McMillan for his critical reading of this paper. We thank Ms Akari Nagasaki, for her fine technical assistance on this project. Filaggrin/ichthyosis/eczema research in the McLean laboratory is supported by grants from the British Skin Foundation, National Eczema Society (UK), and the UK Medical Research Council ( reference number G0700314) and donations from anonymous families affected by eczema in the Tayside Region of Scotland. This work was supported in part by Grants-in-Aid from the Ministry of Education, Science, Sports, and Culture of Japan to M. Akiyama (Kiban B 18390310 and Kiban B 20390304).	AALTOKORTE K, 1995, J AM ACAD DERMATOL, V33, P969, DOI 10.1016/0190-9622(95)90288-0; Chamlin SL, 2002, J AM ACAD DERMATOL, V47, P198, DOI 10.1067/mjd.2002.124617; Hannifin JM, 1980, ACTA DERM-VENEREOL, V92, P44; Hata M, 2002, LAB INVEST, V82, P1451, DOI 10.1097/01.LAB.0000036874.83540.2B; Holm EA, 2006, J AM ACAD DERMATOL, V55, P772, DOI 10.1016/j.jaad.2006.03.036; Hubiche T, 2007, ACTA DERM-VENEREOL, V87, P499, DOI 10.2340/00015555-0329; Hudson TJ, 2006, NAT GENET, V38, P399, DOI 10.1038/ng0406-399; Irvine AD, 2006, J INVEST DERMATOL, V126, P1200, DOI 10.1038/sj.jid.5700365; Jakasa I, 2006, BRIT J DERMATOL, V155, P104, DOI 10.1111/j.1365-2133.2006.07319.x; Jakasa I, 2007, J INVEST DERMATOL, V127, P129, DOI 10.1038/sj.jid.5700582; Leung DYM, 2000, J ALLERGY CLIN IMMUN, V105, P860, DOI 10.1067/mai.2000.106484; Leung D.Y.M., 1995, J INVEST DERMATOL, V105, P37; Nomura T, 2008, J INVEST DERMATOL, V128, P1436, DOI 10.1038/sj.jid.5701205; Nomura T, 2007, J ALLERGY CLIN IMMUN, V119, P434, DOI 10.1016/j.jaci.2006.12.646; Palmer CNA, 2006, NAT GENET, V38, P441, DOI 10.1038/ng1767; Rawlings A V, 2004, Dermatol Ther, V17 Suppl 1, P43, DOI 10.1111/j.1396-0296.2004.04S1005.x; Roll Antonie, 2004, Curr Opin Allergy Clin Immunol, V4, P373, DOI 10.1097/00130832-200410000-00008; Sandilands A, 2007, NAT GENET, V39, P650, DOI 10.1038/ng2020; Smith FJD, 2006, NAT GENET, V38, P337, DOI 10.1038/ng1743; STALDER JF, 1993, DERMATOLOGY, V186, P23; Sugarman JL, 2003, ARCH DERMATOL, V139, P1417, DOI 10.1001/archderm.139.11.1417; Tanaka A, 2006, EXP DERMATOL, V15, P283, DOI 10.1111/j.0906-6705.2006.00404.x; Tomita Y, 2005, EXP DERMATOL, V14, P619, DOI 10.1111/j.0906-6705.2005.00341.x; Weidinger S, 2006, J ALLERGY CLIN IMMUN, V118, P214, DOI 10.1016/j.jaci.2006.05.004; YAMAMOTO Y, 1994, ACTA DERM-VENEREOL, P34	25	84	92	1	6	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	0022-202X			J INVEST DERMATOL	J. Invest. Dermatol.	MAR	2009	129	3					682	689		10.1038/jid.2008.280		8	Dermatology	Dermatology	410IA	WOS:000263569500022	18818676	
J	Gilman, SE; Gardener, H; Buka, SL				Gilman, Stephen E.; Gardener, Hannah; Buka, Stephen L.			Maternal smoking during pregnancy and children's cognitive and physical development: A causal risk factor?	AMERICAN JOURNAL OF EPIDEMIOLOGY			English	Article						child; child development; cognition; growth; intelligence; pregnancy; smoking	CIGARETTE-SMOKING; CHILDHOOD; EXPOSURE; OUTCOMES; AGE; PSYCHOPATHOLOGY; INTELLIGENCE; ASSOCIATION; PERFORMANCE; POPULATION	There remains considerable debate regarding the effects of maternal smoking during pregnancy on children's growth and development. Evidence that exposure to maternal smoking during pregnancy is associated with numerous adverse outcomes is contradicted by research suggesting that these associations are spurious. The authors investigated the relation between maternal smoking during pregnancy and 14 developmental outcomes of children from birth through age 7 years, using data from the Collaborative Perinatal Project (1959-1974; n = 52,919). In addition to adjusting for potential confounders measured contemporaneously with maternal smoking, the authors fitted conditional fixed-effects models among siblings that controlled for unmeasured confounders. Results from the conditional analyses indicated a birth weight difference of -85.63 g associated with smoking of >= 20 cigarettes daily during pregnancy (95% confidence interval: -131.91, -39.34) and 2.73 times' higher odds of being overweight at age 7 years (95% confidence interval: 1.30, 5.71). However, the associations between maternal smoking and 12 other outcomes studied (including Apgar score, intelligence, academic achievement, conduct problems, and asthma) were entirely eliminated after adjustment for measured and unmeasured confounders. The authors conclude that the hypothesized effects of maternal smoking during pregnancy on these outcomes either are not present or are not distinguishable from a broader range of familial factors associated with maternal smoking.	[Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA; [Gilman, Stephen E.; Gardener, Hannah] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Gardener, Hannah] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA; [Buka, Stephen L.] Brown Univ, Dept Community Hlth, Providence, RI 02912 USA	Gilman, SE (reprint author), Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, 677 Huntington Ave, Boston, MA 02115 USA.	sgilman@hsph.harvard.edu	Buka, Stephen/H-7335-2014; Gilman, Stephen/E-7632-2010	Buka, Stephen/0000-0002-8578-9308; Gilman, Stephen/0000-0002-8331-6419	National Research Service Award; Harvard Training Program in Psychiatric Epidemiology and Biostatistics [T32 MH17119]; Transdisciplinary Tobacco Use Research Center [P50 CA084719]; National Institutes of Health; Robert Wood Johnson Foundation	This research was supported in part by a National Research Service Award from the Harvard Training Program in Psychiatric Epidemiology and Biostatistics (grant T32 MH17119) and a Transdisciplinary Tobacco Use Research Center grant (grant P50 CA084719) from the National Institutes of Health, as well as by the Robert Wood Johnson Foundation. The authors appreciate the efforts and contributions of Dr. Andrea Roberts and Kathleen McGaffigan for data management, programming, and manuscript preparation.	Allison P. D., 2005, FIXED EFFECTS REGRES; Batty GD, 2006, PEDIATRICS, V118, P943, DOI 10.1542/peds.2006-0168; BAUMAN KE, 1991, HEALTH PSYCHOL, V10, P282, DOI 10.1037//0278-6133.10.4.282; BOSLEY ARJ, 1981, LANCET, V1, P337; Brennan PA, 2002, AM J PSYCHIAT, V159, P48, DOI 10.1176/appi.ajp.159.1.48; Breslau N, 2005, INT J EPIDEMIOL, V34, P1047, DOI 10.1093/ije/dyi163; Breslau N, 2007, INT J EPIDEMIOL, V36, P832, DOI 10.1093/ije/dym134; Broman SH, 1975, PRESCHOOL IQ PRENATA; Chen AM, 2006, INT J EPIDEMIOL, V35, P121, DOI 10.1093/ije/dyi218; CNATTINGIUS S, 1993, AM J OBSTET GYNECOL, V168, P16; Cornelius MD, 2001, J DEV BEHAV PEDIATR, V22, P217; Ernst M, 2001, J AM ACAD CHILD PSY, V40, P630, DOI 10.1097/00004583-200106000-00007; Eskenazi B, 1999, ENVIRON HEALTH PERSP, V107, P991; Faden VB, 2000, J SUBST ABUSE, V12, P329, DOI 10.1016/S0899-3289(01)00052-9; FERGUSSON DM, 1993, PEDIATRICS, V92, P815; Fried PA, 2001, NEUROTOXICOL TERATOL, V23, P421, DOI 10.1016/S0892-0362(01)00160-X; GARN SM, 1980, LANCET, V2, P912; Gilman SE, 2003, J EPIDEMIOL COMMUN H, V57, P802, DOI 10.1136/jech.57.10.802; Gilman SE, 2008, AM J PUBLIC HEALTH, V98, P448, DOI 10.2105/AJPH.2006.102772; HARDY JB, 1972, LANCET, V2, P1332; Haustein KO, 1999, INT J CLIN PHARM TH, V37, P417; Hill SY, 2000, J STUD ALCOHOL, V61, P661; Jaakkola JJK, 2004, AM J PUBLIC HEALTH, V94, P136, DOI 10.2105/AJPH.94.1.136; JASTAK J., 1965, WIDE RANGE ACHIEVEME; KARON JM, 1982, AM J EPIDEMIOL, V116, P852; Kaufman JS, 2008, INT J EPIDEMIOL, V37, P624, DOI 10.1093/ije/dyn035; KEITH IM, 1988, HISTOL HISTOPATHOL, V3, P215; Klebanoff MA, 1998, AM J EPIDEMIOL, V148, P259; Kodl MM, 2004, ADDICT BEHAV, V29, P273, DOI 10.1016/j.addbeh.2003.08.003; Kolas T, 2000, ACTA OBSTET GYN SCAN, V79, P644, DOI 10.1034/j.1600-0412.2000.079008644.x; KUCZMARSKI R. J., 2002, 2000 CDC GROWTH CHAR; Martin RP, 2006, J PEDIATR PSYCHOL, V31, P490, DOI 10.1093/jpepsy/jsj041; Misra DP, 2005, EPIDEMIOLOGY, V16, P288, DOI 10.1097/01.ede.0000158198.59544.cf; Mortensen EL, 2005, PAEDIATR PERINAT EP, V19, P4, DOI 10.1111/j.1365-3016.2004.00622.x; MYRIANTHOPOULOS NC, 1968, SOC SCI MED, V2, P283, DOI 10.1016/0037-7856(68)90004-8; NAEYE RL, 1981, OBSTET GYNECOL, V57, P18; NAEYE RL, 1984, OBSTET GYNECOL, V64, P601; National Center for Health Statistics, 2000, CDC GROWTH CHARTS US; Nichols PL, 1981, MINIMAL BRAIN DYSFUN; Niswander KR, 1972, WOMEN THEIR PREGNANC; Nystad W, 1997, EUR RESPIR J, V10, P1046, DOI 10.1183/09031936.97.10051046; O'Callaghan MJ, 1997, J PAEDIATR CHILD H, V33, P497, DOI 10.1111/j.1440-1754.1997.tb01658.x; OLDS DL, 1994, PEDIATRICS, V93, P221; RUBIN DB, 1996, J AM STAT ASSOC, V91, P473, DOI DOI 10.2307/2291635; SAS Institute Inc, 2004, BAS SAS 9 1 3 PROC G; SHAFFER D, 1985, ARCH GEN PSYCHIAT, V42, P342; Silberg JL, 2003, BIOL PSYCHIAT, V53, P130, DOI 10.1016/S0006-3223(02)01477-4; Thapar A, 2003, AM J PSYCHIAT, V160, P1985, DOI 10.1176/appi.ajp.160.11.1985; Thorndike R., 1986, STANFORD BINET INTEL; Wakschlag LS, 2002, DEV PSYCHOPATHOL, V14, P351; Wechsler D., 1949, WECHSLER INTELLIGENC; Weissman MM, 1999, J AM ACAD CHILD PSY, V38, P892, DOI 10.1097/00004583-199907000-00020; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	53	84	84	2	16	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0002-9262	1476-6256		AM J EPIDEMIOL	Am. J. Epidemiol.	SEP 1	2008	168	5					522	531		10.1093/aje/kwn175		10	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	343MZ	WOS:000258859500008	18653646	
J	Anderson, SD; Kippelen, P				Anderson, Sandra D.; Kippelen, Pascale			Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Review						epithelial injury; airway smooth muscle; mast cells; microvascular permeability; eicosanoids; beta(2)-agonists	CROSS-COUNTRY SKIERS; CHLORINATED SWIMMING POOLS; FISH-OIL SUPPLEMENTATION; INDUCED PLASMA EXUDATION; MAST-CELL ACTIVATION; INDUCED ASTHMA; INDUCED BRONCHOSPASM; BRONCHIAL HYPERRESPONSIVENESS; SMOOTH-MUSCLE; PASSIVE SENSITIZATION	Exercise-induced bronchoconstriction (EIB) is a consequence of evaporative water loss in conditioning the inspired air. The water loss causes cooling and dehydration of the airway surface. One acute effect of dehydration is the release of mediators, such as prostaglandins, leukotrienes, and histamine, that can stimulate smooth muscle, causing contraction and a change in vascular permeability. Inspiring cold air increases dehydration of the surface area and causes changes in bronchial blood flow. This article proposes that the pathogenesis of EIB in elite athletes relates to the epithelial injury arising from breathing poorly conditioned air at high flows for long periods of time or high volumes of irritant particles or gases. The evidence to support this proposal comes from many markers of injury. The restorative process after injury involves plasma exudation and movement of cells into the airways, a process repeated many times during a season of training. This process has the potential to expose smooth muscle to a wide variety of plasma- and cell-derived substances. The exposure to these substances over time can lead to an alteration in the contractile properties of the smooth muscle, making it more sensitive to mediators of bronchoconstriction. It is proposed that cold-weather athletes have airway hyperresponsiveness (AHR) to pharmacollogic agents as a result of epithelial injury. In those who are allergic, AIIR can also be expressed as EIB. The role of beta(2)-receptor agonists in inhibiting and enhancing the development of AHR and EIB is discussed.	[Anderson, Sandra D.] Royal Prince Alfred Hosp, Dept Resp & Sleep Med, Camperdown, NSW 2050, Australia; Univ Aberdeen, Sch Med Sci, Aberdeen AB9 1FX, Scotland	Anderson, SD (reprint author), Royal Prince Alfred Hosp, Dept Resp & Sleep Med, 11 W,50 Missenden Rd, Camperdown, NSW 2050, Australia.	sandya@med.usyd.edu.au		Anderson, Sandra/0000-0002-6308-8770			AITKEN ML, 1985, AM REV RESPIR DIS, V131, P357; Ammit AJ, 1997, AM J RESP CRIT CARE, V155, P1123; Ammit AJ, 2000, AM J RESP CRIT CARE, V161, P257; Anderson GP, 2006, CLIN REV ALLERG IMMU, V31, P119, DOI 10.1385/CRIAI:31:2:119; Anderson SD, 2006, CLIN REV ALLERG IMMU, V31, P163, DOI 10.1385/CRIAI:31:2:163; Anderson Sandra D, 2004, Paediatr Drugs, V6, P161, DOI 10.2165/00148581-200406030-00003; ANDERSON SD, 1979, LANCET, V2, P629; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P419, DOI 10.1067/mai.2000.108914; ANDERSON SD, 1985, EUR J RESPIR DIS, V67, P20; Anderson SD, 2000, J ALLERGY CLIN IMMUN, V106, P453; Anderson SD, 2006, J ALLERGY CLIN IMMUN, V117, P767, DOI 10.1016/j.jaci.2005.12.1355; Anderson SD, 2005, CURR ALLERGY ASTHM R, V5, P116, DOI 10.1007/s11882-005-0084-y; ANDERSON SD, 1992, THORAX, V47, P748, DOI 10.1136/thx.47.9.748; ANDERSON SD, 1984, J ALLERGY CLIN IMMUN, V73, P660, DOI 10.1016/0091-6749(84)90301-4; Anderson S, 2003, J ALLERGY CLIN IMMUN, V111, P44; Anticevich SZ, 1996, CLIN EXP ALLERGY, V26, P549, DOI 10.1046/j.1365-2222.1996.d01-341.x; ANTICEVICH SZ, 1995, EUR J PHARMACOL, V284, P222; ARGYROS GJ, 1993, AM REV RESPIR DIS, V147, P1419; BACKER V, 1991, J ALLERGY CLIN IMMUN, V88, P68, DOI 10.1016/0091-6749(91)90302-5; Baki A, 2002, ARCH DIS CHILD, V86, P38, DOI 10.1136/adc.86.1.38; BALUK P, 1994, AM J PHYSIOL, V266, pL461; BANNER AS, 1984, NEW ENGL J MED, V311, P883, DOI 10.1056/NEJM198410043111404; Baraniuk JN, 1999, AM J RESP CRIT CARE, V160, P655; BARNES NC, 1984, THORAX, V39, P500, DOI 10.1136/thx.39.7.500; Berger P, 1998, AM J RESP CRIT CARE, V157, P610; Bernard A, 2005, TOXICOL APPL PHARM, V206, P185, DOI 10.1016/j.taap.2004.10.022; Bernard A, 2003, OCCUP ENVIRON MED, V60, P385, DOI 10.1136/oem.60.6.385; Bernard A, 2007, PEDIATRICS, V119, P1095, DOI 10.1542/peds.2006-3333; Bernard A, 2006, ENVIRON HEALTH PERSP, V114, P1567, DOI 10.1289/ehp.8461; Bonsignore MR, 2001, AM J PHYSIOL-LUNG C, V281, pL668; Bonsignore MR, 2003, MED SCI SPORT EXER, V35, P1146, DOI 10.1249/01.MSS.0000074581.08023.25; Boulet LP, 2005, CLIN INVEST MED, V28, P15; Bradding P, 2006, J ALLERGY CLIN IMMUN, V117, P1277, DOI 10.1016/j.jaci.2006.02.039; Brannan JD, 2006, EUR RESPIR J, V27, P944, DOI 10.1183/09031936.06.00078205; Brannan JD, 2003, EUR RESPIR J, V22, P491, DOI 10.1183/09031936.03.00113403; Brightling CE, 2002, NEW ENGL J MED, V346, P1699, DOI 10.1056/NEJMoa012705; Broeckaert F, 2000, ENVIRON HEALTH PERSP, V108, P533, DOI 10.2307/3454615; Button B, 2007, J PHYSIOL-LONDON, V580, P577, DOI 10.1113/jphysiol.2006.126086; Caillaud C, 2003, CAN J APPL PHYSIOL, V28, P793; Carbonnelle S, 2002, BIOMARKERS, V7, P464, DOI 10.1080/13547500210166612; Carroll NG, 2002, THORAX, V57, P677, DOI 10.1136/thorax.57.8.677; Carroll NG, 2002, EUR RESPIR J, V19, P879, DOI 10.1183/09031936.02.00275802; Chen BT, 2000, AM J RESP CRIT CARE, V162, P1715; Chen BT, 2001, J APPL PHYSIOL, V90, P821; CHEN WY, 1977, RESPIRATION, V34, P305; Chetta A, 2007, PULM PHARMACOL THER, V20, P1, DOI 10.1016/j.pupt.2005.10.009; Chimenti L, 2007, AM J RESP CRIT CARE, V175, P442, DOI 10.1164/rccm.200608-1086OC; Cockcroft DW, 1998, J ALLERGY CLIN IMMUN, V102, pS96, DOI 10.1016/S0091-6749(98)70038-7; Coreno A, 2000, J ALLERGY CLIN IMMUN, V106, P500; Crimi N, 2005, J ALLERGY CLIN IMMUN, V115, P870, DOI 10.1016/j.jaci.2005.01.041; Dahlen SE, 2004, THORAX, V59, P453, DOI 10.1136/thx.2004.026641; Davis Beth E, 2003, Can Respir J, V10, P23; DAVISKAS E, 1991, RESP PHYSIOL, V84, P115, DOI 10.1016/0034-5687(91)90023-C; Douwes J, 2002, THORAX, V57, P643, DOI 10.1136/thorax.57.7.643; Duong M, 2008, CHEST, V133, P404, DOI 10.1378/chest.07-2048; Dwyer TM, 1997, AM J PHYSIOL-LUNG C, V272, pL1121; Ernst P, 2002, EUR RESPIR J, V20, P635, DOI 10.1183/09031936.02.00962002; Evans DW, 1997, THORAX, V52, P136; Fernandes DJ, 2003, J APPL PHYSIOL, V95, P844, DOI 10.1152/japplphysiol.00192.2003; FISCHER AR, 1995, AM J RESP CRIT CARE, V152, P1203; Fitch KD, 2006, CLIN REV ALLERG IMMU, V31, P259, DOI 10.1385/CRIAI:31:2:259; Folkesson HG, 1996, J CLIN INVEST, V97, P664, DOI 10.1172/JCI118463; Freed AN, 1997, J APPL PHYSIOL, V83, P1884; FROSSARD N, 1989, J PHARMACOL EXP THER, V248, P292; Gauvreau GM, 1997, AM J RESP CRIT CARE, V156, P1738; Gibson PG, 2001, CHEST, V119, P1329, DOI 10.1378/chest.119.5.1329; Gleeson M, 2007, J APPL PHYSIOL, V103, P693, DOI 10.1152/japplphysiol.00008.2007; Greiff L, 2003, CLIN PHYSIOL FUNCT I, V23, P301, DOI 10.1046/j.1475-0961.2003.00519.x; Greiff L, 2005, CLIN PHYSIOL FUNCT I, V25, P241, DOI 10.1111/j.1475-097X.2005.00615.x; Greiff L, 1998, THORAX, V53, P1010; Gulliksson M, 2006, ALLERGY, V61, P1473, DOI 10.1111/j.1398-9995.2006.01213; Gulliksson M, 2007, BBA-MOL CELL BIOL L, V1771, P1156, DOI 10.1016/j.bbalip.2007.06.001; HABY MM, 1994, EUR RESPIR J, V7, P43, DOI 10.1183/09031936.94.07010043; Hallstrand TS, 2007, AM J RESP CRIT CARE, V176, P1072, DOI 10.1164/rccm.200707-1098OC; Hallstrand TS, 2007, J ALLERGY CLIN IMMUN, V119, P1092, DOI 10.1016/j.jaci.2007.01.005; Hallstrand TS, 2005, J ALLERGY CLIN IMMUN, V116, P586, DOI 10.1016/j.jaci.2005.04.035; Hallstrand TS, 2005, AM J RESP CRIT CARE, V172, P679, DOI 10.1164/rccm.200412-1667OC; Hancox RJ, 2002, AM J RESP CRIT CARE, V165, P1068, DOI 10.1164/rccm.200111-091BC; Haney S, 2005, RESP MED, V99, P566, DOI 10.1016/j.rmed.2004.10.014; Haney S, 2006, CLIN REV ALLERG IMMU, V31, P181, DOI 10.1385/CRIAI:31:2:181; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Hashimoto S, 2000, AM J RESP CRIT CARE, V162, P1075; Helenius I, 2002, J ALLERGY CLIN IMMUN, V109, P962, DOI 10.1067/mai.2002.124769; Helenius IJ, 1998, ALLERGY, V53, P346, DOI 10.1111/j.1398-9995.1998.tb03904.x; Helenius IJ, 1998, J ALLERGY CLIN IMMUN, V101, P646; Hemingson Howard B, 2004, Can Respir J, V11, P399; Hermans C, 1998, EUR RESPIR J, V11, P801, DOI 10.1183/09031936.98.11040801; Hilberg T, 2007, CURR ALLERGY ASTHM R, V7, P27, DOI 10.1007/s11882-007-0027-x; Hofstra WB, 2000, PEDIATR PULM, V29, P415, DOI 10.1002/(SICI)1099-0496(200006)29:6<415::AID-PPUL1>3.0.CO;2-7; Holzer K, 2003, AM J RESP CRIT CARE, V167, P534, DOI 10.1164/rccm.200208-916OC; Holzer K, 2002, J ALLERGY CLIN IMMUN, V110, P374, DOI 10.1067/mai.2002.127784; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Johnson M, 2006, J ALLERGY CLIN IMMUN, V117, P18, DOI 10.1016/j.jaci.2005.11.012; Johnson PRA, 1997, EUR RESPIR J, V10, P38, DOI 10.1183/09031936.97.10010038; Jonasson G, 2000, PEDIATR ALLERGY IMMU, V11, P120, DOI 10.1034/j.1399-3038.2000.00067.x; JONES A, 1994, BRIT J GEN PRACT, V44, P127; Joos GF, 2004, EUR RESPIR J, V23, P76, DOI 10.1183/09031936.03.00101902; Kanazawa H, 2002, CHEST, V122, P166, DOI 10.1378/chest.122.1.166; Kanazawa H, 2002, THORAX, V57, P885, DOI 10.1136/thorax.57.10.885; KANAZAWA H, 2007, DRUG TARGETS, V6, P133; Kanazawa H, 2008, J ALLERGY CLIN IMMUN, V121, P390, DOI 10.1016/j.jaci.2007.09.026; Kanazawa H, 2007, CHEST, V131, P1035, DOI 10.1378/chest.06-2758; Karjalainen EM, 2000, AM J RESP CRIT CARE, V161, P2086; Kay LJ, 2007, BRIT J PHARMACOL, V152, P323, DOI 10.1038/sj.bjp.0707400; Kemp JP, 1998, J PEDIATR-US, V133, P424, DOI 10.1016/S0022-3476(98)70281-1; Koskela H, 2000, CLIN EXP ALLERGY, V30, P1627; Kujala UM, 2003, ARCH INTERN MED, V163, P1064, DOI 10.1001/archinte.163.9.1064; Lakind JS, 2007, BIOMARKERS, V12, P445, DOI 10.1080/13547500701359327; Langdeau JB, 2000, AM J RESP CRIT CARE, V161, P1479; LARSSON K, 1993, BRIT MED J, V307, P1326; Lazarowski ER, 2004, J BIOL CHEM, V279, P36855, DOI 10.1074/jbc.M405367200; Leuppi JD, 1998, EUR RESPIR J, V12, P13, DOI 10.1183/09031936.98.12010013; Mak JCW, 2000, MOL PHARMACOL, V57, P857; Mannix ET, 1999, CHEST, V115, P649, DOI 10.1378/chest.115.3.649; MCFADDEN ER, 1990, LANCET, V335, P880; MCFADDEN ER, 1986, J CLIN INVEST, V78, P18, DOI 10.1172/JCI112549; McGraw DW, 2007, J CLIN INVEST, V117, P1391, DOI 10.1172/JCI30489; McGraw Dennis W, 2005, Proc Am Thorac Soc, V2, P292, DOI 10.1513/pats.200504-027SR; McGraw DW, 2003, J CLIN INVEST, V112, P619, DOI 10.1172/JCI200318193; McGraw DW, 2005, P AM THORAC SOC, V2, P311; Mickleborough TD, 2006, CHEST, V129, P39, DOI 10.1378/chest.129.1.39; Mickleborough TD, 2003, AM J RESP CRIT CARE, V168, P1181, DOI 10.1164/rccm.200303-373OC; Moloney ED, 2003, RESP MED, V97, P1; Nagase T, 1996, AM J RESP CRIT CARE, V154, P1551; NALINE E, 1989, AM REV RESPIR DIS, V140, P679; Nanson CJ, 2001, RESP PHYSIOL, V127, P259, DOI 10.1016/S0034-5687(01)00251-1; NICOLAI T, 1993, AM REV RESPIR DIS, V147, P565; NIEMAN DC, 1990, J SPORT MED PHYS FIT, V30, P316; Nightingale JA, 1999, THORAX, V54, P1061; OCAIN CF, 1980, J APPL PHYSIOL, V49, P875; OMORI C, 1995, J APPL PHYSIOL, V78, P2169; OMORI C, 1995, J APPL PHYSIOL, V78, P1043; PAGE S, 2001, AM J PHYSIOL-LUNG C, V281, P1313; PERSSON CG, 2008, PULMONARY EPITHELIUM; Persson CGA, 1996, PULM PHARMACOL, V9, P129, DOI 10.1006/pulp.1996.0015; PERSSON CGA, 1991, CLIN EXP ALLERGY, V21, P17, DOI 10.1111/j.1365-2222.1991.tb00799.x; Persson CGA, 1998, EUR RESPIR J, V11, P958, DOI 10.1183/09031936.98.11040958; PISARRI TE, 1992, J APPL PHYSIOL, V73, P2305; Potts J, 1996, SPORTS MED, V21, P256, DOI 10.2165/00007256-199621040-00002; Potts JE, 1994, THESIS U BRIT COLUMB; ProvostCraig MA, 1996, J ASTHMA, V33, P67, DOI 10.3109/02770909609077764; Rouadi P, 1999, J APPL PHYSIOL, V87, P400; Rundell KW, 2005, INHAL TOXICOL, V17, P99, DOI 10.1080/08958370590899479; Rundell KW, 2001, MED SCI SPORT EXER, V33, P208; Schmidt D, 1999, EUR RESPIR J, V14, P315, DOI 10.1034/j.1399-3003.1999.14b13.x; SOLWAY J, 1991, J APPL PHYSIOL, V71, P2077; SONT JK, 1995, AM J RESP CRIT CARE, V152, P38; Stensrud T, 2007, MED SCI SPORT EXER, V39, P1681, DOI 10.1249/mss.0b013e31813738ac; Storms W, 2004, RESP MED, V98, P1051, DOI 10.1016/j.rmed.2004.05.008; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; Subbarao P, 2006, J ALLERGY CLIN IMMUN, V117, P1008, DOI 10.1016/j.jaci.2005.11.048; Sue-Chu M, 2000, RESPIRATION, V67, P417, DOI 10.1159/000029541; Sue-Chu M, 1999, RESP MED, V93, P719, DOI 10.1016/S0954-6111(99)90039-2; SueChu M, 1996, RESP MED, V90, P99, DOI 10.1016/S0954-6111(96)90206-1; Sue-Chu M, 2002, EUR RESP J S38, V20, p410s; Swystun VA, 2000, J ALLERGY CLIN IMMUN, V106, P57; van der Woude HJ, 2001, THORAX, V56, P529, DOI 10.1136/thorax.56.7.529; Van Rensen ELJ, 2002, AM J RESP CRIT CARE, V165, P1275, DOI 10.1164/rccm.2110092; Watson N, 1998, CLIN EXP ALLERGY, V28, P679; Watson N, 1997, AM J RESP CRIT CARE, V155, P839; Weinberger M, 2006, NEW ENGL J MED, V355, P852, DOI 10.1056/NEJMc066282; Wilber RL, 2000, MED SCI SPORT EXER, V32, P732, DOI 10.1097/00005768-200004000-00003; Yoshikawa T, 1998, EUR RESPIR J, V12, P879, DOI 10.1183/09031936.98.12040879	163	84	85	2	13	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					225	235		10.1016/j.jaci.2008.05.001		11	Allergy; Immunology	Allergy; Immunology	337HO	WOS:000258426300001	18554705	
J	Ege, MJ; Herzum, I; Buchele, G; Krauss-Etschmann, S; Lauener, RP; Roponen, M; Hyvarinen, A; Vuitton, DA; Riedler, J; Brunekreef, B; Dalphin, JC; Braun-Fahrlander, C; Pekkanen, J; Renz, H; von Mutius, E				Ege, Markus Johannes; Herzum, Ileana; Buechele, Gisela; Krauss-Etschmann, Susanne; Lauener, Roger P.; Roponen, Marjut; Hyvaerinen, Anne; Vuitton, Dominique A.; Riedler, Josef; Brunekreef, Bert; Dalphin, Jean-Charles; Braun-Fahrlaender, Charlotte; Pekkanen, Juha; Renz, Harald; von Mutius, Erika		Protection Against Allergy Study	Prenatal exposure to a farm environment modifies atopic sensitization at birth	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						prenatal exposure; atopic sensitization; cord blood; farming; microbial components	HOUSE-DUST; ALLERGIC DISEASES; EARLY-LIFE; CHILDREN; ASTHMA; PARSIFAL; PROJECT	Background: Previous cross-sectional surveys have suggested that maternal exposure to animal sheds during pregnancy exerted a protective effect on atopic sensitization in children lasting until school age. Objective: We sought to evaluate the effects of maternal exposure to animal sheds and other farm-related exposures during pregnancy on cord blood IgE levels in a prospective birth cohort. Methods: Pregnant women living in rural areas in Austria, Finland, France, Germany, and Switzerland were recruited in the third trimester of pregnancy. Information on maternal farm-related exposures, nutrition, and health during pregnancy was obtained by means of interviews. Specific IgE levels for food and common inhalant allergens were assessed in cord blood of 922 children and peripheral blood samples of their mothers. Results: Different sensitization patterns in cord blood of farm and nonfarm children were observed. In multivariable analysis consumption of boiled, but not unboiled, farm milk during pregnancy was positively associated with specific IgE to cow's milk independently from maternal IgE. In contrast, there was an inverse relationship between maternal exposure to animal sheds and cord blood IgE levels against seasonal allergens (adjusted odds ratio, 0.38; 95% CI, 0.21-0.70). This association was not confounded by maternal IgE levels. Maternal contact with hay enhanced the protective effect of exposure to animal sheds on IgE levels to grass pollen in cord blood.	[Ege, Markus Johannes; Krauss-Etschmann, Susanne; von Mutius, Erika] Univ Childrens Hosp, Munich, Germany; [Herzum, Ileana; Renz, Harald] Univ Marburg, Dept Clin Chem & Mol Diagnost, Marburg, Germany; [Buechele, Gisela] Univ Ulm, Inst Epidemiol, Ulm, Germany; [Krauss-Etschmann, Susanne] HelmholtzZentrum Munchen German Res Ctr Environm, Munich, Germany; [Lauener, Roger P.] Univ Zurich, Childrens Hosp, Zurich, Switzerland; [Roponen, Marjut; Hyvaerinen, Anne; Pekkanen, Juha] Natl Publ Hlth Inst, Dept Environm Hlth, Kuopio, Finland; [Vuitton, Dominique A.] Univ Franche Comte, SERF Res Unit, F-25030 Besancon, France; [Riedler, Josef] Childrens Hosp, Schwarzach, Austria; [Brunekreef, Bert] Univ Med Ctr Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands; [Brunekreef, Bert] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands; [Dalphin, Jean-Charles] Univ Hosp, Dept Resp Dis, Besancon, France; [Braun-Fahrlaender, Charlotte] Univ Basel, Inst Social & Prevent Med, Basel, Switzerland; [Pekkanen, Juha] Univ Kuopio, Sch Publ Hlth & Clin Nutr, FIN-70211 Kuopio, Finland	Ege, MJ (reprint author), Dr von Haunersche Kinderklin, Lindwurmstr 4, D-80337 Munich, Germany.	markus.ege@med.uni-muenchen.de	Huttunen, Kati/D-8755-2012; Genuneit, Jon/I-9323-2012; Lauener, Roger/O-8612-2016; Roponen, Marjut/C-2086-2017	Huttunen, Kati/0000-0002-4888-9203; Genuneit, Jon/0000-0001-5764-1528; Lauener, Roger/0000-0002-8412-606X; Roponen, Marjut/0000-0002-4442-9090; brunekreef, bert/0000-0001-9908-0060; Ege, Markus/0000-0001-6643-3923; Krauss-Etschmann, Susanne/0000-0001-5945-5702; von Mutius, Erika/0000-0002-8893-4515	European Union [QLK4-CT-2001-00250]	Supported by the European Union (research grant QLK4-CT-2001-00250).	Alfven T, 2006, ALLERGY, V61, P414, DOI 10.1111/j.1398-9995.2005.00939.x; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Bonnelykke K, 2008, J ALLERGY CLIN IMMUN, V121, P646, DOI 10.1016/j.jaci.2007.12.1149; Boyle RJ, 2006, ALLERGY, V61, P1423, DOI 10.1111/j.1398-9995.2006.01113.x; Douwes J, 1999, J ALLERGY CLIN IMMUN, V103, P494, DOI 10.1016/S0091-6749(99)70476-8; DOUWES J, 1995, APPL ENVIRON MICROB, V61, P1763; Ege MJ, 2007, J ALLERGY CLIN IMMUN, V119, P1140, DOI 10.1016/j.jaci.2007.01.037; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; FERRIS BG, 1978, AM REV RESPIR DIS, V118, P1; Hagendorens MM, 2004, PEDIATR ALLERGY IMMU, V15, P308, DOI 10.1111/j.1399-3038.2004.00169.x; Herzum I, 2005, CLIN CHEM LAB MED, V43, P963, DOI 10.1515/CCLM.2005.165; Holt P, 2004, CHEM IMMUNOL, V84, P102; Korthals M, 2008, J MICROBIOL METH, V73, P49, DOI 10.1016/j.mimet.2008.01.010; Landau LI, 2006, PAEDIATR RESPIR REV, V7, pS251, DOI 10.1016/j.prrv.2006.04.186; Myatt L, 2006, J PHYSIOL-LONDON, V572, P25, DOI 10.1113/jphysiol.2006.104968; PFEFFERLE P, 2008, J ALLERGY C IN PRESS; Prescott SL, 2006, CURR ALLERGY ASTHM R, V6, P75, DOI 10.1007/s11882-006-0014-7; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Riedler J, 2000, CLIN EXP ALLERGY, V30, P194; Rothman K J, 1990, Epidemiology, V1, P43, DOI 10.1097/00001648-199001000-00010; Rowe J, 2007, J ALLERGY CLIN IMMUN, V119, P1164, DOI 10.1016/j.jaci.2007.02.016; Rytkonen J, 2002, PEDIATR ALLERGY IMMU, V13, P269, DOI 10.1034/j.1399-3038.2002.01028.x; Schram D, 2005, ALLERGY, V60, P611, DOI 10.1111/j.1398-9995.2005.00748.x; Stern DA, 2007, J ALLERGY CLIN IMMUN, V119, P351, DOI 10.1016/j.jaci.2006.10.013; Vance GHS, 2005, CLIN EXP ALLERGY, V35, P1318, DOI 10.1111/j.1365-2222.2005.02346.x; von Mutius E, 2006, ALLERGY, V61, P407, DOI 10.1111/j.1398-9995.2006.01009.x; Warner JO, 2004, ARCH DIS CHILD, V89, P97, DOI 10.1136/adc.2003.013029	27	84	85	2	17	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	AUG	2008	122	2					407	412		10.1016/j.jaci.2008.06.011		6	Allergy; Immunology	Allergy; Immunology	337HO	WOS:000258426300030	18678343	
J	Schaub, B; Liu, J; Hoppler, S; Haug, S; Sattler, C; Lluis, A; Illi, S; von Mutius, E				Schaub, Bianca; Liu, Jing; Hoeppler, Sabine; Haug, Severine; Sattler, Christine; Lluis, Anna; Illi, Sabina; von Mutius, Erika			Impairment of T-regulatory cells in cord blood of atopic mothers	JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY			English	Article						adaptive; cord blood; cytokines; innate; IL; regulatory T cells; T(H)17 cells; Toll-like receptor	NEONATAL IMMUNE-RESPONSES; SCHOOL-AGE-CHILDREN; EXPRESSION; STIMULATION; EXPOSURE; ASTHMA; INFLAMMATION; RECEPTOR-2; ALLERGY; FOXP3	Background: Maternal atopy is a strong predictor for the development of childhood allergic diseases. The underlying mechanisms are ill defined, yet regulatory T (Treg) and T(H)17 cells may play a key role potentially shaping the early immune system toward a proallergic or antiallergic immune regulation. Objective: We examined T(H)1/T(H)2, Treg, and T(H)17 cell responses to innate (lipid A/peptidoglycan) and mitogen/adaptive (phytohemagglutinin/Dermatophagoides pteronyssinus 1) immune stimulation in cord blood from offspring of atopic/nonatopic mothers. Methods: Cord blood mononuclear cells from 161 healthy neonates (59% nonatopic, 41% atopic mothers) were investigated regarding Treg and T(H)17 cells (mRNA/surface markers), suppressive function, and proliferation/cytokine secretion. Results: Cord blood from offspring of atopic mothers showed fewer innate-induced Treg cells (CD4(+)CD25(+) high), lower mRNA expression of associated markers (glucocorticoid-induced tumor necrosis factor receptor-related protein/lymphocyte activation gene 3; P < .05), and a trend toward lower Forkhead box transcription factor 3 (Foxp3) expression. Treg cell function was impaired in mitogen-induced suppression of T effector cells in cord blood of offspring from atopic mothers (P = .03). Furthermore, IL-10 and IFN-gamma secretion were decreased in innate-stimulated cord blood of offspring from atopic mothers (P = .04/.05). Innate-induced IL-17 was independent of maternal atopy and highly correlated with IL-13 secretion. Conclusion: In offspring of atopic mothers, Treg cell numbers, expression, and function were impaired at birth. T(H)17 cells were correlated with T(H)2 cells, independently of maternal atopy.	[Schaub, Bianca; Liu, Jing; Hoeppler, Sabine; Haug, Severine; Lluis, Anna; Illi, Sabina; von Mutius, Erika] Univ Children Hosp Munich, Dr Von Haunerschen Kinderspital, Dept Pulm & Allergy, D-80337 Munich, Germany; [Sattler, Christine] Univ Munich, Univ Hosp, Dept Gynecol, Munich, Germany; [Liu, Jing] Jilin Univ, Hosp 2, Dept Resp Med, Changchun 130023, Peoples R China	Schaub, B (reprint author), Univ Children Hosp Munich, Dr Von Haunerschen Kinderspital, Dept Pulm & Allergy, Lindwurmstr 4, D-80337 Munich, Germany.	Bianca.Schaub@med.uni-muenchen.de		von Mutius, Erika/0000-0002-8893-4515			Allakhverdi Z, 2006, J ALLERGY CLIN IMMUN, V118, P1342, DOI 10.1016/j.jaci.2006.07.034; Amoudruz P, 2005, J ALLERGY CLIN IMMUN, V115, P1304, DOI 10.1016/j.jaci.2005.02.036; Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Ege MJ, 2006, J ALLERGY CLIN IMMUN, V117, P817, DOI 10.1016/j.jaci.2005.12.1307; Gavin MA, 2007, NATURE, V445, P771, DOI 10.1038/nature05543; Gold DR, 2006, J ALLERGY CLIN IMMUN, V117, P931, DOI 10.1016/j.jaci.2005.12.1322; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Heinrich J, 2002, Pneumologie, V56, P297, DOI 10.1055/s-2002-30699; Huang CT, 2004, IMMUNITY, V21, P503, DOI 10.1016/j.immuni.2004.08.010; Ivanov S, 2007, AM J RESP CELL MOL, V36, P442, DOI 10.1165/rcmb.2006-0020OC; Lauener RP, 2002, LANCET, V360, P465, DOI 10.1016/S0140-6736(02)09641-1; Liu WH, 2006, J EXP MED, V203, P1701, DOI 10.1084/jem.20060772; Patel M, 2005, EUR J IMMUNOL, V35, P3581, DOI 10.1002/eji.200535421; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; Read S, 2000, J EXP MED, V192, P295, DOI 10.1084/jem.192.2.295; Riedler J, 2001, LANCET, V358, P1129, DOI 10.1016/S0140-6736(01)06252-3; Schaub B, 2006, RESP RES, V7, DOI 10.1186/1465-9921-7-40; Schaub B, 2005, J CLIN IMMUNOL, V25, P329, DOI 10.1007/s10875-005-4180-5; Schaub B, 2004, J INTERF CYTOK RES, V24, P543, DOI 10.1089/jir.2004.24.543; Shimizu J, 2002, NAT IMMUNOL, V3, P135, DOI 10.1038/ni759; Velasco G, 2005, AM J RESP CELL MOL, V32, P218, DOI 10.1165/rcmb.2003-0435OC; Weaver CT, 2006, IMMUNITY, V24, P677, DOI 10.1016/j.immuni.2006.06.002; Wright Anne L., 2004, Journal of Allergy and Clinical Immunology, V113, pS2, DOI 10.1016/j.jaci.2003.09.050	25	84	86	0	14	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0091-6749			J ALLERGY CLIN IMMUN	J. Allergy Clin. Immunol.	JUN	2008	121	6					1491	1499		10.1016/j.jaci.2008.04.010		9	Allergy; Immunology	Allergy; Immunology	313WW	WOS:000256771700028	18539197	
J	Wolf, JM; Nicholls, E; Chen, E				Wolf, Jutta M.; Nicholls, Erin; Chen, Edith			Chronic stress, salivary cortisol, and alpha-amylase in children with asthma and healthy children	BIOLOGICAL PSYCHOLOGY			English	Article						salivary alpha-amylase; cortisol; childhood asthma; chronic stress; socioeconomic status	THREE-MILE-ISLAND; PSYCHOLOGICAL STRESS; SOCIOECONOMIC-STATUS; PSYCHOSOCIAL STRESS; ADRENERGIC ACTIVITY; BETA(2)-ADRENERGIC RECEPTOR; GLUCOCORTICOID-RECEPTOR; WHOLE SALIVA; RESPONSES; IMMUNE	The present study examined whether chronic stress is related to daily life levels of salivary a-amylase (sAA), a marker for sympathetic activity, and cortisol in healthy children versus children with asthma. Children's sAA and cortisol levels were measured repeatedly over 2 days. Chronic stress measures included interviews with children about chronic home life stress and interviews with parents about one marker of socioeconomic status, parental education. Among children with asthma, higher chronic stress was associated with lower daily sAA output, while among healthy children, higher chronic stress was associated with flatter cortisol slopes. In conclusion, chronically stressed children with asthma showed lower salivary a-amylase output, indicating lower sympathetic activity, and implying a possible mechanism for increased susceptibility to symptom exacerbations. In contrast, higher cortisol levels in healthy children with chronic stress may indicate, for example, an increased risk for infectious diseases. This dichotomy emphasizes the different biological effects of chronic stress depending on illness status. (c) 2007 Elsevier B.V. All tights reserved.	[Wolf, Jutta M.; Nicholls, Erin; Chen, Edith] Univ British Columbia, Dept Psychol, Vancouver, BC V6T 1Z4, Canada	Wolf, JM (reprint author), Univ British Columbia, Dept Psychol, 2136 W Mall, Vancouver, BC V6T 1Z4, Canada.	juttawolf@psych.ubc.ca					ARNETZ BB, 1987, PSYCHOSOM MED, V49, P3; Bacharier LB, 2004, AM J RESP CRIT CARE, V170, P426, DOI 10.1164/rccm.200308-1178OC; Bamberger CM, 1996, ENDOCR REV, V17, P245, DOI 10.1210/er.17.3.245; BAUM A, 1983, J CONSULT CLIN PSYCH, V51, P565, DOI 10.1037/0022-006X.51.4.565; BAUM BJ, 1993, ANN NY ACAD SCI, V694, P17; Bosch JA, 2003, PSYCHOSOM MED, V65, P245, DOI 10.1097/01.PSY.0000058376.50240.2D; Bosch JA, 1996, PSYCHOSOM MED, V58, P374; Buske-Kirschbaum A, 2003, PSYCHOSOM MED, V65, P806, DOI 10.1097/01.PSY.0000095916.25975.4F; Buske-Kirschbaum A, 1998, ANN NY ACAD SCI, V840, P747, DOI 10.1111/j.1749-6632.1998.tb09613.x; CAPLAN RD, 1979, J PSYCHOSOM RES, V23, P181, DOI 10.1016/0022-3999(79)90003-5; Chatterton RT, 1996, CLIN PHYSIOL, V16, P433, DOI 10.1111/j.1475-097X.1996.tb00731.x; Chen E, 2006, J ALLERGY CLIN IMMUN, V117, P1014, DOI 10.1016/j.jaci.2006.01.036; Chen E, 2006, HEALTH PSYCHOL, V25, P704, DOI 10.1037/0278-6133.25.6.704; CHIKANZA IC, 1992, ARTHRITIS RHEUM, V35, P1281; Chrousos G P, 1998, Adv Pharmacol, V42, P552; Chrousos GP, 1998, J CLIN ENDOCR METAB, V83, P1842, DOI 10.1210/jc.83.6.1842; Cohen S, 2006, PSYCHOSOM MED, V68, P41, DOI 10.1097/01.psy.0000195967.51768.ea; Cohen S, 2006, PSYCHOSOM MED, V68, P414, DOI 10.1097/01.psy.0000221236.37158.b9; DALLMAN MF, 1994, ANN NY ACAD SCI, V746, P22; De Kloet ER, 1998, ENDOCR REV, V19, P269, DOI 10.1210/er.19.3.269; Dickerson SS, 2004, PSYCHOL BULL, V130, P355, DOI 10.1037/0033-2909.130.3.355; Ehlert U, 2006, J CLIN ENDOCR METAB, V91, P5130, DOI 10.1210/jc.2006-0461; Elenkov IJ, 2000, PHARMACOL REV, V52, P595; GOLDSTEIN DS, 2000, ENCY STRESS, P558; Granger DA, 2006, J SOC PERS RELAT, V23, P267, DOI 10.1177/0265407506062479; GRANGER DA, 2007, HDB PHYSL RES METHOD; Granger DA, 2007, ANN NY ACAD SCI, V1098, P122, DOI 10.1196/annals.1384.008; HAMMEN C, 1991, J ABNORM PSYCHOL, V100, P555, DOI 10.1037/0021-843X.100.4.555; HAMMEN C, 1999, UCLA LIFE STRESS INT; Heim C, 2000, PSYCHONEUROENDOCRINO, V25, P1, DOI 10.1016/S0306-4530(99)00035-9; JENZANO JW, 1987, ARCH ORAL BIOL, V32, P757, DOI 10.1016/0003-9969(87)90123-3; KAHN JP, 1988, BIOL PSYCHIAT, V23, P335, DOI 10.1016/0006-3223(88)90284-3; KALLENBACH JM, 1985, CHEST, V87, P644, DOI 10.1378/chest.87.5.644; KIRSCHBAUM C, 1994, PSYCHONEUROENDOCRINO, V19, P313, DOI 10.1016/0306-4530(94)90013-2; Kirschbaum C., 2007, ENCY STRESS, P405; KOSTEN TR, 1984, J NERV MENT DIS, V172, P359, DOI 10.1097/00005053-198406000-00007; KVETNANSKY R, 2000, ENCY STRESS, P63; MacArthur Research Network on SES and Health, 2000, SAL CORT MEAS; Mannino DM, 1998, MMWR-MORBID MORTAL W, V47, P1; MENDEL CM, 1992, J ANDROL, V13, P107; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Miller GE, 2002, HEALTH PSYCHOL, V21, P531, DOI 10.1037//0278-6133.21.6.531; Miller GE, 2007, PSYCHOL BULL, V133, P25, DOI 10.1037/0033-2909.133.1.25; Nater UM, 2006, PSYCHONEUROENDOCRINO, V31, P49, DOI 10.1016/j.psyneuen.2005.05.010; Nater UM, 2005, INT J PSYCHOPHYSIOL, V55, P333, DOI 10.1016/j.ijpsycho.2004.09.009; Nater UM, 2007, PSYCHONEUROENDOCRINO, V32, P392, DOI 10.1016/j.psyneuen.2007.02.007; *NHLBI, 1997, PUBL NIH; *NHLBI, 2002, GUID DIAGN MAN ASTHM; Pearson-Murphy BE, 2000, GLUCOCORTICOIDS OVER, P244; Pruessner JC, 2003, PSYCHONEUROENDOCRINO, V28, P916, DOI 10.1016/S0306-4530(02)00108-7; Pruessner JC, 1999, PSYCHOSOM MED, V61, P197; Rantonen PJF, 2000, ACTA ODONTOL SCAND, V58, P160; Rohleder N, 2004, ANN NY ACAD SCI, V1032, P258, DOI 10.1196/annals.1314.033; Rohleder N, 2006, PSYCHOPHYSIOLOGY, V43, P645, DOI 10.1111/j.1469-8986.2006.00457.x; Sandberg S, 2000, LANCET, V356, P982, DOI 10.1016/S0140-6736(00)02715-X; Sanders VM, 1997, J IMMUNOL, V158, P4200; Sapolsky RM, 2000, ENDOCR REV, V21, P55, DOI 10.1210/er.21.1.55; SCHAEFFER MA, 1984, PSYCHOSOM MED, V46, P227; Sears MR, 1998, CLIN EXP ALLERGY, V28, P82; SEARS MR, 1998, CLIN EXP ALLERGY, V28, P90; SKOBELOFF EM, 1992, JAMA-J AM MED ASSOC, V268, P3437, DOI 10.1001/jama.268.24.3437; Skosnik PD, 2000, INT J PSYCHOPHYSIOL, V36, P59, DOI 10.1016/S0167-8760(99)00100-2; Smith P. M., 1996, SALIVA ORAL HLTH, P9; Tabachnick B. G., 2001, USING MULTIVARIATE S; van Stegeren A, 2006, PSYCHONEUROENDOCRINO, V31, P137, DOI 10.1016/j.psyneuen.2005.05.012; Van Cauter E, 1995, PRINCIPLES PRACTICE, P41; Vedhara K, 2002, J PSYCHOSOM RES, V53, P1153, DOI 10.1016/S0022-3999(02)00343-4; VINING RF, 1983, CLIN CHEM, V29, P1752; Yehuda R, 2000, J CLIN PSYCHIAT, V61, P14	69	84	86	6	20	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0301-0511			BIOL PSYCHOL	Biol. Psychol.	APR	2008	78	1					20	28		10.1016/j.biopsycho.2007.12.004		9	Psychology, Biological; Behavioral Sciences; Psychology; Psychology, Experimental	Psychology; Behavioral Sciences	297MR	WOS:000255621300003	18243483	
J	Runswick, S; Mitchell, T; Davies, P; Robinson, C; Garrod, DR				Runswick, Sarah; Mitchell, Thomas; Davies, Paul; Robinson, Clive; Garrod, David R.			Pollen proteolytic enzymes degrade tight junctions	RESPIROLOGY			English	Article						allergy; asthma; pollen; proteolytic enzyme; rhinitis; tight junction	DUST-MITE ALLERGEN; AMBROSIA-ARTEMISIIFOLIA POLLEN; EPITHELIAL-CELLS; ASTHMA; DER-P-1; PURIFICATION; ALPHA(1)-ANTITRYPSIN; PROTEINASES; PERMEABILITY; PEPTIDASE	Background and objective: Asthma and allergic rhinitis are significant, increasing causes of morbidity worldwide. Pollen, a major cause of seasonal rhinitis/conjunctivitis, carries proteolytic enzymes on its surface. We showed previously that peptidase allergens from house dust mites compromise epithelial barrier function by degrading the extracellular domains of the tight junction proteins, occludin and claudin, thus facilitating allergen delivery across epithelial layers. In this study, we aimed to determine whether peptidases from allergenic pollens should similarly be considered to have a role in disrupting tight junctions. Methods: Diffusates from stored pollen of Giant Ragweed, White Birch and Kentucky Blue Grass, and fresh pollen from Easter Lily were applied to confluent monolayers of Madin-Darby canine kidney (MDCK) and Calu-3 cells in serum-free medium. Immunofluorescence was performed for the tight junction proteins, occludin, claudin-1 and ZO-1. The effect of pollen diffusate on occludin was studied by Western blotting, and enzymatic activity in the diffusates was demonstrated by zymography. The ability of protease inhibitors to block the action of the diffusate on tight junctions was investigated. Results: Diffusates from all four allergenic pollens caused loss of immunofluorescence labelling for tight junction proteins on MDCK and Calu-3 cells. The effect was blocked by inhibitors of serine and cysteine proteases. Degradation of occludin was demonstrated by Western blotting and zymography indicated that diffusates contain proteolytic activity. Conclusion: Pollen peptidases directly or indirectly disrupt epithelial tight junctions, and this activity should be considered as a possible mechanism for facilitating allergen delivery across epithelia.	Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England; St Georges Univ London, Ion Channels & Cell Signalling Ctr, Div Basic Med Sci, London, England; James Cook Univ N Queensland, Discipline Pharm, Townsville, Qld 4811, Australia	Garrod, DR (reprint author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	david.garrod@manchester.ac.uk		Robinson, Clive/0000-0001-6253-7864; Garrod, David/0000-0003-0300-3947	Medical Research Council [G0001362]; Wellcome Trust		Aijaz S, 2006, INT REV CYTOL, V248, P261, DOI 10.1016/S0074-7696(06)48005-0; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; Bagarozzi DA, 1996, J BIOL CHEM, V271, P26227; Bagarozzi DA, 1998, AM J RESP CELL MOL, V18, P363; Bagarozzi DA, 1998, PHYTOCHEMISTRY, V47, P593, DOI 10.1016/S0031-9422(97)00634-1; BROIDE DH, 1992, J ALLERGY CLIN IMMUN, V89, P958, DOI 10.1016/0091-6749(92)90218-Q; Cortes L, 2006, J ALLERGY CLIN IMMUN, V118, P878, DOI 10.1016/j.jaci.2006.05.029; D'Amato G, 2002, EUR RESPIR J, V20, P763, DOI 10.1183/09031936.02.00401402; Eden E, 2003, CHEST, V123, P765, DOI 10.1378/chest.123.3.765; FAHY JV, 1995, AM J RESP CRIT CARE, V152, P53; Ghaemmaghami AM, 2002, CLIN EXP ALLERGY, V32, P1468, DOI 10.1046/j.1365-2745.2002.01504.x; Gough L, 2003, CLIN EXP ALLERGY, V33, P1159, DOI 10.1046/j.1365-2222.2003.01716.x; Gough L, 2001, CLIN EXP ALLERGY, V31, P1594, DOI 10.1046/j.1365-2222.2001.01207.x; Grobe K, 1999, EUR J BIOCHEM, V263, P33, DOI 10.1046/j.1432-1327.1999.00462.x; Hassim Z, 1998, THORAX, V53, P368; Hou JH, 2006, J BIOL CHEM, V281, P36117, DOI 10.1074/jbc.M608853200; HYDE JS, 1979, ANN ALLERGY, V43, P8; Kalsheker NA, 1996, BIOCHEM BIOPH RES CO, V221, P59, DOI 10.1006/bbrc.1996.0544; Levenson T, 1997, ALLERGY ASTHMA PROC, V18, P213, DOI 10.2500/108854197778594016; Matheson NR, 1998, J BIOL CHEM, V273, P16771, DOI 10.1074/jbc.273.27.16771; Messent AJ, 2000, INVEST OPHTH VIS SCI, V41, P8; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141; Poppelmann M, 2002, ELECTROPHORESIS, V23, P993, DOI 10.1002/1522-2683(200204)23:7/8<993::AID-ELPS993>3.0.CO;2-V; Radlowski Marek, 2005, Journal of Applied Genetics, V46, P247; Raftery MJ, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-10; RUDOLPH R, 1978, ALLERGY, V33, P310, DOI 10.1111/j.1398-9995.1978.tb01556.x; Salib RJ, 2003, CLIN OTOLARYNGOL, V28, P291, DOI 10.1046/j.1365-2273.2003.00706.x; Sigsgaard T, 2000, EUR RESPIR J, V16, P50, DOI 10.1034/j.1399-3003.2000.16a09.x; STEWART GA, 2000, ASTHMA RHINITIS, V2, P1107; STEWART GA, 2003, MIDDLETONS ALLERGY P, P585; Stick SA, 2003, AM J RESP CELL MOL, V28, P641, DOI 10.1165/rcmb.F271; VERCELLI D, 1989, EUR J IMMUNOL, V19, P1419, DOI 10.1002/eji.1830190811; Wan H, 2000, CLIN EXP ALLERGY, V30, P685, DOI 10.1046/j.1365-2222.2000.00820.x; Wan H, 1999, J CLIN INVEST, V104, P123, DOI 10.1172/JCI5844; Wan H, 2001, CLIN EXP ALLERGY, V31, P279, DOI 10.1046/j.1365-2222.2001.00970.x; Widmer F, 2000, CLIN EXP ALLERGY, V30, P571, DOI 10.1046/j.1365-2222.2000.00784.x; Winton HL, 1998, CLIN EXP ALLERGY, V28, P1273; Winton HL, 1998, BRIT J PHARMACOL, V124, P1048, DOI 10.1038/sj.bjp.0701905	39	84	87	0	8	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1323-7799			RESPIROLOGY	Respirology	NOV	2007	12	6					834	842		10.1111/j.1440-1843.2007.01175.x		9	Respiratory System	Respiratory System	226WI	WOS:000250618800008	17986111	
J	Narita, S; Goldblum, RM; Watson, CS; Brooks, EG; Estes, DM; Curran, EM; Midoro-Horiuti, T				Narita, Shin-ichiro; Goldblum, Randall M.; Watson, Cheryl S.; Brooks, Edward G.; Estes, D. Mark; Curran, Edward M.; Midoro-Horiuti, Terumi			Environmental estrogens induce mast cell degranulation and enhance IgE-mediated release of allergic mediators	ENVIRONMENTAL HEALTH PERSPECTIVES			English	Article						allergy; asthma; beta-hexosaminidase; environmental estrogen; estradiol; estrogen receptor alpha; IgE; mast cells	PITUITARY-TUMOR CELLS; MEMBRANE ESTROGEN; POSTNATAL EXPOSURE; PROLACTIN-RELEASE; ASTHMA; ALPHA; XENOESTROGENS; STIMULATION; MECHANISMS; RECEPTORS	BACKGROUND: Prevalence and morbidity of allergic diseases have increased over the last decades. Based on the recently recognized differences in asthma prevalence between the sexes, we have examined the effect of endogenous estrogens on a key element of the allergic response. Some lipophilic pollutants have estrogen-like activities and are termed environmental estrogens. These pollutants tend to degrade slowly in the environment and to bioaccumulate and bioconcentrate in the no chain; they also have long biological half-lives. OBJECTIVES: Our goal in this study was to identify possible pathogenic roles for environmental estrogens in the development of allergic diseases. METHODS: We screened a number of environmental estrogens for their ability to modulate the release of allergic mediators from mast cells. We incubated a human mast cell line and primary mast cell cultures derived from bone marrow of wild type and estrogen receptor alpha (ER-alpha)-deficient mice with environmental estrogens with and without estradiol or IgE and allergens. We assessed degranulation of mast cells by quantifying the release of beta-hexosaminidase. RESULTS: All of the environmental estrogens tested caused rapid, dose-related release of beta-hexosaminidase from mast cells and enhanced IgE-mediated release. The combination of physiologic concentrations of 17 beta-estradiol and several concentrations of environmental estrogens had additive effects on mast cell degranulation. Comparison of bone marrow mast cells from ER-alpha-sufficient and ER-alpha-deficient mice indicated that much of the effect of environmental estrogens was mediated by ER-alpha. CONCLUSIONS: Our findings suggest that estrogenic environmental pollutants might promote allergic diseases by inducing and enhancing mast cell degranulation by physiologic estrogens and exposure to allergens.	Child Hlth Res Ctr, Dept Pediat, Galveston, TX USA; Univ Texas, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77550 USA	Midoro-Horiuti, T (reprint author), Univ Texas, Med Branch, Child Hlth Res Ctr, Childrens Hosp 2300, 301 Univ Blvd, Galveston, TX 77555 USA.	tmidoro@utmb.edu			NIAID NIH HHS [K08 AI055792, R01 AI052428]; NIEHS NIH HHS [R21 ES016428]		Aravindakshan J, 2004, TOXICOL SCI, V81, P179, DOI 10.1093/toxsci/kfh174; Ayotte P, 2003, ENVIRON HEALTH PERSP, V111, P1253, DOI 10.1289/ehp.6054; Bologa CG, 2006, NAT CHEM BIOL, V2, P207, DOI 10.1038/nchembio775; Bulayeva NN, 2005, AM J PHYSIOL-ENDOC M, V288, pE388, DOI 10.1152/ajpendo.00349.2004; Bulayeva NN, 2004, ENVIRON HEALTH PERSP, V112, P1481, DOI 10.1289/ehp.7175; Burr ML, 2006, THORAX, V61, P296, DOI 10.1136/thx.2005.045682; BUTTERFIELD JH, 1988, LEUKEMIA RES, V12, P345, DOI 10.1016/0145-2126(88)90050-1; Dastych J, 1999, J ALLERGY CLIN IMMUN, V103, P1108, DOI 10.1016/S0091-6749(99)70186-7; de Marco R, 2002, J ALLERGY CLIN IMMUN, V110, P228, DOI 10.1067/mai.2002.125600; DEWAILLY E, 1993, ENVIRON HEALTH PERSP, V101, P618, DOI 10.2307/3431646; Dijkstra A, 2006, J ALLERGY CLIN IMMUN, V117, P604, DOI 10.1016/j.jaci.2005.11.023; Falconer IR, 2006, ENVIRON TOXICOL, V21, P181, DOI 10.1002/tox.20172; Ibarluzea JM, 2004, CANCER CAUSE CONTROL, V15, P591, DOI 10.1023/B:CACO.0000036167.51236.86; Kos M, 2002, J MOL ENDOCRINOL, V29, P281, DOI 10.1677/jme.0.0290281; Lambert KC, 2005, J IMMUNOL, V175, P5716; Metcalfe CD, 2001, ENVIRON TOXICOL CHEM, V20, P297, DOI 10.1897/1551-5028(2001)020<0297:EPOCDI>2.0.CO;2; Newbold RR, 2006, ENDOCRINOLOGY, V147, pS11, DOI 10.1210/en.2005-1164; Odom S, 2004, J EXP MED, V199, P1491, DOI 10.1084/jem.20040382; Solomon GM, 2002, ENVIRON HEALTH PERSP, V110, pA339; Thomas P, 2005, ENDOCRINOLOGY, V146, P624, DOI 10.1210/en.2004-1064; Vartiainen T, 1997, CHEMOSPHERE, V34, P2571, DOI 10.1016/S0045-6535(97)00100-8; Wang SL, 2004, CHEMOSPHERE, V54, P1459, DOI 10.1016/j.chemosphere.2003.08.012; Watson CS, 1999, EXP PHYSIOL, V84, P1013, DOI 10.1111/j.1469-445X.1999.01903.x; Watson CS, 2001, INT IMMUNOPHARMACOL, V1, P1049, DOI 10.1016/S1567-5769(01)00036-4; Watson CS, 2003, EXP BIOL MED, V228, P1272; Welshons WV, 2003, ENVIRON HEALTH PERSP, V111, P994, DOI 10.1289/ehp.5494; Wozniak AL, 2005, ENVIRON HEALTH PERSP, V113, P431, DOI 10.1289/ehp.7505; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888; ZAITSU M, 2006, MOL IMMUNOL, DOI DOI 10.1016/J.MOLIMM.2006.09.030	29	84	89	0	9	US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE	RES TRIANGLE PK	NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA	0091-6765			ENVIRON HEALTH PERSP	Environ. Health Perspect.	JAN	2007	115	1					48	52		10.1289/ehp.9378		5	Environmental Sciences; Public, Environmental & Occupational Health; Toxicology	Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology	123ME	WOS:000243299200031	17366818	
J	Matsui, EC; Eggleston, PA; Buckley, TJ; Krishnan, JA; Breysse, PN; Rand, CS; Diette, GB				Matsui, Elizabeth C.; Eggleston, Peyton A.; Buckley, Timothy J.; Krishnan, Jerry A.; Breysse, Patrick N.; Rand, Cynthia S.; Diette, Gregory B.			Household mouse allergen exposure and asthma morbidity in inner-city preschool children	ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY			English	Article							ENVIRONMENTAL TOBACCO-SMOKE; SKIN-TEST SENSITIVITY; COCKROACH ALLERGEN; HOMES; SENSITIZATION; DETERMINANTS; PREVALENCE; SYMPTOMS; SUBURBAN; RISK	Background: Inner-city children experience disproportionate asthma morbidity, and suspected reasons include indoor environmental exposures. Objective: To determine if mouse allergen exposure is a risk factor for asthma morbidity. Methods: Preschool children with asthma were recruited from inner-city Baltimore, MD. Skin testing was performed and blood was collected at the baseline visit for quantification of mouse allergen specific IgE. A questionnaire evaluated symptoms, medication, and health care use at baseline, 3 months, and 6 months. A trained technician collected dust samples from the child's home for analysis of Mus m 1 at baseline, 3 months, and 6 months. Outcomes were compared between mouse-sensitized, highly exposed children and all other children. Results: A total of 127 children had complete data for mouse sensitization status and bedroom settled dust mouse allergen levels at baseline. The mean age of the children was 4.4 years, 92% were African American, and 26% were sensitized to mouse. Mouse-sensitized children exposed to higher levels of Mus in 1 (> 0.5 mu g/g) had 50% more days of symptoms (incidence rate ratio [IRR], 1.5; 95% confidence interval [CI], 1.1-2.1) and 80% more days of beta-agonist use than other children (IRR, 1.8; 95% CI, 1.3-2.5). Children in the sensitized and highly exposed group were also more likely to have an unscheduled physician visit (odds ratio [OR], 3.1; 95% CI, 1.6-6.3), emergency department visit (OR, 2.1; 95% CI, 1.1-4.1), and hospitalization (OR, 36.6; 95% CI, 4.1-327.3) than other children. These associations between mouse allergen exposure and asthma symptoms and morbidity remained statistically significant after adjusting for potential confounders, including atopy and cockroach sensitization and exposure. Conclusions: In mouse-sensitized inner-city children, exposure to mouse allergen may be an important cause of asthma morbidity.	Johns Hopkins Univ, Dept Pediat, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Environm Hlth Sci, Bloomberg Sch Publ Hlth, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Med, Baltimore, MD 21218 USA	Matsui, EC (reprint author), Johns Hopkins Univ Hosp, 600 N Wolfe St,CMSC 1102, Baltimore, MD 21287 USA.	ematsui@jhmi.edu			NHLBI NIH HHS [HL04266, HL67850]; NIAID NIH HHS [AI060955, AI62974]; NIEHS NIH HHS [P30 ES 03819, ES09606]		Arshad SH, 2005, CHEST, V127, P502, DOI 10.1378/chest.127.2.502; ASHER MI, 1995, EUR RESPIR J, V8, P483, DOI 10.1183/09031936.95.08030483; Asmussen L, 1999, PEDIATRICS, V104, part. no., DOI 10.1542/peds.104.6.e71; Chew GL, 2003, ENVIRON HEALTH PERSP, V111, P1348, DOI 10.1289/ehp.6124; Cohn RD, 2004, J ALLERGY CLIN IMMUN, V113, P1167, DOI 10.1016/j.jaci.2003.12.592; CULLINAN P, 1994, OCCUP ENVIRON MED, V51, P589; Eggleston PA, 1998, J ALLERGY CLIN IMMUN, V102, P563, DOI 10.1016/S0091-6749(98)70272-6; EGGLESTON PA, 1995, AM J RESP CRIT CARE, V151, P640; Gautrin D, 2001, AM J RESP CRIT CARE, V163, P899; Gilliland FD, 2001, AM J RESP CRIT CARE, V163, P429; Gruchalla RS, 2005, J ALLERGY CLIN IMMUN, V115, P478, DOI 10.1016/j.jaci.2004.12.006; Hollander A, 1998, SCAND J WORK ENV HEA, V24, P228; Lau Susanne, 2002, Paediatr Respir Rev, V3, P265, DOI 10.1016/S1526-0542(02)00189-6; Litonjua AA, 2001, J ALLERGY CLIN IMMUN, V107, P41, DOI 10.1067/mai.2001.111143; Matsui EC, 2005, J ALLERGY CLIN IMMUN, V115, P358, DOI 10.1016/j.jaci.2004.11.007; Matsui EC, 2004, J ALLERGY CLIN IMMUN, V113, P910, DOI 10.1016/j.jaci.2004.02.034; Mitchell H, 1997, PEDIATR PULM, V24, P237; Morkjaroenpong V, 2002, J ALLERGY CLIN IMMUN, V110, P147, DOI 10.1067/mai.2002.125832; OHMAN JL, 1994, J ALLERGY CLIN IMMUN, V94, P810, DOI 10.1016/0091-6749(94)90147-3; Perry T, 2003, J ALLERGY CLIN IMMUN, V112, P346, DOI 10.1067/mai.2003.1640; Phipatanakul W, 2005, ALLERGY, V60, P697, DOI 10.1111/j.1398-9995.2005.00825.x; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1070, DOI 10.1067/mai.2000.110796; Phipatanakul W, 2000, J ALLERGY CLIN IMMUN, V106, P1075; Rosenstreich DL, 1997, NEW ENGL J MED, V336, P1356, DOI 10.1056/NEJM199705083361904; SCHUMACHER MJ, 1981, J ALLERGY CLIN IMMUN, V68, P310, DOI 10.1016/0091-6749(81)90157-3; Van Asperen P P, 1994, Pediatr Allergy Immunol, V5, P178; Wood RA, 2001, ANN ALLERG ASTHMA IM, V87, P60	27	84	84	0	2	AMER COLL ALLERGY ASTHMA IMMUNOLOGY	ARLINGTON HTS	85 WEST ALGONQUIN RD SUITE 550, ARLINGTON HTS, IL 60005 USA	1081-1206			ANN ALLERG ASTHMA IM	Ann. Allergy Asthma Immunol.	OCT	2006	97	4					514	520				7	Allergy; Immunology	Allergy; Immunology	097AW	WOS:000241419600017	17069107	
J	Card, JW; Carey, MA; Bradbury, JA; DeGraff, LM; Morgan, DL; Moorman, MP; Flake, GP; Zeldin, DC				Card, JW; Carey, MA; Bradbury, JA; DeGraff, LM; Morgan, DL; Moorman, MP; Flake, GP; Zeldin, DC			Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation	JOURNAL OF IMMUNOLOGY			English	Article							SYNTHASE-DEFICIENT MICE; ACUTE LUNG INJURY; INHALED LIPOPOLYSACCHARIDE; TESTOSTERONE; ASTHMA; RATS; ESTRADIOL; RESPONSES; ESTROGEN; HORMONES	The roles of gender and sex hormones in lung function and disease are complex and not completely understood. The present study examined the influence. of gender on lung function and respiratory mechanics in naive mice and on acute airway inflammation and hyperresponsiveness induced by intratracheal LPS administration. Basal lung function characteristics did not differ between naive males and females, but males demonstrated significantly greater airway responsiveness than females following aerosolized methacholine challenge as evidenced by increased respiratory system resistance and elastance (p < 0.05). Following LPS administration, males developed more severe hypothermia and greater airway hyperresponsiveness than females (p < 0.05). Inflammatory indices including bronchoalveolar lavage fluid total cells, neutrophils, and TNF-alpha content were greater in males than in females 6 h following LPS administration (p < 0.05), whereas whole-lung TLR-4 protein levels did not differ among treatment groups, suggesting that differential expression of TLR-4 before or after LPS exposure did not underlie the observed inflammatory outcomes. Gonadectomy decreased airway inflammation in males but did not alter inflammation in females, whereas administration of exogenous testosterone to intact females increased their inflammatory responses to levels observed in intact males. LPS-induced airway hyperresponsiveness was also decreased in castrated males and was increased in females administered exogenous testosterone. Collectively, these data indicate that airway responsiveness in naive mice is influenced by gender, and that male mice have exaggerated airway inflammatory and functional responses to LPS compared with females. These gender differences are mediated, at least in part, by effects of androgens.	NIEHS, Div Intramural Res, NIH, Res Triangle Pk, NC 27709 USA	Zeldin, DC (reprint author), NIEHS, Div Intramural Res, NIH, 111 TW Alexander Dr,Bldg 101,Room D236, Res Triangle Pk, NC 27709 USA.	zeldin@niehs.nih.gov			Intramural NIH HHS [Z01 ES101885-03]		Ashcroft GS, 2002, J CLIN INVEST, V110, P615, DOI 10.1172/JCI200215704; Benten WPM, 1997, FEBS LETT, V407, P211, DOI 10.1016/S0014-5793(97)00346-3; Caracta CF, 2003, MT SINAI J MED, V70, P215; Cuzzocrea S, 2000, ENDOCRINOLOGY, V141, P1455, DOI 10.1210/endo.141.4.7404; de Oliveira APL, 2004, NEUROIMMUNOMODULAT, V11, P20, DOI 10.1159/000072965; Degano B, 2001, AM J RESP CRIT CARE, V164, P1849; Gavett SH, 1999, J CLIN INVEST, V104, P721, DOI 10.1172/JCI6890; Gharaee-Kermani M, 2005, AM J PATHOL, V166, P1593, DOI 10.1016/S0002-9440(10)62470-4; Guo ZY, 2002, J BIOL CHEM, V277, P29600, DOI 10.1074/jbc.M202997200; Haggerty CL, 2003, ANN ALLERG ASTHMA IM, V90, P284; Hollingsworth JW, 2004, AM J RESP CRIT CARE, V170, P126, DOI 10.1164/rccm.200311-1499OC; Kline JN, 1999, AM J RESP CRIT CARE, V160, P297; Lee JJ, 2004, SCIENCE, V305, P1773, DOI 10.1126/science.1099472; Lim CM, 2003, INTENS CARE MED, V29, P453, DOI 10.1007/s00134-002-1529-6; Ma J, 2004, MOL PHARMACOL, V65, P730, DOI 10.1124/mol.65.3.730; MASSARO GD, 1995, P NATL ACAD SCI USA, V92, P1105, DOI 10.1073/pnas.92.4.1105; Michel O, 1996, AM J RESP CRIT CARE, V154, P1641; Michel O, 2001, J ALLERGY CLIN IMMUN, V107, P797, DOI 10.1067/mai.2001.114249; Park KM, 2004, J BIOL CHEM, V279, P52282, DOI 10.1074/jbc.M407629200; Reinhard C, 2002, MAMM GENOME, V13, P429, DOI 10.1007/s00335-002-3005-6; SHIRAI M, 1995, EUR RESPIR J, V8, P272, DOI 10.1183/09031936.95.08020272; Speyer CL, 2005, AM J PHYSIOL-CELL PH, V288, pC881, DOI 10.1152/ajpcell.00467.2004; Tesfaigzi Y, 2001, J APPL PHYSIOL, V91, P2182; Wang GC, 2003, CHINESE J PHYSIOL, V46, P151; WONG CI, 1995, J BIOL CHEM, V270, P19998; Zeldin DC, 2001, AM J RESP CELL MOL, V25, P457	26	84	85	0	5	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	JUL 1	2006	177	1					621	630				10	Immunology	Immunology	055ST	WOS:000238471400073	16785560	
J	Inoue, Y; Matsuwaki, Y; Shin, SH; Ponikau, JU; Kita, H				Inoue, Y; Matsuwaki, Y; Shin, SH; Ponikau, JU; Kita, H			Nonpathogenic, environmental fungi induce activation and degranulation of human eosinophils	JOURNAL OF IMMUNOLOGY			English	Article							MAJOR BASIC-PROTEIN; BLOOD EOSINOPHILS; POTENT ACTIVATOR; MEDIATOR RELEASE; BRONCHIAL-ASTHMA; DE-GRANULATION; STIMULATION; CELLS; ALTERNARIA; RECEPTORS	Eosinophils and their products are probably important in the pathophysiology of allergic diseases, such as bronchial asthma, and in host immunity to certain organisms. An association between environmental fungal exposure and asthma has been long recognized clinically. Although products of microorganisms (e.g., lipopolysaccharides) directly activate certain inflammatory cells (e.g., macrophages), the mechanism(s) that triggers eosinophil degranulation is unknown. In this study we investigated whether human eosinophils have an innate immune response to certain fungal organisms. We incubated human eosinophils with extracts from seven environmental airborne fungi (Alternaria alternata, Aspergillus versicolor, Bipolaris sorokiniana, Candida albicans, Cladosporium herbarum, Curvularia spicifera, and Penicillium notatum). Alternaria and Penicillium induced calcium-dependent exocytosis (e.g., eosinophil-derived neurotoxin release) in eosinophils from normal individuals. Alternaria also strongly induced other activation events in eosinophils, including increases in intracellular calcium concentration, cell surface expression of CD63 and CD11b, and production of IL-8. Other fungi did not induce eosinophil degranulation, and Alternaria did not induce neutrophil activation, suggesting specificity for fungal species and cell type. The Alternaria-induced eosinophil degranulation was pertussis toxin sensitive and desensitized by preincubating cells with G protein-coupled receptor agonists, platelet-activating factor, or FMLP. The eosinophil-stimulating activity in Alternaria extract was highly heat labile and had an M-r of similar to 60 kDa. Thus, eosinophils, but not neutrophils, possess G protein-dependent cellular activation machinery that directly responds to an Alternaria protein product(s). This innate response by eosinophils to certain environmental fungi may be important in host defense and in the exacerbation of inflammation in asthma and allergic diseases.	Mayo Clin, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin, Dept Med, Rochester, MN 55905 USA; Mayo Clin, Dept Otorhinolaryngol, Rochester, MN 55905 USA	Kita, H (reprint author), Mayo Clin, Dept Immunol, Rochester, MN 55905 USA.	kita.hirohito@mayo.edu			NIAID NIH HHS [AI49235]		AAS K, 1980, ALLERGY, V35, P443, DOI 10.1111/j.1398-9995.1980.tb01791.x; ABUGHAZALEH RI, 1989, J IMMUNOL, V142, P2393; Al-Ani B, 2002, J PHARMACOL EXP THER, V300, P702, DOI 10.1124/jpet.300.2.702; AYARS GH, 1985, J ALLERGY CLIN IMMUN, V76, P595, DOI 10.1016/0091-6749(85)90781-X; BACH MK, 1992, IMMUNOLOGY, V75, P680; Black PN, 2000, ALLERGY, V55, P501, DOI 10.1034/j.1398-9995.2000.00293.x; BRAUN RK, 1993, EUR J IMMUNOL, V23, P956, DOI 10.1002/eji.1830230429; BROFMAN JD, 1989, J APPL PHYSIOL, V66, P1867; Bush RK, 2004, J ALLERGY CLIN IMMUN, V113, P227, DOI 10.1016/j.jaci.2003.11.023; CHAM BP, 1994, AM J PATHOL, V144, P1369; D'Souza MP, 2000, JAMA-J AM MED ASSOC, V284, P215, DOI 10.1001/jama.284.2.215; Dill I, 1996, PEDIATR ALLERGY IMMU, V7, P151, DOI 10.1111/j.1399-3038.1996.tb00123.x; Elsner J, 1996, EUR J IMMUNOL, V26, P1919, DOI 10.1002/eji.1830260837; FILLEY WV, 1982, LANCET, V2, P11; GLEICH GJ, 1990, J ALLERGY CLIN IMMUN, V85, P422, DOI 10.1016/0091-6749(90)90151-S; GLEICH GJ, 1979, J IMMUNOL, V123, P2925; GLEICH GJ, 1986, ADV IMMUNOL, V39, P177, DOI 10.1016/S0065-2776(08)60351-X; Grady EF, 1997, AM J PHYSIOL-GASTR L, V273, pG586; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNDEL RH, 1991, J CLIN INVEST, V87, P1470, DOI 10.1172/JCI115155; Halonen M, 1997, AM J RESP CRIT CARE, V155, P1356; HANSEL TT, 1991, J IMMUNOL METHODS, V145, P105, DOI 10.1016/0022-1759(91)90315-7; HORIE S, 1994, J IMMUNOL, V152, P5457; Kato M, 2002, J IMMUNOL, V169, P5252; KAUFFMAN HF, 1995, AM J RESP CRIT CARE, V151, P2109; Kauffman HF, 2000, J ALLERGY CLIN IMMUN, V105, P1185, DOI 10.1067/mai.2000.106210; KEMEN P, 1991, Journal of Clinical Investigation, V87, P2012; KHALIFE J, 1986, J IMMUNOL, V137, P1659; Kheradmand F, 2002, J IMMUNOL, V169, P5904; Kita H, 1999, J IMMUNOL, V162, P6901; Kita H, 2003, MIDDLETONS ALLERGY P, V1, P305; Kobayashi T, 1999, NAT CELL BIOL, V1, P113; KROEGEL C, 1994, J ALLERGY CLIN IMMUN, V93, P725, DOI 10.1016/0091-6749(94)90252-6; KROEGEL C, 1989, J IMMUNOL, V142, P3518; LEIFERMAN KM, 1985, NEW ENGL J MED, V313, P282, DOI 10.1056/NEJM198508013130502; Li CS, 1997, ARCH ENVIRON HEALTH, V52, P72; Logan MR, 2003, J ALLERGY CLIN IMMUN, V111, P923, DOI 10.1067/mai.2003.1573; Mahmudi-Azer S, 2002, BLOOD, V99, P4039, DOI 10.1182/blood.V99.11.4039; Matthews AN, 1998, P NATL ACAD SCI USA, V95, P6273, DOI 10.1073/pnas.95.11.6273; Miike S, 2001, J IMMUNOL, V167, P6615; Mitakakis TZ, 2001, J ALLERGY CLIN IMMUN, V107, P388, DOI 10.1067/mai.2001.112602; MOTOJIMA S, 1989, AM REV RESPIR DIS, V139, P801; Nagase H, 2003, J IMMUNOL, V171, P3977; OHOLLAREN MT, 1991, NEW ENGL J MED, V324, P359, DOI 10.1056/NEJM199102073240602; Ponikau JU, 2005, J ALLERGY CLIN IMMUN, V116, P362, DOI 10.1016/j.jaci.2005.03.049; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; Richardson RM, 1996, J BIOL CHEM, V271, P28717; Romani Luigina, 2004, Nat Rev Immunol, V4, P1; Seminario MC, 1999, J IMMUNOL, V162, P6893; SOLOMON WR, 1975, J ALLERGY CLIN IMMUN, V56, P235, DOI 10.1016/0091-6749(75)90095-0; Steinhoff M, 2005, ENDOCR REV, V26, P1, DOI 10.1210/er.2003-0025; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Tomee JFC, 2000, CLIN EXP ALLERGY, V30, P476, DOI 10.1046/j.1365-2222.2000.00796.x; van Burik JAH, 2001, ANNU REV MICROBIOL, V55, P743, DOI 10.1146/annurev.micro.55.1.743; WAGNER JM, 1993, PLACENTA, V14, P671, DOI 10.1016/S0143-4004(05)80384-4; Williams DL, 1997, MEDIAT INFLAMM, V6, P247, DOI 10.1080/09629359791550; Yoganathan K, 2003, J NAT PROD, V66, P1116, DOI 10.1021/np030146m; Zureik M, 2002, BRIT MED J, V325, P411, DOI 10.1136/bmj.325.7361.411	58	84	88	0	4	AMER ASSOC IMMUNOLOGISTS	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-1767			J IMMUNOL	J. Immunol.	OCT 15	2005	175	8					5439	5447				9	Immunology	Immunology	972GY	WOS:000232443500070	16210651	
J	Behrendt, CE				Behrendt, CE			Mild and moderate-to-severe COPD in nonsmokers - Distinct demographic profiles	CHEST			English	Article						asthma; COPD; epidemiology; nonsmoker	OBSTRUCTIVE PULMONARY-DISEASE; NUTRITION EXAMINATION; NATIONAL-HEALTH; UNITED-STATES; LUNG-DISEASE; POPULATION; ASTHMA; MORTALITY; SAMPLE; NHANES	Study objective: To investigate the risk of COPD among nonsmokers. Design: Case-control study, logistic regression analysis. Setting: Third National Health and Nutrition Examination Survey, from 1988 to 1994. Participants: Community, residents 18 to 80 years of age, of white, black, or Mexican-American ethnicity. Nonsmokers included never-smokers and former smokers with a < 5 pack-year smoking history, who had never smoked cigars or pipes. Measurements: COPD (FEV1/FVC < 70%) was classified as mild (FEV1 >= 80% predicted) or moderate to severe (FEV1 23 to 79% predicted). Results: Among 13,995 examinees, 51.3 +/- 0.4% were female, mean age was 42.2 +/- 0.4 cars, 48.7 +/- 0.9% were nonsmokers, 8.8 +/- 0.3% had mild COPD, and 4.1 +/- 0.3% had moderate-to-severe COPD [+/- SE]. One fourth of mild and moderate-to-severe cases were nonsmokers. Among 7,526 nonsmokers, 4.7 +/- 0.3% had mild COPD (n = 403; age, 60.9 +/- 1.3 years) and were mostly, female (82.5%), while 1.9 +/- 0.3% had moderate-to-severe COPD (n = 92, age 39.3 +/- 1.3) and were mostly male (88.1%). Few nonsmokers with COPD (12.1 +/- 2.4%) had a previous diagnosis of chronic bronchitis or emphysema. Among nonsmokers, physician-diagnosed asthma increased the risk of mild and especially of moderate-to-severe COPD. Independently of asthma, risk of mild COPD in nonsmokers increased with age (doubling every, 12 years), before age 60 was lower among men than women, and was inversely associated with current exposure to tobacco smoke at home and at work. In contrast, the risk of moderate-to-severe COPD in nonsmokers was markedly associated with male gender, peaked in middle age, and was inversely associated with nonwhite ethnicity. COPD risks did not vary by minimal smoking history, longest-held occupation, urban residence, income, allergies, thyroid disease, or Helicobacter pylori antibody. Conclusions: Among nonsmokers, mild and moderate-to-severe COPD are associated with asthma but otherwise have distinct demographic profiles, suggesting that moderate-to-severe disease is not a mere progression of mild COPD.		Behrendt, CE (reprint author), 3413 Paseo Campo, Palos Verdes Estates, CA 90274 USA.	carolynbehrendt@yahoo.com					Bakke P S, 2003, Monaldi Arch Chest Dis, V59, P103; Birring SS, 2002, AM J RESP CRIT CARE, V166, P1078, DOI 10.1164/rccm.200203-245OC; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; Hollowell JG, 2002, J CLIN ENDOCR METAB, V87, P489, DOI 10.1210/jc.87.2.489; Hospers JJ, 1999, AM J RESP CRIT CARE, V160, P1869; Jaakkola MS, 2002, SCAND J WORK ENV HEA, V28, P52; Mannino David M, 2003, Respir Care, V48, P1185; Mannino DM, 2003, THORAX, V58, P388, DOI 10.1136/thorax.58.5.388; Mannino DM, 2003, AM J MED, V114, P758, DOI 10.1016/S0002-9343(03)00185-2; Molfino NA, 2004, CHEST, V125, P1929, DOI 10.1378/chest.125.5.1929; Montnemery P, 2000, EUR J EPIDEMIOL, V16, P1003, DOI 10.1023/A:1011004420173; Pauwels Romain A., 2001, American Journal of Respiratory and Critical Care Medicine, V163, P1256; Pena VS, 2000, CHEST, V118, P981, DOI 10.1378/chest.118.4.981; Sandford AJ, 2002, THORAX, V57, P736, DOI 10.1136/thorax.57.8.736; Shiotani A, 2002, J GASTROENTEROL, V37, P402, DOI 10.1007/s005350200058; Silva GE, 2004, CHEST, V126, P59, DOI 10.1378/chest.126.1.59; Snyder LD, 2004, CHEST, V125, P1719, DOI 10.1378/chest.125.5.1719; Sunyer J, 2001, EUR RESPIR J, V17, P1024, DOI 10.1183/09031936.01.17510240; *US DEP HHS NAT CT, 3 NAT HLTH NUTR EX S; *US DEP HHS NAT CT, 1994, PLAN OP 3 NAT HLTH N; WHITTEMORE AS, 1995, AM J PUBLIC HEALTH, V85, P702, DOI 10.2105/AJPH.85.5.702; 1998, 3 NATL HLTH NUTR EXA; [Anonymous], 1987, AM REV RESP DIS, V136, P1285	23	84	84	1	8	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	SEP	2005	128	3					1239	1244		10.1378/chest.128.3.1239		6	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	964YN	WOS:000231917000029	16162712	
J	Hoffjan, S; Nicolae, D; Ostrovnaya, I; Roberg, K; Evans, M; Mirel, DB; Steiner, L; Walker, K; Shult, P; Gangnon, RE; Gern, JE; Martinez, FD; Lemanske, RF; Ober, C				Hoffjan, S; Nicolae, D; Ostrovnaya, I; Roberg, K; Evans, M; Mirel, DB; Steiner, L; Walker, K; Shult, P; Gangnon, RE; Gern, JE; Martinez, FD; Lemanske, RF; Ober, C			Gene-environment interaction effects on the development of immune responses in the 1st year of life	AMERICAN JOURNAL OF HUMAN GENETICS			English	Article							INTERFERON-GAMMA PRODUCTION; DAY-CARE ATTENDANCE; BLOOD MONONUCLEAR-CELLS; ASTHMA SUSCEPTIBILITY GENE; HYGIENE HYPOTHESIS; HIGH-RISK; ALLERGIC DISEASES; ATOPIC DISEASE; AGE-CHILDREN; IFN-GAMMA	Asthma is a common disease that results from both genetic and environmental risk factors. Children attending day care in the 1st year of life have lower risks for developing asthma, although the mechanism for this "day care" effect is largely unknown. We investigated the interactions between day care exposure in the 1st 6 mo of life and genotypes for 72 polymorphisms at 45 candidate loci and their effects on cytokine response profiles and on the development of atopic phenotypes in the 1st year of life in the Childhood Onset of Asthma ( COAST) cohort of children. Six interactions ( at four polymorphisms in three loci) with "day care" that had an effect on early-life immune phenotypes were significant at P < .001. The estimated false-discovery rate was 33%, indicating that an estimated four P values correspond to true associations. Moreover, the " day care" effect at some loci was accounted for by the increased number of viral infections among COAST children attending day care, whereas interactions at other loci were independent of the number of viral infections, indicating the presence of additional risk factors associated with day care environment. This study identified significant gene-environment interactions influencing the early patterning of the immune system and the subsequent development of asthma and highlights the importance of considering environmental risk factors in genetic analyses.	Univ Chicago, Dept Human Genet, Chicago, IL 60637 USA; Univ Chicago, Dept Stat, Chicago, IL 60637 USA; Univ Chicago, Dept Obstet & Gynecol, Chicago, IL 60637 USA; Univ Wisconsin, Dept Pediat, Madison, WI USA; Univ Wisconsin, Dept Med, Madison, WI USA; Univ Wisconsin, Dept Biostat & Med Bioinformat, Madison, WI USA; Univ Wisconsin, Wisconsin State Lab Hyg, Madison, WI 53706 USA; Roche Mol Syst, Alameda, CA USA; Univ Arizona, Tucson Resp Ctr, Tucson, AZ USA	Ober, C (reprint author), Univ Chicago, Dept Human Genet, 920 E 58th St,CLSC 507C, Chicago, IL 60637 USA.	c-ober@genetics.uchicago.edu			NCRR NIH HHS [M01 RR003186, M01 RR03186]; NHLBI NIH HHS [P01 HL070831, R01 HL61879, P01 HL70831]; NICHD NIH HHS [R01 HD061879]; NIDDK NIH HHS [R01 DK055889, R01 DK55889]; NIMH NIH HHS [R01 MH061879]		Bach JF, 2002, NEW ENGL J MED, V347, P911, DOI 10.1056/NEJMra020100; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; Barr CS, 2004, ARCH GEN PSYCHIAT, V61, P1146, DOI 10.1001/archpsyc.61.11.1146; Beasley R, 2002, J ALLERGY CLIN IMMUN, V109, pS482, DOI 10.1067/mai.2002.122716; BENJAMINI Y, 1995, J ROY STAT SOC B MET, V57, P289; Berman DM, 2004, CANCER RES, V64, P6820, DOI 10.1158/0008-5472.CAN-04-1916; Bourgain C, 2003, AM J HUM GENET, V73, P612, DOI 10.1086/378208; Braun-Fahrlander C, 2002, NEW ENGL J MED, V347, P869, DOI 10.1056/NEJMoa020057; Braun-Fahrlander C, 2001, CLIN EXP ALLERGY, V31, P1799, DOI 10.1046/j.1365-2222.2001.01269.x; BURR M L, 1989, Archives of Disease in Childhood, V64, P1452; Celedon JC, 1999, PEDIATRICS, V104, P495, DOI 10.1542/peds.104.3.495; Celedon JC, 2003, AM J RESP CRIT CARE, V167, P1239, DOI 10.1164/rccm.200209-1063OC; Colilla S, 2003, J ALLERGY CLIN IMMUN, V111, P840, DOI 10.1067/mai.2003.170; Copenhaver CC, 2004, AM J RESP CRIT CARE, V170, P175, DOI 10.1164/rccm.200312-1647OC; Coulter AA, 2003, PHYSIOL GENOMICS, V14, P139, DOI 10.1152/physiolgenomics.00057.2003; Dilda CL, 2002, GENETICS, V162, P1655; Gereda JE, 2000, LANCET, V355, P1680, DOI 10.1016/S0140-6736(00)02239-X; GERN JE, 2003, J ALLERGY CLIN IMMUN, V113, P307; Haby MM, 2000, PEDIATR PULM, V30, P377, DOI 10.1002/1099-0496(200011)30:5<377::AID-PPUL3>3.0.CO;2-3; Hoffjan S, 2004, J ALLERGY CLIN IMMUN, V113, P511, DOI 10.1016/j.jaci.2003.10.044; Hoffjan S, 2003, RESPIR RES, V4, DOI 10.1186/1465-9921-4-14; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Kondo N, 1998, CLIN EXP ALLERGY, V28, P1340; Koppelman GH, 2003, CLIN EXP ALLERGY, V33, P170, DOI 10.1046/j.1365-2222.2003.01591.x; Kramer U, 1999, LANCET, V353, P450, DOI 10.1016/S0140-6736(98)06329-6; Lemanske RF, 2002, PEDIATR ALLERGY IMMU, V13, P38, DOI 10.1034/j.1399-3038.13.s.15.8.x; Leng SG, 2004, CANCER EPIDEM BIOMAR, V13, P1631; Liao SY, 1996, CLIN EXP ALLERGY, V26, P397, DOI 10.1111/j.1365-2222.1996.tb00555.x; Liu AH, 2003, J ALLERGY CLIN IMMUN, V111, P471, DOI 10.1067/mai.2003.172; Martin LJ, 2002, GENET EPIDEMIOL, V22, P105, DOI 10.1002/gepi.0135; MARTINEZ FD, 1995, J ALLERGY CLIN IMMUN, V96, P652, DOI 10.1016/S0091-6749(95)70264-4; Martinez FD, 2001, RESPIR RES, V2, P129, DOI 10.1186/rr48; McIntire JJ, 2004, SPRINGER SEMIN IMMUN, V25, P335, DOI 10.1007/s00281-003-0141-3; Merikangas KR, 2003, SCIENCE, V302, P599, DOI 10.1126/science.1091468; Mirel DB, 2002, DIABETES, V51, P3336, DOI 10.2337/diabetes.51.11.3336; Neaville WA, 2003, J ALLERGY CLIN IMMUN, V112, P740, DOI 10.1067/mai.2003.1716; Nicolae D, 2005, AM J HUM GENET, V76, P349, DOI 10.1086/427763; Padyukov L, 2004, ARTHRITIS RHEUM, V50, P3085, DOI 10.1002/art.20553; Pohl D, 1997, ALLERGY, V52, P732, DOI 10.1111/j.1398-9995.1997.tb01230.x; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Reifsnyder PC, 2000, GENOME RES, V10, P1568, DOI 10.1101/gr.147000; Rinas U, 1993, Pediatr Allergy Immunol, V4, P60, DOI 10.1111/j.1399-3038.1993.tb00068.x; Rowe J, 2004, J ALLERGY CLIN IMMUN, V113, P710, DOI 10.1016/j.jaci.2003.12.585; Sheikh A, 2003, J ALLERGY CLIN IMMUN, V111, P131, DOI 10.1067/mai.2003.8; Smart JM, 2002, CLIN EXP ALLERGY, V32, P796, DOI 10.1046/j.1365-2222.2002.01391.x; Storey JD, 2002, J ROY STAT SOC B, V64, P479, DOI 10.1111/1467-9868.00346; TANG M, 1993, CLIN EXP IMMUNOL, V92, P120; TANG MLK, 1994, LANCET, V344, P983, DOI 10.1016/S0140-6736(94)91641-1; Umetsu DT, 2003, J ALLERGY CLIN IMMUN, V112, P480, DOI 10.1067/mai.2003.1717; Ungerer MC, 2003, GENETICS, V165, P353; von Mutius E, 2000, CLIN EXP ALLERGY, V30, P1230; VONMUTIUS E, 1994, BRIT MED J, V308, P692; WARNER JA, 1994, CLIN EXP ALLERGY, V24, P423, DOI 10.1111/j.1365-2222.1994.tb00930.x; Weiss LA, 2005, AM J HUM GENET, V76, P33, DOI 10.1086/426697; Weiss ST, 2002, NEW ENGL J MED, V347, P930, DOI 10.1056/NEJMe020092; Werner M, 2003, J ALLERGY CLIN IMMUN, V112, P323, DOI 10.1067/mai.2003.1648; Wickens KL, 1999, EPIDEMIOLOGY, V10, P699, DOI 10.1097/00001648-199911000-00009	57	84	86	2	11	UNIV CHICAGO PRESS	CHICAGO	1427 E 60TH ST, CHICAGO, IL 60637-2954 USA	0002-9297			AM J HUM GENET	Am. J. Hum. Genet.	APR	2005	76	4					696	704		10.1086/429418		9	Genetics & Heredity	Genetics & Heredity	904RS	WOS:000227516000016	15726497	
J	Sakai, K; Norback, D; Mi, YH; Shibata, E; Kamijima, M; Yamada, T; Takeuchi, Y				Sakai, K; Norback, D; Mi, YH; Shibata, E; Kamijima, M; Yamada, T; Takeuchi, Y			A comparison of indoor air pollutants in Japan and Sweden: formaldehyde, nitrogen dioxide, and chlorinated volatile organic compounds	ENVIRONMENTAL RESEARCH			English	Article						formaldehyde; nitrogen dioxide; chlorinated VOC; indoor air pollution; international comparison	SICK BUILDING SYNDROME; EXPOSURE; PREVALENCE; SYMPTOMS; EMISSION; PRODUCTS; ASTHMA; AREAS; TEAM	Indoor and outdoor concentrations of formaldehyde (HCHO), nitrogen dioxide (NO2), and selected chlorinated volatile organic compounds (chlorinated VOC) were measured in 37 urban dwellings in Nagoya, Japan, and 27 urban dwellings in Uppsala, Sweden, using the same sampling procedures and analytical methods. Indoor as well as outdoor air concentrations of HCHO, NO2, and chlorinated VOC were significantly higher in Nagoya than in Uppsala (P<0.01), with the exception of tetrachlorocarbon in outdoor air. In Nagoya, HCHO and NO2 concentrations were significantly higher in modern concrete houses than in wooden houses and higher in newer (less than 10 years) than in older dwellings (P < 0.01), possibly due to less natural ventilation and more emission sources in modern buildings. Dwellings heated with unvented combustion sources had significantly higher indoor concentrations of NO2\ than those with clean heating (P<0.05). Moreover, dwellings with moth repellents containing p-dichlorobenzene had significantly higher indoor concentrations of p-dichlorobenzene (P < 0.01). In conclusion, there appear to be differences between Nagoya and Uppsala with respect to both indoor and outdoor pollution levels of the measured pollutants. More indoor pollution sources could be identified in Nagoya than in Uppsala, including construction and interior materials emitting VOC, use of unvented combustion space heaters, and moth repellents containing p-dichlorobenzene. (C) 2003 Elsevier Inc. All rights reserved.	Nagoya City Publ Hlth Res Inst, Mizuho Ku, Nagoya, Aichi 4678615, Japan; Univ Uppsala, Dept Med Sci Occupat & Environm Med, S-75185 Uppsala, Sweden; Nagoya Univ, Sch Hlth Sci, Dept Med Technol, Higashi Ku, Nagoya, Aichi 4618673, Japan; Nagoya Univ, Grad Sch Med, Dept Environm & Occupat Hlth, Showa Ku, Nagoya, Aichi 4668550, Japan; Natl Inst Radiol Sci, Res Ctr Radiat Emergency Med, Inage Ku, Chiba 2638555, Japan	Sakai, K (reprint author), Nagoya City Publ Hlth Res Inst, Mizuho Ku, 1-11 Hagiyama Cho, Nagoya, Aichi 4678615, Japan.			Norback, Dan/0000-0002-5174-6668			Ando M, 2002, B NATL I HLTH SCI, V120, P6; ARAKI A, 1999, JPN J PUBL HLTH, V50, P769; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Brinke JT, 1998, INDOOR AIR, V8, P140, DOI DOI 10.1111/J.1600-0668.1998.T01-1-00002.X; Craighead John E., 1995, P29; Engvall K, 2001, INT ARCH OCC ENV HEA, V74, P270, DOI 10.1007/s004200000218; FISCHMAN ML, 1997, OCCUPATIONAL ENV MED, P726; HARTWELL TD, 1992, ATMOS ENVIRON A-GEN, V26, P1519, DOI 10.1016/0960-1686(92)90136-9; HODGSON M, 1992, ANN NY ACAD SCI, V641, P21, DOI 10.1111/j.1749-6632.1992.tb16529.x; Janson C, 2001, EUR RESPIR J, V18, P598, DOI 10.1183/09031936.01.00205801; *JAP MIN HLTH WELF, 1999, REP IND AIR POLL VOL; *KAG KOG NIPP, 1994, HDB KAG KOG NIPP, P747; Kamijima M, 2002, J OCCUP HEALTH, V44, P186, DOI 10.1539/joh.44.186; KOREN HS, 1992, ARCH ENVIRON HEALTH, V47, P39; KOSTIAINEN R, 1995, ATMOS ENVIRON, V29, P693, DOI 10.1016/1352-2310(94)00309-9; Levy JI, 1998, J AIR WASTE MANAGE, V48, P553, DOI 10.1080/10473289.1998.10463704; Matsumura T., 1996, J JPN SOC ATMOS ENV, V31, p154A; MATTHEWS T G, 1986, Environment International, V12, P301, DOI 10.1016/0160-4120(86)90043-7; MELIA RJW, 1990, ATMOS ENVIRON B-URB, V24, P177, DOI 10.1016/0957-1272(90)90023-N; MOLHAVE L, 1986, Environment International, V12, P167, DOI 10.1016/0160-4120(86)90027-9; *NIH SCI JAP, 1998, EST FORM EXP DWELL J; NORBACK D, 1995, OCCUP ENVIRON MED, V52, P388; NORBACK D, 1990, SCAND J WORK ENV HEA, V16, P121; NORBACK D, 1990, BRIT J IND MED, V47, P733; NORBACK D, 1991, BRIT J IND MED, V48, P451; NORBACK D, 1995, VOLATILE ORGANIC COM, P179; OLANSANDAN, 1998, J ENV CHEM, V8, P47; OTSON R, 1994, ATMOS ENVIRON, V28, P3563, DOI 10.1016/1352-2310(94)00201-U; Pappas G P, 2000, Int J Occup Environ Health, V6, P1; PELLIZZARI E D, 1986, Environment International, V12, P619, DOI 10.1016/0160-4120(86)90104-2; *PHARM SOC JAP, 1990, STAND METH AN HYG CH, P1387; PICKRELL JA, 1983, ENVIRON SCI TECHNOL, V17, P753, DOI 10.1021/es00118a012; SAITO I, 1999, ANN REP TOKYO METROP, V50, P235; Sakurai H, 2002, J OCCUP HEALTH, V44, P267; TAMAKAWA K, 1993, J ENV CHEM, V3, P709; WALLACE LA, 1987, ENVIRON RES, V43, P290, DOI 10.1016/S0013-9351(87)80030-0; Wieslander G, 1997, INT ARCH OCC ENV HEA, V69, P115; YAMANAKA S, 1979, ATMOS ENVIRON, V13, P407, DOI 10.1016/0004-6981(79)90297-X; YOSHIDA T, 1998, J JPN SOC ATMOS ENV, V33, P371	39	84	87	5	29	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0013-9351			ENVIRON RES	Environ. Res.	JAN	2004	94	1					75	85		10.1016/S0013-9351(03)00140-3		11	Environmental Sciences; Public, Environmental & Occupational Health	Environmental Sciences & Ecology; Public, Environmental & Occupational Health	758DD	WOS:000187616500010	14643289	
J	Jaakkola, MS; Piipari, R; Jaakkola, N; Jaakkola, JJK				Jaakkola, MS; Piipari, R; Jaakkola, N; Jaakkola, JJK			Environmental tobacco smoke and adult-onset asthma: A population-based incident case-control study	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							RESPIRATORY SYMPTOMS; PASSIVE SMOKING; EXPOSURE; NONSMOKING	Objectives. The authors assessed the effects of environmental tobacco smoke (ETS) on the development of asthma in adults. Methods. In the Pirkanmaa district of South Finland, all 21- to 63 year-old adults with new cases of asthma diagnosed during a 2.5-year period (n=521 case patients. out of 441000 inhabitants) and a random sample of control subjects from the source population (932 control subjects) participated in a population-based incident case-control study. Results. Risk of asthma was related to workplace ETS exposure (adjusted odds ratio [OR] = 2.16; 95% confidence interval [CI] = 1.26, 3.72) and home exposure (OR = 4.77; 95% CI = 1.29, 17.7) in the past year. Cumulative ETS exposure over a lifetime at work and at home increased the risk. Conclusions. This study indicates for the first time that both cumulative lifetime and recent ETS exposures increase the risk of adult-onset asthma.	Finnish Inst Occupat Hlth, Helsinki, Finland; Univ Helsinki, Dept Publ Hlth, Environm Epidemiol Unit, Helsinki, Finland	Jaakkola, MS (reprint author), Univ Birmingham, Inst Occupat Hlth, Birmingham B15 2TT, W Midlands, England.		Jaakkola, Jouni/G-4314-2012				American Thoracic Society, 1995, AM J RESP CRIT CARE, V152, P1107; *COMM NAT ASTHM PR, 1994, ASTHM PROGR 1994 200, P16; FLODIN U, 1995, EPIDEMIOLOGY, V6, P503, DOI 10.1097/00001648-199509000-00007; Greenland S., 1998, MODERN EPIDEMIOLOGY; GREER JR, 1993, J OCCUP ENVIRON MED, V35, P909, DOI 10.1097/00043764-199309000-00014; Hoffmann D, 1997, J TOXICOL ENV HEALTH, V50, P307, DOI 10.1080/009841097160393; Hu FB, 1997, J ASTHMA, V34, P67, DOI 10.3109/02770909709071205; JAAKKOLA JJK, 1995, AM J EPIDEMIOL, V141, P755; Jaakkola MS, 1999, AM J EPIDEMIOL, V150, P1223; Jaakkola MS, 1997, EUR RESPIR J, V10, P2384, DOI 10.1183/09031936.97.10102384; Jaakkola MS, 2002, ENVIRON HEALTH PERSP, V110, P543; Jaakkola MS, 1999, ENVIRON HEALTH PERSP, V107, P829, DOI 10.2307/3434561; JAAKKOLA MS, 2002, SCAND J WORK ENV S2, V28, P54; Jaakkola MS, 2000, EUR RESP MONOGR, V15, P322; LEUENBERGER P, 1994, AM J RESP CRIT CARE, V150, P1222; MIETTINE.OS, 1974, AM J EPIDEMIOL, V99, P325; NG TP, 1993, J EPIDEMIOL COMMUN H, V47, P454, DOI 10.1136/jech.47.6.454; ROBBINS AS, 1993, INT J EPIDEMIOL, V22, P809, DOI 10.1093/ije/22.5.809; Strachan DP, 1998, THORAX, V53, P204; THORN J, 2001, ALLERGY, V56, P282; *US EPA OFF HLTH E, 1992, EPA PUBL; VILJANEN AA, 1982, SCAND J CLIN LAB INV, V42, P5	22	84	85	0	3	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	1015 FIFTEENTH ST NW, WASHINGTON, DC 20005 USA	0090-0036			AM J PUBLIC HEALTH	Am. J. Public Health	DEC	2003	93	12					2055	2060		10.2105/AJPH.93.12.2055		6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	748WH	WOS:000186848400024	14652334	
J	Jenkins, HA; Cherniack, R; Szefler, SJ; Covar, R; Gelfand, EW; Spahn, JD				Jenkins, HA; Cherniack, R; Szefler, SJ; Covar, R; Gelfand, EW; Spahn, JD			A comparison of the clinical characteristics of children and adults with severe asthma	CHEST			English	Article						adult-onset asthma; childbood-onset asthma; glucocorticoids; National Heart, Lung, and Blood Institute; guidelines; severe asthma	AIR-FLOW OBSTRUCTION; CHILDHOOD-ONSET; LUNG-FUNCTION; POPULATION; SAMPLE	Objectives: This study sought to better define the clinical characteristics of severe asthma in both children and adults, and to evaluate the effect of asthma duration on multiple parameters of disease severity. Design: Retrospective analysis of prospectively collected data on 275 patients (125 children) with severe asthma who were admitted to a tertiary asthma referral center. Methods: Demographics, lung function (ie, spirometry and body box plethysmography), glueocorticoid (GC) pharmacokinetic studies, and lymphocyte stimulation assays were performed on all patients. Results: Children were as likely to require therapy with high-dose inhaled GCs and long-term therapy with oral GCs, and to have had a prior intubation, yet they had significantly less airflow limitation (mean [+/-SEM] (.) FEV1, 74.0 +/- 2.1% predicted vs 57.1 +/- 1.8% predicted, respectively; p < 0.0001), less resistance to airflow (mean airway resistance, 140.3 +/- 8.5% predicted vs 311 +/- 18% predicted, respectively; p < 0.0001), and larger lung volumes (mean total lung capacity, 116.4 1.6% predicted vs 105.3 +/- 1.8% predicted, respectively; p < 0.0001) compared to adults. Children were more likely to be male and to display greater responsiveness to GCs in vitro. Lung function impairment was associated with asthma duration in children and in adults with onset of asthma in childhood, while there was no relationship between disease severity and asthma duration among those with adult-onset asthma. Despite significant differences in disease duration, patients with adult-onset asthma had equally compromised lung function compared to adults with long-standing asthma. Conclusions: Children with severe asthma tended to be male, to have less severe airflow obstruction, and to display greater responsiveness to GCs in vitro compared to adults. Symptoms and episodic acute declines in lung function may precede chronic airflow limitation in this group of children. As such, it may be more relevant to follow the deterioration in lung function over time in children. Finally, disease severity in children and adults whose onset of asthma occurred in childhood was related to disease duration, but not in patients with onset of asthma in adulthood.	Natl Jewish Med & Res Ctr, Div Clin Pharmacol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Div Allergy Clin Immunol, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Ira J & Jacqueline Neimark Lab Clin Pharmacol Ped, Denver, CO 80206 USA; Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA	Spahn, JD (reprint author), Natl Jewish Med & Res Ctr, Div Clin Pharmacol, 1400 Jackson St,K-926, Denver, CO 80206 USA.						Bacharier LB, 2002, J ALLERGY CLIN IMMUN, V109, pS266, DOI 10.1016/S0091-6749(02)81946-7; Bratton DL, 2001, PEDIATR PULM, V31, P177, DOI 10.1002/ppul.1027; BROWN PJ, 1984, THORAX, V39, P131, DOI 10.1136/thx.39.2.131; BURROWS B, 1991, J ALLERGY CLIN IMMUN, V88, P870, DOI 10.1016/0091-6749(91)90243-H; BUSSE W, 1995, AM J RESP CRIT CARE, V151, P1635; Busse William W., 2000, Journal of Allergy and Clinical Immunology, V106, P1033; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594; Eid N, 2000, PEDIATRICS, V105, P354, DOI 10.1542/peds.105.2.354; Fuhlbrigge AL, 2001, J ALLERGY CLIN IMMUN, V107, P61, DOI 10.1067/mai.2001.111590; Gelb AF, 2002, CHEST, V121, P715, DOI 10.1378/chest.121.3.715; Hankinson JL, 1999, AM J RESP CRIT CARE, V159, P179; HILL MR, 1990, CLIN PHARMACOL THER, V48, P390; JENKINS MA, 1994, BRIT MED J, V309, P90; Lange P, 1998, NEW ENGL J MED, V339, P1194, DOI 10.1056/NEJM199810223391703; PEAT JK, 1987, EUR J RESPIR DIS, V70, P171; Segala C, 2000, ALLERGY, V55, P634, DOI 10.1034/j.1398-9995.2000.00488.x; Spahn JD, 1996, J ALLERGY CLIN IMMUN, V98, P1073, DOI 10.1016/S0091-6749(96)80194-1; YUNGINGER JW, 1992, AM REV RESPIR DIS, V146, P888	18	84	90	0	5	AMER COLL CHEST PHYSICIANS	NORTHBROOK	3300 DUNDEE ROAD, NORTHBROOK, IL 60062-2348 USA	0012-3692			CHEST	Chest	OCT	2003	124	4					1318	1324		10.1378/chest.124.4.1318		7	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	733LU	WOS:000186002500021	14555561	
